id|nct_id|group_type|title|description
11018393|NCT04647422|Experimental|AUD patients|Alcohol Use Disorder patients
11018394|NCT04647422|Experimental|AUD controls|Healthy control participants matched to group 1
11018395|NCT04647422|Experimental|First-degree relatives|Healthy first-degree relatives of AUD patients
11018396|NCT04647422|Experimental|First-degree controls|Healthy control participants matched to group 3
11018397|NCT04647409|Other|participants|
11018398|NCT04647396|Experimental|Intervention group|
11018399|NCT04647396|No Intervention|Control group|
11018400|NCT04647383|Experimental|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
11018401|NCT04647383|Experimental|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
11018402|NCT04647383|Experimental|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
11018403|NCT04647383|Experimental|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
11018404|NCT04647370|Active Comparator|Remote ischemic preconditioning|
11018405|NCT04647370|Sham Comparator|Sham remote ischemic preconditioning|
11018406|NCT04647357|Experimental|SHR-1316|
11018407|NCT04647344|Experimental|Nonsquamous NSCLC|
11018408|NCT04647344|Experimental|Squamous NSCLC|
11018409|NCT04647318|Experimental|Compassion focused imagery, relaxation imagery and control task|Participants engage in three tasks (compassion focused imagery, relaxation imagery and control task), three or four times every three days.
11018410|NCT04647305|Experimental|Closed face shield + Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
11018411|NCT04647305|Active Comparator|Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial. Additionally, each participant will receive an educational intervention (video).
11018412|NCT04647292|Experimental|Target systolic blood pressure 115-125 mmHg|Recommended target SBP 115-125 millimetres of mercury (mmHg).
11018413|NCT04647292|Active Comparator|Target systolic blood pressure 130-139 mmHg|Target SBP 130-139 mmHg (per American Stroke Association, European Stroke Organisation guidelines).
11018414|NCT04647279||Normal control group|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
11018415|NCT04647279||Osteopenia|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
11018416|NCT04647279||Osteoporosis|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
11018417|NCT04647240|Active Comparator|Dermacyte® Liquid (human amniotic fluid)|Dermacyte® Liquid (human amniotic fluid) solution 1.0mL to 2.0mL weekly
11018418|NCT04647240|Placebo Comparator|Placebo (0.9% saline)|Matching placebo solution 1.0mL to 2.0mL weekly
11018419|NCT04647227|Other|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
11018420|NCT04647214||Bimatoprost intracameral implant (DURYSTA) 10μg|Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
11018421|NCT04647201||Control|Non-sepsis and non-GI adults
11018422|NCT04647201||Sepsis patients without GI|Patients who meet the criteria of sepsis3.0 with AGI grade I or less
11018423|NCT04647201||Sepsis patients with GI|Patients who meet the criteria of sepsis3.0 with AGI grade II or above
11018424|NCT04647188||Urology group|Includes patients undergoing prostatectomy (n=100)
11018425|NCT04647188||Colorectal group|Includes patients undergoing anterior rectal resection (n=100)
11018426|NCT04647188||Thoracic group|Includes patients undergoing lobectomy (n=100)
11018427|NCT04647188||Gynaecological group|Includes patients undergoing hysterectomy (n=100)
11018428|NCT04647188||HpB group|Includes pancreatic tumour resection patients (n=50)
11018429|NCT04647188||Ear, Nose & Throat group|Includes patients undergoing tongue base mucosectomy (n=50)
11018430|NCT04647175|Other|Fermented aronia - aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
11018431|NCT04647175|Other|Fermented aronia - placebo - aronia|The participants receive each intervention for 8 weeks in the stated order.
11018432|NCT04647175|Other|Placebo - aronia - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
11018433|NCT04647175|Other|Placebo - fermented aronia - aronia|The participants receive each intervention for 8 weeks in the stated order.
11018434|NCT04647175|Other|Aronia - placebo - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
11018435|NCT04647175|Other|Aronia - fermented aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
11021941|NCT04623372|Experimental|suture|
11018436|NCT04647162|Active Comparator|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
11018437|NCT04647162|Experimental|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
11018438|NCT04647149|Experimental|Early Time-Restricted Eating|8-hour eating window between 08:00 and 16:00
11018439|NCT04647149|Experimental|Delayed Time-Restricted Eating|8-hour eating window between 12:00 and 20:00
11018440|NCT04647149|Experimental|Control|12-hour eating window between 08:00 and 20:00
11018441|NCT04647136|Active Comparator|Fertility Health Screening|Clinic-based fertility health screening and counselling
11018442|NCT04647136|Active Comparator|Fertility Awareness Tools|Online intervention to provide fertility education and behavioural nudge for optimal reproductive timing.
11018443|NCT04647136|No Intervention|Control|No intervention but exposed to usual information from the media on fertility and family benefits (no different from general population).
11018444|NCT04647123||Hopeless teeth|The teeth that can not be treated periodontally and who are desperate for extraction will be included in this group.
11018445|NCT04647123||Periodontitis|Teeth diagnosed with periodontitis will be included in this group.
11018446|NCT04647123||Gingivitis|Teeth diagnosed with gingivitis will be included in this group.
11018447|NCT04647123||Healthy|Teeth diagnosed with helthy will be included in this group.
11018448|NCT04647110||Swedish Anaplastic lymphoma kinase (ALK) positive Non-small cell lung cancer (NSCLC) patients|
11018449|NCT04647097|Active Comparator|Standard intervention plus repeated intervention|Patients randomized to the standard intervention plus repeated intervention arm
11018450|NCT04647097|Active Comparator|Standard intervention only|Patients randomized to the standard intervention only arm
11018451|NCT04647084|Experimental|Intradermal Lidocaine 2%|
11018452|NCT04647084|Experimental|Buzzy|
11018453|NCT04647071|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
11018454|NCT04647071|Experimental|Intervention|Garlic concentrated extract plus onion concentrated extract plus microcrystalline cellulose (9892- Capsules®) up to 400 mg.
11018455|NCT04647058|Active Comparator|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
11018456|NCT04647058|Experimental|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
11018457|NCT04647045|Active Comparator|IBS-C group|77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days
11018458|NCT04647045|Other|Non-IBS group|88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
11018459|NCT04647032|Experimental|Theta Stimulation Group|This group will receive 6 Hz (theta) stimulation
11018460|NCT04647032|Active Comparator|Delta Stimulation Group|This group will receive 1 Hz (delta) stimulation
11018461|NCT04647019|Experimental|Blueberry|
11018462|NCT04647019|Placebo Comparator|Placebo|
11018463|NCT04647006|Other|Conventional Thyroidectomy|Conventional Thyroidectomy
11018464|NCT04647006|Active Comparator|Transoral endoscopic thyroidectomy vestibular approach|Transoral endoscopic thyroidectomy vestibular approach
11018465|NCT04646980|Experimental|Biobran/MGN-3|This arm consisted from 20 males and 20 females. Biobran/MGN-3 was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
11018466|NCT04646980|Placebo Comparator|Placebo|This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
11018467|NCT04646967|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen postoperatively as needed.
11018468|NCT04646967|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
11018469|NCT04646954|Experimental|Study group|All eligible participants are included in the study group
11018470|NCT04646941||T2DM with OSA|Type 2 diabetes patients with obstructive sleep apnea
11018471|NCT04646941||T2DM without OSA|Type 2 diabetes patients without obstructive sleep apnea
11018472|NCT04646915||Patients with CuRC undergoing day surgery|Patients with CuRC undergoing laparoscopic colectomy or anterior resection in day surgery center.
11018473|NCT04646902||HTN_OSA|"Patients with hypertension* with obstructive sleep apnea**
~* Hypertension will be defined as: i) use of antihypertensive drug(s) and stable dose for at least 2 weeks prior to inclusion; or ii) in untreated patients: office systolic blood pressure values >= 140 mmHg and/ or diastolic blood pressure values >= 90 mmHg.
~** OSA will be defined with a polysomnography level 1, 2 or 3 performed within the previous twelve months with:
~an apnea-hypopnea index > 5 events per hour (with more than 50% of obstructive events) associated with symptoms (associated sleepiness, fatigue, insomnia, snoring, subjective nocturnal respiratory disturbance or observed apnea) or medical/psychiatric disorder (hypertension, coronary artery disease, atrial fibrillation, congestive heart failure, stroke, diabetes, cognitive dysfunction, or mood disorder), OR
~an apnea-hypopnea index > 15 events per hour, AND
~no significant changes in health, medications, or lifestyle since the polysomnography."
11018474|NCT04646902||HTN_NoOSA|Patients with hypertension without obstructive sleep apnea
11018475|NCT04646902||NoHTN_OSA|Patients without hypertension with obstructive sleep apnea
11018476|NCT04646902||NoHTN_NoOSA|Patients without hypertension without obstructive sleep apnea (healthy controls)
11018477|NCT04646889|Experimental|Renal Impairment|Subjects with various degrees of renal impairment
11018478|NCT04646889|Experimental|Normal Renal Function|Subjects with normal renal function
11018479|NCT04646876|Active Comparator|intervention arm ( Group A )|"including 30 patients Group A was given magnesium Sulphate
~Administration regimen of Mgso4 was as following:
~Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs."
11018480|NCT04646876|Placebo Comparator|Placebo arm (Group B )|including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate
11018481|NCT04646863|Experimental|group A|consists of 20 patients received a multiwave locked system laser
11018482|NCT04646863|Experimental|group B|consists of 20 patients received Pilates exercises
11018483|NCT04646863|Experimental|group C|consists of 20 patients received a multiwave locked system laser and Pilates exercises
11018484|NCT04646837|Experimental|Experimental Arm|Durvalumab 1000 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IB-IIIA NSCLC adult patients followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 15000mg Q4W for 8 months
11018485|NCT04646824|Experimental|ahead|A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
11018486|NCT04646811|Experimental|Tricuspid valve|tricuspid valve percutaneous repair strategy with clip for the tricuspid valve
11018487|NCT04646811|Other|Best medical treatment|
11018488|NCT04646798|Active Comparator|Hemi Arthroplasty (HA) of the elbow.|Hemi Arthroplasty (HA) of the elbow, where the surgeon replaces the bottom of the humerus bone at the elbow.
11018489|NCT04646798|Active Comparator|Total Elbow Arthroplasty (TEA).|Total Elbow Arthroplasty (TEA), where the surgeon fits a new elbow joint replacing damaged parts of the humerus bone and forearm bone that it joins onto.
11018490|NCT04646785|Experimental|Mindfulness-based cognitive therapy (MBCT) added to treatment as usual|Patients in the MBCT arm will in addition to their treatment as usual be invited to participate in MBCT.
11018491|NCT04646785|Active Comparator|Treatment as usual (TAU)|Patients in this arm will receive treatment as usual.
11018492|NCT04646759|Experimental|Fulvestrant Combined With Pyrotinib|Fulvestrant, 500 mg, was injected intramuscularly on D1, D15, D28, D28, once every 28 days； Pyrotinib, 400mg, orally administered daily.
11018493|NCT04646759|Active Comparator|Capecitabine Combined With Pyrotinib|Capecitabine, 1000mg / m^2, twice daily; Pyrotinib, 400mg, orally administered daily.
11018494|NCT04646746|Experimental|100 g of 100% wheat bread|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
11018495|NCT04646746|Experimental|Nude barley 50%|"Intake of 250 ml of tap water and 100 g of bread baked with 50% nude barley flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
11018496|NCT04646746|Experimental|Nude barley 75%|"Intake of 250 ml of tapwater and 100 g of bread baked with 75% nude barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
11018497|NCT04646746|Experimental|Gen-modified high-amylose barley|"Intake of 250 ml of tap water and 100 g of bread baked with 50% gene-modified high-amylose barley and 50% wheat. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
~The gene-modified barley is produced by researchers at Aarhus and Copenhagen Universities as published in 'Carciofi M, et al., Concerted suppression of all starch branching enzyme genes in barley produces amylose-only starch granules. BMC Plant Biol. 2012 Nov 21;12:223. doi: 10.1186/1471-2229-12-223' The wheat flour is standard commercial available flour."
11018498|NCT04646733|Experimental|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet.
11018499|NCT04646733|Active Comparator|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water.
11018500|NCT04646720||Neck pain patients|Patients with neck pain evaluated with new technologies and face-to-face
11018501|NCT04646707|Experimental|Study group|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
11018502|NCT04646707|Placebo Comparator|Placebo Group|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
11018503|NCT04646694|Experimental|Study Group 1|Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
11018504|NCT04646694|Placebo Comparator|Study group 2|Patient will receive Placebo at a matching dose every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Placebo for three days or nine doses total.
11018505|NCT04646681|Experimental|Group 1|
11018506|NCT04646681|No Intervention|Group 2|
11018507|NCT04646668|Active Comparator|E-Cigarette then Heat not burn.|We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
11018508|NCT04646668|Active Comparator|Heat not burn then E-Cigarette|We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.
11018509|NCT04646655|Active Comparator|Enoxaparin at prophylactic dose|Enoxaparin at prophylactic dose: standard 4.000 IU QD via subcutaneous injection (6000 IU if body weight>100 kg)
11018539|NCT04646421||Control group: clients not reached for the motivational intervention|Clients aimed to be reached for the same intervention, but who were not reached and therefore were not exposed to the intervention.
11018510|NCT04646655|Experimental|Enoxaparin at therapeutic dose|"Enoxaparin at therapeutic dose : 70 U/Kg b.i.d. (every 12 h)
~In order to easily calculate the correct therapeutic dose of enoxaparin for each patient, a simplified categorization will be applied, as follows:
~weight < 65 Kg: 4.000 IU b.i.d. (every 12 h)
~weight ≥ 65 Kg: 6.000 IU b.i.d. (every 12 h)
~weight ≥ 100 Kg: 8.000 IU b.i.d. (every 12 h) The most appropriate dose will be evaluated in patients with creatinine clearance between 30 and 50 ml/min"
11018511|NCT04646629|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment"
11018512|NCT04646629|Sham Comparator|sham electroacupuncture treatment|"sham electroacupuncture treatment participants in the control group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
11018513|NCT04646616|Experimental|Community popular opinion leader (POL)|After successful completion of the new COVID-19 training module, POLs will reach out to members of their social networks to model and diffuse social norms to reduce the risk of COVID-19 infection and transmission, screen for symptoms and counsel regarding COVID-19, SAVAME syndemic factors, and refer at-risk or affected individuals to appropriate community services (e.g. free COVID-19 testing and treatment, mental health services, substance use services, violence prevention, support groups, etc.). As in other POL based interventions and pragmatic trials, POLs be asked to follow up with their community contacts to monitor their situation and provide additional support, but there will be flexibility with the frequency and number of follow up contacts depending on their needs identified and the preferences of the community contact. POLs will be continually supported by the research team via face-to-face biweekly booster sessions (if COVID-19 situation requires it) or by zoom.
11018514|NCT04646603|Experimental|MRG-001|"Single SC dose of 0.01 mL/kg MRG-001 (n=4) will be administered every other day for the duration of 5 days totaling 3 injections.
~Single SC dose of 0.02 mL/kg MRG-001 (n=4) will be administered every other day for the duration of 5 days totaling 3 injections."
11018515|NCT04646603|Placebo Comparator|Placebo|"Single SC dose of 0.01 mL/kg Sterile Injectable Saline (n=2) will be administered every other day for the duration of 5 days totaling 3 injections.
~Single SC dose of 0.02 mL/kg Sterile Injectable Saline (n=2) will be administered every other day for the duration of 5 days totaling 3 injections."
11018516|NCT04646590|Experimental|Investigational Vaccine|Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
11018517|NCT04646590|Placebo Comparator|Placebo comparator|Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
11018518|NCT04646577|Active Comparator|Active|
11018519|NCT04646577|Sham Comparator|Sham|
11018520|NCT04646564|Active Comparator|control arm|standard of care
11018521|NCT04646564|Experimental|study arm|radiotherapy + standard of care
11018522|NCT04646538|Experimental|X3 group|
11018523|NCT04646512|Active Comparator|Taurine group and exercise|Intervention with taurine supplementation and physical training.
11018524|NCT04646512|Placebo Comparator|Placebo group and exercise|Intervention with placebo supplementation and physical training.
11018525|NCT04646499|Experimental|Gamma Stimulation Group|This group will receive gamma stimulation
11018526|NCT04646486|No Intervention|Baseline|Usual practice.
11018527|NCT04646486|Experimental|Intervention|Video debriefing
11018528|NCT04646473|Experimental|App only|Sweetgoals app only
11018529|NCT04646473|Experimental|App plus Incentives|SweetGoals app + incentives=yes + coaching=no
11018530|NCT04646473|Experimental|App plus Coaching|Sweetgoals app + incentives=no + coaching=yes
11018531|NCT04646473|Experimental|App plus Coaching plus Incentives|Sweetgoals app + incentives=yes + coaching=yes
11018532|NCT04646460|Experimental|Observed Success - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
11018533|NCT04646460|Experimental|Observed Failure - Experienced Failure|"This participant group (N=30) will witness a failed placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
11018534|NCT04646460|Experimental|Observed Success - Experienced Failure|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will not display reduced pain expressions after receiving the cream) and experience a failed placebo during the experience phase (i.e. the experimenter will not reduce the intensity of the pain stimuli after applying the cream)."
11018535|NCT04646460|Experimental|Observed Failure - Experienced Success|"This participant group (N=30) will witness a successful placebo during the observation phase (i.e. the demonstrator will display reduced pain expressions after receiving the cream) and experience a successful placebo during the experience phase (i.e. the experimenter will reduce the intensity of the pain stimuli after applying the cream)."
11018536|NCT04646447|Experimental|L-serine treatment|All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.
11018537|NCT04646434|Experimental|Supportive Care (brain and muscle monitoring, questionnaire)|Patients perform standard of care Kegel exercises while undergoing brain and muscle activity monitoring by EEG and EMG, respectively, before surgery, 6 weeks after surgery, and at 3, 6, and 12 months after surgery. Patients complete questionnaires over 5-10 minutes about urinary function
11018538|NCT04646421||Motivational intervention - clients reached|Gamblers successfully reached with the motivational telephone intervention.
11018762|NCT04644939|Placebo Comparator|Conventional group|Patients will receive bowel preparation instructions in a conventional way
11018540|NCT04646421||Prospective intervention group|Clients subject to the prospective study part (target N 200), who are successfully reached by the intervention from November, 2020, and who provide informed consent to the web survey study. Studied as a cohort without control group, but with the pre-intervention situation as their own control condition.
11018541|NCT04646408||Participants with CKD|Recruitment is from a cohort of HIV positive individuals of African ancestry with Chronic Kidney Disease CKD defined as eGFR <60 mL/min/1.73m2, and/or albumin/creatinine ratio >30 mg/mmol or protein/creatinine ratio >50 mg/mmol Anticipated n=75
11018542|NCT04646408||Participants with diabetes|"Recruitment is from a cohort of HIV positive individuals of African ancestry with diabetes. Diabetes is defined as being on diabetic medications or HbA1c >48 mmol/mol.
~Anticipated n=75"
11018543|NCT04646408||Participants with ischaemic heart disease/stroke|Recruitment is from a cohort of HIV positive individuals of African ancestry with previous ischaemic heart disease or stroke Anticipated n=50
11018544|NCT04646408||No CKD/DM/CVD cohort|"Recruitment is from a cohort of HIV positive individuals of African ancestry who do not have CKD, diabetes or prior ischaemic heart disease/stroke.
~Anticipated n=200"
11018545|NCT04646395|Experimental|Tafasitamab and Acalabrutinib|"Acalabrutinib will be administered continuously at the dose of 100 mg BID (equivalent to a total daily dose of 200 mg), from day 1 to day 28 of each cycle for 24 cycles.
~Tafasitamab will be administered 12 mg/kg iv on days 1, 8, 15 and 22 for the first 3 cycles. Then patients will continue treatment until cycle 24 with tafasitamab 12mg/kg iv on day 1"
11018546|NCT04646382|Placebo Comparator|Control|Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
11018547|NCT04646382|Experimental|Intervention|Garlic concentrated extract. Onion concentrated extract. Microcrystalline cellulose (9892- Capsules®) up to 400 mg.
11018548|NCT04646369|Active Comparator|"screening as usual"|"Participants in the screening as usual' group will have a symptoms scores report of results sent to their provider based on their Screening Wizard responses."
11018549|NCT04646369|Experimental|Screening Wizard 2.0|Participants in the Screening Wizard 2.0 Report group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses.
11018550|NCT04646369|Experimental|Screening Wizard 2.0 + SOVA|Participants in the Screening Wizard 2.0 + SOVA group will have a symptoms scores report of results and treatment preferences, barriers, and recommendations sent to their provider based on their Screening Wizard responses. This group will also receive access to the SOVA website aimed at addressing perceptions about mental health providing support to teens through peer interaction.
11018551|NCT04646356|Active Comparator|Tacrolimus immediate-release capsules|subjects will be treated with a 6 months course of oral low-dose tacrolimus capsules to be taken twice daily starting dose of 0.025 mg/kg/day, adjusted to maintain drug blood levels of 2-5ng/ml
11018552|NCT04646356|Placebo Comparator|Placebo|Subjects will be given placebo oral capsules to be taken twice daily for 6 months.
11018553|NCT04646343||group for cross cultural adaptation of questionnaire|Pre final French version of the CISS and PWES will be administered to French native speaking patients suffering from various hand injuries. 30 patients are sufficient. They will be asked to write commentaries on difficulties of questionnaire's items, especially comprehension of the different items (clear or unclear).If the item is considered unclear, the patient is asked to provide suggestions for making the item clearer .The distribution of the responses will be examined for searching missing responses. An item considered unclear by 20 % or more of the patients must be re-evaluated . The definitive version of French-CISS and French PWES (F-CISS and F- PWES) and the verification of the different stages of the cross-cultural adaptation will be validated during a new consensus meeting.
11018554|NCT04646343||group for validation of questionnaire|For the second part (validation study) we will administered F-CISS, F-PWES, F-DASH, F-HFS, F-SF 36 questionnaires and a pain VAS to a population of in and outpatients with hand injuries. We aim to include patients during one year for a total expected of 100 patients.
11018555|NCT04646330|Experimental|1|AK104+anlotinib
11018556|NCT04646330|Experimental|2|AK104+anlotinib
11018557|NCT04646317|Experimental|Dexmedetomidine|Dexmedetomidine infusion four 50 ml syringes containing 1 microgram per ml dexmedetomidine
11018558|NCT04646317|Placebo Comparator|normaL SALINE 0.9%|Four 50 ml syringes of .9 % Normal SALINE
11018559|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants in the objective feedback group will receive a report that compares their performance in Set 1 to that of the staff surgeons' using the target interval as a reference. Participants receiving objective feedback will then complete Sets 2 and 3 knowing what factors to improve upon.
11018560|NCT04646304|No Intervention|No Feedback|Participants receiving no feedback will complete all sets with no intervention.
11018561|NCT04646291||Heterosexual Females with a Male partner|This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
11018562|NCT04646291||Females in LGBTQ Relationships|This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
11018563|NCT04646291||Solo parent|This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle. However, it might also be a male who is using a surrogate female.
11018564|NCT04646278|Experimental|Hyperemic stimuli|Hyperemic stimuli of coronary flow by adenosine or nicorandil injection
11018565|NCT04646265|Experimental|periodontal treatment|non-surgical root debridement
11018566|NCT04646239||Participants in the CROWN CORONATION trial|The CROWN CORONATION trial will randomly allocate adult participants to a single intramuscular injection of MMR vaccine or Placebo (0.9% saline).
11018567|NCT04646226|Active Comparator|fistula surgically placed|Randomized group to have surgically placed fistula for permanent hemodialysis access
11018568|NCT04646226|Active Comparator|graft surgically placed|Randomized group to have surgically placed graft for permanent hemodialysis access
11018569|NCT04646213|Experimental|Therapy|psychotherapeutic intervention
11018594|NCT04646135|Experimental|Sequence 1|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:
~Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hours
~Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hours
~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
11018763|NCT04644926|Experimental|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is performed at inclusion and repeated 12 h and 24 h later.
11018570|NCT04646200|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
11018571|NCT04646200|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
11018572|NCT04646187|Experimental|Intervention group|In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
11018573|NCT04646187|No Intervention|Control group|Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.
11018574|NCT04646174|Experimental|Multi-component Behavioral Treatment|This treatment consists of nine weekly phone-based individual treatment sessions, 45-60 minutes each, delivered by a trained study therapist.
11018575|NCT04646174|Experimental|Self-guided Treatment|This treatment consists of self-help materials from the American Lung Association that address evidence-based smoking cessation and self-management strategies.
11018576|NCT04646161||prostaglandins before iud insertion group|this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion
11018577|NCT04646161||placebo group|this group will receive placebo tablet before mirena iud insertion
11018578|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
11018579|NCT04646148|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
11018580|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES recieve prompting Text messages,
11018581|NCT04646148|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages, and financial Incentives to attend yoga classes
11018582|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
11018583|NCT04646148|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes and One-on-One individual sessions with a Yoga Instructor
11018584|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages and One-on-One individual sessions with a Yoga Instructor
11018585|NCT04646148|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive financial Incentives to attend yoga classes, prompting Text messages and One-on-One individual sessions with a Yoga Instructor
11018586|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos
11018587|NCT04646148|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages or One-on-One individual sessions with a Yoga Instructor, but DOES receive financial Incentives to attend yoga classes and Personal Practice Videos
11018588|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, or One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos and prompting Text messages
11018589|NCT04646148|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages and financial Incentives to attend yoga classes
11018590|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
11018591|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages but DOES receive financial Incentives to attend yoga classes, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
11018592|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive prompting Text messages, One-on-One individual sessions with a Yoga Instructor and Personal Practice Videos
11018593|NCT04646148|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
11018595|NCT04646135|Experimental|Sequence 2|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:
~Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hours
~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours
~Day 3: Continuous Infusion at 0.03 mg/kg/hour LZ"
11018596|NCT04646135|Experimental|Sequence 3|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:
~Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hours
~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours
~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
11018597|NCT04646109|No Intervention|Control Group|"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with PCR positivity in respiratory tract samples were included into the study. They were randomized to the control and study group, respectively. Hydroxychloroquine, favipiravir and azithromycin (HFA) standard treatment protocol were given to the control group as recommended in the COVID-19 (SARS-CoV-2 Infection) Guide prepared by the Republic of Turkey Ministry of Health."
11018598|NCT04646109|Experimental|Study Group|In addition to HFA treatment, ivermectin 200 micrograms/kg/day (9mg between 36-50 kg, 12mg between 51-65 kg, 15mg between 66-79 kg and 200 micrograms/kg in > 80 kg) in the form of a solution prepared for enteral use was added (HFA+I) to the treatment protocol of the study group's for five days. Blood sample was taken with the first dose of ivermectin and haplotype analysis was performed in ABCB1 and CYP3A4 genes in the whole study group.
11018599|NCT04646096|Experimental|Mako THA 4.0 group|Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
11018600|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using Inferior pedicle|Wise pattern reduction mammaplasty using Inferior pedicle
11018601|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using superomedial pedicle|
11018602|NCT04646057|Experimental|Treatment Arm|
11018603|NCT04646057|No Intervention|Historical Control Arm|
11018604|NCT04646044|Experimental|Bempegaldesleukin IV + Standard of Care|
11018605|NCT04646044|Placebo Comparator|Placebo + Standard of Care|
11018606|NCT04646018|Experimental|Lumbar Manipulation Group|Group that receives experimental lumbar non-thrust manipulation
11018607|NCT04646018|Sham Comparator|Sham Manipulation Group|Group that receives sham lumbar non-thrust manipulation
11018608|NCT04646005|Experimental|Cemiplimab+ISA101b|
11018609|NCT04645992|Active Comparator|study group|study group will receive only one session of yoga eye exercise for 20 minutes followed by transcutaneous electrical nerve stimulation by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
11018610|NCT04645992|Sham Comparator|control group|control group will be treated with the same protocol as the study group but with the unit of transcutaneous electrical nerve stimulation is off .
11018611|NCT04645979||Participants|Participants who used betamethasone plus loratadine to treat allergic rhinitis within the previous two months.
11018612|NCT04645966|Experimental|MenABCWY with PLP - 6 months of age|Participants 6 months of age vaccinated with MenABCWY on a 2+1 (2 primary vaccinations and a booster dose) schedule, and given Prophylactic Liquid Paracetamol (PLP) during primary vaccinations.
11018613|NCT04645966|Experimental|MenABCWY - 6 months of age|Participants 6 months of age vaccinated with MenABCWY on a 2+1 schedule
11018614|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimenrix, with PLP - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (60-µg Dose) and Nimenrix on a 2+1 schedule, with PLP during primary vaccinations
11018615|NCT04645966|Experimental|Bivalent rLP2086 (60-µg Dose) and Nimenrix - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (60-mcg Dose) and Nimenrix on a 2+1 schedule
11018616|NCT04645966|Experimental|Bivalent rLP2086 (120-µg Dose) and Nimenrix, with PLP - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations.
11018617|NCT04645966|Experimental|Bivalent rLP2086 (120-µg Dose) and Nimenrix - 2 months of age|Participants 2 months of age vaccinated with Bivalent rLP2086 (120-µg Dose) and Nimenrix on a 2+1 schedule
11018618|NCT04645966|Experimental|MenABCWY with PLP - 2 months of age|Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, and given PLP during primary vaccinations.
11018619|NCT04645966|Experimental|MenABCWY - 2 months of age|Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule
11018620|NCT04645966|Experimental|Bexsero and Nimenrix with PLP - 2 months of age|Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, and given PLP during primary vaccinations
11018621|NCT04645966|Experimental|Bexsero and Nimenrix - 2 months of age|Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule
11018622|NCT04645966|Experimental|MenABCWY with / without PLP - 2 months of age|Participants 2 months of age vaccinated with MenABCWY on a 2+1 schedule, with a determined ratio of participants given or not given PLP during primary vaccinations.
11018623|NCT04645966|Experimental|Bexsero and Nimenrix with / without PLP - 2 months of age|Participants 2 months of age vaccinated with Bexsero and Nimenrix on a 2+1 schedule, with a determined ratio of participants given or not given PLP during primary vaccinations
11018624|NCT04645953|Experimental|1mg AZ010|Single orally-inhaled dose
11018625|NCT04645953|Experimental|3mg AZ010|Single orally-inhaled dose
11018626|NCT04645953|Experimental|Placebo|Single orally-inhaled dose
11018627|NCT04645940|Experimental|Fed/Fasted|fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
11018628|NCT04645940|Experimental|Fasted/Fed|fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
11018629|NCT04645927|Placebo Comparator|Placebo control beverage group|The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
11018761|NCT04644939|Experimental|Interventional group|Patients will receive bowel preparation instructions in a conventional way in addition to a telephone call for education purposes one day prior to procedure
11018630|NCT04645927|Experimental|Experimental flax beverage group|Flax beverage (30 gr daily, oral) is presented in liquid form in plain unmarked packages. For 180 days (6 months) participants will consume 2 servings of 330 ml of flax beverage (treatment group; 30 gms flax/day beverage) per day.
11018631|NCT04645914|No Intervention|No smokers|Healthy subjects who do not consume any nicotine products
11018632|NCT04645914|Experimental|Smokers/Vapers|Healthy subjects who consume nicotine products
11018633|NCT04645901|Experimental|SYHA1805|Part 1: Subjects will receive a single dose of oral SYHA1805 tablets. Part 2: Subjects will receive single ascending doses of SYHA1805 tablets. Part 3: Subjects will receive a single dose SYHA1805 tablets in a fasted state and a single dose of SYHA1805 tablets after a high-fat, high-calorie meal, with sequence determined by randomization.
11018634|NCT04645901|Placebo Comparator|Placebo|Subjects will receive the matching placebo tablets.
11018635|NCT04645888|Active Comparator|Articaine|"All surgeries were performed by the same surgeon and monitored by the same person. 4 % articaine with 1:200.000 epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.
~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
11018636|NCT04645888|Active Comparator|Bupivacaine|"All surgeries were performed by the same surgeon and monitored by the same person. % 0.5 bupivacaine without epinephrine was administered to the patients in regional block of the inferior alveolar nerve technique at the first surgery. At the second intervention, patients received the other anesthetic solution which was not used at the first intervention.
~1.5 cc of the solution was used to anesthetize the inferior alveolar and lingual nerve and the remaining 0.5 cc was infiltrated to anesthetize the buccal nerve."
11018637|NCT04645875|Experimental|Sit regimen|Participants will be instructed to restrict walking and standing to ≤1 h/day each (total ≤2 h/day ) and the remainder of the waking day will be seated apart from visiting the toilet.
11018638|NCT04645875|Experimental|SitLess regimen|Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
11018639|NCT04645849|Other|"Cohort A or End of treatment"|16 patients recruited at the end of breast cancer treatment and followed during 9 months
11018640|NCT04645849|Other|"Cohort B or Diagnosis"|Patients recruited at breast cancer before any treatment: one blood sample to provide comparative values.
11018641|NCT04645836|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.
~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
11018642|NCT04645836|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
11018643|NCT04645823|Active Comparator|Spinal fentanyl|Using a combined spinal epidural technique a single dose of 20 µg of fentanyl diluted into 2 ml with NaCl 0.9 % will be injected into the CSF at lower lumbar interspace. An epidural catheter is left in place for subsequent analgesic doses.
11018644|NCT04645823|Experimental|Epidural lidocaine and fentanyl|Using a catheter in the epidural space in the lower lumbar interspace a single dose of lidocaine (80 mg) and fentanyl (100 µg) is given. The epidural catheter is left in place for subsequent analgesic doses.
11018645|NCT04645810|Experimental|Experimental: High-Dose-Rate prostate brachytherapy|High-Dose-Rate brachytherapy, 2 fractions
11018646|NCT04645797|Experimental|APR003 Dose Escalation|This portion of the study will evaluate the safety and pharmacokinetics of a range of APR003 doses administered once a week for 21 days in subjects with advance colorectal cancer (CRC) with metastases to the liver and to determine the RP2D.
11018647|NCT04645784|Experimental|Intervention|Receives the supporting student-athlete mental wellness module
11018648|NCT04645784|No Intervention|Waitlist|Receives no intervention
11018649|NCT04645771|Experimental|Microwave ablations|A total of 50 patients with varicose veins of lower extremities treated with microwave ablation catheter were selected to observe their annual venous closure rate and postoperative adverse reactions.
11018650|NCT04645758|Active Comparator|Dry Needling Group or (DN)|Dry needling for 5 mins on the flexor group of muscles of dominant forearm.
11018651|NCT04645758|Active Comparator|Extra corporeal Shockwave therapy Group or (ESWT)|Delivering of Shock wave pulses of 1250 at the energy intensity of 0.58 mj/mm2 on the flexor group of muscles of dominant forearm
11018652|NCT04645745|Experimental|myo-inositol plus alpha-lactalbumin|
11018653|NCT04645732|Experimental|Personalized exercise therapy and self-management program in addition to usual care|"Participants randomized to the personalized exercise therapy and self-management program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. Within one week of randomization, the participants will receive a telephone call from a member of the project team to discuss any barriers or special requirement needs that they may have in order to personalize the treatment as much as possible. Based on prior trial experience, this will also support retention of the participants in the study. The program will consist of 18 exercise sessions and six self-management sessions distributed across the program.
~Furthermore, this group will receive the treatment described under usual care below."
11018678|NCT04645550|Experimental|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for six months.
11018654|NCT04645732|Active Comparator|Usual care alone|Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
11018655|NCT04645719|Placebo Comparator|Lactate ringer group|Patients will receive only general anesthesia
11018656|NCT04645719|Active Comparator|Real weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the actual body weight
11018657|NCT04645719|Active Comparator|Corrected ideal weight group|Patients who will receive general anesthesia and magnesium sulfate infused at a dose of 15 mg.kg-1.h-1 based on the corrected ideal weight
11018658|NCT04645693||HIV Subjects with Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with no diagnosis of non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
11018659|NCT04645693||HIV Subjects without Non-Communicable Diseases|Patients living with HIV on Antiretroviral Therapy drugs for at least one year with a diagnosis of one or more systemic non-communicable diseases (diabetes, insulin resistance, hyperlipidemia/dyslipidemia, vascular disease, and/or osteoporosis).
11018660|NCT04645680|Experimental|Arm I (isocaloric high-fiber diet)|Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
11018661|NCT04645680|Active Comparator|Arm II (isocaloric diet)|Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
11018662|NCT04645667||Adult patients of allogeneic hematopoietic HCT|Patients who receive their first allogeneic HCT transplant and who receive tacrolimus for aGVHD prophylaxis per standard of care.
11018663|NCT04645654|Experimental|Hypnosis|3 sessions of script-based hypnosis (analgesic suggestions) + recordings provided for self-hypnosis
11018664|NCT04645654|No Intervention|Standard of care|Standard of care ERAS based optimized multimodal analgesia, without any complementary medicine
11018665|NCT04645641|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
11018666|NCT04645628|Experimental|All subjects will have an MRI examination|
11018667|NCT04645615|Experimental|CURE AF|
11018668|NCT04645602|Experimental|Lenvatinib + Pembrolizumab|"Participants will take:
~Lenvatinib - At a pre-determined dose, 1x daily during each 3 week study cycle up to 35 cycles/2 years
~Pembrolizumab - At a pre-determined dose, 1x on Day 1 of each 3 week study cycle up to 35 cycles/2 years
~Participants will be given a drug diary and asked to document information in the drug diary about the study treatment.
~Participants will be asked to check their blood pressure 3x every week and document in a supplied diary.
~Participants will be followed up to one (1) year after study treatment."
11018669|NCT04645589||Myfortic|Oral administration
11018670|NCT04645576|Other|Midface zone|Injection in the mid-facial areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
11018671|NCT04645576|Other|Temple|Injection in the temples (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
11018672|NCT04645576|Other|Jaw-line|Injection in the jaw-line areas (split-face). One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded).
11018673|NCT04645576|Experimental|Chin|The chin will only receive one injection of Art Filler Volume.
11018674|NCT04645563||Whatsapp Group|"This group includes 54 patients who have consulted via whatsapp. The ID physician will be consulted for all the subjects once laboratory results and CT reports were complete. All the consultations were performed with the same smartphone, and every Whatsapp consultation held since the very beginning of the pandemic was evaluated.
~In this type of consultation, Thorax CT images of the patient were turned into a video of approximately 30-35 seconds, and during this video recording, the patient's clinical condition and laboratory results were also transferred to the ID physician. The ID physician, on the other hand, will state his/her admission-discharge decision via Whatsapp as hospitalization or discharge. Eventually the consultation result will be recorded in the patient's folder. The moment the video was sent will be recorded as the beginning of the patient's consultation period and response time to whatsapp video will be saved as consultation response time."
11018675|NCT04645563||Bedside Consultation Group|"This group includes 90 patients who have consulted bedside. The patients that has problems which are concerning multiple consultation will be excluded.
~The ED physician wrote a consultation note over the hospital information system by specifying the patient's clinical status, history and laboratory parameters. A physician will be consulted for all the eligible subjects after their laboratory results and CT reports were complete. The ID physician examined the subjects at the bedside within 30 minutes (the legal response time in Turkey) of seeing the consultation request. Consultation response time will be saved as time between entering consultation information through the system to completion of the consultation note Although the consultant ID physicians will be informed via Whatsapp, they held the consultation at the bedside for the subjects they deemed appropriate."
11018676|NCT04645550|Experimental|Apixaban with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Apixaban 2.5mg bid for six months.
11018677|NCT04645550|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for six months irrespective of the occurrence of portal vein thrombus.
11018797|NCT04644692||Case group: patients with heart failure with preserved ejection fraction|
11018679|NCT04645537||FinACAF cohort|The study cohort consists of all patients with AF diagnosis (ICD-10 I48) living in Finland during 1.1.2004-31.12.2018. The study cohort is obtained from data of Finnish national registries. Patients with permanent residence in Finland less than 12 months prior to index date and patients with age below 18 years at index date are excluded from the study.
11018680|NCT04645524|Experimental|AD182|Oral capsule administered before bed
11018681|NCT04645524|Experimental|AD504|Oral capsule administered before bed
11018682|NCT04645524|Placebo Comparator|Placebo|Oral capsule administered before bed
11018683|NCT04645511|Experimental|Chronic sinusitis: Balloon sinuplasty|30 patients with chronic maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
11018684|NCT04645511|Sham Comparator|Chronic sinusitis: Placebo|30 patients with chronic maxillary sinusitis that are randomized to be treated with sham surgery.
11018685|NCT04645511|Experimental|Recurrent sinusitis: Balloon sinuplasty|30 patients with recurrent maxillary sinusitis that are randomized to be treated with the real Balloon sinuplasty procedure of maxillary sinuses.
11018686|NCT04645511|Sham Comparator|Recurrent sinusitis: Placebo|30 patients with recurrent maxillary sinusitis that are randomized to be treated with sham surgery.
11018687|NCT04645498||Metabolism, Inborn Errors|Patient affected by an inherited metabolic disease
11018688|NCT04645485|Experimental|Experimental arm|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
11018689|NCT04645472||CT-Ultrasound group|
11018690|NCT04645459|Experimental|low phosphorus meal group (LP group)|The proteins of the low phosphorus meal had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process.
11018691|NCT04645459|Placebo Comparator|control group|The boiling method did not process for the control meals.
11018692|NCT04645446|Experimental|Pro-ocular™ 1% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.7 mg of progesterone
11018693|NCT04645446|Experimental|Pro-ocular™ 0.5% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.35 mg of progesterone
11018694|NCT04645446|Placebo Comparator|Placebo topical gel|Multidose formulation identical in appearance to Experimental Products despensing unit doses of 0.07 g of topical gel containing 0 mg of progesterone
11018695|NCT04645433||Favipiravir therapy|Favipiravir was advised to all patients with severe pneumonia and progressing pneumonia findings or worsening clinical manifestations except pregnant, breast feeding, postpartum woman. PCR results were not waited to start favipiravir in this group of patients and continued if it would be negative but tomography findings were consistent with COVID-19. Loading dose was 1600 mg twice a day. Maintenance dose was 600 mg per 12 hours for four days.
11018696|NCT04645433||Lopinavir-ritonavir therapy|Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
11018697|NCT04645420|Experimental|Apremilast|"15 PsA patients with active disease and naïve to conventional synthetic and biologic disease modifying anti-rheumatic drugs.
~Treatment with apremilast orally in the whole group (n = 15). Escalating dose the first Week (10 mg once day1, 10 mg bid day2, 10 mg-20 mg day3, 20 mg bid day4, 20 mg-30 mg day5, 30 mg bid on day6), and 30 mg bid from day7 until week24."
11018698|NCT04645407|Experimental|FZHY Group|conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
11018699|NCT04645407|No Intervention|Control Group|conventional therapy
11018700|NCT04645394|Placebo Comparator|Placebo|The participants are receiving 1 dose of each in the stated order.
11018701|NCT04645394|Active Comparator|Fermented aronia high dose|The participants are receiving 1 dose of each in the stated order.
11018702|NCT04645394|Active Comparator|Fermented aronia low dose|The participants are receiving 1 dose of each in the stated order.
11018703|NCT04645394|Active Comparator|Aronia|The participants are receiving 1 dose of each in the stated order.
11018704|NCT04645381||Participants with RA|
11018705|NCT04645368||Longidaze|80 subjects Longidaze® (bovhyaluronidase azoxymer), lyophilisate for solution for injection
11018706|NCT04645368||Dynamic control|80 subjects Patients not receiving active therapy
11018707|NCT04645355|Experimental|New-onset guttate psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
11018708|NCT04645355|Experimental|Chronic plaque psoriasis|Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
11018709|NCT04645342|Experimental|Baylis Versacross RF wire|Device: Baylis Versacross radiofrequency wire
11018710|NCT04645342|Active Comparator|Baylis RF Needle|Device: conventional Baylis radiofrequency needle
11018711|NCT04645329|Experimental|group I (no immobilization)|patients will be allowed to freely use their arm without any immobilization after surgery
11018712|NCT04645329|Active Comparator|group II (3-week immobilization)|patients will be kept in an immobilization device for three weeks after surgery
11018713|NCT04645316|Active Comparator|Sevoflurane|Sevoflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
11018714|NCT04645316|Active Comparator|Desflurane|Desflurane will use for anesthesia maintenance for liver donor hepatectomy surgery
11018715|NCT04645316|Placebo Comparator|Total intravenous anesthesia|Total intravenous anesthesia (propofol/remifentanyl) will use for anesthesia maintenance for liver donor hepatectomy surgery
11036184|NCT04525794|Experimental|BRight DCB|
11018716|NCT04645303|Experimental|Hyaluronic acid|1mL of hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1-pulley.
11018717|NCT04645303|Active Comparator|Triamcinolone acetonide|1 mL of Triamcinolone acetonide 10mg/ml infiltration at A1-Pulley under ultrasound guidance after subcutaneous 2% lidocaine without epinephrine infiltration of the skin overlying the A1 pulley.
11018718|NCT04645290|Experimental|"Intervention group: Educational Intervention KARER"|General objective of the intervention: Implement self-care strategies and care actions aimed at people facing chronic diseases with disabilities, applying knowledge, ability and attitudes that allow them to act in a timely manner, reducing the risk of complications, improving well-being and the quality of life of the person cared for and of himself. Through face-to-face, virtual interdisciplinary educational actions (B-learning) and with simulation support.
11018719|NCT04645290|No Intervention|Usual Care|The people assigned to this group will receive their own responses from the institution providing care services to which they belong. These instructions consist of: information on the disease process and treatment received from the medical group, information on assistance by the nursing group and finally, the administrative procedures carried out by social work.
11018720|NCT04645277||Patients with MRI using two dimensional reconstruction|
11018721|NCT04645277||Patients with MRI using three dimensional reconstruction|
11018722|NCT04645264|Experimental|Indwelling Foley|Indwelling Foley placed during surgery
11018723|NCT04645264|Active Comparator|Straight Catheter|straight catheterization (in-and-out straight catheterization) will take place at the end of the surgery
11018724|NCT04645264|No Intervention|No Catheter|Patient is not catheterized
11018725|NCT04645238||Static Stretching|
11018726|NCT04645238||PNF Stretching|
11018727|NCT04645212||1|Subjects who received a dose of ADVM-022 in a prior clinical study.
11018728|NCT04645186||Calcium Phosphate Cement (CPC)|Evaluation of CPC in long bone & extremities
11018729|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
11018730|NCT04645173||Tyrx Envelope|Participants who received a Tyrx envelope during CIED implantation
11018731|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
11018732|NCT04645160|Experimental|1/ Phase I|Tivozanib, P.O. daily at 1.0 mg (given on Days 1-21 of every 28-day cycle) with intra-patient escalation to 1.5 mg daily (given on Days 1-21 of every 28-day cycle) and possible dose de-escalation to 1.0 mg every other day (without interruption for a 28-day cycle) if needed to determine RP2D
11018733|NCT04645160|Experimental|2/ Phase II|Tivozanib at the RP2D established in Phase I
11018734|NCT04645147|Experimental|EBV gp 350 Ferritin Vaccination|Adult participants with or without prior EBV infection will receive 3 doses of vaccine
11018735|NCT04645134||Inactive|Older adults who have a sedentary or under-active lifestyle.
11018736|NCT04645134||Highly Active|Older adults who have a highly active lifestyle.
11018737|NCT04645121||Hemodialysis group|Subjects receiving maintenance hemodialysis for at least three months
11018738|NCT04645121||Case group|Healthy subjects with eGFR above 60 ml/min/1.73m2
11018739|NCT04645108|Experimental|Coached|
11018740|NCT04645108|Active Comparator|No Coach|
11018741|NCT04645095|Active Comparator|Conventional TENS|Frequency:80 Hz, duration:100 μs
11018742|NCT04645095|Active Comparator|Burst TENS|Frequency:100 Hz, fr mod: 0, 200 µs, 2 Bps Hz
11018743|NCT04645095|Active Comparator|Modulated TENS|Frequency:80 Hz, fr mod: 50%, Amplitude mode: 40%, duration: 200 µs
11018744|NCT04645069|Experimental|ADG126 Dose Escalation Level 1|
11018745|NCT04645069|Experimental|ADG126 Dose Escalation Level 2|
11018746|NCT04645069|Experimental|ADG126 Dose Escalation Level 3|
11018747|NCT04645069|Experimental|ADG126 Dose Escalation Level 4|
11018748|NCT04645069|Experimental|ADG126 Dose Escalation Level 5|
11018749|NCT04645056|Experimental|Intervention group|"a. Intervention Group: Neck stretching and movement
~The patient starts the stretching exercises the morning after surgery with instructions from a trained professional at the department. The patient is informed that the stretching exercises will not affect the surgical wound. The patient is instructed in performing five repetitions of each of the following nine exercises three times each day in four weeks:
~Relax shoulders and neck sufficiently
~Look down - Stretching and movement
~Look to each side - movement
~Lower the head to each side - stretching
~Lower the head diagonally to each side - stretching
~Small nod movements
~Lift the shoulders - movement
~Roll the shoulders - movement
~Lift the arms - movement
~The first stretching session is observed by the instructor who gives feedback and correct the exercises, if necessary. Furthermore, the patient is given a training brochure."
11018750|NCT04645056|No Intervention|Control group|b. Control group The patients in the control group are not instructed in any intervention but are answering completely similar questionnaires as the intervention group.
11018751|NCT04645043|Experimental|US_Eso|US application on the participant
11018752|NCT04645030||Patients suspected of pneumonia|Patients suspected for pneumonia after initial evaluation by the treating physician.
11018753|NCT04645017|Experimental|Intergenerational Music Program|An intergenerational music program will be administered by adolescent musicians for older adults with early-stage cognitive decline.
11018754|NCT04645004|Other|Aspirin|81mg aspirin daily
11018755|NCT04644991|Active Comparator|Group 1|Experimental group consisting of transfemoral amputees who kinesiology tape will be applied
11018756|NCT04644991|Sham Comparator|Group 2|The placebo group of transfemoral amputees who shame kinesiology tape will be applied
11018757|NCT04644978||Trainees and specialists in child and adult psychiatry|"The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing I agree on the website, after reading the information leaflet and the informed consent form."
11018758|NCT04644965||Abdominal Wall Defect|patients born with an abdominal wall defect
11018759|NCT04644965||Control Group|age and sex matched Control Group
11018760|NCT04644952||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
11019081|NCT04642846|Experimental|one application of SDF|
11018764|NCT04644900|Active Comparator|the Mouthwash group|Patients in the mouthwash group received 15 ml of honeysuckle antibacterial mouthwash and vomited it out after 2 minutes
11018765|NCT04644900|Active Comparator|the gum group|patients in group gum chewed one piece of herbal sugar-free gum for 2 minutes and then spat it out.
11018766|NCT04644887|Experimental|Healthy diet CC genotype|The participants will follow the intervention diet during the 12-week intervention period.
11018767|NCT04644887|Active Comparator|Control diet CC genotype|The participants will follow the control diet during the 12-week intervention period.
11018768|NCT04644887|Experimental|Healthy diet GG genotype|The participants will follow the intervention diet during the 12-week intervention period.
11018769|NCT04644887|Active Comparator|Control diet GG genotype|The participants will follow the control diet during the 12-week intervention period.
11018770|NCT04644874||Older cancer patients|All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,
11018771|NCT04644861|Other|Elders aged 70|Program of adapted physical activity
11018772|NCT04644848|Experimental|Pre-sentinel node biopsy ultrasonographical tattooing|Preoperative ultrasonographical tattooing of the suspicious lymph nodes. Sentinel Lymph Node Biopsy (SLNB),
11018773|NCT04644835|Experimental|LESW group|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
11018774|NCT04644835|Sham Comparator|Control group|This group of patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
11018775|NCT04644822|Experimental|[18F]PSMA-1007 Injection|A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)
11018776|NCT04644809|Experimental|LY3561774 (Part A)|Single ascending doses of LY3561774 administered subcutaneously (SC).
11018777|NCT04644809|Experimental|LY3561774 (Part B)|Repeat doses of LY3561774 administered SC.
11018778|NCT04644809|Experimental|LY3561774 (Part C)|Single doses of LY3561774 administered SC in Japanese Participants.
11018779|NCT04644809|Placebo Comparator|Placebo (Part A, B & C)|Placebo administered SC.
11018780|NCT04644796|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
11018781|NCT04644796|Active Comparator|Liposomal bupivacaine|Patients in this group will be given the study drug (liposomal bupivacaine).
11018782|NCT04644783|Experimental|Blood test with assays|Ten patients with FPIES exhibiting reactions to 2-3 foods, and up to 10 exhibiting FPIES reactions to 4 or more foods will be recruited.
11018783|NCT04644770|Experimental|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
11018784|NCT04644770|Experimental|Part 2: Dose Expansion|Participants will receive intravenous (IV) injection of JNJ-69086420 at one of the RP2D(s) determined in Part 1.
11018785|NCT04644757|Experimental|Treatment|
11018786|NCT04644744|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of end-ischemic Hypothermic machine perfusion (HOPE) for a minimum of 2 hours (until hepatectomy)
11018787|NCT04644744|Experimental|Normothermic machine perfusion (NMP)|Application of end-ischemic normothermic machine perfusion (NMP) for a minimum of 4 hours (up to 24 hours)
11018788|NCT04644744|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
11018789|NCT04644718|Experimental|Anodal-tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with real tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
11018790|NCT04644718|Sham Comparator|sham tDCS with speech therapy|The participant will complete six consecutive weeks of SLT accompanied with sham tDCS. Each session starts with 20 minutes of tDCS followed by the SLT program.
11018791|NCT04644705|Active Comparator|Part A: verum niclosamide|"The SAD cohorts are planned as follows:
~Cohort A1: 200 mg (fasted conditions) Cohort A2: 600 mg (fasted conditions) Cohort A3: 1600 mg (fasted and fed conditions)"
11018792|NCT04644705|Placebo Comparator|Part A: placebo to niclosamide|"The SAD cohorts are planned as follows:
~Cohort A1: placebo to niclosamide 200 mg (fasted conditions) Cohort A2: placebo to niclosamide 600 mg (fasted conditions) Cohort A3: placebo to niclosamide 1600 mg (fasted and fed conditions)"
11018793|NCT04644705|Active Comparator|Part B: verum as solution (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
11018794|NCT04644705|Active Comparator|Part B: verum as chewing tablet (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
11018795|NCT04644705|Active Comparator|Part C: verum (niclosamide and camostat)|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
11018796|NCT04644705|Placebo Comparator|Part C: placebo to niclosamide and camostat|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
11018798|NCT04644692||Control Group:Never diagnosed with either preserved or altered ejection fraction heart failure.|Non dyspnoeic patients with no history of Heart failure.
11018799|NCT04644679|Active Comparator|48-hr|48-hr electrocardiographic monitoring
11018800|NCT04644679|Experimental|7-day|7-day electrocardiographic monitoring
11018801|NCT04644640|Active Comparator|Telerehabilitation|
11018802|NCT04644640|Active Comparator|In-Person Rehabilitation|
11018803|NCT04644627|Experimental|Single arm|Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.
11018804|NCT04644614|Active Comparator|Group 1: Magnetic Stimulation|Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.
11018805|NCT04644614|Sham Comparator|Group 2: Sham Magnetic Stimulation|"The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient.
~During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device."
11018806|NCT04644588||Children being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and hand function using postural zone software to assess scapular alignment and pediatric arm function test toassess upper limb function .
11018807|NCT04644575|Experimental|Arm A: Previously treated in BIVV001 study|This arm includes all participants who have completed the previous phase 3 studies on BIVV001, as well as participants who have completed Arm B or Arm C of this study rolling over in Arm A, and participants who will have completed any future BIVV001 study who will be proposed to continue BIVV001 treatment. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once-weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
11018808|NCT04644575|Experimental|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll into arm A.
11018809|NCT04644575|Experimental|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
11018810|NCT04644562|Experimental|patients undergoing Lower Limb vascular Surgery|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
11018811|NCT04644549||Subjects with CLN6 Batten disease|
11018812|NCT04644549||Subjects with juvenile CLN3 Batten disease|
11018813|NCT04644536||Granules in long bone & extremities|Filling of post-traumatic or surgically created bone defects
11018814|NCT04644536||Wedges in long bone & extremities|Osteotomies with fixation
11018815|NCT04644536||HA paste in long bone & extremities|Filling of post-traumatic or surgically created bone defects
11018816|NCT04644536||Granules in Spine|Spinal cage filling
11018817|NCT04644536||HA paste in Spine|Spinal cage filling
11018818|NCT04644510||Lung ultrasonography group|Patient which benefited from a Lung ultrasonography during the medical consultation
11018819|NCT04644497||Transphyseal drilling technique|
11018820|NCT04644497||Physeal sparing drilling technique|
11018821|NCT04644484|Experimental|Experimental Group: SYN023+Rabies Vaccine|"SYN023:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.
~Dosage form: 6mg/2mL, liquid, Dosage: 0.3 mg/kg of SYN023 Frequency/duration: at Day 1
~Rabies vaccine :
~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
11018822|NCT04644484|Active Comparator|Control Group: HRIG+Rabie Vaccine|"HRIG:Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible Dosage form: 100 IU/mL, liquid, Dosage: 20 IU/kg Frequency/duration: at Day 1
~Rabies vaccine :
~Interventions: should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use Dosage: 1 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29"
11018823|NCT04644445|No Intervention|Control|Standard bariatric clear liquid diet to be started 4 hours after surgery
11018824|NCT04644445|Experimental|Intervention|Bariatric full liquid diet (clear liquid diet + protein shakes) to be started 4 hours after surgery
11018825|NCT04644432|Experimental|A - for patients with a DNA mutation that match a targeted treatment|"Listed below are the possible study drugs and dosages:
~Erlotinib 150 mg once a day for 4 weeks.
~Osimertinib 80 mg once a day for 4 weeks.
~Alectinib 600 mg twice a day for 4 weeks
~Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks
~Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week
~Olaparib 400 mg twice a day for 4 weeks
~Pembrolizumab iv infusion 2 mg/kg every 3rd week
~Cabozantinib 60 mg once a day for 4 weeks
~Crizotinib 250 mg twice a day for 4 weeks
~Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week
~Imatinib 400 mg once a day for 4 weeks
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
11018885|NCT04644029|Experimental|ISL QM|ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil fumarate) once daily
11019082|NCT04642846|Experimental|two application of SDF one month apart|
11018826|NCT04644432|Experimental|B - for patients with an angiogen profile|"Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
11018827|NCT04644432|Experimental|C - for patients with an immune profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
11018828|NCT04644432|Experimental|D - for patients that have neither mutations nor an immune- or angiogen profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.
~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
11018829|NCT04644419|No Intervention|Control|Patients in the control arm will receive standard of care.
11018830|NCT04644419|Experimental|Palliative And supportive Care inTervention (ACT)|This ancillary study does not include intervention development component. The detail intervention can be found in the parent study protocol (NCT04570709).
11018831|NCT04644380|Experimental|Treatment Group|During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
11018832|NCT04644367|Experimental|Tai Chi group|The Tai Chi (TC) group will receive or be taught TC in a class size consisting of about 5-12 students. Classes will be taught by a TC master with more than 4 years of experience practicing either Yang or Wu style TC. The participants will be allowed to practice TC at home and during their leisure time so long as they keep an activity log of their daily TC practice. This monitoring form (i.e. activity log or journal) will be distributed to all members of this group and collected weekly.
11018833|NCT04644367|Active Comparator|Regular Physical Activity (control) group|The regular physical activity (control) group will be asked to maintain or engage in at least 60 minutes of regular physical activity. The participants will be instructed as to the type of regular PA that they may engage in. These types of PA include: walking, cleaning or performing chores inside the home, and/or climbing the stairs. No restriction will be made to limit others forms of physical activity; individuals in the control group will be permitted to engage in organized sports, instructor-led class such as boxing, dance, etc. to ensure the participant recruitment process is feasible. Similar to the TC group, participants in this group will be asked to complete an activity log (or journal) that will be collected weekly to monitor their regular PA levels.
11018834|NCT04644354||Group A - Advanced Preterm Labor (aPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions 4 or more in 20 minutes and cervical dilatation at 2 cm and above
11018835|NCT04644354||Group B - Threatened Preterm Labor (tPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions less then 4 in 20 minutes and cervical dilatation less then 2 cm
11018836|NCT04644341||COVID survivors|Individuals who were infected by CPVID-19 and recovered.
11018837|NCT04644328|Experimental|Intervention|Treatment: individuals receive up to 10 Facebook ads over a 2 week period. The ad contains a short video recorded by a physician using a script that discusses the importance of staying safe during Thanskgiving by considering not traveling and using a mask when appropriate.
11018838|NCT04644328|No Intervention|Control|There are no procedures
11018839|NCT04644315|Experimental|ALK-positive Solid Tumors|Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
11018840|NCT04644302||non-COVID sepsis|Patients admitted to ICU with sepsis of non-COVID origin
11018841|NCT04644302||COVID sepsis|Patients admitted to ICU with sepsis of COVID origin
11018842|NCT04644289|Other|cohort A - olaparib monotherapy|Olaparib tablets 2 × 300 mg per day for 3 weeks prior to surgery until one day prior to surgery or withdrawal of informed consent and as maintenance for 24 months after completion of primary therapy (chemotherapy).
11018843|NCT04644289|Other|cohort B - olaparib + durvalumab combination|Olaparib tablets 2 × 300mg per day for 4 weeks plus durvalumab 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle).
11018844|NCT04644276|Active Comparator|Mask with Mask Adhesive/Arm 1|Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
11018845|NCT04644276|Placebo Comparator|Mask without Mask Adhesive/Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.
11018846|NCT04644263||Validity and reliability|
11018847|NCT04644250|Experimental|Arm1|Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
11018848|NCT04644237|Experimental|Trastuzumab deruxtecan 6.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 6.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
11018849|NCT04644237|Experimental|Trastuzumab deruxtecan 5.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 5.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
11018850|NCT04644224|Experimental|Group I (coaching session, navigation session, support group)|Parents/caregivers whose churches are randomized to Group I, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
11018851|NCT04644224|Experimental|Group II (coaching session, navigation session, support group)|Families whose churches are randomized to Group II, attend monthly health coaching sessions over 1 hour each for 12 months, 9 resource navigation sessions over 12 months, and monthly support groups for 12 months.
11018852|NCT04644224|Active Comparator|Group III (educational handbook)|Families whose churches are randomized to Group III, receive an educational handbook on cancer prevention.
11018886|NCT04644029|Active Comparator|FTC/TDF QD|FTC/TDF (emtricitabine/tenofovir disoproxil fumarate) once daily AND placebo to ISL (islatravir) once monthly
11018930|NCT04643769|Placebo Comparator|Placebo - 100 mg|Placebo comparator for ORIN1001 at 100 mg
11036185|NCT04525781||1|
11018853|NCT04644211|Experimental|Ruxolitinib Stage 1|"In stage 1, participants will be divided into two cohorts:
~Very low, Low, and Intermediate-risk ETpatients with significant symptom burden and Low-risk PV patients with significant symptom burden
~Study cycles are 28 days long, participants in both cohorts will receive:
~Ruxolitinib 2x daily for 6 study cycles."
11018854|NCT04644211|Experimental|Ruxolitinib Stage 2|"Stage 2 will commence based on 3 or more participants in Stage 1 showing a predetermined positive response to Ruxolitinib.
~In stage 2, participants will be divided into two cohorts:
~Very low, Low, and Intermediate-risk ET patients with significant symptom burden and Low-risk PV patients with significant symptom burden
~Study cycles are 28 days long, participants in both cohorts will receive:
~Ruxolitinib 2x daily for 6 study cycles."
11018855|NCT04644198|Active Comparator|Convalescent Plasma Treatment|Convalescent Plasma
11018856|NCT04644198|No Intervention|Control|Standard of care
11018857|NCT04644185|Experimental|SCTA01 Low Dose+BSC|SCTA01in a lower dose+best supportive care
11018858|NCT04644185|Experimental|SCTA01 High Dose+BSC|SCTA01in a higher dose+best supportive care
11018859|NCT04644185|Active Comparator|Placebo+BSC|SCTA01 excipients+best supportive care
11018860|NCT04644172|Experimental|Immediate Treatment|The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
11018861|NCT04644172|Other|Delayed Treatment|Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.
11018862|NCT04644159||Housolds|Pupils, teachers and non-teaching staff who attended schools of the city during the 2019-2020 school year and members of their households
11018863|NCT04644159||Subjects hospitalized or residing in health care facilities|Residents and patients from retirement homes and long-term care units
11018864|NCT04644159||Staff of health care institutions|Staff of health care institutions
11018865|NCT04644146||SEVERE|Patients affected by SARS-CoV2 infection with severe lung dysfunction needing oxygen complementation and critical care supports - criteria 18-70yr old and without any comorbidities
11018866|NCT04644146||CONTROL|Patients affected by SARS-CoV2, as shown by PCR and/or antigen testing diagnosis and without any or minor clinical expression
11018867|NCT04644133||Healthy|Subjects without bowel issues will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
11018868|NCT04644133||Constipation|Subjects diagnosed with constipation will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
11018869|NCT04644133||Fecal Incontinence|Subjects diagnosed with fecal incontinence will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
11018870|NCT04644120|Experimental|Group 1: ABBV-47D11 Dose A|Participants will receive ABBV-47D11 Dose A on Day 1.
11018871|NCT04644120|Placebo Comparator|Group 1: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
11018872|NCT04644120|Experimental|Group 2: ABBV-47D11 Dose B|Participants will receive ABBV-47D11 Dose B on Day 1.
11018873|NCT04644120|Placebo Comparator|Group 2: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
11018874|NCT04644120|Experimental|Group 3: ABBV-47D11 Dose C|Participants will receive ABBV-47D11 Dose C on Day 1.
11018875|NCT04644120|Placebo Comparator|Group 3: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
11018876|NCT04644081|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of a total of 12 (social distancing) group training sessions (60-90 minutes) and will deliver two sessions on a weekly basis for six weeks.
11018877|NCT04644081|Active Comparator|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of counselling services).
11018878|NCT04644068|Experimental|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
11018879|NCT04644068|Experimental|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
11018880|NCT04644068|Experimental|Module 3: AZD5305 + Paclitaxel + Carboplatin|AZD5305 + Paclitaxel + Carboplatin
11018881|NCT04644055||Chronic liver disease with liver cirrhosis|Evaluation of the right and left hepatic lobe with EUS-guided share wave evaluation. All patients with chronic liver disease will have a transient elastography evaluation, EUS- elastography of the liver and an EUS-guided liver biopsy.
11018882|NCT04644055||Control patients|Patients without history of chronic liver disease after clinical and transient elastography evaluation will be submitted for EUS-guided share wave evaluation of the liver. Patients were originally undergoing EUS evaluation for evaluation of suspected subepithelial lesions.
11018883|NCT04644042|Experimental|Glenohumeral arthroscopy and arthroscopic subacromial decompression|
11018884|NCT04644042|Active Comparator|Glenohumeral arthroscopy and skin incision|
11042887|NCT04478955||normal|no make up
11018887|NCT04644016|Experimental|Participants with non-malignant and malignant hematologic disorders|Participants with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
11018888|NCT04644003|Experimental|STP1 Low Dose|1 capsule and 1 tablet per intake
11018889|NCT04644003|Experimental|STP1 High Dose|1 capsule and 1 tablet per intake
11018890|NCT04644003|Placebo Comparator|Placebo|1 placebo capsule and 1 placebo tablet per intake
11018891|NCT04643990||LDT Combined with TDF for Treatment|The patients take one tablet of LDTand one tablet of TDF every night and continue to 12 months.
11018892|NCT04643990||Only TAF treatment.|The patients take one tablet of TAF every night and continue to 12 months.
11018893|NCT04643977|Experimental|mesohyal ARGIBENONE|Name of the investigation medical device: mesohyal ARGIBENONE Code of the MD for the purpose of the clinical investigation: mARG-01-17 GMDN code: 59131 mARG-01-17 is a dermal filler recommended for cutaneous filling, facial wrinkle improvement and general condition of the skin, which is administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging.
11018894|NCT04643964|Experimental|Entrée: Cognitive Skills|
11018895|NCT04643964|Experimental|Entrée: Behavioral Skills|
11018896|NCT04643964|Experimental|Entrée: Interpersonal Skills|
11018897|NCT04643964|Experimental|Sampler Skills|
11018898|NCT04643964|No Intervention|Control|Participants are not given videos to watch until their involvement in the study ends.
11018899|NCT04643938||Two spontaneous abortions|No intervention
11018900|NCT04643938||three spontaneous abortions|No intervention
11018901|NCT04643938||Four or more spontaneous abortions|No intervention
11018902|NCT04643925|Experimental|hCG priming|"Control cycle: A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy.
~Study cycle: hCG priming by Ovitrelle 260 IE once daily for 8 weeks followed by a standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6 followed by a single blastocyst transfer at day 5."
11018903|NCT04643912|Experimental|Injured wrist or ankle|"Child with trauma needing wrist or ankle x-ray:
~Will receive vibration analysis blinded to x-ray findings."
11018904|NCT04643899|No Intervention|Control group|Patients benefiting only from the usual nutritional rehabilitation program G1a: diabetic patients G1b: non-diabetic patients
11018905|NCT04643899|Experimental|Electrostimulation group|Patients benefiting from the usual program AND muscle electrostimulation sessions G2a: diabetic patients G2b: non-diabetic patients
11018906|NCT04643886|Experimental|Cohort with Genetic Profile A|"Subjects will have Genetic Profile A.
~Intervention: Biological: GEM103."
11018907|NCT04643886|Experimental|Cohort with Genetic Profile B|"Subjects will have Genetic Profile B.
~Intervention: Biological: GEM103"
11018908|NCT04643873|Experimental|Experimental group 1|physical activity counseiling +pilates exercise group
11018909|NCT04643873|Experimental|Experimental group 2|only physical activity counseiling group
11018910|NCT04643873|No Intervention|Control Group|only followed by family physician
11018911|NCT04643860||General population|Subjects, at low and high risk of SARS-Cov-2, who undergo the nasopharyngeal swab procedure for the diagnosis of SARS-CoV-2 infection will be consecutively recruited at the Clinic Laboratory of IRCCS Neuromed in Pozzilli and Diagnostica Medica Spa in Avellino, Italy.
11018912|NCT04643847|Experimental|Stereotactic radiosurgery with Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
11018913|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.05mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.05mcg/kg iv q 12h, for 10 days, starting within 6h of birth
11018914|NCT04643821|Experimental|NAC 25mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 25mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
11018915|NCT04643821|Experimental|NAC 40mg/kg, calcitriol 0.03mcg/kg|N-acetylcysteine 40mg/kg iv q 12h, calcitriol 0.03mcg/kg iv q 24h, for 10 days, starting within 6h of birth
11018916|NCT04643808|Experimental|taVNS once daily|taVNS paired with bottle feeding once daily for 2-3 weeks
11018917|NCT04643808|Experimental|taVNS twice daily|taVNS paired with bottle feeding twice daily for 2-3 weeks
11018918|NCT04643795|Experimental|40 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
11018919|NCT04643795|Experimental|60 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
11018920|NCT04643795|Experimental|80 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
11018921|NCT04643795|Experimental|100 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
11018922|NCT04643782|Active Comparator|ANNE + HST|"Subjects will wear the ANNE One and HST for 1 night.
~This will serve to determine the diagnosis of moderate or severe OSA by determining a patient's Apnea-Hypopnea Index (AHI) using the ANNE One system against the Home Sleep Apnea Test (HST) over 1 night worn concomitantly"
11018923|NCT04643782|Active Comparator|ANNE + PSG|"Subjects will wear the ANNE One during an attended PSG study for 1 night.
~This will server to determine the diagnosis of moderate or severe OSA by determining a patient's Apnea-Hypopnea Index (AHI) using the ANNE One system against the Polysomnography (PSG) over 1 night worn concomitantly"
11018924|NCT04643782|Experimental|ANNE Only|"Subjects will wear the ANNE One only at home for 3 nights.
~This will serve for evaluation of AHI over multiple nights with the ANNETM One alone"
11018925|NCT04643769|Experimental|25 mg ORIN1001 (Active)|25 mg ORIN1001
11018926|NCT04643769|Experimental|50 mg ORIN1001 (active)|50 mg ORIN1001
11018927|NCT04643769|Experimental|100 mg ORIN1001 (active)|100 mg ORIN1001
11018928|NCT04643769|Placebo Comparator|Placebo - 25 mg|Placebo comparator for ORIN1001 at 25 mg
11018929|NCT04643769|Placebo Comparator|Placebo - 50 mg|Placebo comparator for ORIN1001 at 50 mg
11018931|NCT04643756|Active Comparator|Conventional Physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound. Procedure/Device: Conventional Physiotherapy Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm2 and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
11018932|NCT04643756|Active Comparator|Conventional Physiotherapy + Kinesiotaping|Kinesiotaping application in addition to classical electrotherapy method consisting of tens, hotpack and ultrasound.It will be applied to reduce pain, increase proprioception and awareness. Kinesiotaping will be re-applicated every day. Space taping will be applied to the waist area. Space taping creates a vacuum effect on the skin, loosening the adhesions in the tissue layers. With this lifting effect, it creates a space under the skin, causing an increase in circulation and a decrease in pain. Four pieces of I-tape will be used for taping. The middle point of the first tape will be attached with maximum tension. The ends of the tape will be tensionless. The second tape will also be applied at a 90 degree angle. The third and fourth tapes will be taped at an angle of 45 degrees.
11018933|NCT04643743||Subjects who did receive POLYPATCH® for vascular angioplasty|Subjects who did receive POLYPATCH® at least one year ago for vascular angioplasty. 2 main sub-populations will be studied depending on location of surgery (carotid and femoral) but data will be collected for all subjects who did receive POLYPATCH.
11018934|NCT04643730|Experimental|Reflexology Group|Foot Reflexology was applied to the babies before heel lancing
11018935|NCT04643730|Experimental|Acupressure Group|Acupressure was applied to the babies before heel lancing
11018936|NCT04643730|Active Comparator|Control Group|No pre-application was made to the babies in the control group as a routine procedure
11018937|NCT04643717||intensive care patients|
11018938|NCT04643704||FPIES|100 patients
11018939|NCT04643704||IgE mediated food allergy|100 patients
11018940|NCT04643704||Celiac disease|100 patients
11018941|NCT04643704||Control group|100 patients
11018942|NCT04643691|Experimental|losartan / spironolactone|Losartan 50 mg and Spironolactone 25 mg pillules oral use
11018943|NCT04643691|No Intervention|usual care|Usual care of COVID-19 infection in intensive care
11018944|NCT04643678|Active Comparator|Anakinra Group|Anakinra + Standard of Care
11018945|NCT04643678|Other|Standard of Care Group|Standard of Care Alone
11018946|NCT04643665||No grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
11018947|NCT04643665||Grade 3 Pulmonary graft dysfunction at postoperative day 3|patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
11018948|NCT04643652|No Intervention|Control|Usual Care
11018949|NCT04643652|Experimental|Intervention|Implementation of a Noise Reduction Bundle
11018950|NCT04643639|Experimental|Active|
11018951|NCT04643639|No Intervention|Control|
11018952|NCT04643626|Experimental|IG|artificial intelligence dietary application, iDSA, will be introduced and installed. Explanation on the function and application of iDSA will be given. Daily energy and macro-nutrients requirement target will bed set. The daily energy and macronutrients requirement target is secured by password. Subjects will record their daily dietary intake (food with cooking method and portion size) and nutrition impact symptoms via smartphone application at least 3 times a week. Subjects able to keep track their intake at home. During follow up session, subjects show the iDSA diet intake summary records to Researcher for further assessment.
11018953|NCT04643626|No Intervention|CG|CG will receive conventional dietitian care includes nutrition care process using conventional 24 hours diet recall method for dietary assessment
11018954|NCT04643613|Experimental|PCNF|Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks (84 days).
11018955|NCT04643600|Active Comparator|Smokers|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients who are smokers will have recorded : the age of onset of smoking, the year of smoking experience and the average number of cigarettes smoked per day. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
11018956|NCT04643600|Active Comparator|Non - smokers|All patients will be maesured: body weight, height, BMI (body mass index), waist circumference, pulse (cp), saturation (SpO2), blood pressure, respiratory index and thoracic spine mobility index measured. All patients will do a 6-minute walk test and test on a bicycle erogometer. The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
11018957|NCT04643587|Experimental|CSL787 (SAD dose 1)|Inhalation by mouth of a nebulized aerosol in healthy subjects
11018958|NCT04643587|Experimental|CSL787 (SAD dose 2)|Inhalation by mouth of a nebulized aerosol in healthy subjects
11018959|NCT04643587|Experimental|CSL787 (SAD dose 3)|Inhalation by mouth of a nebulized aerosol in healthy subjects
11018960|NCT04643587|Experimental|CSL787 (SAD dose 4)|Inhalation by mouth of a nebulized aerosol in healthy subjects
11018961|NCT04643587|Experimental|CSL787 (MAD dose 1)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
11018962|NCT04643587|Experimental|CSL787 (MAD dose 2)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
11018963|NCT04643587|Experimental|CSL787 (MAD dose 3)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
11018964|NCT04643587|Placebo Comparator|Placebo|Inhalation by mouth of a nebulized aerosol
11019083|NCT04642820|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
11018965|NCT04643574|Experimental|NeoTIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (fludarabine and cyclophosphamide), Low Dose Irradiation (LDI), ex vivo expanded Tumor Infiltrating Lymphocyte (TIL), enriched for tumor antigen specificity (NeoTIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
11018966|NCT04643561|Experimental|intervention|5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention
11018967|NCT04643522||Before COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed before the diagnosis of COVID-19.
11018968|NCT04643522||After COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed after the diagnosis of COVID-19.
11018969|NCT04643509||cardiac surgery|patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery
11018970|NCT04643496||Patients requiring ileocolic resection for Crohn disease.|All consecutive patients requiring an ileocolic resection for Crohn disease, between January 2010 and March 2020 at the Digestive Surgery Units of CHU Montpellier.
11018971|NCT04643483|Experimental|Certolizumab pegol low dose arm|"Participants randomized to certolizumab pegol (CZP) who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 100 mg CZP subcutaneously (sc) every 2 weeks (Q2W).
~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by placebo and a maintenance dose of 200 mg CZP sc Q2W."
11018972|NCT04643483|Experimental|Certolizumab pegol high dose arm|"Participants randomized to CZP who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 200 mg CZP sc Q2W.
~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 300 mg CZP sc Q2W."
11018973|NCT04643483|Active Comparator|Adalimumab reference arm|"Participants randomized to adalimumab who weigh ≥17 kg to <40 kg will receive a loading dose of 80 mg at Week 0 and 40 mg at Week 2, followed by a maintenance dose of 20 mg sc Q2W.
~Participants randomized to Adalimumab who weigh ≥40 kg will receive a loading dose of 160 mg at Week 0 and 80 mg at Week 2, 40 mg and placebo at week 4 followed by a maintenance dose of 40 mg sc and placebo Q2W."
11018974|NCT04643470|Experimental|Zanubrutinib Low Dose|Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks
11018975|NCT04643470|Experimental|Zanubrutinib High Dose|Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks
11018976|NCT04643470|Experimental|Zanubrutinib Medium Dose|Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks
11018977|NCT04643470|Experimental|Placebo|Participants will receive placebo to match zanubrutinib for 72 weeks
11018978|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018979|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018980|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 3|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018981|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 4|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018982|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 5|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018983|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018984|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018985|NCT04643457|Placebo Comparator|Part A: Intravenous Placebo arm|Subjects randomized to this arm will receive Placebo to maintain the blinding.
11018986|NCT04643457|Placebo Comparator|Part A: Subcutaneous Placebo arm|Subjects randomized to this arm will receive Placebo to maintain the blinding.
11018987|NCT04643457|Experimental|Part B: Intravenous UCB9741 arm|Subjects randomized to this arm will receive a pre-specified single dose of UCB9741.
11018988|NCT04643457|Placebo Comparator|Part B: Intravenous Placebo arm|Subjects randomized to this arm will receive Placebo to maintain the blinding.
11018989|NCT04643418|Experimental|MPB-1734, single arm, dose escalation|intravenous, once per 3 weeks, starting at 10 mg/m˄2
11018990|NCT04643405|Experimental|APG1387 in combination with Gemcitabine and Nab-Paclitaxel|
11018991|NCT04643392||Patients with Lipedema|Participants who were diagnosed with upper extremity lipedema by a lymphologist.
11018992|NCT04643379|Experimental|Olaparib + Pembrolizumab + Carboplatin AUC|"-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows:
~Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles.
~Pembrolizumab 200 mg intravenous (IV) Day 1.
~Carboplatin AUC 5 IV on Day 1 for up to six cycles."
11018993|NCT04643366|Experimental|Concurrent Chemotherapy/ Radiation Therapy|5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) four 14-day cycles will be given before CRT starts. Pelvic Intensity-modulated radiation therapy (IMRT): 25 Gy in 5 fractions over 5 days + Continuous infusion 5-fluorouracil (5-FU) for 4 days (96 hours) followed by four 14-day cycles of (mFOLFOX6) to be given after CRT ends.
11018994|NCT04643353|Experimental|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.
~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia)with SMOOTH mode setting, which enables non-ablative, thermal-only operation). The parameters are selected based on extensive preclinical and clinical studies.
~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
11018995|NCT04643353|Active Comparator|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
11018996|NCT04643340||active group 1|This group will train the insular cortex by real-time fMRI
11018997|NCT04643340||active group 2|This group will train the visual cortex by real-time fMRI
11018998|NCT04643340||sham|This group will only train the insula by a particular strategy
11018999|NCT04643327|Experimental|Active arm|125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days
11019000|NCT04643327|Placebo Comparator|Placebo arm|125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days
11019001|NCT04643314|Experimental|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:
~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
11019002|NCT04643314|No Intervention|Traditional intraoperative teaching|"Subjects randomized to this group will undergo their usual residency training.
~The recordings of the 5 submitted consecutive laparoscopic cholecystectomy procedures performed by the participant as the primary operator will be stored. However participants in this arm of the study will not have access to the uploaded videos until the end of the study."
11019003|NCT04643301|Experimental|Adding Liraglutide to current treatment program|Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
11019004|NCT04643288|Experimental|OFD control group|open flap debridement for periodontal intrabony defects
11019005|NCT04643288|Experimental|n-HA bone graft intervention group|Nanocrystalline Hydroxyapatite (n-HA) bone graft substitute was added to periodontal intrabony defects
11019006|NCT04643275|Experimental|Non-invasive lipolysis of the upper arms|The treatment administration phase consists of four (4) treatment visits, delivered 5- 10 - days apart. Each therapy session will last 30 minutes. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
11019007|NCT04643262||Intraoperative morbidity and mortality|Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
11019008|NCT04643262||peri-operative morbidity and mortality (<30 days)|Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
11019009|NCT04643262||Post-operative morbidity and mortality (>30 days)|Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
11019010|NCT04643249|Experimental|Active|Daily treatment
11019011|NCT04643236|Experimental|periodontal health educational group (test)|25 subjects diagnosed with gingivitis received periodontal health education session
11019012|NCT04643236|Active Comparator|oral hygiene motivation group (control)|25 subjects diagnosed with gingivitis received standard oral hygiene motivation session
11019013|NCT04643223|Active Comparator|Kinesio tape with tension|The intervention group will receive the elastic bandage - kinesio tape with tension between seventy to ninety percent on the selected hypertrophic scar. The application of kinesio tape follows a protocol, which involves the cleaning of the selected scar with liquid soap, drying, alcohol application for sebum removal, scar measurement and marking of the therapeutic zone and anchors. Following the application of the kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the Vancouver assessments and collections of scarring material for the histopathology will be carried out, in the time intervals corresponding to the beginning of the study intervention / entry (time 0), 45 days and 90 days after being eligible, to agree to participate in the study study and intervention.
11019014|NCT04643223|Sham Comparator|Kinesio tape without tension|The controlled sham group will receive the application of kinesio tape without tension will follow the same protocol above, including the three moments of evaluation, beginning of the intervention (time 0), 45 days and 90 days, after the beginning of the intervention.
11019015|NCT04643210|Experimental|F2F MoB EI and access to MoB Digital Platform (MoB DP) group|"The design of the face-to-face Management of my Bipolarity educational intervention (F2F MoB EI) will rely on the Colom & Vieta model, Cognitive- Behavioural techniques and the results of the relevant literature review and data acquired in the qualitative research of bipolar disease patients' educational needs. A textbook will be devised explaining in detail the step-by-step process and the techniques of the experimental educational method of the MoB F2F EI.
~This group will also receive the technology-based intervetion, which regards access to the MoB DP. This is an ecosystem where the participants will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile."
11019016|NCT04643210|Active Comparator|The MoB DP group|This group will receive the technology-based intervention, which regards access to the MoB DP. The structure of the MoB DP has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
11019017|NCT04643197|Experimental|Experimental arm|Abdominal fascia will be closed with barbed suture.
11019018|NCT04643197|Active Comparator|Control|Abdominal fascia will be closed with non-barbed suture.
11019087|NCT04642781||healthy children aged 8-13years (schoolgrade 2-5)|Primary school children are asked to read a German text presented on a laptop screen
11019019|NCT04643184|Experimental|Management Program|Comanagement program (cardiological-geriatric) to carry out during hospitalization a comprehensive evaluation that allows to know the medical and socio-environmental needs of the patients to plan the required care at home and achieve an effective transition.
11019020|NCT04643184|No Intervention|Usual Care|Usual care during hospitalizacion and discharge.
11019021|NCT04643171|Experimental|Exercised group|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
11019022|NCT04643171|Active Comparator|group of electroacupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6, 5 times per week, for 12 week
11019023|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 1|Randomised participants will receive oral inhalation of AZD1402 Dose 1 via DPI.
11019024|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 2|Randomised participants will receive oral inhalation of AZD1402 Dose 2 via DPI.
11019025|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 3|Randomised participants will receive oral inhalation of AZD1402 Dose 3 via DPI.
11019026|NCT04643158|Placebo Comparator|Part 1 and Part 2: Placebo to AZD1402 Dose 1, Dose 2, and Dose 3|Randomised participants will receive oral inhalation of matching placebo via DPI.
11019027|NCT04643145|Active Comparator|Ureteral catheter|This group will receive ureteral catheter for 2 days after the procedure
11019028|NCT04643145|Active Comparator|Indwelling double J stent|This group will receive indwelling double J stent for 2-4 weeks after the procedure
11019029|NCT04643132|Placebo Comparator|Normal saline in male patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
11019030|NCT04643132|Placebo Comparator|Normal saline in female patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
11019031|NCT04643132|Active Comparator|S-ketamine in male patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
11019032|NCT04643132|Active Comparator|S-ketamine in female patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
11019033|NCT04643119|Active Comparator|Cruciate-Retaining Insert|
11019034|NCT04643119|Experimental|Medial-Congruent Insert|
11019035|NCT04643106|Experimental|Hemostatic agent group|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.
11019036|NCT04643106|Active Comparator|Suturing group|During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.
11019037|NCT04643093|Active Comparator|Pitavastatin|Pitavastatin
11019038|NCT04643093|Active Comparator|Ezetimibe|Ezetimibe
11019039|NCT04643093|Experimental|1PC111|1PC111
11019040|NCT04643080|No Intervention|Control|Subjects were asked to avoid consuming fermented foods for 12 weeks.
11019041|NCT04643080|Experimental|Yogurt|Subjects were asked to consume 6 oz. of yogurt daily for 12 weeks.
11019042|NCT04643067|Active Comparator|0.15mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
11019043|NCT04643067|Active Comparator|0.6mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
11019044|NCT04643067|Active Comparator|2mg KPG-818 dose|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
11019045|NCT04643067|Placebo Comparator|Placebo arm|After providing informed consent, patients will be assessed for study eligibility at the Screening visit. A total of 8 patients will be randomized to receive this dose level of KPG-818 in a double-blind fashion. Patients will receive treatment for 12 weeks with a 4-week safety follow-up. Capsules of this level of dosage will be taken orally in the morning once a day. All patients will return for follow-up visits after their final dose. The total duration of study participation for each patient (from Screening through Follow-up visit) is anticipated to be approximately 20 weeks.
11019046|NCT04643054|Experimental|Ovotransferrin|Dietary Supplement: Ovotransferrin
11019047|NCT04643054|No Intervention|Standard of care|Standard of care
11019048|NCT04643041|Experimental|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3W) therapy and start watch and wait.
11019049|NCT04643028|Other|Home exercise|The exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
11019050|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
11019051|NCT04643028|Other|Cervical stabilization|In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
11019052|NCT04643015||Study Participants|Patients of any age, including males and females, who are being treated in the Department of Pediatrics and are already scheduled to undergo MRI
11019053|NCT04643002|Active Comparator|Arm A (control): isatuximab +pomalidomide +dexamethasone|"Isatuximab dose, intravenous (IV) weekly (QW) × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
~Pomalidomide dose os (PO) daily Day 1 to Day 21.
~Dexamethasone dose PO QW."
11019054|NCT04643002|Experimental|Arm B (experimental): isatuximab + SAR439459 (antiTGFβ) + dexamethasone)|"SAR439459 dose, IV Q2W.
~Isatuximab dose, IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
~Dexamethasone fixed dose and schedule: QW PO"
11019055|NCT04642989|Sham Comparator|Healthy Control + Sham Treatment|Healthy participants who received the sham treatment
11019056|NCT04642989|Active Comparator|Healthy Control + Facial Effleurage|Healthy participants who received the Facial Effleurage treatment
11019057|NCT04642989|Active Comparator|Acute Rhinosinusitis + Antibiotics|Sick participants who received the recommended antibiotics
11019058|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment|Sick participants who received the sham treatment
11019059|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage|Sick participants who received the Facial Effleurage treatment
11019060|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment + Antibiotics|Sick participants who received the recommended antibiotics and the sham treatment
11019061|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage + Antibiotics|Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
11019062|NCT04642976||Atrial fibrillation ablation|All patients undergoing ablation with undergo pre-procedural CT as well as HFS mapping and ablation of GPs.
11019063|NCT04642963|Experimental|Cardiac Radiosurgery|Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.
11019064|NCT04642950|Experimental|NPC-26|Sargramostim (125 μg) will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
11019065|NCT04642950|Placebo Comparator|NP-26 Placebo|Physiological saline will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
11019066|NCT04642937|Experimental|hP1A8|Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
11019067|NCT04642924|Experimental|Locally Advanced Rectal Cancer|Patients included with locally advanced rectal cancer SGM-101 10mg, 3-5 days prior to surgery
11019068|NCT04642924|Experimental|Recurrent rectal cancer|Patients included with (locally) recurrent rectal cancer SGM-101 10mg, 3-5 days prior to surgery
11019069|NCT04642898|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
11019070|NCT04642898|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
11019071|NCT04642898|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
11019072|NCT04642898|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
11019073|NCT04642898|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
11019074|NCT04642898|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
11019075|NCT04642885||dyad|parent with dementia and an adult child who is a caregiver
11019076|NCT04642872|Experimental|infant cimt|
11019077|NCT04642872|Active Comparator|Infant BIT|
11019078|NCT04642872|Active Comparator|Infant CIMT/BIT|
11019079|NCT04642872|Active Comparator|Conventional Therapy|
11019080|NCT04642859|Experimental|Dyslexia|Students with dyslexia before and after the intervention
11019084|NCT04642820|Experimental|MethamphetamineThen Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
11019085|NCT04642807|Active Comparator|"Group 1 Long-arm full cast and routine follow-up"|Patients assigned to Group 1 will be placed in a long arm cast, at 90-100 degrees in neutral rotation. A referral will then be made to the orthopedic department and the patient reviewed at week 3 with cast removal, clinical assessment and radiographic assessment as determined by the normal practice at the local center.
11019086|NCT04642807|Experimental|"Group 2 Long-arm soft cast and no clinical or radiographic follow-up"|"Patients assigned to group 2 will be placed in a long arm cast at 90-100 degrees in neutral rotation. They will be given verbal and written information on the injury, when and how to remove the cast and contact details if there are any concerns.
~Since they will not be attending clinical follow-up, an email or telephone survey will be undertaken at 3 weeks and after 6 months. The survey will inquire initially about pain, unplanned returns to the Family Physician and hospital, complications, parent/patient satisfaction and a standardized patient reported outcome score will be taken. Please see attached documentation for the itemized survey questions. The 6 month follow-up will include photographs and an illustrated guide will be given to the families on how to obtain pictures of maximal flexion, extension and the child's carrying angle (attached). Measurements of range of motion from photographs are considered comparable to clinical assessment of range of motion"
11019088|NCT04642768|Experimental|3-Hydroxybutyrate treatment|KetoneAid Ketone Ester 0,5g/kg (max. 50g) bolus
11019089|NCT04642768|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
11019090|NCT04642755||Group 1|LTBI+ and severe to moderate malnutrition
11019091|NCT04642755||Group 2|LTBI+ and uncontrolled DM
11019092|NCT04642755||Group 3|LTBI+ and helminth infection
11019093|NCT04642755||Group 4|LTBI+ with more than one of the above conditions (severe to moderate malnutrition, DM, helminth infection)
11019094|NCT04642755||Group 5|"Healthy LTBI+ controls who are negative for all of the above conditions (severe to moderate malnutrition, DM, helminth infection)"
11019095|NCT04642755||Group 6|Healthy LTBI negative controls with none of the above conditions (severe to moderate malnutrition, DM, helminth infection).
11019096|NCT04642742||Plant sterol chewable|
11019097|NCT04642729|Other|ReLex Smile surgery|The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
11019098|NCT04642729|Other|fresh corneal lenticule implantation|Using VisuMax Femtosecond Laser we make intrastromal pocket incision 2-3 mm in periphery of cornea (Because the macular dystrophy is in the center more progressive) and 150 µm deep to put fresh corneal lenticule. After one month using VisuMax we create a flap using autologous serum with purpose to remove more dead keratocytes and adding live keratocytes with aim to regenerate the metabolism of cornea.
11019099|NCT04642716|Other|Salivary free amino acids profile observation|Saliva samples of periodontitis patients and healthy controls were collected. The AA analysis of the saliva was performed by LC-MS/MS by using the Thermo Scientific TSQ Quantum Access MAX (Thermo Scientific, Schaumburg, IL, USA) .
11019100|NCT04642703||COVID-19 ventilated patients subjected to tracheostomy|Patients who receive percutaneous or surgical tracheostomy due to prolonged mechanical ventilation. The indication is made by an experts team and based on national guidelines
11019101|NCT04642703||COVID-19 ventilated patients without tracheostomy|Patients supported with mechanical ventilation by 10 days or more in who an experts team of physicians decided do not perform a tracheostomy
11019102|NCT04642690||Group 1-NSE|Patients found to have grossly normal squamous epithelium during endoscopy
11019103|NCT04642690||Group 2-EEG|Patients found to have grossly apparent erosive esophagitis >1cm with Los Angeles Classification A-D
11019104|NCT04642690||Group 3-NDBE Short|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Short Segment)
11019105|NCT04642690||Group 4-NDBE Long|Patients with non-dysplastic Barrett's Esophagus (NDBE) > 1cm (Long Segment)
11019106|NCT04642690||Group 5|Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
11019107|NCT04642690||Group 6-Esophagectomy|Patients undergoing resection of esophageal cancer
11019108|NCT04642690||Group -7 Pilot and Feasibility|Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques
11019109|NCT04642677|Experimental|Group A|"Patients and caregivers were received palliative sedation with healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock)."
11019110|NCT04642677|No Intervention|Group B|Patients and caregivers were received palliative sedation without intervention.
11019111|NCT04642664|Experimental|Apatinib plus Camrelizumab|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.
~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
11019112|NCT04642651|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
11019113|NCT04642651|Placebo Comparator|Control group|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
11019114|NCT04642638|Experimental|Phase 2: INO-4800 Dose Group 1|Participants will receive one intradermal (ID) injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
11019115|NCT04642638|Experimental|Phase 2: INO-4800 Dose Group 2|Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
11019116|NCT04642638|Placebo Comparator|Phase 2: Placebo Dose Group 1|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
11019117|NCT04642638|Placebo Comparator|Phase 2: Placebo Dose Group 2|Participants will receive two ID injections of placebo followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
11019118|NCT04642638|Experimental|Phase 3: INO-4800 Optimum Dose Group|Participants will receive either one or two 1.0 mg ID injections of INO-4800 based on results from Phase 2 segment, followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
11019119|NCT04642638|Placebo Comparator|Phase 3: Placebo Optimum Dose Group|Participants will receive either one or two ID injections of placebo based on results from Phase 2 segment, followed by EP using the CELLECTRA® 2000 device on Day 0 and Day 28.
11019120|NCT04642625||wound infiltration analgesia|25 patients who underwent wound infiltration analgesia
11019121|NCT04642625||ultrasound-guided bilateral erector spina plan block analgesia|25 patients who underwent ultrasound-guided bilateral erector spina plan block analgesia
11019122|NCT04642625||wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia both together|25 patients who underwent wound infiltration and ultrasound-guided bilateral erector spina plan block analgesia
11019123|NCT04642612||Treatment Arm|Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.
11019124|NCT04642599|Experimental|Chronic Cerebellar Stroke|Participants with a chronic cerebellar stroke
11019406|NCT04640831|Experimental|GH001 dose C|
11019125|NCT04642599|Active Comparator|Healthy Individuals (Controls)|healthy participants
11019126|NCT04642586|Experimental|Hypertensive participants|diagnosed HTA within 5 years, treated or confirmed by Ambulatory Blood Pressure Measure;
11019127|NCT04642586|Experimental|Normotensive participants|absence of HTA confirmed by Ambulatory Blood Pressure Measure
11019128|NCT04642560||child hospitalized|Any child hospitalized in pediatric or neonatal resuscitation and benefiting from the establishment of antibiotic treatment for an episode of suspected bacterial infection, community or nosocomial
11019129|NCT04642547|Experimental|Combination therapy with Lenvatinib and Gefitinib|First week: Gefitinib 125mg/day, Lenvatinib 8mg/day if body weight ≤ 60Kg and 12mg/day if body weight > 60Kg. If the patient is well tolerated, the dose of Gefitinib will be adjusted to 250 mg/day after one week, and the dose of Lenvatinib will remain the same (8mg/day for weight ≤ 60Kg and 12mg/day for weight > 60Kg). Route of administration: Oral.
11019130|NCT04642534||Postpartum women who had gestational diabetes mellitus|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
11019131|NCT04642534||Postpartum women after an uneventful pregnancy|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
11019132|NCT04642521||Iron deficiency anaemia|Preoperatively, participants who are iron deficient with or without anaemia will receive intravenous iron (Monofer) as per ProPBM protocol.
11019133|NCT04642521||No iron deficiency anaemia|Patient in this group will not be given intravenous iron.
11019134|NCT04642508|Other|Prepectoral Reconstruction|Women with breast cancer or with high risk for breast cancer in whom a sparing mastectomy and prepectoral reconstruction was performed
11019135|NCT04642495||Human subjects aged 4 and above|Human volunteers aged 4 and above.
11019136|NCT04642482|Experimental|Synbiotic|"A fine powder to be taken orally consists of
~Viable cell 1,0 x 10^9 Colony Forming Unit of :
~Lactobacillus plantarum 8,55 mg
~Streptococcus thermophilus 8,55 mg
~Bifidobacterium bifidum 2,55 mg
~Fructooligosaccharide 480 mg
~Additional components : isomalt, xylitol"
11019137|NCT04642482|Active Comparator|Placebo|A powder of 5 gram maltodextrin is given as active comparator, taken orally.
11019138|NCT04642469|Experimental|Durvalumab|Intravenous administration of Durvalumab
11019139|NCT04642469|Placebo Comparator|Placebo|Intravenous administration of placebo
11019140|NCT04642456|Other|Control group|"Healthy subjects or volunteers
~Intervention:
~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis EOS stereoradiographic full body exam"
11019141|NCT04642456|Other|ASD group|"Patient group with ASD
~Intervention:
~Balance Assesment Scale Trunk strength measurement with EMG MRI spine/pelvis 2 EOS stereoradiographic full body exam Balance Assesment Scale 2 Trunk strength measurement with EMG 2"
11019142|NCT04642443|Active Comparator|Intracranial Hemorrhage|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:
~A molded plastic headpiece containing the antenna array
~An intermediate control unit that contains:
~a. The driving electronics for the array of antennae
~A processing control unit that contains:
~A spectrum analyzer
~The operating software that controls the device function and data acquisition, processing and archiving.
~The user interface for inputting patient information and displaying the output of the data"
11019143|NCT04642443|Active Comparator|Traumatic Brain Injury|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts:
~A molded plastic headpiece containing the antenna array
~An intermediate control unit that contains:
~a. The driving electronics for the array of antennae
~A processing control unit that contains:
~A spectrum analyzer
~The operating software that controls the device function and data acquisition, processing and archiving.
~The user interface for inputting patient information and displaying the output of the data"
11019144|NCT04642430|Active Comparator|Apixaban group|"5 mg PO, twice daily for 12 months of treatment. A dose reduction* to 2.5 mg twice daily will apply if patients meet 2 of 3 following criteria: age > 80 years; weight < 60 kg; creatinine >133 micromol/L.
~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
11019145|NCT04642430|Active Comparator|Rivaroxaban Group|"20 mg PO, once daily for 12 months of treatment. A dose reduction* to 15 mg daily will apply to patients with creatinine clearance <50 ml/min.
~*Patients with AF who are receiving DOAC should have their renal function assessed at baseline and at least annually"
11019146|NCT04642417|Experimental|Experimental|intervention give experience dietary fiber literacy
11019147|NCT04642417|No Intervention|No Intervention|give standard education
11019148|NCT04642404|Experimental|Epidiolex 10mg/kg single dose|After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
11019149|NCT04642404|Experimental|Epidiolex 20mg/kg single dose|The 20mg/kg dose is the maximum recommended daily dose from the manufacturer. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
11019214|NCT04642001|Experimental|Group G4|Photon Laser III-DMC (with irradiation emission) + Sensodyne® Rápido Alívio/GSK
11019337|NCT04641260|Experimental|Fezolinetant: Fed State then Fasted State|Participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 2.
11048708|NCT04438096|Experimental|300 mg|
11019150|NCT04642404|Placebo Comparator|Placebo group|Placebo drug will be a solution with the same taste, texture and color as the drug. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
11019151|NCT04642391||RAI|Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol <9mcg/dL.
11019152|NCT04642391||Non-RAI|Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol >= 9mcg/dL.
11019153|NCT04642378|Experimental|iNCDSS group|Artificial intelligence assisted insulin titration system group
11019154|NCT04642378|Active Comparator|Routine treatment group|Physician decided insulin titration group
11019155|NCT04642365|Experimental|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
11019156|NCT04642365|Experimental|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
11019157|NCT04642365|Experimental|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
11019158|NCT04642352||SLN intervention group|Participants will undergo a superior laryngeal nerve (SLN) block
11019159|NCT04642339|Experimental|Vaccine Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2 infection
11019160|NCT04642339|Placebo Comparator|Placebo|Placebo
11019161|NCT04642326|Experimental|Test Group: experimental - UVC Therapy applied|Test: Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy
11019162|NCT04642326|No Intervention|Control Group|Control: Antiviral + Antimalarial + Antibiotic Treatment
11019163|NCT04642313|Placebo Comparator|PLACEBO group|Placebo treatment: starch tablets (250 mg)
11019164|NCT04642313|Experimental|Magnesium group|Magnesium group: Magnesium gluconate (250 mg)
11019165|NCT04642313|Experimental|Potassium group|Potassium group: Potassium chloride (250 mg)
11019166|NCT04642313|Experimental|Magnesium + Potassium group|Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
11019167|NCT04642300|Active Comparator|Holmich Protocol|Treatment will be administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions
11019168|NCT04642300|Active Comparator|Myofascial Release Technique|Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.
11019169|NCT04642287|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
11019170|NCT04642287|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
11019171|NCT04642274|Experimental|ERAS|
11019172|NCT04642274|No Intervention|Control|
11019173|NCT04642261|Experimental|Empagliflozin group|Empagliflozin 10mg daily for 52 weeks
11019174|NCT04642261|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks
11019175|NCT04642248|Active Comparator|Non-intervention|This group will have the analysis and their data will be used to determine risk factors for developing running injuries.
11019176|NCT04642248|Experimental|Intervention|This group will get a personalized program based off of 3D and movement analysis results to judge the ability to reduce musculoskeletal injuries.
11019177|NCT04642235|Experimental|Nature Nook|Nature Nook builds on our prior work with a standard vacant lot greening intervention involving: removing trash, grading the land, planting new grass and trees, installing a low wooden perimeter fence, and regular maintenance. This greening intervention was designed as a blight removal strategy. People in this arm receive no intervention.
11019178|NCT04642235|Experimental|Nature Coach|The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
11019179|NCT04642235|Experimental|Nature Nook + Nature Coach|This is a combined arm: a place-based intervention (Nature Nook) and a person-based intervention (Nature Coach).
11019180|NCT04642235|No Intervention|Control|The study lots randomly selected for this arm, as well as the participants living near them, receive no intervention.
11019181|NCT04642222|Experimental|APOLO-Teens Intervention Group (APOLO-Teens group)|In addition to the Treatment As Usual for pediatric obesity offered in Portuguese public hospitals, participants in this group receive the APOLO-Teens web-based intervention. It comprises three key components: 1) a manualized psychoeducational intervention implemented via Facebook® private groups, including cognitive-behavioral therapy strategies; 2) A weekly self-monitoring system (the APOLO-Teens web application) with automatic feedback messages assessing hours of physical activity, sedentary time, and consumption of fruits and vegetables; and 3) Monthly chat sessions.
11019365|NCT04641156|Experimental|Exercise group|Subjects in this group received additional planned exercise therapy program
11019407|NCT04640831|Experimental|GH001 dose D|
11019182|NCT04642222|Active Comparator|Treatment As Usual (TAU) Control Group (TAU control group)|Treatment As Usual control group receives the standard intervention for pediatric obesity offered in Portuguese public hospitals. It comprises pediatric or/and nutritional appointments, usually a 30-minute appointment every 3 months. These appointments usually include a physical examination (weight, height) and personalized dietary/lifestyle recommendations. The Treatment As Usual intervention is common to the APOLO-Teens group and TAU control groups.
11019183|NCT04642209||Aggregometry|surgical timing will be guided by the results obtained by aggregometry
11019184|NCT04642157|Experimental|ELIOS group|In addition to receiving the same generic mental health resources as in the control group, the participants of the ELIOS arm will benefit from the intervention of the ELIOS team.
11019185|NCT04642157|Other|control group|Participants of the control arm will receive generic professional help contacts.
11019186|NCT04642144|Experimental|Yerba mate and carbohydrate|Consumption of yerba mate infusion and carbohydrate-based meal.
11019187|NCT04642144|Active Comparator|Yerba mate and fasting|Consumption of yerba mate infusion and stay in a fasting state.
11019188|NCT04642144|Active Comparator|Carbohydrate and water|Carbohydrate meal consumption and water intake.
11019189|NCT04642131|Experimental|Personalized insoles|Personalized insoles without supplementation
11019190|NCT04642131|Experimental|Caffeine supplementation|Standard insoles with caffeine supplementation (3mg/kg)
11019191|NCT04642131|Placebo Comparator|Control condition|Standard insoles without supplementation
11019192|NCT04642118|Experimental|Pulmonary recruitment maneuver 30 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.
~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 30 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
11019193|NCT04642118|Active Comparator|Pulmonary recruitment maneuver 40 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.
~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 40 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
11019194|NCT04642118|No Intervention|Control|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.
~The patients in this group will not be received any positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist."
11019195|NCT04642105|Experimental|Hospital-based study|The investigators will select 15 patients with refractory focal epilepsy who are admitted to the videoEEG room for longterm videoEEG recording as part of a presurgical evaluation. The Sensor-Dot and Plug 'n Patch recordings will be compared with the gold-standard videoEEG recordings.
11019196|NCT04642105|Experimental|Home-based study|The investigators will select 30 patients with refractory focal epilepsy, 15 patients with refractory idiopathic generalized epilepsy and 15 patients with frequent tonic-clonic seizures, i.e. a group at increased risk for sudden unexpected death in epilepsy (SUDEP).
11019197|NCT04642092|Experimental|PsicAP protocol|The treatment of the experimental group will be according to the PsicAP protocol: seven sessions of a psychological treatment based on transdiagnostic approaches, collaborative interventions, group-sessions, and evidence-based psychological techniques derived from cognitive behavioral therapy.
11019198|NCT04642092|Active Comparator|Conventional treatment|The control group will have seven sessions based on the typical psychological services that currently are offered in the Dominican Primary Care Units.
11019199|NCT04642079|Experimental|Cohort 1: =>15 through 23 months of age|20vPnC
11019200|NCT04642079|Experimental|Cohort 2: 2 through 4 years of age|20vPnC
11019201|NCT04642079|Experimental|Cohort 3: 5 through 9 years of age|20vPnC
11019202|NCT04642079|Experimental|Cohort 4: 10 through 17 years of age|20vPnC
11019203|NCT04642066|Experimental|Active Group|Healthy volunteers were followed during the 5-month CWI exposition under standard conditions (three times per week 7-10 min). Neoprene equipment was not allowed; volunteers with followed weight or muscle mass changes over 5% were excluded
11019204|NCT04642066|Sham Comparator|Sham control|Control without CWI exposition
11019205|NCT04642053|Experimental|Immediate Treatment|Participants in the Immediate Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin between 1-3 weeks following the diagnostic evaluation.
11019206|NCT04642053|Experimental|Delayed Treatment|The Delayed Treatment Group serves as a control during the period in which participants are waiting to begin treatment. A delayed treatment onset is employed to control for maturation effects. Participants in the Delayed Treatment Group will receive DTTC Treatment four times per week (45-minute sessions each) for 8 weeks. Total duration will be 180 minutes/week over 32 sessions. Treatment will begin after an 8-week delay following the diagnostic evaluation.
11019207|NCT04642040|Experimental|Pulmonary Rehabilitation|Patients are included in a personalized pulmonary telerehabilitation program consisting of patient education, respiratory and peripheral muscle training, and breathing strategies for 4 weeks. In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive instructional exercise videos for these 3 days.
11019208|NCT04642027|Active Comparator|Conventional|Conventional sEBRT
11019209|NCT04642027|Experimental|Hypofractionation|Hypofractionated sEBRT
11019210|NCT04642014|Experimental|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
11019211|NCT04642001|Other|Group G1|Photon Laser III-DMC (without radiation emission) + My First- Colgate
11019212|NCT04642001|Experimental|Group G2|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rápido Alívio/GSK
11019213|NCT04642001|Experimental|Group G3|Photon Laser III-DMC (with irradiation emission) + My First- Colgate
11019215|NCT04641975|Experimental|Mirabegron Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily pediatric equivalent dose (PED) low dose of IP (Investigational Product) orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
11019216|NCT04641975|Placebo Comparator|Placebo Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
11019217|NCT04641975|Experimental|Mirabegron Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
11019218|NCT04641975|Placebo Comparator|Placebo Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
11019219|NCT04641962|Experimental|Phase 2: low dose ASP0367|Participants will receive ASP0367 once daily in the morning for 2 weeks.
11019220|NCT04641962|Experimental|Phase 2: high dose ASP0367|Participants will receive ASP0367 once daily in the morning for 2 weeks.
11019221|NCT04641962|Placebo Comparator|Phase 2: Placebo|Participants will receive placebo once daily in the morning for 2 weeks.
11019222|NCT04641962|Experimental|Phase 3: ASP0367|Participants will receive ASP0367 once daily in the morning for up to 52 weeks.
11019223|NCT04641962|Placebo Comparator|Phase 3: Placebo|Participants will receive placebo once daily in the morning for up to 52 weeks.
11019224|NCT04641962|Experimental|Open Label Extension: ASP0367|Participants will receive ASP0367 once daily in the morning for 24 weeks.
11019225|NCT04641949|Active Comparator|Methoxyflurane|Inhalation methoxyflurane 99,9%, 3 ml, single dose. Intravenous NaCl 9 mg/ml, XX ml, single dose.
11019226|NCT04641949|Active Comparator|Fentanyl|Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.
11019227|NCT04641949|Placebo Comparator|Placebo|Intravenous NaCl 9 mg/ml, XX ml, single dose. Inhalation NaCl 9 mg/ml, 3 ml, single dose.
11019228|NCT04641936||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
11019229|NCT04641936||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
11019230|NCT04641923|Experimental|Seprafilm|Antiadhesion barrier applied
11019231|NCT04641923|No Intervention|No seprafilm|No barrier applied
11019232|NCT04641897|Other|Sequence A|Sequence A: Low RR for 12 hours - High RR for 12 hours
11019233|NCT04641897|Other|Sequence B|Sequence B: High RR for 12 hours - Low RR for 12 hours.
11019234|NCT04641871|Experimental|Sym021+Sym022 [ARM A]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
11019235|NCT04641871|Experimental|Sym021+Sym023 [ARM B]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
11019236|NCT04641858|Active Comparator|BCG-Denmark|Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the right upper deltoid muscle. Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
11019237|NCT04641858|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color and appearance as the resuspended BCG vaccine.
11019238|NCT04641845|Experimental|Heel height increases|All participants consecutively walked with four heel height conditions (0 millimeter, 3 millimeter, 5 millimeter and 8 millimeter). The order of the heel height conditions was randomized.
11019239|NCT04641832|Experimental|Chronic cannabis use and subconcussive head impacts|"Group: Chronic cannabis users Criteria: self-reported chronic THC use (average use once per week but not dependent). Urine cannabis test must show positive.
~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
11019240|NCT04641832|Active Comparator|Non-cannabis use and subconcussive head impacts|"Group: Non cannabis users Criteria: self-reported none THC use. Urine cannabis test must show negative.
~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
11019366|NCT04641143|Active Comparator|Troriluzole|Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.
11019241|NCT04641819|Experimental|Yangzheng Compound Mixture plus conventional treatment|"Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least.
~Conventional treatment:
~Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.
~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
11019242|NCT04641819|Other|conventional treatment only|"Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.
~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
11019243|NCT04641806||Lymphoma cases|Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. Past history of B-cell NHL in remission, active surveillance or during first-line or second-line treatment Affiliated with a social security, consenting to the study
11019244|NCT04641806||Controls|"Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. No past history of lymphoma .
~Affiliated with a social security, consenting to the study"
11019245|NCT04641793|Experimental|SCI|
11019246|NCT04641793|Experimental|STROKE|
11019247|NCT04641793|Experimental|UNIMPAIRED|
11019248|NCT04641780||Rexulti Tablets|Target is 300 patients in the Philippines diagnosed with Schizophrenia and Major Depressive Disorder
11019249|NCT04641767||BIOTRABIS>18 - Pathologic patients|Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.
11019250|NCT04641767||BIOTRABIS>18 - Control patients|Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
11019251|NCT04641767||BIOTRABIS<18 - Pathologic patients|Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).
11019252|NCT04641767||BIOTRABIS<18 - Control patients|Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms
11019253|NCT04641754|Experimental|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 21-days cycle.
11019254|NCT04641741||Control|Healthy adults
11019255|NCT04641741||Severe eosinophilic asthma|Severe uncontrolled asthma according to ERS/ATS criteria and persistent eosinophilia in blood (>300 cells/μL)
11019256|NCT04641728|Experimental|pembrolizumab plus olaparib|Until RECIST-based confirmation of progressive disease (PD), death, manifestation of intolerable toxicity, or participant withdrawal from the study, study participants will continue intravenous infusion of pembrolizumab 200 mg every three weeks (Q3W) in combination with oral olaparib 300 mg twice daily (BID) (combination therapy)
11019257|NCT04641702|Experimental|Pharmacologic challenge|Measurement of esophageal response to edrophonium and atropine using functional lumen imaging probe (FLIP)
11019258|NCT04641689|Active Comparator|Desk Only|Participants will receive a height-adjustable desk to use in their home work environment.
11019259|NCT04641689|Active Comparator|Program Only|Participants will receive 12 weeks of online content to support reductions in sedentary behavior while working from home. Content will be based on social cognitive theory.
11019260|NCT04641689|Experimental|Desk + Program|Participants will receive a height-adjustable desk to use in their home work environment AND 12 weeks of online content to support reductions in sedentary behavior while working from home.
11019261|NCT04641689|No Intervention|Waitlist Control|Participants will receive the intervention (desk + program) after all follow-up data have been collected.
11019262|NCT04641676|Other|Foundation medicine NGS in parallel with local NGS|The patient will have in parallel FMI NGS test and Local reimbursed NGS test.
11019263|NCT04641676|Other|Foundation Medicine NGS|The patient will have only FMI NGS test.
11019264|NCT04641676|Experimental|LB Foundation Medicine NGS test|The patient do not have enough biopsy material or have tumor not accessible for a biopsy will have a liquid biopsy Foundation Medicine test.
11019265|NCT04641663|Experimental|100 RDD|100% of recommended daily dose (RDD) of the MORNING tablet dose (5 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
11019266|NCT04641663|Experimental|80 RDD|80% of recommended daily dose of the MORNING tablet dose (4 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
11019267|NCT04641663|Experimental|60 RDD|60% of recommended daily dose of the MORNING tablet dose (3 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
11019268|NCT04641637|Other|Selective catheterization of segmental or more peripheral arteries in TACE|From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders.
11019269|NCT04641624||Premature ovarian insufficiency (POI)|"POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotrophins and low estradiol.
~The study population will be consisted of 45 women with POI as study group."
11019270|NCT04641624||Control group|45 patients with normal healthy women as control group.
11019271|NCT04641611|Active Comparator|Cavoatrial cannulation|Cannulation of the atrium with 2-stage venous cannula.
11019272|NCT04641611|Experimental|Bicaval cannulation, slush|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. Slush is placed on the right atrium and right ventricle.
~This technique is not routinely used in CABG operations."
11019408|NCT04640831|Experimental|GH001 Individualized Dosing|
11019273|NCT04641611|Experimental|Bicaval cannulation|"Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures.
~This technique is not routinely used in CABG operations."
11019274|NCT04641598|Experimental|Endometrial scratch|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The cervix will be grasped with a single tooth tenaculum and an endometrial biopsy pipelle inserted into the uterine cavity to the depth of the uterine fundus. Suction will be applied and the pipelle will be completely withdrawn in a single pass. All instruments will be removed from the vagina after hemostasis is ensured.
11019275|NCT04641598|Sham Comparator|Sham procedure|A speculum will be inserted into the vagina and the cervix cleansed with betadine (or alternative if allergy). The motions of grasping the cervix with a single tooth tenaculum and inserting the biopsy pipelle will be simulated, but not actually performed. All instruments will then be removed from the vagina.
11019276|NCT04641585|Experimental|Patients affected by Brugada Syndrome 1|Patients with spontaneous or drug-induced Brugada Syndrome 1
11019277|NCT04641585|Active Comparator|Controls|Patients with no condition associated with spontaneous or drug-induced Brugada Syndrome 1
11019278|NCT04641572|No Intervention|Supine position|group A ( control ) will follow the hospital routine positions either supine or lateral during labor
11019279|NCT04641572|Experimental|Upright position|Group B (intervention) will follow the Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions. Then the researcher will register the time ( minutes/hours) that will be taken and which will be more preferable by the participant.
11019280|NCT04641559|Experimental|Personalized nutrition group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue during four months.
11019281|NCT04641559|Experimental|Personalized Plan group|Intervention group that will receive personalized nutrition advice through the ALDI's catalogue and behavioural change program during four months.
11019282|NCT04641559|Placebo Comparator|Control group|General recommendations but not personalization nor behavioural change advice will be implemented during four months.
11019283|NCT04641546|Experimental|Occupation-Based Intervention + Therapeutic Exercise Intervention Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of 30 minutes therapeutic exercise followed by 30 minutes of occupation-based intervention.
11019284|NCT04641546|Experimental|Therapeutic Exercise Control Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of therapeutic exercise only.
11019285|NCT04641533|Experimental|L-PRF + DPSC|Mandibular third molars were extracted and DPSC with L-PRF placed into the socket.
11019286|NCT04641533|Active Comparator|L-PRF|Mandibular third molars were extracted and L-PRF placed into the socket
11019287|NCT04641507|Active Comparator|Tamsulosin treated group|83 patient with lower ureteric stone will take tamsulosin 0.4 mg once daily .Therapy will be given for a maximum of 4 weeks.
11019288|NCT04641507|Active Comparator|Tadalafil treated group|83 patients with lower ureteric stone will take tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
11019289|NCT04641494|Placebo Comparator|Placebo|28 subject received 2 capsules 3times a day for 12 weeks Each capsule contain 1gm (High Oleic Acid Safflower oils)
11019290|NCT04641494|Active Comparator|CLA group|Participants received 2 capsules3 times a day for 12 weeks Each capsule is 1 gm and it provided 0.75 gm CLA in a 50:50 mixture
11019291|NCT04641481|Experimental|Study vaccine|BBV152B (6µg-Algel-IMDG)
11019292|NCT04641481|Placebo Comparator|Placebo|Phosphate buffered saline with Alum (without antigen)
11019293|NCT04641468|Other|Mediana 010 or 001 left main bifurcation lesion|DCB alone combined with retracted DES implantation if necessary (d-p-d strategy)
11019294|NCT04641455|Experimental|A mucolytic solution|mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy
11019295|NCT04641455|Active Comparator|B mucolytic solution|mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy
11019296|NCT04641455|Placebo Comparator|C Water|100 ml of water 20-30 minutes prior to upper endoscopy
11019297|NCT04641455|No Intervention|D No intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
11019298|NCT04641442|Experimental|MAS825|Experimental drug
11019299|NCT04641442|Placebo Comparator|Placebo|Placebo comparator
11019300|NCT04641429|Experimental|Qigong|Participants in the experimental group receive Qigong exercise training.
11019301|NCT04641429|Active Comparator|stretching|Participants in the control group receive stretching exercise training.
11019302|NCT04641416||Noninvasive pump monitoring|All patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.
11019303|NCT04641403|No Intervention|Group 1 (Standard IV analgesia group (SA), n=40):|In this group, the block will be administered with normal saline (NS) and all port sites will be infiltrated with NS.
11019304|NCT04641403|Active Comparator|Group 2 (Local analgesia group (LA), n=40):|In this group, the block wiil be administered with NS and local anesthetic will be administered to the port sites.
11019305|NCT04641403|Experimental|Group 3 (two qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, right sided two-quadrant block will be performed using bupivacaine.
11019306|NCT04641403|Experimental|roup 4 (Four qudrant-Laparoscopic-assisted transversus abdominis plane block (LTAP) group, n=40)|After the infiltration of all ports sites with NS, bilateral four-quadrant block will be performed using bupivacaine.
11019307|NCT04641390||Casos|altered vaginal microbiome resistant to drug treatment
11019308|NCT04641390||Controles|Altered vaginal microbiome not resistant to drug treatment
11019367|NCT04641143|Placebo Comparator|Placebo|Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.
11019409|NCT04640818||CLAD-GROUP|Patients with cladribine therapy
11019309|NCT04641390||semen donors|The semen donors included in the present work will be men between 18 and 35 years old who are included in the donation program of Instituto Bernabeu after having passed a series of physical, psychological, analytical, genetic and serological evaluations and are considered suitable for donation as established by Royal Decree-Law 9/2014. Likewise, donors are subjected to a series of seminal quality evaluations and seminal freeze-thaw tests in order to guarantee their fertile potential. In this way, the donors who are part of the Instituto Bernabeu donation program also comply with current legal regulations with a strict evaluation to be considered the gold standard of potentially fertile semen. In addition, it will be necessary for them to provide a signed informed consent accepting their participation in the study.
11019310|NCT04641377|Experimental|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
11019311|NCT04641377|Active Comparator|Health education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
11019312|NCT04641364|Placebo Comparator|Control: placebo|Subjects received 0.9% sodium chloride injection.
11019313|NCT04641364|Active Comparator|Control: Human Serum Albumin(HSA)|Subjects received Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
11019314|NCT04641364|Experimental|Experimental:recombinant human albumin|Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study. For the multiple dose study, subjects received recombinant Human Serum Albumin, 10 g for each day, three days for a cycle, and totally three cycles.
11019315|NCT04641351|Experimental|corticosteroid|"Triamcinolone extended release (32 mg) administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.
~Knee injury and Osteoarthritis Outcome Score (KOOS) pain at 6 and 12 months
~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months
~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months
~3D bone shape from MRI Osteoarthritis Knee Score (MOAKS) using statistical shape modeling at 3 and 12 months
~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
11019316|NCT04641351|Placebo Comparator|Placebo|"Normal saline of 5 mL administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.
~KOOS pain at 6 and 12 months
~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months
~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months
~3D bone shape from MRI using statistical shape modeling at 3 and 12 months
~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
11019317|NCT04641338|Experimental|Intervention group|
11019318|NCT04641338|Active Comparator|Control group|
11019319|NCT04641325|Experimental|Exercise Intervention Group|Group of 10 randomized patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
11019320|NCT04641325|Other|Current Care Group|Group of 10 randomized patients will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening), however will not receive the exercise intervention until the second phase of the study. CCG will serve as the control for the first phase.
11019321|NCT04641312|Experimental|LY3457263 - Part A|Escalating single doses of LY3457263 administered subcutaneously (SC) to healthy participants
11019322|NCT04641312|Placebo Comparator|Placebo - Part A|Placebo administered SC to healthy participants
11019323|NCT04641312|Experimental|LY3457263 - Part B|Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
11019324|NCT04641312|Placebo Comparator|Placebo - Part B|Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
11019325|NCT04641299|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection.
11019326|NCT04641299|Experimental|AZD8233 high dose|AZD8233 high dose for subcutaneous injection.
11019327|NCT04641299|Experimental|AZD8233 medium dose|AZD8233 medium dose for subcutaneous injection.
11019328|NCT04641299|Experimental|AZD8233 low dose|AZD8233 low does for subcutaneous injection.
11019329|NCT04641286||Stroke|Individuals admitted to the Hyper Acute Stroke Unit.
11019330|NCT04641273|Experimental|Part A: BAY1817080 150 mg BID|In Part A, Participants will be randomized to this arm with BAY1817080 150 mg BID.
11019331|NCT04641273|Placebo Comparator|Part A: Placebo BID|In Part A, Participants will be randomized to this arm with placebo for BAY1817080.
11019332|NCT04641273|Experimental|Part B: BAY1817080 25 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 25 mg BID and placebo for pregabalin.
11019333|NCT04641273|Experimental|Part B: BAY1817080 75 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 75 mg BID and placebo for pregabalin.
11019334|NCT04641273|Experimental|Part B: BAY1817080 150 mg BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with BAY1817080 150 mg BID and placebo for pregabalin.
11019335|NCT04641273|Placebo Comparator|Part B: Placebo BID|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and placebo for pregabalin.
11019336|NCT04641273|Active Comparator|Part B: Pregabalin|In Part B, New participants will be screened for this part of the study and will be randomized to this arm with placebo for BAY1817080 and pregabalin.
11019404|NCT04640831|Experimental|GH001 dose A|
11019338|NCT04641260|Experimental|Fezolinetant: Fasted State then Fed State|Participants will receive a single oral dose of fezolinetant in fasted state on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant in fed state on day 1 of study period 2.
11019339|NCT04641247|Experimental|Participants receiving niraparib|Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
11019340|NCT04641234||Cohort 1|Adult Belgian patients diagnosed with neovascular age-related macular degeneration (nAMD) with treatment-naïve study eye.
11019341|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
11019342|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
11019343|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
11019344|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
11019345|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
11019346|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
11019347|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
11019348|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
11019349|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
11019350|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
11019351|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
11019352|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
11019353|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
11019354|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
11019355|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
11019356|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
11019357|NCT04641195|Placebo Comparator|Placebo- Placebo|Participants in the PLACEBO-PLACEBO group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
11019358|NCT04641195|Experimental|Vitamin D- Placebo|Participants in the VITAMIN D-PLACEBO group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and daily placebo zinc supplements.
11019359|NCT04641195|Experimental|Placebo-Zinc|Participants in the PLACEBO-ZINC group will receive a placebo vitamin D bolus at the hospital followed by placebo daily vitamin D maintenance doses and actual daily zinc supplements.
11019360|NCT04641195|Experimental|Vitamin D- Zinc|Participants in the VITAMIN D-ZINC group will receive an actual vitamin D bolus at the hospital followed by actual daily vitamin D maintenance doses and actual daily zinc supplements.
11019361|NCT04641182||Prone position|Prone position per institutional protocol and as indicated by the treating physician
11019362|NCT04641182||No prone position|The control group will not be in prone position
11019363|NCT04641169|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations
~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
11019364|NCT04641156|Experimental|Low level LASER Therapy|Subjects in this group received low-level laser therapy
11019405|NCT04640831|Experimental|GH001 dose B|
11019368|NCT04641130|Experimental|Exposure to birch pollen|"Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.
~The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.
~If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).
~Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.
~A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures."
11019369|NCT04641117|Experimental|Exercise|Six months of power training
11019370|NCT04641104|Experimental|Thiamine|Patients in this arm will receive a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9%.
11019371|NCT04641104|Placebo Comparator|Placebo|Patients in this arm will receive a solution of 100 ml of NaCl 0.9% alone.
11019372|NCT04641091||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)
~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
11019373|NCT04641091||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients or one leg in healthy volunteers (total 1 site)
~physical assessment: Color-Coded Duplex Sonography / treadmill examination to determine actual walking distance / Ankle-Brachial Index / defined walking distance of 150 meters under medical supervision"
11019374|NCT04641078|Experimental|Arm A|SBRT + 6 months of darolutamide (600 mg b.i.d.)
11019375|NCT04641078|Other|Arm B|SBRT only
11019376|NCT04641065|Experimental|Music Intervention Group|The music intervention group will be listened to Traditional Turkish Military music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
11019377|NCT04641065|No Intervention|No Intervention Group|The control group patients will receive standard care only
11019378|NCT04641052|Experimental|Music Intervention Group|The music intervention group will be listened to the music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
11019379|NCT04641052|No Intervention|No Intervention Group|The control group patients will receive standard care only
11019380|NCT04641039|Active Comparator|Anterior annulus removal|In these patients the anterior portion of the annulus fibrosus will be removed when inserting a complete lumbar disc prosthesis
11019381|NCT04641039|Active Comparator|Anterior annulus replacement|In these group of patients the anterior portion of the annulus fibrosus will be opened up in to flaps hinged lateraly and replaced once the complete lumbar disc prosthesis is inserted
11019382|NCT04641026|Active Comparator|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
11019383|NCT04641026|Active Comparator|Deuterium oxide-labeled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
11019384|NCT04641026|Placebo Comparator|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
11019385|NCT04641026|Placebo Comparator|Deuterium oxide-labeled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
11019386|NCT04641013||People with HIV over the age of 55 years|
11019387|NCT04641013||People without HIV over the age of 55 years|
11019388|NCT04640987|Experimental|Experimental: Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. The participant's cells will then be manipulated via a T-allo10 cell addback. Participants will be followed for outcomes for two years.
11019389|NCT04640974|Experimental|Cingal|
11019390|NCT04640961|Experimental|Cingal|
11019391|NCT04640948|Experimental|High flow nasal therapy (HFNT)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
11019392|NCT04640948|Active Comparator|Low flow oxygen (LFO)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
11019393|NCT04640922|Active Comparator|Gedea Pessary|pHyph, vaginal tablet, daily in Part 1 and once weekly in Part 2
11019394|NCT04640922|Placebo Comparator|Placebo|placebo, vaginal tablet, daily in Part 1 and once weekly in Part 2
11019395|NCT04640909|Other|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
11019396|NCT04640896|Sham Comparator|Lidocaine skin wheal|They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
11019397|NCT04640896|Active Comparator|Trigger point injection with normal saline|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
11019398|NCT04640896|Experimental|Trigger point injection with bupivacaine|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine HCl + intra- and postoperative standardized analgesia regimen
11019399|NCT04640883|Experimental|Sprints during low-intensity cycling|
11019400|NCT04640883|Active Comparator|Low-intensity cycling|
11019401|NCT04640857|Experimental|Test group: Silk'n Toothwave with an electromagnetic field|Silk'n Toothwave with an electromagnetic field use twice a day for 3 months.
11019402|NCT04640857|Sham Comparator|Control group: Silk'n Toothwave with-out an electromagnetic field|Silk'n Toothwave without an electromagnetic field use twice a day for 3 months.
11019403|NCT04640844|Experimental|patients hospitalized|for surgery of the aorta and / or arteries of the lower limbs.
11019410|NCT04640818||CD20-GROUP|Patients with anti CD20 therapy (ocrelizumab or rituximab)
11019411|NCT04640805|No Intervention|Control group (standard fortification)|Pasteurized Donor Human Milk (PDHM) will be fortified as per unit protocols, at 1 packet of Human Milk Fortifier (Similac) to every 25ml PDHM at a feed volume of 80ml/kg/day
11019412|NCT04640805|Experimental|Intervention group (modified targeted fortification)|Pasteurized Donor Human Milk (PDHM) will be analyzed using the Miris Human Milk Analyzer, and PDHM with a fat content of 3.8g/dL or higher will be selected. Additional protein will be added using liquid protein fortifier (Similac) at 1ml to every 25ml PDHM to give an additional 0.67g/dL protein.
11019413|NCT04640792|No Intervention|Common Colonoscopy (Group A)|Patients will be examined with Conventional Colonoscopy (CC)
11019414|NCT04640792|Experimental|Magentiq Eye Assisted Colonoscopy (Group B)|Patients will be examined with Magentiq Eye Assisted Colonoscopy (MEAC)
11019415|NCT04640779|Experimental|Treatment (selinexor, choline salicylate)|Patients receive selinexor PO BIW on days 1, 3, 8, 10, 15, 17, 22, and 24, and choline salicylate PO TID on days 1-28. Patients undergoing pharmacokinetic analysis receive choline salicylate beginning on D3C1 and beginning on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patents who achieve >= stable disease continue treatment for an additional 6 cycles (maximum of 12 cycles) at the discretion of the treating physician and patient.
11019416|NCT04640766|Experimental|Participants with ADHD|
11019417|NCT04640740|Experimental|anterolateral approach (ALA)|anterolateral surgical approach of total hip arthroplasty
11019418|NCT04640740|Experimental|posterior approach (PA)|posterior surgical approach of total hip arthroplasty.
11019419|NCT04640727|Experimental|open reduction and internal fixation|open reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
11019420|NCT04640727|Experimental|closed reduction and internal fixation|closed reduction and internal fixation used in treating completely displaced and rotated lateral condylar fracture in children
11019421|NCT04640714|Experimental|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|"Participants with advanced cancer will receive a video visit conducted by an oncology Nurse Practitioner (NP) within three (3) business days of hospital discharge.
~The visit will involve: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
~Participant and clinician may also be interviewed for their feedback on the video visit.
~The ultimate goal of the intervention is to improve patients' confidence in managing their health condition and reduce burdensome health care utilization after discharge, particularly reducing 30-day hospital readmissions."
11019422|NCT04640662|Experimental|Platelet-Rich plasma|2 ml PRP using commercial kit- YCell Biokit
11019423|NCT04640662|Active Comparator|Prolotherapy|2 ml 16.5% Dextrose solution
11019424|NCT04640649|Experimental|Prediction Algorithm|Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
11019425|NCT04640649|No Intervention|Control|Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
11019426|NCT04640636|Experimental|Ketamine|Ketamine hydrochloride 0.5 mg/kg IM single injection
11019427|NCT04640636|Active Comparator|midazolam|Midazolam 0.06 mg/kg IM single injection
11019428|NCT04640623|Experimental|Cohort 1: TAR-200 and Cetrelimab|TAR-200 is placed into the bladder through an inserter on Day 0 and will be dosed every 21 days for up to the first 24 weeks (6 months), then every 12 weeks through Week 96 (Study Year 2). In addition, Cetrelimab will be administered.
11019429|NCT04640623|Experimental|Cohort 2: TAR-200|TAR-200 is placed into the bladder through an inserter on Day 0 and will be dosed every 21 days for up to the first 24 weeks (6 months), then every 12 weeks through Week 96 (Study Year 2).
11019430|NCT04640623|Experimental|Cohort 3: Cetrelimab|Participants will receive Cetrelimab.
11019431|NCT04640610||Adenoidectomy / tonsillectomy|Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.
11019432|NCT04640571|Experimental|placebo, then metformin, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
11019433|NCT04640571|Experimental|metformin, then polysorbate 80, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
11019434|NCT04640571|Experimental|polysorbate 80, then placebo, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
11019435|NCT04640571|Experimental|polysorbate 80, then metformin, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
11019436|NCT04640571|Experimental|placebo, then polysorbate 80, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
11019437|NCT04640571|Experimental|metformin, then placebo, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
11019438|NCT04640558||Group 1. Latent Myofascial Trigger Point Group|24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.
11019439|NCT04640558||Group 2. Non-Latent Myofascial Trigger Point Group|24 participants who don't have latent myofascial trigger point.
11019440|NCT04640545|Experimental|LBL-007+Toripalimab|LBL-007 DoseA/DoseB/DoseC Q2W iv+Toripalimab 3mg/kg Q2W iv
11019441|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 1|"TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
11019442|NCT04640532|Experimental|Cohort 1 (R/R MF), Dose Level 2|"TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
11019443|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 1|"TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
11019532|NCT04640012|Placebo Comparator|Placebo|Placebo orally administered
11019444|NCT04640532|Experimental|Cohort 2 (R/R MF), Dose Level 2|"TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.
~KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1."
11019445|NCT04640532|Experimental|Cohort 3 (JAKi Intolerant MF)|KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
11019446|NCT04640519|Experimental|TASC Intervention|TASC patients will receive a BP monitoring kit and electronic tablet and tailored infographics, and attend 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
11019447|NCT04640519|Active Comparator|TASC Control|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
11019448|NCT04640493|Experimental|SLGT2-SDB|Patients with newly diagnosed SDB will be given dapagliflozin (standard dosage, 10mg)
11019449|NCT04640480|Experimental|Cohort 1|Dosage 1
11019450|NCT04640480|Experimental|Cohort 2|Dosage 2
11019451|NCT04640480|Experimental|Cohort 3|Dosage 3
11019452|NCT04640480|Experimental|Cohort 4|Dosage 4
11019453|NCT04640480|Experimental|Cohort 5|Dosage 5
11019454|NCT04640480|Experimental|Cohort 6|Dosage 6
11019455|NCT04640467||Pregnant women|Women with uncomplicated singleton pregnancy who are planning a vaginal delivery, gestational age from 36 ± 0/7 weeks until onset of active labor (cervical dilatation ≤ 4cm) and cephalic presentation
11019456|NCT04640441|No Intervention|Control group|Participants in the control group received usual care.
11019457|NCT04640441|Experimental|Sit-to-stand care group|Intervention was provided once daily by trained nurses for a maximum of 14 days or until hospital discharge or death.
11019458|NCT04640415|No Intervention|No alarms|
11019459|NCT04640415|Active Comparator|Active alarms|
11019460|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
11019461|NCT04640402|Experimental|Low-dose vaccine (18-59 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
11019462|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
11019463|NCT04640402|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
11019464|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Two dose regimen|two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
11019465|NCT04640402|Experimental|Low-dose vaccine (60-85 years) & Three dose regimen|three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
11019466|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Two dose regimen|two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
11019467|NCT04640402|Experimental|High-dose vaccine (60-85 years) & Three dose regimen|three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
11019468|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
11019469|NCT04640402|Placebo Comparator|Low-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
11019470|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
11019471|NCT04640402|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
11019472|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
11019473|NCT04640402|Placebo Comparator|Low-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
11019474|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Two dose regimen|two doses of placebo at the schedule of day 0, 21.
11019475|NCT04640402|Placebo Comparator|High-dose placebo (60-85 years) & Three dose regimen|three doses of placebo at the schedule of day 0, 14, 28.
11019476|NCT04640389||Urban|Urban adolescents living in Moshi District, Tanzania, who are between 10-14 years of age.
11019477|NCT04640389||Rural|Rural adolescents living in Kilosa District, Tanzania, who are between 10-14 years of age.
11019478|NCT04640376|Experimental|Paracetamol UNIFLASH 125mg|1 sachet Paracetamol UNIFLASH 125mg + 2 placebo capsule
11019479|NCT04640376|Placebo Comparator|Placebo|1 Placebo sachet + 2 placebo capsule
11019480|NCT04640376|Active Comparator|Paracetamol 500mg|1 Placebo sachet + 1 placebo capsule + 1 capsule Panadol 500mg
11019481|NCT04640376|Active Comparator|Paracetamol 1000mg|1 Placebo sachet + 2 capsules Panadol 500mg
11019482|NCT04640337|Experimental|Group E1: IPE applied, participants believe they are receiving IPE.|IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
11019483|NCT04640337|Placebo Comparator|Group E2: IPE applied, participants believe they are receiving placebo.|IPE will be applied following the standard protocol for PT. Subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
11019484|NCT04640337|Placebo Comparator|Group P1: IPE not applied, participants believe they are receiving IPE.|The needle will be inserted under the skin but the current will not be passing through. The subjects will see a shame video on the ultrasound screen so they will believe that the IPE is being performed.
11019485|NCT04640337|Placebo Comparator|Group P2: IPE not applied, participants believe they are receiving placebo.|The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
11019486|NCT04640324|No Intervention|NAFLD wild type control group|Consisted of not treated NAFLD wild type patients
11019487|NCT04640324|Active Comparator|NAFLD wild type treated group|Consisted of NAFLD wild type patients treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
11019533|NCT04639999||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
11019534|NCT04639986|Experimental|Arm A|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle.
11019488|NCT04640324|Experimental|NAFLD mutated treated group|Consisted of NAFLD patients carrying at least one mutation among PNPLA3, TM6SF2, MBOAT7 genes, treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
11019489|NCT04640311|Experimental|Part A: Daprodustat Dissolution 1/Dissolution 2/Reference|
11019490|NCT04640311|Experimental|Part A: Daprodustat Dissolution 2/Reference/Dissolution 1|
11019491|NCT04640311|Experimental|Part A: Daprodustat Reference/Dissolution 1/Dissolution 2|
11019492|NCT04640311|Experimental|Part B: Daprodustat Process 1/ Process 2|
11019493|NCT04640311|Experimental|Part B: Daprodustat Process 2/ Process 1|
11019494|NCT04640298|Experimental|Cingal|
11019495|NCT04640285|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS Tobacco Flavor Period 2 - RELX ENDS Menthol Flavor Period 3 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 4 - Usual Brand Cigarette
11019496|NCT04640285|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS Menthol Flavor Period 2 - Usual Brand Cigarette Period 3 - RELX ENDS Tobacco Flavor Period 4 - Nicorette White Ice Mint Nicotine Polacrilex Gum
11019497|NCT04640285|Experimental|Product Use Sequence 3|Period 1 - Usual Brand Cigarette Period 2 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 3 - RELX ENDS Menthol Flavor Period 4 - RELX ENDS Tobacco Flavor
11019498|NCT04640285|Experimental|Product Use Sequence 4|Period 1 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 2 - RELX ENDS Tobacco Flavor Period 3 - Usual Brand Cigarette Period 4 - RELX ENDS Menthol Flavor
11019499|NCT04640272|Experimental|RBM-007 injectable solution|intravitreal injection
11019500|NCT04640259||EGFR|
11019501|NCT04640259||ROS1|
11019502|NCT04640259||ALK|
11019503|NCT04640259||KRAS|
11019504|NCT04640259||NSCLC Other|
11019505|NCT04640246|Experimental|TBX-3400|TBX-3400 by intravenous infusion
11019506|NCT04640233|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
11019507|NCT04640233|Placebo Comparator|Control Group|Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21
11019508|NCT04640220|Experimental|Adhesive capsulitis in breast cancer survivors|Intra-articular steroid injection
11019509|NCT04640194|Other|Control group|Standard of care alone
11019510|NCT04640194|Experimental|Treatment group A|Alteplase (low dose) on top of standard of care
11019511|NCT04640194|Experimental|Treatment group B|Alteplase (high dose) on top of standard of care
11019512|NCT04640181|Active Comparator|Adaptive Dosing: Enoxaparin|"Low 40mg subcutaneous (SQ) daily, or
~Intermediate 40mg SQ q12 hours, or
~Therapeutic 1mg/kg SQ q12 hours"
11019513|NCT04640181|Active Comparator|Adaptive Dosing: Rivaroxaban|"Low 10mg po daily
~Intermediate 10mg po daily
~Therapeutic 20mg po daily"
11019514|NCT04640168|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
11019515|NCT04640168|Experimental|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
11019516|NCT04640155|Other|Regular Diet|
11019517|NCT04640155|Experimental|Low FODMAP|
11019518|NCT04640142|Experimental|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion
11019519|NCT04640129|Active Comparator|TDF group|tenofovir 300mg taken orally per day.
11019520|NCT04640129|Experimental|peg-IFN-α plus TDF group|peg-IFN-α 180ug given subcutaneous injection per week combined with tenofovir 300mg taken orally per day .
11019521|NCT04640116|Experimental|TIPS combined with microwave ablation|
11019522|NCT04640103||adjuvant therapy|Patients who received immonotherapy in adjuvant treantment stage only
11019523|NCT04640103||neoadjuvant therapy|Patients who received immonotherapy in neoadjuvant treantment stage and achieved R0 resection
11019524|NCT04640090|Experimental|Smartphone app|All participants in this single-arm study will receive two months of subsidized, full access to the smartphone wellness application.
11019525|NCT04640077|Other|Part A Validation of Remote Scale Assessments|"Alternating at-home and on-site cognitive and functional scale assessments
~Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site"
11019526|NCT04640077|Other|Part B Donanemab|Donanemab administered intravenously (IV)
11019527|NCT04640064||Patient with type 1 diabetes|Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included.
11019528|NCT04640051||LAAO group|Patients scheduled for LAAO with Amplatzer Amulet (Abbott) and for whom a 3D in silico simulation by FEops HEARTguide is available and reviewed before implantation
11019529|NCT04640038|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
11019530|NCT04640025|Experimental|itacitinib|Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.
11019531|NCT04640012|Experimental|DC371739 100mg|Single dose of 100 mg tablet orally administered
11056476|NCT04382729|Experimental|NMES Group|
11019535|NCT04639986|Active Comparator|Arm B|"Recommended doses and schedules as per package insert depending on region.
~Eribulin (1.4 mg/m2 of eribulin mesylate or 1.23 mg/m2 of eribulin IV on Days 1 and 8 of a 21-day cycle)
~Capecitabine (1000 to 1250 mg/m2 PO twice daily on Days 1 to 14 of a 21-day cycle)
~Gemcitabine (800 to 1200 mg/m2 IV on Days 1, 8, and 15 of a 28-day cycle)
~Vinorelbine (25 mg/m2 IV on Day 1 weekly)"
11019536|NCT04639973|Experimental|Group 1 (First trimester ultrasound)|
11019537|NCT04639973|Active Comparator|Group 2 (Second trimester anatomy ultrasound)|
11019538|NCT04639960|Experimental|Risperidone|
11019539|NCT04639960|Placebo Comparator|Placebo|
11019540|NCT04639947|Experimental|EyeCheck|EyeCheck pressures will be measured with contact lens in place
11019541|NCT04639947|Active Comparator|Traditional Tonometer (Goldmann and Tonopen)|Pressures will be measured with both Goldmann and Tonopen (both traditional tonometers to take the intraocular pressure (IOP) measurements of the eye).
11019542|NCT04639934||Breast cancer patients|Breast cancer patients being seen at SingHealth
11019543|NCT04639921|Experimental|active - placebo|intake of socalled gluten bars two daily for seven days, followed by one week wash-out, and then placebo bars for seven days
11019544|NCT04639921|Placebo Comparator|placebo - active|intake of placebo bars two daily, followoed by wash-out for one week, and gluten bars (experimental) for seven days.
11019545|NCT04639908||barriers|find out what are the barriers
11019546|NCT04639908||facilitators|find out what are the facilitators
11019547|NCT04639895|Experimental|Virtual Reality|Standard treatment protocol and 12 sessions (30 minutes each) of personalized cognitive activities in a virtual city environment (Reh@City).
11019548|NCT04639895|Experimental|Paper and Pencil|Standard treatment protocol and 12 sessions (30 minutes each) of personalized paper-and-pencil cognitive activities,using the Task Generator tool.
11019549|NCT04639895|Active Comparator|Control Group|The standard treatment protocol.
11019550|NCT04639882|Experimental|Control-Remote-$0|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure remotely
~are compensated $0 for completing the baseline and intervention procedure"
11019551|NCT04639882|Experimental|Control-Remote-$30|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure remotely
~are compensated $30 for completing the baseline and intervention procedure"
11019552|NCT04639882|Experimental|Control-InPerson-$0|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $0 for completing the baseline and intervention procedure"
11019553|NCT04639882|Experimental|Control-InPerson-$30|"In this condition, Participants:
~receive attention control feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $30 for completing the baseline and intervention procedure"
11019554|NCT04639882|Experimental|PNF-Remote-$0|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure remotely
~are compensated $0 for completing the baseline and intervention procedure"
11019555|NCT04639882|Experimental|PNF-Remote-$30|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure remotely
~are compensated $30 for completing the baseline and intervention procedure"
11019556|NCT04639882|Experimental|PNF-Inperson-$0|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $0 for completing the baseline and intervention procedure"
11019557|NCT04639882|Experimental|PNF-Inperson-$30|"In this condition, Participants:
~receive personalized normative feedback
~complete the baseline and intervention procedure in the research lab
~are compensated $30 for completing the baseline and intervention procedure"
11019558|NCT04639869|Experimental|Phenyramydol then Cabral|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
11019559|NCT04639869|Active Comparator|Cabral then Phenyramydol|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
11019560|NCT04639869|Experimental|Phenyramydol then Cabral Replicate|Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
11019561|NCT04639869|Active Comparator|Cabral then Phenyramydol Replicate|Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
11019562|NCT04639856|Active Comparator|on-pump CABG|CABG using Cardiopulmonary Bypass Machine
11019563|NCT04639856|Active Comparator|off-pump CABG|CABG without Cardiopulmonary Bypass Machine
11019564|NCT04639843|Experimental|1- Experimental Treatment: Dose Escalation|Duvelisib (PO BID) at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of C1 and days 1-14 of all other cycles of each 21- day cycle (max 8 cycles) with CC-486 (5-azacitidine) (PO) at 300mg/day on days 1-10, romidepsin at 12mg/m2 (IV) on Days 1 and 8 of each cycle and doxorubicin (IV) at 25 mg/ m2 on Day 1 of cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy), to determine RP2D of duvelisib and doxorubicin
11019565|NCT04639843|Experimental|2 - Experimental Treatment: Dose Expansion|Duvelisib (PO BID) at RP2D on days -14 to 14 of C1 and days 1-14 of all other 21-day cycle (max 8 cycles) with CC-486 (5-azacitidine) at 300mg/day (PO) on days 1-10, romidepsin at 12mg/m2 (IV) on days 1 and 8 of each cycle, and doxorubicin at 25 mg/m2 on day 1 of Cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy
11019566|NCT04639830||Children with a clinical referral for a sleep study|Children between 6 months and 8 years who have a clinical referral for a sleep study.
11019567|NCT04639830||Children with a known risk|Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder.
11019568|NCT04639830||Children with no known risk|Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders.
11020772|NCT04631328|Experimental|Intervention|Growing Together program
11019569|NCT04639817||Levofloxacin targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
11019570|NCT04639817||TMP/SMX targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
11019571|NCT04639804|Active Comparator|Tegoprazan 50 mg|Multiple doses of tegoprazan alone once daily (QD) for 7 days
11019572|NCT04639804|Active Comparator|NSAIDs|Multiple doses of NSAIDs alone twice daily (BID) for 7 days
11019573|NCT04639804|Active Comparator|Tegoprazan 50 mg + NSAIDs|Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days
11019574|NCT04639791||Severe asthma patients|on step 4& 5 of GINA treatment
11019575|NCT04639778|Active Comparator|Control Group|In the control group, patients will follow a care pathway respecting the current recommendations : a systematic clinical visit scheduled each year with the multidisciplinary team.
11019576|NCT04639778|Experimental|Experimental Group|In the intervention group, patients will follow a new care pathway with visits triggered by weight evolution
11019577|NCT04639765|No Intervention|No video|This condition involves no video presentation.
11019578|NCT04639765|Experimental|CBT without Personalization|Video provides information about cognitive behavioral therapy.
11019579|NCT04639765|Experimental|CBT with Personalization|Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
11019580|NCT04639765|Experimental|ADM without Personalization|Video provides information about antidepressant medications.
11019581|NCT04639765|Experimental|ADM with Personalization|Video provides information about antidepressant medications and describes how treatment can be personalized.
11019582|NCT04639765|Experimental|Combined Treatment without Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
11019583|NCT04639765|Experimental|Combined Treatment with Personalization|Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.
11019584|NCT04639752|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
11019585|NCT04639752|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
11019586|NCT04639739|Experimental|anti-CD19 CAR NK cells|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
11019587|NCT04639726|Active Comparator|Whey Protein|
11019588|NCT04639726|Placebo Comparator|Placebo|
11019589|NCT04639713|Experimental|Tixel 2|Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject would be questioned about pain level, subjective dountime assessment and subjective response assessment. Images would be taken at baseline and in Follow-Up visits
11019590|NCT04639700|Experimental|Psycho-educational intervention|All participants will receive receive 4 individual sessions with an interventionist in addition to the standard post-hospital HSCT information for patient follow-up care as provided by the patient's oncologist
11019591|NCT04639687|Experimental|Immediate intervention|If randomized to this group, household of child and participating caregiver receives 12 weekly deliveries of vegetables plus added whole grains, along with text messages containing links to cooking instruction videos
11019592|NCT04639687|Other|Wait list control (delayed intervention)|If randomized to this group, participants do not get any intervention activities for the first 12 weeks, and their outcome data at V2 contribute as controls. For ethical reasons, this low-income population ultimately gets the intervention (food)later, and data after they receive the intervention contributes to follow-up data only.
11019593|NCT04639674|Experimental|AST-120|"sachet Three times a day. (2g/pack*3pack/box)
~1 month"
11019594|NCT04639674|No Intervention|Control|No intervention
11019595|NCT04639622|Other|asymptomatic at-risk individual|First-degree relative of a family member affected with the frontotemporal dementia.
11019596|NCT04639622|Other|symptomatic individual|Patient who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum
11019597|NCT04639609|Experimental|Group 1 : Patients|
11019598|NCT04639609|Other|Group 2 : healthy volunteers|
11019599|NCT04639596|Experimental|MBTS|It will consist of four hours of sailing and mindfulness training at the Jordanelle Reservoir. Boats and skippers will be provided by Park City Sailing Association, a non-profit community organization.
11019600|NCT04639596|Experimental|SRT|SRT will occur on four separate occasions during the summer of 2019. SRT will consist of 4 hours of bowling at a community bowling alley.
11019601|NCT04639583|Experimental|Observational Arm|Any infant consented to participate in the study will have the NIRS applied for the first 96 hours of life. It will be the goal to apply the NIRS sensors in the first 12 hours of life. All infants will have the same treatment if in the study, but clinicians will not be able to see the data obtained so that there is no clinical interpretation during this time.
11019602|NCT04639570|Experimental|KneuroKnits group|Participants in the KneuroKnits group
11019603|NCT04639557|Experimental|Virtual Intervention|Mothers in this group will participate in 16, once per week, scheduled 2-hour virtual group therapy sessions through Zoom for Healthcare. These sessions will include both visual media (e.g., presentations, recorded examples of skills), and discussions. A technician will be present in the virtual group therapy session to manage the technical component. These sessions will be supplemented with a 1-hour drop-in session moderated by a facilitator each week in which participants will be able to clarify topics for that week, discuss the material in more depth, and/or connect with other participants to share about the skill practice.
11019604|NCT04639557|Experimental|Therapy Intervention Pre-recorded|Mothers in this group will have access to short pre-recorded videos of the presentations with facilitator commentary (i.e., 10-12 minutes) with additional video material as warranted each week (e.g., recorded examples of skill practice) for a maximum of 30-minutes of material per week. This arm will also have a 1-hour drop-in session each week with a group facilitator to moderate homework check-ins and discussion of the material.
11019605|NCT04639544|Placebo Comparator|Control group|Volunteers will take 1 capsule per day with maltodextrin for 6 months
11019606|NCT04639544|Experimental|Probiotic group|Volunteers will take 1 capsule per day with the Lactobacillus strain for 6 months
11019607|NCT04639531|Experimental|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from Virtual Reality-base Intelligent O&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O&M skill training programs in virtual streets.
11019608|NCT04639531|Active Comparator|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from human Certified O&M Specialists (COMS) in real streets
11019609|NCT04639531|Placebo Comparator|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O&M) difficulties watching low vision education videos and discuss low vision issues not related to O&M with COMSs.
11019610|NCT04639518|Experimental|Sub-study 1|Pre-term formulas with HMO
11019611|NCT04639518|Experimental|Sub-study 2|Pre-term formulas without HMO
11019612|NCT04639505||ELISA|ELISA kit detecting the serum AMH level
11019613|NCT04639505||Chemiluminescence|CLIA method detecting the serum AMH level
11019614|NCT04639492|Experimental|MBS oral solution|fermented soybean extract-MBS
11019615|NCT04639466|Experimental|Arm I (COH04S1)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
11019616|NCT04639466|Active Comparator|Arm II (COH04S1, placebo)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.
11019617|NCT04639466|Placebo Comparator|Arm III (placebo)|Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
11019618|NCT04639453||Stroke|Individuals with post-stroke hemiparesis in subacute phase will be included in the study.
11019619|NCT04639440||Obese or overweight patients|
11019620|NCT04639440||Patients without overweight|
11019621|NCT04639414|Experimental|Combined treatment with Empagliflozin and Semaglutide|Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly
11019622|NCT04639414|Experimental|Empagliflozin monotherapy|Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
11019623|NCT04639414|Placebo Comparator|Placebo|Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
11019624|NCT04639401|Experimental|persons with Multiple Sclerosis|
11019625|NCT04639401|Placebo Comparator|Healthy controls|
11019626|NCT04639388|Experimental|22q11.2DS|Children aged from 4 to 13 years old with 22q11.2 deletion syndrome
11019627|NCT04639388|Active Comparator|Control Group (Non22q11.2DS)|Children aged from 4 to 13 years old without developmental disease
11019628|NCT04639375|Experimental|Vaccinated with polio vaccine (IPV)|All subjects will receive polio vaccine: IPV as manufactured by Sanofi Pasteur for distribution in the United States
11019629|NCT04639362|Experimental|Intensification|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
11019630|NCT04639362|Experimental|Observation|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
11019631|NCT04639349|Experimental|Exercised group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
11019632|NCT04639349|Other|control group|The control group will not be trained
11019633|NCT04639336||Patients with Pompe disease|
11019634|NCT04639323||Overall eligible participants|Eligible participants whose varix size will be measured by endoscopists and endoscopic ruler will receive standard esophagogastroduodenoscopy
11019635|NCT04639310|Experimental|XEN496|24-day dose titration period to a top dose of 21 mg/kg/day. Subjects continue at the top dose, or the highest tolerated dose up to the top dose, for 12-week maintenance period. If the subject does not immediately enter into the separate open-label extension (OLE) study, the maintenance period will be followed by a 18-day taper period.
11019636|NCT04639310|Placebo Comparator|Placebo|To maintain the blinded aspect of the study, subjects will be titrated on placebo over the 24-day period and remain at this dose for the 12-week maintenance period. If the subject does not immediately enter into the separate OLE study, the maintenance period will be followed by a 18-day taper period.
11019637|NCT04639297|Experimental|NeuroVision® IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
11019638|NCT04639297|Active Comparator|Conventional hospital based IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
11019639|NCT04639284||Combinational therapy|Participants who receive systemic treatment with an anti-angiogenic agent, including sorafenib, lenvatinib, apatinib, and bevacizumab, in combination with an anti-PD-1/PD-L1 antibody, including pembrolizumab, nivolumab, sintilimab, toripalimab, camrelizumab, tislelizumab, and atezolizumab.
11019640|NCT04639271|Experimental|Pyrotinib Plus Trastuzumab And Abraxane|Pyrotinib Plus Trastuzumab And Abraxane
11019734|NCT04638725||HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)|
11019735|NCT04638725||HER2 positive breast cancer treated with TDM1 and neratinib|
11019641|NCT04639258|Experimental|Medtronic Evolut™ PRO+ System|All study subjects in Cohort A (Moderate, Symptomatic Aortic Stenosis) and Cohort B (Severe, Asymptomatic Aortic Stenosis) will be treated with the Medtronic Evolut™ PRO+ TAVR System.
11019642|NCT04639245|Experimental|Treatment (FH-MagIC TCR-T cells, atezolizumab)|"LYMPHODEPLETION: Patients receive cyclophosphamide IV and fludarabine IV on days -4, -3, and -2 before each T-cell infusion.
~T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion.
~In the Phase II portion of the study, patients will receive atezolizumab IV every 3 weeks beginning 24-72 hours after T cell infusion. Atezolizumab will be given for at least 1 year in the absence of disease progression or unacceptable toxicity. If an alternative PD1 inhibitor is instead available for a patient, it may be substituted instead."
11019643|NCT04639232|Placebo Comparator|Control group|Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.
11019644|NCT04639232|Experimental|Prob-milk|Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.
11019645|NCT04639232|Experimental|Voluntas-Prob|Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain
11019646|NCT04639219|Experimental|T-DXd|T-DXd monotherapy
11019647|NCT04639206|Experimental|HOBSCOTCH group|Participants in this study arm will receive the HOBSCOTCH intervention immediately.
11019648|NCT04639206|No Intervention|Wait-listed control|Participants in this study arm will be wait-listed for 6 months and will then receive the HOBSCOTCH intervention.
11019649|NCT04639193|Experimental|Placebo, then Dual-Therapy, then Single/Triple-Therapy|"Subjects will start with a 3-day PLACEBO regimen:
~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.
~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.
~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
11019650|NCT04639193|Experimental|Dual-Therapy, then Placebo, then Single/Triple-Therapy|"Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:
~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.
~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.
~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.
~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:
~Day 1: Acetazolamide 250mg at bedtime at home.
~Day 2: Acetazolamide 500mg at bedtime at home.
~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
11019651|NCT04639180|Experimental|Treatment group (Camrelizumab Plus Apatinib)|Drug: Camrelizumab; Drug: Apatinib
11019652|NCT04639180|No Intervention|Control group (Active surveillance)|
11019653|NCT04639167|Experimental|Paths to everyday life (PEER)|The Paths to everyday life (PEER) intervention added to service as usual (SAU) consists of a 10-week group course and an opportunity of individual companionship to persons with mental vulnerability and mental health difficulties. The 10 week group sessions is facilitated by two volunteer peers with their own lived experiences with mental vulnerability.
11019654|NCT04639167|No Intervention|Service as usual (SAU)|Participants who will be allocated to the control group of the trial will receive service as usual (SAU) by their social security officer, or no specific service if the participant has been referred to the trial by self-referral. Participants who are referred to the trial via §82 in the municipality, can receive other §82 offers depending on the individual municipality.
11019655|NCT04639154|Placebo Comparator|control group|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
11019656|NCT04639154|Active Comparator|tramadol 50|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
11019657|NCT04639154|Active Comparator|tramadol 100|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
11019658|NCT04639141|Active Comparator|Synbiotic|"Dosing: one sachet/dose per day for 12 weeks. The combination includes: Lactobacillus rhamnosus (1x10^10 CFU/dose), Lactobacillus plantarum (4 x 10^9 CFU/dose), Bifidobacterium animalis subsp. lactis (5 x 10^9 CFU/dose), Bifidobacterium longum (1 x 10^9 CFU/dose) + 4g/dose of partially hydrolysed guar gum (PHGG).
~Mode of administration: oral."
11019659|NCT04639141|Active Comparator|Gut-directed Hypnotherapy|"Schedule: Six, 1-hour sessions over 12 weeks + daily at-home audio (optional 5-20 min).
~Mode: face-to-face (virtual and/or in person) sessions. Overview: based on the Manchester model of GDH adapted for use in children with ASD. The GDH core therapy focus areas will be relaxation, control of gut function and ego-strengthening. Optional at-home audio will be a summary of content from the session for the previous in clinic session."
11019660|NCT04639141|Experimental|Combined|Includes both the daily oral synbiotic + six, 1-hour GDH sessions over 12 week intervention.
11019661|NCT04639128|No Intervention|No-Device|No placement of an adductor canal catheter
11019662|NCT04639128|Experimental|Device|Placement of an adductor canal catheter
11019663|NCT04639115|Experimental|Ozanimod in subjects with mild hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with mild hepatic impairment
11019736|NCT04638712|Other|Group 1 without trastuzumab|
11019737|NCT04638712|Other|Group 2 with trastuzumab|
11019664|NCT04639115|Experimental|Ozanimod in subjects with moderate hepatic impairment|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in subjects with moderate hepatic impairment
11019665|NCT04639115|Experimental|Ozanimod in healthy subjects|Participants will receive ozanimod 0.23 mg once daily (QD) on Days 1 to 4, 0.46 mg QD on Days 5 to 7, and 0.92 mg QD on Day 8 in healthy subjects
11019666|NCT04639102|Experimental|PATH Intervention|Patients in the treatment arm will receive a personalized plan of care upon discharge from the emergency department.
11019667|NCT04639102|No Intervention|Routine Care|Patients in the control arm will receive standard-of-care services (the care plan that the emergency physician would normally offer if PATH were not available) without PATH enrollment.
11019668|NCT04639089|Experimental|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure|We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure
11019669|NCT04639089|Placebo Comparator|We will apply 10cm saline on the sternal edge before sternal closure|We will apply 10cm saline on the sternal edge before sternal closure
11019670|NCT04639076|Active Comparator|Behavioral Weight Loss Group|Participants in this arm will receive a standard behavioral weight loss approach that recommends a calorie deficit based on starting weight, a standard activity minute goal progression based on baseline activity and standard behavioral weekly counseling.
11019671|NCT04639076|Experimental|Personalized Behavioral Weight Loss Group|Participants in this arm will receive a personalized weight loss approach that recommends either a low carbohydrate or low fat calorie reduced diet; personalized activity plan with either daily or weekly bout-related goals; and eating frequency of either 3 times per day or 5-6 times per day.
11019672|NCT04639063||Cesarean sectioned|All females who treated in our hospital by Cesarean section operation during two-years-period
11019673|NCT04639063||Complicated with Abdominal wall endometriosis|All the surgically excised endometrioma cases during the same time period
11019674|NCT04639050|Experimental|Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
11019675|NCT04639050|Placebo Comparator|Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
11019676|NCT04639050|Experimental|Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
11019677|NCT04639050|Placebo Comparator|Cohort 2: Placebo|Participants will receive matching placebo to dose level 2 Q4W for 28 weeks followed by a 28-week safety follow-up period.
11019678|NCT04639050|Experimental|Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
11019679|NCT04639050|Placebo Comparator|Cohort 3: Placebo|Participants will receive matching placebo to dose level 3 Q4W for 28 weeks followed by a 28-week safety follow-up period.
11019680|NCT04639050|Experimental|Cohort : Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
11019681|NCT04639050|Placebo Comparator|Cohort 4: Placebo|Participants will receive matching placebo to dose level 4 Q4W for 28 weeks followed by a 28-week safety follow-up period.
11019682|NCT04639037|Active Comparator|Manual adjustment of vasopressor|Fluid and vasopressor will be managed as standard practice guided by the EV1000 monitoring device (manually infusion of both fluid and vasopressors) Objective being to maintain MAP within a target MAP range of 80-90 mmHg (fluid will be optimized and stroke volume index will be maintained within normal values)
11019683|NCT04639037|Experimental|Automated adjustment of vasopressor|Fluid will be managed using the EV1000 monitoring in order to optimize stroke volume index and vasopressor will be automatically deliver by a closed-loop system to maintain the MAP within the target range of 80-90 mmHg
11019684|NCT04639024|Experimental|ADCT-301 Infusion|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
11019685|NCT04639011|Active Comparator|Group A Placebo|Participants randomized to Group A will receive placebo (sugar pill) and Boston Medical Center (BMC) standard of care.
11019686|NCT04639011|Experimental|Groups B Intervention|Participants randomized to Group B will receive duloxetine and Boston Medical Center (BMC) standard of care.
11019687|NCT04638998||Healthy Control|The healthy control group are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. This cohort do not experience any Gulf War Illness symptoms.
11019688|NCT04638998||Gulf War Illness|The GWI cohort are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. The men in this cohort will also meet the Kansas Inclusion Criteria for GWI.
11019689|NCT04638985|Experimental|group 1 (sIPV+DTaP+MMR)|150 subjects; simultaneously administration of sIPV+DTaP+MMR as booster immunization at the age of 18 months old, 0.5 ml each, respectively
11019690|NCT04638985|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
11019691|NCT04638985|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
11019692|NCT04638985|Active Comparator|group 4 (MMR)|150 subjects; vaccination of 0.5 ml MMR as booster immunization at the age of 18 months old
11019693|NCT04638972||Tactile Sense Method|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
11019738|NCT04638699|No Intervention|Phase 1 Survey of the actual state|
11019739|NCT04638699|Other|Phase 2 Survey after the OptiScreen training|
11019740|NCT04638673|Experimental|Active-Active Stimulation Group|This group will be randomized into the active stimulation group for weeks 1&2 of stimulation and active stimulation during weeks 3&4 of stimulation of study participation.
11019694|NCT04638972||Radiographic Method (digital periapical radiography)|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
11019695|NCT04638972||Ipex® EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
11019696|NCT04638972||Propex® pixi EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
11019697|NCT04638959||GC|patients diagnosed with GC
11019698|NCT04638959||HC|patients diagnosed with chronic gastritis by histopathology
11019699|NCT04638946|Experimental|Titration to high intensity exercise|
11019700|NCT04638946|Active Comparator|Low intensity exercise|
11019701|NCT04638933||OSA patients|Patients with proven OSA (apnea-hypopnea index ≥20/h, ESS >10, age ≥18 years) and initiation of CPAP treatment
11019702|NCT04638920||Exacerbators|Patients with COPD exacerbation
11019703|NCT04638907||Observational study group|Consenting adult male patients undergoing elective robot-assisted prostatectomy. No further selection or randomisation. Enrollment as availability for the study.
11019704|NCT04638881|Experimental|Magnesium sulfate 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
11019705|NCT04638881|Placebo Comparator|Normal saline 0.9% 50 mg/kg bolus + 25 mg/kg/hr infusion|Bolus to be administered at start of mucosal incision, followed by infusion. Infusion to be terminated at extubation.
11019706|NCT04638868|Experimental|Isolation of circulating tumor cells|Both portal venous and peripheral blood will be obtained from the patient and subjected to analysis for pancreatic cancer circulating tumor cells
11019707|NCT04638855|Experimental|Medicurtain®|Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery
11019708|NCT04638855|Sham Comparator|Placebo|No device after hysteroscopy surgery
11019709|NCT04638842|Experimental|Grief COVID intervention|Participants in this group will receive 12 sessions of a multi-component psychological intervention focused on the reduction of symptoms of anxiety, depression, hopelessness, and post-traumatic stress, and the increase of the quality of sleep and perception of the quality of life.
11019710|NCT04638842|No Intervention|Waiting List group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 12 sessions will receive the intervention.
11019711|NCT04638829|Other|Avatrombopag|Avatrombopag 20 mg oral tablet formulation for 90 days
11019712|NCT04638816|Experimental|Restylane Volyme|Hyaluronic Acid
11019713|NCT04638816|Experimental|Restylane Lyft Lidocaine|Hyaluronic Acid
11019714|NCT04638803|Experimental|Crossover (fasted)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol, on Day 15 subjects are dosed with 40 µg of (-)-FCF. Both treatment will be administered under the fasted conditions.
11019715|NCT04638803|Experimental|Single Group (fed)|On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
11019716|NCT04638790|Experimental|Early favorable HL|HL without adverse prognostic factors
11019717|NCT04638790|Experimental|Early unfavorable HL|Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)
11019718|NCT04638790|Experimental|Advanced stages HL|(age less than 50 years)
11019719|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and PFC|
11019720|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and sham rTMS over PFC|
11019721|NCT04638777|Sham Comparator|Sham rTMS over M1 and PFC|
11019722|NCT04638764|Active Comparator|Aerobic interval training with high loads resistance training|"Patient to be randomised into combined aerobic training with high loads resistance training group."
11019723|NCT04638764|Active Comparator|Aerobic interval training with low loads resistance training|"Patient to be randomised into combined aerobic training with low loads resistance training group."
11019724|NCT04638764|Active Comparator|Aerobic interval training|"Patient to be randomised into aerobic training training group."
11019725|NCT04638751||NSCLC|Stage 3 or stage 4 non-small cell lung cancer patients, being administered checkpoint inhibitor therapy for the first time. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11019726|NCT04638751||Triple-negative breast cancer|Stage 3 or stage 4 metastatic triple-negative breast cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11019727|NCT04638751||Colorectal cancer|Stage 3 or stage 4 colorectal cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11019728|NCT04638751||Pancreatic cancer|Stage 3 or stage 4 pancreatic cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11019729|NCT04638738||Pre-implementation|Pre-implementation of digital alerting sensor systems
11019730|NCT04638738||Post-implementation|Implementation of digital alerting sensor systems
11019731|NCT04638725||HER2 positive breast cancer treated only with trastuzumab|
11019732|NCT04638725||HER2 positive breast cancer treated with pertuzumab|
11019733|NCT04638725||HER2 positive breast cancer treated with neratinib|
11019741|NCT04638673|Sham Comparator|Sham-Active Stimulation Group|This group will be randomized into the sham stimulation group for weeks 1&2 of stimulation and active stimulation for weeks 3&4 of stimulation of study participation.
11019742|NCT04638660|Experimental|Phentolamine Ophthalmic Solution 0.75%|One drop in both eyes at or near bedtime (8PM to 10PM)
11019743|NCT04638660|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|One drop in both eyes at or near bedtime (8PM to 10PM)
11019744|NCT04638647|Experimental|Secukinumab s.c.|All participants will receive a starting dose of 150mg s.c. secukinumab Q4W with the option to increase to the maximum dose of 300 mg Q4W
11019745|NCT04638634|Experimental|CSL760 (low dose)|Administered as an intravenous infusion
11019746|NCT04638634|Experimental|CSL760 (high dose)|Administered as an intravenous infusion
11019747|NCT04638608|Other|EMBRACE (Relatives)|Feasibility test of a new palliative rehabilitation blended learning program for relatives of people with ALS/cognitive impairments
11019748|NCT04638608|Other|EMBRACE (Health care providers)|Feasibility test of a new palliative rehabilitation blended learning program health care providers helping people with ALS/cognitive impairments
11019749|NCT04638595||Normative|50 neurotypical pediatric subjects
11019750|NCT04638582|Experimental|Neoadjuvant pembrolizumab + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles.
~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
11019751|NCT04638582|Experimental|Neoadjuvant pembrolizumab and chemotherapy + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles in combination with standard of care histology-specific chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 3 cycles.
~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
11019752|NCT04638569|Active Comparator|Ultrasound-guided obturator nerve block group|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.
11019753|NCT04638569|Active Comparator|obtutaror nerve block with anatomical landmarks|In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.
11019754|NCT04638556||Normal|A healthy, disease-free population.
11019755|NCT04638556||T2DM|T2DM group was simple type 2 diabetes mellitus.
11019756|NCT04638556||DPN|The screening criteria for T2DM patients with DPN are as follows: 1. Clear history of type 2 diabetes mellitus. 2. Neuropathy at or after the diagnosis of diabetes. 3. The clinical symptoms and signs were consistent with those of DPN. Clinical symptoms include: numbness or sensation; tingling or tingling; pain; abnormal sensitivity or tenderness after touching. 4. Examination: A. abnormal temperature sense; B. 10 g nylon thread examination, foot sensation decreased or disappeared; C. abnormal vibration sense; D. ankle reflex disappeared; e. two or more items of nerve conduction velocity were slowed down (electromyography or sensory threshold measurement). 5. Nerve injury caused by other diseases or drugs was excluded. Two of the above five items were abnormal, or clinical symptoms + 1 item were abnormal.
11019757|NCT04638543|Experimental|ABP-671|The study will consist of three sequential groups with escalating total daily ABP-671 doses. Each group is further divided into two dose cohorts with either QD or BID dosing.
11019758|NCT04638543|Placebo Comparator|Placebo|
11019759|NCT04638530|Other|Residents|All residents will participate in the activity
11019760|NCT04638517|Active Comparator|Danazol|800mg daily in two divided doses orally for 12 months. In subjects who have difficulty tolerating danazol / placebo, the dose will be reduced by 200mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200mg/day dose reductions will be allowed until a tolerated dose is achieved. Background antifibrotic therapy is allowed.
11019761|NCT04638517|Placebo Comparator|Placebo|Matching placebo capsules.
11019762|NCT04638504||11-14 weeks of normal pregnancy.|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
11019763|NCT04638504||11-14 week obese pregnant|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
11019764|NCT04638504||24-28 week normal pregnant|24-28. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery, and maternal uterine artery dopes will be examined ultrasonographically.
11019765|NCT04638504||24w-28w obese normal pregnant|24w-28w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
11019766|NCT04638504||37w -40w normal pregant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
11019767|NCT04638504||37-40 w obese normal pregnant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
11019768|NCT04638491|Experimental|single-arm|PM01183-Dose Escalation
11019769|NCT04638465||A - Surgery Only|"Participants with the following diagnosis will receive transoral robotic surgery with neck dissection:
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN0 or N1 (single node)
~Tonsil - Stage: cT1-3, cN0 or N1 (single node)
~Unknown primary - Stage: cT0 N1 (single node)
~Radiation also given if indicated by intermediate or high risk features following surgery."
11019812|NCT04638192|Experimental|subject-specific tACS|Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency
11019813|NCT04638192|Experimental|standard tACS|Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency
11019770|NCT04638465||B - Surgery with Adjuvant Therapy|"Participants with the following diagnosis will receive surgery followed by 6 Cycles of Cisplatin 40 mg/m2:
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT1-2, cN1 (2-4 nodes) or N2
~Tonsil - Stage: cT1-3, N1 (2-4 nodes)
~Radiation also given if indicated by intermediate or high risk features following surgery."
11019771|NCT04638465||C - Concurrent Chemo/Radiation Therapy - Dose Level 1|"Participants with the following diagnosis will receive 6 Cycles of Cisplatin 40 mg/m2 + 60 Gy Radiation:
~Tonsil - Stage: cT1-3, N2
~Unknown Primary - Stage: cT0, N2"
11019772|NCT04638465||D - Concurrent Chemo/Radiation Therapy - Dose Level 2|"Participants with the following diagnosis will receive 7 Cycles of Cisplatin 40 mg/m2 + 70 Gy Radiation:
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cT3-4, any N
~Base of Tongue/Non-Tonsil Oropharynx - Stage: cAny T, N3
~Tonsil - Stage: cT1-3, N3
~Tonsil - Stage: cT4, any N
~Unknown Primary - Stage: cT0, N3"
11019773|NCT04638452|Other|Epidemiology|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
11019774|NCT04638439|Experimental|P1101 + Nivolumab + Entecavir|
11019775|NCT04638426|Experimental|Treatment A|HL237 tab. 200mg/day
11019776|NCT04638426|Experimental|Treatment B|HL237 tab. 400mg/day
11019777|NCT04638426|Experimental|Treatment C|HL237 tab. 800mg/day
11019778|NCT04638426|Placebo Comparator|Placebo|Placebo of HL237 tab.
11019779|NCT04638413|Experimental|Walking regimen (W)|
11019780|NCT04638413|Experimental|Gamified inhibitory control training (PolyRules!)|
11019781|NCT04638413|Experimental|Walking regimen + gamified inhibitory control training (W+PolyRules!)|
11019782|NCT04638400|Active Comparator|Simvastatin|Obese subjects with elevated cholesterol
11019783|NCT04638400|Active Comparator|Ezetimibe|Obese subjects with elevated cholesterol
11019784|NCT04638387|Experimental|PB125|Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience). Treatment will last 12 weeks.
11019785|NCT04638387|Placebo Comparator|Placebo|Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience). Treatment will last 12 weeks. Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
11019786|NCT04638361||No laryngeal mobility disorder post cardiac surgery|No Follow up, no questionnaires and no nasofibroscopic control.
11019787|NCT04638361||Laryngeal mobility disorder post cardiac surgery|During a follow-up consultation, questionnaires will be offered to assess the child's quality of life.
11019788|NCT04638348|Experimental|New Biofeedback|Women allocated to the new biofeedback group will be instructed to attach the biofeedback device to their underpants and then perform pelvic floor muscle training.
11019789|NCT04638348|Active Comparator|Conventional Biofeedback|Women allocated to the conventional biofeedback group will undergo pelvic floor muscle training with the conventional biofeedback probe inserted in the vagina
11019790|NCT04638348|Active Comparator|Control group|The control group will perform pelvic floor muscle training without any biofeedback device.
11019791|NCT04638335||travelers over the age of 60|blood sample taken to test the presence of Anti-HAV antibodies
11019792|NCT04638335||travelers having lived in a tropical country for more than 5 years|blood sample taken to test the presence of Anti-HAV antibodies
11019793|NCT04638322|Experimental|HIFT Group|This group receives physical training based on exercises of high intensity interval functional training.
11019794|NCT04638322|No Intervention|No intervention group|This group does not receive any treatment.
11019795|NCT04638309|Experimental|Cohort 1|Dose level 1
11019796|NCT04638309|Experimental|Cohort 2|Dose level 2
11019797|NCT04638309|Experimental|Cohort 3|Dose level 3
11019798|NCT04638296||Physicians|surgeons, anesthesiologists, and surgical residents
11019799|NCT04638296||Nurses|OR Nurses
11019800|NCT04638283|Experimental|Interventioh group|"The intervention consists of
~Eight group sessions of two hours duration, focusing on GMT and ADHD. The Group consists of six participants and is directed by one neuropsychologist and one psychologist.
~Four individual sessions with the neuropsychologist/psychologist directing the Group where the participant is guided through the process of formulating GAS-goals.
~Bi-weekly Telephone follow up focusing on GAS-goal attainment the thre first months following the Group session phase."
11019801|NCT04638283|No Intervention|Control Group|Participants in the Control Group receive TAU. Participation in the study does not influence decisions regarding pharmacological interventions in either of the groups.
11019802|NCT04638270|Experimental|anti-CD19 FasT CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.
~3×10^5 /KG 6×10^5 /KG 1×10^6/KG"
11019803|NCT04638257|Experimental|Lactobacilli|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14 Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
11019804|NCT04638257|Placebo Comparator|Placebo|Receives placebo
11019805|NCT04638244|Experimental|BOMI Group (Intervention Group)|Listening to an expert-selected, theory-guided and self-chosen song each day actively in a personalized and focused way (Brief Online Music Intervention: BOMI) for 3 months
11019806|NCT04638244|Active Comparator|POM Group (Control Group)|Receiving psychoeducational online message (POM) (for focused reading for 5 minutes) daily for 3 months
11019807|NCT04638231|Active Comparator|Text Message Group|This group will receive daily supportive messages through Short Messaging Service (SMS) on their mobile phones in addition to standard care
11019808|NCT04638231|Experimental|Email Message Group|This group will receive same supportive message as the Text Message group but through their email addresses, in addition to receiving standard care
11019809|NCT04638218|Experimental|Augmented Reality|The system provides visual and audio feedback which makes the rehabilitation training process more relaxing, interesting and convenient to guide the patients performing appropriate upper-limb, lower-limb exercises and balance training.
11019810|NCT04638205||Suicide attempt cases|Adolescents and young adults who attempted suicide between 7 and 30 days prior the inclusion
11019811|NCT04638205||Non-suicidal controls|Adolescents and young adults without history of suicide attempt or ideation
11020773|NCT04631328|No Intervention|Control|
11019814|NCT04638192|Sham Comparator|Sham tACS|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect
11019815|NCT04638179||HF-PAC|(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
11019816|NCT04638179||HF-non PAC|(2)The control group received traditional health education in general care and routine health care.
11019817|NCT04638166|Experimental|Mineral water group|The mineral water group were instructed to consume 1.25L of a commercially supplied bicarbonate rich mineral water per day at meal times, supplemented by other fluid intake up to 2.5 - 3L/day.
11019818|NCT04638166|Active Comparator|Plain water group|The plain water group consumed only plain water up to 2.5 - 3L/day.
11019819|NCT04638153|Experimental|Low Dose|Low Dose
11019820|NCT04638153|Experimental|Medium Dose|Medium Dose
11019821|NCT04638153|Experimental|High Dose|High Dose
11019822|NCT04638140||Healthy hip population|
11019823|NCT04638140||Hip defect population|
11019824|NCT04638127|Experimental|PREEMIE PROGRESS|PREEMIE PROGRESS is an innovative, video-based intervention that applies evidence-based family management theories to better equip parents to meet the chronic, complex healthcare needs of their preterm infant.
11019825|NCT04638127|Active Comparator|Attention Control|"To maintain their attention, control parents will view Welcome Videos that explain hand hygiene, visitor IDs, parking, etc. on their mobile devices."
11019826|NCT04638114|Experimental|CAM lesion|Mini-Open DAA Hip Arthroscopy
11019827|NCT04638114|Other|PINCER impingement|Mini-Open DAA Hip Arthroscopy
11019828|NCT04638101|Experimental|Intervention group (RCT)|Participants from the intervention group participated in the mindfulness-based intervention between Time 1 and Time 2.
11019829|NCT04638101|Experimental|Waiting group (RCT)|Participants from the waiting group took part in the mindfulness-based intervention between Time 2 and Time 3.
11019830|NCT04638088||robot-assisted laparoscopy|radical prostatectomy performed by robot-assisted laparoscopy
11019831|NCT04638088||conventional laparoscopy|radical prostatectomy performed by conventional laparoscopy
11019832|NCT04638088||laparotomy|radical prostatectomy performed by laparotomy
11019833|NCT04638075|No Intervention|Group A Bottle Supplementation|Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
11019834|NCT04638075|Experimental|Group B SNS Supplementation|Group B will supplement using the SNS. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the SNS per standard of care. The mother will assemble the SNS, place it clamped and in position at the nipple prior to breastfeeding (see SNS instructions for use). The mother will initiate breastfeeding for up to 5 minutes and then unclamp the SNS to begin supplementation for up to 25 minutes. The SNS will contain either EBM, DHM, formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of SNS use will be determined by the neonate's physician. The mother will pump and hand express after feeding sessions per the IBCLC's recommendation. Them mother will document each feeding session in the feeding log provided at the bedside.
11019835|NCT04638062|Experimental|Post Isometric Relaxation|"This study ARM will receive following therapies
~Post isometric relaxation (Upper Trapezius and Levator Scapulae muscles)
~Isometric neck strengthening exercises
~Cryotherapy"
11019836|NCT04638062|Experimental|Myofascial Release Therapy|"This study ARM will receive following therapies
~Myofascial release therapy (Upper Trapezius and Levator Scapulae muscles
~Isometric neck strengthening exercises
~Cryotherapy"
11019837|NCT04638049|Active Comparator|Prostate (Bed) only RadioTherapy (PBRT)|Primary, adjuvant or salvage RT of the prostate (bed) without RT of the pelvic nodal regions in the small pelvis, according to local hospital guidelines and protocols.
11019838|NCT04638049|Active Comparator|Whole Pelvis RadioTherapy (WPRT)|Primary, adjuvant or salvage RT of the pelvic nodal regions in the small pelvis with possible additional RT of the prostate (bed), according to local hospital guidelines and protocols.
11019839|NCT04638036|Experimental|NIR endoscopy and surgery with cetuximab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, cetuximab-IRDye800CW will be administered to a total of 15 patients with proven locally advanced rectal cancer
11019840|NCT04638010|Experimental|Cancer control navigation (CNN) plus General referral (usual care)|"Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
~Additionally, Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only."
11019841|NCT04638010|Active Comparator|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
11019842|NCT04637997|Other|Study group 1|Wearing of compression stockings class I between Investigation day 28 to 56. Wearing of compression stockings class II between Investigation day 56 to 84.
11019843|NCT04637997|Other|Study group 2|Wearing of compression stockings class II between Investigation day 28 to 56. Wearing of compression stockings class I between Investigation day 56 to 84.
11065179|NCT04320641|No Intervention|control|
11019844|NCT04637984|Experimental|Implementation Group|Predictions will be provided to the rehabilitation team and discussed with the patient and their family. Patients will receive a multidisciplinary rehabilitation according to their individual needs.
11019845|NCT04637984|No Intervention|Control Group|This group will not received any information on the PREP2
11019846|NCT04637971|Experimental|Coaching|The present intervention is a structured, group-based coaching program that is facilitating an active process of change through the identification of achievable personal goals, the formulation of action plans, the provision of constructive feedback, and progressive monitoring of goal attainment.
11019847|NCT04637971|Active Comparator|Self-help tips plus telephone support|Self-help tips including stress coping methods. Our project staff will contact the subject to encourage her to make use of the tips we sent her.
11019848|NCT04637958||pain|THA
11019849|NCT04637958||no pain|THA
11019850|NCT04637945|Placebo Comparator|placebo|The placebo will be delivered in softgels consisting of colorant, olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, glycerin and water.
11019851|NCT04637945|Experimental|ACRB|The ACRB product will be delivered in softgels consisting of anthocyanin-rich blend. Each softgel will contain: i) 49 mg bilberry extract; ii) 101 mg black currant extract; and iii) 303 mg black rice extract. The high ACRB will deliver at least 108 mg anthocyanins. The product will also contain olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, and water.
11019852|NCT04637932|Active Comparator|Use of endotracheal tube During Percutaneous Dilatation Tracheostomy|Group 1 was determined as endotracheal tube
11019853|NCT04637932|Active Comparator|Use of Pro-seal LMA and Bronchoscopy During Percutaneous Dilatation Tracheostomy|group 2 as pro-seal laryngeal mask group.
11019854|NCT04637919|Experimental|IN-B001 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11019855|NCT04637919|Experimental|IN-B001 CVA16 B dose|Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11019856|NCT04637919|Experimental|IN-B001 Bivalent C dose|Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11019857|NCT04637906|Experimental|L-arginine|Bioarginina®, 2 orally administered vials per day
11019858|NCT04637906|Placebo Comparator|Placebo|2 orally administered vials per day of Bioarginina® without L-arginine
11019859|NCT04637867|Other|RT-PCR confirmed COVID-19 patients|RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.
11019860|NCT04637854|Experimental|Operating Microscope.|"Surgical technique is the same used for extraction of the lower third molar. Patients will be enrolled (baseline) whenever sign their written informed consent to participate to the study, after having read and understand the informative pamphlet.
~The intervention will be performed under local anesthesia (mepivacaine 20 mg/ml with adrenaline 1:100000) and by the use of microscope.
~At the end of the surgical procedure, all patients will receive a 100mg Nimesulide cpr and apply the ice pack on the cheek.
~At the end of each procedure will give post-operative instructions for all patients and prescribe an antiseptic therapy with chlorhexidine coll. 0.2% 3 times/ day for 10 days from the day following the intervention and anti-inflammatory therapy Nimesulide 100 mg cpr to take up to 2 times / day for up to 4 days.
~Each patients will be recalled for follow-up visits at 7 days."
11019861|NCT04637854|Active Comparator|Surgical Loupes with coaxial illumination.|The same as above but the intervention will be performed with the use of surgical loupes
11019862|NCT04637854|Active Comparator|Naked Eye.|The same as above but the intervention will be performed at naked eyes
11019863|NCT04637841|Active Comparator|Diabetes Mellitus Kinesiology Taping Group|Kinesiology tape will be applied to the left foot of the participants in diabetes mellitus group.
11019864|NCT04637841|Active Comparator|Kinesiology Taping Control Group|Kinesiology tape will be applied to the left foot of the healthy participants in the control group.
11019865|NCT04637841|Active Comparator|Diabetes Mellitus Myofascial Release Group|Myofascial Release Technique will be applied to the right foot of the participants in diabetes mellitus group.
11019866|NCT04637841|Active Comparator|Myofascial Release Control Group|Myofascial Release Technique taping will be applied to the right foot of the healthy participants in the control group.
11019867|NCT04637828|Experimental|GNS561 plus standard of care|All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
11019868|NCT04637828|No Intervention|standard of care|All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
11019869|NCT04637815|Experimental|Intervention|The intervention will consist of four sessions spaced two weeks apart that will last approximately 30 minutes each and consist of two parts: a network interview to capture network data about the time period since their last interview and a discussion of a resulting network visualization conducted in a motivational interviewing style. Participants will receive the intervention as part of existing case management.
11019870|NCT04637815|Active Comparator|Usual Care|As part of residency, participants receive regular case management meetings.
11019871|NCT04637802|Active Comparator|Pre-operative and Post-operative Education intervention|This arm receives access to Patient Education intervention in the pre- and post-operative phases.
11019872|NCT04637802|Experimental|Pre-operative CBT intervention (SurgeryPal), Post-operative Education intervention|This arm receives access to CBT intervention in the pre-operative phase and Patient Education in the post-operative phase.
11019873|NCT04637802|Experimental|Pre-operative Education intervention, Post-operative CBT intervention (SurgeryPal)|This arm receives access to Patient Education intervention during the pre-operative period and CBT intervention during the post-operative period.
11019874|NCT04637802|Experimental|Pre-operative and Post-operative CBT intervention (SurgeryPal)|This arm receives access to CBT intervention during the pre-operative and post-operative period.
11019875|NCT04637789|Other|controlled group|
11019876|NCT04637789|Experimental|experimental group|
11019877|NCT04637776||Patients with Heart Failure|Patients with heart failure who were discharged within the past month after hospitalization for any reason.
11067970|NCT04300881|No Intervention|Control|
11019878|NCT04637763|Experimental|Dose Escalation of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
11019879|NCT04637763|Experimental|Expansion of CB-010|Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
11019880|NCT04637750|Experimental|Educational intervention|Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
11019881|NCT04637750|No Intervention|Control group|GPs not receiving any informative intervention
11019882|NCT04637737|Experimental|Training group|
11019883|NCT04637737|Other|Control group|
11019884|NCT04637724|Experimental|active tDCS|active prefrotal tDCS: 20 mins pes tDCS session, twice a day for 5 days. Total of 10 ative tDCS sessions.
11019885|NCT04637724|Sham Comparator|Sham tDCS|Sham prefrontal tDCS: sham stimulation 20 mins per session, twice a day for 5 days. Total of 10 sham stimulation sessions
11019886|NCT04637711|Experimental|Specific surgical Intervention|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery
11019887|NCT04637711|No Intervention|Extensive lesion excision|
11019888|NCT04637698|Experimental|Dose expansion|OH2 injection will be administered at 1E+07 CCID50/mL .
11019889|NCT04637685|Active Comparator|Standard pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg
11019890|NCT04637685|Active Comparator|Low or physiological pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg
11019891|NCT04637659||Healthy non-treated teeth|Healthy teeth being treated for restorative or prosthodontics reasons
11019892|NCT04637659||Healthy treated teeth|Teeth being retreated for restorative or prosthodontics reasons
11019893|NCT04637659||Irreversible pulpitis|Teeth being treated because of a poor pulpal status
11019894|NCT04637659||Post-treatment apical periodontitis|Teeth being retreated due to the presence of an apical lesion
11019895|NCT04637659||Necrosis|Teeth being treated because of pulpal necrosis
11019896|NCT04637646||children with MPS|
11019897|NCT04637633|Experimental|Cyclosporine A|All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
11019898|NCT04637620|Experimental|NMDAE|An NMDA enhancer
11019899|NCT04637620|Active Comparator|SSRI|Sertraline (selective serotonin reuptake inhibitor)
11019900|NCT04637620|Placebo Comparator|Placebo|Placebo
11019901|NCT04637607|Experimental|Group A|The subjects will receive true auricular acupoints stimulation during the first round of play. After finishing the first round, the subjects will receive sham auricular acupoints stimulation.
11019902|NCT04637607|Other|Group B|The subjects will receive sham auricular acupoints stimulation during the first round of play. After finishing the first round, the subjects will receive true auricular acupoints stimulation. (Crossover)
11019903|NCT04637594|Active Comparator|Arm A (immune checkpoint inhibitor)|"CONTINUATION OF ICI TREATMENT:
~Patients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity."
11019904|NCT04637594|Experimental|Arm B (immune checkpoint inhibitor)|"DISCONTINUATION OF ICI TREATMENT:
~Patients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion."
11019905|NCT04637581|Experimental|Wraparound|Wraparound is a 12-month intervention including a family-centered discovery process to identify values, needs, and strengths to help the family be successful in reaching family functioning and parental recovery goals; weekly or twice weekly family meetings with the Wraparound coordinator; intensive care coordination among systems and providers (substance use disorder, mental health, schools, pediatrics, homeless shelters, etc.); and bi-monthly family-centered team meetings (including the family's natural and professional supports) to discuss strategies, progress and continued needs. Wraparound coordinators (2) work with up to 10 families at a time and receive extensive training (including observation) and supervision by expert trainers at University of New Hampshire.
11019906|NCT04637581|No Intervention|treatment-as-usual|"The treatment-as-usual group will receive a packet of local services and referral contacts and treatment as usual as directed by any healthcare providers working with the family. The project team will contact treatment-as-usual families on a monthly basis to confirm any services the family may be receiving, provide reminders of scheduled assessment dates, and give small incentives ($10 gift card) when families report changes in contact information to reduce risk for loss to follow-up."
11019907|NCT04637568||Maxillary Deficiency|59 CT scans of patients with maxillary deficiency requiring Le Fort osteotomy
11019908|NCT04637568||Control|61 CT scans of healthy patients
11019909|NCT04637555|Experimental|LCZ696 (sacubitril/valsartan)|Following start of treatment, patients will receive LCZ696. Possible doses are level 1, 2, and 3 (50, 100 and 200 mg twice daily respectively)
11019910|NCT04637542|Experimental|Control Group (Traditional)|"Application in the Control Group: After the theoretical lesson, the control group was taken to the Anatomy Laboratory. The laboratory consists of three application rooms, one control room and one analysis room. The Anatomy of the Organs Forming the Genital System was explained using an anatomical model of the genital system organs by a researcher responsible for the human anatomy course. Students were given time until the end of the lesson to work on the models. During this time, their questions were answered. At the end, all of the students were given a State Inventory by the researcher and asked to fill it in. Students were then asked to use textbooks and atlases to study for the Knowledge Test (post-test) which took place three days later."
11019948|NCT04637230||Ventricular Tachycardia, Nonsustained|Patients with episodes of nonsustained ventricular tachycardia in between sinus beats
11019949|NCT04637217||Control|
11019950|NCT04637217||Diabetes mellitus without Diabetic Retinopathy|
11019951|NCT04637217||Diabetes mellitus with Diabetic Retinopathy|
11019911|NCT04637542|Experimental|Experimental Group (Mobile)|"Application in Experimental Group: After the theoretical lesson, students in the experimental group were taken to an empty classroom. The mobile application was installed on the smartphones of the students in the experimental group by the researchers and they were told not to share it with anyone until the end of the study. At the end of the study, the mobile application was also installed on the phones of the students in the control group due to ethical sensitivity. Anatomy of Organs Forming the Genital System was explained on the mobile application containing the genital system organs. The students were allowed to ask questions and the questions were answered. Afterwards, all students in the experimental group were given a State Inventory by the researcher and asked to fill it in. Students were then asked to study using the genitalsystem.apk mobile application until the Knowledge Test (post-test) which took place three days later."
11019912|NCT04637529|Experimental|S (+) - Ibuprofen|S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
11019913|NCT04637529|Active Comparator|Ibuvix® - ibuprofen|Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
11019914|NCT04637516|Active Comparator|Programme Version 60 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 60 sec"
11019915|NCT04637516|Placebo Comparator|Programme Version 300 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 300 sec"
11019916|NCT04637503|Experimental|effectiveness of CAR-T cells targeting GD2, PSMA and CD276|Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB
11019917|NCT04637490|Experimental|patellar resurfacing|patellar resurfacing in TKA
11019918|NCT04637490|No Intervention|non-resurfacing|non-resurfacing TKA
11019919|NCT04637477|Experimental|Virtual ELM|
11019920|NCT04637464|Experimental|Experimental group|"Discontinuation of empirical antibiotics, despite neutrophil count below 0.5x10⁹ cells/L, after 48 hours of apyrexia and clinical stability.
~A child is considered clinically stable when there is resolution of all symptoms and signs of infection, and normalization of vital signs including heart rate, respiratory rate, oxygen saturation, blood pressure, and daily diuresis."
11019921|NCT04637464|No Intervention|Control group|Discontinuation of antibiotics when neutrophil count is equal to or above 0.5x10⁹ cells/L, and the child is afebrile and clinical stable OR the child has received 10 days of antibiotics and have been afebrile and clinically stable for 7 days
11019922|NCT04637451|Experimental|Gingival Unit Graft|For test group, gingival recessions were treated with gingival unit graft.
11019923|NCT04637451|Other|Connective Tissue Graft|For Control group, gingival recessions were treated with connective tissue graft.
11019924|NCT04637438|Active Comparator|Fecal Microbiota Transplantation|
11019925|NCT04637438|Placebo Comparator|Plasebo|
11019926|NCT04637425|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
11019927|NCT04637425|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
11019928|NCT04637412|Experimental|Control label|"Participant will see a QR code and footnote saying, Scan the QR code for more menu information. The label will be applied to all menu items displayed."
11019929|NCT04637412|Experimental|Icon plus text added sugars label|Participant will see a label containing an icon plus text label with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 18 variations of icons and text in this arm.
11019930|NCT04637412|Experimental|Icon only added sugars label|Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
11019931|NCT04637399||Ulcerative Colitis|Participants diagnoses with Ulcerative Colitis.
11019932|NCT04637399||Crohn's Disease|Participants diagnosed with Crohn's Disease.
11019933|NCT04637386||Group A (inevitable/incomplete abortion):|Includes 15 patients with severe vaginal bleeding or part of the product of conception pass through the cervix, cx opened, and -ve fetal pulse.
11019934|NCT04637386||Group B (with vaginal bleeding during cerclage placement):|Includes 15 patients with vaginal bleeding during cerclage
11019935|NCT04637373|Experimental|the group|Women aged 18-40 years who admit to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment, are having Hysteroscopy assisted suction curettage as detailed previously. retained products of conception found at the end of the procedure, and intrauterine adhesions found on follow up are compared to the data in the literature.
11019936|NCT04637360|Experimental|Cinacalcet treatment|hyperparathyroid dialysis patients using cinacalcet and active vitamin D for 6 months
11019937|NCT04637360|Experimental|traditional therapy active vitamin D|hyperparathyroid dialysis patients using traditional therapy active vitamin D without use cinacalcet for 6 months.
11019938|NCT04637347|Other|IP-ISV|In-plane infraclavicular subclavian vein catheterization
11019939|NCT04637347|Other|IP-SSV|In-plane supraclavicular subclavian vein catheterization
11019940|NCT04637308|Experimental|Succinylated gelatin|The patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day.
11019941|NCT04637308|No Intervention|Control|Observation.
11019942|NCT04637282|Other|PLX-200|This is an open-label, non-comparator, non-randomized study of PLX-200 in patients with CLN3 disease.
11019943|NCT04637269|Experimental|BCMA CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
11019944|NCT04637230||Sinus Rhythm|Subjects/patients in normal sinus rhythm
11019945|NCT04637230||Atrial Fibrillation|Patients with atrial fibrillation
11019946|NCT04637230||Atrial Premature Complexes|Patients with atrial premature complexes in between sinus beats
11019947|NCT04637230||Ventricular Premature Complexes|Patients with ventricular premature complexes in between sinus beats
11021808|NCT04624334||Adults with motility disorder|
11019952|NCT04637204||Subgroup 1|Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
11019953|NCT04637204||Subgroup 2|Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
11019954|NCT04637204||Subgroup 3|Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
11019955|NCT04637204||Subgroup 4|Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)
11019956|NCT04637191|Experimental|MentalPlus®|This group performed the task in the digital game for 25 minutes and later will be evaluated with standardized and validated neuropsychological tests for the studied population.
11019957|NCT04637178|Experimental|Resistance training added to endurance training|Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks
11019958|NCT04637178|Other|Endurance training|Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks
11019959|NCT04637152|Active Comparator|Group A: Usual recommended therapy|Antihypertensive regimen based on the usual recommended (optimized) therapy.
11019960|NCT04637152|Experimental|Group B: Sacubitril/Valsartan|Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.
11019961|NCT04637139|Experimental|Group 1|VBR 300 mg solution containing 2 µCi [14C]VBR
11019962|NCT04637126||mechanically ventilated and sedated patients with sinus rhythm|all mechanically ventilated and sedated patients with sinus rhythm hospitalized in our ICU and fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure
11019963|NCT04637113||All patients admitted to the PICU meeting eligible criteria|This is a non-interventional study.
11019964|NCT04637100|Experimental|Experimental|The patient will utilize their personal mobile or tablet device to play a pre-selected set of problem-solving games for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
11019965|NCT04637100|Active Comparator|Control|The patient will utilize their personal mobile or tablet device to watch a pre-selected set of stroke-related educational videos for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
11019966|NCT04637087|Experimental|Atrial Fibrillation Risk Estimation Tool|For eligible patients presenting with an acute ischemic stroke, a clinical atrial fibrillation risk estimation tool will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the stroke neurologist caring for the patient when they first open the patient's chart. The neurologist may accept the automatically generated atrial fibrillation risk score displayed in the BPA, may modify some of the inputs of the score based on the patient's personal medical history and re-calculate, or may choose to dismiss the BPA.
11019967|NCT04637061||REC4T study patients|Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)
11019968|NCT04637035|Experimental|Supportive Oncology Care at Home|"Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital.
~The Supportive Oncology Care at Home intervention consists of three key components:
~Daily monitoring of patient-reported symptoms, vital signs, and body weight.
~Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight.
~Structured communication with the oncology team regarding care delivered to ensure continuity of care."
11019969|NCT04637022||3D laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 3D laparoscopic camera
11019970|NCT04637022||4k laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 4k laparoscopic camera
11019971|NCT04637009|Experimental|Part 1 (dose escalation)|Oral administration of TAS1553 once daily at specific time points.
11019972|NCT04637009|Experimental|Part 2 (dose expansion)|Oral administration of TAS1553 once daily at specific time points.
11019973|NCT04636996|Experimental|artificial intelligence assisted follow-up group|artificial intelligence assisted follow-up group
11019974|NCT04636996|Placebo Comparator|Control group|Control group
11019975|NCT04636983|Experimental|BV100|BV100 intravenous infusion
11019976|NCT04636983|Placebo Comparator|Placebo|Saline intravenous infusion
11019977|NCT04636970|No Intervention|Control group|Patients randomised to control group will get usual recommendations regarding physical activity after a discharge from inpatient cardiac rehabilitation.
11019978|NCT04636970|Experimental|Intervention group|Patients randomised to intervention group will continue home exercise training that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after. Study participants well receive telephone calls every other week and were asked to answer questions regarding their health and physical activity.
11019979|NCT04636957|Experimental|ciprofloxacin 0.3% plus fluocinolone acetonide 0.025%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h , morning and evening) for 7 consecutive days.
11019980|NCT04636957|Active Comparator|ciprofloxacin 0.3%|Warm the otic solution by holding the vial in the hands for 1 to 2 minutes. Twist off the vial cap. Tilt the subjects' head to one side to keep the affected ear up. Instill the content of 1 vial in the ear (0.25mL). Gently pull the outer ear lobe upward and outward to allow the solution to flow into the ear canal. Keep the subjects' head tilted sideways for approximately 5 minutes to allow the drug time to penetrate the ear. Use twice daily (every 12±1h, morning and evening) for 7 consecutive days
11019981|NCT04636918|Other|Single arm|Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
11021809|NCT04624334||Healthy adults|
11019982|NCT04636905||Survivorship Wellness Group|Participants will be enrolled in a 15 week program to assess quality of life and general health outcomes
11019983|NCT04636892|Experimental|Severe aortic stenosis|"Patients with echocardiographic evidence of severe aortic stenosis as defined by:
~Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2"
11019984|NCT04636892|Experimental|Severe mitral regurgitation|"Patients with echocardiographic evidence of severe mitral regurgitation as defined by:
~Central jet MR >40% LA or holosystolic eccentric jet MR
~Vena contracta ≥0.7 cm
~Regurgitant volume ≥60 mL
~Regurgitant fraction ≥50%
~ERO ≥0.40 cm2
~Angiographic grade 3 to 4+"
11019985|NCT04636892|Experimental|Heart Failure with Reduced EF <35%|Patients with echocardiographic evidence of left ventricular ejection fraction of < or = to 35%
11019986|NCT04636892|Experimental|Pulmonary Hypertension|Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) >20mmHg
11019987|NCT04636892|Experimental|Suspected coronary artery disease|Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease
11019988|NCT04636879|Experimental|• Group 1. Positive expectation|"Dry needling is a very effective tool used in the treatment of nonspecific neck pain, which we hope will reduce your neck pain."
11019989|NCT04636879|Active Comparator|• Group 2. Neutral Expectation|"Dry needling is an indicated tool used in the treatment of nonspecific neck pain, but its efficacy is unknown."
11019990|NCT04636879|Active Comparator|• Group 3. Negative Expectation|"Dry needling is not a very effective treatment tool for nonspecific neck pain, so we expect your neck pain to increase a bit."
11019991|NCT04636866||Gastric ulcer|
11019992|NCT04636866||Duodenal ulcer|
11019993|NCT04636853|Experimental|Affected Individual|A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
11019994|NCT04636840|No Intervention|Control Group|Care as usual-referral to nationwide resources for eating disorders (NEDA)
11019995|NCT04636840|Experimental|Experiemental Group A- Mobile App with Social Networking Feature|Access to Space From Body and Eating Concerns program on SilverCloud Health App in addition to access to Private Facebook group for social networking support.
11019996|NCT04636840|Experimental|Experimental Group B- Mobile App Only|Access to Space From Body and Eating Concerns program on SilverCloud Health App.
11019997|NCT04636827|Experimental|group 1 (sIPV+DTaP+HepA)|150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively
11019998|NCT04636827|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
11019999|NCT04636827|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
11020000|NCT04636827|Active Comparator|group 4 (HepA)|150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old
11020001|NCT04636814|Experimental|CHF6001 1600µg|
11020002|NCT04636814|Experimental|CHF6001 3200µg|
11020003|NCT04636814|Placebo Comparator|Placebo|
11020004|NCT04636814|Active Comparator|Roflumilast|
11020005|NCT04636801|Experimental|CHF6001 1600µg|
11020006|NCT04636801|Experimental|CHF6001 3200µg|
11020007|NCT04636801|Placebo Comparator|CHF6001 Placebo|
11020008|NCT04636788|Other|pancreatic cancer group|"pancreatic cancer, anticipated participants: 68
~other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34"
11020009|NCT04636775||Immunotherapy naïve NSCLC patients|Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade
11020010|NCT04636762|Experimental|Treatment (etoposide, cisplatin, carboplatin, radiation, Atezolizumab)|Participants receive EC/EP chemotherapy combined with Atezolizumab for 2 cycles, and the efficacy is evaluated 2 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy with EC/EP(2 cycles) + Atezolizumab will be initiated. After concurrent chemoradiotherapy+ Atezolizumab, Atezolizumab was maintained until PD or intolerance or for at most 2 years. Participants with brain metastases will receiveradiotherapy forbrain metastases during the first 2 cycles of chemotherapy.
11020011|NCT04636749|Active Comparator|Erbium laser|Treatment with Erbium laser
11020012|NCT04636749|Sham Comparator|Sham laser|Treatment with sham laser
11020013|NCT04636736||HIV POLISH (PL)|HIV infected people with polish nationality, who most probably acquired infection in Poland
11020014|NCT04636736||HIV MIGRANTS (M)|HIV infected people, originating from outside of Poland, where they were diagnosed with HIV infection
11020015|NCT04636723||CSS Patients|HNC patients presenting chronic systemic symptoms
11020016|NCT04636723||Healthy Controls|Non-clinical controls
11020017|NCT04636710|Experimental|Sentinal Node Identification|"Within standard of care treatment for inflammatory breast cancer, participants will undergo a series of Lymphoscintigraphies: an imaging procedure to determine where their lymphatic system drains from their breast.
~Prior to neoadjuvant chemotherapy
~Day before surgery
~These two imaging studies will be compared and the information used during participant's surgery to perform the sentinel node biopsy procedure.
~During surgery participants will have a blue dye injected to affected breast to map drainage and identify sentinal nodes. The sentinal nodes will be removed first, followed by standard of care procedure to remove all axillary lymph nodes.
~After surgery, a small amount of tissue from the tumor removed during surgery will be evaluated.
~Participants will complete a Lymphedema Questionnaire after each Lymphoscintigraphy then every 6 months for 2 years post surgery."
11020018|NCT04636697|Placebo Comparator|Placebo|Placebo (0.5 mL)
11020019|NCT04636697|Experimental|3.75 µg of CoVLP Vaccine adjuvanted|3.75 µg of CoVLP adjuvanted vaccine with AS03 adjuvant (0.5 mL)
11020020|NCT04636684|Experimental|patients undergoing surgical valve replacement for degenerative aortic stenosis|
11020081|NCT04636320|Experimental|Patient group COVID-19|120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization
11020082|NCT04636320|Active Comparator|Healthy volunteer group|120 healthy volunteers. Age- and sex-matched controls
11020083|NCT04636294||COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.|
11020605|NCT04632511|Other|Obese group|Metabolome measurements on feces and urine.
11020021|NCT04636671|Experimental|Methylprednisolone|"A. On day 1, loading dose of methylprednisolone (MP) 80 mg IV in 30 minutes, promptly followed by continuous infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.
~B. From day 2 to day 8: infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h.
~C. From day 9 and beyond:
~If not intubated patient and PaO2/FiO2 > 200, taper to MP 20 mg IV in 30 minutes three times a day for 3 days, then MP 20 mg IV twice daily for 3 days, then MP 20 mg IV once daily for 2 days, then switch to MP 16 mg/day PO for 2 days, then MP 8mg/day PO for 2 days, then MP 4mg/day PO for 2 days;
~If intubated patient or PaO2/FiO2 <= 200 with at least 5 cmH2O CPAP, continue infusion of MP 80 mg/day in 240 mL of normal saline at 10 mL/h until PaO2/FiO2 > 200 then taper as in a)"
11020022|NCT04636671|Active Comparator|Dexamethasone|"A. Dexamethasone (DM) 6 mg IV in 30 minutes or PO from day 1 to day 10 or until hospital discharge (if sooner).
~B. After day 10 study treatment is interrupted."
11020023|NCT04636658|Active Comparator|Incentive spirometer training|Incentive spirometer training
11020024|NCT04636658|Experimental|diaphragmatic resistance exercises|Incentive spirometer training with diaphragm breathing with resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient
11020025|NCT04636645|Active Comparator|Normal Treadmill|After completion of the baseline evaluation, Group A participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. For each session, 20% support will be given to participants
11020026|NCT04636645|Experimental|Anti-gravity treadmill with lower limb positive pressure|Group B participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
11020027|NCT04636645|Experimental|Anti-gravity treadmill with without lower limb positive pressure|Group C participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
11020028|NCT04636632|Experimental|Weekly Arm|fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy
11020029|NCT04636632|Active Comparator|Triweekly Arm|fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy
11020030|NCT04636619|Active Comparator|Incomplete polypectomy report|An online course will be offered that will explain the technique for excision of lesions with a cold loop and the importance of complete resection, techniques to determine the edges of the lesion and possible remains at the polypectomy base through images, video clips. and interaction with the speakers
11020031|NCT04636619|Active Comparator|On-line training course|Each participant will receive the global data, the results obtained by all the endoscopists (anonymously except for each interested party, the rest being identified by codes), as well as a detailed analysis of their results, comparing them with the joint data and the 3 tertiles.
11020032|NCT04636606|Active Comparator|Home Exercise|Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.
11020033|NCT04636606|Active Comparator|Manual Therapy Combined with Home Exercise|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.
~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
11020034|NCT04636606|Active Comparator|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|"Orofacial Myofunctional therapy includes stretching the tongue muscles, tongue rotation exercises, isometric and isotonic strengthening of the tongue, special maneuver, effortful swallow exercise, strengthening exercise of hyoidal muscles.
~Manual Therapy includes deep friction massage and myofascial relaxation techniques to masticatory and neck muscles, active and resistant temporomandibular joint movements, temporomandibular joint distraction and mobilization, stretching techniques to the temporomandibular joint, mobilization of upper cervical joints.
~Home Exercise program includes educational training program about parafunctional activities of patients having oral dysphagia with temporomandibular disorders. Program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises."
11020035|NCT04636593|Experimental|Induction group|If the lung V20 of initial radiation plan is equal to or more than 28%, then the patient will receive 2 months almonertinib before concurrent thoracic radiotherapy
11020036|NCT04636593|Experimental|Concurrent group|If the lung V20 of initial radiation plan is less than 28%, then the patient will receive concurrent thoracic radiotherapy with almonertinib.
11020037|NCT04636580|Experimental|anxious parent|Parents were divided into two groups anxious and non-anxious.
11020038|NCT04636580|Experimental|non-anxious parent|Parents were divided into two groups anxious and non-anxious.
11020039|NCT04636567|Experimental|Nerindocianine for injection|One Arm: Nerindocianine for Injection (0.055 mg/kg body weight); solution, intravenous, one time administration during surgery.
11020040|NCT04636541|Experimental|Goal Management Training|GMT modules were adapted for French-speaking patients with PD-MCI. Each session was reduced from nine 90-120-minute sessions (original GMT) to five 60-90-minute sessions, one session per week, in order to avoid fatigue. As for original GMT, participants were given exercises between sessions (mindfulness exercises and metacognitive reflections). In original-GMT, some information is repeated several times, but not in Adapted-GMT. Exercises demanding motor dexterity, such as card distribution, were removed. Adapted-GMT included information on PD-MCI and executive dysfunction (some psychoeducation). In addition, Adapted-GMT modules were administered individually with an iPad, as opposed to a power-point group presentation in original-GMT. A workbook was handed to participants, as in previous studies.
11020117|NCT04636008|Experimental|Experimental arm|Sintilimab+Hypofractionated radiotherapy
11020157|NCT04635774|Placebo Comparator|Placebo Group|The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).
11020041|NCT04636541|Active Comparator|Psychoeducation sessions coupled mindfulness exercises|Five modules were designed as a discussion with patients and caregivers about various PD symptoms: module I-brain and motor symptoms; module II-autonomic symptoms; module III- psychological symptoms; module IV-brain and cognition; and module V-cognitive impairments in PD. Patients were handed the information book about the five modules at the beginning of the study. The objective was to improve their understanding of their condition and to discuss other components that could affect their cognitive abilities. After the 40-60-minute informative part, mindfulness exercises were offered for 20-30 minutes per session. Participants were not invited to practice exercises between sessions, but 3/6 participants reported they did.
11020042|NCT04636528|Experimental|Digital Rehabilitation|Home-based 8-week rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist
11020043|NCT04636528|Active Comparator|Conventional Rehabilitation|Outpatient clinic-based 8 week rehabilitation program with face-to-face PT sessions
11020044|NCT04636515|Experimental|Single Arm|
11020045|NCT04636502||Cohort|Participants who had treated with fSCIG (HyQvia) for not more than 27 months and SCIG 20% (Cuvitru) for not more than 35 months.
11020046|NCT04636489|Experimental|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.
11020047|NCT04636489|Placebo Comparator|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.
11020048|NCT04636476|Other|Modified Nesbit technique followed by dorsal dartos flap|Modified Nesbit technique to correct penile curvature followed by dorsal dartos flap to correct penile torsion
11020049|NCT04636463|Experimental|Hand Surgery with Music|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) while listing to music
11020050|NCT04636463|No Intervention|Hand Surgery without Music (Control Group)|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) without listening to music
11020051|NCT04636450|Active Comparator|Adult manual instrumentation|Primary mandibular molars who are treated with a manual pulpectomy and a K-file system.
11020052|NCT04636450|Experimental|Pediatric manual instrumentation|Primary mandibular molars treated with a manual pulpectomy and a Kedo-SH system.
11020053|NCT04636450|Active Comparator|Adult rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system.
11020054|NCT04636450|Experimental|Pediatric rotatory instrumentation|Primary mandibular molars treated with a rotatory technique pulpectomy and a Kedo-S system
11020055|NCT04636437|Experimental|DOR 100 mg + TAF/FTC (or TAF/3TC, depending on location)|
11020056|NCT04636437|Experimental|DOR 100 mg + TDF/FTC (or TDF/3TC, depending on location)|
11020057|NCT04636437|Experimental|Continuation of entry INSTI+TAF/FTC (or TAF/3TC)|
11020058|NCT04636424|Experimental|spastic diplegic group|assessment of the speed and weight distribution during gait
11020059|NCT04636424|Experimental|hemiplegic group|assessment of the speed and weight distribution during gait
11020060|NCT04636411|Experimental|Intervention group|This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients
11020061|NCT04636411|Active Comparator|Control group|This group will receive the standard care for diabetic patients
11020062|NCT04636398|Experimental|MESSAGE mHealth group intervention|Participants in the one arm will be exposed to the mHealth group intervention. As this is a pilot developmental study, the participants will be exposed to various strategies for information delivery (live presentation at a scheduled time versus voice recording accessible at any time), discussion facilitation (heavily managed with request to speak vs. natural discussion participation), and text communication management (moderator-facilitated vs. group-led).
11020063|NCT04636372|Experimental|Intense pulsed light therapy group|
11020064|NCT04636372|Experimental|Hot compress massage group|
11020065|NCT04636372|Experimental|Intense pulsed light therapy and hot compress massage group|
11020066|NCT04636359|Experimental|Long term course of migraine patient without aura|Patients in this group have the history of migraine without aura more than 5 years.
11020067|NCT04636359|Experimental|Short term course of migraine patient without aura|Patients in this group have the history of migraine without aura equal or less than 5 years.
11020068|NCT04636346||COMPASS (Psychoeducational / Behavioral Program)|Group Acceptance and Commitment Therapy program as part of clinical service for cancer patients
11020069|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 14.
11020070|NCT04636333|Experimental|Middle-dose vaccine (18-59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14 28.
11020071|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 14.
11020072|NCT04636333|Experimental|High-dose vaccine (18-59 years) & Three dose regimen|Two doses of High-dose vaccine at the schedule of day 0, 14, 28.
11020073|NCT04636333|Experimental|Middle-dose vaccine (> 59 years) & Three dose regimen|Three doses of middle-dose experimental vaccine at the schedule of day 0, 14, 28.
11020074|NCT04636333|Experimental|High-dose vaccine (> 59 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
11020075|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 14.
11020076|NCT04636333|Placebo Comparator|Middle-dose placebo (18-59 years) & Three dose regimen|Three doses of middle-dose placebo at the schedule of day 0, 14, 28.
11020077|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 14.
11020078|NCT04636333|Placebo Comparator|High-dose placebo (18-59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
11020079|NCT04636333|Placebo Comparator|Middle-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
11020080|NCT04636333|Placebo Comparator|High-dose placebo (> 59 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
11020084|NCT04636281|Experimental|Passive static stretching exercise|Group 1 will receive passive static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
11020085|NCT04636281|Experimental|Active static stretching|Group 2 will receive active static stretching. All subjects will be assessed before the intervention through likert muscle soreness scale, Numeric Rating Pain Scale and range of motion for Shoulder, elbow, and wrist by a Goniometer. After that all subjects will perform eccentric exhaust weight exercises in the gym of all mentioned joints, three sets at each joint. Before giving the intervention they will assess of all mentioned parameters.
11020086|NCT04636268|Experimental|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.
~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
11020087|NCT04636255|Experimental|Exercise training group|Patients in the experimental group, under clinic follow up will perform combined exercise training for 16 weeks
11020088|NCT04636255|Sham Comparator|Control Group|Patients will be only clinically followed up. They will not perform exercise training.
11020089|NCT04636242|Experimental|Group 1: Phototherapy Group|patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be applied to the area of the shoulder where the 5-ALA was administered
11020090|NCT04636242|Active Comparator|Group 2: Control Group|patient will undergo standard of care surgery
11020091|NCT04636229|Experimental|ASA|Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)
11020092|NCT04636229|Placebo Comparator|Placebo|Participants receive a single IA injection of 4 mL of normal saline
11020093|NCT04636216|Experimental|Community Parent Education Program (COPE) parent training program|Parents will enroll in an 8-week, group parenting program.
11020094|NCT04636203||General population|A sample of 3,000 men and women, residents in the territories of ASST Sette Laghi (Lombardia) and of Molise Region will be randomly selected from the municipal registries, and will be invited to participate.
11020095|NCT04636203||Healthcare workers (HCWs)|All HCWs from the occupational registries of ASST Ospedale di Circolo Varese (Lombardia) and IRCCS Neuromed Pozzilli (Molise) will be invited to participate, up to reach 500 recruited subjects.
11020096|NCT04636190|Other|Triathlon All-Polyethylene Tibia Knee|All subjects enrolled will have received the Triathlon All-Polyethylene Tibia Knee device.
11020097|NCT04636177|Active Comparator|Standard Physiotherapy Rehabilitation (SPR)|Sessions are individually-tailored and based on the Guide to Physical Therapy Practice 3.0 consisting of 1) therapeutic exercise, 2) balance and proprioception, 3) strength training, and 4) use of modalities (e.g., heat/cold pack). Patients will be given a structured Home Exercise Program (HEP) with prescribed exercises for home. SPR participants will be allocated a VR headset for recreational use.
11020098|NCT04636177|Experimental|Pain Rehabilitation Virtual Reality (PRVR)|Sessions will follow the same guidelines as SPR, with half of the physiotherapy (PT) sessions delivered in virtual reality (VR). VR in PT will engage participants in a series of immersive games customized to align with individual PT needs. Patients in the PRVR arm will be given a structured HEP to practice prescribed exercises at home with integrated VR activities. PRVR participants will be allocated a VR headset for use in PT sessions and with HEP.
11020099|NCT04636164|Experimental|DNN group|using deep neural networks for skin lesion diagnosis
11020100|NCT04636164|No Intervention|Control group|conventional diagnosis
11020101|NCT04636151|Experimental|Individual Treatment|Participants will have up to three individual sessions with a study therapist. One or more treatment modules will be presented in each session.
11020102|NCT04636151|Experimental|Group Treatment|Participants will have up to three group sessions with a study therapist. One or more treatment modules will be presented in each session.
11020103|NCT04636151|Experimental|Workshops|Participants will have one workshop with a study therapist. All three treatment modules will be presented in one session.
11020104|NCT04636138|Experimental|Single arm|
11020105|NCT04636125|Other|Revision Total Shoulder Arthroplasty|Routine cultures are taken at the time of surgery. All patients are seen by an Infectious Disease Specialist and placed on 2 weeks oral doxycycline 100 mg (or alternative based on allergy or sensitivity) pending culture results.
11020106|NCT04636112||control group|Patients hospitalized and diagnosed as non-AMI during the same time period were matched. All patients underwent coronary angiography and CAD was defined as at least one main coronary artery with > 50% narrowing of luminal diameter.
11020107|NCT04636112||AMI group|Patients were diagnosed as MI when a cardiac biomarker (preferably cardiac troponin) rose or fell at least one value in its 99th percentile upper reference limit and at least one of the following criteria was met, including ischemic symptoms, electrocardiogram (ECG) changes of new ischemia, pathologic Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy.
11020108|NCT04636099|Experimental|CTA Group|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
11020109|NCT04636099|No Intervention|Non-CTA Group|The CTA group was routinely peformed upper abdomen enhenced without CT Angiography before surgery
11020110|NCT04636086|Experimental|Test treatment|Test Treatment: Ampoule for enteral use containing 25,000 IU/mL of cholecalciferol taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
11020111|NCT04636086|Placebo Comparator|Placebo treatment|Placebo Treatment: Ampoule of placebo for enteral use containing excipient only taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
11020112|NCT04636073|Experimental|Leaflex™ Performer|
11020113|NCT04636060|Experimental|Iron-treatment group|
11020114|NCT04636034|Experimental|Local anesthetic|
11020115|NCT04636034|Placebo Comparator|Placebo|
11020116|NCT04636034|Sham Comparator|"Sham-block with Placebo"|
11020118|NCT04635995|Experimental|Monotherapy dose escalation|The monotherapy dose escalation phase includes 8 dose levels of LVGN7409. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
11020119|NCT04635982|Placebo Comparator|Placebo Group|With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
11020120|NCT04635982|Experimental|Experimental Group|In rectus femoris, origin was under the anterosuperior iliac spines, and taping finished with a Y-shape pattern under the patella. After that, an I-shaped KT was applied over vastus medialis and vastus lateralis muscles in both quadriceps. Finally, subjects were taped with a Y-shaped KT at the gluteus maximus muscles. Tape tension was between 25% and 50%.
11020121|NCT04635982|No Intervention|Control Group|It has not done any intervention in this group.
11020122|NCT04635969|Experimental|Experimental: Children training|All registered participants in intervention group will participate in a series of trainings on sexuality education.
11020123|NCT04635969|No Intervention|Control: No intervention|All registered participants in control group will not participate in a series of trainings on sexuality education.
11020124|NCT04635956|Experimental|Study group|Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab
11020125|NCT04635943|Active Comparator|Ivermectin|Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.
11020126|NCT04635943|Placebo Comparator|Placebo|Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.
11020127|NCT04635930|Experimental|Taping plus Traditional exercises|"kinesio tape for improving the alignment of the scapula by inhibiting the hyperactive upper trapezius and facilitating the weak serratus anterior muscleStretching of the tight muscles of upper limb.
~Reaching forward sidewise and backward.
~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).
~Prone lying weight bearing on elbows (four point kneeling)
~side sitting with weight bearing on the effected side, for 5 minutes.
~Wall pushups.
~Catching and throwing of ball"
11020128|NCT04635930|Active Comparator|Traditional exercises|"Stretching of the tight muscles of upper limb.
~Reaching forward sidewise and backward.
~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).
~Prone lying weight bearing on elbows (four point kneeling)
~side sitting with weight bearing on the effected side, for 5 minutes.
~Wall pushups.
~Catching and throwing of ball"
11020129|NCT04635917|Experimental|Personalized diet - Black adults|Young Black adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
11020130|NCT04635917|Experimental|Personalized diet - White adults|Young White adults in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting their dietary goals, participants will be provided with nuts, fruits, and vegetables.
11020131|NCT04635917|Other|Conventional dietary advice- Black adults|Young Black adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
11020132|NCT04635917|Other|Conventional dietary advice- White adults|Young White adults will receive non-personalized, conventional dietary advice based on the MyPlate guidelines.
11020133|NCT04635904|Experimental|Imaginal exposure|A behavioral intervention in imagery
11020134|NCT04635904|Experimental|Imagery rescripting|A different behavioral intervention in imagery
11020135|NCT04635891||Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits will occur per standard of care.
11020136|NCT04635878||Sepsis group|patients suffering from sepsis hospitalized in intensive care unit
11020137|NCT04635878||Control group|patients without infection hospitalized in intensive care unit
11020138|NCT04635865|Experimental|3D-printed patient-specific plate group|3D-printed patient-specific plate will be used for reconstruction in this patient group
11020139|NCT04635865|Active Comparator|Conventional plate group|conventional commercial plates will be used for reconstruction in this patient group
11020140|NCT04635852|Experimental|Fentanyl|Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet)
11020141|NCT04635852|Active Comparator|Immediate release morphine|Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)
11020142|NCT04635839|Active Comparator|Standard Dosing|Standard dose of unfractionated heparin
11020143|NCT04635839|Active Comparator|Gestational Age-Based Dosing|Dose of unfractionated heparin based on trimester of pregnancy
11020144|NCT04635826|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
11020145|NCT04635826|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo
11020146|NCT04635826|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
11020147|NCT04635826|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall
11020148|NCT04635813||Group 1 - COVID group|Patients that underwent surgery during COVID-19 pandemic
11020149|NCT04635813||Group 2 - control group|Patients that underwent surgery during 2019
11020150|NCT04635800|Experimental|Cohort 1|Cohort 1; open-label, non-randomized, single administration
11020151|NCT04635800|Experimental|Cohort 2|Cohort 2; open-label, non-randomized, single administration
11020152|NCT04635800|Experimental|Cohort 3|Cohort 3, open-label; non-randomized, single administration
11020153|NCT04635800|Experimental|Cohort 4|Cohort 4, open-label, non-randomized, single administration
11020154|NCT04635787||Healthy Adults|Adults 18 years or older
11020155|NCT04635787||COVID19|Adults 18 years or older diagnosed with COVID 19
11020156|NCT04635774|Active Comparator|Treatment Group|The treatment group will receive 40 IU via four activations of an intranasal spray.
11020606|NCT04632511|Other|Children with overweight, not yet obese|Metabolome measurements on feces and urine.
11020158|NCT04635761|Experimental|Prevention (AIR Program)|Participants complete the Roswell Awareness, Information and Resources for Lung Cancer Screening (AIR) Program over 45 minutes and then receive the High-Risk Lung Cancer Tip Sheet..
11020159|NCT04635735|Experimental|Ipilimumab After Stem Cell Transplantation|The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
11020160|NCT04635722|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
11020161|NCT04635709|Experimental|behavioral therapy|applying biofeedback training on the pelvic floor muscles
11020162|NCT04635709|Experimental|interferential therapy (IF)|Interferential current was applied to the body using four surface electrodes placed on the lower abdomen and lower buttocks.
11020163|NCT04635696|Experimental|Treatment|Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
11020164|NCT04635696|Placebo Comparator|Control|Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
11020165|NCT04635683|Experimental|Treatment (lenalidomide, umbralisib, ublituximab)|Patients receive lenalidomide PO QD on days 1-21 and umbralisib PO QD on days 1-28. Beginning in cycle 2, patients also receive ublituximab IV over 90 minutes to 4 hours on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial or complete response after cycle 6 continue treatment of lenalidomide PO QD and umbralisib PO QD for 12 additional cycles, and ublituximab IV on day 1 of subsequent even cycles (8, 10, 12, 14, 16, and 18). Patients with stable disease after cycle 6 may continue on treatment for an additional 12 cycles at the discretion of the investigator.
11020166|NCT04635670|Placebo Comparator|Placebo|Soluble powder for oral use twice daily
11020167|NCT04635670|Active Comparator|Active|The investigational product is soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
11020168|NCT04635657||Meningioma Group|This group will include all patients in the study, regardless of location (frontal or temporal lobe) or surgical approach (endoscopic endonasal or craniotomy). Fifty patients will be included in the cohort
11020169|NCT04635644|Active Comparator|Erector Spinae Plane Block|Patients will receive Erector spinae plane block.
11020170|NCT04635644|Active Comparator|Intrathecal morphine ITM|Patients will receive Intrathecal morphine.
11020171|NCT04635631|Experimental|talazoparib|1 mg QD
11020172|NCT04635618|Experimental|Intervention I: Cognitive Behavioral Brief-Telepsychotherapy|Four sessions of cognitive-behavioral therapy (CBT) conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content and content related to CBT technique.
11020173|NCT04635618|Experimental|Intervention II: Brief Interpersonal Telepsychotherapy|Four sessions of interpersonal therapy (IPT) conducted by video call by a psychologist, accompanied by the sending of 2 to 3 minute videos with psychoeducational content and content related to the ITP technique.
11020174|NCT04635618|Active Comparator|Active Comparator: Telepsychoeducation group|One single session of psychoeducation conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content for 4 weeks.
11020175|NCT04635605|Experimental|Methylene Blue|Methylene Blue 100 mg capsules. Patients will receive Methylene blue (MB) capsules of 100mg every 12 hours for a total of 5 days.
11020176|NCT04635605|Active Comparator|control group|The control intervention would be the group receiving 100 mg placebo capsules twice a day for five consecutive days
11020177|NCT04635579|Experimental|Anterior cruciate ligament reconstruction group|Single session blood flow restriction of lower limb to individuals who have undergone anterior ligament reconstruction surgery
11020178|NCT04635579|Active Comparator|Control group|Single session blood flow restriction of lower limb to individuals who have no musculoskeletal injuries
11020179|NCT04635566|Active Comparator|Mebeverine|Mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
11020180|NCT04635566|Placebo Comparator|Placebo|Placebo one time/day at the evening.
11020181|NCT04635540|Experimental|Interventional Arm|The Interventional Arm will receive the educational brochure and complete the study tasks and questionnaires.
11020182|NCT04635527|Experimental|IBI318 combined with conventional TACE (cTACE)|
11020183|NCT04635527|Placebo Comparator|Placebo combined with conventional TACE (cTACE)|
11020184|NCT04635514||Study group of 32 subjects|"Thirty-two women who presented with symptomatic lateral vaginal prolapse (deep dyspareunia, sensation of vaginal fulness, and heaviness) composed the study's group.
~The surgical lateral vaginal reconstruction (lateral colporrhaphy) of the lateral vaginal wall was administered."
11020185|NCT04635501|Experimental|ABS 5.6.7|Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
11020186|NCT04635488||Trainning group|70% of the whole participants would be randomly divided into the training group to build the predicition model.
11020187|NCT04635488||validation group|30% of the whole participant would be divided into the validation group to validate the model
11020188|NCT04635475|No Intervention|Control Group|Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
11020189|NCT04635475|Experimental|Intervention Group|Consented parents of a concussed high school student who will receive the CDC Head's Up Concussion Guidelines and intervention RTL Student Protocol during a five week program. 75 Participants.
11020190|NCT04635462|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
11021942|NCT04623372|Experimental|Directed wound healing|
11020191|NCT04635462|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
11020192|NCT04635449|Active Comparator|Intervention|age-specific information, complemented by a follow-up targeted telephone call
11020193|NCT04635449|No Intervention|Treatment as usual|usual information given at PICU discharge
11020194|NCT04635436||Pathologic group|At least 20 participants with various orthopaedic or neurologic conditions (for example, post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions) will be enrolled.
11020195|NCT04635423|Experimental|V503|Participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
11020196|NCT04635423|Placebo Comparator|Placebo|Participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.
11020197|NCT04635358|Experimental|Intervention|Setting up hypnosis sessions, psychological and nutritional assistance.
11020198|NCT04635345|Experimental|Vibrator Therapy + dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel) plus an external vibrator.
11020199|NCT04635345|Active Comparator|Dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel).
11020200|NCT04635332|Experimental|Intervention|In the intervention arm, participants will be exposed to the developed intervention materials and face to face group sessions.
11020201|NCT04635332|Active Comparator|Control arm|In the control arm, participants will only be given the developed intervention materials. Face to face group sessions will not be held for the control arm.
11020202|NCT04635319||18-40 years old of both sexes|patient from 18 to 40 years old seeking orthodontic treatment
11020203|NCT04635306|Experimental|Low Nitrogen GEBT test meal|GEBT test meal containing low %N content (below 7%)
11020204|NCT04635293|Active Comparator|patients who were administered levosimendan at a dose of 0.1µg/Kg/min for 24 hours prior to surgery|
11020205|NCT04635293|Placebo Comparator|patients who were not administered levosimendan prior to surgery|
11020206|NCT04635280|Experimental|Closed-loop automatic insulin delivery system|Adults type 1 diabetic patients equiped with a closed-loop automatic insulin delivery system (or artificial pancreas)
11020207|NCT04635267||patients with ARDS|
11020208|NCT04635254|Active Comparator|Halophites-based cream 24 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
11020209|NCT04635254|Active Comparator|Halophites-based cream 48 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
11020210|NCT04635241|Experimental|Inhaled heparin|Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days
11020211|NCT04635241|No Intervention|Standard care|Standard care
11020212|NCT04635215||Participants|There are not multiple groups in this study
11020213|NCT04635202|Experimental|group A|patients (n=30) in this group will receive 16 weeks of elliptical training on elliptical trainer, 3 times per week. the training will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
11020214|NCT04635202|Other|Group B (control group)|patients (n=30) in this group will receive general advises on maintaining physical activities
11020215|NCT04635189|Experimental|Experimental Arm:single|Patients will be treated with 1800 milligrams of Daratumumab via subcutaneous injection or 16 mg/kg Daratumumab via IV weekly, 25 milligrams of Lenalidomide taken oral daily, and 20 milligrams of Dexamethasone orally or through IV 60 minutes prior to the first infusion of daratumumab.
11020216|NCT04635176|Placebo Comparator|Sham iPACK block|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
11020217|NCT04635176|Active Comparator|Real IPACK block.|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
11020218|NCT04635150|Experimental|Post-intervention parents and staff|An educational intervention for the multidisciplinary staff of a neonatal intensive care unit.
11020219|NCT04635137|Experimental|Ablation and Cementoplasty|All patients undergoing thermal ablation and cementoplasty procedure for one or more painful bone lesion
11020220|NCT04635124|Active Comparator|1: Dog visit with a dog, no additional activity (D)|The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. Apart from the visitor, an observer is present.
11020221|NCT04635124|Experimental|2: Dog visit with an additional activity (DA)|"The nursing home resident receives 12 10-minute visits in their own room. The visitor is accompanied with a dog, and the resident can touch the dog. During the visit, the visitor offers the resident to participate in an activity that involves interacting with the dog.
~Apart from the visitor, an observer is present."
11020222|NCT04635124|Active Comparator|3: Visit without dog, with an additional activity (A)|"The nursing home resident receives 12 10-minute visits in their own room. During the visit, the visitor offers the resident to participate in an activity.
~Apart from the visitor, an observer is present, but no dog is present.."
11020223|NCT04635111||Symptomatic TGCT Participants|Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
11020224|NCT04635098|Experimental|dexmedetomidine|0.5μg/kg bolus injection in 10 minutes followed by 0.1µg/kg/hr pump infusion from 22:00 pm to 6:00 am
11020225|NCT04635098|Placebo Comparator|saline|the same rate as dexmedetomidine
11020267|NCT04634825|Experimental|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
11022211|NCT04621669|Experimental|metformin hydrochloride ,SHR3680|
11020226|NCT04635085|Experimental|Empowerment-based Cognitive behavioral therapy for insomnia for MCI (intervention)|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups.
11020227|NCT04635085|No Intervention|Social Activities provided by the community centers (active control)|The control group will not receive any structured cognitive training or sleep promoting interventions during the study period. The participants in the control group will continue to participate in the social activities offered by the elderly community centers. They have access to the newspapers, board games and computer facility in the centers. Upon completion of collecting all evaluation data for both groups at the three different time points, the empowerment-based CBT-I will be offered to participants in the control group.
11020228|NCT04635072|Experimental|Stabilised Whole Rice Bran (SWRB)|"Patients with mild AD will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, one time per day.
~Patients with moderate disease will be instructed to use SWRB as a cleanser as above. In addition, they will also use SWRB as an emollient after constituting it into a paste as in instructions, apply at night and leave it overnight."
11020229|NCT04635059|Experimental|Pacritinib|Pacritinib is an oral drug.
11020230|NCT04635046||Patients with tears to their peroneal tendons|Patients with pain over their peroneal tendons clinically, with a verified injury to either of the two tendons on MRI, where we might expect a tendon transfer of the peroneus longus, or extirpation of the peroneus longus, during surgery.
11020231|NCT04635033||Intervention|2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months
11020232|NCT04635020|Experimental|Stable glaucoma iStent|Cataract surgery combined with iStent inject
11020233|NCT04635020|Experimental|Stable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
11020234|NCT04635020|Active Comparator|Stable glaucoma|Cataract surgery
11020235|NCT04635020|Experimental|Unstable glaucoma iStent|Cataract surgery combined with iStent inject
11020236|NCT04635020|Experimental|Unstable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
11020237|NCT04635007|Experimental|Group 1: Tranexamic acid group|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
11020238|NCT04635007|Experimental|Group 2: Misoprostol group|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
11020239|NCT04634994|Experimental|[F-18]SDM-8 tracer|Subjects will be administered standardized questionnaires for cognitive testing/other co-morbidities. They will undergo PET Scan and 3T Brain MRI. For PET Scan, an intra-arterial catheter will be inserted into the radial artery for [F-18]SDM-8 metabolite blood sampling by a trained anesthesiologist. Allen's test will be performed prior to insertion of the intra-arterial catheter. If arterial line can't be established to obtain metabolite samples, a venous line will be placed. In addition, an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer. Radiopharmaceutical will be injected as a bolus (approximately 5mCi for [F-18]SDM-8 followed by 5 mL of saline). The PET session will last up to 120 min. A head support apparatus will be used to minimize head motion. Brain PET data acquisition will begin at the moment of radiotracer injection. For MRI, several pulse sequences will be performed, no IV contrast will be used.
11020240|NCT04634981||Group general anesthesia (G)|patients will positioned with pelvic wedge on operating table and preoxygenated. Then rapid sequence induction with precalculated doses of propofol (2 mg/kg) and rocuronium (0.9 mg/kg) will followed by endotracheal intubation. After delivery of the baby, fentanyl will be administered. Later, anesthesia will be maintained with isoflurane (1%).
11020241|NCT04634981||Group Spinal anesthesia (S)|all parturients will co-loaded with 500 ml of colloid solution. In the left lateral position, the patients' back will be cleaned with povidone iodine. In the meantime, the spinal anesthetic drug and local anesthetic drug will be prepared. After wiping povidone iodine with alcohol, a rapid single shot of 2.5 ml of 0.5% hyperbaric bupivacaine will be administered intrathecally using 22 G spinal needle. Oxygen will be administered using simple face mask till the delivery of the baby.
11020242|NCT04634968|Experimental|intervention group|The interactive Brief MI-based text message communication via instant messaging apps (e.g., WhatsApp, WeChat) will be applied in the intervention group. The chatting function of WhatsApp and WeChat will be used as the intervention platform. The intervention will start on the first day after the participants join the follow-up group. The whole interactive text-communication intervention lasts for 1 month. The frequency of message communication will be at least twice a week. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
11020243|NCT04634968|Placebo Comparator|control group|The participants in the control group will receive general health communication twice every week via SMS. The communication lasts for 1 month. After completing the intervention, participants will be invited to complete an individualized telephone-based interview for collecting further information on the intervention content.
11020244|NCT04634955|Active Comparator|S1 transforaminal injection with oboique view|S1 transforaminal injection with oblique fluoroscopic view
11020245|NCT04634955|Active Comparator|S1 transforaminal injection with AP view|S1 transforaminal injection with anteroposterior fluoroscopic view
11020246|NCT04634942|Experimental|Cold Spray Group|Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
11020266|NCT04634838|Other|MedCu Antibacterial Wound Dressings with Copper Oxide|Wound dressings impregnated with copper oxide microparticles will be applied in wounds treated with antibacterial wound dressings with silver that their sizes were not reduced by at least 50% during three weeks of treatment.
11020247|NCT04634942|Experimental|ShotBlocker Group|ShotBlocker group injection process step; In addition to the IM injection procedure steps, after cleansing the skin of the patients in this group, the protruding part of the ShotBlocker was placed in contact with the skin. ShotBlocker was pressed firmly against the skin and the injection was made through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
11020248|NCT04634942|No Intervention|Control Group|Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
11020249|NCT04634942|Placebo Comparator|Cold Spray Placebo Group|Cold spray placebo group injection procedure step; In addition to the IM injection procedure steps, the patients in this group were treated with tap water in a cold spray bottle after cleansing the skin. After spraying 3 puffs of tap water in a placebo bottle at a distance of 20 cm to the skin, the injection was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
11020250|NCT04634942|Placebo Comparator|ShotBlocker Placebo Group|ShotBlocker placebo group injection procedure step; In addition to the IM injection procedure steps, in patients in this group, the non-protruding part of the ShotBlocker was placed in contact with the skin after skin cleaning. ShotBlocker was pressed firmly against the skin and the injection was applied through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed.
11020251|NCT04634929||bariatric surgery participants|participants with obesity planning to undergo bariatric surgery
11020252|NCT04634929||conservative diet participants|participants with obesity planning to controlled conservative behavioral weight loss program
11020253|NCT04634916|Experimental|EndoAVF|
11020254|NCT04634903|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
11020255|NCT04634903|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
11020256|NCT04634903|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
11020257|NCT04634890|Other|Type 2 Diabetes|Subjects with type 2 diabetes, diagnosed within the last 3-5 years, treated with metformin only as an anti-diabetic drug
11020258|NCT04634890|Other|Prediabetes|Subjects with prediabetes, defined as impaired fasting glucose or/and impaired glucose tolerance
11020259|NCT04634890|Other|Normoglycemia|Subjects with normal fasting glucose and normal glucose tolerance
11020260|NCT04634877|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
11020261|NCT04634877|Placebo Comparator|Placebo + Chemotherapy|Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
11020262|NCT04634864|Active Comparator|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation
11020263|NCT04634864|Sham Comparator|sham tDCS|40 minutes of 0mA intensity. the session starts with a ramp up to 2mA, but machine is switched off after 2 minutes of stimulation.
11020264|NCT04634851|Experimental|Intervention|These participants will get virtual home visits with the urologist and dietitian
11020265|NCT04634851|No Intervention|Control|These participants will get standard urologist and dietitian counseling
11023234|NCT04614532|Other|patients with alzheimer's disease|
11020268|NCT04634825|Experimental|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
11020269|NCT04634812|Experimental|[14C]-KBP-5074|
11020270|NCT04634799|Active Comparator|TM5614|TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days
11020271|NCT04634799|Placebo Comparator|Placebo|Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days
11020272|NCT04634773|Experimental|Group 1: Early Degeneration ('Disease')|Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
11020273|NCT04634773|Active Comparator|Group 2: No Degeneration ('Healthy')|Those who have posterior subluxation of the humeral head and show no signs of degeneration.
11020274|NCT04634747|Experimental|PVX-410/pembrolizumab/chemotherapy|
11020275|NCT04634721|Active Comparator|Laparoscopic TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
11020276|NCT04634721|Active Comparator|Ultrasaund TAP block|injecting bupivacaine in transversus abdominis plane to block the somatic nerves
11020277|NCT04634721|No Intervention|no TAP block|no TAP block would be done
11020278|NCT04634708||Pediatric patients on EXCOR VAD support|
11020279|NCT04634682|Experimental|MYODM|MYODM, three times a day, orally
11020280|NCT04634682|No Intervention|No intervention|Patients will follow the same evaluation schedule but will not receive MYODM
11020281|NCT04634669|Experimental|AXS-05|
11020282|NCT04634656|Active Comparator|Group L|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery.
11020283|NCT04634656|Placebo Comparator|Group C|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery.
11020284|NCT04634617||Observational (questionnaires)|Patients complete questionnaires over 45-60 minutes consisting of demographic, treatment, lifestyle, disease, and comorbidity questions, as well as multiple study instruments assessing quality of life as it pertains to common toxicities of uterine cancer treatment.
11020285|NCT04634604|Active Comparator|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.
11020286|NCT04634604|Experimental|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
11020287|NCT04634591||Obesity - undergoing bariatric surgery|Patients with morbid obesity, treated with the bariatric surgery
11020288|NCT04634591||Obesity - without bariatric surgery treatment|Patients with morbid obesity, not treated with the bariatric surgery
11020289|NCT04634591||Non-obese|Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
11020290|NCT04634578|Experimental|Bevacizumab- 0.063 mg|Participants will receive a single intravitreal injection of 0.063 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
11020291|NCT04634578|Experimental|Bevacizumab- 0.25 mg|Participants will receive a single intravitreal injection of 0.25 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
11020292|NCT04634565|Experimental|PF-06651600|PF-06651600 200 milligrams(mg) once daily for 10 days
11020293|NCT04634552|Experimental|Part 3: Cohort A (Talquetamab)|Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
11020294|NCT04634552|Experimental|Part 3: Cohort B (Talquetamab)|Cohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
11020295|NCT04634539|Experimental|Gemcitabine + Nab-paclitaxel + L-glutamine|For the dose-finding portion of this study, all subjects will receive a combination of L-glutamine, gemcitabine, and nab-paclitaxel which will be preceded by a 1-week (+/- 1 day) administration of L-glutamine. This 1-week administration of L-glutamine will facilitate measurement of baseline and post-glutamine monotherapy plasma metabolite levels prior to addition of gemcitabine and nab-paclitaxel. The combination therapy will be administered over 28-day cycles during the treatment period until disease progression, treatment intolerance, or withdrawal from the study. Patients are expected to be on treatment for 12 cycles.
11020296|NCT04634513|Experimental|Cohort 1: Shigella Vaccine at 10^8 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
11020297|NCT04634513|Experimental|Cohort 2: Shigella Vaccine at 10^9 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
11020298|NCT04634513|Experimental|Cohort 3: Shigella Vaccine at 10^10 cfu or Placebo|3:1 randomization to one dose of vaccine or placebo (Cohort n=8)
11020299|NCT04634513|Experimental|Cohort 4: Shigella Vaccine or Placebo|2:2:1 randomization to receive either two doses of vaccine, 1 dose of vaccine and one dose of placebo, or two doses of placebo at Days 1 and 29 (Cohort n=30)
11020300|NCT04634500|Experimental|Study group|DWP16001 A mg, Dapagliflozin placebo
11020301|NCT04634500|Active Comparator|Control group|DWP16001 A mg placebo, Dapagliflozin
11020302|NCT04634474|Experimental|Pain on Endotracheal Suction|Before and after endotracheal aspiration, the pain of the patient will be evaluated according to the DAS and VAS scale. VAS scores will be compared with DAÖ scores. Aspiration process will be applied to all patients by the same nurse. According to the DAQ, the pain will be assessed by a volunteer nurse who is not a researcher.
11020303|NCT04634448|Other|Interval appendectomy|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
11020304|NCT04634448|Other|Follow-up MRI|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
11020305|NCT04634435|Experimental|Newly diagnosed multiple myeloma patients|Newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)
11020306|NCT04634422|Experimental|Plasma Exchange and convalescent Plasma|2 plasma exchange procedures within 24 hours and in addition 2 bags of CCP (equalling 600 ml CCP) infused at the end of the 2nd procedure.
11020307|NCT04634422|No Intervention|Control without intervention|Standard care without the use of PLEX or convalescent plasma.
11020308|NCT04634409|Experimental|LY3819253 + LY3832479|LY3819253 + LY3832479 administered IV.
11020309|NCT04634409|Experimental|LY3819253|LY3819253 administered IV.
11020310|NCT04634409|Placebo Comparator|Placebo|Placebo administered IV.
11020311|NCT04634396|Other|Experimental TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACICS. Participants will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1 hour sessions by a trained interventionalist
11020312|NCT04634383|Experimental|WFMA Cortical Visual Prosthesis Single-arm Study|The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
11020313|NCT04634370|Experimental|Intervention|"Each patient will receive on dose of intravenous natural killer cell in following levels:
~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
11020314|NCT04634357|Experimental|ET140203 T-Cells|ET140203 T-Cells
11020315|NCT04634344|Experimental|DZD2269 as monotherapy|
11020316|NCT04634331|Active Comparator|Traditional Multi-Modal Training|A physical therapist will provide 1:1 multi-modal training. Multi-modal training is the simultaneous performance of a motor and a cognitive task (i.e. marching while answering math questions)
11020317|NCT04634331|Experimental|Augmented Reality Multi-Modal Training|Multi-modal training will be administered via the Microsoft HoloLens 2 augmented reality head set. Augmented reality allows user to see the real world, and inserts holograms into the environment. For example, the user could see boxes on the ground that they need to step around when walking. The boxes are not real, but rather a hologram that only the user can see. The augmented reality device will instruct the participant on the motor and cognitive task that should be performed simultaneously in a similar manner to the physical therapist in the traditional multi-modal training group. The intervention will be overseen by a physical therapist.
11020318|NCT04634318|Active Comparator|Respiratory rehabilitation program group (RR).|Post-COVID-19 patients carrying out a respiratory rehabilitation program (RR).
11020319|NCT04634318|Experimental|Respiratory tele-rehabilitation program group (TRR).|Post-COVID-19 patients carrying out a respiratory tele-rehabilitation program (TRR).
11020320|NCT04634305||Total elbow arthroplasty|Total elbow arthroplasty, all indications combined
11020321|NCT04634292||Children with cerebral palsy 7-9 years|21 children
11020322|NCT04634292||Children with cerebral palsy 10-12 years|21 children
11020323|NCT04634292||Healthy children 7-9 years|21 children
11020324|NCT04634292||Healthy children 10-12 years|21 children
11020325|NCT04634279|Experimental|Collaborative Care Plus|Intervention is administered to patients in this arm. Care to be delivered via collaborative care. The supplement intervention adds family involvement in care and Caring Contacts, a suicide prevention method.
11020326|NCT04634279|No Intervention|Control|Patients in this arm will receive enhanced usual care.
11020327|NCT04634266|Experimental|Experimental intervention|Transcatheter tricuspid valve treatment (TTVT) plus optimal medical therapy (OMT)
11020328|NCT04634266|No Intervention|Control intervention|OMT for severe tricuspid regurgitation in right-sided heart failure
11020329|NCT04634253|Experimental|LY3462817 Low Dose|LY3462817 given intravenously (IV).
11020330|NCT04634253|Experimental|LY3462817 High Dose|LY3462817 given IV.
11020331|NCT04634253|Placebo Comparator|Placebo|Placebo given IV.
11020332|NCT04634240|Experimental|Complete Revascularization|Routine PCI (percutaneous coronary intervention) of all suitable coronary artery stenoses of >70% in vessels ≥2.5mm in diameter.
11020333|NCT04634240|No Intervention|Medical Therapy Alone|No revascularization of coronary artery lesions.
11020334|NCT04634227|Experimental|Gemcitabine + High-Dose Ascorbate|Ascorabte is administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator. Treatment will be terminated with progression of disease. Disease will be assessed by CT of the chest, abdomen and pelvis or MRI of the lesion every 2 cycles for progression.
11020335|NCT04634214||COVID 19 positive patients without diabetes|COVID 19 positive patients without diabetes
11020336|NCT04634214||COVID 19 positive patients with diabetes|COVID 19 positive patients with diabetes
11020337|NCT04634201|Experimental|Experimental group|
11020338|NCT04634201|Sham Comparator|control group|
11020396|NCT04633850||Before implementation|Perineural bupivacaine without adjuvants.
11020397|NCT04633850||After implementation|Perineural bupivacaine with adjuvants (adrenaline) and intravenous dexamethasone.
11086130|NCT04173065|Experimental|5.0 mg|
11020339|NCT04634188||Meningioma Group|"This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.
~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
11020340|NCT04634188||Glioma Group|"This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.
~After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors."
11020341|NCT04634188||Brain Metastasis Group|This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.
11020342|NCT04634175|Experimental|Mind-body group|The mind-body group will practice mind-body intervention.
11020343|NCT04634175|Active Comparator|Sham group|The sham group will practice sham intervention.
11020344|NCT04634162|Experimental|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
11020345|NCT04634162|Placebo Comparator|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
11020346|NCT04634149|Experimental|Group A: Moderate Hepatic Impairment|
11020347|NCT04634149|Experimental|Group B: Severe Hepatic Impairment|
11020348|NCT04634149|Experimental|Group C: Normal Hepatic Function|
11020349|NCT04634136|Active Comparator|Active Substance: Full-spectrum Medical Canabis Product (HemPhar)|For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
11020350|NCT04634136|Placebo Comparator|Placebo|For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
11020351|NCT04634123|Experimental|Primary anterior teeth pulpotomy by White Portland Cement|
11020352|NCT04634123|Other|Primary anterior teeth pulpotomy by White MTA|
11020353|NCT04634110|Experimental|Patients with ALK+ NSCLC and brain metastases|Including patients with brain metastases from ALK (anaplastic lymphoma kinase) positive NSCLC (non-small cell lung cancer), who are either neurologically asymptomatic or who have only mild neurologic symptoms (RTOG [Radiation therapy Oncology Group] acute neurologic morbidity score 0-2) from their brain metastases, who are TKI (tyrosine kinase inhibitor) naïve or who have had prior exposure to crizotinib, but who are naïve to brigatinib and other ALK TKIs including alectinib, lorlatinib, and ceritinib.
11020354|NCT04634097|Experimental|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:
~A. DECLIC program set up in the centers, open to concerned patients.
~B. 3 training sessions :
~one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.
~one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).
~for healthcare professionals in order to train them as educators in this program.
~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
11020355|NCT04634097|Other|Standard group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
11020356|NCT04634084|Experimental|Experimental group|
11020357|NCT04634084|Active Comparator|Control Group|
11020358|NCT04634071|Experimental|Group 1: Varenicline, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020359|NCT04634071|Experimental|Group : Varenicline, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020360|NCT04634071|Experimental|Group 3: Varenicline, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020361|NCT04634071|Experimental|Group 4: Varenicline, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020362|NCT04634071|Experimental|Group 5: Buproprion, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020363|NCT04634071|Experimental|Group 6: Buproprion, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020364|NCT04634071|Experimental|Group 7: Buproprion, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020365|NCT04634071|Experimental|Group 8: Buproprion, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020366|NCT04634071|Experimental|Group 9: Nicotine, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020367|NCT04634071|Experimental|Group 10: Nicotine, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020398|NCT04633837|No Intervention|Group 1 Control|Group 1 will undergo standard rotator cuff repair without the ECM injection.
11020368|NCT04634071|Experimental|Group 11: Nicotine, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020369|NCT04634071|Experimental|Group 12: Nicotine, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
11020370|NCT04634058|Experimental|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 antibody combined with CTLA-4 antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
11020371|NCT04634045|Experimental|Web-Based Treatment|A web-based treatment for pediatric overweight or obesity will be piloted with 10 caregiver and child pairs. Assessments will take place pre (0 months), post intervention (3.5 months) and at six months post-intervention (9.5 months) to evaluate patient outcomes, acceptability and feasibility.
11020372|NCT04634032||Hernia|Patients planned to undergo routine indirect inguinal hernia repair procedure
11020373|NCT04634032||Control|Patients planned to undergo routine circumcision procedure
11020374|NCT04634019|No Intervention|Control arm|Providers in control facilities will not receive any additional training or knowledge assessments.
11020375|NCT04634019|Experimental|Financial incentive arm|Providers in treatment facilities will be visited once a quarter for a knowledge assessment using vignettes. Facilities performing well in this assessment will receive a quarterly bonus payment, which will be distributed among providers.
11020376|NCT04634006|Active Comparator|active tDCS 1|Anodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the cathode will be placed over the the vertex (Cz), using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
11020377|NCT04634006|Active Comparator|active tDCS 2|Anodal tDCS will be applied over the right IFG (1/3 of the distance between F8 and C6) according to the 10-20 EEG electrode systems and the cathode will be placed posterior to left mastoid, using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
11020378|NCT04634006|Sham Comparator|sham tDCS|Anodal tDCS will be applied over the left DLPFC (N=13) or right IFG (N=12) according to the 10-20 EEG electrode systems and the cathode will be placed over vertex or posterior to left mastoid, respectively, using square saline-soaked sponge pads 25 cm2. Sham stimulation will be maintained for 19 min without current flow by increasing current for 30 s followed by a decrease for 30 s.
11020379|NCT04633993|Experimental|PCSMP|Patient-centered self-management program for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
11020380|NCT04633993|No Intervention|Usual Care|Routine care.
11020381|NCT04633980|Experimental|Experimental group|
11020382|NCT04633954|Experimental|Brimonidine Group|Patients in this arm receive an extra drop of brimonidine in addition to routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
11020383|NCT04633954|No Intervention|Control Group|Patients in this arm only receive routine eye drops prior to femtosecond laser assisted cataract surgery (FLACS)
11020384|NCT04633941||Post Bariatric Surgery|Post Bariatric Surgery more than 6 month. Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
11020385|NCT04633941||Medical Weight Management|Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
11020386|NCT04633928|Experimental|N-TEC|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membranes for about 2 weeks to allow cells to produce extracellular matrix containing cartilage specific proteins. The tissue engineered graft is then implanted in the nasal septum in an interposition graft with a temporoparietal fascia flap.
11020387|NCT04633915||Dialysis|Patients with CKD stage 5, treated with maintenance hemodialysis
11020388|NCT04633915||Healthy|Volunteers who are not dialysis-dependent
11020389|NCT04633902|Experimental|Olaparib + Pembrolizumab|This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration including mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCA, FANCD2, MRN11A, PALB2, RAD50, RAD51, RAD54B.
11020390|NCT04633889|Experimental|Deferoxamine|Deferoxamine 30mg/kg intravenous infusion (diluted in 100mL normal saline) administered over 12 hours
11020391|NCT04633889|Placebo Comparator|Placebo|Normal saline (100mL) intravenous infusion over 12 hours
11020392|NCT04633876|Active Comparator|Control group|The subjects allocated to this group receive some results from baseline measurements (as do subjects in the intervention) but do not receive lifestyle counselling
11020393|NCT04633876|Experimental|Individual coaching|These subjects receive individual counselling during the study.
11020394|NCT04633876|Experimental|Group coaching|These subjects receive individual counselling during the study.
11020395|NCT04633863|Experimental|MDI - 101|Artificial tear containing arabinogalactan, trehalose and hyaluronic acid
11020399|NCT04633837|Active Comparator|Group 2: ECM Injectable graft|Group 2 will undergo rotator cuff repair and receive 2cc of the injectable extracellular matrix injection placed into the glenohumeral joint space via a transtendon approach at the end of the surgery
11020400|NCT04633824||Patients with private insurance|
11020401|NCT04633824||Patients with public/self-payer insurance|
11020402|NCT04633811|Experimental|Controlled Diet and Weight Loss Program|Subjects will consume a low oxalate diet with blood and urine collections to establish baseline levels before undergoing a weight loss program with Optifast VLCD products. After completing the weight loss program, subjects will once again consume a low oxalate diet with blood and urine collections to observe any changes that may have occurred due to the weight loss.
11020403|NCT04633798|Experimental|IPL/Lipiflow|the group in which patients treated with IPL combined with lipiflow
11020404|NCT04633798|Active Comparator|IPL/MGX|the group in which patients treated with IPL combined with meibomian gland massage
11020405|NCT04633785||wrist BP|
11020406|NCT04633772|Placebo Comparator|Placebo|
11020407|NCT04633772|Experimental|Angiotensin-(1-7)|
11020408|NCT04633759|Experimental|Blood Flow Restriction Exercise|Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
11020409|NCT04633746||sepsis with AKI|Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
11020410|NCT04633746||Sepsis without AKI|Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
11020411|NCT04633733|Experimental|Single arm|"This single arm is conducted in fixed-sequence(Treatment A ->(washout period) -> Treatment B -> Treatment C -> Maintenance treatment).
~Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days"
11020412|NCT04633720|Experimental|Evaluation of intratidal compliance|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.
~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg
~Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg
~Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg
~Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
11020413|NCT04633707|Experimental|Adjunctive morning BLT group|treat subjects with adjunctive BLT in the morning
11020414|NCT04633707|Experimental|Adjunctive noon BLT group|treat subjects with adjunctive BLT in the afternoon
11020415|NCT04633707|Placebo Comparator|Adjunctive placebo therapy group|treat patients with adjunctive dim red light in the afternoon
11020416|NCT04633694|Experimental|Insect protein|The participants are are given insect protein
11020417|NCT04633694|Experimental|Pea protein|The participants are are given pea protein
11020418|NCT04633694|Experimental|Whey protein|The participants are are given whey protein
11020419|NCT04633681|Experimental|Cake matrix|3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
11020420|NCT04633681|Experimental|Biscuit matrix|3 phases of 2-week daily consumption of cake product containing 1) sucrose, 2) Neotame 1, 3) Stevia Reb M. Randomised cross-over with 2-week wash-out between phases.
11020421|NCT04633681|Experimental|Yoghurt matrix|3 phases of 2-week daily consumption of yoghurt product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
11020422|NCT04633681|Experimental|Chocolate matrix|3 phases of 2-week daily consumption of chocolate product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
11020423|NCT04633681|Experimental|Cereal matrix|3 phases of 2-week daily consumption of cereal product containing 1) sucrose, 2) sweetener blend 1, 3) sweetener blend 2. Randomised cross-over with 2-week wash-out between phases.
11020424|NCT04633681|Experimental|Universal Eating Monitor study|A sub-group of the yoghurt matrix will be selected for assessment of eating rate and microstructure of feeding using Universal Eating Monitors.
11020425|NCT04633681|Experimental|fMRI study|A sub-group of the chocolate matrix will be selected for assessment of neural activation to images of food using fMRI.
11020426|NCT04633668|Experimental|CBT-p|cognitive behavioral therapy, Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
11020427|NCT04633668|Active Comparator|Self-monitoring|Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
11020428|NCT04633655||Patients who are receiving a neurotoxic chemotherapy|"List of neurotoxic drugs eligible for enrolment
~Platinum drugs
~Taxanes
~Vinca alkaloids
~Epothilones
~Proteasome inhibitors
~Thalidomide
~Vedotin-based drugs
~checkpoint inhibitors
~Any combination of the aforementioned drugs"
11020429|NCT04633642|Experimental|Ultrasound Group (UAW group)|UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
11020430|NCT04633642|Active Comparator|Surgical group|"All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.
~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus."
11020431|NCT04633629||Patients with acute heart failure|Patients hospitalized for acute heart failure in medical department.
11020432|NCT04633616|Experimental|Tailored Delivery of Education|Communication will be tailored as the mode of weblink delivery will be customized to patient preference.
11020433|NCT04633616|Placebo Comparator|Non-tailored Delivery of Education|Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy.
11020534|NCT04632914|Experimental|trunk stabilizing exercise|trunk stabilizing exercises three times/week for four weeks
11020607|NCT04632511|Other|Normal-weight control group|Metabolome measurements on feces and urine.
11020434|NCT04633603||All patients|There is no pre-specified group or subgroup of participant(s) assigned to receive the specific intervention(s) (or no intervention) according to the protocol. All patients get the same possibility to register their data and follow management advice.
11020435|NCT04633590|Experimental|home-based exergaming|The home-based exergame intervention will take place in an unsupervised place of the participant's choosing. Participants will be provided with all of the equipment and receive training on how to use the system
11020436|NCT04633590|Active Comparator|gym-based training|As suggested in the American Diabetes Association (ADA) position statement on exercise and diabetes (Colberg et al., 2016) the aim of this session will be to create an individualised exercise programme tailored to the specific needs of each participant. Participants will be given a specific gym induction with a gym instructor at a dedicated gymnasium in the Bern area (Migros Fitnessclub). During this session the training will be adapted to the participants needs. As suggested in the ADA position statement on exercise and diabetes the aim of the program will be for the participants to engage in at least 150 min of moderate to vigorous intensity exercise (defined as a HR of 50-70% HRmax) or 75 min of vigorous intensity (defined as a HR of 70-85% HRmax) or interval training per week by the end of the program. Participants will be encouraged to train 3 times per week. Participants will also be advised of the benefits of resistance training.
11020437|NCT04633577|Experimental|Group Lidocaine|20 eligible patients are received 1.5mg/kg 1%lidocaine intravenously over 30-60s. Then, 4mg/kg/h lidocaine infused intravenously until end of procedure.
11020438|NCT04633577|Placebo Comparator|Group Control|2020 eligible patients are received equal 0.9% normal saline.
11020439|NCT04633564|Experimental|MYL-1402O|"Patients will begin Period 1 receiving bevacizumab combination therapy (MYL-1402O15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as MYL-1402O ).
~In Period 2, eligible patients will continue to receive bevacizumab ( MYL- 1402O) every 3 weeks as monotherapy."
11020440|NCT04633564|Active Comparator|Avastin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin).
~In Period 2, eligible patients will continue to receive bevacizumab (Avastin) every 3 weeks as monotherapy."
11020441|NCT04633551|Experimental|Intervention|Participants in this arm will receive a commercially available anti-inflammatory supplement.
11020442|NCT04633551|No Intervention|Control|Participants in this arm will not receive a commercially available anti-inflammatory supplement.
11020443|NCT04633525|Experimental|Optimum Cup Orientation|
11020444|NCT04633512|Experimental|ActivSight Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=14/20) Patients undergoing cholecystectomy with ActivSight (n=14/14)
11020445|NCT04633512|No Intervention|Non-ActivSight (Comparison) Group|Patients undergoing intestinal anastomoses (colorectal and bariatric) without ActivSight (n=6/20)
11020446|NCT04633499|Active Comparator|dmPFC tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the dmPFC while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
11020447|NCT04633499|Experimental|rTPJ tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the rTPJ while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
11020448|NCT04633499|Active Comparator|Social cognition tasks in younger participants|Participants will conduct two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking but without tDCS stimulation.
11020449|NCT04633473|Experimental|SIBTime|50 primary parents will be assessed at enrollment, then provided the SIBTime technology and exposed to the learning routines for 4 weeks, and then re-assessed at 4 weeks (after treatment completion).
11020450|NCT04633460|Experimental|Ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
11020451|NCT04633460|Placebo Comparator|Placebo|KE-free solution
11020452|NCT04633447|Experimental|Group 1: Guselkumab|Participants will receive guselkumab dose 1 intravenously (IV) at week 0, 4, and 8 and guselkumab dose 2 subcutaneously (SC) every 4 weeks (q4w) from week 12 through week 48. This will be in combination with a protocol specified 26-week GC taper.
11020453|NCT04633447|Experimental|Group 2: Placebo|Participants will receive matching placebo IV at week 0, 4 and 8 and matching placebo SC q4 weeks from week 12 through week 48. This will be in combination with a protocol-specified 26-week GC taper.
11020454|NCT04633434|Experimental|The Talk Parenting Skill for Alexa|52 parents will be assessed at enrollment, then provided an Amazon Echo Dot and exposed to the prototype Bedtime Routine module of the Talk Parenting program for 6 weeks, and then re-assessed at 6 weeks (at treatment completion)
11020455|NCT04633421|Experimental|PRECISe protocol EN (8g protein/100kcal)|Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
11020456|NCT04633421|Active Comparator|PRECISe protocol EN (5g protein/100kcal)|Enteral (EN) feed with 5 grams protein per 100 kcal (1.2 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
11020457|NCT04633408|Experimental|Intervention|The investigators will recruit 15 Latino caregivers for each study arm (total sample size of 30). The sample size was based on a rule of thumb of 12 to 15 participants per group for pilot studies. This group will have access to the app.
11020458|NCT04633408|No Intervention|Control|12 to 15 participants, will not have access to the app.
11020459|NCT04633395|Experimental|Music before bedtime|Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks. Participants will also receive the sleep hygiene guidelines, and be told to follow these.
11020460|NCT04633395|Active Comparator|Sleep hygiene|Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
11020535|NCT04632914|Active Comparator|cardiac rehabilitation programe|cardiac rehabilitation program three times/week for four weeks
11020608|NCT04632498|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
11020461|NCT04633382|Experimental|Conducting research of enhanced recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.
~Refusal from complete starvation. Carbohydrate drink 2 hours before surgery.
~Refusal of cleansing enemas.
~Refusal of premedication. NSAIDs 30 minutes before surgery
~Prevention of thromboembolic complications
~Multimodal analgesia: epidural catheter, paracetamol.
~Minimally invasive access.
~Prevention of hypothermia
~Targeted infusion therapy.
~Failure or limited time use of drainages: gastric, intra-abdominal, bile duct drainage.
~Early activation of the patient.
~Early enteral nutrition.
~Prevention of nausea and vomiting."
11020462|NCT04633382|Placebo Comparator|Conducting research of traditional recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.
~Fasting for 2 days
~Use of cleansing enemas. Bowel preparation
~Premedication
~Prevention of thromboembolic complications
~Without multimodal analgesia
~Traditional access.
~Prevention of hypothermia
~Targeted infusion therapy.
~Use of drains: gastric, intra-abdominal, bile duct drainage.
~Activation of patients within 2 days.
~Enteral nutrition after 2 days after surgery.
~Without the use of metoclopramide"
11020463|NCT04633369|Experimental|Fructo-oligosaccharide|Fructo-oligosaccharide
11020464|NCT04633369|Experimental|Arabinogalactan|Arabinogalactan
11020465|NCT04633369|Experimental|Glucomannan|Glucomannan
11020466|NCT04633356|Experimental|EUS-portal pressure gradient measurement (PPGM)|All patients would receive measurement of PPGM using the study device
11020467|NCT04633343|Experimental|Small Volume Breath Group|Small volume breath and fast breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation
11020468|NCT04633343|Experimental|Large Volume Breath Group|Large volume breath and slow breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation.
11020469|NCT04633330|Experimental|Study Arm|Active Hexose Correlated Compound (AHCC) capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal)
11020470|NCT04633330|Placebo Comparator|Control Arm|Simulation of Active Hexose Correlated Compound (AHCC) capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal)
11020471|NCT04633317|Experimental|Group A Regimen|Randomized 80 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium generated by a pneumatic nebulizer or a vibrating mesh nebulizer every 12 hours for 7-10 days
11020472|NCT04633317|No Intervention|Group B Regimen|Randomized 40 subjects diagnosed with pneumonia of carbapenem-resistant gram negative bacteria will received inhaled colistimethate sodium intravenous every 12 hours for 7-10 days
11020473|NCT04633304|Other|AVF|Single arm study using primary and secondary end points as comperators between subjects.
11020474|NCT04633278|Experimental|CMP-001 and Pembrolizumab|All subjects will receive CMP-001 IT and pembrolizumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
11020475|NCT04633265|Experimental|ECG-I Mapping and Ablation of drivers|ECG-I Mapping will be performed and drivers will be ablated as directed by ECG-I.
11020476|NCT04633252|Experimental|1/Dose Escalation|Docetaxel plus M9241 dose escalation with optional prednisone and ADT as part of SOC
11020477|NCT04633252|Experimental|2/Safety Run-in|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
11020478|NCT04633252|Experimental|3/mCSPC: Dose Expansion|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
11020479|NCT04633252|Experimental|4/mCRPC: Dose Expansion|Docetaxel plus M9241 RP2D plus M7824 with optional prednisone and ADT as part of SOC
11020480|NCT04633239|Experimental|Treatment (abemaciclib, olaparib)|Patients receive olaparib PO BID on days 1-28 and abemaciclib PO BID on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11020481|NCT04633226|Experimental|V114|Participants receive 4 total doses of V114, administered at ~2, 4, 6, and 12-15 months of age.
11020482|NCT04633213|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
11020483|NCT04633213|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
11020484|NCT04633200|Experimental|Intervention|Participants in the intervention arm will receive a mobile app to support their daily PrEP adherence.
11020485|NCT04633200|No Intervention|Control|Participants in the control group will receive a 2-page PrEP patient education document based information about PrEP from on the CDC website.
11020486|NCT04633187|Experimental|EDP-938|
11020487|NCT04633187|Placebo Comparator|Placebo|
11020488|NCT04633174|Experimental|Sous vide device|The intervention will be the use of a sous vide device to heat the water bath to 39oC, rather than the traditional methods of manual water exchanges or placing the frostbitten tissue under running water.
11020489|NCT04633148|Experimental|UniCAR02-T-pPSMA|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.
11020490|NCT04633135|No Intervention|Control|Households enrolled in the control arm of the study did not receive either improved cookstove
11020491|NCT04633135|Experimental|Gyapa/Gyapa|Households enrolled in the Gyapa/Gyapa arm of the study received two Gyapa stoves for free
11020492|NCT04633135|Experimental|Gyapa/Philips|Households enrolled in the Gyapa/Philips arm of the study received one Gyapa stove and one Philips stove for free
11020493|NCT04633135|Experimental|Philips/Philips|Households enrolled in the Philips/Philips arm of the study received two Philips stoves for free
11020494|NCT04633122|Experimental|Ripretinib|50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.
11020495|NCT04633122|Active Comparator|Sunitinib|12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.
11020496|NCT04633109||normal weight|Normal weight adults with BMI ranging from 18.5-24.9; men and women; age range 18-69years; written informed consent
11020497|NCT04633109||obese|Subjects with obesity as defined by BMI >= 30; men and women; age range 18-69 years; written informed consent
11020536|NCT04632901||Testing of Visual Acuity (VA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
11020498|NCT04633096|Experimental|tailored feedback|Using a randomized-controlled study design one third of the participants will receive individually tailored feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
11020499|NCT04633096|Experimental|standardized feedback|Using a randomized-controlled study design one third of the participants will receive a standard feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
11020500|NCT04633096|No Intervention|no feedback|Using a randomized-controlled study design one third of the participants will not receive any feedback.
11020501|NCT04633083|Other|Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbosacral level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbosacral level ii. Scapular plane abduction under 150°
~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
11020502|NCT04633083|Other|No Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbar level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbar level ii. Scapular plane abduction under 150°
~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
11020503|NCT04633057|Experimental|TJ101|TJ101 1.2 mg/kg once a week for 52weeks
11020504|NCT04633057|Active Comparator|NordiFlex|NordiFlex Injection 0.034 mg/kg once a day for 52 weeks
11020505|NCT04633044|Placebo Comparator|Placebo|400 mg of lactose daily for 12 weeks
11020506|NCT04633044|Experimental|Supplement|400 mg of betaine daily for 12 weeks
11020507|NCT04633031||Group 1|Cheneau brace
11020508|NCT04633031||Group 2|Boston brace
11020509|NCT04633018|Experimental|Patient-centered asthma intervention feasibility|Investigate the effect of the patient-centered asthma intervention using the AsthmaMD app on school days missed and medication adherence.
11020510|NCT04633018|Experimental|Wait list control|Control group with usual care (not using app).
11020511|NCT04633005|Experimental|Polypill Arm|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include metoprolol succinate (a beta-blocker), empagliflozin (an SGLT2-inhibitor), and spironolactone (a mineralocorticoid antagonist). Three dose formulations of the pill, varied in metoprolol succinate dose, will be available for up-titration of the beta-blocker dose per ACC/AHA/HFSA guidelines.
11020512|NCT04633005|Active Comparator|Control Arm|Patients will receive GDMT as usually prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
11020513|NCT04632992|Experimental|Arm A: Entrectinib|Participants in this treatment arm must have a positive biomarker result for ROS1 gene fusion.
11020514|NCT04632992|Experimental|Arm B: GDC-0077|Participants in this treatment arm must have a positive biomarker result for PI3K activating mutations (PIK3CA).
11020515|NCT04632992|Experimental|Arm C: Alectinib|Participants in this treatment arm must have a positive biomarker result for ALK rearrangement.
11020516|NCT04632992|Experimental|Arm D: Ipatasertib|Participants in this treatment arm must have a positive biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
11020517|NCT04632992|Experimental|Arm E: Atezolizumab + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
11020518|NCT04632992|Experimental|Arm F: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have a positive biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
11020519|NCT04632992|Experimental|Arm G: PH FDC SC|Participants in this treatment arm must have a positive biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
11020520|NCT04632992|Experimental|Arm H: PH FDC SC + Investigator's Choice of Chemotherapy|Participants in this treatment arm must have a positive biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
11020521|NCT04632992|Experimental|Arm I: Trastuzumab Emtansine + Tucatinib|Participants in this treatment arm must have a positive biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
11020522|NCT04632992|Experimental|Arm J: Trastuzumab Emtansine + Atezolizumab|Participants in this treatment arm must have a positive biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
11020523|NCT04632979|Experimental|Backward runners|Training protocol patients
11020524|NCT04632966|Experimental|PTP-001 - Low Dose (100 mg)|intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline
11020525|NCT04632966|Experimental|PTP-001 - High Dose (200 mg)|intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline
11020526|NCT04632953||Previously Treated with Triheptanoin|Patients who have been previously treated with triheptanoin through Ultragenyx studies: UX007-CL201 (NCT01886378), UX007-CL202 (NCT02214160), or UX007-EAP (NCT03773770).
11020527|NCT04632953||Currently Treated with Triheptanoin|New patients enrolling into the DMP currently being treated with triheptanoin (excluding those in the previously treated with triheptanoin cohort).
11020528|NCT04632953||Triheptanoin Naïve|New patients enrolling into the DMP with no exposure to triheptanoin.
11020529|NCT04632953||Triheptanoin Naïve Transitioned toTriheptanoin|Patients already enrolled into the triheptanoin naïve cohort but transition to triheptanoin during the DMP after enrollment.
11020530|NCT04632940|Experimental|Arm A|pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
11020531|NCT04632940|Placebo Comparator|Arm B|matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
11020532|NCT04632927|Experimental|Secukinumab 300 mg|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until week 24
11020533|NCT04632927|Active Comparator|Ustekinumab 45 mg / 90 mg|Ustekinumab 45 mg / 90 mg will be administered at Baseline, week 4 and 16
11020537|NCT04632901||Testing of Critical Visual Acuity (CVA) Group|The same participants will undergo VA and CVA test with two different Landolt C charts under the same lighting conditions.
11020538|NCT04632888|Experimental|Study group/Telephone support for breastfeeding follow-up|"Study group: The women in the study group will be provided with a video call every day for the first week after discharge from the hospital, to provide consultancy to the mother on the matters she needs and to be recorded in the Baby Monitoring Form. The general appearance of the baby, observation during sucking, jaundice, drowsiness, reluctance to suck will be observed. The consultancy will be provided to the mother on these issues.
~In the following weeks, the consultancy will continue to be given to the study group by making a video talk one week apart.
~The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded."
11020539|NCT04632888|No Intervention|Control Group|"Control Group: No additional attempt or routine call will be made to mothers in the control group. The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded.
~The control group will be called to fill in the scales for monitoring purposes."
11020540|NCT04632875|Experimental|Loving-Kindness Meditation|4-week guided Loving-Kindness Meditation training (administered online).
11020541|NCT04632875|Experimental|Relaxation Meditation|4-week guided Relaxation Meditation training (administered online).
11020542|NCT04632862|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
11020543|NCT04632862|Placebo Comparator|DWP16001 Amg Placebo|DWP16001 Amg Placebo, Tablets, Orally, Once daily
11020544|NCT04632849|Experimental|GEM + CGM|A self-directed lifestyle intervention for controlling Type 2 Diabetes
11020545|NCT04632836||NIV participant (non invasive-ventilation participant)|"From patient:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~equipment data (type, indication, parameters, observance, usage data),
~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)
~From partner:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
11020546|NCT04632836||CPAP participant (continuous positive airway pressure participant)|"From patient:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~equipment data (type, indication, parameters, observance, usage data),
~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)
~From partner:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
11020547|NCT04632836||LTOT participant (long term oxygen therapy participant)|"From patient:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~equipment data (type, indication, parameters, observance, usage data),
~medical data (EFR, blood gas, respiratory polygraphy, pulse oxymetry, medical history, smoking status)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)
~From partner:
~demographics data (date of birth, gender, socio-professional category, education level, morphometric data)
~responses of questionnaires (WHOQOL-BREF questionnaire, PSQI index, HADS scale, study specific questionnaire)"
11020548|NCT04632823|Experimental|Comprehensive non-pharmacological program intervention|The experimental group receives usual diabetes care plus 24 weeks of the comprehensive non-pharmacological program intervention.
11020549|NCT04632823|No Intervention|Usual diabetes care|This group is control, the patients receive usual diabetes care routines.
11020550|NCT04632810|Experimental|Ketogenic diet + weight loss|
11020551|NCT04632810|Active Comparator|non-Ketogenic diet + weight loss|
11020552|NCT04632810|Active Comparator|Ketogenic eucaloric diet|
11020553|NCT04632797|Active Comparator|Cryocompression|Patients in this group receive cryocompression for the hands.
11020554|NCT04632797|Active Comparator|Cryotherapy|Patients in this group receive cryotherapy for the hands.
11020555|NCT04632784|Experimental|Artiflex Presbyopic|About 125 - 140 subjects will receive the Artiflex Presbyopic lens bilaterally and will be followed for a period of 3 years.
11020556|NCT04632771||Pilot survey: non-pregnant, non-lactating women|Survey of non-pregnant, non-lactating women 15-49 years of age (n=250)
11020557|NCT04632771||Pilot survey: lactating women|Survey of lactating women 15-49 years of age who are currently breastfeeding a child 4-18 months of age (n=250)
11020558|NCT04632771||Pilot survey: children|Survey of children 2-5 years of age (n=250)
11020559|NCT04632771||RID Pilot 1|Two-week study to assess total body vitamin A stores in a sample of non-pregnant, non-lactating women 15-49 years of age (n=30)
11020560|NCT04632771||RID Pilot 2|"Kinetic study with Super-woman design to develop a prediction equation to assess total body vitamin A stores among non-pregnant, non-lactating women 15-49 years of age (n=123)"
11020561|NCT04632771||Focus group discussions|Focus group discussions conducted among women of reproductive age, older women, and men (n=120 total)
11020562|NCT04632771||Market assessment|Survey of retail outlets selling fortified staple foods and/or bouillon (n=50 shop owners or operators)
11020563|NCT04632771||Recipe observations|Observations of cooking of local dishes by selected participants (n=50) enrolled in the pilot survey.
11020564|NCT04632758|Experimental|WX-0593 Tablets|Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
11020565|NCT04632758|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
11020566|NCT04632745|Other|Cast Group|participant with distal radius fracture will be treated with short arm fiberglass cast
11020567|NCT04632745|Other|Splint Group|participant with distal radius fracture will be treated with short arm velcro wrist splint
11020568|NCT04632732||COVID+, SARS|patients COVID+ SARS mechanically ventilated and/or needing more than 6L/min of O2-40% FiO2 for a SpO2 equal or above 90% for more than 24hours.
11024422|NCT04606615||Children: AD only|atopic dermatitis and no food allergy
11020569|NCT04632732||COVID+, nonSARS|patients COVID+ nonSARS respiratory symptomatic, with or without lung infiltrates, non mechanically ventilated, and needing less than 6L/min O2-40% FiO2 for a SpO2 equal or above 90%. They are hospitalized on floors (pulmonolgy, internal medecine or in intensives cares units).
11020570|NCT04632732||COVID-, ARDS|patients are in ARDS according to the Berlin definition and the lung injury is categorized in the direct form (e.g. pneumonia, aspiration).
11020571|NCT04632732||COVID-, nonARDS|patients are not in ARDS according to the Berlin definition but are respiratory symptomatic, with or without lung infiltrates and needing less than 6L O2/min-40% FiO2 for a SpO2 equal or above 90%.
11020572|NCT04632732||COVID-, control, MV+|patients hospitalized and mechanically ventilated for non-respiratory reasons (post hoc with sex-age matching).
11020573|NCT04632732||COVID-, control, MV-|non mechanically ventilated patients hospitalized for non-respiratory reasons (post hoc with sex-age matching).
11020574|NCT04632719|Experimental|Covid-19 Study Group|The Study Group will be the group that was remiss for COVID-19 and has some of the mentioned comorbidities as asthma, cardiovascular disease, cancer even if controlled by drugs or treatments.
11020575|NCT04632719|Active Comparator|Covid-19 Control Group|The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen cognitive functions' impairment after the remission of the symptoms of COVID-19.
11020576|NCT04632706|Experimental|50mcg/kg (oral)|Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 50mcg/kg from D2 to D28
11020577|NCT04632706|Experimental|75mcg/kg (oral)|Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 75mcg/kg from D2 to D28
11020578|NCT04632706|Experimental|100mcg/kg (oral)|Starting Active IMP dose of 200 mcg/kg on D1 followed by daily doses of 100mcg/kg from D2 to D28
11020579|NCT04632706|Placebo Comparator|Matching Placebo (oral)|Placebo using tablets identical to the Active IMP
11020580|NCT04632693|Experimental|CAF with SCTG and vitamin C|Coronally advanced flap with subepithelial connective tissue graft and vitamin C.
11020581|NCT04632693|Active Comparator|CAF with SCTG|Coronally advanced flap with subepithelial connective tissue graft.
11020582|NCT04632680|Experimental|PVI followed by targeting of drivers|Patients will undergo intra-procedural mapping using the ECG-I. The pulmonary veins will be isolated. Drivers will then be targeted as guided by the ECG-I system aiming for termination of AF.
11020583|NCT04632667|Active Comparator|Comparison School Group|
11020584|NCT04632667|Experimental|Intervention School Group|
11020585|NCT04632654|Experimental|PAfitME|For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention.
11020586|NCT04632654|No Intervention|Attention Control|For 6 weeks, the attention control group will receive National Cancer Institute-based survivorship education and exergame equipment (Wii Fit and Xbox Kinect without PAfitME).
11020587|NCT04632641|Experimental|VASCADE® MVP Venous Vascular Closure System (VVCS)|VASCADE® MVP Venous Vascular Closure System (VVCS) will be used as closure strategy for femoral venous access sites.
11020588|NCT04632641|Active Comparator|Figure 8 Suture|Figure 8 suture will be used as a closure technique for femoral venous access sites.
11020589|NCT04632641|Active Comparator|Manual Compression|Manual compression will be used as a closure technique for femoral venous access sites.
11020590|NCT04632628|Experimental|NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia|This is a pilot trial with one treatment condition (CBT-I).
11020591|NCT04632602|Other|patients in prone position followed by dorsal decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
11020592|NCT04632602|Other|dorsal decubitus followed by prone decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
11020593|NCT04632589|Experimental|Losartan|6 weeks of daily (50mg/day) oral losartan potassium tablet
11020594|NCT04632589|Placebo Comparator|Placebo|6 weeks of daily oral placebo tablet
11020595|NCT04632576|Experimental|auricular acupuncture|"auricular acupuncture is one of the many forms of acupuncture, and is a distinctive part of Chinese medicine that has been practiced in China for thousands of years. It is employed by placing fine needles in specifically designated puncture points on the external ear."
11020596|NCT04632576|No Intervention|Control|No intervention is given.
11020597|NCT04632563||Member of BioResource|Any BioResource member who consents to take part in the study and completes the study questionnaire.
11020598|NCT04632550|Active Comparator|Circumferential pulmonary vein isolation(CPVI) group|
11020599|NCT04632550|Experimental|Posterior box isolation(POBI) group|
11020600|NCT04632550|Experimental|POBI+Anterior linear ablation(AL) group|
11020601|NCT04632537|Active Comparator|TICE BCG (for intravesical use, Merck) BCG LIVE|Participants randomized to the BCG arm will receive Tice® BCG (for intravesical use) BCG LIVE is a live freeze-dried vaccine made from an attenuated strain of Mycobacterium bovis. The freeze-dried vaccine will be delivered in vials, each containing 1 to 8 x108 colony forming units (CFU). Tice® BCG (for intravesical use) BCG LIVE will be reconstituted in ~5 mL of preservative-free saline, as needed for yielding 2- x107 CFU/ mL. [34] Administration of 0.1 mL will contain 2x106 CFU, which accounts for approximately 0.1 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally. A sterile tuberculin 1mL syringe and sterile fine short needle (25 or 26 gauge with 3/8-3/4 length), will be used for each injection. The injection should be made slowly after inserting the needle ~2 mm into the superficial layer of the dermis of the upper arm (usually deltoid area), to make a symmetrical superficial bleb.
11020602|NCT04632537|Placebo Comparator|placebo vaccine|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
11020603|NCT04632524|Active Comparator|MgSO4|Group (Mg So4) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery.
11020604|NCT04632524|Placebo Comparator|Placebo|Group (P) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse
11020609|NCT04632498|No Intervention|Wait-list Control (WL)|Patient Control receiving no treatment
11020610|NCT04632498|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
11020611|NCT04632485||Aim 1: Ultrasound Only|Approximately 280 asymptomatic participants will participate in ultrasound (US) studies and blood work.
11020612|NCT04632485||Aim 2: Ultrasound and MRI|A sub-group of 40 at risk volunteers determined from the clinical ultrasound scans and bloodwork from Aim 1 will be asked to participate in a longitudinal US and MRI study. Participants will be selected from a population of individuals that do not have significant atherosclerosis, but present with increased risk due to the presence of soft, lipid rich plaque that are hypoechogenic or echolucent on ultrasound B-mode images. These participants may also satisfy the current clinical guidelines of increased vessel diameter and decreased blood flow velocity with ultrasound that may result in plaque deposition for being in the at risk population. Participants will receive US, strain and shear wave imaging every 2 years after the first scan in Aim 1 and MRI Imaging in Year 1 and Year 5: separated by 4 years
11020613|NCT04632472|Active Comparator|Active fixation bipolar lead|Left ventricular bipolar pacemaker lead, fixated by a side helix
11020614|NCT04632472|Placebo Comparator|Passive fixation quadripolar lead|Left ventricular quadripolar passive fixation pacemaker lead
11020615|NCT04632459|Experimental|pembrolizumab plus ramucirumab|"Ramucirumab 8mg/kg on q2W
~Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)
~If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles"
11020616|NCT04632433|Experimental|single arm|Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
11020617|NCT04632420||Women with child birth|Women attending chronic pain clinic who have previously experienced childbirth
11020618|NCT04632420||Women without childbirth|Women attending chronic pain clinic who have not previously experienced childbirth
11020619|NCT04632407|Experimental|"Flax milk"|"A total of 30 women will receive flax (FLX) milk on a daily basis for a total of 4 months. The FLX milk will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3."
11020620|NCT04632407|Experimental|"Oat fibre milk"|"A total of 30 women will receive the oat fiber milk on a daily basis for a total of 4 months. The oat fibre milk will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water."
11020621|NCT04632394||Cases|Patients with scar-dependent ventricular tachycardia, requiring ablation. These patients will have satisfied the inclusion/exclusion criteria and be put forward for VT ablation. They will undergo the previously described study protocol, including generation of a computational model of the heart from their cardiac MRI and a VT ablation where we will study the points of interest generated from the MRI model in detail.
11020622|NCT04632381|Active Comparator|Active Arm, Zota Cohort 1|0.01 mg/kg zotatifin
11020623|NCT04632381|Active Comparator|Active Arm, Zota Cohort 2|0.02 mg/kg zotatifin
11020624|NCT04632381|Active Comparator|Active Arm, Zota Cohort 3|0.035 mg/kg zotatifin
11020625|NCT04632381|Placebo Comparator|Placebo|5% dextrose injection, USP
11020626|NCT04632368|Active Comparator|Transcendental Meditation Intervention Arm|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to a randomized group of eligible HCPs ( N=40)providing care during COVID-19 pandemic.
11020627|NCT04632368|No Intervention|Treatment as usual(TAU) Control Arm|Control group consists of eligible HCPs who are randomized to control group(N=40) and would not receive any intervention. At the end of 3 month study period, control group participants would be eligible for TM training.
11020628|NCT04632342|Experimental|Experimental group 1|HL301 1,200mg/day
11020629|NCT04632342|Experimental|Experimental group 2|HL301 1,800mg/day
11020630|NCT04632342|Placebo Comparator|Control group|Placebo
11020631|NCT04632316|Experimental|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
11020632|NCT04632303|Experimental|Early Palliative Care|Baseline palliative care visit within 10 calendar days of registration/randomization and palliative care visits (either at clinic or at home) or phone calls (if a visit is not feasible) at least every four weeks throughout the patient's life. Referral to exercise training and nutritional specialist.
11020633|NCT04632303|No Intervention|Standard Care Arm|Palliative care visit only upon request from attending oncologist(s) or patient/family.
11020634|NCT04632290|Experimental|All participants|All participants receive the same intervention.
11020635|NCT04632277|Placebo Comparator|Placebo|"A tap water,"
11020636|NCT04632277|Experimental|Expermental recieve low MG|Low Mg bottle water (50mg/l)
11020637|NCT04632277|Experimental|Expermental recieve high MG|high Mg bottle water (100 mg/l)
11020638|NCT04632264|Experimental|Pre-placental group|"Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our intervention group. Saline placebo will be initiated post placenta delivery (within 15 seconds)."
11020639|NCT04632264|Other|Post-placental group|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).
11020640|NCT04632251|Other|Familiarisation|The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study.
11020641|NCT04632238|No Intervention|Control|
11020642|NCT04632238|Experimental|Metrics-driven quality improvement (MDQI) intervention|
11020643|NCT04632225|Active Comparator|Engensis|64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
11020644|NCT04632225|Placebo Comparator|Placebo|32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
11020645|NCT04632212|Experimental|1|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (ON)
11020646|NCT04632212|Experimental|2|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (OFF)
11020647|NCT04632212|Experimental|3|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (ON)
11020648|NCT04632212|Experimental|4|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (OFF)
11020649|NCT04632212|Experimental|5|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (ON)
11020650|NCT04632212|Experimental|6|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (OFF)
11020651|NCT04632212|Experimental|7|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (ON)
11020652|NCT04632212|Experimental|8|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
11020653|NCT04632212|Experimental|9|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (ON)
11020654|NCT04632212|Experimental|10|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (OFF)
11020655|NCT04632212|Experimental|11|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (ON)
11020656|NCT04632212|Experimental|12|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (OFF)
11020657|NCT04632212|Experimental|13|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (ON)
11020658|NCT04632212|Experimental|14|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (OFF)
11020659|NCT04632212|Experimental|15|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (ON)
11020660|NCT04632212|No Intervention|16|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
11020661|NCT04632199|Experimental|111In-IPN01087 Low dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a low mass dose of IPN01087
11020662|NCT04632199|Experimental|111In-IPN01087 High dose|Single intravenous injection of 220 MBq 111In-IPN01087 with a high mass dose of IPN01087
11020663|NCT04632186|Experimental|Intervention|"3 sessions with 3 different interventions 1) Transcutaneous electric nerve stimulation (TENS)- at the shoulder according to current best evidence and practice 2) EXOPULSE Mollii suits- local stimulation at the shoulder, 3) EXOPULSE Mollii suit- according to current best experienced practice
~The order in which the participants´ receive the different treatments will be randomized.
~Each session lasts for approximately 2.5 hours (approximately 60 min for assessment, 30 min for settings and adjustments and 60 min for treatment)"
11020664|NCT04632160|Experimental|Treatment|Treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
11020665|NCT04632147|Experimental|Pranayama Group|Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 1 day a week for 8 weeks, under the supervision of a physiotherapist, in the hospital. The training program will last 8 weeks.
11020666|NCT04632147|No Intervention|Control Group|No intervention will be made to this group.
11020667|NCT04632134|Experimental|Transcutaneous vagal nerve stimulation (tVNS)|"After positioning the tVNS electrodes in the right ear but without delivering tVNS (Sham tVNS), above mentioned signals will be recorded for 10 minutes while supine, for 15 minutes during 75° head-up tilt.
~The same protocol will be performed during active tVNS.
~The tVNS will be performed while 15 minutes in supine position and during 75°head-up Tilt.
~Thereafter, every patient will be provided with a Nemos© device and electrodes for home daily stimulation. Daily stimulation will consist of 4 hours of stimulation organized as 4 sessions each lasting 1 hour, to be applied at the patient's convenience."
11020668|NCT04632121||Group A|will receive standard treatment + 20 mg nicorandil prior to PPCI, and then maintained on 20 mg b.i.d for 3 months .
11020669|NCT04632121||Group B|will be given standard treatment, without nicorandil loading or maintainance.
11020670|NCT04632108|Experimental|ASKB589 Injection|
11020671|NCT04632095|Active Comparator|Sternotomy AVR|Aortic valve replacement due to sternotomy
11020672|NCT04632095|Active Comparator|Mini AVR|Aortic valve replacement due to parasternal right anterior mini-thoracotomy
11020673|NCT04632082|Experimental|Intervention: Telepsychoeducation with personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology. The intervention is complemented by the sending of 4 videos of 2 to 3 minutes, with psychoeducational content, sent each week by the therapist.
11020674|NCT04632082|Active Comparator|Comparator: Telepsychoeducation without personalized videos|One psychoeducation session administered by a therapist by video call, with interventions focused on promoting protective factors and reducing common risk factors for psychopathology.
11020675|NCT04632069|Experimental|NAC + taVNS|NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
11020676|NCT04632056||Beovu|Brolucizumab (Genetical Recombination) 6 mg (0.05 mL) is administered by intravitreal injection every 4 weeks for the first three doses(loading phase). In the following maintenance phase, Brolucizumab is basically administered every 12 weeks. The interval between treatments is adjusted as appropriate according to the symptoms. The interval between two doses should not be shorter than 8 weeks
11020677|NCT04632043|Active Comparator|Early intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for more than mask venturi 50% to maintain a SpO2 >92%) for at least 48 hours will undergo intubation.
11020678|NCT04632043|Active Comparator|Delayed intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for more than mask venturi 50% to maintain a SpO2 >92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.
11020679|NCT04632030|Active Comparator|Control|The tobacco power wall and number of products appears in a typical format: large power wall with a large number of products (defined here as three large cabinets)
11020680|NCT04632030|Experimental|Small|The tobacco power wall and number of tobacco products appear in their smallest format: small power wall with a small number of products displayed (defined here as one large cabinet)
11020738|NCT04631588|Placebo Comparator|Double Blind Randomized Placebo|Participants will receive placebo at Baseline (Day 1)
11020681|NCT04632030|Experimental|Medium|The tobacco power wall and number of tobacco products appear in a format sized between the control and small conditions: a medium sized power wall with a medium number of products displayed (defined here as two large cabinets).
11020682|NCT04632017||pPROM|Singleton pregnancies admitted for pPROM to the Obstetrics ward
11020683|NCT04632017||Control group|Healthy pregnant women matched for gestational age
11020684|NCT04632004|Other|Questionnaire survey|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
11020685|NCT04631991||Non-pathological high myopia|Comprehensive ophthalmologic examination
11020686|NCT04631991||Control|Comprehensive ophthalmologic examination
11020687|NCT04631978||Underweight|Comprehensive ophthalmologic examination
11020688|NCT04631978||Control|Comprehensive ophthalmologic examination
11020689|NCT04631965||Cohort in Finland|253 young patients who attend clinics in Finland with no hospital-wide transition support service available
11020690|NCT04631965||Cohort in Australia|250 young patients who attend clinics in Victoria, Australia and who have received support from a hospital-wide transition support service
11020691|NCT04631952|Experimental|Online exercise|SMS messages on encouraging active lifestyle plus an online exercise video
11020692|NCT04631952|Active Comparator|SMS message|SMS messages on encouraging active lifestyle
11020693|NCT04631939|Experimental|study intervention|"The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world Macu'ta. The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions."
11020694|NCT04631939|Sham Comparator|control intervention|The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.
11020695|NCT04631926|Other|Hip Muscle Exercises|Hip Muscle Exercises
11020696|NCT04631900|Experimental|Spiritual Intervention Programme|"The intervention is a 6 weeks' programme. The Christianity approach as the framework for spiritual intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group.
~Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose."
11020697|NCT04631900|No Intervention|Wait-list Control group|Participants recruited in the waitlist control will be initially tested to generate pre-test scores and will then tested six weeks later which is equivalent to the timespan between the pre-test and post-test for the experimental spiritual programme. In between these two testing sessions, the waitlist control group will not receive any type of spiritual intervention. For ethical reasons, following the second testing session, the participants in the waitlist group will be given the opportunity to participant in the spiritual intervention programme.
11020698|NCT04631887|Experimental|Intervention Arm: Doing What Matters in Times of Stress: An Illustrated Guide|The intervention arm will receive the assigned intervention for five weeks. They will receive the intervention materials and will be called by psychologists three times (at the beginning, middle and end) during the intervention.
11020699|NCT04631887|No Intervention|Control Arm: Wait List|The control arm has no intervention. The participants in the control arm will receive the intervention after the post-assessments are completed.
11020700|NCT04631874|Experimental|Sequence A(RT)|Reference drug (Champix) -> washout -> test drug (CDFF0318)
11020701|NCT04631874|Experimental|Sequence B(TR)|Test drug (CDFF0318) -> washout -> reference drug (Champix)
11020702|NCT04631848||ULTRASCORE™ Focused Force PTA Balloon|
11020703|NCT04631835|Experimental|HS-10352|There are five escalating dose cohorts
11020704|NCT04631822|Active Comparator|Dexamethasone, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.
~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 4 mg dexamethasone."
11020705|NCT04631822|Active Comparator|Dexmedetomedine, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.
~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 0.5 Mg/kg dexmedetomidine."
11020706|NCT04631809|Active Comparator|invasive Coronary Angiography alone|
11020707|NCT04631809|Experimental|CT-Coronary Angiography + invasive Coronary Angiography|
11020708|NCT04631770|Experimental|Mediastinal lymph node dissection group|A
11020709|NCT04631770|Active Comparator|Mediastinal lymph node non-dissection group|B
11020710|NCT04631757|Experimental|Camrelizumab plus Chemoradiotherapy|Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
11020711|NCT04631744|Experimental|Cabozantinib Arm|
11020712|NCT04631731|Experimental|Immune-checkpoint inhibitors (ICIs)|
11020713|NCT04631731|Active Comparator|ICIs + platinum-based chemotherapy|
11020714|NCT04631731|Experimental|ICIs + kinase inhibitors|
11020715|NCT04631718||MRI based abdominal QSM|Participants with known or suspected iron overload with past serum ferritin >500 will be recruited in this study.
11020739|NCT04631575|Experimental|Healthy participants|Intervention: Drug: SHR6390 single dose
11020740|NCT04631575|Experimental|Mild liver impairment|Intervention: Drug: SHR6390 single dose
11020741|NCT04631575|Experimental|Moderate liver impairment|Intervention: Drug: SHR6390 single dose
11020742|NCT04631562|Experimental|ALXN1820|Participants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
11020774|NCT04631315|Experimental|Intervention|Difluprednate Ophthalmic Emulsion 0.05%
11020716|NCT04631705|Experimental|SARS-CoV-2-uninfected and -infected individuals (Group 1A-1B-1C-(1D)-2C) open label|"Experimental: SARS-CoV-2-uninfected and -infected individuals (Group 1A-1B-1C-(1D)-2C) open label During the dose escalation phase, SARS-CoV-2-uninfected (Groups 1A-C) and SARS-CoV-2-infected individuals (Group 2C) will receive a single inhalation of DZIF-10c at the specified dose on day 0.
~Group 1A (n=3-6): 2.5 mg/kg of DZIF-10c p.o. Group 1B (n=3-6): 10 mg/kg of DZIF-10c p.o. Group 1C (n=6): 40 mg/kg of DZIF-10c p.o. Should the dose escalation phase in Group 1C be completed without dose-limiting toxicities, an additional three participants of healthy volunteers will be enrolled to receive a single 40 mg/kg inhalation of DZIF-10c Group 2C (n=3-6): 40 mg/kg of DZIF-10c p.o.
~Should a maximum tolerated dose be defined during the dose escalation phase in healthy volunteers, participants in group 2C or group 2D will receive DZIF-10c at this maximum tolerated dose."
11020717|NCT04631705|Placebo Comparator|SARS-CoV-2-infected individuals (Group 2D) Placebo double blind randomized|"Group 2D (n=13): sterile normal saline (NaCl 0.9%)
~Should a maximum tolerated dose be defined during the dose escalation phase in healthy volunteers, participants in group 2C or group 2D will receive DZIF-10c at this maximum tolerated dose."
11020718|NCT04631692|No Intervention|Usual care|Usual care in participating primary care practices.
11020719|NCT04631692|Active Comparator|Health literacy intervention|Health literacy intervention combining health literacy and colorectal cancer screening training for general practitioners with a short brochure and video targeting eligible patients.
11020720|NCT04631679||Group A: anemic patients with iron treatment|For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20%, ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
11020721|NCT04631679||Group B: non-anemic patients without iron treatment|For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
11020722|NCT04631666|Experimental|SARS-CoV-2-uninfected and -infected individuals (Group 1A-1B-1C-(1D)-2C) open label|"During the dose escalation phase, SARS-CoV-2-uninfected (Groups 1A-C) and SARS-CoV-2-infected individuals (Group 2C) will receive a single intravenous infusion of DZIF-10c at the specified dose on day 0.
~Group 1A (n=3-6): 2.5 mg/kg of DZIF-10c i.v. Group 1B (n=3-6): 10 mg/kg of DZIF-10c i.v. Group 1C (n=6): 40 mg/kg of DZIF-10c i.v. Should the dose escalation phase in Group 1C be completed without dose-limiting toxicities, an additional three participants of healthy volunteers will be enrolled to receive a single 40 mg/kg infusion of DZIF-10c Group 2C (n=3-6): 40 mg/kg of DZIF-10c i.v.
~Should a maximum tolerated dose be defined during the dose escalation phase in healthy volunteers, participants in group 2C or group 2D will receive DZIF-10c at this maximum tolerated dose."
11020723|NCT04631666|Placebo Comparator|SARS-CoV-2-infected individuals (Group 2D) Placebo double blind randomized|"Group 2D (n=13): sterile normal saline (NaCl 0.9%)
~Should a maximum tolerated dose be defined during the dose escalation phase in healthy volunteers, participants in group 2C or group 2D will receive DZIF-10c at this maximum tolerated dose."
11020724|NCT04631653|Experimental|Verisee|Screening diabetic retinopathy using Verisee software
11020725|NCT04631627|Active Comparator|aspirin group|aspirin,tablet,100/150mg per day,(BMI<30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks<16 to 35 weeks or the day of delivery.
11020726|NCT04631627|Sham Comparator|control group|with no intervention
11020727|NCT04631614|Experimental|Manual therapy plus muscle strengthening exercises|The procedures to be performed with participants in the experimental group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) two ankle manual therapy techniques - [a] passive calf muscle stretching and [b] ankle joint mobilization; (3) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
11020728|NCT04631614|Active Comparator|Muscle strengthening exercises|The procedures to be performed with participants in the control group are as follows: (1) warm up with a walk or exercise bike for 5 minutes; (2) five muscle strengthening exercises focusing on quadriceps and posterolateral hip complex - [a] clam exercise, [b] hip abduction exercise in side lying, [c] knee extension exercise in a sitting position, [d] squat exercise and [e] forward lunge exercise.
11020729|NCT04631601|Experimental|AMG 160 and Enzalutamide: Dose Exploration|The dose-exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of AMG 160 in combination with enzalutamide.
11020730|NCT04631601|Experimental|AMG 160 and Enzalutamide: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of AMG 160 in combination with enzalutamide.
11020731|NCT04631601|Experimental|AMG 160 and Abiraterone: Dose Exploration|The dose exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of AMG 160 in combination with abiraterone.
11020732|NCT04631601|Experimental|AMG 160 and Abiraterone: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of AMG 160 in combination with abiraterone.
11020733|NCT04631601|Experimental|AMG 160 and AMG 404: Dose Exploration|The dose-exploration part of the study will estimate the MTD/RP2D of AMG 160 in combination with AMG 404.
11020734|NCT04631601|Experimental|AMG 160 and AMG 404: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of AMG 160 in combination with AMG 404.
11020735|NCT04631601|Active Comparator|AMG 404 Monotherapy|Part 3 of this study (AMG 404 monotherapy) is being conducted to evaluate the preliminary anti-tumor activity of PD-1 inhibition in the mCRPC population.
11020736|NCT04631588|Experimental|Open Label BOTOX|Participants will receive BOTOX at Baseline (Day 1)
11020737|NCT04631588|Experimental|Double-Blind Randomized BOTOX|Participants will receive BOTOX at Baseline (Day 1)
11020771|NCT04631341|No Intervention|Normal Control Group|Don't take melatonin supplements
11020743|NCT04631562|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
11020744|NCT04631549|Experimental|Healthy participants|Intervention: Drug: SHR3680 single dose
11020745|NCT04631549|Experimental|Mild liver impairment|Intervention: Drug: SHR3680 single dose
11020746|NCT04631549|Experimental|Moderate liver impairment|Intervention: Drug: SHR3680 single dose
11020747|NCT04631536|Experimental|Endothelial Dysfunction Protocol|"Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin, nicorandil, l-arginine, folic acid and nebivolol) in patients already on optimal medical therapy for the treatment of COVID0-19 virus.
~Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc).
~Atorvastatin Atorvastatin will be provided as a 40 mg tablet to be given PO once daily. This dose was suggested because high intensity statin has been associated with a better endothelial profile (Int J Cardiol 2017 Oct 1;244:112-118.-- Eur J Clin Pharmacol 2014 Oct;70(10):1181-93)
~Nicorandil Nicorandil 10 mg PO BID as the recommended dose for coronary vasodilatation by the manufacturer
~Nebivolol Nebivolol 5 mg PO ONCE daily while keeping Heart Rate (HR) between 50-90 bpm
~Folic Acid Folic Acid 5 mg po once daily
~L-Arginine L-Arginine 1 g po TID"
11020748|NCT04631536|Placebo Comparator|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
11020749|NCT04631523||IGD Group|The eligibility criteria were for IGD group as follows: being male in age between 10-18 years old; having accepted the research on a voluntary basis and signed the informed consent and being diagnosed with IGD according to DSM-5. Healthy adolescents in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
11020750|NCT04631523||Healthy Group|The eligibility criteria were for healthy group as follows: being male in age between 10-18 years old and having accepted the research on a voluntary basis and signed the informed consent. The adolescents with IGD in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
11020751|NCT04631510|Experimental|Critically ill patients|Administer gabapentin 300 mg PO at 8 PM for sleep
11020752|NCT04631497||Healthcare workers|The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
11020753|NCT04631484|Experimental|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
11020754|NCT04631484|Placebo Comparator|Placebo|Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.
11020755|NCT04631471|Active Comparator|Ibudilast|Increasing dose of Ibudilast up to 100mg/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
11020756|NCT04631471|Placebo Comparator|Placebo|Increasing dose of matched placebo containing mannitol instead of ibudilast up to 10 pills/day for up to 10 weeks prior to cervical decompressive surgery and up to 24 weeks after cervical decompressive surgery
11020757|NCT04631445|Experimental|Ketogenic (KD) + Triplet|Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
11020758|NCT04631445|No Intervention|Non-ketogenic + Triplet|Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
11020759|NCT04631432||Study participation|All participants will complete the same protocol
11020760|NCT04631419|Experimental|Maxillary flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 maxillary arches (experimental side) before canine retraction.
11020761|NCT04631419|Active Comparator|Maxillary control group|Canine retraction will be done on the other side without Laser corticotomy .
11020762|NCT04631419|Experimental|Mandibular flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 mandibular arches (experimental side) before canine retraction.
11020763|NCT04631419|Active Comparator|Mandibular control group|Canine retraction will be done on the other side without Laser corticotomy .
11020764|NCT04631406|Experimental|Neural Stem cells injected intracerebrally|Subject cohorts will be treated with increasing doses of Neural Stem Cells injected intracerebrally using a traditional 3+3 trial design
11020765|NCT04631380|No Intervention|CONTROL|THIS GROUP WILL RECEIVE THE PROTCOLL TREATMENT GIVEN TO PATIENTS COVID -POSITIVE TESTED.
11020766|NCT04631380|Experimental|PRAYER|THIS GROUP WILL RECEIVE THE SAME TREATMENT GIVEN TO THE CONTROL GROUP, PLUS PRAYERS BY THEOLOGIANS WHOSE PRAYERS INTERCEDE IN FAVOR OF THEIR PROMPT RECOVERY
11020767|NCT04631367|Experimental|Kukaa Salama: mHealth intervention|This is a pre-test/post-test trial, therefore all participants will receive the Kukaa Salama mHealth intervention and will be offered a COVID-19 prevention parcel.
11020768|NCT04631354|Experimental|Sequence A|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S-770108 inhaler at a target peak inspiratory flow rate (PIFR) of 15 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 30 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
11020769|NCT04631354|Experimental|Sequence B|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S- 770108 inhaler at a target PIFR of 30 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 15 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
11020770|NCT04631341|Experimental|Melatonin Group|Take melatonin supplements
11086131|NCT04173065|Experimental|10 mg|
11020775|NCT04631315|Active Comparator|Comparator|Prednisolone Acetate 1% - Phenylephrine 0.12% Ophthalmic Suspension
11020776|NCT04631302|Experimental|Mindfulness|
11020777|NCT04631302|Active Comparator|Light Physical Exercise|
11020778|NCT04631289||metformin/non-metformin group|"Preadmission metformin exposure was defined as a record of metformin usage in Medications on admission in MIMIC-III.
~Metformin group included non-AKI type 2 diabetes patients with preadmission metformin exposure.
~Non-metformin group included non-AKI type 2 diabetes patients without preadmission metformin exposure."
11020779|NCT04631276|Experimental|Single evaluation of H3 receptor occupancy|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 2.5, 25 mg TS-091 prior to an evaluation of H3 recepto occupancy
11020780|NCT04631276|Experimental|Multiple evaluations of H3 receptor occupancy|Subjects received single-dose of 5, 12.5, 25 mg TS-091 prior to Multiple evaluations of H3 recepto occupancy
11020781|NCT04631263|Experimental|Treatment Group|
11020782|NCT04631263|No Intervention|Control Group|
11020783|NCT04631250|Experimental|Right: daylight illumination|The right side of the face was treated using daylight PDT
11020784|NCT04631250|Experimental|Left face: conventional illumination with red light|The left side was treated with conventional PDT.
11020785|NCT04631237||Focus Groups|N=52
11020786|NCT04631237||Cognitive Interviews|N=24
11020787|NCT04631237||Survey|N=600
11020788|NCT04631211|Experimental|Thrombosomes Low Dose|
11020789|NCT04631211|Experimental|Thrombosomes Medium Dose|
11020790|NCT04631211|Experimental|Thrombosomes High Dose|
11020791|NCT04631211|Active Comparator|Liquid Stored Platelets (Control)|
11020792|NCT04631198|No Intervention|No Intervention: GROUP CONTROL|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, expiratory flow acceleration, fractional inspiration in times, diaphragmatic breaths and aspiration when required
11020793|NCT04631198|Experimental|Active Comparator: INTERVENTION GROUP|The patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
11020794|NCT04631185|Active Comparator|SPD (Arm A)|Single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD): Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
11020795|NCT04631185|Experimental|WPO (Arm B)|The patients assigned to this arm will receive same pre-op and intraoperative antibiotics similar to SPD (Arm A). In addition, patients in this group will receive one week of post-operative antibiotics (WPO). The post-operative antibiotic will be a first generation Cephalosporin of their surgeon's choice.
11020796|NCT04631159|Experimental|Mobile app group|They are required to wear fitness watches to record steps ,patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel.
11020797|NCT04631159|Placebo Comparator|Control group|they are required to wear fitness watches to record steps ,patients will be asked to self-manage and there is no intervention during the tracking process.
11020798|NCT04631146||Camrelizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
11020799|NCT04631133||Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirmann MRI class.)|"Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification) in the following indications:
~Massive herniated disc in young adults
~Recurrent herniated disc or herniated disc accompanying an L5 sacralization transitional anomaly, treated by discectomy
~Degenerative disc disease at a segment adjacent to a fusion
~Degenerative lesions with or without Modic 1
~Lumbar canal stenosis treated by partial laminotomy"
11020800|NCT04631120|Active Comparator|Standard of Care|The proposed arm will involve an initial assessment using the Clinical Dementia Rating (CDR) Scale and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score for patients and Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard educational material from the AA and Association for the Advancement of Retired Persons (AARP). Two phone sessions with a study nurse will occur post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment; a summary of these and professional education on national evidence-based guidelines will be mailed to the patient's PCP of record. Education provided in this arm will be both patient- and caregiver-centered.
11020801|NCT04631120|Experimental|Integrated Dementia Practice Unit Arm|"The integrated practice unit design is a coordinated, team-based, comprehensive, technology enabled, family focused care delivery design comprised of:
~Dementia Central: Nurses, physicians, psychologists, social workers, and other relevant healthcare providers that will meet monthly to review participants progress and issues. Telehealth visits would facilitate home care.
~Dementia Mobile: A nurse and lay health educator team will perform monthly visits, conduct assessments of subjects and provide education/coaching.
~Dementia Link: Technologies that facilitate communication between Dementia Central and Dementia Mobile and foster proactive collaboration/coaching for study subjects include an mHealth software that allows for real time intervention/communication between professional teams and dyads, combined with management of dyads for multiple parameters like health metrics, behavioral measures and stress management and a portal tailored to specific clinical needs."
11020802|NCT04631107|Experimental|AD109 dose1|
11020803|NCT04631107|Experimental|AD109 dose2|
11020804|NCT04631107|Placebo Comparator|Placebo|
11020805|NCT04631094|Experimental|Group 1|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
11020806|NCT04631094|Experimental|Group 2|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
11020807|NCT04631094|Experimental|Group 3|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
11020808|NCT04631094|Experimental|Group 4|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
11020809|NCT04631094|No Intervention|Group 5|The group that will undergo standard hospital blood collection procedure.
11020810|NCT04631081|Active Comparator|Occlusive dressing group|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film according. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing
11020811|NCT04631081|Active Comparator|Surgical group|In surgical group, coverage with a bipedicled palmar island flap will be performed ambulatory, either on admission if patients are directly oriented to the Hand Surgery department, or within 48h of initial visit for patients addressed from the Emergency department. The flap group will be evaluated on admission, at 48h, and 6 weeks.
11020812|NCT04631068|Active Comparator|Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)|"The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.
~Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
11020813|NCT04631068|Placebo Comparator|J&J TECNIS ZCB00 Intraocular Lens (IOL)|"The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.
~Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification."
11020814|NCT04631055|Experimental|DCB group|use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.
11020815|NCT04631055|Active Comparator|wingspan group|use wingspan stent system made by Stryker Neurovascular.
11020816|NCT04631042||impulsive compulsive|Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.
11020817|NCT04631029|Experimental|Treatment (carboplatin, etoposide, atezolizumab, entinostat)|"INDUCTION THERAPY: Patients receive carboplatin IV over 30-60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, atezolizumab IV over 30-60 minutes on day 1, and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive atezolizumab IV over 30 minutes on day 1 and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity."
11020818|NCT04631016|Experimental|MEDI3506|Approximatley 161 participants will be randomzed to recieve MEDI3506
11020819|NCT04631016|Placebo Comparator|Placebo|Approximatley 161 participants will be randomzed to recieve placebo
11020820|NCT04631003|Other|Dynamic testing|"There are only one arm in this study. All patients get the same diagnostics and therapy. The preoperative assessments consist of an arthroCT of the wrist as well as the collection of demographic data, accident mechanism, medication intake, etc. within the scope of the usual medical history on the emergency ward. With the arthro-CT, in addition to the fracture balance, the proof of a possible rupture of the scapholunary tape apparatus takes place.
~The dynamic determination of the scapholunary instability takes place during the osteosynthesis of the radius fracture.
~With the dynamic functional test, the change of the scapholunary distance is assessed by illumination by movement of the wrist from the radial abduction into the ulnar abduction, before and after the execution of the osteosynthesis of the distal radius fracture.
~Subsequently, the results of the scapholunary dissociation of the arthro-CT are checked with the results of the intraoperative dynamic test for correlation."
11020821|NCT04630990||Participants Treated With Elagolix|Participants will receive Elagolix according to the local label.
11020822|NCT04630977|Experimental|Multi-Ingredient Pre-workout Supplement|"This group of participants will intake a multi-ingredient supplement around ~15 minutes before every workout.
~The nutritional information of the supplement is: ~90 Kcal. for 25g of powder: carbohydrates -isomaltulose, fructose, maltodextrin- 15 g, essential amino-acids -Beta-alanine: 2.5g, L-arginine AKG: 2.5g, L-Leucine: 800mg, Taurine: 500mg, L-citrulline: 500mg- 6.8 g, Creatine monohydrate: 2.0g, Guarana Extract: 800mg, total caffeine: 160mg, and Magnesium: 112.5mg.
~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).
~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.
~The training sessions and the nutritional guideline will be the same for the three groups."
11020823|NCT04630977|Active Comparator|Isocaloric Placebo|"This group of participants will intake an isocaloric (only carbohydrates: Maltodextrin) supplement comparator, around ~15 minutes before every workout.
~The nutritional information of the supplement is: ~90 Kcal. for 23g of powder.
~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).
~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.
~The training sessions and the nutritional guideline will be the same for the three groups."
11020824|NCT04630977|Sham Comparator|Control|"These participants will drink a non-caloric admixture with the same taste, texture and flavour.
~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).
~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.
~The training sessions and the nutritional guideline will be the same for the three groups."
11020825|NCT04630964|Experimental|psilocybin|25 mg Single Oral Dose
11020826|NCT04630964|Active Comparator|placebo|100 mg Single Oral Dose
11020827|NCT04630951|Experimental|Strength training based on low loads with blood flow restriction (Experimental group I)|"Squat
~Single Deadlift
~Back Squat"
11020828|NCT04630951|Experimental|Strenght training based on high loads (Experimental group II)|"Squat
~Single Deadlift
~Back Squat"
11020868|NCT04630691||T2DM|Patients with HbA1c above 6,5
11127306|NCT03884166||control|
11020829|NCT04630938|Active Comparator|G-M|Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.
11020830|NCT04630938|Active Comparator|G-ML|Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.
11020831|NCT04630938|Placebo Comparator|G-0|Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.
11020832|NCT04630925|Active Comparator|isCGM-arm|CGM data will be viewed real-time and used to adjust diabetes treatment
11020833|NCT04630925|No Intervention|POC-arm|POC glucose readings are used to adjust diabetes treatment. CGM data are blinded to all and only gathered for comparison purposes to intervention group.
11020834|NCT04630912|Experimental|Acceptance and Commitment Therapy|12 weekly, 90 minute ACT sessions with person with dementia (with a review at week 6)
11020835|NCT04630899|Experimental|Active Joint Mobilization|
11020836|NCT04630899|Experimental|Passive Joint Mobilization|
11020837|NCT04630886|Experimental|Tranexamic acid|The TXA group will use 1% lidocaine with 1:200,000 epinephrine and 50mg/ml TXA.
11020838|NCT04630886|Active Comparator|Control|The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
11020839|NCT04630873|Active Comparator|LOW-HIGH VOLUME|Initially a low volume of the drug (100IU botulinum toxin diluted in 2 ml) after a safe washout period of 6 months the same patients will be injected with a high volume (100IU botulinum toxin in 4 ml) of the drug.
11020840|NCT04630873|Experimental|HIGH-LOW VOLUME|initially a high volume of the drug (100IU botulinum toxin diluted in 4 ml) after a safe washout period of 6 months the same patients will be injected with a low volume (100IU botulinum toxin in 2 ml) of the drug.
11020841|NCT04630860|Experimental|56mg dose group|
11020842|NCT04630860|Experimental|84mg dose group|
11020843|NCT04630860|Experimental|112mg dose group|
11020844|NCT04630847|Experimental|Autism Subjects|These subjects will be administered fecal microbiota transplant by colonoscopy
11020845|NCT04630834|Active Comparator|Intervention group|Intervention Group: ibuprofen 10 mg/kg (maximum 600mg) plus acetaminophen 15mg/kg (maximum 650mg)
11020846|NCT04630834|Placebo Comparator|Placebo Group|Placebo Group: Ibuprofen 10mg/kg (maximum 600 mg) plus placebo 15mg/kg (maximum 650mg)
11020847|NCT04630821|Experimental|Treatment with Dilute Sodium Hypochlorite solution|Subjects will be treated with the dilute bleach compresses daily (Monday through Friday) for the first 3 weeks of therapy. The bleach solution will be prepared and compresses applied for a 20 minute duration prior to radiation therapy. The compress can be applied within an hour of radiation therapy. Subjects will apply Aquaphor® ointment twice a day, once immediately after the radiation treatment and once in the evening. On days the experimental subjects do not receive radiation therapy, they will continue to moisturize their skin twice a day (AM and PM) with Aquaphor® ointment.
11020848|NCT04630808|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
11020849|NCT04630808|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
11020850|NCT04630795||3D printed insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest, while the Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
11020851|NCT04630782||Aim 1|"The investigators will compare PET-MRI imaging and stool biomarkers between patients with VEDOSS/early SSc (n=40) and those with late SSc (n=20) not on immunosuppressive treatment.
~Participants will undergo a PET-MRI scan once at baseline."
11020852|NCT04630782||Aim 2|"In early SSc patients (n=35), the investigators will determine change in biomarker levels from pre-treatment baseline to 6 months (primary end-point) and 12-months (secondary end-point) following MMF treatment.
~Participants will undergo PET-MRI scans at baseline, 6-month and 12-month."
11020853|NCT04630782||Exploratory aim|"In patients with VEDOSS/early SSc (n=15) not on immunosuppressive treatment, the investigators will characterize imaging and stool biomarker changes over one year.
~Participants will undergo PET-MRI scans at baseline and 12-month."
11020854|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^7 cells/dose on Day 1, 8, and 15|
11020855|NCT04630769|Experimental|Monotherapy: IP FT516 at 3 x 10^8 cells/dose on Day 1, 8, and 15|
11020856|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^8 cells/dose on Day 1, 8, and 15|
11020857|NCT04630769|Experimental|Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6|
11020858|NCT04630769|Experimental|Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6|
11020859|NCT04630756|Experimental|AZD4573: Cohorts 1, 2, and 3|"Each cohort (1, 2, and 3) has a different target dose level.
~Participants will receive intravenous ascending doses of AZD4573 once weekly with oral acalabrutinib twice daily continuously in Part A. In Part B, participants will receive the RP2D of AZD4573 from Part A."
11020860|NCT04630743|Other|Cognitive and Behavioral Intervention|Non-pharmacological strategies for the Management of episodic breathlessness
11020861|NCT04630730|Experimental|Recombinant intravesical BCG|"The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment.
~Thereafter, atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine for a total of 4 cycles.
~After surgery it will be administered alone in the adjuvant setting for 13 cycles."
11020862|NCT04630717|Active Comparator|control group|normal discussion before general anesthesia induction
11020863|NCT04630717|Active Comparator|Hypnosis group|hypnosis session before general anesthesia induction
11020864|NCT04630704||Non vascular repeatibility|This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
11020865|NCT04630704||Non vascular physiology|This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
11020866|NCT04630704||CLTI physiology|This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
11020867|NCT04630691||Control|Patients with HbA1c around 6,0
11020869|NCT04630678|Experimental|Virtual Reality Group|"The first group was received conventional physiotherapy and virtual reality therapy for 60 minutes.
~The conventional physiotherapy interventions, including joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles and special for the needs of the child, was applied to both groups. The virtual reality group received that simulate daily life and contain individual scenarios by using the USE-IT system for thirty minutes. USE-IT (Most Rehabilitation, Ankara, Turkey) is a 2D non-immersive virtual reality system that plays games on a 50-inches touchscreen. The children played the matching, plumber, plumber, math, and car wash games in accordance with their reaching map results. The treatment were given three times a week for eight weeks."
11020870|NCT04630678|Active Comparator|Activity Training (Control) Group|The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
11020871|NCT04630665|Other|thin buccal bone|immediate implant placement in thin buccal bone wall socket
11020872|NCT04630665|Other|≥1 buccal bone|immediate implant placement in 1 mm or more buccal bone thickness socket
11020873|NCT04630652|Experimental|Psoriasis treatment with risankizumab|Moderate-to-severe psoriasis treatment with risankizumab for 16 weeks
11020874|NCT04630626||Simplify Disc|Extended follow-up of IDE Subjects treated with the Simplify Cervical Artificial Disc during IDE G140154
11020875|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
11020876|NCT04630600|Other|Control|Normal waiting room
11020877|NCT04630600|Experimental|Intervention#1|Waiting room with partially-equipped aquarium (without fish)
11020878|NCT04630600|Experimental|Intervention#2|Waiting room with fully-equipped aquarium (with fish)
11020879|NCT04630587|Experimental|Indirect restorations|For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.
11020880|NCT04630587|Active Comparator|Direct restorations|The direct composite restorations are performed based on normal treatment practices. For both direct and indirect restorations, commercially available short-fibre reinforced composite material (everX Flow, GC) is used for core material (replacing dentin) and flowable composite material (G-ænial® Universal Injectable, GC) for surface (replacing enamel), according the manufacturer´s instructions. The occlusion and articulation are checked and adjusted, and the restoration is finished with polishing instruments.
11020881|NCT04630574||Patients with Huntington's disease|Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.
11020882|NCT04630561|Experimental|Intervention Group|Subjects will participate in a 15 minute postural intervention program 2-3 times per week
11020883|NCT04630561|No Intervention|Control Group|Subjects will NOT participate in any postural intervention.
11020884|NCT04630548|Active Comparator|post placental IUD insertion|Following placental delivery, uterine cavity will be examined to exclude the presence of malformations or fibroids. Uterus will be stabilized by grasping it at fundus and the copper IUD (CuT 380 IUD) will be placed (within 10 minutes following the placental delivery) through the uterine wall incision high up in the uterine fundus (either by hand or using its applicator).
11020885|NCT04630548|Active Comparator|post puerperal IUD insertion|IUD will be inserted 6 - 8 weeks following caesarean delivery (during the post puerperal visit).
11020886|NCT04630535||Obstructive Sleep Apnea|Pacient with OSA (AHI≥5) undergoing aorto-bifemoral bypass
11020887|NCT04630535||Without Obstructive Sleep Apnea|Patinets without OSA undergoing aorto-bifemoral bypass
11020888|NCT04630522|Experimental|JMT103- 120 mg SC Q4W|Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.
11020889|NCT04630522|Experimental|JMT103- 120 mg SC Q8W|Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.
11020890|NCT04630522|Experimental|JMT103- 180 mg SC Q8W|Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.
11020891|NCT04630496|Experimental|PRE-OPERATIVE EXERCISE TRACKING|"Participant baseline information will be collected from their electronic medical records.
~After enrollment, participants will be provided a mobile device (Fitbit) to wear for tracking steps for 1 week prior to their scheduled surgery.
~Participants will keep a log of daily steps for the 1 week they are wearing the device and receive one progress check-in call during the week.
~The device and log will be turned in either on a pre-surgery clinic visit or on the day of surgery whichever comes first."
11020892|NCT04630483||Group I: INHA|Inhalational anesthesia (INHA)
11020893|NCT04630483||Group II: TIVA|Total intravenous anesthesia (TIVA)
11020894|NCT04630470|Placebo Comparator|The placebo control group|Each patient received the massage therapy with baby oil on both lower leg areas for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
11020895|NCT04630470|Experimental|The study group|Each patient received the massage therapy with lavender oil on both lower legs for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
11020896|NCT04630457|Active Comparator|Meridium-RoFT|order of existing prosthesis-Meridium prosthesis-RoFT prosthesis
11020897|NCT04630457|Active Comparator|RoFT-Meridium|order of existing prosthesis-RoFT prosthesis-Meridium prosthesis
11020898|NCT04630444|Experimental|Intervention Group|30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).
11021051|NCT04629482||Children with typical development|Children with typical development
11020899|NCT04630431||Observational (questionnaire, medical record review)|Patients complete a questionnaire about their preferences, understanding, and attitudes regarding clinical trials. Patients also have their medical records reviewed.
11020900|NCT04630418|Experimental|NanoSilk Cosmo|Participants will receive a 30 mL jar of NanoSilk Cosmo
11020901|NCT04630405|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
11020902|NCT04630405|Active Comparator|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
11020903|NCT04630392|Experimental|Intervention Group|There are two intervention groups: treadmill walking only, whole-body vibration plus treadmill walking.
11020904|NCT04630379|Experimental|Group A (visit with neuro-oncologist)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months to address concerns that are identified via the survey and the domain of concern identified by patient and caregiver.
11020905|NCT04630379|Experimental|Group B (visit with neuro-oncologist and palliative care team)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist and palliative care team monthly for 6 months to address concerns that are identified by the survey and domains of concerns. Caregivers also attend support sessions led by a social worker monthly for 6 months.
11020906|NCT04630379|Active Comparator|Group C (visit with neuro-oncologist, palliative care team)|Patients and primary caregiver complete quality of life portion of the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months and address important concerns that come up on the survey. Patients may also receive palliative care consultation as deemed appropriate by the neuro-oncologist.
11020907|NCT04630366|Experimental|NST-1024|NST-1024 capsules given once daily for up to 14 days
11020908|NCT04630366|Placebo Comparator|Placebo|Matching placebo capsules to NST-1024 given once daily for up to 14 days
11020909|NCT04630353|Experimental|HB-201 Intratumorally on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
11020910|NCT04630353|Experimental|HB-201 Intravenously on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
11020911|NCT04630353|Experimental|HB-201 Intratumorally 7 to 14 days before chemoradiation|Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype.
11020912|NCT04630340|Active Comparator|STEADES-2 (Intervention) arm|"Subjects in the intervention arm will fill up the questionnaire embedded in the STEADES app and be inducted to the use of STEADES-2 device by the CRC. The CRC will assist to download the STEADES app into the subject's smartphone; demonstrate the use of the app and the procedure for the serious games; and linkage to the virtual coach. The subject will use the STEADES-2 device to assess their smoking status and play the game according to the stipulations in the protocol. The STEADES-2 app provides a portal for the subject to interact with the assigned virtual coach and for motivation messages to be delivered to them. The primary outcome is total smoking cessation as measured by
~exhaled breath carbon monoxide using the STEADES-2 device and
~urine cotinine level which indicates the nicotine from the cigarette smoking The secondary outcome is the score using the System Usability Scale (SUS) to assess the use and experience in using the STEADES-2 system"
11020913|NCT04630340|No Intervention|Usual Care|"In the control arm, the subjects will be enrolled into the existing smoking cessation program at the respective polyclinic, which covers smoking cessation advice, together with an exhaled breath analyzed using a commercially available eCO measurement device by a trained nurse counsellor. They will complete a questionnaire and their smoking status will be re-assessed at 12 weeks after their enrolment. The primary outcome is total smoking cessation at the end of the study:
~as measured by the exhaled breath carbon monoxide level determined by the STEADES-2 device and
~urine cotinine levels which is a marker of nicotine level from smoking"
11020914|NCT04630327||Breast Cancer Patients|Breast cancer patients with no history of previously diagnosed depression or anxiety and who have been referred to or have been receiving treatment at Almaty Oncology Center
11020915|NCT04630314||Consecutive patients treated with covered stents post PCI CAP|
11020916|NCT04630301||Measurement of pleural pressure|a. Patients admitted to the Johns Hopkins Hospital with spontaneous, iatrogenic, or tension pneumothorax referred to the Division of Interventional Pulmonology for thoracostomy will be recruited. Using standard sterile technique, a 14fr catheter will be inserted into the pleural space. An electronic manometer (Compass, Medline Industries, Inc.) will be connected in-line to the introducer needle and Ppl will be recorded for 3-5 respiratory cycles. After measurement, the manometer will be removed and the catheter will remain in place per routine standards of practice.
11020917|NCT04630288||Clopidogrel|Clopidogrel is a prodrug that requires metabolic activation in two stepsby hepatic CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Consequently, due to the irreversible binding to the P2Y12 receptor,platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days) and recovery of normal platelet function occurs at a rate consistent with the normal platelet turnover. Clopidogrel was approved by the European Commission on 15 July 1998 for the secondary prevention of atherothrombotic events in adult patients with ACS.
11020918|NCT04630288||Ticagrelor|Ticagrelor is a nucleoside analogue member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is a selective and reversible ADP- receptor antagonist acting on the platelet P2Y12 receptor. This prevents the binding of ADP to the receptor which attenuates plateletactivation and aggregation.The drug was approved by the European Commission on December 3, 2010, for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]) including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
11020919|NCT04630262|Active Comparator|ATTUNE Cementless CR Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Cruciate Retaining Configuration.
11024423|NCT04606615||Children: NC|Normal Control
11020920|NCT04630262|Active Comparator|ATTUNE Cementless PS Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Posterior Stabilizing Configuration.
11020921|NCT04630249|Experimental|Listening to Women|This group will receive text-message based SBIRT with phone based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, other drugs including prescription medication), and domestic violence.
11020922|NCT04630249|No Intervention|Treatment as Usual|This group will receive in-person screening and referral to treatment assessment. The same screening tools are used to assess substance abuse and mental health problems in LTW and TAU groups.
11020923|NCT04630236|Other|Ultrasound|
11020924|NCT04630223||intrauterine growth retardation|Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
11020925|NCT04630223||healthy fetuses|Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
11020926|NCT04630210|Experimental|A: Letrozole|Letrozole 2.5 mg/day oral until surgery
11020927|NCT04630210|Experimental|B: Letrozole + atezolizumab|Letrozole 2.5 mg/day oral until surgery and Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
11020928|NCT04630210|Experimental|C: Atezolizumab|Atezolizumab 840 mg IV single-dose 14 days (+/- 4 days) before surgery
11020929|NCT04630210|No Intervention|D: Observation|Observation until surgery
11020930|NCT04630197|Experimental|e-CBT|16 total (1 per week) e-CBT sessions will occur with each session having approximately 30 slides coupled with interactive videos. The content and format of these online sessions are designed to mirror in-person CBT for OCD. Slides will highlight a different topic each week and include general information, skill overview, and homework. The homework included in each session will be submitted through the platform and reviewed by a clinician with personalized feedback provided within 3 days of submission. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. Moreover, exposure and ritual prevention therapy will be incorporated into the CBT program as this is the suggested route of treatment for OCD.
11020931|NCT04630184|Experimental|Virtual reality and exercice|This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
11020932|NCT04630184|Placebo Comparator|Placebo and exercice|This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
11020933|NCT04630184|No Intervention|waiting list|This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
11020934|NCT04630171|Experimental|Group 1: VerTouch for labor epidural or spinal anesthesia procedure|VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
11020935|NCT04630171|Active Comparator|Group 2: Ultrasound (US) for labor epidural or spinal anesthesia procedure|Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
11020936|NCT04630171|Active Comparator|Group 3: Control group, palpation for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure in women requesting labor analgesia.
11020937|NCT04630171|Experimental|Group 4: VerTouch for lumbar puncture procedure|VerTouch utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
11020938|NCT04630171|Active Comparator|Group 5: Ultrasound (US) for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
11020939|NCT04630171|Active Comparator|Group 6: Control group, palpation for lumbar puncture procedure|Control group, palpation utilized for identification of site for lumbar puncture procedure in patients who require a therapeutic lumbar puncture.
11020940|NCT04630158|Placebo Comparator|SAF312 Placebo|Randomized to a 1:1:1 topical eye drops, twice daily
11020941|NCT04630158|Experimental|SAF312 dose 1|Randomized to a 1:1:1 topical eye drops, twice daily
11020942|NCT04630158|Experimental|SAF312 dose 2|Randomized to a 1:1:1 topical eye drops, twice daily
11020943|NCT04630145|Experimental|Group A: Bedaquiline (BDQ) + Clarithromycin (CAM) + Ethambutol (EB)|Participants will receive BDQ 400 milligrams (mg) (4*100 mg tablets) once daily (qd) from Week 1-2 (loading phase), BDQ 200 mg (2*100mg tablets) bi-weekly (biw) from Week 3 to 48 (maintenance phase) and CAM 400 mg twice daily (2*200 mg tablets) along with EB 500-750 mg qd or maximum daily dose of 1.0 gram for up to Week 48.
11020944|NCT04630145|Active Comparator|Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB|Participants will receive maximum of 4 capsules of RFP 450 mg daily (or maximum daily dose of 600 mg), CAM 400 mg (2*200 mg tablets) twice a day along with EB 500-750 mg daily followed by 2 capsules of RBT 150 mg once a day (qd) or maximum daily dose of 1.0 gram for up to Week 48.
11020945|NCT04630132||Frailty Group|"The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:
~Decreased grip strength
~Self-reported exhaustion
~Unintentional weight loss of more than 4.5 kg over the past year
~Slow walking speed
~Low physical activity"
11020946|NCT04630132||Non-Frailty Group|"The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:
~Decreased grip strength
~Self-reported exhaustion
~Unintentional weight loss of more than 4.5 kg over the past year
~Slow walking speed
~Low physical activity"
11020947|NCT04630119||Study group of female homemakers with chronic neck pain|All female patients aged between 18-55 years with chronic neck pain (pain lasting for more than 3months) who were homemakers were included in the study. All participants reported the presence of pain in the preceding one week
11020980|NCT04629950|Placebo Comparator|Placebo|Participants receive a placebo tablet matching rimegepant orally every other day for 16 weeks.
11020981|NCT04629937|Experimental|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
11024424|NCT04606602|Experimental|30 mg|
11020948|NCT04630093|Experimental|Panel-based pharmacogenetic genotyping|All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
11020949|NCT04630080|Experimental|Scalp Cooling|
11020950|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 1a|Participants will receive SC dose A of AZD3427 or placebo matched to AZD3427 on Day 1.
11020951|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 2a|Participants will receive SC dose B of AZD3427 or placebo matched to AZD3427 on Day 1.
11020952|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 3a|Participants will receive SC dose C of AZD3427 or placebo matched to AZD3427 on Day 1.
11020953|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 4a|Participants will receive SC dose D of AZD3427 or placebo matched to AZD3427 on Day 1.
11020954|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 5a|Participants will receive IV dose B of AZD3427 or placebo matched to AZD3427 on Day 1.
11020955|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 6a|Participants of Japanese descent will receive SC dose C of AZD3427 or placebo matched to AZD3427 on Day 1.
11020956|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 1b|Participants with HFrEF will receive SC dose A of AZD3427 or placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
11020957|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 2b|Participants with HFpEF will receive SC dose A of AZD3427 or placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
11020958|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 3b|Participants with HFrEF will receive SC dose B of AZD3427 or placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
11020959|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 4b|Participants with HFpEF will receive SC dose B of AZD3427 or placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
11020960|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 5b|Participants with HFrEF will receive SC dose C of AZD3427 or placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
11020961|NCT04630067|Experimental|AZD3427 and Placebo: Cohort 6b|Participants with HFpEF will receive SC dose C of AZD3427 or placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
11020962|NCT04630054|Experimental|Mask Intervention|"Communities and individuals randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use.
~In the community experiment, every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people.
~In the individual experiment, individuals randomized to the intervention arm will not be asked to recommend masks to others, but will also not be discouraged from recommending mask use to others."
11020963|NCT04630054|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
11020964|NCT04630041|Experimental|Social Needs Assessment|Patients in the Emergency Department will complete a social needs assessment screener that may refer them to 211 services
11020965|NCT04630028|Experimental|Induction Period (I): Ustekinumab|All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
11020966|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)|Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
11020967|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)|Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
11020968|NCT04630015||Observational (surveys)|Patients complete surveys over 5-10 minutes at baseline (i.e. before participating in the program), and at 9 and 15 weeks follow up on the impact of COVID-19 on survivorship. Patients also complete a survey assessing how patients rate telehealth classes in the Survivorship Wellness program.
11020969|NCT04630002|Experimental|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
11020970|NCT04630002|Experimental|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
11020971|NCT04630002|Experimental|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
11020972|NCT04629989|Active Comparator|Low-flow nasal cannula|The standard oxygen delivery system (low-flow nasal cannula) is worn by the patient, without the DTM or the SM
11020973|NCT04629989|Experimental|Double-Trunk Mask|The Double-Trunk Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
11020974|NCT04629989|Experimental|Surgical Mask|The Surgical Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
11020975|NCT04629976|Experimental|NCO-48 Fumarate 4 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
11020976|NCT04629976|Experimental|NCO-48 Fumarate 20 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
11020977|NCT04629976|Active Comparator|Tenofovir alafenamide 25 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
11020978|NCT04629963|Experimental|Pain Evaluation|Subjects receive the United Nations Istanbul Protocol (UNIP) evaluation. Subjects will complete the validated, self-administered pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Subjects will receive a non-invasive physical exam and pain assessment by a pain specialist.
11020979|NCT04629950|Experimental|Rimegepant|Participants receive a rimegepant 75 mg tablet orally every other day for 16 weeks.
11020982|NCT04629924|Experimental|sleeper one|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).
~Osteocentral anesthesia performed with the SleeperOne® 5 system (Dental Hi Tec) loaded with Articaine 1/200000 carpule."
11020983|NCT04629924|Active Comparator|conventional technique|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).
~Anaesthesia using a conventional technique, i.e. a metal syringe loaded with Articaine 1/200000 carpule."
11020984|NCT04629911|Experimental|HFNO arm|Patients will receive HFNO therapy during laryngomicrosurgery.
11020985|NCT04629885|Experimental|Oxytocin 400 IU|1mL Oxytocin 400 IU vaginal gel once daily for 12 weeks
11020986|NCT04629885|Placebo Comparator|Placebo|1mL Placebo vaginal gel once daily for 12 weeks
11020987|NCT04629872|Experimental|endovascular treatment with fingolimod|
11020988|NCT04629872|No Intervention|endovascular treatment without fingolimod|
11020989|NCT04629859|Experimental|study arm|dento skeletal class III patients will undergo a mandibular setback surgery and maxillary advancement
11020990|NCT04629859|Experimental|controlled arm|dento skeletal class III patients will undergo a mandibular setback surgery
11020991|NCT04629846|Experimental|Trastuzumab Plus（+） QL1209 + Docetaxel|Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
11020992|NCT04629846|Active Comparator|Trastuzumab Plus（+） Pertuzumab + Docetaxel|Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery
11020993|NCT04629833|Experimental|MC0518|Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
11020994|NCT04629833|Active Comparator|Best Available Therapy (BAT)|Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
11020995|NCT04629820|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
11020996|NCT04629820|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).
11020997|NCT04629807|Active Comparator|Demineralized Bone Matrix (DBM)|
11020998|NCT04629807|Active Comparator|Cellular Bone Matrix (CBM)|
11020999|NCT04629794|Active Comparator|Demineralized Bone Matrix|
11021000|NCT04629794|Active Comparator|Bone Morphogenic Protein|
11021001|NCT04629781|Experimental|Docetaxel micellar|Trial Treatment with Docetaxel micellar
11021002|NCT04629768|Other|Duodenal EMR + PuraStat|PuraStat will be applied to the defect after duodenal EMR of the lesion
11021003|NCT04629755|Experimental|Intervention|The intervention was delivered via a series of daily text messages to mobile phones. Participants first were delivered an introductory text message at 6:00 pm on Day 7 of the study. This message alerted the participants to expect their first suggestion via text message at 8:00 am the following morning. For the next 14 days (Days 8 - 22), participants received one of 14 suggestions in random order. The specific daily suggestions varied in length and complexity: The simplest ones included text messages and a brief audiofile delivered via text; the more complex suggestions included text messages and a link to a web-page, which included text or embedded audiofiles describing why a suggestion was being made, how to engage in the suggested practice, and audiotaped exchanges between members of the production team describing what it was like to try the practices themselves. Some suggestions were supplemented with additional reminder and check-in text messages at noon and 4:00 pm.
11021004|NCT04629755|No Intervention|Control|Assessment only.
11021005|NCT04629742|Experimental|Seawater Pizza|Administration of a seawater pizza
11021006|NCT04629742|Active Comparator|Standard Pizza|Administration of a Standard pizza
11021007|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-Cell Lymphoma|FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma
11021008|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
11021009|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma
11021010|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, CLL|FT819 single-dose monotherapy in adult subjects with r/r CLL
11021011|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, CLL|FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL
11021012|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, CLL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL
11021013|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-ALL|FT819 single-dose monotherapy in adult subjects with r/r B-ALL
11021014|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-ALL|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL
11021015|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-ALL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL
11021016|NCT04629716||Intervention|The intervention group will be comprised of adults 50 and older who report severe or chronic pain, are newly registered for the Medical Marijuana Registry in the State of Florida, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, gender, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
11021048|NCT04629495|Active Comparator|RAPA (rapamycin) treatment group|Subjects will receive active drug
11021049|NCT04629495|Placebo Comparator|Placebo group|Subjects will receive placebo
11021050|NCT04629482||Children with attention deficit hyperactivity disorder with developmental delays|Children with attention deficit hyperactivity disorder with developmental delays
11604982|NCT00612040|Experimental|SIBA (E)|
11021017|NCT04629716||Control|The control group will be comprised of adults 50 and older who report severe or chronic pain, have no prior history of medical marijuana use, can communicate in English, and are willing and able to complete study procedures. The control group will be age, gender, and race matched. The primary study outcome is simulated driving performance (i.e. errors in response time, attention, and executive functioning tasks that predict on-road performance). Secondary outcomes include adverse effects.
11021018|NCT04629703|Active Comparator|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care|Fostamatinib (150 mg twice daily for 14 days) + Standard of Care
11021019|NCT04629703|Placebo Comparator|Placebo (twice daily for 14 days) + Standard of Care|Placebo (twice daily for 14 days) + Standard of Care
11021020|NCT04629690|No Intervention|Control Arm|The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit
11021021|NCT04629690|Experimental|SOLAR arm|The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.
11021022|NCT04629677||Cohort A (questionnaire, medical record review)|Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
11021023|NCT04629677||Cohort B (medical record review)|Patients' medical records are reviewed retrospectively.
11021024|NCT04629664|Active Comparator|FX-322|FX-322, 1 dose (N=24)
11021025|NCT04629664|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
11021026|NCT04629651|Experimental|Captopril|"In phase I, Cohorts of 3 patients each will receive doses of captopril with a goal dose of 150mg total by mouth (PO) daily. Initial dose per patient will start at 12.5 mg daily, which will then be increased on weekly intervals as tolerated. To be administered per the intra-patient dose escalation scheme below
~Phase I:
~Day 0: 12.5mg/day Day 7: 12.5mg twice daily Day 14: 12.5mg three times daily Day 21: 25mg three times daily Day 28: 50mg three times daily
~Phase II: The efficacy of captopril will be assessed in the Phase II portion. Captopril given at Maximum Tolerated Dose - bone marrow evaluation to be done at 6 months"
11021027|NCT04629638||covid -19 positive pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth.
11021028|NCT04629638||covid -19 negative pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-negative pregnant women in the 3rd month after birth.
11021029|NCT04629625|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
11021030|NCT04629625|Active Comparator|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
11021031|NCT04629625|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
11021032|NCT04629612|Experimental|Regional anesthesia|Regional block applied according to surgical area
11021033|NCT04629612|No Intervention|No Regional anesthesia|No regional anesthesia applied
11021034|NCT04629599|Experimental|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
11021035|NCT04629599|Active Comparator|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
11021036|NCT04629586||Individuals diagnosed with type 1 diabetes|"T1D Exchange Registry is currently looking for participants:
~Of all ages, genders, races, and ethnic groups
~Living in the United States
~Diagnosed with type 1 diabetes
~Currently taking insulin or have had a pancreatic or islet cell transplant"
11021037|NCT04629573|Active Comparator|Group 1|Epidural Anesthesia
11021038|NCT04629573|Active Comparator|Group 2|General Anesthesia
11021039|NCT04629560|Experimental|Miracle Fruit Arm|Patient will be randomly assigned, by a computer generated randomization, to receive one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures.
11021040|NCT04629560|No Intervention|Control Arm (supportive measures only)|standard of care supportive measures
11021041|NCT04629547|Experimental|Poor sleep treatment group|100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
11021042|NCT04629547|Placebo Comparator|Poor sleep control grop|100 participants will be randomized to take placebo daily at h.s. for two years.
11021043|NCT04629534|Experimental|Group A|
11021044|NCT04629534|Placebo Comparator|Group B|
11021045|NCT04629521|Experimental|CyPass Micro-Stent|CyPass Micro-Stent placed in the angle of the eye at the conclusion of cataract surgery (COMPASS trial)
11021046|NCT04629508|Experimental|Part 1 : Dose Escalation of itacitinib|Participants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
11021047|NCT04629508|Experimental|Part 2 : Dose Expansion of itacitinib|Participants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
11024425|NCT04606602|Placebo Comparator|Placebo|
11021052|NCT04629469|Experimental|Hyperfine|"Patients who have a standard of care MRI, CT or US of the head will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology within +/- 24 hours of their standard of care exam. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
~Patients can have more than one standard of care MRI, CT or US of the head during their inpatients stay, thus will be eligible for a Hyperfine MRI at the following timelines/frequencies:
~With each standard of care brain MRI
~With each standard of care head CT
~A maximum of once per week and within +/- 24 hours of head US."
11021053|NCT04629456|Experimental|group 1|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
11021054|NCT04629456|Experimental|Group 2|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion(24).
11021055|NCT04629443|Experimental|S64315 (also referred as MIK665) with azacitidine|
11021056|NCT04629430|Experimental|Prebiotic diet|2 servings a day of pre-biotics every day from time of admission for HSCT through 100 days following HSCT
11021057|NCT04629417|Experimental|Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
11021058|NCT04629417|Active Comparator|OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
11021059|NCT04629404|Experimental|LY03003|
11021060|NCT04629404|Placebo Comparator|Placebo|
11021061|NCT04629391|Active Comparator|Anatomic TSA|The control group will receive through a deltopectoral approach an anatomic total shoulder arthroplasty (TSA) for a primary glenohumeral arthritis
11021062|NCT04629391|Experimental|RTSA|The experimental group will receive through a deltopectoral approach a reverse total shoulder arthroplasty RTSA for a primary glenohumeral arthritis
11021063|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus pyrazinamide|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
11021064|NCT04629378|Experimental|Meropenem and amoxicillin/clavulanate plus bedaquiline|Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus bedaquiline 400 mg orally once daily. All study treatments will be administered for 14 consecutive days.
11021065|NCT04629378|Active Comparator|Rifafour standard of care treatment|Rifafour e275® administered orally once daily for 14 consecutive days. Rifafour e275® will be administered according to the South African National TB Treatment Guidelines. The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
11021066|NCT04629365|Experimental|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
11021067|NCT04629365|Active Comparator|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
11021068|NCT04629352|Experimental|Verum Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
11021069|NCT04629352|Placebo Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Sham-tDCS, no current will be delivered beyond initial ramp-up time.
11021070|NCT04629339|Experimental|INCB086550|INCB086550 will be administered orally twice a day.
11021071|NCT04629326|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans
11021072|NCT04629313||periodontal disease group|"Gingivitis: consisted of individuals with a BOP score of 10% or greater and PD≤3mm with no attachment or radiographic bone loss.
~SI Periodontitis: consisted of individuals with interdental AL of 1-2 mm, radiographic bone lose less than 15%, PD≤4 mm and no tooth loss due to periodontitis.
~SII Periodontitis: consisted of individuals with interdental AL of 3-4 mm, radiographic bone lose less than %15-% 33 at coronal third, PD≤5 mm and no tooth loss due to periodontitis.
~SIII Periodontitis: consisted of individuals with interdental AL ≥5 mm, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≤4 SIV Periodontitis: consisted of individuals with interdental AL ≥5 mm teeth, radiographic bone lose extending to middle or apical third of the root, PD≥6 mm and tooth loss due to periodontitis of ≥5 teeth with complexity factor (high level tooth mobility, posterior bite collapse…)"
11021073|NCT04629313||periodontal healthy group|consisted of individuals with clinically healthy gingiva on an intact periodontium who had a BOP score less than 10% and PD≤3mm, showed no attachment loss or radiographic bone loss
11021104|NCT04629131|Experimental|Cohort 4 TNM002 250 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
11021105|NCT04629118||Selution SLR™ 018 Drug Eluting Balloon|Subjects will undergo fistuloplasty with the study device - Selution SLR™ 018 Drug Eluting Balloon
11021074|NCT04629300|Experimental|Supportive Care Mobile Application|"Complete study questionnaires at two time points:
~upon enrollment at baseline prior to randomization
~approximately 12 weeks after the baseline assessment time point.
~Participants will be provided with a study-issued tablet computer to access mobile app and receive a comprehensive tutorial and detailed instructions on how to use the app.
~Participants will have approximately 10 weeks to complete the intervention modules at self initiated pace. The app will provide prompts as reminders to complete the modules.
~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
11021075|NCT04629300|Active Comparator|Usual Care|"Complete study questionnaires at two time points:
~upon enrollment at baseline prior to randomization
~approximately 12 weeks after the baseline assessment time point.
~Participants will receive standard oncology care. Study staff will monitor participant use of supportive care services, such as social work, psychology, psychiatry, and palliative care."
11021076|NCT04629287|Experimental|KPCXM18 for injection|KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route
11021077|NCT04629287|Placebo Comparator|Placebo|Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
11021078|NCT04629274|Experimental|Test of Imotopes® candidates on blood cells of patients with stabilized NMO|To test in vitro the binding of different Imotopes® to class II HLA antigens on PBMC isolated from patients presenting a diagnosed and stabilized neuromyelitis optica spectrum disorders, as well as their ability to generate a cytolytic response directed against the immune cells involved in the maintenance and triggering of the disease (i.e. non-cytolytic T cells recognising the same epitopes and antigen presenting cells (APC) presenting the same epitopes).
11021079|NCT04629261|Experimental|Users with no incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will not receive a discount fee for enrollment.
11021080|NCT04629261|Experimental|Users with incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will do receive a discount fee for enrollment.
11021081|NCT04629261|No Intervention|Non-users|Participants with an age range similar to the intervention groups, who work or lives nearby ECOBICI's bicycle station, that are not enrolled in the ECOBICI program or in a health related program (ex. reducing weight).
11021082|NCT04629248|Experimental|Open Label Treatment: Obinutuzumab|Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and Anti-PLA2R autoantibody titer (using Euroimmun ELISA).
11021083|NCT04629248|Active Comparator|Open Label Treatment: Tacrolimus|Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and Anti-PLA2R autoantibody titer (using Euroimmun ELISA).
11021084|NCT04629235|Active Comparator|24 hours of bedrest|- 24 hours of bedrest
11021085|NCT04629235|Experimental|Intervention group|- Wonder around after 8 hours of bedrest
11021086|NCT04629209|Experimental|Arm A: ONC201 with Surgical Resection in Glioblastoma|Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
11021087|NCT04629209|Experimental|Arm B: ONC201 in Glioblastoma|Unequivocal evidence of recurrence (progressive disease) on contrast-enhanced brain CT or MRI as defined by RANO criteria, or have documented recurrent glioma on diagnostic biopsy. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
11021088|NCT04629196|Experimental|IV Weight-Based Induction Dose|
11021089|NCT04629196|Active Comparator|Standard Subcutaenous Dose|
11021090|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^11 live cells)|HV subjects receive SYNB8802 (1 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
11021091|NCT04629170|Experimental|MAD HV: SYNB8802 (3 x 10^11 live cells)|HV subjects receive SYNB8802 (3 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
11021092|NCT04629170|Experimental|MAD HV: SYNB8802 (1 x 10^12 live cells)|HV subjects receive SYNB8802 (1 x 10^12 live cells) TID for 5 days in the MAD study (Part 1).
11021093|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 1)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
11021094|NCT04629170|Experimental|MAD HV: SYNB8802 (optional cohort 2)|HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
11021095|NCT04629170|Placebo Comparator|MAD HV: Placebo|HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
11021096|NCT04629170|Other|Crossover Arm 1: SYNB8802 crossover to Placebo|In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
11021097|NCT04629170|Other|Crossover Arm 2: Placebo crossover to SYNB8802|In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
11021098|NCT04629157|Experimental|All patients|All patients entering the study will undergo paired testing of a lateral flow device using an anterior nasal swab and an RT-PCR using a nose and throat swab.
11021099|NCT04629144|Experimental|Belimumab|Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.
11021100|NCT04629144|Placebo Comparator|Placebo|Placebo of Belimumab administered subcutaneously weekly from week 0 to week 24.
11021101|NCT04629131|Experimental|Cohort 1 TNM002 10 μg/kg/Placebo|Sentinel dosing will be conducted for Cohort 1. Two participants will be dosed (1 with TNM002, 1 with placebo) at least 72 hours prior to subsequent dosing. The remaining participants will only be dosed if no significant safety signals are identified in the sentinel participants. In total, eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
11021102|NCT04629131|Experimental|Cohort 2 TNM002 35 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
11021103|NCT04629131|Experimental|Cohort 3 TNM002 100 μg/kg/Placebo|Eight subjects will be randomly assigned to receive either TNM002 or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo).
11021141|NCT04628832|Experimental|Prescribing Information + PMP Use Mandate|
11021142|NCT04628832|No Intervention|Control / As-Usual|
11021106|NCT04629105|Active Comparator|Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.
11021107|NCT04629105|Placebo Comparator|Cohort (SARS-CoV-2): Arm 2 (Placebo)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.
11021108|NCT04629105|Active Comparator|Cohort 2 (Flu): Arm 3 (LMSCs)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.
11021109|NCT04629105|Placebo Comparator|Cohort 2 (Flu): Arm 4 (Placebo)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.
11021110|NCT04629066|No Intervention|Usual care|Usual care will include regularly scheduled visits with the clinical heart failure care team and medical therapy as prescribed by that team.
11021111|NCT04629066|Experimental|Remote prescription for aerobic exercise|The exercise prescription will be created by an exercise physiologist after incorporating remotely collected data from a patient directed smartphone app assessing HF symptom severity, vital signs, weight, and blood sugar, and cardiac implant measures of physical activity, heart rate, heart failure volume status and heart rhythm, and Fitbit measures of physical activity.
11021112|NCT04629053||Patients with an acute febrile illness|Patients with acute febrile illness, 4,800 children and 2,400 adults, divided equally across three countries (Laos, Myanmar and Bangladesh) and three age groups: >28 days to <5 years; ≥5 years to <15 years, and ≥15 years of age.
11021113|NCT04629040|Experimental|Intervention|
11021114|NCT04629040|Placebo Comparator|Control|
11021115|NCT04629001||with Covid-19 infection|
11021116|NCT04629001||without Covid-19 infection|
11021117|NCT04628988|Experimental|CC-90011 in combination with Abiraterone and Prednisone|Oral administration (PO) of CC-90011 monotherapy administered once per week (QW), for 4 weeks. From cycle 2 onwards, all participants will receive 60 mg of CC-90011 PO QW, in combination with 100 mg of abiraterone PO daily, and 5 mg of prednisone PO every 12 hours (10mg QD)
11021118|NCT04628975|Experimental|with transillumination|The nurses will use the Transillumination method for a period P1. Then these same nurses will use the control method (without transillumination) for a period P2.
11021119|NCT04628975|No Intervention|without transillumination (control method)|The nurses will use the control method for a period P1. Then these same nurses will use the Transillumination method for a period P2.
11021120|NCT04628962||Asthma-COPD Overlapped (aCOPD)|30 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
11021121|NCT04628962||Non-Exacerbator COPD (neCOPD)|30 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
11021122|NCT04628962||frequent Excacerbator with Emphysema COPD (eeCOPD)|30 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
11021123|NCT04628962||frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)|30 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
11021124|NCT04628962||Asthma patients (AST)|30 subjects affected by asthma comparable by age and sex with the other recruited subjects
11021125|NCT04628962||Healthy subjects (CTRL)|200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
11021126|NCT04628949|Experimental|aScope™ Duodeno endoscope and aBox™ Duodeno|Eligible subjects who are undergoing non-emergent, clinically indicated ERCP using aScope™ Duodeno endoscope and aBox™ Duodeno.
11021127|NCT04628936|Experimental|KZR-616 45 mg + standard therapy (open-label)|All patients will receive a subcutaneous (SC) injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 through Week 48 (EOT Visit).
11021128|NCT04628923|Experimental|QLB|"With the patient in the lateral decubitus and the block side independent, a curvilinear ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.
~The probe is shifted slowly to the lateral side until the transverse processes disappear and the QL muscle is evident in its long axis attached caudally to the iliac crest with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, QL, and PM muscles respectively."
11021129|NCT04628910|Active Comparator|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
11021130|NCT04628910|Experimental|Simulated Flotation Therapy|Participants will utilize the Zerobody dry flotation therapy.
11021131|NCT04628884|Active Comparator|Protamine dosing according the total heparin administrated|The protamine dose will be calculated according to the total heparin administered including the heparin dose add during the pump purge, 1 mg of protamine for each 100 IU of heparin
11021132|NCT04628884|Experimental|Protamine dosing according the residual heparin determined by a pharmacokinetic model|The protamine dose will be calculated according to the residual heparin estimated before the separation of the cardiopulmonary bypass using a pharmacokinetic model, 1 mg of protamine for each 100 IU of residual heparin
11021133|NCT04628871||Subjects who received SB-318|Subjects who received SB-318 in clinical study SB-318-1502
11021134|NCT04628871||Subjects who received SB-913|Subjects who received SB-913 in clinical study SB-913-1602.
11021135|NCT04628871||Subjects who received SB-FIX|Subjects who received SB-FIX in clinical study SB-FIX
11021136|NCT04628858||Primary group|
11021137|NCT04628845|Placebo Comparator|SRP and endontic treatment without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals without using laser 940nm.
11021138|NCT04628845|Active Comparator|SRP and endodontic treatment with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
11021139|NCT04628832|Experimental|PMP Use Mandate|
11021140|NCT04628832|Experimental|Prescribing Information|
11021143|NCT04628819|Experimental|Babybiane Imedia|Patients receive Babybiane Imedia once daily during seven days.
11021144|NCT04628819|Placebo Comparator|Placebo|Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.
11021145|NCT04628806||HSP70CTC|Isolation of circulating tumor cells by HSP70
11021146|NCT04628793|Experimental|Cohort 1|Single dose administration of PF-06842874 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
11021147|NCT04628793|Experimental|Cohort 2|Single dose administration of PF-06842874 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
11021148|NCT04628793|Experimental|Cohort 3|Single dose administration of PF-06842874 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
11021149|NCT04628780|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07209960 at escalating dose levels
11021150|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
11021151|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 2 (RCC)|Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
11021152|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 3 (UC)|Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1
11021153|NCT04628767|Experimental|Arm A (durvalumab, chemotherapy)|Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
11021154|NCT04628767|Active Comparator|Arm B (chemotherapy)|Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
11021155|NCT04628767|Experimental|Arm C (durvalumab, gemcitabine hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
11021156|NCT04628754|Experimental|Intervention|Resistance exercise and dietary protein guidance
11021157|NCT04628754|No Intervention|Control|Usual care
11021158|NCT04628741|Active Comparator|Dynamic Coaching Model|The Dynamic Coaching Model is an established treatment approach that entails training college students with executive function impairments (e.g., those with a history of traumatic brain injury) to rely on their own executive functions in order to problem solve and reason in real-life situations requiring them to do so (e.g., taking college classes).
11021159|NCT04628741|Experimental|Apprenticeship Approach for College Students|The Apprenticeship Approach is a novel treatment approach that incorporates explicit education about: (a) traumatic brain injury definition; (b) traumatic brain injury symptomatology; and (c) individuals who may be able to provide assistance to the individual with traumatic brain injury into the existing Dynamic Coaching Model.
11021160|NCT04628728||Current referral letters|One letter will be chosen from the selection of current referral letters (of average quality according to the results of the study mentioned above). Any data that would allow identification of the respective patient (i.e. name, date of birth, social insurance number, address) will be anonymised (not blackened in order not to disturb fluent reading).
11021161|NCT04628728||New referral letters|The other one will be a corrected version of the first letter according to the ELGA (Elektronische Gesundheitsakte) requirements and the identified needs of patients and stakeholders (see Previous Work 1).
11021162|NCT04628715|Experimental|Supervised RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The main goal during this intervention is to breath at resonance frequency which is slower than the usual breathing frequency. Participants will be guided towards this lower breathing frequency by using appropriate breathing techniques and the provision of a breathing pacer during the supervised sessions. During home practice, the participants will be provided with an application which will visualise a breathing pacer at their resonance frequency. At the third session, participants will no longer receive a breathing pacer but are instructed to breath in phase with their heart rate which is visualised on the computer screen instead of the breathing pacer.
11021163|NCT04628715|Sham Comparator|Supervised sham RSA biofeedback|5 weeks with weekly supervised sessions of 30 minutes and daily home practice sessions of 20 minutes. The latter sessions can be divided into four bouts of 5 minutes which can be spread across the day. The sham-control treatment will follow the same steps as outlined in the supervised intervention arm. However, the participants in this control group will not receive any information regarding their own heart rate and they will not practice at their resonance frequency. Instead, a default mode will be shown during the sessions and in their application for home practice.
11021164|NCT04628715|Experimental|Non-supervised RSA biofeedback|1 short guided session (10 minutes) and daily practice (20 minutes; 4 bouts of 5 minutes) for 5 weeks. The biofeedback protocol will be provided by an application, similar to the supervised protocol but without guidance throughout the sessions, except for the first session. During this first session, the information will be provided about the application and the heart rate sensor (Polar band) which will detect changes in heart rate during the training. In addition, the resonance frequency of the participant will be determined. In the first two weeks, participants will be asked to breath according to their resonance frequency. During the last 3 weeks, participants are asked to breath in phase with their heart rate, which is recorded with the heart rate sensor and displayed on the mobile device.
11021165|NCT04628715|No Intervention|No intervention|No intervention is given.
11021166|NCT04628702|Experimental|Intervention group|receives tablet-training
11021167|NCT04628702|No Intervention|Control group|no training
11021168|NCT04628689|Active Comparator|Group 0.25% bupivacaine|30 ml 0.25% bupivacaine
11021169|NCT04628689|Active Comparator|Group 0.375% bupivacaine|0.375% bupivacaine
11021170|NCT04628676|Experimental|TXA group|tranexamic acid added to irrigation solution
11021171|NCT04628676|Experimental|EPN group|epinephrine added to irrigation solution
11021172|NCT04628663|Active Comparator|DEX group|Dexmedetomidine given at a bolus dose of 1,0 μg/kg 10min before induction of anesthesia and then after as a continuous infusion 0,4-0,8 μg/kg/h until the end of the surgery.
11021173|NCT04628663|Placebo Comparator|Placebo group|Normal saline given as a bolus dose 10min before induction of anesthesia and then after as a continuous infusion until the end of the surgery.
11021174|NCT04628637||Control Group|"Inclusion Criterias are consisted of; Not to have known acute, subacute or chronic disease history, Not to suffer from any infection in the last fortnight, Not to be on a particular medication, Presenting to the ED with reasons other than infectious complaints, and Giving their written consent to participate in the study.
~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease"
11021175|NCT04628637||Covid-19 (-) Pneumonia Group|Inclusion Criterias are consisted of; Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria To have nasopharyngeal swab samples taken in the ED were negative for PCR, and To give their informed consent to participate in the study. Exclusion Criteria The exclusion criteria consisted of diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative
11021176|NCT04628637||Covid-19 Infection Group|"This cohort included the patients InculUsion Criteria Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria and whose PCR tests were positive To have Covid-19 PCR tests were positive as a result of contact tracing, Presenting to the ED for further examination.
~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative."
11021177|NCT04628624|Placebo Comparator|Placebo group|Placebo - capsulated, colour matched potato starch (~450mg per capsule) - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
11021178|NCT04628624|Experimental|Green tea 1|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
11021179|NCT04628624|Experimental|Green tea 2|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG + 150mg quercitin and 150mg alpha lipoic acid - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
11021180|NCT04628611|Active Comparator|Video laryngoscopy Group (V) using Storz c-mac laryngoscope|video laryngoscope without a channel used for endotracheal intubation, the device used to obtain a view of the larynx, and the endotracheal tube is passed through the vocal cords independent of the device. The device is connected to the monitor via connecting cable
11021181|NCT04628611|Active Comparator|The flexible intubating laryngoscopy Group (F) using Storz flexible intubation video endoscope set|The flexible intubating scope is used to locate the vocal cords and acts as a stylet for the endotracheal tube once the scope is placed into the trachea.This device consists of a flexible insertion cord that contains a small camera at the tip, used to transmit images to camera head. The cord includes a channel for a light source, a working channel for suction or administration of oxygen or local anesthetic, and a cable that allows the operator to flex the tip of the scope. The cord attaches to a handle with a light source,camera head control lever for flexion/extension of the tip, and a working channel port. The device is connected to the monitor via connecting table
11021182|NCT04628598|Experimental|Home visiting pregnant women|The pregnant women in the experimental group will be given education and care with home visits.
11021183|NCT04628598|No Intervention|Control Group|Home visits will not be made to the control group, only the primary care antenatal care will be followed.
11021184|NCT04628585||Subjects with sickle-cell disease|Subjects treated with ex vivo gene therapy drug products in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study
11021185|NCT04628572||Cohort 1|Eligible adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice
11021186|NCT04628559|Active Comparator|Dexmedetomine|Patients recieving Dexmedetomidine.
11021187|NCT04628559|Active Comparator|Ketamine|Patients recieving Ketamine.
11021188|NCT04628559|Placebo Comparator|Placebo|Patients recieving Saline.
11021189|NCT04628546|Experimental|Intervention|
11021190|NCT04628546|No Intervention|Assessment Only|
11021191|NCT04628533|Experimental|Four Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 16 weeks in a well-established behavioral weight loss program.
11021192|NCT04628533|Active Comparator|Six Month Duration|Participants will meet weekly online via video chat with an experienced behavioral weight loss counselor in a synchronous 1-hour chat session for 24 weeks in a well-established behavioral weight loss program.
11021193|NCT04628520|Sham Comparator|Maintenance|Oral hygiene instruction and periodontal maintenance
11021225|NCT04628312|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
11021226|NCT04628299|Placebo Comparator|Sham Laser|A non-emission laser will be applied in plantar fascia
11021194|NCT04628520|Active Comparator|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
11021195|NCT04628520|Active Comparator|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
11021196|NCT04628507||Patients undergoing IVF|
11021197|NCT04628494|Experimental|Epcoritamab (GEN3013; DuoBody®CD3xCD20)|Epcoritamab will be administered in Cycles of 28 days until disease progression
11021198|NCT04628494|Active Comparator|Investigator's choice of chemotherapy|R-GemOx will be administrated in Cycles of 28 days. BR will be administrated in Cycles of 21 days.
11021199|NCT04628481|Experimental|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
11021200|NCT04628481|Placebo Comparator|Placebo|matching placebo b.i.d. for 13 cycles of 14 days on/14 days off
11021201|NCT04628468|Experimental|Possibility to use the mobile application without a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and no predefined traditional physiotherapy.
11021202|NCT04628468|Experimental|Possibility to use the mobile application with a predefined number of physiotherapy sessions|Rehabilitation after hip or knee arthroplasty with the option to use a mobile application and a predefined number of traditional physiotherapy sessions
11021203|NCT04628468|No Intervention|Usual care|Rehabilitation after hip or knee arthroplasty without the use of a mobile application.
11021204|NCT04628455|Other|Inversion and Snaring|needlescopic inversion, snaring, and excision of the hernia sac using two Suture Grasper Sevice of Mediflex Company and a home made snare
11021205|NCT04628442||TIP-OB (Office-Based)|Those in TIP-OB will be undergoing regularly scheduled office-based procedures at the otolaryngology clinic at UCSF Mount Zion campus. The investigators will be collecting nasal mucus and blood samples during each of their visits to the clinic, up to 9 times.
11021206|NCT04628442||TIP-OR (Operating Room)|Those in TIP-OR will be undergoing regularly scheduled surgeries in the operating room at UCSF Parnassus or Mount Zion campus. The investigators will be collected nasal polyp tissue, nasal mucus if possible, and blood samples during each of their surgeries, up to 9 times. The investigators will also collect inferior turbinate tissue if consented to.
11021207|NCT04628429||Episodic Migraine|All patients who have been diagnosed with migraine without aura or migraine with aura according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
11021208|NCT04628429||Chronic Migraine|All patients who have been diagnosed with chronic migraine (≥15 headache days per month 8 of which with migrainous features) according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
11021209|NCT04628429||Healthy Control|Controls must be healthy (free of any diagnosed chronic disease, acute infection requiring medication, family history or personal history of migraine), chosen to be as similar as possible to migraine patients, in terms of age and sex.
11021210|NCT04628416|Experimental|Experimental arm|
11021211|NCT04628416|Other|Control|
11021212|NCT04628403|No Intervention|control|
11021213|NCT04628403|Experimental|shock waves|
11021214|NCT04628403|Experimental|massage|
11021215|NCT04628403|Experimental|lasertherapy|
11021216|NCT04628390|Experimental|Experimental|The low-power therapeutic diode laser will be applied with a wavelength 810nm ± 15nm, output power 0-2 W CW / 0-4.8 W peak power (pulse mode), for a time of 20 seconds per centimeter at lo along the buccal surface of the root of the upper and lower teeth.
11021217|NCT04628390|Placebo Comparator|Placebo|A simulation of the application of therapeutic laser will be carried out as a placebo effect, for a time of 20 seconds per centimeter along the vestibular surface of the root of the upper and lower teeth.
11021218|NCT04628377||Diagnostic Accuracy Cohort|Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
11021219|NCT04628377||Prognosis Cohort|Prognosis cohort, in which angiography-derived IMR will be measured in the culprit vessel after successful revascularization. Those patients have follow-up data after 10 years from index procedure. This cohort is STEMI subgroup derived from Institutional registry of Samsung Medical Center, whose results were previously published (JACC Cardiovascular Intervention. 2019 Apr 8;12(7):607-620.) Among 490 STEMI patients from the overall study cohorts, 309 patients with available angiograms and who were suitable for angiographic FFR and IMR measurement will be analyzed. Primary clinical outcome will be cardiac death at 10 years from index procedure. Secondary outcome will be any myocardial infarction, ischemia-driven revascularization, definite or probable stent thrombosis, congestive heart failure admission at 10 years from index procedure.
11021220|NCT04628351|Experimental|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
11021221|NCT04628351|No Intervention|Control Group|Routine patient training was given to the patients in the control group by a nurse working in the clinic.
11021222|NCT04628338|Experimental|IFN-γ|100mcg IFN-γ subcutaneously three times per week (Weeks 0-7), once per week (Weeks 8-12)
11021223|NCT04628325|Experimental|high dose furosemide plus HSS|Patients treated high dose furosemide plus HSS
11021224|NCT04628325|Active Comparator|high dose furosemide alone|Patients treated high dose furosemide alone
11024426|NCT04606602|Experimental|100 mg|
11021227|NCT04628299|Experimental|Experimental group Myofascial Induction|Myofascial Induction in plantar fascia
11021228|NCT04628286|Placebo Comparator|Sham Laser|Placebo laser application in plantar fascia
11021229|NCT04628286|Experimental|Experimental group Myofascial Induction|Myofascial Induction technique application in plantar fascia
11021230|NCT04628273||radiolucent stone group|
11021231|NCT04628273||radiopaque stone group|
11021232|NCT04628247|Experimental|Study group|They will receive the same traditional physical therapy exercise program in addition to gait training on spring gravity bar for one hour
11021233|NCT04628234||Patients with an onco-hematologic solid tumor in palliative care|
11021234|NCT04628221|Other|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
11021235|NCT04628208||Negative for COVID-19|Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
11021236|NCT04628208||Positive for COVID-19|Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
11021237|NCT04628169||group A|group A : placental tissue of 30 patients with placenta accreta
11021238|NCT04628169||group B|group B : placental tissue of 20 normal pregnancy as a control group
11021239|NCT04628156||Outpatients in Cerebral Palsy Greece - Open Door|Outpatients with a diagnosis of cerebral palsy
11021240|NCT04628143|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
11021241|NCT04628143|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
11021242|NCT04628117|No Intervention|Control|Nutritional counselling by individualized nutritional plan for 8 weeks.
11021243|NCT04628117|Experimental|Oral nutritional supplementation|Nutritional counselling by individualized nutritional plan plus oral nutritional supplementation for renal disease (237 mls per day) for 8 weeks.
11021244|NCT04628104||COVID-19 patients presented with myocardial infarction|
11021245|NCT04628104||Non-COVID-19 patients presented with myocardial infarction|
11021246|NCT04628091|Experimental|Test group|Test group is composed of 20 women of reproductive age devoid of any pathology coming to the hospital for a salpingectomy for contraceptive purposes or for a total hysterectomy.
11021247|NCT04628065|Experimental|Intervention Arm|Participants will receive a text message everyday to build behavioral skills and practice self-monitoring of three behavior goals: (1) reduce TV time to less than 2 hours per day; (2) take 10,000 steps or more every day; (3) do 20 minutes or more of structures exercise like prenatal yoga or dance videos every day. Participants will also receive two health coaching mobile phone session; an introduction session and one problem solving session.
11021248|NCT04628052|Experimental|Music|
11021249|NCT04628052|No Intervention|No-Music|
11021250|NCT04628039|Other|Rehabilitation-focused program|Subjects will receive multiple services in a rehabilitation-focused program
11021251|NCT04628026|Experimental|1|standard chemotherapy in combination with venetoclax
11021252|NCT04628026|Placebo Comparator|2|standard chemotherapy in combination with placebo
11021253|NCT04628013|Experimental|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied for a single treatment in Aim 1 and after a washout period, will be applied 3x/week for 2-weeks (6 sessions) for Aim 2.
11021254|NCT04628000||Vitamin D deficiency and COVID19|Vitamin D deficiency and COVID19
11021255|NCT04627987||Main study|Patients with severe, symptomatic aortic stenosis will be recruited and followed up with primary outcome of heart failure death and hospitalisation (n=192). Of these, 170 will have an implantable cardiac monitor placed to detect presence and burden of non-sustained VT.
11021256|NCT04627974||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
11021257|NCT04627961|Experimental|Patient|Patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease
11021258|NCT04627935||COPD patients|Patients with a diagnosis of COPD aged over 60 years
11021259|NCT04627922|Experimental|N-acetyl cysteine (NAC) & cognitive behavioral therapy|N-acetyl cysteine (NAC) & cognitive behavioral therapy experimental arm consists of 30 daily cigarette smokers with current TUD and CUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and CUD.
11021260|NCT04627922|Placebo Comparator|Placebo Comparator: Placebo & cognitive behavioral therapy|Placebo comparator & cognitive behavioral therapy arm consists of 30 daily cigarette smokers with current TUD and CUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and CUD.
11021261|NCT04627909||Group under Robot treatment|Interaction with the Humanoid Robot for 15 minutes
11021262|NCT04627909||Group involved with medical personnel|Interaction with medical personnel for 15 minutes
11021263|NCT04627909||Control group|Exclusive interaction with the caregiver for 15 minutes
11021264|NCT04627896|Experimental|Katty focal therapy|Patients fulfilling inclusion criteria undergo focal treatment with Trinity-guided Katty device
11021265|NCT04627883|Other|Group 1:2|Patients in the control group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2.
11021266|NCT04627883|Other|Group 2:1|Patients in the IRV group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1.
11021267|NCT04627870|Experimental|DCB group|use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis
11021268|NCT04627870|Active Comparator|PTA group|use PTA balloon to treat intracranial in-stent restenosis
11021269|NCT04627857|Active Comparator|Arm 1: Manual toothbrush|
11021270|NCT04627857|Experimental|Arm 2: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
11021271|NCT04627857|Experimental|Arm 3: Manual toothbrush and water flosser (Philips Sonicare AirFloss Ultra)|
11021272|NCT04627857|Experimental|Arm 4: Sonic toothbrush (Philips Sonicare ProtectiveClean) and water flosser|
11024427|NCT04606602|Experimental|300 mg|
11021273|NCT04627844|Placebo Comparator|Delayed Feeds|"Patients will receive tube feeds beginning at 6 hours after PEG tube placement. This is our institutions current practice
~Intervention Type: Dietary"
11021274|NCT04627844|Experimental|Immediate Feeds|"Patients will receive tube feeds beginning immediately after PEG tube placement.
~Intervention Type: Dietary"
11021275|NCT04627831|Experimental|CE-Iohexol|Subject is randomized to receive CE-Iohexol Injection
11021276|NCT04627831|Active Comparator|Omnipaque™ (Iohexol)|Subject is randomized to receive Omnipaque™ Iohexol Injection
11021277|NCT04627818||patients with a mullerian variation|patients with a mullerian variation
11021278|NCT04627805|No Intervention|Phase 2: Usual Care|The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
11021279|NCT04627805|Experimental|Phase 3: MyPath Pilot|Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
11021280|NCT04627792|Other|Waitlist Group|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
11021281|NCT04627779|Experimental|Male Group|
11021282|NCT04627779|Active Comparator|Female Group|
11021283|NCT04627766|Experimental|Monitored children|PICU Children that will be monitored with the device
11021284|NCT04627753|Experimental|Lenalidomide and Rituximab therapy|"The clinical trial drug is administered in one cycle for 28 days and is administered as follows.
~Drug : Rituximab It will be administered 375 mg/m² IV infusion Day 1. (Rituximab: up to 6 cycles)
~Drug : Lenalidomide It will be administred 20 mg PO day 1 -21.
~The medication is taken for up to 2 years, and if there is no recurrence, it is stopped after 2 years
~, Or stop when disease progression is confirmed during the administration period."
11021285|NCT04627740|Experimental|CART treatment|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
11021286|NCT04627727|Experimental|low FODMAP diet|
11021287|NCT04627714|Experimental|Early Fencing|"patients of the Early Fencing arm will start adapted fencing practice (1h30/week) within 4 weeks after the breast surgery and for a duration of 3 months"
11021288|NCT04627714|Experimental|Delayed Fencing|"patients of the Delayed Fencing arm will start adapted fencing practice (1h30/week) 3 months after the breast surgery and for a duration of 3 months"
11021289|NCT04627701|Experimental|ClearRing Device|
11021290|NCT04627688|Active Comparator|Standard dietary advices|
11021291|NCT04627688|Experimental|Time restricted feeding|
11021292|NCT04627675|Experimental|1A: Age 18-50; CORVax|Healthy volunteers age 18-50 will receive CORVax
11021293|NCT04627675|Experimental|1B: Age 18-50; CORVax + pIL-12|Healthy volunteers age 18-50 will receive CORVax + pIL-12
11021294|NCT04627675|Experimental|2A: Age > 50; CORVax|Healthy volunteers age > 50 will receive CORVax
11021295|NCT04627675|Experimental|2B: Age > 50; CORVax + pIL-12|Healthy volunteers age > 50 will receive CORVax + pIL-12
11021296|NCT04627662|Other|Care Partners|Based on previous work, we will recruit up to 75 Care Partners and their 75 care recipients with dementia. This allows for 20% attrition. We will recruit participants from three Alzheimer's Disease Research Centers (ADRCs) located at OHSU, University of Kentucky (UK) and Emory University. We anticipate we will recruit equal numbers from each site (e.g. 25 families from each site); however, these are not firm quotas. We may have more from one site than another.
11021297|NCT04627636|Experimental|study group|which treated with MTrPs release combined with shockwave therapy and conventional program
11021298|NCT04627636|Experimental|control group|which treated with conventional physical therapy program
11021299|NCT04627623||Screened arm|"6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).
~From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies."
11021300|NCT04627584|Active Comparator|MW33 injection-1200mg|
11021301|NCT04627584|Active Comparator|MW33 injection-2400mg|
11021302|NCT04627584|Placebo Comparator|Placebo|
11021303|NCT04627571||Patient Population|Patients diagnosed with neurotrophic keratopathy.
11021304|NCT04627558||stroke patients, balance assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
11021305|NCT04627545|Experimental|IVF: 2h exposure|Half of a patients' oocytes will be subjected to 2h exposure to sperm
11021306|NCT04627545|Active Comparator|IVF: overnight exposure|Half of a patients' oocytes will be subjected to overnight incubation with sperm (=usual practice).
11021307|NCT04627532|Experimental|Treatment|PF-07304814 assignment
11021308|NCT04627532|Placebo Comparator|Placebo|Placebo assigned
11021309|NCT04627519|No Intervention|SoC alone|Standard of Care alone (days 1 to 9)
11021310|NCT04627519|Experimental|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after meal (every 12 hours) for 9 days to be provided together with Standard of Care.
11024428|NCT04606602|Experimental|600 mg|
11021311|NCT04627506|No Intervention|Control Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.
~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design.
~Standardized anesthesia and surgical management will be conducted according to routine institutional practice."
11021312|NCT04627506|Experimental|Study Group|"Bilateral NIRS will be used to measure rSO2 intraoperatively.
~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
11021313|NCT04627493|No Intervention|Waitlist (Control)|Usual care
11021314|NCT04627493|Experimental|Exercise|Online exercise program
11021315|NCT04627480|Experimental|Experiment Arm|Active Fisher Wallace device for full 8 weeks
11021316|NCT04627480|Sham Comparator|Sham Arm|Sham Fisher Wallace device for 4 weeks, then cross over at 4 weeks to active device.
11021317|NCT04627467|Experimental|Chloroquine 150mg base|Volunteers received chloroquine tablets orally at days 0, 15, 30, 45, 60 and 75.
11021318|NCT04627454|Experimental|dynamic cervical implant|dynamic cervical implant in treatment of cervical disc disease
11021319|NCT04627454|Experimental|discectomy|insertion of dynamic cervical implant post cervical discectomy single level
11021320|NCT04627441|Experimental|TESS-EES|Transcutaneous Electrical Spinal Stimulation (TESS), used during the first month of training sessions, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
11021321|NCT04627428|Experimental|50,000 cells|Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.
11021322|NCT04627428|Experimental|150,000 cells|Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.
11021323|NCT04627428|Experimental|250,000 cells|Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.
11021324|NCT04627415|Experimental|Face to Face Treatment|The F2F version of PEAK contains 10 BPE sessions (1.5 hours each). Session content includes: 1) Introduction to ADHD, 2) Attending, Rewards and Ignoring, 3) General Behavior Management Strategies, 4) Problem-Solving Approach, 5) Preventive Intervention, 6) Instructive Interventions, 7) Response Strategies, 8) Extending What Works to Community Settings, 9) Promoting Early Reading and Math Skills, and 10) Effective Communication Strategies. Each session contains didactic instruction and activities designed to enhance engagement. Sessions include video examples and interactive activities. Weekly homework is assigned for strategy practice. At the start of the following session, the leader checks in with families on the use of the chosen strategy. The session leader praises successes and troubleshoots challenges. The intervention also includes optimistic training which aims to identify/improve pessimistic thinking patterns that parents have about their parenting and child's behaviors.
11021325|NCT04627415|Experimental|Online Treatment|For the online version of the program, in addition to content regarding an overview of ADHD, the initial session consists of brief video clips demonstrating how to access PEAK sessions on the Internet, and an orientation to online content (e.g., handouts, interactive chat sessions, research team contact links). Prior to the session, parents are provided with password-protected individual access codes. Similar to the F2F program, check-ins are provided weekly via each parent's preferred mode of communication (i.e., text, internet, phone) to query strategies implemented, praise success, and troubleshoot alternative strategies. Parents in the online condition will also receive supplemental optimistic training to improve pessimistic thinking patterns about their child and parenting.
11021326|NCT04627415|Other|Waitlist Control|The comparison condition is a waitlist control group that will receive no intervention throughout the intervention timeframe. Instead, participants will receive wellness information about typical child development and constructs unrelated to the intervention content. Subsequent to the 12-month follow-up assessment, they will be provided access to the online version of the program. To encourage ongoing participation in the absence of services, parents will be informed that, at the end of the intervention timeframe, they will receive support (i.e., weekly contact to answer questions) while they complete the online program.
11021327|NCT04627402|Experimental|Injection combo agents|Intravitreous injection of triamcinolone acetonide (TA) and conbercept.
11021328|NCT04627402|Active Comparator|Injection single agent|Intravitreous injection of conbercept only.
11021329|NCT04627389|Experimental|study arm|20 patients with a unilateral cleft lip will be repaired with orbicularis oris muscle Z-plasty modification of modified Millard technique
11021330|NCT04627389|Active Comparator|controlled arm|20 patients with a unilateral cleft lip will be repaired with modified Millard technique
11021331|NCT04627376|No Intervention|Control|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires.
11021332|NCT04627376|Experimental|Intervention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
11021333|NCT04627363|Experimental|HAIC plus Bevacizumab and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.
11021334|NCT04627350||LDCT|Single arm - all patients undergo low-dose CT (LDCT) examination of lungs
11021335|NCT04627337|Experimental|Saccharomyces boulardii (1 capsule of 250 ug BID) + Dietary advice|Patients received 1 capsule of Saccharomyces boulardii 250 ug BID plus dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
11021336|NCT04627337|Active Comparator|Dietary advice without medication|Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
11021405|NCT04626856|Experimental|Low dosage in adolescents|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
11021337|NCT04627324|Experimental|The smart toothbrush and smart mirror (STM) system toothbrushing instruction (TBI)|Participants received using the STM system TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
11021338|NCT04627324|Active Comparator|conventional toothbrushing instruction (TBI)|Participants received using conventional TBI. The plaque indexes were evaluated at baseline, immediately after TBI (day 0), 1 week, 1 month and 10 month (1st study only) after TBI.
11021339|NCT04627298|Active Comparator|Video Game|This arm tests use of video game to help preteens in the decision to pursue HPV vaccination. Participants in the intervention group are asked to play the Land of Secret Gardens game and complete 3 tasks: (1) play a shield game with blue spikey virus balls, (2) find hidden objects in 4 different garden sheds, and (3) create a potion (vaccine). Participants in the intervention arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance, the Physical/Emotional/Narrative Presence Scale (PENS) to gauge preteens' immersion in the game, and game play experience.
11021340|NCT04627298|No Intervention|No Video Game|This arm does not test the video game. Participants in the comparison arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance.
11021341|NCT04627285|Experimental|Lacosamide|Subjects in this arm will receive various single doses of lacosamide
11021342|NCT04627272|Experimental|AutoDX and Gold Standard|A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
11021343|NCT04627259||patient|patients with thumb pain or functional problems
11021344|NCT04627246|Experimental|PEP-DC + Nivolumab + SOC|PEP-DC: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides Nivolumab SOC: Standard of Care Chemotherapy
11021345|NCT04627233|Placebo Comparator|No intervention:control group|
11021346|NCT04627233|Experimental|Experimental:Intervention group|
11021347|NCT04627220||group 1|Group 1: Pressure of arterial oxygen> 200 mmHg during the coronary surgery
11021348|NCT04627220||group 2|Group 2: Pressure of arterial oxygen<200 mmHg and >80 mmHg during the coronary surgery
11021349|NCT04627207|Experimental|Reference-Reference-Test|Sequence 1
11021350|NCT04627207|Experimental|Reference-Test-Reference|Sequence 2
11021351|NCT04627207|Experimental|Test-Reference-Reference|Sequence 3
11021352|NCT04627194||Mild and asymptomatic COVID-19 patients|Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
11021353|NCT04627194||Moderate severity COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia] at the time of hospitalization.
11021354|NCT04627194||Severe-to-critical COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) < 90% on room air] or for critical COVID-19 disease presentation [including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium] at the time of hospitalization.
11021355|NCT04627194||COVID-19 survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
11021356|NCT04627194||COVID-19 non-survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
11021357|NCT04627181|Experimental|FCM + placebo|"Ferric carboxymaltose: Single dose, 500 mg
~Placebo: Single dose"
11021358|NCT04627181|Experimental|B12 + placebo|"Hydroxycobalamine: Single dose, 1000 mcg
~Placebo: Single dose"
11021359|NCT04627181|Experimental|FCM +B12|"Ferric carboxymaltose: Single dose, 500 mg
~Hydroxycobalamine: Single dose, 1000 mcg"
11021360|NCT04627181|Placebo Comparator|Placebo + placebo|"Placebo: Single dose
~Placebo: Single dose"
11021361|NCT04627168|Experimental|Spinal cord injured persons|Persons living with spinal cord injury presenting with constipation due to neurogenic bowel dysfunction.
11021362|NCT04627168|Experimental|Persons without neurogenic bowel dysfunction|Abled-bodied persons with chronic constipation.
11021363|NCT04627155|Experimental|7mg dose group|
11021364|NCT04627155|Experimental|14mg dose group|
11021365|NCT04627142|Experimental|Expansion dose 1|Part C: Combination therapy expansion part
11021366|NCT04627142|Experimental|Expansion dose 2|Part C: Combination therapy expansion part
11021367|NCT04627129|Experimental|SHR2554+Itraconazole|SHR2554 50 mg QD on Day 1 and Day 8, Itraconazole 200 mg once daily (QD) from Study Day 4 - 12
11021368|NCT04627116|Experimental|Tecarfarin 10mg|
11021369|NCT04627116|Experimental|Tecarfarin 20mg|
11021370|NCT04627116|Experimental|Tecarfarin 30mg|
11021371|NCT04627116|Experimental|Tecarfarin 40mg|
11021372|NCT04627103|Experimental|Device Placement|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.
11021373|NCT04627090||LCH Patients|Adult patients with LCH, diagnosed starting from January 2001
11021374|NCT04627077||SIC drug therapy patients|Patients with a cancer diagnosis currently being treated at SIC clinic
11021375|NCT04627064|Experimental|Abemaciclib-Arm 1|"Arm 1
~Abemaciclib will be taken at a standard recommended starting dose 2X daily during 28 day study cycles and will be taken until radiographic progression, unacceptable toxicity or withdrawal.
~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both Arm 1 and Arm 2."
11021376|NCT04627064|Experimental|Abemaciclib and MK-6482-Arm 2|"Arm 2
~Arm 2 will start enrolling only after there is experience with Arm 1 to see what abemaciclib effects are when given alone,
~Dose escalation will occur following a 3+3 design.
~Abemaciclib will be taken 2X daily uring 28 day study cycle
~MK-6482 will be taken 1x daily during 28 day study cycle
~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both arms."
11021377|NCT04627051|Experimental|Dysfunction AV graft|Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty
11021378|NCT04627038|Experimental|LY3556050|LY3556050 given orally
11021379|NCT04627038|Placebo Comparator|Placebo|Placebo given orally
11021380|NCT04627025|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
11021381|NCT04627025|Placebo Comparator|Placebo|Placebo for apraglutide, SC injection once weekly
11021382|NCT04626999|Active Comparator|Synovial fluid COMP|Knee joint fluid is aspirated for ELISA COMP examination
11021383|NCT04626999|Active Comparator|MRI T2 Mapping|Affected knee is subjected to an MRI T2 mapping examination to see the condition of cartilage
11021384|NCT04626999|Active Comparator|Instability Examination|Lachmant Test, Pivot shift test and Rolimeter Measurement
11021385|NCT04626986|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
11021386|NCT04626986|Active Comparator|breast conserving surgery|Breast-conserving surgery refers to the removal of the primary tumor and adjacent breast tissue, supplemented by postoperative radiotherapy.Its principle is to remove the primary tumor completely while meet patient's cosmetic satisfaction.The combined treatment of early breast cancer with radiotherapy and chemotherapy is the same as radical surgery or modified radical surgery in terms of local and regional control rate and long-term survival rate. Breast conserving surgery and postoperative comprehensive treatment have become one of the main methods for the treatment of early breast cancer.
11021387|NCT04626973|Experimental|Intensive-targeting group|
11021388|NCT04626973|Active Comparator|Conventional-targeting group|
11021389|NCT04626960||Patient|OAB patients
11021390|NCT04626960||Control|Healthy
11021391|NCT04626947|Other|Open label|Single arm
11021392|NCT04626934|Active Comparator|control group|Patients in the control group will recieve conventional occupational therapy treatment: 3 weeks of all together 12 sessions, 45 minutes each.
11021393|NCT04626934|Experimental|Intervention group|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
11021394|NCT04626921|Experimental|Active treatment with 30 mg of CNM-Au8|Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.
11021395|NCT04626908|Experimental|Administration of GC022F CAR-T cells|Each subject receive GC022F CAR T-cells by intravenous infusion
11021396|NCT04626895|Other|Scalp Cooling|Patients who be will using the scalp cooling device during chemotherapy will be enrolled in tis arm
11021397|NCT04626895|No Intervention|Non Scalp-Cooling|Patients who do not use scalp cooling device during chemotherapy will be enrolled in this arm.
11021398|NCT04626882|Active Comparator|Staged in-hospital CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
11021399|NCT04626882|Experimental|Immediate CR (complete revascularization)|Non-infarct related artery (IRA) will be revascularized immediately after PCI for IRA (during primary PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
11021400|NCT04626869|Active Comparator|Interscalene block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) to detect the brachial plexus. At the cervical level 5-6, the posterior brachial plexus will be approached as in-plane from the posterior with the needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed with stimulation in the upper extremity muscles with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
11021401|NCT04626869|Active Comparator|Anterior suprascapular nerve block|"patients will be placed in a semi-sitting position with their heads facing the opposite side. Linear ultrasound probe (GE Loqic P9 7-15 MHz) will be placed in the suprascapular region in a coronal oblique manner. The omohyoid muscle, under it the suprascapular nerve, the brachial plexus and the subclavian artery will be identified. The suprascapular nerve will be approached from the posterior as in-plane with a needle (Contiplex C, Braun) through the catheter. The nerve structure will be confirmed by stimulation in the supraspinous muscle with a nerve stimulator and 5 ml 0.5% Bupivacaine will be injected."
11021402|NCT04626856|Experimental|Low dosage in adults|Low dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
11021403|NCT04626856|Experimental|Medium dosage in adults|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
11021404|NCT04626856|Experimental|High dosage in adults|High dosage Inactivated Rotavirus vaccine (Vero cell) in adults aged 18-49 years old on day 0, 28
11024429|NCT04606602|Experimental|900 mg|
11021406|NCT04626856|Experimental|Medium dosage in adolescents|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
11021407|NCT04626856|Experimental|High dosage in adolescents|High dosage Inactivated Rotavirus vaccine (Vero cell) in adolescents aged 6-17 years old on day 0, 28
11021408|NCT04626856|Experimental|Low dosage in infants (7-71 months old)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
11021409|NCT04626856|Experimental|Medium dosage in infants (7-71 months old)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
11021410|NCT04626856|Experimental|High dosage in infants (7-71 months old)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 7-71 months old on day 0, 28
11021411|NCT04626856|Experimental|Low dosage in infants (2-6 months old, two-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
11021412|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, two-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
11021413|NCT04626856|Experimental|High dosage in infants (2-6 months old, two-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28
11021414|NCT04626856|Experimental|Low dosage in infants (2-6 months old, three-dose)|Low dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
11021415|NCT04626856|Experimental|Medium dosage in infants (2-6 months old, three-dose)|Medium dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
11021416|NCT04626856|Experimental|High dosage in infants (2-6 months old, three-dose)|High dosage Inactivated Rotavirus vaccine (Vero cell) in infants aged 2-6 months old on day 0, 28, 56
11021417|NCT04626856|Placebo Comparator|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
11021418|NCT04626856|Placebo Comparator|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
11021419|NCT04626843|Experimental|Intermittent fasting|
11021420|NCT04626830|Experimental|Mobile Application Intervention|Participants in the intervention group will receive 6 months the mobile application (OKTED) for improving symptoms and adherence to oral anticancer agents. The mobile application will consist of three modules. The first module will include OAA-specific information, a calendar in which start/end dates can be record, and a medication reminder. The second module will include information about common and urgent symptoms and recommendations for the management of these symptoms. The last module will comprise a question and answer section.
11021421|NCT04626830|No Intervention|Standard Care|Participants in the control group will receive standard oncology care only.
11021422|NCT04626817|Active Comparator|Isotretinoin receiving group|Isotretinoin receiving group for acne vulgaris
11021423|NCT04626817|Placebo Comparator|Local treatment receiving group|Local treatment receiving group for acne vulgaris
11021424|NCT04626804|Experimental|1 Test the usability, perceptions, and acceptability of R/S|Dyads will use the R/S unit for 90 days, unless they request it to be removed prior to the end of the study. . The primary outcome is a caregiver-assessed measure usability.
11021425|NCT04626791|Experimental|Treatment (modified VR-CAP, acalabrutinib)|"CYCLES 1, 3, AND 5: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive bortezomib SC on days 1, 8, and 15, rituximab (or rituximab and hyaluronidase human) IV, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1, and prednisone PO on days 1-5.
~CYCLES 2, 4, AND 6: Patients receive acalabrutinib PO BID on days 1-21. Patients also receive rituximab (or rituximab and hyaluronidase human) IV on day 1 and cytarabine IV on days 1-2.
~Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
11021426|NCT04626778|Active Comparator|Peroxyl|1.5% Hydrogen Peroxide mouthwash
11021427|NCT04626778|Placebo Comparator|placebo mouthwash|0.0% Hydrogen peroxide mouthwash
11021428|NCT04626765|Experimental|volunteer|The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens
11021429|NCT04626752|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) Multiple Myeloma (MM)
11021430|NCT04626739|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) non-Hodgkin lymphoma
11021431|NCT04626726|Experimental|Volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with acute B lymphocytic leukemia expressing specific target antigens
11021432|NCT04626713|Experimental|Intervention|Participants will undergo a brief interactive psychoeducation session four times a week for two weeks. For each session, participants will wear a commercially available Electroencephalography (EEG) headset and play a downloaded online game for a total of 30 minutes. Participants can feel free to play the game for more than the instructed frequency during their 2-week intervention participation.
11021433|NCT04626713|No Intervention|Waitlist control|Participants in Waitlist Control will receive no intervention in the first four weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
11021434|NCT04626700|Experimental|iNAP|
11021435|NCT04626700|Active Comparator|CPAP|
11021436|NCT04626687|Experimental|test DCB group|use the DCB made by Acotec Scientific
11021437|NCT04626687|Active Comparator|RESTORE DCB group|use the DCB made by CARDIONOVUM GmbH
11021438|NCT04626674|Experimental|SRP-9001|Patients will receive single intravenous (IV) infusion of SRP-9001 on Day 1.
11021439|NCT04626661||Health volunteers|The study population will consist, initially, of healthy volunteers. This group was chosen to perform measurements on, to eliminate the effect of critical illness and interventions on the critically ill patients and to better explore the effect of time-since-application of the 5-aminolevulinic acid-patches.
11021511|NCT04626297|Placebo Comparator|Placebo|Placebo given by SC injection.
11021512|NCT04626284|Experimental|Donors After Circulatory Determined death|Recipients receiving an organ from donors after circulatory determined death
11021513|NCT04626258|Active Comparator|Active comparator: Fluconazol|Once a month one capsule Fluconazol 150 mg
11021440|NCT04626661||Patients admitted to the ICU after neurosurgery|This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
11021441|NCT04626648|No Intervention|Surgery without intraoperative pause|Surgical procedure without pause
11021442|NCT04626648|Experimental|Surgery with intraoperative pause|Three-minute long intraoperative pause, including a sugar-containing drink
11021443|NCT04626635|Experimental|Dose Escalation|Variety of mixed advanced solid tumor types
11021444|NCT04626635|Experimental|Dose Expansion A|Microsatellite-Stable Colorectal Cancer (MSS CRC)
11021445|NCT04626635|Experimental|Dose Expansion B|Triple Negative Breast Cancer (TNBC)
11021446|NCT04626635|Experimental|Dose Expansion C|Cutaneous Squamous Cell Carcinoma (CSCC)
11021447|NCT04626635|Experimental|Dose Expansion D|Non-Small Cell Lung Cancer (NSCLC)
11021448|NCT04626622||ARVI and influenza prophylaxis with Kagocel (n=50)|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.
~Group of patients receiving Kagocel for prevention of ARVI and influenza"
11021449|NCT04626622||ARVI and influenza prophylaxis without any antiviral medicines (n=25)|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
11021450|NCT04626609||EoE group|Patients with confirmed eosinophilic esophagitis
11021451|NCT04626609||GERD group|Patients with gastro-esophageal reﬂux disease
11021452|NCT04626609||Control group|Individuals with no esophageal disease
11021453|NCT04626596|Experimental|ENG implant|Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
11021454|NCT04626583|Active Comparator|Low dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 µL at the low dose level.
11021455|NCT04626583|Active Comparator|Medium dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL at the medium dose level.
11021456|NCT04626583|Active Comparator|High dose of allogeneic MSC|Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 µL each at the high dose level.
11021457|NCT04626570|Experimental|Cognitive and Behavioural Therapy plus Management as usual|12 sessions of CBT during 18 weeks AND management of obesity with nutritional and dietary treatment as usual
11021458|NCT04626570|No Intervention|Management as usual|management of obesity with nutritional and dietary treatment as usual
11021459|NCT04626557||Women with astma|At the 7th (±2 day) cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
11021460|NCT04626557||Women without asthma|At the 7th (±2 day) cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
11021461|NCT04626544||Dizziness|Patients with dizziness referred to a secondary referral center
11021462|NCT04626544||Healthy controls|Healthy controls without dizziness or neck pain symptoms for the last 3 months
11021463|NCT04626531|Experimental|Intervention Group|After the pre-tests (Self-Care Activities, Self-Efficacy, Quality of Life) , the patients were given web based education and containing information and recommendations on self-management strategies for three months.
11021464|NCT04626531|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
11021465|NCT04626518|Experimental|Coformulation MK-1308A|Participants will receive MK-1308A (coformulation of MK-1308 25 mg and pembrolizumab 400 mg). MK-1308A will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years).
11021466|NCT04626518|Experimental|Coformulation MK-4280A|Participants will receive MK-4280A (coformulation of MK-4280 800 mg and pembrolizumab 200 mg). MK-4280A will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
11021467|NCT04626518|Experimental|Pembrolizumab + MK-4830|Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to ~2 years).
11021468|NCT04626518|Experimental|Pembrolizumab + MK-6482|Participants will receive pembrolizumab 400 mg PLUS MK-6482 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). MK-6482 will be administered orally once-daily (QD) until progressive disease or discontinuation.
11021469|NCT04626518|Experimental|MK-6482 + Lenvatinib|Participants will receive MK-6482 120 mg PLUS lenvatinib 20 mg. Both MK-6482 and lenvatinib will be administered orally QD until progressive disease or discontinuation.
11021470|NCT04626518|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
11021471|NCT04626505|Experimental|Ziltivekimab 15 mg|Participants will receive ziltivekimab 15 mg for 12 weeks.
11021472|NCT04626505|Experimental|Ziltivekimab 30 mg|Participants will receive ziltivekimab 30 mg for 12 weeks.
11021473|NCT04626505|Placebo Comparator|Placebo (ziltivekimab)|Participants will receive placebo (ziltivekimab) for 12 weeks.
11021474|NCT04626492||F0|Normal control group
11021475|NCT04626492||F1|Grade 1 of liver fibrosis
11021476|NCT04626492||F2|Grade 2 of liver fibrosis
11021477|NCT04626492||F3|Grade 3 of liver fibrosis
11021478|NCT04626492||F4|Hepatic cirrhosis
11021746|NCT04624867|Experimental|HP-1050 patch|HP-1050 and Xulane will be administered simultaneously.
11021479|NCT04626479|Experimental|Coformulation MK-1308A + Lenvatinib|Participants will receive MK-1308A (coformulation of MK-1308 25 mg and pembrolizumab 400 mg) PLUS lenvatinib 20 mg. MK-1308A will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
11021480|NCT04626479|Experimental|Coformulation MK-4280A + Lenvatinib|Participants will receive MK-4280A (coformulation of MK-4280 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. MK-4280A will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
11021481|NCT04626479|Experimental|Pembrolizumab + MK-6482 + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS MK-6482 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Both MK-6482 and lenvatinib will be administered orally QD until progressive disease or discontinuation.
11021482|NCT04626479|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
11021483|NCT04626466||Non-metastatic prostate, rectum, anal canal, endometrium, or cervix carcinoma Radiotherapy treatment|
11021484|NCT04626453|Experimental|sedentary older adults with Type 2 Diabetes|Sedentary older adults with Type 2 Diabetes as the intervention group will do a 2-month home exercise.
11021485|NCT04626453|No Intervention|Active older adults with Type 2 Diabetes|Active older adults with Type 2 Diabetes will not do exercise.
11021486|NCT04626453|No Intervention|Healthy older adults|Healthy older adults will not do exercise.
11021487|NCT04626440||Group 1|Group 1 [(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available]
11021488|NCT04626440||Group 2|subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
11021489|NCT04626440||Group 3|Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 [(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC].
11021490|NCT04626427|Experimental|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
11021491|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fed condition|Single dose of 30 mg ferric maltol capsule in a fed condition
11021492|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fasted condition|Single dose of 30 mg ferric maltol capsule in a fasted condition
11021493|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fed condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
11021494|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fasted condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
11021495|NCT04626401|Placebo Comparator|Control diet during immobilisation|A 2 day controlled dietary intervention.
11021496|NCT04626401|Experimental|Branched chain amino acid restricted diet during immobilisation|A 2 day branched chain amino acid restricted dietary intervention.
11021497|NCT04626375|Placebo Comparator|Placebo|Placebo (2 vials per os without active substance every 12 hours)
11021498|NCT04626375|Active Comparator|Bioarginine|Bioarginine (2 vials per os of 1.66 g every 12 hours)
11021499|NCT04626362|Experimental|Experimental: Cranberry juice consumption|Participants will be provided cranberry juice to consume for 21 days
11021500|NCT04626362|Experimental|Placebo juice consumption|Participants will be provided placebo juice to consume for 21 days
11021501|NCT04626349|Experimental|FOCUS+|Dyads in the FOCUS+ arm will receive the face-to-face nurse-led FOCUS+ program.
11021502|NCT04626349|Experimental|iFOCUS|Dyads in the iFOCUS arm will receive the web-based iFOCUS program.
11021503|NCT04626349|No Intervention|Standard care|Dyads in the control group will receive standard care as usual, as determined by the healthcare system in the participating countries. The dose and frequency of usual care will be as deemed appropriate by the medical practitioner in charge of their treatment.
11021504|NCT04626336||Patients who undergo a cystectomy|Patients who undergo a cystectomy for cancer or not, since 2010 to 2020
11021505|NCT04626323|Experimental|RYGB (intervention arm)|Thirty (30) obese patients with DKD will undergo gastric bypass. Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA. The surgical procedure will consist of a laparoscopic surgery performed by an experienced surgeon (approximately 6000 bariatric surgeries), who is accredited as surgeon of excellence by the Brazilian Society of Bariatric and Metabolic Surgery and Surgical Review and Surgical Review Corporation program since 2009.
11021506|NCT04626323|Active Comparator|BMT (control arm).|Thirty (30) obese patients with DKD will undergo best medical treatment for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA.
11021507|NCT04626310|Experimental|Dialectical behavior therapy - emotion regulation skills training|Dialectical behavior therapy - emotion regulation skills training
11021508|NCT04626310|Experimental|Dialectical behavior therapy - interpersonal effectiveness skills training|Dialectical behavior therapy - interpersonal effectiveness skills training
11021509|NCT04626310|Active Comparator|Non-skills-oriented interpersonal psychotherapy group|Non-skills-oriented interpersonal psychotherapy group
11021510|NCT04626297|Experimental|Lebrikizumab|Lebrikizumab given by subcutaneous (SC) injection.
11024430|NCT04606602|Experimental|100 mg multi dose|
11021514|NCT04626258|Experimental|L-Mesitran|The first month every day apply L-mesitran, the next five months apply L-mesitran every week on the vagina
11021515|NCT04626245|Experimental|Mindfulness training|Phone-delivered mindfulness training
11021516|NCT04626245|Other|Treatment as usual|Prenatal care
11021517|NCT04626232|Experimental|N SLEEVE|Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
11021518|NCT04626232|Other|SLEEVE|The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
11021519|NCT04626219|Experimental|1|Period of 12 hours where participants eat regulated meals
11021520|NCT04626219|Experimental|2|Period of 12 hours where participants do not eat anything
11021521|NCT04626206||Imaging to asess treatment response post-SRS|"There will be only one group. All recruited patients will have 3 scans, the multi-parametric MRI, contrast-clearance analysis MRI (TRAMs) and 18F-choline-PET/CT.
~This is a non interventional study. Only the results of the contrast-clearance analysis MRI (TRAMs) will be used to make clinical decisions (as this is the current standard of care at the recruiting site). The multi-parametric MRI and 18F-choline PET/CT will be treated as research scans."
11021522|NCT04626193|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline,Levofloxacien,tinadizole
11021523|NCT04626193|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole,amoxicilline
11021524|NCT04626180|Active Comparator|Regular Extubation|
11021525|NCT04626180|Experimental|Pre Extubation Manual Hyperinflation|
11021526|NCT04626167|Experimental|Intervention group|Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or construction.
11021527|NCT04626154|Active Comparator|Respiratory insufficiency or distress|Patients demonstrating respiratory insufficiency or distress.
11021528|NCT04626154|Sham Comparator|No respiratory insufficiency or distress.|Patients NOT demonstrating respiratory insufficiency or distress.
11021529|NCT04626141|Experimental|Abaloparatide group|Patients in the experimental group will receive abaloparatide after their surgery.
11021530|NCT04626141|Placebo Comparator|Control group|Patients in the control group will receive a placebo after their surgery.
11021531|NCT04626128|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of 0.03mg CLS-AX
11021532|NCT04626128|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of 0.06mg CLS-AX
11021533|NCT04626128|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of 0.1mg CLS-AX
11021534|NCT04626102|No Intervention|Enrollment|"Participants were recruited by using a convenience sampling method. Potential participants were reached through lecturers and professors who are teaching classes at different universities in Istanbul, Turkey.
~Participants were asked to fill out a questionnaire package covering Demographic Information Form, Eating Disorders Examination Questionnaire (EDEQ), Eating Attitudes Test - 40 (EAT-40), Body Image Satisfaction Questionnaire (BISQ), and Sociocultural Attitudes towards Appearance Questionnaire-4-Revised (SATAQ-4R). Filling out the questionnaire package took approximately 25-minutes."
11021535|NCT04626102|Experimental|Intervention Period|"Participants were randomly assigned to one of these conditions:
~Experimental condition: Healthy Eating Attitudes and Behaviours Group Program - 6 weekly sessions, each session was about 45-minutes to 60-minutes
~Active control condition: Eating Disorders and Body Dissatisfaction: A Group Work - single session about 1.5 hours to 2 hours
~Wait-list control condition: Participants in this condition were informed that they will be asked to fill out questionnaires that sent to them, and at the end of 6 months, they will be invited to participate in Healthy Eating Attitudes and Behaviours Group Program."
11021536|NCT04626089|Experimental|Metformin glycinate|620 mg bid (PO) plus standard treatment for 14 days
11021537|NCT04626089|Placebo Comparator|Placebo|Placebo tablets bid (PO) plus standard treatment for 14 days
11021538|NCT04626076||Aga Khan University|Pakistan
11021539|NCT04626076||Wits Reproductive Health Institute|South Africa
11021540|NCT04626076||African Medical and Research Foundation- Uganda|Uganda
11021541|NCT04626076||African Medical and Research Foundation- Kenya|Kenya
11021542|NCT04626076||African Medical and Research Foundation- Zambia|Zambia
11021543|NCT04626076||African Medical and Research Foundation- Senegal|Senegal
11021544|NCT04626076||World Mosquito Program|Indonesia
11021545|NCT04626076||54Gene|Nigeria
11021546|NCT04626076||African Institute of Biomedical Science & Technology|Zimbabwe
11021547|NCT04626063|Active Comparator|Isolated non-steroid anti-inflammatory drug group|A isolated NSAIDs group received 400 mg etodolac twice a day for 10 days in treatment of acute low back pain.
11021548|NCT04626063|Experimental|Non-steroid anti-inflammatory drug plus magnesium group|This group received 400 mg etodolac twice a day and 365 mg magnesium oral supplementation once a day for 10 days in treatment of acute low back pain.
11021549|NCT04626063|Active Comparator|Non-steroid anti-inflammatory drug plus paracetamol group.|This group 400 mg etodolac twice a day and 500 mg paracetamol twice a day for 10 days in treatment of acute low back pain.
11021550|NCT04626050|Experimental|Medical Music (Phase I)|Participants will complete four medical music sessions that are 30 minutes in length each.
11021551|NCT04626050|Experimental|Narrative Writing (Phase I)|Participants will complete four narrative writing sessions that are 30 minutes in length each.
11021552|NCT04626050|Active Comparator|Interpersonal Psychotherapy (Phase II)|IPT is comprised of ten 75-minute sessions, scheduled twice weekly.
11021553|NCT04626050|Active Comparator|Prolonged Exposure Therapy (Phase II)|ET is comprised of ten 75-minute sessions scheduled twice weekly with prolonged imaginal exposure that last 45-60 minutes.
11021586|NCT04625907|Experimental|CT1A: VHR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
11021805|NCT04624347|No Intervention|No Acess to Video and Movement curves|without caregivers' access to videos and movement (4 days)
11021554|NCT04626037|Experimental|All Participants in Group Zoom Sessions|During each session, the mother-child dyads will meet with trained Nurture Specialists virtually. The entire procedure will be done on Zoom or in person depending on school scaled opening. Each group session will begin with introductions and reintroduction's of the mothers and children. Returning mothers will be asked how they have progressed using the Cuddle and Calm and mutual narrative over the week and what their experience with their child after the session has been. All mother-child pairs will then be asked to interact, with the child sitting on the mother's lap face-to-face. The rest of the session may continue with: (1) Reading Cuddle and Calm Book (2) Mutual Mother and Child Emotional Exchange Prompts (3) Mothers Support Circle to identify and engage members of the mother's family in helping the dyad with emotional connection (4) Plans for continuing the work in the family.
11021555|NCT04626024|Experimental|All Subjects Enrolled (stop taking TKI)|Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for > 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
11021556|NCT04626011|Active Comparator|Group One|Participants receiving full mouth disinfection and extractions in one stage.
11021557|NCT04626011|Active Comparator|Group Two|Participants receiving full mouth disinfection at stage one and extractions at stage two after 7 days.
11021558|NCT04625998|Experimental|Intervention|Elementary schools and Head Start centers in the intervention catchment areas implemented (1) an enhanced Coordinated Approach To Child Health (CATCH) program for elementary schools using the CATCH Coordination Guide (Enhanced CATCH Elementary School Program), and (2) CATCH Early Childhood program for Head Start Centers.
11021559|NCT04625998|No Intervention|Comparison|Elementary schools and Head Start centers in the comparison catchment area used their regular school and early care and education (ECE) nutrition and physical activity programs. Elementary schools were required by law to implement a coordinated school health program.
11021560|NCT04625985|Experimental|Metformin glycinate|620 mg bid (PO) for 14 days plus standard treatment
11021561|NCT04625985|Placebo Comparator|Placebo|Placebo tablet bid (PO) for 14 days plus standard treatment
11021562|NCT04625972|Experimental|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
11021563|NCT04625972|Placebo Comparator|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
11021564|NCT04625959|Active Comparator|Base BT|16 weekly sessions of behavioral therapy.
11021565|NCT04625959|Experimental|Base BT + Distress Tolerance|16 weekly sessions of behavioral therapy with distress tolerance components of MABTs.
11021566|NCT04625959|Experimental|Base BT + Emotion Regulation|16 weekly sessions of behavioral therapy with emotion regulation components of MABTs.
11021567|NCT04625959|Experimental|Base BT + Mindful Awareness|16 weekly sessions of behavioral therapy with mindful awareness components of MABTs.
11021568|NCT04625959|Experimental|Base BT + Values|16 weekly sessions of behavioral therapy with values components of MABTs.
11021569|NCT04625959|Experimental|Base BT + Distress Tolerance and Emotion Modulation|16 weekly sessions of behavioral therapy with emotion regulation and distress tolerance components of MABTs.
11021570|NCT04625959|Experimental|Base BT + Distress Tolerance and Mindful Awareness|16 weekly sessions of behavioral therapy with distress tolerance and mindful awareness components of MABTs.
11021571|NCT04625959|Experimental|Base BT + Distress Tolerance and Values|16 weekly sessions of behavioral therapy with distress tolerance and values components of MABTs.
11021572|NCT04625959|Experimental|Base BT + Emotion Modulation and Mindful Awareness|16 weekly sessions of behavioral therapy with emotion regulation and mindful awareness components of MABTs.
11021573|NCT04625959|Experimental|Base BT + Mindful Awareness and Values|16 weekly sessions of behavioral therapy with values and mindful awareness components of MABTs.
11021574|NCT04625959|Experimental|Base BT + Emotion Modulation and Values|16 weekly sessions of behavioral therapy with emotion regulation and values components of MABTs.
11021575|NCT04625959|Experimental|Base BT + EM, DT, MA|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and distress tolerance components of MABTs.
11021576|NCT04625959|Experimental|Base BT + DT, ER, and V|16 weekly sessions of behavioral therapy with emotion regulation, distress tolerance, and values components of MABTs.
11021577|NCT04625959|Experimental|Base BT + DT, MA, and V|16 weekly sessions of behavioral therapy with distress tolerance, mindful awareness, and values components of MABTs.
11021578|NCT04625959|Experimental|Base BT + ER, MA, and V|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, and values components of MABTs.
11021579|NCT04625959|Experimental|Base BT + ER, MA, V, DT|16 weekly sessions of behavioral therapy with emotion regulation, mindful awareness, distress tolerance, and values components of MABTs.
11021580|NCT04625946|Experimental|Metformin|Standard of care ablation with recommendations for lifestyle modification and metformin.
11021581|NCT04625946|Other|Standard of care|Standard of care ablation with recommendations for lifestyle modification.
11021582|NCT04625920|Experimental|Virtual reality|women allocated to undergo hysteroscopy with Vr System
11021583|NCT04625920|Experimental|Standart care|women allocated to undergo hysteroscopy without VR
11021584|NCT04625907|Experimental|Phase 1b Dose finding: VHR induction - IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.
~Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
11021585|NCT04625907|Active Comparator|CT1A: VHR induction - IVADO|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4"
11021806|NCT04624334||Children with motility disorder|
11021587|NCT04625907|Active Comparator|CT1B: HR Induction IVA|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
11021588|NCT04625907|Experimental|CT1B: HR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.
~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
11021589|NCT04625907|Experimental|RT1A: Preoperative Radiotherapy|To be given either 41.4 Gy or 50.4 Gy prior to surgery
11021590|NCT04625907|Active Comparator|RT1A: Post operative radiotherapy|To be given either 41.4 Gy or 50.4 Gy following surgery
11021591|NCT04625907|Experimental|RT1B: Radiotherapy for resectable disease: dose escalated|To receive 50.4 Gy
11021592|NCT04625907|Active Comparator|RT1B: Radiotherapy for resectable disease: standard dose|To receive 41.4 Gy
11021593|NCT04625907|Experimental|RT1C: Radiotherapy for unresectable disease: dose escalated|To receive 59.4 Gy
11021594|NCT04625907|Active Comparator|RT1C: Radiotherapy for unresectable disease: standard dose|To receive 50.4 Gy
11021595|NCT04625907|Experimental|RT2: Radiotherapy to primary tumour and involved lymph nodes|Radiotherapy to the primary tumour and involved regional lymph nodes only
11021596|NCT04625907|Experimental|RT2: Radiotherapy to all metastatic sites|Radiotherapy given to all metastatic sites
11021597|NCT04625907|Experimental|CT2A: VHR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
11021598|NCT04625907|No Intervention|CT2A: Maintenance -Stop treatment|To stop treatment at the point of randomisation
11021599|NCT04625907|Experimental|CT2B: HR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
11021600|NCT04625907|No Intervention|CT2B: HR Maintenance - Stop Treatment|To stop treatment at the point of randomisation
11021601|NCT04625907|Active Comparator|Relpased Chemotherapy - VIR|Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5
11021602|NCT04625907|Experimental|Relapsed Chemotherapy - VIRT|Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 given orally on days 1-5
11021603|NCT04625894|Experimental|Treatment Arm|Patients with oligometastatic gastrointestinal cancer will receive multisite SABR, followed by Camrelizumab within one week from completion of radiation. Camrelizumab for injection at 200 mg, d1, q2w, 14-day cycle will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
11021604|NCT04625881|Active Comparator|Active product|A powder containing 20 g of apple derived fiber will be consumed daily
11021605|NCT04625881|Placebo Comparator|Placebo|A rice derived placebo devoid of fiber and aromatized with apple fragancy will be provided
11021606|NCT04625868|Experimental|Soft tissue surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
11021607|NCT04625868|No Intervention|Soft tissue surgery - no video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
11021608|NCT04625868|Experimental|Bone/joint surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
11021609|NCT04625868|No Intervention|Bone/joint surgery - no video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
11021610|NCT04625855|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr
11021611|NCT04625842|Experimental|Patient focus group|Patients who received radiation treatment
11021612|NCT04625842|Experimental|Family focus group|Family of patients who received radiation treatment
11021613|NCT04625816|Experimental|Arthroscopic shoulder surgery patients|
11021614|NCT04625803|Experimental|chemotherapy, PD-1 inhibitor and Apatinib|Participants received 5 preoperative cycles of PD-1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery. Apatinib,PD-1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.
11021615|NCT04625790|Experimental|Study group|After randomization, this group will take 10 sessions of 1-Hz low frequency rTMS will be applied to the inferior frontal gyrus of the right frontal lobe for 20 minutes during the stroke treatment process before 10 days of speech therapy. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
11021616|NCT04625790|Placebo Comparator|Control group|This group will take 10 sessions of sham rTMS for 20 minutes during the stroke treatment process before 10 days of speech therapy. The sham therapy will consist of positioning the coil on the cranium at the same spot, but without a magnetic stimulation, only with the device open and the sounds will be audible. Speech therapy will be given to each patient by the same therapist who is qualified in this field, and the treatment will last 10 days, 60 minutes a day.
11021617|NCT04625777|No Intervention|Waitlist control|In this waitlist control condition, participants will not receive any programming intervention. They will know that they have access to stress reduction programming after a certain date. They will also provide survey data at 3 time points and heart rate variability data at 2 time points while waiting. The survey questions will include a wide variety of stress items.
11021618|NCT04625777|Experimental|One of three stress reduction interventions|There are three stress reduction interventions: Mindfulness Based Stress Reduction, Daily Examen, and stress inoculation.
11021619|NCT04625764|Experimental|patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB|
11021620|NCT04625751||T2DM +CAN|
11021621|NCT04625751||T2DM -CAN|
11021622|NCT04625751||Healthy control|
11021807|NCT04624334||Healthy children|
11021623|NCT04625738|Experimental|MSC Arm|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.
~day 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg"
11021624|NCT04625738|Placebo Comparator|Placebo Arm|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
11021625|NCT04625725|Experimental|AZD7442|"Approximately 5000 participants will be randomized in a 2:1 ratio
~• Arm 1 (n=approximately 3333) will receive a single dose (× 2IM injections) of 300 mg of AZD7442"
11021626|NCT04625725|Placebo Comparator|Placebo|"Approximately 5000 participants will be randomized in a 2:1 ratio
~• Arm 2 (n=approximately 1667) will receive saline placebo"
11021627|NCT04625712|Experimental|Group A (experimental arm, surgery intervention)|Cholecystectomy within the first week after a mild acute biliary pancreatitis.
11021628|NCT04625712|Active Comparator|Group B (active comparator, surgery intervention)|Cholecystectomy four weeks later a mild acute biliary pancreatitis.
11021629|NCT04625699|Experimental|durvalumab+ tremelimumab|durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
11021630|NCT04625686||Inpatient Treatment|
11021631|NCT04625686||OCIC Treatment|
11021632|NCT04625686||Telehealth Therapy Treatment|
11021633|NCT04625686||No Show Group|
11021634|NCT04625673|Active Comparator|Group A|Group A will wear the OsciPulse device for the first 24 hours then switch to the standard IPC device for the second 24 hours.
11021635|NCT04625673|Active Comparator|Group B|Group B will wear the standard IPC device for the first 24 hours then switch to the OsciPulse device for the second 24 hours.
11021636|NCT04625660|Experimental|Single Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
11021637|NCT04625647|Experimental|Treatment (AMG 510)|Patients receive AMG 510 PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11021638|NCT04625634|Experimental|Consecutive work|Subjects will complete 2 consecutive days of simulated firefighting tasks in the heat. The simulated work consists of 20 minutes of simulated structural work in a hot environment, followed by 20 minutes of seated rest in a temperate room, mimicking a typical recovery period in structural firefighting. Subjects then re-enter the environmental chamber and complete 23 minutes of simulated overhaul work in a temperate environment.
11021639|NCT04625608|Other|Standard care|Participants in this arm shall receive 3.6 ml/kg of water a minimum of 1 hour prior to the induction of general anaesthesia. This is standard practice in the 2 participating institutions.
11021640|NCT04625608|Experimental|Paracetamol arm|Participants in this arm shall receive 3 ml/kg of water plus 15 mg/kg of oral paracetamol suspension a minimum of 1 hour prior to the induction of general anaesthesia.
11021641|NCT04625595|Experimental|350 mg BID (700 mg total daily dose) of active drug or placebo|Low dose, drug IMT-002
11021642|NCT04625595|Experimental|1050 mg QD (1050 mg total daily dose) of active drug or placebo|Moderate dose, drug IMT-002
11021643|NCT04625595|Experimental|700 mg BID (1400 mg total daily dose) of active drug or placebo|Moderate to high dose, drug IMT-002
11021644|NCT04625595|Experimental|1050 mg BID (2100 mg total daily dose) of active drug or placebo|High dose, drug IMT-002
11021645|NCT04625582|Experimental|Face-to-face intervention|90 trainees at Vigo Family Medicine and Community Nursing Training Unit
11021646|NCT04625582|Experimental|Online intervention|70 trainees at Aragón Family Medicine and Community Nursing Training Unit
11021647|NCT04625582|No Intervention|Usual training|180 trainees at Balearic Islands Family Medicine and Community Nursing Training Unit
11021648|NCT04625556||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
11021649|NCT04625556||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
11021650|NCT04625556||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
11021651|NCT04625556||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
11021652|NCT04625543|Experimental|intervention group|Neoadjuvant immunotherapy (PD-1) plus concurrent chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
11021653|NCT04625543|Active Comparator|controll group|Neoadjuvant chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
11021654|NCT04625530|Experimental|ferric carboxymaltose|ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7.
11021655|NCT04625530|Experimental|tranexamic acid|tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively
11021656|NCT04625530|Experimental|ferric carboxymaltose and tranexamic acid|"ferric carboxymaltose (Ferinject® 1000 mg/20 ml) between day -27 and day
~-7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by Infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively will be administered."
11021657|NCT04625530|No Intervention|"no treatment accordingly current standard of care"|"no treatment accordingly current standard of care will be given"
11021658|NCT04625517|Experimental|Breast cancer patients|Patients with ipsilateral intact biopsy-proven breast cancer
11021659|NCT04625504|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
11021660|NCT04625504|No Intervention|Wait-list Control (WL)|Patients Control receiving no treatment
11021661|NCT04625504|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
11021662|NCT04625491||Location on lower limb|Proximal (thigh) Medium (leg) Distal (ankle and foot)
11021663|NCT04625478||Patients having had an osteo-articular infection with Stahylococcus|Patients having had an osteo-articular infection with Stahylococcus managed at the Croix Rousse hospital
11021664|NCT04625465|No Intervention|No Intervention, No Intervention (AA)|Participants do not receive text messages during Interval 2 or Interval 3.
11021665|NCT04625465|Active Comparator|No Intervention, Attention-Control Texts (AB)|Participants do not receive text messages during Interval 2. Participants receive attention control text messages during Interval 3.
11021666|NCT04625465|Experimental|No Intervention, CBT Texts (AC)|Participants do not receive text messages during Interval 2. Participants receive CBT text messages during Interval 3.
11021667|NCT04625465|Active Comparator|Attention-Control Texts, No Intervention (BA)|Participants receive attention control text messages during Interval 2. Participants do not receive text messages during Interval 3.
11021668|NCT04625465|Active Comparator|Attention-Control Texts, Attention-Control Texts (BB)|Participants receive attention control text messages during Interval 2. Participants receive attention control text messages during Interval 3.
11021669|NCT04625465|Experimental|Attention-Control Texts, CBT Texts (BC)|Participants receive attention control text messages during Interval 2. Participants receive CBT text messages during Interval 3.
11021670|NCT04625465|Experimental|CBT Texts, No Intervention (CA)|Participants receive CBT text messages during Interval 2. Participants do not receive text messages during Interval 3.
11021671|NCT04625465|Experimental|CBT Texts, Attention-Control Texts (CB)|Participants receive CBT text messages during Interval 2. Participants receive attention control text messages during Interval 3.
11021672|NCT04625452|Experimental|BBCC+5A's+GS|Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)
11021673|NCT04625452|No Intervention|Normal care|They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)
11021674|NCT04625439|Experimental|Personality Feedback|The intervention arm will read about the Five-Factor model and receive a feedback report with individualized personality results and self-management recommendations.
11021675|NCT04625439|No Intervention|No-feedback Control|The control arm will read about the Five-Factor model but will not receive feedback or their personality results until after the study.
11021676|NCT04625426|Experimental|3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant|"Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).
~The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer."
11021677|NCT04625426|Experimental|Conveen EasiCleanse and Conveen Critic Barrier|Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.
11021678|NCT04625426|Active Comparator|Soap and water / Incontinence wipes and Conveen Critic Barrier|Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.
11021679|NCT04625413|Experimental|Experimental: Experimental Arm: single|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.
11021680|NCT04625400|Experimental|post intubation tracheal stenosis patients|all ICU patients who were mechanically ventilated will be assessed for the possibility of presence of tracheal stenosis using spirometery and dyspnea will be assessed using (mMRC) score, chest X-ray to assess the location of tracheal stenosis and finally flexible bronchoscopy to confirm the presence of stenosis and identify the proper management.
11021681|NCT04625387|Experimental|Dry Needle plus exercise|Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
11021682|NCT04625387|Experimental|Dry Needling alone|Group B received Dry Needling alone having 25 individuals. Treatment lasted four weeks duration, twice a week.
11021683|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（pilot trial arm）|Healthy subjects receive single dose of tablets HEC122505MsOH
11021684|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）|Healthy subjects receive single dose of HEC122505MsOH or matching placebo
11021685|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
11021686|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
11021687|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
11021688|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
11021689|NCT04625361|Experimental|Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）|Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
11021690|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
11021691|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
11021692|NCT04625361|Experimental|Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）|Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
11021693|NCT04625348|Experimental|residents|daily care of 40 residents will be provided on the Ultracore Repose® mattress
11021694|NCT04625335|Experimental|Group 1: Intervention First|Adult, healthy volunteers will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test. Following the crossover, these participants will then complete the Cold Pressor Test without prior massage.
11021695|NCT04625335|Experimental|Group 2: Intervention Last|Adult, healthy volunteers will complete the Cold Pressor Test without prior massage. After crossover, they will receive the intervention (prophylactic therapeutic massage) before completing the Cold Pressor Test.
11021729|NCT04625036||Group 1: COVID-19 patients|Patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
11021696|NCT04625322|No Intervention|Referral to outpatient specialty for HCV care|Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
11021697|NCT04625322|Experimental|Receive HCV care during inpatient admission by a hospitalist|CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
11021698|NCT04625309|Experimental|Sport|This group will be made up of subjects with a spinal cord injury that are actively participating in adaptive sports teams.
11021699|NCT04625309|No Intervention|No sport|This group will be made up of subjects with a spinal cord injury that are not actively participating in any sports team.
11021700|NCT04625296||Healthcare professional|Communities Health professionals (doctors, nurses, physiotherapist) Working in the city, In metropolitan France, Having managed patients with COVID-19
11021701|NCT04625283|Experimental|Ketamine|Participants in this arm will receive intraoperative ketamine bolus (0.5mg/kg) followed by continuous infusion 5 mcg/kg/min and also will receive postoperative ketamine infusion (2.5 mg/kg/min, up to 100kg max) for 48 hours.
11021702|NCT04625283|Placebo Comparator|Saline|Participants in this arm will receive an equivalent volume of intraoperative saline bolus followed by continuous saline infusion and also will receive postoperative saline infusion for 48 hours.
11021703|NCT04625270|Experimental|Part A|To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)
11021704|NCT04625270|Experimental|Part B|To determine the efficacy of the optimal regimen identified from Part A
11021705|NCT04625244|No Intervention|Group 1: In-person therapy|Patients will receive the standard of care, in-person therapy. Patients will meet with a Certified Hand Therapist starting 4 weeks after surgery. These sessions will occur once per week for 7 weeks and will last approximately 30 minutes. Patients will undergo massage, range of motion, and strength exercises on a graduated basis. They will also receive instructions for how to perform the exercises at home, outside of therapy.
11021706|NCT04625244|Experimental|Group 2: Telehealth program|Participants will be sent video links to three therapy videos demonstrating postoperative recovery exercises. Participants will meet with a Certified Hand Therapist over video call starting 4 weeks after surgery. These virtual meetings will occur once per week for 7 weeks and will last approximately 15 minutes. During these calls, therapists will monitor progress, answer questions, and observe subjects' technique for range of motion and strength exercises.
11021707|NCT04625231|Experimental|Shared-Decision Making Tool Group|
11021708|NCT04625231|No Intervention|Standard of Care Group|
11021709|NCT04625205|Experimental|NEO-PTC-01 Part 1 dose finding phase|
11021710|NCT04625205|Experimental|NEO-PTC-01 Part 2 dose expansion phase|
11021711|NCT04625192|Experimental|Sinus lifting with trephine osteotomy|
11021712|NCT04625179|Experimental|Melatonin and hyaluronic acid and sinus membrane elevation|melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement
11021713|NCT04625179|Active Comparator|sinus membrane elevation without any materials|no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.
11021714|NCT04625153|Experimental|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
11021715|NCT04625153|Experimental|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
11021716|NCT04625127|Experimental|Aim 2: Efficacy of the GaitBetter to improve motor-cognitive function of chronic stroke survivors|The investigators propose a single-arm, non-randomized study to test the hypothesis that the GaitBetter training is effective in improving gait and cognition in individuals with chronic stroke. This design was chosen given the expected stability of functional recovery in this population.
11021717|NCT04625127|Experimental|Aim 3: Efficacy of the GaitBetter to improve rehabilitation outcomes in sub-acute stroke survivors|The investigators propose a randomized, controlled study to evaluate the effects of using the GaitBetter system in patients with subacute stroke on recovery trajectory.
11021718|NCT04625114|Experimental|Camostat|camostat 100mg 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
11021719|NCT04625114|Placebo Comparator|Placebo|Placebo 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
11021720|NCT04625101|Experimental|NBI-827104|NBI-827104 administered orally for 13 weeks.
11021721|NCT04625101|Placebo Comparator|Placebo|Placebo administered orally for 13 weeks.
11021722|NCT04625088|Experimental|Standardized liquid test meal|
11021723|NCT04625088|Experimental|Atropine + Standardized liquid Test meal|
11021724|NCT04625075||Healthy Volunteer|Age and sex matched healthy volunteer
11021725|NCT04625075||COVID-19 with myocardial injury|Patients hospitalised with severe COVID-19 infection and evidence of myocardial. Involvement: elevation of plasma cardiac troponin concentration (>99th centile of the upper reference limit), abnormalities on electrocardiography or abnormal echocardiography. Some patients will have suspected myocarditis or takotsubo cardiomyopathy. We will identify subgroups of interest who have left/right ventricular systolic dysfunction ± regional wall motion abnormalities, on echocardiography.
11021726|NCT04625075||COVID-19 without myocardial injury|Patients hospitalised with severe COVID-19 infection but without known elevation of plasma cardiac troponin concentration, clinically significant ECG abnormalities or an abnormal echocardiogram.
11021727|NCT04625062|Experimental|Condition 1: Visual-acoustic biofeedback|Visual-acoustic biofeedback treatment (behavioral) administered via telepractice
11021728|NCT04625062|Experimental|Condition 2: Motor-based treatment|Motor-based articulation treatment administered via telepractice
11021730|NCT04625023||Cohort of BC patients|Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.
11021731|NCT04625010|Experimental|Group 2 (Swaddling group)|Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
11021732|NCT04625010|Experimental|Group 3 (Maternal Holding group)|Maternal holding group: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
11021733|NCT04625010|No Intervention|Group 1|In the control group, the heel stick procedures were conducted using the standard method and the neonates received no interventions during the procedures.
11021734|NCT04624997||Patient suspected COVID-19|"Follow-up of patients as usual in care for infection. No specific puncture. Blood sample collect at admission and every 72h during hospitalisation for hemostasis evaluation, DNA extraction, Circulating endothelial cells measuring.
~Sampling can be delayed for 24h to match a planned blood collection for care or other research."
11021735|NCT04624984|Experimental|PD-1 Inhibitor or PD-1 Inhibitor with GVD|"All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen.
~Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial."
11021736|NCT04624958|Experimental|zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance|"Part A (Zanubrutinib and Rituximab): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve CR.
~PART B (Consolidation chemotherapy of R-DHAOx): Patients receive R-DHAOx regimen every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Elderly patients (> 65 years old) and patients who achieved CR and minimal residual disease negative after PART B receive zanubrutinb maintenance therapy. Young patients (<65 years old) who achieved CR but minimal residual disease positive after PART B can receive autologous stem cell transplantation and then zanubrutinb maintenance therapy. Patients with PD, SD or PR after PART B quit the trial.
~ZANUBRUTINB MAINTENANCE: Patients receive zanubrutinib every day for up to one year."
11021737|NCT04624945||SICU cohort|150 subjects with the admission diagnosis of neurological haemorrhage (e.g. subarachnoid haemorrhage, intracerebral haemorrhage etc), admitted to SICU of National University Hospital, Singapore, who are expected to stay for more than 48 hours, will be recruited and enrolled. Frequency of blood sampling will be stipulated atday 1/2/3/4/5 to draw clinical relevance. An additional 0.5 tablespoonful (7.7ml) of blood will be taken daily from each subject as well as residual blood from routine laboratory test blood samples.
11021738|NCT04624932|Experimental|Risk Reframing (RR) Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.
~Chapter 1: reflecting on their own childhood play activities; what they got out of these experiences; outdoor play activities of the children at their center; what they do to promote children's outdoor play; what gets in the way in promoting children outdoor play.
~Chapter 2: imagining themselves in six video segments where they must decide how to communicate with parents; and, whether they allow children to engage in rough and tumble play, play at heights, play with tools, play at speed/mud play, and resolve conflicts amongst themselves
~Chapter 3: reflecting on their barriers and things that helped them promote and support the children's outdoor play at their center. Participants to assess whether there is anything they want to change to set a realistic goal, outlining steps for attaining that goal."
11021739|NCT04624932|Sham Comparator|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play.
~It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety."
11021740|NCT04624919|Active Comparator|Hot/Dry|
11021741|NCT04624919|Experimental|Warm/Humid|
11021742|NCT04624906|Experimental|Single arm intervention|"100 mg acalabrutinib (ACP-196) oral capsules twice daily for 1 year
~Bendamustine and rituximab will be given for 6 x 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)."
11021743|NCT04624893||Pola BR/R|Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
11021744|NCT04624880||Participants with HIP previously measured|This cohort of patients will have their genetics analyzed and compared to their HIP scores.
11021745|NCT04624880||Participants without HIP measured|This cohort of patients from the control group of the knee replacement trial (who did not have their HIP measured) will have their genetics, pain, and opioid use analyzed, and compared to the genetics, pain, and opioid use of the hypnosis group from that trial.
11604983|NCT00612040|Experimental|IGlar|
11021747|NCT04624854|Placebo Comparator|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
11021748|NCT04624854|Experimental|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
11021749|NCT04624841|Experimental|ICG group|"Participants receive an intravenous injection of 0.05 mg/kg of ICG 45 minutes preoperatively.
~A Pinpoint Endoscopic Fluorescence System (Novadac Technologies Inc., Canada) for ICG Fluorescence Observation with the easy switchable white light-fluorescent mode is used.
~Before dividing any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of ICG as initially used.
~After the division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage."
11021750|NCT04624841|No Intervention|No ICG Group|No ICG is administered after randomization of the patient to a control group and hence will not produce any enhancement of the image on A Pinpoint Endoscopic Fluorescence System for ICG Fluorescence Observation. This will continue as a routine Laparoscopic cholecystectomy without fluorescent imaging enhancement.
11021751|NCT04624828|Experimental|Stereotactic body radiation treatment (SBRT)|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).
~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
11021752|NCT04624802|Experimental|maternal exercise training group|Pregnant women in experimental group are invited to participate in 16 exercise weekly classes for 40 min including 15 min aerobic exercise，10 min relaxation exercise, and 15 min aerobic exercise, from week 16 to week 32 of gestation, and receive antenatal care and examination regularly.
11021753|NCT04624802|No Intervention|antenatal care group|Pregnant women in antenatal care group receive antenatal care and examination regularly.
11021754|NCT04624789||GM1-Gangliosidosis - Sialidosis|"Confirmed diagnosis of:
~GM1-Gangliosidosis Morquio B Variant
~Sialidosis
~Galactosialidosis"
11021755|NCT04624789||GM2-Gangliosidoses|"Confirmed diagnosis of:
~Tay-Sachs Disease, incl. B1-Variante
~Sandhoff Disease
~GM2-Activator-Deficiency"
11021756|NCT04624776|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
11021757|NCT04624776|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
11021758|NCT04624763|Experimental|LBBP group|In this arm, a left bundle branch pacing(LBBP) lead is attempted to be placed.
11021759|NCT04624763|Active Comparator|RVP group|In this arm, a right ventricular pacing(RVP) lead are placed.
11021760|NCT04624750|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
11021761|NCT04624711|Experimental|Eribulin Mesylate Combined With Anlotinib|Patients receive eribulin mesylate plus anlotinib.
11021762|NCT04624698|Experimental|Implantation|Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.
11021763|NCT04624672|Placebo Comparator|Control Arm|Once weekly injection of placebo 4-6 months at prescribed dose
11021764|NCT04624672|Active Comparator|Test Arm|Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose
11021765|NCT04624659|Experimental|Double blind FT-4202 Low Dose|
11021766|NCT04624659|Experimental|Double blind FT-4202 High Dose|
11021767|NCT04624659|Experimental|Double Blind Placebo|
11021768|NCT04624659|Experimental|Open label FT-4202|
11021769|NCT04624633|Experimental|Cohort 1-Relapsed Disease|"Participants with relapsed disease
~Treatment with Acalabrutinib & Umbralisib beginning C1D1,
~Ublituximab beginning C7D1
~Assessment of treatment response
~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
11021770|NCT04624633|Experimental|Cohort 2-Treatment Naive|"Participants with previously untreated disease
~Treatment with Acalabrutinib & Umbralisib beginning C1D1,
~Ublituximab beginning C7D1
~Assessment of treatment response
~Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years"
11021771|NCT04624620|Experimental|Pilot|Participants will participate in a 16 week, culinary intensive study that will consist of 2 hour virtual classes taught by a chef, a dietitian, and a health coach that focus on diet, culinary competency, daily physical activity, mindfulness and support for behavior change.
11021772|NCT04624607|Experimental|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive transspinal stimulation over the thoracolumbar region and non-invasive brain stimulation during assisted stepping.
11021773|NCT04624607|Experimental|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive brain stimulation and non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping.
11021774|NCT04624594|Experimental|Artificial Intelligence (AI) Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the AI group then performed 10 more practice repetitions with real-time audiovisual feedback from the app followed by one minute of rest. The AI's design provided one piece of feedback, if necessary, with a vocal statement and on-screen video per repetition (e.g. when a participant performed a squat repetition with their neck flexed downward, AI suggested keeping their head up with on-screen instruction). Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
11021775|NCT04624594|Active Comparator|Physical Therapist Group|"To determine baseline ability and serve as their own control, participants in both groups performed 10 bodyweight squat control repetitions without feedback followed by one minute of rest. Those in the PT group (n=15) also performed 10 practice repetitions with one piece of feedback per repetition, if necessary, from the PT followed by one minute of rest. Participants in both groups then performed 10 test repetitions without feedback followed by one minute of rest."
11021776|NCT04624581|Experimental|Patient with fibromyalgia syndrome|250 patients with fibromyalgia syndrome (according to American College of Rheumatology 2016) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate the distribution of gene polymorphism.
11021777|NCT04624581|Sham Comparator|Healthy subjects|50 healthy matched volunteers (age, sex and menopausal status for women) will realize explorations to characterize central sensitization: reflex nociceptive flexion threshold by electrophysiological measure and blood sampling for evaluate distribution of gene polymorphism
11021778|NCT04624568|Experimental|Papilocare group|"Papilocare® for 6 months according to the following schedule:
~1 self-applying single dose per day for 21 days over 28 during the first month, then 1 day over 2 during the following 5 months, with a 7-day break during the menstrual period. (This break must be respected even in menopausal women or women undergoing artificial amenorrhea (amenorrhea induced by certain contraceptives: implant, hormonal IUD, micro-progestogen)."
11021779|NCT04624568|No Intervention|Control group|No treatment for 12 months. Smear and HPV test will be perform by all patients at 6 and 12 months
11021780|NCT04624542||group 1|Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.
11021781|NCT04624542||control group|-30 healthy active individuals ranging from 18-36 yrs as a controlled group
11021782|NCT04624516|Experimental|Intervention group|The group received training in self-structured foot exercise and they were encouraged to do self-structure foot exercise 3 times a week. They received usual care
11021783|NCT04624516|No Intervention|Control Group|the group received usual care
11021784|NCT04624490|Experimental|Hyperpolarized 129Xe|Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.
11021785|NCT04624477||Active Surveillance|Patients under active surveillance choose to not have immediate thyroid surgery. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if received). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
11021786|NCT04624477||Immediate Thyroid Surgery (total or partial thyroidectomy)|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
11021787|NCT04624464||Cohort 1: VRE negative at admission|"150 patients meeting the following inclusion criteria:
~≥ 18 years
~Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days
~High risk of exposure to antibiotics during the stay
~Written informed consent of the patient after clarification has been given
~Exclusion criteria:
~Already known current or documented past colonisation or infection by VRE
~Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use)."
11021788|NCT04624464||Cohort 2: VRE positive at admission|"A total 20 known VREf-positive patients meeting the following inclusion criteria:
~Intestinal VREf colonization already known at the time of admission (e.g. based on examinations during previous stays or in external facilities)
~Accommodation in a single room or alternatively multi-bed room with single occupancy on standard wards
~Expected stay of at least 7 days"
11021789|NCT04624438|Experimental|Electromyostimulation - EMS|Experimental group comprised of healthy young adults that undergoes unilateral isometric training using electromyostimulation over quadriceps femoris
11021790|NCT04624438|Experimental|Voluntary activation - VOLUNTARY|Experimental group comprised of healthy young adults that undergoes unilateral isometric training based on voluntary activation of quadriceps femoris
11021791|NCT04624438|Experimental|Combination of EMS and VOLUNTARY - COMBINED|Experimental group comprised of healthy young adults that undergoes unilateral isometric training that combines electromyostimulation and voluntary activation of quadriceps femoris.
11021792|NCT04624438|No Intervention|Control group - CONTROL|Group of healthy young adults who received no intervention.
11021793|NCT04624425|Experimental|Segmental breathing exercises|Segmental breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
11021794|NCT04624425|Active Comparator|Buteyko breathing exercises|Buteyko breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
11021795|NCT04624412|Experimental|Continuous Aerobic Moderate Intensity Exercise|(Treadmill walking exercise) 50% - 70% of max Heart Rate (HR) (3-6 METS)
11021796|NCT04624412|Experimental|Continuous Aerobic (Mild intensity Exercise)|(Treadmill walking exercise) 30% -50 % of max HR (1-3 METS)
11021797|NCT04624399|Experimental|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
11021798|NCT04624386||Postmenopausal/Study|Women older than 45 years of age and who have not had any menstruation for the past 12 months are considered as having entered menopause. These women are included in this group.
11021799|NCT04624386||Premenopausal/Control|Healthy women who are still having regular menstruations are included in this group
11021800|NCT04624373||Identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
11021801|NCT04624373||Non identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
11021802|NCT04624360|Experimental|Study Drug A|Dexamethasone 8mg intravenous administration stat dose post clamping of the umbilical cord
11021803|NCT04624360|Placebo Comparator|Study Drug B|Normal saline 2cc intravenous stat dose administered after clamping of the umbilical cord
11021804|NCT04624347|Experimental|Acess to Videos and Movement curves|with caregivers' access to videos and movement curves (4 days)
11021810|NCT04624321|Experimental|Access to tool|Access to the digital tool. They use the tool at their own and do the different themes that are available. They are recommended to use it at least every other week.
11021811|NCT04624321|Placebo Comparator|Usual care|They are followed by their ordinary healthcare provider.
11021812|NCT04624308|Experimental|TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab|TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or >75%PR. If not, operation is suggested.
11021813|NCT04624295|Active Comparator|Early Antiplatelet Therapy|
11021814|NCT04624295|Placebo Comparator|Non-Early Antiplatelet Therapy|
11021815|NCT04624282||Patients with chronic superficial gastritis|Patients with chronic superficial gastritis
11021816|NCT04624282||Patients with chronic atrophic gastritis|Patients with chronic atrophic gastritis
11021817|NCT04624282||Patients with gastric carcinoma|Patients with gastric carcinoma
11021818|NCT04624269|Experimental|Hydroxychloroquine sulfate Tablets|drug:Hydroxychloroquine sulfate Tablets,0.1mg bid po
11021819|NCT04624269|Placebo Comparator|placebo|drug:placebo,0.1mg bid po
11021820|NCT04624256|Experimental|Treatment (radiotherapy, genomic DNA testing)|Patients undergo SBRT per standard of care, then undergo collection of cheek swab and blood samples for the analysis of germline biomarkers. Afterwards, patients and their physicians engage in discussion about which form of radiotherapy to proceed with. Based on the decision, patients predicted to be at low risk of toxicity with SBRT continue to receive SBRT over 14 days while patients predicted to be at high risk of toxicity with SBRT will be counseled to undergo either conventionally fractionated radiotherapy over 63-70 days, moderate hypofractionated radiotherapy over 28-35 days, or may opt to still receive SBRT over 14 days per standard of care.
11021821|NCT04624243|Experimental|MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 8 mg once daily (QD) in the acute treatment period from Week 1-6 followed by MK-8189 8 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
11021822|NCT04624243|Experimental|MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 16 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 16 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
11021823|NCT04624243|Experimental|MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 24 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
11021824|NCT04624243|Active Comparator|Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive MK-8189-matching placebo QD from Week 1-12.
11021825|NCT04624243|Experimental|Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189-matching placebo QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
11021826|NCT04624230|Experimental|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
11021827|NCT04624217|Experimental|SHR-1701|SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel
11021828|NCT04624204|Experimental|Group A - Pembrolizumab 200 mg|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg every 6 weeks (Q6W) plus olaparib matching placebo twice daily (BID) for 12 months or until specific discontinuation criteria are met.
11021829|NCT04624204|Experimental|Group B - Pembrolizumab 200 mg plus Olaparib 300 mg BID|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg Q6W plus olaparib 300 mg BID for 12 months or until specific discontinuation criteria are met.
11021830|NCT04624204|Placebo Comparator|Group C (Pembrolizumab and Olaparib Matching Placebos)|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab placebo (saline) Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab placebo (saline) Q6W plus olaparib matching placebo for 12 months or until specific discontinuation criteria are met.
11021831|NCT04624191|Experimental|Intervention Group|Intervention group participants will be asked to measure their oxygen saturation on a daily basis.
11021832|NCT04624191|No Intervention|Control Group|Usual Care
11021833|NCT04624178|Experimental|Rucaparib in combination with Nivolumab|"One treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks.
~Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy."
11021834|NCT04624152|Experimental|Normobaric Hypoxia|"Large weather balloons will be filled with a normobaric hypoxic inspirate (FiO2 = 0.15) produced by a nitrogen generator (CAT 12; Colorado Altitude Training, Boulder, CO) to simulate an altitude of 2600 m (8500 ft). Participants breathed this inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).
~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
11021865|NCT04623866|Active Comparator|Huaiqihuang Group|Huaiqihuang granules 60g/1.73m2 bid 24 weeks
11021866|NCT04623866|Active Comparator|Valsartan group|Valsartan granules 80mg/1.73m2 based qd 24 weeks
11021835|NCT04624152|Placebo Comparator|Normobaric Normoxia|"Large weather balloons will be filled with room air (FiO2 = 0.21). Participants breathed this normobaric normoxic inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).
~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
11021836|NCT04624139|Experimental|Intervention, group 1|Combined intervention of stress reducing I-CBT and physiotherapy.
11021837|NCT04624139|Active Comparator|Active control group, group 2|Physiotherapy only
11021838|NCT04624126|Experimental|3D-Erect arm|Participants will be asked to use the 3D-printed penile device during their intercourse with partners.
11021839|NCT04624113|Experimental|Phase I: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).
~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend on dose level assigned
~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
11021840|NCT04624113|Experimental|Phase 2: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).
~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend of recommended phase 2 determined in Phase I portion of study.
~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
11021841|NCT04624100||All consecutive patients with primary ventral or incisional hernia|
11021842|NCT04624087|Experimental|High Dose|Participants will perform the food-specific computerized go/no-go training four times per week for 4 weeks.
11021843|NCT04624087|Experimental|Low Dose|Participants will perform the food-specific computerized go/no-go training one time per week for 4 weeks.
11021844|NCT04624087|Active Comparator|Active Control|Participants will perform the generalized, nonfood-specific computerized go/no-go training one time per week for 4 weeks.
11021845|NCT04624074|Experimental|Teen Marijuana Checkup - adapted|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
11021846|NCT04624061|Experimental|Intervention|"The integrated HIV/HTN care model with the following components;
~Training and capacity building on the INTEGRATED HIV/HTN model and NCD care
~Integrated HIV/HTN care delivery model by promoting HTN screening and care in HIV clinics.
~HMIS enhancements through mentorship and coaching on the use of NCD registers and NCD patient cards and HTN data capture in the (Electronic Medical Record) EMR system.
~SMS and/or WhatsApp for data coordination and communication among providers, District Health officers (DHOs) and study team (Mentors) to strengthen feedback."
11021847|NCT04624061|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV and Hypertension care visits at the health facilities include;a) Provision of BP machines b)Provision of NCD register and NCD patient card and ; c) Following MOH treatment guidelines
11021848|NCT04624048||University population|Survey to analyze the impact of COVID-19.
11021849|NCT04624035|Active Comparator|Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.|Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
11021850|NCT04624035|Active Comparator|Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults|Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
11021851|NCT04623996|Experimental|Single Arm TP-0184|TP-0184 is administered orally once a day
11021852|NCT04623983|Experimental|resilient bonding tray|Patients receiving resilient orthodontic bonding trays
11021853|NCT04623983|Experimental|rigid bonding tray|Patients receiving rigid orthodontic bonding trays
11021854|NCT04623970|Experimental|Propofol sedation group|Patients in this experimental group received propofol sedation agent.
11021855|NCT04623970|Experimental|Ketofol 1:3 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:3 mixture.
11021856|NCT04623970|Experimental|Ketofol 1:4 sedation group|Patients in this experimental group received ketofol sedation agent as a 1:4 mixture.
11021857|NCT04623957|Experimental|ForgTin|Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
11021858|NCT04623957|No Intervention|No intervention|Patients randomized into group 2 will receive no device for a duration of 3 months.
11021859|NCT04623944|Experimental|NKX101 - CAR NK cell therapy|"All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX101.
~Part 1: haploidentical related donor derived NKX101 will be used
~Part 2: either haploidentical related donor derived or unrelated donor derived NKX101 will be used"
11021860|NCT04623931|Experimental|Treatment (temozolomide, radiation therapy)|Patients receive temozolomide PO daily and radiation therapy over 5 days a week (weekdays only) for 6 weeks. Beginning 28 days after the last dose of radiation therapy, patients receive temozolomide PO for 12 months in the absence of disease progression or unacceptable toxicity.
11021861|NCT04623918|Experimental|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
11021862|NCT04623918|Active Comparator|Control rice|Control rice (C4)
11021863|NCT04623892|Experimental|TQB2618|TQB2618 administered intravenously (IV) on Day 1 of each 21-day.
11021864|NCT04623879||F508del homozygous adult CF patients|F508del homozygous adult CF patients who commenced treatment with LUM-IVA
11021867|NCT04623853|Experimental|Aim 2|Participants will carry out a protocol comprised of treadmill walking in a laboratory setting while wearing the Dynamic AFO device.
11021868|NCT04623853|Experimental|Aim 3|"Participants will be asked to take the Dynamic AFO home and wear the device for up to 4 weeks. The device will be set in either an adjustment-capable mode, or a locked mode that functions similar to their own orthotic--the order in which they are tested will be randomized."
11021869|NCT04623840|Experimental|Exercised group|.(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
11021870|NCT04623840|Active Comparator|non-exercised group|(n=30) will be sedentary obese men with ED. All participants will receive only five milligrams of tadalafil, one time per day, for eight weeks.
11021871|NCT04623814|Experimental|Food effect|HEC113995 20mg will be administered fasted, with regular meal or with high-fat meal for once.
11021872|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 10mg|HEC113995 10mg will be administered fasted for 10 days
11021873|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 20mg|HEC113995 20mg will be administered with food for 10 days
11021874|NCT04623814|Experimental|Multiple Ascending Doses-HEC113995 40mg|HEC113995 40mg will be administered with food for 10 days
11021875|NCT04623814|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo arms will be administered fasted or with food for 10 days
11021876|NCT04623801|Experimental|Participants with papillary microcarcinoma (PTMC)|Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.
11021877|NCT04623788||Myocarditis|Twenty patients with acute myocarditis will be recruited if the diagnosis has been made by a cardiologist based on clinical, biochemical, electrographic and imaging data. This reflects the diagnostic criteria set out by the European Society of Cardiology (ESC) Task force 2013.
11021878|NCT04623788||Takotsubo Cardiomyopathy|Twenty patients with takotsubo cardiomyopathy will be recruited. The diagnosis will be made according to the Mayo clinic and the European Society of Cardiology (ESC) Heart Failure Association criteria, including a normal coronary angiogram, typical appearances on cardiac imaging including ventriculography, and no evidence of fibrosis on cardiac magnetic resonance imaging.
11021879|NCT04623788||Reversible Ischaemia|Forty patients who have undergone stress echocardiography or magnetic resonance imaging; twenty with positive (areas of reversible akinesis/hypokinesis during pharmacological stress), and twenty with a negative stress result (no reversible wall motion abnormalities during pharmacological stress) as per international guidelines. They will be matched for age and sex.
11021880|NCT04623788||Healthy Volunteer|Twenty healthy volunteers of comparable age and sex to the other cohorts.
11021881|NCT04623775|Experimental|Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))|
11021882|NCT04623775|Experimental|Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))|
11021883|NCT04623775|Experimental|Part 2: Arm C (Nivolumab + Relatlimab Dose 1 or Dose 2 + PDCT)|
11021884|NCT04623775|Placebo Comparator|Part 2: Arm D (Nivolumab + Placebo + PDCT)|
11021885|NCT04623762|No Intervention|Control group|yoga was not done
11021886|NCT04623762|Experimental|Experimental group|yoga was done
11021887|NCT04623749|Active Comparator|Percutaneous US guided FNAC in pancreatic masses|
11021888|NCT04623749|Active Comparator|EUS guided FNAC in pancreatic masses|
11021889|NCT04623736|Experimental|quitSTART|
11021890|NCT04623723|Sham Comparator|Perio Slim (PS)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with PS (DS-016A, EMS® Piezon, Switzerland) scaler tip
11021891|NCT04623723|Active Comparator|Conventional scaler tip|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with conventional (FS-407, EMS® Piezon, Switzerland) scaler tip
11021892|NCT04623710|Experimental|Cohort 1: Severe Impaired Renal Function|Participants will receive ALXN2050.
11021893|NCT04623710|Experimental|Cohort 2: Moderate Impaired Renal Function|Participants will receive ALXN2050.
11021894|NCT04623710|Experimental|Cohort 3: Mild Impaired Renal Function|Participants will receive ALXN2050.
11021895|NCT04623710|Experimental|Cohort 4: Healthy Control|Participants will receive ALXN2050.
11021896|NCT04623684|Experimental|Study Group|Mydriasis with microdrops
11021897|NCT04623684|Active Comparator|Control Group|Mydriasis with standard drops
11021898|NCT04623671|Active Comparator|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
11021899|NCT04623671|Placebo Comparator|Placebo|Matching placebo solution
11021900|NCT04623658||Sacrococcygeal teratoma|Fetuses and infants diagnosed with sacrococcygeal teratoma and cared for between 2007 and 2017 in the main Parisian fetal medicine and pediatric surgery units: Necker-Enfants Malades Hospital, Antoine Béclère Hospital, Armand Trousseau Hospital, Robert Debré Hospital and Le Kremlin-Bicêtre Hospital.
11021901|NCT04623645|Experimental|ultrasound group|patient using ultrasound technique.probe will be placed over submandibular area, the thyrohoid muscle and thyrohyoid membrane will be identified between greater horn fo hyoid bone and thyroid cartilage , 3 ml of lignocaine will be placed on space between thim and the procedure will repeated on contra lateral side.
11021902|NCT04623645|Active Comparator|anatomical blind group|patient using anatomical land mark technique, internal branch of superior laryngeal nerve will be blocked slightly anterior to greater horn of hyoid bone . by 3 ml lignocaine . the procdure will be repeated on contra lateral side .
11021938|NCT04623398|Placebo Comparator|Placebo|"Capsules containing lactose monohydrate in all points resembling the capsules of active ingredients.
~Capsules of pla62.5 mg, pla125 mg and pla250 mg (pla=placebo)"
11021939|NCT04623385|Active Comparator|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
~The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
11024431|NCT04606602|Experimental|200 mg multi dose|
11021903|NCT04623632|Active Comparator|Bupivacaine|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique; syringes contained bupivacaine 0.25% 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
11021904|NCT04623632|Placebo Comparator|Placebo|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique syringes contained either normal saline 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
11021905|NCT04623619|Experimental|Acetyl L-Carnitine|Acetyl L-Carnitine
11021906|NCT04623619|No Intervention|Standard of care|Standard of care
11021907|NCT04623606|No Intervention|Prospective Control (Untreated) and historical controls|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database
11021908|NCT04623606|Experimental|Treatment|Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
11021909|NCT04623593|Active Comparator|ACDF|Anterior cervical discectomy and fusion.
11021910|NCT04623593|Experimental|ACDA|Anterior cervical discectomy with arthroplasty.
11021911|NCT04623580||Inguinal or femoral hernia repair|All consecutive inguinal or femoral hernia repair (primary or mesh)
11021912|NCT04623567|Experimental|Jiangtang Tiaozhi Recipe Group|Jiangtang Tiaozhi formula granule (30g per bag), 1 bag per time, twice a day, take it with warm water after meals.
11021913|NCT04623567|Active Comparator|Metformin Group|500mg metformin tablet per time, 3 times a day, take it with meals.
11021914|NCT04623554|Active Comparator|Intervention arm|Prehabilitation program
11021915|NCT04623554|No Intervention|Control arm|Usual care
11021916|NCT04623541|Experimental|Experimental|Experimental: Epcoritmab Open label single arm
11021917|NCT04623528||Pericarditis patients with constrictive physiology|Patients with pericarditis and signs of constrictive physiology (increased ventricular coupling)
11021918|NCT04623528||Pericarditis patients without constrictive physiology|Patients with pericarditis but without signs of constrictive physiology (normal ventricular coupling)
11021919|NCT04623528||Dilated cardiomyopathy patients with biventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular and right ventricular ejection fraction less than 35%
11021920|NCT04623528||Dilated cardiomyopathy patients with preserved right ventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular ejection fraction less than 35%, and right ventricular function >45%
11021921|NCT04623528||Patients with pulmonary arterial hypertension|Cohort of patients with pulmonary hypertension, either idiopathic or secondary to pulmonary emboli
11021922|NCT04623528||Control group|Cohort of subjects with no evidence of pericarditis, pulmonary hypertension, dilated cardiomyopathy and normal findings at cardiovascular magnetic resonance imaging
11021923|NCT04623515||Surgery Only Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
11021924|NCT04623515||Surgery and Radiation Therapy Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
11021925|NCT04623502|Experimental|13C-Glucose|
11021926|NCT04623502|Experimental|13C-Acetate|
11021927|NCT04623502|Experimental|13C-Lactate|
11021928|NCT04623502|Experimental|13C-Glutamine|
11021929|NCT04623502|Experimental|13C-Fructose|
11021930|NCT04623476|Experimental|Pathophysiological Excision for Chron's disease|Consecutive patients (>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD
11021931|NCT04623463|Other|Exercise intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
11021932|NCT04623450|Experimental|High Carbohydrate Meal|A smoothie including maltodextrin and low-fat strawberry yoghurt - 289 kcal, 61g carbohydrate, 6.7g protein, 1.9g fat.
11021933|NCT04623450|Experimental|High Fat Meal|A smoothie including double cream and low-fat strawberry yoghurt - 312 kcal, 13.3g carbohydrate, 7g protein, 25.5g fat.
11021934|NCT04623450|Experimental|High Protein Meal|A smoothie including whey protein and low-fat strawberry yoghurt - 307 kcal, 13.6g carbohydrate, 57g protein, 2.7g fat.
11021935|NCT04623411|Experimental|Intervention Group|Neonatal resuscitation training with classical method and serious game simulation method
11021936|NCT04623411|Experimental|Control Group|Neonatal resuscitation training with classical method.
11021937|NCT04623398|Experimental|Lithium|"Li+ is an FDA (NDA: 016834) and ANSM (AMM 3400931376339) approved drug. There are two lithium salts that are marketed in France, Teralithe LI (cp 250mg) and Teralithe LP (cp 400mg).
~The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials."
11021940|NCT04623385|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
11021943|NCT04623359|Experimental|Patients|Patient with constipation will have a high resolution manometry
11021944|NCT04623359|Other|Healthy volunteers|Healthy volunteers will have a high resolution manometry
11021945|NCT04623346||Weber B-type Ankle fractures in prepandemic period|Patients with AO Weber B-type ankle fracture in prepandemic period
11021946|NCT04623346||Weber B-type Ankle fractures in pandemic period|Patients with AO Weber B-type ankle fracture in pandemic period
11021947|NCT04623346||Wrist fractures in prepandemic period|Patients with extraarticular distal radius fracture in prepandemic period
11021948|NCT04623346||Wrist fractures in pandemic period|Patients with extraarticular distal radius fracture in pandemic period
11021949|NCT04623346||Proximal humerus fractures in prepandemic period|Patients with 2-part,3-part and 4-part fractures in prepandemic period
11021950|NCT04623346||Proximal humerus fractures in pandemic period|Patients with 2-part,3-part and 4-part fractures in pandemic period
11021951|NCT04623333|Experimental|TQB2450 injection|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
11021952|NCT04623320||NAFLD+T1DM+|Subjects with type 1 diabetes and ultrasound-defined NAFLD
11021953|NCT04623320||NAFLD-T1DM+|Subjects with type 1 diabetes without ultrasound-defined NAFLD
11021954|NCT04623307||Brain damage patients|Brain damage patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
11021955|NCT04623307||Brain edema patients|Brain edema patients were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
11021956|NCT04623307||Healthy subjects|Healthy subjects were monitored the human brain activity by the non-contact DCS-Speckle multi-parameter imager.
11021957|NCT04623294||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
11021958|NCT04623294||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
11021959|NCT04623294||Deep coma patients for HLH Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
11021960|NCT04623294||Deep coma patients for LHL Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
11021961|NCT04623294||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
11021962|NCT04623294||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
11021963|NCT04623281||Observational group|Observational group of 10 haemodialysis patients following usual care for 3 weeks.
11021964|NCT04623268||Adult offspring|Adult female and male offspring to AAA patients 45-80 years of age at inclusion Children to detected AAA patients. Found in the Multigeneration registry
11021965|NCT04623268||Control group|Matched women and men, without parents with AAA. Matched in the Swedish Multigeneration registry
11021966|NCT04623255|No Intervention|STANDARD OF CARE|Standard patient care for severe COVID-19
11021967|NCT04623255|Active Comparator|Plasma exchange|Standard patient care for severe COVID-19 with. plasma exchange daily for 5 days x 3 courses as required
11021968|NCT04623242|Experimental|Gantenerumab|
11021969|NCT04623242|Experimental|Solanezumab|
11021970|NCT04623242|Placebo Comparator|Matching placebo (Gantenerumab)|
11021971|NCT04623242|Placebo Comparator|Matching Placebo (Solanezumab)|
11021972|NCT04623229|Experimental|MCS|
11021973|NCT04623229|Experimental|ReLACS Early|
11021974|NCT04623229|Experimental|ReLACS Standard|
11021975|NCT04623216|Experimental|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
11021976|NCT04623216|Experimental|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
11021977|NCT04623216|Experimental|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
11021978|NCT04623216|Experimental|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
11021979|NCT04623216|Experimental|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to < 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
11021980|NCT04623203||children with migraine|Children that were diagnosed at the neurology clinic with migraine at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
11021981|NCT04623203||children with TTH|children that were diagnosed at the neurology clinic with TTH at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
11021982|NCT04623190|Experimental|Providers|-All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline. The providers will be delivering the PREVENT tool.
11021983|NCT04623190|Active Comparator|Patients - Wait-List Control|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail
~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
11021984|NCT04623190|Experimental|Patients - PREVENT Tool|"Complete questionnaires and accelerometry at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months and 6-months after the clinic visit electronically and by mail
~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
11021985|NCT04623177||Anticoagulation|Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
11021986|NCT04623177||Thromboprophylaxis|Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
11021987|NCT04623177||No heparin|Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission
11021988|NCT04623164|No Intervention|1 Group (Control)|ten students with healthy periodontium
11021989|NCT04623164|Experimental|2 Group|ten patients receiving standard non-surgical periodontal treatment (NSPT)
11021990|NCT04623164|Experimental|3 Group|ten patients receiving standard non-surgical periodontal treatment NSPT + 28-day chronotherapy with complex phytoadaptogens (CFA)
11021991|NCT04623151|Experimental|Online leaflet in narrative format|
11021992|NCT04623151|Active Comparator|Online leaflet in non-narrative format|
11021993|NCT04623151|No Intervention|No leaflet (control)|
11021994|NCT04623138||Garmin Study Device Group|Individuals who are randomly assigned to receive the Garmin vívosmart® 4
11021995|NCT04623138||Empatica Study Device Group|Individuals who are randomly assigned to receive the Empatica E4
11021996|NCT04623125|Experimental|Spaced Repetition|Two weeks (10 sessions) of online picture-naming training with 60 words.
11021997|NCT04623112|Other|FC Deactivated|Frequency Compression feature on hearing aids is deactivated for 4 weeks
11021998|NCT04623112|Experimental|FC activated & set to default|Frequency compression feature activated on hearing aids and set to default software settings for 4 weeks.
11021999|NCT04623112|Experimental|FC activated and set to hearing loss|Frequency Compression feature activated on hearing aids and set to hearing loss cut-off for 4 weeks
11022000|NCT04623099|Other|Standard dosing|Patients randomized to standard dosing (std) will initiate escitalopram at 5 mg daily and will then increase to 20 mg/day at week 4.
11022001|NCT04623099|Experimental|Pharmacogenetically-guided escitalopram dosing|Patients randomized to PGx-guided treatment, escitalopram titration will be based on CYP2C19 phenotype and predicted escitalopram exposure. In poor metabolizers (PM), escitalopram will be initiated at 5 mg daily and increased to 10 mg daily at week 4.
11022002|NCT04623086|Experimental|Insulin Glargine and Insulin Degludec|Insulin glargine, 100 units per mL injected subcutaneously daily Insulin Degludec, 100 units per mL injected subcutaneously daily
11022003|NCT04623086|Placebo Comparator|Insulin Degludec and placebo|Insulin Degludec, 100 units per mL injected subcutaneously daily Placebo, 9g/L sodium chloride (normal saline) injected subcutaneously daily
11022004|NCT04623073||Patients who underwent DAA THA|Patients who underwent DAA THA by a single surgeon who routinely documents the distance from the should of the stem to the upper end of the EO footprint
11022005|NCT04623060|Experimental|Intervention|3 sessions/week for 6 weeks
11022006|NCT04623047||Adults 18 years of age and up|The study will recruit any adult over the age of 18 years.
11022007|NCT04623034|Experimental|400 mg MSI-195 - SAD|400 mg MSI-195 (within Stage 1, single ascending dose)
11022008|NCT04623034|Experimental|800 mg MSI-195 - SAD|800 mg MSI-195 (within Stage 1, single ascending dose)
11022009|NCT04623034|Experimental|1600 mg MSI-195 -SAD|1600 mg MSI-195 (within Stage 1, single ascending dose)
11022010|NCT04623034|Experimental|800 mg MSI-195 - fasted|800 mg MSI-195 fed (within Stage 2, cross-over comparison)
11022011|NCT04623034|Experimental|1600 mg SAM-e Complete TM - fasted|1600 mg SAM-e Complete (within Stage 2, cross-over comparison)
11022012|NCT04623034|Experimental|800 mg MSI-195 - fed|800 mg MSI-195- fed (within Stage 2, fed arm)
11022013|NCT04623021|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
11022014|NCT04623021|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
11022015|NCT04623008|Experimental|Goal-Oriented Episodic Future Thinking (GOEFT) Intervention|In addition to usual prenatal care, intervention participants will receive a 20-week intervention via web and individual health counseling. The intervention topics focus on stress management, healthy eating, and physical activity.
11022016|NCT04623008|No Intervention|Usual Prenatal Care|The usual prenatal care group will receive usual care from their providers
11022017|NCT04622995||Exposed|Patients prescribed a benzodiazepine plus opiate substitution therapy.
11022018|NCT04622995||Unexposed|Patients prescribed opiate substitution therapy.
11022019|NCT04622982|Experimental|All participants|Obese subjects with BMI >= 30 and with one or more of metabolic comorbidities (type 2 diabetes mellitus, dyslipidemia, high blood pressure, hyperuricemia, and others).
11022020|NCT04622969|Experimental|Intervention|Provide the 15-week Healthy Child Development Program intervention
11022021|NCT04622969|No Intervention|Wait list control|
11022022|NCT04622956|Experimental|Experimental|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
11022023|NCT04622956|No Intervention|Control Group|GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and mycophenolate mofetil (15 mg/kg/dose p.o. t.i.d. initiated on day +5). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present.
11022107|NCT04622423||Healthy volunteers|Negative control for the clinical study.
11022024|NCT04622943|Experimental|firearms safety|Children will spend two 30-minute sessions engaged on ShootSafe, an internet-based training program on firearms safety.
11022025|NCT04622943|Active Comparator|nutrition|Children will spend two 30-minute sessions engaged on nourishinteractive.com, an internet-based training program on nutrition and exercise.
11022026|NCT04622930|Experimental|Experimental: Smartphone-delivered CBT for SAD|12-week Smartphone delivered CBT for SAD.
11022027|NCT04622930|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for SAD following the 12-week waitlist control).
11022028|NCT04622917|Active Comparator|Methylprednisolone|Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage
11022029|NCT04622917|Placebo Comparator|Sodium Chloride (NaCl)|NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage
11022030|NCT04622904|Active Comparator|lidocaine-magnesium group|combination of lidocaine and magnesium infusions
11022031|NCT04622904|Active Comparator|lidocaine-ketamine group|combination of lidocaine and ketamine infusions
11022032|NCT04622904|Active Comparator|lidocaine group|lidocaine infusion alone
11022033|NCT04622891|Experimental|clarithromycin|clarithromycin group
11022034|NCT04622891|Active Comparator|Azithromycin|azithromycin group
11022035|NCT04622891|Placebo Comparator|control|control group
11022036|NCT04622878|Other|acute lower limb ischemia patients|patients with no palpable pulsations or audible signals in the lower limb
11022037|NCT04622865|Experimental|Masitinib plus Isoquercetin plus Best Supportive Care|"Patients will receive oral masitinib dose of 3 mg/kg/day for 4 days then 4.5 mg/kg/day.
~The dose of isoquercetin will be 1 g/day by oral route. Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs."
11022038|NCT04622865|Active Comparator|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs, or biologics drugs.
11022039|NCT04622852||Group A: ALPS-PHP device|Patients operated with angular stable plate for displaced PHF with an ALPS plate
11022040|NCT04622852||Group B: Philos device|Patients operated with angular stable plate for displaced PHF with a Philos plate
11022041|NCT04622839|Experimental|Group 1|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
11022042|NCT04622839|Experimental|Group 2|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
11022043|NCT04622839|Experimental|Group 3|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
11022044|NCT04622826|Experimental|sequential immune plasma infused patients|immune covid 19 plasma infusion
11022045|NCT04622813|Placebo Comparator|Placebo group|
11022046|NCT04622813|Experimental|Multimodal group|
11022047|NCT04622800|Other|Individuals applied with proprioceptive neuromuscular fasilition techniques|No exercise intervention was made.
11022048|NCT04622787||Tuscany, Italy|Infants at risk of Cerebral Palsy in Tuscany, Italy
11022049|NCT04622787||Infants at risk of Cerebral Palsy in Georgia|Infants at risk of Cerebral Palsy in Georgia
11022050|NCT04622787||Sri-Lanka|Infants at risk of Cerebral Palsy in Sri-Lanka
11022051|NCT04622787||Denmark|Infants at risk of Cerebral Palsy in Denmark
11022052|NCT04622787||Infants at risk of Cerebral Palsy in the Netherlands|the Netherlands
11022053|NCT04622787||remote Queensland, Australia|Infants at risk of Cerebral Palsy in remote Queensland, Australia
11022054|NCT04622787||Medical professionals|Medical/healthcare providers from all involved geographic locations that work with infants at risk or with diagnosis of cerebral palsy will be provided opportunities for the participation in face-to-face and/or e-learning platform trainings on the the international early detection guidelines.
11022055|NCT04622774|Experimental|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
11022056|NCT04622761|No Intervention|control|Immediate surgery (radical prostatectomy) (standard care)
11022057|NCT04622761|Experimental|treatment|"14 days prior to starting Cabazitaxel patients will take 50mg Bicalutamide once daily for 21 days.
~7 days prior to starting Cabazitaxel patients will be given 3 months LHRH treatment via injection. The entire dose will be administered via one injection 7 days prior to starting Cabazitaxel. This may be either leuprorelin or goserelin acetate and should be given as per local practice.
~At least 30 minutes prior to each administration of Cabazitaxel, patients will be administered IV premedication consisting of:
~50mg Ranitidine 10mg Chlorphenamine 8mg Dexamethasone Daily from Day 1 until end of Cabazitaxel treatment patients will take 10mg Prednisolone once daily from Day 1 until end of Cabazitaxel treatment Day 1 of each cycle - Patients will receive Cabazitaxel 25 mg/m2 intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles."
11022058|NCT04622748||COVID-19|Recovered COVID-19 patients in Wuhan
11022059|NCT04622748||Healthy Control|Uninfected people in Wuhan
11022060|NCT04622735|Experimental|FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
11022061|NCT04622735|Active Comparator|Paracetamol 500 mg (X2)|Each dose: 2 tablets (included in masking capsule)
11022062|NCT04622735|Active Comparator|Nefopam hydrochloride 30 mg (X2)|Each dose: 2 tablets (included in masking capsule)
11022063|NCT04622722|Active Comparator|Group A|Group A: Drinking Nutren Diabetes provides energy at 360 kcal per 360 ml
11022064|NCT04622722|Placebo Comparator|Group B|Group B: Having Isocaloric diet provide 360 kcal.
11022106|NCT04622423||Primary not-MTS PDAC|Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.
11022065|NCT04622709|Experimental|Study drug administration: furosemide|Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant.
11022066|NCT04622696||Prospective - Performance Cohort|Subjects will undergo an ultrasound-guided breast biopsy procedure with placement of HydroMARK Breast Biopsy Site Marker per site standard of care and will return to the office at 6-12 weeks post-implant for ultrasound imaging to evaluate device visibility.
11022067|NCT04622696||Retrospective - Safety Cohort|Device-related adverse events will be collected via retrospective medical chart review for a minimum of 90 days post-HydroMARK Breast Biopsy Site Marker implant (unless the subject was exited according to the medical records due to the implant being removed/explanted or subject death).
11022068|NCT04622683|Experimental|Control Group- Healthy, Lean Individuals|Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.
11022069|NCT04622683|Active Comparator|Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance|Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
11022070|NCT04622670|Experimental|Group I (yoga group)|Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over 5-10 minutes and receive a yoga manual and DVD during and after CRT.
11022071|NCT04622670|Active Comparator|Group II (wait list control)|Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
11022072|NCT04622657|Experimental|parkinson disease|Assessment
11022073|NCT04622644|Experimental|Single Arm|All patients perform StrokeWave exam, after NCCT and before CTA acquisition.
11022074|NCT04622631||PRRT positive|patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans
11022075|NCT04622631||PRRT negative|no response to PRRT treatment
11022076|NCT04622618|Active Comparator|G 300|The patients will receive 300 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
11022077|NCT04622618|Active Comparator|G 600|The patients will receive 600 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
11022078|NCT04622618|Active Comparator|G 900|The patients will receive 900 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
11022079|NCT04622605|Experimental|Treatment Group|Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent
11022080|NCT04622592|Experimental|Vaccine (15 µg/strain) adjuvanted with AS03|Treatment group 1: 15 µg/strain QVLP vaccine adjuvanted with AS03
11022081|NCT04622592|Experimental|Vaccine (15 µg/strain) adjuvanted with AS03 (half-dose)|Treatment group 2: 15 µg/strain QVLP vaccine adjuvanted with AS03 (half-dose)
11022082|NCT04622592|Experimental|Vaccine (30 µg/strain) adjuvanted with AS03|Treatment group 3: 30 µg/strain QVLP vaccine adjuvanted with AS03
11022083|NCT04622592|Experimental|Vaccine (30 µg/strain) adjuvanted with AS03 (half-dose)|Treatment group 4: 30 µg/strain QVLP vaccine adjuvanted with AS03 (half-dose)
11022084|NCT04622592|Active Comparator|Vaccine (30 µg/strain) unadjuvanted|Treatment group 5: 30 µg/strain QVLP vaccine unadjuvanted
11022085|NCT04622592|Active Comparator|Vaccine (60 µg/strain) Fluzone HD Quad|Treatment group 6: 60 µg/strain Fluzone HD Quad vaccine
11022086|NCT04622592|Experimental|Vaccine (45 µg/strain) adjuvanted with AS03|Treatment group 7: 45 µg/strain QVLP vaccine adjuvanted with AS03
11022087|NCT04622592|Experimental|Vaccine (45 µg/strain) adjuvanted with AS03 (half-dose)|Treatment group 8: 45 µg/strain QVLP vaccine adjuvanted with AS03 (half-dose)
11022088|NCT04622579|Experimental|lenalidomide combined with rituximab|Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
11022089|NCT04622566|Experimental|Lenvatinib and Pembrolizumab in Resectable mucosal Melanoma.|
11022090|NCT04622553|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
11022091|NCT04622540|Experimental|Experimental group|Application of external biliary drainage
11022092|NCT04622540|No Intervention|Control group|Conventional duct-to-duct anastomosis (with or without internal stent)
11022093|NCT04622527|Active Comparator|A = Virtual Reality paradigm A|Paradigm A with virtual reality headgear
11022094|NCT04622527|Active Comparator|B = Virtual Reality paradigm B|Paradigm B with virtual reality headgear
11022095|NCT04622527|Sham Comparator|C = Non-Virtual Reality paradigm A|Paradigm A without virtual reality headgear
11022096|NCT04622527|Sham Comparator|D = Non-Virtual Reality paradigm B|Paradigm B without virtual reality headgear
11022097|NCT04622514|Experimental|people-centered integrated care|
11022098|NCT04622514|Active Comparator|usual care|
11022099|NCT04622488|Active Comparator|Diclofenac Potassium|In the form of insitu gel can be applied as solution or suspension that undergoes gelation after administration.
11022100|NCT04622488|Experimental|Calcium Hydroxide|
11022101|NCT04622475|Experimental|Treatment|Fecal Microbiota Transplant (FMT) Capsule
11022102|NCT04622462||Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia|"No evidence of dysplasia
~Mild dysplasia
~Moderate dysplasia
~Severe dysplasia"
11022103|NCT04622449||Chronic liver disease with anemia|All patients with anemia as diagnosed by WHO criteria in patients with liver disease of any etiology.
11022104|NCT04622423||PDAC liver-MTS|Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.
11022105|NCT04622423||CRC liver-MTS|Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).
11022108|NCT04622397|Active Comparator|Group T (tranexamic acid),n=15|Group T: tranexamic acid 10 mg/kg will be injected locally
11022109|NCT04622397|Placebo Comparator|Group S (saline) (n=15)|Group S saline will be injected
11022110|NCT04622384||ICU patients|Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
11022111|NCT04622371|Experimental|moderate exercises group|Patients received 30 minutes of aerobic exercise at 40-60% of maximum heart rate
11022112|NCT04622371|Experimental|Light exercises group|Patients treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
11022113|NCT04622358|Experimental|AD-214-02/Rabeprazole|Period 1 : Test Drug(AD-214-02) Period 2 : Reference Drug(Rabeprazole)
11022114|NCT04622358|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole) Period 2 : Test Drug(AD-214-02)
11022115|NCT04622345|Experimental|VSJ-110 Solution|
11022116|NCT04622345|Placebo Comparator|Placebo Solution|
11022117|NCT04622332|Experimental|SIR1-365|SIR1-365 dose 1 daily for 14 days
11022118|NCT04622332|Placebo Comparator|Matching placebo|Matching placebo dose 1 daily for 14 days
11022119|NCT04622319|Experimental|Trastuzumab deruxtecan (T-DXd)|Participants who will be randomized to receive trastuzumab deruxtecan (T-DXd) at a starting dose of 5.4 mg/kg.
11022120|NCT04622319|Active Comparator|Trastuzumab ematansine (T-DM1)|Participants who will be randomized to receive trastuzumab ematansine (T-DM1) at a starting dose of 3.6 mg/kg.
11022121|NCT04622306|Active Comparator|Control|Commercial Natural Rubber Latex Male Condom
11022122|NCT04622306|Experimental|Polyurethane Condom A|Polyurethane Condom A (002)
11022123|NCT04622306|Experimental|Polyurethane Condom B|Polyurethane Condom B (001)
11022124|NCT04622293|Experimental|Solriamfetol|Those who are receiving solriamfetol will receive 37.5 mg, 75 mg, or 150 mg. Patients will begin at a 75 mg dose and then after three days titrate up or down as needed, determined by consultation visits with primary investigator. Solriamfetol will be taken orally.
11022125|NCT04622293|Placebo Comparator|Placebo|Those who are not receiving solriamfetol will receive the placebo drug, which will be encapsulated in matching capsules to reduce any bias or speculation with participants.
11022126|NCT04622267|Active Comparator|Standard suture|Standard antimicrobial suture (vicryl) - control arm
11022127|NCT04622267|Experimental|Barbed suture|Barbed suture type is STRATAFIX Symmetric PDS Plus Knotless Tissue
11022128|NCT04622254|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection.
11022129|NCT04622254|Experimental|MP: NT201 (incobotulinumtoxinA): LCL, Placebo: GFL/ HFL|Intramuscular injection.
11022130|NCT04622254|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection.
11022131|NCT04622254|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection.
11022132|NCT04622241|Experimental|Eave Tubes - Traditional House|Installation of eave tubes in traditional homes.
11022133|NCT04622241|Experimental|Eave Tubes - Modern House|Installation of eave tubes in modern homes.
11022134|NCT04622241|Experimental|Eave Ribbons - Traditional House|Installation of eave ribbons in traditional homes.
11022135|NCT04622241|Experimental|Eave Ribbons - Modern House|Installation of eave ribbons in modern homes.
11022136|NCT04622241|Experimental|Full House Screening - Traditional House|Installation of full house screening, includes screening eaves and windows, in traditional homes.
11022137|NCT04622241|Experimental|Full House Screening - Modern House|Installation of full house screening, includes screening eaves and windows, in modern homes.
11022138|NCT04622241|Experimental|Partial House Screening - Traditional House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
11022139|NCT04622241|Experimental|Partial House Screening - Modern House|Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
11022140|NCT04622241|No Intervention|Control - Traditional House|Control group with no intervention in traditional homes
11022141|NCT04622241|No Intervention|Control - Modern House|Control group with no intervention in modern homes.
11022142|NCT04622228|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
11022143|NCT04622215|Other|ICIQ questionnaire|
11022144|NCT04622202|Active Comparator|pregabalin|oral capsule pregabalin 150 mg.
11022145|NCT04622202|Placebo Comparator|multivitamin|oral multivitamin capsule.
11022146|NCT04622189|Experimental|Action observation training for the upper limb rehabilitation|Neurorehabilitation training for the upper limb using AOT consists of watching videos related to every day actions. The subjects will be asked to reproduce, as accurately as possible, the actions proposed by the system, that will record their execution. In order to keep high motivation and participation in activities, simple games of skill will also be created that will involve the patient on both the motor and cognitive side. The training program includes 250 videos of every day transitive and intransitive actions: 20 consecutive sessions of 1 hour, five times a week over four weeks.
11022147|NCT04622176||Patients with rectal cancer|Patients with rectal cancer will be included and asked to participate in the study where a MMUS will be used after resection to test diagnostic accuracy.
11022148|NCT04622163|Experimental|Secondary Mentor Plus Career Development Resources|Subjects will be assigned a secondary mentor for 6 months. Subjects will also receive career development resources.
11022149|NCT04622163|Other|Career Development Resources Alone|Subjects will not be assigned a secondary mentor. Subjects will receive career development resources only.
11022150|NCT04622150|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the experimental intervention, Customized Adherence Enhancement (CAE).
11022151|NCT04622150|Active Comparator|Enhanced Treatment as Usual (eTAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (eTAU).
11022152|NCT04622137|No Intervention|Arm sling only group (group S)|Participants used only arm sling for clavicula fracture
11022153|NCT04622137|Active Comparator|Arm sling with kinesiotaping therapy group (group K).|Participants used arm sling and the investigators applied kinesiotheraphy for clavicula fracture
11022154|NCT04622124|Placebo Comparator|Part 1 Single Ascending Dose (SAD) study|The single ascending dose trial set up 7 dose groups of 2.5, 5, 10, 20, 40, 60 and 80 mg. The 2.5 mg dose group was the exploratory part with open label, while the other dose groups were double-blind. 8 subjects were randomly enrolled in each dose group, 6 of whom received FCN-207 tablets and 2 of whom received placebo. This part of the study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic studies of single dose FCN-207 tablets in healthy volunteers.
11022155|NCT04622124|Experimental|Part 2 Food-effect study|Twelve subjects were enrolled and randomly divided into two groups. The subjects were given FCN-207 tablets after fasting and high-fat diet with double Cross experiment , and feces samples were collected for metabolism/excretion characteristics study.
11022156|NCT04622124|Placebo Comparator|Part 3 Multiple Ascending Dose (MAD) study|A total of 16 subjects were randomly assigned to each dose group for multiple dose study , including 12 who received FCN-207 tablets and 4 who received placebo for a 10-day administration cycle. The dosage of multiple administration was based on the results of single ascending dose study results , and the method of drug administration refers to the results of the food influence test.
11022157|NCT04622111|Experimental|CPL207280|"PART A: 8 cohorts are to receive single dose of IMP.Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.
~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
11022158|NCT04622111|Placebo Comparator|Placebo|PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
11022159|NCT04622111|Experimental|CPL207280 120 mg + Metformin 750 mg|1 cohort (total of 12 participants) are to receive single dose of IMP in fed and fasted state, IMP with metformin and metformin alone to assess the effect of food and metformin on bioavailability of CPL207280. There is to be one week wash-out between four treatments periods for this cohort.
11022160|NCT04622098||patients with SEL|"Any patient with detected sub-epithelial lesion during upper endoscopy either symptomatized or accidently discovered.
~Patients diagnosed by EUS, CT scan or surgically removed lesions."
11022161|NCT04622085|Experimental|ANIMERS Chiara LA|
11022162|NCT04622085|Active Comparator|JUVÉDERM VOLUMA®|
11022163|NCT04622072|Experimental|Experimental group|For dose escalation phase, subjects are enrolled for different doses of the experimental drug.
11022164|NCT04622059|Experimental|acoustic stimulation|Fetuses in the group A (n=105) received an acoustic stimulation
11022165|NCT04622059|No Intervention|no acoustic stimulation|Fetuses in the group B (n=105) no intervention was performed
11022166|NCT04622046|Experimental|ALXN2060|Participants will receive ALXN2060.
11022167|NCT04622033|Experimental|Brodalumab 210mg|
11022168|NCT04622020||Adult patients with chronic neck pain (> 3 months) following whiplash injury|Cervical plexus block with local anaesthesia followed by Cervical Plexus block with depot steroids
11022169|NCT04622007|Experimental|Tomi + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.
11022170|NCT04622007|Placebo Comparator|Pbo + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.
11022171|NCT04622007|Experimental|B1 Tomi + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.
11022172|NCT04622007|Placebo Comparator|Pbo + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.
11022173|NCT04621994|Active Comparator|Steri Strips Arm|
11022174|NCT04621994|Experimental|Dermabond Arm|
11022175|NCT04621981|Experimental|Sodium Bicarbonate Ringer's Solution|Intravenous drip, 500~1000ml per time. Infusion speed: 15ml/kg/h or according to guidelines or department routine.
11022176|NCT04621981|Active Comparator|Normal Saline|"Intravenous drip, 500~1000ml per time. Dosage depends on age、weight and symptoms.
~Infusion speed: According to the department process or clinician's decision."
11022177|NCT04621942|Experimental|Training group|12 women after mastectomy. Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Moreover, women from training group participated in rehabilitation gymnastics twice a week.
11022178|NCT04621942|Active Comparator|Control group|12 women after mastectomy. All women participated in rehabilitation gymnastics twice a week.
11022179|NCT04621929|Experimental|Allocated to intervention/treatment|Daily phentermine/topiramate x 18 months
11022180|NCT04621929|Active Comparator|Allocated to pragmatic control|Remain on their current regimen
11022181|NCT04621916|Active Comparator|Emicizumab + FVIII weekly|In addition to emicizumab prophylaxis,participants will receive non-prophylactic exposure to FVIII concentrates through weekly 50 IU/kg ±10% doses - the choice of FVIII concentrate is at the discretion of the PI.
11022182|NCT04621916|Active Comparator|Emicizumab only|Participants will only receive emicizumab prophylaxis.
11022183|NCT04621903|Experimental|Ayurveda|
11022184|NCT04621890|Experimental|AIM2DOSE|"The intervention consists of a Klue app using an Apple Watch. Users of the app must wear the watch on their dominant hand. The app constantly evaluates the movement of each participant's dominant hand by analyzing signals from the accelerometer and gyroscope in the device. By evaluating a real-time accelerometer and gyroscope data, the app can accurately identify repetitive movements that are consistent with eating. Dr Vleugel has collected over 1.5 million gesture events in a database to date. Her software detects nearly 100% of meals within the first five minutes with very few false positives. Furthermore, the app correctly distinguishes between sips and bites 98% of the time. This novel use of a commonly available health wearable has not previously been reported as an adjunct to diabetes care in youth."
11022208|NCT04621682|Active Comparator|Non technical skills and check list|10 hours of training in non-technical skills and checklists in high Fidelity simulation
11022209|NCT04621682|Active Comparator|check list|Control: 10 hours of standard training with checklists in high Fidelity simulation
11022210|NCT04621669|Experimental|digoxin, Rosuvastatin calcium,SHR3680|
11022185|NCT04621890|Experimental|COIN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary incentives for dosing insulin at mealtimes. Mealtimes will be defined based on hour of the day and the presence of a carbohydrate entry associated with the insulin bolus. Breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will reimburse youth up to $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus completed (maximum $1.50/day). We will offer the opportunity for youth to earn a bonus reimbursement of up to $5.00/week for weeks during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth up to $2.00 per week for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum $24.00). Therefore, maximum total incentive available is $210.
11022186|NCT04621890|No Intervention|Control|This group will engage have usual diabetes care without intervention. They will fill out all questionnaires, attend clinic visits and provide A1C samples at the same times as the participants in the other groups.
11022187|NCT04621877|Experimental|"Volunteer-delivered Behavioral Activation - Do More, Feel Better"|"Do More, Feel Better (DMFB) is a streamlined, simplified version of Behavioral Activation (BA) delivered by lay volunteers to depressed senior center clients."
11022188|NCT04621877|Active Comparator|Master's Level Clinician-delivered Behavioral Activation|Traditional Behavioral Activation (BA) delivered by master's level mental health clinicians
11022189|NCT04621851||Retrospective cohort|Patients who discontinued before the opening of this study will contribute to the retrospective cohort.
11022190|NCT04621851||Prospective cohort|Patients who will discontinue after it will contribute to the prospective cohort.
11022191|NCT04621851||Retrospective/Prospective cohort|Patients who discontinued before the opening of this study but will continue their discontinuation after it, will contribute to both cohorts.
11022192|NCT04621838|Experimental|Assigned intervention.|"Silicone Foam Dressing. Silicone Foam Lite.
~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silicone Foam dressing and Silicone Foam Lite Dressing."
11022193|NCT04621825|Experimental|Assigned intervention|"ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam.
~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam."
11022194|NCT04621799|Experimental|Fibrin Group|Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin
11022195|NCT04621786|Experimental|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
11022196|NCT04621773||PGS(Preimplantation Genetic Screening)|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure
11022197|NCT04621773||SP(spontaneous pregnancy )|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.
11022198|NCT04621760|Experimental|HIV Prevention DST Intervention|Participants in this arm will receive the HIV prevention DST intervention and will receive the intervention immediately before their provider visit.
11022199|NCT04621760|Active Comparator|Standard Counseling|Participants in this arm will receive usual care.
11022200|NCT04621747|Experimental|Study group|healthy volunteers aged 18-35, balanced sex ratio, all of them undergoing the same battery of psychophysical explorations.
11022201|NCT04621734|Active Comparator|Nasal bridle to secure feeding tube|The nasal bridle will be used to secure the nasoenteric feeding tube.
11022202|NCT04621734|Placebo Comparator|Adhesive Tape use to secure feeding tube|Adhesive tape will be used as standard of care to secure the nasoenteric feeding tube.
11022203|NCT04621721|Experimental|Intervention Group|The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
11022204|NCT04621721|Active Comparator|Attention Control Group|The Attention Control group will receive an educational intervention via a journal in which to record their clinic appointments, and standardized American Cancer Society pamphlets which have been adjusted to fit within the journal binding for easy reference. At each data collection encounter, the intervention research assistant will discuss the information in each pamphlet, allowing time for questions related to the material. The educational materials consist of 1) Emotions and Breast Cancer; 2) Body Image and Sexuality After Breast Cancer; 3) Follow up Care After Breast Cancer Treatment; 4) Nutrition and Cancer. Sessions last approximately 45-60 minutes and occur at the same intervals as the intervention group and will precede data collection. Attention Control group participants will receive telephone calls every other week which will entail a social visit and reminder of data collection/attention intervention appointments to further equalize contact.
11022205|NCT04621708|Experimental|Left DLPFC iTBS rTMS|
11022206|NCT04621695|Other|Rubber band ligation|Rubber band ligation is performed by a suction device that allows a rubber band to be applied at the base of the haemorrhoid via a proctoscope. Maximal suction force used is 40 mmHg. A maximum of 3-4 bands are used per session. This rubber band constricts the blood supply causing it to become ischaemic before being sloughed approximately 1-2 weeks later. The resultant fibrosis reduces any element of haemorrhoidal prolapse that may have been present. No sedation is required for this day-care procedure. Patients are asked to administer an enema 2 hours prior to the procedure.
11022207|NCT04621695|Other|Hemorrhoidectomy|"There are two main excisional procedures currently carried out: open (Milligan and Morgan) and closed (Ferguson). Both have the intention of excising the haemorrhoidal cushions. The procedure is performed under either general or spinal anaesthesia in a day-care setting.
~Patients were asked to administer an enema 2 hours prior to the procedure."
11022212|NCT04621656||Type 2 Diabetes|Individuals that have been previously diagnosed with Type 2 Diabetes. Those with Fasting Blood Glucose levels 126 mg/dL in two separate tests and/or HbA1C values greater than 6.5%. Individuals may take Metformin, SGLT2 inhibitors, of GLP-1 therapeutics. Not including those using Insulin therapeutics.
11022213|NCT04621656||Pre-Diabetes|Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
11022214|NCT04621656||Healthy|Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
11022215|NCT04621643|Experimental|digital cognitive behavioral therapy (dCBT-I)|
11022216|NCT04621643|Active Comparator|Patient education about sleep (PE)|
11022217|NCT04621630|Experimental|Single Dose|Single dose administration
11022218|NCT04621630|Experimental|Multiple Dose|Multiple dose administration
11022219|NCT04621630|Experimental|Solid Dose Comparison|Solid dose administartion
11022220|NCT04621617|Active Comparator|Albumin + Midodrine + SMT|Human albumin plus oral midodrine
11022221|NCT04621617|Active Comparator|Albumin + SMT|Human albumin plus placebo of midodrine
11022222|NCT04621617|Placebo Comparator|SMT|standard medical therapy plus placebo of midodrine
11022223|NCT04621604|Experimental|Patients|
11022224|NCT04621591|Experimental|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care EGD procedure performed using the Saneso 360° gastroscope. Immediately thereafter Patients will then have an EGD procedure using a standard Gastroscope (Olympus GIF 180) performed by a second endoscopist.
11022225|NCT04621578|Experimental|Transcutaneous electrical acupoint stimulation arm|Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.
11022226|NCT04621578|Sham Comparator|Sham stimulation arm|Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.
11022227|NCT04621565|Experimental|Hydrocortisone withholding group|Patients receive no hydrocortisone
11022228|NCT04621565|Active Comparator|Hydrocortisone group|Patients receive routine hydrocortisone
11022229|NCT04621539||Infected without an SMO|Defined as an acute infection not associated with admission to the intensive care unit (ICU), mechanical ventilation, or the use of vasopressors.
11022230|NCT04621539||Infected with an SMO|defined as an acute infection associated with intensive care unit (ICU) admission, mechanical ventilation, or vasopressor use.
11022231|NCT04621526|Active Comparator|dexmedetomidine- ketamine|patients will receive combination of ketamine 1.5mg/kg and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
11022232|NCT04621526|Active Comparator|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
11022233|NCT04621513|Experimental|Collaborative Care Model of TCM and WM|Traditional Chinese Medicine(TCM):laser acupuncture and massage education. Western Medicine (WM):intra-nasal corticosteroid with singulair
11022234|NCT04621513|Active Comparator|Western medicine|Western Medicine (WM):intra-nasal corticosteroid with singulair
11022235|NCT04621500|Other|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
11022236|NCT04621487|Active Comparator|concomitant|Concomitant therapy consists of 14 days pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg all twice daily.
11022237|NCT04621487|Active Comparator|tailored|Tailored therapy consists of 14 days antibiotic therapy according to H. Pylori strains antibiotic sensitivity test together with pantoprazole 40 mg twice daily.
11022238|NCT04621461|Placebo Comparator|Experimental Arm #1|Hydroxychloroquine, Azithromycin and Placebo
11022239|NCT04621461|Experimental|Experimental Arm #2|Hydroxychloroquine, Azithromycin, and Zinc sulfate
11022240|NCT04621448|Experimental|Immediate Start|The Immediate Start group will participate in the 12-week Moving Together program after completing the baseline assessment. Moving Together is a gentle, live-streaming, group movement program designed specifically for people with memory loss (PWML) and caregivers (CG) to do together. It is based on the in-person Preventing Loss of Independence through Exercise (PLIÉ) and Paired PLIÉ programs. The program combines physical movements to help maintain daily function with mindful body awareness exercises and social interactions to provide a comprehensive, multi-domain program.
11022241|NCT04621448|Experimental|Delayed Start|A Delayed Start group will be encouraged to continue with their usual daily activities during the first 12 weeks of the study and will begin the Moving Together program after completing the mid-point assessment.
11022242|NCT04621435|Experimental|Dosimetry population (Cohort 1)|PET imaging will begin 30 +/-10 minutes, 60 +/-15 minutes and 120 +/-20 minutes after injection. Contrast may be administered if clinically indicated.
11022243|NCT04621435|Experimental|Participants with metastatic disease (Cohort 2)|Participants with metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if clinically indicated.
11022244|NCT04621435|Experimental|Participants without metastatic disease (Cohort 3)|Participants without metastatic disease will have PET imaging 50-100 minutes after injection of 68Ga-FAP-2286. Contrast may be administered if if clinically indicated.
11022245|NCT04621409|Experimental|liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
11022246|NCT04621409|Placebo Comparator|Placebo|IV infusion of saline, approximately 5 hours
11022247|NCT04621396||Next Generation Cohort|We will follow the children from mothers who either have T2D, GDM, or are controls.
11022588|NCT04619251|Experimental|SRD part, active drug, extensive metabolizers|
11022248|NCT04621383|Experimental|whey protein plus collagen group|Participants received a dose of 30 grams of whey protein plus 20 grams of collagen seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
11022249|NCT04621383|Placebo Comparator|whey protein plus maltodextrin group|Participants received a dose of 30 grams of whey protein plus 20 grams of maltodextrin seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
11022250|NCT04621370|Active Comparator|Arm A|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy
~Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1
~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total
~Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
11022251|NCT04621370|Active Comparator|Arm B|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy
~Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1
~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles
~Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
11022252|NCT04621357|Experimental|Patient with intracerebral haemorrhage|Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
11022253|NCT04621331|Experimental|Roxadustat|Starting doses of 20, 50, 70 or 100 mg based on weight.
11022254|NCT04621318|Experimental|SB16|SB16 (proposed denosumab biosimilar)
11022255|NCT04621318|Active Comparator|EU Prolia|EU sourced Prolia (denosumab)
11022256|NCT04621318|Active Comparator|US Prolia|US sourced Prolia (denosumab)
11022257|NCT04621305|Placebo Comparator|group P (Placebo group)|Patients were assigned to group P (Placebo group) using a computer-generated random number table
11022258|NCT04621305|Experimental|group B (Bolus group)|Patients were assigned to group B (Bolus group) using a computer-generated random number table
11022259|NCT04621305|Experimental|group C (continuous infusion group)|Patients were assigned to group C (continuous infusion group) using a computer-generated random number table
11022260|NCT04621279||Mild Hypoxic Ischemic Encephaolpathy|"Infant ≥ 360/7 weeks with evidence of BOTH 1) perinatal event fetal acidosis and 2) encephalopathy on exam.
~Perinatal depression as defined by NICHD based on at least one of the following; pH <7.00 in a cord gas or Base deficit ≥15 mmol/L in a gas (arterial or venous) obtained at <60 min of age, Apgar score <5 at 10 minutes, or Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP).
~Mild encephalopathy, as defined by PRIME-study 1-6 hours after birth. At least 1 of 6 Sarnat criteria is scored as a mild, moderate, or severe abnormality, and Fewer than 3 of 6 Sarnat criteria are scored as a moderate or severe abnormality"
11022261|NCT04621266|Experimental|Home-based peer support intervention|Participants will receive intervention on top of standard usual care.
11022262|NCT04621266|No Intervention|Standard usual care|Participants will receive standard usual care.
11022263|NCT04621253|Active Comparator|Ciprofloxacin|Day 1: 750 mg ciprofloxacin capsule in the morning and evening Day 2: 750 mg ciprofloxacin capsule in the morning and evening Day 3: 750 mg ciprofloxacin capsule in the morning and evening Day 4: Study day, 750 mg ciprofloxacin 1h prior to 1000 mg metamizole.
11022264|NCT04621253|Active Comparator|Fluconazole|Day 1: 400 mg fluconazole in the morning, placebo capsule in the evening Day 2: 200 mg fluconazole in the morning, placebo capsule in the evening Day 3: 200 mg fluconazole in the morning, placebo capsule in the evening Day 4: Study day, 200 mg fluconazole 1h prior to 1000 mg metamizole.
11022265|NCT04621253|Placebo Comparator|Placebo|Day 1: placebo capsule in the morning and evening Day 2: placebo capsule in the morning and evening Day 3: placebo capsule in the morning and evening Day 4: Study day, placebo capsule 1h prior to 1000 mg metamizole.
11022266|NCT04621240|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
11022267|NCT04621227|Other|Period 1|Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.
11022268|NCT04621214||Group-A|Group A were performing their duties on visual triage
11022269|NCT04621214||Group-B|Group A were performing their duties on Audio-visual triage
11022270|NCT04621188|Experimental|Lorlatinib|100 mg once daily
11022271|NCT04621175|Active Comparator|EAA+W & Carbohydrate: Balance (BAL) first, then Deficit (DEF)|Participants will consume an essential amino acid plus whey (EAA+W) beverage with added Carbohydrate during energy balance (BAL) first, then again during energy deficit (DEF).
11022589|NCT04619251|Placebo Comparator|SRD part, placebo|
11022272|NCT04621175|Active Comparator|EAA+W & Carbohydrate: DEF first, then BAL|Participants will consume an essential amino acid plus whey beverage with added Carbohydrate during energy deficit first, then again during energy balance.
11022273|NCT04621175|Active Comparator|EAA+W & EAA: BAL first, then DEF|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy balance first, then again during energy deficit.
11022274|NCT04621175|Active Comparator|EAA+W & EAA: DEF first, then BAL|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy deficit first, then again during energy balance.
11022275|NCT04621162|Experimental|Positive Expectations (initial)|
11022276|NCT04621162|Experimental|Negative Expectations (initial)|
11022277|NCT04621162|Placebo Comparator|Neutral Expectations (initial)|
11022278|NCT04621162|Experimental|Positive Expectations (during intervention)|
11022279|NCT04621162|Experimental|Negative Expectations (during intervention)|
11022280|NCT04621162|Placebo Comparator|Neutral Expectations (during intervention)|
11022281|NCT04621149|Placebo Comparator|placebo|1 liter of filtered water
11022282|NCT04621149|Active Comparator|chlorine dioxide aqueous solution (AS)|1 liter of filtered water with AS
11022283|NCT04621149|Active Comparator|placebo with zinc acetate (ZA)|1 liter of filtered water with ZA
11022284|NCT04621149|Active Comparator|AS with ZA|1 liter of filtered water with AS and ZA
11022285|NCT04621149|Active Comparator|placebo with famotidine, lactoferrin and green tea extract (FLG)|1 liter of filtered water with FLG
11022286|NCT04621149|Active Comparator|AS with FLG|1 liter of filtered water with AS and FLG
11022287|NCT04621149|Active Comparator|placebo with ZA and FLG|1 liter of filtered water with ZA and FLG
11022288|NCT04621149|Active Comparator|AS with ZA and FLG|1 liter of filtered water with AS, ZA, and FLG
11022289|NCT04621136|Experimental|Ripasudil eye drops|Ripasudil eye drops
11022290|NCT04621123|Experimental|Experimental group|Subjects randomized to convalescent anti-SARS-CoV-2 MBT plasma plus SMT will receive one infusion of 200 to 250 ml of ABO-compatible convalescent plasma obtained from a convalescent donor.
11022291|NCT04621123|Placebo Comparator|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 250 ml of sterile saline solution 0.9%.
11022292|NCT04621110|Experimental|intranasal dexmedetomidine and fentanyl|Dexmedetomidine (precedex®) and fentanyl will be administered by intranasal routes, seeing if both sedative (dexmedetomidine) and analgesic (fentanyl) can give enough sedation for procedure
11022293|NCT04621110|Active Comparator|intravenous ketamine and midazolam|ketamine (ketalar®) and midazolam intravenous will be using to compare the efficiency of intranasal drugs
11022294|NCT04621097|Experimental|pulsed electro magnetic field|30 patients will receive the physical therapy program in form of low frequency pulsed electro magnetic field application. with frequency 15hz, and low intensity with flux density of 20 Gauss (2mT), in pulse duration 200 usec , pulsed rectangular pulses for 60 min is applied to the dorsal surface of lower leg , ankle and foot in addition to their regular medications prescribed , 3 times per week for 8 week
11022295|NCT04621097|Experimental|Treadmilltraining|"In this group, 30 patient will receive the physical therapy program in form of supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
~At first , a 5 minutes- warm up period will be allowed, it will include stretching exercises for calf muscles , hamstrings and quadriceps (i.e. each for at least 10 -15 seconds) . Patients should start with walking on the treadmill at a comfortable speed, and should not stop at the onset of leg pain but instead , he/she would continue until moderate pain is reached. At this point, he/she has to rest until pain completely subsides, then walking is resumed again . The intensity of exercise will be determined by claudication pain scale, and should not exceed the score of 4 on this scale. The exercise can be progressed if the patient can walk continuously for 10 minutes without the need to stop."
11022296|NCT04621097|Placebo Comparator|medications|It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
11022297|NCT04621071|Experimental|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
11022298|NCT04621071|Placebo Comparator|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Patients will take two capsules a day (one closed capsule to swallow and one open capsule mixed with maple syrup) from Day 1 to Day 10 and one closed capsule to swallow from Day 11 to Day 25.They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
11022299|NCT04621058|Experimental|D VITAMIN GROUP|"The administration of vitamin D will be carried out using the following treatment scheme:
~If vitamin D deficiency (< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (< 40 ng/ml): treatment with 1 capsule of 0.266 mg
~Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study.
~In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges."
11022300|NCT04621058|Placebo Comparator|PLACEBO GROUP|The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.
11022301|NCT04621045|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
11022335|NCT04620798|No Intervention|Control (Delayed)|Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
11022590|NCT04619251|Experimental|DDI part, poor metabolizers|DDI part will be initiated after SRD part
11022302|NCT04621045|Active Comparator|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
11022303|NCT04621032||OSA +|Patients with visceral obesity and newly diagnosed Obstructive Sleep Apnea (during the study)
11022304|NCT04621032||OSA -|Patients with visceral obesity in whom Obstructive Sleep Apnea diagnosis have been excluded (during the study)
11022305|NCT04621019|Experimental|Non-invasive lipolysis and circumference reduction of the abdomen|The treatment administration phase consists of four (4) treatment visits, delivered at least 1 week apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.
11022306|NCT04621006||UC group|Patients with active ulcerative colitis
11022307|NCT04620993||Group 1: pregnant women with pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy and have pelvic girdle pain.
11022308|NCT04620993||Group 2:pregnant women without pelvic girdle pain|This group will consist of pregnant women who are in the 2nd or 3rd trimester of pregnancy but have not pelvic girdle pain.
11022309|NCT04620993||Group 3: healthy women|This group will consist of healthy women who have not been pregnant.
11022310|NCT04620980||Cases|"Participants will be assessed for disease progression: Hoehn and Yahr stadium, MDS-UPDRS part III, MoCA test, no motor symptoms, therapy and LID occurrence.
~Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.
~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
11022311|NCT04620980||controls|"Participants will be assessed for the presence of disease. Participants will be subjected to peripheral blood sampling for the purification of DNA, RNA, plasma and serum.
~DNA of each participant will be analysed by targeted resequencing of a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID)."
11022312|NCT04620967|Experimental|Iasp-Fiasp|First period: Insulin pump with Iasp Second period: Insulin pump with Fiasp
11022313|NCT04620967|Experimental|Fiasp-Iasp|First period: Insulin pump with Fiasp Second period: Insulin pump with Iasp
11022314|NCT04620954|Experimental|Intervention|
11022315|NCT04620928|Experimental|Concept Retrieval|Patients will be given behavioral intervention, and their brain activity recorded.
11022316|NCT04620915|Experimental|High-level construal|"Participants will be sent messages asking them to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014)."
11022317|NCT04620915|Experimental|Effortful down-regulation of craving for cigarettes|"Participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences)."
11022318|NCT04620915|Experimental|Up-regulation of goal energization|Participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking.
11022319|NCT04620915|Placebo Comparator|Treatment-as-usual control|Participants will be sent generic messages through NCI's text messaging cessation program, SmokefreeTXT (National Cancer Institute, 2013).
11022320|NCT04620902||Dementia|Dementia
11022321|NCT04620902||MCI|Mild cognitive impairment
11022322|NCT04620902||SCD|Subjective cognitive decline
11022323|NCT04620902||HC|Cognitively healthy control
11022324|NCT04620889||PVP|Bypass or reconstruction of diseased or occluded blood vessels
11022325|NCT04620889||AV Access|Arteriovenous shunting for blood access.
11022326|NCT04620876|Experimental|Bimodal and coaxial high resolution imaging of the retina|Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT)
11022327|NCT04620863|Experimental|tDCS group|Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
11022328|NCT04620863|Sham Comparator|Sham Group|The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
11022329|NCT04620850|Experimental|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time) Acupressure at below knee the point ai locate about4 finger spcae below patella on the lateral side of tibia bone
11022330|NCT04620850|No Intervention|No acupressure|Standard post-operative care
11022331|NCT04620837|Experimental|Treatment Arm|Tislelizumab：200mg Q3W IV Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.
11022332|NCT04620824||Trial Participants|"Overall Description of Trial Participants: The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. No change in the surgical procedure or recruiting results from this study and the use of the samples.
~Inclusion Criteria: The samples included in this project will be from patients undergoing elective surgery in the HPB Unit of the Leicester General Hospital. The criteria for inclusion of spleen samples from radical surgery are adult age and presence of splenic tissue in the discarded material after hepato-pancreato-biliary surgery.
~Exclusion Criteria: The main exclusion criterion is acute invasive bacterial and viral infection, but these patients are automatically excluded from major surgery. Vulnerable groups will not be recruited."
11022333|NCT04620811|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive up to 18 monthly doses (3mg/kg) of lirentelimab (AK002)
11022334|NCT04620798|Experimental|Intervention|Participants will be given their results of their antibody test immediately (within 24 hours) and will be followed and surveyed to see if having this knowledge changes their engagement with SARS-CoV-2 prevention behaviors.
11022377|NCT04620551||PD with DBS|Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
11022336|NCT04620785|Experimental|methylene blue/IPL|"will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.
~This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions."
11022337|NCT04620785|Experimental|IPL|will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.
11022338|NCT04620785|Placebo Comparator|saline|will undergo intralesional saline.
11022339|NCT04620772|Experimental|Cyclophosphamide arm|Participants randomized to the cyclophosphamide arm will be administered 750 mg/m2 body weight (rounded off to the nearest 50 mg above the calculated value) of cyclophosphamide diluted in normal saline every month (Total 6 months) along with equal dose of mesna 50% administered prior to infusion and 50% after the infusion of cyclophosphamide
11022340|NCT04620772|Other|Placebo arm|Participants randomized to the placebo group will be given similar quantity of normal saline and mesna as described above
11022341|NCT04620759|Experimental|Psilocybin Treatment|Participants will be administered 25mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.
11022342|NCT04620759|Placebo Comparator|Placebo|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.
11022343|NCT04620746|Active Comparator|Skin Testing Arm|These subjects with reported PCN allergy and reported low risk responses will receive skin testing followed by oral challenge
11022344|NCT04620746|Active Comparator|Direct Oral Challenge|These subjects with reported PCN allergy and low risk responses will bypass skin testing and have direct oral challenge with amoxicillin
11022345|NCT04620733|Experimental|Seladelpar 10 mg|
11022346|NCT04620733|Placebo Comparator|Placebo|
11022347|NCT04620733|Experimental|Seladelpar 5 mg|
11022348|NCT04620720|No Intervention|control group|routuine analgesics wil be given
11022349|NCT04620720|Experimental|intervention group|patient will receive cap gabapentin 1200 mg 2 hours before surgery
11022350|NCT04620707|Experimental|RGS based therapy|
11022351|NCT04620707|Active Comparator|Treatment as usual|
11022352|NCT04620694||Radial artery cannulation|Patients whom radial artery was cannulated at the beginning of the surgery.
11022353|NCT04620694||Aortic cannulation (brachial or femoral artery)|"Patients whom femoral or brachial artery was cannulated at the beginning of the surgery.
~Active comparator"
11022354|NCT04620681|Experimental|Phase 1 Dose Level 1|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10^6 CD4 T Cells/kg
11022355|NCT04620681|Experimental|Phase 1 Dose Level 2|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10^7 CD4 T Cells/kg
11022356|NCT04620681|Experimental|Phase 1 Dose Level 3|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10^7 CD4 T Cells/kg
11022357|NCT04620681|Experimental|Phase 2 -Treatment at Maximum Tolerated Dose (MTD)|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.
11022358|NCT04620668|Experimental|Treatment Group (Wysa)|
11022359|NCT04620668|No Intervention|Control Group|
11022360|NCT04620655|Experimental|RD13-01 cell infusion|
11022361|NCT04620642||Registry group|Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
11022362|NCT04620629||control group|Late premature and term babies without any disease
11022363|NCT04620629||probiotic group|Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.
11022364|NCT04620629||antibiotic group|Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.
11022365|NCT04620616|Experimental|Product Use Sequence 1|"Products use sequence:
~Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS"
11022366|NCT04620616|Experimental|Product Use Sequence 2|"Products use sequence:
~Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor"
11022367|NCT04620616|Experimental|Product Use Sequence 3|"Products use sequence:
~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor"
11022368|NCT04620616|Experimental|Product Use Sequence 4|"Products use sequence:
~Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor"
11022369|NCT04620616|Experimental|Product Use Sequence 5|"Products use sequence:
~Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor"
11022370|NCT04620616|Experimental|Product Use Sequence 6|"Products use sequence:
~Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS"
11022371|NCT04620603|Experimental|LDR + Nivolumab|Participants will receive one treatment of brachytherapy on treatment day 1 (LDRD1). After a minimum of 7 days but no more than 30 days to allow antigenic release, participants will then begin immunotherapy treatment with Nivolumab at the standard FDA approved dose of 480mg given on the first day of every 28 day cycle. Participants can receive up to 12 doses of Nivolumab.
11022372|NCT04620590|Experimental|Treatment Arm|Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
11022373|NCT04620577||Antibiotic group|Infusion of ceftriaxone sodium needle (2g, solvent 100ml normal saline) within 1h before and 12h after PTCD.
11022374|NCT04620577||No-antibiotic group|Infusion of Normal saline within 1h before and 12h after PTCD.
11022375|NCT04620564||Patients|
11022376|NCT04620564||Relatives|
11022591|NCT04619238||no urinary incontinence|patients without UI
11022378|NCT04620538||Controls|Healthy Controls with or without risk factors for Chronic Liver Disease (i.e. patients referred due to concerns re: liver disease but found to have no evidence of chronic liver disease following assessment)
11022379|NCT04620538||Fibrosis|Patients with evidence of Liver Fibrosis on the basis of current diagnostic techniques / expert opinion.
11022380|NCT04620538||Compensated Cirrhosis|Patients with evidence of Compensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
11022381|NCT04620538||Decompensated Cirrhosis|Patients with evidence of Decompensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
11022382|NCT04620538||Hepatocellular Carcinoma|Patients with evidence of Hepatocellular Carcinoma on the basis of current diagnostic techniques / expert opinion.
11022383|NCT04620525||Participants with the relevant condition|Participants with the relevant condition
11022384|NCT04620525||Healthy controls|Healthy controls
11022385|NCT04620499|Experimental|Experimental|EEG-guided drug prescription
11022386|NCT04620499|No Intervention|Control|Will receive EEG, but drugs will be prescribed as usual
11022387|NCT04620486|Experimental|Active Best Practice Alert|Care providers taking care of these patients will receive a Best Practice Alert (BPA) in the electronic medical record (EMR) one hour before an antibiotic expires with no subsequent doses ordered. The BPA will prompt the care provider to re-order the antibiotic and give information on recommended dosage and frequency based on indication and patient characteristics.
11022388|NCT04620486|No Intervention|Inactive Best Practice Alert|The Best Practice Alert described in the Experimental Arm will not be active for patients in this arm. Care providers will proceed with usual care.
11022389|NCT04620473|Experimental|Anlotinib+Capeox|neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
11022390|NCT04620473|Active Comparator|Capeox|neoadjuvant treatment with Capeox
11022391|NCT04620460|Active Comparator|LIFUS-left DLPFC|20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.
11022392|NCT04620460|Sham Comparator|LIFUS-SHAM|20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.
11022393|NCT04620447|Active Comparator|Mindfulness Meditation|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 7
~Final number of participants: 118
~Mindfulness Meditation intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
11022394|NCT04620447|Active Comparator|Cognitive Behavior Therapy|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 19
~Final number of participants: 102
~Cognitive Behavior Therapy intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
11022395|NCT04620447|Active Comparator|Novel 'Intelligent Virtual Reality Therapy System' (IVRTS)|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 10
~Final number of participants: 115
~Novel 'Intelligent Virtual Reality Therapy System' (IVRTS) was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
11022396|NCT04620447|No Intervention|Control Group|"A 7-week intervention course (In this case, no intervention) was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.
~Number of Participants: 125
~Dropouts: 0
~Final number of participants: 125
~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
11022397|NCT04620434||patient|39 patients who are planning surgeries that require general anesthesia and tracheal intubation
11022398|NCT04620421|Experimental|Training group (Rhythm-based multitask training)|Randomized to participate in the rhythm-based multitask training intervention
11022399|NCT04620421|No Intervention|Control group (Continuation of regular activity schedule)|Randomized to the control group who is encouraged to continue their regular everyday routines, which may include self-administrated training exercises.
11022400|NCT04620408|Experimental|Group A|The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.
11022401|NCT04620408|Experimental|Group B|Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.
11022402|NCT04620395|No Intervention|Joint tap|Joint tap and aspiration of synovial fluid
11022403|NCT04620395|Experimental|Punch biopsy|Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane
11022592|NCT04619238||stress urinary incontinence|patients with SUI
11022404|NCT04620382|Active Comparator|Midodrine|Single oral dose of midodrine (5-10mg) combined with sham abdominal compression
11022405|NCT04620382|Experimental|Abdominal Compression|Abdominal compression (up to 40 mmHg) combined with a placebo pill
11022406|NCT04620369|Experimental|Arm A (rose geranium in sesame oil nasal spray)|Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
11022407|NCT04620369|Placebo Comparator|Arm B (isotonic nasal saline)|Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.
11022408|NCT04620356|Experimental|DryNites arm|"Participants in this arm use DryNites every night for 4 weeks (run-in period), an additional 4 weeks (intervention core trial period), and an optional additional 4 weeks (extension period). All participants in this arm also receive absorbent bad mats to use every night."
11022409|NCT04620356|No Intervention|No Pants arm|"Participants in this arm use DryNites every night for 4 weeks only during the initial run-in period. Thereafter, participants in this arm do not use DryNites during the 4 week intervention core trial period or the optional additional 4 weeks extension period. All participants in this arm also receive absorbent bad mats to use every night."
11022410|NCT04620343|Active Comparator|Phase 1, Group 1|"Patients are provided with basic information and breathing advice with biofeedback (IBA).
~This is the reference treatment against which the other methods will be measured."
11022411|NCT04620343|Experimental|Phase 1, Group 2|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT)
11022412|NCT04620343|Experimental|Phase 1, Group 3|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with speech therapy
11022413|NCT04620343|Experimental|Phase 1, Group 4|Patients are provided with basic information and breathing advice with biofeedback (IBA) and treated with inspiratory muscle training (IMT) and speech therapy
11022414|NCT04620343|No Intervention|Phase 2, Group 1|Groups 2,3,4 in Phase 1 Wait for therapy effect
11022415|NCT04620343|Experimental|Phase 2, Group 2|If patients from Phase 1, Group 1 (reference treatment) have unchanged CLE-scoring, they are treated with inspiratory muscle training (IMT) and speech therapy.
11022416|NCT04620343|Experimental|Phase 3, Group 1|Treated with Surgery, supraglottoplasty - full procedure
11022417|NCT04620343|Experimental|Phase 3, Group 2|Treated with Surgery, supraglottoplasty mini-invasive procedure
11022418|NCT04620343|No Intervention|Phase3, Group 3|Non-surgery control group
11022419|NCT04620330|Experimental|Part A|To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the expansion phase (Part B).
11022420|NCT04620330|Experimental|Part B|To determine the efficacy of the optimal regimen identified from Part A
11022421|NCT04620317|Active Comparator|Synbiotic|The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.
11022422|NCT04620317|Placebo Comparator|Placebo|Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.
11022423|NCT04620304|Experimental|Cohort A|receive 4 weekly fixed doses of UB-421 SC at 250 mg
11022424|NCT04620304|Experimental|Cohort B|receive 4 weekly fixed doses of UB-421 SC at 500 mg
11022425|NCT04620304|Experimental|Cohort C|receive 4 weekly fixed doses of UB-421 SC at 700 mg
11022426|NCT04620291|Experimental|Cohort A|250 mg UB-421 SC: ART-treated subjects
11022427|NCT04620291|Experimental|Cohort B|500 mg UB-421 SC: ART-treated subjects
11022428|NCT04620291|Experimental|Cohort C|700 mg UB-421 SC: ART-treated subjects
11022429|NCT04620291|Experimental|Cohort D|500 mg UB-421 SC: Treatment naive subjects
11022430|NCT04620291|Experimental|Cohort E|700 mg UB-421 SC: Treatment naive subjects
11022431|NCT04620265|Experimental|Treadmill training 100%|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
11022432|NCT04620265|Experimental|Treadmill training 75%|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
11022433|NCT04620265|Experimental|Treadmill training 50%|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
11022434|NCT04620265|Experimental|Treadmill training 25%|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
11022435|NCT04620265|Sham Comparator|Conventional program|This group received the conventional exercise program only.
11022436|NCT04620252|Experimental|Chewing calcium supplements|"Participants will be given one of 4 different treatments to chew: a negative control group and 3 calcium supplements with different calcium compositions.
~Participants will be randomized to determine the sequence of exposure to the different treatments."
11022437|NCT04620252|Experimental|Fluoride rinse|Participants will rinse with an over the counter sodium fluoride rinse for 1 min, either alone or after having chewed with the calcium supplement providing the maximum calcium release in arm 1.
11022438|NCT04620239|Experimental|TOOKAD VTP|"Patients entered in the study will undergo an induction treatment phase consisting of 1-3 TOOKAD VTP treatments provided 4 weeks (28 +/-3 days) apart.
~Patients achieving CR at the induction treatment phase will be allowed into the maintenance treatment phase of the study. The patients will be followed over a period of 12 months post PRE, to assess the duration of response and its safety, and to provide planned maintenance treatment. Repeated maintenance VTP treatments during this period will be provided for patients who show evidence of tumor recurrence that is deemed treatable as defined by these criteria: Up to 2 low-grade tumors with the largest tumor (index tumor) <15 mm in diameter, in up to 2 anatomical locations in the calyces, renal pelvis or the ureter (ureter involvement should be in one anatomical location with no more than 20 mm of contiguous ureteral length)."
11022439|NCT04620226|No Intervention|Conventional Serum Testing|Participants will be screened by conventional HCV antibody (anti-HCV) serology and if screen positive, a second sample will be collected and tested for HCV RNA using a standard commercial assay.
11022440|NCT04620226|Experimental|Rapid Point-of-Care Testing|Participants will be screened using the OraQuick® Rapid Anti-HCV Point-of-Care Test (OraSure) and if screen positive, an additional whole blood sample will be collected and tested for HCV RNA using Xpert® HCV RNA (Cepheid) point-of-care testing and confirmed using a standard commercial assay.
11022441|NCT04620213|Experimental|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
11022442|NCT04620213|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
11022443|NCT04620200|Experimental|ARM A|2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care
11022444|NCT04620200|Experimental|ARM B|2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
11022445|NCT04620187|Experimental|Standard of Care + T-DM1 in HER2-Positive Salivary Gland Cancer|"Participants will undergo standard of care surgery followed by standard of care radiation and chemotherapy with the addition of T-DM1.
~Study cycles are 21 days (3 weeks):
~Participants will be given the study treatment T-DM1 at a predetermined dose (3.6 mg/kg) intravenously once (1x) every 3 weeks for up to 52 weeks (or about 1 year).
~Participants will be given standard of care radiation and chemotherapy
~Radiation will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1
~Chemotherapy (cisplatin 40 mg/m2 intravenously or carboplatin AUC 2 intravenously) will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, and Cycle 3 Day 1
~Participants will be followed for 3 years."
11022446|NCT04620174|Other|Custom-made zirconia crowns Group|Ten decayed primary molars will be restored with custom-made zirconia crowns.
11022447|NCT04620174|Other|Prefabricated zirconia crowns Group|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
11022448|NCT04620174|Other|Control Group|Twenty intact contralateral teeth will be evaluated as the controls (10 molars will be the controls for custom-made ZrCs and 10 molars will be the controls for prefabricated ZrCs).
11022449|NCT04620161|Experimental|Pradigastat Tablets 20mg|The patients in this arm will receive one tablet a day of Pradigastat 20mg and one tablet a day of Pradigastat 40mg matching placebo
11022450|NCT04620161|Experimental|Pradigastat Tablets 40mg|The patients in this arm will receive one tablet a day of Pradigastat 40mg and one tablet a day of Pradigastat 20mg matching placebo
11022451|NCT04620161|Placebo Comparator|Placebo|The patients in this arm will receive one tablet a day of Pradigastat 20mg matching placebo and one tablet a day of Pradigastat 40mg matching placebo
11022452|NCT04620148|Experimental|TAK-242|Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
11022453|NCT04620148|Placebo Comparator|Placebo|Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days
11022454|NCT04620135|Experimental|Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle|1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.
11022455|NCT04620135|Active Comparator|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|1 drop ripasudil twice dairy in the morning and evening in each eye.
11022456|NCT04620122|Experimental|intervention group|Progressive Muscle Relaxation Training and Music Therapy are applied to the intervention group.
11022457|NCT04620122|No Intervention|control group|No intervention is applied to the control group.
11022458|NCT04620109|Placebo Comparator|SDE Placebo|Subjects will receive placebo (drops without drug).
11022459|NCT04620109|Active Comparator|SDE 0.03 mg/eye|Actual dose is 0.03 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 0.5 mg/mL for 1 time.
11022460|NCT04620109|Active Comparator|SDE 0.06 mg/eye|Actual dose is 0.06 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 1.0 mg/mL for 1 time.
11022461|NCT04620109|Active Comparator|SDE 0.12 mg/eye|Actual dose is 0.12 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 2.0 mg/mL for 1 time.
11022462|NCT04620109|Active Comparator|SDE 0.24 mg/eye|Actual dose is 0.24 mg/eye by 60μL KDR2-2 eyedrops of a concentration of 4 mg/mL for 1 time.
11022463|NCT04620109|Active Comparator|RDE 0.06 mg/eye|The actual dosage is 0.06 mg/eye given 4 times a day for a maximum daily dosage of 0.24mg (60μL KDR2-2 eyedrops concentration of 1.0 mg/mL), which will continues for 6 days plus 1 administration of 0.06 mg/eye in the morning of Day 7. That cohort only started after safety proof from SDE 0.24 mg/eye cohort.
11022464|NCT04620109|Active Comparator|RDE 0.12 mg/eye|The actual dosage is 0.12 mg/eye given 4 times a day for a maximum daily dosage of 0.48mg (60μL KDR2-2 eyedrops concentration of 2.0 mg/mL), which will continues for 6 days plus 1 administration of 0.12 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
11022465|NCT04620109|Active Comparator|RDE 0.24 mg/eye|The actual dosage is 0.24 mg/eye given 4 times a day for a maximum daily dosage of 0.96mg (60μL KDR2-2 eyedrops concentration of 4.0 mg/mL), which will continues for 6 days plus 1 administration of 0.24 mg/eye in the morning of Day 7. That cohort might be optional based on emerging data from this study.
11022466|NCT04620109|Placebo Comparator|RDE Placebo|Subjects will receive placebo (drops without drug).
11022467|NCT04620083|No Intervention|Control Group|For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week.
11022468|NCT04620083|Experimental|Experimental 3-day Normal Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 3 days per week.
11022469|NCT04620083|Experimental|Experimental 5-day Intensive Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 5 days per week. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.
11022470|NCT04620070|No Intervention|Conventional|In the Netherlands, out-of-hospital cardiac arrest (OHCA) is managed by paramedics. In this study, in the conventional arm, OHCA is managed by a physician of the Helicopter Emergency Medical Services (HEMS), but without the possibility of prehospital ECPR.
11022593|NCT04619238||overactive bladder|patients with OAB
11022471|NCT04620070|Experimental|Intervention group|OHCA managed by the physician of the HEMS team, but with the possibility of prehospital ECPR.
11022472|NCT04620057|Experimental|Butyrate + standard care for pediatric obesity|standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)
11022473|NCT04620057|Placebo Comparator|placebo + standard care for pediatric obesity|standard care for pediatric obesity + placebo (cornstarch)
11022474|NCT04620044|Experimental|Kaledo Game|Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
11022475|NCT04620044|Experimental|Education|"The students in the training group were trained for 20 minutes once a week for 12 weeks. Training subjects were prepared in line with health belief model components.
~The following subjects were included in the training content. What is obesity?Risk factors for obesity, Characteristics of obese individuals, What is a healthy diet?Relationship between unhealthy nutrition and obesity, The consequences of unhealthy diet Health problems caused by obesity, What should be done to prevent and control obesity. How should nutrition be to lose weight? Positive results which show up with weight loss, Barriers to a healthy diet, Ways to reduce and eliminate barriers How to take action to lose weight?, Benefits of weight loss, Success stories in the fight against obesity, How are eating habits changed?, How can we achieve self-efficacy to change eating habits?"
11022476|NCT04620044|Experimental|Control|There was no intervention in the control group.
11022477|NCT04620031|Experimental|HSK3486|
11022478|NCT04620031|Active Comparator|Propofol|
11022479|NCT04620018|Active Comparator|Pre and post op Antibiotic|subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
11022480|NCT04620018|Active Comparator|Pre-op antibiotic|subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery)
11022481|NCT04620018|Active Comparator|Post-op antibiotic|subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
11022482|NCT04620005||ECMO|The first group will include practitioners who work in intensive care unit with ECMO services
11022483|NCT04620005||Non-ECMO|The second group will include practitioners who work in non-ECMO inventive care unit
11022484|NCT04619979||Spinal anesthesia group|
11022485|NCT04619979||General anesthesia group|
11022486|NCT04619953|Active Comparator|Postural Stability group (PSg)|The Postural Stability group (PSg) will perform 30 minutes of conventional neuromotor rehabilitation and 20 minutes of dynamic postural stability training.
11022487|NCT04619953|Active Comparator|Cognitive-Motor group (CMg)|The Cognitive-Motor group (CMg) performed 30 minutes of conventional neuromotor rehabilitation and 20 minutes of cognitive-motor training.
11022488|NCT04619940|Experimental|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
11022489|NCT04619940|Active Comparator|Standard goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
11022490|NCT04619927|Experimental|Intervention group|The intervention includes testing of patients for carriage of the CYP2C19*2 and *3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
11022491|NCT04619927|Active Comparator|Comparison group|The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19*2 and *3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.
11022492|NCT04619914|Experimental|Group A (clomiphene citrate & estradiol group)|included 35 anovulatory PCO patients who received clomiphene citrate (Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14
11022493|NCT04619914|Experimental|Group B (Letrozole group)|included 35 anovulatory PCO patients who received letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 5 mg daily from cycle day 3 to day 7.
11022494|NCT04619901||Parents only|
11022495|NCT04619901||Children and Parents|
11022496|NCT04619888||HeartLogic cohort|Patients implanted with a defibrillator enabling HeartLogic
11022497|NCT04619875|Other|Lactulose|
11022498|NCT04619875|Other|KB5|
11022499|NCT04619875|Other|SG1|
11022500|NCT04619862|Experimental|Medication|"Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.
~The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day."
11022501|NCT04619862|Placebo Comparator|Placebo|Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.
11022502|NCT04619849|Experimental|palmaris longus and carpal tunnel|EMG measurements of median and ulnar nerves will be made in patients with palmaris longus muscle.
11022503|NCT04619836||segmentation type 2 diabetes patitents|Those type 2 diabetes patients, who have segmenteted for four groups to organinize cervices and self care
11022504|NCT04619836||Non-segmentation type 2 diabetes patients|Those type 2 diabetes patiets who have not segementated
11022505|NCT04619836||Segmentation substance abuse clients|Those type substance abuse clients, who have segmenteted for four groups to organinize cervices and self care
11022594|NCT04619238||mix urinary incontinence|patients with MUI
11022506|NCT04619836||Non-segmentation substance abuse clients|Those type substance abuse clients, who have not segmenteted
11022507|NCT04619823|Other|Patient infected by arboviruses|
11022508|NCT04619810|Other|Intervention arm|quasi-experimental pre-post study
11022509|NCT04619797|Experimental|Tiragolumab+Atezolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with tiragolumab in combination with atezolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab in combination with atezolizumab and pemetrexed on Day 1 of each 21-day cycle.
11022510|NCT04619797|Placebo Comparator|Placebo+Pembrolizumab+Pemetrexed+Carboplatin or Cisplatin|Induction treatment with placebo in combination with pembrolizumab plus pemetrexed and cisplatin or carboplatin will be administered to participants on Day 1 of each 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo in combination with pembrolizumab and pemetrexed on Day 1 of each 21-day cycle.
11022511|NCT04619784|Experimental|Treatment Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Patients will receive 12 sessions of pilates. Patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.
11022512|NCT04619784|Other|Control Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Their routine medical treatments were continued
11022513|NCT04619771|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
11022514|NCT04619758|Experimental|Emollient Group|Mothers of the neonates in group A will be advised massage with sunflower oil.
11022515|NCT04619758|No Intervention|Non-Emollient Group|Mothers of the neonates in group B will be advised massage without any emollient.
11022516|NCT04619745|Experimental|Intervention Group|All children enrolled in the study will complete five study visits. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity. The intervention group will complete individualized, parent-led, home and play-based activity plans for 6 months, beginning as soon as the child returns to the inpatient unit. The activities in the plan will be tailored to each phase of treatment (in hospital, discharge to week 7, week 8 to 6 months), follow a standardized format and provide content individualized to each child's age and previous visit assessments.
11022517|NCT04619745|Experimental|Wait List Control Group|All children enrolled in the study will complete five study visits. After the first visit is complete, children will be randomized to either the intervention or wait-list control study group. Control participants will follow the same schedule of assessments at each visit, but the intervention will be provided between the 12-month and 16-month assessments. All participants will complete all outcome measures (including surveys, questionnaires, and motor skill assessments) at or after each 1-hour assessment visit. Children will be given an omni-directional accelerometer to wear on a waist-worn belt for 7 days after each visit to assess daily physical activity.
11022518|NCT04619732|Experimental|Marginal Kidneys|"Transplant patients receiving kidneys from deceased marginal donors: aged >= 60, or >= 50 with comorbid renal impairment, hypertension, or cerebrovascular disease.
~Following consent, kidneys will be cold perfused with preserving solution for 2-4 hours as per standard of care at the study centre. During this period, the kidneys will be monitored for creatinine, glucose, and lactate concentrations using three microdialysis probes placed into the tissue, the vein, and the ureter. Data will be blinded to clinicians.
~The probes will be removed at the end of the perfusion period and the organs will be transplanted or discarded according to clinical protocol. If transplanted, the study will monitor the patient's recovery for the first 30 days."
11022519|NCT04619719|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen Therapy (HBOT) + Standard of Care (SOC) as defined by current best practice treatments for COVID-19
11022520|NCT04619719|No Intervention|Standard of Care|Standard of Care (SOC) as defined by current best practice treatments for COVID-19
11022521|NCT04619706|Experimental|Arm A: FSD201 600 mg|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
11022522|NCT04619706|Experimental|Arm B: FSD201 1200 mg|Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
11022523|NCT04619706|Placebo Comparator|Arm C: Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
11022524|NCT04619693||The study population|The study population corresponds to patients hospitalized for proven SARS-COV-2 pneumonia with an indication (hypoxemia) for dexamethasone (see eligibility criteria)
11022525|NCT04619680|Experimental|Nintedanib|150 mg po twice a day
11022526|NCT04619680|Placebo Comparator|Placebo|placebo equivalent po twice a day
11022527|NCT04619667|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
11022528|NCT04619667|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
11022584|NCT04619277||Pecking University Shougand Hospital|Department of Cardiology, Peking University Shougang Hospital, Peking, China
11022529|NCT04619667|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
11022530|NCT04619654|Experimental|Cataract Surgery with concurrent MIGS|
11022531|NCT04619641|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
11022532|NCT04619641|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
11022533|NCT04619641|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
11022534|NCT04619628|Placebo Comparator|Saline|Normal saline
11022535|NCT04619628|Experimental|Low dose cohort 1|COVI-VAC, single dose
11022536|NCT04619628|Experimental|Medium dose cohort 1|COVI-VAC, single dose
11022537|NCT04619628|Experimental|High dose cohort 1|COVI-VAC, single dose
11022538|NCT04619628|Experimental|Low dose cohort 2|COVI-VAC, two doses 28 days apart
11022539|NCT04619628|Experimental|Medium dose cohort 2|COVI-VAC, two doses 28 days apart
11022540|NCT04619628|Experimental|High dose cohort 2|COVI-VAC, two doses 28 days apart
11022541|NCT04619615|Experimental|Asynchronous self-directed digital training|A digital training program platform that delivers an interactive case-based modular curriculum covering evidence-based psychotherapy principles and IPT-specific principles and strategies with homework will take roughly 13 hours to complete, with 4.5 hours of online learning, and an additional 7.5 hours of reading and homework assignments. The reading and homework includes viewing captioned videotaped role plays and completing self-directed lesson plans. The digital curriculum leverages audio, video, and visual content, and is self-directed - for completion within a 2-week period. Residents can access this content through a smartphone, tablet or computer at their own pace, revisit modules and digital content as needed, and access a curated list of additional resources to supplement their learning.
11022542|NCT04619615|Active Comparator|Synchronous large group online workshop|This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional ~7.5 hours in total).
11022543|NCT04619602|Experimental|SNO therapy|Intervention will be 4 hours of inhaled SNO agent in enrollment blocks of three subjects/dose (2, 5, 10, 15, 20ppm) to infants.
11022544|NCT04619563|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
11022545|NCT04619550|Other|Exercise intensity|Jogging or walking at RPE 9, 11, 13, and 15
11022546|NCT04619537|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
11022547|NCT04619524|Experimental|A: Patients undergo cycle with the transfer of fresh embryos|In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.
11022548|NCT04619524|Experimental|B: Patients undergo cycle with the transfer of frozen embryos|In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.
11022549|NCT04619498|Experimental|PediAppRREST app|The teams assigned to the PediAppRREST arm will manage the simulated scenario of pediatric cardiac arrest using the new PediAppRREST tablet app as a cognitive aid.
11022550|NCT04619498|Active Comparator|CtrlPALS+|The teams assigned to the CtrlPALS+ arm will manage the simulated scenario of pediatric cardiac arrest using the American Heart Association Pediatric Advanced Life Support 2015 (AHA-PALS-2015) pocket reference card.
11022551|NCT04619498|No Intervention|CtrlPALS-|The teams assigned to the CtrlPALS- arm will manage the simulated scenario of pediatric cardiac arrest using no PALS-related cognitive aids.
11022552|NCT04619485|Sham Comparator|SHAM LASER|Group A: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to zero potence.
11022553|NCT04619485|Active Comparator|EFFECTIVE LASER|Group B: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to regular potence.
11022554|NCT04619472|Experimental|Radiofrequency Ablation|The subjects will first undergo interventional bronchoscopy to reach the target lesion through the bronchial pathway. Then the lung lesions will be treated with radiofrequency ablation using the pulmonary radiofrequency ablation system and the disposable pulmonary radiofrequency ablation catheter.
11022585|NCT04619264|Experimental|Papacarie-Duo|
11022586|NCT04619264|Active Comparator|Atraumatic Restorative Treatment|
11022587|NCT04619251|Experimental|SRD part, active drug, poor metabolizers|
11022555|NCT04619459|Experimental|Newborns receiving Kangaroo Mother Care (KMC)|The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. At Minute 5, the newborns' Apgar scores were assessed and recorded during KMC. The newborn's examination and injections (Hepatitis-B and K vit) were postponed until the first breastfeeding took place. A pediatrician performed a detailed examination of the newborns under the radiant infant warmer after the first breastfeeding. Following the examination, the newborn was positioned on the mother's breast for KMC. During this KMC, the newborn was administered 1 mg K vitamin in the right leg and 0.5 ml Hepatitis-B vaccine in the left leg via intramuscular injections. The KMC session was continued for 3 hours. Care attempt of mothers such as episiotomy repair was taken that the position of KMC.
11022556|NCT04619459|No Intervention|Newborns receiving standard postpartum care (SPC):|He received the standard care of the hospital. KMC not applied.
11022557|NCT04619446||Removable Twin Block appliance group|Patient to be treated with removable twin block appliance that are known Class II skeletal and dental subjects.
11022558|NCT04619446||Fixed Functional Appliance AdvanSync group|Patients to be treated with fixed functional appliance, AdvanSync (Molar-to-Molar) Class II Corrector
11022559|NCT04619433|Experimental|Treatment group A|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
11022560|NCT04619433|Placebo Comparator|Treatment group B|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
11022561|NCT04619420|Experimental|JNJ-63733657|Participants will receive single dose of JNJ-63733657 low dose or high dose administered by intravenous (IV) infusion every 4 weeks.
11022562|NCT04619420|Placebo Comparator|Placebo|Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks.
11022563|NCT04619407||teacher|"Employed in a school in Mecklenburg-Vorpommern
~Age between 18 to 67 years
~Willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
11022564|NCT04619407||pupils|"Attending school in Mecklenburg-Vorpommern
~Age between 6 to 17 years
~Agreement to participate
~Legal representative willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
11022565|NCT04619407||childcare educators|"Employed in a kindergarten in Mecklenburg-Vorpommern
~Age between 18 to 67 years
~Willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR, additionally blood samples for SARS-CoV-2 antibody testing will be taken at the beginning and at the end of the study"
11022566|NCT04619407||preschoolers|"Attending kindergarten in Mecklenburg-Vorpommern
~Age between 3 to 6 years
~Agreement to participate
~Legal representative willing and able to provide informed consent
~Over 5 months: Monthly nasopharyngeal swabs for SARS-CoV-2 PCR"
11022567|NCT04619394|No Intervention|Control Group (CG)|Control Group (CG): Formed by those pregnant women who do not perform any physical exercise, only the basic and instrumental activities of daily life (ABVD and AIVD respectively) and intensity of the physical labor load of very light to moderate. The period from 10-12 SG to 37-41 SG.
11022568|NCT04619394|Active Comparator|Experimental Group 1 (GE1)|Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
11022569|NCT04619394|Active Comparator|Experimental Group 2 (GE2)|Experimental Group 2 (GE2): In this third and last group, we incorporated the AIPAP program into the exclusive programs of each monitor in the various public and private sports centers and swimming pools in the South of the Autonomous Community of Galicia. The researcher trained in this method, together with the monitors who voluntarily wish to do so, will translate said format and program into their sessions.
11022570|NCT04619381||African Americans with Coronary Artery Disease|African Americans with Coronary Artery Disease and currently taking clopidogrel
11022571|NCT04619355||TVC K-Registry|
11022572|NCT04619342|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.
11022573|NCT04619342|Active Comparator|GSMs-TACE Group|Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.
11022574|NCT04619329|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using Lobaplatin and GSMs (150-350μm, 350-560μm, 560-710μm or 710-1000μm), patients will receive surgical resection 15-30 days later, as specified per protocol.
11022575|NCT04619329|Active Comparator|Surgical Resection Group|Patients will receive surgical resection, as specified per protocol.
11022576|NCT04619316|Other|BRAF wild type|In BRAF wild type patients trametinib 2mg (1-0-0) is applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
11022577|NCT04619316|Other|BRAF V600E Mutation|In BRAF wild type patients trametinib 2mg (1-0-0) and dabrafenib 75mg (2-0-2) are applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
11022578|NCT04619303|Experimental|Dexamethasone Implant|Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.
11022579|NCT04619303|Active Comparator|Bevacizumab|Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
11022580|NCT04619290|Experimental|Methylene blue treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
11022581|NCT04619290|Active Comparator|Conventionally treated group|Patients will be included in this group with the following symptoms: with at least one of the following symptoms: headache, nausea, dyspnea, myalgia, vomiting. Also that they meet the inclusion criteria
11022582|NCT04619277||Ulsan Medical Center|Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea
11022583|NCT04619277||Queen Elizabeth Hospital|Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia
11022595|NCT04619238||Urge|patients with urge incontinence
11022596|NCT04619225|Experimental|Group 1: Dominant Hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand
11022597|NCT04619225|Experimental|Group 2: Non-Dominant Hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand
11022598|NCT04619212|Other|Standard of Care|Standard of Care
11022599|NCT04619212|Other|new device|new device
11022600|NCT04619199|Experimental|Idiopathic Pulmonary Fibrosis|Blood sample were performed during the study for all patients.
11022601|NCT04619173|Experimental|Thoracic manipulation|additional thoracic manipulation along with hotpack, transcutaneous electrical nerve stimulation ,serratus anterior,pectoralis major,minor, posterior capsular stretches..
11022602|NCT04619173|Active Comparator|Conventional Physical Therapy Program|hot pack transcutaneous electrical nerve stimulation, serratus,anterior,pectoralis major, minor, posterior capsular stretches.
11022603|NCT04619160|Active Comparator|propofol|
11022604|NCT04619160|Active Comparator|sevoflurane|
11022605|NCT04619147||Patients without invasive fungal infections (IFI)|This will be our control cohort. Most of the patients would have been on posaconazole prophylaxis.
11022606|NCT04619147||Patients with invasive fungal infections (IFI)|This will be the group that we will be interested in. IFI would be diagnosed based on EORTC/ MSG definitions, and most of them would have been on posaconazole prophylaxis. Underlying risk factors of acquiring IFI in this cohort of patients will be compared with that of the control cohort.
11022607|NCT04619134|Experimental|NCSR Program|Non Pain Contingent Spinal Rehabilitation
11022608|NCT04619134|Active Comparator|Conventional Physical therapy|Conventional Physical Therapy
11022609|NCT04619121|Experimental|Treatment with real NIR-tPBM on top of standing pharmacotherapy|NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, 20 minutes a day, for 8 consecutive weeks.
11022610|NCT04619121|Sham Comparator|Sham device on top of standing pharmacotherapy|Sham device with neglectable energy to the dorsolateral prefrontal cortex, bilaterally and simultaneously, 20 minutes a day, for 8 consecutive weeks.
11022611|NCT04619095|Experimental|Psyllium|Participants are asked to daily consume 5 grams psyllium for 2 weeks, after which they are asked to daily consume 10 grams psyllium for the remainder of the intervention (i.e. 10 weeks).
11022612|NCT04619095|Placebo Comparator|Placebo|Participants are asked to daily consume 5 grams maltodextrin for 2 weeks, after which they are asked to daily consume 10 grams maltodextrin for the remainder of the intervention (i.e. 10 weeks).
11022613|NCT04619082|Experimental|TAF prophylaxis|Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients
11022614|NCT04619069|Active Comparator|Arm 1: Standard of Care|Intermittent Hormone treatment (minimum of 8 months)
11022615|NCT04619069|Experimental|Arm 2: SBRT to mets|"Intermittent Hormone treatment (minimum of 8 months)
~+ SBRT to all sites of metastatic disease"
11022616|NCT04619056|Experimental|Cohort 1|CEB-01 with total SN-38 dose: 9 mg
11022617|NCT04619056|Experimental|Cohort 2|CEB-01 with total SN-38 dose: 18 mg
11022618|NCT04619056|Experimental|Cohort 3|CEB-01 with total SN-38 dose: 36 mg
11022619|NCT04619043|Experimental|Ankle Orthotic|The participant will wear two different ankle orthotics, their currently prescribed orthotic and the experimental orthotic.
11022620|NCT04619030|Experimental|Augmented Reality Leaflet|Patient Leaflet with Augmented reality component
11022621|NCT04619030|Active Comparator|Traditional Leaflet|Traditional leaflet without Augmented Reality component
11022622|NCT04619017|Experimental|Segmental allergen challenge|Allergic individuals with and without asthma will be enrolled.
11022623|NCT04619004|Experimental|Study Group 1: Patritumab deruxtecan 5.6 mg/kg|Study Group 1 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan 5.6 mg/kg IV Q3W
11022624|NCT04619004|Experimental|Study Group 2: Patritumab deruxtecan Up-Titration|Study Group 2 will be participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation randomized to receive patritumab deruxtecan up-titration IV Q3W
11022625|NCT04618991|Experimental|Adult patients with SAHOS for whom maxillary transversal surgery|Adult patients with SAHOS for whom maxillary transversal surgery is recommended.
11022626|NCT04618978|Other|PSG and actigraphy device evaluations|All patients will be evaluated and diagnosed according to the records by Gold standard for PLMs diagnosis and also by the actigraphy devices recording.
11022627|NCT04618965|Placebo Comparator|Control (Placebo) group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
11022628|NCT04618965|Experimental|Intrathecal dexmedetomidine group|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
11022629|NCT04618965|Experimental|Intravenous dexmedetomidine group|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
11022630|NCT04618952|Active Comparator|treatment|patients received calcium D
11022631|NCT04618952|Placebo Comparator|control|patients received placebo
11022632|NCT04618939|Experimental|BR-TD-1001|Randomized subjects were assigned to receive a single dose of BR-TD-1001
11022633|NCT04618939|Active Comparator|Td-pur inj|Randomized subjects were assigned to receive a single dose of Td-pur inj
11022634|NCT04618926||intubating Laryngeal Tube Suction Disposable|intubating Laryngeal Tube Suction Disposable Airway control
11022635|NCT04618926||intubating laryngeal Tube suction Disposable|intubating laryngeal Tube Suction Disposable
11022636|NCT04618913||VTE and history of cancer|VTE and history of cancer
11022637|NCT04618913||VTE and active cancer|VTE and active cancer
11022638|NCT04618900|Experimental|Osteotome-mediated sinus floor elevation with Bio-Oss collagen|Sinus floor elevation with a grafting material (Bio-Oss collagen)
11024432|NCT04606602|Experimental|300 mg multi dose|
11022639|NCT04618900|Placebo Comparator|Osteotome-mediated sinus floor elevation with no grafting material|Sinus floor elevation with no grafting material
11022640|NCT04618887||Meige sydrome patients|
11022641|NCT04618874|Experimental|ROSE group|Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation
11022642|NCT04618874|No Intervention|US NAB group|Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation
11022643|NCT04618861||Control Group|"This cohort involved the volunteers who had no known acute, subacute or chronic disease history, who did not suffer from any infection in the last fortnight, who were not on a particular medication, who presented to the ED with reasons other than infectious complaints, and who gave their written consent to participate in the study.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
11022644|NCT04618861||CT (+), PCR (-) Covid-19 Suspected Pneumonia Group|"This group consisted of patients who applied to the emergency department with symptoms of Covid-19, whose thorax CT according to RSNAEC criteria showed typical Covid-19 pneumonia findings, but whose RT-PCR test was negative in the swab sample taken in the emergency room.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
11022645|NCT04618861||CT (+), Covid-19 Pneumonia Group|"This cohort consisted of the patients (a) who applied to the emergency department with SARS-CoV-2 symptoms and was diagnosed with SARS-CoV-2 infection according to WHO guideline (13) (b) whose CT imagings were compatible with SARS-CoV-2 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria (14), (c) whose nasopharyngeal swab samples taken in the ED were positive for RT-PCR, and (d) who gave their informed consent to participate in the study.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
11022646|NCT04618861||CT (-), PCR (+) Covid-19 infection group|"This cohort included the patients (a) who presented to the Covid-19 outpatient polyclinic of the ED with pneumonia symptoms, (b) whose CT imaging's were compatible with Covid-19 pneumonia in accordance with the RSNAEC criteria and whose PCR tests were positive, (c) whose SARS-CoV-2 PCR tests were positive as a result of contact tracing, and (d) who presented to the ED for further examination.
~The exclusion criteria consisted of diagnosis of kidney and liver failure, acute pulmonary embolism, chronic inflammatory disease history (rheumatological disease, autoimmune disease), pregnancy, presence of any cancer diagnosis, chronic obstructive pulmonary disease, asthma disease, and history of cerebrovascular disease. In addition, the patients whose CT imagings were compatible with Covid-19 pneumonia but whose PCR tests were negative were also excluded from the study."
11022647|NCT04618848||Adult Oncology Patients|Adult oncology patients
11022648|NCT04618835||Emergency presentations|Patients discharged after a presentation to practitioners in the community, primary and secondary care.
11022649|NCT04618822|Experimental|Teaching involving whole-body movements|
11022650|NCT04618822|Experimental|Teaching involving hand movements|i.e. arms and hands
11022651|NCT04618822|Active Comparator|teaching involving minimal motor movements|i.e. seated on a chair using paper and pencil
11022652|NCT04618809|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire, which evaluates the approach to older mGC patients at each site.
~Phase 2 - Providers participate in an hour-long didactic session and begin enrolling eligible metastatic gastric cancer (mGC) patients. Enrolled mGC patients complete a comprehensive geriatric assessment (CGA). Providers complete the treatment plan and review of geriatric assessment questionnaires, which also includes an evaluation of their overall view of the utility of the geriatric assessment.
~Phase 3 - Follow-up chart reviews (2-3 months post intervention) are completed to assess for actual implementation of recommended interventions identified by the geriatric assessment."
11022653|NCT04618783|Experimental|Low-dosage experimental group|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses
11022654|NCT04618783|Experimental|Medium-dosage experimental group|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses
11022655|NCT04618783|Experimental|High-dosage experimental group|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
11022656|NCT04618783|Active Comparator|Control wIPV group|Three doses of control wIPV, vaccinated within one-month interval between doses
11022657|NCT04618783|Active Comparator|Control sIPV group|Three doses of control sIPV, vaccinated within one-month interval between doses
11022658|NCT04618770|Other|Triathlon PSR Tibial Insert|Cases receiving a Triathlon Total Knee with the Triathlon PSR Tibial Insert
11022659|NCT04618757|Experimental|Hedonic Reward|Participants' reward for meeting monthly step targets is in the form of reimbursements of up to $50 for expenses on hedonic activities of their choice
11022660|NCT04618757|Experimental|Cash Reward|Participants' reward for meeting monthly step targets is in the form of $50 cash disbursements
11022661|NCT04618744|Placebo Comparator|Placebo|Fish oil
11022662|NCT04618744|Experimental|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
11022663|NCT04618718|Experimental|Intervention|ProtEmbo device will be used as distal protection device in subjects undergoing TAVR
11022664|NCT04618705|No Intervention|control group|Participants who have not smoked for at least 10 years
11022665|NCT04618705|No Intervention|smoking group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years.
11022666|NCT04618705|Experimental|smoking cessation group|Participants who have smoked cigarettes (at least 5 cigarettes per day) for at least 2 years and who are planning to quit smoking.
11022667|NCT04618692|Active Comparator|Surgical Loupes|In this group , patients will undergo biliary reconstruction using surgical loupe
11022668|NCT04618692|Active Comparator|Microscope|In this group , patients will undergo biliary reconstruction using microscope
11022669|NCT04618679||18F-FDOPA PET|Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
11022670|NCT04618666|Experimental|laparoscopic and open appendectomy|comparative study between laparoscopic and open appendectomy
11022671|NCT04618653||Early AA Attenders with Alcohol Use Disorder|observational study that includes three fixed assessments (Baseline, 3, and 6-month). Subset of participants will also provide daily EMA data.
11022672|NCT04618640|Experimental|DTaP-IPV combination vaccine|DTaP-IPV 0.5ml IM boosting
11022673|NCT04618614|Experimental|HD-tDCS S1 1 mA|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
11022674|NCT04618614|Active Comparator|HD-tDCS M1 1 mA|Single session of 15-min HD-tDCS to the right primary motor cortex with an intensity of 1 mA. The session will last approximately one hour.
11022675|NCT04618614|Sham Comparator|Sham control|Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
11022676|NCT04618601|Active Comparator|High-dose spironolactone|Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure
11022677|NCT04618601|No Intervention|Standard of care|Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily
11022678|NCT04618588|Experimental|"Sinus elevation using Low Window Sinus Lift technique"|
11022679|NCT04618575|Experimental|Ursodeoxycholic acid combined with total glucosides of paeony|
11022680|NCT04618575|Other|Ursodeoxycholic acid only|
11022681|NCT04618562|Experimental|Revival Active Program|Revival Program included supervised play group, twice a week followed by home practice.
11022682|NCT04618549|Active Comparator|Direct anterior approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by direct anterior approach, using a regular OR table, without hip hyperextension.
11022683|NCT04618549|Active Comparator|Mini Posterior Approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a mini posterior approach.
11022684|NCT04618549|Active Comparator|Lateral approach|Patients with a femoral neck fracture, treated by hemiarthroplasty by a lateral (Hardinge) approach.
11022685|NCT04618536|Experimental|Inorganic sunscreen|
11022686|NCT04618536|Experimental|Organic sunscreen|
11022687|NCT04618523|Experimental|Artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
11022688|NCT04618523|Experimental|Artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
11022689|NCT04618510|Experimental|SEED 1-dayPure EDOF soft contact lens|The participant will be requested to wear the daily disposable lens 8-10 hours per day and replaced daily. All participants will be followed for 12 months (followup visit schedule; 3 months, 6 months, 12 months) post-contact lens wear.
11022690|NCT04618510|Sham Comparator|Single vision spectacle lens|The participant will be requested to wear the spectacle lens daily. All participants will be followed for 12 months (follow up visit schedule; 3 months, 6 months, 12 months) post spectacle lens wear.
11022691|NCT04618497|Experimental|Inhalational methoxyflurane (Penthrox)|
11022692|NCT04618497|Active Comparator|Intramuscular ketorolac|
11022693|NCT04618484|Experimental|Biomodulation|6-weeks post-operative cryo-, photo- and electro-biomodulation protocol after repair
11022694|NCT04618484|No Intervention|Control|standard rehabilitation after repair
11022695|NCT04618471|Experimental|WaveWriter Settings|
11022696|NCT04618458|Experimental|Intervention Arm|Eligible overweight/obese children and their overweight/obese parent (N=20 families) will receive the same telehealth diabetes prevention intervention based on Power to Prevent and delivered by a trained lifestyle coach. Families will meet weekly for 11-weeks (60-min sessions), and then monthly (60-min sessions) for 4 pilot behavioral reinforcement maintenance sessions (15 sessions total). Participants will meet in their respective groups (n=5 families per group) via videoconference using Wi-Fi-enabled tablets with cellular connectivity for the entire intervention. Sessions will consist of nutrition and physical activity behavior change strategies (20 min), problem solving and decision-making skills to circumvent barriers to behavioral change (20 min), and family goal setting and action planning (20 min). Assessment measures will be collected from the child and parent participants at baseline, 12-weeks (post-intervention), and 30-weeks (follow-up).
11022697|NCT04618445||Undergraduate students|prevalence of TMD among undergraduate students
11022698|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
11022699|NCT04618406|Experimental|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
11022700|NCT04618406|Active Comparator|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
11022978|NCT04616430|Placebo Comparator|Control|Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
11022701|NCT04618393|Experimental|EMB-02|"In Phase I part: participants enrolled in the different time will receive EMB-02 once weekly (IV) at different ascending dose levels.
~In Phase II part: participants will receive EMB-02 once weekly (IV) at previously defined RP2D."
11022702|NCT04618380||Bilateral trifocal implantation|Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
11022703|NCT04618380||Myopic monovision|The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
11022704|NCT04618380||Hybrid monovision|Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
11022705|NCT04618380||Premium monovision|Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
11022706|NCT04618367|Experimental|HAIC plus Lenvatinib and Sintilimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 200 mg intravenously every 3 weeks.
11022707|NCT04618354||LADA group|The patient was diagnosed with late-onset autoimmune diabetes (LADA).
11022708|NCT04618354||T1DM group|The patient was diagnosed with classic type 1 diabetes (T1DM) .
11022709|NCT04618354||T2DM group|The patient was diagnosed with type 2 diabetes (T2DM).
11022710|NCT04618328|Experimental|ATRA treatment group|ATRA is given at a daily dose of 10 mg twice daily orally for 12 weeks
11022711|NCT04618315|Active Comparator|Audiology-Based Best Practice|Hearing aids will be fit using current best practices used by audiologists to fit hearing aids.
11022712|NCT04618315|Experimental|Consumer Decides|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying loudness levels.
11022713|NCT04618315|Experimental|Efficient Fitting|Hearing aids will be self fit by patients using an interactive application on a tablet computer. Patients will choose their preferred hearing aid settings after comparing four settings with varying base and treble settings.
11022714|NCT04618289|Experimental|Vitamin D Group|The vitamin D3-fortified fruit juice supplement that will be used is vitamin D3 cholecalciferol (4000 IU, 100 mcg, Fiatec Biosystem Sdn Bhd, Selangor, Malaysia).
11022715|NCT04618289|Placebo Comparator|Placebo Group|The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
11022716|NCT04618276|Experimental|Arm A (MAL group)|"Skin swab for culture in the groin for baseline
~PDT with 5% topical methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
~Skin swab for culture
~Skin antisepsis
~Skin swab for culture"
11022717|NCT04618276|Experimental|Arm B (Methylene Blue group)|"Skin swab for culture in the groin for baseline
~PDT with 0.01% methylene blue based photosensitizer (NF-031)
~Skin swab for culture
~Skin antisepsis
~Skin swab for culture"
11022718|NCT04618276|No Intervention|Control group|"Skin swab for culture in the groin for baseline
~NO PDT
~Skin antisepsis
~Skin swab for culture"
11022719|NCT04618263|Experimental|GATE-101, 5 mg IV, Single Dose|GATE-101, 5 mg IV, Single Dose, with follow up of 28 days
11022720|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose|GATE-101, 15 mg IV, Single Dose, with follow up of 28 days
11022721|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose|GATE-101, 50 mg IV, Single Dose, with follow up of 28 days
11022722|NCT04618263|Experimental|GATE-101, 150 mg IV, Single Dose|GATE-101, 150 mg IV, Single Dose, with follow up of 28 days
11022723|NCT04618263|Experimental|GATE-101, 450 mg IV, Single Dose|GATE-101, 450 mg IV, Single Dose, with follow up of 28 days
11022724|NCT04618263|Experimental|GATE-101, 15 mg IV, Single Dose, Lumbar Catheter|GATE-101, 15 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
11022725|NCT04618263|Experimental|GATE-101, 50 mg IV, Single Dose, Lumbar Catheter|GATE-101, 50 mg IV, Single Dose, with Lumbar Catheter for collection of cerebrospinal fluid (CSF) PK samples, with follow up of 28 days
11022726|NCT04618263|Experimental|GATE-101 5 mg IV, Five Daily Doses|GATE-101 5 mg IV, Five Daily Doses, with follow up for 28 days from first dose
11022727|NCT04618263|Experimental|GATE-101 15 mg IV, Five Daily Doses|GATE-101 15 mg IV, Five Daily Doses, with follow up for 28 days from first dose
11022728|NCT04618263|Experimental|GATE-101 150 mg IV, Five Daily Doses|GATE-101 150 mg IV, Five Daily Doses, with follow up for 28 days from first dose
11022729|NCT04618263|Placebo Comparator|Placebo Comparator, Single Dose|Placebo Comparator, Single Dose, with follow up for 28 days
11022730|NCT04618263|Placebo Comparator|Placebo Comparator, Five Daily Doses|Placebo Comparator, Five Daily Doses, with follow up for 28 days from first dose
11022731|NCT04618250|Experimental|Coordinated, co-produced health care|
11022732|NCT04618250|No Intervention|Care as usual|Care as usual
11022733|NCT04618224||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language
~30 patients with low vision (LVG) with adequate literacy of written Greek language
~These patients are tested on the digital reading test DDART."
11022734|NCT04618224||Study group|The same patients as those in the control group (NVG, LVG) are tested on the online version of the Greek digital reading test DDART (wDDART).
11022735|NCT04618211|Other|Low dose/placebo|Single low dose of PHA-022121 or placebo
11022736|NCT04618211|Other|Medium dose/placebo|Single medium dose of PHA-022121 or placebo
11022737|NCT04618211|Other|High dose/placebo|Single high dose of PHA-022121 or placebo
11022738|NCT04618198|No Intervention|Diagnosis dependent / conventional dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days
~If subsequent TB test positive, then WHO recommended weight-based anti-TB therapy x 28 days"
11022739|NCT04618198|Experimental|Immediate anti-TB therapy/conventional dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric WHO recommended weight-based dose anti-TB therapy x 28 days
11023061|NCT04615910|Experimental|Verapamil|Patients treated with Verapamil within the Ver-A-T1D trial
11022740|NCT04618198|Experimental|Diagnosis dependent/sepsis specific dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days
~If subsequent TB test positive, then sepsis specific dose anti-TB therapy x 28 days"
11022741|NCT04618198|Experimental|Immediate anti-TB therapy/sepsis specific dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric sepsis specific dose anti-TB therapy x 28 days
11022742|NCT04618185||p.Phe508del homozygous genotype|People with CF with 2 copies of p.Phe508del and previously eligible for Symkevi (Tezacaftor/Ivacaftor)
11022743|NCT04618185||p.Phe508del - minimal function genotype|People with CF with 1 copy of p.Phe508del and not previously eligible for any CFTR modulator
11022744|NCT04618172|Experimental|Exercising group|This group practises 30 minute long aerobic exercises twice a week besides filling out the questionnaires.
11022745|NCT04618172|No Intervention|Control group|This group fills out the questionnaires without practising 30 minute long aerobic exercises twice a week.
11022746|NCT04618159|Other|Helipyl|helipyl wil be given to 10 children with asymptomatical helicobacter pylori infection
11022747|NCT04618146|Placebo Comparator|Group C|given intrathecal bupivacaine 12.5 mg.
11022748|NCT04618146|Active Comparator|Group M25|given intrathecal bupivacaine 12.5mg + morphine 25 microgram.
11022749|NCT04618146|Active Comparator|Group M50|given intrathecal bupivacaine 12.5mg + morphine 50 microgram.
11022750|NCT04618133|Experimental|Early time-restricted eating|Duration: 12 weeks
11022751|NCT04618133|Experimental|Late time-restricted eating|Duration: 12 weeks
11022752|NCT04618133|Active Comparator|Active control|Duration: 12 weeks
11022753|NCT04618120|Experimental|Virtual Reality-based Exercise Group|"Virtual reality-based exercises, breathing exercises and patient education on general considerations.
~Virtual reality-based exercises were done using the Microsoft Xbox 360 Kinect system. Among the 'Kinect Sports' games, especially tennis, table tennis, boxing and bowling games including upper extremity movements were selected. These games require all-directional and repetitive motion of the shoulder and elbow joint. Patients played the games using the operated / affected side arms. Between games, the patient was rested in a chair. In the meantime, deep breathing exercises were done.
~The patients participated in virtual reality-based exercises 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). Each exercise session was set to last 30-40 minutes in total."
11022754|NCT04618120|Experimental|Exercise Group|"Stretching exercises, range of motion exercises, posture exercises, breathing exercises and patient education on general considerations.
~11 different exercises consisting of shoulder range of motion in all directions, stretching exercises, posture exercises and breathing exercises were performed in the presence of a physiotherapist.The patients participated in this exercise program 3 days a week (15-18 sessions in total) during the radiotherapy treatment continued (5-6 weeks). One session of the exercises was completed in an average of 30-40 minutes. The same exercises were repeated in each session."
11022755|NCT04618120|No Intervention|Control Group|Only patient education on general considerations.
11022756|NCT04618107|Experimental|Wide awake surgery|Wide awake local anaesthesia was used as mode of aneasthesia for tendon repair surgery. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
11022757|NCT04618107|Active Comparator|General anaesthesia|Tendon repair surgeries were performed under general anaesthesia. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
11022758|NCT04618094|Experimental|High intensity interval group|
11022759|NCT04618094|Active Comparator|Moderate continous intensity group|
11022760|NCT04618094|No Intervention|non-exercising group|
11022761|NCT04618081||Participants with FL or MZL|Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.
11022762|NCT04618055|Experimental|NiTiDent Tuah Porous NiTi Dental Implants|
11022763|NCT04618055|Active Comparator|Control Implant|
11022764|NCT04618042|Experimental|FX06|
11022765|NCT04618042|Placebo Comparator|Placebo|
11022766|NCT04618029|Experimental|Treatment Group|"Home Assessment and Modification A two-component individualized home hazards management program will be provided for each participant in the intervention group according to the results of the HOME FAST. Basic home safety strategies and basic modifications are developed and will be prescribed for this study according to the HOME FAST assessment (weeks et al. 2010)
~Education Education on optimization of functional performance in the home will be provided via pamphlets on fall prevention, including energy conservation techniques (Chumbler et al., 2010), ergonomics (Edwards et al., 2019) and task simplification techniques (Wesson et al., 2013) will be provided. These techniques will also be provided for participants' caregivers."
11022767|NCT04618029|No Intervention|Controlled Group|1. Standard Care The standard care defined for this study is any care that are provided from the respective hospital. This will include common therapies and interventions for stroke rehabilitation in general.
11022768|NCT04618016||With Vitamin E|
11022769|NCT04618016||Without Vitamin E|
11022770|NCT04618003||Athletes with Spinal Cord Injury|Group of athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
11022771|NCT04618003||Non-athletes with spinal cord injury|Group of non-athletes with spinal cord injury that was assessed at rest and during a physical activity in virtual reality.
11022772|NCT04618003||Able-bodied control group|Group of non-athletes able-bodied control subjects that was assessed at rest and during a physical activity in virtual reality.
11022773|NCT04617977|Experimental|Parent-child I-BMS intervention group|Children with eczema and their parent caregivers will attend the six sessions simultaneously in a parallel group format. Parent caregivers will attend the parents group in the first 2.5 hours; while children will attend the children group in the first 2.5 hours. Both parents and children will later reunite in the joint group in the final 0.5 hours.
11022774|NCT04617977|Experimental|Parent only I-BMS intervention group|Only parent caregivers of children with eczema will attend the six sessions. The content of the 2.5-hour parents group will be the same as the one in Arm 1 (Parent-child I-BMS intervention group), with an additional 0.5 hour of reflective discussion among group members.
11022775|NCT04617977|Active Comparator|Parent only health education active control group|Only parent caregivers of children with eczema will attend the six sessions. Each session consists of teaching in the first 2.5 hours and Q&A in the final 0.5 hour.
11022776|NCT04617964||IUGR|sample of 40 pregnant women affected by intrauterine growth restriction (IUGR) Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
11022777|NCT04617964||NORMAL|Ssample of 40 healthy pregnant women Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
11022778|NCT04617951|Experimental|Ishige Okamurae extracts group|This group takes Ishige Okamurae extracts for 12 weeks.
11022779|NCT04617951|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
11022780|NCT04617938|Experimental|TACUNA|Randomized participants will attend 3 TACUNA workshops, focused on behavioral, physical, and spiritual domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use. They will also attend a wellness gathering, focused on healthy social networks and engaging in traditional practices.
11022781|NCT04617938|Active Comparator|Opioid education|Randomized participants will attend 1 opioid education workshop, focused on behavioral and physical domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use.
11022782|NCT04617925|Experimental|belantamab mafodotin|Belantamab mafodotin will be administered as an IV infusion at a dose of 2.5 mg/kg every six weeks until progression of disease, unacceptable toxicity or subsequent therapy, for a maximum of eight doses (approximately 12 months), according to the response adapted modifications
11022783|NCT04617912|Experimental|PennPET Explorer|"All subjects will be scanned in the CT scanner and then the scanner bed will be moved into position in the PennPET Explorer for initiation of the PET scan. For all PET scans a radioactive imaging drug is used.
~The radiotracer injection may be performed according to one of the following scenarios:
~As part of a clinical standard-of-care (SOC) PET/CT scan (using an FDA-approved radiotracer; the PennPET Explorer cannot yet accommodate a study that requires a commercially available 510(k)-approved instrument for clinical results, subjects in this group will be scanned on both a commercial instrument and the PennPET Explorer),
~As part of another research study (using either an FDA-approved radiotracer or an investigational radiotracer),
~As a research injection designed specifically to utilize the PennPET Explorer (using an FDA-approved radiotracer)."
11022784|NCT04617899|Experimental|Novasight IVUS/OCT|A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
11022785|NCT04617886|Experimental|Sadness condition|
11022786|NCT04617886|Experimental|Happiness condition|
11022787|NCT04617873|Active Comparator|active stimulation group|The patients in this group will receive DBS and SCS stimulation from month 3 to month 5.
11022788|NCT04617873|Sham Comparator|sham stimulation group|The patinets in this group will receive sham stimulation from month 3 to month 5.
11022789|NCT04617860|Experimental|WVE-120102 (Dose A)|
11022790|NCT04617847|Experimental|WVE-120101 (Dose A)|
11022791|NCT04617834||Quality Surveillance Data|For this quality surveillance study, data will be collected retrospectively through electronic health record (EHR) queries for all eligible patients treated for acute cardiovascular symptoms by one of the study sites.
11022792|NCT04617821|Experimental|albumin bound paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine were given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles.
11022793|NCT04617821|Active Comparator|mFOFLIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
11022794|NCT04617808||Headache pattern|Telephone call from center 15 for the headache pattern
11022795|NCT04617795|Experimental|Basal-Bolus (Group A)|"2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:
~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:
~4 weeks Omnipod 5 system use in Automated Mode with simplified bolus"
11022796|NCT04617795|Experimental|Basal (Group B)|"2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:
~2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by:
~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:
~If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR
~If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus"
11022797|NCT04617782|Experimental|Treatment A|5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
11022798|NCT04617782|Experimental|Treatment B|10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
11022799|NCT04617782|Active Comparator|Treatment C|10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
11022800|NCT04617769|Placebo Comparator|Psychoeducation alone (PSYED)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors.
11022801|NCT04617769|Active Comparator|Psychoeducation followed by exposure (PSYED+EXP)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated.
11022862|NCT04617314|Experimental|RC108|Participants will be allocated to one of the following dose groups: 0.1, 0.3, 0.9, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC108-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
11022802|NCT04617769|Experimental|Psychoeducation & exposure/Antagonistic Actions (PSYED+EXP+AA)|"The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated. Antagonistic action strategies during exposure to the trauma-videoclips will include (a) adopting an open posture; (b) eating a palatable snack; (c) smiling; and (d) wishing on high levels of emotional distress (e.g., come on distress hit me with your best shot). The participant will engage in all of the four antagonistic actions for the six exposure trials."
11022803|NCT04617756|Experimental|Durvalumab+Gemcitabine/Cisplatin or with Gemcitabine/Carboplatin|This is a single arm including 2 different cohorts : Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles and Cohort 2 includes patients on 40mg/ML Gemcitabine/450mg Carboplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles..
11022804|NCT04617743||High residual volume|Bladder tumor patients with high residual volume
11022805|NCT04617743||Low residual volume|Bladder tumor patients with low residual volume
11022806|NCT04617730|Active Comparator|Control arm|
11022807|NCT04617730|Experimental|Interventional arm|
11022808|NCT04617704|Experimental|Experimental:GC012F treatment|BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0
11022809|NCT04617691|Experimental|Group 1: Guselkumab PFS-U|Participants will receive single intravenous (IV) guselkumab formulation using UltraSafe Plus Passive Needle Guards (PFS-U) to create the IV solution.
11022810|NCT04617691|Experimental|Group 2: Guselkumab FVP|Participants will receive single IV guselkumab formulation using Final Vialed Product (FVP) to create the IV solution.
11022811|NCT04617678|Active Comparator|Prospective Prehabilitation|Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
11022812|NCT04617678|No Intervention|Retrospective Control|Retrospectively comparing patients that did not enroll into the prehabilitation program for head and neck cancer.
11022813|NCT04617665|Other|One-handed mask ventilation|For the one-handed mask ventilation, only one hand can be used to achieve the face mask seal. The left thumb and index finger form a ''C,'' providing anterior pressure over the mask, while the third, fourth, and fifth fingers form an ''E'' to lift the jaw.
11022814|NCT04617665|Other|Two-handed mask ventilation|For the two-handed mask ventilation, the provider's thumb and thenar eminence of each hand are held parallel, adjacent to the mask connector, and depress each side of the mask. The second through fifth digits wrap around and elevate the mandible to draw it anteriorly into the mask establishing both a jaw-thrust and chin-lift maneuver when appropriate.
11022815|NCT04617652|Active Comparator|Group M|Magnesium group
11022816|NCT04617652|Placebo Comparator|Group C|Control group
11022817|NCT04617639|Experimental|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
11022818|NCT04617639|Active Comparator|Control group I|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
11022819|NCT04617639|Other|Control group II (observation group)|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel.
11022820|NCT04617626|Other|Azithromycin|All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
11022821|NCT04617613|Active Comparator|Standard triple therapy|Standard triple therapy group received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 14 days.
11022822|NCT04617613|Experimental|Quadruple therapy group|Quadruple therapy group received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily after meals for 14 days.
11022823|NCT04617600|Active Comparator|Mineral trioxide aggregate (MTA)|Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
11022824|NCT04617600|Experimental|TheraCal PT|Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
11022825|NCT04617587|Experimental|Early Intervention|All the enrolled preterm infants are assigned to receive the early neurodevelopmental intervention during the NICU stay.
11022826|NCT04617574||AEON Endostapler|Stapling performed with AEON Endostapler
11022827|NCT04617574||Endo GIA Reloads with Tri-Staple Technology|Stapling performed with Endo GIA Reloads with Tri-Staple Technology
11022828|NCT04617561|Active Comparator|Ursodeoxycholic Acid group|Ursodeoxycholic Acid 13-15mg/kg/d
11022829|NCT04617561|Experimental|Ursodeoxycholic Acid+Low Dose Glucocorticoid group|Ursodeoxycholic Acid 13-15mg/kg/d+prednisolone 12mg/d in induction period and 2-4mg/d in maintenance period
11022830|NCT04617548|Experimental|tDCS and CO-OP Group|One-hour session three times per week for 4 weeks. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. Following each tDCS session, the participants will complete a sensations questionnaire.The basis for each session will be task-based practice of client-chosen goals and the use of cognitive strategies using CO-OP.
11022831|NCT04617522|Experimental|Subjects with Advanced or Metastatic Solid Tumor and Moderate Liver Impairment|Eight subjects with moderate hepatic impairment will be enrolled at each dose level. The dose-escalation plan will start at 7.5 mg/kg sacituzumab govitecan and escalate to 10 mg/kg if deemed to be safe. If sacituzumab govitecan 7.5 mg/kg is not safe, the dose will be reduced to 5 mg/kg sacituzumab govitecan
11022832|NCT04617522|Experimental|Subjects with Advanced or Metastatic Solid Tumor and Normal Liver function|8 subjects with normal hepatic function will receive sacituzumab govitecan 10 mg/kg
11022833|NCT04617509|Experimental|Part I GS-248 Formulation A|Formulation A given in fasting state.
11022834|NCT04617509|Active Comparator|Part I GS-248 Formulation B|Formulation B given in fasting state.
11022835|NCT04617509|Other|Part II GS-248 Formulation A or B|Formulation A or B given in fed condition
11022836|NCT04617496|Experimental|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features that encourage a higher level of speech performance.
11022837|NCT04617496|Active Comparator|Control group|Health education
11022838|NCT04617483|Experimental|Aged 26-45, Commercial Scale|Commercial scale inactivated SARS-CoV-2 vaccine in adults aged 26-45 years.
11022839|NCT04617483|Experimental|Aged 18-59, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in adults aged 18-59 years.
11022840|NCT04617483|Experimental|Aged ≥60, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in elderly aged above 60 years.
11022841|NCT04617457|Experimental|NAPOX chemotherapy|NAPOX chemotherapy in 14-day cycles with the four IMPs given intravenously in the following order: nal-irinotecan, oxaliplatin, folinic acid and 5-fluouracil.
11022842|NCT04617444|Experimental|Intervention group|
11022843|NCT04617444|Active Comparator|Control group|
11022844|NCT04617431|Experimental|Intervention group|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
11022845|NCT04617431|No Intervention|Control group|"The participants of control group had a wearable device and could upload their dietary diary to the health management platform every day. But no LINE group was created, and no reminding."
11022846|NCT04617418||subjects with refractory focal epilepsy with a seizure frequency|The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.
11022847|NCT04617405||Type A|Healthy normal-weight pregnant women
11022848|NCT04617405||Type B|Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)
11022849|NCT04617405||Type C|Pregnant women with type 2 diabetes
11022850|NCT04617405||Type D|Healthy overweight pregnant women
11022851|NCT04617392|Active Comparator|controlled group|25 patients after bariatric-metabolic surgery without controlled postprocedural training
11022852|NCT04617392|Experimental|active group|25 patients after bariatric-metabolic surgery with controlled postprocedural training
11022853|NCT04617379|Experimental|Active Treatment Group|15 minutes daily stretch for 1 year
11022854|NCT04617379|No Intervention|Control Group|No stretches
11022855|NCT04617366|Experimental|Individualized rTMS strategy|The individualized strategy will adjust the rTMS parameters promptly based on the results of fNIRS. This arm selects either the high-frequency rTMS to the contralesional dorsal premotor cortex (PMd) or the low-frequency rTMS to the contralesional primary motor cortex (M1) based on the lateralization index of the PMd measured by fNIRS.
11022856|NCT04617366|Active Comparator|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1.
11022857|NCT04617353|Experimental|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
11022858|NCT04617353|Other|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
11022859|NCT04617340|No Intervention|Usual care group|No pharmacist will be actively involved in the medication review, counseling or discharge and post-discharge procedure. In both groups the best possible preadmission drug list will be compiled for inpatients within 72 hours after admission to the geriatric ward. If potentially dangerous or life-threatening drug errors are observed in the usual care group, this will be communicated to the treating physician
11022860|NCT04617340|Experimental|Intervention group|"The clinical pharmacist-collaborative service in the intervention group comprises six steps based on the clinical pharmacy intervention proposal of Van der Linden et al (Drugs Aging 2020).
~The first three steps focus on optimizing the drug therapy of geriatric inpatients. The remaining steps target a safe transition from the hospital to the community."
11022861|NCT04617327|Experimental|Experimental : Short Course Pre-operative RadiothErapy|"As part of the planning process, you need to undergo a CT Simulation.It is special type of CT scan used to measure and design the radiation fields to precisely target the tumor.It is done at the Radiation Oncology Department at the MUHC. Some patients may be asked to also undergo an MRI Simulation, and the CT simulation. You may asked to provide a blood sample to ensure good kidney function prior to the CT and MRI scans. Both CT and MRI simulations are considered standard of care.
~Once the simulation studies are done, there is about a 2 week waiting period for radiation planning prior to starting the radiation treatments.
~The hypofractionation technique will be delivering five fractions (one fraction delivered every 2nd day) of 7 Gy daily of external beam radiotherapy (EBRT) over a period of one and half weeks for a total of 35 Gy. The treatment should last approximately 30 minutes. Once treatments are done, there is a 4 to 6 week wait for surgery."
11022892|NCT04617132||Online Mindfulness Group|Families with PPDA receiving evidence-based MBCT/MBSR intervention
11022863|NCT04617301||Group 1. Internal root resorption (IRR)|Internal root resorption is the progressive destruction of intraradicular dentin and dentinal tubules along the middle and apical thirds of the canal walls as a result of clastic activities. It is seen as a radiolucent area around the pulpal cavity, usually of incisors and mandibular molars. The various etiological factors suggested for internal root resorption include traumatic injury; infection and orthodontic treatment.
11022864|NCT04617301||Group 2. external cervical resorption (ECR)|"Cementum is considered to protect the underlying root dentin from being resorbed. It is broadly accepted that damage to or deficiency of this protective cementum layer below the epithelial attachment exposes the root surface to osteoclasts, which then resorb the dentin.
~Clinical sign; Located in cervical region of tooth Pink spot might be noted by patient/dentist Tooth usually responds positively to vitality tests unless there is pulpal involvement (in very advanced cases) Spontaneous and profuse bleeding on probing Sharp, thinned out edges around the resorptive cavity"
11022865|NCT04617301||Grup 3. external replacement resorption (ERR)|external replacement resorption also known as trauma-induced resorption - and this resorption may occur in teeth that also have external inflammatory resorption. This review will not discuss external replacement resorption in detail but it will be mentioned where relevant as both types of resorption may occur in some cases. This is because replacement resorption is a consequence of the same injuries that typically cause external inflammatory resorption - such as intrusion and avulsion where there is significant damage to the external root surface during the injury, as well as sometimes during the repositioning/ replantation of the tooth.
11022866|NCT04617288|Experimental|Mean and standard deviations of age and height between group A and B|100 subjects with a mean age of 30.82±6.75 (group A, 31.42±6.67; group B, 30.82±6.82) ranging from 20 to 45 years, with a mean height of 165.52±7.85 (group A, 164.92±7.79; group B, 166.12±7.87) centimeters
11022867|NCT04617288|Experimental|Between group comparison of VAS, NDI and ROM|VAS, NDI and Neck ROM between two groups were compared at pretest (0 day) and posttest (end of two weeks)
11022868|NCT04617275|Experimental|Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
11022869|NCT04617275|Experimental|Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
11022870|NCT04617275|Experimental|Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
11022871|NCT04617275|Experimental|Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
11022872|NCT04617275|Placebo Comparator|Arm 5 - Placebo in subjects with T2DM and Obesity|Matching Placebo tablets taken twice a day (BID)
11022873|NCT04617275|Experimental|Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
11022874|NCT04617275|Experimental|Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
11022875|NCT04617262|Experimental|Remote Problem Management Plus|Five individual sessions of low-intensity psychological intervention
11022876|NCT04617249|Active Comparator|Giving median anesthesia|
11022877|NCT04617249|Active Comparator|Giving paramedian anesthesia|
11022878|NCT04617236|Experimental|Cultivando la Salud Educational Intervention|After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
11022879|NCT04617236|No Intervention|Control|No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
11022880|NCT04617223|Other|Treatment|
11022881|NCT04617210||Surgical Cohort|Elderly patients aged 65 and above who are planned for major non-cardiac surgery predicted to be at least 2 hours in duration and requiring at least 1 postoperative stay in hospital.
11022882|NCT04617197|Experimental|Variable-frequency combination 1|Non disclosure
11022883|NCT04617197|Active Comparator|Variable-frequency combination 2|Non disclosure
11022884|NCT04617197|Placebo Comparator|Control (Placebo)|Non-disclosure
11022885|NCT04617184||Inflammatory Bowel Disease|any patient with IBD will be included in the registry
11022886|NCT04617171|Experimental|Benralizumab|Benralizumab 30 mg given in the form of subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
11022887|NCT04617171|Placebo Comparator|Placebo|Normal Saline given subcutaneously every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
11022888|NCT04617158|Active Comparator|Early adjustable suture surgery|Suture adjustment after 2 hours of surgery
11022889|NCT04617158|Active Comparator|Late adjustable suture surgery|Suture adjustment after 24 hours of surgery
11022890|NCT04617145|Active Comparator|Aerobic exercise group|Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week.
11022891|NCT04617145|Active Comparator|Resistive exercise group|Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Sessions were conducted three sessions/week for eight weeks.
11022893|NCT04617119|Experimental|Conventional physical therapy treatment and IMT|"The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
~In addition, the patient will receive inspiratory muscle training (IMT) by using a threshold IMT device. Patient will ask to use the device twice daily. In each time, patient will perform 3 sets of 10 breaths with 1-minute rest between sets.
~Exercise intensity will start with 10 % of pre-measured maximal inspiratory pressure.
~Once the patient successfully completed 30 breath twice a day, the exercise load will increase 5% more in the subsequent training session.
~This treatment protocol will perform daily for 2 weeks."
11022894|NCT04617119|Active Comparator|Conventional physical therapy|The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
11022895|NCT04617106|Active Comparator|Conventional Palpation group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using the conventional palpation method.
11022896|NCT04617106|Active Comparator|DNTP group|In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using USG-guided dynamic needle tip positioning method.
11022897|NCT04617093|Experimental|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
11022898|NCT04617080|Active Comparator|SUPRACOR Regular|
11022899|NCT04617080|Experimental|SUPRACOR Strong|
11022900|NCT04617067|Experimental|All Patients|Open Label: Paricalcitol 12mcg once daily, orally every day of each 28 day cycle PLUS GEM (1000mg/m2) and Nab-paclitaxel (Abraxane®) (125mg/m2) on days 1, 8 and 15 of each cycle.
11022901|NCT04617054|Experimental|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106|
11022902|NCT04617028|Experimental|Jaktinib|Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.
11022903|NCT04617028|Active Comparator|Hydroxycarbamide|Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.
11022904|NCT04617015|Experimental|Ipratropium bromide|All subjects will receive ipratropium bromide HFA and will have spirometry performed before and after ipratropium.
11022905|NCT04616989|Experimental|Psycho-education intervention arm|Participants will receive psycho-education materials
11022906|NCT04616989|Active Comparator|Comparator arm|Participants will receive COVID-19 leaflets
11022907|NCT04616976||convalescent plasma therapy group|the patients received convalescent plasma therapy
11022908|NCT04616976||Control group|the patients with similar situation without convalescent plasma therapy
11022909|NCT04616963|Other|FTC 200 mg / TDF 300 mg and FTC 200 mg / TAF 25 mg|"Phase I: Participants will continue or initiate F/TDF for PrEP for a minimum 12-week lead-in period prior to switching to F/TAF.
~Phase II: Participants will be switched to study-provided F/TAF for PrEP until 48 weeks after initiation. Participants will receive study treatment for the duration of the study unless they meet criteria for discontinuation."
11022910|NCT04616937|Active Comparator|Galacto-oligosaccharides (GOS) Group|Daily dose of GOS over 4 weeks
11022911|NCT04616937|Placebo Comparator|Placebo group|Daily dose of maltodextrin over 4 weeks
11022912|NCT04616924|Experimental|RHB-204|Each capsule contains clarithromycin 158.3mg; rifabutin 40mg; clofazimine 13.3mg.
11022913|NCT04616924|Placebo Comparator|Placebo|Matching placebo will contain riboflavin, a type of B vitamin, which may discolor urine in a similar fashion as RHB-204.
11022914|NCT04616911|Active Comparator|Rerouting seton|Placement of seton with rerouting of the fistula tract around the internal anal sphincter
11022915|NCT04616911|Active Comparator|LIFT|Ligation of the intersphincteric fistula tract
11022916|NCT04616898|Active Comparator|Diode Laser Treatment Only|Group 1: Patient 1- Laser Only This patient will present 20+, 14, 7, and 1 days prior to his/her scheduled abdominoplasty. Between 20 and 30 days prior, the patient will receive the first laser treatment on the 20+ day site 1. 14 days prior, the patient will receive laser treatment on the 14 day site 2. 7 days prior, the patient will receive laser treatment on the 7 day site 3. 1 day prior to the scheduled abdominoplasty, the patient will receive laser treatment on the 24 hour site 4.
11022917|NCT04616898|Active Comparator|Diode Laser and RadioFrequency Treatment|This patient will present 14 days and 7 days prior to his/her scheduled abdominoplasty. 14 days prior, the patient will be treated at site 1 with the laser and radiofrequency and site 3 with the laser only. 7 days prior, the patient will be treated at site 2 with the laser and radiofrequency and site 4 with the laser only.
11022918|NCT04616898|Active Comparator|Multiple Diode Treatments|These patients will present for three treatments, each four weeks apart, with the abdominoplasty scheduled four weeks following the last laser treatment. These patients will receive laser treatment every four weeks for twelve weeks on the sites labelled Multiple Tx below (sites 1 and 2) on Days -90, -60, and -30 prior to abdominoplasty. At the final treatment (Day -30), two additional diodes will be placed on the sites labelled Single Tx below (sites 3 and 4). 4 diodes total will be used at this visit. Four weeks following this last treatment, the scheduled abdominoplasty will be performed and the pannus containing the treated tissue will be excised.
11022919|NCT04616872|Experimental|Methotrexate-LDE|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
11022920|NCT04616872|Placebo Comparator|Placebo-LDE|Lipid nanoparticle (LDE)
11022921|NCT04616859|Experimental|Alcohol and Energy Drink (AmED)|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml"
11022922|NCT04616859|Active Comparator|Alcohol and Energy drink Placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)"
11022945|NCT04616716|Experimental|4|"Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3
~FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3"
11022923|NCT04616859|Active Comparator|Alcohol placebo and Energy drink|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL"
11022924|NCT04616859|Placebo Comparator|Alcohol placebo and Energy drink placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).
~Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL"
11022925|NCT04616846|No Intervention|Control cohort|
11022926|NCT04616846|Experimental|Infected cohort|
11022927|NCT04616794|Experimental|Cognitive Engagement Group|Participants eligible to enter this group must show low cognitive engagement in cognitively stimulating activities, defined as a score < 22 on the Cognitive Activity Questionnaire (CAQ)
11022928|NCT04616794|Experimental|Physical Activity Group|Participants eligible to enter this group must have a low level of physical activity defined as less than 600 MET-min/week (~150 minutes/week) of moderate to vigorous physical activity (MVPA), measured using the International Physical Activity Questionnaire - short form (IPAQ-SF)
11022929|NCT04616794|Experimental|Diet Group|Participants eligible to enter this group must have a low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale (MDS).
11022930|NCT04616794|Experimental|Multi-modal Group|Participants eligible to enter this group must be eligible for at least two of the three single-arm conditions.
11022931|NCT04616781|Active Comparator|Ketone ester with alcohol consumption|Drink a single dose of ketone ester 1.9 kcal/kg, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
11022932|NCT04616781|Placebo Comparator|Isocaloric dextrose placebo drink with alcohol consumption|Drink a single dose of Isocaloric dextrose placebo drink, complete 1 hour MRI scan, drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
11022933|NCT04616768|No Intervention|Arm A - Control|An arm of 25 patients will not receive PRO surveys, a Fitbit device, or patient feedback texts messages. They will receive shortened utility surveys at 3 and 6 months following enrollment, but their clinicians will not receive dashboards or utility surveys.
11022934|NCT04616768|Experimental|Arm B - Intervention without text feedback|"An arm of 50 enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months."
11022935|NCT04616768|Experimental|Arm C - Intervention with text feedback|"An arm of 50 enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months. Patients in this arm will receive an additional text prior to appointments that summarizes their symptoms and incorporates an active nudge question."
11022936|NCT04616755|Active Comparator|Bonded retainer 13-23|This group have bonded retainer behind six front teeth in the maxilla to keep front teeth stable.
11022937|NCT04616755|Active Comparator|Bonded retainer 12-22|This group have bonded retainer behind four front teeth in the maxilla to keep front teeth stable.
11022938|NCT04616755|Active Comparator|Vacuum-formed retainer|This group have Vacuum-formed retainer covering all erupted teeth in maxilla to keep front teeth stable
11022939|NCT04616742|Experimental|[14C]SHR6390|
11022940|NCT04616729|Experimental|GnRH agonist Depot form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix or Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 3.75 mg Depot form will be used for final oocyte maturation. Ganirelix/Cetrorelix 0.25mg daily (in the morning) will resume for 7 days from the evening of the day of oocyte retrieval onwards. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval.
11022941|NCT04616729|Active Comparator|GnRH agonist Daily form|Ovarian stimulation will be performed using a fixed antagonist protocol with Follitropin Alfa (daily in the evening) and Ganirelix/Cetrorelix (daily in the morning). Selection of the daily gonadotropin dose will be based on ovarian reserve parameters (AMH and AFC) and BMI. Co-administration of 5 mg of letrozole daily (in the morning) commencing on the first day of gonadotropin administration and continuing throughout the ovarian stimulation will be performed as this reduces oestradiol concentrations. GnRH agonist Triptorelin 0.2 mg Daily form will be used for final oocyte maturation. Hormone analysis, analysis of haematology and biochemistry and a pelvic ultrasound scan will be done on days 3, 5 and 7 after oocyte retrieval. The first administration of Triptorelin 3.75mg depot will be scheduled on the first day of the menstrual cycle after oocyte retrieval. To prevent the flare-up produced by the GnRH agonist, daily doses of 0.25mg of Ganirelix/Cetrorelix will be given for seven days.
11022942|NCT04616716|Experimental|1|"Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3
~FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3"
11022943|NCT04616716|Experimental|2|"Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3
~FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3"
11022944|NCT04616716|Experimental|3|"Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3
~FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3"
11024433|NCT04606602|Experimental|600 mg multi dose|
11022946|NCT04616716|Experimental|5|"Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3
~FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3"
11022947|NCT04616716|Experimental|6|"Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3
~FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3"
11022948|NCT04616703||BMI < 25 kg/m2|Those with NFAT and BMI < 25 kg/m2.
11022949|NCT04616703||BMI 25-30 kg/m2|Those with NFAT and BMI 25-30 kg/m2.
11022950|NCT04616703||BMI > 30 kg/m2|Those with NFAT and BMI > 30 kg/m2.
11022951|NCT04616677|Active Comparator|Parts 1 and 2: Cohort 1 (JNJ-42847922)|Healthy participants with normal renal function [estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter (mL)/minute (min)] will receive single oral dose of JNJ-42847922 on Day 1.
11022952|NCT04616677|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with severe renal impairment (eGFR 15 to 29 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
11022953|NCT04616677|Experimental|Part 2 (Optional): Cohort 3 (JNJ-42847922)|Participants with moderate renal impairment (eGFR 30 to 59 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
11022954|NCT04616651|Active Comparator|Pre-Chatbot survey arm|Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
11022955|NCT04616651|Experimental|Post-Chatbot survey arm|Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)
11022956|NCT04616638|Experimental|RT-POWER Intervention|Six familiarization sessions and 20 RT-POWER sessions.
11022957|NCT04616638|Active Comparator|Control Intervention|Six control familiarization sessions and 20 traditional RT sessions.
11022958|NCT04616625||Methamphetamine exposed|Infants born to mothers with prenatal history of MA use during current pregnancy and/or positive meconium toxicology positive for MA in infant.
11022959|NCT04616625||Methamphetamine non-exposed|Infants born to mothers without prenatal history of MA use during this pregnancy and negative meconium toxicology for MA in infant.
11022960|NCT04616612|Experimental|SystemCHANGE (TM)|"SystemCHANGE™ focuses on using patients' already established and reliable systems to support medication-taking, rather than focusing on personal effort and remembering.When applied to medication adherence, the goal is to reduce medication-taking variability and move towards consistently taking medication with a 6-hour window of time (for daily medications like RAAS) and avoid missing medications. SystemCHANGE™ improvement cycles rely on efficient use of performance feedback in order to make decisions about whether system solutions work or if there is a need to select other solutions."
11022961|NCT04616612|Active Comparator|Attention Control|Participants in the attention control will receive educational materials about chronic kidney disease (CKD). The content will be focused on diet, exercise, and living with CKD.
11022962|NCT04616586|Experimental|Arm A|Drug - Siltuximab
11022963|NCT04616586|Other|Arm B|Comparator - Normal Saline
11022964|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery with trabeculotomy using OMNI surgical System|
11022965|NCT04616573|Active Comparator|Ab-interno transluminal viscoelastic delivery using OMNI surgical System|
11022966|NCT04616573|Active Comparator|iStent Inject implantation|
11022967|NCT04616560|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 35 cycles in the absence of disease progression or unacceptable toxicity.
11022968|NCT04616547|Experimental|Supportive care (tin Sn 117m DTPA)|Patients receive tin Sn 117m DTPA IV over 5-10 minutes on day 1. Treatment repeats every 8 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive tin Sn 117m DTPA for an additional 2 cycles if pain recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans, or evidence of clinical progression.
11022969|NCT04616534|Experimental|Treatment (gemcitabine, BAY 1895344)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, and BAY 1895344 PO BID on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11022970|NCT04616521|Experimental|Asymmetric DBS group|In this arm, a one-staged combined unilateral STN and contralateral GPi DBS will be implanted into PD patients. For postural instability and gait difficulty (PIGD)-dominant patients, the GPi in the side contralateral to the leg with longer step length will be targeted. For tremor-dominant (TD) patients, the STN in the side contralateral to the body side that mostly affected will be targeted. For PD patients of mixed type, the choice of target will depend on the judgement of a multidisciplinary team based on clinical features.
11022971|NCT04616508|Experimental|Behavioral testing|
11022972|NCT04616495||Liver transplanted patients|
11022973|NCT04616482||Digital therapeutic carbohydrate restriction (TCR) program|The intervention involves 12 weeks of online/app-based behaviour change coaching. Each week the participant focuses on a different aspect of healthy eating habits designed to cut sugar and refined carbohydrates while encouraging and providing resources for lower-carbohydrate food options. Education is done through short videos and information sheets. Participants set goals and complete worksheets/tasks based on their individual goals.
11022974|NCT04616469|Active Comparator|Root canal treatment using RaCe rotary system|Canal shaping using RaCe rotary system powered with endodontic motor with real time torque monitoring capacity
11022975|NCT04616469|Experimental|Root canal treatment using TruNatomy rotary system|Canal shaping using TruNatomy rotary system powered with endodontic motor with real time torque monitoring capacity
11022976|NCT04616456|Experimental|Multiple System Atrophy (MSA)|Eight subjects with probable MSA diagnosis will be recruited for this study. Each subject will undergo an [F-18]PBR06 PET and MRI scan at baseline, and will receive the experimental drug, verdiperstat (BHV-3241) under supervision of clinic staff. A follow-up [F-18]PBR06 PET and MRI scan will be performed after 6 months (26 weeks) of taking verdiperstat.
11022977|NCT04616443|Experimental|Dose escalation|"The HX008 injection is combined with OH2 injections at 10ˆ6 and 10ˆ7 CCID50/mL at a fixed dose of 200 mg, respectively.
~OH2 will be injected individually in the first week, followed by every two weeks while HX008 will be injected every three weeks after the first injection which will be in the second week."
11024434|NCT04606602|Placebo Comparator|Placebo multi dose|
11022979|NCT04616430|Active Comparator|Topical Endoxifen 10mg/breast/day|10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
11022980|NCT04616430|Active Comparator|Topical Endoxifen 20mg/breast/day|20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
11022981|NCT04616417|Experimental|Investigational Oocyte Cryopreservation|All subjects will undergo controlled ovarian hyperstimulation. They will be treated with variable dosages of injectable gonadotrophins over a period of 8 to 12 days. Response will be monitored using vaginal ultrasound and serum estradiol levels. When appropriate follicle maturation has been achieved, a single dose of human chorionic gonadotropin (hCG) will be administered to induce final oocyte maturation. Thirty-six hours after hCG administration, the subject will undergo standard transvaginal oocyte retrieval under ultrasound guidance. The procedure takes approximately 20 minutes and is carried out under conscious sedation with Fentanyl and Versed. The oocytes are immediately handed off to the embryology technicians in the IVF laboratory.
11022982|NCT04616404|Active Comparator|Intervention Group|
11022983|NCT04616404|Placebo Comparator|Control Group|
11022984|NCT04616391|No Intervention|MDI group:|The patient continues MDI treatment as per routine procedures
11022985|NCT04616391|Experimental|AHCL group|The patient will use MiniMed 780G AHCL system
11022986|NCT04616378|Other|Phase 2 Prescribed Prosthesis|Participants everyday use of prosthesis
11022987|NCT04616378|Experimental|Phase 2 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
11022988|NCT04616378|Other|Phase 3 Prescribed Prosthesis|Participants everyday use of prosthesis
11022989|NCT04616378|Experimental|Phase 3 Robotic Prosthetic Leg|Robotic prosthetic leg with powered knee and passive ankle
11022990|NCT04616378|Experimental|Phase 3 No Prosthesis|Participant performs tasks with no prosthetic device attached
11022991|NCT04616365|Experimental|Semi-Elective Lung Transplantation|Planned Semi-Elective Lung Transplantation Using 10°C Cold Static Preservation
11022992|NCT04616339|Experimental|Treatment Sequence 1|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D)
11022993|NCT04616339|Experimental|Treatment Sequence 2|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment D); Period 4 (Treatment C).
11022994|NCT04616339|Experimental|Treeatment Sequence 3|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment A); Period 3 (Treatment C); Period 4 (Treatment D).
11022995|NCT04616339|Experimental|Treatment Sequence 4|Participants will receive a single 100 mg dose of each formulation of PF-06882961 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment C)
11022996|NCT04616326|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.
~Participants may be eligible for optional open-label extension at the end of the double-blind period."
11022997|NCT04616326|Placebo Comparator|Placebo|"Placebo administered by SQ injection.
~Participants may be eligible for optional open-label extension at the end of the double-blind period."
11022998|NCT04616313||c-cigarette never users|Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.
11022999|NCT04616313||former or current c-cigarette users|Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.
11023000|NCT04616313||never smokers|Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.
11023001|NCT04616287|Experimental|dementia with Lewy bodies|
11023002|NCT04616287|Active Comparator|Alzheimer disease|
11023003|NCT04616287|Sham Comparator|healthy elderly subjects|
11023004|NCT04616274||Venetoclax|Adult CLL patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025.
11023005|NCT04616261|Experimental|SET-HIGH|High volume speed endurance training
11023006|NCT04616261|Experimental|SET-LOW|Low volume speed endurance training
11023007|NCT04616248|Experimental|Cohort A (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
11023008|NCT04616248|Experimental|Cohort B (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
11023009|NCT04616235|Placebo Comparator|CON|This group will do intense aerobic exercise without concomitant IL-6R blockade
11023010|NCT04616235|Active Comparator|BLOCK|This group will do intense aerobic exercise with concomitant IL-6R blockade
11023011|NCT04616222||CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery
11023012|NCT04616222||Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery
11023013|NCT04616209|Experimental|PB103 (donor-derived NK cells) infusion|Cohort 1: 0.5×10^9，Cohort 2:1×10^9 or Cohort 3: 1.5×10^9 cells
11023014|NCT04616196|Experimental|Dose Escalation of NKTR-255 with Cetuximab|Establish RP2D, of NKTR-255 with cetuximab.
11023015|NCT04616196|Experimental|Dose expansion of NKTR-255 with Cetuximab|The RP2D of NKTR-255 will be evaluated in expansion Cohorts A and B.
11023016|NCT04616183|Experimental|Arm A (ERK1/2 inhibitor LY3214996, cetuximab)|Patients receive ERK1/2 inhibitor LY3214996 PO QD on days 1-28 and cetuximab IV over 1-2 hours on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11023062|NCT04615910|Placebo Comparator|Placebo|Patients treated with placebo within the Ver-A-T1D trial
11023235|NCT04614532|Other|control subject|Matching by age (± 5 years), gender, and grade level
11023017|NCT04616183|Experimental|Arm B (ERK1/2 inhibitor LY3214996, cetuximab, abemaciclib)|Patients receive ERK1/2 inhibitor LY3214996 and cetuximab as in Arm A. Patients also receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11023018|NCT04616170|Active Comparator|Hip Flexion|Patients in this arm will be randomized to the routine and common position of hip flexion at the time of delivery of the fetal vertex.
11023019|NCT04616170|Experimental|Hip extension|Patients in this arm will be randomized to hip extension at the time of delivery of the fetal vertex.
11023020|NCT04616157|Experimental|ICBT-I|The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
11023021|NCT04616144|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal lenticule implantation as allogenic implant that will be taken from myopic patients to implant in hyperopic patients with high astigmatism using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity(far,intermediate,near vision) and secondary objective to stabilize(decrease) high astigmatism by reducing K values.
11023022|NCT04616118|Experimental|Phone|Participants randomized to this arm will receive usual care via telephone only
11023023|NCT04616118|Experimental|Video|Participants randomized to this arm will receive usual care via video call
11023024|NCT04616105|Experimental|Cohort 1|Single ascending subcutaneous (SC) dose 1 of REGN6490 or matching placebo
11023025|NCT04616105|Experimental|Cohort 2|Single ascending subcutaneous (SC) dose 2 of REGN6490 or matching placebo
11023026|NCT04616105|Experimental|Cohort 3|Single ascending subcutaneous (SC) dose 3 of REGN6490 or matching placebo
11023027|NCT04616105|Experimental|Cohort 4|Single ascending intravenous (IV) dose 4 of REGN6490 or matching placebo
11023028|NCT04616092|Experimental|FERINJECT Group|Patients with FERINJECT injection
11023029|NCT04616092|No Intervention|Observation Group|Patients without FERINJECT injection
11023030|NCT04616079|Experimental|IV Cohort 1|Single intravenous (IV) dose 1 of REGN6490 or matching placebo
11023031|NCT04616079|Experimental|IV Cohort 2|Single IV dose 2 of REGN6490 or matching placebo
11023032|NCT04616079|Experimental|IV Cohort 3|Single IV dose 3 of REGN6490 or matching placebo
11023033|NCT04616079|Experimental|IV Cohort 4|Single IV dose 4 of REGN6490 or matching placebo
11023034|NCT04616079|Experimental|IV Cohort 5|Single IV dose 5 of REGN6490 or matching placebo
11023035|NCT04616079|Experimental|SC Cohort 1|Single subcutaneous (SC) dose 1 of REGN6490 or matching placebo
11023036|NCT04616079|Experimental|SC Cohort 2|Single SC dose 2 of REGN6490 or matching placebo
11023037|NCT04616079|Experimental|SC Cohort 3|Single SC dose 2 of REGN6490 or matching placebo
11023038|NCT04616066|Experimental|Dates Arm|Consumption of Khalas dates (3 dates =30g undried dates) twice daily (phytoestrogen content 329ug/100g)
11023039|NCT04616066|Experimental|Raisins Arm|Consumption of Raisins (30g twice daily, phytoestrogen content of 9.6ug/100g)
11023040|NCT04616053|Experimental|Intervention group|IMPACT intervention
11023041|NCT04616053|No Intervention|Control group|Usual care
11023042|NCT04616040||unresectable locally advanced/recurrent or metastatic esophageal cancer|
11023043|NCT04616027|Experimental|Healthy participants with normal renal function|This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
11023044|NCT04616027|Experimental|Participants with T2DM with normal renal function|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
11023045|NCT04616027|Experimental|Participants with T2DM with mild renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
11023046|NCT04616027|Experimental|Participants with T2DM with moderate renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
11023047|NCT04616027|Experimental|Participants with T2DM with severe renal impairment|This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
11023048|NCT04616014|Other|ORMD-0801 QD|8 mg QD, daily, in the morning
11023049|NCT04616014|Other|ORMD-0801 BD|8 mg BD, daily in the morning and in the evening
11023050|NCT04616001|Experimental|IVIG|IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days
11023051|NCT04615988||Participants being treated with immunotherapy|Participants who are to receive standard of care immunotherapy targeting PD-1 or PDL1 as treatment for malignancy
11023052|NCT04615975|Experimental|Intervention|Patients will receive 21 days of a very low carbohydrate mediterranean ketogenic diet with phytoextracts and 7 days of a low carbohydrate diet
11023053|NCT04615962|Experimental|SNG100|Combination of low potency steroid with hydrating and moisturizing agents
11023054|NCT04615962|Active Comparator|Hydrocortisone|This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).
11023055|NCT04615962|Active Comparator|Mometasone furoate|This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
11023056|NCT04615949|Experimental|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx
11023057|NCT04615949|Placebo Comparator|Placebo|Placebo
11023058|NCT04615936|Experimental|Methylene Blue-Photodisinfection|The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
11023059|NCT04615923|Experimental|Pridopidine|Pridopidine is administered orally twice daily for 24 weeks.
11023060|NCT04615923|Placebo Comparator|Matching Placebo|Matching placebo is administered orally twice daily for 24 weeks.
11023063|NCT04615897|Experimental|Experimental aging|The subjects received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
11023064|NCT04615897|No Intervention|Control Aging|The subjects doesn´t received 16 sessions (Two per week) of exercise with new tecnology between two measurements of the variable.
11023065|NCT04615884|Experimental|Chinese herbs formula: Shu Yu Wan|Participants will receive Shu Yu Wan capsules, to take 3 times daily for 6 weeks.
11023066|NCT04615884|Placebo Comparator|Placebo|Participants will receive capsules to take 3 times daily for 6 weeks.
11023067|NCT04615871|Experimental|semaglutide|Eligible subjects randomized to this arm will receive semaglutide 0.25 mg s.c. after randomization (Day 0), then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21 in addition to standard of care.
11023068|NCT04615871|No Intervention|control|Eligible subjects randomized to the control arm will receive no active treatment, only standard of care.
11023069|NCT04615858|Active Comparator|Genepro Generation 3|1 scoop, 11g, Genepro Generation 3 Protein daily will be used by Group A (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
11023070|NCT04615858|Active Comparator|Whey Protein|1 scoop, 30g, Whey Protein daily will be used by Group B (20 participants) 10 male, 10 female participants 6 months post bariatric surgery.
11023071|NCT04615845|Experimental|Cellgram-DC-PC|Cellgram-DC-PC is injected subcutaneously near the inguinal lymph nodes
11023072|NCT04615832|Active Comparator|Comparator full face mask 1|
11023073|NCT04615832|Active Comparator|Comparator full face mask 2|
11023074|NCT04615832|Active Comparator|Comparator full face mask 3|
11023075|NCT04615832|Experimental|Toffee Full Face Mask|
11023076|NCT04615819|Experimental|Arm 1|KTFT
11023077|NCT04615819|Experimental|Arm 2|PN
11023078|NCT04615806|Experimental|NIR-ICG|After positioning,Indocyanine green（ICG） dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.
11023079|NCT04615806|No Intervention|Control|This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.
11023080|NCT04615793|No Intervention|CONTROL GROUP|The control group will receive flexibility exercises and strength training focusing on the trunk and lower limb muscles, postural control exercise in different positions and different surfaces and general endurance training . Control group will receive intervention in the form of five minutes warm up followed by 12 minutes of walking at their comfortable pace and concluded with a five minutes cool down
11023081|NCT04615793|Experimental|EXPERMINTAL GROUP|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements will done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises will done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 6 weeks
11023082|NCT04615780|Experimental|mouthwash with green tea group|The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily.
11023083|NCT04615780|Placebo Comparator|mouthwash with tap water group|The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
11023084|NCT04615767|Experimental|D-chiro-inositol|Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days
11023085|NCT04615754|Experimental|3-OHB vs Saline|3-OHB will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
11023086|NCT04615754|Experimental|Saline vs 3-OHB|Saline will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account
11023087|NCT04615741|Experimental|Trauma Informed Yoga|Participants will receive 8 x 60 min group-based yoga sessions, delivered synchronously over Zoom.
11023088|NCT04615741|Experimental|Trauma Informed Psychotherapy|Participants will receive 8 x 90 min group-based psychotherapy sessions, delivered synchronously over Zoom.
11023089|NCT04615741|No Intervention|Control|These participants will not receive an intervention.
11023090|NCT04615728||pre-COVID cohort|Patients recruited from 1st November 2019 to 9th March 2020
11023091|NCT04615728||COVID cohort|Patients recruited from 10th March 2020 to 5th July 2020
11023092|NCT04615715|Experimental|CMV Risk-Reduction Intervention|One-on-one CMV prevention and education visit followed by 12 weeks of CMV prevention and education text messages
11023093|NCT04615715|Placebo Comparator|Stress Reduction Messaging|One-on-one stress reduction messaging visit followed by 12 weeks of reducing stress text messages
11023094|NCT04615702||application of recent guidelines in the management of acute biliary pancreatitis|all patients subjected to the following: Confirmation of the diagnosis of acute pancreatitis, Diagnosis of the cause either biliary or not, Severity scoring and Evidence based management regarding Initial management, Intervention as indicated, Prevention of recurrence and Follow up
11023095|NCT04615689||Infants with febrile urinary tract infection|The investigators will recruit infants hospitalized for acute febrile urinary tract infection. Before starting antibiotics treatment, The investigators will collect feces with the informed consents from infants' parents.
11023096|NCT04615689||Healthy infants|The investigators will recruit healthy controls from the clinics for routine check up with the informed consents from infants' parents.
11023097|NCT04615663||face-to-face patients|During this visit, the investigator will complete the SMI score.
11023098|NCT04615663||Email patients|this visit at M0 + 7d will correspond to the emailing of the Mc_QoL and Burden_MCD questionnaires completed by the patient.
11023099|NCT04615650|Active Comparator|Surgical treatment|Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.
11023100|NCT04615650|Experimental|Non-surgical treatment|Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.
11023101|NCT04615637|Experimental|Sensors|All subjects will follow the same experimental procedure: a recording using classical MEG followed by a recording in the same condition with the OPM He4 prototype.
11023102|NCT04615624|Experimental|Furosemide|When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.
11023103|NCT04615624|Placebo Comparator|Placebo|When patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.
11023104|NCT04615611|Experimental|salbutamol|salbutamol, 800 microgram from metered dose inhaler
11023105|NCT04615611|Placebo Comparator|placebo|placebo
11023106|NCT04615598|Experimental|Action observation group|
11023107|NCT04615598|Placebo Comparator|Placebo group|
11023108|NCT04615585|Experimental|Aloe Vera + Scaling and root planing|
11023109|NCT04615585|Active Comparator|Scaling and root planing|
11023110|NCT04615559|Experimental|contrast enhanced ultrasound|CEUS will be performed at one month post-op, six months post-op and at one year.
11023111|NCT04615546|Experimental|Remote Phase: PBH Patients|Participants will wear continuous glucose monitor (CGM) in a blinded manner (cannot see data output) for 20 days followed by in an unblinded manner (can see data output) for 20 days.
11023112|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions. This group will also wear CGM during a portion of the metabolic tests. May include participants from the Remote Phase or newly enrolled participants.
11023113|NCT04615546|No Intervention|In-Clinic Phase: Surgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
11023114|NCT04615546|No Intervention|In-Clinic Phase: Nonsurgical Controls|Participants will attend 5-8 study visits over the period of approximately 1 month, with metabolic parameters assessed under a variety of conditions.
11023115|NCT04615546|No Intervention|In-Clinic Phase: PBH Patients with indwelling gastrostomy tube|Participants will undergo standardized mixed meal tolerance tests via oral, gastrostomy tube, and concomitant oral + gastrostomy tube routes of delivery with metabolic parameters assessed.
11023116|NCT04615533||Frail older adults, assessment|Frail older adults, assessment Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinetti Blance and Gait Scale
11023117|NCT04615481|Experimental|Elliptical Training Group|Total 30 minutes of elliptical cross training, including warm up, progressive elliptical training and cool down.
11023118|NCT04615481|Experimental|Ergo-metric Training Group|Total 30 minutes of ergometric training
11023119|NCT04615468|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
11023120|NCT04615455|Experimental|Adipose tissue-derived mesenchymal stem cells (ASCs)|One transconjunctival injection of allogeneic ASCs into the LG in one eye.
11023121|NCT04615455|Placebo Comparator|Placebo (vehicle, Cryostor CS10)|One transconjunctival injection of Cryostor CS10 into the LG in one eye.
11023122|NCT04615442|Experimental|All subjects|Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2 periods of 4h during the video EEG.
11023123|NCT04615429|Experimental|Mesenchymal Stromal cells|Approximately 1x10E6 MSC/kg
11023124|NCT04615429|Placebo Comparator|Control group|Solution identical to experimental treatment, without the MSC
11023125|NCT04615416|Experimental|Emotion Regulation Training via Telehealth|All participants will receive 9 sessions of Emotion Regulation Training delivered via telehealth. These individualized therapy sessions are 1-hour in length and occur semi-weekly over the course of four weeks.
11023126|NCT04615403|Experimental|Implantation and Exchange|Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.
11023127|NCT04615377|Experimental|Kaia hip and knee pain app|Kaia software application: Kaia Knee and Hip pain app (version 2.37.0) The Kaia Knee and Hip pain app is an investigational device, which is intended as a digital aid for the self-management of osteoarthritis for use by adults (between 22 to 75 years old) without supervision by healthcare professionals in a home setting.
11023128|NCT04615377|Active Comparator|Treatment as usual|Participants will be encouraged to continue the treatment that they have been on without restriction
11023129|NCT04615351|Active Comparator|Metformin|Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
11023130|NCT04615351|No Intervention|Routine Care|Discharge information about maintaining a healthy diet
11023131|NCT04615338||Homicidal group|The group of patients presented with homicidal open neck injuries
11023132|NCT04615338||Suicidal group|The group of patients presented with suicidal open neck injuries
11023133|NCT04615338||Accidental group|The group of patients presented with accidental open neck injuries
11023134|NCT04615325|Experimental|Single ascending dose stage|Patients will receive a single dose of RO7303359, in multiple escalating cohorts (A-D)
11023135|NCT04615325|Experimental|Expansion cohort stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
11023136|NCT04615325|Experimental|Optional cohort E|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
11023137|NCT04615325|Experimental|Optional cohort F|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
11023138|NCT04615312|Experimental|a CDK4 / 6 inhibitor and a MEK inhibitor|Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment
11023139|NCT04615299|Active Comparator|Auricular acupuncture|Auricular (Battlefield) acupuncture needles will be utilized in the test arm, location of needles and stickers will be placed according to 5 VA approved BFA auricular acupuncture points associated with PONV, pain, and anxiety respectively
11023210|NCT04614714|Experimental|Placebo First|Mothers will receive placebo during the first 7 days of intervention, then NR for the 7 days following washout.
11023140|NCT04615299|Sham Comparator|Sham acupuncture|The control arm will receive sham or placebo acupuncture via pressing of a blunt needle on the specified BFA locations and then application of adhesive stickers. In the control group simulating acupuncture, the needles will never enter the patients' skin and will give the impression to the patient that the procedure has taken place.
11023141|NCT04615286|Experimental|Short course|Antibiotic course of 2-3 weeks overall duration for treating pleural infection
11023142|NCT04615286|Active Comparator|Long course|Antibiotic course of 4-6 weeks overall duration for treating pleural infection
11023143|NCT04615273|Experimental|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
11023144|NCT04615273|Placebo Comparator|Placebo|Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection
11023145|NCT04615273|Active Comparator|Somatropin|Somatropin administered once-daily by subcutaneous injection
11023146|NCT04615260|Other|Single arm subject is own control|Posterolateral fusion is bilateral, patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.
11023147|NCT04615247|Experimental|Yoga Program|The study yoga intervention is designed to provide instruction and practice in selected yoga postures and techniques chosen by an expert panel for their potential to improve pelvic pain in women.
11023148|NCT04615247|Active Comparator|Physical Conditioning Program|A low-impact, muscle stretching and strengthening program.
11023149|NCT04615234||Experimental: Treated with Genetic Test Guide (TGTG)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder guided with the pharmacogenomic test (PGs)
11023150|NCT04615234||Control: Treated as Usual (TAU)|Antidepressant monotherapy treatments according to good clinical practice for major depressive disorder.
11023151|NCT04615221|Other|Graft recipient|During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.
11023152|NCT04615221|Other|Living donor|The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.
11023153|NCT04615221|Other|Witness|10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.
11023154|NCT04615195||children between 8 and 15 years old|answer to the CRIES 13 questionnaire
11023155|NCT04615182|Experimental|OCS Preservation|
11023156|NCT04615169|Experimental|multi-component cognitive intervention using simulated everyday tasks (MCI-SET)|the 12-week intervention, 2 hours weekly session of MCI-SET.
11023157|NCT04615156|Experimental|Evaluation for adverse events from 18F-2-fluoro-2-deoxy-D-glucose produced by a new manufacturer|
11023158|NCT04615143|Experimental|Tislelizumab|Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w*2 cycles)
11023159|NCT04615130|Experimental|Intervention|Patients will undergo 6 weeks of outpatient rehabilitation.
11023160|NCT04615130|No Intervention|Control|Patients will receive no intervention throughout the 6 weeks period.
11023161|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
11023162|NCT04615104||Pelvic Ring Fracture|Patients with pelvic ring fractures.
11023163|NCT04615104||Acetabular Fracture|Patients with acetabular fractures.
11023164|NCT04615078|Experimental|"Telemonitoring group"|Medical Telemonitoring in Non-Invasive Ventilation
11023165|NCT04615078|No Intervention|"Standard of Care group"|Standard medical follow-up: standard home Non-Invasive Ventilation service, with transmission of their ventilator data without analysis leading to alerts
11023166|NCT04615052|Experimental|Exercise group|
11023167|NCT04615052|No Intervention|Control group|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
11023168|NCT04615026||COVID 19 patients|all patients with positive SARS-CoV 2 swap
11023169|NCT04615013|Experimental|Treatment (NBTXR3,IMRT, chemotherapy|Patients receive NBTXR3 IT or IN on day 1. Beginning day 15, patients undergo IMRT 5 days per week for 6 weeks for a total of 28 fractions, in the absence of disease progression or unacceptable toxicity. Concurrent with IMRT, patients receive a chemotherapy regimen consisting of either fluorouracil and oxaliplatin with or without leucovorin, oxaliplatin and capecitabine, docetaxel and fluorouracil with or without leucovorin, docetaxel and paclitaxel, or carboplatin and paclitaxel per physician discretion.
11023170|NCT04614987||Participants undergoing CAR T transfusion|Participants will undergo baseline examination followed by evaluations between Days 3 and 5 post-transfusion and finally on Day 30 post-transfusion. At baseline this will include plasma testing, lumbar puncture (voluntary), neuroimaging (voluntary) and neuropsychiatric performance testing (voluntary). Between post-transfusion Day 3 and day 5, participants will undergo repeat exam, plasma testing, lumbar puncture (voluntary), and neuroimaging (voluntary). Finally, Day 30 testing will again test all modalities, including serum, CSF/lumbar puncture (voluntary), brain imaging (voluntary), and formal neuropsychiatric performance testing (voluntary).
11023171|NCT04614974|Experimental|Speech Language Therapy Alone|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
11023172|NCT04614974|Active Comparator|Speech Language Therapy and Acid Suppression Therapy|Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
11023173|NCT04614961||Patients with overweight, obesity or after bariatric surgery|Patients with overweight, obesity or after bariatric surgery
11023174|NCT04614948|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57.
11023175|NCT04614948|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Day 1 and Day 57.
11023176|NCT04614935|No Intervention|Standard of Care|Pediatric patients with functional constipation who are treated with medications and/or behavioral therapies as they would be if they were not enrolled in the study. In addition to standard of care treatment, these families will fill out a brief quality of life survey.
11023177|NCT04614935|Experimental|Action Plan|Pediatric patients with functional constipation who are treated with standard of care medications and/or behavioral therapies and are also provided with a medication adherence log along with a constipation action plan. These families will also fill out a brief quality of life survey.
11023178|NCT04614922|Experimental|Acceptance and Commitment Therapy|
11023179|NCT04614922|Other|control group|
11023180|NCT04614909|Experimental|Arm A Newly diagnosed glioblastoma treated with pamiparib|Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
11023181|NCT04614909|Experimental|Arm B Recurrent glioblastoma treated with pamiparib|Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
11023182|NCT04614909|Experimental|Arm C Recurrent glioblastoma treated with olaparib|Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
11023183|NCT04614896|Experimental|Ultrasound for measuring DOI in tongue tumors|All patients included with tongue carcinoma
11023184|NCT04614883|Other|Asymptomatic patients|Patient with no symptom of COVID-19 infection but for whom a PCR test needs to be done because he has been in contact with a COVID-19 positive person
11023185|NCT04614883|Other|Symptomatic patients with positive PCR|Patients with symptoms of COVID-19 and whose PCR result is positive
11023186|NCT04614883|Other|Symptomatic patients with negative PCR but with seroconversion within 4 to 8 weeks|Patients with symptoms of COVID-19 and whose PCR result is negative at inclusion but presents a seroconversion within 4 to 8 weeks post inclusion
11023187|NCT04614857|Experimental|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
11023188|NCT04614844|Experimental|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
11023189|NCT04614844|Active Comparator|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
11023190|NCT04614831||Psoriasis and Psoriatic Arthritis|The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis
11023191|NCT04614818||pulmonary lymphoepithelioma-like carcinoma|The primary site of lymphoepithelioma-like carcinoma locates in the lungs.
11023192|NCT04614818||lymphoepithelioma-like carcinoma of thymus|The primary site of lymphoepithelioma-like carcinoma locates in the thymus.
11023193|NCT04614818||lymphoepithelioma-like carcinoma of salivary glands|The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.
11023194|NCT04614818||lymphoepithelioma-like carcinoma of stomach|The primary site of lymphoepithelioma-like carcinoma locates in the stomach.
11023195|NCT04614818||lymphoepithelioma-like carcinoma of esophagus|The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.
11023196|NCT04614818||lymphoepithelioma-like carcinoma of liver|The primary site of lymphoepithelioma-like carcinoma locates in the liver.
11023197|NCT04614818||lymphoepithelioma-like carcinoma of ovaries|The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.
11023198|NCT04614818||lymphoepithelioma-like carcinoma of cervix|The primary site of lymphoepithelioma-like carcinoma locates in the cervix.
11023199|NCT04614818||lymphoepithelioma-like carcinoma of tonsil|The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.
11023200|NCT04614792|Experimental|active treatment|open label experimental treatment
11023201|NCT04614779|Experimental|CN128 Group|"All subjects will be given the lower (10 mg/kg bw, bid) or higher dose (15 mg/kg bw, bid) for 24 or 48 weeks, according to the administration plan.
~The dosage form is tablets."
11023202|NCT04614766|Experimental|Combination Therapy|Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
11023203|NCT04614766|Active Comparator|Lutathera® only|Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
11023204|NCT04614753|Active Comparator|Muscadine Wine First|Participants in this arm will receive Muscadine wine for 28 days. After a 14 day wash-out period, participants will receive Sprite for 28 days.
11023205|NCT04614753|Active Comparator|Sprite First|Participants in this arm will receive Sprite for 28 days. After a 14 day wash-out period, participants will receive Muscadine wine for 28 days.
11023206|NCT04614740|Experimental|VC004|1. Dose escalation stage: subjects in the 50 mg, 100 mg, 200 mg, and 300 mg dose groups took a single oral dose on the first day; starting from the fourth day, each group of subjects took the corresponding dose twice a day. 2. Dose expansion stage: subjects in the 100mg and 200mg dose groups took the corresponding dose twice a day on an empty stomach; 3. Phase II clinical trial stage: oral administration twice a day before meals, and the dosage is to be determined.
11023207|NCT04614727|Experimental|polymeric nano calcium fluoride containing varnish, NANO SEAL.|
11023208|NCT04614727|Other|Casein Phosphopeptide Amorphous Calcium Phosphate Containing Fluoride Varnish,MI varnish|CPP-ACP with 5%NaF
11023209|NCT04614714|Experimental|NR First|Mothers will receive NR during the first 7 days of intervention, then placebo for the 7 days following washout.
11023211|NCT04614688|Experimental|Patient Education Group|Patients in this group will undergo the standard physician-led informed consent process and then be provided with an interactive patient education platform for hysteroscopy on a tablet available in the clinic for up to one hour of time. After the patient has explored the patient education platform, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
11023212|NCT04614688|No Intervention|Standard Consent Group|Patients in this group will undergo the standard physician-led informed consent process only. After they have consented to the surgery, they will be given a post-consent survey which will measure their understanding of the surgery, their readiness for the surgery, and their satisfaction with the consent process.
11023213|NCT04614675|Active Comparator|Transarticular lateral release (TALR)|TALR The first toe is pulled distally for access into the lateral aspect of first MTPJ. A No.15 beaver blade is advanced from the medial incision laterally to divide the lateral capsule vertically and adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
11023214|NCT04614675|Active Comparator|Percutaneous lateral release (PCLR)|PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
11023215|NCT04614662|Experimental|Intervention|"Participants enrolled at intervention sites will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback and links to symptom management care pathways sent to their healthcare providers.
~Symptom screening using SPARK can be performed at any time and as often as desired, but screening will be prompted three times weekly for eight weeks.
~Each day the participant completes symptom screening and has at least one severely bothersome symptom, the primary healthcare team will receive an email summarizing the symptom report and highlighting symptoms that are a lot or extremely bothersome.
~Upon study activation, we will work with each of the 10 intervention sites to develop site-specific, adapted care pathways that consider relevant work flows, institutional culture and available resources."
11023216|NCT04614662|No Intervention|Control|At control sites, usual care will be provided, which may or may not include symptom screening, access to CPGs or care pathways. Participants will complete SSPedi to obtain the primary outcome at weeks 0, 4 and 8 but the scores will not be revealed to providers and will not be linked to care pathways.
11023217|NCT04614636|Experimental|FT538 Monotherapy|FT538 monotherapy in subjects with r/r AML
11023218|NCT04614636|Experimental|FT538 in Combination with Daratumumab|FT538 in combination with daratumumab in subjects with r/r MM
11023219|NCT04614636|Experimental|FT538 in Combination with Elotuzumab|FT538 in combination with elotuzumab in subjects with r/r MM
11023220|NCT04614623|No Intervention|Current Diabetes Management Continued|Continued Insulin Delivery Method and Current Clinic Care of Diabetes
11023221|NCT04614623|Experimental|Video Conferencing+Current Insulin Delivery|Patients continue current insulin delivery modality but receive enhanced clinical management support via video conferencing link by diabetes coordinator
11023222|NCT04614623|Experimental|AHCL pump without Video Conferencing|Patients switch to use of an Advanced Hybrid Closed Loop pump without Video Conferencing standard support
11023223|NCT04614623|Experimental|AHCL pump+Video Conferencing|Patients will use Advanced Hybrid Closed Loop pump with enhanced clinical support via video conferencing
11023224|NCT04614610|Active Comparator|Lidocaine|Lidocaine 1.5mg/kg (Max: 200mg) in dextrose 5% 100mL over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
11023225|NCT04614610|Placebo Comparator|Placebo|Dextrose 5% 100mL (placebo) over 10 minutes along with either morphine 0.1-0.15mg/kg IV OR hydromorphone 0.01-0.02mg/kg IV.
11023226|NCT04614597||Three-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 2, 3, and 4 months of age, collected two blood samples and laboratory test results were available.
11023227|NCT04614597||Two-dose schedule for Sabin IPV|Subjects already vaccinated Sabin IPV at 4 and 8-11 months of age, collected two blood samples and laboratory test results were available.
11023228|NCT04614584|Experimental|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
11023229|NCT04614584|Placebo Comparator|Placebo|Placebo 30 mg PO Daily x 4 days
11023230|NCT04614571|Other|Gluten Challenge|
11023231|NCT04614558|Experimental|Isatuximab for MGRS|Subjects will receive Isatuximab for 6 months and will be followed for an additional one year post therapy for outcome follow-up.
11023232|NCT04614545|Experimental|Virtual Visits|"All patients will be seen face to face on visit 1. Patient will be evaluated by an obesity-medicine specialist and also by a registered dietitian and exercise physiologist via telemedicine. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated), and will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored remotely and patients will receive a remote scale and a remote blood pressure cuff.
~Subjects will then initiate 3 one to one virtual visits with the obesity specialist. On each of this visit the five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. A personalized nutrition and exercise program will be developed. If felt relevant by the provider, subjects may also be referred to a mental health specialist and/or sleep clinic. All medical care will be provided virtually."
11023233|NCT04614545|Active Comparator|Face to face visits|"All patients independently of the randomization arm will be seen face to face on visit 1. Patients will be evaluated by an obesity-medicine specialist and patient will also be seen face to face by a registered dietitian and exercise physiologist. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated). Patients will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored in each of the visits.
~Subjects will then initiate 3 face to face visits with the obesity specialist provider every 4 weeks. The five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress.
~The patient will be provided a personalized nutrition and exercise program and may be referred to a mental health specialist and/or sleep clinic per provider discretion. All medical care will be provided via a face-to-face manner."
11023236|NCT04614519|Active Comparator|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
11023237|NCT04614519|Experimental|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
11023238|NCT04614506||Subject with DS|Participants will complete two visits spaced out by 4 - 8 weeks to undergo neurophysiological assessments (Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]).
11023239|NCT04614493|Experimental|Ultrasound experimental arm|Standard of Care + 15 Ultrasound BBB opening
11023240|NCT04614493|Other|Control arm|Standard of Care
11023241|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells, intracoronary infusion|
11023242|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells, retrograde infusion|
11023243|NCT04614467|Placebo Comparator|Placebo via intracoronary infusion|
11023244|NCT04614467|Placebo Comparator|Placebo via retrograde infusion|
11023245|NCT04614454|Experimental|Experimental arm|Devices will be programmed by our study coordinator to provide a sham signal or the experimental signal. The location of the ENSO device will be determined by the location of the pain with the goal of placing the unit at the top of the dermatological level corresponding to the pain. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
11023246|NCT04614454|Sham Comparator|Sham arm|The sham unit looks identical to the experimental unit. There may be a sensation experienced by subjects with the sham device but it does not deliver an electric current as the experimental units. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
11023247|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
11023248|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
11023249|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
11023250|NCT04614428|No Intervention|Standard Care Group|Participants will receive the standard care provided by their institution.
11023251|NCT04614428|Active Comparator|RESILIENCE Program group|Participants will receive the RESILIENCE Program on top of the standard care provided by their institution.
11023252|NCT04614415|Experimental|Treatment group|group 1 will be treated with autocrosslinked Hyaluronic acid
11023253|NCT04614415|Placebo Comparator|control group|group 2 treated with placebo (isotonic saline solution).
11023254|NCT04614389|Other|CEUS and SWE|CEUS & SWE
11023255|NCT04614376||Control Group|The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
11023256|NCT04614376||Case Group|The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.
11023257|NCT04614363|Experimental|68 Ga PSMA|Comparison between the results of 68 Ga-PSMA PET/CT to conventional imaging (bone scan, CT) in men with high risk prostate cancer.
11023258|NCT04614350|Experimental|A-Active|Markman Biologics, LLC microsurfaced ADM
11023259|NCT04614350|Active Comparator|B-Control|AlloDerm ADM
11023260|NCT04614337|Experimental|LUM-201 (0.8 mg/kg/day)|
11023261|NCT04614337|Experimental|LUM-201 (1.6 mg/kg/day)|
11023262|NCT04614337|Experimental|LUM-201 (3.2 mg/kg/day)|
11023263|NCT04614337|Active Comparator|rhGH (34 µg/kg/day)|
11023264|NCT04614324|Experimental|RhinAer ARC Stylus Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve.
11023265|NCT04614311|Active Comparator|Intervention|Intra-articular corticoisteroid injections into active joints
11023266|NCT04614311|No Intervention|Comparator|No intra-articular injections
11023267|NCT04614298|Experimental|KHK4827 210 mg SC (Subcutaneous)|Single SC administration
11023268|NCT04614298|Placebo Comparator|Placebo SC|Single SC administration
11023269|NCT04614285|Experimental|Partial excavation|The treatment will be performed after applying local anesthetic according to individual needs. The intervention group will receive partial removal of the carious lesion; In the inner part of the lesion, the caries removal will be limited to reach leathery or slightly soft dentin by probing. The restorations will be placed according to evidence based methods and the material used according to the operators material of choice.
11023270|NCT04614285|Active Comparator|Complete excavation|The treatment will be performed after applying local anesthetic according to individual needs. The control group will receive the same treatment procedure as the intervention group, but the excavation procedure will include total removal of the carious tissue. The total caries removal will be ensured with hardness on probing and the visual examination. Photographs will be used as benchmark.
11023271|NCT04614272|Experimental|active prayer group|the active prayer group will mediate over an active type of prayer
11023272|NCT04614272|Experimental|passive prayer group|the passive prayer group will mediate over a passive type of prayer
11023273|NCT04614272|Sham Comparator|control group|the control group will read a poem
11023274|NCT04614259|Experimental|intravenous analgesia|
11023275|NCT04614259|Experimental|infraorbital nerve block|
11023276|NCT04614246|Experimental|BAY1817080 150 mg|Participants will receive 150 mg of BAY1817080 twice daily over a 12-week intervention period
11023277|NCT04614246|Experimental|BAY1817080 75 mg|Participants will receive 75 mg of BAY1817080 twice daily over a 12-week intervention period
11023278|NCT04614246|Experimental|BAY1817080 25 mg|Participants will receive 25 mg of BAY1817080 twice daily over a 12-week intervention period
11023279|NCT04614246|Active Comparator|Elagolix|Participants will receive 150 mg of Elagolix once daily over a 12-week intervention period
11023280|NCT04614246|Placebo Comparator|Placebo|Participants will receive placebo matching BAY1817080 twice daily over a 12-week intervention period
11023281|NCT04614233|Experimental|Oleoylethanolamide (OEA)|Participants will be randomly assigned to take 2 capsules of OEA daily for 8 months, followed by 1 month of 2 capsules of placebo daily, then 3 months of OEA daily, then 1 month of placebo, ending with 3 months of OEA.
11023282|NCT04614233|Placebo Comparator|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months.
11023283|NCT04614194|Experimental|Arm A: Abemaciclib + Letrozole|Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
11023284|NCT04614194|Experimental|Arm B: Letrozole|Patient will take daily letrozole only (Arm B) according to treatment arm for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
11023285|NCT04614181|Experimental|Carbohydrate and protein loading|Nestle Resource drink
11023286|NCT04614181|Active Comparator|Usual care|Usual fracture care as determined by clinical team
11023287|NCT04614168|Active Comparator|Group 1 - Standard Care|This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
11023288|NCT04614168|Experimental|Group 2- Automated insulin delivery and low carbohydrate diet|This group will be placed on an automated insulin delivery system: Tandem t:slim x2 insulin pump with Control IQ technology and Dexcom G6 continuous glucose monitor. They will also be asked to follow a low-carbohydrate diet of 30-40g of carbohydrate per main meal. At baseline they will have a 20-day period of blinded continuous glucose monitoring. Participants in this group will undergo a stepped hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
11023289|NCT04614155|Experimental|Screening (questionnaire, health education, self-collection)|Participants complete questionnaires, take part in a health education session, and receive HPV self-collection kit.
11023290|NCT04614142|Experimental|Experimental: Glecaprevir/pibrentasvir for HCV+ kidney transplant recipient|"Glecaprevir (100mg) / pibrentasvir (40mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor.
~Subject will receive first dose on day 3 (+/- 2 days) post-kideny transplantation and continue daily for 8 weeks."
11023291|NCT04614129|Experimental|Low-Dose CT|Low Dose CT Scan of the Chest
11023292|NCT04614116|Other|Biopsy without cold induction|Participants will undergo a fat biopsy after the first scan, without cooling
11023293|NCT04614116|Other|Biopsy with cold induction|Participants will undergo a fat biopsy after the second scan, with cooling
11023294|NCT04614103|Experimental|Cohort 1|Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1) (tumor proportion score [TPS] < 1%) prior to their CPI treatment.
11023295|NCT04614103|Experimental|Cohort 2|Patients whose tumors expressed PD-L1 (TPS ≥ 1%) prior to their CPI treatment.
11023296|NCT04614103|Experimental|Cohort 3|"Patients whose tumors do not express PD-L1 (TPS < 1%) prior to their CPI treatment and who are unable to safely undergo a surgical harvest for TIL generation due to at least one of the following:
~Unacceptable surgical risk
~Surgically approachable lesion is required for Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessment"
11023297|NCT04614103|Experimental|Cohort 4|Patients who have been previously treated with LN-145 in Cohort 1, 2, or 3 of this study.
11023298|NCT04614090||99 warfarin patients|warfarin patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture. All patients on warfarin were reversed if necessary to INR≤1.5 before surgery using vitamin K and/or four-factor prothrombin complex concentrate (PCC)
11023299|NCT04614090||99 patients without anticoagulants|As a 1:1 ratio control group matched for age, gender and surgical implant. All patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture.
11023300|NCT04614077||A( saline)|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
11023301|NCT04614077||B specific solution|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
11023302|NCT04614064|Experimental|COPD patients|As per inclusion and exclusion criteria for COPD patients
11023303|NCT04614064|Experimental|Healthy volunteers|As per inclusion and exclusion criteria for healthy volunteers
11023304|NCT04614051|Experimental|Cellgram-DC|Cellgram-DC is injected Subcutaneous injection near the upper arm lymph nodes
11023305|NCT04614025|Experimental|PLX-PAD Treatment|"PLX-PAD 300 million cells (20 million/mL) administered via 15 IM injections (1 mL each).
~Single administration in addition to best standard medical care."
11023306|NCT04614025|No Intervention|Control Group|Best standard medical care
11023307|NCT04614012|Experimental|hyperimmune plasma|treated with hyperimmune plasma
11023308|NCT04613999|Other|Single Arm|Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
11023309|NCT04613986|No Intervention|Standard|Standard of care according to our current in house SOP
11023310|NCT04613986|Experimental|Treatment|Standard of care according to our current in house SOP + Therapeutic Plasmaexchange (d1, 3, 5)
11023311|NCT04613973||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
11023312|NCT04613973||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
11023313|NCT04613960|Active Comparator|Magnesium arm|patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.
11023314|NCT04613960|Placebo Comparator|Placebo arm|patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.
11023315|NCT04613947|Active Comparator|Control|The group with standard (written and verbal) information without multiple intelligence test
11023316|NCT04613947|Experimental|Visual/Spatial:|The group with higher visual intelligence according to the multiple intelligence test results and watch video. Also, will given with a written informed consent document
11023317|NCT04613947|Experimental|Verbal/Linguistic|The group with higher verbal/linguistic intelligence according to the multiple intelligence test results and verbally informed in detail about the operation. lso, will given with a written informed consent document
11023318|NCT04613947|Experimental|Bodily/Kinesthetic|The group with higher bodily/kinesthetic intelligence according to the multiple intelligence test results and informed with a dental model. lso, will given with a written informed consent document
11023319|NCT04613921||Group 1|patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
11023320|NCT04613921||Group 2|patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD > 20) at the time of listing (n=500)
11023321|NCT04613921||Group 3|patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)
11023322|NCT04613908|Active Comparator|standard care or usual rehabilitation|It will consist of the usual treatment performed by the intensive care physiotherapist, it will be applied every day that the study lasts.
11023323|NCT04613908|Experimental|neuro muscular electro stimulation|They received 5 sessions per week (except weekends) of neuromuscular electrostimulation of 30 minutes duration. Also, every day that the study is carried out in the morning and in the afternoon, the subjects will receive the usual treatment performed by the intensive care physiotherapist.
11023324|NCT04613908|Experimental|early mobilization protocol|Throughout the duration of the study, an early mobilization protocol will be applied to apply a specific treatment based on different levels of treatment for each subject of the group; It differs from the usual procedure in protocolized progression according to the objectives reached by the patient, unlike the usual treatment, where the progression is in accordance with the clinical criteria of the treatment professional.
11023325|NCT04613895|Experimental|fed state group|just after a meal
11023326|NCT04613895|Experimental|fasted state group|before a meal
11023327|NCT04613882|Experimental|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
11023328|NCT04613882|Active Comparator|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
11023329|NCT04613882|Active Comparator|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
11023330|NCT04613869|Experimental|High-dose esketamine group|After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
11023331|NCT04613869|Experimental|Low-dose esketamine group|After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
11023332|NCT04613869|Placebo Comparator|Control group|PCIA formula: 6mg of hydromorphone + 10mg of tropisetron into 100ml of 0.9% sodium chloride injection, the first dose is 20ug/kg, the background dose is 2ug/kg/h, and the single dose is 4ug/kg/time.
11023333|NCT04613856|Active Comparator|Current Best Practice - 237 mL water bolus|
11023334|NCT04613856|Experimental|New Intervention - 500 mL water bolus|
11023335|NCT04613843|Active Comparator|Water stirring|
11023336|NCT04613843|Experimental|No water stirring|
11023337|NCT04613830|Active Comparator|Erector spinae group|patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae.
11023338|NCT04613830|Placebo Comparator|Opioid GROUP|Patient in group T will intravenously administrate dose of 1 mg/kg/8hr tramal ( opioid) to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic.
11023339|NCT04613804|Experimental|Toripalimab group|Toripalimab 240mg ivgtt Q21d
11023340|NCT04613778|Experimental|Laser acupuncture|Laser acupuncture with knee-chest position
11023341|NCT04613778|No Intervention|No intervention|usual care with knee-chest position
11023342|NCT04613765||Non-migrants|"53 non-migrant patients will be enrolled. Non-migrants will be defined as the group of native-born persons with a Belgian nationality or with a foreign nationality but with both parents native-born."
11023343|NCT04613765||Migrants|"60 migrant patients will be enrolled. This group will include both First Generation (FG) migrants defined as the group of foreign-born persons and Second Generation (SG) migrants defined as people native-born but with either a foreign nationality or with one or both parents foreign-born."
11023344|NCT04613752|Experimental|experimental group|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
11023345|NCT04613739|Experimental|Insurance navigation|The intervention group will be offered access to AAFA's insurance chat bot and navigation services. Navigation will be provided through AAFA's existing online patient community platform that provides assistance with clinical, educational and financial questions and includes secure, personal messaging capabilities that will be supplemented with telephonic outreach.
11023346|NCT04613739|No Intervention|Wait-list controls|Control subjects will be offered the chat bot after completion of data collection for the intervention group (after completion of the four-month follow-up surveys)
11023347|NCT04613726|Placebo Comparator|IV 10 ml normal saline|Control group consisted of patients receiving IV 10 ml normal saline.
11023348|NCT04613726|Active Comparator|IV 8 mg ondansetron in 10 ml of normal saline|This group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
11023436|NCT04613089||CLN7 Disease|Patients with genetic mutations in the CLN7/MFSD8 gene.
11023349|NCT04613726|Active Comparator|IV 3 mg granisetron in 10 ml of normal saline|This group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
11023350|NCT04613713|Experimental|Somatocognitive physiotherapy|Somatocognitive therapy is a multi-modal physiotherapy intervention utilized for women with longstanding chronic pelvic pain and provoked vestibulodynia developed at the beginning of the 2000s as a collaboration between the department of psychosomatic medicine, Oslo University Hospital (OUH) and department of physiotherapy (OsloMet)
11023351|NCT04613713|Active Comparator|Treatment as usual|The participants randomized to the treatment as usual group will follow available treatment options based on the current recommendations from Vulva clinic at Oslo University Hospital, a center that is specialized in treatment of vulvar conditions.
11023352|NCT04613700|Active Comparator|Secretin|
11023353|NCT04613700|Placebo Comparator|Placebo|
11023354|NCT04613687|Experimental|URGOBD001|Compression bandage
11023355|NCT04613674|Experimental|Arm A|
11023356|NCT04613674|Experimental|Arm B|
11023357|NCT04613661||Researcher 1|The first researcher assessing elbow, wrist, and ankle spasticity, respectively
11023358|NCT04613661||Researcher 2|The second researcher assessing elbow, wrist, and ankle spasticity, respectively
11023359|NCT04613648||Group A|Painful and stiff hemiplegic side shoulders of stroke patients
11023360|NCT04613648||Group B|Asymptomatic non-hemiplegic side shoulders of stroke patients
11023361|NCT04613648||Group C|Non-dominant side shoulders of healthy volunteers
11023362|NCT04613635|Experimental|Stratafix|
11023363|NCT04613635|Active Comparator|Vicryl|
11023364|NCT04613622||Venetoclax|Adult patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from August 2020 to December 2025.
11023365|NCT04613609|Placebo Comparator|Placebo|E-cigarette containing no nicotine.
11023366|NCT04613609|Active Comparator|Nicotine|E-cigarette containing nicotine
11023367|NCT04613596|Experimental|Phase 2 Combination with Pembrolizumab TPS <1% , TPS >/= 1%|A Phase 2 MRTX849 in combination with pembrolizumab in patients with NSCLC
11023368|NCT04613583||SAFeR Fetuses|Different maternal lifestyle factors: smoking, BMI, social deprivation, alcohol use, medicines. Depends on specific subproject analyses.
11023369|NCT04613570|Experimental|Yearly endoscopy|Upper gastrointestinal endoscopy every year (12-16 months)
11023370|NCT04613570|Other|Endoscopy every 3 years|Upper gastrointestinal endoscopy every three years (32-40 months)
11023371|NCT04613557|Experimental|CYAD-211|Infusion post preconditioning non-myeloablative chemotherapy
11023372|NCT04613544||Atrial Fibrillation|Atrial fibrillation diagnosed patients.
11023373|NCT04613531||Participants with PD|patients with clinically diagnosed Parkinson's disease
11023374|NCT04613531||Participants without PD|participants clinically diagnosed without Parkinsons' Disease
11023375|NCT04613518|Experimental|BMS-986165 Dose 1|
11023376|NCT04613518|Experimental|BMS-986165 Dose 2|
11023377|NCT04613518|Placebo Comparator|Placebo|
11023378|NCT04613505||Phase 1: Instrument Development|Parents will be asked to participate in a semi-structured interview with one of the researchers that will explore their attitudes toward day of surgery consent. Particular attention will be given to a) study designs, b) previous research experience, and c) previous medical experiences.
11023379|NCT04613505||Phase 2: Questionnaire Adaptation|Parents will be given approximately 5 minutes to review a questionnaire we developed using participant responses in Phase 1. After reviewing the questionnaire, participants will be asked to participate in a semi-structured interview with one of the investigators.
11023380|NCT04613505||Phase 3: Questionnaire Application & Development of Day of surgery consent Table of Guidelines|Participants will be asked to complete the questionnaire developed in Phase 2.
11023381|NCT04613505||Phase 4: Table of Guidelines Refinement|Participants will be given approximately 5 minutes to review the table of guidelines developed in Phase 3. After reviewing the guidelines, participants will be asked to participate in a semi-structured interview with one of the investigators.
11023382|NCT04613492|Experimental|Single dose MEDI9253, sequential Durvalumab|Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing
11023383|NCT04613492|Experimental|Multiple dose MEDI9253, sequential Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;
11023384|NCT04613492|Experimental|Multiple dose MEDI9253, concurrent Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.
11023385|NCT04613453|Experimental|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
11023386|NCT04613453|Active Comparator|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
11023387|NCT04613440|Other|Standard of care - Proband-mediated cascade testing|Probands randomized to the standard of care group will be instructed to share a family letter (providing information on the familial mutation) with their FDRs and encourage FDRs to complete genetic testing.
11023388|NCT04613440|Other|Intervention - Facilitated cascade testing|In the intervention group, a patient navigator will provide facilitated support, including an initial genetic counseling call, an email with a link to an educational video, and, for individuals who are interested in completing testing - a link to create an account for a free saliva kit and a follow-up call to discuss the results and ensure participants are connected with their primary care provider or other clinician, as appropriate.
11023389|NCT04613427||Unruptured intracranial aneurysm|Patients admitted at Haukeland University Hospital in the study period for treatment of UIA.
11023390|NCT04613427||Aneurysmal subarachnoid hemorrhage|Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH.
11023391|NCT04613414|Experimental|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
11023392|NCT04613414|No Intervention|Usual Care|Scheduled for sleep physician appointment approximately 6 months after home sleep apnea test/triage
11023393|NCT04613401||VAD-patients with Telemonitoring|
11023394|NCT04613375|Other|All participants|1 arm study
11023437|NCT04613089||CLN8 Disease|Patients with genetic mutations in the CLN8 gene.
11024628|NCT04605484|Experimental|Viralym-M|Cohort A, Arm 1: Regimen A
11023395|NCT04613362|Experimental|TENACITY Telehealth Cognitive Behavioral Therapy|Six sessions of standardized Cognitive Behavioral Therapy for patients with diagnosed chronic migraine headaches will be delivered by a clinical health psychologist via telehealth platform. All patients have access to a set of standardized educational, headache self-management materials.
11023396|NCT04613362|Active Comparator|Usual Care Outpatient Cognitive Behavioral Therapy Face to Face|Usual care Cognitive Behavioral Therapy will be delivered by clinical health psychologists for patients with diagnosed chronic migraines face to face at the VAMC outpatient clinics. All patients have access to a set of standardized educational, headache self-management materials.
11023397|NCT04613310|Other|Saliva and nasopharyngeal swabs|One patient will have 4 swabs taken, 2 saliva for PCR and RDT, 2 nasopharyngeal for PCR and RDT
11023398|NCT04613297|Other|COVID-19 uninfected patients|Patient with negative PCR result
11023399|NCT04613297|Other|non-hospitalized COVID-19 infected patients|Patient with positive PCR result who does not require hospitalization for COVID-19
11023400|NCT04613297|Other|hospitalized COVID-19 infected patients|Patient with positive PCR who require hospitalization for COVID-19
11023401|NCT04613284|Experimental|Endostar combined Radiation|
11023402|NCT04613271|Experimental|Group 1|"Assignment of Administration Group 1:
~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
11023403|NCT04613271|Active Comparator|Group 2|Administration Group 2: Azithromycin 500 mg once a day for 5 days.
11023404|NCT04613258|Active Comparator|SCAR Porridge Group|There were 22 subjects in the intervention group (I) who received 50 g of SCAR porridge once per day, along with dietary counseling.
11023405|NCT04613258|Active Comparator|Counseling Group|21 subjects in the control group (C) who only received dietary counseling
11023406|NCT04613245||Patient with asthma|
11023407|NCT04613232|Experimental|Apple Watch|The research intervention is continuously monitoring of heart rate and physical activity (minimum 12h/day) with a smartwatch which is connected to a smartphone.
11023408|NCT04613206|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.7 mL HD-IIV (60µg of each influenza antigen) 28-42 days apart
11023409|NCT04613206|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.5 mL SD-IIV (15µg of each influenza antigen) 28-42 days apart
11023410|NCT04613206|Experimental|One Dose High Dose Quadrivalent Inactivated Influenza Vaccine|one dose of 0.7 mL HD-IIV (60µg of each influenza antigen) followed by placebo 28-42 days later
11023411|NCT04613193|Active Comparator|Strict BP intervention group|SBP < 120 mmHg and a reduction in SBP of >= 15 mmHg
11023412|NCT04613193|Other|Conventional BP control group|In patients < 75 years: SBP = 135 mmHg In patients >/= 75 years: SBP = 145 mmHg
11023413|NCT04613180|Placebo Comparator|Group I (control group)|40 patients with obstructive bronchitis who received placebo
11023414|NCT04613180|Active Comparator|Group II|40 patients who received oral montelukast sodium oral, at a dosage of 0.2-0.4 mg/kg/day
11023415|NCT04613167|Experimental|Alirocumab|The first group of patients will receive 150 mg of alirocumab every two weeks subcutaneously for 6 months
11023416|NCT04613167|Experimental|Evolocumab|the second group of patients will receive evolocumab 140 mg every two weeks subcutaneously for 6 months
11023417|NCT04613167|Experimental|Control group|Control group will be included in the treatment after 6 months. During this time, the control group will not receive treatment with alirocumab or evolocumab, only standard guidelines-based treatment
11023418|NCT04613154|Active Comparator|Magnesium|Given 1000 mg oral magnesiumcitrate once daily (4*250mg) during the day of surgery and the next 6 Days.
11023419|NCT04613154|Placebo Comparator|Placebo|Given placebo once daily during the day of surgery and the next 6 Days.
11023420|NCT04613141|Sham Comparator|Mobility-plus|"Mobility-plus is a pseudo placebo comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease."
11023421|NCT04613141|Experimental|WalkingTall-PD|WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
11023422|NCT04613128||Pediatric|Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.
11023423|NCT04613115||Group A|patients without uremia and variant arteries
11023424|NCT04613115||Group B|patients without uremia, but with variant arteries
11023425|NCT04613115||Group C|patients with uremia ,without variant arteries
11023426|NCT04613115||Group D|patients with uremia and variant arteries
11023427|NCT04613102|Experimental|interventional arm, phase 2|"All participant of phase 2 will receive CBD cream for their chronic wound treatment.
~This is an open-label part of the study."
11023428|NCT04613102|Experimental|Interventional arm, phase 3|"Each participants of the phase 3 will receive the active study medication (AVCN583601) during the entire study treatment period on the one of his body sides, and placebo cream - on the other body side simultaneously (left/right). So, each participant will be his own control.
~The research support pharmacy will randomize, which side of the body participant should apply CBD cream on, and provide two jars with the study medications, labeled accordingly ( Left /Right)."
11023429|NCT04613089||CLN1 Disease, Haltia-Santavuori Disease|Patients with genetic mutations in the CLN1/PPT1 gene, causing a lysosomal enzyme deficiency of PPT1.
11023430|NCT04613089||CLN2 Disease, Jansky-Bielschowsky Disease|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1.
11023431|NCT04613089||CLN2 Disease - ERT (Brineura) treated|Patients with genetic mutations in the CLN2/TPP1 gene, causing a lysosomal enzyme deficiency of TTP1, previously and/or currently receiving enzyme-replacement therapy (ERT) with Cerliponase alpha (Brineura).
11023432|NCT04613089||CLN3 Disease, Spielmeyer-Vogt-Sjögren-Batten Disease|Patients with genetic mutations in the CLN3 gene.
11023433|NCT04613089||CLN4 disease, Parry disease|Patients with genetic mutations in the CLN4/DNAJC5 gene.
11023434|NCT04613089||CLN5 Disease|Patients with genetic mutations in the CLN5 gene.
11023435|NCT04613089||CLN6 Disease, Kufs Disease Type A|Patients with genetic mutations in the CLN6 gene.
11023438|NCT04613089||CLN10 Disease|Patients with genetic mutations in the CLN10/CTSD gene, causing a lysosomal enzyme deficiency of Cathepsin D.
11023439|NCT04613089||CLN11 Disease|Patients with genetic mutations in the CLN11/GRN gene.
11023440|NCT04613089||CLN12 Disease|Patients with genetic mutations in the CLN12/ATP13A2 gene.
11023441|NCT04613089||CLN13 Disease, Kufs Disease Type B|Patients with genetic mutations in the CLN13/CTSF gene, causing a lysosomal enzyme deficiency of Cathepsin F.
11023442|NCT04613089||CLN14 Disease|Patients with genetic mutations in the CLN14/KCTD7 gene.
11023443|NCT04613076|Experimental|"Me cuido y me siento mejor"|Patients in the primary care clinics assigned to the intervention will receive eight sessions of a computer-assisted, psycho-educational intervention delivered by trained therapists; structured telephone calls by social worker to monitor clinical progress and treatment adherence; usual medical care for chronic diseases; and access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles. Study therapists will receive biweekly and monthly supervision by psychologist and psychiatrist, respectively. A monthly meeting will be held between the PCC team and a member of the research team to ensure continuity of care.
11023444|NCT04613076|Active Comparator|Enhanced Usual Treatment|The patients in the primary care clinics assigned to the comparator will receive the usual treatment for depression and their physical conditions -all the guaranteed interventions for people with depression, hypertension, and/or diabetes in primary care, according to the Clinical Guidelines for the Treatment of Depression- and their associated basket of health benefits included in the Regime of Explicit Health Care Guarantees. They will have access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles.
11023445|NCT04613050|Active Comparator|Group A (Respiratory Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive respiratory training for 6 weeks.
11023446|NCT04613050|Active Comparator|Group B : (Aerobic Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive aerobic training for 6 weeks
11023447|NCT04613050|No Intervention|Group C : (control group)|It will include 20 patients of both sexes, recovered from COVID-19 infection on medical drugs only will receive no exercise as control group.
11023448|NCT04613037|Experimental|Treatment arm|Fecal Microbial Transplantation in adults with Atopic Dermatitis
11023449|NCT04613024|Experimental|Experiment|Topamax randomized group
11023450|NCT04613024|Active Comparator|Control|Gabapentin randomized group
11023451|NCT04612998|Sham Comparator|Comparator group|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
11023452|NCT04612998|Active Comparator|Active control group|Active control group consisted of patients performing CSEA in the sitting position.
11023453|NCT04612985|Experimental|Procedures with XACT Robotic System|Device: XACT Robotic System The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous lung procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
11023454|NCT04612972|Experimental|Investigational vaccine 1. Wuhan|
11023455|NCT04612972|Experimental|Investigational vaccine 2. Beijing|
11023456|NCT04612972|Placebo Comparator|Placebo/Aluminum Adjuvant of Inactivated SARS CoV|
11023457|NCT04612959|Experimental|Psychosexual care|The psychosexual caring program will be conducted online psychoeducation as a group intervention. The program includes four sessions with home assignments and home readings papers.
11023458|NCT04612959|No Intervention|Standard care|Standard care includes the information given by the nurse about the treatment methods to be applied once.
11023459|NCT04612946|Experimental|Intervention Arm|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit and asked for permission to be referred (name and phone number) to the LCS navigator at Penn Medicine to schedule a telemedicine visit. Patients will also be given the option to directly contact the LCS navigator.
11023460|NCT04612946|Active Comparator|Control Arm|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their primary care providers.
11023461|NCT04612933|Experimental|Intervention group (Telemedicine)|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.
~Patients will follow their usual treatment."
11023462|NCT04612933|No Intervention|No intervention|"All appointments, scheduled and non-scheduled are by face-face communication with the health care professionals.
~Patients will receive their usual treatment."
11023463|NCT04612920|Experimental|Study Group|Participants will receive ibuprofen 800mg every eight hours and acetaminophen 1000mg every eight hours, given at the same time, along with oxycodone five mg every six hours PRN for breakthrough pain.
11023464|NCT04612920|No Intervention|Standard Group|Participants will receive current OU standard of care therapy which includes ibuprofen 800mg every eight hours as needed (PRN), acetaminophen 1000mg every eight hours PRN, and oxycodone five mg every six hours PRN.
11023465|NCT04612907|Active Comparator|Moderate hypo-fractionation|Radiotherapy to the prostate delivered in 3Gy fractions x 19
11023466|NCT04612907|Experimental|Ultra hypo-fractionation|Radiotherapy to the prostate delivered in 6.1Gy fractions x 6
11023467|NCT04612894|Experimental|Neoadjuvant Camrelizumab + Apatinib|Apatinib 250mg, po qd, and Camrelizumab 200mg, iv q2w as neoadjuvant treatment. 28 days as one cycle, for at least two cycles.
11023468|NCT04612881||fitostimoline vaginal pessaries|
11023469|NCT04612868|Experimental|AEYE Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
11023993|NCT04609228||Blood-transfusion non-acceptors|Blood-transfusion non-acceptors
11023470|NCT04612855||Painful post-traumatic trigeminal nerve injuries|Patients presenting with painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
11023471|NCT04612855||Non-painful post-traumatic trigeminal nerve injuries|Patients presenting with non-painful post-traumatic trigeminal nerve injuries according to the recent ICOP criteria.
11023472|NCT04612855||Temporary nerve injuries|Patients with a trigeminal nerve injury with symptom resolution within 3 months after data of trauma.
11023473|NCT04612855||Persistent nerve injuries|Patients with a trigeminal nerve injury and complaints persisting longer than 3 months after the trauma.
11023474|NCT04612842|Experimental|Motivational Interviewing (MI) goup|The MI experimental group will receive all the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 12-month period. MI is an evidence-based communication approach for various health behavior change.
11023475|NCT04612842|No Intervention|Control group|The control group participants will only receive study measurements at baseline, 3-, 6-, and 12-months after the benchmark STEADI clinic visit.
11023476|NCT04612829|Experimental|Intervention- Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
11023477|NCT04612803||IBS-D + dermatographism|IBS-D patients with dermatographism. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
11023478|NCT04612790|Experimental|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.
~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
11023479|NCT04612790|Experimental|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
11023480|NCT04612777|Experimental|Opening Doors to Recovery|Participants will receive services from the team of three ODR navigators: one professional social worker, one navigator who is a family member of someone with SMI, and one peer navigator with lived experience.
11023481|NCT04612777|Active Comparator|Intensive Case Management or Case Management|Participants randomized to the control group will either receive standard services of Intensive Case Management or Case Management, depending on the services that are available in their county.
11023482|NCT04612751|Experimental|DS-1062a|Dose Escalation and Dose Expansion: DS-1062 in combination with durvalumab in participants with advanced or metastatic NSCLC without actionable genomic alterations and previously treated with platinum-based chemotherapy with or without prior immunotherapy.
11023483|NCT04612738|Active Comparator|Group 1:Advance care planning conversation game, 'Hello'|"The 'Hello' game is a commercially available serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The game is played with 4 - 5 players, with each receiving a game booklet and chips. A play reads the first question in the book. Then each player writes down their answers individually and takes turns sharing their answers with the group. Players control what they share, how long they share and when to move to the next questions. During the conversation, plays can acknowledge others for a thoughtful, poignant or even funny comments by giving them a chip. A pre-game coin flip determines whether the player with the most chips wins the game (heads) or player with the least chips win (tails) the game.
~Other names; previously name My Gift of Grace"
11023484|NCT04612738|Active Comparator|Group 2: The Conversation Project (CP) Starter Kit|The 'CP Starter Kit' (available for free online) is an 11-page workbook with open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so.
11023485|NCT04612738|Placebo Comparator|Group 3: Control Arm (Placebo control game, 'Table Topics')|A placebo/attention control l conversation game called 'Table Topics' will be used. Table Topics is a general conversation starter game that is unrelated to advance care planning. It involves answering open-ended questions in a group setting about a variety of topics.
11023486|NCT04612725|Experimental|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
11023487|NCT04612725|Experimental|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
11023488|NCT04612725|Experimental|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
11023489|NCT04612725|Experimental|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
11023490|NCT04612725|Experimental|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
11023491|NCT04612712|Experimental|Donafenib+ KN046|Donafenib 50mg BID/100 mg BID/200 mg BID orally + KN046 5mg/kg Q3W iv
11023492|NCT04612699|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+ Placebo 75mg Bid
11023493|NCT04612699|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 50mg*2 Bid
11023494|NCT04612699|Experimental|Jaktinib 100mg Bid|Jaktinib 50mg*2 Bid+ Placebo 75mg Bid
11023495|NCT04612699|Placebo Comparator|Placebo|Placebo 50mg*2 Bid+ Placebo 75mg Bid
11023496|NCT04612686||Frail|"At screening participants will be classed as frail if their Electronic Frailty Index score is >0.24 and if their Clinical Frailty Scale score is 6. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 3 or more frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as frail.
~All participants will receive the same assessment procedures."
11023520|NCT04612530|Experimental|Arm B: IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will first receive (an incomplete) IRE of the primary pancreatic tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
11023497|NCT04612686||Pre-frail|"At the point of screening, participants will be classed as pre-frail if their Electronic Frailty Index score is 0.13-0.24 and if their Clinical Frailty Scale score is 4-5. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 1 or 2 frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as pre-frail.
~All participants will receive the same assessment procedures."
11023498|NCT04612686||Non-frail|"At the point of screening, participants will be classed as non-frail if their Electronic Frailty Index score is 0-0.12 and if their Clinical Frailty Scale score is 1-2. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting no frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as non-frail.
~All participants will receive the same assessment procedures."
11023499|NCT04612673|Experimental|Treatment|Participants received Sintilimab, 200mg, iv, d1, Q3W,and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
11023500|NCT04612660|Experimental|Specific Education and Dynamic Group|"Motivational group education specifically focused on cervical cancer prevention;
~Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
~Engaging community bilingual physicians in cervical cancer screening and referral;
~Patient navigation assistance."
11023501|NCT04612660|Active Comparator|General Health Education|Comparison group participants received general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
11023502|NCT04612647|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)-[Parents and Children-Workshop Group]. In addition to the workshops, this group and the home-based group will receive information (activity booklets) and physical education (physical activity)-related equipment.
11023503|NCT04612647|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops, but they will receive the same information (activity booklets) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
11023504|NCT04612647|No Intervention|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks and 3 months after the completion of the 12-week period. Immediately following the follow-up test (3 months after the intervention), participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
11023505|NCT04612634|Experimental|Research Group 1|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
11023506|NCT04612634|Active Comparator|Research Group 2|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
11023507|NCT04612634|Active Comparator|Research Group 3|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
11023508|NCT04612608|No Intervention|Control|Usual Care
11023509|NCT04612608|Active Comparator|Intervention|Intervention arm
11023510|NCT04612595||Group A|Group A are males with CKD stage 1-2.
11023511|NCT04612595||Group B|Group B are males with CKD stage 3-4.
11023512|NCT04612595||Group C|Group C are females with CKD stage 1-2.
11023513|NCT04612595||Group D|Group D are females with CKD stage 3-4.
11023514|NCT04612582|Experimental|Group1|Group1 is the AL amyloidosis patients who have bortezomib-thalidomide-dexamethason-based regimens for their treatment.
11023515|NCT04612582|Experimental|Group2|Group2 is the AL amyloidosis patients who have bortezomib-cyclophosphamide-dexamethason-based regimens for their treatment.
11023516|NCT04612556||late-onset severe eosinophilic asthma and fixed obstruction|Patients with late-onset severe eosinophilic asthma and fixed obstruction will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
11023517|NCT04612543|Active Comparator|Genial Posterior Composite with Polyethylene fiber|The enamel and dentin were conditioned with bonding procedure.After bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus - Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
11023518|NCT04612543|Active Comparator|Genial Posterior Composite|The enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
11023519|NCT04612530|Active Comparator|Arm A: Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will start with the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
11023681|NCT04611308||cases|
11023682|NCT04611308||controls|
11023521|NCT04612530|Experimental|Arm C: CpG + IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), a toll-like receptor ligand (CpG) will be administered into the primary pancreatic tumor. A week later, the patient will receive (an incomplete) IRE of the primary tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
11023522|NCT04612517|Experimental|ZP7570|Three ascending doses of ZP7570
11023523|NCT04612517|Placebo Comparator|Placebo|Corresponding volume of placebo
11023524|NCT04612504|Experimental|Part 1 Cohort 1: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 1, SynOV1.1 will be administered at 3×10^11 VP by IT injection, Q3W.
11023525|NCT04612504|Experimental|Part 1 Cohort 2: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 2, SynOV1.1 will be administered at 1×10^12 VP by IT injection, Q3W.
11023526|NCT04612504|Experimental|Part 1 Cohort3: SynOV1.1 dose escalation|In SynOV1.1 dose escalation Cohort 3, SynOV1.1 will be administered at 3×10^12 VP by IT injection, Q3W.
11023527|NCT04612504|Experimental|Part 2 Cohort 1: SynOV1.1 in combination with Atezolizumab dose escalation|"Recommended dose for combination study (RDCS) of SynOV1.1will be established based on results from Part 1.
~SynOV1.1 will be administered intratumorally at 0.5 × RDCS every 3 weeks up to 6 doses. Atezolizumab will be administered at the dose of 1200 mg in 3-week cycles."
11023528|NCT04612504|Experimental|Part 2 Cohort 2: SynOV1.1 in combination with Atezolizumab dose escalation|"Recommended dose for combination study (RDCS) of SynOV1.1will be established based on results from Part 1.
~SynOV1.1will be administered intratumorally at RDCS every 3 weeks up to 6 doses. Atezolizumab will be administered at the dose of 1200 mg in 3-week cycles."
11023529|NCT04612504|Experimental|Dose expansion|In dose expansion study, Atezolizumab will be administered intravenously at the dose of 1200 mg and SynOV1.1 will be administered by IT injection every 3 weeks for up to 6 cycles.
11023530|NCT04612491||Pre-operative Consultation|
11023531|NCT04612491||No consultation|
11023532|NCT04612478|Other|Clinic-Based Physical Therapy|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
11023533|NCT04612478|Other|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program. The SDEP manual will provide detailed instructions on exercises, such as repetitions, frequency, and required equipment, which can be implemented in the home environment. The basis for the exercise regimen is derived from the American Academy of Orthopaedic Surgeons (AAOS) sample home based exercise program available in handout form. The program provides instructions on exercises, repetitions or duration, frequency, and required equipment which can be implemented in the home environment.
11023534|NCT04612478|No Intervention|Observational|Patients who are unwilling to be randomized will be enrolled in an observational arm of the study. They will be asked to complete all baseline and follow-up assessments, and participation in formal PT or SDEP will be documented.
11023535|NCT04612465|Experimental|ASC(Autologous Adipose-derived Mesenchymal Stem Cells)|
11023536|NCT04612465|Placebo Comparator|Fibringlue|
11023537|NCT04612452||Lighthouse Trust in Lilongwe|
11023538|NCT04612452||CIDRZ in Lusaka|
11023539|NCT04612439|Experimental|VABB Elite 10G|Vacuum-assisted Elite 10G
11023540|NCT04612439|Active Comparator|BARD 14G CNB|BARD 14G Core needle
11023541|NCT04612426|Experimental|Brain-computer Interface-Pedaling Training System|
11023542|NCT04612426|Sham Comparator|Traditional Pedaling Training System|Patients wear the same EEG equipment that only collect data, but not guide training.
11023543|NCT04612413|Placebo Comparator|Cohort 1|375 ml Ringer's lactate solution
11023544|NCT04612413|Experimental|Cohort 2|Single IV dose of Allocetra-OTS contain 5x10^9 cells
11023545|NCT04612413|Experimental|Cohort 3|Single IV dose of Allocetra-OTS contain 10x10^9 cells
11023546|NCT04612413|Experimental|Cohort 4|Single or two IV doses of Allocetra-OTS contain 10x10^9 cells in each dose
11023547|NCT04612400|Experimental|Low|Low dose (6.3g) EAA/whey protein supplement
11023548|NCT04612400|Experimental|High|High dose (12.6g) EAA/whey protein supplement
11023549|NCT04612387|Experimental|Mind-body Intervention arm|Online yoga, meditation and nutrition tips.
11023550|NCT04612374|Experimental|Phase 1: Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
11023551|NCT04612374|Experimental|Phase 1: Experimental: Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
11023552|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
11023553|NCT04612374|Experimental|Phase 2: Revised Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
11023554|NCT04612361||non impaired sleep group|about 200-250 patients
11023555|NCT04612361||insomnia group|about 200 patients
11023556|NCT04612361||sleep deprived group|about 200-250 patients
11023557|NCT04612348||NJ tube fed|Critically ill children receiving nutrition via a nasojejunal feeding tube.
11023558|NCT04612348||NG tube fed|Critically ill children receiving nutrition via a nasogastric feeding tube.
11023559|NCT04612335|Experimental|Watchful waiting|the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate <110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
11023560|NCT04612335|Other|Routine care|Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
11023561|NCT04612322||Patients undergoing coronary microvascular function assessment|
11023562|NCT04612309||Treated|Patient with colorectal cancer already treated with immunotherapy
11023563|NCT04612283|Active Comparator|NGA-01 gel|A formulation with natural ingredients expected to be used for joint pain in Osteoarthritis
11023564|NCT04612283|Placebo Comparator|Placebo gel|Placebo gel with no active ingredient
11023565|NCT04612270|Experimental|Participants for blood collection|The blood samples of all participants will be treated equally according to the study protocol. No intervention in-vivo.
11023566|NCT04612257|Experimental|Insulin alone closed-loop|Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
11023567|NCT04612231|Active Comparator|T-STEP Intervention|The T-STEP is a comprehensive 12-week transition program that will be delivered in a community college setting. The curriculum includes 36 hours of group-based instruction delivered within a traditional school academic semester (i.e., 24 ninety-minute classes across 12 weeks). Students also participate in a weekly community-based internship to practice the skills learned in the intervention group (2 hours per week for 12 weeks). In addition, students participate in 12 hours of manualized individual counseling services that are traditionally available on a college campus (e.g., job exploration/career counseling, academic counseling, and self-advocacy counseling).
11023568|NCT04612231|Active Comparator|Counseling Only Intervention|Participants in the Counseling Only condition will receive the same manualized counseling sessions that are included in the T-STEP program. Specifically, 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
11023569|NCT04612205|Experimental|group A|females complain from SUI treated by TECAR and pelvic floor exercises
11023570|NCT04612205|Active Comparator|group B|females treated by pelvic floor exercises only
11023571|NCT04612192|Experimental|Active light|active blue-enriched bright light
11023572|NCT04612192|Placebo Comparator|Placebo light|dim red placebo light
11023573|NCT04612179||All Comer Patients|All-comer patients (≥80 years) affected by acute coronary syn-drome (NSTE-ACS), stabile angina, or silent angina, who qualify for percutaneous coronary intervention (PCI) according to ESC-treatment guidelines and physicians' clinical routine estimation.
11023574|NCT04612166|Experimental|Intervention|Patients will receive a medication action plan approved by themselves and their primary care providers to reduce their medications. They will also receive check in calls and follow ups from study health coaches to monitor their progress. During health coaching sessions motivational interviewing techniques and patient empowerment strategies will be used by trained health coaches.
11023575|NCT04612166|No Intervention|Control|Will participate in assessments for the study (baseline and 6 month follow up) and will complete 24 months of falls calendars. No intervention will be given to this group, but standard practices of care delivered by the MercyOneSM Health Network.
11023576|NCT04612140|Experimental|Radiosurgery|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
11023577|NCT04612140|Active Comparator|Repeated catheter ablation|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
11023578|NCT04612127|Experimental|Experimental group - Spinach|"Consumption for 90 days of spinach extract (1000mg)
~Four capsules will be consumed per day, two with breakfast and two with lunch."
11023579|NCT04612127|Placebo Comparator|control group Placebo (sucrose)|Four capsules will be consumed per day, two with breakfast and two with lunch.
11023580|NCT04612114||Possible OSA|Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
11023581|NCT04612088|Experimental|Bariatric Multivitamin|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
11023582|NCT04612088|No Intervention|Waitlist|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
11023583|NCT04612075||All patients referred to fast track clinical pathway for HNC cancer|MRI as part of staging, including a 5-minute additional sequence.
11023584|NCT04612075||Patients with locally advanced HNC|FDG-PET/MRI
11023585|NCT04612062|Experimental|Healthy Subjects (Part A)|
11023586|NCT04612062|Experimental|Atopic Dermatitis (Part B)|
11023683|NCT04611295|Experimental|Teleneurological evaluation and support|teleneurological evalutaion using a medical device certified as telemedicine system
11023684|NCT04611282|Experimental|Microsurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using microsurgery technique.
11023994|NCT04609228||Blood-transfusion acceptors|Blood-transfusion acceptors
11023587|NCT04612049||Children with hemiplegia|40 children with hemiplegia, 7-16 years-old at Gross Motor Function Classification System (GMFCS) Levels I-III and Manual Ability Classification System (MACS) Levels I-II will be recruited as participants. This age range was chosen based on our preliminary research in which children under the age of 7 had difficulty attending to repetitive task practice. Individuals will be recruited without regard to race or ethnicity. Our goal is to have a study sample that is 50% male and 50% female, and approximates the population of the Greater Boston, MA region.
11023588|NCT04612049||Typically developing children|40 typically developing children, 7-16 years-old.
11023589|NCT04612036||Journey II Bi-Cruciate Stabilized|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
11023590|NCT04612036||Journey II Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
11023591|NCT04612036||Journey II Bi-Cruciate Retaining|Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
11023592|NCT04612023|Active Comparator|1 mL NyDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 1 mL NyDYN injection.
11023593|NCT04612023|Active Comparator|2 mL NuDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL NyDYN injection.
11023594|NCT04612023|Placebo Comparator|Placebo of Sterile Saline|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL dose of sterile saline.
11023595|NCT04612010|Active Comparator|Alpha frequency|Wobble oscillation will revolve the individual alpha frequency
11023596|NCT04612010|Active Comparator|Alpha frequency plus|Wobble oscillation will revolve the individual alpha frequency plus 0.5Hz
11023597|NCT04612010|Sham Comparator|Theta frequency|Wobble oscillation will revolve the individual theta frequency
11023598|NCT04611997|Experimental|Group A|Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group)
11023599|NCT04611997|Placebo Comparator|Group B|Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)
11023600|NCT04611984|Experimental|Piezocision|Piezocision was performed on the mesial and distal side of the maxillary right canine tooth which was served as the piezocision group. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
11023601|NCT04611984|Active Comparator|Control|Maxillary left canine served as the control group and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
11023602|NCT04611971|Active Comparator|Active Arm: Benlysta + Candin|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously.
11023603|NCT04611971|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta.
11023604|NCT04611958|Experimental|Bupivacaine arm|Participants undergoing ERCP as part of routine clinical care will be consented for this study.
11023605|NCT04611932|Experimental|Reference-Reference-Test|
11023606|NCT04611932|Experimental|Reference-Test-Reference|
11023607|NCT04611932|Experimental|Test-Reference-Reference|
11023608|NCT04611906||Stroke patient|Patients who have acute cerebral ischemic symptoms attributed by cSVD can be recruited into this study. Eligible patients will be screened by Neurologists based on the inclusion and exclusion criteria. The time window for recruitment of the patient is 4 weeks from the qualifying stroke.
11023609|NCT04611893||Ischemic stroke patient|Ischemic stroke patients who are on dabigatran, apixaban and rivaroxaban based on the above inclusion and exclusion criteria will be recruited from the Prince of Wales Hospital, either in-patient or out-patient clinic
11023610|NCT04611880|Other|Single Arm Study|Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion. Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle. On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual. Crizanlizumab will be administered over 30 minutes by IV infusion
11023611|NCT04611867|Experimental|Intervention Arm|"The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:
~Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff
~Daily monitoring of self-reporting by study staff
~Intervention if required based on self-reporting
~Reports to oncologists (at consultation)
~Information module about treatment, side effects and contact information"
11023612|NCT04611867|No Intervention|Standard Arm|"Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. call early and often."
11023613|NCT04611854|Active Comparator|ICBT for alcohol misuse: Guidance|In this arm, participants will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
11023614|NCT04611854|Experimental|ICBT for alcohol misuse: Self-Guidance|Participants who select this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol each week and measures of depression and anxiety administered at the beginning of week 5. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation).
11023685|NCT04611282|Active Comparator|Macrosurgery group|All defects were treated with a CPF plus an SCTG by the same investigator using macrosurgery technique.
11025209|NCT04601584|Experimental|GNR-084, 60 ng/kg|Anti-CD19 / CD3 antibody
11023615|NCT04611828|Experimental|Philips SmartSleep Device|"Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):
~continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities
~block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation
~in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave
~Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation"
11023616|NCT04611815|Active Comparator|Robotic-assisted total knee arthroplasty|Patients undergoing robotic-assisted total knee arthroplasty with use of Journey II BCS implants
11023617|NCT04611815|Active Comparator|Conventional total knee arthroplasty|Patients undergoing conventional total knee arthroplasty with use of Journey II BCS implants
11023618|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
11023619|NCT04611802|Placebo Comparator|Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
11023620|NCT04611789|Experimental|LY3832479|LY3832479 administered subcutaneously (SC).
11023621|NCT04611789|Placebo Comparator|Placebo|Placebo administered SC.
11023622|NCT04611776|Experimental|Arm A: Atezolizumab + platinum-doublet followed by atezolizumab maintenance|
11023623|NCT04611776|Placebo Comparator|Arm B: Placebo + platinum-doublet followed by placebo maintenance|
11023624|NCT04611763|Experimental|Pre FA Group|
11023625|NCT04611763|Active Comparator|Post FA Group|
11023626|NCT04611750|Experimental|Active Medication (AD036)|Participants will take AD036 QHS for 14 days.
11023627|NCT04611750|Placebo Comparator|Placebo Medication|Participants will take placebo QHS for 14 days.
11023628|NCT04611737|Experimental|Experimental group|The researcher interviews with participants for 3 times.
11023629|NCT04611737|No Intervention|Control group|The participants receive usual care.
11023630|NCT04611724|Experimental|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
11023631|NCT04611711|Other|decitabine＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine (10mg ivgttqd, d1-5) combined with TQB2450 injection (1200mg ivgtt, d5)
11023632|NCT04611711|Other|decitabine + anlotinib ＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine and Anlotinib (decitabine 10mg ivgtt qd, d1-5; Anlotinib 8mg po.qd, d5-18) combined with TQB2450 injection (1200mg ivgtt, d5), using the traditional 3+3 experimental design (First enroll 3 subjects. If 1 case of DLT is observed, 3 more subjects need to be added to the same dose group to further evaluate the toxicity) to observe DLT to evaluate MTD. The trial starts from the 8mg dose of Anlotinib Start.
11023633|NCT04611698|Experimental|Immediate loading group|Visit 1 Implant surgery + Device loading Baseline Visit 2 Followup examination 2 weeks (2/+ 5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
11023634|NCT04611698|Experimental|2-week loading group|Visit 1 Implant surgery Baseline Visit 2 Device loading 2 weeks (2/+5 days) Visit 3 Followup examination 3 months (± 1 week) Visit 4 Followup examination 6 months (± 1 week) Visit 5 Followup examination 12 months (± 1 month)
11023635|NCT04611685|Experimental|NSAIDs|Parecoxib (iv.) for once & Loxoprofen (po.) for routine use during the first 3 postop. days.
11023636|NCT04611685|Active Comparator|Tramadol|Tramadol (im.) for once & Tramcontin (po.) for routine use during the first 3 postop. days.
11023637|NCT04611672||Patients with stroke|Patients with stroke of all subtypes, with and without different Kind of Lysis therapy
11023638|NCT04611672||Controls|Healthy controls of all Ages above 18 years
11023639|NCT04611659|Active Comparator|Information Only|Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
11023640|NCT04611659|Experimental|Motivational Interviewing and Educational Training (MIET)|Women randomized to the treatment group will complete the baseline survey and receive the same brochure; however, they also will receive structured education regarding unintended pregnancies among women using opioids, potential complications associated with opioid, alcohol, and other drug use, and education on contraceptive use (with an emphasis on LARC). This structured education will be coupled with a brief, initial MI conversation. The interventionist will receive respective patients' MINI for opioids,37 contraceptive survey, and WHO-QOL-B from the research coordinator, and the answers to the survey forms will expedite the conversation around each woman's contraceptive desires.
11023641|NCT04611646|Experimental|Heat-suit training|Low-intensity endurance training with heat suit
11023642|NCT04611646|Other|Non-heat-suit training|Low-intensity endurance training without heat suit
11023643|NCT04611620||Breast Cancer and Colorectal Cancer Survivors|The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
11023644|NCT04611594|Experimental|Fluid restriction|Prescription to ingest approximately 20 ml / kg of ideal weight.
11023645|NCT04611594|No Intervention|Control|Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.
11023646|NCT04611581||PD patients with apathy|PD patients with apathy according to the diagnostic criteria by Robert et al. 2018
11023647|NCT04611581||PD patients with impulse control disorder|PD patients with a) at least one item >2 or b) at least two items >1 on the hyperdopaminergic subscale of the Ardouin Scale of Behaviour in Parkinson's Disease
11023648|NCT04611581||PD patients without any relevant neuropsychiatric symptoms|PD patients with a score <2 on each item of the Ardouin Scale of Behaviour in Parkinson's Disease
11023721|NCT04610983|Experimental|Treatment 2 - Solid food matrix|Vegetable encapsulated algal oil integrated with a solid food product (extruded snack) to deliver 400 mg DHA.
11023722|NCT04610970|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
11023649|NCT04611568|Experimental|Prevention (health educational campaign)|"MEDIA CAMPAIGN: Participants view digital media strategies.
~PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.
~MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.
~HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture."
11023650|NCT04611555||CI users|
11023651|NCT04611542|Experimental|FIR Prototype Evaluation|30 fathers in recovery from opioid-use disorder will receive the prototype FIR online intervention.
11023652|NCT04611529|Experimental|Oral ibuprofen + topical diclofenac|Oral ibuprofen 400mg Topical diclofenac 2gm
11023653|NCT04611529|Active Comparator|Oral ibuprofen + topical placebo|Oral ibuprofen 400mg Topical placebo
11023654|NCT04611529|Active Comparator|Oral placebo + topical diclofenac|Oral placebo Topical diclofenac 2gm
11023655|NCT04611503|Experimental|Subretinal injection of rAAV.hPDE6A|Single subretinal injection of rAAV.hPDE6A
11023656|NCT04611477|Placebo Comparator|Placebo|One capsule/day to be taken orally 30 minutes before breakfast
11023657|NCT04611477|Active Comparator|Synbiotic365 Ver 5|One capsule/day to be taken orally 30 minutes before breakfast
11023658|NCT04611477|Active Comparator|Synbiotic365 Ver 7|One capsule/day to be taken orally 30 minutes before breakfast
11023659|NCT04611464||Single-group cross-sectional cohort|"Patients who have previously received off-label prescriptions of misoprostol for lumbar spinal stenosis for any duration and who are willing to provide verbal and informed consent.
~Once enrolled, patients will complete the Swiss Lumbar Spinal Stenosis Questionnaire (SSSQ) as well as the Oswestry Disability Index (ODI). The SSSQ will elicit patients' responses specifically related to their usage of misoprostol for lumbar spinal stenosis.
~Then their walking tolerance will be assessed by having them walk along a measured walkway of up to 500 feet to determine the onset of their neurogenic claudication symptoms at a certain distance, their claudication distance.
~Prescription information on dosage and frequency of misoprostol use, and any reported side effects with use of this medication, and any cessation or stoppage of use of this medication will all be recorded."
11023660|NCT04611451|Experimental|whole body vibration group|Patients in the WBV exercise group; 24 sessions of TVT exercise 3 days a week (with at least 1 day of rest between each session) was performed under the supervision of a physician for a total of 8 weeks. Patients in the WBV exercise group were also shown a classic lumbar home exercise program and they were asked to apply for 8 weeks
11023661|NCT04611451|Active Comparator|exercise|The second group (control) only received classical lumbar home exercise program.
11023662|NCT04611438|Experimental|CBD|The patient would be on cannabidiol for 24 weeks and would go through laboratory, electroencephalography, and neuropsychological tests before, during, and after intervention.
11023663|NCT04611425|Experimental|Remimazolam|"Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours.
~The dose of Remimazolam will be adapted according to our ICU protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale)"
11023664|NCT04611412||1 group|Group I consisted of 17 people (16.83%) with a uniform type of obesity
11023665|NCT04611412||2 group|Group II included 38 children with AO, and 20 of them had normal BLOOD pressure
11023666|NCT04611399|Experimental|VR Group|The treatment for the participants allocated to the VR Group consists of 3 individual sessions of 40 minutes each, for a period of three weeks. The participant in each session will try the virtual reality psychoeducational content (i.e., MIND-VR) for 15 minutes and, subsequently, the virtual content for relaxation (i.e., COVID Feel Good) for 15 minutes.
11023667|NCT04611399|Active Comparator|Non-VR Group|"The treatment for the participants allocated to the Non-VR Group consists of 3 individual sessions of 40 minutes each, for a period of three weeks.
~Participants allocated to this group will try the contents in a traditional non-immersive modality: for 15 minutes they will be asked to read a PowerPoint presentation containing the same words and images in static form on a desktop of virtual psychoeducational content and, subsequently, to listen for 15 minutes to an audio for relaxation."
11023668|NCT04611399|No Intervention|Waiting List Group|The WL Group will undergo pre- and post-protocol tests without undergoing any treatment.
11023669|NCT04611386||rivaroxaban group|20 rivaroxaban using patients
11023670|NCT04611386||apixaban group|20 apixaban using patients
11023671|NCT04611386||edoxaban group|20 edoxaban using patients
11023672|NCT04611386||control group|5 control group patients
11023673|NCT04611373|Experimental|A|Acetazolamide tablet 25mg/ tablet, 2 tablets a day; Levamisole 25mg/ tablet, 6 tablets/day continuous medication; Continue treatment until the disease progresses
11023674|NCT04611360|Experimental|Anodal Transcranial Direct Current Stimulation Group|Anodal Transcranial Direct Current Stimulation and Conventional training exercises
11023675|NCT04611360|Active Comparator|Conventional Training Exercises Group|Conventional Training Exercises : Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk
11023676|NCT04611347|Active Comparator|Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
11023677|NCT04611347|Active Comparator|Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
11023678|NCT04611334|Experimental|experimental group|HRV biofeedback
11023679|NCT04611334|No Intervention|control group|routine care
11023680|NCT04611321|Experimental|Phase Ib/II|Patients with advanced CSCC. IBI318 administered intravenously every 2 weeks.
11023686|NCT04611269||Adult, patients with COVID-19 admitted to the ICU requiring mechanical ventilation|"This is a prospective cohort study including patients >18 years RT-PCR positive for SARS Cov-2 admitted to the ICU that require mechanical ventilation. Epidemiological data, comorbidities, previous signs of symptoms of COVID-19. On admission, severity of disease scores, laboratory management data, blood gases and acid-base chemistry,respiratory and mechanical ventilation management,and complications (Development of ARDS, septic shock, acute kidney injury, thromboembolic events, infections and septic shock, will be recorded. If patients die, causes of death will be recorded.Treatments administered by attending physicians will be registered.
~Dates of hospital and ICU admission, of death and/or discharge will be recorded.
~No intervention will be administered. Follow-up will continue until death or ICU/hospital discharge"
11023687|NCT04611256|Experimental|MSC transfusion|
11023688|NCT04611256|Active Comparator|Control|
11023689|NCT04611243||Kaletra, beta interferon +- ribavirin|Patients received lopinavir/ ritonavir 400mg/100mg (Kaletra) BD po for 7-14 days, Interferon beta-1b 0.25mg (8 MIU) subcutaneous alt day (maximum 7 doses) up to 14 days of symptom onset +- ribavirin 400mg bd for up to 14 days
11023690|NCT04611243||Remdesivir|Patients received remdesivir 200mg on first day followed by 100 mg daily for 5 to 10 days
11023691|NCT04611243||Supportive treatment|Patients only received antipyretic as needed
11023692|NCT04611230||Adult Volunteers (Low Risk Group)|Volunteers with jobs that do not require close contact with (i.e., within 6 feet of) the general public or co-workers.
11023693|NCT04611230||Adult Volunteers (Medium - Low Risk Group)|Volunteers with jobs that require in-frequent contact with (i.e., within 6 feet of) the general public or co-workers.
11023694|NCT04611230||Adult Volunteers (Medium - High Risk Group)|Volunteers with jobs that require frequent contact with (i.e., within 6 feet of) the general public or co-workers.
11023695|NCT04611230||Adult Volunteers (High Risk Group)|Volunteers with jobs that require frequent and/or close contact with (i.e., within 6 feet of) individuals with high potential for exposure to known or suspected sources of COVID-19.
11023696|NCT04611217|Experimental|High Fiber diet|Group receiving a high fiber diet
11023697|NCT04611217|Other|Low Fiber diet|Control group receiving a low fiber diet
11023698|NCT04611191|Experimental|Team Sports|Elderly men and women performing team sports in local sports clubs
11023699|NCT04611191|Experimental|Control|Elderly men and women continue their normal lifestyle
11023700|NCT04611178||CIV-ABAO|CIV-ABAO
11023701|NCT04611165|Experimental|single|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.
~Prescription dose to PTVs as according to the following schema:
~PTV1: 30 - 50 Gy /10 fx, 5Gy fraction dose, 5 days/week (The prescribed dose to PTV will be decided by physician depending on the dose-volume histogram (DVH) constraints of the normal tissues, such as liver, bowel, etc. The detail of DVH constraints of normal tissues are summarized in the following table) PTV2: 30 Gy /10 fx, 3Gy fraction dose, 5 days/week"
11023702|NCT04611152|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
11023703|NCT04611152|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
11023704|NCT04611139|Experimental|SP-2577 Plus Pembrolizumab|
11023705|NCT04611126|Other|Without Ipilimumab|"At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.
~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1."
11023706|NCT04611126|Other|With Ipilimumab|"At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.
~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1"
11023707|NCT04611113|Experimental|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
11023708|NCT04611113|Active Comparator|Control nutritional support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
11023709|NCT04611100|No Intervention|Conventional|Patient receive endoscopic placement of metallic biliary stent for obstructive jaundice
11023710|NCT04611100|Experimental|Radiofrequency ablation|Patient receive endoscopic intraductal radiofrequency ablation before placement of biliary stent for obstructive jaundice
11023711|NCT04611087||Observational (focus group, interview)|"PHASE I: Participants attend 4 sessions of focus groups.
~PHASE II: Participants attend virtual Zoom interviews or one-on-one interviews."
11023712|NCT04611061||ARVI and influenza prophylaxis with Kagocel|"Prophylaxis according to routine practice and instructions for medical use of Kagocel.
~Group of patients receiving Kagocel for prevention of ARVI and influenza"
11023713|NCT04611061||ARVI and influenza prophylaxis without any antiviral medicines|Group of patients receiving no any antiviral medicines for prevention of ARVI and influenza
11023714|NCT04611048|Experimental|Main study|Several electrophysiological and behavioural tests will be performed to properly diagnose the patients/check that the healthy controls do not suffer of neuropathy.
11023715|NCT04611035||Patient|Patient with first-line gastrointestinal cancers and patient with advanced and refractory GI cancers (>1 line of treatment), or post-progression biopsy)
11023716|NCT04611022|Experimental|Patients Eligible for HPV Vaccine|
11023717|NCT04611009|Experimental|motor training|intervention: motor training
11023718|NCT04611009|Active Comparator|awareness training|intervention: mindfulness exercises
11023719|NCT04610983|Experimental|Control|Control 2 * Gel Encapsulated Algal Oil Capsules (each containing 200mg DHA) Total dose of 400mg DHA.
11023720|NCT04610983|Experimental|Treatment 1 - Semi-Solid food matrix|Vegetable encapsulated algal oil integrated with a semi-solid food product (soup) to deliver 400 mg DHA.
11023723|NCT04610957|Experimental|The 1st group|included eighty (80) women receiving Clomiphene citrate (CC) in the form of (Clomid 50 mg tablet, Sanofi Aventis, France) at dose (100 mg/day in two divided doses, starting from day 3 to day 7 of the cycle), plus Phytoestrogens (Isoflavonoids) in the form of (RosaFem 800 mg tablet, DeluxLab, Egypt) at dose (1600 mg/day in two divided doses (each dose one tablet), starting from day 3 to day 12 of the cycle
11023724|NCT04610957|Experimental|The 2nd group|included eighty (80) women receiving Clomiphene citrate only, at dose (100 mg/day, starting from day 3 to day 7 of the cycle).
11023725|NCT04610944|Experimental|Intervention|Intervention nursing homes will receive the training and control nursing homes will complete assessments, but not receive the training.
11023726|NCT04610944|Active Comparator|Waitlist Control|After the intervention nursing homes complete the training, the waitlist control nursing homes will crossover and complete the training.
11023727|NCT04610931|Experimental|Cybertherapy|use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
11023728|NCT04610931|Active Comparator|Treatment as usual|Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
11023729|NCT04610918||Cases - Pediatric Intestinal Failure Patients|DXA BIA Skin fold measurements Strength tests Physical activity monitoring
11023730|NCT04610918||Controls|BIA Skin fold measurements Strength tests Physical activity monitoring
11023731|NCT04610905|No Intervention|Control group|This group will be asked to maintain their daily routine.
11023732|NCT04610905|Experimental|Reducing sedentary behavior|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours.
11023733|NCT04610905|Experimental|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. Additionnaly they need to be active in periods of at least 10 minutes.
11023734|NCT04610892|Experimental|MEDI6570 Low dose|Monthly Subcutaneous administration.
11023735|NCT04610892|Experimental|MEDI6570 Medium dose|Monthly Subcutaneous administration.
11023736|NCT04610892|Experimental|MEDI6570 High dose|Monthly Subcutaneous administration.
11023737|NCT04610892|Placebo Comparator|Placebo|Monthly Subcutaneous administration.
11023738|NCT04610879|Active Comparator|Carbamazepine plus sleep intervention|
11023739|NCT04610879|Active Comparator|Carbamazepine plus standard care|
11023740|NCT04610879|Active Comparator|Levetiracetam plus sleep intervention|
11023741|NCT04610879|Active Comparator|Levetiracetam plus standard care|
11023742|NCT04610879|Active Comparator|No AED plus sleep intervention|
11023743|NCT04610879|No Intervention|No AED plus standard care|
11023744|NCT04610866|Experimental|1|Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
11023745|NCT04610840|Active Comparator|Direct puncture|Direct puncture of the caliceal system performed under ultrasound or Xray control
11023746|NCT04610840|Active Comparator|Non-direct puncture|Puncture of the caliceal system performed under ultrasound or Xray control and retrograde contrast
11023747|NCT04610827|Active Comparator|Ferrous sulfate daily|Subject will take 3 mg/kg oral iron in the morning
11023748|NCT04610827|Active Comparator|Ferrous sulfate twice daily|Subjects will take 1.5 mg/kg oral iron twice daily
11023749|NCT04610827|Active Comparator|Ferrous sulfate every other day|6 mg/kg oral iron every other day in the morning
11023750|NCT04610814||Blood products during transport|Administration of appropriate blood products during transport
11023751|NCT04610814||Standard of Care|Receiving standard prehospital air medical care
11023752|NCT04610801|No Intervention|No treatment|No treatment given
11023753|NCT04610801|Experimental|Treatment|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nosetrils, every 6 hours
11023754|NCT04610801|Placebo Comparator|Placebo|Saline nasal spray, 2 puffs per nosetrils, every 6 hours
11023755|NCT04610788||SSc-PAH Group|Scleroderma patients referred for a clinically indicated right heart catheterization (RHC).
11023756|NCT04610788||IPAH Group|Presumed/known IPAH patients referred for a clinically indicated right heart catheterization (RHC).
11023757|NCT04610775|Other|Small Cuff (0, +1, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Small
11023758|NCT04610775|Other|Small Cuff (0, +2, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Small
11023759|NCT04610775|Other|Small Cuff ( +1, 0, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Small
11023760|NCT04610775|Other|Small Cuff ( +1, +2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Small
11023761|NCT04610775|Other|Small Cuff ( +2, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Small
11023762|NCT04610775|Other|Small Cuff ( +2, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Small
11023763|NCT04610775|Other|Regular Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Regular
11023764|NCT04610775|Other|Regular Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Regular
11023765|NCT04610775|Other|Regular Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Regular
11023766|NCT04610775|Other|Regular Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Regular
11023767|NCT04610775|Other|Regular Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Regular
11023768|NCT04610775|Other|Regular Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Regular
11026141|NCT04594681|Placebo Comparator|Placebo|
11023769|NCT04610775|Other|Large Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Large
11023770|NCT04610775|Other|Large Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Large
11023771|NCT04610775|Other|Large Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Large
11023772|NCT04610775|Other|Large Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Large
11023773|NCT04610775|Other|Large Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Large
11023774|NCT04610775|Other|Large Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Large
11023775|NCT04610775|Other|Extra Large Cuff (0, -2, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Extra Large
11023776|NCT04610775|Other|Extra Large Cuff (0, -1, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Extra Large
11023777|NCT04610775|Other|Extra Large Cuff (-1, 0, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Extra Large
11023778|NCT04610775|Other|Extra Large Cuff (-1, -2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Extra Large
11023779|NCT04610775|Other|Extra Large Cuff (-2, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Extra Large
11023780|NCT04610775|Other|Extra Large Cuff (-2, 0, -1 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Extra Large
11023781|NCT04610762||(Ex) Drug users recognized at-risk population of infection with Hepatitis C virus|
11023782|NCT04610736|Experimental|Single arm|Temozolomide 10 mg/ml, Oral suspension
11023783|NCT04610710|Active Comparator|Operation|Operation for severe endometriosis
11023784|NCT04610710|Active Comparator|Fertility treatment|Fertility treatment for women with severe endometriosis.
11023785|NCT04610697|Experimental|Cognitive Remediation|"Participants in the cognitive remediation condition will complete computerised exercises followed by 10-15-minute bridging discussions delivered using tele-heath.
~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
11023786|NCT04610697|Active Comparator|Active control|"Participants in the active control condition will also complete computerised exercises followed by 10-15-minute bridging discussions delivered using tele-heath.
~More details regarding treatment and control conditions will be provided following study completion to ensure participant blinding."
11023787|NCT04610684|Experimental|Study Treatment Arm|4 cycles of induction treatment with Atezolizumab (1200 mg on Day 1) combined with carboplatin (5-6 AUC on Day 1) and etoposide (80-100 mg/m2 on Days 1-3). After 4 cycles of induction treatment, subjects will receive atezolizumab maintenance 1200 mg on Day 1 of each 3-week cycle.
11023788|NCT04610671|Experimental|Participants Receiving CG0070 & Nivolumab|Both CG0070 (x 6 instillations) and nivolumab (x 2 doses) will be administered at their single-agent dose and schedule.
11023789|NCT04610658|Experimental|Phase 1 Dose Level 1: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 1: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 1.5 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 1 every 3 weeks.
11023790|NCT04610658|Experimental|Phase 1 Dose Level 2: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 2: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 2.6 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 2 every 3 weeks.
11023791|NCT04610658|Experimental|Phase 1 Dose Level 3: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
11023792|NCT04610658|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Participants will be treated with nivolumab 1mg/kg, ipilimumab 3mg/kg plus maximum tolerated dose of lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at MTD every 3 weeks.
11023793|NCT04610645||Head and Neck Cancer Patients|Patients with adjuvant or definitve radiotherapy or radio-chemotherapy for head and neck cancer
11023794|NCT04610619||RYR1 related malignant hyperthermia/rhabdomyolysis|
11023795|NCT04610606|Experimental|Multimodal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization (diet + mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids) and relaxation strategies.
11023796|NCT04610606|No Intervention|Standard of care (SOC)|Education on benefits of physical activity and healthy diet, with no specific information.
11023797|NCT04610593|Experimental|Intervention Group|This group will receive a Mindfulness-based intervention for 8 weeks, and after the intervention this participants will continuous their treatment as usual
11023798|NCT04610593|No Intervention|Treatment as Usual|Patients in the control group received treatment as usual in the hemodialysis setting: Carry out hemodialysis sessions three times a week, on alternate days, for approximately 4 hours added to appointments and procedures performed by professionals from different areas (medicine, nursing, nutrition, physical education, social work, pharmacy, psychology).
11023989|NCT04609254|Experimental|First Group|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
11023799|NCT04610580|Experimental|Crossover ALXN1840 Sequence 1|Participants will first receive a single dose of ALXN1840 test formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 reference formulation on Day 1 of Period 2.
11023800|NCT04610580|Experimental|Crossover ALXN1840 Sequence 2|Participants will first receive a single dose of ALXN1840 reference formulation on Day 1 of Period 1. After a washout period of 14 days, they will then receive a single dose of ALXN1840 test formulation on Day 1 of Period 2.
11023801|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 1|Participants will receive a single dose of ALXN1840.
11023802|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 2|Participants will receive a single dose of ALXN1840.
11023803|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 3|Participants will receive a single dose of ALXN1840.
11023804|NCT04610580|Experimental|Parallel Dose-proportionality Extension: ALXN1840 Dose 4|Participants will receive a single dose of ALXN1840.
11023805|NCT04610567|Experimental|MTX-LDE phase 1|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
11023806|NCT04610567|Experimental|MTX-LDE phase 2|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
11023807|NCT04610567|Placebo Comparator|Placebo-LDE phase 2|Lipid nanoparticle (LDE)
11023808|NCT04610541|Experimental|Remdesivir-HU|"Day 1 - single loading dose of remdesivir-HU 200 mg given by intravenous infusion
~• Day 2 onwards - 100 mg given once daily by intravenous infusion."
11023809|NCT04610528|Experimental|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
11023810|NCT04610515||Symptomatic Individuals with infection with SARS-COV2 (ie exposed cohort)|Symptomatic Individuals test positive for SARS-COV2. Participants will be enrolled soon after infection and followed to assess for long term outcomes.
11023811|NCT04610515||Symptomatic Individuals without infection with SARS-COV2 (ie unexposed cohort)|Symptomatic Individuals test negative for SARS-COV2. Participants will be enrolled soon after testing and followed to assess for long term outcomes.
11023812|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation S|"Experimental equine Imunoglobulins antiSARSCov Formuation S"
11023813|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation M|"Experimental equine Imunoglobulins antiSARSCov Formuation M"
11023814|NCT04610489|Other|Study Population|All subjects will undergo bilateral mid-turbinate swabs for COVID Antigen (Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA)) as well as bilateral rt-PCR testing (Quest SARS-CoV-2 rRT-PCR).
11023815|NCT04610476|No Intervention|Control group|Individual previous stable glucocorticoid/DMARD therapy is continued
11023816|NCT04610476|Experimental|Reduction group|Individual previous stable dosage of glucocorticoids/DMARDs will be stepwise reduced according to a predefined algorithm
11023817|NCT04610463|Other|Standard|Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
11023818|NCT04610450|Experimental|RCI-BE-10|Robot assisted cochlear implant surgery.
11023819|NCT04610437|Active Comparator|intramedullary reabsorbable fixation system PLLA.|Arthrodesis interphalangeal with intramedullary reabsorbable fixation system PLLA.
11023820|NCT04610437|Placebo Comparator|K-wire|Arthrodesis interphalangeal with kirschner wire
11023821|NCT04610424|Experimental|Cooperative Parent Mediated Therapy|"Cooperative Parent Mediated Therapy (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015). CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016). The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019)."
11023822|NCT04610424|Active Comparator|Control|Control group
11023823|NCT04610411|Experimental|surgical navigation|standard surgical method except for navigated instrumentation of pedicle screws and rod implants
11023824|NCT04610411|Active Comparator|standard surgical method|standard surgical method established at the institution
11023825|NCT04610398|Active Comparator|Dexamethasone group|The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators.
11023826|NCT04610398|Placebo Comparator|Placebo/ Control group|The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
11023827|NCT04610385||ileal conduit|
11023828|NCT04610385||cutaneous ureterostomy|
11023829|NCT04610372|Active Comparator|standard|External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks
11023830|NCT04610372|Experimental|High dose rate brachytherapy|A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.
11023831|NCT04610372|Experimental|Permanent seed implant brachytherapy|A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate
11023832|NCT04610372|Experimental|Stereotactic body radiotherapy|36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.
11023833|NCT04610359|Experimental|Stem cell group|Interstitial cystitis patients who receive submucosal injection of hESC-MSCs
11023834|NCT04610346|Other|Immediate|Participants in this group will begin the training protocol immediately (within 1 week) after baseline pre-training evaluation is completed.
11023835|NCT04610346|Other|Delayed|Participants in the delayed arm will participate in two pre-training evaluations, one immediately upon enrollment and one at the end of the delay period immediately before beginning training
11023836|NCT04610333|Experimental|School teacher training|"Teacher training programme:
~MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
~Four-day residental course
~3 x 2 seminar days
~Modified MBSR programme delivered to the students:
~- 1hour group session once a week in 10 weeks taught by the educated teachers on class"
11023837|NCT04610333|No Intervention|Usual practice|
11023838|NCT04610320|Experimental|Daratumumab-SC Injection|"Participants will receive a subcutaneous dose of Daratumumab-SC (1800 mg) weekly for 8 doses and then every other week for 2 doses.
~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
11023839|NCT04610307|Placebo Comparator|control group|patients receiving 1 % plain xylocaine
11023840|NCT04610307|Experimental|intervention group|patients receiving buffered 1 % xylocaine
11023841|NCT04610294|Experimental|Aerus air sterilization|Aerus air sterilization system will be used in an operating room, in addition to routine room air filtration
11023842|NCT04610294|Active Comparator|Conventional air handling|Only routine room air filtration will be used in an operation room.
11023843|NCT04610281|No Intervention|Control|"Wards without the Inner Garden biofeedback tool"
11023844|NCT04610281|Experimental|Inner Garden|"Wards with the Inner Garden biofeedback tool"
11023845|NCT04610268|Experimental|tDCS group|The anode of tDCS is placed on the occipital lobe and the cathode on the frontal lobe, or the anode of tDCS is placed on the left temporal lobe and the cathode on the right temporal lobe.
11023846|NCT04610255|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
11023847|NCT04610255|Experimental|Dynamic myofascial release|Experimental group was given Dynamic myofascial release along with the cervical isometrics and muscle stretching
11023848|NCT04610242|Experimental|Experimental group|Patients undergo diagnostic tests before the initial infusion of rituximab, including skin prick tests, intradermal tests, and challenge tests successively. If the skin test shows a positive result, the patient will receive desensitization procedure, and if the skin test is negative, the challenge test will be done, meaning normal infusion of rituximab according to manufacturer instructions. All the HSRs in the process of desensitization or normal infusion will be recorded. Peripheral blood will be drawn from all the subjects during their infusion to investigate the mechanism of HSRs to rituximab.
11023849|NCT04610229|Experimental|Treated with hypofractionation|1
11023850|NCT04610216||Bilateral users: two implant systems|For bilateral CI users two Naida CI M sound processors (one per ear) will be used during the study.
11023851|NCT04610216||Bimodal users: hearing aid contralateral|For bimodal subjects there will be one Naida CI M sound processor on the implanted ear as well as one hearing aid on the contralateral ear.
11023852|NCT04610203|Placebo Comparator|Glucose|Glucose - 50 g
11023853|NCT04610203|Experimental|Nutralys S85 Plus 25 g|Nutralys S85 Plus Pea Protein 25 g + 50 g Glucose
11023854|NCT04610203|Experimental|Nutralys S85 Plus 50 g|Nutralys S85 Plus Pea Protein 50 g + 50 g Glucose
11023855|NCT04610190|Experimental|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 20-30 minutes functional gait training on varied environments with device.
11023856|NCT04610164|Experimental|Group 1: TXA group|Patient will receive 1 gram intravenous TXA prior to surgery
11023857|NCT04610164|No Intervention|Group 2: Control Group|Patient will not receive TXA prior to surgery
11023858|NCT04610151|Experimental|Guided Imagery|Guided Imagery Intervention:The pretest data of the patients with a pain score of 4 or higher according to VAS were collected. Afterwards, the experiment group patients were applied guided imagery.
11023859|NCT04610151|No Intervention|No-Reflexology Application , control group.|No intervention was applied on the control group patients.
11023860|NCT04610138|Experimental|Active treatment with 60 ml low-dose ZnAg|(Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours
11023861|NCT04610138|Experimental|Active treatment with 60 ml high-dose ZnAg|(Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
11023862|NCT04610138|Placebo Comparator|60 ml matching placebo|60 ml matching placebo, po q12 hours
11023863|NCT04610125|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
11023864|NCT04610099|Active Comparator|Standard SG|100 patients undergo a standard sleeve gastrectomy
11023865|NCT04610099|Experimental|Banded SG|100 patients undergo a banded sleeve gastrectomy
11023866|NCT04610086||False negative FIT|Participants in the colorectal cancer screening program, with a positive FIT and with a normal colonoscopy
11023867|NCT04610086||Polyps|Participants in the colorectal cancer screening program, with a positive FIT and diagnosed of colorectal polyps in the colonoscopy
11023868|NCT04610086||Colorectal cancer|Participants in the colorectal cancer screening program, with a positive FIT diagnosed by colorectal cancer
11023869|NCT04610073|Experimental|Interactive multimedia training|the intervention group 1 completed the pretest knowledge, attitude, and behavior questionnaire. Then, interactive multimedia was made available to this group. The questionnaire was completed again by the group, one week after completion of training, and then one month afterward.
11023870|NCT04610073|Experimental|illustrated booklet|First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
11023871|NCT04610073|Experimental|No Intervention|In the control group, no intervention was performed. Only before the intervention, one week and one month after the intervention, they completed the knowledge, attitude and behavior questionnaires.
11023872|NCT04610060|Experimental|Power walking group|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.
~Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018)."
11023990|NCT04609254|Experimental|Second Group|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
11023873|NCT04610060|Active Comparator|Standardised outpatient cardiac rehabilitation group|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines where provided for four weeks. The program consisted of warm up, aerobics, strengthening and cool down exercises based on ACSM Guidelines described in Table 1 (Deborah, Jonathan, Gary & Meir, 2018).
11023874|NCT04610047|Experimental|Norketotifen|Norketotifen oral capsules, twice daily for 7 days
11023875|NCT04610047|Placebo Comparator|Placebo|Placebo oral capsules, twice daily for 7 days
11023876|NCT04610034|Experimental|"Resilient Caregivers"|Intervention program
11023877|NCT04610034|Other|Control group|Care as usual
11023878|NCT04610021|Placebo Comparator|Control|Control group: autologous bone + bench bone
11023879|NCT04610021|Experimental|i-Factor|I-Factor group: autologous bone + bench bone + i-Factor™ bone graft
11023880|NCT04610008||APON|Retrospective review of routine clinical images from patients with an acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
11023881|NCT04610008||No APON control|Retrospective review of routine clinical images from patients with NO acquired pit of the optic nerve (APON), and a documented diagnosis of primary open angle glaucoma or normal tension glaucoma
11023882|NCT04609995|No Intervention|No financial incentive|No financial incentives will be provided for completing a PrEP evaluation
11023883|NCT04609995|Active Comparator|Fixed incentive|A fixed incentive ($25 Amazon.com gift card) will be provided for completing a PrEP evaluation
11023884|NCT04609995|Active Comparator|Lottery incentive|An entry into a lottery for a 20% chance to win a $100 Amazon.com gift card will be provided for completing a PrEP evaluation
11023885|NCT04609982|Experimental|wearing ear plugs|
11023886|NCT04609982|No Intervention|Not wearing ear drops|
11023887|NCT04609969|Experimental|Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
11023888|NCT04609956|Experimental|virtual reality|Experimental arm is a virtual reality headphones
11023889|NCT04609956|Other|standard|Control arm is a usual practice (hydroxyzine + patient music with headphones)
11023890|NCT04609943|Experimental|Drug Dose 1|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163 Dose 1.
11023891|NCT04609943|Experimental|Drug Dose 2|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163 Dose 2.
11023892|NCT04609943|Experimental|Drug Dose 3|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163 Dose 3.
11023893|NCT04609943|Experimental|Drug Dose 4|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163 Dose 4.
11023894|NCT04609943|Experimental|Drug Dose 5|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163 Dose 5.
11023895|NCT04609930||The study population|Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1
11023896|NCT04609917||trainee group|Patients with native papilla who underwent selective biliary cannulation with trainee involvement
11023897|NCT04609917||non-trainee group|Patients with native papilla who underwent selective biliary cannulation without trainee involvement
11023898|NCT04609904|Experimental|BGF MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
11023899|NCT04609904|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
11023900|NCT04609904|Active Comparator|BFF MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide, glycopyrronium, and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
11023901|NCT04609904|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressired metered dose inhaler 320/9 μg
11023902|NCT04609891|Experimental|Avatrombopag Tablets Oral|When patient is diagnosed with thrombocytopenia induced by chemotherapy of malignant tumor, avatrombopag will be given to patients as a therapeutic plan.
11023903|NCT04609878|Experimental|BGF MDI 320/28.8/9.6 μg|BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
11023904|NCT04609878|Experimental|BGF MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)
11023905|NCT04609878|Active Comparator|BFF MDI 320/9.6 μg|BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide, glycopyrronium, and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)
11023906|NCT04609878|Active Comparator|Symbicort®|Budesonide/ formoterol fumarate pressired metered dose inhaler 320/9 μg
11023907|NCT04609865|Experimental|Lidocaine 2%|The lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours,and then 0.6mg/kg/h for 14 days or until extubation.
11023908|NCT04609865|Placebo Comparator|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
11023909|NCT04609852|Experimental|Cohort 1: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
11023910|NCT04609852|Experimental|Cohort 2: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
11023911|NCT04609852|Experimental|Cohort 3: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
11023912|NCT04609852|Experimental|Cohort 4: E8001 or Placebo|Participants will receive specified dose of E8001 or placebo (isotonic sodium chloride solution), infusion, intravenously, once on Day 1.
11023913|NCT04609839||Patient admitted to intensive care unit for COVID-19|
11023914|NCT04609826|Experimental|Arm A: JNJ-74856665|Participants will receive JNJ-74856665 orally once daily in a 21-day cycle. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until a RP2D has been identified.
11023915|NCT04609826|Experimental|Arm B: JNJ-74856665 + AZA|Participants will receive JNJ-74856665 once daily in combination with AZA administered intravenously (IV) or subcutaneously (SC) once daily for 7 days starting on Day 1 of each 28-day cycle.
11023916|NCT04609813|Experimental|Cytology sample collection|A nurse who has received related operation training uses the Shikang No. 1 collection device to collect cytology samples.
11023917|NCT04609787|Experimental|All participants|Quantitative sensory testing will be completed and current pain levels obtained. 20-minutes of immersive virtual reality will be completed, and then complete quantitative sensory testing again. We will compare pre-IVR quantitative sensory testing with post IVR levels.
11023918|NCT04609761|Experimental|IVIG treatment|Single-arm open-label
11023919|NCT04609748|Active Comparator|The group that received nimesulide|
11023920|NCT04609748|Experimental|The group that received CBD Oil|
11023921|NCT04609735|Experimental|Experimental: Electric DN, Manual therapy, exercise and US|Dry needling, manual therapy, exercise and ultrasound
11023922|NCT04609735|Active Comparator|Active comparator: Manual therapy, exercise and ultrasound|Active comparator: Manual therapy, exercise and ultrasound
11023923|NCT04609722|Experimental|intervention group|Solution-Focused Support Program will apply to the participants.
11023924|NCT04609722|No Intervention|control group|No intervention will be applied to the parents in the control group.
11023925|NCT04609709|Experimental|thrust manipulation, electric dry needling and exercise|thrust manipulation, electric dry needling and exercise
11023926|NCT04609709|Active Comparator|non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|non-thrust mobilization, soft-tissue mobilization, exercise and TENS
11023927|NCT04609696|Experimental|Part 1: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 1 formulation under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
11023928|NCT04609696|Experimental|Part 1: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 1 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
11023929|NCT04609696|Experimental|Part 1: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fasted conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
11023930|NCT04609696|Experimental|Part 2: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 2 formulation under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
11023931|NCT04609696|Experimental|Part 2: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as the PIC 2 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fed conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
11023932|NCT04609696|Experimental|Part 2: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:
~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fasted conditions.
~There will be a washout period of at least 5 days between each danicopan dosing."
11023933|NCT04609683|Experimental|Hydrostasis group|"50 study subjects scheduled for an EP procedure will have AleriTM sensors on subject's bicep, forearm, or wrist, to start data collection.
~Measurements will be made from the subject for a period of approximately 1 hours prior to the EP procedure. . Measurements will continue as patient is moved to the operating room. Once the EP procedure is complete, the subject will be transferred from the operating room to a hospital room, where they will stay overnight. Measurements will be made for 3-5hours post-operation.Detailed analysis will investigate how does AleriTM data correlate with known measures such as saline volume/rate, urine production volume, USG, Blood osmolality and body weight;"
11023934|NCT04609670|Experimental|[14C]-ALXN2050|Participants will receive [14C]-ALXN2050.
11023935|NCT04609657|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
11023936|NCT04609657|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
11023937|NCT04609657|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
11023938|NCT04609657|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
11023939|NCT04609657|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
11023940|NCT04609657|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
11023991|NCT04609254|Experimental|Third group|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
11023941|NCT04609644|No Intervention|Passive|"Passive arm participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are commercially available and have not been modified for this study. Participants will be asked to use these devices regularly throughout study Year 1. Participants can optionally continue to use devices during Year 2, if they have met requirements during Year 1 to keep study devices. To be eligible to keep devices, participants must meet pre-specified levels of adherence to study procedures.
~Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. However, passive participants will not have access to the Study App features designed to support asthma self-management."
11023942|NCT04609644|Experimental|Active|"Active arm participants will be sent the same devices, also at no cost, and asked to use them in the same manner.
~Only the active arm will have access to Study App features for asthma self-management, including:
~Smart nudges that may promote proactive asthma self-management
~Asthma symptom and trigger tracking
~Evidence-based asthma education
~The ability to photograph and easily reference an asthma action plan from a healthcare provider.
~A 90-day summary of self-reported asthma symptoms/triggers and device-recorded heart rate and respiratory rate. This summary can be shared with providers.
~In-app viewing of active asthma medications, refills available, and phone numbers to call for refills (subject to prescription benefits).
~Active participants can, but are not required to, use the Study App in Year 2. Those who choose to may keep using study devices in Year 2, provided they meet requirements to keep devices. These requirements are the same for both arms."
11023943|NCT04609631|Experimental|Tai Chi (5 times/week)|5 sessions of Tai Chi per week for 12 weeks
11023944|NCT04609631|Experimental|Tai Chi (3 times/week)|3 sessions of Tai Chi per week for 12 weeks
11023945|NCT04609631|Experimental|Tai Chi (1 time/week)|1 session of Tai Chi per week for 12 weeks
11023946|NCT04609631|Active Comparator|cognitive behavior therapy (CBT)|1 session of CBT per week for 12 weeks
11023947|NCT04609631|No Intervention|Waiting-list|Participants will maintain their routine treatment and life style for 12 weeks.
11023948|NCT04609618|Experimental|Obstructive Sleep Apnea patients|Appscent device will discharge odor during the in lab night sleep
11023949|NCT04609605|Experimental|patients with acute pulmonary embolism|speckle tracking echocardiography for patient with acute pulmonary embolism
11023950|NCT04609592|Experimental|Lutathera|2 cycles of 177Lu Dotatate, followed by cytoreductive surgery, followed by additional 177Lu Dotatate (up to 2 cycles) for residual disease as determined by 68Ga DOTA TATE PET/CT
11023951|NCT04609579|Experimental|SNX281 Monotherapy|"SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 66 participants will take part in this arm of the study.
~Subjects enrolled in the dose expansion phase of this arm may be eligible to add pembrolizumab to their SNX281 therapy following identification of the maximum tolerated dose (MTD) or optimal dose of SNX281 in combination with pembrolizumab. Subjects must, in the opinion of the Investigator, have demonstrated tolerance to SNX281 and have experienced sub-optimal response to therapy (i.e., disease stability for 4 cycles or progression on treatment with SNX281 at any time)."
11023952|NCT04609579|Experimental|SNX281 in Combination with Pembrolizumab|SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter. Participants will also receive pembrolizumab once every cycle for up to 6 cycles. The combination of SNX281 and pembrolizumab will be given for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 and pembrolizumab (or SNX281 alone) beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 62 participants will take part in this arm of the study.
11023953|NCT04609566|Experimental|Combination Therapy|brentuximab vedotin + pembrolizumab
11023954|NCT04609553|Active Comparator|Usual care including ROR|Literacy promotion is a pediatric standard of care. Participants in this group will receive usual care that includes ROR, a primary care literacy promotion intervention.
11023955|NCT04609553|Experimental|ROR plus text messages|In addition to ROR, participants will receive three text messages per week, plus one interactive follow-up message per month, for the study period with scheduled breaks.
11023956|NCT04609553|Experimental|ROR plus text messages plus connection to community resources|In addition to ROR and text messages, participants will be referred to a county-based single point of entry system for referrals to community resources. This system simplifies access to poverty-reducing resources by creating a centralized access point, maintaining an updated data base of resources with existing capacity to support families, and providing case management.
11023957|NCT04609540||Pyrotinib and Trastuzumab group|Dual anti-HER2 therapy (pyrotinib and trastuzumab) and chemotherapy
11023958|NCT04609514|Experimental|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
11023959|NCT04609514|Active Comparator|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches, along with technical smartphone coaching for the first 4 weeks of the study.
11023960|NCT04609488||COVID|
11023961|NCT04609488||non-COVID|
11023962|NCT04609475|Experimental|Osseodensification technique|
11023963|NCT04609475|Active Comparator|Motor driven expanders' technique|
11023964|NCT04609462|Active Comparator|Conventional oxygen therapy (COT) group|Oxygen therapy will be delivered by conventional nasal cannula / prongs, venturi mask, or mask with reservoir, with flows between 3 and 15 liters / minute, to ensure SpO2 ≥ 92%.
11023988|NCT04609267|Experimental|Mirror Baseline|Half of the participants will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa at their first appointment. At their second appointment 1-month later, they will will complete the PHQ-9 in the traditional paper format.
11023992|NCT04609241|Experimental|Administration of CD79b CAR-T Cell|
11026142|NCT04594681|Experimental|KHK4951|
11023965|NCT04609462|Experimental|High-flow nasal cannula (HFNC) group|Breathing support with High-Flow oxygen therapy, flow will be initiated between 50 and 60 liters / minute. FiO2 60% to 100% with the objective of reaching SpO2 ≥ 92%. Adequate wetting of the system should be ensured according to the recommendations of the HFNC device manufacturer. FiO2 may be decreased gradually according to the patient's individual condition, trying to maintain SpO2 ≥ 92%.
11023966|NCT04609449|Experimental|Long biliopancreatic limb|Patients submitted to long biliopancreatic limb Roux-en-Y gastric bypass.
11023967|NCT04609449|Active Comparator|Standard biliopancreatic limb|Patients submitted to standard Roux-en-Y gastric bypass.
11023968|NCT04609436||Single arm|This is a single arm trial. The patient is his own control.
11023969|NCT04609423|Experimental|Cod liver oil|supplementation for 6 months
11023970|NCT04609423|Placebo Comparator|Corn oil (placebo)|supplementation for 6 months
11023971|NCT04609410|Experimental|Deep neuromuscular blockade|"During surgery, deep neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring, aiming for a Post-Tetanic Count (PTC) = 0 or PTC = 1 and Train of Four Count (TOFC) = 0. TOF and PTC measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored PTC is > 1.
~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided."
11023972|NCT04609410|Active Comparator|Moderate neuromuscular blockade|"During surgery, a moderate neuromuscular blockade will be achieved with the use of train of four (TOF) monitoring. TOF and Post-Tetanic Count (PTC) measurements will be performed every 15 minutes. Boluses of 0,1 mg/kg Rocuronium will be administered if monitored TOF count is ≥ 1 and/or PTC > 5.
~Complete neuromuscular blockade reversal at the end of surgery will be achieved with an i.v. bolus of Sugammadex (variable dose according to depth of residual blockade) if TOF ratio is ≤ 0.9. If TOF ratio is > 0.9, pharmacological neuromuscular blockade reversal can be avoided."
11023973|NCT04609397|Experimental|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
11023974|NCT04609397|Experimental|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
11023975|NCT04609397|Placebo Comparator|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
11023976|NCT04609384||Prior to installation of device|Health care workers who perform the surgical rub prior to installation of the device that should increase the time spend on surgical rub.
11023977|NCT04609384||Post device installation|Health care workers who perform the surgical rub following installation of the device that should increase the time spend on surgical rub.
11023978|NCT04609371|Experimental|self-care tools|"Arms Assigned Interventions Experimental: self-care tools
~The tools are adapted from those successfully deployed in the DIRECTsc depression self-care project focusing on patients with depressive symptoms, but abbreviated to meet the needs of the proposed short-term intervention for a broader sample of patients to include those with anxiety symptoms and with minimal symptoms. Tools will include individual chapters of the Antidepressant Skills Workbook; the mood monitoring tool; a workbook on managing worry; relaxation audio files and information on exercise and healthy eating. In view of the short duration of the intervention (8 weeks), a maximum of 2 tools will be sent to each participant.
~An algorithm will determine which self-care tools, matched to the specific mental health symptoms reported by participants, will be sent to the participants."
11023979|NCT04609371|Experimental|coaching|Participants will receive the algorithm-determined self-care tools, matched to the specific mental health symptoms reported by participants as in the first arm. They will ALSO be offered up to 3 coach calls. Coaching by a trained lay coach will be structured and guided by a manual. Trained lay coaches will call participants in the week following delivery of the toolkit to guide them through the self-care toolkit over an 8-week period. Coaches will contact participants a maximum of 3 times, with calls expected to average 15-20 minutes. Call content will be guided by a structured coaching manual adapted from those used in the team's previous two RCTs of the self-care materials. The coaches will follow structured agendas, keep records of all contacts.
11023980|NCT04609358|Experimental|Intervention group|The patients' nutrition were supported according the the algorithm of the enteral nutrition.
11023981|NCT04609358|No Intervention|Control group|The patients' nutrition were supported according the prescription of the physicians and dietician in our hospital.
11023982|NCT04609319||Cohort 1|
11023983|NCT04609306|Experimental|Subjects getting 3% H2O2 applied to the incision|For the experimental cohort, a lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes. Following the 3 minutes, the sponge will be removed, the wound will be flushed with 100 mL of normal saline, and the exposed dermis will be swabbed and sent for culture.
11023984|NCT04609306|No Intervention|Subjects not getting 3% H2O2 applied to the incision|In the control cohort, the dermis will be swabbed and sent for culture immediately after the skin incision is made and the knife is removed from the field.
11023985|NCT04609293||Camrelizumab+apatinib+Hypofractionated radiation therapy|"Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
~Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
~Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy."
11023986|NCT04609280|Experimental|Reduced C/L elective nodal volume|All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
11023987|NCT04609267|Experimental|Paper Baseline|Half of the participants will complete the PHQ-9 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the PHQ-9 on the Mirror device equipped with Amazon Alexa.
11023995|NCT04609215|Experimental|ALECSAT|"This is an exploratory single arm study. 20 patients will be included with the objective to investigate the safety, tolerability and trends of efficacy of ALECSAT for the treatment of recurrent TNBC.
~ALECSAT is a form of adoptive cell therapy medicinal product. ALECSAT is an abbreviation for Autologous Lymphoid Effector Cells Specific Against Tumor. ALECSAT is an autologous product that induces an immune response against a broad repertoire of CTAs expressed on cancer cells (including TNBC) leading to killing of these cells.
~Patients will receive standard treatment with carboplatin and gemcitabine along with ALECSAT."
11023996|NCT04609202|Experimental|Nurse led person centred care|Participants in the nurse led, person centred care arm will receive person centred follow up after hospitalization for atrial fibrillation. The person centred care and usual care routines are provided by nurses.
11023997|NCT04609202|Active Comparator|Usual care|Participants in the usual care arm will receive care as usual, ie follow up by doctors after hospitalization for atrial fibrillation.
11023998|NCT04609189|Experimental|Pearlium®/EffectiCal®|
11023999|NCT04609189|Active Comparator|Calcium Carbonate/Vitamin D3|
11024000|NCT04609176|Experimental|Camrelizumab+Apatinib+SOX|Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
11024001|NCT04609176|Experimental|Camrelizumab+Apatinib|Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
11024002|NCT04609150||Multiple myeloma patients with vertebral fractures|Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events
11024003|NCT04609137|Experimental|Early drain removal|Participants will have an early drain removal (before postoperative day 3 (POD 3)) if specific conditions will be verified
11024004|NCT04609137|Active Comparator|Standard drain removal|Participants will receive the current standard of care at San Raffaele Hospital.
11024005|NCT04609124||Intervention group:|Patients (n=35) fasting for 8 hours and received 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
11024006|NCT04609124||Control group:|Patients (n=35) fasting for 8 hours and received intravenous 10 mL saline 0.9% as placebo
11024007|NCT04609111|Active Comparator|No aspirin|To start prasugrel monotherapy before the index percutaneous coronary intervention (PCI) and to change into clopidogrel monotherapy at 1-month after the PCI.
11024008|NCT04609111|Active Comparator|1-month DAPT|To start dual antiplatelet therapy comprising of aspirin and prasugrel before the index percutaneous coronary intervention (PCI) and to change into aspirin monotherapy at 1-month after the PCI.
11024009|NCT04609098|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
11024010|NCT04609098|Experimental|DP with 0.415mg/kg Tafenoquine (TQ)|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
11024011|NCT04609098|Experimental|DP with 0.83 mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
11024012|NCT04609098|Experimental|DP with 1.66mg/kg TQ|Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.
11024013|NCT04609085||Participants with Rare Diseases|Participants with history of rare disease
11024014|NCT04609072||Healthy volunteers|Up to 200,000 men and women aged 40 to 65 years, with no personal history of cancer, and patients or members of participating integrated health care systems.
11024015|NCT04609059|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
11024016|NCT04609059|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
11024017|NCT04609046|Experimental|Treatment (rituximab, methotrexate, lenalidomide, nivolumab)|"INDUCTION: Patients receive rituximab IV on day 1, methotrexate IV over 2 hours or PO on day 2, lenalidomide PO daily on days 5-14, and nivolumab IV over 30 minutes on day 14. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.
~MAINTENANCE: Within 5 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
11024018|NCT04609033|Active Comparator|bupivacaine group|
11024019|NCT04609033|Active Comparator|bupivacaine + morphine|
11024020|NCT04609033|Active Comparator|bupivacaine + morphine + ketamine|
11024021|NCT04609033|Placebo Comparator|isotonic saline|
11024022|NCT04609020|Experimental|JUVÉDERM, BOTOX|Facial filler injections (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine and/or JUVÉDERM VOLUX with Lidocaine) will be administered into areas that the subject desires and qualified for per the inclusion/exclusion criteria and within the approved clinical indications at Visits 1 and 2. BOTOX administered at Visit 3. BOTOX touch up treatment administered at Visit 4 if needed.
11024023|NCT04609007|Active Comparator|Treatment as usual|The TAU condition consists of a single session of regular help-line telephone counselling
11024024|NCT04609007|Experimental|Cognitive behavioral therapy|The experimental condition consists of a single session of regular help-line telephone counselling plus four therapist guided online CBT sessions.
11024025|NCT04608981|Experimental|Prednisolone premedication|Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
11024026|NCT04608981|Experimental|Diclofenac potassium premedication|Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
11024027|NCT04608981|Placebo Comparator|Placebo|Placebo tablet 1 hour before starting endodontic treatment.
11024028|NCT04608955|Experimental|Arm A: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
11024029|NCT04608955|Experimental|Arm B: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
11024030|NCT04608955|Experimental|Arm C: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
11024031|NCT04608955|Active Comparator|Arm D: Standard treatment|Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
11024032|NCT04608955|Experimental|Arm E: WX-081+MBT|Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
11024033|NCT04608955|Active Comparator|Arm F: Bedaquiline+MBT|Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
11024034|NCT04608942|Experimental|Jett Plasma Medical Lift Application|In the study group, the plasma jet will be applied to the superior and inferior eyelid margin in both eyes.
11024035|NCT04608942|Active Comparator|Mechanical Debridement|In the control group, the mechanical debridement of the superior and inferior eyelid margin with a scalpel blade will be performed.
11024036|NCT04608929|Experimental|Intervention|The arm where the Kegel exercise focused intervention is applied
11024037|NCT04608929|Experimental|Control|The arm where home follow-up and scale evaluations are made
11024038|NCT04608916|Active Comparator|Scalpel incision group|This group of patients will receive skin incision made with use of a scalpel blade.
11024039|NCT04608916|Experimental|Electrocautery incision group|This group of patients will receive skin incision made with use of electrocautery.
11024040|NCT04608903|Experimental|Sulforaphane Group|Administration of 4g L-Sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.
11024041|NCT04608903|Placebo Comparator|Placebo Group|Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.
11024042|NCT04608890||Long-standing T1D patients|Patients with long-standing type 1 diabetes
11024043|NCT04608890||Healthy volunteers|Healthy volunteers
11024044|NCT04608877|Placebo Comparator|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
11024045|NCT04608877|Experimental|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
11024046|NCT04608864|Experimental|varicocelectomy arm|The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele
11024047|NCT04608864|No Intervention|Control (No varicocelectomy) arm|Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI
11024048|NCT04608851|Experimental|Nissle group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
11024049|NCT04608851|Placebo Comparator|Control group|Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days
11024050|NCT04608838|Experimental|JTR-161|
11024051|NCT04608838|Placebo Comparator|Placebo|
11024052|NCT04608812|Experimental|Direct Infusion of OS2966|OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery using the Infuseon Cleveland Multiport Catheter
11024053|NCT04608786|Experimental|Combined the therapy using Capecitabine and PD-L1|PD-L1 antibody ZKAB001 D1 5mg/kg every three weeks,up to 16 cycles or 1 year of treatment or the patient has tumor recurrence or metastasis Capecitabine 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis
11024054|NCT04608773|Other|Biotene Spray, followed by Refresh Spray|The Biotene Spray followed by Refresh Spray Arm will be asked to complete a 2 week trial using Biotene Spray first, then will be asked to complete a 2 week trial using Refresh Spray second. (after the appropriate 1 week washout periods have been completed)
11024055|NCT04608773|Other|Refresh Spray, followed by Biotene Spray|The Refresh Spray, followed by Biotene Spray Arm will be asked to complete a 2 week trial using Refresh Spray first, then will be asked to complete a 2 week trial using Biotene Spray second. (after the appropriate 1 week washout periods have been completed)
11024056|NCT04608760|Active Comparator|Meksibel|Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
11024057|NCT04608760|Active Comparator|Indometacin|Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
11024058|NCT04608760|Active Comparator|Meloksicam|Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
11024059|NCT04608760|Active Comparator|Oktride|Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
11024060|NCT04608747|Experimental|Intervention arm|After an overnight fast, participants subjected to baseline measurements and blood and urine collection and then consumed an amount of 50 g of tahini. Blood and urine collection and other measurements were repeated 4 h postprandially.
11024061|NCT04608734|Experimental|Buccal midazolam|
11024062|NCT04608734|Active Comparator|Intranasal midazolam|
11024063|NCT04608721||Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI).
11024100|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 2)|Soft capsule for oral administration
11024101|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 3)|Soft capsule for oral administration
11024064|NCT04608708||Group 1. Periapical Cemento-Osseous Dysplasia|In Periapical Cemento-Osseous Dysplasia , the lower anterior teeth are usually affected. In these lesions, normal bone is replaced by fibrous tissue that contains amorphous vascularised calcifications. In the early stage, it can mimic a periapical lesion, but it is usually associated with vital teeth, without any clinical complaint, and it requires no intervention. Histopathologically, the lesion is similar to fibrous dysplasia and ossifying fibroma.
11024065|NCT04608708||Group 2. Focal Cemento-Osseous Dysplasia|It occurs in a single area of the posterior teeth. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
11024066|NCT04608708||Grup 3. Florid Cemento-Osseous Dysplasia|When the lesions involve two or more quadrants of the jaw, it is defined as Florid Cemento-Osseous Dysplasia. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
11024067|NCT04608695|No Intervention|Control ovary|
11024068|NCT04608695|Experimental|Punctured ovary|
11024069|NCT04608682|Experimental|Sugammadex group|
11024070|NCT04608682|Sham Comparator|control group|
11024071|NCT04608669|Other|Temperature comparison|
11024072|NCT04608669|Active Comparator|No change|
11024073|NCT04608656|Experimental|Intervention arm 1: Livestock feed only|Households in villages assigned to intervention arm 1 will receive a pre-defined amount of feed to maintain two tropical livestock units for a total of 60 days during the dry season (when animals would be moved away in search of pastures).
11024074|NCT04608656|Experimental|Intervention arm 2: 1. Provision of Livestock feeds, 2. Nutrition counselling|Households recruited into intervention arm two will receive livestock feeds similar to intervention arm 1 and will be enrolled in a nutritional education and counselling program through Infant and Young Child Nutrition (IYCF) feeding program and household food utilization. The IYCF program through the Baby Friendly Community Initiative (BFCI) will include the promotion of exclusive breastfeeding in the first six months, continued breastfeeding up to the age of two years, adequate complementary feeding, hygiene promotion and the uptake of child health services including immunization, treatment of illness, moderate and severe acute malnutrition and micro-nutrient supplementation.
11024075|NCT04608656|No Intervention|Control arm|The households recruited under this arm will receive none of the two study interventions. These households will receive identical assessment and data collection like other study households in the study. Their access to support through other interventions will be monitored. Households within the control arm will receive nutritional counselling and education given outside of the project. This is mainly at health facilities when mothers present for antenatal care or visit health facilities seeking healthcare. On some occasions in places where community health volunteers are present, nutritional counselling and education may be provided at the community level. The study instruments have been designed to collect information at the household level if such nutritional counselling and education has been provided.
11024076|NCT04608630|Active Comparator|Denosumab|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
11024077|NCT04608630|Active Comparator|Zoledronic acid|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride, administered via intravenous infusion over at least 15 minutes on Study Day 1.
11024078|NCT04608630|Placebo Comparator|Placebo|Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
11024079|NCT04608617||Pre-Viz|Pre-Viz LVO implementation patient data utilized as a control data set
11024080|NCT04608617||Post-Viz|Patient data collected post-Viz LVO implementation
11024081|NCT04608604|Active Comparator|Physiotherapy 1|
11024082|NCT04608604|Active Comparator|Physiotherapy 2|
11024083|NCT04608578|Experimental|Intervention group|The intervention group gain access to the game after filling in the baseline online questionnaire. The participants are asked to play at least two characters in the game. They have two weeks to play the game.
11024084|NCT04608578|No Intervention|Control group|Waitlist control group
11024085|NCT04608565|Other|Remote biomonitoring sensor device|250 readings for a power of 80% and to detect a 5% difference in measurements with 95% confidence interval from mothers and newborns was ascertained. Once 3 probes were strapped (radiant warmer, RBM device and multichannel), a waiting period of 10 minutes for temperature stabilization was given. First RBM device & multichannel probe provided readings continuously (every few seconds); Then radiant warmer probe and manual thermometer readings were taken every 15 minutes for 5 timings: 0, 15, 30, 45 and 60 minutes. Participant safety for newborns was ensured following routine appropriate care protocols.
11024086|NCT04608552|Active Comparator|Active Myofunctional Therapy|Active Myofunctional Therapy is comprised of five 30-minute weekly sessions for 4 weeks.
11024087|NCT04608552|Sham Comparator|Inactive Myofunctional Therapy|Sham MT will be comprised of recommendations for five 30-minute nasal breathing exercises each week, use of nasal lavage with application of 10ml of saline in each nostril two times per day.
11024088|NCT04608539|Experimental|Intravenous iron group|Single-dose intravenous infusion of 20 mg/kg body weight ferric derisomaltose/iron isomaltoside 1000 (MonoFer®)
11024089|NCT04608539|Active Comparator|Oral iron group|Oral therapy with 100 mg oral ferrous sulfate twice daily
11024090|NCT04608526||Group 1|Patients without deep dentin caries / apical rarefying osteitis
11024091|NCT04608526||Group 2|Patients with deep dentin caries / apical rarefying osteitis on the right or left sides
11024092|NCT04608526||Group 3|Patients with deep dentin caries / apical rarefying osteitis on either the right and left side
11024093|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 1)|Soft capsule for oral administration
11024094|NCT04608513|Placebo Comparator|Placebo single dose (dose level 1)|Soft capsule for oral administration
11024095|NCT04608513|Experimental|ACT-1014-6470 single dose (dose level 2)|Soft capsule for oral administration
11024096|NCT04608513|Placebo Comparator|Placebo single dose (dose level 2)|Soft capsule for oral administration
11024097|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 1)|Soft capsule for oral administration
11024098|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 1)|Soft capsule for oral administration
11024099|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 2)|Soft capsule for oral administration
11024102|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 3)|Soft capsule for oral administration
11024103|NCT04608513|Experimental|ACT-1014-6470 multiple dose (dose level 4)|Soft capsule for oral administration
11024104|NCT04608513|Placebo Comparator|Placebo multiple dose (dose level 4)|Soft capsule for oral administration
11024105|NCT04608500|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
11024106|NCT04608500|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
11024107|NCT04608487|Experimental|Fludarabine + Cyclophosphamide + Axicabtagene Ciloleucel|"Two (2) cohorts of particpants: Cohort 1: relapsed/refractory primary CNSL (PCNSL) and secondary CNSL without systemic aggressive B cell non-Hodgkin lymphoma (NHL) including diffuse large B cell lymphoma (DLBCL), high grade B cell lymphoma (HGBL), primary mediastinal large B cell lymphoma (PMBL), and transformed follicular lymphoma (tFL). Cohort 2: relapsed/refractory systemic aggressive B cell non-Hodgkin lymphoma, including DLBCL, HGBL, PMBL, and tFL, with either active CNSL or previously treated CNSL
~Prior to receiving axi-cel, participants will undergo leukapheresis and the need for a Ommaya reservoir placement will be assessed and administered.
~Day -5 to Day -3 of 28 day study cycle Fludarabine and cyclophosphamide; Day -1 admitted to hospital, receive axi-cel on day 0; Till at least cycle day 7 hospital monitoring; post treatment follow up will occur on day 14 and day 28 of cycle 1, monthly in cycles 2, 3, 6, 9,12,15,18,21,24, then yearly after cycle 24."
11024108|NCT04608474|Experimental|Evolocumab only|This arm includes subjects who are treated using Evolocumab.
11024109|NCT04608474|Experimental|Evolocumab plus statin|This arm includes subjects who are treated using a combination of Evolocumab and a statin-based drug.
11024110|NCT04608461|Experimental|pumpkin seeds extract containing cream|Intervention-pumpkin seeds extract containing cream, dose-twice daily for 12 weeks
11024111|NCT04608448|Active Comparator|Topical Rapamycin|Ointment is applied to a color coded area on the subject forearm daily.
11024112|NCT04608448|Placebo Comparator|Placebo|Placebo ointment is applied to a color coded area on the subject forearm daily.
11024113|NCT04608435||Male Group|
11024114|NCT04608435||Female Group|
11024115|NCT04608422|Experimental|Electrical stimulation|The patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.
11024116|NCT04608422|No Intervention|Control|The patients only will be evaluated and reassessed.
11024117|NCT04608409|Experimental|Lapatinib - Group 1|Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).
11024118|NCT04608409|Experimental|Lapatinib - Group 2|Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).
11024119|NCT04608409|Experimental|Lapatinib - Group 3|Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).
11024120|NCT04608409|Experimental|Lapatinib - Group 4|Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).
11024121|NCT04608396|Experimental|AXS-05|
11024122|NCT04608396|Placebo Comparator|Placebo|
11024123|NCT04608370|Experimental|Active tPBM session group|Participants in the active tPBM group will take active tPBM session, which include 12 minutes active tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
11024124|NCT04608370|Active Comparator|Sham tPBM session group|Participants in the sham tPBM group will take sham tPBM session, which include 12 minutes sham tPBM by a 1064nm laser to the left forehead , 6 minutes resting-state fNIRS measurement, and 8 minutes digital n-back task-an ubiquitous cognitive task for working memory.
11024125|NCT04608344|Experimental|Sequence AB|Atorvastatin (ATV) 40 mg (Day 1); Washout period (Day 2); Pravastatin (PRA) 40 mg + Rosuvastatin (ROS) 10 mg (Day 3); Washout period (Days 4-6) in Treatment A Period 1; Filgotinib (FIL) 200 mg (Days 7-11). FIL 200 mg + ATV 40 mg (Day 12 ); FIL 200 mg (Day 13); FIL + PRA 40 mg + ROS 10 mg (Day 14); FIL 200 mg (Days 15-17) in Treatment B Period 2.
11024126|NCT04608344|Experimental|Sequence BA|FIL 200 mg (Days 1-5); FIL 200 mg + ATV 40 mg (Day 6); FIL 200 mg (Day 7); FIL + PRA 40 mg + ROS 10 mg (Day 8); FIL 200 mg (Days 9-11); Washout period (Days 12-17) in Treatment B Period 1. ATV 40 mg (Day 18); Washout period (Day 19); PRA 40 mg + ROS 10 mg (Day 20) in Treatment A Period 2.
11024127|NCT04608331|Experimental|Dexmedetomidine group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
11024128|NCT04608331|Placebo Comparator|Placebo group|Patient-controlled analgesia is established with morphine (0.5 mg/ml) in a total volume of 160 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours after surgery.
11024129|NCT04608318|Experimental|I (Ibrutinib)|Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.
11024130|NCT04608318|Experimental|VG (Obinutuzumab + Venetoclax)|12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone
11024131|NCT04608318|Experimental|VI (Venetoclax + Ibrutinib)|15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles
11024132|NCT04608305|Experimental|phase I - Group Ia, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0
11024133|NCT04608305|Experimental|phase I - Group Ib, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0
11024134|NCT04608305|Experimental|phase I - Group Ic, Prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0
11024135|NCT04608305|Experimental|phase I - Group Id, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
11024178|NCT04608071||C group|In C group, patients underwent conventional Corpak protocol
11024136|NCT04608305|Experimental|phase II - Group IIa, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
11024137|NCT04608305|Experimental|Phase II - Group IIb, Prime, low dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.
11024138|NCT04608305|Experimental|phase II - Group IIc, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
11024139|NCT04608305|Experimental|phase II - Group IId, Prime, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.
11024140|NCT04608305|Experimental|Phase II - Group IIe, prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
11024141|NCT04608305|Experimental|Phase II - Group IIf, Prime, high dose, elderly subjects|Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.
11024142|NCT04608305|Experimental|phase II - Group IIg, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
11024143|NCT04608305|Experimental|phase II - Group IIh, prime-boost, low dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
11024144|NCT04608292|Active Comparator|Single-voxel MRS|MRS
11024145|NCT04608292|Active Comparator|Multi-voxel MRSI|MRSI
11024146|NCT04608292|Active Comparator|Magnetization Transfer Imaging|MTI
11024147|NCT04608292|Active Comparator|Single-voxel MRS + ClearMate(TM)|MRS+CM
11024148|NCT04608292|Active Comparator|Multi-voxel MRSI + ClearMate(TM)|MRSI+CM
11024149|NCT04608292|Active Comparator|Magnetization Transfer Imaging + ClearMate(TM)|MTI+CM
11024150|NCT04608292|Active Comparator|Single-voxel MRS + CM + Blood Sampling|MRS+CM+B
11024151|NCT04608292|Active Comparator|Multi-voxel MRSI + CM + Blood Sampling|MRSI+CM+B
11024152|NCT04608292|Active Comparator|Magnetization Transfer Imaging + CM + Blood Sampling|MTI+CM+B
11024153|NCT04608266|Experimental|Camostat mesylate|Camostat mesylate, oral administration 600mg/day
11024154|NCT04608266|Placebo Comparator|Placebo|Placebo tablets, oral administration
11024155|NCT04608253||All enrolled subjects received an 11C-choline PET/CT prior to enrollment.|Patients with biochemically proven primary hyperparathyroidism who underwent parathyroid surgery after localization by means of 11C-choline PET/CT and negative or discordant first-line imaging
11024156|NCT04608227||Third trimester pregnant women undergoing ceasarean section|
11024157|NCT04608214|Experimental|Alisporivir|Administration of alisporivir and standard of care (SOC)
11024158|NCT04608214|Active Comparator|Standard of care (SOC)|Locally accepted regimen protocols for patient care
11024159|NCT04608201|Experimental|NICOTINE transdermal patch|NICOTINE 7 mg / 24h, transdermal patch
11024160|NCT04608201|Placebo Comparator|Placebo of NICOTINE transdermal patch|Placebo of nicotine patch
11024161|NCT04608188|Experimental|Summer Program|Children in the intervention will attend a summer day camp operated at their school.
11024162|NCT04608188|No Intervention|No Program|The control children will not receive an intervention of any kind and will be asked to go about their summer as they typically would.
11024163|NCT04608175|Experimental|Acupuncture group|"The experimental group will receive the standard treatment administered in these cases (analgesic regimen and nursing care procedures), in addition to the following acupuncture therapy.
~In the first visit (preoperative), the anamnesis and energy diagnosis of each patient will be carried out following the practices of Traditional Chinese Medicine (TCM) to design a personalized treatment based on the patient's medical history. A treatment of approximately 10 to 12 acupuncture points will be designed considering the TCM diagnosis and medical history of each patient. Both TCM diagnosis and the points used will be reassessed in each session. The points belonging to the upper extremity of the affected breast will be treated on the contralateral side, taking care not to insert any needle in the limb on the affected side. No points in the operated region will be used."
11024164|NCT04608175|No Intervention|Control group|The control group will only receive standard care procedures (analgesic regimen and nursing care procedures), although they will have the same follow up visits as the patients in the intervention group to facilitate analysis of the study variables.
11024165|NCT04608162|Active Comparator|Group I|Group one received PEMF and exercise (PEMF+EX)
11024166|NCT04608162|Placebo Comparator|Group II|Group two received placebo PEMF and exercise (PPEMF+EX)
11024167|NCT04608162|Active Comparator|Group III|Group three will be treated by PEMF alone (PEMF)
11024168|NCT04608149||Subjects treated with Carpediem system|All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.
11024169|NCT04608136|Experimental|Yolk ketogenic diet|consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
11024170|NCT04608136|Experimental|White ketogenic diet|consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
11024171|NCT04608136|Active Comparator|Control group|decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
11024172|NCT04608123||DBS Patients with NFS|Patients with PD treated with STN DBS between 2016 and 2019 who underwent NFS testing in pre and post-op conditions
11024173|NCT04608110|Experimental|Azacitidine + Cedazuridine|"Drug: Azacitidine Tablets for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
~Drug: Cedazuridine Tablets for oral administration"
11024174|NCT04608097|Experimental|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
11024175|NCT04608097|Placebo Comparator|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
11024176|NCT04608084|Experimental|Treatment group|Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
11024177|NCT04608071||M group|In M group, patients underwent modified post-pyloric feeding tube bedside placement
11024179|NCT04608071||EM group|In EM group, patients received standard electromagnetic guided tube placement.
11024180|NCT04608058|Experimental|Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, asynchronous Diabetes self-management training, using digital storytelling was made available to this group. Post-test data were collected 3 months after the pretest."
11024181|NCT04608058|Experimental|No Intervention|"At first, participants' demographic data, the levels of self-management, and HbA1c were documented at the commencement of the study. Then, the control group received the clinics' routine training. Post-test data were collected 3 months after the pretest."
11024182|NCT04608045|Experimental|CPX-POM, 900 mg/m2 by 20 minute IV infusion|
11024183|NCT04608032|Experimental|Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz]|to inform the patient about cognitive impairments and their repercussions ; to train the patient in problem-solving skills through exercices ; to implement strategies in daily life. Duration : two month. Frequency : Two one hour individual sessions and one hour of at-home training per week. Modalities : pen and papers exercices (tools (token, cards, maps and chessboard). Modules : Psychoeducation, Attention, Memory, Executive functions, Social cognition and metacognition, Functional impairments
11024184|NCT04608032|Active Comparator|[THoR] Recovery-Oriented Therapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' and functional impact, social skills, motivation and the regulation of sleep and daily activities
11024185|NCT04608019|Experimental|Immediate Antibiotics|increased airway clearance plus early initiation of oral antibiotics
11024186|NCT04608019|Experimental|Tailored Therapy|increased airway clearance alone, with addition of antibiotics for worsening symptoms or failure to improve
11024187|NCT04608006||Vaginal Delivery|Delivered both twins vaginally
11024188|NCT04608006||C-Section Delivery|Delivered both twins by Cesarean Section
11024189|NCT04608006||Vaginal/C-Section Delivery|Delivery first twin vaginally and second twin By C-Section.
11024190|NCT04607993|Experimental|Prone position ventilation technique|Prone position ventilation for children with congenital heart disease after surgery
11024191|NCT04607993|No Intervention|Control group|conventional postoperative position, no prone position ventilation
11024192|NCT04607980|Experimental|Treatment Group A (ABP 654)|Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to [<=] 100 kg) or 90 mg (baseline BW greater than [>] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.
11024193|NCT04607980|Experimental|Treatment Group B (Ustekinumab - ABP 654)|Participants will receive SC injection of ustekinumab,45 mg (baseline BW <= 100 kg) or 90 mg (baseline BW > 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.
11024194|NCT04607967|No Intervention|"Conventional oxygen-therapy (study group CO)"|"Patients randomized in the Coventional Oxygen group will be treated according to the national and international recommandations with a conventional oxygen-therapy device (nasal cannula or nasal-oral mask).
~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
11024195|NCT04607967|Experimental|"High Flow Nasal Oxygen (study group HNFO)"|"Patients randomized in the HNFO group will be treated according to the CE Certification with the high flow nasal oxygen device.
~Treatment failure will be evaluated after 4 hours by the need for a therapeutic escalation."
11024196|NCT04607954|Experimental|Treatment (durvalumab, topotecan hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11024197|NCT04607941||Cases|Subjects diagnosed as positive for SARS-CoV-2 infection
11024198|NCT04607941||Close Subjects|"Subjects living within the same household as cases:
~close cases if tested positive for SARS-CoV-2 following contact tracing recommendations
~close controls if tested negative for SARS-CoV-2 following contact tracing recommendations"
11024199|NCT04607941||Control Subjects|Controls selected within the population to allow for an age, gender and location of residence-matched analysis with cases
11024200|NCT04607928|Placebo Comparator|Placebo|No anti-fibrotic treatment. Patients in placebo and treatment arm may be on corticosteroid treatment
11024201|NCT04607928|Experimental|Treatment|Pirfenidone
11024202|NCT04607915|Experimental|Intervention for TECC Model|
11024203|NCT04607902|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
11024204|NCT04607902|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
11024205|NCT04607902|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
11024206|NCT04607889||Part 1 - Attribute development|An elicitation phase to develop the list of attributes and levels based on literature review and telephone interviews with patients.
11024207|NCT04607889||Part 2 - Pilot study|A pilot phase consisting of a self-administered, online survey, to be completed by patients and physicians, followed by telephone interviews with a subsample of participants.
11024208|NCT04607889||Part 3 - Main study|The main study, with a self-administered, online survey, to be completed by cancer patients and physicians.
11024209|NCT04607876|Active Comparator|Standard of Care|The FAR Control Arm will involve risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
11024210|NCT04607876|Other|Enhanced Intervention|"This intervention will involve risk factor assessment and web based risk factor management.
~Technological facilitators including a population health care management portal which will be used to facilitate risk factor management to monitor risk factor control, and to facilitate new symptom and complications management;
~Telemedicine to allow FAR Coordinator and providers capability for evaluation and management in home/facility, which facilitates real time communication and collaboration and virtual evaluation of the subject when higher level of intervention is required
~Educational portal provides a common educational platform for professional and subject education around stroke symptoms, complications, recovery and risk factor management, and lifestyle changes.
~FAR EI teams will be coordinated at FAR Central where a centralized group of specialists initiate and monitor risk factor mitigation strategies tailored to the individual participant."
11024211|NCT04607863||Low back pain|Patients with low back pain
11024212|NCT04607863||No low back pain|No low back pain patients
11024213|NCT04607850|Experimental|Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)
11024214|NCT04607850|Experimental|Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
11024215|NCT04607850|Experimental|Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)
11024216|NCT04607850|Experimental|Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
11024217|NCT04607850|Experimental|Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)
11024218|NCT04607850|Experimental|Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)
11024219|NCT04607850|Experimental|Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)
11024220|NCT04607850|Experimental|Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)
11024221|NCT04607850|Placebo Comparator|Group 6 Placebo Saline|Sodium Chloride (0.9%)
11024222|NCT04607837|Experimental|Etrasimod 2 mg|
11024223|NCT04607837|Placebo Comparator|Placebo|
11024224|NCT04607824||Duchenne Muscular Dystrophy group|Forty-five male subjects were included in the Duchenne Muscular Dystrophy (DMD) group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer.
11024225|NCT04607824||Typical Development group|Forty-five male subjects were included in the healthy Typical Development (TD) control group and they were assessed for twenty minutes at rest sitting, and then five minutes whilst performing the maze task on a computer
11024226|NCT04607811|No Intervention|Control arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will complete study surveys at baseline and the end of the 8 week intervention.
11024227|NCT04607811|Experimental|Gamification arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will have a weekly step goal they are encouraged to meet. Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
11024228|NCT04607798|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments.
11024229|NCT04607785|Active Comparator|Miswak mouthwash group|Miswak sticks were bought from local markets, Baghdad, Iraq, washed with cold water and dried then crushed into powder. Later,7 grams of the miswak powder weighted and added to 350 ml of distilled water (D.W.) in a conical flask for 24 hours. Finally, the solution then filtered and stored in tightly closed bottles in a cool place.9
11024230|NCT04607785|Other|Chlorhexidine mouthwash group|0.12% chlorhexidine gluconate mouthwash for seven days
11024231|NCT04607772|Experimental|Arm A: Selinexor with Bendamustine and Rituximab (S-BR))|Participants will receive a dose of 40 or 60 or 80 milligrams (mg) of selinexor oral tablets once weekly on Days 1, 3, and 8 for Cycle 1 up to 6 (each cycle consists of 21 days) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an intravenous (IV) dose of bendamustine 90 milligram per square meter (mg/m^2) on Days 1 and 2 and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment.
11024232|NCT04607772|Experimental|Arm B: Selinexor with Polatuzumab Vedotin and Rituximab (S-PR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 3, and 8 for Cycle 1 up to 6 (each cycle consists of 21 days) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 milligram per kilogram (mg/kg) and IV dose of rituximab 375 mg/m^2 on Day 1 during primary treatment.
11024233|NCT04607772|Experimental|ArmC: Selinexor, Polatuzumab Vedotin, Bendamustine, Rituximab (S-PBR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 3, and 8 for Cycle 1 up to 6 (each cycle consists of 21 days) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of polatuzumab vedotin 1.8 mg/kg and IV dose of rituximab 375 mg/m^2 on Day 1, and IV dose of bendamustine 90 mg/m^2 on Days 1 and 2 during primary treatment.
11024234|NCT04607772|Experimental|Arm D: Selinexor, Rituximab, Gemcitabine, Oxaliplatin (S-R-GemOx)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1 and 3 for Cycle 1 up to 6 (each cycle consists of 14 days ) during primary treatment and on Days 1, 8, 15, 22 during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2, IV dose of gemcitabine 1000 mg/m^2, and Oxaliplatin IV dose of 100 mg/m^2 on Day 1 during primary treatment.
11024235|NCT04607772|Experimental|Arm E: Selinexor with Ibrutinib and Rituximab (S-IR)|Participants will receive a dose of 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 8, and 15 for Cycle 1 up to 6 during primary and continuous treatment (each cycle consists of 28 days). participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and ibrutinib oral dose of 420 or 560 mg on Day 1 to 28 during primary treatment. Participants will also receive ibrutinib oral dose of 420 mg daily during continuous treatment.
11024236|NCT04607772|Experimental|Arm F: Selinexor with Lenalidomide and Rituximab (S-LR)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets once weekly on Days 1, 8, and 15 for Cycle 1 up to 6 during primary and continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 during the continuous treatment.
11024237|NCT04607772|Experimental|Arm G: Selinexor with Lenalidomide and Tafasitamab (S-LT)|Participants will receive a dose of 40 or 60 mg of selinexor oral tablets once weekly on Days 1, 8, and 15 for Cycle 1 up to 3 during primary treatment and Days 1, 8, 15, and 22 during continuous treatment (each cycle consists of 28 days per cycle). During the primary treatment (Cycle 1 to 12), participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg during the continuous treatment on Days 1 and 15.
11024238|NCT04607772|Experimental|Arm H: Selinexor with Venetoclax (S-V)|Participants will receive 40 or 60 or 80 mg of selinexor oral tablets once weekly on Days 1, 8 and 15 for Cycle 1 up to 6 of primary and continuous with treatment duration (28 days per cycle). Participants who receive 40 and 60 mg of selinexor during primary treatment will also receive oral dose of venetoclax 200 mg on Days 1 to 7 then 400 mg on Days 8 to 28 for cycle 1; 400 mg daily for Cycle 2 to 6 (each cycle=28 days). Participants who receive 60 and 80 mg of selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7 then 600 mg on Days 8 to 28 for Cycle 1; 600 mg daily for Cycle 2 to 6 (each cycle=28 days). Participants who receive 80 mg selinexor during primary treatment will also receive venetoclax 400 mg orally on Days 1 to 7, then 600 mg from Days 8 to 14, then 800 mg from Day 15 to 28 for Cycle 1; 800 mg daily for Cycle 2 to 6 (each cycle=28 days). Participants during continuous treatment will also receive venetoclax 400 mg orally daily.
11024239|NCT04607759|Experimental|Experimental group (cucumber)|"Consumption for 90 days of cucumber extract (20mg/day)
~Two capsules a day orally for 90 days."
11024240|NCT04607759|Placebo Comparator|control group Placebo (sucrose)|Two capsules a day orally for 90 days.
11024241|NCT04607746|Experimental|Capsule|Participants will swallow the capsule for imaging prior to completing colonoscopy. Capsule swallow may be 1 day prior or 3-6 weeks prior to colonoscopy.
11024242|NCT04607733|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS)
11024243|NCT04607733|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by subcutaneous injection (SC) via an autoinjector (AI)
11024244|NCT04607720|Experimental|the artificial-EUS-FNA group|the first two passes were made without the AI-assisted diagnosis system guidance during EUS-FNA, and then two passes were made under guidance from the AI-assisted diagnosis system
11024245|NCT04607720|Experimental|the AI-EUS-FNA group|the first two passes were made with the AI-assisted diagnosis system guidance and then another two manual passes without the AI-assisted diagnosis system guidance.
11024246|NCT04607707||Postmenopausal Women|Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.
11024247|NCT04607694|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
11024248|NCT04607694|Active Comparator|Photon radiotherapy|Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
11024249|NCT04607681|Experimental|1 GROUP|"Patients who agree to participate in the study will be informed about the study and their written and verbal consent will be obtained. At this stage, which will last 6 weeks for each patient;
~On the first day, the patients will be evaluated first by filling the Individual Descriptive Features Form, Information Need Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT),
~In order for the patients in the intervention group to use the web-based asthma education program, a web-based asthma education program will be introduced by giving their username and password.
~After 6 weeks of training, second data will be collected on the web in the intervention group."
11024250|NCT04607681|No Intervention|2 GROUP|"Written and verbal consents will be obtained from patients who agree to participate in the study by providing information about the study.
~At this stage, which will take 6 weeks for each patient; On the first day, the patients will first be evaluated by filling the Individual Descriptive Characteristics Form, Information Requirement Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Second data after 6 weeks will be collected in the control group via Google form or phone call"
11024251|NCT04607668|Experimental|trilaciclib + FOLFOXIRI/bevacizumab|"During Induction the following study drugs are administered on Day 1:
~Irinotecan- IV Oxaliplatin - IV Leucovorin- IV Fluorouracil - continuous infusion (CI) over 48 hours beginning on Day 1; Bevacizumab - IV
~Following completion of Induction, patients will continue in Maintenance, where they will continue to receive trilaciclib per randomization allocation. Trilaciclib will be administered prior to infusional-5FU/leucovorin/bevacizumab at the same dose and schedule used during Induction."
11024499|NCT04606264|Active Comparator|Major Abdominal: Fluid Therapy Stroke Volume Optimization|
11029986|NCT04568304|Experimental|Toripalimab Injection + chemotherapy group|
11024252|NCT04607668|Placebo Comparator|placebo + FOLFOXIRI/bevacizumab|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib
11024253|NCT04607655|Experimental|Oral GB1211, 100 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
11024254|NCT04607655|Experimental|Oral GB1211, 10 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
11024255|NCT04607655|Placebo Comparator|Oral GB1211, Placebo, twice a day|Placebo is administered as inhalation once a day
11024256|NCT04607642|Experimental|A BMX-001|Patients will receive standard of care radiation therapy plus Cisplatin. BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
11024257|NCT04607642|Placebo Comparator|B Placebo|Patients will receive standard of care radiation therapy plus Cisplatin. Placebo will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
11024258|NCT04607629|Experimental|Genolar® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
11024259|NCT04607629|Active Comparator|Xolair® + Symbicort®|omalizumab & inhalation of budesonide+formoterol
11024260|NCT04607616|Experimental|3 baselines sessions Treatment As Usual (TAU)|Patients received 3 baseline sessions before interactive guidance therapy
11024261|NCT04607616|Experimental|4 baselines sessions TAU|Patients received 4 baseline sessions before interactive guidance therapy
11024262|NCT04607616|Experimental|5 baselines sessions TAU|Patients received 5 baseline sessions before interactive guidance therapy
11024263|NCT04607616|Experimental|6 baselines sessions TAU|Patients received 6 baseline sessions before interactive guidance therapy
11024264|NCT04607616|Experimental|7 baselines sessions TAU|Patients received 7 baseline sessions before interactive guidance therapy
11024265|NCT04607616|Experimental|8 baselines sessions TAU|Patients received 8 baseline sessions before interactive guidance therapy
11024266|NCT04607603|Experimental|Cannabidiol|In the Cannabidiol (CBD) arm CBD will be titrated up to 600 mg per die (titration 1 week) in capsules (3 daily doses) and maintained at 600mg per die (3 daily doses) for 7 weeks
11024267|NCT04607603|Placebo Comparator|Placebo|In the placebo arm the placebo comparator will be administered in capsules in 3 daily doses
11024268|NCT04607590||Group I (DY)|Patients and their partners attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy.
11024269|NCT04607590||Group II (PY)|Patients attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy. Once data collection is completed, partners will be offered intervention materials, and encouraged to attend yoga classes at the Integrative Medicine Clinic.
11024270|NCT04607590||Group III (WLC)|Patients and their partners receive usual care. Once data collection is completed, couples may participate in the DY or PY program of their choice over 60 minutes each. Partners are also offered intervention materials along with five 60 minute optional yoga sessions.
11024271|NCT04607564|Experimental|No comparison pilot group|Attendance at ten Ntombi Vimbela workshops running for a total 35 hours over six weeks.
11024272|NCT04607551|Experimental|Prone positionning|
11024273|NCT04607551|Active Comparator|Supine position|
11024274|NCT04607538||Patellar instability, but no patellar dislocation or dysplasia|This group consist of patients in age from 15-20 years old in the Faroe Islands, who experience patellar instability, but have not experienced a patellar dislocation and do not have femoral trochlear dysplasia
11024275|NCT04607538||Patiens with patellar dislocation, but no trochlear dysplasia|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have experience one or more patellar dislocations, but do not have femoral trochlear dysplasia
11024276|NCT04607538||Patients with trochlear dysplasia|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have experienced either patellar instability or patellar dislocation, and have femoral trochlear dysplasia.
11024277|NCT04607525|Experimental|Group D|Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline
11024278|NCT04607525|Placebo Comparator|Group C|Patients received equal volume and rate of normal saline as Group D.
11024279|NCT04607512|Experimental|Telaglenastat|800 mg telaglenastat (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
11024280|NCT04607512|Placebo Comparator|Telaglenastat Placebo|800 mg placebo (4 x 200 mg tablets) administered twice daily (BID) on Days 1 3, with a single dose administered on the morning of Day 4
11024281|NCT04607512|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin (1 x 400 mg tablet) administered on the morning of Day 4
11024282|NCT04607499||Pregnant women|Pregnant women without intervention
11024283|NCT04607486||CVA and spasticity|Adults with first-ever chronic CVA and leg spasticity
11024284|NCT04607486||CVA without spasticity|Control group
11024285|NCT04607486||healthy subjects|Control group
11024286|NCT04607473|Experimental|ABUS|ABUS is performed by experienced technicians using a GE inveniaTM. Each breast is imaged in three views with an automated 15.4-cm 14-6-MHz linear- array transducer, which acquires up to 1000 two-dimensional images in the transverse plane, imaging the breast in three parts: the central (anteroposterior), lateral, and medial portions of the breast. To ensure inclusion of all breast tissue, particularly in participants with very large breasts, additional views are obtained as deemed necessary by the technician to cover the entirety of the breast.
11024287|NCT04607460|Experimental|EMG-Biofeedback|Participants will receive an EMG-Biofeedback device and a software installed on a tablet or smart phone. During the 8 weekly sessions participants will be instructed on how to use the device by a trained biofeedback instructor.
11024288|NCT04607460|No Intervention|Treatment as usual|Participants in this group will receive no active treatment.
11024289|NCT04607447|Active Comparator|Atorvastatin plus Dexamethasone tablets|
11024290|NCT04607447|Experimental|drugs+low intracranial pressure strategy treatment|Drugs means treatment with Atorvastatin plus Dexamethasone tablets
11024291|NCT04607421|Experimental|Safety Lead-in Cohort 1|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
11024292|NCT04607421|Experimental|Safety Lead-in Cohort 2|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
11024293|NCT04607421|Experimental|Phase 3 Arm A|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks
11024294|NCT04607421|Experimental|Phase 3 Arm B|Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks -OR- Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks
11024295|NCT04607421|Active Comparator|Phase 3 Arm C|"Every two weeks:
~Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR-
~Every two weeks:
~Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR-
~Every two weeks:
~Irinotecan 180 mg/m2 (90-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)"
11024296|NCT04607408|Experimental|Part A, Group 1: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 2.5 mcg GLA-SE, to be administered as a 0.25 mL intramuscular (IM) injection into either thigh at Weeks 0, 8, 16, 32, and 54.
11024297|NCT04607408|Placebo Comparator|Part A, Group 2: Placebo|Participants will receive Placebo to be administered as a 0.25 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
11024298|NCT04607408|Experimental|Part B, Group 3: CH505TF gp120 + GLA-SE|Participants will receive 100 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
11024299|NCT04607408|Placebo Comparator|Part B, Group 4: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
11024300|NCT04607408|Experimental|Part C, Group 5: CH505TF gp120 + GLA-SE|Participants will receive 20 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
11024301|NCT04607408|Placebo Comparator|Part C, Group 6: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
11024302|NCT04607408|Experimental|Part C, Group 7: CH505TF gp120 + GLA-SE|Participants will receive 100 mcg Stable CH505TF gp120 admixed with 5 mcg GLA-SE, to be administered as a 0.5 mL IM injection into either thigh at Weeks 0, 8, 16, 32, and 54.
11024303|NCT04607408|Placebo Comparator|Part C, Group 8: Placebo|Participants will receive Placebo to be administered as a 0.5 mL IM injection, into either thigh at Weeks 0, 8, 16, 32, and 54.
11024304|NCT04607395||pre-operative radiographs of deep carious lesion|
11024305|NCT04607382||Low-dose estrogen progestin products (LEP)|The patients in the LEP cohort should not have taken LEP in the last 2 months before the enrollment in the study, and will take LEP during the study period.
11024306|NCT04607382||Non-LEP|Those patients in the Non-LEP cohort should not have taken LEP in the last 2 months before the enrollment and will take NSAIDs and/or Chinese medicine (CM) during the study period.
11024307|NCT04607369||Groups in General all were done under the wcgIRB, even those that were Practice groups|"Groups 1-3 were practice groups, gathering smartphone app installation, functional and usability feedback in preparation for later phase groups
~Groups 4a and 4b Cohort 1 and 2 is the FDA application finalized and submitted study groups
~Group 5-6 currently in continuing clinical trial during FDA application process"
11024308|NCT04607369||1,2,3 Developmental team, Technician and Non-Clinical Groups are all PRACTICE groups|Individuals on the developmental team and Technicians, medical students, post doctor research fellows included in this group. Non-clinical groups were individuals that are not in formal medical practice who agreed to try the app
11024309|NCT04607369||4a. Cohort 1. FDA group|Patients in Neuro-Ophthalmology of Texas (NOT) PLLC practice which has referrals from multiple practices including retinal patients.
11024310|NCT04607369||4b. Cohort 2. FDA group|Patients in NOT practice
11024311|NCT04607369||5. Retinal in continuing clinical trial during FDA decision|Patients in Macula, Vitreous, Retina-Physicians and Surgeons-
11024312|NCT04607369||6. At Home in continuing clinical trial during FDA decision|Patients in all practices who wish to work with Neuro-ophthalmology of Texas (NOT) where patients will be educated at home via app video clips and brochure, and as necessary, online training with COA (ophthalmic assistants/technicians or other trained educators) in order to do remote physiologic vision monitoring and screening.
11024313|NCT04607356|Active Comparator|Evidence-informed care|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises.
11024314|NCT04607356|Experimental|Evidence-informed care + Blood Flow Restriction (BFR)|Standardized, evidence based rehabilitation program for lateral epicondylalgia to include: discussion of ergonomics, home exercise program performance, use of any prescribed splint or brace, forearm and shoulder stretches, soft tissue mobilization, and performance of standard resistance exercises with the addition of BFR while performing resistive exercises.
11024500|NCT04606264|Active Comparator|Major Abdominal: Fluid Therapy Maintain Euvolemia|
11024315|NCT04607343|Experimental|Assigned Interventions|Patients will undergo a conventional flexible nasopharyngeal laryngoscopy in which the degree of obstruction and the laryngopharyngeal sensitivity during wakefulness will be determined. Electrostimulation will be applied at different submandibular points with increasing intensity until the contraction of the dilation muscles of the airway or until the patient cannot tolerate the electrostimulation. The presence of contraction of stimulated muscles will be determined by external and endoscopic inspection.
11024316|NCT04607330|Experimental|High protein liquid|A ready to use, low calorie, low volume, ready to use, high protein liquid modular (HPLM) feed for adults.
11024317|NCT04607317|Experimental|Exercise Intervention|Participants in this arm will be enrolled in a teleheatlh-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day). Participants will meet weekly 1:1 with a trained health coach via a Webex platform. Weekly exercise goals will be tailored to the individual's abilities and specific barriers. Coaching will utilize social cognitive theory and self-determination theory to develop self-efficacy for sustainable behavior change.
11024318|NCT04607317|Active Comparator|Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks. They will contine to wear the Garmin activity tracker and can view their activity but will not be given an exercise program. They will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygeine.
11024319|NCT04607304|Experimental|ABCA2 GIRMS|Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized
11024320|NCT04607291|Experimental|Health services research (Witness CARES services) Intervention|Patients who are not prepared for a colonoscopy or stool test receive educational materials, messages, and videos electronically or by mail with information about colorectal screening and are followed up by phone within 2 weeks. Patients desiring colonoscopy, receive navigators assistance with obtaining the screening (e.g.,determining gastrointestinal doctor, scheduling appointment, prep materials and process, transportation, escort). Patients desiring a stool test, receive navigators assistance by facilitating fecal tests.
11024321|NCT04607278|Experimental|Probiotic|Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
11024322|NCT04607278|Active Comparator|Prebiotic|The prebiotic (Inulin) was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
11024323|NCT04607278|Placebo Comparator|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
11024324|NCT04607265||Ventricular tachycardia (VT) group|NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.
11024325|NCT04607265||Control group|NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.
11024326|NCT04607252|Experimental|Metformin plus megestrol acetate|Metformin 1500mg per day plus megestrol acetate 160mg per day.
11024327|NCT04607252|Active Comparator|Megestrol acetate|Megestrol acetate 160mg per day.
11024328|NCT04607239|Experimental|Telemonitoring|"In addition to the usual care, this group benefits from a weekly telephone call by the Clinical Research Associate (CRA) for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.
~This group will also benefit from a monthly call by the attending physician for treatment titration and side effects check."
11024329|NCT04607239|Other|Conventional|"This group will benefit form the usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.
~The usual care includes attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician."
11024330|NCT04607226|Experimental|Active tVNS - 2 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 2 Hz stimulation frequency
11024331|NCT04607226|Experimental|Active tVNS - 8 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 8 Hz stimulation frequency
11024332|NCT04607226|Experimental|Active tVNS - 30 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 30 Hz stimulation frequency
11024333|NCT04607226|Experimental|Active tVNS - 100 Hz|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle with 100 Hz stimulation frequency
11024334|NCT04607226|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
11024335|NCT04607213|Active Comparator|Advancement-rotation approach|
11024336|NCT04607213|Experimental|Straight-line approach|
11024337|NCT04607200|Experimental|Monotherapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks for up to 24 months
11024338|NCT04607200|Experimental|Combination Therapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks + AGEN1884 - dose of 1 mg/kg IV every 6 weeks (following AGEN2034 infusion), for up to 24 months
11024339|NCT04607187||Normals, Dupuytren's subjects with and without treatment|Ultrasound analysis of patient receiving treatment for Dupuytren's
11024340|NCT04607174||Pathologic group|At least 20 participants with various neurologic or orthopaedic conditions (for example, hemiparesis post-stroke, multiple sclerosis, traumatic knee injuries, knee osteoarthritis) will be enrolled.
11024341|NCT04607148|Experimental|RG6147 20 mg Q4W|Participants will receive 20 milligrams (mg) RG6147 via ITV injection every 4 weeks (Q4W).
11024342|NCT04607148|Experimental|RG6147 20 mg Q8W|Participants will receive 20 mg RG6147 via ITV injection every 8 weeks (Q8W).
11024343|NCT04607135|Experimental|Acoustic radiation force impulse (ARFI)|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
11024344|NCT04607135|Active Comparator|MR-ultrasound fusion|Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
11024345|NCT04607122|Experimental|Landiolol group|Landiolol infusion (2µg/kg/min) administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
11024346|NCT04607122|Placebo Comparator|Placebo group|Saline solution infusion administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
11024347|NCT04607096|Active Comparator|Prediabetic subjects - cluster 3|Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
11024348|NCT04607096|Active Comparator|Prediabetic subjects - cluster 5/6|Presence of a cluster 5/6 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
11024349|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)|Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
11024350|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)|Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
11024351|NCT04607083||Patients with at least one diminutive rectosigmoid polyp|"Consecutive adult (>18 years) outpatients undergoing elective colonoscopy, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
~Exclusion criteria:
~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer
~patients with inadequate bowel preparation
~patients in which caecal intubation was not achieved or scheduled for partial examinations
~polyps could not be resected due to ongoing anticoagulation preventing resection and pathologic assessment
~patients undergoing urgent colonoscopy."
11024352|NCT04607070||Stroke patient|This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018.
11024353|NCT04607057|Experimental|experimental group (Arm A)|"Preparation of parenteral nutrition (PN): Among winuf(1820cc for central vein, 1,450cc for peripheral vein), smofkabaven(986cc for central vein, 1206cc for peripheral vein), and nutriplex(1875cc for central vein, 1,250cc for peripheral vein) Amount of PN: Total energy expenditure (TEE) of the patients will be calculated with Harris-Benedict Equation, activity factor, and stress factor. The amount of calorie from oral intake will be subtracted from TEE then the remainder will be provided through PN.
~Route of PN Injection: PICC (percutaneously-inserted central catheter) will be secured for PN for the central vein. PN for the peripheral vein will be injected directly through peripheral superficial vein.
~Day0 : fasting(NPO) + crystalloid fluid
~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid
~POD#2 : Semifluid diet (SFD) + crystalloid fluid
~POD#3 : Semifluid diet (SFD) + PN
~POD#4-7: Soft blended diet (SBD) + PN"
11024354|NCT04607057|No Intervention|control group (Arm B)|"Day0 : fasting(NPO) + crystalloid fluid
~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid
~POD#2 : Semifluid diet (SFD) + dextrose 5% water
~POD#3 : Semifluid diet (SFD) + dextrose 5% water
~POD#4-7: Soft blended diet (SBD)"
11024355|NCT04607031||ischemic stroke patients|20 patients with ischemic stroke, onset within 24 hours, NIHSS≥8
11024356|NCT04607018|Active Comparator|Chronic intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product already before the study started (since 28 days before or even longer)
11024357|NCT04607018|Active Comparator|Naive intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product only since the first day of the study
11024358|NCT04607005|Experimental|Participants receiving mepolizumab + Standard of care (SoC)|Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
11024359|NCT04607005|Placebo Comparator|Participants receiving placebo + SoC|Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
11024360|NCT04606992|Experimental|CELS resection|All patients included in the study will be in this arm
11024361|NCT04606979|Experimental|Parkinson Disease - Group 1a - Active tDCS first|Half of the subjects with PD will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive sham (placebo) tDCS.
11024362|NCT04606979|Sham Comparator|Parkinson Disease - Group 1b - Sham tDCS first|Half of the subjects with PD will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive active (anodal, real) tDCS.
11024363|NCT04606979|Experimental|Healthy Controls - Group 2a - Active tDCS first|Half of the healthy controls will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive sham (placebo) tDCS.
11024364|NCT04606979|Sham Comparator|Healthy Controls - Group 2b - Sham tDCS first|Half of the healthy controls will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive active (anodal, real) tDCS.
11024365|NCT04606966|Experimental|Therapeutic Horseback Riding|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual. Participants will have an assigned horse and volunteer(s) Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table for five minutes, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for two minutes while watching a 1-minute sand timer, then, participants will then don their riding helmets and enter the riding arena. Each week after conclusion of the THR intervention, participants will again sit with their group at an art table for 20 minutes followed by doing another saliva sample.
11024386|NCT04606836|Experimental|Prospective Cases|These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
11024387|NCT04606836|No Intervention|Retrospective Controls|Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.
11024501|NCT04606264|Active Comparator|Major Abdominal: Analgesia Adjuncts Ketamine|
11024502|NCT04606264|Active Comparator|Major Abdominal: Anesthesia Adjuncts Lidocaine|
11024366|NCT04606966|Active Comparator|Barn Activity|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor. Participants will have one assigned volunteer and will have no contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse in for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table for five minutes, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for two minutes while watching a 1-minute sand timer. Each week after conclusion of the BA intervention, participants will again sit with their group at an art table for 20 minutes followed by doing another saliva sample
11024367|NCT04606966|No Intervention|Waitlist|Those assigned to the waitlist group will not have any horse-related intervention during a 10-week waiting period. Following this waiting period and the completion of post assessments, participants in this condition will begin a Hybrid group (see Hybrid Arm)
11024368|NCT04606966|Experimental|Hybrid|Participants who complete the Waitlist Arm and post assessments, will begin a Hybrid group that will consist of a 5- week one hour Barn Activity (BA) group condition that consists of a small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor. Participants will have one assigned volunteer and will have no contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse in for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM. After the first 5 weeks of BA, participants will then complete 5-weeks of Therapeutic Horseback Riding small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual. Participants will have an assigned horse and volunteer(s) Group times will be between 1:00-5:00 PM.
11024369|NCT04606953|Experimental|Attention Process Training (APT-II)|Patients in the experimental group receive the APT-II training program (Attention Process Training) individually with a psychologist for 8 weeks (2 sessions/week). The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to each patient's profile in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains towards the most problematic daily activities in order to reduce the impact of the patients' cognitive problems in their daily lives.
11024370|NCT04606953|No Intervention|Standard care|Patients in the control group receive standard routine care.
11024371|NCT04606940||IO-KIN|Patients with a histological or cytological confirmed recurrent, metastatic or advanced HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or unknown origin (but being treated as HNSCC). Patients who are going to receive at least one dose of anti-PD1 antibody (nivolumab or pembrolizumab).
11024372|NCT04606927|Active Comparator|Natriuresis guided treatment|
11024373|NCT04606927|No Intervention|Standard of care|
11024374|NCT04606914|Experimental|neoadjuvant chemotherapy regimen|"IV Carboplatin AUC 5 (Q21 days) 7 cycles (first cycle is Carbo alone, dosing for C1D1 will be provider's choice)
~IV Mirvetuximab 6 mg/kg (adjusted ideal body weight) day 1 (Q21 days) 6 cycles (starting with cycle #2)"
11024375|NCT04606901|Active Comparator|Sugammadex|Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.
11024376|NCT04606901|Active Comparator|Neostigmine/Glycopyrrolate|Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade
11024377|NCT04606888|Experimental|Transcutaneous electrical acupoint stimulation group|Transcutaneous electrical acupoint stimulation group patients received Transcutaneous electrical acupoint stimulation (Neiguan [PC6], Yintang [GV 29], Zusanli [ST36]) for 30 min before the induction of anaesthesia until the end of the surgery and the night before operation, the first, second and third night after operation 30 min once a day with an altered frequency 2/100 Hz, disperse-dense waves, adjusted electricity intensity which was less than 10 mA.
11024378|NCT04606888|No Intervention|Control group|In Control group, except the electronic stimulation was not applied, the treatment was the same as the Transcutaneous electrical acupoint stimulation group.
11024379|NCT04606875||Control Group|Subjects will have no personal or family psychiatric history and no suicide attempts.
11024380|NCT04606875||Patients with Suicidal Ideation and Low Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
11024381|NCT04606875||Patients with Suicidal Ideation and High Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
11024382|NCT04606862|Experimental|Investigational Arm|The patients enrolled into the investigational arm at each participating hospital will be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis.
11024383|NCT04606862|No Intervention|Control Arm|The patients enrolled into the control group of each participating hospital will not be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis. These patients will be monitored according to each institution's standard sepsis screening practices.
11024384|NCT04606849|Other|Physician Survey|A modified version of a previously validated REDCap questionnaire will be administered to Instacare clinicians in the cluster where ePNa-CheXED was deployed via email at 6 months after ePNa-CheXED implementation. Our questionnaire includes questions on respondent demographics and Likert-style questions about respondents' experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components
11024385|NCT04606849|Other|Adapt ePNa-CheXED for InstaCares|"Adapt ePNa-CheXED for Instacares and after in silico testing, pilot it among super user clinicians during Instacare shifts and assess its usability. ePNa needs adaptation for more limited patient data available in Instacare clinics, calibration of severity measures for lower observed mortality, and a chest imaging prompt in patients with pneumonia signs and symptoms. ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in <1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion)."
11024388|NCT04606823|Other|Single-arm|In this single-arm study the patients will be undergoing a minimally invasive surgery after which they will re-visit the clinic at five occasions for follow-up visits (1-3 extra compared to routine clinical practice at the hospitals) and complete a quality of life-questinnaire three months after surgery.
11024389|NCT04606810|Active Comparator|Arm1, Participants received the multidisciplinary educational intervention at baseline|Participants in arm1 received the usual care plus the multidisciplinary educational intervention consisting of an educational DVD followed by a teleconference at baseline.
11024390|NCT04606810|Other|Arm2, Participants in arm2 received the educational intervention after 3 months|Participants in group 2 first received usual care, and after 3 months were offered the multidisciplinary educational intervention.
11024391|NCT04606797|Experimental|Nicotine Replacement Therapy|
11024392|NCT04606797|No Intervention|Control|
11024393|NCT04606784|Experimental|Ampion|Ampion
11024394|NCT04606784|Other|Standard of Care|Standard of Care
11024395|NCT04606771|Experimental|Arm A|"Savolitinib 300 mg oral QD
~Osimertinib 80 mg oral QD"
11024396|NCT04606771|Experimental|Arm B|"Savolitinib 300 mg oral QD
~Placebo to Osimertinib 80mg oral QD"
11024397|NCT04606758|Active Comparator|PCNL under fluoroscopic control|
11024398|NCT04606758|Active Comparator|PCNL under ultrasound control|
11024399|NCT04606719|Other|Blood Clot|It is induced through apical foramen by penetrating the periapical area by stainless steel file size 30 to fill the root canal system by growth factors also to be considered as scaffold
11024400|NCT04606719|Active Comparator|Standard PRF|Standard Platelet-rich fibrin will be prepared by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 3000 rpm for 10 min. After centrifugation, three layers will formed in the test tube-base layer of RBCs, top layer of a-cellular plasma, and a PRF clot in the middle. This clot will then pressed between two gauze pieces to form a membrane.
11024401|NCT04606719|Experimental|Advanced PRF|A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
11024402|NCT04606706|Experimental|Maternal, lactating mother & young child (Intervention)|mHealth education intervention for 6 months
11024403|NCT04606706|No Intervention|Maternal, lactating mother & young child (Control)|Conventional health education
11024404|NCT04606693|No Intervention|Patients with negative diagnosis of SAHS|Patients with low risk or negative diagnosis of SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit
11024405|NCT04606693|Other|Patients with positive diagnosis of SAHS|Patients with intermediate or high risk of SAHS and positive diagnosis
11024406|NCT04606680|Experimental|Heat application group|Participants will receive heat application at acupoints plus lifestyle modification. Participants will receive heat application treatment once every other day, 3 times per week, for 4 consecutive weeks.
11024407|NCT04606680|Experimental|Medicated plaster group|Participants will receive medicated plaster at acupoints plus lifestyle modification. Participants will receive medicated plaster at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
11024408|NCT04606680|Experimental|Herb-partitioned moxibustion group|Participants will receive herb-partitioned moxibustion at acupoints plus lifestyle modification. Participants will receive herb-partitioned moxibustion at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
11024409|NCT04606667|Experimental|Multi component program|"The intervention lasted 16 weeks, with the evaluations carried out at baseline, after 8 weeks and at the end.
~The multi-component exercise program took place in day centers or collective residences. It was supervised by physiotherapists. The classes took place 3 times a week, at the same hour and on alternate days, for 45-60 minutes, for a total of 48 sessions. The program consisted on a warm-up (5 min) with exercises and walking, a balance and strength training (35-40 min) with exercises repeated 3 times and held for 15 seconds flexibility / relaxation (5 to 10 mins) periods. The strength training is performed with the resistance of the body weight or accessible and low cost equipment, with two series of 10 to 15 repetitions, after maximum resistance was calculated.
~The flexibility and cooling training consists of 3 repetitions maintained for 15 seconds."
11024410|NCT04606654|Experimental|Handgrip strength training with Blood flow restriction|"Three sessions per week will be given to individual subject. and training will be with Blood flow restriction.
~Subjects will be followed for two weeks for;
~Hand grip strength
~Forearm circumference"
11024411|NCT04606654|Active Comparator|Handgrip strength training without Blood flow restriction|"Three sessions per week will be given to individual subject and training will be without Blood flow restriction.
~Subjects will be followed for two weeks for;
~Hand grip strength
~Forearm circumference"
11024412|NCT04606641|Experimental|Goal specific functional tasks with mirror therapy):|"The session will be performed thrice in a week for total of 4 weeks. Each session will last for 20 minutes. Mirror therapy procedure and functional tasks will be explained to the patient before the start of treatment.
~In this group, a mirror will be placed in the sagittal plane of the patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror"
11024413|NCT04606641|Active Comparator|Goal specific functional tasks without mirror therapy|"Session will be performed thrice in a week for total 4 weeks. Each session will last for 20 minutes.
~The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks as mentioned in the table below Functional tasks will be same in both groups"
11024414|NCT04606628|Experimental|Intervention|Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks.
11024415|NCT04606628|Experimental|Placebo|Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks.
11024416|NCT04606615||Adults: AD + FA|Adults: atopic dermatitis and food allergy to peanut
11024417|NCT04606615||Adults: AD - FA|Adults: atopic dermatitis and no food allergy
11024418|NCT04606615||Adults: NC|Adults: Normal Control
11024419|NCT04606615||Children: AD+ Peanut|Children: atopic dermatitis and food allergy to peanut
11024420|NCT04606615||Children: AD + Milk|atopic dermatitis and food allergy to milk
11024421|NCT04606615||Children: AD + Egg|atopic dermatitis and food allergy to egg
11024435|NCT04606589|No Intervention|Standard-of-care|The standard-of-care arm will receive intermittent monitoring of pulse rate and blood oxygen saturation with a conventional pulse oximeter. Temperature and respiratory rate will also be monitored intermittently with a digital thermometer and manual counting of breaths respectively.
11024436|NCT04606589|Experimental|neoGuard vital signs monitor|The intervention group will receive continuous vital signs monitoring of pulse rate, blood oxygen saturation, temperature and respiratory rate with the neoGuard device.
11024437|NCT04606576|Placebo Comparator|Placebo|Fish Oil
11024438|NCT04606576|Experimental|ORMD-0801 QD|8 mg ORMD-0801 administered QD at night
11024439|NCT04606576|Experimental|ORMD-0801 BID|8 mg ORMD-0801 administered at night and in the morning 45 minutes before breakfast.
11024440|NCT04606563|Experimental|Losartan|Patients will initially receive 25 mg oral losartan, increased to 50 mg after 24 hours and then increased to a max dose of 100 mg after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at 25 or 50 mg.
11024441|NCT04606563|No Intervention|Usual Care Control|Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
11024442|NCT04606550|Experimental|Vaginal Laser HR+|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
11024443|NCT04606550|Active Comparator|Vaginal Estrogen HR-|The women in the vaginal estrogen group will be prescribed and asked to administer: Conjugated estrogen cream (Premarin®): 0.5 g of cream intravaginally daily (using applicator or fingertip) for two weeks (fourteen days) then 0.5 g twice weekly for 24 ± 2 additional weeks.
11024444|NCT04606550|Active Comparator|Vaginal Laser HR-|During our study, women will undergo treatment intravaginally and vulvar with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy). A treatment cycle includes three laser applications (every 40-50 days, approximately 6 weeks). The procedure will be performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
11024445|NCT04606537|Experimental|Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)|
11024446|NCT04606537|Experimental|Cohort 2 (Effects of CYP3A4 induction on KBP-5074)|
11024447|NCT04606524||study group|25 postmenopausal females will be included in this study
11024448|NCT04606524||control group|25 premenopausal females will be included in this tudy
11024449|NCT04606511|Other|Breast cancer patients with lymphedema|
11024450|NCT04606511|Other|Breast cancer patients without lymphedema|
11024451|NCT04606498||1- Retrospective|Retrospective Seraph® 100 - this group will be composed of subjects that were treated with Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site. A waiver of informed consent will be requested from the Institutional Review Board (IRB) to allow the collection of these retrospective data
11024452|NCT04606498||2 - Prospective|Prospective Seraph® 100 - To identify prospective Seraph® 100 patients, the individual site investigators will review currently admitted ICU patients for inclusion criteria and exclusion criteria. The study team will then ask the physician caring for the patient to contact the study team should the patient require therapy with Seraph® 100. Additionally, the study team will review the medical records of admitted patients to see if they have recently been started on Seraph. Patients found to meet eligibility will be offered the opportunity to consent and participate in the study. Note that patients that were started on Seraph® 100 before the date of approval but are still admitted, will not be eligible to give biospecimens.
11024453|NCT04606498||3 - Historical Control|The historical control group will be a sample of convenience, composed of patients admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site. A waiver of informed consent will be requested from the IRB to allow the collection of these retrospective data
11024454|NCT04606485|Placebo Comparator|Placebo group|"Since acupressure administration was reported to have placebo effects, a placebo group was used to investigate the true effect of acupressure use. The application of placebo may consist of moderate pressure on an incorrect acupuncture point or a light touch on a real acupuncture point. This will allow us to determine the contribution of the placebo effect resulting from direct human contact and interaction in the light touch group.
~At postoperative 0, 4, and 8 hours, a light touch was applied to the ST25 (Stomach Meridian 25th point), CV12 (Conception Vessel Meridian 12th point), TH6 (Triple Heater Meridian 6th point) and HT7 (Shenmen point points) for one second. No patients experienced pain or a feeling of pressure."
11024455|NCT04606485|Experimental|Experimental group|"As invasive acupuncture may cause hematoma and the wristband method of non-invasive acupressure may cause patient discomfort, itching, swelling of the wrist, and skin destruction, manual acupressure was applied in this study to reduce the risk of complications to a minimum.
~The frequency and duration of the application of acupressure was decided from a scan of literature and expert opinion. The first acupressure session was applied in the first postoperative hour immediately after routine treatment and care of the patients who came to the ward from the recovery unit. Acupressure by applying pressure with the thumbs for a total of 12 mins, as 3 mins at each of the ST25, CV12, TH6 and HT7 acupuncture points, was performed at 0, 4 and 8 hours postoperatively. The acupuncture points were determined using the measurements of the patient's own fingers."
11024456|NCT04606472|Experimental|Study treatment|Participants receive SI-B003 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
11024503|NCT04606264|Active Comparator|Major Abdominal: Anesthesia Adjuncts Ketamine and Lidocaine|
11024504|NCT04606264|No Intervention|Major Abdominal: No Anesthesia Adjuncts|
11024505|NCT04606264|Active Comparator|Major Abdominal: Intraoperative Opioid|
11024506|NCT04606264|No Intervention|Major Abdominal: No Intraoperative Opioid|
11024457|NCT04606459|Active Comparator|Optimal medical therapy|"Optimal medical therapy consisting of acetyl salicylic acid, statins, beta-blockers, calcium channel-antagonists, ranolazine will be administered at the discretion of the physician as recommended by the most recent European Society of Cardiology (ESC) guidelines.
~Long-acting nitrates will not be administered unless for patients with fractional flow reserve (FFR)<0.8 or with previously reported good response. Short-acting nitrates may be administered in patients in whom concomitant epicardial spasm is suspected, but they have no documented effect on microvascular angina."
11024458|NCT04606459|Experimental|Coronary sinus reducer|The device being studied is the Neovasc Reducer™ System. Each patient in the Reducer group will be implanted with a single Reducer according to the instructions for use.
11024459|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 1|PF-07248144 Monotherapy Escalation
11024460|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 2|PF-07248144 Monotherapy Escalation
11024461|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 3|PF-07248144 Monotherapy Escalation
11024462|NCT04606446|Experimental|1A Monotherapy Escalation Dose Level 4|PF-07248144 Monotherapy Escalation
11024463|NCT04606446|Experimental|1B Combination Dose Finding Arm level 1|PF-07248144 with Fulvestrant Combination Dose Finding
11024464|NCT04606446|Experimental|1B Combination Dose Finding Arm Level 2|PF-07248144 with Fulvestrant Combination Dose Finding
11024465|NCT04606446|Experimental|1C Combination Dose Finding Arm Level 1|PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
11024466|NCT04606446|Experimental|1C Combination Dose FInding Arm Level 2|PF-07248144 with Letrozole + Palbociclib Combination Dose Finding
11024467|NCT04606446|Experimental|2A Monotherapy Dose Expansion Arm|PF-07248144 Monotherapy Dose Expansion
11024468|NCT04606446|Experimental|2B Combination Dose Expansion Arm|PF-07248144 with either Fulvestrant or Letrozole + Palbociclib Dose Expansion
11024469|NCT04606433|Experimental|Study treatment|Patients receive GNC-038 as intravenous infusion for one cycle. Participants with no intolerable AEs could continue for another three cycles. Participants with a clinical benefit after four cycles' treatment could also receive additional treatment for another four cycles at the same dose level.
11024470|NCT04606420|Experimental|Experimental (Intervention) Group|These patients will receive the comprehensive lifestyle medicine intervention from day 1 through the end of the study. They will be tested at baseline, after 20 weeks, and after 40 weeks. There may be subsequent testing after 2 years.
11024471|NCT04606420|No Intervention|Control (Non-Intervention) Group|"These patients will be asked to continue their current diet and lifestyle without making any changes for 20 weeks. They will be tested at baseline and after 20 weeks. Then, they will cross over and receive the same lifestyle medicine intervention for 20 weeks and will be tested again after 20 weeks of the intervention and also after 40 weeks of the intervention. There may be subsequent testing after 2 years."
11024472|NCT04606407|Experimental|Treatment|Inhaled NO delivered using LungFit™ in addition to standard of care
11024473|NCT04606407|No Intervention|Standard of care|Standard of care
11024474|NCT04606394|Other|Open label treatment|All subjects receive Trelegy and Ventolin for 2 weeks
11024475|NCT04606381|Experimental|Part 1: Ami-LC-MD and Ami-LC|Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
11024476|NCT04606381|Experimental|Part 2: Ami-HC and Ami-HC-CF|Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
11024477|NCT04606368|Experimental|Interventional cohort|Each subject will serve as their own control. Left side of lower jaw and submental area is control side. Right side of subject's lower jaw and submentum area will receive treatment.
11024478|NCT04606355|Experimental|PDI Check|Autostereoscopic, dynamic forced choice game (ie on Nintendo 3DS)
11024479|NCT04606355|Active Comparator|Conventional Near Vision Testing tools|Rosenbaum or HOTV near card, Ishihara color plates, Innova Rabin color test, Titmus Stereo test
11024480|NCT04606329|Experimental|LuminoMark inj.|Injection LuminoMark inj. 0.2mL once in this study.
11024481|NCT04606329|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
11024482|NCT04606316|Experimental|Nivolumab and Ipilimumab Before and After Surgery|"One dose of nivolumab plus ipilimumab will be administered 14(±5) days before surgery.
~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
11024483|NCT04606316|Experimental|Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab After Surgery|"One dose of nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.
~After surgery, participants receive nivolumab alone every 4 weeks."
11024484|NCT04606316|Experimental|Placebo-Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab and Ipilimumab After Surgery|"One dose of placebo-nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.
~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 12 weeks and then nivolumab alone every 4 weeks."
11024485|NCT04606303|Experimental|Toripalimab Combined With Platinum-containing Dual-agent.|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer.
11024486|NCT04606290|Active Comparator|Manual|Fixed dose oxygen
11024487|NCT04606290|Experimental|O2matic|Automated oxygen titration
11024488|NCT04606277||Young Adult|
11024489|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Hydration Gatorade:|
11024490|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Hydration CarbRich Beverage|
11024491|NCT04606264|Active Comparator|Major Abdominal: Preoperative Oral Analgesia Adjunct|
11024492|NCT04606264|No Intervention|Major Abdominal: No Preoperative Oral Analgesia Adjunct|
11024493|NCT04606264|Active Comparator|Major Abdominal: Neuraxial Analgesia|
11024494|NCT04606264|Active Comparator|Major Abdominal: Regional Analgesia|
11024495|NCT04606264|Active Comparator|Major Abdominal: PONV Prophylaxis Perphenazine|
11024496|NCT04606264|Active Comparator|Major Abdominal: PONV Prophylaxis Aprepitant|
11024497|NCT04606264|Active Comparator|Major Abdominal: Primary Anesthetic Volatile Agent|
11024498|NCT04606264|Active Comparator|Major Abdominal: Primary Anesthetic TIVA|
11024507|NCT04606264|Active Comparator|Major Abdominal: Postoperative Oral Analgesia Adjunct|
11024508|NCT04606264|No Intervention|Major Abdominal: No Postoperative Oral Analgesia Adjunct|
11024509|NCT04606264|Active Comparator|Orthopedic: Preoperative Oral Hydration Gatorade|
11024510|NCT04606264|Active Comparator|Orthopedic: Oral Hydration CarbRich Beverage|
11024511|NCT04606264|Active Comparator|Orthopedic: Preoperative Oral Analgesia Adjunct Gabapentin|
11024512|NCT04606264|No Intervention|Orthopedic: No Preoperative Oral Analgesia Adjunct|
11024513|NCT04606264|Active Comparator|Orthopedic: Neuraxial Analgesia|
11024514|NCT04606264|Active Comparator|Orthopedic: Regional Analgesia|
11024515|NCT04606264|Active Comparator|Orthopedic: PONV Prophylaxis Perphenazine|
11024516|NCT04606264|Active Comparator|Orthopedic: PONV Prophylaxis Aprepitant|
11024517|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic Volatile Agent|
11024518|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic Spinal|
11024519|NCT04606264|Active Comparator|Orthopedic: Fluid Therapy Stroke Volume Optimization|
11024520|NCT04606264|Active Comparator|Orthopedic: Fluid Therapy Maintain Euvolemia|
11024521|NCT04606264|Active Comparator|Orthopedic: Analgesia Adjuncts Ketamine|
11024522|NCT04606264|Active Comparator|Orthopedic: Intraoperative Opioid|
11024523|NCT04606264|No Intervention|Orthopedic: No Intraoperative Opioid|
11024524|NCT04606264|Active Comparator|Orthopedic: Postoperative Oral Analgesia Adjunct|
11024525|NCT04606264|No Intervention|Orthopedic: No Postoperative Oral Analgesia Adjunct|
11024526|NCT04606264|Active Comparator|Orthopedic: Primary Anesthetic TIVA (Propofol)|
11024527|NCT04606251|Experimental|Arm 1: Exercise Group|This group will consist of the subjects taken for 6 weeks of exercise.
11024528|NCT04606251|No Intervention|Arm 2: Control Group|This group will consist of the subjects who did not receive any intervention for 6 weeks and were evaluated before and after 6 weeks.
11024529|NCT04606238|No Intervention|Group without DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
11024530|NCT04606238|Other|Group with DA|adult patients with incurable, stage IV disease (Prostate-, Breast-, Pancreatic-, Stomach- and Colorectal cancer) in an advanced treatment stage.
11024531|NCT04606225|Experimental|Losartan group|Drug: Losartan
11024532|NCT04606225|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
11024533|NCT04606212|Experimental|Losartan group|
11024534|NCT04606212|Placebo Comparator|Placebo group|
11024535|NCT04606199|Experimental|Mindfulness-based intervention|Participants will be randomly assigned to an app-based intervention that includes brief (<5 min) audio-guided mindfulness and compassion-based practices.
11024536|NCT04606199|No Intervention|No intervention|Participants will continue their normal activities and not practice any form of mindfulness mediation at the time of app-notification.
11024537|NCT04606186|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
11024538|NCT04606186|Placebo Comparator|Placebo-lozenges (BioGaia)|
11024539|NCT04606173|Experimental|Standard Practice plus TEACH|Primary care teamlets will receive standard organizational education and support regarding suicide prevention and also engage in Team Education for Adopting Changes in Healthcare (TEACH) huddles.
11024540|NCT04606173|No Intervention|Standard Practice|Standard Practice condition will involve the current evidence-based support included in web-based provider-trainings and electronic medical record reminders/templates that are standard within an organization
11024541|NCT04606160|Experimental|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
11024542|NCT04606160|No Intervention|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
11024543|NCT04606147|Experimental|Group 1 ((Serratus Anterior Plane Block SAPB)) N=3o|Patients received Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
11024544|NCT04606147|Experimental|Group 2 ((Erector Spinae Plane Block ESPB)) N=3o|Patients received Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Then patients were transferred to the operating room.
11024545|NCT04606134|Experimental|Experimental|
11024546|NCT04606134|Placebo Comparator|Control|
11024547|NCT04606108|Experimental|Experimental|camrelizumab in combination with Liposome doxorubicin and Ifosfamide intervention
11024548|NCT04606095|Experimental|Aim 1 - Healthy control|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
11024549|NCT04606095|Experimental|Aim 1 - Fibromyalgia participant|Participants will have three visits for this part along with a run-in observation period. An EEG with Quantitative Sensory Testing (QST) will be performed at visit 1 along with other measures. Additionally, the an MRI will be done at visit 2 along with other measures.
11024550|NCT04606095|Experimental|Aim 3 - HD-tDCS of M1|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
11024551|NCT04606095|Experimental|Aim 3- HD-tDCS of ES|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
11024552|NCT04606095|Sham Comparator|Aim 3 - Sham|There will be two weeks of treatment in which participants will have 5 daily sessions of focused HD-tDCS or Sham per week.
11024553|NCT04606082|Experimental|Group 1|Granulocyte Colony Stimulated Factor was intrauterine injected once at ovum pick up day
11024554|NCT04606082|Active Comparator|Group 2|500 IU Human Chorionic Gonadotropins was injected intrauterine once at ovum pick up day
11024591|NCT04605783|Experimental|Travelan®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
11024555|NCT04606069|Experimental|Active Arm|Regadenoson will be given intravenously as 5 ug/kg loading dose (up to 400 mg/patient) over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
11024556|NCT04606069|Placebo Comparator|Control Arm|The same volume of saline will be given intravenously for 30 mins followed by a continuous infusion for 6 hours.
11024557|NCT04606056||Patients who underwent contrast enhanced CT scans|
11024558|NCT04606043|Experimental|Sandblasting|The enamel surfaces will be subjected to sandblasting prior to acid etching
11024559|NCT04606043|Active Comparator|Acid Etching Alone|Acid etching will be applied alone before the rebounding procedures
11024560|NCT04606030|Experimental|BioBridge treatment group|Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation
11024561|NCT04606030|Active Comparator|Control group|Vascularized Lymph Node Transplant surgery (VLNT) only
11024562|NCT04606017||Vitamain D|This group of patients were supplemented with Vitamin D Combined With Calcium 0.6g/d.
11024563|NCT04606017||Control|"The other group were not interfered
~."
11024564|NCT04606004|Experimental|Experimental (standard of care + stool application)|In addition to standard of care, they will apply stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time.
11024565|NCT04606004|Active Comparator|Control group (standard of care)|Will follow standard of care for skin care pre-operatively. They will not be applying ostomy stool output to the skin but can apply an OTC skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.
11024566|NCT04605991|Experimental|LY900014|LY900014 given via subcutaneous (SC) injection
11024567|NCT04605978|Experimental|S95011 concentrate for solution for infusion|S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
11024568|NCT04605978|Placebo Comparator|S95011 Placebo concentrate for solution for infusion|S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
11024569|NCT04605952||SARS-CoV-2 IgG antibody positive between 28th June to 15th July 2020|As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for SARS-CoV-2 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020. All those who initially tested SARS-CoV-2 IgG antibody positive were retested at 45-65 days
11024570|NCT04605939|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated lievr fibrosis for 68Ga-DOTA-FAPI PET/MR imaging.
11024571|NCT04605926|Experimental|EQ001|EQ001 administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
11024572|NCT04605926|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
11024573|NCT04605913|Experimental|Modified GCN+TTF treatment|The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
11024574|NCT04605900|Experimental|Standard Footwear (SF)|Intervention: plantar orthoses, education on foot self-care and appropriate standard footwear.
11024575|NCT04605900|Experimental|Orthopedic Footwear (OF)|Intervention: plantar orthoses, education on foot self-care and orthopedic footwear.
11024576|NCT04605887|Active Comparator|treatment group|Ang 1-7 subcutaneously 500 mcg/kg /day
11024577|NCT04605887|Placebo Comparator|control group|NaCl 0.9% subcutaneously 2.0 cc once a day
11024578|NCT04605874|Experimental|2 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 2 cigarillos per pack.
11024579|NCT04605874|Experimental|4 cigarillos per pack|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to receive 4 cigarillos per pack.
11024580|NCT04605861|Experimental|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on abdomen, thigh or upper arm.
11024581|NCT04605861|Placebo Comparator|Placebo|Placebo (Liraglutide Injection simulator), once a day, injected subcutaneously on abdomen, thigh or upper arm.
11024582|NCT04605848|Experimental|BAT group|"Patients will be divided in two groups for statistical analysis:
~patients with detectable BAT by PET-CT (BAT+)
~patients with no detectable BAT by PET-CT (BAT-)"
11024583|NCT04605835||Main group|484 children with congenital obstructive uropathies
11024584|NCT04605809|Experimental|combined motor and cognitive training|The combined motor and cognitive training group will undertake physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training.
11024585|NCT04605809|Active Comparator|motor training alone|The motor training alone group will train the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group.
11024586|NCT04605809|Active Comparator|cognitive training alone|The cognitive training alone group will train the same set of cognitive training while sitting as the combined motor and cognitive training group.
11024587|NCT04605809|No Intervention|no intervention control group.|No intervention control group will maintain habit and daily activity.
11024588|NCT04605796|Experimental|Single Arm|"Experimental group:
~Toripalimab combined with Bevacizumab"
11024589|NCT04605783|Experimental|Bimuno®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
11024590|NCT04605783|Experimental|Florastor®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
11024592|NCT04605783|Placebo Comparator|Placebo|Placebo will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
11024593|NCT04605770|Experimental|pemetrexed+cisplatin|Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.
11024594|NCT04605757||Patients with acute respiratory failure due to SARS-COV-2|Patients admitted to hospital with acute respiratory failure due to SARS-COV-2 infection causing pneumonia
11024595|NCT04605731|Experimental|Treatment (durvalumab, tremelimumab)|Patients undergo standard of care radioembolization with Yttrium-90 SIR-spheres intra-arterially over 60-90 minutes on day -14. Patients then receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on day 1. Cycles with durvalumab repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
11024596|NCT04605718|Experimental|Part 1 (SAD)|Due to mandatory sentinel dosing, participants will be divided into two groups: 2 participants will be dosed on one day (sentinel group with 1 on active treatment and 1 on placebo) and remaining participants of the dose cohort (randomized as 5 on active treatment and 1 on placebo) at the earliest 24 hours after the first dosing occasion.
11024597|NCT04605718|Experimental|Part 2 (MAD)|In each dose cohort, a minimum of 4 participants and a maximum of 12 participants will receive either multiple IV doses of RO72232809 or placebo daily for 10 days (3:1 ratio of active:placebo treatment). Based upon the review of emerging data, there will be the option to adjust the number of participants on active treatment and placebo per dose level.
11024598|NCT04605705||Group 1|NIRS values will be recorded during the surgery and until 24 hours postoperatively. No intervention will be done.
11024599|NCT04605705||Group 2|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
11024600|NCT04605679|Experimental|Recipient of HCV positive kidney graft|A single center, open-label, pilot study examining 20 adult HCV negative kidney transplant patients who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after kidney transplantation, unless extenuating clinical circumstances arise (such as the development of fibrosing cholestatic HCV, which would prompt earlier treatment, or clinical events or comorbidities which would prompt delay in treatment).
11024601|NCT04605666|Experimental|CAR-T group|
11024602|NCT04605653|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
11024603|NCT04605640|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating. Participants will be followed by daily self-weighing for 1 year after intervention.
11024604|NCT04605627||Chronic coronary syndrome|50 patients with chronic coronary disease
11024605|NCT04605627||Non ST segment-elevation myocardial infarction|75 patients with non ST-elevation myocardial infarction
11024606|NCT04605627||ST-elevation myocardial infarction|75 patients with ST segment-elevation myocardial infarction
11024607|NCT04605614|Experimental|Treatment (pembrolizumab, 64Cu-DOTA-pembrolizumab, PET)|Patients receive pembrolizumab IV over 30 minutes, and within 6 hours also receive 64Cu-DOTA-pembrolizumab via slow IV push over > 1 minute on day 0. Patients then undergo PET over 60 minutes on day 1.
11024608|NCT04605601|Experimental|Study Group|
11024609|NCT04605601|Other|Control Group|
11024610|NCT04605588|Active Comparator|Active Study Drug|5 day dosing of Nitazoxanide, Ribavirin & Hydroxychloroquine sulfate
11024611|NCT04605588|Placebo Comparator|Placebo|5 day dosing of placebo
11024612|NCT04605575|Experimental|Pyrotinib plus vinorelbine|
11024613|NCT04605562|Experimental|IC+CCRT with palbociclib|If patients were non-Immune Subtype.
11024614|NCT04605562|Experimental|IC+CCRT with galunisertib and PD-1 blocking antibody|If patients were Evaded Immune Subtype.
11024615|NCT04605562|Experimental|IC+CCRT with PD-1 blocking antibody|If patients were Active Immune Subtype.
11024616|NCT04605549|Experimental|CIN-107 Dose 1|
11024617|NCT04605549|Experimental|CIN-107 Dose 2|
11024618|NCT04605549|Experimental|CIN-107 Dose 3|
11024619|NCT04605549|Placebo Comparator|Placebo for CIN-107|
11024620|NCT04605536|Other|Intervention|Give explanations about conventional capsule endoscopy and watch animation videos
11024621|NCT04605536|Other|Control|Give explanations about conventional capsule endoscopy
11024622|NCT04605523||Patients with Ataxia Telangiectasia|
11024623|NCT04605523||Healthy controls|
11024624|NCT04605510|Experimental|Intervention Group|24 female participants with non-specific neck pain included in the mobilization group will undergo detailed manual cervical examination. In the evaluation, the most painful segment with dysfunction will be selected and mobilization application and algometric measurements will be performed on this segment. Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied in 3 sets, 30 seconds, to the segment with the detected dysfunction.
11024625|NCT04605510|No Intervention|Healthy Control Group|Healthy volunteer participants included in the control group will only be applied an evaluation protocol and blood samples will be taken without any application.
11024626|NCT04605497|Experimental|Intervention Arm|Use of Dexcom G6 real-time CGM to monitor blood glucose levels continually.
11024627|NCT04605497|Other|Referent Arm|Self-capillary blood glucose monitoring (SCBG) testing 4x/day with blinded CGM every 2 weeks.
11024629|NCT04605484|Experimental|Viralym-M and Placebo|Cohort A, Arm 2: Regimen B
11024630|NCT04605484|Placebo Comparator|Placebo|Cohort A, Arm 3: Regimen A
11024631|NCT04605484|Experimental|Cohort B, Arm 1|Following interim analysis, optimal Viralym-M dosing regimen from Cohort A
11024632|NCT04605484|Placebo Comparator|Cohort B, Arm 2|Same dosing interval as Cohort B, Arm 1
11024633|NCT04605471||PMS I study|"'PMS I' was conducted in contrast-enhanced X-ray examination between June 1999 and November 2003 in 27 countries in Europe, Africa and Asia and comprised 74,717 patients of which 2,172 were children and 32,103 were elderly patients.
~Ref. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11."
11024634|NCT04605471||IMAGE study|"'IMAGE' consists of 44,835 patients with contrast-enhanced X-ray examination and was conducted in 21 European and Asian countries from February 2008 to September 2009, 1,451 patients were children, and 15,654 were elderly patients.
~Ref. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang SX, et al. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012;53(2):179-86."
11024635|NCT04605471||TRUST study|"'TRUST' assessed the safety and tolerability of Ultravist in patients undergoing cardiac catheterization. It was conducted from August 2010 to September 2011 in China and included 17,513 patients of which 12 were children and 8,918 were elderly patients.
~Ref. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015;31(7):1281-91."
11024636|NCT04605471||Ultravist in CT study|"'Ultravist in CT' was performed with focus on contrast-enhanced CT examination between November 2006 and December 2008 and included 15,168 patients in Germany, Iran, Romania and Saudi Arabia. A total of 417 patients were children, 7,453 were elderly patients.
~Ref. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014;55(6):707-14."
11024637|NCT04605458|Experimental|Contingency Management|
11024638|NCT04605458|Active Comparator|Standard Care|
11024639|NCT04605445|Experimental|1 visit endodontics|Root canal treatment is performed in one visit.
11024640|NCT04605445|Active Comparator|2 visits endodontics|Root canal treatment is performed in two visits.
11024641|NCT04605432|Experimental|PEG-FFI prep|"On the day before colonoscopy, an experienced researcher would go to the ward to have a face-to-face conversation with the patient to know if patients have the risk factors for bowel preparation failure.
~The bowel preparation regimens for patients with risk factors would be optimized. In addition to drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min, the patient also drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at 20:00- 21:00 hours on the day before the colonoscopy. Patients without risk factors drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
~Patients would received a booklet to explain the details of diet restriction, preparation method and the pictures of bowel preparation of results.The researcher would give a detailed oral explanation of the booklet."
11024642|NCT04605432|Active Comparator|PEG-nonFFI prep|Patients in the PEG-nonFFI group would only receive routine patient education on bowel preparation of colonoscopy, which was completed by ward nurse. all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
11024643|NCT04605419|Experimental|Calcium electroporation|Calcium chloride
11024644|NCT04605393|Placebo Comparator|Placebo/Placebo|Oral placebo followed by inhalation of placebo cannabis.
11024645|NCT04605393|Experimental|Placebo/THC|Oral placebo followed by inhalation of cannabis containing THC.
11024646|NCT04605393|Experimental|CBD/THC|Oral CBD 1000mg followed by cannabis containing THC.
11024647|NCT04605380||Novices|Junior doctors/interns
11024648|NCT04605380||Intermediates|Specialist trainees/Residents
11024649|NCT04605380||Experts|Consultants/Attendings
11024650|NCT04605367|Experimental|100% PP, a-TDCS|"After the pre-test:
~repetition of the correct sequence as many times as possible (12 blocks of 30s).
~After the post-test:
~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
11024651|NCT04605367|Experimental|100% PP, sham TDCS|"After the pre-test :
~physical repetition of the correct sequence as many times as possible, during 12 blocks of 30s.
~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
11024652|NCT04605367|Experimental|100% MP, a-TDCS|"After the pre-test :
~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.
~After the post-test:
~Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm².)"
11024653|NCT04605367|Experimental|100% MP, sham TDCS|"After the pre-test :
~mental repetition of the correct sequence as many times as possible, during 12 blocks of 30s.
~After the post-test : sham stimulation (gradual increase in current for 30 seconds until 1mA, immediately followed by a gradual decrease for 30 s until 0mA."
11024654|NCT04605367|Experimental|50% MP and 50% PP, a-TDCS|"After the pre-test :
~mental repetition of the correct sequence as many times as possible, during 6 blocks of 30s. Then physical repetition of the correct sequence as many times as possible, during 6 blocks of 30s.
~After the post-test : they will receive the real stimulation. Anodal stimulation (intensity : gradual increase for 30s until 1mA, will remain constant for 15min, gradual decrease for 30s until 0mA ;current density : 0.04 mA/cm²."
11024655|NCT04605367|Experimental|50% MP and 50% PP, sham TDCS|For both tasks, the training modalities are the same. After the pre-test, this group will have to mentally repeat the correct sequence as many times as possible, during 6 blocks of 30s. Then they will have to physically repeat the correct sequence as many times as possible, during 6 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the sham stimulation. The sham stimulation will be consisted of a gradual increase in current for 30 seconds until 1mA, immediately followed by gradual decrease for 30 s until 0mA.
11024829|NCT04604106||Healthy subject group|Infant aged 12 months (± four weeks) without a history of general anesthesia
11024656|NCT04605367|No Intervention|No practice, No stimulation|After the pre-test, this group will read an article for 12 minutes. After this training, they will perform the post-test. Immediately after this, they will read another article during 15 minutes.
11024657|NCT04605341|Active Comparator|group one|patient with metacarpal fracture that will use minipate for fixation
11024658|NCT04605341|Active Comparator|gruop two|patient with metacarpal fracture that will use buried k wires for fixation
11024659|NCT04605302|Experimental|Single Arm Tandem Study|Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy
11024660|NCT04605289|Experimental|Group I (study group)|Scaling and root planing + intra-pocket application of 2% Cymbopogon citratus (lemon-grass) gel
11024661|NCT04605289|Placebo Comparator|Group II (control group)|Scaling and root planing +intra-pocket application of placebo gel
11024662|NCT04605276||Indication for prostate cancer|"Male patients of age ≥18 suspected for prostate cancer who are scheduled for systematic and/or targeted biopsy after mpMRI examination.
~No intervention study"
11024663|NCT04605263|Active Comparator|STN DBS|Subjects will receive traditional bilateral STN devices and stimulation.
11024664|NCT04605263|Experimental|STN-PPN DBS|Patients will be implanted with both bilateral STN and bilateral PPN devices. These patients will undergo a crossover between 3 and 15 months post-op in which they will double-blindly receive PPN stimulation for six months and have stimulation turned off for six months. All patients will receive stimulation from 0-3 months post-op (mapping visits occur in this window) and from 15-27 months.
11024665|NCT04605250|Other|Adults undergoing abdominal surgery with laparotomy|Respiratory variability before and after abdominal surgery
11024666|NCT04605224||Culinary class (intervention group)|The culinary class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
11024667|NCT04605224||Social studies class (control group)|The social studies class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
11024668|NCT04605211|Experimental|Being Present (Supportive Care)|Patients and caregivers receive Being Present intervention consisting of online audio-based mindfulness meditation exercise over 15 minutes at least 5 times per week, daily meditation reminders, and online webinars over 30-60 minutes every week.
11024669|NCT04605198|Experimental|Modified Mindfulness-based Stress Reduction|
11024670|NCT04605198|Active Comparator|Health Promotion Attention Control|
11024671|NCT04605185|Experimental|Donafenib/JS001/TACE|Donafenib and JS001 Combined With TACE
11024672|NCT04605172||Lockdown Group|newborn born prematurely during confinement (1st March - 1st June 2020)
11024673|NCT04605172||Control group|newborn born prematurely in comparative years over the same period (1st March - 1st June from 2015 to 2019)
11024674|NCT04605159|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group will receive a single dose of RSV MAT vaccine at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm
11024675|NCT04605159|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group will receive a single dose of Placebo at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm
11024676|NCT04605146|Experimental|Tele-monitoring group|"In the experimental group, in addition to routine practice, each patient will benefit of a tele-monitoring of one year, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.
~50 patients are expected in this arm."
11024677|NCT04605146|No Intervention|Control group|"In the control group, patients will have a routine follow-up as per institutional practice, and a long term follow-up up to 5 years to evaluate the Overall Survival and the Progression-Free Survival. Quality of life questionnaire will also be filled in at inclusion, M3 and M12.
~50 patients are expected in this arm."
11024678|NCT04605133||ARDS|Patients with mild or severe ARDS necessitating of prone position during mechanical ventilation
11024679|NCT04605120|Experimental|Allogeinic Bone Paste|Supercritical CO2 viral-inactivated allogeinic bone paste derived from human living donor femoral heads
11024680|NCT04605107|Experimental|A test|Epifasi 5000 I.U. Ampoules
11024681|NCT04605107|Active Comparator|B reference|Pregnyl 5000 I.U. Ampoules
11024682|NCT04605094|Experimental|Benralizumab|
11024683|NCT04605094|Experimental|Placebo / Benralizumab|
11024684|NCT04605081|Experimental|Naltrexone+Bupropion Medication|
11024685|NCT04605081|Placebo Comparator|Placebo|
11024686|NCT04605068|Active Comparator|Transverse preputial island flap (Duckett's technique)|72 patients (Group I) with penoscrotal hypospadias with chordee
11024687|NCT04605068|Active Comparator|Double-faced preputial flap (DFPF)|72 patients (Group II) with penoscrotal hypospadias with chordee
11024688|NCT04605055|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
11024689|NCT04605055|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
11024690|NCT04605042|Experimental|WET First group|COOK ECHO-HD 22-C EchoTip Procore needle biopsy in WS-SNP-WS-SNP sequence
11024691|NCT04605042|Experimental|STANDARD first group|COOK ECHO-HD 22-C EchoTip Procore needle in SNP-WS-SNP-WS sequence
11024692|NCT04605029||Critically Ill patients|No Intervention
11024693|NCT04605016|Experimental|Hydrophilic surface implants|
11024694|NCT04605016|Active Comparator|Hydrophobic surface implants|
11024695|NCT04605003|Active Comparator|Conventional Autoclave|The conventional autoclave is the gold standard of sterilising all medical equipments.
11024696|NCT04605003|Active Comparator|Novel rig-S|A novel devise used with the high level disinfectant
11024697|NCT04604977|Other|Mindfulness by Smartphone|an approach that is alternative to current practice, particularly as far as reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness
11024698|NCT04604964||Patients undergoing recto-sigmoid resection plus anastomosis|Patients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
11024699|NCT04604951|Experimental|Moderate|Group 1: Moderate 2 times per week transcutaneous spinal cord stimulation.
11024700|NCT04604951|Experimental|Intensive|Group 2: Intensive 5 times per week transcutaneous spinal cord stimulation.
11024701|NCT04604938|Experimental|Losartan group|Drug: Losartan
11024702|NCT04604938|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
11024703|NCT04604925||Remote patient monitoring for hypertension|RPM Integration: All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
11024704|NCT04604925||Usual care|Matching patients from control practices will be selected from remaining Northwestern Medical Group primary care sites and be chosen to provide as sufficiently large number of eligible patients for comparison. These groups will contribute EHR data through the NM EDW but will not have any new procedures put in place
11024705|NCT04604912||Peanut-allergic patients' group|The aim is to include 30 patients with peanut allergy. Those patients will undergo diagnostic food challenges (incremental doses) while blood will be samples before, during and after the testing. The patients will receive standard of care during and after the challenge. Allergic symptoms will be treated according to established guidelines.
11024706|NCT04604912||Control group|The aim is to include 20 control participants, 10 peanut-tolerant and 10 fish-tolerant individuals. Those participants will undergo diagnostic food challenges (incremental or single doses) while blood will be samples before, during and after the testing. Same safety measures will be applied for food challenges of control individuals, as for the allergic patients.
11024707|NCT04604899|Experimental|Retreated subjects|Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
11024708|NCT04604886|Experimental|Passive Leg Raising|Passive leg raising (PLR) test is used to predict fluid responsiveness, which is performed by raising the legs of the patient to 45°. Cardiac output will be collected from both PAC and LiDCO before and after PLR.
11024709|NCT04604886|Experimental|Dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
11024710|NCT04604873|No Intervention|No hospital one day care|No hospital one day care
11024711|NCT04604873|Other|Hospital one day care|Hospital one day care
11024712|NCT04604860|Experimental|EL-FIT|Patients using the EL-FIT app
11024713|NCT04604847|Other|Total knee arthroplasty|patient operated for a total knee arthroplasty
11024714|NCT04604834|Experimental|PFAT first|1 eyedrop of PFAT every 2 hours in study eye.
11024715|NCT04604834|Experimental|APRP first|1 eyedrop of APRP every 2 hours in study eye.
11024716|NCT04604834|Experimental|APRP+PFAT first|1 eyedrop of PFAT and APRP every 2 hours in study eye.
11024717|NCT04604821|Experimental|Enhanced Milieu Teaching|Child-caregiver dyads receive up to 24 speech-language therapy sessions (50minutes, 2x per week for 3 months) where parents are taught by the interventionist to use Enhanced Milieu Teaching Strategies. Children and their families may continue to participate community-based educational programs.
11024718|NCT04604821|Other|Community Treatment as Usual|Child-caregiver dyads may continue to participate in community-based educational programs. Researchers provide up to 4 educational sessions to caregivers (50 minutes, every 3 weeks). During educational sessions parents are taught developmental milestones from the CDC Learn the Signs Act Early Public Health Campaign.
11024719|NCT04604808||Non hypocalcemic group|Patients that don't develop post-thyroidectomy hypocalcemia
11024720|NCT04604808||Hypocalcemic group|Patients that develop post-thyroidectomy hypocalcemia
11024721|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,3,4,microdose and placebo (Sequence A)|In Part A, participants will receive dose levels (DLs) 1, 3, 4, microdose of GSK3915393, and placebo in a pre-determined sequence (Sequence A). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and pharmacokinetic data.
11024722|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,4,microdose and placebo (Sequence B)|In Part A, participants will receive dose levels 1, 2, 4, microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence B). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and pharmacokinetic data.
11024723|NCT04604795|Experimental|Part A:GSK3915393 DLs 1,2,3,microdose and placebo (Sequence C)|In Part A, participants will receive dose levels 1, 2, 3, microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence C). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and pharmacokinetic data.
11024724|NCT04604795|Experimental|Part A:GSK3915393 DLs 2,3,4,microdose and placebo (Sequence D)|In Part A, participants will receive dose levels 2, 3, 4, microdose of GSK3915393 and placebo in a pre-determined sequence (Sequence D). There will be a washout period of at least 7 days between each dose. Oral dose levels will be determined based on safety, tolerability and pharmacokinetic data.
11024725|NCT04604795|Experimental|Part B: Cohort 1: Participants receiving GSK3915393 DL X|Participants will receive GSK3915393 dose level X twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and pharmacokinetic data from Part A.
11024726|NCT04604795|Placebo Comparator|Part B: Cohort 1: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level X during Part B of the study.
11024727|NCT04604795|Experimental|Part B: Cohort 2: Participants receiving GSK3915393 DL Y|Participants will receive GSK3915393 dose level Y twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and pharmacokinetic data from Part A and Part B.
11029987|NCT04568304|Placebo Comparator|Placebo + chemotherapy group|
11024728|NCT04604795|Placebo Comparator|Part B: Cohort 2: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Y twice daily during Part B of the study
11024729|NCT04604795|Experimental|Part B: Cohort 3: Participants receiving GSK3915393 DL Z|Participants will receive GSK3915393 dose level Z twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and pharmacokinetic data from Part A and Part B.
11024730|NCT04604795|Placebo Comparator|Part B: Cohort 3: Participants receiving placebo|Participants will receive placebo matching GSK3915393 dose level Z twice daily during Part B of the study.
11024731|NCT04604795|Experimental|Part C: CeD participants receiving GSK3915393|Participants with CeD will receive GSK3915393 twice daily during Part C of the study. Dose will be determined based on safety, tolerability and pharmacokinetic data. Participants will also receive gluten daily on Days 8 to 10.
11024732|NCT04604795|Placebo Comparator|Part C: CeD participants receiving placebo|Participants with CeD will receive placebo matching GSK3915393 twice daily during Part C of the study. Participants will also receive gluten daily on Days 8 to 10.
11024733|NCT04604782|Experimental|adolescents aged 12 to <18 years|
11024734|NCT04604782|Experimental|children aged 2 to <12 years|
11024735|NCT04604782|Experimental|infants aged 1 to <24 months and who weigh at least 3 kg|
11024736|NCT04604769||Daily routine, control group|ICU medical staff were asked about their stress and causes of stress during their daily professional life.
11024737|NCT04604769||During Covid-19|ICU medical staff were asked about their stress and causes of stress in their daily professional life during COVID-19 crisis.
11024738|NCT04604756|Experimental|Losartan group|Drug: Losartan
11024739|NCT04604756|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
11024740|NCT04604743|Experimental|Intervention|2 Clinics
11024741|NCT04604743|No Intervention|Control|2 Clinics
11024742|NCT04604730|Experimental|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
11024743|NCT04604730|Active Comparator|Anastomosis with protective stoma|Anastomosis with protective stoma
11024744|NCT04604717|Experimental|Pulmonary rehabilitation|8 weeks of pulmonary rehabilitation (twice weekly training) Exercise and education sessions accompanied by home exercise program
11024745|NCT04604717|No Intervention|Control group|Usual medical treatment for 8 week period
11024746|NCT04604704|Experimental|Treatment with LDN and NAD+|LDN will be used at a dosage of 4.5 mg/day, which will be taken orally in the form of capsules. NAD+ will be administered using the IontoPatch iontophoresis patch containing 400 mg of NAD+ solution which is worn on the skin for 4-6 hours once per week.
11024747|NCT04604704|No Intervention|Control group|Patients will regular health care.
11024748|NCT04604691|Experimental|Blinatumomab Treatment|
11024749|NCT04604678|Experimental|Treatment with Metformin and LDN|Patients will be treated with 1500 mg/day of metformin and 4.5 mg/day of LDN for a total of 4 weeks.
11024750|NCT04604678|No Intervention|Regular health care comparison group|Patients will receive regular health care and will serve as a control group.
11024751|NCT04604665|Experimental|High frequency postural change|"Repositioning or rotation of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency. It has to be performed on each patient between an interval less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each of the postural changes to right lateral, supine, left lateral, supine.
~Repositioning will be provided until a patient is discharged from UCI, die or begin ambulation, along the time pertain in ICU. When providing each repositioning avoid dragging the patient, the shear, the friction so as not to increase the risk of UPP. This must be applied avoiding massage.
~When laying the patient on her side (right or left), the body should maintain a fetal position, using pillows or support surfaces between the legs, between the arms and between the ankles."
11024752|NCT04604665|Active Comparator|Low frequency postural change|"Postural changes will be made one every 4 to 6 hours or more hours (for example each 12 or 16 hours). Position changes will be made from the right lateral position to the supine position, and then to the left lateral position or from left to right. Avoid dragging the patient, the shear, the friction so as not to increase the risk of UPP. This must be applied avoiding massage.
~When laying the patient on her side (right or left), the body should maintain a fetal position, using pillows between the legs, between the arms and between the ankles. Each patient in a 45 ° lateral position should have back protection with pillows or support surfaces. The skin should be kept clean and dry especially in those who suffer from incontinence."
11024753|NCT04604652|Experimental|Open-label|HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
11024754|NCT04604639||Out-of-hospital cardiac arrest|Patients suffering an out-of-hospital cardiac arrest to who the ambulance service was requested to attend.
11024755|NCT04604626||Population 1|Adults and children with severe obesity ie (BMI> 35 kg / m² for adults and Z BMI score> 3DS for age and sex for children) and / or eating disorders with genetic diagnosis as part of care.
11024756|NCT04604626||Population 2|Adults and children with obesity and / or eating disorders hypothalamic lesion (craniopharyngioma example).
11024757|NCT04604613||Ancillary-Correlative (biospecimen collection, node mapping)|Patients undergo hysterectomy and sentinel lymph node mapping. Patients may also undergo bilateral salpingo-oophorectomy at the direction of the treating physician. If peritoneal disease or other contraindications to lymphatic mapping are detected at the time of surgery, mapping and sentinel node biopsy are performed at the surgeon's discretion. At the time of hysterectomy, patients undergo collection of tissue for molecular testing. Before and after surgery, patients also undergo collection of blood samples for tumor marker analysis.
11024758|NCT04604600|Experimental|amyloid PET、T807 PET|PET/CT
11024759|NCT04604587|Experimental|amyloid PET、T807 PET|PET/CT
11024760|NCT04604574|Other|Pre/Post-Intervention|Patients who receive the novel IHSS intervention will be compared to historical controls who received the abstinence-based treatment model.
11024789|NCT04604392|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
11029988|NCT04568291|Active Comparator|routine treatment|routine treatment
11024761|NCT04604561||Participants receiving SmartClip|Participants will undergo a preoperative physical exam and at least one preoperative ultrasound demonstrating the mass for resection. The SmartClip will be placed under ultrasound guidance. Post-placement mammogram will be obtained after placement of the clip. The SmartClip can be placed up to 30 days prior to the planned surgical resection. At the time of definitive surgery, the Envisio system will be used to identify the clip and the targeted lesion for resection. Intraoperatively, a specimen radiograph will be performed to confirm the presence of the SmartClip and the targeted lesion in the surgical specimen. The breast surgical specimen will be sent for gross examination, including measurements of the tumor in 3 axes. Immediately post-procedure, the performing surgeon will fill out a questionnaire to determine the ability of localizing in-breast lesions using the Envisio Navigation and SmartClip system in surgery.
11024762|NCT04604561||Radiologist Placing SmartClip|Radiologist will place SmartClip under ultrasound guidance. A Post-placement mammogram will be obtained after placement of the SmartClip. Immediately post-procedure, the performing radiologist will fill out a questionnaire.
11024763|NCT04604561||Surgeon|The surgeon will use the EnVisio™ Navigation System to identify the SmartClip and the targeted lesion for resection. Immediately post-procedure, the performing surgeon will fill out a questionnaire
11024764|NCT04604548|Experimental|Open Label treatment|Oral administration of 100 mg KH176 twice daily
11024765|NCT04604535|Active Comparator|Concentrated beetroot juice|70mL of concentrated beetroot juice with 400mg nitrate
11024766|NCT04604535|Placebo Comparator|Placebo|70mL of concentrated beetroot juice with <0.01mmol/L nitrate
11024767|NCT04604522||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of blood samples and 3 brushings of the airway during SOC bronchoscopy. After the bronchoscopy, patients undergo 2 nasal brushings (swabs). Patients' medical records are also reviewed for data collection.
11024768|NCT04604509|Experimental|Group I (varenicline, counseling)|Participants receive varenicline PO daily or BID for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
11024769|NCT04604509|Experimental|Group II (NRT, counseling)|Participants receive NRT consisting of a patch, lozenges, or gum daily for 6 weeks in the absence of unacceptable toxicity. Participants who quit smoking continue treatment for 6 additional weeks in the absence of unacceptable toxicity. Participants also receive behavioral smoking cessation counseling.
11024770|NCT04604509|Experimental|Group III (varenicline or NRT, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 additional weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
11024771|NCT04604509|Experimental|Group IV (varenicline or NRT, counseling)|Participants switch to a different therapy and receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
11024772|NCT04604509|Experimental|Group V (higher dose varenicline or NRT, counseling)|Participants receive a higher dose and continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive behavioral smoking cessation counseling.
11024773|NCT04604509|Experimental|Group VI (varenicline or NRT, bupropion, counseling)|Participants continue to receive varenicline as in Group I or NRT as in Group II for 6 weeks depending on which group they were assigned to. Participants also receive bupropion PO daily for 6 weeks and behavioral smoking cessation counseling.
11024774|NCT04604509|Experimental|Group VII (varenicline and NRT, counseling)|Participants receive varenicline as in Group I and NRT as in Group II for 6 weeks. Participants also receive behavioral smoking cessation counseling.
11024775|NCT04604496|Experimental|PF-06882961 participants without Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
11024776|NCT04604496|Experimental|PF-06882961 participants with mild Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
11024777|NCT04604496|Experimental|PF-06882961 participants with moderate Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
11024778|NCT04604496|Experimental|PF-06882961 participants with severe Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
11024779|NCT04604483|Experimental|PTNS|Treatment with PTNS for chronic anal fissure, treatment to be given for 30 minutes during 10 consecutive work Days.
11024780|NCT04604470||Standard treatment|Chemotherapy Chemoradiotherapy Radiotherapy Immunotherapy Or a combination of above
11024781|NCT04604470||ImmunoSABR treatment|"SABR combined immunotherapy
~Radiotherapy combined immunotherapy"
11024782|NCT04604457|No Intervention|Standard of Care|Palliative care specialists would not reach out to primary care providers. Palliative care needs would be met via existing mechanisms.
11024783|NCT04604457|Experimental|Predictive Model|Palliative care specialists review recommendations from the predictive model and contact a patient's primary care provider (PCP) when appropriate to recommend a palliative care consult.
11024784|NCT04604444|Experimental|Multimodal Intensive Rehabilitation of Aphasia/AOS (MIRAA)|A minimum of 3 hour speech-language training daily during 10 days.
11024785|NCT04604431|Experimental|Intervention (CDS Tool Integrated)|Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.
11024786|NCT04604431|No Intervention|Control (No CDS Tool Integrated)|No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.
11024787|NCT04604405|Experimental|Self contrast|Retinal microcirculation, choroid microcirculation, axial length, diopter before intervention
11024788|NCT04604392|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel.
11024828|NCT04604106||Patient group|Infant aged 12 months (± four weeks) with a history of general anesthesia exposure
11029989|NCT04568291|Experimental|model treatment|model treatment
11024790|NCT04604392|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
11024791|NCT04604366|Active Comparator|vaginal mesoprostol|Vaginal dose---800 microgram 3 hourly two doses
11024792|NCT04604366|Experimental|sublingual mesoprostol|Sub lingual 600 microgram 3 hourly two doses
11024793|NCT04604353|Experimental|PRS score group|Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation
11024794|NCT04604353|Active Comparator|CCS score group|Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation
11024795|NCT04604340|Active Comparator|transfemoral access|control
11024796|NCT04604340|Active Comparator|transradial access|case
11024797|NCT04604327|Active Comparator|Prophylactic bemiparin (3,500 IU/day)|Bemiparin 3,500 IU daily for 10 days
11024798|NCT04604327|Experimental|Full therapeutic bemiparin (weight adjusted)|Bemiparin at full therapeutic dose, adjusted to body weight, for 10 days
11024799|NCT04604314|Experimental|Endocrown Onlay Restoration|Endocrown onlay preparation = Buccal and lingual walls are intact with an occlusal-gingival height at least equal to half the original crown height of the tooth. Remaining buccal and lingual walls maintain a thickness ≥ 2.0 mm.
11024800|NCT04604314|Experimental|Endocrown Shoulder Restorations|Endocrown shoulder preparation = Buccal and/or lingual walls are less than half the original occlusal-gingival height of the tooth or the buccal or lingual surfaces were previously prepared axially due to a prior restoration.
11024801|NCT04604301|Experimental|Crown, 1.0mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.0 mm delivered with a conventional Calcium Aluminate Ionomer cement
11024802|NCT04604301|Experimental|Crown, 1.5mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.5 mm delivered with a conventional Calcium Aluminate Ionomer cement
11024803|NCT04604301|Experimental|Crown, 1.0mm thickness, dual cure resin cement|occlusal thickness of 1.0 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
11024804|NCT04604301|Experimental|Crown, 1.5mm thickness, dual cure resin cement|occlusal thickness of 1.5 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
11024805|NCT04604275|Experimental|Sucrase intervention followed by placebo|Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
11024806|NCT04604275|Experimental|Placebo followed by sucrase intervention|Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.
11024807|NCT04604262|Experimental|Treatment Group|Waterpik® in addition to the manual toothbrush
11024808|NCT04604262|No Intervention|Control|Manual toothbrush
11024809|NCT04604236|Experimental|Mapping Enhanced Counseling (MEC)|MEC will target attitudes and norms. Attitudes include motivation for change, such as problem recognition and a belief that treatment will help. Subjective norms include normative beliefs about SU in adolescence (e.g., belief that it is ok to allow SU with parental supervision; experimentation is normal) and expectations about treatment.
11024810|NCT04604236|Experimental|Active Linkage (AL)|AL will target perceived control. Perceived control includes perceived logistical barriers and the degree to which individuals feel they can overcome them.
11024811|NCT04604223|Experimental|Pioglitazone|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total.
11024812|NCT04604223|Placebo Comparator|Placebo|Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
11024813|NCT04604210|Experimental|Dysphoric target|"The dysphoric target is a region in the dorsolateral prefrontal cortex. TMS targeted to this region has been shown to be more effective for depression than anxiety."
11024814|NCT04604210|Experimental|Anxiosomatic target|"The anxiosomatic target is a region in the dorsomedial prefrontal cortex. TMS targeted to this region has been shown to be more effective for anxiety than depression."
11024815|NCT04604197|Experimental|Angiography and Clinical Follow up|After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
11024816|NCT04604197|Active Comparator|Clinical Follow up|After PCI. The patient is randomized to a Clinical Follow to 36 months
11024817|NCT04604184|Experimental|Treatment group|
11024818|NCT04604184|Placebo Comparator|Placebo group|
11024819|NCT04604171|Experimental|Action Observation Training|Conventional treatment for 60 mins plus Action Observation Training for 30 mins
11024820|NCT04604171|Active Comparator|Task Oriented Training|Conventional treatment for 60 mins plus Task Oriented Training for 30 mins
11024821|NCT04604158|Experimental|Elly Mobile Phone Application|
11024822|NCT04604145|Other|Positive NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a positive NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
11024823|NCT04604145|Other|10th Negative NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a 10th negative NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
11024824|NCT04604132|Experimental|Derazantinib|In Substudies 1 and 3.1, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib.
11024825|NCT04604132|Experimental|Derazantinib-paclitaxel-ramucirumab|In Substudies 2 and 3.2, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-paclitaxel-ramucirumab in combination.
11024826|NCT04604132|Experimental|Derazantinib-atezolizumab|In Substudy 3.3, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive derazantinib-atezolizumab in combination.
11024827|NCT04604132|Active Comparator|Standard of care|In Substudy 3.4, patients with HER2-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring FGFR genetic aberrations will receive the Standard of Care drugs paclitaxel-ramucirumab in combination.
11031678|NCT04556448|Active Comparator|Traditional braces|Clear braces
11024830|NCT04604093||SMBG, self-monitoring of blood glucose|Subjects will be randomized to continue use traditional SMBG, self-monitoring of blood glucose, to manage their diabetes.
11024831|NCT04604093||FreeStyle Libre 2|Subjects will be randomized to use the FreeStyle Libre 2 Flash Glucose Monitoring System to manage their diabetes.
11024832|NCT04604080||single group|Respondents will be given survey form, filled and will be collected back
11024833|NCT04604067|Experimental|Arm with 4 cohorts|"Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles.
~Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline:
~Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (>2log10 reduction of ctDNA)) results:
~Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent.
~Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent.
~Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total).
~Follow up: Patients off treatment will be followed for 5 years."
11024834|NCT04604054|Experimental|Group 1|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Granulocyte Colony Stimulating Factor as a treatment.
11024835|NCT04604054|Active Comparator|Group 2|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Human Chorionic Gonadotropin as a treatment.
11024836|NCT04604028|Experimental|Lenalidomide and low-dose cyclophosphamide|Oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide [Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days
11024837|NCT04604002|Experimental|Subjects with Normal Eyes|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects without ophthalmic pathology
11024838|NCT04604002|Experimental|Subjects with Pathology|OCT, Color Fundus Photography and OCT Angiography as per protocol in subjects with retinal vascular pathology
11024839|NCT04603989|Experimental|HNC042|HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route
11024840|NCT04603989|Placebo Comparator|Placebo|Placebo, multiple ascending doses, Intravenous route
11024841|NCT04603976|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
11024842|NCT04603963|No Intervention|group control|alternate exercises: in one day breathing exercises, active or with a load of large muscle groups (according to tolerance) with a maximum limit of 2 kg, sedation out of bed, walking. On another day aerobic exercise with cycle ergometer limited to 30 minutes.
11024843|NCT04603963|Experimental|intervention group|He received the same intervention as the control group, associating respiratory muscle training 1 time a day with power breathe 3 series of 10 repetitions (started with 30% of the Pimax value) with readjusted load every 7 days.
11024844|NCT04603950|Experimental|study group|The first 20 patients received Continue Adductor Canal Block + Infiltration between the Popliteal Artery and Capsule of the Knee
11024845|NCT04603950|Sham Comparator|control group|The second 20 patients received Continue Adductor Canal Block alone
11024846|NCT04603937|Experimental|KSI-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) once every 4 weeks for 3 monthly doses followed by an individualized dosing regimen (every 8 to 24 weeks) via intravitreal injection from Week 16 to Week 100.
11024847|NCT04603937|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 5 monthly doses followed by aflibercept (2 mg) once every 8 weeks via intravitreal injection from Week 24 to 100.
11024848|NCT04603924|Experimental|ANA001|Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
11024849|NCT04603924|Placebo Comparator|Matching Placebo|Subjects in the comparator arm will receive matching placebo (hydroxypropylmethylcellulose (HPMC)) (4 capsules, by mouth twice a day) for the 7-day treatment duration.
11024850|NCT04603911|Active Comparator|Control|Control arm will receive standard of care solution for the ESPB block
11024851|NCT04603911|Active Comparator|Liposomal Bupivicaine|Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block
11024852|NCT04603898|Experimental|Controlled Dietary Study|Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for four days. After two days of equilibration, subjects will ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on day 3. The following day (Day 4), blood and urine will be collected.
11024853|NCT04603885|Experimental|Aerobic exercise group|Aerobic exercise will be measured with a Polar United fitness watch. Heart rate during exercise will be measured using a Polar United fitness watch, which has been validated for monitoring moderate and high intensity physical activity.
11024854|NCT04603885|Placebo Comparator|Attention control group|The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
11024855|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells and dasatinib|Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.
11024856|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells|Dose levels of CAR-T cells are based on clinical trials of similar foreign products.
11024857|NCT04603859|Experimental|Elective induction of labour|Elective induction of labour at 39 gestational weeks and 0 to 3 days.
11024858|NCT04603859|No Intervention|Expectant management|Awaiting spontaneous labor.
11032767|NCT04549259|Experimental|Stigma Reduction + SBCM|
11024859|NCT04603846|Experimental|Combined treatment group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
11024860|NCT04603833|Experimental|SHR3680+Docetaxel|
11024861|NCT04603833|Active Comparator|SHR3680|
11024862|NCT04603833|Active Comparator|Docetaxel|
11024863|NCT04603807|Experimental|Entrectinib|Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
11024864|NCT04603807|Active Comparator|Crizotinib|Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
11024865|NCT04603794|Active Comparator|1% Hydrogen Peroxide Mouth Rinse|30 second oral rinse with 1% Hydrogen Peroxide
11024866|NCT04603794|Active Comparator|0.12% Chlorhexidine Gluconate Mouth Rinse|30 second oral rinse with 0.12% Chlorhexidine Gluconate
11024867|NCT04603794|Active Comparator|0.5% Povidone Iodine Mouth Rinse|30 second oral rinse with 0.5% Povidone Iodine Mouth wash
11024868|NCT04603794|Placebo Comparator|0.9% Normal Saline Mouth Rinse|30 second oral rinse with 0.9% Normal Saline
11024869|NCT04603781|Active Comparator|CBD-Isolate 300 mg.|Nightly administration of 300 mg. of CBD-Isolate for 28 consecutive days
11024870|NCT04603781|Active Comparator|Full Spectrum CBD Oil 300 mg.|Nightly administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days
11024871|NCT04603781|Placebo Comparator|Placebo oil|Nightly administration of 300 mg. of Placebo Oil for 28 consecutive days
11024872|NCT04603768|Experimental|Theraband exercises|Group A: baseline physical therapy treatment along with theraband exercises
11024873|NCT04603768|Experimental|Co-contraction exercises|Group B: baseline physical therapy treatment along with co-contraction exercises
11024874|NCT04603768|Experimental|isometric exercises|Group C: baseline physical therapy treatment along with isometric exercises
11024875|NCT04603742|Experimental|Anakinra IV|Patients in the intervention arm will receive anakinra IV (N=50) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
11024876|NCT04603742|Placebo Comparator|Normal Saline IV|Patients in the placebo arm will receive normal saline IV (N=50) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
11024877|NCT04603729|Active Comparator|group 1 dexamethasone|participants will receive dexamethasone 8mg/day Intravenous for 5 days
11024878|NCT04603729|Active Comparator|group 2 methylprednisolone|participants will receive methylprednisolone 1mg/kg/day intravenous for 5 days
11024879|NCT04603716|Experimental|Eccentric Muscle Energy Technique|conventional physical therapy Along with eccentric muscle energy technique
11024880|NCT04603716|Experimental|concentric muscle energy technique|Conventional physical therapy along with concentric muscle energy technique
11024881|NCT04603703|Experimental|HVLAT Manipulation|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics, HVLAT
11024882|NCT04603703|Active Comparator|Conventional physical therapy|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics
11024883|NCT04603690|Experimental|Colchicine|"This arm will receive Colchicine + Standard care as per hospital guidelines.
~The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half."
11024884|NCT04603690|No Intervention|Control group|This arm will receive standard care as per the hospital guidelines.
11024885|NCT04603677||Acute phase of SARS-CoV-2 infection|Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.
11024886|NCT04603677||Convalescent phase of SARS-CoV-2 infection|Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.
11024887|NCT04603664||study group|blood sampling and measduring of serum NGAL and cystatin c every other day and serum urea and creatinine every day
11024888|NCT04603638|Active Comparator|magnesium|participations will be given intravenous magnesium.
11024889|NCT04603638|Placebo Comparator|control|participations will be given intravenous isotonic.
11024890|NCT04603625|Experimental|sitting position centering femoral heads|sitting position centering femoral heads according to Lespargot diagram
11024891|NCT04603625|Active Comparator|Usual postural management|sitting with the trunk aligned and hips abducted to facilitate activities of daily living
11024892|NCT04603612|Other|NMIBC patients|Patients with diagnosed bladder tumors seen the urology department (Urology and Nephrology Center, Mansoura University, Egypt) will be assessed for eligibility to the study and inclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study and will be provided with an informed consent form. Study participants will be enrolled, and the appropriate scheduled procedures will be performed.
11024893|NCT04603599||benign endometrial changes|
11024894|NCT04603599||endometrial hyperplasia|
11024895|NCT04603599||endometrial cancer|
11024896|NCT04603586|Experimental|Arm A|SBRT with BED 60-70Gy combined with Gemcitabine + albumin-bound paclitaxel
11024897|NCT04603586|Experimental|Arm B|SBRT with BED >70Gy combined with Gemcitabine + albumin-bound paclitaxel
11024898|NCT04603573|Experimental|(intervention)|Fluoride varnish (Duraphat 50 mg/ml dental suspension (PL 00049/0042). Group (1)
11024899|NCT04603573|Active Comparator|comparator|Resin based fissure sealant (Dentsply Ltd, Stonehouse, UK; CE0086).group (2)
11024900|NCT04603560|Experimental|Provider Dashboard|
11024901|NCT04603560|Experimental|Pharmacist E-Detailing|
11024902|NCT04603560|No Intervention|Control|
11024903|NCT04603534|Experimental|Intervention group|
11024904|NCT04603521||Hypertrophic cardiomyopathy (HCM)|Survival after Myectomy Operation
11024905|NCT04603508|Experimental|Berlim 25/10|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/10 association, oral;
~1 tablet empagliflozin placebo, oral;
~1 tablet rosuvastatin calcium placebo, oral."
11024906|NCT04603508|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/10 association placebo, oral;
~1 tablet empagliflozin , oral;
~1 tablet rosuvastatin calcium, oral."
11024907|NCT04603495|Experimental|CPI-0610 + ruxolitinib|CPI-0610 monohydrate tablets + ruxolitinib phosphate tablets
11024908|NCT04603495|Active Comparator|Placebo + ruxolitinib|Matching placebo tablets + ruxolitinib phosphate tablets
11024909|NCT04603482|Experimental|Self-Management|
11024910|NCT04603482|Active Comparator|Attention Control Condition|
11024911|NCT04603469||Trisomy 21 patients|Children <18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3
11024912|NCT04603456|Experimental|Probiotic Group|consisted of 15 cases who received probiotics only. A drug called Lacteol fort (Rameda Company) . A sachet was taken once daily for three months. Each sachet contains 10 billions lactobacilli.
11024913|NCT04603456|Experimental|SLIT Group|included 15 children who received SLIT for 6 months. Standardized Timothy Grass Pollen (Phleum pratense)
11024914|NCT04603456|Experimental|Combined treatment Group|included 15 children who received probiotics and SLIT. A drug called Lacteol fort was administered A sachet was taken once daily for 3 months . Standardized Timothy Grass Pollen was taken for 6 months
11024915|NCT04603443|Experimental|BCAA 20g/daily|Branched Chain Amino Acids, 10g BID x 12 weeks
11024916|NCT04603443|Experimental|BCAA 40g/daily|Branched Chain Amino Acids, 20g BID x 12 weeks
11024917|NCT04603443|Experimental|BCAA 60 g/daily|Branched Chain Amino Acids, 30g BID x 12 weeks
11024918|NCT04603443|Placebo Comparator|Placebo 60 g/daily|Protein without BCAA, 30g BID x 12 weeks
11024919|NCT04603430||Physical Therapy Students|Students will be participating in a focus group and completing a survey.
11024920|NCT04603430||Senior STEPS Participants|Seniors will be participating in a focus group, completing a survey, and researchers will be conducting a retrospective chart review on relevant documented health outcomes of the STEPS program.
11024921|NCT04603417||Patients|Patients with CRPS diagnosis
11024922|NCT04603417||Controls|Healthy controls with known Neurological Disorders
11024923|NCT04603391|Experimental|Exposure A|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)
11024924|NCT04603391|Active Comparator|Exposure B|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.
11024925|NCT04603378|Other|KB195|
11024926|NCT04603378|Other|Polydextrose|
11024927|NCT04603378|Other|Pullulan|
11024928|NCT04603378|Other|Maltodextrin|
11024929|NCT04603365|Experimental|Treatment (pamiparib, temozolomide)|Patients receive PO BID on days 1-28 and temozolomide PO QD on days 1-7. Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.
11024930|NCT04603352|Experimental|Intervention group: Hip Helpers home program|Participants in the intervention group will be given a custom pair of Hip Helpers® to use at home. Parents will begin the Hip Helpers® home program upon study entry and stop the program once the child is able to pull to stand independently. The Hip Helpers® home program protocol, which consists of using the orthotic garment twice daily for 30 minutes each time, will be given to the parents and supervised by the physical therapist. The Hip Helpers® should be donned when the child is actively playing, and not used sleep or when child is inactive.
11024931|NCT04603352|No Intervention|Control group: No additional home program|Participants assigned to the control group will continue with their usual care.
11024932|NCT04603339|Experimental|Intervention Arm|Single arm trial, all participants will receive the intervention
11024933|NCT04603326||Non-manifesting LRRK2 mutation carriers|Patients must have confirmed LRRK2 G2019S mutation Age 30 years or older at date of informed consent.
11024934|NCT04603326||LRRK2 Parkinson Disease (PD) Participants:|Patients must have confirmed LRRK2 G2019S mutation Patients must meet the MDS criteria for Parkinson's disease Disease duration: any Age 30 years or older at time of PD diagnosis.
11024935|NCT04603326||Idiopathic PD (iPD) Particpants:|Patients must meet the MDS criteria for Parkinson's disease. Disease duration: any Age 30 years or older at time of PD diagnosis.
11024936|NCT04603326||Control (C) Participants:|Age 30 years or older at date of informed consent.
11024937|NCT04603313||Experimental group|12 departments in mainland France covered by the tele-advice system open to general practitioners
11024938|NCT04603313||Control group|84 departments in mainland France not covered by the tele-advice system.
11024939|NCT04603300|Active Comparator|Active treatment|INT301 dosing as determined by cohort assignment
11024940|NCT04603300|Placebo Comparator|Placebo|Placebo as determined by cohort assignment
11024941|NCT04603287|Experimental|Study treatment|Participants receive SI-B001 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
11024942|NCT04603274|Other|upper extremity diagnosed with carpal tunnel syndrome|8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
11024943|NCT04603261||eGFR <30 mL/min/1.73m2|Patients with eGFR <30 mL/min/1.73m2 in absence of dialysis referred for an elective procedure with intravascular administration of iodinated contrast material at Maastricht UMC+.
11024944|NCT04603261||eGFR 30-59 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
11024945|NCT04603261||eGFR >=60 mL/min/1.73m2|For each included patient with eGFR <30 mL/min/1.73m2, two patients matched for age, sex and contrast procedure type will be included: one with eGFR 30-59 mL/min/1.73m2 and one with eGFR >=60 mL/min/1.73m2.
11024946|NCT04603248|Experimental|Single Arm|
11024947|NCT04603235|Experimental|Intervention|This is a quasi-experimental study
11024948|NCT04603222|Experimental|Treatment Group|Group treating blepharitis with SUMMIT BRUSH and Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
11024949|NCT04603222|Active Comparator|Control Group|Group treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser once a day
11024950|NCT04603209||IORT|Participants will undergo partial mastectomy for treatment of early stage breast cancer. IORT will then be delivered following surgical resection of the tumor. After surgery, participants are followed under routine care.
11024951|NCT04603196||Patients with Multiple Sclerosis with obstructive sleep apnea|Patients with Multiple Sclerosis with obstructive sleep apnea
11024952|NCT04603196||Patients with MS without obstructive sleep apnea|Patients with MS without obstructive sleep apnea
11024953|NCT04603183|Experimental|Interventional Arm (Arm A)|Abemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
11024954|NCT04603183|Active Comparator|Control Arm (Arm B)|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
11024955|NCT04603157|No Intervention|Standard of Care Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will continue to follow the treatment recommendations of the primary care physician
11024956|NCT04603157|Experimental|Hybrid Exercise Training Group|Subject with diagnosed with postural orthostatic tachycardia syndrome will follow a hybrid exercise training program
11024957|NCT04603131|Experimental|BBV87 - 10 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
11024958|NCT04603131|Placebo Comparator|Placebo|Placebo administered intramuscularly on Day 0, 29 and 57
11024959|NCT04603131|Experimental|BBV87 -30 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
11024960|NCT04603131|Experimental|BBV87 -20 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
11024961|NCT04603118|Other|The patients with Idiopathic intracranial hypertension (IIH)|33 patients who applied to the neurology clinic with the pre-diagnosis of IIH were performed lumbar puncture. 25 of them diagnosed with IIH. Optic nerve sheath diameter was measured by optic ultrasonography from both eyes before and after the LP.
11024962|NCT04603118|Other|Control group|In the control group, optic nerve sheath diameter was measured from both eyes by optic ultrasonography.
11024963|NCT04603105||Single Study Cohort|Patients will be recruited from the main study after being determined to having COVID-19 and Cancer
11024964|NCT04603092|Experimental|Disadvantaged women in primary setting receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This group will receive the digital health literacy intervention.
11024965|NCT04603092|No Intervention|Disadvantaged women in primary setting not receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This control group will not receive the digital health literacy intervention.
11024966|NCT04603079|Experimental|Currently practicing nurses who will receive intervention|An intervention for COVID-19 preventive protocols will be delivered to the nurses in the experiment group.
11024967|NCT04603079|No Intervention|Currently practicing nurses who will not receive intervention|No intervention for COVID-19 preventive protocols will be delivered to the nurses in the control group.
11024968|NCT04603066|Experimental|Ondansetron + Tariquidar|
11024969|NCT04603066|Placebo Comparator|Ondansetron + Placebo|
11024970|NCT04603053|Experimental|CBot-A Group|Participants randomly assigned to this arm will receive access to CBot-A app.
11024971|NCT04603053|No Intervention|Wait List Group|Participants randomly assigned to this arm will be offered the intervention after the completion of the trial.
11024972|NCT04603040|Experimental|Experimental group|Experimental group:ToripalimabTreatment
11024973|NCT04603027|Experimental|Cohort 1|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 0.8 x 10^11 cells, capsule, once daily, 16 weeks
11024974|NCT04603027|Experimental|Cohort 2|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 3.2 x 10^11 cells, capsule, once daily, 16 weeks
11024975|NCT04603027|Experimental|Cohort 3|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 8.0 x 10^11 cells, capsule, once daily, 16 weeks
11024976|NCT04603014|Experimental|Interdialytic peritoneal ultrafiltration|Will receive incremental interdialytic peritoneal ultrafiltration with a 10% dextrose solution, twice a week for three consecutive weeks
11024977|NCT04603001|Experimental|Dose Escalation Arm A|Patients not requiring a strong CYP3A4 inhibitor.
11024978|NCT04603001|Experimental|Dose Escalation Arm B|Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
11024979|NCT04603001|Experimental|Cohort 1|Patients with R/R AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
11024980|NCT04603001|Experimental|Cohort 2|Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
11024981|NCT04603001|Experimental|Cohort 3|Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation,
11024982|NCT04603001|Experimental|Cohort 4|Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
11024983|NCT04602988||Patients admitted to an inpatient hospital unit|Patients admitted to an inpatient hospital unit will receive EEG based monitoring of mental status
11024984|NCT04602975|Experimental|Adults cohort 1 vaccinees|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.
11024985|NCT04602975|Placebo Comparator|Adults cohort 1 placebo recipients|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.
11024986|NCT04602975|Experimental|Children cohort 2 vaccinees|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.
11025480|NCT04599686|Active Comparator|ADT|Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.
11024987|NCT04602975|Placebo Comparator|Children cohort 2 placebo recipients|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.
11024988|NCT04602975|Experimental|Infants cohort 3A vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
11024989|NCT04602975|Placebo Comparator|Infants cohort 3A placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
11024990|NCT04602975|Experimental|Infants cohort 3A vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
11024991|NCT04602975|Placebo Comparator|Infants cohort 3A placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
11024992|NCT04602975|Experimental|Infants cohort 3B vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
11024993|NCT04602975|Placebo Comparator|Infants cohort 3B placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
11024994|NCT04602975|Experimental|Infants cohort 3B vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
11024995|NCT04602975|Placebo Comparator|Infants cohort 3B placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
11024996|NCT04602962||Fertility preservation performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
11024997|NCT04602962||Fertility preservation not performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
11024998|NCT04602949|Experimental|COVID-19 patients|subjects who were found as COVID-19 positive patients by swab RT-PCR
11024999|NCT04602949|Other|Healthy controls|subjects who were found as COVID-19 Negative, by swab RT-PCR
11025000|NCT04602936|Active Comparator|Solriamfetol|All medication will be 37.5 mg encapsulated soriamfetol tablets or matching encapsulated placebo tablets supplied in numbered containers for dispensing to patients. The minimum dose of solriamfetol during the trial will be 37.5 mg/day; the maximum dose will be 150 mg/day. At the Baseline Visit (Visit 0), participants will be instructed to take one capsule of solriamfetol 37.5 mg or matching placebo in the morning for the first 7 days. Thereafter, at Visit 1, solriamfetol or placebo will be increased to 75 mg/day, if tolerated. Beginning on day 15 (Visit 2), solriamfetol or placebo will be increased to 150 mg/day, if tolerated. Study medication dosage may be decreased, or a scheduled increase may not be made, because of side effects. Study medication will be administered as a single daily dose in the morning.
11025001|NCT04602936|Placebo Comparator|Placebo|Placebo (i.e., inactive compound for comparison)
11025002|NCT04602923|Experimental|XEN Gel Stent implantation|Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation
11025003|NCT04602923|Experimental|Trabeculectomy|Participants suffering from glaucoma who are candidates for trabeculectomy
11025004|NCT04602923|Experimental|GDD implantation|Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)
11025005|NCT04602910|Experimental|the phases of planning and acting|Each part of the website page was assessed for comprehensibility and usability by patients. Health care providers were asked to assess the acceptability of the website. A 5-point Likert scale was used for patient and health care provider ratings for each item. If the score were less than 3, then we would modify the website content based on the user feedback from patients and health care providers
11025006|NCT04602897|Experimental|cough group|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
11025007|NCT04602897|No Intervention|control|the control group received no pain management at all during different steps of IUD insertion
11025008|NCT04602884|Experimental|COVID-19 Positive patients|subjects who were found COVID-19 Positive according to swab test.
11025009|NCT04602884|Other|Healthy subjects|subjects who were found COVID-19 Negative according to swab test.
11025010|NCT04602871|Experimental|COVID 19 Positive patients|Patients with COVID-19, qPCR for SARS-CoV-2 confirmed
11025011|NCT04602871|Other|Healthy subjects|COVID-19 Negative subjects
11025012|NCT04602858|Experimental|Reactive Balance Training|"Participants randomised to the intervention group will initially undertake 3 x 40 min training sessions of reactive balance training over 3 weeks followed by 3-monthly retraining sessions at 3, 6 and 9 months, and final assessment at month 12.
~During the training, participants will be exposed to unpredictable slips and trips whilst they are walking on the Trip and Slip Walkway (Okubo et al. 2019). They will be required to consistently walk at their normal walking pace using our gait regulation protocol (i.e. individually adjusted stepping tiles and metronome). Each training session will involve up to 30 trips and slips which progress in unpredictability.
~Participants will also receive a Staying active and on your feet fall prevention booklet containing guidance regarding fall risk factors including exercise, diet, vision, footwear, medications and home safety."
11025013|NCT04602858|Active Comparator|Control|"After exposing the control group to one trip and one slip at baseline, participants will then be provided with the Staying active and on your feet fall prevention booklet, an educational booklet providing guidance on fall risk factors including exercise, diet, vision, footwear, medications and home safety. The control group will then return for a reassessment after 12 months."
11025014|NCT04602845|Experimental|Remimazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 3 mg/2ml remimazolam.
~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Remimazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
11025094|NCT04602286|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce pain intensity and unpleasantness."
11025521|NCT04599335|No Intervention|Negative|
11025015|NCT04602845|Active Comparator|Midazolam group|"Drug administration: 50ug fentanyl and 50mg flurbiprofen at the beginning of induction and pre-prepared drugs labeled inducers, which contained 2.5 mg/2ml midazolam.
~Successful sedation is defined as MOAA/S score less than or equal to 4 points during the whole process of the treatment. If MOAA/S score was greater than 4 points, a single dose of Midazolam (1 mg) is allowed to deepen sedation. if three times of deepen sedation within 15 minutes still can not achieve successful sedation, this progress will define as failure sedation."
11025016|NCT04602832|Experimental|ENHANCE Treatment Group|The ENHANCE program was tailored to address the current health and well-being challenges faced by individuals living in the COVID-19 pandemic. The contents of each week will focus on a new evidenced-based principle that has been shown in research to decrease negative thinking and emotions, as well as increase positive thinking, emotions, and overall physical and mental health and well-being. Each week participants will focus on the skills and methods of implementing happiness and well-being into their daily routine.
11025017|NCT04602832|No Intervention|Wait-List Control Group|Over the course of the study, participants will be asked to refrain from accessing the ENHANCE program materials to ensure the integrity of the research design. At the end of the study duration, participants will receive the full ENHANCE program.
11025018|NCT04602819|Experimental|Experimental|
11025019|NCT04602806||Moderate to Severe TBI Subjects|Adult patients (age 18-65y inclusive) presenting to the Emergency Department (ED) with a history of acute TBI as per American Congress of Rehabilitation Medicine (ACRM) Criteria (i.e., patient has sustained a traumatically-induced physiological disruption of brain function).
11025020|NCT04602780||CI users|
11025021|NCT04602767|Experimental|Vasopressin|Low dose vasopressin as first line vasopressor in cardiac surgery.
11025022|NCT04602767|Experimental|Phenylepherine|Low dose phenylephrine as first line vasopressor in cardiac surgery
11025023|NCT04602754|Experimental|BERLIM 25/20|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/20 association, oral;
~1 tablet empagliflozin placebo, oral;
~1 tablet rosuvastatin calcium placebo, oral."
11025024|NCT04602754|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:
~1 tablet Berlim 25/20 association placebo, oral;
~1 tablet empagliflozin, oral;
~1 tablet rosuvastatin calcium, oral."
11025025|NCT04602741|Experimental|A4i Intervention|"App4Independence (A4i)
~Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.
~Specific A4i functionality includes:
~Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.
~Fostering illness self-management through evidence-informed content.
~A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).
~Daily wellness and goal attainment check-ins.
~An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.
~Passively collected data on phone use as a proxy for sleep.
~A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU)."
11025026|NCT04602741|No Intervention|Treatment As Usual|Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
11025027|NCT04602728|Experimental|Back2Life Program|Youth with chronic SCD pain and their parents or caregivers receiving an adaptive cognitive behavioral treatment program for pain coping skills.
11025028|NCT04602715|Experimental|MET-2 20 g|Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
11025029|NCT04602715|Placebo Comparator|Placebo|Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
11025030|NCT04602689|Experimental|Fibrin glue group|Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD
11025031|NCT04602689|No Intervention|Control group|No intervention after gastric ESD
11025032|NCT04602676|Experimental|Diarrheal Assessment with DEP, then diarrheal assessment|Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
11025033|NCT04602676|Experimental|Diarrheal Assessment, then Diarrheal assessment with DEP|Participants will go through a 4 week period where clinicians will use a rehydration calculator. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm.
11025034|NCT04602663|Experimental|follow up every week|Variceal Band ligation every week.
11025035|NCT04602663|Experimental|follow up every 2 weeks|Variceal Band ligation every 2 weeks
11025036|NCT04602663|Experimental|follow up every 3 weeks|Variceal Band ligation every 3 weeks
11025037|NCT04602663|Experimental|follow up every 4 weeks|Variceal Band ligation every 4 weeks
11025038|NCT04602650||Type 2 Diabetic|Type 2 diabetic individuals of Mexican descent.
11025039|NCT04602650||Non-diabetic Controls|Non-diabetic individuals of Mexican descent.
11025040|NCT04602637||P1|
11025041|NCT04602637||P2|
11025042|NCT04602637||P3|
11025043|NCT04602624|Experimental|SAGE-718|Participants will receive a single dose of SAGE-718 oral tablets, once daily in the morning for 14 days.
11025044|NCT04602611|No Intervention|Standard of Care|Standard of Care
11025045|NCT04602611|Experimental|Oncology Nurse Navigation|Standard of Care + Oncology Nurse Navigation
11025046|NCT04602598|Experimental|Zanubrutinib|Zanubrutinib orally at a dose of 80mg BID for 24 weeks
11025576|NCT04598919|Placebo Comparator|Placebo|matching placebo once daily by mouth for 24 weeks
11025047|NCT04602585|Experimental|Experimental|After discharge, the program manager will link the participants with a VHT nearest to them. The participants (randomized to the intervention arm) will be informed during the consent procedure that they will undergo 6 psycho-education sessions (1 per month) together with a family member at the participant's residence. The VHTs and participants will meet and schedule appointments for the next engagements. This shall be done on a case by case basis. Some psycho-education sessions could take place in the patient's residence, others in the nearest public space (school or church or mosque compounds). The investigators will document where the majority of these sessions happen. This will help the investigators document feasibility. The PI and RAs will sit in some of the sessions during the pilot phase of data collection to ensure fidelity to the manual.
11025048|NCT04602585|Placebo Comparator|Usual care arm|Participants will receive usual care
11025049|NCT04602572||Non-surgical group.|Patients will be offered a standardized program comprised of individual consultations by a trained nurse every 3 months over 2 years, participation in a lifestyle course with 13 group sessions focusing on healthy diet and physical activity, and pharmacotherapy.
11025050|NCT04602572||Surgical group|After completing the systematic work-up and the lifestyle course, eligible subjects will be offered bariatric surgery. The surgical procedure will be chosen at the surgeon's discretion taking into consideration the target weight, comorbidities, risk of complications, the patient's ability to cope with side effects and complications, and the patient's motivation.
11025051|NCT04602559|Experimental|MOBIDERM Panty group|"MOBIDERM Panty group :
~All patients will wear the Panty MOBIDERM device for 12 weeks, day and night recommended. A removable pad is also recommended to be worn additionnaly to the panty."
11025052|NCT04602546|Active Comparator|Sevoflurane alone|"Sevoflurane will be administered in steps to achieve a loss of consciousness via a tight-face mask by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until MOAA/S scales at values less than 2 is reached.
~The equilibration time for each targeted concentration will be approximately 12 minutes to maintain a constant ETSEVO. The BIS™ value, MOAA/S score and picture recall test will be assessed when the patient is awake and at the different ETSEVO concentrations.
~ETSEVO is decreased by the same steps until consciousness is regained."
11025053|NCT04602546|Active Comparator|Sevoflurane with Remifentanil Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, an initial IV bolus of remifentanil will be given followed by the start of an infusion. Approximately within 7 minutes, the infusion rate of remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml.
~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of less than 2 is reached.
~ETSEVO is decreased by the same steps until consciousness is regained."
11025054|NCT04602546|Active Comparator|Sevoflurane with Fentanyl Group|"Two (2) minutes before starting sevoflurane, to attain an effect-site targeted concentration of fentanyl of 2 ng/mL, an initial IV bolus of fentanyl will be given followed by the start of an infusion. Approximately within 10 minutes, the infusion rate of fentanyl may be adjusted to maintain the effect-site concentration of fentanyl of 2 ng/ml.
~Sevoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness by increasing the end-tidal concentration of Sevoflurane (ETSEVO). Targeted concentration for ETSEVO are 0.25, 0.5, 0.75, 1, 3, 4, 5% or higher until an MOAA/S score of equal to or less than 2 is reached.
~ETSEVO is decreased by the same steps until consciousness is regained."
11025055|NCT04602546|Active Comparator|Desflurane Group|"Due to desflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to desflurane. Once correct LMA placement has been confirmed, there will be an equilibrium time of approximately 15-20 minutes to allow the effect site concentration of propofol to reach a level consistent with a pharmacodynamic effect of consciousness as measured by a MOAA/S score of 2 or 3. Desflurane will then be administered via a tight-face mask at the targeted end-tidal concentration (ETDES) of 2, 5, 7, 8, 9, 10 %, or higher until an MOAA/S score of less than 2 is reached.
~The BIS™ value will be correlated with desflurane ETDES concentration. ETDES is decreased by the same steps until consciousness is regained."
11025056|NCT04602546|Active Comparator|Isoflurane Group|"Due to isoflurane being a volatile agent and not well tolerated as an induction agent, an initial IV bolus of 1% propofol provided at 2mg/kg, with supplemental boluses given at the investigators discretion in order to achieve LMA insertion, will be administered 15-20 minutes prior to isoflurane.Isoflurane will be administered via a tight-face mask in steps to achieve a loss of consciousness (MOAA/S of 0,1) by increasing the end-tidal concentration of Isoflurane (ETISO). Targeted concentration for ETISO are 0.25, 0.5, 0.75, 1, 1.5% or higher until MOAA/S scales at values less than 2 is reached.
~The BIS™ value will be correlated with desflurane ETISO concentration. ETISO is decreased by the same steps until consciousness is regained."
11025057|NCT04602533|Experimental|Durvalumab|"Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy)
~Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities."
11025058|NCT04602533|Other|Control group|"Induction phase: Radiochemotherapy according to guideline
~Maintenance: Standard of care"
11025059|NCT04602520||Dying patients|"Behavioral: Focused end of life conversations to promote connections among patients, family members and clinicians.
~All eligible dying patients and families in the 3 participating acute care wards are invited to participate in wish elicitation and implementation. For clinician interviews, criterion sampling will be used, based on involvement in the care of enrolled dying patients. We will use qualitative and quantitative methods to collect and analyze data. Quantitative data will include characteristics of patients, families and clinicians. Qualitative data will be based on interviews. Pending the pandemic burden, and the status of their grief, family members of deceased patients may be invited for an interview later months after the death of their loved one."
11025060|NCT04602507|Experimental|Intervention|50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
11025061|NCT04602507|Placebo Comparator|Control|50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
11025169|NCT04601857|Experimental|Futibatinib and Pembrolizumab (Cohort A)|Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.
11025062|NCT04602494|Experimental|Varenicline|Participants will receive varenicline 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
11025063|NCT04602494|Placebo Comparator|Placebo|Participants will receive identical placebo 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks added to 12 weeks of group behavioral and texting support specifically designed for teen vaping cessation
11025064|NCT04602468||Standard group|The standard testing group will be available for both age cohorts with sites having a predefined recruitment cap for each testing group. The standard testing will involve the following assessments; sweat chloride, LCI, height/weight/BMI, FEV1, airway sampling (micro), FeNO, liver function testing, liver ultrasound, liver examination, stool collection, blood collection, abdominal symptom score, CFQ-R, pharmacy records medication pick up rate, adherence questionnaires, MEMs caps and antibiotic use.
11025065|NCT04602468||Advanced group|In addition to all elements of the standard testing group, the advanced testing group will undergo: Ultra-low dose spirometry-controlled CT scanning, sputum collection and nasal lavage collection. This will be available for both age cohorts with sites having a predefined recruitment cap for each testing group.
11025066|NCT04602455|Experimental|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a week webinar for 30 minutes during the four weeks. UCLA Loneliness scale was recorded prior to the start of the study and at its end after the duration of 4 weeks. The score was reviewed to see the changes in the loneliness scale.
11025067|NCT04602455|No Intervention|Control Group|The control group had no change in their daily routines.
11025068|NCT04602442|Experimental|EXO-1|Participants (n=30) in this group will receive standard therapy and exosomes of the first type.
11025069|NCT04602442|Experimental|EXO-2|Participants (n=30) in this group will receive standard therapy and exosomes of the second type.
11025070|NCT04602442|Placebo Comparator|Placebo|Participants (n=30) in this group will receive standard therapy and inhalation placebo solution.
11025071|NCT04602416||Control (Health)|The control had two sessions: the Introduction and another on Health. The health sessions were based on topics used by United States Peace Corps medical officers training volunteers about how to stay healthy in Tanzania: nutrition, worms, HIV/AIDS, and first aid.
11025072|NCT04602416||Entrepreneurship|The sessions for this arm were six: the two sessions of the Control arm, plus Sources of Capital, Marketing, Saving and Investing Profit, and Writing a Business Plan. Each session lasted one day.
11025073|NCT04602416||Beekeeping|The Beekeeping arm had six sessions: the two sessions of the Control arm, plus Beginning Beekeeping, Environment-Forests-Bees, Building a Beehive, and Harvesting.
11025074|NCT04602416||All Interventions|This arm was 10 sessions, and included all sessions of the Control, Entrepreneurship, and Beekeeping
11025075|NCT04602403|Placebo Comparator|placebo group|people who given placebo to become agroup of comparison with the other group
11025076|NCT04602403|Active Comparator|tamsulosin group|people who given tamsulosin to know the effect on ureteroscopy and compare with the control group
11025077|NCT04602390|Experimental|ANK-700 SAD Cohort 1, Dose A|All enrolled patients will receive one dose of ANK-700 Dose A
11025078|NCT04602390|Experimental|ANK-700 SAD Cohort 2, Dose B|All enrolled patients will receive one dose of ANK-700 Dose B
11025079|NCT04602390|Experimental|ANK-700 SAD Cohort 3 Dose C|All enrolled patients will receive one dose of ANK-700 Dose C
11025080|NCT04602390|Experimental|MAD Cohort 4 ANK-700 Dose A or Placebo|All enrolled patients will receive three doses of ANK-700 Dose A or placebo
11025081|NCT04602390|Experimental|MAD Cohort 5 ANK-700 Dose B or placebo|All enrolled patients will receive three doses of ANK-700 Dose B or placebo
11025082|NCT04602377|Experimental|Pembrolizumab|Single arm study
11025083|NCT04602364||Miga-Fab patients|Miga-Fab is a French prospective, observational cohort study of patients with Fabry disease treated with migalastat
11025084|NCT04602325||Inherited Hyperammonemias|"A clinical diagnosis of 1 of 7 diagnosed urea cycle disorders:
~N-acetylglutamate Synthetase Deficiency (NAGS)
~Carbamyl Phosphate Synthetase Deficiency (CPSD)
~Ornithine Transcarbamylase Deficiency (OTCD)
~Argininosuccinate Synthetase Deficiency (ASD)
~Argininosuccinate Lyase Deficiency (ALD)
~Arginase Deficiency (AD)
~Hyperammonemia-Hyperornithinemia-Homocitrullinuria (HHH)
~A clinical diagnosis of 1 of 2 organic acidemias:
~Propionic Acidemia (PA)
~Methylmalonic Acidemia (MMA)"
11025085|NCT04602325||Acute Metabolic Disorder + Neurological Sequelae|"Acute metabolic disorder without hyperammonemia but with neurological sequelae:
~Maple Syrup Urine Disease (MSUD)
~Glutaric Acidemia (GA1)"
11025086|NCT04602325||Fatty Acid Oxidation Disorders|"Acute metabolic disorder without hyperammonemia and without neurological sequelae:
~Medium Chain-Acyl CoA Dehydrogenase Deficiency
~Very Long Chain-Acyl CoA Dehydrogenase Deficiency
~Trifunctional Protein Deficiency
~Long Chain Hydroxyacyl-CoA Dehydrogenase Deficiency
~Carnitine Palmitoyltransferase I or II Deficiency
~Carnitine/Acylcarnitine Translocase Deficiency
~Primary Carnitine Transport Deficiency"
11025087|NCT04602325||Hypoxic-Ischemic Encephalopathy|Patients with hypoxic-ischemic encephalopathy
11025088|NCT04602312|Experimental|Mindfulness meditation|"focussed attention mindfulness meditation technique taught as means to reduce coronavirus-related catastrophizing."
11025089|NCT04602312|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
11025090|NCT04602312|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit expectancy-mediated (but not mindfulness-mediated) reductions in coronavirus-related catastrophizing.
11025091|NCT04602312|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
11025092|NCT04602299|Experimental|Set the minimum time of gastroscopy|
11025093|NCT04602299|No Intervention|Observe the procedure time of gastroscopy|
11025866|NCT04596722|Active Comparator|Assigned Interventions|oral active pomella taken by mouth once per day
11025095|NCT04602286|Sham Comparator|Specific sham mindfulness meditation|a training session designed to specifically match the real mindfulness training while lacking the proposed active elements of mindfulness training. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
11025096|NCT04602286|Sham Comparator|General sham mindfulness meditation|a training session designed to generally match focussed-attention mindfulness meditation while maintaining greater distance from proposed mindfulness mechanisms. Delivered as a means to elicit placebo-mediated (but not mindfulness-mediated) reductions in pain intensity and unpleasantness
11025097|NCT04602286|No Intervention|Book listening control|"this group completes no meditation training. They listen to a spoken excerpt from the audiobook The Natural History and Antiquities of Selborne"
11025098|NCT04602273||High Risk MDS|New diagnosed patients treated with Azacitidine 75 mg/sqm SC QD on a 28 days based cycles (both 7-0-0 and 5-0-2 regimens are allowed) until disease progression, unacceptable toxicity, death or investigator decision
11025099|NCT04602260||Prospective Cohort|The prospective cohort will assess patients upon admission to general internal medicine, at hospital discharge, and at 3, 6, and 12-month follow-up.
11025100|NCT04602260||Retrospective Cohort|The retrospective cohort will assess patients at 3, 6, and 12-months after being discharged from the hospital.
11025101|NCT04602247|Experimental|SIC|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.
11025102|NCT04602247|Experimental|SIC + AA combined|100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid
11025103|NCT04602247|Active Comparator|FeSO4|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe
11025104|NCT04602247|Active Comparator|FeSO4 + AA combined|6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid
11025105|NCT04602247|Experimental|EP + FeSO4 combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe
11025106|NCT04602247|Experimental|EP + FeSO4 + AA combined|100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid
11025107|NCT04602234|Experimental|LUS group|
11025108|NCT04602234|No Intervention|No LUS group|
11025109|NCT04602221|Experimental|Lamotrigine treatment (T1)|
11025110|NCT04602221|Experimental|BI 409306 treatment (T2)|
11025111|NCT04602221|Placebo Comparator|Placebo treatment (R)|
11025112|NCT04602221|Experimental|BI 425809 treatment (T3)|
11025113|NCT04602208||Focal HIFU for primary localized prostate cancer|Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
11025114|NCT04602182|Experimental|music therapy gruop (experimental group)|Experimental group: Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
11025115|NCT04602182|Active Comparator|control group|Control group: Patient will follow the usual clinical practice for the weaning from mecanichal ventilation to the end of the weaning.
11025116|NCT04602169|Active Comparator|PVI only group|Patients allocated to this group will receive PV re-isolation alone
11025117|NCT04602169|Active Comparator|PVI + SVC group|Patients allocated to this group will receive PV re-isolation with SVC isolation.
11025118|NCT04602156|Experimental|Group T|Patients will be randomized to undergo PC catheter placement (8-French) using the trocar method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
11025119|NCT04602156|Active Comparator|Group S|Patients will be randomized to undergo PC catheter placement (8-French) using the Sellinger method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
11025120|NCT04602143|Experimental|Testosterone gel 4 weeks|Patients with low ovarian reserve received 4-week TTG application before controlled ovarian hyperstimulation.
11025121|NCT04602143|Experimental|Testosterone gel 6 weeks|Patients with low ovarian reserve received 6-week TTG application before controlled ovarian hyperstimulation.
11025122|NCT04602143|No Intervention|Control group|Patients with low ovarian reserve received no medication before controlled ovarian hyperstimulation.
11025123|NCT04602130|Experimental|Massage|Massages were performed starting from the face, focused on the newborns forehead, and then around the eyes and cheeks with gentle touches. Then, newborns' chest area and the upper and lower extremities were massaged. Finally, newborns'were placed prone position and the back was massaged. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
11025124|NCT04602130|Experimental|Sponge Bathing|In the sponge bathing group, the newborns' eyes, faces (outward from the midline), around the ear and the back of the ear were wiped from the inside out with cotton wipes and dried. Then, the chest area and arms, abdomen and back, legs and feet, respectively, were wiped and dried. Finally, the genital area was cleaned, before diapering the newborn. Nurses recorded newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form
11025125|NCT04602130|Experimental|Tub bathing|In the tub bathing group, before being immersed in the tub, the newborns' faces and heads were cleaned outwards from the midline and dried. Then, the neck, chest, arms, back, legs and genital area were soaped, before the full body was rinsed and dried. Finally, umbilical cord care was performed, and the baby was diapered. Nurses recorded the newborns' physiological measurements (pulse, respiration, oxygen saturation and body temperature) on the Newborn Follow-up Form.
11025126|NCT04602130|No Intervention|Control|The newborns in the control group did not undergo any intervention other than standard clinical practices. All physiological measurements (pulse, respiration, oxygen saturation and body temperature) were performed by nurses and recorded on the Newborn Follow-up Form.
11025170|NCT04601857|Experimental|Futibatinib and Pembrolizumab (Cohort B)|All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors).
11025867|NCT04596722|Placebo Comparator|Placebo|oral placebo taken by mouth once per day
11025127|NCT04602117|Experimental|Vic-trastuzumab duocarmazine (SYD985)|single-arm, phase I trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel. The study contains 2 cohorts. Cohort A is the de-escalation cohort. Patients with certain HER-positive advanced solid tumors or HER2-low breast cancer will be enrolled in this cohort. Cohort B is the expansion cohort, in which only patients with HER2-positive or HER2-low breast cancer can be enrolled. Treatment will be administered on an outpatient basis.
11025128|NCT04602104|Experimental|Phase 1: hMSC-Exos low dose|hMSC-Exos low-dose group
11025129|NCT04602104|Experimental|Phase 1: hMSC-Exos medium dose|hMSC-Exos medium-dose group
11025130|NCT04602104|Experimental|Phase 1: hMSC-Exos high dose|hMSC-Exos high-dose group
11025131|NCT04602104|Experimental|Phase 2: hMSC-Exos dosage 1|basic treatment+hMSC-Exos (a quarter of MTD/day)
11025132|NCT04602104|Experimental|Phase 2: hMSC-Exos dosage 2|basic treatment+hMSC-Exos (MTD/day)
11025133|NCT04602104|Placebo Comparator|Phase 2: control group|basic treatment+normal saline
11025134|NCT04602078|Experimental|AUREA single-arm|"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.
~Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles."
11025135|NCT04602065|Experimental|Previously received anti-PD1/PD-L1 antibodies|Patients previously received anti-PD1/PD-L1 antibodies, except for those were primarily refractory to them.
11025136|NCT04602065|Experimental|Patients previously never received anti-PD1/PD-L1 antibodies|Patients previously never received anti-PD1/PD-L1 antibodies.
11025137|NCT04602052|Active Comparator|Medical arm|Those who choose medical abortion receive mifepristone 200 mg on day 1 and are appointed to return to SPHMMC 24-48 hours later for admission and misoprostol administration.
11025138|NCT04602052|Experimental|Surgical arm|Those who chose surgical abortion are given mifepristone 200 mg with or without laminaria and appointed to return the next day for surgical abortion.
11025139|NCT04602039|Experimental|People without Diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
11025140|NCT04602039|Experimental|Participants with Pre-diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
11025141|NCT04602039|Experimental|Participants with Type 2 diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
11025142|NCT04602026|Active Comparator|Arm I (best practice)|Non-frail patients receive standard of care.
11025143|NCT04602026|Active Comparator|Arm II (best practice)|Frail patients receive standard of care.
11025144|NCT04602026|Experimental|Arm III (physical therapy consultation, exercise intervention)|Frail patients undergo a physical therapy consultation and complete home exercises 3 days per week.
11025145|NCT04602013|Experimental|Immunotherapy combined with chemoradiotherapy|"Immunotherapy combined with chemoradiotherapy
~Sintilimab Body weight <60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W.
~Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).
~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)
~Radiotherapy The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week)."
11025146|NCT04602000|Experimental|CT-P59 Arm 1|
11025147|NCT04602000|Experimental|CT-P59 Arm 2|
11025148|NCT04602000|Placebo Comparator|Placebo|
11025149|NCT04601987|Active Comparator|Counseling about the Maternal Benefits of Breastfeeding|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the maternal health benefits of breastfeeding.
11025150|NCT04601987|Active Comparator|Counseling about the benefits of Smoke-free Homes|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the health benefits of smoke free homes.
11025151|NCT04601974|Experimental|lentiviral gene therapy treatment (Intervention Arm)|Patients will receive a single dose of lentiviral gene therapy treatment administered once intracranially
11025152|NCT04601961|Active Comparator|SEVO Group|Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.
11025153|NCT04601961|Experimental|TIVA group|The patients in TIVA group will be anaesthetized using total intravenous propofol.
11025154|NCT04601948|Experimental|Intervention|Participants will receive a Fitbit activity monitor and access to the mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
11025155|NCT04601935|Experimental|LCAR-BCX cells product|Each subject will be given a single-dose infusion in each dose levelThe dose-finding phase of this study is designed primarily using the Bayesian optimal interval (BOIN) method, which is combined with accelerated titration at the beginning of the study to assess incidence of DLT (dose-limiting toxicity) and estimate MTD (maximum tolerated dose).
11025156|NCT04601922||Emergency Medicine Consultants|
11025157|NCT04601922||General Practitioners|
11025158|NCT04601922||Acute care nursing staff|
11025159|NCT04601922||Patients presenting with suspected cardiac chest pain|
11025160|NCT04601909|Active Comparator|FX-322|FX-322, 1 dose (N=24)
11025161|NCT04601909|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
11025162|NCT04601896||Live patients admitted for Refractory Cardiac Arrest with ECMO|
11025163|NCT04601896||Live patients quality of life admitted for Refractory Cardiac Arrest without ECMO|
11025164|NCT04601883|Experimental|Colchicine|Tablet colchicine 0.5 mg administered two times daily
11025165|NCT04601883|Placebo Comparator|Placebo|Tablet placebo administered two times daily
11025166|NCT04601870|Experimental|No Financial Incentive|N=180 participants randomized to not be offered monetary incentive to participate in an intervention to quit smoking.
11025167|NCT04601870|Experimental|Financial Incentive (25 dollars)|N=180 randomized participants will be offered a 25 dollar incentive to participate in an intervention to quit smoking.
11025168|NCT04601870|Experimental|Financial Incentive (50 dollars)|N=180 randomized participants will be offered a 50 dollar incentive to participant in an intervention to quit smoking.
11025171|NCT04601844|Experimental|Cohort 1|Cemdisiran at dose 1 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
11025172|NCT04601844|Experimental|Cohort 2|Cemdisiran at dose 2 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
11025173|NCT04601844|Experimental|Cohort 3|Cemdisiran at dose 2 SC single dose and pozelimab at dose 2 SC single dose, both administered on day 1
11025174|NCT04601831|Experimental|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.
~*If >5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (>=7.5 cm in largest dimension) sites be treated."
11025175|NCT04601818|Experimental|Interventional arm|During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.
11025176|NCT04601818|No Intervention|Retrospective arm|Outcomes will be compared to conventional transplant patients matched by age, medical diagnosis, BMI, lung allocation score and donor type ( DCD vs. NDD) using a 1:2 matching.
11025177|NCT04601805||Group (1) : Patient diagnosed with IBD with no treatment received|
11025178|NCT04601805||Group(2): Patient diagnosed with IBD and received treatment for a long time|
11025179|NCT04601792|Experimental|Individualized Decoction|"It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For subjects with lung and spleen qi deficiency syndrome, the investigators added Radix Codonopsis Pilosulae, Pericarpium Citri Reticulatae, and Atractylodes Macrocephala Koidz. The investigators can adjust the individualized decoction in accordance with the change in the patient's condition throughout the whole study duration.
~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
11025180|NCT04601792|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.
~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
11025181|NCT04601792|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
11025182|NCT04601779|Other|Cluster I|Cluster I is randomized to start the PUF-VIPP intervention phase July 1 2021
11025183|NCT04601779|Other|Cluster II|Cluster II is randomized to start the PUF-VIPP intervention phase November 1, 2021
11025184|NCT04601779|Other|Cluster III|Cluster IiI is randomized to start the PUF-VIPP intervention phase March1, 2022
11025185|NCT04601766|Experimental|Group A|
11025186|NCT04601766|Experimental|Group B|
11025187|NCT04601753||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
11025188|NCT04601740||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
11025189|NCT04601727||Rectal cancer patients|
11025190|NCT04601701|Experimental|CRVO: Bevacizumab and intravitreal Dexamethasone.|Participants with CRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
11025191|NCT04601701|Active Comparator|CRVO: Bevacizumab|Participants with CRVO will receive a combination of Bevacizumab only.
11025192|NCT04601688|Experimental|BRVO: Bevacizumab and intravitreal Dexamethasone|Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
11025193|NCT04601688|Active Comparator|BRVO: Bevacizumab|Participants with BRVO will receive Bevacizumab only.
11025194|NCT04601675|Experimental|Diabetic ME: Ranibizumab and intravitreal Dexamethasone|Participants with diabetic macular edema will receive a combination of Ranibizumab and intravitreal Dexamethasone
11025195|NCT04601675|Active Comparator|Diabetic ME: Ranibizumab|Participants with diabetic macular edema (ME) will receive Ranibizumab only.
11025196|NCT04601662|Experimental|Corticision|Patients in this group will be subjected to corticision to accelerate orthodontic movement
11025197|NCT04601662|Active Comparator|Traditional treatment|Patients in this group will undergo normal traditional treatment without any acceleration method.
11025198|NCT04601649|Experimental|Intervention|Participants will take part in the PrEP Talk intervention sessions.
11025199|NCT04601649|No Intervention|Control|Participants will receive standard care.
11025200|NCT04601636|Active Comparator|Active Prewarming group (PW group)|Group randomized to receive at least 30 minutes of active prewarming before induction of anesthesia, combined to active warming intraoperatively.
11025201|NCT04601636|Placebo Comparator|Control group (C group)|Group randomized to receive the standard care : passive prewarming before induction of anesthesia combined to active warming intraoperatively.
11025202|NCT04601610|Experimental|Cohort 1|Subjects who have not received first-line system treatment previously;
11025203|NCT04601610|Experimental|Cohort 2|Subjects who have received at least first-line system treatment
11025204|NCT04601584|Experimental|GNR-084, 0.01 ng/kg|Anti-CD19 / CD3 antibody
11025205|NCT04601584|Experimental|GNR-084, 0.1 ng/kg|Anti-CD19 / CD3 antibody
11025206|NCT04601584|Experimental|GNR-084, 1 ng/kg|Anti-CD19 / CD3 antibody
11025207|NCT04601584|Experimental|GNR-084, 4 ng/kg|Anti-CD19 / CD3 antibody
11025208|NCT04601584|Experimental|GNR-084, 20 ng/kg|Anti-CD19 / CD3 antibody
11025210|NCT04601571|Active Comparator|Feeding Tube Placement using CORTRAK stylet|Subjects will already have a feeding tube placed and are undergoing X-rays for placement confirmation.
11025211|NCT04601571|No Intervention|Feeding Tube Placement using X-Ray|Routine X-ray is used to confirm feeding tube placement
11025212|NCT04601558|No Intervention|Control group|The first group of participants was control group. The number of participant was 70, and the participants in this group after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
11025213|NCT04601558|Sham Comparator|Passive-intervention group|The second group of participant was passive-intervention group. There were 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, they were receiving remainder on their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease.
11025214|NCT04601558|Active Comparator|Active-intervention group|The third group of participant was active-intervention group. There were also 70 participants. This group of women after recruitment received letter with their own cardiovascular risk factors and count of their 10-year risk of cardiovascular disease. After this letter, every two months, active-intervention group were receiving Cochrane abstracts in the form of blog-shots.
11025215|NCT04601545|Experimental|VR therapy group|Pulmonary rehabilitation supplemented by VR therapy
11025216|NCT04601545|Active Comparator|Active Control Group|Pulmonary rehabilitation supplemented by Schultz Autogenic Training
11025217|NCT04601532|Active Comparator|Silver sulfadiazine|Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
11025218|NCT04601532|Experimental|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
11025219|NCT04601519||Socialmedia-type 1 diabetes|Participants are recruited via Facebook groups of subjects having type 1 diabetes and being users of Abbott Freestyle to participate in an online anonymous questionnaire.
11025220|NCT04601506|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
11025221|NCT04601506|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
11025222|NCT04601506|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
11025223|NCT04601506|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
11025224|NCT04601493|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
11025225|NCT04601493|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
11025226|NCT04601493|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
11025227|NCT04601493|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
11025228|NCT04601480|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
11025229|NCT04601480|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
11025230|NCT04601480|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
11025231|NCT04601480|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
11025232|NCT04601467|Experimental|AZD5718|Patients will receive once daily oral dose of AZD5718 for 12 months
11025233|NCT04601467|Placebo Comparator|Placebo|Patients will receive once daily oral dose of placebo matched to AZD5718 for 12 months
11025234|NCT04601454|Experimental|Spinal Cord Stimulation|Enrolled subjects are implanted with a spinal cord stimulation system that is activated and programmed to on-label parameters.
11025235|NCT04601441|Other|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
11025236|NCT04601428|Experimental|Investigational Arm|
11025237|NCT04601415||GP Referrals|Patients with HF referred by GP to echo department
11025238|NCT04601415||Echo patients|Non-selected patients attending echo department in hospital
11025239|NCT04601402|Experimental|GEN-001 with avelumab|"Dose Escalation Cohort includes patients with advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination) will be enrolled. 3 or 6 patients will be enrolled per escalating or de-escalating dose levels.
~Dose Expansion Cohort includes patients with advanced or metastatic NSCLC, SCCHN, and UC who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)will be enrolled."
11025240|NCT04601389|Experimental|"GNR-044 (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
11025241|NCT04601389|Active Comparator|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
11025242|NCT04601376|Experimental|Mobile monitoring group|
11025243|NCT04601363||Patients with Personalized SpineRods|The patient is being treated with the patient-specific rod with a surgery date planned
11025244|NCT04601363||Patient with other hardware|Patients with other hardware not patient-specific
11025245|NCT04601350|Experimental|Remimazolam 1|
11025246|NCT04601350|Experimental|Remimazolam 2|
11025247|NCT04601350|Experimental|Remimazolam 3|
11025248|NCT04601350|Experimental|Remimazolam 4|
11025249|NCT04601337||Brachial plexus and/or nerve transfer surgery patients|Patients set to undergo brachial plexus reconstruction or nerve transfer surgery that are 18 years or older.
11025250|NCT04601324|Active Comparator|Dymista (Azelastine hydrochloride and fluticasone propionate)|Participants will receive standard of care, which includes twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride and 50 mcg of fluticasone propionate per spray) separated by 12 hours.
11025251|NCT04601324|Experimental|Fluticasone Propionate and Rupatadine|Participants will administer fluticasone propionate nasal spray once daily (2 sprays in each nostril, 50 mcg fluticasone propionate per spray)and 1 tablet of Rupatadine (10mg) once daily in the morning.
11025252|NCT04601311|Experimental|Guided self-determination|3 to 5 one-hour digital or analogue guided self-determination sessions
11025253|NCT04601311|Active Comparator|Personal support in goal-pursuing|Up to five personal goal pursuing support sessions
11025254|NCT04601298||heteromorphic|
11025255|NCT04601298||atypical|
11025256|NCT04601285|Experimental|Dose Escalation|
11025257|NCT04601272||Breast Cancer Screening|Women between the ages of 35-55 when they received a decision aid for breast cancer screening with no prior diagnosis of breast cancer. These people will see items only pertaining to breast cancer screening.
11025258|NCT04601272||Colon Cancer Screening|Men and women between the ages of 45-75 when they received a decision aid for colon cancer screening with no prior diagnosis of colon cancer. These people will see items only pertaining to colon cancer screening.
11025259|NCT04601272||Prostate Cancer Screening|Men between the ages of 45-74 when they received a decision aid for prostate cancer screening with no prior diagnosis of prostate cancer. These people will see items only pertaining to prostate cancer screening.
11025260|NCT04601272||Lung Cancer Screening|Men and Women between the ages of 50-80 when they received a decision aid for lung cancer screening with no prior diagnosis of lung cancer. These people will see items only pertaining to lung cancer screening.
11025261|NCT04601259|Experimental|Orkla corn plaster with Salicylic acid|
11025262|NCT04601259|Active Comparator|Orkla corn protector without salicylic acid|
11025263|NCT04601233|Experimental|Treatment open label arm|Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.
11025264|NCT04601207|Experimental|Solutech™- TC10|10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic
11025265|NCT04601207|Active Comparator|MCT-diluted Cannabis Product|10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic
11025266|NCT04601194|Experimental|Coaching and Virtual Provider Group|Mental Health Coaching and assigned practice with a Virtual Provider Program
11025267|NCT04601181|Experimental|ThisCART22 cells injection|In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
11025268|NCT04601155||AlloSure Group|Patients will have quarterly AlloSure cfDNA testing (every 3 months) and DSA as part of their post-transplant surveillance for a period of 5 years. For the quarterly AlloSure tests, approximately 20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) to analyze the presence of donor-derived cell-free DNA.
11025269|NCT04601155||Control Group|The control group was never followed with AlloSure as part of their post-transplant follow-up care. Matched control data will originate from UNOS SRTR data.
11025270|NCT04601142||glucocorticoid sensitive (GS) group|
11025271|NCT04601142||glucocorticoid resistance (GR) group|
11025272|NCT04601129||patients|undergoing a minimally invasive nephrectomy, eligible to an Enhanced Recovery After Surgery Program.
11025273|NCT04601116|Active Comparator|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg tablets per day for 2 years
11025274|NCT04601116|Placebo Comparator|Placebo|Placebo tablets 1 per day for 2 years.
11025275|NCT04601077|Active Comparator|Nitric Oxide|Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
11025276|NCT04601077|Placebo Comparator|Placebo|Placebo of Nitric Oxide (NO) lozenges taken twice daily by mouth for 30 days
11025277|NCT04601064|Experimental|Collaborate Care (CC) Model|For patients randomized to the CC arm, in addition to the provider being alerted to the positive Mental Health and Substance Use Disorder screener, the patient will also be assigned to a peer case manager (P-CM). The P-CM will provide longitudinal care for the patient as part of their care management case load. The collaborative care support team will include the P-CM, a consultant addiction psychiatrist and the patient's HIV provider who will implement a stepped care program consisting of: 1) an initial assessment, determination of and implementation of an individualized care plan to provide; 2) psychosocial and medication adherence support; 3) evidence-based brief intervention incorporating motivational interviewing informed strategies; 4) measurement-based care for Mental Health and Substance Use Disorder provided directly by the HIV primary care provider or in collaboration with specialty Mental Health and Substance Use Disorder services.
11025308|NCT04600830|Experimental|Dry Needling Group|Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
11025346|NCT04600557|Experimental|Self-compassion plus compassion from others|Both describing a shameful experience using a self-compassionate prompt and receiving compassionate responses from confederates
11025347|NCT04600557|Active Comparator|Sharing-only control|Describing a shameful experience using a neutral prompt and receiving no verbal responses from confederates
11025278|NCT04601064|No Intervention|Usual Care (UC)|For patients randomized to the UC referral arm, the patient's HIV provider will receive an electronic alert of the patient's positive screen for a Mental Health and Substance Use Disorder. The patient will not be contacted by the P-CM. The provider, at their discretion, will initiate referral to the psychiatry service available onsite. For patients with Substance Use Disorder, providers refer to the in-clinic Substance Use Disorder treatment program that is managed by a nurse practitioner with Substance Use Disorder care experience. Once referred, the patient is seen by the nurse practitioner (separate from the HIV provider) who manages prescription of and assessment of adherence to buprenorphine, including monitoring of urine toxicology results with support from an addiction counselor. The Bartlett Clinic runs 2 substance use groups weekly and has processes for referral to a higher level of Substance Use Disorder care at offsite Substance Use Disorder treatment programs.
11025279|NCT04601051|Experimental|Part 1: NTLA-2001|Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001 on Day 1 and will then be followed for up to 24 months.
11025280|NCT04601051|Experimental|Part 2:|Participants will receive the optimal biologically active dose (OBD) of NTLA-2001 identified in Part 1 as a single dose on Day 1 and will then be followed for up to 24 months.
11025281|NCT04601038|Other|MCI|Individuals with mild cognitive impairment due to Alzheimer's disease
11025282|NCT04601038|Other|Cognitively Normal|Individuals who are cognitively normal but who are at risk for Alzheimer's disease
11025283|NCT04601025|Experimental|Yoghurt|
11025284|NCT04601025|Experimental|Chickpea+Yoghurt|
11025285|NCT04601025|Experimental|Oat+Yoghurt|
11025286|NCT04601012||Patients with COVID19|The patients with previous diagnosis of COVID19
11025287|NCT04601012||Control subjects|Healthy subjects without actual and previous ocular diseases
11025288|NCT04600999|Experimental|Group Avigan|Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.
11025289|NCT04600999|No Intervention|Group Control|Supportive care (symptomatic therapy)
11025290|NCT04600986|Experimental|New oocyte triggering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl) and in addition a repeat dose of 0.1 mg s.c triptorelin (decapeptyl) will prescribed 12 h following the first dose.
11025291|NCT04600986|Other|Routine oocyte trigering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl), 35 h prior to oocyte retrieval.
11025292|NCT04600973|Active Comparator|Surveillance with Technical Assistance|Surveillance will be offered to 3 teams with Technical Assistance (TA) in block randomization. For the 3 sites randomized to Surveillance, the surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported.
11025293|NCT04600973|Active Comparator|Surveillance with EBIP Coaching|Surveillance will be offered to 3 teams with Evidence-Based Infection Prevention Bundle (EBIP) coaching in block randomization. For the 3 sites randomized to Surveillance, the surveillance tool will execute regularly updated reports (continually updated with laboratory data entry of ESKAPE pathogen isolation results), which generates a set of data that will populate series of tables and graphs for each site based on data collection form as previously reported. EBIP involves evidence-based improvements in perioperative hand hygiene, environmental cleaning, vascular care, and patient decolonization. Please refer to our recently published trial and protocol for details on our EBIP strategies to be used during the team-based coaching intervention. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention.
11025294|NCT04600973|Active Comparator|Technical Assistance No Surveillance|TA will have monthly scheduled TA calls (60 minutes each) with each team individually to review and discuss the protocol interventions (as is done in the EBIP group) and allow for a consultation with experts on the peri-operative interventions. Surveillance toolkit will only be used for transmission data collection.
11025295|NCT04600973|Active Comparator|EBIP Coaching No Surveillance|Please refer to our recently published trial and protocol for details on our EBIP strategies to be used during the team-based coaching intervention. Each participating site will receive monthly team-based coaching to establish a multidisciplinary team charged with continuously improving transmission and infection prevention. Surveillance toolkit will only be used for transmission data collection.
11025296|NCT04600960|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take eltrombopag at the indicated dose.
11025297|NCT04600947|Experimental|LP002|Participants will receive LP002 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W) for up to 24 months.
11025298|NCT04600934|Active Comparator|Standard POBA (plain old balloon angioplasty)|The first 50 patients will be pre-treated with standard POBA
11025299|NCT04600934|Experimental|Shockwave|The second 50 patients will be treated primarily with Shockwave
11025300|NCT04600921|Active Comparator|Ertugliflozin|The subject will receive Ertugliflozin 5mg.
11025301|NCT04600921|Placebo Comparator|Placebo|The subject will receive Placebo 5mg.
11025302|NCT04600908||Non-physician staff|All non-physician staff who have had commuting accidents
11025303|NCT04600895|Experimental|Favipiravir|
11025304|NCT04600895|Placebo Comparator|Placebo|
11025305|NCT04600869|Experimental|Nursing Group|Nurses in the control group accepted the other non-fertility (standard) nursing training for the intervention, whereas those in the experimental group accepted the oncofertility training. Based on research ethics and design, a standard education course was held for the control group after completing data collection in the nursing experimental group. We began to recruit patients into the patient experimental group after all nurses completed their educational courses.
11025306|NCT04600843|Experimental|Physical therapy with Patient education|Treated with proper physical therapy treatment protocol according to patient presenting condition and patient education manual
11025307|NCT04600843|Experimental|Physical Therapy without patient Education|Treated with proper physical therapy treatment protocol according to patient presenting condition
11025348|NCT04600544||Severe lumbar disc degeneration|Patients with severe lumbar disc degeneration
11025349|NCT04600544||Mild lumbar disc degeneration|Patients with mild lumbar disc degeneration
11025309|NCT04600830|Active Comparator|Foam Roller Group|The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
11025310|NCT04600817|Experimental|TJ107|
11025311|NCT04600817|Placebo Comparator|TJ107Placebo|
11025312|NCT04600804||All patients registered in the MCL0208 trial|"About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.
~In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only."
11025313|NCT04600791|Experimental|BATwire Kit|Subjects will be implanted using the BATwire Percutaneous Implant Kit
11025314|NCT04600778|Placebo Comparator|placebo|twice daily
11025315|NCT04600778|Experimental|Cavosonstat 5 mg|twice daily
11025316|NCT04600778|Experimental|Cavosonstat 10 mg|twice daily
11025317|NCT04600778|Experimental|Cavosonstat 25 mg|twice daily
11025318|NCT04600765|Other|Diet Before|Feeding subject typical American diet as defined by USDA.
11025319|NCT04600765|Active Comparator|Diet After|Feeding subject diet analogous to typical American diet as defined by USDA, but with known Bisphenol A sources eliminated
11025320|NCT04600752|Experimental|Participants receiving Augmentin (ES)-600|Eligible participants will receive Augmentin (ES)-600 at 90/6.4 mg/kg/day administered in two divided doses, every 12 hours with food for 10 days.
11025321|NCT04600739||AVD Patients|Patients suffering from aortic valve stenosis receiving replacement of the diseased valve using a TAVI procedure.
11025322|NCT04600726||older adults with known mild NCD|Older adults with known mild neuro-cognitive disorders
11025323|NCT04600726||older adults with non-communicable diseases|older adults with non-communicable diseases such as diabetics, hypertension and chronic obstructive airway diseases
11025324|NCT04600726||Older adults with healthy condition|Older adults who are free from neuro-cognitive disorders and non-communicable diseases
11025325|NCT04600713|Experimental|PT-X and IMT|Physiotherapist-led exercise-based cardiac rehabilitation (PT-X) and inspiratory muscle training (IMT).
11025326|NCT04600713|No Intervention|Control|The participants in the control group will be offered PT-X at the end of the control period.
11025327|NCT04600700||CDSS weaning group|This group will be exposed to the CDSS to inform inotrope weaning
11025328|NCT04600687|Experimental|Intervention Arm|Participants will be enrolled in a single arm with a cross over design. Each participant will receive both placebo tablets about 30 minutes apart. Questionnaires will be completed prior to and after each placebo tablet is swallowed.
11025329|NCT04600674|Experimental|delayed cord clamping|DCC performed at 60 sec after birth
11025330|NCT04600674|Experimental|early cord clamping|ECC performed at 15 sec after birth
11025331|NCT04600661|Experimental|control group (Traditional therapy group)|control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training
11025332|NCT04600661|Experimental|Experimental group I (BFR training group)|Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.
11025333|NCT04600661|Experimental|Experimental group II (Neuromuscular training group)|Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises
11025334|NCT04600648|Active Comparator|Weight loss with bariatric surgery|Patients scheduled to undergo bariatric surgery will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
11025335|NCT04600648|Active Comparator|Weight Loss|Patients to receive lifestyle weight loss treatment will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
11025336|NCT04600635||patients with a medical history of obesity|Patients included are subject who entered a structured program of care for their obesity, with or without bariatric surgery.
11025337|NCT04600622|Experimental|Intervention Arm|Participants will receive Rural Diabetes One-Day Education and Care program (R-D1D). A one time, 8-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
11025338|NCT04600622|Active Comparator|Active Comparator|Participants will receive diabetes education materials.
11025339|NCT04600596||Roux-en-Y gastric bypass patients|Severely obese non-diabetic adult female patients scheduled for RYGB.
11025340|NCT04600596||Obese (BMI ≥ 35) controls|Severely obese non-diabetic adult female patients not undergoing surgery.
11025341|NCT04600596||Lean (BMI ≤ 25) controls|Lean healthy non-diabetic adult females.
11025342|NCT04600583|Active Comparator|Alignment according to Functional Alignment philosophy|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System aligned according to Functional Alignment philosophy. This method of implant alignment is defined by a patient's native joint line as well as the soft tissue envelope. Triathlon Total Knee System components will be positioned relative to intra-operative soft tissue laxity assessment. A mobile application (KneeBalancer) will be used to assist surgeon decision making during the dynamic joint balancing surgical step.
11025343|NCT04600583|Active Comparator|Alignment to the patient's natural Mechanical axis|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System neutrally aligned to the Mechanical axis. More specifically, the femoral component and tibial component are aligned 0° to the mechanical axis of each respective limb. Femoral component rotation is fixed to the trans-epicondylar axis. Soft tissue releases are performed at the discretion of the surgeon to achieve balance and full range of motion.
11025344|NCT04600557|Experimental|Self-compassion only|Describing a shameful experience using a self-compassionate prompt and receiving no verbal responses from confederates
11025345|NCT04600557|Experimental|Compassion from others only|Describing a shameful experience using a neutral prompt and receiving compassionate responses from confederates
11025350|NCT04600531|Experimental|Group 1a - Conventional tDCS - Anodal first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
11025351|NCT04600531|Sham Comparator|Group 1b - Conventional tDCS - Sham first|Half of all subjects will receive Conventional tDCS (randomly assigned). Within this Conventional tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
11025352|NCT04600531|Experimental|Group 2a - HD tDCS - Anodal first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive sham (placebo) tDCS.
11025353|NCT04600531|Sham Comparator|Group 2b - HD tDCS - Sham first|Half of all subjects will receive High Definition (HD) tDCS (randomly assigned). Within this HD tDCS condition, half of the subjects will receive sham (placebo) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects will receive active (anodal, real) tDCS.
11025354|NCT04600518||Low risk|good prognosis with surgery only and adjuvant chemotherapy patients
11025355|NCT04600518||Intermediate risk|moderate prognosis
11025356|NCT04600518||High risk|poor prognosis
11025357|NCT04600505|Experimental|Treatment Sequence ABC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment B; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
11025358|NCT04600505|Experimental|Treatment Sequence BCA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment C; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
11025359|NCT04600505|Experimental|Treatment Sequence CAB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment A; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
11025360|NCT04600505|Experimental|Treatment Sequence ACB|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment A; Treatment C; Treatment B) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
11025361|NCT04600505|Experimental|Treatment Sequence BAC|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment B; Treatment A; Treatment C) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
11025362|NCT04600505|Experimental|Treatment Sequence CBA|Participants will be randomized to one of the 6 different treatment sequences. Each participant will receive 3 single-dose treatments of BGF MDI (Treatment C; Treatment B; Treatment A) in 3 treatment periods, with first dose on Day -1 for all treatment periods.
11025363|NCT04600492|Active Comparator|Active Comparator: Active drug group Riociguat|Riociguat 0.5mg、1.0mg、2.5mg
11025364|NCT04600492|Placebo Comparator|Placebo group|Placebo 0.5mg、1.0mg、2.5mg
11025365|NCT04600479|Experimental|prevalence and follow-up of HCV positive patients|"Cross-sectional assessment of prevalence : evaluation of the prevalence of HCV, HBV and HIV viral infections
~Cohort follow-up of HCV positive patients : evaluation of care pathway and barriers to care for hepatitis C"
11025366|NCT04600466||Retrospective Non-Hispanics|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
11025367|NCT04600466||Retrospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
11025368|NCT04600466||Prospective Non-Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
11025369|NCT04600466||Prospective Hispanic|Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
11025370|NCT04600453|Experimental|Training group|"Multicomponent exercise group (intervention): The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day (morning and evening).
~The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RMcombined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital."
11025371|NCT04600453|No Intervention|Usual care group|Usual care
11025372|NCT04600440|Experimental|Plasma treatment|Convalescent plasma 200 ml daily during three days
11025373|NCT04600440|No Intervention|No plasma|Best conventional treatment
11025399|NCT04600284|Experimental|Sequence 6|Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
11025400|NCT04600271||Study Group|Patients over the age of 18 and who undergone major elective non-cardiac abdominal surgery.
11025401|NCT04600258|Experimental|Chocolate Group|Administration of 40g dark chocolate per day, for 2 months
11025402|NCT04600258|No Intervention|Control Group|No intervention and analysis will be performed before and after 2 months
11025403|NCT04600245|Experimental|M-FAM|Will undergo the procedure with assistance from the M-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
11025374|NCT04600427|Experimental|Epidural anesthesia|The patient will be positioned appropriately and the T11-12 (if not accessible we will accept 1-2 spaces above or below) interspace landmarked using established ultrasound guidance techniques. The patient's back will be prepped and draped in a sterile fashion. An epidural catheter will be inserted into the T11-12 interspace with a midline or paramedian approach using a 17G Tuohy needle. Plain preservative free bupivicaine 0.25% will be the local anesthetic used. After a 2-3 mL test dose to rule out intrathecal catheter positioning, a loading dose of 5-8 mL will be administered over 5-10 minutes to further rule out intravascular positioning of the catheter. Successful epidural placement will be defined by catheter insertion and confirmed by sensory blockade assessed by ice or pin prick testing. When correct positioning is confirmed, a continuous infusion of 3 mL per hour of bupivacaine 0.25% plain solution will begin.
11025375|NCT04600414|Active Comparator|Collaborative Care for Mental Health Disorders|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for mental health disorders.
11025376|NCT04600414|Experimental|Collaborative Care for Opioid Use Disorder|Collaborative Care Management is an integrated care model that operationalizes the principles of the chronic care model to improve access to evidence-based treatments for opioid use disorder.
11025377|NCT04600401|Experimental|Participants integrate the Mentis Plus+ program|Mentis Plus+ Program was developed based in The Multifactorial Model of Positive Mental Health and its construction resulted from a systematic literature review and validation through focus group. The duration of the Mentis Plus+ program depends on the number of the six factors to be worked on. The Mentis Plus+ lasts at least 7 weeks (1 session per week, lasting 1 hour) and can work individually or in groups (2-12 people). There will be 2 initial sessions of 1 hour each and 3 sessions for each factor to work with duration of 1 hour. Still, a final session and a follow-up session (3-6 months after the program) will be held.
11025378|NCT04600401|No Intervention|Participants on a waiting list (Control Group)|Participants in the control group were told they were on a waiting list for 3-6 months, as a minimum, before they integrate the Mentis Plus+ program. Given the preventive nature of this study, a waiting list control group won't bring risks or damages to participants
11025379|NCT04600375|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP
~Survey A
~Routine clinic visit
~Verbal consultation only
~Survey B
~Verbal consultation AND Written Action Plan
~Survey C"
11025380|NCT04600375|Experimental|Experimental: Written Action Plan|"INTERVENTION GROUP
~Survey A
~Routine clinic visit
~Verbal consultation AND Written Action Plan
~Survey C"
11025381|NCT04600362|Experimental|Dupilumab|Patients randomized to this arm will receive two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by single 300 mg injection of Dupilumab every 2 weeks (q2w) from week 2 to week 16.
11025382|NCT04600362|Placebo Comparator|Placebo|Patients randomized to this arm will receive identically matching doses of placebo. Two subcutaneous injections of placebo as a loading dose (to mimic the experimental Dupilumab arm) on Day 1 followed by a single injection q2w from Week 2 to Week 16.
11025383|NCT04600349|Experimental|Identity Oriented Psychotrauma Therapy (IOPT)|35 participants will be randomly allocated to the IOPT group. They will attend 10 groups of IOPT every two weeks and they will work 10 Intentions. The groups will be conducted by clinicians or psychotherapists specialized in IOPT. IOPT represents a group treatment developed by Franz Ruppert 20 years ago. It is an effective therapeutic intervention, offering access to less conscious aspects of our psyche, with the help of other persons, named 'representatives.' The method is based on the theory of multigenerational psychotraumatology developed by Ruppert. Although it is very often and widely used all over the world, it has not previously been the subject of randomized controlled trials (RCT), and therefore, its potential efficacy is unknown. In the current study, we want to test this new intervention model on autoimmune thyroiditis.
11025384|NCT04600349|Active Comparator|Treatment as Usual|35 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
11025385|NCT04600336|Experimental|Arm A (low-dose oxybutynin)|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
11025386|NCT04600336|Experimental|Arm B (high-dose oxybutynin chloride)|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
11025387|NCT04600336|Placebo Comparator|Arm C (low-dose placebo)|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm A per physician discretion.
11025388|NCT04600336|Placebo Comparator|Arm D (high-dose placebo)|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm C per physician discretion.
11025389|NCT04600323|Placebo Comparator|Placebo|Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day
11025390|NCT04600323|Experimental|Sodium bicarbonate|Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.
11025391|NCT04600310|Other|Study Arm 1 Conventional Prep/Control|The preoperative preparation for the control group will use ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) that will be applied to the skin using a sponge-on-a-stick method; this solution is widely recognized as optimal. After the alcohol-based solution has evaporated (no less than 3 minutes), the patient extremity is draped for surgery.
11025392|NCT04600310|Other|Study Arm 2 ULTRAPREP Group/Intervention Arm|ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) will be poured into the ULTRAPREP bag which will be placed on the patient's extremity while in the holding area; it will be removed only after scrub time of 3 minutes is complete and the patient has been transferred to the OR, anesthetized, and positioned. The patient is draped only after the solution has evaporated (no less than 3 minutes).
11025393|NCT04600297|Experimental|3D printed resin composite posterior FDP|Three units posterior fixed dental prosthesis made with 3D printed resin composite material
11025394|NCT04600284|Experimental|Sequence 1|Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
11025395|NCT04600284|Experimental|Sequence 2|Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
11025396|NCT04600284|Experimental|Sequence 3|Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
11025397|NCT04600284|Experimental|Sequence 4|Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
11025398|NCT04600284|Experimental|Sequence 5|Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
11025404|NCT04600245|Experimental|CARTOSOUND-FAM|Will undergo the procedure with assistance from the CARTOSOUND-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
11025405|NCT04600232|Experimental|Diagnosis arm|Urine TB-LAM, sputum smear, Gene Xpert, mycobacterial culture
11025406|NCT04600206||Patients|Adult patients across all phases of advanced disease (UICC stage IV solid tumor or stage III lung or ovarian tumor) from diagnosis to terminal stages
11025407|NCT04600206||Caregivers|Adult informal caregivers of patients who are diagnosed with stage IV solid tumors or stage III lung or ovarian tumors
11025408|NCT04600193|Experimental|Phosphate modified diet with organic phosphate|
11025409|NCT04600193|Experimental|Phosphate modified diet with inorganic phosphate|
11025410|NCT04600180||Palliative treatment with immunotherapy|
11025411|NCT04600167|Experimental|Isoniazid and Rifapentine (INH-RPT)|Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
11025412|NCT04600167|Placebo Comparator|Control|Participants in the control arm will receive placebo once weekly for 12 weeks.
11025413|NCT04600154|Experimental|MS-20|4ml, twice, daily
11025414|NCT04600154|Placebo Comparator|Placebo|4ml, twice, daily
11025415|NCT04600141|Active Comparator|Group 1 - Therapeutic anticoagulation|"(I) intravenous UFH started at a dose of 18 IU/kg/h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value; OR
~(II) subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours."
11025416|NCT04600141|Active Comparator|Group 2 - Prophylactic anticoagulation|"(I) subcutaneous UFH 5,000 IU every 8 hours; OR
~(II) subcutaneous LMWH - enoxaparin 40 mg daily."
11025417|NCT04600141|Experimental|Group 3 - Therapeutic anticoagulation with tocilizumab|"(I) Intravenous UFH initiated at a dose of 18 IU / kg / h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value associated with 8 mg / kg / tocilizumab infusion / intravenous dose in a single dose; OR
~Subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours associated with an infusion of tocilizumab 8 mg / kg / dose in a single dose."
11025418|NCT04600141|Experimental|Group 4 - Prophylactic anticoagulation with tocilizumab|"(I) subcutaneous UFH 5,000 IU every 8 hours associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose; OR
~(II) subcutaneous LMWH - enoxaparin 40 mg daily associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose."
11025419|NCT04600128|Active Comparator|Dairy-based Greek yogurt|Plain dairy-based Greek yogurt
11025420|NCT04600128|Active Comparator|Dairy-based cheddar cheese|Mild dairy-based cheddar cheese
11025421|NCT04600128|Active Comparator|Plant-based Greek yogurt|Plain plant-based Greek yogurt
11025422|NCT04600128|Active Comparator|Plant-based cheese|Medium cheddar plant-based cheese
11025423|NCT04600115|Experimental|MRI vs.PET with/without Cardiac disease|Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
11025424|NCT04600102||GROUP 1|Healthy able-bodied individuals with no history of lower extremity trauma.
11025425|NCT04600102||GROUP 2|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
11025426|NCT04600089|Placebo Comparator|Standard of Care|Participants in this group will receive standard of care as well as a saline infusion during the study period.
11025427|NCT04600089|Experimental|Sub-Dissociative Ketamine|Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
11025428|NCT04600076|Experimental|BabyCenter site and the community group|
11025429|NCT04600063|Other|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
11025430|NCT04600063|Experimental|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
11025431|NCT04600050|Active Comparator|Control group: stroke patients with education|
11025432|NCT04600050|Experimental|Experimental: stroke patients with exercise|
11025433|NCT04600037|Active Comparator|Group 1|Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
11025434|NCT04600037|No Intervention|Group 2|Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
11025435|NCT04600024||Piriformis syndrome group|Patients who were diagnosed as PS by diagnostic injection with ultrasound guidance
11025436|NCT04600024||Age and sex match control group|Patients who were excluded from the diagnosis of PS and had anteroposterior (AP) direct radiographic imaging
11025437|NCT04599998||COVID-19 inpatients|Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
11025438|NCT04599985|Experimental|Star excursion balance training (SEBT)|Received star excursion balance training (SEBT) program. Performed 3-trials in all 8 directions of the SEBT grid.
11025868|NCT04596709|Active Comparator|Vitalose|dissolved in water
11025439|NCT04599985|Active Comparator|Simplified star excursion balance training (SSEBT)|Received simplified star excursion balance training (SSEBT) program. Performed 3-trials in all 3 directions of SSEBT grid.
11025440|NCT04599972|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
11025441|NCT04599972|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
11025442|NCT04599959|Experimental|Swab|
11025443|NCT04599959|Experimental|Salivette|
11025444|NCT04599946|Experimental|Experimental formula|Infant and follow-on goat milk formula
11025445|NCT04599946|Active Comparator|Control formula|Infant and follow-on cow milk formula
11025446|NCT04599933|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
11025447|NCT04599933|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
11025448|NCT04599920|Active Comparator|Red meat supplementation providing 25% of protein intake|A diet supplemented with 760 g of cooked and boneless red meat per week, corresponding the average consumption of red meat in Finnish men.
11025449|NCT04599920|Experimental|Red meat mostly replaced with legume-based foods|A diet supplemented with legume-based foods providing 20% of protein intake and with 200 g per week of red meat providing 5% of protein intake.
11025450|NCT04599894|Sham Comparator|control group|Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
11025451|NCT04599894|Experimental|study group|Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
11025452|NCT04599881|Experimental|PTR-01 3 mg/kg|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg every other week for a total of 7 doses.
11025453|NCT04599868|Active Comparator|low dose of magnesium sulfat|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 1g / h ( low dose group
11025454|NCT04599868|Active Comparator|High dose of magnesium sulfat|patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h ( high dose group )
11025455|NCT04599855|Experimental|Esketamine 56 Milligram (mg)|Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale [MADRS] assessment).
11025456|NCT04599855|Experimental|Esketamine 84 mg|Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
11025457|NCT04599855|Experimental|Placebo|Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
11025458|NCT04599842|No Intervention|GROUP SA|Group SA was categorized as the group which spinal anaesthesia alone (SA) was performed
11025459|NCT04599842|Active Comparator|GROUP SA+ESP|Group SA+ESP was categorized as group which SA+ESP block was performed.
11025460|NCT04599829||Orthosis Group 1|Use of AnkleSTRONG100 device
11025461|NCT04599829||Control Group 1|Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
11025462|NCT04599829||Orthosis Group 2|Use of AnkleSTRONG500 device
11025463|NCT04599829||Control Group 2|Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
11025464|NCT04599829||Orthosis Group 3|Use of AnkleSTRONG900 device
11025465|NCT04599829||Control Group 3|Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
11025466|NCT04599816|Active Comparator|levosimendan administration at a dose of 3 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 3 mcg/kg after anesthesia induction
11025467|NCT04599816|Active Comparator|levosimendan administration at a dose of 6 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 6 mcg/kg after anesthesia induction
11025468|NCT04599816|Active Comparator|levosimendan administration at a dose of 12 mcg/kg after anesthesia induction|levosimendan will be administered at a dose of 12 mcg/kg after anesthesia induction
11025469|NCT04599803|Experimental|Participants diagnosed with Obstructive Sleep Apnea|This will be a single arm study of participants that are diagnosed with Obstructive Sleep Apnea (OSA) during the study. Upon confirmation of OSA and prescription of positive airway pressure (PAP) therapy, the participant will begin using the Verily Sleep Apnea (VSA) app to supplement PAP treatment.
11025470|NCT04599790|Experimental|TACE-Len-Sin|TACE combined with lenvatinib and sintilimab.
11025471|NCT04599777|Experimental|TACE-Sor-Tis|TACE combined with sorafenib and tislelizumab.
11025472|NCT04599764|Active Comparator|Anodal Stimulation|Participants will receive anodal tDCS daily for two weeks
11025473|NCT04599764|Active Comparator|Anodal tDCS with Cognitive training|Participants will receive anoale tDCS daily and cognitive training for two weeks
11025474|NCT04599764|Sham Comparator|sham stimulation|Participants will receive cathodal tDCS daily for two weeks
11025475|NCT04599751|Experimental|Hair removal treatment|Trio laser module (Alma Lasers)
11025476|NCT04599738|Placebo Comparator|Wheat muffin|Muffin made with 100% wheat flour
11025477|NCT04599738|Experimental|Finger millet grain muffin|Muffin made with 50% wheat flour and 50% finger millet crushed grain
11025478|NCT04599725||Pregnant people|
11025479|NCT04599699|Experimental|1|"Simultaneously integrated boost or sequential integrated boost
~Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.
~Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy."
11025869|NCT04596709|Active Comparator|isomaltulose|dissolved in water
11025481|NCT04599686|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
11025482|NCT04599673|Experimental|AMNIOGEN|Intraoperative1 kit of AMNIOGEN injection into shoulder joint after RCT repair.
11025483|NCT04599673|Placebo Comparator|Normal saline|Intraoperative 10 ml of normal saline injection into shoulder joint after RCT repair.
11025484|NCT04599660||Low Risk GISTs|This cohort include patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020.
11025485|NCT04599634|Experimental|Experimental treatment: FL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax 800mg PO combination administered to 6 patients for six (6) cycles (28-days each, Cycles 1-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 600mg with magrolimab and obinutuzumab.
11025486|NCT04599634|Experimental|Experimental treatment: MZL, MCL, and CLL Dose-finding|Magrolimab IV with a 1 mg/kg priming dose followed by 30mg/kg loading and maintenance doses + obinutuzumab IV 1000mg + venetoclax ramp-up to target dose of 400mg over 5 weeks (35 days, Cycle 1) administered to 6 patients. Triplet combination of magrolimab + obinutuzumab + venetoclax (target dose, no ramp-up) will continue for five (5) additional cycles (28-days each, Cycles 2-6); further treatment with additional cycles will be response-adapted. Note: DLT assessment of the magrolimab + obinutuzumab + venetoclax triplet will take place during Cycle 1. If =2 patients experience DLT, an additional 6 patients will be enrolled at DL(-1) of venetoclax 200mg with magrolimab and obinutuzumab.
11025487|NCT04599621||patients with unstable angina|This group included patients with frequent anginal attacks, with a burdened history and comorbid conditions.
11025488|NCT04599595||Multiple Scerosis (MS) Group|This group will be composed by 150 MS patients who, consecutively, from the start of the study, will refer to the MS clinic of the Neurology Unit of the Ferrara University Hospital, Italy. The first 50 patients with a PACQoL score ≥ 32 will be asked to be willing to enter the next phase of the study that continues at the Coloproctological Outpatient Clinic of Ferrara University Hospital, Italy with an appointment provided by the neurologist with a pre-established schedule (with written consent).
11025489|NCT04599582|Active Comparator|SP-CL|
11025490|NCT04599582|Active Comparator|Corail|
11025491|NCT04599556|Experimental|T-ALL|
11025492|NCT04599556|Experimental|T-NHL|
11025493|NCT04599556|Experimental|AML|
11025494|NCT04599543|Experimental|Administration of IL3 CAR T-cells|
11025495|NCT04599530|Other|Biomechanical|All experimental tasks will be evaluated on biomechanical outcome measures
11025496|NCT04599530|Other|Psychological|All experimental tasks will be evaluated on psychological outcome measures
11025497|NCT04599530|Other|Physiological|All experimental tasks will be evaluated on biomechanical outcome measures
11025498|NCT04599530|Other|Performance|All experimental tasks will be evaluated on biomechanical outcome measures
11025499|NCT04599504|Experimental|Lisdexamfetamine dimesylate|
11025500|NCT04599504|Placebo Comparator|Placebo|
11025501|NCT04599491|Experimental|INTELLiVENT-ASV with sidestream capnography|Patients randomized into the 'Sidestream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring.
11025502|NCT04599491|Active Comparator|INTELLiVENT-ASV with mainstream capnography|Patients randomized into the 'Mainstream capnography'-arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring.
11025503|NCT04599478|Experimental|Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
11025504|NCT04599478|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.
11025505|NCT04599478|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.
11025506|NCT04599478|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
11025507|NCT04599465|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
11025508|NCT04599452|Experimental|10 patients with recurrent refractory elderly AML were treated|The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
11025509|NCT04599439||High arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass > 5.15 g will be considered at highest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
11025510|NCT04599439||Low arrhythmia risk|Patients with a cardiac magnetic resonance-derived border zone channel (BZC) mass < 5.15 g will be considered at lowest risk for developing ventricular arrhythmias (VA) or sudden cardiac death (SCD).
11025511|NCT04599426|Experimental|Test Group|10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.
11025512|NCT04599387|Active Comparator|Supervised Exercise arm|
11025513|NCT04599387|Placebo Comparator|Usual care arm|
11025514|NCT04599374||high TSH and high FT4|patients with high TSH and high FT4
11025515|NCT04599374||high TSH and low FT4|patients with high TSH and low FT4
11025516|NCT04599374||high TSH and high FT3|patients with high TSH and high FT3
11025517|NCT04599374||high TSH and low FT3|patients with high TSH and low FT3
11025518|NCT04599361||Patients with CHD|"outpatient cardiology practices, hospitals with a cardiology department and hospitals with a cardiology and heart surgery department (n=20) in Germany Patients with chronic coronary heart disease and 2- or 3-vessel or main-vessel disease who are being treated at one of the recruitment sites with a promptly planned intervention for myocardial revascularization who are insured with pre-specified German health insurance companies (BARMER or TK)
~Patients will receive questionnaires."
11025519|NCT04599348|Experimental|Active Ginseng treatment|People with CFS or Fibromyalgia will receive HRG 80 Red GInseng
11025520|NCT04599335|Experimental|HA + Lidocaine|
11025522|NCT04599322|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
11025523|NCT04599309||PRE-MERIDIAN|Patients with a histological or cytological diagnosis of LA-HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx (stage III HPV positive or stage III-IV HPV negative). Patients who are candidates for standard definitive treatment such as surgery followed by radiotherapy +/- chemotherapy, or definite radiotherapy, or definite chemoradiotherapy.
11025524|NCT04599296|Active Comparator|Hip Brace|This group will be assigned to wear a hip brace post surgery.
11025525|NCT04599296|No Intervention|No Intervention|This group will not be assigned a hip brace after surgery.
11025526|NCT04599283|Active Comparator|Symptomatic|"You have to be a male patient.
~You must have a smartphone (iPhone or Android).
~You are at least 35 years old and have already been diagnosed with BPH or Overactive Bladder (OAB) condition OR you are presenting at least one of the following BPH / OAB symptoms:
~1. Frequent or urgent need to urinate 2. Increased frequency of urination at night (nocturia) 3. Difficulty starting urination 4. Weak urine stream or a stream that stops and starts 5. Dribbling at the end of urination 6. Inability to completely empty the bladder 7. Experience urge incontinence - the involuntary loss of urine immediately following an urgent need to urinate"
11025527|NCT04599283|Active Comparator|Asymptmatic|"You have to be a male patient.
~You must have a smartphone (iPhone or Android).
~You are at least 18 years old and have not been diagnosed with BPH or OAB, and you are not presenting any of the above symptoms."
11025528|NCT04599270|Experimental|Intervention group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.
~If adolescent have not risk personality traits, the patient will go out of the study.
~If adolescent have risk personality traits, other tests and scales will be performed to study the intensivity of dependance of substance use and the patient will be randomized.
~If he is randomized in intervention group, the patient will follow PREVENTURE program (2 session of 90 min), within 3 months after inclusion and will meet again the psychologist at 1, 3, 6 and 12 month after sessions to answer the same tests and scales."
11025529|NCT04599270|Active Comparator|Control group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.
~If adolescent have not risk personality traits, the patient will go out of the study.
~If adolescent have risk personality traits, other tests and scales will be performed to study the severity of substance use disorders and the patient will be randomized.
~If he is randomized in control group, the patient will follow routine care and meet again the psychologist at 1, 3, 6 and 12 month after inclusion to answer the same tests and scales."
11025530|NCT04599257|Experimental|Hip and thigh circumference changes|"The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits. All of the study subjects will receive the treatment with the subject device.
~At the baseline visit, MRI imaging will be performed; the subject's weight and hip and thigh circumference will be recorded. Photos of the treated area will be taken.
~The treatment administration phase will consist of four (4) treatments, delivered once a week. The applicator of the device will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
~At the last therapy visit, the subject's weight and hip and thigh circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire to fill in."
11025531|NCT04599244|Experimental|emergency pulpotomy|intervention arm
11025532|NCT04599244|Active Comparator|complete pulp extirpation|control arm
11025533|NCT04599231|Experimental|Study group|"The investigators would perform the following tests preoperatively on the study subjects.
~Hospital Anxiety and Depression Scale (HADS)
~Amsterdam Preoperative Anxiety and Information Scale (APAIS)
~Coping and Adaptation Processing Scale-Short Form (CAPS-SF)
~Quality of Recovery -15 (QOR-15)"
11025534|NCT04599218|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as an ultrasound guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy.
11025535|NCT04599205|Experimental|Microneedling group A|"Patients will be subjected to the following:
~Combined laser (power=3.6 mJ) and topical tranexamic acid (TXA) (one finger unit) gel on the right half of the face.
~Combined microneedling (by dermapen) and topical TXA gel only on the left half. Self application of topical TXA gel (2 finger units) on both sides on daily base."
11025536|NCT04599205|Experimental|Laser group B|"Patients will be subjected to the following:
~Combined laser(power=3.6 mJ) and topical TXA gel (one finger unit) on the right half.
~Laser (power=3.6 mJ) only on the left one."
11025537|NCT04599205|Experimental|Gel group C|patients will be subjected to: Daily application of topical TXA gel (2 finger units) on both face sides.
11025538|NCT04599192||Women Presenting with Cardiac Ischemia|Women presenting with cardiac ischemia as indicated by standard of care non-invasive stress testing with cardiac magnetic resonance (CMR), SPECT myocardial perfusion, and PET myocardial perfusion imaging. This cohort of women must also meet the clinical criteria to undergo coronary angiography. Women may be approached for consent either before or after their coronary angiography procedure.
11025539|NCT04599179||Group 1|Patients underwent placement of a self-expandable metal stent (SEMS)
11025540|NCT04599179||Group 2|Patients underwent to stomach-partitioning gastrojejunostomy
11025541|NCT04599166|Experimental|Participant arm|Participants will be recruited to complete the WWYC intervention.
11025542|NCT04599153|Experimental|High initial|At the one month follow-up, the shunt is adjusted into a high opening pressure (2.5), which is crossed over to 1.0 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
11025543|NCT04599153|Experimental|Low initial|At the one month follow-up, the shunt is adjusted into a low opening pressure (1.0), which is crossed over to 2.5 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
11025753|NCT04597489||Angiography only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
11025544|NCT04599140|Experimental|Treatment (SX-682, nivolumab)|"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.
~COMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
11025545|NCT04599127|Experimental|Mobilization with movement|Mobilization with movement on the shoulder abduction and external rotation
11025546|NCT04599127|Placebo Comparator|Conventional physical therapy|Postural correction exercise and muscle strengthening of the rotator cuff muscle and surrounding muscle on the subacromial region
11025547|NCT04599114|Experimental|VIRTUES Arm|Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
11025548|NCT04599101|Active Comparator|Nose frida nasal suction device|nose frida nasal suction device to clear nasal secretions
11025549|NCT04599101|Active Comparator|Bulb syringe nasal suction device|bulb syringe nasal suction device to clear nasal secretions
11025550|NCT04599088|Experimental|Brain functional MRI with simplified urodynamics|Females with urgency urinary incontinence
11025551|NCT04599075|Experimental|Intravenous Insulin Infusion|Patients will be randomized to discontinuation of the CSII pump intrapartum and initiation of IV insulin infusion per hospital protocol.
11025552|NCT04599075|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Patients will be randomized to continuation of their CSII pump intrapartum and will be managed in accordance with the CSII hospital protocol.
11025553|NCT04599062|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy
~Talimogene Laherparepvec Dose Levels:
~Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly
~Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks"
11025554|NCT04599049|Other|six sessions of online classes and training day camps in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by training day camps in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.
~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
11025555|NCT04599036|Experimental|Feasibility|To explore if the feasibility of adding an EMG controlled device to the acute rehabilitation for stroke subjects with severe arm deficit.
11025556|NCT04599023||MS patients including CIS|Patients with a diagnosis of MS, including Clinically Isolated Syndrome (CIS), who have the ability to understand the audio and visual instructions for the MSPT modules and whose visual function that does not preclude an ability to see the screen of the MSPT tool.
11025557|NCT04599010|Active Comparator|Calorie-restricted arm|Permissive feeding volume restriction to 110 ± 10 mL/kg/day without increasing the milk calorie density, for 2-weeks
11025558|NCT04599010|Active Comparator|Standard feeding|The standard feeding approach will include an oral feeding volume goal of 150 ± 10 mL/kg/day during the 2-week study period
11025559|NCT04598997||600 patients involved in the prospective study|These patients will be contacted by telephone follow-up, offered participation in the study and sent the information and non-opposition letter. In case of refusal, data will not be used.
11025560|NCT04598997||1000 patients involved in a non-human study|To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiograms performed in a stable disease context will also be identified.
11025561|NCT04598984||Low levels of serum adipokines|
11025562|NCT04598984||High levels of serum adipokines|
11025563|NCT04598971||Cystitis|Patients with lower UTI will be included in this group
11025564|NCT04598971||Pyelonephritis|Patients with higher UTI will be included in this group
11025565|NCT04598958|Experimental|IMPROVE|A cluster of 6 health facilities are to receive the IMPROVE Intervention. The IMPROVE intervention includes: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees with particular attention to HIV-positive women to minimize loss to follow-up.
11025566|NCT04598958|No Intervention|Standard of care|A cluster of 6 health facilities receive Standard of Care. Routine health facility services offering the national standard of care for pregnant and breastfeeding women in Lesotho
11025567|NCT04598945|Experimental|Adults|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
11025568|NCT04598945|Experimental|Children|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
11025569|NCT04598932||1: Normal Controls|Patients with normal corneas without any prior surgery to serve as the control group
11025570|NCT04598932||2 Keratoconus|Patients with various stages of keratoconus
11025571|NCT04598932||3: LASIK|Patients with normal corneas who are undergoing laser in situ keratomileusis (LASIK)
11025572|NCT04598932||Group 4: PRK|Patients with normal corneas who are undergoing photorefractive keratectomy (PRK)
11025573|NCT04598932||5: SMILE|Patients with normal corneas who are undergoing small incision lenticular extraction (SMILE)
11025574|NCT04598932||6: CXL|Patients with keratoconus who are undergoing corneal cross-linking (CXL)
11025575|NCT04598919|Active Comparator|Saracatinab|saracatinib 125 mg once daily by mouth for 24 weeks
11025577|NCT04598906|Experimental|Virtual environment rehabilitation - Paper-pencil rehabilitation|The participants in this arm completes Virtual environment rehabilitation as the first condition and then crossover to Paper-pencil rehabilitation.
11025578|NCT04598906|Experimental|Paper-pencil rehabilitation - Virtual environment rehabilitation|The participants in this arm completes Paper-pencil rehabilitation as the first condition and then crossover to Virtual environment rehabilitation.
11025579|NCT04598893||Teplizumab|Participants who received teplizumab in the PROTECT study
11025580|NCT04598893||Placebo|Participants who received placebo in the PROTECT study
11025581|NCT04598880|Experimental|Pleinvue|Subjects receive polyethylene glycol + ascorbate (PEG1A) as laxative treatment for colonoscopy preparation.
11025582|NCT04598880|Experimental|Citrafleet|Subjects receive sodium picosulfate + magnesium citrate (PSCM) as laxative treatment for colonoscopy preparation.
11025583|NCT04598867|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner for 32 weeks.
11025584|NCT04598867|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, and dinner for 8 weeks.
11025585|NCT04598867|Active Comparator|Afobazol 30 mg/day|Patients assigned to the Afobazol 30 mg/day group will receive 1 tablet of Afobazol (10 mg) before breakfast, before lunch and before dinner for 8 weeks.
11025586|NCT04598854|Experimental|Treatment group|The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
11025587|NCT04598854|Sham Comparator|Control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
11025588|NCT04598828|Experimental|Treatment 1|Participants will receive Experimental treatment 1 stimulation for a duration of 12 weeks, twice daily for 19 minutes
11025589|NCT04598828|Experimental|Treatment 2|Participants will receive Experimental treatment 2 stimulation for a duration of 12 weeks, twice daily for 19 minutes
11025590|NCT04598815|Experimental|Sirolimus and Placebo|Sirolimus for 12 weeks, followed by a 12-week wash-out period, and by a 12-week follow-up period.
11025591|NCT04598815|Experimental|Placebo and Sirolimus|Placebo for 12 weeks, followed by a 12-week wash-out period, and by a 12-week treatment with Sirolimus.
11025592|NCT04598802||Covera Plus|
11025593|NCT04598763|Other|classic group|"the classic group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove)"
11025594|NCT04598763|Other|intensive|"the intensive group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce)."
11025595|NCT04598737|Experimental|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
11025596|NCT04598737|Experimental|Lithium disilicate|Lithium disilicate laminate veneer treatment
11025597|NCT04598724||Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
11025598|NCT04598724||Care Givers for Bladder Cancer Patient Participants|Participants will be scheduled for one-on-one interviews that will occur over Zoom or telephone.
11025599|NCT04598711|Experimental|Remote Limb Ischemic Conditioning (RLIC)|"RLIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 200 mmHg on the more involved thigh. RLIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RLIC is performed on visits 1-14.
~Interventions:
~Behavioral: RLIC
~Behavioral: Muscle power training
~Behavioral: Balance training
~Behavioral: Treadmill training"
11025600|NCT04598711|Sham Comparator|Sham Conditioning|"Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved thigh. Sham involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. Sham conditioning is performed on visits 1-14.
~Interventions:
~Behavioral: RLIC
~Behavioral: Muscle power training
~Behavioral: Balance training
~Behavioral: Treadmill training"
11025601|NCT04598672|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
11025602|NCT04598646|Experimental|Cario-Oncology Rehabilitation (CORE)|"CORE consists of exercise therapy, CVD risk factor management for the first 6 months and behavioural support for 2 years.
~Exercise therapy: Staff will prescribe and deliver a standardized, yet individually tailored (based on CPET results), aerobic exercise programs consisting of two days of supervised, facility-based high-intensity interval training (HIIT) and one day of supervised home-based moderate-intensity continuous training (MICT) per week. Exercise HRs and durations will be monitored using an accurate commercially available wrist-worn HR monitor and PA tracker (e.g., Apple watch).
~CVD risk factor management: CVD risk factors will be assessed and treated according to Canadian guidelines.
~Behavioural support: All participants will receive a planned sequence of educational and instructional material via email and ongoing PAYA-CS tailored education and peer support during the follow-up period using a peer support online system."
11025603|NCT04598646|Active Comparator|Support|The Support group will receive the behavioural support only. The timing and nature of all education, information, and Young@Heart-based peer support provided to Support participants will be identical to what is provided to CORE participants. The key difference in the long-term behavioural support strategy between CORE and Support participants is how weekly exercise goals are defined. Unlike the CORE participants who will be encouraged to use the PAI Score, Support participants will be given the challenge of meeting and maintaining the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).
11025646|NCT04598334||COVID-19 positive by RT-PCR|specified number of COVID-19 positive patients will be followed up from admission to outcome (discharge/death/referral). Blood samples will be tested at different time points; cytokines and stool microbiota will be tested at the end of the study and we will analyze the study findings.
11025754|NCT04597489||Subgroup ACS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.
~This subgroup consists of patients presenting with ACS."
11025870|NCT04596709|Placebo Comparator|sucrose|dissolved in water
11025604|NCT04598646|Active Comparator|Passive Behavioural Support (PBS) Groups|All PBS cohort participants will receive the same wrist-worn HR monitor and PA tracker as the CORE and Support participants. However, PBS participants will be blindly randomized to one of two passive behavioural support interventions (PBS1 and PBS2). PBS1 participants will be asked to download the same PAI Health application as CORE participants and will similarly be given the challenge of meeting and maintaining a weekly PAI Score ≥100 throughout the 18-month follow-up period. PBS2 participants will be asked to download and use the Map My Walk (Under Armour, Baltimore) application and will be challenged to meet and maintain the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week). PBS participants will not receive any additional interventions and will be followed up with and reassessed at 12- and 24-months.
11025605|NCT04598633|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
11025606|NCT04598633|Placebo Comparator|Placebo-lozenges (BioGaia)|
11025607|NCT04598607|Experimental|Hypidone Hydrochloride 60mg|30mg(10mg×3) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
11025608|NCT04598607|Experimental|Hypidone Hydrochloride 80mg|40mg(10mg×4) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
11025609|NCT04598607|Experimental|Hypidone Hydrochloride 100mg|50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
11025610|NCT04598607|Placebo Comparator|Placebo 60mg|3 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
11025611|NCT04598607|Placebo Comparator|Placebo 80mg|4 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
11025612|NCT04598607|Placebo Comparator|Placebo 100mg|5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
11025613|NCT04598594|Experimental|Nicotine patch|
11025614|NCT04598594|Placebo Comparator|Placebo patch|
11025615|NCT04598581|Active Comparator|Low Dose Radiation Therapy (LD-RT)|
11025616|NCT04598581|Sham Comparator|Sham irradiation|
11025617|NCT04598568||balanSys UNI knee prosthesis|Participants treated with a balanSys® UNI knee prosthesis
11025618|NCT04598542|Experimental|TA injection followed by LOR injection|IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.
11025619|NCT04598542|Experimental|LOR injection followed by TA injection|IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.
11025620|NCT04598529|Active Comparator|A2 milk|A2 milk, organic, 200ml, twice daily
11025621|NCT04598529|Placebo Comparator|Conventional milk|Pasteurized semi-skimmed milk, organic, 200ml, twice daily
11025622|NCT04598503||cases|All the babies admitted to the hospital with congenital anomalies during this period were included
11025623|NCT04598503||control|newborns without congenital anomalies
11025624|NCT04598490|Experimental|Healed extraction site|Old Extraction Space
11025625|NCT04598490|Experimental|unhealed extraction site|Recent Extraction space
11025626|NCT04598477|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
11025627|NCT04598464|Experimental|Exercise group|The home-based training program
11025628|NCT04598464|No Intervention|control group|All patients participated in a one-session educational program conducted by the investigators at each clinic.
11025629|NCT04598451|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
11025630|NCT04598451|Experimental|placebo|patients receiving placebo on top of prednisone
11025631|NCT04598438|Experimental|Music intervention treatment group|Participants attending the music behavioral early intervention program
11025632|NCT04598438|Active Comparator|Arts and crafts active control group|Participants attending the arts and crafts developmental enhancement program
11025633|NCT04598425|Experimental|Cognitive behavioral therapy for insomnia (CBTi)|
11025634|NCT04598412||Mexican sample|Aged >60 years (n = 187)
11025635|NCT04598412||German sample|Aged >75 years (n = 97)
11025636|NCT04598412||Northamerican sample|Aged >60 years (n = 200)
11025637|NCT04598412||British sample|Aged >70 years (n = 38)
11025638|NCT04598399|Experimental|MBRP program:|
11025639|NCT04598399|Active Comparator|Standard care|
11025640|NCT04598386|Experimental|PR Lotion Topical Solution|Approximately 50 grams of PR Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. This lotion will be applied once during the 4th of session of their PR Lotion Phase and will remain on the skin for approximately 4.5 hours.
11025641|NCT04598386|Placebo Comparator|Placebo Lotion Topical Solution|Approximately 50 grams of the Placebo Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. The only difference in ingredients for this Placebo Lotion will be the exclusion of the sodium bicarbonate ingredient. This lotion will be applied once during the 4th of session of their Placebo Lotion Phase and will remain on the skin for approximately 4.5 hours.
11025642|NCT04598373||IDT patients|Allocated to an IDT program
11025643|NCT04598373||Non-IDT patients|Not allocated to an IDT program
11025644|NCT04598360|Experimental|Experimental: Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS
11025645|NCT04598347||Pregnant women diagnosed with SARS-CoV-2|Pregnant women diagnosed with SARS-CoV-2 infection(by PCR on nasopharyngeal aspirate or serology)that have an indication to perform an invasive technique(chorionic biopsy or amniocentesis) along thegestation.The sample size will depend on the duration of theSARS-CoV-2 pandemic.Initially we propose a study period of 18months in which we would have an approximate total of 225pregnant women with indication of invasive technique.It is planned to conduct a PCR study for SARS-CoV-2 in amniotic fluid or chorionic villi to thosepregnant women diagnosed with SARS-CoV-2 infection(approximately 5% of the total pregnant womenwith indication of invasive technique (11-12 pregnant women)).This determination is made as part of theroutine clinical practice in the context of the study of screening for perinatal infections
11025750|NCT04597502|Experimental|Oral TC, Topical Placebo|Oral TC, Topical Placebo on both forearms and dorsal hands
11025751|NCT04597502|Experimental|Oral TC, Topical TC|Oral TC, Topical TC on both forearms and dorsal hands
11025647|NCT04598321|Experimental|Planned Therapy|Talazoparib monotherapy as 1 mg capsule orally on a daily basis for three cycles, defined as a 21-day period, prior to surgery. Volunteers will continue treatment to complete three cycles, unless disease progression or unacceptable toxicity occurs.Volunteers who complete neoadjuvant treatment with talazoparib should undergo surgical cytoreduction within three weeks of their last dose of talazoparib. All volunteers should then undergo standard of care adjuvant therapy using carboplatin and paclitaxel. For volunteers, who agree to continue talazoparib as maintenance therapy, treatment should begin three weeks (+/- 2 weeks) from the end of adjuvant chemotherapy or after cytoreductive surgery alone.
11025648|NCT04598308||patients undergoing invasive assessment of the microcirculation|All patients are eligible for participation in this registry if they are undergoing coronary angiography with or without coronary intervention for any reason and if an indication for the foreseen intracoronary physiologic measurements is present according to the discretion of the investigating operator. There are no specific exclusion criteria other than contraindications for physiologic measurements in general.
11025649|NCT04598295|Experimental|microbial consortia (DS-01)|DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
11025650|NCT04598295|Placebo Comparator|placebo|Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
11025651|NCT04598282|Placebo Comparator|Control Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID (four times daily) for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
11025652|NCT04598282|Active Comparator|Treatment Arm|All subjects enrolled in the study will receive the standard of care that includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion). The treatment arm will also receive the placement of PROKERA SLIM for 5-7 days. A second PROKERA SLIM may be applied based on investigator's discretion. For patients with bilateral involvement only the worse eye will be enrolled for the treatment arm.
11025653|NCT04598269|Experimental|ATI-1777 topical solution 2.0% w/w|ATI-1777 topical solution 2.0% w/w, twice daily
11025654|NCT04598269|Placebo Comparator|Vehicle|Vehicle topical solution, twice daily
11025655|NCT04598256||Children who underwent endoscopic procedures|"Children between the ages of 1-18 who were underwent endoscopic procedures
~Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure
~Patients who volunteered to study"
11025656|NCT04598243|Experimental|Treatment of CFS/FMS with the nutritional combination|
11025657|NCT04598230|Active Comparator|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy and one of three study medications (fluoxetine, sertraline, or escitalopram).
11025658|NCT04598230|Active Comparator|Cognitive behavioral therapy (CBT)|Participants randomized to this arm will receive cognitive behavioral therapy (CBT) only
11025659|NCT04598204|Experimental|Treatment Arm|To treat the enrolled patients with oral rapamycin at an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
11025660|NCT04598191|Placebo Comparator|Control group|Participants in this group are administered inhaled normal saline.
11025661|NCT04598191|Experimental|iloprost group|Participants in this group are administered inhaled iloprost.
11025662|NCT04598178||Taiwan Cohort|For normative Taiwan people, cognitive function will be assessed by the Taiwan version of questionnaire Qmci (Qmci-TW) on Day 0, Day 1, Day 7, Day 180.
11025663|NCT04598165|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages.
11025664|NCT04598165|No Intervention|No SMS Control|Control receiving standard of care.
11025665|NCT04598152|Experimental|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
11025666|NCT04598139||Study group|
11025667|NCT04598126|Active Comparator|Traditional physical therapy|Traditional physical therapy
11025668|NCT04598126|Experimental|patient education manual +traditional physical therapy|Patient education manual +traditional physical therapy
11025669|NCT04598113|Active Comparator|Effective Traction/Sham Traction|Group of patients treated firstly with Effective Traction then with Sham Traction
11025670|NCT04598113|Sham Comparator|Sham Traction/Effective Traction|Group of patients treated firstly with Sham Traction then with Effective Traction
11025671|NCT04598100|Active Comparator|FOCUS-EC|"FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment & combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's home activity, primary activity and discussion, selection of a new home activity, and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions."
11025752|NCT04597489||Angiography + FFR|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
11025794|NCT04597203|Experimental|split face - left side|
11025795|NCT04597203|Active Comparator|split face - right side|
11025672|NCT04598100|No Intervention|Web-Based Family Education|Families in the WB condition will be provided access to online educational materials covering topics such as typical child development, effects of early childhood separations, common child reactions to family stress, and the importance of self-care. CDM families in this condition will also have access to the standard services that are available to OEF/OIF/OND veterans through the VHA system, TriCare, and California Department of Veterans Affairs.
11025673|NCT04598087|Experimental|Prehabilitation|"Tailored exercise prescription involving aerobic and resistance training, supported by a clinical exercise physiologist.
~Tailored nutritional recommendations (including for those at risk of malnutrition)"
11025674|NCT04598087|No Intervention|Usual Care|Usual care across the perioperative period is managed by a multidisciplinary team and involves specific protocols on items such as early mobilization, prophylaxis against thromboembolism, routine postoperative intensive care admission, and pain management
11025675|NCT04598074|Experimental|Opioid Package Prototype (OPP)|Oxycodone 5mg tablets dispensed in the Opioid Package Prototype (OPP) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
11025676|NCT04598074|Active Comparator|Usual Care (standard amber vial)|Oxycodone 5mg tablets dispensed in the standard amber vial (usual care) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
11025677|NCT04598061||Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery|Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery
11025678|NCT04598048||EMMACE 3|Participants who were recruited to the EMMACE 3 study and have agreed to contact for further research.
11025679|NCT04598035||Primary Group|Patients with chronic low back pain that candidates them for surgical implant of a SCS device, and received a permanent SCS device.
11025680|NCT04598035||Control Group|Patients with chronic low back pain that are candidates for a surgical implant of a SCS device and do not receive a permanent SCS device after trial leads are placed.
11025681|NCT04598022||vegan|subjects having a vegan nutrition pattern for at least the last 3 months
11025682|NCT04598022||vegetarian|subjects having a vegetarian nutrition pattern for at least the last 3 months
11025683|NCT04598022||omnivores|subjects having a omnivore nutrition pattern for at least the last 3 months
11025684|NCT04598009|Experimental|Treatment (binimetinib, imatinib)|Patients receive binimetinib PO BID on days 1-28 and imatinib PO QD on days 1-28. Cycles repeat every 28 days
11025685|NCT04597996|Experimental|Web Based Education|A pre-test will be applied. Web-based education will be conducted. The post-test will be applied 3 months after Web-based education is completed.
11025686|NCT04597996|No Intervention|No Intervention Group|The control group will not have any intervention during the study.
11025687|NCT04597983|Experimental|2S-hesperidin|This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks
11025688|NCT04597983|Placebo Comparator|Placebo|This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks
11025689|NCT04597970|Experimental|cTACE-HAIC(oxaliplatin and raltitrexed)|Patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle
11025690|NCT04597957|Experimental|Fresh Rx Intervention group|The Fresh Rx intervention group will receive up to 8 visits to the community based farmers market with $10 incentive for fruits and vegetables at each visit.
11025691|NCT04597957|Active Comparator|Diabetic Standard of Care Control group|Diabetic standard of care control group will receive no incentive for the community based farmers market.
11025692|NCT04597944||Participants with Hereditary or Acquired Angioedema|Participants older than 18 years that are diagnosed with Hereditary or Acquired Angioedema and treated by lanadelumab.
11025693|NCT04597931|Experimental|SC Romosozumab 210 mg/monthly|SC Romosozumab 210 mg/monthly
11025694|NCT04597931|Active Comparator|IV Zoledronic acid 5 mg|IV Zoledronic acid 5 mg
11025695|NCT04597918|Experimental|Faricimab|
11025696|NCT04597905||CD Participants|Participants diagnosed with CD from the 7 participating countries will take part in survey to collect data regarding their preferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
11025697|NCT04597905||UC Participants|Participants diagnosed with UC from the 7 participating countries will take part in survey to collect data regarding theirpreferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
11025698|NCT04597879||Severe traumatic brain injury|
11025699|NCT04597879||Severe trauma without brain trauma|
11025700|NCT04597879||Healthy controls|
11025701|NCT04597866||CRPS|
11025702|NCT04597840|Experimental|biosynthetic mesh group|Patient will undergo incisional hernia repair with biosynthetic mesh reinforcement. Based on the discretion of the surgeon, two types of biosynthetic mesh from different brand can be used: the Phasix mesh from BARD or the BioA mesh from GORE. These two biosynthetic meshes are resorbable, which means they are gradually absorbed by the body.
11025703|NCT04597840|Other|standard of repair group|Patient will undergo incisional hernia repair according to the standard of repair, which is simple suture or mesh reinforcement (using synthetic or biological meshes).
11025704|NCT04597827||Semantic dementia|Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)
11025705|NCT04597827||Alzheimer's disease|NIAAA 2011 criteria
11025706|NCT04597827||Control|MMSE above 27, no neurological or psychiatric disorder
11025707|NCT04597814||interstitial lung disease patients|interstitial lung disease patients who need lung transplantation
11025708|NCT04597814||non- interstitial lung disease patients|non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
11025709|NCT04597801|Experimental|Fluorescein sodium|A single dose of fluorescein sodium is applied before brain tumor resection. 20-40 minutes prior to the planned tumor resection, a bolus of 5 mg per kg body weight is administered intravenously, staining tumor tissue with fluorescent dye to visualize tumor cells.
11025710|NCT04597788|Experimental|Protein supplemented very low calorie diet program|The lifestyle intervention using protein supplemented very low calorie meals will be implemented with individual counseling sessions for 12 months. Initial intensive weight loss stage will be delivered during the first 4 month period with total meal replacement to partial meal replacement using protein supplemented very low calorie meals. During the weight loss maintenance stage, regular intermittent very low calorie meal replacement one week per month will be delivered for the entire period. Mobile counseling will be offered to help patients achieve weight loss as well as weight loss maintenance.
11025711|NCT04597788|Active Comparator|Conventional low calorie diet program|The conventional low calorie diet program will be offered to participants assigned to control group using educational material and individual counseling sessions for 12 months. Mobile counseling will be also offered for weight loss and weight loss maintenance.
11025712|NCT04597775|Experimental|Arm 1 hydroxychloroquine 800mg day 1 and hydroxychloroquine 400mg day 2-5|hydroxychloroquine 800mg (400mg twice daily) given orally on day 1, (loading dose) hydroxychloroquine. Then 400mg (200mg 2 tablets) on day 2,3, 4 and 5.
11025713|NCT04597775|Active Comparator|Arm 2 hydroxychloroquine 400mg day 1 and hydroxychloroquine 200mg day 2-5|hydroxychloroquine 400mg (200mg twice daily) Given orally first day (loading dose), then 200mg once daily on day 2,3, 4 and 5.
11025714|NCT04597775|No Intervention|No Intervention|No Intervention- SARS-CoV-2 surveillance Standard control measures in the country of interest such as self isolation, good personal hygiene and good nutrition.
11025715|NCT04597762|Experimental|right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye
11025716|NCT04597762|Experimental|left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone|Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye
11025717|NCT04597749|Experimental|Concurrent PSG, HSAT, and Screener App Test|Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone.
11025718|NCT04597736|Experimental|cohort|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
11025719|NCT04597723|Experimental|80% oxygen|80% oxygen given group
11025720|NCT04597723|Experimental|60% oxygen|60% oxygen given group
11025721|NCT04597723|No Intervention|routine hospital care|The patients in this group received routine hospital care.
11025722|NCT04597697|Experimental|Subjects with normal hepatic function|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
11025723|NCT04597697|Experimental|Subjects with mild hepatic impairment, child-pugh grade A|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
11025724|NCT04597697|Experimental|Subjects with moderate hepatic impairment, child-pugh grade B|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
11025725|NCT04597697|Experimental|Subjects with severe hepatic impairment, child-pugh grade C|The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.
11025726|NCT04597684|Active Comparator|Treatment/Intervention|Total Knee Arthroplasty (TKA) with cementless knees
11025727|NCT04597684|Active Comparator|Control|Total Knee Arthroplasty (TKA) with cemented knees
11025728|NCT04597671|Experimental|Arm A|Durvalumab with low-dose PCI
11025729|NCT04597671|Active Comparator|Arm B|Durvalumab with observation
11025730|NCT04597658|Active Comparator|Conventional rehabilitation|
11025731|NCT04597658|Experimental|Body weightsupported treadmill training|
11025732|NCT04597645|Experimental|Elastic band (EB)|EB group participants who are attending sheltered employment will received Elastic Thera band training program two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainer) over 16 weeks for a total of 32 sessions.
11025733|NCT04597645|No Intervention|Control group (CG)|Control group participants will receive usual care.
11025734|NCT04597632|Experimental|brolucizumab 6 mg|Participants will receive brolucizumab 6 mg/0.05 mL solution by intravitreal injection in a Treat-to-Control regimen with injection intervals from 4 up to 20 weeks. Intervals may be changed in steps of 4 weeks at a time per investigators' decisions determined by the disease activity.
11025735|NCT04597619|No Intervention|Pre-Implementation Cohort|Cohort undergoing PCNL prior to implementation of the novel nonopioid pathway
11025736|NCT04597619|Experimental|Implementation Cohort|Cohort undergoing PCNL with implementation of the novel nonopioid pathway
11025737|NCT04597606||Cohort|"All patients will be performed a basal test that consist on continuous cyclergometer exercise, under constant load, with spontaneous breathing, after that the same exercise protocol performed will be carried out under non-invasive ventilation (NIV test). Parameters will be titrated previosuly.
~Finally the patient will perform the same exercise at a constant load under high flow oxygen therapy ( HFNC test)."
11025738|NCT04597593||ADR Group|ISTH bleeding scale Major Bleeding
11025739|NCT04597593||Control Group|No ADR, No Treatment Failure
11025740|NCT04597593||Treatment Failure Group|Recurrent MI, Ischemic stroke, Other thromboembolic disorders
11025741|NCT04597567|Active Comparator|Metal removal|
11025742|NCT04597567|No Intervention|Metal retention|
11025743|NCT04597554|Experimental|Cranberry|4 oz. cranberry beverage (breakfast) and 2 chewable cranberry gummies (lunch) per day for 8 weeks.
11025744|NCT04597554|Placebo Comparator|Placebo|4 oz. placebo beverage (breakfast) and 2 chewable placebo gummies (lunch) per day for 8 weeks.
11025745|NCT04597541|Experimental|1|AK112
11025746|NCT04597528||Elective induction group|Nulliparous singleton gestations undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age
11025747|NCT04597515|Experimental|Robot Reduction|The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .
11025748|NCT04597502|Placebo Comparator|Oral Placebo, Topical Placebo|Oral Placebo, Topical Placebo on both forearms and dorsal hands
11025749|NCT04597502|Experimental|Oral Placebo, Topical TC|Oral Placebo, Topical TC on both forearms and dorsal hands
11025871|NCT04596709|Placebo Comparator|glucose|dissolved in water
11025755|NCT04597489||Subgroup CCS|"Patients were stratified by index diagnoses, i.e. acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) according to the index hospital admission diagnosis.
~This subgroup consists of patients presenting with CCS."
11025756|NCT04597489||Subgroup revascularization|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.
~This subgroup consists of patients undergoing revascularization after an angiography (with or without FFR) during the index hospital stay."
11025757|NCT04597489||Subgroup optimal medical therapy|"Patients were stratified by the type of treatment, i.e. percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or conservative management with optimal medical therapy (OMT) alone, based on the procedure codes during the index hospital stay.
~This subgroup consists of patients undergoing optimal medical therapy after an angiography (with or without FFR) during the index hospital stay."
11025758|NCT04597476|Experimental|Fucoidan Group|Fucoidan powder at 4.4 g per sachet (dose) for oral administration. Fucoidan 4.4 g, PO, bid for 24 weeks
11025759|NCT04597476|Placebo Comparator|Potato starch|Potato starch at 4.4 g per sachet (dose) for oral administration. Potato starch 4.4 g, PO, bid for 24 weeks
11025760|NCT04597463|Experimental|Endometrial injury|Endometrial injury before the embryo transfer of a frozen cycle
11025761|NCT04597450|Experimental|Lu AG06466|
11025762|NCT04597450|Placebo Comparator|Placebo|
11025763|NCT04597437|Experimental|Zanamivir|In the treatment group, participants will receive 600 mg for adults and 12 mg/kg in children intravenously every twelve hours for 5 days adjusted for renal function.
11025764|NCT04597437|Placebo Comparator|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
11025765|NCT04597424|Experimental|doxycycline and Bexsero® vaccine|-doxycycline will be taken by participants as PEP (prophylaxy post exposition) and participants will received Meningococcal B vaccine (Bexsero®) at D0 and M2
11025766|NCT04597424|Experimental|doxycycline|-doxycycline will be taken by participants as PEP (prophylaxy post exposition)
11025767|NCT04597424|Experimental|Bexsero® vaccine|-Meningococcal B vaccine (Bexsero®) at D0 and M2
11025768|NCT04597424|No Intervention|No treatment|-no doxycycline and no Bexsero® vaccine
11025769|NCT04597411|Experimental|Group A (Men with castrate levels of testosterone)|Men with castrate levels of testosterone that have received prior cytotoxic chemotherapy and/or novel androgen axis drugs will receive a dose of 225^Ac-PSMA-617 via intravenous injection no more frequently than every 8 weeks (+/- 1 week) for no more than 6 cycles.
11025770|NCT04597411|Experimental|Group B (Men previously treated with lHRH agonists or orchiectomy and primary anti-androgen therapy)|Men previously treated with lHRH agonists or orchiectomy and primary anti-androgen therapy that have not received prior cytotoxic chemotherapy or novel androgen axis drugs will receive a dose of 225^Ac-PSMA-617 via intravenous injection no more frequently than every 8 weeks (+/- 1 week) for no more than 6 cycles.
11025771|NCT04597398||Group A|A total of 39 patients underwent the procedure prior to June 2019
11025772|NCT04597398||Group B|11 patients underwent the procedure as of June 2019
11025773|NCT04597385||Long-term Follow-Up|No intervention.
11025774|NCT04597372|Experimental|Tamsulosin|
11025775|NCT04597372|Placebo Comparator|Placebo|
11025776|NCT04597359|Experimental|Arm A (green tea catechins)|Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
11025777|NCT04597359|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO BID for up to 6 months.
11025778|NCT04597333|Active Comparator|2nd Dinoprostone.|Women induced with a second dinoprostone insert.
11025779|NCT04597333|Active Comparator|Cervical ripening balloon.|Women induced with a cervical ripening balloon.
11025780|NCT04597320|Active Comparator|Fentanyl group|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
11025781|NCT04597320|Experimental|Esketamine group|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
11025782|NCT04597307||IN.PACT™ Admiral™ DCB Cohort|De novo patients not previously treated with a DCB who are successfully treated with the IN.PACT™ Admiral™ DCB (ability to cross the target lesion).
11025783|NCT04597294|Experimental|Perioperative FLOT + prophylactic HIPEC + surgery|After 4 doses of preoperative FLOT chemotherapy diagnostic laparoscopy will be performed - patients without distant metastases will be randomised, in those randomised to experimental arm HIPEC with irinotecan will be performed (a dose of 300 mg/m2 body surface area will be administered over 45 minutes at a temperature of 42 degrees Celsius)
11025784|NCT04597294|Active Comparator|Perioperative FLOT + surgery|Standard treatment regimen for advanced gastric cancer
11025785|NCT04597281|Experimental|Mediterranean lifestyle|Mediterranean lifestyle, including dietary advice and physical activity advice. In addition, families receive extra-virgin olive oil and fish and two sessions of physical activity per week, for free.
11025786|NCT04597281|No Intervention|Usual care|General care by their pediatricians.
11025787|NCT04597268|Experimental|dexmedetomidine|IV dexmedetomidine
11025788|NCT04597268|Experimental|ketamine|IV ketamine
11025789|NCT04597268|Active Comparator|Midazolam|IV midazolam
11025790|NCT04597255|Experimental|Holographic optical coherence tomography|Healthy phakic participants
11025791|NCT04597229|Active Comparator|Instant multigrain|Oral instant multigrain supplement
11025792|NCT04597229|No Intervention|Standard care|Standard care without oral instant multigrain supplement
11025793|NCT04597216|Other|unique arm|there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
11025796|NCT04597190|Active Comparator|SSRI Then Augmentation by WET|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment augmented by Written Exposure Therapy (WET) delivered by an integrated behavioral health consultant.
11025797|NCT04597190|Active Comparator|SSRI Then Switch to SNRI|Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment switched to the SNRI (serotonin-norepinephrine reuptake Inhibitor) venlafaxine.
11025798|NCT04597190|Active Comparator|WET Then Switch to SSRI|Integrated behavioral health consultants will deliver WET. Patients who do not respond to treatment by four months will be switched to one of three SSRIs (sertraline, fluoxetine or paroxetine).
11025799|NCT04597177||ST-IMRT|standard parotid sparing IMRT
11025800|NCT04597177||SW-IMRT|swallowing sparing IMRT
11025801|NCT04597164|Experimental|Artificial liver support system group|100 patients in this group will receive treatment of double plasma molecular adsorption system, low volume plasma exchange, and comprehensive internal medical treatment
11025802|NCT04597164|No Intervention|Comprehensive medical treatment group|100 patients in this group will receive comprehensive internal medical treatment.
11025803|NCT04597151|Experimental|Supportive care (diet education)|Patients attend group diet education sessions over 1.5-2 hours every 2 weeks (weeks 1, 3, and 5).
11025804|NCT04597125|Experimental|Arm A|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive radium-223 dichloride
11025805|NCT04597125|Active Comparator|Arm B|Participants with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH will be randomized to receive second novel anti-hormonal therapy (NAH)
11025806|NCT04597112|Experimental|Myofascial Release Group|Intervention group, who received conventional therapy and myofascial release therapy.All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. In the intervention group, the myofascial release technique will be applied to the wrist flexors and extensors, elbow flexors and extensors, pectoralis, supraspinatus, infraspinatus, trapezius muscles, starting from the fingers after the conventional treatment, 3 days a week for 4 weeks.
11025807|NCT04597112|Active Comparator|Exercise Group|The control group will consist of patients who received conventional therapy and exercise therapy. All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. After conventional treatment, a program consisting of neck extension, lateral flexion and rotation range of motion, stretching of the trapezius muscles and strengthening of the neck extensor muscles will be applied to the control group in the presence of a physiotherapist 3 days a week for 4 weeks.
11025808|NCT04597099|Experimental|Flutamide|Prior to the first or second admission (randomly determined), subjects will be pretreated for 4 weeks with Flutamide (250 mg twice daily)
11025809|NCT04597099|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
11025810|NCT04597086|Experimental|Group I (BWLT, best practice)|Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.
11025811|NCT04597086|Active Comparator|Group II (standard of care)|Patients receive standard of care during hospital stay.
11025812|NCT04597073|No Intervention|Healthy|included individuals with probing depth (PD) ≤3mm, no sites with attachment loss, and no radiographic evidence of alveolar bone resorption. They exhibited no sign of inflammation (GI=0).
11025813|NCT04597073|Experimental|Gingivitis|had varying degrees of gingival inflammation (GI≥1), PD≤3mm with no clinical attachment loss or with no alveolar bone destruction.
11025814|NCT04597073|Experimental|Chronic Periodontitis|was defined as those who were with PD ≥ 4mm, clinical attachment loss (CAL) ≥ 2mm, and who had bone loss affecting >30% of the existing teeth on clinical and radiographic examination.
11025815|NCT04597060|Experimental|Split Keloid - first side|
11025816|NCT04597060|Experimental|Split Keloid - second side|
11025817|NCT04597047|Other|All Patients:|Capillary and Venous Blood Collections
11025818|NCT04597034|Experimental|AN69 Oxiris|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.
~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.
~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.
~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
11025819|NCT04597034|Active Comparator|AN69 Standard|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.
~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.
~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.
~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
11025820|NCT04597008|Active Comparator|Control|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1 gram of Vancomycin powder in their wound bed immediately before wound closure.
11025821|NCT04597008|Experimental|Treatment|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1 gram of Vancomycin powder AND a dose of 1.2 grams of Tobramycin powder in their wound bed immediately before wound closure.
11025822|NCT04596995|Experimental|Rozanolixizumab Maintenance Treatment Arm|All study participants will begin with the Maintenance Treatment Arm. 30% of the study participants are planned to be randomized to enter an 4 months Exploratory Treatment Arm, and then return back to the Maintenance Treatment Arm. Study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Maintenance Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
11025823|NCT04596995|Experimental|Rozanolixizumab Exploratory Treatment Arm|Study participants randomized to the Exploratory Arm will receive a fixed-unit dose of rozanolixizumab across body weight tiers during the Exploratory Treatment Period. Dose frequency will be adjusted based on platelet count values or medical needs.
11025824|NCT04596969|Experimental|SFD Tapioca 20g|20g soluble fiber dextrin derived from tapioca
11025825|NCT04596969|Experimental|SFD Tapioca 40g|40g soluble fiber dextrin derived from tapioca
11025826|NCT04596969|Experimental|SFD corn 20g|40g soluble fiber dextrin derived from corn
11025827|NCT04596969|Experimental|SFD corn 40g|
11025828|NCT04596969|Placebo Comparator|Control|Maltodextrin
11025829|NCT04596956|Experimental|sodium bicarbonate Ringer injection|
11025830|NCT04596956|Active Comparator|Ringer lactate solution|
11025831|NCT04596930|Experimental|LITT arm|Patients will be randomized to receive biopsy and LITT (n=10)
11025832|NCT04596930|No Intervention|biopsy arm|Patients will be randomized to receive biopsy alone (n=10)
11025833|NCT04596917|Experimental|Preferred music listening|Patients will be randomized to listen to music with iPod that has preferred music selections that patients can choose.
11025834|NCT04596917|Experimental|Hypnotic music with relaxation breathing|Patients will be randomized to listen to hypnotic music with relaxation breathing narrative.
11025835|NCT04596904|Experimental|Lavender oil group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
11025836|NCT04596904|Placebo Comparator|Distilled water group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
11025837|NCT04596891|Experimental|Intervention|Remotely delivered psychotherapy combining exposure therapy with mindfulness
11025838|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV
11025839|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV
11025840|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV
11025841|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV
11025842|NCT04596865||Pancreatic ductal adenocarcinoma|Patients who underwent pancreaticoduodenectomy for PDAC between 01/06/2010 and 31/05/2015
11025843|NCT04596865||Ampullary cancer|Patients who underwent pancreaticoduodenectomy for ampullary cancer between 01/06/2010 and 31/05/2015
11025844|NCT04596865||Distal extrahepatic cholangiocarcinoma|Patients who underwent pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma between 01/06/2010 and 31/05/2015
11025845|NCT04596852|Experimental|Healthy children|
11025846|NCT04596852|Experimental|Children with cerebral palsy|
11025847|NCT04596839|Experimental|Remdesivir with Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
11025848|NCT04596839|Other|Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy.
11025849|NCT04596826|Experimental|healthy subjects|
11025850|NCT04596826|Experimental|glaucoma patients|
11025851|NCT04596826|Placebo Comparator|healthy volunteers|
11025852|NCT04596826|Placebo Comparator|Glaucoma patients|
11025853|NCT04596813|No Intervention|standard of care|
11025854|NCT04596813|Active Comparator|standard of care and treatment with the Cytosorb® device|
11025855|NCT04596800|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
11025856|NCT04596800|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
11025857|NCT04596787||Non-Obese Patients (Group NO: body mass index (BMI) <30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
11025858|NCT04596787||Obese Patients (Group O: body mass index (BMI) ≥30)|Patients received bilateral single injection ultrasound (US)-guided bilateral thoracic paravertebral block (TPVB) at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
11025859|NCT04596774||Group 1|Group 1 patients were applied traditional approach. Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
11025860|NCT04596774||Group 2|Group 2 received Enhanced Recovery After Surgery (ERAS) approach. Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
11025861|NCT04596761|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
11025862|NCT04596761|Experimental|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
11025863|NCT04596748|Placebo Comparator|Placebo|Participants will be taking a placebo supplement that they will be taking by mouth once per day.
11025864|NCT04596748|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
11025865|NCT04596735||Patients undergoing general endotracheal anesthesia that will be extubated following the procedure|Patients 60 years of age and older undergoing general anesthesia and non-cardiac surgery will be observed by a member of the research team independent from the team caring for the patient at the time of emergence and extubation
11032768|NCT04549259|Experimental|Stigma Reduction + Technology Detailing|
11025872|NCT04596696|Other|Single arm Rotavac|Single arm Open Label study without comparator
11025873|NCT04596683|Experimental|Interested in SDS NSM or SSM|Patients interested same day discharge after NSM or SSM that do not have conditions that would exclude them. Based on discharge outcome after surgery, will be split into SDS group and Admit group.
11025874|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy|"Cancer patients who have not undergone radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.
~Interventions:
~Drug: 68Ga-ICAM-1pep Device: PET/CT"
11025875|NCT04596670|Experimental|68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy|"Cancer patients post-radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.
~Interventions:
~Drug: 68Ga-ICAM-1pep Device: PET/CT"
11025876|NCT04596657|Experimental|Intervention|
11025877|NCT04596657|No Intervention|Control|
11025878|NCT04596644|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
11025879|NCT04596631|Experimental|Semaglutide - max. tolerated dose|Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
11025880|NCT04596631|Placebo Comparator|Placebo (semaglutide)|Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
11025881|NCT04596618|Active Comparator|Forearm Cooling|Participants will be actively cooled during rest breaks.
11025882|NCT04596618|No Intervention|No Forearm Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
11025883|NCT04596605|Experimental|T2309|4 capsules daily for 12 weeks
11025884|NCT04596605|Active Comparator|Nutrof Total|2 capsules daily for 12 weeks
11025885|NCT04596592||Transgender|
11025886|NCT04596592||Cisgender|
11025887|NCT04596579||Participants age 18-34|Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.
11025888|NCT04596579||Participants age 35-54|Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
11025889|NCT04596579||Participants age 55-64|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
11025890|NCT04596579||Participants 65 and over|Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
11025891|NCT04596566|Other|CD-TDI|Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.
11025892|NCT04596566|No Intervention|Conventional management|Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24HR food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare
11025893|NCT04596553|Active Comparator|Essential Amino Acid|Participants will consume 1 dose of: 15 g crystalline essential amino acid supplement (Pure Encapsulation Essential Aminos 180) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
11025894|NCT04596553|Active Comparator|Collagen Peptide|Participants will consume 1 dose of: 15g collagen peptide (Gelita TENDOFORTE) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
11025895|NCT04596553|Placebo Comparator|Maltodextrin Placebo|Participants will consume 1 dose of:15 g maltodextrin (Canadian Protein Maltodextrin) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
11025896|NCT04596540|Experimental|SEL-212A|IV infusion of SEL-212A every 28 days for a total of up to 12 infusions
11025897|NCT04596540|Experimental|SEL-212B|IV infusion of SEL-212B every 28 days for a total of up to 12 infusions
11025898|NCT04596540|Placebo Comparator|Placebo|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
11025899|NCT04596527|Experimental|18F-FMPP PET MPI (following off-study 13N-ammonia PET MPI)|"Imaging Procedure: 18F-FMPP PET Day 1: All subjects will receive rest and stress IV boluses of 18F-FMPP injections in a large peripheral vein. The dosages of 18F-FMPP Injection administered at rest and during stress conditions are 2.5 mCi and 6.0 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor.
~Imaging Procedure: 13N-Ammonia PET All subjects will receive 2 IV boluses of 13N-ammonia Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of 13N-ammonia Injection administered at rest and during stress conditions is 20mCi and 20 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor."
11025900|NCT04596514|Experimental|Intervention group - REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
11025901|NCT04596514|Active Comparator|Control group - ACLS|Advanced cardiovascular life support as described in the guidelines
11025902|NCT04596501|Experimental|Early postmenopausal women|Healthy sedentary early postmenopausal women
11025903|NCT04596501|Experimental|Late postmenopausal women|Healthy sedentary late postmenopausal women
11025943|NCT04596189|Placebo Comparator|Placebo|Sterile placebo for Dupilumab will be provided in identically matching pre-filled syringes to deliver 2 mL.
11025944|NCT04596176|No Intervention|Business As Usual|Families who were involved in the child welfare services
11025945|NCT04596176|Active Comparator|Intensive Supportive Housing for Families|Families who were randomly assigned in this group
11025904|NCT04596488|Experimental|Efavirenz 400mg+TDF+3TC|Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.
11025905|NCT04596475|Experimental|Treatment Arm|
11025906|NCT04596462|Experimental|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
11025907|NCT04596449|Experimental|healthy volunteers|
11025908|NCT04596423||A|Extended fetal heart examination
11025909|NCT04596423||B|Modified extended heart examination
11025910|NCT04596423||C|Sief_Twist sign only examination
11025911|NCT04596410|Experimental|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
11025912|NCT04596410|Active Comparator|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day
11025913|NCT04596397|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
11025914|NCT04596397|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.
11025915|NCT04596384|Experimental|Group I (telemonitoring program, actigraph, TapCloud)|Before surgery, patients complete a functional and nutritional assessment. The home environment of patients will also be assessed. Based on findings, patients undergo personalized prehabilitation. Patients also wear an actigraph throughout the study to measure and record daily steps taken and sedentary time. Patients use the TapCloud app on a smart device (phone, tablet) or home computer to collect, track, and report their symptoms. Based on patient input in the TapCloud app, a real-time alert is sent to an RN when predetermined thresholds are met. RNs then contact the patient via the TapCloud app and further phone calls if necessary. Patients, caregivers and surgeons may also participate in a focus group in-person, via telephone, or videoconferencing.
11025916|NCT04596384|Active Comparator|Group II (surgeon-only perioperative care program)|Patients and their families meet with the surgeon at least once before surgery. After surgery, patients are managed daily during post-operative care. Patients may receive a referral for functional and nutritional prehabilitation at the discretion of the surgeon/surgical team. Patients and their families receive instructions to follow the standard procedures for reporting problems between clinic visits, including contacting their surgical team if symptoms become severe and physical function worsens; and the use of the hospital call line to report problems. Patients, caregivers and surgeons may receive the opportunity to participate in focus group in-person, via telephone, or videoconferencing.
11025917|NCT04596358||Healtcare workers|Women who work as nurses or doctors in public hospitals of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
11025918|NCT04596358||Non-Healthcare workers|Women who perform technical and managerial professions in a public administration body of which anthropometric and haematochemical data have been collected. Workers were given a questionnaire for the evaluation of the adherence to the Mediterranean diet.
11025919|NCT04596345||University students|"This group will include all those participants who declare to be attending a study program to get a higher education degree.
~No intervention will be applied."
11025920|NCT04596345||Non-university-attending peers|"This group will include all those participants who are not attending a study program to get a higher education degree.
~No intervention will be applied."
11025921|NCT04596332||Group A|Patients with the initial central venous pressure(CVP1) <8 mm Hg
11025922|NCT04596332||Group B|Patients with 8≤CVP1≤12mm Hg
11025923|NCT04596332||Group C|Patients with CVP1>12 mm Hg
11025924|NCT04596319|Experimental|AP-PA02|Anti-pseudomonal bacteriophage
11025925|NCT04596319|Placebo Comparator|Placebo|Inactive isotonic solution
11025926|NCT04596306||UNDER 70 Y-O|
11025927|NCT04596306||OVER 70 Y-O|
11025928|NCT04596293|Experimental|BBT-401-1S mid-dose|
11025929|NCT04596293|Experimental|BBT-401-1S high-dose|
11025930|NCT04596293|Placebo Comparator|Placebo|
11025931|NCT04596280||Hinchey Classification|
11025932|NCT04596280||AAST classification|
11025933|NCT04596280||WSES classfication|
11025934|NCT04596267|Experimental|Pitolisant|Subjects will take an 8.9 mg dose (two 4.45 mg pills) of pitolisant once per day on day 1 through 4. On day 5, 8.9 mg will be taken in front of staff prior to an alcohol self administration trial.
11025935|NCT04596267|Placebo Comparator|Placebo|Subjects will take an placebo once per day on day 1 through 4. On day 5, a placebo will be taken in front of staff prior to an alcohol self administration trial.
11025936|NCT04596254|Other|Juice Intake|
11025937|NCT04596241|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.
11025938|NCT04596228|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device
11025939|NCT04596202|Experimental|Supine Position|It is the supine position. The body parts of the patient stand as if the patient is standing upright. The head, neck and shoulders should be supported with a pillow placed under the head. Arms are aside and body muscles are relaxed. The upper arms should lie on both sides of the body, should slightly be moved away from the body and should be supported by a pillow.
11025940|NCT04596202|Experimental|Prone Position|It is the position where the patient lies face down with his/her head turned to the side. Arms are stretched to both sides of the head. The prone position (prone lying) is a relaxing and resting position.
11025941|NCT04596202|Experimental|Lateral position|Lateral position is the left or right lateral lying position. The lateral position is given to the patient to provide proper anatomical lying and to reduce lateral flexion of the back and the strain of the large back muscles. This position prevents pressure on the bones in the back.
11025942|NCT04596189|Experimental|Dupilumab|Sterile Dupilumab 150 mg/mL will be provided in pre-filled syringes (2.25 total volume) to deliver 300 mg in 2 mL.
11025946|NCT04596176|Active Comparator|Program Supportive Housing for Families|Families who were randomly assigned in this group
11025947|NCT04596163|Active Comparator|Intervention|Ultrasound guided Regional block using 0.25% levobupivacaine (local anaesthetic agent) 20ml (50mg) on each side of the sternum over 1-2 minutes after general anaesthesia before surgery.
11025948|NCT04596163|Placebo Comparator|Control|Ultrasound guided Regional block using 20ml of 0.9% normal saline on each side of the sternum after general anaesthesia before surgery.
11025949|NCT04596150|Experimental|ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative|CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer
11025950|NCT04596150|Experimental|ARM B - CX-2009 Monotherapy, TNBC|CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC)
11025951|NCT04596150|Experimental|ARM C - CX-2009 Combination therapy, TNBC|CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC
11025952|NCT04596137|Experimental|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
11025953|NCT04596124|Experimental|fitostimoline plus cream|
11025954|NCT04596124|Experimental|fitostimoline plus gauze|
11025955|NCT04596124|Active Comparator|connettivina bio plus cream|
11025956|NCT04596124|Active Comparator|connettivina bio plus gauze|
11025957|NCT04596098||Group A|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient not previously followed in Grenoble University Hospital for a chronic disease.
11025958|NCT04596098||Group B|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient followed in Grenoble University Hospital for a chronic disease.
11025959|NCT04596085|Active Comparator|Investigational product|Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy
11025960|NCT04596085|Placebo Comparator|Placebo|Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy
11025961|NCT04596072|No Intervention|control|basic treatment+ Cognitive rehabilitation training
11025962|NCT04596072|Experimental|treatment|basic treatment+ Cognitive rehabilitation training+Chinese traditional rehabilitation
11025963|NCT04596046|Active Comparator|Group S (systemic-peroral steroid)|Medication of oral methylprednisolonewas administered to the patients following the adjustment based on the severity of the lesion and regarding the clinic. The prednisolone dose was 0.5 mg/kg/day in patients with painful, small (<5.0 cm) unilateral lesions whereas in multiple, bilateral lesions with the diameter of ≥5 cm or for those who had significant cutaneous ulceration, the prednisolone dose was specified as 1 mg/kg/day
11025964|NCT04596046|Experimental|Group L (local-intralesional steroid)|Triamcinolone acetonidewas administered to the patients through injecting inside the lesion. The practice was based on the dose of TCA administered in acute and chronic inflammatory skin lesions. If the lesion is single-focused and small (<5.0 cm), 20mg / mL TCA was injected and if the lesion is multifocal or large (>5.0 cm) then 40mg / mL TCA was injected into the lesion with the guidance of ultrasonography
11025965|NCT04596033|Experimental|Multiple Low Dose (MLD)|GEN-011 is administered by IV infusion at 4-week intervals, up to 5 doses maximum. Each dose is followed by IL-2 administration. MLD patients will not undergo lymphodepletion.
11025966|NCT04596033|Experimental|Single High Dose (SHD)|GEN-011 is administered as a single IV infusion at the maximum available cell yield, after the patient completes a fludarabine/cyclophosphamide lymphodepletion regimen. The single GEN-011 dose is followed by IL-2 administration.
11025967|NCT04596020|Experimental|Blood Flow Restriction Group|This group will perform 2 lower extremity exercises (sitting unilateral knee extension, standing unilateral knee curl) under occlusion (i.e., BFR) for 4 sets (30/15/15/15 reps) each followed by 2 shoulder exercises (scaption and sidelying external rotation) 3 sets x 15 reps each. Exercises will be performed at 30% of 1RM.
11025968|NCT04596020|Active Comparator|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
11025969|NCT04596007|Experimental|HEC83518 tablets|There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
11025970|NCT04596007|Placebo Comparator|placebo tablets|There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
11025971|NCT04595994|Experimental|Selinexor + Gemcitabine|"Dose escalation levels (Phase I):
~All included patients will take both drugs:
~Selinexor weekly (given on days 1,8 and 15 of each cycle) will be dispensed at different dose levels: dose level 1:60 mg, dose level 2: 60 mg, dose level 3: 60 mg, and dose level 4: 80 mg).
~Gemcitabine weekly (given on days 1, 8 of each cycle) will be administered at different dose levels: (dose level 1:1000 mg/m2 (30 min), dose level 2:1000 mg/m2 (10 mg/m2/min), dose level 3:1200 mg/m2 (10 mg/m2/min) and dose level 4: 1200 mg/m2 (10 mg/m2/min)).
~Selinexor: tablet (20 mg tablets) Oral use.
~Gemcitabine: Concentrate for solution for infusion. Intravenous use."
11025972|NCT04595981|Experimental|Chemo-embolization|Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)
11025973|NCT04595968|Experimental|Vestal DM active device|100 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
11025974|NCT04595968|Sham Comparator|Vestal DM sham device|100 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
11025975|NCT04595955|Experimental|Intervention group|This arm uses the CMyLife platform for at least 6 months
11025976|NCT04595955|No Intervention|Control group|This arm does not use the CMyLife platform
11025977|NCT04595942|Active Comparator|Midodrine|5mg midodrine three times a day
11025978|NCT04595942|Active Comparator|Fludrocortisone|0.1 mg fludrocortisone two times a day
11025979|NCT04595942|Sham Comparator|Lifestyle modification|Education , salt and water intake, counter-pressure maneuvers
11025980|NCT04595929|Experimental|PIPAC group|"Staging laparoscopy + peritoneal lavage.
~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.
~Radical gastrectomy with D2 - lymph node dissection.
~Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
~Adjuvant chemotherapy according to indications."
11026143|NCT04594668|No Intervention|Standard treatment|Standard intensive care
11025981|NCT04595929|Active Comparator|Control group|"Staging laparoscopy + peritoneal lavage.
~4 cycles of neoadjuvant chemotherapy: FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m² every 2 weeks.
~Radical gastrectomy with D2 - lymph node dissection.
~Adjuvant chemotherapy according to indications."
11025982|NCT04595916|Experimental|Polyene Phosphatidylcholine|
11025983|NCT04595916|Active Comparator|Magnesium Isoglycyrrhizinate|
11025984|NCT04595903|Experimental|Hemopurifier®|The Hemopurifier® will be placed within the extracorporeal circuit, all connections secured, treatment will utilize a blood pump at an initial flow rate of 100mL/min. The blood flow rate is to be increased gradually in a stepwise fashion over the first minutes of treatment to a maximum blood flow rate of 200mL/min. The circuit must be continually monitored for blood leaks and blood clotting within the filter. If the treatment is halted before 4 hours, another filter may be connected, and the treatment may be restarted with a goal of achieving a minimum of 4 hours of therapy. If the filter shows signs of clotting or blood leaks, the treatment must be paused, the blood will be returned to the patient and a new filter will be placed into the extracorporeal circuit. The therapy will be resumed with consideration of altering the level of anticoagulation.
11025985|NCT04595890|Experimental|Intervention Group|Injection of Autologous Nucleated Cells
11025986|NCT04595877|Experimental|Dipyrone group|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
11025987|NCT04595877|Placebo Comparator|Placebo group|The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
11025988|NCT04595864|Experimental|treatment group|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
11025989|NCT04595864|No Intervention|control group|no neo-adjuvant treatment before operation
11025990|NCT04595851|Other|Pharmacist Coordinated care Oncology Model (PCOM)|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and primary care pharmacists.
11025991|NCT04595838|Experimental|Arm A:Best supportive oral care and Chemo Mouthpiece|Patients will receive best supportive oral care along with using the Chemo Mouthpiece device
11025992|NCT04595838|Other|Arm B Best supportive oral care only|Patients will receive best supportive oral care only.
11025993|NCT04595825|Experimental|CM-101|
11025994|NCT04595825|Placebo Comparator|Placebo|
11025995|NCT04595812|Active Comparator|Misoprostol group|receive two tablets of 200µg misoprostol (Pfizer Limited, United Kingdom) administered into the posterior fornix of the vagina 1 hour before the onset of surgery
11025996|NCT04595812|Active Comparator|Oxytocin group|After induction of general anaesthesia and immediately prior to the operation, an infusion of 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h will be started during myomectomy.
11025997|NCT04595812|Experimental|Carbetocin group|receive 100 μg IV Carbetocin (1ml) [Pabal, Ferring (UK)] in 5 ml saline over 1 minute just before skin incision
11025998|NCT04595812|Active Comparator|pericervical tourniquet group|pericervical tourniquet using a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision.
11025999|NCT04595786|Active Comparator|TXA group|The TXA group will receives Tranexamic acid intraoperative.
11026000|NCT04595786|Placebo Comparator|Placebo group|The TXA group will receives 0.9% saline intraoperative.
11026001|NCT04595773|Experimental|Aerobic Exercise Training and Education (AET+)|Participants will perform both exercise training and education for 10 weeks
11026002|NCT04595773|Other|Education only (CON)|Participants will perform only education for the first 10 weeks, then cross-over to perform exercise in the second 10 weeks
11026003|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
11026004|NCT04595747|Experimental|Treatment (rogaratinib)|Patients receive rogaratinib PO BID on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11026005|NCT04595721|No Intervention|Standard of care|Participants will receive standard injection procedures
11026006|NCT04595721|Active Comparator|Visual distraction|Participants engage in visual distraction during the injection procedures
11026007|NCT04595721|Active Comparator|Physical distraction|Participants engage in physical distraction during the injection procedures
11026008|NCT04595708|Experimental|Intervention - Calls|Participants randomized to the intervention will receive a call of between 5 - 10 minutes in length each by a consistent caller, five times a week, Monday through Friday for 4 consecutive weeks to check in on them. After the first week of calls, subjects in the intervention arm will be asked if the frequency of calls is acceptable or if they would like to reduce the call frequency, potentially to a minimum of twice per week.
11026009|NCT04595708|No Intervention|Control - No calls|Participants randomized to a control group will not receive the intervention calls. The control group will receive calls from a member of the research team at the beginning of the study to collect baseline survey data and at the post-4-week period to collect post-study survey data.
11026010|NCT04595695|Experimental|Transparent Mask|Surgeons will be provided a transparent mask for use during in-person clinic visits with a new patient. Otherwise, visits will be conducted as per usual and the patient will be surveyed immediately after the visit.
11026011|NCT04595695|Active Comparator|Covered Mask|Surgeons will be instructed to wear a typical, covered mask for the in-person clinic visit with a new patient. The visit will be conducted as it typically would, and the patient will be surveyed immediately after the visit.
11026012|NCT04595682|Experimental|Study Participants|Participants in this group will track their menstrual cycle, provide daily saliva samples, and undergo two rounds of alcohol sensitivity testing (with both placebo and alcohol).
11026013|NCT04595669|Experimental|Personalised advice|
11026014|NCT04595643|Experimental|Specialized dysphagia treatment|Dysphagia treatment is provided by occupational therapists specialized in dysphagia.
11026015|NCT04595617|Experimental|Patients with diagnosis of Glanzmann Thrombastenia (GT)|Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months
11026144|NCT04594668|Active Comparator|Senicapoc|Senicapoc
11026016|NCT04595604|Experimental|Trimodal prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:
~Physical status (walking, respiratory training) Nutrition (nutritional supplements) Mental status (weekly groups led by clinical psychologist on anxiety and depression management).
~Each patient will be treated in an ERAS program preoperatively."
11026017|NCT04595604|Active Comparator|ERAS + nutritional prehabilitation|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
11026018|NCT04595591|Active Comparator|Group Ⅰ|titration dosing speeds of propofol at 2mg/kg/min
11026019|NCT04595591|Active Comparator|Group Ⅱ|titration dosing speeds of propofol at 1mg/kg/min
11026020|NCT04595591|Active Comparator|Group III|titration dosing speeds of propofol at 0.5mg/kg/min
11026021|NCT04595578|Active Comparator|Cerebellar rTMS + Physical therapy|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
11026022|NCT04595578|Sham Comparator|Sham stimulation + Physical therapy|Sham stimulation was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator. Sham stimulation was delivered to the cerebellum for 5 seconds at 55 second intervals in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
11026023|NCT04595565|Experimental|Sacituzumab govitecan|Sacituzumab govitecan is administered intravenously 10 mg/kg body weight on days 1, 8 q3w for eight cycles.
11026024|NCT04595565|Other|Treatment of physician´s choice|TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or Observation.
11026025|NCT04595552|Experimental|Study group|Children with cochlear implant were given Auditory training and language therapy
11026026|NCT04595539|Experimental|Simultaneous interventions|In this condition, both interventions are proposed simultaneously. Condition 1 is spread over 5 weeks with 5 weekly laboratory sessions of 2-hours (one hour of BATD and one hour of ATT separated by a break). A 30-minutes ATT sessions at home were prescribed between sessions for a total of 5 laboratory ATT sessions and 5 at home ATT sessions.
11026027|NCT04595539|Experimental|Sequential interventions|In this condition, the interventions are introduced sequentially. Condition 2 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 4 with of one hour of ATT followed by one hour of BATD separated by a break). A six 30-minutes ATT sessions were prescribed between the first 4 sessions of ATT for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
11026028|NCT04595539|Experimental|Sequential interventions in reverse order|In this condition, the interventions are introduced sequentially in the reverse order than the condition 2. Condition 3 is spread over 7 weeks with 8 weekly laboratory sessions, 7 sessions of 1-hour and one session of 2-hours (Sessions 5 with of one hour of BATD followed by one hour of ATT separated by a break). A six 30-minutes ATT sessions were prescribed between the 4 last sessions for a total of 4 laboratory ATT sessions and 6 at home ATT sessions.
11026029|NCT04595526|Active Comparator|Tracheal suction|Uses the local standard procedure of tracheal suction to obtain secretions from the lower respiratory tract
11026030|NCT04595526|Experimental|Forced expiratory technique and induced sputum|This procedure is without suction. The patient's attempts to deliver a sputum sample after forced exhalation and coughing technique. Regardless of the result the patient then receives hypertonic saline by an inhalation mask to induce the sputum. If the patient cannot deliver a sample, tracheal suction will be performed in order to obtain a specimen for the analyses.
11026031|NCT04595513|Experimental|Stage 1 Open Label|Phase I, open-label PK and initial safety analysis. TAVT-18 administered orally twice/daily to achieve precision dosing target of 10 ng/ml. Whole blood sirolimus levels will be assessed at defined intervals on days 1, 7, and 14. After day 14, participants in Stage 1 can elect to continue open-label treatment with TAVT-18 until 12 months of age.
11026032|NCT04595513|Placebo Comparator|Stage 2 Randomized|Phase II, randomized, double- blind, placebo-controlled safety and efficacy of TAVT-18 to prevent or delay seizure onset in TSC infants. TAVT-18, or matching placebo, administered orally twice/daily and steady state sirolimus levels in whole blood will be assessed at defined intervals to achieve precision dosing target of 10 ng/ml.
11026033|NCT04595500||GERD|
11026034|NCT04595500||Control|
11026035|NCT04595487|Experimental|left ventricular septal pacing|Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
11026036|NCT04595487|Active Comparator|right ventricular pacing|Implantation of a pacemaker with the ventricular lead placed in the RV.
11026037|NCT04595474||Study Cohort|533 adult subjects with type 1 diabetes with no secondary causes of fatty liver
11026038|NCT04595461|Placebo Comparator|Control|Standard of care patient education with verbal and written education
11026039|NCT04595461|Experimental|Video Group|Patient education supplemented with four short youtube videos regarding chronic rhinosinusitis and endoscopic sinus surgery
11026040|NCT04595448||Patients|Patients suffering from moderate tricuspid valve regurgitation
11026041|NCT04595448||Controls|Cardiovascular healthy, age, gender and weight matched controls.
11026042|NCT04595435||Cohort A- Preoperative Prospective|Subjects are eligible to receive IORT and have agreed to participate in the study prior to any intervention.
11026043|NCT04595435||Cohort B- Postoperative Prospective|Subjects who have had IORT performed within the previous 6 month who agree to participate.
11026044|NCT04595422|Experimental|Call center staff (educational intervention)|Participants undergo training consisting of a 60-minute educational session.
11026045|NCT04595422|Experimental|Callers substudy (LCS educational materials, questionnaire)|Participants are referred to lung cancer screening educational materials. Participants also complete questionnaires at 1 week and 6 months after referral to educational materials.
11026046|NCT04595409|Experimental|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive subcutaneous injections of FYB202 as detailed in the protocol.
11026047|NCT04595409|Active Comparator|Stelara® (Ustekinumab)|Patients will receive subcutaneous injections of Stelara® as detailed in the protocol.
11026048|NCT04595383|No Intervention|Control|Usual care and usual communication with health professional
11026049|NCT04595383|Experimental|Intervention|They will be trained to use the ti.care platform and will be able to use it as a communication channel for any questions or clarification they require during the time elapsed between routine control visits. This platform will be a complement to the visits, but in no case will it replace them or be used as a diagnostic or therapeutic method. The platform does not have any treatment algorithm and only aims to facilitate communication between the patient at home and the health professional, both the doctor and the nurse educator. It will be used in a preventive and advisory manner for the patient for follow-up. In no case it will be used for emergencies. Daily during working hours from Monday to Friday, health professionals will review patient requests and respond to them.
11026050|NCT04595370|Experimental|AZD9977 Dose A + dapagliflozin 10 mg|Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
11026051|NCT04595370|Experimental|AZD9977 Dose B + dapagliflozin 10 mg|Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
11026052|NCT04595370|Experimental|AZD9977 Dose C + dapagliflozin 10 mg|Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
11026053|NCT04595370|Experimental|AZD9977 Dose C|Participants will receive once daily oral dose C of AZD9977 alone for 12 weeks.
11026054|NCT04595370|Experimental|Dapagliflozin 10 mg|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
11026055|NCT04595370|Placebo Comparator|Placebo|Participants will receive once daily oral dose of placebo matched to AZD9977 or dapagliflozin for 12 weeks.
11026056|NCT04595344|Active Comparator|Diagnostic cystoscopy group-1 (DCG-1)|patients listened to binaural beats
11026057|NCT04595344|Placebo Comparator|Diagnostic cystoscopy group-2 (DCG-2)|patients listened to classical music
11026058|NCT04595344|Sham Comparator|Diagnostic cystoscopy group-3 (DCG-3)|patients no audio only headphones
11026059|NCT04595344|Active Comparator|Ureteral stent removal group-1 (USRG-1)|patients listened to binaural beats
11026060|NCT04595344|Placebo Comparator|Ureteral stent removal group-2 (USRG-2)|patients listened to classical music
11026061|NCT04595344|Sham Comparator|Ureteral stent removal group-3 (USRG-3)|patients no audio only headphones
11026062|NCT04595331|No Intervention|Treatment Group in pivotal study|followed for long-term safety and effectiveness with no additional treatment
11026063|NCT04595331|Experimental|Control Group in the pivotal study|receiving treatment in the extension study
11026064|NCT04595318|Active Comparator|Standard clinical care|Four weeks of medication-assisted treatment (MAT) with standard clinical care (SCC). MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
11026065|NCT04595318|Active Comparator|Standard clinical care and varenicline|Four weeks of MAT with standard clinical care plus varenicline therapy (SCC and VT). Varenicline therapy included a one-month supply of standard doses: 0.5mg for the first three days, 0.5mg twice a day for the following four days, and 1 mg twice a day for the remaining 21 days. MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
11026066|NCT04595305|Other|Treatment Arm - Standard of Care|Implantation of CRT-P or CRT-D for a clinical indication as per standard of care.
11026067|NCT04595292||older adults, assessment|
11026068|NCT04595279|Experimental|Smoking sessions|This is the single arm that will go through cigarette smoking sessions
11026069|NCT04595266|Active Comparator|Control|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
11026070|NCT04595266|Experimental|Experimental|Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
11026071|NCT04595253|Experimental|acupressure|After recruitment, participants will be randomized to receive acupressure or control group. In the acupressure group, participants will receive acupressure treatment.
11026072|NCT04595253|No Intervention|routine care|After recruitment, participants will be randomized to receive acupressure or control group. In the control group, participants will receive routine care, including routine pain control.
11026073|NCT04595227||Normal Subjects|Healthy eyes had intraocular pressure of less than 22 mmHg with no history of increased intraocular pressure and normal standard automated perimetry (SAP) results.
11026074|NCT04595227||Suspect Glaucoma|Eyes with suspect glaucoma were defined as those with suspicious neuroretinal rim thinning or retinal nerve fiber layer (RNFL) defects on masked stereophotographic assessment, without repeatable abnormal SAP results. Eyes with suspect glaucoma also included those with intraocular pressure (IOP) > 21 mm Hg but with healthy-appearing optic discs and without repeatable abnormal SAP results
11026075|NCT04595227||Primary Open Angle Glaucoma, early stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -0.01dB≤MD≤-6.00dB)
11026076|NCT04595227||Primary Open Angle Glaucoma, moderate stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -6.01≤MD≤-12.00dB)
11026452|NCT04592640|Experimental|Uremic Calciphylaxis Patients|Human amniotic mesenchymal stem cells (hAMSCs)
11026077|NCT04595227||Primary Open Angle Glaucoma, advanced stage|Eyes were classified as glaucomatous if they had repeatable (≥2 consecutive) abnormal SAP(Humphrey) test results or progressive glaucomatous changes on masked grading of stereophotographs, with or without abnormal SAP results. Abnormal SAP results were defined by a pattern standard deviation outside the 95% confidence limits or glaucoma hemifield test results outside the reference range.( -12.00≤MD≤-20.00dB)
11026078|NCT04595188|Experimental|Sulphur amino acids in Adults > 60|"Total sulphur amino acid, as methionine only: all subjects will receive up to 7 methionine test levels, without dietary cysteine, assigned in random order.
~Minimum methionine, with excess dietary cysteine: all subjects will receive up to 7 methionine test levels, in the presence of excess and constant dietary cysteine, assigned in random order."
11026079|NCT04595162|Experimental|CAR-T treatment group|The patients will receive one dose of GC019F.
11026080|NCT04595149|Other|Immunotherapy|Adding bintrafusp alfa (a combined TGF-β en PDL-1 inhibitor) to definitive chemoradiation with Paclitaxel and Carboplatin
11026081|NCT04595136|Experimental|COVID19-0001-USR|Group 1 Patients with SARS-COV-2 (COVID19) positive test will receive Investigational Drug administer by nebulization ( COVID-19-0001-USR) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
11026082|NCT04595136|Placebo Comparator|Normal Saline|Group 2 of patients with positive tests intervention SARS-COV-2 (COVID19) with placebo (i.e., normal saline 0.9% NS) plus standard baseline treatment for covid provided by Primary care provider ( Azithromycin, dexamethasone, and/or anticoagulants) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
11026083|NCT04595097|Experimental|Intervention Group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will performe endurance training or interval training at moderate to high intensities. IMT in both groups will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the intervention group will be set initially at a load of 50% of patients' maximal inspiratory mouth pressure (MIP). This initial load will be continuously and gradually increased to the highest tolerable intensity during each of the supervised sessions.
11026084|NCT04595097|Active Comparator|Control group|The training volume will be 24 sessions. Training frequency will be 3 sessions per week. Duration of training sessions will be around 60min. Patients will performe endurance training or interval training at moderate to high intensities. Sham IMT will be performed using the PowerBreathe KHP2 device (POWERbreatheKHP2, HaB, International, Southam, UK). Training intensity in the control group will be set at 10% baseline PImax and will be not modified throughout the intervention period.
11026085|NCT04595084|Experimental|MBCT-R + CHA-MW|Mindfulness-Based Cognitive Therapy (MBCT) is an effective group intervention for depression and anxiety that combines mindfulness training with elements of cognitive therapy. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
11026086|NCT04595084|Active Comparator|iCBT (MoodGym) + CHA-MW|MoodGym is a form of iCBT, which an evidence-based online program for depression, anxiety, stress and general psychological well-being. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
11026087|NCT04595084|Active Comparator|CHA-MW|Participants randomized to the CHA-MW arm will only receive CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
11026088|NCT04595071|No Intervention|Standard Control|Use of standard two-site myoelectric control of multi-articulating hand.
11026089|NCT04595071|Experimental|Voice Recognition Control|Use of voice recognition control in addition to standard two-site myoelectric control of a multi-articulating hand.
11026090|NCT04595058|Active Comparator|EUSDB-LAMS|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent . Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.
~EUSDB-LAMS (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent)"
11026091|NCT04595058|Experimental|EUSDB-LAMS-Pigtail|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents without coaxial plastic stent. Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.
~In this arm, a double pigtail through the lumen apposing metal stent will be inserted as an axis-orienting stent.
~EUSDB-LAMS-Pigtial (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent through LAMS)"
11026092|NCT04595045|Experimental|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
11026093|NCT04595019|Active Comparator|5 fraction|MRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
11026094|NCT04595019|Experimental|2 fraction|MRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.
11026095|NCT04595006|Experimental|Cold Stimulation (CS)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour daily for the next 12 weeks or 3 months.
11026096|NCT04595006|Experimental|Browning Nutraceutical (BN)|Subjects will consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
11026097|NCT04595006|Experimental|Cold Stimulation and Browning Nutraceutical (CSBN)|Subjects will undergo a mild cold stimulation of about 14 degrees Celsius by wearing a cooling vest for approximately an hour and consume 2000mg of curcumin daily for the next 12 weeks or 3 months.
11026098|NCT04594980|Other|Minimally invasive TLIF|Patients will undergo a single level decompression and fusion using a minimally invasive technique. Followed posterior screw fixation is mandatory.
11026099|NCT04594980|Other|Open TLIF|Patients will undergo a single level decompression and fusion using an open traditional technique. Followed posterior screw fixation is mandatory.
11026100|NCT04594954|Experimental|Diet + Exercise + FMT|
11026101|NCT04594954|Active Comparator|Diet+Exercise|
11026102|NCT04594941|Experimental|Group 1|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the HPLC method
11026103|NCT04594941|Experimental|Group 2|7 evaluable subjects to receive 2 doses of Flurpiridaz (18F) Injection manufactured by the SPE method
11026104|NCT04594941|Experimental|Group 3|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method
11026140|NCT04594694|Experimental|Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 400 mg SR Bezafibrate (BZF) 200 mg Placebo
11026105|NCT04594941|Experimental|Group 4|7 evaluable subjects to receive 1 dose of Flurpiridaz (18F) Injection manufactured by the SPE method followed by 1 dose of Flurpiridaz (18F) Injection manufactured by the HPLC method
11026106|NCT04594928|Experimental|GLPG3667 Dose A|Daily doses of GLPG3667 for 4 weeks.
11026107|NCT04594928|Experimental|GLPG3667 Dose B|Daily doses of GLPG3667 for 4 weeks.
11026108|NCT04594928|Placebo Comparator|Placebo|Placebo to match will be administered as capsules for daily oral use.
11026109|NCT04594915||Study Group|Patients diagnosed with AF who are currently using Edoxaban for stroke prevention in Turkey.
11026110|NCT04594902|Experimental|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
11026111|NCT04594902|Active Comparator|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
11026112|NCT04594889|Experimental|Sirolimus|Sirolimus eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
11026113|NCT04594889|Active Comparator|Paclitaxel|Paclkitaxel eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
11026114|NCT04594876|Other|Flouroscopic guidance Cervical Epidural injection|Group (P) flouroscopic guidance cervical epidural injection
11026115|NCT04594876|Other|Flouroscopic guidance cervical facet injection|Group (F) Flouroscopic guidance cervical facet injection
11026116|NCT04594863||cachexia|patients suffering from cachexia recently
11026117|NCT04594863||no cachexia|patients are not suffering from cachexia recently
11026118|NCT04594850|No Intervention|Placebo-Control group|Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.
11026119|NCT04594850|Experimental|Injection group: Cellgram-ED|Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.
11026120|NCT04594837|Experimental|Unpowered Physical Therapy Robot (Phase I)|2 weeks (3 sessions per week, total 6 sessions, ~30-45 minutes duration each session) of over-ground gait training while wearing the unpowered robot (mass only, no robotic active assistance) on foot drop in chronic hemiparetic stroke patients. f training with the unpowered robot does not significantly improve key foot drop outcomes as hypothesized, then Phase II will consist of a two group design comparing PTR (Physical Therapy while wearing Robot group) vs. PT (Physical Therapy only). If Phase I shows that wearing the unpowered robot improves the foot drop outcomes, then Phase II will use a three group randomized study design comparing PTR, PT and UPTR (Unpowered Physical Therapy Robot) groups
11026121|NCT04594837|Experimental|PTR (Physical Therapy while wearing Robot group) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
11026122|NCT04594837|Experimental|PT (Physical Therapy Only) (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
11026123|NCT04594824||Term neonates|
11026124|NCT04594824||Preterm neonates|
11026125|NCT04594811|Experimental|Phase 1: Dose escalation|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.
~Nivolumab will be administered on Day 1 of every 4 week cycles (Q4W)."
11026126|NCT04594811|Experimental|Phase 2: NT-17 and Nivolumab|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W) at the recommended phase 2 dose (RP2D) identified during Dose escalation phase.
~Nivolumab will be administered on Day 1 of every 4 week cycles (Q4W)."
11026127|NCT04594811|Active Comparator|Phase 2: Nivolumab Alone|Nivolumab will be administered on Day 1 of every 4 week cycles (Q4W).
11026128|NCT04594798|Experimental|Experimental: Polatuzumab Vedotin and R-CHOP|The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
11026129|NCT04594772|Experimental|Neoadjuvant therapy|All patients will receive Neoadjuvant therapy.
11026130|NCT04594759|Experimental|Treatment Group|
11026131|NCT04594746|Experimental|Oral Amiodarone|Amiodarone hydrochloride 2000 mg
11026132|NCT04594746|Placebo Comparator|Placebo|Oral placebo
11026133|NCT04594733|Active Comparator|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Participants will be randomized to 8 weeks of placebo, minimum 2 week washout period, and then 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily) followed by a final 2 week washout
11026134|NCT04594733|Active Comparator|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|Participants will be randomized to 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily), minimum 2 week washout period, and then 8 weeks of placebo followed by a final 2 week washout
11026135|NCT04594720||Thyroid cancers|Enrolled study population have papillary thyroid cancers and benign thyroid tumors
11026136|NCT04594707|Experimental|PRM-151|"Corhort A: Participants entering, following participation in study PRM-151-202.
~Cohort B: Participants entering, following participation in study WA42293."
11026137|NCT04594694|Active Comparator|Treatment A: BZF 200 mg IR|Bezafibrate (BZF): 200 mg IR Ocaliva (OCA) Placebo Bezafibrate (BZF) 400 mg Placebo
11026138|NCT04594694|Active Comparator|Treatment B: BZF 400 mg SR|Bezafibrate (BZF): 400 mg SR Ocaliva (OCA) Placebo Bezafibrate (BZF) 200 mg Placebo
11026139|NCT04594694|Experimental|Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR|Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 200 mg IR Bezafibrate (BZF) 400 mg Placebo
11026145|NCT04594642|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
11026146|NCT04594642|Experimental|Dose Expansion in Subjects with DLBCL or HGBL|An expansion cohort in subjects with DLBCL or HGBL will be enrolled after RP2D is established.
11026147|NCT04594642|Experimental|Dose Expansion in Subjects with FL|An expansion cohort in subjects with FL will be enrolled after RP2D is established.
11026148|NCT04594629|Sham Comparator|nitroglycerine group|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
11026149|NCT04594629|Active Comparator|PGI2 group|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres.
11026150|NCT04594616|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
11026151|NCT04594616|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
11026152|NCT04594603||Group(1): Cataract with no diabetic retinopathy|
11026153|NCT04594603||Group (2): Cataract associated with diabetic retinopathy|
11026154|NCT04594590||Patients with SLC25A46 deficiency|Male and female patients from age 2 to age 65 with clinically confirmed SLC25A46 mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
11026155|NCT04594577|Experimental|Fluispotter|Fluispotter automated blood sampling system
11026156|NCT04594551|Experimental|Group 1: VRVg-2 + HRIG|"VRVg-2 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21
~+ HRIG at D0"
11026157|NCT04594551|Active Comparator|Group 2: Verorab + HRIG|"Verorab 4 injections: 2 at Day 0, 1 at Day 7, 1 at Day 21
~+ HRIG at D0"
11026158|NCT04594525|Experimental|Perinatal women receiving Low intensity psychosocial interventions|One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low intensity psychological interventions through Telemental health.
11026159|NCT04594525|No Intervention|Participants-Perinatal women (pregnant women and post-partum) not receiving intervention|One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention through Telemental health.
11026160|NCT04594512|Other|LENTICULE IMPLANTATION|The present study may suggest that this procedure safely, reliably, and effectively increases corneal thickness and improves visual acuity with no adverse effects. It may even provide new avenues in the treatment of corneal ectasia. Stem cells and live keratocytes are well organized based on cornea transparency and in anterior segment OCT.
11026161|NCT04594473|No Intervention|Standard of Care (SOC)|Participants randomized to SOC will be instructed to continue their typical lifestyle activity.
11026162|NCT04594473|Experimental|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|Participants randomized to CORE will be instructed to follow the clinical algorithm for this study. An in-clinic assessment consisting of two questionnaires will be used to identify the appropriate pathway for triage. Participants will be triaged into one of three pathways: Physical Medicine & Rehabilitation, Personal Optimism With Exercise Recovery, or Exercise Self-Management.
11026163|NCT04594460|Experimental|experimental Group|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
11026164|NCT04594460|Active Comparator|Control Group|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
11026165|NCT04594447|Other|Physica KR|Subject that receive Physica Kinematic Retaining total Knee replacement system
11026166|NCT04594447|Other|Physica CR|Subject that receive Physica Cruciate Retaining total Knee replacement system
11026167|NCT04594434|Experimental|protocol EMDR + SB / SMP protocol (adjusted)|"Association of a positive memory with the recommended therapy based on EMDR."
11026168|NCT04594434|Active Comparator|protocol EMDR (standard).|"recommended therapy based on EMDR."
11026169|NCT04594408|No Intervention|No epinephrine or TXA|No intervention given.
11026170|NCT04594408|Active Comparator|Epinephrine in irrigation fluid|Epinephrine intervention used.
11026171|NCT04594408|Experimental|Intravenous TXA|Tranexamic acid intervention used.
11026172|NCT04594408|Experimental|Epinephrine and TXA|Epinephrine and tranexamic acid intervention used.
11026173|NCT04594395||Healthy volunteers|Any adult aged 18 to 65 years of age living in Phnom Penh that is sufficiently healthy and willing to undergo fingerstick by the mobile unit for SARS-CoV-2 ELISA assays.
11026174|NCT04594395||Household contacts|Adult relatives of the healthy volunteers.
11026175|NCT04594382|Active Comparator|T30/60|Before extubation, opioid administration will be given by a single dose of opioids in case of measured PDR values of ≥12.
11026176|NCT04594382|Active Comparator|Non-T30/60|A standardized single dose of opioid will be given intravenously before extubation, regardless of the measured pupillometry PDR values.
11026177|NCT04594382|No Intervention|Standard Care group|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
11026178|NCT04594369|Experimental|Brensocatib 10 mg|Participants will receive brensocatib 10 mg once daily, for 52 weeks.
11026179|NCT04594369|Experimental|Brensocatib 25 mg|Participants will receive brensocatib 25 mg once daily, for 52 weeks.
11026180|NCT04594369|Placebo Comparator|Placebo|Participants will receive a brensocatib-matching placebo once daily.
11026580|NCT04591704||Control groups|COVID-19 patients without diabetes mellitus
11026181|NCT04594356||Patients with COVID-19 infection|"As part of this research, existing clinical data of patients infected with COVID-19 is collected from the patients' computerized medical records.
~During the hospitalization of the patients, in addition to the clinical and laboratory data collected, the dosage of IL-6, apparently playing a central role in the worsening of the symptoms of COVID-19, was performed. The remainder of the contents of the tube used to perform this assay will allow further research by assaying the DNA-myeloperoxidase (DNA-MPO) complexes. These complexes reflect a phenomenon called netosis, most likely involved in the widespread inflammation that patients have suffered from."
11026182|NCT04594343|Experimental|Disulfiram|
11026183|NCT04594343|Placebo Comparator|Placebo|
11026184|NCT04594330|Active Comparator|Group 1 - 30 COVID-19 patients aged ≥ 18 years old receiving the investigational drug|Group 1 - 30 COVID-19 patients receiving standard therapy and the investigational drug (Virgin Coconut Oil)
11026185|NCT04594330|Placebo Comparator|Group 2 - 30 COVID-19 patients aged ≥ 18 years old receiving placebo|Group 2 - 30 COVID-19 patients receiving standard therapy and placebo
11026186|NCT04594317|Experimental|low level laser therapy|970 ± 15-nm diode laser (Biolase Epic X, Biolase, Irvine, California, USA)will be activated at 0.5 W and 10 Hz at a distance of approximately 10 mm to the tissue around the apex of the root. A circular movement will be performed during application. Pulse duration will be 0.5 s, and pulse pause will be 50%. Total application time will be30 s for the tooth. For this application, a 200-μm optical tip will be used.
11026187|NCT04594317|Active Comparator|Calcium hydroxide intracanal medication|calcium hydroxide paste (Metapaste, Meta Biomed Co., Ltd, Korea) will be inserted in the canal using disposable plastic tip and placed at a distance 1 or 2 mm less than the working length.
11026188|NCT04594304|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports upon survey completion, and their PCP will receive automatic supports in the EMR to assess and treat the patient's alcohol and/or tobacco use. In cases where a patient does not have risky alcohol and tobacco use, a personalized eToolkit based on their physical activity levels will be administered, and their PCP will receive automatic supports in the EMR to facilitate physical activity discussions. Intervention arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and a 3 months follow-up e-survey following their appointment. Resources will be automatically produced for the patient and PCP following completion of the baseline e-survey.
11026189|NCT04594304|No Intervention|Usual care|The control arm will not receive intervention materials. Control arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and 3 months follow-up e-survey following their appointment.
11026190|NCT04594278|Experimental|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
11026191|NCT04594265|Experimental|3-OHB Monoester|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
11026192|NCT04594265|Placebo Comparator|Placebo Treatment|Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
11026193|NCT04594265|Active Comparator|3-OHB Monoester in presence of low-dose insulin clamp|Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
11026194|NCT04594252|Experimental|ALXN1840|Participants will be administered repeat doses of ALXN1840 30 milligrams (mg) for 15 days.
11026195|NCT04594239|Experimental|Treatment, needle|
11026196|NCT04594239|Experimental|Treatment, cannula|
11026197|NCT04594239|Other|Untreated-control / delayed-treatment, needle|
11026198|NCT04594239|Other|Untreated-control / delayed-treatment, cannula|
11026199|NCT04594226|Experimental|EA combined with medication group|Patients in this group will receive electroacupuncture combined with gabapentin.
11026200|NCT04594226|Active Comparator|Medication group|Participants in this group will only receive gabapentin.
11026201|NCT04594213|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection
11026202|NCT04594213|Experimental|MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL|Intramuscular injection
11026203|NCT04594213|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection
11026204|NCT04594213|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection
11026205|NCT04594200|Experimental|Experimental Arm 1: Harms Emphasis - Simple Comparator - No Viral Rx Pad - No Repeat|The standard approach to providing feedback on antibiotic prescribing tends to focus on lack of benefit for certain conditions. We will compare this against an emphasis on potential harms caused by unnecessary use of antibiotics. In particular, we will provide an infographic to highlight the frequency of antibiotic side effects and emphasize the principle of 'do no harm' in relation to this data. We hypothesize adding an emphasis on harms will change risk perception and intention and thus change antibiotic prescribing behaviour.
11026206|NCT04594200|Experimental|Experimental Arm 2: No Harms Emphasis - Complex Comparator - No Viral Rx Pad - No Repeat|The standard approach to providing feedback on antibiotic prescribing is to provide a simple comparator to represent a target or benchmark, for example, by comparing the recipient's prescribing to the unadjusted median and 25th percentile of all eligible primary care physicians). We will test this against more complex peer comparators (i.e., 25th percentile after adjusting prescribing rates for case-mix and practice characteristics) to represent a 'fair' and achievable target for antibiotic prescribing
11026207|NCT04594200|Experimental|Experimental Arm 3: No Harms Emphasis - Simple Comparator - Viral Rx Pad - No Repeat|The standard approach to providing feedback on antibiotic prescribing is to provide some accompanying information to discourage inappropriate prescribing. We will compare this against the addition of resources meant to enact the intention to prescribe less, namely, the Choosing Wisely Canada Viral Prescription Pad. We hypothesize that adding this resource will increase self-efficacy and thus change antibiotic prescribing behaviour.
11026243|NCT04594044|Experimental|Individual HRT and ERP|Individual treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
11026783|NCT04590261|Other|Group 2|Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, > 5 L/mn Oxygen treatment
11026208|NCT04594200|Experimental|Experimental Arm 4: No Harms Emphasis - Simple Comparator - No Viral Rx Pad - Repeat Letter|We will assess the impact of sending a repeat letter at 1 month to half of the physicians. The aim of the repeat letters at 1 month is to assess if sending a repeat letter at one month will increase salience of and engagement with the feedback and thereby increase effectiveness of the feedback.
11026209|NCT04594200|Experimental|Experimental Arm 5: Harms Emphasis - Simple Comparator - No Viral Rx Pad - Repeat Letter|
11026210|NCT04594200|Experimental|Experimental Arm 6: Harms Emphasis - Complex Comparator - No Viral Rx Pad - Repeat Letter|
11026211|NCT04594200|Experimental|Experimental Arm 7: Harms Emphasis - Complex Comparator - Viral Rx Pad - Repeat Letter|
11026212|NCT04594200|Experimental|Experimental Arm 8: No Harms Emphasis - Complex Comparator - Viral Rx Pad - No Repeat Letter|
11026213|NCT04594200|Experimental|Experimental Arm 9: No Harms Emphasis - Complex Comparator - No Viral Rx Pad - Repeat Letter|
11026214|NCT04594200|Experimental|Experimental Arm 10: Harms Emphasis - Complex Comparator - No Viral Rx Pad - Repeat Letter|
11026215|NCT04594200|Experimental|Experimental Arm 11: No Harms Emphasis - Simple Comparator - Viral Rx Pad - Repeat Letter|
11026216|NCT04594200|Experimental|Experimental Arm 12: Harms Emphasis - Simple Comparator - Viral Rx Pad - Repeat Letter|
11026217|NCT04594200|Experimental|Experimental Arm 13: Harms Emphasis - Complex Comparator - No Viral Rx Pad - No Repeat Letter|
11026218|NCT04594200|Experimental|Experimental Arm 14: Harms Emphasis - Simple Comparator - Viral Rx Pad - No Repeat Letter|
11026219|NCT04594200|Experimental|Experimental Arm 15: No Harms Emphasis - Simple Comparator - No Viral Rx Pad - No Repeat Letter|
11026220|NCT04594200|Experimental|Experimental Arm 16: No Harms Emphasis - Complex Comparator - Viral Rx Pad - Repeat Letter|
11026221|NCT04594187|Experimental|Group I (immunotherapy, radiation therapy)|Within 12 weeks of SLNB, patients start nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). Immunotherapy planned to begin at any time after SLNB.
11026222|NCT04594187|Active Comparator|Group II (immunotherapy)|Patients planned to undergo immunotherapy.
11026223|NCT04594174||Responders|
11026224|NCT04594174||Non responders|
11026225|NCT04594161|Active Comparator|Percutaneous Nephrostomy|drainage of the kidney by means of a percutaneous Nephrostomy
11026226|NCT04594161|Active Comparator|Double J catheter|drainage of the kidney by means of a double J catheter
11026227|NCT04594148|Experimental|Weight-shift training|The experimental group will receive a single session of 10x 2.5min of weight-shift training with the VR Wasp Game
11026228|NCT04594148|No Intervention|Passive control|The passive control group will not receive any form of training. Instead, they will relax for 25min (i.e. talking with the researcher and/or reading a magazine)
11026229|NCT04594135|Experimental|anti-CD5 CAR T cells|Experimental: anti-CD5 CAR T cells Dose escalation phase: anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells with an escalation approach, 1e6 to 5e6 CAR-T cells/kg
11026230|NCT04594122|No Intervention|Control|No intervention in this group
11026231|NCT04594122|Experimental|Intervention|Hygiene package, training, branding, and certification
11026232|NCT04594109|Active Comparator|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
11026233|NCT04594109|Experimental|Tailored Counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
11026234|NCT04594096|Experimental|Immediate Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.
~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.
~Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual."
11026235|NCT04594096|Experimental|Delayed Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.
~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.
~Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits)."
11026236|NCT04594083|Experimental|Palm Stimulator|The Palm Stimulator was placed in the palm of the child's active hand 20 seconds before the injection. It ensured by researcher that the apparatus was held tightly in the child's palm throughout the procedure. The apparatus was taken back from the child after completing the injection process.
11026237|NCT04594083|Experimental|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
11026238|NCT04594083|No Intervention|Control|The routine IM injection was applied to the children in the control group.
11026239|NCT04594070|Active Comparator|Daily iron supplementation|Oral ferrous sulfate, 325 mg, take once daily
11026240|NCT04594070|Experimental|Alternate day iron supplementation|Oral ferrous sulfated, 650mg, taken once daily every other day
11026241|NCT04594057|Active Comparator|Early Start|Begin 6 weeks of gaze and postural stability training 10-14 days following surgery.
11026242|NCT04594057|Experimental|Delayed Start|Begin 6 weeks of gaze and postural stability training 6 weeks following surgery.
11026784|NCT04590261|Other|Group 3|Physician examination in the Pneumology ward, Cochin Hospital
11026244|NCT04594044|Experimental|Group HRT and ERP|Group treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
11026245|NCT04594031|Experimental|ECT-001-CB|"An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.
~Patients will receive standard supportive care and GVHD prophylaxis"
11026246|NCT04594018|Experimental|FINLÂNDIA|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:
~1 tablet finasteride placebo, oral, once a day.
~1 mL Finlândia hair lotion, topical, twice a day."
11026247|NCT04594018|Active Comparator|Minoxidil + finasteride|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:
~1 tablet finasteride, oral, once a day.
~1 mL minoxidil hair lotion, topical, twice a day."
11026248|NCT04594005|Experimental|abemaciclib+paclitaxel|
11026249|NCT04593992|Experimental|HTEMS|High-tone external muscle stimulation 5 times within a week for 12 weeks
11026250|NCT04593992|Placebo Comparator|Placebo|Placebo stimulation 5 times within a week for 12 weeks
11026251|NCT04593966||Pediatric AVM|"AVM patients' age under 18-years-old who underwent intervention in investigators' institution.
~Patients' lesions were located in eloquent and confirmed by image."
11026252|NCT04593966||Adult AVM|"AVM patients' age over 18-years-old who underwent intervention in investigators' institution.
~Patients' lesions were located in eloquent and confirmed by image."
11026253|NCT04593953|No Intervention|CONTROL|Standard general anesthesia
11026254|NCT04593953|Experimental|TLIP|Standard general anesthesia + TLIP block
11026255|NCT04593940|Active Comparator|Remdesivir + infliximab or matching placebo|infliximab (single dose IV 5mg/kg given on day 1) or matching placebo
11026256|NCT04593940|Active Comparator|Remdesivir + abatacept or matching placebo|abatacept (single dose IV 10 mg/kg up to 1,000 mg given on day 1) or matching placebo
11026257|NCT04593940|Active Comparator|Remdesivir + cenicriviroc or matching placebo|cenicriviroc [tablet, Day 1/Loading Dose: 450 mg (300mg morning and 150mg evening) Day 2 - 29/Maintenance Dose: 300 mg (150 mg BID) through Day 29]. or matching placebo
11026258|NCT04593927||Mayzent|Patients administered Mayzent by prescription
11026259|NCT04593914|Experimental|Cavilon Advanced Skin Protectant|"Cavilon Advanced Skin Protectant forms a film barrier intended to protect intact or damaged skin. It is effective in conditions where skin is frequently or continuously exposed to moisture and caustic irritants such as feces, digestive fluids, wound drainage and urine. Cavilon Advanced Skin Protectant also can be used in areas exposed to friction and shear from bedding, clothing, shoes or any other material that would rub against the skin.
~The skin barrier protectant will be applied on the irradiated skin from the third week of radiotherapy until 1 week after the final radiotherapy session."
11026260|NCT04593901|Other|Video and App Review|Single arm study in which home healthcare workers review and provide feedback on scripts and/or videos and on the usefulness, usability, and desirability of an interactive app in an iterative, participatory manner.
11026261|NCT04593888|No Intervention|No intervention|The group will be followed without any intervention, with regular visits at the research clinic.
11026262|NCT04593888|Experimental|Gluten reduced diet|"Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten.
~The group will be followed with regular visits at the research clinic."
11026263|NCT04593862|Experimental|Exercise Group|The exercise intervention will consist of 36 high-volume high-intensity interval sessions over a 12-week period. The exercise frequency will be three times per week during the 6 weeks of intravesical therapy and the 6 weeks of recovery (total 12 weeks) prior to a surveillance cystoscopy.
11026264|NCT04593862|No Intervention|Usual Care:|Patients randomized to the control group will be asked not to initiate any exercise program or to increase their exercise level from baseline during the 12-week study. After the post-intervention assessments and 3-month cystoscopy, patients in the control group will be offered a 4-week supervised exercise program at the Behavioural Medicine Fitness Centre, University of Alberta.
11026265|NCT04593849|Active Comparator|group A (Ru-Yih-Jin- Huang-Saan group)|Herbal medicine(Ru-Yih-Jin- Huang-Saan) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
11026266|NCT04593849|Experimental|group B (Wan-Yin-Gao-Jia-Jean-Wey group)|Herbal medicine (Wan-Yin-Gao-Jia-Jean-Wey) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
11026267|NCT04593849|Placebo Comparator|placebo group( topical agent without therapeutic effects)|topical agent without therapeutic effects will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
11026268|NCT04593849|No Intervention|control group|only oral analgesics will be applied to patients
11026269|NCT04593836|Experimental|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
11026270|NCT04593836|Placebo Comparator|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
11026271|NCT04593823|Experimental|Furoscix Infusor|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).
11026272|NCT04593823|No Intervention|Continued Medical Therapy|The subjects enrolled in this arm will receive treatment as usual
11026273|NCT04593810|Experimental|INTELLiVENT-ASV|Use of INTELLIVENT-ASV after intubation and during all mechanical ventilation in the ICU.
11026274|NCT04593810|Active Comparator|Conventional ventilation|Use of conventional ventilation after intubation and during all mechanical ventilation in the ICU.
11026275|NCT04593797||Patients undergoing major upper abdominal surgery|major open upper abdominal surgery eg pancreatic, liver surgery
11026276|NCT04593784|Experimental|Cohort 1|Subjects receive 10 mg apixaban orally every 12 hours on Days 1 to 3, with a final dose in the morning on Day 4. On Day 4, approximately 4 hours after administering apixaban, study drug (ciraparantag or placebo) will be intravenously administered.
11026339|NCT04593329|Active Comparator|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:
~1 tablet dipyrone, oral;
~1 tablet Tiradentes association placebo, oral;
~1 capsule tramadol placebo, oral."
11026277|NCT04593784|Experimental|Cohort 2|Subjects receive 20 mg rivaroxaban orally once daily in the morning on Days 1 to 4. On Day 4, approximately 4 hours after administering rivaroxaban, study drug (ciraparantag or placebo) will be intravenously administered.
11026278|NCT04593771|Experimental|Experimental group|80 healthy people were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD once.
11026279|NCT04593771|Other|control group|80 healthy people were randomly assigned to the experimental group and the control group. The control group was injected with BCG-PPD was marketed once.
11026280|NCT04593758|Experimental|CPI-613 + Hydroxychloroquine|dosing regimen was 2.5 mg/kg hydroxychloroquine PO followed 2 hours later by 1,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 2.5 mg/kg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.
11026281|NCT04593745|Other|ALL AIEOP-BFM induction|Intraocular pressure messured in children treated with steroids
11026282|NCT04593719|Experimental|Experiment|Lactation management model is applied to the experimental group.
11026283|NCT04593719|No Intervention|Control|Lactation management model is not applied to the control group.
11026284|NCT04593706|Active Comparator|keloids|each patient will be injection by all 4 steroids for comparison patients with 4 or more keloids will be injection with each steroid for different keloid
11026285|NCT04593706|Active Comparator|hypertrophic scars|each patient will be injection by all 4 steroids for comparison patients with a 11 cm hypertrophic scar will be injected by all 4 steroids along the scar with a 1 cm distance between each steroid
11026286|NCT04593693|Other|Invia Motion Endure NPWT system|Use of Negative Pressure Wound Thearpy
11026287|NCT04593680|Experimental|20 HIV-negative TGM will take daily TDF/FTC-based PrEP|"MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption.
~MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants.
~PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively.
~Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: plasma for testosterone, emtricitabine (FTC) and tenofovir (TFV), with an additional tenofovir alafenamide (TAF)."
11026288|NCT04593680|Experimental|20 HIV-negative TGM will take daily F/TAF-based PrEP|"MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption.
~MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants.
~PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively.
~Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: arm 2, measurement; and peripheral blood mononuclear cells (PBMC) for emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) intracellular quantification."
11026289|NCT04593667|Other|Full Inflation|100% TR Band inflation relative to recommended inflation with 15-18 cc air injected in TR band bladder
11026290|NCT04593667|Other|Mid Inflation|75% TR Band inflation relative to recommended inflation with 11-14 cc air injected in TR band bladder
11026291|NCT04593667|Other|Low Inflation|50% TR Band inflation relative to recommended inflation with 8-9 cc air injected in TR band bladder
11026292|NCT04593654||low dose thromboprophylaxis|Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin
11026293|NCT04593654||medium dose thromboprophylaxis|Daily dose of >4500 IU but <175 IU/kg of body weight tinzaparin or >5000 IU but <200 IU/kg of body weight dalteparin
11026294|NCT04593654||high dose thromboprophylaxis|Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin
11026295|NCT04593641|Experimental|Cohort 1 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59
~CT-P59 will be administered
~Drug: Placebo
~Placebo-matching CT-P59"
11026296|NCT04593641|Experimental|Cohort 2 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59
~CT-P59 will be administered
~Drug: Placebo
~Placebo-matching CT-P59"
11026297|NCT04593641|Experimental|Cohort 3 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59
~CT-P59 will be administered
~Drug: Placebo
~Placebo-matching CT-P59"
11026298|NCT04593628|Experimental|All Participants|
11026299|NCT04593615|Experimental|Group A|Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)
11026300|NCT04593615|Placebo Comparator|Group B|Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)
11026301|NCT04593602|Experimental|Early Mobilization Intervention|The bedside nurse determines the prehospital Level of Function based on patient and family report and current Level of Function based on nursing mobility assessment. Each Level of Function has 3 primary activities designed to promote the patient to the next level. The nurse leads mobility activities based on the patient's current Level of Function once per shift, twice daily (AM+PM). If a patient is able to complete each of the 3 activities, the nurse on the subsequent shift will assess whether the Level of Function can be advanced. Physiotherapy consultation is available if required, although not obligatory. Patients are encouraged to spend as much time in the chair and ambulatory as possible.
11026302|NCT04593602|Active Comparator|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
11026303|NCT04593589|Experimental|Transplantation|Submandibular Gland Stem Cell Transplantation
11026304|NCT04593576|Experimental|Structured physical activity/outdoor sports.|Out door sports and structured physical activity protocol will be administered on children with Autism.
11026305|NCT04593576|Active Comparator|Intensive table teaching control group|Control group will only be exposed to intensive table teaching instead of physical activity protocol.
11026306|NCT04593563|Experimental|Psilocybin 25mg|Psilocybin 25mg Single does with supportive conditions.
11026338|NCT04593329|Experimental|TIRADENTES|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:
~1 tablet Tiradentes association, oral;
~1 capsule tramadol placebo, oral;
~1 tablet dipyrone placebo, oral."
11032769|NCT04549259|Experimental|Stigma Reduction|
11026307|NCT04593550||Observational (BrainCheck, 3D-CAM, EEG)|Patients undergo cognitive function assessment BrainCheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3D-confusion assessment over 10 minutes BID on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). Patients also undergo EEG during surgery and collection of blood samples 30-60 minutes after surgery.
11026308|NCT04593537||MDD group|Participants with current major depressive disorder (MDD)
11026309|NCT04593537||Control group|Participants without a family and personal history of a mood disorder, schizophrenia or substance/alcohol abuse but other disorders often co-morbid with MDD are allowed such as anxiety disorders
11026310|NCT04593524|Active Comparator|Treatment Group|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
11026311|NCT04593524|Active Comparator|Counseling Group|24 participants which only receives nutritional counseling for 28 days
11026312|NCT04593511|Experimental|Formulation 1|a single dose of LY03009 F1
11026313|NCT04593511|Experimental|Formulation 2|a single dose of LY03009 F2
11026314|NCT04593511|Experimental|Formulation 3|a single dose of LY03009 F3
11026315|NCT04593511|Experimental|Formulation 4|a single dose of LY03009 F4
11026316|NCT04593498||ESVEA|ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats.
11026317|NCT04593498||Non-ESVEA|Participants not meeting inclusion criteria
11026318|NCT04593485|Experimental|Cohort 1|patients with postoperative recurrence of malignant melanoma of the female genital tract requiring adjuvant therapy, Camrelizumab for injection
11026319|NCT04593485|Experimental|Cohort 2|patients with metastatic or unresectable malignant melanoma of the female genital tract, Camrelizumab for injection
11026320|NCT04593472|Experimental|SHARE|"SHARE components include: 1) a letter from the practice introducing the initiative, 2) access to a designated person (medical assistant, social worker, nurse, or lay person) trained to lead advance care planning discussions, 3) person-family agenda-setting to align perspectives about the role of the caregiver and stimulate discussion about goals of care, and 4) education about communication and available resources, including a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor, a blank easy to complete advance directive, and facilitated registration to the patient portal (for patient and caregiver participants) to extend electronic interactions and information access to family."
11026321|NCT04593472|Placebo Comparator|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
11026322|NCT04593459|Experimental|Probiotic|"Probiotic product consisting of these 7 bacterial strains:
~Lactobacillus salivarius W57
~Lactobacillus casei W56
~Lactobacillus rhamnosus W71
~Lactococcus lactis W58
~Enterococcus faecium W54
~Lactobacillus plantarum W62
~Lactobacillus acidophilus W22
~Additional ingredients: Corn starch, maltodextrin, fructo-oligosaccharides, galacto-oligosaccharides, polydextrose, plant proteins, potassium chloride, magnesium sulfate, bacterial strains, manganese sulfate, lactose, 2000 IU vitamin D
~Participants ingest one sachet of powder (5 grams) in 200 ml of water per day for 6 months"
11026323|NCT04593459|Placebo Comparator|Placebo|"Similar to probiotic product in optics and smell, less ingredients and no bacterial strains or vitamin D
~Ingredients: Corn starch, maltodextrin, potassium chloride, magnesium sulphate, manganese sulphate"
11026324|NCT04593459|Active Comparator|Metformin|"Metformin is an established drug for treating PCOS-related symptoms. The investigators are comparing the probiotic not only to a placebo group, but also to the benchmark treatment.
~Participants in the metformin arm will start treatment with 500 mg daily for the first week, then increasing the dose to 2x500 mg daily for the duration of the intervention."
11026325|NCT04593446|Experimental|Oral Sulfate Tablet(ORA·FANGⓇ)|Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery
11026326|NCT04593446|Active Comparator|Sodium Picosulfate Solution(PicosolutionⓇ)|Subjects who are randomized into experimental arm will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery
11026327|NCT04593433|Experimental|Intervention|Group with the virtual museum guided tours
11026328|NCT04593407|Active Comparator|Endoscopic Mucosal Resection (EMR):|Piecemeal EMR is a conventional endoscopic resection technique. A submucosal injection of a large volume of a solution (normal saline or other) with or without dilute epinephrine (1/10,000) with or without indigo carmine is performed. Then, sequential piecemeal resection is performed with use of a combination of stiff-type snares. At the end of the procedure when macroscopically visible adenoma has been totally resected, a snare tip soft coagulation (STSC) of the margin of the scar is performed to eliminate non visible residual neoplastic tissue. This procedure is quicker and safer than ESD but led to more recurrent disease (around 20% with the standard technique but recently reduced to 5% after the introduction of STSC)
11026329|NCT04593407|Experimental|: Endoscopic Submucosal Dissection (ESD):|ESD is a newer resection technique that allows en bloc resection for large LSLs. A submucosal injection is also needed but, in this case, different endo-knives are used to achieve the resection instead of diathermic snares. The en bloc resection allows a more precise pathological analysis and the risk of recurrence is lower (<2%) when margins are tumor-free.
11026330|NCT04593394||Severe asthma|Gina-guidlines treatment-step 4 or 5
11026331|NCT04593394||Mild-moderate asthma|Gina-guidlines treatment-step 1-3 and good asthma-controll (Score om asthma controll test over 20)
11026332|NCT04593394||Subjects without asthma|Matches control-group without asthma
11026333|NCT04593381|Experimental|SBRT treatment|Intervention: Radiation: SBRT
11026334|NCT04593368|Experimental|FMT|
11026335|NCT04593355||HCV|
11026336|NCT04593342|Active Comparator|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
11026337|NCT04593342|Sham Comparator|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
11032770|NCT04549259|Experimental|SBCM + Technology Detailing|
11026340|NCT04593329|Active Comparator|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:
~1 capsule tramadol, oral;
~1 tablet dipyrone placebo, oral;
~1 tablet Tiradentes association placebo, oral."
11026341|NCT04593316||Exertional heatstroke group|Patients presenting or having presented exertional heatstroke.
11026342|NCT04593316||Control group|Healthy people who never experienced exertional heatstroke.
11026343|NCT04593303|Active Comparator|Internal iliac artery group|Bilateral internal Iliac artery ligation will be done followed by urinary bladder dissection then bilateral uterine artery ligation then manual removal of the placenta then cervico isthmic compression suture. (holding the upper border of the cervix by 4 Allis's forceps then suturing the cervix with the anterior uterine wall using continuous suture), Nelaton catheter18 gauge or Hegar's dilator will be inserted inside cervical canal during Cervico isthmic tamponed suture to ensure patency of cervical canal. .
11026344|NCT04593303|Other|No internal iliac artery group|Bladder dissection then bilateral uterine artery ligation then cervico isthmic suture without internal iliac artery ligation
11026345|NCT04593290|Experimental|Mild Cognitive Impairment (MCI)|MCI is defined as an early stage of cognitive decline that lies between normal age-matched cognitive function and the onset of very mild forms of dementia, and is associated with a slight but noticeable decline in abilities such as memory and thinking skills. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
11026346|NCT04593290|Active Comparator|Cognitively Healthy|This group is 40-85 years old and has no significant neurological or psychiatric disease. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
11026347|NCT04593277|Experimental|Arm I (INSPIRE, telehealth care)|Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.
11026348|NCT04593277|Active Comparator|Arm II (control website)|Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
11026349|NCT04593277|Active Comparator|Group 0 (INSPIRE, printed material)|Patients have access to the digital INSPIRE program and receive printed SCP materials without telehealth.
11026350|NCT04593264|Active Comparator|Traditional Supervised Prehabilitation with a Physical Therapist|
11026351|NCT04593264|Experimental|Self-guided Home-based Prehabilitation|
11026352|NCT04593251|Experimental|CALY-002|
11026353|NCT04593251|Placebo Comparator|Placebo|
11026354|NCT04593238|Experimental|Double antibiotic paste intra-canal medication group (n=25)|500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.
11026355|NCT04593238|Active Comparator|Calcium hydroxide intra-canal medication group (n=25)|Calcium hydroxide paste (Metapaste) placed inside the root canal for 1 week
11026356|NCT04593225|Experimental|TAU + multicomponent treatment VIRTUAL SFCAMINA|VIRTUAL SFCAMINA is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
11026357|NCT04593225|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
11026358|NCT04593225|Active Comparator|Physiotherapy part of VIRTUA SFCAMINA|The physiotherapy part of the VIRTUAL SFCAMINA is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
11026359|NCT04593212||Septic Shock Survivors|
11026360|NCT04593212||Septic Shock Non-Survivors|
11026361|NCT04593199|Sham Comparator|Physical Activity Tracking App Only|Over a 4-week period, participants were asked to use the Fitbit app to track their daily physical activity.
11026362|NCT04593199|Active Comparator|Physical Activity Tracking + Gamified Smartphone App|Over a 4-week period participants were asked to use the Fitbit app to track their daily physical activity. Additionally, they were asked to use the gamified smartphone app, Draco, during the intervention period.
11026363|NCT04593186|Experimental|Trans-oral magnifying endoscopy with NBI|Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
11026364|NCT04593160|Experimental|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
11026365|NCT04593160|Experimental|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
11026366|NCT04593160|Placebo Comparator|Placebo|Preoperative single dose of placebo
11026367|NCT04593147|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with Sn-2 Palmitate, Alpha Lactalbumin and Lactoferrin to better mimic human milk.
11026368|NCT04593147|Active Comparator|Brand|A commercially available Infant Formula, for healthy term infants 0 to 2 months of age (Enfamil TM, Milk-Based Powder with Iron).
11026369|NCT04593134|Experimental|exercise group|A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a Week.
11026370|NCT04593134|No Intervention|usual-care group|These participants follows the standard post-surgery follow-up consisting of counseling by dietitians, nurses and doctors.
11026371|NCT04593121|Experimental|Cohort 1A|Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
11026372|NCT04593121|Experimental|Cohort 2A|Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
11026373|NCT04593121|Experimental|Cohort 3A|Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
11026374|NCT04593121|Experimental|Cohort 4A|Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
11026375|NCT04593121|Experimental|Cohort 5A|Participants will receive Dose 2 of BIIB107 or placebo intravenous (IV) on Day 1.
11026376|NCT04593121|Experimental|Cohort 6A|Participants will receive Dose 5 of BIIB107 or placebo IV on Day 1.
11026377|NCT04593121|Experimental|Cohort 1B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
11026378|NCT04593121|Experimental|Cohort 2B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
11026379|NCT04593121|Experimental|Cohort 3B|Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
11026380|NCT04593108||Letrozole misoprostol|"Group (A):
~A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
11026381|NCT04593108||Misoprostol,placebo|"Group (B):
~A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
11026382|NCT04593095|Experimental|Experimental|Each SSC session will last 2-hr during the day including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise. The 2-hr SSC will be followed by a 1-hr quiet period where infants will rest in their incubator/crib with a pad immersed with their mother breast milk for olfactory stimulation and where the control of light and noise levels will be continued. The NeuroN-QI will be done 4 times/wk for each dyad.
11026383|NCT04593095|No Intervention|Control|Mothers-infant dyads will do 4 SSC/wk. During these sessions, no attempt will be made by the RA to control the light and noise levels nor to encourage auditory stimulation. The SSC periods will not be followed by a quiet period nor olfactory stimulation.
11026384|NCT04593082||Pediatric MS Subjects|Subjects with pediatric MS will undergo fasting lab work, non-contrasted MRI, DEXA scan, and surveys.
11026385|NCT04593082||Healthy controls|Non-MS pediatric control subjects who will undergo fasting lab work, DEXA scan, and surveys for comparison to control group.
11026386|NCT04593069|Other|COVID-19 patients|Neurocognitive impairment in COVID-19 patients
11026387|NCT04593056||Warfarin|Reference group
11026388|NCT04593056||Rivaroxaban|Exposure group
11026389|NCT04593043||Warfarin|Reference group
11026390|NCT04593043||Dabigatran|Exposure group
11026391|NCT04593030||Warfarin|Reference group
11026392|NCT04593030||Apixaban|Exposure group
11026393|NCT04593017|Experimental|Active Probiotic|Probiotic contain active microorganism
11026394|NCT04593017|Placebo Comparator|Placebo Probiotic|Probiotic with no active microorganism
11026395|NCT04593004|Experimental|Teledermatology|
11026396|NCT04593004|Active Comparator|Face-to-face consultation|
11026397|NCT04592991|Active Comparator|AAA Group|"Participants with AAA will undergo routine clinical evaluation of AAA including ultrasound and CT and scheduling of open surgical repair as directed by the treating physician. We will record age and tobacco use of participant. If participant has not had a renal function blood test performed within the past 90 days, we will draw approximately 2 teaspoons of blood for a creatinine test. We will also ask the participant's permission to use a contrast dye for the CT portion of the PET-CT scan. If the participant agrees we will additional questions to gauge eligibility to receive the contrast dye.
~If available, we would like to collect any discarded AAA tissue from the surgical procedure. This discarded tissue will be kept as part of a Washington University vascular research repository. If the participant agrees to this there will be a separate consent form to sign allowing the collection of the leftover tissue along with some information about medical history."
11026398|NCT04592991|Active Comparator|Aortoiliac Occlusive Disease Group|Participants with non-aneurysmal aortoiliac occlusive disease, will be eligible for the study based on lifestyle limiting claudication (lack of blood flow to muscles causing cramping), pain in the feet or toes at rest, and/or tissue loss (leg or foot ulcers that don't heal or gangrene) that requires aortofemoral bypass. The aortofemoral bypass is not part of this research study.
11026399|NCT04592978|Experimental|Pain-Alcohol Personalized Feedback Intervention|
11026400|NCT04592978|Active Comparator|Control Personalized Feedback Intervention|
11026401|NCT04592965|Experimental|Clinical and neuropsychological examinations|Participants will be assessed by means of validated and lab-tailored clinical scales, alongside with semi-structured interviews, to assess the status of the disease (PD), amongst others, such as cognitive capabilities.
11026402|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation|Participants will manipulate a patented robotic system designed to induce the PH and other accompanying bodily illusions. At the end, participants will report on various subjective experiences, by answering a structured questionnaire.
11026403|NCT04592965|Experimental|Resting-state fMRI acquistion|We will acquire resting-state data in the MRI scanner for all the participants. Respiration and heart beat rate data will also be acquired.
11026404|NCT04592965|Experimental|Robot induced PH, through sensorimotor stimulation (MRI)|All healthy participants, and all patients who are deemed capable of performing the robotic manipulation task in the MRI scanner, will take part on this arm. Participants will perform a robotic manipulation task, with a patented robotic system, capable of inducing the PH and other accompanying bodily illusions in the MRI scanner. At the end participants will report on the various subjective experiences, by answering a structured questionnaire.
11026405|NCT04592952|Experimental|Single-Arm|"Provocation Phase: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
~Open-Label Treatment Phase: Erenumab packed in a SureClick® Autoinjector Pen (AI)"
11026406|NCT04592939|Other|Group 1: immediate weight bearing|
11026407|NCT04592939|Other|Group 2: 6 week toe touch weight bearing|
11026408|NCT04592926|Experimental|Accuro ultrasound|
11026409|NCT04592926|Sham Comparator|Control|
11026410|NCT04592913|Placebo Comparator|Arm B|placebo product and FLOT chemotherapy
11026411|NCT04592913|Experimental|Arm A|Durvalumab and FLOT chemotherapy
11026412|NCT04592900|Experimental|the control group|the control group Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and balance training exercises and gait training in open environment.
11026413|NCT04592900|Experimental|the virtual reality group|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
11026414|NCT04592900|Experimental|the Biodex Balance Training group|Group 3 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
11026415|NCT04592887|Experimental|FLASH radiotherapy for painful bone metastasis(-es)|
11026416|NCT04592874|Experimental|AL002 Dose 1|AL002 every 4 weeks
11026417|NCT04592874|Experimental|AL002 Dose 2|AL002 every 4 weeks
11026418|NCT04592874|Experimental|AL002 Dose 3|AL002 every 4 weeks
11026419|NCT04592874|Placebo Comparator|Placebo|Placebo every 4 weeks
11026420|NCT04592861|Experimental|Carbon ion radiotherapy|Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday). The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
11026421|NCT04592861|Active Comparator|Routine standard of care|Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
11026422|NCT04592848||Population study|"Female patients who undergone a cystectomy and/or urinary diversion for a non-malignant disease at Lyon Sud Hospital between January 2007 and December 2019."
11026423|NCT04592835|Experimental|Cohort 1 (288mg)|72 mg/0.3 mL x 4 injection sites
11026424|NCT04592835|Experimental|Cohort 2 (576 mg)|144 mg/0.6 mL x 4 injection sites
11026425|NCT04592835|Experimental|Cohort 3 (960 mg)|216 mg/1.0 mL x 4 injection sites
11026426|NCT04592822|Experimental|Treatment T|30 minutes after the start of a standard breakfast, subjects will take one straw of WD-1602 Dabigatran Etexilate Mesylate Granules (150 mg) in 100 mL water as oral administration.
11026427|NCT04592822|Active Comparator|Treatment R|30 minutes after the start of a standard breakfast, subjects will receive a single Pradaxa® 150 mg capsule swallowed with 240 mL water as oral administration.
11026428|NCT04592809|Active Comparator|Ketamine|0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
11026429|NCT04592809|Active Comparator|Midazolam|0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
11026430|NCT04592796||Nursing-home residents|Older adults in a nursing-home who report a self-perception of poor sleep quality
11026431|NCT04592783|Experimental|Tight Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 140/90 mmHg
11026432|NCT04592783|Experimental|Liberal Blood Pressure Control|Antihypertensive medications will be initialed once BP is at or above 150/95 mmHg
11026433|NCT04592770|Experimental|The experimental intervention (walk):|In this group, the nature walk will take place in a conserved and by far the largest recreational area of Karachi city. The safari park covering an area of 148 acres (0.60 km2), It has a zoo, geared with woodland, mountain viewing, safari tracks, as well as two natural lakes. The experiment will take place in the afternoon on a 5 km marked area. The duration of the stretching exercise sessions will be of 10 minutes followed by 50 minutes' walk session five times per week (total 12 weeks). participants will be asked to walk at moderate pace.
11026434|NCT04592770|Placebo Comparator|The control intervention (sit & relax):|Subjects will undergo 12 weeks of nature therapy that includes exposure to natural landscapes. The duration of the sessions will be 60 minutes five times per week. The subjects will be asked to sit and relax in the evening, in the same recreational area which is used for the experimental group.
11026435|NCT04592757|Experimental|Subacute stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
11026436|NCT04592757|Experimental|Chronic stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
11026437|NCT04592744|Experimental|Intervention|Patients assigned to the study group will receive Ang 2 infusion in addition to standard vasopressor regimen. Ang 2 is currently approved at UCLA as a second line vasopressor and will be used as such for the purposes of our study. Hemodynamic goals will be established at the beginning of the case by the anesthesiology and surgical teams. Ang 2 will be started as a second vasopressor once the norepinephrine dose has reached 0.05mcg/kg/min. Ang 2 will be initiated at a starting dose of 5ng/kg/min. That dose will be up titrated one time to 10ng/kg/min as vasopressor requirements escalate. Once a patient is on the 10ng/kg/min dose of ang 2, no additional up titration will be performed. Hemodynamic management will continue throughout the case with titration of other vasopressors as needed. Ang 2 will be continued throughout the intraoperative period but will be weaned off prior to leaving the operating room.
11026438|NCT04592744|Active Comparator|Control|Patients assigned to the control group will undergo intraoperative management with a standard vasopressor regimen composed of norepinephrine, vasopressin and epinephrine based on hemodynamic goals established by the surgical and anesthesia teams prior to surgery.
11026439|NCT04592731|Experimental|Gel containing Acetylated Natural Nucleotides|
11026440|NCT04592731|Placebo Comparator|Vehicle Gel|
11026441|NCT04592718|Experimental|Slow deep breathing plus breath counting|Participants in this group will do a daily 5-min slow deep breathing exercise (6 breaths/minute) and will also count their breaths
11026442|NCT04592718|Active Comparator|Normal-paced breathing plus breath counting|Participants in this group will do a daily 5-min normal-paced breathing (15 breaths/minute) and will also count their breaths
11026443|NCT04592718|No Intervention|Control|Participants in this group will serve as a control and will not do any breathing exercises or breath counting.
11026444|NCT04592705|Experimental|Therapeutic plasma exchange|
11026445|NCT04592692|Experimental|Inhibitors|Patients with inhibitors to FVIII
11026446|NCT04592692|Other|Non-inhibitors|Patients without inhibitors to FVIII
11026447|NCT04592679|Experimental|FES-C|
11026448|NCT04592679|Active Comparator|Standard|
11026449|NCT04592666|Experimental|Combinational therapy|
11026450|NCT04592666|Active Comparator|Single TKI|
11026451|NCT04592653|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of ALKS 4230.
11026453|NCT04592627||Simulated home environment visit with the dyad participants|The cohort consists of six stroke survivor-informal caregiver (e.g., spouse or family member) dyads. Individual dyads will participate in the simulated home environment visit while the investigative team collects the data.
11026454|NCT04592614|Experimental|High dose|CTM-NS participants receiving monthly virtual group meetings for 2 years (24 meetings total)
11026455|NCT04592614|Experimental|Low dose|CTM-NS participants receiving quarterly virtual group meetings for 2 years (8 meetings total)
11026456|NCT04592601|Experimental|S.L.I.M.M.S. Procedure|Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure
11026457|NCT04592588|Experimental|Common Elements Toolbox (COMET)|The Common Elements Toolbox is an online intervention consisting of modules from empirically supported treatments for common mental health problems.
11026458|NCT04592588|Sham Comparator|Wait-list control condition|
11026459|NCT04592575||TBI that are positive on screening tool|Patients that are identified on the AbilityLab Vestibular screening tool as possibly having vestibular dysfunction
11026460|NCT04592575||TBI patients not positive on screening tool|Patients that are not identified on the Ability Lab Vestibular screening tool as possibly having vestibular dysfunction
11026461|NCT04592562|Experimental|GAE Arm|Patients who meet study eligibility will be scheduled to undergo the Genicular Artery Embolization procedure and will subsequent be followed for 12 months after their procedure.
11026462|NCT04592549|Experimental|Low dose IM injection of active drug or placebo|"Subjects in cohort 1 will receive a low dose IM injection of either active drug or placebo.
~Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo"
11026463|NCT04592549|Experimental|High dose IM injection of active drug or placebo|"Subjects in cohort 2 will receive a high dose IM injection of either active drug or placebo.
~Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo"
11026464|NCT04592549|Experimental|Low dose IV infusion of active drug or placebo|"Subjects in cohort 3 will receive a high dose IV infusion of either active drug or placebo.
~Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo"
11026465|NCT04592549|Experimental|High dose IV infusion of active drug or placebo|"Subjects in cohort 4 will receive a high dose IV infusion of either active drug or placebo.
~Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo"
11026466|NCT04592536|Experimental|CVL-865|High dose CVL-865 (25mg) Low dose CVL-865 (7.5mg)
11026467|NCT04592536|Active Comparator|Alprazolam|Active Comparator Alprazolam with extended release oral tablets; 1 tablet BID
11026468|NCT04592536|Placebo Comparator|Placebo|Placebo Comparator matching oral tablets for CVL-865, capsule for Alprazolam
11026469|NCT04592523||All Participants|Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.
11026470|NCT04592497|Experimental|QDOT|will undergo the AF ablation procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system
11026471|NCT04592497|Active Comparator|standard|will undergo the AF ablation procedure with assistance standard Thermocool Smartouch SF system
11026472|NCT04592484|Experimental|CDK-002|
11026473|NCT04592471||Orthosis Group 1|Use of kneeMID500 device
11026474|NCT04592471||Control Group 1|Control Group of the kneeMID500 Orthosis Group - No use of the device
11026475|NCT04592471||Orthosis Group 2|Use of kneeSTRONG700 device
11026476|NCT04592471||Control Group 2|Control Group of the kneeSTRONG700 Orthosis Group - No use of the device
11026477|NCT04592458|Experimental|Experimental|10 transfusion dependent β-thalassemia major subjects who are 8-16 years older will be transplanted with β-globin restored autologous hematopoietic stem cells that are modified with lentiviral vector LentiHBBT87Q encoding the human β-globin gene.
11026478|NCT04592445|Active Comparator|Axon Treatment Arm|Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
11026479|NCT04592445|Sham Comparator|Sham Control Arm|Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
11026480|NCT04592432|Experimental|SIGN@L-A followed by SIGN@L-B|"Participants in this arm will have access to the prototype SIGN@L-A of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-B."
11026481|NCT04592432|Experimental|SIGN@L-B followed by SIGN@L-A|"Participants in this arm will have access to the prototype SIGN@L-B of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-A."
11026482|NCT04592419|Experimental|KS-301 (Arm A)|Intravitreal injection of KSI-301 (5 mg) at Day 1, Week 4, and once every 8 weeks through Week 20 followed by an individualized dosing regimen of Intravitreal injection of KSI-301 (5 mg) from Week 24 to Week 44.
11026483|NCT04592419|Active Comparator|Aflibercept (Arm B)|Intravitreal injection of Aflibercept (2 mg) once every 4 through Week 20 followed by an individualized dosing regimen of Intravitreal injection of Aflibercept (2 mg) once every 4 from Week 24 to Week 44.
11026484|NCT04592393|Experimental|Abbreviated PB MRI|Short and Focused non-contrast MRI for surveillance
11026485|NCT04592380|Experimental|Stage 1: Clevidipine (double-blinded)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Clevidipine will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter per the Food and Drug Administration (FDA) approved clevidipine label, to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
11026609|NCT04591457|Active Comparator|Insulin Glargine Lantus|Drug product Insulin Glargine, Pen Injector [Lantus] 100 IU/mL (PT. Sanofi-Aventis)
11032771|NCT04549259|Experimental|SBCM|
11026486|NCT04592380|Placebo Comparator|Stage 1: Placebo (double-blinded)|Placebo will be administered in a double-blinded fashion intravenously to all patients randomized to the clevidipine arm in Stage 1. Placebo will be initiated at an initial rate of 2 mg/h for the first 1.5 minutes (90 seconds) and titrated thereafter according to the same dosing instructions as for clevidipine to achieve the target SBP +/- 5 mmHg. If the target SBP is achieved at any of the titration doses, that rate may be continued for up to 24 hours. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
11026487|NCT04592380|Experimental|Stage 2: Clevidipine (open-label)|Clevidipine (0.5 mg/mL in 20% lipid emulsion) will be administered in an open-label fashion intravenously to all patients randomized to the clevidipine arm in Stage 2, following the same dosing instructions as in the clevidipine arm in Stage 1. If the desired BP lowering effect is not attained within 30 minutes or not maintained thereafter, any alternative antihypertensive agent may be used per institutional treatment practice, with or without stopping the study drug infusion.
11026488|NCT04592380|Active Comparator|Stage 2: Standard of Care (open-label)|For patients randomized to SOC, the infusion must be continuous, administered per the institution's treatment practice, and dose titration must be performed to a maximum allowed or maximum tolerated dose to achieve target SBP. If treatment with an alternative IV anti-hypertensive agent is required, the patient will be transitioned to an alternative IV antihypertensive agent according to the institutional standard of care.
11026489|NCT04592354|Active Comparator|Oxaloacetate Therapeutic Arm|"Anhydrous Enol-Oxaloacetate
~A 500 mg oxaloacetate capsule taken by mouth twice a day
~Planned study duration is 6 weeks with an interim assessment at the end of 2 weeks and final assessment at 6 weeks"
11026490|NCT04592354|Placebo Comparator|Placebo Arm|"Rice Flour
~A 500 mg rice flour capsule taken by mouth twice a day"
11026491|NCT04592341|Experimental|Gantenerumab|Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103.
11026492|NCT04592328||Patients planned for elective open cardiac surgery|
11026493|NCT04592315|Experimental|1|Dose 5 mg
11026494|NCT04592315|Experimental|2|Dose 10 mg
11026495|NCT04592315|Experimental|3|Dose 20 mg
11026496|NCT04592315|Experimental|4|Dose 40 mg
11026497|NCT04592315|Experimental|5|Dose 60 mg
11026498|NCT04592315|Experimental|6|Dose 80 mg
11026499|NCT04592302||Smoking Cessation Group|participants are required to cease smoking for 4 weeks prior to and 2 weeks after TJA without any nicotine replacement (any other smoking cessation aids the patient chooses will be allowed)
11026500|NCT04592302||Smoker Group 2|participants who are allowed to continue smoking and using nicotine in any form at their own discretion during the perioperative period
11026501|NCT04592289|Experimental|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery
~Day prior to surgery:
~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml
~18.00 - 19.00 Clear fluids 500 ml
~19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml
~20.00 - 21.00 Clear fluids 500 ml"
11026502|NCT04592289|Active Comparator|Mechanical bowel preparation only|"Day prior to surgery:
~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml
~18.00 - 19.00 Clear fluids 500 ml
~19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml
~20.00 - 21.00 Clear fluids 500 ml"
11026503|NCT04592276|Experimental|PS128|Each PS128 capsule contained 3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg .
11026504|NCT04592276|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
11026505|NCT04592263||Group 1 - Qualitative phase|4 focus groups and 6 semi-structured interviews.
11026506|NCT04592263||Group 2 - Quantitative phase|Pilot study of the tools developed from phase 1.
11026507|NCT04592250||Observational (survey)|Participants will complete a survey packet that is estimated to take about 30 minutes. The survey packet will be collected at baseline and at 6 months.
11026508|NCT04592237|Experimental|Group I (niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive niraparib orally PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11026509|NCT04592237|Experimental|Group II (cetrelimab, niraparib)|"INDUCTION: Patients receive cabazitaxel IV over 60 minutes and carboplatin IV over 60 minutes on day 1. Beginning cycle 2, patients also receive cetrelimab IV over 30-60 minutes on day 1. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive cetrelimab IV over 30 minutes on day 1 and niraparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11026510|NCT04592211|Experimental|olaparib+pembrolizumab+paclitaxel|
11026511|NCT04592198|Experimental|A (Buccal 0.25 Mg)|Palonosetron HCl Buccal Film 0.25 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
11026512|NCT04592198|Experimental|B (Buccal 0.5 Mg)|Palonosetron HCl Buccal Film 0.5 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
11026513|NCT04592198|Active Comparator|C (IV Injection 0.25 Mg)|IV palonosetron 0.25 Mg (ALOXI®) and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
11026603|NCT04591496|Experimental|SmartFeeding4Kids Social Support|SmartFeeding4Kids Social Support: parenting: information about children's healthy diet and effective parental feeding practices, with behavioral intervention and social support (6 sessions plus 2 brief booster sessions online intervention)
11026604|NCT04591496|Active Comparator|SmartFeeding4Kids Health|SmartFeeding4Kids Health: information about children's healthy diet and effective parental feeding practices (6 sessions plus 2 brief booster sessions online intervention)
11026605|NCT04591483||Affected|Patients with Stargardt-like macular dystrophy3 who are >= 10 years of age.
11026606|NCT04591470||General population|
11026514|NCT04592172|Experimental|Bedtime Routine Education|50 families will be randomly assigned to receive the bedtime routine intervention, 3 Cs for Bedtime ZZZs delivered by research assistants at the 12-month and 15-month well-child visits, in additional to receiving usual clinical care. The intervention will take approximately 30-45 minutes to implement at each study visit. Research assistants will be trained and supervised by board-certified Behavioral Sleep Medicine providers. This intervention focuses on developing an individualized bedtime routine, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling, based on parent's preferences. Families will receive appropriate materials for their bedtime routine, including a CuddleBright kit, bedtime books, toothbrush/toothpaste, and the created bedtime chart to take home.
11026515|NCT04592172|No Intervention|Control group|50 families will be randomly assigned to control group (usual care).
11026516|NCT04592159|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
11026517|NCT04592159|Placebo Comparator|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
11026518|NCT04592146|Active Comparator|Control group|Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
11026519|NCT04592146|Experimental|Intervention group|"Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person.
~As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected."
11026520|NCT04592133||Scoliosis Patients|
11026521|NCT04592133||Control Group|
11026522|NCT04592120|Experimental|Coalition Check-Up|The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
11026523|NCT04592120|No Intervention|Technical assistance as usual|Coalitions in the comparison condition will receive a feedback report but no additional support from technical assistance providers beyond what is already available to them.
11026524|NCT04592094|Experimental|Blueback® Physio|Classic protocole with the use of Blueback® Physio during physiotherapy sessions, , and using the Blueback® Physio in the active mode (patient and physiotherapists see the biofeedback in real time)during the tests required by the protocol of the study.
11026525|NCT04592094|No Intervention|Standard Care|Classic protocole without the use of Blueback® Physio during physiotherapy sessions, and using the Blueback® Physio in the blind mode during the tests required by the protocol of the study
11026526|NCT04592081|Experimental|DEXTENZA placed within the upper canaliculus|Dextenza placed within the upper canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
11026527|NCT04592081|Active Comparator|DEXTENZA placed within the lower canaliculus|Dextenza placed within the lower canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
11026528|NCT04592068||Retinal multi-diseases diagnosed by DL algorithm|
11026529|NCT04592068||Retinal multi-diseases diagnosed by expert panel|
11026530|NCT04592042|Experimental|Feel-Good-Group|Pre-post assessment of feasibility and putative efficacy of an emotion-oriented cognitive-behavioral group intervention over 8 sessions and four weeks.
11026531|NCT04592029|Experimental|TACE-Sin-Bev|TACE combined with sintilimab and bevacizumab.
11026532|NCT04592016|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 6 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
11026533|NCT04592016|Experimental|Pivotal Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of diclofenac using dermal open flow microperfusion (dOFM) after topical application of diclofenac sodium products in 20 participants. Additionally systemic appearance of diclofenac is measured by blood sampling.
11026534|NCT04591990|Experimental|AVP + placebo hydrocortisone|REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.
11026535|NCT04591990|Experimental|placebo AVP + hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
11026536|NCT04591990|Experimental|AVP + hydrocortisone|REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
11026537|NCT04591990|Experimental|placebo AVP + placebo hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone
11026538|NCT04591977|Experimental|Self-Sampling Kit|Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
11026539|NCT04591964|Active Comparator|baseline|standard medical therapy + using of mobile application + improving therapy
11026540|NCT04591964|No Intervention|Control|standard medical therapy
11026607|NCT04591470||Pazients undergone inguinal hernia correction|
11026608|NCT04591457|Experimental|Insulin Glargine Sansulin|Drug product Insulin Glargine, Sansulin Log-G 100 IU/mL (PT. Sanbe Farma)
11032772|NCT04549259|Experimental|Technology Detailing|
11026541|NCT04591951|Active Comparator|I2-ART Group|I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
11026542|NCT04591951|Placebo Comparator|Control Group|"The caregivers in the control group will receive usual care."
11026543|NCT04591938|Other|Single arm|Fantom Encore Bioresorbable scaffold implantation
11026544|NCT04591925|Experimental|"Investigative Device - SteadiSet™ device with coil-reinforced soft polymer indwelling cannula"|Participants are randomized into the investigational device (SteadiSet™) insulin infusion set group and then switched to a Commercially available infusion set (using a soft Teflon indwelling cannula) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the investigational infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Control device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
11026545|NCT04591925|Active Comparator|Commercially available Insulin Infusion device using a soft Teflon indwelling cannula|Participants are randomized into the Commercially available insulin infusion set (using a soft Teflon indwelling cannula) group and then switched to Investigative Device infusion set (SteadiSet™) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the Control infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Investigational Device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
11026546|NCT04591912|Experimental|mind. body. voice.|The 10-week mind. body. voice. program.
11026547|NCT04591912|No Intervention|Control|Assessment-only control
11026548|NCT04591899|Experimental|CAD/CAM SS|
11026549|NCT04591899|Active Comparator|Conventionally manufactured SS|
11026550|NCT04591886|Experimental|mind. body. voice.|The 10-week mind. body. voice. program
11026551|NCT04591886|No Intervention|Control|Assessment-only control
11026552|NCT04591873||Critical patients in the emergency department|
11026553|NCT04591860|Active Comparator|Sutures only|"Patients with a large hiatal hernia undergo the cruroplasty with sutures only.
~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
11026554|NCT04591860|Active Comparator|Absorbable Mesh|"Patients with a large hiatal hernia undergo the cruroplasty with mesh implantation.
~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
11026555|NCT04591860|Active Comparator|Pledgeted sutures|"Patients with a large hiatal hernia undergo the cruroplasty with pledgeted sutures.
~A large hiatal hernia is defined as > 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically."
11026556|NCT04591847|Experimental|Vitamin D supplemented group|Vitamin D2 20000 IU 1 tab oral weekly start at GA 18 -22 weeks until delivery
11026557|NCT04591847|Experimental|Placebo group|Placebo drug (Appearance same as Vitamin D2) 1 tab oral weekly start at GA 18 -22 weeks until delivery
11026558|NCT04591834||Observational|No Intervention
11026559|NCT04591808|Experimental|S05167|
11026560|NCT04591808|Active Comparator|Lipitor®|
11026561|NCT04591808|Active Comparator|Coversyl®|
11026562|NCT04591795|Experimental|100 mg SHT extract|Drug: Sahastara remedy alcoholic extract comparison with diclofenac
11026563|NCT04591795|Experimental|25 mg dicolfenac|Drug: diclofenac comparison with diclofenac
11026564|NCT04591782|Experimental|PomJuice (PJ)|8 oz of PJ
11026565|NCT04591782|Active Comparator|Sugar Water|8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
11026566|NCT04591782|Other|Water|8 oz of water
11026567|NCT04591769|Experimental|Group T(Tapered- shaped)|Tracheal intubation using TaperedGuard Tracheal Tube
11026568|NCT04591769|Active Comparator|Group C(Cylindrical-shaped)|Tracheal intubation using Hi-Contour Tracheal Tube
11026569|NCT04591756|Active Comparator|N95 Filtering Facepiece Respirator|Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear
11026570|NCT04591756|Active Comparator|Elastomeric Half-Mask Respirator with P100 filters|Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear.
11026571|NCT04591743|Experimental|Experimental group|
11026572|NCT04591743|Placebo Comparator|Placebo group|
11026573|NCT04591730||Type I maternity|Fathers who experienced a first childbirth in a type I maternity in Lorraine.
11026574|NCT04591730||Type II maternity|Fathers who experienced a first childbirth in a type II maternity in Lorraine.
11026575|NCT04591730||Type III maternity|Fathers who experienced a first childbirth in a type III maternity in Lorraine.
11026576|NCT04591717|Experimental|Cohort 1 (n = 10): hAd5-S-Fusion+N-ETSD at 5 × 1010 VP per dose|(n = 10): hAd5-S-Fusion+N-ETSD at 5 × 1010 VP per dose
11026577|NCT04591717|Experimental|Cohort 2 (n = 10): hAd5-S-Fusion+N-ETSD at 1 × 1011 VP per dose|(n = 10): hAd5-S-Fusion+N-ETSD at 1 × 1011 VP per dose
11026578|NCT04591717|Experimental|Cohort 3 (n = 15): hAd5-S-Fusion+N-ETSD at 1 × 1011 VP per dose (or 5 × 1010 VP per dose)|(n = 15): hAd5-S-Fusion+N-ETSD at 1 × 1011 VP per dose (or 5 × 1010 VP per dose)
11026579|NCT04591704||Diabetic groups|COVID-19 patients with diabetes mellitus
11026581|NCT04591678||SMA nusinersen adult cohort|"The nusinersen treatment will be given as standard of care. The treatment (which is NOT research, but the standard care) will be given by an injection into the cerebrospinal fluid (fluid in your spine) through a needle inserted into your lower back. Participants will receive a 12 mg (5 mL) dose during each administration/injection, which will occur on the following days: 1 (baseline), 15, 29, and 60. Following the 60 day treatment, participants will receive treatment every 4 months (6, 10, 14 etc.).
~After the 60 day, 6 month, 10 month, 14 month, 18 month and 22 month treatments the study team will see each participant afterwards to collect information to evaluate your general health, function and response to the treatment for the study."
11026582|NCT04591652|Experimental|99mTc-MIRC208 SPECT/CT scan|The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.
11026583|NCT04591639|Other|Patients with heart failure without type 2 diabetes|60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
11026584|NCT04591639|Other|Patients with heart failure with type 2 diabetes|60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation.
11026585|NCT04591626|Experimental|Dulaglutide|Dulaglutide administered subcutaneously (SC) in combination with insulin glargine given SC.
11026586|NCT04591626|Placebo Comparator|Placebo|Placebo administered SC in combination with insulin glargine given SC.
11026587|NCT04591613|Other|Standardized clinical and paraclinical follow-up|"Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format.
~All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
~Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
~Total serum, plasma and naso-paaryngeal samples will be collected."
11026588|NCT04591600|Experimental|Ivermectin-Doxycycline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
11026589|NCT04591600|Active Comparator|Control|Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.
11026590|NCT04591587|Active Comparator|Smile Group|Twenty patients (20) underwent SMILE surgery (first group)
11026591|NCT04591587|Active Comparator|Lenticule Group|Twenty patients (20) underwent lenticule implantation (second group)
11026592|NCT04591574|Other|Intervention Group|All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital.
11026593|NCT04591574|Active Comparator|Usual care group|Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital
11026594|NCT04591548||Endometriosis|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
11026595|NCT04591548||Primary infertility|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
11026596|NCT04591535|Experimental|WD-1603 (tablet strength 1) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
11026597|NCT04591535|Experimental|WD-1603 (tablet strength 2) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
11026598|NCT04591535|Experimental|WD-1603 (tablet strength 3) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
11026599|NCT04591535|Experimental|WD-1603 (tablet strength 4) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
11026600|NCT04591522|Experimental|FMT group|Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.
11026601|NCT04591522|No Intervention|control group|
11026602|NCT04591496|Experimental|SmartFeeding4Kids|SmartFeeding4Kids: information about children's healthy diet and effective parental feeding practices, with a behavioral intervention (6 sessions plus 2 brief booster sessions online intervention)
11026610|NCT04591444|Active Comparator|ClinproTM White Varnish|"Application of ClinproTM White Varnish containing sodium fluoride (5%) and Tricalcium phosphate (TCP).
~A technology that allows calcium and phosphate ions to coexist with fluoride ions separately, forming a more resistant mineral on the tooth surface (3M ESPE Clinpro White Varnish; 3M ESPE Clinpro 5000)."
11026611|NCT04591444|Active Comparator|ClinproTM XT Varnish|"Application of ClinproTM XT Varnish, a resin-modified glass ionomer sealant.
~Creates a protective layer on exposed dentin, which is durable and has the ability to release fluoride, calcium and phosphate into the surroundings. (3M ESPE Clinpro XT Varnish)."
11026612|NCT04591444|Placebo Comparator|Placebo Group|Participants who were part of the placebo group continuously used only the conventional toothpaste provided in the oral hygiene kit during the initial four weeks of the research and received a simulated treatment.
11026613|NCT04591431|Experimental|Tailored Therapy|"Patients will be treated with target therapy and/or immunotherapy according to their genomic profile evidenced by the FO (Foundation One) profiling. Patients will be treated with one or more drugs of the following list according to their genomic profile and independently from their type of cancer:
~TARGETED THERAPY (MOLECULAR TARGET) ERLOTINIB (EGFR mutation) TRASTUZUMAB, PERTUZUMAB, TDM1, LAPATINIB (ERBB2 amplifications/mut) EVEROLIMUS (mTOR mutations, AKT mut) VEMURAFENIB, COBIMETINIB (BRAFV600E mutations) ALECTINIB, BRIGATINIB (ALK, RET) PALBOCICLIB (CDK4/6, CDKN2A/p16) PONATINIB (Bcr-abl) VISMODEGIB (SMO/PTCH1) ITACITINIB (JAK mutation) INCB054828 (FGFR1/2/3) IPATASERTIB (PI3K, AKT, PTEN) ENTRECTINIB (NTRK1/2/3 -TRK fusion proteins-, ROS1)
~IMMUNOTHERAPY (BIOMARKERS) ATEZOLIZUMAB, NIVOLUMAB, IPILIMUMAB (MSI, HIGH TUMOR MUTATIONAL BURDEN, OTHER ) Drugs will be administered according to their respective SmPCs (or IBs in case of drugs under development)."
11026614|NCT04591431|Active Comparator|Standard of Care|Patients will be treated according the current version of the AIOM (Italian Association of Medical Oncology) guidelines for their type of cancer. As an example, patients could be treated with standard chemotherapy and/or targeted therapy according to the histological results.
11026615|NCT04591418|Active Comparator|Rotary handpieces|
11026616|NCT04591418|Experimental|Er:YAG laser|
11026617|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 360 children (5-11 years old) on 0 day
11026618|NCT04591405|Placebo Comparator|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
11026619|NCT04591405|Experimental|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.3 logCCID50/ml] in 5640 children (5-11 years old) on 0 day
11026620|NCT04591405|Placebo Comparator|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
11026621|NCT04591392|Experimental|Device|ASD closure with the Carag Bioresorbable Septal Occluder
11026622|NCT04591379|Experimental|Intervention arm|
11026623|NCT04591366|Active Comparator|Control|Standard skin prep prior to procedure will be performed and an adhesive iodine-infused barrier dressing will be applied post procedure but prior to taking the culture swab and closing the incision.
11026624|NCT04591366|Experimental|Intervention|Standard skin prep prior to procedure plus an adhesive iodine-infused barrier dressing prior to incision, post procedure a culture swab will be taken and the incision closed.
11026625|NCT04591353|Experimental|"Investigational group (PENG Block group)"|Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
11026626|NCT04591353|Active Comparator|Control group|"Control group participants will be transferred to the block area preoperatively, and care will proceed as if they were receiving injection.
~Patients will be placed in the supine position resting comfortably. Standard noninvasive monitors will be applied, and oxygen will be administered via nasal cannula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area. The ultrasound probe will be used to identify the iliopubic eminence (IPE). Only skin will be numbed using 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected."
11026627|NCT04591340||test group|all the patients treated with HSCT are with nutrition risk, so they will be all included to accept nutrition therapy.
11026628|NCT04591327||general anesthesia|
11026629|NCT04591327||spinal anesthesia|
11026630|NCT04591314|Experimental|Neurofeedback participants|All the participants studied.
11026631|NCT04591301|Experimental|HEC113995 PA•H2O 2.5mg|Healthy subjects are given HEC113995 PA•H2O 2.5 mg in a single dose.
11026632|NCT04591301|Active Comparator|HEC113995 PA•H2O 5mg|Healthy subjects are given HEC113995 PA•H2O 5 mg in a single dose.
11026633|NCT04591301|Active Comparator|HEC113995 PA•H2O 10mg|Healthy subjects are given HEC113995 PA•H2O 10 mg in a single dose.
11026634|NCT04591301|Active Comparator|HEC113995 PA•H2O 20mg|Healthy subjects are given HEC113995 PA•H2O 20 mg in a single dose.
11026635|NCT04591301|Active Comparator|HEC113995 PA•H2O 40mg|Healthy subjects are given HEC113995 PA•H2O 40 mg in a single dose.
11026636|NCT04591301|Active Comparator|HEC113995 PA•H2O 60mg|Healthy subjects are given HEC113995 PA•H2O 60 mg in a single dose.
11026637|NCT04591301|Active Comparator|HEC113995 PA•H2O 80mg|Healthy subjects are given HEC113995 PA•H2O 80 mg in a single dose.
11026638|NCT04591301|Placebo Comparator|placebo|Healthy subjects are given placebo in a single dose.
11026639|NCT04591288|Experimental|FES + Treadmill|Functional Electrical stimulation walking group.
11026640|NCT04591288|Active Comparator|Treadmill only|Treadmill walking group (no electrical stimulation).
11026641|NCT04591288|No Intervention|Control|"Control group.
~After control period of 12 weeks, they are randomized into FES + Treadmill or Treadmill group."
11026642|NCT04591275|Experimental|CMAB807|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
11033012|NCT04547504|Active Comparator|Pembrolizumab|Pembrolizumab
11026643|NCT04591275|Active Comparator|Prolia®|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
11026644|NCT04591262|Experimental|PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV|PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
11026645|NCT04591249|Other|Usual postoperative care|Participants randomized to usual care group will receive postoperative care as determined by their treating surgeon.
11026646|NCT04591249|Experimental|Usual postoperative care + Physical activity intervention|Participants randomized to the physical activity intervention group will receive usual postoperative care as determined by their treating surgeon and novel physical activity intervention.
11026647|NCT04591236|Experimental|Gait training with brain stimulation|Treadmill gait training and transcranial direct current stimulation (tDCS) on the leg motor areas
11026648|NCT04591236|Active Comparator|Gait training with sham brain stimulation|Treadmill gait training and anodal sham transcranial direct current stimulation (tDCS) on the leg motor areas
11026649|NCT04591223|Experimental|TAU + six weekly sessions of competency-based module (CbM)|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider as well as a well-designed, one on one structural physical workout module to be offered by a licensed senior physical trainer in public sports ground or gymnasium.
11026650|NCT04591223|No Intervention|TAU|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider.
11026651|NCT04591210|No Intervention|No Treatment (Standard of Care)|Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
11026652|NCT04591210|Experimental|ACEi treatment|The physician will initiate any ACE inhibitor and dose at their discretion.
11026653|NCT04591210|Experimental|ARB treatment|The physician will initiate any ARB and dose at their discretion.
11026654|NCT04591184|Experimental|Active VAX-001|Dose-ranging, 2 dose levels and 2 age groups. 24 subjects receiving active i.m. vaccine/arm
11026655|NCT04591184|Placebo Comparator|Placebo|placebo injection. 12 subjects receiving placebo/arm
11026656|NCT04591171|Experimental|n-of-1 trial guided clinical decision making|
11026657|NCT04591158|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
11026658|NCT04591145||Observational group|Patients received bowel preparation and colonoscopy. The withdrawal phase video was saved and their lesions detection was record.
11026659|NCT04591132|Experimental|kinematic analysis|each patient with a diagnosis of parkinsonism, ataxia, chorea, dystonia or tremor will be asked to perform some motor tasks routinely used in clinical evaluation wearing inertial sensors.
11026660|NCT04591119|Active Comparator|Transversus Thoracic Muscle Plane Block (TTMPB) Group|At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
11026661|NCT04591119|Active Comparator|Parasternal Intercostal Block (PSIB) Group|At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
11026662|NCT04591119|No Intervention|Control Group|At the control group, no intervention for pain management will be done.
11026663|NCT04591106||Group 1|50 healthy subjects and 50 subjects with NAFLD between ages of 6-17 years old. Will receive 1 MRI/MRE exam. the MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
11026664|NCT04591106||Group 2|60 subjects with Liver Disease and Fibrosis between ages of 6-17 years old. Will receive 1 MRI/MRE exam. the MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
11026665|NCT04591106||Group 3|15 healthy subjects and 15 at-risk subjects (mother had gestational diabetes) between ages of 1-6 months old. Will receive 1 MRI scan.
11026666|NCT04591093|Active Comparator|CI with FineHearing with 10 more apical electrodes activated then 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated first during 1 month then FineHearing Strategy with 10 more basal electrodes activated during 1 month
11026667|NCT04591093|Active Comparator|CI with FineHearing with 10 more basal electrodes activated then 10 more apical electrodes activated|Cochlear implant with FineHearing Strategy with 10 more basal electrodes activated first during 1 month then FineHearing Strategy with 10 more apical electrodes activated during 1 month
11026668|NCT04591080|Experimental|GUMMETAL TiNbTaZr|"TiNbTaZr (Beta-Titanium) Alloy used to manufacture orthodontic archwires. We will be using an archwire with the size of 0.016 x 0.022"
11026669|NCT04591080|Active Comparator|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
11026670|NCT04591067||Hip Dysplasia group|Subjects who have undergone a periacetabular osteotomy (PAO) for hip dysplasia within the last 1-5 years.
11026671|NCT04591054|Active Comparator|Extended Vision IOL|Vivity
11026672|NCT04591054|Active Comparator|Neutral Aspheric Monofocal IOL|enVista [MX60E]
11026673|NCT04591041|Experimental|Training by Mixed Reality Simulation|
11026674|NCT04591041|Active Comparator|Training by Mannequin Based Simulation|
11026675|NCT04591028|Other|Intervention|Injection of Indocyamine Green.
11026676|NCT04591015|Experimental|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
11026677|NCT04591015|Active Comparator|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
11026678|NCT04591002|Active Comparator|Osemertinib|
11026679|NCT04591002|No Intervention|Observation|
11026680|NCT04590989|Experimental|Personalized Plan (PP)|"Each subject in the PP group will be allocated to one of five clusters based on their metabolic and genetic health biomarkers from samples of urine, plasma, serum and saliva. Up to 58 biomarkers will be included to characterize the 5 metabolic clusters/processes in the PREVENTOMICS platform: 1) oxidative stress; 2) inflammation; 3) carbohydrate metabolism; 4) lipid metabolism; and 5) microbiota-generated metabolites. Simple Feast will create 5 different menus (for each of the five clusters), and meals will be delivered for each subject that matches their most compromised metabolic process for a period of 10 weeks, 6 days per week, including breakfast and dinner. Moreover, a personalized Do's push notifications will be sent via SMS from the predefined ONMI's evidence-based behavioral change program. The program is personalized based on user reports from a behavioral questionnaire at V1, and incorporates inputs from the genetic/nutritional data insights from the PREVENTOMICS platform."
11026681|NCT04590989|Placebo Comparator|Control Group|"Dietary intervention:
~The second group of 50 subjects will receive meals from Simple Feast, after integrating their metabolic profile and other blood biomarkers by PREVENTOMICS, which are based on general dietary recommendations of macronutrients composition.
~Behavioral intervention:
~Subjects will also receive nudges, after filling out ONMI's behavioral questionnaire at V1, but that will not be personalized (i.e. basic information that is available online from NHS and WHO)."
11026682|NCT04590976||Healthcare Professionals (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
11026683|NCT04590976||Stage 1 (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
11026684|NCT04590976||Stage 2 (n = 10)|"Intervention: Single, Think Aloud Interview Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed."
11026685|NCT04590976||Stage 3 (n = 300)|Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit
11026686|NCT04590963|Experimental|Arm A (monalizumab and cetuximab)|monalizumab in combination with cetuximab
11026687|NCT04590963|Active Comparator|Arm B (placebo and cetuximab)|placebo in combination with cetuximab
11026688|NCT04590950||Single-group study|Severe haemophilia B patients substituted with eftrenonacog-alfa
11026689|NCT04590937|Experimental|Reference|
11026690|NCT04590937|Experimental|BI 730357|
11026691|NCT04590911|Experimental|CEP intervention|Cognitive Enrichment Program (CEP) : tailored for individuals who sustain a TBI in later adulthood. The CEP is a 12-week multimodal intervention structured into three modules designed to simultaneously address cognitive problems resulting from TBI, as well as age-related cognitive issues in the following domains: self-awareness, attention and memory, and executive functions.
11026692|NCT04590911|No Intervention|Usual care|Usual care : interventions within a holistic interdisciplinary rehabilitation program focused on resuming daily activities and social roles, if needed, as determined by treating physician; does not include any form of cognitive rehabilitation.
11026693|NCT04590898||significant peri-device leakage after LAA occlusion|Peri-device leakage closure after left atrial appendage occlusion
11026694|NCT04590885|Other|Couple Communication and Support|CCST includes components to assist couples in communicating effectively, decreasing avoidance of important cancer-related issues, and providing each other with support. It includes training in skills for sharing one's thoughts and feelings and listening to one's partner and responding in a supportive manner, and joint problem solving. Participants will be asked to participate inactivities at home between sessions to strengthen skills acquisition.
11026695|NCT04590885|Other|Healthy Lifestyle Informaion|Healthy Lifestyle Information provides couples with health information relevant to cancer in a supportive environment. Sessions focus on the following topics: fatigue, sleep disturbance, nutrition, physical activity, survivorship care plans, and palliative care. Patients and partners are invited to discuss their experiences around the session topics with the therapist and ask questions about the information presented.
11026696|NCT04590872|Experimental|Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)|After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.
11026697|NCT04590859||Penile block|Patients undergoing procedure with penile block
11026698|NCT04590859||caudal block|Patients undergoing procedure with caudal block
11026699|NCT04590846|Experimental|Constipation Health Education|"Health education leaflets are distributed once a week, and students are asked to bring it back to their parents to read. The activity of seeing leaflets, accumulating points, and redeeming prizes is adopted. a reply slip is designed in the weekly health education content, containing 3-5 test questions. Parents need to complete the answers and sign after reading the health education content. Those who have a high degree of correctness and fully paid in within 4 weeks will receive additional points. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. The points of the parent health education receipt and the points of the children will be combined and calculated, and the weight will be set according to the total number of points for the draw."
11026734|NCT04590573|Experimental|CBCT|Cognitive behavioural couple therapy (CBCT), 5-session
11026735|NCT04590573|Experimental|EFCT|Emotion focused couple therapy (EFCT), 5-session
11026736|NCT04590573|Active Comparator|Control|Social activity wait-list groups (Control), 5-session
11026737|NCT04590560|No Intervention|1-year screening interval|Women will follow the normal screening program (they will be invited to screen every year)
11026738|NCT04590560|Experimental|2-year screening interval|Women will be invited to screen every two years
11026785|NCT04590261|Other|Group 4|Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
11026700|NCT04590846|Active Comparator|General Health Course|"In order to correctly evaluate the effectiveness of health education intervention, only the parents of the experimental group will receive the health education leaflet during the intervention period. However, after the end of the trial, an electronic file of parental health education in the control group will be provided. Students are required to keep a  Stool diary record sheet  every day, and it will be posted in the contact book. Children who have confirmed records and turned in will get 10 points a week, and those who turned in all 8 weeks without random answers can get extra points. After the children's points are counted, a lottery will be drawn based on the total number of points. Since the experimental group and the control group have different benchmarks for points, the lottery will be drawn separately from each school. During the lottery process, the time will be announced in advance, and the number will be randomly selected by the computer in a live broadcast method."
11026701|NCT04590833|Experimental|Aerobic exercise group|
11026702|NCT04590833|Placebo Comparator|Attention control group|
11026703|NCT04590820|Experimental|Tazemetostat + Rituxan|"Tazemetostat 800 mg BID is administered daily starting on Cycle 1 Day 1.
~Rituximab will be administered by either Subcutaneous injection or IV infusion on Day 1, 8, 15, and 22 of Cycle 1, and then on Day 1 of Cycles 3 through 6, accounting for an additional 4 doses, i.e., a total of 8 doses of rituximab in 6 cycles."
11026704|NCT04590807|Active Comparator|Posterior spinal fusion with pedicle screws|
11026705|NCT04590807|Active Comparator|Anterior vertebral body tethering|
11026706|NCT04590794||covid 19|Patients admitted with covid 19
11026707|NCT04590781|Experimental|Part A: XmAb18087 Monotherapy|Part A, will enroll subjects with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
11026708|NCT04590781|Experimental|Part B: XmAb18087 + pembrolizumab|Part B, will enroll subjects with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
11026709|NCT04590781|Experimental|Part C: XmAb18087 monotherapy|Part C will enroll subjects with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
11026710|NCT04590768|Experimental|Fermotein™|daily lunch with 11 grams of Fermotein™ dry powder, mixed in bread, soup or a burger
11026711|NCT04590768|Active Comparator|Matched control products|daily lunch with a control bread matched in macronutrient content. Control meat alternative burgers and soup from the local supermarket.
11026712|NCT04590755|Experimental|Interactive father-child sessions and use of website|Intervention group will receive the Run Daddy Run intervention.
11026713|NCT04590755|No Intervention|No intervention (no interactive father-child sessions and use of website)|Intervention group will not receive the Run Daddy Run intervention.
11026714|NCT04590742|Placebo Comparator|Group 1|Placebo Tablet
11026715|NCT04590742|Active Comparator|Group 2|Melatonin (6mg)
11026716|NCT04590729|Experimental|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
11026717|NCT04590729|Experimental|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 15 minutes for 3 hours to match the total exercise duration in the first protocol.
11026718|NCT04590729|No Intervention|Sitting|Sitting control.
11026719|NCT04590703||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
11026720|NCT04590703||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
11026721|NCT04590677||Group 1|Pregnant women at 36 weeks gestational age, who are not expected to have risk factors for preterm birth, n=150.
11026722|NCT04590677||Group 2|Pregnant women who have presented with signs and symptoms of threatened preterm labour (e.g. ruptured membranes, contractions, bleeding), at or after 24 weeks gestation, n=50.
11026723|NCT04590664|Experimental|Treatment (verteporfin)|Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11026724|NCT04590651|Experimental|Standard PHACO cataract surgery|In this group normal phacoemulsification cataract surgery will be preformed.
11026725|NCT04590651|Experimental|PHACO + extra aspiration|In this group an extra one minute anterior chamber angle aspiration will be preformed at the end of a standard cataract operation.
11026726|NCT04590625|Experimental|Group1|"Neoadjuvant therapy:
~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.
~Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.
~Adjuvant therapy:
~After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.
~Adjuvant therapy is 3 cycles
~maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
11026727|NCT04590625|Experimental|Group2|"1.Adjuvant therapy:
~After primary cytoreductive surgery,patients will received adjuvant therapy:
~Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.
~Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years."
11026728|NCT04590612|Active Comparator|Carbidopa-Levodopa|Patients will be randomized to any of the 2 arms. In Levodopa/carbidopa arm, patients will be taking Carbidopa-Levodopa (25-100mg) three times a day for the duration of the study.
11026729|NCT04590612|Experimental|Citalopram|Patients will be randomized to any of the 2 arms. In Citalopram arm, patients will be taking Citalopram (20mg) daily for the duration of the study.
11026730|NCT04590599|Experimental|Placebo+Sintilimab|
11026731|NCT04590599|Experimental|IBI310+Sintilimab|
11026732|NCT04590586|Experimental|Placebo and standard of care (SoC)|
11026733|NCT04590586|Placebo Comparator|Apremilast and standard of care (SoC)|
11026739|NCT04590560|Experimental|3-tailored screening interval|the screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)
11026740|NCT04590547|Experimental|GLS-1027 120 mg|One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily
11026741|NCT04590547|Experimental|GLS-1027 360 mg|Three 120 mg pills of GLS-1027 given by mouth once daily
11026742|NCT04590547|Placebo Comparator|Placebo|Three Placebo pills given by mouth once daily
11026743|NCT04590534|Experimental|study Group A|patients will receive one capsule of [garcinia 500 mg and chromium 281 mg] 3 times daily for 12 weeks.
11026744|NCT04590534|Active Comparator|Active control Group B|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
11026745|NCT04590534|Placebo Comparator|Placebo Group C|patients will receive placebo 3 times daily for 12 weeks
11026746|NCT04590521|Experimental|Intervention|A standard 3-dose schedule (0, 1 and 6 months) of licensed HPV vaccine (Cervarix®, GSK) will be administered to all participants intramuscularly.
11026747|NCT04590508|Experimental|Xanthohumol|Participants will take capsules containing 24 mg of xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
11026748|NCT04590508|Placebo Comparator|Placebo|Participants will receive capsules filled with a rice protein vehicle by mouth once daily with the first daily meal.
11026749|NCT04590495|Active Comparator|300 mg Cannabidiol (CBD) oil|
11026750|NCT04590495|Placebo Comparator|Placebo|
11026751|NCT04590482|Experimental|letrozole then misoprostol|description:letrozole 2.5 mg each 12hours for 2 days at home followed by misoprostol 800mcg vaginally at hospital repeated after 4 hours if needed
11026752|NCT04590482|Placebo Comparator|placebo then misoprostol|Description:placebo each 12 hours for 2days at home followed by 800mcg misoprostol vaginally at hospital and repeat dose after 4 hours if needed
11026753|NCT04590469|Experimental|WHELD training/virtual coaching programme supported with digital resources|WHELD training/virtual coaching programme supported with digital resources
11026754|NCT04590469|No Intervention|Treatment as Usual|Usual Best practice
11026755|NCT04590456|Experimental|Placebo group|
11026756|NCT04590456|Experimental|PEMF group|
11026757|NCT04590443|Experimental|NMP in Infrapiriformis level|Participants in this group received NMP of the sciatic nerve in the gluteus region
11026758|NCT04590443|Experimental|NMP in middle thigh level|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
11026759|NCT04590443|Experimental|NMP in middle distal level|Participants in this group received NMP of the sciatic nerve before popliteus region
11026760|NCT04590430|Experimental|HFB30132A|Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
11026761|NCT04590430|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
11026762|NCT04590417|Other|20 HIV-negative TGW|A single-arm prospective PK study of HIV-negative TGW taking FHT and daily PrEP.
11026763|NCT04590404|Experimental|MIST (Metabolism-Informed Smoking Treatment)|At hospital discharge, participants randomized to the MIST precision care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescriptions will be informed by nicotine metabolism (i.e., NMR result) such that faster metabolizers are prescribed varenicline and slower metabolizers are prescribed NRT.
11026764|NCT04590404|Active Comparator|Usual Care|At hospital discharge, participants randomized to the Usual Care arm will receive a prescription for medication (either varenicline or NRT). Post discharge, participants will receive automated phone calls via TelASK to promote continued engagement. Medication prescription will not be informed by nicotine metabolism.
11026765|NCT04590391|Other|Visual and Auditory Breathing-swallowing Coordinated Training device|
11026766|NCT04590378||Covid-19 Patients with Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
11026767|NCT04590378||Covid-19 Patients without Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
11026768|NCT04590365|Experimental|Coldamaris plus|verum Coldamaris plus i.e. Iota-carrageenan 0.12% in 0.5% saline
11026769|NCT04590365|Placebo Comparator|Coldamaris sine|Coldamaris sine i.e. 0.5% saline
11026770|NCT04590352||Index case and household contacts|"nasophryngeal and throat swab at day 0.
~collection of mucosal lining fluid: day 0, 7, 14, 28 for index case and day 0, 3, 6, 28 for household contacts.
~fingerprick at day 28 (optional).
~daily record of symptoms from day 0-28."
11026771|NCT04590339|Active Comparator|Repositioning the bone window|Computer guided inferior alveolar nerve lateralization and implant placement with subsequent repositioning of the osteotomized bone window.
11026772|NCT04590339|Active Comparator|Augmentation using sticky bone|Computer guided inferior alveolar nerve lateralization and implant placement with grafting around the implant using sticky bone
11026773|NCT04590326|Experimental|Module 1|REGN5668 and cemiplimab
11026774|NCT04590326|Experimental|Module 2|REGN5668 and REGN4018
11026775|NCT04590313|Active Comparator|Arthrodesis|MTPJ I Arthrodesis
11026776|NCT04590313|No Intervention|Watchful waiting|No intervention, patient information leaflet
11026777|NCT04590300|Other|Schizophrenia|"1 questionnaire at the beginning of the study, before FTE program
~1 questionnaire at the end of FTE"
11026778|NCT04590300|Other|Bipolar disorder|"1 questionnaire at the beginning of the study, before FTE program
~1 questionnaire at the end of FTE"
11026779|NCT04590287||Patients after ischemic stroke|The analysis included the presence of CVD risk factors in patients after ischemic stroke durning in the early rehabilitation.
11026780|NCT04590287||Patients after hemorrhagic stroke|The analysis included the presence of CVD risk factors in patients after hemorrhagic stroke durning in the early rehabilitation.
11026781|NCT04590274|Experimental|Regimen|0-400 mg Hydroxychloroquine 0-500 mg Azithromycin 0-50 mg elemental Zinc 0-3,000 mg Vitamin C 0-5,000 IU Vitamin D3 0-1200 mg N-acetylcysteine 0-600 mg Elderberry 0-600 mg Quercetin
11026782|NCT04590261|Other|group 1|Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
11026786|NCT04590248|Experimental|Adavosertib|Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
11026787|NCT04590235|Experimental|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. Then, selumetinib 25 mg/m^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
11026788|NCT04590222||Female, BMI≥30, mild|"Females:
~Obese BMI≥30 With Mild infection n = 10"
11026789|NCT04590222||Female, BMI≥30, severe|"Females:
~Obese BMI≥30 With severe infection n = 10"
11026790|NCT04590222||Female, BMI<30, mild|"Females:
~Non-Obese BMI<30 With Mild infection n = 10"
11026791|NCT04590222||Female, BMI<30, severe|"Females:
~Non-Obese BMI<30 With severe infection n = 10"
11026792|NCT04590222||male, BMI≥30, mild|males: Obese BMI≥30 With Mild infection n = 10
11026793|NCT04590222||male, BMI≥30, severe|males: Obese BMI≥30 With severe infection n = 10
11026794|NCT04590222||male, BMI<30, mild|males: Non-Obese BMI<30 With Mild infection n = 10
11026795|NCT04590222||male, BMI<30, severe|males: Non-Obese BMI<30 With severe infection n = 10
11026796|NCT04590222||Healthy donors from the EFS (Etablissement Français du Sang, St Louis)|Healthy donors from the EFS (Etablissement Français du Sang, St Louis) including 5 men and 5 women
11026797|NCT04590209|Experimental|Acrosyndrome|"The blood sample, skin biopsy and other biological samples will be taken from patients
~The precise description of the semiology of skin lesions, their topography, as well as the analysis of the entire skin integument and mucous, cardiac and pulmonary auscultation and neurological examination will be done as required."
11026798|NCT04590196|Experimental|treatment|
11026799|NCT04590196|Placebo Comparator|control|
11026800|NCT04590183|Experimental|The experimental group|
11026801|NCT04590183|Sham Comparator|The control group|
11026802|NCT04590157|Experimental|study group|received pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints
11026803|NCT04590157|Experimental|control group|received pelvic floor muscle training
11026804|NCT04590144|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead
11026805|NCT04590131|Experimental|Hubrid revaskularization|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
11026806|NCT04590131|Active Comparator|Endovascular treatment|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
11026807|NCT04590118|Experimental|Experimental: it-hMSC|Single intravenous infusion of 0.5×10^6, 1×10^6, 2×10^6 it-hMSC/kg
11026808|NCT04590118|Placebo Comparator|Placebo-controlled: Placebo|Single intravenous infusion of 1 ml/kg placebo
11026809|NCT04590105|Experimental|App Subject|"Users who were assigned to use a smartphone app downloaded a free app from the iOS App or Google Play stores titled SB Colonoscopy Prep. The app informed subjects about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite."
11026810|NCT04590105|Active Comparator|Written Instruction Subjects|Subjects in the control group were given a three-page document that described the procedure and instructed users on how to take the preparation medications. The written instructions had a list of frequently asked questions about colonoscopies and the URL of a website where users could view the animated video that was included in the app. The written instructions also contained the time and date of the procedure. All subjects were instructed to arrive one hour before their scheduled procedure.
11026811|NCT04590092|No Intervention|Control|Study Participants who do not receive a pessary. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and will continue to have standard antenatal care with their maternity provider.
11026812|NCT04590092|Experimental|Pessary|Study Participants who are fitted with a pessary for urinary incontinence. This group will be given an information pamphlet on pelvic floor (Kegel) exercises in pregnancy and pessary use in pregnancy. They will continue to have standard antenatal care with their maternity provider.
11026813|NCT04590079|Experimental|First intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment and daily sessions with the medical device - 1 month of wash-out - 3 months of conventional pain treatment.
11026814|NCT04590079|Experimental|Second intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment - 1 month of wash-out - 3 months of conventional pain treatment and daily sessions with the medical device.
11026815|NCT04590066|No Intervention|Holdout control|Participants will only receive the standard pharmacy messaging.
11026816|NCT04590066|Experimental|Unpacking Risks Treatment|Participants will be asked to think about the risks of catching the flu this flu season and to respond with the location they are most likely to catch the flu out of a list of given options (e.g. at work, at home).
11026817|NCT04590066|Experimental|Unpacking Risks Control|Participants will be asked to think about the risks of catching the flu this flu season and to respond to confirm that they have received the message.
11026818|NCT04590066|Experimental|Active Commitment Treatment|"Participants receive a gain framed notification that they are eligible for a flu shot. In addition, participants are told Many people find it helpful to make a plan to get their shot and are asked to commit by texting back I will get a flu shot. Depending on their response, participants receive a general reminder or a commitment reminder 3 days later."
11026819|NCT04590066|Experimental|Active Commitment Control|Participants receive a gain framed notification that they are eligible for a flu shot. Participants receive a general reminder 3 days later.
11026820|NCT04590066|Experimental|Self-Generated Social Norms Treatment|Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
11026821|NCT04590066|Experimental|Self-Generated Social Norms Control|articipants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
11027800|NCT04583566||COVID-19 Severe Symptoms|Patients with severe symptoms need oxygen and ventilation.
11026822|NCT04590066|Experimental|Foot-in-the-Door Treatment|Participants will first receive a message enjoining them to encourage someone else to receive a flu vaccine this year. They will then be given a message that they might copy-paste to forward to friends, thereby lowering the effort costs of messaging others. They will receive a reminder 3 days later.
11026823|NCT04590066|Experimental|Foot-in-the-Door Control|Participants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
11026824|NCT04590066|Experimental|Prosocial Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (i.e., protecting loved ones; preserving scarce resources).
11026825|NCT04590066|Experimental|Self-Oriented Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot.
11026826|NCT04590066|Experimental|Prosocial + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (e.g., protecting loved ones; preserving scarce resources). The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
11026827|NCT04590066|Experimental|Self-Oriented + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
11026828|NCT04590066|Experimental|Dynamic + Static Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before and how many Americans got their flu shot last year.
11026829|NCT04590066|Experimental|Dynamic Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before.
11026830|NCT04590066|Experimental|Dynamic Norms Control|Participants will only receive a text message encouraging them to get a flu shot. They will not receive any norm information.
11026831|NCT04590066|Experimental|Sharing Humor|Participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
11026832|NCT04590066|Experimental|Humor Placebo|Participants will receive a text message encouraging them to get the flu shot. This message will include the same joke but participants will not be encouraged to share it.
11026833|NCT04590066|Experimental|No Humor Condition|Participants will receive a text message encouraging them to get the flu shot.
11026834|NCT04590066|Experimental|Connecting the Past Self to the Future Self Treatment|"Participants will receive a text message prompt to recall the negative experience of getting sick. When asked, Do you wish you could have avoided getting sick by getting a simple shot?, participants will have the chance to respond Y for yes or N for no. Regardless of their response, they will be prompted with a second text message to connect their past experience with present-day opportunities for preventative care (getting a flu shot) to protect the future self from the flu."
11026835|NCT04590066|Experimental|Connecting the Past Self to the Future Self Control|In the first text message, participants will receive a simple text message encouragement to receive a flu shot. In the second text message, they will receive a reminder of the appointment time and provider name.
11026836|NCT04590066|Experimental|Reverse Inference Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are healthier, wealthier, and more educated.
11026837|NCT04590066|Experimental|Reverse Inference Control Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are less likely to get the flu.
11026838|NCT04590053|Experimental|COVID-19|Up to 24 subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
11026839|NCT04590040|Placebo Comparator|Toothpaste 1|Toothpaste 1 containing 0% nano-hydroxyapatite (HAP) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
11026840|NCT04590040|Active Comparator|Toothpaste 2|Toothpaste 2 containing 15% nano-HAP will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
11026841|NCT04590040|Active Comparator|Toothpaste 3|Toothpaste 3 containing 5% potassium nitrate (KNO3) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
11026842|NCT04590014|Active Comparator|Conventional HVNI Device Design (Control)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea.
11026843|NCT04590014|Experimental|New HVNI Device Design (Randomized)|The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
11026844|NCT04590001|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD device.
11026845|NCT04589988|Experimental|REBIL- Intervention arm|Participants in this arm will receive the Removing Environmental Barriers to Independent Living (REBIL) intervention.
11026846|NCT04589988|Sham Comparator|Waitlist Attentional control|Participants in this arm will receive a sham intervention until the 6 month follow-up visit. At that point participants in this arm will receive the full REBIL intervention.
11026847|NCT04589962||Percutaneous Group|
11026848|NCT04589962||Surgical Group|
11026849|NCT04589949|Experimental|ConvP|300 mL convalescent plasma with a minimum of neutralizing antibodies
11026850|NCT04589949|Active Comparator|FFP|300 mL Fresh Frozen plasma
11026851|NCT04589936|Experimental|COVID-19|Non-ventilated patients with COVID-19
11026852|NCT04589936|Active Comparator|Pneumonia control|Patients with pneumonia unrelated to COVID-19 requiring supplemental O2.
11026906|NCT04589611|Placebo Comparator|Phase IIa Part 1 Placebo|10 subjects will be randomized to amobarbital/Gel-One single dose.
11026853|NCT04589923||Group 1 - participants expected to have abnormal oxygen saturation|Within each study session, participants will have their oxygen saturation, heart rate and respiratory rate measured three times using standard of care equipment and methods. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's primary and secondary objectives only. The app does not return any measurements to the user or participant.
11026854|NCT04589923||Group 2 - participants expected to have abnormal blood pressure|Within each study session, participants will have their blood pressure and respiratory rate measured three times using standard of care equipment. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's secondary objectives only. The app does not return any measurements to the user or participant.
11026855|NCT04589910|Other|Ultra-sound arm|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
11026856|NCT04589897|Experimental|Experimental|Manuka honey sinus rinse
11026857|NCT04589897|Active Comparator|Standard|Standard sinus rinse
11026858|NCT04589884||Parathyroid disease|
11026859|NCT04589884||Thyroid disease|
11026860|NCT04589884||Liver tumors and metastases|
11026861|NCT04589884||Digestive tumors|
11026862|NCT04589884||Digestive perfusion|
11026863|NCT04589871|Experimental|Group A|Group A received a taping technique in addition to the supervised exercises protocol
11026864|NCT04589871|Active Comparator|Group B|Group B received supervised exercises protocol only
11026865|NCT04589858|Active Comparator|Group A|Received a supervised exercise protocol including both strengthening and stretching exercises for specific muscle groups.
11026866|NCT04589858|Experimental|Group B|Received manual therapies including both myofascial mobilization and manipulation technique in addition to a supervised exercise protocol.
11026867|NCT04589845|Experimental|Cohort A: ROS1 fusion-positive tumors|Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) >/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
11026868|NCT04589845|Experimental|Cohort B: NTRK1/2/3|Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA >/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
11026869|NCT04589845|Experimental|Cohort C: ALK fusion-positive tumors|Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.
11026870|NCT04589845|Experimental|Cohort D: TMB-high tumors|Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged >/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle.
11026871|NCT04589845|Experimental|Cohort E: AKT1/2/3 mutant-positive tumors|Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants <35 kg, 300 mg for participants >/= 35 and <45 kg, 400 mg for those >/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
11026872|NCT04589845|Experimental|Cohort F: HER2 mutant-positive tumors|Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.
11026873|NCT04589845|Experimental|Cohort G: MDM2-amplified, TP53 wild-type tumors|Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle.
11026874|NCT04589845|Experimental|Cohort H: PIK3CA multiple mutant-positive tumors|Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.
11026875|NCT04589832|Experimental|Study Treatment Arm|Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIST 1.1 criteria), unacceptable toxicity, subject withdrawal of informed consent, or subject death either from progression of disease, the therapy itself, or from other causes.
11026876|NCT04589819|Active Comparator|Teriparatide|Study participants will be randomized into either the study medication arm or a placebo arm. The study medication Forteo (teriparatide [rDNA origin] injection) (El-Lilly, Indiana, USA), will be administered via an blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection.
11026877|NCT04589819|Placebo Comparator|Placebo|The placebo will be administered in a replica, blinded, injection pen in the same fashion. The study participant will self-administer the medication after being given a teaching session on medication administration by the study nurse.
11026878|NCT04589806|Experimental|2-stage ridge splitting with simultaneous implant placement|
11026879|NCT04589793|No Intervention|Control|Conventional treatment
11026880|NCT04589793|Active Comparator|Intervention|Motivational interview
11026881|NCT04589780||Posture Assessment|Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958
11026882|NCT04589780||Sagittal spinal alignment and mobility|Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device.
11026883|NCT04589780||Injury risk assessment|Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS
11026884|NCT04589767||children admitted in PICU|children enrolled will be evaluated by two nurses using CAPD Italian version. One nurse will repeat the evaluation two minutes later.
11026885|NCT04589754|Experimental|Sintilimab plus chemotherapy|Adriamycin and ifosfamide combined with sintilimab in the treatment of advanced or unresectable soft tissue sarcoma
11026886|NCT04589741|Experimental|toripalimab combined with CAV / IE regimen|toripalimab combined with CAV / IE regimen in patients with advanced or unresectable bone and soft tissue sarcomas who failed standard treatment
11026887|NCT04589728||Study group|All patients being observed during the study duration.
11026888|NCT04589715|Experimental|electroacupuncture group|patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
11026889|NCT04589715|Sham Comparator|sham electroacupuncture group|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
11026890|NCT04589702||females with isolated patellofemoral arthritis|those with anterior knee pain
11026891|NCT04589702||healthy females|those without anterior knee pain
11026892|NCT04589689|Experimental|Intervention Group|The intervention group will participated in the The Insul-In This Together intervention, which consists of 6 weekly 30-minute online family sessions to discuss topics related to diabetes distress and parent-teen communication. Sessions include structured education, discussions, and skill-building activities related to parental involvement, parental monitoring, and parent-adolescent conflict. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week follow-ups (after every 2 sessions for the intervention group and later the control group). Participants will be asked to report their A1Cs (or gathered from chart review) at baseline, 6, and 12-month follow up.
11026893|NCT04589689|Experimental|Waitlisted Control Group|The waitlisted control group will receive the same intervention as the intervention group, but at the 6-month follow-up mark. The intervention will be conducted by the PI or clinically trained research staff via Zoom. Online surveys, and glucose monitoring data will be captured at baseline and 3,6 and 12-month follow-ups. Brief surveys will also be conducted at 2-, 4-, and 6-week from baseline. Participants will be asked to report their A1Cs (or gathered from chart review).Participants will be asked to report their A1Cs (or gathered from chart review) at baseline, 6, and 12-month follow up.
11026894|NCT04589676|Active Comparator|Face-to-face training|Participants in the face-to-face training condition will receive training in groups of 20. Standardized content will teach them to use the PulsePoint app, respond safely to calls, and administer Naloxone.
11026895|NCT04589676|Experimental|Online training|Participants in the online training condition will receive training in groups on Smartphones and other devices at their own pace. Standardized content will teach them to use the PulsePoint app, respond safely to calls, and administer Naloxone.
11026896|NCT04589663|Experimental|Mometasone furoate followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 followed by a single inhaled dose of QMF149 on Day 6
11026897|NCT04589650|Experimental|Adult cohort (group 1)- Alpelisib|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
11026898|NCT04589650|Placebo Comparator|Adult cohort (group 1)- Placebo|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo (125 mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
11026899|NCT04589650|Experimental|Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib|During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
11026900|NCT04589650|Placebo Comparator|Pediatric cohort (group 2: 6 to 17 years old)-Placebo|During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo (50mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
11026901|NCT04589650|Experimental|Pediatric cohort (group 3: 2 to 5 years old)- Alpelisib|Pediatric participants (2 to 5 years old) will receive alpelisib at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2. An extrapolation approach will be used for dose selection for this group.
11026902|NCT04589624|Active Comparator|Arm I ( Health Volunteer MRI)|Healthy volunteers undergo MRI over 30 minutes.
11026903|NCT04589624|Experimental|Arm II (Thyroid Cancer Patient hpMRI)|Patients with thyroid cancer undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
11026904|NCT04589611|Experimental|Phase I single amobarbital/Gel-One dose|Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
11026905|NCT04589611|Active Comparator|Phase IIa Part 1 amobarbital/Gel-One dose|20 subjects will be randomized to amobarbital/Gel-One single dose.
11033624|NCT04543344|Experimental|High Dose|Repeated multiple doses
11026907|NCT04589611|Active Comparator|Phase IIa Part 2 amobarbital/Gel-One dose|20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
11026908|NCT04589611|Placebo Comparator|Phase IIa Part 2 placebo|20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
11026909|NCT04589598|Experimental|FNS|those who are treated with femoral neck system (FNS)
11026910|NCT04589598|Active Comparator|MCS|those who are treated with multiple cannulated screw (MCS)
11026911|NCT04589585|Experimental|DiVeRt treatment|DiVeRt device to be used in the single arm
11026912|NCT04589572|Experimental|XLIF - group|
11026913|NCT04589572|Active Comparator|PLIF - Group|
11026914|NCT04589559|Experimental|Intervention: Heart Rate Variability Biofeedback|Participants in this intervention group complete at-home heart rate variability biofeedback (HRVB) training using a wrist-worn heart rate monitor and a smartphone app. They complete at least 10 minutes per day of HRVB training on at least 5 days per week for 3 weeks.
11026915|NCT04589546|Experimental|Vitamin B3|
11026916|NCT04589546|Placebo Comparator|Placebo|
11026917|NCT04589533||EDUCATIONAL PROGRAM GROUP|This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
11026918|NCT04589533||CONTROL GROUP|Control group will not receive educational program. This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
11026919|NCT04589520|Experimental|HeartBot Group|The HeartBot group downloaded the app and used it daily for 21 days based on a calendar that provided them with step by step outlines of the tools for each day.
11026920|NCT04589520|No Intervention|Control Group|The control group did not download the app and experienced no change to their daily routines.
11026921|NCT04589494|Active Comparator|tramadol group|tramadol hydrochloride 100 mg three times daily
11026922|NCT04589494|Active Comparator|morphine group|morphine 30 mg twise times daily
11026923|NCT04589481|Experimental|candy intake|
11026924|NCT04589468|Experimental|Dose Escalation|Fifty (n=50) patients with post-treatment breast, prostate, or colorectal cancer and detectable ctDNA. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
11026925|NCT04589468|Experimental|Dose Expansion|An independent cohort of 36 post-treatment patients with breast, prostate, or colorectal cancer (n=12 per type) and detectable ctDNA. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
11026926|NCT04589455|Experimental|hennep extract|A hennep extract administered in soft gel capsules in a fasted state
11026927|NCT04589455|Experimental|hennep extract + high fat meal|A hennep extract administered in soft gel capsules in a fed state
11026928|NCT04589442|Active Comparator|Standard of Care Dermal Graft|Standard of care cryopreserved cadaveric split thickness skin grafts
11026929|NCT04589442|Experimental|Standard of Care Dermal Graft - Microsurfaced|Microsurfaced cryopreserved cadaveric split thickness skin grafts
11026930|NCT04589429|Active Comparator|MN group|intrathecal morphine 300 micrograms+1mg nalbuphine
11026931|NCT04589429|Placebo Comparator|M group|intrathecal morphine 300 micrograms
11026932|NCT04589416|Active Comparator|Single Bond 2|Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
11026933|NCT04589416|Active Comparator|Clearfil SE Bond|Clearfil SE bond is traditional two step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
11026934|NCT04589416|Active Comparator|Tri-S Bond|Tri-S bond is traditional one step self-etch adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
11026935|NCT04589403|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.
11026936|NCT04589403|Experimental|OPT101|The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.
11026937|NCT04589390|Other|Selexipag|Selexipag will be up titrated for a period that will last 12 weeks (Phase 2). The initial dose will be 200 mcg of selexipag every 12 hours, with weekly dose increases of 200 mcg, up to the maximum dose of 1600 mcg every 12 hours or until the classic side effects of the prostacyclin pathway drugs (headache, mandibular pain), among others) arise. The dose will then be reduced by 200 mcg per dose, and this will be the maximum dose considered for that particular patient, maintained in Phase 3 (16 weeks).
11026938|NCT04589377|Experimental|Mindfulness Training|Participants receive 20 minutes of mindfulness training per day for five continuous days (Monday through Friday). Training is delivered remotely to participants' computers and smartphones.
11026939|NCT04589377|No Intervention|No-Training|Participants do not receive training. On Monday and Friday, they listen to a 20 minute audiobook to match for time.
11026940|NCT04589364|Experimental|abobotulinum toxin A|"Abobotulinum Toxin Type A (Dysport) dose was investigated:
~dose: 100 units ( various units each site depend on clinical )"
11026941|NCT04589364|Experimental|neubotulinum toxin A|"Neubotulinum Toxin Type A (Neuronox) dose was investigated:
~dose: 33.33 units ( various units each site depend on clinical )"
11027229|NCT04587492||Children with SMA|All children with SMA are eligible for the study
11026942|NCT04589351|Active Comparator|Ezetimibe|One treatment period of 16 weeks with1 capsule of ezetimibe 10mg per day, as add-on to standard care.
11026943|NCT04589351|Placebo Comparator|Placebo|One treatment period of 16 weeks with 1 capsule of matching placebo per day, as add-on to standard care.
11026944|NCT04589338|Experimental|Endurance training group|
11026945|NCT04589338|Experimental|Resistance training group|
11026946|NCT04589338|No Intervention|Control group|
11026947|NCT04589325|Experimental|Ixekizumab|
11026948|NCT04589325|Placebo Comparator|Placebo|
11026949|NCT04589312|Active Comparator|Pregnant women not living with HIV, Td vaccine|
11026950|NCT04589312|Experimental|Pregnant women not living with HIV, Tdap vaccine|
11026951|NCT04589312|Active Comparator|Pregnant women living with HIV, Td vaccine|
11026952|NCT04589312|Experimental|Pregnant women living with HIV, Tdap vaccine|
11026953|NCT04589299|Active Comparator|Patients treated with immunoglobulin intravenously (IVIG)|Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
11026954|NCT04589299|Active Comparator|Patients treated with immunoglobulin subcutaneously (SCIG)|Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).
11026955|NCT04589286|Experimental|Pack Health's Digital Life Coaching (DLC)|Participants will receive 16 weeks of access to a trained human life coach employed by Pack Health. Coaches will communicate via phone calls, text messages, emails, and links to web-based Pack Health resources plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
11026956|NCT04589286|Active Comparator|Quasi-usual care control arm|Participants will receive usual supportive care for stem cell transplantation plus the addition of generic wellness-related electronic handouts at the time of each email reminder for participant-reported outcome (PRO) assessments
11026957|NCT04589273|Experimental|Alginate capsule|The participants of this arm will be give the alginate capsules
11026958|NCT04589273|Placebo Comparator|Placebo|The participants of this arm will be give the placebo capsules
11026959|NCT04589260|Experimental|TD-1058|"Part A (SAD): 6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of TD-1058
~Part B (MAD): 6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of TD-1058
~Part C (IPF subjects): 8 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of TD-1058"
11026960|NCT04589260|Placebo Comparator|Placebo|"Part A (SAD): 2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of placebo
~Part B (MAD): 2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of placebo
~Part C (IPF subjects): 4 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of placebo"
11026961|NCT04589247||Patients with cancer treated with definitive-intent radiotherapy|Histologically confirmed loco-regional to advanced primary cancer, including but not limited to lung cancer, esophageal, or gastro-intestinal cancers at risk of developing radiotherapy-related toxicity.
11026962|NCT04589234|Experimental|Saltikva with FOLFIRINOX|30 patients will be enrolled to receive standard of care FOLFIRINOX with oral Salmonella-IL2 (Dose 10-9) every 2 weeks for 2 years
11026963|NCT04589234|Experimental|Saltikva with Gemcitabine/Abraxane|30 patients will be enrolled to receive standard of care Gemcitabine/Abraxane with oral Salmonella-IL2 (Dose: 10-9) every 3 weeks for 2 years
11026964|NCT04589221||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification
~Soft and hard foods manipulated by cooking method"
11026965|NCT04589208|Experimental|Ketamine|ketamine
11026966|NCT04589195|Experimental|Mindfulness Training (MT) Group|Participants will receive four weeks of MT.
11026967|NCT04589195|Active Comparator|Wait List MT Group|Participants will receive four weeks of MT training after a five week washout period.
11026968|NCT04589182|Experimental|Verum|Patients will receive all-night auditory stimulation during sleep over 3 nights using a portable, safe, in-home device (MSHL-SleepBand). This device records biosignals (EEG) and precisely plays tones (between 30-70 dB) targetted to the up-phase of sleep slow waves.
11026969|NCT04589182|Sham Comparator|Sham|Patients will receive all-night sham stimulation over 3 nights, i.e. the wearable stimulation device will be applied (EEG will be recorded), but no tones will be played.
11026970|NCT04589169||Positive cohort|Patients who develop delirium
11026971|NCT04589169||Experimental control group|Patients who do not develop delirium
11026972|NCT04589143|Experimental|Experience group|In this group,participants take agomelatine at a dose of 25-50 mg/d for 8 weeks.
11026973|NCT04589143|Placebo Comparator|Contral group|In this group,participants take a placebo at a dose of 25-50 mg/d for 8 weeks.
11026974|NCT04589130|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets.
11026975|NCT04589130|Placebo Comparator|Placebo|Group given placebo
11026976|NCT04589117|Experimental|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.
~The progression of writing exercises flows as follows:
~Week 1: Writing to expressive difficult emotions
~Week 2: Writing to cultivate compassion & forgiveness
~Week 3: Writing to nurture positive emotions
~Week 4: Writing to invite insight, perspective, & growth"
11026977|NCT04589104|Experimental|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:
~Week 1: Writing to expressive difficult emotions
~Week 2: Writing to release & integrate difficult emotions
~Week 3: Writing to nurture gratitude
~Week 4: Writing to enhance strengths & resources
~Week 5: Writing to cultivate positive meaning & savor goodness
~Week 6: Writing to invite insight, perspective, & growth"
11026978|NCT04589091||Group(1): Patient who underwent PRK|
11026979|NCT04589091||Group(2): Patient underwent LASIK|
11026980|NCT04589078||Interficial Intelligence|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
11026981|NCT04589065|Experimental|Selective Cytopheretic Device|
11026982|NCT04589039||Participants with Ovarian Cancer|Participants diagnosed with ovarian cancer (including fallopian tube or primary peritoneal cancer) who have been prescribed with niraparib for the first time in a real-world setting, and who are in a complete or partial response to first-line platinum-based chemotherapy or who had complete or partial response to 2 or more line of platinum-based chemotherapy or who have been treated with 3 or more prior chemotherapy regimens with either breast cancer susceptibility gene (BRCA) mutation (irrespective of platinum sensitivity) or platinum-sensitive homologous recombination deficiency (HRD) positive will be observed prospectively over 24-month period, or until treatment discontinuation, or until end of study, which occurs first.
11026983|NCT04589026|Active Comparator|Active Arm: Candin + Consentyx|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Cosentyx injection subcutaneously.
11026984|NCT04589026|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% NaCl, and no Cosentyx.
11026985|NCT04589000|Experimental|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.
~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
11026986|NCT04589000|No Intervention|control|No accupressure will be applied. Milk will be expressed for a total of 15 minutes, 1 time on the post-op 0th day, 2 times on the post-op 1st day and once on the post-op 2nd day for a total of 15 minutes and will be recorded in the milk measurement table.
11026987|NCT04588987|Experimental|Neoadjuvant group|Patients need to treat with PD-1 and apatinib before surgery. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
11026988|NCT04588987|Experimental|Adjuvant group|Before surgery, patients no need to treat with PD-1 and apatinib. Sequential therapy with PD-1 and apatinib when patients accepted surgery.
11026989|NCT04588974||Screening|Sixty-five cirrhotic patients with portal hypertensive symptoms (such as platelets count less than 100,000) will be enrolled to evaluate for the presence and stage of esophageal varices by using a magnetic-assisted capsule endoscope system with or without 3D image processing.
11026990|NCT04588974||Follow-up|Thirty-five cirrhotic patients with a history of endoscopy-confirmed esophageal varices will be included for the follow-up examination by using the magnetic-assisted capsule endoscope system with or without 3D images.
11026991|NCT04588974||Control|Another 40 volunteers with GI symptoms but no known gastrointestinal disease will be enrolled as the control group.
11026992|NCT04588961|Active Comparator|Control group|Patients undergoing trapeziectomy with suspensionplasty for primary basal thumb osteoarthritis
11026993|NCT04588961|Active Comparator|Study group|Patients undergoing joint alloplasty using prothesis for primary basal thumb osteoarthritis
11026994|NCT04588948|Experimental|Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
11026995|NCT04588948|Experimental|Non-Vitrectomized Eyes|The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate.
11026996|NCT04588935|Active Comparator|Group 1|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
11026997|NCT04588935|Active Comparator|Group 2|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and ramipril
11026998|NCT04588922|Experimental|GFH009|
11026999|NCT04588896|Experimental|CGM+LMP|Continuous glucose monitoring (CGM) for 8 weeks in conjunction with lifestyle modification
11027000|NCT04588896|Other|LMP only|Lifestyle modification only
11027001|NCT04588883|Experimental|Intervention Arm|Patients, adults and adolescents, will be recruited from patient registries at 7 government operated HIV clinics in Meru County, Kenya. Patients will complete validated questionnaires at baseline, 1.5 year and 3 years into a novel adaptation of a community empowerment program. The program utilizes savings- and internal-lending/group-based microfinance process to facilitate exchange of savings amongst patients and adolescent guardians. A byproduct of this process is the development of social capital, which will be used to facilitate education, peer learning, and collective problem solving to improve determinants of well-being and clinical adherence among participants. Expected outcomes include improved viral suppression, ART adherence, clinical attendance, and mental health.
11027002|NCT04588870|Experimental|Preoperative Cochlear Implant|The intervention will be the use of a surgical simulation system preoperatively by the surgeon to develop the surgical plan to optimize electrode array placement with respect to scalar location and modiolar distance.
11027003|NCT04588857|Experimental|Active drug|dexamethasone 24 mg i.v., single dose
11027004|NCT04588857|Placebo Comparator|Placebo|saline i.v., single dose
11027005|NCT04588844|Experimental|Growth Hormone group|Growth Hormone pretreatment for 6 weeks before ovarian stimulation
11027006|NCT04588844|No Intervention|Control group|No pretreatment before ovarian stimulation
11027007|NCT04588831|Experimental|Pre-fabricated|
11027008|NCT04588831|Experimental|Mouth-formed|
11027009|NCT04588831|Experimental|Custom-fitted|
11027010|NCT04588818|Experimental|Adalimumab plus Methotrexate|
11027011|NCT04588805||Colorectal Cancer Patients|
11027012|NCT04588792|Experimental|Inhaled Furosemide|40 mg furosemide per dose, given by nebulization (4 mL of 10 mg/mL furosemide in 0.9% saline solution) over 30 mins four times daily (Q6H) for up to 28 days
11027013|NCT04588792|Placebo Comparator|Nebulized Saline|Placebo, given by nebulization (4 mL of 0.9% saline solution) over 30 mins four times daily (Q.I.D.) for up to 28 days
11027014|NCT04588779|Experimental|Graston|Ultrasound, Graston technique, piriformis stretching, home plan (hip abductor and extensor strengthening)
11027015|NCT04588779|Active Comparator|Manual myofascial release|Ultrasound, Manual myofascial release, piriformis stretching, home plan (hip abductor and extensor strengthening)
11027016|NCT04588766||constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
11027017|NCT04588766||control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
11027018|NCT04588753|Active Comparator|Active Isolated Stretch|active isolated stretching, strengthening exercises
11027019|NCT04588753|Active Comparator|Post Facilitation Stretch|Post Facilitation Stretching, strengthening exercises
11027020|NCT04588740|Active Comparator|Dietary nitrate|The active treatment, beetroot juice (BEET IT, James White Drinks, Ipswich, UK), contains 6.2mmol of inorganic nitrate. Participants will continue supplementation until they complete all testing visits.
11027021|NCT04588740|Placebo Comparator|Placebo|The placebo beet root juice is made by the same company (BEET IT, James White Drinks, Ipswich, UK) and contains no inorganic nitrate.
11027022|NCT04588727|Experimental|AZD3366 dose 1 Part A|In Part A, 6 Caucasian subjects will receive AZD3366 dose 1 and 2 Caucasian subjects will receive placebo
11027023|NCT04588727|Experimental|AZD3366 dose 2 Part A|In Part A, 6 Caucasian subjects will receive AZD3366 dose 2 and 2 Caucasian subjects will receive placebo
11027024|NCT04588727|Experimental|AZD3366 dose 3 Part A|In Part A, 6 Caucasian subjects will receive AZD3366 dose 3 and 2 Caucasian subjects will receive placebo
11027025|NCT04588727|Experimental|AZD3366 dose 4 Part A|In Part A, 6 Caucasian subjects and 4 Japanese subjects will receive AZD3366 dose 4 and 2 Caucasian subjects and 1 Japanese subject will receive placebo
11027026|NCT04588727|Experimental|AZD3366 dose 5 Part A|In Part A, 6 Caucasian subjects and 4 Japanese subjects will receive AZD3366 dose 5 and 2 Caucasian subjects and 1 Japanese subject will receive placebo
11027027|NCT04588727|Experimental|AZD3366 dose 6 Part A|In Part A, 6 Caucasian subjects and 4 Japanese subjects will receive AZD3366 dose 6 and 2 Caucasian subjects and 1 Japanese subject will receive placebo
11027028|NCT04588727|Experimental|AZD3366 dose X Part B|In Part B, 12 Caucasian subjects will receive AZD3366 dose X (a dose resulting in predicted therapeutic exposure) + ticagrelor + ASA
11027029|NCT04588727|Placebo Comparator|Placebo dose X Part B|In Part B, 12 Caucasian subjects will receive placebo + ticagrelor + ASA
11027030|NCT04588714|Experimental|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|"RENEW is a 12-week program in which participants are paired with a peer mentor who serves as their health coach throughout the intervention period. The website serves as the program workbook to help promote skill practice and attainment in areas like goal setting, pacing, relaxation, etc."
11027031|NCT04588701||persons with anal fistulas|all persons with anal fistulas treated by a single surgeon over 22 years
11027032|NCT04588688|Experimental|Mifepristone|Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.
11027033|NCT04588662||Uveal Melanoma|Diagnosis of uveal melanoma Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent
11027034|NCT04588649|Other|THK-5351|Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical
11027035|NCT04588649|Other|AV-45|Name: [18F]AV-45, (E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical
11027036|NCT04588636|Active Comparator|Behavioral and self-care therapy control group|Subjects received verbal and written information on the etiology and prognosis of TMDs. In addition, advice on habits and behavior changes, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
11027037|NCT04588636|Active Comparator|Rigid occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a rigid occlusal splint
11027038|NCT04588636|Active Comparator|Soft occlusal splint group|Subjects in this group received behavioral and self-care therapy, in combination with a soft occlusal splint
11027039|NCT04588636|Placebo Comparator|Non-occlusive splint group|Subjects in this group received behavioral and self-care therapy, in combination with a non-occlusive splint
11027040|NCT04588623|Active Comparator|Omnibiotic Stress Repair (OBSR)|After randomisation, patients will receive a box with one sachet containing 3g of OBSR for each day.
11027041|NCT04588623|Placebo Comparator|Placebo|After randomisation, patients will receive an identical box with one sachet containing 3g of Placebo for each day.
11027042|NCT04588571|Experimental|Endovascular treatment|Patients (n=55) with recanalization of the femoral-popliteal arterial segment (TASC II, type D) above the knee with a biomimetic braided nitinol stent.
11027043|NCT04588571|Active Comparator|Open surgery|Patients (n=55) with femoropopliteal proximal bypass with a prolonged atherosclerotic lesion of the femoropopliteal arterial segment (TASC II, type D).
11027044|NCT04588558|Experimental|Flywheel exercise|The term isoinertial is derived from the words iso (same) and inertial (resistance), which define the primary concept of the isoinertial system in a terminology or that expresses both the concentric and eccentric phases of the same muscle contraction. Isoinertial refers to resistance used in exercise training, maintaining a constant inertia throughout the range of motion, a constant resistance in all respects, and facilitating maximum muscle strength. All participants received home exercise for 8 weeks.
11027045|NCT04588558|Active Comparator|Electrotherapy modality|"Electrotherapy modalities especially transcutaneous electrical nerve stimulation (TENS) and ultrasound is used to treat OA.
~All participants received home exercise for 8 weeks."
11027230|NCT04587479|Experimental|JAB-8263|Monotherapy, dose escalation
11028255|NCT04580173||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
11027046|NCT04588558|Active Comparator|Home exercise|All participants received home exercise three times a week for 8 weeks. Home exercises are structured with squats. The exercise program includes stretching exercises and strengthening (isometric and isotonic) exercises.
11027047|NCT04588545|Experimental|Radiation Therapy followed by 10 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 1 of 4 with 10 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
11027048|NCT04588545|Experimental|Radiation Therapy followed by 20 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 2 of 4 with 20 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
11027049|NCT04588545|Experimental|Radiation Therapy followed by 40 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 3 of 4 with 40 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
11027050|NCT04588545|Experimental|Radiation Therapy followed by 80 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 4 of 4 with 80 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
11027051|NCT04588532|Experimental|doxepin|"Drug: Doxepin + BAM8-22 Doxepin will be applied for 1.5 hrs followed by the application of BAM8-22. 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Doxepin + Histamine Doxepin will be applied for 1.5 hrs followed by the application of Histamine. 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Doxepin + Cowhage Doxepin will be applied for 1.5 hrs followed by the application of cowhage. 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Doxepin + Placebo Doxepin will be applied for 1.5 hrs followed by the application of placebo. 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
11027052|NCT04588532|Experimental|itch|"Drug: BAM8-22 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Histamine 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Cowhage 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop
~Drug: Placebo 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
11027053|NCT04588519|Experimental|Active Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA
11027054|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Lower Trapezius group|Rotator cuff tears excluding the subscapularis muscle repaired using Lower Trapezius tendon
11027055|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Latissimus Dorsi group|Rotator cuff tears excluding the subscapularis muscle repaired using Latissimus Dorsi tendon
11027056|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Pectoralis group|Rotator cuff tears involving the subscapularis muscle repaired using Pectoralis tendon
11027057|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Latissimus Dorsi group|Rotator cuff tears involving the subscapularis muscle repaired using Latissimus Dorsi tendon
11027058|NCT04588480|Experimental|BNT162b2|BNT162b2 (intramuscular injection)
11027059|NCT04588480|Placebo Comparator|Placebo|Placebo (intramuscular injection)
11027060|NCT04588467|Active Comparator|Conservative group|Conservative treatment included dietary modification (intake of at lest 3 liters of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application (Lidocaine 2.5%+Prilocaine 2.5%, 2g twice a day) for 10 days
11027061|NCT04588467|Experimental|Surgical group|Thrombectomy and local excision of external hemorrhoids were performed with the patient in the lithotomy position under local infiltrative anesthesia with UltracainDS 1:200000 1.7ml
11027062|NCT04588454|Experimental|18F-PSMA-1007 PET/CT|
11027063|NCT04588441|Experimental|Adenosine|Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
11027064|NCT04588428|Experimental|Part 1: INO-4700 Group A|Participants will receive one ID injection of 0.6 milligram (mg) of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
11027065|NCT04588428|Experimental|Part 1: INO-4700 Group B|Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
11027066|NCT04588428|Experimental|Part 1: INO-4700 Group C|Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
11027067|NCT04588428|Experimental|Part 1: INO-4700 Group D|Participants will receive two ID injections (in an acceptable location on two different limbs) of 0.5 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
11027801|NCT04583566||COVID-19 Mild Symptoms|Patients with moderate symptoms, like normal flu symptoms. They do not need oxygen or ventilation
11027068|NCT04588428|Experimental|Part 1: INO-4700 Group E|Participants will receive two ID injections (in an acceptable location on two different limbs) of 1.0 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
11027069|NCT04588428|Placebo Comparator|Part 1: Placebo Group F|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
11027070|NCT04588428|Placebo Comparator|Part 1: Placebo Group G|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
11027071|NCT04588428|Placebo Comparator|Part 1: Placebo Group H|Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
11027072|NCT04588428|Placebo Comparator|Part 1: Placebo Group I|Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
11027073|NCT04588428|Experimental|Part 2: Parts 2A and 2B|Participants will receive ID injection of INO-4700 based on optimal dose and regimen selection in Part 1 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4 or Week 8 and a booster dose at Week 48 (only for Part 2B participants receiving a third dose).
11027074|NCT04588415|Experimental|Virtual Support Group Arm|Those with severe symptoms (indicated by an ICG-r score >25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the virtual support groups. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were >6 months post-loss, and those with higher baseline symptom levels. However, no participant in our study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the family members.
11027075|NCT04588415|No Intervention|Non-Virtual Support Group Arm|Family members that choose not to participate in the Virtual Support Group will be part of this non-intervention arm
11027076|NCT04588389|Active Comparator|Group 1 Standard of Care|Group I will receive the standard of care multimodal pharmacological management.
11027077|NCT04588389|Experimental|Group 2 Standard of Care + QL Block II|Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.
11027078|NCT04588389|Experimental|Group 2 Standard of Care + QL Block III|Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.
11027079|NCT04588376|Experimental|Clinician-level and clinic-level monthly feedback|Group of 22 clinics to receive clinician-level and clinic-level monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
11027080|NCT04588376|Active Comparator|Clinic-level only monthly feedback|Group of 17 clinics to receive clinic-level only monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
11027081|NCT04588363||SARS-CoV-2 positive children|"Individuals less than 21 years of age who fulfill one or more of the following criteria:
~SARS-CoV-2 detection from a respiratory specimen, and/or
~Meets criteria for MIS-C, and/or
~Meets criteria for MIS-C, except has involvement of only 1 organ system"
11027082|NCT04588350|Experimental|i-SEP autotransfusion system|Use of i-SEP autotransfusion system during the surgery
11027083|NCT04588324|Experimental|Phase 1 Dose-Escalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
11027084|NCT04588324|Experimental|Phase 2 Dose-Expansion|SHR2150 RP2D will be combined with chemotherapy plus PD-1 or CD47 antibody in 3-week treatment cycles.
11027085|NCT04588311|Active Comparator|Erythropoietin (EPO)|Epoetin alfa 40,000 IU (1mL pre-filled syringe) will be given by subcutaneous injection to eligible patients on Study Days 1 and 8 during the intensive care unit stay.
11027086|NCT04588311|Placebo Comparator|Placebo|Sodium Chloride 0.9% (1mL in volume) will be given by subcutaneous injection to eligible patients allocated to the placebo arm on Study Days 1 and 8 during the intensive care unit stay.
11027087|NCT04588298|Experimental|AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.
11027088|NCT04588298|Experimental|AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.
11027089|NCT04588298|Experimental|AZD9833 Dose C (Optional)|Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.
11027090|NCT04588298|Experimental|AZD9833 Dose D (Optional)|Post-menopausal participants will receive once daily oral dose D of AZD9833 in stage 2 of the study.
11027091|NCT04588298|Experimental|AZD9833 Dose E (Optional)|Post-menopausal participants will receive once daily oral dose E of AZD9833 in stage 2 of the study.
11027092|NCT04588298|Experimental|AZD9833 Dose F (Optional)|Pre-menopausal participants will receive once daily oral dose F of AZD9833 in stage 2 of the study.
11027093|NCT04588298|Experimental|Fulvestrant 500 mg (Optional)|Post-menopausal participants will receive intramuscular (IM) injection of fulvestrant 500 mg in stage 2 of the study.
11027094|NCT04588285|Experimental|Ambroxol|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
11027095|NCT04588285|Experimental|Placebo|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
11027096|NCT04588272||2 liters|40 patients will receive O2 supply at rate of 2 liters per minute and then an arterial blood gas (ABG) sample is taken and compared with capnographic measures from DualGuard.
11027097|NCT04588272||4 liters|40 patients will receive receive O2 supply at rate 4 liters per minute and then an arterial blood gas (ABG) sample is taken and compared with capnographic measures from DualGuard.
11027098|NCT04588272||6 liters|: 40 patients will receive O2 supply at rate 6 liters per minute and then an arterial blood gas (ABG) sample is taken and compared with capnographic measures from DualGuard.
11027099|NCT04588259|Experimental|Faster aspart|4 daily injections of faster aspart given with insulin degludec and with or without metformin
11027100|NCT04588259|Active Comparator|Insulin aspart|4 daily injections of insulin aspart given with insulin degludec and with or without metformin
11027802|NCT04583566||Control Healthy|Healthy group with out any infection or symptoms.
11027101|NCT04588246|Experimental|Arm I (salvage SRS, memantine, HA-WBRT)|Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
11027102|NCT04588246|Active Comparator|Arm II (salvage SRS)|Patients undergo salvage SRS.
11027103|NCT04588233|Experimental|Administration of Melatonin|
11027104|NCT04588233|Placebo Comparator|Administration of Placebo|
11027105|NCT04588220||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
11027106|NCT04588220||Control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
11027107|NCT04588207|Experimental|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
11027108|NCT04588207|Experimental|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
11027109|NCT04588194|Experimental|Romiplostim, Rituximab, Dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.
11027110|NCT04588181|Experimental|CBT 6 sessions|
11027111|NCT04588181|Active Comparator|CBT 12 sessions|
11027112|NCT04588168|Experimental|Experimental: Chemotherapy + mpMRI + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology
~Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy"
11027113|NCT04588168|Experimental|Experimental: Chemotherapy + surgery|"Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology
~Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy"
11027114|NCT04588155||Chronic Low-Back Pain|Subjects diagnosed with Chronic Low-Back Pain in rehabilitation program: functional assessment (with temporal and kinematic analysis) and clinical assessment.
11027115|NCT04588155||Healthy|Healthy subjects: functional assessment (with temporal and kinematic analysis)
11027116|NCT04588142|Experimental|Experimental group|Participants are randomized to receive probiotics for 6 weeks
11027117|NCT04588142|Placebo Comparator|Placebo group|Participants are randomized to receive placebo for 6 weeks
11027118|NCT04588129|Experimental|LB-102 50 mg, single dose Cohort 1|LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.
11027119|NCT04588129|Experimental|LB-102 xx mg, single dose Cohort 2|LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.
11027120|NCT04588129|Experimental|LB-102 xx mg, single dose Cohort 3|LB-102 formulated capsule will be administered orally once daily for one day in up to 4 subjects.
11027121|NCT04588129|Experimental|LB-102 xx mg, multiple dose Cohort 4|LB-102 formulated capsule will be administered orally twice daily for one day in up to 4 subjects.
11027122|NCT04588116|Experimental|The web- based occupational therapy intervention SEE|The web-based intervention starts with eight educational modules focusing on engagement in activities and strategies to support an active life. The modules, that is delivered on a secure national health platform, include short education videos followed by self-reflections and digital assignments supporting the change process. The occupational therapist provides feedback after each assignment and, also, meet the patients for face- to- face online guiding sessions at three times during these first two- three weeks of the intervention. Thereafter, an individually tailored activity plan with goals and activity-based strategies are established. During the change process, the patients receive continued support from the occupational therapist until the goals are achieved.
11027123|NCT04588103|No Intervention|Control|Participants will be asked to maintain their regular physical activity habits for the duration of the 8-week intervention period.
11027124|NCT04588103|Experimental|Heat therapy|Participants will be asked to undergo 45 minutes of lower limb hot water immersion (42 degrees C) 3 times per week for 8 weeks.
11027125|NCT04588103|Experimental|Exercise training|Participants will be asked to undergo 45 minutes of moderate-intensity cycling exercise (~40-59% VO2 reserve) 3 times per week for 8 weeks.
11027126|NCT04588103|Experimental|Combined training|Participants will be asked to undergo 90 minutes of moderate-intensity cycling exercise and lower limb hot water immersion sequentially 3 times per week for 8 weeks.
11027127|NCT04588090|Experimental|Experimental group|The concurrent 3 weeks treatment group（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing 3 weeks chemotherapy）
11027128|NCT04588090|Placebo Comparator|Standard chemoradiation group|Standard chemoradiation（external radiation plus intraluminal after-loading irradiation+concurrent platinum-containing weekly chemotherapy）
11027129|NCT04588077|Experimental|Cirrhosis, 3-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
11027130|NCT04588077|Active Comparator|Cirrhosis, 2-dose regimen|Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
11027131|NCT04588077|Experimental|Non cirrhosis, 3-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
11027132|NCT04588077|Active Comparator|Non cirrhosis, 2-dose regimen|Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
11027133|NCT04588064|Experimental|18F-FDG PET/CT scan|Each subject receives a single intravenous injection of 18F-FDG, and undergo PET/CT imaging within the specified time.
11027134|NCT04588051|Experimental|Cabozantinib|
11027135|NCT04588038|Experimental|Treatment (efineptakin alfa)|Patients receive one dose of efineptakin alfa IM.
11027136|NCT04588025|Active Comparator|Healthy Volunteers|
11027137|NCT04588025|Active Comparator|Pancreatic Cancer Participants|
11028256|NCT04580173||0 < SYNTAX score <=22|Low SYNTAX group
11028257|NCT04580173||23<=SYNTAX score<=32|Intermediate SYNTAX group
11027138|NCT04588012|Experimental|Online self-help the OurRelationship.dk program|Couples in the intervention condition will receive the full OurRelationship program including the three modules, the Observe, the Understand, and the Respond module. The program takes 6-8 hours to complete the program after the randomization. The second coach call will take place after the Observe phase. The third coach call will take place after the Understand phase. The fourth coach call will take place after the Respond phase.
11027139|NCT04588012|Active Comparator|"Off line self-help the book Pas på Parforholdet"|"Couples in the active control group receive two copies of the book Pas på parforholdet, når kærligheden er kommet for at blive [Take care of your relationship when love is here to stay] by Mattias Stølen Due (2016). This book includes general research based knowledge on maintaining a healthy relationship as well as questions and exercises for couples to do on their own. To support couples in an activate self-help approach, a sheet with guidelines on using the book will help couples plan their reading and couple conversations. Regular questionnaires will be sent to couples in the control group (matched timely to the questionnaires received by the intervention group). As such, the active control condition will mirror the benefit that couples are likely to get from using well-chosen, solid literature with the addition of any benefit that the research participation (filling in questionnaire) will generate."
11027140|NCT04587999|Experimental|bladder stimulation|
11027141|NCT04587999|Active Comparator|Quick wee|
11027142|NCT04587986|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of BTL-703 will be applied over the umbilicus. The active group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
11027143|NCT04587986|Sham Comparator|Sham control|The treatment administration phase will also consist of three (3) treatments, delivered once a week. The sham group will receive a treatment with the intensities of the magnetic field and radiofrequency energy set to 5% of the maximum device output.
11027144|NCT04587973|Active Comparator|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml) plus dexmedetomidine 1 mcg/kg
11027145|NCT04587973|Active Comparator|Group Ropivacaine|Plain ropivacaine group - Preoperative bilateral erector spinae plane block with ropivacaine 0,375% (40 ml)
11027146|NCT04587973|Placebo Comparator|Group Control|Control group - Preoperative bilateral erector spinae plane block with N/S 0,9% (40 ml)
11027147|NCT04587960|Active Comparator|Primary closure of Cesarean wound|Immediate closure of skin incision where healing occurs by primary intention
11027148|NCT04587960|Experimental|Delayed primary closure of Cesarean wound|Delayed closure of skin incision following regular wound dressing for 2 to 3 days.
11027149|NCT04587934|Experimental|iRes Warmer with ResusView|iRes Warmer with ResusView program with experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
11027150|NCT04587934|Active Comparator|iRes Warmer without ResusView|An external non-experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
11027151|NCT04587921|Experimental|Patients monitored with oximeter|The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
11027152|NCT04587908|Experimental|TAS-205|
11027153|NCT04587908|Placebo Comparator|Placebo|
11027154|NCT04587895|Experimental|MI Intervention|The VITAAL exergame intervention for MI includes 36 training sessions with three sessions per week, each lasting around 45 minutes (30 minutes real training time) resulting in 12 weeks of training (two weeks of break/holiday allowed). A training session includes an individually calculated amount of strength, cognitive-motor and balance training, which remains the same over the 12 week intervention period.
11027155|NCT04587895|Active Comparator|MI Control|"Participants of the MI control group are instructed to do a non-individualized conventional training including 15 minutes walking exercise (in nature or on treadmill) and additional 15 minutes of strength, balance, and cognitive-motor exercises (at the therapy centre or at home). The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu). The participants will receive a training booklet with the exercises. In total there are three different training programs which are divided according to their level of difficulty. Participants are instructed to start with the first level for four weeks and then go on to the next level for another 4 weeks. The control group training in this study includes 36 training session with three sessions per week, each lasting around 45 minutes resulting in 12 weeks of training (two weeks of break/holiday allowed)."
11027156|NCT04587895|Experimental|UI Intervention|For the incontinent women in this study, the VITAAL exergame intervention will last over 12 weeks and consists of three parts 1) VITAAL exergame (2 sessions/week) lasting 45 minutes each (30 minutes real training time) at the physio centre, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home.
11027157|NCT04587895|Active Comparator|UI Control|The control group training will last over 12 weeks. The training sessions will be divided in three parts 1) 30 minutes of brisk walking (2 sessions/week, 2) PFM exercises according to a training booklet (3 sessions/week) lasting 10 minutes each at home and 3) education related to UI at home. The PFM training booklet will be based on two studies that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises. The PFMT program will consist of 4 PFM exercises and will be divided into three phases allowing for the gradual progression in treatment (from first to third month), with gradual increase in difficult exercises in terms of duration, repetition and position. Each phase will last four weeks.
11027158|NCT04587882|Experimental|Telehealth|Participants will be provided with a smartwatch, have access to activity tracking and goal setting through the VALENTINE app, receive micro-randomized, contextually tailored notifications, and receive weekly activity summaries via email, which will be provided to participants and to their exercise physiologist while enrolled in cardiac rehabilitation.
11027159|NCT04587882|Active Comparator|Control|Participants will continue to receive usual care and a smartwatch but without access to the micro-randomized notifications or weekly activity summaries.
11028258|NCT04580173||SYNTAX score>=33|High SYNTAX group
11027160|NCT04587869|Experimental|Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
11027161|NCT04587869|No Intervention|Wait-list control|Participants who are referred to the wait-list control group will be offered the opportunity to participate in intervention sessions after they have completed their 12-month study participation.
11027162|NCT04587856|Other|Biological evaluation|evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
11027163|NCT04587843|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets
11027164|NCT04587843|Placebo Comparator|Placebo|Group given placebo
11027165|NCT04587830|Experimental|ADI-PEG 20 plus Radiotherapy and Temozolomide|"ADI-PEG 20 Dose: 18 and 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
~Radiotherapy Dose: 60 Gy in 30 daily (Monday-Friday) fractions of 2 Gy each; to start within 5 weeks of surgery (diagnostic and/or resection)
~Temozolomide Dose: 75 mg/m2 daily during radiotherapy; 150-200 mg/m2 for 5 days every 4 weeks (1 cycle) x 6 cycles during maintenance period Route of Administration: oral or intravenous"
11027166|NCT04587817||Camrelizumab+Hypofractionated radiation therapy|"Camrelizumab: 200mg every 2 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
~Hypofractionated Radiotherapy(SABR): tumor center dose of 24-32Gy/8Gy/3-4f and surrounding important organs at risk ≤3.0Gy will be performed when one week following completion of the first immunotherapy. And the routine radiotherapy will be started with reaching a radical cure dose for the tumor margin. Generally, the radiotherapy will end before the fourth immunotherapy."
11027167|NCT04587804|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|simultaneous treatment by repetitive pulse magnetic stimulation and radiofrequency energy for toning of abdomen and reduction of subcutaneous fat
11027168|NCT04587791|Active Comparator|CBD 400mg|CBD 400 mg
11027169|NCT04587791|Active Comparator|CBD 800mg|CBD 800mg
11027170|NCT04587791|Active Comparator|CBD 1200mg|CBD 1200mg
11027171|NCT04587791|Placebo Comparator|Saline|saline
11027172|NCT04587778|Experimental|Esketamine ((S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.
~In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan."
11027173|NCT04587778|Experimental|Racemic ketamine ((R,S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.
~In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan."
11027174|NCT04587765|Experimental|Extra sports group|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
11027175|NCT04587765|No Intervention|Conventional group|The group follows the schedule of school teaching programme. Students arrange their own after-school time after school.
11027176|NCT04587752|Experimental|CBT for Weight Bullying|Cognitive-Behavioral Therapy (CBT) for children who have experienced weight-related bullying
11027177|NCT04587739|Experimental|Experimental group|
11027178|NCT04587726|Experimental|Edutainment Body Image Video 100%|Behavioural: Girl's room video - watching 100% of the video
11027179|NCT04587726|Experimental|Edutainment Body Image Video 50%|Behavioural: Girl's room video - watching 50% of the video
11027180|NCT04587726|Experimental|Edutainment Body Image Video 25%|Behavioural: Girl's room video - watching 25% of the video
11027181|NCT04587726|Active Comparator|Control Video 100%|"Chicken Girl's Episode - 100%
~Appearance neutral episode matched for target audience and video length"
11027182|NCT04587726|Active Comparator|Control Video 50%|"Chicken Girl's Episode - 50%
~Appearance neutral episode matched for target audience and video length"
11027183|NCT04587726|Active Comparator|Control Video 25%|"Chicken Girl's Episode - 25%
~Appearance neutral episode matched for target audience and video length"
11027184|NCT04587713|Experimental|Part A, Sequence 1|"Part A, Sequence 1 = Treatment (Tx) C, Tx A, Tx C, Tx A
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout between treatments"
11027185|NCT04587713|Experimental|Part A, Sequence 2|"Part A, Sequence 2: Tx D, Tx B, Tx D, Tx B
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027186|NCT04587713|Experimental|Part A, Sequence 3|"Part A, Sequence 3: Tx C, Tx A, Tx D, Tx B
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027187|NCT04587713|Experimental|Part A, Sequence 4|"Part A, Sequence 4: Tx D, Tx B, Tx C, Tx A
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027188|NCT04587713|Experimental|Part A, Sequence 5|"Part A, Sequence 5: Tx A, Tx C, Tx A, Tx C
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027189|NCT04587713|Experimental|Part A, Sequence 6|"Part A, Sequence 6: Tx B, Tx D, Tx B, Tx D
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027190|NCT04587713|Experimental|Part A, Sequence 7|"Part A, Sequence 7: Tx A, Tx C, Tx B, Tx D
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027191|NCT04587713|Experimental|Part A, Sequence 8|"Part A, Sequence 8: Tx B, Tx D, Tx A, Tx C
~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
11027192|NCT04587713|Experimental|Part B,Treatment A|Single oral dose of Treatment A on Day 1
11027193|NCT04587700||Non-marijuana user|Has never consumed marijuana or has abstained for at least the past 12 months
11027194|NCT04587700||Chronic Marijuana User|Has used marijuana in any form at least once a week for the past 3 months
11027231|NCT04587453|Experimental|Tralokinumab+TCS|Week 0 to Week 16: Tralokinumab will be given as subcutaneous injections. Participants will receive tralokinumab loading dose on Day 0 followed by multiple tralokinumab injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
11027195|NCT04587687|Experimental|Treatment (brentuximab vedotin, bendamustine)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and bendamustine IV over 60 minutes on days 1 and 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who respond to combination treatment and do not experience excessive toxicity may continue to receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
11027196|NCT04587674|Other|Spinal Cord Stimulation|
11027197|NCT04587661|Active Comparator|off-the-shelf digital CBT|standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
11027198|NCT04587661|Experimental|adapted digital CBT|has content or references to SCD, chronic pain, and the unique challenges facing minority groups
11027199|NCT04587635|Active Comparator|PHGG fiber|PHGG Fiber
11027200|NCT04587635|Placebo Comparator|Placebo Maltodextrin|Maltodextrin
11027201|NCT04587622|Experimental|Group 1 - Healthy subjects with normal hepatic function|Healthy subjects with normal hepatic function - Control
11027202|NCT04587622|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment: Child-Pugh A (Score 5-6)
11027203|NCT04587622|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment: Child-Pugh B (Score 7-9)
11027204|NCT04587622|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment: Child-Pugh C (Score 10-15)
11027205|NCT04587609|No Intervention|Control - Standard UBI|Participants will continue to be monitored as a part of their standard UBI and receive educational material about distracted driving in the enrollment period
11027206|NCT04587609|Other|Free Phone mount|Participants in this arm will be monitored through standard UBI, receive educational material about distracted driving in the enrollment period, and free phone mounts
11027207|NCT04587609|Other|Commitment + Habit tips|Participants in this arm will receive educational material about distracted driving during the enrollment period, be sent a free phone mount with installation instructions, sign a personalized commitment contract to reduce their phone use, set personal phone use reduction goals, and be sent personalized habit tips framed to help them reduce their handheld phone use while driving;
11027208|NCT04587609|Other|Habit Formation + Social Gamification|Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
11027209|NCT04587609|Other|All + Contest Financial Incentive|Participants in this arm will receive all of the treatments of arm 4 plus be entered into a financial incentive contest where they can either finish in the highest level and split the prize money amongst all participants that reached that level, and the safest driver (driver ranked #1 on the leader board of their group) will receive a small weekly financial prize.
11027210|NCT04587596||Clinical staff|All clinical staff employed at one surgery in Middlesbrough, UK who wish to participate
11027211|NCT04587583|Active Comparator|WeCareAdvisor|immediate use of the WeCareAdvisor tool for a 1 month period
11027212|NCT04587583|Active Comparator|WeCareAdvisor after 1 month|after a wait period of 1 month, use of the WeCareAdvisor tool for a 1 month period
11027213|NCT04587570|Experimental|Group 1: Infiltration of PRP|The proband gets Platelet Rich Plasma injected in the thumb saddle joint.
11027214|NCT04587570|Experimental|Group 2: Infiltration of Fat|The proband gets fat injected in the thumb saddle joint.
11027215|NCT04587570|Experimental|Group 3: Infiltration of PRP and Fat|The proband gets a mixture of Platelet Rich Plasma (PRP) and Fat injected in the thumb saddle joint.
11027216|NCT04587570|Placebo Comparator|Group 4: Infiltration of NaCl|The proband gets NaCl injected in the thumb saddle joint.
11027217|NCT04587557|Experimental|ASD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for children with Autism Spectrum Disorder
11027218|NCT04587557|Active Comparator|ASD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for children with Autism Spectrum Disorder
11027219|NCT04587557|Experimental|TD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for typically developed children
11027220|NCT04587557|Active Comparator|TD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for typically developed children
11027221|NCT04587544|Experimental|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
11027222|NCT04587544|No Intervention|No Intervention|The participants would not receive Cold Water Intervention. However, they are allowed to received the usual care
11027223|NCT04587531|Active Comparator|Active CES Therapy|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
11027224|NCT04587531|Sham Comparator|Sham CES Therapy|Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
11027225|NCT04587518|Experimental|Immediate Treatment|Participants in this group will receive the intervention immediately.
11027226|NCT04587518|Experimental|Waitlist/Delayed Treatment|Participants in this group will receive the intervention after an 18-week wait.
11027227|NCT04587505|Active Comparator|Epidural anesthesia and analgesia|Epidural catheter insertion: Th 12- L 1 or Th 11 - Th 12 using the midline approach. Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml). Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml).
11027228|NCT04587505|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
11027232|NCT04587453|Placebo Comparator|Placebo+TCS|Week 0 to Week 16: Placebo will be given as subcutaneous injections. Participants will receive placebo loading dose on Day 0 followed by multiple placebo injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
11027233|NCT04587440|Experimental|Patient|"All patients will have a clinical examination before surgery and another 3 months after surgery, each including :
~A medical examination
~3 pelvic inclination measurements (1 sitting, 1 lying and 1 standing). These measurements will be done by ultrasound devices.
~2 EOS X-rays (1 standing and 1 sitting) of the lower limbs and spine
~Harris hip score
~Pain quantification thanks to an EVA scale
~hand-ground distance"
11027234|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
11027235|NCT04587414|Experimental|eHealth + counselling contacts|6-month eHealth physical activity intervention complemented by face-to-face and telephone counselling contacts on physical activity..
11027236|NCT04587414|Experimental|eHealth|6-month eHealth physical activity intervention
11027237|NCT04587414|Other|Usual care|Usual care of type 2 diabetics within the primary health care setting.
11027238|NCT04587401|Experimental|normotensive patients|Cerebral perfusion of normotensive patients who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
11027239|NCT04587401|Experimental|patients with high blood pressure diagnosis|Cerebral perfusion of patients with high blood pressure diagnosis who will have lumbar surgery at the prone position will be measured by transcranial doppler ultrasonography
11027240|NCT04587401|Experimental|patients who do not know they are hypertensive but actual blood pressure is high|cerebral perfusion of patients who do not have high blood pressure diagnosis but actual preoperative blood pressure is higher than normal levels will be measured by transcranial doppler ultrasonography during lumbar surgery
11027241|NCT04587362||Psoriatic Arthritis|Subjects newly diagnosed with psoriatic arthritis (< 5 years), confirmed by a rheumatologist and fulfilling the CASPAR criteria.
11027242|NCT04587362||Psoriasis without musculoskeletal symptoms|Patients with dermatologist confirmed psoriasis, without any history of Psoriatic Arthritis, and musculoskeletal symptoms.
11027243|NCT04587362||Non-Inflammatory Rheumatic conditions|Patients with non-inflammatory rheumatic conditions such as osteoarthritis, non-specific back pain, soft tissue rheumatism, degenerative tendinopathy and fibromyalgia. Patients with present or past history of psoriasis, psoriatic arthritis, known or suspected rheumatic inflammatory conditions (e.g. rheumatoid arthritis, spondyloarthritis and gout), and/or inflammatory bowel disease will be excluded.
11027244|NCT04587349|Active Comparator|Exercise+FU 2/week|Post stroke group that received 2 years of intensive therapy. (2/week)
11027245|NCT04587349|Active Comparator|Exercise+FU 3/week|Post stroke group that received 2 years of intensive therapy. (3/week)
11027246|NCT04587349|Active Comparator|physiotherapy|Post stroke group that received 2 years of traditional physiotherapy. (3/week)
11027247|NCT04587349|No Intervention|Exercise+FU - controll|He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
11027248|NCT04587336||Aim 0 - Cognitive Interview|Cognitive Interviews: Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
11027249|NCT04587336||Aim 1 - Baseline Survey|Conduct Baseline Survey: Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
11027250|NCT04587336||Aim 3 - TARDIS Pilot|TARDIS Intervention: Design & pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors
11027251|NCT04587323||Group 1:|Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);
11027252|NCT04587323||Group 2:|Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).
11027253|NCT04587323||Group 3:|Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)
11027254|NCT04587323||Group 4:|Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).
11027255|NCT04587284||Patients with robot-assisted laparoscopic radical prostatectomy|
11027256|NCT04587284||Patients with open retropubic radical prostatectomy|
11027257|NCT04587284||Patients with laparoscopic radical prostatectomy|
11027258|NCT04587271|Experimental|Lactating Mothers (Moringa)|Lactating mothers.
11027259|NCT04587271|Experimental|Breastfeeding Infants (Moringa)|Breastfeeding infants from lactating mothers
11027260|NCT04587271|Experimental|Children (Moringa)|Children from 6-59 months of age.
11027261|NCT04587271|Placebo Comparator|Lactating Mothers (placebo)|Lactating mothers.
11027262|NCT04587271|Placebo Comparator|Breastfeeding Infants (placebo)|Breastfeeding infants from lactating mothers
11027263|NCT04587271|Placebo Comparator|Children (placebo)|Children from 6-59 months of age.
11027264|NCT04587258||Breast Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.
11027265|NCT04587258||Colorectal Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies
11027266|NCT04587245||Physicians|Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients
11027267|NCT04587219|Experimental|Gam COVID Vac Vaccine|the test drug will be administered according to the prime-boost scheme: the introduction of component 1 (Ad26) will be carried out on the 1st day, and component 2(Ad5)- on the 21st day of the study.
11027268|NCT04587206|Experimental|Experimental: Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
11027269|NCT04587206|Experimental|Experimental: Sequence2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition
~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
11027270|NCT04587193|Experimental|PD participants|Subjects will participate in a total of 10 walking sessions, twice per week for 5 weeks, while wearing a robotic-assist gait training device. There will also be 3 additional visits for assessments at: baseline (up to 1 prior to treatment), post (1 week after last treatment), and final (4-6 weeks after last treatment).
11027271|NCT04587180||Patients with cutting-through|Patients who had cutting-through during the lateral knotless anchor fixation.
11027272|NCT04587180||Patients without cutting-through|Patients who didn't have cutting-through during the lateral knotless anchor fixation.
11027273|NCT04587167|Experimental|HPV ECHO|Clinics randomly assigned to this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. The intervention has a curriculum of 10 sessions focused on the evidence-based Announcement Approach. Sessions will be 60 minutes in duration and held every other weekly for 4 months at regularly scheduled times.
11027274|NCT04587167|Experimental|HPV ECHO+|Clinics randomly assigned to this arm will receive the HPV ECHO intervention plus a systems communication strategy to deliver recall notices to parents who initially decline HPV vaccination. This arm includes 12 primary care clinics in Pennsylvania.
11027275|NCT04587167|No Intervention|Control|Clinics randomly assigned to this arm will receive no ECHO interventions. This arm includes 12 primary care clinics in Pennsylvania.
11027276|NCT04587154|Experimental|Intervention Group|This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
11027277|NCT04587154|No Intervention|Control Group|This arm will not change their diet for the duration of the study. They will also weigh themselves each week and report weight and hot flash frequency/severity weekly.
11027278|NCT04587141|Experimental|Sucrosomial iron|One or two capsules/die of sucrosomial iron will be assumed by the participant, depending on hemoglobin (Hb) concentration and participant body weight, for 8 weeks. Each capsule contains 30 mg of iron.
11027279|NCT04587141|Active Comparator|Ferric gluconate|Ferric gluconate will be administered by iv infusion, 125 mg of elemental iron once or twice weekly for 4 or 8 weeks depending on Hb concentration and patient body weight.
11027280|NCT04587141|Active Comparator|Ferric carboxymaltose|Two or three iv infusions of 500-1000 mg of elemental iron will be given as ferric carboxymaltose, over a 4 week period. Dosage and number of infusions will be established depending on Hb concentration and patient body weight.
11027281|NCT04587128|Experimental|Cohort A: No Previous EGFR|"Participant who have not be previously exposed to anti-EGFR therapies and are in the first or second-line metastatic treatment setting.
~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle"
11027282|NCT04587128|Experimental|Cohort B: Retreatment|"Participants with treatment refractory disease who have previously benefitted (greater than or equal to 4 months ago) from anti-EGFR therapy.
~Panitumumab (6mg/kg) or Cetuximab 500mg (per treating physician) on day 1 and 15 of a 28-day cycle, +/- Irinotecan (180mg/m^2) every 2 two weeks per standard of care"
11027283|NCT04587115|Placebo Comparator|Oxycodone|This arm will be considered the control arm, containing oxycodone as the placebo.
11027284|NCT04587115|Experimental|Oxycodone and Risperidone|Administration of oxycodone plus risperidone in a single capsule
11027285|NCT04587115|Experimental|Oxycodone and Ziprasidone|Administration of oxycodone and risperidone in a single capsule
11027286|NCT04587102|Active Comparator|whole body viberation :group A|will receive low vibrational training in the form of whole body vibration for 8 weeks
11027287|NCT04587102|Active Comparator|Yoga group (B)|will receive Yoga exercises for 8 weeks
11027288|NCT04587089|Experimental|Conventional Treatment + Guedes-Pinto Paste Group|In this group, the conventional endodontic treatment will be made, the canals will be irrigated and filled with Guedes-Pinto paste.
11027289|NCT04587089|Experimental|Irrigation + Guedes-Pinto Paste Group|In this group,the canals will be irrigated and filled with Guedes-Pinto paste.
11027290|NCT04587089|Experimental|Irrigation + aPDT + Guedes-Pinto Paste Group|In this group, the canals will be irrigated, antimicrobial photodynamic therapy will be performed and the canals will be filled with Guedes-Pinto paste.
11027291|NCT04587063|Active Comparator|Standard Email|"The standard of care email is the same as one used in prior outreach efforts at the health system, emphasizing reduced cost for medications and convenience."
11027292|NCT04587063|Experimental|Email with Healthcare Cost Savings|The email emphasizes future reductions in healthcare costs due to increased adherence with mail-order pharmacy, in addition to mentioning reduced prices for medications. It also uses fear appeals by stating the risk of hospital stays and how mail-order pharmacy could be an easily-achievable way to avoid this negative consequence.
11027293|NCT04587063|Experimental|Email with Endorsement|The email is a letter from a doctor at the health system's health plan--who may been seen as a trusted source of information--encouraging the benefits of using a mail-order pharmacy.
11027294|NCT04587063|Experimental|Email with Comparison Table|The email includes a table comparing the benefits and drawbacks of mail-order and chain pharmacies, which appeals to their sense of agency and allows them to make the choice that best suits them.
11027295|NCT04587063|No Intervention|No Contact|Members do not receive an email.
11027296|NCT04587050||Cohort 1|Women with perinatally acquired HIV aged 18 or over who are sexually active
11027297|NCT04587050||Cohort 2|Women with perinatally acquired HIV aged 18 or over who are not sexually active
11027298|NCT04587037|Experimental|Fascia lata group|
11027299|NCT04587037|Experimental|Dermal allograft group|
11027300|NCT04587024|Other|mHealth intervention|mHealth intervention
11027301|NCT04587024|Placebo Comparator|standard of care|post-transplant standard of care
11027302|NCT04587011|Experimental|T1|Tegoprazan A mg or placebo
11027303|NCT04587011|Experimental|T2|Tegoprazan B mg or placebo
11027304|NCT04587011|Experimental|T3|Tegoprazan C mg or placebo
11027305|NCT04587011|Experimental|T4|Tegoprazan D mg or placebo
11027306|NCT04587011|Experimental|T5|Tegoprazan E mg
11027307|NCT04587011|Experimental|T6|Nexium injection 40 mg
11027308|NCT04586998|Experimental|"Exhaled drug monitor Edmon"|Comparison between propofol in exhaled breath and blood plasma
11027803|NCT04583514|Experimental|Control|The control group will be expected to maintain their weight within 1 kg of baseline weight throughout the duration of the study.
11027309|NCT04586985|Experimental|Single ascending dose cohorts in healthy subjects (Part A)|Subjects will be randomized to 3:2 to receive a single dose FTX-6058 or placebo. Up to 6 cohorts of 5 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 30 mg (Cohort 4), 60 mg (Cohort 5), and 90 mg (Cohort 6).
11027310|NCT04586985|Experimental|Multiple ascending dose cohorts in healthy subjects (Part B)|Subjects will be randomized 6:2 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 4 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4).
11027311|NCT04586985|Experimental|Pilot Food Effect Cohort in healthy subjects (Part C)|"Ten subjects will be randomized to receive two single doses of FTX-6058 with and without a high fat meal. The dose of FTX-6058 will be one half of the highest tolerated dose from Part A.
~Dosing Period 1: Single dose within 30 minutes of high-fat meal.
~Washout Period: Interval of 7 ± 2 days
~Dosing Period 2: Single dose without high fat meal."
11027312|NCT04586985|Experimental|Potential for CYP3A Induction Cohort (Part D)|Sixteen subjects will receive 3 mg midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 once daily. On Day 12, 3 mg midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
11027313|NCT04586959|Experimental|Surgery With UM (Arm MAN UA)|Subjects that undergo a MIS approach with a uterine manipulator (experimental arm)
11027314|NCT04586959|Active Comparator|Surgery Without UM (Arm Control)|Subjects that undergo a MIS approach without a uterine manipulator (control arm)
11027315|NCT04586933|Active Comparator|Omega-3|"0,9 gram omega-3/capsule x 4 = 3,6 gram omega-3 daily
~It will be investigated whether diet optimization followed with supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used"
11027316|NCT04586933|Placebo Comparator|Placebo capsules|Soya oil
11027317|NCT04586920|Experimental|LY3509754 - Part A|Escalating doses of LY3509754 administered orally
11027318|NCT04586920|Placebo Comparator|Placebo - Part A|Placebo administered orally
11027319|NCT04586920|Experimental|LY3509754 plus Itraconazole - Part B|LY3509754 and Itraconazole administered orally
11027320|NCT04586920|Placebo Comparator|Placebo plus Itraconazole - Part B|Placebo and Itraconazole administered orally
11027321|NCT04586920|Experimental|LY3509754 plus Midazolam - Part C|Multiple doses of LY3509754 administered orally. Some participants will also receive midazolam orally.
11027322|NCT04586920|Placebo Comparator|Placebo plus Midazolam - Part C|Multiple doses of placebo administered orally. Some participants will also receive midazolam orally.
11027323|NCT04586920|Experimental|LY3509754 (Japanese) - Part D|Multiple doses of LY3509754 administered orally to Japanese participants
11027324|NCT04586920|Placebo Comparator|Placebo (Japanese) - Part D|Placebo administered orally to Japanese participants
11027325|NCT04586907|Experimental|LY3537021 (Part A)|LY3537021 administered subcutaneously (SC).
11027326|NCT04586907|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
11027327|NCT04586907|Experimental|LY3537021 (Part B)|LY3537021 administered SC.
11027328|NCT04586907|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
11027329|NCT04586894||Patients|
11027330|NCT04586868|Experimental|A psychotic disorder|Patients, age 13-19 years old, diagnosed with a psychotic disorder (WHO ICD-10 )
11027331|NCT04586855||Healthy persons|Noninvasive ventilation and Cough Assist
11027332|NCT04586842|Experimental|Community-based Occupational Therapy|
11027333|NCT04586829|Active Comparator|Conventional diet|Conventional diet. (50% carbohydrate, 30% lipids, 20% protein). Current dietary recommendations from official guidelines will be reinforced.
11027334|NCT04586829|Experimental|Ketogenic diet|Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.
11027335|NCT04586816|Placebo Comparator|vehicle only-placebo|Vehicle cream base containing no maple leaf extract to be applied twice daily to the face
11027336|NCT04586816|Experimental|1% red maple leaf extract|lotion preparation with 1% red maple leaf extract to be applied twice daily to the face
11027337|NCT04586816|Experimental|5% red maple leaf extract|lotion preparation with 5% red maple leaf extract to be applied twice daily to the face
11027338|NCT04586803|Experimental|A|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
11027339|NCT04586803|Experimental|B|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
11027340|NCT04586803|Experimental|C|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
11027341|NCT04586803|Experimental|D|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
11027342|NCT04586803|Experimental|E|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
11027343|NCT04586803|Experimental|F|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
11027344|NCT04586790|Experimental|midodrine group|midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine
11027345|NCT04586790|Experimental|minirin group|the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin
11027346|NCT04586790|Experimental|control group|the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
11027347|NCT04586777|Experimental|Anodal tvDCS|20 minutes of anodal tvDCS will be applied over the spine at 2.5mA.
11027348|NCT04586777|Experimental|Cathodal tvDCS|20 minutes of cathodal tvDCS will be applied over the spine at 2.5mA.
11027349|NCT04586777|Sham Comparator|Sham tvDCS|20 minutes of sham tvDCS will be applied over the spine.
11027350|NCT04586751|Active Comparator|study group|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed. In specific, using the in-plane insertion technique, after visualization of the entire needle as a bright hyperechoic line and aiming between pectoralis major and pectoralis minor at the 3rd rib level, 2 ml of normal saline 09% will be injected first, to verify the correct position of the needle. Followingly, 10 mL ropivacaine 0.5% will be injected in order to block the lateral and medial pectoral nerves. Finally, another 15 ml of ropivacaine 0.5% plus 4 mg of dexamethasone will be injected between the pectoralis minor muscle and the anterior serratus muscle,at the level of the 4th and 5th ribs, after negative aspiration, to block the intercostal and intercostobrachial nerves. Using the color Doppler the vessels will be identified, so that their puncture is avoided during the procedures.
11027351|NCT04586751|Sham Comparator|control group|no regional block will be performed
11027352|NCT04586738|Other|Non-resorbable uveoscleral implant associated with absorbable collagen matrix|non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix
11027353|NCT04586738|Other|Isolated absorbable collagen matrix implant|non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant
11027354|NCT04586725|Active Comparator|No encouragement during the walking tests|Patients will be randomised to six tests at one week apart
11027355|NCT04586725|Active Comparator|Encouragement every minute|Patients will be randomised to six tests at one week apart
11027356|NCT04586725|Active Comparator|Encouragement every two minutes|Patients will be randomised to six tests at one week apart
11027357|NCT04586712|Experimental|Active CBD-extract high dose|High Dose (1000mg/30mL hemp extract = 62.5mg/day)
11027358|NCT04586712|Experimental|Active CBD low dose|Low Dose (500mg/30mL hemp-extract = 25mg/day)
11027359|NCT04586712|Placebo Comparator|Vehicle-Control (Placebo)|(0mg/30mL hemp extract = no hemp extract)
11027360|NCT04586699|Experimental|CogTMS|rTMS iTBS protocol paired with an attention-to-breath task
11027361|NCT04586686|Other|Group 1: right ovarian biopsy|Patients in group 1 will undergo a laparoscopy for an ovarian biopsy from the right ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
11027362|NCT04586686|Other|Group 2: left ovarian biopsy|Patients in group 2 will undergo a laparoscopy for an ovarian biopsy from the left ovary. They will then continue with a controlled ovarian stimulation, using a GnRH antagonist protocol. This will be started with Corifollitropin alfa 0.15 mg in the evening. On day six the antagonist, Ganirelix, will be added in the morning. If needed stimulation can be continued after seven days using follitropin beta daily in the evening (dosage ranging from 200-300 IE depending on AMH levels). Agonist trigger Triptorelin 0.2 mg will be administered for ovulation induction. In case of LH levels <2 IU/L at the start of ovarian stimulation, a dual ovulation strategy will be adapted: Triptorelin 0.2mg and choriongonadotropin 2500 IU (or choriongonadotropin alfa 250 µg) will be given. A transvaginal oocyte retrieval will be planned 36 hours after triggering.
11027363|NCT04586673|Experimental|ChAdOx1.tHIVconsv1 low dose|3 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^9 vp
11027364|NCT04586673|Experimental|ChADOx1.tHIVconsv1 higher dose|10 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10^8 pfu and MVA.tHIVconsv4 at 0.9 x 10^8 pfu.
11027365|NCT04586660|Experimental|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone [GCTB], or multiple lesions including pulmonary metastases).
11027366|NCT04586660|Experimental|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
11027367|NCT04586647|Experimental|Noom Health Weight Program|
11027368|NCT04586647|No Intervention|Wait List Control|
11027369|NCT04586634|Active Comparator|Peristeen|Subjects to use newly developed Peristeen cone catherter device
11027370|NCT04586634|No Intervention|Standard of care|subjects continue with their standard of care treatment
11027371|NCT04586621|Experimental|Atoldys/ Lexilens - SHAM|
11027372|NCT04586621|Experimental|SHAM- Atoldys/ Lexilens|
11027373|NCT04586608|Active Comparator|active comparator|
11027374|NCT04586608|Other|soybean oil-based IVFE|soybean oil-based IVFE
11027375|NCT04586595|Experimental|Intervention arm|GP trainees in this arm will receive the REVISiT intervention which will involve having their prescribing reviewed and feedback provided, at two time points (approximately 100 prescriptions at each time point) separated by approximately a 3-month time period.
11027376|NCT04586595|No Intervention|Control arm|GP trainees in this arm will continue with training as usual and will have their prescribing (approximately 200 prescriptions) reviewed once but representing two time points - separated by an approximate 3-month time period. Feedback will occur at one time point, to cover the review for the 200 prescriptions.
11027377|NCT04586582||ST-segment resolution <40.15%|ST-segment resolution <40.15%
11027378|NCT04586582||ST-segment resolution >40.15%|ST-segment resolution >40.15%
11027379|NCT04586569|No Intervention|Standard Education|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham.
11027380|NCT04586569|Experimental|Pediatric Interactive Relational Agent (PIRA)|This group will receive the standard of care pre-operative education that all children get prior to ORL surgery at BCH Waltham and will be given access to an interactive, online educational tool for use prior to surgery. This Pediatric Interactive Relational Agent (PIRA) will be able to be accessed as many times as the family would like prior to surgery.
11027403|NCT04586426|Experimental|Part 1: Step-up Dosing and Dose Escalation|Participant will receive step-up doses of talquetamab and teclistamab prior to Cycle 1 Day 1; thereafter, the participant will receive treatment doses of talquetamab and teclistamab in 28-day cycles.
11027381|NCT04586556|Experimental|Artificial intelligence for real-time detection and monitoring of colorectal polyps|A standard colonoscopy will be performed according to the standard of routine care. All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards. The AI system will capture video of the procedure in real time, and provide additional information on the detection of polyps, follow-up and prediction of pathology.
11027382|NCT04586543|Experimental|Selegiline+ Docetaxel|Selegiline and plus Docetaxel
11027383|NCT04586543|Active Comparator|Docetaxel|Docetaxel
11027384|NCT04586530|Experimental|Memory and Attention Adaptation Training (MAAT)|"A videoconference-delivered cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8 weekly 45-minute visits with a survivor workbook, that targets: 1) enhancement of survivor self-awareness of at risk situations where memory failures occur; 2) emotion regulation through modification of survivor causal attributions and negative cognitive appraisals of memory failures; and 3) training in compensatory strategies to improve performance on daily tasks for which memory."
11027385|NCT04586530|Active Comparator|Supportive Therapy (ST)|"Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors consisting of 8, 45-minutes visits. ST, emphasizes non-specific psychotherapeutic factors of clinician-participant alliance: empathy, support and warmth. ST will be directed at concerns with cancer survivorship and CRCD. Clinicians will set expectations with ST participants that they will be provided validation of experience, support, and encouragement of building their own coping resources if asked directly about what to do about cognitive problems. ST emphasizes reflective listening to help deepen knowledge of the emotional experience of the participant."
11027386|NCT04586517|Experimental|Intervention group|Participants will receive supervised heavy-load resistance training twice a week during treatment with chemotherapy (approximately 16-weeks). After end of chemotherapy, participants will be encouraged to continue the training program and are provided with 12-month membership at a local gym.
11027387|NCT04586517|Active Comparator|Control group|Participants will be encouraged to continue with their usual activities during chemotherapy and not start resistance training (approximately 16-weeks). After end of chemotherapy participants will be offered to attend a 2-week introduction to the strength-training program and provided with a 12-month membership at a local gym.
11027388|NCT04586504|Experimental|0.2 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.2 mg/kg.
11027389|NCT04586504|Experimental|0.3 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.3 mg/kg.
11027390|NCT04586504|Experimental|0.4 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.4 mg/kg.
11027391|NCT04586504|Experimental|0.5 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.5 mg/kg.
11027392|NCT04586491|Experimental|Study group/ Oral care protocol with saline solution|All patients took oral care protocol in the unit with saline solution
11027393|NCT04586491|Experimental|Control group/ Oral care protocol with sodium bicarbonate solution|All patients took oral care protocol in the unit with sodium bicarbonate solution
11027394|NCT04586478|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
11027395|NCT04586465|Experimental|Neoadjuvant ICI combination with chemotherapy for stage Ⅱ-Ⅲ NSCLC|Eligible patients with clinical stage Ⅱ-Ⅲ NSCLC will receive dynamic PET-CT before and after 3 cycles neoadjuvant pembrolizumab plus chemotherapy, then patients receive surgical resection. Changes in tumor size were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Net uptake rate constant of FDG-Ki value based on dynamic PET will be calculated to evaluate Ki changes before and after treatment. Pathological tumor response were evaluated according to IASLC recommendations. Dynamic PET will be compared with RECIST whether it can better predict the pathological tumor response and disease free survival.
11027396|NCT04586452|Experimental|AAA Group (Aim 3A)|40 (20 men; 20 women) participants with a diagnosis of AAA (40-80 years) will undergo a PET/CT scan prior to their scheduled surgical repair of their condition. The radiotracer, 64Cu-DOTA-ECL1i, will be injected to detect CCR2+ inflammatory cells. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
11027397|NCT04586452|Experimental|Non-AAA Group|10 (5 men; 5 women) participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard of care. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
11027398|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens.
11027399|NCT04586452|Other|Radiotracer and CCR2 (Aim 2B)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair.
11027400|NCT04586452|Experimental|AAA Group (Aim 3B-Reproducibility)|20 (10 men; 10 women) will receive a second PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
11027401|NCT04586439|Experimental|Panel A: JNJ-73763989|Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
11027402|NCT04586439|Experimental|Panel B: J NJ-73763989|Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.
11027832|NCT04583319||SARS-CoV-2 Negative|participants tested negative for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
11027404|NCT04586426|Experimental|Part 2: Dose Expansion|Participants will receive treatment doses (combination of talquetamab and teclistamab) which will be determined by the RP2R(s) of the study treatment identified in Part 1.
11027405|NCT04586413||Non-hospitalised post-COVID-19 patients|This cohort will have had a confirmed positive test for COVID-19 or antibody test confirming they had COVID-19 but they were not hospitalised for this
11027406|NCT04586413||Hospitalised post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised but were not in an Intensive Care Unit
11027407|NCT04586413||Intensive care post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised in an Intensive Care Unit
11027408|NCT04586387|Experimental|Active brain stimulation|
11027409|NCT04586387|Sham Comparator|Inactive brain stimulation|inactive TMS
11027410|NCT04586374||Control Group|Transported patients with full monitoring (including an arterial line), without inotropic/vasoactive support.
11027411|NCT04586374||Study Group|Transported patients with full monitoring and vasoactive/inotropic support being delivered by a syringe driver.
11027412|NCT04586361|Experimental|Experimental group 1|Intraoperative1 kit of Platelet-rich plasma(PRP) injection into knee joint after anterior cruciate ligament (ACL) reconstruction.
11027413|NCT04586361|Experimental|Experimental group 2|Intraoperative1 kit of PRP+Hyaluronic acid(HA) injection into knee joint after ACL reconstruction.
11027414|NCT04586361|Placebo Comparator|Experimental group 3|Intraoperative 20 ml normal saline injection into knee joint after ACL reconstruction.
11027415|NCT04586348|Experimental|Low Iodine Supplement|Iodine (potassium iodide) 20 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
11027416|NCT04586348|Active Comparator|Standard Iodine Supplement|Iodine (potassium iodide) 200 μg Beta carotene (All trans-beta- carotene) 1500 μg; Vitamin E (dl-alphatocopheryl acetate) 13.5 mg AT; Vitamin D3 (cholecalciferol) 10 μg; Vitamin C (ascorbic acid granular) 60 mg; Niacinamide 18 mg; Pantothenic acid (calcium d- pantothenate) 6 mg; Vitamin B6 (DC pyridoxine hydrochloride) 1.9 mg; Vitamin B1 (thiamine mononitrate) 1.4 mg; Vitamin B2 (riboflavin) 1.4 mg; Biotin 30 μg; Vitamin B12 (methyl-cobalamin) 2.6 μg; Folic Acid 0.4 mg; Levomefolic acid 0.1 mg; Calcium (carbonate DC) 250 mg; Magnesium (oxide granular) 50 mg; Iron (ferrous fumarate) 20 mg; Zinc (oxide) 10 mg; Manganese (sulphate) 2 mg; Copper (sulphate) 1 mg; Selenium (rice chelate) 30 μg
11027417|NCT04586335|Experimental|CYH33 in Combination with Olaparib|CYH33 in Combination with Olaparib; 20 mg CYH33 QD in combination with olaparib 300 mg BID. Two additional dose levels of CYH33 at 30 mg QD and CYH33 at 40 mg QD in combination with olaparib 300 mg BID will be evaluated.
11027418|NCT04586309|Experimental|Early TM Training|This group will receive training in Transcendental Meditation and will complete assessments at baseline, 1 month and 3 months.(3 assessments in total).
11027419|NCT04586309|Active Comparator|Delayed TM training|This arm will complete the baseline, 1 month and 3 month assessments and then will receive the TM training, followed by additional 1 month and 3 month post-training assessments (5 in total)
11027420|NCT04586296|Experimental|Telemedicine Group|Group that will be receiving the telemedicine intervention in addition to the standard of care post-op.
11027421|NCT04586296|No Intervention|Standard Treatment|Patients will be receiving the standard of care, post op visits at 2, 6, and 12 weeks.
11027422|NCT04586283|Experimental|Maternal Prone Position|Participants will initially be assessed in left-lateral position for 20 minutes. Participants will then be asked to lie in a prone position for 30 minutes supported by a specially designed pillow. Participants will then return to a left-lateral position for 20 minutes.
11027423|NCT04586270|Experimental|TAS0612 Escalation|TAS0612 administered orally
11027424|NCT04586270|Experimental|TAS0612 Expansion|TAS0612 administered orally
11027425|NCT04586257|Experimental|Group I|patients in this group will receive Erector spinae plane block after induction of general anesthesia.
11027426|NCT04586257|Experimental|Group II|patients in this group will receive thoracolumbar interfascial plane block after induction of general anesthesia
11027427|NCT04586244|Experimental|Treatment Group A|pemigatinib will be administered to participants with tumors that harbor the FGFR3 mutations or rearrangements
11027428|NCT04586244|Experimental|Treatment Group B|pemigatinib + retifanlimab will be administered to participants with tumors that harbor the FGFR3 mutations or rearrangements
11027429|NCT04586244|Experimental|Treatment Group C|pemigatinib × 2 weeks followed by retifanlimab will be administered to participants with tumors that harbor the FGFR3 mutations or rearrangements
11027430|NCT04586244|Experimental|Treatment Group D|epacadostat + retifanlimab will be administered to participants who do not have FGFR3 mutations and rearrangements
11027431|NCT04586244|Experimental|Treatment Group E|retifanlimab monotherapy will be administered to participants who do not have FGFR3 mutations and rearrangements
11027432|NCT04586244|Experimental|Treatment Group F|epacadostat monotherapy will be administered to participants who do not have FGFR3 mutations and rearrangements
11027433|NCT04586231|Experimental|Belzutifan + Lenvatinib|Belzutifan 120 mg and lenvatinib 20 mg orally once a day
11027434|NCT04586231|Active Comparator|Cabozantinib|Cabozantinib 60 mg orally once a day
11027435|NCT04586218|Active Comparator|Manual control of vasopressor infusion|"Vasopressor will be manually titrated by intensive care unit nurses in charge of the patients to maintain mean arterial pressure > 65 mmHg.
~Fluid administration consists in optimization of stroke volume during the perioperative period"
11027436|NCT04586218|Experimental|Computer guided vasopressor infusion|"Vasopressor will be titrated automatically by ta closed-loop system under the supervision of the anesthesiologists in charge of the patients to maintain mean arterial pressure > 65 mmHg.
~Fluid administration consists in optimization of stroke volume during the perioperative period"
11027594|NCT04585139|Active Comparator|Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM|1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.
11027437|NCT04586192|Experimental|COMET|Participants receive modules focused on cognitive restructuring, gratitude, behavioral activation and self-compassion. Participants were randomized to receive 3 of the 4 possible modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.Participants in the intervention condition were randomized to receive descriptions of the four modules at the beginning of the intervention that were phrased to focus on building and improving strengths (positive) or reducing negative emotions and behaviors (negative).
11027438|NCT04586192|Sham Comparator|Self-Awareness Control|Participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
11027439|NCT04586192|No Intervention|Waitlist|Participants filled out all pre-test and post-test measures without having access to COMET of the active control exercises. Participants in this condition will receive access to COMET at the end of the study.
11027440|NCT04586179|Active Comparator|Aerobic (treadmill) Exercise|Participants will wear a heart rate monitor and complete the Buffalo Concussion Treadmill Test
11027441|NCT04586179|Experimental|Dynamic Exercise|Participants will wear a heart rate monitor and complete a dynamic exertion assessment that incorporates directional changes that incrementally increases in exercise intensity
11027442|NCT04586166|Experimental|RP Sling Group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure
11027443|NCT04586166|Experimental|SIS Group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure
11027444|NCT04586153|Experimental|Meplzaumb|This arm is combined with 3 groups, low dose, middle dose, and high dose. Low dose group: First dose: 0.12 mg/kg - Day 1; second dose: control - Day 8 Middle dose group: First dose: 0.2 mg/kg - Day 1; second dose: 0.2 mg/kg - Day 8 High dose group: First dose: 0.3 mg/kg - Day 1; second dose: 0.3 mg/kg - Day 8
11027445|NCT04586153|Placebo Comparator|Placebo|First dose: control - Day 1; second dose: control - Day 8
11027446|NCT04586140||Patients with COVID-19 infection|This study will be carried out on patient data usually collected as part of their care. The patients were infected with COVID-19 and hospitalized between 03/25/2020 and 05/07/2020, and who benefited from GAREC's intervention.
11027447|NCT04586140||Nursing staff AND GAREC Members|This study also concerns data collected in the context of semi-structured interviews with health professionals, in a prospective manner. These are caregivers who are members of GARED or who called on GAREC between 25/03/2020 and 07/05/2020.
11027448|NCT04586127|Experimental|Adolescents and Young Adults Needs Assessment & Service Bridge (AYA NA-SB)|Subjects will complete 2 online surveys over the course of 1 month; each should take about 15 minutes to complete.
11027449|NCT04586114||Early corticosteroid|Corticosteroid treatment within first seven days after ICU admission
11027450|NCT04586114||Late corticosteroid|Corticosteroid treatment later than seventh day's after ICU admission
11027451|NCT04586114||No corticosteroid|No corticosteroid treatment during ICU stay
11027452|NCT04586101|Experimental|Training intervention|
11027453|NCT04586101|No Intervention|Control interverntion|
11027454|NCT04586088|Experimental|Apatinib plus Camrelizumab arm|Subjects receive apatinib plus camrelizumab
11027455|NCT04586075||Undiagnosed Disease Group|Blood or other relevant biological samples obtained from consenting research subjects will be banked and extracted for DNA and RNA.
11027456|NCT04586049||Veterans with GWI|Veterans with GWI who served in the Gulf War between 1990 and 1991
11027457|NCT04586049||Veterans without GWI (Controls)|Veterans without GWI who served in the Gulf War between 1990 and 1991
11027458|NCT04586036|Experimental|young healthy adults|
11027459|NCT04586036|Experimental|young adults with chronic ankle joint instability|
11027460|NCT04586023|Experimental|fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
11027461|NCT04586023|Active Comparator|teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
11027462|NCT04586010|Experimental|fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
11027463|NCT04586010|Active Comparator|teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
11027464|NCT04585997|Active Comparator|Mepolizumab|Mepolizumab
11027465|NCT04585997|Active Comparator|Omalizumab|Omalizumab
11027466|NCT04585984|Placebo Comparator|Control|140 men will be taking a placebo once a day during 21 days prior to the start of the IVF/ICSI cycle.
11027467|NCT04585984|Experimental|Experimental|140 men will be taking the probiotic compound (50% of each probiotic: Lactobacillus rhamnosus and Bifidobacterium longum at a dose of 10^9 cfu/day) once a day for 21 days prior to the start of the IVF/ICSI cycle.
11027468|NCT04585971||Subjects|Cerebral blood flow of a subject is measured using three methods in both common carotid and vertebral arteries. 1) Phase-contrast MR 2) Doppler sonography 3) Signal Intensity Gradient (SIG) To determine whether there is a correlation between the measured values, the correlation coefficient is calculated and analyzed.
11027469|NCT04585958|Experimental|Treatment (trastuzumab deruxtecan, olaparib)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11027470|NCT04585945||Group 1 (Cases)|Patients that test positive for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
11027471|NCT04585945||Group 2 (Control)|Historic group of patients delivering prior to the COVID-19 pandemic.
11027472|NCT04585932|Active Comparator|Group I (apalutamide, leuprolide, degarelix)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
11027473|NCT04585932|Experimental|Group II (apalutamide, leuprolide, degarelix, RT)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo RT between cycles 4-7 in the absence of disease progression or unacceptable toxicity.
11027474|NCT04585919|Experimental|Paired Screening Intervention|
11027595|NCT04585126|No Intervention|General anesthesia without intermediate cervical block|General anesthesia performed by the anesthesiologist
11027475|NCT04585919|No Intervention|Usual Care Control|In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.
11027476|NCT04585906|Experimental|Sessions with a community mental health specialist|Those randomized into the intervention group will receive 5-15 hour-long sessions with a community mental health specialist, taking place over 12 weeks. The common elements treatment approach intervention includes psychoeducation and addresses safety (when identified as a problem area). It can also include teaching relaxation, cognitive coping, exposure-trauma memories, exposure-live, cognitive restructuring, behavioral activation, and problem solving.The exact number of sessions will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues).
11027477|NCT04585906|Active Comparator|Wait-list|This study employs a wait-list control design. Participants in the control group will be asked to wait until the intervention group has all begun the intervention sessions before they begin.
11027478|NCT04585893|Experimental|Single Arm Rituximab|"The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually.
~High-risk patients (defined as patients with ECOG performance status >2 or hemoglobin <8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2).
~Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone."
11027479|NCT04585880|Experimental|Virtual Collaborative Care Clinic|The Virtual Collaborative Care Clinic arm participants use a home blood pressure monitor and routine blood pressure measurements will be uploaded to a dashboard monitored by clinical pharmacists. Blood pressure will be managed aggressively by the clinical pharmacists in coordination with Primary Care Physicians.
11027480|NCT04585880|No Intervention|Control Intervention|The control intervention will consist of providing the participant with educational material and a home blood pressure monitor. The patients in the control group will not have support from Virtual Collaborative Care Clinic pharmacists. Routine blood pressure measures using their device will not be collected via the dashboard and will not be available for pharmacist review. Participants will continue to see their physicians for their usual care for blood pressure management.
11027481|NCT04585867|Active Comparator|Liposomal bupivacaine|Exparel (266mg) given by surgeon just prior to sternal closure
11027482|NCT04585867|Active Comparator|Bupivacaine|40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure
11027483|NCT04585854|Other|Control|Control population who will undergo two cardiovascular magnetic resonance exams: one at rest and one after drinking caffeine.
11027484|NCT04585841|Experimental|Intervention group|Cancer patients receiving cannabidiol
11027485|NCT04585841|No Intervention|Control group|Cancer patients not receiving cannabidiol
11027486|NCT04585828|Experimental|Bili Cocoon|The infants will be treated with phototherapy using a double sided fiber optic pad called Bili Cocoon with an irradiance of 30 uW/cm2/nm from both sides.
11027487|NCT04585828|Active Comparator|Conventional blue light|The infants will be treated with blue light from above at 30 Uw/cm2/nm which is the standard treatment.
11027488|NCT04585815|Experimental|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
11027489|NCT04585802||Suicide Attempters (1)|patients with a suicide attempt
11027490|NCT04585802||Suicide Ideators (2)|patients with suicidal ideation
11027491|NCT04585802||Control Group (3)|patients without suicide attempt and without suicide ideation
11027492|NCT04585789|Experimental|Panel 1 Arm 1: JNJ-73763989+ JNJ-56136379+ NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) along with JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets) once daily up to 48 weeks.
11027493|NCT04585789|Experimental|Panel 1: Arm 2: JNJ-73763989 + NA|Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with NA treatment (either ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks.
11027494|NCT04585789|Experimental|Panel 2: Arm 1: JNJ-73763989+ JNJ-56136379+ NA|Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks.
11027495|NCT04585789|Experimental|Panel 2: Arm 2: JNJ-73763989 + NA|Participants will receive JNJ-73763989 SC injection once every 4 weeks (last injection at Week 44) along with NA treatment (either ETV, tenofovir disoproxil or TAF tablets) once daily up to 48 weeks.
11027496|NCT04585776|Experimental|LY900014 + Insulin Degludec|LY9000014 and insulin degludec given subcutaneously (SC).
11027497|NCT04585763|Experimental|Single Arm|
11027498|NCT04585750|Experimental|Phase 1 Dose Escalation|Multiple dose levels of PC14586 will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D).
11027499|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort A|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort A participants will have advanced solid tumors harboring a p53 Y220C mutation who meet all eligibility criteria and have measureable disease per RECIST 1.1.
11027500|NCT04585750|Experimental|Phase 2 Dose Expansion, Cohort B|Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort B participants will have advanced solid tumors harboring a p53 Y220C mutation who do not meet all eligibility criteria (e.g. have a primary central nervous system (CNS) tumor) and do not have measurable disease per RECIST 1.1.
11027501|NCT04585737|Experimental|Treatment group 1|Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.
11027502|NCT04585737|Active Comparator|Treatment group 2|Treatment Group 2 (n=74): Stay on baseline regimen consisting of FDC of B/F/TAF (50mg/200mg/ 25mg) (taken as prescribed) without regard to food.
11027688|NCT04584515|Experimental|IMP4297 100 mg|Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.
11027503|NCT04585724|Experimental|Treatment (abemaciclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive abemaciclib PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
11027504|NCT04585724|Experimental|Treatment (palbociclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive palbociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
11027505|NCT04585724|Experimental|Treatment (ribociclib)|Beginning within 2 weeks prior to stereotactic radiosurgery, patients receive ribociclib PO QD on days 1-21. Treatment continues in the absence of disease progression or unacceptable toxicity.
11027506|NCT04585711|Other|Optimal dosing|Obese children (≥ 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.
11027507|NCT04585698||headache patients|
11027508|NCT04585698||healthy subjects|
11027509|NCT04585685|Experimental|2 week baseline, CPT + SC|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
11027510|NCT04585685|Experimental|2 week baseline, SC + CPT|Participants in this arm are randomized to a 2-week baseline period with repeated weekly assessment after the initial intake. Following the 2-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
11027511|NCT04585685|Experimental|4 week baseline, CPT + SC|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 12 weekly sessions of Cognitive Processing Therapy (CPT), followed by a 3-week return to baseline period, followed by 6 weekly sessions of Self-Compassion Therapy (SC).
11027512|NCT04585685|Experimental|4 week baseline, SC + CPT|Participants in this arm are randomized to a 4-week baseline period with repeated weekly assessment after the initial intake. Following the 4-week baseline, participants are randomly assigned to receive 6 weekly sessions of Self-Compassion Therapy (SC), followed by a 3-week return to baseline period, followed by 12 weekly sessions of Cognitive Processing Therapy (CPT).
11027513|NCT04585672|Other|Healthy and Cirrhosis|Ammonia infusion with and without ammonia targeting
11027514|NCT04585659|Experimental|Qigong Intervention|60-90 minute community qigong classes, once per week plus at least 10 minutes of home practice
11027515|NCT04585659|No Intervention|Wait-List Control|Participants asked not to do any qigong, yoga or taichi for 10 weeks. Participants have the option to cross-over to the experimental arm after 10 weeks of no intervention.
11027516|NCT04585633||Low Risk|no complication develop within 30 days after the operation and high GOS value
11027517|NCT04585633||High Risk|"complication or complications develop within 30 days after the operation and low GOS value
~Complications:
~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),
~İntracranial hypertension requiring post op surgical drainage,
~Status epilepticus or seizures,
~The need for tracheal intubation or use of mechanical ventilation after surgery,
~Decrease in GKS,
~Unmanageable agitation that requires restriction or sedation,
~Need for respiratory failure and oxygen therapy,
~Unexpected serious motor deficit
~Died"
11027518|NCT04585620|Active Comparator|BTX-A|"Onabotulinum toxin A is reconstructed with 4 ml of normal saline in a vial containing 100 U (Allergen Units).
~At a single treatment session, test subjects receive a series of subcutaneous injections with 2,5 U Onabotulinum toxin A equivalent to 0,1 ml of solution after reconstruction. One injection is given per 1 square centimeter in the painful area in relation to the scar on the chest wall. The maximum number of subcutaneous injections is 40, equivalent to a maximum dose of 100 U of Onabotulinum toxin in a total volume of 4 ml solution. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes."
11027519|NCT04585620|Placebo Comparator|Placebo|At a single treatment session, test subjects receive a series of subcutaneous injections with one injection per 1 square centimeter in the painful area in relation to the scar on the chest wall with an inert solution, i.e. 0.1 ml injections of normal saline up to a total volume of 4 ml, depending on the area of the painful area. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.
11027520|NCT04585607|Experimental|Expanded hemodialysis (HDx)|HDx therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
11027521|NCT04585607|Active Comparator|Conventional hemodialysis|Conventional hemodialysis therapies be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
11027522|NCT04585594|Experimental|Mi Propio Camino (MPC; My Own Way)|Participants will complete the MPC intervention alongside usual care for hypertension
11027523|NCT04585594|Active Comparator|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|Participants will complete the HCP intervention alongside usual care for hypertension.
11027524|NCT04585581|Experimental|diet + training|
11027525|NCT04585581|Active Comparator|controls|
11027526|NCT04585555||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patient using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
11027527|NCT04585542|Experimental|Polyethylene glycol 3350 (MiraLax)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut."
11027528|NCT04585542|Experimental|Sodium polystyrene sulfonate (Kayexalate)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
11027727|NCT04584151|No Intervention|standard of care|Peri operative analgesia by opioid
11027728|NCT04584151|Experimental|Continuous regiona analgesia|Peri operative algesia by continuous bilateral ESP catheters
11027529|NCT04585542|Experimental|Patiromer (Veltassa)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
11027530|NCT04585542|Experimental|Sodium zirconium cyclosilicate (Lokelma)|"Participants will be randomized to one of four study arms. They will receive one dose of the study drug.
~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g)."
11027531|NCT04585516||Patient with suspected colorectal cancer|All patients that were admitted to the department of surgery with suspected colorectal cancer between January 2016 and December 2018 (n=459).
11027532|NCT04585516||Patients admitted according to the standardized course of care for colorectal cancer|All patients that were admitted to the endoscopy department according to the standardized course of care for colorectal cancer between September 2016 and December 2018 (n=1271).
11027533|NCT04585516||Patients < 50 years that were admitted for gastroscopy|All patients younger than 50 years that were admitted to the endoscopy department for a gastroscopy between jan 2018 and April 2019 (n= 1915)
11027534|NCT04585516||Patients >80 years that were admitted for colonoscopy|All patients older than 80 years that were admitted to the endoscopy department for a colonoscopy between Sept 2016 and Jan 2019 (n= 981)
11027535|NCT04585503|Experimental|Central nervous system monitoring|Each 20 patients will be implanted with subdural or intra cortical electrodes
11027536|NCT04585490|Experimental|Cohort 1 minimal residual disease positive (MRD+)|Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy [carboplatin/pemetrexed] and durvalumab (1500 mg IV every 21 days, for 1 year), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks.Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.
11027537|NCT04585490|Experimental|Cohort 2 minimal residual disease negative (MRD )|Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab(10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.
11027538|NCT04585477|Experimental|Cohort 1 minimal residue disease positive(MRD+)|"Subjects with detectable ctDNA (MRD+) will receive up to 12 cycles of durvalumab (1500mg dose by intravenous (by vein) injection every 28 days). ctDNA will be re checked following 2 cycles (8 weeks) of durvalumab and compared to baseline levels. In the absence of progression or toxicity after 2 cycles, subject will continue with durvalumab to complete 1 year of treatment about 10 additional cycles).
~Subjects will be monitored for secondary endpoints of progression free survival (PFS) and overall survival (OS)."
11027539|NCT04585477|Active Comparator|Cohort 2 minimal residue disease negative (MRD-)|Subjects with undetectable ctDNA (MRD) will receive Standard of care and no treatment
11027540|NCT04585464|Experimental|Healthy Volunteer: Single Ascending Dose|"Single oral ascending dose in healthy volunteers
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
11027541|NCT04585464|Experimental|Healthy Volunteer: Multiple Ascending Dose|"Multiple oral ascending doses in healthy volunteers
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
11027542|NCT04585464|Experimental|Healthy Volunteer: Food Effect|"Crossover food effect (fed versus fasted) single oral dose in healthy volunteers
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
11027543|NCT04585464|Experimental|Becker Muscular Dystrophy: Multiple Ascending Dose|"Multiple oral ascending doses in adults with Becker muscular dystrophy
~Interventions:
~Drug: EDG-5506 Drug: Placebo"
11027544|NCT04585451||Chronic Pain Patients|
11027545|NCT04585451||Healthy Controls|
11027546|NCT04585438|Experimental|Single trans-mucosal bio-adhesive disc containing Diclofenac Potassium|Premedication 1 hour before starting endodontic treatment.
11027547|NCT04585438|Placebo Comparator|Placebo Control|Premedication 1 hour before starting endodontic treatment. Identically-appearing trans-mucosal bio-adhesive disc (Does not contain medication)
11027548|NCT04585425|Other|Control|Treatment as usual including sleep hygiene advice
11027549|NCT04585425|Experimental|Intervention|Treatment as usual (sleep hygiene advice) and bedtime music listening
11027550|NCT04585412|Experimental|Palonosetron (Stothu®)|Stothu® Solution for Injection 0.25 mg/5 mL
11027551|NCT04585412|Active Comparator|Palonosetron (Aloxi®)|Aloxi® Solution for Injection 0.25 mg/5mL
11027552|NCT04585399|Experimental|Contingency Management|Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
11027553|NCT04585399|No Intervention|Standard Care|Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
11027554|NCT04585386|Experimental|ATLAS|"Medical device named ATLAS which is an active corset (rigid lumbar restraint) and connected."
11027555|NCT04585386|Active Comparator|Standard lumbar support belt|Standard lumbar support belt : LombaSkin® or Lombogib®
11027556|NCT04585373|Experimental|(24 hours)|kinesio-tapping along with conventional therapy
11027557|NCT04585373|Experimental|(48hours)|kinesio-tapping along with conventional therapy
11027558|NCT04585373|Experimental|(72 hours)|kinesio-tapping along with conventional therapy
11027559|NCT04585360||Patient with Behcet disease|adult patient with Behcet's disease followed regularly in the internal medicine department of Bicetre
11027560|NCT04585347|Experimental|Regimen A|ALZ-801 171 mg tablet, fasting, once
11027561|NCT04585347|Experimental|Regimen B|ALZ-801 205 mg tablet, fasting, once
11027562|NCT04585347|Experimental|Regimen C|ALZ-801 205 mg tablet, after food once
11027563|NCT04585347|Experimental|Regimen D|ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once
11027564|NCT04585334|Experimental|Arm A Tricortin|Tricortin 1000 by intramuscular route
11027565|NCT04585334|Active Comparator|Arm B Itami|Itami Diclofenac sodium medicated plaster by topical application
11027566|NCT04585334|Placebo Comparator|Arm C Placebo|Placebo
11028259|NCT04580160|Experimental|Duo Venous Stent System Implantation|
11027567|NCT04585321|Other|T-R|"Part 1 (QD) and part 2 (BID):
~Period 1: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster.
~Period 2: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac."
11027568|NCT04585321|Other|R-T|"Part 1 (QD) and part 2 (BID):
~Period 1: Reference drug (R): Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac.
~Period 2: Test drug (T): Diclofenac Sodium 140mg Medicated Plaster EQI7, topical plaster."
11027569|NCT04585308|Experimental|Single arm|Patients with severe native aortic valve stenosis who meet the commercially approved indications for TAVR.
11027570|NCT04585295|Experimental|Betaine|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.
~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.
~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
11027571|NCT04585295|Experimental|Placebo|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.
~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.
~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
11027572|NCT04585295|Experimental|NOW Foods Big 6|"Aim 1: To evaluate the impact of preloaded betaine supplementation on fluid compartments in male athletes aged 18-45 years old.
~Aim 2: To determine the degree to which preloading with betaine impacts heat tolerance relative to placebo in male athletes aged 18-45 years old.
~Aim 3: To determine the degree to which preloading with betaine impacts exercise metabolism and performance in the heat relative to placebo in male athletes aged 18-45 years old."
11027573|NCT04585282|Experimental|intervention group|The study group was treated with intensive cognitive behavioral therapy for insomnia.
11027574|NCT04585282|Active Comparator|control group|The control group was treated with traditional cognitive behavioral therapy for insomnia.
11027575|NCT04585269|Experimental|Bright IDEAS-YA|Intervention consists of six 45-minute one-on-one sessions between a patient and a trainer, who teaches the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach and worksheets. In addition, participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer Network (NCCN) adolescent and young adult patient guidelines.
11027576|NCT04585269|No Intervention|Enhanced Usual Care|Participants in this arm will receive a standardized list of resources from the National Comprehensive Cancer network (NCCN) adolescent and young adult patient guidelines.
11027577|NCT04585256|Active Comparator|Trendelenburg|Women positioned in the trendelenburg position during external cephalic version.
11027578|NCT04585256|No Intervention|Control|Women positioned on their back during external cephalic version.
11027579|NCT04585243|Experimental|Self-Sampling Kit|Participants will be mailed a Self-Sampling kit (Evalyn Brush) to collect samples for analysis for HPV/Cervical cancer screening.
11027580|NCT04585230|Active Comparator|Group 1: (CBD + MO cohort)|Roll on stick containing CBD and mineral oils (CBD + MO cohort)
11027581|NCT04585230|Active Comparator|Group 2: (MO cohort)|Roll on stick containing mineral oils only (MO cohort)
11027582|NCT04585230|Active Comparator|Group 3: (CBD Cohort)|Roll on stick containing CBD only (CBD cohort)
11027583|NCT04585230|Placebo Comparator|Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)|Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
11027584|NCT04585217|Active Comparator|Plain gut suture|Plain gut suture closure of blepharoplasty incision
11027585|NCT04585217|Active Comparator|Polypropylene suture|Polypropylene suture closure of blepharoplasty incision
11027586|NCT04585204|Active Comparator|50 gr-100 gr OGTT|patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT
11027587|NCT04585204|Active Comparator|75 gr OGTT|patients are tested by 75 gr OGTT
11027588|NCT04585191|Experimental|Pre-Visit Conversation Aid|"Patients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
11027589|NCT04585191|Active Comparator|General Health Education Handout|"Patients in the attention control arm will receive an existing 1-page health education handout entitled Embracing Life as You Age which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well."
11027590|NCT04585165||Risk of HIV acquisition|Individuals reporting behavioral risk of HIV acquisition.
11027591|NCT04585152|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells) How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
~Where: in Hospital When and how much: once; diluted in 1000 ml of normal saline."
11027592|NCT04585152|Active Comparator|Mycophenolate mofetil|"Drug Name: Mycophenolate Mofetil (MMF)
~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis Procedures: MMF 1,200 mg/m2 orally divided in 2 daily doses"
11027593|NCT04585139|Other|Phase 1 -- Introduction to Dexcom G6 CGM|A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM
11028400|NCT04579198|Experimental|Families receiving intervention|
11027596|NCT04585126|Active Comparator|General anesthesia with intermediate cervical block|General anesthesia performed by the anesthesiologist associated with an echoguided intermediate cervical block (bilateral in total thyroidectomy, unilateral in partial thyroidectomy) : 10 to 30cc of ropivacaine (2 to 3,75 %)
11027597|NCT04585113||People with hand OA awaiting surgery|Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.
11027598|NCT04585100|Experimental|Bioequivalent test of FM101 oral solution and FM101 tablet|
11027599|NCT04585100|Experimental|Phase 2a|
11027600|NCT04585087|Experimental|Healthy adult men|"Participants will initially be seen for a pre-study assessment (2 hours). They will then be studied for up to 6 times (6 different levels of threonine intake). Each set of experiments will be 9-days in length. During the first 2 days, a pre-adaptation (milkshake) diet will be consumed. For the remaining 7 days, a protein liquid drink and protein-free cookies will be consumed. All of the diets will be provided by the investigators.
~During each 9-day experiment, participants are expected to come to the Clinical Research Centre at the Hospital for Sick Children for breath and urine collection (5 hours total for each visit)"
11027601|NCT04585061|Active Comparator|sweet test group|Local anesthesia with conventional syringe Procedure: Local anesthesia with conventional syringe + xylitol sublingual tablet Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.
11027602|NCT04585061|Active Comparator|Virtual reality group|"Local anesthesia with conventional syringe + VR device Device: Local anesthesia with conventional syringe + VR device Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.
~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized."
11027603|NCT04585048|No Intervention|waiting list|waiting list
11027604|NCT04585048|Experimental|treatment|treatment with the Integrated Behavioral Therapy fo Selective Mutism
11027605|NCT04585035|Experimental|Dose escalation of D-1553 monotherapy|Phase 1a will evaluate up to 7 sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
11027606|NCT04585035|Experimental|Dose combination of D-1553 with other therapies|Phase 1b will determine the MTD of D-1553 in combination treatment in subjects with advanced or metastatic NSCLC, CRC and other solid tumors. There are multiple groups in Phase 1b for different tumor types and treatment combinations to evaluate safety, MTD and RP2D.
11027607|NCT04585035|Experimental|Phase 2 of D-1553 monotherapy and combination therapies|The Phase 2 portion is a multi-arm, parallel, open label study to evaluate the efficacy of D- 1553 single agent and combination treatments in subjects with advanced or metastatic solid tumors with KRas G12C mutation. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose.
11027608|NCT04585022|Active Comparator|Magnum|A metal-on-metal large diameter head total hip arthroplasty
11027609|NCT04585022|Active Comparator|Recap|A metal-on-metal hip resurfacing arthroplasty
11027610|NCT04585009|Experimental|Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
11027611|NCT04585009|Experimental|Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
11027612|NCT04585009|Experimental|Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
11027613|NCT04585009|Experimental|Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
11027614|NCT04585009|Experimental|Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
11027615|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
11027616|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo. There will be at least 10 days of wash-out period between doses for each participant.
11027617|NCT04585009|Experimental|Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
11027618|NCT04585009|Experimental|Cohort 3: Participants receivings repeated doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
11027619|NCT04585009|Experimental|Cohort 4: Participants receiving repeat doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
11027620|NCT04585009|Experimental|Cohort 5: Participants receiving repeat doses of GSK3923868|Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
11027621|NCT04584996||Pancreatic cancer|Patients being evaluated at MDT for suspected Pancreatic Ductal Adenocarcinoma (PDAC), via radiological test (e.g. endoscopic ultrasound (EUS), endoscopic retrograde cholangiography (ERCP), cross-sectional imaging), serum tumour marker (i.e. CA 19-9), or other diagnostic procedure
11027622|NCT04584996||Control|Patients diagnosed and/or due to undergo surgery for benign pathology (e.g. gallstones, chronic pancreatitis, etc); or patients with a diagnosis of a pre-malignant lesion (e.g. pancreatic intraductal papillary mucinous neoplasm); Pancreatic Neuroendocrine Tumour, or a Biliary Tract Cancer (i.e. cholangiocarcinoma; gallbladder cancer; ampullary cancer)
11027623|NCT04584983|Active Comparator|usual prescribed intralipid (UL) regimen|
11027624|NCT04584983|Experimental|restricted prescribed intralipid (RL) regimen|
11027625|NCT04584970|Experimental|Virtual reality device|Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
11027626|NCT04584970|Active Comparator|iPad device|Participants will be offered an iPad device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
11027627|NCT04584957|Active Comparator|VAC therapy|Prophylactic ciNPWT therapy positioning YES. Patients enrolled for placement of the device over a closed incision immediately post-operatively.
11027628|NCT04584957|No Intervention|Standard Closure|Prophylactic ciNPWT therapy positioning NO. Patients enrolled for standard laparotomic closure without ciNPWT positioning
11027629|NCT04584944||Healthy adult men|Healthy young men, 20- 44 years old
11027630|NCT04584944||Healthy adult women|Healthy young women, 20- 44 years old
11027631|NCT04584931|Experimental|Treatment of gingival recession with colored composite|Composite restoration will be applied to the gingival recession defect
11027632|NCT04584931|Active Comparator|Treatment of gingival recession with coronally advanced flap|coronally advanced flap at the gingival defect
11027633|NCT04584892||Haemophilia A|Patients enrolled will have Haemophilia A (any severity), needing turoctocog alpha prophylactic therapy.
11027634|NCT04584879|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
11027635|NCT04584879|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
11027636|NCT04584879|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
11027637|NCT04584879|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
11027638|NCT04584879|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
11027639|NCT04584879|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
11027640|NCT04584866|Active Comparator|Study Intervention|Endonasal endoscopic pituitary surgery in semi-sitting position
11027641|NCT04584866|Active Comparator|Control Intervention|Endonasal endoscopic pituitary surgery in supine position
11027642|NCT04584853|Active Comparator|Endocrine Therapy only|
11027643|NCT04584853|Experimental|Endocrine Therapy with abemaciclib|
11027644|NCT04584840|No Intervention|Group 1 (non-surgical treatment)|"Soft diet.
~Suspension of the use of prostheses or intraoral devices.
~Oral hygiene guidelines.
~Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.
~Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotic treatment can be prolonged indefinitely until infection and symptoms are controlled."
11027645|NCT04584840|Experimental|Group 2 (surgical treatment)|"Same guidelines of conservative treatment plus surgical treatment according to the following protocol:
~Specific protocol for surgical treatment:
~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.
~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.
~Secure a two layered waterproof closure without tension (simple or with local flaps).
~Samples will be sent for Pathological and microbiological analysis.
~Stitches removal after two weeks
~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
11027646|NCT04584827||complication positive (up to 30 days after surgery)|"Complications:
~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),
~İntracranial hypertension requiring post op surgical drainage,
~Status epilepticus or seizures,
~The need for tracheal intubation or use of mechanical ventilation after surgery,
~Decrease in GKS,
~Unmanageable agitation that requires restriction or sedation,
~Need for respiratory failure and oxygen therapy,
~Unexpected serious motor deficit
~Died"
11027647|NCT04584827||complication negative (up to 30 days after surgery)|No complications are seen within 30 days and the patient is healthy
11027648|NCT04584814|Active Comparator|Babies born Preterm|Preterm babies, healthy at the time of the study , free of neonatal diseases and/or sequelae or malformations or genetic diseases
11027649|NCT04584814|Active Comparator|Newborn born at term|Term healthy babies, without respiratory and/or cardiovascular malformations or genetic diseases
11027650|NCT04584801||Part A|"Development Phase Any adult (between 18 to 80 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator <0.70)
~Cohort A (N=50): COPD stage 1
~Cohort B (N=50): COPD stage 2
~Cohort C (N=50): COPD stage 3
~Cohort D (N=50): COPD stage 4
~Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)"
11027651|NCT04584801||Part B|"Validation Phase
~Cohort A (N=50): COPD stage 1
~Cohort B (N=50): COPD stage 2
~Cohort C (N=50): COPD stage 3
~Cohort D (N=50): COPD stage 4
~Cohort E (N=50): Suspected COPD"
11027729|NCT04584125|Experimental|Ex vivo cross linking of donor corneal tissue|The donor corneal tissue used in the penetrating keratoplasty procedures will previously undergo ex vivo crosslinking.
11027896|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavyor extensive COVID-19 exposure in the workplace or home environment
11027652|NCT04584775|Experimental|Traditional Chinese Medicine plus Standard Care|Participants in this group will receive standard Palliative Care and will additionally see a practitioner of Traditional Chinese Medicine. No strict protocol for the actual intervention exists (pragmatic approach). The participants will at least receive acupuncture and/or chinese herbal medicine. The standard care will include any established medical intervention according to currently available guidelines in palliative care.
11027653|NCT04584775|Other|Standard Care|The standard care will include any established medical intervention according to currently available guidelines in palliative care.
11027654|NCT04584762|Sham Comparator|Sham treatment|"The AVPI device software is set in sham mode which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
11027655|NCT04584762|Experimental|Active Treatment|"The AVPI device software is set in active mode which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used."
11027656|NCT04584749|Experimental|LIDOCAINE|"2% lidocaine will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.
~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
11027657|NCT04584749|Placebo Comparator|PLACEBO|"0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction . After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine/placebo.
~The study medication will be prepared in a 20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing Physiological Serum as assigned by the patient. The syringes prepared by the pharmacy will be identical in all cases, with a label specifying the title of this test and the identification number of the patient"
11027658|NCT04584736|Experimental|Livalo 2mg, Ezetrol 10mg|Pitavastatin 2mg, Ezetimibe 10mg
11027659|NCT04584736|Active Comparator|Livalo 2mg|Pitavastatin 2mg
11027660|NCT04584736|Experimental|Livalo 4mg, Ezetrol 10mg|Pitavastatin 4mg, Ezetimibe 10mg
11027661|NCT04584736|Active Comparator|Livalo 4mg|Pitavastatin 4mg
11027662|NCT04584710|Experimental|10 mg daily RTB101|"RTB101
~TORC1 inhibitor"
11027663|NCT04584710|Placebo Comparator|Placebo|Placebo
11027664|NCT04584697|Experimental|COVI-AMG|A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
11027665|NCT04584697|Placebo Comparator|Placebo|A single injection of placebo will be given on Study Day 1. Standard of care will be maintained for all subjects throughout the study.
11027666|NCT04584684|Placebo Comparator|Saline|Subject participants will rinse mouth one time for 60 seconds with 10 mL of Isotonic Saline.
11027667|NCT04584684|Active Comparator|1.5-2% w/v Hydrogen Peroxide|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 1.5-2% w/v hydrogen peroxide rinse.
11027668|NCT04584684|Active Comparator|0.12% Chlorhexidine Gluconate|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 0.12% Chlorhexidine Gluconate.
11027669|NCT04584684|Active Comparator|21% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 10 mL 21% ethanol plus essential oils.
11027670|NCT04584684|Active Comparator|1% w/v Povidone-iodide|Subject participants will rinse mouth one time for 60 seconds with 10 mL 1% w/v povidone-iodide.
11027671|NCT04584684|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 10 mL 0.075% Cetylpyridinium Chloride.
11027672|NCT04584671||Mild COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of mild COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
11027673|NCT04584671||Severe COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of severe COVID-19 infection, including at least 50 participants who were hospitalized with COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
11027674|NCT04584645|Experimental|cardiovascular disorders digital intervention arm (CVD-I)|Individuals with cardiovascular disease who receive a targeted digital intervention aimed at increasing influenza vaccination
11027675|NCT04584645|No Intervention|cardiovascular disorders without digital intervention arm|Individuals with cardiovascular disease who receive no intervention
11027676|NCT04584632|Experimental|EVSS|Efemoral Vascular Scaffold System (EVSS)
11027677|NCT04584593|Other|SARV-Cov|Men will give semen, saliva, urine and blood specimens
11027678|NCT04584580|Active Comparator|Therapeutic dose low-molecular-weight heparin (LMWH)|Therapeutic dose low-molecular-weight heparin from admission until the end of hospital stay Enoxaparin 1 mg/kg subcutaneous every 12 hours
11027679|NCT04584580|Experimental|D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy|"from admission until the end of hospital stay. Patients will be stratified according to their body weight and D-dimer level and receive LMWH
~D-Dimer level Body Weight LMWH dose
~<1 mg/dl <100kg Enoxaparin 40mg OD 100-150kg Enoxaparin 40mg BD >150kg Enoxaparin 60mg BD
~1-3 mg/ dl <100kg Enoxaparin 40mg BD 100-150kg Enoxaparin 80mg BD >150kg Enoxaparin 120mg BD
~>3 mg/ dl Enoxaparin 80mg BD"
11027680|NCT04584567|Experimental|DOXY ZINC|Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)
11027681|NCT04584567|Placebo Comparator|DOXY PLACEBO|Doxycycline daily dosing (100mg) placebo of Zinc
11027682|NCT04584567|Placebo Comparator|PLACEBO|placebo of Doxycycline daily dosing placebo of Zinc
11027683|NCT04584554|Experimental|Intervention|
11027684|NCT04584541|Other|case|Index cases (RA and SpA patients under immunosuppressive treatments)
11027685|NCT04584541|Other|controls|Members of index cases family cluster infected with the same viral strain
11027686|NCT04584528|Other|EHR-embedded Individualized Pain Plan (IPP)|The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
11027687|NCT04584515|Experimental|IMP4297 40 mg|Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.
11027689|NCT04584502|Experimental|Intervention as adjunct to Treatment as Usual|Participants will attend an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
11027690|NCT04584502|No Intervention|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
11027691|NCT04584476|Experimental|SCR group|underwent superior capsular reconstruction
11027692|NCT04584476|Other|Partial group|underwent partial rotator cuff repair
11027693|NCT04584450||1|COVID-19 survivors.
11027694|NCT04584437|Other|Infrared Energy and Vitamin C Supplement|Vitamin C:10 grams as Supplement Infrared Sauna: 60 minutes exposure.
11027695|NCT04584398|Experimental|Intervention|The intervention group (A) will perform respiratory muscle training and steam inhalation with WellO2 device for 30 days.
11027696|NCT04584398|No Intervention|Control|The control group (B) will continue on their conventional treatment without respiratory muscle training or steam inhalation with WellO2. After 30 days, the group B performs the same 30-day intervention with the WellO2 device (test) as the group A.
11027697|NCT04584385||Childhood epilepsy|Children with refractory tonic, myoclonic or atonic seizures
11027698|NCT04584372|Active Comparator|High-nitrate (HI-NI) intervention|The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
11027699|NCT04584372|Placebo Comparator|Low-nitrate (LO-NI) intervention|The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
11027700|NCT04584359|Experimental|HVLA techiniques (G1)|Performed with thrust (also known as HVLA) in the sacroiliac joint and T10-L2 level
11027701|NCT04584359|Experimental|Global osteopathic protocol (G2)|Several elements were emphasized - myofascial, bone, and visceral.
11027702|NCT04584359|Experimental|Pelvic floor muscle training (G3)|Muscle Training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes.
11027703|NCT04584359|No Intervention|Control group (G4)|No intervention and was simply evaluated and re-evaluated.
11027704|NCT04584346|Experimental|Arm A|Ketogenic Diet
11027705|NCT04584346|Active Comparator|Arm B|Standard American Diet and Ketogenic Diet
11027706|NCT04584333|Experimental|INTERVENTION|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established.
11027707|NCT04584333|No Intervention|NO INTERVENTION|Group 2 (non-intervention group): you will receive the usual information regarding the characteristics of your injuries and the role of tobacco and alcohol in their evolution and the importance of abandoning these habits.
11027708|NCT04584320||Premature neonates with necrotizing enterocolitis|
11027709|NCT04584320||Premature neonates without necrotizing enterocolitis|
11027710|NCT04584307|Experimental|Elotuzumab + Pomalidomide|Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
11027711|NCT04584294|Experimental|Intervention (MyPath)|Patients scheduled to see providers randomized to this arm will receive a weblink to the decision tool via text message after study enrollment and prior to their scheduled visit.
11027712|NCT04584294|No Intervention|Uusal Care|Patients scheduled to see providers randomized to the usual care arm will receive no intervention and will receive usual primary care.
11027713|NCT04584268|Experimental|mindfulness|3 30 minute in person interventions as well as promotion and involvement of self-guided meditations on the Insight Timer smart phone application
11027714|NCT04584268|Active Comparator|control|standard medical resident education
11027715|NCT04584255|Experimental|Arm A TNBC|"Participants will be randomized 1:1 to treatment with the combination (Arm A)
~Niraparib-Daily beginning with week 1, day 1
~Dostarlimab-Once every three weeks beginning with week 1, day 1"
11027716|NCT04584255|Experimental|Arm B TNBC|"Participants will be randomized 1:1 to treatment with the combination (Arm B)
~3-week lead-in of niraparib monotherapy followed by treatment with the combination
~Niraparib Daily beginning with week 1, day 1
~Dostarlimab Once every three weeks beginning with week 4, day 1"
11027717|NCT04584255|Experimental|Arm C ER+/HER2-|"exploratory cohort of estrogen receptor (ER) positive HER2-negative participants will be enrolled to Arm C.
~Niraparib Daily beginning with week 1, day 1
~Dostarlimab Once every three weeks beginning with week 1, day 1"
11027718|NCT04584242|Experimental|Pioglitazone|
11027719|NCT04584242|Experimental|Evogliptin|
11027720|NCT04584229||question not suitable for study|question not suitable for study
11027721|NCT04584216|Experimental|Steam Eye Mask With Acupoints Stimulation|"The Steam Eye Mask with acupoints stimulation (SEM with acupoints stimulation), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.
~Also, on the eyebrow have the acupoints made by nonwoven fabric can use hands to massage.
~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes and use hands to massage the acupoints on the eyebrows for the first 3 minutes."
11027722|NCT04584216|Active Comparator|Steam Eye Mask|"The Steam Eye Mask (SEM), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.
~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes."
11027723|NCT04584177|Experimental|Arm-hand BOOST + Control|First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
11027724|NCT04584177|Experimental|Control + Arm-hand BOOST|First 4 weeks control program, afterwards 4 weeks arm-hand boost program
11027725|NCT04584164|No Intervention|Control arm|This arm involves patients applying the basic hygiene rules (with mouthwashes) without the sialendoscopy method.
11027726|NCT04584164|Experimental|Sialendoscopy arm|This arm involves patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
11027730|NCT04584112|Experimental|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
11027731|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four cycles.
11027732|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four cycles.
11027733|NCT04584086|Experimental|MRI 3 Tesla|Patients will be followed by 3 Tesla MRIs during the study
11027734|NCT04584073|Active Comparator|Adenoidectomy|Adenoidectomy
11027735|NCT04584073|Active Comparator|Adenoidectomy and Myringotomy|Adenoidectomy and Myringotomy
11027736|NCT04584073|Active Comparator|Adenoidectomy,Myringotomy and Tympanostomy tube application|Adenoidectomy and Myringotomy and Tympanostomy tube application
11027737|NCT04584060||Conventional|Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
11027738|NCT04584060||ERAS|Preoperative information, education and counselling, If possible, Clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, Short acting anesthetic agents,avoid opioid agents, Post operative nausea and vomiting prophylaxis, Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off, Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward, Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, Removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
11027739|NCT04584047|Experimental|Intervention group|This arm had blood collected at the time of CVS.
11027740|NCT04584034|Active Comparator|Salbutamol|Salbutamol inhalation 4x200ug daily for 7 days, delivered using a Babyhaler
11027741|NCT04584034|Placebo Comparator|Placebo|Placebo 4 x 2 inhalations daily for 7 days, delivered using a Babyhaler
11027742|NCT04584021||Stress study participants|Adults who reported stress problems derived from work
11027743|NCT04584008|Experimental|Matched Targeted Agent|Matched Targeted Agent
11027744|NCT04584008|Active Comparator|Unmatched Therapy|Unmatched Therapy
11027745|NCT04583995|Experimental|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
11027746|NCT04583995|Placebo Comparator|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
11027747|NCT04583995|Experimental|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
11027748|NCT04583995|Placebo Comparator|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
11027749|NCT04583982||Prospective Study Arm SARS-CoV-2 negative and positive samples|
11027750|NCT04583969|Experimental|Remdesivir + Lenzilumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 doses. N=100.
11027751|NCT04583969|Active Comparator|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab placebo infusion every 8 hours starting on Day 1 for a total of 3 doses. N=100.
11027752|NCT04583956|Active Comparator|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab placebo infusion (300-mg x 4 vials) once on Day 1. N=100.
11027753|NCT04583956|Experimental|Remdesivir + Risankizumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab infusion (300-mg x 4 vials) once on Day 1. N=100.
11027754|NCT04583930||Patients with Haemophilia A|
11027755|NCT04583904||Adults - inpatient|
11027756|NCT04583904||Adults- ambulatory|
11027757|NCT04583904||Children|
11027758|NCT04583891|Experimental|IntelliCare|IntelliCare is a self-guided, fully automated suite of apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
11027759|NCT04583891|Active Comparator|Patient Education|The patient education app will contain psychoeducational information about distress prevalence and distress management. It will serve as an active control condition to compare with the IntelliCare apps.
11027760|NCT04583865||teleconsultation|Patient with teleconsultation of pre-anesthesia
11027761|NCT04583852|Experimental|brightening micro-needle patch|apply brightening micro-needle patch to one of the two assigned spots on the face according to the instructions on the package
11027762|NCT04583852|Placebo Comparator|Placebo|apply placebo micro-needle patch to another one of the two assigned spots on the face according to the instructions on the package
11027799|NCT04583579|Experimental|New Scleral Lens Wearers|All patients will be asked to wear scleral lenses for the duration of this study.
11027763|NCT04583839|Experimental|Navigation Group|Women who are randomized into SWEET will be assigned to a patient navigator. The navigator will meet women during hospitalization, at postpartum appointments, during primary care appointments, and as needed. At these face-to-face meetings, the navigator will perform education about the postpartum OGTT, post-GDM management plan, diabetes mellitus risks, lifestyle modification, and primary care transition. The navigator will facilitate the development of an individualized GDM Care Plan in conjunction with the patient and the medical team. The navigator will assess individual barriers to T2DM screening and prevention. At appointments, the navigator will also ensure a woman understands her diabetes-related care plan and will perform health education and barrier-reducing tasks as needed.
11027764|NCT04583839|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
11027765|NCT04583826|Experimental|CAVA|20 participants will wear the CAVA device, and a consumer-grade sleep monitoring device, and undergo polysomnography, for one night. 40 participants will wear the CAVA device and undergo polysomnography for two nights
11027766|NCT04583813|Active Comparator|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
11027767|NCT04583813|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 24 months
11027768|NCT04583787|Experimental|Patients with suspected CAD|
11027769|NCT04583774|Other|Anorexia Nervosa Group|Participants with anorexia nervosa
11027770|NCT04583774|Other|Healthy Control Group|Participants who are considered to be healthy controls
11027771|NCT04583761||cases|Healthcare workers with mild symptoms of COVID-19 and a positive RT-PCR test for SARS-CoV-2
11027772|NCT04583761||controls|Healthcare workers with mild symptoms of COVID-19 and a negative RT-PCR test for SARS-CoV-2
11027773|NCT04583748|Experimental|Sahaj Samadhi Meditation|Participants randomized to the Sahaj Samadhi Meditation (SSM) arm will undergo SSM training in groups of 10. SSM will be delivered virtually using the Cisco WebEx platform by trained, certified non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
11027774|NCT04583748|Active Comparator|Health Enhancement Program|Participants randomized to the Health Enhancement Program (HEP) arm will undergo HEP training in groups of 10. HEP will be delivered virtually using the Cisco WebEx platform by trained non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
11027775|NCT04583748|No Intervention|Treatment as Usual|Participants randomized to the Treatment as Usual (TAU) arm will continue to receive their treatment as usual. The usual standard of care for irreversible age-related vision patients includes no active treatment since eye surgeons have done all that could possibly be done to restore vision.
11027776|NCT04583735|Other|TEPEZZA|8 infusions of TEPEZZA (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) with a final visit at Week 24 (Treatment Period)
11027777|NCT04583735|Placebo Comparator|Placebo|Placebo once every 3 weeks
11027778|NCT04583722|Other|AX oleoresin|Raw AX oleoresin, 15 mg AX (in 4 pululan capsules)
11027779|NCT04583722|Experimental|AX-olive oil-PP emulsion|Microencapsulated AX (1%:2%:3% (AXO:OO:PP, %w/v ratio) + 0.15% maltodextrin). 15 mg AX (in 4 pululan capsules)
11027780|NCT04583709|Experimental|ECG Belt|ECG belt will be used to record ECG during baseline rhythm, LBBP in unipolar and bipolar configurations and / or during HOT-CRT using HBP or LBBP. These ECG belt characteristics would then be compared with baseline and existing data on RV pacing and traditional Biventricular pacing.
11027781|NCT04583696|Experimental|Walnut Consumption of Healthy Volunteers|
11027782|NCT04583683|Active Comparator|Intensive lifestyle modification: Very low calorie diet|Patients will undergo a very low calorie diet
11027783|NCT04583683|Active Comparator|Metabolic Surgery|Patients will undergo either sleeve gastrectomy or roux-en-y gastric bypass
11027784|NCT04583670||30 general practitioners, who will use ultrasound during their consultations|
11027785|NCT04583657|Placebo Comparator|Control|"Consumption of two classical eggs per day during three months. The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%."
11027786|NCT04583657|Experimental|Test|Consumption of two test eggs per day during three months. These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%, total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
11027787|NCT04583644|Experimental|Device - FETO|Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of balloon using the BALT GOLDBAL2 balloon and BALTACCIBDPE100 catheter.
11027788|NCT04583631||Chronic adenoiditis|Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis.
11027789|NCT04583631||Adenoid hypertrophy|Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group.
11027790|NCT04583618|Experimental|SP0202-IIb|One dose at Day 1
11027791|NCT04583618|Experimental|SP0202-VI|One dose at Day 1
11027792|NCT04583618|Experimental|SP0202-VII|One dose at Day 1
11027793|NCT04583618|Active Comparator|Prevnar 13|One dose at Day 1
11027794|NCT04583618|Active Comparator|Pneumovax 23|One dose at Day 1
11027795|NCT04583605||PREVENA|A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
11027796|NCT04583605||NON PREVENA|A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors
11027797|NCT04583592|Experimental|Camostat Mesilate|Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.
11027798|NCT04583592|Placebo Comparator|Placebo|Participants will receive placebo for 14 days in addition to standard of care treatment.
11027804|NCT04583514|Experimental|Overfeeding|The overfeeding group will be subjected to a similar relative change in energy intake, in which their dietary intake will be 30% more kcal/d than needed for weight maintenance.
11027805|NCT04583501|Experimental|Omalizumab|Ex vivo exposure of excised human surgical polyp tissue to omalizumab.
11027806|NCT04583488|Experimental|Intraperitoneal docetaxel|Participants will receive intraperitoneal docetaxel combined with the standard of care. A standard 3 + 3 dose escalation design will be used according to the dose escalation plan.
11027807|NCT04583462|Experimental|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
11027808|NCT04583462|Placebo Comparator|Placebo|Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm), started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
11027809|NCT04583449|Experimental|Outcome imagery|Outcome imagery condition participants will be asked to visualize themselves successfully wearing a face covering in all required public places/situations over coming week, and to imagine how they would feel. The importance of imagining distinctive relevant visual imagery linked to having successfully routinely worn face covering will be underscored in this passage. Outcome imagery participants will then be asked to write in a free-text box how they would feel having successfully worn a face covering in required public places/situations over the week ahead.
11027810|NCT04583449|Experimental|Process imagery|Process imagery condition participants will be asked to visualize the kinds of strategies involved in successfully wearing a face covering in all required public places/situations over the coming week. The importance of imagining distinctive relevant visual imagery linked to having effective strategies involved in successfully wearing a face covering in required public places/situations over the week ahead will be underscored in this passage. Process imagery participants will then be asked to write in a free-text box about the kinds of strategies that would be involved in successfully wearing a face covering in all required public places/situations over the coming week.
11027811|NCT04583449|Experimental|Combined imagery (outcome imagery and process imagery)|A third experimental condition will receive both outcome and process imagery exercises to read and complete in sequential order.
11027812|NCT04583449|No Intervention|Public health message|A fourth condition will involve viewing a UK Government public health message (HM Government, 2020) circulated on social media as an image concerning the importance of wearing face covering while in public places.
11027813|NCT04583436|Experimental|Endovascular recanalization|"Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
~n=45"
11027814|NCT04583436|Active Comparator|Open surgery|"Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
~n=45"
11027815|NCT04583423|Experimental|MK-3655 Low Dose|MK-3655 low dose by subcutaneous (sc) injection once every 4 weeks (Q4W).
11027816|NCT04583423|Experimental|MK-3655 Middle Dose|MK-3655 middle dose by sc injection Q4W.
11027817|NCT04583423|Experimental|MK-3655 High Dose|MK-3655 high dose by sc injection Q4W.
11027818|NCT04583423|Placebo Comparator|Placebo|Matching placebo to MK-3655 by sc injection Q4W.
11027819|NCT04583410|Experimental|Nicotine patch|
11027820|NCT04583410|Placebo Comparator|Placebo patch|
11027821|NCT04583397|Experimental|Experimental: WiFi - Sham|first intervention WiFi, second intervention sham
11027822|NCT04583397|Experimental|Experimental: Sham - WiFi|first Intervention sham, second Intervention WiFi
11027823|NCT04583384|Other|Assigned Intervention|"Addition to the cervical angio-MRI, of a sequence of 1H-SRM 3T (SUCCESS) centered on the lesion studied, performed according to the following parameters: PRESS asymmetric monovoxel PROBE, TE 144 ms, TR 2500 ms, 768 or 1024 medium."
11027824|NCT04583371|No Intervention|GROUP CONTROL|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.
~In the control group, patients will be ventilated for 1 minute with 100% inspired oxygen (FiO2), followed by three aspirations for 15 seconds and with an interval of 30 seconds."
11027825|NCT04583371|Active Comparator|INTERVENTION GROUP|"For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique.
~In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the supine position, the headboard elevated to 30º in assisted pressure-controlled ventilatory mode, increasing 10 cmH2O in inspiratory pressure and in assisted ventilation mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, with Ppeak not exceeding 40 cmH2O and drive pressure not exceeding 15 cmH2O in both ventilation modes, and then a new aspiration in the same way as the control group."
11027826|NCT04583358|Active Comparator|AMT-101|AMT-101 Tablet
11027827|NCT04583358|Placebo Comparator|Placebo|Placebo Tablet
11027828|NCT04583345||Hypertensive|Diagnosis of hypertension
11027829|NCT04583345||Healthy|Healthy blood pressure level and absence of any chronic disease
11027830|NCT04583332|Other|Rhymes, Individual Items in Rhymes, Objects|Existing method Post intervention
11027831|NCT04583319||SARS-CoV-2 Positive|patients tested positive for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
11027833|NCT04583306||Healthy Subjects|40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
11027834|NCT04583306||COVID-19 Positive|40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
11027835|NCT04583306||COVID-19 Negative|40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
11027836|NCT04583293||COVID AKI|Participants who were admitted to the hospital with COVID-19 and developed AKI during their hospital stay.
11027837|NCT04583293||COVID non-AKI|Participants who were admitted to the hospital with COVID-19 and did not develop AKI during their hospital stay.
11027838|NCT04583280|Experimental|Rilematovir|Participants will receive rilematovir orally based on body weight and age group.
11027839|NCT04583280|Experimental|Placebo|Participants will receive matching placebo of rilematovir based on body weight and age group.
11027840|NCT04583267|Experimental|PrEP|
11027841|NCT04583254|Experimental|Arm 1 EBRT+High-dose (HDR) Brachytherapy Experimental|
11027842|NCT04583254|Active Comparator|Arm 2 EBRT+High-dose (HDR) Brachytherapy Standard of Care|
11027843|NCT04583241||BJI group|"Patients with an BJI on material (prosthesis or other implant) infected by Streptococcus aureus* Patients are follow-up during two years after surgery.
~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
11027844|NCT04583241||Control Group With material|"Patients with mechanical problems on implanted equipment (control cohort), without infection* Patient of this group are follow-up until surgery.
~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
11027845|NCT04583241||Group osteomyelitis|"Patients with chronic hematogenous osteomyelitis* Patient of this group are follow-up until surgery.
~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
11027846|NCT04583241||Control Group with cruciate ligament surgery|Patients having cruciate ligament surgery Patient of this group are follow-up until surgery.
11027847|NCT04583228|Experimental|Sequence 1|Random allocation to HLX71 2.5 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
11027848|NCT04583228|Experimental|Sequence 2|Random allocation to HLX71 5 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
11027849|NCT04583228|Experimental|Sequence 3|Random allocation to HLX71 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
11027850|NCT04583228|Experimental|Sequence 4|Random allocation to HLX71 15 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
11027851|NCT04583215|Active Comparator|Active PAS|After completing the N-back and PAS-EEG at Visit 3, MCI participants randomized to the active condition will receive a 10-session course of PAS (Visits 4-13), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
11027852|NCT04583215|Sham Comparator|PAS-Control (PAS-C)|After completing the N-back and PAS-EEG at Visit 3, MCI participants randomized to the sham condition will receive a 10-session course of PAS-C (Visits 4-13), followed by the three follow-up assessments at 0 days, 7 days, and 28 days post intervention.
11027853|NCT04583215|No Intervention|Healthy Control|Healthy Controls will complete screening and baseline N-Back and PAS-EEG. They will not complete the 10-session course of PAS or follow-up assessments.
11027854|NCT04583202|Placebo Comparator|Placebo exposure|All patients undergo 2 placebo exposures
11027855|NCT04583202|Experimental|Birch Pollen Exposure|All patients undergo 4 allergen exposures
11027856|NCT04583189|Other|Test rapid antigenic and Test RT-PCR|
11027857|NCT04583163||Neuro-critical Care Patients|"Up to 12 subjects will be recruited over a 1 year period. Patients enrolled in the study are recruited from the pool of neuro-critical care patients admitted to the surgical intensive care unit (SICU).
~To meet study inclusion, transcranial Doppler (TCD) testing will be ordered as part of the standard of care for these patients. The test will not be ordered solely for research purposes. There are no known side effects from the non-invasive measurement of cerebral blood flow using ultrasound.
~Three different TCD technicians will perform triplicate readings on 3 consecutive days on up to 12 patients already undergoing TCD as ordered by their treating team. Standard of care on specific neuro critical care patients (such as cerebral aneurysms) is to undergo daily TCD monitoring to assess for possible vasospasm. Patients will be in the supine position while measurements are obtained. The probe will be placed in the preauricular region of the temporal window."
11027858|NCT04583150||Obese women with planned surgery (BS group)|Obese women with planned BS procedure in standard care
11027859|NCT04583150||Obese women with no planned surgery (control group)|Obese women matched for age and BMI who did not undergo surgery
11027860|NCT04583137|Experimental|Buffered lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution combined with bicarbonate 8.4% in a 1:10 ratio.
11027861|NCT04583137|Experimental|Plain lidocaine|Each participant receives a single intranasal application of atomized 1 mL lidocaine 5% solution.
11027862|NCT04583124|Experimental|ATENTO-B|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed before the begining of medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).
~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
11027894|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
11027895|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current),typically but not always supported by a positive PCR test for viral RNA
11027863|NCT04583124|Active Comparator|ATENTO-T|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed throughout medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).
~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
11027864|NCT04583111|Experimental|Domperidone group|Patients in Domperidone group took 10mg of domperidone 30min before PEG.
11027865|NCT04583111|Experimental|Sulpiride group|Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.
11027866|NCT04583111|No Intervention|Control group|Patients in Control group followed the regular routine of 3L split-dose of PEG.
11027867|NCT04583098||carbapenem-resistant Enterobacteriaceae|
11027868|NCT04583098||vancomycin-resistant Enterococci|
11027869|NCT04583085||CP + CHD group|This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
11027870|NCT04583085||CP group|25 patients with chronic periodontitis who were systemically healthy were selected
11027871|NCT04583085||HP group|25 patients who were systemically and periodontally healthy, were considered as HP group.
11027872|NCT04583072||Non-Hispanic White men|Self-identified as White Non-Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
11027873|NCT04583072||African/Black men|Self-identified as African or Black men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
11027874|NCT04583072||Hispanic White men|Self-identified as White Hispanic men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
11027875|NCT04583072||Asian men|Self-identified as Asian men, with age range (45.0 - 75.0 years), without prior evidence of prostate cancer
11027876|NCT04583059|Experimental|Taping Group|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lower end of the shank. Second step involved application of the stirrup. During this step, the foot was held in neutral, and the tape applied to pass from the medial side of the ankle, under the foot just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. The second step was repeated to apply the second stirrup. Both ends of the stirrups were firmly attached to the anchor tape applied during the first step and this attachment was reinforced with a locking tape during the third and final step by once again applying the tape circumferentially just above the malleolar level at the lower end of the shank. Taping was applied by a physical therapist according to the health association requirements
11027877|NCT04583059|Experimental|Bandaging Group|Standard 10 cm width elastic bandage was used. The elastic bandage was wrapped around the ankle joint to form an 8-figure shape starting from the forefoot. Then, the bandage was taken diagonally upwards, steeply enough to go well above the heel. Then, the bandage was taken around the lower calf area to form an anchor. Then its diagonally taken down across the midfoot. Again the bandage was wrapped around the forefoot and going diagonally up to finish off around the lower calf, leaving the heel open. During the bandage application process, the therapiest didn't stretch the bandage, because bandage does note need to be stretched during the application, as the bandage becomes naturally tight when its layers wraped over each others. the participant was asked to wear his/her sport shoes over the bandage during the measurement procedures.
11027878|NCT04583046|Placebo Comparator|placebo|normal saline inhalation group
11027879|NCT04583046|Experimental|iloprost group|iloprost inhalation group
11027880|NCT04583033|Experimental|Cognitive Behavioral Therapy (CBT) Group|Participants will receive CBT intervention bi-weekly for total of six (6) sessions.
11027881|NCT04583033|No Intervention|Control Group|Participants will not receive any intervention as part of the study.
11027882|NCT04583020|Experimental|Neoadjuvant PD-1 inhibitor|Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.
11027883|NCT04582994||Young participants|"30 young participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:
~Day 1. Beta tACS (22Hz)
~Day 2. Alpha tACS (10 Hz)
~Day 3. Sham tACS"
11027884|NCT04582994||Old participants|"30 old participants will perform the Mental Time Travel task while tACS stimulation is delivered at three different frequencies on the posterior parietal cortex. Interventions are administered in three different sessions in a pseudo-randomized order as described below:
~Day 1. Beta tACS (22Hz)
~Day 2. Alpha tACS (10 Hz)
~Day 3. Sham tACS"
11027885|NCT04582981|Experimental|Arm A|Combination treatment of Fruquintinib and Raltitrexed
11027886|NCT04582981|Experimental|Arm B|Monotherapy of Fruquintinib
11027887|NCT04582968|Experimental|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Fractionated stereotactic radiotherapy(FSRT) or whole brain radiation therapy (WBRT) Drug: Pyrotinib combined with capecitabine pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
11027888|NCT04582955|Experimental|Arm A|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
11027889|NCT04582942|Placebo Comparator|PEG (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will only be PEG.
11027890|NCT04582942|Experimental|PEG+lactulose (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will be PEG combined with lactulose.
11027891|NCT04582929|Experimental|50 unit of Neubotulinum Toxin Type A (Neuronox)|50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
11027892|NCT04582929|Experimental|100 unit of Neubotulinum Toxin Type A (Neuronox)|100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
11027893|NCT04582916|Other|One Arm|All subject receive the same tests
11027897|NCT04582877|Other|FFR Measurement in Intermediate-Grade Coronary Stenosis|Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).
11027898|NCT04582864|Experimental|Flotetuzumab (MGD006)|"Will start on cycle 1 day 1 on the dose escalation ramp schedule of MGD006 as a continuous intravenous (IV) infusion. Patients will be initiated on MGD006 at 30 ng/kg/day and have their MGD006 dose increased daily to a target goal of 500 ng/kg/day by day 7
~Patients will continue on MGD006 at 500 ng/kg/day for the remaining 21 days of the 28 day cycle. On cycle 1 day 14 patients will undergo a bone marrow biopsy
~On cycle 1 day 28, patients will undergo bone marrow biopsy for assessment of disease status. Patients with progressive disease will go off study. Patients with stable disease (SD) or better will proceed to cycle 2. Cycle 2 treatment assignment will be further stratified based on patients achieving CRi or better versus achieving SD/partial remission (PR)
~Patients achieving a CRi or better will proceed to cycle 2 with MGD006 on a 28 day cycle. Patients achieving SD or a PR will proceed to cycle 2 with MGD006 + DLI at the start of cycle 2"
11027899|NCT04582838||Spontaneous breathing ICU non-COVID|"Spontaneously breathing non-COVID-19 critically ill patients with sinus rhythm.
~Inclusion and exclusion criterion are listed elsewhere."
11027900|NCT04582838||Spontaneous breathing ICU COVID|"Spontaneously breathing COVID-19 critically ill patients with sinus rhythm.
~Inclusion and exclusion criterion are listed elsewhere."
11027901|NCT04582812|Experimental|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training|
11027902|NCT04582812|Active Comparator|Isolated high-intensity inspiratory muscle training|
11027903|NCT04582799|Active Comparator|Standard of Care (NIV)|Patients in the control group will be treated with non-invasive ventilation only.
11027904|NCT04582799|Experimental|Extracorporeal CO2 Removal (NIV+ECCO2R)|Patients in the treatment group will be treated with non-invasive ventilation combined with Extracorporeal CO2 Removal.
11027905|NCT04582786|Active Comparator|Standard group|Standard treatment (morphine) administered according to usual practice
11027906|NCT04582786|Experimental|Test group: Infusion with bolus|STR-324 or placebo infusion started with a initial bolus
11027907|NCT04582786|Experimental|Test group: Infusion without bolus|STR-324 or placebo infusion started without a initial bolus
11027908|NCT04582760|Experimental|early mobilization Arm|In addition to conventional bedside physical therapy, the mobilization program will be administered for 30 mins per session, two sessions per day, 7 days per week, until the patients are discharged from the ICU.
11027909|NCT04582760|No Intervention|non-early mobilization Arm|Conventional bedside physical therapy will be administered for 30 mins per session, one session per day, 5 days per week (only on working days), until the patients are discharged from the ICU.
11027910|NCT04582747||Major abdominal Surgery patients|Major Abdominal Surgery Patients
11027911|NCT04582734|Experimental|Intervention group - cognitive behavioral therapy|The intervention consists of three parts: 1) screening of hospitalised and outpatient cardiac patients at four university hospitals using the Hospital Anxiety and Depression Scale (HADS), scores ≥8 are invited to participate. (2) Assessment of type of anxiety by Structured Clinical Interview for DSM Disorders (SCID). (3) Investigator-initiated randomised clinical superiority trial with blinded outcome assessment, with 1:1 randomisation to cognitive-behavioural therapy (CBT) performed by a cardiac nurse with CBT training, plus usual care or usual care alone.The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
11027912|NCT04582734|No Intervention|Usual Care group|The usual care group (control group) will receive usual care which consists cardiac disease control and treatment.
11027913|NCT04582721|Active Comparator|CON-SCS with subcutaneous stimulation|7 days Conventional Spinal Cord Stimulation with subcutaneous stimulation
11027914|NCT04582721|Active Comparator|HF-SCS|7 days High Frequency Spinal Cord Stimulation
11027915|NCT04582721|Active Comparator|Combination Therapy|7 days a combination of CON-SCS with subcutaneous stimulation and HF-SCS
11027916|NCT04582708|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after abdominal surgery.
11027917|NCT04582695|Active Comparator|Written Exposure Therapy|
11027918|NCT04582695|Experimental|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|
11027919|NCT04582669|Placebo Comparator|Sodium Chloride 0.9%|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
11027920|NCT04582669|Active Comparator|Intralesional Triamcinolone 10 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
11027921|NCT04582669|Experimental|Intralesional Triamcinolone 20 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
11027922|NCT04582669|Experimental|Intralesional Triamcinolone 40 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
11027923|NCT04582656|Experimental|Targeted microwave ablation|Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
11027924|NCT04582643|Experimental|6P intervention|6P assessment along with education provided based on the 6P components.
11027925|NCT04582630||Omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
11027926|NCT04582630||Control (standart)|Standart medical nutrition therapy
11027927|NCT04582617|Active Comparator|Cocoa extract + multivitamin|
11027928|NCT04582617|Active Comparator|Cocoa extract + multivitamin placebo|
11027929|NCT04582617|Active Comparator|Cocoa extract placebo + multivitamin|
11027930|NCT04582617|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
11028024|NCT04581915|Experimental|Interventional|Participants to receive Triazavirin 250mg po 8 hourly for 5 days
11028025|NCT04581915|Placebo Comparator|Control|Participants to receive placebo po 8 hourly for 5 days
11028403|NCT04579172|Experimental|Group B|Resection of the infiltrated part of anterior uterine wall
11027931|NCT04582604|Experimental|Ruxolitinib combined with Decitabine|Ruxolitinib and Decitabine conditioning regimen All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Decitabine. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), decitabine (20 mg/m2/day, days -15 to -10), cytarabine (4 g/m2/day, days -10 to -9 (for unrelated donors or haploidentical donors; and 4 g/m2/day, days -9 for sibling donors)), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4);carmustine(BCNU)(250mg/m2/day, day -3),
11027932|NCT04582591|Experimental|Cannabidiol|Patients will receive cannabidiol in conjunction with their standard chemotherapy treatment
11027933|NCT04582578|No Intervention|Control Group|The control group will be treated with practice guideline optimal medical therapy for HF.
11027934|NCT04582578|Experimental|BiV-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
11027935|NCT04582578|Experimental|CS-CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive Conduction System(CS)-CRT.
11027936|NCT04582565|Active Comparator|Control group|Control group will have standard of care, consisting of verbal and written information on lymphoedema prevention and standard access to breast care nurse.
11027937|NCT04582565|Experimental|Combination product|Decongestive lymphatic therapy (DLT). DLT group will involve manual lymphatic drainage with a trained manual lymphatic drainage therapist.
11027938|NCT04582552||Ovarian cancer patients treated with PARP inhibitors|PARP inhibitors therapy until disease progression
11027939|NCT04582539|Experimental|INCB000928|INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.
11027940|NCT04582526|Experimental|Intervention arm|BMS program
11027941|NCT04582513||Pre-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed according to current hospital standard without a standardized checklist.
11027942|NCT04582513||Post-checklist implementation group|Patients undergoing major elective surgery where intraoperative handover occurs. This handover is performed after implementation of the AnCHor-CHecklist, a standardized checklist based on the SBAR concept.
11027943|NCT04582500||patients undergoing CTC receiving iohexol|Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for clinical purposes. They will be given 50 ml of Iohexol as a oral contrast
11027944|NCT04582487|Other|Biological evaluation|A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.
11027945|NCT04582474|Experimental|Dengue module and rapid diagnostic tests|
11027946|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region abdomen|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
11027947|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region upper arm|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
11027948|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region thigh|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
11027949|NCT04582435|Experimental|Insulin icodec|Participants will receive individualised weekly doses of insulin icodec
11027950|NCT04582422|Experimental|Touch Therapy|"The main purpose is to provide Touch Therapy intervention measures, the degree of fear of dental treatment for preschool children.
~Use the chip chip tool (PCT) to ask the children's degree of fear of dental treatment. The control group uses questionnaires to ask the caregiver's age, social and economic status, education, past dental experience, etc. In the intervention group, the questionnaire was used to ask the caregiver's age, socioeconomic status, education, past dental experience, etc. During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation , Ask the children how scared they are after seeing a doctor,"
11027951|NCT04582422|No Intervention|dental education|The Chip Chip Tool (PCT) asked the children how scared they were about dental visits. The control group used questionnaires to ask the caregiver 's age, socioeconomic status, education, past dental experience, etc. before the visit to provide routine dental care, provide dental health education, how to use toothbrush Dental floss education,
11027952|NCT04582409|Experimental|HSY244|HSY244 concentrate solution for injection via intravenous infusion
11027953|NCT04582409|Placebo Comparator|Placebo|Placebo concentrate solution for injection via intravenous infusion
11027954|NCT04582396|Experimental|Stellate Ganglion Block + Psychoeducation|For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
11027955|NCT04582396|Placebo Comparator|Normal saline injection + Psychoeducation|For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
11027956|NCT04582383|Experimental|Spironolactone|In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
11027957|NCT04582383|Active Comparator|Doxycycline hyclate|This arm is an active-comparator arm in which participants will receive doxycycline hyclate 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
11027958|NCT04582370|Experimental|Theater program|"The design of the 10-week theater program is based on the principles of acting as written and practiced by Constantin Stanislavski in his revolutionary text on acting: An Actor Prepares [Stanislavsky C, 1989]. The exercises target concentration, voice, physical skills, emotion memory, observation, and dramatic analysis and include 3 components: 1. Preparation for the Actor (which involves relaxation , collaboration, movement, posture, and vocality; 2. Learning the Components of the Repeatable Acting Process (which involves physicality, attention, and concentration); and 3. Synthesizing Components into Characterization (which involves creativity and emotional expression).
~Each of these components will be addressed during each of 20 sessions through the use of group warm ups, group ensemble exercises, and group recitations. Participants will perform physical, mental, and emotional exercises similar to those given to beginning acting students in traditional theater schools."
11027959|NCT04582370|No Intervention|Wait-list control|During the study period, the control group will not receive any type of intervention. However, they will be offered the same theater program experience after the primary data collection period ends.
11027960|NCT04582357|Experimental|Exercise arm|This arm is the only arm of the study, every patient is included in this arm, the patients will follow the physical activity program
11027961|NCT04582344|Experimental|SARS-COV-2 Vaccine|600 SU of SARS-CoV-2 virus antigen, intramuscular injection, two doses given 14 days apart.
11027962|NCT04582344|Placebo Comparator|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, intramuscular injection, two doses given 14 days apart.
11027963|NCT04582331||COVID-19 positive|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 positive status is confirmed by diagnostic testing and clinical diagnosis.
11027964|NCT04582331||COVID-19 negative, symptomatic|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 negative status is confirmed by diagnostic testing and clinical diagnosis.
11027965|NCT04582331||Normal Healthy Volunteers|Asymptomatic healthy participants recruited from hospital staff or co-living family members, or co-living family member of a COVID-19 positive study participant.
11027966|NCT04582318|Experimental|Part 1 Dose Level 1 - Active|
11027967|NCT04582318|Placebo Comparator|Part 1 Dose Level 1 - Placebo|
11027968|NCT04582318|Experimental|Part 1 Dose Level 2 - Active|
11027969|NCT04582318|Placebo Comparator|Part 1 Dose Level 2 - Placebo|
11027970|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 1 - Active|
11027971|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 1 - Placebo|
11027972|NCT04582318|Active Comparator|Part 2 Multi-Dose Level 2 - Active|
11027973|NCT04582318|Placebo Comparator|Part 2 Multi-Dose Level 2 - Placebo|
11027974|NCT04582305|Active Comparator|Bleomycin jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
11027975|NCT04582305|Placebo Comparator|Placebo jet-injections|This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
11027976|NCT04582279|Experimental|Recieving Ultrasound|Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
11027977|NCT04582266||Arm 1|Pregnant women hospitalized and receiving RDV for treatment of COVID-19.
11027978|NCT04582266||Arm 2|Non-pregnant women of childbearing potential hospitalized and receiving RDV for treatment of COVID-19.
11027979|NCT04582253||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:
~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
11027980|NCT04582253||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
11027981|NCT04582253||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
11027982|NCT04582227||The ETT group|Oral endotracheal intubation via direct laryngoscopy will be performed. The ETT cuff will be inflated to 25 cmH2O using a manometer.
11027983|NCT04582227||The LMA group|The Ambu aura-i LMA size will be chosen and inserted using the recommended single-handed rotational technique. Subsequently, a manometer was used to inflate the cuff to 60 cm H2O.
11027984|NCT04582214|Experimental|OLE Therapy with The MetaNeb® System|Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.
11028053|NCT04581707||Quattroplasty Double Balloon Catheter Stop'n GO|
11028054|NCT04581694|Experimental|TAVI without contrast|
11028055|NCT04581681|Experimental|Group CBT for Perinatal Anxiety|Using cognitive-behavioural therapy principles, this group therapy is intended to treat perinatal anxiety.
11027985|NCT04582214|No Intervention|Control Group|The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.
11027986|NCT04582201|Experimental|Dosage and Cohorts|"Cohort 1 100 × 106 iNKT Cohort 2 300 × 106 iNKT Cohort 3 1000 × 106 iNKT
~Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized patients as a single IV infusion."
11027987|NCT04582175||group A|patients who received complete revascularization by angioplasty during the PPCI
11027988|NCT04582175||Group B|patients who underwent complete revascularization by angioplasty in a staged procedure
11027989|NCT04582162|Experimental|Unsplinted implants|
11027990|NCT04582162|Active Comparator|Splinted implants|
11027991|NCT04582149|Experimental|EyeControl Eye-tracking Device|Ventilated ICU patients using the EyeControl wearable, eye-tracking device.
11027992|NCT04582136|Experimental|Sirolimus plus SOC|Sirolimus plus standard therapy (SOC) for SLE; Generic name: sirolimus (0.5mg capsule); Dosage: 1.5mg/day; Administration route: Oral
11027993|NCT04582136|Placebo Comparator|Placebo plus SOC|Placebo plus standard therapy (SOC) for SLE; Drug: Placebo comparator plus SOC; Administration route: Oral
11027994|NCT04582123|Other|comparison of two cross pin fixation methods|Fixation of supracondylar humerus fractures with 2 crossed pins and 3 crossed pins are compared in terms of Flynn's criteria
11027995|NCT04582110||Patients with Beta Thalassemia|Patients with previous diagnosis of Beta Thalassemia
11027996|NCT04582110||Control Group|Healthy fellow eyes without actual and previous ocular trauma
11027997|NCT04582097|Experimental|Ramipril|Ramipril, 2.5 mg daily, administered orally for 16 weeks
11027998|NCT04582097|Placebo Comparator|Placebo|Placebo, matched for the interventional drug, administered orally, daily for 16 weeks
11027999|NCT04582084||Autoimmune Arthritis|Patients with autoimmune arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, receiving biosimilar etanercept in real-world settings
11028000|NCT04582071|Experimental|Arm 1 (Psychotherapy, Intervention arm)|Subjects undergoing a 3 step IPAA will receive the four sessions of psychotherapy preceding and following their first surgery only, and receive an additional set of questionnaires again after their third surgery.
11028001|NCT04582071|No Intervention|Arm 2 (Non-Therapy, Control Arm)|Subjects will receive questionnaires which will be administered remotely via telemedicine if patient and psychologist/ research team member are unable to meet in person.
11028002|NCT04582058|No Intervention|Control Group (CG)|Control Group (CG): normally follow up, without mobile health
11028003|NCT04582058|Experimental|Interventional Group (IG)|Interventional Group (IG): Mobile Health to patients with an orientation about daily activities and protocol of physical exercise
11028004|NCT04582045||low risk, silver impregnated|low risk, silver impregnated
11028005|NCT04582045||low risk, border bandage|low risk, border bandage
11028006|NCT04582045||high-risk, silver impregnated|high-risk, silver impregnated
11028007|NCT04582045||high-risk, wound vacuum|high-risk, wound vacuum
11028008|NCT04582032|Active Comparator|Dexketoprofen group,|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in dexketoprofen group were administered intravenous dexketoprofen (50 mg/2ml) and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
11028009|NCT04582032|Other|Saline group|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in control group were administered intravenous 2 ml of saline and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
11028010|NCT04582019|Active Comparator|Patients with polyurethane DJ stent|Polyurethane DJ stent, 6Fr. The stent will be removed using flexible cystoscopy.
11028011|NCT04582019|Active Comparator|Patients with polyurethane DJ stent with magnet|Polyurethane DJ stent with magnet (Blackstar, Urotech), 7Fr. The stent will be removed under ultrasound control using a magnetic retriever
11028012|NCT04582006||LSG|Patients undergoing laparoscopic sleeve gastrectomy.
11028013|NCT04582006||LRYGB|Patients undergoing laparoscopic Roux-en-Y gastric bypass.
11028014|NCT04581993|Experimental|Intervention|"Pregnant and lactating women (PLW) will receive wheat soya blend (WSB) and children aged 6-23 months will receive lipid-based nutrient supplement (LNS).
~Social and behavior change communication (SBCC), community mobilization, referrals, identification of model families, food demonstrations, local recipe) ration/beneficiary entitlement cards will be provided for easy verification and tracking during delivery of intervention."
11028015|NCT04581993|No Intervention|Control|Control districts will receive routine health care services available in the study area.
11028016|NCT04581980|No Intervention|Control|This arm will receive no exercise
11028017|NCT04581980|Experimental|Moderate Intensity Exercise|"This group will exercise on a treadmill at moderate intensity. Moderate intensity will be defined by an individualized effort level (rating of perceived exertion, RPE) of 10. A heart rate monitor will be utilized at all times to record heart rate."
11028018|NCT04581980|Experimental|High Intensity Exercise|"This group will exercise on a treadmill at high intensity. High intensity will be defined by an individualized effort level (rating of perceived exertion, RPE) of 16. A heart rate monitor will be utilized at all times to record heart rate."
11028019|NCT04581954|Active Comparator|Standard of care|
11028020|NCT04581954|Active Comparator|Fostamatinib|
11028021|NCT04581954|Active Comparator|Ruxolitinib|
11028022|NCT04581941||Patients with essential tremor|Patients with essential tremor who have clinically been deemed candidates for DBS (Deep Brain Stimulation) surgery. Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses. This intervention is not part of the study. The investigators are going to recruit patients who receive the Medtronic Percept device, which allows for brain signal recordings (this feature is FDA approved). The investigators will be conducting an observational study using this device to collect data that the subjects receive as standard of care.
11028023|NCT04581928||COVID-19|Highly educated people Low educated people
11036042|NCT04526873|No Intervention|Control|No intervention control group
11028026|NCT04581902|Experimental|Morning rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
11028027|NCT04581902|Experimental|Afternoon rTMS treatment|Eligible participants will be assigned to the afternoon treatment group. Prior to the onset of rTMS treatment, EEG scans and magnetic resonance imaging (MRI) sessions including diffusion weighted imaging will be recorded as baseline measures. These measures will also be repeated at treatment midpoint and within one month of rTMS discontinuation in order to track structural and functional changes that occur over the course of treatment. Participants will complete an initial screening followed by 30-40 daily sessions of repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC), completed with their TMS provider.
11028028|NCT04581889||Children|Children from1 to 18 years, enrolled in kindergartens, primary, or secondary school located in city of Tübingen, Germany.
11028029|NCT04581889||Adult comparator|Adults of unknown status of previous SARSCoV-2 infection.
11028030|NCT04581889||Adult validation|Adults who report a history of SARS-CoV-2 infections between 1. February 2020 and the time point of sampling.
11028031|NCT04581876|Experimental|raltitrexed for injection + nab-paclitaxel|Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
11028032|NCT04581863|Active Comparator|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
11028033|NCT04581863|Experimental|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
11028034|NCT04581824|Experimental|Participants receiving dostarlimab plus chemotherapy|Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
11028035|NCT04581824|Active Comparator|Participants receiving pembrolizumab plus chemotherapy|Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
11028036|NCT04581811|Experimental|Prolonged Proning Arm|Patients will receive 24 hours in the prone position followed by 8 hours in the supine position for the duration of the study
11028037|NCT04581811|Active Comparator|Traditional Proning Arm|Patients will receive standard 16 hour prone positioning followed by 8 hours in the supine position for the duration of the study
11028038|NCT04581798||OSA|Patients with OSA confirmed by polysomnography, aged 35-65
11028039|NCT04581798||Non-OSA|Patients without OSA aged 35-65
11028040|NCT04581785|Experimental|Dose Level 1 Part A|3 year-olds to12 year-olds
11028041|NCT04581785|Experimental|Dose Level 1 Part B|6 month to 2 year-olds
11028042|NCT04581785|Experimental|Dose Level 2 Part A|3 year-olds to12 year-olds
11028043|NCT04581785|Experimental|Dose Level 2 Part B|6 month to 2 year-olds
11028044|NCT04581772|Experimental|Cohort A|
11028045|NCT04581772|Experimental|Cohort B|
11028046|NCT04581759|Experimental|RIPC|Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after endovascular treatment while in-hospital.
11028047|NCT04581759|Sham Comparator|foundational treatment group (FT)|Patients in the FT group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs, during the study period without remote ischemic postconditioning after endovascular treatment.
11028048|NCT04581746|Other|experimental arm|questionnaire and follow-up visit
11028049|NCT04581733|Experimental|Participants ≤12.0 years (Group A)|Group A: Male or female participants ≤12.0 year old. All participants will receive MT1621 starting on Day 1
11028050|NCT04581733|Experimental|Participants >12.0 years (Group B)|Group B: Male or female participants >12.0 years old (≤7 participants on ventilatory support) All participants will complete a 9-month run-in phase (MT1621 will not be administered). After the completion of the 9-month run-in phase, all participants will receive MT1621.
11028051|NCT04581720|Experimental|Participants|The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
11028052|NCT04581707||Kyphoplasty Single Balloon Catheter Allevo|
11028056|NCT04581681|Active Comparator|Waitlist Control|This is a control condition in which patients are randomly assigned to the waitlist control condition before receiving the treatment.
11028057|NCT04581668|Other|Neurally adjusted ventilatory assist first|Ventilation in NAVA mode then ventilation in conventional mode
11028058|NCT04581668|Other|Conventional ventilation first|Ventilation in conventional mode then ventilation in NAVA mode
11028059|NCT04581629|Experimental|CLTX-305|CLTX-305 (encaleret) dose finding study to determine safety, tolerability and dose response during three (3) periods of this study with dose levels at QD and BID; up to 26 weeks of active treatment per participant
11028060|NCT04581616|Active Comparator|ICNB group|After patient was turned to lateral decubitus position, local anesthetics is injected around incision site and ICNB is performed once after surgeon geys into chest cavity.
11028061|NCT04581616|Experimental|ESPB group|After patient was turned to lateral decubitus position, ESPB is performed via ultrasound guided technique before sound incision.
11028062|NCT04581603|Active Comparator|TOP + CBT-I|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Cognitive Behavioral Therapy for Insomnia (CBT-I) and TOP for the next 8 weeks.
11028063|NCT04581603|Placebo Comparator|TOP + SHE|This arm will consist of patients stabilized on topiramate (TOP) for 6 weeks up to a final dose of 200 mg per day or less and treated with Sleep Hygiene Education (SHE) and TOP for the next 8 weeks.
11028064|NCT04581590|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training + cognitive training.
11028065|NCT04581590|Sham Comparator|Sham group|In the group G2 will be administered: tDCS active + dual-task motor training
11028066|NCT04581577||Adult patients with neuromuscular or neurological disorders|Telephone questionnaires administered directly to patients over 16 years of age with neuromuscular or neurological disorders
11028067|NCT04581577||Parents of paediatric patients with neuromuscular or neurological disorders|Telephone questionnaires administered to the parents of patients over 16 years of age with neuromuscular or neurological disorders
11028068|NCT04581564|Experimental|Rhythm intervention|
11028069|NCT04581564|Active Comparator|Non-rhythm intervention|
11028070|NCT04581551|Experimental|Stroke group|"SWE for 6 shoulder muscles will be performed by 2 assessors in randomised order.
~m. supraspinatus
~m. infraspinatus
~m. rhomboideus major
~m. deltoideus
~m. pectoralis major
~m. pectoralis minor"
11028071|NCT04581551|Active Comparator|Healthy controls|"SWE for 6 shoulder muscles will be performed by 1 assessors.
~m. supraspinatus
~m. infraspinatus
~m. rhomboideus major
~m. deltoideus
~m. pectoralis major
~m. pectoralis minor"
11028072|NCT04581538|No Intervention|Control group|This arm is being provided with continued home care as it was before
11028073|NCT04581538|Experimental|E-learning platform & networking platform|This arm is being provided with the e-learning platform and networking platform as components of the 24-h-quAALity package
11028074|NCT04581538|Experimental|Entire intervention|This arm is being provided with the entire intervention (e-learning platform, networking platform and digital care documentation)
11028075|NCT04581525|Experimental|tDCS of DLPFC|Subjects will receive 20 minutes of active transcranial direct current stimulation at 1.4mA applied to the left dorsolateral prefrontal cortex (DLPFC). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
11028076|NCT04581525|Experimental|tDCS of M1|Subjects will receive 20 minutes of active transcranial direct current stimulation at 1.4mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
11028077|NCT04581525|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Subjects will undergo stimulation once a day for 10 consecutive weekdays.
11028078|NCT04581512|Experimental|EP0042|
11028079|NCT04581499|Experimental|DynamiCare Motivation Support Program|Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.
11028080|NCT04581499|Other|Untreated or Routine Care Control Group|Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.
11028081|NCT04581486|Experimental|OMI intervention|Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
11028082|NCT04581486|Other|Control intervention (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
11028083|NCT04581473|Experimental|CT041 autologous CAR T-cell injection|This study will be divided into three phases, phase Ib dose exploration phase and dose extension phase and phase II effectiveness and safety confirmation phase.
11028084|NCT04581460||Patients|Patients entered in the register of the reference Center for Hereditary Immune Deficits (CEREDIH), hospital Necker-Enfants Malades, Paris, and having reported at least one pregnancy or attempted pregnancy
11028085|NCT04581447|Experimental|Metformin + Standard care|"The pharmacological treatment (Metformin) will start at dose of 850 mg once daily and, at one month, increased to 850 mg twice daily. The dosage will be adjusted if necessary because of gastrointestinal symptoms and information on dose change during follow-up will be collected Adherence to study medications will be assessed by pills count and plasmatic dosage (Metformin group).
~All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups."
11028253|NCT04580199|Active Comparator|monopolar radiofrequency|using radiofrequency for ablation of thyroid nodule
11028086|NCT04581447|Other|Standard Care|All participants will receive standardized lifestyle recommendations regularly during all the time of the study Lifestyle recommendations will be provided by a nutritionist/diabetologist every 4 months at each study visit and reinforced by dedicated consultations with a dietician and a physical activity coach as usually performed in each center. This follow-up will be standardized for each center and applied equally to patients of both groups.
11028087|NCT04581434|Experimental|Trauma-Focused Therapy|Patients randomized to Trauma Focused Therapy will receive either Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT). According to standard VA practice, assignment will be determined according to which trauma-focused therapy the assigned provider is verified to provide; if the assigned therapist is verified in both PE and CPT, the provider will decide which treatment to deliver. PE and CPT are both recommended as frontline treatments by all published PTSD guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted.
11028088|NCT04581434|Experimental|Non-Trauma-Focused Therapy|"Those randomized to non-trauma-focused therapy will receive present centered therapy (PCT). Originally designed as a strong comparator for psychotherapy research that included the components of good therapy, PCT is now a bona-fide PTSD treatment suggested at the second tier in multiple clinical practice guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted."
11028089|NCT04581421|Experimental|High Carb first|
11028090|NCT04581421|Experimental|Low Carb first|
11028091|NCT04581408|Experimental|Orkambi|"Generic name: Lumacaftor/Ivacaftor
~Dosage form: tablet
~Dosage: each tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor
~Frequency: two tablets twice a day."
11028092|NCT04581395|Other|Not pretreated|Succinylcholine administration with no Rocuronium pre-treatment
11028093|NCT04581395|Active Comparator|Pre-treated 1 minute before succinylcholine administration|Succinylcholine administration 1 minute following Rocuronium pre-treatment
11028094|NCT04581395|Active Comparator|Pre-treated 2 minutes before succinylcholine administratjion|Succinylcholine administratjion 2 minutes following Rocuronium pre-treatment
11028095|NCT04581382|Experimental|Treatment (radiation therapy, plasma exchange, immunotherapy)|Patients undergo radiation therapy daily on days 1-5 (weekdays). Patients then undergo therapeutic plasma exchange over 1-2 hours on days 4-6 or 5-7. Beginning on day 7, patients receive pembrolizumab IV or nivolumab IV. Treatment with pembrolizumab continues every 3 weeks or treatment with nivolumab continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
11028096|NCT04581369|Active Comparator|Direct Intervention|"Initial Evaluation: Prior to discharge, the care coordinator will review the hospital discharge plan, obtain the approval of the patient's physicians to co-manage the patient's care, and schedule a visit with the patient at their place of discharge.
~Participants in this arm will receive direct interaction with a care coordinator to develop an individualized care plan. Frequent assessments, at least once every two weeks, will occur to continue to follow or to modify the care plan based on the needs of the patient.
~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians and their participation in this study will be ended."
11028097|NCT04581369|Sham Comparator|Standard of Care|Prior to hospital discharge, the care coordinator will identify the primary care and/or hepatology provider of patients in the usual care group and will ensure follow up appointments at the time of hospital discharge. The coordinator will compose and send a letter to the primary care and/or hepatology provider summarizing the patient's diagnosis, hospital course, discharge medications, and the plan of follow-up care. If the patient does not already have a primary care or hepatology provider, the coordinator will work with the patient to identify a new provider. Subjects in this group will receive no further intervention.
11028098|NCT04581369|Placebo Comparator|Caregiver|The caregivers of people with cirrhosis will be enrolled in the study. They will complete the assessments at baseline, 3 months and 6 months.
11028099|NCT04581356|Experimental|voxelotor|Voxelotor 1500mg daily orally
11028100|NCT04581343|Experimental|Canakinumab, spartalizumab, nab-paclitaxel and gemcitabine|Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.
11028101|NCT04581330|Experimental|DEKA SmartXide C02 laser|One half of the subject's neck will be treated with ablative fractional CO2 laser.
11028102|NCT04581330|No Intervention|Control|The other half of the subject's neck will not be treated with the ablative fractional CO2 laser.
11028103|NCT04581317|Experimental|Phase 1 (meals only)|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.MOW will once a week deliver in-person enough frozen meals to cover lunch for 5 days and breakfast for 7 days. Study staff will call the participants twice a week to ask 5 questions about their health, mood, and meal consumption.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure Fried Frailty Phenotype(FFP), MHS, CES-D, MOCA, Activities of Daily Living (ADL)/Instrumental activities of daily living(IADL)s, NSI, and ZCBI. Caregivers will not receive meals during this first phase as the focus is on the nutritional status of the cognitively impaired older adult.
11028104|NCT04581317|Experimental|Phase 2 (Meals + Amazon Echo Show 8 (AES 8) basic usage)|Participants will have meals delivered and the AES device installed for basic usage
11028105|NCT04581317|Experimental|Phase 3 (meals + AES 8 advanced )|Participants will have meals delivered and the AES device installed for advanced usage
11028106|NCT04581304|Experimental|Bio-Oss Collagen|Transcrestal approach sinus augmentation using Geistlich Bio-Oss Collagen®.
11028107|NCT04581304|Active Comparator|Bio-Oss Granules|Transcrestal approach sinus augmentation using Geistlich Bio-Oss®.
11028108|NCT04581291|Experimental|Intervention group|
11028109|NCT04581291|Experimental|Control group|
11028110|NCT04581265|Experimental|nab-PTX, ifosfamide and cisplatin|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.
11028111|NCT04581239|Active Comparator|Active neural mobilization|Therapist supervised active neural mobilization of sciatic nerve in lumber radiculopathy patients
11028112|NCT04581239|Experimental|passive neural mobilization|Therapist done passicive neural mobilization of sciatic nerve in lumber radiculopathy patients
11028113|NCT04581226|Experimental|Lung ultrasound|Sonographic assessments including the lung consolidation score, B-line score and Lung aeration score will be recorded 1min. after intubation, at end of surgery and 2h postoperatively.
11028114|NCT04581200|Experimental|Lift mobile mindfulness program|Will receive standard dose Lift mobile mindfulness program intervention content, app-based response to elevated symptoms, and no introductory call from a therapist. This program lasts 1 month and includes 4 unique weeks' worth of audio, video, and text content.
11028115|NCT04581200|No Intervention|Usual care control|Usual care.
11028116|NCT04581174|Experimental|1st degree of hypertrophy according to Camacho|Patients with 1st degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
11028117|NCT04581174|Experimental|2nd degree of hypertrophy according to Camacho|Patients with 2nd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
11028118|NCT04581174|Experimental|3rd degree of hypertrophy according to Camacho|Patients with 3rd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
11028119|NCT04581174|Experimental|4th degree of hypertrophy according to Camacho|Patients with 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
11028120|NCT04581161|Experimental|Life2000® Ventilator|Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.
11028121|NCT04581161|No Intervention|Control Group|Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record.
11028122|NCT04581148||M6|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M6) with residual blood samples.
11028123|NCT04581148||M12|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M12) with residual blood samples.
11028124|NCT04581148||M18|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M18) with residual blood samples.
11028125|NCT04581148||M24|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M24) with residual blood samples.
11028126|NCT04581135||COVID-19 Lung|COVID-19 survivors in Switzerland
11028127|NCT04581122|Experimental|Selective lymphadenectomy|
11028128|NCT04581122|No Intervention|Systematic lymph node dissection|
11028129|NCT04581109|Experimental|Patients with metastatic prostate cancer|
11028130|NCT04581083||Volunteer participants|Samples of volunteer participants will be collected after informed consent and classified as symptomatic, asymptomatic and negative.
11028131|NCT04581057|Experimental|First CVE|
11028132|NCT04581031|Other|Wearable monitors - Isansys Patient Status Engine|All patients will wear the continuous vital sign monitoring sensors.
11028133|NCT04581018|Active Comparator|Health supplements + standard care|28 days of health supplements (Synbiotic) daily plus standard care
11028134|NCT04581018|No Intervention|Standard care|No intervention
11028135|NCT04581005|Experimental|Supervised Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.
~This group will receive a supervised, in-hospital training."
11028136|NCT04581005|Experimental|Home-based Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.
~This group will receive a home-based training."
11028137|NCT04580992||Ajmaline group|
11028138|NCT04580979||Patients with ferredoxin reductase deficiency|Male and female patients from age 2 to age 65 with clinically confirmed FDXR mutations. Both living and deceased patients will be included, if eligible. For deceased patients, the patient's medical history records will be reviewed, and an interview of the parent(s) or caregiver(s) will be performed.
11028139|NCT04580966|Experimental|Inquiry Based Stress Reduction (IBSR) workshop|Participants of this group received an IBSR intervention workshop.
11028140|NCT04580966|No Intervention|Control group|Participants of this group did not take a part in the workshop.
11028141|NCT04580953|Experimental|Treatment with CardiaCareTM RR2|
11028142|NCT04580940||Subjects with complex pancreaticobiliary disease|All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.
11028143|NCT04580927|Experimental|Randomized to breastfeeding self-efficacy enhancing intervention with nurse|Participants receiving breastfeeding self-efficacy enhancing nurse-led intervention plus postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
11028144|NCT04580927|No Intervention|Randomized to usual postpartum care|Participants receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment, routine postpartum hospital breastfeeding support, as-needed community breastfeeding support, and postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
11028145|NCT04580927|No Intervention|Non-randomized observational arm|Participants who are not planning to breastfeed receiving postpartum standard of care consisting of postpartum medical visits with their obstetrics care provider and for cardiovascular risk assessment.
11028146|NCT04580914|Experimental|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
11028147|NCT04580901|Experimental|Group interpersonal psychotherapy|Group IPT consists of 12 weeks of virtually-delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions, with the first 12 sessions taking place twice weekly (acute phase) for 6 weeks and the last 3 sessions occurring every other week (maintenance phase) for 6 weeks.
11036990|NCT04520256|Experimental|Dysregulated Eating, VR|
11028148|NCT04580901|No Intervention|Usual care|Usual care refers to any care that the women wish to access, and there are no limits on the women in either group. It may include, but is not limited to, the family physician, obstetrician, and/or midwife, participation in regional standard perinatal depression programming, private therapy, online therapies, medication, etc.
11028149|NCT04580888|Experimental|Intervention arm|Assessment using an early transthoracic echocardiography (after 500 mL of fluids) to identify the hemodynamic profile responsible for the acute circulatory failure associated with sepsis / septic shock and to guide ongoing treatment (therapeutic algorithm) and monitor its efficacy and tolerance.
11028150|NCT04580888|Other|Control arm|Conventional management according to current standards of care based on SSC recommendations, including a standardized fluid resuscitation of 30 mL/kg.
11028151|NCT04580875|Other|Patients' demographics and injury pattern|This study will be conducted out at 3 pediatric surgery tertiary centers (Al-Azhar University hospitals in Cairo, Prince Mohammed bin Abdulaziz Hospital in Riyadh and Maternity & Children's Hospital in Bisha) on patients aged from 1-14 years presenting to the ER by penetrating abdominal trauma in the period from April 2017 to March 2022. Responders to initial resuscitation will be managed by minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures). The total anatomical region of interest is defined as the cylindrical area bounded superiorly by the nipple line and the inferiorly by symphysis pubis. All patients enrolled in the study will give a written informed consent even for possible conversion to laparotomy if necessary.
11028152|NCT04580862|Experimental|group 1 Non-surgical endodontic retreatment in single visit|Single visit treatments have gained more popularity. Completing the treatment in a single appointment has many advantages including reduction in treatment time and cost, lower risk of micro leakage and recontamination of root canals between appointments
11028153|NCT04580862|Active Comparator|group 2 Non-surgical endodontic retreatment in Two-visit|Two-visit endodontic treatment with intra-canal medication was traditionally found to be effective in decreasing the number of flare-up in all retreatment cases and in reducing postoperative pain of previously symptomatic teeth
11028154|NCT04580849|Experimental|telerehabilitation with dance (Parkinson's)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
11028155|NCT04580849|Active Comparator|telerehabilitation with dance (Healthy controls)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
11028156|NCT04580836|Experimental|Treatment (MRI-guided SBRT)|Patients undergo an MRI scan to check the status and location of the disease, including the motion of the tumor during breathing. Two weeks after MRI, patients undergo SBRT over 1-2 hours on 3 non-consecutive weekdays in the absence of disease progression or unacceptable toxicity.
11028157|NCT04580823|No Intervention|Control|Fasting without exogenous ketone salt supplement
11028158|NCT04580823|Experimental|Fasting with exogenous ketone salt supplement|Fasting with exogenous ketone salt supplement
11028159|NCT04580823|Experimental|Post-Prandial with exogenous ketone salt supplement|Post-Prandial with exogenous ketone salt supplement
11028160|NCT04580810|Experimental|CBT4CBT in the Black Church|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:
~Understanding and changing patterns of alcohol use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
11028161|NCT04580810|No Intervention|Community Based Treatment as Usual|Treatment as usual, typically groups, offered by a specialty community based treatment center (MCCA)
11028162|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR1_fed|Participants receive single doses of immediate release (IR) followed by modified release (MR) MR1 and MR2, all in fasted condition followed by MR1 in fed condition in Periods 1-4
11028163|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR1_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR1 in fed condition in Periods 1-4
11028164|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR1_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR1 in fed condition in Periods 1-4
11028165|NCT04580797|Experimental|PF-06700841: IR, MR1, MR2, MR2_fed|Participants receive single doses of IR followed by MR1 and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
11028166|NCT04580797|Experimental|PF-06700841: MR1, MR2, IR, MR2_fed|Participants receive single doses of MR1 followed by MR2 and IR, all in fasted condition followed by MR2 in fed condition in Periods 1-4
11028167|NCT04580797|Experimental|PF-06700841: MR2, IR, MR1, MR2_fed|Participants receive single doses of MR2 followed by IR and MR1, all in fasted condition followed by MR2 in fed condition in Periods 1-4
11028168|NCT04580797|Experimental|PF-06700841 MR3 (Dose A) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose A) or matching placebo for 7 days under fasted condition
11028169|NCT04580797|Experimental|PF-06700841 MR3 (Dose B) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose B) or matching placebo for 7 days under fasted condition
11028170|NCT04580797|Experimental|PF-06700841 MR3 (Dose C) or matching placebo|Participants receive dosing regimen 1 of MR3 (Dose C) or matching placebo for 7 days under fasted condition
11028171|NCT04580784|Experimental|Hypofractionation|Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.
11028172|NCT04580771|Experimental|Treatment (radiation therapy, cisplatin, PDS0101)|Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
11028173|NCT04580758|Active Comparator|Fractional laser with PRP fluid|Fractional CO2 laser then the PRP is injected afterwards
11028174|NCT04580758|Active Comparator|Fractional laser with PRP gel|Fractional CO2 laser then the PRP gel is injected afterwards
11028175|NCT04580745|Experimental|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.
~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.
~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
11028254|NCT04580199|Active Comparator|laser photocaugulation|using laser for ablation of thyroid nodule
11028176|NCT04580745|Experimental|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.
~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
11028177|NCT04580732|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
11028178|NCT04580732|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
11028179|NCT04580719||Patiente|Patients aged 18 to 50, presenting menstrual cycles, consulting in the obstetrics and gynecology department of the University Hospital of Reims whatever the reason for consultation can participate in the study after signing the consent of no opposition. Participation in the study will not change the patient's medical management.
11028180|NCT04580693||Healthy Volunteers/Control|Age and body surface area (BSA) matched volunteers who are sedentary or normally active. Normally active is defined as less than 5 hours of exercise per week. Healthy volunteer subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
11028181|NCT04580693||Hypertrophic Cardiomyopathy/HCM|HCM subjects are patients that are age and BSA-matched with the athletes who then have an established clinical diagnosis of HCM without left ventricular (LV) outflow tract obstruction. There can be no anticipated changes to baseline exercise program (if any) over the study period. HCM subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
11028182|NCT04580693||Endurance Athletes|Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
11028183|NCT04580667||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from normal tissues shortly after the start of radiotherapy provides an early indication of patients at high risk of radiation-related toxicity. Blood specimens for RadTox test will be collected: (a) prior to radiotherapy (T0); (b) after the 2nd but before the 4th radiotherapy dose during week 1 (T1); (c) on Week 2 during radiotherapy (T2); and (d) 3 months after completion of radiotherapy (T3).
11028184|NCT04580654|Experimental|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
11028185|NCT04580654|Experimental|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
11028186|NCT04580654|Experimental|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
11028187|NCT04580654|Experimental|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
11028188|NCT04580654|Experimental|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
11028189|NCT04580641||Subjects with migraine|No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.
11028190|NCT04580615|Experimental|Inpatients subjects|Inpatients subjects diagnosed with a Respiratory disease/impairment or subjects with no known Respiratory disease/impairment
11028191|NCT04580602||ADR Group|Major Bleeding BARC Bleeding Criteria Type 2,3,5
11028192|NCT04580602||Control Group|No ADR or treatment failure, case-control matched to experimental groups
11028193|NCT04580602||Treatment Failure Group|Major Adverse Cardiovascular Events (MACE)
11028194|NCT04580589||Adverse Drug Reaction on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience major bleeding per International Society of Thrombosis and Haemostasis criteria. This is an observational study, so there will be no intervention.
11028195|NCT04580589||Treatment Failure on DOAC|Participants on Direct Oral Anti-coagulants (DOACs) who experience treatment failure (e.g., recurrent MI, systemic embolism, ischemic stroke, etc.). This is an observational study, so there will be no intervention.
11028196|NCT04580589||Case Control|Participants on Direct Oral Anti-coagulants (DOACs) who experience neither major bleeding or treatment failure.
11028197|NCT04580576||Female group|Pediatric female patients undergoing hematopoietic stem cell transplantation
11028198|NCT04580576||Male group|Pediatric male patients undergoing hematopoietic stem cell transplantation
11028199|NCT04580563|Experimental|Experimental group|"The experimental group will receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.
~OctaplasLG® is a donor plasma product, with unique features compared to standard fresh frozen plasma: standardized concentrations of natural pro-/anti-coagulation factors; a standardized volume; pathogen free. OctaplasLG® should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
11028200|NCT04580563|Placebo Comparator|Control group|The control group will receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 if prothrombin time is below 50%.
11028201|NCT04580550|Other|Axial length variability|Aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of AL.
11028202|NCT04580537|Experimental|Laser-assisted Enstilar delivery|Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
11028203|NCT04580537|Active Comparator|Enstilar|Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)
11028204|NCT04580524|Active Comparator|Phasix Mesh|Phasix mesh will be used in the repair of the hernia
11028205|NCT04580524|Active Comparator|Current Care|The hernia will be repaired with either synthetic mesh or suture repair, as determined by the operating surgeon.
11028206|NCT04580498|Experimental|Treatment group A|SHR-1701+Paclitaxel+carboplatin
11028207|NCT04580498|Experimental|Treatment group B|SHR-1701
11028208|NCT04580485|Experimental|Treatment Group A (TGA) - INCB106385|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.
~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
11028209|NCT04580485|Experimental|Treatment Group B (TGB) - INCB106385+INCMGA00012|"In part 1 dose escalation, the dose levels will be escalated following a BOIN design.
~In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE."
11028210|NCT04580472|Placebo Comparator|Placebo - leg|If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.
11028211|NCT04580472|Experimental|Antibiotic- leg|The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered
11028212|NCT04580472|Placebo Comparator|Placebo- nose|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.
11028213|NCT04580472|Experimental|Antibiotic- nose|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
11028214|NCT04580472|Placebo Comparator|Placebo- ear|If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.
11028215|NCT04580472|Experimental|Antibiotic- ear|The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.
11028216|NCT04580459|Experimental|CARE Parenting Group Treatment|Participants receive the CARE mentalizing-focused group parenting intervention.
11028217|NCT04580459|Other|Treatment as Usual (TAU)|Participants continue to receive treatment as usual in the outpatient child mental health clinic.
11028218|NCT04580446|Experimental|Hypofractionated radiotherapy with concurrent chemotherapy (weekly cisplatin 40 mg/m2)|"Level 1: 44.4 Gy in 12 fractions, 4 fractions/week
~Level 0: 46.5 Gy in 15 fractions, 5 fractions/week
~Level -1: 52 Gy in 20 fractions, 5 fractions/week"
11028219|NCT04580433|Experimental|Time-Restricted Feeding|Participants will receive 16:8 TRF.
11028220|NCT04580420|Experimental|Open-Label DCR-PHXC|Open-Label monthly subcutaneous injection of DCR-PHXC based on age and weight.
11028221|NCT04580407|Experimental|TAK-672|TAK-672 will be administered at an initial dose of 200 U/kg with intravenous infusion at a rate of 1-2 mL/min. Subsequent doses will be determined based on the post-infusion factor VIII activity (FVIII:C) achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer (when available)
11028222|NCT04580394|Experimental|AD109|Oral capsule administered before sleep
11028223|NCT04580394|Active Comparator|Atomoxetine|Oral capsule administered before sleep
11028224|NCT04580394|Active Comparator|R-oxybutynin|Oral capsule administered before sleep
11028225|NCT04580394|Placebo Comparator|Placebo|Oral capsule administered before sleep
11028226|NCT04580381||Standard Interval Dosing (SID)|Patients continuing Natalizumab treatment with standard interval dosing defined as > 11 infusions per year
11028227|NCT04580381||Extended Interval Dosing (EID)|Patients switching to extended interval dosing defined as ≤ 10 infusions per year
11028228|NCT04580368|Experimental|CFTR modulator or other therapies|CFTR modulator or active therapy
11028229|NCT04580355|Experimental|FMUD + Placebos|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
11028230|NCT04580355|Active Comparator|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
11028231|NCT04580342|Experimental|Ivabradine group|
11028232|NCT04580342|Experimental|propranolol group|
11028233|NCT04580329|Experimental|NMES group|
11028234|NCT04580329|Experimental|control group|
11028235|NCT04580316|Experimental|Experimental group|75 children were managed during intervention using Parental Active Presence.
11028236|NCT04580316|Placebo Comparator|control group|75 children were managed with passive parent presence.
11028237|NCT04580303|Active Comparator|Uniform 0.1-mL 1-Aliqout GRID Injection Technique|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
11028238|NCT04580303|Active Comparator|Uniform 0.3-mL 2-Aliquot GRID Injection Technique|Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)
11028239|NCT04580277|Experimental|Chronic pouchitis|This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks
11028240|NCT04580264|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
11028241|NCT04580251||Magnetic marker Magseed|Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.
11028242|NCT04580251||Iodine seed 125I marker|Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
11028243|NCT04580251||Carbon suspension|Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
11028244|NCT04580238|Experimental|Treatment Arm|The treatment group will consist of 40 patients randomly allocated to receiving Botox according to the treatment regime.
11028245|NCT04580238|Active Comparator|Control|The control group will consist of 40 patients randomly allocated to Non-Botox, standard of care treatments, to a total study population of 80 patients.
11028246|NCT04580225|Active Comparator|Group A: Four-Corner Arthrodesis|
11028247|NCT04580225|Active Comparator|Group B: Partial Wrist Arthrodesis with Triquetral Excision|
11028248|NCT04580212|Experimental|Intervention arm|
11028249|NCT04580212|No Intervention|Control arm|
11028250|NCT04580199|Active Comparator|total thyroidectomy|excision of thyroid gland
11028251|NCT04580199|Active Comparator|hemi thyroidectomy|excision half of thyroid gland
11028252|NCT04580199|Active Comparator|ethanol ingection|ingection of ethanol into thyroid nodule under guidance of ultrasound
11028260|NCT04580147|Experimental|Intervention (serial IAI)|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
11028261|NCT04580147|Sham Comparator|Control|Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
11028262|NCT04580134|Experimental|Biotype 1 - Clozapine (B1C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
11028263|NCT04580134|Placebo Comparator|Biotype 1 - Risperidone (B1R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
11028264|NCT04580134|Active Comparator|Biotype 2 - Clozapine (B2C)|Target doses will be up to clozapine 500mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day)].
11028265|NCT04580134|Placebo Comparator|Biotype 2 - Risperidone (B2R)|Target doses will be up to risperidone 6mg po qd. In addition, several concomitant (open label) medications for symptomatic management will be available via the study protocol [non-benzodiazepine sleep aid (melatonin, hydroxyzine); motor side effect treatments (benztropine, propranolol)]. The doses for these medications will be consistent with those routinely used in a clinical practice: melatonin [up to 10mg at bedtime], hydroxyzine [up to 100mg at bedtime]; benztropine [up to 4mg/day (2mg twice/day)], propranolol [up to 40mg/day (20mg twice/day
11028266|NCT04580121|Experimental|RO7283420 Part A|Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.
11028267|NCT04580121|Experimental|RO7283420 Part B|Multiple-participant cohorts of >= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A of RO7283420 once Q3W starting on C1D1 up to Cycle 6 to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
11028268|NCT04580121|Experimental|RO7283420 Part C|Participants will receive the respective RP2D for Group I and Group II.
11028269|NCT04580108||Patients with systemic lupus erythematosus|Patients with systemic lupus erythematosus enrolled in the PLUS cohort between 2007 and 2010
11028270|NCT04580095|Experimental|With AI algorithm|"In the With AI algorithm arm, the sonographer will perform the echocardiographic exam using the AI algorithm."
11028271|NCT04580095|No Intervention|Without AI algorithm|"In the Without AI algorithm, the echocardiographic exam will be performed without the use of the AI algorithm."
11028272|NCT04580082|Experimental|Mindfulness lessons|"There are 14 lessons in total, each lasting approximately 20 minutes. Participants will be asked to listen to one lesson per day for 14 consecutive days, but to allow for possible missed days, they will have up to 25 days to complete as many of these 14 lessons as they can. The lessons will be delivered via the internet, and participants can use a variety of devices (e.g. smartphone, desktop computer, laptop computer, tablet) to access them. While the lessons cannot be downloaded, they are available for streaming anytime and anywhere there is an internet connection. Participants are welcome to revisit any lesson they have listened to previously, but are not allowed to skip ahead to other lessons until they have completed all preceding lessons. This is done because the lessons build on one another, which means that skipping lessons makes continued participation difficult. We will be able to track each participant's usage pattern and will analyze differences across users."
11028273|NCT04580082|Other|Delayed-start Mindfulness Lessons|"The control group will not receive the intervention until the intervention group has completed lesson listening. During this waiting period, they will receive periodic emails letting them know that their turn to listen to lessons is coming soon.
~Once available, the control group will have 25 days to listen to the 14 lessons."
11028274|NCT04580069|Experimental|Lymphatic drainage|Patients subjected to manual lymphatic drainage
11028275|NCT04580069|Experimental|Connective tissue|Patients subjected to connective tissue massage
11028276|NCT04580069|Active Comparator|control group|Subjects hat followed standard rehabilitative treatment
11028277|NCT04580056||Incision Group|Women following IVF treatment with donor oocytes who underwent during hysteroscopy fundus endometrial scratching by incision, before embryo transfer.
11028278|NCT04580056||No incision Group|Women following IVF treatment with donor oocytes who underwent office hysteroscopy without fundus endometrial scratching by incision, before embryo transfer.
11028279|NCT04580043|Experimental|cTBS + Habit Override Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Habit Override Training.
11028280|NCT04580043|Active Comparator|Sham TBS + Habit Override Training|Sham Transcranial Magnetic Stimulation, paired with Habit Override Training.
11028281|NCT04580043|Active Comparator|cTBS + Sham Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Sham Training.
11028282|NCT04580043|Sham Comparator|Sham TBS + Sham Training|Sham Transcranial Magnetic Stimulation, paired with Sham Training.
11028283|NCT04580030||hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
11028977|NCT04575337||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
11028284|NCT04580030||no hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
11028285|NCT04580004|Experimental|Medication Optimization Group|Patients randomized to the medication optimization group will receive an evidence-based medication recommendation intervention.
11028286|NCT04580004|No Intervention|Control Group|Patients in the control group will receive the same intervention, delayed 2 weeks after the intervention group. During those initial 2 weeks they will act as a control.
11028287|NCT04579991|Active Comparator|Active Group|Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
11028288|NCT04579991|Placebo Comparator|Placebo Group|Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.
11028289|NCT04579978||Subjects with advanced solid tumors starting immunotherapy|Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors
11028290|NCT04579978||Subjects with advanced solid tumors receiving ICIs|Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors
11028291|NCT04579965|Other|combined contraceptive pills|treat patients with isthmocele with oral contraceptive pills
11028292|NCT04579965|Other|Misotac|treat patients with isthmocele with misotac.
11028293|NCT04579952|Experimental|Intervention Group|The IG will receive a 20 minute program of active tDCS (2mA intensity, anode placed on primary motor cortex controlateral to the TKA, cathode placed on controlateral supraorbital region) followed by a 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
11028294|NCT04579952|Placebo Comparator|Control Group|The CG will receive a 20 minute program of sham tDCS (15 seconds of activation and then no stimulation, same position of IG) followed by the same 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
11028295|NCT04579939|Experimental|Experimental|All 10 participants will go through the experimental arm receiving the dextrose candy oral glucose tolerance test.
11028296|NCT04579926|Experimental|Pinpoint App|Tablet and smartphone application.
11028297|NCT04579913||iTind subjects|Patient who participated previously in the MT-03 study in the iTind arm
11028298|NCT04579900|Experimental|Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
11028299|NCT04579900|Active Comparator|Non Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
11028300|NCT04579887|Experimental|Brain changes triggered by PH induction in Parkinson's disease|Clinical and neuropsychological evaluations + Sensorimotor task for PH-induction
11028301|NCT04579874|Experimental|LIVERFASt validation|blood draw for LIVERFASt
11028302|NCT04579861||Very high human development|Countries classified as very high human development as per the United Nations development programme.
11028303|NCT04579861||High human development|Countries classified as high human development as per the United Nations development programme.
11028304|NCT04579861||Medium human development|Countries classified as medium human development as per the United Nations development programme.
11028305|NCT04579861||Low human development|Countries classified as low human development as per the United Nations development programme.
11028306|NCT04579848|Active Comparator|Methotrexate|"Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.
~Additional Folic acid 1mg prescribed daily."
11028307|NCT04579848|Placebo Comparator|Placebo|"3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.
~Additional Folic acid 1mg prescribed daily."
11028308|NCT04579822||Pregnant women vaccinated with a QIV|Women aged 20-44 years who had received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
11028309|NCT04579822||Pregnant women unvaccinated with a QIV|Women aged 20-44 years who had not received a QIV during their pregnancy between September 22, 2020, and April 30, 2021, under the national immunization program in South Korea.
11028310|NCT04579809|Active Comparator|children below six years|children below sex years both genders
11028311|NCT04579809|Active Comparator|cooperative children|repair of the tendos by modified kessler
11028312|NCT04579796|Experimental|women with first trimester missed abortion|
11028313|NCT04579783|Active Comparator|Ultrasound intracarpal corticosteroid injection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.
~1st injection (0 week): 40mg triamcinolone acetonide (40mg/mL ) with 4mL normal saline, 2nd injection (6 week): 5 mL normal saline"
11028314|NCT04579783|Active Comparator|Ultrasound guided intracarpal dextrose hydro-dissection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.
~Group B: 1st injection (0 week): 5 mL 5% dextrose, 2nd injection (6 week): 5 mL 5% dextrose"
11028315|NCT04579770|Placebo Comparator|Placebo|Only carbohydrates will be provided
11028316|NCT04579770|Experimental|Ketone ester|Ketone ester with carbohydrates will be provided
11028317|NCT04579770|Experimental|Ketone ester + bicarbonate|Ketone ester with bicarbonate and carbohydrates will be provided
11028318|NCT04579770|Experimental|Bicarbonate|Bicarbonate and carbohydrates will be provided
11028319|NCT04579757|Experimental|Surufatinib and tislelizumab (dose escalation_Part 1)|In Part 1 (dose escalation), surufatinib and will be administered orally (PO) once daily (QD) and tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).
11028320|NCT04579757|Experimental|Surufatinib and tislelizumab (indication specific_Part 2)|In Part 2, the indication-specific expansion portion of the study, patients will receive surufatinib at the Recommended Phase 2 Dose (RP2D) dose selected in Part 1 with 200 mg tislelizumab IV, Q3W
11028321|NCT04579731||Fecal Impaction (LUTD-FI)|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
11028401|NCT04579185|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
11028322|NCT04579731||Lower Urinary Tract Dysfunction Not Related to Fecal Impaction|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI). They serve as a control group.
11028323|NCT04579718||Eclipse|
11028324|NCT04579718||Zeus Cloud TPS V1.0|
11028325|NCT04579705|Experimental|Group I (Brushed-1 minute)|Surgical hand scrubbing will be performed in 1 minute using a brush.
11028326|NCT04579705|No Intervention|Group II (Brushless-1 minute)|Surgical hand scrubbing will be performed in 1 minute without using a brush.
11028327|NCT04579705|Experimental|Group III (Brushed-2 minutes)|Surgical hand scrubbing will be performed in 2 minute using a brush.
11028328|NCT04579705|No Intervention|Group IV (Brushless-2 minutes)|Surgical hand scrubbing will be performed in 2 minute without using a brush.
11028329|NCT04579692|Experimental|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain called central lateral thalamic nucleus. Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
11028330|NCT04579679|Experimental|Surufatinib|"Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
~Cohort D:
~Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1"
11028331|NCT04579666|Experimental|1,080 mg pegcetacoplan (APL-2)|administered subcutaneously twice weekly
11028332|NCT04579666|Placebo Comparator|Placebo administered subcutaneously twice weekly|
11028333|NCT04579653|Experimental|Group A: Experimental|Within-subjects design with a randomization of the order of tVNS administered parameters
11028334|NCT04579653|Active Comparator|Group B: Active Comparator|Within-subjects design with a randomization of the order of tVNS administered parameters
11028335|NCT04579640|No Intervention|Control|Standard of care (national recommendation of 400 IU/day vitamin D)
11028336|NCT04579640|Experimental|Intervention: Lower-dose vitamin D|Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
11028337|NCT04579640|Experimental|Intervention: Higher-dose vitamin D|Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L
11028338|NCT04579627||Hospital Doctors|Hospital doctors working at Royal Cornwall Hospital during the COVID-19 pandemic
11028339|NCT04579614|Active Comparator|Organizational Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own, and with the organizational target. These updates and targets are sent bi-weekly."
11028340|NCT04579614|Experimental|Achievable Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a static and achievable target based on their previous year's flu vaccination success rate."
11028341|NCT04579614|Experimental|Variable|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a variable target that will fluctuate bi-weekly, based on their previous bi-weekly flu vaccination success rate."
11028342|NCT04579601||ERAS group|We recruited 50 patients throughout 2018 and 2019, patients undergoing thoracic surgery within an ERAS program
11028343|NCT04579601||Standard group|A group of 50 patients selected randomly prior the implementation of the ERAS program, in 2016.
11028344|NCT04579588||COVID-19 participants|
11028345|NCT04579588||Control participants|
11028346|NCT04579562||COVID-19 positive AKI|
11028347|NCT04579562||COVID-19 positive no AKI|
11028348|NCT04579562||COVID negative AKI|
11028349|NCT04579549|Experimental|Repeat Testing for SARS-CoV-2|Anyone over the age of 5yrs old with consent to provide a saliva sample for SARS-CoV-2 assay will be eligible to participate. Assay takes 20 minutes.
11028350|NCT04579536|Experimental|Study group|This is the study group; it will consist of 84 first permanent molars. These molars will be sealed using light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA). reapplication will be done after 3,6, 12, and 18 months.
11028351|NCT04579536|Other|Control group|This group will consist of 84 first permanent molars. These molars will receive 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA). These molars will serve as a control group. reapplication will be done after 3,6, 12, and 18 months.
11028352|NCT04579523|Experimental|Arm A (²¹¹At-OKT10-B10, fludarabine, TBI, HCT)|Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 IV on day -7 (day -10 to -5) and fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo TBI and allogeneic HCT on day 0.
11028353|NCT04579523|Experimental|Arm B (²¹¹At-OKT10-B10, chemotherapy, TBI, HCT)|Patients with HLA-matched haploidentical donors receive ²¹¹At-OKT10-B10 IV on day -8 (day -14 to -7), fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on day -6 and -5. Patients then undergo TBI on day -1 and allogeneic HCT on day 0.
11028354|NCT04579510|Active Comparator|nOPV2 only|Participants in this arm will receive nOPV2 at 6, 10, and 14 weeks of age
11028355|NCT04579510|Active Comparator|nOPV2 and bOPV|Participants in this arm will receive both nOPV2 and bOPV at 6, 10, and 14 weeks of age
11028356|NCT04579510|Active Comparator|bOPV only|Participants in this arm will receive bOPV at 6, 10, and 14 weeks of age
11028357|NCT04579497|Experimental|38° C footbath|Footbath with warm water at a constant temperature of 38° C
11028358|NCT04579497|Experimental|40° C footbath|Footbath with warm water at a constant temperature of 40° C
11028359|NCT04579497|Experimental|42° C footbath|Footbath with warm water at a constant temperature of 42° C
11028360|NCT04579497|Experimental|Rising temperature footbath|Footbath with warm water rising from 38° C to 42° C
11028361|NCT04579471||Transplanted patients|All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven
11028402|NCT04579172|Experimental|Group A|Circular isthmic-cervical sutures
11028362|NCT04579471||Transplanted patients with past SARS-CoV-2 infection|Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity
11028363|NCT04579471||Transplanted patients without past SARS-CoV-2 infection|100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection
11028364|NCT04579458||COVID-19 Positive|COVID-19 positive in nasopharyngeal swabs and tears or saliva.
11028365|NCT04579445||TAVI patients|Severe aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) (there will be a retrospective part: documentation of 30 patients who underwent TAVI; and a prospective part enrolling 50 patients undergoing TAVI)
11028366|NCT04579432|Experimental|Training Group|
11028367|NCT04579432|No Intervention|Control Group|
11028368|NCT04579419|Experimental|Sodium Bicarbonate|
11028369|NCT04579419|Placebo Comparator|Normal Saline|
11028370|NCT04579406||non-diabetic group|The non-diabetic patients undergoing non-cardiac surgery.
11028371|NCT04579406||Diabetic group|The diabetic patients without peripheral neuropathy undergoing non-cardiac surgery.
11028372|NCT04579406||Diabetic neuropathic group|The diabetic patients with peripheral neuropathy undergoing non-cardiac surgery.
11028373|NCT04579393|Active Comparator|Intervention|fostamatinib in combination with standard of care (SOC) for the treatment of COVID-19
11028374|NCT04579393|Placebo Comparator|Intervention - Placebo|Placebo in combination with standard of care (SOC) for the treatment of COVID-19
11028375|NCT04579380|Experimental|Single Arm|Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
11028376|NCT04579367||Bempedoic acid and/or fixed-dose combination with ezetimibe|Participants with hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.
11028377|NCT04579354|No Intervention|Standardized Anaesthesia briefing|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia. This corresponds to the current procedure before an operation.
11028378|NCT04579354|Experimental|Virtual reality (VR) tour|standardised anaesthesia information sessions, consisting of a detailed explanation of the anaesthesia procedure by the anaesthetist A specific information sheet is used to explain the procedure and the form of anaesthesia.Subsequently, the patients are shown a virtual tour of the operation using VR glasses. This includes the way through the clinic to the operating theatre: Admission -> inpatient preparation for the operation -> administration of premedication -> way to the operating theater -> OP preparation (holding) -> safe surgery
11028379|NCT04579341|Active Comparator|probiotics arm|probiotics administered in addition to insulin regimen
11028380|NCT04579341|No Intervention|control|regular insulin regimen
11028381|NCT04579328|Experimental|Lessons with Growth Mats|Participants, clustered by neighbor groups, will be given lessons on stunting. During the lessons the trainers will use the growth mats to demonstrate their points. In these villages, village-wide events will expose the full community to the messages in combination to the mats.
11028382|NCT04579328|No Intervention|Lessons without Mats|Participants, clustered by neighbor groups, will be given lessons on stunting without the aid of the growth mats. In these villages, village-wide events will expose the full community to the messages without the aid of the mats.
11028383|NCT04579315|Active Comparator|Intervention group, NNRD group|"Main principles of the interventional whole food approach are:
~Maximum of 850 mg phosphorous/day
~Protein: 0.8 g/kg/day
~80% vegetable products; 20% animal products
~Maximum of 5-7 g NaCl/day (table salt)
~Fresh raw products
~Seasonal oriented
~Fish: At least once a week
~Vegetarian: At least once a week
~Wide range of fruit and vegetables
~Easy to follow in daily practice
~Rich in flavors
~Sufficient content of micro- and macronutrients"
11028384|NCT04579315|No Intervention|Control group|There is no intervention, patients are following their habitual diet
11028385|NCT04579302|Experimental|serratus anterior block|serratus anterior block with 20 ml bupivacaine
11028386|NCT04579302|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
11028387|NCT04579302|Sham Comparator|control group|sham block with 20 ml saline
11028388|NCT04579276|Experimental|"surgical method"|
11028389|NCT04579276|Active Comparator|"anesthetic method"|
11028390|NCT04579263|Experimental|Patient with diabetes mellitus type 1 (T1DM)|Treatment by transplantation of fecal microbiota
11028391|NCT04579263|Experimental|Patient with diabetes mellitus type 2 (T2DM)|Treatment by transplantation of fecal microbiota
11028392|NCT04579250|Experimental|Group 1|20 mcg IM at Day 0
11028393|NCT04579250|Experimental|Group 2A|60 mcg IM at Day 0 and Week 16
11028394|NCT04579250|Experimental|Group 2B|60 mcg IM at Day 0 and Week 16
11028395|NCT04579237||1/All Subjects|Data will be derived from primary studies on all subjects.
11028396|NCT04579224|Active Comparator|Arm I (standard of care chemotherapy)|Patients receive 1 of the 3 standard of care chemotherapy regimens based on treating investigator's choice: Choice A: Patients receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice B: Patients receive gemcitabine IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Choice C: Patients receive paclitaxel IV on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11028397|NCT04579224|Experimental|Arm II (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11028398|NCT04579224|Experimental|Arm III (eribulin, gemcitabine)|Patients receive eribulin IV over 2-5 minutes and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11028399|NCT04579211||Adults with a diagnosis of CF with history of negative NTM sputum cultures|Male or female participants age 18 or greater at time of enrollment with diagnosis of CF consistent with the 2017 CFF Guidelines and NTM culture status of negative (as defined by at least 3 negative sputum cultures over the past 3 years) and no known history of previous positive cultures for pathogenic NTM by chart review.
11028404|NCT04579159|Other|only control group|To investigate the specificity of the wearable and to gather more information on ECG abnormalities in the population studied, a randomly selected group of participants without wearable-detected AA within 8 weeks of screening (same number as screen-positives and verified by Telecare) will also be invited to obtain a 14day Tele ECG (patch).
11028405|NCT04579146||HIV-1 patients and treated effectively for more than 12 months|X-ray examination with contrast by a 64-slice CT coronary angiography.
11028406|NCT04579133|Experimental|durvalumab plus olaparib|Durvalumab 1500 mg IV week 0, 3, 6 plus Olaparib tablets will be given orally on a continuous dosing schedule 300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min) to complete 9 weeks of treatment.
11028407|NCT04579133|Experimental|durvalumab alone|Durvalumab 1500 mg IV week 0, 3, 6 to complete 9 weeks of treatment
11028408|NCT04579120||African American|African American participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
11028409|NCT04579120||Non-Hispanic White|Non-Hispanic White participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
11028410|NCT04579107|Other|Contrast Enhanced Mammography|All included women go through a Contrast Enhanced Mammography added to the standard of care examinations.
11028411|NCT04579094||1/elderly dependent persons|
11028412|NCT04579094||2/healthcare workers (HCW)|
11028413|NCT04579068|Experimental|Screening and Brief Intervention of Problematic Alcohol Use|We plan to test the feasibility and effectiveness of the delivery of the peer-based SBIRT using the RAPS4-QF screening tool with CDU students. Furthermore, we will compare delivery by AAPLs' race/ethnicity, drinking status (abstainer vs. non-abstainer), and adverse life experiences. Following the screening by AAPLs, we expect a 30% detection of problematic alcohol use (i.e. high episodic drinking [HED] or AUD) and at-risk alcohol use. Participants that screen positive will receive brief motivational interviewing and referral to treatment and will be contacted 6 months following the SBIRT to assess their drinking behaviors. We expect that participants will decrease their alcohol consumption or drinking risk at the 6-month follow up.
11028414|NCT04579055|Experimental|1-min STS test: chair seat height adjusted to 90° knee flexion|In this experimental condition, the patient performs the 1-minute sit to stand test on an individually adjusted seat height of 90° knee joint flexion.
11028415|NCT04579055|Active Comparator|1-min STS test: chair seat height standardized of 46cm|In this experimental condition, the patient performs the 1-minute sit to stand test on a standard height chair of 46cm.
11028416|NCT04579042|Experimental|Septoplasty Using Cartilaginous Batten Graft|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
11028417|NCT04579029|Experimental|Surgical Cohort|"Patients randomised to the surgical group will undergo near infrared spectroscopy imaging to assess suitability and plan the surgical procedure.
~Limb measurements with perometry and bio-impedance spectroscopy will be performed at baseline. Under general anaesthetic multiple LVA bypass procedures will be performed on the affected arm. Near infrared spectroscopy imaging will be used throughout. One week after discharge the patient will return for the bandages to be removed and the wounds inspected for any evidence of infection before renewing the bandage. Again, two weeks after surgery, the patient will return for inspection of wound and removal of sutures. It is at this point that the surgical patients will be returned into a standard lymphoedema compression garment, fitted by the research nurse. Thereafter, standard follow up (Bilateral) measurements and checks will be done at 1 month, 3 months, 6 months and 1 year."
11028418|NCT04579029|No Intervention|Non-surgical cohort|"The main intervention for the non-surgical group largely encompasses limb measurements with perometry and bio-impedance spectroscopy at baseline before a compression garment is applied. The compression garments will be measured and fitted by a trained lymphoedema specialist and will be given the standard advice as is best practice for such patients currently. This cohort will likewise be followed up at 1 month, 3 months, 6 months and 1 year and undergo perometry readings and measurements with comparable collection of data.
~For patients in both surgical and non-surgical groups, the compression garments will be measured and fitted by a trained lymphoedema specialist and they will be given the standard advice as is best practice for such patients currently. For each patient key details of the surgical technique, garment specification, imaging results and perometry/BIS measurements will be recorded on a study specific form for subsequent entry onto the database."
11028419|NCT04579016|Active Comparator|Standard care|Standard care
11028420|NCT04579016|Experimental|PAIGE2 intervention|One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
11028421|NCT04579003|Experimental|Mobilization|Mobilization, heat application, ultrasound, TENS
11028422|NCT04579003|Active Comparator|Mobilization with movement|Mobilization with movement, heat application, ultrasound, TENS
11028423|NCT04578990|Experimental|Walking intervention group|It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.
11028424|NCT04578990|Experimental|Strength intervention group|The training program consists of performing a training program with resistance exercises for 36-72 weeks.
11028425|NCT04578990|Experimental|Concurrent intervention group|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.
11028426|NCT04578990|No Intervention|Control group|It will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level.
11028427|NCT04578951||Patients receiving a prosthesis from the FHK® range|
11028428|NCT04578938|Experimental|Ketamine + Cognitive Training|
11028429|NCT04578938|Sham Comparator|Ketamine + Sham Training|
11028430|NCT04578938|Active Comparator|No-infusion (TAU) + Cognitive Training|
11028431|NCT04578938|Sham Comparator|No-infusion (TAU) + Sham Training|
11028498|NCT04578535|Experimental|Part 1 Treatment Arm 3: HYQVIA|Participants from part 1 of study in treatment arm 3 will receive SC infusion of HYQVIA 0.4 g/kg at week 1 without ramp-up dosing.
11028499|NCT04578535|Experimental|Part 2 Treatment Arm 4: HYQVIA|Participants from part 2 of study in treatment arm 4 will receive SC infusion of HYQVIA 0.25 g/kg at week 1 and ramp up to full TDL (1.0 g/kg) at week 8.
11028432|NCT04578925|Experimental|Happy, Healthy, Loved|"Both parents will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. For the next 6 weeks participants' will receive 4 personalized text messages per week based on their tablet survey responses. Participants will be asked one yes/no question each week (still breastfeeding? Text Y for yes, N for no). Once a no response has been received from a participant, all remaining text messages will emphasize coping and partner support rather than breastfeeding."
11028433|NCT04578925|No Intervention|Control|Control group participants will complete surveys on a tablet during the postpartum hospital stay. Surveys cover three topic areas related to breast-feeding; modeling and feedback, partner support, and stress coping. The control group participants will be sent 4 text messages per week for the first 6 weeks, but the content of the texts will be non-breastfeeding related. The content will instead summarize infant development facts.
11028434|NCT04578912|Active Comparator|CBIT + rTMS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with 1 Hz repetitive Transcranial Magnetic Stimulation (rTMS).
11028435|NCT04578912|Active Comparator|CBIT + cTBS|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with continuous Theta Burst Stimulation (cTBS).
11028436|NCT04578912|Sham Comparator|CBIT + Sham|Participants in this arm will receive Comprehensive Behavioral Intervention for Tics (CBIT) with either a cTBS or rTMS sham treatment.
11028437|NCT04578899|Active Comparator|Transvertebral magnetic stimulation (Experimental group)|Experimental intervention will receive non-invasive transvertebral magnetic stimulation of the sacral spine roots (level S2-S3).
11028438|NCT04578899|Placebo Comparator|Transvertebral magnetic stimulation (Control group)|"Control group will receive an equivalent number of stimulation sessions using the placebo option."
11028439|NCT04578886|Placebo Comparator|Placebo|Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
11028440|NCT04578886|Experimental|Guanfacine|Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
11028441|NCT04578873|Experimental|QPX7831 SAD Cohorts|oral, single ascending dose (or placebo)
11028442|NCT04578873|Experimental|QPX7831 MAD Cohorts|oral, multiple ascending dose (or placebo)
11028443|NCT04578860|Active Comparator|Treatment as usual|Usual treatment of sleep disorders consist of adequate sleep hygiene entails the behaviors, practices, rituals, and habits.
11028444|NCT04578860|Experimental|Music Intervention|Using the app Music Care
11028445|NCT04578860|Placebo Comparator|White Noise|Using an app producing white noise (like rain, storm, fan, wind...)
11028446|NCT04578847|Experimental|The TKI dose reduction|Imatinib, nilotinib, dasatinib or bosutinib; the two stage of TKI dose reduction phase for 12 months (6 months and 6 months, respectively).
11028447|NCT04578834|Experimental|LNP023 200mg b.i.d|
11028448|NCT04578834|Placebo Comparator|Placebo to LNP023 200mg b.i.d|
11028449|NCT04578821|Experimental|Deney group|"Education Program:The education program consists of theoretical didactic education, case discussion, film and video screening in class, Web-based laboratory work, SSI practice, poster preparation and awareness activities for a total of 12 weeks and 2 hours per week (24 hours per week).
~Theoretical didactic education, film screening, video screening, Web-based laboratory work, Social Security Institution study, poster preparation, poster presentation at University Campus."
11028450|NCT04578821|No Intervention|Kontrol group|The control group participated in the courses and practices included in the routine curriculum.
11028451|NCT04578795|Experimental|Pt underwent single use flexible ureteroscopy|Patients with renal stones who will operated by single use flexible ureteroscopy
11028452|NCT04578782|Experimental|BOTOX|155 UI of Botox were injected according to the approved PREEMPT protocol (the only FDA-approved injection pattern for chronic migraine), in 31 sites. From visit 5, the PREEMPT 'follow-the-pain' paradigm was applied in patients falling in the 'non-responder' or 'partial responder' classes after the first BoNT-A injection, with the possibility to increase the doses up to 195 UI in maximum 39 sites. The injections were every 3 months for 4 cycles
11028453|NCT04578769|Active Comparator|conventional myotomy|conventional myotomy for achalasia type I, II and III
11028454|NCT04578769|Experimental|short myotomy|modified myotomy (short myotomy) for achalasia type I and II
11028455|NCT04578769|Experimental|full-thickness myotomy|modified myotomy (full-thickness myotomy) for achalasia type I and II
11028456|NCT04578769|Experimental|tailored myotomy|modified myotomy (tailored myotomy) for achalasia type III
11028457|NCT04578756|Experimental|Cariprazine Dose 1|"Rollover and De Novo Participants with Schizophrenia 13 to 18 years (rollover) and 13 to17 years (de novo)
~Rollover and De Novo Participants with Bipolar I Disorder 10 to 12 years (weighing ≤40 kg), 10 to 12 years (weighing >40 kg), 13 to 18 years (rollover), and 13 to17 years (de novo)"
11028458|NCT04578756|Experimental|Cariprazine Dose 2|"Rollover and De Novo Participants with Schizophrenia 13 to 18 years (rollover) and 13 to17 years (de novo)
~Rollover and De Novo Participants with Bipolar I Disorder 10 to 12 years (weighing ≤40 kg), 10 to 12 years (weighing >40 kg), 13 to 18 years (rollover), and 13 to17 years (de novo)"
11028459|NCT04578756|Experimental|Cariprazine Dose 3|"Rollover and De Novo Participants with Schizophrenia 13 to 18 years (rollover) and 13 to17 years (de novo)
~Rollover and De Novo Participants with Bipolar I Disorder 10 to 12 years (weighing ≤40 kg), 10 to 12 years (weighing >40 kg), 13 to 18 years (rollover), and 13 to17 years (de novo)"
11028460|NCT04578756|Experimental|Cariprazine Dose 4|"Rollover and De Novo Participants with Schizophrenia 13 to 18 years (rollover) and 13 to17 years (de novo)
~Rollover and De Novo Participants with Bipolar I Disorder 13 to 18 years (rollover), and 13 to17 years (de novo)"
11028461|NCT04578743|Experimental|Graded Exercise|ClearPlay(TM): a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, will provide a telemetry-based graded exercise program for 20 minutes each day, identifying a heart rate target that will be advanced weekly for up to 8 weeks as symptoms resolve.
11028462|NCT04578743|Experimental|Passive Stretching|ClearPlay(TM): we have created a passive stretching program (placebo arm) downloadable to an Apple i-touch or i-phone device, that will provide a telemetry-based guided passive stretching program for 20 minutes each day for up to 8 weeks as symptoms resolve.
11029028|NCT04574947|Active Comparator|Intravenous lidocaine|
11028463|NCT04578717|Experimental|Air-abrasion + Etch & rinse adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by etch&rinse adhesive application using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
11028464|NCT04578717|Experimental|Air-abrasion + Self-etch adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by self-etch adhesive application which was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
11028465|NCT04578717|Experimental|Etch & rinse adhesive|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
11028466|NCT04578717|Experimental|Self-etch adhesive|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
11028467|NCT04578704|Experimental|Vacuum formed retainer group|It will be constructed following manufacturer's instructions for the thickness.
11028468|NCT04578704|Experimental|Fixed bonded retainer group|fixed bonded wire will be bonded on individual tooth extended distal to extraction space that were previously closed by fixed appliances treatment.
11028469|NCT04578704|Experimental|Vacuum formed retainer and fixed bonded retainer|Double regime retainer that will be consisted of bonded retainer and vacuum formed retainer for upper and lower arch.
11028470|NCT04578691|Experimental|"Anatase Spine Surgery Navigation System"|"Using Anatase Spine Surgery Navigation System in pedicle screw placement in spine surgery"
11028471|NCT04578691|Active Comparator|Medtronic Stealthstation S7 Treatment Guidance System|Using Medtronic Stealthstation S7 Treatment Guidance System in pedicle screw placement in spine surgery
11028472|NCT04578678||Apathy Group|Patients diagnosed with apathy
11028473|NCT04578678||Dysarthria Group|Patients diagnosed with dysarthria
11028474|NCT04578678||No Apathy and Dysarthria Group|Patients diagnosed with neither apathy nor dysarthria
11028475|NCT04578678||Apathy and Dysarthria Group|Patients diagnosed with apathy as well as dysarthria
11028476|NCT04578665|Experimental|Healthy Participants Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
11028477|NCT04578665|Experimental|Healthy Participants Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
11028478|NCT04578665|Experimental|Clinical Populations Ankle Robot (M1)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
11028479|NCT04578665|Experimental|Clinical Populations Bilateral Lower Limb Exoskeleton (H3/X2)|The investigators will look at how the task performance and motor performance of individuals in dyadic physical interactions are affected.
11028480|NCT04578652|Active Comparator|MET|MET (850 mg po bid - standard of care) + Fiber placebo daily
11028481|NCT04578652|Active Comparator|FIBER|Fiber supplementation [35g fiber daily] + MET placebo po bid
11028482|NCT04578652|Experimental|FIBER + MET|Fiber supplementation [35g fiber daily] + MET 850 mg po bid
11028483|NCT04578639|Experimental|Rituximab|Rituximab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial dose; 1000 mg Subsequent doses; 500 mg
11028484|NCT04578639|Active Comparator|Ocrelizumab|Ocrelizumab will be given as infusion at week 0, week 26, week 52, week 78, and week 104 unless there is a reason for schedule modifications (see Section 6.3). Each infusion is given over approximately 4 hours and follow local guidelines for infusion. Initial and subsequent doses; 600 mg
11028485|NCT04578626|Experimental|dry needling group|Dry needling treatment on right or left side of the face (depending on randomization)
11028486|NCT04578626|No Intervention|control group|No treatment on left or right side of the face (depending on randomization)
11028487|NCT04578613|Experimental|ICP-022|ICP-022 will be orally administered until disease progression or unacceptable toxicity.
11028488|NCT04578613|Active Comparator|Chlorambucil combined with Rituximab|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles.
11028489|NCT04578600|Experimental|Treatment (lenalidomide, oral azacitidine, obinutuzumab)|Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11028490|NCT04578587||Reliability|Intra-rater and inter-rater
11028491|NCT04578574|Experimental|BI-TDCS Stimulation Group|Participants in this group will receive the BI and TDCS interventions for 10 sessions over two weeks.
11028492|NCT04578561||Prophylactic mesh|Patients who received a prophylactic mesh after emergency surgery due to high risk of incisional hernia.
11028493|NCT04578561||Suture|Patients who's laparotomies closure was using only suture without any abdominal wall reinforcement
11028494|NCT04578548|Experimental|GLPG2737|GLPG2737 will be administered orally once daily with food for 52 weeks.
11028495|NCT04578548|Placebo Comparator|Placebo|Matching placebo will be administered orally once daily with food for 52 weeks.
11028496|NCT04578535|Experimental|Part 1 Treatment Arm 1: HYQVIA|Participants from part 1 of study in treatment arm 1 will receive subcutaneous (SC) infusion of HYQVIA 0.1 g/kg at week 1 and ramp up to full TDL (0.4 g/kg) at week 8.
11028497|NCT04578535|Experimental|Part 1 Treatment Arm 2: HYQVIA|Participants from part 1 of study in treatment arm 2 will receive SC infusion of HYQVIA 0.2 g/kg at week 1 and ramp up to full TDL (0.4 g/kg) at week 5.
11028500|NCT04578535|Experimental|Part 2 Treatment Arm 5: HYQVIA|Participants from part 2 of study in treatment arm 5 will receive SC infusion of HYQVIA 0.5 g/kg respectively at week 1 and ramp up to full TDL (1.0 g/kg) at week 5.
11028501|NCT04578535|Experimental|Part 2 Treatment Arm 6: HYQVIA|Participants from part 2 of study in treatment arm 6 will receive SC infusion of HYQVIA 1.0 g/kg at week 1 without ramp-up dosing.
11028502|NCT04578509||All patient|Ambulatory adults or children requiring screening for SARS-CoV-2 by nasopharyngeal swab
11028503|NCT04578496|Experimental|Afamelanotide|
11028504|NCT04578483||PCA group|Patients receiving patient-controlled analgesia (PCA) will be allocated to PCA group.
11028505|NCT04578483||ERDS group|Patients receiving one dose of extended-release dinalbuphine sebacate (ERDS) by ultrasound-guided muscle injection will be allocated to ERDS group.
11028506|NCT04578483||PRN group|Patients receiving analgesics other than ERDS and PCA will be allocated to PRN group.
11028507|NCT04578470|No Intervention|Group C|Patients with replete VitaminD levels (≥30ng/ml) will be serving as a control in group C. Group C will not receive any Vitamin D intervention for the entire 12- month study period but will receive dietary interventions.
11028508|NCT04578470|Experimental|Group A|Group A will be prescribed Vitamin D supplementation in the form of daily 2000 IU cholecalciferol (two tablets)for 13 weeks, and daily1000 IU cholecalciferol(1tablet) for another 13 weeks and then treatment will be discontinued but dietary interventions will continue across the 12-month study period.
11028509|NCT04578470|Placebo Comparator|Group B|Group B will be prescribed placebo of Vitamin D with two tablets daily for 13 weeks then 1 tablet daily for13 weeks then no treatment for 26 weeks but dietary interventions will continue across the 12-month study period.
11028510|NCT04578457|Active Comparator|Hearing Aid without NR(0) enabled|Hearing Aid without Noise Reduction (NR 0) enabled serves as reference condition.
11028511|NCT04578457|Experimental|Hearing Aid with NR (1)|Hearing Aid with Noise Reduction I (NR) enabled.
11028512|NCT04578457|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
11028513|NCT04578457|Experimental|Hearing Aid with NR(3)|Hearing Aid with Noise Reduction III (NR) enabled.
11028514|NCT04578431|Experimental|Intervention groups|The participants will be given a beverage containing four artificial sweeteners (intervention) at baseline
11028515|NCT04578418|Active Comparator|Collagen + heavy slow resistance group|Daily collagen supplementation + heavy slow resistance training three times weekly for 12 weeks.
11028516|NCT04578418|Experimental|Placebo + heavy slow resistance group|Daily placebo supplementation + heavy slow resistance training three times weekly for 12 weeks.
11028517|NCT04578405|Active Comparator|Extracorporeal anastomosis|
11028518|NCT04578405|Experimental|Intracorporeal anastomosis|
11028519|NCT04578392|Active Comparator|high ligation of ileocolic artery|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
11028520|NCT04578392|Active Comparator|mesenteric sparing for a primary ileocolic resection|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
11028521|NCT04578366|Experimental|Shockwavetherapy Group/Experimental group|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
11028522|NCT04578366|Active Comparator|Conventional Group|Conventional therapy hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
11028523|NCT04578353|Experimental|AquaPass System|Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
11028524|NCT04578327|Experimental|Aim 1|Data from Specific Aim 1 will be used to test the following hypotheses: H1a. The body-powered prosthetic devices are embodied more than passive and myoelectric prosthetic devices. H1b. Passive cosmetic devices are embodied less than actuated cosmetic devices (agency). H1c. Body-powered terminal devices are embodied less than myoelectric terminal devices (agency).
11028525|NCT04578327|Experimental|Aim 3|Data from Specific Aim 3 will be used to test the following hypotheses: H3a. The maximum number of channels elicits more embodiment than the minimum number. H3b. The sensory feedback from passive spatial locations of the hand increases the embodiment compared to sensory feedback just from the grasping spatial locations.
11028526|NCT04578314|Experimental|Relating module + Treatment as usual|Participants in this arm will receive 16 weekly sessions with Relating Therapy (RT) over 5 months in addition to their treatment as usual.
11028527|NCT04578314|Active Comparator|Treatment as usual|Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include Cognitive Behavior Therapy or psychodynamic interventions.
11028528|NCT04578301||Surgery|Patients with and without liver cirrhosis undergoing surgery.
11028529|NCT04578288|Active Comparator|Standard Blood Pressure management|The standard blood pressure management is maintenance of intraprocedural pre-recanalization SBP between 140-180 mmHg for all patients who receive endovascular thrombectomy for acute ischemic stroke in anterior circulation.
11028530|NCT04578288|Experimental|Individualized Blood Pressure management|The study intervention would be maintaining the intraprocedural pre-recanalization blood pressure in individualized SBP target ranges depending on the systolic blood pressure of the patient at presentation (=baseline SBP or bSBP).
11028531|NCT04578262|Experimental|Epley Manoeuvre|Epley manoeuvre in participants with Multiple Sclerosis who suffer from benign paroxysmal positional vertigo. Only one administration.
11028532|NCT04578262|Sham Comparator|Sham Manoeuvre|The second group will received a sham manoeuvre. However after the experimental intervention ends, this groups will also receive Epley manoeuvre.
11028533|NCT04578249|Placebo Comparator|Clear goggles|Patients recovering from CABG surgery will be given clear goggles to wear at nighttime.
11028534|NCT04578249|Experimental|Blue-light blocking goggles|Patients recovering from CABG surgery will be given blue-light blocking goggles to wear at nighttime.
11028561|NCT04578028|Experimental|ONO-2808 Part A - Fasted|Single ascending dose of ONO-2808 or placebo orally under fasted conditions
11028535|NCT04578236|Experimental|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
11028536|NCT04578236|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
11028537|NCT04578223||Study group|Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i.
11028538|NCT04578223||Control group|Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only.
11028539|NCT04578210|Experimental|Arm A: allogeneic T memory cells|patients will receive memory T cells
11028540|NCT04578210|Experimental|Arm B: allogeneic NK cells|patients will receive NK cells
11028541|NCT04578184|Other|Epithelial thickness map evaluation in keratoconus patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
11028542|NCT04578184|Other|Epithelial thickness map evaluation in healthy cornea patients|Patients included in the study will be measured with the corneal acquisition mode, also allowing for epithelium thickness data, on each device without pupil dilatation Each patient will be measured three times with both devices. The corneal epithelial thickness will be measured as the distance between the air-tear and the epithelium-Bowman interfaces.
11028543|NCT04578171||Study population|Subjects with severe asthma treated with mepolizumab
11028544|NCT04578158|Experimental|Quercetin Phytosome|Patients will be treated (as add on therapy) with 2 tablets, each 500 mg of Quercetin Phytosome plus the standard COVID-19 treatment as per the hospital guidelines.
11028545|NCT04578158|No Intervention|Standard treatment|This arm will receive standard COVID-19 treatment as per the hospital guidelines.
11028546|NCT04578145|Other|Female sex workers (FSW)|Female sex workers (FSWs) community is the only group which has implemented the study intervention. This group has been underlined as the one of key affected populations (KAPs) that hold an increasing number of HIV incidence and prevalence recently in Indonesia even though it is approximately 226,791 FSWs by 2016 and around 5,254,065 clients access their services per year (MoH, 2017). The condition will be worst because the transmission definitely will continue to clients' sexual partner and moreover, their babies if their HIV status has not been known earlier. It means that lowering the transmission of HIV infection for FSWs, it will simultaneously lower its transmission to their sexual partners and furthermore their babies.
11028547|NCT04578132||Genitourinary cancer patients that suffered COVID-19|Patients diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ) that suffered from COVID-19 infection prior to cancer treatment, during treatment, or after treatment.
11028548|NCT04578119|No Intervention|Conventional Intubating Technique|'Conventional technique' means that endotracheal intubation is performed with the videolayngoscope blade lifting up the epiglottis.
11028549|NCT04578119|Experimental|Sliding Intubating Technique|'Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
11028550|NCT04578106|Experimental|Omission of surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
11028551|NCT04578106|No Intervention|Surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
11028552|NCT04578093|Experimental|Intervention|Will receive adjusts curriculum
11028553|NCT04578093|No Intervention|Control|Will receive unadjusted curriculum
11028554|NCT04578080|Experimental|Anodal-tDCS & PT|"Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere.
~Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
11028555|NCT04578080|Experimental|Cathodal-tDCS & PT|"Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the supraorbital area of affected hemisphere, Cathodal on the motor area (M1) of unaffected hemisphere.
~Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
11028556|NCT04578080|Active Comparator|Sham-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area of affected hemisphere, Cathodal on the supraorbital area of affected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity.
11028557|NCT04578067|Experimental|Intervention|culturally tailored intervention package on changes in lifestyle-habits
11028558|NCT04578067|No Intervention|Control|
11028559|NCT04578041|Experimental|Arm 1: TRPMS + Aerobic Physical Activity Program|
11028560|NCT04578041|Active Comparator|Arm 2: TRPMS + Adaptive Cognitive Training|
11028562|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part A- Fasted|Single ascending dose of ONO-2808 or placebo orally under fasted conditions
11028563|NCT04578028|Experimental|ONO-2808 Part A - Fed|Single dose of ONO-2808 or placebo orally under fed conditions
11028564|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part A - Fed|Single dose of ONO-2808 or placebo orally under fed conditions
11028565|NCT04578028|Experimental|ONO-2808 Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
11028566|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
11028567|NCT04578028|Experimental|ONO-2808 Part C|Multiple ascending doses of ONO-2808 or placebo orally
11028568|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part C|Multiple ascending doses of ONO-2808 or placebo orally
11028569|NCT04578028|Experimental|ONO-2808 Part D|Single or multiple doses of ONO-2808 or placebo in Japanese healthy volunteers
11028570|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part D|Single or multiple doses of ONO-2808 or placebo in Japanese healthy volunteers
11028571|NCT04578015|Active Comparator|Metronidazole 500 mg|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
11028572|NCT04578015|Placebo Comparator|Placebo|Participants in this arm will receive placebo
11028573|NCT04577963|Experimental|Part 1|Approximately 6-12 patients will be enrolled to receive fruquintinib in combination with tilelizumab and assessed for DLTs during the 28-day DLT observation period
11028574|NCT04577963|Experimental|Part 2|"Approximately 60 patients with TNBC will be enrolled, up to 30 patients in each cohort. Patients will be enrolled to one of the following two cohorts:
~Cohort A (TNBC, IO-Treated): Patients must have advanced TNBC who have progressed on at least one cytotoxic therapy in the metastatic setting. Patients must have also received prior therapy with an immune checkpoint inhibitor.
~Cohort B (TNBC, IO-Naïve): Patients must have advanced TNBC who have progressed on at least one cytotoxic therapy in the metastatic setting. Patients must not have received prior therapy with an immune checkpoint inhibitor."
11028575|NCT04577950|Experimental|Arm with procedure: identification of lymphatic drainage of the uterus following 3 sites injections|A radiocolloid (Nanocoll® marked with Technetium 99), a fluorochrome (ICG) and a blue dye (Bleu Patenté®) will be injected in submucosal tissue to see the differences in lymphatic drainage between three different injection sites. Indeed, ICG will be injected under the endometrium, whereas Nanocoll® will be injected in the cervix and Bleu Patenté® in the uterine isthmus, at the transition between the cervix and the uterine corpus.
11028576|NCT04577937|Experimental|PSG in LAM patients|Patients affected by LAM underwent whole-night PSG
11028577|NCT04577924||Road traffic injury victims|"All RTI patients presenting to ED within 24 hours of injury is included in the study..
~Individual's not consenting to be part of the study or withdrawing consent later on would be excluded. We also would exclude cases where pre-hospital care provider could not be traced or where reliable data patient could not be collected even after repeated interview."
11028578|NCT04577885|Experimental|experimental group|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
11028579|NCT04577872|Experimental|Supine group (n=22)|The 22 participants with lower muscle strength (under 60 microvolt) comprised the supine group.
11028580|NCT04577872|Experimental|Sitting group (n=19)|The 19 participants with higher muscle strength (over 60 microvolt) formed the sitting group.
11028581|NCT04577872|No Intervention|Control group (n=14)|The control group comprised 7 individuals with lower muscle strength (under 60 microvolt) and 7 with higher muscle strength (over 60 microvolt)
11028582|NCT04577859|Active Comparator|Study group|Those randomized to the study group will receive the esophageal cooling device- the ensoETM probe, during AF ablation treatment, under general anaesthetic. The cooling device is set to 4 degrees covering ablation of the left atrial posterior wall.
11028583|NCT04577859|Active Comparator|Control group|Those randomized to the control group will receive standard of care, which is an esophageal temperature monitoring probe during their AF ablation procedure, under general anaesthetic. The esophageal temperature probe is sited close to the level of ablation (the probe should be at the esophageal level where, opposite this, the ablation catheter is at, in the endocardial aspect of the posterior left atrium).
11028584|NCT04577846|Active Comparator|Intervention Arm|The intervention arm will be administered, either Cefazolin iv every 8 hours while NPO or cefalexin 500 mg q8 hours per oral if tolerating a diet.
11028585|NCT04577846|Placebo Comparator|Control|Controls will be provided with initially IV placebo while NPO and then with a placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
11028586|NCT04577833|Experimental|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
11028587|NCT04577833|Experimental|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
11028588|NCT04577833|Experimental|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
11028589|NCT04577833|Experimental|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
11028590|NCT04577820|Experimental|garetosmab|
11028591|NCT04577807|Experimental|Arm 1: PVSRIPO Only|PVSRIPO (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions given every 3 or 4 weeks
11028781|NCT04576624|Sham Comparator|Social Activities|Social Activities Group will receive twenty-two group sessions
11028592|NCT04577807|Experimental|Arm 2: PVSRIPO and anti-PD-1|PVSRIPO (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions and anti-PD-1 therapy given every 3 or 4 weeks as per the anti-PD-1 approved package insert
11028593|NCT04577794|Experimental|GLPG3970|Participants will receive GLPG3970 solution, orally, once daily for 6 weeks
11028594|NCT04577794|Placebo Comparator|Placebo|Participants will receive placebo solution, orally, once daily for 6 weeks.
11028595|NCT04577781|Experimental|GLPG3970|Participants will receive GLPG3970 solution, orally, once daily for 6 weeks.
11028596|NCT04577781|Placebo Comparator|Placebo|Participants will receive placebo solution, orally, once daily for 6 weeks.
11028597|NCT04577768|Experimental|HD-tDCS 2 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 2 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
11028598|NCT04577768|Experimental|HD-tDCS 1.5 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 1.5 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
11028599|NCT04577768|Sham Comparator|Control|Single session of 20-min of sham HD-tDCS. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
11028600|NCT04577755|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with complete response, partial response, or stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
11028601|NCT04577729|Experimental|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
11028602|NCT04577729|Placebo Comparator|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
11028603|NCT04577716||Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak
11028604|NCT04577716||No Endoleak Group|Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak
11028605|NCT04577716||Pre-EVAR Group|Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care
11028606|NCT04577703|Experimental|CT053PTSA (dose escalation)|"Patients were treated in 5 dose cohorts of 15 mg, 30 mg, 60 mg, 100 mg, and 150 mg QD capsules.
~Patients receive treatment with CT053PTSA once on Cycle 0 Day 1 following a 7-day treatment-free withdrawal period to observe the safety and pharmacokinetic of CT053PTSA.
~After that, Patients receive treatment with CT053PTSA per orally, beginning on Cycle 1 Day 1 for 28 day following a 7-day treatment-free withdrawal period to observe efficacy of CT053PTSA and determine to continue taking medicine or not. Each cycle had 28 days."
11028607|NCT04577690|Experimental|PECS block|A PECS block of 0.25 % bupivacaine with epinephrine 1:200000 (below the toxic dose limit of 3 mg/kg) in divided doses to cover the fascial planes identified in PECS I and PECS II. At the completion of surgery, the wound will be infiltrated with up to 0.2 ml/kg of 0.25 % bupivacaine into the wound.
11028608|NCT04577690|Active Comparator|Infiltration|At the completion of surgery, the EP cardiologist will infiltrate the wound with up to 0.8 ml/kg of 0.25 % bupivacaine with epinephrine 1:200000.
11028609|NCT04577677|Experimental|optimization of control anesthetic condition|
11028610|NCT04577677|Experimental|understanding tDCS effect on motor learning|
11028611|NCT04577677|Experimental|understanding tDCS effects on cortical excitability|
11028612|NCT04577677|Experimental|optimizing peripheral nerve stimulation protocols|
11028613|NCT04577677|Experimental|Effect peripheral nerve stimulation on motor learning|
11028614|NCT04577664|Active Comparator|TT group|
11028615|NCT04577664|Active Comparator|ST group|
11028616|NCT04577651|Experimental|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with a 16-contact Directional Lead
11028617|NCT04577638|Experimental|Nivolumab and accelerated IMRT|
11028618|NCT04577625|Active Comparator|L. reuteri Low Dose|L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.
11028619|NCT04577625|Active Comparator|L. reuteri High Dose|L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.
11028620|NCT04577625|Placebo Comparator|Placebo|The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.
11028621|NCT04577612|Experimental|Group 1|150 mg CBD
11028622|NCT04577612|Experimental|Group 2|300 mg CBD
11028623|NCT04577612|Experimental|Group 3|600 mg CBD
11028624|NCT04577612|Placebo Comparator|Group 4|Placebo MCT oil
11028625|NCT04577599|Other|Single Arm|Mobile Low-dose Computed Tomography (LDCT) Screening
11028626|NCT04577586||Water|Patients who ingested only water as an oral contrast
11028627|NCT04577586||Milk|Patients who ingested milk as an oral contrast
11028628|NCT04577586||Mannitol|Patients who ingested mannitol as an oral contrast
11028629|NCT04577573|Active Comparator|No cognitive feedback|Perform task without cognitive feedback.
11028630|NCT04577573|Active Comparator|Intermediate feedback.|Perform task with intermediate feedback.
11028631|NCT04577573|Experimental|Enhanced feedback|Perform task with virtual reality and/or haptic feedback.
11028632|NCT04577560|Experimental|MII with PB biopsy|Five selected MII will undergo sequential polar biopsy; on day 0 [PB1] (36-42 hours post trigger injection) and if fertilization occurred on day 1 [PB2] (17-20 hours post ICSI). On day 5, 6 or 7, the resulting blastocyst will be biopsied.
11028633|NCT04577560|Experimental|MII with no PB biopsy|MII will not go under polar body biopsy. On day 5, 6 or 7, the resulting blastocyst will be biopsied.
11028634|NCT04577547|Experimental|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
11028635|NCT04577547|Experimental|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
11029029|NCT04574947|Experimental|Topical lidocaine|
11028636|NCT04577547|Experimental|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
11028637|NCT04577547|Experimental|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
11028638|NCT04577547|Experimental|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
11028639|NCT04577547|Experimental|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
11028640|NCT04577547|Experimental|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
11028641|NCT04577547|Experimental|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
11028642|NCT04577534|Experimental|Tocilizumab (TCZ)|Participants will receive one infusion of iv TCZ (according to weight of patient)
11028643|NCT04577534|No Intervention|standard of care (no TCZ)|Participants will receive standard of care
11028644|NCT04577508|Experimental|Functional Remediation|Functional Remediation
11028645|NCT04577508|Other|Control|Treatment as usual
11028646|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
11028647|NCT04577469|Experimental|500 mg sulfadoxine / 25 mg pyrimethamine tablet|500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once.
11028648|NCT04577469|Active Comparator|G-COSPE® tablets|G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once.
11028649|NCT04577443|Active Comparator|Adenosine|
11028650|NCT04577443|Placebo Comparator|Saline|
11028651|NCT04577430|Experimental|Loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 0.5 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the operation finished.
11028652|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the surgery finished.
11028653|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 1 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 1 μg/kg per hour during the operation until 0.5 h before the surgery finished.
11028654|NCT04577430|Placebo Comparator|Normal saline|
11028655|NCT04577417||ADHD|Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date
11028656|NCT04577417||Control|Adolescents, male or female, ages 13-19, with normal health status and development
11028657|NCT04577404|Experimental|MT-1186|Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
11028658|NCT04577391|Experimental|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the use of involved side as maximum as possible. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating). In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook the role of the child's dominant hand.
11028659|NCT04577391|Active Comparator|Bimanual training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
11028660|NCT04577378|Active Comparator|13 cis retinoic acid doses orally|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
11028661|NCT04577378|Sham Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
11028662|NCT04577378|No Intervention|control|No intervention
11028663|NCT04577352|Experimental|Vatiquinone|Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.
11028664|NCT04577352|Placebo Comparator|Placebo|Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.
11028665|NCT04577339||Adult patients with acute abdominal conditions|"All adult patients >=16years of age on all general adult wards (excluding maternity) between 2013 and 2020 with the following inclusion and exclusion criteria:
~Inclusion criteria:
~Must have an acute intestinal condition, based on their ICD-10 codes and OPSC-4 codes
~Must be >= 16 years of age at the time of admission
~Have at least one full set of vital signs recorded on the day of admission
~Have at least one full set of routine blood tests recorded on the day of admission
~Exclusion criteria:
~Maternity admissions during/after pregnancy
~Patients admitted or undergoing abdominal surgery for a second time or more"
11028782|NCT04576624|No Intervention|Passive Control|Control group will receive patient education materials with each assessment
11029030|NCT04574947|Placebo Comparator|Placebo|
11028666|NCT04577326|Experimental|Engineered Autologous T Cells|Following eligibility screening and enrollment, patients will undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMCs), to enable generation of M28z1XXPD1DNR. Following successful M28z1XXPD1DNR CAR T-cell manufacturing, patients will be reevaluated for eligibility. A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m2 will be administered 2-7 days before the infusion. A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. All patients will be monitored in the hospital for a minimum of 48 h following the administration of CAR T cells.
11028667|NCT04577313|Active Comparator|Continuous Counseling|Receives up to 16 weekly behavioral counseling sessions over the phone to achieve optimal medication adherence. Counseling adjusts to patient needs and determines the dose to achieve optimal adherence / HIV suppression, in contrast to the fixed dose condition that does not adjust to patient response.
11028668|NCT04577313|Active Comparator|Fixed Counseling|Receives up to five weekly behavioral counseling sessions over the phone focused on improving HIV medication adherence / viral suppression.
11028669|NCT04577300|Experimental|Dual Implantation|
11028670|NCT04577300|Experimental|Single Implantation|
11028671|NCT04577300|Sham Comparator|Sham Implantation|
11028672|NCT04577287|Experimental|Cathodal-tDCS & PT|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the supraorbital area of affected hemisphere, Cathodal on the motor are (M1) of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
11028673|NCT04577287|Experimental|Anodal-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor are (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
11028674|NCT04577274|Experimental|smoothie with regular formulas (SM)|Participants were given 300 kcal smoothie with regular formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
11028675|NCT04577274|Experimental|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal smoothie with low carbohydrate formulas within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
11028676|NCT04577274|Active Comparator|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal Glucerna within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes.
11028677|NCT04577261||FNS Participants|Participants who will undergo surgery to treat a fractured femoral neck using the FNS (Femoral Neck System)
11028678|NCT04577235|Experimental|Survivors group|Lung ultrasound score and computed tomography score were evaluated in the surviving group
11028679|NCT04577235|Experimental|Non survivors group|Lung ultrasound score and computed tomography score were evaluated in the non surviving group
11028680|NCT04577222|Experimental|Adipose Flap|Covering neurovascular bundle with fat
11028681|NCT04577222|No Intervention|Control|No adipose flap
11028682|NCT04577209|Experimental|Pediatric Patients|Participants undergoing anesthesia-related aerosol generating medical procedures (AGMPs) and pediatric otolaryngologic surgeries will have a local exhaust ventilation system to the exposure seen by the medical providers during the AGMPs and surgeries.
11028683|NCT04577196||Briefing supported by the trauma dashboard|During the entire chain of transmission (from the initial phone call to the end of the briefing to the trauma team) the trauma leader will be provided with a trauma dashboard to synthesize and disseminate the available information about the arriving patient.
11028684|NCT04577196||Briefing without the trauma dashboard|The transmission chain will not be supported by any specific tool.
11028685|NCT04577183|Experimental|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
11028686|NCT04577170||Fabry disease|
11028687|NCT04577170||Healthy|age and sex matched
11028688|NCT04577157|Experimental|Intervention Arm|"The participants in the in the intervention group will receive thrice-weekly reminder modules using WhatsApp intervention in addition to the standard care (as per being practiced routinely in the hospitals). This intervention includes thrice-weekly reminder modules using WhatsApp (written and voice message) services. The intervention will be focused on treatment adherence. The participants in the intervention group will also receive image messages, mobile Graphic-based Reminder (GBR) for medication reminders along with WhatsApp (written and voice message). An Information and Technology (IT) facilitator will be responsible for the overall messaging and preservation of its record in the computer. The schedule of mobile health application (WhatsApp) using a reminder module is as under."
11028689|NCT04577157|No Intervention|Control Arm|Participants in the control group will receive no intervention except in standard care (as per being practiced routinely in the hospitals).
11028690|NCT04577144||Individuals who participated in the RECOVER study|Individuals who enrolled in the Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery (RECOVER) study. Individuals who received at least one injection in a SUBLOCADE Phase III program were eligible to participate in the original study.
11028691|NCT04577131|Experimental|With check-ins|Daily blood pressure monitoring with weekly check-ins
11028692|NCT04577131|No Intervention|Without check-ins|Daily blood pressure monitoring without weekly check-ins
11028693|NCT04577118|Other|iotaSOFT Insertion System|The iotaSOFT Insertion System is a surgical device that aids the surgeon in implanting cochlear electrode arrays by controlling the speed and distance of implant insertion. All subjects enrolled in the trial will have the iotaSOFT Insertion System used during surgery.
11028694|NCT04577105||Suspected, probable, or confirmed COVID-19 case|Patients who come to the emergency room with symptoms compatible with a suspected, probable, or confirmed case of SARS-CoV2 infection, in which a chest computed tomography (CT) scan was requested for suspected COVID-19 pneumonia, will be evaluated. On April 1 and August 28, 2020.
11028695|NCT04577092|Active Comparator|Motor-Cognitive|"In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
~In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed."
11028696|NCT04577092|Active Comparator|Motor-Motor|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips. After warm up period; participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion. In cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
11028697|NCT04577079||IPMF Screened|Patient screened and assessed by intelligent patient flow management system.
11028698|NCT04577066|Experimental|Group 1 (GA2)|Volunteers will be exposed to GA2-infected mosquito bites.
11028699|NCT04577066|Active Comparator|Group 2 (GA1)|Volunteers will be exposed to the GA1-infected mosquito bites.
11028700|NCT04577066|Placebo Comparator|Group 3 (Placebo)|Volunteers will be exposed to uninfected mosquito bites.
11028701|NCT04577053|Experimental|PEMF Therapy|Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
11028702|NCT04577053|No Intervention|Control|Control group will not receive treatment.
11028703|NCT04577040||1|Tadalafil in moderate puts
11028704|NCT04577040||2|Tadalafil in severe puts
11028705|NCT04577040||3|Tadalafil with sildosin in moderate luts
11028706|NCT04577040||4|Tadalafil with sildosin in severe luts
11028707|NCT04577027|Experimental|vitiligo patients|Thirty Patients complaining of generalized non segmental vitiligo will be recruited in this study. They will be chosen from the attendants of the out-patient clinics of Dermatology, Assiut university hospital. six patches will be selected in each patient.
11028708|NCT04577014|Experimental|Phase I: Safety Run-In / Dose Level 0|A safety run-in (dose level 0 in Table 1, below) will be performed and enroll 6 patients with advanced high-grade sarcoma who are treatment naïve. Cycle one will consist of gemcitabine plus docetaxel at the institution's standard dose and schedule: 900 mg/m2 of gemcitabine on days 1 and 8, and 75 mg/m2 of docetaxel on day 8. Intravenous INCMGA00012 at a flat dose of 210 mg will be administered every 3 weeks starting on C2D1 for a total of two cycles (cycles 2 and 3).
11028709|NCT04577014|Experimental|Phase I: Dose De-escalation Level 1|"If ≤ 1 patient out of 6 at dose level 0 has a dose-limiting toxicity during this safety run-in, then the dose de-escalation portion of the protocol will commence.
~Dose Level 1:
~INCMGA00012 (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 900 mg/m2 Docetaxel (Day 8) - 75 mg/m2"
11028710|NCT04577014|Experimental|Phase I: Dose De-escalation Level -1|"Dose Level -1:
~INCMGA00012 (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 750 mg/m2 Docetaxel (Day 8) - 60 mg/m2"
11028711|NCT04577014|Experimental|Phase I: Dose De-escalation Level -2|"Dose Level -2:
~INCMGA00012 (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 675 mg/m2 Docetaxel (Day 8) - 50 mg/m2"
11028712|NCT04577014|Experimental|Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma|"(UPS/MFS)
~After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with INCMGA00012) for cycle 1, with INCMGA00012 added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with INCMGA00012 will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of INCMGA00012 treatment."
11028713|NCT04577014|Experimental|Liposarcoma/LPS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with INCMGA00012) for cycle 1, with INCMGA00012 added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with INCMGA00012 will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of INCMGA00012 treatment.
11028714|NCT04577014|Experimental|Leiomyosarcoma/LMS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with INCMGA00012) for cycle 1, with INCMGA00012 added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with INCMGA00012 will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of INCMGA00012 treatment.
11028715|NCT04577014|Experimental|Vascular Sarcoma|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with INCMGA00012) for cycle 1, with INCMGA00012 added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with INCMGA00012 will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of INCMGA00012 treatment.
11036991|NCT04520256|Experimental|Social Support, Dysregulated Eating, VR|
11028716|NCT04577014|Experimental|Other Soft tissue sarcoma/STS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with INCMGA00012) for cycle 1, with INCMGA00012 added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with INCMGA00012 will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of INCMGA00012 treatment.
11028717|NCT04577001|Experimental|Letrozole Group|Subjects with hepatopulmonary syndrome will get the study drug letrozole
11028718|NCT04577001|Placebo Comparator|Placebo Group|Subjects with hepatopulmonary syndrome will get the study placebo
11028719|NCT04576988|Experimental|Sotatercept plus background PAH theraphy|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy
11028720|NCT04576988|Placebo Comparator|Placebo plus background PAH therapy|Placebo administered (SC) every 21 days plus background PAH therapy
11028721|NCT04576975|Experimental|Ketamine|This group will receive a bolus dose of Ketamine [Ketamine HCL - Sterop, Belgium] (0.3 mg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which Ketamine infusion (500 mg vial diluted over 50 cc infusion syringe, concentration 10 mg/ml) will start with rate of 0.3 mg/kg/hr till 10 Minutes before the end of the surgery
11028722|NCT04576975|Experimental|Dexmedetomidine|This group will receive a bolus dose of Dexmedetomidine [Precedex® -Hospira, USA] (0.5 µcg/kg) by the ideal body weight diluted with 0.9% Normal Saline over 10 minutes by 20 ml syringe infused before induction. After which, the Dexmedetomidine infusion (200 µcg vial diluted over 50 cc infusion syringe, concentration 4 µcg/ml) will start with rate of 0.5 µcg/kg/hr till 10 Minutes before the end of the surgery
11028723|NCT04576975|Placebo Comparator|Normal Saline 0.9%|This group will receive a bolus dose of NS 0.9% over 10 minutes by 20 ml syringe infused before induction. After which, NS 0.9% (50 ml over 50 cc syringe) will be infused.
11028724|NCT04576962||Children aged 14 years or younger|All children in Indiana aged 14 years and younger who received the first dose of HPV vaccine during the 2017 and 2018 calendar years. This is a non-interventional study, with data to be analyzed at the county level only.
11028725|NCT04576949|Placebo Comparator|Placebo + Behavioral Support|one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
11028726|NCT04576949|Experimental|Cytisinicline + Placebo + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
11028727|NCT04576949|Experimental|Cytisinicline + Behavioral Support|one cytisinicline tablet PO TID plus behavioral support for 12 weeks
11028728|NCT04576923|Experimental|Liver Incyte|Patients with known or suspected Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH) will be scanned with Liver Incyte.
11028729|NCT04576910|Experimental|"Group A(Sabin IPV+ bOPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 1 of preliminary study (NCT03147560).
11028730|NCT04576910|Experimental|"Group B(Sabin IPV+ Sabin IPV+ bOPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
11028731|NCT04576910|Experimental|"Group C(Sabin IPV+ Sabin IPV+ bOPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 2 of preliminary study (NCT03147560) after randomization.
11028732|NCT04576910|Experimental|"Group D(Sabin IPV+ Sabin IPV+ Sabin IPV+bOPV)"|Give the 4th doses of polio vaccine with bOPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
11028733|NCT04576910|Experimental|"Group E(Sabin IPV+ Sabin IPV+ Sabin IPV+Sabin IPV)"|Give the 4th doses of polio vaccine with Sabin IPV for participants in the Group 3 of preliminary study (NCT03147560) after randomization.
11028734|NCT04576897|Experimental|Liver Incyte|Patients with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplantation will be scanned with Liver Incyte.
11028735|NCT04576884||Group 1|participants of less than 18 years old
11028736|NCT04576884||Group 2|participants aged from 18 years to 40 year
11028737|NCT04576884||Group 3|participants aged from 41 years to 60 years
11028738|NCT04576884||Group 4|participants over 60 years old
11028739|NCT04576871|Experimental|All Subjects|
11028740|NCT04576858||Cohort 1: Surgical resection + perioperative chemotherapy|
11028741|NCT04576858||Cohort 2: Neoadjuvant chemoradiotherapy followed by surgery|
11028742|NCT04576858||Cohort 3: Definitive chemoradiotherapy|
11028743|NCT04576858||Cohort 4: Chemotherapy with the aim to prolong life expectancy|
11028744|NCT04576858||Cohort 5: Non-chemotherapeutic palliation|E.g. Palliative radiotherapy
11028745|NCT04576845||Study Group|The study will be performed on Caucasian origin children who are among 2 to 6 years of age. The study group will be composed of children (n=31) who had CMA (Ig E-mediated and/or non-Ig E-mediated and/or mixed type) proved with oral food challenge tests in their early childhood (in ages of 0-2). The inclusion criteria to the study group will be to undergo a Cow's milk elimination (CME) diet or took a hypoallergenic formula in 0-2 years of age for at least 3 months or longer due to CMA allergy and improved afterward, and/or to eliminate other nutrients (e.g., eggs, potatoes, wheat flour, soybean, etc.) other than cow's milk between the ages of 0-2 for at least 3 months or longer, and/or to add these nutrients back to their diet in the last 3 months, and/or not receiving hypoallergenic formula for the last 3 months, not to be on the CME diet at present. Thus, no children in the study and control groups will be on a dietary restriction during the study.
11028746|NCT04576832|Experimental|Cohort A (MT group)|Participants will receive 4 weeks of mindfulness training and then followed by 5 months of mindfulness app usage.
11028747|NCT04576832|Active Comparator|Cohort B (Wait-list group)|Participants will begin with 4 weeks of no training interval followed by 4-weeks of mindfulness training and then followed by 4 months of mindfulness app usage.
11028783|NCT04576611|Experimental|face-to-face|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using face-to-face modality guided by a health professional.
11028974|NCT04575363|Experimental|pancreatic adenocarcinoma patient|patient with pancreatic ductal adenocarcinoma
11028748|NCT04576819||Sepsis cohort|"Inclusion criteria
~Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)
~Treatment with an institutional, evidence-based guideline management bundle for sepsis
~Within 24 hrs of sepsis recognition
~Exclusion criteria:
~alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),
~uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),
~advanced directives limiting resuscitative efforts,
~organ transplant recipient on immunosuppressive agents,
~known pregnancy,
~inability to obtain informed consent,
~HIV/AIDS with CD4 count < 200,
~absolute neutrophil count < 500"
11028749|NCT04576806|Active Comparator|Body temperature fluid bolus of crystalloid|Fluid bolus at 38 degrees celsius of 500ml crystalloid over 15 minutes
11028750|NCT04576806|Experimental|Room temperature fluid bolus of crystalloid|Fluid bolus at 22 degrees celsius of 500ml crystalloid over 15 minutes
11028751|NCT04576793|Experimental|Cognitive impairment|"Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties
~Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties
~Amnestic Alzheimer's disease - a typical version of Alzheimer's disease with memory difficulties"
11028752|NCT04576793|Active Comparator|No cognitive impairment|Healthy controls
11028753|NCT04576780||Referred Patients with Large, Complex Colorectal Polyps|Patients referred from outside community care hospitals or ambulatory endoscopy centers to the therapeutic endoscopy group at St. Michaels Hospital via the new integrated management pathway for endoscopic resection of a large or complex colorectal polyp.
11028754|NCT04576767||Experimental group|interventions:general anesthesia drugs:propofol、muscle relaxant、pain relievers(fentanbyl、sufentanil)
11028755|NCT04576767||control group|interventions:intraspinal anesthesia drugs:ropivacaine、pain relievers(fentanbyl、sufentanil)
11028756|NCT04576754|Experimental|WB001|
11028757|NCT04576754|Sham Comparator|Comparison Condition|
11028758|NCT04576741|Experimental|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
11028759|NCT04576741|Experimental|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
11028760|NCT04576728|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
11028761|NCT04576728|Placebo Comparator|Placebo|Human albumin 1%
11028762|NCT04576715|Experimental|TEaM Intervention Group|Dedicated Provider Education plus Information Technology Support. The IT support includes addition of an eMR concussion screening, followed by an alert to the provider, followed by a structured assessment / evaluation template.
11028763|NCT04576715|Active Comparator|Control Group|Standard medical protocol for the management of mTBI in children. This group will not receive interventional Provider Training on the TEaM concussion evaluation examination and utilization of the eMR template.
11028764|NCT04576702|Experimental|Investigational aIIV group|aIIV will be administered as a single dose intramuscularly on Day 1
11028765|NCT04576702|Active Comparator|licensed IIV type 1 group|IIV will be administered as a single dose intramuscularly on Day 1
11028766|NCT04576702|Active Comparator|licensed aIIV group|aIIV will be administered as a single dose intramuscularly on Day 1
11028767|NCT04576702|Active Comparator|licensed IIV type 2 group|IIV will be administered as a single dose intramuscularly on Day 1
11028768|NCT04576689|Experimental|Low dose|One (1) IBE-814 IVT Implant (70 μg Dexamethasone) Route of administration: intravitreal injections
11028769|NCT04576689|Experimental|High dose|Two (2) IBE-814 IVT Implant (140 μg Dexamethasone) Route of administration: intravitreal injections
11028770|NCT04576676||Essential Tremor|"Subjects must be 50 years of age or older.
~Subjects must have been diagnosed with Essential Tremor
~Subjects must live within 3 hours of UTSW
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
11028771|NCT04576676||Parkinson's Disease|"Subjects must be 50 years of age or older.
~Subjects must have been diagnosed with Parkinson's Disease
~Subjects must live within 3 hours of UTSW
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
11028772|NCT04576676||Healthy Individuals|"Healthy individuals living within 3 hours of UTSW
~Subjects must be 50 years of age or older
~You are healthy and have not being diagnosed with any neurological disease
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
11028773|NCT04576676||Essential Tremor and Parkinson's Disease|"Subjects must be 50 years of age or older.
~Subjects must have been diagnosed with Essential Tremor
~Subjects must have been diagnosed with Parkinson's Disease preceded by at least 3 years of enrollment in study
~Subjects must live within 3 hours of UTSW
~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
11028774|NCT04576663|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
11028775|NCT04576663|Experimental|0.3125 μg/kg/min group|A maintenance dose of phenylephrine (0.3125 μg/kg/ min) infusion simultaneous with subarachnoid block
11028776|NCT04576663|Experimental|0.625 μg/kg/min group|A maintenance dose of phenylephrine (0.625 μg/kg/ min) infusion simultaneous with subarachnoid block
11028777|NCT04576663|Experimental|0.9375 μg/kg/min group|A maintenance dose of phenylephrine (0.9375 μg/kg/ min) infusion simultaneous with subarachnoid block
11028778|NCT04576650|Experimental|Summit system|Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
11028779|NCT04576637|Experimental|Neurophysiological monitoring during induction|
11028780|NCT04576624|Experimental|Lifestyle Intervention|Subjects in the Lifestyle Intervention group will, in six months, receive sixteen group sessions and six individualized treatment sessions.
11028975|NCT04575350||Cohort|no intervention.
11028784|NCT04576611|Experimental|self-managed|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using self-managed modality through BackFit App.
11028785|NCT04576598|Experimental|Self-management group to increase physical activity levels|This group will perform a self-management program along 6 months. This program will aim to increase the level of physical activity and adherence to healthier lifestyle habits and will be carried out through several sessions that will incorporate: education, goal setting, identification of barriers, self-control and feedback.
11028786|NCT04576598|Active Comparator|Control group|This group will participate in the initial educational session and will be given a leaflet with recommendations for physical activity to follow throughout the six months.
11028787|NCT04576585|Experimental|Appetite lexicon training group|They will get appetite lexicon training in week three.
11028788|NCT04576585|Active Comparator|taste Lexicon training|They will get taste lexicon training In week three.
11028789|NCT04576559|Experimental|Modified dental visual aids|
11028790|NCT04576559|Active Comparator|Regular dental visual aids|
11028791|NCT04576546|Active Comparator|comparator group|myo-inositol treatment
11028792|NCT04576546|Experimental|study group|D-chiro-inositol treatment
11028793|NCT04576533|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
11028794|NCT04576533|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
11028795|NCT04576520|Experimental|pharmacopuncture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
11028796|NCT04576520|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
11028797|NCT04576507|Experimental|Dose A, followed by Dose B|On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
11028798|NCT04576494|Experimental|5q-SMA type 2 and type 3 adults|5q-SMA type 2 and type 3 adults
11028799|NCT04576481|Active Comparator|Group 1: Text Messaging|Consist of daily text messages on shared reading
11028800|NCT04576481|Experimental|Group 2: Text Messaging + Coaching|Will consist of Group 1 plus personalized coaching.
11028801|NCT04576481|Experimental|Group 3: Text Messaging + Coaching + Lottery|Will consist of Group 2 plus availability of a weekly lottery.
11028802|NCT04576468|Experimental|open flap debridement|envelope full thickness flap reflection, removal of granulation tissue then suturing with simple loop sutures.
11028803|NCT04576468|Experimental|perforated membrane (PM)|envelope full thickness flap reflection, removal of granulation tissue placing resorbable membrane after perforating it over the vertical defect then suturing with simple loop sutures.
11028804|NCT04576468|Experimental|leucocyte platelet rich fibrin (L-PRF)|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF in the defect then suturing with simple loop sutures.
11028805|NCT04576468|Experimental|L-PRF + PM|envelope full thickness flap reflection, removal of granulation tissue after withdrawal of blood and placing it in intraspin centrifuge , placing the resulting L-PRF covered by resorbable membrane after perforating it in the defect then suturing with simple loop sutures.
11028806|NCT04576455|Experimental|GDC-9545|
11028807|NCT04576455|Active Comparator|Physician's Choice of Endocrine Monotherapy|The physician's choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.
11028808|NCT04576442|Experimental|Asthma-PASS Intervention|Collaboration with PCPs to optimize management. Community Health Worker (CHW) to ensure PCP plan is followed. Two asthma education sessions with children/caregivers focusing on self-efficacy and physical activity promotion. Promotion of asthma awareness in school. School personnel training in asthma
11028809|NCT04576442|Active Comparator|Asthma Management Comparison Group|Includes two sessions of basic asthma education and PCP notification of child's asthma severity level.
11028810|NCT04576429|Experimental|experimental group|
11028811|NCT04576429|Active Comparator|comparator group|
11028812|NCT04576416|Experimental|Intervention|During the three months the intervention group will receive access to the AI augmented digital educational platform and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
11028813|NCT04576416|No Intervention|Control|The control group continues its standard clinical practice without access to the E-app, but does register skin lesions throughout the full 3 month period.
11028814|NCT04576403|Active Comparator|Intervention group|Activated mittens
11028815|NCT04576403|Sham Comparator|Control group|Deactivated mittens
11028816|NCT04576390|Active Comparator|Group O|On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
11028817|NCT04576390|Active Comparator|Group P|On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care & will label the syringes as antiemetic.
11028818|NCT04576377|Experimental|Influenza vaccination|
11028819|NCT04576377|Placebo Comparator|Placebo|
11028820|NCT04576364|Active Comparator|12-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 12-hour postpartum Mgso4
11028821|NCT04576364|Active Comparator|24-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 24-hour postpartum Mgso4
11028822|NCT04576351||1|"Sub cohort 1:
~Participants in the WHO NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS CoV-2 infected patients.
~Eligibility: consenting adults (age ≥18) hospitalized with definite COVID-19 included in the WHO COVID-19 Study. Participants invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected."
11028932|NCT04575623||Control group|It will consist of 80 healthy age matched Persons with no previous or recent history of headache.
11028823|NCT04576351||2|"Sub cohort 2:
~Patients with COVID-19 and neurological symptoms related to COVID-19 admitted to the Norwegian Departments of Neurology or other relevant Departments (both hospitalized and outpatient visits) and persons with neurological symptoms participating in other COVID-19 studies and not already participating in the WHO NOR Solidarity multicenter trial."
11028824|NCT04576338||College Students|The cohort consists of Black and White college students at a university in a southeastern state in America.
11028825|NCT04576325|Experimental|Voriconazole Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 10 mg of Voriconazole Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
11028826|NCT04576325|Placebo Comparator|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
11028827|NCT04576312|Experimental|Cohort 1|IP Single and Total Dose* (Inhalation): 4 mL0.1% / 3.4 mg Duration of Treatment: 1 day
11028828|NCT04576312|Experimental|Cohort 2|IP Single and Total Dose* (Inhalation): 1 mL1% /8.4 mg Duration of Treatment: 1 day
11028829|NCT04576312|Experimental|Cohort 3|IP Single and Total Dose* (Inhalation): 3 mL1%/25.2 mg Duration of Treatment: 1 day
11028830|NCT04576312|Experimental|Cohort 4|IP Single and Total Dose* (Inhalation): 6 mL 1% /50.5 mg Duration of Treatment: 1 day
11028831|NCT04576312|Experimental|Cohort 5|IP Single and Total Dose* (Inhalation): 6 mL1% /50.5mg 30 mL/252mg Duration of Treatment: 2.5 days
11028832|NCT04576299||Healthcare workers.|"Survey developed specifically for the objective of this study: Healthcare worker perception of patient safety in times of pandemic.
~The application will be done through a digital questionnaire in the surveymonkey platform (Link of the instrument: https://es.surveymonkey.com/r/COVIDSP)"
11028833|NCT04576286|Experimental|Holmium en bloc resection|Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency
11028834|NCT04576286|Active Comparator|bipolar en bloc resection|bipolar en bloc tumor resection of urinary bladder tumors
11028835|NCT04576273||Non-parasitic|
11028836|NCT04576273||Parasitic|
11028837|NCT04576260|Experimental|CBT-I Group|Participants in the CBT-I group will undertake weekly sessions for a duration of 8 weeks with a trained psychologist through Zoom or Skype Calls.
11028838|NCT04576260|No Intervention|Control group|The control group will be asked to maintain the usual lifestyle for the duration of the study
11028839|NCT04576247|Experimental|Combined aerobic and resistance exercise|12 weeks of supervised resistance exercise and unsupervised aerobic exercise.
11028840|NCT04576234|Experimental|intermittent entral feeding group|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest) by using syringe pump and Feeds were administered according to guidelines as the head of the patient's bed was elevated at least 30 degrees from the horizontal before initiating feeding, the feeding schedule was started at a rate of 50 ml/hr in adults to promote tolerance,the administration rate of isotonic formulas increased in 20-25 ml/hr increments every eight hours until the desired rate was achieved, the tube was flushed regularly with 20 to 30 ml of warm water every four hours during continuous feeding and before and after intermittent feeding and medication administration, the gastric residual volume was checked every 4-6 hr routinely
11028841|NCT04576234|Experimental|, feeding bag group|Feeding bag group received hospital blended formual which was 300 ml of feeds every 2hrs with 4hrs rest at night and given in 10 minutes with following the same guidelines in the intermittent enteral feeding group
11028842|NCT04576221|Experimental|stacked breathing group|experimental group received staked breathing exercise for 7 days , 3 sessions per day, 7-8 times per session
11028843|NCT04576221|Experimental|CPAP group|experimental group received NIV with CPAP mask
11028844|NCT04576208|Experimental|Cohort 1|TAK-788 160 mg, capsules, orally, once daily (QD) with or without a low-fat meal until disease progression or as assessed by the investigator during every 3-week cycle.
11028845|NCT04576208|Experimental|Cohort 2|TAK-788 160 mg, capsules, orally, QD with or without a low-fat meal and antidiarrheal prophylaxis administered during the first 8 weeks of treatment until disease progression or as assessed by the investigator during every 3-week cycle.
11028846|NCT04576195|Experimental|Real PENS|One single session of PENS
11028847|NCT04576195|Sham Comparator|Sham PENS|One single session of Sham-PENS
11028848|NCT04576182|Experimental|Supportive-Expressive|Participants will receive supportive-expressive treatment for 16 weeks.
11028849|NCT04576182|Experimental|Emotion-Focused|Participants will receive Emotion-Focused treatment for 16 weeks.
11028850|NCT04576169|Experimental|Central or Radial Tear: Arthroscopic debridement|Arthroscopic debridement
11028851|NCT04576169|Placebo Comparator|Central or Radial Tear: Sham surgery|Diagnostic arthroscopy only (placebo surgery).
11028852|NCT04576169|Experimental|Ulnar Tear: Arthroscopic or open repair|Arthroscopic or open repair
11028853|NCT04576169|Active Comparator|Ulnar Tear: Physiotherapy|Diagnostic arthroscopy and physiotherapy
11028854|NCT04576156|Experimental|Imetelstat|Participants will receive imetelstat at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
11028855|NCT04576156|Active Comparator|Best Available Therapy (BAT)|Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
11028856|NCT04576143|Active Comparator|epirubicin/CTX × 4 - docetaxel × 4, every 3 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 21 days); Cycle 5-8: Docetaxel i.v. 100mg/m2 (One cycle = 21 days) .
11028857|NCT04576143|Experimental|epirubicin/CTX × 4 - paclitaxel × 4, every 2 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 14 days); Cycle 5-8:Paclitaxel i.v. 175mg/m2 (One cycle = 14 days) .
11028858|NCT04576130|Experimental|ICD-implantation|Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
11028859|NCT04576130|No Intervention|Standard care|Guideline directed medical therapy
11036992|NCT04520256|Experimental|Exercise, VR|
11028860|NCT04576117|Experimental|Arm I (selumetinib, vinblastine)|Patients receive vinblastine sulfate IV over 1 minute or IV infusion on days 1, 8, 15, and 22 of cycles 1-17, and selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity.
11028861|NCT04576117|Active Comparator|Arm II (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity.
11028862|NCT04576104|Active Comparator|Arm I (megestrol acetate)|Prior to standard of care surgery, patients receive megestrol acetate PO BID for 4 weeks in the absence of disease progression or unacceptable toxicity.
11028863|NCT04576104|Experimental|Arm II (megestrol acetate, metformin hydrochloride)|Prior to standard of care surgery, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 4 weeks in the absence of disease progression or unacceptable toxicity.
11028864|NCT04576091|Experimental|Treatment (pembrolizumab, BAY1895344, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Starting on day 7, patients also receive BAY1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment for a total of 9 doses during cycle 2. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
11028865|NCT04576078|Experimental|NEFOPAM 60mg PO/ 8 hours|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h.
11028866|NCT04576078|Placebo Comparator|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h.
11028867|NCT04576065|No Intervention|Usual Care|Patients randomized to usual care will follow-up with primary care providers and specialists as recommended by hospital providers, or seek medical care as needed after hospital discharge.
11028868|NCT04576065|Experimental|Intervention|Patients randomized to intervention will have 6 months of access after hospital discharge for telehealth visits with a nurse practitioner and an activity tracker providing data to the nurse practitioner about subject's daily level of activity.
11028869|NCT04576052||antibiotic-coating|patients who have been treated with an antibiotic-coated nail for tibia-fracture
11028870|NCT04576052||non-coated|patients who have been treated with a non-coated nail for tibia fracture
11028871|NCT04576039|Experimental|presenting with thickened endometruim|women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.
11028872|NCT04576026|Experimental|Ketone esters|Ketone esters will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
11028873|NCT04576026|Active Comparator|Placebo|Iso-caloric carbohydrate drink will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
11028874|NCT04576013|Experimental|Active PNS during training|Individuals in this group will receive active PNS while participating in 2 hours of motor training of the affected arm.
11028875|NCT04576013|Active Comparator|Active PNS before training|Individuals in this group will receive 2 hours of active PNS before participating in 2 hours of motor training of the affected arm.
11028876|NCT04576013|Sham Comparator|Sham PNS during training|Individuals in this group will receive 2 hours of sham PNS while participating in 2 hours of motor training of the affected arm.
11028877|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed tofacitinib as part of their routine medical care.
11028878|NCT04575974||Adolescents 13-19 years|All adolescents between 13-19 years of age in North Trøndelag county were invited to participate in HUNT 3 and followed up after 11 years.
11028879|NCT04575961|Other|Pembrolizumab + Chemotherapie|pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin or carboplatin monotherapy)
11028880|NCT04575948|Experimental|Moringa Oleifera mouth wash|According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
11028881|NCT04575948|Placebo Comparator|Base formula of mouth wash|Base formula of mouthwash
11028882|NCT04575948|Active Comparator|Chlorhexidine|Commercial 0.12% chlorhexidine digluconate mouthwash
11028883|NCT04575935|Experimental|Arm A (MIS, standard of care chemotherapy)|Patients undergo MIS within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. If during MIS the surgeon thinks complete gross resection can only be accomplished by performing an open procedure, patients may undergo laparotomy instead. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
11028884|NCT04575935|Active Comparator|Arm B (laparotomy, standard of care chemotherapy)|Patients undergo laparotomy within 6 weeks after last cycle of standard of care neoadjuvant chemotherapy. Within 6 weeks after surgery, patients receive standard of care chemotherapy.
11028885|NCT04575922|Experimental|Nivolumab+Ipilimumab+Radiation Therapy (RT)|"Study cycles are 6 weeks long, participants will receive:
~Cycle 1: Nivolumab every 2 weeks during cycle, Ipilimumab 1x on Day 1 of cycle, and Radiation Therapy every other weekday or 2 days for a total of 3 treatments during week 1 of Cycle 1 only.
~Cycles 2-4: Nivolumab every 2 weeks during each cycle, Ipilimumab 1x on Day 1 of each cycle
~Cycles 5-Disease Progression: Nivolumab every 2 weeks during each cycle"
11028886|NCT04575909|Experimental|Recognition, Production Implicit-Explicit|Treatment will begin with 6 visits of emotional prosody recognition treatment followed by 6 visits of emotional prosody production treatment (1-3 implicit, 4-6 explicit).
11028887|NCT04575909|Experimental|Recognition, Production Explicit-Implicit|Treatment will begin with 6 visits of emotional prosody recognition treatment followed by 6 visits of emotional prosody production treatment (1-3 explicit, 4-6 implicit).
11028888|NCT04575909|Experimental|Production Implicit-Explicit, Recognition|Treatment will begin with 6 visits of emotional prosody production treatment (1-3 implicit, 4-6 explicit) followed by 6 visits of emotional prosody recognition treatment.
11028889|NCT04575909|Experimental|Production Explicit-Implicit, Recognition|Treatment will begin with 6 visits of emotional prosody production treatment (1-3 explicit, 4-6 implicit) followed by 6 visits of emotional prosody recognition treatment.
11028973|NCT04575402||Veterans with prostate cancer|Prostate cancer patients recruited from the Veteran Affairs Oncology Clinic (Durham, NC).
11028890|NCT04575896|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive glecaprevir/pibrentasvir 300 mg/120 mg once daily by mouth for 2 weeks
11028891|NCT04575883|Experimental|MedBIKE HIIT|MedBIKE HIIT Exercise Program
11028892|NCT04575870||Treatment Group 1: 90 min waiting period|Participants undergo their planned tracheobronchoscopy + 90 minute waiting period prior to modified functional endoscopic swallowing exam
11028893|NCT04575870||Treatment Group 2: 66 min waiting period|Participants undergo their planned tracheobronchoscopy + 66 minute waiting period prior to modified functional endoscopic swallowing exam
11028894|NCT04575870||Treatment Group 3: 46 min waiting period|Participants undergo their planned tracheobronchoscopy + 46 minute waiting period prior to modified functional endoscopic swallowing exam
11028895|NCT04575870||Treatment Group 4: 28 min waiting period|Participants undergo their planned tracheobronchoscopy + 28 minute waiting period prior to modified functional endoscopic swallowing exam
11028896|NCT04575870||Treatment Group 5: 13 min waiting period|Participants undergo their planned tracheobronchoscopy + 13 minute waiting period prior to modified functional endoscopic swallowing exam
11028897|NCT04575857||Statin arm|To receive pill packet with atorvastatin (40mg/day) which will be taken nightly.
11028898|NCT04575857||Placebo arm|To receive pill packet with placebo which will be taken nightly
11028899|NCT04575844|No Intervention|Control|24 weeks of observation
11028900|NCT04575844|Experimental|Exercise Alone|24 weeks of treatment
11028901|NCT04575844|Experimental|Liraglutide Alone|24 weeks of treatment
11028902|NCT04575844|Experimental|Exercise + Liraglutide|24 weeks f treatment
11028903|NCT04575831|Experimental|Intervention|The intervention arm will receive a 12-week multimodal intervention featuring exercise, nutrition, and palliative symptom management.
11028904|NCT04575818|Experimental|GLPG4059 SAD|Single doses of GLPG4059 at up to 6 dose levels in ascending order
11028905|NCT04575818|Placebo Comparator|Placebo SAD|Single doses of placebo
11028906|NCT04575818|Experimental|GLPG4059 FE fasted|Single dose of GLPG4059 in fasted state
11028907|NCT04575818|Experimental|GLPG4059 FE fed|Single dose of GLPG4059 in fed state
11028908|NCT04575805|Experimental|Internet-delivered Combined Cognitive Bias Modification|CBM Version 1 is the combination of internet-delivered Cognitive Bias Modification-Interpretation and internet-delivered Cognitive Bias Modification-Attention interventions taking place over 4 weeks (eight sessions, twice per week).
11028909|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Interpretation|CBM Version 2 is an internet-delivered Cognitive Bias Modification-Interpretation intervention taking place over 4 weeks (eight sessions, twice per week).
11028910|NCT04575805|Experimental|Internet-delivered Cognitive Bias Modification-Attention|CBM Version 3 is an internet-delivered Cognitive Bias Modification-Attention intervention taking place over 4 weeks (eight sessions, twice per week).
11028911|NCT04575805|No Intervention|Wait-List Control|This arm is wait-list control group which will also receive internet-delivered Combined Cognitive Bias Modification intervention after the follow-up assessment
11028912|NCT04575792||C group|C group: control group, children who do not practice oral habits.
11028913|NCT04575792||E group|E group: exposed group, children who practicing oral habits.
11028914|NCT04575779||Group A|Cyclosporin of a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
11028915|NCT04575779||Group B|Administer cyclosporin daily dose of 3 mg/kg/day in a continuous infusion over 23 h every 24 h.
11028916|NCT04575766|Experimental|Dose escalation study of FT-7051|
11028917|NCT04575740|Experimental|Positive Airway Pressure Device|All participants will receive PAP therapy
11028918|NCT04575727|Experimental|Health Volunteers|In the first stage, five healthy human subjects will receive a microdose (10 µg) of [11C]MPC6827, immediately followed by whole body PET/CT to determine dosimetry and perform an initial safety evaluation of the radiotracer. A dose of 20 mCi [11C]MPC6827 will be administered and serial whole body PET scans will be acquired up to 2 hours post injection.
11028919|NCT04575727|Experimental|Patients with Neurodegenerative Disorders|Up to 30 patients with neurodegenerative disorders will receive a microdose (10 µg) of [11C]MPC6827 and be imaged dynamically for up to 90 minutes using PET/CT for research purposes.
11028920|NCT04575714||Acute low back pain|Adult patients with acute low back pain
11028921|NCT04575701||Ulcerative Colitis (UC)|This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
11028922|NCT04575701||Crohn's disease (CD)|This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
11028923|NCT04575701||IBD unclassified|This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
11028924|NCT04575688|Active Comparator|Periarticular Injection|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a periarticular injection by the surgeon using 10 milliliters of Exparel mixed with 10 milliliters of bupivicaine 0.5 percent at the end of the procedure.
11028925|NCT04575688|Active Comparator|Popliteal Block|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a popliteal block by the anesthesiologist using 30 milliliters of bupivicaine 0.5 percent in the pre-operative area, prior to surgery, using an ultrasound machine for guidance.
11028926|NCT04575675|Experimental|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
11028927|NCT04575675|Placebo Comparator|Standard of care|Standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
11028928|NCT04575662|Experimental|STAR Treatment|Patients performing STAR treatment
11028929|NCT04575636|Other|Lymphedema patients|MRL examination in lymphedema patients
11028930|NCT04575636|Other|Healthy volunteers|MRL examination in healthy volunteers
11028931|NCT04575623||Study group|It will consist of 100 patients suffering from migraine according to international classification of headache
11028976|NCT04575337||AD group|Dementia is diagnosed according to the 2011 NIA-AA criteria.
11028933|NCT04575610|Experimental|PF-06650833 + Standard of Care|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric [NG] tube, orogastric [OG] tube, or equivalent) if unable to take tablets by mouth (PO). All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
11028934|NCT04575610|Active Comparator|Placebo + Standard of Care|Matching placebo tablets will be administered.
11028935|NCT04575597|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028936|NCT04575597|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028937|NCT04575597|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028938|NCT04575597|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028939|NCT04575597|Experimental|Part 2: Molnupiravir|Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
11028940|NCT04575597|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028941|NCT04575584|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028942|NCT04575584|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028943|NCT04575584|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028944|NCT04575584|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028945|NCT04575584|Experimental|Part 2: Molnupiravir|Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
11028946|NCT04575584|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
11028947|NCT04575558|Experimental|Hydroxychloroquine + Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD, both for 7 days
11028948|NCT04575558|Placebo Comparator|Hydroxychloroquine + Placebo tablets|Hydroxychloroquine 400mg PO BID 2 times a day + Placebo, both for 7 days
11028949|NCT04575545||HIV positive patients|
11028950|NCT04575545||Patients taking PrEP|
11028951|NCT04575519|Active Comparator|Control group|Standard of Care (SoC) TB treatment + placebo twice daily during first 4 weeks of TB treatment followed by placebo once daily for an additional 4 weeks.
11028952|NCT04575519|Experimental|SoC TB + ASA group|Standard of Care (SoC) TB treatment + acetylsalicylic acid 300mg twice daily during first 4 weeks of TB treatment followed by aspirin 300mg once daily for an additional 4 weeks.
11028953|NCT04575519|Experimental|SoC TB + IBU group|Standard of Care (SoC) TB treatment + ibuprofen 400mg twice daily during first 4 weeks of TB treatment followed by ibuprofen 400mg once daily for an additional 4 weeks
11028954|NCT04575506|No Intervention|Control group|
11028955|NCT04575506|Active Comparator|Obesity-Non-hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
11028956|NCT04575506|Experimental|Obesity-Hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
11028957|NCT04575493|Experimental|Test Group|No of enrolled Pts. 102 Drug Cap. Crano-cure 500mg. Quantity 500 mg Bd Usage 1 cap Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
11028958|NCT04575493|Active Comparator|control group|No of enrolled Pts. 103 Drug Tab. Ciprofloxacin 500mg Quantity 500mg Bd Usage 1 Tab Bd Duration of study 14 days Follow up 1st follow up after 2 weeks 2nd follow up after 4 weeks
11028959|NCT04575480|Active Comparator|Group 1|Group 1 will undergo SWL with 3 days between each session.
11028960|NCT04575480|Active Comparator|Group 2|Group 2 will undergo SWL with 7 days between each session
11028961|NCT04575480|Active Comparator|Group 3|Group 3 will undergo SWL with 14 days between each session.
11028962|NCT04575467|Experimental|CBL-514 480 mg|
11028963|NCT04575467|Experimental|CBL-514 640 mg|
11028964|NCT04575467|Experimental|CBL-514 800 mg|
11028965|NCT04575454|Other|Comatose or post-comatose patients|
11028966|NCT04575441|Experimental|Pilates Ball Exercises|Various exercises are conducted with using pilates ball. Sensory feedbacks like proprioception and vestibulation are given. Many physical fitness parameters like balance, coordination, speed and agility are used in this exercise program. Children are taken to the program for 40 min, twice a week during 6 weeks.
11028967|NCT04575441|No Intervention|Without exercise|The children in this group are not included in any kind of exercise/sport program during 6 weeks.
11028968|NCT04575428|Experimental|Splanchnic nerve block|
11028969|NCT04575415||Arm 1:Bevacizumab plus Erlotinib/Gefitinib/Icotinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus first-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Erlotinib 150 mg tablets once daily or Gefitinib 250mg once daily or Icotinib 125mg three times a day would be administered.
11028970|NCT04575415||Arm 2:Bevacizumab plus Afatinib/Dacomitinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus second-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks.Afatinib 40 mg or clinical routine dose once daily or Dacomitinib 45mg or clinical routine dose once daily or clinical routine dose would be administered.
11028971|NCT04575415||Arm 3:Bevacizumab plus Osimertinib|Patients with EGFR-mutant NSCLC would receive bevacizumab plus third-generation EGFR-TKIs in clinical routine care. Bevacizumab 15 mg/kg or clinical routine dose would be intravenous infusion on day 1 once every 3 weeks. Osimertinib 80 mg tablets once daily would be administered.
11028972|NCT04575402||CSMC prostate cancer patients receiving ADT|Prostate cancer patients recruited from oncology clinic at Cedars-Sinai Medical Center.
11036993|NCT04520256|Experimental|Social Support, Exercise, VR|
11028978|NCT04575337||pre-MCI group|β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment; not up to MCI or cognitive impairment.
11028979|NCT04575337||Other neurodegenerative diseases|Frontotemporal Dementia; or Parkinson's disease
11028980|NCT04575337||Cognitive normal group|Individuals are with normal cognitive function and ≥ 60 years old.
11028981|NCT04575324|Experimental|Intervention Arm|Participants will receive the telemedicine linkage intervention.
11028982|NCT04575324|No Intervention|Control Arm|Participants will receive a standard referral to an in-person MOUD treatment appointment, which typically occurs within 24-72 hours. They also receive a bus pass to cover transportation (both directions), as well as an appointment reminder card.
11028983|NCT04575311|Active Comparator|Active: Dose Escalation|Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 or matching placebo will be random.
11028984|NCT04575311|Placebo Comparator|Placebo: Dose Escalation|Participants will receive matching placebo as a single oral dose. Assignment to receive AB680 or matching placebo will be random.
11028985|NCT04575285|Experimental|Electroencephalogram (EEG)|All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.
11028986|NCT04575272|Experimental|Continuous Deep Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately deep to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
11028987|NCT04575272|Active Comparator|Continuous Superficial Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately superficial to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
11028988|NCT04575259|Experimental|ANAVEX2-73 Active|Oral capsules
11028989|NCT04575233|Experimental|Laparoscopic Transversus Abdominis Plane (L-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under laparoscopic control
11028990|NCT04575233|Active Comparator|Ultrasound Transversus Abdominis Plane (U-TAP) group|Patients will undergo the planned laparoscopic colectomy according to the standard of treatment. A solution of 15 ml of Ropivacaine (0.2%) is then injected for postoperative pain under ultrasound control
11028991|NCT04575220|Experimental|tele-exercise|Subjects will perform three sessions/week of home exercise using bicycles for 12 weeks
11028992|NCT04575207|Experimental|caFFR-guided|Participants who are randomly assigned to caFFR-guided group will receive the detection of Coronary Angiography-Derived Fractional Flow Reserve (caFFR) Measurement System. The online caFFR value is used to guide the PCI strategy. If caFFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when caFFR > 0.80.
11028993|NCT04575207|Active Comparator|FFR-guided|Participants who are randomly assigned to FFR-guided group will receive the detection of pressure wire. The FFR value is used to guide the PCI strategy. If FFR ≤ 0.80, PCI treatment will be performed in lesions and optimal medicine treatment will be performed when FFR > 0.80.
11028994|NCT04575194|Active Comparator|Liraglutide 3 mg|Patients will be prescribed sc liraglutide 3 mg/day along with a dietary and physical activity intervention.
11028995|NCT04575194|Active Comparator|Naltrexone/bupropion 32/360 mg|Patients will be prescribed oral naltrexone/bupropion 32/360 mg/day along with a dietary and physical activity intervention.
11028996|NCT04575181|Experimental|NNC0286-0965|NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial
11028997|NCT04575181|Active Comparator|Insulin glargine|Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial
11028998|NCT04575168||Positive for COVID-19|Subjects positive for COVID-19 as indicated by the Standard of Care test.
11028999|NCT04575168||Negative for COVID-19|Subjects negative for COVID-19 as indicated by the Standard of Care test.
11029000|NCT04575155|Experimental|TEAM Strategy|Patients randomized to the TEAM intervention arm will receive at least one call from a Walgreens pharmacist to help them with their complex Rx regimens. Pharmacists will have read/write EHR access with established Epic security points. Through shared access to patients' medical records, pharmacists can perform comprehensive medication therapy management services, document and communicate patients' Rx challenges for review and action by primary care providers. After the pharmacist calls the patient for a Comprehensive Medication Review, they will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit.
11029001|NCT04575155|No Intervention|Enhanced Usual Care|Patients randomized to enhanced usual care will have the medical record available to a Walgreens pharmacist with 'read only' access. All patients at the five targeted health centers already have read-only access in place. This means the Walgreens pharmacist will have the capability to review a patient's record as necessary. The pharmacist may refer to the EHR as needed and in a reactive manner; such as if a patient were to request a medication requiring review for billing purposes (i.e. verify insurance, prior authorizations), or if a patient safety concern was raised (e.g. potential drug-drug or drug- disease interaction, therapeutic duplication, etc.). Similarly, read only EHR access means pharmacists must continue to use existing communication channels (e.g. phone, fax) to contact prescribers.
11029031|NCT04574934|Experimental|the study group|study group received the traditional physical therapy program plus aquatic therapy
11029032|NCT04574934|No Intervention|the control group|control group received traditional physical therapy program only.
11029645|NCT04570735||patients with type 2 diabetes and diabetic kidney disease|
11029002|NCT04575142|Experimental|CO2 laser device group|Participants who will be undergoing laser treatment for their vocal nodes with a specific laser device. AcuPulse Duo, a CO2 laser is absorbed by water found in soft tissues and is independent of tissue color. It is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. The absence of a long healing process means that most patients can resume their normal activities even on the same day The CO2 laser is the preferred laser for use in the operating room.
11029003|NCT04575129||Study Group|No intervention will be applied
11029004|NCT04575116|Experimental|Tafamidis Free acid tablet then tafamidis meglumine capsule|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
11029005|NCT04575116|Experimental|Tafamidis meglumine capsule then Tafamidis Free acid tablet|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
11029006|NCT04575103|Active Comparator|Antipsychotics|Patients treated with antipsychotics as provided by their psychiatrist in order to treat disease best possible and in accordance with guidelines.
11029007|NCT04575103|No Intervention|Control|Healthy controls, not treated with antipsychotics.
11029008|NCT04575090||Sub-Study 1|Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
11029009|NCT04575090||Sub-Study 2|"Subjects will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1.
~Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
~Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored"
11029010|NCT04575064|Other|Standard of Care (SoC)|This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
11029011|NCT04575064|Experimental|Remdesivir + SoC|Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
11029012|NCT04575051|Active Comparator|Residents|Residents will be exposed to the Consult Model and then the Engage Model. Hearing Specific Quality of Life and Satisfaction with Social Participation are the outcome measures. Hearing Specific Quality of Life is measured using the HHIE with a range of scores from 0-40 with a lower score revealing less handicap. Satisfaction with Social Participation is measured using the Satisfaction with Participation in Discretionary Social Activities Short form 7a with a range of scores from 7-35 with a higher score meaning higher satisfaction.
11029013|NCT04575051|Active Comparator|Family|Families will be surveyed related to burden during the Consult and Engage Model of Care. Family Burden will be measured using the Zarit Burden scale with a range of scores from 0-16 and a lower scoring revealing less burden.
11029014|NCT04575051|Active Comparator|Staff|Staff of the Assisted Living/Personal Care Facilities will be surveyed related to work satisfaction during the Consult and Engage Model of Care. Staff work satisfaction will be measured with the Michigan Organizational Assessment Questionnaire (MOAQ) with a range of scores from 3-18 and a lower score revealing higher satisfaction.
11029015|NCT04575038|Experimental|Brequinar 100 mg|Brequinar oral capsules 100 mg x 5 days
11029016|NCT04575038|Placebo Comparator|Placebo|Placebo for Brequinar capsules x 5 days
11029017|NCT04575025||Tabrecta tablets|Patients administered Tabrecta by prescription
11029018|NCT04575012|Experimental|Deferred invasive strategy|
11029019|NCT04575012|Other|Early invasive strategy|
11029020|NCT04574999|Experimental|0.005% Estriol group|0.005% Estriol (50 μg/g) gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
11029021|NCT04574999|Placebo Comparator|Placebo group|Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
11029022|NCT04574973|Experimental|Anodal tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
11029023|NCT04574973|Experimental|Cathodal tDCS|Subjects will receive 20 minutes of active, excitatoryinhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
11029024|NCT04574973|Experimental|Dual tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere and inhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
11029025|NCT04574973|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the affected upper extremity.
11029026|NCT04574960|Experimental|Neoadjuvant Chemotherapy Arm|Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).
11029027|NCT04574960|Active Comparator|Adjuvant Chemotherapy Arm (Standard of Care)|"Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy.
~Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin.
~Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles.
~Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles."
11029033|NCT04574921|Experimental|Active|Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
11029034|NCT04574921|Sham Comparator|Sham|Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
11029035|NCT04574908|Active Comparator|Blinded Ward 1|Continuous ward monitoring with hallway monitor screens covered. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.
11029036|NCT04574908|Experimental|Unblinded Ward 2|Continuous ward monitoring with hallway monitor screens accessible for viewing but with alarm limits more narrow. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will be able to view the hallway monitors showing the vital signs in all of the rooms and/or log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.
11029037|NCT04574908|Active Comparator|Blinded Ward 2|Continuous monitoring accessible to clinicians with pre-specified alerts at Systolic Blood Pressure alert <70, no Mean Arterial Pressure alert, heart rate >150 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <80%. Every 4 hourly checks by nursing teams unless otherwise ordered. These alarms are consistent with current standard of care.
11029038|NCT04574908|Experimental|Unblinded Ward 1|Continuous monitoring accessible to clinicians with pre-specified alerts at Mean Arterial Pressure (MAP) <65 mmHg, heart rate >110 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <90%. Every 4 hourly checks by nursing teams unless otherwise ordered.
11029039|NCT04574895|Other|VTE risk prediction scores|Patients in the intervention arm will have their VTE risk prediction scores presented to the study team daily on weekdays via an automated report, which will list patients in descending order of risk severity for review by the VTE research team each weekday. Starting with the highest risk patients, the VTE research team will review each patient and clinical situation, and then the VTE research team will directly discuss risks/benefits of prophylactic anticoagulation with the admitting team. Patients with a risk score <1% will not be reviewed, and the investigators anticipate most of the intervention arm patients will fall into this category (based on our previous data, the investigators anticipate >90% of all patients will score <1%). The VTE risk report will be re-calculated based on updated EHR data every day at midnight.
11029040|NCT04574895|No Intervention|Standard of care|Patients randomized to the control arm will continue to receive current standard of care anticoagulation practice, which is at the discretion of the admitting team. In general, nearly no pediatric patients are offered prophylactic anticoagulation unless a previous VTE has been identified. This currently is at the discretion of the provider and no risk scoring is used. VTE risk prediction scores will be calculated and stored for analysis, these will not be visible to the study team in real time.
11029041|NCT04574882||Case|Patients ages 40-74 with and without CHD (IICD 10: I63, I20-I25 ) within the last 6 months who receive care in the University of Pennsylvania Health System (UPHS).
11029042|NCT04574882||Control|Patients aged 40-74 who have non-cardiovascular-related chief compliant.
11029043|NCT04574869|Experimental|RLS-0071 administered as Single-Ascending Low Dose|Patients will receive a single low-dose infusion of RLS-0071 or placebo.
11029044|NCT04574869|Experimental|RLS-0071 administered as Single-Ascending High Dose|Patients will receive a single high-dose infusion of RLS-0071 or placebo.
11029045|NCT04574869|Placebo Comparator|Placebo administered as Single-Ascending Doses|Placebo will be administered at the same volume and duration of IV infusion corresponding to the dosing cohort schedules.
11029046|NCT04574869|Experimental|RLS-0071 administered as Multiple-Ascending Low Doses|Patients will receive treatment with RLS-0071 low dose or placebo approximately 3 days (i.e., q8 hours [± 1 hour] for 9 consecutive doses).
11029047|NCT04574869|Experimental|RLS-0071 administered as Multiple-Ascending High Doses|Patients will receive treatment with RLS-0071 high dose or placebo approximately 3 days (i.e., q8 hours [± 1 hour] for 9 consecutive doses).
11029048|NCT04574869|Placebo Comparator|Placebo administered as Multiple-Ascending Doses|Placebo will be administered approximately 3 days (i.e., q8 hours [± 1 hour] for 9 consecutive doses).
11029049|NCT04574856|Experimental|Patients with Newly Diagnosed Glioblastoma|Patients will receive dose-intensified, adaptive photon radiation therapy
11029050|NCT04574843|Experimental|Embolization arm|Intervention: Embolization of middle meningeal artery Device: Onyx, squid, Phil
11029051|NCT04574817|Experimental|HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
11029052|NCT04574804|Experimental|online training program|online training program Participants receive access to online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis, which they will be instructed to and encourage to complete over the 6 intervention period.
11029053|NCT04574804|No Intervention|control group|control group Participants do NOT receive access to the online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis during the intervention period.
11029054|NCT04574791|No Intervention|Multimodal Pain Regimen|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol.
11029055|NCT04574791|Experimental|Multimodal Pain Regimen + Tizanidine|current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients <65 years and 15 mg IV Q8h for patients who are >65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge
11029056|NCT04574778|No Intervention|Group 1: IV acetaminophen 1000 mg and oral placebo|group 1 (control group) will receive 1000 mg of oral acetaminophen preoperatively and IV placebo infusion intraoperatively 30 minutes prior to surgical closure
11029057|NCT04574778|Placebo Comparator|Group 2: IV placebo and oral acetaminophen 1000 mg|group 2 (intervention group) will receive an oral placebo preoperatively and 1000 mg infusion of IV acetaminophen intraoperatively 30 minutes prior to surgical closure
11029058|NCT04574765||Healthcare Worker|Individuals who work within a food production, healthcare, research or clinical organization of participating institutions.
11029059|NCT04574726|Experimental|virtual environment|Balance test in virtual environment with a virtual reality software executed in a 6DOF Occulus Quest helmet and a motion capture software with a Kinect Azure DK camera.
11029060|NCT04574726|Active Comparator|reel environment|Balance test in real environment with a motion capture software and a Kinect Azure DK camera.
11029061|NCT04574713|Experimental|Candesartan 8 mg|
11029062|NCT04574713|Experimental|Candesartan 16 mg|
11029063|NCT04574713|Placebo Comparator|Control group|
11029064|NCT04574700|Experimental|knee joint mobilization and traction|Tibiofemoral, Tibiofibular joint anterioposterior mobilization, keltonborn knee traction Transcutaneous electrical nerve stimulation(TENS) and quadriceps strengthening
11029065|NCT04574700|Active Comparator|Post isometric relaxation|Post isometric relaxation on hamstring, TENS and quadriceps strengthening.
11029066|NCT04574687|Active Comparator|Group A|Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
11029067|NCT04574687|Experimental|Group B|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
11029068|NCT04574674|Experimental|Flexibility exercise group|"Participants will be asked to follow a 12-week flexibility exercise training programme. Participants will be asked to perform a minimum amount of flexibility exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.
~Participants will perform 6 flexibility exercises per week (2 different for legs, 1 shoulder and arms, 1 chest, 1 back and 1 core). Passive static stretching exercises will be performed."
11029069|NCT04574674|Experimental|Resistance exercise group|"Participants will be asked to follow a 12-week home-based exercise programme. Participants will be asked to perform a minimum amount of resistance exercise of 1 set/week for each of six exercises and will have the opportunity to increase their volume of exercise to 2 sets or 3 sets/week per exercise if it is their choice.
~Participants in the resistance exercise group will be asked to perform a total of 6 exercises per week (2 different leg exercises, 1 shoulder exercise, 1 chest exercise, 1 back exercise and 1 core exercise). Body weight and resistance bands exercises will be used. Participants will be asked to perform each set to complete as many repetitions as possible until fatigue."
11029070|NCT04574661|Active Comparator|Static stretching|Static stretching to lower limb muscles
11029071|NCT04574661|Experimental|Intermittent occlusion|Intermittent occlusion to lower limb
11029072|NCT04574648|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the non-adherence information such that community pharmacists can view the information prior to dispensing medications.
11029073|NCT04574648|No Intervention|Standard care (ADE information retained locally)|Patients in the control arm will have their information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their information will not be visible to other providers via PharmaNet.
11029074|NCT04574635||Cohort 1 (surgery patients)|Patients undergo collection of blood samples at baseline prior to surgery, at 6 weeks, 3, 6, and 12 months post-surgery, every 6 months during year 2, and at the time of recurrence (if applicable).
11029075|NCT04574635||Cohort 2 (post-operative radiation +/- chemotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, at 6 weeks, 3, 6, and 12 months post-radiotherapy, every 6 months during year 2, and at the time of recurrence (if applicable).
11029076|NCT04574635||Cohort 3 (definitive chemoradiotherapy patients)|Patients undergo collection of blood samples at baseline prior to the first fraction of radiation, during week 4 of radiotherapy, on the day of the final fraction of radiotherapy, at 3 months post-radiotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
11029077|NCT04574635||Cohort 4 (systemic treatment patients)|Patients undergo collection of blood samples at baseline prior to initiation of chemotherapy or immunotherapy, at 4 weeks and 8 weeks after initiation of chemotherapy or immunotherapy, every 3 months during years 1 and 2, and at the time of recurrence (if applicable).
11029078|NCT04574622|Experimental|Five true ESWT sessions|"A total of five sessions (1x/week) were conducted.
~A total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
11029079|NCT04574622|Experimental|Three true ESWT sessions and two sham ESWT sessions|"A total of three true ESWT (week 1, 3 and 5) and two sham ESWTs in (week 2 and 4) were conducted.
~For true ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars.
~For sham ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle with a 1 cm gap between between the probe and subject's skin. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
11029080|NCT04574609|No Intervention|no hypnotherapy|"A control group of patients receiving the usual management for PAC and chemotherapy sessions."
11029081|NCT04574609|Experimental|hypnotherapy|"A hypnotherapy group of patients benefiting from hypnotherapy sessions prior to PAC and chemotherapy cures in addition to the usual management."
11029082|NCT04574596||3GCRceftriaxone-resistant-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
11029083|NCT04574596||3GCSceftriaxone-susceptible-E. coli|Positive blood culture for above resistant e coli. Observational there will be no intervention
11029084|NCT04574583|Experimental|1/Sequential Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN M7824 +CV301
11036994|NCT04520256|Experimental|Dysregulated Eating, Exercise, VR|
11029085|NCT04574583|Experimental|2/Combination Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN Escalating doses of SX-682 + M7824 + CV301
11029086|NCT04574583|Experimental|3/Disease-Specific Expansion|RP2D of SX-682 + M7824 + CV301
11029087|NCT04574570|Other|interventional patient|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
11029088|NCT04574544|Experimental|Zinc supplementation|The 25 supplemented children had received an oral dose of 10 mg of zinc sulphate per day for 14 days
11029089|NCT04574544|Experimental|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
11029090|NCT04574518|Experimental|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
11029091|NCT04574518|Other|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
11029092|NCT04574505|Experimental|NUT|1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
11029093|NCT04574505|Placebo Comparator|Placebo|1 tablet of Placebo per day + standard diet for 8 weeks
11029094|NCT04574492||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
11029095|NCT04574479|Placebo Comparator|Placebo|Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
11029096|NCT04574479|Experimental|Fascia iliaca block|Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
11029097|NCT04574466|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by a physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
11029098|NCT04574466|Experimental|Problem Management Plus|"The participants who are assigned to the intervention group will receive five sessions of PM+, a psychological intervention which has been developed by the WHO. PM+ is a new short, transdiagnostic (i.e., not specifically aimed at treating a certain mental disorder) program aiming to reduce common mental health symptoms and improve psychosocial functioning.
~PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, and accessing social support. These elements have been recommended in recent WHO guidelines. PM+ has proven to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan."
11029099|NCT04574453|Experimental|Iracross|1 course of IRACROSS (crosslinked 2% Hyaluronic Acid) at baseline, consisting of a mono-dose intra-articular administration (2ml).
11029100|NCT04574453|Active Comparator|Iraline|1 course of IRALINE (linear 2% Hyaluronic Acid); each course consists of 3-5 intra-articular administrations (2ml) at weekly intervals (from week 1 to 3, 4 or 5, depending on each patient's need)
11029101|NCT04574440||multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap during surgery. The patient's surgery and subsequent medical care will not be altered.
11029102|NCT04574414||Children with Attention Deficit Hyperactivity Disorder|Cases
11029103|NCT04574414||Children without Attention Deficit Hyperactivity Disorder|Population controls
11029104|NCT04574401|Experimental|Dose escalation|Dose-cohort escalation of a single intravenous injection of IS-002 at four different dose levels
11029105|NCT04574388|Active Comparator|open label placebo|participants will take open label placebo pills TID and in conjunction with other PRN analgesics
11029106|NCT04574388|No Intervention|treatment as usual|participants will take PRN analgesics as usual
11029107|NCT04574362|Active Comparator|Rimegepant 75mg|One 75mg oral disintegration tablet
11029108|NCT04574362|Placebo Comparator|Placebo|Matching placebo
11029109|NCT04574336|Experimental|Surgical Treatment|Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method
11029110|NCT04574336|Active Comparator|Non-surgical treatment|Treatment of humeral shaft fracture with sling and/or functional brace
11029111|NCT04574323|Experimental|Paleolithic lifestyle group|The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
11029112|NCT04574323|Other|Standard diet group|This group is on a standard diet while receiving radiotherapy.
11029113|NCT04574310||Frozen embryo transfer (FET)|Collect retrospectively data on embryo implantation rate
11029114|NCT04574310||Intracytoplasmic sperm injection (ICSI)|Collect retrospectively data on embryo implantation rate
11029115|NCT04574310||oocyte donation|Collect retrospectively data on embryo implantation rate
11029116|NCT04574284|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11029117|NCT04574284|Experimental|TQB2450|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
11029118|NCT04574271|Experimental|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
11029119|NCT04574271|Active Comparator|Usual dietary advice and exercise prescription|Generalized dietary advice and exercise prescription in elder subjects.
11029120|NCT04574245||Resectable group|
11029121|NCT04574245||Potentially resectable group|
11029122|NCT04574245||Unresectable group|
11029123|NCT04574232|Other|athletic subjects|athletic subjects who may need intra-articular knee infiltration
11029124|NCT04574219|Other|Feasibility/Acceptability|This arm will be used to assess the feasibility and acceptability of using FaceTime during induction.
11029125|NCT04574219|Other|Coaching prior to surgery|
11029126|NCT04574219|Other|Coaching day of surgery|
11029127|NCT04574206|Experimental|Elaborative Reminiscence (ER)|ER is a communication strategy used between a caregiver and child to support children's cognitive and emotional development. ER involves a caregiver and child jointly reminiscing about a past event that they personally experienced, to co-create a coherent narrative that describes the event from both their perspectives. ER consists of two crucial elements, the use of elaborative language (e.g. open ended questions, contributing new information to the conversation) and specific talk focused on recollections of the past as opposed to observations of the present.
11029128|NCT04574206|Sham Comparator|Present Tense Talk (PTT)|PTT is an active control intervention, designed to ensure that caregivers/ guardians in this group spend a similar amount of time engaging in conversation with their children but do not use elaborative reminiscing language. The focus will be on describing activities as they are happening in real time; PTT caregivers will be asked to avoid reference future or past events .
11029129|NCT04574193|Experimental|Continuing Care App|Participants will receive the Continuing Care app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy).
11029130|NCT04574193|Active Comparator|Treatment As Usual|Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.
11029131|NCT04574180|Active Comparator|Group 1|Zirconia crown anterior (NuSmile, Houston, Texas, USA).
11029132|NCT04574180|Active Comparator|Group 2|Zirconia crown posterior (NuSmile, Houston, Texas, USA).
11029133|NCT04574180|Active Comparator|Group 3|Stainless steel crown (3M-ESPE, St. Paul, Minnesota, USA)
11029134|NCT04574180|Active Comparator|Group 4|Strip Crown (3M-ESPE, St. Paul, Minnesota, USA)
11029135|NCT04574167|Experimental|tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes)
11029136|NCT04574167|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
11029137|NCT04574154|Experimental|FIB|ultrasound guided Fascia Iliaca Block
11029138|NCT04574154|Experimental|ESPB|ultrasound guided Erector Spinae Plane Block
11029139|NCT04574141|Experimental|spray before tablet|
11029140|NCT04574141|Experimental|tablet before spray|
11029141|NCT04574128|Experimental|Retransfusion of cardiotomy blood or not|Intervention group does not get cardiotomy blood retransfusion via heart-and lung machine while control does.
11029142|NCT04574128|No Intervention|No retransfusion of cardiotomy blood|
11029143|NCT04574115|Experimental|Study Eye|study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.
11029144|NCT04574115|Active Comparator|Control Eye|Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
11029145|NCT04574102|Experimental|Study Eye|Omega Refractive capsule, model V, with an FDA approved intraocular lens.
11029146|NCT04574102|Active Comparator|Control Eye|FDA approved Intraocular Lens
11029147|NCT04574089|Experimental|Baofukang Suppository 7 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days
11029148|NCT04574089|Experimental|Baofukang Suppository 14 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days
11029149|NCT04574076||N8-GP|Patients with haemophilia A
11029150|NCT04574063|No Intervention|Breast cancer risk leaflet only|
11029151|NCT04574063|No Intervention|Breast cancer risk leaflet PLUS SNPs|
11029152|NCT04574063|Experimental|Lifestyle website only|
11029153|NCT04574063|Experimental|Lifestyle website PLUS SNPs|
11029154|NCT04574063|Experimental|Lifestyle website PLUS group coaching|
11029155|NCT04574063|Experimental|Lifestyle website PLUS group coaching PLUS SNPs|
11029156|NCT04574050|Experimental|SELF-BREATHE|Access to a self -guided, internet -based intervention for patients with chronic breathlessness known as SELF-BREATHE
11029157|NCT04574050|No Intervention|Control|standard / currently available NHS care
11029158|NCT04574037||follow up of stroke patients with a upper limb deficit|Usual follow up of stroke patients with a upper limb deficit
11029159|NCT04574024|Experimental|Cohort A: Treatment with NBT-NM108�|Patients will receive NBT-NM108 at 60 g/day for 8 weeks.
11029160|NCT04574024|Placebo Comparator|Cohort B: Non-treatment|Patients will not receive NBT-NM108.
11029161|NCT04574011|Experimental|Fluid challenge responder|If the ratio of the stroke volume change after passive leg raising is the same or larger than 10%, the patient is assigned to RESPONDER group.
11029162|NCT04574011|Experimental|Fluid challenge non-responder|If the ratio of the stroke volume change after passive leg raising is less than 10%, the patient is assigned to RESPONDER group.
11029163|NCT04573985|Experimental|Serious Game Eurekoi intervention|1 session in group using the serious game eurekoi
11029164|NCT04573985|No Intervention|Control group|no intervention
11029165|NCT04573972|Active Comparator|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
11029166|NCT04573972|Experimental|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
11029167|NCT04573959|Experimental|SV-3 Capsule Endoscopy|CapsoCam SV-3 Capsule Endoscopy system will perform in a manner consistent with the performance of the CapsoCam SV-3 capsule endoscopy systems.
11029168|NCT04573946|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11029169|NCT04573946|Active Comparator|Vitamin D placebo + fish oil|
11029170|NCT04573946|Active Comparator|Vitamin D + fish oil placebo|
11029171|NCT04573946|Active Comparator|Vitamin D + fish oil|
11029172|NCT04573920|Experimental|Atrasentan|Once daily oral administration of 0.75 mg atrasentan for 52 weeks.
11029173|NCT04573907|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
11029174|NCT04573907|Active Comparator|Reference formulation of Levothyroxine|Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
11029175|NCT04573894||Positives blood cultures|Collection of clinical and biological data of patients with blood cultures positives for potential contaminants, as well as PCT levels measurements, from January 2016 to May 2019 at the Nancy CHRU
11029176|NCT04573881|Experimental|Treatment Group|This is a single arm study that intends to treat all enrolled subject with the histotripsy device.
11029177|NCT04573855|Experimental|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
11029178|NCT04573855|No Intervention|Control|
11029179|NCT04573829|Experimental|Non-drug approaches at home|Non-drug approaches at home three visits per week during six months and psycho-education for the caregivers one time per week for six months.
11029180|NCT04573803|Experimental|MAST DURATION - <3 months|TBI patients with early seizures (within first 7 days following trauma) will receive a short course of up to 3 months of either Phenytoin Sodium or Levetiracetam.
11029181|NCT04573803|Experimental|MAST DURATION - >6 months|TBI patients with early seizures (within first 7 days following trauma) will receive a longer course of at least 6 months of either Phenytoin Sodium or Levetiracetam.
11029182|NCT04573803|Experimental|MAST PROPHYLAXIS - Phenytoin Sodium|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Phenytoin Sodium as seizure prophylaxis.
11029183|NCT04573803|Experimental|MAST PROPHYLAXIS - Levetiracetam|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Levetiracetam as seizure prophylaxis. Dosing will be as prescribed clinically by the treating physician.
11029184|NCT04573803|No Intervention|MAST PROPHYLAXIS - no treatment|TBI patients, without an acute symptomatic seizure, will not receive any anti-epileptic drug.
11029185|NCT04573790||Trained in eFONA|Trained participants completed our eFONA workshop within the last six month prior to participating in this study
11029186|NCT04573790||Untrained in eFONA|Untrained participants had never taken part in our institutional eFONA workshop
11029187|NCT04573777|Experimental|Intervention Repatha|
11029188|NCT04573764|Active Comparator|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|
11029189|NCT04573764|Placebo Comparator|Placebo|
11029190|NCT04573751|Sham Comparator|Standard therapy|No intracoronary epinephrine and verapamil
11029191|NCT04573751|Active Comparator|Epinephrine|Intracoronary bolus epinephrine injection requires two ampoules each of 1:1,000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline solution (to 20 μg/mL epinephrine solution); therefore, a 5-mL syringe contains 100 μg of epinephrine. Intracoronary epinephrine will be administered at a dose of 100 μg and at a lower dose of 80 μg in patients with blood pressure >160 mmHg
11029192|NCT04573751|Active Comparator|Verapamil|Intracoronary verapamil is administered at a dose of 0.5 mg.
11029193|NCT04573751|Active Comparator|Epinephrine + verapamil|Intracoronary administration of epinephrine at a dose of 80-100 μg and verapamil at a dose of 0.5 mg.
11029194|NCT04573738|Experimental|Robotic transanal surgery|Robotic assisted transanal total mesorectal excision for rectal cancer patients
11029195|NCT04573738|Active Comparator|Laparoscopic transanal surgery|Laparoscopic transanal total mesorectal excision for rectal cancer patients
11029196|NCT04573725|Experimental|5 mg|Period in which participants received single-dose of 5 mg TS-142 prior to bedtime
11029197|NCT04573725|Experimental|10 mg|Period in which participants received single-dose of 10 mg TS-142 prior to bedtime
11029198|NCT04573725|Experimental|30 mg|Period in which participants received single-dose of 30 mg TS-142 prior to bedtime
11029199|NCT04573725|Placebo Comparator|Placebo|Period in which participants received single placebo prior to bedtime
11029200|NCT04573712|Experimental|Fatigue Severity Scale scores assessment|Fatigue Severity Scale scores assessment
11029201|NCT04573673|Experimental|PTNS verum|Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.
11029202|NCT04573673|Sham Comparator|PTNS placebo|Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).
11029203|NCT04573660||XIENCE PRIME BTK|Participants in the XIENCE PRIME BTK arm will receive XIENCE PRIME BTK
11029204|NCT04573660||Absolute Pro LL|Participants in the Absolute Pro LL arm will receive Absolute Pro LL
11029205|NCT04573660||Supera 7.5 Outer Diameter (OD)|Participants in the Supera 7.5 OD arm will receive Supera 7.5 OD
11029206|NCT04573660||Xpert Pro|Participants in the Xpert Pro arm will receive Xpert Pro
11029207|NCT04573660||Pacel Pacing Catheters|Participants in the Pacel Pacing Catheters arm will receive Pacel Pacing Catheters (pacel bipolar pacing catheter [BPC] or pacel flow directed bipolar pacing catheter [FDPC])
11029208|NCT04573660||Amplatzer Vascular Plugs|Participants in the Amplatzer Vascular Plugs (AVP) arm will receive Amplatzer Vascular Plugs (AVP I/ AVP II/ AVP 4)
11029209|NCT04573660||Pressure Wire|Participants in the Pressure Wire arm will receive Pressure Wire X
11029210|NCT04573660||Multilink BMS|Participants in the Multilink BMS arm will receive either MULTI-LINK 8/ MULTILINK 8 Long Length (LL)/ MULTILINK 8 Small Vessel (SV)
11029211|NCT04573647||Treatment group|All participants in this trial will be in the treatment group. They will administer Oxervate following the FDA approved guidelines: 1 drop to the affected eye 6 times per day for 8 weeks.
11029212|NCT04573634||Health Care Workers|Health-care workers undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
11029213|NCT04573634||Eligible Patients|Patients undergoing standard of care assessment of SARS-CoV-2 serology testing at UKHC.
11029214|NCT04573634||Quarantining Individuals|Individuals with a COVID-19 exposure requiring quarantine who are asymptomatic and who will receive standard of care SARS-CoV-2 PCR testing.
11029215|NCT04573621|Active Comparator|Pelvic drain|Placement of a pelvic drain
11029216|NCT04573621|Experimental|No pelvic drain|No pelvic drain placed
11029217|NCT04573608|Experimental|Papacarie-Duo|
11029218|NCT04573608|Active Comparator|Atraumatic Restorative Treatment|
11029219|NCT04573582|Experimental|Enasidenib (CC-90007) tablet|Participants will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
11029220|NCT04573556||Lemborexant|Participants with insomnia will initiate treatment with lemborexant 5 milligram (mg), tablet, orally as per the clinical judgment of the treating physician as part of routine clinical care. Dosage and administration of lemborexant tablet will be according to package insert and actual dosing and frequency will be decided by physician including dose escalation from initial dose of 5 mg up to 10 mg once daily. All participants will be observed prospectively for up to 24 weeks.
11029221|NCT04573543||Patients with Non-alcoholic fatty liver disease|120 patients diagnosed with NAFLD
11029222|NCT04573543||Controls|40 healthy controls
11029223|NCT04573530|Experimental|We Walk Plus Intervention|The intervention group will receive a Fitbit, SMS and will be assigned to a private Fitbit community (4-5 participants per group) for 12 weeks. During the intervention, participants will receive weekly personalized SMS on their mobile phones including encouraging messages, reminders, and tips to increase steps, and weekly step goals. The investigators will use a secure, web-based platform, iCardia, to support continuous real-time remote monitoring of activity data from Fitbit devices and personalized communication via SMS based on incoming data. The investigators will set up the Fitbit networking settings on participants' phones to give notifications when there are posts to this group. Individual goals and a weekly team goal of steps will be set up by the research team. Each member will be awarded a badge upon reaching each individual's weekly goal. Teams will also be awarded badges when all team members reach their individual weekly goals.
11029224|NCT04573530|No Intervention|Attention control group|The attention control group will also receive a Fitbit and will be asked to continue with normal daily activities. During the initial in-person session, they will receive the same PA recommendations as the intervention group to walk at least 30 minutes for 5 days or more a week or 10,000 steps a day. However, a plan for improving PA will not be discussed.
11029225|NCT04573517|Experimental|Early amniotomy|Subjects randomized to this arm will undergo amniotomy within 2 hours of removal of Foley balloon.
11029226|NCT04573517|Active Comparator|Delayed amniotomy|Subjects randomized to this arm will undergo amniotomy at least 4 hours after removal of Foley balloon.
11029227|NCT04573504|Experimental|Antibiotic Group|The antibiotic regimen chosen is based on the Royal College of Obstetricians and Gynecologists' recommendations (Augmentin and Flagyl or Clindamycin and Flagyl if they are allergic to Penicillin). The dosage for the antibiotics are the following: Flagyl 500mg po BID (twice a day) X 5 days, Clindamycin 400 mg po TID (three times a day) X 5 days, Augmentin 875mg po BID X 5 days.
11029228|NCT04573504|Placebo Comparator|Placebo Group|Women randomized not to receive antibiotics will be given placebo tablets postpartum, so they will all have an identical experience to the women in the experimental (antibiotic) group.
11029229|NCT04573491|Experimental|Pharmacogenetic test|Medication review including results from pharmacogenetic testing
11029230|NCT04573478|Experimental|Atrasentan|Once daily oral administration of 0.75 mg atrasentan for 132 weeks
11029231|NCT04573478|Placebo Comparator|Placebo|Once daily oral administration of placebo for 132 weeks
11029232|NCT04573465|Experimental|Phone Coaching Condition|Participants will receive weekly, 10-15 minute phone coaching from a trained peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. Coaches will adhere to an ACT-based protocol that includes reinforcing adherence, identifying and problem solving non-adherence, strengthening and generalizing ACT skills, and using ACT skills to increase commitment to ongoing program adherence.
11029233|NCT04573465|Experimental|Text Message Coaching Condition|Participants assigned to the text messaging condition will receive weekly text messages from their peer-support coach throughout the 10 weeks that they use ACT Guide, an online program for general mental health. These text messages will reflect content delivered in the phone coaching group, but through a briefer protocol that accounts for the abbreviated, asynchronous nature of texting. Text messages will similarly focus on reinforcing adherence, problem solving non-adherence, strengthening ACT skills, and using ACT to increase program adherence. However, these areas will be covered in short messages and with limited exchanges between participants and coaches due to the asynchronous nature of texting.
11029234|NCT04573465|Active Comparator|No Coaching Condition|Participants will be asked to use ACT Guide, an online program for general mental health, over the course of 10 weeks while receiving no coaching.
11029235|NCT04573452||Normal pregnancy group|
11029236|NCT04573452||Placenta accreta at 32 weeks group|
11029237|NCT04573452||Placenta accreta at 37 weeks group|
11029238|NCT04573426||Overweight/Obese+Drug+Stigma|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
11029239|NCT04573426||Overweight/Obese+Drug+Control|40 participants with overweight or obesity will consume 1,000mg of acetaminophen in a liquid vehicle briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
11029240|NCT04573426||Overweight/Obese+Placebo+Stigma|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
11029396|NCT04572581|Experimental|Exclusively Human Milk Diet|This group will receive human milk only. If the mother is not producing enough breast milk, this group will receive donor milk supplementation.
11029241|NCT04573426||Overweight/Obese+Placebo+Control|40 participants with overweight or obesity will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short control vignette meant to have no impact on their emotional state.
11029242|NCT04573426||Normal Weight+Placebo+Stigma|40 participants with normal weight will consume a placebo solution briefly following the start of the appointment. After one hour, they will read a short vignette meant to induce weight stigma.
11029243|NCT04573413|Experimental|r-TMS group|The interventions have a total administration time of 75 minutes per day. For rTMS stimulation, the coil will be positioned tangentially on the target area. Each rTMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The CCT (i.e. visual scanning treatment) involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities.Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the rTMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
11029244|NCT04573413|Sham Comparator|SHAM group|SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the experimental group.
11029245|NCT04573387|Active Comparator|Fixed-time drainage|Drainage will be removed after 48 hours.
11029246|NCT04573387|Experimental|Exhaustive drainage|Drainage will be removed when postoperative hematoma volume is minimized with repeated urokinase injection into hematoma cavity through catheter.
11029247|NCT04573374|Active Comparator|Biodentine|Biodentine (BD; Septodont, St Maur-des-Fosses, France) is a calcium silicate capping material. Biodentine is mixed according to manufacturer's instructions and placed in a 2-3 mm layer above the pulp tissue using an amalgam carrier and gently packed using a condenser. Initial setting is achieved after 12 minutes.
11029248|NCT04573374|Active Comparator|Portland cement|Preparation of Portland cement: Industrial Portland cement is mixed with Bisthmus oxide or Barium sulphate radio-opacifier in a 3:1 ratio. The mix is sieved through silk sieve then sterilized in hot air oven at 135 ֯C for 2 hours. Portland cement is mixed in a 3:1 powder: distilled water ratio and placed in the pulp chamber and condensed against a moist cotton pellet. A small cotton pellet moistened with saline is placed in the pulp chamber against PC for 5 seconds to ensure water uptake then removed
11029249|NCT04573361|No Intervention|Group Control|Patients having no access to chiropractic treatment during the trial
11029250|NCT04573361|Experimental|Group Chiropractic Care one session|Patients having access to in-person chiropractic treatment once during the trial
11029251|NCT04573361|Experimental|Group Chiropractic Care multiple sessions|Patients having access to in-person chiropractic treatment more than once during the trial
11029252|NCT04573348||Groups 1-4|no intervention will be performed in this study, only blood drawn
11029253|NCT04573322|Experimental|Lead-in 0.25 mg/kg|0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
11029254|NCT04573322|Experimental|Lead-in 0.50 mg/kg|0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
11029255|NCT04573322|Experimental|Lead-in 1.0 mg/kg|1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
11029256|NCT04573322|Experimental|Lead-in 1.5 mg/kg|1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
11029257|NCT04573322|Experimental|Randomized Active TSC|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
11029258|NCT04573322|Placebo Comparator|Randomized Placebo|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
11029259|NCT04573309|Experimental|ALXN1840|Participants will be administered ALXN1840 at a dose of 15 milligrams (mg)/day on Day 1 through Day 28 and then increased to 30 mg/day on Day 29 through Day 39
11029260|NCT04573296|Active Comparator|Participants using Vitadio Health|The participants will go through six month program after randomisation focusing on changing dietary habits, increase physical activity and maintenance of lifestyle habits and weight loss achieved during the core program.
11029261|NCT04573296|Other|Control group|Participants in the control group will receive standard care health education from primary care providers in the clinic.
11029262|NCT04573270|Experimental|COVID-19 Patients Experimental|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
11029263|NCT04573270|Placebo Comparator|COVID-19 Patients Placebo|13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
11029264|NCT04573270|Experimental|Healthcare Providers Experimental|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
11029265|NCT04573270|Placebo Comparator|Healthcare Providers Placebo|7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.
11029266|NCT04573257||normotensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
11029267|NCT04573257||Prehypertension group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
11029397|NCT04572581|No Intervention|Formula-based Diet|If the mother is not producing enough breast milk, this group will receive formula supplementation (the standard of care).
11037297|NCT04518241|Experimental|Condition 7|Core, fixed compensation
11029268|NCT04573257||hypertensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
11029269|NCT04573231|Experimental|18F-DCFPyL PSMA-based PET/CT|"18F-DCFPyL whole body PET/CT scan
~Review of relevant imaging and medical record information
~Blood draw for circulating tumor cells (CTCs)
~Analysis of diagnostic tissue specimens"
11029270|NCT04573218|Placebo Comparator|Group A|Glucose.
11029271|NCT04573218|Active Comparator|Group B|250 mg Oil Palm Phenolics.
11029272|NCT04573205|Experimental|> 50 years|"Healthy individuals > 50 years of age divided into age groups 50-59 years, 60-69 years and >70 years, approximately 20 participants in each group.
~Vaccinated with 4 doses FSME immune Adult intramuscular injection according to the recommended primary vaccine Schedule in Sweden for individuals > 50 years of age, at time 0, 1, 2 and 7 months."
11029273|NCT04573205|Active Comparator|< 40 years|Healthy individuals < 40 years of age. Vaccinated with 3 doses FSME immune Adult intramuscular injection according to the standard recommended primary vaccine at time 0, 1, and 7 months.
11029274|NCT04573192|Experimental|Phase 1 part: Dose Finding|"Phase I part:
~Dose Finding Patients will be treated in cohorts according to a traditional 3+3 design with lomustine on Day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26, of a 42-days cycle at different dose levels.
~The RD will be confirmed following a traditional 3+3 design.
~Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
~The dose of 13 ug/kg L19TNF will be declared the RD in case none of three or not more than one out of 6 patients experienced a DLT. Dose limiting toxicity will be assessed during the dose-escalation from Day 1 through Day 42 after the first administration of lomustine and study drug (Cycle 1). Not more than 2 patients might be treated simultaneously in Cycle 1."
11029275|NCT04573192|Experimental|Phase II part: Signal Seeking|"118 Patients will be randomized 1:1 and treated with either lomustine on day 1 and L19TNF on Days 1, 3 and 5, and on Days 22, 24, and 26 of a 42-days cycle at the RD established in the phase I part of the study or with lomustine on day 1 of a 42-days cycle.
~Treatment Arm 1: L19TNF plus Lomustine
~Treatment Arm 2: Lomustine"
11029276|NCT04573166|Experimental|CURB procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation (CURB)
11029277|NCT04573153|Experimental|Treatment Arm|Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
11029278|NCT04573153|Placebo Comparator|Placebo Arm|Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
11029279|NCT04573140|Experimental|Phase I adult (Stratum 1)|A maximum of 28 adult patients will be enrolled in dose-escalation study using the BOIN design with an initial embedded accelerated titration design (ATD).
11029280|NCT04573114||Stroke subjects|
11029281|NCT04573114||Healthy|
11029282|NCT04573101|No Intervention|Before intervention|Participants answer questionnaire before any stimulus is given.
11029283|NCT04573101|No Intervention|After intervention|Participants answer questionnaire after the series of stimulus is given.
11029284|NCT04573101|Experimental|N1 (Ney - Improvisation- Saba Re)|Improvisation with Ney, on Saba maqam on Re.
11029285|NCT04573101|Experimental|O1 (Oud - Improvisation- Saba Re)|Improvisation with Oud, on Saba maqam on Re.
11029286|NCT04573101|Experimental|Q1(Qanun - Improvisation- Saba Re)|Improvisation with Qanun, on Saba maqam on Re.
11029287|NCT04573101|Experimental|N2 (Ney - Improvisation- Saba Sol)|Improvisation with Ney, on Saba maqam on Sol.
11029288|NCT04573101|Experimental|O2 (Oud - Improvisation- Saba Sol)|Improvisation with Oud, on Saba maqam on Sol.
11029289|NCT04573101|Experimental|Q2 (Qanun - Improvisation- Saba Sol)|Improvisation with Qanun, on Saba maqam on Sol.
11029290|NCT04573101|Experimental|N3 (Ney - Improvisation- Kurd Re)|Improvisation with Ney, on Kurd maqam on Re.
11029291|NCT04573101|Experimental|O3 (Oud - Improvisation- Kurd Re)|Improvisation with Oud, on Kurd maqam on Re.
11029292|NCT04573101|Experimental|Q3 (Qanun - Improvisation- Kurd Re)|Improvisation with Qanun, on Kurd maqam on Re.
11029293|NCT04573101|Experimental|N4 (Ney - Improvisation- Kurd Sol)|Improvisation with Ney, on Kurd maqam on Sol.
11029294|NCT04573101|Experimental|O4 (Oud - Improvisation- Kurd Sol)|Improvisation with Oud, on Kurd maqam on Sol.
11029295|NCT04573101|Experimental|Q4 (Qanun - Improvisation- Kurd Sol)|Improvisation with Qanun, on Kurd maqam on Sol.
11029296|NCT04573101|Experimental|N5 (Ney - Known music- Kurd Re)|Known music with Ney, on Kurd maqam on Re. (El Rabii)
11029297|NCT04573101|Experimental|O5 (Oud - Known music- Kurd Re)|Known music with Oud, on Kurd maqam on Re. (El Rabii)
11029298|NCT04573101|Experimental|Q5 (Qanun - Known music- Kurd Re)|Known music with Qanun, on Kurd maqam on Re. (El Rabii)
11029299|NCT04573101|Experimental|N6 (Ney - Known music- Kurd Sol)|Known music with Ney, on Kurd maqam on Sol. (El Rabii)
11029300|NCT04573101|Experimental|O6 (Oud - Known music- Kurd Sol)|Known music with Oud, on Kurd maqam on Sol. (El Rabii)
11029301|NCT04573101|Experimental|Q6 (Qanun - Known music- Kurd Sol)|Known music with Qanun, on Kurd maqam on Sol. (El Rabii)
11029302|NCT04573101|Experimental|N7 (Ney - Known music- Saba Re)|Known music with Ney, on Saba maqam on Re. (Howa Sahih)
11029303|NCT04573101|Experimental|O7 (Oud - Known music- Saba Re)|Known music with Oud, on Saba maqam on Re. (Howa Sahih)
11029304|NCT04573101|Experimental|Q7 (Qanun - Known music- Saba Re)|Known music with Qanun, on Saba maqam on Re. (Howa Sahih)
11029305|NCT04573101|Experimental|N8 (Ney - Known music- Saba Sol)|Known music with Ney, on Saba maqam on Sol. (Howa Sahih)
11029306|NCT04573101|Experimental|O8 (Oud - Known music- Saba Sol)|Known music with Oud, on Saba maqam on Sol. (Howa Sahih)
11029307|NCT04573101|Experimental|Q8 (Qanun - Known music- Saba Sol)|Known music with Qanun, on Saba maqam on Sol. (Howa Sahih)
11029353|NCT04572802||control group|Coronary heart disease population: after coronary angiography, Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease
11029444|NCT04572152|Experimental|AK119/ AK104|Single-arm
11029445|NCT04572139||Young participants|18-45 years old
11029308|NCT04573088|Experimental|ABICOL|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
11029309|NCT04573088|No Intervention|CONTROL|No acceptance-based intervention or other discussion related to the patients' fears and worries will be applied.
11029310|NCT04573075|Other|no outlet|no outlet is used after colorectal resection and forming of a primary anastomosis
11029311|NCT04573075|Active Comparator|loop ileostomy|loop ileostomy is applied after colorectal resection and forming of a primary anastomosis
11029312|NCT04573075|Experimental|ghost ileostomy|ghost ileostomy or ghost stoma (synonyms) is performed after colorectal resection and forming of a primary anastomosis
11029313|NCT04573062||Post COVID patients|Individuals whom have previously had COVID-19 infection.
11029314|NCT04573049|Experimental|Levosimendan|Levosimendan 0.1µg/kg/min will last for 24h after the valve is released.
11029315|NCT04573049|Placebo Comparator|Placebo|5% glucose 0.1µg/kg/min administration will continue for 24h after the valve is released.
11029316|NCT04573036|Experimental|HRS4800 tablets cohort 1|
11029317|NCT04573036|Experimental|HRS4800 tablets cohort 2|
11029318|NCT04573036|Experimental|HRS4800 tablets cohort 3|
11029319|NCT04573036|Experimental|HRS4800 tablets cohort 4|
11029320|NCT04573036|Experimental|HRS4800 tablets cohort 5|
11029321|NCT04573036|Placebo Comparator|Placebo tablets|
11029322|NCT04573023|Experimental|JR-141 2.0 mg/kg/week|
11029323|NCT04573023|Other|administered as the standard of care: idursulfase (ELAPRASE®)|standard of care-controlled study
11029324|NCT04573023|Other|Rescue arm|
11029325|NCT04573010|Experimental|Intervention|Repatha
11029326|NCT04572997|Experimental|Full analysis set (FAS)|The full analysis set (FAS) consisted of all patients who received at least one dose of study drug.
11029327|NCT04572984|Experimental|EBUS-TBNA-TBMCB|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was followed by endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMCB)
11029328|NCT04572984|No Intervention|EBUS-TBNA|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed
11029329|NCT04572945||1) diabetic CKD patient (stage 1- stage 5 non D )|
11029330|NCT04572945||2) diabetic CKD patient (stage 5 D)|
11029331|NCT04572932|Active Comparator|group 1:Probiotic arm|first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks
11029332|NCT04572932|Active Comparator|Group 2:Placcebo arm|the second group received only itopridehcl 50mg by the same dose for four weeks.
11029333|NCT04572919|Active Comparator|group A|Patients were randomly assigned to undergo lateral advancement flap
11029334|NCT04572919|Active Comparator|group B|Patients were randomly assigned to undergo classic Limberg flap
11029335|NCT04572906|Experimental|NTX-001|NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.
11029336|NCT04572906|No Intervention|Standard of Care|standard suture neurorrhaphy
11029337|NCT04572893|Experimental|MYK-491|Primary DCM due to MYH7 or TTN Variant
11029338|NCT04572880|Active Comparator|Trabeculectomy|
11029339|NCT04572880|Active Comparator|XEN®|
11029340|NCT04572880|Active Comparator|Preserflo®|
11029341|NCT04572867|Experimental|Aquapheresis|Per protocol, if randomized to Aquapheresis arm (AQ), all diuretics are discontinued and AQ will be administered as per established protocol. BMP and CBC will be checked prior to initiation and as needed, 7-10 days, 30, 60 and 90 days post discharge. Note, aquapheresis rate is to be decreased by 100 cc/hr if Hgb increases by 1gm/dL, and stopped if rate is decreased to 50 cc/hr or reaches euvolemia, whichever comes first.
11029342|NCT04572867|Active Comparator|IV Diuretics|Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If a patient in IV arm is refractory to maximum 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
11029343|NCT04572854|Experimental|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
11029344|NCT04572854|Other|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
11029345|NCT04572841|Experimental|SAR441344|SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)
11029346|NCT04572841|Placebo Comparator|Placebo|Matching placebo
11029347|NCT04572828|Active Comparator|Group 1: Waiting 1 Minute After Paracervical Block|
11029348|NCT04572828|Active Comparator|Group 2: Waiting 3 Minute After Paracervical Block|
11029349|NCT04572828|Placebo Comparator|Group 3: Control Group|
11029350|NCT04572828|Active Comparator|Group 4: Waiting 60 Minute After Taking Oral NSAIDs|
11029351|NCT04572815|Experimental|Arm I (ustekinumab)|Between days -10 and -5, patients receive ustekinumab IV 1 day prior to start of HCT conditioning therapy. Beginning 8 weeks after receiving IV ustekinumab, patients receive ustekinumab SC on days 50, 100, and 160 post-HCT in the absence of grade III-IV acute GVHD, disease relapse or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
11029352|NCT04572815|Placebo Comparator|Arm II (placebo)|Between days -10 and -5, patients receive a placebo IV 1 day prior to start of HCT conditioning therapy. Beginning 8 weeks after IV placebo, patients receive a placebo SC on days 50, 100, and 160 post-HCT in the absence of grade III-IV acute GVHD, disease relapse, or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
11029395|NCT04572594||Inflammatory myofibroblastic tumor|tissue of Inflammatory myofibroblastic tumor lession
11029446|NCT04572139||Old participants|55-80 years old
11029354|NCT04572802||experimental group (course of disease <5 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).Retrospective examination of patients' data, recording patients' laboratory tests and drug use, taking blood to measure orphanin, and evaluating the severity of coronary artery occlusion with Gensini score.
11029355|NCT04572802||experimental group(course of disease 5-10 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).
11029356|NCT04572802||experimental group(course of disease10-20 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 10 -20years).Finally, the data were obtained to evaluate the relationship between the course of diabetes and the severity of coronary heart disease, as well as the relationship between the course of diabetes and OFQ in patients' blood.
11029357|NCT04572789|Placebo Comparator|placebo|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
11029358|NCT04572789|Experimental|Omega-3|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
11029359|NCT04572776|Experimental|Resiniferatoxin|Single dose of Resiniferatoxin (25 mcg in 3 mL) injected epidurally
11029360|NCT04572776|Active Comparator|Standard of Care|Standard of care treatment as determined by the investigator
11029361|NCT04572763|Experimental|Dose Escalation Copanlisib + Venetoclax|"Phase 1
~Dose escalation will occur using a 3+3 design
~Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle
~Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting"
11029362|NCT04572763|Experimental|Recommended phase II dose (RP2D) Copanlisib + Venetoclax|Patients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
11029363|NCT04572750|Experimental|EMPOWER-ED|Individuals will be given access on their preferred platform to an electronic self-help app focused on reducing benzodiazepine use
11029364|NCT04572750|No Intervention|Control|Individuals will be provided care as usual
11029365|NCT04572737|Experimental|Experimental|Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
11029366|NCT04572724|Experimental|Sacubitril/Valsartan treatment group|"Sacubitril/Valsartan will be administered step by step with a titrated dose. When patients switching to Sacubitril/Valsartan from RAS inhibitor, a washout period of at least 36 hours is required to decrease the risk of angioedema.
~All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis."
11029367|NCT04572724|Active Comparator|RAS inhibitor treatment group|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. All subjects can have a beta-blocker, CCB, and/or alpha-blockers to control BP. Dialysis treatment: patients normally complete hemodialysis or peritoneal dialysis, need to ensure adequate dialysis requirements, no obvious overload, patients achieve dry weight after dialysis.
11029368|NCT04572698|Experimental|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
11029369|NCT04572698|Active Comparator|EYLEA|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
11029370|NCT04572685|Experimental|LY03010 Process 1|"Drug Product of Process 1 ( P1): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.
~LY03010 P1 using a non-sterile Active Pharmaceutical Ingredients (API) with an absolute ethanol recrystallization was manufactured by an optimized production process"
11029371|NCT04572685|Experimental|LY03010 Process 2|"Drug Product of Process 2 (P2): 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study.
~LY03010 P2 using a sterile Active Pharmaceutical Ingredients (API) with an isopropanol recrystallization was manufactured by the same optimized production process as that used in P1."
11029372|NCT04572685|Experimental|INVEGA SUSTENNA|INVEGA SUSTENNA 156 mg/vial; Single Injection on Day 1 during the entire 120 Day's study
11029373|NCT04572672|Active Comparator|Purse lip breathing with number counting arm|"1) Position: The patient lies down in a semi-supine position, the bed is adjusted by 45-60 degrees, 2) Pursed-lip breathing and number counting one and two during inspiration, and 3) Number counting, one, two, three, and four during exhalation for the first 15 minutes (min) of each hour, total study time was 3 hours or until the patient was discharged from the ER."
11029374|NCT04572672|No Intervention|Control arm|The patients who were allocated to the control group received usual nursing care i.e. bed rest in a supine position in a quiet area. Patients were advised to limit their activity. The frequency of the vital signs monitoring and pharmacologic treatment were the same as the intervention group.
11029375|NCT04572659|Experimental|Group intervention|
11029376|NCT04572659|Experimental|Couple intervention|
11029377|NCT04572659|No Intervention|No intervention|
11029378|NCT04572646|Other|NRT proposition and exhaled CO measurement|
11029379|NCT04572633|Experimental|Treatment Group|This is a single are arm study that intends to treat all enrolled subjects with the histotripsy device.
11029380|NCT04572620||group 1(rituximab)|
11029381|NCT04572620||group 2 (abatacept)|
11029382|NCT04572607|No Intervention|Control group 1|
11029383|NCT04572607|No Intervention|Control group 2|
11029384|NCT04572607|No Intervention|Control group 3|
11029385|NCT04572607|No Intervention|Control group 4|
11029386|NCT04572607|No Intervention|Control group 5|
11029387|NCT04572607|No Intervention|Control group 6|
11029388|NCT04572607|No Intervention|Control group 7|
11029389|NCT04572607|Experimental|Honey group 1|
11029390|NCT04572607|Experimental|Honey group 2|
11029391|NCT04572607|Experimental|Honey group 3|
11029392|NCT04572607|Experimental|Honey group 4|
11029393|NCT04572607|Experimental|Honey group 5|
11029394|NCT04572607|Experimental|Honey group 6|
11029398|NCT04572568||experimental group|"Treatment applied accordingly with the following standard criteria , patients are selected into this group:
~Ruptured lesion：
~Lesions not at the brainstem, thalamus, basal ganglia, or deep location，craniotomy can be performed;
~Target embolization of aneurysms and arteriovenous fistulas should be applied;
~Stereotactic radiosurgery for patients with a volume less than 10ml and not in the acute phase(< 3months) of intracranial hemorrhage.
~Unruptured lesion:
~Lesion is not located in the deep brain tissue, and is not located in an important functional area or the fiber bundle is more than 5mm away from the lesion, then surgery or combined surgery can be performed;
~If there are bleeding-related risk factors (aneurysm or high-flow fistula), relevant risk factors should be actively treated with embolization;
~Patients with no indications for craniotomy and poor symptom controlled, or with appropriate volume for radiosurgery or hybrid surgery (embolization +radiosurgery)."
11029399|NCT04572568||control group|Patients who received treatment that did not meet the standard group treatment plan were included in this control group.
11029400|NCT04572555|Experimental|Heat Treatment Group|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak. The subjects were instructed on the application of the thermophores. Thermoforming was applied wrapped in towels in order to shield the subjects from the effects of direct heat. In a study, heat packs that had a temperature of 38.9 °C were used for treatment of dysmenorrhea. In this study, the temperature of the water used in the thermoforming process was 45 °C. Considering the risk of the thermophores cooling down and the shielding provided by the towels, the water temperature was kept higher compared to those in other studies. The temperature of the water was measured using a liquid thermometer. Heat treatment was applied for 20 minutes without interruptions.
11029401|NCT04572555|No Intervention|Control Group|No Intervention
11029402|NCT04572542|Experimental|Camrelizumab + Apatinib + nab-paclitaxel|Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer
11029403|NCT04572516|Experimental|Topical group|Topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
11029404|NCT04572516|Experimental|Injection group|20 units of BTX_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
11029405|NCT04572503|Experimental|Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty In Management of Mild and Moderate Obstructive Sleep Apnea Syndromea using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
11029406|NCT04572490||Narrow platform implant|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
11029407|NCT04572490||Regular platform implants|All measurements will be obtained after dental implant functional loading. Periodontal index will be recorded and alveolar bone loss measurements will be made on periapical radiographs.
11029408|NCT04572477|Other|[18F]THK-5351|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.
~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.
~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.
~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
11029409|NCT04572477|Other|[18F]AV-45|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.
~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.
~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.
~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
11029410|NCT04572464|Experimental|Experimental|Mindfulness Based Guided Meditation
11029411|NCT04572451|Experimental|Nivolumab (Anti-PD-1) + BMS-986253 (Anti-IL-8) + SBRT|480 mg intravenous nivolumab (BMS-936558-01) every 4 weeks + 2,400 mg intravenous BMS-986253 (Anti-IL-8) every 2 weeks + Stereotactic Body Radiotherapy (SBRT)
11029412|NCT04572425|Active Comparator|Guided imagery|10 minutes of guided imagery (using Apple iPad and headphones, subject watches 10 minute video of a guided-imagery session depicting a peaceful walk through a forest with instrumental background music and 2-dimensional imagery)
11029413|NCT04572425|Experimental|Virtual reality|10 minutes of virtual reality (using study-administered Facebook Oculus Go VR headset with headphones, subject engages with VR application Forest of Serenity (Holosphere VR®, Birmingham, UK) that features a forest environment with voice narration that can be played in a seated or fixed position.
11029414|NCT04572412|Experimental|Low Dose Radiotherapy|Low Dose Radiotherapy
11029415|NCT04572399|Experimental|Endotracheal UV Light|Mechanically ventilated patients who will receive UV Light therapy
11029416|NCT04572386|Active Comparator|Light cure universal bond|light cured 3m single bond universal
11029417|NCT04572386|Active Comparator|self cure universal bond|self-cure universal bond (Palfique, Tokuyama, Japan)
11029418|NCT04572373||SMOFlipid group|"TPN and SMOFlipid support were indicated for patients who received NPO for more than 3 days, such as those with repeated laparotomy, staged biliary reconstruction, massive nasogastric (NG) drainage (>500 mL/day), ileus, diarrhoea, poor digestion (NG extraction >50 mL/time), and chylous ascites.
~Furthermore, SMOFlipid was discontinued when the platelet count decreased to 40,000/μL or less. In all cases, heparinisation was prescribed to maintain the aPTT level between 1.5 and 2 times the normal controlled level at least for 10-14 days, with daily blood examination conducted. Oral administration of dipyridamole (75 mg, QID) for 3 months was indicated for stimulation of antiplatelet activity when the platelet count increased to 40,000/μL or more."
11029419|NCT04572373||non SMOFlipid group|On the basis of our experience in patient management at this institute, we allocated patients with a pretransplant platelet count less than 40,000/μL and those with a count more than 40,000/μL to the non-SMOFlipid group and the SMOFlipid group , respectively. Patients with well-tolerated oral intake and those in whom the TPN supplement was discontinued within 10 days were excluded from this study.
11029447|NCT04572139||Oldest old participants|over 80 years old
11029448|NCT04572126|Experimental|Mindfulness Group|Participants in the mindfulness group will receive mindfulness based instructions.
11029420|NCT04572360|Experimental|Cardiorespiratory Exercise plus Chinese Herbal Medicines Group|"Includes:
~1.12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities.
~2.Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
11029421|NCT04572360|Experimental|Cardiorespiratory Exercise Group|"Includes:
~A 12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities."
11029422|NCT04572360|Experimental|Chinese Herbal Medicines Group|"Includes:
~Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
11029423|NCT04572360|No Intervention|Waiting List Group|The waiting list control sign will be adopted to conceal allocation results from the patients and further to reduce selection and confounding bias and increase their adherence to the study. Patients in the waiting list control group will receive no treatment in the study period (including a 12-week intervention period and a 12-week follow-up period). However, they will receive Chinese herbal medicines after the completion of the study (i.e., after the 3rd wave of measurements in the 25th weeks).
11029424|NCT04572347||Nurses working in PUTH|Participants will be recruited from Peking University Third Hospital through cluster sampling. Female registered nurses, licensed practical nurses and/or midwives with informed consent are included in this study. The exclusion criteria are student nurses and training nurses.
11029425|NCT04572334|Other|visual acuity and refractive outcome for Tecnis Eyhance|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
11029426|NCT04572334|Other|visual acuity and refractive outcome for Tecnis ZCB00|Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
11029427|NCT04572308|Experimental|CD7 CAR-T|Patients will be treated with CD7 CAR-T cells
11029428|NCT04572295|Experimental|Part 1 Dose Escalation: E7090 + Fulvestrant or Exemestane|Participants will receive E7090 tablets, orally, once daily in 28 days cycle along with fulvestrant 500 milligram (mg), intramuscular injection on Days 1 and 15 of Cycle 1 and each Day 1 of cycle 2 or later, or along with exemestane 25 mg tablet, orally, once daily in 28 days cycle.
11029429|NCT04572295|Experimental|Part 2 Monotherapy: E7090|Participants will receive E7090 tablets, orally, once daily in 28 days cycle.
11029430|NCT04572295|Experimental|Part 3 Dose Expansion: E7090 + Fulvestrant or Exemestane|"Participants will receive E7090 tablets, orally, once daily along with fulvestrant 500 mg, intramuscular injection on Days 1 and 15, or along with exemestane 25 mg, tablet, once daily in 28 days cycle.
~The dose of E7090 for Part 3 in combination with fulvestrant or exemestane will be determined based on the safety, tolerability, pharmacokinetic (PK), and biomarker data obtained from Part 1."
11029431|NCT04572282|Experimental|Mentora|Remote symptoms monitoring with mobile app
11029432|NCT04572269||Subjects with OSA|Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI >5)
11029433|NCT04572256|Experimental|Montelukast|Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
11029434|NCT04572256|Placebo Comparator|Placebo|Patients will receive an oral placebo daily for 6 months after surgery.
11029435|NCT04572243|Experimental|Lorcaserin (Core Study and Open-label Extension Phase)|Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
11029436|NCT04572243|Placebo Comparator|Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)|Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
11029437|NCT04572217|Experimental|Medication Group|"Adolescent patients post vertical sleeve gastrectomy who have had inadequate weight loss, who consented for use of off-label medications prescribed at the discretion (one or both) of physician.
~Patients will be followed every 2-12 weeks over one year.
~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
11029438|NCT04572217|No Intervention|Non-Medication Group|"Adolescent patients post vertical sleeve gastrectomy who had inadequate weight loss and did not consent for use of off-label medications.
~All patients in this group will continue to follow the standard of care procedures of our multidisciplinary bariatric clinic, including frequent follow-up appointments, nutrition guidance, vitamin supplementation, exercise instruction, and healthy lifestyle education."
11029439|NCT04572204||Conservative group|
11029440|NCT04572204||interventional group|
11029441|NCT04572178|Experimental|Cash payment and brief behavioral counseling|The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
11029442|NCT04572165||Ozempic|First-time ever users of Ozempic®
11029443|NCT04572165||Active comparator|First-time ever users of an active comparator drug
11029449|NCT04572126|Active Comparator|Control Group|Participants in the control group will receive instructions to cope with cravings how they normally would.
11029450|NCT04572113||No collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are not wearing a cervical collar
11029451|NCT04572113||DJO collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a DJO cervical collar
11029452|NCT04572113||Miami J collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a Miami J cervical collar
11029453|NCT04572100|Experimental|Group A - Low Risk|Participants who have low-risk cancer and significant reduction (greater than 50%) in tumor size following induction therapy will be assigned to this group.
11029454|NCT04572100|Experimental|Group B - Intermediate Risk|Participants who have low-risk cancer and intermediate reduction (30-50%) in tumor size or high-risk cancer with significant reduction (greater than or equal to 50%) in tumor size following induction therapy will be assigned to this group.
11029455|NCT04572100|Experimental|Group C - High-Risk|Participants who have high-risk cancer and less than a 50% reduction in their tumor size following induction therapy will be assigned to this group.
11029456|NCT04572100|Experimental|Induction Therapy (Carboplatin and Paclitaxel)|All study participants will be assigned to this group to first receive induction therapy using a combination of carboplatin and paclitaxel. Participant response to this phase of therapy will determine which group (low-risk, intermediate risk or high-risk) the participant will be in.
11029457|NCT04572087|Experimental|Cognitive Control Training + Verum stimulation|This arm consists of the cognitive control training (six sessions) combined with 2mA anodal tDCS over the right dlPFC (F4) during the training for 20 minutes.
11029458|NCT04572087|Active Comparator|Cognitive Control Training + Sham stimulation|This arm consists of cognitive control training (six sessions) with sham-tDCS. 2 mA Sham-tDCS (40 seconds of tDCS) is applied to the right dlPFC (F4) before the trainings starts.
11029459|NCT04572074|Active Comparator|Arm 1 (Guided imagery)|10 minutes of guided imagery experience
11029460|NCT04572074|Experimental|Arm 2 (Virtual reality)|10 minutes of virtual reality experience
11029461|NCT04572048|Other|Single-day NRP training|This group will follow the single-day NRP training course that is currently the standard. It usually takes 8 hours to complete this training course and the nurses are released from their clinical duty to attend the training course.
11029462|NCT04572048|Experimental|Longitudinal one year NRP Training|This group will follow the longitudinal NRP training course. The longitudinal NRP training course will consist of nine 30-minute modules that will be taught every 6-8 weeks over a period of one year. The nurses will attend the different modules of the training course at their work place and during their work shift so they will have to be released from their clinical duty only 30 minutes at a time.
11029463|NCT04572035|Experimental|Exercise only|Undergraduate peer-facilitators part of a curricular kinesiology practicum will facilitate a personalized exercise program adapted to the participant's abilities, teach participants how to exercise, and gauge exercise intensity in a safe manner (26). The CANMAT guidelines will be implemented, with the program consisting of supervised moderate-intensity exercise sessions lasting 30-minutes (plus 10-minutes for warm-up and cool-down), 3 times weekly, for a period of 10-weeks. Participants will start exercising at a low intensity and progressively increase until they are consistently exercising at a moderate intensity. As a result of the uncertainty surrounding the pandemic, the intervention will be conducted either via a virtual platform or in-person at the Exercise and Health Psychology Lab, depending on the health and safety restrictions applicable to when the student enrolls and begins their program.
11029464|NCT04572035|Experimental|Exercise + Self-compassion|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks).
11029465|NCT04572035|Experimental|Exercise + Behavioural Coaching|Participants will undergo the same exercise program as described in the exercise only treatment arm. Participants will receive equal contact supplemental individual manualized strategies each session (+15-20 minutes) centered on behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting).
11029466|NCT04572022|Experimental|Intervention group rehabilitation teaching video instructions|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions module.
11029467|NCT04572022|No Intervention|Control group|Control group receive proximal humerus fracture standard care only.
11029468|NCT04572009|Experimental|Augmented physician|Medical decision assisted by the bio-mathematical model to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
11029469|NCT04572009|Placebo Comparator|Control|Unassisted medical decision to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
11029470|NCT04571996|Experimental|ODM-104 and Panadol Zapp|
11029471|NCT04571970|Experimental|Single Arm|6.5 × 10^10 GC/g brain mass of RGX-121
11029472|NCT04571957||Donors with NASH|Donors with NASH underwent donor optimization protocol
11029473|NCT04571957||Donors without NASH|Donors without NASH
11029474|NCT04571944|Experimental|Suvorexant|Participants will receive 15 mg of suvorexant orally once daily (QD) for 5 to 7 days.
11029475|NCT04571944|Placebo Comparator|Placebo|Participants will receive suvorexant-matching placebo orally QD for 5 to 7 days.
11029476|NCT04571918|Experimental|Group A: Biodegradable spacer|Intervention group
11029477|NCT04571918|Active Comparator|Group B: control group|Control group
11029478|NCT04571905|Other|Syntellix Treatment Arm|General anaesthesia, open fracture reduction, insertion of the appropriate screw with x-ray control and documentation intraoperatively, cast immobilisation Use of bioresorbable Magnezix CS or CBS Screws, if intraoperatively suitable bioresorbable screws not available, use of conventional ostesynthesis screws
11029479|NCT04571892|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
11029538|NCT04571515|Experimental|MR-107A-01 10 mg twice in a 24-hour period|Oral tablet one day of dosing
11037298|NCT04518241|Experimental|Condition 8|Core, lottery prize
11029480|NCT04571879|Experimental|Arm 1|"Nebulized 2% lidocaine hydrochloride 4 mg/kg to be delivered via nebulization (up to a maximum of 15 ml) and given over ½ hr.
~Intranasal midazolam 0.5 mg/kg delivered via intranasal atomization (up to a maximum of 10 mg)."
11029481|NCT04571879|Experimental|Arm 2|"Intranasal midazolam 0.5 mg/kg to be delivered via intranasal atomization (up to a maximum of 10 mg).
~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
11029482|NCT04571879|Placebo Comparator|Arm 3|"Intranasal placebo (normal saline) in a volume comparable to midazolam 0.5 ml/kg to be delivered via intranasal atomization
~Nebulized placebo (Normal saline) in a volume comparable to 2% lidocaine at 4 mg/kg (up to a maximum of 15 ml) and given over ½ hr."
11029483|NCT04571866|Experimental|Beta-glucan bread|Participants will receive a standardised meal consisting of beta-glucan-enriched bread (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participants will be asked to spend approximately 10 minutes consuming the standardised meal.
11029484|NCT04571866|Sham Comparator|Control bread|Participants will receive a standardised meal consisting of a wheat bread with no additives (in an amount corresponding to 25 g of available dietary carbohydrates) and water (250 ml). The bread is produced by NOFIMA AS, one of the collaborating parties. The participant will be asked to spend approximately 10 minutes consuming the standardised meal.
11029485|NCT04571853|Experimental|PNE-explained group|The participants in the PNE-explained group will be explained the fact sheets with an explanatory video (due to COVID-19 circumstances) conducted by the therapist M.S. The video will last one hour approximately and it contains a presentation by Mayte Serrat with a view of the fact sheets. This group will be given one week to watch the video and comprehend its content.
11029486|NCT04571853|Active Comparator|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
11029487|NCT04571853|Active Comparator|TAU group|Participants allocated into this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professional.
11029488|NCT04571840|Active Comparator|mpMRI|Multiparametric MRI
11029489|NCT04571840|Experimental|bpMRI|Biparametric MRI
11029490|NCT04571827|Experimental|Placebo Effect|"Group with positive expectation: it is a very effective technique that achieves excellent results in the improvement of the cervical musculature
~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
11029491|NCT04571827|Experimental|Nocebo Effect|"Group with negative expectation: this is a technique that will cause discomfort in the area of intervention of the cervical muscles after applying it .
~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
11029492|NCT04571827|Experimental|Neutral Effect|"Group with neutral expectations: It's a physical therapy technique used to treat neck pain and we're investigating its effects
~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
11029493|NCT04571814|Experimental|Parent and child intervention|Both parent and child will receive a computerized intervention to reduce error sensitivity.
11029494|NCT04571814|Experimental|Parent intervention and child control|Parent will receive a computerized intervention to reduce error sensitivity and child will receive an active control (a computerized program targeting health behaviors).
11029495|NCT04571814|Experimental|Parent control and child intervention|Child will receive a computerized intervention to reduce error sensitivity and parent will receive an active control (a computerized program targeting health behaviors).
11029496|NCT04571814|Active Comparator|Parent and child control|Both parent and child will receive an active control (a computerized program targeting health behaviors).
11029497|NCT04571801|Active Comparator|1|Standard diagnostics
11029498|NCT04571801|Experimental|2|Standard diagnostics + NGS
11029499|NCT04571788||FCB group|FCB group received FCB implantation
11029500|NCT04571788||Control group|Control group undergoes silicone scleral pad surgery
11029501|NCT04571775|Active Comparator|Qi-Shield user group|
11029502|NCT04571775|Sham Comparator|Sham Qi-Shield user group|
11029503|NCT04571775|No Intervention|No Qi-Shield device group|
11029504|NCT04571762|Experimental|Single arm|Patients with low-risk, intermediate-risk and low-volume metastatic prostate cancer eligible for stereotactic body radiotherapy will be recruited.
11029505|NCT04571749|Experimental|Customized Or to ICU handoff protocol|Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.
11029506|NCT04571736|Active Comparator|access to the internet information platform|usual preoperative information and access to the internet information platform
11029507|NCT04571736|No Intervention|usual preoperative information|medical information delivered to the patient before any surgery
11029508|NCT04571723|Active Comparator|Established Diabetes Prevention Program|This arm will receive the established diabetes prevention program curriculum.
11029509|NCT04571723|Active Comparator|Health Mindset modified Diabetes Prevention Program|This arm will receive the modified curriculum with the added health mindset information.
11029510|NCT04571710|Experimental|Treatment group|Intervention: Drug: SHR1258 400mg
11029511|NCT04571697||Participants Initiating Therapy with Methotrexate or Anti-TNF|Data will be collected for participants initiating therapy with either methotrexate or an anti-tumor necrosis factor (TNF) from united states (US) claims databases: optum de-identified clinformatics data mart database and IBM marketscan medicare supplemental database (MDCR). Data collection period: 01-Jan-2000 through 31-Jul2019.
11029539|NCT04571515|Placebo Comparator|Placebo twice in a 24-hour period|Placebo tablet one day of dosing
11029540|NCT04571502|Experimental|Full Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the experimental arm will have access to use CareHeroes AND the newly developed AAC app. Provider will receive information via the AAC app.
11029512|NCT04571684|Experimental|Intervention Arm (HITSystem 2.1)|Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed.
11029513|NCT04571684|No Intervention|Control Arm (Standard of care)|Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up.
11029514|NCT04571671||Study group|Women with Müllerian anomalies who have received an oocyte donation. The diagnosis of Müllerian anomalies is established when a cavity is demonstrated uterine abnormality with any of the defects described in the American classifications or European in transvaginal ultrasound, hysteroscopy or hysterosalpingography (HSG). The differential diagnosis in case of doubts is established with 3D ultrasound, MRI or hystero / laparoscopy. All the septa have been resected prior to performing the OVODON cycle.
11029515|NCT04571671||Control group|Patients who receive donated oocytes and who do not present Müllerian anomalies. An absence of AM, a transvaginal ultrasound, an HSG or a normal hysteroscopy with a uterine cavity with a normal shape and absence of intracavitary images is considered
11029516|NCT04571658||NEPTUNE Match Participants|"Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas.
~NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years."
11029517|NCT04571645|Experimental|Dociparstat sodium (DSTAT)|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Dociparstat 4 mg/kg IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
11029518|NCT04571645|Placebo Comparator|Placebo|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Placebo IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
11029519|NCT04571632|Active Comparator|Immediate treatment arm:|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1, approximately 2 hours after the last SBRT fraction, intratumoral injection of ipilimumab (Yervoy®, 50mg/10mL solution) at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) and avelumab (Bavencio®, 200mg/10mL solution) at maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) will be performed. Subject will also receive a standard 200mg (fixed dose) intravenous infusion of pembrolizumab (Keytruda®, 100 mg/4mL solution).
~On day 2, autologous, non-substantially manipulated CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be intratumorally administered. Previously cryopreserved CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be thawed before administration.
~On day 21 and every 21 days thereafter, IT injection of ipilimumab and avelumab and IV pembrolizumab at the same dose as on day 1 will be performed. Treatment will be discontinued upon disease progression"
11029520|NCT04571632|Active Comparator|Contemporary control arm|"On day -3, -1 and 1, SBRT fractions of 8 Gy will be administered to subjects. On day 1 and every + 21 days thereafter, subjects will receive a standard 200mg (fixed dose) IV pembrolizumab (Keytruda®, 100 mg/4mL solution) dose.
~On disease progression, intratumoral administration as in the immediate-treatment arm will be conducted. Thus, intratumoral injection of ipilimumab at a maximum total dose of 10 mg and avelumab at maximum total dose of 40 mg will be performed. Administration of pembrolizumab at a dose of 200 mg will be continued.
~Tumor response assessments by whole body PET/CT will be scheduled in week 12 and every 12 weeks thereafter during the treatment phase; . Baseline scan will be performed during screening period Procurement of tumor tissue by fine needle aspirates will be performed at the time of every intra-tumoral study drug administration"
11029521|NCT04571619|Active Comparator|Pain Coping Skills Training|
11029522|NCT04571619|No Intervention|Usual Care|
11029523|NCT04571619|Active Comparator|Buprenorphine|
11029524|NCT04571619|No Intervention|No Buprenorphine|
11029525|NCT04571606|Active Comparator|Liposomal Bupivacaine|Pre-operative ultrasound guided interscalene nerve block with 10 mL 1.3% liposomal bupivacaine (Exparel) and 10 mL 0.5% bupivacaine
11029526|NCT04571606|Active Comparator|Peripheral Nerve Catheter|Pre-operative ultrasound guided interscalene nerve block with 20 mL of 0.25% bupivacaine and placement of peripheral nerve catheter with 10 mL/hr 0.2% bupivacaine infusion via OnQ pump.
11029527|NCT04571593|Experimental|Digital Yoga Nidra|"Participants will voluntarily complete a ~30-minute remote Yoga Nidra practice, synchronously (through Zoom Wednesdays at 10 pm ET) or asynchronously (through YouTube, using the Zoom recording, any time they like).
~They may voluntarily repeat this practice as often as they like. Recordings are updated weekly, to reflect the ongoing Zoom class. Yoga Nidra scripts from Satyananda Saraswati's Yoga Nidra book (1976) are used for this class."
11029528|NCT04571580|Placebo Comparator|placebo|
11029529|NCT04571580|Experimental|reteplase 9mg|
11029530|NCT04571580|Experimental|reteplase 18mg|
11029531|NCT04571567|Experimental|Secukinumab|300mg subcutaneously
11029532|NCT04571528|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
11029533|NCT04571528|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
11029534|NCT04571528|Active Comparator|Physiotherapy part of VIRTUA FIBROWALK|The physiotherapy part of the VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
11029535|NCT04571515|Experimental|MR-107A-01 15 mg once in a 24-hour period|Oral tablet one day of dosing
11029536|NCT04571515|Experimental|MR-107A-01 10 mg once in a 24-hour period|Oral tablet one day of dosing
11029537|NCT04571515|Experimental|MR-107A-01 15 mg twice in a 24-hour period|Oral tablet one day of dosing
11029541|NCT04571502|Active Comparator|Minimal Intervention|TRIADs (caregiver, PWD, and provider) randomly assigned to the minimal intervention arm will have access to use CareHeroes BUT only a paper version of the newly developed AAC app.
11029542|NCT04571489|Experimental|Gimatecan group|All patients will receive gimatecan (0.8mg/m2, on days 1 to 5, PO, every 4 weeks) until progressive disease (PD).
11029543|NCT04571489|Placebo Comparator|placebo group|All patients will receive tegafur, gimeracil and oteracil potassium (40-60mg, twice daily, on days 1 to 14 , PO, every 3 weeks) or gemcitabine (1000mg/m2, on days 1、8, IV, every 3 weeks) until progressive disease (PD).
11029544|NCT04571476|Experimental|UTB-VBN-EBUS group|Ultrathin bronchoscope with a 3.0-mm outer diameter and a 1.7-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN and EBUS.
11029545|NCT04571476|Active Comparator|TB-VBN-EBUS-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using 1.5-mm biopsy forceps and 1.4-mm cytology brush with the guidance of VBN-EBUS and a 1.95-mm outer diameter guide sheath.
11029546|NCT04571476|Active Comparator|TB-VBN-EBUS-non-GS group|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel was used in this group. Specimens were obtained using conventional biopsy forceps and cytology brush with the guidance of VBN and EBUS, but without guide sheath.
11029547|NCT04571463||HUCS A|Mothers visiting the prenatal care units within the Helsinki area.
11029548|NCT04571463||HUCS HAL|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area.
11029549|NCT04571463||PHHYKY A|Mothers visiting the prenatal care units within the Lahti area.
11029550|NCT04571463||PHHYKY HALSO|Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area.
11029551|NCT04571450|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
11029552|NCT04571437|Active Comparator|Chemo endocrine treatment (A)|Letrozole 2.5mg PO daily + Capecitabine 500mg/m2 bid PO continously
11029553|NCT04571437|Active Comparator|Endocrine treatment only (B)|Letrozole 2.5mg PO daily
11029554|NCT04571424|Experimental|Cohort 1: BIIB133 Dose 1|Participants will receive single IV infusion of BIIB133 Dose 1.
11029555|NCT04571424|Experimental|Cohort 2: BIIB133 Dose 2|Participants will receive single IV infusion of BIIB133 Dose 2.
11029556|NCT04571424|Placebo Comparator|Cohort 1-2: Placebo|Participants will receive single IV infusion of matching placebo to BIIB133.
11029557|NCT04571385|Experimental|Part 1: AP30663|Participants will receive single dose of AP30663.
11029558|NCT04571385|Placebo Comparator|Part 1: Placebo|Participants will receive placebo matched to AP30663.
11029559|NCT04571385|Experimental|Part 2: AP30663|Participants will receive a single dose of one of the multiple dose levels of AP30663.
11029560|NCT04571385|Placebo Comparator|Part 2: Placebo|Participants will receive placebo matched to AP30663.
11029561|NCT04571372||Patients with severe aortic stenosis or severe aortic regurgitation|Patients with severe aortic stenosis or severe aortic regurgitation
11029562|NCT04571346|Active Comparator|the classical TOT procedure|performing the trans-obturator procedure through the standard vertical incision
11029563|NCT04571346|Experimental|2 paramedian vertical incisions|performing the trans-obturator procedure through a new technique of 2 paramedian vertical incisions
11029564|NCT04571333|Experimental|Mi2000 Cochlear Implant surgery|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
11029565|NCT04571320|Experimental|Summer STRIPES|Up to two weeks of daily high school orientation (four hours per day) immediately prior to the start of ninth grade, staffed by peer interventionists (2:1 ratio + extra interventionist in case of absences) and a school staff member. Two sessions of summer parent training. During the school year, ninth grade students will continue to meet weekly with their peer interventionists in a group setting under the supervision of the school staff sponsor. School year follow-up component of summer STRIPES will occur for 16 weeks and will include weekly 30 minute meetings between peer and target students. Parent components during the school year will include optional monthly group problem solving sessions with the school staff sponsor and school mental health liaison and a weekly phone call (up to five minutes) from the school staff sponsor to discuss home contingency management.
11029566|NCT04571320|Active Comparator|Enhanced School Services as Usual|Students who are assigned to the SSU plus group will be referred to their identified school counselor for referral to services available in the school setting. The counselor will be provided with a report from the student's intake assessment that summarizes the student's symptoms and presenting problems. The student will also receive new school supplies at the beginning of ninth grade. In our past trials, SSU plus students typically received subject-specific tutoring or after-school homework help. We will systematically track services received by students in the SSU plus condition.
11029567|NCT04571294|Experimental|group A|PALN removal
11029568|NCT04571294|No Intervention|group B|No PALN removal
11029569|NCT04571268||Healthy validation subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for the purpose of developing and validating the biomechanical models used to track scapular motion
11029570|NCT04571268||Healthy comparison subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for comparison of shoulder motion and muscle activation patterns with RCT subjects
11029571|NCT04571268||RCT subjects|Subjects who have sustained a major rotator cuff tear
11029572|NCT04571255|Experimental|Intervention group|Participants in the intervention group will receive a minimum of 3 and a maximum of 6 music therapy sessions (i.e. Music-Assisted Relaxation) during a two weeks time frame.
11029573|NCT04571255|No Intervention|Control Group|Treatment as usual.
11029605|NCT04570995|Placebo Comparator|safflower oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing a placebo oil product (safflower oil) encapsulated in soft gel capsules.
11029606|NCT04570982||Convalescent Plasma with SOC|All patients will receive CPT and SOC
11029607|NCT04570969|No Intervention|standard of care|Peri-operative analgesia by opioids
11029608|NCT04570969|Experimental|Peri operative regional analgesia|Peri-operative analgesia by Continuous bilateral Erector Spinae Catheters
11029574|NCT04571242|Active Comparator|DTM-SCS program|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and participants tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
11029575|NCT04571242|Active Comparator|Conventional SCS program|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test and Control treatments, which may identify the type of treatment to study participants. Also, open communication about sensation of paresthesia and pain relief is important in adjusting program parameters to provide optimal pain relief for participants. The assessments of device performance are done by the participants and not by the site personnel so the lack of blinding of site personnel should not affect results as pain is the major assessment and subjects tend to describe pain truthfully since it affects their everyday life dramatically and not be influenced by knowledge of the device programming.
11029576|NCT04571216|Experimental|NFL-101 Dose 1|50 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
11029577|NCT04571216|Experimental|NFL-101 Dose 2|100 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
11029578|NCT04571216|Placebo Comparator|Placebo|The placebo will consist of two syringes containing 1 mL of dilution solution, two injections at day 1, two injections at day 8, optional injections later on
11029579|NCT04571203|Experimental|Phase I Study of Combined DD Kidney and HCT Transplant|Single arm Phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion
11029580|NCT04571190|Experimental|Prenatal MBSR|The prenatal MBSR program consists of nine two-hour sessions including teachings in mindfulness meditation and yoga. The program is taught by an experienced MBSR instructor with relevant clinical expertise.
11029581|NCT04571190|No Intervention|Usual care|Standard clinical practice, usual care (TAU), imply routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Usual care include a multidisciplinary approach involving preventive counselling by midwifes, physicians and social workers throughout the pregnancy and follow-up until the early post-partum period.
11029582|NCT04571164|Experimental|LY03003|
11029583|NCT04571164|Placebo Comparator|Placebo|
11029584|NCT04571151|Active Comparator|Lexette + Sorilux|"Halobetasol Propionate Topical Foam (Lexette Foam) + Calcipotriol Foam (Sorilux Foam) for 2 weeks
~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.
~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g."
11029585|NCT04571151|Placebo Comparator|Lexette + Vehicle|"Halobetasol Propionate Topical Foam (Lexette Foam) + Vehicle Foam for 2 weeks
~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.
~Vehicle Foam would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application."
11029586|NCT04571151|Active Comparator|Sorilux|"Calcipotriol Foam (Sorilux Foam) for 6 weeks
~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.
~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 6 weeks. SORILUX Foam contains calcipotriene 50 mcg/g."
11029587|NCT04571151|Placebo Comparator|Vehicle|"Vehicle Foam for 6 weeks.
~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.
~Vehicle Foam would be applied over the affected area twice daily for 6 weeks."
11029588|NCT04571138|Experimental|SCRI-CAR22v2|Patients will receive SCRI-CAR22v2 in either Phase I or Phase II
11029589|NCT04571125||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
11029590|NCT04571125||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
11029591|NCT04571112|Experimental|NBM ON|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.
~The NBM ON arm will have constant NBM stimulation for 8 weeks."
11029592|NCT04571112|Sham Comparator|NBM OFF|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.
~The NBM OFF arm will have NBM stimulation turned off for 8 weeks."
11029593|NCT04571073|Experimental|Treatment arm|The only arm in the study was the intervention arm as this is a pilot study.
11029594|NCT04571060|Active Comparator|BHV-3500|Zavegepant (BHV-3500)
11029595|NCT04571060|Placebo Comparator|Placebo|Matching placebo
11029596|NCT04571047||Colorectal cancer patients|Patients diagnosed with colonrectal cancer between 2008-2016
11029597|NCT04571034|Sham Comparator|Control Group|Healthy adults receiving sham comparator.
11029598|NCT04571034|Experimental|Medium-Intensity Roller Massage|Healthy adults receiving medium-intensity roller massage.
11029599|NCT04571034|Experimental|High-Intensity Roller Massage|Healthy adults receiving high-intensity roller massage.
11029600|NCT04571021|Experimental|I-DEPT|Novel triage. The triage nurse can adjust the triage category one level of urgency down or one or two levels up.
11029601|NCT04571021|Active Comparator|DEPT|Existing triage algorithm
11029602|NCT04571008|Placebo Comparator|Placebo|At least 16 weeks of placebo.
11029603|NCT04571008|Experimental|NMN supplementation|At least 16 weeks of NMN.
11029604|NCT04570995|Active Comparator|fish oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing fish oil encapsulated in soft gel capsules.
11029609|NCT04570956|Experimental|Oral Tamoxifen 10 mg/day|Oral Tamoxifen 10 mg/day
11029610|NCT04570956|Experimental|Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day|"Topical 4-OHT (4-hydroxytamoxifen) gel 2 mg/each breast/day
~+oral placebo"
11029611|NCT04570956|Experimental|Control|Oral and gel placebo
11029612|NCT04570943|Experimental|Gabrinox followed by stereotactic radiotherapy|"Gembrax:
~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest
~Folfirinox:
~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
11029613|NCT04570930|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of Health- Related Quality of Life (HRQOL) and receive personalized pushes over a six-month (180 day) period.
11029614|NCT04570930|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period (without the personalized feedback).
11029615|NCT04570917|Experimental|Intervention group (INT)|An online learning module targeted to reduce ageism will be delivered to the INT group.
11029616|NCT04570917|Active Comparator|Control group (CON)|An online learning module on diversity and cultural competence will be delivered to the CON group.
11029617|NCT04570904||Early HCWs|Health Care Workers vaccinated early prior to the influenza season
11029618|NCT04570904||Late HCWs|Health Care Workers vaccinated just prior to the influenza season
11029619|NCT04570904||Inpatients|Inpatients recruited for evaluation of new approaches to influenza diagnosis
11029620|NCT04570891|Experimental|FICB|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
11029621|NCT04570891|Placebo Comparator|Control|No regional block is provided at the end of surgery.
11029622|NCT04570878|Experimental|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
11029623|NCT04570878|Active Comparator|Control|No regional block is provided at the end of surgery.
11029624|NCT04570865|Experimental|Dapagliglozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
11029625|NCT04570852|Experimental|Intensive monitoring of patients|State of the art biochemical assessment of patients with acute pancreatitis including multi-OMICS focusing on transcriptomics and proteomics.
11029626|NCT04570839|Experimental|Dose Escalation Cohorts.|Up to 5 sequential dose escalation cohorts of COM701 in combination with fixed doses of BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks until a maximum tolerated dose or recommended dose for expansion is identified.
11029627|NCT04570839|Experimental|Cohort 1 Expansion Cohort A (ovarian cancer)|Subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with COM701 in combination with BMS-986207 and nivolumab. The study drugs will be administered IV every 4 weeks.
11029628|NCT04570839|Active Comparator|Cohort 1 Expansion Cohort A (ovarian cancer).|Subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with nivolumab monotherapy. The study drug will be administered IV every 4 weeks.
11029629|NCT04570839|Experimental|Cohort 2 Expansion Cohort (endometrial cancer).|Single arm: subjects with MSS-endometrial cancer will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
11029630|NCT04570839|Experimental|Cohort 3 Expansion Cohort (basket cohort - high PVRL2 tumors).|Single arm: subjects with tumor types with high expression of PVRL2 will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
11029631|NCT04570826|Experimental|Meditation program|The experimental group participated in the Meditation program during one month, eight sessions with a total of sixteen hours.
11029632|NCT04570826|Active Comparator|Scientific descriptions about meditation|The control group received scientific descriptions about meditation.
11029633|NCT04570813|Experimental|artistic activities|"participants will do a 3-month cycle of weekly artistic activities at the MAMAC Museum, which are structured 2-h-long art-based workshops"
11029634|NCT04570813|No Intervention|No artistic activities|The control group is composed of participants who do not take part in art-based activities,
11029635|NCT04570787|Active Comparator|No Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. Bladder catheterization is not performed.
11029636|NCT04570787|Active Comparator|Catheterization|After mini-PCNL standardized follow-up protocol supposes drainage the upper urinary tract with nephrostomy, tubeless (using ureteral stent without nephrostomy) or totally tubeless (no drainage) tactics. The bladder is to be drained with the urethral catheter in all cases.
11029637|NCT04570774|Experimental|Facilitatory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
11029638|NCT04570774|Active Comparator|Facilitatory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the affected primary motor cortex of the hand and sham high-frequency rTMS over the ipsilateral cerebellar hemisphere.
11029639|NCT04570774|Experimental|Inhibitory cerebral and cerebellar rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and high-frequency rTMS over the ipsilateral cerebellar hemisphere.
11029640|NCT04570774|Active Comparator|Inhibitory cerebral rTMS group|Patients underwent 10 consecutive daily sessions of continous theta bust stimulation (cTBS) over the unaffected primary motor cortex of the hand and sham rTMS over the ipsilateral cerebellar hemisphere.
11029641|NCT04570761|Experimental|ON-Stim|acoustic stimulation
11029642|NCT04570761|Sham Comparator|OFF-Stim|no acoustic stimulation
11029643|NCT04570748|Experimental|Group A|Direct anterior hip arthroplasty with capsule repair.
11029644|NCT04570748|Active Comparator|Group B|Surgery that the surgeon will not perform capsule repair after performing an initial capsulectomy during total hip arthroplasty
11029646|NCT04570735||patients with type 2 diabetes and no diabetic kidney disease|
11029647|NCT04570735||patients with obesity, no diabetes and no kidney disease|
11029648|NCT04570722|Other|Single arm study|Patients with a history of axillary surgical lymph node procedures (SLNP) presenting for routine radiographic scan will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Patients will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt.
11029649|NCT04570709|No Intervention|Control|Patients in the control arm will receive standard of care.
11029650|NCT04570709|Experimental|Intervention|Patients in the intervention arm will receive the PACT intervention provided by a multidisciplinary team of RNs, OTs, and PTs.
11029651|NCT04570696||Adult haemophilia patients|Adult (≥ 18 years old) haemophilia patients, only men
11029652|NCT04570683|Active Comparator|AFL monotherapy|Singe dose AFL as monotherapy, 100 mJ
11029653|NCT04570683|Active Comparator|AFL+nivolumab|Single dose AFL 100 mJ followed by immediate intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
11029654|NCT04570683|Active Comparator|nivolumab monotherapy|Intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
11029655|NCT04570670|Experimental|Test (BLS-11)|A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1
11029656|NCT04570670|Active Comparator|Reference (Tecfidera)|A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1
11029657|NCT04570657|Experimental|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
11029658|NCT04570657|Experimental|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
11029659|NCT04570657|Placebo Comparator|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
11029660|NCT04570644|Other|Part A|"24 subjects randomized to receive treatment: (A-B) = Single 17.1 mg oral inhaled dose of ALZT-OP1a (cromolyn) via dry powder inhaler and a single oral 10 mg tablet of ALZT-OP1b (ibuprofen) on Day 1. On Day 2, subjects would receive two 17.1 mg doses of ALZT-OP1a via dry powder inhaler and two 10 mg tablets of ALZT-OP1b (ibuprofen), within two minutes of each other.
~(B-A) = Two 17.1 mg doses of ALZT-OP1a (cromolyn) and two doses of 10 mg ALZT-OP1b (ibuprofen) on Day 1 and single 17.1 mg dose of ALZT-OP1a cromolyn 17.1 mg and a single 10 mg dose of ALZT-OP1b (ibuprofen) on Day 2.
~All subjects will have plasma and CSF collected for PK analysis."
11029661|NCT04570644|Other|Part B|"PD - 32 subjects (AD only) will be enrolled in the PD portion of the study. Twenty-four (24) subjects will be assigned to Treatment Group 1 to receive a single (17.1 mg) inhaled dose of ALZT-OP1a (cromolyn) plus a single (10 mg) oral dose of ALZT-OP1b (ibuprofen) daily for 60 days.
~All subjects will have plasma and CSF collected for PD biomarker analysis. Eight (8) A subjects will be assigned to Treatment Group 2 (Control Group) and will not be administered study drug."
11029662|NCT04570631|Experimental|Safety Lead-in|Participants will receive escalating doses of eftozanermin alfa in combination with bortezomib and dexamethasone to determine recommended phase 2 dose (RP2D).
11029663|NCT04570631|Experimental|Dose Expansion|Participants will receive eftozanermin alfa at RP2D determined in Safety Lead-in part in combination with bortezomib and dexamethasone.
11029664|NCT04570618|Sham Comparator|Standard of Care|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines.
11029665|NCT04570618|Experimental|Standard of Care + AlgoDx Sepsis Prediction Algorithm|Subjects are monitored for potential development of sepsis according to the local established clinical management guidelines, and sepsis prediction algorithm alerts are unblinded to clinical staff.
11029666|NCT04570605|Active Comparator|Standard Urotherapy|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management.
11029667|NCT04570605|Experimental|Standard Urotherapy + PTENS|Patients who meet eligibility criteria who will be counselled on standard recommendations for bladder management AND use parasacral percutaneous TENS as additional treatment.
11029668|NCT04570592|Placebo Comparator|Granisetron|Granisetron 1 mg (1ml) + Normal saline 1ml
11029669|NCT04570592|Experimental|Granisetron and Dexamethasone|Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)
11029670|NCT04570579||Observational cohort|"This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day (postoperative day 1), 1 week (postoperative week 1), 1 month (postoperative month 1) and 3 months (postoperative month 3) following surgery."
11029671|NCT04570566|Experimental|titanium mish|horizontal alveolar ridge augmentation with non-resorbable titanium mish .evaluation after 4 months
11029672|NCT04570566|Experimental|pericardium membrane|horizontal alveolar ridge augmentation with resorbable pericardium membrane then .evaluation after 4 month.
11029673|NCT04570553|Experimental|V-care uterine manipulator|Patients in the V-care uterine manipulator arm will undergo standard staging surgery utilizing a V-care uterine manipulator in the standard fashion
11029674|NCT04570553|Active Comparator|Sponge stick|Patients in the sponge stick arm will undergo standard staging surgery utilizing a non-invasive sponge stick for cervical delineation.
11029675|NCT04570540||OSA|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9.
11029708|NCT04570358|Experimental|Static stretching|An 8-week home-based static stretching training for the calf muscles will be performed by group A. Altogether, 10 stretches are performed per leg 4 times a week.
11029676|NCT04570540||OSA+SH|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during sleep, defined by the presence of intermittent hypercapnia as measured by transcutaneous capnometry and arterialized capillary blood gas analysis.
11029677|NCT04570540||OHS|Obstructive Sleep Apnea as confirmed by full-night attended in-lab polysomnography showing an apnea-hypopnea index of >=15 per hour or, alternatively, an apnea-hypopnea index >=5 with excessive daytime sleepiness as defined by an Epworth Sleepiness Scale score >9. Furthermore, co-existing hypoventilation during wakefulness, defined by a PCO2>45mmHg as measured by arterialized capillary blood gas analysis.
11029678|NCT04570527||Obesity|BMI>=25
11029679|NCT04570527||Non-Obesity|BMI<25
11029680|NCT04570514||Obesity|Patients with Obesity. BMI>=25
11029681|NCT04570514||Non-Obesity|Patients without Obesity. BMI<25
11029682|NCT04570501|Experimental|Angiotensin (1-7)|Participants receive treatment for 7 days.
11029683|NCT04570501|Placebo Comparator|Placebo|Participants receive treatment for 7 days.
11029684|NCT04570488|Experimental|Intervention|Display of risk score/ colored flag in Epic patient list column; will be viewable to all frontline workers
11029685|NCT04570488|No Intervention|Control|"No display (hidden) of risk score/ colored flag in Epic patient list column; not viewable to all frontline workers"
11029686|NCT04570475|Experimental|vitamin D+multivitamin|
11029687|NCT04570475|Active Comparator|placebo+multivitamin|
11029688|NCT04570462|Experimental|Experimental Arm- Induction of Mild Hypothermia Protocol|Determination of metabolic rate by the metabolic cart (noninvasive connection of the device to the ventilator for 20 minutes). Initiate hypothermia (established Northwell hypothermia status post cardiac arrest protocol) using the Arctic Sun. The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.
11029689|NCT04570449|Experimental|Fluoxetine|"Participants instructed to take fluoxetine 20 mg capsule orally daily for 8 weeks in the following schedule:
~Week 1 = 1 pill (20 mg), Week 2 = 2 pills (40 mg), Weeks 3-6 = 3 pills (60 mg), Week 7 = 2 pills (40 mg), Week 8 = pill (20 mg)"
11029690|NCT04570449|Placebo Comparator|Placebo|"Participants instructed to take fluoxetine placebo capsule matching fluoxetine orally daily for 8 weeks in the following schedule:
~Week 1 = 1 pill, Week 2 = 2 pills, Weeks 3-6 = 3 pills, Week 7 = 2 pills, Week 8 = pill"
11029691|NCT04570436|Experimental|gabapentin 600 mg|single dose
11029692|NCT04570436|Active Comparator|diazepam 20 mg|single dose
11029693|NCT04570436|Placebo Comparator|placebo|single dose
11029694|NCT04570436|Experimental|gabapentin 1200 mg|single dose
11029695|NCT04570436|Experimental|gabapentin 1800 mg|single dose
11029696|NCT04570423|Experimental|Cohort 1: ≥12 to <18 years|Participants will receive a SC injection of eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
11029697|NCT04570423|Experimental|Cohort 2: ≥6 to <12 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
11029698|NCT04570423|Experimental|Cohort 3: ≥2 to <6 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
11029699|NCT04570423|Experimental|Cohort 4: ≥1 month to <2 years|Participants will receive a SC injection eflapegrastim after completion of each cycle of chemotherapy up to four cycles of treatment (cycle length may vary and can be up to 28 days or more based on the type of chemotherapy regimen selected).
11029700|NCT04570410|Experimental|Subgroup1:Patients who can tolerate cisplatin chemotherapy|"GC plus Tislelizumab Participants receive GC (Gemcitabine plus cisplatin), in combination with Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.
~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W
~Biological: GC GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks"
11029701|NCT04570410|Experimental|Subgroup2:Patients who cannot tolerate cisplatin chemotherapy|"Tislelizumab Participants receive Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.
~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W"
11029702|NCT04570397|Experimental|Interventional arm|ravulizumab
11029703|NCT04570397|No Intervention|Control arm|patients in this arm will recieve standard care
11029704|NCT04570384|Active Comparator|IV L-Citrulline Arm|Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
11029705|NCT04570384|Placebo Comparator|Placebo Arm|Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
11029706|NCT04570371|Experimental|Intervention|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches in which the intervention will be implemented per the study schedule.
11029707|NCT04570371|No Intervention|Control Arm|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches. The control arm consists of all patients receiving surgery in implementation tranches in which the intervention has not been implemented yet (per the study schedule).
11029709|NCT04570358|No Intervention|Control|While group A performs the 8-week static stretching training, group B acts as control group performing its daily life activities as usual.
11029710|NCT04570358|Experimental|Proprioceptive neuromuscular facilitation stretching|After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
11029711|NCT04570358|No Intervention|Follow-up|While group B performs the 8-week proprioceptive neuromuscular facilitation stretching, group A is in its follow-up period performing its daily life activities as usual.
11029712|NCT04570345|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
11029713|NCT04570345|Active Comparator|Aspirin with P2Y12 receptor inhibitor|Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
11029714|NCT04570332|Experimental|Single Arm|Patients will be treated with the combination of BO-112 and pembrolizumab. IT administration of BO-112 will be performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. The order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 23-gauge needles.
11029715|NCT04570319|Experimental|Probiotic Bths-08|a capsule containing the probiotic blend (nutritional complement)
11029716|NCT04570319|Placebo Comparator|Placebo|a capsule containing placebo comparator
11029717|NCT04570306||Belimumab-treated SLE patients|SLE patients with active disease who will be started on add-on treatment with belimumab on top of standard of care.
11029718|NCT04570293|Experimental|The LMP group|The LMP group will receive lidocaine patches (active patches) measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w).
11029719|NCT04570293|Placebo Comparator|The control group|The control group will receive vehicle patches that are identical to the active patch, except for the absence of lidocaine, without any optical differences.
11029720|NCT04570280|Placebo Comparator|Range of Motion Exercises|The patients in the control group will be given the practice of range of motion exercises for 12 weeks, 3 days a week for 50 minutes (1 day accompanied by a physiotherapist).
11029721|NCT04570280|Active Comparator|Range of Motion and Resistive Exercises Group|Patients in this group will be given joint range of motion and resistive exercises with sandbag to the lower extremity for 12 weeks, 3 days a week for 50 minutes (1 day in the presence of a physiotherapist). For the exercises with resistance, the repetition maximum will be calculated and the intensity of the exercises will be adjusted in accordance with the DeLorme protocol.
11029722|NCT04570280|Active Comparator|Range of Motion and Aerobic Exercises Group|Joint range of motion exercises and aerobic exercises on the treadmill will be given to the aerobic exercise arm, 3 days a week for 12 weeks (1 day in the presence of a physiotherapist). For aerobic exercises, the maximum heart rate of the patients will be calculated during exercise and the exercise intensity will be determined by increasing the target heart rate level during the exercise.
11029723|NCT04570267|Experimental|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
11029724|NCT04570267|Experimental|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
11029725|NCT04570267|Placebo Comparator|Placebo|One dose of placebo administered subcutaneously on Day 1
11029726|NCT04570254|Experimental|Patients with septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.
~With the following specifications:
~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.
~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.
~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.
~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.
~The dose of pentoxifylline that all patients will receive is as follows:
~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
11029727|NCT04570254|Experimental|Patients without septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.
~With the following specifications:
~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.
~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.
~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.
~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.
~The dose of pentoxifylline that all patients will receive is as follows:
~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
11029728|NCT04570241|Active Comparator|Group A-Malaria toolkit|School children shall be trained on key malaria messages with a malaria toolkit. From the training received, the pupils will carry out awareness-raising in communities with key messages learnt.
11029729|NCT04570241|No Intervention|Group B-No malaria toolkit|"School children shall not be trained on key malaria messages with a malaria toolkit. Pupils will not carry out awareness-raising in communities with key messages.
~."
11029730|NCT04570228|Active Comparator|Treatment group|Pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization and pulmonary artery angiography.
11029731|NCT04570228|Sham Comparator|Sham control group|A sham treatment of pulmonary artery denervation with the TIVUS™ System will be performed immediately after the right heart catheterization pulmonary artery angiography. The sham procedure will be identical to the denervation procedure, with the only exception that the procedure will use a sham setting on the control console.
11029732|NCT04570215|Active Comparator|Gotcha! Therapy Application|"Participants will receive the Gotcha therapy daily for six weeks.Participants are required to use the app everyday for a maximum of 45 minutes. After this time they enter a twelve week block with no therapy or maintenance of therapy (see Gotcha maintenance arm).
~This aim of this arm is to invesitgate the efficacy of the Gotcha therapy for proper-noun anomia in mild-moderate patients with dementia (Alzheimer's disease, vascular dementia and mixed)"
11029733|NCT04570215|Active Comparator|Gotcha! Therapy Application: Maintenance|"Participants will receive the Gotcha therapy for six weeks as described in the Gotcha arm. After this time they enter a twelve week block of maintenance of therapy gains made in the initial six week therapy block.
~The maintenance block consists of a weekly test of the Gotcha outcome measure to monitor the therapy gains made during the therapy block. If any previously correctly named person is incorrectly named during these weekly tests then the participant must complete a 'top-up' therapy session. They will then be tested again the following week.
~The aim of this arm is to compare Gotcha maintenance with Gotcha, to see if extra testing and therapy is required to maintain gains made during an initial intense therapy block."
11029734|NCT04570202|No Intervention|Usual Care|Subject from this group are screened positive for psychological distress but they will only receive standard of care.
11029735|NCT04570202|Experimental|Eye Movement Desensitization & Reprocessing Group|Subject from this group are screened positive for psychological distress. They will receive 12 sessions of Eye Movement Desensitization & Reprocessing therapy by a trained therapist over three months in addition to standard of care.
11029736|NCT04570189||Phase I|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with the Auscul-X, a conventional stethoscope and an electronic stethoscope (Littmann 3200).
11029737|NCT04570189||Phase II|Twenty subjects, 10 unventilated and 10 ventilated patients, will undergo clinical auscultation of the heart and lungs with an Auscul-X with wireless capability, a conventional stethoscope and an electronic stethoscope (Littmann 3200). Phase II shall begin upon appropriate Health Canada approvals for the Auscul-X with wireless capability.
11029738|NCT04570176|Experimental|Urologic tumor group|patients with adrenal adenoma, muscle-invasive bladder cancer or renal cell carcinoma are included in the experiment.
11029739|NCT04570150|Active Comparator|Sugammadex|
11029740|NCT04570150|Placebo Comparator|Neostigmine|
11029741|NCT04570137|Experimental|1|This arm received the arabinoxylan/ß-glucan mix first.
11029742|NCT04570137|Experimental|2|This arm received the inulin/oligofructose mix first.
11029743|NCT04570124|Experimental|Remote Surveillance|Women will use the home blood pressure monitoring device to record their blood pressure everyday for the first postpartum week, and then weekly until postpartum week 6.
11029744|NCT04570111|Active Comparator|Standard Care Diet|After the controlled feeding study, participants in this group will follow the standard care diet for the remainder of pregnancy with the assistance of a study dietitian. The standard care study diet will provide the standard 40% Carb/20% Pro/40% Fat as energy, distributed consistently across 3 meals and 2 snacks.
11029745|NCT04570111|Experimental|Macro-Optimized Diet (MOD)|After the controlled feeding study, participants in this group will follow the MOD diet for the remainder of pregnancy with the assistance of a study dietitian. The MOD diet will differ from control by macronutrient distribution at breakfast specifically, but also at each eating occasion, although the daily macronutrient distribution is equal to the control diet. At breakfast, the MOD diet will provide 10% Carb/30% Pro/60% Fat.
11029746|NCT04570085|Experimental|Caffeine|after a 3 weeks up titration period, 1 capsule of 200 mg twice a day during 27 weeks (ie 400mg/day)
11029747|NCT04570085|Placebo Comparator|placebo|after a 3 weeks up titration period, 2 capsules per day during 27 weeks
11029748|NCT04570072|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10^10 colony forming unit per 2g sachet.
11029749|NCT04570072|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
11029750|NCT04570059|Experimental|Intervention program|Intervention group
11029751|NCT04570059|Active Comparator|Usual Care|Control group
11029752|NCT04570033|Experimental|patients with hyperparathyroidism|We prospectively enrolled 65 consecutive patients with primary hyperparathyroidism (PHPT) who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study
11029753|NCT04570020||Clinically-Selected Scleral Lens|The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.
11029754|NCT04570020||OCT-Selected Scleral Lens|The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.
11029755|NCT04569994|Experimental|Part 1|Healthy volunteers will receive either NNC0363-0845 or placebo
11029756|NCT04569994|Experimental|Part 2|Participants with T1D will receive either NNC0363-0845 or insulin degludec
11029757|NCT04569981|Active Comparator|Climbing Group (CG)|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
11029758|NCT04569981|Active Comparator|Unsupervised active group (UAG)|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
11029759|NCT04569968|Experimental|Expiratory muscle training group|Daily expiratory muscle training for four weeks will be applied.
11029760|NCT04569968|No Intervention|Control group|Nothing will be applied except for the hospital conventional physiotherapy program.
11029761|NCT04569942|Active Comparator|Vasopressor|a restricted fluids and early vasopressor strategy
11029762|NCT04569942|Active Comparator|Fluids|a larger intravenous (IV) fluid volume and later vasopressor strategy
11029763|NCT04569929|Active Comparator|control|conventionally manufactured Polymethyl Methacrylate (PMMA) mandibular implant overdentures
11029764|NCT04569929|Experimental|intervention|digital light processed (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdentures
11029765|NCT04569916|Experimental|treatment group|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
11029766|NCT04569903|Experimental|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
11029767|NCT04569890|Experimental|CZP|Certolizumab pegol: subcutaneous CZP at 200mg twice a week.
11029768|NCT04569890|Active Comparator|GC+HCQ|"Hydroxychloroquine: HCQ at 200mg daily, and if tolerated, escalated to 400 mg daily.
~Glucocorticoid: continuous usage GC at 10mg a day from Week 0 to Week 52.
~At 24 week, non-responders (ΔDAS28<0.6) will switch to the other group. Participants switched to CZP group will taper their dose of GC gradually, if they have an improvement in disease activity (two successive DAS28<2.6). If participants have a disease flare (increased DAS28>0.6) during a reduction in corticosteroid dose, then they will resume their previous dose. Weekly step-down GC scheme: 10mg-7.5mg-5mg-2.5mg-0mg."
11029769|NCT04569877|Experimental|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution
11029770|NCT04569877|Placebo Comparator|Placebo nebuliser solution|Placebo nebuliser solution
11029771|NCT04569864|Experimental|Mild hypothermia (30-32°C)|During aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest.
11029772|NCT04569864|Active Comparator|Moderate hypothermia (26-28°C)|During aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest.
11029773|NCT04569838|Experimental|Bendamustine hydrochloride injection|Bendamustine hydrochloride injection 120 mg/m² or 100 mg/m² intravenously (IV) on Day 1 and Day 2 of 21-day cycle (6-8 cycles maximum) for non-hodgkin's lymphomas or chronic lymphocytic leukemia. After 6-8 cycles, the course of treatment could be added based on patient's benefit and investigator's determination.
11029774|NCT04569825|Active Comparator|Local Nasal Steroid|Application of Local Nasal Steroid for the COVID-19 patients with anosmia
11029775|NCT04569825|Placebo Comparator|Normal Saline|Application of Normal Saline for the COVID-19 patients with anosmia
11029776|NCT04569812|Experimental|Standard CPR|After Informed Consent Document (ICD) signature, participants were randomised (to the Standard CPR group) to perform standard CPR (30:2) in a flowchart-assisted resuscitation for 5min in a manikin model
11029777|NCT04569812|Experimental|Chest compressions only|After ICD signature, participants were randomised (to the CC only CPR group) to perform chest compressions only in a flowchart-assisted resuscitation for 5min in a manikin model
11029778|NCT04569799|Other|group-1|Following treatment, patients will receive their standard CT or MRI, as routinely ordered in the post-TACE setting. This imaging will be per standard protocol, as directed by hepatology or oncology services, often 2 to 4 months after the treatment. At the same visit, patients will also receive a one-time additional contrast-enhanced ultrasound (CEUS),
11029779|NCT04569786|Experimental|Part 1: 5.00x10⁵ plaque forming units (pfu) (Panel A)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel A) will receive a single dose of V590 5.00x10⁵ pfu or placebo on Day 1.
11029780|NCT04569786|Experimental|Part 1: 2.40x10⁶ pfu (Panel B)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel B) will receive a single dose of 2.40x10⁶ pfu or placebo on Day 1.
11029781|NCT04569786|Experimental|Part 1: 1.15x10⁷ pfu (Panel C)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel C) will receive a single dose of 1.15x10⁷ pfu or placebo on Day 1.
11029782|NCT04569786|Experimental|Part 1: 5.55x10⁷ pfu (Panel D)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel D) will receive a single dose of V590 5.55x10⁷ pfu or placebo on Day 1.
11029783|NCT04569786|Experimental|Part 2: 5.00x10⁵ pfu (Panel E)|Participants in this ≥ 55 years old SARS CoV-2 seronegative cohort (Panel E) will receive a single dose of V590 5.00x10⁵ pfu or placebo on Day 1.
11029784|NCT04569786|Experimental|Part 2: 2.40x10⁶ pfu (Panel F)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel F) will receive a single dose of 2.40x10⁶ pfu or placebo on Day 1.
11029785|NCT04569786|Experimental|Part 2: 1.15x10⁷ pfu (Panel G)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel G) will receive a single dose of V590 1.15x10⁷ pfu or placebo on Day 1
11029786|NCT04569786|Experimental|Part 2: 5.55x10⁷ pfu (Panel H)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel H) will receive a single dose of V590 5.55x10⁷ pfu or placebo on Day 1.
11029787|NCT04569786|Experimental|Part 3: 5.55x10⁷ pfu (Panel I)|Participants in this 18 to 54-year-old SARS-CoV-2 seropositive cohort (Panel I) will receive a single dose of V590 5.55x10⁷ pfu or placebo on Day 1.
11029788|NCT04569773||Participants undergoing surgery for clinical|Participants will be undergoing surgery for clinical stage I endometrioid endometrial cancer
11029789|NCT04569760|Experimental|Cannabinoid Oil - Oral Preparation|"50mg CBD: 2mg of THC in each 1ml drop in MCT Oil, flexibly dosed at 200-800 mg per day.
~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (the maximum of 800 mg/day total dose of High CBD).
~The dose will be titrated in increments of 200 mg (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach 800 mg/day/week by Week 4."
11029790|NCT04569760|Placebo Comparator|Placebo Oil - Oral Preparation|"MCT Oil
~Dosing will start at 2 mls twice a day for one week and be titrated to 4 mls twice/daily for one week. At the end of Week 2, dose may be titrated to 6 mls twice a day ; then at the end of Week 4, dose may be titrated to 8 mls twice daily (a volume equivalent to the maximum of 800 mg/day total dose of High CBD).
~The dose will be titrated in incremental volumes equivalent to 200 mg of active product (4 mls)/day/week if participants are tolerating their current dose, are experiencing no adverse events and have not fully responded so that they may potentially reach the volume equivalent to 800 mg/day/week by Week 4."
11029791|NCT04569747|Experimental|PERTUZUMAB + TRASTUZUMAB + ADJUVANT ENDOCRINE THERAPY|"Study treatment will be administered in 21-day (3- week, +/- 3 days) cycles for one year (18 cycles).
~Trastuzumab + Pertuzumab SC fixed dose combination
~Hormonal therapy- oral, daily per cycle (may add LHRH agonist per investigator discretion)"
11029792|NCT04569734|Experimental|Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score >2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
11029793|NCT04569721|Experimental|CT guided splanchnic cryoablation|Obese patients with type 2 diabetes receiving CT guided splanchnic cryoablation.
11029794|NCT04569708|Experimental|Children and adolescents with epilepsy and controls|Closed loop auditory stimulation during nap
11029795|NCT04569695|Experimental|Part 1: Cohort A: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 once daily (QD) on Day 1 followed by washout period of 4 days and then Dose 1 of JNJ-70033093 QD from Days 5 to 12.
11029796|NCT04569695|Experimental|Part 1: Cohort B: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 twice daily (BID) from Days 1 to 8.
11029797|NCT04569695|Experimental|Part 1: Cohort C: JNJ-70033093|Participants will receive Dose 2 of JNJ-70033093 BID from Days 1 to 8.
11029874|NCT04569032|Experimental|CD30-positive Cohort|Participants with CD30 expression level ≥1% to < 10%
11029990|NCT04568278|Experimental|Intervention Group|a mobile application using the PRO-CTCAE along with usual care
11029798|NCT04569695|Experimental|Part 2: Cohort D: JNJ-70033093|Participants will receive Dose 3 of JNJ-70033093 QD on Day 1 followed by washout period of 4 days and then Dose 3 of JNJ-70033093 BID from Days 5 to 12 in Cohort D. Dose escalation to Part 2: Cohort D will occur only after the safety and tolerability data of the Part 1 are assessed.
11029799|NCT04569682|Active Comparator|transrenal artery perfusion group|
11029800|NCT04569682|Experimental|transrenal vein perfusion group|
11029801|NCT04569669|Experimental|Patients diagnosed with Coronary Artery Disease（CAD）by CCTA|Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.
11029802|NCT04569656|Experimental|treatment|6 week treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg
11029803|NCT04569643||Main|Patients with cerebral small vessel disease and periodic limb movement index equal or more than 15 movements per hour of sleep.
11029804|NCT04569643||Control|Patients with cerebral small vessel disease and periodic limb movement index less than 15 movements per hour of sleep.
11029805|NCT04569630|Experimental|Intervention group|
11029806|NCT04569617|Active Comparator|upper limb endurance protocol|UL endurance protocol - elbow flexion
11029807|NCT04569617|Active Comparator|upper limb strength protocol|UL strength protocol - elbow flexion
11029808|NCT04569617|Active Comparator|lower limb endurance protocol|LL endurance protocol - knee extension
11029809|NCT04569617|Active Comparator|lower limb strength protocol|LL strength protocol - knee extension
11029810|NCT04569604||Postsurgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years after neck surgery
11029811|NCT04569604||Non-surgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years without neck surgery
11029812|NCT04569604||Pseudohypoparathyroidism|Patients with the diagnosis of Pseudohypoparathyroidism
11029813|NCT04569604||Healthy controls|25 controls from the background population matched on age (±3 years), gender and level of education with the 25 patients with postsurgical hypoparathyroidism
11029814|NCT04569591|Experimental|1|patients aged 8 or older with Cushing's Disease who are surgical candidates for resection of ACTH producing pituitary adenoma within 12 weeks of PET imaging
11029815|NCT04569578|Experimental|Policy|The policy will be implemented on preschool level.
11029816|NCT04569578|No Intervention|Regular practice|The control preschool will continue their regular practice.
11029817|NCT04569565|Experimental|PleurX catheter intervention|Participants will undergo placement and follow up monitoring of PleurX catheter.
11029818|NCT04569539|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane
11029819|NCT04569500|Experimental|PETAL program|Patients with total laryngectomy and their close relatives, benefiting from the therapeutic education program PETAL
11029820|NCT04569500|No Intervention|Usual care|Patients with total laryngectomy and their close relatives, benefiting from the usual care
11029821|NCT04569487|Active Comparator|Sarcopenic population|"Diagnosed sarcopenia following definition of the EWGSOP2:
~Muscle strength assessed by the handgrip test <27 kg
~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA <7.0 kg/m2"
11029822|NCT04569487|Active Comparator|Non sarcopenic population|"Non-sarcopenic population adapted from the EWGSOP2:
~Muscle strength assessed by the handgrip test ≥ 27 kg
~Skeletal muscle mass index (Appendicular lean muscle mass) assessed by DXA ≥ 7.0 kg/m2"
11029823|NCT04569474|Experimental|Dressing Group|use of sterile transparent dressing
11029824|NCT04569474|No Intervention|Standard Group|non-sterile transparente dressing
11029825|NCT04569461|Experimental|Single Arm|Subjects with unfavorable localized prostate cancer will be enrolled.This is a single arm, phase II study of pembrolizumab (Keytruda), SBRT, and Short-term Androgen Deprivation Therapy (STADT), known together as trimodality therapy, followed by radical prostatectomy 8 weeks after SBRT.
11029826|NCT04569448|Experimental|Patient|Individuals diagnosed with Bipolar Disorder Type I and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
11029827|NCT04569435|Experimental|ANX005|"Induction dose of ANX005 IV (over 21-hour infusion) on Days 1 and 5 or 6 (5/6).
~Maintenance dose of ANX005 IV (over 4-5 hour infusion) every 2 weeks (Weeks 2, 4, 6, 8, and 10)."
11029828|NCT04569422||ephedrine drop|
11029829|NCT04569409|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
11029830|NCT04569409|Placebo Comparator|Vehicle sheet|Hydrogel sheet without allogenic mesenchymal stem cell
11029831|NCT04569396||Non-Alcoholic Fatty Liver Disease|A total of 72 severely or morbidly obese patients with non-alcoholic fatty liver disease and associated co-morbidities like diabetes and hypertension were enrolled into the study.
11029832|NCT04569383|Experimental|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S
11029833|NCT04569383|Experimental|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S
11029834|NCT04569370||Scoring Factor|Intervention: Procedure: Laparoscopic cholecystectomy
11029835|NCT04569370||Difficult criteria|Intervention: Procedure: Laparoscopic cholecystectomy
11029836|NCT04569357|Experimental|Prospecta|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
11029837|NCT04569357|Placebo Comparator|Placebo|One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
11029838|NCT04569344||Patients with Covid-19|Patients with laboratory test positive for SARS-CoV-2 virus
11029839|NCT04569344||Patients without Covid-19|Patients who do not have a laboratory test positive for SARS-CoV-2 virus
11029875|NCT04569019||Health care workers|The study will be conducted among UCKWUM healthcare professionals, i.e. doctors, nurses, paramedics, laboratory workers, pharmacists, and administration workers. Based on previous research, the group should include at least 200 participants
11029876|NCT04568993|Experimental|proximal phalangeal level|injection in the the tendon sheet over proximal phalanx of finger
11029877|NCT04568993|Active Comparator|volar MCP level|injection above the A1 pulley volar to the MCP joint
11029991|NCT04568278|No Intervention|Controlled Group|Usual care
11029840|NCT04569331|No Intervention|Control group|"Patients undergoing anterior rectal resection with protective ileostomy will follow routine clinical practice.
~During hospital admission for ileostomy closure surgery, the stoma therapist reinforces the information on the possibility of anterior resection syndrome (ARS) and hygienic-dietary measures. At the level of the ARS, the patient is informed of the possibility of increased frequency of bowel movements, evacuation dysfunction, such as urgency to defecate or feeling of incomplete emptying. At the level of diet, an astringent diet is recommended during the first week after ileostomy closure to avoid liquid stools. It is also recommended at the level of perineal hygiene to use a cleanser with a pH similar to that of the skin, applying the least possible force on the skin, dry gently after each bowel movement and apply a skin protection product to avoid dermatitis associated with incontinence."
11029841|NCT04569331|Experimental|Stimulation of efferent loop and rehabilitation pelvic floor|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened every 48-hours the first two weeks and once daily the thrid week.
~Rehabilitation of pelvic floor: 3 months after the ileostomy closure surgery, patient will be referred to the pelvic floor unit for pelvic floor rehabilitation."
11029842|NCT04569318|Experimental|Treatment Arm|Treatment with treatment beam.
11029843|NCT04569305|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy was applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of technique was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
11029844|NCT04569305|Active Comparator|Conventional treatment|Simple moist gauze dressing applied to injured area of foot and ankle after debridement and cleaning of the necrosed/dead tissue. The effect of treatment was assessed through measuring wound surface area covered with healthy granulation tissue measured in centimetre square on follow-up.
11029845|NCT04569292||Cancer patients|"confirmation of COVID-19 in the laboratory (RT-PCR techniques);
~suspected cases of COVID-19; clinically diagnosed based on symptoms (fever> 37.5 °, decrease in oximeter saturation by at least 5%, cough, diarrhea, otitis, dysgeusia, myalgia, arthralgia, conjunctivitis and rhinorrhea) + close contact a COVID-19 subject positive;
~asymptomatic cases; diagnosed based on positive swab results but without symptoms"
11029846|NCT04569279|Active Comparator|Warfarin arm|Patients randomly assigned to (W) group will receive an adjusted dose of warfarin with targeted INR of 2.0 to 3.0.
11029847|NCT04569279|Experimental|Rivaroxaban arm|Patients randomly assigned to (R) group will receive 20mg rivaroxaban daily if CrCl>50 mL/min using Cockcroft-Gault equation or 15mg rivaroxaban daily if CrCl 30-50 mL/min.
11029848|NCT04569266|No Intervention|No specific exercise rehabilitation treatment|"Patients will not benefit from any specific exercise rehabilitation treatment until 6 months post-ICU. They will then be proposed to follow the treatment protocol if efficacy is demonstrated, once their follow-up in the study is completed."
11029849|NCT04569266|Experimental|specific exercise rehabilitation treatment|"Patients will receive a prescription for exercise rehabilitation, at the rate of 2 sessions of approximately 1 hour each per week for 10 weeks.
~Continuous endurance training will start at 60-70% of the patient's maximum power. For patients who are unable to maintain continuous re-training, interval training sequences (30 seconds of effort followed by 30 seconds of rest) may be offered.
~Initially, the effort will be 15 minutes, then gradually increase to reach an exercise duration of 40 minutes or 45-60 minutes for endurance or interval training respectively.
~The power can be adjusted as the patient progresses to reach the target heart rate and dyspnea at 4-6 on the BORG scale.
~All patients will be offered lower limb and upper limb strengthening exercises. Each exercise will consist of 3-4 sets of 6-12 repetitions."
11029850|NCT04569240|Other|Dexcom G6 continuous glucose monitor|All patients will have a Dexcom G6 continuous glucose monitor placed pre-operatively. The glucose readings will be collected for 10 days or upon discharge from the ICU and data will be compared with arterial blood glucose readings or venous Accu-Check Inform II glucose readings
11029851|NCT04569227|Experimental|Active EC-18|
11029852|NCT04569227|Placebo Comparator|Placebo|
11029853|NCT04569214|Placebo Comparator|A - Placebo Control|4 tablets of placebo
11029854|NCT04569214|Experimental|B - PAZ320 Low Dose|2 tablets of PAZ320 and 2 tablet of placebo
11029855|NCT04569214|Experimental|C - PAZ320 High Dose|4 tablet of PAZ320
11029856|NCT04569188|Experimental|convalescent plasma|Cohort of elderly patients treated with convalescent plasma
11029857|NCT04569175|Experimental|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product)
11029858|NCT04569136|Experimental|Intervention group|"Educating the patient about mastitis and self-management strategies
~Treating with therapeutic ultrasound
~Administering and teaching breast massage"
11029859|NCT04569136|Sham Comparator|Sham group|"Educating the patient about mastitis and self-management strategies
~Receiving sham ultrasound
~Administering and teaching breast massage"
11029860|NCT04569136|Other|Usual care group|Receiving usual obstetric care, which may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff
11029861|NCT04569123|Active Comparator|Vibration|The device will deliver imperceptible vibration for the treatment group.
11029862|NCT04569123|Sham Comparator|No Vibration|The device will deliver no vibration for the control group.
11029863|NCT04569110||Pleural infection|Patients with clinically confirmed ongoing pleural infection.
11029864|NCT04569110||Negative control|Patients without pleural infection.
11029865|NCT04569097|Experimental|Patient group|lingual strengthening
11029866|NCT04569097|No Intervention|Healthy controls|Healthy normal swallow
11029867|NCT04569084|Experimental|Oral Edaravone|
11029868|NCT04569084|Experimental|Oral Edaravone and Placebo|
11029869|NCT04569071|Experimental|Sinovation Laser Ablation System treatment|Sinovation Laser Ablation System treatment
11029870|NCT04569058|Experimental|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
11029871|NCT04569045|Experimental|HA + Lidocaine|Sodium Hyaluronate with Lidocaine Hydrochloride
11029872|NCT04569045|Active Comparator|HA|Sodium Hyaluronate
11029873|NCT04569032|Experimental|CD30-negative Cohort|Participants with CD30 expression level < 1%
11030127|NCT04567316|Experimental|BI 1358894|BI 1358894 (part 2)
11029878|NCT04568980||Hormonal contraceptive users|Persons exposed to any hormonal method of birth control. This includes combined oral contraceptive pills, combined transdermal patch, combined vaginal ring, progestin-only pills, depo-medroxyacetate, levonorgestrel intrauterine system/device, hormonal subdermal implant
11029879|NCT04568980||Non-hormonal contraceptive users|Persons exposed to any non-hormonal method of birth control. This includes male or female sterilization methods, Copper intrauterine device, internal/external condoms, diaphragm, cervical cap, withdrawal, sponge, fertility based methods, spermicide
11029880|NCT04568980||Non-contraceptive users|Persons who did not use any method of birth control
11029881|NCT04568967|Experimental|intervention arm|"The intervention arm for this trial consists of testing expectorated sputum and concentrated urine with Ultra and urine with FujiLAM, regardless of presence of TB compatible symptoms.
~To fulfil exploratory objectives we will also collect tongue and stool/rectal swabs in this arm for Xpert Ultra testing."
11029882|NCT04568967|No Intervention|control arm|"The control arm for this trial will consist of:
~Sputum Ultra whenever the patient has cough, fever, weight loss or night sweats and/or Ultra on any tissue (including lymph nodes) from patients with suspected extrapulmonary TB.
~& Urine Alere TB-LAM, if patients have signs and symptoms of TB (pulmonary and/or extrapulmonary), or with advanced HIV disease,or who are seriously ill, or else irrespective of signs and symptoms of 3 TB and with a CD4 cell count of less than 200 cells/mm .
~These testing guidelines are the current WHO recommended TB testing practices for HIV positive inpatients (as of Q1 2020)."
11029883|NCT04568954|Experimental|Xpert MTB/RIF Ultra using GeneXpert Omni Arm|GeneXpert Omni platforms using Xpert MTB/RIF Ultra® cartridges placed at primary health care clinics combined with rapid communication of results and same day TB treatment initiation
11029884|NCT04568954|No Intervention|Standard of care Arm|Standard of care may vary by clinics. Dependent on availability of transport and stock of Xpert cartridges standard of care will be a combination of smear microscopy and off-site Xpert MTB/RIF Ultra® testing.
11029885|NCT04568941|Experimental|Preoperative Vacuum-Assisted Biopsy|Preoperative vacuum-assisted biopsy was performed within 10 days before final surgery. The tumor were excised almost.
11029886|NCT04568941|Experimental|Preoperative Core Needle Biopsy|Preoperative core needle biopsy was performed within 10 days before final surgery. The needle biopsy were performed with 3 needles.
11029887|NCT04568941|Experimental|Intraoperative Excisional Biopsy|The tumor was excised intraoperatively.
11029888|NCT04568928|Experimental|OLTP/PE+FES first, then OLTP/PE+sham FES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE+FES).
~One week break. 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton combined with SHAM functional electrical stimulation (OLTP/PE + shamFES).
~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression. For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. For the sham FES, all parameters will be the same except that a subthreshold current intensity (i.e. not producing palpable muscle contraction) will be delivered. FES timing and duration is already built into the device."
11029889|NCT04568928|Experimental|OLTP/PE+shamFES first, then OLTP/PE+FES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined with SHAM functional electrical stimulation (OLTP/PE+ shamFES).
~One week break. 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton combined with functional electrical stimulation (OLTP/PE + FES).
~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression. For each participant, FES intensity will be set for each muscle in order to elicit a palpable muscle contraction. For the sham FES, all parameters will be the same except that a subthreshold current intensity (i.e. not producing palpable muscle contraction) will be delivered. FES timing and duration is already built into the device."
11029890|NCT04568928|Active Comparator|OLTP/PE noFES|"12 sessions (4-6 weeks) of overground locomotor training program using a powered exoskeleton combined (OLTP/PE) One week break 12 sessions (4 to 6 weeks) of overground locomotor training program using a powered exoskeleton (OLTP/PE)
~Specific level of assistance for each hip and knee, and gait parameters will be set and adjusted during a familiarization period with the PE. Level of PE assistance will then be adjusted weekly to ensure training progression."
11029891|NCT04568915|Experimental|Dry Needling-Group|Tens, Stretching, Strengthening(girdle), Neck Isometrics, DN
11029892|NCT04568915|Active Comparator|Maitland-Group|Tens Stretching, Strengthening(girdle), Neck Isometrics, Maitland joint mobilization
11029893|NCT04568902|Experimental|H3B-6545 300 mg|Participants will receive H3B-6545 300 milligram (mg) tablets, orally, once daily in 28 days cycle.
11029894|NCT04568902|Experimental|H3B-6545 450 mg|Participants will receive H3B-6545 450 mg tablets, orally, once daily in 28 days cycle.
11029895|NCT04568889|Experimental|Government/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
11029896|NCT04568889|Experimental|Government/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
11029897|NCT04568889|Experimental|Government/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
11029898|NCT04568889|Experimental|Government/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
11029899|NCT04568889|Experimental|Researchers/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
11029900|NCT04568889|Experimental|Researchers/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
11029901|NCT04568889|Experimental|Researchers/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
11029902|NCT04568889|Experimental|Researchers/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
11029903|NCT04568889|Experimental|Government/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
11029904|NCT04568889|Experimental|Government/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
11029905|NCT04568889|Experimental|Government/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
11029906|NCT04568889|Experimental|Government/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
11029907|NCT04568889|Experimental|Researchers/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
11029908|NCT04568889|Experimental|Researchers/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
11029909|NCT04568889|Experimental|Researchers/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
11029910|NCT04568889|Experimental|Researchers/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
11029911|NCT04568876|Active Comparator|PEA Group|Normast® MPS (mPEA and umPEA 300mg + 600mg) oral suspension: 2700mg/die in 3 doses for 28 days, in add-on to standard therapy
11029912|NCT04568876|Other|Control Group|Standard therapy only
11029913|NCT04568863|Experimental|Melatonin|(12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
11029914|NCT04568863|Placebo Comparator|Placebo|(6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
11029915|NCT04568837|Experimental|Corticosteroid|Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery
11029916|NCT04568837|No Intervention|Control|Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery.
11029917|NCT04568824|Experimental|GraphoLearn reading intervention|GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
11029918|NCT04568824|Active Comparator|Vektor math control|We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.
11029919|NCT04568811|Experimental|Adenovirus Type-5 Vectored COVID-19 Vaccine|
11029920|NCT04568798|Active Comparator|Sana Device|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
11029921|NCT04568798|Sham Comparator|Sana Sham Device|The sham treatment device is designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
11029922|NCT04568785|Experimental|Brief Intervention group|Intervention consisted of a standardized Brief Intervention, which varied depending on the reason the patient had given for refusing the vaccination.
11029923|NCT04568785|Active Comparator|Control group|the control group intervention was the normal advice that professionals used to give their patients
11029924|NCT04568772|Active Comparator|Atovaquone/Proguanil 250/100 mg|A single oral administration of atovaquone/proguanil 250/100 mg
11029925|NCT04568772|Experimental|Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
11029926|NCT04568772|Experimental|Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
11029927|NCT04568772|Experimental|Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
11029928|NCT04568759|Active Comparator|Standard care group|Observation or brace plus conventional physiotherapy exercises on video
11029929|NCT04568759|Experimental|GPR group|GPR interventions added to standard care (observation or brace)
11029930|NCT04568746|Other|patients with qSOFA ≥ 2|adult patients with a qSOFA score ≥ 2 at the screening in the emergency department, will be referred to the emergency vital room
11029931|NCT04568746|Other|patients with qSOFA <2|adult patients with a qSOFA score < 2 at the screening in the emergency department, will be referred to the box
11029932|NCT04568733|No Intervention|Resting|
11029933|NCT04568733|Experimental|Pilates exercise session|
11029934|NCT04568733|Active Comparator|Treadmill walking at 3.2 kph|
11029935|NCT04568733|Active Comparator|Treadmill walking at 4.8 kph|
11029936|NCT04568720||Shanghai General Hospital|
11029937|NCT04568707|Experimental|Covid-19 infection|Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
11029938|NCT04568694|Experimental|Delayed Lung Transplantation|Patients that received lung(s) delayed for transplantation
11029939|NCT04568694|Active Comparator|Conventional Lung Transplantation|Reference Therapy
11029940|NCT04568681||Patients with dystonia|Patients with dystonia who have clinically been deemed candidates for DBS surgery.
11029941|NCT04568668|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
11029942|NCT04568668|No Intervention|Standard care (ADE information retained locally)|Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their adverse drug event information will not be visible to other providers via PharmaNet.
11029943|NCT04568655||COVID-19 patients need noninvasive ventilation|
11029944|NCT04568642|Active Comparator|Conventional|Device: conventional FiO2 will be selected by the clinician according to the SpO2 target
11029945|NCT04568642|Experimental|Closed-loop|Device: conventional FiO2 will be selected by the closed-loop algorithm according to the SpO2 target
11029946|NCT04568629||Palliative Care Clinicians|Clinicians working in an adult palliative care service
11029947|NCT04568616|Experimental|Treatment|Letrozole 2.5mg tablet administered once daily for 4 to ~12 weeks (window of + 4 weeks for surgical scheduling flexibility) final dose taken the day of surgery.
11029948|NCT04568603|Experimental|Methadone + ISL|Methadone-maintained participants (20 to 200 mg once daily [QD] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9 and ISL 60 mg once on Day 2.
11029949|NCT04568590|Experimental|Vaccine Hesitant|Subjects who consent to this study and deemed vaccine hesitant, they will receive an educational intervention.
11029950|NCT04568577|Experimental|tensioned tape|The tensioned tape group will apply weekly with gradual tension calculated by measuring the initial length of the tape. From the first week of application, there will be a 5% increase in tension up to the fifth week.
11029951|NCT04568577|Active Comparator|tape without tension|The tensionless tape group will receive the application of the tape weekly without tensioning during the five weeks.
11029952|NCT04568564|Experimental|Telerehabilitation Group (TG)|Patients diagnosed with lung cancer and underwent thoracotomy
11029953|NCT04568564|Active Comparator|Control group (CG)|Patients diagnosed with lung cancer and underwent thoracotomy
11029954|NCT04568538|Experimental|İntervention group|"Randomization with a sealed envelope will be applied to mothers who have 2-4 months old babies who apply to Akdeniz University Hospital Pediatric Outpatient Clinic for health control and who accept the study. A pre-test application will be made in the intervention group. The Researcher will fill in the Personal Information Form and the Shaken Baby Syndrome Information and Attitude Assessment Data Form (Pre-Test) at this stage.
~The training prepared to prevent shaken baby syndrome, which was prepared immediately after the end of the pre-test application, will be given to the mothers in the intervention group. The training will be given with mothers using one-to-one face-to-face interview method. Necessary equipment will be provided for training. At the end of the training, the questions of the mothers will be answered and a booklet prepared to prevent shaken baby syndrome will be given and tele-consultancy will be provided for 2 months."
11029955|NCT04568538|No Intervention|Control group|No application will be made to the mothers in the control group after the pre-test application. After 2 months, the final test application will be made. After the last test, the mothers in the control group will be given a training and a booklet prepared to prevent shaken baby syndrome.
11029956|NCT04568525|Active Comparator|COVID - 19 patients|
11029957|NCT04568525|Active Comparator|COVID - 19 and pneumonia patients|
11029958|NCT04568525|Active Comparator|Health patients|
11029959|NCT04568512|Placebo Comparator|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
11029960|NCT04568512|Active Comparator|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
11029961|NCT04568499||Suspected and Confirmed COVID-19 cases|Suspected and confirmed COVID-19 cases (age 5 years and above) identified at health facilities or via mobile teams in Juba, South Sudan and in Eastern Democratic Republic of the Congo.
11029984|NCT04568317|Experimental|Smartwatch group|iCBT intervention 'Space from Depression' with smartwatch as an additional means to self-report data on mood, sleep and physical activity in the 'Space from Depression' program (n=35).
11037617|NCT04515810|No Intervention|Control condition|Usual, standard care.
11029962|NCT04568486|Other|Rural-dwelling older adults (seed) and Key players (alter|Rural-dwelling older adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. This group will be paired with their key players (identified during interviews) to receive the diabetes education. The pair complete the intervention as a dyad.
11029963|NCT04568473|Experimental|PRG Barrier Coat (SHOFU Inc., Japan)|"BioSmart Light Cured Protective Shield with bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology.
~S-PRG filler possesses a three-layer structure with a stabilized glass-ionomer-like structure surrounding multifunctional glass fillers, and is subsequently protected by a surface modified layer."
11029964|NCT04568473|Experimental|EMBRACE™ Varnish (Pulpdent Corporation, USA)|"Resin-based 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release.
~The incorporation of CXP™ (xylitol-coated calcium and phosphate) in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish"
11029965|NCT04568473|Active Comparator|Duraphat® (Colgate Palmolive Company, New York, NY)|It is attributed to the reactivity of the fluoride by adsorbing to the surface and attracting calcium ions forming loosely-bound calcium fluoride (CaF2)- like reservoir which is also considered responsible for the anticaries mechanism and protection against cariogenic acid attack.
11029966|NCT04568460|Experimental|Intervention Group Sessions|Intervention group sessions will be delivered by lay health counselors. The sessions will reflect principles of co-learning, participatory design, and empowerment to promote engagement of young people in critical thinking and problem solving - including modeling, roleplaying, and interactive activities.
11029967|NCT04568460|No Intervention|Standard of Care|This is the standard of care arm. Participants newly diagnosed with HIV will get a referral to the local primary health care setting of their choice for further management, including ART.
11029968|NCT04568447|Experimental|IMOOVE|Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.
11029969|NCT04568434|Experimental|AKCEA-APOCIII-LRx|AKCEA-APOCIII-LRx will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
11029970|NCT04568434|Placebo Comparator|Placebo|AKCEA-APOCIII-LRx-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
11029971|NCT04568421||Treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
11029972|NCT04568421||Not treated with immunomodulatory and/or -suppressive drugs|Patients with rheumatic diseases not treated with immunomodulatory and/or immunosuppressive drugs and with diagnosis of SARS-CoV-2 infection (past or present) with positive test for the virus SARS-CoV-2 from analysis of nasopharyngeal or oropharyngeal swab specimens (reverse transcriptase-polymerase- chain-reaction assay) or by serology, independently of symptoms.
11029973|NCT04568408||Sleep study participants|Adults presenting sleep difficulties or poor sleep quality that are performed a Polisomnography study in a Sleep Unit at hospital.
11029974|NCT04568395|Experimental|PLWH smoker|PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control
11029975|NCT04568382|Experimental|Intervention|Enhanced PVP
11029976|NCT04568382|Active Comparator|Standard|Standard PVP
11029977|NCT04568369|Experimental|Treatment group|Patients will engage in a four-week treatment protocol (20 treatments). This was chosen as it is the midpoint between typical depression and migraine protocol durations. If available, patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. If not available, a standardized atlas brain with Montreal neurologic institute (MNI) coordinates will be used for navigation. The DLPFC will be located through MNI coordinates (-48, 26, 36) vs. (-41, 21, 38). The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, with a frequency of 10 Hz, 10 trains of 60 pulses/train (total of 600 pulses) and inter-train interval of 45s.
11029978|NCT04568369|Sham Comparator|Sham group|In the sham condition, a sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation. Previous sham studies have demonstrated efficacy of the blinding method.
11029979|NCT04568356|Experimental|Antigen rapid test for COVID-19|The same group of patients participated in two arms of the study, one arm was for obtaining data on the rapid antigen test for COVID-19, the comparator arm was to obtain data from the RT-PCR
11029980|NCT04568343|Experimental|small bowel bleeding patient|with suspicious small bowel bleeding,patient will recieve Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule later for evaluations
11029981|NCT04568330|Other|Best support care (BSC)|Interventions for comparison group (group C) who received BSC alone were (1) informed of potential presentations of HFSR, (2) asked for wearing waterproof gloves before execute household or work with water, (3) provided the method of contacting with healthcare specialists for confirming early diagnosis of HFSR, and (4) asked for self-report when they occurred symptoms of HFSR.
11029982|NCT04568330|Experimental|BSC plus moisture cream|The A group with BCS plus moisturizing cream received the interventions as the comparison group, was given the moisturizing cream (dimethicone, fragrance free, Aveeno, United States) for 9 times and was instructed how to use the cream. The education of usage included (1) using the cream twice a day from 3 days before starting sorafenib and each week post starting sorafenib, (2) scooping out nut-sized cream with a unique spoon each time, (3) gently applied the cream evenly on symmetrical palms below wrists and symmetrical soles below ankles each time, (4) wore unique cotton gloves immediately after the appalment of cream for 30 minutes each time.
11029983|NCT04568330|Active Comparator|10% urea-based cream|The B group with BCS plus 10% urea-based cream had the similar interventions as the A group with BCS plus moisturizing cream except being given the cream container with different component (10% urea; Sipharr, Taiwan). The outlook of the containers with the two kinds of cream was the same. All the cream looks white and grey.
11029985|NCT04568317|Active Comparator|Treatment as usual group|iCBT intervention 'Space from Depression' (n=35).
11029992|NCT04568265|Experimental|APG-1387 12 mg combined with entecavir 0.5 mg|
11029993|NCT04568265|Experimental|APG-1387 20 mg combined with entecavir 0.5 mg|
11029994|NCT04568265|Experimental|APG-1387 30 mg combined with entecavir 0.5 mg|
11029995|NCT04568265|Experimental|entecavir 0.5 mg|
11029996|NCT04568252|Experimental|Intervention|Millimetric wave emission bracelet.
11029997|NCT04568252|Sham Comparator|Control|Placebo bracelet.
11029998|NCT04568239||M184V + group and M184 - group|
11029999|NCT04568226|Experimental|ConquerFear Intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consists of 6 individual face-to-face sessions.
11030000|NCT04568226|Placebo Comparator|Standard of Care|Standard of Care serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in the Standard of Care will receive 6 individual face-to-face sessions including 2 relaxation training sessions, 2 dietetic consultation sessions and 2 exercise sessions.
11030001|NCT04568213|Experimental|Hypochlorous Gel Application|
11030002|NCT04568200|Experimental|durvalumab and neoadjuvant therapy|durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
11030003|NCT04568200|Placebo Comparator|normal saline and neoadjuvant therapy|normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
11030004|NCT04568187|Active Comparator|cryolipolysis machine on Left inner thigh|Zeltiq machine as intervention procedure was carried out on left inner thigh (treated side) for 1 hour through cool sculpting procedure with CIF (Cooling Intensity Factor: -73 mW/cm2).
11030005|NCT04568187|Sham Comparator|radiofrequency on right thigh|The radio frequency method was applied on right thigh (control side) as sham procedure for 30 minutes through 3000 Hz- amplitude modulated frequency at once.
11030006|NCT04568174|Active Comparator|PPSGG|sterile liquid, one 1-hour infusion in SAD and multiple infusions in MAD. In SAD multiple cohorts being tested. Dosage and regime in MAD to be defined based on SAD outcome.
11030007|NCT04568174|Placebo Comparator|Placebo|standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
11030008|NCT04568161|Experimental|pre and post chemotherapy assessments|The patients will be assessed before and after chemotherapy treatment.
11030009|NCT04568135||survey|
11030010|NCT04568122|Experimental|Saliva test|Participants perform each test assay, noting the results for comparison by technician, and completing survey questionnaires.
11030011|NCT04568109|Experimental|Exposure-based cognitive-behavior therapy|Patients are treated in accordance with a manualized protocol (Gloster et al., 2011)
11030012|NCT04568109|No Intervention|Wait-List control condition|Patients are assessed prior to and after a 12-week waiting period. Patients are treated after this 12-week delay.
11030013|NCT04568096|Active Comparator|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
11030014|NCT04568096|Placebo Comparator|The standard therapy|The infected patients will receive the standard therapy for COVID-19 for 14 days
11030015|NCT04568083||Ticagrelor cohort|Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
11030016|NCT04568083||Non-ticagrelor cohort|Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.
11030017|NCT04568070|Experimental|Stroke|Stroke patients who applied to the Physical Medicine and Rehabilitation outpatient clinic, met the inclusion criteria and volunteered to participate in the study
11030018|NCT04568057|Active Comparator|NIR Transcranial phototherapy device|The active transcranial phototherapy device. 1068 nm NIR Transcranial phototherapy PBM-T device An air-cooled LED helmet with a peak wavelength of 1068 nm, spectral width of 60 nm, and a 6-minute internal timer was used. The average optical power output of the combined arrays is circa 3.8 Watts, 12mw/sq. cm. The total energy to be delivered to the cranium is 1368J (3.8 x 360) per treatment session.
11030019|NCT04568057|Placebo Comparator|Placebo Device.|Placebo cranial device. The external appearance of the device is identical to that of the active device but no NIR light is emitted.
11030020|NCT04568044||Group A: Mild to moderate COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness.
~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
11030021|NCT04568044||Group B: Severe to critical COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness.
~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
11030022|NCT04568044||Group C: Controls (non-pregnant)|"Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness.
~A blood sample will be taken on 1 day and at 1 time point."
11030023|NCT04568044||Group D: Pregnant or postnatal with COVID-19|"Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only.
~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
11030024|NCT04568044||Group E: Pregnant or postnatal with influenza|"Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only.
~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
11030025|NCT04568044||Group F: Pregnant and have received the influenza vaccine|"Current pregnant and have received the influenza vaccine (age 18-50 years old). Singleton pregnancies only.
~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
11030128|NCT04567303|Experimental|Part 1: Intravitreal Injections|RO7250284 administered in ascending dose levels through IVT injections.
11030026|NCT04568031|Experimental|Part I|Cohort A will include healthy participants aged 18 to 55 years. Cohort B will include healthy elderly participants aged ≥ 56 years. In Cohort B, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort B1) and aged ≥ 70 years (Subcohort B2). At least 30% of participants in Cohort B will be secured for participants with age ≥ 70 years.
11030027|NCT04568031|Experimental|Part II|Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
11030028|NCT04568018||1 cohort|"Patients with mild ARDS, who are on spontaneous breathing.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
11030029|NCT04568018||2 cohort|"Patients with moderate ARDS, who are on spontaneous breathing.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
11030030|NCT04568018||3 cohort|"Patients with mild ARDS, receiving NIV and high-flow oxygen therapy.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
11030031|NCT04568018||4 cohort|"Patients with moderate ARDS, receiving NIV and high-flow oxygen therapy.
~Patients who receive surfactant-BL through a mesh-nebulizer combined with the standard COVID-19 therapy, oxygen therapy, NIV and high-flow oxygen therapy according to the following scheme: inhalation of surfactant emulsion at 150 mg every 12 hours on the 1st, 2nd, 3rd, 4th and 5th days of the treatment period, inclusive."
11030032|NCT04567992|Experimental|SCPB|
11030033|NCT04567992|Placebo Comparator|Control|
11030034|NCT04567979||Patients with solid tumors|Patients with solid tumors under chemotherapy and / or radiotherapy treatment at our center.
11030035|NCT04567979||Healthcare workers|Healthcare workers at the chemotherapy and radiotherapy unit in our center.
11030036|NCT04567966|Experimental|Cortical bone plate|A cortical plate was harvested from the external oblique ridge and split in half. Then one plate was fixed at a distance from the atrophied ridge and autogenous bone chips were used to fill the gap between the plate and the ridge.
11030037|NCT04567966|Active Comparator|Cortico-cancellous block graft|A cortico-cancellous block graft was harvested from the symphysis of the mandible and fixed to the atrophied ridge.
11030038|NCT04567953|Experimental|Saliva and NP paired specimen collection|
11030039|NCT04567940|Experimental|Intervention group|Behavioural multicomponent intervention
11030040|NCT04567940|No Intervention|Control group|Usual care
11030041|NCT04567914||Adolescent idiopathic scoliosis|Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness of AIS patients diagnosed by a specialist. Spirometry evaluation was performed by the investigator
11030042|NCT04567914||Adolescent healthy individuals|Healthy adolescents aged 10-18 were selected. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness. Spirometry evaluation was performed by the investigator.
11030043|NCT04567901||Trauma Patients|The enrolled patients experienced trauma from different injuries and were hospitalized for treatment and admitted to the ICU. 700 older trauma patients (age equal to or more than 65 years) were finally included in the study.
11030044|NCT04567888|Active Comparator|Teen Happify Platform condition|
11030045|NCT04567888|No Intervention|Waitlist Control Condition|
11030046|NCT04567875||CRPC patients|CRPC patients without evidence of distant metastasis are eligible
11030047|NCT04567849|No Intervention|Control|No intervention control group
11030048|NCT04567849|Experimental|Nudge: call provider|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call their recent Women's Health provider (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
11030049|NCT04567849|Experimental|Nudge: call tele-nurse|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call Geisinger's nurse triage hotline (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
11030050|NCT04567836||The asymptomatic medical staff cohort|"The cohort of asymptomatic / paucisymptomatic operators will include the cohort of operators who will test positive in the serological analysis.
~From the entire population of hospital workers (over 3000), three controls will be identified for each operator who tested positive for the serological test that were analyzed on the same day and were negative for the serological test."
11030051|NCT04567836||The symptomatic medical staff cohort|The cohort of symptomatic hospital workers who tested positive for the swab includes 250 operators.
11030052|NCT04567823|Experimental|Microalgae I|Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans)
11030053|NCT04567823|Experimental|Microalgae II|Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans)
11030054|NCT04567823|Placebo Comparator|Smoothie|Smoothie (without microalgae) and standardised background diet (defined menu plans)
11030055|NCT04567823|No Intervention|Control|no intervention (no smoothie, no menu plans)
11030056|NCT04567810|Experimental|Part A: 2 mg preparation|Participants receive a single 2 mg dose of anti-SARS-CoV-2 IgY.
11030057|NCT04567810|Experimental|Part A: 4 mg preparation|Participants receive a single 4 mg dose of anti-SARS-CoV-2 IgY.
11030058|NCT04567810|Experimental|Part A: 8 mg preparation|Participants receive a single 8 mg dose of anti-SARS-CoV-2 IgY.
11030059|NCT04567810|Placebo Comparator|Part A: placebo preparation|Participants receive placebo matching anti-SARS-CoV-2 IgY.
11030060|NCT04567810|Experimental|Part B: 6 mg total daily dose|Participants receive a 2 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
11030061|NCT04567810|Experimental|Part B: 12 mg total daily dose|Participants receive a 4 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
11030062|NCT04567810|Experimental|Part B: 24 mg total daily dose|Participants receive a 8 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
11030063|NCT04567810|Placebo Comparator|Part B: 0 mg total daily dose|Participants receive placebo matching anti-SARS-CoV-2 IgY three times daily for 14 days.
11030064|NCT04567797|Experimental|Exoskeleton|To compare the efficacy of four different exoskeleton devices, all participants will be asked to finish simulated construction tasks with each exoskeleton. Additionally, all participants will be asked to finish the same tasks without wearing an exoskeleton for reference.
11030065|NCT04567784|Placebo Comparator|Control|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
11030066|NCT04567784|Experimental|CBD 800mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
11030067|NCT04567771|Experimental|Treatment (radiation therapy, questionnaires)|Patients undergo standard of care proton or intensity modulated radiation therapy. Patients also complete quality of life questionnaires and adverse event assessments over 10-15 minutes each at baseline, at the end of radiation therapy, and at 1 month, 1 year, and 3 years post-radiation therapy.
11030068|NCT04567758|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
11030069|NCT04567758|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
11030070|NCT04567745|Other|Cognitive diagnosis|
11030071|NCT04567732|Experimental|Filtered Autologous Adipose Tissue|based on randomization one of the two knees will be treated with a single injection of Filtered Autologous Adipose Tissue
11030072|NCT04567732|Placebo Comparator|Placebo|based on randomization one of the two knees will be treated with a single injection of Placebo
11030073|NCT04567719||Changes in Taste Perception After Exposure to Chemotherapy|A total of 20 participants with histologically-proven MIBC planning to receive pre-surgery chemotherapy followed by radical cystectomy will be recruited.
11030074|NCT04567706||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.
11030075|NCT04567693|Experimental|Early 1|Advance to spaced-out appointments at month 6 after a single viral load is measured.
11030076|NCT04567693|Experimental|Early 2|Advance to spaced-out appointments at month 6 after two viral loads are measured.
11030077|NCT04567693|No Intervention|Usual Care|Do not advance to spaced-out appointments during study period
11030078|NCT04567680|Experimental|Acceptance and Commitment Therapy to Improve Social Support|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
11030079|NCT04567680|Active Comparator|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
11030080|NCT04567667|Experimental|Group 1|
11030081|NCT04567667|Experimental|Group 2|
11030082|NCT04567641||Enteral Nutrition|
11030083|NCT04567641||Parenteral nutrition|
11030084|NCT04567628||TDM Cohort|Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment will be observed retrospectively.
11030085|NCT04567628||Historical Cohort|Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment will be observed retrospectively.
11030086|NCT04567615|Experimental|Arm A : Nivolumab|
11030087|NCT04567615|Experimental|Arm B : Nivolumab + Relatlimab Dose 1|
11030088|NCT04567615|Experimental|Arm C : Nivolumab + Relatlimab Dose 2|
11030089|NCT04567602||Participants with PAH|Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice.
11030090|NCT04567576||Exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed infection by 2019-nCoV (COVID-19) who at the time of diagnosis (of infection) receive pharmacological treatment with disease modifying antirheumatic drugs (DMARDs).
11030091|NCT04567576||Un-exposed|Patients with underlying rheumatological or autoimmune diseases who have a confirmed 2019-nCoV (COVID-19) infection who at the time of diagnosis (of infection) are not receiving pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs).
11030092|NCT04567563|Active Comparator|Remote Ischemic Condition|
11030093|NCT04567563|No Intervention|Standard of Care|
11030094|NCT04567550|No Intervention|Observation Control Arm|Observation Control
11030095|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
11030096|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
11030097|NCT04567537|Active Comparator|Scars|One half or side of the hypertrophic scar will be randomized to receive laser treatment only. The other side will be left untreated, and each subject will act as their own control.
11031220|NCT04559802|Active Comparator|Submerged|Flaps will be advanced to achieve primary wound closure.
11030098|NCT04567537|Active Comparator|Scleroderma|One half or side of the sclerodermoid lesion will be randomized to receive laser treatment only. The other side will be left untreated, and each subject will act as their own control.
11030099|NCT04567524|Active Comparator|Arm 1|"• LYN-005: Size 00EL capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone.
~AND
~• IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient."
11030100|NCT04567524|Placebo Comparator|Arm 2|"• LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate.
~AND
~• IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets."
11030101|NCT04567511|Experimental|Single Arm|Patients with mild hemophilia A (without inhibitors) will be treated with prophylactic emicizumab. The clinical hemostatic efficacy and safety will be assessed. Secondary outcomes will assess changes in quality of life and joint health in treated patients.
11030102|NCT04567498|Experimental|Presumptive TB patients (395 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
11030103|NCT04567498|Experimental|Residents of area with high risk of TB (1383 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
11030104|NCT04567472|Experimental|Online HEADS: UP|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
11030105|NCT04567459|No Intervention|control group: chemotherapy|No intervention
11030106|NCT04567459|Experimental|experimental group: chemotherapy and nutrition support|Premium amino acids 1pc bid for 6 months
11030107|NCT04567446||Patients who will start cancer treatment|"Collection of biological samples (stool, blood, saliva) and data from patients included in the study will be performed:
~By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).
~Collection of biological resources (all samples will be collected in fresh):
~Stool: collected at diagnosis, before initiating anticancer treatment, during treatment
~Blood: 40 mL collection before, 3 and 6 months of treatment cancer
~Saliva: 5 mL collection before initiation of treatment cancer
~Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
11030108|NCT04567433||CHEST Study|Participants in the CHEST trial long term sepsis cohort
11030109|NCT04567433||ARISE Study|Participants in the ARISE study long term follow-up cohort
11030110|NCT04567433||ADRENAL study|Participants in the ADRENAL study
11030111|NCT04567420|Experimental|Arm A|Palbociclib/Fulvestrant Combination
11030112|NCT04567420|Active Comparator|Arm B|Adjuvant Therapy
11030113|NCT04567407|Experimental|Bilateral erector spinae blocks|All enrolled patients will have bilateral erector spinae blocks (with catheters for postoperative local anesthetic infusion) placed by the by a member of the clinical regional anesthesia team (under the supervision of a member of the research team) in a sterile fashion after the cardiac surgical procedure is completed. Postoperative continuous infusion of local anesthetic (ropivacaine) via the nerve block catheter is initiated and managed by the Acute Pain Service (per standardized, clinical weight-based protocols).
11030114|NCT04567394|Experimental|Intervention|Participants randomized to the Intervention group will complete questionnaires at baseline, 1 month, 3 months, and 6 months and will receive 4 weeks of the PNC-txt intervention.
11030115|NCT04567394|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will complete questionnaires at baseline, 1 month, 3 months, and 6 months.
11030116|NCT04567381|Active Comparator|Treatment as Usual|Treatment as Usual (TAU)/Control. Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
11030117|NCT04567381|Experimental|Enhanced Services|Enhanced Services/Treatment (ES). Participants randomized to the ES intervention will receive intensive community-based case management.
11030118|NCT04567355|Experimental|Migraine Manager|The Migraine Manager portal intervention is comprised of 16 modules that are assigned in an individually tailored manner to participants based on their answers to a brief assessment battery. Once assessments are completed, a treatment plan consisting of recommended modules is automatically generated for patient and parent guidance, and the user is directed to the list of recommended modules. Participants will also complete online daily diaries for eight weeks.
11030119|NCT04567355|No Intervention|Attention Control|Participants in this arm will complete the online daily diaries for eight weeks (i.e., equal time as the Migraine Manager arm) through the portal but will be restricted from receiving intervention content; they will also receive equal number of communications via the portal as the Migraine Manager arm. Data from migraine daily diaries will not be available to AC participants or their clinicians as this would likely be used clinically and lead to contamination of the control arm resulting from varying levels of intervention across participants based on their data.
11030120|NCT04567342|Experimental|Arm 1|
11030121|NCT04567342|Experimental|Arm 2|
11030122|NCT04567342|Experimental|Arm 3|
11030123|NCT04567342|Experimental|Arm 4|
11030124|NCT04567329|Experimental|NOV03|100% perfluorohexyloctane 4 times daily (QID)
11030125|NCT04567329|Placebo Comparator|Saline solution|0.6% sodium chloride solution 4 times daily (QID)
11030126|NCT04567316|Experimental|[14C]-radiolabelled BI 1358894|[14C]-radiolabelled BI 1358894 (part 1)
11030129|NCT04567303|Experimental|Part 2: Port Delivery System with High Dose|RO7250284 administered at a high dose through the PDS implant.
11030130|NCT04567303|Experimental|Part 2: Port Delivery System with Low Dose|RO7250284 administered at a low dose through the PDS implant.
11030131|NCT04567290|Experimental|Chewed ticagrelor|"Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff.
~Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed"
11030132|NCT04567290|Active Comparator|Swallowed ticagrelor|"Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water.
~Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed"
11030133|NCT04567277|Experimental|Early VPS|
11030134|NCT04567264|Experimental|With stimulation|Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.
11030135|NCT04567251|Experimental|Namzaric® arm|Arm 1 will take daily Namzaric® for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
11030136|NCT04567251|Placebo Comparator|Placebo arm|Arm 2 will take daily placebo for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
11030137|NCT04567238|Experimental|Reduced Use Condition|Participants in the reduced use condition will be provided mobile contingency management, in which they are paid to provide marijuana saliva readings that suggest they have been abstinent from marijuana use.
11030138|NCT04567238|No Intervention|Control Condition|Participants in the control condition will be asked to provide marijuana saliva readings, but they are not paid for abstinent readings. Instead, their payments are yoked to the average amount of payment made by two participants in the reduced use condition.
11030139|NCT04567225|Experimental|Early Glargine|All consecutive adult patients getting admitted to Medical ICU and meet the inclusion criteria and accepted to receive insulin glargine early as per the protocol. They will receive insulin glargine 0.4 unit/kg within 4 hours from initiating the IV Insulin Infusion, as per the Cleveland Clinic DKA protocol.
11030140|NCT04567225|Active Comparator|Standard practice (Late Glargine)|Retrospective, prespecified and matched sample of consecutive adults who admitted to the same Medical ICU with a diagnosis of DKA in the period between January 1st 2019 till the Institutional Review Board (IRB) approval date and didn't receive basal insulin before Anion Gap closure.
11030141|NCT04567212||Male-group|in this group we will enroll only male with asthma
11030142|NCT04567212||Female-group|in this group we will enroll only female with asthma
11030143|NCT04567199||Cytosorb recipients|"Patients receiving Cytosorb due to septic shock.
~SOFA score, Changes in catecholamine support after CytoSorb initiation Survival to discharge ICU Survival >28d Thromboembolic events
~General data:
~Need of catecholamines Type of extra-corporal treatments Anticoagulation medication Concomitant allogenic blood products Concomitant factor concentrates Bleeding events Vital signs Underlying Disease SAPSII, SAPSIII, SOFA Scores (on 1st day of treatment) Type of Pathogen (gram+, gram-, fungi) Sepsis Multi Organ Failure
~Data records:
~Myoglobin, CK (creatine kinase), CK-MB, Fibrinogen D-dimers, Antithrombin III, Procalcitonin Creatinin, urea, Natrium, Potassium, Bilirubin, GOT (glutamate-oxalacetate transaminase), GPT, GGT (glutamate-pyruvate transaminase), PT (prothrombin time) aPTT (activated partial thromboplastin time) CRP (C reactive protein) Blood count Further parameters if of interest"
11030144|NCT04567199||Non Cytosorb recipients|"Patients not receiving Cytosorb due to septic shock.
~Patients not treated with CytoSorb under suspicion for inflammation, septic shock or SIRS will be searched for same characteristics as the first group.
~These groups will be matched when parameters like epidemiology, infectious parameters, prognostic scores, age, gender amount of catecholamines fit best.
~Parameters as in Group of Cytosorb recipients"
11030145|NCT04567173|Experimental|Anti-SARS-CoV-2 convalescent plasma|About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
11030146|NCT04567173|No Intervention|Standard of care|Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways
11030147|NCT04567160|Active Comparator|Propofol group|Induction and maintenance of general anesthesia using propofol
11030148|NCT04567160|Active Comparator|Sevoflurane group|Induction and maintenance of general anesthesia using sevoflurane
11030149|NCT04567147|Experimental|Probiotic|Formula probiotic contains freeze-dried Lactobacillus casei, Bafidobacterium animals, Bifidobacterium longum, Bifidobacterium bidium and Lactobacillus plantarum, each at a dosage of 3.0E+10 CFU per 2g sachet.
11030150|NCT04567147|Placebo Comparator|Placebo|Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.
11030151|NCT04567121|Other|Intensive intervention group|intensive life-style and care intervention
11030152|NCT04567121|Other|Standard intervention group|standard life-style and care intervention
11030153|NCT04567108|Active Comparator|Maintain SSBs (Control)|Instruction to maintain baseline intake of SSBs
11030154|NCT04567108|Experimental|Substitute Aspartame ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame
11030155|NCT04567108|Experimental|Substitute Sucralose ASBs|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose
11030156|NCT04567108|Experimental|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water
11030157|NCT04567082||Cancer group|
11030158|NCT04567082||Control group|
11030159|NCT04567069|Experimental|DC vaccine|Vaccine made from autologous dendritic cells loaded with MG-7 antigen.
11030160|NCT04567069|Experimental|DC vaccine + CTL (cytotoxic lymphocyte)|Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.
11030161|NCT04567069|Experimental|DC vaccine + PD-1 monoclonal antibody (Sintilimab Injection)|Sintilimab injection is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
11030162|NCT04567056||Cancer group|Patients with verified head and neck squamous cell carcinomas
11030163|NCT04567056||Control group|Matched control group without active or earlier cancer and a normal ENT examination.
11030164|NCT04567043|Experimental|Mindfulness-Oriented Recovery Enhancement+JITAI|Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
11030165|NCT04567043|Active Comparator|Supportive Psychotherapy|Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
11030166|NCT04567030|Experimental|Experimental group A (AI Group: EG-A)|Behavioral: AI intervention For the EG-A, a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
11030167|NCT04567030|Experimental|Experimental group B (AI with humanized Group: EG-B)|"Behavioral: AI intervention For the EG-B,a AI scan box will give to patients that taking mouth image at home once a week until six-month. The AI will send automated message to patients' mobile phone telling about their oral hygiene condition, gum condition, tooth condition.
~The humanized counseling will also send to patients' mobile phone about each patients oral hygiene condition and advises."
11030168|NCT04567030|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
11030169|NCT04567004|Other|Control|The control arm will show the products with no label.
11030170|NCT04567004|Experimental|Nutriscore Label|The Nutriscore label applies a letter grade (A, B, C, D or E) to a product based on certain nutrient criteria.
11030171|NCT04567004|Experimental|Adapted Peruvian Nutrient Label|"The adapted label is a black octagon with the words in Spanish saying Excess of sugar,Excess of saturated fat, or Excess of salt/sodium depending on the nutrition contents of the product. Below the octagon is a box with words in Spanish saying Avoid high consumption"
11030172|NCT04567004|Experimental|Guideline Daily Amount Label|The Guideline Daily Amount label highlights the nutrient contents of the product by serving. It lists the calories, total fat, saturated fat, sugar, and sodium, as well are their % of the daily value.
11030173|NCT04566991|Experimental|Deferoxamine lower dose|Deferoxamine 32 Milligram Per Kilogram (mg/kg)
11030174|NCT04566991|Experimental|Deferoxamine higher dose|Deferoxamine 48 mg/kg
11030175|NCT04566991|Placebo Comparator|Placebo|normal saline
11030176|NCT04566978|Experimental|Cohort 1|Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
11030177|NCT04566978|Experimental|Cohort 2|Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
11030178|NCT04566978|Experimental|Cohort 3|Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
11030179|NCT04566978|Experimental|Cohort 4|Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
11030180|NCT04566965||Full-Time CCHMC Employees|All CCHMC full-time residents and fellows who have some direct contact with patients and their families as part of normal workplace duties.
11030181|NCT04566952|Experimental|Anlotinib combined With dose-reduced olaparib|Anlotinib-olaparib combination therapy until disease progression
11030182|NCT04566926|Experimental|Part 1: Cohort 1 (Placebo or JNJ-64140284)|Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.
11030183|NCT04566926|Experimental|Part 1: Cohort 2 (Placebo or JNJ-64140284)|Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
11030184|NCT04566926|Experimental|Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)|Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.
11030185|NCT04566926|Experimental|Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)|Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.
11030186|NCT04566913|Experimental|Patients recruited from Cairo University|"After Cone beam CT assessment , The patient is assigned for nonsurgical periodontal phase then an impression is taken for stent formation to facilitate tissue thickness measurement .
~> After 2 weeks , the patient is assigned for surgical phase to extract the palatal and apical aspect of the tooth and leave the buccal portion .
~Socket preservation is attempted in the socket , using 'genbioss ' bone graft. Modified free gingival graft is done on the pontic site to cover the buccal root shield and the bone graft .
~Post operative instructions include :
~Analgesics (Prufen 400 mg ) three times for three days
~Antibiotic (Augmentin 1gm ) twice daily for one week The patient will be assured to contact the operator of any unexpected complications occured ."
11030187|NCT04566900|Experimental|Active Treatment|Subjects will be given a choice of videos consisting of still images set to music. Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range. Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.
11030188|NCT04566900|Sham Comparator|Placebo|Video and music progression will be random and will not depend on brain activity. Any progression will be by random chance alone.
11030189|NCT04566887|Experimental|Acalabrutinib with R-CHOP chemotherapy|Acalabrutinib 100mg twice per day orally with standard of care R-CHOP chemotherapy by IV every 21 days for a maximum of six cycles.
11030190|NCT04566874|Other|Spira-A with HCT/p DBM|Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM
11030191|NCT04566874|Active Comparator|Medtronic PEEK ALIF with Infuse|Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)
11030276|NCT04566367|Active Comparator|Standard White Light Imaging|In this group the participants will be examined by white light endoscopy first and secondly with blue laser imaging technique during the same gastroscopy.
11030192|NCT04566861|Experimental|Anxious pregnant women - intervention group|100 pregnant women who have at least mild anxiety will be randomized to the intervention group where they will receive six one-on-one core sessions of Cognitive Behavioral Therapy during pregnancy (plus possible booster sessions)
11030193|NCT04566861|No Intervention|Anxious pregnant women - enhanced usual care group|100 pregnant women who have at least mild anxiety will be randomized to the enhanced usual care group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
11030194|NCT04566861|No Intervention|Non-anxious pregnant women - healthy control|100 pregnant women who do not have symptoms of anxiety or depression be followed in the healthy control group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
11030195|NCT04566848||Gastrointestinal cancers|Patients with advanced stage colorectal cancer, gastric cancer and pancreatic cancer who develop malignant ascites
11030196|NCT04566848||Control|Patients with intraabdominal ascites with benign reasons (liver cirrhosis, Congestive heart failure, etc.) .
11030197|NCT04566835|Experimental|Education Group|Taking the Health Promotion Program with cartoons and comics for Children with Asthma
11030198|NCT04566835|Other|Control Group|Taking standart care
11030199|NCT04566822|Experimental|High-touch intervention|"6 live video coaching sessions
~Coaching/feedback is tailored to the individual and adaptive to their progress
~Member can send the Coach messages between sessions, but the Coach will not respond until the live session"
11030200|NCT04566822|Experimental|medium-touch intervention|"3 live video coaching sessions
~2 live videos are optional (recommended for end of Weeks 3 and 5, but member can take advantage of them anytime)
~2-4 pre-recorded video sessions at end of the week. Pre-recorded videos provided in the absence of live sessions
~Chat messaging between sessions with 24-48 hour response time"
11030201|NCT04566822|Experimental|low-touch intervention|"1 Live video coaching session (week 1)
~Chat messaging with 24-48 hour response time"
11030202|NCT04566822|Sham Comparator|Sleep education control|"Weekly sleep education for six weeks
~No interaction with coach"
11030203|NCT04566809|Experimental|Experimental group: FES+CBA|FES+CBA participants executed FES and CBA treatment which means that during the stimulation they manipulated different tools. In particular, for the first ten sessions the participants were invited to manipulate specific objects: squares, rectangles and pyramids of different sizes; touch on plastic test tubes coated with materials of different consistency; these two exercises were performed both with open and closed eyes. Finally, for the last ten sessions the participants were asked to execute specific tasks, depending on person's life before the lesion.
11030204|NCT04566809|Active Comparator|Control Group: FES|FES participants received only FES to improve their manipulating skills without the interaction with objects, but only with the muscle contraction induced by the devices.
11030205|NCT04566796|Active Comparator|(Group N)|patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
11030206|NCT04566796|Experimental|(Group S)|the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
11030207|NCT04566783||Women and men fulfilling PGAD-criteria|"Inclusion criteria:
~- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum & Nathan (2001).
~Exclusion criteria:
~- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.
~Age:
~- 18 - 65 years of age
~Gender:
~- Female and male subjects"
11030208|NCT04566783||Controls|"Inclusion criteria:
~- Age and education matched healthy controls."
11030209|NCT04566770|Experimental|MID A|20 participants(18-49), Ad5-nCoV , two doses, Intramuscular administration
11030210|NCT04566770|Placebo Comparator|MID B|10 participants(18-49), Ad5-nCoV-placebo , two doses, Intramuscular administration
11030211|NCT04566770|Experimental|MIN A|100 participants(6-17), Ad5-nCoV , two doses, Intramuscular administration
11030212|NCT04566770|Placebo Comparator|MIN B|50 participants(6-17), Ad5-nCoV-placebo , two doses, Intramuscular administration
11030213|NCT04566770|Experimental|OLD A|100 participants(56 years of age and above), Ad5-nCoV , two doses(Low dose), Intramuscular administration
11030214|NCT04566770|Experimental|OLD B|100 participants(56 years of age and above), Ad5-nCoV , two doses(Middle dose), Intramuscular administration
11030215|NCT04566770|Placebo Comparator|OLD C|50 participants(56 years of age and above), Ad5-nCoV-placebo , two doses, Intramuscular administration
11030216|NCT04566770|Experimental|EBOV A|34 participants, Ad5-nCoV , two doses, Intramuscular administration
11030217|NCT04566770|Placebo Comparator|EBOV B|17 participants, Ad5-nCoV , two doses, Intramuscular administration
11030218|NCT04566757|Experimental|Umbilical Cord Plasma Infusion|Infusion of 50cc of Umbilical Cord Blood Plasma bi-monthly for 6 months
11030219|NCT04566744|Experimental|Physical tool use, tool making and construction|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a physical tool, making a physical tool or building a construction. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools as well as when we build constructions.
11030220|NCT04566744|Experimental|Use of modern physical tools and stone tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a modern physical tool or a stone tool. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools irrespective of whether they are modern or old (i.e., stone tools).
11030277|NCT04566367|Experimental|Blue Light Imaging|In this group the participants will be examined by blue laser imaging technique first and secondly with standard white light during the same gastroscopy.
11030530|NCT04564703|Experimental|cohort 2|Iberdomide will be given orally at 1.0 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
11030221|NCT04566744|Experimental|Use of modern physical, arbitrary and digital tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when watching video clips of individuals using either a modern physical tool, an arbitrary tool (e.g., a washing machine) or a digital tool (e.g., a touchscreen). Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we observe others using different kinds of tools, which have appeared progressively over technological evolution.
11030222|NCT04566744|Experimental|Physical tool use and Internet|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when estimating the capacity to solve a mechanical problem with modern physical tools either alone or with the help of a Internet Tutorial. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we imagine and estimate solving a mechanical problem alone or with the help of the Internet;
11030223|NCT04566731|Active Comparator|tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of tDCS for 20 minutes using a montage in which an anode (1.5 mA) is placed over F7 (left frontotemporal lobe) and the cathode will be place on O1 (left occipital) using the 10-20 EEG mapping system. Subjects will participate in a modified constraint-induced language therapy.
11030224|NCT04566731|Sham Comparator|Sham tDCS + CILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham tDCS for 20 minutes using a montage in which an anode is placed of F7 and cathose is placed over O1. Subjects will participate in a modified constraint-induced language therapy,
11030225|NCT04566718||Group A|Obese women who have been treated with metformin for one year prior to the study.
11030226|NCT04566718||Group B|Obese women who have been treated with metformin for at least three years prior to the study.
11030227|NCT04566705||Women with uterine rupture|Women with uterine rupture
11030228|NCT04566705||Women without uterine rupture|Women without uterine rupture
11030229|NCT04566692|Experimental|Treatment-experienced Cohort|Treatment-experienced participants will receive IGSC 20% at 2 different dosing frequencies using a subcutaneous (SC) infusion pump during 2 treatment periods (16 weeks per treatment period). In treatment period 1, treatment-experienced participants will receive 16 weekly IGSC 20% doses from Week 0 to Week 15. For participants entering study on intravenous immune globulin (IVIG), IGSC 20% will be dosed at 1.37 times the equivalent weekly dose and participants entering on subcutaneous immunoglobulin (SCIG) will receive the same milligram/kilogram (mg/kg) equivalent weekly dose as given prior to entry, without using a dose adjustment factor (DAF). In treatment period 2, treatment-experienced participants will receive biweekly IGSC 20 % (i.e, IGSC 20% every 2 weeks) for a total of 9 doses, with the first IGSC 20% dose administered at Week 16 and the final dose given at Week 32.
11030230|NCT04566692|Experimental|Treatment-naïve Cohort|Treatment-naïve participants will receive a loading dose of 150 mg/kg/day IGSC 20% for 5 consecutive days (Week 0, Days 1 to 5) followed by weekly maintenance infusions of 150 mg/kg IGSC 20% starting Week 1 (Day 8) through Week 32. IGSC 20% infusion will be administered using an SC infusion pump.
11030231|NCT04566679|Experimental|Butyrate|oral butyrate (500mg) once or twice per day
11030232|NCT04566679|Placebo Comparator|Placebo|oral placebo once or twice per day
11030233|NCT04566666|Placebo Comparator|Placebo of SCD-044 product|Placebo of SCD-044 study drug
11030234|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 tablets at Dose 1
11030235|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 tablets at Dose 2
11030236|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 tablets at Dose 3
11030237|NCT04566653||dialysis-dependent|chronic kidney disease patients with hyperkalaemia and dialysis-dependent
11030238|NCT04566653||non-dialysis-dependent|chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent
11030239|NCT04566627|Experimental|YSLQQ group|"Schools in this group implemented Yo Sé Lo Que Quiero program. This is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
11030240|NCT04566627|No Intervention|Control Group|Schools in this group implemented the usual preventive actions to reduce substance use. Usually, these actions are not manualized.
11030241|NCT04566614||Biliary Tract Cohort|Patients with suspected biliary tract cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
11030242|NCT04566614||Bladder Cancer Cohort|Patients with suspected bladder cancer (localised and metastatic) will be offered ctDNA to support their diagnosis, in cases where cystoscopy and biopsy are difficult to obtain due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. A positive ctDNA result will be supportive of a diagnosis of bladder cancer, their treatment may be prioritised and decided based on this result in conjunction with radiological findings, patient presentation and after discussion between the treating physician and patient
11030278|NCT04566354|Other|Sprint exercise|Three bouts of 30-s sprint exercise with 20 min rest in between. Three fat biopsies obtained ar rest before first sprint, 15 min after and 120 min after third sprint Blood samples from stomach vein and arteria during the whole experiment
11030279|NCT04566341||Feasibility of OCT TCE in identifying signs of PD|Participants that fulfill our Inclusion/Exclusion criteria will be asked to swallow our Capsule Imaging device.
11030310|NCT04566107|No Intervention|Enhanced Usual Care|The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
11030243|NCT04566614||Pancreatic Cancer Cohort|Patients with suspected pancreatic cancer will be offered ctDNA to support a diagnosis in patients with suspected early stage, locally advanced and advanced disease. This includes patients with tumours that are technically challenging to access with invasive biopsy or due to limitations in endoscopic ultrasound due to the COVID-19 pandemic. Patients with histological diagnosis will not be eligible for this study. Patients with suspected cancer will have ctDNA result (positive or negative) discussed at MDT in conjunction with PREVAIL-imaging risk stratification pathway to risk stratify in terms of cancer risk (low, intermediate and high risk), serum tumour markers and patient presentation which will dictate the appropriate treatment. Those with metastatic disease will have their treatment decision based on ctDNA result, radiology and patient characteristics after discussion between the treating clinician and patient
11030244|NCT04566614||Gastrointestinal Stromal Tumour Cohort|Those with suspected Gastrointestinal Stromal Tumour Cohort (GIST) are eligible for this study. KIT and PDGFR mutation detected using ctDNA in conjunction with radiological features will be supportive of a diagnosis of GIST. This may allow for the use of directed targeted therapy, or prioritise surgical resection in some cases. Patients with histological diagnosis will not be eligible for this study. However, patients with inadequate tissue for KIT/PDGFR analysis will be eligible for PREVAIL-ctDNA to confirm the diagnosis of GIST and help guide treatment decisions
11030245|NCT04566614||Lung Cancer Cohort|The use of ctDNA in the diagnosis and adaptive management of patients with lung cancer is well established, however not funded by NHS. As aerosol-generating bronchoscopy procedures have reduced due to the COVID-19 pandemic, patients with suspected lung cancer may be offered ctDNA to support the diagnosis. A positive ctDNA result in conjunction with radiological findings will assist in prioritising those suitable for upfront surgical resection, radiotherapy or systemic anti-cancer treatment. It may provide sufficient genotypic information to guide standard of care targeted therapies (usually two tests are required - biopsy and then next generation sequencing of extracted DNA), including in patients without sufficient tissue for EGFR and ALK testing which can be detected using ctDNA. The use of ctDNA to guide treatment decisions in this cohort will not require signed consent as it is considered a standard approach (not yet NHS funded)
11030246|NCT04566614||Colorectal Cancer Cohort|Patients with suspected colorectal cancer will often be referred following either suspicion on imaging or faecal immunochemical testing (FIT). FIT testing results will be used to prioritise patients for screening colonoscopy, in conjunction with the PREVAIL-imaging risk stratification pathway
11030247|NCT04566601|Experimental|BI 1358894 dose group 1|
11030248|NCT04566601|Placebo Comparator|Placebo|
11030249|NCT04566601|Experimental|BI 1358894 dose group 2|
11030250|NCT04566601|Experimental|BI 1358894 dose group 3|
11030251|NCT04566601|Experimental|BI 1358894 dose group 4|
11030252|NCT04566588|Experimental|Early apical release holmium enucleation of the prostate|Early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
11030253|NCT04566588|Active Comparator|Classic holmium enucleation of the prostate|Classic holmium enucleation of the prostate (HoLEP), as a surgical treatment for benign prostatic hyperplasia
11030254|NCT04566562||Study Group|Brain scans, cognitive tests, blood biomarkers
11030255|NCT04566549|Placebo Comparator|Placebo group|Shampoo base without probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance.
11030256|NCT04566549|Active Comparator|Test group|Shampoo base with probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance、Heat-killed Lactobacillus paracasei powders (5x10^8 cells/ g-shampoo).
11030257|NCT04566536||Surgery|Patients ≥ 18 years old scheduled for robotic surgery (all specialties except ENT)
11030258|NCT04566523||Control Group|Chronic respiratory patients who undergo a home-based exercise training program with a rehabilitation coach supervision.
11030259|NCT04566523||Tele Group|Chronic respiratory patients who undergo a home-based exercise training program online.
11030260|NCT04566510|Experimental|Royal Guard|alpha-cypermethrin + pyriproxyfen (PPF)
11030261|NCT04566510|Active Comparator|PermaNet 3.0|deltamethrin + piperonyl butoxide (PBO)
11030262|NCT04566497|Experimental|Experimental|no systematic stress testing during follow-up
11030263|NCT04566497|Active Comparator|Active Comparator|systematic annual stress testing during follow-up
11030264|NCT04566484|Experimental|BBV87vaccine(BBV87 20 µg/ BBV87 40 µg)|"The test article, inactivated Chikungunya virus vaccine 'BBV87', is available in a 2 mL clear glass USP Type 1 vial that contains a single dose of 0.5 mL of the vaccine as singlehuman dose (SHD). Vials are stoppered and sealed with tear-down aluminum seals.
~• Route: BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm. 0.5 mL of the investigational vaccine (BBV87 20 µg/ BBV87 40 µg) will be administered."
11030265|NCT04566484|Placebo Comparator|Normal Saline|Each 0.5 ml vial of placebo will contain normal saline.The placebo will be given to participants intramuscularly in the deltoid region of the upper arm.0.5 mL of placebo will be administered.
11030266|NCT04566471||PPP and GPP|Palmoplantar pustulosis (PPP) and Generalized pustular psoriasis (GPP) are rare chronic inflammatory skin diseases, characterized by repeated episodes of sterile pustules in several months or years, associated with erythrokeratodermia generally. Both two diseases are easy to cause skin rupture, leading to bleeding and pain.
11030267|NCT04566458||Single arm|Her2 positive mBC patients who have received at least 3 lines of treatment in the metastatic setting.
11030268|NCT04566445|Experimental|GT005 Dose 1|Approximately 60 subjects are planned, with subjects randomised to GT005 Dose 1.
11030269|NCT04566445|Experimental|GT005 Dose 2|Approximately 60 subjects are planned, with subjects randomised to GT005 Dose 2.
11030270|NCT04566445|No Intervention|Untreated control|Approximately 60 subjects are planned, with subjects randomised to untreated control.
11030271|NCT04566432||Immune checkpoint inhibitors|
11030272|NCT04566432||Targeted therapy|Targeting ALK, ROS1, MET ex14 skipping
11030273|NCT04566419|Active Comparator|Control group|Oxygen delivered by Venturi Mask
11030274|NCT04566419|Experimental|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
11030275|NCT04566380|Experimental|ONO-4538 group|Specified Dosage and Duration of Treatment
11030280|NCT04566328|Active Comparator|Arm A (daratumumab, lenalidomide, dexamethasone)|INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
11030281|NCT04566328|Experimental|Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11030282|NCT04566328|Active Comparator|Arm C (daratumumab, lenalidomide, dexamethasone)|"CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity."
11030283|NCT04566315|Other|ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS|SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT
11030284|NCT04566302|Experimental|SECM Skin Imaging|The SECM skin imaging procedure will be very similar to that by the FDA approved RCM devices. First, the skin lesion (such as a mole) will be identified on a forearm of the subject. The lesion will be imaged first with a dermatoscope, and then with the SECM device. A dermatoscope is a hand-held device used for the visual observation of the epidermis. It is a superior surface contact microscope used to examine skin lesions.
11030285|NCT04566289||PiCSO treatment group|PiCSO treatment as per IFU
11030286|NCT04566276|Experimental|Adult Cohort 1: 10 µg|12 healthy adults aged 18-55 years will receive 10 µg of the vaccine IM
11030287|NCT04566276|Experimental|Adult Cohort 2: 25 µg|12 healthy adults aged 18-55 years will receive 25 µg of the vaccine IM
11030288|NCT04566276|Experimental|Adult Cohort 3: 50 µg|12 healthy adults aged 18-55 years will receive 50 µg of the vaccine IM
11030289|NCT04566276|Experimental|Adult Cohort 4: 100 µg|12 healthy adults aged 18-55 years will receive 100 µg of the vaccine IM
11030290|NCT04566276|Experimental|Elderly Cohort 1 :10 µg|12 elderlies aged 65-75 years will receive 10 µg of the vaccine IM
11030291|NCT04566276|Experimental|Elderly Cohort 2: 25 µg|12 elderlies aged 65-75 years will receive 25 µg of the vaccine IM
11030292|NCT04566276|Experimental|Elderly Cohort 3: 50 µg|12 elderlies aged 65-75 years will receive 50 µg of the vaccine IM
11030293|NCT04566276|Experimental|Elderly Cohort 4: 100 µg|12 elderlies aged 65-75 years will receive 100 µg of the vaccine IM
11030294|NCT04566263|Other|Successful embolization of intracranial aneurysms|Successful embolization of intracranial aneurysms defined by angiographic occlusion of greater than or equal to 90% at 6 months.
11030295|NCT04566250|Active Comparator|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:
~A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).
~A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.
~Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
11030296|NCT04566250|Other|Standard of Care|The control group is standard of care, which typically includes a prescription for an opioid.
11030297|NCT04566237|Experimental|24 months follow up after vitrectomy|Objective Scatter Index (OSI) and Average Lens Density (ALD) at inclusion, then 3 months, 12 months and 24 months after vitrectomy
11030298|NCT04566224|Experimental|Macintosh 2 group|Using Macintosh size 2 blade for direct laryngoscope intubation according to randomization
11030299|NCT04566224|Active Comparator|Macintosh 3 group|Using Macintosh size 3 blade for direct laryngoscope intubation according to randomization
11030300|NCT04566211|Experimental|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
11030301|NCT04566211|Active Comparator|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
11030302|NCT04566185||Patients with recurrent glioblastoma|
11030303|NCT04566172|Experimental|Prehabilitation program|Patient undergoing thoracic or upper abdominal surgery as part of their regular medical care will be approached. Participants will receive a prehabilitation program that includes an inspiratory muscle training that they will do leading up to the day of their surgery.
11030304|NCT04566159|Experimental|CBI + CHW|2 Session Computer Delivered Intervention with use of Nicotine Replacement Therapy and Community Health Worker Follow Up
11030305|NCT04566159|Other|Routine Care|Routine Tobacco Cessation Advice to Stop Smoking and Nicotine Replacement Therapy as offered by the inpatient team
11030306|NCT04566146|Other|45 patients with subacromial impingement syndrome|Forty-five patients between the age 18 and 45 years old, will be referred by orthopaedist as subacromial impingement syndrome (stage Ⅰ and ⅠⅠ Neer's classification)
11030307|NCT04566133|Experimental|1/Arm 1|Trametinib + hydroxychloroquine (HCQ)
11030308|NCT04566120|Experimental|Cinnamon extract mouthwash|Participants will be exposed to cinnamon extract mouthwash and will be instructed to use 10 ml of cinnamon extract mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
11030309|NCT04566120|Active Comparator|Chlorohexidine based mouthwash|Participants will be exposed to chlorohexidine based mouthwash. and will be instructed to use 10 ml of 0.12% chlorhexidine based mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
11031370|NCT04558515||Control|Symptomatic patients negative for malaria by PCR
11030311|NCT04566107|Experimental|mHealth|The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
11030312|NCT04566107|Experimental|mHealth Plus|The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
11030313|NCT04566081|Active Comparator|iTALKbetter: deterministic|"Participants will receive the deterministic version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.
~iTALKbetter:deterministic version will randomise the order all of the words that are to be trained and participants will cycle through all of these words regardless of their performance until complete at which point the order is re-randomised and participants begin the cycle again."
11030314|NCT04566081|Active Comparator|iTALKbetter: reactive|"Participants will receive the reactive version of the iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.
~iTALKbetter reactive version is identical to the deterministic version for the first cycle only. From then on the words participants are trained on can change depending on their performance on that word over a number of cycles. Words that participants are failing to retrieve over a number of cycles will be retired from the therapy as they are deemed too difficult for a given participant. Similarly words that are correctly retrieved over a number of consecutive cycles are also retired from the therapy as they are deemed to have been learned. In this way iTALKbetter reactive version will gradually give each participant a personalised corpus of words that they can train on, focusing on the words where they stand to make the most improvements."
11030315|NCT04566068|Experimental|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors. Interventionists will participate in weekly supervision. Approximately half of participants will be asked to wear sleep trackers for one-week prior to starting the intervention (T0) and one-week after completing the intervention (T1).
11030316|NCT04566068|Placebo Comparator|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
11030317|NCT04566055||Prospective observational cohort|
11030318|NCT04566042|Experimental|ACT video game|
11030319|NCT04566029||Cases|Patients who have been responding to treatment for a long time
11030320|NCT04566029||Controls|Patients who do not respond to treatment
11030321|NCT04566016|Experimental|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1).
11030322|NCT04566016|Active Comparator|General anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
11030323|NCT04566003|Experimental|[18F]PI-2620 PET, then [18F]GTP1 PET|Participants will undergo one [18F]PI-2620 PET imaging session, then one [18F]GTP1 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18F]PI-2620 or 7mCi of [18F]GTP1.
11030324|NCT04566003|Experimental|[18F]GTP1 PET, then [18F]PI-2620 PET|Participants will undergo one [18F]GTP1 PET imaging session, then one [18F]PI-2620 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18F]PI-2620 or 7mCi of [18F]GTP1.
11030325|NCT04565990|Experimental|Selexipag|Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.
11030326|NCT04565977||Retrospective Cohort|All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
11030327|NCT04565964|Other|Health behaviors|Health behavior intervention for one month will be provided to every participant. We will teach children's guardians (care-giver) how to change the health behaviors to clean indoor environment, including the health behaviors in bedroom, kitchen room, restroom, refrigerator, washing machine, and incense burning hall.
11030328|NCT04565951|Experimental|treatment arm|Participants in this arm will receive the intervention, PsychArmor S.A.V.E.
11030329|NCT04565951|Sham Comparator|sham arm|"Participants in this arm will receive a sham training, not the intervention, consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
11030330|NCT04565938|Experimental|one-step self-etch adhesive with enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive with enamel etching
11030331|NCT04565938|Experimental|one-step self-etch adhesive without enamel etching|Non carious cervical lesions which will receive composite-resin restorations, with one-step self-etch adhesive without enamel etching
11030332|NCT04565938|Experimental|two-step etch-and-rinse adhesive|Non carious cervical lesions which will receive composite-resin restorations, with a two step etch-and-rinse adhesive
11030333|NCT04565925|Experimental|Sildenafil 20mg TID then Placebo TID|Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
11030334|NCT04565925|Experimental|Placebo TID then Sildenafil 20mg TID|Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
11030335|NCT04565912|Experimental|Sage extract mouthwash|Natural product mouthwash
11030336|NCT04565912|Active Comparator|Chlorohexidine mouthwash|Synthetic mouthwash
11030337|NCT04565899|Experimental|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
11030338|NCT04565899|Other|Usual care|Care received before active implementation begins, which includes passive access to tools in the EHR.
11030339|NCT04565886|Sham Comparator|control|Non-surgical mechanical instrumentation 3x. Each time the laser will be held in place but will not be activated.
11030340|NCT04565886|Experimental|laser|Non-surgical mechanical instrumentation 3x with adjunctive diode laser application according to the protocol of the Department of Periodontology, University of Bern
11030341|NCT04565873||P1|Primigravida in group 1
11030342|NCT04565873||M1|Multipara in group 1
11030343|NCT04565873||P2|Primigravida in group 2
11030344|NCT04565873||M2|Multipara in group 2
11030345|NCT04565860|Active Comparator|X-tra fil (bulk-filling) (X-traB)|X-tra fil composite placed as bulk-filling
11030346|NCT04565860|Active Comparator|X-tra fil (incremental) (X-traI)|X-tra fil composite placed as incremental
11030347|NCT04565860|Active Comparator|Filtek Bulk (bulk-filling) (FBB)|Filtek Bulk composite placed as bulk-filling
11030348|NCT04565860|Active Comparator|Filtek Bulk (incremental) (FBI)|Filtek Bulk composite placed as incremental
11030349|NCT04565847|Active Comparator|Healthy Control - Active Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
11030350|NCT04565847|Placebo Comparator|Healthy control - Placebo Arm|Healthy Controls Mannitol-Induced Cough Challenges on Visit 2 to determine elligibility (cough response). Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively. Nebulized 0.9% Saline given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4.
11030351|NCT04565834||Suicidal patients|Patients who have made at least one attempt to commit suicide.
11030352|NCT04565834||Control group|"This group will consist of two types of people:
~75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and
~150 patients suffering from depression but have never attempted to commit suicide."
11030353|NCT04565821|Experimental|Feasibility of trans-nasal IPD probe|The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability
11030354|NCT04565795|Experimental|Placement of ureteral stent post ureteroscopy|Subjects with unilateral ureteral or renal stone fragments who have undergone an uncomplicated ureteroscopy (UURS)
11030355|NCT04565769||Cancer patients with metastatic melanoma|Forty two cancer patients with metastatic melanoma included prior to treatment with ICI.
11030356|NCT04565769||Healthy controls|Forty two age- and gender- matched healthy controls.
11030357|NCT04565756|Experimental|Dose Escalation Cohort 1|Each subject will receive a low-dose 0.5 mg/mL (0.05%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
11030358|NCT04565756|Experimental|Dose Escalation Cohort 2|Each subject will receive a mid-dose 1 mg/mL (0.1%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
11030359|NCT04565756|Experimental|Dose Escalation Cohort 3|Each subject will receive a high-dose 1.5 mg/mL (0.15%) of EXN407 or placebo twice a day in 14 doses over a 7 day period.
11030360|NCT04565756|Experimental|Dose Expansion Cohort|The highest well-tolerated dose of EXN407 will be evaluated where subjects will receive EXN407 at the selected dose or placebo twice a day for up to 84 days resulting in a total of 168 doses
11030361|NCT04565743|Active Comparator|Intervention|Multiprofessional education for health professionals in primary care on secondary prevention of osteoporotic fractures. Identification and referral of patients with recent osteoporotic fracture.
11030362|NCT04565743|No Intervention|Control|No intervention from study. No restrictions regarding education or the local organization of care for the prevention of osteoporotic fractures.
11030363|NCT04565730|Active Comparator|Grup I= General anesthesia group|After applying standard ASA monitoring; 2-2,5 mg/kg propofol, and 0,6 mg/kg rocuronium IV will be performed for general anesthesia induction, and then orotracheal intubation will be performed. The patients will be placed in the supine position. General anesthesia will be maintained with sevoflurane in the mixture of oxygen-fresh air. Controlled mechanical ventilation will be initiated with a tidal volume of 8-10 ml/kg at 12 breaths per minute (I:E ratio 1:2), a fresh gas flow rate of 2 L per min, end tidal CO2 value at 30-35 mmHg, and peak airway pressure of maximally 30 cm H2O. All patients will undergo cesarean delivery surgery with the same technique by the same surgical team.
11030364|NCT04565730|Active Comparator|Grup II= Spinal anesthesia group|A standardized spinal anesthesia will administrated to the patients. After skin disinfection, 25G needle will used for puncture at the level of L2-L3 or L3-L4. After observing the cerebrospinal fluid, 15 mg bupivacaine (marcain spinal heavy) will be administered into the subarachnoid space. The level of anesthesia below T6 will be controlled.
11030365|NCT04565717|Experimental|Part A: ALN-HSD|Participants will be administered a single dose of ALN-HSD.
11030366|NCT04565717|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of ALN-HSD-matching placebo.
11030367|NCT04565717|Experimental|Part B: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
11030368|NCT04565717|Placebo Comparator|Part B: Placebo|Participants will be administered multiple doses of ALN-HSD-matching placebo.
11030369|NCT04565704|Experimental|Development of novel optical imaging technologies|Consented participants will allow their endoscopist to collect 3 additional biopsies from the participants. These biopsies will be used to develop our imaging techniques at our lab. We will use the standard of care histology images from the endoscopy procedure as a control comparison.
11030370|NCT04565691|Experimental|Bacteremia inducing arm|As mentioned the participants will be their own controls at the different time-points.
11030401|NCT04565509|Active Comparator|Focus/Targeted Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the FG input.
11030371|NCT04565678|Experimental|Treatment Sequence 1: ABCD|Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
11030372|NCT04565678|Experimental|Treatment Sequence 2: BDAC|Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
11030373|NCT04565678|Experimental|Treatment Sequence 3: CADB|Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
11030374|NCT04565678|Experimental|Treatment Sequence 4: DCBA|Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
11030375|NCT04565665|Experimental|Phase II Arm I (mesenchymal stem cells)|Patients receive MSCs as in the Pilot study.
11030376|NCT04565665|Active Comparator|Phase II Arm II (standard of care)|Patients receive standard of care.
11030377|NCT04565665|Experimental|Pilot study (mesenchymal stem cells)|Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
11030378|NCT04565652|Experimental|ICD Defibrillation|Detection of ICD shock during elective ICD implant using the investigational device
11030379|NCT04565639|Experimental|Experimental Power Hand Orthosis|Participants will test the improved grip strength using the powered hand orthosis system.
11030380|NCT04565639|Experimental|Experimental Power Hand Orthosis - Tasks of Daily Living|Participants will test the improved ability to perform tasks of daily living using the powered hand orthosis system.
11030381|NCT04565626|Experimental|Intervention|Participants will receive additional exercise by independent use of a peddle bike on the weekends. This is in addition to their usual physiotherapy
11030382|NCT04565626|No Intervention|Control|This arm will receive usual physiotherapy
11030383|NCT04565613|No Intervention|Standard care group|The participants will receive feeding as per standard of care (without protein or any other supplementations).
11030384|NCT04565613|Experimental|Study interventional group|The participants will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds.
11030385|NCT04565600|Experimental|Etoricoxib|The patients received oral etoricoxib from the day of chemotherapy to the 7th day after chemotherapy, one tablet (60 mg) each time, once per day.
11030386|NCT04565600|No Intervention|Control|Observation.
11030387|NCT04565587|Other|Videofluoroscopy|All participants will undergo a Videofluoroscopy when swallowing different viscosity levels of the thickener Tsururinko Quickly (japanese thickener)
11030388|NCT04565574|Experimental|Part A: E7090 35 mg (Fasted + Fed + Fed)|Participants will receive E7090 35 milligram (mg) tablet, orally on Day 1 of Treatment Period 1 in fasted state, followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fed state (high-fat meal). A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
11030389|NCT04565574|Experimental|Part A: E7090 35 mg (Fed + Fasted + Fed)|Participants will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 1 in fed state (high-fat meal), followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fasted state. A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
11030390|NCT04565574|Experimental|Part B: E7090 35 mg + Rabeprazole 20 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rabeprazole 20 mg tablets, orally, once daily on Days 7 to 10, and then followed by E7090 35 mg tablet and rabeprazole 20 mg tablets, orally on Day 11 in fasted state.
11030391|NCT04565574|Experimental|Part C: E7090 35 mg + Rifampin 600 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rifampin 600 mg capsules, orally, once daily on Days 7 to 12, then followed by E7090 35 mg tablet and rifampin 600 mg capsules, orally on Day 13 in fasted state, and then by rifampin 600 mg capsules, orally, once daily on Days 14 to 18.
11030392|NCT04565561||Neovas BRS group|Neovas BRS group, n=20
11030393|NCT04565561||DCB group|DCB group, n=20
11030394|NCT04565548|Experimental|Intervention|Participants will receive the newly developed theory-guided program for 12 weeks.
11030395|NCT04565548|Active Comparator|Control|Participants will receive the usual care and non-hypertension related text messaging for 12 weeks.
11030396|NCT04565535|Experimental|Intervention arm|Liver donors undergoing lifestyle optimisation
11030397|NCT04565535|No Intervention|Control arm|Liver donors who continue normal lifestyle.
11030398|NCT04565522||Hemodialysis or peritoneal dialysis patients|Hemodialysis or peritoneal dialysis Covid negative patients
11030399|NCT04565522||dialysis staff healthcare professionals|dialysis staff Covid negative healthcare professionals
11030400|NCT04565509|Active Comparator|General Message|In phase 1, three schools will be randomized to a messaging strategy that is developed from focus groups that generally describes COVID-19 and the importance of testing.
11030485|NCT04565041|Experimental|Social Support|
11030402|NCT04565509|Active Comparator|Best Message Alone|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy alone to begin at 7 months after testing starts.
11030403|NCT04565509|Active Comparator|Best Message + Augmented Message or Implementation Strategy|In phase 2, the schools will be randomized a second time after data analysis at 5 months to determine which communication strategy is determined to provide the best uptake of testing by students and staff. Three schools will be randomized to receive the best messaging strategy plus an augmented messaging or implementation strategy. The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
11030404|NCT04565496|Experimental|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
11030405|NCT04565483|Experimental|BENRALIZUMAB|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion after a one-month screening period. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
11030406|NCT04565457||Participants Scanned|All participants will be scanned with a CBCT system equipped with 2D antiscatter grid technology, referred to as research CBCT. Each participant will also be scanned with a standard clinical CBCT as part of their standard clinical care, which will serve as the baseline, or control.
11030407|NCT04565444|Experimental|Ketone|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and carbohydrate control.
11030408|NCT04565444|Experimental|Ketone + Protein|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight) and 10g of whey protein.
11030409|NCT04565444|Experimental|Protein|Carbohydrate control and 10g of whey protein.
11030410|NCT04565431||Group 1: Multiple Sclerosis|"Individuals with RRMS who are going to be starting Tysabri as determined by Neurologist as part of clinical care.
~Intervention: Drug: Tysabri"
11030411|NCT04565431||Group 2: Healthy Controls|Healthy individuals who are age, gender and education matched to the MS group.
11030412|NCT04565418|Experimental|Exercise training|12 week high-intensity interval training (3 sessions per week): Before and after exercise, subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws and indirect calorimetry.
11030413|NCT04565405|Experimental|AB (Detergent (A) followed by sterile water (B))|"Sequence: Detergent (A) followed by sterile water (B)
~The inner cannula will be cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the first visit, and then cleaned with sterile water in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
11030414|NCT04565405|Experimental|BA (Sterile water (B) followed by detergent (A))|"Sequence: Sterile water (B) followed by detergent (A)
~The inner cannula will be cleaned with sterile water in the first visit, and then cleaned with commercially available tracheostomy cleaning fluid / powder (Ex: Trachoe - Kapitex healthcare, UK) in the second visit, at a minimum period of 24 hrs apart. Laboratory analysis of colony counts will be conducted on the saline flushing pre- and post-decontamination for each washing."
11030415|NCT04565392|Experimental|famotidine twice daily|A 20-mg tablet of Pepcid AC(R) plus 1000 IU vitamin D3 and 1000 mg vitamin C in the morning with breakfast and a 20-mg tablet of Pepcid AC plus 1000 mg vitamin C in the evening with supper
11030416|NCT04565392|Other|famotidine once daily|Low-dose comparator. A 20-mg tablet of Pepcid AC(R) plus 1000 IU vitamin D3 and 1000 mg vitamin C in the morning with breakfast and 1000 mg vitamin C in the evening with supper
11030417|NCT04565379|Active Comparator|NuSepin® 0.1 mg|NuSepin® 0.1 mg/kg in 100 ml normal saline infusion
11030418|NCT04565379|Active Comparator|NuSepin® 0.2 mg|NuSepin® 0.2 mg/kg in 100 ml normal saline infusion
11030419|NCT04565379|Placebo Comparator|Placebo|100 ml normal saline infusion
11030420|NCT04565366||Spinal Cord Injury|Individuals recently admitted to hospital and diagnosed with acute, traumatic spinal cord injury.
11030421|NCT04565366||Trauma Control|Individuals recently admitted to hospital and diagnosed with an acute, traumatic injury that is not spinal cord injury.
11030422|NCT04565366||Healthy Control|Generally healthy individuals not recently diagnosed with an acute, traumatic injury (including spinal cord injury).
11030423|NCT04565353|No Intervention|Holdout control|Participants will only receive the standard appointment reminders from their providers.
11030424|NCT04565353|Experimental|Default Reservations Opt-Out Condition|"The day before their scheduled appointment, participants receive a text reading: A flu shot has been reserved for you to receive at your appointment tomorrow. Reply Y if you want this shot held for you, N if you don't. The text will include a picture of a vial that says Your Flu Shot on it."
11030425|NCT04565353|Experimental|Default Reservations Opt-In Condition|"The day before their scheduled appointment, participants receive a text reading: Reply Y if you would like to receive a flu shot at your appointment tomorrow, N if not. The text will include a picture of vial with no text on it."
11030426|NCT04565353|Experimental|Intergroup Competition Treatment Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind another region in flu shot rate last year (your region and another region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
11030427|NCT04565353|Experimental|Intergroup Competition Control Condition|"Three days before their scheduled appointment, participants will receive a text message with information about how much your region lagged behind the target flu shot rate of 70% last year (your region will depend on the study site and include realistic flu shot rates based on historical CDC data). Participants will receive a reminder message on the day of the appointment."
11030486|NCT04565028|Experimental|Contingency Management (CM)|Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
11037927|NCT04513548|Experimental|Ligelizumab|
11030428|NCT04565353|Experimental|Flu Shot for You Symbolic Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity to dedicate getting the flu shot to someone by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
11030429|NCT04565353|Experimental|Flu Shot for You Herd Immunity Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also be told that they have the opportunity of getting the flu shot to protect a vulnerable loved one by texting back the initials of an individual. Participants will receive a reminder message on the day of the appointment.
11030430|NCT04565353|Experimental|Flu Shot for You Control Condition|Three days before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot. They will also receive a reminder message on the day of the appointment. They will not receive any further information, nor will they be asked to respond with initials of an individual.
11030431|NCT04565353|Experimental|Prosocial Condition|The day before their scheduled appointment, participants will receive a message describing the pro-social benefits of getting a flu shot, and a reminder to ask for their flu shot. The described pro-social benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting loved ones from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting loved ones from serious complications from the flu). Participants will also receive a reminder message on the day of the appointment.
11030432|NCT04565353|Experimental|Self-Oriented Condition|The day before their scheduled appointment, participants will receive a message describing the self-oriented benefits of getting a flu shot, and a reminder to ask for their flu shot. The described self-oriented benefits will vary whether they emphasize the COVID-19 pandemic (e.g., protecting oneself from the risk of hospital-acquired COVID-19 infection) or not (e.g., protecting oneself from serious complications from the flu).
11030433|NCT04565353|Experimental|Information Vivid Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain vivid information about getting the flu. Participants will also receive a reminder message the day before the appointment.
11030434|NCT04565353|Experimental|Information Basic Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain basic information about getting the flu. Participants will also receive a reminder message the day before the appointment.
11030435|NCT04565353|Experimental|Information Control Condition|Three days before their scheduled appointment, participants will receive a message inviting them to watch a 2-minute wellness video and answer some related questions, as well as encouragement to get the flu shot. In this condition, the video will contain information about exercising. Participants will also receive a reminder message the day before the appointment.
11030436|NCT04565353|Experimental|Sharing Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
11030437|NCT04565353|Experimental|No Humor Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get the flu shot.
11030438|NCT04565353|Experimental|Healthy Habits Easy Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of easy health behaviors (e.g., whether they walked 500 feet yesterday, at least two serving of fruits and vegetables in the last week, and slept at least 6 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
11030439|NCT04565353|Experimental|Healthy Habits Difficult Health Behavior Condition|The day before their scheduled appointment, participants will be asked if they have completed a series of difficult health behaviors (e.g., whether they walked 3 miles yesterday, ate 4-6 servings of fruits and vegetables yesterday, and slept at least 9 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
11030440|NCT04565353|Experimental|Healthy Habits Control Condition|The day before their scheduled appointment, participants will receive a text message encouraging them to get a flu shot.
11030441|NCT04565353|Experimental|Just-In-Time Reminders 24-Hour Condition|Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 24 hours before their appointment.
11030442|NCT04565353|Experimental|Just-In-Time Reminders 15-Minute Condition|Just-In-Time Reminders 15-Minute Condition: Seventy-two hours before their appointment, participants will receive a text message alerting them to the availability of the flu vaccine at their upcoming appointment. Participants will be told they'll receive a reminder, which they can opt-out from receiving. The text message reminder will be sent 15 minutes before their appointment.
11030443|NCT04565340||Induction of labor with Foley catheter|Induction of labor with Foley catheter
11030444|NCT04565340||Induction of labor with Propess|Induction of labor with Propess
11030445|NCT04565327|Experimental|Cohort A: Single Dose/Image|Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over less than one minute then undergo MRI over 5 minutes at baseline
11030446|NCT04565327|Experimental|Cohort A: Multiple Dose/Images|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute then undergo MRI over 5 minutes at baseline and 4 weeks after beginning treatment
11030447|NCT04565314|Experimental|Eggs|Mother/child dyads will be enrolled at child age 0-14 days and mothers will immediately begin consuming 2 eggs daily. Eggs will be provided by the study team to the mother, who will prepare them as she desires. Intervention will continue through child age 6 months, and the child will be followed for growth through age 12 months. The rational is that egg consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to the Plumpy'Mum group and to historical controls from prior studies in the area.
11030487|NCT04565015|Experimental|GC5107|Immune Globulin Intravenous (Human), 10% Liquid
11030727|NCT04563338|Experimental|Arm C (Lung Cancer)|Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
11030448|NCT04565314|Experimental|Plumpy'Mum|Mother/child dyads will be enrolled at child age 0-14 days and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue through child age 6 months, and the child will be followed for growth through age 12 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to the egg group and to historical controls from prior studies in the area.
11030449|NCT04565301|Placebo Comparator|Group C|The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).
11030450|NCT04565301|Active Comparator|Group D|The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
11030451|NCT04565301|Active Comparator|Group N|The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.
11030452|NCT04565288|Experimental|Atomoxetine|Atomoxetine (40 mg/day for 3 days then 80 mg/day thereafter) during a 6-week medication trial
11030453|NCT04565288|Placebo Comparator|Placebo|Identical matching placebo capsules
11030454|NCT04565275|Experimental|ICP-192|"Dose Escalation Phase ICP-192
~Dose Expansion Phase ICP-192"
11030455|NCT04565262|Experimental|NAs+IFN-α|NAs+IFN-α/ 96w
11030456|NCT04565262|Other|NAs+(IFN-α+ NAs )|NAs/48w+(IFN-α+ NAs)/96w
11030457|NCT04565249|Experimental|PLN-74809 Dose 1|Dose level 1 of PLN-74809
11030458|NCT04565249|Experimental|PLN-74809 Dose 2|Dose level 2 of PLN-74809
11030459|NCT04565249|Experimental|PLN-74809 Dose Level 3|Dose level 3 of PLN-74809
11030460|NCT04565236|Experimental|Children < 12 years of age|Previously treated severe hemophilia A patients <12 years of age
11030461|NCT04565236|Experimental|Adolescents and adults ≥12 to 65 years of age|Previously treated severe hemophilia A patients ≥12 to 65 years of age
11030462|NCT04565223|Experimental|Cognitive behavioral therapy (CBT)|"5 sessions of Cognitive behavioral therapy for insmonia and an extra session for benzodiazepine withdrawal (if necessary).
~The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal"
11030463|NCT04565223|No Intervention|Usual care|Usual care from GPs or nurses
11030464|NCT04565210|Experimental|Oriental music|Infants assigned to this group will be exposed to oriental music.
11030465|NCT04565210|Active Comparator|Western music|Infants assigned to this group will be exposed to western music.
11030466|NCT04565210|Placebo Comparator|Silence / control|Infants assigned to this group will be exposed to the same protocol but using a track of silence.
11030467|NCT04565197|Experimental|Group intervene with convalescent plasma|"Review effect of Plasma therapy as clinical trial among hospitalized patients with COVID-19 infection.
~Transfuse 2 aliquots of plasma (200 mL x 2) per patient.
~Transfuse first aliquot for 2-3 hours (~1.4 to 2 mL/min)
~Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
11030468|NCT04565184|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
11030469|NCT04565184|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
11030470|NCT04565171|Experimental|Participants with renal impairment|Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.
11030471|NCT04565171|Experimental|Participants with normal renal function|Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.
11030472|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
11030473|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
11030474|NCT04565145|Experimental|Kava Pharmacokinetics Group|75 mg kava dietary supplement capsules per day for one week.
11030475|NCT04565145|Placebo Comparator|Placebo|Three placebo capsule per day for one week
11030476|NCT04565132|Experimental|HD-tDCS|Each patient received a total of six sessions of anodal HD-tDCS of right DLPFC.
11030477|NCT04565119||Severe traumatic brain injury (TBI)|This observational study is ancillary to the Brain Oxygen Optimization in Severe TBI Phase 3 (BOOST-3) trial (NCT 03754114). All participants in Bio-BOOST are enrolled in BOOST-3.
11030478|NCT04565093|Experimental|iPACK|In this group, participants will receive a peripheral nerve anesthetic block that is iPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) to cover posterior knee pain after total knee arthroplasty (TKA). This anesthetic block will be performed by assigned anesthesiologist under ultrasound guidance.
11030479|NCT04565093|Placebo Comparator|Periarticular local infiltration analgesia (LIA)|In this group, participants will receive a mixture of bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) that will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This local anesthetic infiltration is commonly performed by the operating orthopedic surgeon during TKA for postoperative pain control.
11030480|NCT04565080||FMD Patients|adult FMD patients who participated in protocol 07-N-0190
11030481|NCT04565080||PD Patients|adult PD patients who participated in protocol 01-N-0206
11030482|NCT04565067||1|COVID-19 recovered adult patients
11030483|NCT04565054|Experimental|Abemaciclib plus ET|Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
11030484|NCT04565054|No Intervention|Standard-of-care ET|"Standard-of-care ET according to clinical guidelines.
~Premenopausal patients:
~Either aromatase inhibitor + GnRH agonist
~or Tamoxifen +/- GnRH-agonist (as per investigator´s decision) or
~Postmenopausal patients:
~Either Aromatase inhibitor
~or Tamoxifen OR"
11030488|NCT04565002|Experimental|EG|The TEDS protocol will consist of the following parameters: a) frequency of 30 Hz; b) pulse width of 0.4 ms; c) respiratory rate of 15 irpm; d) holding time of 1 s; e) rise time of 1 s; f) 2 s descent time; and g) 2 s non-stimulus time. Phrenics equipment (Dualpex 961, Quark®) will be used. The positioning of the electrodes will be performed according to a study by Cancelliero et al. (2012), who proposed the placement of two electrodes in the right and left paraxiphoid regions, and two others in the direction of the axillary midline, over the seventh intercostal space, also on the right and left sides.
11030489|NCT04565002|No Intervention|CG|The control group will undergo the same assessments as the experimental group, but the TEDS will not be applied.
11030490|NCT04564989||HPV+ OPSCC Patients|Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
11030491|NCT04564976|Experimental|Social Support|
11030492|NCT04564963|Experimental|Cryotherapy|Cold therapy
11030493|NCT04564963|No Intervention|No cryotherapy|Standard practices for pain management
11030494|NCT04564950||Control|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
11030495|NCT04564950||Periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
11030496|NCT04564950||Coronary heart disease|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
11030497|NCT04564950||Coronary heart disease + periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
11030498|NCT04564937|Experimental|SCT510A dose level 1 treatment|SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously
11030499|NCT04564937|Experimental|SCT510A dose level 2 treatment|SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously
11030500|NCT04564937|Experimental|SCT510A dose level 3 treatment|SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously
11030501|NCT04564937|Experimental|SCT510A dose level 4 treatment|SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously
11030502|NCT04564924||MRI & DXA patients|No intervention
11030503|NCT04564924||MRI & DXA volunteers|No intervention
11030504|NCT04564911|Experimental|Flash Glucose Monitoring and Education|Participants randomised to the experimental arm will receive an education package and wear the flash glucose monitoring system. They will use sensor glucose data for self-management.
11030505|NCT04564911|Active Comparator|Capillary Glucose Monitoring and Education|Participants randomised to the control arm will receive an education package and self-manage their glucose levels utilising a standard capillary blood glucose device, and keeping a glucose diary for the duration of the intervention period.
11030506|NCT04564898|Experimental|trifluridine/tipiracil plus capecitabine and bevacizumab|
11030507|NCT04564885|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis at 2 contiguous levels
11030508|NCT04564885|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc at 2 contiguous levels
11030509|NCT04564872|Experimental|HSK7653 10 mg|
11030510|NCT04564872|Experimental|HSK7653 25 mg|
11030511|NCT04564872|Active Comparator|Linagliptin 5 mg|
11030512|NCT04564859|Experimental|Noninvasive Ventilation group|Noninvasive Ventilation group initial setting： Insp. Pressure：12 ~ 16 centimeter of water Exp. Pressure ： 4 ~ 6 centimeter of water FiO2：Keep oxygen saturation measured by pulse oximeter：> 92% By condition, gradually tap 2~3 centimeter of water inspiratory positive airway pressure Keep Tidal volume：6~10 ml/kg
11030513|NCT04564859|Active Comparator|Heated Humidified High-Flow Nasal Cannula group|Heated Humidified High-Flow Nasal Cannula group initial setting： Flow setting: 50 L/m FiO2：Keep oxygen saturation measured by pulse oximeter > 92% temperature:37 ℃ By condition, gradually tap Flow 5 L/m
11030514|NCT04564846|Placebo Comparator|Placebo|Subjects will be administered a single capsule of placebo( fish oil); placebo will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
11030515|NCT04564846|Active Comparator|ORMD-0801|Subjects will be administered a single 8mg capsule of ORMD-0801; study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime.
11030516|NCT04564833|Experimental|Low Dose RBT-1|45 mg SnPP/240 mg FeS
11030517|NCT04564833|Experimental|High Dose RBT-1|90 mg SnPP/240 mg FeS
11030518|NCT04564833|Placebo Comparator|Placebo|Normal saline
11030519|NCT04564807|Active Comparator|Web-Based Insomnia Education Program|Adult heavy drinkers with insomnia.
11030520|NCT04564807|Experimental|SHUTi Intervention|Adult heavy drinkers with insomnia.
11030521|NCT04564768|Experimental|Intervention group|Online Mindfulness-Based Cancer Recovery
11030522|NCT04564768|No Intervention|Control group|Treatment as usual
11030523|NCT04564742|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo
11030524|NCT04564742|Placebo Comparator|Placebo|Placebo matching dapagliflozin
11030525|NCT04564729|Experimental|Decision Aid|The shared decision aid (SDA) includes factual information about the World Health Organization pain ladder, the 0-10 numeric rating score pain scale, pharmacologic pain management options, opioid medication benefits and risks and predicted post-discharge opioid requirements based on previous modeling in total knee arthroplasty patients. Subjects in the decision aid group will view the decision aid and have the opportunity to participate in shared decision-making for their discharge opioid prescriptions.
11030526|NCT04564729|No Intervention|Control|Subjects in the control group will undergo standard care and discharge practices. Baseline pain and psychosocial factors will be documented as well as postoperative pain and analgesic consumption.
11030527|NCT04564716|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
11030528|NCT04564716|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
11030529|NCT04564703|Experimental|cohort 1|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
11037928|NCT04513548|Placebo Comparator|Placebo|
11030531|NCT04564703|Experimental|cohort 3|Iberdomide will be given orally at 1.3 mg/day, from day 1 to 21 of a 28-day cycle, continuously, until progressive disease (PD) or unacceptable toxicity.
11030532|NCT04564690|Experimental|QUARTET®|Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks
11030533|NCT04564690|Experimental|Control|Consumption of three regular hen eggs per day for three weeks
11030534|NCT04564677||Patients eligible for laparoscopic ventral mesh rectopexy|Female patients with primary rectal prolapse, rectocele and/or enterocele eligible for laparoscopic ventral mesh rectopexy (LVMR)
11030535|NCT04564664|Other|High-flow nasal cannula oxygen therapy|
11030536|NCT04564664|Other|Standard oxygen therapy|
11030537|NCT04564651|Experimental|platelet transfusion treatment|
11030538|NCT04564651|No Intervention|standard medical treatment|
11030539|NCT04564625||Fracture and Vitamin D assessment|All patients between 18 and 25 years treated for fractures at Methodist Dallas Medical Center (MDMC) with an index admission vitamin D assessment will be enrolled. This study will consider any patients with an index admission occurring between February 2016 and February 2020. No changes to care or intervention will occur and this study will be conducted completely via chart review. The aim is to identify 100 subjects with a one-year follow-up appointment for their injury to determine the rate of nonunion and vitamin D levels. As patients receive vitamin D supplementation as standard of care if index values are low, impact will be assessed through relative deficiency and clinical outcomes. Data collected from subjects without need for supplementation may be used to generate a threshold.
11030540|NCT04564612|Experimental|Part 1|Participants will receive single oral dose of BIIB091 on Day 1 of each study period, in fasted state, for up to 5 periods. There will be a minimum 7-day washout between Day 1 of each study period.
11030541|NCT04564612|Experimental|Part 2: Cohort A|Participants receiving single oral dose of BIIB091 on Day 1 of Period 1A in fed state will receive single oral dose of BIIB091 on Day 1 of Period 2A in fasted state. Participants receiving single oral dose of BIIB091 on Day 1 of Period 1A in fasted state will receive single oral dose of BIIB091 on Day 1 of Period 2A in fed state. Participants will then receive rabeprazole 20 milligram (mg) tablets, orally, twice daily (BID) for 3 days (Days -3, -2, and -1) of Period 3A in fed state followed by combination of rabeprazole 20 mg tablets, orally and BIIB091, orally, on the 4th day (Day 1) of Period 3A in fasted state. There will be a minimum 7-day washout between Day 1 of each study period.
11030542|NCT04564612|Experimental|Part 2: Cohort B|Participants will receive single oral dose of BIIB091 on Day 1 of Period 1B in fasted state followed by itraconazole 100 mg capsules, orally, BID for 1 day (Day -4) of Period 2B in fed state followed by itraconazole 100 mg capsules, orally, once daily (QD) for 2 days (Days -3, -2) of Period 2B in fed state followed by itraconazole 100 mg capsules, orally, QD for 1 day (Day -1) of Period 2B in fasted state. Participants will then receive combination of itraconazole 100 mg capsules, orally and BIIB091, orally on 5th day (Day 1) of Period 2B in fasted state followed by itraconazole 100 mg capsules, orally on 6th day (Day 2) of Period 2B in fed state. There will be a minimum 7-day washout between Day 1 of each study period.
11030543|NCT04564612|Experimental|Part 3|Participants will receive BIIB091, orally, QD or BID for at least 7 days in fasted or fed state.
11030544|NCT04564599||alcohol- and drug-related motor vehicle collisions|Number of alcohol- and drug-related motor vehicle collisions
11030545|NCT04564599||auto-ped alcohol- and drug-related collisions|Number of auto-ped alcohol- and drug-related collisions
11030546|NCT04564586|Other|Enhanced Intervention Group (EIG)|The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
11030547|NCT04564573||antidepressant treatment group|participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
11030548|NCT04564573||non-antidepressant treatment group|participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
11030549|NCT04564560||Patients treated with Zenith Alpha Spiral-Z®|Patients that from January 2017 until December 2019 received endovascular aortic repair with the Zenith Alpha Spiral-Z® at St. Olavs Hospital
11030550|NCT04564547|Experimental|Group 1: ISL 20 mg + MK-8507 100 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) [Part 1].
11030551|NCT04564547|Experimental|Group 2: ISL 20 mg + MK-8507 200 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
11030552|NCT04564547|Experimental|Group 3: ISL 20 mg + MK-8507 400 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
11030553|NCT04564547|Active Comparator|Group 4: BIC/FTC/TAF|Participants receive placebo to ISL + placebo to MK-8507 QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).
11030554|NCT04564534||Study cohort|"Adult (>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up.
~The MoCA will be administered by trained professionals with MoCA certification.
~Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure."
11030555|NCT04564521|Experimental|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
11030556|NCT04564521|Active Comparator|Normal saline|Normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy.
11030557|NCT04564495|Experimental|Live zoom exercise classes|Participants will engage in a live zoom exercise session. Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
11030558|NCT04564495|Active Comparator|Recorded zoom exercise classes|Participants will undergo 45 minutes of aerobic exercise intervention, three times a week, for a period of 12 weeks, using a pre-recorded class that they can do according to their own schedule. Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
11030559|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CRT)|
11030560|NCT04564482|Other|Short-course preoperative radiotherapy (SCPRT)|
11030561|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CROSS protocol)|
11030562|NCT04564456|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11030563|NCT04564456|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
11030564|NCT04564443|Experimental|(Medaxis Debritom+™) micro jet lavage|Medaxis Debritom+™ is a high-quality, micro water jet debridement device designed to remove fibrin, necrotic tissue, and biofilm from wound surfaces by mechanical cleaning and stimulation of the diabetic foot wound
11030565|NCT04564443|Active Comparator|Sharp Surgical Debridement|Use of a surgical scalpel or curette to remove fibrin, necrotic tissue and biofilm from wound surfaces by mechanically cleaning the wound
11030566|NCT04564430|Placebo Comparator|Control group|IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
11030567|NCT04564430|Experimental|Intervention group|Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
11030568|NCT04564417|Experimental|Monotherapy dose escalation: W0180|Participants will receive W0180 in a 21-day cycle until the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) for the single-agent identified.
11030569|NCT04564417|Experimental|Combination dose escalation: W0180+Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) followed by W0180 in a 21-day Cycle until the MTD in combination is identified or an RDE in combination is established.
11030570|NCT04564417|Experimental|Dose expansion|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion Q3W followed by an RDE dose of W0180 in a 21-day cycle.
11030571|NCT04564391|Active Comparator|Whey protein supplement, 2x 30g/day|"Three weeks, twice daily supplementation with 30 g of whey protein (=60 g / day), flavour choice chocolate or vanilla"
11030572|NCT04564391|Active Comparator|Casein supplement, 2x 30g/day|"Three weeks, twice daily supplementation with 30 g of casein (=60 g / day), flavour choice chocolate or vanilla"
11030573|NCT04564378||Mild Fuchs Dystrophy|
11030574|NCT04564378||Severe Fuchs Dystrophy|
11030575|NCT04564365||with beta-blocker|
11030576|NCT04564365||without beta-blocker|
11030577|NCT04564352||2|Adansonia digitata (Baobab)
11030578|NCT04564339|Experimental|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
11030579|NCT04564339|Placebo Comparator|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
11030580|NCT04564339|Experimental|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
11030581|NCT04564339|Placebo Comparator|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
11030582|NCT04564326|Active Comparator|Group C|Patients will be assigned to receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
11030583|NCT04564326|Experimental|Group P|Patients will be assigned to receive Pericapsular Nerve Group Block (PENG Block) before positioning the patient for spinal anesthesia.
11030584|NCT04564326|Experimental|Group F|Patients will be assigned to receive Fascia Iliaca Block (F.I Block) before positioning for spinal anesthesia.
11030585|NCT04564313|Experimental|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
11030586|NCT04564300|Experimental|Oral contraceptive users|
11030587|NCT04564300|Active Comparator|Non-oral contraceptive users|
11030588|NCT04564287||Patient|Patients with history of Covid-19 infection and persistent neurological symptoms
11030589|NCT04564274||1|patients with rare and common diseases
11030590|NCT04564261|Experimental|myPlan Teen Group|Personalized Healthy Relationship and Safety Planning Tool.
11030591|NCT04564261|Active Comparator|Usual Care Teen Control Group|Usual Care Teen Relationships and Health Resource.
11030592|NCT04564248|Experimental|website access for families|
11030593|NCT04564248|No Intervention|standard care|
11030594|NCT04564235|Experimental|Indication for a genome-wide analysis in the proband|
11030595|NCT04564222|Experimental|Micronutrient Enriched Crackers (MECs)|"Micronutrient Enriched Crackers (MECs) are a deep-fried snack product rich in iron, zinc, calcium, and vitamin A made from chicken liver and chicken eggshell powder.
~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
11030596|NCT04564222|Placebo Comparator|Placebo|"Placebo Crackers are a deep-fried snack product made from the basic cracker ingredients (mainly wheat flour) with the addition of Pangium edule seeds to provide a color similar to the intervention product (MECs).
~Consume daily, 75 gram/day, during pregnancy (from 14 weeks gestation to delivery) and lactation (from delivery to 5 months post-partum)."
11031182|NCT04560062||Population in Esmeraldas|576 randomly chosen patients with diabetes in Eloy Alfaro District, Esmeraldas (Ecuador)
11030597|NCT04564209|Experimental|Treatment|The treatment group will be exposed to the infographic intervention when they present for clinic/study visits. During their visit with the provider, the provider offer health education while using infographics.
11030598|NCT04564209|No Intervention|Control|The control groups will receive standard health education.
11030599|NCT04564196||Induction of Labor|"Samples collected from women who present for induction of labor.
~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
~Samples will be collected at the following time points for patients presenting for induction of labor:
~A) Baseline: At presentation to labor and delivery unit and prior to initiation of augmentation of labor. A total of 2 samples, individual samples will be taken approximately 5 minutes apart.
~B) End of 1st stage of labor: At complete cervix dilatation and prior to starting to push. A total of 2 samples will be taken approximately 5 minutes apart.
~C) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 2 samples will be taken approximately 5 minutes apart."
11030600|NCT04564196||Spontaneous Labor|"Samples will be collected from women who present in spontaneous labor
~- The parturient will be asked to breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
~Samples will be taken at the following endpoints:
~A) End of 1st stage of labor: At completely cervix dilated and prior starting pushing. A total of 2 samples will be taken approximately 5 minutes apart.
~B) End of 3rd stage of labor: Immediately (within 30 minutes) of delivery of the neonate. A total of 2 samples will be taken approximately 5 minutes apart."
11030601|NCT04564183||Full Cohort|Entire study population
11030602|NCT04564183||Sub-Cohort|Randomly selected sub-cohort from the larger group of all participants
11030603|NCT04564170||ED|Patients with Eating Disorders
11030604|NCT04564170||HC|Healthy Controls without eating disorders
11030605|NCT04564157|Experimental|Adjuvant treatment + Adjuvant maintenance treatment|"Adjuvant treatment:
~Paclitaxel: 200mg/m2 infusion over 3 hours
~Carboplatin: AUC5 at the end of the Paclitaxel infusion
~Nivolumab: 360 mg intravenous Q3W
~It has to start within 3-10 weeks from surgery and the first administration has to be done within 1-3 days from randomization. 4 cycles will be administered at 21day intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment. Patients must discontinue treatment if there is evidence of disease relapse.
~After the 4 cycles of chemo-immunotherapy the patient will receive:
~Adjuvant maintenance treatment: Nivolumab: 480 mg IV Q4W It will start after 4 weeks from day 1 cycle 4 of adjuvant treatment. 6 cycles will be administered every 28 days. A CT-SAN must be done within +/- 7 days from day 28 of the 3rd cycle of adjuvant maintenance treatment and within +/- 7 days at the end of the 6th cycle. Patients must discontinue treatment if there is evidence of disease relapse at 3rd cycle CT-SCAN."
11030606|NCT04564157|Active Comparator|Control arm: Adjuvant treatment|"Adjuvant treatment:
~Paclitaxel: 200mg/m2 infusion over 3 hours
~Carboplatin: AUC5 at the end of the Paclitaxel infusion Adjuvant treatment has to start within 3-10 weeks from surgery and the first administration and has to be done within 1-3 days from randomization. 4 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) after surgery. A CT-SAN must be done after the 4 cycles of adjuvant treatment.
~Observation: 2 observation visits will be done at 3 months and at 6 months from day 21 of cycle 4 of adjuvant treatment."
11030607|NCT04564144|Experimental|Volunteers receiving the prepared orodispersible tablets|6 human volunteers will receive the prepared orodispersible tablets plus a commercial one all containing Meclizine HCl in a parallel manner.
11030608|NCT04564131|Experimental|reflexology practice|"Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism.
~Experimental group participants will be given 10 sessions of reflexology massage twice a week for 5 weeks. A total of three follow-ups will be performed in the 1st session, the 5th session and the 10th session. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied."
11030609|NCT04564131|Experimental|Control|Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism. 1. 3. 5. A total of three follow-ups will be done once in the week. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied.
11030610|NCT04564118||Group 1|retrospective data on treatment from EMC
11030611|NCT04564118||Group 2|Treatment assignment using medicBC CDSS platform in the same cohort of patients
11030612|NCT04564105|Other|Staff of the ICU|The whole staff (nurses and doctors) of the ICU will be recruited to this trial. When they give their informed consent, video-recording of the intubations will be started. After 20 videos, simulations will be run. Also simulations will be recorded. Thereafter 20 further real-life intubations will be recorded. Staff intubating patients before and after won't be same but they will be adjusted for experience related to intubations.
11030613|NCT04564092|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.
11030614|NCT04564066|Experimental|efgartigimod IV|intravenous infusions of efgartigimod
11030615|NCT04564066|Experimental|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
11030616|NCT04564053|Experimental|LNA043 - lower dose cohort|randomized in 2:1 ratio to receive LNA043 lower dose or placebo
11030617|NCT04564053|Experimental|LNA043 - higher dose cohort|randomized in 2:1 ratio to receive LNA043 higher dose or placebo
11030618|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 1|"Part 1: Participants will receive Treatment A (100 mg AT suspension in water via NG administration) in Period 1, Treatment B (100 mg acalabrutinib capsule suspension via NG administration) in Period 2, and Treatment C (100 mg AT suspension in water via NG administration plus 20 mg rabeprazole) in Period 3.
~Part 2: Participants will receive Treatment D (100 mg AT suspension in water via NG administration) in Period 1 and Treatment A in Period 2."
11030619|NCT04564040|Experimental|Acalabrutinib Treatment Sequence 2|"Part 1: Participants will receive Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3.
~Part 2: Participants will receive Treatment A in Period 1 and Treatment D in Period 2."
11030620|NCT04564027|Experimental|Cohort A|Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.
11030621|NCT04564027|Experimental|Cohort B|Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.
11030622|NCT04564014|Experimental|ISSS Intervention|The intervention group will receive 5 weekly ISSS sessions in addition to the information about mental health, depression, anxiety and available treatment and community resources also recived by the control group.
11030623|NCT04564014|Active Comparator|Wait-list control group|Members will receive information about mental health, depression, anxiety and available treatment and community resources but not ISSS during the intervention period.
11030624|NCT04564001|Experimental|A ( Infliximab)|Infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 following prescription recommendations
11030625|NCT04564001|Experimental|B (Tocilizumab)|Tocilizumab : 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 following prescription recommendations
11030626|NCT04563975|Experimental|Arms|Toripalimabs plus Docetaxel for 4-8 cycles
11030627|NCT04563962|Experimental|Contingency Management-ART|Contingency management intervention with incentives tied to provision of urine samples with detectable levels of Tenofovir (TFV).
11030628|NCT04563962|Active Comparator|Contingency Management-Methamphetamine|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
11030629|NCT04563936|Experimental|LY01005|
11030630|NCT04563936|Active Comparator|Zoladex®|
11030631|NCT04563923|Experimental|Drug|"Patients in this group will additionally receive 3 s.c. injections of avdoralimab every week during 12 weeks
~They receive 0.05% Clobetasol propionate cream as follows:
~Patients of less than 45kg of body weight: 2 tubes of 10g/d
~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
11030632|NCT04563923|Other|Conventional therapy|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:
~Patients of less than 45kg of body weight: 2 tubes of 10g/d
~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
11030633|NCT04563910||less than 2 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
11030634|NCT04563910||2-5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
11030635|NCT04563910||more than 5 episodes|Patients were classified into 3 groups according to number of episodes (1-2 episodes, 3-5 episodes, more than 5 episodes)
11030636|NCT04563897||HBV/HCV|
11030637|NCT04563897||Fatty liver disease|
11030638|NCT04563897||Liver background after systematic treatment|
11030639|NCT04563897||normal hepatic background|
11030640|NCT04563884||Patients with deafness|Patients aged 12 months to 17 years with deafness
11030641|NCT04563884||Controls|Normal-hearing patients aged 12 months to 17 years
11030642|NCT04563871|Experimental|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
11030643|NCT04563858||Cardiac patients|
11030644|NCT04563845|Experimental|Part 1: Sentinal Cohort 1|Participants will be randomized in a 3:1 ratio to evaluate QD dosing of GSK3640254 or placebo. Participants will be administered GSK3640254 500 milligram (mg) or placebo with approximately 240 milliliters (mL) of water following ingestion of a moderate fat meal.
11030645|NCT04563845|Experimental|Part 1: Sentinal Cohort 2|Participants will be randomized in a 3:1 ratio to evaluate BID dosing of GSK3640254 or placebo. The maximum dose would be GSK3640254 500 mg BID or placebo BID with approximately 240 mL of water following ingestion of a moderate fat meal.
11030646|NCT04563845|Placebo Comparator|Part 2: Main QTc Study|Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin [400 mg] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.
11030647|NCT04563832|Other|Control group|standardized respiratory management.
11030648|NCT04563832|Experimental|Experimental group|same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)
11030649|NCT04563819||Newborns with DDH|Newborns (born 1988-90) with sonographic hip dysplasia (DDH)
11030650|NCT04563819||Newborns without DDH|Newborns (born 1988-90) without sonographic hip dysplasia (DDH)
11030651|NCT04563819||Hip dysplasia at skeletal maturity|Subjects that show signs of acetabular dysplasia at skeletal maturity (age 17-19 years), in 2007-09, when hip radiographs and salivary samples were collected.
11030652|NCT04563806|Experimental|Device feasibility (MRI-guided surgery)|Patients undergo standard of care spine surgery with MRI-based image guidance.
11030653|NCT04563793||Superion IDS|All patients to receive IDS for the treatment of their moderate Lumbar Spinal Stenosis Symptoms.
11030654|NCT04563767||Infinitome|All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
11030655|NCT04563754|Experimental|mHRME and HRA|"5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.
~This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging."
11030656|NCT04563741|Experimental|MOVE!+UP (intervention)|usual care enhanced with MOVE!+UP (intervention)
11030657|NCT04563741|Active Comparator|MOVE! (control condition)|usual care enhanced with MOVE! (control condition)
11030798|NCT04562857|Active Comparator|Central sleep apnea|interval exercises (intervention) on bicycle for patients with AF and CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
11030658|NCT04563728|Active Comparator|Camera Group|"1) The camera(s) will be a stationary device installed by the study technician on the ceiling of a common living area of the participant's home. The camera(s) will record video and audio data to be stored in our secure data base. The cameras will be purchased from YI Technology (see more details in Section 1.7). A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Highlighted video and audio data will be reviewed daily by the study technician. If there is evidence of abuse, exploitation, and neglect on these video and audio data, a report will be made to APS and the IRB."
11030659|NCT04563728|Active Comparator|Mock Camera Group|"2) The mock camera(s) will be a stationary device installed on the ceiling of a common living area of the participant's home. They will not record video or audio but will be installed with a sensor chip and a Wi-Fi connection, which will notify the study team if the device has been touched, tampered, altered, or disrupted power sources. After installing the device, the study technician and study coordinator will test the anti-tampering sensor to ensure potential future tampering will be detected. A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Daily check-ins to assess whether elder abuse may have been experienced by the participant will occur by phone or other preferred mode of communication. In the event of reported abuse, exploitation, and neglect, despite not being mandatory reporters, we will report to NJ APS and the IRB."
11030660|NCT04563728|No Intervention|Usual Care|Each participant will receive educational packages about elderly community-living.
11030661|NCT04563715|Active Comparator|Standard of Care|HIV counseling and testing
11030662|NCT04563715|Experimental|Standard of Care plus Network Intervention|Network intervention
11030663|NCT04563702|Experimental|Low Dose VXA-CoV2-1|Low dose (1E10 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1. A subset will also receive a second dose at Day 29
11030664|NCT04563702|Experimental|High Dose|High Dose (1E11 I.U.) of VXA-CoV2-1 oral tableted vaccine dispensed at Day 1
11030665|NCT04563689|Experimental|actve|oral rinse
11030666|NCT04563689|Placebo Comparator|placebo|distilled water,
11030667|NCT04563663|Experimental|One session|One session of talus posteriorization.
11030668|NCT04563663|Experimental|Two sessions|Two sessions of talus posteriorization.
11030669|NCT04563663|Experimental|Three sessions|Three sessions of talus posteriorization.
11030670|NCT04563663|Experimental|Four sessions|Four sessions of talus posteriorization.
11030671|NCT04563650|Experimental|COVID-19 positive resident|
11030672|NCT04563650|Active Comparator|COVID-19 negative resident|
11030673|NCT04563637||Computer Based Vision|A 15 second long video will be obtained at the research site using a smart phone or tablet. Then subjects will undergo a whole body dual energy x-ray absorptiometry scan . Then the subject will go home and take a second 15 second long video. The videos will then be analyzed by computer based vision application and the body fat percentage measured by dual energy x-ray absorptiometry scan will be compared.
11030674|NCT04563624|Experimental|ceramic cad cam blocks|
11030675|NCT04563624|Active Comparator|composite cad cam blocks|
11030676|NCT04563611|No Intervention|Muscle strength|Participants hamstring muscle strengths will be evaluated with Cybex isokinetic dynamometer
11030677|NCT04563611|No Intervention|Hamstring Muscle Architecture|In this study, the pennation angle (PA), muscle thickness (MT) and fascicle length (FL) values of the BFub were determined as B-Mode, 2D USG (Frequency, 10 Mhz: Depth, 6 cm) (Aloka SD3000, Ultrasonographic System, Aloca Inc, Japan).
11030678|NCT04563611|No Intervention|Cognitive Function|The lower (reaction time and visual-perceptual ability) and upper level (working memory, inhibitory control and cognitive flexibility) cognitive functions of the individuals participating in the study will be evaluated in computer environment with the Delis-Kaplan Executive Function System Battery (D-KEFS ™) and Stop Signal Task software.
11030679|NCT04563611|No Intervention|Reaction Time|In our study, an 8-channel sEMG device will be used to determine the reaction time of the hamstring muscles.
11030680|NCT04563611|Experimental|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. The hands and arms will be positioned on the chest and held by the physical therapist at the heels of the individuals. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed
11030681|NCT04563611|Experimental|Askling L-Protocol|The protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening.
11030682|NCT04563611|Experimental|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
11030683|NCT04563598||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
11030684|NCT04563598||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
11030685|NCT04563585||Muscle strength|Maximal voluntary isometric (MVIC) knee flexion and extension strength were measured using a handheld dynamometer (HDD) (Lafayette Instrument Company, Lafayette, IN).
11030686|NCT04563585||Lower Extremity Vertical Power|Lower extremity vertical power was identified through the use of the VertiMetric (Lafayette Instrument Company, Lafayette, IN) according to protocols suggested by Ambegaonkar et al.
11030687|NCT04563585||Trunk Extension Endurance|Trunk extension endurance was measured using the Biering-Sorensen test as previously described
11030688|NCT04563585||Upper Limb Performance|The Davies test (DT) was used to assess upper body agility and stabilization.The Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) was utilized to assess shoulder performance function and stability according to protocol suggested by Goldbeck and Davies.
11030689|NCT04563585||Lower Limb Performance|The Shark Skill Test (SST) was developed in order to assess lower extremity agility and neuromuscular control.
11030690|NCT04563572|Experimental|PPG Smartwatch|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.
~CardioWatch 287 is a novel non-invasive monitoring device manufactured by the MMT company. The device monitors heart rhythm, heart rate (HR) and respiratory rate (RR) based on peripheral PPG signal.
~In this arm, we will test the quality of the algorithm integrated into the smartwatch."
11030691|NCT04563572|Experimental|PPG Bracelet|"The Preventicus Heartbeats algorithm ist a certified tool for detection of Atrial Fibrillation. It differentiates accurately between regular rhythm, single premature beats and the absolute arrhythmia concordant with AF. The Preventicus algorithm is device-agnostic, meaning that any wearable device capable of recording PPG-signals can be used for data collection.
~A PPG-sensor is also integrated into a bracelet Basler Band manufactured by the MMT company, which is a simplified multisensory device.
~In this arm, we will test the quality of the algorithm integrated into the bracelet."
11030692|NCT04563559|Other|DEXTENZA vs prednisolone acetate 1%)|Subjects will randomly receive Dextenza or prednisolone acetate 1% in the first eye after surgery. At the time of the second eye surgery, the other eye will receive the drug that the first eye did not receive. Subjects will receive both drugs during the course of the study and therefore there is only 1 ARM for this study.
11030693|NCT04563546|Other|MI Patients in northern Tanzania|Patients presenting to KCMC emergency department with acute MI
11030694|NCT04563533|Experimental|adults of phase I|Healthy people aged 18-59
11030695|NCT04563533|Experimental|teenagers of phase I|Healthy people aged 6-17
11030696|NCT04563533|Placebo Comparator|elderly of phase I|Healthy people 60 years old and above
11030697|NCT04563533|Experimental|Toddler of phase I|Healthy people aged 2-5
11030698|NCT04563533|Placebo Comparator|Infants of phase I|6 weeks old-2 years old healthy person
11030699|NCT04563533|Experimental|elderly of phase II|Healthy people 60 years old and above
11030700|NCT04563533|Placebo Comparator|Toddler of phase II|Healthy people aged 2-5
11030701|NCT04563533|Experimental|Infants of phase II|6 weeks old-2 years old healthy person
11030702|NCT04563520|Experimental|Experimental treatment|"Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI. If there is less than a good' response in bleed event response efficacy as stated above at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with max dose no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days without further discussion with the PI."
11030703|NCT04563507|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
11030704|NCT04563507|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
11030705|NCT04563494|Active Comparator|IV Dexmethsone and oral placebo|
11030706|NCT04563494|Active Comparator|Oral dexamethasone and IV placebo|
11030707|NCT04563481|Experimental|Telerehabilitation|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients via telerehabilitation for 3 sessions per week.
11030708|NCT04563481|Experimental|Rehabilitation by Physiotherapist in the Clinic|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist in the clinic for 3 sessions per week.
11030709|NCT04563468|Experimental|Strength inspiratory muscle training group|Strength IMT
11030710|NCT04563468|Sham Comparator|Endurance inspiratory muscle training group|Endurance IMT
11030711|NCT04563442||covid 19|complications and comorbidities
11030712|NCT04563429|Experimental|Treatment Group|
11030713|NCT04563429|No Intervention|Control Group|
11030714|NCT04563416||Patients who need undergo magnifying endoscopy|
11030715|NCT04563403|Experimental|Treatment with Multiple Stimuli|Projection-based augmented reality therapy (P-ARET) with Multiple Stimuli (MS) (P-ARET MS). Intervention group that receives P-ARET treatment varying the stimuli available in the system (different cockroaches in colour, size, etc).
11030716|NCT04563403|Experimental|Treatment with Single Stimuli|Projection-based augmented reality therapy (P-ARET) with Single Stimuli (SS) (P-ARET SS). Intervention group that receives P-ARET treatment using a single stimulus (one cockroach).
11030717|NCT04563390|Experimental|Projection-based augmented reality exposure therapy|Intervention group that receives the projection-based augmented reality to carry out the exposure therapy for cockroach phobia.
11030718|NCT04563390|Experimental|In vivo exposure|Intervention group that receives traditional in vivo exposure therapy for cockroach phobia.
11030719|NCT04563390|No Intervention|WL Control|Waiting list control group.
11030720|NCT04563377|Experimental|ChAdOx1.HTI and MVA.HTI vaccination|"1x dose of ChAdOx1.HTI at 5 x 10^10 vp
~1x dose of MVA.HTI at 2 x 10^8 pfu"
11030721|NCT04563364|Experimental|Hospital-Home|This group will receive an interdisciplinary intervention of education to parents for get better outcomes of motor development.
11030722|NCT04563364|Active Comparator|Control Intervention|Control group will receive a conventional treatment given by the institutions
11030723|NCT04563351|Active Comparator|conventional inferior alveolar nerve block (IANB)|37 patients received Inferior Alveolar Nerve Block (IANB) for dental treatment of mandibular posterior teeth.
11030724|NCT04563351|Experimental|Intraligamentary Anesthesia (ILA)|35 patients received Intraligamentary Anesthesia (ILA) for dental treatment of mandibular posterior teeth.
11030725|NCT04563338|Experimental|Arm A (Liver Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
11030726|NCT04563338|Experimental|Arm B (Lung Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
11030799|NCT04562844|Experimental|Social cognition|
11030728|NCT04563325|Active Comparator|Experimental|"< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).
~=/> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).
~Treatment will be adjusted according to microbiological findings."
11030729|NCT04563325|Active Comparator|Standard|"IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:
~< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).
~>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).
~Treatment will be adjusted according to microbiological findings."
11030730|NCT04563312|No Intervention|Balance Assessment|The Flamingo Balance Test and Y Balance Test were used to evaluate static and dynamic balance, respectively.
11030731|NCT04563312|No Intervention|Coordination Assessment|Coordination was assessed using the Hexagon Test.
11030732|NCT04563312|No Intervention|Lower Extremity Functional Performance Assessment|Lower extremity functional performance was evaluated using the Single Leg Hop Test.
11030733|NCT04563312|Experimental|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
11030734|NCT04563299|Experimental|Dextenza|Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)
11030735|NCT04563299|Active Comparator|Topical Corticosteroids|Topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
11030736|NCT04563273|Experimental|Healthy people aged 18-45|Healthy people aged 18-45 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
11030737|NCT04563273|Experimental|Healthy people aged 46-65|Healthy people aged 46-65 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
11030738|NCT04563273|Experimental|Healthy people aged 11-17.|Healthy people aged 11-17 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
11030739|NCT04563273|Experimental|Healthy people aged 6-10|Healthy people aged 6-10 has 40 subjects,and it is considered as BCG purified protein derivative(BCG-PPD) skin test and Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10（EC） detection result all negative.
11030740|NCT04563260|Placebo Comparator|Control group|Control group receives the intravenous normal saline 2 mL.
11030741|NCT04563260|Experimental|Palonosetron group|Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.
11030742|NCT04563247||Asymptomatic frontline HCWs for COVID 19|All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.
11030743|NCT04563234|Experimental|COFLEX training|Neurocognitive training, delivered via a mobile device app
11030744|NCT04563234|Active Comparator|Crossword group|Access to crossword puzzles via a mobile device app
11030745|NCT04563221|Experimental|Balloon occlusion microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.
11030746|NCT04563221|Experimental|Standard microcatheter|Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.
11030747|NCT04563208|Placebo Comparator|Arm A: Placebo|Placebo administered
11030748|NCT04563208|Active Comparator|Arm B: Ribavirin/Nitazoxanide (RBV/NTZ)|Ribavirin/Nitazoxanide (RBV/NTZ) administered
11030749|NCT04563195|Other|open label|open label study; all subjects will receive the same drug at the same dose
11030750|NCT04563182||Muscle strength|GMed strength was assessed with the use of a Lafayette Manual Muscle Tester (Lafayette Instruments; Lafayette, Indiana, USA).
11030751|NCT04563182||Horizontal Jumping Performance|Lower extremity horizontal jumping was measured using the single leg hop (SLH) test as previously described
11030752|NCT04563182||Vertical Jumping Performance|To measure the single-leg vertical jump (SLVJ), the participants stood on the ground with their foot flat distributing their weight evenly on both feet.
11030753|NCT04563182||Dynamic Balance|The Y-Balance Test (YBT) was used to dynamic balance
11030754|NCT04563182||Static Balance|The Stork balance test (SBT) was used to measure static balance performance
11030755|NCT04563169|Experimental|Video consultation|Patients in the video consultation group will receive video consultations.
11030756|NCT04563169|No Intervention|Face-to-Face consultation|Patients in the usual care group will receive face-to-face consultations.
11030757|NCT04563156||Severe Covid-19 Survivors|Severe Covid-19 survivors previously admitted in the hospital
11030758|NCT04563143|Other|Novel stimulation|All subjects will undergo periods of stimulation using novel stimulation patterns
11030759|NCT04563130|Experimental|Cryocompression|Patients will be randomized to receive cryocompression on one hand and foot using ice bags and compression socks.
11030760|NCT04563130|No Intervention|Control|Patients will be randomized to receive no intervention on the opposite hand and foot.
11030761|NCT04563117||Automatic registration|
11030762|NCT04563117||Point-based registration|
11030763|NCT04563091|Experimental|Interventional group|"The study population will consist of 6 evaluable, outpatient patients with chronic kidney failure who need to perform hemodialysis thrice weekly for their survival.
~In the case of drop out of a patient will be enrolled another patient to arrive at 6 patients evaluable both at the end of Period A and at the end of Period B of the study"
11030764|NCT04563078|Experimental|Transcranial Magnetic Stimulation (TMS)|TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
11030765|NCT04563078|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS)|Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
11030899|NCT04562220|Active Comparator|Control Group|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions.
11030766|NCT04563065|Experimental|Exercise group|"The design of the physical exercise program will be supported by the Canadian and Spanish Guidelines for exercise throughout pregnancy (11,13) and published by Barakat model (10).
~Frequency: The program will consist of three weekly sessions. The duration of every session will be 55-60 minutes. The intensity of the workload will be 55-60% of the maximum maternal Heart Rate, and controlled by Polar monitor (FT60). Likewise, once a week, the Borg Scale of Perceived Effort will be administered to participants, in order to have a more reliable assessment of the intensity of the activities, 12-14 (moderate; out of a 20 point scale) will be the level used.
~The minimum adherence required for the participants will be 80% of the total sessions (approximately 80 sessions)."
11030767|NCT04563065|No Intervention|Control group|"Women randomly assigned to the control group (CG) received general advice from their health care provider about the positive effects of physical activity. Participants in the CG had their usual visits with health care providers during pregnancy, which were equal to the exercise group. Women were not discouraged from exercising on their own. However, women in the CG were asked about their exercise once each trimester using a Decision Algorithm (by telephone)."
11030768|NCT04563052|Experimental|Education|Air pollution educational module exposure.
11030769|NCT04563039|Experimental|Acoustic Enhancer with Ureteroscopic Laser Lithotripsy|
11030770|NCT04563039|Active Comparator|Standard Ureteroscopic Laser Lithotripsy|
11030771|NCT04563026|Experimental|DUR-928 (30 mg)|
11030772|NCT04563026|Experimental|DUR-928 (90 mg)|
11030773|NCT04563026|Placebo Comparator|(Placebo) Sterile Water for Injection|
11030774|NCT04563013|Sham Comparator|Sham tVNS|The participants under conventional radiochemotherapy were applied with sham tVNS at the earlobe for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
11030775|NCT04563013|Active Comparator|tVNS|The participants under conventional radiochemotherapy were applied with transcutaneous vagus nerve stimulation at the tragus for 30min and the current intensity was set according to the minimum value of pain threshold. The intervention would last until to the end of conventional radiochemotherapy.
11030776|NCT04563000|Experimental|Vitamin C|Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
11030777|NCT04563000|Placebo Comparator|Placebo|Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
11030778|NCT04562987|Active Comparator|Core|All participants will receive the Core component, which includes access to weekly telecoaching, weekly emails from the interventionist, a smartphone app, and a Fitbit monitor. Telecoaching will include discussion of general cancer-related and wellness topics, and the smartphone app will have basic activity monitoring features.
11030779|NCT04562987|Experimental|Move|Telecoaching calls for Move participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on reducing prolonged sitting. Smartphone app features include activity monitoring that visualizes progress toward Move-based goals and goal achievement badges specific to Move.
11030780|NCT04562987|Experimental|Exercise|Telecoaching calls for Exercise participants will be based in social cognitive theory to encourage behavior adoption and goal setting focused on engaging in 30 minutes of moderate-intensity physical activity per day (in 10+ minute bouts). Smartphone app features include activity monitoring that visualizes progress toward Exercise-based goals and goal achievement badges specific to Exercise.
11030781|NCT04562987|Experimental|Combo (Move+Exercise)|Includes telecoaching that encourages behavior adoption and goal setting focused on reducing prolonged sitting and engaging in 30+ minutes of physical activity per day. Participants are able to visualize progress toward Move and Exercise goals and are eligible to receive achievement badges for Move and Exercise.
11030782|NCT04562974|Experimental|One group of 30 healthy subjects|Perception and memory tasks inside a MRI-scanner for all participants
11030783|NCT04562961|Experimental|Schizophrenia caregiver (relative)|
11030784|NCT04562935||Pediatric intensive care|Children admitted to a pediatric intensive care unit before one year of age and admitted for to days or more and treated with mechanical ventilation and alive at follow
11030785|NCT04562935||non-pediatric intensive care|Children that are matched by year of birth, birth weight within 100 g and municipality at birth
11030786|NCT04562922|Experimental|Lifemel|"LifeMel is bee-honey obtained using Zuf Globus Ltd technology: it is produced in Israel and distributed by VitalMel in Italy. In Italy Ministry of Health has listed it as a food supplement.
~Two tea spoons (5 g each) of honey were administered to subjects on each day of the chemotherapy treatment."
11030787|NCT04562909||Premature children|Premature children born before than 32 weeks were included.
11030788|NCT04562909||Healthy Control Group|Age matched healthy controls
11030789|NCT04562896|No Intervention|No Device|Participants will be evaluated without a CDO.
11030790|NCT04562896|Experimental|CDO-A|The first design variant will be designated CDO-A
11030791|NCT04562896|Experimental|CDO-B|The second design variant will be designated CDO-B
11030792|NCT04562896|Experimental|CDO-C|The third design variant will be designated CDO-C
11030793|NCT04562883|Experimental|Single Culture|"Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the washing dish containing Maturation Medium and wash them thoroughly. Then transfer COCs one by one to the Culture dish with Maturation Medium."
11030794|NCT04562883|Experimental|Group Culture|"Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the washing dish containing Maturation Medium (Group Culture) by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the IVM dish with Maturation Medium (Group Culture)."
11030795|NCT04562870|Experimental|Arm S: Selinexor|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Selinexor 60 mg oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.
11030796|NCT04562870|Active Comparator|Arm PC: Physician's Choice Treatment|Participants with MF who had previously received at least 6 months of treatment with JAK 1/2 inhibitor will receive Physician's choice treatment which will be administered as per clinical practice.
11030797|NCT04562857|Active Comparator|obstructive sleep apnea|interval exercises (intervention) on bicycle for patients with AF and OSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
11030800|NCT04562831|Experimental|Newly diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)
~Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)
~Placebo"
11030801|NCT04562831|Experimental|Earlier diagnosed ALS patients|"High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)
~Placebo"
11030802|NCT04562818||Daunorrubicin|Patient treated with daunorrubicin
11030803|NCT04562818||Idarrubicin|Patient treated with idarrubicin
11030804|NCT04562805|Experimental|DynamX Bioadaptor|Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor
11030805|NCT04562805|Active Comparator|Medtronic Resolute Onyx Stent|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
11030806|NCT04562792|Experimental|Patients with relapsed/refractory ALL and AML|Patients in this arm will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
11030807|NCT04562779|Experimental|XR Naltrexone|Participants will receive a single dose of extended-release, injectable naltrexone prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
11030808|NCT04562779|Experimental|IV Ketamine|Participants will receive a single dose of intravenous ketamine (0.5mg/kg over 40 minutes) prior to hospital discharge, in addition to enhanced linkage to follow-up addiction care.
11030809|NCT04562779|Active Comparator|Linkage|Participants will receive no single-dose addiction medication prior to hospital discharge, but will receive enhanced linkage to follow-up addiction care.
11030810|NCT04562766|Experimental|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label
11030811|NCT04562766|Placebo Comparator|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks.
11030812|NCT04562753|Active Comparator|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
11030813|NCT04562753|Active Comparator|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
11030814|NCT04562740|Experimental|ABLUMINUS DES|"ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.
~Sirolimus drug dosage on the ABLUMINUS DES drug eluting stent system is determined by Concept Medical to deliver the optimal dose of sirolimus to the abluminal surface of the BTK lesions."
11030815|NCT04562727|Experimental|Only MWA|Only preform MWA, chemotherapy isn't necessary
11030816|NCT04562727|Active Comparator|MWA combined with perioperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed before MWA and after MWA
11030817|NCT04562727|Experimental|MWA combined with postoperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed after MWA
11030818|NCT04562714|Experimental|Intervention (FGM + DSME)|Study participants randomized to the intervention arm will be provided with a FreeStyle Libre flash glucose monitor (FGM) system to use for 16 weeks in Phase 1. Study participants will receive one training session on proper use of the FGM and encouraged to test at least 4 times per day: fasting and post-meals. Participants will also receive six diabetes self-management education (DSME) sessions, consisting of four individual in-clinic sessions and two telephone sessions.
11030819|NCT04562714|Other|Control (DSME alone)|Study participants in the control arm will receive six diabetes self-management education sessions matched to time and location of the intervention group. The sessions will consist of four individual in-clinic sessions and two telephone sessions over 16 weeks. Control participants will be encouraged to self-monitor blood glucose four times daily (fasting and post-meals) as per existing diabetes self-care guidelines
11030820|NCT04562688|Experimental|Arm A|Participants assigned to Arm A will be waitlisted (no active intervention) for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
11030821|NCT04562688|Experimental|Arm B|Participants assigned to Arm B will engage in CICADAS app only for the first 16 weeks of the intervention period. Participants will After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period.
11030822|NCT04562688|Experimental|Arm C|Participants assigned to Arm C will engage in PEERS + CICADAS for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to No-Contact (no active intervention) for the second 16 weeks of the intervention period.
11030823|NCT04562675|Experimental|Intervention group (IG)|LHA intervention group (IG)
11030824|NCT04562675|Placebo Comparator|Control group (CG)|brochure-only control group (CG)
11030825|NCT04562662|Experimental|Intervention group|Single arm (all participants receive interventions)
11030826|NCT04562649|Experimental|Intervention|Wise App that delivers medication adherence reminders and community health worker sessions
11030827|NCT04562649|No Intervention|Control|Standard of care
11030828|NCT04562636|Experimental|Environment-focused Meatless Monday messages|Four environmental messages from the Meatless Monday campaign.
11030829|NCT04562636|Experimental|Health-focused Meatless Monday messages|Four health messages from the Meatless Monday campaign.
11030830|NCT04562636|Other|Neutral Message|Four neutral messages about checking one's credit score.
11030831|NCT04562623||Cohort A : High grade serous ovarian carcinoma|
11030832|NCT04562623||Cohort B :Breast carcinoma SBR grade II or III|Breast carcinoma SBR grade II or III superior to 3 cm
11030833|NCT04562623||Cohort C : Extended Breast carcinoma In situ|Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy
11030834|NCT04562610|Active Comparator|Group A: All oral pre-operative analgesics|"Group A patients will be administered the following medications in the preoperative holding area:
~Acetaminophen 1,000 mg by mouth prior to operation
~Celecoxib 200mg by mouth prior to operation
~Tranexamic acid 2 grams by mouth prior to operation
~Gabapentin 600mg by mouth prior to operation"
11030900|NCT04562207|Experimental|Patients|Addition of a nasopharyngeal swab before surgery
11030901|NCT04562194|Other|Intervention|NeVa Stent Retriever
11038026|NCT04512924|Active Comparator|Group 1|
11030835|NCT04562610|Active Comparator|Group B: Intravenous agents|"Group B patients will receive:
~Acetaminophen (Ofirmev) 1,000mg intravenous prior to operation
~Celecoxib 200mg by mouth prior to operation
~Tranexamic acid 2grams intravenous at start of operation
~Gabapentin 600 mg by mouth prior to operation"
11030836|NCT04562597|Placebo Comparator|Dose Response Curve Placebo|5-10 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
11030837|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 50 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
11030838|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 100 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
11030839|NCT04562597|Active Comparator|Dose Response Curve N-acetylcysteine 150 mg/kg|5-10 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
11030840|NCT04562597|Experimental|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteine dose is identified, 10-15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.
11030841|NCT04562597|Placebo Comparator|Placebo|10-15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.
11030842|NCT04562584|Experimental|MyHomeDoc|Comparison of MyHomeDoc pulse oximetry readings with arterial blood saturation laboratory analysis in the same subject
11030843|NCT04562571|Experimental|Charter & patient information leaflets|A public commitment charter promoting antibiotic stewardship, signed by the general practitioner (GP) and displayed in the practice waiting room; a non-prescription pad, to be distributed to patients when an antibiotic is not needed; and a patient information leaflet to be used when antibiotics were prescribed
11030844|NCT04562571|No Intervention|Control|No intervention, eligible general practitioners randomised in the control group not informed of the intervention
11030845|NCT04562558|Experimental|Arm1-Methotrexate|Patients receive methotrexate intramuscularly（50mg） on Days 1, 3, 5, 7 (4 doses per cycle) with Leucovorin (15mg) on Days 2, 4, 6, 8. Repeat every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment. If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
11030846|NCT04562558|Experimental|Arm 2-Dactinomycin|Patients will receive IV pulse actinomycin-D (1.25mg/m2，2mg max dos) every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment.If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
11030847|NCT04562545|Active Comparator|Maximum Bite Advancement|
11030848|NCT04562545|Experimental|Incremental Bite Advancement|
11030849|NCT04562519|Experimental|diabetic HD group|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
11030850|NCT04562519|Active Comparator|Nondiabetic goup|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
11030851|NCT04562506|Active Comparator|Real rTMS stimulation|real deep excitatory, high frequency rTMS with H-coil stimulation
11030852|NCT04562506|Sham Comparator|Sham rTMS stimulation|sham high frequency H-coil stimulation
11030853|NCT04562493|Active Comparator|Magnesium sulphate group|Effect of transforaminal Magnesium sulphate on oxidative stress markers and radicular pain
11030854|NCT04562493|Experimental|Ozone Group|Effect of transforaminal Ozone on oxidative stress markers and radicular pain
11030855|NCT04562493|Other|Steroid group|Effect of transforaminal steroids on oxidative stress markers and radicular pain
11030856|NCT04562480|Experimental|Treatment (hypofractionated radiation therapy, resection)|Patients undergo hypofractionated radiation therapy QD (except weekends and holidays) over 3 weeks for a total of 15 fractions. Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
11030857|NCT04562467|Experimental|Icosapent Ethyl + Standard of Care|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT
11030858|NCT04562467|No Intervention|Standard of Care|Standard of care therapy (including statin therapy as per inclusion criteria)
11030859|NCT04562454|Experimental|Normal group|Specific diet with CGM for 5days
11030860|NCT04562454|Experimental|T1DM group|Specific diet with CGM for 5days
11030861|NCT04562454|Experimental|T2DM group|Specific diet with CGM for 5days
11030862|NCT04562454|Experimental|other type of diabetes group|Specific diet with CGM for 5days
11030863|NCT04562441|Experimental|Axitinib and Avelumab|"Axitinib: 5 mg bd po Day 1 to Day 28
~Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks"
11030864|NCT04562428|Experimental|XSLJZ|Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
11030865|NCT04562428|Placebo Comparator|XSLJZ Placebo|10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
11030866|NCT04562415|Active Comparator|Active rTMS group|chronic ischemic stroke patients receiving active low frequency repetitive transcranial magnetic stimulation therapy and physical therapy
11030867|NCT04562415|Active Comparator|Active cTBS group|chronic ischemic stroke patients receiving active continuous theta burst stimulation therapy and physical therapy
11030868|NCT04562415|Sham Comparator|Sham cTBS group|chronic ischemic stroke patients receiving sham continuous theta burst stimulation therapy and physical therapy
11030869|NCT04562402|Active Comparator|Phacoemulsification with endoscopic cyclophotocoagulation|Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.
11030870|NCT04562402|Active Comparator|Phacoemulsification alone|Cataract extraction via phacoemulsification.
11031015|NCT04561362|Experimental|Cohort B-2 - Dose expansion (BT8009 and nivolumab)|Participants will receive a selected dose of BT8009 and a standard dose of nivolumab. It is expected that approximately 40 participants will participate in this dose expansion arm.
11030871|NCT04562389|Experimental|Phase 1a: Cohort 1: Selinexor 40 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 40 milligrams (mg) of selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg twice a day (BID).
11030872|NCT04562389|Experimental|Phase 1a: Cohort 2: Selinexor 60 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 60 mg of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
11030873|NCT04562389|Experimental|Phase 1a: Cohort -1: Selinexor 20 mg and Ruxolitinib 15/20 mg|Participants with MF will receive a dose of 20 mg of selinexor oral tablet twice weekly (BIW) of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
11030874|NCT04562389|Experimental|Phase 1b: RP2D: Selinexor and Ruxolitinib 15/20 mg|Participants with MF will receive recommended safe dose (estimated in Phase 1a) of selinexor oral tablets on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
11030875|NCT04562389|Experimental|Phase 2: Selinexor RP2D and Ruxolitinib 15/20 mg|Participants with MF will receive recommended safe dose (estimated in Phase 1b) of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle and ruxolitinib oral tablets 15 or 20 mg BID.
11030876|NCT04562389|Active Comparator|Phase 2: Ruxolitinib 15/20 mg|Participants with MF will receive ruxolitinib oral tablets 15 or 20 mg BID.
11030877|NCT04562376|Experimental|Group A|The program consists of high-intensity resistance training for 60 minutes twice a week for group A during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group A will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
11030878|NCT04562376|Active Comparator|Group B|The program consists of high-intensity resistance training for 60 minutes once a week for group B during 12 weeks at the Karolinska University Hospital under the supervision of a physiotherapist. Participants in group B will have different possible training alternatives every week to ensure availability, and they will train in groups of three to five persons/session.
11030879|NCT04562363||Low risk of herniation.|Use of any method of suturing, including modified.
11030880|NCT04562363||The average risk of hernia formation|The application of modified methods of closure of laparotomy wound.
11030881|NCT04562363||high risk of herniation|The use of alloplastic methods of closure of laparotomy wound.
11030882|NCT04562363||The presence of eventrations|The use of alloplastic methods of suturing a laparotomic wound in the absence of suppuration.
11030883|NCT04562350|Experimental|Intervention group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Anoia in the course of 2020-21.
11030884|NCT04562350|No Intervention|Control group|A sample of students aged 12 to 16 years from middle school and high school in the sanitary region of Osona in the course of 2020-21.
11030885|NCT04562337|Experimental|SHR1316+Chemotherapy +Radiotherapy|Paiticipant receive SHR-1316 、Chemotherapy and Radiotherapy
11030886|NCT04562324|Experimental|Experimental:|NF group participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin or norepinephrine reuptake inhibitors (SNRI) or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
11030887|NCT04562324|Experimental|Healthy Experimental:|Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
11030888|NCT04562324|Sham Comparator|Healthy Sham Comparator|Sham group participants receive 24 min NF sessions with pseudo-random numbers, 2-3 days per week, for 2 weeks
11030889|NCT04562324|Sham Comparator|Sham Comparator|Sham Comparator: Sham group participants receive 24 min NF sessions with pseudo-random numbers, 2-3 days per week, for 2 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors (SNRI), benzodiazepines, tricyclic antidepressants, other antidepressants, antipsychotics, other sedative-hypnotics
11030890|NCT04562311|Experimental|Chidamide with Immunotherapy|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
11030891|NCT04562298|Experimental|LCAR-M23 Chimeric Antigen Receptor T cell|
11030892|NCT04562272|Active Comparator|Mechanical unloading|Mechanical unloading by Impella-CP for 36-48 hours, on top of the standard treatment
11030893|NCT04562272|No Intervention|Standard care|Standard treatment of AMI after PCI according to guidelines.
11030894|NCT04562259||patients with Kimmerle's anomaly|patients who have a complete or incomplete bony bridge over the posterior arch of the first cervical vertebra
11030895|NCT04562246||PCR positive subjects|Patients who receive positive test result from RT-PCR for SARS-CoV-2.
11030896|NCT04562233|Experimental|Intervention arm|Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each onto Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30-45-minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20-25-minute workout; 5-10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location incase of an emergency.
11030897|NCT04562233|Other|Control Arm|"The attention control arm will include a printed, individualized resistance-based physical activity program.
~Participants randomized to the control arm will also be given a printed or digital individualized, resistance-based physical activity program and told to aim to for three exercise sessions per week. Control participants will follow the same measurement schedule as intervention participants."
11030898|NCT04562220|Experimental|Vibration Group|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
11031183|NCT04560049|Experimental|Phenolisation|Surgical pit excision and phenolisation of sinus tract
11030902|NCT04562181|Experimental|Interventions|Anesthesia will be induced with bolus infusion using propofol, sufentanil and cis-atracurium intravenously. The patients will be intubated subsequently. TOF (T4/T1) will be calculated continuously using muscle relaxation monitoring. Anesthesia are maintained with a combination of sevoflurane, propofol, sufentanil and cis-atracurium. Anti-emetic and opioids will be routinely administrated prior to abdominal closure. Neostigmine will be administrated for reversing the residual neuromuscular blockade after the patient get his breath. Tracheal extubating is indicated by a TOF value above 70% in addition to other physical signs.
11030903|NCT04562168|Experimental|Diagnostic Test: ML model|The diagnostic capacity of the ML model will be compared with that of the general practitioners and with dermatologist.
11030904|NCT04562155|Experimental|BAY1817080 dose A BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
11030905|NCT04562155|Experimental|BAY1817080 dose B BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
11030906|NCT04562155|Experimental|BAY1817080 dose C BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
11030907|NCT04562155|Placebo Comparator|Placebo|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
11030908|NCT04562129|Experimental|Treatment|HD IL2 (600,000 units/kg/dose IV) will be given during week 1 of the 2 initial cycles or each course. Ipilimumab will be given concurrently at the low dose of 1 mg/kg on Day 1 of the 2 initial cycles of each course for up to 2 doses, total. Nivolumab will be given on Day 1 of the 3rd cycle of each course. No systemic treatment will be administered during the 4th cycle. Patients without evidence of disease progression (RECIST v.1.1) or limiting toxicities will be offered additional courses of treatment for up to a maximum of 3 courses, total.
11030909|NCT04562116|Experimental|CYP 450 Substrates plus Nemolizumab|Participants will receive 1 single oral dose of selected, commercially available, cytochrome P450 substrates (CYP450-S) on Day 1 and after a 1-week washout period, participants will receive a 60 milligram (mg) loading dose of nemolizumab via 2 consecutive subcutaneous (SC) 30-mg injections at the Week 1 visit, followed by a single 30-mg injection once in every 4 weeks (Q4W) at Week 5 and Week 9. Participants will receive a second oral dosing of CYP450-S at Week 10.
11030910|NCT04562103|Experimental|Epinephrine QLB|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
11030911|NCT04562103|Active Comparator|Plane QLB|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
11030912|NCT04562090|Experimental|Mirabegron 25 mg|Participants will receive 25 mg of mirabegron, once daily orally in the morning around the same time of day and around time of food intake (i.e., within 1 hour after breakfast).
11030913|NCT04562090|Experimental|Mirabegron 50 mg|Participants will receive 50 mg of mirabegron, once daily orally in the morning around the same time of day and around time of food intake (i.e., within 1 hour after breakfast).
11030914|NCT04562064||keratoconus group|patients with keratoconus implanted with the Myoring 360 degree, KeraRing 355 degree, KeraRing one segment, KeraRing two segments ICRS .corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system .pentacam data that will be included
11030915|NCT04562051||stratified prophylaxis group|The process of stratified prophylaxis was as follows. 1) If the recipient's HBsAb level is more than 100 IU/L and the donor is HBV DNA-, the recipient will not receive any preventive measures; 2) If the recipient's HBsAb is more than 100 IU/L and the donor is HBV DNA+, the recipient receives antiviral treatment for 1 month; 3) If the recipient's HBsAb is between 10 and 100 IU/L, the recipient is treated with single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status; 4) If the recipient's HBsAb is less than 10 IU/L, the recipient will receive single dose HBIG and antiviral treatment for 1 month regardless of the donor's HBV DNA status.
11030916|NCT04562051||Routine prophylaxis group|Transplant centers adopted routine prophylaxis based on clinical experience
11030917|NCT04562038|Experimental|YC-PEM e-PRO|Participants are administered an electronic patient-reported outcome measure to obtain information about parent priorities, and they obtain a summary report of their responses to share with their early intervention team for discussion during the annual IFSP meeting.
11030918|NCT04562038|No Intervention|Family Assessment|Participants are scheduled to complete a semi-structured family interview to obtain information about parent priorities, for use during the annual IFSP meeting
11030919|NCT04562025|Experimental|UC-MSCs treatment group|"Conventional treatment plus UC-MSCs:
~Participants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2，week3)."
11030920|NCT04562025|Placebo Comparator|Placebo control group|"Conventional treatment plus Placebo:
~Without UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2，week3."
11030921|NCT04562012||Malagasy Participants|Malagasy Participants. Subjects will be recruited at rural health centers throughout Madagascar. Participants will be comprised of rural people with symptoms consistent with plague. The Madagascar Ministry of Public Health requires declaration of all suspected human plague cases and collection of biological samples (sputum and/or bubo aspirates) from these cases for medical workup for confirmation.
11030922|NCT04562012||USN Health Research Center|USN Health Center Participants. The subject population will consist of active duty US Naval personnel and DoD beneficiaries presenting to participating study sites in the United States with influenza-like symptoms (fever, cough, sore throat). Since the US is non-endemic for plague, all participants will be presumed to be negative for Y. pestis.
11030923|NCT04561999||Patients with Superficial Lymphadenopathy|
11030924|NCT04561986|No Intervention|Arm A: Standard of care (SOC)|Tacrolimus (target concentration 6 ±1 µg/L) + MPA (1.5-2 g/day as tolerated) + steroids (recirculated, if not already done within last 3 months, starting at 20 mg/day prednisolone for two weeks, then tapered over 2 months to not less than 5 mg/day), all oral administration
11030925|NCT04561986|Active Comparator|Arm B: SOC + tocilizumab (TCZ)|SOC + TCZ (162 mg every week, subcuataneous administration)
11031016|NCT04561362|Experimental|Cohort C - Renal Insufficiency (BT8009 alone)|Participants will receive a selected dose of BT8009. It is expected that approximately 12 participants will participate in this arm.
11030926|NCT04561960|Active Comparator|Control|"Participants will be trained to perform oral hygiene using the modified bass technique.
~The participants will be asked to brush their teeth twice daily using a manual tooth brush and fluoridated toothpaste containing 1450ppm of fluoride"
11030927|NCT04561960|Experimental|Miswak|Participants will be trained to chew and condition a miswak stick Participants will be asked to use the miswak stick twice daily
11030928|NCT04561960|Experimental|Miswak Paste|"Participants will be trained to perform oral hygiene using the modified bass technique.
~The participants will be asked to brush their teeth twice daily using a manual tooth brush a non-fluoridated toothpaste containing miswak extract"
11030929|NCT04561947|Active Comparator|TT+CTG|The combined connective tissue graft (CTG) with tunnel technique (TT)
11030930|NCT04561947|Experimental|TT+CGF|The combined concentrated growth factor (CGF) membrane with tunnel technique (TT)
11030931|NCT04561934|Experimental|resin modified glassionomer cement|Application of Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE)
11030932|NCT04561934|Active Comparator|silver diamine flouride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
11030933|NCT04561921|Experimental|megnesium sulphate|Injection of 1.8 mL of an anaesthetic solution containing 1% magnesium sulphate , and 1.8% mepivacaine HCL with .06mg Levonordefrin HCl during inferior alveolar nerve block.
11030934|NCT04561921|Active Comparator|mepivacaine HCl|Injection of 1.8 mL of a local anaesthetic solution containing 1.8% mepivacaine HCL with .06mg Levonordefrin HCL during inferior alveolar nerve block
11030935|NCT04561908|Experimental|Transcatheter microguidewire drilling|"Through femoral vein, 6F MP1 guidecatheter was introduced into right atrium and engaged on fossa ovalis. Through guidecatheter, the hard back-end of microguidewire (0.014-inch BMW; Abbott, Plymouth, Minnesota, USA) was advanced to drill through fossa ovalis in the aid of a balloon (3.0 mm×15 mm; NC TREK, Abbott, Plymouth, Minnesota, USA). Over the fixed guidewire, the balloon crossed and overrode atrial septum with proximal portion in guidecatheter-tip, and the guidecatheter was advanced gently to slip into left atrium during balloon dilation."
11030936|NCT04561895||control group|healthy volunteers with absence of NAFLD
11030937|NCT04561895||test group|patients with confirmed NAFLD diagnosis
11030938|NCT04561882|Experimental|Transcatheter exclusion of atrial septal aneurysm|Transcatheter reconstruction of atrial septum might be achieved with PFO occluder through transseptal perforation in patients with ASA.
11030939|NCT04561856|Active Comparator|Group1|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume intravenously.
11030940|NCT04561856|Active Comparator|Group2|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 0.15 mg/kg dexamethasone (maximum of 4 mg) in 2 ml volume perinural plus 2 ml of normal saline intravenously.
11030941|NCT04561856|Placebo Comparator|Group3|will include 33 patients: each one will receive US guided fascia-iliaca block with 0.7 ml/kg of bupivacaine 0.25% plus 2 ml of normal saline perinural plus 2 ml of normal saline intravenously.
11030942|NCT04561843||case group|Women complaining of any of the pelvic floor disorder symptoms such as: Pelvic organ prolapse (POP), Stress urinary incontinence (SUI), urgency symptoms of obstructed defecation, fecal incontinence (FI), pelvic pain, and/or sexual problems.
11030943|NCT04561843||control group|Women not complaining of any of the pelvic floor disorder symptoms
11030944|NCT04561830|Active Comparator|group 1|underwent laparoscopic-assisted excision of mesorectum
11030945|NCT04561830|Active Comparator|group 2|open excision of mesorectum
11030946|NCT04561817|Active Comparator|PI3K/AKT mutations (altered)|Participants with recurrent epithelial ovarian cancer with PI3K/AKT mutations (altered)
11030947|NCT04561817|Active Comparator|Without PI3K/AKT mutations (non-altered)|Participants with recurrent epithelial ovarian cancer without PI3K/AKT mutations (non-altered)
11030948|NCT04561804||LISESTYLE INTERVENTION|LOW CARB LOW GLYCEMIC LOAS DIET
11030949|NCT04561804||WEGHT LOSS SURGERY|SLEEVE OR MINBYPASS SURGERY
11030950|NCT04561791|Experimental|Feasibility of TCE & Prevalence of BE|"Feasibility of using tethered capsule endomicroscopy as a screening method for Barrett's esophagus in the primary care practice environment
~Determine the prevalence of Barrett's esophagus in a primary care practice cohort at MGH"
11030951|NCT04561778|Active Comparator|HOT-CRT|Subjects randomized to HOT-CRT will undergo CRT as described below. His bundle pacing lead will be placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and LV timing may be optimized to achieve maximal resynchronization. This will be at the discretion of the implanting physician. Only FDA approved leads and devices will be used.
11030952|NCT04561778|Active Comparator|Biventricular Pacing|Subjects randomized to biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.Only FDA approved leads and devices will be used.
11030953|NCT04561765|Experimental|iCanCope|In this group, individuals will receive the iCanCope-NF program. The intervention will be delivered on a restricted password-protected mobile application. Participants will be encouraged to log onto the pain diary app (via automated alerts) once per day over the 8-week period to complete pain diary entries and develop and track their goals related to their pain, physical, social activities, sleep, as well as work through content based on their goals.
11030954|NCT04561765|Experimental|iCanCop+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
11031013|NCT04561362|Experimental|Cohort A-2 BT8009 and Nivolumab Dose Escalation|Participants will receive increasing doses of BT8009 and a standard dose of nivolumab. It is expected that approximately 20 participants will participate in this dose escalation arm
11031045|NCT04561128|Placebo Comparator|Placebo|Placebo comparator: placebo
11030955|NCT04561765|No Intervention|Control Group|The control group is designed to assess for potential effects on outcomes of time, attention, during the study. In addition to usual care, participants will be required to complete baseline and follow-up assessments similar to that of the intervention groups. They will be given that patient education, through preapproved flyers and information found from national websites regarding pain management, but no self-management strategies or opportunities for social support. They will not have access to the mobile application during the course of experiment; however, the control group will be offered the full iCanCope-NF program following the trial (T2) for a period of 2 months after the study is over.
11030956|NCT04561752|Experimental|Treatment Sequence A-B|Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
11030957|NCT04561752|Experimental|Treatment Sequence B-A|Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
11030958|NCT04561739|Experimental|Drug-coated balloon|
11030959|NCT04561739|Active Comparator|Drug-eluting stent|
11030960|NCT04561726|Experimental|Study Group|"All of the 20 participants in the study group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
~Additionally, CTM was applied to the volunteers in study group for 6 weeks, 2 sessions in a week.CTM applied to lumbosacral area (basic region), lower toracal, scapular, interscapular and cervical regions, respectively."
11030961|NCT04561726|Active Comparator|Exercise Group|All of the 20 participants in the exercise group were asked to do the given 11 home exercises (balance, stretching and strengthening exercises) twice a week for 6 weeks. The exercises were progressed day by day. All of the exercises were taught in the first assessment day, after the all measurements collected. All participants were controlled every week by social media and face-to-face conversations.
11030962|NCT04561713|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|Children aged 8 to 12 diagnosed with ADHD
11030963|NCT04561713|Sham Comparator|Control|Control group of healthy ADHD children matched in age, gender and laterality to children in ADHD group
11030964|NCT04561700|Experimental|Reporting of sucking patterns captured by Instrumented Bottle|Weekly reporting on objective measurements of sucking activity during oral feeding
11030965|NCT04561700|Sham Comparator|Control|Weekly reporting on traditional measurements of sucking activity during oral feeding (no objective measurements reported)
11030966|NCT04561687|Active Comparator|Azelastine and Nasal Budesonide|Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
11030967|NCT04561687|Active Comparator|Montelukast and Nasal budesonide|Montelukast 5mg 6-14years old and 10mg for older
11030968|NCT04561687|Placebo Comparator|Nasal Budesonide and Placebo|Placebo once daily
11030969|NCT04561674|Experimental|Experimental Group|"The patients in the experimental group participated in Web-Based Patient Education with Colostomy and Ileostomy on computer between the third and seventh days after surgery.
~The cards with the website address, username and the website QR code were given to the patients in order to be able to receive education after discharge.The patient and her family received the training from any computer or smartphone connected to the internet."
11030970|NCT04561674|No Intervention|Control group|The clinical routine was applied to the control group.
11030971|NCT04561661|Active Comparator|Conservative treatment|Fracture treated with closed reduction, custom made orthosis and early mobilization.
11030972|NCT04561661|Active Comparator|Surgery|Fractures treated with closed reduction, percutaneous pinning (k-wires) and plaster.
11030973|NCT04561648|Experimental|High Dose of Unfractionated Heparin|100 IU/Kg of Unfractionated Heparin
11030974|NCT04561648|Active Comparator|Standard Dose of Unfractionated Heparin|5000 IU of Unfractionated Heparin.
11030975|NCT04561635|Experimental|Intervention group|The intervention group was supplemented with three sachets of MMS each week for every other day for a period of 12 months. Each sachet containing 1 g consisting of ten vitamins and five minerals. It was to be sprinkled over a cooked meal or dissolved in a drink for the child. Written instruction for using and storing the MMS in simple language with visuals was given prior to the supplementation. The intervention group also received health and nutrition advice at 3, 6 and 9 months after supplementation begins.
11030976|NCT04561635|No Intervention|Control group|The control group received health and nutrition advice that were similar to intervention group and delivered by the investigator at 3, 6 and 9 months after the study began.
11030977|NCT04561622||Bipolar patients|Bipolar patients (type I,II, NOS) of the bipolar disorder expert center of CHU Grenoble Alpes.
11030978|NCT04561622||Healthy controls|Volunteers without any psychiatric disease matching inclusion criteria
11030979|NCT04561609|Active Comparator|CO2 treated|Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs
11030980|NCT04561609|Placebo Comparator|control|Patients receiving placebo treatment with air on lower limbs
11030981|NCT04561596|Experimental|Autohypnosis|
11030982|NCT04561596|Other|Control|
11030983|NCT04561583|Other|LED light source system for endoscope|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).Test grop use LED light source system for endoscope
11030984|NCT04561583|Other|Pinpoint Endoscopic Fluorescence Imaging System|This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).control group use Pinpoint Endoscopic Fluorescence Imaging System (Model: PC9000)
11030985|NCT04561570||Study Group: Vivity ACRYSOF IQ IOL|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
11030986|NCT04561570||Control Group: ACRYSOF IQ IOL|Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
11038027|NCT04512924|Experimental|Group 2|
11030987|NCT04561557|Experimental|CAR T cells therapy，Dose level 1: 0.5 × 10^6 CAR-T cells/Kg|"The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting toxicity (DLT) occurs and at least one subject benefits from the treatment, there will be two options for the investigator based on the available data: 1) three more subjects will be enrolled in the 0.5 × 10^6 CAR-T cells/Kg group and DLT will be evaluated in a total of six subjects; 2) another three subjects will be treated with 1 × 10^6 CAR-T cells/Kg instead of 0.5 × 10^6 CAR-T cells/Kg.
~If DLT occurs in one of the first three subjects, three more subjects will be enrolled in this cohort to reach the total subjects of six."
11030988|NCT04561557|Experimental|CAR T cells therapy，Dose level 2: 1 × 10^6 CAR-T cells/Kg|If neither DLT nor efficacy is shown in the first three subjects, the dose of CAR-T cells will be increased to 1 × 106 CAR-T cells/kg to assess DLT.
11030989|NCT04561557|Experimental|CAR T cells therapy，Dose level 3: 0.25 × 10^6 CAR-T cells/Kg|If DLT occurs in two subjects, whether to test the safety and efficacy in 0.25 × 10^6 CAR-T cells/kg group will be determined by the investigator based on the initial data of efficacy, PK and PD.
11030990|NCT04561544|Experimental|Intervention in Fall 2020|Participants will receive the intervention in Fall 2020
11030991|NCT04561544|Other|Intervention in Spring 2021|Control in Fall 2020
11030992|NCT04561531|Experimental|Intermittent bolus|In intermittent bolus of 3%NaCl group ,patients will receive intermittent bolus of 3%NaCl 150 ml in 30 minutes and then follow plasma sodium,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
11030993|NCT04561531|Experimental|Traditional continuous drip|In traditional continuous drip of 3%NaCl group ,patients will receive 3%NaCl adjust rate start from 1 ml/kg/hr and follow plasma sodium every 1 hour,observe glasglow coma scale and level of consciousness until improvement of consciousness and achieve target plasma sodium which is 5 mmol/L in 6 hours and should not be overcorrected which defined that plasma sodium change should not be more than 12 mmol/L in 24 hours and 18 mmol/L in 48 hours.
11030994|NCT04561518||Patients with ATTR amyloidosis|Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
11030995|NCT04561518||Pre-symptomatic Carriers|Pre-symptomatic carriers with a known disease-causing TTR mutation will be eligible for the study and will follow routine clinical care.
11030996|NCT04561505|Active Comparator|Holmium laser enucleation of prostate|patients that undergo Holmium laser enucleation of prostate (HoLEP) procedure
11030997|NCT04561505|Active Comparator|monopolar transurethral resection of prostate|patients that undergo monopolar transurethral resection of prostate
11030998|NCT04561479|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training, inspiratory muscle training and progressive resistance training
11030999|NCT04561479|Sham Comparator|Control Group|Control group will receive alternative upper extremity exercises and breathing exercises.
11031000|NCT04561466|Experimental|treatment group|"14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.
~Befizal® 200 mg will be tested for one year"
11031001|NCT04561453||Resected Biliary Duct Cancer|
11031002|NCT04561440||molecular karyotyping|
11031003|NCT04561440||cytogenic karyotyping|
11031004|NCT04561427||Pediatric Patients with narcolepsy|"Patients between 0 and 18 years old
~Patients diagnosed with primary or secondary narcolepsy
~From both gender"
11031005|NCT04561414|Other|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope
11031006|NCT04561414|Other|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)
11031007|NCT04561401|Experimental|rTMS + IPRP|25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
11031008|NCT04561401|Active Comparator|IPRP|Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
11031009|NCT04561388|Other|Cochlear implant candidates with measurable residual hearing|"Electrocochleography responses to acoustic will be recorded during the cochlear implantation and the 6 first months of use of the cochlear implant.
~A pure tone audiometry will be done prior and after the implantation. Speech audiometry will be done twice after the cochlear implantation."
11031010|NCT04561375|Active Comparator|Intervention Group|30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
11031011|NCT04561375|Placebo Comparator|Control Group|placebo sublingual sufentanil preoperatively and 100 µg fentanyl at induction of anesthesia
11031012|NCT04561362|Experimental|Cohort A-1 BT8009 Monotherapy Dose Escalation|Participants will receive increasing doses of BT8009. It is expected that approximately 34 participants will participate in this dose escalation arm.
11031014|NCT04561362|Experimental|Cohort B-1 - Dose expansion (BT8009 alone)|Participants will receive a selected dose of BT8009. It is expected that approximately 40 participants will participate in this dose expansion arm
11031017|NCT04561349|Experimental|Task-oriented training (TOT)|Task-oriented training consisted of different functional tasks for lower limbs to improve balance and walk
11031018|NCT04561349|Active Comparator|Conventional rehabilitation treatment|Conventional rehabilitation treatment includes mat activities and range of motion (ROM) of all limbs, Lower limb strengthening and stretching, walking, cycling
11031019|NCT04561336|Experimental|avelumab plus cetuximab|avelumab at a dose of 10 mg/kg once every 2 weeks plus cetuximab at a starting dose of 400 mg/m2 by i.v.infusion over 120 minutes at first dose and at the dose of 250 mg/ m2 by i.v.infusion over 60 minutes for subsequent infusions every week.
11031020|NCT04561310|Experimental|Post facilitation stretch|Post facilitation stretch with Maitland mobilization
11031021|NCT04561310|Active Comparator|Active release technique|Active release technique with Maitland mobilization
11031022|NCT04561297|Experimental|Biopsied Patients|Patients scheduled for a breast biopsy will have breast tissue dielectric constant measurements made prior to the biopsy
11031023|NCT04561284|Experimental|Indigestible fiber supplementation|Participants will receive an indigestible fiber supplementation (classified) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals.
11031024|NCT04561284|Placebo Comparator|Placebo supplementation|Participants will receive placebo supplementation (Maltodextrin) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals. The amount of maltodextrin taken will be isocaloric with the amount of indigestible fiber.
11031025|NCT04561271|Experimental|foot reflexology|patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music
11031026|NCT04561271|Sham Comparator|toucher massage|patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
11031027|NCT04561258|Experimental|Low Dose Cohort|A single infusion of ≥1x10e8 and <1x10e9 genetically modified T cells.
11031028|NCT04561258|Experimental|High Dose Cohort|A single infusion of ≥1x10e9 and <5x10e9 genetically modified T cells.
11031029|NCT04561245|Experimental|ALT-801 (Part 1)|Escalating doses of ALT-801 administered once
11031030|NCT04561245|Placebo Comparator|Placebo (Part 1)|Placebo administered once
11031031|NCT04561245|Experimental|ALT-801 (Part 2)|Escalating doses of ALT-801 administered once weekly for 6 weeks
11031032|NCT04561245|Placebo Comparator|Placebo (Part 2)|Placebo administered once weekly for 6 weeks
11031033|NCT04561232|Other|Locomotor Learning|"This study has three phases. The first phase of the study will be the observation of early spontaneous leg movements which will be measured monthly from 1-4 months of age.
~The prone locomotor intervention phase using the Self-Initiated Prone Progression Crawler (SIPPC) will occur from 5-9 months of post-term age, or end earlier if the child achieves the ability to crawl six feet. Treatment will occur at an intensity of 3 times per week for 15-30 minutes. Infants will use the SIPPC for the duration of each therapy session
~The upright locomotor intervention phase using DWS will occur from 9-18 months of age, or begin earlier if the child achieves the ability to crawl six feet before 9 months of age, and end earlier if the child achieves independent walking before 18 months of age. Treatment will occur at an intensity of 3 times per week for 30 minutes. Infants will receive dynamic weight support (DWS) for the duration of the 30-minute therapy session."
11031034|NCT04561219|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
11031035|NCT04561219|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days
11031036|NCT04561206|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
11031037|NCT04561193||Retrospective Cohort|Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.
11031038|NCT04561180|Placebo Comparator|Arm 1: SOC + DEX + EG-HPCP-03a placebo|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-HPCP-03a placebo for 3 additional weeks.
11031039|NCT04561180|Experimental|Arm 2: SOC + DEX + Low Dose EG-HPCP-03a|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-HPCP-03a Low dose for 3 additional weeks.
11031040|NCT04561180|Experimental|Arm 3: SOC + DEX + High Dose EG-HPCP-03a|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-HPCP-03a High dose for 3 additional weeks.
11031041|NCT04561167|Experimental|Cuspal reduction in MOD Cavity in endodontically treated teeth|Cavity design is of prime importance for the restoration of endodontically treated teeth. The cavity design plays an important role in the protection of the remaining tooth structure as well as the restoration. Cuspal reducuction and further coverage by the CAD/CAM generated indirect resin composite restoration has been proved in literature by the retrospective study done by (Chrepa V et al 2014) which studied 189 posterior endodontically treated teeth receiving indirect composite onlays with a median follow up time of 37 months and suggested this type of restoration as a viable option with 100% tooth survival and 96.8% restoration survival.
11031042|NCT04561167|Active Comparator|No cuspal reduction in endodontically treated teeth|In the present study, choosing the comparator to be the cavity design without cuspal reduction and further coverage (inlay) is done as an attempt to reduce the application of inlays in endodontically treated teeth. In accordance to the in-vitro study done by (M. D. Al Amri et al 2016) which tested the fracture resistance of endodontically treated mandibular first molars with conservative access cavity and different restorative techniques, catastrophic failures were highest in the composite group (100%), followed by the inlay and the amalgam groups (91.67%) and this was referred to the adhesive bonding mechanism of the composite restoration and the wedging effect of the inlay and the amalgam restorations (Rivera EM andWalton RE 2015)
11031043|NCT04561154|Experimental|patient hospitalized between march 1 and june 30, 2020|patient hospitalized between march 1 and june 30, 2020
11031044|NCT04561128|Experimental|SHR-1819|Experimental: SHR-1819
11031046|NCT04561115|Active Comparator|Gamunex-C|Participants will receive Gamunex-C by means of an infusion pump at an individualized dose (based on historical IVIG treatment dose) between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. Gamunex-C will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
11031047|NCT04561115|Experimental|IVIG-PEG|Following treatment with Gamunex-C, participants will receive IVIG-PEG by means of an infusion pump at an equivalent dose between 200 to 800 mg/kg per infusion at an infusion rate of 1 mL/kg/min or up to 8 mL/kg/min depending on participant tolerance. IVIG-PEG will be administered every 3 weeks or 4 weeks for at least 6 or 5 doses for an approximate maximum duration of up to 6 months.
11031048|NCT04561102||COVID-19 asymptomatic population|COVID-19 asymptomatic Rollins College community
11031049|NCT04561089||COVID-19 asymptomatic population|COVID-19 asymptomatic Illumina personnel
11031050|NCT04561076|Experimental|Sequence 1|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
11031051|NCT04561076|Experimental|Sequence 2|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
11031052|NCT04561076|Experimental|Sequence 3|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
11031053|NCT04561063|No Intervention|Arm A: No pharmacological intervention (PPE only)|No intervention
11031054|NCT04561063|Active Comparator|Arm B: Nitazoxanide (NTZ)|Nitozoxanide administered
11031055|NCT04561063|Active Comparator|Arm C: Sofosbuvir/daclatasvir (SOF/DCV).|Sofosbuvir/daclatasvir administered
11031056|NCT04561037|Active Comparator|Control Group|Control group patients received traditional physical therapy treatment. The traditional physical therapy treatment program consisted of TMJ mobilization techniques include distraction, anterior glide, anterior glide with pre-positioned mouth opening, medial/lateral glides, caudal-anterior-medial (CAM) glide, and CAM glide with pre-positioned mouth opening and isometric exercises against resistance for muscles of mastication.
11031057|NCT04561037|Experimental|Study Group|Study group patients received PEMFT, using EMG 8400 PEMF device (made in Italy, by EME) in addition to physical therapy treatment program.
11031058|NCT04561024||RT-PCR Positive Patients|RT-PCR confirmed patients positive for SARS-CoV-2
11031059|NCT04561024||Negative patients|RT-PCR confirmed patients negative for SARS-CoV-2 or patients with CXR performed before the emergence of COVID-19 pandemic
11031060|NCT04561011|Experimental|Persons with Mild Traumatic Brain Injury (mTBI)|
11031061|NCT04560998|Experimental|Semaglutide|Semaglutide given in addition to standard-of-care treatment
11031062|NCT04560998|Placebo Comparator|Placebo (semaglutide)|Placebo given in addition to standard-of-care treatment
11031063|NCT04560985|Experimental|Hydrophilic sealant|UltraSeal XT hydro™ sealant ®
11031064|NCT04560985|Active Comparator|Hydrophobic sealant|Helioseal-F Sealant ®
11031065|NCT04560972|Experimental|Treatment (LB-100, carboplatin, etoposide, atezolizumab)|"INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11031066|NCT04560959|Experimental|tACS arm|The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.
11031067|NCT04560946|Experimental|PACT|Personalized Augmented Cognitive Training (PACT)
11031068|NCT04560946|Active Comparator|ETAU|Enhanced Treatment As Usual (ETAU)
11031069|NCT04560920|Experimental|Experimental|This group will contribute PGD and it will be available in the study visit.
11031070|NCT04560920|No Intervention|Control|This group will contribute PGD but it will not be available during a study visit, it will be available to the provider in a subsequent visit.
11031071|NCT04560907|Experimental|Aquablation|
11031072|NCT04560907|Active Comparator|HoLEP|
11031073|NCT04560894|Experimental|SCT-I10A+SCT510|
11031074|NCT04560894|Active Comparator|Sorafenib|
11031075|NCT04560881|Experimental|Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
11031076|NCT04560881|Placebo Comparator|Placeboof Inactivated SARS-CoV-2 vaccine, manufactured by BIBP|Intramuscular injection
11031077|NCT04560868|Active Comparator|Control|
11031078|NCT04560868|Experimental|Experimental|
11031079|NCT04560855||Covid19 Patients|Patients diagnosed as COVID-19 positive and managed on an outpatient basis.
11031080|NCT04560842|Experimental|Conventional oxygen devise|Chose devise to keep patient's SpO2 > 92%
11031081|NCT04560842|Active Comparator|High flow nasal cannula|High flow oxygen device
11031082|NCT04560816|Experimental|Treatment Sequence 1|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: ALXN1840.
~Period 2: Placebo-matching ALXN1840.
~Period 3: Moxifloxacin."
11031083|NCT04560816|Experimental|Treatment Sequence 2|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: ALXN1840.
~Period 2: Moxifloxacin.
~Period 3: Placebo-matching ALXN1840."
11031084|NCT04560816|Experimental|Treatment Sequence 3|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Placebo-matching ALXN1840.
~Period 2: ALXN1840.
~Period 3: Moxifloxacin."
11031085|NCT04560816|Experimental|Treatment Sequence 4|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Placebo-matching ALXN1840.
~Period 2: Moxifloxacin.
~Period 3: ALXN1840."
11031086|NCT04560816|Experimental|Treatment Sequence 5|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Moxifloxacin.
~Period 2: ALXN1840.
~Period 3: Placebo-matching ALXN1840."
11031087|NCT04560816|Experimental|Treatment Sequence 6|"On Day 1 of each period, participants will receive a single dose of the following study interventions:
~Period 1: Moxifloxacin.
~Period 2: Placebo-matching ALXN1840.
~Period 3: ALXN1840."
11031088|NCT04560803|Experimental|Epidermal Grafting|This irradiated area of the skin will be treated with autologous epidermal grafts
11031089|NCT04560803|No Intervention|No treatment|This irradiated area will not receive any treatment
11031090|NCT04560790|Experimental|BD111 Adults single group Dose|Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
11031091|NCT04560777|Experimental|experimental arm|CO-OP intervention
11031092|NCT04560764|Experimental|Virtual Reality + Action Observation Therapy|Participants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
11031093|NCT04560764|Sham Comparator|Virtual Reality + Landscape video|Participants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
11031094|NCT04560751||Lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within ten days after TACE.
11031095|NCT04560738|Experimental|Administration of [14C]-CC-92480|[14C]-CC-92480 will be administered as an oral solution. A single oral dose of [14C]-CC-92480, containing approximately 2 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
11031096|NCT04560725|Experimental|[68Ga] P137|Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo [68Ga]P137 PET/CT scans.
11031097|NCT04560712|Experimental|Arm I (acupuncture, usual care)|Beginning the day after surgery, patients undergo acupuncture sessions over 25 minutes QD for up to 7 days. Patients also undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
11031098|NCT04560712|Active Comparator|Arm II (usual care)|Patients undergo usual care including preoperative visits to the primary surgical team, anesthesia preoperative evaluation, referrals to other specialties for perioperative evaluation and optimization of comorbid conditions if necessary, surgical operations, postoperative hospitalization, and post-discharge clinic visits.
11031099|NCT04560699|Active Comparator|Physiotherapeutic group|medical care and physiotherapeutic treatment
11031100|NCT04560699|Active Comparator|medical care group|Medical care
11031101|NCT04560686|Experimental|Treatment (bintrafusp alfa, surgical resection)|Patients receive bintrafusp alfa IV on days 1, 15, and 29 in the absence of unacceptable toxicity. Within 4-6 weeks after last dose of bintrafusp alfa, patients undergo surgery at the discretion of the treating surgeon. Within 8 weeks after surgery, patients may receive chemotherapy or undergo radiation therapy at the discretion of the treating physician.
11031102|NCT04560673|Experimental|Group I (neurofeedback training, duloxetine)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
11031103|NCT04560673|Experimental|Group II (neurofeedback training)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks.
11031104|NCT04560673|Experimental|Group III (duloxetine)|Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
11031105|NCT04560660|Experimental|Ketamine and prolonged exposure (PE)|Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
11031106|NCT04560660|Placebo Comparator|Midazolam and prolonged exposure (PE)|Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
11031107|NCT04560647||Psoriasis|Subjects diagnosed with psoriasis.
11031108|NCT04560647||Control|Subjects who do not have psoriasis.
11031109|NCT04560634||Normal Diastolic Function|Diastolic Function within normal values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
11031110|NCT04560634||Impaired Diastolic Function|Diastolic Function with pseudonormal pattern or impaired values (defined in terms of E wave and A wave velocity and Deceleration Time according to the American Society of Echocardiography and the European Association of Echocardiography)
11031111|NCT04560621|Experimental|MAPS+|
11031112|NCT04560621|No Intervention|Standard of Care|
11031113|NCT04560595|Experimental|Caffeine Reduction Manual|"Weekly caffeine consumption is to be measured before and after using the caffeine reduction program, which has been summarized in a Guide to Caffeine Reduction and Cessation manual to help people reduce their caffeine use."
11031114|NCT04560582||Kidney Transplant Patients with Failed Allograft|All participants are assigned to a single cohort of kidney transplant patients with failed allograft requiring dialysis.
11031115|NCT04560569|Experimental|Group A|ABT weekly and 3BNC117 bi-weekly
11031116|NCT04560569|Experimental|Group B|both ABT and 3BNC117 treatment bi-weekly
11031117|NCT04560556||POC Testing Alone|POC HIV testing (the current standard of care) will be conducted for persons entering jail during the first two-month period.
11031118|NCT04560556||POC and 4th Generation Testing|POC plus 4th Generation HIV Testing will be conducted for persons entering jail during the second two-month period.
11031119|NCT04560556||4th Generation Testing Alone|4th Generation HIV Testing will be conducted for persons entering jail during the third two-month period.
11031120|NCT04560543|Experimental|McCall suture|
11031121|NCT04560543|No Intervention|standard cuff closure|
11031122|NCT04560517||Anorexia Nervosa|
11031123|NCT04560517||Healthy Control Subjects|
11031124|NCT04560504|Placebo Comparator|Control Group|Receive 12 sessions (2 sessions per week, one hour each) of leisure activities e.g. watching TV, card and chess games, reading or non action computer game
11031125|NCT04560504|Active Comparator|Intervention Group|Receive 12 sessions (2 sessions per week, one hour each) of version and vergence eye movement training
11031126|NCT04560491||Frozen section|Patients underwent intraoperative sentinel node examination by frozen section
11031127|NCT04560491||Scrape cytology|Patients underwent intraoperative sentinel node examination by scrape cytology
11031128|NCT04560478|Active Comparator|Pro Seal Sealant|ProSeal Sealant was applied to the facial surfaces of the maxillary anterior teeth (canine to canine)
11031129|NCT04560478|Active Comparator|MI Varnish|MI Fluoride Varnish was applied to the maxillary anterior teeth (canine to canine)
11031130|NCT04560465|Experimental|group A: Cases that had tranexamic acid infusion|Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
11031131|NCT04560465|Placebo Comparator|Group B: Control|control were given perioperative placebo at the rate of 100mls per hour
11031132|NCT04560439|Experimental|Treatment (METFIT program)|Patients undergo METFIT program for 16 sessions over 6 months.
11031133|NCT04560426|Experimental|Naked eyes & Instrument assistance|Identify the parathyroid glands through the experience of surgeons and assistance of instrument.
11031134|NCT04560426|No Intervention|Naked eyes only|Identify the parathyroid glands only through the experience of surgeons.
11031135|NCT04560400|Sham Comparator|No Concussion Conventional KD|Participants without concussion history perform conventional King-Devick Test.
11031136|NCT04560400|Active Comparator|No Concussion Reverse KD|Participants without concussion history perform reverse King-Devick Test.
11031137|NCT04560400|Sham Comparator|Single Concussion Conventional KD|Participants with 1 concussion history perform conventional King-Devick Test.
11031138|NCT04560400|Active Comparator|Single Concussion Reverse KD|Participants with 1 concussion history perform reverse King-Devick Test.
11031139|NCT04560400|Sham Comparator|Multiple Concussion Conventional KD|Participants with 2 or more concussion history perform conventional King-Devick Test.
11031140|NCT04560400|Active Comparator|Multiple Concussion Reverse KD|Participants with 2 or more concussion history perform reverse King-Devick Test.
11031141|NCT04560387|Experimental|Interventional|"Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight.
~Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI > 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI > 35 kg/m2 and a presence of metabolic or other complications)."
11031142|NCT04560387|No Intervention|Conservative|Routine treatment of obesity
11031143|NCT04560374|Experimental|Experimental Group|Crochet octopus was delivered to the hands of the neonates in the experimental group 10 minutes before heel lance process and they were contacted with the crochet octopus up to 10 minutes after the procedure.
11031144|NCT04560374|No Intervention|Control Group|Control group neonates were performed all the process without delivering them any crochet octopus.
11031145|NCT04560361|Experimental|Electroacupuncture group|Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and use a 0.30mm×40mm acupuncture needle to penetrate the skin 10mm obliquely through the fixed insulating gasket at Ashi point; According to the above operation, the SJ6 and GB34 point of the affected side are directly penetrated into the skin 15-20mm. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-3mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture for 30 minutes.
11031146|NCT04560361|Sham Comparator|Sham electroacupuncture group|Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and pierce the foam pad obliquely with a blunt needle at the local Ashi point and reach the insulating glue layer, the patient has a feeling of needle resistance; the SJ6 and GB34 point of the affected side used a comforting blunt needle to pierce the foam pad and reach the insulating adhesive layer, the patient has a feeling of needle resistance. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-3mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture for 30 minutes.
11031147|NCT04560348|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program An 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure games, and one adventure day camp (2 sessions). One session per week, 3 hours for each session. A variety of cognitive behavioral skills are taught in lectures and these skills are practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. The adventure training includes a day adventure camp and five 40-minute adventure games in the beginning of each workshop. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework are used in the intervention program.
11031148|NCT04560335|Experimental|Coach to fit|CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about 15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.
11031149|NCT04560335|Other|Treatment as usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
11031180|NCT04560075|Active Comparator|Psychoeducational Videos (PE) Only|Participants will receive a web link to a library of 4 PE videos. These brief 2-minute videos include general information about self-care during college.
11031181|NCT04560062||Population in Quito|576 randomly chosen patients with diabetes in District 17D06, Quito (Ecuador)
11031150|NCT04560322|Experimental|Venetoclax-Obinutuzumab +/- Ibrutinib|"A treatment cycle is defined as 28 consecutive days. Participants with undetectable MRD (uMRD) at 1 year will complete an additional 1 year of VO then stop therapy.
~Participants with high detectable MRD at 1 year will complete an additional 1 year of VO plus ibrutinib (I) then stop therapy.
~Participants with low detectable MRD at 1 year will complete an additional 1 year of VO alone. If this eradicates MRD, they will stop therapy. If there is still residual MRD, they will complete an additional 1 year of IVO then stop therapy.
~If progression occurs on VO, I will be added and IV will be administered indefinitely. After 2 years, V may be stopped and I continued as monotherapy at investigator discretion.
~Infused Study Drug: Obinutuzumab on Days 1, 2, 8, and 15 of Cycle 1 and then on Day 1 of Cycles 1-6
~Oral Study Drugs: Venetoclax daily starting on Cycle 1 Day 22
~Oral Drug: ibrutinib daily for Days 1-28 (if applicable)"
11031151|NCT04560309|Experimental|Glutamine|Intravenous L-alanyl-L-glutamine 0.5 mg/kgbw
11031152|NCT04560309|Placebo Comparator|Control|Intravenous NaCl 0.9%
11031153|NCT04560296|Experimental|Nurse-led e-Health program|The intervention group will consist of 80 participants who will engage in Nurse-led e-Health program.
11031154|NCT04560296|Active Comparator|usual self-management and follow up with doctors/nurse|The participants will receive the usual self-management and follow up with doctors/nurse as planned.
11031155|NCT04560283|Experimental|Experimental group receiving HYALOGYN®|
11031156|NCT04560283|Placebo Comparator|Control group undergoing expectant management|
11031157|NCT04560270|Experimental|Only arm|Blood samples to analyze ctDNA
11031158|NCT04560257|Experimental|Group intervene with HFNC|Review effect of HFNC as clinical trial among hospitalized patients with COVID-19 infection.
11031159|NCT04560244|Experimental|SHR 1701+radiotherapy|SHR-1701 Simultaneously Combined with High Fractionation and Low-dose Radiotherapy
11031160|NCT04560231|Experimental|Group intervene with Remdesivir|Review effect of Remdesivir as clinical trial among hospitalized patients with COVID-19 infection. 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
11031161|NCT04560218|Experimental|Uterotonic agents group A|Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab
11031162|NCT04560218|Experimental|Uterotonic agents group B|Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab
11031163|NCT04560218|No Intervention|Uterotonic agents group C|Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab
11031164|NCT04560205|Experimental|Group intervene with Tocilizumab|"Review effect of Tocilizumab as clinical trial among hospitalized patients with COVID-19 infection.
~Participants with severe disease will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab. Specifically, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory biomarkers."
11031165|NCT04560192|Active Comparator|Intervention group|Treatment with the mindfulness based emotion regulation therapy (MBERT) in block 1, no study-treatment in block 2 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy).
11031166|NCT04560192|Other|Treatment as usual (TAU)|No study-treatment in block 1 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy), treatment with the mindfulness based emotion regulation therapy (MBERT) in block 2.
11031167|NCT04560192|No Intervention|Control condition|Healthy subjects will get a single TSST session.
11031168|NCT04560179|Experimental|Treatment Arm|The phase 1 trial will last up to 14 days, with each infant receiving a specified dose of tobramycin solution for inhalation every 12 hours, administered via vibrating mesh nebulizer. The drug dosage (78mg, 150mg, 216mg, or 300mg) will be determined as per the inter-patient dose escalation 3+3 design protocol. During the trial, each infant will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Clinical data will also be recorded daily throughout the trial.
11031169|NCT04560179|No Intervention|Observational Arm|Enrolled infants who are ineligible to participate in the phase-1 trial (lack of parental consent, research tracheal aspirate negative for a pathogenic GNR) will undergo collection of clinical and respiratory mechanics data for 14 days after ineligibility to participate in the phase-1 trial is established.
11031170|NCT04560166|Active Comparator|irinotecan and temozolomide and naxitamab and GM CSF|Each treatment cycle is 21 days
11031171|NCT04560166|Active Comparator|irinotecan and temozolomide|Each treatment cycle is 21 days
11031172|NCT04560153|Experimental|patient living with HIV|
11031173|NCT04560140|Experimental|Intervention group|Eligible participants will be randomly assigned to receive usual care with the novel 24-week Narrative and Skills-building Intervention.
11031174|NCT04560140|No Intervention|Usual care group|Participants will receive usual stroke care.
11031175|NCT04560127|Experimental|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
11031176|NCT04560114|Experimental|Essential oils|Inhalation will be carried out via an inhaler stick containing essential oils (Mentha x Piperita; Citrus Limon; Zingiber Officinale)
11031177|NCT04560088|Experimental|Mindfulness|Mindfulness using an individual mobile health mindfulness-based intervention training. These sessions are intended to act as a general introduction to mindfulness meditation and incorporate techniques such as breath awareness and body scanning.
11031178|NCT04560088|Active Comparator|Breathing|Breathing control intervention will use an individual breathing app. The intervention is designed to be structurally equivalent to the mindfulness-based study intervention on key common factors of psychosocial interventions: (a) the number of sessions, (b) the length of sessions, and (c) delivery format.
11031179|NCT04560075|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages will receive a monthly check-in text prompt. Based on their response, the participants then receive either general psychoeducational videos and prompts to continue to monitor mental health or are then prompted to endorse stressors and symptoms they are experiencing to prompt awareness of treatment targets in daily life.
11038345|NCT04510558|Sham Comparator|Control (no mesh)|
11031184|NCT04560049|Active Comparator|Silver Nitrate Irrigation|Surgical pit excision and silver nitrate irrigation of sinus tract
11031185|NCT04560036|Other|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
11031186|NCT04560023|Experimental|Exposition to multimedia content|Ad hoc design multimedia content in a tablet (video with sound and subtitles).
11031187|NCT04560023|No Intervention|Standard procedures|Standard procedures.
11031188|NCT04560010|Experimental|Group 1|TXA
11031189|NCT04560010|No Intervention|Group 2|no TXA
11031190|NCT04559997|Experimental|Exercise+FU|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 6 years.
11031191|NCT04559997|Active Comparator|Exercise|After 3 weeks of intensive treatment, no special exercises are performed as a control.
11031192|NCT04559997|No Intervention|Controll|No intervention.
11031193|NCT04559984|Experimental|JUVÉDERM VOLUX®|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional touch-up treatment at week 4 if agreed upon by both the participant and Treating Investigator.
11031194|NCT04559984|Other|Control- No treatment|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
11031195|NCT04559971|Experimental|1.0mg/kg|Drug: SLN124
11031196|NCT04559971|Placebo Comparator|Placebo|
11031197|NCT04559971|Experimental|3.0mg/kg|Drug: SLN124
11031198|NCT04559971|Experimental|Optional Cohort|An additional dose level may be explored
11031199|NCT04559958||non-dialysis CKD group|Participants with estimated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2 more than three months and without regular dialysis will be enrolled in non-dialysis CKD group.
11031200|NCT04559958||ESRD group|Participants with eGFR ≤15 mL/min/1.73 m2 and underwent regular dialysis will be recruited in ESRD group.
11031201|NCT04559958||control group|Participants with eGFR ≧60 mL/min/1.73 m2 and without evidence of kidney damage such as albuminuria or abnormal findings on renal imaging will be enrolled in control group.
11031202|NCT04559945|Experimental|Aveir Leadless Pacemaker|VVIR pacing
11031203|NCT04559932|Experimental|Intervention|The knowledge and self-efficacy pre-tests will be completed at the start of the course and the post-test will be completed after the course at the end of the day. Study participants will complete tests independently using paper and pencil. Six weeks and six months post course completion, the knowledge and self-efficacy tests will be completed using REDcap (Research Electronic Data Capture), a secure web application for building and managing online surveys and databases or via telephone as per participant preference. Study participants will be sent a link to complete the tests online for the subsequent study visits. Study participants will receive 2 reminder emails (1 week apart) and 1 reminder phone call after the email reminders (if applicable) to complete the tests. Monthly telephone calls by the RA will be made to review the HCP experience logs.
11031204|NCT04559932|No Intervention|Control|Study participants in the control arm will be offered complementary attendance in the Health Tech Junior enterostomy and vascular access competency based training course while awaiting their session. This is being done to minimize the potential confound of generalized improvements in self-efficacy that may occur as a result of participating in an 8 hour learning opportunity at SickKids. The control group will also complete the tracheostomy course during session 3 and 4 but this will occur outside the window of data collection for the study procedures. Data collection intervals as described above for the intervention group will be followed for the control group.
11031205|NCT04559919||Adults with epilepsy|"Adults over 18 years of age, with an unprovoked seizure in the last year or epilepsy, resident in VGR at the time of inclusion.
~Based on the clinical information, patients can be categorized into relevant groups; single seizure, seizure-free with epilepsy, and drug-resistant epilepsy. Subgroups may also be selected based on age, sex, epilepsy sub-diagnosis, cause of epilepsy, use of a particular antiepileptic drug, or experience of a particular side effect."
11031206|NCT04559906|Experimental|Group A|Spray and Stretch technique Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
11031207|NCT04559906|Active Comparator|Group B|Sustain pressure release Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
11031208|NCT04559893|Experimental|Collaborative Care|Intervention is administered to patients in this arm. Care to be delivered via collaborative care.
11031209|NCT04559893|No Intervention|Control|Patients in this arm will receive enhanced usual care.
11031210|NCT04559880|Experimental|Tranexamic Acid|"Intra-procedural tranexamic acid (TXA) - 1 gram, IV
~Post-procedural tranexamic acid (TXA) - 1 gram, oral, three times per day for 5 days"
11031211|NCT04559867|Active Comparator|Needle Knife Fistulotomy|The study doctor will gain access to the bile ducts using the cutting technique called a needle knife fistulotomy. When using this technique, the study doctor makes a cut directly into the bile duct.
11031212|NCT04559867|Active Comparator|Sphincterotomy|The study doctor will gain access to the bile ducts using the cutting technique called a sphincterotomy. Using this method, a heated metal wire cuts the opening to the bile duct after a wire has been passed into it.
11031213|NCT04559854|Experimental|Mindful After Cancer|Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.
11031214|NCT04559841|Active Comparator|bone substitute; NanoBone® (group 1, control group)|a synthetic bone substitute consisting of nanocrystalline hydroxyapatite and silica fabricated in a sol-gel process.
11031215|NCT04559841|Experimental|simvastatin + NanoBone (group 2, test group)|medications used to treat hypercholesterolemia
11031216|NCT04559828|Active Comparator|Pomace olive oil|50 g of pomace olive oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
11031217|NCT04559828|Active Comparator|High-oleic sunflower oil|50 g of high-sunflower oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
11031218|NCT04559815||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
11031219|NCT04559802|Experimental|Transmucosal (Non-Submerged)|Flaps will be adapted to the healing abutments for a trans-mucosal healing up on closure
11031221|NCT04559789|Experimental|Digital Lifestyle Intervention|Participants randomized to the intervention arm will receive access to a digital intervention consisting of the MindMate cognitive health app and Neurotrack's personalized health coaching platform.
11031222|NCT04559789|Active Comparator|Health Education|Participants randomized to the control arm will receive digital health education materials that mirror the content in the app.
11031223|NCT04559776|Experimental|typically developing toddlers|toddlers with a typical development and with less than 3 years old and less than 6 months of independent walking
11031224|NCT04559776|Experimental|unilateral cerebral palsy toddlers|toddlers with a unilateral cerebral plasy and with less than 3 years old and less than 6 months of independent walking
11031225|NCT04559763||Healthy Adult Volunteers|
11031226|NCT04559750|Experimental|Internet-delivered CBT|10 weeks of CBT delivered via the Internet.
11031227|NCT04559737|No Intervention|Usual Care|Patients will receive Auto-Monitoring text messages. The Auto-Monitoring tool that will be used is a function within Somnoware (Somnoware, Inc.) patient management platform, which is the national KP benchmarked platform for sleep management software. No active patient outreach is delivered until a video appointment visit at 3 months. During the first 3 months, patients are instructed to contact the sleep center if they experience trouble with using CPAP. CPAP Follow-Up Questionnaire will be delivered to patient at 3 months which will include questions to assess perception of CPAP use, sleep-wake pattern, degree of sleepiness (Epworth Sleepiness Scale; FOSQ-10), and perception of care. This follow-up process is standard of care at KP SBC.
11031228|NCT04559737|Active Comparator|Active Management|In addition to Auto-Monitoring, all patients (strugglers and successful users) will also be scheduled for a sleep respiratory care coordinator (RCC) video appointment visit for check-up at 1 month, 2 months, and 3 months. CPAP Follow-Up Questionnaire will be delivered to patient at 3 months.
11031229|NCT04559737|Active Comparator|Management by Exception|Patients will also receive Auto-Monitoring. A population management dashboard will be used to automatically identify CPAP strugglers and a video appointment visit will be scheduled for these select patients for troubleshooting at 1 month, 2 months, and 3 months. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months.
11031230|NCT04559724|Experimental|Indego-Assisted Gait Rehabilitation|"Every session of Indego-assisted gait rehabilitation will last 30 minutes, excluding preparation times (dressing, measurements, and adaptation of the brace to the anthropological measures of the various patients). The Indego program will be set based on the patient's ambulatory abilities, assessed by the Functional Ambulation Classification (FAC):
~subjects unable to walk or high-.assistance needed (FAC = 0-2): Motion + program;
~Subjects able to walk with mid/mini assistance or with supervision only (FAC = 3-5): Therapy + program.
~During the treatment, the program change from Motion + to Therapy + is allowed based on the experts' opinion."
11031231|NCT04559711|Experimental|Intervention arm|Strengthening coverage and quality of nutrition services including MMS during ANC
11031232|NCT04559711|No Intervention|Comparison arm|Existing provision of nutrition services during ANC.
11031233|NCT04559698|Experimental|immediate training group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the immediate training group will take part in the first 11-week course.
11031234|NCT04559698|Experimental|waitlist control group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the waitlist control group will take part in the second 11-week course.
11031235|NCT04559685|Experimental|Arm A Dose-escalation|In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed ALA dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.
11031236|NCT04559685|Experimental|Arm B Time-escalation|In Arm B, the time-escalation cohort, the ALA and power/energy dose combination will be fixed. Participants will be enrolled into two time cohorts (2 days and 6 days post-SDT).
11031237|NCT04559672||Laminoplasty Group|Patients who underwent cervical laminoplasty surgery due to myelopathy.
11031238|NCT04559672||Laminectomy and Fusion Group|Patients who underwent cervical laminectomy and fusion surgery due to myelopathy.
11031239|NCT04559646||"Group A Haemoblock"|"100 patients. Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
11031240|NCT04559646||"Group B Control"|100 patients. Saline solution will be used after pocket formation during pacemaker implantation.
11031241|NCT04559633|Experimental|Anxious school refusal|Adolescents with anxious shool refusal will beneficiate of cognitive and behavioral therapy (CBT) in order to help them to return back to school
11031242|NCT04559620|Experimental|Maternal voice|Mother's voice will be played for 1 week between week 2 and 3 of life
11031243|NCT04559620|No Intervention|Control|NO intervention between week 2 and 3
11031244|NCT04559607|Experimental|Experimental group: TACE+Camrelizumab+Apatinib|Camrelizumab (iv. infusion of 200 mg); Apatinib (po. administration of 250 mg); TACE
11031245|NCT04559607|Active Comparator|Control group: TACE|TACE
11031246|NCT04559581||Patients newly initiating Nintedanib|
11031247|NCT04559568|Experimental|LY3522348 (Part A)|LY3522348 administered orally.
11031248|NCT04559568|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
11031249|NCT04559568|Experimental|LY3522348 (Part B)|LY3522348 administered orally. Some participants will also receive midazolam.
11031250|NCT04559568|Placebo Comparator|Placebo (Part B)|Placebo administered orally. Some participants will also receive midazolam.
11031251|NCT04559542||Female material art athletes|Females practicing material art during recruitment time, in Oslo-area in Norway
11031252|NCT04559529|Experimental|Levetiracetam (LEV), then Placebo|Participants will first receive two 250mg LEV capsules on the same day. After one week, they will receive two placebo capsules on the same day.
11031253|NCT04559529|Experimental|Placebo, then Levetiracetam (LEV)|Participants will first receive two placebo capsules on the same day. After one week, they will receive two 250mg LEV capsules on the same day.
11031286|NCT04559217|Experimental|Single arm with 68Ga-DOTATATE|all participants will undergo a PET scan with 68Ga-DOTATATE
11031287|NCT04559204|Experimental|experimental group|408 subjects from experimental group will be simultaneously administrated with one dose of IIV (0.5 ml) and one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
11041751|NCT04486794|Active Comparator|Treatment at Month 1|
11031254|NCT04559516|Experimental|Mobile application-based home exercise intervention|"The exercise program will be administered over 12 weeks through the Ethica mobile app. Participants will perform exercise sessions at home guided by instructional video accessed via Ethica, six days per week. The program will include a combination of education, endurance, strength, and respiratory muscle training.
~The Ethica mobile app will provide a daily alert and a daily exercise video. There will be background monitoring of step counts and actigraphy will be monitored for one week intervals at baseline, at week six, and at week twelve."
11031255|NCT04559516|Active Comparator|Standard care|No supervised exercise session will be performed. Symptoms and quality of life will be monitored in the same manner as the intervention group, and participants will receive the same educational message alerts through the Ethica app as the exercise intervention group.
11031256|NCT04559503|Experimental|İntervention Group|Progressive relaxation exercises were applied once a day for four weeks in the intervention group in addition to the standard treatments. The patients were called 3 times each week on the telephone, and it was monitored whether they continued to do the exercises.
11031257|NCT04559503|No Intervention|Control group|The control group received standard treatment.
11031258|NCT04559490||Standard formula|Participants receiving intact protein lactose-based formula, exclusively for at least 3 months.
11031259|NCT04559490||Sensitive|Participants receiving intact protein glucose/sucrose- based formula, exclusively for at least 3 months.
11031260|NCT04559477|Experimental|Static extension endurance exercise|static back extension endurance exercise
11031261|NCT04559477|Active Comparator|Dynamic extension endurance exercise|dynamic back extension endurance exercise
11031262|NCT04559464|Other|AeriSeal and Zephyr Valve Treatment|"Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-).
~Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR)."
11031263|NCT04559438|Experimental|Rotary Neoniti GPS|Glide path preparation using Rotary Neniti GPS file (Neolix, châtres-la-Forêt, France).
11031264|NCT04559438|Active Comparator|Stainless steel K-files|Glide path preparation using manual stainless steel K-files #10, #15 (Dentsply Maillefer, Ballaigues, Switzerland).
11031265|NCT04559425||Prospective observational cohort 1|Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
11031266|NCT04559425||Prospective observational cohort 2|Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops
11031267|NCT04559412|Experimental|Sofusa Enbrel|Enbrel® administered by the Sofusa® DoseConnect™ delivery system
11031268|NCT04559386|Experimental|Overall trial|People who complete the questionnaire.
11031269|NCT04559373|Experimental|Virtual Reality and Field Practice Training (VRFT)|Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.
11031270|NCT04559360|Active Comparator|Active group - PRESTOapp users|Once users are recruited, an independent researcher will randomize the participants using a 1:1 sequential method in two groups of 76 individuals and will assign a 6-digit identification code (IC) to each participant. The IC will be given to the participant on a reminder card and will be used to access the app guaranteeing its confidentiality. The name of the subjects and their respective code will be stored in independent servers for methodological, security and legal reasons. The intervention group will be asked to use the app for a period of 2 months. The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
11031271|NCT04559360|No Intervention|Control group|The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
11031272|NCT04559347|Experimental|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic
11031273|NCT04559347|Active Comparator|Continuous catheter infusion ropivacaine|Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic
11031274|NCT04559334|Other|open label|All participants will receive Tetrasodium EDTA Catheter Lock Solution (KiteLock™ 4% Sterile Catheter Lock Solution)
11031275|NCT04559321|Active Comparator|Holmium laser|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser.
11031276|NCT04559321|Experimental|Trilogy|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with LithoClast Trilogy EMS and 1.5 mm x 440 mm probe
11031277|NCT04559308|Experimental|metformin arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.
11031278|NCT04559308|Active Comparator|control arm|4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.
11031279|NCT04559295|Experimental|Stem Cells (BMC)|Subjects in the BMC arm received an injection of bone marrow concentrate
11031280|NCT04559295|No Intervention|Control|Subjects in the control arm received no treatment for their condition
11031281|NCT04559282|Experimental|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
11031282|NCT04559282|Experimental|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
11031283|NCT04559269||Cohort 1|Cohort of 98 patients suffering from sleep disorders hospitalized between September 2017 and January 2019 in the Sleep Medicine Center of the Croix Rousse Hospital (Lyon) for objective sleepiness evaluation with polysomnography and MWT.
11031284|NCT04559256|Other|Tricuspid Cardiopulmonary Exercise testing|Patient receiving cardiopulmonary exercise testing
11031285|NCT04559230|Experimental|Sacituzumab govitecan|Dosing will be at 10 mg/kg on days 1 and 8 of a 21-day cycle
11031288|NCT04559204|Active Comparator|control group A|408 subjects from control group A will be only administrated with one dose of IIV (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
11031289|NCT04559204|Active Comparator|control group B|408 subjects from control group B will be only administrated with one dose of PPV23 (0.5 ml). Blood samples are collected before vaccination and one month (30 days) later.
11031290|NCT04559191|No Intervention|HbA1c-guided group|Glycemic control is controlled by guideline-recommended HbA1c control.
11031291|NCT04559191|Active Comparator|CGM-guided group|Glycemic control is controlled by CGM-guided control.
11031292|NCT04559165|Experimental|sericin and chitosan cream|Apply sericin and chitosan cream on pressure ulcer 2 times/day for 21 days.
11031293|NCT04559165|Active Comparator|Cavilon cream|Apply cavilon cream on pressure ulcer 2 times/day for 21 days.
11031294|NCT04559152|Experimental|Zinc Supplementation Group|Zinc capsule (20mg) was taken in the morning after meals once daily for 12 weeks. All subjects in this arm were also given iron and folic acid tablets in accordance with the Indonesian government program.
11031295|NCT04559152|Placebo Comparator|Placebo Group|Placebo (sugar tablet) was taken in the morning after meals once daily for 12 weeks. All subjects were also given iron and folic acid tablets in accordance with the Indonesian government program. Each placebo tablet was inserted into a capsule of the same shape and color with zinc capsule
11031296|NCT04559139|Active Comparator|Arm I (surgery, adjuvant therapy)|Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine IV over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11031297|NCT04559139|Experimental|Arm II (neoadjuvant therapy, surgery, adjuvant therapy)|Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized), then undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11031298|NCT04559126|Experimental|EDP-297 SAD Cohorts|EDP-297 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral solution, once daily in one single administration
11031299|NCT04559126|Experimental|EDP-297 MAD Cohorts|EDP-297 Dose 1, Dose 2 and Dose 3 oral solution, once daily for 14 days
11031300|NCT04559126|Placebo Comparator|EDP-297 SAD Placebo Cohort|Matching placebo, oral solution, once daily in one single administration
11031301|NCT04559126|Placebo Comparator|EDP-297 MAD Placebo Cohort|Matching placebo, oral solution, once daily for 14 days
11031302|NCT04559113|Experimental|Group intervene with Methylprednisolone|"Review effect of Methylprednisolone as clinical trial among hospitalized patients with COVID-19 infection.
~Anyone of the following Corticosteroids dose will be given to moderate disease patients of COVID-19
~0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or
~Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day. *Note: in Diabetic patients' dose of methyl prednisolone should be divided in doses preferably 40mg BD."
11031303|NCT04559100||Severe and critical COVID-19 survivors|"Radiological alterations assessed by chest radiography and/or thoracic computed tomography Lung function alterations assessed by spirometry, diffusing capacity for carbon monoxide, 6 minute walk.
~Quality of life alterations: saint george respiratory questionnaire"
11031304|NCT04559087|Experimental|Natural Orifice Specimen Extraction Surgery|
11031305|NCT04559087|Sham Comparator|Conventional laparoscopy|
11031306|NCT04559074|Experimental|Interventional|Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
11031307|NCT04559074|No Intervention|Observational|This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.
11031308|NCT04559048||FK506-treated group|In FK506-treated group, the patients who underwent liver transplant are treated with FK506 immunosuppressive therapy.
11031309|NCT04559048||control group without FK506 treatment|In control group, the patients who underwent liver transplant are treated without FK506.
11031310|NCT04559035|Other|Betadine|"Intervention - twice-a-day nasal lavage Twice-a-day virucidal group: Participants randomized to betadine will receive 2 gallon jugs of distilled water, two NeilMed Sinus Irrigation bottles and 28 salination packets (with some extras), OR one Navage unit with 28 SaltPods (and some extras), and a cardboard receptacle labeled used saline containers to keep track of adherence.
~Those randomized to receive betadine will also receive one bottle of povidone-iodine, a one-sheet instruction with photographs demonstrating how to add ½ tsp betadine in addition to the salination packet to the sinus irrigation bottle or Navage unit reservoir prior to SaltPod, along with a ½ tsp measuring spoon."
11031311|NCT04559035|Other|Baking Soda|"Twice-a-day alkalinized group: Participants randomized to alkalinization will receive 2 gallon jugs of distilled water, two Neilmed bottles with 28 saline packets, OR one Navage unit with 28 SaltPods, and a cardboard receptacle labeled used saline containers to keep track of adherence. Those randomized to alkalinization will also receive a box of baking soda, ½ tsp measuring spoon and instructions on how to add the baking soda."
11031312|NCT04559022|Other|Fat Grafting for Acne Scar Treatment|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
11031313|NCT04558996||OBS COVID 3|"Objective/s The purpose of this study was to test if pregnant patients with COVID-19 have more obstetrical morbidity than those non-infected.
~Determine the variables that are associated with more maternal and neonatal morbidity.
~Quantify the risk of adverse pregnancy outcomes (e.g., miscarriage, stillbirth, growth restriction) and neonatal outcomes (e.g., NICU, prematurity, death, birth defects).
~Design Longitudinal cohort case study to quantify the obstetrical and perinatal morbi-mortality throughout all hospitals in Spain with a universal, consecutive PCR based screening program.
~Recruitment: 1st March 2020 to 30 September 2020. Spanish sites collected in Appendix 1."
11031314|NCT04558996||OBS COVID 4|Substudy 4. Epidemiological prevalence study Objective/s Determine the prevalence of SARS_COV2 infection in Spanish pregnant women Design Cross-sectional study. The nQuery Advisor Release 7.0 software was used to calculate the sample size, based on the available data. As we do not have data on the prevalence of COVID-19, we set an expected percentage of 50% (a situation that maximizes the sample size) of asymptomatic women during delivery. We determined the sample size for a COVID-19 delivery prevalence study with an expected prevalence of 50%, a 95% confidence level and 5% accuracy, resulting in a sample size of 1056 pregnant women.
11031315|NCT04558983||Retinitis Pigmentosa|Patients with Retinitis Pigmentosa
11031316|NCT04558957|Experimental|FLEBOGRIF|Interventions will be performed using Flebogrif catheter.
11031317|NCT04558944|No Intervention|Control group|This group received pain and pruritus medication as needed, received the usual physical therapy as per the protocol of our burn unit, as well as compression garments, silicone sheets and gels and moisturizing cream twice a day. Additionally, the patients were advice on reducing sun exposure and applying +50SPF sunblock on a daily basis.
11031318|NCT04558944|Experimental|Extracorporeal Shock Wave Therapy group|This group received the same treatment as the control group plus Extracorporeal Shock Wave Therapy (The DermaPACE® System, SANUWAVE Health Inc., USA) with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
11031319|NCT04558931|Experimental|A - Isatuximab/CellProtect|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).
~CellProtect will be given IV infusion at the dose of 3x10^7 cells/kg day 29 , 43 and 3-10x10^7 on day 57.
~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
11031320|NCT04558931|Active Comparator|B - Isatuximab|"Isatuximab will be given intravenously (IV) at the dose of 10 mg/kg on Days 1, 8, 15, 22 (cycle 1), 36, 50 (cycle 2), 64, 78 (cycle 3) and monthly thereafter (cycles 4-36).
~Each cycle will be 28 days, after completion of third cycles, patients will continue with Isatuximab alone until disease progression, unacceptable AE, death, completion of 3 years of treatment or patient's decision to discontinue, whichever occurs first."
11031321|NCT04558918|Experimental|LNP023 monotherapy|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
11031322|NCT04558918|Active Comparator|anti-C5 antibody treatment|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
11031323|NCT04558905|Active Comparator|Usual Medical Care Model|All the patients will receive face-to-face medical visits
11031324|NCT04558905|Experimental|Hybrid Medical Care Model|The patients will receive alternating face-to-face medical visits and video medical consultations
11031325|NCT04558892|Experimental|Nephrotic syndrome - fixed dose (NS-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
11031326|NCT04558892|Experimental|Nephrotic syndrome - adjusted dose (NS-AD)|Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
11031327|NCT04558892|Active Comparator|Control - fixed dose (C-FD)|Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
11031328|NCT04558879|Experimental|Cardiovascular training|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and through a linear progression will reach vigorous intensity; then, this intensity will be maintained until the end of the intervention. Each session will include five minutes of warm-up and cool-down performed at the beginning and the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool down. CT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
11031329|NCT04558879|Experimental|Resistance training|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
11031330|NCT04558866|Experimental|ExBAT Arm|Testosterone Cypionate 400 mg IM on Day 1 and Darolutamide 1,200mg/day (two 300 tablets every 12 hours) p.o. for 28 days, from day 29 to day 56 followed by a washout period of 7 days (63-day cycles), until loss of benefit (disease progression and/or limiting toxicity).
11031331|NCT04558853|Experimental|Autologous NK cells|"The investigation product is a cell suspension based on ex vivo expanded NK cells from patients with MM. The treatment is strictly autologous. The IP is given as three infusions with escalating doses.
~Mode of administration Intravenous infusions. Dose levels
~First infusion; 5x10^6 cells/kg body weight
~Second infusion; 50x10^6 cells/kg body weight
~Third infusion; 100x10^6 cells/kg body weight"
11031332|NCT04558840|Active Comparator|Enhanced Recovery After Surgery (ERAS) Arm|"ERAS Arm will undergo multimodal regiment:
~Before Surgery- gabepentin 300mg and celecoxib 400mg once the day before surgery and again 3 hours prior to surgery.
~During surgery- subjects will receive ketorolac 30mg IV ketorolac once (15mg for patients age 64 years and above).
~Post-operatively- Gabapentin 100mg three times daily for POD0-7, ketorolac 10mg four times daily for POD1-5 days, and ondansetron 4mg as needed for nausea; patients will also have a prescription for hydrocodone-acetaminophen 5/325mg tabs that they may fill if needed for emergency/breakthrough pain."
11031333|NCT04558840|Active Comparator|Current Practice Arm|The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.
11041789|NCT04486482|Other|KB109 + Self Supportive Care (SSC)|
11031334|NCT04558827|Experimental|Low Carb / Time Restricted Feeding|Participants will eat a low carbohydrate diet (30-60 grams) in a time restricted feeding window (2 meals within 8 hours) daily for the duration of the study (6 months).
11031335|NCT04558814|Other|Systemic lupus erythematosus patients|Evaluation of serum galectin-9 level
11031336|NCT04558814|Other|Control group|Evaluation of serum galectin-9 level
11031337|NCT04558801|Experimental|Mobile application-based lifestyle change program|"This arm receives the mobile application-based lifestyle change program at baseline. The mobile application-based lifestyle change program consists of twice a week content for the first 6 months, continuing with less frequent content for the following 6 months. The follow-up period is 6 months. Weight is measured and blood samples (lipids, glucose and metabolic syndrome measures) are collected at 0, 6, 12, and 18 months.
~The mobile application-based counselling contains aspects of cognitive behavior therapy and persuasive system design and consists of twice a week reminders, tasks, self-monitoring, and reflection."
11031338|NCT04558801|Active Comparator|"The waiting-list control"|"The waiting-list control arm will receive mobile application-based lifestyle change program after 6 months, following same principles as Mobile application-based lifestyle change program-arm, excluding follow-up period (6 months of waiting list, 6 months of more intense and 6 months of less intense application use)."
11031339|NCT04558788||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
11031340|NCT04558788||Colitis|Patients with active colitis
11031341|NCT04558788||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
11031342|NCT04558775||Observational Cohort|
11031343|NCT04558762||Women who had a MUS inserted.|Women who underwent surgery with insertion of a MUS due to SUI 2006-2010 in Sweden with the MUS coming out retropubic (TVT) or through foramen obturatorium (TOT).
11031344|NCT04558762||Controls|Women who have not had a MUS inserted due to stress urinary incontinence. Matched in age.
11031345|NCT04558749||Study group|The study population comprised women that will attend their routine visit to the antenatal clinic. The study population will be recruited by using simple random sampling method after verbal consent will be obtained. Resident in the Department of Obstetrics and Gynaecology who will be trained to administer the questionnaire will interview women. Face masks will be provided to the study population during the process of data collection.
11031346|NCT04558736|Experimental|Haploidentical HCT|"To assess the safety and efficacy of haploidentical donor transplantation for patients with severe aplastic anemia or telomere biology disorders who lack an available HLA-matched donor. The goal of this study is to develop a novel, reduced-toxicity, post-transplant pharmacologic immunosuppression (GVHD prophylaxis)- free, highly tolerogenic haploidentical transplant regimen that is associated with few post- transplant complications or late toxicities and is available promptly to all patients, irrespective of matched donor availability.
~Cells for infusion are prepared using the CliniMACS System."
11031347|NCT04558723|Experimental|ICD group|Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.
11031348|NCT04558723|No Intervention|Optimal HF care group|Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.
11031349|NCT04558710||CGM|CGM users
11031350|NCT04558710||SMBG|Non-CGM users
11031351|NCT04558697|Experimental|Shepherd's Purse extractum oleosum vagitories|Vagitories containing Calendulae extractum oleosum 5,5% (w/w), Bursae pastoris extractum oleosum 5,5% (w/w), Matricariae extractum oleosum 5,5% (w/w), Hyperici extractum oleosum 5,5% (w/w) and Millefolii extractum oleosum 5,5% (w/w) as active component
11031352|NCT04558697|Experimental|Tea tree oil vagitories|Vagitories containing tea tree oil, 200 mg per each vagitorie as active component
11031353|NCT04558697|Experimental|Hyperici extractum oleosum vagitories|Vagitories containing Hyperici extractum oleosum 32% (w/w) as active component
11031354|NCT04558697|Active Comparator|Vagitories - Probiotic|Commercially available vagitories with probiotic
11031355|NCT04558684|Experimental|radiotherapy, chemotherapy and PD1 inhibitor|Treatment will comprise 5 daily fractions of radiotherapy at 5 Gy per fraction followed by chemotherapy and immunotherapy. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard surgery.
11031356|NCT04558645||Patients with type 1 diabetes mellitus|Patients with Type 1 diabetes mellitus willing to participate in the study
11031357|NCT04558645||Healthy controls|Healthy controls without chronic disease willing to participate in the study
11031358|NCT04558619|Other|Kōmmour Prenatal|
11031359|NCT04558606|Experimental|Sonic toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).
~Each patient is instructed by the hygienist in the correct use of the sonic toothbrush"
11031360|NCT04558606|Active Comparator|Manual toothbrush|"All patients receive full periodontal charting, a session of professional oral hygiene and OHI (oral hygiene instruction).
~Each patient is instructed by the hygienist in the correct use of the manual toothbrush"
11031361|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
11031362|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
11031363|NCT04558580|No Intervention|Standard of Care|
11031364|NCT04558580|Experimental|Rufinamide|
11031365|NCT04558567|Other|Open-Label|
11031366|NCT04558554|Experimental|Pharmacy-based PrEP delivery|Participants in this experimental arm (which includes all participants) will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) at community pharmacies in Kenya.
11031367|NCT04558541|Experimental|Sensitivity to phonological rules: Children|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
11031368|NCT04558541|Experimental|Sensitivity to semantic category cues: Children|Arm 1.Referential cue during OR learning.
11031369|NCT04558515||Case|Symptomatic patients positive for malaria by PCR
11031371|NCT04558502|Experimental|minocycline-based bismuth quadruple regimen|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and bismuth potassium citrate 200 mg twice daily for 14 days.
11031372|NCT04558502|Active Comparator|clarithromycin-based bismuth quadruple regimen|Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and bismuth potassium citrate 200 mg twice daily for 14 days.
11031373|NCT04558489|Experimental|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
11031374|NCT04558489|Active Comparator|Usual Care/IPR Only|Participants will be randomized via online survey to usual care/IPR only (Information, Psychoeducation & Referral) which they have received through their care visit prior to being referred to the study.
11031375|NCT04558476|Experimental|Convalescent Plasma|2 units of plasma ( 400-500ml) from 2 different donnors duration of treatment =2 h
11031376|NCT04558476|Other|Standard of care|Standard of care according the last gold standards
11031377|NCT04558463|Experimental|Favipiravir|The favipiravir group received loading dose and maintenance dose of Favipiravir for 2 up to 7 days in addition to standard therapy
11031378|NCT04558463|Active Comparator|Oseltamivir|The oseltamivir group was given oseltamivir for 7 days.
11031379|NCT04558450|Other|Group 1|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in intensive care unit
11031380|NCT04558450|Other|Group 2|Patients with confirmed infection by SARS-Cov-2, requiring a hospitalization in a medicine unit
11031381|NCT04558450|Other|Group 3|Patients with confirmed infection by SARS-Cov-2, not requiring hospitalization
11031382|NCT04558450|Other|Group 4|4) individuals having performed a test for SARS-Cov-2 infection, but resulted to be negative
11031383|NCT04558424|Experimental|Intervention group|This group will consist of 50 patients who will be treated with zinc and vitamin C at a dose of 220 mg and 1 gram orally daily for 10 days in addition to their standard treatment
11031384|NCT04558424|Placebo Comparator|Placebo group|This group will consist of 50 patients who will receive placebo at a dose same dose for 10 days in addition to their standard treatment.
11031385|NCT04558411|No Intervention|Control Group (assessment only)|This group will receive assessments only.
11031386|NCT04558411|Experimental|Assessment + Intervention Group|This group will receive assessments and the 14 brief intervention videos.
11031387|NCT04558398|Experimental|Resistance exercise training group|"Participants with either prostate or colorectal cancer (no neoadjuvant chemotherapy) randomized to this arm will engage in a 4-week home based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 8 sessions.
~Each session will include:
~2 min warm-up jogging on the spot
~2 sets of 12-15 repetitions of:
~Squats
~Hip flexion
~Hip extension
~Hip abduction
~Seated row
~Bench press
~Lateral raises
~2 min jogging on the spot cooldown. With resistance bands used to provide resistance."
11031388|NCT04558398|No Intervention|Control group prior to surgery|Participants with prostate or colorectal cancer (no neoadjuvant chemotherapy planned) who are randomized to this control arm will be asked to maintain their routine levels of activity prior to their surgery
11031389|NCT04558398|No Intervention|Planned neoadjucant chemotherapy|"Participants with colorectal or oesophageal cancer with planned neoadjuvant chemotherapy will be assessed at baseline, then on the day of surgery following completion of their chemotherapy.
~The study will not decide upon who receives neoadjuvant chemotherapy and will not affect the chemotherapy regimen decided upon by the clinical team."
11031390|NCT04558398|No Intervention|Breast and Oesophageal Cancer participants|Participants diagnosed with breast or oesophageal cancer will undergo baseline study day in order to allow for comparison across the 4 cancer types
11031391|NCT04558372|Experimental|Group 1- 43 COVID-19 patients|COVID-19 patients breath normally via disposable non-rebreathing mask
11031392|NCT04558372|Experimental|Group 2- 40 non COVID-19 patients|Non COVID-19 patients breath normally via disposable non-rebreathing mask
11031393|NCT04558372|Experimental|Group 3- 1460 suspected COVID-19 patients|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
11031394|NCT04558359|Active Comparator|Standard of Care Cohort|Patients in this group will receive standard of care treatment.
11031395|NCT04558359|Experimental|Angiotensin II Cohort|Patients in this group will receive angiotensin II.
11031396|NCT04558346|Placebo Comparator|Placebo|Placebo (40ug/kg) will be self-administered twice daily for 14 days.
11031397|NCT04558346|Experimental|Ghrelin (OXE-103)|OXE-103 (40ug/kg) will be self-administered twice daily for 14 days.
11031398|NCT04558333||LTx (lung transplant) patients|identification of possible biomarkers
11031399|NCT04558307||Observational Intervention|Rapid SARS-CoV-2 testing strategy
11031400|NCT04558307||Behavioral Intervention|Community-driven messages to promote COVID-19 testing
11031401|NCT04558294|Experimental|100 μg LSD + Ketanserin placebo|
11031402|NCT04558294|Experimental|100 μg LSD + Ketanserin (40mg)|
11031403|NCT04558281|Experimental|Active Treatment|This group will receive a single injection nerve block followed by an infusion of ropivacaine (continuous block)
11031404|NCT04558281|Placebo Comparator|Placebo|This group will receive a single injection nerve block followed by an infusion of normal saline
11031405|NCT04558268|Experimental|treatment group|
11031406|NCT04558268|Placebo Comparator|placebo group|
11031407|NCT04558242|Active Comparator|Genix LLLT Therapeutic Cap|This is a low-level light device containing 150, 650 nanometer LEDs and 50, 940 nanometer LEDs of equal energy output, fixed at 10 milliwatts in a low profile helmet.
11031408|NCT04558242|Sham Comparator|Sham Non-therapeutic Placebo Cap|Sham Placebo Cap low profile helmet containing no low-level light.
11031409|NCT04558229|No Intervention|Standard of Care Clinician Counseling|
11031410|NCT04558229|Experimental|Additional Standardized Counseling|
11031542|NCT04557332|Experimental|Mobile app|In this arm, participants received a mobile app to support ART medication adherence.
11031411|NCT04558216|Experimental|Vonoprazan single doses / rifampin single doses|Participants will be administered a single oral dose of 20 mg of vonoprazan oral tablets on Day 1 and Day 17. Participants will also be administered single daily doses of 600 mg rifampin oral capsules on Days 3 through 18.
11031412|NCT04558190|Experimental|Lipid infusion + MitoQ|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion
11031413|NCT04558190|Placebo Comparator|Lipid infusion + placebo|Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion
11031414|NCT04558190|No Intervention|Control|Subjects undergo a hyperinsulinemic isoglycemic clamp
11031415|NCT04558190|Other|Lipid infusion + beta2-agonist|Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol
11031416|NCT04558177|Experimental|Stimulation Group|Will receive ~1.5mA transcranial stimulation for 20 minutes, 5x per week from a direct current stimulator
11031417|NCT04558177|Sham Comparator|Device placed only, no stim|Same as experimental group but the stimulation from the direct current stimulator will be initiated and then stopped
11031418|NCT04558164|Experimental|Active TBS|Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80% of motor threshold (MT).
11031419|NCT04558164|Sham Comparator|Sham TBS|Sham stimulation will be delivered at 10% of motor threshold (MT), with all other parameters matching the active TBS condition.
11031420|NCT04558151|Experimental|Training arm|Patients will be instructed by physiotherapists to perform inspiratory muscle training containing of 30 breaths twice a day for 14-18 days before surgery.
11031421|NCT04558151|No Intervention|Control arm|No preoperative inspiratory muscle training
11031422|NCT04558138|Experimental|Discharge day of surgery|Patient discharges day of surgery and given surveys to complete at home on post operative day (POD) #1 and #7.
11031423|NCT04558138|No Intervention|Discharge post operative day 1|Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
11031424|NCT04558125|Experimental|TNKase|TNKase infusion plus standard of care which can be heparin or lovenox
11031425|NCT04558125|Placebo Comparator|Placebo|Placebo infusion plus standard of care which can be heparin or lovenox
11031426|NCT04558112|Experimental|100 mg L-DOPA|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
11031427|NCT04558112|Placebo Comparator|Placebo|Complete a ~40 min fMRI scan with either hearing their trauma or neutral narrative, ingest a pill (placebo or 100mg L-DOPA) upon leaving the scanner and wait in a waiting room for ~45 minutes, then undergo a 7 min resting-state fMRI scan.Participants return ~24 hours later for Day 2 fMRI, in which they will complete a single ~40-minute fMRI scan while listening to either their trauma or neutral narrative.
11031428|NCT04558099|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
11031429|NCT04558099|No Intervention|Wait-list control|Usual practice
11031430|NCT04558086|Experimental|Reduce pain and fear|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
11031431|NCT04558086|Experimental|control group|To develop the intervention strategies of hospitalized school-age children with IV placement, using photo book to further examine the effectiveness of reducing IV pain and fear.
11031432|NCT04558073|Experimental|Body Project (BP)|The BP intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
11031433|NCT04558073|Experimental|Healthy Weight Program (HW)|The HW intervention includes four one-hour sessions given over a month by two facilitators. The sessions will be held on a collaborative platform in groups of six people.
11031434|NCT04558073|No Intervention|Waiting-list (WL)|The waiting list will consist of two assessments each separated by a one-month interval. Following this waiting time, participants will receive the BP intervention.
11031435|NCT04558060|Experimental|Virtual Standardized Patient|Training for 45 minutes at each training time point with a computer program that presented a virtual human patient and two simulated patient encounters. The virtual standardized patient involves a branching story line. Participants select 1 of 3 computer-generated response options at each conversational pause: 1) a response that is consistent with the principles and skills of MI, 2) an MI inconsistent response, or 3) a response that is mixed - partly consistent and partly inconsistent with MI.
11031436|NCT04558060|Active Comparator|Academic Study|Study of a summary handout of motivational interviewing concepts and techniques for 45-minutes.
11031437|NCT04558034|Active Comparator|Interventioncryotherapy/control|Subjects will have one mitt/one slipper and serve as their own control
11031438|NCT04558034|No Intervention|standard of care|Subjects will have two mitts/slippers
11031439|NCT04558021|Experimental|Intervention Arm-I|Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
11031440|NCT04558021|Placebo Comparator|Intervention Arm-II|10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
11031441|NCT04558008|Experimental|Online MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
11031442|NCT04558008|No Intervention|Wait-list control|Usual practice
11031443|NCT04557995|Experimental|Erythropheresis treatment|Erythropheresis treatment was was added to routine treatment
11031444|NCT04557995|No Intervention|Routine treatment|Oxygen delivery and basic care
11031543|NCT04557332|No Intervention|Control|In this arm, participants received care as usual.
11031445|NCT04557982||Children aged 3 < 4 years|Children aged 3 < 4 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
11031446|NCT04557982||Children aged 4 < 5 years|Children aged 4 < 5 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
11031447|NCT04557982||Children aged 5 < 6 years|Children aged 5 < 6 years will be recruited using convenience sampling and meeting the inclusion criteria (child Czech-speaking, able to distinguish between small/medium sized/large toy, willing to cooperate, parent/significant other is present and signs informed consent). The child will be explained the use of the S-COS, and S-FPS and self-reports pain intensity immediately prior to the procedure (Time 0), immediately after the procedure (Time 1) and after 5-10 minutes (Time 2). Furthermore, at Time 0, 1 and 2, the child´s pain level is independently assessed by the attending nurse and by the researcher.
11031448|NCT04557969||1/ Cohort 1|Patients with histologically confirmed or clinical presentation suspicious of GIST
11031449|NCT04557956|Experimental|PHASE I (tazemetostat, dabrafenib, trametinib)|Patients receive tazemetostat PO BID, dabrafenib PO BID, and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11031450|NCT04557956|Active Comparator|PHASE II, ARM I (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients may crossover to Arm II after completion of radiation therapy.
11031451|NCT04557956|Experimental|PHASE II, ARM II (tazemetostat, dabrafenib, trametinib)|Patients receive tazemetostat orally PO BID, dabrafenib PO BID, and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11031452|NCT04557943|Active Comparator|Sodium Hyaluronate|Hyaluronate sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
11031453|NCT04557943|Experimental|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:
~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
11031454|NCT04557930|No Intervention|Control|The control arm occurs prior to receipt of the video game intervention. Each hospital group 'crosses over' from control to intervention at a randomized time point.
11031455|NCT04557930|Experimental|Video Game Intervention|Each hospital group 'crosses over' from control to intervention at a randomized time point by receiving a study iPad and playing the video game loaded on the iPad.
11031456|NCT04557904|Experimental|Group A: Craniocervical flexion exercises|Exercise protocol were performed over a 4 week duration under the command of a supervisor. Subjects were asked not to obtain any other particular intervention for cervical ache. Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible.
11031457|NCT04557904|Experimental|Group B: Scapular stabilization exercises|Group B performed scapular stabilization workout for 30 minutes per session, three days a week for four weeks. The scapular stabilization exercises were made up of four stages
11031458|NCT04557878|Experimental|Hypertonic Dextrose Solution|
11031459|NCT04557878|Active Comparator|Liquid Phase Concentrated Growth Factor (LPCGFs)|
11031460|NCT04557865|Experimental|Participants receving 18F-PMPBB3 (APN-1607) PET imaging|Single arm, open label
11031461|NCT04557852||Anterior transvaginal mesh group|Women received anterior transvaginal mesh surgery without concomitant mid-urethral sling surgery.
11031462|NCT04557839|Active Comparator|Traditional physical therapy balance exercise|Traditional physical therapy including balance exercise on mate and swiss ball.
11031463|NCT04557839|Experimental|proprioception based balance training|proprioception based balance training with eye open and close on soft , firm and foam surface.
11031464|NCT04557826|Experimental|RD19 Experimental Device|RD19 Experimental Device used twice/day for 3 minutes each use at least 4 hours, and preferably 8-12 hours, apart
11031465|NCT04557813||IC before start of any treatment|Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
11031466|NCT04557813||IC after start of any treatment|IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.
11031467|NCT04557813||Deceased patients|Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.
11031468|NCT04557800|Experimental|DNL151|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
11031469|NCT04557800|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
11031470|NCT04557787|Active Comparator|Intermittent catheter; SpeediCath® standard Female|Standard of care
11031471|NCT04557787|Experimental|New intermittent catheter variation 1 for females|Intermittent catheter variation 1 for females. The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
11031472|NCT04557787|Experimental|New intermittent catheter variation 2 for females|Intermittent catheter variation 2 for females. The new catheters are not named at this point but are intended for intermittent drainage of the bladder.
11031473|NCT04557774||Liver cirrhosis group|All included patients were asymptomatic at the baseline with no evidence of neurological impairment. Patients with a history of moderate alcohol drinking plus hepatitis B/C virus infection, medication for sedation, MELD (Model for End-stage Liver Disease) score of more than 20, OHE, seizure, head trauma, stroke, dementia, Parkinson's disease, or any kind of focal neurologic deficits were excluded. Any patients who were suspected of alcohol induced direct neurologic damages such as Wernicke's encephalopathy, alcohol induced spinal cord disease, or alcohol induced peripheral nerve disease were excluded. After evaluating the data including the laboratory findings, image findings, endoscopic findings, and medical records of all these patients, as well as liver biopsy findings for some patients, we sub-classified these 88 patients into two groups: alcoholic LC and viral LC. Finally, 80 patients (viral: 37; alcohol: 43) with compensated LC were prospectively considered in this study.
11031474|NCT04557761|Experimental|Closure with microMend® Arm|The microMend® wound closure product will be used to close the Subject's laceration. The wound will be covered with a non-stick dressing.
11031475|NCT04557761|Active Comparator|Closure with Sutures Arm|The Subject's laceration will be closed with sutures. The standard method for suture closed wounds will be followed in accordance with regular institutional policies and procedures.
11031476|NCT04557748||Prospective Observational Cohort Study|Men and women with lower urinary tract symptoms.
11031477|NCT04557748||Prospective Observational Cohort Study Controls|Men and women who do not have urinary dysfunction.
11031478|NCT04557748||Central Sensitization Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
11031479|NCT04557748||Central Sensitization Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
11031480|NCT04557748||Physical Activity and Sleep Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
11031481|NCT04557748||Physical Activity and Sleep Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
11031482|NCT04557748||Organ-Based Study|Women enrolled in the Prospective Observational Cohort Study with urinary urgency, with and without urgency incontinence.
11031483|NCT04557748||Organ-Based Study Controls|Women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency pr urgency incontinence.
11031484|NCT04557748||Qualitative Assessment of Patients with Urinary Urgency Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency who have treatment plans prescribed at the baseline visit.
11031485|NCT04557735|Experimental|Ravulizumab plus Best Supportive Care|Participants will receive ravulizumab plus Best Supportive Care as background therapy.
11031486|NCT04557722|Active Comparator|Group 1: 0-30° technique.|Procedure: 0-30° Biplanar Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
11031487|NCT04557722|Active Comparator|Group 2: new 0-90° technique.|Procedure: new 0-90° Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
11031488|NCT04557709||Observational (chart review)|Patients' medical charts are reviewed.
11031489|NCT04557696|No Intervention|Control Group|Standard oncology curriculum for medical trainees in oncology programs.
11031490|NCT04557696|Experimental|Reflective Group|Standard oncology curriculum with standardized patient simulation, in addition to the REFLECT Curriculum workshops for medical trainees in oncology programs.
11031491|NCT04557657|Experimental|Control Group Resin cement|Control group Using resin cement
11031492|NCT04557657|Active Comparator|Intervention Group Active Cement|Intervention Group Using active cement bio activa
11031493|NCT04557644|Active Comparator|medical staff treating patients with scabies|
11031494|NCT04557644|Active Comparator|family infested with scabies|
11031495|NCT04557618|Experimental|Auricular VNS Stimulation|Participants receive twice daily auricular vagal nerve stimulation
11031496|NCT04557618|Sham Comparator|Sham Auricular VNS Stimulation|Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied
11031497|NCT04557605|Active Comparator|No face mask|Progressive step-exercise cycling test to exhaustion wearing no face mask
11031498|NCT04557605|Experimental|Disposable face mask|Progressive step-exercise cycling test to exhaustion wearing a 3-ply disposable face mask
11031499|NCT04557605|Experimental|Cloth face mask|Progressive step-exercise cycling test to exhaustion wearing a cloth face mask
11031500|NCT04557579||Bifocal group|Patients in bifocal group implanted with Restor +2.5D IOL (Alcon, Fort Worth, TX, USA) in bilateral eyes
11031501|NCT04557579||Extended depth of focus group|Patients in extended depth of focus group implanted with EDOF Symfony IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
11031502|NCT04557579||Monofocal group|Patients in monofocal group implanted with Sensar AR40e IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
11031503|NCT04557566|Active Comparator|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
11031504|NCT04557566|No Intervention|Control|Wait list control
11031505|NCT04557553|Experimental|Lagenbone|Lagenbone 500mg capsules, 8 capsules by mouth every day for 12 months.
11031506|NCT04557540|Experimental|Arm I (Fasting WORD)|Participants receive the Fasting WORD intermittent fasting weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
11031507|NCT04557540|Experimental|Arm II (The WORD)|Participants receive The WORD CER weight loss intervention consisting of 16 small-group lessons over 1.5 hours each QW for 2 months and then Q2W for 4 months.
11031508|NCT04557527|Other|control|Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.
11031509|NCT04557527|Active Comparator|treatment|Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.
11031541|NCT04557345||Control|In subjects who come to donate blood products altruistically, in the blood bank service of the INC, with prior informed consent, the subjects will be matched with PO patients of CVA by age and gender.
11031510|NCT04557514|Active Comparator|platelet rich plasma injection in post burn facial scar|"prp in subgroup allocation 1:1 Obtain WB by venipuncture in acid citrate dextrose (ACD) tubes
~Do not chill the blood at any time before or during platelet separation.
~Centrifuge the blood using a 'soft' spin.
~Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).
~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.
~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.
~Remove PPP and suspend the platelet pellets in a minimum quantity of plasma (2-4 mL) by gently shaking the tube."
11031511|NCT04557514|Active Comparator|fat injection in post burn facial scar|After aspiration of the fatty tissue, it is important that nonviable components of the aspirate, such as oil, blood, and local anesthetics are removed and, at the same time, the quality, integrity, and viability of the adipocytes and the inherent mesenchymal stem cells in the aspirate be maintained. Processing techniques are sedimentation , filtering and washing There is no consensus as to the optimal method of fat graft preparation.
11031512|NCT04557501|Active Comparator|Control - SOC Treatment|Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.
11031513|NCT04557501|Experimental|Experimental - PSMAiTx|Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.
11031514|NCT04557488|Experimental|Music therapy|The treatment group will receive social skill intervention using music therapy in groups of eight. A certified music therapist with prior experience with children with ASD and ID will be the trainer for the treatment group. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to facilitate the group activities, manage unexpected situations, and ensure the safety of the participants.
11031515|NCT04557488|Experimental|Behavioral-based social skill training|The control group will receive behavioral-based social skill training in groups of eight. The trainer will be a registered social worker with experience in providing social skill training for children with ASD and ID. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to provide support.
11031516|NCT04557475|Experimental|ASA Group|Receives standard of care and intervention.
11031517|NCT04557475|No Intervention|SOC Group|Receives standard of care (SOC), only
11031518|NCT04557462|Experimental|LNP023|All participants are receiving 200mg b.i.d
11031519|NCT04557449|Experimental|Monotherapy Escalation Arm 1|PF-07220060 Monotherapy Escalation
11031520|NCT04557449|Experimental|Monotherapy Escalation Arm 2|PF-07220060 Monotherapy Escalation
11031521|NCT04557449|Experimental|Monotherapy Escalation Arm 3|PF-07220060 Monotherapy Escalation
11031522|NCT04557449|Experimental|Monotherapy Escalation Arm 4|PF-07220060 Monotherapy Escalation
11031523|NCT04557449|Experimental|1B Combination Dose Finding Arm 1|PF-07220060 with Letrozole combination Escalation
11031524|NCT04557449|Experimental|1B Combination Dose Finding Arm 2|PF-07220060 with Letrozole Combination Escalation
11031525|NCT04557449|Experimental|1C Combination Dose Finding Arm 1|PF-07220060 with Fulvestrant Combination Escalation
11031526|NCT04557449|Experimental|1C Combination Dose Finding Arm 2|PF-07220060 with Fulvestrant Combination Escalation
11031527|NCT04557436|Other|Standard of care|"Follow-up period:
~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.
~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.
~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m
~Physical examination, ECOG
~Laboratory tests
~Vital signs (temperature, BP, HR, respiratory rate, weight)
~Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)
~Chimerism and MRD in blood and bone marrow (if sampled)
~Adverse events
~Concomitant treatments"
11031528|NCT04557423|Active Comparator|Evidence-Based Intervention|Culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided.
11031529|NCT04557423|Experimental|HPV Self-Sampling|Previously tested evidence-based intervention (i.e. culturally appropriate educational intervention focused on cervical cancer screening, with navigation assistance provided). Participants will also receive a self-sampling kit.
11031530|NCT04557410|Experimental|Receiving Supplement|Participants receive supplement PolyMVA. Dose is 2 teaspoons twice a day.
11031531|NCT04557397|Other|Part A|Subjects will receive fruquintinib, alone and with itraconazole.
11031532|NCT04557397|Other|Part B|Subjects will receive fruquintinib, alone and with rifampin.
11031533|NCT04557384|Experimental|Ramucirumab|Ramucirumab given subcutaneously (SC).
11031534|NCT04557371|Experimental|Developmental Serum|The participants will apply a developmental serum topically to the face twice daily (morning and evening) to freshly cleansed with normal moisturizing routine for 21 days.
11031535|NCT04557371|Experimental|Developmental Lotion|The participants will apply a developmental lotion topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
11031536|NCT04557371|Experimental|Developmental Cream|The participants will apply a developmental cream topically to the face twice daily (morning and evening) to freshly cleansed skin for 21 days.
11031537|NCT04557358||Rheumatic diseases outpatients|"All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic.
~In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)"
11031538|NCT04557345||Biological prostheses INC|"Prosthetic valve manufactured in the National Institute of Cardiology Ignacio Chávez."
11031539|NCT04557345||Imported Biological aortic prostheses|St Jude EPIC and Carpentier-Edwards Perimount
11031540|NCT04557345||Mechanical prostheses|St Jude Masters HP, Carbomedics Standart, ON-X Life Technologies, Edwards Mira, Carbomedics Orbis, Medtronic Hall and Medtronic ATS.
11031544|NCT04557319|Experimental|GNR-038, 25 МЕ/kg|Recombinant C1-esterase (25 ME/kg) inhibitor intravenous infusion
11031545|NCT04557319|Experimental|GNR-038, 50 МЕ/kg|Recombinant C1-esterase (50 ME/kg) inhibitor intravenous infusion
11031546|NCT04557319|Experimental|GNR-038, 100 МЕ/kg|Recombinant C1-esterase (100 ME/kg) inhibitor intravenous infusion
11031547|NCT04557306|Experimental|CBT101 q2w|CBT101 (2-6 x 10^9 cells), every 2 weeks
11031548|NCT04557306|Experimental|CBT101 q4w|CBT101 (2-6 x 10^9 cells), every 4 weeks
11031549|NCT04557293|Experimental|CPAP Treatment|Patients with OSA will undergo cognitive assessment before starting CPAP treatment and after six months of CPAP use.
11031550|NCT04557293|No Intervention|Control Group|We will enrol a control group of subjects without sleep disorders and comparable to OSA patients for age and schooling. Control group will undergo cognitive assessment.
11031551|NCT04557280|Experimental|Treatment A: liquid formulation via auto-injector|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an auto-injector forming an integral ready-to-use single-dose drug delivery system.
11031552|NCT04557280|Experimental|Treatment B: liquid formulation via syringe|Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe.
11031553|NCT04557280|Experimental|Treatment C: lyophilizate-based formulation via syringe|Selatogrel will be administered as a reconstituted lyophilizate-based formulation for injection.
11031554|NCT04557267|Experimental|Group A (dosage A)|The lower dose of the active drug
11031555|NCT04557267|Experimental|Group B (dosage 2)|The middle dose of the active drug
11031556|NCT04557267|Experimental|Group C (dosage 3)|The higher dose of the active drug
11031557|NCT04557267|Placebo Comparator|Group D (placebo)|Placebo
11031558|NCT04557254||silver-triclosan graft implantation (SynG group)|
11031559|NCT04557254||standard Dacron graft implantation (DacrG group)|
11031560|NCT04557241|Experimental|Brief Intervention arm|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process (as described in the Intervention section). This arm will introduce the intervention and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection.
11031561|NCT04557241|Placebo Comparator|Placebo Control arm|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (As described in the Placebo Control section). This arm will introduce the control infographic and then instruct the participant to review it carefully (including a mandated pause on the infographic screen) before continuing to the remaining data collection."
11031562|NCT04557228|Placebo Comparator|Placebo|Study participants will receive 4 weeks of supplementation with 400mg placebo supplements
11031563|NCT04557228|Experimental|Phosphatidylserine Supplementation|Study participants will receive 4 weeks of supplementation with 400mg phosphatidylserine supplements.
11031564|NCT04557215|Active Comparator|Standard dose for IBS-D|Rifaximin 550 mg
11031565|NCT04557215|Placebo Comparator|Traveler's diarrhea dose + placebo|Rifaximin 200 mg + placebo
11031566|NCT04557215|Experimental|Traveler's diarrhea dose + NAC|Rifaximin 200 mg plus N-acetylcysteine (NAC) 600 mg days
11031567|NCT04557202|Active Comparator|Group A|Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively
11031568|NCT04557202|Placebo Comparator|Group B|62 patients who underwent non-stented ureteroscopy and laser and received placebo.
11031569|NCT04557189|Experimental|Group A|Ondansetron placebo-matching intravenous (IV) injection, once immediately before induction of anesthesia and prophylaxis followed by TAK-951 4 mg subcutaneous (SC) injection once 30 to 45 mins before the end of surgery.
11031570|NCT04557189|Experimental|Group B|Ondansetron IV 4 mg once for not less than 30 seconds immediately before induction of anesthesia followed by TAK-951 placebo-matching injection SC administered 30 to 45 minutes before the end of surgery.
11031571|NCT04557176|Experimental|POC CRP-based TB screening|Participants randomized to the intervention arm will undergo POC CRP-based TB screening at study entry. Participants with elevated POC CRP levels (≥8 mg/L) will be regarded as screen-positive and will be referred for confirmatory TB testing. Participants with non-elevated POC CRP levels (<8 mg/L) will be regarded as screen-negative and will be assessed for TPT eligibility.
11031572|NCT04557176|No Intervention|Symptom-based TB screening|Participants randomized to the control arm will undergo symptom-based TB screening at study entry. Participants reporting ≥1 TB symptom (current cough, fever, night sweats, weight loss) will be regarded as screen-positive and will be referred for confirmatory TB testing, in accordance with WHO guidelines. Participants with none of the 4 TB symptoms will be regarded as screen-negative and will be assessed for TPT eligibility.
11031573|NCT04557163|Experimental|Subjects receiving TS-142 and itraconazole|Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.
11031574|NCT04557150|Experimental|Part I: Dose Escalation|Participants will receive RO7425781 as intravenous (IV) and/or subcutaneous (SC) infusion in a step-up dosing fashion.
11031575|NCT04557150|Experimental|Part II: Dose Expansion|Dose Expansion cohorts with IV and/or SC administration will be initiated at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) determined from Part I: Dose Escalation.
11031576|NCT04557137||NET|"Study A:
~A cross-sectional study that investigates 250 patients (Cohort A) with neuroendocrine neoplasia, encompassing both patients with neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).
~Study B:"
11031577|NCT04557137||Newly diagnosed NET|A prospective study that investigates 30 newly diagnosed NET patients over three months (Cohort B) who are offered palliative treatment with somatostatin analogues.
11031578|NCT04557124|Experimental|USS|social cognitive training
11031579|NCT04557124|Active Comparator|MovingForward|problem solving training
11031580|NCT04557098|Experimental|Part 3: Teclistamab|Participants in all cohorts will receive teclistamab SC at an RP2D.
11031581|NCT04557085|Placebo Comparator|Placebo|Placebo
11031582|NCT04557085|Experimental|Cenobamate 100 mg/day|Cenobamate 100 mg/day
11031583|NCT04557085|Experimental|Cenobamate 200 mg/day|Cenobamate 200 mg/day
11031584|NCT04557085|Experimental|Cenobamate 400 mg/day|Cenobamate 400 mg/day
11031585|NCT04557072||The selective alpha-blockade group|Patients treated with selective alpha-blockade before pheochromocytoma surgery
11031586|NCT04557072||The non-selective alpha-blockade group|Patients treated with non-selective alpha-blockade before pheochromocytoma surgery
11031587|NCT04557059|Active Comparator|Interventional Cohort (Group 1): RT+ LHRHa|Participants who are PSMA-PET-positive will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation on Day 1 and at Day 85, or as a 6-monthly depot preparation on Day 1.
11031588|NCT04557059|Experimental|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants who are PSMA-PET-positive receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation on Day 1 and at Day 85, or as a 6-monthly depot preparation on Day 1. Participants will also receive 240 milligram (mg) of apalutamide starting at Day 1 as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
11031589|NCT04557059|No Intervention|Observational Cohort(Group3) PSMA-PET Negative Particitpans|Participants who are PSMA-PET-negative at screening,, will be enrolled in the Observational Cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year.
11031590|NCT04557046|Other|Group A: Sample Collection|Nasal Swab and Saliva Sample Collection
11031591|NCT04557046|Other|Group B: Sample Collection|Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection
11031592|NCT04557046|Other|Group C: Sample Collection|Nasal Swab, Throat Swab and Saliva Sample Collection
11031593|NCT04557046|Other|Group D: Sample Collection|Nasopharyngeal Swab and Saliva Sample Collection
11031594|NCT04557046|Other|Group E: Sample Collection|Nasal swab
11031595|NCT04557033|Experimental|Mindful Meditation|"The activity will include a guided mindfulness meditation and the creation of a digital image on an iPad.
~The My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
~Participants will be asked to complete brief surveys before and after the intervention activity."
11031596|NCT04557020|Experimental|Arm A|
11031597|NCT04557020|Active Comparator|Arm B|
11031598|NCT04557007||Treatment-naive NSCLC patients|Treatment-naive NSCLC patients receiving immunotherapy (pembrolizumab) alone or in combination With chemotherapy divided in groups based on treatment administered. Clinical information will be gathered at start of treatment and at evaluations every 3rd month.
11031599|NCT04556994|Active Comparator|Phase 1 Cardiac Rehabilitation|Phase 1 Cardiac Rehabilitation
11031600|NCT04556994|Experimental|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Phase 1 Cardiac Rehabilitation with lower limb paddling
11031601|NCT04556981|Experimental|M72/AS01E vaccine|
11031602|NCT04556981|Placebo Comparator|Placebo|
11031603|NCT04556955|Placebo Comparator|post isometric relaxation and exercises|Group A included Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier and conventional exercise program ; this program included Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions).This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the End of treatment, i.e. ROM, pain intensity by NPRS and PPT , functional disability.
11031604|NCT04556955|Experimental|Graston technique and exercises|Group B included Graston Technique to Upper Trapezius and Levator Scapulae.This instrumented-assisted soft tissue massage applied with deeper pressure to the area of concern.The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions). This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the END of treatment , i.e. ROM, pain intensity by NPRS and PPT , functional disability.
11031605|NCT04556942|Experimental|Group 1 (Immediate Group)|"Group 1:
~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:
~Flow mediated dilation measurement
~Blood pressure, pulse, blood oxygenation saturation measurement
~Fit bit tracker counting steps and distance during 7 days
~SGRQ (St Georg Respiratory Questionnaire)
~Withdrawal of a blood sample for preservation for later examinations
~This group will receive endobronchial valve placement (EVP) within 1-2 weeks after T0.
~At T1 which will be 4-6 weeks after EVP the measurements done at T0 will be repeated."
11031606|NCT04556942|Other|Group 2 (Delayed Group)|"Group 2:
~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:
~Flow mediated dilation measurement
~Blood pressure, pulse, blood oxygenation saturation
~Fit bit tracker counting steps and distance during 7 days
~SGRQ (St Georg Respiratory Questionnaire)
~Withdrawal of a blood sample for preservation for later examinations
~This group will receive endobronchial valve placement (EVP) 6-8 weeks after T0. A few days before that the investigators repeat the measurement taken at T0."
11031607|NCT04556929|Experimental|Intraoperative imaging of 5-ALA during tumour resection|Participants will undergo 5-ALA guided tumour resection via craniotomy with the aim of achieving maximal safe tumour resection without significant neurological deficit. On completion of tumour resection, digital images will be taken of the resection cavity under blue light using (i) an in-built camera in the operative microscope and (ii) an ultra-high sensitivity camera attached to the side arm of the operative microscope. Biopsies approximately 5x5x5mm in size will then be taken from the anterior, posterior, lateral and inferior areas of the resection cavity which were imaged. These biopsies will be analysed by histopathology to determine the presence of glioma cells.
11031676|NCT04556461|Experimental|Tralokinumab|Tralokinumab 600mg loading dose s.c., followed by 300mg every other week.
11031608|NCT04556916|Experimental|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
11031609|NCT04556916|Experimental|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
11031610|NCT04556903|Experimental|Bilateral Arm Training|Bilateral Arm Training
11031611|NCT04556903|Active Comparator|modified constrained induce movement therapy|modified constrained induce movement therapy
11031612|NCT04556890|Experimental|Active rTMS/Active iTBS DFPLC/Sham Pain M1|
11031613|NCT04556890|Experimental|Sham rTMS/ Active iTBS Pain|
11031614|NCT04556890|Experimental|Active rTMS/Active iTBS|
11031615|NCT04556877||Intraabdominal pressure under 12 mmHg|Patients with intraabdominal pressure under 12 mmHg
11031616|NCT04556877||Intraabdominal pressure between 12-20 mmHg|Patients with intraabdominal pressure between 12-20 mmHg
11031617|NCT04556877||Intraabdominal pressure over 20 mmHg|Patients with intraabdominal pressure over 20 mmHg
11031618|NCT04556864||Description Group|"For each patient included in the study, the secondary variables will be noted in the patient's data collection logbook.
~This is followed by radial artery cannulation (if absent), and connection to the HemoSphere/EV1000 platform
~After the daily visit, the PI/collaborating investigators (CI) will measure the clinical, treatment, and mechanical ventilation parameters of the patient during the last 24 hours.
~Daily arterial analysis will be requested
~This information collection process will be followed for 5 days. At the end of the information collection period, the IP will perform two downloads, the engineering download, and the standard download in which the values are monitored every 20 seconds.
~These will be noted in the secondary variables of the data collection logbook, along with the patients' ICU discharge date.
~In-hospital mortality will be monitored during admission to a conventional hospital ward.
~Records will be closed upon discharge of the patient."
11031619|NCT04556851|Experimental|HSK7653 10 mg|
11031620|NCT04556851|Experimental|HSK7653 25 mg|
11031621|NCT04556851|Placebo Comparator|Placebo|
11031622|NCT04556838|Experimental|VVN001, 1%|VVN001, 1% ophthalmic solution
11031623|NCT04556838|Experimental|VVN001, 5%|VVN001, 5% ophthalmic solution
11031624|NCT04556838|Placebo Comparator|Vehicle|VVN001 Ophthalmic Solution Placebo
11031625|NCT04556825|Experimental|Study group|Arthroscopic treatment with PRP injection
11031626|NCT04556825|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
11031627|NCT04556812|Experimental|Study group|"underwent four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
11031628|NCT04556812|Placebo Comparator|Control group|traditional soft tissue surgery
11031629|NCT04556799|Experimental|Study group|3D osteotomy template for derotation osteotomy with the aid of computer-assisted simulated surgery technique
11031630|NCT04556799|Experimental|Control group|traditional osteotomy technique
11031631|NCT04556786|Experimental|Transitions of care|The study participants in this aim received usual care plus medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist.
11031632|NCT04556786|No Intervention|Usual care|The study participants in this arm received usual care.
11031633|NCT04556773|Experimental|Module 1: T-DXd + capecitabine|T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
11031634|NCT04556773|Experimental|Module 2: T-DXd + durvalumab + paclitaxel|T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
11031635|NCT04556773|Experimental|Module 3: T-DXd + capivasertib|T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
11031636|NCT04556773|Experimental|Module 4: T-DXd + anastrozole|T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
11031637|NCT04556773|Experimental|Module 5: T-DXd + fulvestrant|T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
11031638|NCT04556760|Experimental|Cohort 1|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (72 mg AZD9567 followed by 40 mg prednisolone [AB sequence group] or 40 mg prednisolone followed by 72 mg AZD9567 [BA sequence group]).
11031639|NCT04556760|Experimental|Cohort 2|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (40 mg AZD9567 followed by 20 mg prednisolone [AB sequence group] or 20 mg prednisolone followed by 40 mg AZD9567 [BA sequence group]).
11031640|NCT04556760|Active Comparator|Cohort 3|Participants will be randomised in a ratio of 1:1 to receive placebo and prednisolone over two 72 hour periods in a cross over design (placebo followed by 5 mg prednisolone [AB sequence group] or 5 mg prednisolone followed by placebo [BA sequence group]).
11031641|NCT04556747|Other|VR - Distraction|
11031642|NCT04556747|Other|VR - Biofeedback|
11031643|NCT04556734|Experimental|Etrasimod 2 mg|
11031644|NCT04556734|Placebo Comparator|Placebo|
11031645|NCT04556721|Experimental|Sugammadex|After surgery and general anesthesia, a clinically-appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade. Either 2 mg/kg or 4 mg/kg dosing will be used based on the level of neuromuscular blockade at the time of reversal. Administer as single IV bolus injection infused over 10 seconds into existing IV line. Dose is based on actual body weight (mg/kg).
11031646|NCT04556708|Active Comparator|saline control group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
11031647|NCT04556708|Active Comparator|ozone group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozoned water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
11031677|NCT04556448|Experimental|Aligners|Invisalign treatment
11031648|NCT04556708|Active Comparator|chlorhexidine group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
11031649|NCT04556695||Questionnaire survey|An initial online questionnaire, based on the International Sedentary Assessment Tool (ISAT), will be distributed to General Practice Specialty Trainees (GPSTs) and General Practitioners (GPs) throughout Northern Ireland.
11031650|NCT04556695||Accelerometer study|A purposive sample of approximately 20 questionnaire respondents will be asked to participate in the accelerometer study. This purposive sample will be based on responses to the online questionnaire. The aim will be to obtain a varied sample, based on questionnaire responses, by selecting individuals with a range of demographic characteristics and self-reported levels of sedentary behaviour.
11031651|NCT04556695||Semi-structured interview study|A purposive sample comprising participants of the accelerometer study will be asked to participate in semi-structured interviews. This purposive sample will be based on the accelerometer data. The aim will be to obtain a varied sample, based on accelerometer data, by selecting individuals with a range of different levels of sedentary behaviour, demographic and workplace characteristics. The final number of participants will depend on the saturation of information.
11031652|NCT04556682||Patients who underwent Rotational atherectomy (RA)|The device contains rapidly rotating burr that is coated with microscopic diamond chips, which debulks the calcified plaque by grinding the calcified atheroma into small particles facilitating stent passage and expansion. Both transfemoral or transradial approach can be used. Regular PCI guidewire can be used to cross the often complex anatomy then switching to a rotablation dedicated guidewire over a microcatheter. Burr sizes vary from 1.25mm up to 1.75mm (in certain cases bigger calibers may also be used) aiming to achieve plaque modification .
11031653|NCT04556682||Patients who underwent Intravascular lithotripsy (IVL)|The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable. These emitters create sonic pressure waves that selectively fracture calcium and alter vessel compliance facilitating stent passage and expansion. It is available in 2.5- to 4.0-mm diameters and 12 mm in length, with an inflation pressure of 4 atm used for delivering the treatment. Every catheter can emit a maximum of 80 pulses at a rate of one pulse per second. The IVL balloon catheter is chosen based on the reference lumen of the vessel and after pre-dilatation of the lesion (preferably with a non-compliant balloon) 10-30 pulses are given, usually with interval deflation to allow distal perfusion. If the lesion exceeds the 12 mm balloon length, the balloon can be repositioned and the IVL repeated .
11031654|NCT04556669|Experimental|CD22（aPD-L1）CAR-T cells|
11031655|NCT04556656|Experimental|Pridopidine|45 mg pridopidine twice daily (BID)
11031656|NCT04556656|Placebo Comparator|Placebo|Matching placebo
11031657|NCT04556643|Experimental|Intervention Group|Two sessions will be given to pregnant women in Intervention group. One session breathing exercises training will be given during first stage of labor by the investigator. During training all participants in Intervention group will be instructed to perform breathing exercises during the second stage of labor.
11031658|NCT04556643|No Intervention|Control Group|Usual hospital delivery protocol will be followed.
11031659|NCT04556617|Experimental|PLX2853 + Abiraterone Acetate + Prednisone|"Phase 1b (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 15 evaluable subjects with mCRPC will be enrolled.
~Phase 2a (PLX2853 + Abiraterone Acetate + Prednisone Combination): Up to 19 evaluable subjects with mCRPC will be enrolled."
11031660|NCT04556617|Experimental|PLX2853 + Olaparib|"Phase 1b (PLX2853 + Olaparib Combination): Up to 18 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled.
~Phase 2a (PLX2853 + Olaparib Combination): Up to 58 evaluable subjects with homologous recombination repair (HRR) gene-mutated mCRPC will be enrolled."
11031661|NCT04556604||1|First cycle of the audit on consenting practice pre intervention
11031662|NCT04556604||2|Second cycle of the audit on consenting practice to assess change following intervention
11031663|NCT04556604||3|Third cycle of the audit on consenting practice to assess long term compliance
11031664|NCT04556591|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of health related quality of life (HRQOL) over a three-month (90 day) period (without the personalized feedback).
11031665|NCT04556591|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of health related quality of life (HRQOL) and receive personalized pushes over a three-month (90 day) period.
11031666|NCT04556578|Experimental|High-flow ECCO2R|Extracorporeal support using high flow circulation
11031667|NCT04556565||General population|A representative sample of the general adult population (including those tele-working and working outside of home)
11031668|NCT04556565||Cases and contacts|Recently isolated or quarantined COVID-19 cases and close contacts
11031669|NCT04556565||Healthcare workers|Healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers)
11031670|NCT04556552|Experimental|Active non-invasive Vagal nerve stimulation (VNS)|Active non-invasive Vagal Nerve Stimulation (nVNS) with opioid cues.
11031671|NCT04556552|Sham Comparator|Sham stimulation|Sham stimulation of vagus with opioid cues
11031672|NCT04556539|Experimental|SC10914 group|
11031673|NCT04556526|Experimental|Group A: Ad26.ZEBOV, MVA-BN-Filo|Participants will receive intramuscular (IM) injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp]) on Day 1, followed by modified vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U]) on Day 57.
11031674|NCT04556526|Other|Group B: No vaccination during pregnancy|Participants (pregnant women) in control Group B will not receive any vaccination during pregnancy. However, women in this group will receive the 2-dose vaccination regimen at the earliest 6 weeks after delivery/termination of pregnancy that is Dose 1 of Ad26.ZEBOV vaccine (0.5 mL) (5*10^10 vp) on Day 1 by IM injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 Inf U) vaccine by IM injection 56 days after Dose 1.
11031675|NCT04556513||Patient|Patient hospitalized in ICU for PCR-proven SARS-COV-2 infection
11031679|NCT04556435||LC Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.
11031680|NCT04556435||Control Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).
11031681|NCT04556422|Active Comparator|Sauna alone|Sauna exposure for 30 minutes
11031682|NCT04556422|Experimental|Exercise and Sauna|Cycling exercise for 15 minutes followed by sauna for 15 minutes
11031683|NCT04556409|Experimental|group A|15 women were treated by low intensity pulsed ultrasound (5 min, 0.5 w/cm2, 1MHZ with 20% duty cycle, 3 times/ week for 4 weeks.
11031684|NCT04556409|Experimental|group B|15 women were treated by low level laser therapy (Gallium Aluminum Arsenide Laser), 808nm, 4J/cm2, pulsating signal, 60 seconds for each point, 30 Mw/cm2, 3 times/week for 4 weeks.
11031685|NCT04556409|Placebo Comparator|group C|15 women were the control group who received only relaxation training, 3 times/week for 4 weeks.
11031686|NCT04556396|Experimental|Intervention arm|This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
11031687|NCT04556396|No Intervention|Retrospective arm|This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.
11031688|NCT04556383|Experimental|GB004 dose A|GB004 dose A for oral administration
11031689|NCT04556383|Experimental|GB004 dose B|GB004 dose B for oral administration
11031690|NCT04556383|Placebo Comparator|Placebo|Placebo for oral administration
11031691|NCT04556370|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
11031692|NCT04556370|Experimental|0.025 μg/kg/min group|A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
11031693|NCT04556370|Experimental|0.050 μg/kg/min group|A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
11031694|NCT04556370|Experimental|0.075 μg/kg/min group|A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block
11031695|NCT04556357|Active Comparator|Control group|Phenylephrine infusion simultaneous with subarachnoid block
11031696|NCT04556357|Experimental|Norepinephrine group|Norepinephrine infusion simultaneous with subarachnoid block
11031697|NCT04556344|Experimental|Emotional skills|3 individual sessions in which patients are going to learn how to identify, understand, express and regulate emotions
11031698|NCT04556344|Sham Comparator|Short free talk and relaxation|3 individual sessions in which patients are going to follow relaxation instructions after a non-directive talk about their current or past experience of cancer.
11031699|NCT04556305|Experimental|Mind - BrainHQ cognitive training intervention|The Mind intervention uses the evidence-based BrainHQ computerized cognitive training program. BrainHQ focuses on improving memory, attention, sensory function, and working memory, and has demonstrated efficacy in improving memory among healthy older adults and adults with heart failure. BrainHQ is tailored to the individual, and program difficulty automatically progresses based on performance. Training occurs during three 30-minute sessions per week, for a total of 36 hours. Participants will complete the BrainHQ program on an iPad tablet, which will be provided to them.
11031700|NCT04556305|Experimental|Move - lifestyle physical activity intervention|"The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit active minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings."
11031701|NCT04556305|Experimental|MindMoves - cognitive training and lifestyle physical activity|Participants who are assigned to this condition will complete both the Move lifestyle physical activity program and the Mind BrainHQ cognitive training intervention simultaneously for 24 weeks (see Move and Mind descriptions). Participants will receive both a Fitbit and iPad tablet to complete the combined MindMoves intervention.
11031702|NCT04556305|No Intervention|Usual Care|Participants in the usual care group do not receive any Mind- or Move-related intervention, and will receive their usual care from their cardiology provider.
11031703|NCT04556292|Experimental|SC10914 group|
11031704|NCT04556279||hyperaldosteronism surgical treatment|Hypertensive patients with primary hypersldosteronism, treated with surgery
11031705|NCT04556279||hyperaldosteronism medical treatment|Hypertensive patients with primary hypersldosteronism, treated with aldosterone blockade.
11031706|NCT04556279||hypertensive control|Hypertensive patients shown not to have primary hyperaldosteronism
11031707|NCT04556266|Experimental|Cohort -1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 1 x 10^4 cells/kg"
11031708|NCT04556266|Experimental|Cohort 1|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 1 x 10^5 cells/kg"
11031709|NCT04556266|Experimental|Cohort II|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 2 x 10^5 cells/kg"
11031710|NCT04556266|Experimental|Cohort III|"Cohorts of 3-6 patients each will be treated with escalating doses of consolidative modified T cells at Day 30 (+/- 5 days) post allo-HSCT
~Total T-Cell Dose: 4 x 10^5 cells/kg"
11031711|NCT04556253|Experimental|treatment arm|Subjects will receive AK104 by intravenous administration.
11031805|NCT04555616|Experimental|Individualized Environmental Design Protocol|Alzheimer's disease patients and caregivers.
11031712|NCT04556227|Experimental|Simultaneous Cycle/Cognitive Training|After discharge from the hospital the group will engage in recumbent cycling with simultaneous cognitive training on a tablet.
11031713|NCT04556227|No Intervention|Usual Care|After discharge from the hospital the group will complete baseline activies.
11031714|NCT04556214|Experimental|Liver Transplant|The patients will be transplanted according to standard procedures by the institutional protocol. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
11031715|NCT04556201|Experimental|Thulium Fiber Laser lithotripsy|Subjects who have a medical indication for ureteroscopy, percutaneous nephrolithotomy (PCNL) or mini PCNL
11031716|NCT04556188||Cases|RHD patients undergoing Cardiac surgery at Addis Abeba University Hospital
11031717|NCT04556188||RHD controls|RHD patients not offered Cardiac surgery
11031718|NCT04556188||Anticoagulation controls|Norwegian patients on anticoagulant therapy due to mechanical valve implants
11031719|NCT04556175|Experimental|Oral Health|Motivational interviewing sessions will involve in-person visits by Community Health Workers focused on the mitigation of behavioral risk factors for early childhood caries, with two sessions provided before childbirth and four more sessions at 6, 12, 18 and 24 months after childbirth. Children receive up to 4 fluoride varnish applications during the study. Early cohort of enrollees will be followed up in a 7th visit solely for oral health assessment.
11031720|NCT04556175|Active Comparator|Healthy Lifestyle|Didactic educational sessions delivered in-person by Community Health Workers cover nutrition and diet, physical activity, breastfeeding/formula feeding, substance use, mental/emotional health, personal and family goals, prenatal/postpartum health care access, labor and delivery, family support, infant/child care, oral health, and development milestones. Children receive up to 2 fluoride varnish applications during the study. Early cohort enrollees will be followed up in a 7th visit solely for oral health assessment.
11031721|NCT04556149||Case|Inpatients with confirmed COVID-19 with pulmonary symptoms
11031722|NCT04556149||Matched Control|Inpatients without COVID-19 with non-pulmonary diagnoses or symptoms
11031723|NCT04556136|Experimental|Standing Phototherapy Kiosk (SPK)|Volunteers assigned to this group were administered phototherapy treatments in a standing phototherapy kiosk once every other week, for 10 weeks. The treatment usually lasts no more than 10 minutes and is based on the Fitzpatrick skin type classification tool, which is self-reported via the computer touch screen in the kiosk.
11031724|NCT04556136|Active Comparator|Oral Supplement|Volunteers assigned to this group were provided with a 10-week supply (70 pills) of a vitamin D3 supplement. Consented subjects were instructed to take one 600 IU pill by mouth each day for ten weeks. They were instructed to take this with a meal. This dose is the RDA for adults between 18 and 70 years old according to the Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.
11031725|NCT04556123|Experimental|BIS-guided decongestion|
11031726|NCT04556123|Active Comparator|Decongestion based on clinical judgement|
11031727|NCT04556110|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
11031728|NCT04556110|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
11031729|NCT04556097|Experimental|Early Training|Nurse care managers will be randomized to either early or delayed adapted Care Ecosystem training. The Early Training arm will be the first group to receive training and the first to have the opportunity to use the training in a clinical setting. We anticipate that each nurse care manager will manage 10 PWLD and we anticipate a 50% response rate/data availability, yielding 75 patients per arm.
11031730|NCT04556097|Active Comparator|Delayed Training|The Delayed Training arm will be the second group of nurse care managers to receive training.
11031731|NCT04556084|Experimental|Blinatumomab|Up to 2 cycles of continuous infusion blinatumomab will be given based on the end of Cycle 1 disease response. Cycle 2 of blinatumomab can be given to subjects who have achieved remission (< 5% marrow blasts) after Cycle 1 but have persistent disease identified by multi-parameter flow cytometry (minimal residual disease (MRD) positive ≥ 0.01%) after Cycle 1.
11031732|NCT04556071|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until disease progression
11031733|NCT04556058|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
11031764|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 1 group|Two subjects in this group will receive NL005 for 0.05ug/kg respective in D1.
11031765|NCT04555824|Experimental|Dose 2 groupRecombinant Human Thymosin β4|Two subjects in this group will receive NL005 for 0.25ug/kg respective in D1.
11031734|NCT04556058|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
11031735|NCT04556045|Experimental|Radiation therapy + exercise therapy (RT+ET) group|The RT+ET group will receive the exercise intervention. At their baseline visit, they will meet with the exercise physiologist, each participant will be provided a personalized exercise prescription to follow at home and will be asked to record what they do in between daily radiation treatment visits on the exercise tracking log provided to them. Participants will exercise between 1 and 7 times/week depending on the patient's tolerance to the treatment and exercise prescription. The exercise physiologist will meet with the participant at every radiation treatment visit for a brief 15-30 minute exercise counseling check in. After the participant's five radiation treatments, the exercise physiologist will follow-up with the participants via phone call once per week for 4 weeks during the follow-up period.
11031736|NCT04556045|Experimental|Radiation therapy (RT) group|The RT group will continue with their usual care. The study team will provide patients with an educational pamphlet at the end of their baseline visit. Additionally, the participant's medical record will be reviewed for serious adverse events during their time on study. Baseline and final measurements will be obtained.
11031737|NCT04556032|Experimental|L-Ergothioneine 10 mg/d|Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.
11031738|NCT04556032|Experimental|L-Ergothioneine 25 mg/d|Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.
11031739|NCT04556032|Placebo Comparator|Placebo|Participants will receive placebo orally once daily for 16 weeks.
11031740|NCT04556006|No Intervention|Control|The patients in the control group received only the standard care provided by the clinicians. After the collection of post-test data, the content of the training was also explained to these patients and the study was completed by giving them the training guide.
11031741|NCT04556006|Active Comparator|İntervention|The training program was applied by the researcher who also work as an academic nurse. The contact information of the patients was obtained and the contact information of the researcher was also given to the patients. In order to consolidate the information given, the training guide was given to the patients in the intervention group. After the training, the patients in the intervention group were contacted again in the 2nd week by using face-to-face interview and in the 4th-8th and 12th weeks by phone calls. During these interviews, the questions of the patients, if any, were answered and the problems they faced regarding the disease management were tried to be solved. In the last interview, an appointment day was determined to meet face-to-face at home, workplaces or hospital according to the preferences of the patients.
11031742|NCT04555993|Active Comparator|Transversus abdomis plane block|Patients will receive Transversus abdomis plane block
11031743|NCT04555993|Experimental|Erector spinae plane block|Patients will receive Erector spinae plane block.
11031744|NCT04555980|Experimental|Warm patch|the injection site was covered with warm patch.
11031745|NCT04555980|Placebo Comparator|Cotton patch|the injection site was covered with cotton patch.
11031746|NCT04555967||Transcatheter aortic valve implantation|
11031747|NCT04555941|Experimental|active iTBS|The patient is treated with iTBS stimulation according to protocol with an active coil.
11031748|NCT04555941|Sham Comparator|Sham iTBS|The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.
11031749|NCT04555915||Intervention group|Intervention Group of the SafeboosC Phase III Trial
11031750|NCT04555915||Control group|Control Group of the SafeboosC Phase III Trial
11031751|NCT04555902|Active Comparator|Standard Mailer and Small Gift|A postcard encourages mammograms and includes a small gift.
11031752|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and Small Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; a small gift is included.
11031753|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and No Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; the small gift is not included.
11031754|NCT04555889|Experimental|lung recruitment maneuver (LRM) group|The lung recruitment maneuver (LRM) will be done by increasing of PEEP 0,2 cm H2O every 3 minutes, until reach the opening pressure. After that PEEP decrease gradually until get the closing pressure. Than the investigators will back to the opening pressure for 3 minutes, and the final PEEP will be put backo 0,2 above closing pressure.
11031755|NCT04555889|No Intervention|without lung recruitment maneuver (LRM) group|Another group get standart protocol only.
11031756|NCT04555876|Experimental|high tone external muscle stimulation|"- HiTop 191 appliance (gbo Medizintechnik AG, Rimbach, Germany) Device HiToP® 4 touch gbo Medizintechnik AG, this modern high-tech design with brushed aluminum surface and the 15 TFT LC D full color touch screen monitor offer to the health care professional an indispensable feature."
11031757|NCT04555876|Experimental|stationary bicycle|supervised regular aerobic exercise program on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks.
11031758|NCT04555863|Experimental|haMSter app|Patients receiving the app for personal use for 6 months
11031759|NCT04555850|Experimental|Recombinant Human Thymosin β4 0.5ug/kg|10 subjects in this group will receive NL005 for 0.5ug/kg respective.Continuous administration for 10 days.
11031760|NCT04555850|Experimental|Recombinant Human Thymosin β4 2.0ug/kg|10 subjects in this group will receive NL005 for 2.0ug/kg respective.Continuous administration for 10 days.
11031761|NCT04555850|Experimental|Recombinant Human Thymosin β4 5.0ug/kg|10 subjects in this group will receive NL005 for 5.0ug/kg respective.Continuous administration for 10 days.
11031762|NCT04555850|Other|Placebo|Two subjects in each dose group (0.5/2/5ug/kg) were given placebo for 10 days.A total of six participants were given a placebo.
11031763|NCT04555837|Experimental|Treatment (alisertib, pembrolizumab)|Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11031766|NCT04555824|Experimental|Dose 3 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 0.5ug/kg respective in D1.
11031767|NCT04555824|Experimental|Dose 4 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 2ug/kg respective in D1.
11031768|NCT04555824|Experimental|Dose 5 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 5ug/kg respective in D1.
11031769|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 6 group|Eight subjects in this group will receive NL005 for 12.5ug/kg respective in D1.
11031770|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 7 group|Eight subjects in this group will receive NL005 for 25ug/kg respective in D1.
11031771|NCT04555824|Placebo Comparator|Placebo|Two subjects in each dose group（0.5/2/5/12.5/25ug/kg）were given placebo respective in D1. A total of 10 subjects were given placebos.
11031772|NCT04555811|Experimental|FT596 + Rituximab Dose Level 1: 9x10^7 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 (±1 day) administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
11031773|NCT04555811|Experimental|FT596 + Rituximab Dose Level 2: 3x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 (±1 day) administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
11031774|NCT04555811|Experimental|FT596 + Rituximab Dose Level 3: 9x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 (±1 day) administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
11031775|NCT04555798|Placebo Comparator|Group A|Group A continue on the same conventional way of management as mentioned above with conventional way of ventilation and broad spectrum antibiotics coverage
11031776|NCT04555798|Active Comparator|Group B|group B who connected to (A-VECMO).with venous access from femoral vien and arterial cannulation using the femoral artery
11031777|NCT04555785|Experimental|Platelet transfusion with Wilate ®|
11031778|NCT04555785|Placebo Comparator|Platelet transfusion with Placebo|
11031779|NCT04555772||Healthy Group|Patients who had been treated and recovered physically and gained cognitive functions completely.
11031780|NCT04555772||Sequel Group|Patients who could not gain their physical and cognitive functions.
11031781|NCT04555772||Exitus Group|Patients who did not respond to the treatments and lost their lives within 28 days of admission.
11031782|NCT04555759|Experimental|Patient with spinal cord injuries|
11031783|NCT04555746|Experimental|Physical activity|Physical activity
11031784|NCT04555746|No Intervention|Control|Waiting list
11031785|NCT04555733|Experimental|Cohort 1: Lemborexant 5 mg|Participants will receive a single dose of lemborexant 5 milligram (mg) tablet, orally on Day 1.
11031786|NCT04555733|Experimental|Cohort 2: Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1 followed by a washout period of approximately 14 days further followed by multiple doses of lemborexant 10 mg tablets, orally, once daily from Day 15 through Day 28.
11031787|NCT04555733|Experimental|Cohort 3: Lemborexant 25 mg|Participants will receive a single dose of lemborexant 25 mg (1*5 mg tablet and 2*10 mg tablet), orally on Day 1.
11031788|NCT04555720|Experimental|Interdisciplinary Care|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participant's doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
11031789|NCT04555720|No Intervention|Standard of Care|If assigned to standard of care, group participants will have a normally scheduled visit with neurologist.
11031790|NCT04555707|Experimental|Otezla + Enstilar|
11031791|NCT04555694|Active Comparator|Restasis and Lotemax|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes and Lotemax ophthalmic solution twice a day in both eyes.
11031792|NCT04555694|Active Comparator|Restasis and Dextenza|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes, as well as receiving Dextenza insertion in both lower lids.
11031793|NCT04555694|Active Comparator|Restasis|10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes
11031794|NCT04555668|Experimental|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch
11031795|NCT04555668|Active Comparator|Hamstring Stretch Program|Hamstring Stretch Program and Knee -flexor eccentric training
11031796|NCT04555655|Experimental|Chicken extract supplement|
11031797|NCT04555655|Experimental|Peptides supplement|
11031798|NCT04555655|Placebo Comparator|Placebo|
11031799|NCT04555642||therapy group|lymphoma patients after chemotherapy or immunotherapy scheme
11031800|NCT04555642||healthy control group|Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.
11031801|NCT04555629|Experimental|Advanced Cognitive Stimulation Therapy Hong Kong|"Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. It has also been translated and adapted for the Hong Kong Chinese population.
~ACST-HK will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee, or care home staff."
11031802|NCT04555629|No Intervention|Treatment as usual|Standard care in care homes
11031803|NCT04555616|Placebo Comparator|Control Group|Alzheimer's disease patients and caregivers.
11031804|NCT04555616|Experimental|Standard Environmental Design|Alzheimer's disease patients and caregivers.
11041790|NCT04486482|Other|Self Supportive Care (SSC) Alone|
11031806|NCT04555590|No Intervention|Pre H-HOPE Cohort|The Pre-H-HOPE Comparison Cohort will not receive the H-HOPE intervention, and represents the prior standard (non-HOPE).
11031807|NCT04555590|Experimental|H-HOPE Cohort|The H-HOPE Cohort will receive the H-HOPE intervention.
11031808|NCT04555577|Experimental|Stage I (nedisertib, radiation therapy, temozolomide)|"CONCURRENT: Patients undergo standard of care radiation therapy daily (Monday-Friday) for 30 fractions. Patients also receive nedisertib PO on each day of radiation therapy and given 1-2 hours before each treatment fraction. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
~ADJUVANT: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
11031809|NCT04555577|Experimental|Stage II (nedisertib, radiation, temozolomide, surgery)|"CONCURRENT: Patients receive nedisertib and undergo standard of care radiation therapy as in Stage I. Within 1-14 days after the completion of radiation therapy, patients undergo surgical resection.
~ADJUVANT: Patients receive temozolomide as in Stage I."
11031810|NCT04555564|Experimental|Technicium 99 MAA|Participants will receive bronchial artery administration of Technicium 99 MAA
11031811|NCT04555551|Experimental|Targeted MCARH109 CAR Modified T cells|Patients will undergo leukapheresis of peripheral blood for further T cell enrichment; activation and genetic modification using a lentiviral vector encoding a GPRC5D targeted CAR (MCARH109). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. These modified T cell infusions will be administered 2-7 days following completion of conditioning chemotherapy.
11031812|NCT04555538||Atrial Fibrillation Group|
11031813|NCT04555538||Non-Atrial Fibrillation Group|
11031814|NCT04555525|Experimental|sarecycline|weight-based dose per label by mouth once daily for 12 weeks
11031815|NCT04555525|Other|Centrum Adult Multivitamin|one tablet by mouth daily for 12 weeks
11031816|NCT04555512|Active Comparator|Standard-care interval-training group|Subjects will complete a standard interval-training program that remains constant for the entire 12 weeks of cardiac rehabilitation.
11031817|NCT04555512|Experimental|Progressive interval-training group|Subjects will complete an interval-training program during which the number of intervals and the duration of each interval are changed across the 12-week cardiac rehabilitation program.
11031818|NCT04555499||Suspected stroke|Patients with suspected stroke who are evaluated by paramedics
11031819|NCT04555486|Experimental|DCR-PHXC|Participants that are at least 12 years old will receive a single dose of 3 mg/kg DCR-PHXC (or nedosiran) via subcutaneous (SC) injection. Participants that are 6-11 years old will receive a single dose of 3.5 mg/kg DCR-PHXC (nedosiran) via SC injection.
11031820|NCT04555486|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|Participants will receive a single dose of Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo.
11031821|NCT04555460|Active Comparator|Decompressive surgery|Decompressive surgery was performed with a large hemicraniectomy that removed, ipsilateral to the stroke, a bone flap as large as possible including temporal, frontal, parietal, and some occipital squama.
11031822|NCT04555460|Active Comparator|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke. Administration of intravenous mannitol (0.25 to 0.5 g/kg) or furosemide was given only in patients whose condition was rapidly worsening because of brain edema, without additional recommendations on loading doses.
11031823|NCT04555447|Experimental|Healthy-agavins|Agavins are branched neo-fructans and were supplemented for a 5-week dose-escalation period in lean participants
11031824|NCT04555447|Placebo Comparator|Healthy-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in lean participants
11031825|NCT04555447|Experimental|Obese-agavins|Agavins are branched neo-fructans that were supplemented for a 5-week dose-escalation period in obese participants
11031826|NCT04555447|Placebo Comparator|Obese-placebo|Maltodextrin was used as placebo and supplemented for a 5-week dose-escalation period in obese participants
11031827|NCT04555434|Experimental|Probiotics group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
11031828|NCT04555434|Placebo Comparator|Placebo group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
11031829|NCT04555421|Experimental|Lumen device usage and diet guidelines|
11031830|NCT04555408|Active Comparator|blue light group|The blue light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
11031831|NCT04555408|Active Comparator|bright light group|The bright light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
11031832|NCT04555408|Placebo Comparator|dim light group|The dim light will be applied five times a week for the first two weeks. For the next two weeks, this treatment will be applied three times a week.
11031833|NCT04555395||gonadal|
11031834|NCT04555395||extra-gonadal|
11031835|NCT04555395||chemotherapy|
11031836|NCT04555395||without chemotherapy|
11031837|NCT04555382||AKI group|this group are included patients who have not occured acute kidney injury at first, however acute kidney injury are occured soon afterwards during the observation period.
11031838|NCT04555382||non-AKI group|this group are included patients who have not occured acute kidney injury during the observation period.
11031839|NCT04555369|Experimental|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
11031840|NCT04555343|Experimental|Intervention- TXA|"Drug: one-time intravesical administration of 1gm of TXA instilled via urinary catheter, instilled for 15min before continuous bladder irrigation treatment beings.
~1gm of TXA will be mixed with 100cc NS"
11031985|NCT04554342|Experimental|healthy participants starting with candy V03|
11031841|NCT04555330|Experimental|Visual Feedback|Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level and motivation to move. This information will be visible to the health personnel, the patients and visitors.
11031842|NCT04555330|Other|Control Group|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.No feedback on physical activity is provided.
11031843|NCT04555317|No Intervention|Standard of Care|No intervention. Standard of care cancer pathway followed.
11031844|NCT04555317|Active Comparator|Musculoskeletal Health Package|3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
11031845|NCT04555304|Experimental|KH903 + Paclitaxel|IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
11031846|NCT04555304|Active Comparator|Placebo + Paclitaxel|IV Placebo IV paclitaxel 80 mg/m²
11031847|NCT04555291|Experimental|Drug Ropivacaïne 2 mg/ml|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
11031848|NCT04555291|Placebo Comparator|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
11031849|NCT04555278|Experimental|Active rTMS + Motor control exercises|Active (real) repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
11031850|NCT04555278|Sham Comparator|Sham rTMS + Motor control exercises|Sham repetitive transcranial magnetic stimulation (20 minutes), immediately followed by a session of motor control exercises taught and supervised by a physiotherapist (30 minutes).
11031851|NCT04555278|Experimental|Active rTMS|Active (real) repetitive transcranial magnetic stimulation (20 minutes).
11031852|NCT04555278|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (20 minutes).
11031853|NCT04555265|Other|Thermal ablation group|Patients with hepatocellular carcinoma treated by thermal ablation
11031854|NCT04555252||Cephalic Duodenopancreatectomy|Patients who underwent scheduled cephalic duodenopancreatectomy and hospitalized in intensive care.
11031855|NCT04555239|Active Comparator|Standard of Care, Upper Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
11031856|NCT04555239|Active Comparator|Standard of Care, Lower Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
11031857|NCT04555239|Experimental|FDM, Upper Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
11031858|NCT04555239|Experimental|FDM, Lower Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
11031859|NCT04555226|Active Comparator|Standard treatment group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
11031860|NCT04555226|Experimental|Experimental group|Open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
11031861|NCT04555213|Experimental|Dose Escalation Cohort 1 - NOX66 400mg|NOX66 400 mg suppository OD
11031862|NCT04555213|Experimental|Dos Escalation Cohort 2 - NOX66 600mg|NOX66 600 mg suppository OD
11031863|NCT04555213|Experimental|Dose Escalation Cohort 3 - NOX66 800mg|NOX66 800 mg daily (400 mg suppository BID)
11031864|NCT04555213|Experimental|Dose Escalation Cohort 4 - NOX66 1200mg|NOX66 1200 mg daily (600 mg suppository BID)
11031865|NCT04555213|Experimental|Dose Escalation Cohort 5 - NOX66 1800mg|NOX66 1800 mg daily (600 mg suppository TID)
11031866|NCT04555213|Experimental|Dose Expansion - NOX66 Recommended Phase 2 Dose|Dose Expansion: NOX66 RP2D
11031867|NCT04555187||Covid19-positive|Covid19 test positive. age >= 18 y.
11031868|NCT04555187||Covid19-negative|Covid19 test negative. age >=18y
11031869|NCT04555174||Orsiro Mission DES|All subjects will be implanted with the Limus Eluting Orsiro Mission Stent System and followed up until 60 months.
11031870|NCT04555161|Experimental|Aria CV Pulmonary Hypertension System|Treatment with the Aria CV Pulmonary Hypertension System
11031871|NCT04555148|Placebo Comparator|Placebo|Saline
11031872|NCT04555148|Experimental|Low dose Treatment|Low dose treatment
11031873|NCT04555148|Experimental|Medium dose Treatment|Medium dose Treatment
11031874|NCT04555148|Experimental|High dose Treatment|High dose Treatment
11031875|NCT04555135|Experimental|Colonoscopy Procedure with EndoVigilant Software|Colonoscopy Procedure is performed with EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
11031876|NCT04555135|No Intervention|Colonoscopy Procedure without EndoVigilant Software|Colonoscopy Procedure is performed without EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
11031877|NCT04555122|Experimental|Intervention Group|Advertisements will be sent to participants mobile devices to attempt to increase adherence to stay-at-home orders and social distancing. There are 3 types of advertisements. This will occur for 7 days.
11031878|NCT04555122|No Intervention|Control Group|Control Group will be people who will not receive any advertisements.
11031879|NCT04555109||COVID-19 Convalescents|The cohort will include up to 1000 persons recovered from COVID-19, ages 17 - 65, that will provide a written consent form to participate in the study, complete questionnaires and provide a blood sample.
11031880|NCT04555096|Experimental|Active GC4419|Arm A
11031881|NCT04555096|Placebo Comparator|Placebo|Arm B
11031882|NCT04555083||CAI group|Case group is CAI group that recruit patients complain of ankle insatiability and giving way mainly
11031883|NCT04555083||control group|control group recruits participants with non injured ankle, matched with case group in gender and dominant limb
11031986|NCT04554342|Experimental|healthy participants starting with candy V04|
11031884|NCT04555057|Experimental|Music therapy group|"One day before surgery, the participants of music therapy group choose the music they want to listen in the operating room. The total playing time of the selected music is recommended between 5 and 10 minutes.
~On the day of surgery, after entering the operating room, listen to personally selected music through the speaker. After the music is over, start anesthesia induction."
11031885|NCT04555057|No Intervention|Control group|The participants of control group wear earmuff to block noise after entering the operating room until induction of anesthesia. All other treatments proceed as conventional treatments.
11031886|NCT04555044|Experimental|Clinolipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
11031887|NCT04555044|Active Comparator|Intralipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
11031888|NCT04555031|Experimental|kalifilcon A lenses|
11031889|NCT04555031|Active Comparator|Dailies Total 1|
11031890|NCT04555031|Active Comparator|Precision 1|
11031891|NCT04555031|Active Comparator|Biotrue ONEday|
11031892|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
11031893|NCT04554992|Experimental|Treatment|All subjects recruited will be transfused with COVID 19 convalescent plasma. A prospective comparison with matched historical controls receiving standard care will be employed.
11031894|NCT04554979||Group 1|Duration of COVID-19 symptoms less than 12 days
11031895|NCT04554979||Group 2|Duration of COVID-19 symptoms equal or more than 12 days
11031896|NCT04554966|Experimental|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
11031897|NCT04554966|Experimental|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
11031898|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
11031899|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
11031900|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
11031901|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
11031902|NCT04554966|Experimental|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
11031903|NCT04554940|Experimental|Vosoritide + Standard of Care|Standard of Care treatment for cervicomedullary compression and once daily subcutaneous injection of vosoritide at 30μg/kg (ages 0 - <2 years old) or 15 μg/kg (ages >2 years old)
11031904|NCT04554940|No Intervention|Standard of Care Alone|Institutional standard of care monitoring and treatment for cervicomedullary compression
11031905|NCT04554927|Experimental|WEB-application|
11031906|NCT04554927|Active Comparator|Standard accompaniment|
11031907|NCT04554914|Experimental|EBV+ PID LPD|Participants with newly diagnosed or relapsed/refractory EBV+ PID LPD will receive IV tabelecleucel.
11031908|NCT04554914|Experimental|EBV+ AID LPD|Participants with newly diagnosed or relapsed/refractory EBV+ AID LPD will receive IV tabelecleucel.
11031909|NCT04554914|Experimental|EBV+ PTLD CNS|Participants with newly diagnosed or relapsed/refractory EBV+ PTLD CNS will receive IV tabelecleucel.
11031910|NCT04554914|Experimental|EBV+ PTLD (ineligible for first-line therapy or CD20 negative)|Participants with EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease will receive IV tabelecleucel.
11031911|NCT04554914|Experimental|EBV+ sarcoma, including LMS|Participants with newly diagnosed or failed systemic first-line therapy for EBV+ sarcoma will receive IV tabelecleucel.
11031912|NCT04554914|Experimental|CAEBV/ HLH|Participants with newly diagnosed or previously treated CAEBV or EBV viremia with HLH will receive IV tabelecleucel.
11031913|NCT04554901|Other|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
11031914|NCT04554888|Experimental|Doxepin Application|During the session each forearm of the subject will be divided into four squared areas (2.5x2.5 cm), see Figure 4. Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours 48. At the end of the pre-treatment period, the patches will be removed and the skin will be cleaned with alcohol.
11031915|NCT04554888|Experimental|Itch Induction|After Doxepin removal, Then tests with papain, cowhage, histamine or vehicle will be conducted. Each substance will be randomly applied in two areas, one pretreated with doxepin and one with no pre-treatment.
11031916|NCT04554875||Cohort 1|Derivation Cohort of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
11031917|NCT04554875||Cohort 2|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
11031918|NCT04554875||Cohort 3|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
11031919|NCT04554875||Cohort 4|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
11031920|NCT04554862|Active Comparator|the intervention group (M) magnesium sulfate|a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
11031921|NCT04554862|Active Comparator|the intervention group (K) ketorolac|a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
11031987|NCT04554342|Experimental|healthy participants starting with candy V05|
11031988|NCT04554329|Active Comparator|bandage contact lens|A bandage contact lens was applied on the eye at the end of the surgery, and the eye was not covered with a patch.
11031922|NCT04554836|Experimental|FOLFIRI + cetuximab|"Patients in Arm A will receive FOLFIRI + cetuximab until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first. The recurrence of RAS-mutation without PD to switch back to FOLFIRI. In case of repeated conversion to RAS wild-type without PD, treatment will shift to FOLFIRI + cetuximab again, and so on. Switches of treatment will proceed until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.
~[FOLFIRI = Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)]"
11031923|NCT04554836|Other|FOLFIRI|Patients in Arm B will continue therapy with FOLFIRI until PD, unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.
11031924|NCT04554823|Placebo Comparator|Control Group|Will attend lectures on health education.
11031925|NCT04554823|Experimental|Exercise Group|Will be subjected to a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and Will attend lectures on health education.
11031926|NCT04554810|Active Comparator|Intervention group|Intervention group participants are the refugees who received the medication management review service and pharmacist's counselling. They have been assessed at baseline and at follow-up after 3 months) home visits.
11031927|NCT04554810|No Intervention|Control group|Control group participants are the refugees who did not received the medication management review service and no pharmacist's counselling wsa provided to them during the study period. They have been assessed at baseline and at follow-up (after 3 months) home visits.
11031928|NCT04554797|Experimental|Regional Hypothermia group|
11031929|NCT04554797|No Intervention|Control group|
11031930|NCT04554784|Active Comparator|Conventional|Conventional pain treatment.
11031931|NCT04554784|Active Comparator|Bowen|Patients will be referred to Occupational Therapist for Bowen therapy.
11031932|NCT04554771|Experimental|ADAM12 high with tocilizumab and standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
11031933|NCT04554771|Active Comparator|ADAM12 high with standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
11031934|NCT04554771|Experimental|ADAM12 low with tocilizumab and standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
11031935|NCT04554771|Active Comparator|ADAM12 low with standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
11031936|NCT04554758|Experimental|Sleeve gastrectomy|200 obesity patients who undergo laparoscopic sleeve gastrectomy
11031937|NCT04554758|Experimental|Roux-en-Y gastric bypass|200 obesity patients who undergo laparoscopic Roux-en-Y gastric bypass
11031938|NCT04554732|Experimental|Part 1 - Initial group treatment|For part 1 of the study, subjects will be enrolled into a prospective single arm phase where all of them get the study treatment. We plan to enroll up to 25 subjects to have 20 evaluable subjects to this phase.
11031939|NCT04554719|Experimental|68Ga-DOTA-FAPI PET/MR|Investigators select subjects from patients with suspected or diagnosed or treated malignant tumors who have completed 18F-FDG PET/CT imaging, focusing on malignant tumors with poor results of FDG PET/CT imaging, such as brain tumors, liver tumors, digestive system tumors and peritoneal, greater omentum, and mesenteric metastatic tumors. Patients undergo 68Ga-DOTA-FAPI PET/MR imaging within one week.
11031940|NCT04554706|Experimental|a JITAI interactive narrative condition (Narrative JITAI)|This arm is an exploratory condition, which tested whether story-based JITAI would be an effective way to deal with rumination.
11031941|NCT04554706|Experimental|a JITIAI non-interactive condition|This arm uses the regular JITAI ( mobile phone delivered) intervention to provide treatment for ruminative thoughts.
11031942|NCT04554706|No Intervention|a wait-list control condition|Participants in this arm will be put on a waitlist without receiving active treatment upon the end of the study.
11031943|NCT04554693|Experimental|Metronidazole|Metronidazole
11031944|NCT04554693|Placebo Comparator|Placebo|Halal and Kosher certified gelatin placebo capsules
11031945|NCT04554680|Experimental|Treatment Group|Patients with progressive, metastatic or locally advanced, unresectable radioiodine (RAI)-refractory thyroid cancer of follicular cell origin with mutation involving MAPK signalling pathway, including BRAFV600E mutation or RAS mutation.
11031946|NCT04554667|Experimental|Exercise Intervention|Single exercise arm
11031947|NCT04554654||frozen embryo transfer cycles|patients undergoing frozen embryo transfer with artificial hormone replacement
11031948|NCT04554641|Experimental|BioKult Advanced|This is a single arm study, all participants will take Bio-kult Advanced for 56 days (+/- 2days). Participants will be required to take 4 capsules daily.
11031949|NCT04554628|Active Comparator|Urinary human neutrophil gelatinase-associated lipocalin|Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement
11031950|NCT04554628|Active Comparator|Urinary human kidney injury molecule 1 (U-KIM1)|Urinary human kidney injury molecule 1 (U-KIM1) measurement group
11031951|NCT04554615|Active Comparator|Conventional Insulin Therapy|CIT was provided as a continuous infusion of 50 IU of Actrapid HM in 50 ml of 0.9% sodium chloride using a pump, Infusion was adjusted to achieve BG level in range of 180-200 mg/dl.
11031952|NCT04554615|Active Comparator|Intensive Insulin Therapy|IIT was provided as an insulin infu-sion at rate of 1 mU/kg/min and was adjusted to achieve target BG level in range of 80-110 mg/dl.
11032020|NCT04554043|Experimental|SHR7280 dose 1(male)|oral administration for 14 days,Phase I(PART 1)
11031953|NCT04554602||Patient with endometriosis or suspicion of endometriosis|"Information and collection of the non-objection before inclusion
~Interrogation, clinical examination, EHP30 and SF36 form at inclusion
~MRI, pelvic ultrasound (coupled with fusion ultrasound)
~Laparoscopy if indicated after MRI, ultrasound and fusion ultrasound
~Monitoring by form and fusion ultrasound at 6 months and then once a year for 3 years"
11031954|NCT04554602||Patient with other gynaecological pathology|"Information and collection of the non-opposition before inclusion
~Interrogation, clinical examination, EHP30 and SF36 form at inclusion
~MRI, pelvic ultrasound (coupled with fusion ultrasound)
~laparoscopy if indicated after MRI, ultrasound and fusion ultrasound"
11031955|NCT04554589|Active Comparator|intervention group|receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .
11031956|NCT04554589|Placebo Comparator|placebo group|receive normal saline 2 ml IV every 8 hours daily .
11031957|NCT04554576|Experimental|6-week self-management and remote feedback for 6 months|All participants will receive the 6-week self-management program and after, half the group will be randomized to an every 6th week healthcare provider feedback phone or video visit session for 6 months (4 visits over 24 months).
11031958|NCT04554576|Active Comparator|6-week self-management and control group for 6 months|All participants will receive the 6-week self-management program and after, half will be randomized to a 6 month control grup
11031959|NCT04554563|Experimental|Training group|4-week core stability training
11031960|NCT04554563|No Intervention|Control group|Standard physical therapy
11031961|NCT04554537|Placebo Comparator|Brain Health Workshop|The BHW training has been used in multiple prior studies as a comparison training program in cognitive training trials It consists of sessions of fact-based information about the brain but does not train cognitive strategies. Topics include neuroanatomy, neuroplasticity, and effects of TBI on cognitive functioning. Other sessions focus on diet, exercise, sleep, and social functioning and their relationships to brain health. Participants are encouraged to share how the topics impact their lives. Participants are given take-home reading materials on related topics that were then discussed at the last session. At home, they were instructed to watch assigned videos but had no other homework.
11031962|NCT04554537|Experimental|SMART|"SMART emphasizes top-down processing by targeting focused attention, assimilation of information, and mental flexibility and innovation, all higher-order cognitive functions driven by the frontal lobes. SMART was delivered in small groups (n = 2 to 8) consisting of two 3-hour sessions over two days, followed by one 3-hour session a month later. Overall, sessions focused on strategic attention, integrative reasoning, and cognitive control functions (Chapman, 2014). Training consists of initial sessions of skills training with the one-month follow-up session being a booster session consisting of review. We modified the training such that all sessions included skills training with briefer review. The first two sessions consisted of strategic attention and integrated reasoning and the final session discussed innovation."
11031963|NCT04554524|Experimental|Chemotherapy+Pembrolizumab|Chemotherapy combined with pembrolizumab.
11031964|NCT04554511||Training cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
11031965|NCT04554511||Validation Cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
11031966|NCT04554498|Experimental|Hemodiafiltration with ATA filter|patients with clinical history of hypersensitivity to polisulfone/poliethersulfone dialysis filters or hypersensitivity to drugs or generic allergens.
11031967|NCT04554498|Active Comparator|Hemodiafiltration with Helixone filter|no history of hypersensitivity to polisulfone/poliethersulfone dialysis filters is assessed; no history of hypersensitivity to drugs or generic allergens is assessed.
11031968|NCT04554485|Experimental|Blinatumomab followed by high-dose chemotherapy|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
11031969|NCT04554472||Study group|Patients with a distal radius fracture requiring surgery who meet the exclusion and inclusion criteria
11031970|NCT04554459|Experimental|ponatinib plus reduced-intensity chemotherapy|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
11031971|NCT04554446|Experimental|T-MSAT(Motion style acupuncture treatment using Traction)|T-MSAT group receives 3 sessions of T-MSAT; on 2nd, 3rd, 4th day after hospitalization. A trained doctor of Korean medicine with clinical experience conducted the T-MSAT. And T-MSAT group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
11031972|NCT04554446|Active Comparator|Korean medicine treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
11031973|NCT04554433|Active Comparator|Intervention|A ) Treatment group will receive a combination of Asprin in anti - inflammatory dose and controlled ethanol vapor inhalation in concentraions and technique according to their medical condition .
11031974|NCT04554433|No Intervention|Control|B ) Control group : will receive the standard protocol . Data collection will include : sociodemographic data , clinical history , results of follow up ( daily or according to clinical situation ) Follow up : to record any side effects of drugs , and swab will be taken for PCR .
11031975|NCT04554420|Experimental|Youth Participatory Action Research-Mental Health Curriculum|Youth will be engaged with youth participatory approaches in learning about the intersection of mental health and systemic/community level issues.
11031976|NCT04554407|Experimental|Treatment Group|All participants receive the SOMAVAC® 100 Sustained Vacuum System
11031977|NCT04554394|Experimental|CellFX Treated Wart Lesion|CellFX device using pre-defined energy protocols
11031978|NCT04554381|Experimental|JL1|JL1 on acute leukemia
11031979|NCT04554381|Experimental|JL1 and acute leukemia|Assesment of JL1 expression on acute leukemia
11031980|NCT04554368||IA-CEFDCT group|95 patients who underwent IA-CEFDCT and MT for acute anterior stroke.
11031981|NCT04554355|Experimental|Intervention group|Participants in this group will receive a three-month PA intervention (60 minutes/session, two sessions/week).
11031982|NCT04554355|No Intervention|Control group|No intervention will be provided, participants in this group need to attend the regular school activities as normal.
11031983|NCT04554342|Experimental|healthy participants starting with candy V01|healthy participants testing a candy in 5 different variations by (unstimulated and stimulated) salivary flow rate (before and after comparison)
11031984|NCT04554342|Experimental|healthy participants starting with candy V02|
11031989|NCT04554329|Active Comparator|eye patching|Antibiotic eye ointment was applied on the eye, and the eye was covered with a patch at the end of the surgery.
11031990|NCT04554316|Active Comparator|Parallel placement|Steri-strips will be placed in-line (parallel) with the surgical incision.
11031991|NCT04554316|Active Comparator|Perpendicular placement|Steri-strips will be placed perpendicular to the surgical incision.
11031992|NCT04554303||S-amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
11031993|NCT04554303||Amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
11031994|NCT04554290||positive temporal artery biopsy|all adult patients with significant inflammation shown on temporal artery biopsy
11031995|NCT04554277|No Intervention|Control|Usual management of heart failure. The sST-2 level will be blunted.
11031996|NCT04554277|Experimental|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
11031997|NCT04554238|Experimental|Armeo spring group|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.
11031998|NCT04554238|Active Comparator|Occupational Therapy group|It consists of 5 weeks of intervention, with 3 treatment sessions per week, 40 minutes each time. The patient performs active exercises of the paretic upper limb: bimanual play activities, weight bearing, reaches in various planes of motion that favor shoulder flexion, elbow extension, forearm supination, and dissociated finger movements. In addition to passive mobilizations of the shoulder, elbow and wrist and tactile and proprioceptive sensory stimulation and the use of paretic limbs as support or carrying out prehensions.
11031999|NCT04554225||Pulmonary disease patients|Patients with COPD or other pulmonary disease starting to use ambulatory oxygen therapy
11032000|NCT04554212|Active Comparator|Knee Aspiration, BFRT|Participants will receive a knee aspiration and an intraarticular injection of saline (0.9%) at baseline visit. Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
11032001|NCT04554212|Active Comparator|Sham Aspiration, BFRT|Patients will receive a sham knee aspiration (subcutaneous lidocaine injection) at baseline visit. Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
11032002|NCT04554212|Active Comparator|Knee Aspiration, Sham BFRT|Participants will receive a knee aspiration and an intraarticular injection of saline (0.9%) at baseline visit. Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
11032003|NCT04554212|Sham Comparator|Sham Aspiration, Sham BFRT|Patients will receive a sham knee aspiration (subcutaneous lidocaine injection) at baseline visit. Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
11032004|NCT04554199|Experimental|EEG and MMSE measurements before receiving RPD|EEG and MMSE were measured for all participant before wearing the removable partial dentures.
11032005|NCT04554199|Experimental|EEG and MMSE measurements after receiving RPD|EEG and MMSE were measured for all participant after wearing the removable partial dentures
11032006|NCT04554186|Experimental|Serratus anterior plane block|20 patients will receive SAP block with 0.4 ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
11032007|NCT04554186|Active Comparator|Thoracic Paravertebral block|20 patients will receive TPVB 0.4ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
11032008|NCT04554186|Placebo Comparator|Control group|20 patients will receive Fentanyl patch 50 microgram
11032009|NCT04554173||surgical resection neurogenic tumors|
11032010|NCT04554147|Experimental|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.
~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
11032011|NCT04554121|Experimental|Brain Basics|Brain Basics is a cognitive remediation intervention that emphasizes training in early auditory processing.
11032012|NCT04554121|Active Comparator|Brain Training|Brain Training is a cognitive remediation intervention that targets a range of cognitive abilities
11032013|NCT04554108|Active Comparator|Intravenous antibiotic treatment|Intravenous antibiotic treatment started during an initial hospitalization of 3 days, with continuation of oral antibiotic therapy at home for a total duration of antibiotic therapy of 3 weeks
11032014|NCT04554108|Experimental|oral antibiotic treatment|Oral antibiotic treatment started in hospital then continued at home for a total duration of 3 weeks of antibiotic therapy
11032015|NCT04554082||Preoperative Clinical characteristics and metabolic biomarkers|BMI and biochemical parameters including trace elements in patients undergoing laparoscopic sleeve gastrectomy before surgery
11032016|NCT04554082||9 months' Postoperative metabolic biomarkers|BMI and biochemical parameters including trace elements in patients 9 months after laparoscopic sleeve gastrectomy
11032017|NCT04554056|Experimental|MW05 300μg/kg|Subjects will receive MW05(300 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
11032018|NCT04554056|Experimental|MW05 500μg/kg|Subjects will receive MW05(500 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
11032019|NCT04554056|Active Comparator|PEG-rhG-CSF|Subjects will receive PEG-rhG-CSF(100 μg/kg s.c.) on day 3 of each cycle (6~10 a.m.)
11032021|NCT04554043|Experimental|SHR7280 dose 2(male)|oral administration for 14 days,Phase I(PART 1)
11032022|NCT04554043|Experimental|SHR7280 dose 3(male)|oral administration for 14 days,Phase I(PART 1)
11032023|NCT04554043|Experimental|SHR7280 dose 4(male)|oral administration for 14 days,Phase I(PART 1)
11032024|NCT04554043|Experimental|SHR7280 dose 5(male)|oral administration for 14 days,Phase I(PART 1)
11032025|NCT04554043|Experimental|SHR7280 dose 1(female)|oral administration for 21 days,Phase I(PART 2)
11032026|NCT04554043|Experimental|SHR7280 dose 2(female)|oral administration for 21 days,Phase I(PART 2)
11032027|NCT04554043|Experimental|SHR7280 dose 3(female)|oral administration for 21 days,Phase I(PART 2)
11032028|NCT04554043|Experimental|SHR7280 dose 4(female)|oral administration for 21 days,Phase I(PART 2)
11032029|NCT04554017|Experimental|Intervention arm - All participant (Single arm)|Participants received education or health talks on dietary and physical activity behaviours linked to hypertension
11032030|NCT04554004|Experimental|Study group|All consecutive patients undergoing outine CT angiography and dynamic CT-myocardial perfusion imaging(MPI) will be potentially eligible for inclusion in the trial. Assessment of coronary stenosis severity using invasive fractional flow reserve (FFR) and the status of myocardial microcirculation perfusion including coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed as part of invasive coronary angiography(CAG).
11032031|NCT04553991|Active Comparator|QL block group|For the ultrasound-guided quadratus lumborum block group, the patient was placed in lateral position . QL was identified medial to the aponeurosis of transversus abdominis muscle. Then the needle was inserted from supero-anterior to postero-inferior and advanced using in plane technique till the needle tip reached the anterolateral border of the QL at its junction with transversalis fascia.An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
11032032|NCT04553991|Active Comparator|TAP block group|For the ultrasound-guided TAP block,The probe was placed in the mid-axillary line above the level of the anterior superior iliac spine, then slided cranially till the three abdominal wall muscles identified (External oblique muscle (EAO), internal oblique muscle (IOM) and transverse abdominis muscle (TAM)). The needle was advanced using in-plane technique till it reached the transvers abdominis plane. An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
11032033|NCT04553978|Experimental|Treatment A|"After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.
~Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary."
11032034|NCT04553978|Experimental|Treatment B|"At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.
~Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary."
11032035|NCT04553952||Gummy smile (GS(+))|
11032036|NCT04553952||Gumms smile(GS(-))|
11032037|NCT04553939|Experimental|Toripalimab in Combination With Gemcitabine Therapy|
11032038|NCT04553913|Experimental|cooling device placed|A basic medical grade cooling pad will be secured to the non operative leg. Intermittent coolness will be assessed and subject will inform recovery room staff when sensation returns.
11032039|NCT04553887|Experimental|Cohort 1|Previously treated NSCLC patients with EGFR exon 20 insertion mutantion
11032040|NCT04553887|Experimental|Cohort 2|NSCLC Patients with uncommon EGFR Mutation
11032041|NCT04553861||Healthy subjects|Healthy subjects without blood pressure difference on both arm
11032042|NCT04553848|Experimental|Augmented Reality+ Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) incorporating augmented feedback games chosen to address clinically perceived deficits using the C-Mill training system.
11032043|NCT04553848|Active Comparator|Treadmill training|Participants allocated to this group will receive treadmill training with body weight support (BWS) using the C-Mill training system.
11032044|NCT04553848|Active Comparator|Over ground training/standard of care|Participants allocated to this group will receive over ground balance and mobility training that would be considered standard of care in outpatient rehabilitation.
11032045|NCT04553835|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
11032046|NCT04553835|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
11032047|NCT04553835|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
11032048|NCT04553835|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
11032049|NCT04553822|Experimental|Assisted autogenous drainage group (DAA)|The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes.
11032050|NCT04553822|Experimental|Group prolonged slow expiration (ELPr)|This technique is applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume.
11032051|NCT04553822|Active Comparator|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer.
11032052|NCT04553809|Active Comparator|Kontrol|Patients undergoing examination for lung cancer with the use of electromagnetic navigation bronchoscopy for biopsy sampling
11032053|NCT04553809|Experimental|Intervention|Patients undergoing examination for lunge cancer with the use of electromagnetic navigation bronchoscopy and radial endobronchial ultrasound for biopsy sampling.
11032054|NCT04553796||diabetic participants|
11032055|NCT04553796||prediabetic participants|
11032056|NCT04553796||non diabetic participants|
11032057|NCT04553770|Active Comparator|Arm A (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
11032058|NCT04553770|Experimental|Arm B (trastuzumab deruxtecan, anastrozole)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle and anastrozole PO QD on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
11032059|NCT04553757||Observational (survey)|Patients complete a seizure assessment survey over 5 minutes at each clinic visit.
11032060|NCT04553744||Observational (survey)|Participants complete an online survey over 5-10 minutes asking how they would manage lymph node basins in the extremity sarcoma.
11032061|NCT04553731|Experimental|mHealth group|
11032062|NCT04553731|No Intervention|general care|
11032063|NCT04553718|Experimental|experimental|
11032064|NCT04553705|Experimental|Omega-3/thymoquinone supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA) (3% thymoquinone) per day for one month.
~In addition to the standard care"
11032065|NCT04553705|Experimental|Omega-3/thymoquinone / Indian Costus supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.
~In addition to the standard care"
11032066|NCT04553705|Experimental|Omega-3/thymoquinone / Quinine pills|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.
~In addition to the standard care"
11032067|NCT04553705|Experimental|Omega-3/thymoquinone / Anise seed capsule|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.
~In addition to the standard care"
11032068|NCT04553705|Experimental|Omega-3/thymoquinone / Deglycyrrhizinated Licorice|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.
~In addition to the standard care"
11032069|NCT04553705|Active Comparator|Active Comparator: standard care|The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia
11032070|NCT04553692|Experimental|IGM-8444 Single Agent Escalation|IGM-8444 will be administered intravenously as a single agent.
11032071|NCT04553692|Experimental|IGM-8444 Single Agent Alternate Dosing Escalation|IGM-8444 will be administered intravenously as a single agent on an alternate dosing schedule.
11032072|NCT04553692|Experimental|IGM-8444 + FOLFIRI Escalation|IGM-8444 will be administered intravenously in combination with FOLFIRI.
11032073|NCT04553692|Experimental|IGM-8444 Single Agent Expansion|IGM-8444 will be administered intravenously as a single agent in disease specific cohorts.
11032074|NCT04553692|Experimental|IGM-8444 + FOLFIRI Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI.
11032075|NCT04553692|Experimental|IGM-8444 + FOLFIRI + Bevacizumab Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI with bevacizumab.
11032076|NCT04553666|Experimental|Intervention Group|Four 200mg EGCG pills and one 250mg Vitamin C pill taken one time each day
11032077|NCT04553666|No Intervention|Usual Care Group|No study pills
11032078|NCT04553653|No Intervention|Baseline|Data on diagnosis and care of patients presenting with acute severe hypertension will be collected at baseline (prior to the implementation of a checklist)
11032079|NCT04553653|Experimental|Intervention arm|The intervention arm will be enrolled after the checklist implementation.
11032080|NCT04553640|Experimental|Group A/Intervention Curriculum|Virtual patient (VP) cases and feedback available through solving VP cases and participants' self-report on the diagnosis of dizzy patients in the emergency department.
11032081|NCT04553640|Active Comparator|Group B/Control curriculum|Online articles on dizziness AND regular emergency department clinical rotations
11032082|NCT04553627|Experimental|Interventional cohort|Zeltiq system is a thermoelectric device that applies controlled cooling ot skin. The CoolAdvantage applicators use gentle vacuum pressure to draw tissue into the cup shaped applicator. A gelpad is applied to skin to improve thermal coupling between participant and the applicator cooling surface.
11032083|NCT04553614|Active Comparator|Exercise Referral Scheme|The active Sefton (AS_ERS) is a traditional exercise referral programme providing highly discounted access to council operated leisure centres and a number of partner gyms. Within this access patients will have access to gym and swimming facilities (£2 per visit) and exercises classes (£3 per visit). During the patients first meeting with their LDO a progressive personalised exercise programme will be developed. Following this the patient will attend their local gym or leisure centre for an induction with a staff member(£7 one off fee), enabling them to attend the centre at any time and complete the designed exercise programme. All exercise programmes will be different, but in general will include moderate intensity exercise on gym equipment (treadmill, ergometer etc.) and some basic resistance training. Patients may replace these gym sessions with exercises classes run by the facility. Patients will be encouraged to exercise 3-5 time per week.
11032084|NCT04553614|Experimental|Home-based HIIT|Participants will be instructed to complete each training session in a place of their choosing. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest. During the intervals participants will be advised to reach a heart rate of approx. 90% of their predicted maximum heart rate (220-age). The 1 minute interval will be split between 2 consecutive 30 second exercises. The research team have a library of 18 exercises, with 9 suggested exercise pairs. The participant will be advised to complete 4 intervals during weeks 1 and 2, with the number of intervals increasing by 1 every 2 weeks (maximum of 9 intervals). The participant will be advised to train 3x per week.
11032085|NCT04553601|Experimental|8F-FDG PET/CT and PET/CT-guide targeted biopsy|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time.
11032086|NCT04553588|Active Comparator|Opioid Disposal Pouch|an opioid disposal pouch to inactivate and dispose of unused opioid medication within the first 30 days after surgery
11032087|NCT04553588|No Intervention|Usual Care|usual medication disposal includes multiple options as desired by patient; for example, flushing down toilet, giving to local pharmacist, giving to police department etc.
11032088|NCT04553575||CoViD-19 patients cohort|Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
11041897|NCT04485728|No Intervention|Standard of Care (Control)|
11032089|NCT04553562|Experimental|Acupuncture group|For acupuncture group, sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads. The participants will be treated three times a week, on alternate days, for 6 successive weeks; 18 sessions for each patient in total.
11032090|NCT04553562|Sham Comparator|Sham acupuncture group|For the sham acupuncture group, aterile adhesive pads will be placed after skin disinfection on the acupoints and needles with a blunt tip will be inserted at the same acupoints in the acupuncture group without penetrating the skin.No manipulation of needles will be conducted. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
11032091|NCT04553562|No Intervention|Waiting list group|For the waiting list group, patients will receive no treatment in the first 6 weeks and will receive the same treatment used in the acupuncture group according to patients' preference.
11032092|NCT04553549||Transradial approach|"The procedure will be done using standard criteria as per operator preference. All interventional cases at our institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
11032093|NCT04553536|Active Comparator|Opioid analgesics|Mu-opioid receptor agonists (remifentanil, sulfentanil) will be used as the only analgesic(s) in the surgery.
11032094|NCT04553536|Experimental|Ketamine|Esketamine will be used as the only anagesic in the surgey.
11032095|NCT04553523|Other|Single Arm|Subjects with mild to moderate POAG undergoing cataract surgery & implantation of the Hydrus Microstent
11032096|NCT04553510|Experimental|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
11032097|NCT04553510|Active Comparator|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
11032098|NCT04553497|Active Comparator|Rehabilitation and interferential current therapy|Flipping a coin was used for simple randomization (tails - interferential current). In this arm, interferential current therapy was applied to the patients in addition to the rehabilitation program.
11032099|NCT04553497|Sham Comparator|Rehabilitation and sham interferential current therapy|Flipping a coin was used for simple randomization (heads - sham). In this arm, sahm interferential current therapy was applied to the patients in addition to the rehabilitation program.
11032100|NCT04553484|Experimental|Measuring cardiovascular performance and blood flow|
11032101|NCT04553471|Experimental|SBRT|5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
11032102|NCT04553458||Favorable outcome|Cure or stable disease
11032103|NCT04553458||Unfavorable outcome|Progressive (deteriorate/Recurrence) or Death
11032104|NCT04553445|Experimental|Chronotype|Determination whether monthly migraine load is affected by exercise in sync with chronotype
11032105|NCT04553445|Experimental|Green exercise|Determination whether monthly migraine load is affected by exercise in a natural environment
11032106|NCT04553432|Experimental|Omnigen + OmniLenz|Omnigen amniotic membrane 17mm disk with 6mm central aperture place under 18mm OmniLenz bandage contact lens
11032107|NCT04553432|Active Comparator|OmniLenz|Bandage contact lens alone
11032108|NCT04553419|Experimental|Cephalexin|Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
11032109|NCT04553419|Placebo Comparator|Placebo|The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
11032110|NCT04553406|Experimental|SPR720 low dose|SPR720 500 mg (2 capsules of 250 mg SPR720 and 2 capsules of placebo) administered orally once daily for 28 days
11032111|NCT04553406|Experimental|SPR720 high dose|SPR720 1000 mg (4 capsules of 250 mg SPR720) administered orally once daily for 28 days
11032112|NCT04553406|Placebo Comparator|Placebo|4 capsules of placebo once daily for 28 days
11032113|NCT04553406|Active Comparator|Standard of Care (SOC)|"Clarithromycin 500-1000 mg plus ethambutol HCl 15 mg/kg po once daily or Azithromycin 250-500 mg plus ethambutol HCl 15 mg/k po once daily. Optional rifampin 600 mg or rifabutin 300 mg po once daily may be added to the SOC regimen for up to 28 days.
~Additional SOC treatments may be considered in consultation with the medical monitor."
11032114|NCT04553393|Active Comparator|Tandem CAR19/20 engineered T cells|Tandem dual Specificity targeting CD19 and CD20 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.
11032115|NCT04553393|Experimental|Tandem CAR19/20 engineered T cells plus chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
11032116|NCT04553393|Experimental|Tandem CAR19/20 engineered T cells plus decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
11032117|NCT04553393|Experimental|Tandem CAR19/20 engineered T cells plus chidamide+decitabine|The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance
11032118|NCT04553380|Experimental|community patient group|The community doctor adjusts the basic insulin dosage daily according to the fasting blood glucose of the patient under the guidance of the specialist.
11032119|NCT04553380|Active Comparator|inpatient group|Endocrinologists in the in-patient department use the same basic insulin dose adjustment regimen to treat patients.
11032120|NCT04553367|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
11032176|NCT04553029||Group 4: Post-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
11032729|NCT04549415|Active Comparator|metformin|Metformin, 1000 mg b.i.d, 12 months
11032121|NCT04553367|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
11032122|NCT04553328|Active Comparator|Group T|Group (T) received ultrasound guided (US) combined ipsilateral transverse abdominis plane (TAB) and ilioinguinal- iliohypogastric (ILIH) nerve block
11032123|NCT04553328|Active Comparator|Group I|Group (I) received US guided ipsilateral illioinguinal- illiohypogastric nerve block only.
11032124|NCT04553315|Experimental|intervention group|Intervention group was received Chest mobility exercises with Incentive spirometer and segmental breathing exercise and breath stacking technique . The patient in the intervention group was instructed to perform the exercises 3 times per day, 7-8 times per session for one week. Ensure that the patient fully hydrated by maintaining normal daily water requirement in the form of (30-35ml/kg/day) with restriction of intravenous fluids.
11032125|NCT04553315|Experimental|control group|control group will receive only routine hospital care
11032126|NCT04553302||Psoriatic Arthritis|Patients diagnosed with PsA according to CASPAR criteria by the rheumatologist were included.
11032127|NCT04553302||Rheumatoid Arthritis|Patients diagnosed with RA according to ACR / EULAR 2010 criteria by the rheumatologist were included.
11032128|NCT04553302||Asymptomatic Healthy Group|Participants had any neurological and/or rheumatological diseases, no complaints about the upper extremity. Participants diagnosed with OA according to traditional clinical criteria were excluded from the study.
11032129|NCT04553289|Experimental|exercising into pain|The participants will train during 12 with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. One exercise will be performed with pain ranging between 4 and 7 on a NPRS (Numeric Pain Rating Scale) and the rest of the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. At week 9, patients will continue to exercise with pain between 0 and 2 in all exercises. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
11032130|NCT04553289|Active Comparator|exercising with no/slight pain|The participants will train during 12 weeks with progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, including 2 in closed kinetic chain exercises and 2 executed with the elastic band or with dumbbell/weight. All the exercises will be performed with no/slight pain, ranging between 0 and 2 on NPRS. 10/15 minutes of manual therapy (posterior capsular release) will be applied during the physiotherapy session.
11032131|NCT04553263|Experimental|Contrave|Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
11032132|NCT04553263|Experimental|Bupropion|Participants will receive daily extended-release oral bupropion (Wellbutrin XL) at a dose of 450 mg. The dose will be titrated: 150 mg on Days 1 and 2, 300 mg on Days 3 and 4, and 450 mg on Day 5. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone. A reduction to 300 mg will permitted to alleviate medication-related adverse effects if they occur.
11032133|NCT04553263|No Intervention|Treatment As Usual|Participants will complete inpatient treatment as usual and will not receive any medication. This arm serves as a TAU control to compare outcomes versus Bupropion and Contrave arms.
11032134|NCT04553250|Active Comparator|Conventional technique|"In this group, double-staple colorectal anastomosis will be performed following the technique described by Lee et al: Prior to firing the endostapler, a suture will be placed on the rectal stump that includes both dog ears. After the punch comes out of the endostapler, the point will be tied, which will invaginate the two corners of the staple line on the same punch. Subsequently, the endostapler will be closed and fired, including the dog ears in the anastomotic rims"
11032135|NCT04553250|Active Comparator|Lateral invagination technique|In this group, the circular endostapler will be fired in a conventional way, that is, without having invaginated the two corners of the staple line.
11032136|NCT04553237||Patients over 90 years old|
11032137|NCT04553237||Patients between 70 and 89 years of age.|
11032138|NCT04553224|Other|All Subjects|Clinical and instrumental measurements
11032139|NCT04553211|Experimental|Expedited Partner Therapy (EPT)|Participants in the EPT arm will receive up to five partner antibiotic treatment packets to deliver to their recent sexual partners following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The intervention will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
11032140|NCT04553211|No Intervention|Control|Participants in the control arm will receive standard-of-care counseling on partner notification following a diagnosis of gonorrhea (GC) and/or chlamydia (CT). The same counseling will be repeated with all subsequent episodes of GC and/or CT infection during the 12-month follow-up period.
11032141|NCT04553198|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 3 weeks.
11032142|NCT04553198|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 3 weeks.
11032143|NCT04553185||Parkinson's disease patients|Patients with idiopathic or familial Parkinson's disease
11032144|NCT04553172||Affected family members|Affected family members
11032145|NCT04553172||Affected PM|Affected PM
11032203|NCT04552821||Sepsis complicated with mild ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for mild ARDS
11032475|NCT04551144||transwomen|Subjects starting estradiol therapy as part of standard of care for gender incongruence
11032146|NCT04553159|Experimental|Adipose Derived Stem Cell(ADSC) arm|"Participants allocated to this arm will have tumescent liposuction performed on them to obtain lipoaspirate. The lipoaspirate will then be processed to obtain the stromal vascular fraction. This Adipose derived stromal vascular fraction which contains stem cells will then be infiltrated into the keloid tissue as a single dose infiltration.
~This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6)."
11032147|NCT04553159|Active Comparator|Triamcinolone Acetanoide (TAC) arm|Participants in this arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid. This will be a single dose infiltration of 40mg/cubic centimetres of keloids.
11032148|NCT04553146|Experimental|Interventional arm|immediate implant placement in posterior sites using a custom-made sealing socket abutment combined to alveolar ridge preservation
11032149|NCT04553133|Experimental|PF-07104091|CDK2 monotherapy
11032150|NCT04553133|Experimental|PF-07104091 + palbociclib|CDK2 + palbociclib
11032151|NCT04553133|Experimental|PF-07104091 + palbociclib + letrozole|CDK2 + palbociclib + letrozole
11032152|NCT04553120|Experimental|Alternating treatments condition - 10 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
11032153|NCT04553120|Experimental|Alternating treatments condition - 9 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
11032154|NCT04553120|Experimental|Alternating treatments condition - 13 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
11032155|NCT04553120|Experimental|Alternating treatments condition - 12 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
11032156|NCT04553107|Experimental|Deprescribing Intervention|
11032157|NCT04553107|Active Comparator|Usual Care|
11032158|NCT04553094|No Intervention|Group 1|No physical training
11032159|NCT04553094|Experimental|Group 2|Endurance training
11032160|NCT04553094|Experimental|Group 3|Muscle building training
11032161|NCT04553094|Experimental|Group 4|Training combining endurance + muscle building
11032162|NCT04553081|Active Comparator|Dovato|We aim to include 120 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=40) or to switch to the dual regimen DTG/3TC (Dovato) (N=80).
11032163|NCT04553081|Active Comparator|Biktarvy|We aim to include 120 adult HIV-infected patients with HIV RNA < 50 copies/mL for at least 3 months on any stable 2nd generation integrase based triple therapy antiretroviral regimen. Patients will be randomized 1:2 to switch to or stay on the triple regimen BIC/TAF/FTC (Biktarvy) (N=40) or to switch to the dual regimen DTG/3TC (Dovato) (N=80).
11032164|NCT04553068|Experimental|EVO100 gel|EVO100 vaginal gel, 5 g
11032165|NCT04553068|Placebo Comparator|Placebo gel|Placebo vaginal gel, 5 g
11032166|NCT04553055||community pharmacists|
11032167|NCT04553042|Experimental|Treatment Sequence ABC|Participants will receive a single dose of seltorexant as formulation (Test 1) (Treatment A) in Treatment Period 1, followed by a single dose of seltorexant as formulation (Test 2) (Treatment B) in Treatment Period 2, followed by a single dose of seltorexant as formulation (Reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
11032168|NCT04553042|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
11032169|NCT04553042|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
11032170|NCT04553042|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
11032171|NCT04553042|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
11032172|NCT04553042|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
11032173|NCT04553029||Group 1: Peri-menopausal woman|Grouping is based on Peri-menopausal woman
11032174|NCT04553029||Group 2: Post- menopausal woman|Grouping is based on Post-menopausal woman
11032175|NCT04553029||Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS|Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
11032507|NCT04550923|Active Comparator|Control device (rigid) group|Use rigid (PEEK) interbody fusion device .
11032177|NCT04553016|Experimental|1: Vaccine|"At Week 0, volunteers receive 5.0 x 10^10 virus particles (vp) of ChAdOx1.tHIVconsv1 (C1) administered intramuscularly (IM). The dose is divided in 2 and administered in the deltoid muscle of each arm.
~At week 4,1.0 x 10^8 Plaque forming units (PFU) of MVA.tHIVconsv3 (M3) administered IM and 0.9 x 10^8 PFU of MVA.tHIVconsv4 (M4) are administered IM simultaneously, one into the deltoid muscle of each arm."
11032178|NCT04553016|Placebo Comparator|2. Placebo|Normal sterile saline (0.9% Sodium Chloride solution) administered IM as Placebo, the volume is matched to that of the vaccines and administered in the deltoid muscle of each arm at Week 0 and at week 4 .
11032179|NCT04553003|Experimental|glucocorticoid+hepatoprotectant group|glucocorticoid 0.4mg/kg/d+hepatoprotectant for 7d
11032180|NCT04553003|Active Comparator|hepatoprotectant group|hepatoprotectant for 7d
11032181|NCT04552990|Experimental|Tumor Excision, No Illumination|The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.
11032182|NCT04552990|Experimental|PDT treatment with jet-injections|Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.
11032183|NCT04552977|Experimental|fluzoparil+temozolomide|Participants receive fluzoparil and temozolomide
11032184|NCT04552964|Other|Single arm|This will be a single centre, single-arm, prospective pilot study.
11032185|NCT04552951|Active Comparator|Active|Receiving 1 dose of 100.000 iu of Cholecalciferol when the COVID 19 Disease is diagnosed
11032186|NCT04552951|No Intervention|Control|No vitamin D
11032187|NCT04552938||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA between June 2018 and May 2019.
11032188|NCT04552925|Active Comparator|Exercise Group|Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
11032189|NCT04552925|Experimental|EMG-BF Group|EMG-BF group will receive the same exercises as with the other group, but deltoid re-education exercises were performed under the guidance of EMG-BF device. All subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
11032190|NCT04552912|Experimental|Build Stamina Group|The Build StaMINA (Biobehavioral Self-Management INtervention using physical Activity) is a tailored evidence-based physical activity (PA) program designed to improve endurance, strength, and balance which are all areas of physical function, that adults with acute leukemia (AL) post-induction are known to have diminished capacity. The Build StaMINA program will be tailored to their current Physical Function, per assessment. The detailed PA prescription includes each exercise in the program as well as the frequency, number of repetitions each day and rate of perceived exertion (RPE) for each exercise. The repetitions and RPE are based on the participants' current Physical Function Assessment and will be assigned based on our evidence-based algorithm.
11032191|NCT04552912|No Intervention|Attention-Control Group|Participants assigned to the attention control group will have a Physical Function Assessment at baseline after informed consent has been provided and prior to randomization. Participants will also be asked to complete questionnaires regarding at baseline, 6-weeks and 3 months. Those in the attention-control group will also receive a newsletter detailing the benefits of participating in regular PA as well as regular phone calls by study team to discuss general health and wellbeing at the same schedule as intervention group.
11032192|NCT04552899|Experimental|PRM-151|Participants will receive intravenous (IV) infusions of PRM-151 over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
11032193|NCT04552899|Placebo Comparator|Placebo|Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
11032194|NCT04552886|Experimental|Dendritic cell vaccine: Starting dose|This arm will evaluate the safety of administering a total dendritic cell dose of 3.5 x 10^6. A total of 3-6 patients will be enrolled with this dose. If this dose is associated with unacceptable side effects, as detailed in the study protocol, no further patients will be enrolled at this dose.
11032195|NCT04552886|Experimental|Dendritic cell vaccine dose de-escalation|If unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 1.75 X 10^6.
11032196|NCT04552886|Experimental|Dendritic cell vaccine dose escalation one|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 3.5 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 7.0 X 10^6.
11032197|NCT04552886|Experimental|Dendritic cell vaccine dose escalation two|If no unacceptable side effects, as detailed in the study protocol, are identified at a total dose of 7.0 x 10^6, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1.4 X 10^7.
11032198|NCT04552873|Experimental|EXPERIMENTAL GROUP|the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)
11032199|NCT04552873|Placebo Comparator|CONTROL GROUP|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
11032200|NCT04552860|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
11032201|NCT04552847|Experimental|Patients|"In the main part of the trial (part A) 75 patients with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/CT scan.
~In part B of the trial 10 up to 20 patients with with cytologically and/or histologically confirmed neuroendocrine tumors of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin will receive a single intravenous injection of Al18F-NOTA-octreotide. At two hours after tracer injection they will undergo a whole-body PET/MR scan."
11032202|NCT04552821||Control|Non-sepsis and non-ARDS adults receiving mechanical ventilation
11032204|NCT04552821||Sepsis complicated with moderate/severe ARDS|Patients who meet the criteria of sepsis-3, and also meet the criteria of Berlin diagnostic for moderate/severe ARDS
11032205|NCT04552808|Experimental|Yimitasvir Phosphate Capsules|The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A
11032206|NCT04552795|Experimental|Open-Label 3TC|12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
11032207|NCT04552782|Experimental|Alcohol CBM + PTSD CBM|
11032208|NCT04552782|Experimental|Alcohol CBM + PTSD Sham|
11032209|NCT04552782|Experimental|Alcohol Sham + PTSD CBM|
11032210|NCT04552782|Sham Comparator|Alcohol Sham + PTSD Sham|
11032211|NCT04552769|Experimental|Abemaciclib|Each cycle of therapy will be 28 days long. A completed cycle will be twice daily abemaciclib. Number of Cycles: until progression or unacceptable toxicity develops
11032212|NCT04552756|Experimental|Patients irradiated for high-grade glioma|Participants who receive radiotherapy or radiochemotherapy for glioblastoma (grade IV), anaplastic astrocytoma (grade III) or anaplastic oligodendroglioma (grade III).
11032213|NCT04552743|Experimental|MGTA-145 and Plerixafor HSC Mobilization|Patients after screening will undergo baseline evaluation during the premobilization phase up to 30 days before mobilization. Patients will undergo sequential administration of plerixafor 0.24 mg/kg subcutaneously followed 2 hours later by MGTA-145 at 0.03 mg/kg intravenously (3 to10 minute infusion). This will be followed by apheresis. A second day of mobilization and apheresis will be pursued in patients who have not collected 6.0 x 106 CD34+ cells/kg in one session.
11032214|NCT04552717|Other|Intervention|"Participants will complete a web based pre-assessment and then given access to the app Grief Coach for three months followed by a web based post-assessment and an interview via telephone regarding their experiences of using the app."
11032215|NCT04552704|Experimental|Phase I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 with standard of care (i.e., steroids per treating physician and best supportive care) in the absence of disease progression or unacceptable toxicity.
11032216|NCT04552704|Experimental|Phase II, Arm I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
11032217|NCT04552704|Placebo Comparator|Phase II, Arm II (placebo)|Patients receive placebo IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
11032218|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation, Parent Education|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum) and Parent Education
11032219|NCT04552678|Experimental|Healthy Eating, Active Play, Self-Regulation|Classrooms receive all curricula (Food Literacy, Healthy Eating, Active Play, Self-Regulation Curriculum), but no Parent Education
11032220|NCT04552678|Experimental|Healthy Eating, Active Play, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, and Parent Education
11032221|NCT04552678|Experimental|Healthy Eating + Active Play|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Active Play Curriculum, but no Parent Education
11032222|NCT04552678|Experimental|Healthy Eating, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, and Parent Education
11032223|NCT04552678|Experimental|Healthy Eating + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, the Self-Regulation Curriculum, but no Parent Education
11032224|NCT04552678|Experimental|Healthy Eating + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, and Parent Education
11032225|NCT04552678|Experimental|Healthy Eating Only|Classrooms receive the core Food Literacy Curriculum, the Healthy Eating Curriculum, but no Parent Education
11032226|NCT04552678|Experimental|Active Play, Self-Regulation, Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, and Parent Education
11032227|NCT04552678|Experimental|Active Play + Self-Regulation|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, the Self-Regulation Curriculum, but no Parent Education
11032228|NCT04552678|Experimental|Active Play + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, and Parent Education
11032229|NCT04552678|Experimental|Active Play Only|Classrooms receive the core Food Literacy Curriculum, the Active Play Curriculum, but no Parent Education
11032230|NCT04552678|Experimental|Self-Regulation + Parent Education|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, and Parent Education
11032231|NCT04552678|Experimental|Self-Regulation Only|Classrooms receive the core Food Literacy Curriculum, the Self-Regulation Curriculum, but no Parent Education
11032232|NCT04552678|Experimental|Food Literacy + Parent Education|Classrooms receive the core Food Literacy Curriculum, and parents are invited to complete web-based education modules.
11032233|NCT04552678|Experimental|Food Literacy Only|Classrooms only receive the core Food Literacy Curriculum, and no other intervention materials or parent education.
11032234|NCT04552665||Adults|Patients who have cardiac arrhythmia
11032235|NCT04552652|Experimental|High-intensity interval training - telerehabilitation|12 weeks of high-intensity interval training. Three sessions per week will be performed (36 total sessions).
11032236|NCT04552652|Active Comparator|Moderate-intensity continuous training - telerehabilitation|12 weeks of moderate-intensity continuous training. Three sessions per week will be performed (36 total sessions).
11032237|NCT04552639|Active Comparator|Treatment as usual|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, excluding the NEAT group.
11032238|NCT04552639|Experimental|Treatment as usual and NEAT group|Treatment as usual is offered. This includes; individual therapy, group therapy, dietetic support, occupational therapy, nursing and psychiatry, alongside NEAT group.
11032239|NCT04552626|Experimental|Prolonged sitting (social breaks)|
11032240|NCT04552626|Experimental|Prolonged sitting with step-up exercise break|
11032241|NCT04552626|Experimental|Prolonged sitting with simple resistance activity breaks|
11032242|NCT04552613|Experimental|Standard programme group|EGFR-TKI targeted therapy
11032243|NCT04552613|Active Comparator|controlled programme group|EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
11032244|NCT04552600|Experimental|NuvastaticTM 1000 mg|NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months.
11032245|NCT04552600|Active Comparator|Placebo|NuvastaticTM (without active) will be given orally, three times per day for 12 months
11032246|NCT04552587|Experimental|HEART|Patients and caregivers will complete a HEART visit virtually or in person. The visit includes a needs assessment that generates a tailored care plan with messages, referrals and educational materials for discussion with a nurse. Caregivers will receive brief training about the HEART App and then use the App for 4 weeks with bi-weekly real-time prompts and feedback.
11032247|NCT04552574|Experimental|Intervention group|All subjects will intake HMR(Home meal replacement)-type omega-3-balanced-diet for 4 weeks.
11032248|NCT04552574|No Intervention|Control group|No intervention for 4 weeks.
11032249|NCT04552561|Experimental|My MS Toolkit|10 Participants asked to use My MS Toolkit and meet weekly with a study coach via telephone.
11032250|NCT04552548|No Intervention|Control group|the patients will receive regular analgesics (1 µg /kg fentanyl with induction and 15mg/kg paracetamol before extubation)
11032251|NCT04552548|Active Comparator|TAP group|the patients will receive bilateral TAP block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
11032252|NCT04552548|Active Comparator|quadratus lumborum group|the patients will receive bilateral quadratus lumborum block using (0.5 ml/ kg bupivacaine 0.25%) in each side + regular analgesics.
11032253|NCT04552535||Second line (2L) afatinib|Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
11032254|NCT04552535||Second line (2L) chemotherapy|Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
11032255|NCT04552522|Experimental|Shrimp allergy with Intend to eat shrimp|Case shrimp Immunoglobulin E mediated allergy and intend to eat shrimp and start oral immunotherapy for shrimp
11032256|NCT04552522|No Intervention|Shrimp allergy with avoid shrimp|Case shrimp allergy with avoid shrimp
11032257|NCT04552509|Other|Observation|Observational study of patient efficacy and side effects
11032258|NCT04552483|Experimental|Nitazoxanide|Patients received nitazoxanide 500mg 8/8hours, for 5 days.
11032259|NCT04552483|Placebo Comparator|Placebo|Patients received placebo 500mg 8/8hours, for 5 days.
11032260|NCT04552470|Placebo Comparator|Placebo|
11032261|NCT04552470|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
11032262|NCT04552470|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
11032263|NCT04552470|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
11032264|NCT04552457|Experimental|No activity restrictions|
11032265|NCT04552457|Active Comparator|Activity restrictions|
11032266|NCT04552444||the death group|Through the corresponding treatment, the patients who died within 28 days
11032267|NCT04552444||the survival group|Through the corresponding treatment, the patients who survived within 28 days
11032268|NCT04552431|Placebo Comparator|Placebo|Men assigned to placebo
11032269|NCT04552431|Experimental|Ciprofloxacin alone|Men assigned to Ciprofloxacin alone
11032270|NCT04552431|Experimental|Tamsulosin alone|Men assigned to Tamsulosin alone
11032271|NCT04552431|Experimental|Combination of ciprofloxacin and tamsulosin|Men assigned to a combination of ciprofloxacin and tamsulosin
11032272|NCT04552418|Experimental|Potato-based dietary starch supplement|Patients undergoing cancer treatment with dual immune checkpoint inhibitors (ICI) will receive potato-based dietary starch supplements.
11032273|NCT04552405|Other|FAP patients|FAP patients who underwent prophylactic total colectomy
11032274|NCT04552379|Active Comparator|Interferon|Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
11032275|NCT04552379|No Intervention|Standard of Care|Standard of Care; following national guidelines regarding self-isolation and infection prevention
11032276|NCT04552366|Experimental|Group A: Intramuscular administration|24 subjects. 5E10 VP of Ad5-nCoV on Day 0 and on Day 56.
11032277|NCT04552366|Experimental|Group B: Mixed administration|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0 and a mucosal administration of 2E10 VP on Day 28.
11032278|NCT04552366|Experimental|Group C: Mucosal administration, high dose|24 subjects. A mucosal administration of 2E10 VP of Ad5-nCoV on Day 0 and Day 28.
11032279|NCT04552366|Experimental|Group D: Mucosal administration, low dose|24 subjects. A mucosal administration of 1E10 VP of Ad5-nCoV on day 0 and Day 28.
11032280|NCT04552366|Active Comparator|Group E: Intramuscular administration, one dose|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0.
11032281|NCT04552366|Experimental|Group F: Intramuscular administration, two doses|24 subjects. Two intramuscular administrations of 5E10 VP of Ad5-nCoV at left and right arms on day 0.
11032282|NCT04552353|Experimental|Vaway Lyo-Injection|Voriconazole, 200 mg/vial
11032283|NCT04552353|Active Comparator|Vfend Lyo-Injection|Voriconazole, 200 mg/vial
11032284|NCT04552327|Experimental|Solcera|
11032285|NCT04552327|Placebo Comparator|Placebo|
11032286|NCT04552327|Active Comparator|Solaraze|
11032287|NCT04552314||patients after primary MMC-augmented trabeculectomy|
11032288|NCT04552301|Experimental|Cognitive Processing Therapy and Targeted Asthma Education|Intervention group - Cognitive Processing Therapy and Targeted Asthma Education
11032289|NCT04552301|Active Comparator|Psychotherapy and General Asthma Education|Control group - Psychotherapy and General Asthma Education
11032290|NCT04552288|Experimental|Participants with eosinophil-related cutaneous events|Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
11032291|NCT04552275|Other|HALT Cohort|Patients who develop HALT
11032292|NCT04552275|Other|Control Group|Patients who do not develop HALT
11032690|NCT04549636||asthmatic COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have asthma
11032293|NCT04552262|Experimental|BAY2327949 / Placebo|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
11032294|NCT04552262|Experimental|Placebo / BAY2327949|Each participant will receive two treatments: a single dose of 90 mg BAY 2327949 (Treatment A) and a single dose of placebo to BAY 2327949 (Treatment B), with a washout period of at least 7 days before the second treatment.
11032295|NCT04552249||Group 1|
11032296|NCT04552249||Group 2|
11032297|NCT04552249||Group 3|
11032298|NCT04552249||Group 4|
11032299|NCT04552249||Group 5|
11032300|NCT04552249||Group 6|
11032301|NCT04552223|Experimental|Nivolumab Plus Relatlimab Group|Participants in this group will receive Nivolumab and Relatlimab administered together on Day 1 of every 4 week cycle. Both drugs will be administered until disease progression or intolerable toxicity for up to 24 months.
11032302|NCT04552197|Experimental|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
11032303|NCT04552197|Experimental|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
11032304|NCT04552197|Experimental|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
11032305|NCT04552197|Active Comparator|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
11032306|NCT04552197|Experimental|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
11032307|NCT04552197|Experimental|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
11032308|NCT04552184|Active Comparator|GPOEM|
11032309|NCT04552184|Sham Comparator|SHAM|
11032310|NCT04552171|Experimental|Access to Game Plan app and 24-hour helpline|Participants in this condition will be provided access to the Game Plan app and encouraged to use it after they complete their baseline assessments and STI testing has been completed. These participants will also be provided with access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not.
11032311|NCT04552171|No Intervention|Access to a 24-hour helpline|"Participants in this condition will be provided access to a 24-hour helpline that provides free HIV/STI test counseling, which they can elect to use or not. Use of this comparison condition is intended to provide a real-world test of the added benefit of using Game Plan, above and beyond the current standard of care for HIV/STI self-testing, which involves providing users with access to a 24-hour helpline."
11032312|NCT04552158|No Intervention|controlled group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management only
11032313|NCT04552158|Experimental|experimental group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management and nutritional management in the form of the Mediterranean diet
11032314|NCT04552145|Active Comparator|surgery|Decompression surgery
11032315|NCT04552145|Active Comparator|physiotherapy|Physical therapy program
11032316|NCT04552132|Experimental|GentleWave|Patients randomly assigned to the GentleWave group will receive irrigation and activation of irrigants with the GentleWave device (multisonic energy) by Sonendo.
11032317|NCT04552132|Active Comparator|EndoActivator|Patients randomly assigned to the EndoActivator group will receive irrigation via a side-vented needle and activation using the EndoActivator (sonic energy) by Dentsply Sirona.
11032318|NCT04552119||HEALICOIL Knotless Suture REGENESORB|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless REGENESORB
11032319|NCT04552119||HEALICOIL Knotless PEEK|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless PEEK
11032320|NCT04552106|Active Comparator|Group 1|10 subjects
11032321|NCT04552106|Active Comparator|Group 2|10 subjects
11032322|NCT04552106|Active Comparator|Group 3|10 subjects
11032323|NCT04552106|Active Comparator|Group 4|10 subjects
11032324|NCT04552106|Active Comparator|Group 5|10 subjects
11032325|NCT04552093|Experimental|Colorectal liver metastases|Patients with potentially resectable colorectal liver metastases will undergo hepatic artery infusion pump placement. Subsequent hepatic artery infusion of floxuridine via the HAIP as well as standard of care Dutch systemic chemotherapy (FOLFOX or FOLRIRI) will be administered in a combined chemotherapy schedule.
11032326|NCT04552080|Active Comparator|Test: Amoxicillin|
11032327|NCT04552080|Placebo Comparator|Comparator: Placebo|
11032328|NCT04552067|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
11032329|NCT04552067|Active Comparator|Enoxamed|patients are given a curative dose of Enoxaparin (ENOXA)
11032330|NCT04552054|Active Comparator|CT guided localization|Computerized Tomography(CT)-guided percutaneous lung puncture staining marker localization
11032331|NCT04552054|Experimental|MR+3D guided localization|Mixed reality(MR)+3D printing-guided percutaneous lung puncture staining marker localization
11032332|NCT04552041|Experimental|Prospecta|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
11032333|NCT04552041|Placebo Comparator|Placebo|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
11032334|NCT04552015|Other|volunteers|two different types of diagnostic tools (TST vs microneedle) will be used to screen for latent TB infection
11032508|NCT04550910|Other|Arm A|40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy
11032335|NCT04552002|Experimental|Synbiotic group|"Intervention group:
~Will receive synbiotic supplements: one capsule/day. Each capsule contains 20 billion CFU multi-strain probiotics + prebiotics (inulin and oligosaccharides) for a duration of 6 months."
11032336|NCT04552002|No Intervention|Placebo group|Will receive a placebo. The placebo will be similar to the synbiotic supplements in appearance.
11032337|NCT04551989||Participants with EGPA who have received NUCALA treatment|Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.
11032338|NCT04551976|Experimental|Mindful Video Game Then Laundry Group|Receive mindfulness prompt and play their video game first and fold laundry second.
11032339|NCT04551976|Experimental|Mindful Laundry Then Video Game Group|Receive mindfulness prompt and fold laundry first, play their video game second.
11032340|NCT04551976|No Intervention|Control Video Game Then Laundry Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will play their video game first and fold laundry second.
11032341|NCT04551976|No Intervention|Control Laundry Then Video Game Group|Control condition that receives no mindfulness prompt and is asked to complete activities like they normally would. They will fold laundry first and will play their video game second.
11032342|NCT04551963|Experimental|Zanubrutinib + Moderate CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg twice daily (BID) + fluconazole (days 4 - 10), zanubrutinib 320 mg once daily (QD) (days 13 - 19), zanubrutinib 80 mg BID + diltiazem (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
11032343|NCT04551963|Experimental|Zanubrutinib + Strong CYP3A|Cycle 1 (28 days): Zanubrutinib 80 mg QD + voriconazole (days 4 - 10), zanubrutinib 320 mg QD (days 13 - 19), zanubrutinib 80 mg QD + clarithromycin (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
11032344|NCT04551950|Experimental|Cohort 1A:M7824+cisplatin/carboplatin+paclitaxel+bevacizumab|
11032345|NCT04551950|Experimental|Cohort1B:M7824+cisplatin or carboplatin+paclitaxel|
11032346|NCT04551950|Experimental|Cohort 2: M7824+cisplatin+ radiotherapy|
11032347|NCT04551937|Placebo Comparator|Control|4-5 week period where participant will consume control beverage
11032348|NCT04551937|Experimental|Prebiotic|4-5 week period where participant will consume the intervention beverage
11032349|NCT04551924|Experimental|dose 1|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
11032350|NCT04551924|Experimental|dose 2|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
11032351|NCT04551924|Experimental|dose 3|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
11032352|NCT04551924|Experimental|dose 4|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
11032353|NCT04551924|Active Comparator|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
11032354|NCT04551911|Experimental|30 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
11032355|NCT04551911|Placebo Comparator|0 mcg calcifediol Extended-Release (ER) Capsule|Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed.
11032356|NCT04551898|Experimental|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
11032357|NCT04551898|Experimental|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
11032358|NCT04551898|Experimental|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
11032359|NCT04551898|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
11032360|NCT04551885|Experimental|FT516 in combination with avelumab|
11032361|NCT04551872|Experimental|Obese High Risk|200 participants with BMI ≥30 and 10-year ASCVD risk ≥20%
11032362|NCT04551872|Experimental|Obese Low Risk|200 participants with BMI ≥30 and 10-year ASCVD risk <7.5%
11032363|NCT04551872|No Intervention|Non-Obese High Risk|100 participants with BMI 18-25 and 10-year ASCVD risk ≥20%
11032364|NCT04551872|No Intervention|Non-Obese Low Risk|100 participants with BMI 18-25 and 10-year ASCVD risk <7.5%
11032365|NCT04551859|Other|Sacrospinofixation|After accepting the surgeon's proposal to perform a sacrospinofixation to treat the pelvic organ prolapse, participation in this study will be proposed to the patient. It will not change the management or the course of the surgery
11032366|NCT04551846|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
11032367|NCT04551846|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
11032368|NCT04551833|Experimental|Group (T) : 30 patients (Tramadol group)|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 1.5 mg/kg Tramadol.
11032369|NCT04551833|Experimental|Group (D) : 30 patients (Dexamethasone group):|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 8mg of Dexamethasone
11032370|NCT04551820||Regular Hours|These subjects have undergone a cholecystectomy during regular hours at the Institution.
11032371|NCT04551820||After Hours|These subjects have undergone a cholecystectomy during after hours at the Institution.
11032372|NCT04551807|Active Comparator|Modified natural cycle|corpus luteum present
11032373|NCT04551807|Active Comparator|Programmed cycle|corpus luteum absent
11032400|NCT04551586|Experimental|Sequence 2|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).
~Period 2: ACH-0145228 as power-in-capsule under fasted conditions (reference).
~Period 3: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).
~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
11032533|NCT04550728|Active Comparator|Robot|Participants in this group will have ankle robot training only
11032374|NCT04551794|Experimental|Online self-help program with additional peer support|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
11032375|NCT04551794|No Intervention|No intervention: waitlist-control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 9 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
11032376|NCT04551794|Experimental|Online self-help program with therapeutic guidance|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences and difficulties concerning the program on a weekly basis with a therapeutic guide on the phone.
11032377|NCT04551781|Experimental|steroid|20 mg prednisolone for 14 days
11032378|NCT04551781|Placebo Comparator|control|controll
11032379|NCT04551768|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
11032380|NCT04551768|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
11032381|NCT04551755|Active Comparator|Ivermectin plus Doxycycline plus standard care|Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours 2) Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes 3) Standard symptomatic and supportive treatment; Tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements
11032382|NCT04551755|Placebo Comparator|Placebo plus standard care|"1) Standard symptomatic and supportive treatment with placebo; Standard treatment includes tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements.
~Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days"
11032383|NCT04551729|Active Comparator|Fluid restriction|Patient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
11032384|NCT04551729|Experimental|Liberal fluid intake|Patient will receive a lifestyle advice for liberal fluid intake for 3 months.
11032385|NCT04551703|Experimental|Adrenaline saline irrigation|Adrenaline saline irrigation will be prepared by adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000
11032386|NCT04551703|No Intervention|Normal saline irrigation|Normal saline bag will be used for irrigation during the procedure
11032387|NCT04551677|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to < 36 months|0.5-mL dose of Fluzone Quadrivalent vaccine single injection at Day 01. For participants for whom 2 doses of influenza vaccine are recommended as per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose will be administered at Day 28.
11032388|NCT04551677|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to < 9 years|0.5-mL dose of Fluzone Quadrivalent vaccine single injection at Day 01. For participants for whom 2 doses of influenza vaccine are recommended as per ACIP guidance, a second dose will be administered at Day 28.
11032389|NCT04551677|Experimental|Fluzone High-Dose vaccine Group 3: adults ≥ 65 years|0.7-mL dose of Fluzone High-Dose vaccine single injection at Day 01.
11032390|NCT04551664|Experimental|EVT group|Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.
11032391|NCT04551664|Active Comparator|Best medical management group|Patients in this group will receive best medical management alone.
11032392|NCT04551651|Active Comparator|ApplTree reminder app intervention|A reminding app developed with features that, based on previous research, will increase use and ease of use for individuals with ABI when setting smartphone reminders.
11032393|NCT04551651|Active Comparator|Google Calendar reminder app intervention|A widely available calendar app that can be used to set reminders.
11032394|NCT04551638||Online Videogame Players|One cohort of healthy young adults players of online video games.
11032395|NCT04551612||Patients with cholesteatoma|Patients with cholesteatoma in one ear that will compared with the other healthy one.
11032396|NCT04551599|Experimental|Part 1: Sequence 1|"Healthy, young, adult participants will receive danicopan once each Period as follows:
~Period 1: Danicopan administered under fed conditions.
~Period 2: Danicopan administered under fasted conditions.
~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
11032397|NCT04551599|Experimental|Part 1: Sequence 2|"Healthy, young, adult participants will receive danicopan once each Period as follows:
~Period 1: Danicopan administered under fasted conditions.
~Period 2: Danicopan administered under fed conditions.
~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
11032398|NCT04551599|Experimental|Part 2|Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.
11032399|NCT04551586|Experimental|Sequence 1|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).
~Period 2: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).
~Period 3: ACH-0145228 as power-in-capsule under fasted conditions (reference).
~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
11032473|NCT04551157|No Intervention|Treatment as usual|No change to routine care.
11032474|NCT04551144||Transmen|Subjects starting testosterone therapy as part of standard of care for gender incongruence
11032730|NCT04549415|Active Comparator|lifestyle modification|Lifestyle modification Standard Principles
11032401|NCT04551586|Experimental|Sequence 3|"Participants will receive ACH-0145228 once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: ACH-0145228 as power-in-capsule under fasted conditions (reference).
~Period 2: ACH-0145228 as an immediate-release tablet under fasted conditions (test-fasted).
~Period 3: ACH-0145228 as an immediate-release tablet under fed conditions (test-fed).
~There will be a washout period of at least 5 days between each ACH-0145228 dosing."
11032402|NCT04551573|Experimental|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
11032403|NCT04551573|Experimental|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
11032404|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
11032405|NCT04551547|Experimental|Experimental Vaccine-low dosage|low dosage inactivated SARS-CoV-2 vaccine
11032406|NCT04551547|Experimental|Experimental Vaccine-medium dosage|medium dosage inactivated SARS-CoV-2 vaccine
11032407|NCT04551547|Placebo Comparator|Placebo|No active ingredient in the placebo
11032408|NCT04551534|Experimental|DNL201|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
11032409|NCT04551534|Placebo Comparator|Placebo|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
11032410|NCT04551521|Experimental|BRAF V600E/K|
11032411|NCT04551521|Experimental|ERBB2|
11032412|NCT04551521|Experimental|ALK|
11032413|NCT04551521|Experimental|PI3K/AKT|
11032414|NCT04551521|Experimental|PI3K-AKT-TAX|
11032415|NCT04551521|Experimental|MAPK|
11032416|NCT04551521|Experimental|Immune evasion|
11032417|NCT04551495|Experimental|Single Arm|Subjects will receive four 28-day cycles of letrozole 2.5 mg daily in combination with entrectinib 600 mg daily. Pre-menopausal women will receive goserelin 3.6 mg every 28 days.
11032418|NCT04551482|Experimental|Oxytocin|Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
11032419|NCT04551482|Placebo Comparator|Placebo|Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
11032420|NCT04551469|Experimental|Treatment Arm|30 minutes of listening to music
11032421|NCT04551469|No Intervention|Standard of Care|actual sounds of the intensive care unit environment
11032422|NCT04551456|Placebo Comparator|Placebo Infusion PBS|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.
~Assigned Interventions:
~Biological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo"
11032423|NCT04551456|Experimental|Single dose Infusion WJMSCs|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.
~Biological/Vaccine:
~WJMSCs Vs.placebo"
11032424|NCT04551456|Experimental|Infusion WJMSCs multiple doses|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.
~Biological/Vaccine:
~WJMSCs Vs.placebo"
11032425|NCT04551443|Placebo Comparator|Placebo PBS|Standard therapy+Intravenous infusion PBS in patients with AMI
11032426|NCT04551443|Active Comparator|WJMScs|Standard therapy+Intravenous infusion WJMSCs in patients with AMI
11032427|NCT04551430|Experimental|Cohort A: Cabozantinib|Patients randomized to Cohort A will take cabozantinib at a dose of 60 mg by mouth once each day of each 28-day cycle. At time of progression, patients will continue on cabozantinib daily but will reduce their dose to 40 mg. They will cross over into Cohort B and initiate treatment.
11032428|NCT04551430|Experimental|Cohort B: Cabozantinib + Nivolumab + Ipilimumab|"Patients randomized to Cohort B will take cabozantinib at a dose of 40 mg by mouth once each day. Nivolumab will given IV at a dose of 3 mg/kg over approximately 30 minutes every 3 weeks for 4 doses, followed by 480 mg over approximately 30 minutes every 4 weeks until treatment discontinuation. Ipilimumab will be given IV at a dose of 1 mg/kg over approximately 30 minutes every 3 weeks for 4 doses.
~Participants who cross-over from Cohort A into Cohort B They will cross over into Cohort B will initiate treatment with nivolumab at a dose of 3 mg/kg IV over approximately 30 minutes and ipilimumab at a dose of 1 mg/kg IV over approximately 30 minutes. Nivolumab and ipilimumab will be given every 3 weeks for 4 doses. Nivolumab will then be continued at a dose of 480 mg IV over approximately 30 minutes every 4 weeks, with cabozantinib to continue at 40 mg every day."
11032429|NCT04551417|Active Comparator|Dorsal onlay graft urethroplasty|
11032430|NCT04551417|Experimental|Ventral onlay graft urethroplasty|
11032431|NCT04551404|Experimental|Study Intervention(s) A|"TRNS bilateral temporal regions combined with AS for 20 minutes
~Sham-tRNS bilateral temporal regions combined with Sham-AS for 20 minutes"
11032432|NCT04551404|Experimental|Study Intervention(s) B = Control Intervention|"TRNS bilateral temporal regions for 20 minutes
~Sham-tRNS bilateral temporal regions for 20 minutes"
11032433|NCT04551391||Case|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:
~Previous (within 3 years) eGFR >45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND
~Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND
~Increasing creatinine >= 27μmol/L above index value within 48 hours"
11032434|NCT04551391||Control|"(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR > 60).
~This group will be recruited contemporaneously with, and matched to, AKI participants by:
~Age (± 5 years)
~Sex
~AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not"
11032435|NCT04551378||Observational (survey)|Patients and survivors complete a survey online over 20-30 minutes at baseline about COVID-19 specific psychological distress, health care utilization, health behavior, social and financial disruptions, HRQoL, their social support, perceived benefits under times of stress, and the ability to manage stress. Patients and survivors may be contacted again at 6 months and 1 year for COVID-19 research.
11032436|NCT04551365|Experimental|Obese patients I|Undergoing lifestyle changes (rehabilitation) along daily intake of chitosan supplement, 4 capsules twice daily at main meals.
11032437|NCT04551365|Placebo Comparator|Obese patients II|Undergoing lifestyle changes (rehabilitation) along daily intake of placebo, 4 capsules twice daily at main meals.
11032438|NCT04551365|Experimental|Control I|Daily intake of chitosan supplement, 4 capsules twice daily at main meals.
11032439|NCT04551365|Placebo Comparator|Control II|Daily intake of placebo 4 capsules twice daily at main meals.
11032440|NCT04551352|Experimental|Part I: Single Participant Cohorts (IV)|Part I is a dose escalation in single participant cohorts. RO7293583 will be administered intravenously (IV) every three weeks (Q3W). The starting dose will be 0.045mg and the maximum dose explored will be 1.5mg.
11032441|NCT04551352|Experimental|Part II: Multiple Participant Cohorts (IV/SC)|Multiple ascending dose-escalation of RO7293583 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation will be determined by Part I and RO7293583 will be administered IV or SC every 3 weeks. Dose-escalation will be undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. Fractionated, step up or subcutaneous dosing may be implemented. The maximum dose explored will be 600mg IV and 160mg SC
11032442|NCT04551339|Active Comparator|High dose Zinc (PreserVision AREDS formulation gel tabs)|Subjects will have a high dose Zinc supplementation in combination with Copper, Vitamin C/E and beta-carotene
11032443|NCT04551339|Active Comparator|Centrum Adult (under 50) multivitamin|Subjects in this arm will have Centrum Adult (under 50) multivitamin supplement
11032444|NCT04551326|Experimental|hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
11032445|NCT04551313|Experimental|social skill training group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
11032446|NCT04551313|Active Comparator|control group|Regular therapy
11032447|NCT04551300|Experimental|VS-505 250mg|VS-505 250mg (one 250 mg capsule) oral administration three times a day with meal, daily total dosage 750mg.
11032448|NCT04551300|Experimental|VS-505 500mg|VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
11032449|NCT04551300|Experimental|VS-505 750mg|VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
11032450|NCT04551300|Experimental|VS-505 1500mg|VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
11032451|NCT04551300|Experimental|VS-505 2250mg|VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
11032452|NCT04551300|Active Comparator|Sevelamer Carbonate 1600mg|Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.
11032453|NCT04551287||Training cohort|The training cohort was retrospectively enrolled from Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangdong Province, China. Female patients who were 18 years or older with clear diagnostic results of cervical liquid-based cytological examination were included.
11032454|NCT04551287||Validation cohort 1|The validation cohort 1 was retrospectively enrolled from the same institution with the same inclusion/exclusion criteria. This cohort was designed to verify the accuracy of the AI platform.
11032455|NCT04551287||Validation cohort 2|The validation cohort 2 was enrolled in the same institution from July 15, 2020 with the same inclusion/exclusion criteria. This cohort was designed to compare the diagnostic capabilities between primary cytopathologists and AI platforms with cervical TCT.
11032456|NCT04551274|Experimental|Music Therapy|Participants in the music therapy group will complete a 4 week music therapy program, with a minimum of 2 sessions per week.
11032457|NCT04551274|No Intervention|Control|Control group participants will not experience any intervention
11032458|NCT04551261|Experimental|Part A|Subjects will receive GLS4 and RTV on Day 1, TAF on Day 5-14, GLS4 and RTV and TAF on Day15.
11032459|NCT04551261|Experimental|Part B|Subjects will receive TAF on Day 1, GLS4 and RTV on Day 5-14, GLS4 and RTV and TAF on Day15.
11032460|NCT04551248||PCV13 recipients (children)|Children < 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018 under the national childhood immunization program in South Korea.
11032461|NCT04551248||PPSV23 recipients (elderly adults)|Persons 65 years or older who had received at least one dose of PPSV23 between January, 2014 and December, 2018 under the national immunization program in South Korea.
11032462|NCT04551248||Influenza vaccine recipients (elderly adults)|Persons 65 years or older who had received at least one dose of influenza vaccine (as comparator) between January, 2014 and December, 2018 under the national immunization program in South Korea.
11032463|NCT04551222|Active Comparator|Probenecid|1 gr. orally of probenecid twice daily for 180 days
11032464|NCT04551222|Placebo Comparator|Placebo|identical placebo (to probenecid tablets) for 180 days
11032465|NCT04551209|Experimental|Apical patency group|Patients in which apical patency is maintained.
11032466|NCT04551209|No Intervention|Non- apical patency group|Patients in which apical patency is not maintained
11032467|NCT04551196|Active Comparator|Alternating Regimen|A regimen of acetaminophen and ibuprofen alternating doses every 3 hours.
11032468|NCT04551196|Active Comparator|Combined Regimen|A regimen of acetaminophen and ibuprofen dosed together every 6 hours.
11032469|NCT04551183|Experimental|OnlyGroup|Patients are their own witnesses
11032470|NCT04551170|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
11032471|NCT04551170|Placebo Comparator|Placebo|Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
11032472|NCT04551157|Experimental|Video Viewing|Participants will receive the intervention where they will view two patient information videos. The first video will be viewed within the first week of their inpatient stay and the second video will be viewed just before discharge.
11032476|NCT04551131|Experimental|Frontline Arm|"Safety Phase:
~Patients with newly diagnosed HLH will receive ruxolitinib PO or NGT, dexamethasone, PO or IV and etoposide IV.
~Expansion Phase:
~Patients with newly diagnosed HLH treatment will begin with ruxolitinib PO or NGT at the MTD dose. Dexamethasone will be administered PO or IV. Etoposide IV will be added based on disease response."
11032477|NCT04551131|Experimental|Salvage Arm|Patients with relapsed/refractory HLH will receive ruxolitinib PO or NGT and dexamethasone PO or IV. Etoposide IV will be added based on disease response.
11032478|NCT04551118|Experimental|tACS group|Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
11032479|NCT04551118|Experimental|tDCS group|Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
11032480|NCT04551118|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current continued less than 30s.
11032481|NCT04551105|Active Comparator|First session: manual review first and then review with CADx|"Each rater will interpret the Dataset A cases in different random order without any assistance of artificial assistance first, and then interpret the Dataset B cases in different random order with BR-USCAD DS."
11032482|NCT04551105|Active Comparator|First session: review with CADx first and then manual review|"Each rater will interpret the Dataset A cases in different random order with BR-USCAD DS first, and then interpret the Dataset B cases in different random order without any assistance of artificial assistance."
11032483|NCT04551105|Active Comparator|Second session: manual review first and then review with CADx|"At least 4 weeks after first session for memory washing out. Each rater will interpret the Dataset A cases in different random order without any assistance of artificial assistance first, and then interpret the Dataset B cases in different random order with BR-USCAD DS."
11032484|NCT04551105|Active Comparator|Second session: review with CADx first and then manual review|"At least 4 weeks after first session for memory washing out. Each rater will interpret the Dataset A cases in different random order with BR-USCAD DS first, and then interpret the Dataset B cases in different random order without any assistance of artificial assistance."
11032485|NCT04551092|Experimental|Single|Single group to receive intervention
11032486|NCT04551079|Experimental|TAK-994 Dose A+ Placebo + TAK-994 Dose B|TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
11032487|NCT04551079|Experimental|TAK-994 Dose B + TAK-994 Dose A + Placebo|TAK-994 Dose B tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
11032488|NCT04551079|Experimental|Placebo + TAK-994 Dose B+ TAK-994 Dose A|TAK-994 placebo-matching tablets, orally, on Days 1 and 2 of Treatment Period 1, followed by TAK-994 Dose B tablets orally, on Days 1 and 2 of Treatment Period 2, further followed by TAK-994 Dose A tablets, orally, on Days 1 and 2 of Treatment Period 3. A Washout Period of at least 7 days will be maintained between each treatment period.
11032489|NCT04551066|Experimental|Group A : parsaclisib + ruxolitinib|Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
11032490|NCT04551066|Placebo Comparator|Group B : placebo + ruxolitinib|Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
11032491|NCT04551053|Experimental|Group A : ruxolitinib +parsaclisib|Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
11032492|NCT04551053|Placebo Comparator|Group B : ruxolitinib + placebo|Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
11032493|NCT04551040|Experimental|Primary Cohort|Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.
11032494|NCT04551027|Experimental|compensatory cognitive treatment|compensatory cognitive treatment intervention, focusing on learning cognitive strategies to overcome cognitive deficits.
11032495|NCT04551027|No Intervention|control group|standard ambulatory treatment
11032496|NCT04551014|Experimental|With EverLift|Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.
11032497|NCT04551014|Experimental|Without EverLift|Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.
11032498|NCT04551001|Experimental|Cold forcep|Cold forcep polypectomy performed for polyps <=3mm.
11032499|NCT04551001|Experimental|Cold snare|Cold forcep polypectomy performed for polyps <=3mm.
11032500|NCT04550988||Adult patients with severe haemophilia A or B|
11032501|NCT04550975|Experimental|Advanced Cognitive Stimulation Therapy|Advanced Cognitive Stimulation Therapy (ACST), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. ACST will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee or care home staff.
11032502|NCT04550975|No Intervention|Treatment as usual|Standard care in care homes
11032503|NCT04550962||Participants with asthma|Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
11032504|NCT04550949|Experimental|QL1206|QL1206 injection(120mg)was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
11032505|NCT04550949|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
11032506|NCT04550923|Experimental|Investigational device (non-rigid) group|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
11032763|NCT04549259|Experimental|Social Support + SBCM|
11032509|NCT04550910|Experimental|Arm B|28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy
11032510|NCT04550897|Experimental|BM7PE treatment|"The BM7PE treatment will be administered as a 20-minute i.v. infusion. The treatment is repeated after 2 weeks (day 15). The patients will be treated as in-patients and will stay at the hospital until toxicity have decreased to grade 2 and or plasma AST and or ALT levels has started to decrease. For at least a minimum of 3 days.
~The dose administered to the patient will be 2.5, 5.0, 7.5, 10.0, 15.0 and 20.0 μg/kg body weight."
11032511|NCT04550845|Experimental|Specific Aim 1|In specific aim 1, twelve focus group interviews (AA and rural White men with localized prostate cancer and caregivers, N = 50 dyads or N = 100 participants) will be conducted to explore comprehension of prognostic genomics as well as facilitators and barriers to genomic health literacy and to assess the acceptability and value of the revised PCLA education video.
11032512|NCT04550845|Experimental|Specific Aim 2|In specific aim 2, participants will be randomized into intervention versus control group. Twenty focus groups (AA and rural White men with localized prostate cancer and caregivers, N = 80 dyads or N = 160 participants) will be conducted to culturally conceptualize the study intervention and to provide qualitative contextual evaluation. The design for this aim is a randomized controlled, parallel group, repeated measures, non-blinded trial, with a nurse-delivered tailored prostate cancer education, communication coaching, and the prognostic genomics revised Prostate Cancer Literacy Video compared to the prognostic genomics revised Prostate Cancer Literacy Video.
11032513|NCT04550832|Active Comparator|Arm1(D0)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will not administered
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
11032514|NCT04550832|Experimental|Arm2(D400)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 400 mg orally once daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
11032515|NCT04550832|Experimental|Arm3(D800-OD)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 800 mg orally once daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
11032516|NCT04550832|Experimental|Arm4(D1200)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 1200 mg orally once daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
11032517|NCT04550832|Experimental|Arm5(D800-BD)|"Participants receive the following medication for the duration of 16weeks together with food.
~Delpazolid : Will be dosed 800 mg orally twice daily
~Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week.
~Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg.
~Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily"
11032518|NCT04550819|Experimental|IEBSs in malignant extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with malignant extrahepatic biliary stricture
11032519|NCT04550819|Active Comparator|CPBSs in malignant extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with malignant extrahepatic biliary stricture
11032520|NCT04550819|Experimental|IEBSs in benign extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with benign extrahepatic biliary stricture
11032521|NCT04550819|Active Comparator|CPBSs in benign extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with benign extrahepatic biliary stricture
11032522|NCT04550806||GDM|
11032523|NCT04550806||non-GDM|
11032524|NCT04550793||Intervention|The stroke patients who receive botulinum toxin injection at affected brachialis and/or biceps brachials.
11032525|NCT04550793||Control|The stroke patients who do not receive botulinum toxin injection at affected brachialis and/or biceps brachials in the past 3 months.
11032526|NCT04550780||The study population|The study population will comport all beneficiaries in the national French SNDS database who were prescribed mepolizumab and for whom health resource use data is available for the 12 months preceding and following a first filled prescription for mepolizumab.
11032527|NCT04550767||local infections|local infections
11032528|NCT04550767||systemic infections|systemic infections
11032529|NCT04550754||Patients hospitalized for tramadol withdrawal|Patients hospitalized for tramadol withdrawal in Montpellier University Hospital and Nîmes University Hospital from 01/01/2015 to 31/12/2019
11032530|NCT04550741|Experimental|Telerehabilitation|Experimental group of 100 patients using the M-Réhab BPCO telerehabilitation solution. The solution will be provided during the fourth and final week of RR's stay during which patients will be trained to use all of the solution's features. Patients will carry out the entire post-rehabilitation using the remote rehabilitation solution and will benefit from medical assessments by teleconsultation at 1, 3, 6 and 12 months as well as assessments at 3, 6 and 12 months by filling. electronic auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
11032531|NCT04550741|No Intervention|Standard chronic care|following usual standard chronic care. Patients will receive during the last week of stay in the center, the usual advice to continue physical activity and nutritional advice at home. The evaluations at 3, 6 and 12 months will be done by electronic filling of auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
11032532|NCT04550728|Experimental|FES+robot|Participants in this group will have FES during ankle robot training
11032764|NCT04549259|Experimental|Social Support + Technology Detailing|
11032534|NCT04550715|Experimental|Brief intervention (BI) then Portal|The BI will be delivered at intake and the portal will occur for 4 weeks starting at intake.
11032535|NCT04550715|Experimental|Brief intervention (BI) then Enhanced Usual Care (EUC)|The BI will be delivered at intake and EUC will be added 4 weeks later.
11032536|NCT04550715|Experimental|Enhanced Usual Care (EUC) then Portal|EUC will be delivered at intake and the portal will occur for 4 weeks starting at intake.
11032537|NCT04550715|Active Comparator|Enhanced Usual Care (EUC) then EUC|EUC will be delivered at intake and delivered again 4 weeks later.
11032538|NCT04550702||Women received Mirabegron|Women with overactive bladder syndrome received Mirabegron
11032539|NCT04550689|Active Comparator|Xenograft|
11032540|NCT04550689|Active Comparator|Allograft|
11032541|NCT04550676|Experimental|High intensity interval training|
11032542|NCT04550676|Active Comparator|Continuous moderate intensity exercise|
11032543|NCT04550663|Experimental|KD-025 CAR-T cells|NKG2D-based CAR-T cells infusion
11032544|NCT04550650|No Intervention|Controll|No intervention
11032545|NCT04550650|Experimental|Training grp|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
11032546|NCT04550650|Experimental|PNF|2 years long, You have only treated patients with the PNF technique.
11032547|NCT04550650|Experimental|Spinning group|Patients developed endurance for 2 years. They worked using a spinning bike.
11032548|NCT04550650|Experimental|Balance|Neurorehabilitation 2 years long intervention, administered daily, targeted postural instability, balance
11032549|NCT04550637||Anticoagulant therapy after percutaneous left atrial appendage|Oral apixaban
11032550|NCT04550624|Experimental|Interventional Arm|This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with advanced cholangiocarcinoma (CCA) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
11032551|NCT04550611|Experimental|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|will receive blood group -specific MP-IVIG in a regimen of 2 g/kg bodyweight, usually as 0.4 g/kg bodyweight per day for five consecutive days within two weak of onset of symptoms.
11032552|NCT04550611|Experimental|plasmapheresis|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
11032553|NCT04550598|Experimental|HD-tCES|The experiment group will receive active HD-tCES.
11032554|NCT04550598|Sham Comparator|Sham HD-tCES|The sham control group will receive sham HD-tCES.
11032555|NCT04550559|Active Comparator|Group 1|The patients in group 1 were instructed to masturbate at least 3-4 times a week
11032556|NCT04550559|Other|Group 2|The patients in group 2 were prescribed oral tamsulosin 0.4 mg once daily
11032557|NCT04550559|No Intervention|Group 3|The patients in group 3 acted as controls and received only standard medical therapy
11032558|NCT04550546|Experimental|Nystatin treatment|Participants will be given 1-week supply of nystatin suspension (6ml 600,000 U/mL) and be instructed to rinse the mouth with nystatin for 1 minute and spit out the suspension, at a frequency of four times a day, for a duration of 1 week. Participants will be instructed to spit the suspension after the oral rinse and do not swallow the suspension, and they will be instructed to avoid eating, drinking and brushing their teeth for 30 minutes.
11032559|NCT04550520|Experimental|healthy adult volunteers|Healthy volunteers: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
11032560|NCT04550520|Experimental|adult patients with diabetes insipidus|Adult patients with a known central diabetes insipidus: The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon).
11032561|NCT04550507|Experimental|Group A: Mindful Sensory Awareness|Group A: Mindful Sensory Awareness receives the mindful sensory awareness intervention during the first 8-week period, and receives no active intervention delivery during the second 8-week period.
11032562|NCT04550507|Other|Group B: Mindful Sensory and Body Awareness|Group B: Mindful Sensory and Body Awareness receives no active intervention delivery during the first 8-week period, and during the second 8-week period receives an intervention combining the mindful sensory awareness content received by Group A with the mindful body awareness check-in approach.
11032563|NCT04550494|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11032564|NCT04550481|Experimental|Prevention (lisinopril)|Patients receive lisinopril PO QD for 24 weeks in absence of unacceptable toxicity.
11032565|NCT04550468|Experimental|Low-Carb High-Fat Breakfast|Participants will follow a daily low carbohydrate high fat breakfast intervention for 3 months.
11032566|NCT04550468|Active Comparator|"Low fat Standard Care Control Breakfast"|"Participants will follow a daily low fat standard care control breakfast intervention for 3 months."
11032567|NCT04550455|Experimental|Cladribine Tablets|All participants will receive cladribine tablets according to the current United States Federal Food and Drug Administration (FDA) package guidelines.
11032568|NCT04550442|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO daily on days 1-14 and azacitidine IV over 15 minutes or SC on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
11032569|NCT04550429|Active Comparator|60 mmHg MyoSure Hysteroscopic Morcellator Device|The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
11032570|NCT04550429|Sham Comparator|80 mmHg MyoSure Hysteroscopic Morcellator Device|This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study
11032571|NCT04550416|Experimental|ProMark Information and Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
11032572|NCT04550416|No Intervention|Standard Practice|Physicians will care for online virtual patients as they normally would in practice.
11032573|NCT04550377|Experimental|Cannabidiol Group 1|40 participants will be titrated to a maximum dose of Cannabidiol 400 mg daily over 2 weeks for a total of 8 weeks treatment.t.
11032574|NCT04550377|Experimental|Cannabidiol Group 2|40 participants will be titrated to a maximum dose of Cannabidiol 600 mg daily over 2 weeks for a total of 8 weeks treatment.
11032575|NCT04550377|Placebo Comparator|Placebo Group|40 participants will be given a placebo for a total of 8 weeks treatment.
11032576|NCT04550351|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
11032577|NCT04550351|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
11032578|NCT04550351|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
11032579|NCT04550338|Experimental|Tranexamic Acid Treatment|
11032580|NCT04550338|Placebo Comparator|Placebo Treatment|
11032581|NCT04550325|Experimental|Immune gamma globulin (IgG)|Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion
11032582|NCT04550299|Active Comparator|Group A|single bundle technique with the use of bioabsorbable implants
11032583|NCT04550299|Active Comparator|Group B|single bundle technique with the use of Bio-Intrafix
11032584|NCT04550299|Active Comparator|Group C|double bundle technique with the use of bioabsorbable implants
11032585|NCT04550299|Active Comparator|Group D|double bundle technique with the use of Bio-Intrafix
11032586|NCT04550286|Experimental|Intervention Group|"Intervention points in time include:
~Baseline measure
~Installation of the study app
~Advice on general enhancements regarding study environment and behavior (BCT 4.1)
~Students are to develop up to three action plans (BCT 1.4) and coping plans (BCT 1.2) to reduce smartphone interference during exam preparation periods by putting the smartphone away
~Students receive weekly questionnaire (t1-t3) and one questionnaire after their first exam (t4). All these questionnaires concern their academic performance and well-being. A short questionnaire (t5) asks for the participants' exam grades approx. 2 months after their exam. A time period of 2 months has been chosen to ensure that universities have enough time to announce the grades.
~During the whole period of the study, the mobile application tracks the students' smartphone behavior (i.e., daily smartphone use, daily screen activations, and specific app usage)."
11032587|NCT04550286|Active Comparator|Control Group|Control points in time include all parts except for number 4. Here students in the control group will receive questionnaires on general health behavior in order to achieve an equal questionnaire completion time compared to the intervention group.
11032588|NCT04550273|Experimental|study group|The study group (n=20) will receive three sessions of aerobic walking exercise per week for 3 months in addition to the traditional medical treatment
11032589|NCT04550273|No Intervention|control group|The control group (n=20) will receive no training
11032590|NCT04550260|Experimental|Arm 1: Durvalumab + definitive CRT|Durvalumab + concurrent chemoradiation
11032591|NCT04550260|Placebo Comparator|Arm 2: Placebo + definitive CRT|Placebo + concurrent chemoradiation
11032592|NCT04550247||Nivolumab treatment|Administered according to the market authorization in France
11032593|NCT04550234|Active Comparator|Treatment 1|Eligible subjects will receive verinurad ph2b (free combination) capsule and allopurinol ph2b tablet in fasted state on Day 1.
11032594|NCT04550234|Experimental|Treatment 2|Eligible subjects will receive verinurad and allopurinol ph3 (fixed dose combination) capsule in fasted state on Day 1.
11032595|NCT04550234|Experimental|Treatment 3|Eligible subjects will receive verinurad and allopurinol ph3 (fixed dose combination) capsule in fed state on Day 1.
11032596|NCT04550221|Experimental|Intervention|The Shauriana intervention is aimed at promoting sexual health and preventing HIV through a comprehensive prevention toolbox including PrEP. Components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions.
11032597|NCT04550221|Active Comparator|Standard care|Standard care includes clinic-based HIV counseling and testing, screening for symptoms of sexually transmitted infections (STI), and individual counseling about HIV prevention methods. Standard of care counseling for HIV prevention in Kenya includes general information about HIV transmission and discussions of risk reduction including condom use. PrEP counseling sessions focus on PrEP knowledge, adherence tips, and strategies to address adherence barriers.
11032598|NCT04550208||Healthy basketball or volleyball players|Basketball and volleyball players Landing biomechanics of different landing tasks is investigated in a population of volleyball and basketball players
11032599|NCT04550195|Experimental|Part A Single Ascending Dose (SAD) Cohort A1|
11032600|NCT04550195|Experimental|Part A SAD Cohort A2|
11032601|NCT04550195|Experimental|Part A SAD Cohort A3|
11032602|NCT04550195|Experimental|Part A SAD Cohort A4|
11032603|NCT04550195|Experimental|Part A SAD Cohort A5|
11032604|NCT04550195|Experimental|Part A SAD Cohort A6|
11032605|NCT04550195|Experimental|Part B Multiple Ascending Dose (MAD) Cohort B1|
11032606|NCT04550195|Experimental|Part B MAD Cohort B2|
11032607|NCT04550195|Experimental|Part B MAD Cohort B3|
11032608|NCT04550195|Experimental|Part B MAD Cohort B4|
11032609|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C1|
11032610|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C2|
11032611|NCT04550195|Experimental|Part C MAD in Japanese Healthy participants Cohort C3|
11032765|NCT04549259|Experimental|Social Support|
11032612|NCT04550182|Experimental|Individual positioning schedule|Pressure ulcer prevention cares are provided according to the positioning schedule for every patient.
11032613|NCT04550182|No Intervention|Standard care|Pressure ulcer prevention cares are provided according to usual practice of the ICU. Frequency and modality of positioning applied to the patients are collected.
11032614|NCT04550169||Intensive Care Coordination|Intensive Care Coordination along with Standard of Care
11032615|NCT04550169||Control|Standard of Care alone
11032616|NCT04550156|No Intervention|Control Arm|Patients are treated according to current local standards
11032617|NCT04550156|Experimental|Colorectal Bundle Arm|Patients are treated according to the colorectal bundle
11032618|NCT04550143||Septic Shock|
11032619|NCT04550130|Experimental|low dose (1.8 L)|Patients in this arm will be treated with one column (Leukapheresis) and 1.8 L blood will be filtered.
11032620|NCT04550130|Experimental|high dose (3.6 L)|Patients in this arm will be treated with Two column (Leukapheresis) and 3.6 L blood will be filtered.
11032621|NCT04550117|Experimental|Intraspinal Pressure Monitoring|A fiberoptic pressure monitoring device will be placed into the subarachnoid space at the site of traumatic spinal cord injury
11032622|NCT04550104|Active Comparator|Radiotherapy only|
11032623|NCT04550104|Experimental|Olaparib + radiotherapy|
11032624|NCT04550104|Experimental|AZD1390 + radiotherapy|
11032625|NCT04550104|Experimental|TBD1 + radiotherapy|DDRi to be decided
11032626|NCT04550104|Experimental|TBD2 + radiotherapy|DDRi to be decided
11032627|NCT04550104|Experimental|TBD3 + radiotherapy|DDRi to be decided
11032628|NCT04550078|Active Comparator|Calcium Carbonate|800 mg calcium as calcium carbonate in capsules consumed orally once with a standardized meal.
11032629|NCT04550078|Experimental|Calcium-enriched permeate|800 mg calcium as calcium permeate in capsules consumed orally once with a standardized meal.
11032630|NCT04550078|Placebo Comparator|Maltodextrin|0 mg calcium as placebo capsules with maltodextrin consumed orally once with a standardized meal.
11032631|NCT04550065|Experimental|Intervention arm|Digital game
11032632|NCT04550039|Experimental|Body-weight-supported treadmill training|Participants complete prescribed gait training program for at least three weeks or until they discharge.
11032633|NCT04550039|Experimental|EksoNR exoskeleton|Participants complete prescribed gait training program for at least three weeks or until they discharge.
11032634|NCT04550026|Experimental|Inhalation of HTP|Inhalation of HTP for 30 minutes
11032635|NCT04550026|Active Comparator|Sham inhalation of HTP|Sham usage of HTP for 30 minutes
11032636|NCT04550013|Active Comparator|Heavy-Slow Resistance training|Heavy-Slow Resistance training. Three times weekly for 12 weeks.
11032637|NCT04550013|Experimental|Low-Load Blood Flow Restriction training|Low-Load Blood Flow Restriction training. Three times weekly for 12 weeks
11032638|NCT04549987|Experimental|Without changing working archwire|Extraction space closed using the same working archwire throughout 3 visits after insertion
11032639|NCT04549987|Experimental|With changing working archwire|The extraction space closed having the working archwire changed monthly.
11032640|NCT04549974|Experimental|Passive heat exposure|
11032641|NCT04549961||patients admitted to intensive care units|all patients that are present on an intensive care unit on nutritionday
11032642|NCT04549948|Experimental|0.017X0.025 Stainless Steel Archwire|Leveling of COS using 0.017X0.025 Stainless Steel (SS) Archwire A reverse COS using 0.017X0.025 SS was used to correct the excessive COS in the lower arch.
11032643|NCT04549948|Experimental|0.019X0.025 Stainless Steel Archwire|A reverse COS using 0.019X0.025 SS was used to correct the excessive COS in the lower arch.
11032644|NCT04549948|Experimental|0.021X0.025 TMA archwire|A reverse COS using 0.021X0.025 TMA archwire was used to correct the excessive COS in the lower arch.
11032645|NCT04549935|Active Comparator|Group A Dextenza|Drug: Dextenza 0.4mg Opthalmic Insert The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion, The attributes of the insert reduce risks for improper corticosteriod tapering and unwanted peaks and troughs in drug concentration.
11032646|NCT04549935|Active Comparator|Group B Topical Prednisolone|Drug: Topical Prednisolone Standard of care topical drop treatment
11032647|NCT04549922|Placebo Comparator|Placebo|1.2 mL Normal Saline, single dose subcutaneous, after randomization
11032648|NCT04549922|Active Comparator|ISIS 721744|1.2 mL ISIS 721744, single dose subcutaneous, after randomization
11032649|NCT04549909||preimplantation genetic testing for aneuploidy (PGT-A) Group|Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) (transfer of own frozen embryo)
11032650|NCT04549909||endometrial receptivity array (ERA) Group|Patients who have undergone frozen embryo transfer (FET) with endometrial receptivity array (ERA) test (embryos from own or donated oocytes)
11032651|NCT04549909||CONTROL OWN (CO) Group|Control group of FET from own oocytes (without ERA or PGT-A)
11032652|NCT04549909||CONTROL DONATED(CD) Group|Control group of FET from donated oocytes (without ERA or PGT-A)
11032653|NCT04549896|Experimental|CT scan|CT scan with a last generation 256 slice machine of occluded coronary artery before CTO PCI
11032654|NCT04549896|Active Comparator|Control|No CT scan before CTO PCI
11032655|NCT04549883|Experimental|Performing after session|LB control during hip extension after intervention
11032656|NCT04549870|Active Comparator|Roflumilast|Roflumilast 500 microgram daily (capsule)
11032657|NCT04549870|Placebo Comparator|Placebo|Placebo (capsule)
11032658|NCT04549857|Experimental|intervention group|The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.
11032659|NCT04549857|Placebo Comparator|Placebo group|The placebo group only used base oil (sweet almond oil).
11032660|NCT04549857|No Intervention|Control group|No intervention
11032687|NCT04549636||healthy COVID-19+|Individuals who recently recovered from COVID-19 and who have no history of lung disease
11032688|NCT04549636||asthmatic COVID-19+|Individuals who recently recovered from COVID-19 and who have asthma
11032689|NCT04549636||healthy COVID-19-|Individuals who have not been diagnosed with COVID-19 and who have no history of lung disease
11032661|NCT04549844|Active Comparator|the intervention group (G A)|Group general anaesthesia plus peribulbar block : Total 35 cases who will receive general anesthesia with peribulbar block (bupivacaine 0.5 % xylocaine 2% hyaluronidase with total volume 0.06 mg \kg (bupivacaine : (xylocaine :hyaluronidase ) 1:1) Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
11032662|NCT04549844|Placebo Comparator|the control group (G B )|"General group: Total 35 cases who will receive general anesthesia only, i.e., without peribulbar block. (Fentanyl 1µg\kg, atracurium 0.5 mg\kg and propofol 2mg \kg.
~After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane."
11032663|NCT04549831||SARS-CoV-2 PCR positive individuals|Adult (> o equal to 18 years) SARS-CoV-2 PCR positive individuals with different clinical outcome: from asymptomatic to severely affected COVID-19 patients.
11032664|NCT04549818|Experimental|sacral neuromodulation|Sacral neuromodulation group, will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
11032665|NCT04549818|No Intervention|medical therapy|this group will be treated with sustained release morphine tablets for pain control
11032666|NCT04549805||Patients without myocardial injury|Patients without myocardial injury will be recruited in a 2:1 fashion stratified by peak high-sensitivity cardiac troponin I concentration above and below a threshold of 5 ng/L.
11032667|NCT04549792|Experimental|Open Label|
11032668|NCT04549779|Experimental|Group I (low volume)|patients will receive 5 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
11032669|NCT04549779|Experimental|Group II (intermediate volume)|patients will receive 10 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
11032670|NCT04549779|Experimental|Group III (high volume)|patients will receive 15 ml levobupivacaine 0.25% ultrasound-guided interscalene brachial plexus block.
11032671|NCT04549753|Experimental|tDCS stimulation group|Patients receive four sessions of tDCS stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system.
11032672|NCT04549727||infants with surgical NEC|Infants who undergo surgery for NEC disease
11032673|NCT04549727||Infants with GI surgical diseases other than NEC|Infants who undergo surgery for other GI diseases than NEC
11032674|NCT04549714|Experimental|High AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
11032675|NCT04549714|Experimental|Middle AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
11032676|NCT04549714|Experimental|Low AI in paroxysmal atrial fibrillation|In this group,patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
11032677|NCT04549701|Experimental|CAVAL US group|Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.
11032678|NCT04549701|Active Comparator|Standard of care group|Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.
11032679|NCT04549688|Experimental|Focal therapy|
11032680|NCT04549675|Experimental|Arm 1 Sun Safe Partners Online Intervention|Web-based intervention called Sun Safe Partners Online. Website developed by the study team. Participants received individual username and password to login.
11032681|NCT04549675|Active Comparator|Generic Online Sun Safety Information intervention|Publicly online available skin cancer and sun protection information emailed to participants in 4 seperate email links.
11032682|NCT04549662|Experimental|Group A|Powdered formula containing whey protein and arginine (Active A) and lipid bolus containing omega 3 fatty acids. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
11032683|NCT04549662|Active Comparator|Group B|Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
11032684|NCT04549662|Placebo Comparator|Comparator|Powdered formula containing whey protein (Active B) and placebo oil. Participants will mix the powder (Active B) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
11032685|NCT04549649|Experimental|Group A (Experimental oocyte triggering approach)|0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) associated with two ampoules of Ovitrelle (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be administered subcutaneously simultaneously for final oocyte triggering.
11032686|NCT04549649|No Intervention|Group B (Routine oocyte triggering approach)|Two ampoules of Ovitrelle® (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be injected subcutaneously for final oocyte triggering.
11032766|NCT04549259|Experimental|Stigma Reduction + SBCM + Technology Detailing|
11032691|NCT04549623|Experimental|Group ETCO2|Novel end-tidal carbon dioxide monitoring device is used for sedation.
11032692|NCT04549623|Experimental|Group Reg|Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.
11032693|NCT04549610|Experimental|HMB supplementation|"The experimental procedure for each participant in this group includes a one week HMB supplementation.
~HMB will be administered in the form of blinded capsules containing 0.5 g HMB free acid per capsule. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 8 capsules (4 x 2 capsules) of HMB in a split dose per day. On training days the supplements will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals during the day."
11032694|NCT04549610|Placebo Comparator|Placebo treatment|The experimental procedure for each participant in this group includes a one-week placebo (PLA) administration. PLA (corn starch) will be placed in the blinded capsules form. PLA will be ingested with at least 250 mL of water. Each participant in this group will ingest 8 placebo capsules a day. On training days the PLA capsules will be taken in the morning (2 capsules), 1.5 hours before training session (2 capsules), immediately after training (2 capsules) and before sleep (2 capsules). On rest days the supplements will be taken in the morning (2 capsules), around midday (2 capsules), in the afternoon (2 capsules) and before bedtime (2 capsules) at possibly similar (approx. 4 hours) intervals.
11032695|NCT04549597|Experimental|Cohort 1: Straight Switch|Patients stop taking phosphate binders and start tenapanor 30 mg twice daily
11032696|NCT04549597|Experimental|Cohort 2: Decrease Phosphate Binder by 50%|Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
11032697|NCT04549597|Experimental|Cohort 3: Phosphate Binder Naive|Phosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID
11032698|NCT04549584||metaplastic breast cancer|Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
11032699|NCT04549584||non-metaplastic breast cancer|Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer
11032700|NCT04549571|Experimental|Arm I: (iCanDecide - ESE)|Patients utilize the iCanDecide - ESE website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
11032701|NCT04549571|Active Comparator|Arm II: (iCanDecide - S)|Patients utilize the iCanDecide - S website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
11032702|NCT04549571|Experimental|Clinics 1-5: (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 1-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032703|NCT04549571|Experimental|Clinics 6-8 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 10-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032704|NCT04549571|Experimental|Clinics 9-11 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 20-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032705|NCT04549571|Experimental|Clinics 12-14 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 30-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032706|NCT04549571|Experimental|Clinics 15-17 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 40-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032707|NCT04549571|Experimental|Clinics 18-20 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 50-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032708|NCT04549571|Active Comparator|Clinics 21-25 (usual care)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and continue to provide breast cancer surgical care per their usual care. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
11032709|NCT04549545|Active Comparator|Vivaer Procedure|"The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat (touch up) procedures will be permitted after the initial procedure through the end of the study (24 months)."
11032710|NCT04549545|Sham Comparator|Sham Control Procedure|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
11032727|NCT04549441||GA|The participants undergo distal radius plating surgery via general anesthesia induced by an anesthesiologist. The anesthesia team continuously monitored patients' intraoperative physiological status. MAP and HR in group B were marked after induction (T1) and at the other six same time points as in the group WALANT.
11032728|NCT04549428|Experimental|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1,200 mg by intravenous infusion every 21 days on an outpatient basis until progression, intolerance or loss of clinical benefit, according to the its approved prescribing information. Palliative radiation therapy will be delivered concomitant to the 2nd dose of atezolizumab as a single fraction of 8 Gy
11032711|NCT04549532|Experimental|T-MD Intervention Group|Participants will be prescribed 1+ interventions tailored to affected domains.Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.Autonomic-Graded aerobic exercise. Perform daily aerobic exercise, goal 80% HR max on a stationary bike/treadmill/walking/jogging.
11032712|NCT04549532|Active Comparator|Behavioral Management|Participants in control group will receive standardized behavioral management strategies including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion. Clinicians will discuss and review a behavioral strategies handout with each participant and answer any questions they may have about the information in the handout. Contact time between clinicians and patients will be similar to avoid effects associated with more or less contact time.
11032713|NCT04549519||Stable group|Participants display knee valgus less or equal to 15° at 45° knee flexion in the descending phase of the squat on both legs
11032714|NCT04549519||Unstable group|Participants display knee valgus greater than 15° at 45° knee flexion in the descending phase of the squat on one leg or both legs
11032715|NCT04549506||ASD group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. All ASD participants were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders 5th Edition's (DSM-5) diagnostic criteria (APA, 2013) and conﬁrmed by clinical consensus. ASD individuals were recruited from a community autism program and referred to children's health doctors and child psychiatrists. Exclusion criteria for all participants were neurological abnormalities, a history of epilepsy or seizures, head trauma and IQ <75. The subjects did not participate in any intervention or drug programs during the experimental period.
11032716|NCT04549506||Control group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. The participants in the age- and sex-matched control group were recruited from the local community, and screened for major psychiatric illnesses by conducting structured interviews.
11032717|NCT04549493|Active Comparator|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, & Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
11032718|NCT04549493|Active Comparator|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
11032719|NCT04549493|Active Comparator|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
11032720|NCT04549480|Experimental|Bosutinib capsule|Bosutinib pediatric capsule to healthy participants
11032721|NCT04549480|Active Comparator|Bosutinib tablet|Bosutinib tablet to healthy participants
11032722|NCT04549467|Experimental|Dolutegravir + lamivudine|Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD
11032723|NCT04549467|Active Comparator|Dolutegravir + emtricitabine/tenofovir (FTC/TDF)|Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
11032724|NCT04549454|Experimental|Intervention App|Students in arm of the study will have a parent who has access to the following content in the parent app: (a) FITSTART+ PBI materials (personalized normative feedback quiz, information on college student drinking, and alcohol-specific advice for parents of first year students); (b) general advice for parents of college students (e.g., improving communication; reducing conflict); (c) information about university resources; and (d) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
11032725|NCT04549454|Placebo Comparator|Control App|Students in this arm of the study will have a parent who has access to the following content in the parent app: (a) general advice for parents of college students (e.g., improving communication; reducing conflict); (b) information about university resources; and (c) a community section (parents can view other parent profiles, submit family photos, and view family photos submitted by other parents).
11032726|NCT04549441||WALANT|The participants undergo distal radius plating surgery via wide-awake local anesthesia no tourniquet technique. In this group, mean arterial pressure, heart rate, and numeric rating scale for pain were measured by nursing staff in the operation theatre seven times perioperatively, namely before surgery (T0) and at the time of injection of local anesthesia (T1), skin incision (T2), fracture reduction (T3), plating and screwing (T4), skin closure (T5), surgery completion (T6).
11032731|NCT04549402|Experimental|Mirror Therapy group|The intervention will consist of the visualization of movement through the Mirror Therapy VR® application, broadcast on a mobile device and visualized with virtual reality glasses. The knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (walking and feeding, respectively).
11032732|NCT04549402|Active Comparator|Video group|The intervention will consist of the visualization of movement through the reproduction of an immersive 360º video broadcast on a mobile device and viewed with virtual reality glasses. Knee extension and ankle dorsiflexion movements (quadriceps and sural triceps), together with elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
11032733|NCT04549402|No Intervention|Control group|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
11032734|NCT04549389|Active Comparator|Group A|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (1/week) by using Dornier Aries 2 shockwave machine (energy level 7)
11032735|NCT04549389|Active Comparator|Group B|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (2/week) by using Dornier Aries 2 shockwave machine (energy level 7)
11032736|NCT04549376|Experimental|PVP-I 0.4% NI|Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
11032737|NCT04549376|Experimental|PVP-I 0.5% NI|Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
11032738|NCT04549376|Experimental|PVP-I 0.6% NI|Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
11032739|NCT04549376|Experimental|PVP-I NS 0.5% NS|Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
11032740|NCT04549376|Experimental|PVP-I 0.6% NS|Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
11032741|NCT04549376|Placebo Comparator|DW NI|Arm-6 will receive distilled water through nasal irrigation
11032742|NCT04549376|Placebo Comparator|DW NS|Arm-7 will receive distilled water through nasal spray
11032743|NCT04549363|Experimental|Participants undergoing Impression cytology|Impression cytology will be performed on some participants who received or are receiving treatment with belantamab mafodotin for relapsed/refractory multiple myeloma (RRMM) and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
11032744|NCT04549363|Experimental|Participants undergoing Superficial keratectomy|Superficial keratectomy will be performed on participants with Grade 2 or 3 Common Terminology Criteria for Adverse Events (CTCAE) corneal symptoms, in addition to evidence of corneal deposits.
11032745|NCT04549337|Experimental|4X4|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up with a heart rate of 60-70% of HRmax followed by 4 intervals of 4 minutes at an intensity that will induce at least 85% of HRmax (we will start with 75% of watt max).
~Each interval is separated by 3-minute active pauses, biking at 50-70% of HRmax. Following this a 3-minute cooldown (at warm up intensity) will be performed."
11032746|NCT04549337|Active Comparator|6X1|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up on 30% of watt-max followed by 6 intervals of 1 minute at 100% of the watt-max.
~Each interval is interspersed by 3-minute active pauses at 30% of watt-max. Following this a 7-minute cooldown (at warm up intensity) will be performed."
11032747|NCT04549337|Active Comparator|10-20-30|"An exercise training protocol with a duration of 38 minutes consisting of a 10 minutes warm up at 60-70% of HRmax followed by 3 intervals of 5 minutes interspersed by 3 minutes on 50-70% of HRmax.
~Each interval consists of 5 minutes of 5 repeated 30-20-10 intervals, consisting of 30 seconds at easy pace, 20 seconds at medium pace and 10 seconds at all-out. Following this a 7-minute cooldown (at warm up intensity) will be performed."
11032748|NCT04549324||Sleep Apnea (AHI ≥ 15 per hour)|Patients with moderate/severe sleep apnea (Apnea/hypopnea-index ≥ 15 per hour).
11032749|NCT04549324||Non-Sleep Apnea (AHI < 5 per hour)|Patients without sleep apnea (Apnea/hypopnea-index < 5 per hour).
11032750|NCT04549311|Active Comparator|Packing cavity + antibiotic|"Incision and drainage of perianal abscess (standard of care), packing for hemostasis then daily packing until healing + post-operative prescription of antibiotics.
~Use of antibiotics in peri-procedural timeframe (i.e. before the abscess is drained and up to 12 hrs post-drainage) at discretion of treating clinician."
11032751|NCT04549311|Active Comparator|Packing cavity + no antibiotic|"Incision and drainage of perianal abscess (standard of care), packing for hemostasis then daily packing until healing + no post-operative use of antibiotics.
~Use of antibiotics in peri-procedural timeframe (i.e. before the abscess is drained and up to 12 hrs post-drainage) at discretion of treating clinician."
11032752|NCT04549311|No Intervention|No packing cavity + no antibiotic|"Incision and drainage of perianal abscess (standard of care), packing for hemostasis then packing removed by the patient the day following the procedure and no additional packing + no post-operative use of antibiotics.
~Use of antibiotics in peri-procedural timeframe (i.e. before the abscess is drained and up to 12 hrs post-drainage) at discretion of treating clinician."
11032753|NCT04549311|Experimental|No packing cavity + antibiotic|"Incision and drainage of perianal abscess (standard of care), packing for hemostasis then packing removed by the patient the day following the procedure and no additional packing + post-operative prescription of antibiotics.
~Use of antibiotics in peri-procedural timeframe (i.e. before the abscess is drained and up to 12 hrs post-drainage) at discretion of treating clinician."
11032754|NCT04549298||Patients with grade 2 and 3 LV diastolic dysfunction|Patients with high filling pressure
11032755|NCT04549298||Patients with normal and grade 1 LV diastolic dysfunction|Patients with normal filling pressure
11032756|NCT04549285|Experimental|hCT-MSC infusion|Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician.
11032757|NCT04549272||Patients with Patent Foramen Ovale|
11032758|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM + Tech Detailing|
11032759|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM|
11032760|NCT04549259|Experimental|Social Support + Stigma Reduction + Technology Detailing|
11032761|NCT04549259|Experimental|Social Support + Stigma Reduction|
11032762|NCT04549259|Experimental|Social Support + SBCM + Technology Detailing|
11032773|NCT04549259|No Intervention|HIV Information Only|This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.
11032774|NCT04549220||Delivery (Birth) Cohort|All women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age delivering a live infant or stillbirth at Kawempe Referral Hospital over a 6-month pilot phase will be invited to participate in the study until a sample size of at least 5000-6000 women is achieved.
11032775|NCT04549220||Active Surveillance Cohort|This is expected to improve capacity for managing and investigating infants <3 months of age presenting with suspected sepsis at Kawempe Neonatal Intensive Care Unit (NICU), Postnatal Ward, and Acute Paediatric Wards and Mulago Hospital Paediatric Acute Care Unit, through provision of supplies for blood culture, CSF culture and nasopharyngeal swabs. Mothers/caretakers of Neonates that are diagnosed with GBS through this active case surveillance will be invited to participate in the study and will be enrolled following written informed consent.
11032776|NCT04549207|Active Comparator|Standard BMA frequency|Continue standard BMA frequency (every 4 or 12 weeks) as administered previously. If a change in BMA frequency (every 4 weeks to every 12 weeks OR every 12 weeks to every 4 weeks) was prescribed by the physician, this would still be considered on protocol treatment.
11032777|NCT04549207|Active Comparator|De-escalate BMA to once every 24 weeks|Bone modifying agent once every 24 weeks.
11032778|NCT04549194|Experimental|Tyrosine - External Operation|1-month L-Tyrosine treatment following 4-month external operation
11032779|NCT04549194|Experimental|Placebo - External Operation|1-month Placebo treatment following 4-month external operation
11032780|NCT04549194|Experimental|Tyrosine - Rear Base|1-month L-Tyrosine treatment following 4 months at rear base
11032781|NCT04549194|Experimental|Placebo - Rear Base|1-month Placebo treatment following 4 months at rear base
11032782|NCT04549181|No Intervention|Phase I: Qualitative|Rural HF dyads will participate in a one-time semi-structured interview to explore the types of HF-related problems that rural HF dyads experience and how these problems are managed.
11032783|NCT04549181|Experimental|Phase II: Problem-Solving for Rural HF Dyads|The dyadic problem-solving intervention will be provided by a HF specialist nurse. The nurse will conduct the initial telehealth (virtual, telephone) session and provide dyads with an intervention booklet containing examples of common HF-related problems experienced by rural dyads and suggested management strategies tailored to the rural sociocultural context. The nurse will lead dyads in a card sorting task intended to help dyads prioritize current HF-related problems and will guide dyads in developing management strategies for the highest priority problem. Dyads will utilize these strategies until the next session at which time the nurse will guide dyads in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Dyads will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, including those specific to the rural population.
11032784|NCT04549168|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
11032785|NCT04549168|Placebo Comparator|Placebo|Participants will receive one placebo matched to lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
11032786|NCT04549155|Experimental|Network-guided TMS|The study comprises one arm of five sessions. In Day 1 (~1.5 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (~1 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. In Days 3-5 (each comprising a ~2.5 hr session) a few days later participants will undergo combined TMS-fMRI sessions. In the scanner, participants complete four fMRI runs: 2 runs using either a network-based or standard target location, counterbalanced across participants. Active and Sham TMS trials are intermixed within each run.
11032787|NCT04549142||Pregnant women- high level pollution|Exposed to high levels of pollution (PM2.5)
11032788|NCT04549142||Pregnant women- low level pollution|Exposed to low levels of pollution (PM2.5)
11032789|NCT04549142||Non-pregnant women-high level pollution|Exposed to high levels of pollution (PM2.5)
11032790|NCT04549142||Non-pregnant women-low level pollution|exposed to low levels of pollution (PM2.5)
11032791|NCT04549129|Experimental|Intervention group|Participants randomized to the intervention group will receive breastfeeding education and teaching of hand expression using a breastfeeding education video and associated breastfeeding website, as well as hands-on teaching of hand expression techniques during their 36 week visit.
11032792|NCT04549129|Active Comparator|Control group|Participants randomized to the control group will receive usual breastfeeding education during their 36-week visit.
11032793|NCT04549116|Experimental|Investigational|Progesterone-IBSA 25mg, twice daily (BID) subcutaneous (SC) injection every 12 hours and Crinone Placebo, once daily (QD) intravaginally.
11032794|NCT04549116|Active Comparator|Comparator|Crinone 8%, 90 mg, QD intravaginally and Progesterone-IBSA Placebo, BID SC Injection every 12 hours
11032795|NCT04549103|Experimental|Intervention Group|Intervention group will receive the 16-week Baduanjin exercise intervention.
11032796|NCT04549103|No Intervention|Control Group|Control group will not receive the exercise intervention, but they will attend four education classes about managing their health status.
11032797|NCT04549090||No QL block group|These patients will not be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
11032798|NCT04549090||QL block group|These patients will be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
11032799|NCT04549077||Cystic Fibrosis Patients|Patients with Cystic Fibrosis.
11032800|NCT04549077||Historical Controls|Patients diagnosed with solid tumors, who have had a normal chest CT scan during screening for possible metastasis
11032801|NCT04549064||Patients with pancreatic cancer|Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.
11032802|NCT04549064||Healthy Control|healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.
11032803|NCT04549051|Experimental|Tenex plus local anesthetic|Use of the TENEX device for sectioning of the CHL
11032804|NCT04549051|Other|Local Anesthetic|Only Local anesthetic will be injected into the CHL. This arm will have the option to cross over into Tenex arm at 1 month
11032805|NCT04549038|Experimental|Cases|Patients randomized to the cases group will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. All patients will receive 100% of their daily nutrition.
11032806|NCT04549038|No Intervention|Controls|Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
11032807|NCT04549025|Experimental|JTX-4104|Drug: JTX-4014
11032808|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 1)|"Drug: JTX-4014
~Drug: Vopratelimab Other Name: JTX-2011"
11032809|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 2)|"Drug: JTX-4014
~Drug: Vopratelimab Other Name: JTX-2011"
11032810|NCT04549012|Active Comparator|group A|will receive oxytocin
11032811|NCT04549012|Active Comparator|group B|will receive tranexamic acid plus oxytocin
11032812|NCT04548999|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
11032813|NCT04548999|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
11032814|NCT04548986|Other|single arm|single arm study
11032815|NCT04548973|Experimental|Esketamine Group|At the beginning of the operation, 0.25mg/kg ketamine was administered intravenously, and normal saline was diluted to 2mL to assist sedation and analgesia
11032816|NCT04548973|Placebo Comparator|Control Group|At the beginning of the operation, 2ml normal saline was given intravenously
11032817|NCT04548960|Other|cancer patients|cancer patients To explore the phenomena of resistance during the therapeutic response and/or the progression of the pathology, the investigatorswill used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) from blood and tumor samples and immunological profil by ELISA
11032818|NCT04548947|Experimental|Cold snare polypectomy with a submucosal injection|The procedure will include a cold snare polypectomy with a submucosal injection done prior to the resection.
11032819|NCT04548934|Active Comparator|No PPE|Cardiopulmonary resuscitation without wearing personal protective equipment (PPE)
11032820|NCT04548934|Experimental|PPE|Cardiopulmonary resuscitation while wearing personal protective equipment (PPE)
11032821|NCT04548921||Participants with Friedreich's Ataxia|Participant diagnosed with Friedreich's Ataxia aged between 2 and 50 years of age
11032822|NCT04548895||LTCF residents and involved health practitioners|"The intervention will take place in nursing homes, assisted living facilities and long-term care facilities (LTCF) in the United States (henceforth collectively referred to as LTCF).
~Staff who work in the participating LTCF ≥ 20 hours/week and who have direct contact with the residents are also eligible to participate and to employ the biometric monitoring equipment in their private residences."
11032823|NCT04548882|Experimental|Calypso Knee System|Calypso Knee System
11032824|NCT04548869|Experimental|CDX-0159|10 patients with Cold Contact Urticaria and 10 patients with Symptomatic Dermographism will be enrolled and treated with a single dose of CDX-0159
11032825|NCT04548856|Other|IA-Microsurgical clipping group (ruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of an acutely ruptured cerebral aneurysm
11032826|NCT04548856|Other|IB-Microsurgical clipping group (unruptured aneurysms)|This subgroup includes patients who underwent microsurgical clipping of unruptured cerebral aneurysm
11032827|NCT04548856|Other|IIA-Endovascular embolization group (ruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of an acutely ruptured cerebral aneurysm
11032828|NCT04548856|Other|IIB-Endovascular embolization group (unruptured aneurysms)|This subgroup includes patients who underwent endovascular embolization of unruptured cerebral aneurysm
11032829|NCT04548843|Experimental|Cohort 1 & Cohort 2|"3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells).
~3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells)."
11032830|NCT04548830|Experimental|Transbronchial cryobiopsy|All study participants will undergo transbronchial biopsies via our proposed standardized cryo-biopsy protocol in place of the traditional forceps transbronchial biopsy that is typically used at MSK.
11032831|NCT04548817||Neurocutaneous Melanocytosis|Participants will have Neurocutaneous Melanocytosis (NCM) Including Cutaneous and CNS Involvement
11032832|NCT04548804|Experimental|Control|Control subjects receiving body-surface potential mapping (BSPM) and CT-scan.
11032833|NCT04548804|Experimental|Diseased|Diseased subjects receiving body-surface potential mapping (BSPM) and CT-scan. Outcome measures from these procedures will be compared to controls.
11032834|NCT04548791|Experimental|Cohort 1|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 10 μg/kg, 20 μg/kg, 30 μg/kg, 40 μg/kg, and 60 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 20 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
11032971|NCT04547816|Experimental|biofeedback and tibial neuromodulation (BFB+TNM)|
11032972|NCT04547816|Experimental|BFB+TNM + pelvic floor muscles training (PFMT)|
11032835|NCT04548791|Experimental|Cohort 2|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
11032836|NCT04548791|Experimental|Cohort 3|For Phase 1, a Coagulation Factor VIIa variant by intravenous route, 18 μg/kg, followed by ascending doses by subcutaneous route, 30 μg/kg, 45 μg/kg, 60 μg/kg, 120 μg/kg, and 180 μg/kg, for PK and PD assessment. For Phase 2, Coagulation Factor VIIa, 60 μg/kg by subcutaneous route, administered on demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis.
11032837|NCT04548778||exocrine pancreatic insufficiency (PEI)|Established diagnosis of PEI based on a routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
11032838|NCT04548778||no exocrine pancreatic insufficiency (no PEI)|No evidence of PEI according to routine clinical diagnostic work-up including a treat-to-diagnose approach using Pancreatic Enzyme Replacement Therapy (PERT).
11032839|NCT04548765|Active Comparator|Standard Letter|The standard letter describes the importance of getting screened and instructs recipients how to use the FIT kit for screening at home.
11032840|NCT04548765|Experimental|Letter with Risks|The standard letter is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; it also explains why test kits are being sent to disarm skepticism about the program.
11032841|NCT04548765|Experimental|Letter with Risks and Options|In addition to the enhancements added by the letter with risks, the letter also includes a table comparing FIT kit and colonoscopy. Presenting different screening options allows recipients to make the choice that best suits them. In addition, presenting multiple options increases the chance that recipients get screened in one way or another.
11032842|NCT04548765|Experimental|Letter with Risks, Options, and Consequences for Inaction|In addition to the enhancements added by the letter with risk, the comparison table includes comparisons of the consequences of getting screened vs. waiting for symptoms to appear.
11032843|NCT04548752|Experimental|Arm A (olaparib, pembrolizumab)|Patients receive olaparib PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 19, patients receive olaparib PO BID on days 1-42 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11032844|NCT04548752|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11032845|NCT04548726||Sapien 3|Patients with aortic stenosis treated with Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) TAVI
11032846|NCT04548726||Myval|Patients with aortic stenosis treated with Myval (Meril Life Sciences Pvt. Ltd., India) TAVI
11032847|NCT04548713|Experimental|4% EDTA CVC Lock|Patients in this group will be given 4% EDTA as their CVC locking solution.
11032848|NCT04548713|Active Comparator|Standard of Care Saline CVC Lock|Patients in this group will be given standard of care saline as their CVC locking solution.
11032849|NCT04548700|Experimental|Dose-finding and dose-expansion|"Dose-finding stage: Patients with treatment-naïve PTCL will receive sequentially higher doses of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 days per cycle). The initial dose of liposomal mitoxantrone hydrochloride is 12 mg/m2.
~Dose-expansion stage: Patients with treatment-naïve PTCL will receive liposomal mitoxantrone hydrochloride at RP2D in combination with Cyclophosphamide, Vincristine and Prednisone for 6 cycles (planned) (28 or 21 days per cycle)."
11032850|NCT04548687|Active Comparator|carbon dioxide insufflation|patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities, supplemented with carbon dioxide insufflation during surgery + standard methods of deaeration of cardiac cavities
11032851|NCT04548687|Other|no carbon dioxide|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
11032852|NCT04548674|Placebo Comparator|Positive Control Group|Whiteness HP 35%
11032853|NCT04548674|Experimental|Laser Group|Whiteness HP 35% + Laser
11032854|NCT04548674|Experimental|CPP Group|Whiteness HP 35% + CPP
11032855|NCT04548674|Experimental|Nano Group|Whiteness HP 35% + NANO
11032856|NCT04548674|No Intervention|Negative Control|Without intervention
11032857|NCT04548661|Experimental|Povidone-iodine solution|
11032858|NCT04548661|Placebo Comparator|Saline|
11032859|NCT04548661|No Intervention|No irrigation|Standard incision management
11032860|NCT04548648|Other|Open-label, single-arm|A multicenter open-label, single-arm, phase 2 study designed to investigate the antitumor effects of acalabrutinib in subjects with relapsed primary central nervous system lymphoma (PCNSL), and relapsed secondary CNS lymphoma (SCNSL) with no evidence of current systemic disease. Subjects will receive acalabrutinib at the dose of 100 mg every 12 hours. Prophylactic administration of broad spectrum triazole antifungal agent isavuconazole will be performed while subjects receive acalabrutinib.
11032861|NCT04548635|Experimental|VR-PAT|Virtual Reality administered during burn dressing changes
11032862|NCT04548635|No Intervention|Control|Dressing changes performed without Virtual Reality (other distraction methods available in the home allowed).
11032863|NCT04548622|Experimental|Non-randomized bilateral rTMS|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
11032864|NCT04548609|Experimental|Inhibitory Control/ Fear Extinction|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Fear Extinction. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11032865|NCT04548609|Experimental|Inhibitory Control/ Goal-Orientated vs Habit-Based Behavior|This arm will investigate the effect of tDCS on tasks assessing Inhibitory Control/ Goal-Orientated versus Habit-Based Behavior. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11032866|NCT04548583|Experimental|remestemcel-L (75 million cells)|Targeted endoscopic delivery of remestemcel-L, at a dose of 75 million cells into the submucosal layer of the colon wall at baseline
11032867|NCT04548583|Experimental|remestemcel-L (150 million cells)|Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.
11032868|NCT04548583|Placebo Comparator|Placebo|Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 75 or 150 million cells into the submucosal layer of the colon wall.
11032869|NCT04548570||approximation of both recti group|
11032870|NCT04548570||non approximation of both recti group|
11032871|NCT04548557|No Intervention|Control|They will not receive any intervention
11032872|NCT04548557|Experimental|IVIG group|They will reveive intravenous immunoglobulin therapy
11032873|NCT04548544|Experimental|TARA training|
11032874|NCT04548544|No Intervention|Control|
11032875|NCT04548531|No Intervention|Usual Care Arm|This arm will be a usual care arm. Patients may call to schedule a colonoscopy or other tests as desired.
11032876|NCT04548531|Experimental|Shared Decision Making Arm|This is the intervention arm. Patients will receive a shared decision making information sheet in the mail and will be able to receive decision coaching from study staff to support selection of an option if desired.
11032877|NCT04548518|Active Comparator|GPO Tri Fluvac vaccine|408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.
11032878|NCT04548518|Active Comparator|Licensed Influenza vaccine|408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
11032879|NCT04548479|Active Comparator|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure (PEP) breathing
11032880|NCT04548479|No Intervention|INS group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Inspiratory incentive spirometry breathing
11032881|NCT04548466|No Intervention|CONTROL group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
11032882|NCT04548466|Experimental|PEP group|Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
11032883|NCT04548453|Experimental|Uterine EMG during labor|Multichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor.
11032884|NCT04548440|Experimental|Preoperative Sintilimab plus Nab-paclitaxel and Cisplatin|"Patients receive the following regimen every 3 weeks:
~Sintilimab 200mg IV on Day 1; Albumin-bound paclitaxel 125 mg/m2 IV on Day 1 and Day 8; Cisplatin 75mg/m2 IV on Day 1; Standard hydration regimen on Day 0-3
~After 2-4 cycles, radiological evaluation and multidisciplinary assessment will be performed. If radical resection is possible, surgery is to be performed 3-6 weeks after the last chemotherapy session. In the case of a R0 resection, the investigator will decide whether to perform adjuvant therapy depending on the patient's condition; in the case of R1 or R2 resection, concurrent chemoradiotherapy is recommended. If the multidisciplinary assessment considers that radical resection is not possible, radical concurrent chemoradiotherapy is performed."
11032885|NCT04548427|Experimental|CKD-352|
11032886|NCT04548427|Active Comparator|Diquafosol Sodium 3%|
11032887|NCT04548414||Sepsis group|The patients in this group are diagnosed sepsis with the sepsis 3.0 definition.
11032888|NCT04548414||Control group|The recruited volunteers in this group are healthy.
11032889|NCT04548401||Antiplatelet-N group|Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy
11032890|NCT04548401||Antiplatelet-Y group|Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)
11032891|NCT04548388|Experimental|Bobath approach|Bobath approach
11032892|NCT04548388|Experimental|whole body vibration|whole body vibration
11032893|NCT04548362|Experimental|Meat meals|This arm contains a 4-way cross-over intervention study with meats
11032894|NCT04548362|Experimental|Starchy meals|This arm contains a 4-way cross-over intervention study with
11032895|NCT04548349|Experimental|Altreno Group|
11032896|NCT04548349|Experimental|BPO Group|
11032897|NCT04548349|No Intervention|Control Group|During the entire study period, the subjects in the control group will not be allowed to use any antibacterial wash, other than approved OTC cleansers.
11032898|NCT04548336|Experimental|Motor Imagery|
11032899|NCT04548336|Experimental|Action Observation|
11032900|NCT04548336|Placebo Comparator|Placebo group|
11032901|NCT04548323||Motor Imagery in Sedentary subjects|
11032902|NCT04548323||Motor Imagery active subjects|
11032903|NCT04548310||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
11032904|NCT04548310||Healthy group|Healthy individuals without chronic disease
11032905|NCT04548297||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
11032906|NCT04548297||Healthy group|Healthy individuals without chronic disease
11032907|NCT04548284|Experimental|Periorbitally Injected Glucocorticoids|Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
11032908|NCT04548284|No Intervention|Observe|Observe and wait.
11032973|NCT04547816|Experimental|BFB+TNM+PFMT+diet modification|
11032909|NCT04548271|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
11032910|NCT04548258|Experimental|electric welded metal framework|using electric welding device to intraorally join metal framework where the study aim to save time and cost and eliminate lab errors
11032911|NCT04548258|Experimental|conventional cast metal technique|using the conventional casting technique to join metal framework and compare it with the electric welding technique
11032912|NCT04548245||Term|
11032913|NCT04548245||Preterm|
11032914|NCT04548219|Experimental|Mirikizumab (Reference)|Reference formulation of mirikizumab administered as a subcutaneous (SC) injection.
11032915|NCT04548219|Experimental|Mirikizumab (Test)|Test formulation of mirikizumab administered as a SC injection.
11032916|NCT04548206|Experimental|Pilates training|60 minutes of Pilates training will be performed for 8 weeks.
11032917|NCT04548206|Placebo Comparator|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
11032918|NCT04548193|Experimental|Arm A (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM A: Patients receive mailed educational materials about the importance of consuming cruciferae, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
11032919|NCT04548193|Active Comparator|Arm B (educational materials, phone call, phone messages)|HEALTHY EATING PROGRAM B: Patients receive mailed educational materials about general fruit and vegetable intake, setting healthier eating goals, and the importance of keeping track of what they eat. Patients also receive one phone call from study staff to make sure they understood the educational materials received and 11 IVR phone messages over 6 months.
11032920|NCT04548180||TBI BIAFAC|100 TBI subjects with BIAFAC will be enrolled. No intervention
11032921|NCT04548154|Experimental|Proximal Resistance Training|Participants will receive 6 one-on-one supervised intervention visits and 8 telerehabilitation visits over 10 weeks. For the first 4 weeks intervention frequency will start with 1x/ week in clinic and 1x/ week via telerehabilitation, and the participant will be asked to perform exercises 2x/ week independently. For the final 6 weeks there will be 1x week supervised visits (weeks 6 and 8 in person, and weeks 5,7, 9, and 10 via telerehabilitation) and the participant will be asked to perform exercises 3x/ week independently.
11032922|NCT04548141|Experimental|Active adults|Adults coming for a visit for sports activity participation and submitted the SAPHIR questionnaire
11032923|NCT04548128|Experimental|Treatment Arm|The treatment arm will have the HM3 LVAS implanted utilizing a technique other than full median sternotomy (e.g. thoracotomy).
11032924|NCT04548115|Experimental|ARTISAN Condition|Participants assigned to this arm will engage in ARTISAN, a 5-weekly, 15-hour group-based arts and heritage intervention programme with specific intervention components including curated museum tours, facilitated storytelling and professionally-led art-making. The weekly intervention covers the five ARTISAN themes of national heritage, social bonds, adversity and resilience, dreams and aspiration, and community art exhibition.
11032925|NCT04548115|Experimental|Intergenerational Participatory Arts Condition|Participants assigned to this arm will engage in the participatory arts-making component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based professionally-led art-making that covers the five ARTISAN themes.
11032926|NCT04548115|Experimental|Intergenerational Art-space Condition|Participants assigned to this arm will engage in the cultural space component of the ARTISAN Intervention framework. Youths and senior participants in this condition will engage in a 5-weekly, 5-hour, group-based a group-based curated museum tour that covers the five ARTISAN themes.
11032927|NCT04548115|Experimental|Inter-generational Storytelling Condition|Participants assigned to this arm will engage in the storytelling component of the ARTISAN Intervention framework. Youths and senior participants in this condition will be paired to engage in a 5-weekly, 5-hour, group-based guided storytelling activity that covers the five ARTISAN themes.
11032928|NCT04548115|Experimental|Control Condition|Participants assigned to this arm will engage in a 5-weekly, 5-hour, group-based physical activity session conducted in the community.
11032929|NCT04548102|Experimental|Fetal Movement Counting|Fetal movement counting
11032930|NCT04548102|No Intervention|standard antenatal follow up care|Women in the control group received the antenatal hospital standard care.
11032931|NCT04548089|Experimental|Immediate Intervention Group|Participants assigned to the immediate intervention group will engage in a 4-week 2.5-hour Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) with intervention elements of brief psycho-education, weekly mindfulness meditation, facilitated creative art making, reflective writing, group sharing and discussion.
11032932|NCT04548089|Experimental|Waitlist Control Group|Participants assigned to the wait-list control group will not receive Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) until one month after baseline assessment.
11032933|NCT04548063|Experimental|6,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 6,000 words.
11032934|NCT04548063|Experimental|4,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 4,000 words.
11032935|NCT04548063|Experimental|2,000 word consent form|Subjects who are receiving cancer therapy or have been treated for cancer in the past will be asked to review a mock consent form of approximately 2,000 words.
11032936|NCT04548050||mothers informed by untrained nurse|
11032937|NCT04548050||mothers informed by trained nurse|
11032938|NCT04548050||mothers informed by nurses trained 6 months ago|
11032939|NCT04548037||Patients with transient global amnesia|
11032940|NCT04548037||Healthy volunteers|
11032974|NCT04547803|Experimental|Video Visit and Standard of Care|Participants will participate in a video visit and standard of care
11032975|NCT04547803|Active Comparator|Standard of Care|Participants will participate in standard of care for discharged patients.
11032941|NCT04548011|Experimental|Three times a week group|Twenty participants in three times a week group will receive acupuncture treatment 3 times per week (every other day) for 4 weeks, 12 sessions totally. The acupuncture operation as above. Participants will not be not allowed to take any other medication or accept any treatment for FD. should not be accepted during the study. In case of unbearable symptoms, the assistant researchers will detailly document.
11032942|NCT04548011|Experimental|Once a week group|Twenty participants in once a week group will receive acupuncture treatment 1 time per week for 4 weeks (Weekly fixed day), 4 sessions totally. Other inventions will be same as the Three times a week group.
11032943|NCT04548011|No Intervention|Waiting for treatment group|After the health education（such as dietary adjustment for FD patients）, the participants will be followed up for 4 weeks. At the end of the follow-up, the patients could be given free acupuncture treatment (the invention will be similar with that of the Three times a week group) for 4 weeks at will.
11032944|NCT04547998|Experimental|Spray-On Skin™ Cells 1:5 with NB-UVB|Skin cell suspension at 3 expansion ratios (donor area : recipient area), prepared using the RECELL System, will be applied to an ablated (de-epithelialized) area of depigmentation, followed by targeted phototherapy using NB-UVB. Each participant will be randomized to receive treatment of a portion of their depigmented lesion with cell suspension prepared at 1:5.
11032945|NCT04547998|Experimental|Spray-On Skin™ Cells 1:10 with NB-UVB|Skin cell suspension at 3 expansion ratios (donor area : recipient area), prepared using the RECELL System, will be applied to an ablated (de-epithelialized) area of depigmentation, followed by targeted phototherapy using NB-UVB. Each participant will be randomized to receive treatment of a portion of their depigmented lesion with cell suspension prepared at 1:10.
11032946|NCT04547998|Experimental|Spray-On Skin™ Cells 1:20 with NB-UVB|Skin cell suspension at 3 expansion ratios (donor area : recipient area), prepared using the RECELL System, will be applied to an ablated (de-epithelialized) area of depigmentation, followed by targeted phototherapy using NB-UVB. Each participant will be randomized to receive treatment of a portion of their depigmented lesion with cell suspension prepared at 1:20.
11032947|NCT04547998|Active Comparator|NB-UVB only|Each subject will serve as their own control, with a portion of the depigmented lesion receiving no RECELL treatment but receiving the same targeted NB-UVB as the investigational treatment area.
11032948|NCT04547985|Placebo Comparator|Placebo|23 randomized patients will take placebo daily for 8 weeks.
11032949|NCT04547985|Active Comparator|Naltrexone|23 randomized patients will take naltrexone daily for 8 weeks
11032950|NCT04547972|Active Comparator|Higher-load limbs|This treatment arm will have participants performing resistance training with loads of ~80% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
11032951|NCT04547972|Active Comparator|Lower-load limbs|This treatment arm will have participants performing resistance training with loads of ~30% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
11032952|NCT04547959|Experimental|C-CURVE PEEK|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in PEEK or Titane is used
11032953|NCT04547959|Experimental|C-CURVE Titane|According the routine practice of the investigator surgeon, the interbody cage C-CURVE in PEEK or Titane is used
11032954|NCT04547946||dabrafenib + trametinib|Patients administered dabrafenib and trametinib
11032955|NCT04547933||OAB-wet|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency and urinary incontinence (UI) were allocated to the overactive bladder syndrome (OAB) -wet group.
11032956|NCT04547933||OAB-dry|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency but without incontinence were allocated to the OAB-dry group.
11032957|NCT04547933||UI|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of UI but without urgency were allocated to the UI group.
11032958|NCT04547933||Nocturia|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 2 episodes of nocturia but without urgency and UI were allocated to the nocturia group.
11032959|NCT04547933||Frequency|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 8 episodes of daytime frequency but without urgency, UI and nocturia were allocated to the frequency group.
11032960|NCT04547933||Normal|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women without urgency, UI, nocturia nor frequency were allocated to the normal group.
11032961|NCT04547907|Experimental|nab-PHP|Albumin binding paclitaxel + trastuzumab+ patuzumab
11032962|NCT04547907|Active Comparator|TCbHP|Docetaxel + carboplatin + trastuzumab + patuzumab
11032963|NCT04547894|Experimental|ASC09F|ASC09F one tablet at a time, once per day, up to 7 days.
11032964|NCT04547868|Experimental|Coffee|Caffeinated coffee beverage
11032965|NCT04547868|Active Comparator|Decaffeinated coffee|Decaffeinated coffee beverage
11032966|NCT04547868|Placebo Comparator|Warm water|Warm water beverage
11032967|NCT04547855|Experimental|experimental group|anlotinib combined with dose-dense temozolomide
11032968|NCT04547842|Active Comparator|Group M: patients receive Mirtazapine|the patient will receive an oral disintegrating tablet (ODT) of mirtazapine 30 mg with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 min as a placebo 1 h preoperatively
11032969|NCT04547842|Active Comparator|Group D: patients receive Dexamethasone|the patient will receive a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 min, 1 h preoperatively.
11032970|NCT04547829|Experimental|PEG-rhG-CSF|pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection
11032976|NCT04547790|Experimental|Psyllium group|Subjects will take psyllium once daily for the first three days, then twice daily starting Day 4 until the end of the study.
11032977|NCT04547790|Experimental|Wheat Dextrin group|Subjects will take wheat dextrin once daily for the first three days, then twice daily starting Day 4 until the end of the study.
11032978|NCT04547777|Experimental|D2C7-IT + 2141-V11|Single D2C7-IT intratumoral infusion (4613.2 ng/mL in 36 mL) over 72 hours followed by single 2141-V11 infusion (5 dose levels) over 7 hours
11032979|NCT04547764|Experimental|TAP group|
11032980|NCT04547764|Active Comparator|Vitapex group|
11032981|NCT04547751||Adult|Patients aged 18yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
11032982|NCT04547751||Minor|Patients aged 14-17yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
11032983|NCT04547738||Tuberculosis (TB) index patients|- Patients (older than 5 years) diagnosed with TB before initiation of TB treatment
11032984|NCT04547738||TB contacts|- Children (5-17 years old), who had contact with TB index patients
11032985|NCT04547725|Experimental|CRS-IP|Stage IV gastric cancer with limited peritoneal carcinomatosis (peritoneal carcinomatosis index [PCI] ≤ 10)
11032986|NCT04547699|Placebo Comparator|HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein,
11032987|NCT04547699|Experimental|CYK+ high HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma),and 5ng/mL LIF (SRP9001 Sigma).
11032988|NCT04547699|Active Comparator|CYK+low HSA|A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF (SRP9001 Sigma).
11032989|NCT04547686|Experimental|Smoke-Free Homes intervention|Participants in the intervention condition will receive the expanded Smoke-Free Homes intervention. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
11032990|NCT04547686|Active Comparator|Control|The usual care/control arm will receive mailed information on the QL (quitline), and a connection to the QL at their request. Follow-up will be at six and twelve months, including saliva cotinine validation for reported 7-day cessation.
11032991|NCT04547673||NPC group|Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
11032992|NCT04547673||Non-NPC group|Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
11032993|NCT04547660|Experimental|Convalescent Plasma|Transfusion of 2 aliquots of 300 ml of frozen convalescent plasma, 2 days apart, thawed at 37 degrees Celsius before infusion. Best supportive care except for investigational interventions.
11032994|NCT04547660|Active Comparator|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
11032995|NCT04547634|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
11032996|NCT04547634|No Intervention|Control|Subjects will be told to continue with their normal activity of daily living. After the intervention in the experimental group, the control group will be offered intervention.
11032997|NCT04547621|Experimental|HSRT+IMRT+Temozolomide|"Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.
~Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.
~Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy."
11032998|NCT04547608|Other|group PRi|received immediate injection of rocuronium after propofol administration,
11032999|NCT04547608|Other|group PRd|rocuronium injection when bispectral index score became below 60 after propofol administration
11033000|NCT04547595|No Intervention|CONTROL|Standard care
11033001|NCT04547595|Active Comparator|Hypnosis|Standard care + intervention
11033002|NCT04547582|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
~Participants in this study receive spinal cord stimulation will be trans-tibial amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
11033003|NCT04547569|Experimental|Adaptation to altered auditory feedback|fMRI measurement of brain activity during speech production under altered auditory feedback
11033004|NCT04547569|Experimental|Speech production|fMRI measurement of brain activity during normal speech production
11033005|NCT04547569|Experimental|Vibrotactile discrimination|fMRI measurement of brain activity during a vibrotactile discrimination task
11033006|NCT04547556|Experimental|Intervention|
11033007|NCT04547556|No Intervention|Standard of Care|
11033008|NCT04547543|Other|Video consultation|Patients in this group will have a continuous positive pressure follow-up visit by videoconsultation
11033009|NCT04547543|No Intervention|Face-to-face consultation|Patients in this group will have a continuous positive pressure follow-up visit by face-to-face consultation
11033010|NCT04547530|Active Comparator|Vitamin D|"Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.
~If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.
~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
11033011|NCT04547530|Placebo Comparator|Placebo|"Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.
~If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.
~The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice."
11033013|NCT04547504|Active Comparator|Chemotherapy-Pembrolizumab|Chemotherapy and Pembrolizumab
11033014|NCT04547491|Other|GDT group|Cardiac optimization with goal-directed therapy, liberal use of vasopressor agents.
11033015|NCT04547491|Experimental|HPI group|Hemodynamic management HPI-based, protocol-based use of fluids, vasopressors and inotropes.
11033016|NCT04547452|Experimental|Sintilimab Combined with SBRT|"Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.
~Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year."
11033017|NCT04547452|Active Comparator|Sintilimab|Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
11033018|NCT04547439|Active Comparator|Control|Placebo
11033019|NCT04547439|Active Comparator|Melatonin|Melatonin
11033020|NCT04547426|Active Comparator|red wine and snuff|regular red wine and moist snuff
11033021|NCT04547426|Active Comparator|red wine and nicotine-free snuff|regular red wine and nicotine-free snuff
11033022|NCT04547426|Active Comparator|non alcoholic red wine and regular moist snuff|non alcoholic red wine and regular moist snuff with nicotine
11033023|NCT04547426|Placebo Comparator|non-alcoholic red wine and nicotine-free snuff|Non-alcoholic red wine and nicotine-free snuff
11033024|NCT04547413|No Intervention|Control Arm|"Control Arm will will complete a total of three visits:
~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment
~Monthly: Prevention Maintenance Intervention Messages from months 2-11
~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey
~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
11033025|NCT04547413|Active Comparator|Intervention Arm|"Intervention Arm will will complete a total of four visits:
~Visit 1 (Day 1): Recruitment/Baseline Biological Testing, if needed; completion of baseline study surveys including Knowledge Assessment
~Visit 2 (Day 2-30): Group Intervention Session, Feedback form, and post-intervention knowledge assessment (for intervention arm only)
~Monthly: Prevention Maintenance Intervention Messages from months 2-11
~Visit 3 (Day 180): 6 Month Follow-up biological testing and study survey
~Visit 4 (Day 365): 12 Month Follow-up biological testing and study surveys"
11033026|NCT04547400||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
11033027|NCT04547400||Healthy group|Healthy individuals without chronic disease
11033028|NCT04547387||Carotid Artery Stenting|Consecutive patients with symptoms or signs of ischemic cerebral injury eligible for endovascular carotid artery revascularization using direct carotid artery access and MicroNET covered carotid stent plaque exclusion under cerebral protection by temporary flow reversal
11033029|NCT04547374||Cohort 1 - GaH Intervention|Cohort 1 - GaH intervention group
11033030|NCT04547374||Cohort 2 - Standard-of-care control group|"Cohort 2 - Standard-of-care control group
~*Importantly, these individuals are eligible for referral to GaH at the discretion of their physicians.*"
11033031|NCT04547361|Experimental|Cohort 1: Dose 1 E2511 or Placebo|Participants will receive Dose 1 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
11033032|NCT04547361|Experimental|Cohort 2: Dose 2 E2511 or Placebo|Participants will receive Dose 2 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
11033033|NCT04547361|Experimental|Cohort 3: Dose 3 E2511 or Placebo|Participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 (Treatment Period 1) under fasted condition followed by Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 7 (Treatment Period 2) under fed condition. A washout period of 6 days will be maintained between the doses.
11033034|NCT04547361|Experimental|Cohort 4: Dose 4 E2511 or Placebo|Participants will receive Dose 4 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
11033035|NCT04547361|Experimental|Cohort 5: Dose 5 E2511 or Placebo|Participants will receive Dose 5 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
11033036|NCT04547361|Experimental|Cohort 6: Dose 6 E2511 or Placebo|Participants will receive Dose 6 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
11033037|NCT04547361|Experimental|Cohort 7: Dose 3 E2511 (Elderly Participants) or Placebo|Elderly participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
11033038|NCT04547348|Experimental|Denosumab treated group|Participants will receive a 60 mg subcutaneous injection of Prolia upon randomization and on week 28 after the first injection provided remission of the Charcot foot has not been achieved by then
11033039|NCT04547348|Placebo Comparator|Placebo treated group|Participants will receive an injection of placebo produced by the same provider as the prolia drug of equivalent volume at the same time points as the treated group
11033040|NCT04547335||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
11033041|NCT04547322|Experimental|VR application group|The experimental group received VR application in the preoperative period for 10 minutes.
11033042|NCT04547322|No Intervention|Control group|The control group received the routine procedure in the unit clinic where the study was conducted. The routine procedure of the unit includes patients are taken to the operating room on a stretcher and wait on the stretcher in the surgery waiting room until the operation room is prepared.
11033043|NCT04547309|Experimental|68Ga/18F-HER2 Affibody PET/CT scan|
11033044|NCT04547296|Experimental|BRS group|After entering the operating room, this group were pre-dilated with sodium bicarbonate ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h sodium bicarbonate ringer's solution during the operation.
11033045|NCT04547296|Experimental|ARS group|After entering the operating room, this group were pre-dilated with acetate ringer ringer's solution (30 min, 8 ml/kg), and maintained with 4-5 ml/kg/h acetate ringer's solution during the operation.
11033046|NCT04547283|Active Comparator|Usual Care|Participants randomized to this arm will remain in their clinician's team standard practice and their natural choice of position, which is anticipated to favor a supine (rather than prone) position.
11033084|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 4）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
11033047|NCT04547283|Experimental|Awake-Prone Positioning Strategy|Participants randomized to this arm will receive guidance from their Inpatient treatment team to assume the prone position for as much time as is tolerable during hospitalization.
11033048|NCT04547257|Experimental|Treatment|Extracorporal therapy with Seraph 100 blood filter
11033049|NCT04547257|No Intervention|Control|patients receive antibiotics only as standard of care
11033050|NCT04547244||T2DM patients with CRTd with automatic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.
11033051|NCT04547244||T2DM patients with CRTd with echocardiographic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.
11033052|NCT04547231||Deferral of PCI group|Patients with a vessel determined to defer revascularization after FFR measurement who undergo CCTA within 90 days before FFR measurement will be included.
11033053|NCT04547231||PCI group|Patients with a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) with available coronary CT angiography within 90 days before FFR measurement will be included.
11033054|NCT04547218||Elderly patients|Above 65 year old patients undergoing elective surgery
11033055|NCT04547205|Experimental|AK109|
11033056|NCT04547192|No Intervention|Pre TIF introduction|Emergency Health Service prior to introduction of TIF.
11033057|NCT04547192|Experimental|Post introduction of TIF|Emergency Health Service after introduction of TIF.
11033058|NCT04547179|Experimental|BLAfit® usage|In this arm, subjects will used the fixed orthotic device called BLAfit® for one minute of facial exercise a day for three months.
11033059|NCT04547179|Experimental|fremanezumab-vfrm|Subjects in this arm will receive three Ajovy® (fremanezumab-vfrm) injections at the start of month 2. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
11033060|NCT04547179|Placebo Comparator|Saline injection|This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
11033061|NCT04547166|Experimental|HLX10 + HLX04|
11033062|NCT04547166|Placebo Comparator|placebo + Avastin ®|
11033063|NCT04547153|Experimental|LD-FUD|5-Fu 200mg/m2/day continuously for 20 days; Docetaxel 25mg/m2, days 5, 12 and 19; Every four weeks.
11033064|NCT04547140|Experimental|Liquid Alpha1-Proteinase Inhibitor+Standard Medical Treatment|Participants will receive the first Intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) (120 milligram per kilogram [mg/kg]), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11033065|NCT04547140|Placebo Comparator|Placebo+Standard Medical Treatment|Participants will receive IV infusions of 0.9% Normal Saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11033066|NCT04547127|Experimental|Convalescent anti-SARS-CoV-2 MBT Plasma + SMT|Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11033067|NCT04547127|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
11033068|NCT04547114||SARS-CoV-2- infected|Detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
11033069|NCT04547114||non infected|Lack of detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
11033070|NCT04547101|Experimental|AK104|
11033071|NCT04547088|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy. Every patient will receive Apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
11033072|NCT04547049|Active Comparator|Non-first-degree donor|Each patient receive graft from a non-first degree donor aged ≤40
11033073|NCT04547049|Active Comparator|First-degree donor|Each patients receive graft from a first-degree donor aged >50
11033074|NCT04547036||Endothelial cell count measurment|
11033075|NCT04547023|Experimental|Fasting before gestational diabetes screen|Fasting for at least 6 hours prior to the 1-hour gestational diabetes screen.
11033076|NCT04547023|Active Comparator|Fed before gestational diabetes screen|Liberal per oral intake within 2 hours of the 1-hour gestational diabetes screen.
11033077|NCT04547010|Experimental|Intervention group|In four weeks of intervention study the participants instructed to receive (60 mg) of soy-isoflavone supplement per day, after this period the Bone Mineral Density was assessed by Dual X-ray Absorptiometry scan to evaluate the effect of soy-isoflavone supplement on Bone mineral density.
11033078|NCT04546997||Patients with ocular blunt trauma|Patients with previous ocular blunt trauma in one eye.
11033079|NCT04546997||Control Group|Healthy fellow eyes without actual and previous ocular trauma
11033080|NCT04546984|Experimental|Single dose of HEC96719 （Part 1，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC96719 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
11033081|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 1）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
11033082|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 2）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
11033083|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 3）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
11033085|NCT04546984|Experimental|Mulltiple doses HEC96719（ Part 2, Cohort 5）|Healthy subjects receive multiple doses of HEC96719 or matching placebo
11033086|NCT04546971|Active Comparator|Brief intervention|A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.
11033087|NCT04546971|Experimental|Brief Intervention plus Telehealth Counseling|A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.
11033088|NCT04546958|Active Comparator|Nutritional counseling arm|Nutritional counseling, targeting daily protein intake 1.2 g/kg Dietitian will provide one-to-one dietary education, 30 minutes duration, on a monthly basis
11033089|NCT04546958|Experimental|Nutritional counseling plus whey protein supplements arm|Nutritional counseling plus whey protein supplements, targeting daily protein intake 1.5 g/kg In addition to receiving nutritional counseling, participants are instructed to take an additional whey protein supplement at the dose of ~0.3 g/kg protein intake.
11033090|NCT04546945||control cases|normal healthy person
11033091|NCT04546945||Patients|Patients with hematologic malignancies. Newly diagnosed.
11033092|NCT04546932|Experimental|Lung-protective mechanical ventilation|Vt=7 ml/kg IBW; an intraoperative 10 cmH2O in PEEP, recruitment maneuvers applying a stepwise increase in PEEP.
11033093|NCT04546932|No Intervention|Conventional mechanical ventilation|the tidal volume was set at 10 ml/kg IBW without PEEP and (recruitment maneuvers) RM
11033094|NCT04546906|Experimental|CD22 CAR-T|Patients will be treated with CD22 CAR-T cells
11033095|NCT04546893|Experimental|1904B CAR-T|Patients will be treated with CD19 CAR-T cells
11033096|NCT04546880|Experimental|Group 1:Breathing and Stabilization Exercise Group|Breathing exercises combined with stabilization exercises
11033097|NCT04546880|Active Comparator|Group 2: Stabilization Exercise Group|Only Stabilization exercises therapy
11033098|NCT04546867|Other|Sonography arm|Sonography is being performed by expericenced investigators to visualize a pancreatic stent in the pancreatic duct. If the stent is being visualized, an endoscopy will be performed to remove the stent. Otherwise, x-ray will be needed to confirm the sonographic finding of a dislodged pancreatic stent with no further need of intervention. If x-ray finds a pancreatic stent in situ opposingly to ultrasound, an endoscopy will be performed to confirm the stents position and eventually remove it.
11033099|NCT04546854|Experimental|Conservative - Binding Appeal|
11033100|NCT04546854|Experimental|Liberal - Individulizing Appeal|
11033101|NCT04546841|Experimental|Vaccination|"A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.
~Part I: Age 18-55 at the time of screening, n=12
~Part II: Age 56-74 years at the time of screening, n=12
~Part III: Age ≥ 75 years at the time of screening, n=12"
11033102|NCT04546828|Experimental|Gemcitabine, Cisplatin, and Nab-Paclitaxel|"Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:
~Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:
~Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days"
11033103|NCT04546815||Gram-positive cocci infection|No intervention. The clinical data of patients (including demographic information, details of anti-infective therapy, imaging and laboratory testings) will be collected and analyzed.
11033104|NCT04546802|Active Comparator|Immediate treatment|This group will undergo immediate treatment of the HCV once HCC complete response (CR) has been confirmed
11033105|NCT04546802|Active Comparator|Delayed treatment|This group will delay commencement of the HCV treatment until 6 months after HCC complete response (CR) has been confirmed
11033106|NCT04546789|Experimental|Group 1: Normal Hepatic Function|Healthy participants who have normal hepatic function with sex, age (± 10 years; >= 18 years old and =< 79 years old), and weight (± 10 percent; >= 50 kilogram (kg) and =< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
11033107|NCT04546789|Experimental|Group 2: Mild Hepatic Impairment|Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
11033108|NCT04546789|Experimental|Group 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).
11033109|NCT04546776||Faecal and saliva sampling|A minimum of 4 and a maximum of 8 sample sets will be asked for over the study period
11033110|NCT04546763||Paroxysmal Atrial Fibrillation Patients|This will be a single arm study of patients with paroxysmal atrial fibrillation. Subjects will be wearing the Study Watch and Zio XT Patch concurrently for up to 14 days.
11033111|NCT04546750||Patients without Varicose Veins|Individuals who do not have varicose veins of lower legs: C0, C1 classes according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
11033112|NCT04546750||Patients with Varicose Veins|Individuals who have varicose veins of lower legs: C2 Ep class according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
11033113|NCT04546724|Active Comparator|VLA1553|
11033114|NCT04546724|Placebo Comparator|Placebo|
11033115|NCT04546711||Ketogenic Diet|"Baseline Assessments
~Ketogenic diet intervention
~3 and 6 month Assessments"
11033116|NCT04546698||Multiple Sclerosis patients with an acute relapse|Multiple Sclerosis diagnosed according to Mc Donald's criteria with an acute relapse
11033117|NCT04546698||Multiple sclerosis pataients treated with Natalizumab|Multiple Sclerosis patients diagnosed according to Mc Donald's criteria and treated with Natalizumab since 6 cures
11033118|NCT04546698||Healthy people|
11033119|NCT04546685|Other|Usual Care (waitlist)|Participants will continue their usual clinical care.
11033120|NCT04546685|Experimental|Single-Session Pain Relief Skills Class (Empowered Relief)|A 2-hour class that will be delivered by a clinical psychologist via videoconference to participant cohorts.
11033121|NCT04546672|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
11033122|NCT04546672|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+Glycopyrrolate 0.2 mg per 1 mg of neostigmine administered) IV once at the end of surgery
11033123|NCT04546659|Experimental|Group A|Osteoarthritic patient receiving Conventional therapy and Retrowalking
11033124|NCT04546659|Active Comparator|Group B|Osteoarthritic patient receiving Conventional therapy
11033125|NCT04546646|Experimental|GROUP A (Elastic Band Exercises)|Warm up: for 10 min, Exercise: Lower limb exercises using elastic band for 30 min. Cool down: Self-stretches 5 min.
11033126|NCT04546646|No Intervention|GROUP - B (No Intervention)|Routine activities of daily living
11033127|NCT04546633|Experimental|KAF156 and LUM-SDF QD for 2 days in fasted condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
11033128|NCT04546633|Experimental|KAF156 and LUM-SDF QD for 2 days in fed condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
11033129|NCT04546620|Active Comparator|Arm A Control|6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy every 21 days.
11033130|NCT04546620|Experimental|Arm B Experimental|1 cycle of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy followed by 5 cycles of R-CHOP + acalabrutinib taken twice daily for 21 day cycles.
11033131|NCT04546607|Experimental|Nuvastatic TM|Nuvastatic TM (C5OSEW5050ESA) capsule 1000 mg administered orally 3 times a day for 9 weeks.
11033132|NCT04546607|Placebo Comparator|Placebo|Excipient, without Nuvastatic TM (C5OSEW5050ESA) capsule administered orally 3 times a day for 9 weeks.
11033133|NCT04546594||Orthopedic surgery|
11033134|NCT04546594||Thoracic surgery|
11033135|NCT04546594||Gynecological surgery|
11033136|NCT04546581|Experimental|Intervention Group|Participants in this group will receive the investigational product and standard of care (SOC).
11033137|NCT04546581|Placebo Comparator|Control Group|Participants in this group will receive a placebo and standard of care (SOC).
11033138|NCT04546568|Experimental|Servo control - Leoni plus CLAC|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.
~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
11033139|NCT04546568|Active Comparator|Servo control - IntellO2 Precision Flow, Vapotherm|"Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.
~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
11033140|NCT04546555|Placebo Comparator|No pacing|
11033141|NCT04546555|Experimental|Bachmann's bundle pacing|
11033142|NCT04546555|Experimental|Bachmann's bundle and His bundle pacing|
11033143|NCT04546555|Experimental|Bachmann's bundle, His bundle and nocturnal pacing|
11033144|NCT04546542||pSS patients under Hydroxychloroquine (HCQ) 2016-AAO dose|Patients under Hydroxychloroquine (HCQ) 2016-American Academy of ophtalmology (AAO) dose will have HCQ blood levels, disease activity and adherence evaltuated at study entry and before 3 and 6-months.
11033145|NCT04546529|Active Comparator|TsMS active|Patients undergoing real Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
11033146|NCT04546529|Sham Comparator|TsMS sham|Patients undergoing placebo Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
11033147|NCT04546516||HYAcorp Lips|HYAcorp Lips is indicated for the restoration of volume and contour of the lips.
11033148|NCT04546516||HYAcorp Face|HYAcorp Face is indicated for volume replacement (filling of folds), medium to deep folds, nasolabial folds, cheek area, glabella. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
11033149|NCT04546503|Active Comparator|Continuous Regional Analgesia group|Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4 + perinerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H
11033150|NCT04546503|Experimental|Control Group|group with general anesthesia and without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4
11033151|NCT04546490|Experimental|Pressure release|It will be applied with the patient in a supine position. The therapist will clamp his first and second fingers over the Myofascial Trigger Point located on the upper trapezium, it will be marked previously. The pressure will increase as the therapist perceives a reduction in the resistance offered by the soft tissue under his finger within a period of 90 seconds.
11033152|NCT04546490|Experimental|Ischemic pressure|Patient in supine position, the therapist performs pressure with first and second finger in PGM marked previously, this is performed until the patient tolerance, when the patient refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier. Repeat the process for 90 seconds.
11033153|NCT04546490|No Intervention|Control Group|Patient in supine position on the stretcher, the therapist performs a clamp with the first and second finger on the upper trapezius muscle without making any pressure on it during 90 seconds
11033154|NCT04546477|Other|Single Arm|"135 patients stratified in 2 groups:
~90 FEM-POP patients: SFA-P1
~45 Isolated POP Patients: P1, P2, P3 only"
11033155|NCT04546464|Experimental|Experimental Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately
~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
11033156|NCT04546464|No Intervention|Standard care|
11033157|NCT04546451|Experimental|Music practice|Patients will receive Music Practice interventions of 45 minutes twice a week over 6 months, provided by a professional musician
11033158|NCT04546451|Experimental|Psychomotor therapy|Patients will receive Psychomotor interventions of 45 minutes twice a week over 6 months, provided by a professional psychomotor therapist
11033159|NCT04546451|Active Comparator|Social animation|Patients will receive Social animation interventions of 45 minutes twice a week over 6 months, provided by professional psychologists
11033160|NCT04546438|Experimental|MiraDry® treatment|"The miraDry System is a noninvasive method that utilizes microwave energy to destroy the sweat glands at the dermal-fat interface.
~Each participant will be scheduled one MiraDry ® treatment with the possiblity of a second intervention approximately three months apart if the primary objective is not fullfilled efter the first."
11033161|NCT04546425|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
11033162|NCT04546425|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
11033163|NCT04546412||Fresh oocytes|Sibling oocytes not subjected to vitrification prior to assessment
11033164|NCT04546412||Vitrified-thawed oocytes|Sibling oocytes subjected to vitrification using the Cryotop® - Open System and thawing prior to assessment
11033165|NCT04546399|Experimental|Arm G (dexamethasone, blinatumomab, nivolumab, methotrexate)|Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2, and methotrexate IT, cytarabine IT, or ITT IT on days 1 and 15 of cycle 1 (methotrexate on day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy), methotrexate IT on days 1 and 15 of cycle 2, and leucovorin calcium IV or PO q6h for 2 doses on days 2 and 16. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
11033166|NCT04546399|Experimental|Group 1, Arm A (dexamethasone, blinatumomab, methotrexate)|Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, methotrexate IT, cytarabine IT, or ITT IT on days 1 and 15 of cycle 1 (methotrexate on day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy), and methotrexate IT on days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
11033167|NCT04546399|Experimental|Group 1, Arm B (dexamethasone, blinatumomab, methotrexate)|Patients receive dexamethasone, blinatumomab, and methotrexate, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
11033168|NCT04546399|Experimental|Group 2, Arm C (dexamethasone, blinatumomab, methotrexate)|Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
11033169|NCT04546399|Experimental|Group 2, Arm D (dexamethasone, blinatumomab, methotrexate)|Patients receive dexamethasone, blinatumomab, and methotrexate as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
11033170|NCT04546399|Experimental|Group 3, Arm E (dexamethasone, blinatumomab, methotrexate)|See Detailed Description.
11033171|NCT04546399|Experimental|Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)|See Detailed Description.
11033172|NCT04546399|Experimental|Groups 2-3 reinduction (vincristine sulfate, dexamethasone)|Patients receive vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, 15, and 22, dexamethasone PO or IV on days 1-14, doxorubicin hydrochloride IV over 1-15 minutes on day 1, methotrexate IT on days 1, 8, and 29 (day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy) (days 8 and 29 for CNS 1/2 patients at relapse only), pegaspargase IM or IV over 1-2 hours on days 2 and 16, cytarabine IT on days 4 and 11 (CNS 2 patients at relapse only), then Q2W until 3 consecutive samples are clear of blasts, and ITT IT on days 8, 15, 22, and 29 (CNS 3 patients at relapse only). Treatment continues in the absence of disease progression or unacceptable toxicity.
11033173|NCT04546360||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement based on two-dimensional shear wave elastography, gallbladder wall thickness, spleen thickness, spleen long diameter and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, albumin, prothrombin time, international normalized ratio).
11033174|NCT04546347|Experimental|14CAZD9833 Infusion NMT 22.8 kBq/5mL|Dose 1 14CAZD9833 Solution for Infusion
11033175|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet type A
11033176|NCT04546347|Experimental|AZD9833 Oral Solution|Dose 1 AZD9833 oral solution
11033177|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 1|Dose 1 AZD9833 film-coated tablet type B
11033178|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 2|Dose 2 AZD9833 film-coated tablet type A
11033179|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 2|Dose 2 AZD9833 film-coated tablet type B
11033180|NCT04546334|Experimental|Group A|Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block
11033181|NCT04546334|Experimental|Group B|Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment.
11033182|NCT04546334|Experimental|Group C|Patients that will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment.
11033183|NCT04546321||HIE group (I)|All fullterm newborn admitted to the NICU with Hypoxic Ischemic Encephalopathy during the study period
11033184|NCT04546321||TTN group(II)|All fullterm babies with Transient Tachypnea of the Newborn admitted to the NICU during the study period
11033185|NCT04546308|Experimental|Exercise training|The participants will undergo 8 weeks of whole-body resistance exercise training followed by a 4-week detraining. The central hemodynamic and muscle stiffness variables will be measured pre, post-training, and post-detraining.
11033186|NCT04546308|No Intervention|Sedentary control|The participants will undergo 12 weeks of intervention without exercise training. The central hemodynamic and muscle stiffness variables will be measured pre, 8th, and 12th week.
11033187|NCT04546295|Experimental|Brushlink|
11033188|NCT04546295|Active Comparator|CHX|
11033189|NCT04546295|Placebo Comparator|Interproximal Brush|
11033190|NCT04546282||Osimertinib treated patients|Patients with metastatic adenocarcinoma of the lung for whom a 3rd generation TKI therapy is proposed and a search for resistance mutation by blood analysis as part of the usual management.
11033191|NCT04546269|Experimental|Fully-guided|Single-tooth implant placed using a fully computer-guided approach
11033192|NCT04546269|Active Comparator|Conventionally guided|Single-tooth implant placed using a conventionally guided approach
11033193|NCT04546256|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11033194|NCT04546256|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
11033195|NCT04546243||osteosarcoma patients receiving resections|
11033196|NCT04546243||osteosarcoma patients receiving radiotherapy|
11033197|NCT04546230|Experimental|E group|Low-Thoracic Epidural Anesthesia
11033198|NCT04546230|Active Comparator|G group|General Anesthesia
11033199|NCT04546217|Experimental|Treadmill training +Transfer package (TT+TP)|"The TT+TP group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist. In combination with the gait training, participants in this group will also receive a group of behavioral strategies called the Transfer Package (TP). Each intervention session will last 1.5h, 1h for the gait training and 30 minutes dedicated for the transfer package.
~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
11033200|NCT04546217|Active Comparator|Treadmill training (TT)|"The TT group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist.
~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
11033201|NCT04546178|Experimental|PE+ intervention group|This group will participate in 15 sessions of PE+ therapy and participate in frequent symptom assessments; this is the same group of participants as the pre-intervention scores group, but they have crossed over from pre-intervention phase into intervention (active) phase.
11033202|NCT04546178|Active Comparator|Pre-intervention scores group (TAU)|This group will participate in symptom assessments but will not receive the PE+ intervention until the begin the active part of the trial. Participants in this group have been diagnosed with a psychotic disorder, have also experienced adversity, and use substances. This group will receive medication for psychosis as well as access to standard education programs and clinical care; thus treatment as usual (TAU).
11033203|NCT04546165|Active Comparator|manipulation group|manipulation plus exercise
11033204|NCT04546165|Active Comparator|myofascial release group|suboccipital inhibition plus exercise
11033205|NCT04546165|Active Comparator|exercise group|only exercise
11033206|NCT04546152||HYAPROF® SOFT|HYAPROF® SOFT is indicated for volume replacement (filling of folds), fine to medium folds, lip augmentation, periorbital region.
11033207|NCT04546152||HYAPROF® BALANCE|HYAPROF® BALANCE is indicated for volume replacement (filling of folds), deep folds, nasolabial folds, cheek area, glabella folds. It is not intended for injection to the periorbital region (eyelid, crow's feet, circles under the eyes).
11033208|NCT04546139||amateur badminton player|
11033209|NCT04546139||elite badminton player|
11033210|NCT04546126|Experimental|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take
~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
11033211|NCT04546126|Experimental|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
11033212|NCT04546113|Active Comparator|Paravertebral Block|If the patient is randomized to group Paravertebral Block, the anesthesiologist performs TPVB before induction of general anesthesia. The patient is positioned in lateral décubitus position. The anesthetist performs the bilateral paravertebral block with ultrasound identification of the paravertebral space at the T4-T5 level. Slow injection of 0.3 to 0.35 ml / kg of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of NaCl 0.9%) after aspiration test.
11033213|NCT04546113|Experimental|Erector Spinae Plane Block|"If the patient is randomized to group Erector Spinae Plane Block, the anesthesiologist performs the ESPb block before induction of general anesthesia. The patient is positioned in a right lateral decubitus position. The anesthesiologist performs the erector block of the spine ESP with ultrasound identification at the T4-T5 level (identify the 1st rib on ultrasound then the space T4 to T5). Slow injection of 20 ml of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of 0.9% NaCl) after aspiration test.
~The patient is then turned in left lateral decubitus position and the contralateral block is performed according to the same procedure."
11033243|NCT04545892|Experimental|Capsaicin|From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
11033244|NCT04545879|Experimental|Raw garlic juice|Raw garlic juice treatment group
11033474|NCT04544410|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 24 weeks.
11033214|NCT04546100|Experimental|Maternal-Infant Exercise Program|"In the postpartum period, give the intervention group Maternal-Infant Exercise Program and encourage them to do exercise. The Parent-Child Exercise Program can be divided into three stages. Videos will be provided in each stage. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
11033215|NCT04546100|Placebo Comparator|Regular postpartum exercise guidance|"Another group will receive Regular postpartum exercise guidance. The guidance includes chest exercises, neck exercises, leg exercises, hip exercises, abdominal exercises, vagina contraction exercises, and uterine contraction exercises, starting from the third day after delivery to one month after delivery. The detail information will refer to the General Hospital of Tri-Services Provided the postpartum health education manual-postpartum exercise (p.8-10)"
11033216|NCT04546087|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
11033217|NCT04546074|Experimental|Treatment|
11033218|NCT04546061|Experimental|Project Uplift Intervention|A 6-month long intervention for young adult sexual and gender minorities, ages 18-35.
11033219|NCT04546048|Experimental|Exercise group (EG)|The exercise group (EG) were received an 8-week resistance training program in addition to standard post-transplant physiotherapy follow-up.
11033220|NCT04546048|No Intervention|Control Group (CG)|"The control group (CG) were received only standard physiotherapy program.
~The usual post-transplant care consisting of preoperative patient education, respiratory physiotherapy program, active/active assistive exercises of cervical, upper and lower extremities, and early mobilization.
~Patients were instructed about the postoperative physiotherapy process including all details within the preoperative education. Respiratory physiotherapy consisted of positioning, lung expansion exercises and bronchial hygiene techniques.
~They were allowed to pursue their normal daily activities and mobilized as early as possible when clinically stable."
11033221|NCT04546035|Experimental|500 pulses|In this group, patients received one single rESWT session consisting of 500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
11033222|NCT04546035|Experimental|1,000 pulses|In this group, patients received one single rESWT session consisting of 1,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
11033223|NCT04546035|Experimental|1,500 pulses|In this group, patients received one single rESWT session consisting of 1,500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
11033224|NCT04546035|Experimental|2,000 pulses|In this group, patients received one single rESWT session consisting of 2,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
11033225|NCT04546022|Other|GSP measurement|For the GSP measurement, subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes. Sixty minutes after- G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of GSP value.
11033226|NCT04546009|Experimental|GDC-9545 + Letrozole-matched Placebo + Palbociclib|
11033227|NCT04546009|Active Comparator|Letrozole + GDC-9545-matched Placebo + Palbociclib|
11033228|NCT04545996|Active Comparator|Cervical Rang of Motion Exercises.|Cervical exercises for mechanical neck pain.
11033229|NCT04545996|Experimental|Cervical Exercises.|Cervical exercises for the management of mechanical neck pain.
11033230|NCT04545983|Active Comparator|ACD|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
11033231|NCT04545983|Experimental|ACDA|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
11033232|NCT04545970|Active Comparator|Anti-aging Serum|"Dosage form: Serum composed of water, thickener, and bioactive ingredients including antioxidants and peptides.
~Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.
~Study Duration: 12 weeks."
11033233|NCT04545970|Placebo Comparator|Placebo Serum|"Dosage form: Serum composed of water and thickener. Frequency of Dosage: Two times daily. Subjects are asked to pump 2x and apply on global face morning and evening.
~Study Duration: 12 weeks."
11033234|NCT04545957|Experimental|Phase I MRI Simulation|"This research study involves a screening period to determine eligibility.
~- Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data."
11033235|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track A|MR-only Radiation Therapy Simulation MRI-simulation and synthetic CT to plan treatment
11033236|NCT04545957|Experimental|Phase II MR Simulation Protocol: Track B|Adjusted Margin or / Dose Painted RT Based on Imaging of MR Simulator (e.g. biological imaging or higher resolution imaging)
11033237|NCT04545944|Experimental|Midazolam single doses / Vonoprazan multiple doses|Single oral doses of 2 mg of midazolam syrup on Day 1 and Day 9 and twice daily (BID) doses of 20 mg vonoprazan oral tablets on Days 2 through 10
11033238|NCT04545931|Experimental|Posterior tibial nerve stimulation|First arm will undergo posterior tibial nerve stimulation ( one session per week for 12 weeks )
11033239|NCT04545931|Experimental|Desmopressin|Second arm will receive medical treatment (desmopressin 0.2 mg . single evening dose ) for 12 weeks
11033240|NCT04545918||Infertile Female|80 consecutive female patients with infertility undergoing an ovarian stimulation with use of exogenous gonadotropins.
11033241|NCT04545905||Pregnant women attending first ANC visit|Pregnant women attending their first ANC visit at selected health facilities in Gaoua, Banfora, and Orodara districts.
11033242|NCT04545905||New New Project cross-sectional participants|Children under 5 enrolled in the New Nets Project cross-sectional survey conducted in Gaoua, Banfora and Orodara districts.
11033245|NCT04545866|Experimental|budesonide with surfactant|Infants randomized to the intervention arm receive a dose of surfactant (poractant alfa; Curosurf) mixed with budesonide (Pulmicort nebulizing suspension) within 50 hours of birth and administered via endotracheal tube.
11033246|NCT04545866|Active Comparator|surfactant alone|Infants randomized to the active control arm receive a dose of surfactant (poractant alfa; Curosurf).
11033247|NCT04545840||Study group|Zirconia Implants will be placed. More than one implant can be placed in the same patient, as long as the subject presents natural teeth adjacent to the implant site.
11033248|NCT04545814|Experimental|Stereotactic Radiosurgery|SRS will be delivered utilizing gamma knife or linear accelerator-based techniques.
11033249|NCT04545801|Active Comparator|Ketamine Group|Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia
11033250|NCT04545801|Placebo Comparator|Placebo Group|
11033251|NCT04545788|Active Comparator|A|4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx: Moxifloxacin) A group is the control group which includes injectable drugs (AM).
11033252|NCT04545788|Experimental|B|4-6 INH EMB PZA Pto LZD Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, LZD: Linezolid, Cfz: Clofazimine, Mfx: Moxifloxacin) B group is the experimental groups which is total oral short-term therapy.
11033253|NCT04545788|Experimental|C|4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (BDQ: Bedaquiline, LZD: Linezolid, Mfx: Moxifloxacin, CS: Cycloserine, Cfz: Clofazimine) C group is another experimental groups which is also total oral short-term therapy, and includes new anti-TB drugs: BDQ.
11033254|NCT04545762|Experimental|Treatment Regimen|"Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices
~CAR-T cell manufacturing (estimated ~13-14 days)
~Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.
~CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes."
11033255|NCT04545749|Experimental|Group A (Low dose)|20 subjects will be enrolled to receive low dose of UB-612 vaccine.
11033256|NCT04545749|Experimental|Group B (Medium dose)|20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
11033257|NCT04545749|Experimental|Group C (High dose)|20 subjects will be enrolled to receive high dose of UB-612 vaccine.
11033258|NCT04545736|Experimental|Metformin|Oral administration of metformin
11033259|NCT04545723|No Intervention|Control group|In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
11033260|NCT04545723|Active Comparator|Intervention group|In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
11033261|NCT04545710|Experimental|Single Arm, POC|"Single arm, POC Safety and Efficacy
~Osimertinib 80 mg QD Abemaciclib 150mg BID"
11033262|NCT04545697|Experimental|Patient Decision Support|Instructions will be provided for installation and use of a smartphone recording app 7-60 days before an oncology consultation. Participants will share the recording with the Patient Support Corps (PSC), who will summarize the recording, send it to the participant's oncologist for review, then return an annotated summary to the participant within a week of the consultation.
11033263|NCT04545684|Experimental|Mental practice|
11033264|NCT04545684|Placebo Comparator|Placebo group|
11033265|NCT04545671||Patients already implanted with study lens|No intervention as patients are already implanted.
11033266|NCT04545645|Active Comparator|Neural Stress Provoked by the Median Nerve|
11033267|NCT04545645|Experimental|Neural stress provocation with cognitive auditory distraction|
11033268|NCT04545645|Experimental|Providing neural stress with a motor distraction|
11033269|NCT04545645|Experimental|Neural stress provocation with both distractions|
11033270|NCT04545632||Patients|Patients receiving chemotherapy with ethanol-containing docetaxel
11033271|NCT04545619|Experimental|Paroxysmal and Early Persistent AFIB|
11033272|NCT04545606|Experimental|In-person CBT for insomnia in children with autism|In-person cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted at the Thompson Center. In-person treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
11033273|NCT04545606|Experimental|Remote CBT for insomnia in children with autism|Remote/videoconferenced cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
11033274|NCT04545606|Experimental|Remote behavioral SHARE for insomnia in children with autism|Remote/videoconferenced behavioral sleep hygiene and related education (SHARE) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep and related health related concerns/interests.
11033275|NCT04545593|Experimental|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) consists of 10 sessions focused on mental health (PM) and 36 sessions focused on physical health (SB), along with a group maintenance component.
11033276|NCT04545593|Active Comparator|Enhanced Usual Care|The Enhanced Usual Care condition includes written materials on depression and anxiety and 4 calls to participants over the course of 6 months to assess symptoms and safety.
11033277|NCT04545580|Placebo Comparator|Treatment period: Placebo|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with matching placebo.
11033278|NCT04545580|Experimental|Treatment period: BAY1817080|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with BAY1817080.
11033279|NCT04545567|Experimental|RocketAP|Adolescents will be assessed for a 70 hour period on the Rocket AP. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the USS Virginia system under the same conditions.
11033280|NCT04545567|Active Comparator|USS Virginia|Adolescents will be assessed for a 70 hour period on the USS Virginia system. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the Rocket AP system under the same conditions.
11033281|NCT04545554|Experimental|Romosozumab|
11033282|NCT04545541|Experimental|Nebulised heparin|"Participants assigned to nebulised UFH will receive nebulised UFH in addition to the standard care required as determined by the treating team. Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days."
11033283|NCT04545541|No Intervention|Control group|"Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin (Australia, Ireland).
~Participants assigned to placebo will receive Nebulised 0.9% Sodium Chloride (5 mL) administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days (USA)."
11033284|NCT04545528||Test group|100 Patients that were referred to our stone clinic for follow up with risk factors for stone recurrence like metabolic syndrome and diabetes, uric acid stones etc. In addition to seeing our urologist and nephrologist these patients will also be referred to a nutritionist in order to balance risk factors and will be followed for one year with our usual blood tests and imaging
11033285|NCT04545528||Control group|100 Patients that were referred to our stone clinic for follow up without risk factors for stone recurrence will see our urologist and nephrologist and will be followed for one year with our usual blood tests and imaging
11033286|NCT04545515|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
11033287|NCT04545502||Gelsoft Plus - Straights and Bifurcated|Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
11033288|NCT04545502||Gelsoft Plus - Extra-Anatomical|Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
11033289|NCT04545502||Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall|Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
11033290|NCT04545502||Gelweave - Abdominal, Thoracic, Thoracoabdominal|"Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:
~Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.
~Thoracic aorta or arteries arising from the thoracic aorta.
~Abdominal and thoracic aorta requiring a thoracoabdominal repair"
11033291|NCT04545502||Gelweave - Valsalva|Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.
11033292|NCT04545489|Experimental|Nurse-led intervention group|Participants randomized to the nurse-led intervention will have 4 visits over 12 months with study staff. In addition, they will also receive focused communication from the intervention nurse, with additional BP monitoring support and medication management for 12 months.
11033293|NCT04545489|Active Comparator|Education control group|Participants randomized to the education control group will have 4 visits over 12 months and will receive education materials related to CVD risk reduction.
11033294|NCT04545476|Experimental|APIS Biomaterial on the Head|Participants in this group will receive the experimental APIS Biomaterial on the Head. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
11033295|NCT04545476|Experimental|APIS Biomaterial on the Lower Extremities|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
11033296|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
11033397|NCT04544943|Experimental|Cohort 4|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa, The total body surface area (BSA) dosed will be 40% BSA
11033297|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
11033298|NCT04545463|Active Comparator|Insoluble Fibre|Cookies with insoluble fibre (wheat bran)
11033299|NCT04545463|Active Comparator|Soluble Fibre|Cookies with soluble fibre (Psyllium plantago)
11033300|NCT04545463|Experimental|FIBRACEP|Cookies with FIBRACEP
11033301|NCT04545450|Active Comparator|Testosterone Undecanoate plus dutasteride|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day
11033302|NCT04545450|Placebo Comparator|Testosterone Undecanoate plus placebo|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill
11033303|NCT04545437||ICU|Patients treated on a general adult intensive care unit
11033304|NCT04545424|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
11033305|NCT04545424|Active Comparator|Usual Temperature Management|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
11033306|NCT04545411|Active Comparator|Treatment A|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 70mg in 1mL solution REMD-477
11033307|NCT04545411|Placebo Comparator|Treatment B|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 1mL solution Placebo
11033308|NCT04545398|Experimental|Pasture-raised|The meal contains grass/pasture fed beef
11033309|NCT04545398|Experimental|Grain-fed|The meal contains grain-fed beef
11033310|NCT04545398|Placebo Comparator|Meat Alternative|The meal contains a meat alternative
11033311|NCT04545398|Experimental|Lamb|The meal contains lamb
11033312|NCT04545385|Experimental|TEV-48574|The patients will receive the investigational medicinal product (IMP) loading dose on the day of randomization and the subsequent corresponding IMP maintenance dose every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
11033313|NCT04545385|Placebo Comparator|Placebo|Matching Placebo
11033314|NCT04545372|Experimental|the study group|the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.
11033315|NCT04545372|No Intervention|the control group|control group (GB)was treated only by the disease modifying drug (interferon beta-1a)
11033316|NCT04545359|Experimental|Neurofeedback Group|Participants from this group perform actual neurofeedback training, i.e they are instructed to control -- decrease -- in real-time a sound that is inversely related to the amplitude of their own alpha activity, obtained from Melomind EEG signals.
11033317|NCT04545359|Sham Comparator|Control Group|Participants from this group perform sham neurofeedback based on the feedback sounds generated by the participants from the Neurofeedback Group at the same step of the training program.
11033318|NCT04545346|No Intervention|Wait-listed control|Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.
11033319|NCT04545346|Experimental|Low Glutamate diet|Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
11033320|NCT04545333||ALL|patients diagnosed with acute lymphoblastic leukemia
11033321|NCT04545333||CLL|patients diagnosed with chronic lymphocytic leukemia
11033322|NCT04545333||MM|patients diagnosed with multiple myeloma
11033323|NCT04545333||NHL|patients diagnosed with non-Hodgkin lymphoma
11033324|NCT04545320|Placebo Comparator|Usual care control group|Subjects in the usual care control group will receive a health education program to provide the usual care information. This program will include 3-month biweekly sessions (70 minutes each session, total 6 sessions) for obesity-related health briefing, dietary caloric restriction advice, lifestyle counselling/consultation and stretching exercise.
11033325|NCT04545320|Experimental|HIIT group|A 3-month intervention of HIIT will be given to participants allocated to this group. The once-a-week HIIT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform brisk walking for four 4-min bouts at 85%-95% maximal heart rate (HRmax) with a 3-min active recovery walk at 50%-70% HRmax between each session. There will be a 5-min warm-up and cool-down in each exercise session. The duration of each exercise session will be 35 minutes. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
11033326|NCT04545320|Experimental|MICT group|A 3-month intervention of MICT will be given to participants allocated to this group. The once-a-week MICT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform mild walking exercise for ~47 minutes at an intensity of 65-75% HRmax. This exercise volume matches the HIIT volume. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
11033327|NCT04545307|Experimental|Allogenic transplant of BM-MSCs|"Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo button (pellet) is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
11033359|NCT04545086|Experimental|MT Group|Music Therapy was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
11033360|NCT04545086|No Intervention|Control Group|Routine Information was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation was done.
11033361|NCT04545073||Post-refractive trifocal IOL|
11033328|NCT04545294|Experimental|Active theta (6Hz) in-phase tACS|θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.
11033329|NCT04545294|Sham Comparator|Sham tACS|During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
11033330|NCT04545281|Experimental|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft implantation at iliac artery
11033331|NCT04545268|Sham Comparator|Control group|
11033332|NCT04545268|Experimental|NMES group|
11033333|NCT04545255|Active Comparator|active|A shockwave device with a probe that conveys shockwave energy
11033334|NCT04545255|Sham Comparator|sham|A shockwave device with specially designed probe which has the shockwave energy blocked
11033335|NCT04545242|Active Comparator|Dexamethasone (low dose)|Dexamethasone: 6 mg/iv/day during 10 days.
11033336|NCT04545242|Active Comparator|Dexamethasone (moderate dose)|Dexamethasone: 20 mg/iv/ daily from day of randomization (day 1) during 5 days, followed by 10 mg/iv/ daily from Day 6 to Day 10 of randomization.
11033337|NCT04545229|Experimental|Active VR-PAT|Active VR-based Pain Alleviation Tool (VR-PAT) group played smart phone VR-PAT during the burn dressing changes.
11033338|NCT04545229|Experimental|Passive VR-PAT|Passive VR-based Pain Alleviation Tool (VR-PAT) group watched smart phone VR-PAT games without interaction during the burn dressing changes.
11033339|NCT04545229|No Intervention|Standard Care Control|Standard care control group used regular distraction such as background music or no distraction.
11033340|NCT04545216||UT4M 40|athletes participating to the 40 km mountain race.
11033341|NCT04545216||UT4M 160|athletes participating to the 160 km mountain race.
11033342|NCT04545216||UTV 55|athletes participating to the 55 km mountain race.
11033343|NCT04545203|Experimental|Slow-Stroke Back Massage Group|
11033344|NCT04545203|No Intervention|Control group|
11033345|NCT04545190|Active Comparator|Glucose|"Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml).
~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).
~Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade.
~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only)"
11033346|NCT04545190|Placebo Comparator|Placebo|"Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml).
~Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g).
~Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade.
~(The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only)"
11033347|NCT04545177|Experimental|Tissue Preservation System (TPS)|Tumor tissue will be obtained, processed, and then transported remotely to undergo multiple tests, including gene panel DNA sequencing, DNA methylation array, and bulk as well as single-cell transcriptome analyses (RNA-seq)
11033348|NCT04545164|No Intervention|Usual Care|Participants in the usual care arm will receive no specific trial intervention. Usual care includes tests routinely available at Zomba Central Hospital, including (but not limited to) conventional (plain film) chest X-ray, urine Alere LAM and sputum Xpert Mtb/Rif on treating clinician request.
11033349|NCT04545164|Experimental|DCXR-CAD and FujiLAM and usual care|Participants randomized to the intervention arm will receive TB screening using DCXR-CAD and urine FujiLAM. The CAD score and FujLAM results will be appended into their medical notes for treating clinicians to see. If patients have a CAD score above a pre-determined threshold the study team will attempt to collect sputum for Xpert Mtb/Rif. Chest X-ray images will be available for clinicians to view. This is in addition to usual care (detailed above).
11033350|NCT04545164|Other|Diagnostic cohort|Patients in the observational enhanced diagnostic arm will receive an enhanced package of diagnostics. This is a smaller arm (1 in 9 of all clusters) and is observational only - participants in this arm do not contribute to trial outcomes.
11033351|NCT04545151|Experimental|Verapamil SR|Eligible participants will be randomised into the verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
11033352|NCT04545151|Placebo Comparator|Placebo|"Eligible participants will be randomised into the Placebo arm and receive instructions on frequency of administration (daily intake).
~40 participants on the control arm are expected to complete the trial."
11033353|NCT04545138|Experimental|cognitive training during treadmill training group|Cognitive training combine treadmill training is an intervention that can challenge participants by practicing different tasks simultaneously.
11033354|NCT04545138|Active Comparator|treadmill training group|Treadmill training as an active control.
11033355|NCT04545112|Experimental|XABG|
11033356|NCT04545099|Experimental|Sugammadex|Administration of Sugammadex
11033357|NCT04545099|Active Comparator|Neostigmine|Administration of Neostigmine
11033358|NCT04545086|Experimental|VBE Group|Video Based Education was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
11033362|NCT04545060|Experimental|VIR-7831|
11033363|NCT04545060|Placebo Comparator|Placebo|
11033364|NCT04545047||Exposed|The exposed group is comprised of Veterans who were admitted as inpatients within a VA medical center within 15 days of a positive SARS-CoV-2 test and who received COVID-19 convalescent plasma therapy within 30 days of admission.
11033365|NCT04545047||Unexposed|The unexposed group is comprised of Veterans who were admitted as inpatients within a VA medical center within 15 days of a positive SARS-CoV-2 test and who do not receive COVID-19 convalescent plasma therapy. These subjects are included if they were in-hospital at the same time or after the first subject receives convalescent plasma therapy at a particular site.
11033366|NCT04545034|Experimental|Water aerobic exercise protocol|Walter aerobic exercise session would be used to treat blood pressure in elderly hypertensive people.
11033367|NCT04545034|No Intervention|Control Group|No exercise intervention would be used.
11033368|NCT04545021||Cognitive Behavioral Stress Management (CBSM) - PC Survivor|Participant receives standard cognitive behavioral stress management from the Parent study NCT03344757.
11033369|NCT04545021||CBSM - PC Survivor Partner|The survivor partner does not receive any intervention.
11033370|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor|Participant receives culturally adapted cognitive behavioral stress management from the Parent study NCT03344757.
11033371|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor Partner|The survivor partner does not receive any intervention.
11033372|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 600 mg three times daily
11033373|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine|N-Acetyl Cysteine 1,200 mg three times daily
11033374|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
11033375|NCT04545008|Experimental|High Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 1,800 mg three times daily
11033376|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
11033377|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
11033378|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
11033379|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
11033380|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
11033381|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
11033382|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
11033383|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily
11033384|NCT04544995|Experimental|Part 1A: Dose escalation phase: Niraparib tablet+ Dostarlimab|In Part 1A, participants will receive niraparib tablet in combination with dostarlimab. Up to 4 dose-level cohorts are planned and the starting dose of niraparib tablet will be 100 milligrams (mg) daily. Additional dose levels will be determined with consideration to comprehensive safety data and exposure data from population PK. The dostarlimab starting dose will be 3 milligrams per kilograms (mg/kg), administered every 3 weeks with possible escalation to 7.5 mg/kg (with maximum dose of 500 mg) or de-escalation to 1 mg/kg.
11033385|NCT04544995|Experimental|Part 1B: Dose escalation phase: Niraparib AAOLF + Dostarlimab|In Part 1B, participants will receive niraparib AAOLF in combination with dostarlimab. Up to 3 dose-level cohorts are planned and the starting dose level for niraparib AAOLF will be determined by population PK modelling using the RP2D from Part 1A. The starting dose level for dostarlimab will be the RP2D as determined from Part 1A.
11033386|NCT04544995|Experimental|Part 2: DE phase: Participants with osteosarcoma (tablets)|In Part 2, participants with osteosarcoma who are able to swallow tablets and weigh >=20 kg will be eligible to receive the RP2D of niraparib along with dostarlimab once the RP2D for the niraparib tablets or dostarlimab is determined in Part 1A of the study.
11033387|NCT04544995|Experimental|Part 2: DE phase: Participants with osteosarcoma (AAOLF)|In Part 2, participants with osteosarcoma who are not able to swallow tablets or weigh <20 kg will be eligible to receive the RP2D of niraparib AAOLF with dostarlimab once the RP2D for the niraparib AAOLF and dostarlimab is determined in Part 1B of the study.
11033388|NCT04544995|Experimental|Part 2: DE phase: Participants with neuroblastoma (tablet)|In Part 2, participants with neuroblastoma who are able to swallow tablets and weigh >=20 kg will be eligible to receive the RP2D of niraparib along with dostarlimab once the RP2D for the niraparib tablets and dostarlimab is determined in Part 1A of the study.
11033389|NCT04544995|Experimental|Part 2: DE phase: Participants with neuroblastoma (AAOLF)|In Part 2, participants with neuroblastoma who are not able to swallow tablets or weigh <20 kg will be eligible to receive the RP2D of niraparib AAOLF with dostarlimab once the RP2D for the niraparib AAOLF and dostarlimab is determined in Part 1B of the study.
11033390|NCT04544982|Active Comparator|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
11033391|NCT04544982|Placebo Comparator|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
11033392|NCT04544969||Chemotherapy|Patients treated with palliative chemotherapy
11033393|NCT04544956|Experimental|Participants receiving 300 mg GSK3228836|Eligible participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
11033394|NCT04544943|Experimental|Cohort 1|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa, The total body surface area (BSA) dosed will be 40% BSA
11033395|NCT04544943|Experimental|Cohort 2|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa, The total body surface area (BSA) dosed will be 40% BSA
11033396|NCT04544943|Experimental|Cohort 3|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa, The total body surface area (BSA) dosed will be 40% BSA
11033398|NCT04544930|Experimental|therapist-guided|Therapist-guided Internet treatment based on cognitive behavior therapy (ICBT).
11033399|NCT04544917|Experimental|SmartManage Group|Participants in this group will receive ten 90-minute weekly therapist delivered SmartManage group sessions via video conference. Participants will have access to the SmartManage web platform, which will also guide the live intervention sessions.
11033400|NCT04544917|Active Comparator|Educational Control Group|Participants in this group will view ten weekly control content video recorded sessions.
11033401|NCT04544904|No Intervention|Usual Care|Patients will receive the usual care.
11033402|NCT04544904|Experimental|PAARx|Patients will be prescribed technology-based physical activity programming.
11033403|NCT04544904|Experimental|PAARx and JM|Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.
11033404|NCT04544878||Pediatric patients|All term children from birth to 18 years of age admitted in the PICU
11033405|NCT04544878||Adult patients|All patients >18 years of age
11033406|NCT04544865|Experimental|Gastric and thoracic staple line reinforcement|ECHELON ENDOPATH Staple Line Reinforcement is used during a gastric or thoracic procedure.
11033407|NCT04544852|Placebo Comparator|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge."
11033408|NCT04544852|Active Comparator|Targeted intervention programme|"Intervention B involves a targeted intervention programme tackling issues relating to a lack of education, inconvenience and cost would improve screening rates amongst the spouses."
11033409|NCT04544839|Experimental|ADLC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the ADLC (test) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the ADLC group will receive the LOC attachments.
11033410|NCT04544839|Active Comparator|LOC attachment in first phase|Each patient will receive 2 implants in the canine region. Three months later, each patient will be randomized and half of the patients will receive first the LOC (control) device (first phase). In the second phase of the crossover trial (6 months after the start of the first phase), the attachments will be replaced. Patients previously allocated to the LOC group will receive the ADLC attachments.
11033411|NCT04544826|Experimental|Cohort 1: JNJ-77474462 (Low Dose) or Placebo|Participants will receive single low dose of JNJ-77474462 or matching placebo as subcutaneous (SC) injection.
11033412|NCT04544826|Experimental|Cohort 2: JNJ-77474462 (Medium Dose) or Placebo|Participants will receive single medium dose of JNJ-77474462 or matching placebo as SC injection.
11033413|NCT04544826|Experimental|Cohort 3: JNJ-77474462 (High Dose) or Placebo|Participants will receive single high dose of JNJ-77474462 or matching placebo as SC injection.
11033414|NCT04544813|Experimental|Cohort A: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 subcutaneously (SC).
11033415|NCT04544813|Experimental|Cohort B: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
11033416|NCT04544813|Experimental|Cohort C: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
11033417|NCT04544813|Experimental|Cohort D: JNJ-77474462 SC (Wave 1)|Participants will receive single dose of JNJ-77474462 SC.
11033418|NCT04544813|Experimental|Cohort E: JNJ-77474462 IV (Wave 1)|Participants will receive single dose of JNJ-77474462 intravenously (IV).
11033419|NCT04544813|Experimental|Cohort F: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
11033420|NCT04544813|Experimental|Cohort G: JNJ-77474462 SC (Wave 2)|Participants will receive single dose of JNJ-77474462 SC.
11033421|NCT04544813|Experimental|Cohort H: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
11033422|NCT04544813|Experimental|Cohort I: JNJ-77474462 IV (Wave 2)|Participants will receive single dose of JNJ-77474462 IV.
11033423|NCT04544813|Active Comparator|Cohort J: Anakinra SC|Participants will receive a SC injection of anakinra once daily for 3 days.
11033424|NCT04544787|Active Comparator|Group 1|50 OPV-vaccinated adults to receive 1 dose of nOPV2 candidate 1
11033425|NCT04544787|Active Comparator|Group 2|50 OPV-vaccinated adults to receive 2 doses of nOPV2 candidate 1, administered 28 days apart;
11033426|NCT04544787|Active Comparator|Group 3|50 OPV-vaccinated adults to receive 1 dose of nOPV2 candidate 2
11033427|NCT04544787|Active Comparator|Group 4|50 OPV-vaccinated adults to receive 2 doses of nOPV2 candidate 2, administered 28 days apart
11033428|NCT04544787|Active Comparator|Group 5|16 to 44 IPV-only vaccinated adults to receive 2 doses of nOPV2 candidate 1, administered 28 days apart
11033429|NCT04544787|Active Comparator|Group 6|16 to 44 IPV-only vaccinated adults to receive 2 doses of nOPV2 candidate 2, administered 28 days apart
11033430|NCT04544787|Placebo Comparator|Group 7|16 to 44 IPV-only vaccinated adults to receive placebo, administered 28 days apart
11033431|NCT04544774||Allergic rhinitis patients|Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.
11033432|NCT04544761||1-5 Years post|Persons with Spinal Cord Injury occurring between 1-5 years prior
11033433|NCT04544761||5-15 Years post|Persons with Spinal Cord Injury occurring between 5-15 years prior
11033434|NCT04544761||>15 Years post|Persons with Spinal Cord Injury occurring at least 15 years prior
11033435|NCT04544748|Other|Cohort 1|GNR-051 (0.1 mg/kg)
11033436|NCT04544748|Other|Cohort 2|GNR-051 (0.3 mg/kg)
11033437|NCT04544748|Other|Cohort 3|GNR-051 (1 mg/kg)
11033438|NCT04544748|Other|Cohort 4|GNR-051 (3 mg/kg)
11033439|NCT04544748|Other|Cohort 5|GNR-051 (10 mg/kg)
11033440|NCT04544735|Experimental|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will will integrate two key components: pelvic health PT interventions (i.e., vaginal dilators, Pelvic Floor Muscle Training) and coping skills training for managing symptoms and improving treatment adherence. The intervention aims to improve women's sexual function after pelvic radiation
11033441|NCT04544722|Experimental|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
11033442|NCT04544722|Active Comparator|Lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
11033443|NCT04544709|Other|Discogenic Low Back Pain|Patient with Refractory Discogenic Low back pain who will be scheduled for platelet rich plasma injection as standard of care.
11033444|NCT04544696||Patients with chronic non cancer pain|Patients with chronic non cancer pain, treated with opioids and having completed the POMi questionnaire
11033445|NCT04544683|Other|Cervical Pain for 6 months or less and scheduled for TFESI|Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to and before receiving a first cervical TFESI. The baseline examination and all baseline questionnaires will be completed within 2 weeks before the first cervical TFESI. Participants will be given a daily pain diary chart to record NRS and percentage improvement during the 1st month post-injection. Participants will be contacted in the 1st week post-injection with a standardized questionnaire about their symptoms and a reminder about the 4 week (+/- 1 week) post-injection follow up. Routine scheduled follow-up by clinic visit or telephone call will occur at 4 weeks (+/- 1 week), 8 weeks (+/- 2 weeks), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month), at which times all follow-up measures will be obtained.
11033446|NCT04544657||stroke group|
11033447|NCT04544657||normal group|
11033448|NCT04544644|Experimental|treatment arm|AK104+anlotinib
11033449|NCT04544631|Experimental|Active VR|"Participants in the active VR group played a virtual reality game entitled Virtual River Cruise. In this game, an otter floats down a river on a boat and players activate snow-blowing statues along the shore by focusing on them. The statues will emit snow if they are correctly aimed at by the child, and a thermometer placed in the front of the boat shows decreased temperatures as more snowflakes are blown. As feedback to reinforce continued engagement, a scoreboard placed beside the thermometer will show children the number of statues he/she has activated. Additionally, as the temperature drops, snow and ice will start piling up on the boat and its surroundings, providing an enhanced cooling experience for pediatric burn patients. Children interact with the immersive virtual reality environment by tilting their head, minimizing potential interference with the dressing change procedure."
11033450|NCT04544631|Experimental|Passive VR|Participants in the passive VR group were immersed in the same virtual reality environment as the active VR group, without any interactions with the VR game.
11033451|NCT04544631|No Intervention|Standard Care Control|Participants in the standard group received routinely used distraction tools provided in the clinical setting, such as iPads, music, books, and/or talking.
11033452|NCT04544618|Experimental|Active intervention group|Participants will be exposed to a virtual reality simulation of the operating room environment for a minimum of ten minutes.
11033453|NCT04544618|Placebo Comparator|Control intervention group|Participants will explore a non-surgery related virtual reality simulation, pre-programmed to the virtual reality headset for a minimum of ten minutes.
11033454|NCT04544618|No Intervention|Treatment as usual group|Participants will receive standard of care with no additional intervention aside from information received at their surgical oncology appointment and optional preoperative education classes (available to all patients).
11033455|NCT04544592|Experimental|UCD19 CART infusion|Lymphodepleting chemotherapy following by infusion of UCD19 CAR-T
11033456|NCT04544579||Ascending aortic dissection patients|Ascending aortic dissection patients
11033457|NCT04544566|Experimental|Test product A new adhesive material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
11033458|NCT04544566|Experimental|Test product B new adhesion material|The adhesives in the ostomy tapes are developed to make the tape seal to the skin and thereby minimise the risk of leakage episodes. At the same time, the tape should be easy to remove without affecting the skin.
11033459|NCT04544566|Active Comparator|Comparator|The comparator product is Brava Elastic tape which is already on the market and will be used within the in-tended use in this clinical investigation.
11033460|NCT04544553|Other|SMS reminder|This arm receive SMS reminder for the follow-up of DR Screening
11033461|NCT04544553|Other|No SMS reminder|This arm did not receive SMS reminder for the follow-up of DR Screening
11033462|NCT04544540|Experimental|One-Unit|Patients will be randomized to receive 1-unit of red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 1-unit
11033463|NCT04544540|Experimental|Two-Unit|Patients will be randomized to receive 2-unit sof red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 2-units
11033464|NCT04544501|Experimental|Culturally-Targeted Video|
11033465|NCT04544501|Active Comparator|FORCE Fact Sheet|
11033466|NCT04544475|Experimental|Investigational|
11033467|NCT04544475|Active Comparator|Standard of Care|
11033468|NCT04544462||Infertile patients|Patients attending an IVF center for infertility treatment
11033469|NCT04544449|Experimental|fenebrutinib|Participants will receive oral fenebrutinib and intravenous (IV) ocrelizumab-matching placebo.
11033470|NCT04544449|Active Comparator|ocrelizumab|Participants will receive intravenous (IV) ocrelizumab and oral fenebrutinib-matching placebo.
11033471|NCT04544436|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
11033472|NCT04544436|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
11033473|NCT04544410|Experimental|Tildacerfont Group|Tildacerfont administered daily via oral tablet for 24 weeks at dose level 1.
11033475|NCT04544371||normal weight patients|patients with body mass index =18-24.9 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area in semi-sitting and right lateral positions
11033476|NCT04544371||obese patients|patients with body mass index >30 kg/m2 will be examined by abdominal ultrasound to assess gastric antrum cross sectional area semi-sitting and right lateral positions
11033477|NCT04544358|Experimental|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
11033478|NCT04544358|No Intervention|Control|Randomized to wait list, received BAILAMOS© program after data collection.
11033479|NCT04544345|Experimental|His bundle pacing, AV optimized|Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.
11033480|NCT04544345|Sham Comparator|Backup VVI pacing|Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.
11033481|NCT04544332||Unsweetened Supplement|Infants will receive 10 exposures to the unsweetened small quantity lipid nutritional supplement (SQ-LNS) at home
11033482|NCT04544332||Sweetened Supplement|Infants will receive 10 exposures to the sweetened small quantity lipid nutritional supplement (SQ-LNS) at home
11033483|NCT04544319|Experimental|Arm I|Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
11033484|NCT04544319|Experimental|Arm II|Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg
11033485|NCT04544306|No Intervention|Control arm|Standard of Care (intravenous antimicrobial therapy according to the American Heart Association Guideline 2015)
11033486|NCT04544306|Experimental|Partial oral treatment arm|The mode of antimicrobial delivery is switched to oral therapy after at least 10 days of IV therapy, guided by antimicrobial susceptibility
11033487|NCT04544293|Experimental|Molgramostim|Double-blind treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
11033488|NCT04544293|Placebo Comparator|Placebo|Double-blind treatment with placebo nebulizer solution once daily for 48 weeks, followed by open-label treatment with molgramostim nebulizer solution 300 µg once daily for 48 weeks
11033489|NCT04544280|Experimental|Intervention|
11033490|NCT04544267|Experimental|QIV-HD|One injection of QIV-HD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
11033491|NCT04544267|Active Comparator|QIV-SD|One injection of QIV-SD on Day 0. For participants for whom 2 doses of influenza vaccine are recommended, a second dose is administered on Day 28.
11033492|NCT04544254|Active Comparator|Bilateral transversus thoracis muscle plane block|Regional block will be performed after induction of anesthesia by anesthesiologist on duty who is not part of investigators for this study. The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided
11033493|NCT04544254|Placebo Comparator|Control|Needle will be put in the superficial skin on the same area as transversus thoracis muscle plane block area without any drugs injected into the injection area
11033494|NCT04544241|Experimental|Clergy Wives and Widows|We will provide cancer survivorship and caregiving leadership education and activities for African American Clergy Wives and Widows by creating an educational partnership program aimed towards church-based health education on cancer survivorship and caregiving
11033495|NCT04544228|Experimental|ketamine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml ketamine
11033496|NCT04544228|Experimental|Neostigmine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml neostigmine
11033497|NCT04544228|Active Comparator|Control|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml normal saline.
11033498|NCT04544215|Experimental|MPCs-derived exosomes Dosage 1|low-dose group
11033499|NCT04544215|Experimental|MPCs-derived exosomes Dosage 2|high-dose group
11033500|NCT04544215|Placebo Comparator|No exosomes|No MPCs-derived exosomes
11033501|NCT04544189|Experimental|Alpelisib+Fulvestrant (randomized cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
11033502|NCT04544189|Placebo Comparator|Placebo+Fulvestrant (randomized cohort)|Placebo (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
11033503|NCT04544189|Experimental|PK cohort (open label cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
11033504|NCT04544176||Cohort|This group will include patients attending outpatient appointments who will be assessed as to whether they develop COVID-19 infection, and use this to quantify the risk of COVID-19.
11033505|NCT04544176||Cross-Sectional|This group will include all patients offered outpatient appointments. The rate of patients attending, not attending or cancelling their appointment throughout the pandemic will be assessed.
11033506|NCT04544163|Experimental|Magnesium sulphate- Fentanyl|30 mg per kg MgSo4 infusion in 100 ml saline over 10 minutes
11033507|NCT04544163|Experimental|Fentanyl 4 mic|4 mic per kg fentanyl i.v
11033508|NCT04544163|Active Comparator|Fentanyl|2 mic per kg fentanyl i.v
11033509|NCT04544163|Experimental|Lidocaine- Fentanyl|Lidocaine 1.5 mg/kg
11033510|NCT04544137|Experimental|BOKS + SFSP|Children randomized to the BOKS + SFSP will be invited to attend the one-hour BOKS program four days per week for eight weeks during the summer. The BOKS program will be run by Lifespan employed staff in the hour before the SFSP lunch service at two community locations.
11033511|NCT04544137|No Intervention|SFSP|Children randomized to the SFSP alone group will be asked to participate in the SFSP as they would have otherwise.
11033540|NCT04543916|Experimental|Dose Level 2|Venetoclax 100mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
11033512|NCT04544124|Experimental|Contingency management for treatment attendance|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
11033513|NCT04544124|Experimental|Contingency management for methamphetamine abstinence|Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their abstinence from methamphetamine.
11033514|NCT04544124|No Intervention|Treatment-as-usual|Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
11033515|NCT04544111|Experimental|Cohort A-BRAF WT tumors|Cohort A (BRAF WT tumors): trametinib (T) 2mg by mouth daily plus PDR001 400mg IV every 4 weeks
11033516|NCT04544111|Experimental|Cohort B-BRAF Mutant|Cohort B (BRAF Mutant, resistant to previous BRAF inhibitors): dabrafenib (D) 150 mg twice daily (OR at dose the patient previously tolerated) plus PDR001 400mg IV every 4 weeks.
11033517|NCT04544098|Experimental|PRRT with 177Lu-DOTATATE|Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
11033518|NCT04544085|No Intervention|control group|Patients in the control group will not receive any noise management intervention
11033519|NCT04544085|Experimental|experimental group|Patients in the experimental group will receive noise management. The intervention measures mainly include the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.We will strengthen the education of medical staff to ensure the effective implementation of the noise management.
11033520|NCT04544059|Experimental|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 [capped at 2.0 mg], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
11033521|NCT04544046|Active Comparator|Usual Care|Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.
11033522|NCT04544046|Experimental|Supportive Oncology Care at Home|"The research study procedures include:
~Remote monitoring of symptoms, vitals, and body weight
~Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms)
~Data collection from medical record"
11033523|NCT04544033||mild group|"Amendment to MOH COVID-19 Protocol:
~Patient with mild clinical symptoms & clinically table.
~CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line."
11033524|NCT04544033||moderate group|"Amendment to MOH COVID-19 Protocol:
~Patient with non-specific and specific respiratory infection (pneumonia).
~CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening)."
11033525|NCT04544033||severe group|"Amendment to MOH COVID-19 Protocol:
~Patients with respiratory distress (RR > 30/min, Sa02 < 92 at room air).
~Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours.
~CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening)."
11033526|NCT04544020||subjects|subjects with alcoholic hepatitis receiving NG feeding
11033527|NCT04544007|Experimental|Administer Poly-ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
11033528|NCT04543994|Experimental|Remestemcel-L (75 million cells)|Targeted endoscopic delivery of remestemcel-L at a dose of 75 million cells into the submucosal layer of the colon wall at baseline.
11033529|NCT04543994|Experimental|Remestemcel-L (150 million cells)|Targeted endoscopic delivery of remestemcel-L at a dose of 100 million cells into the submucosal layer of the colon wall at baseline..
11033530|NCT04543994|Placebo Comparator|Placebo|Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 75 or 150 million cells into the submucosal layer of the colon wall.
11033531|NCT04543968|Experimental|EVOO intake|"MD patients will receive EVOO daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving EVOO as their dietary supplements for another 6 months.
~Doses of EVOO intake: (1) Toddlers,1-3 y, 25 ml/day; (2) Kindergarten kids, 4-6 y, 30 ml/day; (3) Primary school age, 7-12y, 40 ml/day; (4) Secondary school age, 13-17y, 50 ml/day"
11033532|NCT04543968|Experimental|EVOO intake and withdraw|"MD patients will receive EVOO daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving EVOO as their dietary supplements for another 6 months.
~Doses of EVOO intake: (1) Toddlers,1-3 y, 25 ml/day; (2) Kindergarten kids, 4-6 y, 30 ml/day; (3) Primary school age, 7-12y, 40 ml/day; (4) Secondary school age, 13-17y, 50 ml/day"
11033533|NCT04543955|Experimental|Arm 1: Low-Dose Telotristat|Participants in this group will receive 750mg Telotristat per day.
11033534|NCT04543955|Experimental|Arm 2: High-Dose Telotristat|Participants in this group will receive 1500mg Telotristat per day.
11033535|NCT04543942|Experimental|Males|Participants in this group will be adult male heavy drinkers.
11033536|NCT04543942|Experimental|Females|Participants in this group will be adult female heavy drinkers. Data will be segregated by menstrual cycle phase - the late follicular or mid-luteal phase.
11033537|NCT04543929|Active Comparator|exercise|exercise prescription + standard of care
11033538|NCT04543929|No Intervention|no exercise|no exercise prescription + standard of care
11033539|NCT04543916|Experimental|Dose Level 1|Venetoclax 50mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
11041898|NCT04485715|Experimental|AI-aided group|
11033541|NCT04543916|Experimental|Dose Level 3|Venetoclax 200mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
11033542|NCT04543916|Experimental|Dose Level 4|Venetoclax 400mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
11033543|NCT04543916|Experimental|Dose Level 5|Venetoclax 600mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
11033544|NCT04543916|Experimental|Phase 2 Expansion Cohort|Venetoclax recommended phase 2 dose (RP2D) by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
11033545|NCT04543903|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11033546|NCT04543890|Active Comparator|Hyperfrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
11033547|NCT04543890|Experimental|Hypofrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/15 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
11033548|NCT04543877|Experimental|Inulin and Ty21a Vaccine|Participants will consume 12 grams/day of inulin for 4 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 6 weeks.
11033549|NCT04543877|Placebo Comparator|Maltodextrin and Ty21a Vaccine|Participants will consume 12 grams/day of maltodextrin (control) for 4 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 6 weeks.
11033550|NCT04543864|Experimental|electric welded metal framework|
11033551|NCT04543864|Experimental|conventional casted metal framework|
11033552|NCT04543851|Experimental|CARA positioning|Planning and Treatment using the CARA Device
11033553|NCT04543838|Experimental|EEG & SSEP monitoring|Intervention will include standard of care pain management during the postoperative period. Participants in this arm will receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP). EEG will be used to manage blood pressure.
11033554|NCT04543838|Active Comparator|Standard of Care|Control will include standard of care pain management during the postoperative period. Participants in this arm will not receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP).
11033555|NCT04543825|Experimental|CPET|Patients with cirrhosis who have been wait listed for liver transplant or are undergoing liver transplant evaluation and will undergo cardiopulmonary exercise testing (CPET).
11033556|NCT04543812|Experimental|PBF-1681 (ferric citrate)|PBF-1681 (ferric citrate) will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
11033557|NCT04543812|Placebo Comparator|Placebo|Matching placebo will be dosed two times a day with the 2 largest meals (preferred) or three times a day with meals.
11033558|NCT04543799||A1|"Group A1 consists of patients with prostate cancer receiving ADT as part of their standard care for either locally advanced or metastatic disease.
~Group A1 consists of a combination of two groups; B1, metastatic patients receiving ADT both with and without an oral AR targeted agent, and not receiving radiotherapy and B2, locally advanced patients receiving ADT alongside radiotherapy"
11033559|NCT04543799||A2|patients with localised prostate cancer receiving radiotherapy only
11033560|NCT04543786|Experimental|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation on lower back for 30-60 minutes for 5 consecutive days.
11033561|NCT04543773|Experimental|rTMS|Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
11033562|NCT04543760|Other|[PP sequence 1] - Wash-out - [SP sequence 2]|
11033563|NCT04543760|Other|[SP sequence 1] - Wash-out - [PP sequence 2]|
11033564|NCT04543747||Patients implanted with HVAD System|Patients who require treatment with HVAD for use as bridge to cardiac transplantation (BTT) or destination therapy (DT) within the re-examination period are eligible for enrollment into the MCS Korea PMS. Patient consent may be obtained prior to HVAD implant or after receiving HVAD implant. Waiver of consent may be allowed if allowed by site's Institutional Review Board (IRB) or Ethics Committee (EC).
11033565|NCT04543721||24-h-ABPM|
11033566|NCT04543708|Active Comparator|Incision drainage|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Incision drainage arm will benefit from drainage of the tonsillar abscess under local anesthesia and then be hospitalized for intravenous antibiotics. If the incision drainage fails, they will get a tonsillectomy under general anesthesia."
11033567|NCT04543708|Active Comparator|Tonsillectomy|"Adult with clinical suspicion of tonsillar abscess who underwent a CT-scan confirming the abscess will be randomly assigned to one arm or the other. Tonsillectomy arm will benefit from tonsillectomy under general anesthesia and then be hospitalized for intravenous antibiotics."
11033568|NCT04543695|Active Comparator|adjuvant chemotherapy group|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
11033569|NCT04543695|Experimental|consolidation chemotherapy group|concurrent chemoradiotherapy → consolidation chemotherapy → TME (experimental group)
11033570|NCT04543695|Experimental|induction chemotherapy group|induction chemotherapy → concurrent chemoradiotherapy →TME ( experimental group).
11033571|NCT04543682|Experimental|First intervention group (0.125 ng/kg/min Iloprost)|The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS, Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.
11033572|NCT04543682|Experimental|Second intervention group (0.25 ng/kg/min Iloprost)|The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS, Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.
11033621|NCT04543357||All participants|Household contacts of a participant in study C3391003
11033573|NCT04543682|Other|Control intervention group|Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS).
11033574|NCT04543669|Experimental|Adacel®|All participants will receive one booster dose of commercially available Adacel® (TdaP-Tetanus, diphtheria, acellular pertussis) vaccine
11033575|NCT04543656|Experimental|AI-Based Lifestyle Recommendations Group|Participants in this group receive AI-based, personalized lifestyle recommendations based on analysis of their activity tracker and blood pressure data.
11033576|NCT04543656|Active Comparator|Control Group|Participants in this group do not receive the lifestyle recommendations, but are provided with an identical activity tracker and blood pressure monitor.
11033577|NCT04543643|Experimental|Carvedilol+ berberine|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85mm Hg and HR 55/min. Berberine is started at a dose of 0.3g twice per day.
11033578|NCT04543643|Active Comparator|Carvedilol|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85 mm Hg and HR 55/min.
11033579|NCT04543630|Active Comparator|Particulated autogenous bone|Particulated autogenous bone is considered the gold standard for sinus floor augmentation. The bone will be harvested locally
11033580|NCT04543630|Experimental|Advanced platelet-rich fibrin|Advanced platelet-rich fibrin will be be obtained through a blood sample from the participant
11033581|NCT04543617|Experimental|Arm A: Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab.
11033582|NCT04543617|Experimental|Arm B: Tiragolumab Placebo + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab matching placebo.
11033583|NCT04543617|Placebo Comparator|Arm C: Tiragolumab Placebo + Atezolizumab Placebo|Participants will receive matching placebos to tiragolumab and atezolizumab.
11033584|NCT04543604|Experimental|Test group1 - Leaflet with visual aid|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. Along, pictograms were supplemented to display the prevalence of disease with and without the known indicator.
11033585|NCT04543604|Experimental|Test group2 - Leaflet with visual aid (L-NVA)|Information concerning etiology, prevalence, risk indicators and preventive measures of peri-implantitis were included. Relevant scientific bibliography supported the statements. No pictograms were supplemented.
11033586|NCT04543604|No Intervention|• Control group - No leaflet (NL)|Only verbal information was provided to the patient during initial interview.
11033587|NCT04543591|Experimental|Ravulizumab plus Best Supportive Care|
11033588|NCT04543591|Other|Best Supportive Care|
11033589|NCT04543578||Patients unfit for Surgery with mild-moderate acute cholecyst|Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.
11033590|NCT04543578||Patients unfit for Surgery with severe acute cholecystitis|Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.
11033591|NCT04543578||Patients suitable for Surgery with high and intermediate risk|"Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.
~High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.
~Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP."
11033592|NCT04543578||Patients suitable for Surgery with low risk|"Admission in Surgery Department. According to the AC severity:
~Mild-moderate AC: check de ASA/Charlson comorbidity index.
~ASA I-II/Charlson <6: laparoscopic cholecystectomy
~ASA > =III/Charlson >=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)
~Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy."
11033593|NCT04543565|Experimental|Trial group|subject in this group will receive Pradefovir mesylate tablet and the placebo of tenofovir disoproxil fumarate tablet, once daily for 96 weeks
11033594|NCT04543565|Active Comparator|Control group|subject in this group will receive tenofovir disoproxil fumarate tablet and the placebo of Pradefovir mesylate tablet, once daily for 96 weeks.
11033595|NCT04543552||Bladder Scan|Subjects who are scheduled to undergo urodynamic studies.
11033596|NCT04543539||IN.PACT™ AV Access PAS Primary Cohort|The primary cohort consists of enrolled subjects treated with the IN.PACT™ AV DCB according to labeling requirements who meet the inclusion/exclusion criteria for the primary cohort.
11033597|NCT04543539||IN.PACT™ AV Access PAS Extended Cohort|The extended cohort consists of enrolled subjects who do not meet the eligibility criteria for the primary cohort and receive the IN.PACT™ AV DCB device for treatment of stenosis in the AV circuit.
11033598|NCT04543526||Obese patients|Obese patients eligible for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.
11033599|NCT04543513|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
11033600|NCT04543500|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
11033601|NCT04543500|Active Comparator|Sham Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left postcentral gyrus. Participants in this arm will receive sham feedback while attempting to modulate their neural activity during an emotional cognitive control task.
11033602|NCT04543487|Experimental|Control Group|Group name
11033603|NCT04543474|Active Comparator|Group 1|Patients starting with a low lactose diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low FODMAP diet for 3 weeks
11033622|NCT04543344|Experimental|Low Dose|Repeated multiple doses
11033604|NCT04543474|Active Comparator|Group 2|Patients starting with a low FODMAP diet for 3 weeks, followed by a wash out phase of 3 week, before crossing over to the low lactose diet for 3 weeks.
11033605|NCT04543448|Other|Traditional Rehabilitation|Traditional Rehabilitation program was included strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs in all individuals. Indıvıduals participated in 2 training sessions per week for 4 weeks. Each training session consisted of a 5-minute non-balance coordination exercise, a 30-minute balance and coordination exercise, a 10-minute stretching and strengthing.
11033606|NCT04543448|Experimental|Cervical Mobilization|Cervical Mobilization program, cervical mobilization techniques were applied to the patients for 30 minutes in addition to the traditional program. Cervical mobilization includes suboccipital relaxing techniques, myofascial muscle relaxing techniques for Levator scapula, trapezius, scalenes muscles. These techniques were applied bilaterally.
11033607|NCT04543422|Experimental|Green tea extracts|Patients in this arm received green tea extract capsules
11033608|NCT04543422|Placebo Comparator|Placebo|Patients in this arm received placebo treatment
11033609|NCT04543409|Experimental|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
11033610|NCT04543409|Placebo Comparator|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
11033611|NCT04543396|Experimental|Physical Thearpy + Resistance Training|Subjects will receive standard of care treatments from their physical therapist. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
11033612|NCT04543396|No Intervention|Physical Thearpy|Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
11033613|NCT04543396|Experimental|Chiropractic Care + Resistance Training|Subjects will receive standard of care treatments from their chiropractor. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
11033614|NCT04543396|No Intervention|Chiropractic Care|Subjects will receive standard of care treatments from their chiropractor. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
11033615|NCT04543383|Experimental|Part 1: Group 1|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: ABC1, BC1A, C1AB, BAC1, C1BA and AC1B in period 1, period 2 and period 3 respectively where, Treatment A= Dose 1 of JNJ-70033093 +Dose 3 of 4F-PCC; Treatment B=Dose 2 of JNJ-70033093+Dose 3 of 4F-PCC; Treatment C1=Dose 2 of JNJ-70033093+Placebo with a washout period of 14 days to 21 days between Day 1 of each study period.
11033616|NCT04543383|Experimental|Part 1: Group 2|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: ABC2, BC2A, C2AB, BAC2, C2BA and AC2B in period 1, period 2 and period 3 respectively where, Treatment A= Dose 1 of JNJ-70033093 +Dose 3 of 4F-PCC; Treatment B=Dose 2 of JNJ-70033093+Dose 3 of 4F-PCC; Treatment C2=Dose 1 of JNJ-70033093+Placebo with a washout period of 14 days to 21 days between Day 1 of each study period.
11033617|NCT04543383|Experimental|Part 2: Group 1|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E in period 1, period 2 and period 3 respectively where, Treatment D=Dose 1 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment E=Dose 2 of JNJ-3093+Dose 4 of rFVIIa; Treatment F1=Dose 2 of JNJ-70033093+Placebo with a washout period of 4 days between Day 1 of each study period.
11033618|NCT04543383|Experimental|Part 2: Group 2|Participants will receive a single oral dose of JNJ-70033093 after high fat meal and IV injection of the reversal agent Recombinant Human Factor VIIa (rFVIIa) or placebo 4 hours after administration of JNJ-70033093 on Day 1 in following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E in period 1, period 2 and period 3 respectively where, Treatment D=Dose 1 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment E=Dose 2 of JNJ-70033093 +Dose 4 of rFVIIa; Treatment F2=Dose 1 of JNJ-70033093 +Placebo with a washout period of 4 days between Day 1 of each study period.
11033619|NCT04543370|Experimental|Treatment A|2 mg midazolam on Day 1 and 36 mg deflazacort on Day 2.
11033620|NCT04543370|Experimental|Treatment B|2000 mg edasalonexent TID on Day 1 to Day 11 with 2 mg midazolam on Day 10 and with 36 mg deflazacort on Day 11.
11033623|NCT04543344|Placebo Comparator|placebo|Repeated multiple doses
11033625|NCT04543331||treatment naïve patients|Patients being the first time treated for nAMD
11033626|NCT04543331||pre-treated patients|Patients already being treated for nAMD
11033627|NCT04543318|Experimental|Deep temporal nerves group|this group will use deep temporal nerves for reactivation of affected upper facial nerve branch
11033628|NCT04543318|Active Comparator|Masseteric nerve group|this group will use masseteric nerve for reactivation of affected upper facial nerve branch (gold standard)
11033629|NCT04543305|Experimental|PRT1419|PRT1419 will be administered orally
11033630|NCT04543292|Experimental|MATFILL|Prosthetic chimney filling with MATFILL prior to other sealing materials to protect the screww head.
11033631|NCT04543279|Experimental|Part A: Fostamatinib|The starting dose of fostamatinib is 100 mg twice daily (BID). After the first cycle, if no major dose related safety issue is observed and the platelet count is less than 50K/microL, then the fostamatinib dose will be increased to 150 mg BID for the next 2 cycles; otherwise the dose may be continued at 100 mg BID.
11033632|NCT04543279|Experimental|Part B: Fostamatinib + Ruxolitinib|"After 3 cycles of fostamatinib monotherapy, all patients with a sustained platelet count ≥ 50K/microL, will continue on the current fostamatinib dose plus ruxolitinib at the recommended dose per standard prescribing guidelines for an additional 9 cycles.
~Patients who do not reach platelet count of at least 50K/microL but who achieve clinical benefit per the treating provider may continue on single agent fostamatinib for up to 12 total treatment cycles. If these patients achieve a sustained platelet count of ≥ 50K/microL at any point prior to Cycle 10 Day 1, then they may be eligible to enroll in Part B of the study and continue treatment with fostamatinib and ruxolitinib for the remainder of the study."
11033633|NCT04543266||Patients with Progressive Disease|Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease
11033634|NCT04543266||Patients without Progressive Disease|Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease
11033635|NCT04543253||Standard of care CS|Patients undergoing curative surgery for any type of CS who will be followed through standard of care after surgery
11033636|NCT04543253||MUSE intervention CS|Patients undergoing curative surgery for any type of CS who will be introduced to and provided MUSE for use after surgery
11033637|NCT04543227||Retrospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries between August 2015 - August 2019.
11033638|NCT04543227||Retrospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure between August 2015 - August 2019.
11033639|NCT04543227||Prospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries after July 2020.
11033640|NCT04543227||Prospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure after July 2020.
11033641|NCT04543201|Experimental|Early STructured Advanced care Referrals by Telehealth|"Early START visit using checklist over telephone or zoom:
~A telehealth visit conducted within 4 months of patient diagnosis, with the goal of encouraging patients to discuss and document their end-of-life wishes prior to the onset of cognitive impediments common among patients with late-stage high grade glioma."
11033642|NCT04543188|Experimental|PF-07284890 (Part A monotherapy)|Monotherapy dose escalation of PF-07284890
11033643|NCT04543188|Experimental|PF-07284890+binimetinib (Part A combo-therapy)|Combination dose escalation of PF-07284890 + binimetinib
11033644|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 1)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or Non-Small Cell Lung Cancer (NSCLC), with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
11033645|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 2)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
11033646|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 3)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
11033647|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 4)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and prior BRAF inhibitor utilization
11033648|NCT04543188|Experimental|Expansion Phase (Part B Cohort 5)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
11033649|NCT04543188|Experimental|Drug-Drug Interaction Substudy|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
11033650|NCT04543175||Chemotherapy breast cancer patients|Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.
11033651|NCT04543162||patients with Mild Traumatic Brain Injury|patients with Mild Traumatic Brain Injury
11033652|NCT04543149||Case|Patients with idiopathic granulomatous mastitis
11033653|NCT04543149||Control|Healthy volunteers
11033654|NCT04543136|Active Comparator|SpeediCath® standard Male|Standard of care
11033655|NCT04543136|Experimental|New intermittent catheter variation 1 for male|New intermittent catheter variation 1 for male.
11033656|NCT04543136|Experimental|New intermittent catheter variation 2 for male|New intermittent catheter variation 2 for male
11033657|NCT04543123|Sham Comparator|sham tDCS treatment group|the current rose slowly for 30 seconds, descended for 30 seconds, and then remained at zero for 29 minutes
11033658|NCT04543123|Experimental|active tDCS treatment group|2mA of current was delivered during the 30 minutes of treatment
11033659|NCT04543110|Experimental|Single Arm|Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
11033660|NCT04543097|No Intervention|Usual care|Participants randomised to the usual care arm will continue to receive care as usual for their health and vocational needs. For most patients, this will comprise usual clinical care, without formal vocational advice.
11033661|NCT04543097|Experimental|Usual care plus vocational support|Vocational support following a stepped care model based on the principles of case management in addition to usual primary care.
11033662|NCT04543084|Other|Single-Subject Design|Each participant will go through a baseline phase and then an intervention phase.
11033663|NCT04543071|Experimental|Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel|Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified.
11033664|NCT04543058|Experimental|BeatPark Experimental Group|Group of participants who will make its self-rehabilitation in walking program using BeatPark application, delivering synchronized music adapted to the patient walking progression.
11033665|NCT04543058|Active Comparator|Control Group with Music at Random Tempo|Group of participants who will make its self-rehabilitation in walking program using an application delivering music at random tempo.
11033666|NCT04543058|Active Comparator|Control Group without Music|Group of participants who will make its self-rehabilitation in walking program using an application without music.
11033667|NCT04543045||Stage 1|20 patients will be interviewed once, which will be approximately 60 minutes in duration. The interviews will be audio recorded.
11033668|NCT04543045||Stage 2|Five patients who participated in stage 1 will take part in a cognitive interview, which will be approximately 60 minutes in duration.The interviews will be audio recorded.
11033669|NCT04543032|Experimental|study group|the patients in this group will receive sensorimotor training for 6 weeks in addition to medical care.
11033670|NCT04543032|No Intervention|control group|the patients in this group will receive medical care only.
11033671|NCT04543006|Other|Covid-19|only arm: Covid-19 proven by PCR
11033672|NCT04542993|Active Comparator|Resveratrol and Zinc Picolinate combination therapy|Resveratrol and Zinc Picolinate combination therapy
11033673|NCT04542993|Placebo Comparator|Resveratrol Placebo and Zinc Placebo combination therapy|Placebo Resveratrol and Placebo Zinc combination therapy
11033674|NCT04542980||SARS-CoV2 Positive|"Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus.
~A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus."
11033675|NCT04542980||Control|Control tear and serum samples will be selected from Namida Lab's own biorepository.
11033676|NCT04542967|No Intervention|Control group|They will receive the standard care for critically ill inpatients.
11033677|NCT04542967|Experimental|Convalescent plasma group.|They will receive standard care for patients with severe COVID-19 disease and convalescent plasma disease.
11033678|NCT04542941|Active Comparator|Intervention arm|The participants will receive COVID Convalescent Plasma in addition to the standard of care received by all COVID 19 patients
11033679|NCT04542941|No Intervention|Control arm|The participants under this arm will receive the COVID 19 standard of care
11033680|NCT04542928|Placebo Comparator|routine care|The controlled group will receive routine functional treatment activities, a facial cleansing instruction and five facial cleansing videos.
11033681|NCT04542928|Experimental|experimental group|experimental group is required to receive a nurse leading 50- minute face care group every two weeks
11033682|NCT04542915||U.S. licensed dental hygienists|Dental hygienists licensed in the United States. No intervention will be administered.
11033683|NCT04542902|Experimental|Allergic asthma patients|Allergic asthma patients and sensitization to house dust mites (D. pteronyssinus) allergen.
11033684|NCT04542902|Experimental|Severe eosinophilic asthma patients|
11033685|NCT04542902|Active Comparator|Healthy subjects as a control group|Healthy subjects without allergic and other chronic respiratory diseases (control group).
11033686|NCT04542889|Experimental|Absolute coronary resistances and IMR after angioplasty|Patients with STEMI by acute occlusion of a large caliber coronary artery that had been admitted to hospital less than 12 hours and revascularized by primary angioplasty with good final result.
11033687|NCT04542876|Experimental|Ayurveda|Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.
11033688|NCT04542863|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans.
11033689|NCT04542850|Other|Moderate group and Severe Group|Moderate group - not requiring assisted ventilation and Severe group - requiring assisted ventilation. Both groups will be administered 5-aminolevulinic acid (5-ALA) is a natural delta amino acid widely present in nature that can be found in common food. 5-ALA combined with sodium ferrous citrate (SFC) produces the nutritional dietary supplement 5-ALA-Phosphate + SFC (5-ALA + SFC).
11033690|NCT04542837|Experimental|KN046 plus Lenvatinib|
11033691|NCT04542824|Experimental|epcoritamab|Open label, single arm trial where epcoritamab will be administered
11033692|NCT04542811|Experimental|Intervention group|Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
11033693|NCT04542811|No Intervention|Control Group|Control group will take only their migraine prophylaxis treatment. Participants will followed-up 3 months.
11033694|NCT04542798|Experimental|NPPG (neuropatic pain group) PRF|Pulsed radiofrequency neuromodulation of dorsal root ganglia
11033695|NCT04542798|Active Comparator|NPPG (neuropatic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
11033696|NCT04542798|Experimental|NMPG (nociceptive/mechanic pain group) WCRF|Water cooled radiofrequency of the medial branch of the dorsal nerve
11033697|NCT04542798|Active Comparator|NMPG (nociceptive/mechanic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
11041899|NCT04485715|No Intervention|control group|
11033698|NCT04542785|Experimental|Lenient rate control|Treating physicians will target a resting heart rate between 80 and 110 beats per minute on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
11033699|NCT04542785|Active Comparator|Strict rate control|Treating physicians will target a resting heart rate a mean resting heart rate < 80 bpm on a 12-lead resting ECG measured over 1 minute after 5 minutes of rest.
11033700|NCT04542772|Experimental|Mirror Therapy + Standard of Care|Participants in this group will receive standard of care based on their needs along with mirror therapy education.
11033701|NCT04542772|Active Comparator|Standard of Care|Participants in this group will receive only standard of care based on their needs.
11033702|NCT04542759|Active Comparator|Besifloxacin|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
11033703|NCT04542759|Placebo Comparator|Hydroxypropyl methylcellulose|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
11033704|NCT04542746|Experimental|Minimally invasive surgical technique|The intra-bony defects of subjects allocated in test group were treated with a combination of minimally invasive surgical technique (MIST) and enamel matrix derivative( EMD).
11033705|NCT04542746|Active Comparator|Conventional open flap debridement with papilla preservation|The intra-bony defects of control group were treated using a combination of conventional open flap debridement with papilla preservation (COFD+PP) and EMD.
11033706|NCT04542733|Active Comparator|mTORi|Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.
11033707|NCT04542733|Active Comparator|Leflunomide|Patient will receive leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter, and tacrolimus with target concentration of 3-6 ng/mL. Duration for this regimen would be at least 3 months.
11033708|NCT04542720|Experimental|Decompression|
11033709|NCT04542720|Active Comparator|Extension Fusion|
11033710|NCT04542707|Active Comparator|Joint manipulation|Grade V-Thrust manipulation with audible sound and without audible sounds of T7, MTP 2 and MCP2 joints.
11033711|NCT04542707|Active Comparator|Exercise|Aerobic, anaerobic, and yoga exercises
11033712|NCT04542707|Active Comparator|Soft tissue massage|Instrument assisted soft tissue massage
11033713|NCT04542694|Experimental|Favipiravir (Areplivir)|"Arm 1 (n=100) receives the study drug Areplivir film-coated tablets:
~on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient."
11033714|NCT04542694|Active Comparator|Standard of care|"Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes.
~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
11033715|NCT04542681|Placebo Comparator|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo (0.9% normal saline) (n=10)
11033716|NCT04542681|Active Comparator|MANP - 1st Cycle|Subjects will receive a single SQ injection of 2.5 μg/kg MANP (n=10)
11033717|NCT04542681|Active Comparator|MANP - 2nd Cycle|Subjects will receive a single SQ injection of 5 μg/Kg MANP (n=10)
11033718|NCT04542668|Other|Cycling as first intervention|Cycling -> Running -> Inotropy -> Resting
11033719|NCT04542668|Other|Running as first intervention|Running -> Cycling -> Inotropy -> Resting
11033720|NCT04542655|Other|Cycling first|Ergometer cycling then treadmill running then rest
11033721|NCT04542655|Other|Running first|Treadmill running then ergometer cycling then rest
11033722|NCT04542642|Active Comparator|reSET-O|Prescription Digital therapeutic
11033723|NCT04542642|Experimental|PEAR-008|Investigational Digital Therapeutic
11033724|NCT04542629|Experimental|RITUXIMAB|rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses
11033725|NCT04542629|Active Comparator|KETOGENIC DIET|"The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.
~Diets that produce a state of ketosis are referred to as ''ketogenic"
11033726|NCT04542629|Active Comparator|TRACE ELEMENTS|. Essential trace elements that include zinc, copper, magnesium, and selenium
11033727|NCT04542629|Active Comparator|CORTICOSTEROID|corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month
11033728|NCT04542616|Active Comparator|Baerveldt 350|The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
11033729|NCT04542616|Active Comparator|Ahmed ClearPath 250|The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
11033730|NCT04542603|Experimental|treatment naivete women with stage 1-4 newly diagnosed ovarian|
11033731|NCT04542564|Experimental|telemedicine group|The HT app (HealthCap) allows patients to record their home BP measurements (HBPM) and can automatically provide mean BP values from the previous 7 or 30 days. 1-2 week prior to a scheduled physician, HealthCap and a research assistant will remind patients to take dual BP readings both in the morning and evening for 1 week for doctors' management. The mean values of the 7-day home BP will be checked before the index consultation. If the home BP control was optimal (i.e. ≤135/85 mmHg), other important parameters will be checked automatically by a questionnaire in the app: (i) if they have good drug compliance and if they experienced any side effects,(ii) if they have symptoms suggestive of target organ damages such as chest pain or hemiplegia, and (iii) if they have any problem(s) that need to consult a physician. If no complaints are identified, the patient can collect medications directly from the clinic and the physician appointment will be deferred for 3 months
11033732|NCT04542564|Placebo Comparator|usual care|Patients in the usual care group will be asked to refrain from downloading or using any health care apps related to HT
11033868|NCT04541589|Active Comparator|Arm 2|Arm 2 - Iscalimab Dose 2 and Placebo
11033733|NCT04542551|Active Comparator|Without stricture - dilation with 60-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 60-Fr dilator
11033734|NCT04542551|Sham Comparator|Without stricture - dilation with 15-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 15-Fr dilator (sham)
11033735|NCT04542551|Active Comparator|Non severe stricture - dilation with 60-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 60-Fr dilator
11033736|NCT04542551|Active Comparator|Non severe stricture - dilation with 46-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 46-Fr dilator
11033737|NCT04542551|Active Comparator|Severe stricture - dilation with 60-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 60-Fr dilator
11033738|NCT04542551|Active Comparator|Severe stricture - dilation with 46-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 46-Fr dilator
11033739|NCT04542538||COVID-19 critical care patients|All patients who have received intensive care with COVID-19 in Sweden until May 27, 2020. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
11033740|NCT04542538||Sepsis critical care patients|All patients who have received intensive care with severe sepsis or septic shock in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
11033741|NCT04542538||ARDS critical care patients|All patients who have received intensive care with ARDS in Sweden between 2011 and 2016. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
11033742|NCT04542499|Experimental|Tavapadon|Participants will receive a tavapadon tablet titrated 5 to 15 milligrams (mg) once daily (QD) orally for 27 weeks.
11033743|NCT04542499|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
11033744|NCT04542486|Experimental|The conventional approach:|Gingivoplasties and removal of excess gingival tissues through the conventional scalpel technique using a reverse bevel.
11033745|NCT04542486|Active Comparator|The intervention approach:|"Gingivoplasties and elimination of excess gingival tissues through the use of Thermacut burs."
11033746|NCT04542473|Active Comparator|Pancreatic Enzymes (PE)|"Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day:
~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)
~---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667"
11033747|NCT04542473|Placebo Comparator|Placebo-PE|"Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands:
~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)
~----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil"
11033748|NCT04542473|Active Comparator|Ursodeoxycholic acid (UA)|The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
11033749|NCT04542473|Placebo Comparator|Placebo-UA|The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
11033750|NCT04542460|No Intervention|Optimal Medical Treatment|CTO patients receiving optimal medical treatment
11033751|NCT04542460|Active Comparator|Optimal Medical Treatment and PCI|CTO patients receiving PCI in ajunction to optimal medical treatment
11033752|NCT04542447|Active Comparator|Nuvastatic + standard treatment|5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
11033753|NCT04542447|Placebo Comparator|Placebo|5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
11033754|NCT04542434|Experimental|Niclosamide|
11033755|NCT04542434|Placebo Comparator|Placebo|
11033756|NCT04542421|Experimental|Lung ultrasound Implementation arm|Hospitalists undergo training to use lung ultrasound in their patients hospitalized with COVID
11033757|NCT04542408|Experimental|Intensive anticoagulation strategy|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC
11033758|NCT04542408|Other|Moderate anticoagulation strategy|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban
11033759|NCT04542395|Experimental|Increasing Uptake of COVID-19 Testing and Vaccination|"This is a pre-experimental one group pretest-posttest design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
11033760|NCT04542382|Experimental|Placebo and Rosuvastatin|Subjects will be dosed with placebo tablet and Rosuvastatin 10mg tablet
11033761|NCT04542382|Experimental|Eltrombopag and Rosuvastatin|Subjects will be dosed with Eltrombopag 75mg tablet and Rosuvastatin 10mg tablet
11033762|NCT04542369|Experimental|ES-SCLC|Induction therapy: BGB-A317 200mg, qd, ivgtt, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles. Maintenance therapy: BGB-A317 200mg, qd, ivgtt, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death).
11033763|NCT04542356|Experimental|experimental group|patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
11033764|NCT04542356|Placebo Comparator|control group|patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC<1✕109/L
11033765|NCT04542343|Experimental|Risk Reduction of COVID-19 Among African American Parishioners|"This arm will implement one group pretest-posttest design to improve COVID associated health outcomes of AA older parishioners in collaboration with trained young church-based health educators."
11033766|NCT04542330|Active Comparator|BCG-Denmark|"Participants that are randomized to the active comparator arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.
~Each 0.1 ml dose of vaccine contains between 200,000 to 800,000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
11033767|NCT04542330|Placebo Comparator|Control|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
11033768|NCT04542317|Experimental|REACH VN|A multi-component behavioral intervention to support family caregivers of persons with dementia. Participants will receive 4-6 sessions in-person or by phone over the course of 2-3 months.
11033769|NCT04542317|Placebo Comparator|Enhanced control|A single session focused on education about the nature of dementia.
11033770|NCT04542304|Active Comparator|Metolazone then placebo|Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.
11033771|NCT04542304|Placebo Comparator|Placebo then Metolazone|Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.
11033772|NCT04542291|Experimental|Dapagliflozin|"Dapagliflozin is an oral drug which will be administered on an outpatient basis. Dosing will start at 5 mg QD and will increase to 10 mg QD after 2 weeks if the patient is tolerating the 5 mg dose. Dapagliflozin will be given for a total of 8 weeks (2 weeks at 5 mg and 6 weeks at 10 mg)
~Treatment with dapagliflozin will be initiated on Cycle 1 Day 1 of standard of care chemotherapy."
11033773|NCT04542278|Active Comparator|Steroids|Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care
11033774|NCT04542278|No Intervention|No Steroids|Pre-operative Standard of Care
11033775|NCT04542265|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
11033776|NCT04542265|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
11033777|NCT04542265|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil A + vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
11033778|NCT04542265|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
11033779|NCT04542252|Experimental|Group 1|SyB V-1901 alone, Simultaneous administration of SyB V-1901 and cyclosporine, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
11033780|NCT04542252|Experimental|Group 2|Simultaneous administration of SyB V-1901 and cyclosporine, SyB V-1901 alone, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
11033781|NCT04542239||Infants with GER|Infants (N=25) meeting inclusion/exclusion criteria
11033782|NCT04542239||Controls without GER|Infants (N=10) meeting inclusion/exclusion criteria, but no GER
11033783|NCT04542226||Adult patients hospitalized with COVID-19|Patients eligible for enrollment into the study
11033784|NCT04542213|Experimental|DPP4 inhibitor + insulin|Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
11033785|NCT04542213|Active Comparator|Insulin scheme alone|Patients assigned to this group will receive only a basal-bolus insulin scheme
11033786|NCT04542161|Active Comparator|NAC 900mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
11033787|NCT04542161|Active Comparator|NAC 3600mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
11033788|NCT04542161|Placebo Comparator|NAC 0mg/day (Placebo)|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
11033789|NCT04542148|Experimental|Sliding Scale Insulin|Addition of supplemental sliding scale insulin to home insulin regimen for maximum of 5 days after antenatal corticosteroids
11033790|NCT04542148|Experimental|Up-Titration of Home Insulin|Increase in home insulin regimen based on standardized algorithm for maximum of 5 days after antenatal corticosteroids
11033791|NCT04542148|Experimental|Continuous Insulin Infusion|Discontinuation of home insulin regimen and receipt of continuous insulin infusion for maximum of 5 days after antenatal corticosteroids
11033792|NCT04542135|Active Comparator|Sulindac|sulindac 150 mg
11033793|NCT04542135|Placebo Comparator|Placebo|placebo pill
11033794|NCT04542122|No Intervention|Choices then judgements|
11033795|NCT04542122|Active Comparator|Judgements then choices|Switch in the order of clinical cases in the survey
11033838|NCT04541797|Placebo Comparator|Control|Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
11033839|NCT04541797|Experimental|Intervention|Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
11042776|NCT04479839||Microcuff ETT|Patients intubated with microcuff ETT
11033796|NCT04542109|Experimental|READyR A|Group A will start the READyR intervention immediately after the baseline Session 1. The READyR program consists of a 3-session, values-based needs assessment intervention designed to match objectively-assessed in-home activity patterns with subjective reports of participants' care values. The goal of the intervention is to address unmet dementia-related care needs and help couples prepare for the future, and reduce strain on their relationship, and help maintain their health and well-being. Session 2 will occur approximately 3 weeks after Session 1, and Session 3 will occur approximately 3 weeks after Session 2. Session 3 also includes follow-up assessments.
11033797|NCT04542109|Active Comparator|READyR B (wait list comparison)|Group B - the wait list comparison group - will have a 60-minute support session (comparator intervention) about 3 weeks after the baseline Session 1. The support session will include general information about dementia-related care needs that does not take into account the individual participant's care values or objective in-home activity patterns. They will also receive a check-in call approximately 3 weeks later, with follow-up assessments. Group B will begin the READyR intervention sessions following completion of follow-up assessments.
11033798|NCT04542096||Group1|Patients receiving invasive respiratory therapy (intubated)
11033799|NCT04542096||Group2|Patients receiving non-invasive respiratory therapy.
11033800|NCT04542083||COVID-19 period|Admissions from January to December 2020
11033801|NCT04542083||Control period|Admissions from January 2018 to December 2019
11033802|NCT04542070|Experimental|Participants receiving CAB LA + RPV LA regimen|Participants will be offered the option to start with a month long oral lead in or to start long acting intramuscular injections (OLI or D2I). On Day 1, participants who choose to participate in OLI will be administered CAB 30 milligrams (mg) + RPV 25 mg once daily orally for one month. At the Month 1 visit, last dose of oral CAB + RPV will be given followed by the first CAB LA 600 mg + RPV LA 900 mg intramuscular (IM) injection (within 2 hours of the final oral dose). The second IM injection with CAB LA 600 mg and RPV LA 900 mg will be administered at Month 2 followed by the same Q2M until Month 12. In D2I, at Day 1, eligible participants will receive the first injection of CAB LA 600 mg + RPV LA 900 mg as initial loading dose. The second and third injections (CAB LA 600 mg + RPV LA 900 mg) will be administered at Month 1 and Month 3 followed by the same Q2M until Month 11.
11033803|NCT04542070|Active Comparator|Participants receiving BIK|Participants will receive BIK, that is a combination of Bictegravir (BIC) 50 mg + Emtricitabine (FTC) 200 mg + Tenofovir alafenamide (TAF) 25 mg orally, administered once daily until Month 12.
11033804|NCT04542057|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
11033805|NCT04542057|Placebo Comparator|Arm 2|Placebo Nebulized BID
11033806|NCT04542031|Other|Survey|Survey to be distributed at 6 and 12 months
11033807|NCT04542018|Experimental|Study patients with IBS-D|Patients with diarrhea-predominant IBS who will undergo a low FODMAP diet for 4 weeks
11033808|NCT04542005|Experimental|q3h albuterol|Using q3h as discharge criteria from hospital
11033809|NCT04542005|No Intervention|q4h albuterol|Using q4h as discharge criteria from hospital
11033810|NCT04541992||Airborne Group|Participants in this group will be tested for balance and agility within a 20 minute time frame.
11033811|NCT04541979|Active Comparator|Aerosolized DNase I|
11033812|NCT04541979|Placebo Comparator|NaCl|
11033813|NCT04541966||Nuchal translucency> = 99th percentile and <3.5mm|Nuchal translucency> = 99th percentile and <3.5mm
11033814|NCT04541966||Nuchal translucency> = 3.5 mm|Nuchal translucency> = 3.5 mm
11033815|NCT04541953|Active Comparator|Telerehabilitation|
11033816|NCT04541953|Active Comparator|In-Person Rehabilitation|
11033817|NCT04541940|Active Comparator|Telerehabilitation|
11033818|NCT04541940|Active Comparator|In-Person Rehabilitation|
11033819|NCT04541927||BCL11B|BCL11B intragenic pathogenic variant
11033820|NCT04541914|Experimental|Validation group|Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)
11033821|NCT04541901|Experimental|Intervention|
11033822|NCT04541901|Active Comparator|Comparator|
11033823|NCT04541901|No Intervention|Control|
11033824|NCT04541888|Experimental|Experimental Group|322 subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
11033825|NCT04541888|Placebo Comparator|Control group|322 subjects will be treated with Placebo : 0 g: 0mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
11033826|NCT04541875||Cystic fibrosis|"Patients aged 18+ and diagnosed with cystic fibrosis.
~Patients will answer the MAR-Scale once every three months for a year."
11033827|NCT04541875||Hemophilia A or B|"Patients aged 18+ and diagnosed with hemophilia A or B.
~Patients will answer the MAR-Scale once every three months for a year."
11033828|NCT04541875||Idiopathic pulmonary fibrosis|"Patients aged 18+ and diagnosed with idiopathic pulmonary fibrosis.
~Patients will answer the MAR-Scale once every three months for a year."
11033829|NCT04541875||Myasthenia gravis|"Patients aged 18+ and diagnosed with myasthenia gravis.
~Patients will answer the MAR-Scale once every three months for a year."
11033830|NCT04541875||Sickle cell disease|"Patients aged 18+ and diagnosed with sickle cell disease.
~Patients will answer the MAR-Scale once every three months for a year."
11033831|NCT04541862||Critically ill patients|
11033832|NCT04541849||Critically ill patients|
11033833|NCT04541836||healthy control|healthy volunteer with no clinically relevant finding on physical examination at screening visit will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later.
11033834|NCT04541836||PSP|"Patients fulfill the criteria of NINDS-SPSP clinical criteria for the diagnosis of PSP as possible or probably PSP will receive one baseline 18F-PMPBB3 tau PET scan, and another follow up scan 1.5yr later."
11033835|NCT04541823|Experimental|Desflurane|Patients allocated to this arm will receive desflurane during the maintenance of anesthesia.
11033836|NCT04541823|Placebo Comparator|Propofol|Patients allocated to this arm will receive propofol during the maintenance of anesthesia
11033837|NCT04541810||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
11042777|NCT04479839||Non-microcuff ett|Patients intubated with regular ETT
11033840|NCT04541784|Active Comparator|3 counselling sessions with gynaecology-oncology nurses|Patients randomized to the control group will receive standardized care, 3 counselling sessions with a gynaecology-oncology nurse and written information at three points in time during 6 months after diagnosis/surgery.
11033841|NCT04541784|Experimental|Mobile app and 3 counselling sessions (WOMAN-PROIII)|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III. Counselling sessions will take place at 3 points in time during 6 months after diagnosis/surgery. Additionally, the gynaecology-oncology nurse will instruct the patient to use the mobile app. It includes a diary for symptom assessment and gives graphical feedback. Further, the app includes disease and treatment related information. If a symptom occurs the app will give an evidence-based recommendation (Kobleder et al., 2016). The patients can use the app whenever they want for a period of six months."
11033842|NCT04541771|Experimental|drug group|The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
11033843|NCT04541771|Placebo Comparator|control group|this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed
11033844|NCT04541758|Experimental|surgical treatment|Minimally invasive internal fixation under spontaneous respiratory anesthesia and analgesic treatment and chest strap fixation
11033845|NCT04541758|Experimental|Conservative treatment|analgesic treatment and chest strap fixation
11033846|NCT04541732|Experimental|Thoracic epidural block|Patients will receive thoracic epidural block following induction of general anaesthesia
11033847|NCT04541732|Active Comparator|Bilateral quadratus lumborum block|Patients will receive Ultrasound-guided bilateral quadratus lumborum block following induction of general anaesthesia
11033848|NCT04541719|Active Comparator|Patient-controlled remifentanil analgesia|Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery
11033849|NCT04541719|Placebo Comparator|Epidural analgesia|Patients will received continuous epidural analgesia starting from labour pain until delivery
11033850|NCT04541706|Experimental|Lorlatinib|The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
11033851|NCT04541693|Other|Hip revision|Revision to cup and stem, cup only or stem only.
11033852|NCT04541680|Experimental|Nintedanib|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
11033853|NCT04541680|Placebo Comparator|Placebo|Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.
11033854|NCT04541667|Active Comparator|Air for luminal inflation|Patients randomized into this arm will have luminal inflation using air.
11033855|NCT04541667|Active Comparator|Carbon Dioxide for luminal inflation|Patients randomized into this arm will have luminal inflation using carbon dioxide.
11033856|NCT04541654||Variant in the TP53 Gene in blood or saliva|Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history
11033857|NCT04541641|Experimental|osteotome group|
11033858|NCT04541641|Experimental|New Reverse Drilling technique|
11033859|NCT04541628|Experimental|SIG-001|B-Domain Deleted Human Factor VIII (BDD-hFVIII) Producing Spheres
11033860|NCT04541615|Active Comparator|Group 1: Online didactic to proficiency PBP+|Group 1 Pre-trained group will receive information on how to optimally perform the ORSI chicken anastomosis task and the material will be delivered online via the ORSI e-learning platform. They will be given access to the material two weeks before their training. Unlike the other groups, Group 1 will be required to study the material to a pre-defined performance benchmark or proficiency level. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
11033861|NCT04541615|Active Comparator|Group 2: Online didactic PBP+|The Pre-trained group (Group 2) will receive the exact same information as Group 1 on how to optimally perform the ORSI chicken anastomosis task but they are not required to study the material to a pre-defined proficiency benchmark. The time they spend on the task and effort expended will be logged. Once the online course is completed, participants have to perform the orsi chicken anastomosis task.
11033862|NCT04541615|Active Comparator|Group 3: Standard training group|The standard trained group will receive face-to-face lectures on how to perform the ORSI chicken anastomosis task. It will not differ from what they would normally receive during a traditional surgery training course when they arrive at the ORSI academy for their training. The content of the face-to face lecture is the same as in the e-learning courses. After the face-to face lecture, the participants have to perform the orsi chicken anastomosis task.
11033863|NCT04541615|Active Comparator|Group 4: Apprenticeship Group|The apprenticeship trained group will not receive face-to-face lectures or e-learning on how to perform the ORSI chicken anastomosis task. They will however receive hands-on practical one-to-one training during a traditional surgical training course, with deliberate practice. During this course, clinicians will train the participants on how to perform the orsi anastomosis task. They will also receive published materials describing how best to perform the task and mentoring on suturing and knot tying by a task expert who will guide their performance.
11033864|NCT04541602||Dysphagia-positive|"critically ill patients more than 17 years of age
~matching study inclusion criteria
~confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later
~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
11033865|NCT04541602||Dysphagia-negative|"critically ill patients more than 17 years of age
~matching study inclusion criteria
~newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later
~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
11033866|NCT04541602||Controls|"healthy volunteers without any neuromuscular disease
~swallowing dysfunction ruled out using FEES"
11033867|NCT04541589|Active Comparator|Arm 1|Arm 1 - Iscalimab Dose 1
11033869|NCT04541576|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
11033870|NCT04541563|Experimental|Immediate Treatment Arm|The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
11033871|NCT04541563|Sham Comparator|Delayed Treatment Arm|In the delayed treatment arm, the participants will receive a sham device that looks exactly the same, but only provides treatment for 2 seconds. At week 4, sham arm participants will be unblinded and shipped an active device (limited to Level 2 output even if a participant raises the dial beyond that). The delayed arm participants will continue with active devices for the remaining 4 weeks of the trial.
11033872|NCT04541550|Experimental|Low Dose AMP-001|25mg AMP-001 in 3ml Saline
11033873|NCT04541550|Experimental|Medium Dose AMP-001|50 mg AMP-001in 3 ml Saline
11033874|NCT04541550|Experimental|High Dose AMP-001|75 mg AMP-001 in 3 ml Saline
11033875|NCT04541537|Experimental|Sorbstar®|Odour sampling : rub hands with Sorbstars® before and post-surgery
11033876|NCT04541537|Experimental|Dog Detection|Odour sampling :sleep over a night with a compress on the affected breast before and after surgery
11033877|NCT04541511|Experimental|Healthy subject|"Healthy subject will be asked to performed two 6-minutes walking test : one in a corridor and one on the non-motorized treadmill.
~Oxygen saturation, heart rate and Borg score will be collected before and after each test."
11033878|NCT04541511|Experimental|Patients|Patients will be asked to to performed a 6-minutes walking test on the non-motorized treadmill and to answer a questionnaire regarding the acceptability and ease of use of the new method.
11033879|NCT04541498||Population of Poland|
11033880|NCT04541498||Patients with Acute Coronary and Cerebral Syndromes|
11033881|NCT04541485|Experimental|Experimental: Cohort 1 (96 mg)|24 mg/0.1 mL x 4 sites
11033882|NCT04541485|Experimental|Experimental: Cohort 2 (288 mg)|72 mg/0.3 mL x 4 sites
11033883|NCT04541485|Experimental|Experimental: Cohort 3 (480 mg)|120 mg/0.5 mL x 4 sites
11033884|NCT04541485|Experimental|Experimental: Cohort 4 (672 mg)|168 mg/0.7 mL x 4 sites
11033885|NCT04541485|Experimental|Experimental: Cohort 5 (960 mg)|240 mg/1.0 mL x 4 sites
11033886|NCT04541459|Sham Comparator|Sham Qi-Shield user group|
11033887|NCT04541459|Active Comparator|Qi-Shield user group|
11033888|NCT04541446|Experimental|Residents to receive Dynamic Haptic Robotic Training|
11033889|NCT04541446|Experimental|Residents to receive Advanced Dynamic Haptic Robotic Training|
11033890|NCT04541433|Experimental|AZD9833 monotherapy|Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
11033891|NCT04541420||Eribulin|Eribulin 1.4mg/m2 d1,8 iv q3w
11033892|NCT04541407|Experimental|Exon 19 deletions or L858R point mutations in exon 21|Will include patients with exon 19 deletions or L858R point mutations in exon 21 of the epidermal growth factor receptor (EGFR) gene. Temozolomide plus Osimertinib will be the study drug combination administered. Osimertinib will be given at a fixed dose of 80 mg daily for dose level 1, with a potential to increase to 160 mg daily for dose level 2. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level.
11033893|NCT04541407|Experimental|Patients with anaplastic lymphoma kinase (ALK) fusions|Will include patients with anaplastic lymphoma kinase (ALK) fusions. Temozolomide plus Lorlatinib will be the study drug combination administered. Lorlatinib will be given at a fixed dose of 100 mg daily. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level depending on tolerability.
11033894|NCT04541394|Experimental|MolecuLight group|Patients with infected wounds received MolecuLight photography during debridement operation to evaluate the adequacy of remission of infected biofilm and facilitate wound healing
11033895|NCT04541394|No Intervention|Control group|Patients with infected wounds received debridement operation by surgeon's clinical experiences to decide the extension of wounds
11033896|NCT04541381|No Intervention|Control Group (No PGx Test)|Participants assigned to the control group will not take a genotyping/PGx test during the start of treatment and will instead receive standard chemotherapy without their doctors receiving any genetic information based on the participants' PGx test results. Blood samples for participants in this group will be stored and tested for genotyping six months later after treatment (or earlier if the participant experiences side effects).
11033897|NCT04541381|Experimental|Pharmacogenomics (PGx Testing) Group|Participants enrolled in the pharmacogenomics (PgX) testing group will give a blood sample for immediate genotyping/PGx testing. Once the results from these tests are in, cancer doctors caring for each participant will have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription based on genetic information found in their PGx test results.
11033898|NCT04541368|Experimental|Administration of CS1 Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
11033899|NCT04541355|Experimental|Cohort A: Weekly Cisplatin + STS|Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients receive cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every 7 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
11033900|NCT04541355|Experimental|Cohort B: High Dose Cisplatin + STS|Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients receive high-dose cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11033901|NCT04541342|Experimental|osteoarthritic with genu varus|initial arthroscopy and high tibial osteotomy to be followed later by a second look arthroscopy with plate removal
11033902|NCT04541329|Experimental|Tildrakizumab treatment|
11033903|NCT04541316||Short term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-5 weeks post implantation
11042888|NCT04478955||eyeliner only|three days a week at least for 6 months
11033904|NCT04541316||Mid term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-4 months post implantation
11033905|NCT04541316||Long term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 6-8 months post implantation
11033906|NCT04541303|Experimental|Intervention|Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
11033907|NCT04541303|Placebo Comparator|Placebo|Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.
11033908|NCT04541290|Experimental|Treatment|Women with stage 1-2 lymphedema due to breast cancer treatment
11033909|NCT04541277|Experimental|Tislelizumab with DAN hypmethylation agent +/- chemotherapy|"Decitabine, 20 mg/m2/d, IV, on days 1-5; or Azacitidine, 75 mg/m2/d,SC, on days 1-7.
~Aclamycin hydrochloride, 20 mg/d, IV, on day 1, 3, and 5 (For relapse/resistance AML, on days 1-5.); or idarubicin hydrochloride,10 mg/d, IV, on day 1, 3, and 5.
~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cytarabine,100 mg, IV, q12h/d. For patients with one of the following conditions, cytarabine,10 mg, SC, q12h/d: (1) There are obvious heart, lung, and kidney complications; (2) Bone marrow is hypoproliferative; (3) Age> 75 years old; (4) Age> 60 years old who are unfit for standard-dose chemotherapy.
~Recombinant human granulocyte colony stimulating factor injection, 5 μg/kg, SC, from day 0 to stop of chemotherapy after the WBC count exceeds 10.0×10^9/L; or Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC, on day 0.
~Tislelizumab,200 mg, IV, on the next day after chemotherapy was stopped."
11033910|NCT04541264||model reconstruction cohort|200 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.
11033911|NCT04541264||model validation cohort|100 patients will be recruited prospectively during the period from May 2020 to April 2021 as validation group.
11033912|NCT04541251|Experimental|Camrelizumab + Nab-paclitaxel + Carboplatin|
11033913|NCT04541238||Novel template report|"The last 100 consecutive and anonymized MRI investigations for primary perianal fistula reported according to standard practice by dedicated radiologists (the last 10 reports from each of 10 international centers) are reviewed blindly and independently by two experienced radiologists (based on case load, years of experience and publications on anal fistula) using a novel template incorporating 8 key descriptors.
~A third independent experienced radiologist will resolve any disagreement and assess the presence of descriptors in the original report compared to the novel template."
11033914|NCT04541225|Experimental|Phase 1 Dose Escalation|NUV-422 administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
11033915|NCT04541225|Experimental|Phase 2 Dose Expansion|NUV-422 administered at the recommended Phase 2 dose (RP2D).
11033916|NCT04541212||Cohort A|Prospective
11033917|NCT04541212||Cohort B|Retrospective/Prospective
11033918|NCT04541199|Active Comparator|Conventional|
11033919|NCT04541199|Experimental|Closed-loop|
11033920|NCT04541186|Active Comparator|Dose 1|BIO89-100 administered subcutaneously
11033921|NCT04541186|Active Comparator|Dose 2|BIO89-100 administered subcutaneously
11033922|NCT04541186|Active Comparator|Dose 3|BIO89-100 administered subcutaneously
11033923|NCT04541186|Active Comparator|Dose 4|BIO89-100 administered subcutaneously
11033924|NCT04541186|Placebo Comparator|Placebo|Placebo administered subcutaneously
11033925|NCT04541173|Active Comparator|Arm A|TARE alone
11033926|NCT04541173|Experimental|Arm B|TARE then Bevacizumab and Atezolizumab
11033927|NCT04541160||Suspected community-acquired pneumonia patients|Suspected community-acquired pneumonia patients that will be evaluated by an imaging method
11033928|NCT04541147|Experimental|Dexamethasone plus analgesics|oral dexamethasone of 0.5mg/kg/day (max of 8mg/day), administered on post-operative days 1,3,5,7 in addition to standardized course of analgesics (opioids/acetaminophen/NSAIDs).
11033929|NCT04541147|Active Comparator|analgesics alone|standardized course of analgesics (opioids/acetaminophen/NSAIDs)
11033930|NCT04541134|Other|Group 1|
11033931|NCT04541134|Other|Group 2|
11033932|NCT04541121|Experimental|3D printed model|Mother is given 3D printed model of fetus' face
11033933|NCT04541121|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
11033934|NCT04541108|Experimental|BMS-986299, Relatlimab, Ipilimumab, & Nivolumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to three days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile dextrose) or subtherapeutic microdoses of BMS-986299, relatlimab, ipilimumab as single agents or combined with nivolumab. Each microdose is simultaneously and percutaneously injected in a columnar fashion through each of 8 or 5 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
11033935|NCT04541108|Experimental|TAK-676, Cisplatin, 5-FU, & Paclitaxel|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-676, cisplatin, 5-fluorouracil (5-FU), or paclitaxel as single agents or in combination. Each microdose is simultaneously and percutaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
11033936|NCT04541095|Experimental|EX_IMF group|Infants will receive infants formula with large amounts of beta-palmitate (EX_IMF).
11033937|NCT04541095|Active Comparator|ST_IMF group|Infants will receive infants formula with low amounts of beta-palmitate (ST_IMF).
11033938|NCT04541095|No Intervention|HM group|Infants will receive human milk (HM).
11033939|NCT04541082|Experimental|ONC206|
11033940|NCT04541069|Experimental|Social Communication and Emotional Skill Development (SCESD)|This arm will get the intervention which is the Early Childhood Development (ECD) training.
11033941|NCT04541069|No Intervention|Control|This arm will not get any intervention.
11033978|NCT04540770|Placebo Comparator|Part A 3 (5 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
11033942|NCT04541056|Experimental|Goal Management Training (GMT)|"GMT will be administrated in a group-based format over 6 sessions (minimum two weeks between each session). Homework assignments between sessions are included. Following the fourth session, text messages reading Stop! (a key instruction in GMT) will be sent to all GMT participants every day to maximize adherence to training (28 per participant). Homework assignment will also include the logging of automatic thoughts and an examination of the relationship between situations, thoughts, and accompanying emotions."
11033943|NCT04541056|Active Comparator|Waitlist/Brain Health Workshop (BHW)|The adults participating in the control condition will approximately one year from waitlist, be offered a psycho-educative training program, the BHW, in groups aimed at providing a better understanding of cognitive sequelae after treatment for childhood ALL.
11033944|NCT04541043|Experimental|active treatment|Nefecon 16 mg once daily by mouth for 9 months
11033945|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
11033946|NCT04541017|Experimental|Arm I (magrolimab, mogamulizumab)|Patients receive magrolimab IV over 2-3 hours weekly during cycles 1-2, Q2W during cycles 3-12. Patients also receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11033947|NCT04541017|Active Comparator|Arm II (mogamulizumab)|Patients receive mogamulizumab IV over at least 60 minutes weekly during cycle 1, then Q2W during cycles 2-12. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who have received at least 2 full treatment cycles and have PD or have received at least 6 full treatment cycles and have SD may crossover to Arm I.
11033948|NCT04541004|Experimental|HDM SLIT Tablet|House dust mite (HDM) Sublingual allergy immunotherapy tablet
11033949|NCT04540991|Active Comparator|Ankylos dental implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Ankylos dental implants (Dentsplay Sirona, Charlotte, USA) areused in the first group of patients.
11033950|NCT04540991|Active Comparator|Dentium SuperLine implant group|Patients are divided into two groups depending on the dental implant system used in the therapy. Dentium SuperLine implants (Dentium Co., Seoul, Korea) is used in the second group of patients-.
11033951|NCT04540965|Experimental|Telaglenastat and Famotidine|Famotidine
11033952|NCT04540965|Placebo Comparator|Telaglenastat and Placebo for Famotidine|Placebo for famotidine
11033953|NCT04540952|Experimental|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
11033954|NCT04540952|Active Comparator|Control|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
11033955|NCT04540939|Experimental|Mindfulness-Based Cognitive Therapy|
11033956|NCT04540939|Experimental|Muscle Relaxation Therapy|
11033957|NCT04540926|Experimental|COVID-19 Pneumonia control group|COVID-19 pneumonia patients with standar treatment: enoxaparin 0.5 mg/kg S.C. once, Clarithromycin 500 mg twice an metylprednisolone 0.5 mg/kg once endovenous.
11033958|NCT04540900|Active Comparator|KB301|non-integrating HSV-1 vector expressing human type III collagen injection
11033959|NCT04540900|Placebo Comparator|Placebo|sterile isotonic saline injection
11033960|NCT04540887|Experimental|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
11033961|NCT04540874|Experimental|Treatment group|
11033962|NCT04540874|Placebo Comparator|Placebo group|
11033963|NCT04540848|Experimental|Exparel plus supraclavicular block|
11033964|NCT04540848|Active Comparator|Bupivacaine HCL plus supraclavicular block|
11033965|NCT04540848|Active Comparator|supraclavicular block only|
11033966|NCT04540835|Experimental|Teethmate|Half of the cavities will be applied Teethmate Desensitizer following manufacturer instructions before restoration
11033967|NCT04540835|No Intervention|Negative Control|Half of the cavities will be restored without application of Teethmate Desensitizer
11033968|NCT04540822|Experimental|peripheral venous catheter with compress|Insertion of a peripheral venous catheter with a compress inserted below the catheter-extension tube junction
11033969|NCT04540822|Active Comparator|peripheral venous catheter without compress|Insertion of a peripheral venous catheter without any compress inserted below the catheter-extension tube junction.
11033970|NCT04540809||Psoriatic arthritis group (PsAG)|The evaluation was made using dynamometer, goniometer, mobile application, and Purdue pegboard test.
11033971|NCT04540796|Experimental|Part A: Dose Escalation|Participants will receive weekly administration of JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along to the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
11033972|NCT04540796|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
11033973|NCT04540783|Active Comparator|Group 1 - G1|bitemporal anodal stimulation and cathodal stimulation at supraorbital region.
11033974|NCT04540783|Active Comparator|Group 2 - G2|dorsolateral prefrontal anodal stimulation and cathodal stimulation at contralateral supraorbital region.
11033975|NCT04540783|Sham Comparator|Group 3 - G3|sham anodal stimulation over bitemporal or dorsolateral prefrontal cortex (randomized) and sham cathodal over the orbitofrontal region.
11033976|NCT04540770|Placebo Comparator|Part A 1 (1 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
11033977|NCT04540770|Placebo Comparator|Part A 2 (3 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
11033979|NCT04540770|Experimental|Part B 1 (Selected Dose)|"At the end of Part A, the SRC will review the accumulated unblinded data of safety, tolerability, PK (any available data), and immunogenicity (any available data) to select a dose to initiate Part B in MS subjects. Part B will be conducted in multiple-dose, uncontrolled, and open-label manner to explore the safety, tolerability, PK, and immunogenicity in MS subjects. Only one cohort will be enrolled to receive 3 repeated doses of the selected HuL001 dose, which will be administered bi-weekly.
~A total of 6 MS subjects will be enrolled in this multiple-dose cohort."
11033980|NCT04540757||Surgery|Surgery and systemic anti-cancer therapy (with or without radiotherapy) given in any order
11033981|NCT04540757||No surgery|Radiotherapy and systemic anti-cancer treatment given in any order (with or without adjuvant immunotherapy if indicated).
11033982|NCT04540744|Experimental|Treatment ABC|Participants will receive a single oral dose of fixed dose combination (FDC) 1 of macitentan/tadalafil (10 milligram [mg]/20 mg) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of FDC 2 of macitentan/tadalafil (10 mg/20 mg) in fasted conditions (test) (Treatment B) in treatment period 2 followed by a single oral dose of a free combination of 10 mg macitentan and 20 mg tadalafil in fasted conditions (reference) (Treatment C) in treatment period 3 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
11033983|NCT04540744|Experimental|Treatment BCA|Participants will receive Treatment B in treatment period 1 followed by Treatment C in treatment period 2 followed by Treatment A in treatment period 3 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
11033984|NCT04540744|Experimental|Treatment CAB|Participants will receive Treatment C in treatment period 1 followed by Treatment A in treatment period 2 followed by Treatment B in treatment period 3 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
11033985|NCT04540744|Experimental|Treatment ACB|Participants will receive Treatment A in treatment period 1 followed by Treatment C in treatment period 2 followed by Treatment B in treatment period 3 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
11033986|NCT04540744|Experimental|Treatment CBA|Participants will receive Treatment C in treatment period 1 followed by Treatment B in treatment period 2 followed by Treatment A in treatment period 3 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
11033987|NCT04540744|Experimental|Treatment BAC|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 followed by Treatment C in treatment period 3 on Day 1. Study drug intake in subsequent treatment periods in an individual participant will be separated by a washout period of at least 10 days.
11033988|NCT04540731||NAFLD and diabetes/NASH and fibrosis|Patients with NAFLD and type 2 diabetes (or insulin-resistance) or with any stage of fibrosis in the inclusion visit will be followed over time in a prospective cohort study with scheduled visits. Patients without diabetes/insulin-resistance or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study.
11033989|NCT04540731||NAFLD without diabetes/NASH without fibrosis|Patients without diabetes (or insulin-resistance) or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study
11033990|NCT04540718|No Intervention|Control|Participants in this group continues with their sedentary behavior
11033991|NCT04540718|Active Comparator|Exercise only|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and will sit in the exercise laboratory for 15 minutes whilst the experimental group uses the sauna.
11033992|NCT04540718|Experimental|Exercise and sauna|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and incorporates sauna bathing (heat therapy) immediately after exercise.
11033993|NCT04540705|Experimental|Part 1: Nivolumab + bempeg + axitinib|
11033994|NCT04540705|Experimental|Part 2 Arm A: Nivolumab + bempeg + axitinib|
11033995|NCT04540705|Experimental|Part 2 Arm B: Nivolumab + axitinib|
11033996|NCT04540692|Active Comparator|Start with Cyclophosphamide + Doxorrubicin|Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.
11033997|NCT04540692|Experimental|Start with Docetaxel or Paclitaxel|Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.
11033998|NCT04540679|Active Comparator|Inpatient - Standard Care Delayed Platform|Patient will receive standard inpatient care and provided access to the platform 6 weeks after inpatient discharge with support provided by the VIP coach.
11033999|NCT04540679|Active Comparator|Inpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the inpatient program
11034000|NCT04540679|Active Comparator|Outpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the outpatient program. If patient is transitioning from the inpatient program, their access to the platform will be guided by which group they were originally assigned to (i.e. if a 6 week delay is applicable).
11034001|NCT04540666|Experimental|VR group|VR program will be displayed throughout the surgery.
11034002|NCT04540666|Placebo Comparator|Non-VR group|VR program will be turned off throughout the surgery.
11034003|NCT04540653|Other|Standard vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, aged ≥50 years old, using a standard vaccination schedule (three doses of 20 μg, in months 0, 1, 6).
11034004|NCT04540653|Experimental|Reinforced vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, in individuals aged ≥50 years, using a reinforced vaccination schedule (three doses of 40 μg, in months 0, 1, 6).
11034005|NCT04540640|Experimental|Subnormothermic Perfusion|Kidneys retrieved for transplantation will undergo subnormothermic oxygenated perfusion using the study device and perfusion solution for at least 1 hour prior to transplantation into the recipient.
11034006|NCT04540627|Placebo Comparator|Placebo|Sodium Chloride 0.9% Solution (Normal Saline)
11034007|NCT04540627|Active Comparator|Palivizumab (Synagis™)|Sterile vial 50mg/0.5mL
11034008|NCT04540614|Experimental|Intervention|70 participants receiving active comparator treatment plus experimental
11034009|NCT04540614|Active Comparator|Control|70 participants receiving active comparator treatment
11034010|NCT04540601|Active Comparator|Cancer patients, randomized A|Patients in high-dose antiresorptives with bone metastases
11034011|NCT04540601|No Intervention|Cancer patients, randomized B|Drug Holiday as standard operation procedure
11034012|NCT04540588|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11034013|NCT04540575|Active Comparator|Mother Provides MOM|Receive Rush NICU standard of care lactation support
11034014|NCT04540575|Experimental|NICU Acquires MOM|Receive economic interventions in addition to Rush NICU standard of care lactation support
11034015|NCT04540562|Experimental|Intervention|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
11034016|NCT04540549|Experimental|intervention group|Jogging or cycling ≥5 days/week, 30-60 min/d
11034017|NCT04540549|No Intervention|control group|The control group was encouraged to maintain their lifestyle.
11034018|NCT04540523|Experimental|Exergaming intervention group|30 minutes of exergaming per session and 5 sessions of exergaming play per week for a 6-month period.
11034019|NCT04540523|Active Comparator|Traditional Physical Activity|Phone consultations and workshops for parents to offer 5 times, 30 minutes per session; traditional physical activity at home for 6 months.
11034020|NCT04540523|No Intervention|Attention control group|Continue with usual activities at home with emailed physical activity tips.
11034021|NCT04540510|Active Comparator|OPEP therapy added to standard pneumonia care|The intervention group will be asked to use an OPEP device twice daily, with the help of study investigators, for a total of at least 5 minutes per session. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the pneumonia.
11034022|NCT04540510|Active Comparator|Standard pneumonia care|The control group will continue to receive the usual care that their hospital team prescribe for them to treat the pneumonia.
11034023|NCT04540497|Experimental|VIB0551|Inebilizumab administered as an IV infusion.
11034024|NCT04540497|Placebo Comparator|Placebo|Placebo administered as an IV infusion.
11034025|NCT04540484||ALGH Physicians|Attending physicians on the medical staff, fellow physicians, and resident physicians that work at Advocate Lutheran General Hospital (ALGH) from March 1st, 2020 and forward.
11034026|NCT04540484||Household Members|Household members above age 18 who lived in household of ALGH physician who tested positive for COVID-19 IgG antibodies, and who lived with that physician for at least 2 consecutive weeks.
11034027|NCT04540471|Experimental|MT group|The participants in MT group will receive music therapy 1 day per week for 1 hour with total 12hours in12 consecutive weeks after initial enrollment. Initial evaluation at the first session, including patient's vital sign, consciousness and spirit. The music therapy will consist of therapeutic singing, interpersonal communication, melody intonation therapy and rhythmic hands slapping. During therapeutic singing session, the music therapists will sing a song first and then the patients sing it after them. Interpersonal communication activity will be led by the music therapist and passed on to one patient to another patient. Melody intonation therapy will comprise communication, chatting and read aloud by using melody.
11034028|NCT04540471|Placebo Comparator|Control group|control groups will receive comprehensive in-patient education program for 12 consecutive weeks
11034029|NCT04540458|Other|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
11034030|NCT04540458|Other|Placebo|Mother or Mother/Father is given printed picture of 3D ultrasound of fetus
11034031|NCT04540445||Concussed Cohort|The concussed cohort will consist of children ages 5-17 diagnosed with a concussion within 72 hours following injury and recruited from a pediatric emergency department.
11034032|NCT04540445||Healthy Matched Controls|The healthy matched control cohort consists of children 5-17, who are age and gender matched to concussed subjects who will be recruited from affiliated pediatric primary care and adolescent clinics.
11034033|NCT04540432|Experimental|Profile AB|Patients on non-steroidal anti-inflammatory drugs followed by biotherapy.
11034034|NCT04540432|Experimental|Profile AM|Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate.
11034035|NCT04540432|Experimental|Profile AMB|Patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate and then biotherapy if there is no improvement with methotrexate.
11034036|NCT04540432|Experimental|Profile A|Patients on non-steroidal anti-inflammatory drugs.
11034037|NCT04540419|Experimental|Ad5-nCoV single dose|375 subjects, Ad5-nCoV containing 5E10 vp, single dose
11034038|NCT04540419|Placebo Comparator|Placebo single dose|125 subjects, Placebo containing 0 vp, single dose
11034039|NCT04540406|Experimental|NBT-NM108 + Usual Care|
11034040|NCT04540406|Active Comparator|Usual Care Only|
11034041|NCT04540393|Experimental|Arm A|Single arm
11034042|NCT04540367|No Intervention|No Intervention: Control|Participants in this group performed the exercises without the blood flow restriction therapy cuff
11034043|NCT04540367|Experimental|Experimental: BFR|Participants in this group performed the exercises with the blood flow restriction therapy cuff
11034044|NCT04540354|Experimental|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
11034045|NCT04540354|Active Comparator|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
11034046|NCT04540341|Experimental|Mulligan mobilization group|Painless movement
11034047|NCT04540341|Experimental|Core stabilization group|Abdominal drawing-in maneuver
11034048|NCT04540341|Active Comparator|conventional therapy group|Ultrasound TENS Hotpack
11034049|NCT04540328|Other|Non-surgical peridontal treatment|Patients with chronic periodontitis received non-surgical periodontal treatment, including scaling and root planing and polishing within 14 days under local anesthesia with manual and ultrasonic devices and standardized oral hygiene instructions including methods of tooth-brushing and interdental cleaning were also given to each one. A professional supragingival plaque control was applied on a regular basis every month.
11034050|NCT04540315|Experimental|Intervention - MobiMD app|Intervention group will receive notifications to their smart device through MobiMD app. Participants will be asked to fill out reports and upload all clinically relevant data using the app. Engaging with the app will be in addition to the standard of care follow-up.
11034051|NCT04540315|Active Comparator|Standard of Care|The standard of care control group will receive conventional postoperative care. Participants will download the app only to provide baseline information and patient-reported surveys at the designated timepoints.
11034052|NCT04540302|Experimental|AVF Peripheral study treatment group|Subjects randomised to treatment with the WRAPSODY Endovascular Stent Graft
11034053|NCT04540302|Other|AVF Peripheral control group|Subjects randomised to treatment with standard percutaneous transluminal angioplasty (PTA)
11034054|NCT04540302|Experimental|AVG Anastomosis|All subjects in this single arm cohort will receive treatment with the WRAPSODY Endovascular Stent Graft
11034055|NCT04540289|Active Comparator|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
11034056|NCT04540289|Experimental|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
11034057|NCT04540263||Sleeve Gastrectomy|Patients who underwent Sleeve gastrectomy operation
11034058|NCT04540263||Gastric Bypass|Patients who underwent Gastric Bypass operation
11034059|NCT04540250||Study group of Rheumatoid arthritis patients|RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.
11034060|NCT04540237||Case|Patients with idiopathic granulomatous mastitis
11034061|NCT04540237||Control|Healthy volunteers
11034062|NCT04540224||Luminal A|Breast cancer patients with Luminal A phenotype
11034063|NCT04540224||Luminal B|Breast cancer patients with Luminal B phenotype
11034064|NCT04540224||Triple Negative|Breast cancer patients with Triple negative phenotype
11034065|NCT04540224||Control|Healthy volunteers
11034066|NCT04540211|Experimental|Atezolizumab + Tiragolumab + PC|Participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
11034067|NCT04540211|Placebo Comparator|Placebo + PC|Participants will receive atezolizumab matching placebo and tiragolumab matching placebo on Day 1 of each 21-day cycle during the study followed by paclitaxel and cisplatin on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity, during the induction treatment phase.
11034068|NCT04540198|Experimental|GamePlan4Care (GP4C)|Participants in this arm will have access to full functionality and content of the online system GamePlan4Care (GP4C) including educational resources, skills training, and support tailored to their unique caregiving needs. Additional individualized feedback will be automatically generated based on responses to online questions and will include links to relevant site educational/skill-building content. Participants will be assigned a Dementia Care Specialist who will facilitate caregiver interactions with the online material and provide skills training via telephone or web-video conference. Study participants assigned to GP4C will receive 9 automated emails and 4 phone calls over a 6-month period.
11034069|NCT04540198|Active Comparator|Resources4Care (R4C)|"Participants in this arm will receive access to Resources4Care (R4C), a feature-limited version GamePlan4Care system. R4C will serve as an online hub for articles and videos about Alzheimer's disease and dementia. Educational topics will included information on: 1) Alzheimer's Disease & Dementia, 2) Caregiving, 3) Caregiver Stress and 4) Home Safety. R4C will present a page on each topic with active links to two additional online sources on the same topic. Study participants assigned to R4C will receive two emails from their DCS encouraging the caregiver to review specific education materials. Each email will be followed by brief check-in calls (15-min each) at three months and five months after randomization."
11034070|NCT04540185|Experimental|Standard dose bivalent oral polio vaccine|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
11034071|NCT04540185|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|Saline administered orally on a sugar lump
11034072|NCT04540185|Experimental|Standard dose of NA-831|Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally
11034073|NCT04540185|Placebo Comparator|Comparable Placebo- 30mg|30 mg of placebo in a capsule administered orally
11034074|NCT04540185|Experimental|Standard dose of bivalent OPV and NA-831|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally
11034075|NCT04540185|Placebo Comparator|Comparable Placebo|Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally
11034076|NCT04540172|Experimental|Music Therapy|music therapy was applied in the practice room. Environmental noise was reduced as much as possible; the room was dimly lit. The students were asked to close their eyes after sitting comfortably in a chair and focus on the music by asking them to imagine a different memory and place that would relax them instead of the thoughts that occupied their minds. The music was played through a portable computer for 15 minutes under the supervision of the researchers using an mp3 player program on the computer.
11034131|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
11034132|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
11034133|NCT04539795|Active Comparator|Alvelestat oral tablet - dose 3|MPH966
11034077|NCT04540172|Experimental|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercises were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association. Warning messages were hung on the door of the room, environmental noise was reduced as much as possible, and the room was provided with dim lighting. The students were asked to close their eyes and breathe deeply after sitting comfortably in a chair. After taking two deep breaths, they were told to dangle their arms and relax as much as possible. The hands, shoulders, neck, chest, abdomen, hips, legs, feet, toes, and facial muscles were made to relax while they breathed and relaxed while exhaling. They were asked to store the experience into their memories thoroughly so that they could recall this feeling for comfort during the day."
11034078|NCT04540172|No Intervention|Control|No additional method was applied in the control group.
11034079|NCT04540159||Case|Advanced stage Colorectal cancer patients with intraabdominal ascites
11034080|NCT04540159||Control|Liver cirrhosis and congestive heart failure patients with intraabdominal ascites
11034081|NCT04540146||Case|End Stage Colorectal Cancer patients with intraabdominal ascites
11034082|NCT04540146||Control|Congestive heart failure and liver cirrhosis patient who had intraabdominal ascites
11034083|NCT04540133|Experimental|dexamethasone 0.5mg/5ml solution in Mucolox™ (group A)|Dexamethasone solution (0.5mg/5ml) in Mucolox™ three times a day (TID) swish and spit for 4 weeks
11034084|NCT04540133|Active Comparator|dexamethasone 0.5mg/5ml solution (Arm B)|Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks
11034085|NCT04540120|Experimental|dapansutrile capsules|A total of 40 subjects will receive 4x 250mg dapansutrile capsules BID for 14 days
11034086|NCT04540120|Placebo Comparator|placebo capsules|A total of 40 subjects will receive 4x 250mg placebo capsules BID for 14 days
11034087|NCT04540107|Experimental|Group I (MRI, MRSI)|Patients undergo MRI and MRSI scans over 1 hour at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
11034088|NCT04540107|Experimental|Group II (MRI, hyperpolarized carbon C 13 pyruvate, MRSI)|Patients undergo MRI scan at baseline. Patients then receive hyperpolarized carbon C 13 pyruvate IV over less than 1 minute and undergo MRSI scan at baseline. Patients then continue to undergo MRSI scans that follow the clinical MRI schedule set by doctors to monitor patients' care.
11034089|NCT04540094|Experimental|5% Human Albumin Solution|Participants allocated to the treatment arm will receive intravenous 5% Human Albumin Solution (HAS) administered as the sole intravenous fluid during the initial 6-hour resuscitation period. The clinician can deliver up to 10ml/kg in the first 3 hours using 250ml boluses of HAS based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). After 3 hours further HAS boluses up to 6 hours post-randomisation will be at clinical discretion and will be documented in the CRF. Patients in the albumin arm should not receive balanced crystalloid as a resuscitation fluid in the first 6 hours.
11034090|NCT04540094|Active Comparator|Intravenous balanced crystalloid|Participant allocated to the usual care arm will receive intravenous balanced crystalloid administered as the sole intravenous fluid during the initial 6 hour resuscitation period. The clinician can deliver up to 30ml/kg in the first 3 hours using 250ml boluses of balanced crystalloid based on clinical judgement, using clinical assessment supplemented by technology if that is their usual practice. This will be followed by repeat clinical assessment after each bolus (including vital signs; lactate testing). Thereafter, further crystalloid boluses up to 6 hours will be at the discretion of the clinical team and will be documented in the CRF. Patients in the balanced crystalloid arm should not receive albumin as a resuscitation fluid in the first 6 hours.
11034091|NCT04540081|Experimental|CLOVER arm|This arm will contain clinics that utilize the CLOVER intervention
11034092|NCT04540081|No Intervention|Standard of Care arm|This arm will contain clinics that do not utilize the CLOVER intervention
11034093|NCT04540068||Patients with Lumbar Disc Herniation|Patients with a lumbar disc herniation on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
11034094|NCT04540068||Patients with Lumbar Spinal Stenosis|Patients with a lumbar spinal stenosis on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
11034095|NCT04540055||Paravertebral (Group P)|Patients underwent MRM under the combination of general anesthesia and paravertebral block.
11034096|NCT04540055||General Anesthesia (Group G)|Patients underwent MRM under general anesthesia.
11034097|NCT04540042|Experimental|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
11034098|NCT04540042|Placebo Comparator|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
11034099|NCT04540042|Experimental|SelK2 (Part 2)|I.V., single-dose (Day 1)
11034100|NCT04540042|Placebo Comparator|Placebo (Part 2)|I.V., single-dose (Day 1)
11034101|NCT04540029||COVID-19 Exposed Pregnancy (CEP)|Women who were pregnant and delivered during the outbreak of COVID-19 pandemic in Italy, and their infants.
11034102|NCT04540029||Non-Exposed Pregnancy (NEP)|Women who were pregnant and delivered during an anticipated COVID-19 free period in Italy, and their infants.
11034103|NCT04540016|Other|Arm Ⅰ|25 mg of 80 µCi [14C]HSK7653.
11034104|NCT04540003|Experimental|Access to School Based Health Centre|Of the eight school in the intervention arm, four schools will be linked to a school based health center (SBHC) at Sprucecourt or Nelson Mandela Park Public Schools (established in partnership with the department of Pediatrics at St. Michael's hospital) and four schools will be linked to a SBHC at Parkdale Public School (established in partnership with St. Joseph's Health Centre). SBHC pediatricians will attend School Support Team (SST) meetings at all intervention schools and students with developmental concerns identified at the SST meetings will be referred to the SBHC.
11034105|NCT04540003|No Intervention|Control Arm: Standard of care|Of the eight schools assigned to the control condition, four will be in the South East area of the city closer to Nelson Mandela Park PS and four will be in the South West area of the city closer to St. Josephs Health Center. The eight schools will be subject to standard of care which is: when a child is identified by the SST (no pediatrician present), students identified with developmental concerns are advised to access a pediatric/developmental assessment in the community.
11035430|NCT04530760||control group|patients with no intraabdominal hypertension
11034106|NCT04539990|Experimental|Behavioral Sleep Treatment|"Parents of children with autism will come to two group meetings (up to 5 families in each group) where they will be receive information regarding sleep hygiene and behavioral techniques for reducing sleep onset delays and night awakenings. The program will last 8 weeks. Meetings will be held on week 1 and week 3. In addition parents will receive a weekly phone call where they will be asked about their ability to implement the behavioral techniques.
~Sleep of the children will be measured using questionnaires, sleep diaries and with a Fitbit sensor before and after the program."
11034107|NCT04539977|Experimental|ES-SCLC|"Induction therapy: TQB2450 1200mg, d1, q3w, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles.
~Maintenance therapy: TQB2450 1200mg, d1, q3w, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
11034108|NCT04539977|Experimental|LS-SCLC|"Neoadjuvant therapy: TQB2450 1200mg, d1, q3w, 2-4 cycles; cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 2-4 cycles.
~Surgery or/and radiotherapy: the patients will receive surgery or/and radiotherapy, or multi-disciplinary treatment.
~Adjuvant therapy: TQB2450 1200mg, d1, q3w, thereafter until progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen [except radiotherapy], withdrawal of informed consent or death)."
11034109|NCT04539964|Experimental|Treatment|Active (therapeutic) stimulation for 1 min once per day
11034110|NCT04539964|Sham Comparator|Control|Sham (nontherapeutic) stimulation for 1 min once per day
11034111|NCT04539951|Active Comparator|serotonin treatment|In Experimental phase I，all recruited subjects provide written informed consent before any related procedures. and All included participants will take Sertraline during the first 4 weeks. The total duration of the first-step treatment is 12 weeks so that it has the adequate time to wait for the response.
11034112|NCT04539951|Active Comparator|sequenced treatment alternatives|If participants in In Experimental phase I do not achieve remission, they will be encouraged to move to the next treatment level (Experimental phase II). The second-step therapy consists of five switching or augment programs including higher-than-usual-maximal dosage of Sertraline, Fluvoxamine, Venlafaxine, augmentation with Memantine or Aripiprazole. There will be an equal number of partial responders and non-responder in each arm.
11034113|NCT04539938|Experimental|Single Arm|Tucatinib + trastuzumab deruxtecan
11034114|NCT04539925||Industrial area|
11034115|NCT04539925||Non-industrial area|
11034116|NCT04539912|Experimental|angulated screw-retained group(AG)|
11034117|NCT04539912|Active Comparator|cemented group (CG)|
11034118|NCT04539899|Experimental|VR+|For patients in the experimental group, using the virtual reality helmet, the caregiver will position the helmet on the patient when she is placed on the gynecological examination table. He or she will make sure that the patient can see and hear the current sequence. The caregiver can then proceed with the different steps of the IUD insertion. Once the procedure is completed, the caregiver will indicate to the patient that she can remove the headphones.
11034119|NCT04539899|No Intervention|VR-|For patients in the control group, without a helmet, the course of the consultation will not be modified.
11034120|NCT04539886|Experimental|CellFX System|The CellFX System consists of a electrical pulse console combined with a handpiece coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm). Based on the size of the SH lesion and treatment tip used, a predetermined treatment energy setting is selected to deliver a sequence of electrical pulses to the SH lesion area directly beneath the treatment tip.
11034121|NCT04539886|Active Comparator|Intralesional Electrodesiccation|Intralesional Electrodesiccation involves using a Hyfrecator electrosurgical unit and a non-insulated epilation needle electrode to apply a high-frequency electric current within the lesion.
11034122|NCT04539873|Active Comparator|COLHICINE PLUS STANDARD TREATMENT|Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
11034123|NCT04539873|Placebo Comparator|STANDARD TREATMENT|In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment
11034124|NCT04539860||Healthy Controls|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
11034125|NCT04539860||Patients|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
11034126|NCT04539847|Experimental|High-end hearing aid|Patients will be fitted with premium level hearing aid technology
11034127|NCT04539847|Experimental|Basic hearing aid|Patients will be fitted with basic level hearing aid technology
11034128|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).
11034129|NCT04539808|Experimental|Treatment (mFOLFIRINOX, chemotherapy)|"mFOLFIRINOX REGIMEN: Oxaliplatin intravenously (IV) over 2 hrs, leucovorin calcium IV over 2 hrs, and irinotecan hydrochloride IV over 90 minutes on day 1. Also receive fluorouracil IV over 46 hrs starting on day 1. Repeats every 14 days for up to 4 cycles. Those with response and no disease progression may receive an additional 2 months.
~GA REGIMEN: Those with disease progression or toxicity to mFOLFIRINOX switch to GA regimen comprising gemcitabine hydrochloride IV over 30-60 mins and nab-paclitaxel IV over 30-40 mins on days 1, 8, and 15. Repeats every 28 days for 2 cycles.
~LOSARTAN: Cycle 1 day 1, start losartan potassium orally once daily until end of RT.
~RT/SURGERY: Short-course RT for 10 fractions over 5 days weekly or long-course RT with 15-25 fractions over 5 days weekly along with oral capecitabine twice daily on Monday-Friday or fluorouracil IV over 5-7 days weekly until completion of RT. Patients then undergo surgery 1-4 weeks following RT (see Detailed Description)."
11034130|NCT04539795|Placebo Comparator|Placebo oral tablet|placebo
11034134|NCT04539782|Experimental|Physiotherapy intervention|Pelvic floor muscle training given by a physiotherapist in four sessions and follow up phone calls twice in 14 weeks
11034135|NCT04539782|No Intervention|No intervention|Standard care
11034136|NCT04539769|Active Comparator|BI group|Conventional Billroth I reconstruction
11034137|NCT04539769|Experimental|BII group|Billroth II reconstruction with 100-cm long biliopancreatic limb
11034138|NCT04539769|Experimental|RY group|Roux-en-Y reconstruction with 100-cm long Roux limb
11034139|NCT04539756|Active Comparator|Active control condition|Participants in the active control condition will receive the same number of text message reminders and will complete the same number of writing activities as the intervention group. The writing activity for the active control condition will ask them to list their activities for that day.
11034140|NCT04539756|Experimental|Positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
11034141|NCT04539730|Active Comparator|Ropivacaine Standard of Care Group|Participants undergoing elective Total Knee Arthoplasty (TKA) surgery that are randomized to the control group will undergo an ultrasound-guided Adductor Canal Block (ACB) with standard of care (SoC) Ropivacaine post TKA surgery.
11034142|NCT04539730|Experimental|Liposomal Bupivacaine Intervention Group|Participants undergoing elective TKA surgery that are randomized to the intervention group will undergo an ultrasound-guided ACB with Liposomal Bupivacaine post TKA surgery.
11034143|NCT04539691|Experimental|Magnet group|Women wearing magnet
11034144|NCT04539691|Sham Comparator|Sham group|Women wearing sham
11034145|NCT04539665|Experimental|Intervention Arm|Prospective study arm involving an extended mesenteric ileocolic excision.
11034146|NCT04539665|No Intervention|Control Arm|Historical controls from a retrospective chart review of patients who had a limited ileocolic resection.
11034147|NCT04539652|Experimental|Experimental group|
11034148|NCT04539639|Experimental|Jaktinib 50mg Bid|Jaktinib 50mg Bid+ Placebo 50mg Bid+Placebo 75mg Bid
11034149|NCT04539639|Experimental|Jaktinib 75mg Bid|Jaktinib 75mg Bid+ Placebo 100mg Bid
11034150|NCT04539639|Experimental|Jaktinib 100mg Bid|Jaktinib 100mg Bid+ Placebo 75mg Bid
11034151|NCT04539639|Placebo Comparator|placebo|Placebo 100mg Bid+ Placebo 75mg Bid
11034152|NCT04539626|Experimental|Estrogen Therapy|"Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg
~Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)"
11034153|NCT04539626|No Intervention|Control Group|Patients who will receive conventional COVID-19 treatment
11034154|NCT04539613||group1|Group 1(50 case) which will receive hp FSH (fostimon ibsa) (150 IU per ampoule)will be started on day 2 of menstruation and then after six days, HMG (meriofert ibsa), 150 Iu, s.c) will be added
11034155|NCT04539613||group2|Group 2(50 case) will be treated with recombinant FSH alone (Gonal-F) (150 IU per ampoule)
11034156|NCT04539600|Experimental|induction chemotherapy + anti-PD-1 antibody|Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.
11034157|NCT04539587||adjuvant hormonal therapy for breast cancer|Women more than 18 years old, with hormone receptor-positive early BC, with completed surgery as well as chemotherapy and/or radiotherapy, if indicated, and had begun their hormonal therapy for less than 6 months.
11034158|NCT04539574|Experimental|Diagnostic (7T MRI)|Patients undergo 7T MRI over 60 minutes.
11034159|NCT04539561|Experimental|Pigmentation|Treatment of Hand Pigmentation Using PiQo4 Laser System
11034160|NCT04539548|Experimental|Dextenza|1 dosing group - Approximately 30 subjects treated with Dextenza
11034161|NCT04539548|Active Comparator|Prednisolone|1 dosing group - Approximately 30 subjects treated with Prednisolone
11034162|NCT04539535|Experimental|Down syndrome|We did the General Movements Assessment on standard mattress and experimental mattress in infants with Down syndrome on the same day.
11034163|NCT04539535|Experimental|Typically infants|We did the General Movements Assessment on standard mattress and experimental mattress in typically infants on the same day.
11034164|NCT04539522|Experimental|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
11034165|NCT04539522|Active Comparator|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
11034166|NCT04539509|Active Comparator|Monitoring|Participants will be given a heart rate monitor to wear on their wrist for the duration of the study (i.e. until recovered, or 8 weeks post-injury, whatever comes first).
11034167|NCT04539509|Placebo Comparator|Monitoring + Treadmill Test|In addition to wearing the heart rate monitor, participants will undergo a treadmill test at each appointment.
11034168|NCT04539509|Experimental|Monitoring + Treadmill Test + Specific Exercise Prescription|In addition to wearing the heart rate monitor, and completing a treadmill test at each appointment, participants will receive an exercise prescription based on the results of the treadmill test. They will be prescribed 30 minutes of structured aerobic exercise, 5 times per week, at a heart rate determined by their treadmill test.
11034169|NCT04539496|Experimental|dose confirmation and the phase II study|To determine the MTD and RP2D of XZP-3287; To determine the RP2D of XZP-3287 combined with endocrine therapy; To determine the efficacy and safety of XZP-3287 in HR positive HER2 negative advanced breast cancer
11034170|NCT04539483|Experimental|HDIT101|Topical application of HDIT101 solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
11034171|NCT04539483|Placebo Comparator|Placebo to HDIT101|Topical application of placebo solution to orolabial herpes lesion (4 times over 2 days). Blinded study drug will be applied to 2 lesions in the study
11034172|NCT04539470|Experimental|Cohort A: UTTR1147A Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive UTTR1147A dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
11034173|NCT04539470|Experimental|Cohort B: UTTR1147A Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive UTTR1147A dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
11034174|NCT04539470|Experimental|Cohort C: UTTR1147A Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive UTTR1147A dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
11034175|NCT04539457|No Intervention|Usual care|Neither the 'Desktop Helper (version 10)' will be integrated in the EMR system nor the 'e-learning' will be offered to GPs. However, to prevent attenuation of usual care, GPs will be free to adjust any medication on their own initiative or to use any other aid to decrease inappropriate prescribing in COPD patients.
11034176|NCT04539457|Active Comparator|Only desktop helper|Only the 'Desktop Helper (version 10)' will be integrated in the EMR system. Specifically, GPs will receive a notification about the 'Desktop Helper (version 10)'. This notification will inform general practitioners about the option in the Medicom Smart Module to identify COPD patients with comorbidities who have one or more 'medication-comorbidity clashes' (i.e. undesired interactions between medications for COPD and comorbid conditions).
11034177|NCT04539457|Active Comparator|Only E-learning|Only the 'e-learning' will be offered to GPs. Herein, GPs, will be invited to perform an e-learning module which provide information about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
11034178|NCT04539457|Active Comparator|Both dekstop helper and e-learning|Both 'Desktop Helper (version 10)' will be implemented in the EMR system. GPs will subsequently be notified about the possibility to detect COPD patients with 'medication-comorbidity clashes'. The implementation of the 'Desktop Helper (version 10), will be accompanied by e-learning offered to GPs. about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
11034179|NCT04539444|Experimental|CD19/22 CART cells combined with PD-1 inhibitors|Patients will receive PD-1 inhibitor on the first day after CART cell infusion
11034180|NCT04539431||Retrospective|The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.
11034181|NCT04539431||Prospective|A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.
11034182|NCT04539418|Active Comparator|Vitamn K2 Treated patients|Vitamin K2 will be given to patients randomized to ARM 1 three times a week at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
11034183|NCT04539418|Placebo Comparator|Placebo Group|Placebo will be given to patients randomized three times a week to ARM 2 at the end of each dialysis session to prevent it being lost through the ultrafiltration membrane (in order to use the same dialysis access) intravenously to ensure its bioavailability.
11034184|NCT04539405||Memsorb|M for memsorbTM group with the minimal gas flow possible (sevoflurane administration at 0.2L.min-1) with the ventilator Draeger A-500 Perseus,
11034185|NCT04539405||Dräegersorb|D for DraegersorbTM group with gas flow at 2L.min-1 (classical sevoflurane administration) with the same ventilator Draeger A-500 Perseus.
11034186|NCT04539392||Infertile couple|
11034187|NCT04539379|Active Comparator|magnesium sulfate|intravenous infusion of magnesium sulfate at a dose of 4 gm intravenously over 20 min as a loading dose then MgSO4 intravenous infusion is continued at a rate of 1 gm/h for 24 h or until obtain and stabilize the targeted blood pressure..
11034188|NCT04539379|Active Comparator|labetolol|The patients will be given intravenous infusion of labetolol (Trandate™, 5mg/ml) available in 20 ml ampoules containing 100mg labetalol (5mg/ml). Starting the infusion with 20mg/h and then titrate to obtain and stabilize the targeted blood pressure by adjusting the infusion as required every 15 - 30min to a maximum dose of 160mg/hr.
11034189|NCT04539366|Experimental|Treatment (GD2 CAR T)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive fludarabine phosphate IV daily on days -5 to -2 and cyclophosphamide IV daily on days -4 to -2.
~GD2CART: Patients receive GD2CART cells IV on day 0."
11034190|NCT04539353||chronic pain|Patients with chronic pain, regardless of the cause of the pain.
11034191|NCT04539340|Other|Cohort 1 GNR-055 (0.3 mg/kg)|GNR-055 (0.3 mg/kg) Single intravenous administration GNR-055
11034192|NCT04539340|Other|Cohort 2 GNR-055 (0.5 mg/kg)|GNR-055 (0.5 mg/kg) Single intravenous administration GNR-055
11034193|NCT04539340|Other|Cohort 3 GNR-055 (1 mg/kg)|GNR-055 (1 mg/kg) Single intravenous administration GNR-055
11034194|NCT04539340|Other|Cohort 4 GNR-055 ( 2 mg/kg)|GNR-055 ( 2 mg/kg) Single intravenous administration GNR-055
11034195|NCT04539340|Other|Cohort 5 GNR-055 (3 mg/kg)|GNR-055 (3 mg/kg) Single intravenous administration GNR-055
11034196|NCT04539314|Active Comparator|Control group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)
11034197|NCT04539314|Active Comparator|TAP group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 0.5 μg / kg as an adjuvant
11034198|NCT04539314|Active Comparator|Dexmedetomidine group|TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 1 μg / kg as an adjuvant
11034199|NCT04539301||Derivation cohort|In the derivation cohort, we will determined the conversion factor linking apixaban, rivaroxaban, fondaparinux, or danaparoid measured level, on the one hand, and heparin anti-Xa activity, on the other hand.
11034200|NCT04539301||Validation cohort|"In the validation cohort, for each tested anticoagulant, we will used the conversion factor determined in the derivation cohort to infer the estimated level of anticoagulant from heparin anti-Xa activity:
~estimated anticoagulant level = conversion factor for this anticoagulant × heparin anti-Xa activity
~The agreement between measured and estimated levels of each factor-Xa inhibitor will be assessed."
11034201|NCT04539288||Gestational diabetes mellitus|Women who were diagnosed GDM in 24-28 gestation weeks.
11034320|NCT04538482|Experimental|DASH Diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber)
11034202|NCT04539275|Experimental|Convalescent Plasma|The study intervention consists of intravenous administration of 200-500mL of convalescent plasma administered in two equally divided doses, less than 12 hours apart.
11034203|NCT04539275|Placebo Comparator|Masked Saline Placebo|The study intervention consists of intravenous administration of 200-500mL of 0.9% saline administered in two equally divided doses, less than 12 hours apart.
11034204|NCT04539262|Experimental|Remdesivir (RDV), Part A|Participants will receive 31 mg inhaled RDV daily for 5 days
11034205|NCT04539262|Experimental|RDV + Placebo, Part A|Participants will receive 31 mg inhaled RDV for 3 days followed by placebo through Day 5
11034206|NCT04539262|Placebo Comparator|Placebo, Part A|Participants will receive placebo daily for 5 days
11034207|NCT04539262|Experimental|RDV, Part B (Optional)|Participants will receive 62 mg inhaled RDV daily for up to 5 days
11034208|NCT04539262|Experimental|RDV + Placebo, Part B (Optional)|Participants will receive 62 mg inhaled RDV for up to 3 days followed by placebo through Day 5
11034209|NCT04539262|Placebo Comparator|Placebo, Part B (Optional)|Participants will receive placebo daily for 5 days
11034210|NCT04539262|Experimental|RDV+ Placebo, Part C|"Up to two regimens from Part A and/or Part B will be evaluated in Part C. Either one RDV-containing regimen + placebo, or two RDV-containing regimens + placebo will be selected.
~Participants will receive up to 2 of the following 4 treatments:
~31 mg inhaled RDV daily for 5 days, 31 mg inhaled RDV daily for 3 days followed by placebo daily for 2 days, or 62 mg inhaled RDV daily for up to 5 days, or 62 mg inhaled RDV daily for up to 3 days followed by placebo for 2 days"
11034211|NCT04539262|Placebo Comparator|Placebo, Part C|Participants will receive placebo daily for 5 days
11034212|NCT04539249|Experimental|Magnesium sulphate|Combination of intravenous magnesium sulphate, intravenous paracetamol and rectal diclofenac
11034213|NCT04539249|Active Comparator|Pentazocine|Combination of intramuscular pentazocine, intravenous paracetamol and rectal diclofenac
11034214|NCT04539236|Experimental|Luspatercept + Lenalidomide|"Lenalidomide (LEN) administered at a fixed dose of 5mg PO daily for 21 days of a 21 day cycle and Luspatercept at 1.0 mg/kg subcutaneously on Day 1 of each cycle, escalated to 1.75 mg/kg with a safety assessment for dose limiting toxicities (DLTs) (assessment period of first 28 days of treatment).
~A standard 3+3 design will be used to identify the MTD of Luspatercept in combination with LEN. The Phase II portion will involve an expansion cohort with LEN dosed at 5mg PO daily for 21 days of the 21-day cycle, and Luspatercept at the MTD determined from the Phase Ib.
~Treatment with LEN and luspatercept will continue as long as a participant is deriving benefit from the drugs, defined as hematologic improvement."
11034215|NCT04539223|Active Comparator|Drug (Evolocumab)|Individuals randomized to this arm will administer Evolocumab subcutaneously (SC) every two weeks (Q2W) for 26 weeks.
11034216|NCT04539223|No Intervention|No Drug (Standard of Care)|Individuals randomized to this arm will not administer a placebo.
11034217|NCT04539210|Experimental|Electric Welded Metal Framework|A preexisting or prepared flat surface area of the welding abutment of implant at central incisor position at one side (right or left) will serve as the welding point. A titanium bar will be shaped following the curvature of the implants positioned. At this point, temporary titanium implant abutments will be welded with the titanium bar in the oral cavity, using the Syncrystallization Unit. Finally, the prosthetic framework, created by welding the titanium bar to the implant abutments, will be removed and opaque will be applied in order to avoid metal shining through the acrylic resin. The framework is picked up to denture with hard liner, and screwed to the denture.
11034218|NCT04539210|Experimental|cast metal framework|On a verified analogue model, occlusion blocks will be constructed for adjustment of vertical dimension and bite registration. Afterwards, CCM abutments will be fastened over the analogues of the placed implants, followed by waxing, spruing and casting. The resultant cast metal framework will be inserted inside the patient's mouth on the right or left installed implants to insure passivity of fit. In case of framework misfit, separation will be performed using a disc, followed by intraoral splinting and soldering. After framework soldering, another try-in will be done to insure framework fit.
11034219|NCT04539197||IgG4-RD group|300 IgG4-RD were enrolled and followed up for more than 6 months. Peripheral blood of all patients were collected at baseline, disease remission and relpase for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline, each follow up were collected.
11034220|NCT04539197||other autoimmune disease group|200 patients( RA, SLE, pSS, BD, et al) were enrolled in this study. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
11034221|NCT04539197||IgG4-RD mimicker group|60 IgG4-RD mimickers (pancreatic cancer, cholangiocarcinoma, vasculitis, lymphoproliferative diseases, inflammatory bowel disease, kimura disease) were collected. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
11034222|NCT04539197||healthy control group|100 healthy controls were collected. Peripheral blood of healthy controls were collected at baseline for plasmablast/plasma cells detection. Demographic features of healthy controls were collected.
11034223|NCT04539184|Experimental|Motion Style Acupuncture treatment|Motion Style Acupuncture treatment (2-3 times/week, 2 weeks)
11034224|NCT04539184|Active Comparator|Acupuncture treatment|Acupuncture treatment (2-3 times/week, 2 weeks)
11034225|NCT04539171|Experimental|Intervention|Pain neuroscience education (Health education) and Physical exercise program: 6 weekly sessions (2 hours each), and a reminder session one month later
11034226|NCT04539171|No Intervention|Control|Standard of care.
11034227|NCT04539158|Active Comparator|single-DCCV group|"Patients randomized to single-DCCV will be given a single 200J shock using the primary (or right anterior-left posterior) pair of pads."
11034228|NCT04539158|Experimental|dual-DCCV group|"Patients assigned to dual-DCCV will receive two simultaneous 200J shocks (from both the primary and secondary set of defibrillator pads), totaling 400J delivered."
11034229|NCT04539145|Experimental|Chocolate PTA balloon|
11034230|NCT04539145|Other|POBA|Intervention with regular baloon
11034277|NCT04538833|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of paclitaxel/docetaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
11034398|NCT04537936|Experimental|Meaning Centered Psychotherapy for Latinos (MCP-L)|
11034399|NCT04537936|Active Comparator|Control|
11034231|NCT04539132|Experimental|Intervention Group|"The intervention group will participate in the 6-month interdisciplinary comprehensive rehabilitation program. The ABI Wellness (ABIW) program aimed at this population would be 7 hours a week (2 days per week will be scheduled for the intervention group), consisting of around 4 hours of cognitive training (through specified drills, cognitive exercises focused on executive functioning), 1 hour of physical exercise, 1 hour of mindfulness sessions (meditation) and scheduled break times."
11034232|NCT04539132|No Intervention|Control Group|"The non-intervention group or control group will have all the same pre-tests administered as the intervention group, however, will not participate in the cognitive program. The control group will be required to complete the assessment periods only, however, keep a record of their daily activities in a log format which is presented in the materials included herein. No other intervention or programming will be provided."
11034233|NCT04539119|Experimental|Entecavir and Tenofovir|
11034234|NCT04539119|Active Comparator|Entecavir|
11034235|NCT04539093||End-stage heart failure patients requiring lvad support|Patients with end-stage heart failure with reduced ejection fraction, requiring mechanical circulatory support.
11034236|NCT04539080||Pre-operative transversus abdominis plane block|
11034237|NCT04539080||Post-operative transversus abdominis plane block|
11034238|NCT04539067|Experimental|HMG group|Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG
11034239|NCT04539067|Experimental|H FSH plus HHMG|Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation
11034240|NCT04539054|Experimental|Pre-Workout Condition|This condition consisted of the ingestion of one serving of the pre-workout supplement.
11034241|NCT04539054|Experimental|Caffeine Condition|This condition consisted of the ingestion of 6 mg of caffeine per kg of body mass.
11034242|NCT04539054|Placebo Comparator|Placebo condition|This condition consisted of the ingestion of a placebo.
11034243|NCT04539041|Experimental|Cohort A NIO752|4 injections of NIO752 at dose A
11034244|NCT04539041|Experimental|Cohort B NIO752|4 injections of NIO752 at dose B
11034245|NCT04539041|Placebo Comparator|Placebo|4 injections of placebo
11034246|NCT04539041|Experimental|Cohort C NIO752|4 injections of NIO752 at dose C
11034247|NCT04539041|Experimental|Cohort D NIO752|4 injections of NIO752 at dose D
11034248|NCT04539041|Experimental|Cohort E NIO752|4 injections of NIO752 at dose E
11034249|NCT04539041|Experimental|Cohort F NIO752|4 injections of NIO752 at dose F
11034250|NCT04539015||Group-I|Patients randomized to the Group-I will receive PREVENA Plus, which is currently being used at our institution (Prevena, KCI) and it is FDA-approved device. Dressings will be applied under sterile conditions at the end of the surgery while still in the operating room and will continuously apply for 5 days.
11034251|NCT04539015||Group-II|"Subjects randomized to SOC surgical incision dressing arm will receive SOC dressing for 4 days immediately following surgery. The closed incision will be covered with materials which may include sterile gauze pieces, surgical tape and tegaderm.
~Any material used for the SOC dressing will be documented."
11034252|NCT04539002|Experimental|MS: Cycle|Twenty-two participants in the clinical trial arm will be randomized to MS:Cycle: an aerobic exercise intervention on a stationary ergometer. Participants will exercise thrice weekly for 30 minutes with graded supervision for 24 weeks.
11034253|NCT04539002|Active Comparator|MS: Take Control|Twenty-two participants in the clinical trial arm will be randomized to MS: Take Control (MSTC): a monthly, hour-long MS education control group led by a trained facilitator.
11034254|NCT04538989|Experimental|RZ358 Cohort 1|
11034255|NCT04538989|Experimental|RZ358 Cohort 2|
11034256|NCT04538989|Experimental|RZ358 Cohort 3|
11034257|NCT04538989|Experimental|RZ358 Cohort 4|
11034258|NCT04538976|No Intervention|Control|Patients in the control group will receive standard care.
11034259|NCT04538976|Active Comparator|Sildenafil|Patients in the Sildenafil group will receive standard care and targeted Sildenafil-treatment.
11034260|NCT04538963|Experimental|Banded Tooth|This tooth will have an orthodontic band and glass ionomer cement placed as an intervention for interproximal incipient caries.
11034261|NCT04538963|No Intervention|Non-banded Tooth|This tooth will be monitored per standard of care; encourage good dental hygiene at home.
11034262|NCT04538950|Other|Checkpoint Inhibitor (ICI)|Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.
11034263|NCT04538937||Subjects with eosinophilia and respiratory manifestation|
11034264|NCT04538937||Healthy subjects|
11034265|NCT04538924|Other|MINOCA (group I) - conventional MI treatment|Traditional MI treatment with optimal doses of statin, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), beta-blockers (BB) and dual antiplatelet therapy (DAPT).
11034266|NCT04538924|Other|MINOCA (group II)|Treatment with a low-dose statin and ACEI/ARB. In case of vasospasm, calcium channel blockers.
11034267|NCT04538911|Experimental|Experimental group|80 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
11034268|NCT04538911|Other|control group|80 tuberculosis patient were randomly assigned to the experimental group and the control group. The experimental group was injected with BCG-PPD drug once, while the control group was injected with BCG-PPD drug once
11034269|NCT04538885|No Intervention|control group|No intervention
11034270|NCT04538885|Experimental|experimental group|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)
11034271|NCT04538872|Experimental|MS group implicit|
11034272|NCT04538872|Experimental|MS group explicit|
11034273|NCT04538872|Active Comparator|HC group implicit (Healthy Controls)|
11034274|NCT04538872|Active Comparator|HC group explicit (Healthy controls)|
11034275|NCT04538846|Experimental|Culinary Art Therapy Group|Patients with eating disorders that will participate in a weekly session of culinary art therapy group.
11034276|NCT04538846|No Intervention|No Culinary Art Therapy Intervention|Patients with eating disorders that are not scheduled to come to the outpatients ward on the day of intervention.
11034278|NCT04538833|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of paclitaxel/docetaxel application, (placebo as a single infusion)
11034279|NCT04538820|Active Comparator|control|patients with BMI=18.5-24.9 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
11034280|NCT04538820|Active Comparator|4 mg|patients with BMI>30 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
11034281|NCT04538820|Active Comparator|8 mg|patients with BMI>30 kg/m2 will be received 8 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
11034282|NCT04538807||Lumbar disc herniation|Patients are complaining of lower extremity radiating pain due to lumbar disc herniation.
11034283|NCT04538794|Experimental|CDX-0159|CDX-0159 every 4-8 weeks
11034284|NCT04538794|Placebo Comparator|Normal Saline|Normal saline every 4-8 weeks
11034285|NCT04538781||Same Day Discharge|Patients undergoing a-fib ablation procedures who were closed with VASCADE MVP and were discharged the same day.
11034286|NCT04538768|Experimental|Mesh Augmentated|
11034287|NCT04538768|Other|Direct Suture|
11034288|NCT04538755|Placebo Comparator|Placebo|Placebo capsule 4 hours before sleep
11034289|NCT04538755|Active Comparator|DAW2020|DAW2020 capsule 4 hours before sleep
11034290|NCT04538742|Experimental|Module 1- T-DXd and Durvalumab|T-DXd and Durvalumab
11034291|NCT04538742|Experimental|Module 2- T-DXd and Pertuzumab|T-DXd and Pertuzumab
11034292|NCT04538742|Experimental|Module 3- T-DXd and Paclitaxel|T-DXd and Paclitaxel
11034293|NCT04538742|Experimental|Module 4- T-DXd and Durvalumab and Paclitaxel|T-DXd and Durvalumab and Paclitaxel
11034294|NCT04538742|Experimental|Module 0- T-DXd|T-DXd
11034295|NCT04538716|Experimental|SVF-gel|Transconjunctival blepharoplasty associated with associated with stromal vascular fraction gel (SVF-gel)
11034296|NCT04538716|Experimental|fat transposition|Transconjunctival blepharoplasty associated with fat transposition
11034297|NCT04538690|No Intervention|Control Group|Age and sex matched non interventional, healthy control group
11034298|NCT04538690|Experimental|Exercise Group|Individuals who are taken part of shoulder exercises with painful shoulder disorders.
11034299|NCT04538677||F2F-Group|Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.
11034300|NCT04538677||VC-group|Patients who preferred a video consult were seen over a video connection.
11034301|NCT04538664|Experimental|Arm A: Amivantamab + Chemotherapy|"Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.
~Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles.
~Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3."
11034302|NCT04538664|Experimental|Arm B: Chemotherapy Alone|"Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.
~Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles."
11034303|NCT04538638|Active Comparator|Mesenteric Sparing ileocolic resection|Standard procedure for CD, ileocolic resection without removal of the mesentery.
11034304|NCT04538638|Active Comparator|Central mesenterectomy ileocolic resection|Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.
11034305|NCT04538625|Placebo Comparator|Placebo|Subjects randomized to the placebo arm, will receive oral doses of matching placebo tablets twice daily with or without food.
11034306|NCT04538625|Experimental|Crofelemer|Subjects randomized to the crofelemer arm, will receive oral doses of crofelemer 125mg delayed-release tablets twice daily with or without food.
11034307|NCT04538612|Experimental|measure capillary refill time|
11034308|NCT04538599|Experimental|RD13-01 cell infusion|
11034309|NCT04538573|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during during hydrotherapy, physiotherapy and occupational therapy.
11034310|NCT04538573|Active Comparator|Standard Treatment|Standard treatment during hydrotherapy, physiotherapy and occupational therapy.
11034311|NCT04538560|Experimental|Polar body biopsy group|The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
11034312|NCT04538560|No Intervention|Control group|The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.
11034313|NCT04538547|Experimental|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
11034314|NCT04538547|Active Comparator|Non Accelerated Radiotherapy|Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.
11034315|NCT04538534|Experimental|nicardipine and isosorbide dinitrate|"A Cocktail of 1 mg of Isosorbide Dinitrate associated to 1 mg of nicardipine will be put in a syringe than diluted in saline serum to have a volume of 3cc.
~The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization."
11034316|NCT04538534|Active Comparator|isosorbide dinitrate|Isosorbide Dinitrate: 1 mg will be diluted in saline solution as to have a 3cc volume The obtained solution will be administered in an intra-arterial fashion via the trans-radial sheath after randomization
11034317|NCT04538521|Experimental|Niacin in early-stage mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
11034318|NCT04538508|Experimental|Diathermy|Participants that receive 10 sessions of radiofrequency diathermy of 12 minutes of duration
11034319|NCT04538508|Active Comparator|Control|Participants that perform supervised exercises for three weeks
11034321|NCT04538482|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber)
11034322|NCT04538469||Group 1|Admitted prior to COVID visitation restrictions introduced
11034323|NCT04538469||Group 2|Admitted following the introductions of visitation restrictions due to COVID 19 pandemic
11034324|NCT04538456||used electronic Patient Reported Outcome Measures|Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.
11034325|NCT04538456||never used electronic Patient Reported Outcome Measures|Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.
11034326|NCT04538443||hemodialysis group|One hundred children with ESRD who are treated with hemodialysis and their caregivers will participate in this study. They will be recruited from Nephrology Unit at Abo-Elreesh Hospital, Cairo University
11034327|NCT04538430|Other|Axial Low Back Pain|Patient diagnosed with axial low back pain not responding to conservative measures and no symptoms of radiculopathy, that is scheduled to have a SPRINT percutaneous peripheral nerve stimulator placed as standard of care.
11034328|NCT04538417|Other|Residual Limb Pain in affected amputated limb|Patient has residual limb pain in amputated limb and is scheduled to receive standard of care treatment of cooled radiofrequency ablation.
11034329|NCT04538391|Active Comparator|bupivacaine group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.
11034330|NCT04538391|Active Comparator|meloxicam group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.
11034331|NCT04538391|Active Comparator|placebo group|included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.
11034332|NCT04538378|Experimental|1/Arm 1|Combination of durvalumab and olaparib
11034333|NCT04538365|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
11034334|NCT04538365|Experimental|Hand antisepsis with triclosan solution|Effectiveness of pre-surgical hand washing in reducing bacterial load using triclosan 0.5% solution
11034335|NCT04538352|Experimental|Once-weekly sc semaglutide combined with once-daily insulin|Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
11034336|NCT04538352|Experimental|MDI requiring multiple daily injections of insulin|Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.
11034337|NCT04538326|Other|Single|Participants exercised in two counter balanced blocks: repeated (standard of care and self-paced repeated custom game) and random (Kinect game and game-paced random custom game). Exercise bouts were for 8.5 minutes with ten minutes of rest in between so they could return to physiological baseline. Data were collected in a single session lasting two hours.
11034338|NCT04538313|Experimental|High dose group|10^10 TIL
11034339|NCT04538313|Experimental|Low dose group|10^9 TIL
11034340|NCT04538313|Experimental|Extension set|The number of TIL is decided by dose escalation experiment.
11034341|NCT04538300|Active Comparator|Group Gum|"Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
~Degree of nausea and Abramowitz Emezis score were evaluated as the interventions. If PONV persists second chewing gum was gived. 15 minutes later PONV was evaluated. If PONV was persisted ondansetron 4 mg, then dexamethasone 4 mg , then propofol 10 mg intravenously were given, respectively."
11034342|NCT04538300|Active Comparator|Group Control|In Group Control, Degree of nausea and Abramowitz Emezis score were evaluated as the interventions in recovery room. If patients with moderate and severe nausea were given 4 mg ondansetron intravenously. If PONV continues, we planned to give dexamethasone 4 mg and propofol 10 mg intravenously, respectively.
11034343|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1010|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010
11034344|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1020|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1020
11034345|NCT04538287|Active Comparator|AtaCor StealthTrac Lead Model AC-1030|Subjects inserted with the AtaCor StealthTrac Lead Model AC-1030
11034346|NCT04538274|Experimental|Patient researcher intervention|Intervention conducted by trained patient researchers to restart CPAP in addition to usual care
11034347|NCT04538274|No Intervention|Usual care|Usual care
11034348|NCT04538261|Sham Comparator|Control|Non-inflation of the balloon device
11034349|NCT04538261|Experimental|Intervention|Inflation of the balloon device
11034350|NCT04538248||Continuous|Continuous
11034351|NCT04538248||Discontinuous|Discontinuous
11034352|NCT04538235||Bi-block (Serratus and erector spinae block) group|"The Bi-block consisted in performing an ESP block followed by a SAP block on the side ipsilateral to the thoracic surgery. For the ESP block, 40 ml of Ropivacaine 2mg/ml were injected under the erector spinae muscle plane, at the level of the 4th thoracic vertebra. For the SAP block, 40 ml of Ropivacaine 2 mg/ml were injected under the serratus anterior muscle plane. The cumulative dose of Ropivacaine did not exceed 3 mg/kg.
~Regional anesthesia was performed before surgery."
11034353|NCT04538235||Thoracic Epidural Analgesia (TEA) group|"The thoracic epidural was performed according to a standardized protocol, with a Tuohy needle via the median puncture technique, at the level of T4-T5 intervertebral space. After a test dose of 2 to 3 ml of Lidocaine, 5 to 10 ml of a mixture of Ropivacaine 2 mg/ml and Sufentanil 0.5 µg / mL were injected. Epidural continuous administration was performed with the same mixture of anesthetic connected to a CADD Solis ™ pump set according to a PCEA protocol adapted to the patient's weight (continuous flow rate from 3 to 6 ml/h, self-administered bolus dose from 3 to 5 ml, refractory period 30 min).
~Regional anesthesia was performed before surgery."
11034354|NCT04538209||canditates for variceal eradication|patients with documented liver cirrhosis (Based on clinical, laboratory and ultrasonographic findings) undergoing either primary or secondary prophylaxis variceal eradication at endoscopy unit of El-Rajhi hospital, Assuit University
11034355|NCT04538196|Experimental|R Education|Invervention: Resident who receives education on documentation and coding at the beginning of the surgical rotation
11034356|NCT04538196|No Intervention|R no Education|Resident who does not receive information on documentation and coding at the beginning of the surgical rotation
11034357|NCT04538183|Experimental|WO 5000|Body lotion pH 4 for topical application
11034358|NCT04538183|Experimental|WO 5001|Body lotion pH 5.8 for topical application
11034359|NCT04538183|No Intervention|No product use|Untreated control area
11034360|NCT04538170||ORC|Group orchidectomy following cancer
11034361|NCT04538170||GAC|Group sex reassignment surgery
11034362|NCT04538157|Experimental|Comprehensive Geriatric Assessment|Specialist co-ordinated care (known as comprehensive geriatric assessment, or CGA) was developed to address medical, social, mental health, and physical needs with the help of a skilled multi-disciplinary team.
11034363|NCT04538157|No Intervention|Usual Care|Usual Care
11034364|NCT04538144||Younger participants|Individuals aged 18-39 years
11034365|NCT04538144||Older participants|Individuals aged 65 years or older
11034366|NCT04538131|Active Comparator|conventional SCS|
11034367|NCT04538131|Experimental|sensor-driven position-adaptive SCS|
11034368|NCT04538118||Patient with a shoulder problem|Patients with shoulder problems between 18-65 years of age and being volunteered
11034369|NCT04538105|Sham Comparator|Sham Injection|20cc of Normal Saline 0.9%
11034370|NCT04538105|Experimental|Articular Branch Block (ABB)|20cc of 0.5% Bupivacaine with epinephrine 1:200,000
11034371|NCT04538092|No Intervention|Control|Standard post op complex spine orders placed for patients undergoing deformity correction
11034372|NCT04538092|Experimental|ERAS|Enhanced recovery after surgery protocol is applied to the patients undergoing deformity correction
11034373|NCT04538079||Feasibility/Accuracy/Reproducibility|The first 20 participants will be analysed for feasibility and the first 40 ECHOs for accuracy/reproducibility of non-invasive Cardiac Output Monitoring with ECHO as reference Method.
11034374|NCT04538079||Prediction of Circulatory Failure|Together with the Feasibility/Accuracy/Reproducibility Cohort this group's results will be analysed for prediction of circulatory failure defined as an ultrasound abnormality (IVH grade 3 - 4) or death within the first two weeks of life.
11034375|NCT04538066|Active Comparator|Bryostatin 1|20ug Bryostatin will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
11034376|NCT04538066|Placebo Comparator|Placebo|Placebo will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
11034377|NCT04538053|Active Comparator|Intervention|Children will receive high-dose oral cefalexin 37.5 mg/kg/dose (max 1.5 g) four-times daily (QID) for 2 to 4 days followed by oral cefalexin 25 mg/kg/dose (max 1 g) QID for a total course of 3 weeks
11034378|NCT04538053|Active Comparator|Standard Therapy|Children will receive IV cefazolin 50 mg/kg/dose (max 2 g) three-times daily (TDS) for 2 to 4 days followed by oral cefalexin 25 mg/kg/dose (max 1 g) four-times daily (QID) for a total course of 3 weeks
11034379|NCT04538040|Experimental|Biktarvy + Doravirine Switch|bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets + doravirine 100mg tablets taken orally once per day
11034380|NCT04538027|Active Comparator|6 weeks|Microdiscectomy was done at 6 weeks of starting symptoms
11034381|NCT04538027|Active Comparator|3 months|Microdiscectomy was done at 3 months of starting symptoms
11034382|NCT04538027|Active Comparator|6 months|Microdiscectomy was done at 6 months of starting symptoms
11034383|NCT04538014|Experimental|Lu AF88434|
11034384|NCT04538001|Experimental|Balloon implantation|Arthroscopic implantation of this sub-acromial balloon
11034385|NCT04538001|Active Comparator|Rotator cuff repair|Partial rotator cuff repair
11034386|NCT04537988|Experimental|Feasibility and usability intervention trial|Pre-post evaluation of a 3-month pilot-trial of an electronic health (eHealth) intervention
11034387|NCT04537975|Active Comparator|C2Rx|Hemofiltration device
11034388|NCT04537975|Active Comparator|Standard of Care (SOC)|Standard of Care based on protocol inclusion/exclusion criteria
11034389|NCT04537962|Active Comparator|Colgate Periogard and Peroxyl® - ICU patients|Arm 1 - patients hospitalized in the ICU with orotracheal intubation - undergo disinfection of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution ( Peroxide and Chlorhexidine Group)
11034390|NCT04537962|Active Comparator|Colgate Periogard® - ICU patients|Arm 1 - patients hospitalized in the ICU with orotracheal intubation - undergo disinfection of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution (Chlorhexidine Group);
11034391|NCT04537962|Active Comparator|Colgate Peroxyl®|Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 1.5% hydrogen peroxide solution (Peroxide Group)
11034392|NCT04537962|Active Comparator|Colgate Periogard®|Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 0.12% chlorhexidine gluconate (Chlorhexidine Group)
11034393|NCT04537962|Active Comparator|Colgate Peroxyl® and Periogard®|Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 1.5% hydrogen peroxide solution (Peroxide Group); mouthwash with 0.12% chlorhexidine gluconate (Chlorhexidine Group); mouthwash with 1.5% hydrogen peroxide followed by mouthwash of 0.12% non-alcoholic decorexidine solution (Peroxide and Chlorhexidine Group)
11034394|NCT04537962|Active Comparator|Colgate Total® Mouthwash|Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate (Cetylpyridinium Group).
11034395|NCT04537962|Placebo Comparator|Placebo|Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with distilled water (Placebo Group).
11034396|NCT04537949|Experimental|Part A participants aged 18 to 55 years|Escalating dose levels
11034397|NCT04537949|Experimental|Part A participants aged 56 to 85 years (optional)|Escalating dose levels
11034400|NCT04537923|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week with insulin glargine (U100) administered SC.
11034401|NCT04537923|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week with insulin glargine (U100) administered SC.
11034402|NCT04537923|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week with insulin glargine (U100) administered SC.
11034403|NCT04537923|Active Comparator|Insulin Lispro (U100)|Insulin lispro (U100) administered SC three times a day with insulin glargine (U100) administered SC.
11034404|NCT04537910|Experimental|LY3819253|LY3819253 administered subcutaneously (SC).
11034405|NCT04537910|Placebo Comparator|Placebo|Placebo administered SC.
11034406|NCT04537897|Experimental|BI 474121|
11034407|NCT04537897|Experimental|BI 474121 + Midazolam|
11034408|NCT04537897|Placebo Comparator|Placebo group|
11034409|NCT04537884|Experimental|Treatment with UBX1325|UBX1325, single intravitreal injection, ascending dose
11034410|NCT04537871||Observational (physical assessment)|Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
11034411|NCT04537858|Experimental|Virtual reality therapy first|Subjects with COVID-19 who will start the first day of the protocol with Virtual Reality tasks in the morning and then in the second period, in the afternoon, will perform the conventional exercises (n = 25)
11034412|NCT04537858|Experimental|Conventional therapy first|Subjects with COVID-19 who will start the first day with conventional exercises in the morning and in the second period, in the afternoon, will perform activity with virtual reality (n = 25).
11034413|NCT04537845||with cancer pain|
11034414|NCT04537845||without cancer pain|
11034415|NCT04537832||Group 1|Subjects from 6 through 60 months of age (at baseline) who have SCN1A+ Dravet Syndrome. Clinical, neurocognitive, laboratory, the burden of disease, and health care resource utilization will be assessed.
11034416|NCT04537819|Experimental|The main group|"1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Imupret oral drops in the age-related dosage of 6 times per day for 6 days with the subsequent transition to the regime of 15 drops / 3 times in a day according to the patient's condition.
~6. Paracetamol as antipyretic, if necessary."
11034417|NCT04537819|Other|The comparison group|1. soft diet; 2. Elimination of factors that irritate the mucous membrane of the pharynx (thermal, chemical); 4. Local NSAIDs - benzydamine hydrochloride. 5. Paracetamol as antipyretic, if necessary.
11034418|NCT04537806|Experimental|Brexanolone|Participants receiving mechanical ventilation as standard of care will receive brexanolone as a single, continuous, intravenous (IV) infusion for 60 hours.
11034419|NCT04537806|Placebo Comparator|Placebo|Participants receiving mechanical ventilation as standard of care will receive matching placebo as a single, continuous, IV infusion for 60 hours.
11034420|NCT04537793|Experimental|Part A: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
11034421|NCT04537793|Experimental|Part B: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
11034422|NCT04537780|Placebo Comparator|group 1|(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..
11034423|NCT04537780|Experimental|Group 2|"Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.
~The treatment duration will be 12 weeks."
11034424|NCT04537767|Experimental|ES group|Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
11034425|NCT04537767|Placebo Comparator|control group|Patients randomly assigned to the control group were treated with placebo.
11034426|NCT04537754|Experimental|clinician|Comparison of LED and diode laser
11034427|NCT04537741|Experimental|NSTEMI scheduled for angiography|
11034428|NCT04537728|Experimental|My Healthy Brain Version 2|an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of CD
11034429|NCT04537715|Experimental|Part 1: Tazemetostat and Itraconazole Drug Interaction Cycle 1|"Subjects in Part 1 of the study will receive a single oral 400 mg dose of Tazemetostat on Day 1, 15 and 36. The subjects will receive Tazemetostat (oral 400 mg dose) tablets to be taken twice daily from Day 3 - 14 and Day 21 - 35. In addition, the subjects will receive oral 200 mg itraconazole daily from Day 18 - 38.
~Subjects may discontinue from the study after completion of Cycle 1 or can continue treatment (Cycle 2+ onwards) until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. For subjects continuing Tazemetostat treatment at the recommended therapeutic dose (oral 800 mg Tazemetostat twice daily [12 hours apart]), Cycle 2 will begin on day 40 (Cycle 2 Day 1) and each subsequent cycle from Cycle 2+ onwards will be of 28-day duration. Safety and tolerability will be assessed throughout the subject's participation."
11034430|NCT04537715|Experimental|Part 2:Tazemetostat and Rifampin Drug Interaction Cycle 1|"Subjects in Part 2 of the study will receive a single oral 800 mg dose of Tazemetostat on Day 1, 15 and 24. The subjects will receive Tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 3 - 14 and Day 17 - 23. In addition, the subjects will receive oral 600 mg rifampin daily from Day 17 - 25.
~Subjects may discontinue from the study after completion of Cycle 1 or can continue treatment (Cycle 2+ onwards) until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. For subjects continuing Tazemetostat treatment at the recommended therapeutic dose (800 mg Tazemetostat twice daily [12 hours apart]), Cycle 2 will begin on day 27 (Cycle 2 Day 1) and each subsequent cycle from Cycle 2+ onwards will be of 28-day duration. Safety and tolerability will be assessed throughout the subject's participation."
11034490|NCT04537208|Experimental|Group 2 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1
11034491|NCT04537208|Experimental|Group 3 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1
11034492|NCT04537208|Experimental|Group 4 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1
11034431|NCT04537702|Active Comparator|Tradition Counseling Group (TG)|After completion of baseline surveys, the TG subjects will be referred to a formal pre-test consultation with a genetic counselor. TG subjects will complete an electronic family history questionnaire (FHQ) within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review errors and clarify any ambiguities in the pedigree. The TG subjects will then meet with the genetic counselor. After counseling, participants will be given the option to undergo a multi-gene panel genetic test. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice, patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. Subjects will complete a post-education distress and anxiety survey (IES) either via an email link to a confidential REDCap survey link 1-2 weeks after formal consultation.
11034432|NCT04537702|Experimental|Streamlined Group (SG)|"After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. All subjects will then have the option to opt out and receive formal genetic counseling prior to making a decision about testing. If the subject elects to undergo genetic testing, she will fill out the standard genetic testing consent form. As per standard practice of the clinical genetic service at Duke Cancer Institute (DCI), patients will also be asked to provide consent for somatic tumor testing of surgical (non-cytologic) specimen. SG subjects will complete an FHQ within one week of the primary visit. A member of the genetics team will curate the results by contacting the subject to review common errors and clarify any ambiguities in the pedigree. Subjects will complete a post-education distress and anxiety survey (IES) via either an email link to a confidential REDCap survey link or over the phone 1-2 weeks after education."
11034433|NCT04537689|Experimental|Ixekizumab|"Participants will be offered ixekizumab as first-line systemic treatment for moderate to severe PsO. The indication for ixekizumab will be equivalent to current registered indications. Standard dose of subcutaneous ixekizumab for moderate to severe PsO will be given at 160 mg at week 0, followed by ixekizumab 80mg at weeks 2, 4, 6, 8, 10 and 12, then 4 weekly thereafter, for a total duration of 6 months.
~Ixekizumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO.
~Relapses will be managed as per standard care."
11034434|NCT04537689|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.
~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
11034435|NCT04537676||DFU Participants|A cohort of 200 DFU patients who have been prescribed the Podimetrics System by their healthcare providers will be recruited upon providing informed consent. Potential participants will be asked to indicate their interest in participating in this patient empowerment study during their initial phone consultation for mat set-up with the Podimetrics care-management team. Participants will be followed for one year and answer a set of identical questionnaires at three time points: at baseline, at 6-month and at 12-month post enrollment.
11034436|NCT04537663|Experimental|Bacille Calmette-Guérin (BCG)|Intradermal injection of BCG-Vaccine SSI [Statens Serum Institut]) - Danish strain 1331.
11034437|NCT04537663|Placebo Comparator|Placebo|Intradermal injection of sterile 0.9% NaCl.
11034438|NCT04537637||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
11034439|NCT04537624||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
11034440|NCT04537611|Experimental|dHb contrast compared to gadolinium contrast imaging|Subjects will be referred for a clinical gadolinium contrast perfusion exam. Gas manipulation will be supplied by a programmable computer-controlled gas delivery system while subjects are in the MRI scanner. In addition to their prescribed clinical scans, two additional scans will be obtained: 1) a structural sequence (, followed by 2) a BOLD-EPI sequence while inducing changes of PO2. PO2 will be held at a baseline of 45-50 mmHg for 60s. For 10 s, the lung PO2 will be transiently raised to peak PO2 of 90-120 mmHg (normoxia) within 2 s transition, and then returned to baseline. Alternatively, the baseline may be at normoxia and the gas challenges will target PO2 of 45-50 mmHg. A total of 4 such ventilatory challenges will be applied over 6 min while maintaining normocapnia.
11034441|NCT04537598|Active Comparator|patient controlled analgesia|30 patients will receive only postoperative IV PCA alone for postoperative analgesia.
11034442|NCT04537598|Active Comparator|Patient controlled analgesia and ESPB|30 patients will receive postoperative IV PCA in addition to ESPB for postoperative analgesia.
11034443|NCT04537585|Experimental|Tomeka|Number of participants with treatment-TOMEKA® usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour
11034444|NCT04537585|Experimental|"Vernonia amygdalina"|"Number of participants with Vernonia amygdalina herbs usage as assessed by Education [ Time Frame: 18 months ] Change people's behaviour"
11034445|NCT04537572|Other|Sample Collection Method|All subjects will provide samples via traditional phlebotomy, finger-stick, and saliva collection.
11034446|NCT04537559||Per and post COVID-19 period|Patients hospitalized between 1.3.2020 and 31.7.2020
11034447|NCT04537559||Pre COVID-19 period|Patients hospitalized between 1.3.2019 and 31.7.2019
11034448|NCT04537546|Experimental|Elasto compression belt|all patients must wear the belt 2 months after laparoscopic digestive surgery.
11034449|NCT04537533|Experimental|first group|1st group (A) will include 30 patients: each one will receive 15mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 10mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
11034450|NCT04537533|Active Comparator|second group|2nd group (B) will include 30 patients: : each one will receive 5mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 1mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
11034451|NCT04537533|Placebo Comparator|Third group|3rd group (C){controlled group} will include 30 patients: each one will receive saline (placebo) injection and infusion all through the operation.
11034452|NCT04537520|Experimental|Experimental Group|treatment with the device Kerecis Omega3 Wound
11034453|NCT04537520|No Intervention|Control Group|treatment with SOC treatment
11034493|NCT04537208|Placebo Comparator|Group 5 (18 - 49 years of age)|1 injection of placebo at Day 1
11034494|NCT04537208|Experimental|Group 6 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1 and Day 22
11034495|NCT04537208|Experimental|Group 7 (18 - 49 years of age)|2 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1 and Day 22
11034454|NCT04537507||Patients underwent coronary angiography|We reviewed medical notes of patients hospitalized for coronary angiography because of exacerbated angina (recurrent chest pain, classical stable angina, long history of chest pain/angina or other symptoms such as dyspnea). We excluded patients with acute coronary syndromes (ACS), Tako-tsubo cardiomiopathy and history of ischemic heart disease, as well as those referred for coronary angiography before heart valve surgery. Prior cardiosurgical valve replacement was also the exclusion criterion.
11034455|NCT04537494|Active Comparator|Prevention|Oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks
11034456|NCT04537494|Other|Treatment-as-needed|Supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age
11034457|NCT04537481|Experimental|Normal fertilization group|Sperm samples from the successful fertilization IVF cycles were collected.
11034458|NCT04537481|Experimental|Low fertilization group|Sperm samples from the low fertilization IVF cycles were collected.
11034459|NCT04537468|Other|Skin sample collection|Skin sample collection for gene expression analyses.
11034460|NCT04537455|Experimental|Abnormal cardiac conduction|patients with abnormal cardiac conduction will undergo an ultra-high frequency electrocardiogram
11034461|NCT04537442|Experimental|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
11034462|NCT04537429|Experimental|Eptinezumab|
11034463|NCT04537416||Women with recurrent pregnancy loss|consecutive women at least 18 years old but not greater than 40 years old with a chief complaint of recurrent pregnancy loss
11034464|NCT04537403|Experimental|Aim 1A|Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery
11034465|NCT04537403|Experimental|Aim 1B|Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery
11034466|NCT04537390|Other|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
11034467|NCT04537377|Experimental|VTX-801|
11034468|NCT04537364||pediatric patients with CAKUT|"This cohort is composed of pediatric children diagnosed of CAKUT from Shanghai peri-conceptional parent-offspring cohort (SPCC) clinic research related outpatient and high-risk newborns referral outpatient, and those who are enrolled in nephrology department and urinary surgery department with CAKUT diagnosis.
~By diagnostic tests for predicting renal parenchymal damage in this cohort, data of kidney images, urinary biomarkers and disease genes can be collected."
11034469|NCT04537351|Experimental|CYP-001|The investigational medicinal product used in this study is known as CYP-001. The active agent in CYP-001 is Cymerus™ MSCs. CYP-001 is supplied as 100 million Cymerus MSCs formulated in 20 mL cryoprotectant medium. On D1 and D3, each participant randomised to receive CYP-001 will receive an IV infusion of 2 million Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells per infusion).
11034470|NCT04537351|No Intervention|Standard of care|Control participants will be randomised to received standard of care treatment.
11034471|NCT04537338||Active / Recovered Cases|"Active Cases:
~Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.
~Most of the cases of Covid-19 are treated at CCSS hospitals or clnics.
~Recovered cases:
~Are subjects previously diagnosed with Covid-19 via a positive PCR test who were considered recovered because they had two consecutive negative PCR tests."
11034472|NCT04537338||Community control group|The community control group will be frequency-matched on age, sex and area of residence. Two controls per case will be selected as follows
11034473|NCT04537338||Household survey|"Are a household contact of a person diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.
~A household will be defined as a group of persons living together who share a kitchen. To be considered eligible for inclusion a contact must have spent at least one night per week in the living area since onset in the index case."
11034474|NCT04537325|Active Comparator|RenalGuard group|
11034475|NCT04537325|No Intervention|Control group|
11034476|NCT04537312|Experimental|Supportive care (RNSM, surveys)|RNMS Surveys
11034477|NCT04537299|Experimental|Treatment Group|Subjects will receive treatment drug (Fisetin)
11034478|NCT04537299|Placebo Comparator|Placebo Group|Subjects will receive placebo
11034479|NCT04537286|Experimental|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
11034480|NCT04537273||Localy advanced Cervical Cancer|Patients with Localy advanced Cervical Cancer confirmed by pathology, clinical exams and computed tomography scan, treated with concurrent chemoradiotherapy.
11034481|NCT04537260|No Intervention|Control Arm (Standard of Care)|The control group took the knowledge-based survey about induction of labor prior to meeting their provider (midwife or obstetrician) on the day of scheduled induction. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction with the labor and delivery process.
11034482|NCT04537260|Experimental|Intervention Arm (Educational video)|The intervention group had the opportunity to watch the 3-minute educational video. The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8. After watching the video, the participant was asked to take the knowledge-based survey. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction.
11034483|NCT04537247|Experimental|Open partial nephrectomy (Group A)|patients in this group will have open partial nephrectomy for their renal tumors.
11034484|NCT04537247|Experimental|Robotic partial nephrectomy (group B)|patients in this group will have robotic partial nephrectomy for their renal tumors.
11034485|NCT04537234|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
11034486|NCT04537234|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
11034487|NCT04537221||No transfusions|Patients receiving no perioperative blood transfusions (PBT)
11034488|NCT04537221||Transfusions|Patients receiving perioperative blood transfusions (PBT)
11034489|NCT04537208|Experimental|Group 1 (18 - 49 years of age)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1
11042889|NCT04478955||mascara only|three days a week at least for 6 months
11034496|NCT04537208|Experimental|Group 8 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1 and Day 22
11034497|NCT04537208|Experimental|Group 9 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1 and Day 22
11034498|NCT04537208|Experimental|Group 10 (18 - 49 years of age)|2 injections of SARS-CoV-2 vaccine formulation 2 without adjuvant at Day 1 and Day 22
11034499|NCT04537208|Placebo Comparator|Group 11 (18 - 49 years of age)|2 injections of placebo at Day 1 and Day 22
11034500|NCT04537208|Experimental|Group 1 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1
11034501|NCT04537208|Experimental|Group 2 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1
11034502|NCT04537208|Experimental|Group 3 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1
11034503|NCT04537208|Experimental|Group 4 (50 years of age and older)|1 injection of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1
11034504|NCT04537208|Placebo Comparator|Group 5 (50 years of age and older)|1 injection of placebo at Day 1
11034505|NCT04537208|Experimental|Group 6 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 1 with adjuvant 1 at Day 1 and Day 22
11034506|NCT04537208|Experimental|Group 7 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 1 with adjuvant 2 at Day 1 and Day 22
11034507|NCT04537208|Experimental|Group 8 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 1 at Day 1 and Day 22
11034508|NCT04537208|Experimental|Group 9 (50 years of age and older)|2 injections of SARS-CoV-2 vaccine formulation 2 with adjuvant 2 at Day 1 and Day 22
11034509|NCT04537208|Placebo Comparator|Group 11 (50 years of age and older)|2 injections of placebo at Day 1 and Day 22
11034510|NCT04537195|Experimental|Intervention Group|ADSMP-C
11034511|NCT04537195|No Intervention|Control Group|Wait-list control group
11034512|NCT04537182|Experimental|LVRS treatment group|A bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) is performed under general anesthesia with double lumen endobronchial intubation. Unilateral treatment is accepted in cases with severe adhesions or intraoperative instability making a bilateral procedure unsafe.
11034513|NCT04537182|Active Comparator|BLVR study group|Unilateral bronchoscopic lung volume reduction with endobronchial valves (EBV) is performed using a flexible bronchoscope under general anesthesia and under full attendance of an anesthesiologist. Valves are placed unilaterally in segmental or subsegmental bronchi in the target lobe with the goal of complete atelectasis.
11034514|NCT04537169||Mild congenital ptosis|children with mild congenital ptosis
11034515|NCT04537169||Moderate congenital ptosis|children with moderate congenital ptosis
11034516|NCT04537169||Severe congenital ptosis|children with severe congenital ptosis
11034517|NCT04537156|Experimental|HPV vaccine (6,11,16,18,31,33,45,52,58 Types)|Participants in this arm would receive 270μg/0.5ml HPV vaccines (6,11,16,18,31,33,45,52,58 Types).
11034518|NCT04537156|Active Comparator|HPV vaccine (16,18 Types)|Participants in this arm would receive 60μg/0.5ml HPV vaccines (16,18 Types).
11034519|NCT04537143||Control|Non-AMD eyes
11034520|NCT04537143||AMD|AMD eyes
11034521|NCT04537130|Experimental|Experimental|The investigational medical product, the IN01 vaccine, will be administered in two phases to those patients in the experimental arm: the induction phase and the maintenance phase. During the induction phase IN01 vaccine will be administered on day 1 and will be repeated on Day 14, Day 28, Day 42 and day 56. During the maintenance phase, the vaccination will be administered every 2 months with the same dosage and administration mode as during induction.
11034522|NCT04537130|No Intervention|Control|The patients enrolled in the control arm of the study will receive standard of care.
11034523|NCT04537117||Pediatric dentists|Pediatric dentists following Facebook groups for pediatric dentists and practicing dentistry nowadays
11034524|NCT04537091|Experimental|ESWT group: rESWT|rESWT treatment was applied to patients
11034525|NCT04537091|Experimental|PRP group: PRP injection|PRP treatment was applied to patients
11034526|NCT04537078|Active Comparator|the progestin primed double stimulation group|luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphastonat 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness ≥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.
11034527|NCT04537078|Active Comparator|the flexible GnRh antagonist|This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle >18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle >18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
11034528|NCT04537065||preterm infants without ROP|
11034529|NCT04537065||preterm infants with regressed ROP|
11034530|NCT04537065||preterm infants with threshold ROP|
11034531|NCT04537065||full-term infants|
11034532|NCT04537052|Experimental|Onl Femoral vein|Ultrasound-guided controlled injection begins, and the venous diameter and gap between valves are reduced
11034533|NCT04537039|Other|All the participants.|This study only includes 1 arm.
11034645|NCT04536389||group A|women with normal uterine cavity and normal cervix by office hysteroscopy.
11034534|NCT04537026|Experimental|Transforaminal epidural Amniotic Fluid injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position will be confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. Then 1 mL of Amniotic Fluid combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
11034535|NCT04537026|Active Comparator|Transforaminal epidural dexamethasone injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. 1 mL of dexamethasone sodium phosphate (10 mg/mL) combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
11034536|NCT04537000|No Intervention|control group|The strategies of red blood cell transfusion for the pediatric patients in this group will be made by the attending doctors in charge based on the current transfusion guidelines. The attending doctors decide when to start blood red cell transfusion and order the volume of the blood red cell as the usual clinical practice.
11034537|NCT04537000|Experimental|study group|For study group, the clinical condition score must be identified every time red blood cell transfusion is considered. The strategies of red blood cell transfusion for the pediatric patients in this group, including the trigger and the volume, will be made based on the comparison between the clinical condition score and the Hb concentration.
11034538|NCT04536987|Experimental|low-dosage robot therapy|12 sessions of robotic therapy over 4-5 weeks
11034539|NCT04536987|Experimental|hi-dosage robot therapy|24 sessions of robotic therapy over 8-10 weeks
11034540|NCT04536961|Experimental|Part A: Reference Treatment|
11034541|NCT04536961|Experimental|Part A Prototype|
11034542|NCT04536961|Experimental|Part C Reference Treatment|
11034543|NCT04536961|Experimental|Part C: Prototype|
11034544|NCT04536961|Experimental|Part B: Treatment 1|
11034545|NCT04536961|Experimental|Part B: Treatment 2|
11034546|NCT04536961|Experimental|Part B: Treatment 3|
11034547|NCT04536961|Experimental|Part B: Treatment 4|
11034548|NCT04536961|Experimental|Part B: Treatment 5|
11034549|NCT04536948|Experimental|Group 1|Cooling gel application
11034550|NCT04536948|Active Comparator|Group 2|Cold pack was applied
11034551|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 1|
11034552|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 2|
11034553|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 3|
11034554|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 4|
11034555|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 5|
11034556|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 6|
11034557|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 7|
11034558|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 8|
11034559|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 9|
11034560|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 10|
11034561|NCT04536922|Experimental|iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
11034562|NCT04536909||Non-surgical|A non-surgical group for comparison, they will conduct a training program tailored for the kyphoscoliotic patients. The inclusion criteria is the same as for the surgical group.
11034563|NCT04536909||Surgical|Patients operated with correction of kyphotic- or scoliotic deformity.
11034564|NCT04536896|Active Comparator|Traditional face-to-face teaching method|In this arm, participants underwent a 6-hour traditional face-to-face lecture on breastfeeding education in a classroom at a university. Course was divided into 4 1.5-hour sessions during a time span of two weeks.
11034565|NCT04536896|Experimental|Breastfeeding smartphone app|In this group, participants downloaded a smartphone application which contained an online breastfeeding education course. Participants freely navigated through the smartphone app during a time span of two weeks.
11034566|NCT04536883|Experimental|Microscopy confocal|"The fibroscopy is carried out according to the usual procedure of the service. During the fibroscopy, for all patient, the confocal microscopy procedure begins.
~After the end of confocal procedure, 5 to 6 transbronchial biopsies are performing"
11034567|NCT04536870|Experimental|STAREE Statin group|Participants in STAREE trial randomised to statin
11034568|NCT04536870|Experimental|STAREE Placebo group|Participants in STAREE trial randomised to placebo
11034569|NCT04536857||Parkinson's Disease|Subjects who have a PD diagnosis
11034570|NCT04536857||Multiple System Atrophy|Subjects who have an MSA diagnosis
11034571|NCT04536857||Progressive Superanuclear Palsy|Subjects who have a PSP diagnosis
11034572|NCT04536857||Age-matched controls|Subjects who do not have a diagnosed neurological disorder
11034573|NCT04536844|Experimental|Telehealth follow-up group|Rheumatoid arthritis patients in remission who will be followed by an electronic app
11034574|NCT04536844|Placebo Comparator|Conventional follow-up group|Rheumatoid arthritis patients in remission who will attend conventional prescheduled visits in the outpatient clinic
11034873|NCT04534699|Experimental|Hepatic Impaired|KBP-5074 0.5mg tablet orally, Single dose
11034575|NCT04536831|Experimental|Vitamin D group|Consisted of 48 patients selected on admission via lottery method those will be given Vitamin D mega dose
11034576|NCT04536831|Placebo Comparator|Normal Saline group|Consisted of 48 patients selected on admission via lottery method those will be given Normal saline
11034577|NCT04536818||Time to surgery ≤12 hours|Waiting time to surgery ≤12 hours from hospital presentation.
11034578|NCT04536818||Time to surgery >12 hours|Waiting time to surgery >12 hours from hospital presentation.
11034579|NCT04536805|Experimental|Metformin + SBRT at total dose of 30 Gray (Gy)|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy, (day 0 to day 10)"
11034580|NCT04536805|Experimental|Metformin + SBRT at total dose of 36 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy (day 0 to day 12)"
11034581|NCT04536805|Experimental|Metformin + SBRT at total dose of 25 Gy|"Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
~Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 5 Gy (day 0 to day 10)"
11034582|NCT04536792|Experimental|Part 1: Single Ascending Dose (SAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.
11034583|NCT04536792|Experimental|Part 2: Multiple Ascending Dose (MAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days.
11034584|NCT04536792|Experimental|Part 3: Sickle Cell Disease (SCD) Phase|Participants will receive a range of selected ascending doses of AG-946, orally, QD for 28 days.
11034585|NCT04536779|Experimental|Individuals with low mobility (Disabled and Elder)|minimum 8-10 training sessions in at least three months.
11034586|NCT04536766|Experimental|Enhanced Sleep Health Education|50 families will be randomly assigned to receive sleep health education delivered in two telephone sessions by Beds for Kids staff members, in addition to receiving the standard Beds for Kids program (bed, bedding, written sleep education materials). The first session will occur approximately 2-3 days before bed delivery. The second 15-20-minute session will occur approximately one week following bed delivery. Sleep health education training and supervision of Beds for Kids staff members will be provided by board-certified Behavioral Sleep Medicine providers. Sleep health information will be manualized and will consist of evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs.
11034587|NCT04536766|Active Comparator|Beds for Kids Standard Program|50 families will be randomly assigned to the standard Beds for Kids program, which includes a bed, bedding, and written sleep education materials.
11034588|NCT04536753||Suspected large for gestational age (LGA)|Women with pregnancies suspected to be complicated by fetuses weighing more than the 90th centile on customised growth chart and induced for this reason prior to 287 days as the main indication without diabetes.
11034589|NCT04536753||Women with diabetes (DM)|Women with diabetes in pregnancy induced at between 259 and 266 days if on treatment and 273 days if gestational diabetes managed with diet alone.
11034590|NCT04536753||Control|All other women induced at or after 280 days of gestation
11034591|NCT04536740|Other|PDL-treated PWS|PWS treated with PDL before will be treated with PDT
11034592|NCT04536740|Experimental|without treatment PWS|PWS without treatment before will be treated with PDT
11034593|NCT04536727|Experimental|Intervention|The 8-week intervention will consist of the Fit & Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content.
11034594|NCT04536727|Placebo Comparator|Wait list|Participants randomized to the wait list group, receive the 8-week Fit & Strong! intervention after the intervention group has completed it.
11034595|NCT04536714|Experimental|Intervention group|34 participants. Received Pythagorean Self-Awareness program
11034596|NCT04536714|No Intervention|Control group|35 participants. Received usual care
11034597|NCT04536701|Experimental|Dementia/Caregiver Dyad|All dementia/caregiver dyads will have in-home acoustic monitoring to classify mood and will be provided mindfulness-based stress reduction recommendations via a smart phone.
11034598|NCT04536688|Experimental|RGLS4326 1 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses
11034599|NCT04536688|Experimental|RGLS4326 0.3 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses
11034600|NCT04536688|Experimental|RGLS4326 0.1 or 0.5 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses
11034601|NCT04536675|Experimental|VI/UME|Anoro (Vilanterol 25mcg/Umeclinidium 62.5mcg) in Ellipta device Inhaled through mouth once daily
11034602|NCT04536675|Placebo Comparator|Control|Placebo (including lactose monohydrate) in Ellipta device Inhaled through mouth once daily
11034603|NCT04536662|Experimental|Group hydrocortisone|
11034604|NCT04536662|Experimental|Group Prednisone|
11034605|NCT04536662|Experimental|Group Dexamethasone|
11034606|NCT04536649|Experimental|Standard-dose Photon Radiotherapy|The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)
11034607|NCT04536649|Experimental|Standard-dose Proton Radiotherapy|The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
11034608|NCT04536649|Experimental|Standard-dose Proton Radiotherapy plus Carbon-Ion Boost|The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).
11034609|NCT04536636|Active Comparator|Control|The patients on this arm received usual medical care
11034610|NCT04536636|Active Comparator|DHA supplementation|The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)
11034611|NCT04536623|Experimental|SIESTA-Rehab Protocol|This inpatient rehabilitation floor will be trained to implement the SIESTA-Rehab protocol. Nurses will be empowered to reduce unnecessary disruptions and subjects will be screened for sleep-disordered breathing. Subjects will utilize wearable sensor technology.
11034612|NCT04536623|No Intervention|Standard of Care|This inpatient rehabilitation floor will continue to implement usual care.
11034613|NCT04536610|Experimental|Experimental group|Providing structured OP education in addition to the informative leaflet. (The leaflet contained the same information as the OP education program)
11034614|NCT04536610|Active Comparator|Control group|Giving only the informative leaflet. (The leaflet contained the same information as the OP education program)
11034615|NCT04536597|Experimental|Quince seed jelly group|
11034616|NCT04536597|Experimental|Breast milk group|
11034617|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
11034618|NCT04536584|Experimental|Arm A: personalized coaching for physical activities|This arm consists of providing patients with a personalized coaching focused on exercise and physical activity, with or without connected watch.
11034619|NCT04536584|Active Comparator|Arm B: standard supportive approach|The standard supportive approach will consist in recommendations made during visits with the oncologist. The delivery of post-treatment care by oncologists and their team systematically provide exercise advice patients including recommendations for strength training and aerobic activity.
11034620|NCT04536571|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
11034621|NCT04536571|Active Comparator|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
11034622|NCT04536558|Experimental|olanzapine plus fosaprepitant-based triple regimen|Olanzapine（5mg p.o. d1-d5）plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
11034623|NCT04536558|Placebo Comparator|Placebo plus fosaprepitant-based triple regimen|Placebo plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
11034624|NCT04536532|Experimental|HEC121120 tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
11034625|NCT04536532|Placebo Comparator|HEC121120 placebo tablets|part 1(Health volunteer): single-Dose Study: There will be a total of 6 dose cohorts: 25 mg、50 mg、100 mg、400 mg、600 mg、800 mg food effect：200 mg multiple-dose study: 200 mg part 2(Patients with chronic hepatitis B): There will be a total of 3 dose cohorts:100、200、400 mg
11034626|NCT04536532|Active Comparator|entecavir tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
11034627|NCT04536532|Placebo Comparator|entecavir placebo tablets|part 2(Patients with chronic hepatitis B): 0.5 mg
11034628|NCT04536519|Active Comparator|Lateral Heel Wedged Insole Alone with physical therapy|"the lateral heel wedged insole (19) comprised non-custom, high density based on insoles of ethyl-vinyl acetate distributed bilaterally, preferably, covered in leather, were used in the study. The insole were equipped with a lateral wedge of 50 to 60.
~In the case of unilateral knee osteoarthritis, the non-wedge insole were used to compensate for possible leg length discrepancy in the contra-lateral leg. Shoes used was based on gymnast type to keep wedge insole in place. This further finalized individual to individual with unanimous decisions of Cordwainers, orthotics, and principal researcher, physiotherapist."
11034629|NCT04536519|Active Comparator|Lateral aand medial Heel Wedged Insole with physiotherapy|medial arch support part were combine with aforementioned lateral heel wedged support, full length support. There is a debate, however, 4 to 6 mm of full length support is considered to be effective for required alteration in mechanics
11034630|NCT04536506|Experimental|Treatment group|Bobath group received 45 min of sessions three times weekly for 12 weeks.
11034631|NCT04536506|Active Comparator|Control group|Vojta group received the following three times weekly for 12 weeks.
11034632|NCT04536493|Active Comparator|1 application|Patients receive single dose LET
11034633|NCT04536493|Active Comparator|3 applications|Patients receive 3 doses of LET
11034634|NCT04536480|No Intervention|Control: Habitual daily eating period|Control: Habitual daily eating period (no meal time restrictions)
11034635|NCT04536480|Experimental|Time Limited Eating|Time Limited Eating: 8-hour eating period (16 hours of daily fasting 5 days per week).
11034636|NCT04536467|Other|Goserelin arm|3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
11034637|NCT04536467|Other|control Arm|Standard chemotherapy
11034638|NCT04536454|Experimental|[18F]FPyGal|"Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.
~After the end of the neo-adjuvant therapy a tracer injection with [18F]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes."
11034639|NCT04536441|Experimental|Treatment|Ultra Brief Online Mindfulness-based Intervention
11034640|NCT04536441|Placebo Comparator|Control|This arm requires participants to answer questions about themselves.
11034641|NCT04536428|Experimental|ClearEndoclip|This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.
11034642|NCT04536428|Active Comparator|EZ clip|This arm is a group in whom EZ clip would be used for the treatment of bleeding.
11034643|NCT04536415|Experimental|Oseltamivir Phosphate 75 mg capsules (Yangtze River)|During the study session, healthy participants will be administered a single dose of Oseltamivir Phosphate capsules 75 mg of Yangtze River Pharmaceutical (Group) Co., Ltd., China under Fed condition.
11034644|NCT04536415|Active Comparator|Tamiflu capsules 75 mg (Genentech, Inc.)|During the study session, healthy participants will be administered a single dose of Tamiflu capsules 75 mg of Genentech, Inc. under Fed condition.
11034646|NCT04536389||group B|women with normal uterine cavity with hysteroscopically detected cervical abnormality.
11034647|NCT04536376|Experimental|Resilience Program|a 4 week program focused on improving resilience
11034648|NCT04536363|Active Comparator|Standard therapeutic protocol|"Dexamethasone (4mg ampoule, intravenous)
~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)
~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)
~Enoxaparin (40mg prefilled syringe)
~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)
~Low molecular weight heparin (5000IU prefilled syringe)"
11034649|NCT04536363|Experimental|Standard Therapeutic Protocol + PGE1 Analog|"Analog of PGE1 + Standard therapeutic protocol
~Standard medical treatment:
~Dexamethasone (4mg ampoule, intravenous)
~Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3)
~Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)
~Enoxaparin (40mg prefilled syringe)
~Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe)
~Low molecular weight heparin (5000IU prefilled syringe)"
11034650|NCT04536350|Experimental|Aviptadil Treatment|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
11034651|NCT04536350|Placebo Comparator|Placebo Treatment|Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days
11034652|NCT04536337|Experimental|ALG-000184|Oral tablet(s) of ALG-000184 in HV or CHB subjects once daily
11034653|NCT04536337|Placebo Comparator|Placebo|Oral tablet(s) of placebo in HV or CHB subjects once daily
11034654|NCT04536311|Experimental|awareness anesthesia|patients receive internal fixation for multiple rib fractures using paravertebral nerve block anesthesia in awareness status and keep spontaneous breath
11034655|NCT04536298|Active Comparator|Vitamin D|Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
11034656|NCT04536298|Placebo Comparator|Placebo|Placebo
11034657|NCT04536272|Active Comparator|Target of 2-2.5 times baseline aPTT (usual care, about 60-75)|Administration of heparin during ECLS with an aPTT target of 2-2.5 times baseline.
11034658|NCT04536272|Active Comparator|Target of 1.5-2.0 times baseline aPTT (45-60 sec.)|Administration of heparin during ECLS with an aPTT target of 1.5-2.0 times baseline.
11034659|NCT04536272|Active Comparator|LMWH guided by weight and renal function.|Administration of LMWH guided by weight and renal function during ECLS.
11034660|NCT04536259|Experimental|Video Default|"The case and response options participants in this group will be asked to consider is provided below.
~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.
~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.
~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
11034661|NCT04536259|Experimental|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.
~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.
~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.
~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
11034662|NCT04536259|Experimental|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.
~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.
~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.
~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
11034663|NCT04536246|Active Comparator|BQT Group|Procedure on this arm = bone quadriceps tendon reconstruction
11034664|NCT04536246|Other|SBHT Group|Procedure on this arm = single-bundle hamstring tendon reconstruction
11034665|NCT04536233|Placebo Comparator|control group|
11034666|NCT04536233|Experimental|experimental group|
11034667|NCT04536220||pancreatic mass diagnosed benign|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
11034668|NCT04536220||pancreatic mass diagnosed malignant|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
11034669|NCT04536207|Experimental|the study group|Group (A) the study group received cryotherapy
11034670|NCT04536207|No Intervention|the control group|Group (B) the control group not received cryotherapy
11034671|NCT04536194|Experimental|norepinephrine|infusion of norepinephrine with a adjusted dose to elevate 10% of mean arterial pressure
11034672|NCT04536194|Active Comparator|Dopamine|infusion of dopamine with a adjusted dose to elevate 10% of mean arterial pressure
11034673|NCT04536181|Placebo Comparator|3 months group|Subjects will receive 12-weeks of placebo following randomization
11034674|NCT04536181|Experimental|6 months group|12 Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone.
11034675|NCT04536155||patient with chronic pain|
11034676|NCT04536142||Brain tumors|Subjects with operable supratentorial brain tumors
11034677|NCT04536142||Healthy subjects|Healthy subjects
11034678|NCT04536129|Experimental|Group A: glaucoma|OSD patients with glaucoma
11034679|NCT04536129|Active Comparator|Group B: no glaucoma|OSD patients without glaucoma
11034680|NCT04536116|Experimental|MRI simulation|MRI simulation with a Virtual Reality headset
11034681|NCT04536116|No Intervention|Standard medical care|Standard medical care
11034682|NCT04536103||Cleveland Clinic Foundation (CCF) Volunteers|The group will be used for evaluating differences between standard T1rho and T2 imaging vs accelerated T1rho and T2 imaging techniques that will be developed from this study.
11034683|NCT04536103||Traveling Volunteers|The group will be recruited at CCF and be scanned at CCF, University of California San Francisco, University of Kentucky and Albert Einstein College of Medicine.
11034684|NCT04536103||ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).
11034685|NCT04536103||Group Matched to ACL tear Volunteers|This group will be recruited at CCF and scanned at baseline and 1-year at all of the three MR systems at CCF (Siemens, GE, Philips).Traveling Volunteers share the same inclusion and exclusion criteria as this group, therefore subjects can participate the study and serve as subjects within both groups
11034686|NCT04536090|Experimental|Isoquercetin (IQC-950AN)|1000 mg Isoquercetin b.i.d. on day 1, then 500 mg Isoquercetin b.i.d. for 27 more days, plus standard of care (as defined below)
11034687|NCT04536090|No Intervention|Standard of care|This arm will receive standard of care based on national guidelines. This may change as new information regarding best practice emerges.
11034688|NCT04536077|Experimental|CDX-1140 Monotherapy|Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.
11034689|NCT04536077|Experimental|CDX-1140 + CDX-301|Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.
11034690|NCT04536051|Experimental|Group 1a: single dose ChAdOx & paracetamol|Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol
11034691|NCT04536051|Active Comparator|Group 1b: single dose MenACWY & paracetamol|Participants will receive a single dose of MenACWY plus paracetamol
11034692|NCT04536051|Experimental|Group 1c: two dose ChAdOx & paracetamol|Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol
11034693|NCT04536051|Active Comparator|Group 1d: two dose MenACWy/saline & paracetamol|Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol
11034694|NCT04536038|No Intervention|Opt-in|Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the study, or to call or email the study coordinator with questions or for assistance in enrolling.
11034695|NCT04536038|Experimental|Opt-out|Patients randomized to opt-out framing will receive an email that frames participation in the study as part of the standard of care, and will be informed that a study coordinator will be calling them in the coming days to start enrollment in the study unless they opt out of participation.
11034696|NCT04536025||Prosthetists|Up to 24 prosthetists who are actively providing prosthetic care to people with lower limb amputation will be recruited for participating in focus groups to describe their decisional needs for providing prostheses to people with lower limb amputation.
11034697|NCT04536025||People with lower limb amputation|An estimated 14 people within 1 year from lower limb amputation, receiving their first prosthesis will be recruited for individual semi-structured interviews to describe their decisional needs for provision of a prosthesis.
11034698|NCT04536025||Expert working group|The expert working group will consist of at least 5 and up to 12 people with LLA actively receiving prosthetic care, and at least 5 and up to 12 prosthetic care providers with greater than 5 years of experience. Individuals will be invited to join the expert working group based on expertise, and representation of key stakeholders relevant to the prosthetic design process.
11034699|NCT04536012|No Intervention|Control|Via the Way to Health platform, all patients will receive daily text messages that inform them of their previous day's step count for 24 weeks.
11034700|NCT04536012|Experimental|Intervention|"Participants have a 4-week ramp-up towards their step goal and are asked to maintain the goal for the rest of the study. They receive daily texts informing them if they met their step goal and biweekly texts to encourage walking for exercise.
~Participants are entered into a game. Each week they receive 70 points. If the step goal was met they keep their points. If not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level. If not, they drop a level. Participants start in the middle of 5 levels.
~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and partner to discuss ways they can help the participant meet their goal. Every 8 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.
~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
11034701|NCT04535999|Experimental|Open Label|Secukinumab
11034702|NCT04535986|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
11034703|NCT04535986|Placebo Comparator|Arm 2|Placebo Nebulized BID
11034704|NCT04535973||study group|female postmenopausal women with burning mouth syndrome
11034705|NCT04535973||control group|female postmenopausal women without burning mouth syndrome
11034706|NCT04535960|Experimental|Liraglutide|Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks
11034707|NCT04535960|Experimental|Empagliflozin|Empagliflozin Tablets Total Dose 25mg daily for 6 weeks
11034708|NCT04535947|Placebo Comparator|Vehicle|Vehicle
11034709|NCT04535947|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Active
11034710|NCT04535934||1 dose/week followed by 4 doses/week|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 1 dose/week followed by 4 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
11034711|NCT04535934||3 doses/week followed by 7 doses/week.|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 3 doses/week followed by 7 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
11034712|NCT04535921||Prostatectomy|FCR7 questionnaire pre and postoperative
11034713|NCT04535921||Cystectomy|FCR7 questionnaire pre and postoperative, 6 months follow
11034714|NCT04535921||Nephrectomy|FCR7 questionnaire pre and postoperative
11034715|NCT04535921||Orchidectomy|FCR7 questionnaire pre and postoperative
11034716|NCT04535908|Experimental|Hypofractionated radiotherapy|
11034717|NCT04535895|Experimental|Simultaneous integrated boost arm|
11034718|NCT04535869|No Intervention|A)standard therapy group|No intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol
11034719|NCT04535869|Active Comparator|B)Standard Therapy group plus Ant-HCV drugs|Intervention COVID- 19 patients who received a standard therapy group according to the ministry of health protocol plus sofosbuvir 400 mg and Daclatasvir 200mg
11034874|NCT04534699|Experimental|Matched-control Healthy|KBP-5074 0.5mg tablet orally, Single dose
11034720|NCT04535856|Experimental|Low-dose group|"Low-dose group (5 x 10^7cells):
~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 2 vials for low-dose group"
11034721|NCT04535856|Experimental|High-dose group|"High-dose group (1 x 10^8 cells):
~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 4 vials for High-dose group"
11034722|NCT04535856|Placebo Comparator|Control group (placebo)|"Control group (placebo):
~No Drug substance: 4 vials for Place group"
11034723|NCT04535843||myasthenia gravis|300 MG patients are anticipated for precision diagnosis and disease monitoring.
11034724|NCT04535830|Experimental|Flash glucose monitor system(FSL)|Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month.
11034725|NCT04535830|No Intervention|Self-monitoring blood glucose(SMBG)|People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month.
11034726|NCT04535817|Experimental|Treatment Group|Subjects will receive subcutaneous treatment of 300mg of omalizumab during the 24-week treatment period. One injection will be administered every 4 weeks.
11034727|NCT04535804|Active Comparator|Aspirin group|100 mg of low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
11034728|NCT04535804|Placebo Comparator|placebo group|100 mg of placebo was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
11034729|NCT04535791|Experimental|cholecalciferol (Vitamin D)|cholecalciferol 4,000 IU orally daily for 30 days
11034730|NCT04535791|Placebo Comparator|Starch|Starch 500 mg orally daily for 30 days
11034731|NCT04535778|Experimental|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. Participants will also have access to the standard charity resources.
11034732|NCT04535778|Active Comparator|Standard charity resources|Participants will be directed to the standard resources provided by the charities involved in the study.
11034733|NCT04535765|Experimental|experimental group|The experimental group began to perform warm water sitz bath 6 hours after the operation (the day of the operation).Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
11034734|NCT04535765|Other|control group|The control group began to perform warm water sitz bath at 8:00 in the morning on the first day after the operation as usual.Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
11034735|NCT04535752|Experimental|ANX009, Single Ascending Doses|Single dose of ANX009 with a 7-day follow-up before escalation to the next dose level.
11034736|NCT04535752|Placebo Comparator|Placebo, Single Ascending Doses|Single doses of matching placebo
11034737|NCT04535752|Experimental|ANX009, Multiple Ascending Doses|ANX009 once daily on Days 1-14
11034738|NCT04535752|Placebo Comparator|Placebo, Multiple doses|Matching placebo once daily on Days 1-14
11034739|NCT04535739|Experimental|PCI group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。
11034740|NCT04535739|Other|control group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。
11034741|NCT04535713|Experimental|Single arm|A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.
11034742|NCT04535700|Experimental|pioglitazone|
11034743|NCT04535700|Other|Standard of care treatment|
11034744|NCT04535687|Experimental|Treatment group|Fluzoparib alone
11034745|NCT04535674|No Intervention|Standard of Care|
11034746|NCT04535674|Experimental|Standard of Care + Asunercept 25 mg|
11034747|NCT04535674|Experimental|Standard of Care + Asunercept 100 mg|
11034748|NCT04535674|Experimental|Standard of Care + Asunercept 400 mg|
11034749|NCT04535661||non CRE|Children with a negative culture for CRE during their stay in PICU are defined as non CRE.
11034750|NCT04535661||CRE colonization|Children who have a positive culture for CRE during their stay in PICU but lack of clinical symptoms are defined as CRE colonization.
11034751|NCT04535661||CRE infection|Children who have a positive culture for CRE during their stay in PICU combined with clinical symptoms are defined as CRE infection.
11034752|NCT04535635|Experimental|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
11034753|NCT04535635|Placebo Comparator|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
11034754|NCT04535622|Experimental|Exercise group|A structured exercise instruction for facedown posture-related pain will be provided to the patients, and patients will go through three times of self-exercise sessions everyday according to the training provided.
11034755|NCT04535622|No Intervention|Control group|Patients are going to maintain face-down posture but no specific exercise instruction will be provided.
11034756|NCT04535609|Experimental|REN001|Once daily
11034757|NCT04535609|Placebo Comparator|Matched placebo|Once daily
11034758|NCT04535596|Experimental|Conventional Exercises|12 week long strength training exercise with the higher loading (%70-80 of 1 Repetitive Maximum)
11034759|NCT04535596|Experimental|Blood Flof Restriction Exercises|12 week long strength training exercise with the lower loading (%20-30 of 1 Repetitive Maximum) by using cuff around the thigh
11034760|NCT04535583||EMA plus passive sensing|Participants will be responding to up to 3 ecological momentary assessments per day plus carrying a smartphone and wearing a smartwatch. Both the smartphone and smartwatch will passively collect sensor data continuously.
11034761|NCT04535570||Pre Transplant|All 30 volunteers will have the energy expenditure measured in the pre-transplantation in order to compare with post-transplant data.
11034762|NCT04535570||Post Transplant|All 30 volunteers will have the energy expenditure measured in the post transplantation in order to compare with the pre-transplant data.
11034763|NCT04535544|Experimental|Immediate Active Treatment arm: JNJ-73763989 + NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection every 4 weeks (Q4W) along with NA (entecavir [ETV], tenofovir disoproxil, or tenofovir alafenamide [TAF]) once daily for 144 Weeks in Part 1 and 2.
11034764|NCT04535544|Placebo Comparator|Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA|Participants will receive matching placebo to JNJ-73763989 SC injection Q4W along with NA (ETV, tenofovir disoproxil, or TAF) once daily for 52 Weeks followed by JNJ-73763989 SC injection Q4W along with NA once daily for 96 weeks in Part 1 and 2.
11034765|NCT04535531|Experimental|SB206 10.3% berdazimer|SB206 10.3% berdazimer topically once daily
11034766|NCT04535531|Placebo Comparator|vehicle gel|Vehicle gel topically once daily
11034767|NCT04535518|Active Comparator|the standard group|"IVIG 2 g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
11034768|NCT04535518|Experimental|the standard + infliximab group|"IVIG 2 g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
~Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours."
11034769|NCT04535505||pertussis test population|People with clinical diagnosis of suspected pertussis in outpatient and ward in the Children's Hospital of Fudan University will be collected as study subjects. Their nasopharyngeal swabs will be collected. Bordetella isolation culture and identification method is the gold standard, and the new CPA platform based on CRISPR technology is the method to be tested. Diagnostic values of this research platform would be detected.
11034770|NCT04535492||Colorectal Cancer Screening Recommended|The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
11034771|NCT04535492||Lung Cancer Screening Recommended|The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults ages 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
11034772|NCT04535492||Breast Cancer Screening Recommended|The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.
11034773|NCT04535479|Experimental|Individuals with spasticity resulting from stroke|This is an experimental intervention in which individuals will receive dry needling to relieve spasticity in the target muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
11034774|NCT04535479|Experimental|Individuals with no known neurological injury|This is an experimental intervention in which individuals will receive dry needling of an arm or leg muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
11034775|NCT04535453|Experimental|Groups 1-6|Participants will receive Ad26.COV2.S at 2-dose (Groups 1-3) vaccination regimen at different dose levels or single-dose vaccination regimen (Groups 4-5) at different dose levels or placebo (Group 6) on Days 1 and 57.
11034776|NCT04535453|Experimental|Groups 7-8|Participants will receive Ad26.COV2.S at 2-dose (Group 7) vaccination regimen at a fixed dose level or placebo (Group 8) on Days 1 and 29.
11034777|NCT04535453|Experimental|Groups 9-10|Participants will receive Ad26.COV2.S at 2-dose (Group 9) vaccination regimen at a fixed dose level or matching placebo (Group 10) on Days 1 and 85.
11034778|NCT04535440||Rectal varices with bleed|
11034779|NCT04535440||Rectal varices without bleed|
11034780|NCT04535427|Placebo Comparator|Control|Participants in this arm will receive placebo per day.
11034781|NCT04535427|Experimental|Low dose L-arginine|Participants in this arm will receive 9g (3g tid) L-arginine per day.
11034782|NCT04535427|Experimental|High dose L-arginine|Participants in this arm will receive 15g (5g tid) L-arginine per day.
11034783|NCT04535414|Experimental|1/Arm 1|Bethesda protocol (investigational)
11034784|NCT04535414|Active Comparator|2/Arm 2|Cambridge method (control) with confocal endomicroscopy
11034785|NCT04535401|Experimental|Treatment (BAY 1895344, usual chemotherapy)|Patients receive BAY 1895344 PO BID on days 1, 2, 15, and 16 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity.
11034786|NCT04535388|Other|LK scleral lens|LK scleral lens (Lucid Korea LTD, Seoul, Republic of Korea) are worn for 12 weeks.
11034787|NCT04535375|Other|Preterm infants < 28 weeks gestational age|For infants born before 28 0/7 weeks, standard of care consists of brain ultrasound performed on admission, day 1, day 2, day 3, day 7, and then weekly until discharge.
11034788|NCT04535375|Other|Preterm infants born between 28 0/7 and 31 6/7 weeks|For infants born between 28 0/7 and 31 6/7 weeks, brain ultrasound is performed on admission, once between day 1 and 3, once between day 7 and 10, and then 2-weekly until discharge or transfer.
11034789|NCT04535362|Active Comparator|menthol cigarettes|Will smoke only menthol cigarettes for two weeks
11034790|NCT04535362|Active Comparator|non menthol cigarettess|Will only smoke non menthol cigarettes for two weeks
11034791|NCT04535349|Other|No cardiac ATTR amyloidosis|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).
~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging Perugini 0 : no cardiac TTR amyloidosis No further follow-up."
11034792|NCT04535349|Other|Cardiac ATTR amyloidosis, no treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).
~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis but no treament with tafamidis planned.
~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
11034793|NCT04535349|Other|Cardiac ATTR amyloidosis, treatment with tafamidis planned|"Cardiac echocardiography at baseline and whole-body & CZT bone tracer imaging (SPECT).
~day 3 - day 10 : second whole-body & CZT bone tracer imaging (SPECT), test-retest Bone tracer imaging demonstrating cardiac ATTR amyloidosis. Start of the treament with tafamidis.
~Cardiac echocardiography at 3 months and whole-body & CZT bone tracer SPECT and cardiac echocardiography at 6 months"
11034794|NCT04535336|Experimental|Vitality acupunch (VA)|The VA program takes 40 minutes to complete and includes 3 phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allows the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands will be used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group will receive the VA program led by the instructors, who are trained and certified by the PI, 3 times per week and 40 minutes per session for 6 months.
11034795|NCT04535336|Active Comparator|Control|Participants in the control group will continue with their daily activities as usual.
11034796|NCT04535323|Experimental|Treatment Group|Platelet rich plasma will be administered in an array of 6 locations inside the vagina. Each array will receive 5 injections of 0.2 ml PRP. An additional 5 injections of 0.2 ml PRP will be injected at the entrance of the vagina for a total of 7 ml PRP.
11034797|NCT04535310|Experimental|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for a total of two weeks.
11034798|NCT04535284|Experimental|Coaching|"Health Coaching-in-Context includes coaching by trained coaches up to 10 sessions over teleconference."
11034799|NCT04535284|No Intervention|Usual Care|The usual care group does not get any intervention but continues with any of their usual activities that would otherwise would have been provided to them.
11034800|NCT04535271|Experimental|Single arm|Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8
11034801|NCT04535258|Other|First-movers|The first four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
11034802|NCT04535258|Other|Second-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
11034803|NCT04535258|Other|Third-movers|After three months, the next five alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
11034804|NCT04535258|Other|Fourth-movers|After three months, the last four alcohol clinics offers internet-based treatment to the patients who chooses the proportion of internet-based sessions.
11034805|NCT04535245||LCI testing|LCI testing will be performed on all study subjects
11034806|NCT04535219|Experimental|Group A|Participants will have vascular function assessed following total sleep deprivation
11034807|NCT04535219|No Intervention|Group B|Participants will have vascular function assessed following a full night of sleep
11034808|NCT04535219|Experimental|Group C|Participants will have vascular function assessed following total sleep deprivation preceded by exercise
11034809|NCT04535219|No Intervention|Group D|Participants will have vascular function assessed following a full night of sleep
11034810|NCT04535206||With AT-Ⅲ, PC, PS activity decreased|Any decreased in AT-Ⅲ, PC, PS activity before catheter intubation is regarded as the exposure group
11034811|NCT04535206||AT-Ⅲ, PC, PS activity are at normal value|The activities of AT-Ⅲ, PC and PS are all at normal values before catheter intubation
11034812|NCT04535193|Other|Low likelihood of coronary heart disease|Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration.
11034813|NCT04535193|Other|Heart Failure + left ventricular function (LVEF ≤ 35%)|Thorax and total body imaging for quantification of myocardial sympathetic innervation. PET imaging to 100 minutes post-administration
11034814|NCT04535180||Hemophilia|
11034815|NCT04535167|Experimental|PF-07304814|"Part 1:
~Cohort 1-5
~Part 2:
~Cohort 6,7"
11034816|NCT04535167|Placebo Comparator|Placebo|"Part 1:
~Cohort 1-5
~Part 2:
~Cohort 6,7"
11034817|NCT04535141|Experimental|Olanzapine Arm|Olanzapine 5mg tablet with chemotherapy, and 3 days after
11034818|NCT04535141|Placebo Comparator|Placebo Arm|
11034819|NCT04535128||COVID-19 Positive|Patients with positive COVID-19 PCR
11034820|NCT04535115|Experimental|Group 1|Starting LRM (Lung Recruitment Maneuver)
11034821|NCT04535115|Experimental|Group 2|Starting VtC (Tidal Volume Challenge)
11034822|NCT04535102|Experimental|Polatuzumab + BR (minimum 3 cycles)|Patients will be treated with a minimum of 3 cycles up to a maximum six cycles to optimize response prior to ASCT (stem cell transplant) per investigator discretion
11034823|NCT04535089|Active Comparator|dexmedetomdine|IV bolus dose of 0.5ug/kg dexmedetomidine diluted in 10ml saline 1% over ten minutes followed by continuous infusion of 0.5ug/kg/h
11034824|NCT04535089|Active Comparator|lidocaine|IV bolus dose of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h
11034825|NCT04535076|Experimental|Transcatheter Aortic Valve Implantation|
11034826|NCT04535076|Active Comparator|Surgical Aortic Valve Replacement|
11034827|NCT04535063|Other|severe pneumonia arm|patients with severe COVID19 pneumonia defined by: spontaneous breathing patients with respiratory failure requiring O2 nasal cannula more than 3 L/min or reservoir oxygen mask and SaO2 less than 95% or patients with critical pneumonia define by mechanical ventilation with less than 300 mmHg PaO2/FiO2 or shock or multi-organic dysfunction
11034828|NCT04535050|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization
11034829|NCT04535050|Sham Comparator|Sham control|Subjects are treated with renal angiography
11034830|NCT04535037|Experimental|DTPa-HBV-IPV/Hib Investigational Group|All subjects in this group receive 3 doses (2 primary doses and 1 booster dose) of DTPa-HBV-IPV/Hib vaccine co-administered with 3 doses of pneumococcal 13-valent conjugate vaccine at 2, 4, and 12 months of age.
11034831|NCT04535037|Active Comparator|DTaP5-HBV-IPV-Hib Comparator Group|All subjects in this group receive 3 doses (2 primary doses and 1 booster dose) of DTaP5-HBV-IPV-Hib vaccine co-administered with 3 doses of pneumococcal 13-valent conjugate vaccine at 2, 4, and 12 months of age.
11034832|NCT04535024|Experimental|Treatment Arm|"A total of 60 MSS oligometastatic colorectal cancer patients will receive multisite SABR followed by Sintilimab within one week from completion.
~The dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
11034833|NCT04535011|No Intervention|Usual Care|No prevention or educational information verbally or written coinciding with current usual care
11034834|NCT04535011|Experimental|PPKAY|One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use
11034835|NCT04535011|Experimental|PPKAY with Standard Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use.
~Weekly standard text booster until final follow-up (e.g., Reducing your alcohol intake to less than 4 drinks per day reduces your risk of alcohol-related consequences)"
11034836|NCT04535011|Experimental|PPKAY with Personalized Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use Weekly personalized text booster until final follow-up (e.g., Remember to reduce your alcohol less than 4 drinks to achieve your goal of… [being a better husband].)"
11034837|NCT04534998|Experimental|Robotic-assisted partial nephrectomy|Partial nephrectomy will be performed using a robotic-assisted laparoscopic approach.
11034838|NCT04534998|Active Comparator|Open partial nephrectomy|Partial nephrectomy will be performed using an open retroperitoneal approach.
11034839|NCT04534985|Experimental|Time Restricted Feeding|Instructed to eat within an 8-hr window, beginning within 3 hrs of waking. In addition, provide current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
11034840|NCT04534985|Active Comparator|Healthy Eating Advice without Time Restricted Feeding|Curriculum for the healthy eating control group will emphasize current clinical recommendations for the management of ADPKD, as well as chronic kidney disease, including moderate dietary sodium restriction (2.3-3 g), appropriate hydration, protein intake of 0.8/1.0 g/kg ideal body weight, moderate daily phosphate restriction (800 mg), and moderation in caloric intake.
11034841|NCT04534972||Pre-Implementation|The control (pre-implementation) group will be burn patients admitted to the ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
11034842|NCT04534972||Post-Implementation Targeting Normoxia in Burn ICU|The intervention (post-implementation) group will be patients admitted to the burn ICU during the targeting normoxia intervention period of the stepped-wedge design implementation process (up to 19 months).
11034843|NCT04534959|No Intervention|Pre-Implementation|The control (pre-implementation) group will be trauma patients admitted to the surgical/trauma ICU during the site's control period of the stepped-wedge implementation process (up to 22 months).
11034844|NCT04534959|Experimental|Post-Implementation Targeting Normoxia in Trauma ICU|The intervention (post-implementation) group will be patients admitted to the surgical/trauma ICU during the targeted normoxia intervention period of the stepped-wedge implementation process (up to 25 months).
11034845|NCT04534933|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during thoracic surgery. Individualisation will be established by compliance guided end-expiratory and peak pressure setting during double lung ventilation as well as one lung ventilation, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
11034846|NCT04534933|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during thoracic surgery. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure in double lung ventilation and 6ml/kg PBW in one lung ventilation. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
11034847|NCT04534907|Active Comparator|VR(ERP）|The combination of exposure and response prevention (ERP) and VR will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
11034848|NCT04534907|Active Comparator|traditional ERP|The traditional ERP will be applied twice a week for the fist two weeks. For the next four weeks, this treatment will be applied once a week. 8 times in total
11034849|NCT04534894||DM group and DCM group|DM group: type 2 diabetes with normal diastolic function DCM group: type 2 diabetes with diastolic dysfunction
11034850|NCT04534881|Active Comparator|progesterone|subjects on active drug (progesterone)
11034851|NCT04534881|Placebo Comparator|placebo|subjects on placebo
11034852|NCT04534868|Other|Patient Acceptance and satisfaction for teledermoscopy|"The aim of the first part of the study is to evaluate patients' skin monitoring habits, their knowledge of skin cancer, and their preconceptions about new telemedicine tools such as teledermoscopy. This is a written quantitative questionnaire with answers to tick.
~An explanatory folder will be given to patients and they will be asked to read it beforehand in order to allow a good understanding of the terms used and the goal of the project. This part will include 70 to 100 patients.
~The second part of the study is a qualitative study and the aim of it is to evaluate the satisfaction, acceptance and future expectations of those who have benefited from teledermoscopy. Individual and anonymous interviews, lasting 15 to 20 minutes, intended for patients who have benefit of teledermoscopy at the office. An explanatory folder will also be given to the patients concerned in order to explain to them the procedure of the interview. This part will include 8 to 10 patients."
11035571|NCT04529811|Experimental|Formulation 2 - Low Dose|Rifaximin Formulation 2 Capsules
11034853|NCT04534855|Experimental|Treprilimab treatment group|Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity
11034854|NCT04534842|Experimental|SYNB1618|Dose ramp of SYNB1618
11034855|NCT04534829|Experimental|Ultrasound-Guided SIJ RFA|"Utilizing short axis views, the S1, S2 and S3 foramen and tubercles would be localized and marked by a surgical skin marker. Then, the ultrasound transducer will be moved laterally to achieve a long axis view between the S1 and S2 tubercle. Local skin and subcutaneous tissue freezing would be performed with Lidocaine 1% utilizing a 30-gauge needle. An 18-gauge radiofrequency (RF) cannula will be directed utilizing an in-plane approach toward the S2 and S3 lateral branches between the S2 and S3 tubercles. A small amount of 1% lidocaine will be injected in order to provide comfort.
~The RF generator will be set to continuous monopolar RF ablation and the needle will be heated to 80 degrees Celsius for 90 seconds. The needle will then be repositioned proximally to obtain a slightly larger burn in a similar fashion previously described. A similar approach will be utilized for the S1 lateral branch RF ablation between the S1 and S2 tubercles."
11034856|NCT04534829|Active Comparator|Fluoroscopic-Guided SIJ RFA|An anterior-posterior approach is used to identify the S1-S3 foramen. A 3-inch spinal needle would be used for marking. Local tissue freezing would be accomplished with Lidocaine 1% and a 30-G needle. An 18-G RF cannula will be positioned over the 12 o'clock position of the S1 foramen and a second cannula placed in the 2 o'clock or 10 o'clock position for the right and left respectively (4-5 mm distance between the cannula). A small amount of 1% lidocaine will be injected for comfort. A lateral projection is taken to ensure the needles are not placed into the foramen. The RF generator will be set to continuous bipolar RF ablation and heated to 80 degrees Celsius for 90 seconds. Then another 18-G RF cannula will be positioned at the 4 o'clock or 8 o'clock position (4-5 mm distance between the cannula) to achieve the second RF ablation. The third RF ablation will be performed with the RF cannula at the 6 o'clock position. An identical fashion is utilized at the S2 and S3 foramen.
11034857|NCT04534816|Experimental|Indocyanine Green|patients abdominal injuries and repair will be investigated using Indocyanine Green
11034858|NCT04534803|Experimental|BCG Vaccine|Participants randomized to the BCG arm will receive BCG vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
11034859|NCT04534803|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm.
11034860|NCT04534790|No Intervention|Not radiotherapy|control group
11034861|NCT04534790|Experimental|Radiotherapy|patientis with treatment with radiotherapy 1 Gy to Whole lung.
11034862|NCT04534777||Consciousness disorder patients|"The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.
~Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years."
11034863|NCT04534751|Experimental|Intervention Group- Clotting Factor Concentrates|"Fibryga + Octaplex (Fibrinogen + PCC)
~Fibrinogen Concentrate 4g (Fibryga) + Prothrombin Complex Concentrate 2000 IU (Octaplex) in the first and second massive hemorrhage protocol (MHP) packs."
11034864|NCT04534751|Active Comparator|Control Group: Standard FP transfusion|Frozen Plasma (FP)
11034865|NCT04534738|Experimental|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
11034866|NCT04534738|No Intervention|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
11034867|NCT04534725|Experimental|prophylaxis|"This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months.
~Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections."
11034868|NCT04534725|Experimental|Post-Exposure Prophylaxis|"This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days
~Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections."
11034869|NCT04534725|Experimental|Moderate COVID-19 infection|"This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks
~Participants will be followed for 60 days to assess effectiveness and safety."
11034870|NCT04534725|Experimental|Severe COVID-19 infection|"This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.
~Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours.
~Participants will be followed for 60 days to assess effectiveness and safety."
11034871|NCT04534712||PROGRESSION|Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
11034872|NCT04534712||NON PROGRESSION|Cohort B with those who improved by two points on the ordinal scale without any further progression
11035715|NCT04528953|Experimental|Qigong exercise|
11034875|NCT04534686|Experimental|CogXergaming|CogXergaming based cognitive-motor balance training will be delivered to group A using the commercially available Wii-Fit Nintendo and a mouse in conjunction with cognitive training. All participants will undergo 18 sessions of training in a tapering manner for six weeks with 60-90 minutes of training per session, i.e., 3 sessions each week till the 6th week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 to 6 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
11034876|NCT04534686|Experimental|Matter of Balance Training|Participants in group B will undergo matter of balance training for 8 weeks (one session a week for 2 hours/day).
11034877|NCT04534673|Experimental|Intervention group|Pegylated interferon lambda + Standard of care treatment
11034878|NCT04534673|No Intervention|Control group|Standard of care treatment
11034879|NCT04534660|Experimental|Nasolabial Fold|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.
~The study treatment facial areas are the Right and Left nasolabial fold. The Treating Investigator will inject SMI-01 into the mid to deep dermis for correction of moderate to severe wrinkle and folds. The Treating Investigator will determine the appropriate volume of SMI-01 to be injected during initial and touch-up treatment(s)."
11034880|NCT04534660|Experimental|Cheek Augmentation|"SMI-01 is an injectable device comprising silk particles distributed in a hydrogel carrier. The intervention will be administed once, at the Day 1 visit. An optional touch-up treatment is allowed at the Day 30 visit.
~The midface constitutes the area of the face below the eyes and between the nose and the left or right ear. The study treatment facial areas are the Right and Left cheeks. The Treating Investigator will inject SMI-01 deeply (subcutaneous and/or supraperiosteal plane) for cheek augmentation to correct age-related volume deficiency in the midface, i.e., zygomaticomalar region, anteromedial cheek, and/or submalar region"
11034881|NCT04534634|Experimental|Experimental group|IFN-α combined with CAR T-cells therapy
11034882|NCT04534634|No Intervention|Control group|CAR T-cells therapy
11034883|NCT04534621||Brazilian chiropractors|A cross-sectional survey will be performed with this population (Brazilian chiropractors) to assess outcomes regarding what is the current impact and what measures they have implemented while facing the COVID-19 pandemic.
11034884|NCT04534608||Asymptomatic children w/out an underlying condition|
11034885|NCT04534608||Asymptomatic children with underlying condition(s)|
11034886|NCT04534608||Children with COVID-19 symptoms w/out an underlying condition|
11034887|NCT04534608||Children with COVID-19 symptoms with underlying condition(s)|
11034888|NCT04534595||Students attending SBHCs|The students enrolled in 5 schools with the school based health clinic implemented would be studied in terms of their experience during the COVID-19 pandemic.
11034889|NCT04534582|Experimental|HLX14 group|HLX14 are given subcutaneous injection at a single dose of 60 mg.
11034890|NCT04534582|Active Comparator|EU-Prolia® group|EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
11034891|NCT04534556|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
11034892|NCT04534556|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
11034893|NCT04534543|Other|Imaging|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
11034894|NCT04534530||Experimental|"The experimental group systematic screening for ischemic heart disease will be identified during the screening period by performing at least one systematic screening examination, regardless of the frequency, for ischemic heart disease in patients. diabetics at very high cardiovascular risk, without known coronary heart disease, by at least one non-invasive functional cardiovascular exploration outside the resting ECG."
11034895|NCT04534530||Control|"The control group Absence of systematic screening for ischemic heart disease will be identified during the pre-selection period by the absence of a non-invasive functional cardiovascular exploration (examinations mentioned above) in T2D with very high cardiovascular risk, with no known coronary heart disease, apart from performing a resting ECG"
11034896|NCT04534517|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age will be recruited. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
11034897|NCT04534504|Experimental|SG-uncut JJB|For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
11034898|NCT04534504|Active Comparator|SG-JJB|For SG-JJB procedure, after SG was finished, the jejunum was transected 20-cm distal to Treiz ligament. After that, another 200-cm jejunum was measured and side-to-side jejunojejunal anastomosis was made. The anastomotic and mesenteric defects were closed by hand suture.
11034899|NCT04534491|Experimental|Oxytrol|Subjects decided to purchase Oxytrol.
11034900|NCT04534478|Active Comparator|Control Group|Prednisone 0.75mg / Kg / d 4 weeks; 0.5mg / Kg / d 4 weeks; 20mg / d 4 weeks; 10mg / d 6 weeks; 5mg / d 6 weeks (6m)
11034901|NCT04534478|Active Comparator|Experimental group|Prednisone 0.5mg / Kg / d 3 weeks, 20mg / day 3 weeks; 15mg / day 2 weeks; 10mg / day 2 weeks, 5mg / day 2 weeks and discontinue.
11034902|NCT04534465|Experimental|Dosing arm 1|MiraLAX Sachet (17g) + Flavor blend (2g mannitol total)
11034903|NCT04534465|Experimental|Dosing arm 2|MiraLAX Sachet (17g) + Flavor blend + additional 2g mannitol (4g mannitol total)
11034904|NCT04534465|Experimental|Dosing arm 3|MiraLAX Sachet (17g) + Flavor blend + additional 4g mannitol (6g mannitol total)
11034905|NCT04534465|Experimental|Dosing arm 4|MiraLAX Sachet (17g) + Flavor blend + additional 6g mannitol (8g mannitol total)
11034906|NCT04534465|Experimental|Dosing arm 5|MiraLAX Sachet (17g) + Flavor blend + additional 8g mannitol (10g mannitol total)
11034907|NCT04534452|Experimental|Phenylephrine HCl|Subjects have a documented and/or self-reported history of allergic rhinitis with nasal congestion for at least 2 years.
11034908|NCT04534439|Experimental|APX-115|Oral administration of APX-115 400mg, daily
11034909|NCT04534439|Placebo Comparator|Placebo|Oral administration of APX-115-matching placebo 400mg, daily
11034910|NCT04534426|Active Comparator|Postoperative topical arnica montana cream|In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
11034911|NCT04534426|Active Comparator|Postoperative topical mucopolysaccharide polysulfate cream|In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
11034912|NCT04534426|Other|Control group|In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
11034913|NCT04534400||Patients with SARS-CoV-2 infection|
11034914|NCT04534400||Patients with Postoperative hypoxemic respiratory failure|
11034915|NCT04534387|Experimental|Experimental Group|This group will receive the Spanish-Language Hearing Loss Toolkit materials.
11034916|NCT04534387|Active Comparator|Active Control Group|This group will receive standard of care Spanish language information from the American Speech-Language-Hearing Association (ASHA) Audiology Series
11034917|NCT04534374|Experimental|Resistance exercise|The experimental intervention is a session of resistance exercise described in the intervention section.
11034918|NCT04534374|Active Comparator|Stretching exercise|The active control intervention is a session of stretching exercise described in the intervention section.
11034919|NCT04534348||Control|All central-line-associated blood stream infections (CLABSI) diagnosed during the year previous the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
11034920|NCT04534348||CUROS|All central-line-associated blood stream infections (CLABSI) diagnosed during the year after the implementation of 70% isopropyl alcohol-impregnated Curos catheter caps
11034921|NCT04534309|Other|Self-Directed Weight Loss with year-long weight tracking|Written Weight Loss Material.
11034922|NCT04534309|Other|App-Directed Weight Loss with year-long weight tracking|Smart phone Weight Loss App.
11034923|NCT04534309|Other|Coach-Directed Weight Loss with year-long weight tracking|Behavioral Lifestyle Weight Loss Intervention with Smart phone Weight Loss App.
11034924|NCT04534296|Experimental|EM group|Early mobilization will be performed in this arm. Cricically ill children will be assessed for approriate activity within 24 hours of intubation. When the safe criteria is met, early mobilization goals will be set according to the chilren's clinical conditions, developmental maturity, strength and endurance. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily.
11034925|NCT04534296|Active Comparator|RC group|Routine care strategy without early mobilization will be performed in this arm. It includes the clinical status management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
11034926|NCT04534283|Experimental|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
11034927|NCT04534270|Experimental|Dapagliflozin treatment|
11034928|NCT04534257|Experimental|Angioplasty with SELUTION Sirolimus DCB|Subjects with infra-inguinal occlusive lesions will be treated with SELUTION Sirolimus DCB
11034929|NCT04534244|No Intervention|Control group|Treatment of the tributary veins by phlebectomy
11034930|NCT04534244|Experimental|Experimental group|Endovenous steam treatment of the tributary veins
11034931|NCT04534218|Experimental|Experimental|"REGORAFENIB:
~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).
~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.
~METRONOMIC CHEMOTHERAPIES:
~Capecitabine: 625mg/m²/orally twice daily continuously until progression
~Cyclophosphamide: 50 mg per os, daily, for 6 months
~ASPIRIN:
~75 mg orally and daily until progression"
11034932|NCT04534205|Experimental|Part A (Safety run-In) - BNT113 + Pembrolizumab|Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
11034933|NCT04534205|Experimental|Part B (Randomized phase) - BNT113 + Pembrolizumab|BNT113 in combination with pembrolizumab.
11034934|NCT04534205|Active Comparator|Part B (Randomized phase) - Pembrolizumab monotherapy|Pembrolizumab monotherapy.
11034935|NCT04534192|Experimental|JADE balloon|Non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C & D lesions in patients with chronic limb threatening ischemia.
11034936|NCT04534179|Experimental|Vacuum myofascial therapy and physical activity|The protocol would last 5 weeks, group received fifteen 30-minute sessions of vacuum myofascial therapy and fifteen sessions physical activity program similar to the control group per week.
11034937|NCT04534179|Active Comparator|Physical activity Program|The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 30 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
11034938|NCT04534153|Experimental|Fexofenadine without SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
11034939|NCT04534153|Experimental|Fexofenadine and 3 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
11034940|NCT04534153|Experimental|Fexofenadine and 30 mg SLS|Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
11034941|NCT04534140|Experimental|HBKB Capsule|Experimental group participants will take one capsule of the HBKB botanical dietary supplement orally, once daily
11034942|NCT04534140|Placebo Comparator|HBKB Capsule Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
11034943|NCT04534127|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11034944|NCT04534114|Placebo Comparator|Pooled Placebo|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
11034945|NCT04534114|Experimental|40 mg BAY2976217|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
11034946|NCT04534114|Experimental|80 mg BAY2976217|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
11034947|NCT04534114|Experimental|120 mg BAY2976217|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
11034948|NCT04534101||Inpatient Subjects|Inpatients will be presented with an informed consent. If they sign the consent, they will then be given a VR headset pre- programmed with content that they may use for the duration of their stay. GI patients headsets will be collected when they are discharged. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford. Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered. Patient who are hospitalized for chronic pain will be allowed to take the VR headset home for month and be asked to return it at their followup outpatient visit.
11034949|NCT04534101||Outpatient Subjects|Outpatient: Patient's who are about to undergo gastrointestinal disease testing or be seen for an outpatient GI appointment will be presented with an informed consent. If they sign the consent, they will be given the VR headset to use prior to their procedure. There are pain and anxiety analog scales at the end of each program. This data will be downloaded to Stanford Medicine Box.Patient's will not be entering their PHI. we will know who has headsets, as they will be numbered.
11034950|NCT04534088|Active Comparator|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|The VR tool was an attention control and was not weight related.
11034951|NCT04534088|Experimental|Standard Behavioral Weight Loss plus Weight-Related VR app|The Intervention's VR tool was designed to enable practice of behavioral skills taught in weekly group meetings, including managing social and home environmental cues for eating and activity.
11034952|NCT04534075|Experimental|Additional dietary fiber through Psyllium husk|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. Altogether the fifteen capsules contains 5.5 g dietary fiber in psyllium husk.
11034953|NCT04534075|Placebo Comparator|Placebo (no additional dietary fiber)|The participants are allocated to intake the fifteen capsules per day, for example, five capsules three times per day. The capsules contain placebo (maltodextrin) and have a similar look as in the experimental arm.
11034954|NCT04534062|Experimental|Group A|Participants in Group A will perform PNF D2 flexion and extension with free weights (PNF D2 FW) The intensity of exercise will be determined for each individual by using maximum repetition test (1 repetition maximum 1-RM). The intensity will be kept 50 % of the maximal load. 3 sets of PNF D2 FW Flexion (flexion-abduction and external rotation) and PNF D2 FW Extension (extension-adduction-internal rotation) respectively will be performed on each upper limb with 10 repetitions per set. All exercises will be performed with a rest interval of 30 seconds to 1 minute between the sets.
11034955|NCT04534062|Experimental|Group B|Participants in this group will perform 3 sets of PNF D2 flexion (flexion-abduction and external rotation) and extension (extension-adduction-internal rotation) respectively with elastic bands after assessing the 1-RM test starting with a lightest resistance and gradually progressing to the higher level. Subsequently, 71% to 86% of 1-RM will be taken as a target range of the resistance for the training that will be applied through Elastic Resistance Band in accordance with values that are provided on the Thera-Band website. Moreover, each set will consist of 10 repetitions for both D2 flexion and Extension and a resting interval of 60 seconds between two consecutive sets. The procedure will be repeated for both limbs.
11034956|NCT04534062|Experimental|Group C|The participants in the Group C or control group will perform the PNF D2 flexion and extension without any resistance. Three sets consist of 10 repetitions of each pattern for both upper limbs will be performed with an interval of 60 seconds between two consecutive sets.
11034957|NCT04534049|Experimental|Intensive strength training (IST)|
11034958|NCT04534049|Experimental|Strength Endurance training (SET)|
11034959|NCT04534049|Other|Flexibility training (FT)|
11034960|NCT04534036|Active Comparator|Multi-Strain Synbiotic (PDS-08)|PDS-08 is a rationally defined microbial consortium consisting of 9 strains, with FOS-inulin as prebiotic. Participants will be instructed to take 1 sachet daily for the duration of the trial.
11034961|NCT04534036|Placebo Comparator|Placebo|Placebo sachets for PDS-08 will contain potato or tapioca maltodextrin matched for color and texture. Participants will be instructed to take 1 sachet daily for the duration of the trial.
11034962|NCT04534023|Experimental|trial group|
11034963|NCT04534023|Placebo Comparator|control group|
11034964|NCT04534010|Experimental|NACgraft patients|
11034965|NCT04533997|Active Comparator|Intravenous furosemide|
11034966|NCT04533997|Experimental|Hypertonic saline solution plus intravenous furosemide|
11034993|NCT04533763|Active Comparator|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
11034994|NCT04533750|Experimental|Treatment (peposertib, IMRT)|Patients receive peposertib PO QD and undergo IMRT daily Monday-Friday for 7 weeks in the absence of disease progression or unacceptable toxicity.
11034967|NCT04533984|Experimental|Intervention with 28-day self-injection of Forteo|The active study medication FORTEO is recombinant human parathyroid hormone analog, [rhPTH]. The study medication Forteo (teriparatide [rDNA origin] injection) (Eli-Lilly, Indiana, USA), will be self-administered via a blinded injection pen in the abdominal wall or thigh as described in the product guide. Subjects in the teriparatide arm will receive a 20 mcg dose of the medication daily for 28 days. Following this period the participant will receive standard physical therapy until full-return to duty.
11034968|NCT04533984|Placebo Comparator|Placebo with 28-day self injection of inactive substance|Participants will self-administered a placebo substance normal in a replica, blinded, injection pen via in the abdominal wall or thigh daily for 28 days. Following this period the participant will receive standard physical therapy until full-return to duty.
11034969|NCT04533971|Experimental|WBC group|"Criteria
~documented diagnosis of MS,
~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3
~no contraindications for WBC treatments found in the medical examination
~no other serious chronic diseases identified that may affect the results of the tests carried out
~readiness to participate in daily WBC
~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
11034970|NCT04533971|No Intervention|Control Group|"Criteria
~documented diagnosis of MS,
~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3
~no contraindications for WBC treatments found in the medical examination
~no other serious chronic diseases identified that may affect the results of the tests carried out
~readiness to participate in daily WBC
~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
11034971|NCT04533958|Experimental|HypnoVR Arm|During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
11034972|NCT04533958|No Intervention|Control Arm|Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)
11034973|NCT04533945|Other|FreeStyle Libre Device|Inpatients admitted to the medical-surgical units that are eligible for the trial will have the FreeStyle Libre device will be placed by the inpatient diabetes team at the discharge and glucose log will be obtained in 2 weeks followed by Hba1c in 3 months.
11034974|NCT04533932||Elastography|
11034975|NCT04533919||Basic science (dorsal root ganglia collection)|Patients' leftover dorsal root ganglia samples are collected during standard of care surgery.
11034976|NCT04533906|Experimental|Carrageenan|Subjects sucking carageenan containing lozenge
11034977|NCT04533893||BLS Training Group (Students without prior BLS Training)|"After completing training mode of the serious game module, participants were asked to choose the self-test mode of the serious game module.
~the participants were asked to practice their hands-on skills in simulation center under the supervision of educators. After familiarization with the system using self-training mode, the participants were asked to proceed the BLS Hands-on training app with the simulator under the supervision of the educator.
~Conventional OSCE score of each participant was obtained by watching the recorded sessions of BLS trainings."
11034978|NCT04533880|Placebo Comparator|Control|The control group will receive autologous bone obtained from the BTBPB graft harvest
11034979|NCT04533880|Active Comparator|Autologous Bone + DBM|Autologous bone plus demineralized bone matrix
11034980|NCT04533880|Active Comparator|Autologous Bone + Calcium Phosphate Cement|Autologous bone plus calcium phosphate cement
11034981|NCT04533867||Ondansetron|In Group B (n = 50): Intravenous injection of ondansetron 0.1 mg/kg diluted up to 5 mL with normal saline solution in a maximum dose of 8 mg is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
11034982|NCT04533867||Palonosetron|The antiemetics used are palonosetron in Group A (n = 50): Intravenous injection of Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
11034983|NCT04533841|Active Comparator|Misoprostol + propranolol|Patient who receive misoprostol then after 30minutes receive propranolol
11034984|NCT04533841|Placebo Comparator|Misoprostol + placebo|Pt who will receive misoprostol then after 30minutes receive placebo
11034985|NCT04533828|Experimental|68Ga-FAPI-04 PET/CT scanning|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
11034986|NCT04533815|Experimental|LOCK sleep intervention|Nursing home staff receive the LOCK sleep intervention training and thus provide to nursing home residents with dementia the LOCK sleep intervention
11034987|NCT04533789|Experimental|the control group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
11034988|NCT04533789|Experimental|virtual reality|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min.
11034989|NCT04533789|Experimental|Task oriented|Group 3 the study group received the same physical therapy program 30 min. plus task oriented training for 30 min.
11034990|NCT04533776|Experimental|PEER-INTERACTION GROUP SUPPORT|"All the sessions of the research took place in a classroom in the hospital. The sessions lasted an average of 90 minutes with two 45-minute sections. During the break, which lasted about 20 minutes, gluten-free products were offered. During the break, adolescents were given the opportunity to chat and interact with each other.
~Peer interactive group support was implemented for 3 months with an interval of one week. A total of 6 sessions were held with the study group. Adolescents in the study group were contacted by phone before each session. The day before the session, a text message was sent to all participants informing the location and time of the meeting. The contents of the first and second sessions in relation to the study were created beforehand. However, contents of the third, fourth, fifth and sixth sessions were prepared after the first two sessions."
11034991|NCT04533776|Experimental|routine health care- control group|Peer interactive group support was not provided to the control group.
11034992|NCT04533763|Experimental|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
11034995|NCT04533737|Experimental|Arm 1 (brodalumab + dummy 1)|"Participants receive:
~Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.
~Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
11034996|NCT04533737|Active Comparator|Arm 2 (guselkumab + dummy 2)|"Participants receive:
~Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.
~Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
11034997|NCT04533724|Experimental|Study group|Recruit 30 outpatient/inpatient schizophrenia patients (dominant negative symptoms) in Shanghai Mental Health Center .
11034998|NCT04533724|No Intervention|Healthy control group|15 cases of normal healthy people (control group) with similar eating habits and ages in the same region were matched with study group.
11034999|NCT04533711|Experimental|OA-PCP|Participants assigned to the OA-PCP intervention will receive an initial physical activity (PA) coaching call then, 5 more calls over the course of 12 months. Participants, if they agree, will also receive monthly check-in emails between phone calls.
11035000|NCT04533711|Placebo Comparator|Attention Control|Participants assigned to the Attention Control group will receive the same number of phone calls over the course of 12 months, focused on understanding osteoarthritis (OA) and current information on treatment options. Participants, if they agree, will also receive monthly check-in emails between phone calls.
11035001|NCT04533698||Resternotomy|
11035002|NCT04533698||No resternotomy|
11035003|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
11035004|NCT04533685|Active Comparator|Direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) a pre-commitment prompt
11035005|NCT04533685|Active Comparator|Direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
11035006|NCT04533685|Active Comparator|Direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal with a link enabling direct scheduling
11035007|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment + Pre-Appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling, 2) a pre-commitment prompt and 3) pre-appointment reminders that mention asking the provider for a flu vaccine
11035008|NCT04533685|Active Comparator|No direct scheduling + Pre-commitment|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) a pre-commitment prompt
11035009|NCT04533685|Active Comparator|No direct scheduling + Pre-appt reminder|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling and 2) pre-appointment reminders that mention asking the provider for a flu vaccine
11035010|NCT04533685|Active Comparator|No direct scheduling|Participants receive 1) reminder/recall messages regarding influenza vaccination via the patient portal without a link enabling direct scheduling for a flu vaccine appointment
11035011|NCT04533685|No Intervention|Control Arm|Participants will not receive any reminder/recall messages regarding influenza vaccination via the patient portal or other intervention components
11035012|NCT04533672|Experimental|Single study arm|
11035013|NCT04533659|Active Comparator|Control group|This group will receive 4-week diabetes nutrition education with digital self-monitoring for diet and blood glucose.
11035014|NCT04533659|Experimental|Intervention group|This group will receive 4-week personalized behavioral nutrition intervention with digital self-monitoring for diet and blood glucose and diabetes nutrition education. Participants will discuss the personalized nutrition change goals and recommendations based on metabolic profiling for assessing dietary patterns.
11035015|NCT04533646|Experimental|Fixed Dosing, Followed by Carbohydrate Counting|Dosing of premeal insulin with fixed doses
11035016|NCT04533620|Active Comparator|Standardized CIRT|Patients will receive standardized CIRT with a dose of 63 GyE/21 fx.
11035017|NCT04533620|Experimental|Individualized CIRT|A previously predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
11035018|NCT04533607|Active Comparator|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
11035019|NCT04533607|No Intervention|Waitlist control|Services as usual.
11035020|NCT04533594|Experimental|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
11035021|NCT04533581|Experimental|ME-401|
11035022|NCT04533568|Experimental|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
11035023|NCT04533568|Experimental|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
11035024|NCT04533555|Experimental|Universal genetic testing|Detection of genetic risk using a panel of 66 cancer risk genes.
11035025|NCT04533555|Active Comparator|Standard|We will refer a subset of patients who meet guideline criteria based on age, cancer type, and family history, for genetic counseling and testing.
11035026|NCT04533542||Arm I (3 video or telephone conferences)|Participants attend up to 3 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on 3 randomly assigned conditions (combinations of carrier and nicotine concentrations).
11035027|NCT04533542||Arm II (2 video or telephone conferences)|Participants attend up to 2 video or telephone conferences over 2 hours each with a minimum of 24 hours and maximum of 1 week between sessions. Participants take a fixed number of puffs on a nicotine-free condition and 3 randomly assigned conditions (combinations of carrier concentration and nicotine form).
11035028|NCT04533529|Experimental|Seltorexant|Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).
11035029|NCT04533529|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.
11035030|NCT04533516|Experimental|Manual Therapy additional over Inspiratory muscle training|Participants receive manual therapy protocol session three times a week for 12 weeks. The manual therapy protocol session lasts 30 minutes and included of the following manual therapy techniques: suboccipital decompression, gliding of the cervical vertebral articulations in the anterior/posterior direction, myofascial release of sternocleidomastoid and trapezius muscles, gliding of sternoclavicular joint in the anterior/posterior direction, myofascial release of intercostal muscles and paravertebral muscles, diaphragmatic release, rib raising, mobilization of scapulothoracic joint, and gliding of the thoracic vertebral articulations in the anterior/posterior direction. And all participants receive inspiratory muscle training.
11035031|NCT04533516|Active Comparator|Inspiratory Muscle Training|Participants receive only inspiratory muscle training by using Threshold Inspiratory Muscle Training device. Training load is 40% of the measured maximum inspiratory pressure, weekly. Participants receive inspiratory muscle training session for 30 min-per day, 7 days per week, for 12 weeks.
11035032|NCT04533503||HF-OCT imaging|Enrolled subjects who meet lesion-specific eligibility criteria and undergo HF-OCT imaging
11035033|NCT04533490|Experimental|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 (200mg ivgtt q3w) from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
11035034|NCT04533477|Experimental|Routine surgery with reconstructing FCS|The participants undergo FCS reconstruction during the routine standardized surgery.
11035035|NCT04533477|Active Comparator|Routine surgery|The participants undergo routine standardized surgery.
11035036|NCT04533464|Experimental|MultiStem|
11035037|NCT04533464|Placebo Comparator|Placebo|
11035038|NCT04533451|Experimental|Group A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11035039|NCT04533451|Experimental|Group B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV per institutional guidelines on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11035040|NCT04533438|Active Comparator|RhinAer Treatment|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session. Each nostril will be treated at 1, 2, 3, 4 or 5 nonoverlapping positions depending on the size of the target treatment area. Treatment settings to be used are temperature 60 °C, power 4 watts, treatment time 12 seconds, and cooling time 0 seconds
11035041|NCT04533438|Sham Comparator|Control Treatment|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
11035042|NCT04533425||Patients with syncope|Patients who present to the ED with syncope
11035043|NCT04533412|Experimental|Targeted self-management barrier support|Intervention group - Targeted self-management barrier support, home-based pulmonary rehabilitation, and emergency medication with community health workers
11035044|NCT04533412|Active Comparator|Guided COPD education|Control group - Guided COPD education with a COPD educator
11035045|NCT04533399|Experimental|Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
11035046|NCT04533399|Placebo Comparator|Cohort 1 (HIV negative) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
11035047|NCT04533399|Experimental|Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
11035048|NCT04533399|Placebo Comparator|Cohort 2 (HIV positive) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
11035049|NCT04533386|Experimental|BSMM|Intervention arm will include motivational interview-consistent discussion with a peer change agent and use of a mobile application to record and review sexual risk behaviors with participants.
11035050|NCT04533373|Experimental|Neurotized Patients|Neurotization will be performed at the time of reconstruction.
11035051|NCT04533373|No Intervention|Non-Neurotized Patients|No Neurotization will be performed at the time of reconstruction.
11035052|NCT04533360||Community Cohort 1|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
11035053|NCT04533360||Community Cohort 2|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
11035054|NCT04533360||Healthcare Provider Cohort 1|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
11035055|NCT04533360||Healthcare Provider Cohort 2|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
11035056|NCT04533347|Active Comparator|Tafenoquine|Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10
11035057|NCT04533347|Placebo Comparator|Placebo|Placebo two tablets 1x/day on Days 1,2,3 and 10
11035058|NCT04533334||Pediatric|FOB measurement of the distance between carinae and right upper lobe and carinae and labium oris in paediatric population
11035059|NCT04533321|Other|Patients genotyped positive for MET-N375S polymorphism|will be treated with orally administered daily dose of afatinib (Gilotrif®) in a fasting state (1 hour before or 2 hours after meals).
11035160|NCT04532658|No Intervention|Control arm|Surgeons randomly assigned to the control arm
11035060|NCT04533308|Experimental|VR intervention|Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).
11035061|NCT04533308|No Intervention|Control|Patients in the control group will not receive any psychological interventions.
11035062|NCT04533295|Experimental|Acupuncture and IVF|Acupuncture and IVF
11035063|NCT04533295|Sham Comparator|Sham acupuncture and IVF|Sham acupuncture and IVF
11035064|NCT04533295|Other|IVF only|IVF only
11035065|NCT04533282||Acute IHD with STEMI and PCI|"Acute ischemia in IHD is represented by the recruitment of patients presenting with ST-elevation myocardial infarction (STEMI patients) to the Meilahti Cardiac Care Unit (CCU) and admitted for Percutaneous Coronary Intervention (PCI) revascularization. The informed consent and blood samples from these patients will be collected during the first 72 hours after PCI, during their stay either in CCU or medical ward.
~Inclusion of this cohort to the IHD-EPITRAN opens the possibility to identify novel circulative epitranscriptomic biomarkers representing acute ischemic myocardial damage as well as particularly insightful comparison of acute and chronic states of IHD when compared against the second study cohort."
11035066|NCT04533282||Chronic IHD and elective CABG|"The second study cohort composes of patients with stable IHD phenotype with angina pectoris or exertional dyspnea provoked by either moderate or severe physical exertion, corresponding either NYHA or CCS classes II to IV, respectively, destined to undergo an elective coronary artery bypass grafting (CABG) operation as method for revascularization. The duration of stable symptoms must exceed a month in order to exclude acute events.
~The obtained blood samples from this main cohort of the IHD-EPITRAN project provides insightful overview into the circulation-borne RNAs' epitranscriptomic landscape for identification of novel biomarkers for stable IHD. Furthermore, availability of right atrial appendage tissue pieces following CABG surgery from this patient cohort gives invaluable organ-specific information in its own right as well as a crucial reference point, against of which the alterations observed in circulation can be compared."
11035067|NCT04533282||Elective aortic valve stenosis (AVS) replacement therapy|"The third study cohort consists of patients admitted for surgical (open heart surgery) valve replacement due to aortic valve calcification and critical stenosis with no IHD as a comorbidity. As to elective CABG patients, here patients are also required to be either moderately or severely symptomatic equaling NYHA or CCS II to IV classes, respectively.
~This cohort will provide insights into how the pathological pressure overloaded left ventricular remodelling is reflected to the epitranscriptomes of the supposedly relatively spared right atrial appendage tissue and blood RNA. Comparison of this data to the data of the first two IHD study cohorts opens the window to assess the possible differences for these differing pathologies, thus functioning as an active control cohort."
11035068|NCT04533282||IHD-negative healthy controls verified by coronary CT|The fourth study cohort shall consist of patients referred to Meilahti Heart Unit's Coronary Artery Computerised Tomography (CT) Angiogram imaging in order to investigate the possibility of atherosclerotic coronary artery disease (i.e. IHD) behind symptoms such as pressing chest pain (i.e. angina pectoris) or abnormal dyspnea provoked by exertion. Based on the results from CT angiogram, only those patients' blood samples are selected for further study that show negative results for IHD (no visualisation of either atherosclerotic strands or plaques in coronary arteries). This patient cohort functions as a critical IHD-healthy control group in the IHD-EPITRAN project (i.e. negative control).
11035069|NCT04533269|Experimental|Active|Arnica montana and Ledum palustre infused Pad
11035070|NCT04533269|Placebo Comparator|Placebo|Pad (Matching appearance with Active)
11035071|NCT04533243|Experimental|2.5ug/h transdermal fentanyl|
11035072|NCT04533243|Active Comparator|Oral immediate-released morphine|
11035073|NCT04533230|Experimental|Educational intervention with prescription feedback|The manager and physicians at each intervention center will participate in a brief educational intervention about benzodiazepines and benzodiazepine-like hypnotics and receive 12 months of targeted feedback on prescription of these drugs. The education will cover national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics.
11035074|NCT04533230|Active Comparator|Information on guidelines|The manager and physicians at each center in the active control group will receive written information on national and regional treatment guidelines for anxiety, depression, and insomnia, which include guidelines on prescription of benzodiazepines and benzodiazepine-like hypnotics. These centers will not receive the onsite educational intervention or 12 months of targeted prescription feedback.
11035075|NCT04533230|No Intervention|No active intervention: standard care|The manager and physicians at each primary health care center in the passive control group will receive no active intervention. The passive control group will consist of primary health care centers that are not actively participating in the study. Data will be gathered from regional registers and databases. Thus, there will be no need to contact or communicate directly with the centers. This arm will be used only if the General Data Protection Regulation continues to allow access to regional registers and databases in primary health care.
11035076|NCT04533217|Active Comparator|Vertebroplasty|Patients treated with vertebroplasty in addition to regular medical treatment.
11035077|NCT04533217|No Intervention|Regular treatment|Patients treated with regular medical treatment.
11035078|NCT04533204|Experimental|Mnemonic strategy training|Training using mnemonic strategies
11035079|NCT04533204|Active Comparator|Spaced retrieval training|Training using spaced retrieval
11035080|NCT04533178|Active Comparator|Restriction of sports activities|No sports during the 6 week treatment period
11035081|NCT04533178|Experimental|Restriction of sports activities and soft spinal brace|No sports and use of a soft spinal brace 16 hours per day during the 6 week treatment period
11035082|NCT04533165|Experimental|Virtual exercise program|This arm will receive the virtual exercise program.
11035083|NCT04533139||Vaccine, pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
11035084|NCT04533139||Vaccine, post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
11035085|NCT04533139||Vaccine, not receiving transplant|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
11035086|NCT04533113|Experimental|VitreBond LC|VitreBond LC used as a liner after selective carious tissue removal.
11035087|NCT04533113|Experimental|Biodentine|Biodentine used as a liner after selective carious tissue removal.
11035088|NCT04533113|Experimental|Theracal|Theracal used as a liner after selective carious tissue removal.
11035089|NCT04533087||Candida blood stream infection|
11035090|NCT04533087||Aspergillosis|
11035091|NCT04533087||Rare mold infections|
11035092|NCT04533074|Experimental|Single-visit regeneration protocol|
11035093|NCT04533074|Active Comparator|Multiple-visits regeneration protocol|
11035094|NCT04533061||Lung Transplant, Vaccine|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
11035095|NCT04533061||Healthy Control, Vaccine|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
11035096|NCT04533048|Experimental|MW33|
11035097|NCT04533048|Experimental|Placebo|
11035098|NCT04533035||Single cohort|30 patients undergoing hallux valgus surgery
11035099|NCT04533022|Experimental|C21|
11035100|NCT04533009|Active Comparator|tramadol/acetaminophen|Tramadol-paracetamol two tablets 37,5mg/325mg twice daily up to five days for patients undergoing spinal surgery
11035101|NCT04533009|Placebo Comparator|placebo|Placebo two tablets twice daily up to five days for patients undergoing spinal surgery
11035102|NCT04532996|Experimental|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 20-24 sessions.
11035103|NCT04532983|Active Comparator|fixation group|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic),
11035104|NCT04532983|Active Comparator|non fixation group|group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.
11035105|NCT04532970|Placebo Comparator|Standard|"Eligible patients will be randomized to one of the treatment arms, which will involve 5 phone-delivered counseling sessions over a 9 week treatment phase. SC will be based on the 2008 PHS Clinical Practice Guideline (Fiore et al., 2008) and on SC in our ongoing two-site trials (R01DA025078; R01CA165001) This intervention arm will begin with a pre-quit session designed to help participants prepare for their Target Quit Day (TDQ). The TQD session will occur at week 1. The SC arm will focus on self-monitoring, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, relapse prevention, and homework. The pre-quit session prepares participants for their TQD by reviewing their experience with quitting, beliefs about smoking/quitting, perceived barriers to cessation, and creating a quit plan to identify smoking triggers and implement alternative strategies to manage those triggers without smoking."
11035106|NCT04532970|Experimental|BAPS|Key components of BAPS include activity monitoring and rewarding activity scheduling, assessment of personal goals and values, assessment and altering of avoidance behavior and other maladaptive coping strategies, and contingency management. BAPS focuses on reducing stress pile-up and loss of pleasure that accompanies the cessation process and on identifying and establishing environmental/social changes to promote abstinence. BAPS addresses smoking as a behavior that prevents and restricts opportunities for contact with healthy rewarding behaviors. These changes are achieved through altering daily routines previously associated with smoking in ways that increase pleasure and mastery across life domains, reducing rumination, and increasing behavioral skills to prevent return to smoking as a means of avoiding stressors.
11035107|NCT04532957|Experimental|Group 1|Multiple doses 100mg Healthy subjects receive multiple doses of KBP-7072 (100mg) or Placebo (100mg) QD capsules daily for a total of 10 days
11035108|NCT04532957|Experimental|Group 2|Multiple doses 200mg Healthy subjects receive multiple doses of KBP-7072 (200mg) or Placebo (200mg) QD capsules daily for a total of 10 days
11035109|NCT04532957|Experimental|Group 3|Multiple doses dose tbd Healthy subjects receive multiple doses of KBP-7072 (tbd) or Placebo(tbd) QD capsules daily for a total of 10 days
11035110|NCT04532944|Other|patients with MS|20 relapsing-remitting and 20 progressive MS patients
11035111|NCT04532944|Other|healthy controls|15 age- and sex-matched healthy controls
11035112|NCT04532931|Placebo Comparator|Arm A|Paracetamol (SOC)
11035113|NCT04532931|Experimental|Arm B|SOC plus Artesunate-Amodiaquine
11035114|NCT04532931|Experimental|Arm C|SOC plus Pyronaridine-Artesunate
11035115|NCT04532931|Experimental|Arm D|SOC plus Favipiravir plus Nitazoxanide
11035116|NCT04532931|Experimental|Arm E|SOC plus Sofosbuvir/daclatasvir
11035117|NCT04532918|Experimental|Verinurad + allopurinol|The subjects will receive single oral dose of verinurad 7.5 mg and allopurinol 300 mg under fasted condition.
11035118|NCT04532918|Experimental|Verinurad + allopurinol + cyclosporine|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and cyclosporine 600 mg under fasted condition.
11035119|NCT04532918|Experimental|Verinurad + allopurinol + rifampicin|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and rifampicin 600 mg under fasted condition.
11035120|NCT04532905|Sham Comparator|without previous strength training experience|control group will receive intervention as three exercises:dumbbell bent row over, dumbbell deadlift, and dumbbell lunge.
11035121|NCT04532905|Experimental|with previous strength training experience|experimental group will receive intervention as three exercises:dumbbell bent row over, dumbbell deadlift, and dumbbell lunge.
11035122|NCT04532892|Placebo Comparator|Placebo|Morning and night tablets with no active ingrédients. Morning and night tablets are different.
11035123|NCT04532892|Experimental|Dietary supplément|Morning and night tablets with active ingrédients. Morning and night tablets are different.
11035124|NCT04532879|Experimental|All patients enrolled|"Bowel habits before and after the HygiRelief procedure will be assessed.
~Samples will be sent for microbiome evaluation."
11035125|NCT04532866|Experimental|Isolation and Confinement|Six crew members will spend 8 months isolated and confined in the spaceflight analog NEK in Moscow.
11035126|NCT04532866|No Intervention|Control Group|Up to ten participants matched for age, gender, and educational background undergo the same test protocol as the experimental group at identical points in time but without being isolated and confined in the NEK facility.
11035127|NCT04532853||COPD patients|
11035128|NCT04532840|Active Comparator|Group A: (control group)|This group includes 30 patients will receive routine medical treatment and routine physical therapy as (Exercising, Positioning and splinting, Pressure Therapy and Massage).
11035129|NCT04532840|Experimental|Group B: (Study group)|This group includes 30 patients will receive cryotherapy (at least 10 minutes at -14 degree , 2 sessions per week , for 10 weeks ) in addition to routine medical and physical therapy treatment.
11035130|NCT04532827|Experimental|Case formulation with web-program|"The intervention will start with two video meetings with a psychologist to build up and present an individual case formulation, based on behavioral analysis, and to build up a shared decision of individual goals for the web program. The intervention continues with web program consisting of six manualized web-based modules, each at two-week intervals based on relational frame theory (RFT) and acceptance and commitment therapy (ACT).
~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
11035131|NCT04532827|No Intervention|Treatment as usual|"Treatment as usual includes all the routine care that individual receives when he or she is presenting his or her symptoms at the primary or the occupational health care unit (corresponds primary care level treatment) or other unit that recommends the study for the participant. In practice, TAU may vary between the study participants based on their individual needs e.g. treatments for co-morbid somatic diseases or psychiatric disorders that this study will not interfere.
~Both participants in the intervention arm and in the treatment as usual arm will receive usual care, meaning that TAU will be enhanced with the study intervention in the intervention arm. In addition to TAU all participants will be given self-help and educational leaflet based on scientific knowledge related to their condition."
11035132|NCT04532814|Other|Lean|Control
11035133|NCT04532814|Experimental|Obese|
11035134|NCT04532801|Experimental|kisspeptin-10|kisspeptin infusion
11035135|NCT04532801|Placebo Comparator|placebo|placebo
11035136|NCT04532788|Active Comparator|Customized crosslinking|"The standard corneal cross-linking protocol (sCXL) is also called the Dresden protocol. The epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 3 mW/cm2 during 30 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.
~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
11035137|NCT04532788|Active Comparator|Standard crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.
~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
11035138|NCT04532775|Other|group C|"This study was conducted on 100 patients. Patients were divided according to the injected drugs into two equal groups (50 patients each):
~1- Group (C): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of normal saline (0.9 %) with a total volume of 4 ml."
11035139|NCT04532775|Other|group M|2- Group (M): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of preservative free magnesium (200 mg) with a total volume of 4 ml. Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol). Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
11035140|NCT04532762|Experimental|Coldamaris akut|One puff (140µl) into each nostril
11035141|NCT04532762|Placebo Comparator|Placebo|One puff (140µl) into each nostril
11035142|NCT04532749|Experimental|Seltorexant|Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
11035143|NCT04532749|Placebo Comparator|Placebo|Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).
11035144|NCT04532736|Experimental|Methotrexate|10 mg Emthexate, PO, once a week during 8 weeks
11035145|NCT04532736|Active Comparator|Methylprednisolone|8 mg/day Prednol, PO, for 8 weeks
11035146|NCT04532736|Active Comparator|Control|200 mcg/day, intranasal mometasone furoate, for 8 weeks
11035147|NCT04532723|Experimental|ExoAtlet II|Safety/feasibility of utilizing the ExoAtlet II in a clinical setting with a group of individuals with SCI
11035148|NCT04532710|Placebo Comparator|Placebo low dose|Application of 2 placebo eye drops once daily for 8 days.
11035149|NCT04532710|Active Comparator|Tacrosolv low dose|Application of 1 Tacrosolv eye drop once daily for 8 days.
11035150|NCT04532710|Placebo Comparator|Placebo high dose|Application of 1 placebo eye drop once daily for 8 days.
11035151|NCT04532710|Active Comparator|Tacrosolv high dose|Application of 2 Tacrosolv eye drops once daily for 8 days.
11035152|NCT04532697|Active Comparator|Chinese Medicine|Uncaria Rhynchophylla (Gou-Teng)
11035153|NCT04532697|Placebo Comparator|Placebo treatment|Placebo
11035154|NCT04532684|Active Comparator|Duloxetine|30 patients received 60 mg/day of duloxetine HCL orally for 12 weeks
11035155|NCT04532684|Active Comparator|Pregabalin|30 patients received 300 mg/day of pregabalin orally for 12 weeks
11035156|NCT04532671|Other|Poly ether ether ketone (PEEK)|Poly ether ether keton (PEEK) is acknowledged as a high-performance polymer in engineering & medical applications due to its favorable mechanical and chemical properties.
11035157|NCT04532671|Other|CADCAM poly ether ether ketone (PEEK)|PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks.
11035158|NCT04532671|Active Comparator|indirect resin composite|In CAD/CAM resin composite blocks, properties of flexibility and ease of use similar to that of resin composite are combined with durability and surface finish properties similar to that of ceramics
11035159|NCT04532658|Experimental|Intervention arm|Surgeons randomly assigned to the intervention arm
11035161|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
11035162|NCT04532619|Experimental|Intervention|6 weeks of Fathering Through Change videos and 3 individual coaching calls.
11035163|NCT04532619|No Intervention|Control|Links to parenting websites
11035164|NCT04532606|Experimental|Remimazolam group|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain Bispectral Index (BIS) value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
11035165|NCT04532606|Active Comparator|Propofol group|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
11035166|NCT04532593|Experimental|Stem cell group|
11035167|NCT04532593|Placebo Comparator|Control|
11035168|NCT04532580||AI- Aided performances|
11035169|NCT04532580||AI- Unaided performances|
11035170|NCT04532567|Experimental|GLPG1205 dose A|Participants will receive a single dose with dose A of GLPG1205 on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
11035171|NCT04532567|Placebo Comparator|Placebo dose A|Participants will receive a single dose placebo on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
11035172|NCT04532567|Experimental|GLPG1205 dose B|Participants will receive 14 days q.d. dosing with dose B of GLPG1205 on Days 1 to 14.
11035173|NCT04532567|Placebo Comparator|Placebo dose B|Participants will receive 14 days q.d. dosing placebo on Days 1 to 14.
11035174|NCT04532554|Experimental|Growth hormone|Recombinant GH will be used for those patients
11035175|NCT04532554|Placebo Comparator|Placebo|Saline will be used
11035176|NCT04532541||Patients with childhood onset SLE|Participants in this group were derived from patients diagnosed with SLE at an age of less than 18 years old, and these patients were hospitalized in our center. Peripheral blood was collected from the patient and their biological parents for gene analysis to obtain the overall incidence of monogenic lupus in the cohort.
11035177|NCT04532528||Patients receiving standard of care (SOC)|(without advanced educational Intervention)
11035178|NCT04532528||Patients receiving SOC with advanced educational intervention|
11035179|NCT04532515|Experimental|Seal G / Seal-G MIST|"Seal-G Surgical Sealant [Seal-G]- will be applied on colonic anastomosis created by extra-corporal approach.
~Seal-G MIST System [Seal-G MIST]- will be applied on colonic anastomosis created by intra-corporal approach."
11035180|NCT04532502||Study group|All female assistants in anesthesia
11035181|NCT04532489|Other|Group 1|These subjects, 6 planned (3 male, 3 female), will be to obtain normal tissue distribution of [18F]NP-59 and confirm calculated radiation dosimetry and optimal uptake time.
11035182|NCT04532476|Experimental|Laser treated side|Group of 22 participants whose mucose around right maxillary permanent molar was treated with laser.
11035183|NCT04532476|Placebo Comparator|Placebo side|Placebo side was LEFT side.It was treated the same way as right with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so participants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.
11035184|NCT04532463||Amphotericin B,Flucytosine, Fluconazole|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
11035185|NCT04532424|Experimental|Targeting insistence on sameness|
11035186|NCT04532424|Experimental|Targeting stereotyped motor behaviors|
11035187|NCT04532411||Pre-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing prior to implementation of the Hexapod personal protective booths.
11035188|NCT04532411||Post-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing after implementation of the Hexapod personal protective booths.
11035189|NCT04532398|Other|Swallowing test|
11035190|NCT04532385|Experimental|GTE|Green tea extract, 400 mg every 12 hours for 12 weeks
11035191|NCT04532385|Placebo Comparator|Placebo|Calcined magnesia, 400 mg every 12 hours for 12 weeks
11035192|NCT04532372|Experimental|Phase I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Patients may receive SOC drugs in addition to leflunomide.
11035193|NCT04532372|Experimental|Phase II Arm I (leflunomide, SOC)|Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
11035194|NCT04532372|Placebo Comparator|Phase II Arm II (placebo, SOC)|Patients receive placebo PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
11035195|NCT04532346|Experimental|Hydroxychloroquine|Hydroxychloroquine in a dose of 10 mg/kg*d, p.o., bid for 12 months. The maximum daily dose is 400mg.
11035196|NCT04532346|No Intervention|control|control group which do not take hydroxychloroquine for treatment.
11035197|NCT04532333|Experimental|Bivalirudin|Bivalirudin at full dose Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
11035198|NCT04532333|Active Comparator|Heparin|Heparin first dose at 0.6mg/kg(75U/kg) Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
11035199|NCT04532307|Experimental|Standard of Care SOC|Youth friendly services at Isisekelo Sempilo clinics
11035200|NCT04532307|Experimental|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples for gonorrhea, chlamydia and trichomonas
11035201|NCT04532307|Experimental|Peer-support (Thetha-Nami)|Peer support and needs assessment from an area-based peer navigator
11035202|NCT04532307|Experimental|SOC + SRH + peer-support|Combination of all arms
11035203|NCT04532294|Experimental|BGB-DXP593: Dose Level A|Participants will receive BGB-DXP593 10 mg/kg on Day 1
11035204|NCT04532294|Experimental|Placebo: Dose Level A|Participants will receive placebo to match (PTM) BGB-DXP593 10 mg/kg on Day 1
11035205|NCT04532294|Experimental|BGB-DXP593: Dose Level B|Participants will receive BGB-DXP593 30 mg/kg on Day 1
11035206|NCT04532294|Experimental|Placebo: Dose Level B|Participants will receive placebo to match (PTM) BGB-DXP593 30 mg/kg on Day 1
11035207|NCT04532294|Experimental|BGB-DXP593: Dose Level C|BGB-DXP593 at a higher dose determined from the two previous dose levels on Day 1
11035208|NCT04532294|Experimental|Placebo: Dose Level C|Placebo to match (PTM) BGB-DXP593 at a higher dose determined from the two previous dose levels on Day 1
11035209|NCT04532281|Experimental|Administration of Murine CD19 CAR T-cells|
11035210|NCT04532268|Experimental|Administration of Humanized CD19 CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
11035211|NCT04532242|Experimental|fMRI Participants|Participants will be scanned in an fMRI session lasting approximately 45-50 minutes and will be shown negative images for which they will have to take on a cognitive reappraisal tactic. All participants will be taken through the scanner with the same reappraisal protocol for each participant.
11035212|NCT04532229|Experimental|Experimental|Nimotuzumab+CRT(concurrent IMRT and TMZ)
11035213|NCT04532216|Experimental|Study group|
11035214|NCT04532216|Other|Control group|
11035215|NCT04532203|Experimental|Administration of CAR T-cells|Dose escalation follows the standard 3+3 doseescalation design. A total of 3 dose levels are set for subjects.
11035216|NCT04532190|Experimental|Active rTMS|Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
11035217|NCT04532190|Sham Comparator|Sham rTMS|For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
11035218|NCT04532177|Experimental|Active|
11035219|NCT04532164|Experimental|Photoallergic reaction test|During the Induction Phase, participants received Butenafine HCl 1% on the treated irradiated skin test site followed by UV irradiation and on the treated non-irradiated skin test site without UV radiation, two times per week for three consecutive weeks. After 10 days of Rest Phase, during the Challenge Phase, participants received same procedure on the two virgin sites (treated sites) as in Induction Phase, and two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Test sites were evaluated at 24, 48, and 72 hours after irradiation using the same grading scale used during Induction Phase.
11035220|NCT04532151|Other|Early SSc group|"Patients with SSc according to the criteria ACR / EULAR 2013, without scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements.
~Patients will be reassessed at M24. The participation of each subject will be 24 months, with two visits of one hour.
~The clinical data corresponding to the current practice will be collected in a study specific case report form."
11035221|NCT04532151|Other|Established SSc group|"Patients with SSc according to criteria ACR / EULAR 2013 with scleroderma Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The mRSS will be evaluated by an experienced clinician, blinded from imaging measurements. The participation of each subject will be one hour.
~The clinical data corresponding to the current practice will be collected in a study specific case report form."
11035222|NCT04532151|Other|Control group:|"Patient without systemic sclerosis Normal routine clinical examinations and routine biology tests will be performed. For non-invasive imaging specific to the study, various parameters will be measured on the finger and forearm by LC-OCT, LC-OCT-Doppler, HD ultrasound as well as fluid silicone molding in a dimly lit room. The participation of each subject will be one hour.
~The clinical data corresponding to the current practice will be collected in a study specific case report form."
11035223|NCT04532138|Active Comparator|C-MAC Video laryngoscope awake intubation|In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using Videolaryngoscope (C-MAC) with Hyperangulated blade (D-blade) Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied.
11035224|NCT04532138|Experimental|VS-CMAC Rigid Fiberoptic Stylet awake intubation|"In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
~Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied."
11035225|NCT04532125|Experimental|SAD|Part A (SAD) will consist of up to 9 dose level cohorts each composed of 8 subjects
11035226|NCT04532125|Experimental|MAD|Part B (MAD): Up to 32 subjects will be enrolled in up to 4 MAD levels. Each dose level will be composed of 8 subjects.
11035227|NCT04532112|Experimental|Intubated Subjects with the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by anesthesiologists trained in device use.
11035228|NCT04532112|Placebo Comparator|Intubated Subjects without the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by same cohort of anesthesiologists trained in device use.
11035229|NCT04532073|Experimental|Eurythmy therapy exercises|As part of the ENTAiER trial: In group sessions á 5 patients with a qualified therapist: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by an eurythmy manual and an exercise video. This supplements the regular care.
11035230|NCT04532073|Experimental|Tai Chi exercises|As part of the ENTAiER trial:In group sessions of 5 patients each with a qualified teacher: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by a Tai Chi Manual and an exercise video. This complements the regular care
11035327|NCT04531397|Experimental|Dapagliflozin+ACEI treatment|Drug: ACEI, will be given once daily Drug: Dapagliflozin, will be given once daily
11035716|NCT04528953|Active Comparator|continuous walking|
11035231|NCT04532073|Active Comparator|Standard Care Only|"As part of the ENTAiER trial:Brochure with detailed description of various evidence-based measures for fall prevention, prepared for the specific age group (https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf)
~- Recommendation to visit the family doctor and discuss fall prophylaxis with her"
11035232|NCT04532060|Experimental|Antimicrobial Photodynamic Therapy|Patients treated with Antimicrobial Photodynamic Therapy
11035233|NCT04532060|Experimental|Nystatin|Patients treated with Nystatin antifungal drug.
11035234|NCT04532047|Experimental|Experimental: in utero enzyme replacement therapy|ERT will be delivered in utero. Typically, the target of the procedure to administer in utero ERT will be the umbilical vein near the insertion of the umbilical cord into the placenta. The dose of the ERT will be dependent on the specific disease process and enzyme being replaced, and the estimated weight of the fetus. The dosage will be the same as the recommended weight-based postnatal dosing, adjusted for estimated fetal weight. IUERT will be repeated every 2-4 weeks, which is an interval consistent with the standard of care for IUTs (every 2-4 weeks) to avoid excessive access through the umbilical vein. This interval is also consistent with the half-life of each relevant enzyme.
11035235|NCT04532034|Experimental|Peer-Delivered Decision Support Intervention|
11035236|NCT04532021||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
11035237|NCT04532021||control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
11035238|NCT04532008|No Intervention|Control Group|No intervention
11035239|NCT04532008|Experimental|Treatment Group|Experimental group received 12 session of group based depression treatment, a matched savings program, financial literacy training, agricultural training, and a cash transfer.
11035240|NCT04531982|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg taken as two tablets + background antipsychotic, once daily by mouth
11035241|NCT04531982|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
11035242|NCT04531969|Active Comparator|Inpatient group|Spa therapy,HP application, deep heater application, and TENS.
11035243|NCT04531969|Active Comparator|Outpatient group|Spa therapy,HP application, deep heater application, and TENS.
11035244|NCT04531956|No Intervention|Before group|In the before group (BG) GPs will execute care as usual in the decision-making process for a diagnostic trajectory for memory complaints.
11035245|NCT04531956|Active Comparator|After group|In the after group (AG), a patient decision aid will be added to the decision-making process provided by the GP.
11035246|NCT04531943||TGWSM Using Estrogen|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of only estrogen.
11035247|NCT04531943||TGWSM Using Estrogen plus Progesterone|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of TGWSM currently using feminizing hormone therapy consisting of estrogen and progesterone.
11035248|NCT04531943||Cisgender MSM|Cohort 1 participants are in the cross-sectional study and will attend two study visits, participating in study activities for up to 12 weeks. Blood samples and rectal mucosal samples will be obtained. This group of participants in Cohort 1 consists of cisgender MSM.
11035249|NCT04531943||TGWSM Initiating Feminizing Hormone Therapy|Cohort 2 participants are in the longitudinal portion of the study and are TGWSM who are planning to initiate feminizing hormone therapy. Individuals in Cohort 2 will participate in study activities for 18 months.
11035250|NCT04531930||Surgery Group|Colorectal surgery
11035251|NCT04531930||Enhanced Colonoscopy Group|Enhanced colonoscopic treatment and surveillance
11035252|NCT04531930||Self Choice Group|The patients choose the interventional methods, even do nothing.
11035253|NCT04531917|Experimental|Pain Neuroscience Education + Behavioural Graded Activity|Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.
11035254|NCT04531917|Active Comparator|Usual care|"Patients allocated to the control group will receive an information leaflet from Kom op tegen kanker regarding Pain in and after cancer."
11035255|NCT04531891|Experimental|All-out, high-intensity, intermittent exercise protocol|
11035256|NCT04531891|Experimental|5 min, high-intensity, intermittent exercise protocol|
11035257|NCT04531878|Experimental|BSEP trafficking abnormal group|Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
11035258|NCT04531865|Experimental|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
11035259|NCT04531865|Placebo Comparator|Rituximab Only|First course Course Rituximab at Randomization. Addition of Maintenance Placebo tablets matching Mycophenolate mofetil from 4 Month onwards.
11035260|NCT04531852||At risk older adults|Home-dwelling older adults entitled to preventive home visit, who had a risk profile for loss of physical function and disability identified through a multi-domain screening instrument
11035261|NCT04531839|Experimental|Intervention period|The 1.5-year period during which all six participating centers receive evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation, and collaborative learning
11035262|NCT04531839|No Intervention|Baseline period|The 2-year period before the collaborative quality improvement intervention
11035263|NCT04531826|Active Comparator|Group A|Five-strand hamstring autograft group
11035264|NCT04531826|Placebo Comparator|Group B|Quadripled hamstring autograft group
11035265|NCT04531813|Experimental|Cumulative Irritation Test|Participants received butenafine HCl 1% cream on the skin test site, 0.3% solution of sodium lauryl sulfate on the skin Positive Control test site, and a blank patch on the skin Negative Control test site daily (excluding weekends) for 21 days, or 15 applications.
11043362|NCT04475445|Experimental|Interlaminar epidural steroid injection|
11035266|NCT04531800|Experimental|Study Group|The necrotic bone was removed with rotating burs, curettage was performed, and the surface of the bone was smoothened. CGF was then applied to the surgical area in the study group (n=14), and the area was primarily closed after additional releasing incisions were made to the periosteum to assure tension-free soft tissue closure.
11035267|NCT04531800|Experimental|Control Group|The surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy, in the control group (n=14).
11035268|NCT04531787||Vaccine, Pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
11035269|NCT04531787||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
11035270|NCT04531787||Vaccine, Healthy Controls|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
11035271|NCT04531774|Experimental|RECHARGE|4 1-hour sessions of RECHARGE are delivered online using Skype for Business within 2 weeks.
11035272|NCT04531774|Active Comparator|Online self-study of stress management strategies|Self study during 2 weeks.
11035273|NCT04531761|Experimental|Immediate Access to Parent Support Program|
11035274|NCT04531761|No Intervention|Waitlist Control|
11035275|NCT04531748|Active Comparator|Toremifene + Melatonin|"100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening), 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
~60mg oral toremifene daily days 1-14."
11035276|NCT04531748|Active Comparator|Melatonin + Placebo|100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening) and 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
11035277|NCT04531748|Placebo Comparator|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions
11035278|NCT04531735||Group 1|COVID positive infants
11035279|NCT04531735||Group 2|RSV positive infants
11035280|NCT04531722|Experimental|drug-resistant temporal lobe epilepsy|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe. The electro-physiological data that will be gathered is not altered and this methodology will not impact standard clinical care, except and will not to extend the duration in the OR - the measurements will occur during the clinical electrocorticography (ECoG; intracranial electroencephalography (iEEG)) procedure by 15 min.
11035281|NCT04531709||Recently diagnosed TGCT|
11035282|NCT04531709||Long-term survivors of TGCT|
11035283|NCT04531696|Other|Standard|"UPTIDER consists of 8 substudies:
~Pilot phase
~Invasive Lobular Carcinoma (ILC) substudy
~Inflammatory Breast Cancer (IBC) substudy
~Molecular heterogeneity and treatment response substudy
~Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy
~Metabolomics substudy
~Liquid biopsy substudy
~Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different."
11035284|NCT04531683|Experimental|electroacupuncture|patients will receive electroacupuncture at 3 acupoints (Bladder meridian of foot-taiyang 33 and 35（BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 8 weeks(24 times in total), followed with 24-weeks follow up. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 × 40 mm at SP 6. Standardised electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
11035285|NCT04531683|Sham Comparator|sham electroacupuncture|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
11035286|NCT04531683|Other|life style counselling group|patients randomised to this group will receive a one-time life style counselling at the enrolment to improve their daily behaviour to expedite the recovery of their mixed urinary incontinence. Then the patients will be followed up for 20 weeks.
11035287|NCT04531670|Experimental|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
11035288|NCT04531670|Active Comparator|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
11035289|NCT04531657||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
11035290|NCT04531657||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
11035291|NCT04531644|Experimental|Study|the patients in this group will be treated with double stimulation
11035292|NCT04531644|Active Comparator|Control|the patients in this group will be treated with conventional ovarian stimulation
11035293|NCT04531631|Other|Group 1|receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3
11035294|NCT04531631|Other|Group 2|receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3
11035295|NCT04531618|Experimental|Family Nurture Intervention (FNI)|Receives a FNI session over Zoom in the Well Baby Nursery and 3 subsequent Zoom sessions over the next 3 months.
11035296|NCT04531618|No Intervention|Standard of Care (SC)|SC receives the regular standard of care in the Well Baby Nursery and no intervention.
11035367|NCT04531150|Experimental|Cohort 4|Subjects will be randomized to receive either placebo or 320 mg INV-101
11035297|NCT04531605|Experimental|Intervention|"12-week program of combined life-skills training and financial incentives (YBank program) described in more detail below.
~Life-skills training: Every 4 weeks through the 12 week program, life-skills training sessions will be delivered during peer-group sessions at the clinic. Topics include economic empowerment, financial literacy, healthy relationships, and anti-retroviral therapy (ART) adherence.
~Financial incentives: The incentives program combines an immediate financial reward with a long-term savings opportunity. For clinic attendance, 500 RWF (~$0.50) will be deposited into participants' mobile money short-term account, where funds will be immediately accessible, and 1500 RWF (~$1.50) will be deposited into their savings account upon completing the program. If participants demonstrate a suppressed viral load at a clinic appointment, an additional 1000 RWF (~$1) will be deposited to their short-term account and 3000 RWF (~$3) into their saving account."
11035298|NCT04531592|Experimental|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
11035299|NCT04531592|Placebo Comparator|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
11035300|NCT04531579|Experimental|VPA plus SOC|A single dose of 140 mg/kg of VPA plus standard of care
11035301|NCT04531579|Placebo Comparator|Placebo plus SOC|A single dose of isotonic saline solution plus standard of care
11035302|NCT04531566|Experimental|Oral Feed Intervention Group|
11035303|NCT04531566|Active Comparator|Usual care|
11035304|NCT04531553|Active Comparator|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 & T6 with bolus 20 ml of bupivacaine 0.25% then bupivacaine 0.1% infused at a rate of 6 mL/h for 48 hours.
11035305|NCT04531553|Active Comparator|ESPB with bupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of bupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted bupivacaine 0.1%, infused at a rate of 6 mL/h for 48 hours.
11035306|NCT04531553|Active Comparator|ESPB with bupivacaine and dexometedomidne|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of bupivacaine 0.25% plus 0.5mic/ml dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted bupivacaine 0.1% and dexmedetomidine 0.5 μg/mL infused at a rate of 6 mL/h for 48 hours.
11035307|NCT04531540|Experimental|Repeated Insult Patch Test|During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.
11035308|NCT04531527|Experimental|Phototoxicity reaction test|Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
11035309|NCT04531514|Experimental|Sensitivity to phonological rules: Adults|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
11035310|NCT04531514|Experimental|Sensitivity to semantic category cues: Adults|Arm 1. Referential cue during OR learning.
11035311|NCT04531514|Experimental|Sensitivity to phonological rules & referents: Toddlers|Arm 1: OR condition with a referent; Arm 2: OR condition without a referent; Arm 3: Family Resemblance condition with a referent; Arm 4: Family Resemblance condition without a referent.
11035312|NCT04531501||Patients suspected to have Covid-19|Individuals suspected to have COVID-19 who are admitted to Gloucestershire Hospitals NHS Foundation Trust facilities for treatment for COVID-19. Individuals with full mental capacity.
11035313|NCT04531501||Patients tested positive for Covid-19|Individuals tested positive for COVID-19 at Northern Care Alliance NHS Group using an NHS NPS test who are accessible within 24 hours and consent to providing a saliva sample and further NPS sample for Chronomics.
11035314|NCT04531488|Experimental|Powered Mobility Training Simulator|Powered mobility simulator- the McGill Immersive Wheelchair Simulator (MiWe) was developed for adults. In a previous study the simulator was found valid for use with children. Participants were provided a laptop, joystick and the software program- MiWe- to practice at home or school
11035315|NCT04531488|Active Comparator|Training with Powered Wheel Chair|Participants were provided with a powered wheelchair to practice at home or school
11035316|NCT04531475|Experimental|X842 50 mg QD|X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
11035317|NCT04531475|Experimental|X842 100 mg QD|X842 100 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
11035318|NCT04531475|Experimental|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.
11035319|NCT04531462|Experimental|Empagliflozin|
11035320|NCT04531462|Placebo Comparator|Placebo|
11035321|NCT04531436|Experimental|Intervention|Brief mindful eating intervention
11035322|NCT04531423|Experimental|SSRI + golimumab|Participants will be administered with SSRI+golimumab . Golimumab will be administered at the dose of 50mg every month during the acute phase.
11035323|NCT04531423|Active Comparator|SSRI +placebo|Participants will be administered with SSRI+placebo
11035324|NCT04531410|Experimental|Linoleic|Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)
11035325|NCT04531410|Active Comparator|Oleic|Oleic acid 13 g and 600 algal DHA
11035326|NCT04531397|Placebo Comparator|ACEI treatment|Drug: ACEI will be given once daily
11035328|NCT04531384|Experimental|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 weekly individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants.
11035329|NCT04531384|Other|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions, which consisted of weekly group and/or individual therapy, as determined by the clinical team.
11035330|NCT04531371|Experimental|dexemedetomidine|dexemedetomidine was administered intravenously after induction of general anesthesia.
11035331|NCT04531371|Active Comparator|magnesium sulphage|magnesium sulphate was infused through out the surgery after induction of general anaesthesia.
11035332|NCT04531371|Placebo Comparator|saline|nothing was given just saline during the operation.
11035333|NCT04531358|Active Comparator|Callergin|One puff (140 microliter) into each nostril
11035334|NCT04531358|Active Comparator|Alpin Alpensalz|One puff (140 microliter) into each nostril
11035335|NCT04531358|Experimental|no treatment|Patients do not receive a treatment
11035336|NCT04531345||Case Group|Patients with Covid 19 PCR (+) results
11035337|NCT04531345||Control Group|Healthy volunteers
11035338|NCT04531332|Experimental|Continuous infusion|Patients will be received linezolid 600 mg intravenous Loading dose over 30 to 60 minutes followed by 1200 mg/ day by Continuous infusion (50 mg /hr)
11035339|NCT04531332|Active Comparator|Intermittent dosing|Patients will be received Linezolid 600 mg intravenous twice daily over 30 to 60 minutes
11035340|NCT04531319||Case Group|Covid 19 (+) patients
11035341|NCT04531319||Control Group|Healthy volunteers
11035342|NCT04531306|Active Comparator|Pre-tape|
11035343|NCT04531306|Experimental|With tape 1|
11035344|NCT04531306|Experimental|With tape 2|
11035345|NCT04531306|Experimental|Post-tape|
11035346|NCT04531293|Other|Total-breath method followed by standard method|Alveolar volume measurement performed on device EasyOne Pro (TM) according to total-breath method followed by alveolar volume measurement performed on device MasterScreen (TM) according to standard method.
11035347|NCT04531293|Other|Standard method followed by total breath method|Alveolar volume measurement performed on device Masterscreen (TM) according to standard method followed by alveolar volume measurement performed on device EasyOne Pro (TM) according to total-breath method.
11035348|NCT04531280|Experimental|Home hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
11035349|NCT04531267|Active Comparator|Individualized nutrition|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
11035350|NCT04531267|No Intervention|Control group|Participants do not receive any supplements, they stay with the original medication plan.
11035351|NCT04531254||Masking at all times|Children in this group will be asked to wear a face mask/covering in the classroom and common areas during the simulation
11035352|NCT04531254||No mask/masking when physical distancing is not maintained|Children in this group will not be asked to wear a mask (JK-Grade 4) or only asked to wear a mask when physical distancing in the classroom cannot be maintained (Grade 5-Grade 12) during the simulation
11035353|NCT04531241|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to sequence, Test/Control.
11035354|NCT04531241|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to sequence, Control/Test.
11035355|NCT04531228|Experimental|Experimental: TACE-HAIC plus lenvatinib|chemo-lipiodolization, followed by FOLFOX-based chemotherapy artery infusion (HAIC). Lenvatinib was administrated two or four days after TACE-HAIC.
11035356|NCT04531215|Active Comparator|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
11035357|NCT04531215|Active Comparator|ultrasound guided erector spinae|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
11035358|NCT04531202||Patients with confirmed or suspected of coronavirus infe|Clinical and laboratory data will be collected throughout the acute illness period. Research data will be integrated with information available from hospital and regulatory files.
11035359|NCT04531176|Experimental|Obesity-centric approach + AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
11035360|NCT04531176|Experimental|Obesity-centric approach without AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
11035361|NCT04531176|Active Comparator|Usual care approach (Comorbidity-centric approach)|Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.
11035362|NCT04531163|Experimental|Interventional|"First arm is experimental, given (NAC) for 2 months in 1200mg/day dosing.
~Both arms are assigned to pre-treatment analytical tests and post treatment all test analysis are repeated to compare drug effect with placebo group."
11035363|NCT04531163|No Intervention|Non-interventional|Second arm has no intervention. It is only used to compare results of analytical tests with the first interventional arm.
11035364|NCT04531150|Experimental|Cohort 1|Subjects will be randomized to receive either placebo or 20 mg INV-101
11035365|NCT04531150|Experimental|Cohort 2|Subjects will be randomized to receive either placebo or 80 mg INV-101
11035366|NCT04531150|Experimental|Cohort 3|Subjects will be randomized to receive either placebo or 160 mg INV-101
11035368|NCT04531150|Experimental|Cohort 5|Subjects will be randomized to receive either placebo or 500 mg INV-101
11035369|NCT04531137|Experimental|CLA-fortified milk powder|Respondents will receive CLA-fortified milk powder containing 3.4 gram for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
11035370|NCT04531137|Other|Placebo|Respondents will receive a placebo milk powder for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
11035371|NCT04531124||control group without an integrated management|
11035372|NCT04531124||observational group with an integrated management|
11035373|NCT04531098|Experimental|Sci-B-Vac-SciGen|The tri-antigenic HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
11035374|NCT04531098|Active Comparator|Engerix-B|The mono-antigenic HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
11035375|NCT04531098|Experimental|Sci-B-Vac-BTG|The tri-antigenic HepB vaccine, Sci-B-Vac-OLD BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-OLD BTG was supplied in a final volume of 1.2 ml vials
11035376|NCT04531085|Active Comparator|RCT operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
11035377|NCT04531085|Active Comparator|RCT Non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
11035378|NCT04531085|Other|Patient preference operative|Procedure of preference is open reduction and internal fixation (ORIF) with cannulated non-resolvable 4.0mm screw with or without washer. If the fracture fragment is too small or fragmented for screw fixation 1.6mm - 1.8mm Kirshner-wires and/or bone anchor are used. Long arm cast for 4 weeks.
11035379|NCT04531085|Other|Patient preference non-operative|Non-operative treatment means upper limb immobilization with forearm in neutral pro-supination with a long arm cast for 4 weeks.
11035380|NCT04531072|Experimental|ATVr-arm|10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
11035381|NCT04531072|Active Comparator|AL-arm (Control)|10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.
11035382|NCT04531059|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 300mg bid Tetracycline 500mg qid Metronidazole 400mg qid
11035383|NCT04531059|Experimental|Minocycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid Bismuth Potassium Citrate 300mg bid Minocycline 100mg bid Metronidazole 400mg qid
11035384|NCT04531046|Experimental|axicabtagene ciloleucel|Single infusion administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg
11035385|NCT04531033|Placebo Comparator|Placebo|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
11035386|NCT04531033|Experimental|Low dose 10 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
11035387|NCT04531033|Experimental|High dose 15 billion CFU per day|Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.
11035388|NCT04531020||Patients at PACU|Patients undergoing elective surgical or diagnostic intervention admitted to PACU after postanaesthesia recovery
11035389|NCT04531007|Experimental|Intermediate LMS stenosis|Patients with intermediate left main stem stenosis with additional severe downstream lesion will be subject to physiology (FFR and iFR) at multiple sites along the target vessels before and after PCI of the severe lesion located in the downstream vessel. Intravascular imaging (IVUS and OCT) will be performed for additional evaluation of the left main stem stenosis.
11035390|NCT04530981|Experimental|Repaglinide 0.5 mg + Ripretinib 150 mg QD|A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
11035391|NCT04530968||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
11035392|NCT04530968||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
11035393|NCT04530968||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
11035394|NCT04530968||Healthy controls (HCs)|Healthy controls (HCs)
11035395|NCT04530955|No Intervention|Control Arm|"Patients randomized to the Control Arm that have been implanted with the valve-gated pump will be started on an equivalent dose (without change to the medication concentration) as prior to implant. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be modified, the dose can be modified as clinically indicated. Multiple dosing decreases may be performed if the patient is clinically demonstrating a reduction in spasticity that is profound and negatively impacting function, or if the patient is demonstrating signs of baclofen overdose.
~The criteria for dosing decrease will be clinical discretion."
11035425|NCT04530773|Experimental|GROUP2|
11035426|NCT04530773|Experimental|GROUP3|
11035427|NCT04530773|Experimental|GROUP4|
11035428|NCT04530773|Experimental|GROUP5|
11035429|NCT04530760||intraabdominal hypertension group|patients with intraabdominal hypertension defined as intravesical pressure more than 12 mmHg
11035396|NCT04530955|Active Comparator|Study Arm|"Patients randomized to the Study Arm will be started on a 20% dose reduction (without change to the medication concentration) through the newly implanted valve-gated pump. If at any time during the patients' treatment it is determined by the investigator that the patients' treatment dose needs to be increased or decreased, the dose can be increased/decreased as clinically indicated. If the dose increases with the valve-gated pump reach the patients' baseline dose and the patient's spasticity is worse than his or her spasticity at baseline, then the patient will be considered a primary endpoint failure.
~The criteria for dosing increase will be clinical discretion."
11035397|NCT04530942|Experimental|Active DBS then Sham DBS|After 9 months open-lable period, some patients will take DBS ON for one month with the optimal stimulation parameters and then take DBS OFF for one month.
11035398|NCT04530942|Experimental|Sham DBS then Active DBS|After 9 months open-lable period, some patients will take DBS OFF for one month and then take DBS OFF for one month with the optimal stimulation parameters.
11035399|NCT04530929|Active Comparator|Group PROBIOTIC|The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
11035400|NCT04530929|Placebo Comparator|Group PLACEBO|Placebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
11035401|NCT04530916|Experimental|Blueberry|22 g blueberry powder per day
11035402|NCT04530916|Placebo Comparator|Control|22 g placebo control powder per day
11035403|NCT04530903|Experimental|Group Clonidine|Group Clonidine will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine and 75 µg of clonidine per side.
11035404|NCT04530903|Placebo Comparator|Control|Group Control will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine per side; 0.5 ml of 0.9% NaCl will be added to each syringe to homogenise the volume in order to remain blind.
11035405|NCT04530890|Experimental|One arm only|Only one arm with blood samples
11035406|NCT04530877|Experimental|Exclusive enteral nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (>110%-120% of the average requirement).
11035407|NCT04530877|Active Comparator|Infliximab|the participants with active CD accept anti-TNF therapy (Infliximab) at 0week, 2week, 6week, 14week. Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
11035408|NCT04530864|Experimental|DEXTENZA Insert|This prospective study will use a self controlled design for 35 eyes. Patients scheduled to undergo routine cataract surgery in at least one of their eyes will have their pre-surgical measurements performed, IOL calculated and surgery planned. Then they will receive insertion of an intracanalicular dexamethasone insert into the inferior punctum. At 2 weeks (+/- 2 days) post-insertion, patients will return for an identical set of measurements. The IOL will be calculated and the surgery planned based on post-insert data. The insert will be removed if present (manually or via saline irrigation). This self controlled design allows for greater control of potential confounders tied to participants' systemic and ocular health.
11035409|NCT04530851|No Intervention|Conventional care|This group is conventional care of pregnant women after Cesarean section
11035410|NCT04530851|Experimental|ERAS protocol|This protocol for improve outcome of pregnant women after Cesarean section
11035411|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (subcutaneous)|20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
11035412|NCT04530838|Active Comparator|13-valent pneumococcal conjugate vaccine (subcutaneous)|13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
11035413|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (intramuscular)|20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)
11035414|NCT04530825|No Intervention|Providers|"All eligible providers will be sent questionnaires electronically to their email at baseline and follow-up. Providers will be invited to attend a training session to educate them on the PREVENT tool at baseline
~A subset of 5-10 providers will be recruited via email, at the baseline training,or by using snowball-sampling approach within the clinic to participate in qualitative in-depth interviews"
11035415|NCT04530825|No Intervention|Parents|-Focus group discussion
11035416|NCT04530825|Active Comparator|Patients - Wait-List Control|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months after the clinic visit electronically and by mail
~Up to 10 patients will also take part in focus group
~A PREVENT action plan (behavior change prescription, community resources, and education) will be provided to the patient via email after the completion of the follow-up measurement."
11035417|NCT04530825|Experimental|Patients - PREVENT tool|"Complete questionnaires at baseline (administered electronically or by mail; accelerometers administered by mail). Following baseline measurement, patients will be randomized and attend their clinic visit. Follow-up measures will be administered 3-months after the clinic visit electronically and by mail
~Up to 10 patients will also take part in focus group
~At the clinic visit, the provider will use PREVENT tool to discuss risk and deliver a tailored behavioral change plan inclusive of patient-centered community resources. PREVENT will calculate patient's overall risk for developing cardiovascular disease. Physical activity and food intake recommendations are tailored to current weight status and health behaviors using evidence-based recommendations."
11035418|NCT04530812|Experimental|Arm I (commercial kefir beverage)|Patients consume commercial kefir beverage daily for 3 months.
11035419|NCT04530812|Active Comparator|Arm II (usual diet)|Patients maintain usual diet for 3 months.
11035420|NCT04530799||IAPA+|Influenza patients who develop IAPA during ICU admission
11035421|NCT04530799||IAPA-|Influenza patients admitted to the ICU not developing IAPA
11035422|NCT04530786||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
11035423|NCT04530786||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
11035424|NCT04530773|Experimental|GROUP1|
11035431|NCT04530747|Experimental|Metformin|Subjects randomized to this arm will be orally given 2000 mg metformin daily. Metformin dosage will be slowly increased to improve tolerance.
11035432|NCT04530747|Placebo Comparator|Placebo oral capsule|Subjects randomized to this arm will receive placebo matching study drug.
11035433|NCT04530721||stroke group|
11035434|NCT04530721||normal group|
11035435|NCT04530708|No Intervention|A: Standard of care|Normal standard of care and follow-up.
11035436|NCT04530708|Experimental|B: Thoracic radiotherapy|Addition of thoracic radiotherapy to 36 Gy after medical treatment.
11035437|NCT04530695|Experimental|Arm A: Deep Cleaning|participants with periodontitis will undergo treatment by scaling and root planing (SRP)
11035438|NCT04530695|No Intervention|Arm B: No cleaning|participants with periodontitis will undergo no periodontal treatment
11035439|NCT04530669|Experimental|study group|"in the active arm patients will receive high tone power therapy in addition to the physical therapy conventional selected exercise program"
11035440|NCT04530669|Sham Comparator|control group|"the sham arm will receive the same physical exercise program with sham high tone power therapy."
11035441|NCT04530656|Experimental|Middle-dose vaccine (18-55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
11035442|NCT04530656|Experimental|Middle-dose vaccine (> 55 years) & Two dose regimen|Two doses of middle-dose experimental vaccine at the schedule of day 0, 28.
11035443|NCT04530656|Experimental|High-dose vaccine (18-55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
11035444|NCT04530656|Experimental|High-dose vaccine (> 55 years) & Two dose regimen|Two doses of high-dose experimental vaccine at the schedule of day 0, 28.
11035445|NCT04530656|Experimental|High-dose vaccine (18-55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
11035446|NCT04530656|Experimental|High-dose vaccine (> 55 years) & Three dose regimen|Three doses of high-dose experimental vaccine at the schedule of day 0, 14, 28.
11035447|NCT04530656|Placebo Comparator|Middle-dose placebo (18-55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
11035448|NCT04530656|Placebo Comparator|Middle-dose placebo (> 55 years) & Two dose regimen|Two doses of middle-dose placebo at the schedule of day 0, 28.
11035449|NCT04530656|Placebo Comparator|High-dose placebo (18-55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
11035450|NCT04530656|Placebo Comparator|High-dose placebo (> 55 years) & Two dose regimen|Two doses of high-dose placebo at the schedule of day 0, 28.
11035451|NCT04530656|Placebo Comparator|High-dose placebo (18-55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
11035452|NCT04530656|Placebo Comparator|High-dose placebo (> 55 years) & Three dose regimen|Three doses of high-dose placebo at the schedule of day 0, 14, 28.
11035453|NCT04530643|Experimental|HY209 0.3%|multiple dose of HY209 0.3% gel
11035454|NCT04530643|Experimental|HY209 0.5%|multiple dose of HY209 0.5% gel
11035455|NCT04530643|Placebo Comparator|Placebo|multiple dose of Placebo
11035456|NCT04530630|Experimental|Biktarvy|Participants receive a Biktarvy tablet orally once daily with or without food.
11035457|NCT04530617|Active Comparator|Camostat mesilate|100 mg tablet, 600 mg/day. Oral, 2 tablets three times a day, after a meal (600 mg total daily dose) Days 1-14.
11035458|NCT04530617|Placebo Comparator|Camostat Placebo|Matched placebo
11035459|NCT04530617|Active Comparator|Artemisia annua|Tea 225mg per bag,1350 mg/day. Oral, one 8 oz brewed tea (two bags) three times a day, Days 1-14.
11035460|NCT04530617|Placebo Comparator|Artemisia annua Placebo|Matched placebo
11035461|NCT04530604|Experimental|Defibrotide|
11035462|NCT04530591||Patient Participants|"This group of participants will complete a survey about their opioid use history and their preferences for a device-based intervention. They will then participate in a semi-structured interview to provide feedback on non-functional, looks-like prototypes of such a device."
11035463|NCT04530578|Experimental|NEBULIZED HEPARIN|"Nebulized Heparin (UNF)5000 IU in Saline Solution1 ml every 8 hours plus Enoxaparine 40mg /d or 60mg/d, adjusted by BMI and calculated creatinine clearance .
~Device to nebulize without producing aerosolization:
~To nebulized heparin we have a modified a fullface snorkel mask, in which instead of the discharge valve a connector for the Venturi has been placed, and in the air outlet / inlet of the snorkel it has been adapted a connector made with 3D printing for the insertion of a disposable antiviral filter (filters commonly used in Mechanical Respiratory Assistance devices).
~The mask is made of materials that allow its sterilization with the STERRAT Hydrogen Peroxide plasma system, available at the institution."
11035464|NCT04530578|Active Comparator|Enoxaparine|Enoxaparin 40mg/d or 60mg/d adjusted by BMI and calculated creatinine clearance
11035465|NCT04530565|Active Comparator|Arm A (steroid, TKI), Single Arm Run In|Patients receive prednisone PO QD on days 1-21 and ponatinib PO QD or dasatinib PO QD on days 1-21 based on investigator's choice.
11035466|NCT04530565|Experimental|Arm B (steroid, TKI, chemotherapy)|See Detailed Description.
11035467|NCT04530565|Experimental|Arm C (steroid, TKI, chemotherapy, immunotherapy)|"CYCLE 1: Patients receive prednisone PO QD on days 1-21, and ponatinib PO QD or dasatinib PO QD on days 1-21. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28, followed by methotrexate IT on day 28 or 29.
~CYCLE 2: Patients receive prednisone PO QD on days 1-21 and ponatinib PO QD or dasatinib PO QD on days 1-21. Patients also receive dexamethasone PO or IV on day 1 and blinatumomab IV continuously on days 1-28.
~Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
11035468|NCT04530565|Experimental|Arm D (steroid, TKI, chemotherapy, immunotherapy)|"Patients treated on Arm B who remain MRD positive at the end of induction therapy receive blinatumomab based re-induction identical to the regimen described for Arm C.
~Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator, or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care."
11035500|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
11046125|NCT04456062|Experimental|Caring Contacts Group|
11035469|NCT04530565|Experimental|Arm E (steroid, TKI, chemotherapy)|"Patients treated on Arm C who remain MRD positive at the end of induction therapy receive chemotherapy based re-induction which is identical to regimen described for Arm B according to patient's age and the pre-specified chemotherapy arm.
~Patients whose molecular test remains MRD positive after re-induction proceed to follow-up at the discretion of the investigator, or receive anti CD-19 CAR- T cell therapy, inotuzumab ozogamicin, intensive chemotherapy, or palliative care."
11035470|NCT04530552|Experimental|Treatment (apalutamide)|The first 40 patients taking part in this trial receive apalutamide PO TIW for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Based on PSA levels of the first 40 patients, the next group of 40 patients receive apalutamide either QW or QD for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Patients may receive apalutamide for up to 12 weeks before prostate surgery (in the event surgery is delayed).
11035471|NCT04530539|Experimental|Experimental- Melatonin|Patients will receive melatonin
11035472|NCT04530539|Experimental|Experimental- Vit C|Patients will receive vitamin C
11035473|NCT04530539|Placebo Comparator|Control|Patients will receive placebo
11035474|NCT04530513|Experimental|Dose Level 1|
11035475|NCT04530513|Experimental|Dose Level 2|
11035476|NCT04530513|Experimental|Dose Level 3|
11035477|NCT04530513|Experimental|Dose Level 4|
11035478|NCT04530513|Experimental|De-escalation Level|
11035479|NCT04530500||Arm 1|Males first tested positive for SARS-CoV-2 at the site (medical center) with CAG length <24 (based on the CoVAST Test)
11035480|NCT04530500||Arm 2|Males first tested for SARS-CoV-2 at the site (medical center) with CAG length >=24 (based on the CoVAST Test)
11035481|NCT04530487|Experimental|Treatment (conditioning regimen, HSCT)|"CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.
~TRANSPLANT: Patients undergo HSCT on day 0.
~GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90."
11035482|NCT04530474|Experimental|Ivermectin|Single dose of 0.15-2 mg/kg/dose to a maximum of 12 mg
11035483|NCT04530474|Placebo Comparator|Placebo|Single dose of 2-4 placebo pills
11035484|NCT04530448|Active Comparator|Standard of Care|Standard of Care treatment
11035485|NCT04530448|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
11035486|NCT04530435|Experimental|Treatment group|"The participants will be handed three airway resistances equivalent to a resistance of 10-20 cm H2O alongside one PEP flute. Two videos will guide the participants in use of the PEP flute; one with instructions of the rationale and how to use the flute, including how to choose the suitable resistance and one video, which gives instructions of hygienic maintenance.
~Participants in the intervention group will be advised to continue use of their PEP flute in the active intervention period of 30 days or at least if they still have respiratory symptoms. They will receive daily text-messages to prompt their reporting and to use the PEP flute according to instructions."
11035487|NCT04530435|No Intervention|Control group|The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
11035488|NCT04530422|Experimental|• Group I (Sofosbuvir plus Ledipasvir)|Patients assigned to this group (125 patients) were received Sofosbuvir plus Ledipasvir, once daily for 15 to 21 days as minimum and maximum duration of therapy, respectively.
11035489|NCT04530422|Active Comparator|Group II (Oseltamivir plus HCQ & Azithromycin)|"Patients in this group (125 patients) were received the local medical committee of Almaza Fever Hospital guided standard treatment protocol for COVID-19:
~Oseltamivir 150 mg q 12 hours for 10 days ;
~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and
~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.
~Additional conservative medications were also given. Patients were evaluated as scheduled on day 0, 5 & 11 clinically"
11035490|NCT04530409|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
11035491|NCT04530409|Active Comparator|Late CS|Dexamethasone is to be used lately upon the deterioration of cases
11035492|NCT04530396|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
11035493|NCT04530396|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
11035494|NCT04530383|Experimental|Open Label Metformin|Participants with CFRD on highly effective CFTR modulator therapy who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study day 0 after undergoing study procedures. Participants will continue metformin until day 28 (± 3) at which time end of study procedures will be performed.
11035495|NCT04530370|Experimental|Recovered covid 19 plasma|
11035496|NCT04530370|Placebo Comparator|controlled|
11035497|NCT04530357|Experimental|Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
11035498|NCT04530357|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
11035499|NCT04530357|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
11035567|NCT04529811|Experimental|Formulation 1 Capsules - Mid Dose|Rifaximin Formulation 1 Capsules
11035568|NCT04529811|Experimental|Formulation 1 Capsules - High Dose|Rifaximin Formulation 1 Capsules
11035501|NCT04530357|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder
11035502|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
11035503|NCT04530344|Experimental|Cohort A : ruxolitinib cream|Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream or vehicle.
11035504|NCT04530344|Placebo Comparator|Cohort A : Vehicle|Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream
11035505|NCT04530344|Experimental|Cohort B : roxolitinib cream|Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream
11035506|NCT04530331|Experimental|Intervention group|Providing nutrition education.
11035507|NCT04530331|No Intervention|Control group|Without any intervention.
11035508|NCT04530318|Experimental|TolDec|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
11035509|NCT04530318|Placebo Comparator|Placebo|Placebo of dendritic cells
11035510|NCT04530292|Experimental|intervention by a pediatric nurse at the child's home|"The pediatric nurse will visit the patient's home 3 times during the first six months of the discovery of diabetes in children. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit can be organized according to the needs of families.
~The pediatric nurse will ensure the implementation of learning in terms of drug therapy (modality of insulin administration, adaptation of insulin doses) and diet, according to the knowledge acquired during the initial hospitalization. She will offer her help to the families to make a connection with the school and after-school activities of the child.
~In addition to these visits, the child and his family will come to the hospital as part of the regular medical follow-up: consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes."
11035511|NCT04530292|No Intervention|Classic strategy (for retrospective group)|The child and his family benefited from a consultation with a pediatric nurse at 1 month of the discovery of T1D and had medical consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes. The data from this group were collected in a previous study (collection of retrospective data) for children whose parents were in a precarious social situation and whose management was traditional.
11035512|NCT04530279||Referring hospital|Burn assessments performed in referring hospitals
11035513|NCT04530279||Burn centre|Burn assessments performed in the national burn centre
11035514|NCT04530266|Active Comparator|Persons with knee osteoarthritis|
11035515|NCT04530266|Placebo Comparator|Healthy controls|
11035516|NCT04530240||ERA-1 Group|Before the introduction of the MELD≥30 allocation scheme August 2010 - July 2014
11035517|NCT04530240||ERA-2 Group|After the introduction of the MELD≥30 allocation scheme August 2014 - July 2018
11035518|NCT04530227|Experimental|Camrelizumab combined with chemotherapy|"Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy.
~Interventions:
~Biological: Camrelizumab"
11035519|NCT04530201|Other|Sample collection|Women will self-collect two first-void urine samples at home, the day prior to colposcopy. During the colposcopy visit, the clinician will collect an additional cervical smear. Colposcopy and histology results (when available) will be used as reference test.
11035520|NCT04530188|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
11035521|NCT04530188|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already used in our ICU
11035522|NCT04530175||patients with hemodialysis|patient treated with intermittent hemodialysis for chronic renal failure
11035523|NCT04530162||Emergency Medicine Herpes Zoster Patients|Emergency Medicine adult patients with herpes zoster pain onset within 30 days of characteristic dermatomal herpes zoster rash who receive nerve block using bupivacaine and dexamethasone. The patient will be then started on Acyclovir 800 mg five times daily for seven days. For mild to moderate breakthrough pain, the patient will be prescribed a 5-day course of Tylenol 500 mg and Ibuprofen 400 mg taken up to every 8 hours together. For severe breakthrough pain, the patients will be prescribed a two-day course of 7.5 mg morphine sulfate immediate release to be taken up to every 6 hours. The location of the nerve block and dosage of injected medications will depend on the distribution of the affected dermatome.
11035524|NCT04530149|Active Comparator|serratus anterior plane block group|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where either the bupivicaine injected. After the injection, the needle is taken out.
11035525|NCT04530149|Sham Comparator|Sham injection group|The injection of normal saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle. The skin is cleaned with a sterile solution and the needle is guided right next to the chest muscle where saline is injected. After the injection, the needle is taken out.
11035526|NCT04530136|Experimental|Ruconest|Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
11035527|NCT04530136|Other|Standard of Care|
11035528|NCT04530123|Placebo Comparator|Cohort 1: Placebo (2 Infusions)|Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
11035569|NCT04529811|Experimental|Formulation 1 Capsules - Max Dose|Rifaximin Formulation 1 Capsules
11035570|NCT04529811|Placebo Comparator|Formulation 1 Capsules - Placebo|Placebo Formulation 1 Capsules
11035529|NCT04530123|Experimental|Cohort 1: TAK-101 2 mg/kg (1 Infusion) + Placebo (1 Infusion)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
11035530|NCT04530123|Experimental|Cohort 1: TAK-101 2 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20.
11035531|NCT04530123|Placebo Comparator|Cohort 2: Placebo (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
11035532|NCT04530123|Experimental|Cohort 2:TAK-101 4 mg/kg (1 Infusion)+placebo (1 Infusion)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
11035533|NCT04530123|Experimental|Cohort 2: TAK-101 4 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
11035534|NCT04530123|Experimental|Cohort 2: TAK-101 1 mg/kg (2 Infusions)|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg IV infusion, once on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. Cohort 2 would start based on the results of Cohort 1.
11035535|NCT04530110|Experimental|Fremanezumab|The dose of Fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
11035536|NCT04530097|Experimental|RFA+MLT|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
11035537|NCT04530097|No Intervention|RFA|Radiofrequency ablation was performed immediately after enrollment, and a placebo treatment program was given for 6 months after 1 week after radiofrequency.
11035538|NCT04530084|Experimental|Diagnosed with open angle glaucoma|
11035539|NCT04530071|Experimental|CordSTEM-DD(0.7x10^7 cells|Tissuefill+saline+CordSTEM-DD(0.7x10^7 cells)
11035540|NCT04530071|Experimental|CordSTEM-DD(2.1x10^7 cells)|Tissuefill+saline+CordSTEM-DD(2.1x10^7 cells)
11035541|NCT04530058|Placebo Comparator|Control|
11035542|NCT04530058|Experimental|Metformin|
11035543|NCT04530045||critically ill patients|Critically ill patients receiving continuous infusion of piperacillin/tazbactam or cefepim and dosage of plasma concentration of the B lactam administered
11035544|NCT04530032|Experimental|TBI KD|TBI subjects on a ketogenic diet
11035545|NCT04530032|Sham Comparator|TBI SD|TBI subjects on a standard (normal) diet
11035546|NCT04530019||MR Group|Following standard MRI-guided Brachytherapy, patients will have images analyzed for quantification of residual tumor versus fibrosis. We will pilot-test an endovaginal coil, a deflectable MR stylet, real-time planning software, and auto-segmentation of normal and tumor tissue.
11035547|NCT04530006|Experimental|GBM Patients|"This cohort of patients will be asked to orally ingest 200mg dose of FDA approved drug amantadine hydrochloride. This will be done at the following timepoints:
~Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.
~Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days
~Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
11035548|NCT04529993|Experimental|Interstitial pulmonary fibrosis|
11035549|NCT04529993|Experimental|Chronic obstructive pulmonary disease|
11035550|NCT04529993|Experimental|Healthy volunteers|
11035551|NCT04529980|Experimental|Lactobacillus rhanmosus GG(LGG®) Group|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.
11035552|NCT04529980|Placebo Comparator|Placebo Control Group|Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.
11035553|NCT04529954|Experimental|Open-Label Safety|Participants roll-over from DA071976
11035554|NCT04529941|Experimental|Experimental Group|Will receive stimulation ScNS at 3.5mA output
11035555|NCT04529941|Sham Comparator|Control Group|Does not receive therapy
11035556|NCT04529928|Experimental|Implanted|Subjects successfully implanted with the Carillon Mitral Contour System
11035557|NCT04529915||Lung cancer|
11035558|NCT04529915||Healthy|
11035559|NCT04529902||Tumor necrosis factor inhibitors|Reference group
11035560|NCT04529902||Abatacept|Exposure group
11035561|NCT04529876||Tofacitinib|Reference group
11035562|NCT04529876||Abatacept|Exposure group
11035563|NCT04529863||Tocilizumab|Reference group
11035564|NCT04529863||Abatacept|Exposure group
11035565|NCT04529850|Experimental|Open Label Active Arm|90mg GC4419 by IV
11035566|NCT04529811|Experimental|Formulation 1 - Low Dose|Rifaximin Formulation 1 Capsules
11035572|NCT04529811|Experimental|Formulation 2- Mid Dose|Rifaximin Formulation 2 Capsules
11035573|NCT04529811|Experimental|Formulation 2 - High Dose|Rifaximin Formulation 2 Capsules
11035574|NCT04529811|Experimental|Formulation 2 - Max Dose|Rifaximin Formulation 2 Capsules
11035575|NCT04529811|Placebo Comparator|Formulation 2 - Placebo|Placebo Formulation 2 Capsules
11035576|NCT04529811|Experimental|Formulation 3 - Low dose|Rifaximin Formulation 3 Capsules
11035577|NCT04529811|Experimental|Formulation 3 - Mid dose|Rifaximin Formulation 3 Capsules
11035578|NCT04529811|Experimental|Formulation 3 - High dose|Rifaximin Formulation 3 Capsules
11035579|NCT04529811|Experimental|Formulation 3 - Max dose|Rifaximin Formulation 3 Capsules
11035580|NCT04529811|Placebo Comparator|Formulation 3 - Placebo|Placebo Formulation 3 Capsules
11035581|NCT04529785|Active Comparator|SVC only|Patients in Group 1 will receive an SVC isolation only
11035582|NCT04529785|Active Comparator|SVC isolation with substrate modification and VoM inf|Patients in Group 2 will receive an SVC isolation with substrate modification and vein of Marshal ethanol infusion
11035583|NCT04529772|Experimental|acalabrutinib + R-CHOP|Acalabrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
11035584|NCT04529772|Placebo Comparator|placebo + R-CHOP|Placebo plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
11035585|NCT04529759|Active Comparator|Control Infant Formula|Feed ad libitum
11035586|NCT04529759|Experimental|Experimental Infant Formula|Feed ad libitum
11035587|NCT04529746|Experimental|EVERYbody Project: Professional facilitator version|"The EVERYbody Project is a dissonance body image intervention created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and through an iterative process of student-driven feedback. The Body Project manual (Stice et al., 2006) was adapted to retain key dissonance activities while expanding the gender focus, adding an exploration of the diversity characteristics within appearance ideals, and adjusting activities to be inclusive of diversity characteristics. Several adapted versions of the intervention were piloted with groups of college students and further adapted based on feedback.
~Facilitators received 16 hours of training on the EVERYbody Project manual and facilitation guidelines."
11035588|NCT04529746|No Intervention|Waitlist control group|Participants allocated to the waitlist completed assessments at time points parallel to those in the EVERYbody Project condition and were offered the EVERYbody Project upon completing the one-month follow-up assessment.
11035589|NCT04529720||acellular pertussis vaccine|Antibody persistence at 5 years after a single dose vaccination of acellular pertussis vaccines (Pertagen;Boostagen;Adacel)
11035590|NCT04529707|Experimental|Sleep Intervention|All participants will engage in a 12-week, parent mediated sleep intervention with weekly education sessions.
11035591|NCT04529694|Active Comparator|Cognitive-only Intervention|This condition includes cognitive interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
11035592|NCT04529694|Active Comparator|Behavioral-only Intervention|The condition includes behavioral interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
11035593|NCT04529681|Experimental|Intervention Group|Intervention group will be equipped with Stroke Riskometer Apps and informational leaflets. In the beginning of the study, investigators will guide the participants to download and install the Stroke Riskometer Apps and how to use the application to measure, monitor and self-manage the stroke risk. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
11035594|NCT04529681|Other|Control Group|Control group will be given the informational leaflets consist of stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
11035595|NCT04529668|Experimental|group I|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will receive vitamin D supplementation
11035596|NCT04529668|Active Comparator|group II|twenty-five patients with the clinical diagnosis of chronic rhinosinusitis with nasal Polyposis will NOT receive vitamin D supplementation
11035597|NCT04529655||Sepsis|Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment
11035598|NCT04529642||Stroke Group|Inclusion criteria were as follows: age above 18, Mini-Mental State Examination ≥ 24, ability to provide written informed consent and to understand the test instructions, and the presence of a single stroke. Exclusion criteria were as follows: more than one stroke, stroke area other than the cerebral cortex, or concomitant neurological disease and pathology of the locomotor system. This group has been analysed also dividing the subjects according to the stroke phase in 3 subgroups: Acute phase group, Subacute phase group, Chronic stroke group
11035599|NCT04529642||Healthy Group|Healthy subjects age matched with the stroke group
11035600|NCT04529629||primary aldosteronism|
11035601|NCT04529629||pheochromocytoma|
11035602|NCT04529629||adrenocortical carcinoma|
11035603|NCT04529603|Experimental|Arm 1|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
11035604|NCT04529590||Patients with cardiovascular events after 18 years|"Analyzing metabolic markers screened and optimized by multivariate statistical with plasma metabolic profiles from peripheral blood samples of different groups.
~Positive patients' samples will be collected at baseline."
11035605|NCT04529590||Patients without cardiovascular events after 18 years|For negative patients' samples will be collected at baseline as negative control.
11035606|NCT04529577|Experimental|His-bundle pacing first|Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
11035607|NCT04529577|Experimental|RV apical pacing first|Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
11035608|NCT04529564||EAP patients|The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in South Korea and Taiwan during 2018 to 2019.
11035609|NCT04529551|Experimental|1601A, 1601B product use order|Subjects will use 1601A for 1 week and then 1601B for 1 week.
11035610|NCT04529551|Experimental|1601B, 1601A product use order|Subjects will use 1601B for 1 week and then 1601A for 1 week.
11035611|NCT04529538|Experimental|Group1: nOPV1 (IPV History)|20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of novel OPV type 1 (nOPV1) containing 10^6.5 CCID50/dose.
11035612|NCT04529538|Active Comparator|Group 2: mOPV1 (IPV History)|20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of mOPV1 containing 10^6.0 CCID50/dose.
11035613|NCT04529538|Experimental|Group 3: nOPV1 (OPV History)|50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV1 containing 10^6.5 CCID50/dose, given 28 days apart.
11035614|NCT04529538|Active Comparator|Group 4: mOPV1 (OPV History)|25 healthy adults fully vaccinated against polio by OPV will be administered 2 doses of mOPV1containing ≥ 10^6.0 CCID50/dose, given 28 days apart
11035615|NCT04529538|Experimental|Group 5: nOPV3 (IPV History)|20 healthy adults fully vaccinated against polio exclusively by IPV will be administered 1 vaccination of nOPV3 containing 10^6.5 CCID50/dose.
11035616|NCT04529538|Active Comparator|Group 6: mOPV3 (IPV History)|20 healthy adults fully vaccination against polio by exclusively IPV will be administered 1 vaccination of mOPV3 containing ≥ 10^5.8 CCID50/dose.
11035617|NCT04529538|Experimental|Group 7: nOPV3 (OPV History)|50 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of nOPV3 in a dose of 10^6.5 CCID50/dose, given 28 days apart.
11035618|NCT04529538|Active Comparator|Group 8: mOPV3 (OPV History)|25 healthy adults fully vaccinated against polio by OPV will be administered 2 vaccinations of mOPV3 containing ≥ 10^5.8 CCID50/dose, given 28 days apart.
11035619|NCT04529525|Active Comparator|Ivermectin|"The dose of ivermectin in patients who are randomized to the active substance depends on the weight of the patient:
~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
11035620|NCT04529525|Placebo Comparator|Placebo|"The dose of placebo in patients who are randomized to the this depends on the weight of the patient:
~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.
~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
11035621|NCT04529512|Experimental|Receiving DEXTENZA® 1-3 days prior to surgery|Participants to receive DEXTENZA® 1-3 days prior to surgery
11035622|NCT04529512|Experimental|Receiving DEXTENZA® 1-2 weeks prior to surgery|Participants to receive DEXTENZA® 1-2 weeks prior to surgery
11035623|NCT04529512|Experimental|Receiving DEXTENZA® 1 month prior to surgery|Participants to receive DEXTENZA® 1 month prior to surgery
11035624|NCT04529512|No Intervention|Not receiving the DEXTENZA® implant|Participants will not receive the DEXTENZA® implant
11035625|NCT04529499|Experimental|favipiravir + supportive care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets. Tablet Strength 200 mg. Dosage: 1,800 mg BID on Day 1 + 800 mg BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
11035626|NCT04529499|Placebo Comparator|Placebo with Standard of Care|Frequency: Twice daily (morning and evening) Dosage Form: Tablets Dosage: 9 tablets for BID on Day 1 + 4 tablets BID for next 9 days (maximum). On Day 1, the second dose will be administered with at least a 4-hour interval from administration of the first dose.
11035627|NCT04529486|Experimental|Group 1: Kinesio taping|Kinesio taping was applied to the study group to improve posture and improve function in the shoulder area. Measurements were carried out for the study group before and after application (with tape on). The tape was then removed and the measurements were repeated after 1 week.
11035628|NCT04529486|No Intervention|Group 2: Control|No application was made to the control group.
11035629|NCT04529473|Placebo Comparator|Placebo|1 capsule per day, consumed orally, before breakfast for the duration of the study.
11035630|NCT04529473|Experimental|Eubacterium hallii|1 capsule per day, consumed orally, before breakfast for the duration of the study.
11035631|NCT04529460||Previously COVID-19 positive|Previously confirmed PCR positive for COVID-19 And/or positive COVID-19 antibody test in the past six months
11035632|NCT04529460||Previously COVID19 negative|No previous symptoms of COVID-19
11035633|NCT04529447||Patient satisfaction survey|Jaseng Hospital of Korean medicine conducted a pen and paper survey on patient satisfaction with regard to its COVID-19 response in inpatients hospitalized and outpatients visiting during March 23-25, 2020.
11035634|NCT04529434|Experimental|Arm 1|Households living in novel-design houses.
11035635|NCT04529434|Other|Arm 2|Households living in traditional African houses.
11035636|NCT04529421||Students, Higher Education Institution 1|All students at Higher Education Institution 1 who agree to take part in study.
11035637|NCT04529421||Students, Higher Education Institution 2|All students at Higher Education Institution 2 who agree to take part in study.
11035638|NCT04529421||Students, Higher Education Institution 3|All students at Higher Education Institution 3 who agree to take part in study.
11035639|NCT04529421||Students, Higher Education Institution 4|All students at Higher Education Institution 4 who agree to take part in study.
11035640|NCT04529421||Students, Higher Education Institution 5|All students at Higher Education Institution 5 who agree to take part in study.
11035641|NCT04529421||Students, Higher Education Institution 6|All students at Higher Education Institution 6 who agree to take part in study.
11035642|NCT04529421||Students, Higher Education Institution 7|All students at Higher Education Institution 7 who agree to take part in study.
11035643|NCT04529421||Students, Higher Education Institution 8|All students at Higher Education Institution 8 who agree to take part in study.
11035644|NCT04529421||Students, Higher Education Institution 9|All students at Higher Education Institution 9 who agree to take part in study.
11035645|NCT04529421||Students, Higher Education Institution 10|All students at Higher Education Institution 10 who agree to take part in study.
11035746|NCT04528797|No Intervention|Control|No levothyroxine or methylprednisolone administered.
11035646|NCT04529421||Students, Higher Education Institution 11|All students at Higher Education Institution 11 who agree to take part in study.
11035647|NCT04529421||Students, Higher Education Institution 12|All students at Higher Education Institution 12 who agree to take part in study.
11035648|NCT04529408||COVID-19 Follow up clinic|Patients attending routine post-COVID-19 follow up clinic
11035649|NCT04529408||Pulmonary Disease clinic|Patients attending routine outpatient appointment for pulmonary disease
11035650|NCT04529395|Experimental|Aromatherapy group|
11035651|NCT04529395|Active Comparator|Control group|
11035652|NCT04529382||Cohort 1: Unanticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 1 will be FNAIT cases that were not antenatally treated with by maternal IVIg administration (or other forms of fetal therapy).
11035653|NCT04529382||Cohort 2: Anticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 2 will be FNAIT cases which were anticipated antenatally by maternal IVIg administration according to our local protocol.
11035654|NCT04529369|Experimental|Prominent middle lobe BPH satisfactory channel after MLO PVP|
11035655|NCT04529369|Active Comparator|Prominent middle lobe BPH unsatisfactory channel after MLO PVP|
11035656|NCT04529356|Sham Comparator|Simple acetaminophen treatment|Acetaminophen will be taken when patients suffered from headache during the study. No specific dosage and frequency was required for this group as long as the participants record the exact drug usage.
11035657|NCT04529356|Active Comparator|Simple acetaminophen combined with low-frequency rTMS|Apart from acetaminophen usage, low frequency TMS (1HZ) will be used in patients three times a month for 6 months.
11035658|NCT04529356|Experimental|Simple acetaminophen combined with high-frequency rTMS|Apart from acetaminophen usage, high frequency TMS (10HZ) will be used in patients three times a month for 6 months.
11035659|NCT04529343|Experimental|Virtual Reality Group|To the virtual reality group; In addition to upper extremity exercises applied 2 days a week, upper extremity rehabilitation via virtual reality glasses will be performed 3 days a week for 6 weeks and each session will be 45 minutes.
11035660|NCT04529343|Active Comparator|Control Group|Upper extremity exercises will be applied to the participants in the control group 2 days a week for 6 weeks.
11035661|NCT04529330||fractures with blister appeared|tibial plateau fractures with blister observed
11035662|NCT04529330||fractures without blister appeared|tibial plateau fractures without blister observed
11035663|NCT04529317|No Intervention|Regular diet|The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed.
11035664|NCT04529317|Experimental|Quinoa diet|With the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).
11035665|NCT04529304|Experimental|Visual EEG|Individual dosing of anesthetic medications based on EEG AND other standardized clinical observations (BP, HR)
11035666|NCT04529304|Experimental|Blinded EEG|Individual dosing of anesthetic medications based on standardized clinical observations (BP, HR).
11035667|NCT04529291|Other|Group with walking disorder|This Group with walking disorder corresponds to patient reporting walking disorders due to his illness.
11035668|NCT04529291|Other|Group without walking disorder|This Group without walking disorder corresponds to patients not reporting walking disorders due to his illness.
11035669|NCT04529278|Experimental|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).
~The daily dose is then 1.8 mg until week W26."
11035670|NCT04529265|Experimental|Methylene Blue group|The first dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration at 8:00AM on the postoperative first day within one hour; The third dosage: 2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration at 8:00AM on the postoperative second day within one hour.
11035671|NCT04529265|Placebo Comparator|Control group|The first dosage: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour; The second dosage: normal saline in total 50 ml volume intravenous administration at 8:00AM on the postoperative first day within one hour; The third dosage: normal saline in total 50 ml volume intravenous administration at 8:00AM on the postoperative second day within one hour.
11035672|NCT04529252||Spinocerebellar Ataxia and Other Nucleotide Repeat Diseases|Participants with a clinical diagnosis of spinocerebellar ataxia and other nucleotide repeat diseases (not including Huntington's Disease) with or without a genetic mutation and unaffected family members (grandparents, parents, brothers, sisters, cousins, uncles and aunts) who may or may not carry a genetic mutation for the disease.
11035673|NCT04529252||Control Group|Participants with no known medical or family history of inherited neurodegenerative forms of spinocerebellar ataxia or nucleotide repeat diseases (not including Huntington's Disease) and spouses or caregivers of patients with spinocerebellar ataxia and nucleotide repeat diseases (not including Huntington's Disease) will serve as controls in the study.
11035674|NCT04529239||Low to Moderate Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
11035675|NCT04529239||High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
11035676|NCT04529239||Very High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
11035677|NCT04529226|Experimental|Clozapine|Pharmaceutical Form: Tablet ATC Code: N05AH02
11035678|NCT04529226|Active Comparator|Control|Usual antipsychotic medication used in the treatment of treatment-resistant psychosis.
11035679|NCT04529213|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel
11035680|NCT04529213|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel
11035681|NCT04529213|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
11035682|NCT04529200|Experimental|1. Comprehensive fall prevention protocol group (CARE)|every week protocol change for every patient according to 1 repetition maximum
11035683|NCT04529200|Active Comparator|2. Conventional balance training group|conventional protocol commonly used for rehabilitation
11035684|NCT04529187|Active Comparator|DEX group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a dexmedetomidine infusion in a rate of of 0.7 ug.kg-1.hr-1will be initiated. After 5 minutes of dexmedetomidine therapy a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
11035685|NCT04529187|Active Comparator|MID group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a single dose of midazolam (2 mg intravenously) will be given to each participant in this arm. After 5 minutes of midazolam administration a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
11035686|NCT04529174|Active Comparator|Active HDL supplement|25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.
11035687|NCT04529174|Placebo Comparator|Placebo|25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.
11035688|NCT04529161|Experimental|Group A|Diet followed by routine eating
11035689|NCT04529161|Experimental|Group B|Routine eating followed by diet
11035690|NCT04529148|Experimental|The treatment group|Ginkgo biloba dropping pills (63mg / pill), oral, 5 pills each time, three times a day,12 weeks totally. ( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
11035691|NCT04529148|Placebo Comparator|The control group|Mimetic drug of ginkgo biloba dropping pills (63mg / pill),oral, 5 pills each time, three times a day,12 weeks totally.( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
11035692|NCT04529135|Experimental|Dexmedetomidine|IV,0.2~0.8 µg/kg/hr
11035693|NCT04529135|Active Comparator|Remifentanil|IV,0.05~0.2 µg/kg/min
11035694|NCT04529096|Experimental|LY3016859|LY3016859 administered intravenously (IV).
11035695|NCT04529096|Placebo Comparator|Placebo|Placebo administered IV.
11035696|NCT04529083|Experimental|Intervention|Mixed Reality System for virtual mirror therapy
11035697|NCT04529070|Experimental|Intervention + Standard of care|Nightmare Rescripting and Rehearsal: a 10 minute intervention for Primary Care plus Sleep Hygiene handout.
11035698|NCT04529070|Active Comparator|Standard of care|Standard of Care Sleep Hygiene handout alone.
11035699|NCT04529057|Experimental|Tooth-borne (Hyrax) expander|
11035700|NCT04529057|Experimental|Tooth tissue-borne (KBME) expander|
11035701|NCT04529057|Experimental|Bone-borne (MIDME) expander|
11035702|NCT04529044|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30-40 minutes during weeks 1, 8, 16, and 24 in the absence of disease progression or unacceptable toxicity.
11035703|NCT04529031|Active Comparator|RFPP group intervention|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices.
11035704|NCT04529031|Sham Comparator|attentional control condition (group process)|Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy. Parents will receive 4 sessions of relaxation techniques.
11035705|NCT04529018|Experimental|Healthy Volunteers|A group of 5 healthy volunteers will be tested with the PET radiotracer [18F]CETO to assess safety of tracer administration, and evaluate uptake by the normal adrenal glands.
11035706|NCT04529018|Experimental|Patients with primary aldosteronism|A group of 6 patients with Primary Aldosteronism (3 with unilateral and 3 with bilateral disease) will be tested with up to two administrations of the PET radiotracer [18F]CETO, to assess safety of tracer administration, evaluate the ability of [18F]CETO to distinguish between unilateral and bilateral cases of PA, and determine the effect of Dexamethasone in improving the quality of PET-CT images acquired following administration.
11035707|NCT04529005|Experimental|Angiotensin II (Giapreza)|
11035708|NCT04528992|Experimental|Physical Therapy with BFR|Participants will begin BFR therapy as early as 2 weeks after surgery. The initial 2 weeks after surgery, or prior to initiation of BFR will consist of the physical therapy following the surgeon's postoperative protocol.
11035709|NCT04528992|Active Comparator|Physical Therapy without BFR|Participants will undergo standard physical therapy following the surgeon's postoperative protocol.
11035710|NCT04528979|Experimental|Primary root canal treatment|Primary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
11035711|NCT04528979|Experimental|Secondary root canal treatment|Secondary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
11035712|NCT04528966|Experimental|Treatment Group|Group that have received whole-body vibration treatment in addition to conventional physiotherapy
11035713|NCT04528966|Active Comparator|Control group|Group that have received conventional physiotherapy only
11035714|NCT04528953|Experimental|interval group|
11035717|NCT04528927|Experimental|HCQ+Azithromycin|"Hydroxychloroquine (HCQ): 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
~Usual standard treatment"
11035718|NCT04528927|Experimental|HCQ+Azithromycin+Zinc|"HCQ: 600 mg on the 1st day as a starting dose then 200 mg * 2 / D for 9 days
~Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
~Zinc: 220 mg per day for 10 days
~Usual standard treatment"
11035719|NCT04528927|Experimental|Azithromycin+Doxycycline|"Azithromycin: 500 mg (1st day) then 250 mg / D for 4 days
~Doxycycline: 200 mg per day for 10 days.
~Usual standard treatment"
11035720|NCT04528914|Experimental|Low-FODMAP diet|37 participants.
11035721|NCT04528914|No Intervention|Regular diet|"37 participants. The regular diet will reflect the habitual FODMAP intake in a normal diet.
~Diets in both groups will be matched in terms of total energy, fat, protein, carbohydrates and dietary fiber with the usual participant's diet."
11035722|NCT04528888|Active Comparator|LMWH group|The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). Patients in this group will be administered enoxaparin at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment with enoxaparin will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The treatment will be administered subcutaneously, daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
11035723|NCT04528888|Experimental|LMWH + steroids group|"The treatments will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization).
~Patients in this group will receive enoxaparin and methylprednisolone. Enoxaparin will be administered at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered subcutaneously daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14."
11035724|NCT04528888|Experimental|UFH + steroid group|The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
11035725|NCT04528862|Experimental|Nature|
11035726|NCT04528862|Sham Comparator|Urban|
11035727|NCT04528849|Active Comparator|Early dose increment|Patients who have received 25 IU gonadotropin dose increment on 7th day of ovulation induction
11035728|NCT04528849|Active Comparator|Late dose increment|Patients who have received 25 IU gonadotropin dose increment on 14th day of ovulation induction
11035729|NCT04528836|Experimental|Dose Escalation Level 1|80 mg/ oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
11035730|NCT04528836|Experimental|Dose Escalation Level 2|150 mg/ oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
11035731|NCT04528836|Experimental|Dose Escalation Level 3|250 mg/ oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
11035732|NCT04528836|Experimental|Dose Escalation Level 4|400 mg/ oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
11035733|NCT04528836|Experimental|Dose Escalation Level 5|550 mg/ oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
11035734|NCT04528836|Experimental|Dose Escalation Level 6|700 mg/ oral capsules. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).
11035735|NCT04528836|Experimental|Expansion Cohort A: Advanced KRAS G12C NSCLC|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
11035736|NCT04528836|Experimental|Expansion Cohort B: Advanced KRAS G12C non-NSCLC|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
11035737|NCT04528836|Experimental|Expansion Cohort C: Advanced solid tumor with other MAPK-|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
11035738|NCT04528836|Experimental|Expansion Cohort D: Advanced EGFR-mutant NSCLC|MTD/RP2D defined dose. Oral capsules Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)
11035739|NCT04528823|No Intervention|Standard care (control arm)|Strategy 1: Symptoms screen, CXR and TST (standard)
11035740|NCT04528823|Active Comparator|GeneXpert (GX)|Strategy 2: Symptoms screen, Genexpert and TST
11035741|NCT04528823|Active Comparator|CXR for all/NoTST|Strategy 3: Symptoms screen, CXR but NO TST
11035742|NCT04528810||Child injuries|pediatric patients under the age of 18 years newly diagnosed with injuries in the emergency department
11035743|NCT04528797|Experimental|Levothyroxine|Levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
11035744|NCT04528797|Experimental|Methylprednisolone|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later.
11035745|NCT04528797|Experimental|Combination|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later plus levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
11035747|NCT04528784|Experimental|Intervention|Transcutaneous tibial nerve stimulation will be applied as follows: 18 sessions of 30 minutes duration, delivered three times a week over a 6 week period using TENS device with 10 Hertz (Hz), and pulse width 200µs. The intensity of stimulation will be at the sensory and motor threshold by tingling sensation on sole of the foot with flexion of big toe and /or fanning of other toes.
11035748|NCT04528771|Experimental|SNO|14 patients in the S-nitrosylation arm will receive SNO (six-hour treatment with a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr).
11035749|NCT04528771|Placebo Comparator|Placebo|7 patients in the placebo arm will receive nitrogen gas (six-hour treatment).
11035750|NCT04528758|Experimental|Dosimetry group|Patients in the dosimetry group will be imaged with the radio-pharmaceutical Rhodamine 6G at different time points. 0-120, 30-150, 60-180
11035751|NCT04528758|Active Comparator|Stable Heart Patients|Stable heart patients will be given a rest/stress PET/CT with Rhodamine 6G myocardial perfusion study to determine myocardial blood flow
11035752|NCT04528745||Patients with cancer receiving cytostatic treatment|Consecutive patients referred for cytostatic treatment or in treatment with cytostatic agents for colorectal or pancreatic cancer
11035753|NCT04528732|No Intervention|Usual Care|Usual care consists of the traditional clinic intervention that focuses on testing services, ART treatment, and information about disease management.
11035754|NCT04528732|Experimental|Group-Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
11035755|NCT04528732|Experimental|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
11035756|NCT04528719|Experimental|Cohort 1: Dose A in Adults|Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.
11035757|NCT04528719|Experimental|Cohort 2: Dose B in Adults|Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.
11035758|NCT04528719|Experimental|Cohort 3: Dose B in Adults|Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
11035759|NCT04528719|Experimental|Cohort 4: Dose C in Adults|Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.
11035760|NCT04528719|Experimental|Cohort 5: Dose D in Children|Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
11035761|NCT04528719|Experimental|Cohort 6: Dose E in Children|Three total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.
11035762|NCT04528706|Experimental|MIN-102|
11035763|NCT04528693|Experimental|Intervention|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will perform, for a period of 3 months, 3 times a week, strength training, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software.
11035764|NCT04528693|No Intervention|Control|40 women with insulin resistance aged 25-45, BMI 18,5-29,9 will be asked to maintain their current level of physical activity and their diet for a period of 3 months.
11035765|NCT04528680|Experimental|SC9/ABX|Infusion of albumin-bound paclitaxel immediately followed by sonication using the SC9 device and microbubbles in order to open the blood-brain barrier.
11035766|NCT04528667|Experimental|STI-5656|STI-5656 (abivertinib maleate) capsules administered orally 100 mg QD for 7 days, in addition to standard of care
11035767|NCT04528667|Placebo Comparator|Placebo|Placebo capsules administered orally daily for 7 days, in addition to standard of care
11035768|NCT04528654|Experimental|Intervention App Group|The intervention group will be instructed to download the chosen hypertension mobile health app (Sphygmo BP) via a link provided on the platform. The hypertension app has blood pressure tracking and monitoring features and they are instructed to use the app. They will also receive a link to the Heart and Stroke foundation website which includes information on hypertension management and measuring blood pressure.
11035769|NCT04528654|No Intervention|Educational Control Group|The control will comprise usual care including any anti-hypertensive medication and lifestyle changes, and the link to the Heart and Stroke Foundation website which includes information on hypertension management and measuring blood pressure.
11035770|NCT04528641|Experimental|Arm 1 - Low dose|Arm-1 Healthy adult volunteers aged 18-55y will receive IM single dose of 5e10vp. N=15
11035771|NCT04528641|Experimental|Arm 2 - Intermediate dose|Arm-2 Healthy adult volunteers aged 18-55y will receive IM single dose of 1e11vp. N=15
11035772|NCT04528641|Experimental|Arm 3 - High dose|Arm-3 Healthy adult volunteers aged 18-55y will receive IM single dose of 2e11vp. N=15
11035773|NCT04528641|Experimental|Arm 4 - Low dose|Arm-4 Healthy elderly volunteers aged 65-85y will receive IM single dose of 5e10vp. N=15
11035774|NCT04528641|Experimental|Arm 5 - Intermediate dose|Arm-5 Healthy elderly volunteers aged 65-85y will receive IM single dose of 1e11vp. N=15
11035775|NCT04528641|Experimental|Arm 6 - High dose|Arm-6 Healthy elderly volunteers aged 65-85y will receive IM single dose of 2e11vp. N=15
11035776|NCT04528628|Experimental|MDD with melancholic features|
11035777|NCT04528628|Experimental|MDD with atypical features|
11035778|NCT04528628|Experimental|MDD with anxious distress|
11035779|NCT04528628|Experimental|MDD (overall)|
11035780|NCT04528615|Experimental|CCK In-Person Sessions|This group received the in-person CCK intervention.
11035781|NCT04528615|Active Comparator|CCK Printed Materials|This group received select printed CCK materials.
11035782|NCT04528602|Experimental|Control (Extended leg position) Group|In the control (Extended leg position) group of the study, diaper change will be performed after the legs of the babies are brought to extension.
11035783|NCT04528602|Experimental|Experimental (Legs are flexed toward abdomen) Group|In the experimental (Legs are flexed toward abdomen) group, the diaper change will be performed after the legs of the babies are brought closer to the abdomen while maintaining their flexion leg position.
11035784|NCT04528589||Mothers|Women with adverse childhood experiences referred for treatment in gestational week 20-30
11035823|NCT04528238|Experimental|Relaxing Visual Immersion|The patients will benefit a Relaxing Visual Immersion during the intravenous treatment for their cancer.
11035785|NCT04528589||Therapists|Clinicians with experience of providing psychotherapy to women with adverse childhood experiences referred for treatment during pregnancy
11035786|NCT04528576|Experimental|DragonFly-M|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Meditech Co., Ltd
11035787|NCT04528563|Experimental|Ketorolac Tromethamine|IV ketorolac tromethamine, 0.5 mg/kg to a maximum of 30 mg plus IV morphine placebo;
11035788|NCT04528563|Active Comparator|Morphine Sulfate|IV morphine 0.1 mg/kg to a maximum of 5 mg plus IV ketorolac placebo
11035789|NCT04528550|Experimental|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection in acute phase. Each included patient will receive a single dose of 100 million autologous bone marrow-derived mononuclear cells.
11035790|NCT04528550|Placebo Comparator|Control|Included patients will receive the same amount of saline through lumbar injection.
11035791|NCT04528511||Low burden of new-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value<10.87% (previously established) will be divided into the low burden group.
11035792|NCT04528511||High burden of new-onset atrial fibrillation|For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.
11035793|NCT04528485|Experimental|Sea swimming|8 sessions over 4 weeks of swimming-based activities in the sea
11035794|NCT04528472|Experimental|Acupuncture Treatment|Acupuncture Treatment: main point: DU20, DU24, MS7, LI4, ST40 Oral Medicine Rehabilitation Treatment
11035795|NCT04528472|Experimental|Regular Treatment|Acupuncture Treatment Oral Medicine Rehabilitation Treatment
11035796|NCT04528459|Active Comparator|Traditional fluoroscopy|Cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw (current standard of care).
11035797|NCT04528459|Experimental|Stryker© ADAPT™ platform|Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.
11035798|NCT04528446||BoneGN participants|Participants who have already been recruited into the CureGN study, or meet its criteria.
11035799|NCT04528446||Healthy subjects|A reference population of healthy subjects who are age- sex- BMI-matched to the CureGN study participants.
11035800|NCT04528433|Experimental|Medical-education-community Collaborated Intervention|
11035801|NCT04528433|Active Comparator|routine clinical care|
11035802|NCT04528420|Experimental|Optimised arm|Patients will be taken care of early and optimally way.
11035803|NCT04528420|No Intervention|Standard arm|Patients will be monitored as in standard practice
11035804|NCT04528394|Experimental|Photon combined with Carbon ion|The participants received photon: 56 Gy/28 Fx for high-risk area(CTVhigh), 50.4 Gy/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
11035805|NCT04528394|Experimental|Proton combined with Carbon ion|The participants received proton: 56 GyE/28 Fx for high-risk area(CTVhigh), 50.4 GyE/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
11035806|NCT04528381|Other|Laparoscopy|Diagnostic and therapeutic laparoscopy
11035807|NCT04528368|Experimental|Convalescent Plasma + Standard treatment|Participants will receive the standard treatment and convalescent plasma
11035808|NCT04528368|No Intervention|Standard treatment|Participants will receive the standard treatment
11035809|NCT04528329|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
11035810|NCT04528329|Active Comparator|Late CS|Dexamethasone is to be used lately upon the deterioration of cases
11035811|NCT04528316|Active Comparator|Control Group/Pilates Core Stability Exercises program Group|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks
~Stages: Three stages:
~Stage I: Warm-up: consists of four Pilates motions:
~Breathing:
~Rolling back:
~Coccyx-curl:
~Hundred breathing:
~Stage II: Work-out: consists of twelve Pilates motions:
~Single leg stretch:
~Straight leg raise:
~Basic bridge:
~Bridging variation:
~Quadruped:
~Clap with seal motion
~Mermaid twist:
~Swimming:
~Double leg stretch:
~Shoulder bridge:
~Swan dive:
~Leg full front:
~Stage III: Cool-down: consists of three Pilates motions:
~Rest position:
~Cat with arm/leg extension:
~Breathing:"
11035812|NCT04528316|Experimental|Balance Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Balance Program
11035813|NCT04528316|Experimental|Coordination Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Coordination Exercises.
11035814|NCT04528303|Experimental|Whole genome sequencing|
11035815|NCT04528303|Active Comparator|Whole exome sequencing|
11035816|NCT04528290|Experimental|Group A (reference): Current ozanimod capsule formulation|Single oral dose of ozanimod 0.92 mg
11035817|NCT04528290|Experimental|Group B (test): Ozanimod granule formulation|Single oral dose of ozanimod 0.92 mg using Sprinkle capsule. Ozanimod Sprinkle Capsule will be opened, and the entire contents sprinkled onto a teaspoon (5 mL) of applesauce.
11035818|NCT04528277|Experimental|LGTB treatment group|The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw).
11035819|NCT04528277|No Intervention|LGTB no treatment group|The LGTB no treatment group will not take any medication related to preventive treatment of tuberculosis.
11035820|NCT04528277|No Intervention|non-LGTB group|The non-LGTB group will not take any medication related to preventive treatment of tuberculosis.
11035821|NCT04528264|Experimental|Ultrasound guided|Intraoperative high frequency ultrasound used to guide the reduction of depressed zygomatic arch.
11035822|NCT04528264|Other|Conventional blind reduction technique|Conventional blind reduction of zygomatic arch fracture will be conducted without any intraoperative imaging.
11035972|NCT04527276|No Intervention|Placebo Group|Group of patients who received standard oral care
11035824|NCT04528238|No Intervention|No sensitive stimulation|The patients will not receive Relaxing Visual Immersion during the intravenous treatment for their cancer.
11035825|NCT04528212|Experimental|Group I|Glimepiride (4 mg) per Day
11035826|NCT04528212|Experimental|Group II|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
11035827|NCT04528212|Experimental|Group III|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
11035828|NCT04528199|Experimental|[18F]FLOR (FC303)|[18F]FLOR (FC303) PET/CT imaging.
11035829|NCT04528186||1|Low eating index scores(50-70)
11035830|NCT04528186||2|High eating index scores(Above 70)
11035831|NCT04528173|Active Comparator|Traditional Care Group (TCG)|Traditional anesthetic with opioids group will receive institutional standard clinical care for tonsillectomy, including a standardized opioid dose at the beginning of the case and again at the end if needed. Dexmedetomidine and Ketorolac will not be used intra-operatively in this cohort to prevent confounding.
11035832|NCT04528173|Experimental|Opioid-Free Group (OFG)|Opioid-Free group will receive institutional standard clinical care for tonsillectomy, without opioids, but including Dexmedetomidine and Ketorolac.
11035833|NCT04528160|Experimental|Pain neuroscience education and exercise|"This group will receive an 8-week intervention (1 session per week) of pain neuroscience education and exercise.
~PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will include mobility, balance and strength exercises."
11035834|NCT04528160|Active Comparator|Usual care|This group will receive usual care administered by general practitioners at primary care.
11035835|NCT04528147|Experimental|Yi Jin Jing Tiger Roaring Speech Rehabilitation|Yi Jin Jing tiger roaring speech rehabilitation with real-time feedback technique Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total.
11035836|NCT04528147|Experimental|Conventional Speech Rehabilitation|"Patients will receive speech rehabilitation recommended by The Parkinson's Foundation.
~Duration: Each time requires an hour of training; Frequency: three times a week, 4 weeks in total."
11035837|NCT04528134|Experimental|Extended Contact RMGI Varnish/5% Sodium Fluoride Varnish|This group will receive extended contact (XT) varnish on their upper left and lower right teeth, and traditional 5% sodium fluoride varnish on their upper right and lower left teeth.
11035838|NCT04528134|Experimental|Placebo Varnish/Extended Contact RMGI Varnish|This group will receive placebo varnish on their upper left and lower right teeth, and extended contact (XT) varnish on their upper right and lower left teeth.
11035839|NCT04528134|Active Comparator|5% Sodium Fluoride Varnish/Placebo Varnish|This group will receive traditional 5% sodium fluoride varnish on their upper left and lower right teeth, and placebo varnish on their upper right and lower left teeth.
11035840|NCT04528121|Experimental|study group|(CoDuSe) exercise inform of core stability, dual tasking, and sensory strategies the conventional selected exercise program inform of static and dynamic balance training exercises
11035841|NCT04528121|Experimental|control group|the conventional selected exercise program inform of static and dynamic balance training exercises
11035842|NCT04528108|Experimental|ZYZQ Group|ZYZQ group is the experimental group which is treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine for 3 months.
11035843|NCT04528108|Active Comparator|GXN Group|GXN group is the active Comparator group which is treated with Gong Xue Ning capsules for 3 months
11035844|NCT04528095|Experimental|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml
11035845|NCT04528095|Experimental|Clozapine+Amisulpride|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d
11035846|NCT04528095|Experimental|Clozapine+Gingke biloba|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Gingke biloba 120-360mg/d
11035847|NCT04528095|Experimental|MECT|MECT:The treatment lasted for 4 months,16 times in total
11035848|NCT04528095|Experimental|MST|MST:The treatment lasted for 4 months,16 times in total
11035849|NCT04528095|Experimental|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
11035850|NCT04528082|Experimental|Apremilast|Participants will receive apremilast orally in the double-blind 12 week treatment phase. Then the participants will continue to receive apremilast in the active 40 weeks treatment phase.
11035851|NCT04528082|Placebo Comparator|Placebo to Apremilast|Participants will receive the matching placebo orally in the double-blind 12 week treatment phase. Then the participants will receive apremilast in the active 40 weeks treatment phase.
11035852|NCT04528069|Experimental|PanOptix Toric Trifocal IOL|PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
11035853|NCT04528056|Experimental|Ambrisentan+Sulfasalazine|
11035854|NCT04528056|Active Comparator|Ambrisentan+Sulfasalazine's placebo|
11035855|NCT04528056|Experimental|Ambrisentan's placebo+Sulfasalazine|
11035856|NCT04528056|Placebo Comparator|Ambrisentan's placebo+Sulfasalazine's placebo|
11035857|NCT04528043||critically ill patients|critically ill patients admitted in one of the 5 ICUs of the university hospital of Nancy during the year 2016 with documented third group enterobacteriaceae infection and/or colonization with third group enterobacteriaceae
11035858|NCT04528030|Other|Treatment starting with an on ON cycle|The treatment will start ON cycle for 6 hours, followed by OFF cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
11035859|NCT04528030|Other|Treatment starting with an on OFF cycle|The treatment will start OFF cycle for 6 hours, followed by ON cycle for 6 hours, followed by OFF cycle for 6 hours and finished with ON cycle for 6 hours.
11035860|NCT04528017|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
11035861|NCT04528017|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
11035971|NCT04527276|Active Comparator|Chlorhexidine|5 ml of 0,12 % Chlorhexidine (CHX) solution is applied to the intervention group for oral care
11035862|NCT04528004|Experimental|Nicotinamide riboside|"Participants randomized to Nicotinamide Riboside (NR) and scheduled to receive an LVAD will receive nicotinamide riboside (NR) capsules according to the following administration schedule:
~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
11035863|NCT04528004|Placebo Comparator|Placebo|"Participants randomized to Placebo and scheduled to receive an LVAD will receive Placebo capsules according to the following administration schedule:
~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg) Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily Washout Day of LVAD Surgery and/or Day 15: None"
11035864|NCT04527991|Experimental|sacituzumab govitecan|Subjects randomized to the treatment arm will receive 10 mg/kg of sacituzumab govitecan intravenously on Day 1 and Day 8 of 21-day cycles.
11035865|NCT04527991|Active Comparator|Treatment of Physician's Choice|Those randomized to the Treatment of Physician's Choice arm will have the choice of receiving paclitaxel, docetaxel, and vinflunine administered intravenously at SOC doses of 175, 75 and 320 mg/m2 respectively, on Day 1 of 21-day cycles.
11035866|NCT04527978|Other|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
11035867|NCT04527978|Other|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
11035868|NCT04527965|Experimental|Customized diet to reduce liver fat|Ad libitum diet high in plant-derived PUFA and lower in carbohydrates
11035869|NCT04527965|Experimental|Healthy Nordic diet|Ad libitum diet, based on Nordic foods, higher in carbohydrates (high fiber/low GI) and lower in fat but rich in monounsaturated fatty acid (MUFA) and PUFA
11035870|NCT04527965|Active Comparator|Control|Ad libitum diet in accordance with the Nordic Nutrition Recommendations
11035871|NCT04527952|Experimental|Time-restricted feeding (TRF)|Participants will eat the majority of their calories in the day. More specifically participants will consume 70% of their total calories before 5 pm and the remaining 30% after 5 pm.
11035872|NCT04527952|Active Comparator|Intermittent fasting (IF)|This involves eating all of one's meals within a specific time (e.g. 8 hours) frame and fasting for the remaining hours (16 hours) in a day.
11035873|NCT04527952|Active Comparator|Alternate day fasting (ADF)|This involves complete fasting (i.e. no food or caloric containing beverages, only water consumption) for roughly an entire 36-hour period, followed by an ad libitum feeding day.
11035874|NCT04527939|Active Comparator|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
11035875|NCT04527939|Sham Comparator|magnification chromoendoscopy.|magnification chromoendoscopy.
11035876|NCT04527926|Experimental|STEPuP Intervention|STEPuP interventions
11035877|NCT04527926|Active Comparator|Usual Care|Standard of Care
11035878|NCT04527913|Experimental|Control group|15 patients receiving oral hygiene instructions as determined by their group allocation (use of manual toothbrush alone)
11035879|NCT04527913|Experimental|Test group 1|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus dental floss)
11035880|NCT04527913|Experimental|Test group 2|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus interdental brushes)
11035881|NCT04527913|Experimental|Test group 3|15 patients receiving oral hygiene instructions as determined by their group allocation (manual toothbrush plus rubber interdental picks)
11035882|NCT04527900|Experimental|Concurrent chemoradiation|Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
11035883|NCT04527887|Active Comparator|Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)|intracanalicular dexamethasone insert
11035884|NCT04527887|Placebo Comparator|ProLong™ collagen plugs|collagen plug
11035885|NCT04527874|Experimental|Intervention|Clusters in the intervention arm receive the VITAL intervention (see intervention)
11035886|NCT04527874|No Intervention|Control|Clusters in the control arm continue standard of care.
11035887|NCT04527861|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
11035888|NCT04527861|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（3~5 ports）.
11035889|NCT04527848|Experimental|small amount of undiluted C3F8|
11035890|NCT04527848|Active Comparator|large amount of diluted C3f8|
11035891|NCT04527848|Active Comparator|small amount of undiluted SF6|
11035892|NCT04527848|Active Comparator|large amount of diluted SF6|
11035893|NCT04527835||patients suspected for viral myocarditis|All patients admitted with unexplained heart failure in the last 3 months will be investigated for viral myocarditis by the use of 12 lead ECG, echocardiography, Cardiac MRI , coronary angiography, Endomyocardial biopsy ( optional ), serological tests including ELIZA,Extraction of nucleic acid, Determination of viral genome by using PCR., Quantitative real-time PCR to assess viral load, Immunohistochemistry analysis of EMB.
11035894|NCT04527822|Experimental|Discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
11035895|NCT04527822|Active Comparator|Standard Care|
11035896|NCT04527809|Experimental|tDCS-active|tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area.
11035897|NCT04527809|Sham Comparator|tDCS-sham|tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
11035898|NCT04527796|Other|rehabilitation|All included patients get an pre-intervention and a post intervention analysis
11035899|NCT04527783|Experimental|experimental group|"Each subject will perform a variety of VR exercises to reduce impairments in their finger range of motion, speed and strength.
~It includes a glove-shaped sensor device and a software application."
11035900|NCT04527783|Active Comparator|control group|Each subject will perform usual care rehabilitation aimed at improving manual dexterity
11035901|NCT04527770|Active Comparator|dexamethasone group|sonar guided median nerve hydrodissection by lidocaine and dexamethasone
11035902|NCT04527770|Active Comparator|midazolam group|sonar guided median nerve hydrodissection by lidocaine and dexamethasone
11035903|NCT04527757||Paediatric patients with inhalation induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
11035904|NCT04527757||Paediatric patients with intravenous induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O). For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
11035905|NCT04527744|Experimental|the Yonsei point group|Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifacies) will be initially injected at the Yonsei point.
11035906|NCT04527744|Active Comparator|the levator labii superioris alaeque nasi muscle group|For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
11035907|NCT04527718|Experimental|Cohort 1|611 dose 1 (45mg) plus placebo
11035908|NCT04527718|Experimental|Cohort 2|611 dose 2 (150mg) plus placebo
11035909|NCT04527718|Experimental|Cohort 3|611 dose 3 (300mg) plus placebo
11035910|NCT04527718|Experimental|Cohort 4|611 dose 4 (450mg) plus placebo
11035911|NCT04527718|Experimental|Cohort 5|611 dose 5 (600mg) plus placebo
11035912|NCT04527705|Active Comparator|1-vist endodontic retreatment|Non-surgical root canal retreatment performed in one visit
11035913|NCT04527705|Active Comparator|2-vist endodontic retreatment|Non-surgical root canal retreatment performed in two visits
11035914|NCT04527692||Child|Children/adolescents from 1 to 18 years of age with a serious illness requiring follow-up by a regional pediatric palliative care resource team and/or temporarily hospitalized.
11035915|NCT04527692||Parents|Adult person with parental authority over a child between the ages of 1 and 18 who is a carrier of a serious illness and requires follow-up by a regional pediatric palliative care resource team and/or is temporarily hospitalized.
11035916|NCT04527679|Experimental|GC combined Lenvatinib|"GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.
~Lenvatinib (<60kg: 8mg /d; ≥60kg, 12mg)."
11035917|NCT04527666||Anticoagulation group|Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.
11035918|NCT04527666||Control group|Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.
11035919|NCT04527653|Experimental|Tixel Treatment|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology
11035920|NCT04527640|Experimental|Synbiotic Arm|Patients receiving synbiotics: Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 Colony Forming Unit (CFU) and Fructooligosaccharides (FOS) 60 mg, 2 capsules/day for 60 days
11035921|NCT04527640|Placebo Comparator|Placebo Arm|Patients receiving placebo capsules containing saccharum lactis (2 capsules/day for 60 days)
11035922|NCT04527627|Experimental|Experimental Group (EG)|The nursing empowerment intervention will be administered in the experimental group
11035923|NCT04527627|No Intervention|Control Group (CG)|The nursing empowerment intervention will not be administered in the control group
11035924|NCT04527614|Other|COVID+|Participants with a previous SARS-CoV-2 infection
11035925|NCT04527614|Other|COVID-|Participants without a previous SARS-CoV-2 infection
11035926|NCT04527601||ELGAN admissions during peak three months of COVID-19 pandemic|
11035927|NCT04527601||ELGAN admissions in the three corresponding months of 2019|
11035928|NCT04527575|Experimental|"EpiVacCorona (An Open Study)"|Group 1: 14 volunteers who will be vaccinated with the EpiVacCorona vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
11035929|NCT04527575|Experimental|"EpiVacCorona (A Simple, Blind, Randomized Study)"|Group 2: Administration of the EpiVacCorona vaccine, intramuscularly, twice, 21 days spaced apart, at a dose of 0.5 ml (43 volunteers)
11035930|NCT04527575|Placebo Comparator|"Placebo (A Simple, Blind, Randomized Study)"|Group 3: Тhe use of placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) intramuscularly twice space 21 days apart at a dose of 0.5 ml (43 volunteers)
11035968|NCT04527302|Sham Comparator|sham tDCS +exposure based CBT|the exposure and response prevention (ERP) treatment combined with an sham transcranial direct current stimulation over the mPFC will be applied twice a week for the fist two weeks. For the next four weeks, the sham tDCS+ERP will be applied once a week. 8 times in total
11035931|NCT04527562|Active Comparator|TRAETMENT GROUP|Participants in the colchicine treatment group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed.
11035932|NCT04527562|Placebo Comparator|CONTROL /PLACEBO GROUP|"COVID-19 Patients in this arm will receive standard COVID-19 treatment according to national guidelines of Bangladesh and will receive placebo.
~Standard care of enrolled study patients will consist:
~Isolation facility
~Symptomatic treatment with Paracetamol, Fexofenadine
~Steam inhalation/Gurgle of Lukewarm water.
~Ensuring of hand wash (20 seconds each time) and ideally wearing mask.
~Monitoring by the attending nurses."
11035933|NCT04527549|Experimental|Arm A (dabrafenib, trametinib, hydroxychloroquine)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11035934|NCT04527549|Active Comparator|Arm B (dabrafenib, trametinib, placebo)|Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11035935|NCT04527536||early-set BMJ group|Infants were admitted to our hospital at 4-7 days of age and were followed up to 28 days. Other pathological jaundice factors were excluded.Those who met the criteria were the early-onset BMJ group.
11035936|NCT04527536||late-onset BMJ group|Infants were admitted to our hospital after 7 days of age and were followed up to 28-42 days or until the jaundice disappeared. Other pathological jaundice factors were excluded..Those who met the criteria were late-onset BMJ
11035937|NCT04527536||healthy control|During the same period, the healthy newborns who were born in the obstetrics department of our hospital. These newborns were mainly breastfed or breastfed, and grew well. They were enrolled at 7-14 days of age and were followed up to 28-42 days without pathological jaundice.
11035938|NCT04527523||Endothelial Dysfunction Cohort|All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.
11035939|NCT04527510||double reading|Each patient will have the following: Screening whole breast ultrasound.
11035940|NCT04527510||second-reading|Each patient will have the following: Screening whole breast ultrasound.
11035941|NCT04527510||concurrent-reading|Each patient will have the following: Screening whole breast ultrasound.
11035942|NCT04527484|Active Comparator|Group A|SHR-1314 Vial
11035943|NCT04527484|Active Comparator|Group B|SHR-1314 PFS
11035944|NCT04527471|Active Comparator|Ensifentrine + Standard of Care|30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection
11035945|NCT04527471|Placebo Comparator|Placebo + Standard of Care|15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection
11035946|NCT04527458||Hospitalisations|All hospitalised COVID patients
11035947|NCT04527458||Critical care|All hospitalised COVID patients in critical care
11035948|NCT04527445|Experimental|Reduced Radiation Fluoroscopy|Reduced radiation fluoroscopy technique is performed by the C-arm set at 1 pulses-per-second and reduction of current.
11035949|NCT04527445|Active Comparator|Conventional Fluoroscopy|The standard of care is the conventional fluoroscopy, the C-arm is set at 30 pulses-per-second and the current set as the default.
11035950|NCT04527432|Other|All participants|Survey at 6 and 12 months time with optional antibody tests
11035951|NCT04527419|Active Comparator|Systematically mediastinal lymph node dissection group|Patient would receive systematically mediastinal lymph node dissection in surgery.
11035952|NCT04527419|Experimental|No systematically mediastinal lymph node dissection group|Patient would not receive systematically mediastinal lymph node dissection in surgery.
11035953|NCT04527406|Experimental|Early surgical group|The subjects in this group received early surgical treatment, and they are arranged to be admitted to the hospital for surgical treatment after admission. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction.
11035954|NCT04527406|Active Comparator|Traditional surgical treatment|This group of subjects received conservative treatment with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5.
11035955|NCT04527393|Experimental|individualized opioid analgesia regimen group|The dose of oral morphine for patients in the individualized group is determined according to the results of fentanyl test.
11035956|NCT04527393|Active Comparator|conventional opioid analgesia regimen group|Patients in the conventional group are given routine dose of oral morphine.
11035957|NCT04527380|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC).
11035958|NCT04527380|Active Comparator|Adalimumab|Adalimumab given SC. Participants may have the option to switch to ixekizumab given SC during the open label extension period.
11035959|NCT04527367||VHD patients|Patients with moderate and severe valvular heart diseases
11035960|NCT04527354|Experimental|Treamid 50 mg|1 tablet of Treamid 50 mg once a day during 4 weeks of treatment period.
11035961|NCT04527354|Placebo Comparator|Placebo|1 tablet of Placebo once a day during 4 weeks of treatment period
11035962|NCT04527341||cardiac surgery patients in ICU|
11035963|NCT04527328|Experimental|AKST1210 apheresis device|The AKST1210 column will be connected to the dialysis circuit during each dialysis session.
11035964|NCT04527328|Placebo Comparator|Control column|A sham control with no effect on the dialyzed blood will be used.
11035965|NCT04527315||COVID-19 ICU Patients|
11035966|NCT04527315||Control|
11035967|NCT04527302|Active Comparator|active tDCS+exposure based CBT|the exposure and response prevention (ERP) treatment combined with an anode transcranial direct current stimulation over the mPFC will be applied twice a week for the fist two weeks. For the next four weeks, the active tDCS+ERP will be applied once a week. 8 times in total
11035969|NCT04527289|Experimental|Amantadine Group|Group, I are patients who will receive amantadine (100mg) as add on therapy to the standard regimen.
11035970|NCT04527289|Placebo Comparator|Placebo Group|Group II are patients who will be managed with the standard regimen.
11035973|NCT04527263|Active Comparator|group A|subjected to institutional protocol of diagnosis of acute appendicitis
11035974|NCT04527263|Active Comparator|group B|subjected to institutional protocol of diagnosis of acute appendicitis plus measurement of urinary 5-HIAA
11035975|NCT04527250|Experimental|Experimental:1mg|ASC41 one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
11035976|NCT04527250|Experimental|Experimental:2mg|ASC41 two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
11035977|NCT04527250|Experimental|Experimental:5mg|ASC41 one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
11035978|NCT04527250|Experimental|Experimental:10mg|ASC41 two tablets (10mg) single oral dose at Day 1.
11035979|NCT04527250|Experimental|Experimental:20mg|ASC41 four tablets (20mg) single oral dose at Day 1.
11035980|NCT04527250|Placebo Comparator|Placebo:1mg|ASC41 placebo one tablet (1mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
11035981|NCT04527250|Placebo Comparator|Placebo:2mg|ASC41 placebo two tablets (2mg) single oral dose at Day 1 and two tablets daily for 14 days from Day 14 to Day 27.
11035982|NCT04527250|Placebo Comparator|Placebo:5mg|ASC41 placebo one tablet (5mg) single oral dose at Day 1 and once daily for 14 days from Day 14 to Day 27.
11035983|NCT04527250|Placebo Comparator|Placebo:10mg|ASC41 placebo two tablets (10mg) single oral dose at Day 1.
11035984|NCT04527250|Placebo Comparator|Placebo:20mg|ASC41 placebo four tablets (20mg) single oral dose at Day 1.
11035985|NCT04527237|Experimental|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total.Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.
~Application to acupressure points in a certain order; Baihui, Susanli, Hegu, Shenmen and Quchi will be held.
~After 2-3 minutes of approach to the patient and proper positioning, 20 seconds of preparation of each of the notes will be prepared and then 2 minutes acupressure application will be applied to each point."
11035986|NCT04527237|Placebo Comparator|placebo|The false acupressure application steps (temperature of the environment, patient's position, application time, frequency and repetition, evaluation period etc.) will be the same as the acupressure application steps. Unlike acupressure, it will only be in contact with wearing gloves to reduce the electrical effect of touch, away from the actual acupressure points. Touching any part of the body or making skin contact can be an effect alone, as well as other meridians and points are located near the existing meridian and selected points, and entering their area of influence, pressing or scrubbing can cause other effects to be activated.
11035987|NCT04527224|Experimental|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
11035988|NCT04527211|Experimental|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
11035989|NCT04527211|Placebo Comparator|Placebo|Oral administration of placebo of similar characteristics every week for seven weeks
11035990|NCT04527198|Experimental|group 1|Major patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)
11035991|NCT04527185|Experimental|Endotoxin|Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.
11035992|NCT04527185|Placebo Comparator|Placebo|Administered one time during the laboratory session.
11035993|NCT04527172||systemic lupus patients|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
11035994|NCT04527172||Healthy subjects|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
11035995|NCT04527159|Other|desensitizing agents (Fluoraphat Pro and VivaSens®)|"22 participants above the age of 18 years who presented to dental clinics in Riyadh Elm University with dentine hypersensitivity were randomly selected to participate in the study.
~Each participant has at least two teeth with natural hypersensitivity which was not caused by any iatrogenic causes or bad oral habits, so there are 44 cases divided into two groups according to the material used, each group has 22 teeth, that make it applicable to apply the studied material with every patient on individual tooth with the same variables of the oral mouth. When teeth in the hypersensitivity group were evaluated for the level of DH, all teeth were found to have Grade 4 sensitivity."
11035996|NCT04527146|Experimental|IMAGINE-PD/Virtual|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via virtual visit with a genetic counselor.
11035997|NCT04527146|Experimental|IMAGINE-PD/Telephone|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via telephone with a genetic counselor.
11035998|NCT04527146|Experimental|Virtual/Telephone|Pre-test genetic counseling virtual visit with a genetic counselor. Genetic results disclosure via telephone with a genetic counselor.
11035999|NCT04527146|Active Comparator|Virtual/Virtual|Pre-test genetic counseling and genetic results disclosure via virtual visit with a genetic counselor.
11036000|NCT04527133|Experimental|Stage 1/Group 1|Intravenous Aprotinin in addition to standard care: 1 000 000 KIU IV daily during 3 days
11036001|NCT04527133|Experimental|Stage 2/Group 2|Inhaled Aprotinin in addition to standard care: 625 KIU 4 times per day during 5 days
11036002|NCT04527133|Experimental|Stage 2/Group 3|Intravenous Aprotinin in addition to standard care that includes Favipiravir: 1 000 000 KIU IV daily during 5 days
11036003|NCT04527120|Other|Model A first and then B|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
11036004|NCT04527120|Other|Model B first and then A|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
11036005|NCT04527107|Experimental|THR-149 dose level 1|
11036006|NCT04527107|Experimental|THR-149 dose level 2|
11036007|NCT04527107|Experimental|THR-149 dose level 3|
11036008|NCT04527107|Active Comparator|aflibercept|
11036009|NCT04527094||AI_PRF|Adults patients undergoing general anesthesia
11036010|NCT04527081|Experimental|Group A|
11036011|NCT04527081|Experimental|Group B|
11036012|NCT04527081|Experimental|Group C|
11036013|NCT04527068|Experimental|Bevacizumab +Tripleitriumab|Participants receive bevacizumab 7.5mg/kg and tripleitriumab 240mg in day 1 intravenously every 3week until disease progression or unacceptable toxicity
11036014|NCT04527055|Active Comparator|The 14-day bismuth-based quadruple therapy group|The patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
11036015|NCT04527055|Active Comparator|The 10-day bismuth-based quadruple therapy group|The patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
11036016|NCT04527055|No Intervention|The non-H. pylori-infected control|Age- and sex-matched patients who do not have H. pylori infection by endoscopic gastric biopsy are enrolled as the non-H. pylori-infected control.
11036017|NCT04527055|Active Comparator|The probiotic therapy group|"The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of >= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
11036018|NCT04527055|No Intervention|The non-probiotic control group|The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the non-probiotic control therapy and they do not ingest probiotic powder.
11036019|NCT04527029||limb deformity children|the imaging of limb deformity diagnosis by AI
11036020|NCT04527016|Experimental|Microbiota and eosinophils phenotype based therapy|The children will be treated with different protocol(Fluticasone propionate (FP),Azithromycin,or FP+Azithromycin) according to their Blood eosinophils level and airway microbiota pattern for 3 months and follow up for 1 year.
11036021|NCT04527016|Active Comparator|Clinical guidelines based therapy|The children will be treated as directed by their paediatrician, the clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016 (FP or montelukast for 3 months，or intermittent budesonide inhalation suspension during wheezing episode) and follow up for 1 year.
11036022|NCT04527003|Placebo Comparator|Group A - Placebo|Norethindrone acetate (5mg daily) + Placebo
11036023|NCT04527003|Active Comparator|Group B - Low Dose CBD|Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
11036024|NCT04527003|Active Comparator|Group C - High Dose CBD|Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
11036025|NCT04526990|Experimental|Experimental group|20000 participants, Ad5-nCoV , single dose, Intramuscular administration
11036026|NCT04526990|Placebo Comparator|Placebo group|20000 participants, placebo, single dose, Intramuscular administration
11036027|NCT04526977||Cases|HIV-1 infected individuals with previous or current diagnosis of SARS-CoV-2 infection, defined as the presence of suggestive symptoms and a positive PCR from the nasopharyngeal swab.
11036028|NCT04526977||Controls|HIV-1-infected individuals of the same age (range, 5 years) and sex, who not have been diagnosed of clinical (asymptomatic) or confirmed SARS CoV-2 infection, but were positive for IgG antibodies (controls group 1) or with no evidence of SARS-CoV-2 infection (no previous neither current symptoms, negative for IgM/IgG antibodies, controls group 2)
11036029|NCT04526964|Other|Intervention Group (IGr)|Participants of the intervention group (IGr) receive self-management support and skills training based on the modular self-management curriculum during the inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up and a supplementary app.
11036030|NCT04526964|No Intervention|Control Group (CGr)|Participants in the control group (CGr) receive the standard follow-up procedures (care as usual).
11036031|NCT04526951|Active Comparator|Tenecteplase|The total dose of tenecteplase is 0.25 mg/kg body weight, maximum 25 mg. The total dose will be given as an intravenous bolus
11036032|NCT04526951|Active Comparator|acetylsalicylic acid|one tablet of aspirin 300 mg Other Name: Aspirin
11036033|NCT04526938|Experimental|Endovascular repair|Endovascular repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms including those secondary to aortic dissection using a physician-modified endovascular graft.
11036034|NCT04526925|Active Comparator|standard CPET|Standard CPET will be performed without in-line filter
11036035|NCT04526925|Experimental|standard CPET with in-line filter|An in-line filter will be placed on the mouthpiece during standard CPET
11036036|NCT04526912|Experimental|VIB7734 Dose|Participants will receive a single subcutaneous dose of VIB7734.
11036037|NCT04526912|Placebo Comparator|Placebo|Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.
11036038|NCT04526899|Experimental|BNT111 + cemiplimab|
11036039|NCT04526899|Experimental|BNT111 monotherapy|
11036040|NCT04526899|Experimental|Cemiplimab monotherapy|
11036041|NCT04526886|Experimental|Study Arm|All patients in this single-arm study will be exposed to the experimental chemotherapy dose-adjustment algorithm.
11036043|NCT04526873|Experimental|Postcard: non-telehealth, photo|This group receives a postcard that does not include telehealth information and features a stock photo
11036044|NCT04526873|Experimental|Postcard: non-telehealth, salience/humorous cartoon|This group receives a postcard that does not include telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
11036045|NCT04526873|Experimental|Postcard: telehealth, photo|This group receives a postcard that does includes telehealth information and features a stock photo
11036046|NCT04526873|Experimental|Postcard: telehealth, salience/humorous cartoon|This group receives a postcard that includes telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
11036047|NCT04526873|Experimental|Phone call|This group receives a phone call
11036048|NCT04526860|No Intervention|Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
11036049|NCT04526860|Other|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
11036050|NCT04526847|Experimental|Intervention|"Intermittent energy restricted (IER) group:
~IER group will receive 5:2 diet pattern (5 day without energy restriction and 2 days with 75% energy restriction, net weekly energy deficit ~25%)"
11036051|NCT04526847|Active Comparator|Calorie Restricted Diet (CER)|"Continuous energy restricted (CER) group:
~CER group with a low-calorie diet (daily energy deficit ~25%) over the course of six months."
11036052|NCT04526834|Experimental|CD30 positive NHL subtypes|"(ALCL, PTCL-NOS, ENKTCL, DLBCL-NOS, PMBCL)
~Dose Level 1
~Dose Level 2
~Dose Level 3"
11036053|NCT04526821|Experimental|Bovine Lactoferrin|Bovine Lactoferrin plus standard measures of personal protection.
11036054|NCT04526821|Placebo Comparator|Maltodextrin|Maltodextrin plus standard measures of personal protection.
11036055|NCT04526808|Experimental|FODMAP diet|
11036056|NCT04526795|Experimental|Treatment (pegcrisantaspase, fludarabine, cytarabine)|"INDUCTION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-11 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-10. Treatment repeats every 5 weeks for up 3 cycles in the absence of disease progression or unacceptable toxicity."
11036057|NCT04526782|Experimental|Cohort 1 (1rst line)|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
11036058|NCT04526782|Experimental|Cohort 2 (2nd line) - A|Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID
11036059|NCT04526782|Active Comparator|Cohort 2 (2nd line) - B|Docetaxel 75 mg/kg (D1=D22)
11036060|NCT04526769||COVID-19 Patients|All patients aged 18 years and above who present to Fairview/UMN ERs or ICUs with confirmed or suspect COVID-19 based on the attending physician's judgment will be included.
11036061|NCT04526756|Experimental|Intervention group|patients in this group will receive mechanical thrombectomy and standardized drug treatment of acute ischemic stroke
11036062|NCT04526756|No Intervention|control group|patients in this group will receive standardized drug treatment of acute ischemic stroke
11036063|NCT04526743||BS patients|Candidates to primary BS undergoing laparoscopic gastric bypass (LGBP) or laparoscopic sleeve gastrectomy (LSG) from September 2020 to September 2021. Patients will be evaluated prior to BS and at 4 months, 1, 3 and 5 years after BS.
11036064|NCT04526743||no BS patient|A control group of subjects with obesity not candidates to BS matched with the intervention group for age, sex and BMI prior to BS. Patients will be evaluated once.
11036065|NCT04526730|Experimental|Neoadjuvant Treatment|"Neoadjuvant Phase: (3 x 4-week cycles, total 12 weeks): At every cycle, intratumoral tavo-EP will be administered (on Days 1 and 8) concurrently with 480 mg nivolumab IV infusion on Day 8 of each cycle (tavo-EP will be administered prior to nivolumab infusion).
~Definitive Surgery Phase: Surgery may be scheduled about 2-4 weeks after the last dose of nivolumab following radiologic and clinical assessment at that point. Pathologic response will be determined by institutional pathologist.
~Adjuvant Phase: Adjuvant therapy with nivolumab monotherapy will begin approximately 2-4 weeks following definitive surgery; recovery from surgery is required (Day 1 of Cycle 4 will be determined by the treating investigator once the subject is cleared to initiate systemic therapy). Nivolumab (480 mg IV infusion on Day 1 of each 4-week cycle) will be administered for up to 9 cycles during the Adjuvant phase."
11036066|NCT04526717|Other|MPT0B640|There is single Arm in this clinical trials.
11036067|NCT04526704|Experimental|Treatment Continuation Cohort|Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
11036068|NCT04526704|Experimental|Treatment-Free/Re-Treatment Cohort|Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
11036069|NCT04526691|Experimental|DS-1062a|Dose Escalation and Dose Expansion: DS-1062 in combination with pembrolizumab in participants with advanced or metastatic NSCLC without actionable genomic alterations and previously treated with platinum-based chemotherapy with or without prior immunotherapy.
11036070|NCT04526678|Experimental|Iron supplements|The intervention group will ingest 27 mg iron supplement per day for three months while the control group will not ingest iron supplements.
11036071|NCT04526678|No Intervention|Control group|The control group will not ingest iron supplements.
11036072|NCT04526665|Experimental|Elafibranor 80mg|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
11036073|NCT04526665|Placebo Comparator|Placebo|Study subjects will take 1 tablet per day orally before breakfast with a glass of water each morning
11036074|NCT04526652|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine 1mcg/kg
11036075|NCT04526652|Placebo Comparator|Placebo|Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine)
11036076|NCT04526639|Experimental|Virtual Reality games for training executive functions|Virtual Reality games for training three core executive functions
11036077|NCT04526639|Placebo Comparator|Control VR Game on Playground|A relaxing virtual reality game for control group to play in VR playground without training their executive functions
11036116|NCT04526353|No Intervention|No oxybutynin|No treatment affecting bladder function
11036078|NCT04526626|Experimental|High ligation and stripping|High ligation and stripping of long saphenous vein is the traditional standard procedure for the treatment of varicose veins
11036079|NCT04526613||'healthy' LTBI+ controls who are negative for all of the below|'healthy' LTBI+ controls who are negative for all of the below conditions
11036080|NCT04526613||healthy LTBI negative controls with none of the above conditio|healthy LTBI negative controls with none of the above conditions
11036081|NCT04526613||LTBI+ and helminth infection (positive stool qPCR and/or serol|LTBI+ and helminth infection (positive stool qPCR and/or serology
11036082|NCT04526613||LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)|LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)
11036083|NCT04526613||LTBI+ and uncontrolled DM (HbA1c >8%)|LTBI+ and uncontrolled DM (HbA1c >8%)
11036084|NCT04526613||LTBI+ with more than one of the conditions defined in groups 1|LTBI+ with more than one of the conditions defined in groups 1-3
11036085|NCT04526600|No Intervention|No fidget|
11036086|NCT04526600|Experimental|With fidget|The participant is given a specially designed fidget ball
11036087|NCT04526587||Basic science (medical chart review, biospecimen collection)|Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
11036088|NCT04526574|Active Comparator|Coadministration Group|Participants receive injections of pneumococcal vaccine (20vPnC) and influenza vaccine at the same visit, and then receive an injection of saline 1 month later.
11036089|NCT04526574|Active Comparator|Separate Administration Group|Participants receive injections of saline and influenza vaccine at the same visit, and then receive an injection of 20vPnC 1 month later.
11036090|NCT04526561|Active Comparator|Hidradenitis suppurativa TDAP|Axillary hidradenitis suppurativa reconstructed with TDAP
11036091|NCT04526561|Active Comparator|Hidradenitis suppurativa Limberg|Axillary hidradenitis suppurativa reconstructed with a Limberg flap
11036092|NCT04526561|Active Comparator|Breast reconstruction TDAP|Breast reconstruction performed with TDAP
11036093|NCT04526561|Active Comparator|Breast reconstruction latissimus dorsi|Breast reconstruction performed with latissimus dorsi
11036094|NCT04526535||No B-lines|Patients with no significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction
11036095|NCT04526535||B lines|Patients with significant B lines in the lung ultrasound at first 24 hours after acute myocardial infarction (pending establishing an optimal cut-off point)
11036096|NCT04526509|Experimental|Substudy 1: GSK3901961 in previously treated advanced SS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
11036097|NCT04526509|Experimental|Substudy 1: GSK3901961 in previously treated metastatic NSCLC|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as a single IV infusion after completing lymphodepleting chemotherapy.
11036098|NCT04526509|Experimental|Substudy 2: GSK3845097 in previously treated advanced SS|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as a single IV infusion after completing lymphodepleting chemotherapy.
11036099|NCT04526496|Experimental|Single Ascending Doses|50mg-600mg
11036100|NCT04526496|Experimental|Multiple Ascending Doses|dose to be determined
11036101|NCT04526483|Experimental|laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D|
11036102|NCT04526470|Experimental|Alpelisib + Paclitaxel|"Phase IB is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D of alpelisib will be determined based on the MTD and toxicity profiles.
~In phase II part, RP2D from the phase IB part will be applied as follows: alpelisib ( ) mg PO bid daily + paclitaxel ( ) mg/m² IV on D1, 8, and 15 every 4 weeks."
11036103|NCT04526457|Other|Standard of Care|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH and randomized to standard of care with lipid testing only.
11036104|NCT04526457|Other|Genetic Testing|Participants with suspected FH (LDL-C greater than 220 mg/dL) or a previous clinical diagnosis of FH randomized to genetic testing
11036105|NCT04526444|Experimental|Ftiness tracker|Participants in the group A will be provided the fitness tracker Accuro LYNK2 with the computational algorithm PAI.
11036106|NCT04526444|Experimental|Home training platform and fitness tracker|Participants in group B will be provided with both the fitness tracker Accuro LYNK2 with the computational algorithm PAI and access to Les Mills On Demand with the necessary equipment to perform training classes from home.
11036107|NCT04526444|Experimental|Peer support, home training platform and fitness tracker and|Participants in group C will be offered the fitness tracker Accuro LYNK2 with the computational algorithm PAI, Les Mills On Demand and additional peer support via social media.
11036108|NCT04526431||Tacrolimus once-daily|Patients receiving tacrolimus as a once-daily formulation (Envarsus)
11036109|NCT04526431||Tacrolimus bid|Patients receiving tacrolimus as a twice-a-day formulation.
11036110|NCT04526418|Experimental|24/7 EEG™ SubQ System|To demonstrate the electrographic seizure recording effectiveness of the 24/7 EEG™ SubQ system by comparison to simultaneous inpatient video-EEG data.
11036111|NCT04526392||Questionnaire|Patients will choose how they wish to complete the Pubertal Course Questionnaire: electronically (web link), on paper, by telephone, or face-to-face at a follow-up consultation.
11036112|NCT04526379|Experimental|children with PWS|Evaluation of cognitive abilities of children with PWS by several cognitive tasks and neuropsychological tests.
11036113|NCT04526379|Other|non affected children|Evaluation of cognitive abilities of children with PWS compared to a non-pathologic population of children by several cognitive tasks and neuropsychological tests
11036114|NCT04526366||The study population|All (full scientific) study designs and publication types written in English and reporting Bland-Altman test results (or other tests suggesting the presence of the required data) between simultaneous, paired, polysomnography (PSG)-derived AND Continuous Positive Airway Pressure (CPAP)-derived data describing sleep disordered breathing.
11036115|NCT04526353|Experimental|Oxybutynin during 9 months.|0.1mg / kg 2x / day from inclusion and for 9 months.
11036117|NCT04526340|Experimental|Nutrient day|on the nutrient day the subjects will take the testing food/nutrient capsules with 500 ml water
11036118|NCT04526340|Placebo Comparator|Control day|on the control day the subjects will take 500 ml water without nutrient/food capsules
11036119|NCT04526327|Other|exercise group|Female and male patients over 70 years of age with osteoporosis and sarcopenia
11036120|NCT04526314||Stage 3 with adjuvant chemotherapy|
11036121|NCT04526314||Stage 3 without adjuvant chemotherapy|
11036122|NCT04526301||Tablo Hemodialysis System|Home dialysis treatment with the Tablo Hemodialysis System
11036123|NCT04526288|Active Comparator|Arm A (alloHCT)|Patients undergo alloHCT.
11036124|NCT04526288|Experimental|Arm B (CPX-351, alloHCT)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment may repeat for up to 2 cycles (on days 1 and 3 only of cycle 2) in the absence of disease progression or unacceptable toxicity. Within 60 days after completion of CPX-351, patients undergo alloHCT.
11036125|NCT04526262|Experimental|BBB disruption|All participant in this arm will undergo 2 sessions of transcranial magnetic resonance guided focused ultrasound blood brain barrier disruption every 3 months.
11036126|NCT04526236|Placebo Comparator|Methadone 0|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered the placebo drug.
11036127|NCT04526236|Experimental|Methadone 1|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.05 mg/kg.
11036128|NCT04526236|Experimental|Methadone 2|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.1 mg/kg.
11036129|NCT04526236|Experimental|Methadone 3|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.2 mg/kg.
11036130|NCT04526223|Experimental|treatment group|MF patients exposure to ruxolitinib during transplantation
11036131|NCT04526210|Experimental|Treatment A|Participants will receive bupropion.
11036132|NCT04526210|Experimental|Treatment B|Participants will receive bupropion with ALXN1840.
11036133|NCT04526197|Experimental|Treatment A|Participants will receive celecoxib.
11036134|NCT04526197|Experimental|Treatment B|Participants will receive celecoxib with ALXN1840.
11036135|NCT04526184|Active Comparator|healthy group|25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.
11036136|NCT04526184|Active Comparator|patient group|25 individuals will be selected randomly from 103 patients with COPD from hospital records.
11036137|NCT04526171|Experimental|Vaparshun|In intervention clusters, two full day events, with a gap of 4 weeks between the two events, were organized at cluster level. Eligible households with a government or contract tor built toilet were invited to enroll for a toilet makeover. Intervention activities, delivered at cluster level, included films on toilet improvement, comfort and convenience of toile use, addressing pit filling anxiety and celebrating proud toilet owners by providing certificates and acknowledging them during the events.
11036138|NCT04526171|No Intervention|Control Arm|No intervention was delivered to clusters in the control arm.
11036139|NCT04526158|Experimental|Mobile+Group LAMP Mindfulness-Based Intervention|8 weekly interactive online group sessions and access to mobile app
11036140|NCT04526158|Experimental|Mobile LAMP Mindfulness-Based Intervention|8 weekly asynchronous sessions, delivered on mobile app
11036141|NCT04526158|No Intervention|Usual Care|The Usual Care arm will not get access to either intervention
11036142|NCT04526145|Experimental|Stress and emotion Management for Black/African Americ|Four weekly sessions delivered in a group format via Zoom teleconference. The following topics are listed in the workbook: Planning Your Information Diet; My Spheres of Influence Worksheet; Practical Wisdom for Tolerating Uncertainty; Reducing Anxiety With Thought Challenging; Reducing Anxiety Through Distraction Activities; Starting a Planning Practice; Starting a Daily Gratitude Practice; Starting a Daily Breathing Practice; Improving the Quality of Your Social Connections; Developing a Regular Exercise Routine; and Creating Your Stress-Resilience Action Plan. Each session will begin with a 15-30 minute check in on what went well, challenges, and Coronavirus Anxiety workbook. The Coronavirus Anxiety Workbook topics are complementary and the sessions will tie together the themes of comprehensive stress and emotional management through blood pressure knowledge/self-monitoring, diet, interpersonal communication skills building, and sleep hygiene.
11036143|NCT04526132|Experimental|Experimental: group1|Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
11036144|NCT04526132|Placebo Comparator|Experimental: group2|Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
11036145|NCT04526119|Experimental|Z-338|
11036146|NCT04526119|Placebo Comparator|Placebo|
11036147|NCT04526106|Experimental|Part 1: Dose Escalation|Multiple doses of RLY-4008 for oral administration.
11036148|NCT04526106|Experimental|Part 2: Dose Expansion|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
11036149|NCT04526080|Experimental|TheraBionic Arm|Self-administered from the device that delivers low levels of radiofrequency electromagnetic fields into the body with a spoon-shaped antenna placed in the mouth.
11036150|NCT04526080|Placebo Comparator|Placebo Arm|Placebo device that looks and sounds like the active device.
11036151|NCT04526067|Active Comparator|Cognitive Adaptation Training (CAT)|A home delivered adherence intervention used by managed care used to improve outcomes across multiple conditions.
11036152|NCT04526067|Active Comparator|Remote Cognitive Adaptation Training (R-CAT)|A primarily remotely delivered workable adherence intervention used by managed care used to improve outcomes across multiple conditions.
11036153|NCT04526054|Other|anosmic or normosmic COVID-19 patients|Patients will undergo ENT exams, olfactometry and MRI.
11036154|NCT04526041|Other|Professional beatboxer singer|1 professional beatboxer singer will be asked to produced different sounds while undergoing the different procedures. Researchers wil then select the most interesting sounds to be studied.
11036183|NCT04525807||Multiomics arm|Guide therapy based on multi-omics
11036155|NCT04526041|Other|Experimented beatboxer singer|10 experimented beatboxer singer will be asked to reproduced the sounds record by the first subject (professional singer) while undergoing the different procedures.
11036156|NCT04526028||Palbociclib combined with Fulvestrant|
11036157|NCT04526028||Fulvestrant|
11036158|NCT04526015|Experimental|Ilioinguinal iliohypogastric Block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
11036159|NCT04526015|Other|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
11036160|NCT04526002|Experimental|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
11036161|NCT04525989|Experimental|Proton therapy|5 x 5 Gy External radiation therapy with Protons
11036162|NCT04525989|Active Comparator|Photon therapy|5 x 5 Gy External radiation therapy with Photons
11036163|NCT04525963|Experimental|Experimental: Intervention Arm|":In the experimental group,the operating room nurse, who is given intervention training , will be provided to visit the patient before surgery. After the verbal training of the operating room nurse, a printed booklet will be left for the patient to read.
~Assigned Interventions The level of anxiety experienced by the patients increases the postoperative perception and analgesic need, increasing the sequence and anesthetic substance. For these reasons, there is a need for studies to reduce pain distribution and severity by directly dealing with pre- and postoperative anxiety and anxiety levels. Similarly, the role of the operating room nurse in reducing patient anxiety is increasingly recognized. It is observed that the pre-operative visit and education reduce the pre-operative anxiety level in patients undergoing surgical intervention, and the pre-operative visit of the operating room nurse is on the agenda."
11036164|NCT04525963|No Intervention|No Intervention|There will be no intervention in the control group. The procedures of the institution will be applied before and after the operation.
11036165|NCT04525950|Experimental|Navio|Using the new technology during surgery
11036166|NCT04525950|Active Comparator|Conventional|Using the conventional surgical instruments
11036167|NCT04525937||Patients with Severe Aortic Stenosis with Disparities|Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year
11036168|NCT04525937||Medical Providers with Disparities|Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis
11036169|NCT04525924|Experimental|Bright light therapy|Bright light therapy (BLT) will be given via a lightbox device in the morning for 30 minutes after waking up. Duration of therapy will be 7 consecutive days.
11036170|NCT04525911||Symptomatic COVID-19 infection confirmed or probable|Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)
11036171|NCT04525898|Active Comparator|Methadone Group|The methadone group will receive a dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
11036172|NCT04525898|Placebo Comparator|Control Group|The control group will be administered an equal volume of saline in an identical appearing syringe.
11036173|NCT04525885|Experimental|Gefapixant 45 mg twice daily (BID)|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
11036174|NCT04525885|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks). This arm is not included in protocol amendment 5 or later.
11036175|NCT04525885|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
11036176|NCT04525872|Experimental|Premature infants|Premature infants who are expected to receive TPN for a minimum of 5 days and infants with gastrointestinal surgical problems (e.g., ileal atresia, gastroschisis), expected to receive TPN for a minimum of 5 days
11036177|NCT04525859|Experimental|Safety|Six patients will be enrolled in the Phase 1 safety cohort. Patients will have an IR guided biopsy and FNA. Up to four core biopsies and FNAs at one site will be performed prior to intratumoral (IT) administration of Poly-ICLC. Pleural fluid will be collected for research analysis if available. Poly-ICLC will be injected in 2 locations within the pleura. Patients will undergo surgery 21±7 days after the biopsy and Poly-ICLC intratumoral (IT) injection. The type of surgery that will be performed is at the discretion of the thoracic surgeon and per the standard of care. This includes pleurectomy/decortication or extrapleural pneumonectomy. Patients will be evaluated per the standard of care post-operatively. On day 7±4 days a final toxicity assessment, physical exam and research blood will be collected. All post-operative care and monitoring thereafter is as per standard of care.
11036178|NCT04525859|Experimental|Expansion Cohort|If at most one (1) patient in the Phase 1 safety cohort experiences a DLT then a total of thirteen (13) additional patients will be enrolled into the Phase 1b Expansion Cohort. Patients in the Expansion Cohort will receive the same dose and schedule of Poly-ICLC as in the Phase 1 safety cohort. Patients will be followed for safety and tolerability, as well as efficacy. If a total of 4 or more patients experience DLTs then the study will be closed due to excessive toxicity.
11036179|NCT04525846|Experimental|PFMT group|Researcher was trained and test pelvic floor muscle strength by urogynecologist with Brink scores, participants PFMT group were educated by VDO and recieved program of PFMT after consented form 4 weeks reassess Brink score for check compliance of PFMT and followed up by telephone weekly about compliance of PFMT, general symptom, notice self recording book total 12 weeks and evaluate urinary incontinence by UDI-6 questionaires at third trimester
11036180|NCT04525846|Experimental|non PFMT|Randomized to non PFMT group watchful waiting until 36-38 week gestation follow up and evaluate UI by UDI6 questionaires at third trimester sames as intervention group
11036181|NCT04525820|Experimental|High Dose Vitamin D|"Patient will receive a single high dose of vitamin D (140'000) in addition to daily 800 IU of vitamin D.
~The medication be administered orally"
11036182|NCT04525820|Placebo Comparator|Placebo|Patient will receive a single dose of placebo, orally administered and then treatment as usual (daily 800 IU of vitamin D, orally administered)
11036186|NCT04525768||JAK2 mutation Group|Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation.
11036187|NCT04525768||Portal caver cavernoma Group|Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation.
11036188|NCT04525755|Experimental|Varenicline (.5mg BID)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline (.5 mg, 60 tablets total), NRT, or not, with outcomes assessed through 12 weeks of follow-up. 324 participants will be enrolled in this group. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience.
11036189|NCT04525755|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.
11036190|NCT04525755|No Intervention|Control Group|Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. 162 participants will be enrolled in this group.
11036191|NCT04525742|Other|Parents who have a disabled child or children|Parents having disabled child or children will be included in the research and it will be wanted to complete the survey questionary
11036192|NCT04525729|Experimental|Rituximab+RASi(ACEI and/or ARB)|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). If the peripheral blood CD19+B cell count was higher than 5×109/L at 6 months, one additional rituximab treatment will be added.
11036193|NCT04525729|Other|RASi(ACEI and/or ARB）|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject.
11036194|NCT04525716||COVID-19|Patients with confirmed COVID-19 infection
11036195|NCT04525716||Non-COVID-19|Patients without confirmed COVID-19 infection
11036196|NCT04525703|Experimental|Pathways for Parents|
11036197|NCT04525690|Experimental|HCV Screening Default-1 Hospital Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening
11036198|NCT04525690|Experimental|HCV Screening Default-2 Hospitals Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening.
11036199|NCT04525664|Experimental|Participants who test positive for Helicobacter pylori|Participants who test positive for Helicobacter pylori by fecal antigen testing will be offered treatment with triple therapy (clarithromycin 500 mg per os twice daily, amoxicillin 1 g per os twice daily, omeprazole 40 mg per os twice daily) for 14 consecutive days. Two to four weeks following the completion of treatment, participants will repeat fecal antigen testing to confirm whether they eradicated the Helicobacter pylori.
11036200|NCT04525664|Experimental|Patients with dyspepsia and negative for Helicobacter pylori|Participants who report chronic dyspepsia but are negative for Helicobacter pylori by fecal antigen testing will receive daily omeprazole (20 mg per os) for one month. Their symptoms will be reassessed after completion of the month treatment.
11036201|NCT04525651|Experimental|Digital Acupuncture Instrument Group|The needles will be stimulated manually to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness) and then paired electrodes from the digital acupuncture instrument will be attached to the needle handles and another two adjunct acupoints by the research assistant. The electric current will be increased until the needles begin to vibrate slightly.
11036202|NCT04525651|Active Comparator|Manual Acupuncture Group|Patients in the MA group will undergo similar procedures as the EA group except that no current will be output from the instrument.
11036203|NCT04525638|Experimental|177Lu-DOTATATE + Nivolumab|Patients will receive 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion and 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
11036204|NCT04525612|Experimental|68Ga-BNU-PSMA|Each subject receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT imaging within the specificed time.
11036205|NCT04525599|Experimental|Group 1, ASP3772 Low Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a low-dose level.
11036206|NCT04525599|Active Comparator|Group 1, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
11036207|NCT04525599|Experimental|Group 2, ASP3772 Medium Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a medium-dose level.
11036208|NCT04525599|Active Comparator|Group 2, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
11036209|NCT04525599|Experimental|Group 3, ASP3772 High Dose|Participants will receive a single intramuscular injection of ASP3772 administered on Day 1 at a high-dose level.
11036210|NCT04525599|Active Comparator|Group 3, PCV13 Comparator|Participants will receive a single intramuscular injection of the approved dose of PCV13 on Day 1.
11036211|NCT04525586||It's just an observational study, no interventions|children with recurrent wheezing
11036212|NCT04525560|Experimental|PEG-ELS-S|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
11036213|NCT04525560|Active Comparator|PEG-ELS-L|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
11036214|NCT04525547||Patients treated with Nintedanib|
11036215|NCT04525534||Placenta accreta spectrum|Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
11036216|NCT04525534||Phenotypically-matched controlled group|Mother-infant dyads admitted for delivery without placenta accreta spectrum
11046126|NCT04456062|No Intervention|Standard Treatment Group|
11036217|NCT04525521||Non-Atopic Individuals|Individuals with no history of atopic dermatitis, food allergy, asthma, or allergic rhinitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
11036218|NCT04525521||Individuals with Atopic Dermatitis|Individuals with history of atopic dermatitis will be recruited to this cohort. Skin studies (transepidermal water loss and skin tape strips) will be performed on the non-dominant hand at baseline, after hand sanitizer use, and after hand washing with soap and water.
11036219|NCT04525508||Normal glucose tolerance (NGT)|Those of the study population with one normal Oral glucose tolerance test (OGTT)
11036220|NCT04525508||Dysglycemia|Those of the study population with one dysglycemia (IFG and/or IGT)
11036221|NCT04525508||Diabetic OGTT|Those of the study population with one Diabetic OGTT
11036222|NCT04525495|Experimental|Dopamine treatment|
11036223|NCT04525482|No Intervention|Control Group|No intervention was implemented
11036224|NCT04525482|Experimental|Intervention Group|Early goal-directed sedation programs was implemented
11036225|NCT04525469|Experimental|Narrative Exposure Therapy|NET is a fully-manualized evidence-based treatment for PTSD. Participants will receive 6 weekly 60-minute individual sessions of NET.
11036226|NCT04525456|Experimental|Reduxium|1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days
11036227|NCT04525443||Patients with active SARS-CoV-2 infection.|Patients admitted for COVID-19 at Hospital Clínico San Carlos with positive SARS-CoV-2 polymerase chain reaction (PCR).
11036228|NCT04525443||Patients with past, not active, SARS-CoV-2 infection.|Patients with past infection (not active), demonstrated by serology and PCR.
11036229|NCT04525443||People without concurrent or past SARS-CoV-2 infection|Health personnel from the Cardiology Service of Hospital Clínico San Carlos who demonstrate by serology that they have not had SARS-CoV-2 infection.
11036230|NCT04525430|Experimental|Group 1|only childbirth education group
11036231|NCT04525430|Experimental|Group 2|childbirth education and was subjected to a birth plan group
11036232|NCT04525430|No Intervention|Group 3|standard care group
11036233|NCT04525417|Other|hospital healthcare workers|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
11036234|NCT04525417|Other|private health professionals|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
11036235|NCT04525404||Troponin Substudy|Participants with new COVID-19 infection will undergo high-sensitivity Troponin testing; participants with elevated Troponin will undergo MRI, bloodwork, and olfaction testing at Baseline, then repeat MRI, bloodwork and all functional testing at the Recovered (ie 12weeks post diagnosis) phase. Participants with normal Troponin will undergo only olfaction testing and bloodwork at baseline, then MRI, bloodwork and all functional testing at the Recovered phase.
11036236|NCT04525404||Late Cross-Sectional Substudy|Participants with a COVID-19 diagnosis at least 3 months prior to enrollment will undergo MRI, bloodwork and all functional testing at the Recovered phase only.
11036237|NCT04525391|Experimental|Durvalumab+AZD2811 to SCLC patients|"Dosage and Schedule: AZD2811 500mg and durvalumab 1500mg via IV administered on Day 1 for every 3weeks (fixed dosing for subjects > 30 kg body weight for durvalumab). One cycle is consisted of 3 weeks.
~The drug products must be dosed consecutively using different infusion lines. The sequence of infusions is as follows: durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. A waiting time interval of at least 30 minutes between the end of durvalumab infusion and start of AZD2811 infusion should be adhered to."
11036238|NCT04525378|No Intervention|Control|Patients will receive standard care.
11036239|NCT04525378|Experimental|MSC - low dose (2.5x10ˆ7)|Patients will receive standard care plus cell therapy.
11036240|NCT04525378|Experimental|MSC - intermediate dose (5x10ˆ7)|Patients will receive standard care plus cell therapy.
11036241|NCT04525378|Experimental|MSC - high dose (10x10ˆ7)|Patients will receive standard care plus cell therapy.
11036242|NCT04525365|Experimental|Pleural aspiration|Pleural aspiration under sedation
11036243|NCT04525365|Active Comparator|Closed Thoracostomy|Actual management
11036244|NCT04525352|Experimental|Experimental - RP-L401|RP-L401 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with lentiviral vector carrying the TCIRG1 transgene
11036245|NCT04525326|Experimental|standard chemotherapy plus Cetuximab|
11036246|NCT04525326|Experimental|standard chemotherapy plus Bevacizumab|
11036247|NCT04525313||training set|58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2013.01 and 2017.12.
11036248|NCT04525313||validation set|another 58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2018.01 and 2022.12.
11036249|NCT04525300|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
11036250|NCT04525300|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
11036251|NCT04525287||Severe COVID-19|Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.
11036252|NCT04525287||Mild COVID-19|The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.
11036253|NCT04525274|Placebo Comparator|control group|patient will receive 40 ml bupivacaine 0.25% + 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
11036254|NCT04525274|Active Comparator|dexmedetomidine group|patient will receive 40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
11036255|NCT04525274|Active Comparator|ketamine group|patient will receive 40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
11036256|NCT04525248|Active Comparator|High resection|Laparoscopic total colectomy + High resection of rectum
11036257|NCT04525248|Experimental|Low resection|Laparoscopic total colectomy + Low resection of rectum
11036258|NCT04525235|Active Comparator|Rifampicin standard dose|rifampicin standard dose + phenotyping cocktail
11036259|NCT04525235|Experimental|Rifampicin high dose|rifampicin high dose + phenotyping cocktail
11036260|NCT04525222|Experimental|Arm I (Actify, text messages)|Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text messages.
11036261|NCT04525222|Active Comparator|Arm II (Current Standard Care, text messages)|Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text messages.
11036262|NCT04525196|Experimental|Physical activity.|Patients will benefit a physical activity program during their dialysis session.
11036263|NCT04525196|No Intervention|No physical activity.|Patients will have access to their dialysis sessions without additional physical activity.
11036264|NCT04525183|Experimental|Run In|"Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study
~Participants will receive a 6-week Acceptance and Commitment Therapy (ACT) intervention (REVITALIZE)."
11036265|NCT04525183|Experimental|Enhanced Usual Care (EUC)|Participants randomized to EUC will receive educational materials developed by the National Comprehensive Cancer Network (NCCN) about fatigue and exercise during cancer treatment.
11036266|NCT04525183|Experimental|REVITALIZE ACT Intervention|Participants randomized to the REVITALIZE acceptance and commitment therapy (ACT) will receive 6 weekly 50-minute sessions over a 6-week period delivered face-to-face using iPads, computers or tablets, and a HIPAA-compliant platform (Zoom for Healthcare). If participants have difficulty connecting to the platform, telephone sessions are permitted.
11036267|NCT04525170|Experimental|HPT treated|daily wear Hexafocon A rigid contact lens treated with Hydra PEG surface coating
11036268|NCT04525170|Experimental|untreated|daily wear Hexafocon A rigid contact lens
11036269|NCT04525157|Experimental|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
11036270|NCT04525157|Placebo Comparator|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
11036271|NCT04525157|Experimental|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.
~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
11036272|NCT04525144|Experimental|Tebonin Forte|120mg, twice a day, 52 weeks
11036273|NCT04525144|No Intervention|Control|
11036274|NCT04525131|Experimental|CPX-POM|IV over 20 minutes once per day
11036275|NCT04525105||Study group|wıth URGE INCONTINANCE
11036276|NCT04525105||Control group|not urge incontinance
11036277|NCT04525092|Active Comparator|Conventional Hemodialysis|Participants will receive intermittent HD for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode HD).
11036278|NCT04525092|Experimental|Pre-dilution Hemodiafiltration|Participants will receive intermittent pre-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode pre-dilution HDF).
11036279|NCT04525092|Experimental|Post-dilution Hemodiafiltration|Participants will receive intermittent post-dilution HDF for a minimum of 4hours per session, 3 to 4 times/week, using the 5008 High-Volume HDF Machine from Fresenius Medical Care with High Flux FX1000 Dialyzer (Mode post-dilution HDF).
11036280|NCT04525079|Experimental|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
11036281|NCT04525079|Experimental|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
11036282|NCT04525079|Experimental|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
11036283|NCT04525079|Experimental|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
11036284|NCT04525066|Experimental|Treatment Group - Receiving Hyaluronic Acid Injection|Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
11036285|NCT04525066|Placebo Comparator|Control Group - Not Receiving Hyaluronic Acid Injection|Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
11036286|NCT04525040|Experimental|Intervention arm|Children in this arm were given ProbioKid®; one capsule daily, for 6 weeks.
11036287|NCT04525040|Other|Pragmatic arm|Children in this arm received standard of care as usual without a preventive intervention
11036288|NCT04525027||survivors|
11036289|NCT04525027||non survivors|
11036290|NCT04525014|Experimental|RRx-001, Temozolomide and Irinotecan|
11036291|NCT04524988|Active Comparator|Fundamentals of Laparoscopic Surgery (FLS)|This group will undergo 2.5h of training on the current standard laparoscopic simulation trainer (FLS), including the following tasks: peg transfer, intracorporeal knot tying and ligating loop.
11036292|NCT04524988|Experimental|Essentials in Minimally Invasive Gynecology (EMIG)|This group will undergo 2.5h of training on a new gynecology-specific laparoscopic simulation trainer (EMIG), including the following tasks: peg transfer, intracorporeal knot tying and running suture.
11036293|NCT04524975|Experimental|CD-008-0045 60 mg/day|Patients assigned to the CD-008-0045 60 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast, lunch, and dinner for 8 weeks
11036294|NCT04524975|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner, and 1 placebo capsule before lunch for 8 weeks.
11036295|NCT04524975|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, lunch, and dinner for 8 weeks.
11036296|NCT04524962|Experimental|Descartes 30|
11036297|NCT04524949|Experimental|IMCY-0098, low dose|The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).
11036298|NCT04524949|Experimental|IMCY-0098, high dose|The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).
11036299|NCT04524949|Placebo Comparator|Placebo|Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.
11036300|NCT04524936||obese patient with non-alcoholic fatty liver disease|
11036301|NCT04524936||obese patient without non-alcoholic fatty liver disease|
11036302|NCT04524936||control group|
11036303|NCT04524923||cohort group|A hundred typically developing preschool children of both genders with age ranges from three to five years will be included in this study. Visual motor integration, quality of life and cognitive function were assessed by the Peabody Developmental Motor Scale, the Pediatric Quality of Life Inventory™ and the Pediatric Quality of Life Inventory™ cognitive functioning scale respectively
11036304|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
11036305|NCT04524897|Other|The use of Triamcinolone Injection|Triamcinolone acetate (40 mg/mL)
11036306|NCT04524884|Experimental|Cohort A|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive operation treatment if the tumor is evaluated as resectable cases by clinical examination.
11036307|NCT04524884|Experimental|Cohort B|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.
11036308|NCT04524884|Experimental|Cohort C|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will be removed from the study, if the tumor is evaluated as unresectable cases and patients have no potential benefits by clinical examination.
11036309|NCT04524871|Active Comparator|Stage 1: Atezolizumab + Bevacizumab|Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11036310|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tiragolumab|Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11036311|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tocilizumab|Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11036312|NCT04524858|Experimental|ATI-450|Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
11036313|NCT04524845|Experimental|Rebel Reliever|Rebel Reliever (RR) (Thuasne, Levallois Perret, France) with bilateral rigid frames and two hinges. The valgus correction was set by adjusting the medial and lateral frame lengths to a difference of two or three points as dictated by the participant's feeling and comfort. Six straps maintained the brace in place
11036314|NCT04524845|Experimental|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France) made mainly from textile. Upper and lower straps were adjusted to the participant's feeling and comfort.
11036315|NCT04524845|Active Comparator|Unloader One|Unloader One (UO) (Össur, Reykjavik, Iceland), with unilateral frame and one hinge. Upper and lower straps were adjusted to the setting recommended by the fitting instructions and confirmed by the participant's sensation.
11036316|NCT04524845|No Intervention|No orthosis|Control condition without brace
11036317|NCT04524832|Experimental|Semaglutide D 50 mg|Participants will receive once daily semaglutide D formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
11036318|NCT04524832|Experimental|Semaglutide C 50 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
11036319|NCT04524832|Experimental|2 x Semaglutide C 25 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 2 x 25 mg (week 13-16)
11036320|NCT04524832|Experimental|Semaglutide E 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 16 weeks: A) Semaglutide C formulation: 2.4 mg (week 1-2), 5.6 mg (week 3-4) and 11.2 mg (week 5-8). B) Semaglutide E formulation: 25 mg (week 9-12) and 50 mg (week 13-16)
11036321|NCT04524832|Experimental|Semaglutide F 50 mg|Participants will receive once daily semaglutide F formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
11036322|NCT04524819||COPD participants|Saliva and Sputum will be collected from patients when they are unwell with a flare up of the COPS and when they are well
11036323|NCT04524806|Active Comparator|2 mm-thick splint group (2 mm-TSG)|The group which applied the 2 mm thick stabilization splint
11036324|NCT04524806|Active Comparator|4 mm-thick splint group (4 mm-TSG)|The group which applied the 4 mm thick stabilization splint
11036325|NCT04524793|Other|Endovenous Microwave Ablations|Patients that have undergone Endovenous Microwave Ablation from ECO (Nanjing ECO Microwave System Co., Ltd) to treat primary great and short saphenous vein reflux
11036326|NCT04524780|Experimental|left atrial appendage radiography|
11036327|NCT04524780|Experimental|intracardiac echocardiography guidance|
11036328|NCT04524767|Experimental|SBIRT|SBIRT will involve screening with the Patient Health Questionnaire-9 (PHQ-9); brief intervention with Motivational Interviewing (MI); and referral to specialty treatment, as needed for subjects with persistent depressive symptoms.
11036329|NCT04524767|Active Comparator|Referral As Usual|Referral as Usual will involve distributing depression educational materials (e.g., from the National Institute of Mental Health) and contact information for treatment providers in our target community
11036330|NCT04524741|Experimental|left atrial appendage radiography|
11036331|NCT04524741|Experimental|intracardiac echocardiography guidance|
11036332|NCT04524728||Cohort A|Patients that received palbociclib combined with letrozole 2.5 mg
11036333|NCT04524728||Cohort B|Patients that received palbociclib combined with fulvestrant 500 mg
11036334|NCT04524715|Experimental|Active Treatment Group|LLLT Treatment using an UltraSlim red/IR LED device along with all standard treatment measures for COVID19.
11036335|NCT04524715|Sham Comparator|Control Group|Treatment using a Sham comparator along with all standard treatment measures for COVID19.
11036336|NCT04524702|Experimental|Treatment (paricalcitol, hydroxychloroquine, chemotherapy)|Beginning day -14, patients receive paricalcitol IV three times weekly and hydroxychloroquine PO BID. Patients also receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on days 1, 8, 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11036337|NCT04524689|Experimental|SAR408701 + Pembrolizumab|Pembrolizumab will be administered intravenously prior to intravenously adminstration of SAR408701 every 3 weeks
11036338|NCT04524689|Active Comparator|Pembrolizumab|Pembrolizumab - Pembrolizumab will be administered intravenously every 3 weeks. - Type:
11036339|NCT04524676|Experimental|Individualized Treatment Group|
11036340|NCT04524663|Experimental|Camostat mesilate|Patients will receive camostat mesilate for 10 days in addition to standard of care treatment.
11036341|NCT04524663|Placebo Comparator|Placebo|Study participants will receive placebo to match camostat mesilate for 10 days in addition to standard of care treatment.
11036342|NCT04524650||stage 0|without liver function injury or splenomegaly
11036343|NCT04524650||stage 1|occurrence of liver function injury (ALT or AST > 2 ULN (upper limit of normal)
11036344|NCT04524650||stage 2|occurrence of splenomegaly or reduced platelet count (<150 X10^9/L)
11036345|NCT04524650||stage 3|occurrence of portal hypertension and/or gastroesophageal varices
11036346|NCT04524637||Traumatic brain injury|Patients who are delivered within 24 hours after head trauma and sustain isolated traumatic brain injury are included in this study.
11036347|NCT04524624|Experimental|AI-based CDSS|"Automatically identifying acute ischemic stroke lesions on DWI.
~Classification of stroke subtypes and mechanisms.
~Evidence-based alerts and guidelines for early stroke management.
~Guideline-recommended secondary stroke prevention strategies."
11036348|NCT04524624|No Intervention|Usual Care|Usual Care
11036349|NCT04524611|Experimental|Risankizumab Dose A Followed by Dose B|Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous risankizumab dose B every 8 weeks through Week 48.
11036350|NCT04524611|Experimental|Risankizumab Dose A Followed by Dose C|Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous risankizumab dose C every 8 weeks through Week 48.
11036351|NCT04524611|Active Comparator|Ustekinumab|Participants will receive weight-based intravenous ustekinumab at Week 0 followed by subcutaneous ustekinumab every 8 weeks through Week 48.
11036352|NCT04524598|Experimental|Limbix Spark|A 5 week program, focused on behavioral activation, a key CBT skill that provides a sense of pleasure or mastery through self-monitored activities to reduce depressive symptoms and improve functional outcomes.
11036353|NCT04524598|Active Comparator|Psychoeducation|5 weeks of psychoeducation about depression based on the content of the NIMH Teenage Depression e-book and supplemented with content from publicly available government sponsored websites.
11036354|NCT04524585|Experimental|Partial NMB|
11036355|NCT04524572|Experimental|Individual Challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure
11036356|NCT04524572|Experimental|friend challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure in comparison to the group average of all participants randomized to the friend challenge.
11036357|NCT04524572|Experimental|Team challenge|participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their teams' daily step counts and physical activity expenditure in comparison to the group average of other teams.
11036358|NCT04524559|Placebo Comparator|conventional physical therapy training|received 90 minutes conventional physical therapy training focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms.
11036359|NCT04524559|Experimental|oral stimulation|received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time. The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol
11036360|NCT04524533|Experimental|Intervention group|Participants randomized into the intervention arm will watch smoking cessation videos (ready to quit or not ready to quit) during a dental cleaning clinic visit, receive a brochure about EBTs, and participate in a 4-week text message program which consists of automated and tailored text messages to motivate EBT utilization.
11036361|NCT04524533|Active Comparator|Control group|Participants randomized into the control arm will watch a control video during a dental hygiene visit and receive a brochure about EBTs, and text messages for assessment only.
11036362|NCT04524507|Experimental|High-Titer (CCP1)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
11036363|NCT04524507|Active Comparator|Standard-Titer (CCP2)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.
11036364|NCT04524494||RAS- active medication|Patients taking RAS- active medication (ACE- Inhibitor, Angiotensin II AT1 Antagonist (Sartan)) on a daily Basis for at least 6 months for medical reasons
11036365|NCT04524494||no RAS- active medication|Patients not taking RAS- active medication
11036366|NCT04524481||Patients with mild haemophilia A or B|(FVIII or IX >5 %, ≥ 18 years' old)
11036367|NCT04524481||Patients with moderate haemophilia A or B|(FVIII or IX 1-5 %, ≥ 18 years' old)
11036368|NCT04524481||Patients with severe haemophilia A or B|(FVIII or IX <1 %, ≥ 18 years' old)
11036369|NCT04524468||hemodialysis patients|end-stage renal disease patients on hemodialysis
11036370|NCT04524468||peritoneal dialysis patients|end-stage renal disease patients on peritoneal dialysis
11036371|NCT04524455|Experimental|Blinatumomab and AMG 404|
11036372|NCT04524442|Experimental|GEP-NET|One dose of arginine/lysine solution administered intravenously over a 4-hour period
11036373|NCT04524429||Pre-operative Group|This is the group of participants who suffer from obesity and are awaiting bariatric surgery.
11036374|NCT04524429||Post-operative Group|This is the group of participants who suffer from obesity and have received bariatric surgery.
11036375|NCT04524403|Experimental|Miricorlilant - 600 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 600 mg miricorilant once daily for 26 weeks.
11036376|NCT04524403|Experimental|Miricorlilant - 900 mg|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 900 mg miricorilant once daily for 26 weeks.
11036377|NCT04524403|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive placebo once daily for 26 weeks.
11036378|NCT04524390|Experimental|Maralixibat|Maralixibat oral solution administered twice daily, up to 600 microgram per kilogram, for 26 weeks and in the ongoing OLE for all patients.
11036379|NCT04524390|Placebo Comparator|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and elect to continue in the open label extension (OLE) will receive maralixibat after Week 26.
11036380|NCT04524377|Experimental|DBS for Parkinsons Disease|
11036381|NCT04524364|Other|Participants with Paroxysmal Atrial Fibrillation (PAF)|Participants with PAF and who are candidates for catheter ablation will be enrolled.
11036382|NCT04524351|Active Comparator|Posiphen, 80mg|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
11036383|NCT04524351|Active Comparator|Posiphen, 40mg|Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
11036384|NCT04524351|Active Comparator|Posiphen, 20mg|Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
11036385|NCT04524351|Active Comparator|Posiphen, 10mg|Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
11036386|NCT04524351|Active Comparator|Posiphen, 5mg|Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
11036387|NCT04524351|Placebo Comparator|Placebo|Placebo Oral Capsule, taken once per day for 25±2 days.
11036388|NCT04524338|Experimental|At Home tDCS Users|Participants conducting tDCS at home
11036389|NCT04524325|Active Comparator|Trans men|transgender men taking physiologic doses of testosterone for gender affirming hormone therapy
11036390|NCT04524325|No Intervention|control|cisgender women not receiving testosterone and with normal sex hormone levels
11036391|NCT04524312|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
11036392|NCT04524312|Active Comparator|K-Mod|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Bioimplanti K-MOD prosthesis
11036393|NCT04524299|Experimental|Concurrent chemotherapy Twice a Week|During the period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.
11036394|NCT04524299|Active Comparator|Concurrent chemotherapy Once a Week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours.
11036395|NCT04524286||Public - Childbearing Women|Childbearing women living in three deprived areas in a city in the South of England.
11036396|NCT04524286||Staff - Midwives|Midwives working in caseloading teams providing continuity of care to women living in three deprived areas in a city in the South of England.
11036397|NCT04524273|Experimental|Inebilizumab, (AChR-Ab+) MG|"Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the randomized controlled period.
~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183."
11036398|NCT04524273|Placebo Comparator|Placebo, (AChR-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 and on Day 183 of the randomized controlled period.
~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183."
11036399|NCT04524273|Experimental|Inebilizumab, (MuSK-Ab+) MG|"Participants will receive inebilizumab administered IV on Days 1 and 15 of the randomized controlled period.
~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183"
11036400|NCT04524273|Placebo Comparator|Placebo, (MuSK-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 of the randomized controlled period.
~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183"
11036401|NCT04524260|Active Comparator|Painting art therapy|Intervention group
11036402|NCT04524260|Sham Comparator|Usual Care|Control group
11036403|NCT04524221|Experimental|PTG-100|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
11036404|NCT04524221|Placebo Comparator|Placebo|Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
11036405|NCT04524208|Experimental|Treatment-Arm|
11036406|NCT04524195|Experimental|[18F]F-AraG|A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.
11036407|NCT04524182|Other|control group|home-based exercise tailored to each individual's needs (stretching, strengthening, balance and gait exercise and posture exercise)
11036408|NCT04524182|Experimental|mobilization group|"Lumbo-sacral mobilization in addition to home-based exercise tailored to each individual's needs (stretching, strengthening, balance and gait exercise and posture exercise).
~Lumbo-sacral mobilization techniques will be applied for 10 minutes to lumbo-sacral region in the supine position."
11036409|NCT04524169|Experimental|Thymosin Alpha 1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
11036410|NCT04524169|No Intervention|Standard Care|Participants under the regularly treatment
11036411|NCT04524156|Active Comparator|COVIS 19 positive|
11036412|NCT04524156|Sham Comparator|COVID 19 negative|
11036413|NCT04524143|Other|control group|home-based exercise tailored to each individual's needs (stretching, strengthening, balance and gait exercise and posture exercise)
11036414|NCT04524143|Experimental|mobilization group|"Cervical mobilization in addition to home-based exercise tailored to each individual's needs (stretching, strengthening, balance and gait exercise and posture exercise).
~Cervical mobilization techniques will be applied for 10 minutes to cervical region in the supine position."
11036415|NCT04524130|Experimental|Lidocaine and Ketamine|Participants in this arm will receive intra-operative lidocaine and ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
11036416|NCT04524130|Active Comparator|Lidocaine|Participants in this arm will receive only intra-operative ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
11036417|NCT04524130|Placebo Comparator|Placebo|Participants in this arm will receive normal saline, same volume as lidocaine and ketamine.
11036418|NCT04524117||Group A(vulnerable plaque group)|Lipid plaques with fibrous cap thickness less than 65um, erosion and coronary artery dissection detected by OCT are defined as vulnerable plaque.
11036419|NCT04524117||Group B(stable plaque group)|Lipid plaques with fibrous cap thickness more than 65um detected by OCT are defined as vulnerable plaque.
11036420|NCT04524104|Experimental|Lumen treatment|Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at baseline and 14 weeks. Participant will receive an encrypted study iPad enabled with Lumen at baseline. They will complete 8 PST sessions beginning with 4 weekly and then 4 biweekly intervals (i.e., on weeks 1, 2, 3, 4, 6, 8, 10, 12) over 12 weeks on their assigned iPad. Participants will also complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 14), that is, 8 time series. Additionally, participants will complete depressive and anxiety symptoms questionnaire and user experience surveys at all PST sessions.
11036421|NCT04524104|No Intervention|Waitlist Control|"Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at Baseline and 14 weeks.
~Participant will receive an encrypted study iPad at baseline. Participants will complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 14), that is, 8 time series.
~Participants in the waitlist control arm will only complete assessments but will have the option to receive Lumen at the end of the study. The PST module on the study iPad will be disabled until their 14-week assessment is completed, at which time they will have the option to complete 8 PST sessions on their assigned iPads."
11036422|NCT04524078|Experimental|Intensive integrated intervention care program|intensive integrated intervention care program [ICP] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
11036423|NCT04524078|No Intervention|Non intensive integrated intervention care program|
11036424|NCT04524065|Experimental|Early intervention group|The 14 early rehabilitation sessions(10=physical therapy, 4=occupational therapy) occurred per week over a 2-week period (excluding weekends) in the early rehabilitation group for 15 minutes each.
11036425|NCT04524065|No Intervention|Control group|The control group received 2 sessions(physical therapy) per week over a 2-week period for 10 minutes each.
11036426|NCT04524052|Experimental|cohort 1 (144 mg)|Arms (both) 0.1 mL/site*2 sites Hips (both) 0.2 mL/site*2 sites
11036427|NCT04524052|Experimental|cohort 2 (432 mg)|Arms (both) 0.3 mL/site *2 sites Hips (both) 0.6 mL/site*2 sites
11036428|NCT04524052|Experimental|cohort 3 (960 mg)|Arms (both) 0.8 mL/site*2 sites Hips (both) 1.2 mL/site*2 sites
11036429|NCT04524052|Experimental|cohort 4 (1200 mg)|Arms (both) 1.0 mL/site *2 sites Hips (both) 1.5 mL/site*2 sites
11036430|NCT04524039|Experimental|iTBS stimulation|iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
11036431|NCT04524039|Sham Comparator|sham iTBS stimulation|sham iTBS stimulation to left dorsolateral prefrontal cortex (DLPFC), twice daily, 10 days
11036432|NCT04524026|Experimental|Intervention|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before gonadotrophin releasing hormone(GnRH) agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
11036433|NCT04524026|No Intervention|Control group|recFSH from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
11036434|NCT04524013||School aged children|
11036435|NCT04524013||Pregnant women|
11036436|NCT04524000|Experimental|Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)|Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).
11036437|NCT04524000|Experimental|Cohort 2: CDK4/6 inhibitor naive (Part 2)|Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
11036438|NCT04524000|Experimental|Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)|Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
11036439|NCT04523987|Experimental|gemcitabine and nab-paclitaxel chemotherapy|Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.
11036440|NCT04523974||Preemptive and Precise Intervention|Preemptive surgical intervention will be performed on enrolled CKD-SHPT patients. Safety and efficacy of this intervention will be evaluated during peri-operative period, and long-term outcomes will be analyzed during 1-year follow-up.
11036494|NCT04523610|Other|Program Users - Qualitative|Interviews will be conducted with 25 participants regarding their perceptions and experiences in the TIP-OA program.
11036668|NCT04522297|Experimental|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
11036441|NCT04523961|Active Comparator|2.5 g of lidocaine 23% / tetracaine 7% ointment|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion for 60 minutes.
11036442|NCT04523961|Active Comparator|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion for 60 minutes.
11036443|NCT04523948||Cohort One|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
11036444|NCT04523948||Cohort Two|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
11036445|NCT04523948||Cohort Three|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
11036446|NCT04523948||Cohort Four|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
11036447|NCT04523948||Cohort Five|Subjects will be invited to participate in brief weekly in person or telehealth behavioral support with the objective of reducing their rate of combustible tobacco use. Subjects will also be offered the choice of various conventional nicotine replacement aids, snus, electronic cigarette, varenicline or bupropion.
11036448|NCT04523935|Placebo Comparator|Placebo-Sequence 1|The placebo contained fructose powder in packets identical to the medicines.
11036449|NCT04523935|Active Comparator|Drug-Sequence 2|GABA-B agonists, muscarinic acetylcholine receptor antagonists, inhibitors of the vesicular monoamine transporter, benzodiazepines, antiepileptics, and tricyclic antidepressants were used.
11036450|NCT04523922|Experimental|Oxytocin Treatment Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.
~40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session."
11036451|NCT04523922|Active Comparator|Placebo Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).
~Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session."
11036452|NCT04523909||Thoracic aortic surgery patients|
11036453|NCT04523896|Experimental|HDR brachytherapy + SABR|"High-Dose-Rate prostate brachytherapy: a single fraction of 15 Gy to the whole prostate.
~Between 2-4 weeks after the brachytherapy session, SABR treatment will be delivered:
~5 sessions of 5 Gy in consecutive days (i.e monday to friday) to a total dose of 25 Gy to the whole prostate."
11036454|NCT04523883|Experimental|concurrent PD-1|Concurrent Immunotherapy With Postoperative Radiotherapy
11036455|NCT04523883|Active Comparator|Radiotherapy alone|Postoperative Radiotherapy alone
11036456|NCT04523870|Experimental|Saffron|
11036457|NCT04523870|Experimental|Safranal|
11036458|NCT04523870|Placebo Comparator|Placebo|
11036459|NCT04523857|Experimental|A (Abema)|Abemaciclib (150 mg BID)
11036460|NCT04523857|Experimental|B (Abema + HCQ)|"Abemaciclib (100 mg or 150 mg BID*) + Hydroxychloroquine (600 mg BID)
~*Abemaciclib dose will be determined by safety cohort"
11036461|NCT04523844|Active Comparator|Brinzolamide-brimonidine fixed combination|One drop of the brinzolamide-brimonidine fixed combination is instilled in the eyes of patients two hours before the intravitreal injection
11036462|NCT04523844|No Intervention|No topical IOP-lowering medication|No IOP-lowering drops are instilled before the intravitreal injections
11036463|NCT04523831|Active Comparator|Ivermectin and Doxycycline|Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
11036464|NCT04523831|Placebo Comparator|Placebo|Standard treatment
11036465|NCT04523818|Experimental|Treatment (CXRT, chemotherapy, surgery)|Patients receive CXRT consisting of radiation therapy 5 days a week (Monday through Friday) for 2 weeks (10 treatments) and standard of care chemotherapy consisting of capecitabine PO BID or fluorouracil IV continuous Monday to Friday of each radiation week. About 2 weeks later, patients receive standard of care chemotherapy for up to 2 months in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery 3-8 weeks post-chemotherapy completion.
11036466|NCT04523805|Experimental|AUTJUDO-O1|"The judo sessions are performing in a large and well-ventilated space suitable for athletic activities in general and for judo in particular, such that the safety of the participants was maintained. Each participant is outfitted with a judogi (a traditional uniform consisting of a cotton jacket and trousers and a belt).
~The sessions are 75 minutes in duration and were held once a week. Two judo teachers, with degrees in pedagogy and sports sciences and 7th and 6th degree black belts, respectively, led each session, and at least four volunteer judo instructors are present to lend support. The sessions are divided into warm-up, main exercise and cool-down activities. The instructional methodology apply the principles of gradual progression and the main exercise content of the sessions includes: different types of movements and falling techniques, ground control techniques, judo techniques and games."
11036467|NCT04523792|Experimental|Opioid withdrawal patients|Subjects with opioid use disorder seeking treatment and/or experiencing symptoms of opioid withdrawal receive acute administration of SUBOXONE sublingual film followed by SUBLOCADE administration in the 1) ED, 2) Clinical Decision Unit or 3) Inpatient unit combined with 6 months of treatment with SUBLOCADE in the outpatient treatment clinic.
11036495|NCT04523610|Other|Volunteers - Qualitative|15 volunteers taking part in the semi-structured interviews and 16 volunteers participating in the focus groups. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
11036468|NCT04523779|Experimental|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
11036469|NCT04523779|No Intervention|Enhanced Usual Care|EUC participants will receive anxiety education materials, a note in their medical record indicating the presence of elevated anxiety symptoms, and 4 brief monthly check-in calls with project staff. The primary outcome, anxiety symptoms, will be evaluated at 4-, 8- and 12-month follow-ups. Due to ethical concerns of withholding needed treatment, EUC participants will NOT be restricted from receiving mental health services including psychotherapy during the study period. The investigators fully expect that EUC participants may receive anxiety treatments (e.g., antianxiety and antidepressant medications or psychotherapy).
11036470|NCT04523766|Active Comparator|Mindfulness of Breath|
11036471|NCT04523766|Experimental|Mindful Interoceptive Mapping|
11036472|NCT04523740|Experimental|Placebo replacement|Participants will discontinue the paracetamol treatment, and be administered 6 to 8 tablets of placebo per day
11036473|NCT04523740|Active Comparator|Usual care with paracetamol|Participants will continue the paracetamol treatment, and be administered 6 to 8 tablets of 500mg paracetamol per day
11036474|NCT04523727|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 36 weeks at a starting dose based on body weight categories.
11036475|NCT04523714|Active Comparator|Web-based CBT-CP|Interactive Mobile health (mHealth) program in which participants complete eight, approximately weekly sessions focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
11036476|NCT04523714|Active Comparator|Virtual coach-led CBT-CP|Live, coach-led program delivered by telephone or videoconference consisting of eight, approximately weekly sessions focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
11036477|NCT04523714|No Intervention|Usual Care plus information|Receipt of a bound copy of the 2020 edition of the American Chronic Pain Association Resource Guide to Chronic Pain Management and any pharmacologic and nonpharmacologic treatments available to them without restriction.
11036478|NCT04523701|Experimental|Experimental Intervention (treatment)|"Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic).
~SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the white test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution."
11036479|NCT04523701|No Intervention|Control Intervention|Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)
11036480|NCT04523688|Experimental|Experimental treatment|"Induction phase: 4 weekly doses of dendritic cell vaccine (10x10exp6 cells) intradermally administered (weeks 1-4).
~Maintenance phase: 28 days cycles with vaccine administration (start on week 7) and adjuvant temozolomide (150-200mg/m2/day) assumed orally from day 1 to 5 q28 (start on week 5). The combined maintenance treatment will continue until disease progression, unacceptable toxicity or withdrawal of consent by the patient, or up to a maximum of 1 year of treatments.
~After disease progression or the end of maintenance phase, is foreseen a one-year follow-up phase for each subject."
11036481|NCT04523675|Experimental|EXP-NAC|Participated in daily training sessions and three games, and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
11036482|NCT04523675|Experimental|EXP-Pla|Participated in daily training sessions and three games, and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
11036483|NCT04523675|Active Comparator|CON-NAC|Participated in daily training sessions only and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
11036484|NCT04523675|Active Comparator|CON-Pla|Participated in daily training sessions only and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
11036485|NCT04523662|Experimental|Carrelizumab treatment group started during radiotherapy|
11036486|NCT04523662|Experimental|Start the carrelizumab treatment group within 3 days after the|
11036487|NCT04523649|Experimental|Home-based atrial fibrillation screening group|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
11036488|NCT04523649|No Intervention|Control group|Conventional medical care
11036489|NCT04523636|Active Comparator|Custom Splint|Custom Splint- Thermoplastic device fabricated by occupational therapist
11036490|NCT04523636|Active Comparator|Prefabricated Splint|Prefabricated Splint- Commercially available from Restorative Care of America, Inc (RCAI)
11036491|NCT04523623|Experimental|Ibuprofen Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
11036492|NCT04523623|Experimental|Oxycodone Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
11036493|NCT04523610|Experimental|Program Users - Quantitative|The Telehealth Intervention Program (TIP-OA) for older adults was created during the COVID-19 pandemic to support the health of older adults who are isolated or have mental health/cognitive issues. Within the TIP-OA program, trained volunteers provide friendly phone calls once a week to older adults (age 60+). 200 participants will be recruited for the quantitative component of the study.
11036496|NCT04523610|Other|Stakeholders - Qualitative|18 stakeholders (clinicians, community partners, TIP-OA team members) will participate in focus groups and interviews. Specifically, 10 clinicians will participate in one focus group and 8 community partners/team members will participate in interviews. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
11036497|NCT04523597||toracic hyperkyphosis|children with COBB angle ≥ 45˚
11036498|NCT04523597||control|children with kyphosis index < 13 measured using the flexicurve ruler
11036499|NCT04523584||Hepatic Steatosis|<5% liver fat fraction by MRI PDFF
11036500|NCT04523584||No Hepatic Steatosis|>5% liver fat fraction by MRI PDFF
11036501|NCT04523571|Experimental|Low-dose, 18-55 years of age|
11036502|NCT04523571|Experimental|High-dose, 18-55 years of age|
11036503|NCT04523571|Placebo Comparator|Placebo, 18-55 years of age|
11036504|NCT04523571|Experimental|Low-dose, 65-85 years of age|
11036505|NCT04523571|Experimental|High-dose, 65-85 years of age|
11036506|NCT04523571|Placebo Comparator|Placebo, 65-85 years of age|
11036507|NCT04523558|Experimental|Bilateral implantation of LuxSmart hydrophobic IOL|"Cataract surgery will be carried out using standard phacoemulsification technique with a 2.2 mm incision. Investigators will target a 5.5 mm diameter capsulorhexis to allow the optic to be fully overlapped by the anterior capsular rim.
~The intended target of the post-operative refraction will be emmetropia. The patient will be implanted with LuxSmart hydrophobic IOLs in both eyes and followed up for 6 months"
11036508|NCT04523532|Experimental|Group 1: Folate + hazelnut oil|Group 1 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of vegetables rich in folate - 191µg and additionally received 01 capsule containing 25 mg hazelnut oil per day.
11036509|NCT04523532|Placebo Comparator|Group 2: Folate|Group 2 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of folate-rich vegetables - 191 µg and 01 placebo capsule.
11036510|NCT04523532|Experimental|Group 3: Moderate folate + hazelnut oil|Group 3 = in this group, individuals received, during the period of 08 weeks daily, with 300 g of vegetables containing 94 µg of folate and 01 capsule containing 25 mg of hazelnut oil per day.
11036511|NCT04523532|No Intervention|Group 4: Control|Group 4 = in this group, individuals received weekly visits during the 08 week period to maintain their eating habits.
11036512|NCT04523519|Experimental|Video directly observed therapy with contingency management|Video directly observed therapy with contingency management, in addition to Integrated Next-Step Counseling.
11036513|NCT04523519|Placebo Comparator|Integrated Next-Step Counseling|
11036514|NCT04523506|Experimental|the temporomandibular joint (TMJ) group|This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The TMJ group will be injected with two units of Botox into four different injection points to each masseter (16 units of Botox total) at the initial visit. No additional Botox will be injected in subsequent visits. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1
11036515|NCT04523506|Experimental|the perioral group|Biological/Vaccine: Botulinum toxin(Botox) This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The perioral group will be injected with two units of Botox into eight different injection points (16 units of Botox total) around the lips (in the orbicularis oris). Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3.
11036516|NCT04523493|Active Comparator|Experimental group|Toripalimab combined with Lenvatinib
11036517|NCT04523493|Placebo Comparator|Control group|Placebo combined with Lenvatinib
11036518|NCT04523480|Experimental|Testopel 75mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.
11036519|NCT04523480|Active Comparator|Compounded testosterone pellets 100mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.
11036520|NCT04523480|Active Comparator|Compounded Testosterone pellets 200mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.
11036521|NCT04523467|Experimental|Combined group|Anti-angiogenic targeted drug + Rg3 + TACE
11036522|NCT04523467|Active Comparator|Single group|TACE alone
11036523|NCT04523441||Parents|man or woman
11036524|NCT04523441||Professionals|health professionals in charge of monitoring children
11036525|NCT04523428|Experimental|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
11036526|NCT04523415||patients wiht CT data|all patients with CT data are enrolled with this research, and the classification about proximal humeral fractures are identified.
11036527|NCT04523402|Experimental|Neoadjuvant chemotherapy following liver section|"1. GEMOX chemotherapy:
~It is performed within one week after the identification of ICC;
~Day1 Oxaliplatin 85mg/m2 + gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2;
~Three weeks is a course of treatment;
~A total of 3 courses.
~2. Liver resection: It is performed 1 month after chemotherapy"
11036528|NCT04523402|No Intervention|Liver resection|"Liver resection:
~It is performed within one week after the identification of ICC."
11036529|NCT04523389||colorectal cancer|
11036530|NCT04523376|Experimental|Sickle Cell Disease|Patients with Sickle Cell Disease (SCD) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
11036665|NCT04522336|Experimental|Treatment (pembrolizumab, chemoradiotherapy)|See Detailed Description
11036531|NCT04523376|Experimental|Beta Thalassemis Major|Patients with Beta Thalassemis Major (BTM) will be given previously established, disease-specific chemotherapy based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from closely matched unrelated donors.
11036532|NCT04523363|Experimental|Metformin|Study subjects will be randomized to the metformin medication arm. They will take a 500 mg tablet orally twice a day starting at 14 weeks of pregnancy until delivery.
11036533|NCT04523363|No Intervention|Standard of Care|Study subjects will be randomized to standard of care and receive routine prenatal care without further intervention for their prediabetes.
11036534|NCT04523350|Experimental|Instylla HES|
11036535|NCT04523350|Active Comparator|Control|TAE or cTACE
11036536|NCT04523337|Experimental|MISSION-CJ|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services.
11036537|NCT04523337|Experimental|Enhanced Usual Care|Usual care provided by the mental health residential rehabilitation treatment programs, with patients in both groups are enrolled in, in addition to peer support and community outreach case management. Patients receive 2 Peer Support Curriculum sessions per week (24 sessions total). Patients will receive unstructured community outreach and linkage support while enrolled in the mental health residential rehabilitation program. After discharge, patients will continue to receive 1 hour of weekly linkage support per week.
11036538|NCT04523324|Active Comparator|RIV4 (Flublok Quadrivalent)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
11036539|NCT04523324|Active Comparator|IIV4 (Vaxigrip Quadrivalent)|VaxigripTetra™ by Sanofi, Inc., 15µg of HA per strain, egg-based
11036540|NCT04523311|Experimental|Hypnosis + usual care|An online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis. Participants will continue with whatever usual care they receive/undertake.
11036541|NCT04523311|Other|Waitlist control + usual care|The control group will receive no intervention beyond whatever usual care they receive/undertake. After the study is complete, they will be offered the option of participating in the hypnosis intervention.
11036542|NCT04523298|Experimental|Laser|
11036543|NCT04523298|Active Comparator|PFE|
11036544|NCT04523285|Experimental|TQB3728 tablets|TQB3728 tablets administered orally, once a week in 28-day cycle.
11036545|NCT04523272|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11036546|NCT04523272|Active Comparator|Sunitinib Malate Capsules|Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).
11036547|NCT04523246|Experimental|Shingrix|Shingrix Dosage: two .5 ml injections into the deltoid muscle, administered 2 months apart (Day 0 and Day 60).
11036548|NCT04523246|Placebo Comparator|Normal Saline|Sterile Normal Saline Solution, two .5 ml injections into the deltoid muscle, administered 2 months apart (Day 0 and Day 60)
11036549|NCT04523233||Neural tube defects (NTDs)|NTDs are a group of birth defects in which an opening in the spine or cranium remains from early in human development. Neural tube defects may be diagnosed during the ultrasound scan that is carried out around week 12 of the pregnancy or, more likely, during the anomaly scan that is carried out at around weeks 19 to 20.
11036550|NCT04523233||Control group|The control group will be included pregnant women with healthy fetuses (n = 70), who were matched for gestational weeks and maternal age and underwent amniocentesis because of age-related risk or increased risk in the triple test.
11036551|NCT04523220|Experimental|BAY1213790 low dose|Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
11036552|NCT04523220|Placebo Comparator|Placebo low dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
11036553|NCT04523220|Experimental|BAY1213790 high dose|Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
11036554|NCT04523220|Experimental|Placebo high dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
11036555|NCT04523207|Experimental|Apalutamide + Androgen Deprivation Therapy (ADT)|Participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days).
11036556|NCT04523194||Acute Coronary Syndrome|Patients diagnosed with acute coronary syndrome.
11036557|NCT04523194||Stable Angina|Patients diagnosed with stable angina.
11036558|NCT04523181|Active Comparator|Antroquinonol with SOC|Antroquinonol in a dose of 100 mg (1 capsule) administered twice daily (BID) orally, for 14 days.
11036559|NCT04523181|Placebo Comparator|Placebo with SOC|placebo (1 capsule) administered twice daily (BID) orally, for 14 days.
11036560|NCT04523168|Experimental|Chronic Refractory Angina|Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.
11036561|NCT04523155|Experimental|Treatment Sequence AB|Participants randomized to sequence AB will receive 3 months of meals, followed by a 3 month washout period and a 3 month intervention period with no meals.
11036562|NCT04523155|Experimental|Treatment Sequence BA|Participants randomized to sequence BA will receive 3 months of no meals followed by a 3 month washout period and a 3 month intervention period with meals.
11036563|NCT04523142|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
11036564|NCT04523129|Experimental|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
11036565|NCT04523129|Placebo Comparator|Vehicle Ophthalmic solution|Vehicle only
11036566|NCT04523103|No Intervention|Control group|Standard ICSI procedure. The MII oocytes that failed fertilization in IVF cycles were injected with activating sperm.
11036567|NCT04523103|Experimental|A1 assisted activation|The MII oocytes that failed fertilization in ICSI cycles were activated in calcium ionophore A23187 activation solution for two times.
11047433|NCT04446871|Experimental|Methylene blue|Methylene blue
11036568|NCT04523103|Experimental|A2 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 solution for two times.
11036569|NCT04523103|Experimental|A3 assisted activation|Fertilization failure MII oocytes were collected in ICSI cycles. Mechanical activation was done for the MII oocytes, and then the oocytes were transferred into the calcium ionophore A23187 solution for two times.
11036570|NCT04523090|Experimental|Nitazoxanide|Nitazoxaninde, 1000mg (2pills), oral, twice daily for 7 days. To be taken with food.
11036571|NCT04523090|Placebo Comparator|Placebo|Placebo, 2 pills, oral, twice daily for 7 days. To be taken with food.
11036572|NCT04523077||Oral lichen planus|Female patients of the Department of Oral Medicine with oral lichen planus
11036573|NCT04523077||Control|Female patients of the Department of Oral Medicine without oral lichen planus or other immune disorders
11036574|NCT04523064|Active Comparator|SGLT2i (empagliflozin)|Empagliflozin 25 mg 1 time day for three months
11036575|NCT04523064|No Intervention|Standard of care|Standard care treatment of diabetes patients in our center
11036576|NCT04523038||Low albumin|Patients presenting with low albumin levels preoperatively (<3,5 mg/l)
11036577|NCT04523038||Normal albumin|Patients presenting with normal or high albumin levels preoperatively (>3,5 mg/l)
11036578|NCT04523025||Low NLR-ratio|Patients with low NLR ratio (NLR<3)
11036579|NCT04523025||High NLR-ratio|Patients with high NLR ratio (NLR≥3)
11036580|NCT04523012||HIV patients|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
11036581|NCT04522999|Experimental|Photobiomodulation|Valeda™ Light Delivery System
11036582|NCT04522986|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
11036583|NCT04522973|Other|Within group four condition comparison|Participants will receive each of the four conditions. Order of conditions will be assigned using a Latin square model.
11036584|NCT04522960|Experimental|Patients with dementia or mild cognitive impairment due to AD|Dementia or MCI due to AD according to NIA-AA research criteria.
11036585|NCT04522960|Active Comparator|Healthy volunteers|Age-and-gender matched healthy controls.
11036586|NCT04522947|Experimental|fMRI|Participants are delivered sips of appetizing tastes (milkshake) and tasteless solution throughout the task while in the MRI scanner.
11036587|NCT04522934|Experimental|Pain Neuroscience Education|Patients received 24 sessions, in a 8-week period, of multimodal physiotherapy along with four sessions of pain neuroscience education.
11036588|NCT04522934|Active Comparator|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy along with four sessions of biomedical education.
11036589|NCT04522921|No Intervention|Control Group (CG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and regular follow-up.
11036590|NCT04522921|Experimental|Follow-up group (FUG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and increased follow-up.
11036591|NCT04522921|Experimental|Intervention group (IG)|A higher protein diet (25E%/day) for the 10 weeks they attend the camp and increased follow-up.
11036592|NCT04522908|Experimental|Cabozantinib - Single Arm|Single Arm with Cabozantinib starting dose 40 mg for 4 weeks and dose escalation to 60 mg afterwards.
11036593|NCT04522895|Experimental|Consolidation Arm|Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
11036594|NCT04522895|Experimental|Salvage Arm|"Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
~DLI as standard of care can be given to patients optionally after cycle 4, 6 and 8 in case of HLA-identical donors at a dose of 1-5 x10^6 CD3/kg (1st DLI), 5 x10^6 - 5x107 CD3/kg (2nd DLI) and 5x10^7 - 5x10^8 CD3/kg (3rd DLI) or at lower dosages in case of unrelated, mismatched or haploidentical donors. Additional DLI may be given due to the treating physician's decision in case of urgent medical need, but only beyond the fourth cycle of Enasidenib."
11036595|NCT04522882|Experimental|At home clinical data collection|Clinical data will be collected during 7 days: physical activity, sleep duration, chronotype, food and medication intake, glucose level and insulin administration.
11036596|NCT04522869|Experimental|Umbilical cord blood - derived mesenchymal stem cells|17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery
11036597|NCT04522869|No Intervention|Control group|17 patients with BA will be conducted Kasai operation only
11036598|NCT04522856||A|Local
11036599|NCT04522856||B|Nested
11036600|NCT04522843||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
11036601|NCT04522843||Colitis|Patients with active colitis
11036602|NCT04522843||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
11036603|NCT04522830|Experimental|BTL-TML-COVID|BTL-TML-COVID
11036604|NCT04522830|Placebo Comparator|Placebo|Placebo
11036605|NCT04522817|Experimental|CLBS119 Active Treatment|Single administration of CLBS119
11036606|NCT04522804|Experimental|Treatment: all patients|"Subjects will participate in a total of five group sessions. There will be 6 subjects per group and one therapist will be assigned to each subject for a total of 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are Preparatory sessions followed by three Integration sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session."
11036607|NCT04522791|Experimental|RFB+VSOP|"For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.
~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
11036608|NCT04522791|Active Comparator|IR+VSOP|The control IR strategy will be used, set-up of which will be the same as the RFB + VSOP intervention group with IR replacing RFB. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
11036609|NCT04522791|Placebo Comparator|IR only|Participants randomized to this condition will receive weekly in-person check-in visits, and perform daily 10-minute IR, so that the number of treatment contacts (though not duration) will be equivalent. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
11036610|NCT04522778|Experimental|Device|Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear throughout the duration of the study.
11036611|NCT04522778|Active Comparator|Traditional Securement Dressing|Those is the non-device arm will continue to wear a traditional central line securement dressing as is the standard of care.
11036612|NCT04522765||Health|Healthy individuals with no known medical condition and taking no regular medication
11036613|NCT04522765||Acute kidney injury|Individuals with acute kidney injury as defined by KDIGO criteria
11036614|NCT04522765||Chronic kidney disease|Individuals with chronic kidney disease as defined by KDIGO criteria
11036615|NCT04522765||Small vessel vasculitis|Individuals with active small vessel vasculitis an diagnosed by a specialist physician
11036616|NCT04522765||Kidney transplant recipient|Individuals who have received a kidney transplant
11036617|NCT04522765||Kidney donor|Individuals who have donated a kidney for transplantation
11036618|NCT04522752||Gastric Polyp|The included subjects were patients with benign epithelial gastric polyps confirmed by gastroscopy and biopsy pathology. The size and pathology type of polyps were identified. Gastroscopy and biopsy were followed up six, twelve and eighteen months later to observe the relationship between the size, pathology types of polyps and the development of gastric polyps. Other factors including the relationship between helicobacter pylori infection and polyp type were also observed.
11036619|NCT04522739|Experimental|Spironolactone|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for12 months.
11036620|NCT04522739|Placebo Comparator|Placebo|Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
11036621|NCT04522726|Experimental|Treatment group A|"Treatment group A received Weiyang Yupingfang Granules orally for 1 month on the Sanfu days and on theSanjiudays each year for a total of 2 months a year."
11036622|NCT04522726|Experimental|Treatment group B|Treatment group A received Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months a year.
11036623|NCT04522713|Experimental|Large-group transdiagnostic course|6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
11036624|NCT04522674|Experimental|Autologous platelet rich plasma|0.5 mL of activated autologous PRP will be injected by fluoroscopic guidance into the affected lumbar facet joint (s) depending on the number of affected levels. A max of 4 joints will be injected per patient.
11036625|NCT04522661|Experimental|Early Vitrectomy Group|Vitrectomy surgery plus intravitreal antibiotics
11036626|NCT04522661|Active Comparator|Control Group|Intravitreal antibiotics
11036627|NCT04522648|Experimental|Intervention (INT)|INT participants will be asked to perform self-measurements of arm circumference at five points along the arm at home every three months. Additional measurements can be performed if the participants experience signs of BCRL. Participants will report the self-measurements in cm and mm in an online questionnaire, or over the phone to a physiotherapist navigator, along with reporting sign and symptoms of BCRL.
11036628|NCT04522648|No Intervention|Control (CON)|The CON group will follow the usual post-operative care. CON participants will be prompted every 6 months by an online questionnaire to report if they have been diagnosed with BCRL and if so, month of initiation of treatment.
11036629|NCT04522635|Active Comparator|albumin|albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
11036630|NCT04522635|Placebo Comparator|normal saline|0.9% sodium chloride (normal saline (NS)) given intravenously at the start of IHD
11036631|NCT04522622|Experimental|Teriparatide|Patients receive teriparatide 20 micrograms once daily for 18 months
11036632|NCT04522622|Other|Controls|Controls receive no treatment with teriparatide
11036633|NCT04522609|No Intervention|Control group|Guideline recommended pharmacologic therapy
11036634|NCT04522609|Experimental|NMES group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
11036635|NCT04522596|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day for 14 days.
11036636|NCT04522596|Placebo Comparator|Placebo|Placebo inhaled once a day for 14 days.
11036637|NCT04522583||Troponin-positive ED patients|All patients admitted to the ED at the Hillel Yaffe Medical Center in Hadera, Israel, in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (>0.014 nanogram/milliliter).
11036638|NCT04522570|Active Comparator|laser ablation|Percutaneous Laser Ablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
11036639|NCT04522570|Active Comparator|cryoablation|Percutaneous cryoablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
11036640|NCT04522570|Active Comparator|Radiofrequency ablation|Percutaneous radio frequency ablation for the treatment of metastatic cervical lymph nodes with > 0.8 cm diameter with biopsy-proven diagnosis of differentiated thyroid carcinoma or medullary thyroid carcinoma.
11036641|NCT04522557|Experimental|Experimental: Participants with breast cancer enrolled in grou|
11036642|NCT04522544|Experimental|SIRT|Y-90 SIRT + Tremelimumab + Durvalumab
11036643|NCT04522544|Experimental|TACE|TACE + Tremelimumab + Durvalumab
11036666|NCT04522323|Experimental|Dose Exploration|The Dose exploration Phase will evaluate the safety and tolerability of MEDI5752 in combination with axitinib (18 patients)
11036667|NCT04522323|Experimental|Dose Expansion|Evaluate safety and anti-tumor activity of MEDI5752 in combination with axitinib (50 pts)
11036644|NCT04522531|Experimental|Exercise performed on stabil ground|Open cinetic chain shoulder exercise will performed on stabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
11036645|NCT04522518||DD group|160 pairs of children with disabilities 6-12 years of age and their caregivers (n=320)
11036646|NCT04522518||TD group|160 pairs of typically developing children 6-12 years of age and their caregivers (n=320)
11036647|NCT04522492|Experimental|internet CBT|Internet delivered cognitive behavioral therapy, thru 2 booster sessions. Each session will last 50 minutes. Fist session will involve: psychoeducation about the symptoms, evaluation of the skin picking habit, reinforcement of the habit reversal strategies. After 1 week, the second session will be applied, consisting of: strategies to cope with anxiety (breathing and muscle relaxation techniques) and to cope with depressive status (cognitive restructuring techniques).
11036648|NCT04522492|Active Comparator|Quality of life promotion|The therapist will send to the patient 2 videos with strategies to improve quality of life during the pandemia (1 video about social support and one video about sleep hygiene). After 1 week, the therapist will send to the patient another 2 videos with strategies do improve quality of life (dietary guidance and guidance on physical activity)
11036649|NCT04522479|No Intervention|prolonged protocol of early follicular phase|Inject a full dose of GnRH-a in 1st-3rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
11036650|NCT04522479|Experimental|prolonged protocol of middle luteal phase|Inject a full dose of GnRH-a in 21st-23rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
11036651|NCT04522466|Experimental|Patients infected by SARS-CoV-2 treated by Hydroxychloroquine|Blood sample on patients infected by SARS-CoV-2 treated by Hydroxychloroquine
11036652|NCT04522453|Active Comparator|paper mental health Gap Action Program-Intervention Guide|This arm will be training and supervision as usual employing the standard paper version of the mental health Gap Action Program-Intervention Guide. Primary care workers will be trained to use the paper version of this tool and will use the paper version when evaluating patients.
11036653|NCT04522453|Experimental|digital mental health Gap Action Program-Intervention Guide|This arm will be training and supervision in an experimental approach using a digital version of version of the mental health Gap Action Program-Intervention Guide. The digital version allows for interactive decision making on diagnoses and care, and it allows for entering of patient data. Primary care workers in this arm will be trained to use the digital version of this tool and will use the digital version when evaluating patients.
11036654|NCT04522440|Experimental|Inpatients in hospice Ward|Inpatients in hospice Ward with pain control problems
11036655|NCT04522427|Experimental|Multifocal and Extended Depth-of-Focus intraocular lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
11036656|NCT04522427|Active Comparator|Monofocal intraocular Lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
11036657|NCT04522414||Preterm infant|
11036658|NCT04522401||People aged 65 and over|"People aged 65 and over who have had a gerontological evaluation Bien vieillir at the St-Etienne University Hospital Day Hospital."
11036659|NCT04522388|Experimental|Treatment|Nutritional shakes, Ensure Enlive, twice per day orally in patients awaiting lung transplant
11036660|NCT04522375|Experimental|FP-045|FP-045 at one of 3 dose levels to sequential cohorts of adolescent, followed by pediatric subjects
11036661|NCT04522362|Sham Comparator|Control task-|The Control Task was implemented to ensure the specificity of the psychological stress effects had on study outcomes. Therefore, the Control Task had a similar procedure and the same duration of the TSST, lacking except for only the psychologically stressful component. The control task consisted of (a) Participants had a 5-min a preparation section and anticipation phase (5 min ), (b) a reading task where they had to. Then, all participants had to be read a simple text in a low voice (5 min), and (c) an arithmetic section where they were asked to perform an easy mathematical calculation (5 mins).
11036662|NCT04522362|Experimental|Experimental Task- Trier Social Stress Task|"The Trier Social Stress Task (TSST) is a standardized, 15-minute laboratory task designed to induce psychological stress in laboratory settings (Kirschbaum, Pirke, & Hellhammer, 1993). The TSST consists of three continuously successive phases: (a) an anticipation period (5 min); (b) a free speech task (5 min); and (c) a mental arithmetic task (5 min). As is standard in the TSST procedure, participants were told by a research staff member that they would provide a brief speech about their dream job in front of a critical audience. At the end of the speech, a member of the audience instructed the participant to conduct serial subtractions as accurately and quickly as possible."
11036663|NCT04522349|Active Comparator|Greifer then Axon-Hook|T0 + 2 weeks: evaluation with Greifer. T1 + 2 weeks: evaluation with Axon-Hook
11036664|NCT04522349|Active Comparator|Axon-Hook then Greifer|T0 + 2 weeks: evaluation with Axon-Hook. T1 + 2 weeks: evaluation with Greifer
11036669|NCT04522297|Active Comparator|Nor-epinephrine|Intravenous infusion norepinephrine
11036670|NCT04522284|Experimental|CURATE.AI|Subjects will receive XELOX, XELIRI or single agent capecitabine for up to 12 months in 3-week cycles. Maximum dose of capecitabine in the predetermined safety range is set as standard starting dose (i.e. 1000 mg/m2 twice daily for XELOX and XELIRI regimen, 1250mg/m2 twice daily for single agent capecitabine regimen). Minimum dose of capecitabine in the predetermined safety range is 500 mg/m2 twice daily for XELOX and XELIRI regimen, 625mg/m2 twice daily for single agent capecitabine. Subject specific dosing range may alter those numbers to suit the specific circumstances of the subject. Doses of other drugs in XELOX and XELIRI regimens (oxaliplatin and irinotecan, respectively) will be held constant or adjusted at the clinical investigator's discretion. Efficacy and toxicity measurements will be used by CURATE.AI to suggest the recommended dose of capecitabine for the next cycle. CT scans for radiological assessment will be performed after every 2 to 3 cycles of chemotherapy.
11036671|NCT04522271|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5 g/m2 of an individually optimized resistant starch for approximately 5 months
11036672|NCT04522271|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 5 months
11036673|NCT04522258|Placebo Comparator|Placebo|Refined cereal flour
11036674|NCT04522258|Active Comparator|Dietary fiber|Fermentable cereal bran
11036675|NCT04522245|Placebo Comparator|Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
11036676|NCT04522245|Experimental|Noom Health Weight Program|
11036677|NCT04522232|Placebo Comparator|group A|women that underwent conventional Total laparoscopic hysterectomy
11036678|NCT04522232|Experimental|group B|women that underwent Total laparoscopic hysterectomy with prior uterine artery ligation at its origin
11036679|NCT04522219|Experimental|Case group|Diagnosis of adnexal torsion confirmed by the surgical intervention: woman allocated to case group
11036680|NCT04522219|Experimental|Control group|Diagnosis of adnexal torsion not confirmed by the surgical intervention: woman allocated to control group
11036681|NCT04522206|Experimental|Patients undergoing elective spine surgery|
11036682|NCT04522193|Experimental|Experimental group|All children born at the Lille University Hospital during the investigation period with esophageal atresia type III or IV
11036683|NCT04522180|Experimental|IONIS-GHR-LRx Dose 1|Single dose of IONIS-GHR-LRx Dose 1 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
11036684|NCT04522180|Experimental|IONIS-GHR-LRx Dose 2|Single dose of IONIS-GHR-LRx Dose 2 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
11036685|NCT04522180|Experimental|IONIS-GHR-LRx Dose 3|Single dose of IONIS-GHR-LRx Dose 3 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).
11036686|NCT04522167|Experimental|FYB203 (Proposed aflibercept biosimilar)|Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.
11036687|NCT04522167|Active Comparator|Eylea® (Aflibercept)|Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.
11036688|NCT04522154|Other|MR-TTE|Patient receiving cardiac magnet resonance imaging and echocardiography
11036689|NCT04522141|Experimental|Self-control treatment group|The self-control treatment group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit as well as a short interventional input targeting self-control.
11036690|NCT04522141|Active Comparator|Control group|The control group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit.
11036691|NCT04522128|Active Comparator|Feedback Intervention|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.
~Participants randomly allocated to the feedback intervention will then be provided with graphs showing WHOQOL COMBI facet scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important."
11036692|NCT04522128|Experimental|Extended Intervention|"All participants will complete an online questionnaire (as described above).
~Participants randomly allocated to the extended intervention will then be provided with graphs to highlight differences between their actual WHOQoL COMBI scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important.
~Participants will then receive an online intervention that will provide them with behaviour change techniques to help them address the discrepancies in the relevant quality of life domains."
11036693|NCT04522128|Other|Waitlist Control|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.
~Participants randomly allocated to the waitlist control group will then receive their WHOQoL COMBI scores only, with no information about differences between quality of life and importance or intervention materials."
11036694|NCT04522115|Experimental|aerobic training|Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.
11036820|NCT04521374|Experimental|Texture Modified Protein Fortified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 350kcal, 25g protein.
11036695|NCT04522115|Experimental|Resistance training|Resistance exercise training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
11036696|NCT04522102|Experimental|Intervention|Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).
11036697|NCT04522102|No Intervention|Comparator|Avoid antiplatelet therapy.
11036698|NCT04522089|Experimental|AdimrSC-2f Group 1|low dose mcg
11036699|NCT04522089|Experimental|AdimrSC-2f Group 2|low dose mcg+AL
11036700|NCT04522089|Experimental|AdimrSC-2f Group 3|medium dose mcg
11036701|NCT04522089|Experimental|AdimrSC-2f Group 4|high dose mcg
11036702|NCT04522076||COVID-19 with pneumonia|patients with positive COVID 19 by PCR and pneumonia by CT
11036703|NCT04522076||COVID-19 without pneumonia|patients with positive COVID 19 by PCR and absent of pneumonia by CT
11036704|NCT04522076||Patients with pneumonia and without COVID 19|patients with negative COVID 19 by PCR and with pneumonia by CT
11036705|NCT04522076||Patients without pneumonia and COVID 19|Patients with suspected COVID-19 and/or pneumonia at the pre-hospital stage that were not confirmed in hospital
11036706|NCT04522050|Other|Induction chemotherapy + IMRT and concurrent gemcitabine|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m²,d1) every 3weeks for 2 cycles before radiotherapy, and then receive intensity modulated radiotherapy (IMRT) concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. Patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
11036707|NCT04522037||interventional group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic treatment for COVID-19 disease dyspnea.
11036708|NCT04522037||control group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 not receiving morphinic treatment for COVID-19 disease dyspnea.
11036709|NCT04522024|Active Comparator|Mei Mini Maze|Mei Mini Maze procedure (Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side)
11036710|NCT04522024|Experimental|Mei Mini Maze plus epicardial cryoablation|Epicardial focal cryoablation during Mei Mini Maze procedure
11036711|NCT04522011||Group A|D1/2 radical gastrectomy combines intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
11036712|NCT04522011||Group B|D1/2 radical gastrectomy combines postoperative hyperthermic intraperitoneal chemotherapy with docetaxel + oxaliplatin
11036713|NCT04522011||Group|without hyperthermic intraperitoneal chemotherapy
11036714|NCT04521998|Experimental|electroacupuncture|The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.
11036715|NCT04521998|Experimental|Transcutaneous electrical nerve stimulation|The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.
11036716|NCT04521985||thoracolumbar kyphosis|patients undergoing thoracolumbar kyphosis surgery
11036717|NCT04521972|Active Comparator|Group 1|Natural non-augmented labor with room lights ON. This is what is currently done in the hospital, and thus does not change any current medical practices.
11036718|NCT04521972|Active Comparator|Group 2|Augmented labor with room lights ON. This group will be a subgroup of Group 1 (Natural non-augmented labor with room lights ON), as labor-augmentation cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
11036719|NCT04521972|Experimental|Group 3|Natural non-augmented labor with reduced or red room lights.
11036720|NCT04521972|Experimental|Group 4|Augmented labor with reduced or red room lights. This group will be a subgroup of Group 3, as augmented labor cannot be planned for until the patient is in labor or labor needs to be augmented for medical reasons.
11036721|NCT04521959|Active Comparator|Blood Flow Restricted Aerobic and Resistance Exercise Group|kan akımı kısıtlanarak.direnç ve bisikletle aerobik egzersiz uygulanacak
11036722|NCT04521959|Active Comparator|Normal aerobik ve direnç egzersiz grubu|Normal şartlarda aerobik ve direnç egzersizi uygulanacak
11036723|NCT04521946|Experimental|Treatment (chemotherapy, HCT)|Patients receive thiotepa IV over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil PO every 8 hours or IV from days 0-40 and tapered to day 90.
11036724|NCT04521920|Experimental|Medication and telemedicine follow up|All participants are provided with Suboxone and/or PrEP and follow up visits will be conducted via telemedicine
11036725|NCT04521907||Group 1|Group 1 includes patients who underwent cataract surgery with primary IOL implantation
11036726|NCT04521907||Group 2|Group 2 includes patients who underwent cataract surgery with secondly IOL implantation
11036727|NCT04521907||Group 3|Group 3 includes patients who underwent cataract surgery without IOL implantation.
11036728|NCT04521894||Primary PCa without metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies.
11036821|NCT04521361|Experimental|Patients with Low extent of disease|Adult men with bone mCRPC having < 6 bone metastases
11036822|NCT04521361|Experimental|Patients with High extent of disease|Adult men with bone mCRPC having ≥ 6 bone metastases
11036729|NCT04521894||Primary PCa with metastases Group|Participants who are suspected of prostate cancer due to elevated PSA or clinical symptoms but have not received any treatment and eventually confirmed prostate cancer after surgery or biopsies. And the 18F-PSMA-PET/CT scan confirmed metastases.
11036730|NCT04521894||Oligometastatic PCa group|"Oligometastaticis a subgroup of metastatic patients with a limited number of secondary lesions (threshold ranging from 3 to 5) in one or few organs."
11036731|NCT04521894||Biochemical recurrence Group|Proven biochemical recurrence after radical therapy (PSA >0.2 ng/mL after radical prostatectomy, PSA ≥2 ng/mL above the nadir after external-beam radiotherapy) or persisting PSA after radical treatment with rising PSA values.
11036732|NCT04521894||Control Group|Prostate cancer benign prostatic hypertrophy or normal prostate.
11036733|NCT04521881|Active Comparator|Active|A single dose of Tranexamic acid 500mg given by intramuscular injection
11036734|NCT04521881|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
11036735|NCT04521868|Experimental|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia.
11036736|NCT04521868|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
11036737|NCT04521855||Caregivers|Caregivers (family environment or close entourage) for adults and children with cerebral palsy.
11036738|NCT04521842|Placebo Comparator|Standard size femoral head implant|Participants qualified to undergo total hip replacement who will receive standard femoral head size implant
11036739|NCT04521842|Active Comparator|Large size femoral head|Participants qualified to undergo total hip replacement who will receive large femoral head size implant
11036740|NCT04521829|Experimental|VR-enhanced treadmill walking|Participants will be tested during 2 sessions of VR-enhanced treadmill walking.
11036741|NCT04521816|Experimental|Intervention--PACT Intensive Management|"The intervention is the PACT Intensive Management Program (PIM) provides a standardized menu of services, ranging from chart review assessment or in-home assessment, to a time limited intensive care management intervention. The following PIM features are standardized across the PIM demonstration sites:
~A) Chart review assessment template in the EMR; B) Comprehensive assessment template of unmet needs and modifiable risk factors in EMR; C) Transitions in care process (eligibility criteria, clinical protocols); D) Diagnostic home visits process (eligibility criteria, clinical protocols); E) Core risk stratification/Triage process; F) Discharge criteria and note template in EMR; G) Standardized interdisciplinary team (IDT) meeting note procedure and template in EMR."
11036742|NCT04521816|No Intervention|Usual care|High-Risk patients receiving care in PACT.
11036743|NCT04521803|No Intervention|Arm 1: Standard of care (RIF10)|Dosing of the daily oral RHZE fixed dose combination (FDC) will be according to WHO weight bands
11036744|NCT04521803|Experimental|Arm 2: High-dose RIF (RIF35)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used39
11036745|NCT04521790||Arrhythmic (A)|"Arrhythmic Group. To oversimplify, specific subgroups of patients will be considered.
~Group 1: major ventricular arrhythmias (haemodynamically unstable VT, hu-VT; ventricular fibrillation, VF).
~Group 2: other ventricular arrhythmias (high-burden premature ventricular complexes = hb-PVC; nonsustained VT = NSVT; haemodynamically stable VT = hs-VT).
~Group 3: bradyarrhythmias (2nd type II or 3rd degree atrioventricular block = advanced AVB; critical sinus pauses = SND).
~Group 4: supraventricular arrhythmias (atrial fibrillation = AF; atrial flutter = AFlu; atrial tachycardia = AT)."
11036746|NCT04521790||Nonarrhythmic (NA)|"Nonarrhythmic Group. To oversimplify, specific subgroups of patients will be considered.
~Heart failure presentation (and subtypes)
~Chest pain presentation (and subtypes)
~Asymptomatic presentation/screening (and subtypes)"
11036747|NCT04521790||Subgroups|"For specific study aims, different patient subgroups will be compared. The main groups are hereby reported:
~A. Arrhythmic myocarditis subgroups (1-4). B. Non-arrhythmic myocarditis subgroups (i.e.: fulminant, acute coronary syndrome-like, pericarditis-like, heart failure, nonischaemic dilated /hypokinetic cardiomyopathies of unknown aetiology…).
~C. Infectious vs. autoimmune vs. toxic myocarditis. D. Myocarditis treated by aetiology-based treatment vs. isolated cardiac medical treatment.
~E. Myocarditis at different disease stages: acute, hyperacute, fulminant, chronic active, post-inflammatory, or active vs. previous vs. non-myocarditis.
~F. Myocarditis presenting as organ-specific diseases vs. in the context of a genetic disorder or systemic disease.
~G. Myocarditis vs. peri-myocarditis/myo-pericarditis. H. Other subgroups."
11036748|NCT04521777|Experimental|Supportive care (exercise intervention)|Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
11036749|NCT04521764|Experimental|Treatment (MV-s-NAP)|Patients receive MV-s-NAP intratumorally (IT) on day 1 in the absence of disease progression or unacceptable toxicity. After 1 cycle of treatment, patients who experience disease progression proceed to follow-up. Patients who achieve CR, PR, or SD receive MV-s-NAP IT every 21 days for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity.
11036750|NCT04521751|Experimental|EMP16-02 120 mg orlistat/40 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.
~Dosage: 120 mg O/40 mg A (given as 2 capsules EMP16-02-60/20). Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).
~Duration: 26 weeks."
11036823|NCT04521348|Experimental|RAIR-DTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
11036751|NCT04521751|Experimental|EMP16-02 150 mg orlistat/50 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.
~Dosage: 150 mg O/50 mg A (given as 1 capsule EMP16-02-90/30 and 1 capsule EMP16-02-60/20).
~Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).
~Duration: 26 weeks."
11036752|NCT04521751|Placebo Comparator|Placebo|"Dosage form: Matching, oral capsule. Identical in appearance but contain only cellulose.
~Dosage: Placebo (given as 2 placebo capsules) Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).
~Duration: 26 weeks."
11036753|NCT04521738|Experimental|SAR441255|Single dose, subcutaneous, escalating dose
11036754|NCT04521738|Placebo Comparator|Placebo|Single dose, subcutaneous, matched volume
11036755|NCT04521725|No Intervention|Group1: ECG+SpO2 only|Traditional ECG (heart rate) and SpO2 (pulse oximetry) monitoring for resuscitation only.
11036756|NCT04521725|Active Comparator|Group 2: ECG+SpO2+RFM|Addition of Respiratory Function Monitor to ECG and SpO2 during resuscitation.
11036757|NCT04521725|Active Comparator|Group 3: ECG+SpO2+RFM+NIRS|Addition of cerebral NIRS and Respiratory Function Monitor to ECG and SpO2 during resuscitation.
11036758|NCT04521712|Experimental|Postpartum GDM|Women with GDM diagnosed early (< 20 weeks gestation) or with routine 3rd trimester screening (>=24 weeks) will be enrolled in this longitudinal study. All enrolled women will complete a oral glucose tolerance test and wear a continuous glucose monitor for 10 days at the 3 designated study time points (0-4 days, 4-6 weeks, and 6 months after delivery).
11036759|NCT04521699|Experimental|CalmioGo + Standard of care|Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation
11036760|NCT04521699|No Intervention|Standard of Care|Stand of care alone with 12 weeks of Cardiac rehabilitation
11036761|NCT04521686|Experimental|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738 Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
11036762|NCT04521673||infectious uveitis|Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap
11036763|NCT04521673||Control group|Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases
11036764|NCT04521660|Experimental|Intervention group|Patients in the intervention group will wear virtual reality glasses during coronary angiography.
11036765|NCT04521660|No Intervention|Control group|Patients in the control group will not wear virtual reality glasses. They will be given standard care and treatment during the procedure.
11036766|NCT04521647|Experimental|3% Nicotine concentration|Participants will receive 3% nicotine in an e-cigarette with their preferred flavor (menthol or tobacco)
11036767|NCT04521647|Experimental|5% Nicotine concentration|Participants will receive 5% nicotine in an e-cigarette with their preferred flavor (menthol or tobacco)
11036768|NCT04521634||Acute Stroke + Diabetes|People who have experienced and acute stroke and also have diabetes
11036769|NCT04521634||Acute stroke|People without diabetes who have experienced and acute stroke
11036770|NCT04521621|Experimental|Part 1, Cohort A: Triple-Negative Breast Cancer|This arm will enroll participants with triple-negative breast cancer (TNBC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036771|NCT04521621|Experimental|Part 1, Cohort B: Head and Neck Squamous Cell Carcinoma|This arm will enroll participants with head and neck squamous cell carcinoma (HNSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036772|NCT04521621|Experimental|Part 1, Cohort C: Cutaneous Squamous Cell Carcinoma|This arm will enroll participants with cutaneous squamous cell carcinoma (cSCC) solid tumors. Participants receive V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036773|NCT04521621|Experimental|Part 2, Cohort D: Solid Tumors+Liver Metastases, Dose Level 1|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 1 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036774|NCT04521621|Experimental|Part 2, Cohort E: Solid Tumors+Liver Metastases, Dose Level 2|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 2 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036775|NCT04521621|Experimental|Part 2, Cohort F: Solid Tumors+Liver Metastases, Dose Level 3|This arm will enroll participants with solid tumors with liver metastases. Participants receive dose level 3 of V937 intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036776|NCT04521621|Experimental|Part 2, Cohort G: Hepatocellular Carcinoma (HCC)|This arm will enroll participants with hepatocellular carcinoma (HCC) solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036777|NCT04521621|Experimental|Part 2, Cohort H: Gastric Carcinoma|This arm will enroll participants with gastric carcinoma solid tumors. Participants receive the V937 recommended phase 2 dose (RP2D) intratumorally for 8 cycles, and pembrolizumab intravenously for a maximum of 35 cycles. Cycle 1 is 28 days, and cycles 2-35 are 21 days.
11036778|NCT04521608|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants enrolled in the intervention arm will be offered a Home-based pulmonary rehabilitation program with health coaching.
11036779|NCT04521608|No Intervention|Control- Choice|This arm receives the standard of care which includes the choice of PR at a facility or through telehealth. Center based PR involves attending a medical center gym where they can do exercises and receive disease specific education. Telehealth PR is delivered virtually through the computer or telephone.
11036780|NCT04521595|Experimental|weigh smart intervention|open treatment arm to receive group based lifestyle intervention via telehealth.
11036824|NCT04521348|Experimental|MTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
11036781|NCT04521582|Experimental|Active Group|Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within ~1 week and measure blood pressure again. If found high, the participant will be referred to the nearest Health Post. At the Health Posts, if FB-CHWs confirms the diagnosis of hypertension, they will prescribe amlodipine 5 mg/d according to the study protocol and ask the patient to return in ~2 weeks. If blood pressure is controlled (<140/90 mmHg) after ~2 weeks, FB-CHWs will refill amlodipine 5 mg/d for 3 months. If not, FB-CHWs will increase the dose to 10 mg/d and follow up in ~2 weeks. If still not controlled with amlodipine 10 mg, FB-CHWs will refer the patient to the Regional Hospital in Pokhara. In addition, FCHVs will visit patients' homes 3 times (at 3-, 6-, and 9-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.
11036782|NCT04521582|Active Comparator|Comparison Group|"Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within a week or so and measure the blood pressure again. If found high, the participant will be referred to a healthcare facility (the usual care) which can diagnose and manage hypertension. In addition, FCHVs will visit patients' homes once (around 3-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment."
11036783|NCT04521569|Experimental|EVLP with Regadenoson|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the study drug, Regadenoson.
11036784|NCT04521569|Placebo Comparator|EVLP with Steen solution|Following the routine retrieval procedure of the lungs, they will be placed on the EVLP circuit (XVIVO Perfusion System) and infused with the same volume of Steen solution.
11036785|NCT04521556|Active Comparator|Epidural anesthesia and analgesia|"Epidural catheter insertion: Th 9 - Th 10 or Th 10 - Th 11 using the midline approach.
~Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml).
~Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml)."
11036786|NCT04521556|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
11036787|NCT04521530|Experimental|immediate functional loading with temporary crowns|patients were rehabilitated with immediate functionally loaded implants.
11036788|NCT04521530|Experimental|immediate non functional loading with temporary crowns|patients were rehabilitated with immediate non-functionally loaded implants.
11036789|NCT04521517|Experimental|Pamphlet with timing of family planning|"Pamphlet with timing of family planning and Routine service"
11036790|NCT04521517|No Intervention|Only routine service|Receive only routine service
11036791|NCT04521504|Experimental|Biofeedback|Patients were treated with an experimental rehabilitation protocol, based on shoulder kinematic biofeedback.
11036792|NCT04521504|No Intervention|Control|Patients were treated with a standard rehabilitation protocol, based on hospital guidelines.
11036793|NCT04521491|Experimental|FOLFOX4|Patients who will receive FOLFOX4 chemotherapy after liver resection
11036794|NCT04521491|No Intervention|placebo|No adjuvant therapy after liver resection
11036795|NCT04521478|Experimental|Treatment group 1|BI 1358894
11036796|NCT04521478|Placebo Comparator|Placebo group|Placebo
11036797|NCT04521478|Experimental|Treatment group 2|Quetiapine
11036798|NCT04521465||NovaTears® + Omega-3|
11036799|NCT04521452|Experimental|Evogliptin Group|evogliptin 5mg daily
11036800|NCT04521452|No Intervention|Non-evogliptin Group|DM medications except evogliptin and other DPP-4 inhibitors
11036801|NCT04521439|Experimental|MS Patients Group|
11036802|NCT04521439|Sham Comparator|Healthy Volunteers Group|
11036803|NCT04521426||Lung Fibrosis|"probable or confirmed diagnosis of interstitial pulmonary fibrosis (IPF) or other fibrotic lung disease of unknown origin.
~being listed for lung transplantation"
11036804|NCT04521426||COPD standard therapy|"COPD: GOLD stage III or IV
~being listed for lung transplantation
~did not underwent LVR surgery or endoscopic LVR
~not being treated with chronic NIV"
11036805|NCT04521426||COPD with long-term NIV|"COPD: GOLD stage III or IV
~being listed for lung transplantation
~did not underwent LVR surgery or endoscopic LVR
~being treated with chronic NIV before lung transplantation (at least 1 months, at least 4 hours per day)."
11036806|NCT04521413|Experimental|A1: Monotherapy Escalation|Dose escalation arm with CFI-402411. CFI-402411 is administered orally once daily.
11036807|NCT04521413|Experimental|A2: Monotherapy Biomarker|Dose escalation biomarker arm with CFI-402411. CFI-402411 is administered orally once daily.
11036808|NCT04521413|Experimental|A3: Monotherapy Expansion|Dose expansion arm with CFI-402411 at its recommended phase 2 dose.
11036809|NCT04521413|Experimental|B1: Combination Escalation|Dose escalation arm with CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
11036810|NCT04521413|Experimental|B2: Combination Expansion|Dose expansion arm with the recommended phase 2 dose of CFI-402411 in combination with pembrolizumab (at its labeled dose and schedule).
11036811|NCT04521400|Experimental|Arm1|Lopinavir /Ritonavir +high dose Interferon-β 1a
11036812|NCT04521400|Experimental|Arm2|Lopinavir /Ritonavir + Low dose Interferon-β 1a
11036813|NCT04521387|Experimental|N1 Platelet Rich Plasma (PRP)|2ml of autologous platelet rich plasma injection
11036814|NCT04521387|Active Comparator|N2 Corticosteroid (CS)|2ml of 7mg Betamethasone injection
11036815|NCT04521387|Active Comparator|N3 Hyaluronic Acid (HA)|2ml of 40mg hyaluronic acid with mannitol injection
11036816|NCT04521387|Placebo Comparator|N4 Saline (NaCl)|2ml saline (0,9%NaCl) injection
11036817|NCT04521374|Experimental|Standard Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 16g protein.
11036818|NCT04521374|Experimental|Standard Protein Fortified Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 25g protein.
11036819|NCT04521374|Experimental|Texture Modified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 340kcal, 16g protein.
11036989|NCT04520256|Experimental|Social Support, VR|
11036825|NCT04521348|Experimental|ATC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
11036826|NCT04521348|Experimental|DTC unsuitable for RAI arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
11036827|NCT04521335|Experimental|Treatment: all patients|disulfiram and copper gluconate in combination
11036828|NCT04521322|Placebo Comparator|Control|Participants in this arm will receive a nasal spray with placebo
11036829|NCT04521322|Experimental|Experimental|Participants in this arm will receive a nasal spray with Iota-Carrageenan
11036830|NCT04521309|No Intervention|Control|Standard care only n = 10 patients.
11036831|NCT04521309|Experimental|IVIG dose: 0.20 g/kg|Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients
11036832|NCT04521309|Experimental|IVIG dose: 0.25 g/kg|Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
11036833|NCT04521309|Experimental|IVIG dose: 0.30 g/kg|Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
11036834|NCT04521309|Experimental|IVIG dose: 0.35 g/kg|Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
11036835|NCT04521296|Experimental|DWJ1248|Camostat mesylate 100mg
11036836|NCT04521296|Placebo Comparator|Placebo|Placebo
11036837|NCT04521244|Experimental|Thrust joint lumbar manipulation|Thrust joint lumbar manipulation (Lumbar rotation manipulation) ,Moist Hot pack
11036838|NCT04521244|Active Comparator|Lumbar mobilization|Lumbar mobilization (Stretch rotation mobilization), Moist Hot pack
11036839|NCT04521231|Experimental|Blinatumomab: Dose escalation|Cohorts of at least 3 participants each will be treated with escalating doses of blinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.
11036840|NCT04521231|Experimental|Blinatumomab: Dose expansion|Participants will be administered the recommend phase 2 dose (RP2D) determined from dose escalation stage to further assess safety, pharmacokinetics (PK), pharmacodynamic (PD), and efficacy.
11036841|NCT04521218|Experimental|Thrust joint Manipulation|Thrust joint Manipulation, heat application, Strengthening exercise and home plan
11036842|NCT04521218|Active Comparator|Reverse Sustained Natural apophyseal glides|Reverse Sustained Natural apophyseal glides (SNAG), heat application, Strengthening exercise and home plan.
11036843|NCT04521205|Experimental|Standardized FMT|The patients will receive standardized FMT. The FMT was given by capsule. It was given three times a week.
11036844|NCT04521205|Placebo Comparator|Without FMT|The patients will receive FMT with blank capsule.
11036845|NCT04521192|Experimental|TR sequence group|
11036846|NCT04521192|Experimental|RT sequence group|
11036847|NCT04521179|Experimental|KN026 combined with KN046|KN026 combination therapy
11036848|NCT04521166|Experimental|Setting 1|Hearing aid features presented in this arm include omnidirectional microphone settings and fast-acting compression
11036849|NCT04521166|Experimental|Setting 2|Hearing aid features presented in this arm include omnidirectional microphone settings and slow-acting compression
11036850|NCT04521166|Experimental|Setting 3|Hearing aid features presented in this arm include directional microphone settings and fast-acting compression
11036851|NCT04521166|Experimental|Setting 4|Hearing aid features presented in this arm include directional microphone settings and slow-acting compression
11036852|NCT04521153|Experimental|Test group|Preoperative carrelizumab combined with apatinib mesylate (2 treatment cycles) → radical surgery → postoperative TACE treatment → sequential apatinib mesylate combined with carrelizol after TACE Resistance (6 cycles) (Note: Surgery within 2-4 weeks after the last administration of neoadjuvant therapy, postoperative TACE treatment at least 4 weeks after surgery, and carrelizumab combined with apatinib mesylate within 2 weeks after TACE treatment Consistent treatment.)
11036853|NCT04521153|Active Comparator|Control group|Radical surgery→postoperative TACE treatment
11036854|NCT04521140|Experimental|PKP with Dextenza (study)|"Patients undergoing PKP will receive Dextenza insert with:
~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
11036855|NCT04521140|Other|PKP without Dextenza (Controlled)|"Patients undergoing PKP will receive:
~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
11036856|NCT04521140|Experimental|DSEK with Dextenza (study)|"Patients undergoing DSEK will receive Dextenza insert with:
~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
11036857|NCT04521140|Other|DSEK without Dextenza (Controlled)|"Patients undergoing DSEK will receive:
~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
11036858|NCT04521140|Experimental|DMEK with Dextenza (study)|"will receive Dextenza insert with: topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
11036859|NCT04521140|Other|DMEK without Dextenza (Controlled)|"Patients undergoing DMEK will receive:
~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.
~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
11036860|NCT04521127|Active Comparator|Kinesio Taping Group|Kinesio taping will be applied to trapezius muscle
11036861|NCT04521127|Active Comparator|Dry needling Group|Dry needling will be applied to trigger point on trapezius muscle
11036862|NCT04521127|No Intervention|Control Group|Control group will not receive any additional intervention
11036863|NCT04521114|Experimental|Phase II: 525 mg PRO 140 SC weekly|"Drug: 525 mg leronlimab will be administered subcutaneously every week for 13 weeks.
~Other names:
~PRO 140"
11036864|NCT04521114|Experimental|Phase II: 700 mg PRO 140 SC weekly|"Drug: 700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
~Other Names:
~• PRO 140"
11036865|NCT04521114|Placebo Comparator|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
11036866|NCT04521101|Other|VAST Course|
11036867|NCT04521088||visitors of the outpatient clinic for COVID-19|visitors of the outpatient clinic for COVID-19
11036868|NCT04521075|Experimental|Treatment Arm|Combination treatment: anti PD1 + FMT by capsules
11036869|NCT04521062|Other|Dilapan S|Placement of dilators
11036870|NCT04521049|Active Comparator|saxagliptin|patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of <50 mL/min/1.73 m2
11036871|NCT04521049|No Intervention|control|patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
11036872|NCT04521036|Experimental|Convalescent plasma|Standard of care plus 500 mL of convalescent plasma from COVID-19 recovered donors
11036873|NCT04521036|No Intervention|Standard of care|Standard of care (Supportive care, oxygen, antibiotics, no convalescent plasma)
11036874|NCT04521023|Experimental|A|
11036875|NCT04521023|Active Comparator|B|
11036876|NCT04521010||Staff absenteeism|A retrospective analysis of above-mentioned data, covering the period January-April 2019 and January-April 2020, was carried out. The evaluation of the staff's absence included all workers employed under an employment contract: 713 workers in 2019 and 747 workers in 2020.
11036877|NCT04521010||healthcare services|The variable number of employees was a result of the employment dynamics in the subsequent 2 years, due to variable quantity of healthcare services that were contracted with the national payer and changes in the form of employment of some hospital workers
11036878|NCT04520997|Experimental|Down-up|Participants in this group will receive injections in the chin area at baseline and in the nasolabial folds (NLFs) and marionette lines (MLs) at week 3.
11036879|NCT04520997|Experimental|Top-down|Participants in this group will receive injections in the nasolabial folds (NLFs) and marionette lines (MLs) at baseline and in the chin area at week 3.
11036880|NCT04520984|Experimental|Arm 1|Intervention
11036881|NCT04520984|Other|Arm 2|Standard Care
11036882|NCT04520971|Experimental|780G closed-loop|780 closed-loop insulin delivery system
11036883|NCT04520971|Active Comparator|standard of care|standard of care treatment (continue with current treatment of insulin pump without closed-loop or multiple daily insulin injections).
11036884|NCT04520958|Experimental|Mindfulness of Breath|
11036885|NCT04520958|Experimental|Mindfulness of Pain|
11036886|NCT04520958|Active Comparator|Cognitive-Behaviorally Based Pain Psychoeducation|
11036887|NCT04520945|Active Comparator|Active Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
11036888|NCT04520945|Placebo Comparator|Placebo Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
11036889|NCT04520932|Experimental|RFA treatment efficacy|PNETs ablation by radiofrequency treatment (1 to 3 sessions)
11036890|NCT04520906|Experimental|single-arm|Subjects will be treated with microwave ablation.
11036891|NCT04520893|Experimental|VCV pause|volume controlled ventilation with pause time 30%
11036892|NCT04520893|Active Comparator|VCV|volume controlled ventilation (without pause)
11036893|NCT04520893|Active Comparator|PCV-VG|pressure controlled ventilation - volume guaranteed
11036894|NCT04520880||Critically ill SARS-Cov2 patients|Critically ill patients with acute hypoxemic respiratory failure defined as those admitted to ICU and receiving mechanical ventilation (invasive or non-invasive) or high-level supplemental oxygen (via a high-flow nasal cannula or non-rebreathing face mask at a flow rate of 15 L per min or greater), at or during hospitalization
11036895|NCT04520880||Hospitalized non-critically ill SARS-Cov2 symptomatic patients|Hospitalized non-critically ill SARS-Cov2 symptomatic patients
11036896|NCT04520867||Qualifying Subjects|Patients seen in the EGMDC for treatment planning who are recommended to receive neoadjuvant treatment followed by surgery at UCCC Metro
11036897|NCT04520854|Experimental|2-week Telehealth Protocol|Participants randomized to this arm will receive 5 live-video sessions. The first 2 live-video sessions will occur during the first week, last 20 minutes each and separated by 48-72 hours. The last 3 live-video sessions will occur during the second week, last 30-minutes each and separated by 24-48 hours.
11036898|NCT04520854|Active Comparator|2-week Usual Care|The usual care group will be used to reflect the current care provided to patients after discharged from the emergency department for an ankle sprain.
11036899|NCT04520841|Active Comparator|Standard dry dressing in total hip or knee arthroplasty|Standard dressing in total hip or knee arthroplasty surgery revision: a dry sterile dressing is applied on the surgical wound at the end of surgery
11036900|NCT04520841|Experimental|Prevena in total hip or knee arthroplasty|"Prevena incision management system in total hip or knee arthroplastsy surgery revision:
~The Prevena incision management system is applied on the surgical wound at the end of surgery"
11036901|NCT04520841|Active Comparator|Standard dry dressing in lower limb amputation|Standard dressing in lower limb amputation: a dry sterile dressing is applied on the surgical wound at the end of surgery
11036902|NCT04520841|Experimental|Prevena in lower limb amputation|"Prevena incision management system in lower limb amputation:
~The Prevena incision management system is applied on the surgical wound at the end of surgery"
11036903|NCT04520828|Experimental|Postural repositioning|
11036904|NCT04520802||POCD|Patients with postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
11036905|NCT04520802||no POCD|Patients without postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
11036906|NCT04520789|Sham Comparator|RD control group|Conventional Surgery for Retinal Detachment
11036907|NCT04520789|Experimental|RD treatment group1|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study
11036908|NCT04520789|Active Comparator|RD treatment group2|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study, postoperative intervention
11036909|NCT04520776|Experimental|BAGUERA®C|surgical placement of the BAGUERA®C Cervical Disc Prosthesis
11036910|NCT04520776|Active Comparator|Mobi-C®|surgical placement of the Mobi-C® Cervical Disc
11036911|NCT04520763|Experimental|Respiratory Muscle Exercises|Two respiratory muscle exercises
11036912|NCT04520763|No Intervention|Control|The control intervention consists of quiet sitting for 15 min
11036913|NCT04520750|Experimental|Open label treatment arm|PTX-022 QTORIN
11036914|NCT04520737|Active Comparator|16W group|Multimodal prehabilitation program (MPP) will be implemented during 16 weeks, 12 weeks during chemotherapy (CT) and 4 weeks while waiting for surgery.
11036915|NCT04520737|Active Comparator|4W group|Multimodal prehabilitation program (MPP) will start at the end of preoperative chemotherapy (CT) until surgery (4 weeks in total).
11036916|NCT04520724|Experimental|Study group|"30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (ca. 300 kcal; no less than 12 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (12 g of fiber/per roll) for 8 weeks.
~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
11036917|NCT04520724|Placebo Comparator|Placebo group|"30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (ca. 300 kcal; no less than 6 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (6 g of fiber/per roll) for 8 weeks.
~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
11036918|NCT04520698|Experimental|Nursing Home-level UPLIFT-AD intervention|The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
11036919|NCT04520698|No Intervention|Usual Care|
11036920|NCT04520685|Experimental|Arm 1: 12 weeks of study drug then 15 weeks of placebo|Subjects in this group will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.
11036921|NCT04520685|Experimental|Arm 3: 15 weeks of placebo then 12 weeks of study drug|Subjects in this group will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks.
11036922|NCT04520685|Experimental|Arm 3: 27 weeks of study drug|Subjects in this group will receive cannabidiol throughout the entire 27 weeks of treatment.
11036923|NCT04520659|Experimental|Group 1: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
11036924|NCT04520659|Placebo Comparator|Group 1: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11036925|NCT04520659|Experimental|Group 2: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
11036926|NCT04520659|Placebo Comparator|Group 2: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11036927|NCT04520646|Experimental|empagliflozin|empagliflozin is added on the basis of the original treatment
11036928|NCT04520633||control level stable|severe asthma for which the control level is stable (variation in ACT score <3 between M0 and M6) contributing to the test-retest
11036929|NCT04520633||biologic initiation|introduction or modification of biotherapy at M0
11036930|NCT04520620|Experimental|enoxaparin treatment|"Patients infected by SARS-CoV-2 in intensive care unit with enoxaparin treatment will be included.
~They will have enoxaparin pharmacokinetic and ultrasound of the lower limbs at 7, 14 and 21 days after inclusion."
11036931|NCT04520607|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study)
11036932|NCT04520607|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle (same treatment as in the parent-study)
11036933|NCT04520594|Active Comparator|Resistant Starch|Once daily oral consumption of 7.5g/m2 of an individually optimized resistant starch for approximately 6 months
11036934|NCT04520594|Placebo Comparator|Placebo|Once daily oral consumption of a food-grade cornstarch that is readily digestible for approximately 6 months
11036935|NCT04520581|No Intervention|Control|Use in the shape of an endotracheal tube.
11036936|NCT04520581|Experimental|"Group O"|"Just before the induction of medicine is injected, the assistant makes endotracheal tube into O shape."
11036937|NCT04520568|Active Comparator|HFNC group|For HFNC group, F&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).
11036938|NCT04520568|Placebo Comparator|control group|induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.
11036939|NCT04520555|Experimental|Laryngeal mask airway group|Flexible laryngeal mask airway is inserted for general anesthesia
11036940|NCT04520555|Active Comparator|intubation group|Endotracheal intubation was performed for general anesthesia
11036941|NCT04520542|Experimental|acupressure|The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention. Each acupressure point was massaged for 30 seconds to provide circulation before the pressure. After the massage, consecutive pressures were applied for 90 seconds. In each intervention, a total of 8-minute sessions were applied to 4 points as 2 minutes for each point. Consecutive pressures were applied on a frequency that did not disturb the women, did not cause pain, and had a soothing effect. Until the end of the intervention it was continued 2 times a week, 16 times in total in 8 weeks.
11036942|NCT04520542|No Intervention|Control Group|no intervation
11036943|NCT04520529|Other|Patients with primary cutaneous lymphoma|
11036944|NCT04520516|Experimental|tVNS active device|VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
11036945|NCT04520516|Sham Comparator|Sham tVNS device|Sham VAGUSTIM device from Schwa-Medico Length of use : 12 weeks
11036946|NCT04520503||Pre EEG group|This cohort includes all participants in this study. EEG sensor will be attached to the patient's forehead before induction of anesthesia. Patterns of EEG and data will be obtained
11036947|NCT04520490|Active Comparator|Exenatide once weekly extended-release|Weekly subcutaneous injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (2mg) for 24 weeks in randomized intervention.
11036948|NCT04520490|Placebo Comparator|Matching placebo|Weekly subcutaneous injections of placebo for 24 weeks.
11036949|NCT04520464|Active Comparator|Self-test for cervical sample|First sequence will start with self-test. Second sequence will start with traditional method.
11036950|NCT04520464|Active Comparator|Traditional provider for cervical sample|First sequence will start with traditional method. Second sequence will start with self-test method.
11036951|NCT04520451|Experimental|PRN1008 plus glucocorticoids|PRN1008 tablets, 400 mg twice daily from Week 0 to Week 12 plus glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 2 weeks on study)
11036952|NCT04520451|Active Comparator|Glucocorticoids|Glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 12 weeks on study)
11036953|NCT04520438|Experimental|NSPT + L-PRF|Scaling and root planing associated to Leucocyte and Platelet rich Fibrin Membrane and irrigation with exudate of L-PRF.
11036954|NCT04520438|Other|NSPT alone|Only Scaling and root planing
11036955|NCT04520425|Experimental|Intervention|Participants will receive 5 standardized osteopathic manipulative treatments, two weeks apart. (To be considered a study completer, a participant must complete at least 3 of these treatments.) In addition to assessments at intake and during treatments, 1 and 3 months after their last treatment patients will be asked to provide follow-up data. Assessments include the HIT-6, MIDAS, and MSQ surveys, treatment satisfaction assessments, and a headache diary. Participants will also consent to an electronic medical record extraction of medication and healthcare services utilization.
11036956|NCT04520412|Experimental|GV-971|
11036957|NCT04520412|Placebo Comparator|Placebo|
11036958|NCT04520399||violence|
11036959|NCT04520399||non-violence|
11036960|NCT04520386|Experimental|Open label single arm|1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval
11036961|NCT04520373|Experimental|Treatment Group 1: AD-MSC Injection|Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
11036962|NCT04520373|Active Comparator|Treatment Group 2: Best Medical Management|Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
11036963|NCT04520360|Experimental|Types of Carisbamate|"A single 300 mg oral dose of the Oral Suspension Type 1 under fasting conditions
~A single 300 mg oral dose of Oral Suspension Type 2 under fasting conditions
~A single 300 mg oral dose of Oral Suspension Type 2 under fed conditions
~A single oral dose of the 300 mg Oral Tablet under fasting conditions
~A single oral dose of the 300 mg Oral Tablet under fed conditions"
11036964|NCT04520334|Other|Zhineng Qigong|Zhineng Qigong intervention
11036965|NCT04520321|Placebo Comparator|Vehicle (placebo)|Placebo weekly x 4
11036966|NCT04520321|Experimental|Low dose|TTHX1114(NM141) low-dose weekly x 4
11036967|NCT04520321|Experimental|Mid-dose|TTHX1114(NM141) mid-dose weekly x 4
11036968|NCT04520321|Experimental|High-dose|TTHX1114(NM141) high-dose weekly x 4
11036969|NCT04520308|Experimental|dupilumab|
11036970|NCT04520295||HER2 positive cohort|
11036971|NCT04520269|Experimental|Patient with (cfDNA) 1q21.3 copy number amplification|The phase Ib segment will be carried out in a standard 3+3 design. In the phase II portion, 2 parallel cohorts will be enrolled (Cohort A: 1q21.3 amplified breast cancers, Cohort B: 1q21.3 amplified other solid tumors).
11036972|NCT04520256|Experimental|Core Program Only|
11036973|NCT04520256|Experimental|Social Support|
11036974|NCT04520256|Experimental|Dysregulated Eating|
11036975|NCT04520256|Experimental|Social Support, Dysregulated Eating|
11036976|NCT04520256|Experimental|Exercise|
11036977|NCT04520256|Experimental|Social Support, Exercise|
11036978|NCT04520256|Experimental|Dysregulated Eating, Exercise|
11036979|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise|
11036980|NCT04520256|Experimental|Feedback|
11036981|NCT04520256|Experimental|Social Support, Feedback|
11036982|NCT04520256|Experimental|Dysregulated Eating, Feedback|
11036983|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback|
11036984|NCT04520256|Experimental|Exercise, Feedback|
11036985|NCT04520256|Experimental|Social Support, Exercise, Feedback|
11036986|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback|
11036987|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback|
11036988|NCT04520256|Experimental|VR|
11036995|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, VR|
11036996|NCT04520256|Experimental|Feedback, VR|
11036997|NCT04520256|Experimental|Social Support, Feedback, VR|
11036998|NCT04520256|Experimental|Dysregulated Eating, Feedback, VR|
11036999|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback, VR|
11037000|NCT04520256|Experimental|Exercise, Feedback, VR|
11037001|NCT04520256|Experimental|Social Support, Exercise, Feedback, VR|
11037002|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback, VR|
11037003|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback, VR|
11037004|NCT04520243|Experimental|English alphabet illiterate group|Individuals with no self-reported understanding of English alphabet and recognition of <6/10 Sloan Letters
11037005|NCT04520243|Active Comparator|English alphabet literate group|Individuals with self-reported understanding of English alphabet and recognition of ≥6/10 Sloan Letters
11037006|NCT04520230|Experimental|Group 1|Group 1: 15 patients with COPD who will receive inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination (160/4.5mcg) 2 inhalations bid).
11037007|NCT04520230|Experimental|Group 2|Group 2: 15 patients with COPD who will receive inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg inhaled capsule once daily+ Budesonide inhalation 200 mcg twice daily).
11037008|NCT04520230|Experimental|Group 3|Group 3: 15 patients with COPD who will receive long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC). (Tiotropium 18 mcg inhaled capsule once daily+ Formoterol 12 mcg inhaled capsule twice daily)
11037009|NCT04520217|Experimental|4% Imipramine Cream on UVB-Treated Areas|"2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.
~2g of base cream will be applied to the UVB-treated areas on volar forearm and back.
~No cream will be applied to a UVB-treated area on the back"
11037010|NCT04520178|Active Comparator|Low-dose 5HTP|50mg 5-HTP in combination with 50mg carbidopa
11037011|NCT04520178|Active Comparator|High-dose 5HTP|100mg 5-HTP in combination with 50mg carbidopa
11037012|NCT04520178|Sham Comparator|Carbidopa|50mg carbidopa only
11037013|NCT04520178|Placebo Comparator|Placebo|
11037014|NCT04520152|Experimental|Treatment group|Bronchoscopic LTD placement
11037015|NCT04520139|Experimental|Phase 1 Dose Escalation|Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.
11037016|NCT04520139|Experimental|Phase 2 Dose Expansion|Patients will be randomized to receive NAC at the maximum tolerated dose or placebo.
11037017|NCT04520126|Active Comparator|olive extract 1|Fifteen patients will be randomized to receive two Olivomed soft capsules bid for three months (10 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another 3 months.
11037018|NCT04520126|Placebo Comparator|placebo 2|Fifteen patients will be randomized to receive two placebo soft capsules bid for three months. Then they will be crossed over to receive two Olivomed soft capsules bid for three months (10 mg hydroxytyrosol po twice daily)
11037019|NCT04520113|Active Comparator|Standard Tracing|"Households of tuberculosis index patients receive standard household contact tracing during regular weekday business hours."
11037020|NCT04520113|Experimental|Holiday Tracing|Households of tuberculosis index patients in rural South Africa receive household contact tracing during holidays (Christmas and Easter).
11037021|NCT04520113|Experimental|Evening / Weekend Tracing|Households of tuberculosis index patients in urban South Africa receive household contact tracing during evenings and weekends.
11037022|NCT04520100|No Intervention|MRI without intervention|No hypnosis during MRI and care by regular MR technologist
11037023|NCT04520100|Active Comparator|MRI with clinical hypnosis and regular MR tech|Hypnosis during MRI and care by regular MR technologist
11037024|NCT04520100|Active Comparator|MRI with care by MR Tech trained in empathic communication|No hypnosis during MRI and care by MR technologist who have been trained in emphatic communication
11037025|NCT04520087|Experimental|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
11037026|NCT04520074|No Intervention|Follow-up|No interevention
11037027|NCT04520074|Experimental|three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
11037028|NCT04520061||Navigation Intervention|The intervention will be delivered via synchronous videoconferencing (real-time delivery and communication between the navigator and the participant) by a trained patient navigator and will consist of 4, 30-minute sessions delivered every week, over the span of one month. The navigation intervention group will also receive a mailed copy of the brochure.
11037029|NCT04520061||Enhanced Usual Care|Enhanced usual care will consist of an online or mailed health insurance resource guide.
11037030|NCT04520048|Experimental|Women with gestational hypertension and/or preeclampsia|Pregnant patients from the 20th week of amenorrhea with the initial diagnosis of gestational hypertension and/or preeclampsia. Patients in a stable state undergoing follow-up consultation (day hospital and week hospitalisation)
11037031|NCT04520035|Experimental|neoadjuvant chemotherapy with camrelizumab|"paclitaxel and cisplatin
~Carilizumab 200 mg, every 3 weeks, 2 cycles.
~Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
~Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles"
11037032|NCT04520022|Experimental|FURESTEM-CD Inj|
11037033|NCT04520009||Activity Restriction|Discharge orders for activity restriction
11037034|NCT04520009||Activity As Tolerated|Discharge orders written for activity as tolerated
11037035|NCT04519996|Experimental|US Internal Jugular Vein Collapsibility Index|The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility.
11037036|NCT04519996|Experimental|US Inferior Vena Cava Collapsibility Index|The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration.
11037037|NCT04519983|Experimental|Upfront TKI + Salvage SRT|Patients With Brain metastases of EGFR-mutant Non-small Cell Lung Cancer should receive receive Osimertinib as upfront treatment. SRT(32-40 Gy/4-5f) given to progressive or recurrent intracranial lesions as salvage therapy after intracranial failure.
11037038|NCT04519970|Active Comparator|Highest Tier of Case Management (Piggyback) and Biktarvy|The most intensive tier of case management. Includes three appointment reminders; check ins twice per week; travel compensation; housing support; food insecurity support; follow ups for missed appointments and off pill counts; connections with substance use programs; meetings with the benefits department for health insurance needs; childcare support to make appointments; mental healthcare referrals; open pool appointments as back-up options in case of rescheduling needs; late doctor's appointments and prescription pick up for those working during the day; meetings with the health educators to discuss HIV and ART; and re-motivation of HIV treatment every 3 months.
11037039|NCT04519970|Active Comparator|Middle Tier of Case Management (Got Your Back) and Biktarvy|The middle tier (Got Your Back) will work closely with the CORE case managers to augment their work in housing support, transportation assistance, mental healthcare referrals, childcare assistance, substance use program referrals, food insecurity support and health insurance needs. The retention specialist will additionally provide this middle tier 2 reminders for appointments; check ins once per week; follow ups for missed appointments or off pill counts; support with scheduling appointments for limited availability; meetings with the health educators for information on HIV or ART; and re-motivation for treatment at the 6 and 9 month marks of participation.
11037040|NCT04519970|Active Comparator|Lowest Tier of Case Management (Backbone) and Biktarvy|The top tier (Backbone) will need the least amount of support and also have a CORE Center case manager for a majority of the support in housing, food, insurance, transportation, childcare, substance use, and mental healthcare. The retention specialist will still provide an appointment reminder; check ins every other week; text checkups after missed appointments or off pill counts; support with scheduling for appointments or prescription pick up for limited availability; and re-motivation of treatment for HIV at the 9 month mark of study participation.
11037041|NCT04519944||NVAF patients undergoing PCI|Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
11037042|NCT04519931|Experimental|Stress ball|
11037043|NCT04519931|No Intervention|Control group|
11037044|NCT04519918|No Intervention|Standard ICSI procedure|a single spermatozoon was injected into the ooplasm.
11037045|NCT04519918|Experimental|Chemical oocyte activation|After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
11037046|NCT04519918|Experimental|Mechanical oocyte activation|Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
11037047|NCT04519905|Experimental|chemoradiotherapy|50.4Gy/28Fx; Paclitaxel plus carboplatin
11037048|NCT04519905|Active Comparator|radiotherapy|61.2Gy/34Fx
11037049|NCT04519892|Experimental|Receiving PDRC and coach guidance|Intervention group: Receiving PDRC + coach guidance.
11037050|NCT04519892|Active Comparator|Receiving PDRC without coach guidance|Control group: Receiving PDRC only.
11037051|NCT04519879|Experimental|Arm IA (white mushroom extract)|Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
11037052|NCT04519879|Active Comparator|Arm IB (clinical observation)|Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
11037053|NCT04519879|Experimental|Arm IIA (white mushroom extract)|Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
11037054|NCT04519879|Active Comparator|Arm IIB (active surveillance)|Patients undergo active surveillance for 48 weeks.
11037055|NCT04519866|Experimental|Electroacupuncture|In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
11037056|NCT04519866|Active Comparator|Manual acupuncture|In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
11037057|NCT04519853|Experimental|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 30% carbohydrate, 20% protein.
11037058|NCT04519827|Experimental|New Rice-based hydrolysate|The TEST formula is a new Rice-based hydrolysate with new ingredient.
11037059|NCT04519827|Placebo Comparator|Amino-acid based formula|The PLACEBO is an Amino-acid based formula.
11037060|NCT04519814|Experimental|all eligible patients|A total of 40 eyes in 40 consecutive patients, 22 years of age or older, with primary open-angle glaucoma (HPG + NPG), who did not reach target pressure, agree to participate in the study, and will be able to complete clinical follow-up and evaluation.
11037061|NCT04519801|Other|REHAB|Standard post-operative rehabilitation regimen (REHAB) (Control)
11037062|NCT04519801|Experimental|REHAB + BFR|Standard rehabilitation regimen with BFR therapy (REHAB + BFR) (Experimental)
11037063|NCT04519788|Active Comparator|AT-301B|AT-301B consists of edetate disodium, glyceryl monooleate, polysorbate 80, benzalkonium chloride, microcrystalline cellulose and sodium carboxymethylcellulose (vivapur), trisodium citrate dihydrate, and purified water (HCl to adjust pH to 5.0)
11037064|NCT04519788|Placebo Comparator|AT-301A|AT-301A consists of sodium chloride, benzalkonium chloride and purified water (NaOH/HCl to adjust pH to 5.0)
11037065|NCT04519775|Experimental|HOBSCOTCH-V (virtual)|"Participants will receive the HOBSCOTCH intervention consisting of 1:1 sessions delivered once per week, including:
~1 pre-HOBSCOTCH Session (on webcam)
~1 educational session (on webcam)
~6 telephone sessions
~1 wrap-up session (webcam or telephone)
~Participants will also receive 3 booster sessions, via webcam or telephone, once per month."
11037066|NCT04519775|Other|Control|Participants will be wait listed and will receive HOBSCOTCH-V (above) following a 6 month wait period.
11037067|NCT04519762|Sham Comparator|Control group|Management of sepsis/ septic shock via fluids, antibiotics, vasopressors and inotropes.
11037068|NCT04519762|Active Comparator|Study group|Management of sepsis/ septic shock in addition to management of hypophosphatemia.
11037069|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV Titer Group A|Single IV administration of 4D-310 Dose Level 1 - AAV Titer Group A patients
11037070|NCT04519749|Experimental|4D-310 Dose Level 1 - AAV Titer Group B|Single IV administration of 4D-310 Dose Level 1 - AAV titer Group B patients
11037071|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV Titer Group A|Single IV administration of 4D-310 Dose Level 2 - AAV titer Group A patients
11037072|NCT04519749|Experimental|4D-310 Dose Level 2 - AAV Titer Group B|Single IV administration of 4D-310 at Dose Level 2 in AAV titer Group B patients
11037073|NCT04519749|Experimental|4D-310 Dose Expansion|Dose expansion cohort of single IV administration of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
11037074|NCT04519736|Active Comparator|Harmony Dye-VL 500-600nm|The left side of the face will be treated with the Single Band Alma Harmony Dye-VL 500-600nm device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
11037075|NCT04519736|Active Comparator|Palomar MaxG|Right side of the face will be treated with the Dual Band Palomar MaxG device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .
11037076|NCT04519723|Other|Alma Harmony Laser System|There is only one arm. Three hand modules; Dye-VL 500-600nm, High Power QSW 1064nm, and High power Pixel ER:YAG 2940nm laser module with rollers will be utilized in combination in a series of treatments intended to improve skin color, tone, texture and laxity. Subjects will receive up to four treatments administered in intervals of 28 +/- 2 days. Treatment duration of approximately 60 minutes.
11037077|NCT04519710|Experimental|multiple sclerosis or other inflammatory neurological disease|HBV negative
11037078|NCT04519710|Experimental|systemic vasculitis|HBV negative
11037079|NCT04519710|Experimental|an autoimmune disease|HBV negative
11037080|NCT04519697|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
11037081|NCT04519697|Placebo Comparator|Placebo|Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula.
11037082|NCT04519684|Experimental|Mesenchymal stem cells|Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
11037083|NCT04519684|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s).
11037084|NCT04519671|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
11037085|NCT04519671|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)
11037086|NCT04519658|Experimental|CIN-107 Dose 1|
11037087|NCT04519658|Experimental|CIN-107 Dose 2|
11037088|NCT04519658|Experimental|CIN-107 Dose 3|
11037089|NCT04519658|Placebo Comparator|Placebo|
11037090|NCT04519645|Experimental|Lacosamide|Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
11037091|NCT04519645|Active Comparator|Active Comparator|Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
11037092|NCT04519632||Parents|Qualitative interviews
11037093|NCT04519632||Healthcare Professionals|Qualitative interviews
11037094|NCT04519632||Children|Children and young people aged 6-18 years, Qualitative interviews
11037095|NCT04519619||Aflibercept (Eylea, BAY86-5321)|Decision of Eylea treatment is made by attending investigators according to the Japanese Package Insert
11037096|NCT04519606||One-lung ventilation|During one-lung ventilation, the dependent lung (non-operation lung) will be mechanically ventilated with a fixed positive end-expiratory pressure (PEEP) of 4 cmH2O and the peak pressure below 30 cmH2O. Tidal volumes will be titrated from the initial 4 ml/kg predicted body weight (PBW) to 7 ml/kg PBW. Optimal lung compliance is determined by the levels of upper reflection point of the pressure-volume loop closed to 30 cmH2O. Chest tomography will be undertaken with the optimal tidal volume during OLV phase and when the independent lung is completely recruited using the stepwise PEEP increase method.
11037097|NCT04519593|Experimental|Laparoscopic myomectomy with temporary blood supply occlusion|Laparoscopic myomectomy is performed with prior visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
11047434|NCT04446858||With TIPS|Prospective cohort that received TIPS
11037098|NCT04519593|Active Comparator|Conventional laparoscopic myomectomy|Laparoscopic myomectomy is performed without prior temporary blood supply occlusion.
11037099|NCT04519580||Patients with suspected polymyalgia rheumatica|The study investigates patients with suspected polymyalgia rheumatica (PMR). For Patients where the PMR diagnosis is dismissed, the study terminates after the first visit. Patients diagnosed with PMR will be treated with prednisolone with taper corresponding to usual care. At baseline all patients will have medical history taken, physical examination, blood drawn, Synacthen® test, PET/CT, and ultrasound performed. Physical examination, PET/CT, and ultrasound are repeated after 8 weeks of prednisolone treatment while the patients iare on 10 mg prednisolone as well as after prednisolone taper two weeks later, where Synachten® test is also performed. After 10 weeks prednisolone is restarted at 10 mg and the patient is followed by their general practitioner or at the department of rheumatology, where prednisolone is tapered according to usual care. Patients are invited to a follow up visit after one year.
11037100|NCT04519567|Experimental|CTI-1601|
11037101|NCT04519567|Placebo Comparator|Placebo|
11037102|NCT04519554|Other|5FR + 7FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 5FR then 7 FR
11037103|NCT04519554|Other|7FR + 5FR|Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 7FR then 5FR
11037104|NCT04519541|Experimental|Neurolyser XR treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
11037105|NCT04519528||Patients|Minors who required veno-venous or veno-arterial ECMO, in pediatric intensive care unit at Necker Enfants Malades hospital between 2014 and 2019.
11037106|NCT04519515|Experimental|Treatment With Juvederm Vollure Right|Injection of Juvederm Vollure on one half of the face, placebo on the other side
11037107|NCT04519515|Experimental|Treatment Juvederm Vollure Left|Injection of Juvederm Vollure on one half of the face, placebo on the other side
11037108|NCT04519502||Randomly Selected Delivery Dates 2019|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.
11037109|NCT04519502||Randomly Selected Delivery Dates 2020|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020
11037110|NCT04519502||Confirmed COVID-19 Infections|Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.
11037111|NCT04519489|Experimental|PAP therapy with telemonitoring|This arm will consist of 86 subjects.
11037112|NCT04519489|Other|Control group|This arm will consist of 43 subjects.
11037113|NCT04519476|Experimental|Selinexor/Lenalidomide/Steroids|All subjects enrolled will receive: 1) selinexor, PO, at 60 mg once weekly on days 1-28 of a 28-day cycle, 2) lenalidomide, PO, 10 mg daily on days 1-21 of 28-days cycle and 3) methylprednisolone at the same dose and schedule as the last lenalidomide-containing regimen if it contained steroids. If patient's qualifying lenalidomide-containing regimen contained different type of steroid (e.g. prednisone, dexamethasone, etc.) then patient on this study will receive methylprednisolone at the equivalent dose and schedule.
11037114|NCT04519463|Experimental|Xylocaine|30 patients who receive Xylocaine 10% nasal spray
11037115|NCT04519463|Placebo Comparator|Saline|30 patients who receive saline nasal spray
11037116|NCT04519450||ICU patients without an with chronic respiratory diseases|The group will consist of >50 patients admitted to the intensive care unit, of which at least 20 with chronic respiratory diseases. Patients of both sexes, patients with and without chronic respiratory diseases, and also patients requiring mechanical ventilation were included and their demographic characteristics and outcomes registered. All patients will sign an informed consent form before inclusion in the prospective observational study.
11037117|NCT04519437|Experimental|REGN10933+REGN10987|
11037118|NCT04519437|Placebo Comparator|Placebo|
11037119|NCT04519424|Experimental|CSL324|CSL324 administered intravenously
11037120|NCT04519424|Placebo Comparator|Placebo|Normal saline administered intravenously
11037121|NCT04519411|Experimental|Intubated pediatric patients with COVID-19 respiratory failure|
11037122|NCT04519398||COVID-19 patients with proved venous thrombosis|"1st group includes COVID-19 patients with proved
~venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis occurring in more atypical places such as in the veins of the brain, liver, kidney, mesenteric vein and the veins of the arms)
~or arterial thrombosis (heart attacks, strokes)"
11037123|NCT04519398||Asymptomatic COVID-19 & those with mild or moderate disease|2nd group encompasses asymptomatic patients and those with mild or moderate disease, according to current guidelines, without thrombosis: no symptoms or evidence of lower respiratory disease by clinical assessment or imaging and a SpO2 > 94%
11037124|NCT04519398||Severe disease, according to Guidelines, without thrombus|3rd group includes severe disease, according to current guidelines, without thrombosis: respiratory frequency > 30 breaths per minute, SpO2 < 94%, PaO2/FiO2 < 300 mmHg, or lung infiltrates >50%
11037125|NCT04519385|Experimental|Tocilizumab|Tocilizumab
11037126|NCT04519385|Active Comparator|Dexamethasone|Dexamethasone therapy
11037127|NCT04519359|Experimental|Stop Arm|Stop NAs therapy
11037128|NCT04519359|No Intervention|Continue Arm|Continue NAs therapy
11037129|NCT04519346|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with migraine pain
11037130|NCT04519333|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with neck pain related to cervical disc herniation
11037131|NCT04519320|Other|SARS-COV 2 Patients|
11037132|NCT04519307||Group 1|The newborns with covid 19 infection
11037133|NCT04519307||Group 2|The newborns with no covid 19 infection
11037134|NCT04519294|Active Comparator|SURE|
11037135|NCT04519294|Active Comparator|Standard Ureteroscopy (Basketing)|
11037136|NCT04519281||Group (A)|consists of 50 patients undergoing open heart surgeries who will receive IV ascorbic acid
11037137|NCT04519281||Group (B)|consists of 50 patients undergoing open heart surgeries who will not receive ascorbic acid or will receive a placebo (Control Group).
11037138|NCT04519268||Elective Surgical Adult Patients|Adult patients scheduled for an elective general surgical operation.
11037139|NCT04519255||Screening of clinically cured patients with severe COVID-19|①Patients with severe COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
11037140|NCT04519255||Screening of clinically cured patients with mild COVID-19|①Patients with mild COVID-19 cure were determined based on nucleic acid tests, CT examinations, and clinical criteria; ②Age > 18 years, age < 85 years, no gender restriction; ③ All had received COVID-19 drug therapy; ④ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ⑤ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
11037141|NCT04519255||Healthy people who are not infected with COVID-19|① Volunteers who are not infected with COVID-19; ②Age > 18 years, age < 85 years, no gender restriction; ③ ECOG of general condition score: 0-2; No dysfunction of main viscera; Oxygen partial pressure ≥10.64kPa; White blood cells ≥4×109/L; Blood routine hemoglobin ≥9.5g/dL; The absolute count of neutrophils ≥1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤1.5 times the upper limit of normal value; Creatinine ≤1.25 times the upper limit of normal value; The creatinine clearance rate was ≥60ml/min; ④ Can obtain complete follow-up information, understand the situation of this study and sign informed consent.
11037142|NCT04519242|Active Comparator|Patients enrolled in the ORIF group|Open reduction and internal fixation (ORIF), ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation, TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.
11037143|NCT04519242|Active Comparator|Patients enrolled in the PA group|PA will be done by removal of the articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).
11037144|NCT04519229||Children in fostercare in CPP-treatment|Children in foster care taking part in Child-Parent Psychotherapy
11037145|NCT04519216|Active Comparator|Traditional education|Participants in the control group will complete an online unfolding case scenario. Then these same participants will participate in a videoconferencing case based lecture with the academic pediatric fellow
11037146|NCT04519216|Experimental|Telesimulation|Participants in the intervention group will complete an online unfolding case scenario. Then these participants will complete a telesimulation case with a standardized patient via video conferencing.
11037147|NCT04519203|Active Comparator|SPI group|Group of patients where opioid consumption will be guided using SPI target
11037148|NCT04519203|Active Comparator|Control Group|Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period
11037149|NCT04519177|Experimental|Experimental (Early Education)|Firefighters in station randomized to the experimental (early education) will receive the sleep health education program (SHEP) including screening for common sleep disorders. Those found at high risk will be given information about seeking further evaluation, diagnosis and treatment, if necessary.
11037150|NCT04519177|No Intervention|Control (Later education)|Firefighters in station randomized to the control condition will not receive SHEP prior to the data collection.
11037151|NCT04519164|Experimental|Eplerenone|Participants will receive eplerenone, ranging from 25-100mg daily for one year.
11037152|NCT04519164|Active Comparator|Chlorthalidone with potassium chloride|Participants will receive chlorthalidone (6.25-25mg daily for one year) along with potassium chloride (up to 20 mEq daily for one year)
11037153|NCT04519151|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
11037154|NCT04519138|Experimental|Endodrill Model X|Three consecutive samples will be taken using the Endodrill Model X instrument.
11037155|NCT04519138|Active Comparator|Endoscopic ultrasound guided fine-needle aspiration/biopsy|Three consecutive samples will be taken using the the standard method fine-needle aspiration/biopsy.
11037156|NCT04519125|Experimental|Intervention|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
11037157|NCT04519125|Placebo Comparator|Placebo|(1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
11037158|NCT04519112|Experimental|Remote magnetic navigation group|PVC ablation with RMN
11037159|NCT04519112|Active Comparator|Mannual control navigation group|PVC ablation with mannual navigation
11037160|NCT04519086|Experimental|Low-dose CT for acute appendicitis in patients with BMI >30|Low-dose computed tomography (CT) vs. standard CT for diagnosing acute uncomplicated appendicitis in patients with BMI > 30 Laparoscopic appendectomy
11037161|NCT04519073|Placebo Comparator|Placebo|0.5 mL of diluent (phosphate buffer)
11037162|NCT04519073|Experimental|V-306 low dose|V-306 at 15 µg
11037163|NCT04519073|Experimental|V-306 intermediate dose|V-306 at 50 µg
11037164|NCT04519073|Experimental|V-306 high dose|V-306 at 150 µg
11037165|NCT04519060|No Intervention|No eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care.
11037166|NCT04519060|Experimental|Eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care and the application of eye shields. They will be worn until four (4) hours after the last dose of dilating eye drops.
11037167|NCT04519047|Experimental|Rejoint|Rejoint+PRP
11037168|NCT04519047|Active Comparator|Control|Saline+PRP
11037169|NCT04519034||Audit 1|All vitamin D results performed since January 2020 (N= ~15000) together with age, weight and height if available, ethnicity and other relevant laboratory markers (Ca, adjusted calcium, PTH, Mg, phosphate, liver and renal profile, Covid-19 screening, CRP, Haematinics, FBC)
11037170|NCT04519034||Audit 2|All Covid-19 screening results together with vitamin D, ethnicity, age, weight, height, length of stay in hospital including ICU (if applicable), type of illness, recovered or not, associated health conditions, CRP, Ferritin, Haematinics, vitamin A and E, procalcitonin, LDH, INR, fibrinogen, FBC, D-dimers, CK, Troponin-T, cytokines, renal function and electrolytes from patients tested at GSTT NHS Trust.
11037171|NCT04519008|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
11037172|NCT04519008|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
11037173|NCT04518995|Experimental|CTP-543, 8 mg BID|Oral tablet for 24 weeks
11037174|NCT04518995|Experimental|CTP-543, 12 mg BID|Oral tablet for 24 weeks
11037175|NCT04518995|Placebo Comparator|Placebo, BID|Oral tablet for 24 weeks
11037176|NCT04518982|Experimental|The experimental group|
11037177|NCT04518982|Placebo Comparator|The control group|
11037178|NCT04518969|No Intervention|Control|Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed……
11037179|NCT04518969|Experimental|Cytosorb|"CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed…… Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.
~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.
~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
11037180|NCT04518956|Experimental|Inter maxillary fixation and exposure to shockwave therapy|
11037181|NCT04518956|Experimental|Inter maxillary fixation and exposure to low intensity pulsed|
11037182|NCT04518956|Active Comparator|Inter maxillary fixation only|
11037183|NCT04518943|Experimental|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
11037184|NCT04518943|Experimental|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
11037185|NCT04518943|Experimental|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
11037186|NCT04518943|Experimental|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
11037187|NCT04518943|Experimental|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
11037188|NCT04518943|Experimental|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
11037189|NCT04518943|Experimental|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
11037190|NCT04518943|Experimental|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
11037191|NCT04518943|Experimental|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
11037192|NCT04518943|Experimental|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
11037193|NCT04518943|Experimental|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
11037194|NCT04518943|Experimental|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
11037195|NCT04518943|Experimental|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
11037196|NCT04518943|Experimental|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
11037197|NCT04518943|Experimental|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
11037198|NCT04518943|Experimental|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
11037199|NCT04518930|Experimental|high fat|30 participants will be provided with (33) g of roasted, not salted peanuts after-lunch as snack.
11037200|NCT04518930|Experimental|high protein|30 participants will be provided with (148) g of Plain Greek yogurt after-lunch as snack.
11037201|NCT04518930|No Intervention|control|30 participants who will not be provided with any type of snacks after lunch
11037202|NCT04518917||Parkinson disease plus dementia|Participants will have a diagnosis of Parkinson disease plus dementia.
11037203|NCT04518904||Group of poor prognosis|In this group,the patients had suffered from systemic infection,pulmonary complications or died.
11037204|NCT04518904||Group of good prognosis|In this group,the patients were safely discharged without complications.
11037205|NCT04518891|Experimental|Cognitive Functional Therapy (CFT) Group|"There will be 3 main components in the intervention:
~Making sense of pain: the cognitive component will focus on identifying the factors that contribute to pain during examination. This will include discussion on the multidimensional nature of persistent pain, individual beliefs, and how emotions and behaviours regarding movement and lifestyle can reinforce a vicious cycle of pain and disability.
~Controlled exposure: specific functional training is designed to normalise maladaptive or provocative movement and posture. functional integration is directed at activities of daily life that are avoided by the patient. This will vary among individuals but should include basic activities such as rolling in bed, sitting, sitting to standing, walking, bending and lifting.
~Lifestyle change: Physical activity and lifestyle. Patients will be advised to gradually increase physical activity based on their preference, while also focusing on sleep hygiene, stress and management strategies."
11037206|NCT04518891|Sham Comparator|Sham intervention|Patients allocated to the placebo group will be treated with detuned photobiomodulation device using a handheld probe (904Nm Ibramed Infrared - no-visible beam), without any emission of therapeutic dose. Three central sites in the space between T11/T12, L2/L3 and L5/S1 and two points laterally positioned in each anatomical level will be submitted to fake stimulation. Three minutes of fake stimulation will be administered, summing up 27 minutes. In addition, a neutral talking control therapy of at least 15 minutes will be provided to patients in the sham group in each session. Maladaptive beliefs will not be challenged; however, the therapists will be trained to show interest and warmth, empathy and encouraging participants to discuss neutral topics such as hobbies, sports, and current affairs. No advice or problem solving will be given, and any attempt to talk about emotional issues will be kindly discouraged and the talking will be redirect to neutral tropics.
11037207|NCT04518878|Experimental|Fixed Low-dose Eltrombopag and rhTPO|Fixed Low-dose Eltrombopag and rhTPO
11037208|NCT04518865|Experimental|pre-pubertal group.|The patients were allocated into the pre-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS II and CVMS III
11037209|NCT04518865|Experimental|post-pubertal group|The patients were allocated into the post-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS V and CVMS IV
11037210|NCT04518852|Experimental|Treatment group|The participants will receive the combined treatment of local therapy (TACE, oxaliplatin and epirubicin), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
11037211|NCT04518839||Group with regional anaesthesia|
11037212|NCT04518839||Group with general anaesthesia|
11037213|NCT04518826||FFR|In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR <0.9, the operator will dilate the DES-ISR lesion again before another FFR is measured. If FFR>=0.9, DEB will be used and final FFR will be measured at the end of the procedure.
11037214|NCT04518826||CAG|In angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.
11037215|NCT04518813|Experimental|RSP-24|Subjects will perform calibrations on the IMD (Prototype 0.5) for 41 days over a 60 day period.
11037216|NCT04518800|Experimental|Jin Youli(PEG-rhG-CSF)|PEG-rhG-CSF Secondary Prevention：patients with pancreatic cancer who met the eligibility criteria were given secondary prophylactic administration of the Jin Youli(PEG-rhG-CSF).
11037217|NCT04518787||Control|Healthy child
11037218|NCT04518787||Experimental|Patients with language disorder
11037219|NCT04518774|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 3 cycles of ex-vivo expanded allogeneic γδT cells treatments, at four-weeks' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
11037220|NCT04518761||Prospective group|
11037221|NCT04518761||Retrospective group|
11037222|NCT04518748|Experimental|Y-90 SIRT followed by SBRT|Y-90 SIRT followed by SBRT
11037223|NCT04518735||Patients on previous oral anticoagulant treatment|Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication
11037224|NCT04518735||Patients on previous antiplatelet therapy|Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication
11037225|NCT04518735||Patients without antithrombotic therapy|Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy
11037226|NCT04518709|Experimental|Posterior Annulus Elevation Technique Group|In patients who were determined in the treatment group, after the conventional procedure for mitral valve repair was completed, a posterior mitral valve elevation technique will be performed.
11037227|NCT04518709|Placebo Comparator|Without Posterior Annulus Elevation Technique Group|No additional procedure will be done after conventional mitral valve repair
11037228|NCT04518696|Experimental|suprachoroidal buckling treatment group|suprachoroidal buckling for therapy of rhegmatogenous retinal detachment
11037229|NCT04518683|Experimental|Groupe 1 - Study group|"The home program (outside of the sessions with the physiotherapist) will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes (time corresponding to 1 programe). The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.
~The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
11037230|NCT04518683|Active Comparator|Groupe 2 - Control group|"The home program (outside of the sessions with the physiotherapist) will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist.
~This training will work on pelvic floor strength, relaxation and endurance. The program includes 3 levels of difficulty"
11037231|NCT04518657|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and oneonone video chats with a behavioral coach.The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory.Each course consists of an introduction,the primary content,and a take home message.The interactive courses include embedded,supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps,and these steps will be entered into the website so progress can be monitored.The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries.The chats are conducted facetoface through an online videoconferencing platform.The chats occur 7 times during the first 2 months,4 times during the second 2 months,and twice during the final 2 months of the intervention.
11037289|NCT04518254|Experimental|Placebo - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure
11037290|NCT04518254|Experimental|Placebo - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure
11037232|NCT04518657|Sham Comparator|Wellness for MS (WellMS)|Provides an internet website and oneonone video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity.The materials are transformations of brochures provided by the National MS Society,including Gait or Walking Problems:The Basic Facts;MS and Your Emotions;Pain:The Basic Facts; Solving Cognitive Problems;Taming Stress in MS;Food for Thought:MS and Nutrition;and Vitamins,Minerals,and Herbs:An Introduction.The delivery of the internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition,and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
11037233|NCT04518631|Experimental|8-week mindfulness program|8-week .b Foundations course
11037234|NCT04518631|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
11037235|NCT04518618|Experimental|Group F|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml).
11037236|NCT04518618|Experimental|Group FN|Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ugs of fentanyl (0.5 ml) plus 20 ugs naloxone.
11037237|NCT04518605|Experimental|Low protein breakfast|Subject will eat a low protein breakfast and maintain their habitual physical activity.
11037238|NCT04518605|Experimental|High protein breakfast|Subject will eat a high protein breakfast and maintain their habitual physical activity.
11037239|NCT04518605|Experimental|Low protein breakfast and exercise training|Subject will consume a low protein breakfast (bread, jam, juice) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
11037240|NCT04518605|Experimental|High protein breakfast and exercise training|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr) with oats) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
11037241|NCT04518592||Severe Major Depressive Disorder|
11037242|NCT04518592||control , healthy|
11037243|NCT04518579|Active Comparator|Group (EP)|Group (EP) received epidural (fentanyl and bupivacaine) - propofol based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
11037244|NCT04518579|Active Comparator|Group (EH)|Group (EH) received epidural (fentanyl and bupivacaine)- inhalational based anesthetic technique and postoperative analgesia through patient controlled analgesia device (PCA)
11037245|NCT04518566|No Intervention|Placebo|Patients in control arm will have FitBit. However, there are no personalised nudges given to the patients in the control arm. Occasional reminders to encourage adherence to wearing of the FitBit will be sent.
11037246|NCT04518566|Experimental|Nudges|Patients in the intervention arm will be given a FitBit device and will be encouraged to wear it as often as possible. Using FitBit built-in tracking technologies such as PurePulse and SmartTrack54, patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the adaptive intervention platform as developed in Phase 2 for real-time tracking.
11037247|NCT04518553|Active Comparator|active control|antiviraltherapy using HA using antiviralHA drugs of HA to decrease HBV-DNA load. In this group, patients with chronic hepatitis B just take antiviral drug of HAs to control hepatitis B viral without active interference.
11037248|NCT04518553|Experimental|active interference|HA+plasma purification as active interference. HA antiviral therapy using HA plus plasma purification every three months.DFT as plasma purification mode will be used. DFT therapy time lasts 2.5-3 hours each time.After three months, DFT therapy will be used if patients' HBV-DNA loads are higher than cut-off normal level.
11037249|NCT04518540|Experimental|lipoic acid group|The patients will take lipoic acid by intravenous. At the same time, the patients will take take riluzole tablets orally everyday.
11037250|NCT04518540|Experimental|control group|The patients will take riluzole tablets orally everyday.
11037251|NCT04518527|Active Comparator|true taping+ exercise|The true taping method was applied to the first group according to the method determined by Kase. According to this method, a 2-inch (5 cm) wide beige-colored Kinesio tape (Kinesio® Tex Gold FP) was measured from the second-third metacarpal base to the lateral epicondyle while the elbow was extended and the wrist was in the neutral position and the tape was applied in the shape of a 'Y'. In a position where the wrist-ankle extensors were most tense (wrist-ankle extension - forearm pronation), the anchor point of the tape was applied to the insertion of the muscle without creating any tension. Then, the tape was applied to the medial and lateral edges of the wrist extensors by applying a 15-25% tension towards the origin of the muscle. Both ends of the Y-shaped tape were terminated without tension on the lateral epicondyle.
11037252|NCT04518527|Placebo Comparator|sham taping+exercise|In the placebo group, the 10 cm I-shaped tape was placed 5 cm inferior to the lateral epicondyle using the same Kinesio tape in the study group. It was applied transversely, starting from the painless side of the midline on the forearm extensor face directing towards the lateral side of the forearm without a tension.
11037253|NCT04518514|Experimental|Preoperative evaluation and risk assessment via telemedicine|
11037254|NCT04518501|Experimental|study group|Table Olaparib plus table Arsenic Trioxide po
11037255|NCT04518488|Active Comparator|Prehabilitation group|The prehabilitation group will receive a set of exercises designed to strengthen both limbs. The exercises will be taught and illustrated by a trained physiotherapist and are to be done daily during the period prior to surgery. The participant will be coached and supported for the exercise program, twice a week during the pre-operative period.
11037256|NCT04518488|Other|Informational support group (control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period. The intervention will be in the form of telephone or video calls by a trained health professional. These calls will be scheduled twice a week during the pre-operative period.
11037291|NCT04518241|Experimental|Condition 1|Core, fixed compensation, TMQQ, MI sessions
11037292|NCT04518241|Experimental|Condition 2|Core, lottery prize, TMQQ, MI sessions
11037293|NCT04518241|Experimental|Condition 3|Core, fixed compensation, MI sessions
11037294|NCT04518241|Experimental|Condition 4|Core, lottery prize, MI sessions
11037295|NCT04518241|Experimental|Condition 5|Core, fixed compensation, TMQQ
11037257|NCT04518475|Experimental|efficacy of eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.
~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.
~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
11037258|NCT04518475|Active Comparator|efficacy of eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.
~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
11037259|NCT04518462|Experimental|EXPAREL arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL mixed with 20 mL saline
11037260|NCT04518462|Experimental|EXPAREL admix arm|subjects randomized to this treatment arm will receive 20 mL (266 mg)EXPAREL admixed with 20 mL (50 mg) 0.25% bupivacaine HCl.
11037261|NCT04518462|Active Comparator|Bupivacaine HCl Arm|subjects randomized to this treatment arm will receive 40 mL (100 mg)0.25% bupivacaine HCl.
11037262|NCT04518449||SMA group|the medial border along the left side of superior mesenteric artery (SMA)
11037263|NCT04518449||SMV group|the medial border along the left side of superior mesenteric vein (SMV)
11037264|NCT04518423||Elderly people over the age of 65 years|The study group will comprise community dwelling elderly individuals over the age of 65 years who get around by themselves. The subjects will be followed up for 5 years to investigate the frailty and disability development, and survival.
11037265|NCT04518410|Experimental|ACTIV-2 Drug|Participants in this study will be randomized to receive ACTIV2 Drug or placebo
11037266|NCT04518410|Placebo Comparator|Placebo|The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
11037267|NCT04518397|Experimental|Theatre participants|Girls in this arm will participate in the theatre intervention.
11037268|NCT04518371|Experimental|Indirect Restoration|Milled Resin Composite Block, Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments (inorganic pigments such as ferrous oxide or titanium dioxide).
11037269|NCT04518371|Active Comparator|Direct Restoration|"3M™ Filtek™ One Bulk Fill Restorative is a visible light activated, restorative composite optimized to create fast and easy restorations.
~It is composed of fillers which are a combination of a non-agglomerated/non-aggregated 20 nm silica filler, 4 to 11 nm zirconia filler, zirconia/silica cluster filler and ytterbium trifluoride filler consisting of 100nm particles. The inorganic filler loading is about 76.5% by weight (58.5% by volume)."
11037270|NCT04518358|Experimental|Evaluation of Expert Guiding Technology|
11037271|NCT04518345|Experimental|Treatment (dubermatinib)|"FLT3 AML WITH RELAPSED/REFRACTORY DISEASE:
~INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission."
11037272|NCT04518319|Experimental|omega-3 polyunsaturated fatty acids|Patients randomized to the omega-3 polyunsaturated fatty acids will receive treatment with 1200mg per day plus on-going olanzapine.
11037273|NCT04518319|Experimental|Xbox aerobic exercise|Patients randomized to the Xbox aerobic exercise will do Xbox aerobic exercise 30min per day plus on-going olanzapine.
11037274|NCT04518319|Experimental|transcranial direct current stimulation|Patients randomized to the transcranial direct current stimulation will be applied for transcranial direct current stimulation 5 session/week at 2mA, 20min plus on-going olanzapine. The anodal electrode will be placed over the left dorsolateral prefrontal cortex.
11037275|NCT04518319|Experimental|olanzapine|Patients randomized to the olanzapine will receive conventional treatment-olanzapine.
11037276|NCT04518306|Experimental|Triple ¼ (GMRx2)|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
11037277|NCT04518306|Active Comparator|Triple ½ (GMRx2)|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
11037278|NCT04518306|Placebo Comparator|Placebo|Placebo
11037279|NCT04518293|Experimental|Triple - TAI|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
11037280|NCT04518293|Active Comparator|Dual - TA|Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
11037281|NCT04518293|Active Comparator|Dual - TI|Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
11037282|NCT04518293|Active Comparator|Dual - AI|Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
11037283|NCT04518280|Experimental|Consolidation cohort|A total of 65 patients will receive 5*5Gy short-course radiotherapy, followed by 6 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery.
11037284|NCT04518280|Experimental|Induction cohort|A total of 65 patients will firstly receive 2 cycles of CAPOX chemotherapy and PD-1 antibody, then receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery.
11037285|NCT04518267||Civilian group|Participants with civilian status
11037286|NCT04518267||Military group|Participants with military status
11037287|NCT04518254|Experimental|Tyrosine - Test|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure
11037288|NCT04518254|Experimental|Tyrosine - Stress|4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure
11037296|NCT04518241|Experimental|Condition 6|Core, lottery prize, TMQQ
11037299|NCT04518228|Experimental|Component 1: Arm 1.1: Bictegravir (BIC) 50 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving bictegravir (BIC) 50 mg once daily (q.d.), and their infants
11037300|NCT04518228|Experimental|Component 1: Arm 1.2: Doravirine (DOR) 100 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving doravirine (DOR) 100 mg q.d., and their infants
11037301|NCT04518228|Experimental|Component 1: Arm 1.3: Tenofovir alafenamide (TAF) 10 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving tenofovir alafenamide (TAF) 10 mg q.d. boosted with cobicistat, and their infants
11037302|NCT04518228|Experimental|Component 1: Arm 1.4: TAF 25 mg q.d. without boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. without boosting, and their infants
11037303|NCT04518228|Experimental|Component 1: Arm 1.5: TAF 25 mg q.d. with boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. boosted with cobicistat or ritonavir, and their infants
11037304|NCT04518228|Experimental|Component 2: Arm 2.1: CAB LA|Women ≥ 24 weeks gestation who received at least one dose of long-acting injectable formulation of cabotegravir (CAB LA) any dose during pregnancy, and their infants
11037305|NCT04518228|Experimental|Component 3: Arm 3.1: Dolutegravir (DTG) 50 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving dolutegravir (DTG) 50 mg twice daily (b.i.d.) when combined with RIF or 50 mg q.d. if RIF is not part of the TB regimen, and their infants
11037306|NCT04518228|Experimental|Component 3: Arm 3.2: ATV/r or DRV/r|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving atazanavir/ritonavir (ATV/r) ≥ 300/100 mg q.d. or darunavir/ritonavir (DRV/r) ≥ 600/100 mg b.i.d., and their infants
11037307|NCT04518228|Experimental|Component 3: Arm 3.3: Lopinavir/ritonavir (LPV/r) 800/200 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving lopinavir/ritonavir (LPV/r) 800/200 mg b.i.d., and their infants
11037308|NCT04518228|Experimental|Component 4: Arm 4.1: Second-line TB treatment drugs|"Women ≥ 20 weeks gestation receiving at least one of the following second-line TB treatment drugs, and their infants:
~Levofloxacin (LFX) 750mg - 1000mg q.d.
~Clofazimine (CFZ) 100mg q.d.
~Linezolid (LZD) 300mg - 600mg q.d.
~Bedaquiline (BDQ) 200mg three times per week (t.i.w.)
~Delamanid (DLM) 100mg b.i.d.
~Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study"
11037309|NCT04518228|Experimental|Component 5: Arm 5.1: ATV/r|Women post-delivery receiving ATV/r, and their infants
11037310|NCT04518228|Experimental|Component 5: Arm 5.2: DRV/r|Women post-delivery receiving DRV/r, and their infants
11037311|NCT04518228|Experimental|Component 5: Arm 5.3: LPV/r|Women post-delivery receiving LPV/r, and their infants
11037312|NCT04518215|Experimental|ESPB group|Erector Spinae Plain Block
11037313|NCT04518215|Active Comparator|IV Analgesia group|Intra-Venous Analgesia
11037314|NCT04518202|Experimental|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
11037315|NCT04518202|Placebo Comparator|Sham patch|Sham patch applied at 6 hours before the scheduled office hysteroscopy.
11037316|NCT04518189|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
11037317|NCT04518189|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
11037318|NCT04518176|Experimental|study group|patients with twin pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
11037319|NCT04518176|Active Comparator|control group|patients with twin pregnancy undergoing cesarean section received oxytocin only.
11037320|NCT04518163|Experimental|study group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus 1gm tranexamic acid by intravenous infusion
11037321|NCT04518163|Active Comparator|control group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus saline by intravenous infusion
11037322|NCT04518150|Experimental|study group|patients with placenta previa undergoing cesarean section underwent bilateral uterine artery ligation plus insertion of Bakri balloon
11037323|NCT04518150|Active Comparator|control group|patients with placenta previa undergoing cesarean section underwent insertion of Bakri balloon
11037324|NCT04518137|Experimental|ATG-008|Enrolled patients will be treated with ATG-008 at an oral fixed milligram (mg) dose of 30 mg QD
11037325|NCT04518124|Experimental|Propranolol|
11037326|NCT04518111||Unicompartmental Knee Arthroplasty (UKA)|Patients who underwent primary UKA with Oxford Partial Knee with the Microplasty® instrumentation for AMOA.
11037327|NCT04518111||High Tibial Osteotomy (HTO)|Patients who underwent Open Wedge HTO for AMOA.
11037328|NCT04518098|Experimental|Intervention group|"For the intervention group, it consists of leg muscle strengthening and balance training exercises that progress in difficulty. The balance component of the exercise will include knee bend, backwards walking, sideways walking, heel toe stand, heel toe walk, and one-leg stand, as outlined by the Otago program (31). The strength training component will target the lower body muscles by performing isotonic contraction of quadriceps muscles using an exercise band. During the familiarization session, the training load will be tailored and adjusted for each participant to ensure optimal benefit from the exercise.
~Once the familiarization is completed and participants are comfortable with the exercise routines and techniques, they will continue the online strength and balance training for 3 months (20-30 minutes per scheduled session, three times a week), supervised by the CEP."
11037329|NCT04518098|No Intervention|Control group|Participants in the CG will not receive the intervention, and will be advised to carry out their usual daily activities. Data collection for CG participants will also occur at baseline and at 3- and 6-month follow-up by a research nurse blinded to study group allocation. As with the IG, the research nurse will call CG group participants weekly to ask if a fall has occurred.
11037330|NCT04518085|Experimental|Hypnosis + iACT|Single 20 minute medical hypnosis session delivered pre-surgery plus internet-based acceptance and commitment therapy delivered post-surgery
11037331|NCT04518085|Active Comparator|Mindfulness + treatment as usual (TAU)|Single 20 minute mindfulness session delivered pre-surgery plus treatment as usual post-surgery
11037332|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
11037333|NCT04518072||Control group|No prostate cancer (50)
11037334|NCT04518059||Parkinsonism Group|Participants with Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)
11037335|NCT04518059||Control Group|Participants without parkinsonism
11037336|NCT04518046|Experimental|Phase 1: Dose Escalation|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.
11037337|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort A|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment
11037338|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort B|Patients with favorable-risk RCC with clear cell component for first-line treatment.
11037339|NCT04518033|Experimental|Face covering use|Participants will be provided various commercially available face coverings
11037340|NCT04518020|Active Comparator|Short implant|Short implant 6 mm installed
11037341|NCT04518020|Other|Conventional implant + bone augmentation|Standard length implant 13 mm in conjunction with maxillary sinus floor augmentation serves as a control group
11037342|NCT04518007|Active Comparator|hyperbaric oxygen therapy (HBOT) active treatment|The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes, of 100% oxygen at 2 ATA and 5-minute air breaks every 20 minutes.
11037343|NCT04518007|Sham Comparator|sham|All the conditions provided in the HBOT intervention will be provided in the sham intervention. However, in contrast to the HBOT, where the pressure will go up to 2 ATA, in the sham condition the pressure will go up to 1.1 ATA during the first five minutes of the session with noise of circulating air, and then decrease slowly during the next half hour to 1.0 ATA and the oxygen level will be 21% The initial 1.1 ATA level will provide a minimal pressure sensation in the ears, with the same nurse advice on pumping the ears. In the last five minutes of the session, the air will be circulated again with its related noises. Sham and HBOT sessions will never be adjacent, so subjects from the two groups cannot meet and discuss the session and its effects.
11037344|NCT04517994|Experimental|Active Treatment|The intervention includes components from empirically validated interventions for intimate relationship difficulties and PTSD. This includes core themes of trust, self-esteem, power and control, conflict-management skills, and communication skills training.
11037345|NCT04517994|Active Comparator|Supportive Treatment|Broadly based on the principles and techniques of client centered (Rogerian) therapy, and the fundamental principles and practices for experiential group psychotherapy as specified by Yalom. The group also draws upon the work of Murphy's Supportive Therapy protocol specifically for group intervention with domestic abuse perpetrators.
11037346|NCT04517981||Drug intervention|Antidepressant
11037347|NCT04517981||Psychological intervention|Cognitive behavior therapy, sand table therapy
11037348|NCT04517981||Comprehensive intervention|Psychological intervention, community intervention combined with drug intervention
11037349|NCT04517968|Experimental|immediate implant with customized healing abutment|
11037350|NCT04517942|Experimental|EVERYbody Project: Peer facilitator version|"This dissonance-based body image program was created from focus group feedback (Ciao, Ohls, & Pringle, 2017) and piloted in an initial randomized-controlled trial. Based on the Body Project (Stice et al., 2006), it retains key dissonance activities while adapting exercises to have a more inclusive focus (e.g., expanding the gender focus, exploring diversity characteristics within appearance ideals, adjusting activities to be inclusive of diversity).
~Around 10% of the original EVERYbody Project manual was modified to create the Peer Facilitator version for the current trial. Changes focused on adding individual exercises to draw out the critique of diversity in cultural ideals, refining prompts to be more suitable for peer facilitation, and flagging sections of the manual for more expert peer facilitation.
~Peer facilitators received 16 hours of training on the EVERYbody Project manual and peer facilitation guidelines (e.g., group management, handling problems, etc.)."
11037351|NCT04517942|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists (2015 ), and (2) The Mask You Live In (2015). Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.
~Peer facilitators received brief (1 hour) training on the video group manual."
11037352|NCT04517929|No Intervention|control group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia.
11037353|NCT04517929|Experimental|intervention group|Patients in this group will receive recommendations regarding lifestyle change, exercise, and nutrition related to fibromyalgia and group psychotherapy.
11037354|NCT04517916||Zephyr Valve treatment|Patients undergoing the Zephyr Valve treatment for emphysema/COPD
11037355|NCT04517903|Experimental|exploratory phase|eye rubbing questionnaire at baseline and 15 days later
11037356|NCT04517903|Experimental|Confirmatory phase|eye rubbing questionnaire at baseline and at 6 month follow-up
11037357|NCT04517890|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
11037358|NCT04517890|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
11037359|NCT04517877|Experimental|Caring Light Training|Caring Light mobile app with coping skills training.
11037360|NCT04517877|Active Comparator|Educational Training|Traditional educational program.
11037361|NCT04517864|Experimental|Treatment Arm: PF-06651600|ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm
11037362|NCT04517864|Other|Control Arm (Placebo) followed by active therapy extension|matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24
11037363|NCT04517851|Experimental|Treatment (elotuzumab)|Patients receive elotuzumab IV over 1-4 hours on days 1, 8, 15, and 22 of cycles 1-2. Beginning in cycle 3, patients receive elotuzumab IV over 1-4 hours on day 1. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
11037364|NCT04517838||Basic Science (biospecimen collection, laboratory analysis)|Patients undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence for patients with stage I-III, or progressive disease for patients with stage IV. Patients also undergo tumor tissue collection for the evaluation of gene expression and DNA variants.
11037365|NCT04517825||Target Population|HIV positive individuals attending Bugoye ART clinic
11037366|NCT04517812|Experimental|Intervention group|The intervention group will carry out a 12-week exercise-based intervention delivered via the VirtualRehab platform. The exercise-games have been designed from conventional physiotherapy exercises for stroke rehabilitation. A personalised training programme will be created for individual participants by a qualified physiotherapist member of the research team. Each participant will be asked to undertake their set exercise-based training programme for one hour a day, six days a week for 12 weeks.
11037367|NCT04517812|No Intervention|Control group|The control group will undertake the measurement battery and provide the demographic details.
11037368|NCT04517799|Experimental|cannabidiol|cannabidiol arm
11037369|NCT04517799|Placebo Comparator|placebo|placebo arm
11037370|NCT04517786|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
11037371|NCT04517773||study group|Oncological patients
11037372|NCT04517747|Experimental|Ramucirumab plus TAS-102|Ramucirumab 8 mg/kg i.v. on day 1 and day 15 of a 28-day cycle and TAS-102 35 mg/m2/dose p.o. twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle Each cycle will be repeated after 28 days (from day 1) for a maximum of 4 cycles.
11037373|NCT04517734||Pregnant Adolescents|
11037374|NCT04517734||Pregnant Women Carrying Multiple Fetuses|
11037375|NCT04517721|Experimental|Treatment group|"The 4C's-TBuRP for adult burn survivors comprises of two phases:
~Phase 1: Discharge planning/ preparation and day of discharge (Comprehensive assessment and evaluation, Education, guidance, and counselling, Treatment and procedures, Case management (referral for nursing follow-up), multi-disciplinary follow-up and Surveillance)
~Phase 2: Follow-up Phase (2 WeChat Telehealth, 6 structured telephone follow-ups and daytime patient/ family-initiated telephone service; home visit based on meeting criteria) over an 8-week follow-up with delivery of rehabilitation care across the spectrum by trained nurse case managers ongoing assessment, intervention using the Omaha System and delivery of evidence-based care."
11037376|NCT04517721|Active Comparator|Control group|Participants in the control group will receive the care at the discharge planning phase and thereafter continue to utilise the exiting service available at the hospital, that is, medical review in the hospital.
11037377|NCT04517708|Experimental|Intervention group|"Regarding the intervention group, patients were treated with the intervention regimen, which consisted of:
~Nutritional counseling
~Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months."
11037378|NCT04517708|No Intervention|Control group|Patients had diets based on their demands
11037379|NCT04517695||COVID-19 ICU Patients|Patients who are admitted to the ICU with a confirmed SARS-CoV-2 infection
11037380|NCT04517682||Positive for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a positive result.
11037381|NCT04517682||Negative for SARS-CoV-2|Individuals who are symptomatic for COVID 19 disease, at high risk of infection or part of a screening program will provide samples for analysis which may reveal a negative result.
11037382|NCT04517656|Experimental|patients with hematologic malignancy|Adult patient, over 18 years old, suffering from a malignant hemopathy (without exception) for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated
11037383|NCT04517643|Experimental|Therasphere Therapy|All participants will receive the Therasphere Therapy.
11037384|NCT04517630||Severe pneumoniae|Evaluate the progression to AKI during first 30 days of recruitment
11037385|NCT04517617||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
11037386|NCT04517604|Experimental|iTBS+yoga|Participants will receive 6 sessions of intermittent theta burst stimulation (iTBS) and the LoveYourBrain Yoga program. The LoveYourBrain Yoga program was specifically designed for people with TBI.
11037387|NCT04517591|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
11037388|NCT04517591|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels and health nutrition.
11037389|NCT04517565|Experimental|Patients with SWS or high-risk facial port-wine birthmark|All patients with SWS brain involvement (based on previous imaging) or facial port-wine birthmark indicating a high risk for SWS brain involvement will undergo a brain MRI and neuro-psychology testing.
11037390|NCT04517552|Experimental|Experimental: [11C] CS1P1|
11037391|NCT04517539|Experimental|SBRT+GM-CSF+INF-αb|Metastasis lesion will be treated with a SBRT of 30Gy/5F from day 1 to day 5 . Injection of Immunological Agenthuman recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.Subcutaneous injection of Peginterferon alfa-b2(90ug) will be executed in day8. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Injection of Peginterferon alfa-b2(90ug) will be executed in day8 of this cycle.
11037485|NCT04516824||Trauma,Spine cases,Arthroplasty,Arthroscopy, Miscellaneous|
11037552|NCT04516291|Experimental|Vupanorsen 80 mg every 4 weeks|80 milligrams (mg) given subcutaneously every 4 weeks.
11037392|NCT04517526|Experimental|1|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles , followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites
11037393|NCT04517500|Experimental|Home-base pulmonary rehabilitation with mindful breathing modu|Subjects will complete in a home-based pulmonary rehabilitation program and in addition will complete a mindful breathing practice using a module on a computer tablet.
11037394|NCT04517500|Active Comparator|Home-base pulmonary rehabilitation|Subjects will complete 12 week home-based pulmonary rehabilitation with health coaching
11037395|NCT04517487|Active Comparator|VMT recipients|"In order to prevent transfer of pathogens, sperm, or antibiotic-resistant commensals we will establish a vaginal fluid bank in which samples from suitable donors will be kept for future use:
~Donors will be screened using a questionnaire addressing risk factors for potentially transmissible infections, undergo screening for cervico-vaginal infections, cervical cytology screening, and serology analysis for transmittable infections {see detailed screening in Lev-Sagie et al. Nat Med. 2019;25(10):1500-1504. doi: 10.1038/s41591-019-0600-6.}
~The collected samples for VMT will be examined for bacteria,viruses and sperm.
~Before transplantation, patients will be treated with intravaginal antibiotics. A frozen specimen will be thawed at room temperature and will be placed in the patient's vagina.
~Following VMT, patients will be evaluated every 14 days for the first 2 months, then every month for additional 10 months."
11037396|NCT04517487|Placebo Comparator|Placebo|"Vaginal fluid of all recipients will be collected before initiation of the study using the same protocol, will be clearly labeled and will be kept frozen in similar conditions. These samples will be used in the placebo arm for autologous vaginal fluid transplantation.
~Before transplantation, patients will be treated with intravaginal antibiotic.
~Following Placebo, patients will be evaluated every 14 days for the first 2 months, then every month for additional 2-4 months.
~After 4-6 months, patients who initially received placebo will be offered a VMT in case they are still symptomatic and fulfill inclusion criteria, in an open-label phase."
11037397|NCT04517474|Experimental|CANreduce with psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
11037398|NCT04517474|Experimental|CANreduce without psychological support|Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use without psychological support
11037399|NCT04517474|No Intervention|Treatment as usual|Users will be prompt to a web with a list of the treatment centers nearby their postal code
11037400|NCT04517461||Head and neck free flap surgery patients|Patients undergoing head and neck microvascular free flap surgery at Skåne University Hospital, Lund, Sweden.
11037401|NCT04517435|Experimental|ME-401 + R-CHOP|Participants will receive ME-401 dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose R-CHOP. ME-401 (60 mg) will be given on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle with standard dose R-CHOP x 6 cycles.
11037402|NCT04517422|Experimental|Probiotics|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS)status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT7481, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
11037403|NCT04517422|Placebo Comparator|Placebo|The control study product is identical in packaging and formulation except that Lactobacillus plantarum CECT7481, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483 (probiotic bacteria) are not present. The Control product only contains maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
11037404|NCT04517409|Experimental|GDHT|After hepatic resection (Dynamic phase), the patients received an initial hemodynamic assessment based on PPV, CI and MAP. First, preload was optimized by fluid loading until PPV was <14% or VVS <12%, subjects were given 4 ml kg-1 boluses colloid solution every 5 minutes. At this point, the patient's individual preload optimized CI was determined and used as the hemodynamic goal until the end of surgery. Only if this value was below 2.5 L/min/(m2), inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If PPV and CI were within the target range but MAP was below 65 mmHg or PPV/VVS>1,2, vasopressors were started. After the initial assessment, patients were reassessed every 15 minutes intraoperatively to maintain values.
11037405|NCT04517409|Other|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.
~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment"
11037406|NCT04517396|Experimental|Fenofibrate + Usual Care|The randomized intervention will be Fenofibrate, in combination with usual care. Dosing: 145 mg of Tricor or a dose-equivalent preparation
11037407|NCT04517396|Placebo Comparator|Placebo + Usual Care|The randomized intervention will a matching placebo, in combination with usual care.
11037408|NCT04517383|Experimental|POS group|Patients in the POS group will undergo EVT under general anesthesia. After the surgery is done, patients will keep being intubated and mechanically ventilated for 6h, during which period the patients will be sedated with propofol (TCI 1.0~3.0μg/ml) and Dexmedetomidine (0.2~0.7μg/kg/h) to maintain a BIS value of 50~70 and Ramsay sedation score of 5 ~ 6. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs.
11037409|NCT04517383|Active Comparator|Con group|Patients in the Con group will undergo EVT under general anesthesia and will be routinely recovered and extubated immediately after the surgery is done. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs for at least 7h after the surgery. In case the patient shows agitation after extubation, i.e., the Ramsay sedation score is 1, 0.02 ~ 0.1mg/kg of midazolam will be given. If the patient's Ramsay sedation score keeps being 1 and more than 0.2mg/kg of midazolam is given within 1 h, dexmedetomidine or propofol will be administered to calm the patient. Any patients in the Con group receiving dexmedetomidine or propofol within 24h after extubation will be excluded.
11037547|NCT04516317||Group intravenous artesunate (around 300 patients)|Period 2011-2019
11037410|NCT04517370|Active Comparator|Laser treatment|Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.
11037411|NCT04517370|Sham Comparator|Sham treatment|"Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.
~Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study ."
11037412|NCT04517357|Experimental|Doublet Arm Fluzoparib+Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
11037413|NCT04517357|Active Comparator|Single Arm Apatinib|Fluzoparib Orally twice daily
11037414|NCT04517344|Experimental|Arm 1, HFNC 1 L/kg/min|The infant that is randomized to the HFNC therapy arm 1 will be placed on high flow at 1 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%. If FiO2 requirement exceeds 50%, the patient will be excluded from the study.
11037415|NCT04517344|Experimental|Arm 2, HFNC 1.5 L/kg/min|The infant that is randomized to the HFNC therapy arm 2 will be placed on high flow at 1.5 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%. If FiO2 exceeds 50% requirement, patient will be excluded from the study.
11037416|NCT04517344|Experimental|Arm 3, HFNC 2 L/kg/min|The infant that is randomized to the HFNC therapy arm 3 will be placed on high flow at 2 L/kg/min (up to a maximum of 20 L/min) on fraction of inspired oxygen (FiO2) of 21 %. They will remain on FiO2 of 21% for a minimum of 10 minutes while monitoring SpO2. If SpO2 is <90%, FiO2 will be slowly increased to maintain SpO2 ≥ 90 %, with maximum FiO2 of 50%. If FiO2 exceeds 50% requirement, patient will be excluded from the study.
11037417|NCT04517331|Active Comparator|Group S (single injection TPVB group)|Patients received bilateral single injection ultrasound-guided TPVB at the level of T3-T4 with 20 mL bupivacaine 0.375% per injection/side.
11037418|NCT04517331|Active Comparator|Group D (double injection TPVB group)|Patients received bilateral double injection ultrasound-guided TPVB at the level of T2-T3 and T4-T5 with 10 mL bupivacaine 0.375% per injection (20 mL bupivacaine 0.375% per side as the single injection group).
11037419|NCT04517305||Pyrotinib plus vinorelbine|Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.
11037420|NCT04517292|Experimental|Eribulin,cisplatin|EP (Eribulin and cisplatin combination)
11037421|NCT04517292|Active Comparator|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
11037422|NCT04517279|Experimental|Invest in My Recovery Bank|The Invest in My Recovery Bank arm is an intervention focused on enhancing the recovery capital of individuals in early psychosis care. The intervention is provided by a peer provider, operating on the coordinated specialty care team
11037423|NCT04517279|Active Comparator|Usual Care|The peer providers operating under the Usual Care condition will continue to provide peer support services to individuals within the coordinated specialty care team.
11037424|NCT04517266|Experimental|experimental group|whole breast/chest wall irradiation + SVC irradiation
11037425|NCT04517266|Active Comparator|controlled group|whole breast/chest wall irradiation + IMI+SVC irradiation
11037426|NCT04517253|Experimental|Baricitinib|Baricitinib administered orally either by tablet or suspension.
11037427|NCT04517227|Experimental|single arm|All patients enrolled with receive the sequential therapy of TACE, ablation and durvalumab.
11037428|NCT04517214|Experimental|Toripalimab Combined with GP Arm|Systemic chemotherapy for 6 cycles: Toripalimab 240mg d1+Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Toripalimab with Capecitabine: Toripalimab 240mg d1+Capecitabine 1000mg/m2 bid d1-14, q3w
11037429|NCT04517214|Active Comparator|GP Arm|Systemic chemotherapy for 6 cycles: Gemcitabine 1.0g/m2 d1, Cisplatin 80mg/m2 d1, q3w; Followed by Radiotherapy to the nasopharynx and neck; Then maintenance therapy of Capecitabine: Capecitabine 1000mg/m2 bid d1-14, q3w
11037430|NCT04517201|Experimental|AI group|iGMS+iNCDSS group (Artificial intelligence assisted insulin titration system group)
11037431|NCT04517201|Active Comparator|Control group|iGMS+routine treatment group (Physicians decided insulin titration group)
11037432|NCT04517188|Experimental|Halodine Nasal Antiseptic|"Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
~Single topical administration"
11037433|NCT04517175||Myelodysplastic syndrome (MDS) patients|MDS patients will be divided according to prognostic parameters in sub-cohorts.
11037434|NCT04517175||Acute myeloid Leukemia (AML) patients|AML patients will be divided according to prognostic parameters in sub-cohorts.
11037435|NCT04517175||Myelodysplastic syndrome/neoplasm (MDS/MPN) patients|MDS/MPN patients will be divided according to prognostic parameters in sub-cohorts.
11037436|NCT04517162|Active Comparator|Active comparator or polymerized type I collagen|1.5 mL of polymerized type I collagen every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
11037437|NCT04517162|Placebo Comparator|Placebo comparator o placebo|1.5 mL of placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
11037438|NCT04517149|Experimental|4D-125 Dose 1|4D-125 Dose Escalation: Dose 1
11037439|NCT04517149|Experimental|4D-125 Dose 2|4D-125 Dose Escalation: Dose 2
11037440|NCT04517149|Experimental|Dose Expansion|4D-125 Dose Expansion
11037441|NCT04517149|Other|Observational|Natural History
11037442|NCT04517123|No Intervention|Control - Usual Care|Usual Care
11037443|NCT04517123|Experimental|Intervention - Prone Positioning|Prone Positioning
11037444|NCT04517110|Experimental|Pregabalin + Usual Care|300 mg pregabalin taken orally within 2 hours before surgery and 75 mg pregabalin taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
11037548|NCT04516317||Group intravenous quinine (around 300 patients)|Period 2000-2010
11037445|NCT04517110|Placebo Comparator|Placebo + Usual Care|Placebo taken orally within 2 hours before surgery and placebo taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
11037446|NCT04517097||patient group|patients treated in the french anti-cancer center of the study
11037447|NCT04517097||salaried staff group|all salaried staff of the french anti-cancer center of the study
11037448|NCT04517058|Experimental|"Cognitive type depression group"|HAMD-17 greater than 7 with negative HRV changes
11037449|NCT04517058|Active Comparator|"Somatic type depression group"|HAMD-17 greater than 7 with positive HRV changes
11037450|NCT04517045|Sham Comparator|Conventional treatment group|Control the primary disease, prevent infection, reduce gastrointestinal decompression, and actively maintain organ function.
11037451|NCT04517045|Experimental|Conventional treatment plus L92 group|Conventional treatment combined with L92
11037452|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction group|Conventional treatment combined with Dachengqi Decoction
11037453|NCT04517045|Experimental|Conventional treatment plus Dachengqi decoction plus L92 group|Conventional treatment combined with L92 and Dachengqi Decoction
11037454|NCT04517019|Experimental|Arm A (Tracker/daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients phyiscal activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
11037455|NCT04517019|Experimental|Arm B (Tracker/no daily step-count suggestion)|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.
~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
11037456|NCT04517019|No Intervention|Arm C (no activity tracker)|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
11037457|NCT04517006|No Intervention|Track activities|For three weeks research subjects will be keeping track of the things they do without altering their routine in any way.
11037458|NCT04517006|Experimental|Self-focused acts|"For three weeks research subjects will be treating themselves by doing things that they enjoy. These acts don't have to be large or costly, but they should be over and above what they typically do. They are asked to do one (or more) things they enjoy each day for the first three days of each week and report them."
11037459|NCT04517006|Experimental|Prosocial acts|For three weeks research subjects are asked to perform acts of kindness, meaning behaviors that benefit someone else and are over and above what they typically do (i.e., they are not expected of them). These acts should also involve some sacrifice by them (e.g., in effort, energy, time, or money) and be completed for the first three days of each week.
11037460|NCT04516993|Experimental|Tenecteplase arm|
11037461|NCT04516993|Other|nonthrombolysis drug arm|
11037462|NCT04516980||Participants with ankle sprain.|Participants with ankle sprain
11037463|NCT04516980||Participants without ankle sprain|Participants without ankle sprain
11037464|NCT04516967|Active Comparator|Experimental: Avatrombopag|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
11037465|NCT04516967|Placebo Comparator|Placebo Comparator:Placebo|Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
11037466|NCT04516954|Experimental|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
11037467|NCT04516941|Active Comparator|Edoxaban|Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
11037468|NCT04516941|Active Comparator|Colchicine|Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days).
11037469|NCT04516941|No Intervention|No Edoxaban and No Colchicine|No intervention
11037470|NCT04516941|Active Comparator|Edoxaban and Colchicine|"Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
~Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days)."
11037471|NCT04516915|Experimental|IMU-838 + Oseltamivir|Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
11037472|NCT04516915|Active Comparator|Oseltamivir|Oseltamivir (75mg BID) for 14 days
11037473|NCT04516902|Experimental|100 μg LSD + MDMA placebo|100 μg LSD + MDMA placebo
11037474|NCT04516902|Experimental|LSD placebo +100 mg MDMA|LSD placebo +100 mg MDMA
11037475|NCT04516902|Experimental|100 μg LSD + 100 mg MDMA|100 μg LSD + 100 mg MDMA
11037476|NCT04516902|Placebo Comparator|LSD placebo+ MDMA placebo|LSD placebo+ MDMA placebo
11037477|NCT04516889|Experimental|Intervention|The intervention arm will undergo the modified sutured SFIOL technique with double Prolene sutures instead of a single Prolene suture
11037478|NCT04516876|Experimental|Camp-based bimanual intensive training(BIT)|
11037479|NCT04516863|Active Comparator|Patients with depression|"Major depression according to DSM-V and ICD-10 (ICD F32.1, F32.2, F32.3, F33.1, F33.2, F33.3)
~Hamilton Depression Rating Scale > 17"
11037480|NCT04516863|Active Comparator|Healthy controls|- Mental health
11037481|NCT04516850||Patients tested for COVID-19|The nasopharyngeal swabs taken from patients tested for Covid-19 who resulted infected and non-infected will be analyzed to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2.
11037482|NCT04516850||Patients with mild-moderate and severe SARS-CoV-2 infection|Formalin-fixed paraffin will be analysed to determine the association between polymorphism of the HSD3B1 gene and outcomes in COVID-19 affected patients
11037483|NCT04516837|Experimental|eltrombopag plus rhTPO|Combination of eltrombopag and rhTPO
11037484|NCT04516837|Active Comparator|eltrombopag|Eltrombopag monotherapy
11037486|NCT04516811|Experimental|Arm 1|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
11037487|NCT04516811|Placebo Comparator|Arm 2|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines.
11037488|NCT04516798|Experimental|Experiment|Local and whole body vibration were applied
11037489|NCT04516785||Intervention|FIT and urine VOC samples followed by colonoscopy
11037490|NCT04516772|Other|Visian TICL|STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.
11037491|NCT04516759|Experimental|AZD1656 (plus Usual Hospital Care)|50mg film-coated tablets at a dose of 100mg BID
11037492|NCT04516759|Placebo Comparator|Matched Placebo (plus Usual Hospital Care)|Matched placebo tablets
11037493|NCT04516746|Experimental|AZD1222|2 IM doses of 5 × 10^10 vp (nominal, ± 1.5 × 10^10 vp) AZD1222 4 weeks apart
11037494|NCT04516746|Placebo Comparator|Placebo|2 IM doses of saline placebo 4 weeks apart
11037495|NCT04516733|Other|single arm|patient with glioblastoma
11037496|NCT04516720||Primary Nervous System Tumors arm|"The information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.
~Clinical Data and Questionnaires:
~For the retrospective part
~Patient identification based on data from the Medical Information Department (DIM) of the ICM;
~Verification of the eligibility criteria;
~Inclusion of patients in a coded form in BDD-NO;
~Implementation of the database with the data already collected (as an coded EXCEL file) in specific studies (some patients are included in several of these studies): study of diffuse low grade gliomas, study on anaplastic gliomas, study on the place of Bevacizumab in high-grade gliomas, clinical database created
~Collection of clinical data from each patient's medical record
~For the prospective part
~Inclusion of patients in a coded form in BDD-NO;
~Collection of clinical data from each patient's medical record."
11037497|NCT04516694|No Intervention|Control|Usual care reflects the standard treatment currently provided to T1D patients. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
11037498|NCT04516694|Experimental|Gain-framed incentive|"Participants will start off with nothing at the beginning of the treatment period. For each day that participants' meet goals, value will be added to their incentive balance.
~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
11037499|NCT04516694|Experimental|Loss-framed incentive|"Participants will start off at the maximum incentive balance at the beginning of the treatment period and for each day that participants' fail to meet goals, value will be subtracted from their incentive balance over the 12-week.
~All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits."
11037500|NCT04516681|Experimental|Combined Ascorbic Acid with chemotherapy group|Ascorbic Acid with FOLFOXIRI with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
11037501|NCT04516681|Active Comparator|Chemotherapy alone group|standard FOLFOXIRI treatment
11037502|NCT04516655|Experimental|C-R-MTX|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles
11037503|NCT04516629||Experimental|subjects with sub-health status
11037504|NCT04516616|Experimental|Study group|Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.
11037505|NCT04516603|Experimental|Fampridine SR|"Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.
~The single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t½ = 3.61 h) between experimental and control intervention."
11037506|NCT04516603|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of the identical additives formulated for oral administration.
11037507|NCT04516590||autoimmune antigen negative|treated with anti-epilepsy drugs
11037508|NCT04516590||autoimmune antigen positive|whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom
11037509|NCT04516577||Shanghai Pulmonary Hospital|Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.
11037510|NCT04516577||Peking Union Medical College Hospital|Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.
11037511|NCT04516564|Experimental|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects.
11037512|NCT04516564|Experimental|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects.
11037513|NCT04516551|Experimental|anti-CD19 allo-CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determining optimal dosage.
~dosage: the number of anti CD19+CD22 CAR T cells
~-1(if needed) 1×10^6/KG
~3×10^6 /KG 6×10^6 /KG 1×10^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days or bendamustione (90mg/m2 per day) for two days prior to cell infusion."
11037514|NCT04516538|Experimental|Young people|Men or Women under 35 years old
11037515|NCT04516538|Experimental|Old people|Men or Women between 60 and 80 years old
11037516|NCT04516538|Experimental|Very old people|Men or Women over 80 years old
11037517|NCT04516512|Experimental|Investigated arm|Participants included in the study who met inclusion criteria
11037549|NCT04516304|Placebo Comparator|Placebo|Placebo
11037550|NCT04516304|Experimental|Experimental|S-equol
11037551|NCT04516291|Placebo Comparator|Placebo|No drug
11037518|NCT04516499||f-FTLD mutation carriers|All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.
11037519|NCT04516499||Non-mutation carriers from families with f-FTLD mutations|All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.
11037520|NCT04516473||Experimental/Body Contouring Intervention|These are participants who have self-selected to undergo an abdominal body contouring procedure within the course of the study.
11037521|NCT04516473||Control/Post Massive Weight Loss Matched Control|"These are participants who have similar characteristics to the body contouring intervention group, but they will not undergo any surgical procedure during the course of the study.
~The addition of this matched control group with a similar degree of excess skin but who will not be undergoing body contouring surgery will control for any changes in physical function which may occur without any intervention within the testing sessions. This group will also control for any learning effects between testing sessions."
11037522|NCT04516460|Experimental|PuraStat|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection
11037523|NCT04516447|Experimental|Combination with carboplatin|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)
11037524|NCT04516447|Experimental|Combination with PLD|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 50 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle
11037525|NCT04516434|Experimental|Intraurethral Electrical Stimulation|"This procedure is specific to the urethral stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the urethra and positioned with the electrode contact 10-14 mm from the bladder neck to stimulate the proximal urethra. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be 2-20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to the proximal urethra at strong desire to void during cystometry. The participant will then be given permission to void at maximum cystometric capacity with continuous intraurethral stimulation."
11037526|NCT04516434|Experimental|Intravesical Electrical Stimulation|This procedure is specific to the bladder stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the bladder through the urethra and the electrode contacts will be positioned to be floating within the bladder. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be set at 20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to bladder sensory nerves for up to 60 minutes prior to the start of urodynamic studies.
11037527|NCT04516421|Experimental|Experimental group|The experimental group will receive a 12-weeks intervention, with each day a pack of supplementation containing 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
11037528|NCT04516421|Placebo Comparator|Control (Placebo) group|The control (placebo) group will receive a 12-week oat drink, with each day a pack of oat tea containing 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
11037529|NCT04516408|Experimental|Recombinant zoster vaccine|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the vaccine 2 months apart.
11037530|NCT04516408|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the placebo (sterilized water) 2 months apart.
11037531|NCT04516395|Experimental|Optimal antibiotic combination regimens|The patients in the groups will be given the optimal antibiotic combination regimens.
11037532|NCT04516395|Other|Standard antibiotic regimens|The patients in the groups will be given the standard antibiotic regimens.
11037533|NCT04516382|Experimental|Intravenous|PTG-300 Intravenous
11037534|NCT04516382|Experimental|Subcutaneous Low Concentration|PTG-300 Subcutaneous Low Concentration
11037535|NCT04516382|Experimental|Subcutaneous High Concentration|PTG-300 Subcutaneous High Concentration
11037536|NCT04516382|Experimental|Intramuscular|PTG-300 Intramuscular
11037537|NCT04516369|Experimental|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
11037538|NCT04516356|Experimental|Intervention Arm|Korean hand acupressure will be applied to the experimental group 30 minutes before the induction of anesthesia. After determining the pressure / therapy points associated with nausea and vomiting on the patient's hand, a massage will be made for 3-5 minutes with a diagnostic stick. The seeds will then be fixed at these points with a paper patch. Seeds will not be removed for 24 hours. It will be massaged for 3-5 minutes by pressing the seeds every 3-4 hours and making a curling motion at the same time. At the end of the 24th hour, the application will be terminated.
11037539|NCT04516356|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
11037540|NCT04516343|Experimental|User testing|Two sessions of user-centric testing.
11037541|NCT04516343|Experimental|Therapist-guided training|Therapist-guided gait training with the RAAD.
11037542|NCT04516343|Experimental|Assistance training|Assistance training with the RAAD
11037543|NCT04516343|Experimental|Therapist supervised resistance training|Resistance training with the RAAD under therapist supervision.
11037544|NCT04516343|Experimental|Parent supervised resistance training|Resistance training under parent supervision.
11037545|NCT04516330|Active Comparator|unifocal breast cancer|patients having unifocal breast cancer
11037546|NCT04516330|Active Comparator|multicentric breast cancer|patients having multicentric breast cancer
11037553|NCT04516291|Experimental|Vupanorsen 60 mg every 2 weeks|60 mg given subcutaneously every 2 weeks.
11037554|NCT04516291|Experimental|Vupanorsen 120 mg every 4 weeks|120 mg given subcutaneously every 4 weeks.
11037555|NCT04516291|Experimental|Vupanorsen 80 mg every 2 weeks|80 mg given subcutaneously every 2 weeks.
11037556|NCT04516291|Experimental|Vupanorsen 160 mg every 4 weeks|160 mg given subcutaneously every 4 weeks.
11037557|NCT04516291|Experimental|Vupanorsen 120 mg every 2 weeks|120 mg given subcutaneously every 2 weeks.
11037558|NCT04516291|Experimental|Vupanorsen 160 mg every 2 weeks|160 mg given subcutaneously every 2 weeks.
11037559|NCT04516278|Experimental|Biological: bevacizumab|ONS-5010
11037560|NCT04516265|Active Comparator|NGT Group|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
11037561|NCT04516265|Active Comparator|Video-based training group|Trunk training will be done with games developed for the use of children with cerebral palsy.
11037562|NCT04516265|Active Comparator|Video-based training group with theratogs|Video-based trunk training (45 minutes) will apply with Theratogs to the group
11037563|NCT04516252|Experimental|Intervention|
11037564|NCT04516252|Active Comparator|Control|
11037565|NCT04516239|Active Comparator|LDH THA|large diameter head total hip arthroplasty
11037566|NCT04516239|Active Comparator|HR|metal-on-metalhip resurfacing
11037567|NCT04516226|Experimental|Vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of PPROM diagnosis.
11037568|NCT04516226|No Intervention|No vaginal cleansing|This group includes patients diagnosed with PPROM that are randomized to not undergo vaginal cleansing.
11037569|NCT04516213|Experimental|Enteral formula tube feeding|Enterally fed children, ages 1-4, with established enteral feeding access
11037570|NCT04516200|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation will be applied to study group only . Anodal transcranial stimulation will be applied on left somatosensory cortex while the cathodal one will be applied on right supra-orbital area with frequency of 2m.A for 20 minutes.Stimulation will be applied three times per week for two months.
11037571|NCT04516200|Placebo Comparator|traditional physical therapy program|traditional physical therapy program will be applied to both the control group and study group. It will be consist of sensory re-education training and balance training.Exercises will be applied three times per week for two months
11037572|NCT04516174|Experimental|Dex+TAPB group|Patients in Dex+TAPB group will receive the bilateral transversus abdominis plane block with 0.25% ropivacaine 20ml each side before anesthesia and combined with continuous infusion of dexmedetomidine during operation.
11037573|NCT04516174|Placebo Comparator|Control group|Patients in control group will receive the bilateral transversus abdominis plane block with saline 20ml each side before anesthesia and don't receive the infusion of dexmedetomidine during operation.
11037574|NCT04516161||Radium-223 dichloride (Xofigo, BAY88-8223)|Patients with mCRPC who received treatment of Ra-223.
11037575|NCT04516148|Experimental|Antibiotics|Patients randomized to the treatment arm of the study will have orders placed by a physician on the clinical team, with preparation and delivery of the antibiotics dose by the pharmacy following standard procedures. Antibiotic administration will occur after induction of anesthesia, with delivery by the Anesthesia staff no more than one hour prior to incision. Those with known allergy to beta-lactams will receive clindamycin instead of cefazolin.
11037576|NCT04516148|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the study will receive no perioperative antibiotic administration and will proceed with routine pre-operative care.
11037577|NCT04516135|Experimental|Arm A (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
11037578|NCT04516135|Active Comparator|Arm B (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
11037579|NCT04516122||Observational (biospecimen collection, DXA scan)|Patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and at 12 months.
11037580|NCT04516109|Active Comparator|Arthrosocpic labral repair|Patients undergoing arthroscopic labral repair with the use of the modified hip capsule slotted cannula.
11037581|NCT04516109|Active Comparator|Arthroscopic bone grafting|Patients undergoing arthroscopic bone grafting of subchrondral cyst with the use of the modified bone graft delivery tool set and modified hip capsule slotted cannula.
11037582|NCT04516096|Experimental|AMX-0035 long term treatment extension|AMX0035 administered twice daily p.o.
11037583|NCT04516070|Experimental|Treatment (SRS)|Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
11037584|NCT04516057|Experimental|Nabilone Arm|Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.
11037585|NCT04516057|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive placebo capsules.
11037586|NCT04516044||Video game|Patients treated by physicians who were randomized to either play an adventure-based video game that used narrative engagement to recalibrate physician heuristics in trauma triage or a puzzle-based video game that used analogical encoding to recalibrate physician heuristics in trauma triage.
11037587|NCT04516044||Control|Patients treated by physicians who were randomized either to nothing at all or to a text-based educational program.
11037588|NCT04516031|Active Comparator|Mesh-only repair|
11037589|NCT04516031|Active Comparator|Transversus Abdominis Muscl|
11037590|NCT04516018|Experimental|Cold acclimation arm|Intermittent cold exposure inducing at least 1 h of shivering per day for 10 days.
11037591|NCT04516005|Experimental|foot reflexology|Foot reflexology was performed in every participant in the foot reflexology group after resting for 5 minutes in a sitting position by the same researcher who was trained and certified by the Department of Thai Traditional and Alternative Medicine, Ministry of Health.
11037592|NCT04516005|No Intervention|control|The control group received conventional treatment including anti-HT medications according to the standard HT guideline's recommendations. In the end of the follow-up visit, every participants were informed to adhere to their medication and were encouraged to have healthy lifestyles including salt restriction, regular exercise, and consuming healthy diets.
11037593|NCT04515992|Experimental|High Intensity Body-weight Circuit (HIBC)|The at home HIBC intervention program involved the use of both bodyweight and suspension training equipment (TRX® Fit System) with modified movements. The TRX® system was used to modify squats and rows while attached to the top of a door frame.
11037594|NCT04515979|Experimental|vactosertib+Pembrolizumab|Vactosertib (5days on and 2days off) Pembrolizumab 200mg Q3Weeks
11037595|NCT04515966|Active Comparator|Ultrasound-guided steroid injection|Participants with CTS who meet the inclusion criteria are randomized to two groups. One group (or arm) will receive an ultrasound-guided steroid injection in the vicinity of the median nerve within the carpal tunnel. A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine is injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
11037596|NCT04515966|Active Comparator|Wrist splint|Participants in this arm are treated with a wrist splint.
11037597|NCT04515953|Active Comparator|Control|Standard practice of pain management for post-TKA
11037598|NCT04515953|Experimental|ND-340|ND-340 90mg~320mg at dose escalations
11037599|NCT04515927|Experimental|subcutaneous injection of JS002, 450mg, Q4W, 3/13 times.|
11037600|NCT04515914||Decitabine therapy|The patients are treated with decitabine at least 1 cycles
11037601|NCT04515914||non-Decitabine therapy|The Patients are diagnosed as MDS and do not be treated with decitabine therapy
11037602|NCT04515901|Experimental|SPGB|Via a soft tip 20-gauge long IV catheter attached to a 3 mL syringe will be filled with 2 mL of 2% viscous lidocaine. The 2% viscous lidocaine will be administered according to the method of Barre.
11037603|NCT04515901|Placebo Comparator|Placebo|It will be adminstered the same as the experimental arm but with methylcellulose and cherry flavouring to match odour and taste.
11037604|NCT04515888||target population|The target population of the study consists of breast cancer female patients over 50 years old followed for an invasive carcinoma expressing hormone receptors, non metastatic, undergoing adjuvant hormone therapy.
11037605|NCT04515888||control population|The control group will be composed of patients followed for an in situ carcinoma treated by surgery +/- radiotherapy, without hormone therapy.
11037606|NCT04515875|Experimental|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
11037607|NCT04515875|Placebo Comparator|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
11037608|NCT04515862|Experimental|intervention|Intervention group: Mothers in the intervention group were included in the breastfeeding training program with the group training method. The training program was developed by the researchers, and the content of the program was evaluated with the expert opinion of academicians, obstetricians, nurses and breastfeeding counselor midwives working on breastfeeding.
11037609|NCT04515862|No Intervention|control|Control Group:Routine obstetric care and treatment procedures were applied to the mothers in the control group. In the hospital where the study was conducted, all mothers are routinely evaluated for breastfeeding by an infant nurse.
11037610|NCT04515849|Experimental|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
11037611|NCT04515849|Experimental|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
11037612|NCT04515849|Experimental|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
11037613|NCT04515849|Placebo Comparator|Placebo|Placebo administered subcutaneously
11037614|NCT04515849|Active Comparator|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
11037615|NCT04515836|Experimental|Treatment Arm|Olaparib will be given orally to patients in 28-day cycles. Patients will attend the clinic on days 1 (first day of treatment) and 15 of the first cycle following the beginning of study treatment and then every 4 weeks (day 1 of every cycle) until discontinuation of treatment.
11037616|NCT04515810|Experimental|PACT Intervention|"PACT is grounded in decision-making research that indicates individuals often make decisions with the input of social informants or influences.10 PACT will utilize mHealth technology to provide the following empirically based features to meet patients' reported need to incorporate loved ones into the advance care planning (ACP) decision-making process and thus bolster their social networks: Pick one's team of loved ones to be involved in ACP through its shareability feature; Address common barriers of traditional family meetings (e.g., distance of loved ones, domineering family members) by exploiting the ubiquitous access of an online application with the ability to control online ACP meetings; Complete advance directives with the engagement and, if desired, input of loved ones through structured question prompts; Team up with loved ones to share one's wishes both informally through care preference messages and formally through shared advance directive forms."
11037618|NCT04515797|Experimental|Treatment with Direct Acting Antiviral for HCV|4 week treatment period with glecaprevir and pibrentasvir (G/P) within 24 hours of transplant
11037619|NCT04515784|Experimental|Active|Active arm- START-PTSD
11037620|NCT04515784|No Intervention|Control|Control arm
11037621|NCT04515771|Experimental|Active PARTNER-MH|The Active PARTNER-MH arm will test the intervention program starting immediately after enrollment in the study. Participants enrolled into this arm will continue to receive normal mental health services in addition to the peer-administered intervention.
11037622|NCT04515771|Other|Waitlist Control|The Waitlist Control arm will test the intervention program after a waiting period of 6-months following enrollment into the study. During the 6-month waiting period, participants in this arm will continue to receive normal mental health services.
11037623|NCT04515758|Experimental|Exercise and Cognitive Training|Each participant (in a group setting) completes 30 minutes of cognitive training and 1 hour of exercise two days/week.
11037624|NCT04515758|Active Comparator|Exercise Training Only|Each participant (in a group setting) completes 1 hour of exercise two days/week (separate days than the experimental group).
11037625|NCT04515745||ILI/Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration (SSA) databases.
11037626|NCT04515745||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to SSA databases.
11037627|NCT04515732|Experimental|3a (apremilast intervention)|Apremilast in standard dosis (gradual increase 0-30 mg x 2 daily over the first 6 days, hereafter 30 mg x 2 daily) for 6 months, followed by 6 months observation.
11037628|NCT04515732|No Intervention|3b (non-intervention)|Observation
11037629|NCT04515719|Experimental|Belimumab 2mg/kg|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Belimumab 2mg/kg is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
11037630|NCT04515719|Placebo Comparator|Placebo|Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
11037631|NCT04515706|Experimental|Iguratimod|Iguratimod 25 twice a day (bid) on Week 1-48.
11037632|NCT04515706|Placebo Comparator|Placebo|Placebo twice a day (bid) on Week 1-24, and Iguratimod 25 twice a day (bid) on Week 25-48.
11037633|NCT04515693|Experimental|Maximal Assist group|Subjects with acute stroke who ambulate with Maximal assistance of 1.
11037634|NCT04515693|Experimental|Moderate Assist group|Subjects with acute stroke who ambulate with Moderate assistance of 1.
11037635|NCT04515693|Experimental|Minimal Assist group|Subjects with acute stroke who ambulate with Minimal assistance of 1.
11037636|NCT04515693|Experimental|Supervision/Modified Independence/Independence|Subjects who walk without physical assistance of a helper.
11037637|NCT04515667|Experimental|Mindfulness|
11037638|NCT04515667|Placebo Comparator|Control|
11037639|NCT04515654|Experimental|Audience participants|Community members viewed the performance (intervention) and completed pre/post stigma questionnaire
11037640|NCT04515641|Experimental|Moderate Hepatic Impairment|Participants receive a single dose of ISL 60 mg.
11037641|NCT04515641|Experimental|Healthy Controls|Participants receive a single dose of ISL 60 mg.
11037642|NCT04515628|Experimental|Period A: Rosuvastatin|
11037643|NCT04515628|Experimental|Period B: Branebrutinib|
11037644|NCT04515628|Experimental|Period C: Branebrutinib + Rosuvastatin and Branebrutinib|
11037645|NCT04515628|Experimental|Period D: Branebrutinib|
11037646|NCT04515615|Experimental|Camrelizumab and chemotherapy|Participants receive camrelizumab 200 mg intravenously (IV) on the first day (q3w), then oxaliplatin 130 mg/m^2, IV on the first day (q3w), and tegafur gimeracil oteracil potassium capsule 80 mg/m^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Three weeks as a course of treatment, a total of 8 courses.
11037647|NCT04515602|Experimental|Part 1 Arm I (low/medium tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
11037648|NCT04515602|Active Comparator|Part 1 Arm II (low/medium tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
11037649|NCT04515602|Experimental|Part 2 Arm I (high tumor burden)|Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
11037650|NCT04515602|Active Comparator|Part 2 Arm II (high tumor burden)|Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with gBRCA/sBRCA mutation, CR/PR after platinum-based therapy.
11037651|NCT04515589||Main study cohort|The main study cohort in this single-arm cohort is 250 adults with rheumatoid arthritis
11037652|NCT04515576|Experimental|LY3493269|LY3493269 administered Subcutaneous (SC).
11037653|NCT04515576|Active Comparator|Dulaglutide|Dulaglutide administered SC.
11037654|NCT04515576|Placebo Comparator|Placebo|Placebo administered SC.
11037655|NCT04515563|Placebo Comparator|Control Group|Subjects in the care control group will perform once-a-week stretching exercise intervention. Each session lasts for 75 minutes and covers the major muscle groups.
11037681|NCT04515407|Other|Order 3|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 3 will be: Walking, Seated@Rest, Seated@Active.
11037682|NCT04515394|Experimental|Tepotinib + Cetuximab|
11048514|NCT04439643||Sequestered / test|Selected by stratified partitioning
11037656|NCT04515563|Experimental|Low-frequency, moderate-intensity walking group|A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 150-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 150 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
11037657|NCT04515563|Experimental|High-frequency, moderate-intensity walking group|Intervention of high-frequency, moderate-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 50-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 50 minutes of exercise time. If needed, there will be one 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 3.5 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
11037658|NCT04515563|Experimental|Low-frequency, vigorous-intensity walking group|Intervention of low-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with one 75-minute instructor-led session per week. In each session, there will be 5-min warm-up and cool-down, and 75 minutes of exercise time. If needed, there will be two 10-20 min breaks for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
11037659|NCT04515563|Experimental|High-frequency, vigorous-intensity walking group|Intervention of high-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 25-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 25 minutes of exercise time. If needed, there will be a 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting [23]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable [24].
11037660|NCT04515550||Huntington's disease (HD)|people with HD
11037661|NCT04515550||Controls without HD|people without HD
11037662|NCT04515537||conventional therapy plus AFA|Patient using conventional therapy plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
11037663|NCT04515537||conventional therapy plus SVF|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue, evaluted for period of 6 months
11037664|NCT04515537||conventional therapy plus SVF and AFA|Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months
11037665|NCT04515524||ROP patients from VGFTe-ROP-1920|Retinopathy of prematurity (ROP) who were treated with aflibercept and/or laser photocoagulation in study VGFTe-ROP-1920.
11037666|NCT04515511|Experimental|standard care|ICU septic shock patients with refractory hypotension with indwelling pulmonary artery catheter received five sequential intravenous boluses of 100 mL 4% gelatin. Cardiac output measured by thermodilution of PAC before fluid challenge (baseline) and three minutes after each bolus. Fluid responsiveness (FR) was defined as an increase in CO greater than 10% after 500 mL fluid infusion. The smallest volume which can perform an effective fluid challenge was analyzed.
11037667|NCT04515498||CloudCath System|Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis
11037668|NCT04515485||Patients undergoing laparoscopy|The participants are patients that have undergone the laparoscopic surgery.
11037669|NCT04515472|Active Comparator|Healthy Volunteer Male|Healthy male currently on no testosterone treatment
11037670|NCT04515472|Active Comparator|Healthy Volunteer Female|Healthy female currently on no estrogen treatment
11037671|NCT04515472|Active Comparator|MTF group|MTF transgender currently on estrogen treatment
11037672|NCT04515472|Active Comparator|FTM group|FTM transgender group currently on testosterone treatment
11037673|NCT04515459|Other|Patients treated for bone or soft-tissue sarcoma of the limbs|
11037674|NCT04515446|Other|TROD + PCR diagnosis|For each patient positive for flu with a rapid diagnostic test, sequential nasopharyngeal (NP) samples will be collected for quantitative PCR every day from D1 to D8 or until discharge (if before D8). Sequential quantitative PCR will quantify influenza virus load in the upper airways.
11037675|NCT04515433|Experimental|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
11037676|NCT04515433|Placebo Comparator|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
11037677|NCT04515420||Group A|"Group A for patients that will need an infusion of NA solution to meet the desired CPP.
~Group A will be further divided into three sub-groups: A1 for patients that will receive NA in the dose of 0.06-0.12 μg/kg/min, A2 for patients that will receive a dose of 0.13-0.2 μg/kg/min, and A3 for patients that will receive a dose of NA > 0.2 μg/kg/min."
11037678|NCT04515420||Group B|Group B for patients that will not receive NA infusion.
11037679|NCT04515407|Other|Order 1|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 1 will be: Seated@Rest, Seated@Active, Walking.
11037680|NCT04515407|Other|Order 2|All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 2 will be: Seated@Active, Walking, Seated@Rest.
11048709|NCT04438096|Placebo Comparator|Placebo|
11037683|NCT04515381|Experimental|Therapeutic touch group|Each student from the Therapeutic touch (TT) group was given TT sessions via Krieger-Kunz method in a total of 8 times in the manner of twice a week for one group (Monday - Wednesday) and another group (Tuesday - Thursday) for a duration of 1 month (4 week). TT application procedure: The procedure was explained to the student, the student person was concentrated, concentrated practitioner for TT application, the student's entire body was evaluated from head to foot with the practitioner's hands at a distance of about 2 inc, hands were moved regularly and rhythmically to prevent imbalances in the energy field, the energy field was re-evaluated from top to bottom and rebalanced if there was a blocked area, finally, the student was left to rest and response to the treatment was observed. The TT sessions of 20 minutes were applied on the students and they were given a short rest at the end of the session
11037684|NCT04515381|Placebo Comparator|Placebo group|For students in the placebo group, the similar duration (20 minutes) and frequency (2 sessions a week, total of 8 sessions) of TT was applied with hands at a certain distance from the body (approximately 5 cm) and they were moved without a specific order. The application was performed by the other researcher in a separate room to the placebo group.
11037685|NCT04515381|Other|Control group|There was no attempt being made towards the students within the control group. At the end of the 4th week, all students were asked to repeat measurements
11037686|NCT04515368|Experimental|Fendrix|Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.
11037687|NCT04515368|Experimental|Bexsero|Bexsero (Meningococcal group B subunit / Outer Membrane Vesicles, GlaxoSmithKline); 0.5 mL. intramuscular. stat.
11037688|NCT04515368|Experimental|Fluad|Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.
11037689|NCT04515368|Experimental|Seasonal Trivalent Influenza Vaccine|Seasonal Trivalent Influenza Vaccine ('ÄòSTIV'Äô, split virion inactivated, Northern Hemisphere 2016-17, Sanofi Pasteur); 0.5 mL. intramuscular. stat.
11037690|NCT04515355|Experimental|People with MS (PwMS)|People with MS recruited to take part and will be randomised to receive the intervention of online programme of support.
11037691|NCT04515355|No Intervention|People with MS (PwMS) - standard care|People with MS recruited to take part and will be randomised to receive the usual standard of care.
11037692|NCT04515342||Participants|This is a cross-sectional study involving approximately 150 patients. They undergo a physical examination, fill out a questionnaire, have blood samples drawn, undergo a Dual Energy X-ray Absorptiometry (DXA) scan and different physical procedures to assess muscle strength and muscle function.
11037693|NCT04515329|Experimental|Cyclosporine + Artificial Tears|Cyclosporine eye drops twice daily (Treatment) with preservative-free artificial tear drops 4 times a day (Control).
11037694|NCT04515329|Other|Artificial Tears|Preservative-free artificial tear drops 4 times a day (Control).
11037695|NCT04515316|Experimental|healthy adults|Any adult, who is at least eighteen (18-70) years old.
11037696|NCT04515316|Experimental|Patients with intractable epilepsy|Any clinical patient referred to us via the clinical MEG program, and who is at least eighteen (18-70) years old.
11037697|NCT04515290|Experimental|TSG-01-H|Two tablets of TSG-01 per time.
11037698|NCT04515290|Experimental|TSG-01-L|One tablet of TSG-01 and One tablet of Placebo per time.
11037699|NCT04515290|Placebo Comparator|Control|Two tablets of Placebo per time.
11037700|NCT04515277|Active Comparator|40 g (D1)|40 g gum acacia powder (D1). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
11037701|NCT04515277|Active Comparator|20 g (D2)|20 g gum acacia powder (D2). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
11037702|NCT04515277|Other|No treatment (NT)|0 g gum acacia powder. Standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
11037703|NCT04515238|Experimental|BZAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated
~Induction: 6 cycles (q 28d) of Obinutuzumab + Zanubrutinib + Venetoclax
~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Zanubrutinib + Venetoclax
~Maintenance treatment will be continued until (whichever occurs first):
~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity
~maintenance cycle 8
~progression of CLL or start of a subsequent therapy unacceptable toxicity"
11037704|NCT04515225||HIV-infected patients|All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination
11037705|NCT04515212|Active Comparator|Healthy Volunteers|
11037706|NCT04515212|Experimental|Traumatic Brain Injury Patients|
11037707|NCT04515186|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate, 20 mg/kg/day for 20 days parenterally
11037708|NCT04515186|Active Comparator|Miltefosine monotherapy|Miltefosine monotherapy 2.5 mg/kg/day for 28 days orally
11037709|NCT04515186|Experimental|Thermotherapy + miltefosine|"Thermotherapy (one session, 50⁰C for 30 applications*) + miltefosine 2.5 mg/kg/day for 21 days orally."
11037710|NCT04515173|Experimental|Artificial intelligence group|
11037711|NCT04515173|No Intervention|General group|
11037712|NCT04515147|Experimental|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
11037713|NCT04515147|Experimental|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
11037714|NCT04515147|Experimental|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.
~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
11037715|NCT04515147|Experimental|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
11037716|NCT04515147|Active Comparator|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
11037717|NCT04515147|Active Comparator|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
11037718|NCT04515147|Experimental|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
11037719|NCT04515147|Active Comparator|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
11037720|NCT04515147|Experimental|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
11037721|NCT04515147|Active Comparator|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
11037722|NCT04515121|Experimental|HD-tCES & lower limb rehabilitation|The experiment group will receive HD-tCES combined with lower limb rehabilitation of affected side.
11037723|NCT04515121|Sham Comparator|Sham HD-tCES & lower limb rehabilitation|The sham control group will receive sham HD-tCES combined with lower limb rehabilitation of affected side.
11037724|NCT04515108||Group 1 (Pregnants with COVID-19)|Study group included pregnant women with clinically confirmed COVID-19.
11037725|NCT04515108||Group 2 (Pregnants without COVID-19)|Control group consisted of healthy pregnant women in the same number and same gestational week with the Study group.
11037726|NCT04515095|Experimental|Water-only Fasting Group|Participants who voluntarily elect and are approved to water-only fast.
11037727|NCT04515069|Active Comparator|Traditional technique for tooth preparation.|Tooth preparation performed directly on the tooth structure
11037728|NCT04515069|Active Comparator|Aesthetic preevaluative temporary technique|Aesthetic pre-evaluative temporary (APT) was fabricated according the planned wax-up. Once the APT was approved both aesthetically and functionally, tooth preparation was performed through the APT.
11037729|NCT04515056|Experimental|Papain dosage|In the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm). The two areas will be located 4 cm apart. Three areas will be exposed to 10, 50 or 100 µg of papain, while the last area will be used as control (exposed to a vehicle).
11037730|NCT04515056|Experimental|Papain SPT|Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
11037731|NCT04515043|Experimental|INVAC-1|All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
11037732|NCT04515004|Experimental|Intervention|All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.
11037733|NCT04514991|Experimental|Foundation|Subjects assigned to this group will receive Foundation in the bone defect before suturing the surgical site.
11037734|NCT04514991|No Intervention|Control|
11037735|NCT04514978|Experimental|Blood donation and transfusion|Donation and reinfusion of 1 unit whole blood and 130 mL packed red blood cells, respectively. Blood samples were collected at 8 weeks prior to donation for 12 subjects and 2 weeks prior to donation by 12 subjects. Blood samples were collected 3, 7, 14, 21, and 28 days after donation and 3, 6, 24 hours and 2, 3 and 6 days after reinfusion of blood.
11037736|NCT04514978|No Intervention|Control group|Blood samples collected with same frequency as described in the intervention arm.
11037737|NCT04514965||PBC patients offered bezafibrate treatment|"All patients started on bezafibrate treatment are offered inclusion in the study.
~First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion.
~At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus."
11037738|NCT04514939||Group A - Leg elevation|Patients will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
11037739|NCT04514939||Group B- Non Leg elevation|Patients will lie in their hospital bed without leg elevation
11037740|NCT04514926||Healthy Controls|Participants with no history of asthma or other lung diseases.
11037741|NCT04514926||Asthmatics newly prescribed therapeutic proteins|Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.
11037742|NCT04514926||Asthmatics already being treated with therapeutic proteins|Participants with asthma who have already started on therapeutic proteins.
11037743|NCT04514913||Healthy Controls|Participants with no history of asthma or other lung diseases.
11037744|NCT04514913||Asthmatics without mucus plugs|Participants with asthma and no evidence of mucus plugging.
11037745|NCT04514913||Asthmatics with mucus plugs|Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
11037746|NCT04514900|Active Comparator|Video Chat +Personalized Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
11037747|NCT04514900|Active Comparator|Video Chat + Basic Feedback|Participants meet as a group in weekly online video chats facilitated by an experienced behavioral weight control counselor. Participants have access to a website containing interactive weekly modules pertaining to weight loss skills as well as a discussion board where they may interact with other participants in addition to class meetings. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive basic feedback weekly on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
11037779|NCT04514679||Obesity Medicine Program|Usual care in the Obesity Medicine program.
11037780|NCT04514666|Experimental|Liver/kidney transplant|The breath of patients undergoing liver or kidney transplant will be sampled and analysed
11037748|NCT04514900|Active Comparator|Discussion Board for Social Support + Basic Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly basic feedback on self-monitoring. Participants will be asked to weigh daily on a digital scale, which will be provided.
11037749|NCT04514900|Active Comparator|Discussion Board for Social Support+Personalized Feedback|Participants will access a website containing 16 interactive weekly modules pertaining to weight loss skills, as well as a discussion board on which they are encouraged through prompts and posts to interact with other participants for social support. They are asked to self-monitor food and beverage intake in a digital food diary (on a smartphone app) and will receive weekly detailed, personalized feedback on self-monitoring from a trained interventionist. Participants will be asked to weigh daily on a digital scale, which will be provided.
11037750|NCT04514887|Experimental|Mild Hyperventilation|In this study arm, patients were mildly hyperventilated intraoperatively so their end-tidal CO2 levels are brought down to 30-32 mmHg.
11037751|NCT04514887|No Intervention|Control|In this study arm patients' ventilation is managed according to guidelines with end-tidal CO2 levels kept in the normal range of 35-40 mm Hg
11037752|NCT04514861|Other|Tissue Oxygen Dynamics with Lumee Oxygen and TcPO2|Monitoring local subcutaneous tissue oxygen dynamics using the Wireless Lumee Oxygen Platform in correlation to TcPO2 measurements in the arm and foot
11037753|NCT04514848|Experimental|Individuals accessing screening for syphilis and HIV|Individuals at risk for syphilis and HIV (e.g. gay and bisexual men, indigenous communities experiencing a resurgence of syphilis, persons who inject drugs, etc) will undergo testing with both POCT and standard laboratory testing. Individuals testing positive for syphilis or HIV on the POCT will be informed that this is a preliminary positive and standard testing will be done. Individuals testing positive for syphilis on POCT may be offered treatment at the time of testing.
11037754|NCT04514835|Experimental|Cisplatin+Capecitabine+Sintilimab|Cisplatin+Capecitabine+Sintilimab
11037755|NCT04514822|Other|N0 stage|patients without malignant lymph nodes
11037756|NCT04514822|Other|Non-N0 stage|patients with malignant lymph nodes
11037757|NCT04514809|Experimental|Experimental|It consists of 15 mothers who meet the inclusion criteria
11037758|NCT04514809|Experimental|Control Groups|It consists of 15 mothers who meet the inclusion criteria
11037759|NCT04514796|Experimental|40 mg/0.4 mL of SB5|100 mg/mL of SB5
11037760|NCT04514796|Active Comparator|40 mg/0.8 mL of SB5|50 mg/mL of SB5
11037761|NCT04514783|Other|Group 2|Use of scalpel and a spoon-shaped metal instrument (curette).
11037762|NCT04514783|Experimental|Group 1|Use of Debritom+ micro water jet technology
11037763|NCT04514770|Active Comparator|early amniotomy|"Group A:
~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.
~Early amniotomy was performed for the participant of the first group at 3 cementer cervical dilatation with Kocher's forceps provided the head is well fitted to the cervix."
11037764|NCT04514770|Active Comparator|Late amniotomy|"Group B:
~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.
~late amniotomy was performed for the participant of the second group at 7 cementer cervical dilatation."
11037765|NCT04514757|Experimental|Intervention Group|Active tVNS (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to ear at 20 Hz, 200 microseconds at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 6 days post-operatively or discharge.
11037766|NCT04514757|Sham Comparator|Control Group|Sham tVNS will be performed by attaching the Parasym device to the ear and setting output to 0. Stimulation will continue until 6 days post-operatively or discharge.
11037767|NCT04514744|Experimental|Unilateral Immobilization|One leg will undergo 8 days of single-leg immobilization, by means of a removable knee brace.
11037768|NCT04514744|Experimental|Unilateral Resistance Exercise|One leg will undergo 4 sessions of unilateral resistance exercise, over the course of 8 days. Specifically, participants will be asked to perform leg press and leg extension.
11037769|NCT04514731|Experimental|Group M|Patients in the magnesium sulfate group received magnesium sulfate 50 mg/kg for 15 minutes after spinal anesthesia and then 15 mg/kg/hour by continuous intravenous infusion until the end of surgery
11037770|NCT04514731|Placebo Comparator|Group S|Patients in the saline group received the same volume of isotonic saline over the same period with magnesium infusion protocol
11037771|NCT04514718|Active Comparator|low energy holmium laser|30 watts
11037772|NCT04514718|Active Comparator|high energy holmium laser|80-100 watts
11037773|NCT04514705|Experimental|Intervention Group|The exercises performed will attend the musculoskeletal dimension of the body, which includes the muscular strength / endurance indexes, which is part of the functional-motor dimension of physical fitness related to health. The protocol will be applied in the form of sessions lasting approximately 50 minutes, performed three times a week on alternate days, for a period of 6 weeks, totaling 20 sessions. For aerobic exercises, a treadmill will be used and for anaerobic exercises, four exercises involving muscle mobility / strength in upper and lower limbs will be performed at weight training station.
11037774|NCT04514692|Experimental|Phase I -Dose finding, Cohort 1|Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
11037775|NCT04514692|Experimental|Phase I -Dose finding, Cohort 2|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
11037776|NCT04514692|Experimental|Phase I -Dose finding, Cohort 3|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
11037777|NCT04514692|Experimental|Phase II-G-CSF|Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
11037778|NCT04514679||Healthy Lifestyles Program|Usual care in the Healthy Lifestyles Program.
11037781|NCT04514653|Active Comparator|Ranibizumab control|Control treatment arm
11037782|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
11037783|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
11037784|NCT04514640|Experimental|General Meditation|"Participants will be asked to meditate every day during the daytime for at least 10 min/session. Participants can use any general meditation including the Daily Calm which can be found on the homepage or by clicking on the meditate tab in the app. Participants will be asked to not choose any sleep meditations or Sleep Stories."
11037785|NCT04514640|Experimental|Sleep Meditation|"Participants will be asked to meditate every day just before going to bed for at least 10 min/session. Participants can use any sleep meditations which can be found by clicking on the meditate tab and then sleep. Particpiants will be asked to not choose any general meditations including the Daily Calm or Sleep Stories."
11037786|NCT04514640|Experimental|Sleep Stories|"Participants will be asked to listen to a Sleep Story every day just before going to bed for at least 10 min/session. Participants can listen to any Sleep Story which can be found by clicking on the sleep tab. Participants will be asked to not choose any general meditations including the Daily Calm or sleep meditations."
11037787|NCT04514627|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
11037788|NCT04514627|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
11037789|NCT04514614|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
11037790|NCT04514601||Pre-Intervention Group|The verbal and written handover of these patients was observed. This included 146 general orthopaedic admissions patients and 43 trauma patients. All patient data was anonymised.
11037791|NCT04514601||Post-Intervention Group|The verbal and written handover of these patients was observed after the introduction of the intervention. This included 81 general orthopaedic admissions patients and 47 trauma patients. All patient data was anonymised.
11037792|NCT04514588|Other|caffeine consumption and metabolism|Participants will take part in two trials. Each trial will last one day at least one week apart. During the first trial half of the participants will consume caffeine (5mgr/kgr) and the rest only water. During the second trial a crossover design will be applied
11037793|NCT04514588|Other|control|Control group will consume only water (not coffee) and the same parameters will be recorded as previously
11037794|NCT04514575||High-FFP|Patients transfused with an FFP:RBC ratio of 2:3 to 3:3 (0.7 - 1.0)
11037795|NCT04514575||Low-FFP|Patients transfused with an FFP:RBC ratio at or below 1:3 (0.0 - 0.3).
11037796|NCT04514562|Other|Intervention|NeVa Stent Retrievers
11037797|NCT04514549||Cohort 1|will enroll approximately 5 patients with pronounced respiratory dysfunction. Patients may be enrolled with tremors and or seizures. All patients will be observed via Emerald to capture sleep staging, movement and breathing for up to approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. MC10 nPoint data will be captured for at least two 24-hour periods in each of the 4 weeks to assess patch placements for breathing detection. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 1 progresses.Preliminary results from Cohort 1 will determine if Emerald will continue to be evaluated and will inform on MC10 nPoint optimizations for Cohort 2. If preliminary results indicate Emerald is not an effective device, then Emerald will be discontinued
11037798|NCT04514549||Cohort 2|will enroll approximately 15 patients. Patients with pronounced respiratory dysfunction, tremors, seizures, and/or other expanded features of Rett syndrome deemed appropriate may be enrolled. If Emerald is continued, all patients are observed via Emerald to capture sleep staging, movement and breathing up to for approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 2 progresses.
11037799|NCT04514536|Experimental|Health monitoring|Subjects have to monitor their health autonomously using the monitoring platform (connected health devices and app on the touchpad).
11037800|NCT04514523|Experimental|Implementation Arm|
11037801|NCT04514510|Experimental|ISO|Subjects with sickle cell disease
11037802|NCT04514510|Placebo Comparator|Placebo|Subjects with sickle cell disease
11037803|NCT04514497|Experimental|Cohort I (BAY 1895344, irinotecan liposome)|Patients receive BAY 1895344 PO BID on days 1 and 2 and irinotecan liposome IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11037804|NCT04514497|Experimental|Cohort II (BAY 1895344, topotecan)|Patients receive topotecan IV over 30 minutes on days 1-5 and BAY 1895344 PO BID on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11037805|NCT04514484|Experimental|Treatment (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity.
11037806|NCT04514471|Experimental|Unventilated Filter Cigarette|Conventional cigarette with approximately 6-7% (non-menthol) and 5-6% filter ventilation (menthol).
11037807|NCT04514471|Active Comparator|Ventilated Filter Cigarette|Conventional cigarette with approximately 22-26% (non-menthol) and 35-38% filter ventilation (menthol).
11037808|NCT04514458|Experimental|EHR-based alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
11037809|NCT04514458|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
11037810|NCT04514432||When music was available|3 month period during which music was available to patients experiencing agitation
11037811|NCT04514432||When music was not available|3 month period during which music was not available to patients
11037894|NCT04513847||Non-Control|Psoriasis patients treated with biologic
11037812|NCT04514419|Experimental|Trastuzumab + HS627 + Docetaxel|Trastuzumab HS627 Docetaxel
11037813|NCT04514419|Experimental|Trastuzumab + Pertuzumab + Docetaxel|Trastuzumab Pertuzumab Docetaxel
11037814|NCT04514406||APERTO OTW DCB|Dialysis patients treated with APERTO OTW following (re)stenosis of central veins
11037815|NCT04514393|Experimental|methotrexate, ibrutinib, and temozolomide (MIT regimen)|Methotrexate will be given on day 1 of each 28-day cycle；Ibrutinib will be given day 1-28 of each 28-day cycle; Temozolomide will be given day 1-5 of each 28-day cycle. Methotrexate and Temozolomide are given for up to 4 cycles; Ibrutinib is continued until disease progression, intolerable toxicity, or death.
11037816|NCT04514380||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon A.
11037817|NCT04514380||Group N|Patients did not drink carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon B.
11037818|NCT04514367|Experimental|ANX005|IV
11037819|NCT04514354|Experimental|GEST Visit|As described in the detailed study description, the GEST Visit included measures of cardiovascular health at Hartford Hospital. These measures included BMI, waist circumference, exhaled carbon monoxide (CO), vascular health (i.e., carotid intimal medial thickness and arterial stiffness), HRV, resting BP, the GEST, and blood draws pre- and post-GEST to obtain SCD and CVD biomarkers.
11037820|NCT04514354|No Intervention|CONTROL Visit|On either Visit 3 or 4, subjects performed the CONTROL Visit. Resting auscultatory blood pressure was measured according to AHA standards. At the conclusion of CONTROL, subjects were fitted for the ABP monitor. Subjects were instructed to proceed with normal activities, not to exercise, and to keep their arm still and extended at their side when each ABP measurement was being taken. Subjects carried a standard journal, recording activities performed during each measurement, any unusual physical or emotional events, and sleep and wake times. The following morning, subjects detached the monitor and returned it that day to the study investigators.
11037821|NCT04514328|Experimental|one group|patients with mild or moderate Alzheimer disease
11037822|NCT04514315||Minimally invasive aortic valve surgery|Patients undergoing minimally invasive aortic valve surgery
11037823|NCT04514315||Minimally invasive mitral valve surgery|Patients undergoing minimally invasive mitral valve surgery
11037824|NCT04514315||Conventional aortic valve surgery|Patients undergoing conventional aortic valve surgery
11037825|NCT04514302|Placebo Comparator|Placebo|Single dose of 150 mL of saline solution administered intravenously as an infusion at 4.0 mL/min over 40 min. n = 18.
11037826|NCT04514302|Experimental|INOSARS dose 1|Single dose of 2 vials of INOSARS in 150 mL of saline solution administered intravenously as an infusion at 4.0 mL/min over 40 min. n = 16
11037827|NCT04514302|Experimental|INOSARS dose 2|Description: Single dose of 6 vials of INOSARS in 150 mL of saline solution administered intravenously as an infusion at 4.0 mL/min over 40 min. n = 17
11037828|NCT04514289||assesment SLND with enjection by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The first group in which the cervix is injected superficially with 1 mL of ICG ( indocyanine green) at 4 and 8 o'clock quadrans.
11037829|NCT04514289||assesment SLND with hysterescopy by using ICG|Patients who have endometrium cancer; undergo sentinel lymph node detection by using fluorescence imaging with an indocyanine green solution. Two different ways used to assess SLND. The second one which ICG has injected the uterine cavity during hysteroscopy. Our aim is to assess and compare the performance two approaches for sentinel lymph node ( SLND) biopsy.
11037830|NCT04514276|Experimental|consecutive fetoneonatal healthcare|inclusion criteria: pregnant woman having higher risk of early fetal growth restriction, preeclempsia living in studyregion (east-Saxony or east Thuringia) the fetoneonatal pathway consists of four consecutive parts: (1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
11037831|NCT04514276|No Intervention|standard fetoneonatal healthcare|inclusion criteria: due to health insurance data by AOK PPLUS & ikk classics propsensityscorematched pregnant women living in west Saxony and Thuringia, being not part of the intervention group receiving standard health care.
11037832|NCT04514263||Oral Biopsy|Patients with oral lesions undergoing diagnostic or therapeutic biopsies either for benign lesions or potentially malignant disorders or malignant lesions or salivary glands diseases.
11037833|NCT04514237|Experimental|Part 1: Regimens AB(CD)|Participants received 50 milligrams (mg) BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 1, followed by 50 mg BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
11037834|NCT04514237|Experimental|Part 1: Regimens BA(CD)|Participants received 50 milligrams (mg) BOS172767 E2 tablets or matching placebo (Regimen B) in the fasted state in Period 1, followed by 50 mg BOS172767 E1 tablets or matching placebo (Regimen A) in the fasted state in Period 2. In Period 3 and 4, participants received BOS172767-Ex (selected enantiomer from Part 1 [E1 or E2]) tablets or matching placebo (Regimens C and D, respectively) from Regimen A or B in the fasted state. The Period 3 and 4 dose was selected after review of data from Periods 1 and 2. In each Period, dosing occurred on Day 1, and there was a washout period of at least 10 days or 5 half-lives of the parent (whichever is greater) between each dose of investigational medicinal product.
11037835|NCT04514224||Healthy Start Program 1|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
11037836|NCT04514224||Community Health Center 1|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
11037837|NCT04514224||Healthy Start Program 2|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
11037838|NCT04514224||Community Health Center 2|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
11037839|NCT04514224||Healthy Start Program 3|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
11037840|NCT04514224||Community Health Center 3|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
11037841|NCT04514224||Healthy Start Program 4|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
11037842|NCT04514224||Community Health Center 4|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
11037843|NCT04514224||Healthy Start Program 5|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
11037844|NCT04514224||Community Health Center 5|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
11037845|NCT04514224||Healthy Start Program 6|Community Partner with HRSA-funded Healthy Start designation and services a patient population with over 50% identifying African American and/or Black
11037846|NCT04514224||Community Health Center 6|Community Partner with Community Health Center or Federally Qualified Community Health Center designation and services a client population with over 50% identifying African American and/or Black
11037847|NCT04514211||Propofol|General anesthesia using propofol infusion
11037848|NCT04514211||Sevoflurane|General anesthesia using sevoflurane
11037849|NCT04514185|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
11037850|NCT04514185|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
11037851|NCT04514172|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
11037852|NCT04514172|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
11037853|NCT04514159|Experimental|ZN-c5 + abemaciclib combination therapy|Participants will take abemaciclib (150mg) orally twice a day and ZN-c5 (dose escalation) orally once or twice a day to determine the safety, tolerability, and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D).
11037854|NCT04514146||Water-only Fasting Group|Overweight and obese, non-diabetic participants undergoing elective water-only fasting treatment
11037855|NCT04514133|Experimental|Generation Citizen (GC) action civics program|Students in this arm will take part in Generation Citizen (GC) action civics program. GC delivers action civics programming to young people from diverse backgrounds nationwide. GC offers a school-based action civics curriculum in which classes collectively choose a local issue, learn strategies and skills for taking civic action, develop an action plan, and take action on their selected local issue. Students, as a class, tackle topics ranging from health-related (e.g., health of school lunches) to safety-related (e.g. lack of crosswalks) to community social issues (e.g., community-police relations).
11037856|NCT04514133|No Intervention|No Generation Citizen action civics program|Students in this arm will receive no intervention.
11037857|NCT04514120|Experimental|Stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and/or with Allergic Fungal Rhinosinusitis and stable condition
11037858|NCT04514120|Experimental|Non-stable CRS|Patients diagnosed with Chronic Rhinosinusitis including those with or without nasal polyposis and with Allergic Fungal Rhinosinusitis who are experiencing an exacerbation
11037859|NCT04514107|Active Comparator|Control|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD). n=1740
11037860|NCT04514107|Experimental|Intervention|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD) and Wolbachia-infected Aedes aegypti (wMel) mosquitoes. n=1740
11037861|NCT04514094|Experimental|Silver Diamine Fluoride|"Gross debris will be removed with cotton pellets to allow better SDF contact with denatured dentin.
~Cotton rolls will be used to protect surrounding gingival tissues and mucous membranes to avoid pigmentation or irritation.
~Affected tooth surfaces will be dried with a gentle flow of air.
~1-2 drops only of SDF will be used for the whole visit.
~SDF will then be directly applied to affected tooth surfaces only using a micro sponge brush.
~At least one minute will be needed to allow drying of SDF.
~Excess SDF will finally be removed with cotton rolls to minimize systemic absorption.
~When possible, isolation will be continued for up to three minutes.
~After 2-4 weeks: reapplication will be done only to lesions that do not appear arrested (dark and hard)."
11037862|NCT04514094|Active Comparator|Atraumatic Restorative Treatment|"Caries removal by hand instruments with care not to expose the pulp.
~Maximum excavation from the periphery of lesions will be done, to minimize leakage at the restoration margins.
~Cotton roll isolation will then be carried out.
~Cavities will be restored by glass ionomer cement.
~Hand pressure should be applied by a gloved and petroleum jelly coated finger, then, excess material will be removed."
11037863|NCT04514081|Experimental|Chidamide+Decitabine+Camrelizumab|
11037864|NCT04514081|Active Comparator|Decitabine+Camrelizumab|
11037865|NCT04514068|Experimental|Unilateral electroacupuncture of p6 acupoint|
11037866|NCT04514068|Experimental|Bilateral electroacupuncture of p6 acupoint|
11037867|NCT04514068|Sham Comparator|Sham acupuncture of p6 acupoint|
11037895|NCT04513834|Experimental|Multi-faceted intervention|Patient education material on PPI deprescribing will be sent to the patients and their general practitioner (GP) will receive an educational outreach visit by a Delegue d'Assurance Maladie (DAM, healthcare representative )
11037896|NCT04513834|Active Comparator|Educational outreach visit to GPs|GP will receive the educational outreach visit by a DAM (healthcare representative). Their patients will not receive any patient education material.
11037897|NCT04513834|No Intervention|Control|Neither the patients nor their GP will receive any information.
11049445|NCT04433013|Placebo Comparator|Control group|
11037868|NCT04514055|Experimental|De-epithelialized connective tissue graft wall|"Simplified papilla preservation flap will be applied in the narrow interproximal spaces (≤2 mm), where an oblique incision starting from the gingival margin at the buccal-line angle of the involved tooth reaching the mid-interproximal portion of the papilla under the contact point of the adjacent tooth will be performed using a 15c blade.
~A free gingival graft will be obtained from the hard palate and de-epithelized extra-orally.
~A Coronally advanced flap will be performed. The de-epithelialized FGG will be sutured coronally using a 6-0 vicryl suture to the anatomical papillae of the two teeth adjacent to the defect and apically to the periosteum left in place apical to the exposed bone.
~The flap will be sutured using internal Horizontal mattress suture at the base of the simplified papilla and a vertical mattress suture will be placed in a more coronal position so complete soft tissue closure can be obtained."
11037869|NCT04514042|Active Comparator|Standard procedure|Patients with Zenker's diverticulum treated with flexible endoscopy septotomy.
11037870|NCT04514042|Experimental|Investigational procedure|Patients with Zenker's diverticulum treated with peroral endoscopic myotomy.
11037871|NCT04514029|Experimental|Simvastatin and Dexamethasone|Simvastatin 40 mg/day will be started at least 5 days prior to apheresis and will be continued until day +30 after infusion. Intrathecal dexamethasone 8 mg will be administered on days (related to CAR-T infusion) -1, +6, +13, (+/- 2 days).
11037872|NCT04514016||HIV positive participants with positive COVID-19 results|Participants in this group will have a RT-PCR and Coronavirus Disease (COVID) -19 specific antibody testing at baseline, 1 month and 3 month visits.
11037873|NCT04514016||HIV positive participants with negative COVID-19 results|Participants in this group will have a RT-PCR and COVID-19 specific antibody testing at baseline only.
11037874|NCT04514003||SARS-CoV-2 PCR positive cases|Antibody tests will be performed every 6 months for 2 years
11037875|NCT04514003||SARS-CoV-2 PCR negative cases|Antibody tests will be performed every 6 months for 2 years
11037876|NCT04514003||Population controls|A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
11037877|NCT04513990|Experimental|Diagnostic (biospecimen collection)|Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.
11037878|NCT04513977|No Intervention|Usual care|For older adults with cancer with G8 score 14 or less. Randomized to usual oncology care.
11037879|NCT04513977|Experimental|Geriatric Oncology Supportive Clinic|For older adults with cancer with G8 score 14 or less. Randomized to attend Geriatric Oncology Supportive Clinic
11037880|NCT04513964||Control|Patient not suffering from COVID-19
11037881|NCT04513964||COVID-19|Patient who has been infected with COVID-19 with suggestive signs and authentication by PCR or thoracic CT or serology
11037882|NCT04513951|Experimental|mFOLFOXIRI + Cetuximab + Avelumab|"Avelumab, 800 mg intravenous [IV] dose over 60 minutes, day 1, followed by
~Cetuximab, 500 mg/m2 IV dose over 2 hours at cycle 1 (if well tolerated, it is administered over 90 minutes at cycle 2 and over 60 minutes by cycle 3), day 1, followed by
~Irinotecan 150 mg/ m2 IV dose over 60 minutes day 1, followed by
~Oxaliplatin 85 mg/m2 IV dose over 2 hours, day 1 in two-way with
~L-Leucovorin 200 mg/ m2 IV dose over 2 hours, day 1 followed by
~5-fluoruracil 2400 mg/m2 IV dose 48 h-continuous infusion, starting on day 1; to be repeated every 14 days for a maximum of 12 cycles. If no progression occurs during the induction treatment, patients will receive maintenance with 5-FU/LV plus cetuximab and avelumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus cetuximab and avelumab will be repeated biweekly until disease progression, unacceptable toxicity, patient's refusal or consent withdrawal."
11037883|NCT04513925|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
11037884|NCT04513925|Active Comparator|Durvalumab|Participants will receive durvalumab administered IV on Days 1 and 15 of each 28-day cycle for a maximum of 13 cycles.
11037885|NCT04513912|Experimental|Seltorexant|Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
11037886|NCT04513912|Active Comparator|Quetiapine Extended-Release (XR)|Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
11037887|NCT04513899|Experimental|Community Health Worker/Registered Nurse (CHW/RN)|Nurse-led Community Health Worker (CHW/RN) program delivered DOT for HCV treatment.
11037888|NCT04513899|Active Comparator|Clinic-based Standard of Care (cbSOC)|Standard of care for HCV treatment delivered by a clinic-based MD or clinic-based NP at the clinic site
11037889|NCT04513886|Active Comparator|Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes, a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate.
11037890|NCT04513886|Experimental|no Suture Group|After harvesting a subepithelial connective tissue graft using the single incision technique, collagen haemostatic sponge placement and subsequent compression with gauze soaked in saline for 5 minutes no suture was performed.
11037891|NCT04513873|Experimental|Equipment Intervention Group|"The intervention group had equipment that looks like a blood tube in front of them during the blood collection process to divert their attention from the blood collection process to the equipment. This equipment was with a fixed arm on the right and a moving arm on the left with a total height of 80 cm as well as a red light-emitting diode(LED) to stimulate the blood collection. It had some answers to common questions of parents as well as the key concerns of the children like  Will it hurt me?. The equipment was made a musical device by loading the most popular children's songs into its database."
11037892|NCT04513873|No Intervention|No Intervention Group|Standard blood collection procedures were applied to the control group.
11037893|NCT04513847||Control|Psoriasis patients treated with non-biologic
11037898|NCT04513808|Active Comparator|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.
11037899|NCT04513808|Active Comparator|Sevoflurane intravenous anesthesia|Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary
11037900|NCT04513769|Experimental|Study participants|This is a single-arm study so all participants receive the same intervention.
11037901|NCT04513756|Experimental|Active Treatment Group|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques.
11037902|NCT04513756|No Intervention|Treatment As Usual Group|CRA comprising of nine sessions will not be provided to this group. However, patients who will be already receiving treatment from any psychiatric or some other rehabilitation facility will be advised to continue their routine treatment.
11037903|NCT04513743|Experimental|Healthy adults|UNEEG™ medical 24/7 EEG™ SubQ
11037904|NCT04513730|Experimental|pelvic suspension device|A device will be built with the function of keeping the user in position of pelvic suspension promoting lumbar traction that will consist of a structure of pvc pipes and connections and padded material.
11037905|NCT04513717|Active Comparator|RT + ADT for 24 months (De-Intensification)|Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.
11037906|NCT04513717|Experimental|RT + ADT for 12 months (De-Intensification)|Patients undergo RT over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity.
11037907|NCT04513717|Active Comparator|RT + ADT for 24 months (Intensification)|Patients undergo RT over 4-9 weeks and receive ADT as in Arm I.
11037908|NCT04513717|Experimental|RT + ADT, Apalutamide, Abiraterone w/Pred. (Intensification)|Patients undergo radiation therapy over 4-9 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide, abiraterone acetate and prednisone PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
11037909|NCT04513704|Experimental|Oral Semaglutide A|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 2 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
11037910|NCT04513704|Experimental|Oral Semaglutide B|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 4 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
11037911|NCT04513704|Experimental|Oral Semaglutide C|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-specified timing for 6 hours of the pre-dose fast, followed by a 30 minutes post-dose fast.
11037912|NCT04513704|Experimental|Oral Semaglutide D|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days), with a pre-dose fasting time of 2 hours followed by a post-dose overnight fast.
11037913|NCT04513704|Active Comparator|Oral Semaglutide E|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days). Participants will be instructed to take the trial product in the morning after an overnight fast and wait 30 minutes before taking any food, water or other oral medication in accordance with the approved dosing schedule for oral semaglutide.
11037914|NCT04513691||Sample|Asymptomatic newborns 35 weeks or greater GA born at Banner - University Medical Center Phoenix whose mothers were determined or suspected to have CAM.
11037915|NCT04513678|Experimental|ImmunOncoTool Condition|The ImmunOncoTool condition includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention.
11037916|NCT04513678|No Intervention|Control|Participants in the control condition are not assigned an intervention. They receive standard of care.
11037917|NCT04513665|Experimental|Stage 1|Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants.
11037918|NCT04513665|Experimental|Stage 2|If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy.
11037919|NCT04513652|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
11037920|NCT04513652|Placebo Comparator|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
11037921|NCT04513639|Experimental|Arm A|Patients will be followed with MRD assessment every 4 month and start 2.L treatment at loss of MRD negative complete response.
11037922|NCT04513639|Active Comparator|Arm B|Patients will be followed up by standard criteria and start 2.L treatment at progressive disease.
11037923|NCT04513626|Other|Delayed switch|the maintaining of their current ART followed by a switch to doravirine/raltegravir at W48 (delayed switch group).
11037924|NCT04513613||Subjects with a clinical indication for PVI|Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).
11037925|NCT04513587|Experimental|CBT-Based Weight Loss Model|CBT- Based weight loss model
11037926|NCT04513587|Active Comparator|Control|Usual Care
11037929|NCT04513535|Experimental|manual therapy combination 1|Cervical manipulation, Thoracic manipulation
11037930|NCT04513535|Experimental|manual therapy combination 2|Cervical manipulation, glenohumeral mobilization
11037931|NCT04513535|Experimental|manual therapy combination 3|cervical manipulation, sleeper stretch
11037932|NCT04513535|Experimental|manual therapy combination 4|thoracic manipulation, glenohumeral mobilization
11037933|NCT04513535|Experimental|manual therapy combination 5|thoracic manipulation, sleeper stretch
11037934|NCT04513535|Experimental|manual therapy combination 6|glenohumeral mobilization, sleeper stretch
11037935|NCT04513522|Experimental|Nivolumab + ipilimumab|
11037936|NCT04513509|Experimental|rate control|
11037937|NCT04513483|Experimental|CPAP treatment for 12 months|CPAP treatment for 12 months
11037938|NCT04513483|Placebo Comparator|Placebo|observation
11037939|NCT04513470|Experimental|COVID-19|Five subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
11037940|NCT04513457||Liver resection and Neoadjuvant chemotherapy|Liver resection and Neoadjuvant chemotherapy
11037941|NCT04513457||Liver resection and Adjuvant chemotherapy|Liver resection and Adjuvant chemotherapy
11037942|NCT04513457||Liver resection, Neoadjuvant and Adjuvant chemotherapy|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy
11037943|NCT04513457||Liver resection|Liver resection
11037944|NCT04513444|Other|Standard arm (A): music listening therapy|
11037945|NCT04513444|Experimental|Experimental arm (B): music listening and hypnosis therapy|
11037946|NCT04513431|Experimental|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
11037947|NCT04513418|Experimental|Interventional group|Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion from the start of neoadjuvant chemoradiotherapy until surgery. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.
11037948|NCT04513418|No Intervention|Control group|Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.
11037949|NCT04513405|Other|subjects with skin tears (Group A)|"A sample of peripheral venous blood will be taken to measure the levels of estrone and estradiol.
~A skin biopsy on the intact skin area near the skin tear will be performed."
11037950|NCT04513405|Other|subjects without skin tears (Group B)|"A sample of peripheral venous blood will be taken to measure the levels of estrogen.
~A skin biopsy (thin layer) on the intact skin area of the arm will be performed in order to evaluate skin estrogen receptors."
11037951|NCT04513392|Active Comparator|KTP laser treatment|All participants will complete a paper Voice Handicap Index-10 (VHI-10) questionnaire and laryngeal stroboscopy examination at baseline. Local anesthesia will be administered as per standard of care for in-office laryngeal procedures. KTP laser will be utilized to ablate the lesion of interest. Immediately following the procedure, participants will complete a VAS pain scale on paper. Participants will be asked to exercise 3 days of absolute voice rest following the procedure. All patients will have follow-up clinic appointments on POD 7, POD 30, and POD 90 after surgery. At each of the follow-up visit, the patients will fill out a paper VHI-10 questionnaire and undergo stroboscopic examination to assess vocal fold vibratory properties and closure, as well as residual lesions. During the first week post procedure, the participants will continue to complete a daily VAS at home for pain assessment.
11037952|NCT04513392|Experimental|BL laser treatment|The only difference in study procedures between the experimental arm and the control arm is that the experimental arm will use the BL laser. The post-operative instructions and follow-up schedule are identical.
11037953|NCT04513379|Experimental|Trial|EFV 400mg
11037954|NCT04513379|Active Comparator|Control|EFV 600mg
11037955|NCT04513366|Experimental|SEL-212A|"SEL-212A Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)
~Other Names:
~Pegadricase, pegsiticase Drug: SEL-110.36 (0.1 mg/kg) SEL-110.36, ImmTOR"
11037956|NCT04513366|Experimental|SEL-212B|"SEL-212B Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)
~Other Names:
~Pegadricase, pegsiticase Drug: SEL-110.36 (0.15 mg/kg) SEL-110.36, ImmTOR"
11037957|NCT04513366|Placebo Comparator|Placebo|Normal saline
11037958|NCT04513353|Experimental|Digital Healthcare System Rehabilitation|
11037959|NCT04513353|Active Comparator|Conventional Rehabilitation|
11037960|NCT04513340|Experimental|Treatment A|Treatment A will be given under fed conditions by intra-oral single dose administration
11037961|NCT04513340|Experimental|Treatment B|Treatment B will be given intra-orally and orally under fed conditions by single dose administration
11037962|NCT04513340|Experimental|Treatment C|Treatment C will be given orally under fed conditions by single dose administration
11037963|NCT04513340|Experimental|Treatment D|Treatment D will be given orally under fasting conditions by single dose administration
11037964|NCT04513327|Experimental|Digital Healthcare System Rehabilitation|
11037965|NCT04513327|Active Comparator|Conventional Rehabilitation|
11037966|NCT04513314|Active Comparator|Standard of Care Only Group|Patients maintained with mechanical ventilation will be treated with standard of care after cessation of paralytic agents.
11037967|NCT04513314|Active Comparator|Treatment Arm Group|Patients maintained with mechanical ventilation will be treated with standard of care, plus Valproate on Days 1-7 after cessation of paralytic agents, and then augmented by the addition of Quetiapine beginning Days 3-7 if there are no improvement in RASS score.
11037968|NCT04513301|Active Comparator|Sintilimab alone|Sintilimab (200 mg q3w ×2cycle)
11037969|NCT04513301|Experimental|Sintilimab+Radiotherapy|Sintilimab (200 mg q3w ×2cycle)+RT 50-60Gy/25-30f
11037970|NCT04513288|Experimental|Experimental group|Enteral administration of citrulline for 5 days. L-citrulline (Protéocit®). This commercial form consists only of L-citrulline. Each patient will receive 10 grams per day in 2 doses (1 stick/ 12H = 5 grams / 12H). These sticks contain a powder to be resuspended in 50 mL of water for injection (ppi) for 1 stick. They will be delivered in a 50 mL syringe allowing administration of the product through the nasogastric tube. The solution will be prepared just before administration.
11038135|NCT04512079|Active Comparator|Full Dose Enoxaparin|Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
11037971|NCT04513288|Placebo Comparator|Control group|Enteral administration of iso-nitrogenous placebo for 5 days. The placebo used will consist of a mixture of 4 non-essential amino acids. 5 g of L-citrulline provides 1.2 g of nitrogen. For the mixture to be iso-nitrogenous, each of the 4 amino acids will need to provide 0.3 g of nitrogen. The mixture will therefore consist of 21.6% alanine, 32.3% aspartate, 18.2% glycine and 27.9% proline for a total of 8.83 g of amino acids per sachet. 2 administrations (2 sticks) daily for 5 days.
11037972|NCT04513275||schizophrenia patient group|Schizophrenia patients with first episode and disease duration of 5, 10, 20, and 30 years
11037973|NCT04513262||Video-assisted surgery|Patients undergoing video-assisted major abdominal surgery (VAS) in Trendelenburg position. The decision regarding the type of VAS was made by the attending surgeon prior to study inclusion. Twenty-five consecutive patients undergoing classic laparoscopic surgery and twenty-five patients undergoing robotic-assisted surgery will be included in the study.
11037974|NCT04513236|No Intervention|Control|No Airtime Incentive was given for completing the survey
11037975|NCT04513236|Experimental|Pre-survey incentive|0.1X incentive before the survey, 1X afterwards
11037976|NCT04513236|Experimental|Post-survey incentive|1X incentive after the survey
11037977|NCT04513223|Experimental|SHR-A1811|
11037978|NCT04513210||Changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital with changes in the ultrasound on admission, suggesting pneumonia.
11037979|NCT04513210||No changes in the lungs on admission|Patients with Covid-19 infection admitted to the University Hospital without changes in the ultrasound on admission, suggesting pneumonia.
11037980|NCT04513184|Active Comparator|Standard therapy (ST) only|Control. Standard care and treatment only
11037981|NCT04513184|Experimental|DXM|Nasal dexamethasone plus Standard care and treatment
11037982|NCT04513171|Experimental|Y-shape pegylated somatropin low dose|
11037983|NCT04513171|Experimental|Y-shape pegylated somatropin middle dose|
11037984|NCT04513171|Experimental|Y-shape pegylated somatropin high dose|
11037985|NCT04513171|Active Comparator|Norditropin-1|
11037986|NCT04513171|Experimental|Y-shape pegylated somatropin optimal dose|
11037987|NCT04513171|Active Comparator|Norditropin-2|
11037988|NCT04513158|Experimental|Treatment Arm|Study is single arm all patients hospitalized meeting inclusion/exclusion criteria and providing informed consent to receive one unit (approximately 200 mL) of convalescent plasma with data collected daily on routine (non-research) clinical assessments/physical exams and lab results.
11037989|NCT04513145|Experimental|Treatment Group (Ropivacaine)|The treatment group will consist of patients undergoing total knee arthroplasty who receive standardized 100 cc periarticularinjection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients will then receive 10cc of ropivacaineinto their adductor canal.This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
11037990|NCT04513145|Placebo Comparator|Control Group (Saline)|The control group will consist of patients undergoing total knee arthroplasty who receive a standardized periarticular injection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients randomized in this group will then receive 10cc of saline into their adductor canal. This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
11037991|NCT04513132|Active Comparator|HD-CHR|Participants will be intervened with 4×1 ring high-definition montage (HD-tDCS).
11037992|NCT04513132|Sham Comparator|SH-CHR|Participants, as a control group, will receive sham montage of stimulation.
11037993|NCT04513106|Experimental|Advance care planning programme|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
11037994|NCT04513106|Placebo Comparator|Attention control|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants.
11037995|NCT04513093|Experimental|İntervention Group|"The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
~The Bristol Stool Scale and Constipation Severity Scale were re-applied to the individuals in the intervention before, during the second week of practice and at the end of practice (fourth week)."
11037996|NCT04513093|No Intervention|Control Group|"No application was applied to the individuals in the control group. Bristol Stool Scale and Constipation Severity Scale were applied to the individuals in the control group at the same time as (at the beginning, second week and fourth week) the intervention group."
11037997|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Video-chat psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
11037998|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Video-chat psychotherapy (VCP)|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
11037999|NCT04513080|Experimental|Phase 1, Level 2: MBP with weekly VCP|Phase 1 participants who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm), monthly VCP with unlimited MBP (switch/minimal augmentation arm).
11038000|NCT04513080|Experimental|Phase 1 Level 2: MBP with monthly VCP|Phase 1 participants randomized to VCP who do not show 50% reduction in PHQ9 scores will be randomized to either weekly VCP augmented with unlimited MBP (augmentation arm) or monthly VCP with unlimited MBP (switch/minimal augmentation arm).
11038001|NCT04513080|Experimental|Phase 2 Level 1: Message-Based Psychotherapy (MBP)|Phase 2 participants who respond to MBP after 6 weeks of care will continue in this condition for another 6 weeks. Participants who do not respond by week 6 will be randomized to one of two augmentation arms, MBP plus monthly video chat (Premium Plan: PP) or MBP plus weekly video chat (Ultimate Plan: UP) for another 6 weeks of care.
11038002|NCT04513080|Experimental|Phase 2, Level 1: Video-Chat Psychotherapy (VCP)|Phase 2: Weekly psychotherapy appointments that last between 30-45 minutes. Participants who do not respond to this model will be randomized to switch (PP) or augment (UP) VCP.
11038003|NCT04513080|Experimental|Phase 2, Level 2: MBP with monthly VCP|"Phase 2: This intervention will serve as the switch arm for participants who do not respond to VCP by week 6, and one of two augmentation arms for participants who do not respond to MBP. The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist."
11038004|NCT04513080|Experimental|Phase 2, Level 2: MBP with weekly VCP|Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
11038005|NCT04513080|Experimental|Phase 1, Level 1: Incentive 1 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
11038006|NCT04513080|Experimental|Phase 1, Level 1: Incentive 2 + Message-based psychotherapy|In Phase 1, participants will be randomized to one of two incentive levels. After randomization to an incentive level, participants will be randomized to either video-chat psychotherapy (VCP) or message-based psychotherapy (MBP). After six weeks of treatment, participants will move to level 2. Those who have made a 50% reduction to PHQ9 scores to their assigned treatment will continue in that same treatment for 6 more weeks.
11038007|NCT04513067|Experimental|Stage 1: Single agent|Intravenous weekly dose of YQ23 for 4 weeks with an ascending dose levels of 20, 30, 60, 90 and 120 mg/kg will be evaluated.
11038008|NCT04513067|Experimental|Stage 2: Combination Therapy|Intravenous weekly dose of YQ23 for 4 weeks with an ascending dose levels from 20 mg/kg to the MTD obtained from Stage 1 in combination of a fixed dose of 200 mg intravenous pembrolizumab given on the same day following YQ23 administration and every 3 weeks thereafter.
11038009|NCT04513054|Other|Takotsubo Case Arm|A patient that has been diagnosed with Takotsubo Cardiomyopathy from 2010 onwards.
11038010|NCT04513041|Experimental|Pinhole/Tunnel|Participants will receive Pinhole surgical technique for treatment of soft tissue recession at one side of the mouth and Tunnel technique for treatment of soft tissue recession at the other side of the mouth
11038011|NCT04513028|Experimental|Treatment|"All subjects will undergo 21 days of Pembrolizumab followed by 21 days of beta-glucan.
~Pembrolizumab: 200 mg/100mL IV in three week intervals
~Beta-glucan: 500mg (1 capsule) by mouth twice a day for 21 days"
11038012|NCT04513015|Experimental|Antioxidant diet|Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment
11038013|NCT04513015|Active Comparator|Normal diet|Group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex).
11038014|NCT04513002|Other|Group 1: Triheptanoin and no Placebo|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.
~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.
~Group 1: 10%, 20%, 30%, 30%, 30% (no placebo). Group 2: placebo, 10%, 20%, 30%, 30% Group 3: placebo, placebo, 10%, 20%, 30%"
11038015|NCT04513002|Other|Group 2: Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.
~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.
~Group 1: 10%, 20%, 30%, 30%, 30% (no placebo). Group 2: placebo, 10%, 20%, 30%, 30% Group 3: placebo, placebo, 10%, 20%, 30%"
11038016|NCT04513002|Other|Group 3: Placebo, Placebo and Triheptanoin|"Parallel group, placebo-controlled, dose-escalation each 2 months for 12 months. Dose based on percent (%) of calculated caloric intake.
~Thirty participants will be randomised in blocks on a 1:1:1 ratio into one of three groups.
~Group 1: 10%, 20%, 30%, 30%, 30% (no placebo). Group 2: placebo, 10%, 20%, 30%, 30% Group 3: placebo, placebo, 10%, 20%, 30%"
11038017|NCT04512989||Patients undergoing cardiac surgery|
11038018|NCT04512976|Experimental|24 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
11038019|NCT04512976|Experimental|30 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
11038020|NCT04512976|Experimental|38 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
11038021|NCT04512963|Experimental|SAD Phase including Food Interaction|Single Ascending Dose (SAD) study with up to 5 cohorts + Food interaction phase on one cohort
11038022|NCT04512963|Experimental|MAD Phase|Multiple Ascending Dose (MAD) study with up to 2 cohorts
11038023|NCT04512950|Active Comparator|Ringer's lactate|administered as infusions or boluses as per the treating physician
11038024|NCT04512950|Active Comparator|0.9% Saline|administered as infusions or boluses as per the treating physician
11038025|NCT04512937|Experimental|All patients|All patients will be subjects to the intervention of computer navigation-assisted surgery
11038028|NCT04512911|Active Comparator|Patients who didn't fail AAD|This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications
11038029|NCT04512911|Active Comparator|Patients who failed AAD|This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation
11038030|NCT04512898|Experimental|Patient with IBS|Patients with IBS and positive H. pylori.
11038031|NCT04512885||Patients with type 1 diabetes|
11038032|NCT04512885||Health professionals|
11038033|NCT04512872|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in PFS
11038034|NCT04512872|Active Comparator|EU-approved Prolia|60 mg/mL single dose administration, Solution for injection in PFS
11038035|NCT04512859|Experimental|Stellate Ganglion Block|"Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.
~Patients were then assessed using transcranial Doppler"
11038036|NCT04512859|Placebo Comparator|No Stellate Ganglion Block|"patients will receive a stellate ganglion block with 0.9% saline 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.
~Patients were then assessed using transcranial Doppler"
11038037|NCT04512846||CK-SBRT with TACE group|The hepatocellular carcinoma patients (5-10cm）who received SBRT with TACE.
11038038|NCT04512846||CK-SBRT group|The hepatocellular carcinoma patients (5-10cm）who received SBRT alone.
11038039|NCT04512820|Experimental|TRUCLEAR TREATMENT|patients up to 10 weeks of gestation with missed miscarriage undergoing evacuation of products of conception using the TRUCLEAR tissue removal system under direct hysteroscopic visualization
11038040|NCT04512794|Other|Non-randomized|All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.
11038041|NCT04512781|Active Comparator|Conventional Legacy Cannula Design (Control)|During this session, patients will be placed on HVNI therapy with an appropriately fitted Vapotherm conventional legacy cannula. Physiologic and ventilation parameters will be recorded.
11038042|NCT04512781|Experimental|Cannula Design Test #1 (Randomized)|During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
11038043|NCT04512781|Experimental|Cannula Design Test #2 (Randomized)|During this session, patients will be placed on HVNI therapy with one of the next generation cannula designs. Patients will be randomly assigned to Prosoft or Unicorn cannula testing groups. Physiologic and ventilation parameters will be recorded.
11038044|NCT04512768|Active Comparator|Standard ICBT|Participants in the Standard ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia.
11038045|NCT04512768|Experimental|Sleep-Enhanced ICBT|Participants in the Sleep-Enhanced ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. In addition, participants in the Sleep-Enhanced ICBT condition will also receive a newly developed lesson designed to target insomnia.
11038046|NCT04512742|Other|Leishmania infected-Phlebotomus duboscqi human challenge|There is no clear indication in the medical literature to determine which of the major sand fly vectors of Leishmania major - Phlebotomus papatasi or Phlebotomus duboscqi, will be most effective at transmitting infection to a human host. Both species have a similar mode of feeding and can support L. major development. In our previous study, FLYBITE, no significant difference in biting rates on humans was observed. Based on pre-clinical data , Phlebotomus duboscqi was determined to be the lead candidate for use in this study. If all the 6 participants have developed lesions within the 6-month follow up after Leishmania challenge, the challenge phase of the study is completed. If only 5 participants have developed lesions, then a further 6 participants will undergo Leishmania challenge by P. duboscqi. If only 4 or less subjects in the first cohort develop lesions, then the investigators will switch vector to P. papatasi and a further 6 subjects will undergo Leishmania challenge.
11038047|NCT04512716|Experimental|B-Cell Acute Lymphoblastic Leukemia/Diffuse Large B-Cell Lym|Participants will have relapsed or refractory B-Cell Acute Lymphoblastic Leukemia or Diffused Large B-Cell Lymphoma
11038048|NCT04512703||Healthy Control Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
11038049|NCT04512703||Heart Arrhythmia Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
11038050|NCT04512690|Experimental|Epidural electrical stimulation of the cervical spinal cord|Individuals with prior subcortical stroke and hemiparesis of the upper extremity.
11038051|NCT04512677|No Intervention|No Interventions: Control|Conventional clinical treatment and using the ventilatory weaning protocol and standard extubation with the spontaneous breathing test (SBT) with the T-piece in 30 minutes.
11038052|NCT04512677|Experimental|Experimental: Intervention|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
11038053|NCT04512664|Active Comparator|short term group|cold treatment for 4 hours
11038054|NCT04512664|Experimental|long term group|cold treatment for 48 hours
11038055|NCT04512651|Experimental|Intervention Group (IG)|The GI dancers, submitted to tibiotarsal thrust manipulation
11038056|NCT04512651|Sham Comparator|Control Group (CG)|For the CG was performed the simulation of the technique, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
11038057|NCT04512638|Active Comparator|Conservative treatment|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minor debridement. Primary wound closure is not part of this treatment strategy.
11038058|NCT04512638|Experimental|Minimally invasive approach + LPRF|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
11038136|NCT04512079|Experimental|Apixaban|Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
11038059|NCT04512638|Experimental|Primary surgical management|Amoxicillin-based antibiotics and chlorhexidine oral rinse. Removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
11038060|NCT04512625|No Intervention|Control group|Sensitivity level scores were evaluated on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation.
11038061|NCT04512625|Experimental|Group GL (Gluma desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
11038062|NCT04512625|Experimental|Group SF (SheildForce desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
11038063|NCT04512625|Experimental|Group TS (Telio CS desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
11038064|NCT04512612|Active Comparator|Dye based Chromoendoscopy|The patients enrolled in this group will undergo pan-colonic chromoendoscopy evaluation.
11038065|NCT04512612|Active Comparator|High Definition White Light Endoscopy|The patients enrolled in this group will undergo high definition white light endoscopy based evaluation
11038066|NCT04512599|Experimental|Single Arm|Open-label consumption of prebiotic bar(s); 1 bar for 3 days; followed by 2 bars for 7 days
11038067|NCT04512586|Experimental|His-pacing plus AV node ablation|"A His-pacing lead in combination with a backup RV pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. A standard DDD pacemaker or CRT-P device from Medtronic will be used.
~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed."
11038068|NCT04512586|Active Comparator|Pulmonary vein isolation|Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.
11038069|NCT04512560|Experimental|Structured Remote Surgical Coaching|Participants randomized to the intervention group will participate in a 3-month SRSC program in addition to CST. Participants will be asked to provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon prior to the coaching session. Each coach will review the video recording and will identify key themes for discussion. Coaching sessions will be structured using the modified PRACTICE model, will be conducted outside of the clinical environment, and will employ facilitative coaching methods to encourage participants to define specific intra-operative problems and conceptually troubleshoot various solutions.
11038070|NCT04512560|Active Comparator|Conventional Surgical Training|Participants randomized to the control group will continue of their usual general surgery residency training including attending scheduled teaching sessions, and continuing with assigned responsibilities on the ward and in the OR.
11038071|NCT04512547|Experimental|Obese Asthmatics|Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
11038072|NCT04512547|Active Comparator|Obese Non-Asthmatics|The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.
11038073|NCT04512534|Experimental|Sinitilimab+Chidamide|Anti-PD-1 antibody Sintilimab 200mg intravenously every 3 weeks; HDAC inhibitor Chidamide 30mg orally twice every week
11038074|NCT04512521||eosinophilic asthma|
11038075|NCT04512508|Other|Group 1, HIV negative patients.|Only HIV negative patients
11038076|NCT04512508|Other|Group 2, HIV positive patients|Only HIV positive patients
11038077|NCT04512495|Other|Patients with sarcoma|
11038078|NCT04512482|Experimental|Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained.
11038131|NCT04512105|Experimental|Dose Level 2 (DL2)|"Patients receive Pitavastatin (PIT) 4 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.
~If DL1 is well tolerated, the next cohort will progress to this dose level."
11038137|NCT04512066|Experimental|150 mg Once Daily (QD) RO6889450|Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks.
11055317|NCT04391075||Not exposed|Pudendal nerve block is NOT provided
11038079|NCT04512482|Placebo Comparator|Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained.
11038080|NCT04512469|No Intervention|Control Group|The control group will undergo standard running fascial closure with PDS .
11038081|NCT04512469|Experimental|Treatment Group - Mesh|The treatment group will undergo standard running fascial closure with PDS plus a low molecular weight mesh extending 3 cm from the fascial incision.
11038082|NCT04512456|Experimental|Active HIV-infected patients|Exercise training
11038083|NCT04512456|No Intervention|Inactive HIV-infected patients|No intervention.
11038084|NCT04512456|No Intervention|Healthy subjects|No intervention.
11038085|NCT04512443||1|42 women (treated with Daflon 1000 mg (study group))
11038086|NCT04512443||2|41 women (placebo (control group))
11038087|NCT04512430|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment: (Atezolizumab: 1200 mg, IV infusion+Bevacizumab: 15mg/Kg mg, IV infusion+Carboplatin: AUC6, IV infusion+Pemetrexed: 500 mg/m2, IV infusion) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery.Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3).
~Adjuvant treatment: Atezolizumab: 1200 mg, IV infusion Q4W (+/- 3 days) for 6 months (6 cycles) Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+7 days) from surgery and for 6 months (6 cycles)."
11038088|NCT04512417|Experimental|Combined radiotherapy group|
11038089|NCT04512417|Experimental|Immunotherapy alone group|
11038090|NCT04512404||hypercholesterolemia|"3-hydroxy-3-methylglutaric acid coenzyme A (HMG Co-A) reductase inhibitor Types of drug, dosage and frequency is according to the treating physician. This is an observational study.
~Duration of treatment: 3-5 months"
11038091|NCT04512391||Erector Spinae|patients who are administered ultrasound guided ESPB at T4 vertebrae level with long acting local anesthetic (%0,25 bupivacaine) and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
11038092|NCT04512391||Control|patients who are not administered any regional analgesic technique and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
11038093|NCT04512378|Experimental|IU Group Treatment|Clinical intervention arm
11038094|NCT04512365|Placebo Comparator|Placebo oral capsule|Participants will receive a placebo at their first or second laboratory visit.
11038095|NCT04512365|Experimental|THC|Participants will receive THC (7.5 mg) at their first or second laboratory visit.
11038096|NCT04512352|Experimental|Treatment group|Online curriculum has been delivered to this group of participants on an Internet-based platform
11038097|NCT04512352|No Intervention|Wait-list control group|Participants in wait-list control group would not have access to the online curriculum until the intervention process for treatment group is finished.
11038098|NCT04512339|Active Comparator|Dupilumab|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive dupilumab injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
11038099|NCT04512339|Placebo Comparator|Placebo|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive placebo injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
11038100|NCT04512326||Total or subtotal colectomy|Total or subtotal colectomy with ileorectal or ileosigmoid anastomosis
11038101|NCT04512313|Active Comparator|Group receiving rocuronium 0,3 mg/kg|Rocuronium 0,3 mg/kg at induction
11038102|NCT04512313|Active Comparator|Group receiving rocuronium 0,9 mg/kg|Rocuronium 0,9 mg/kg at induction
11038103|NCT04512287|Experimental|Experimental: Autologous PRP followed by Placebo Group|Participants in this group will receive the autologous intervention first, followed by the placebo intervention 6 months later.
11038104|NCT04512287|Experimental|Experimental: Placebo followed by Autologous PRP Group|Participants in this group will receive the placebo intervention first, followed by the Autologous PRP intervention 6 months later.
11038105|NCT04512274|Experimental|Test Article|
11038106|NCT04512274|No Intervention|Negative Control|
11038107|NCT04512261|Experimental|Tucatinib + Pembrolizumab + Trastuzumab|Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
11038108|NCT04512248|Experimental|Quit and Stay Quit Monday Model|
11038109|NCT04512248|No Intervention|Usual Care|
11038110|NCT04512235|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 77 deaths have been observed.
11038132|NCT04512092|Experimental|CMT-C group|Compassion Mind Training for Caregivers (CMT-C) is a 12-session structured program to be delivered in a group format, aiming to cultivate a compassionate-self and compassionate care practices in residential youth care.
11038133|NCT04512092|No Intervention|Control group|This group did not receive any mind training or group intervention during the study.
11038134|NCT04512079|Active Comparator|Prophylactic Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
11038111|NCT04512235|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 77 deaths have been observed.
11038112|NCT04512235|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) with CyBorD according to institutional SoC. Patients should initiate their CyBorD chemotherapy regimen within 7 days of receiving the first dose of study drug. It is the intent of this protocol that patients will receive CyBorD per institution SoC in the study, as long as they are tolerating it. However, after two cycles of CyBorD, if the patient is not benefiting from or tolerating CyBorD in the Investigator's judgement, the investigator may change the CyBorD regimen or stop it.
11038113|NCT04512209|Experimental|DCE-MRI|
11038114|NCT04512196|Experimental|Super-oxidised Solution|Peritoneal lavage with super-oxidised solution of at least 10 cc/kg and wound lavage with super-oxidised solution 1 cc/kg
11038115|NCT04512196|Placebo Comparator|Normal Saline|Peritoneal lavage with normal saline 0.9% of at least 10 cc/kg and wound lavage with normal saline 0.9% 1 cc/kg
11038116|NCT04512183|Experimental|High-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to high-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a reflective debriefing session.
11038117|NCT04512183|Active Comparator|Low-Fidelity Simulation|First, students will go through an inverted class on sepsis. Then, they will be submitted to low-fidelity simulation scenarios to care for patients with sespe. After the scenario, the students' physiological parameters (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation) will be measured. After the scenario, students will go through a feedback session.
11038118|NCT04512170|Experimental|A single dose HEC585（pilot trial arm）|Healthy subjects receive a single dose of HEC585
11038119|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 1）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
11038120|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 2）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
11038121|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 3）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
11038122|NCT04512170|Experimental|Single dose of HEC585 （Part 2，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
11038123|NCT04512157|Experimental|PATHS, Intervention preschools|These preschools implement PATHS for one school year
11038124|NCT04512157|No Intervention|Waitlist control preschools|Preschool as usual, which does have some social emotional learning but not PATHS specifically
11038125|NCT04512144|Experimental|Intervention|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a one month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion.
11038126|NCT04512144|No Intervention|Control|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion.
11038127|NCT04512131||Intermittent hemodialysis|patients who are going to undergo intermittent hemodialysis or patients who are going to switch dialysis mode to intermittent hemodialysis from continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate® platelet function analysis will be checked just before dialysis initiation and immediately after dialysis termination
11038128|NCT04512131||continuous renal replacement therapy|patients who are going to undergo continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate platelet function analysis will be checked within 24 hours after dialysis initiation and 48 hours after taking first blood sample
11038129|NCT04512105|Experimental|Dose Level -1 (DL-1)|"Patients receive Pitavastatin (PIT) 1 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.
~The 1 mg/day dose level will be held in reserve to allow dose reduction in those patients who cannot tolerate DL1."
11038130|NCT04512105|Experimental|Dose Level 1 (DL1)|"Patients receive Pitavastatin (PIT) 2 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.
~This is the starting dose level for the study."
11038315|NCT04510818|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
11038138|NCT04512066|Experimental|45 mg QD RO6889450|Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks.
11038139|NCT04512066|Placebo Comparator|Placebo|Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks.
11038140|NCT04512066|Active Comparator|4 mg QD Risperidone|Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks.
11038141|NCT04512053|Experimental|TAS-303|
11038142|NCT04512053|Placebo Comparator|Placebo|
11038143|NCT04512040|Experimental|Yoga Dyads AD patients and Caregivers|Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
11038144|NCT04512027|Experimental|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class+Stand of care|Tablet chewed for 5 days along and given alongside standard of care
11038145|NCT04512027|No Intervention|Standard of Care|All patients will receive currently practiced standard of care medicines
11038146|NCT04512014||major liver surgery|Patients undergoing major liver surgery
11038147|NCT04512001|Experimental|MSB11456|
11038148|NCT04512001|Active Comparator|RoActemra®|
11038149|NCT04511988|Experimental|Experimental|blood sample (20 ml) and biopsy
11038150|NCT04511975|Experimental|IBI188 + azacitidine|Participants will receive IBI188 in combination with azacitidine
11038151|NCT04511962||Fast track group|Participants randomised to the fast track group will receive the pulmonary rehabilitation intervention 14 ± 7 days after randomisation.
11038152|NCT04511962||Wait list group|Participants randomised to the wait-list group will receive the pulmonary rehabilitation intervention 56 ± 7 days after randomisation.
11038153|NCT04511949|Other|No arm|No arm
11038154|NCT04511936|Active Comparator|i-Lumen AMD Active|
11038155|NCT04511936|Sham Comparator|i-Lumen AMD Sham|
11038156|NCT04511923|No Intervention|Standard Care|Standard care
11038157|NCT04511923|Experimental|Heparin|Standard care plus nebulised unfractionated heparin 25000 units every 6 hours for 10 days
11038158|NCT04511910||Early surgery Group 1|The surgery is performed within the first 3 days
11038159|NCT04511910||Early surgery Group 2|Surgery is performed between the fourth and seventh day
11038160|NCT04511910||Early surgery Group 3|Surgery is performed more than 7 days from the onset of symptoms
11038161|NCT04511897|Experimental|Experimental group|oral An'ningpai Enteric Soft Capsules (300 mg,three times daily) for 12 months.
11038162|NCT04511897|No Intervention|Control group|No experimental durgs used.
11038163|NCT04511871|Experimental|CCT303-406|"To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CCT303-406 cell therapy in patients with HER2-positive (IHC 3+ in ≥50% tumor cells) relapsed or refractory solid tumors.
~Dose cohorts:
~Dose 1: 3x10^5 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
~Dose 2: 1x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
~Dose 3: 3x10^6 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion
~Dose 4: 1x10^7 CCT303-406 CAR-positive T cells/kg body weight, intravenous infusion"
11038164|NCT04511858|Experimental|Running endurance|Athletes wiil run for 5 hours in a row.
11038165|NCT04511858|Experimental|Cycling endurance|Athletes wiil cycle for 5 hours in a row.
11038166|NCT04511845|Experimental|Dose escalation cohort of SPYK04|Patients will receive SPYK04 at escalated dose.
11038167|NCT04511845|Experimental|Expansion part in NSCLC, ovarian cancer and other solid tumors|Patients will receive SPYK04 at the recommended dose.
11038168|NCT04511832|Experimental|Acupuncture to NSAIDs|
11038169|NCT04511832|Experimental|NSAIDs to Acupuncture|
11038170|NCT04511832|Experimental|Combined both acupuncture and NSAIDs|
11038171|NCT04511819|Experimental|Losmapimod|COVID-19 patients with PCR confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 14 days.
11038172|NCT04511819|Placebo Comparator|Placebo|COVID-19 patients with PCR confirmation will receive Placebo twice daily given as two tablets per dose by mouth; for a total of 4 tablets daily for 14 days.
11038173|NCT04511806||Primary Subjects|Children (age 0-21) with a cancer predisposition syndromes (CPS).
11038174|NCT04511806||Relatives of Children with CPS|Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members.
11038175|NCT04511793|Experimental|Hepatic Artery Infusion (HAI)|The Medtronic Synchromed II pump with the Codman® Catheter will be used to create the investigational device. The Medtronic Synchromed II pump is a surgically implantable device that allows for the delivery of high doses of chemotherapy directly to the liver, in order to treat cancer. The device is surgically implanted into a subcutaneous pocket in the abdominal wall, and the catheter is inserted into the arterial system of the liver, allowing for chemotherapeutic delivery.
11038176|NCT04511780||Caregivers|• Caregivers (doctors senior and junior, nurses, aid nurses) involved in the staff (permanent or transient, full or partial time) of ICU patients during Covid-19 outbreak
11038177|NCT04511767||ASD group|the autism spectrum disorder group
11038178|NCT04511767||GDD group|the global developmental disorder group
11038179|NCT04511767||LD group|the language disorder group
11038180|NCT04511754|Experimental|Experiential Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the experiential training condition, the trainees will receive information about the skills with examples and will have opportunity to practice using short video clips of actors portraying clients. The trainees will be asked to respond to the short clips using the skills they learned. A trainer (a graduate student in clinical psychology) will pause and process the trainees' reactions after they respond to each practice video clip and will provide feedback to the trainees about their performance on the practice.
11038181|NCT04511754|Active Comparator|Standard Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the standard training condition, the trainee will receive a lecture about the skills including rationale and research background, examples, and opportunities to ask questions. The standard training condition will not include opportunities for practice or live discussion and feedback from the trainer.
11038182|NCT04511741||invasive mechanical ventilation|
11038183|NCT04511741||non invasive mechanical ventilation|
11038184|NCT04511728|Experimental|HSK3486|
11038185|NCT04511728|Active Comparator|Propofol|
11038186|NCT04511715|Active Comparator|Intravitreal Bevacizumab IVB group|
11038187|NCT04511715|Sham Comparator|undergo regular follow-up for Diabetic Retinopathy|
11038188|NCT04511702|Experimental|Pegloticase 60 Minute Infusion with methotrexate (MTX)|Pegloticase 60 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
11038189|NCT04511702|Experimental|Pegloticase 45 Minute Infusion with methotrexate (MTX)|Pegloticase 45 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
11038190|NCT04511702|Experimental|Pegloticase 30 Minute Infusion with methotrexate (MTX)|Pegloticase 30 Minute Infusion with methotrexate (MTX). Participants will receive MTX (15 mg) (weekly) during the Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 24 weeks
11038191|NCT04511689||test group|bone grafting with gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
11038192|NCT04511689||control group|bone grafting with xenogenic deproteinized bone matrix mixed with autobone
11038193|NCT04511663|Active Comparator|intervention group|The intervention group received assertive community treatment, in which the team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers.
11038194|NCT04511663|Other|control group|The control group received basic public health services which is regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge.
11038195|NCT04511650|Experimental|Razuprotafib|
11038196|NCT04511650|Placebo Comparator|Placebo|
11038197|NCT04511637|Experimental|Test C: 15 mg ODT with water, then 15 mg film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
11038198|NCT04511637|Experimental|Test C: 15 mg film-coated tablet, then 15 mg ODT with water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
11038199|NCT04511637|Experimental|Test D: 15 mg ODT without water, then 15 film-coated tablet|Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state
11038200|NCT04511637|Experimental|Test D: 15 mg film-coated tablet, then 15 mg ODT without water|Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
11038201|NCT04511624|Experimental|Cohort 1|IBI112 SC dose1
11038202|NCT04511624|Experimental|Cohort 2|IBI112 SC dose2
11038203|NCT04511624|Experimental|Cohort 3|IBI112 SC dose3
11038204|NCT04511624|Experimental|Cohort 4|IBI112 IV dose4
11038205|NCT04511624|Experimental|Cohort 5|IBI112 IV dose3
11038206|NCT04511624|Experimental|Cohort 6|IBI112 SC dose5
11038207|NCT04511624|Experimental|Cohort 7|IBI112 IV dose5
11038208|NCT04511611|Experimental|Test A: 10 mg ODT with water, then 10 mg film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
11038209|NCT04511611|Experimental|Test A: 10 mg film-coated tablet, then 10 mg ODT with water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
11038210|NCT04511611|Experimental|Test B: 10 mg ODT without water, then 10 film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
11038211|NCT04511611|Experimental|Test B: 10 mg film-coated tablet, then 10 mg ODT without water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
11038212|NCT04511598|Experimental|Bellus 3D Face Camera Pro|"Every single patient will be diagnosed using 3D imaging system Bellus 3D Face Camera Pro to be compared to the direct measurements obtained from direct anthropometry."
11038213|NCT04511598|Experimental|Planmeca ProMax 3D Proface|"Every single patient will be diagnosed using 3D imaging systems Planmeca ProMax 3D Proface to be compared to the direct measurements obtained from direct anthropometry."
11038214|NCT04511585|Experimental|GLMC experimental arm|GLMC experimental arm receiving a 24-month (6 weeks each year) multilevel and TPB-based program aiming to promote PA practice
11038215|NCT04511585|No Intervention|the control arm|the control arm that do not receive any intervention
11038252|NCT04511299|Experimental|Fish oil-enriched intravenous lipid emulsion|SMOFlipid 20%, given for 3 consecutive days with 1-4 g/kg/day.
11038253|NCT04511299|Active Comparator|Standard intavenous lipid emulsion|Lipofundin 20%, given for 3 consecutive days with 1-4 g/kg/day.
11038216|NCT04511572|No Intervention|Standard Care: burr hole surgery|Patients who have had burr hole evacuation for symptomatic chronic subdural hematomas will be followed in the outpatient clinic after hospital discharge at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
11038217|NCT04511572|Active Comparator|embolisation middle meningeal artery|Besides standard treatment those patient who are allotted to the intervention group will receive embolization of the middle meningeal artery until 72 hours after burr hole evacuation. After hospital discharge follow-up is at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
11038218|NCT04511559||chronic gastritis|This group will include 80 patients with chronic gastritis and the diagnoses will be based on the British Society of Gastroenterology guidelines.
11038219|NCT04511559||Moderate to severe atrophy/intestinal metaplasia/|This group will include 80 patients with Moderate to severe atrophy/intestinal metaplasia/ and the diagnoses will be based on British Society of Gastroenterology guidelines.
11038220|NCT04511559||gastric cancer|This group will include 380 patients with gastric cancer and the diagnoses will be based on British Society of Gastroenterology guidelines.
11038221|NCT04511546|Experimental|BPET Scan|
11038222|NCT04511533|Experimental|Treatment Arm|The recommended dosage of dacomitinib is 45 mg taken orally once a day at approximately the same time each day, until disease progression, participant refusal/lost to follow-up, or unacceptable toxicity occurs.
11038223|NCT04511520|Experimental|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
11038224|NCT04511520|Experimental|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
11038225|NCT04511520|No Intervention|Control|Standard follow-up at the participating heart center
11038226|NCT04511507||liver failure|patients diagnosed with acute liver failure or acute on chronic liver failure in accordance with national guidelines who require 3 consecutive sessions of hemoadsorption
11038227|NCT04511494|Active Comparator|OIT peanut|Children with peanut allergy receiving peanut OIT. Peanut challenge are done before randomization and one and three years after inclusion.
11038228|NCT04511494|No Intervention|Peanut avoidance|Children with peanut allergy not undergoing OIT peanut. Peanut challenge are done Before randomization and one and three years after inclusion.
11038229|NCT04511494|No Intervention|Healthy controls|Control Group with non-allergic, age-matched children. No challenges are performed in this group.
11038230|NCT04511481||platinum-resistant group|
11038231|NCT04511481||platinum-sensitive group|
11038232|NCT04511468|Experimental|Experimental Group|A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard lifestyle counseling
11038233|NCT04511468|Placebo Comparator|Control group|Placebo with standard lifestyle counseling
11038234|NCT04511455|Experimental|Experimental|"Cabozantinib peroral 60 mg/day
~A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib.
~The study treatment will be limited to a maximum of 12 months (including interruptions)."
11038235|NCT04511442||Bariatric surgery|Women with obesity, with a bariatric surgery
11038236|NCT04511442||Control|Women with obesity, without a bariatric surgery
11038237|NCT04511429||Kidney transplant patients|Patients submitted to kidney transplantation.
11038238|NCT04511429||Liver transplant patients|Patients submitted to liver transplantation.
11038239|NCT04511429||Oncological patients|Oncological patients submitted to chemotherapy.
11038240|NCT04511416|Active Comparator|Intervention|Metformin
11038241|NCT04511416|Placebo Comparator|Placebo|Placebo
11038242|NCT04511390|Experimental|Transparent, reusable respirator|Transparent, reusable elastomeric respirator that has been designed to fit multiple different face sizes and shapes.
11038243|NCT04511377|Experimental|Digital Healthcare System Rehabilitation|Rehabilitation using Uincare Homeplus
11038244|NCT04511377|Active Comparator|Conventional Rehabilitation|Rehabilitation using Brochure
11038245|NCT04511364|Experimental|AGN1 treated patients|Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
11038246|NCT04511351|Experimental|RT+GDP+Chidamide|IMRT followed by GDP chemotherapy with chidamide during radiation and chemotherapy phase
11038247|NCT04511351|No Intervention|RT+GDP|IMRT followed by GDP chemotherapy without chidamide during radiation and chemotherapy phase
11038248|NCT04511338|Experimental|Circuit A|Circuit (A) includes the dialyzer with Endexo and the CombiSet bloodline
11038249|NCT04511338|Experimental|Circuit B|Circuit (B) includes dialyzer with Endexo and the Streamline bloodline
11038250|NCT04511325|Other|Potato Regimen Arm|All participants will be randomly assigned to receive the potato regimen daily for the 12-week treatment period, separated by a 2-week washout.The potato regimen (75 grams of baked white russet potato with the skin) and refined grain (100 grams of long grain white rice) regimen will be matched for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day.
11038251|NCT04511325|Other|Refined Grain Regimen Arm|All participants will be randomly assigned to the calorie-matched refined grain daily for the 12-week treatment period, separated by a 2-week washout.The refined grain (100 grams of long grain white rice) regimen will be matched to the potato regimen for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day. Long-grain boiled white rice also has a similar glycemic index to that of a baked white potato.
11038254|NCT04511286|Experimental|Internet-delivered exposure-based treatment|Eight weeks of therapist-guided exposure-based treatment delivered via the Internet.
11038255|NCT04511260|Experimental|VRF Treatment|"A treatment of the vaginal canal using the NuEra Tight VRF small area handpiece. A treatment of the introitus and vestibule using the NuEra Tight VRF small area hand piece (optional).
~Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment."
11038256|NCT04511247|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
11038257|NCT04511247|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
11038258|NCT04511234|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
11038259|NCT04511234|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
11038260|NCT04511221|Placebo Comparator|Placebo|15 mg capsule containing rice maltodextrin and medium chain coconut triglycerides
11038261|NCT04511221|Active Comparator|Bifidobacterium animals subsp. lactis BL04|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 with rice maltodextrin and medium chain coconut triglycerides as a filler material
11038262|NCT04511221|Experimental|Bifidobacterium animals subsp. lactis BL04+PreforPro|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 and 1x10^6 PFU of PreforPro (Commercial phage preparation) with rice maltodextrin and medium chain coconut triglycerides as a filler material
11038263|NCT04511208|Experimental|Cooling Ice vest|Evaluate surgeons' self-rated thermal comfort using the cooling Ice vest during prolonged and strenuous surgery
11038264|NCT04511208|Experimental|without Cooling Ice Vest|Evaluate surgeons' self-rated thermal comfort without using the Cooling Ice Vest during prolonged and strenuous surgery
11038265|NCT04511195|Experimental|Sphaeralcea angustifolia standardized extract|Patients with diagnosis of knee osteoarthritis will be included in the experimental group and assigned the treatment consisting of a topical administration of a gel elaborated with the pharmaceutical formulation prepared with a standardized extract from S. angustifolia, which will be administered three times a day for four weeks.
11038266|NCT04511195|Active Comparator|Diclofenac 2 %|Patients with diagnosis of knee osteoarthritis will be included in the control group and assigned the treatment consisting of a topical administration of a gel elaborated with 2% diclofenac, which be administered three times a day for four weeks
11038267|NCT04511182|Experimental|exercise intervention group|Patients will receive standard medications plus EBCR 。Education covering topics related to AMI and exercise for AMI will be implemented and any consultations on exercise prescription and disease management will be explained by a cardiac rehabilitation team consisting of cardiologists, cardiology nurses and physiotherapists.
11038268|NCT04511182|No Intervention|Usual care group（control）|Patients will receive standard medications according to national guidelines, as well as education and consultations as intervention group. However，no exercise prescription is given,
11038269|NCT04511169|Experimental|remainder|The participants who are inactive for more than 48 hours after recieving new content will recieve a remainder, in the format of a text message and an email.
11038270|NCT04511169|No Intervention|non-remainder|The participants who are inactive for more than 48 hours after recieving new content will NOT recieve a remainder, in the format of a text message and an email.
11038271|NCT04511156|Experimental|Foundational Helping Skills|The Foundational Helping Skills training will be intervention to be evaluated in this study. The Foundational Helping Skills is a flexible curriculum, with an approximate 3-day (20 hour) duration to be modified based on context and personnel. The Foundational Helping Skills is a human-centered design competency-based training in foundational helping skills. The training curriculum has been developed in a modular format, with each module relating to specific foundational helping skills (e.g., non-verbal communication, confidentiality, etc). The training curriculum can be found. The general training outline includes two days of foundational helping skill modules, brief role-play competency assessments at the end of each foundational helping skills training day to inform trainers which competencies need remediation, and a half-day of training that involves a remediation of the specific foundational helping skills that have been identified via the brief role-play assessments.
11038272|NCT04511130|Experimental|MT-401 following HSCT|Treatment with MT-401 at 90 days following HSCT
11038273|NCT04511130|No Intervention|Standard of Care following HSCT|Standard of Care
11038274|NCT04511130|Experimental|MT-401 following relapse|Treatment with MT-401 following relapse after first HSCT
11038275|NCT04511117|Active Comparator|Control Group|Root canal treatment with Mpro gold rotary system and ZOE sealer with composite restorations.
11038276|NCT04511117|Experimental|Endocrown Group|ProTaper Next rotary system and iRoot SP sealer will be used for root canal treatment, followed by endocrown restorations.
11038277|NCT04511104|Active Comparator|Standard of Care|"Standard of care treatment:
~- including passive / assisted / active movements, stretching, functional exercise, scar treatment
~Duration: up to 8 weeks"
11038278|NCT04511104|Experimental|Exercise|"Standard of care + added exercises
~Exercise type: resistance and aerobic exercise
~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)
~Duration: up to 8 weeks"
11038279|NCT04511091||Vats Group|patients underwent planned VATS lobectomy for NSCLC from the Italian VATS Group Database (a validated, risk-adjusted, prospective, outcomes-based program with 50 participating hospitals in Italy) were included in the analysis.
11038280|NCT04511078|Experimental|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
11038312|NCT04510831|Experimental|Refined maize|Two portions of porridge prepared with refined maize flour with extrinsic addition of labelled FeSO4 (isotopic iron 54)
11038313|NCT04510831|Experimental|T.molitor native chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) native chitin and extrinsic addition FeSO4 (isotopic iron 58)
11038314|NCT04510831|Experimental|T.molitor reduced chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) reduced chitin and extrinsic addition FeSO4 (isotopic iron 58)
11038281|NCT04511065|Experimental|Intervention Group|The intervention group will be provided with a survey to determine areas of interest to guide the 7-week literacy intervention plan of completing a newsletter. Students will complete the newsletter virtually using secure Zoom meetings 2x per week for 30 minutes per session. The results of the GORT 5 and TOC will be used to determine the baseline reading skills of the students and each researcher will use the results of the assessments to guide the intervention with the newsletter topic that is chosen by the student. For example, if the GORT 5 notes deficiency with reading accuracy, the focus of the intervention will be ensuring that reading accuracy is a focus of the summary that is crafted by the student for the newsletter.
11038282|NCT04511065|No Intervention|Control Group|The control group will not participate in the newsletter creation for the 7-week study period. These students will engage in the after-school programs at the Center, some of which may be literacy-based, but not the prescriptive model that is being followed by the researchers.
11038283|NCT04511052|Experimental|Carotenoid + Probiotic|"Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement
~Probiotic: 1 capsule daily containing 10 x 10^9 CFU of a proprietary strain
~Total duration: 10 weeks"
11038284|NCT04511052|Placebo Comparator|Carotenoid + Placebo|"Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement
~Placebo: 1 capsule daily containing the same carrier material of the probiotic, that is also similar in size, shape, and taste.
~Total duration: 10 weeks"
11038285|NCT04511039|Experimental|Treatment Arm|Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11038286|NCT04511026|Experimental|Lymphoseek/SPECT-CT/Indocyanine|The subject will receive f 0.5 mL each Lymphoseek into the uterine cervix prior to surgery and subsequent SPECT/CT imaging preoperatively. Intraoperatively, following anesthesia induction, Indocyanine Green (0.5 mL) will be injected into the uterine cervix. Using near-infrared imaging, efferent lymphatic vessels and lymph nodes will be visualized and confirmed by detected radioactivity using a laparoscopic gamma counter. The preoperatively obtained SPECT/CT images will help guide the surgery.
11038287|NCT04511013|Experimental|Arm I (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11038288|NCT04511013|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.
11038289|NCT04511000|Experimental|Experimental group|
11038290|NCT04511000|Active Comparator|Comparator group|
11038291|NCT04510987|Experimental|Experimental: Treatment 1|Participants in Groups 1-4 and Group 6 will receive a single dose of BAY2433334 on one occasion. Participants in Group 5 will receive a single dose of BAY2433334 on a dialysis-free day.
11038292|NCT04510987|Experimental|Experimental: Treatment 2|Participants in Group 5 will receive a single dose of BAY2433334 on a day with dialysis treatment.
11038293|NCT04510974||Cervical SCI|Ages between 21-70 years old Injured between C1-T1 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
11038294|NCT04510974||Thoracic SCI|Ages between 21-70 Injured between T6-T12 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago
11038295|NCT04510974||Able-bodied Control|Ages between 21-70
11038296|NCT04510961|Active Comparator|Paraffin baths therapy (PBT) :group A|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks.
11038297|NCT04510961|No Intervention|Control group (B)|receive routine skin care program ; lifestyle change, emollients and moisturizers
11038298|NCT04510948|Experimental|Intervention (Implementing Patient Priorities Care)|Patient Priorities Care requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences (collectively referred to as health priorities). Participants will be contacted by a trained priorities facilitator in-person or over the phone to elicit their health priorities. This information will be documented in the PPC- GOALS AND PREFERENCES form in the EHR and shared with the clinicians who will then use the Patient Priorities Care approach with patients to inform and guide treatment decisions.
11038299|NCT04510948|No Intervention|Usual Care (Not implementing PPC)|Patients will receive routine clinical care.
11038300|NCT04510935|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
11038301|NCT04510935|Active Comparator|local anesthesia|In this group, patients will receive radiofrequency ablation under local anesthesia.
11038302|NCT04510922|Experimental|Droxidopa|100-600mg droxidopa TID
11038303|NCT04510909|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
11038304|NCT04510896|No Intervention|Pre-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention 6-month period. Only referrals to Michigan Medicine (MM) genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
11038305|NCT04510896|Experimental|Post-InheRET|Determine appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the post-intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
11038306|NCT04510883|Experimental|PACO|Participants are asked to use the intervention for eight weeks.
11038307|NCT04510883|Other|Waiting list + PACO|Participants receive the same intervention, but only after a waiting period of four weeks.
11038308|NCT04510870|Experimental|Experimental group|"infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)
~infusion is NaCl"
11038309|NCT04510870|Experimental|NaCl infusion group|"infusion is NaCl
~infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)"
11038310|NCT04510844|Experimental|Study Drug Group|Participants who will receive a shot of the Evolocumab at Visit 3 and self-administer the rest of the shots at visit 4-7.
11038311|NCT04510844|Placebo Comparator|Placebo group|Participants who will receive a Placebo shot at Visit 3 and self-administer the rest of the shots at visit 4-7.
11038316|NCT04510805|Experimental|Intervention Arm|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.
~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
11038317|NCT04510805|No Intervention|Control Arm|Usual standard of care. Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.
11038318|NCT04510779|Experimental|Heart Failure Patients|This will be a single arm study of heart failure patients with acute decompensation
11038319|NCT04510766||Part A|Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
11038320|NCT04510766||Part B|"FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for liquid biopsy will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent
~(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of liquid biopsy for future analysis."
11038321|NCT04510740||Hepatocellular Carcinoma (HCC)|Patients with Hepatocellular Carcinoma (HCC)
11038322|NCT04510740||Cholangiocarcinoma (CCC)|Patients with Cholangiocarcinoma (CCC)
11038323|NCT04510727|Experimental|OCT Guided C&D Group|Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C&D.
11038324|NCT04510714|Experimental|Microwave ablation arm|Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation
11038325|NCT04510688||Managed Access Program (MAP) patients|Patients with RCC treated with cabozantinib under a Managed Access Program (MAP) prior to Cabometyx® marketing authorization
11038326|NCT04510688||Real World (RW) patients|Patients with RCC treated with cabozantinib as routine clinical prescription (Real World), with treatment started after Cabometyx® marketing authorization
11038327|NCT04510675|Experimental|Test Article|
11038328|NCT04510675|Sham Comparator|Negative Control|
11038329|NCT04510662|Experimental|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
11038330|NCT04510662|No Intervention|Control|Patients in this group will receive standard care.
11038331|NCT04510649|Experimental|Surufatinib and Rabeprazole (Part A)|Part A: Surufatinib 300 mg on study days 1 and 11 Rabeprazole 40 mg on study days 5 - 11
11038332|NCT04510649|Experimental|Surufatinib and Rifampin (Part B)|Part B: Surufatinib 300 mg on study days 1 and 12 Rifampin 600 mg on study days 5-15
11038333|NCT04510636|Experimental|Pembrolizumab and Bendamustine|"The study drugs will be given in 3 week periods called cycles.
~Pembrolizumab is available in powder form or as a liquid for infusion. Pembrolizumab at a dose of 200 mg will be given over 30 minutes, once every cycle for up to 35 cycles (approximately 24 months).
~Bendamustine is available in powder form for injection. Bendamustine at a dose of 90 mg/m2 will be given over 60 minutes, on Days 1 and 2 of every cycle for up to 6 cycles."
11038334|NCT04510623||COVID-19 Patients on ARBs|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.
11038335|NCT04510623||COVID-19 Patients on ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.
11038336|NCT04510623||COVID-19 Patients on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.
11038337|NCT04510623||COVID-19 Patients not on ARBs or ACE inhibitors|This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.
11038338|NCT04510610|Experimental|Camrelizumab plus decitabine|Decitabine 10 mg/day, days 1-5; Camrelizumab 200 mg, day 8, every 3 weeks.
11038339|NCT04510597|Active Comparator|Arm 1: Continued Systemic Therapy Only|"Nivolumab 240 mg IV 1 q 2 weeks
~OR
~Nivolumab 480 mg IV 1 q 4 weeks
~OR
~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID
~OR
~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
11038340|NCT04510597|Experimental|Arm 2: Nephrectomy and Continued Systemic Therapy|"Continued systemic therapy as above, plus:
~Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization."
11038341|NCT04510584|Experimental|Atezolizumab and Bevacizumab|"A cycle will be every 3 weeks.
~Atezolizumab will be given intravenously (by vein) at a dose of 1200 mg once every cycle. Bevacizumab will be given intravenously at a dose of 15 mg/kg once every cycle. Up to 17 cycles of study treatment may be given.
~Participants may be able to receive the study treatment for more than 17 cycles if the participants and the study doctor thinks that they are benefiting."
11038342|NCT04510571|Active Comparator|Protaper Next|Protaper Next group (n=25): The instrumentation of mesial and distal canals were done according to manufacturer's recommendations using X1 and X2 (25.06) at a rotational speed of 300 rpm. Then X3 and X4 (40.06) instruments were used to enlarge distal canals in order to compare the results with the Reciproc Blue group. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
11038343|NCT04510571|Active Comparator|Reciproc Blue|Reciproc Blue group (n=25) : The canals were shaped with in accordance with the manufacturer's recommendations. R25 (25.08) instrument was introduced into the canal with slow pecking movement within a 3 mm range each time. The flutes and remnants were cleaned after 3 pecking moves. Then R40 instrument (40.06) was selected to shape the distal canals as the #20 K file was passively introduced to the working length. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
11038344|NCT04510558|Experimental|Intervention (mesh)|
11038346|NCT04510545||Treatment Group|All patients will undergo CAD of any diminutive polyps found in the rectosigmoid on colonoscopy
11038347|NCT04510532||Patients with Breast Cancer who use pyrotinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
11038348|NCT04510532||Patients with Breast Cancer who use apatinib|The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given apatinib as having HER2-negative breast cancer with no metastasis.
11038349|NCT04510532||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
11038350|NCT04510506|Experimental|Artificial Pancreas Therapy|Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.
11038351|NCT04510506|No Intervention|Usual Care + CGM|Participant will use their usual diabetes care along with a study CGM.
11038352|NCT04510493|Active Comparator|active treatment arm|Treatment with Canakinumab i.v. administered over 2 hours
11038353|NCT04510493|Placebo Comparator|placebo treatment arm|placebo treatment
11038354|NCT04510480||cardiac arrest|"Out of hospital cardiac arrest patients (Historical cohort) from 1st January 2009 and 30th June 2020.
~Out of hospital cardiac arrest patients from 1st July 2020 and 31st December 2025."
11038355|NCT04510467||case group|RMD patients with COVID 19 infection
11038356|NCT04510467||control group|RMD patients without COVID 19 infection
11038357|NCT04510454|Experimental|RT-PCR and ddPCR sampling analyses|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
11038358|NCT04510428|Experimental|OSIG-Eye Drop|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
11038359|NCT04510428|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
11038360|NCT04510415|Experimental|Olmutinib 600mg|HM61713 600 mg (1 x 400 mg + 1 x 200 mg tablets) once daily (QD)
11038361|NCT04510402|Experimental|Safety Analysis|Evaluate safety of PVP-I nasal swabs single daily application
11038362|NCT04510402|Experimental|Tolerability analysis|Investigate the dosing of PVP-I nasal swabs daily single dosing versus double dosing
11038363|NCT04510389|Placebo Comparator|Placebo|volunteers will receive 28 sachets containing 30g of maltodextrin to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
11038364|NCT04510389|Experimental|Whey|volunteers will receive 28 sachets containing 30g of whey protein to be consumed daily for 4 weeks. After that they will return to the 4-week visit and assessment when they will receive 28 sachets for the next 28 days when will return for the final vist and assessment.
11038365|NCT04510376|Experimental|Test article|
11038366|NCT04510376|Active Comparator|Histamine Positive Skin Test Control|
11038367|NCT04510376|Placebo Comparator|Aqueous Negative Control|
11038368|NCT04510350||MS CIS+|
11038369|NCT04510350||Healthy volunteers|
11038370|NCT04510337|Active Comparator|Standard rocuronium|patients received rocuronium 0.6mg/kg
11038371|NCT04510337|Experimental|Magnesium|patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes
11038372|NCT04510324|Active Comparator|Red meat patties|Participants will be randomized to group 1: Red meat, ''Costco Kirkland Signature 1/4 lb Ground Beef Patties'' (Beef burger). Participants will be given two patties per day.
11038373|NCT04510324|Experimental|Plant-based patties|"Participants will be randomized to group 2: plant-based burger which contains no animal products. The Plant-based burger selected is ''Beyond Burger (https://www.beyondmeat.com/products/the-beyond-burger/ ). Participants will be given two patties per day."
11038374|NCT04510311|Experimental|PET/CT scan with radiotracer [18F]3F-PHPG|Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.
11038375|NCT04510311|Active Comparator|Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG|FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
11038376|NCT04510298|Experimental|SP-624|SP-624 oral capsule, 20 mg once daily
11038377|NCT04510298|Placebo Comparator|Placebo|Placebo oral capsule, once daily
11038378|NCT04510285|Placebo Comparator|Arm A|Participants will receive trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) plus placebo
11038379|NCT04510285|Experimental|Arm B|Participants will receive trastuzumab in combination with pembrolizumab 200 mg IV
11038380|NCT04510272|Experimental|High risk critically ill patients|Critically ill patients requiring vasopressor support or mechanical ventilation will receive aloud real time ICU diary reading intervention
11038381|NCT04510259|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthesize the whole upper limb.
11038382|NCT04510246|Experimental|Intervention|Practitioners randomised to the intervention arm will receive the standard of care surveillance letter if the notification is new. Both new and repeat notifications will receive further enhanced case support during the project if required. Support can be provided at the first phone call, or if accepted and required, in a 12-week period during which the DoH health care worker can do follow-up calls with the GP or directly with the patient to inform the patient and enhance linkage back to their GP. At the end of the 12-week period, a follow-up call we be carried out for the project evaluation.
11038383|NCT04510246|No Intervention|Control|All practitioners randomised to this arm will be contacted by telephone approximately 12 weeks after an HCV notification has been made from the laboratory to the Department of Health.This is not current standard practise and will be performed by the DoH HCV health worker for the project evaluation purpose. At this phone call consent will be sought for the GP to provide information on their clinical management of the notified patient. The details of the clinical management survey are provided as Appendix B. Details provided or missing from the standard DoH surveillance form would be confirmed with the GP at this phone call. Three attempts will be made to contact the practitioner to complete the survey within a 30-day period before they are determined to be unable to be contacted.
11055318|NCT04391062|Experimental|intraoperative PDT 400J/cm²|
11038384|NCT04510233|Experimental|Ivermectin nasal spray|Ivermectin administered as nasal spray (one ml in each nostril two times daily)
11038385|NCT04510233|Experimental|Ivermectin oral|Ivermectin administered orally (one tablet 6 mg three times daily) for 72 hours plus the standard care of COVID-19 cases.
11038386|NCT04510233|Experimental|standard care|COVID-19 cases will receive standard of care [oxygen via masks or ventilators]
11038387|NCT04510220|Experimental|Subjects diagnosed with relapsing forms of multiple sclerosis|We plan to enroll 10 subjects with relapsing MS. All enrolled subjects will receive Ofatumumab 20 mg every 4 weeks, subcutaneously for 9 months during the study. Loading doses will be administered initially at 1, 7 and 14 days. During the study period, all enrolled subjects will undergo five PET scans using [F-18] PBR06 at 0, 5, 28, 90 and 273 days after starting treatment with Ofatumumab.
11038388|NCT04510207|Experimental|Investigational Vaccine1|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 & D21.
11038389|NCT04510207|Experimental|Investigational Vaccine 2|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 & D21.
11038390|NCT04510207|Placebo Comparator|Placebo|Participants will receive 2 doses of Placebo according to the immunization schedule of D0 & D21.
11038391|NCT04510194|Experimental|PEP Cohort - Treatment Group|Participants in the PEP cohort of the trial are those who do not test positive for SARS-COV-2 infection at the time of screening but had a close exposure to SARS-CoV-2 infected person (defined by current CDC definition of close contact). Participants in this arm and group will receive metformin.
11038392|NCT04510194|Placebo Comparator|PEP Cohort - Placebo Group|Participants in the PEP cohort of the trial are those who do not test positive for SARS-COV-2 infection at the time of screening but had a close exposure to SARS-CoV-2 infected person (defined by current CDC definition of close contact). Participants in this arm and group will receive placebo.
11038393|NCT04510194|Experimental|Treatment Arm - Treatment Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the metformin.
11038394|NCT04510194|Placebo Comparator|Treatment Arm - Placebo Group|Participants in the treatment arm of the trial are those who test positive for SARS-COV-2 infection at the time of screening. Participants in this arm and group will receive the placebo.
11038395|NCT04510181|Experimental|Amino acid-based blend|The amino acid-based blend will be administered PO daily for the study duration
11038396|NCT04510168||MRI Only|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at least 50-60 people with dementia (as determined by the ongoing NOMAS procedures).
11038397|NCT04510168||MRI and PET|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at 20 participants with dementia and 40 participants without (as determined by the ongoing NOMAS procedures). In addition to MRI, participants in this group will have three PET studies.
11038398|NCT04510155|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
11038399|NCT04510155|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
11038400|NCT04510129||head and neck squamous cell carcinoma (HNSCC)|
11038401|NCT04510129||non-small-cell lung cancer (NSCLC)|
11038402|NCT04510129||small cell lung cancer (SCLC)|
11038403|NCT04510129||urothelial carcinoma (UCC)|
11038404|NCT04510129||gastric or gastroesophageal junction adenocarcinoma|
11038405|NCT04510129||cervical cancer|
11038406|NCT04510129||esophageal squamous cell carcinoma (ESCC)|
11038407|NCT04510129||triple-negative breast cancer (TNBC)|
11038408|NCT04510129||hepatocellular carcinoma (HCC)|
11038409|NCT04510129||renal cell carcinoma (RCC)|
11038410|NCT04510129||colorectal cancer (CRC)|
11038411|NCT04510116|Experimental|AIM preventive intervention|Families were assigned to receive a 6 session, 12 hour prevention program in their community.
11038412|NCT04510116|No Intervention|Control|Families were assigned to no intervention control.
11038413|NCT04510103|Other|Regression Group|The Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then entered a 2-week regression period (no moisturizer usage).
11038414|NCT04510103|Other|Non-Regression Group|The Non-Regression Group received the two test moisturizers to use split-leg (right vs. left lower leg randomized) for 6 weeks and then underwent a physical insult (tape stripping) on the lower legs and continued using the moisturizer for 4 additional days.
11038415|NCT04510090|Experimental|EP547 Single Dose|Single doses of EP547
11038416|NCT04510090|Experimental|EP547 Multiple Doses|Multiple doses of EP547
11038417|NCT04510090|Placebo Comparator|Placebo Single Dose|Single doses of placebo
11038418|NCT04510090|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo
11038419|NCT04510077|Experimental|Prevention (SmartQuit)|Patients use the SmartQuit program to learn and practice skill modules as often as they wish over 6 months.
11038420|NCT04510064|Experimental|Treatment group|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every two weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
11038455|NCT04509791|Active Comparator|1.5 mg ATG/kg|the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio
11055319|NCT04391062|Experimental|intraoperative PDT 600J/cm²|
11038421|NCT04510051|Experimental|Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)|Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
11038422|NCT04510038|Experimental|Active Colchicine Arm|Arm of Covid-19 hospitalized patients (with evidence of cardiac injury) treated with colchicine plus current standard of care.
11038423|NCT04510038|Active Comparator|Control Group|Arm of Covid-19 hospitalized patients (with evidence of cardiac injury) treated with current standard of care only.
11038424|NCT04510025||Non-COVID|We will enrol age, gender, BMI and co-morbidity matched non-COVID control subjects ( no serological evidence of previous infection or active symptoms).
11038425|NCT04510025||COVID-19|Hospitalised patients with moderate to severe infection (admitted for at least 2 days in hospital).
11038426|NCT04510012||Mild COVID-19|SARS-Cov-2 infected individuals with mild symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 1-2)
11038427|NCT04510012||Moderate COVID-19|SARS-Cov-2 infected individuals with moderate symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 3-4)
11038428|NCT04510012||Severe COVID-19|SARS-Cov-2 infected individuals with severe symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 5-8)
11038429|NCT04509999|Experimental|Standard of care and Experimental treatment of Bicalutamide|Each subject will be administered bicalutamide 150 mg daily at 1:1 randomization for up to 4 weeks.
11038430|NCT04509999|Placebo Comparator|Standard of Care and Placebo|Each subject will be administered placebo as formulated at 1:1 randomization for up to 4 weeks.
11038431|NCT04509973|Experimental|Dexamethasone 12 mg|Intravenous bolus injection of dexamethasone 12 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 12 mg at sites, where dexamethasone is not available.
11038432|NCT04509973|Active Comparator|Dexamethasone 6 mg|Intravenous bolus injection of dexamethasone 6 mg once daily in addition to standard care for up to 10 days. We will allow the use of betamethasone 6 mg at sites, where dexamethasone is not available.
11038433|NCT04509960|No Intervention|proseal laryngeal mask insertion|no intervention
11038434|NCT04509960|Experimental|proseal laryngeal mask insertion with laryngoscope|with the help of direct laryngoscopy
11038435|NCT04509947|Experimental|Ad26.COV2.S: High Dose|Participants (healthy adults aged greater than or equal to (>=) 20 to less than or equal to (<=) 55 years [cohort 1] and >= 65 years [cohort 2]) will receive intramuscular (IM) injection of Ad26.COV2.S at high dose, as 2-dose schedule on Day 1 and Day 57.
11038436|NCT04509947|Experimental|Ad26.COV2.S: Low Dose|Participants (healthy adults aged >= 20 to <= 55 years [cohort 1] and >= 65 years [cohort 2]) will receive IM injection of Ad26.COV2.S at low dose, as 2-dose schedule on Day 1 and Day 57.
11038437|NCT04509947|Placebo Comparator|Placebo|Participants (healthy adults aged >= 20 to <= 55 years [cohort 1] and >= 65 years [cohort 2]) will receive IM injection of placebo on Day 1 and Day 57.
11038438|NCT04509934|Active Comparator|Group 1|Connective Tissue Manipulation was performed to participants in Group 1, starting at the end of the menstrual cycle, 5 days a week and for 1 cycle (approximately 3 weeks) until the beginning of the next period.
11038439|NCT04509934|Active Comparator|Group 2|In Group 2, Connective Tissue Manipulation was started with the completion of menstrual cycle performed to participants for 5 days a week and until the other menstrual cycles. At the end of the menstrual cycle, it was restarted and a total of 2 cycles were applied until the second menstrual cycle started (approximately 6 weeks).
11038440|NCT04509921|No Intervention|symptoms group|The asthma treatment adjustments guided by GINA guidelines
11038441|NCT04509921|Experimental|BHR group|The asthma treatment adjustments additionally taking account to the results of the bronchial hyperresponsiveness test
11038442|NCT04509895|Experimental|lateral extensile approach in calcaneal fractures fixation|Lateral extensile approach is the standard approach for intra-articular calcaneal fractures .
11038443|NCT04509895|Experimental|minimally invasive sinus tarsi approach in calc.fixation|Sinus tarsi approach become one of the most frequently applied minimally invasive approaches.
11038444|NCT04509882|Experimental|bear bile pill|Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI).
11038445|NCT04509882|Placebo Comparator|placebo|Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI).
11038446|NCT04509869|Experimental|pre-operative and postoperative|the patients who will undergo the operation to treat the pain
11038447|NCT04509856|No Intervention|Control Group|Routine diabetes education will given to the patients included in the Control Group by a diabetes education nurse. The diabetes education nurse has been working for 10 years in the same center.
11038448|NCT04509856|Experimental|Intervention Group|Intervention Group will take their diabetes education by teach-back educational strategy.
11038449|NCT04509830|Experimental|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator will be performed.cuff weights will be used with 80% of 1 repetition maximum at 3 sets of 8 repetitions with 10-15 second rest between repetitions and 1-2 minute rest between sets.
11038450|NCT04509830|Active Comparator|quadriceps strengthening, stretch for hamstring,cuff muscles|"quadriceps strengthening: multi-angle isometric exercise from sitting position will be performed. cuff weights will be used with 3 sets of 12 repetitions at 40% of 1 reprtition maximum.
~self stretch for hamstring and cuff muscles from supine position. the procedure will be repeated 4 times."
11038451|NCT04509817|Experimental|Acupuncture+Usual care|Subjects in experimental group will receive a standardized acupuncture treatment, 10 times per 4 weeks for 16 weeks with a total of 40 sessions in addition to usual care.
11038452|NCT04509817|Active Comparator|Usual care|Subjects in control group will receive usual care only.
11038453|NCT04509791|Placebo Comparator|placebo|placebo arm
11038454|NCT04509791|Active Comparator|2.5 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
11038456|NCT04509791|Active Comparator|0.5 mg ATG/kg|The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio
11038457|NCT04509791|Active Comparator|0.1 mg ATG/kg|the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio
11038458|NCT04509778||SHARP|ShangHai At Risk for Psychosis
11038459|NCT04509765|Experimental|Patients with Hematologic Malgnancies|
11038460|NCT04509752||Dysphagia clinicians|Clinicians from swallowing centers (from all over the world)
11038461|NCT04509739|Experimental|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.
~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
11038462|NCT04509726|Experimental|EBV TCR-T|
11038463|NCT04509713||infected/positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
11038464|NCT04509713||uninfected/negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
11038465|NCT04509700|Experimental|parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
11038466|NCT04509700|Experimental|parsaclicib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
11038467|NCT04509674|Experimental|Empagliflozin|
11038468|NCT04509674|Placebo Comparator|Placebo|
11038469|NCT04509661|Experimental|Experimental group|Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.
11038470|NCT04509661|Placebo Comparator|Control group|Placebo treatment for the airway limitation.
11038471|NCT04509648|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will receive 5.2 Gy in 5 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular/infraclavicular region, internal mammary nodes, and any part of the axillary bed at risk) and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast.
11038472|NCT04509635|Experimental|Arm A|Using treatment of cetuximab plus chemotherapy. Cetuximab: 500 mg/m2 IV over 2 hours, day 1, every 2 weeks. Chemotherapy: detailed regimen is determined by a multi-disciplinary team.
11038473|NCT04509635|Active Comparator|Arm B|Using treatment of chemotherapy alone. Chemotherapy: detailed regimen is determined by a multi-disciplinary team
11038474|NCT04509622|Experimental|Venetoclax + Low-Dose Cytarabine (LDAC)|Participants will receive venetoclax once daily (QD) on days 1 through 28 plus LDAC QD on days 1 through 10 during the 28-day treatment cycles.
11038475|NCT04509609||LGMD 2E with a genetic diagnosis|Any patient affected by LGMD 2E with a genetic diagnosis
11038476|NCT04509596|Experimental|daily dose of DZD1516|daily dose of DZD1516
11038477|NCT04509583|Experimental|PROFortil group|"Men with increased sperm DNA fragmentation (>=30%) will be indicated for multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months then checked again post-treatment for DF).
~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
11038478|NCT04509583|Other|Vitamin E group|"Any case with high DNA fragmentation index (DFI >=30%) will be randomized indicated only Vitamin E (Enat 400 once per day) in 3 months then checked again post-treatment for (DFI).
~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
11038479|NCT04509570|Other|Treatment: ILI(Intralesional injection)|5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
11038480|NCT04509557|Experimental|50mCi|Using a drug product for which dose is determined (50±5 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
11038481|NCT04509557|Experimental|75mCi|Using a drug product for which dose is determined (75±8 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
11038482|NCT04509557|Experimental|100mCi|Using a drug product for which dose is determined (100±10 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
11038483|NCT04509557|Experimental|125mCi|Using a drug product for which dose is determined (125±13 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
11038484|NCT04509557|Experimental|150mCi|Using a drug product for which dose is determined (150±15 mCi dose), dilute with 0.9% NaCl 5 mL and slowly i.v. inject over 10 minutes, with 500 mL of 0.9% NaCl slowly administered for hydration over approximately 90 minutes from 30 minutes before treatment to 60 minutes after treatment.
11038485|NCT04509531|Experimental|Experimental: SA, ITP and Resilience|1 hour Wise intervention (based on SA, ITP and resilience) consisting on several tasks to be completed online individually.
11038486|NCT04509531|Other|Standard preventive intervention|1 hour educational intervention (about internet risks such as sexting and grooming) consisting on several tasks to be completed online individually.
11038487|NCT04509518|Experimental|Study group|Participants in the study group received exercise therapy program plus additional TENS therapy
11055320|NCT04391062|Experimental|intraoperative PDT 800J/cm²|
11038488|NCT04509518|Other|Control group|Participants in the study group received exercise therapy program plus sham TENS
11038489|NCT04509466|Experimental|dose escalation (part 1)|"dose escalation (part 1):Patients with treatment-naïve, relapsed or refractory extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles. The starting dose of liposomal mitoxantrone hydrochloride is 12mg/m2.dose expansion, treatment-naïve patients (part 2):Patients with treatment-naïve extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles.
~dose expansion, relapsed or refractory patients (part 2):Patients with relapsed or refractor extranodal natural killer/T-cell lymphoma (nasal type) will receive liposomal mitoxantrone hydrochloride at RP2D plus a standard dose of pegaspargase every 21 days (a cycle) for a maximum of 6 cycles."
11038490|NCT04509453|Experimental|McGRATH|
11038491|NCT04509453|Active Comparator|Macintosh|
11038492|NCT04509440|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 3 ml). The injection was done using Lyftgot technique. The subcutaneous injections were done at sensory nerves fascial penetration points and tender areas around the anserine bursa anatomical region.
11038493|NCT04509440|Active Comparator|Corticosteroid group|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
11038494|NCT04509427|Active Comparator|Handouts Only (HO) group|The HO only group will receive program instructions via handouts and videoconferencing with a physical therapist who will provide intervention instruction, assist with program progression, and monitor participant quality of movement and safety.
11038495|NCT04509427|Active Comparator|Handouts plus web-based video (HO+) group|The HO+ group will receive the same intervention as the HO group but they will also have access to web-based videos that will lead them through all exercise/posture routines like a commercial exercise video.
11038496|NCT04509414|Experimental|dexmedetomidine|2ug/kg intranasal atomized dexmedetomidine
11038497|NCT04509414|Active Comparator|midazolam|0.2mg/kg intranasal atomized midazolam
11038498|NCT04509401|Active Comparator|Interventional|High dose of Vitamin B6 with Magnesium. Vitamin B6 will be given orally 150 mg for ages 2-3 years, 200 mg for ages 4-6 years,300 mg for ages 7-8 years and Magnesium will be given orally 50 mg for 2-3 years, 100 mg for ages 7-8 years for three months.
11038499|NCT04509401|Placebo Comparator|Control|Control group will receive oral placebo in the same manner, schedule and time frame.
11038500|NCT04509388|Placebo Comparator|Commercially Available Sports Drink A|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes
11038501|NCT04509388|Experimental|Commercially Available Sports Drink B|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes.
11038502|NCT04509388|Experimental|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available sports water, with small amounts of flavouring, sweetener and electrolytes), but with the addition of a small amount of amino acids (~0.7 g/100 ml).
11038503|NCT04509375||Study Group|Premature babies in the first 28 postnatal days of life, with less than 32 gestational weeks or less than 1500 grams of birth weight, with documented anemia by current accepted transfusion guidelines of Turkish Neonatal Society
11038504|NCT04509349|Active Comparator|Real tACS|For transcranial stimulation, a stimulation method called high-definition tACS (HD-tACS) will be applied to target the primary motor cortex (M1), an area of the brain that is involved in controlling movement, using gel electrodes placed on the scalp. Participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage, to create focused stimulation over the M1 region. A stimulator will be connected to the electrodes to deliver a low-intensity stimulating current to the scalp.
11038505|NCT04509349|Placebo Comparator|Sham tACS|For the transcutaneous ACS, the procedure for real and sham stimulation will be identical to HD-tDCS, but ACS will be delivered to the upper arm contralateral to hand attached to the accelerometer.
11038506|NCT04509336|Experimental|orphenadrine group|orphenadrine
11038507|NCT04509336|Active Comparator|Baclofen group|Baclofen
11038508|NCT04509323|Experimental|Experimental：Huperzine A for Injection+Basic treatment|Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days； Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
11038509|NCT04509323|No Intervention|Control：Basic treatment|Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
11038510|NCT04509310|Experimental|Active Bodysuits|The potential materials that can provide support are 3D printable rigid materials, semirigid foam padding, Velcro tape and stretchable wide waistbands. The 3D printable materials can be very versatile in terms of properties and can be further finished with an epoxy resin or thermoplastics. Different compositions and structures of knitted fabrics will be used in different areas of the proposed bodysuits to provide a close fit, high breathability and effective pain management due to extra support. The fastening system includes a magnetic zipper and pulley system that can be adjusted by pulling on knobs. The pulley system contains a microadjustable dial, super-strong lightweight lacing, and low friction lacing guides.
11038511|NCT04509297|Experimental|High protein milk|Experimental: High protein milk consumption This arm involved High protein milk whole consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
11038512|NCT04509297|Placebo Comparator|Placebo|This arm involved consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime. drink r
11038599|NCT04508660|Experimental|Subjects with facial redness|Topical application twice daily for 4 weeks
11038513|NCT04509284|Experimental|Training|Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
11038514|NCT04509284|Other|Control|Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
11038515|NCT04509271||Normal aged|
11038516|NCT04509271||MCI due to AD|
11038517|NCT04509271||Mild AD|
11038518|NCT04509271||Moderate AD|
11038519|NCT04509271||Severe AD|
11038520|NCT04509271||Dementia with Lewy body|
11038521|NCT04509271||Frontotemporal dementia|
11038522|NCT04509258|Placebo Comparator|control group|this group will have the standard and routine therapy of treatment of acute Aluminium Phosphide poisoning immediately after admission according to PCCA guidelines
11038523|NCT04509258|Active Comparator|N- acetyl cysteine grouo|N-acetyl cysteine will be given at dose of 300mg/kg/d IV in the first day then 150 mg/kg/d IV in addition to standard of care according to PCCA guidelines
11038524|NCT04509258|Active Comparator|Acetyl L-carnitine group|Acetyl L-carnitine will be given at dose of 50 mg/kg IV once to be followed by additional doses of 15 mg/kg IV q4hr infused over 30 min. standard of care according to PCCA guidelines will also be provided
11038525|NCT04509258|Active Comparator|Medicated paraffin oil group|Gastric decontamination with sodium bicarbonate (NaHCO3; 44 mEq, orally) and medicated paraffin oil (200 mL) will be administered in addition to standard of care according to PCCA guidelines
11038526|NCT04509245|Experimental|Effects of a digitally assisted lifestyle intervention|Testing the effects of a low-calorie diet in connection with app-based digital education and behavioral change program on glucose metabolism and disease management.
11038527|NCT04509232|Experimental|group A|- 38% Silver diamine fluoride will be applied to carious lesions by microbrush on the affected surface application time should be 1 min, Application time will be shorter in very young patients.
11038528|NCT04509232|Experimental|group B|"-38% Silver diamine fluoride will be applied by the same protocol as in group A
~Then Glass Ionomer restoration is applied as follows
~Self cure glass ionomer restoration is applied not light cured as light causes oxidation of silver and the filling appears darker.
~Glass ionomer won't be applied immediately after SDF placement it will be applied at time ranging from 2 hours to two days.
~Conditioning of the base of the cavity is done by 3M ESPE conditioner for 10 seconds then rinsing the cavity for 10 to 20 secs.
~Applying High strength hand mix chemical self cure glass ionomer."
11038529|NCT04509219|Experimental|Participants treated with MP pulse|Selected participants will be given MP pulse treatment
11038530|NCT04509206|Experimental|Intervention|Subjects will undergo four nutritional educational classes, lasting 1 hour long, conducted over a two month period. These classes will occur on zoom and subjects will be located in their home.
11038531|NCT04509193||Group A|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on rivaroxaban
11038532|NCT04509193||Group B|Participants with diagnoses of type 2 diabetes and non-valvular atrial fibrillation (NVAF) newly-initiated on warfarin
11038533|NCT04509180|Experimental|Catheter ablation group|Patients undergoing catheter procedure will be put under conscious sedation and local anesthesia. Pulmonary vein isolation and posterior wall isolation will be performed with a radiofrequency ablation catheter (20-45W, open-tip irrigation). Ablation index will be used for the lesion formation guidance (450-500 on anterior aspects; 350-400 on the posterior aspects). A wide antral circumferential ablation will be performed for pulmonary veins and a box lesion set for the posterior left atrial wall. Voltage mapping and signal analysis performed by the operator will be used to assess electrical isolation of the pulmonary veins and posterior wall and to identify gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
11038534|NCT04509180|Active Comparator|Convergent group|Patients undergoing convergent procedure will be put under general anesthesia. A minimally invasive epicardial radiofrequency ablation (30W, 90s) of posterior wall will be performed through a subxiphoid window. Monitoring of the esophageal temperature will be performed with an esophageal temperature probe set at 38°C. Next, an endocardial radiofrequency ablation (20-40W, open-tip irrigation; ablation index 450-500 anteriorly and 350-400 posteriorly) of pulmonary veins in a wide antral circumferential fashion will be performed. Voltage mapping and signal analysis performed by the operator will be used to assess the electrical isolation of the pulmonary veins and posterior wall and to identify the gaps in ablation lines. At the end of procedure, an implantable loop recorder will be inserted in the left parasternal region.
11038535|NCT04509167|Experimental|Treatment|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of ~500ug per peptide once a week for 8 weeks.
11038536|NCT04509154|Experimental|Multimodal pain therapy|"The treatment will last 6 weeks maximum 8 weeks. The three questionnaires will be completed by all study subjects in a maximum time of 10 minutes. Immediately after receiving the two face-to-face sessions; 6 weeks after (8 weeks maximum after treatment) and three months just after having completed treatment.
~The pain management application includes automatic monitoring, skills training, social support, education, goal setting and achievement of 4 components: exercises, psychological well-being, pharmacological and health assets interventions. Every week participants have a look at digital presentations about every component, doing then 3 activities related to each of them.This program will be."
11038537|NCT04509154|Experimental|Standardized treatment.|Both groups (control and intervention) received two face-to-face health education sessions led by nurses and physicians, and had access to a non-interactive web page with material for pain management from a self-help approach.
11038538|NCT04509141|Active Comparator|acupuncture|acupuncture three times a week
11038539|NCT04509141|Active Comparator|standard treatment for migraine by neurologist|standard treatment for migraine that was given by a neurologist
11038540|NCT04509128||A|Subjects hospitalized for a COPD acute exacerbation, undergoing arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, at admission and discharge.
11038595|NCT04508725|Experimental|Doppler Ultrasound|Patients receiving standard of care anti-angiogenesis inhibitor plus immune checkpoint inhibitor will have power doppler imaging at baseline, 3 weeks and 6 weeks.
11055387|NCT04390568|Experimental|Dose group 1|
11038541|NCT04509128||B|Subjects referred for pulmonary rehabilitation (PR) after a hospitalized COPD exacerbation, undergoing pulmonary function test, arterial blood gas analysis, evaluation of presence and grade of dyspnea, handgrip strength test, and diaphragmatic and vastus lateralis muscle ultrasound assessment, before and after PR.
11038542|NCT04509115||Patients given short-acting opioid prescription|Patients not currently using opioids who receive a new short-acting opioid prescription for acute pain will be recruited.
11038543|NCT04509102|Active Comparator|Active|Subjects randomized to Adderall will take an tablet/capsule by mouth daily.
11038544|NCT04509102|Placebo Comparator|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar.
11038545|NCT04509089|Experimental|Experimental|Congestive heart failure patients scheduled for pulmonary artery catheterization (Swan-Ganz)
11038546|NCT04509076|Experimental|PrEP iT! (plus usual PrEP care)|The PrEP iT! intervention is a mobile-optimized website with components tailored for young men who have sex with men on PrEP.
11038547|NCT04509076|Placebo Comparator|Usual PrEP care only|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
11038548|NCT04509063|Other|Detailed information about screening harms|
11038549|NCT04509063|Other|Non-detailed information about screening harms|
11038550|NCT04509050||Part A|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
11038551|NCT04509050||Part B|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
11038552|NCT04509037||Liposuction Assisted Breast Reduction|
11038553|NCT04509037||Open Incision Breast Reduction|
11038554|NCT04509024|Experimental|Incidental training|Participants undergo novel non-linguistic incidental category learning training.
11038555|NCT04509024|Active Comparator|explicit training|Participants undergo traditional explicit language learning.
11038556|NCT04509011|Experimental|Fluobeam® LX|Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands
11038557|NCT04509011|No Intervention|Control|In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).
11038558|NCT04508998|Experimental|Patients with microvascular angina|Patients with clinical features of microvascular angina screened for the main PRIZE trial however not possessing the PHACTR1 GG minor allele single nucleotide polymorphism
11038559|NCT04508985|Experimental|Intervention|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
11038560|NCT04508985|Other|Continuation of standard of care|No intervention, Continuation RAAS inhibitor [continued standard of care].
11038561|NCT04508959||Screened patients|All individuals screened using the hospital's microbiology laboratory.
11038562|NCT04508959||Outpatient (Emergency Department) cases|All individuals seen in the emergency department who test positive for COVID-19.
11038563|NCT04508959||Inpatient (General Medical or Intensive Care) cases|All individuals admitted to a general or intensive care bed who test positive for COVID-19.
11038564|NCT04508946|Active Comparator|Hydrocortisone Monotherapy|Hydrocortisone Monotherapy
11038565|NCT04508946|Experimental|triple therapy regimen (vitamin c - thiamine- hydrocortisone)|triple therapy regimen (vitamin c - thiamine- hydrocortisone)
11038566|NCT04508933||Typical ARDS|ARDS due to non Covid19 causes
11038567|NCT04508933||C-ARDS|ARDS due to Covid19
11038568|NCT04508920||Basal|"All adults (age >18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.
~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2019 ( without covid-19 )"
11038569|NCT04508920||Ourbreak|"All adults (age >18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.
~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2020 ( ongoing covid-19 )"
11038570|NCT04508907|Experimental|Arm 1: Pre-emptive Treatment Arm|Single arm study were all recipients of HCV viremic organs will receive combination therapy.
11038571|NCT04508894|Placebo Comparator|Control group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline
11038572|NCT04508894|Active Comparator|Ketamine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline plus 1 mg\kg ketamine
11038573|NCT04508894|Active Comparator|Dexmedetomidine group|Supraclavicular Brachial Plexus Block using 20 ml 0.5% bupivacaine and 20 ml 0.9% normal saline plus 1µg\kg dexmedetomidine
11038574|NCT04508881|Active Comparator|External ligation|External ligation of the valve tube by vicryl sutures
11038575|NCT04508881|Active Comparator|intraluminal stenting|stenting of the valve tube by prolene suture
11038576|NCT04508868|Experimental|Brief Behavioral Activation with Mental Imagery|Four weekly sessions of Brief Behavioral Activation with Mental Imagery.
11038577|NCT04508868|Placebo Comparator|Minimal Attention Control Intervention|Four weeks with weekly follow-up calls.
11038578|NCT04508855||Cancer patients with atrial fibrillation|"All patients will be assigned to receive subcutaneous LMWH in therapeutic doses
~More specifically the regimens will be as follows:
~Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux <50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, >100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; <50kg, 5000IU, 50-70kg, 7.500 IU, >70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients"
11038596|NCT04508699|Experimental|Developmental language disorder|Children with language impairment but in the absence of cognitive deficits
11038597|NCT04508699|Active Comparator|Typical language|Children with typical language development and typical cognitive development
11038579|NCT04508842|Experimental|CD19/CD22-Dual-STAR-T|CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
11038580|NCT04508829|Experimental|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or TPF regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3+5-FU 750mg/m2, CIV, 120h, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
11038581|NCT04508816|Experimental|Anti-EGFR arm|In the induction chemotherapy phase, TP regimen (Docetaxel 75mg/m2, D1 + DDP 25mg/m2, D1-3, repeat every 3 weeks) or GP regimen (Gemcitabine 1.0g/m2, D1, 8 + DDP 25mg/m2 , D1-3, repeat every 3 weeks) will be used. Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.
11038582|NCT04508803|Experimental|The main research|Patients diagnosed with HER2 negative metastatic breast cancer with BRCA1/2, PALB2, CHEK2 pathogenic/suspected pathogenic germline mutation are recruited.
11038583|NCT04508803|Experimental|Ancillary Exploration research 1|Patients diagnosed with HER2 negative metastatic breast cancer with DDR gene (include ATM、ATR、BAP1、BARD1、BLM、BRIP1、CHEK1、CDK12、FANCA、FANCC、FANCD2、FANCE、FANCF、FANCM、MRE11A、NBN、PTEN、RAD50、RAD51C、RAD51D、WRN)pathogenic/suspected pathogenic germline mutation except BRCA1/2, PALB2 and CHEK2 are recruited.
11038584|NCT04508803|Experimental|Ancillary Exploration research 2|Patients diagnosed with HER2 positive metastatic breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation are recruited.
11038585|NCT04508803|Experimental|Ancillary Exploration research 3|Patients diagnosed with brain metastases breast cancer with DDR gene pathogenic/suspected pathogenic germline mutation who has not undergone or progressed after brain radiotherapyare recruited.
11038586|NCT04508790|Experimental|Treatment (leflunomide, pomalidomide, dexamethasone)|Patients receive leflunomide PO on days 1-28, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11038587|NCT04508764|No Intervention|Usual Care|"For approximately the first 6 months of the study, or until 75 patient with cancer who is initially approached in clinic (probands) are enrolled, the investigators will be enrolling probands into the Usual Care group. During this time, the investigators will clarify usual care regarding cascade genetic testing for each participating clinic and proband participant. The investigators will do this by proband participant surveys, as well as initial provider semi-structured interviews.
~Proband: Complete Cascade Genetic Testing survey. The survey will also contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. At 6 months, there will be a follow-up survey
~Family Member: Complete survey at study entry and at 6 month follow-up"
11038588|NCT04508764|Experimental|FACT Toolkit (FACTT)|"Proband: Introduced to FACTT and will complete Cascade Genetic Testing survey. The survey will contain questions regarding willingness or not to invite each eligible 1st degree family member to participate in the family study. The probands will also fill out assessments of each FACTT component. At 6 months, there will be a follow-up survey.
~Family Member: Introduced to FACTT and will complete surveys at study entry and 6 month follow-up. They will also fill out assessments of each FACTT component"
11038589|NCT04508751|Other|Healthy Pregnancy|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
11038590|NCT04508751|Other|Pregnant Mothers with gestational diabetes|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
11038591|NCT04508751|Other|Pregnant Mothers with infants diagnosed with IUGR|"Patient will have a fetal MRI performed in the third trimester. All MRI scans will be performed on 3 T scanners (e.g., Skyra or Prisma, Siemens). Our newly developed FB-MRI quantification technique leverages a multi-echo 3D stack-of-radial sampling trajectory with golden-angle acquisition ordering to suppress motion artifacts and enable free-breathing imaging of the abdomen in around 5 minutes. In addition, our FB-MRI technique is compatible with data under sampling to accelerate the free-breathing scan to 1-2 min. In this study, we will optimize the parameters of our FB-MRI technique (spatial resolution, spatial coverage, acceleration factor) to balance trade-offs between scan time, image quality, fat quantification accuracy, and patient comfort/compliance. Subjects will be provided ear plugs to limit amount of noise from MRI machines.
~Maternal demographics, pregnancy clinical course and infant growth parameters will be recorded."
11038592|NCT04508738|Experimental|ERP Intervention|Combination of different methods to improve recovery.
11038593|NCT04508738|No Intervention|Control|Passive recovery by sitting on a chair
11038594|NCT04508738|Placebo Comparator|Placebo|A combination of methods similar to the ERP intervention but at an intensity / mixture supposed to be ineffective at improving recovery.
11038598|NCT04508686|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
11038600|NCT04508647|Experimental|Treatment|Treatment-Naive Stage II (non-contiguous), Stage III, Stage IV FL + MZL will receive Ublituximab 900mg IV weekly x 4 doses. End of treatment assessment 8 weeks post last dose of single agent ublituximab will be performed. Patients who achieve less than a complete response will receive a combination of ublituximab AND umbralisib for a total of 12 cycles. (In the combination arm ublituximab will be administered on day 1,8 and 15 on cycle 1 and on day 1 on each cycle thereafter. Umbralisib will be administered at 800 mg daily for 12 cycles)
11038601|NCT04508634|Experimental|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
11038602|NCT04508634|Active Comparator|Metformin Group|Metformin Group
11038603|NCT04508621|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
11038604|NCT04508621|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
11038605|NCT04508608||Ischemic cardiomyopathy group - 1 (ICM-1)|"Inclusion criteria:
~History of myocardial infarction (MI) or revascularization (CABG or PCI);
~> 75% stenosis of left main or proximal left anterior descending artery (LAD) and/ or stenosis of > 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);
~LV ejection fraction (EF) <40% and increase in LV volumes according to echocardiography (ECHO)
~Exclusion criteria:
~Presence of contraindications to the stress test with inotropic stimulation;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
11038606|NCT04508608||Ischemic cardiomyopathy group - 2 (ICM-2)|"Inclusion criteria:
~History of myocardial infarction (MI) or revascularization (CABG or PCI);
~> 75% stenosis of left main or proximal LAD and/ or stenosis of > 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);
~LV EF <40% and increase in LV volumes according to echocardiography (ECHO)
~Exclusion criteria:
~Presence of contraindications to the stress test with inotropic stimulation;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
11038607|NCT04508608||Control group for GBPS.|"Inclusion criteria:
~Absence of obstructive coronary artery lesion;
~Absence of history of MI and revascularization.
~Exclusion criteria:
~Presence of contraindications to the stress test with inotropic stimulation;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
11038608|NCT04508608||Control group for CFR.|"Presence of obstructive coronary artery lesion;
~Indications for coronary artery bypass grafting
~Exclusion criteria:
~Presence of contraindications to the adenosine stress test;
~inflammatory myocardial diseases;
~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;
~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
11038609|NCT04508582||Women with Pre-eclampsia|De novo hypertension after 20 weeks gestation with evidence of end organ dysfunction.
11038610|NCT04508582||Women with Pregnancy-induced hypertension|De novo hypertension after 20 weeks gestation without evidence of end organ dysfunction.
11038611|NCT04508582||Healthy pregnant controls|Low risk women at booking as per NICE guidelines without any medical condition throughout pregnancy
11038612|NCT04508569|Experimental|Big Decisions|
11038613|NCT04508569|Active Comparator|Youth Voices|
11038614|NCT04508543||Minority (Case)|Self-identified as being a member of group traditionally underrepresented in the medical profession relative to the proportion in the general population: African-American/Black, Mexican-American, Native American (American Indians, Alaska Natives, and Native Hawaiians), and mainland Puerto Rican.
11038615|NCT04508543||Caucasian (Control)|Self-identified as Caucasian and Non-Hispanic
11038616|NCT04508530|Experimental|Panzyga|Panzyga 10% IVIG
11038617|NCT04508530|Placebo Comparator|Placebo|Placebo
11038618|NCT04508504|Experimental|Preop PENG Block|Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 30 mL 0.5% ropivacaine in a manner consistent with Girón-Arango et al 2018 (PMID:30063657). Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 30 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence, in 5 mL increments with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
11038619|NCT04508504|Placebo Comparator|Placebo|Patients in the placebo group will receive a subcutaneous injection of 5 mL 0.9% normal saline. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (SonoSite S-Nerve or Export) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) is used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After skin localization with 1-2 mL 1% lidocaine, a 22g 80 mm echogenic block needle (Pajunk SonoBlock II Facet) is advanced lateral to medial, in plane with the ultrasound beam, 1-2 cm beneath the skin, remaining in the subcutaneous tissue. 5 mL of 0.9% normal saline is injected, with periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site wiped clean.
11038620|NCT04508491|Experimental|Rhythm control|Rhythm control with medication or any procedure
11038621|NCT04508491|Active Comparator|Rate control|Rate control with medication or any procedure
11038622|NCT04508478|Experimental|Aerobic training|
11038623|NCT04508478|Active Comparator|Resistance training|
11038624|NCT04508478|Placebo Comparator|Control|
11041002|NCT04491877|Placebo Comparator|Cohort 1 (Placebo)|1 administration of placebo on Day 0
11038625|NCT04508465||OMEGA|Patients who have undergone major emergency abdominal surgery including the stomach, small or large bowel, or rectum for conditions such as perforation, ischemia, abdominal abscess, bleeding or obstruction.
11038626|NCT04508452|Experimental|mXELOXIRI+Bev reintroduction|"Patients will receive mXELOXIRI+BEV as first-line therapy (to be repeated every 2 weeks for a maximum of 12 cycles), followed to initiate a MDT to determine whether to perform a surgery or receive maintenance therapy. Maintenance treatment: CAP+BEV. The following CAP+BEV therapy will be repeated in 2-week cycles.
~At the time of disease progression, patients will be re-introduced XELOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 12 cycles. If no progression occurs during XELOXIRI plus bev, patients will receive maintenance CAP+BEV at the same dose used in the last cycle of the induction treatment."
11038627|NCT04508439|Experimental|Prophylactic enexaparin|Enoxaparin dose of 1mg / kg / dose twice daily
11038628|NCT04508439|Active Comparator|Therapeutic Enoxaparin|Enoxaparin dose of 1mg / kg / dose daily
11038629|NCT04508426|Experimental|Mass Balance|
11038630|NCT04508413|Other|KB295|
11038631|NCT04508400|Experimental|a single dose of fosaprepitant|Participants received a single dose of fosaprepitant (age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
11038632|NCT04508400|Placebo Comparator|a single dose of matched placebo|Participants received a single dose of matched placebo for fosaprepitant administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron (weight based) IV with dexamethasone (weight based) iv/po prior to chemotherapy and up to 72 hours after chemotherapy.
11038633|NCT04508387|Active Comparator|Group HH (heated-humidified) patients|Group HH (heated-humidified) patients were administered 95% humidified CO2 insufflation at 37°C. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
11038634|NCT04508387|Placebo Comparator|Group CD (cold-dry) patients|Group CD (cold-dry) patients were administered dry CO2 via insufflator at room temperature (21°C). All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
11038635|NCT04508374|Experimental|1470 nm diode laser treatment of right HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the right side, while the HS tunnel on the left side will be left as an untreated control.
11038636|NCT04508374|Experimental|1470 nm diode laser treatment of left HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the left side, while the HS tunnel on the right side will be left as an untreated control.
11038637|NCT04508348|Active Comparator|Exclusive Human Milk|Group One will receive an exclusive human milk diet throughout the 28-day feeding period or until hospital discharge
11038638|NCT04508348|Other|Maternal human milk or Formula|Group Two (Control Group) will receive maternal human milk or formula (per standard of care).
11038639|NCT04508322|Active Comparator|Group 1|Early treatment HGA (9 years)
11038640|NCT04508322|Active Comparator|Group 2|Late treatment HGA (11 years)
11038641|NCT04508322|Active Comparator|Group 3|Treatment FA
11038642|NCT04508309|Experimental|Cecolin® at 0 and 6 months|Two doses of Cecolin® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
11038643|NCT04508309|Experimental|Cecolin® at 0 and 12 months|Two doses of Cecolin® given at 0 and 12 months with blood draw at baseline, prior to second dose and one-month post second dose
11038644|NCT04508309|Experimental|Cecolin® at 0 and 24 months|Two doses of Cecolin® given at 0 and 24 months with blood draw at baseline, prior to second dose and one-month post second dose
11038645|NCT04508309|Active Comparator|Gardasil® at 0 and 6 months|Two doses of Gardasil® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
11038646|NCT04508309|Other|Gardasil® at 0 and Cecolin® at 24 months|One dose of Gardasil® at 0 months and one dose of Cecolin® at 24 months with blood draw at baseline, prior to second dose and one-month post second dose.
11038647|NCT04508296|Experimental|GEDVI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI > 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL
11038648|NCT04508296|Experimental|EVLWI-oriented de-escalation|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI > 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI < 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL
11038649|NCT04508257|Experimental|Investigational Formula (Stage 1&2)|Investigational formula contains DHA，ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants.
11038650|NCT04508257|Active Comparator|Control formula (Stage 1&2)|Control formula have comparable macronutrients and micronutrients, but does not contain DHA，ARA and MFGM.
11038651|NCT04508257|Other|Breast feeding|Breast fed of human milk
11038652|NCT04508244|Active Comparator|TBI with positive troponin|Patients will receive IV propranolol for 6 days
11038653|NCT04508244|Placebo Comparator|TBI with negative troponin (a)|Patients will receive IV placebol for 6 days
11038654|NCT04508244|Experimental|TBI with negative troponin (b)|Patients will receive IV propranolol for 6 days
11041077|NCT04491383|Placebo Comparator|Placebo|200mg, twice 1 day, 12 months
11038655|NCT04508231||Hormonal treatment|The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria.
11038656|NCT04508231||Controls|Data for control subjects are retrieved from medical records of healthy non-obese females and males who underwent an initial assessment for gender dysphoria in our department, but not yet receiving hormonal treatment at the time of the present study.
11038657|NCT04508218|Experimental|Protein+ Exercise group|Received oral protein supplementation, exercise program and traditional burn care
11038658|NCT04508218|Experimental|Protein group|Received oral protein supplementation and traditional burn care
11038659|NCT04508218|Experimental|Exercise group|Received exercise program and traditional burn care
11038660|NCT04508218|Other|Control group|Received traditional burn care
11038661|NCT04508205|Experimental|Subjects with redness and bumps and/or blemishes|Topical administration twice daily for 12 weeks
11038662|NCT04508192|Experimental|Copenhagen Adduction|The CA is a high-intensity partner exercise where the player is lying on their side using the elbow of the lower forearm to support their body and the other arm placed along their body. The upper arm is supported by the partner who places their one hand under the knee and the other under the ankle, holding the leg approximately in the height of their hip. The player performs a 3-second concentric movement lifting their body until it reaches a straight line. At the same time, the other leg is adducted so that it touches the other leg. A 3-second eccentric adduction then follows with the body lowered halfway to the ground and the foot of the lower leg touching the ground without supporting the body.
11038663|NCT04508192|Active Comparator|Adductor Squeeze|The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees. The player lies supine with the ball placed between the knees with the knees and hips flexed and the feet flat on the surface with the first toe is pointed straight forward.the player is asked to press against the ball as hard as they can The contraction is held for 10 seconds
11038664|NCT04508179|Experimental|7HP349 Capsules|Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (2-period cross-over)
11038665|NCT04508179|Placebo Comparator|Placebo Capsules|Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)
11038666|NCT04508166|Experimental|Dexmedetomidine|Sublingual dose of dexmedetomidine
11038667|NCT04508166|Active Comparator|Gamma-hydroxybutyrate|Oral dose of gamma-hydroxybutyrate
11038668|NCT04508166|Placebo Comparator|Placebo|Oral (saline) and sublingual (orodispersible tablet) doses
11038669|NCT04508153|Other|Leva PDHS arm|"Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.
~Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks."
11038670|NCT04508153|Other|Kegel arm|Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
11038671|NCT04508140|Experimental|Single Arm|The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
11038672|NCT04508127||Active Procedure|The patients will receive targeted Percutaneous Spinal Cord Stimulation at suitable DRG with Axium SCS system as part of their standard treatment for lumbar pain. The lead placement will happen in 2 stages. First stage involves placement of leads and an externalised device and is a trial stage. Patient deemed to have a good response to first stage will proceed to the second stage to have the permanent implant. Again this is part of our standard care. Normally our drop out rate after first stage is less than 10% and these patients will not have subsequent tests including PET-CT scan and questionnaires.
11038673|NCT04508114|No Intervention|control group|Participants in the control group will not receive the ATP testing result (pretest) immediately until finished the research.
11038674|NCT04508114|Experimental|experimental group|Participants in the experimental group will be informed the ATP testing result (pretest) and receive the explanation by research assistant.
11038675|NCT04508101||drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty with suction drainage positioning
11038676|NCT04508101||non-drainage group|Patients satisfying inclusion criteria who underwent either total as well as unicompartmental knee arthroplasty without suction drainage positioning
11038677|NCT04508088||Crohn Disease|"This group will be 10 adolescent girls, ages 13-20, who have been recently (within 12 months) diagnosed with Crohn Disease.
~All participants will have a single study visit during which the listed diagnostic testing will be performed."
11038678|NCT04508088||Control|"Controls will be matched for age, Tanner staging, and both height percentile and BMI percentile.
~All participants will have a single study visit during which the listed diagnostic testing will be performed."
11038679|NCT04508075|Experimental|SARS-CoV-2 Vaccine|Participants receive 2 doses of SARS-CoV-2 Inactivated Vaccine with 14 days interval, intramuscularly
11038680|NCT04508075|Placebo Comparator|Placebo|Participants receive 2 doses of placebo with 14 days interval, intramuscularly
11038681|NCT04508062|Active Comparator|pectopexy group|this group will only have pectopexy operation
11038682|NCT04508062|Active Comparator|Pectopexy and uterosacral ligaments plication group|this group will have pectopexy operation with bilateral uterosacral ligaments plication
11038755|NCT04507464|No Intervention|Physical Activity Guidelines|Participants will be sent general guidelines for disruption of sedentary time.
11039660|NCT04501367|Experimental|Topical Prednisolone Acetate 1% Group|Patients undergoing vitrectomy with internal limiting membrane peel
11038683|NCT04508049|Other|Early identification of fibrosis.|A pilot study to test the ability of qMT to quantify fibrosis in the post-stenotic human kidney, in comparison to innovative biomarkers of renal dysfunction and tissue damage. We will pursue the Specific Aim that qMT in stenotic human kidneys is feasible and reproducible.
11038684|NCT04508036||Study Group|Premature newborns born before 32nd gestational week and weighing less than 1500 grams.
11038685|NCT04508023|Experimental|Rivaroxaban|Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
11038686|NCT04508023|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
11038687|NCT04508010|Experimental|IVR survey|Participants will receive an IVR survey
11038688|NCT04508010|Experimental|CATI survey|Participants will receive a CATI survey
11038689|NCT04507984||Children with hypercholesterolemia (Slovenia)|Children (aged 5 years) with total cholesterol measurement at primary care pediatricians at the programed visit prior to school entry.
11038690|NCT04507984||Children with hypercholesterolemia (Lower Saxony, Germany)|Children (aged 2-6 years) with LDL-cholesterol measurement during the compulsory routine check-ups and at any voluntary visits to the primary care pediatricians.
11038691|NCT04507984||Children referred for FH genetic analysis (Slovenia and LS)|Children referred for familial hypercholesterolemia genetic analysis to the tertiary center, according to the screening algorithm.
11038692|NCT04507984||Parents and siblings of children with confirmed FH (Slovenia)|Parents or siblings of index cases with completed familial hypercholesterolemia genetic analysis, according to the screening algorithm.
11038693|NCT04507971|Experimental|MET-3 2.5 g daily for 4 weeks|MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
11038694|NCT04507971|Experimental|MET-5 2.5 g daily for 4 weeks|MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.
11038695|NCT04507945|Experimental|living quality|
11038696|NCT04507945|Experimental|complication|
11038697|NCT04507932|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
11038698|NCT04507906|Other|Nivolumab + Anlotinib Arm|
11038699|NCT04507893||SARS-COV-2 PNEUMONIA CONFIRMED BY PCR ON NASOPHARYNGEAL SWAB|Hospitalized patients affected by COVID-19 interstitial pneumonia (with positive PCR on naso-pharyngeal swab)
11038700|NCT04507893||NEGATIVE SARS-COV-2 PNEUMONIA|Hospitalized patients affected by negative COVID-19 interstitial pneumonia (with negative PCR on naso-pharyngeal swab)
11038701|NCT04507880|Experimental|RTSA group|Participants with a complex proximal humerus fracture given a RTSA
11038702|NCT04507880|Active Comparator|Hemiarthroplasty group|Historical cohort of participants, operated with a hemiarthroplasty of the shoulder
11038703|NCT04507867|Sham Comparator|control group|Patients who received the standard diet
11038704|NCT04507867|Experimental|Intervention group|Patients who received the nutritional support system (NSS) and the standard diet
11038705|NCT04507854|Experimental|Operated athletes|
11038706|NCT04507841|Experimental|Niraparib group|Niraparib was used in patients with newly diagnosed ovarian cancer before any treatment. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design.
11038707|NCT04507828|Experimental|Combined DIBH-Expiration Planning Technique|Patients will undergo a 4D scan as well as a DIBH scan and an expiration breath hold scan. In order to develop a combined DIBH-Expiration treatment plan, the DIBH scan, the expiration phase of the 4D scan or the expiration breath hold scan will be used. If the radiation plan meets the coverage goals and normal tissue constraints, the patient will receive treatment using the new DIBH Planning Technique. If coverage and normal tissue constraints are not met per protocol, the patient will be treated per standard of care and not on protocol. Patients treated on protocol will undergo radiation treatment with SBRT for a total of 3 fractions and will receive each fraction no more frequently then every other day. Patients will then be evaluated at 1 month after SBRT completion and every 3 months for 2 years
11038708|NCT04507815|Experimental|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
11038709|NCT04507815|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This ramp up/down method is done at the end of the stimulation period, as well. This method mimics the physical sensation of stimulation typically encountered at the very beginning and end of the intervention period.
11038710|NCT04507802|Experimental|Non invasive ventilation via helmet|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
11038711|NCT04507802|No Intervention|Non invasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
11038712|NCT04507789|Experimental|exercise intervention group|This group will be taken an exercise intervention during their radiotherapy programme.
11038713|NCT04507789|Active Comparator|routine radiotherapy protocol|This group will not be taken into an exercise intervention during their radiotherapy programme.
11038714|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
11038715|NCT04507763||Patients with ankylosing spondylitis|Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease
11038784|NCT04507243|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
11055388|NCT04390568|Experimental|Dose group 2|
11038716|NCT04507750|Experimental|camrelizumab+apatinib mesylate|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
11038717|NCT04507737|Experimental|Critical Care Outreach Team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Critical Care Outreach Team Model consisting of an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
11038718|NCT04507737|No Intervention|Medical Emergency team Model|When a patient deteriorates and is in need of a Rapid Response Team, this arm will deploy a Medical Emergency Team Model, consisting of an ICU-trained Doctor as well as an ICU-trained Nurse with the on-duty physician of the general ward and a nurse from the general ward.
11038719|NCT04507711|Experimental|0 ng/ml|Blood specimen which was added of 0 ul of palonosetron
11038720|NCT04507711|Experimental|5 ng/ml|Blood specimen which was added of 0.2 ul of palonosetron
11038721|NCT04507711|Experimental|50 ng/ml|Blood specimen which was added of 2 ul of palonosetron
11038722|NCT04507711|Experimental|100 ng/ml|Blood specimen which was added of 4 ul of palonosetron
11038723|NCT04507698|Experimental|Supervised Exercise Arm|If participants are placed in the Supervised Exercise Group, they will attend supervised group exercise sessions, which are individually tailored to the participants physical condition, at least once a week, every week for the first year of the study. They will be asked to exercise 3 times a week.
11038724|NCT04507698|No Intervention|Self-Directed Exercise Arm|If Participants are placed in the Self-directed Exercise Group, they will receive usual medical care (standard of care) and be asked to follow their usual exercise and lifestyle routine. They will receive supportive care in the form of newsletters, covering a variety of topics including pain management, bone health, goal setting, taking control of life, and more.
11038725|NCT04507685|Experimental|Low Glycaemic Diet (LG)|Low carbohydrate, low saturated fat diet
11038726|NCT04507685|Active Comparator|Control Diet|High unrefined carbohydrate, low fat diet
11038727|NCT04507672|Placebo Comparator|saline group|Use saline for fluid resuscitation during the first 72 hours after enrollment
11038728|NCT04507672|Experimental|Acetated Ringer's solution group|Use acetated Ringer's solution for fluid resuscitation during the first 72 hours after enrollment
11038729|NCT04507659|Active Comparator|Jaktinib 100mg|100 mg bid.po
11038730|NCT04507659|Active Comparator|Jaktinib 75mg|75 mg bid.po
11038731|NCT04507659|Placebo Comparator|Placebo|Placebo bid.po
11038732|NCT04507646|Experimental|True auricular acupuncture|Effective auricular acupuncture
11038733|NCT04507646|Sham Comparator|Sham auricular acupuncture|Ineffective auricular acupuncture
11038734|NCT04507633|Experimental|ROMA therapy|ROMA therapy combines four elements including reminiscence, reality orientation, music, and art in the intervention.
11038735|NCT04507633|No Intervention|control group|usual care
11038736|NCT04507620||cervical neck collar|
11038737|NCT04507620||head blocks strapped on the backboard|
11038738|NCT04507607|Experimental|Pregnant women with CHB|Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.
11038739|NCT04507607|Active Comparator|women with CHB|Nonpregnant women taking TAF for antiviral therapy were regularly rechecked for liver function, viral load, and antigens.
11038740|NCT04507594||Patients undergoing Thoracic Surgery|
11038741|NCT04507568|Experimental|Person-Centered Model-of-Care|Patients randomized to the person-centered model-of-care will have a 30 minute education session with a radiation therapist in addition to the standard of care, radiation therapy procedures.
11038742|NCT04507568|Other|Standard Model-of-Care|Patients randomized to the standard model of care will be treated as per standard of care.
11038743|NCT04507555|Experimental|Intervention|
11038744|NCT04507555|Active Comparator|Standard Care|
11038745|NCT04507555|No Intervention|Observational|
11038746|NCT04507542|Experimental|Enriched Music-Supported Therapy group|Participants in the eMST-group will follow a 10-week program of Enriched Music-Supported Therapy. The program comprises 3 individual self-training sessions and 1 group session per week (total program duration: 40 hours).
11038747|NCT04507542|Active Comparator|Control group|Participants in the control intervention group will follow the Graded Repetitive Arm Supplementary Program (GRASP, Harris et al., 2009). They will be asked to complete 4 weekly one-hour session for 10 weeks (total program duration: 40 hours).
11038748|NCT04507529|Experimental|Peer-mentoring|Peer-mentoring
11038749|NCT04507516||Water-only Fasting Cohort|Obese/overweight, non-diabetic patients undergoing elective water-only fasting treatment.
11038750|NCT04507490|Experimental|Whole body vibration 6 Hz|application of whole body vibration in the following parameters:frequency 6 Hz, amplitude 4 mm, five cycles lasting 1 minutes and interval between cycles of 1 minute
11038751|NCT04507490|Experimental|Whole body vibration 25 Hz|application of whole body vibration in the following parameters: 25 Hz frequency, 4 mm amplitude, five cycles lasting 1 minute and interval between 1 minute cycles
11038752|NCT04507490|Sham Comparator|Whole body vibration sham|application of whole body vibration in the following parameters: The sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to that of the connected platform for a time equivalent to that of the treatment protocol.
11038753|NCT04507477|Experimental|Rituximab + Ex-vivo lung perfusion|Donor lungs deemed suitable for such patients will undergo ex vivo lung perfusion (EVLP) as per standard practice. In clinical practice almost all adult donor lungs are EBV seropositive. If in the rare case the donor lung is EBV seronegative, then the lung transplant candidate/recipient will no longer need to be part of the study. Therefore, for EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours. Lungs will then be transplanted as per standard procedure.
11038754|NCT04507464|Experimental|Ecological Momentary Intervention|Participants will receive real time physical activity notifications via a wearable activity tracker and smartphone application.
11038756|NCT04507451|Experimental|Trained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle training. This program will be delivered 5 days a week.
~Inspiratory muscle training (IMT): using a threshold IMT device with mouthpiece, 5 sets of 6 breaths, intensity is prescribed at 60% of maximal inspiratory pressure for the first set, and then increased to the highest tolerable intensity to allow completion of the 6th breath Expiratory muscle training (EMT): using a bottle filled with water, starting at 5cm and then increased to 8 cm gradually, 5 sets of 6 breaths
~Training program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
11038757|NCT04507451|Placebo Comparator|Untrained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle exercises that are not planned to train muscles. This program will be delivered 5 days a week.
~Inspiratory exercises: fractionated inspiration, 5 sets of 6 breaths Expiratory exercises: using a bottle filled with water (1 cm)
~Exercises program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
11038758|NCT04507438|Experimental|Donepezil treatment group|Administration of 5mg or 10 mg of donepezil daily
11038759|NCT04507438|Placebo Comparator|Control group|Administration of placebo
11038760|NCT04507425|Active Comparator|Not Intubated|Patients admitted with a trauma injury who do not need to be intubated to receive treatment. Intubated means putting a tube down your throat to keep your airway from collapsing. Participants will be randomized to receive one of the three interventions in this arm.
11038761|NCT04507425|Active Comparator|Intubated Patients Undergoing Extubation|Patients admitted with a trauma injury who had to be intubated for treatment of their injury. Interventions administered after the tube is extubated (removed from throat). Participants will be randomized to receive one of the three interventions in this arm.
11038762|NCT04507412|Experimental|arm A|• 9 mg of i.v. dexamethasone
11038763|NCT04507412|No Intervention|arm B|• no steroid supplementation
11038764|NCT04507399|Experimental|Protein Beverage|Whey Protein Beverage
11038765|NCT04507399|Experimental|Control Beverage|Whey Permeate Beverage
11038766|NCT04507386|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
11038767|NCT04507386|No Intervention|Control|The control group will receive regular medical care and advice on healthy lifestyle, including physical activity and healthy eating recommendations
11038768|NCT04507373|Placebo Comparator|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
11038769|NCT04507373|Active Comparator|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
11038770|NCT04507360|Experimental|Engagement Strategy - 1|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
11038771|NCT04507360|Experimental|Engagement Strategy - 2|Engagement strategies that will be tested in Aim 3 in Y04 will be developed based on learnings from Aims 1 and 2 in Y01-Y03 of the project.
11038772|NCT04507347|Experimental|Test product|Eligible participants will be randomized to receive test product, TRC041266 1500 mg twice daily for 48 weeks.
11038773|NCT04507347|Placebo Comparator|Placebo product|Eligible participants will be randomized to receive matching placebo twice daily for 48 weeks.
11038774|NCT04507321|Experimental|GSK3640254 tablet + [14C]-GSK3640254 IV/[14C] oral suspension|Participants will receive a single oral dose of GSK3640254 200 milligram (mg) (2×100 mg) tablets with a moderate fat meal. Participants will then be administered a 100 microgram (mcg) dose (approximately 3.7 kilobecquerel; 100 nano Curie) of [14C]-GSK3640254 as an IV infusion for 1 hour on Day 1 in treatment Period 1, On Day 1 in treatment Period 2, participants will receive a single oral dose of 85 mg (approximately 3.15 megabecquerel; 85 micro Curie) [14C]-GSK3640254 administered as an oral suspension with a moderate fat meal. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
11038775|NCT04507308|Experimental|Transdiagnostic Sleep and Circadian Intervention|All participants will undergo baseline assessment and then complete a brief, single-session sleep-focused intervention based on psychoeduation and handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth).
11038776|NCT04507295|Active Comparator|volume controlled group|"15 patients in is this group will be ventilated during capnothorax using volume controlled ventilation with the following parameters:
~FIO2 of 60 %.
~Tidal Volume (TV) of 6-8 ml/kg.
~Respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.
~inspiratory to expiratory ratio (I: E) 1:2.
~using a minimal Positive End Expiratory Pressure (PEEP) of 2 cm H2O."
11038777|NCT04507295|Active Comparator|pressure controlled group|"15 patients in is this group will be ventilated during capnothorax using pressure controlled ventilation with the following parameters:
~FIO2 60 %.
~inspiratory pressure adjusted to fulfil the required TV according to the weight of the patient (6-8 ml /kg) then the insufflation pressure will be added to the driving pressure.
~respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.
~I:E ratio of 1:1.5 .
~Using a minimal PEEP of 2 cm H2O."
11038778|NCT04507282||COVID 19 positive patients|
11038779|NCT04507269|Experimental|VIR-2218|Drug: VIR-2218 VIR-2218 given by subcutaneous injection
11038780|NCT04507269|Placebo Comparator|Placebo|Drug: Placebo Saline given by subcutaneous injection
11038781|NCT04507256|Experimental|AZD7442|Participants will receive AZD7442 doses across five fixed-dose cohorts via intravenous (IV) infusions (three cohorts will be administered sequentially, and one cohort will receive co-administration of AZD8895 + AZD1061, mixed into a single infusion) and direct gluteal intramuscular (IM) injections (administered sequentially).
11038782|NCT04507256|Placebo Comparator|Placebo|Placebo will be administered to participants across five fixed-dose cohorts similar to the active treatment.
11038783|NCT04507243|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
11039661|NCT04501354|Experimental|UC-Mesenchymal Stem Cell|Allogeneic Mesenchymal Stem Cell from umbilical cord
11038785|NCT04507217|Experimental|BM without prior radiotherapy|"No Prior Systemic treatment for Stage IV NSQ-NSCLC
~With asymptomatic untreated BM"
11038786|NCT04507217|Experimental|BM with prior radiotherapy|"No Prior Systemic treatment for Stage IV NSQ-NSCLC
~With Clinical stable BM with prior radiotherapy"
11038787|NCT04507204|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
11038788|NCT04507204|Active Comparator|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
11038789|NCT04507178|No Intervention|prophylactic dose LMWH|Patients assigned to the control group will receive standard care according to current protocol with a prophylactic dose of LMWH (nadroparin once daily 2850 AxaIE subcutaneously) starting within 24 hours after coiling, continued until discharge or when mobilized for at least six hours a day.
11038790|NCT04507178|Active Comparator|therapeutic dose LMWH|In the intervention group, the standard prophylactic dose will be replaced by a higher dose of LMWH (nadroparin; twice daily 5700 IE) starting within 24 hours after coiling and continued for 21 days after initial SAH. After this, patients will continue with standard care (prophylactic dose until discharge or when mobilized for more than six hours per day).
11038791|NCT04507165|Experimental|opioid-free general anesthesia|under opioid-free general anesthesia
11038792|NCT04507165|Active Comparator|opioid based general anesthesia|under opioid based general anesthesia
11038793|NCT04507152|Experimental|Blood flow restriction resistance training|
11038794|NCT04507152|Active Comparator|Resistance training|
11038795|NCT04507126|Experimental|BCG Immunization|All participants will receive two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 1.8-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
11038796|NCT04507113|Experimental|Lumbar radiculopathy|Patients with acute lumbar radiculopathy (less than 3 months of evolution)
11038797|NCT04507100|Experimental|Lifestyle and environment intervention|Schools will receive the components of Salud Escolar
11038798|NCT04507100|No Intervention|Wait-list control|Wait-list control of schools without intervention.
11038799|NCT04507087|Experimental|Intervention|See detailed preregistration: https://osf.io/xrckh/registrations
11038800|NCT04507087|Sham Comparator|Control|See detailed preregistration: https://osf.io/xrckh/registrations
11038801|NCT04507074|Experimental|Patients With Obesity|40 subjects aged 35-60 with simple obesity (BMI ≥ 30 kg / m2) and chronic low back pain.
11038802|NCT04507074|Active Comparator|Normal-Weight Patients|20 subjects aged 35-60 with normal body weight (BMI ≤ 24.9 and ≥ 18.5 kg/m2) suffering from chronic low back pain.
11038803|NCT04507061|Experimental|runcaciguat|Participant randomized to this arm will be up-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
11038804|NCT04507061|Placebo Comparator|Placebo|Participant randomized to this arm will be sham-titrated. A 30-day safety follow up will be performed after end of treatment or after early discontinuation from the study.
11038805|NCT04507048|Active Comparator|Passive intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
11038806|NCT04507048|Experimental|Active intervention|"A standardized oral explanation will be given to the patient by a dermatologist, together with the administration of a booklet containing written information of 2 clinical rules for detection of melanoma, as the ABCDE and the ugly duckling rules."
11038807|NCT04507035|Experimental|Anlotinib group|After 2 cycles of anlotinib treatment, we evaluate the therapeutic effect of tumor treatment: If it achieve downgrading and is operable, surgical treatment will be performed; if it is still inoperable and could accept radiotherapy, radiotherapy and chemotherapy will be combined with oral chemotherapy of anlotinib until the end of radiotherapy. Efficiency and side effects will be evaluated within 3 months after therapy. Finally, the survival is in follow-up.
11038808|NCT04507022|Experimental|HRT Plus Aromatase Inhibitor|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups:
~Group A (HRT plus AI): will be given aromatase inhibitor for 5 days only (2.5 mg twice daily), along with the oral 6 mg E2. Then, daily intramuscular (IM) P in oil (100 mg IM P) will be started in addition to the daily dose of oral 6 mg E2.
~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
11038809|NCT04507022|Active Comparator|HRT Only|"Hormone replacement treatment (HRT) will be used in all cases. Exogenous estradiol will be started on day 2 or 3 of the cycle. In all participants, 2 mg oral estradiol valerate, will be administered three times daily. Ultrasound evaluation of endometrium will be performed 10 to 12 days after starting E2. Trilaminar endometrium of 9 mm will be the targeted cutoff . If not yet ready, E2 supplementation will be continued with serial US assessment until the desired cutoff is achieved. Thereafter, participants will be randomized to two groups Group B (HRT only): will be administered daily intramuscular (IM) P in oil (100 mg IM P) in addition to the daily dose of oral 6 mg E2.
~In both groups, embryos will be warmed on the 6th day of P supplementation. Before undergoing FET, endometrial thickness will be re-evaluated. IM P and 6mg E2 will be continued thereafter."
11038810|NCT04507009|Active Comparator|Control|Traditional treatment group which alvogyl applied to the socket after irrigation
11038811|NCT04507009|Experimental|Ozone|Ozone group which Ozone (O3) applied after irrigation of the socket
11038812|NCT04507009|Experimental|CGF +Ozone|CGF + Ozone group which concentrated growth factor (CGF) after Ozone (O3) applied followed by irrigation of the socket.
11038845|NCT04506814|Experimental|Epicardial PVI + Posterior Wall Isolation|Minimally invasive surgical ablation using the convergent approach
11038846|NCT04506814|Experimental|Epicardial PVI + Posterior Wall Isolation + LAA Exlclusio|Minimally invasive surgical ablation using the convergent approach plus LAA exclusion using the clip
11038847|NCT04506801|Placebo Comparator|Placebo|liquid oral formulation 9 drops once a day
11039662|NCT04501341|Experimental|BM-MNC experimental|Autologue bone marrow mononuclear cell
11038813|NCT04506996|Experimental|Intervention Group - Receiving Text Messages|"The 16-weeks text-messaging intervention centered around 8 goal topics: eating only when hungry, increasing PA, eating a lower fat diet, eating less sugar and reducing calories from beverages, exercising more, eating a balance diet, portion control, and making healthier food choices in social situations.
~Messaging
~Sun evening: asked to pick 1 of 3 goal topics
~Mon morning: received a goal to focus on for the week
~Mon evening: asked whether plans were made to reach the goal
~Wed morning: received a tip to help reach goal
~Wed evening: reminded that if having cravings, text tip to automatically receive a tip
~Fri morning: received end of the week congratulations, encouragement to keep goals in mind over the weekend
~Fri evening: asked for weight, congratulated if lost weight, or encouraged if no weight lost"
11038814|NCT04506996|Active Comparator|Control Group - Written Messages|"Participants in the control group, received a printed copy of the same messages that the intervention group received. However, the first eight-weeks' worth of messages and craving tips were given after the baseline assessment, and the rest were given after the first follow-up assessment (~ 8 weeks post randomization).
~The messages for each week were clearly laid out and labeled. Participants were given spaces to record their answers (i.e. to which goal they were selecting for each week). The study staff reviewed the first week's messages together with the study participants to get the participants comfortable with the format that the printed messages were presented in."
11038815|NCT04506983|Experimental|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).
11038816|NCT04506970||Intrauterine Growth Restriction|Pregnant women carrying a fetus identified with intrauterine growth restriction during the third trimester (>28 weeks gestation)
11038817|NCT04506970||Normal pregnancy|Pregnant women identified with an uncomplicated pregnancy during the third trimester (>28 weeks), matched for fetal sex and gestational age with women enrolled in the IUGR group.
11038818|NCT04506944||General population|Whole population of scrub typhus endemic villages
11038819|NCT04506944||hospital case population|cases recruited at study clinics who are not enrolled in general population cohort
11038820|NCT04506944||Serological cohort|random subset of 4000 participants above the age of 10 drawn from general population cohort
11038821|NCT04506931|Experimental|Short Message Service (SMS) survey|Participants will receive an SMS survey
11038822|NCT04506931|Experimental|Interactive Voice Response (IVR) survey|Participants will receive an IVR survey
11038823|NCT04506931|Experimental|Computer Assisted Telephone Interviews (CATI) survey|Participants will receive a CATI survey
11038824|NCT04506918|Experimental|IVR survey|Participants will receive an IVR survey
11038825|NCT04506918|Experimental|SMS survey|Participants will receive an SMS survey
11038826|NCT04506905|Experimental|Part 1 (Panel A) MK-8189|Young adult participants receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
11038827|NCT04506905|Experimental|Part 1 (Panel B) MK-8189|Young adult participants receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
11038828|NCT04506905|Experimental|Part 1 (Panel C) MK-8189|Young adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
11038829|NCT04506905|Experimental|Part 2 (Panel D) MK-8189|Elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
11038830|NCT04506905|Experimental|Part 2 (Panel E) MK-8189|Elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
11038831|NCT04506905|Placebo Comparator|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
11038832|NCT04506905|Placebo Comparator|Part 2 (Panels D, E) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
11038833|NCT04506892|Experimental|Meditation Class|Subjects will undergo an intervention involving meditation classes for 2.5 hours a week for 8 weeks between pre- and post-class MRI
11038834|NCT04506879|Other|Popliteal Sciatic Nerve block|Patients will lie on their chest on the examination couch with both feet rested on the pillow to relax their lower extremity. Ultrasound scan of the nerves in popliteal fossa will be identified and then local anesthetic agents [1.5% lidocaine with 1:200,000 adrenaline and 0.5ml of 8.4% sodium bicarbonate (total 30ml)] will be injected close to the nerves (Common peroneal nerve and tibial nerve). The injections below the bifurcation near the two nerves are expected to produce quicker block than the injections above the bifurcation.
11038835|NCT04506866|Other|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
11038836|NCT04506866|Other|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
11038837|NCT04506866|Other|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
11038838|NCT04506853|Other|Study Procedure|
11038839|NCT04506840|Experimental|Training group|Participants will participate in a program of physical exercise during the adjuvant chemotherapy treatment
11038840|NCT04506840|No Intervention|Not training group|Participants will not do any intervention, they only will be perform the pre and post-tests.
11038841|NCT04506827|Active Comparator|Control group|patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation
11038842|NCT04506827|Experimental|Test group 1|patients in the test group 1 received TCP with particle size from 250 to 1000 µm
11038843|NCT04506827|Experimental|Test group 2|patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid
11038844|NCT04506814|Active Comparator|Endocardial PVI|Endocardial complete PVI
11039663|NCT04501341|Experimental|UC-MSC|Umbilical cord mesenchymal stem cell
11038848|NCT04506801|Experimental|Probiotic|The probiotic contained Lactobacillus acidophilus LA3; 1 · 1011 CFU / g, Bifidobacterium animalis subsp. Lactis BLC1; 1.5 · 1011 CFU / g and Lactobacillus casei BGP93 2 · 1011cfu / g in the form of a liquid oral formulation
11038849|NCT04506775|Experimental|Wrist one|Wrist one will have both the ViTrack wrist cuff on one wrist
11038850|NCT04506775|Active Comparator|Wrist Two|Wrist two and the radial artery catheter in the opposite wrist.
11038851|NCT04506762|No Intervention|Control|Standard of care for peri operative analgesia
11038852|NCT04506762|Experimental|Intervention|Bilateral ESP catheters for peri operative regional analgesia
11038853|NCT04506749|Experimental|Experimental group|"Consumption of antioxidant boiled ham, 100 grams daily to consume during the day.
~Consumption time: 8 weeks."
11038854|NCT04506749|Placebo Comparator|control group Placebo|Consumption of extra boiled ham, 100 grams daily to consume during the day. Consumption time: 8 weeks.
11038855|NCT04506736|Active Comparator|SPV spontanous ventilation|The patients will be ventilated using volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
11038856|NCT04506736|Active Comparator|OLA open lung ventilation|The patients will undergo ARM followed by personalized PEEP.
11038857|NCT04506723|Experimental|Patients with urolithiasis|Patients with confirmed urolithiasis who is assigned to PCNL.
11038858|NCT04506723|Active Comparator|Patients without urolithiasis|Patients with renal tumor without urolithiasis in history who is assigned to partial or radical nephrectomy due to renal tumor.
11038859|NCT04506710||Patients with low-risk prostate cancer|Histologically confirmed low-risk prostate cancer (PSA up to 10 ng / ml; Gleason (3 + 3) = 6 (ISUP 1); tumor stage T2a (low- risk according to the D'Amico scale))
11038860|NCT04506697|Experimental|Patients with LUTS|Patients who are indicated for uroflowmetry
11038861|NCT04506671|Experimental|Cryoablation group|Patients with T1b renal tumor and ECOQ>20
11038862|NCT04506671|Active Comparator|Partial nephrectomy group|Patients with T1b renal tumor
11038863|NCT04506658|Experimental|Intervention group|
11038864|NCT04506658|Sham Comparator|Control group|
11038865|NCT04506645|Experimental|REGN5381|Single dose REGN5381 administered via IV infusion
11038866|NCT04506645|Other|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
11038867|NCT04506619||SHP607 250 mcg/kg/24 hours|Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
11038868|NCT04506619||SHP607 400 mcg/kg/24 hours|Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
11038869|NCT04506619||Standard Neonatal Care|Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203.
11038870|NCT04506606|Experimental|Afferent effect on hemodynamics|Evaluate impact of group III/IV muscle afferents on femoral blood flow
11038871|NCT04506606|Experimental|Afferent effect on fatigue|Evaluate impact of group III/IV muscle afferents on exercise-induced changes in quadriceps twitch force
11038872|NCT04506606|Experimental|Effect of cardiac rehab|Evaluate effect of chronic exercise on influence of muscle afferents on limb blood flow
11038873|NCT04506580|Experimental|Dermabond group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using DERMABOND™ PRINEO™
11038874|NCT04506580|No Intervention|Subcuticular group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using 3-0 Dermalon with subcuticular suture method
11038875|NCT04506567|Experimental|Dose- Fractionated Cohort|
11038876|NCT04506567|Experimental|Multiple Dose Cohort|
11038877|NCT04506554|Experimental|AMVAC + nivolumab|This will be a single-arm, open-label, multicenter phase 2 study of neoadjuvant nivolumab with AMVAC. Approximately 70 evaluable patients will be enrolled into this study. Eligible patients will be those with diagnosis of muscle invasive urothelial carcinoma of the bladder who are cT2 or cT3 but not clinical N1 at diagnosis. Clinical stage is confirmed by transurethral resection of bladder tumor (TURBT#1).
11038878|NCT04506541|Experimental|Kangaroo Care Group|"The pregnant women who were in the kangaroo care group of the study and who were 36-38 weeks of gestation were given 20 minutes of kangaroo care and breastfeeding training by the researcher. A video about kangaroo care and breastfeeding was sent to pregnant women to remind them two weeks after the training. Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room. In the first, third, sixth, and ninth months after the discharge of the mothers who started applying kangaroo care, kangaroo care application status, breastfeeding status, baby's growth, and development status were evaluated. In each follow-up, the baby's height, weight, and head circumference were measured with a standard measuring tool."
11038879|NCT04506541|No Intervention|Control Group|The pregnant women in the control group were not trained other than breastfeeding training given in the hospital. In the maternity room, routine care practices were performed after delivery of the pregnant women. As in mothers in the kangaroo care group, in the first, third, sixth, and ninth months after the discharge of mothers, kangaroo care application situations, breastfeeding conditions, growth, and development of the baby were evaluated.
11038880|NCT04506528||Patients with COVID-19|The cohort analyzed for the first paper will be those who have met COVID-19 criteria and who have been hospitalized. COVID-19 criteria for inclusion in the study include: ICD-10-CM diagnosis of COVID-19, COVID-19 PCR lab test, and/or COVID-19 antibody lab test.
11038881|NCT04506502|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
11038882|NCT04506489||Psychological investigation|
11038883|NCT04506476|Experimental|Activity tracker with weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. We suggest a daily step-count which should improve the patients physical activity during radiotherapy of breast cancer. Patients receive weekly feedback and a new goal with the aim to reach a total of 6000 daily steps, which should be then maintained during radiotherapy."
11039380|NCT04503239||Type 2 Diabetes in GLP-1 with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11038884|NCT04506476|Experimental|Activity tracker without Weekly goals|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy.
~The patients self-document their daily step count during radiotherapy, there will be no recommendation for the daily count of steps."
11038885|NCT04506476|No Intervention|Control arm with no activity tracker|"Patients receive a booklet Physical training, exercise and cancer and an in-person briefing on physical activity during cancer therapy. A fitness tracker will not be provided."
11038886|NCT04506463|Experimental|Arm A|MM-II 1 ml
11038887|NCT04506463|Experimental|Arm B|MM-II 3 ml
11038888|NCT04506463|Experimental|Arm C|MM-II 6 ml
11038889|NCT04506463|Placebo Comparator|Arm 4|Placebo 1ml
11038890|NCT04506463|Placebo Comparator|Arm 5|Placebo 3ml
11038891|NCT04506463|Placebo Comparator|Arm 6|Placebo 6ml
11038892|NCT04506450|Active Comparator|Peripheral nerve block|The participant will receive a combination of lumbar plexus block, sciatic nerve block, lateral femoral cutaneous nerve block and lateral branch of iliohypogastric nerve block
11038893|NCT04506450|Active Comparator|Spinal anesthesia|The participant will receive a combination of spinal anesthesia and lumbar plexus block
11038894|NCT04506437|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
11038895|NCT04506437|Active Comparator|Standard of care, then family-based mental health navigation|During wait-list period receive standard of care engagement practices and services-as-usual, and after the wait-list period the participants receive the family-based navigator intervention combined with mHealth practices
11038896|NCT04506424|Experimental|CT-Based Program for First Year of CI Use|"The Flat Panel CT scan will take place after a CI has been implanted and prior to the CI device activation.
~The CI device will be activated using a CT-based program. The participant may continue to use this program for 1 year. Speech and music perception abilities will be monitored at regular intervals (approx. at 1, 3, 6, and 12 months post-activation).
~After the 1 year of experimental program use, the participant may be switched over to a program that uses only the clinical default settings for 1 month; after which the participant will again complete the speech and music test battery.
~At the end of the 13 month study the participant may choose whether to use the CT-based program or the clinical default program moving forward."
11038897|NCT04506411|Experimental|TPG|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
11038898|NCT04506411|Active Comparator|STE|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
11038899|NCT04506411|Placebo Comparator|Control|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
11038900|NCT04506398||Retrospective cohort|20 HCC patients experienced post-transplant HCC
11038901|NCT04506398||Perspective cohort|20 HCC patients who underwent liver transplant, the patients would be recruited if recurrence would be diagnosed >6 months after liver transplant
11038902|NCT04506385|Active Comparator|A|L. delbrueckii LDD01
11038903|NCT04506385|Active Comparator|B|Bifidobacterium longum DLBL
11038904|NCT04506385|Active Comparator|C|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: low dosage
11038905|NCT04506385|Active Comparator|D|L. plantarum LP01, L.fermentum LF16, L. rhamnosus LR06 and B. longum BL04: high dosage
11038906|NCT04506372|Experimental|Intervention group|Perioperative withdrawal of ACEI/ARB.
11038907|NCT04506372|Active Comparator|Control group|Perioperative continuation of ACEI/ARB.
11038908|NCT04506359|No Intervention|control group|Control Group: Usual care +case manager care, UC group or Control group
11038909|NCT04506359|Experimental|experimental group|The experimental group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1) - usually patients visited hospital in 2 weeks, 1 month, 2 months, 3 months and 6 months (T2-6) after surgery. Patients will receive (a) nurse-guided touch-screen computer screening (assessment) for their psychological and physical distress and care needs during current week; (b) the screening /assessment results will immediately show as the outcome (we are developing a calculation system to sum those scores).
11038910|NCT04506346||OSAHS|patients with OSAHS, undergoing UPPP
11038911|NCT04506333|Experimental|Small Cuff|"Participants with an upper-arm circumference of 6.3-9.4 may be placed in the small cuff arm."
11038912|NCT04506333|Experimental|Medium Cuff|"Participants with an upper-arm circumference of 9.0-14.6 may be placed in the medium cuff arm."
11038913|NCT04506333|Experimental|Lage Cuff|"Participants with an upper-arm circumference of 12.2-17.7 may be placed in the large cuff arm.
~The large cuff arm will use an adaptive study design. Per the AAMI/ESH/ISO standards, at least 1/6 of participants must fall into each cuff size arm for that cuff size, and of the participants assigned to each cuff size, at least 40% of those must fall in the upper and lower half of the cuff's size range. However, we do not anticipate many participants in our age range falling in the upper half of the large cuff size range (upper arm circumference > 14.95).
~Because of this, our plan is to validate the large cuff, but if enrolling a patient with a large cuff would require additional patients be enrolled to reach 1/6 of the total sample, the large cuff will be dropped from consideration and the validation completed with only the small and medium cuffs."
11038914|NCT04506320||Patients with Multiple myeloma|Adult with diagnosis of multiple myeloma treated with Allo-HSCT from related - HLA identical or volunteer unrelated donor or haploidentical related donor performed from January 1, 2009 to december 31, 2018
11038915|NCT04506307|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.
11038916|NCT04506294|Experimental|eScreen Group|After randomization at baseline, use eScreen system (child screening component and parent information component) for 6 weeks.
11038917|NCT04506294|No Intervention|Usual Care Group|Treatment as usual from baseline. Optional access to the game only (no screening, no parent information component) after completion of T3 assessment (~12 weeks)
11039490|NCT04502537||Roxadustat|treatment with roxadustat
11039491|NCT04502537||erythropoietin|treatment with erythropoietin
11038918|NCT04506281|Experimental|Neoadjuvant treatment|"Gemox chemotherapy:
~Day1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.
~Lenvatinib (8mg/d) for 9 weeks of continuous use.
~Toripalimab (240mg, once every 3 weeks), used 3 times. Evaluate the resectability of the operation within 2-4 weeks after the end of the neoadjuvant treatment course, and implement radical resection. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses"
11038919|NCT04506281|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients undergoing resection use capecitabine 2500mg/m2 twice a day, stopping for 1 week as a course of treatment, totaling 8 courses.
11038920|NCT04506268|Experimental|Opt-in Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and invites them to enroll.
11038921|NCT04506268|Experimental|Opt-out Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and informs them that they have been conditionally enrolled.
11038922|NCT04506255|Experimental|Silicone tape|Adult subjects will act as their own control and will be randomized to have silicone tape applied to one half of their abdominoplasty incision. Patients will apply silicone tape on a daily basis, with each piece lasting 24 hours. Tape may be removed for showers and replied after drying. Total length of treatment will be two and a half months.
11038923|NCT04506255|No Intervention|No dressing|Control treatment using the current standard of care at our institution to the other half, which is no dressing after the initial two week post-op period, will be used on the other half of the incision for comparison. Each individual patient will act as their own control.
11038924|NCT04506242|Experimental|apatinib+ Neoadjuvant/Adjuvant camrelizumab|"Neoadjuvant: Prior to surgery, participants receive 3 cycles (cycle length: 2 weeks) of camrelizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with apatinib ,5 days on 2days off].
~Adjuvant: 4-8 weeks following surgery, participants receive up to 12 cycles (cycle length: 2 weeks) of camrelizumab [200 mg, IV; given on cycle day 1]. Participants who can not able to benefit from immunotherapy will not receive camrelizumab adjuvant therapy."
11038925|NCT04506229||COVID-19 positive|
11038926|NCT04506229||COVID-19 negative|
11038927|NCT04506216|Experimental|cohort|adult patients with type 1 diabetes and insulin pump treatment . Duration of participation: 30 minutes
11038928|NCT04506190||Robotic-assisted revisional bariatric surgery|Subjects who undergo robotic-assisted revisional bariatric surgery
11038929|NCT04506190||Laparoscopic revisional bariatric surgery|Subjects who undergo laparoscopic revisional bariatric surgery
11038930|NCT04506177||Permanent Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) suture for vaginal mesh attachment
11038931|NCT04506177||Delayed Absorbable Monofilament Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using delayed absorbable monofilament (polydioxanone, PDS) suture for vaginal mesh attachment
11038932|NCT04506164|Other|Stepped-wedge|This stepped-wedge trial relies on sequential roll-out of eScreening to participating sites over time, while using other sites as controls until they begin implementation.
11038933|NCT04506151|Experimental|Sleep-Opt|12-week intervention that includes self-monitoring, goal setting, motivational enhancement.
11038934|NCT04506151|Active Comparator|Healthy Living|12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.
11038935|NCT04506138|Experimental|Camrelizumab plus Chemotherapy|
11038936|NCT04506125|Experimental|Liberal Group|transfusion of an erythrocyte concentrate in case of haemoglobin below 9.5 g/dL
11038937|NCT04506125|Active Comparator|Restrictive group|transfusion of an erythrocyte concentrate in case of haemoglobin below 7.5 g/dL
11038938|NCT04506112|Experimental|TranS-C + Usual Care|Participants in this group will receive TranS-C and will continue with care in cardiac rehabilitation as usual.
11038939|NCT04506112|No Intervention|Usual Care|Participants in this group will receive only usual care and thus will continue with care in cardiac rehabilitation as usual.
11038940|NCT04506099|Active Comparator|TINS Active|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. For example, a T7 level of injury will have TINS applied to the T8 level. A T2 level of injury will have TINS applied to the T6 level. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
11038941|NCT04506099|Sham Comparator|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
11038942|NCT04506086|Experimental|Blinatumomab|
11038943|NCT04506073|Experimental|MSC+placebo|2 treatment doses + 1 placebo 3 months apart
11038944|NCT04506073|Experimental|MSC|3 treatment doses 3 months apart
11038945|NCT04506073|Placebo Comparator|Placebo|3 placebo doses 3 months apart
11038946|NCT04506047||Acute Myocardial Infarction|Consecutive patients with acute myocardial infarction
11038983|NCT04505800|Placebo Comparator|Maltose|"Placebo is maltose powder capsule (500mg/capsule)
~3g maltose powder per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
11039586|NCT04501874|Placebo Comparator|EMB-001 Placebo|EMB-001 Placebo by mouth twice per day for 12 weeks followed by a 1 week taper
11038947|NCT04506034|Experimental|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
11038948|NCT04506034|Active Comparator|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
11038949|NCT04506034|Placebo Comparator|IV saline infusion|received i.v. saline infusion.
11038950|NCT04506021||Bicarbonate Ringer's Solution|"According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution.
~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
11038951|NCT04506021||Other Crystalloid|"According to the choices of patients' immediate family members, patients will be divided into Other Crystalloid.
~drug dosage form: Solution, Intravenous infusion. the drug dosage frequency and duration were no intervention"
11038952|NCT04506008|Experimental|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy followed by immediate surgical resection
11038953|NCT04505995|Experimental|Intervention group|
11038954|NCT04505982||Tocilizumab intravenous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, intravenous
11038955|NCT04505982||Tocilizumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, subcutaneous
11038956|NCT04505982||Sarilumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with sarilumab, subcutaneous
11038957|NCT04505969||SCD patients and healthcare professionals|
11038958|NCT04505956|Experimental|Moses Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). Moses laser technology will be utilized in distance mode.
11038959|NCT04505956|Active Comparator|Standard Laser Lithotripsy|Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
11038960|NCT04505943|Experimental|isonicotinic acid hydrazide|2vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
11038961|NCT04505943|Active Comparator|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 12 hours before IUD insertion.
11038962|NCT04505943|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 12hours before IUD insertion.
11038963|NCT04505930|Experimental|Intervention Group with active education|The study team provides participants in the intervention group with interventional education, using interactive video watch and dynamic discussion.
11038964|NCT04505930|Active Comparator|Control Group with handouts|The study team provides the participants in the control group with education, using only handouts of vaccinations including HPV, but not using interactive video watch and dynamic discussion
11038965|NCT04505917|Experimental|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
11038966|NCT04505917|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
11038967|NCT04505917|Placebo Comparator|placebo|Placebo Comparator: placebo 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
11038968|NCT04505904|Experimental|Syntocinon First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.
11038969|NCT04505904|Placebo Comparator|Placebo First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received placebo at visit one, and syntocinon at visit two.
11038970|NCT04505891|No Intervention|Usual care|
11038971|NCT04505891|Active Comparator|Education alone|
11038972|NCT04505891|Active Comparator|Education and follow-up|
11038973|NCT04505878|Experimental|Vitamin C Arm|Ascorbic Acid will be administered at a dose of 1500 mg in 100 mL of saline over 30 minutes intravenously once every 6 hours for a total of 72 hours
11038974|NCT04505865|No Intervention|Usual care|Optimally tolerated medical therapy
11038975|NCT04505865|Experimental|Stress reduction|Optimally tolerated medical therapy and stress reduction course for 8 weeks
11038976|NCT04505852|Experimental|EMBRACE USERS|Embrace wristband users
11038977|NCT04505839|Experimental|STP1002|
11038978|NCT04505826|Experimental|OP-1250 Dose Escalation|This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer and to determine the RP2D
11038979|NCT04505826|Experimental|OP-1250 Expansion|This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 monotherapy at the RP2D and to estimate preliminary data of anti-tumor efficacy
11038980|NCT04505813|Experimental|Safety Evaluation Phase|Treatment with NEXI-002 T cells, derived from PBMCs of the patient
11038981|NCT04505813|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI- 002 T cell product at the dose established from the Safety Evaluation Phase.
11038982|NCT04505800|Experimental|Tryptophan supplement|"Pure L-tryptophan in capsules (500mg/capsule)
~3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
11041403|NCT04488978|Active Comparator|Irbesartan high|Irbesartan high, once daily for 8 weeks
11038984|NCT04505787|Experimental|Esflurbiprofen hydrogel patch|"Esflurbiprofen hydrogel patch 165 mg (EFHP) (Teikoku Seiyaku Co.), transdermal patch containing 165 mg S-flurbiprofen, once daily consecutive application over 14 days; each patch to be applied for 24 h, application site: outer ankle (same site and position for all applied patches)"
11038985|NCT04505787|Active Comparator|Froben|"Froben 100 mg comprimidos revestidos (Abbott Laboratórios, Lda., Portugal), immediate release tablets containing 100 mg flurbiprofen, oral multiple dose administration of 1 tablet three times daily (TID) over 4 consecutive days after a light meal"
11038986|NCT04505774|Other|Therapeutic Dose Anticoagulation|increased dose of heparin above standard of care.
11038987|NCT04505774|Other|Prophylactic Dose Anticoagulation|Heparin standard of care
11038988|NCT04505761|Experimental|Intervention group|Participants will receive Virtual Reality as an add-on to standard physiotherapy after COVID-19.
11038989|NCT04505748|Experimental|Self-transfusion group|Patients to whom a self-transfusion device has been used after total knee arthroplasty.
11038990|NCT04505748|No Intervention|Control group|Patients to whom conventional drains have been used after total knee arthroplasty.
11038991|NCT04505735||Normal Control|Adults with no history of memory complaints, diagnosis of MCI, or dementia from a physician
11038992|NCT04505735||Adults with Mild Cognitive Impairment|Adults with cognitive decline verified by a study partner or cognitive impairment verified by the study physician. The cognitive decline has had limited impact on functional activities; general cognition and functional performance are sufficiently preserved such that a diagnosis of dementia cannot be made by the enrolling physician
11038993|NCT04505722|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S at a dose level of 5*10^10 virus particles (vp) as single dose vaccine on Day 1.
11038994|NCT04505722|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Day 1.
11038995|NCT04505696|Other|Speech-Language Pathology Introduction and scope|Demographic Information Section on Knowledge & Awareness Section on Practices
11038996|NCT04505683|Experimental|test drug arm|Benapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
11038997|NCT04505683|Active Comparator|active control arm|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
11038998|NCT04505670|Experimental|Donepezil and Topical Zinc Oxide|donepezil 5mg daily and topical zinc oxide 20% three times daily
11038999|NCT04505670|Placebo Comparator|Placebo and Topical Zinc Oxide|Placebo daily and topical zinc oxide 20% three times daily
11039000|NCT04505657|Experimental|Celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
11039001|NCT04505657|Active Comparator|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
11039002|NCT04505657|Active Comparator|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
11039003|NCT04505644|Experimental|lidocaine patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
11039004|NCT04505644|Active Comparator|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
11039005|NCT04505644|Placebo Comparator|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
11039006|NCT04505618|Other|Controls|Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.
11039007|NCT04505618|Other|Diabetics with and without Diabetic Retinopathy Only|Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.
11039008|NCT04505618|Other|Hypertension Only|Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
11039009|NCT04505618|Other|Diabetics w/ or w/o Diabetic Retinopathy & Hypertension|Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
11039010|NCT04505605||Patient hospitalized without being transferred in the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 (day of the enrollment = the day of hospitalization in the healthcare institution). The total volume of blood collected as part of the research is therefore 5 ml.
11039011|NCT04505605||Patient directly hospitalized in the ICU|A blood sample on a dry tube with a 5 ml separating gel in addition to the blood test made on the basis of the usual medical care, will be taken on D1 and D3 of the admission to intensive care. The total volume of blood collected for research is therefore 10 ml.
11039012|NCT04505605||Patient transferred from an other hospital service to the ICU|A blood sample on a dry tube with 5 ml separating gel in addition to the blood test that will be taken at D1 and D3 of the patient's admission to the intensive care unit, even if it has already been included in the study during the patient's admission to the unit (D1 hospitalization). The total volume of blood collected for the research is therefore 15 ml.
11039013|NCT04505592|Experimental|Tenecteplase|First 20 patients randomized to treatment will receive tenecteplase 0.25 mg/kg (maximum 25 mg). Last 20 patients randomized to treatment will receive tenecteplase 0.50 mg/kg (maximum 40 mg).
11039014|NCT04505592|Placebo Comparator|Placebo|Placebo control
11039015|NCT04505579||Tether|Patients who have received The Tether HUD for treatment of idiopathic scoliosis.
11039016|NCT04505566|Experimental|Adult Type II Diabetics - Moderate NPDR - Ketorolac|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy and HbA1c ≥ 8 randomized to Ketorolac treatment.
11039053|NCT04505397|Experimental|Single Ascending Dose Level 10|4 Subjects will receive one dose of 1000 mg and 2 subjects will receive one dose of placebo
11039017|NCT04505566|Placebo Comparator|Adult Type II Diabetics - Moderate NPDR - Placebo|59 Adult type II diabetic patients with baseline moderate non-proliferative diabetic retinopathy randomized to placebo treatment.
11039018|NCT04505566|Other|Adult Type II Diabetics - No Diabetic Retinopathy (DR)|23 Adult type II diabetic patients with no diabetic retinopathy as a control group.
11039019|NCT04505566|Other|Adult Type 2 Diabetics-Proliferative Diabetic Retinopathy(PDR)|23 Adult type II diabetic patients with proliferative diabetic retinopathy as a control group.
11039020|NCT04505566|Other|Age-matched Non-diabetics|We will also enroll 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole. Removed aqueous fluid that is typically discarded will instead be collected and stored at -80° C. Aqueous fluid will be tested for inflammatory markers as detailed below to provide a reference level for cross-comparison analysis.
11039021|NCT04505553|Experimental|Arm I (acupuncture, acupressure, cryotherapy)|Patients undergo acupuncture during chemotherapy infusion on day 1 and fluorouracil pump disconnect on day 3 of each biweekly chemotherapy infusion over 12 weeks. Patients also undergo self-administered acupressure over 11 minutes daily for 12 weeks and undergo standard of care oral cryotherapy.
11039022|NCT04505553|Active Comparator|Arm II (cryotherapy)|Patients undergo standard of care oral cryotherapy.
11039023|NCT04505540|Active Comparator|Bridge Clinic|Medication assisted treatment supervised by addiction bridge clinic until stabilized in treatment.
11039024|NCT04505540|Active Comparator|Local Waivered Physcian|Medication assisted treatment supervised by local waivered physician.
11039025|NCT04505527|Active Comparator|Recurrent fallers - control group|In this control arm, older adults will have a typical forward walking training that mirror the lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min forward walking. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
11039026|NCT04505527|Experimental|Recurrent fallers - intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
11039027|NCT04505527|Experimental|Older non-fallers intervention group|In this experimental arm, older adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
11039028|NCT04505527|Active Comparator|Younger adult control group|Outcome measures from a young healthy group will also be measured as a reference. Will be used to compare outcome measured between older and young adults. Young adults will have a lateral stepping intervention: 3 days/week for 6 weeks, resulting in a total of eighteen sessions. Each session consists of six trials of 3 min sideways walking across a 10 m walkway changing body direction at the ends, thus alternating lead and lag limbs. The participants can increase their pace at the start of each trial but may not decrease it at the next session.
11039029|NCT04505514|Experimental|Intravenous Iron Group|
11039030|NCT04505514|Active Comparator|Oral Iron Group|
11039031|NCT04505501|Experimental|N-803|N-803 at 6mcg/kg every 3 weeks for 3 doses plus ART (n=10)
11039032|NCT04505501|No Intervention|Control|ART alone (n=5)
11039033|NCT04505488|Experimental|Intervention Group|The intervention group will receive a parent manual, a resource packet, and 12 weekly sessions delivered by the clinician and peer leader.
11039034|NCT04505488|No Intervention|Control Group|The control group will receive a parent manual and a resource packet. Four phone check-ins will be conducted across 12-14 weeks to address questions by the research team.
11039035|NCT04505475||Direct oral anticoagulants|Patients taking dabigatran, ravaroxaban or apixaban
11039036|NCT04505475||Vitamin K antagonists|Patients taking acenocoumarol with therapeutic INR levels (2.0-3.5)
11039037|NCT04505462|Experimental|Study diet|7-day therapeutic diet intervention as experimental group
11039038|NCT04505462|No Intervention|Usual diet|7-day usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet
11039039|NCT04505449||Left heart catheterization|Symptomatic patients who underwent left heart catheterization and coronary angiography.
11039040|NCT04505436|Experimental|HM15211|
11039041|NCT04505436|Placebo Comparator|Placebo|
11039042|NCT04505410|Experimental|Tofacitinib plus FMD group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks with the addition of two, five-day cycles of Fast Mimicking Diet (FMD) daily meals on weeks 2 and 6.
11039043|NCT04505410|Active Comparator|Tofacitinib only group|Participants in this group with UC consuming a standard, regular low-fiber diet will be provided Tofacitinib for eight consecutive weeks.
11039044|NCT04505397|Experimental|Single Ascending Dose Level 1|4 Subjects will receive one dose of 10 mg and 2 subjects will receive one dose of placebo
11039045|NCT04505397|Experimental|Single Ascending Dose Level 2|4 Subjects will receive one dose of 25 mg and 2 subjects will receive one dose of placebo
11039046|NCT04505397|Experimental|Single Ascending Dose Level 3|4 Subjects will receive one dose of 50 mg and 2 subjects will receive one dose of placebo
11039047|NCT04505397|Experimental|Single Ascending Dose Level 4|4 Subjects will receive one dose of 100 mg and 2 subjects will receive one dose of placebo
11039048|NCT04505397|Experimental|Single Ascending Dose Level 5|4 Subjects will receive one dose of 200 mg and 2 subjects will receive one dose of placebo
11039049|NCT04505397|Experimental|Single Ascending Dose Level 6|4 Subjects will receive one dose of 300 mg and 2 subjects will receive one dose of placebo
11039050|NCT04505397|Experimental|Single Ascending Dose Level 7|4 Subjects will receive one dose of 400 mg and 2 subjects will receive one dose of placebo
11039051|NCT04505397|Experimental|Single Ascending Dose Level 8|4 Subjects will receive one dose of 600 mg and 2 subjects will receive one dose of placebo
11039052|NCT04505397|Experimental|Single Ascending Dose Level 9|4 Subjects will receive one dose of 800 mg and 2 subjects will receive one dose of placebo
11039054|NCT04505397|Experimental|Multiple Ascending Dose Level 1|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
11039055|NCT04505397|Experimental|Multiple Ascending Dose Level 2|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
11039056|NCT04505397|Experimental|Multiple Ascending Dose Level 3|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
11039057|NCT04505397|Experimental|Multiple Ascending Dose Level 4|6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.
11039058|NCT04505384|Experimental|Left bundle branch pacing|Left bundle branch pacing
11039059|NCT04505384|Active Comparator|Biventricular pacing|Biventricular pacing
11039060|NCT04505371|No Intervention|Control|
11039061|NCT04505371|Experimental|Intervention|
11039062|NCT04505358|Experimental|30 mg PU AD 3:2 ratio|will be administered orally, as 30 mg active dose strength tablets qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
11039063|NCT04505358|Placebo Comparator|30 mg Placebo 3:2 ratio|will be administered orally, as 30 mg placebo tablets (placebo has no active ingredients) qd on an empty stomach (1 hour prior to food or 2 hours after), at about the same time each day, via standard of care procedures at the site or at home. All subjects will have their first dose administered in clinic following completion of all baseline assessments
11039064|NCT04505345|Experimental|Virtual reality cognitive training|Virtual reality cognitive training consists of a behavioral intervention of 10 sessions of training using virtual reality exercises depicting daily life activities from the Systemic Lisbon Battery aiming cognitive impairments.
11039065|NCT04505345|Other|Treatment-as-usual|Treatment-as-usual for alcohol use disorder (AUD) in our partner institution, a therapeutic community for rehabilitation of AUD, is conducted according to the Minnesota Model requiring alcohol abstinence.
11039066|NCT04505332|Other|orthopedists|orthopedists working actively and performing arthroplasty every day
11039067|NCT04505319|Experimental|DEFINISSE CORE FILLER|"Cross linked sodium hyaluronate 25 mg/ml with 0,3% lidocaine hydrochloride will be inject during the first visit and a touch up after one month if indicated by the physician.
~The filler will inject in the face."
11039068|NCT04505306|Active Comparator|Subthreshold Laser 30%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 30% EndPoint algorithm.
11039069|NCT04505306|Active Comparator|Subtreshold Laser 50%|Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with 50% EndPoint algorithm.
11039070|NCT04505306|Active Comparator|Micropulse Laser|Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle.
11039071|NCT04505293|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ upon arrival to the casualty unit at MRRH following CT. Patients will be scanned using the InfraScanner 2000™ following each subsequent CT as allowed by patient or representative. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
11039072|NCT04505280|Active Comparator|Active|%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks
11039073|NCT04505280|Placebo Comparator|Placebo|0.9% saline injections to greater occipital nerve and cervical region once a week for 4 weeks
11039074|NCT04505267|Experimental|Cohort 1: Treatment (RT)|Patients will receive radiation alone over two-three weeks (5 times weekly) for a total of 10-15 fractions.
11039075|NCT04505267|Experimental|Cohort 2: Treatment (NBTXR3, RT)|Patients receive NBTXR3 IT or intranodally on day 1. Within 15 days, patients undergo RT 5 times weekly (Monday-Friday) over 3 weeks for a total of 10-15 fractions.
11039076|NCT04505254|Experimental|Treatment (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID every 12 hours starting on day 1 of cycle 1, and obinutuzumab IV over 4-6 hours on days 1 and 2 of cycle 3, and day 1 of cycles 4-8. Patients who do not achieve a complete response or remission after cycle 8 may receive single-agent acalabrutinib therapy PO BID for an additional 6 cycles at the discretion of their treating physician. Patients who are in partial response or who have stable disease receive an additional 6 cycles of acalabrutinib PO BID and obinutuzumab IV. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11039077|NCT04505241|Experimental|Adaptive Goal-Setting|Participants in this condition will receive daily step goals calculated as the 60th percentile of their last 9 days of available daily steps data. Goals will be transmitted over text message, and will be accompanied by information about the participant's steps on the previous day and whether they met their goal the previous day.
11039078|NCT04505241|Experimental|Static Goal-Setting|Participants in this condition will receive daily a uniform daily goal of 10,000 steps per day. Participants will receive daily texts including information about the participant's steps on the previous day, whether they met their goal the previous day, and encouraging them to continue striving for 10,000 steps each day.
11039079|NCT04505228|Experimental|Research group|The patients receiving Atropine and the extra Chinese herb formulas treatment
11039080|NCT04505228|Active Comparator|Control group|The patients receiving the basic treatment of atropine
11039113|NCT04505033|Experimental|450 mg s.c.|
11039114|NCT04505033|Placebo Comparator|450 mg placebo|
11039285|NCT04503941|Experimental|Active Comparator|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
11039081|NCT04505215|Experimental|Mulligan Technique|In addition to the exercises applied to the participants in the control group, the participants in this group used Mobilization with movement, which was performed with the principle of painless movement 3 times a week for a total of 12 times a week for 4 weeks. Mobilization with movement has been performed by a certified physiotherapist who has been practicing this technique for 10 years.
11039082|NCT04505215|Experimental|Muscle Energy Technique|In addition to the exercises applied to the participants in the control group, the Janda method (Post Isometric Relaxation Technique) from Muscle Energy Technique (3 times a week) was used 3 times a week for 4 weeks.
11039083|NCT04505215|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the forearm extensors were shown to the participants in the control group for 4 weeks every day of the week.
11039084|NCT04505202|Experimental|Experimental group|0.12% chlorhexidine gluconate
11039085|NCT04505202|Placebo Comparator|Placebo group|sodium bicarbonate
11039086|NCT04505189|Experimental|Treatment|Psilocybin
11039087|NCT04505176||1|20 patients being in the HHHNFC. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
11039088|NCT04505176||2|20 patients in the CPAP group. In this study, it was aimed to monitor continuous oxygen saturation, PI, PVI, transcutaneous PO2 and PCO2 measurements just before, during and after the surfactant application and to compare the results of babies who received nCPAP and HHHFNC support.
11039089|NCT04505163|Active Comparator|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
11039090|NCT04505163|Experimental|Cryoballoon PVI + Posterior Wall Isolation|Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
11039091|NCT04505150|Experimental|Monitoring of lifestyle change activities|The intervention will take place in a primary care setting and will involve the delivery of life-styles-based counselling for the cessation of smoking, taking part in physical activity (counselling and monitoring to promote regular exercise at least 3 days a week) and nutrition (the provision of dietary advice to reduce raw salt consumption) to minimise iodine intake by trained health professionals and community volunteers.
11039092|NCT04505150|No Intervention|lifestyle change activities: non-monitoring|Delivery of life-styles-based counselling for the cessation of smoking, taking part in physical activity (counselling and monitoring to promote regular exercise at least 3 days a week) and nutrition (the provision of dietary advice to reduce raw salt consumption) to minimise iodine intake by trained health professionals and community volunteers. Information booklet describing risk factors and benefits of lifestyle changes will be given. Participants will not be monitored.
11039093|NCT04505137|Experimental|GMA301 1500mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 1500 mg single Intravenous dose of GMA301 Injection.
11039094|NCT04505137|Experimental|GMA301 2000mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 2000 mg single intravenous dose of GMA301 Injection.
11039095|NCT04505124|Experimental|FutureMe|"Participants use the FutureMe app for 12 weeks. The app has the following functionality:
~Opportunity to personalize one's avatar
~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)
~Feedback on health behaviors represented through a Future-self avatar (consequential and visual feedback)
~Individualized shopping tipps"
11039096|NCT04505124|Active Comparator|Control|"Participants use the a control app for 12 weeks. The control app has the following functionality:
~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)
~Feedback on health behaviors represented through conventional dashboards (numeric & text feedback)
~Individualized shopping tipps"
11039097|NCT04505111|Experimental|Prehabilitation + Enhanced Recovery After Surgery|Patients allocated to the intervention group will undergo prehabilitation protocol (nutrition + exercise + psychological counselling), with individualized monitoring by the multidisciplinary team.
11039098|NCT04505111|Active Comparator|Enhanced Recovery After Surgery|Patients allocated to the control group will not undergo any pre-surgical intervention, except for preoperative counselling, already implicated in ERAS®.
11039099|NCT04505098|Active Comparator|Intervention|
11039100|NCT04505098|No Intervention|Usual Care|
11039101|NCT04505085|Experimental|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
11039102|NCT04505085|Experimental|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
11039103|NCT04505072|Experimental|PR-ESSENCE treatment|PR-ESSENCE treatment 10 weeks
11039104|NCT04505072|Active Comparator|Control|Treatment as usual 10 weeks
11039105|NCT04505059|Experimental|Precision cardiac anesthesia|Remifentanil (TCI) for intra-operative analgesia Propofol (TCI) for intra-operative sedation
11039106|NCT04505059|Active Comparator|Conventional cardiac anesthesia|Institutional standard of care.
11039107|NCT04505033|Experimental|50 mg s.c|
11039108|NCT04505033|Placebo Comparator|50 mg placebo|
11039109|NCT04505033|Experimental|150 mg s.c.|
11039110|NCT04505033|Placebo Comparator|150 mg placebo|
11039111|NCT04505033|Experimental|300 mg s.c.|
11039112|NCT04505033|Placebo Comparator|300 mg placebo|
11039115|NCT04505020|Experimental|3D Print + Conventional imaging|Patients in this group allocation will receive a 3D reconstruction of their hip in addition to conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
11039116|NCT04505020|Other|Conventional Imaging|Patients in this group allocation will receive conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
11039117|NCT04505007|No Intervention|Usual clinical care|In this arm, patients with devices and heart failure will undergo usual clinical care. This consists of follow-up as deemed necessary by their primary care providers.
11039118|NCT04505007|Experimental|Specialized clinic|"In this arm, patients with devices and heart failure will be enrolled in a specialized clinic with the following aims:
~Referral to a heart failure nurse practitioner to undergo optimization of medical therapy.
~Optimization of device programming with reduction of ventricular pacing where possible, rate responsiveness when indicated.
~For those patients with CRT - ECG optimization using a previously tested protocol will be performed. This will consist of attempts to achieve the shortest QRS duration with the following guidelines:
~Two BV fusion patterns in leads V1 and V2: QRS normalization or a new or an increased R wave.
~QRS difference ≤-25 ms. Remodelling probability increases as QRS difference takes on larger negative values (QRS difference = BV paced QRS - LBBB QRS duration, in ms)."
11039119|NCT04504994|Experimental|exclusion BPD|cyberball exclusion condition - BPD patients
11039120|NCT04504994|Experimental|over-inclusion BPD|cyberball over-inclusion condition - BPD patients
11039121|NCT04504994|Experimental|exclusion healthy controls|cyberball exclusion condition - healthy controls
11039122|NCT04504994|Experimental|over-inclusion healthy controls|cyberball over-inclusion condition - healthy controls
11039123|NCT04504981|Other|Y2Prevent Intervention|Y2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans.
11039124|NCT04504968|Experimental|Intervention group|Multimodal intervention:
11039125|NCT04504968|Placebo Comparator|Usual care group|Usual care group
11039126|NCT04504955||Atopic Dermatitis|Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
11039127|NCT04504942|Experimental|Leronlimab 525mg|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
11039128|NCT04504929|Sham Comparator|Sham tape|participants received sham taping during pitching, and removed after pitching
11039129|NCT04504929|Experimental|Dynamic tape|participants received dynamic taping during pitching, and removed after pitching
11039130|NCT04504916|Experimental|VLS-101|Open label VLS-101 at 2.5 mg/kg given IV on Day 1 of repeated 21-day cycles.
11039131|NCT04504903|Experimental|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will participate in 12 weekly group sessions to discuss thoughts, feelings, and behaviors that promote work success in the community
11039132|NCT04504903|Active Comparator|Psychoeducation|Veterans in the control group will participate in 12 weekly group sessions in which they will learn more about their mental health conditions.
11039133|NCT04504890||Adults - Diagnosis|Adults seeking treatment for an attention-related disorder
11039134|NCT04504890||Adults - Prescribed|Adults who have been diagnosed with ADHD and prescribed medication treatment for the disorder
11039135|NCT04504890||Children - Diagnosis|Children seeking treatment for an attention-related disorder
11039136|NCT04504890||Children - Prescribed|Children who have been diagnosed with ADHD and prescribed medication treatment for the disorder
11039137|NCT04504877|Experimental|cannabidiol plus general clinical supportive measures|The participants will receive CBD 300mg/daily plus general measures (supporting motivational videos, fitness videos). All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as well as five collections of saliva, in a collecting tube, to assess viral load. They will also be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
11039138|NCT04504877|Other|general clinical supportive measures|The participants will receive general measures (supporting motivational videos, fitness videos) alone. All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern in a collecting tube to assess viral load. Also, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
11039139|NCT04504864|Experimental|low-dose aspirin|Management policy is to use 50 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 50mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke. But this dose is rarely used clinically, especially in East Asia area.
11039140|NCT04504864|Active Comparator|conventional-does aspirin|Management policy is to use 100 mg aspirin per day as a secondary prevention strategy for patients with non-cardioembolic ischemic stroke and microbleeds. 100mg aspirin is recommended by the guideline of ASA/AHA in prevention of stroke, and this dose is widely used clinically.
11039141|NCT04504851|Active Comparator|Arm A (Standard of Care)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid
11039142|NCT04504851|Experimental|Arm B (Standard of Care plus Rosuvastatin)|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol PLUS rosuvastatin, then 16 weeks rifampicin, isoniazid
11039143|NCT04504825|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
11039144|NCT04504825|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
11039145|NCT04504825|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) with CyBorD according to institutional SoC. Patients should initiate their CyBorD chemotherapy regimen within 7 days of receiving the first dose of study drug. It is the intent of this protocol that patients will receive CyBorD per institution SoC in the study, as long as they are tolerating it. However, after two cycles of CyBorD, if the patient is not benefiting from or tolerating CyBorD in the Investigator's judgement, the investigator may change the CyBorD regimen or stop it.
11039146|NCT04504812|Active Comparator|Phase 1: Best Practices|Participants will receive an intervention from the best practices.
11039147|NCT04504812|Active Comparator|Phase 1: Best Practices + Duloxetine|Participants will receive Duloxetine in addition to an intervention from the best practices.
11039148|NCT04504812|Active Comparator|Phase 1:Best Practices + Duloxetine + Pain coping skills|Participants will receive Duloxetine and pain coping skills training in addition to an intervention from the best practices.
11039149|NCT04504812|Active Comparator|Phase 2: Intra-Articular Injection (HA+)|Participants will receive an intra-articular injection.
11039150|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Long Acting Blocks|Participants will receive a nerve blocking procedure.
11039151|NCT04504812|Active Comparator|Phase 2: Nerve Procedure: Nerve Ablation|Participants will receive a nerve ablation procedure.
11039152|NCT04504786|Experimental|Vitality acupunch (VA)|The VA program takes 40 minutes to complete and includes three phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allows the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands will be used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group will receive the VA program led by the instructors, who are trained and certified by the PI, 3 times per week and 40 minutes per session for 6 months.
11039153|NCT04504786|Active Comparator|Control|Participants in the control group will continue with their daily activities as usual.
11039154|NCT04504773|Experimental|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
11039155|NCT04504760|Experimental|ONO-2910 (Part A and B)|
11039156|NCT04504760|Placebo Comparator|Placebo (Part A)|
11039157|NCT04504760|Experimental|ONO-2910 (Part C and D)|
11039158|NCT04504760|Placebo Comparator|Placebo (Part C and D)|
11039159|NCT04504747||RH+|Prospective blood and biopsie analyses
11039160|NCT04504747||HER2+|Prospective blood and biopsie analyses
11039161|NCT04504747||TN|Prospective blood and biopsie analyses
11039162|NCT04504734|Active Comparator|Bucillamine low dose|Bucillamine 100 mg 3 times a day (TID)
11039163|NCT04504734|Active Comparator|Bucillamine high dose|Bucillamine 200 mg 3 times a day (TID)
11039164|NCT04504734|Placebo Comparator|Placebo|Placebo, 3 times a day (TID)
11039165|NCT04504721|Experimental|Light therapy group|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
11039166|NCT04504721|No Intervention|Waiting list group|Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.
11039167|NCT04504708|Experimental|ZX-101A Dose Level 1|Starting dose (SD) of ZX-101A administered orally once daily in a 28-day cycle
11039168|NCT04504708|Experimental|ZX-101A Dose Level 2|2-times the SD of ZX-101A administered orally once daily in a 28-day cycle
11039169|NCT04504708|Experimental|ZX-101A Dose Level 3|3-times the SD of ZX-101A administered orally once daily in a 28-day cycle
11039170|NCT04504708|Experimental|ZX-101A Dose Level 4|4-times the SD of ZX-101A administered orally once daily in a 28-day cycle
11039171|NCT04504708|Experimental|ZX-101A Dose Level 5|5-times the SD of ZX-101A administered orally once daily in a 28-day cycle
11039172|NCT04504695||Thrombectomy group|Major patients requiring management for endovascular thrombosis
11039173|NCT04504695||Aneurysm group|Major patients requiring management for an intracranial aneurysm
11039174|NCT04504682|Experimental|Ambulation|Participants in this arm will be encouraged to ambulate with epidural in place.
11039175|NCT04504682|No Intervention|No Ambulation|This arm will undergo our current standard of care.
11039176|NCT04504669|Experimental|Monotherapy|Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.
11039177|NCT04504669|Experimental|Combination Therapy|Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.
11039178|NCT04504656||1|open surgery
11039179|NCT04504656||2|minimally invasive surgery
11039241|NCT04504266|No Intervention|Control Arm|Recommendations to follow Mediterranean diet and exercise regularly before surgery.
11039180|NCT04504643|Experimental|Technology-assisted circuit training|Multicomponent circuit training using FItLight Trainer™ as an embodied tool to perform motor task. The circuit training is composed by aerobic, muscular, coordination and balance exercises.
11039181|NCT04504643|Experimental|Conventional circuit training|Multicomponent circuit training composed by aerobic, muscular, balance and coordination exercises. Coordination exercises wll be charged of simple dual task cognitive exercises (counting backwards, or making some easy math calculations, repeating words backward, finding words of the same family).
11039182|NCT04504643|Experimental|Nordic Walking|The training sessions are performed in a natural parc, which offers pathways of different lengths and levels of difficulty that will increase over the weeks.
11039183|NCT04504630|Active Comparator|Active HD-tDCS|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting dorsal anterior cingulate region for 20 minutes) across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
11039184|NCT04504630|Sham Comparator|Sham HD-tDCS|Participants will receive 10 sessions of sham stimulation across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
11039185|NCT04504617|Experimental|Intervention Group|This group will consist of six kebeles with a total of 90 pairs of mothers and their children that will receive the nutrition education intervention to enhance complementary feeding practices first. The six lessons will be delivered in a period of 6 weeks. Before the intervention this groups will be assessed with the baseline assessment. After the intervention, this group will be assessed in three time points (post-intervention, follow-up 1 and follow-up 2).
11039186|NCT04504617|Active Comparator|Delayed Intervention Group|This arm will consist of the six kebeles with a total of 90 pairs of mothers and their children that will not receive the intervention immediately. This group will first complete the baseline and the second assessment. After the second assessment, this group will receive the nutrition education intervention to enhance complementary feeding practices. After the intervention, this group will be assessed in two additional time points (post-intervention and follow-up 1).
11039187|NCT04504604|Active Comparator|Cholangiocarcinoma|Eligible patients that present with Cholangiocarcinoma.
11039188|NCT04504604|Active Comparator|Cancer of Unknown Primary (CUP)|Eligible patients with cancer of unknown primary site (CUP).
11039189|NCT04504604|Active Comparator|Other remaining rare cancers (solid tumors & lymphomas)|Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).
11039190|NCT04504578|Experimental|patients with progressive keratoconus with thin corneas|patients with progressive keratoconus with thin corneas , with thickness less than 400 micron ,will do conventional cross linking but with putting contact lens over the cornea ( will receive Contact lens assisted corneal cross liking )
11039191|NCT04504565|Experimental|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTC-3PRGD2, patients underwent single-photon emission computed tomography/COMPUTED tomography (SPECT/CT) examination.
11039192|NCT04504552|Experimental|Single Arm Avelumab|Avelumab monotherapy on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
11039193|NCT04504539|Experimental|mOPV with FIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
11039194|NCT04504539|Experimental|bOPV with FIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
11039195|NCT04504539|Experimental|mOPV with fIPV|mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
11039196|NCT04504539|Experimental|bOPV with fIPV|bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
11039197|NCT04504526|Experimental|68Ga-Pentixafor, PET/CT|PET/CT perform after injecting 68Ga-Pentixafor
11039198|NCT04504500|No Intervention|Observation phase|Routine practice assessment
11039199|NCT04504500|Active Comparator|Intervention phase|Clinical practice assessment after the application of the trial's educational, behavioral and organizational interventions
11039200|NCT04504487|Experimental|Early drain removal - POD3|Drain removal on POD3 if drain bilirubin is less than 3mg/dl and serous in nature.
11039201|NCT04504487|Placebo Comparator|Routine Drain Removal|Drain removed routinely when the output is less than 100ml and serous in nature
11039202|NCT04504461||Laparoscopic Inguinal Hernioplasty. Ambulatory|Laparoscopic Inguinal Hernioplasty performed in ambulatory surgery center
11039203|NCT04504461||Laparoscopic Inguinal Hernioplasty. Hospital Stay|Laparoscopic Inguinal Hernioplasty that have to stay at least 24 hours at the hospital
11039204|NCT04504448|Experimental|HNC664 capsules|HNC664 capsules,single ascending doses Single dose
11039205|NCT04504448|Placebo Comparator|HNC664 placebos|HNC664 placebos,single ascending doses Single dose
11039206|NCT04504448|Experimental|HNC664 capsules FED|HNC664 capsules,food effect,Single dose
11039207|NCT04504435|Experimental|Participants in Cohort 1|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with 20 milligram (mg) and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
11039208|NCT04504435|Experimental|Participants in Cohort 2|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with dose level (DL) 5 and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
11039209|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fasted then fed)|Participants will receive the selected dose level (DLX) of GSK3494245 in the fasted state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fed state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
11039210|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fed then fasted)|Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
11055389|NCT04390568|Experimental|Dose group 3|
11039211|NCT04504422|Experimental|Primary motor cortex|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
11039212|NCT04504422|Experimental|Left dorsolateral prefrontal cortex|The anodic electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
11039213|NCT04504422|Experimental|Ventromedial prefrontal cortex|The anodic electrode is positioned in the ventromedial prefrontal cortex (Fpz) and the cathode electrode on the left dorsolateral prefrontal cortex (F4). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
11039214|NCT04504422|Sham Comparator|Sham stimulation|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA during first 30 seconds, decreases to 0 mA over 30 seconds, and then stops supplying for 19 minutes.
11039215|NCT04504409|Active Comparator|Exercise group (ExG)|The exercise program consisted of; Codman , wand, stretching and strengthening exercises [25] applied twice a day, 5 times a week and duration of 3 weeks in all groups. All exercises were performed for 10 repetitions and 3 sets. Patients performed exercises with under supervision of physiotherapist in the clinic settings. In ExG, patients received only this exercise protocol for 3-weeks.
11039216|NCT04504409|Experimental|KT application combined with exercise (KTG)|Before KT application, their skin was shaved, cleaned with alcohol, and dried. Prior to application, the patient was seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side. KTs (Ares®) tape was used. The first strip was a Y-strip representative of the supraspinatus, which was applied from its insertion to origin with paper off tension. A Y-strip refers to a section of tape that has a portion cut down the middle to produce 2 tails. In KTG, patients wore the KT for a 3-week duration (renewed twice a week periodically in this time).
11039217|NCT04504409|Active Comparator|DN combined with exercise (DNG)|The MTrP dry needling procedure employed was similar to the MTrP injection described by Hong. The MTrP was located by palpating the taut band and identifying the point of maximal tenderness. This was then firmly compressed by the index finger or middle finger of the nondominant hand to direct the placement of the needle tip while inserting the needle. The needle was inserted into the skin at a point above the taut band, approximately 1 cm from the MTrP region. After penetration of the needle into the subcutaneous layer, it was kept there and obliquely (about 45 degrees) directed to the MTrP region under the fingertip of the non-dominant hand. Then, the needle was inserted rapidly into the MTrP region and withdrawn rapidly. In DNG, patients received DN for a 3-week duration (twice a week periodically in this time).
11039218|NCT04504396|Experimental|PB-119 once-weekly-subcutaneous injection|PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150mg once-weekly subcutaneously to patients in active drug group for 24 weeks.
11039219|NCT04504396|Placebo Comparator|Placebo once-weekly-subcutaneous injection|PB-119 150mg matched placebo which will be used in placebo group for 24 weeks.
11039220|NCT04504383|Experimental|PN-943 450 mg BID|Oral administration of PN-943 450 mg BID
11039221|NCT04504383|Experimental|PN-943 150 mg BID|Oral administration of PN-943 150 mg BID
11039222|NCT04504383|Placebo Comparator|Placebo BID|Oral administration of matching placebo
11039223|NCT04504370|Experimental|PB-119 once-weekly-subcutaneous injection|PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150mg once-weekly subcutaneously to patients in active drug group for 24 weeks.
11039224|NCT04504370|Placebo Comparator|Placebo once-weekly-subcutaneous injection|PB-119 150mg matched placebo which will be used in placebo group for 24 weeks.
11039225|NCT04504357|No Intervention|Arm A- No intervention|Participants randomized to Arm A will receive no research intervention.
11039226|NCT04504357|Experimental|Arm B- U=U app|"Participants randomized to Arm B will receive controlled exposure to the tablet-based U=U app."
11039227|NCT04504357|Active Comparator|Arm C- clinical exposure demonstration|Participants randomized to Arm C will be shown U=U videos in clinic waiting rooms and the tablet-based app will be integrated into routine counseling
11039228|NCT04504344|Experimental|Active tDCS|
11039229|NCT04504344|Sham Comparator|Sham tDCS|
11039230|NCT04504331|Experimental|Cohort 1: Infigratinib (100mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 100 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
11039231|NCT04504331|Experimental|Cohort 1: Infigratinib (125mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 125 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + + 20 mg/ day tamoxifen
11039232|NCT04504331|Experimental|Cohort 1: Infigratinib (75mg) + Tamoxifen|In Cohort 1, subjects will receive up to three dose levels of infigratinib - 125 mg, 100 mg, and 75 mg. 75 mg of Infigratinib will be administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen
11039233|NCT04504318|Experimental|Apixaban|Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
11039234|NCT04504318|Active Comparator|Enoxaparin|Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
11039235|NCT04504305|Active Comparator|Neuropaway|
11039236|NCT04504305|Placebo Comparator|Microcystalline cellulose|
11039237|NCT04504292|Experimental|Oral sulfate solution (SuPREP arm)|"Per the package insert: The dose for colon cleansing requires administration of two bottles of SUPREP Bowel Prep Kit. Each bottle is administered as 16 oz of diluted SUPREP solution with an additional 1quart of water taken orally. The total volume of liquid required for colon cleansing (using two bottles) is 3 quarts (approximately 2.8 L) taken orally prior to the colonoscopy outlined below under frequency.
~Two 6 oz bottles of oral solution: Each 6 oz bottle contains: sodium sulfate 17.5 g, potassium sulfate 3.13 g, magnesium sulfate 1.6 g."
11039238|NCT04504292|Active Comparator|Polyethelene Glycol (GoLytely arm)|Polyethylene Glycol Bowel Prep Kit
11039239|NCT04504279|Experimental|FB-401|FB-401 applied topically for 16 weeks.
11039240|NCT04504279|Placebo Comparator|Placebo|Placebo applied topically for 16 weeks.
11039242|NCT04504266|Experimental|Prehab|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
11039243|NCT04504253|Experimental|Creatine monohydrate|"Week 1: Creatine monohydrate 5g PO QID
~Week 2 up to Week 6: Creatine monohydrate 5g PO qday"
11039244|NCT04504253|Placebo Comparator|Placebo|"Week 1: Placebo 5g PO QID
~Week 2 up to Week 6: Placebo 5g PO qday"
11039245|NCT04504240|Experimental|Group A: FAMOTIDINE treatment group|FAMOTIDINE 40mg to 60mg 8hourly in an empty stomach along with other treatments.
11039246|NCT04504240|Active Comparator|Group B: Control group|Treatment as given with a PPI.
11039247|NCT04504227|Placebo Comparator|Thin liquid swallows|Thin liquid swallows of formula or breastmilk
11039248|NCT04504227|Experimental|Slightly thick liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk thickened with Gelmix
11039249|NCT04504227|Experimental|Mildly thick liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk thickened with Gelmix
11039250|NCT04504214|Experimental|Experimental group (EG)|An Experimental Group (EG) of post-stroke subjects having vibration stimulation sessions in addition to traditional rehabilitation
11039251|NCT04504214|Sham Comparator|Control Group (CG)|A Control Group (WG) of post-stroke subjects having placebo/sham vibration sessions (same vibrators used but without the eccentric mass), in addition to traditional rehabilitation
11039252|NCT04504201||Early Breast Cancer Patients|Early breast cancer patients (Stage I-III) who have completed primary treatment with a current Body mass index (BMI) over 30.
11039253|NCT04504201||Medical Oncology Clinicians|Oncology providers associated with community-based practices
11039254|NCT04504188|Experimental|Heart Rate Monitor Enhanced Treatment Optimization|Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.
11039255|NCT04504175|Experimental|Acute|Acute phase: ketamine infusions twice a week for 4 weeks
11039256|NCT04504175|Experimental|Continuation|Continuation: for remitters/ responders, 4 weeks of weekly ketamine infusions
11039257|NCT04504162||outpatient|Patients visiting a psychiatric hospital
11039258|NCT04504149|Experimental|PRIMED|Shared decision making session
11039259|NCT04504149|No Intervention|Usual Care|The investigators will characterize usual care using chart review and administrative data to identify medications (prescribed, filled), number of mental health sessions received, types of providers seen, and the content of treatment sessions as captured in chart notes.
11039260|NCT04504136|Experimental|Healthy Controls|Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).
11039261|NCT04504136|Experimental|Inflammatory Bowel Disease|Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.
11039262|NCT04504136|Experimental|Rheumatoid/Psoriatic Arthritis|Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.
11039263|NCT04504123|Experimental|Doxycycline|Participants received doxycycline hyclate 50 mg capsule orally once a day for 6 months
11039264|NCT04504123|Placebo Comparator|Placebo|Participants received placebo (inactive) capsule orally once a day for 6 months
11039265|NCT04504110|Experimental|Epithelial ovarian cancer|68Ga-FAPI-04 and 18F-FDG PET/CT
11039266|NCT04504097|Experimental|HIV self-testing + m-Health|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics. We will provide a 24-hour contact number to text, managed through WelTel system that will flag these messages in real-time. Participants will also receive a weekly bidirectional SMS hosted by WelTel to check how they are.
11039267|NCT04504097|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics
11039268|NCT04504097|No Intervention|Standard of Care|Participants will receive information about HIV testing, care and support services at MARPI clinics and provide a pamphlet of information about HIV & HIV prevention strategies.
11039269|NCT04504084|Experimental|Decision aid group|Shared decision making using decision aid
11039270|NCT04504084|No Intervention|Controlled group|Standard oral explanation the details of treament options
11039271|NCT04504071|Other|Dacomitinib Arm|This is a single arm study.
11039272|NCT04504058||UFACH|Unsaturated Fatty Acid in Clinical High-risk
11039273|NCT04504045|Experimental|Metformin|Patients will receive metformin 1000-2000 mg daily for 12 weeks.
11039274|NCT04504032|Experimental|Rivaroxaban|
11039275|NCT04504032|Placebo Comparator|Placebo|
11039276|NCT04504019|Experimental|Study Procedure 1|Participants will undergo the USCTR procedure with SX-One MicroKnife®
11039277|NCT04504019|Active Comparator|Study Procedure 2|Participants will undergo the traditional mOCTR procedure.
11039278|NCT04504006||Cohort A|PMMR + TCL, followed by systematic lymphadenectomy in node positive patients.
11039279|NCT04504006||Cohort B|Therapy according to actual guidelines
11039280|NCT04503993|Experimental|Hepatitis B Healthy Planet Arm|This is a single arm study where all patients eligible patients will receive a hepatitis B order set
11039281|NCT04503980|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
11039282|NCT04503967|Experimental|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line treatment of Gastric and Esophageal Cancer patients
11039283|NCT04503954|Experimental|Self-management group|Self-management group Chronic disease self-management program is conduct training skills, person how to live together with personal chronic disease to make life quality better.
11039284|NCT04503954|Placebo Comparator|Control group|Control group will continue general psychiatric intervention.
11039286|NCT04503941|Placebo Comparator|The control group|False Needle treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
11039287|NCT04503928|Experimental|Experimental: Kansui 1g per day x 7 days|Study participants will be given 1 g of Euphorbia kansui Pill for a total of 7 consecutive daily doses.
11039288|NCT04503915|Experimental|Constant group|Women will receive oral estradiol valerate (Progynova®; Bayer Schering Pharma AG, Berlin, Germany) 3 mg bid for 14 days for endometrial priming from the second or third day of the menstrual cycle.
11039289|NCT04503915|Active Comparator|Step -up group|Women will receive estradiol valerate 2mg once daily for 4 days from the second to fifth day,followed by 2mg bid for 4 days from the sixth to ninth day and then 3mg bid for 6 days from tenth to fifteenth day of menstrual cycle.
11039290|NCT04503902|Experimental|JS001+Donafenib|Donafenib 100mg QD/100 mg BID/200 mg BID orally + JS001 240mg Q3W iv
11039291|NCT04503889|Experimental|Real taVNS intervention|taVNS will be administered to cymba conchae of both ears using ECO2-TENS device
11039292|NCT04503889|Sham Comparator|Sham|aVNS will be administered to lobes of both ears using ECO2-TENS device
11039293|NCT04503876|Active Comparator|Decremental PEEP titration following an ARM|PEEP will be titrated in a stepwise decremental fashion following a standardized alveolar recruitment maneuver (ARM). The ARM is a progressive increase of intra-thoracic pressure (pressure controlled mode), with a constant driving pressure of 10 cmH2O and PEEP steps (10-15-20-25-30-35 and 40 cmH2O), reaching a maximum pressure of 50 cmH2O, allowing full recruitment. PEEP steps will be conducted every 2 cmH2O (from 20 to 6 cmH2O), every 5 minutes.
11039294|NCT04503876|Active Comparator|Incremental PEEP titration without any previous ARM|PEEP will be titrated in a stepwise incremental fashion without any previous alveolar recruitment maneuver (ARM). PEEP steps will be conducted every 2 cmH2O (from 6 to 20 cmH2O), every 5 minutes.
11039295|NCT04503863|Experimental|Experimental 1|Single administration of middle dose NPC-22
11039296|NCT04503863|Experimental|Experimental 2|Single administration of high dose NPC-22
11039297|NCT04503863|Placebo Comparator|Experimental 3|Single administration of placebo dose NPC-22
11039298|NCT04503850||Group A Mirabegron|50 patients receiving Mirabegron 50 mg once daily & alpha blocker
11039299|NCT04503850||Group B alpha blocker only|50 patients receiving alpha blocker only
11039300|NCT04503837|Experimental|Intervention|Personalized Mobile Phone Video Recording in addition to Standard care
11039301|NCT04503837|No Intervention|Control|Standard care alone
11039302|NCT04503824||Group IIa: 13 papular OLP|
11039303|NCT04503824||Group IIb: 13 atrophic OLP|
11039304|NCT04503824||Group IIc: 13 erosive OLP|
11039305|NCT04503824||Group I: 13 healthy individuals|
11039306|NCT04503811||Frail Older People|The first phase of the data collection process will include one to one interviews with up to twenty (20) frail older people. The pre-selected inclusion criteria for this category of participants include; older people (aged 65 years and over); individuals diagnosed with frailty and receiving (part of their) care services at the Day Hospital; the capacity to give free and fully informed consent; ability to use the English language, as well as judgement by the clinical staff and/or nominated manager that the potential participant can take part in an in-depth interview.
11039307|NCT04503811||Day Hospital Staff|The second phase of the data collection process will entail one to one interviews with up to ten (10) Staff at the Day Hospital. The study will include staff that routinely work with frail older people at the Day Hospital including nurses (registered and unregistered), doctors, physiotherapists, occupational therapists and therapy assistants that can give free and fully informed consent. Furthermore, the study will include both part-time and full-time staff with a minimum of six months of work experience with frail older people.
11039308|NCT04503798|Experimental|Online Goal Management Training (GMT)|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
11039309|NCT04503798|No Intervention|Treatment-as-usual control group|Participants randomized to this arm will receive no additional information or access to the intervention program. They will continue to receive treatment-as-usual from their care providers.
11039310|NCT04503785||Dysphagia|Patients with Esophageal dysphagia
11039311|NCT04503772|Experimental|Experimental arm (all patients)|"Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS).
~According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS."
11039312|NCT04503759||Foot and Ankle Surgery using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be among those already scheduled for foot and ankle surgery after having failed conservative treatment, or will have had foot and ankle surgery using NanoBone products but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient. The choice of a NanoBone product, as well as the surgery, is or was independent of this research project. Only patients who have had NanoBone implanted and consent to participate and meet the inclusion-exclusion criteria will be included in the registry.
11039313|NCT04503746|Placebo Comparator|Placebo|Placebo twice a day
11039314|NCT04503746|Experimental|ALH-L1005 600 mg|ALH-L1005 300 mg twice a day
11039315|NCT04503746|Experimental|ALH-L1005 1,200 mg|ALH-L1005 600 mg twice a day
11039316|NCT04503733|Experimental|Q4W GMA301 IV injections (300 mg)|
11039317|NCT04503733|Experimental|Q4W GMA301 IV injections (600 mg)|
11039318|NCT04503733|Experimental|Q4W GMA301 IV injections (1000 mg)|
11039319|NCT04503720|Experimental|CLoWI|"CLoWI (ropivacaine) and PCA (normal saline)
~The local anaesthetic infusion will be administered via 2 catheters using a ON-Q® (Halyard) delivery system that will be placed under direct vision by the surgeon at the time of wound closure. 40 mls of 0.25% ropivacaine are infiltrated in the preperitoneal plane. 0.5% ropivacaine will be infused at a rate of 4mls/hour (2mls/hour in each catheter).
~The dosage 40 mls of 0.25% ropivacaine and 0.5% ropivacaine at 4mls/hr (20mg/hr) over 4 days will be less than the recommended toxic dose of 3-4 mg/kg."
11039320|NCT04503720|Active Comparator|PCA|"PCA (Morphine) and CLoWI (normal saline)
~Morphine will be administered via the standard PCA protocol in accordance to the hospital's Acute Pain Service Programme:
~Concentration: 1mg/ml
~Bolus (Loading): 1mg
~Lockout Interval: 5 minutes
~Maximum hourly dose of 10mg"
11039321|NCT04503707||Follitropin Delta|Treatment according to routine clinical practice.
11039322|NCT04503694|Experimental|Single arm|"Eligible subjects will be treated according to the following plan:
~Induction systemic period 1: Consists of treatment with nivolumab (240 mg intravenously on day 1 and 14) and regorafenib (80 mg/day orally from day 1 to 14)
~Standard SCRT: Consists of 25 Gy delivered in 5 fractions (from day 21 to 25)
~Induction systemic period 2: Consists of treatment with nivolumab (240 mg intravenously on day 28, 42 and 56) and regorafenib (80 mg/day orally from day 28 to 49)
~Surgery: Surgical resection will be performed according to the principles of TME (between day 74 and 87, i.e., between 7 to 8 weeks after completion of SCRT)
~Adjuvant chemotherapy: Administration of adjuvant chemotherapy will be left to the discretion of the treating physician The study also includes translational procedures (collection of tumour biopsies, blood and stool samples at pre-specified time points) for exploratory molecular and immune contexture analyses. These are mandatory for all study subjects."
11039323|NCT04503681|Active Comparator|Standard introduction video|
11039324|NCT04503681|Experimental|Enhanced compassion video|
11039325|NCT04503668|Active Comparator|Nk1-RA|Nk1-RA will be given on day 1 of each 3-week chemotherapy cycle, for up to 6 cycles.
11039326|NCT04503668|Experimental|Olanzapine|Olanzapine will be given on days 1-4 of each 3-week chemotherapy cycle, for up to 6 cycles.
11039327|NCT04503655|Experimental|Intervention group|"The randomized centres in this group will be follow a training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
11039328|NCT04503655|No Intervention|Control group|The randomized centres in this group will not change their practices.
11039329|NCT04503642||Intervention Group|The intervention consisted in the closure of the abdominal wall and skin by a second surgical team which included a board-certified surgeon and a resident.
11039330|NCT04503642||Baseline Group|During the baseline period, closure of the abdominal wall was performed by the main surgical team, the same team that performed the whole surgery.
11039331|NCT04503629|Experimental|Anaprazole Sodium 20mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
11039332|NCT04503629|Experimental|Anaprazole Sodium 40mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
11039333|NCT04503629|Active Comparator|Rabeprazole sodium 10mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
11039334|NCT04503616|Experimental|HSCT Patients|Adult patients with hematological malignancies undergoing HLA-haploidentical HSCT from first-or second-degree family donors.
11039335|NCT04503603|Experimental|Lanadelumab|Participants will receive single dose of lanadelumab 300 milligram (mg) IV infusion on Day 1 followed by second dose on Day 4.
11039336|NCT04503603|Placebo Comparator|Placebo|Participant will receive single dose of placebo matching to lanadelumab IV infusion on Day 1 followed by second dose on Day 4.
11039337|NCT04503590|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
11039338|NCT04503577||Bladder cancer patients|
11039339|NCT04503551|Experimental|PDS Arm|Participants randomized to the PDS arm will receive two intravitreal ranibizumab injections and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 36-weeks (Q36W) thereafter
11039340|NCT04503551|Other|Comparator Arm|Participants randomized to the comparator arm will undergo study visits every 4 weeks (Q4W) for comprehensive clinical monitoring until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q36W thereafter. Participants will be eligible to receive intravitreal ranibizumab 0.5 mg injections if treatment eligibility criteria are met.
11039341|NCT04503538|Other|CAR-T cell therapy and Telemedicine|All outpatient CAR-T patients will require assessments for cytokine release syndrome and neurotoxicity three times daily (every 8 hours)
11039342|NCT04503525||COVID 19 hospitalized patients|COVID 19 infected patients admitted in conventional hospitalization for less than 72 hours
11039343|NCT04503512|Active Comparator|Non removal of fat pad|Non removal of fat pad
11039344|NCT04503512|Active Comparator|Removal of fat pad|Removal of fat pad
11039345|NCT04503499|Experimental|Study Group|The group to which the manuel therapy will be applied.
11039346|NCT04503499|No Intervention|Control Group|The control group where only the evaluations will be made.
11039347|NCT04503473|Experimental|High Intensity Stepping Training|The primary goal will be to perform continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). We will also record Ratings of Perceived Exertion (RPE) every 3-5 minutes, with goals of 15-18. Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
11039348|NCT04503473|Active Comparator|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions. The type of therapeutic activities is based on published normative data of typical activities performed during clinical physical therapy sessions with focus on strengthening activities (25% of session); balance activities (25%); locomotor activities (25%), and combined stretching exercises (10-15%) and transfers (10-15%). Intensity of activities will be targeted at 30-40% of their HR reserve in attempts to maintain consistent intensities between training groups.
11039349|NCT04503460|Experimental|Single treatment arm|"All participants who are deemed eligible for inclusion in the study following screening will be enrolled into a single experimental arm which will comprise the following sequential stages:
~Baseline sampling; participants only use 'as required' ipratropium bromide when needed (1 week)
~Salmeterol xinafoate monotherapy 50 μg twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)
~Washout period; participants only use 'as required' ipratropium bromide when needed (2 weeks)
~Salmeterol xinafoate 50 μg / fluticasone propionate 250 μg combination therapy twice in the morning and twice in the evening + 'as required' ipratropium bromide when needed (2 weeks)"
11039350|NCT04503421|Experimental|BFR|"Patient will use the following rehabilitation protocol while incorporating blood flow restriction therapy:
~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only
~Sling immobilization with active wrist and shoulder ROM
~Active extension of biceps to 30 degrees, No active flexion
~6-9 weeks full active extension in brace
~Maintain wrist and shoulder flexibility
~Begin rotator cuff/deltoid isometrics, progress active extension in brace
~Weeks 9-12: Gently advance ROM to tolerance
~Discontinue sling
~Begin active flexion and extension against gravity.
~Advance strength to light resistance, maintain flexibility/ROM
~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
11039351|NCT04503421|No Intervention|Control (no BFR)|"patients will use following rehabilitation protocol without the use of blood flow restriction therapy:
~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only
~Sling immobilization with active wrist and shoulder ROM
~Active extension of biceps to 30 degrees, No active flexion
~6-9 weeks full active extension in brace
~Maintain wrist and shoulder flexibility
~Begin rotator cuff/deltoid isometrics, progress active extension in brace
~Weeks 9-12: Gently advance ROM to tolerance
~Discontinue sling
~Begin active flexion and extension against gravity.
~Advance strength to light resistance, maintain flexibility/ROM
~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
11039352|NCT04503408||cystic fibrosis with abnormal glucose tolerance|cystic fibrosis with abnormal glucose tolerance Cystic fibrosis patients with descripted that impaired glucose tolerance or cystic fibrosis related diabetes by oral glucose tolerance test
11039353|NCT04503408||cystic fibrosis with normal glucose tolerance|cystic fibrosis with normal glucose tolerance Cystic fibrosis patients with descripted that normal glucose tolerance by oral glucose tolerance test
11039354|NCT04503395|Experimental|ESAR|Endovascular Aneurysm Repair + Heli-FX EndoAnchors
11039355|NCT04503395|Active Comparator|FEVAR|Fenestrated EndoVascular Aneurysm Repair
11039356|NCT04503382|Experimental|Kindness media|Short videos of kindness media. As part of a program entitled EnSpire®, this media consists of short videos that display acts of kindness and compassion that are edited together into a single reel.
11039357|NCT04503382|Active Comparator|Standard television|Children's commercial programming--as the control condition, participants watched commercial children's programming such as Disney, Nickelodeon, etc.
11039358|NCT04503369||EMS crews|Crews of Emergency Medical Services
11039359|NCT04503356|Active Comparator|OMNI as a standalone procedure|
11039360|NCT04503356|Active Comparator|OMNI combined with cataract surgery|
11039361|NCT04503343|Other|intervention group|subjects are randomly divided into the intervention group. and they will be given a one-time non-drug intervention(mindfulness training, relaxation training or electrical cerebellar stimulation).
11039362|NCT04503343|No Intervention|control group|subjects are randomly divided into the control group and regularly followed up.
11039363|NCT04503330|Experimental|Patients with iatrogenic PUJO|patients with iatrogenic PUJO or long segment ureteric stricture disease for safety and efficacy of using buccal graft for repair
11039364|NCT04503317|Active Comparator|active acupuncture low level laser iand nasal laser i|active acupuncture low level laser and diet recommendations
11039365|NCT04503317|Sham Comparator|sham laser and diet recommendations|sham laser application and diet recommendations
11039366|NCT04503304|Experimental|HAS group|"hip abductors strengthening group
~Hip abduction -standing[Ferber et al.,2015].
~Sidelying hip abduction(clamshell)[Schache et al.,2016].
~lateral leg raise: in brief, the patients lie down on bed on the unaffected side, with the resistance band positioned around the distal thigh of the affected limb.;later, they raise the above lower limbs upwards for about 30 degrees, stay for 5- 10 s and slowly lay down[Xie et al.,2018].
~pelvic lift training, specifically, patients stand single-leg off the side at a 10-cm step. Later, they begin with the other limb that is lower than the step level, and contract the stance-limb hip abductor to raise the free leg to the step level while keeping the stance knee extended[Xie et al.,2018].
~Stretching Hamstrings [Fukuda et al.,2012]. Number of sets = 3, Repetitions =10 repetitions for each set"
11039367|NCT04503304|Active Comparator|KES group|"knee extensors strengthening group
~Isometric quadriceps setting
~Knee extensions from sitting with knee bend to 90
~Terminal knee extension from sitting.
~Stretching Hamstrings Number of sets = 3, Repetitions =10 repetitions for each set"
11039368|NCT04503291|Experimental|supra-papillary metal stent group|The distal ends of metal stents are located above the major papilla in the common bile duct.
11039369|NCT04503291|Active Comparator|trans-papillary metal stent group|The distal ends of metal stents are located below the major papilla in the duodenum.
11039370|NCT04503278|Experimental|Part 1 CLDN6 CAR-T|Dose escalation in lymphodepleted patients until the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
11039371|NCT04503278|Experimental|Part 2 Vaccine-modulated|Dose escalation until the MTD and/or RP2D.
11039372|NCT04503265|Experimental|AMXI-5001 Treatment|Single Arm Study, all participants will receive AMXI-5001.
11039373|NCT04503252||Study population: patients with CSAI caused by MSSA|Inpatients with CSAI caused by MSSA treated or intended to receive cefazolin within the next 24-48 hours (at least 10 (maximum of 20) critically-ill patients, at least 10 (maximum of 20) patients with an estimated glomerular filtration rate of <60ml/min, at least 10 patients with BSI).
11039374|NCT04503252||Sub-study: Torque Teno virus (TTV) viremia|TTV viral load may indicate the immunological status of the host. The TTV sub-study is to to describe the viral kinetics of TTV in CSAI patients.
11039375|NCT04503252||Sub-study: cefazolin concentrations in sweat|Out of the study population (patients with CSAI) a total of 15 CSAI patients will be included for the substudy investigating cefazolin concentrations in sweat as a non-invasive therapeutic drug monitoring.
11039376|NCT04503239||Prediabetes (both IGT and IFG)|Device: G6 Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11039377|NCT04503239||Type 2 Diabetes on 1 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11039378|NCT04503239||Type 2 Diabetes on 2 or more OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11039379|NCT04503239||Type 2 Diabetes using Basal insulin with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11055390|NCT04390568|Experimental|Dose group 4|
11039381|NCT04503239||Type 2 Diabetes using intense insulin treatment-Multiple Dail|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11039382|NCT04503239||Type 2 Diabetes in MDI or basal insulin plus GLP-1|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
11039383|NCT04503200|Active Comparator|Double guidewire|
11039384|NCT04503200|Active Comparator|Transpancreatic precut|
11039385|NCT04503187||Chronic Stroke|Participants who suffered a single event of cerebral vascular accident at least six months ago before study enrollment.
11039386|NCT04503187||Multiple Sclerosis|Participants who has been diagnosed with multiple sclerosis
11039387|NCT04503187||Healthy control|Age-matched healthy adults who are self-reported healthy and has no known musculoskeletal, neuromuscular, and cardiovascular diseases.
11039388|NCT04503174||Pump Naiive|New to insulin pump use
11039389|NCT04503174||6-13 YO|Subjects between the age of 6-13 years old.
11039390|NCT04503174||14-17 YO|Subjects between the age of 14-17 years old.
11039391|NCT04503174||Adults (18+)|Subjects are 18 years old and older.
11039392|NCT04503174||CGM Naiive|Subjects have not used CGM in the 30 days prior to enrollment.
11039393|NCT04503174||HbA1c more than or equal to 8.5%|Subjects have an HbA1c of more than or equal to 8.5% in the 3 months prior to enrollment.
11039394|NCT04503174||HbA1c less than or equal to 8.5%|Subjects have an HbA1c of less than or equal to 8.5% in the 3 months prior to enrollment.
11039395|NCT04503161|Experimental|Hydrogel recipient|
11039396|NCT04503148|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
11039397|NCT04503148|Active Comparator|inhalation group|Patients receiving inhalation anesthesia using sevoflurane or desflurane
11039398|NCT04503109|Other|Nalu SCS System|All eligible subjects will receive the Nalu Neurostimulation System
11039399|NCT04503096|Experimental|High-dose accelerated rTMS|
11039400|NCT04503083||Migraine patients|"Excellent responder, a patient who experiences a >75% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;
~Responder, a patient who experiences a >50% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;
~Non responder, a patient who experiences a decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days ranging from 26 to 49% during the last 4 weeks of treatment as compared to baseline;
~Full non responder, a patient who experiences a <25% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline."
11039401|NCT04503070||Baseball Batters|Participants must be healthy volunteers who accept all provisions of the study and agree to complete the program in its entirety. Participants should have their own bat and relative experience of at least 2 years of hitting a baseball. Ages accepted will be 16-40.
11039402|NCT04503057||COVID-19 positive|Positive COVID-19 patients with pulmonary infection, ALI or ARDS
11039403|NCT04503057||COVID-19 negative|Negative COVID-19 patients with pulmonary infection, ALI or ARDS
11039404|NCT04503044||CT Lung Cancer Screening Patients|All CT Lung Cancer Screening patients at LHMC from January 1st, 2012 to September 30th, 2014 with an in-network PCP that had baseline CT scans will be scored. A subset of these patients with T4 screening scans will be scored for progression.
11039405|NCT04503031|Active Comparator|cylindrical tube group|The patient in cylindrical tube group (n=26) were intubated with cylindrical shaped endotracheal tube.
11039406|NCT04503031|Experimental|tapergaurd tube group|The patient in taperguard tube group (n=26) was intubated with TaperGuard endotracheal tube.
11039407|NCT04503018||Interviewed -implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
11039408|NCT04503018||Questionnaires - implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
11039409|NCT04503018||Questionnaires - controls|Patients who have had immediate breast reconstruction without complications
11039410|NCT04503005|Active Comparator|Effect of fasting duration|study the effect of different daily fasting duration on body composition and blood lipid and inflammatory markers in healthy adults.
11039411|NCT04503005|Other|Effect of time restricted eating protocol on chronotype|study the effect of 2 month of time restricted eating on the chronotype profile of healthy adults.
11039412|NCT04502992|Other|Single Arm (pre-post, quasi-experimental)|Pre-post intervention, single arm. (Intervention was 4 weeks of Acceptance and Committment therapy, 2 times per week, 90 min per session, in a group setting).
11039413|NCT04502979|Experimental|Responsive Feeding|Intervention families will receive approximately 4 hours of ASL and development specific content related to language and feeding during home visits and phone calls. The initial in-home session with families will focus on teaching ASL signs indicative of hunger, thirst, and satiety. A video and placemat of mealtime signs will be left with families at the completion of the first visit. The remaining sessions, in-home over the next 3 months and by phone monthly thereafter for 6 months total, will focus on reinforcing ASL signing in addition to focused education on particular aspects of language development (receptive language preceding expressive language and increasing intentional communication), feeding development (such as hunger and fullness cues, fear of new foods, the importance of repeated food exposures, variations in intake from meal-to-meal, and the propensity to reject bitter tastes [many vegetables]55], and appropriate portion sizes and variety for healthy growth.
11039414|NCT04502979|No Intervention|Routine Care|No intervention is provided to the families in this group; however, portions of the intervention lessons will be made available after completion of data collection.
11039415|NCT04502966|Experimental|Grazax® +Dupixent®|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:
~Once daily tablet of Grazax® sublingual immunotherapy and
~Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
11039416|NCT04502966|Experimental|Grazax® + Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:
~Once daily tablet of Grazax® sublingual immunotherapy and
~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
11055391|NCT04390568|Experimental|Dose group 5|
11039417|NCT04502966|Placebo Comparator|Grazax® Placebo +Dupixent® Placebo|"Participants randomized to this assignment will receive the following during the initial 2-year period of the trial:
~Once daily tablet of placebo for Grazax® sublingual immunotherapy and
~Placebo for Dupixent® administered every other week (e.g., biweekly) by subcutaneous injection"
11039418|NCT04502953|Active Comparator|Vertical plication|Vertical plication of the rectovaginal septum was done
11039419|NCT04502953|Active Comparator|Horizontal plication|Horizontal plication of the rectovaginal septum was done
11039420|NCT04502940||Mild pancreatitis|Patients with mild acute biliary pancreatitis according to Atlanta classification
11039421|NCT04502940||Moderate Pancreatitis|Patients with moderate acute biliary pancreatitis according to Atlanta classification
11039422|NCT04502940||Severe pancreatitis|Patients with severe acute biliary pancreatitis according to Atlanta classification
11039423|NCT04502940||Control|Healthy volunteers
11039424|NCT04502927|Other|Stroke patients with hand spasticity (n=20)|
11039425|NCT04502927|Other|Healthy volunteers (n=10)|
11039426|NCT04502914|Experimental|The experimental group|The experimental group will consist of wounds treated with the open-to-air strategy.
11039427|NCT04502914|Other|The control group|The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
11039428|NCT04502901|Experimental|Experimental Group -KX0826|KX0826 is tropically applied to the scalp of healthy male subjects once a day for 14 days. The applied dosage cohorts are 2.5mg, 5mg, 10mg and 20mg.
11039429|NCT04502901|Placebo Comparator|Control Group- Placebo|Placebo is tropically applied to the scalp of healthy male subjects once a day for 14 days.
11039430|NCT04502888|Experimental|SL-172154|Intratumoral administration
11039431|NCT04502875|Experimental|Treatment Arm|Intracavernosal infusion of Platelet Rich Plasma
11039432|NCT04502875|Active Comparator|Control Arm|Intracavernosal infusion of Platelet Poor Plasma
11039433|NCT04502862|Experimental|Dupilumab|2 x dupilumab injections as loading dose on Day 1, followed by 1 dupilumab maintenance dose injection every 2 weeks (Q2W) during 12 weeks
11039434|NCT04502862|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 12 weeks
11039435|NCT04502849||"Group Bypass (A)"|50 patients with indications for bypass surgery (chronic lower limb ischemia, stage 2b-4 Fontaine).
11039436|NCT04502849||"Group Endovascular (B)"|50 patients with indications for endovascular angioplasty and stenting (chronic lower limb ischemia, stage 2b-4 Fontaine).
11039437|NCT04502849||"Group Hybrid (C)"|50 patients with indications for hybrid surgery (endovascular angioplasty/stenting and bypass surgery; chronic lower limb ischemia, stage 2b-4 Fontaine).
11039438|NCT04502849||"Group Conservative (D)"|50 patients without indications surgery (conservative treatment, chronic lower limb ischemia, stage 2b-4 Fontaine).
11039439|NCT04502849||"Group Healthy volunteers (E)"|50 healthy subjects.
11039440|NCT04502836|Experimental|preliminary psychological intervention|Participants in this group will receive a psychological intervention providing knowledge and tools for problems solving one hour prior to the ACTH LRH test.
11039441|NCT04502836|No Intervention|control group|Participants in this group will not receive any psychological intervention prior to the test.
11039442|NCT04502823|No Intervention|Control Group|"Clinical practice: Management by Doppler and CTG findings.
~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:
~Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended at at ≥37 weeks.
~Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
11039443|NCT04502823|Experimental|Intervention Group|Management based on sFlt-1/PlGF values
11039444|NCT04502810|Experimental|High-level laser therapy|Real high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
11039445|NCT04502810|Sham Comparator|Sham High-level laser therapy|Sham high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
11039446|NCT04502797|Experimental|Interventional: Electronic Patient Visit Assessment (ePVA)|Participants diagnosed with head and neck cancer randomized to Electronic Patient Visit Assessment intervention
11039447|NCT04502797|No Intervention|Usual care|Participants diagnosed with head and neck cancer randomized to usual care.
11039448|NCT04502784||Chronic Kidney Disease|This group will consist of 10 patients who have previously been diagnosed with chronic kidney disease and are receiving intravenous iron due to anaemia.
11039449|NCT04502784||Intestinal failure|This group will consist of 10 patients who have previously been diagnosed with intestinal conditions and are receiving intravenous iron due to anaemia.
11039450|NCT04502784||Healthy Volunteers|This group will consist of 20 healthy volunteers. This group will act as a comparator for the CKD and intestinal failure groups.
11039451|NCT04502771||Antifungal treatment|Patients receiving antifungal treatment during their stay in Intensive Care Unit
11039452|NCT04502745|Experimental|Treatment Group|During clinically indicated surgery for subdural hematoma, the patient will undergo a single burr hole evacuation with the MICAS device with endoscopic assistance.
11039453|NCT04502732|Other|Treatment|
11039454|NCT04502719||Screened|Patients with liver cirrhosis screened for malnutrition.
11039455|NCT04502706|Experimental|FSI-189 (Monotherapy Dose Escalation)|Participants will receive FSI-189 doses of 10, 30, or 100 mg every 2 weeks for 9 months.
11039456|NCT04502706|Experimental|FSI-189 + Rituximab (Combination Dose Escalation)|Participants will receive FSI-189 doses of 100, 200, 400, or 800 mg every 2 weeks in combination with rituximab at 375 mg/m^2 for 9 months.
11039457|NCT04502706|Experimental|FSI-189 + Rituximab (Pharmacokinetic (PK) Evaluation)|Participants will either receive FSI-189 3 mg at Cycle 1 Day 1, followed by FSI-189 100 mg from Cycle 1 Day 15 onward every 2 weeks or FSI-189 10 mg at Cycle 1 Day 1, followed by FSI-189 200 mg from Cycle 1 Day 15 onward every 2 weeks in combination with rituximab at 375 mg/m^2 for 9 months
11039458|NCT04502706|Experimental|FSI-189 + Rituximab (DLBCL Expansion)|Diffuse large B-cell lymphoma (DLBCL) participants will receive FSI-189 and rituximab with the recommended dose and schedule based on the Monotherapy Dose Escalation, Combination Dose Escalation, and PK Evaluation data.
11039459|NCT04502693|Experimental|MenB_0_2_6 Group|Participants receive rMenB+OMV NZ vaccine as 3 dose schedule at Day 1, 61 and Day 181 or as 2 dose schedule at Day 1 and Day 61 and 1 dose of MenACWY vaccine at Day 211.
11039460|NCT04502693|Experimental|MenB_0_6 Group|Participants receive rMenB+OMV NZ vaccine as 2 dose schedule at Day 1, and Day 181, 1 dose of MenACWY vaccine at Day 61 and 1 dose of Placebo at Day 211.
11039461|NCT04502693|Experimental|ABCWY-1 Group|Participants receive 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
11039462|NCT04502693|Experimental|ABCWY-2 Group|Participants receive 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
11039463|NCT04502693|Experimental|ABCWY-3 Group|Participants receive 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
11039464|NCT04502693|Active Comparator|ACWY Group|Participants, receive 1 dose of MenACWY vaccine at Day 1, 1 dose of placebo at Day 61 and 2 doses of rMenB+OMV NZ vaccine at Day 181 and Day 211.
11039465|NCT04502680|Experimental|Eribulin Mesylate|Patients receive eribulin mesylate following standard adjuvant chemotherapy.
11039466|NCT04502680|No Intervention|Observation|Observation. No intervention.
11039467|NCT04502667|Experimental|cholecalciferol (Vitamin D)|Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
11039468|NCT04502667|No Intervention|Control|No intervention
11039469|NCT04502654||Pilot group|As a pilot Group for observating variable rehabilitation under individual baselines.
11039470|NCT04502641|Experimental|Arm I|Patients receive induction chemotherapy with docetaxel-based, with or without cisplatin or fluorouracil. Treatment repeats every 21 days for 3 courses. Then, patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
11039471|NCT04502641|Active Comparator|Arm II|Patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
11039472|NCT04502628|Experimental|HBOT group|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished.
11039473|NCT04502615|Experimental|Sand|Participants perform 5 single leg hops onto a Sand surface from a 30cm height
11039474|NCT04502615|Active Comparator|Artificial grass|Participants perform 5 single leg hops onto a grass surface from a 30cm height
11039475|NCT04502615|Active Comparator|Firm Ground|Participants perform 5 single leg hops onto a firm ground surface from a 30cm height
11039476|NCT04502602|Experimental|Dose Level -1|Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
11039477|NCT04502602|Experimental|Dose Level 1|Neratinib 160 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
11039478|NCT04502602|Experimental|Dose Level 2|Neratinib 200 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
11039479|NCT04502602|Experimental|Dose Level 3|Neratinib 240 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
11039480|NCT04502602|Experimental|Dose Level 4|Neratinib 240 mg and Niraparib 300 mg by mouth once daily for 28 day cycles.
11039481|NCT04502602|Experimental|Phase 1b: Platinum Resistant Expansion Cohort|This portion of the study provides for cohort expansion to observe for 4 month or greater progression-free survival in patients with platinum resistant ovarian cancer treated at the recommended phase 2 dose (RP2D) determined in Phase I.
11039482|NCT04502589|Active Comparator|perampanel by itself|
11039483|NCT04502589|Active Comparator|Perapanel with Disulfiram|
11039484|NCT04502576|Active Comparator|High-flow nasal cannula|"High-flow nasal cannula will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge. Weaning from high-flow will be considered as standardized criteria are met."
11039485|NCT04502576|Experimental|Helmet noninvasive ventilation|"Patients will receive continuous helmet pressure support ventilation for at least 16 hours/day the first 2 calendar days. Continuous noninvasive ventilation without interruptions will be strongly encouraged in the first 24 hours of treatment. The ventilator will be set in pressure support mode. Use of continuous positive airway pressure by flow generators and Venturi systems instead of pressure support ventilation will be allowed in case of shortage of ventilators. Maintenance of positive end-expiratory pressure ≥ 8-10 during the treatment is mandatory.
~After weaning and during any interruption from noninvasive ventilation, patients will undergo low-flow or high-flow oxygen, according to the decision of the attending physician.
~The treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge."
11039486|NCT04502563|Experimental|Active arm|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
11039487|NCT04502563|Sham Comparator|Control|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
11039488|NCT04502550||Parkinson's Disease patients with DBS|"This cohort will serve as as the observed group, displaying basal ganglia pathology.
~A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a targeted controlled infusion (TCI) system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Experiments will be completed with DBS off."
11039489|NCT04502550||Essential Tremor patients with DBS|"This cohort will serve as a control group (no basal ganglia pathology). A syringe pump controlled by STANPUMP implementing the Eleveld Pharmocokinetics-Pharmacodynamics (PK-PD) model for propofol will be used as a TCI system to achieve plasma target propofol concentrations. Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
~Experiments will be completed with DBS off."
11039492|NCT04502524|Experimental|Arm I (New website program, handout, text message)|Participants complete the new website smoking cessation program which provides values driven, mindfulness based coping skills and utilizes non-judgmental acceptance of uncomfortable internal states like cravings. Participants will also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with all session handouts and available resources provided by the VA for continued support for smoking cessation.
11039493|NCT04502524|Active Comparator|Arm II (Standard care VA website, handout, text message)|Participants use the standard of care website, which provides educational materials about cessation treatments, tools to cope with urges and relapse, how to stay motivated, and brief tips on coping with physical and mental health problems. Participants also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with a handout of available resources provided by the VA for continued support for smoking cessation.
11039494|NCT04502511||Adult critically ill patients in the ICU|Acutely admitted to the ICU
11039495|NCT04502498||60 patients with local advanced bladder cancer|Local advanced bladder cancer patients candidate for radical cystectomy
11039496|NCT04502485|Experimental|Gastric water exchange|Air will be minimally insufflated to partially open the lumen and any residual fluid will be suctioned when the scope passes through the esophagus. Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further. Air will be opened when the scope enter the prepylorus area where there is usually an air pocket. The scope will enter the duodenal bulb and 2nd portion of duodenum where withdrawal inspection will start.
11039497|NCT04502485|Active Comparator|Traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
11039498|NCT04502472|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Patients hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome and meet eligibility criteria
11039499|NCT04502459|Active Comparator|Cement only|The tourniquet was inﬂated just before cement application and deﬂated after its hardening
11039500|NCT04502459|Active Comparator|Skin to Cement|Inﬂation of tourniquet before skin incision and its deﬂation after hardening of cement
11039501|NCT04502459|Active Comparator|Skin to Skin|Inflate of tourniquet before incision and deflate following completion of skin closure
11039502|NCT04502446|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
11039503|NCT04502433|No Intervention|Control cohort|Approximately 28 patients will be included in this main control cohort. An additional exploratory cohort of 6 patients in ECMO will be enrolled by 3 sites. The above-mentioned control cohort population will continue receiving the SoC
11039504|NCT04502433|Experimental|Poractant alfa treated cohort|42 patients will be treated with CUROSURF® (poractant alfa). An additional exploratory cohort of 9 patients in ECMO will be randomised by 3 sites and treated with the poractant alfa
11039505|NCT04502420||Abdominal surgery|People who to be operated in the abdomen are investigated before and after surgery.
11039506|NCT04502407|Experimental|De-intensified Cisplatin-based Chemoradiation|This is a non-randomized study, with all patients undergoing de-intensified post-operative cisplatin-based chemoradiation. Dosage level and duration of administration will be determined by whether the patient is high risk or not as assessed by the treating investigator.
11039507|NCT04502394|Experimental|Cohort 1 (R/R DLBCL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
11039508|NCT04502394|Experimental|Cohort 2 (R/R CLL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.
~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
11039509|NCT04502381|Experimental|Intervention arm|The study participants in the intervention arm will receive nebulization with amphotericin B deoxycholate (10 mg twice a day every alternate day, as described below) along with intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
11039510|NCT04502381|Active Comparator|Conventional arm|Participants will receive treatment with only intravenous liposomal amphotericin B (3 to 5 mg/kg body weight)
11039511|NCT04502342|Active Comparator|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
11039512|NCT04502342|Experimental|Cospherunate/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
11039513|NCT04502342|Experimental|Cospherunate/Phytomedicine/Azithromycine|Patients received Cospherunate (50 mg Artésunate/125 mg Amodiaquine) at the rate of 2 tablets orally twice daily for 6 days and Phytomedicine tablet 350 mg at the rate of 2 tablets orally twice daily for 6 days, and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days.
11039514|NCT04502329|Experimental|IER|Intermittent Energy Restriction
11039515|NCT04502329|No Intervention|CER|Continous Energy Restriction
11039516|NCT04502303|Experimental|Crohn's disease: patients with intestinal stricture|Patients with intestinal strictures confirmed by other modalities, e.g. CT, MR, ultrasound, and endoscopy, will be recruited in the study.
11039517|NCT04502290|Experimental|Combined brain (TMS) and Functional Electrical Stimulation|In this arm of the study participants will receive repeated single pulse TMS synchronously paired with FES
11039518|NCT04502277|Experimental|Flucanazole|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
11039519|NCT04502277|Active Comparator|Diflucan|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
11039520|NCT04502264|Experimental|Botulinum toxin, hand robot training, occupational therapy|Patient would receive Botulinum toxin (Injections of 100~400U of Botox in the upper limb muscle with a 2ml/100U dilution), robot-assisted therapy (Hand of Hope training), and standard occupational therapy.
11039521|NCT04502264|Active Comparator|Botulinum toxin, occupational therapy|Patient would receive Botulinum toxin (Injections of 100~400U of Botox in the upper limb muscle with a 2ml/100U dilution) and standard occupational therapy.
11039522|NCT04502251|Active Comparator|LDN + tDCS|Low Dose Naltrexone and Transcranial Direct Current Stimulation
11039523|NCT04502251|Sham Comparator|LDN + Sham tDCS|Low Dose Naltrexone and Sham Transcranial Direct Current Stimulation
11039524|NCT04502251|Placebo Comparator|Placebo + tDCS|Placebo and Transcranial Direct Current Stimulation
11039525|NCT04502251|Other|Placebo + Sham tDCS|Placebo and Sham Transcranial Direct Current Stimulation
11039526|NCT04502225|Experimental|Elevation of the whole bed (tilt)|Tilt of the whole bed so that the participant's head is raised by 9 and/or 12 inches.
11039527|NCT04502225|Experimental|Elevation of the trunk|Elevation of the trunk by tilting just the head of the bed so that the participant's head is raised by 9 and/or 12 inches.
11039528|NCT04502225|Experimental|Elevation of the whole bed (tilt) - In home|Tilt of the whole bed so that the participant's head is raised by 8 inches.
11039529|NCT04502225|Experimental|Elevation of the trunk - In home|Elevation of the trunk by raising the head 8 inches on a wedge pillow.
11039530|NCT04502212|Experimental|Insonification|All subjects enrolled will receive a 3-day, 15 minute per day ultrasound insonification targeting the portis hepatis (liver).
11039531|NCT04502186|Experimental|Raising Our Spirits Together Intervention|
11039532|NCT04502186|Other|Enhanced Control Condition|
11039533|NCT04502173||Training|Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.
11039534|NCT04502173||Managing PPH|Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.
11039535|NCT04502121|Experimental|Intervention group (IG)|
11039536|NCT04502121|No Intervention|Standard of Care (SOC)|
11039537|NCT04502108||Employees|Employees of the Department of Health Professions, Bern University of Applied Sciences
11039538|NCT04502108||Students|Students of the Department of Health Professions, Bern University of Applied Sciences
11039539|NCT04502095|Experimental|Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.
11039540|NCT04502095|Active Comparator|Group II (standard of care)|Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.
11039541|NCT04502082|Experimental|ET140203 TCells|ET140203 T Cells
11039542|NCT04502069|Experimental|Open label opaganib|opaganib dosed at 500 mg Q12 hours
11039543|NCT04502056|Experimental|AMA RI - B- B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid will include information on the disproportionate impact on communities of color .
11039544|NCT04502056|Experimental|AMA RI - B - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid will not include information on the disproportionate impact on communities of color.
11039545|NCT04502056|Experimental|AMA RI - B- W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid will include information on the disproportionate impact on communities of color.
11039546|NCT04502056|Placebo Comparator|AMA RI - B- W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid will not include information on the disproportionate impact on communities of color.
11039547|NCT04502056|Experimental|AMA RI - W - B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be African American - the message on Covid will include information on the disproportionate impact on communities of color.
11039548|NCT04502056|Experimental|AMA RI - W - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger/doctor in the follow-up AMA videos will be African American - the message on Covid will not include information on the disproportionate impact on communities of color.
11039549|NCT04502056|Experimental|AMA RI - W - W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid will include information on the disproportionate impact on communities of color.
11039550|NCT04502056|Experimental|AMA RI - W - W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid will not include information on the disproportionate impact on communities of color.
11039551|NCT04502056|Experimental|AMA DP - B- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid will include information on the disproportionate impact on communities of color .
11039552|NCT04502056|Experimental|AMA DP - B- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid will not include information on the disproportionate impact on communities of color.
11039659|NCT04501367|Experimental|Second DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
11041900|NCT04485702|Active Comparator|MELT-100|3mg midazolam and 25mg ketamine sublingual tablet
11039553|NCT04502056|Experimental|AMA DP - B- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be white - the message on Covid will include information on the disproportionate impact on communities of color.
11039554|NCT04502056|Experimental|AMA DP - B- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be white - the message on Covid will not include information on the disproportionate impact on communities of color.
11039555|NCT04502056|Experimental|AMA DP - W- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be African American - the message on Covid will include information on the disproportionate impact on communities of color.
11039556|NCT04502056|Experimental|AMA DP - W- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be African American - the message on Covid will not include information on the disproportionate impact on communities of color.
11039557|NCT04502056|Experimental|AMA DP - W- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid will include information on the disproportionate impact on communities of color.
11039558|NCT04502056|Experimental|AMA DP - W- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid will not include information on the disproportionate impact on communities of color.
11039559|NCT04502056|Placebo Comparator|Placebo|The messages will not be related to Covid.
11039560|NCT04502043|Experimental|Exercise therapy|Exercise therapy consists of improving dynamic hip joint stability by means of hip-specific and functional lower limb strengthening, core stability and postural balance exercises.
11039561|NCT04502030|Experimental|Panzyga|
11039562|NCT04502030|Placebo Comparator|Placebo|
11039563|NCT04502017|Active Comparator|Standard Antithrombotic Therapy|OAC for 6 weeks followed by DAPT until 6 month-follow-up, then aspirin alone
11039564|NCT04502017|Active Comparator|Genetic-Tailored AntiThrombotic Strategy|OAC for 6 weeks followed by DAPT (clopidogrel responders) or aspirin plus half-dose OAC (clopidogrel non-responders) until 6 month-follow-up, then aspirin alone
11039565|NCT04502017|Active Comparator|Half-Dose NOAC|Half Dose of Novel OAC
11039566|NCT04502004|No Intervention|Control Group (CG)|"Receive the recommendations of the Clinical Practice Guidelines which consist of: advice on smoking cessation smoking, leaflet with information (tobacco components, treatments to reduce withdrawal syndrome).
~Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
11039567|NCT04502004|Experimental|Experimental Group (EG)|"Receive codes to download the App NoFumo+ . Is a mHealth that offer a CBT program. Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
11039568|NCT04501991||Patients with Type 2 Diabetes|Patients with type 2 diabetes and a scheduled visit during the lockdown for COVID-19
11039569|NCT04501978|Experimental|ACTIV-3 Drug plus SOC|Participants in this study will be randomized to receive ACTIV-3 Drug plus Standard of Care (SOC) or placebo plus SOC
11039570|NCT04501978|Placebo Comparator|Placebo plus SOC|The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
11039571|NCT04501965|Active Comparator|Hydroxychloroquine/Azythromycin|Patients received Hydroxychloroquine 200 mg tablet orally 3 times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
11039572|NCT04501965|Experimental|Quinquina/Azythromycin|Patients receive 3.5g tea bags of Cinchona/Stevia powder orally at the rate of 3 tea bags per day for 10 days
11039573|NCT04501965|Experimental|4plants/Azythromycin|Participants received 4Plants powder in a 3.5g tea bag orally three times daily for 10 days and Azythromycine 250 mg orally at the rate of 2 tablets the first day, then one tablet for 5 days
11039574|NCT04501952|Experimental|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
11039575|NCT04501952|Placebo Comparator|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
11039576|NCT04501939|Experimental|Cirmtuzumab + Venetoclax|All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.
11039577|NCT04501926||Controls|Asthma patients who did not report asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
11039578|NCT04501926||Cases|Asthma patients that reported asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
11039579|NCT04501913||Observational (remote telemonitoring)|Patients undergo remote perioperative telemonitoring with home monitoring devices activity monitor beginning 7 days before surgery and up to 30 days after hospital discharge.
11039580|NCT04501900|Active Comparator|prolonged DAPT group|
11039581|NCT04501900|No Intervention|standard DAPT group|
11039582|NCT04501887||Matched therapy|Molecular profiling performed with actionable molecular alterations detected and target therapy was then conducted
11039583|NCT04501887||Unmatched therapy|Molecular profiling performed with actionable molecular alterations detected but therapy was conducted based on the guideline treatment
11039584|NCT04501887||No marker|Molecular profiling performed without any actionable molecular alterations detected, tranditional therapy based on the guideline was then conducted
11039585|NCT04501874|Active Comparator|EMB-001 Active|EMB-001 Combination product of 720 mg metyrapone/24 mg oxazepam mg by mouth twice per day for 12 weeks followed by a 1 week taper
11056477|NCT04382729|Active Comparator|Control Group|
11039587|NCT04501861|Active Comparator|The use of vasopressin compared with norepinephrine|The investigator hypothesize that the use of vasopressin compared with norepinephrine induces a lower mPAP-to-MAP ratio, in cardiac surgical patients with and without pulmonary hypertension who require intraoperative vasopressor support.
11039588|NCT04501861|Active Comparator|The use of norepinephrine compared with vasopressin|The investigators will compare GLS between patients who received norepinephrine versus vasopressin intraoperatively.
11039589|NCT04501848||Study|parents of obstructive sleep disordered breathing (OSDB) children before and after surgical treatment
11039590|NCT04501848||Control|A group of parents to healthy children comprised the control group.
11039591|NCT04501835||Cardiac implantable electronic device infections|Patients hospitalised in Nancy University Hospital for suspected cardiac implantable electronic device infections
11039592|NCT04501822||Covid19 pneumonia patients|The study includes men and women ≥18 years old with documented COVID-19 pneumonia
11039593|NCT04501809|Active Comparator|Group I (Misoprostol group):|seventy-nine patients will receive a loading dose of moistened misoprostol tablets ( Cytotec pfizer 400 mg) inserted vaginally and it will be followed by maintenance dose (200 mg) after six hours and repeated every 4 hours till the start of effective uterine contraction with maximum five doses in 24 hours duration .
11039594|NCT04501809|Active Comparator|Group II (Combined group):|seventy- nine patients will get intracervical Foleys Catheter insertion .a 16F (french units) Foley catheter will be introduced into the cervical canal to induce cervical ripping. The catheter will be fixed through inflation of the balloon with 30 milliliters of sterile solution when the catheter will be beyond the internal cervical os. After six hours of Foleys catheter fixation, we will start infusion of 10 international units (IU) of oxytocin on 500 ml ringer lactate by rate 125 ml\hr followed by one hour rest to allow diuresis. Increased gradually of oxytocin dose by 5 IU each time until achieving regular uterine contraction, maximum five doses in twenty -four hours duration.
11039595|NCT04501796|Experimental|NT-I7|NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
11039596|NCT04501796|Placebo Comparator|Placebo|Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
11039597|NCT04501783|Experimental|TL-FVP-t (favipiravir) Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC); Days 2-10: 800 mg BID plus SOC.
11039598|NCT04501783|Active Comparator|Standard of Care Arm|Standard of Care including etiotropic therapy according to MoH of Russian Federation Recomendations for COVID-19 (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine, or mefloquine in recomended regimen) up to10 days
11039599|NCT04501770|Experimental|M802|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with M802 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
11039600|NCT04501744|Experimental|M701|Patients will undergo a 2-week screening period and a 4-week core treatment period, and eligible patients who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
11039601|NCT04501731||Young PFT survivors|
11039602|NCT04501731||Age-matching controls|
11039603|NCT04501718|Experimental|Test group|
11039604|NCT04501705|Experimental|test group|
11039605|NCT04501692|Experimental|VivaSight|Intubated with a VivaSight-SL endotracheal tube.
11039606|NCT04501692|Active Comparator|Conventional|Intubated by videolaryngoscopy.
11039607|NCT04501679|Experimental|Nemolizumab|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (>=) 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
11039608|NCT04501679|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing >= 90 kg will receive two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
11039609|NCT04501666|Experimental|Nemolizumab 30 milligram (mg)|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W) and participants >= 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W up to 24 weeks.
11039610|NCT04501666|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive matching placebo of two SC injections at baseline, then one SC injection Q4W and participants weighing >= 90 kg will receive matching placebo of two SC injections at baseline, then two SC injections Q4W up to 24 weeks.
11039611|NCT04501653|Experimental|Psilocybin first|Participants will receive 25 mg of psilocybin at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the control drug (methylphenidate) at their second drug exposure neuroimaging session.
11039612|NCT04501653|Active Comparator|Methylphenidate first|Participants in this group will be randomized to receive 40 mg of methylphenidate at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the active comparator (psilocybin) at their second drug exposure neuroimaging session.
11039613|NCT04501640|Experimental|Mirabegron 25 mg (low-fat)|Participants will receive 25 mg of mirabegron under fed conditions in period 1 and 25 mg of mirabegron under fasted conditions in period 2.
11039614|NCT04501640|Experimental|Mirabegron 25 mg (fasted)|Participants will receive 25 mg of mirabegron under fasted conditions in period 1 and 25 mg of mirabegron under fed conditions in period 2.
11039615|NCT04501640|Experimental|Mirabegron 50 mg (low-fat)|Participants will receive 50 mg of mirabegron under fed conditions in period 1 and 50 mg of mirabegron under fasted conditions in period 2.
11039616|NCT04501640|Experimental|Mirabegron 50 mg (fasted)|Participants will receive 50 mg of mirabegron under fasted conditions in period 1 and 50 mg of mirabegron under fed conditions in period 2.
11039617|NCT04501627||Participants with RE|Participants diagnosed with RE who have received 20 milligram (mg) of vonoprazan in routine clinical practice, will be observed prospectively. Data will be collected from participants' medical records, self-reported questionnaires and recorded information on symptom via diaries.
11039618|NCT04501614|Experimental|Ponatinib|Ponatinib tablet or age appropriate formulation (AAF) in combination with chemotherapy backbone, orally, once daily in both reinduction block and consolidation block (35 days each including 29 days of treatment followed by rest period from chemotherapy for a minimum of 6 days consisting of daily ponatinib only) in phase 1 to determine RP2D. In Phase 2 participants will receive ponatinib at RP2D in combination with chemotherapy backbone at RP2D determined in phase 1.
11039619|NCT04501601|Experimental|Experimental: weight loss program kit|weight loss program kit
11039620|NCT04501588|Experimental|Parent Learning Style 1|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
11039621|NCT04501588|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
11039622|NCT04501588|Active Comparator|Learning Style 1 (Parent)|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
11039623|NCT04501588|Active Comparator|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
11039624|NCT04501575|Experimental|Osteopathic consultation|It consists of 1 session. Each osteopathic session is based on a structural evaluation and treatment tailored to the participant-specific complains
11039625|NCT04501575|Sham Comparator|Osteopathic sham consultation|Osteopathic Sham treatment was applied using manual contact on specific bony surfaces using very light pressure. The practitioner was counting the seconds up to 1 minute between the areas where to apply the light touch without any intention to treat or diagnose.
11039626|NCT04501575|No Intervention|Usual Care|Participants will be on a waiting list, and meanwhile, they are advised to deal with their pain in the way they would, but without using any sort of Manual Therapy.
11039627|NCT04501562||Subject|
11039628|NCT04501536|Experimental|High Frequency|Participants will receive therapy 4 times a week for 10 weeks for 30 minutes per session.
11039629|NCT04501536|Experimental|Low Frequency|Participants will receive therapy 1 time a week for 10 weeks for 2 hours per session.
11039630|NCT04501523|Experimental|A|ctDNA positive, non-pCR Intervention: Tislelizumab(anti-PD1 antibody) combined with capecitabine
11039631|NCT04501523|Active Comparator|B|ctDNA positive, non-pCR Intervention: capecitabine(standard care)
11039632|NCT04501523|Experimental|C|ctDNA positive, pCR Intervention: capecitabine
11039633|NCT04501523|No Intervention|D|Follow up(standard care)
11039634|NCT04501510||HumerusFracture|Patients with humerus fracture
11039635|NCT04501510||RadiusFracture|Patients with radial bone fracture
11039636|NCT04501497||NSCLC cohort (N=800)|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
11039637|NCT04501497||ED-SCLC cohort (N=400)|Patients with extensive disease small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
11039638|NCT04501484|Experimental|Treatment Group|Participants will undergo a thalamotomy contralateral to their previous treatment with MRgFUS using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel).
11039639|NCT04501471|Experimental|SAAF-T|Participants received a 5 session, 10-hour family centered prevention program designed to prevent substance use, conduct problems, and risky sexual behavior
11039640|NCT04501471|Placebo Comparator|Fuel for Families|Participants received a 5 session, 10 hour family centered program that focused on healthy nutrition and exercise.
11039641|NCT04501458|Experimental|Functional community health units|Community health units with active community health workers.
11039642|NCT04501458|No Intervention|Non functional community health units|Community health units without active community health workers.
11039643|NCT04501458|Experimental|Health facilities with oxygen capacity|Health facility with regular oxygen capacity.
11039644|NCT04501458|No Intervention|Health facilities without oxygen capacity|
11039645|NCT04501445|Experimental|Rounding Summary|Surrogates who were assigned to the intervention group received a written rounding summary every day or every other day that the patient is in the ICU.
11039646|NCT04501445|No Intervention|Usual Care|
11039647|NCT04501432||Cardiac Rehabilitation|Participants will be recruited from a group of patients who regularly attended group-based cardiac rehabilitation exercise training at the study site until COVID-19 restrictions (national lockdown) came into force on 10th March 2020.
11039648|NCT04501419|Experimental|Trained radiologists|Trainers will successfully train Nigerian radiologists
11039649|NCT04501419|Experimental|Patients with a suspicious breast mass|Women that present to the hospital with a suspicious breast mass
11039650|NCT04501406|Active Comparator|Pioglitazone|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving pioglitazone 15mg/day.
11039651|NCT04501406|Placebo Comparator|Placebo|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving placebo.
11039652|NCT04501393|No Intervention|0 ml/kg|The participants will not be asked to drink anything at 2 hours prior to planned procedure.
11039653|NCT04501393|Active Comparator|3 ml/kg|The participants will be asked to drink 3ml/kg of clear liquid at 2 hours prior to planned procedure.
11039654|NCT04501393|Active Comparator|7 ml/kg|The participants will be asked to drink 7 ml/kg of clear liquid at 2 hours prior to planned procedure.
11039655|NCT04501393|Active Comparator|10 ml/kg|The participants will be asked to drink 10 ml/kg of clear liquid at 2 hours prior to planned procedure.
11039656|NCT04501380|Experimental|1st regimen|30 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
11039657|NCT04501380|Experimental|2nd regimen|30 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
11039658|NCT04501367|Experimental|DEXTENZA Group|Patients undergoing vitrectomy with internal limiting membrane peel
11039664|NCT04501328|Experimental|CIC+VA-CRAFT|Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
11039665|NCT04501328|Active Comparator|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
11039666|NCT04501315||ICU TBI|Patients treated on the ICU with brain injury
11039667|NCT04501315||ICU tumor|Patients treated on the ICU because of intracranial tumor
11039668|NCT04501315||ICU surgery|Patients treated on the ICU following surgery without brain injury
11039669|NCT04501315||ICU control|Patients treated on the ICU without TBI, tumor or surgery
11039670|NCT04501289|Experimental|Low dose magnesium sulphate|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive low dose magnesium sulphate
11039671|NCT04501289|Experimental|Magnesium sulphate Pritchard regimen|Experimental - participants in this arm will be pregnant women with severe preeclampsia/eclampsia who will receive Pritchard regimen of magnesium sulphate
11039672|NCT04501276|Experimental|ADG116 Dose Escalation Level 1|
11039673|NCT04501276|Experimental|ADG116 Dose Escalation Level 2|
11039674|NCT04501276|Experimental|ADG116 Dose Escalation Level 3|
11039675|NCT04501276|Experimental|ADG116 Dose Escalation Level 4|
11039676|NCT04501276|Experimental|ADG116 Dose Escalation Level 5|
11039677|NCT04501276|Experimental|ADG116 Dose Escalation Level 6|
11039678|NCT04501276|Experimental|ADG116 Dose Escalation Level 7|
11039679|NCT04501276|Experimental|ADG116 Dose Escalation Level 8|
11039680|NCT04501276|Experimental|ADG116 Dose Escalation Level 9|
11039681|NCT04501250|Experimental|Rinsulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
11039682|NCT04501250|Active Comparator|Humulin® NPH|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
11039683|NCT04501237|No Intervention|Bruxers without sleep hygiene instructions|
11039684|NCT04501237|Experimental|Bruxers with sleep hygiene instructions|
11039685|NCT04501224|Experimental|switch to tenofovir alafenamide fumarate|Patients will switch to tenofovir alafenamide fumarate treatment, 25mg，once a day
11039686|NCT04501224|Active Comparator|Continue with the original regimen|Patients will continue with the original regimen treatment, entecavir, 0.5mg once a day, or tenofovir disoproxil fumarate 300mg once a day
11039687|NCT04501211|Other|Patch arm|Transdermal Granisetron patch to be given for application for 24 weeks with 2 weeks on and one week off pattern for a total of 24 weeks
11039688|NCT04501198|Experimental|Moxibustion with characteristic lifestyle intervention of TCM|Participants will receive moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine.In this study, xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course, and the intervention of Xiusheng Decoction and Traditional exercises will last for 8 weeks.While the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
11039689|NCT04501198|Experimental|moxibustion with lifestyle intervention|Participants will receive moxibustion combined with lifestyle intervention. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course,while the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
11039690|NCT04501198|Other|lifestyle intervention|Participants will receive lifestyle intervention which includes modern dietary exercise modifications. Participants will receive this treatment for a 8-session treatment course and 4-session follow-up course.
11039691|NCT04501185||UTS Stem|The subjects who received UTS Stem in total hip arthroplasty.
11039692|NCT04501185||UTF-reduced Stem|The subjects who received UTF-reduced Stem in total hip arthroplasty.
11039693|NCT04501172||Study group|People who use social networks, with permanent residence in Greece, aged above 18 years old and adequate literacy of Greek language
11039694|NCT04501159||End-stage renal disease (ESRD)|Patients with end-stage renal disease undergoing regular haemodialysis 3 times weekly.The investigation will measure cardiac output (CO), oxygen saturation (SaO2), arterial blood gases (ABG) and white blood cell (WBC) count during HD to assess changes in haemodynamics, pH, leukostasis and hypoxia. Patients undergoing regular HD will be recruited with arterial blood samples for gas analysis drawn over three consecutive HD treatments. Arterial samples will be taken at the start, 15 minutes and end of HD treatment for ABG and WBC analysis. Dialysis membrane, ultrafiltration volume, serum and dialysate bicarbonate levels will also be recorded. Regression analysis will be performed with pH, ABG and SaO2. A subset of patients will be used to assess an if cardiac output, WBC or pH better predicts PaO2 during HD.
11039695|NCT04501133|Experimental|Healthy Participants|Healthy participants without motor disorders and medications influencing brain functions will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG is recorded.
11039696|NCT04501133|Experimental|Patients|Participants with Parkinson's Disease or essential tremor will be scanned with MRI and undergo PES and/or single pulse TMS during several visits, each with different stimulation patterns, while HD-EMG and EEG are recorded.
11039697|NCT04501120|Experimental|APG2575 single agent|APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
11039698|NCT04501120|Experimental|APG2575+ reduced-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT.
11039699|NCT04501120|Experimental|APG2575+ standard-dose HHT|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT.
11039700|NCT04501120|Experimental|APG2575+ AZA|APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA.
11039740|NCT04500808|Experimental|Part 2: Open Label Phase: Treatment Sequence BA|Participants will receive Treatment B in period 1 followed by Treatment A in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
11039701|NCT04501107|Experimental|BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Subcutaneous administration of Biochaperone insulin lispro formulation made from a freeze-dried of BioChaperone reconstituted with Humalog® at a dose of 0.2 U/Kg Body Weight (BW).
11039702|NCT04501107|Experimental|Ready-to-use BioChaperone insulin lispro (IMP2)|Subcutaneous administration of ready-to-use Biochaperone insulin lispro formulation at a dose of 0.2 U/Kg BW.
11039703|NCT04501107|Active Comparator|US-approved Humalog® (IMP3)|Subcutaneous administration of US-approved Humalog® at a dose of 0.2 U/Kg BW.
11039704|NCT04501107|Active Comparator|EU-approved Humalog® (IMP4)|Subcutaneous administration of EU-approved Humalog® at a dose of 0.2 U/Kg BW.
11039705|NCT04501094|Experimental|1/Arm 1|Treatment with Bintrafusp alfa (M7824)
11039706|NCT04501081||1|DFNA patients and their family members (affected)
11039707|NCT04501081||2|DFNA patients and their family members (unaffected)
11039708|NCT04501068||Ambu AuraGain|Ambu® AuraGainTM Patients undergoing anesthesia in which airway management includes a Ambu® AuraGainTM supraglottic airway and fulfill the inclusion criteria of the study.
11039709|NCT04501055|Experimental|Perineal nerve block|Man receive the perineal nerve block before under the transperineal prostate biopsy
11039710|NCT04501055|Active Comparator|Periprostatic block|Man receive the periprostatic block before under the transperineal prostate biopsy
11039711|NCT04501042||Obese patients tissue proved NASH|age >20，morbid obesity who will receive bariatric surgery, tissue proved NASH
11039712|NCT04501042||Obese patients tissue proved NAFL|age >20，morbid obesity who will receive bariatric surgery, tissue proved NAFL
11039713|NCT04501042||NASH (before bariatric surgery)|age >20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected before bariatric surgery.
11039714|NCT04501042||NASH (after bariatric surgery)|age >20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected after bariatric surgery.
11039715|NCT04501029|Experimental|Gimatecan group|In Phase Ib study, patients will receive gimatecan at different dose level (0.4mg/m2, 0.6mg/m2,0.8mg/m2, oral, every 4 weeks) until progressive disease (PD).In Phase II study, patients will receive gimatecan at recommended phase II dose level.
11039716|NCT04501016|Experimental|Tailored Intervention|Tailored behavioral counseling combined with tobacco cessation pharmacotherapy.
11039717|NCT04501003|Other|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm.
11039718|NCT04500990||Single agent PD-1/PD-L1 inhibitor|Patients will receive single agent PD-1/PD-L1 inhibitor in a predefined group.
11039719|NCT04500990||Combined immunotherapy|Patients will receive combined immunotherapy in a predefined group. PD-1/PD-L1 inhibitor will be combined with target therapy, such as lenvatinib, enrotinib, herceptin et al.
11039720|NCT04500977|Experimental|Training community health promotion leaderss|Community women are trained in leadership and community-based health promotion skills
11039721|NCT04500964||failed transcather aortic valve (Stenotic)|
11039722|NCT04500964||failed transcather aortic valve (Regurgitation)|
11039723|NCT04500964||failed transcather aortic valve (Regurgitation and stenotic))|
11039724|NCT04500951|Experimental|Optimized resting environment|"The optimized resting environment will consist of the following complex intervention.
~Technically assisted noise control in regards of alarms in the patient room
~Visual signing reminding staff that the patient is not to be disturbed during rest
~Individual optimization of room environment according to information received from relatives
~Individual optimization of room environment and positioning according to systematized knowledge on best practice in the intervention ward including auditory and visual stimuli"
11039725|NCT04500951|Other|Standard resting environment|Standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward.
11039726|NCT04500925||UPSCALED|
11039727|NCT04500925||NOT UPSCALED|
11039728|NCT04500912|Active Comparator|Supraflex Cruz stent|Randomization to Supraflex Cruz stent
11039729|NCT04500912|Active Comparator|Ultimaster Tansei stent|Randomization to Ultimaster Tansei stent
11039730|NCT04500899|Experimental|Mydfrin|Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection.
11039731|NCT04500886|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24 hours after the end of chemotherapy, 6mg for patients with body weight ≥ 45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
11039732|NCT04500886|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24 hours after the end of chemotherapy, 300ug for patients with body weight ≥45kg and 150ug for patients with body weight less than 45kg, Once a day for 3-5 days until the absolute count of neutrophils ≥2×109/L.
11039733|NCT04500860||Group A Tadalafil 5 mg|50 patients subjected to Daily dose of tadalafil 5mg
11039734|NCT04500860||Group B placebo|50 patients subjected to placebo daily
11039735|NCT04500847|Active Comparator|Group 1|25 MCI and early AD subjects
11039736|NCT04500847|Placebo Comparator|Group 2|10 MCI and early AD subjects
11039737|NCT04500834|Experimental|Positive reactions, Concordance with reference allergen|All subjects will be patch tested with 11 experimental and 11 reference allergens. Rates of positive reactions will be evaluated using Cohen's kappa calculation.
11039738|NCT04500808|Experimental|Part 1: Double Blind Phase|Participants will receive macitentan or matching placebo from Day 1 up to Day 13 under fed conditions and will be up-titrated starting with 2 once daily (QD) dosing of Dose 1 from Days 1 to 2 followed by 3 qd doses of Dose 2 of macitentan from Days 3 to 5, followed by qd doses of Dose 3 macitentan from Days 6 to 13.
11039739|NCT04500808|Experimental|Part 2: Open Label Phase: Treatment Sequence AB|Participants will receive Dose 3 of macitentan under fasted conditions (Treatment A) in period 1 followed by Dose 3 of macitentan under fed condition (Treatment B) in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
11039741|NCT04500795|Experimental|Embolization Group|Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
11039742|NCT04500795|No Intervention|Control Group|All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.
11039743|NCT04500782||Patients|Group of patients with CP aged 4 to 10 years.
11039744|NCT04500769|Experimental|Acute Resistance Exercise|Participants will perform four exercises: squat, knee extension, leg press, and lat pulldown at 80% of 1-RM determined during a previous visit.
11039745|NCT04500756|Active Comparator|Metformin group|Participants will either be assigned to take metformin 500 mg daily or an identical pill that contains no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
11039746|NCT04500756|Placebo Comparator|Placebo Group|Participants will either be assigned to take metformin 500 mg daily or an identical pill that contains no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
11039747|NCT04500743|Active Comparator|Dienogest|
11039748|NCT04500743|Active Comparator|GnRH analogue|
11039749|NCT04500730|Experimental|Shaoyao Gancao Decoction Jiawei|"Shaoyao Gancao Decoction Jiawei by adding Pueraria montana, Salvia Miltiorrhiza, into Shaoyao Gancao.
~The medication will be taken twice daily for 28 consecutive days. Each prescription will consist of 4 herbal granules."
11039750|NCT04500717|Active Comparator|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
11039751|NCT04500717|Experimental|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
11039752|NCT04500704|Active Comparator|Almonertinib 110mg PO once daily|Almonertinib 110mg PO once daily.
11039753|NCT04500704|Experimental|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
11039754|NCT04500691||FBSS patients|FBSS patients who are treated with high frequency Spinal Cord Stimulation
11039755|NCT04500678|Experimental|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
11039756|NCT04500678|No Intervention|Observation|Observed without metformin
11039757|NCT04500665|Experimental|Colchicine|Colchicine 0.3 mg once daily
11039758|NCT04500665|Placebo Comparator|Placebo|Placebo once daily
11039759|NCT04500626|Experimental|HBOT|These patients will receive hyperbaric oxygen therapy (HBOT) in addition to usual treatment for COVID-19. HBOT sessions will be 75 minutes in length at a pressure of 2.0 ATA.
11039760|NCT04500626|No Intervention|Control|These patients will receive usual treatment for COVID-19, including oxygenation at normal atmospheric pressure (normobaric oxygenation).
11039761|NCT04500613|Active Comparator|ESPB with Bupivacaine and Dexamethasone|12 pediatric spinal fusion surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.25% bupivacaine with 2mg preservative free dexamethasone with a maximum of 30mL total per side, depending on the patient's weight.
11039762|NCT04500613|Placebo Comparator|No ESPB|12 pediatric spinal fusion surgery patients will be randomized to not receive an intraoperative ultrasound-guided bilateral ESPB. These patients will still receive the standard anesthesia regimen during and after surgery.
11039763|NCT04500600||Observational (questionnaire)|Patients complete an online questionnaire over 10 minutes regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
11039764|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - NHL|Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Mantle Cell Lymphoma (MCL), large cell lymphoma (LCL), and peripheral T-cell lymphoma (PTCL). Subjects must have relapsed or be refractory to at least 2 prior lines of therapy and have either failed or were not eligible for any available therapies expected to provide clinical benefit.
11039765|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - AML|Subjects with relapsed and/or primary refractory AML as defined by WHO 2016 revised criteria, who have either relapsed or are refractory to previously available therapy.
11039766|NCT04500574|Experimental|Latanoprost contact lens|The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop.
11039767|NCT04500574|Placebo Comparator|Topical Latanoprost|The placebo arm will have a commercial contact lens with no drug with a nightly 0.005% latanoprost drop.
11039768|NCT04500561|Experimental|YY-20394|YY-20394 tablets will be given daily for 21 days in 21-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons
11039769|NCT04500548|Experimental|Dose level -1 (nivolumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.
~PART II: Patients receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
11039770|NCT04500548|Experimental|Dose level 1 (nivolumab, ipilimumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.
~PART II: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
11039771|NCT04500535||Cohort 1|Immuno-oncology (IO)-naïve patients
11039772|NCT04500535||Cohort 2|IO-experienced patients for whom last IO discontinuation was not primarily related to IO-toxicity
11039773|NCT04500535||Cohort 3|IO-experienced patients for whom last IO discontinuation was primarily due to IO-toxicity
11039774|NCT04500522|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (INH) 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
11039775|NCT04500522|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
11039776|NCT04500509|Experimental|Group A|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure
11039777|NCT04500509|Placebo Comparator|Group B|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure
11039778|NCT04500496|Experimental|INH|3 tablet of INH 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
11039779|NCT04500496|Active Comparator|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
11039780|NCT04500483||Burn outpatients|Burn patients treated for minor burns in an outpatient setting
11039781|NCT04500483||ICU survivors|Critically ill patients who survived ICU stay and are admitted in a general ward
11039782|NCT04500470|Experimental|Group A|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
11039783|NCT04500470|Placebo Comparator|Group B|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table vaginal placebo by the patient 12 hours before the procedure
11039784|NCT04500457|Experimental|Intervention|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 3 days at home (5 treatment sessions total).
11039785|NCT04500457|No Intervention|Wait-List Control|Participants in this condition will not receive treatment.
11039786|NCT04500444|Experimental|Blood-Flow Restriction Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The blood flow restriction protocol will be applied to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. Before the first application, patients will be evaluated by a specialist physician using ultrasonography and it will be ensured that the arterial blood flow is not restricted as the blood flow restriction restricts only venous blood flow. The pressure threshold at this point is the level to be used in subsequent training sessions and the same person (physician) will be bandaging in the same way during all subsequent training sessions.
11039787|NCT04500444|Sham Comparator|Control Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The sham blood flow restriction protocol will be applied which consists of loose bandaging to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. The same person (physician) will be bandaging in the same way during all subsequent training sessions. The pressure feeling of the patient must correspond to level 0 -not tight at all- before starting the exercise training.
11039788|NCT04500431|Experimental|spCART-269|spCART-269 administered by intravenous (IV) infusion
11039789|NCT04500418|Active Comparator|Cenicriviroc (CVC)|Approximately 122 patients. Day 1: CVC 450 mg (300 mg AM; 150 mg PM; if patients receive their first dose on Day 1 past 2 PM, then their evening dose will be 300 mg and their next dose will be the following AM.) Days 2-28: CVC BID 150 mg (AM/PM). Every dose should be taken with food (within 30 min).
11039790|NCT04500418|Placebo Comparator|Placebo|Approximately 61 patients. A matching placebo will be given to the patients in the Placebo group at an equal volume and at the same schedule.
11039791|NCT04500392|Active Comparator|Control group|Oxygen(up to 6L/min) supplied with a regular nasal catheter
11039792|NCT04500392|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
11039793|NCT04500366|Active Comparator|Socialization|Participants randomized to the socialization arm will receive once-weekly phone calls from medical student volunteers for a total of 12-weeks (n=35). This program pairs health professional student volunteers with older adults in the community to provide social comfort while heightened physical distancing measures are in place during the current COVID-19 pandemic. Attendance and duration of the phone calls will be logged.
11039794|NCT04500366|Experimental|Multi-Modal Frailty Rehabilitation|Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all through a videoconferencing system.
11039795|NCT04500353|Active Comparator|Routine face mask application|Routine application of a face mask shortly after birth to deliver continuous positive airway pressure (CPAP)
11039796|NCT04500353|Experimental|Selective face mask application|Selective application of a face mask to give positive pressure ventilation (PPV) for apnoea or bradycardia [heart rate (HR) < 100 beats per minute (bpm)] at any time in the delivery room (DR); or to give CPAP for signs of respiratory distress after 5 minutes of life
11041901|NCT04485702|Active Comparator|IV midazolam|2mg Intravenous midazolam
11039797|NCT04500340|Experimental|Group Cognitive Behavioral Therapy (Group CBT)|Intervention Group will receive ten-session group CBT for test anxiety. Two sessions will be carried out each week.
11039798|NCT04500340|No Intervention|Control Group|The Control group will be waiting for the control group who will receive intervention if they demand after final assessment for outcome measure.
11039799|NCT04500327|Experimental|CPAP users|The Drive app will be used by CPAP users to identify any major issues with the usability and functionality of the app when used with CPAP therapy.
11039800|NCT04500314|Experimental|Whole body vibration plus routine physical therapy|
11039801|NCT04500314|Active Comparator|Routine physical therapy|
11039802|NCT04500301|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
11039803|NCT04500288|Experimental|LEFT Device Arm|Subjects in this arm will wear the LEFT device for 1 month
11039804|NCT04500275|Experimental|Vancomycin group|"i. Timing of application: the Vancomycin (China Chemical & Pharmaceutical Co., Ltd., CCPC, Taiwan R.O.C.) paste will be spread on sternal edge immediately after sternotomy and before sternal closure.
~ii. Regimen: The Vancomycin paste will be prepared using 2.5 g of Vancomycin powder mixed with 2 ml normal saline for each time. A total of 5 g of Vancomycin powder will be applied during the cardiac surgery."
11039805|NCT04500275|Placebo Comparator|Placebo group|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.
11039806|NCT04500262|Active Comparator|Open-tip pulsed needle biopsy|
11039807|NCT04500262|Active Comparator|Conventional core needle biopsy (CNB)|
11039808|NCT04500249|Experimental|CPB|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique
11039809|NCT04500249|Experimental|CPB with SPI guided analgesia|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
11039810|NCT04500249|Experimental|CPB plus SPI guided analgesia plus carotid artery block|cervical plexus block was performed with 0,5% bupivacaine using Moore's technique combined ith US-guided carotid artery block alongside with SPI-guided rescue analgesia using 1% lidokaine and intravenous fentanyl
11039811|NCT04500236|Active Comparator|General Anesthesia (GA)|Patients undergoing thyroid or breast cancer surgery under general anesthesia
11039812|NCT04500236|Placebo Comparator|Hypno-analgesia (Hyp)|Patients undergoing thyroid or breast cancer surgery under Hypno-analgesia; i.e.hypnosis combined with the use of analgesics.
11039813|NCT04500223|Experimental|Cervical Cranioflexion exercise plus cardiopulmonary exercise|subjects who received Cervical Cranioflexion exercise plus cardiopulmonary exercise
11039814|NCT04500223|Active Comparator|Cervical stretch exercise plus cardiopulmonary rehabilitation|subjects who received Cervical stretch exercise plus cardiopulmonary rehabilitation
11039815|NCT04500210|Placebo Comparator|Placebo|one capsule daily
11039816|NCT04500210|Active Comparator|Turmeric extract|one capsule daily
11039817|NCT04500184||Exercise group|patients who underwent cardiac rehabilitation
11039818|NCT04500184||Control group|patients who did not undergo cardiac rehabilitation
11039819|NCT04500171|Active Comparator|English Original Assessment Tools|Short-Test of Functional Health Literacy in Adults ColoCARE Instruction Sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
11039820|NCT04500171|Active Comparator|Samoan Original Assessment Tools|Samoan Short-Test of Functional Health Literacy in Adults ColoCARE Instruction sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
11039821|NCT04500171|Experimental|English Modified Assessment Tools|Short-Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
11039822|NCT04500171|Experimental|Samoan Modified Assessment Tools|Samoan Short Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
11039823|NCT04500158|Experimental|Local anesthesia|Participants will receive local anesthesia in addition to the standard care general anesthesia
11039824|NCT04500158|No Intervention|Standard care|Participants will receive standard care general anesthesia
11039825|NCT04500145|Active Comparator|SIB-IMRT|patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.
11039826|NCT04500145|Other|routine|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
11039827|NCT04500132|Experimental|EC-18 Arm|EC-18 QD
11039828|NCT04500132|Placebo Comparator|Placebo Arm|Placebo EC-18 QD
11039829|NCT04500119|Experimental|Behavioral Testing|Behavioral and Neuronal Recordings
11039830|NCT04500106||Participants With Nurse Support, Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, using video devices.
11039831|NCT04500106||Participants With Nurse Support, Not Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, not using video devices.
11039832|NCT04500093|Experimental|Capsulotomy with Repair|Repair after capsulotomy in direct anterior hip arthroplasty
11039833|NCT04500093|Active Comparator|Capsuloectomy|Capsuloectomy in direct anterior hip arthroplasty
11039834|NCT04500080|Experimental|PE intervention|Aerobic, resistance, and neuromotor exercise
11039835|NCT04500067|Experimental|Study Group (IVIG)|Patients receive IVIG (trade name - Bioven) with base therapy
11039836|NCT04500067|No Intervention|Control group|Patients receive base therapy only
11039837|NCT04500054|Experimental|Music Intervention Group|The music intervention group listened to the music by the researchers for the duration of 15 minutes one hour before the surgery as well as the standard care.
11039838|NCT04500054|No Intervention|No Intervention Group|The control group patients received standard care only.
11039839|NCT04500041|Active Comparator|Casting|Subjects will be treated with serial casting
11039840|NCT04500041|Active Comparator|Bracing|Subjects will be treated with full-time orthotics (braces)
11041902|NCT04485702|Active Comparator|IV ketamine|6mg Intravenous ketamine
11039841|NCT04500028|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) ( inserted by the study nurse 4 hours before IUD insertion.
11039842|NCT04500028|Placebo Comparator|Placebo Comparator|one tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
11039843|NCT04500015|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
11039844|NCT04500015|Placebo Comparator|Placebo Comparator|3 tablet of placebo self-administered by the patient 12 hours before IUD insertion
11039845|NCT04500002|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
11039846|NCT04500002|Active Comparator|Misoprostol|Misoprostol Alone 800 mcg every three hours up to maximum three doses
11039847|NCT04499989|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
11039848|NCT04499989|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo Comparator self-inserted by the patient 12 hours before IUD insertion.
11039849|NCT04499976|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily dose, 900 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
11039850|NCT04499976|Placebo Comparator|Placebo Comparator|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
11039851|NCT04499963|Experimental|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
11039852|NCT04499963|No Intervention|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
11039853|NCT04499950|Experimental|SLOW-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose <5%, designated slow responders, will continue BWL and initiate Contrave (SLOW-BWL). The SLOW-BWL arm will receive at least 16 weeks of Contrave [as per the Food and Drug Administration (FDA) recommended administration] starting at week 9 and discontinue if ≥5% weight loss is not achieved at month 6.
11039854|NCT04499950|Active Comparator|FAST-BWL|All patients will receive the POWER-remote behavioral weight loss intervention (BWL) and have a behavioral coach for the duration of the 6 month study. During months 1-3, the behavioral coach will call weekly. From months 4-6, the behavioral coach will call monthly. At week 9, those who lose ≥5%, designated fast responders, will continue with BWL alone (FAST-BWL)
11039855|NCT04499937|Experimental|Streak incentive|Subjects start with no money in an account, but they earn a fixed amount with each response. In this arm, each adult report is worth $3.17 so an adult subject can earn up to $200 if he/she responds to all surveys. If an adult completes at least 75% of the reports, he/she will receive an $100 bonus for a total maximum of $300. In this arm, each child report is worth 0.52 cents so a child subject can earn up to $33 if he/she responds to all surveys. If a child completes at least 75% of the reports, he/she will receive a $17 bonus for a total maximum of $50.
11039856|NCT04499937|Experimental|Loss-based incentive|Subjects start with the maximum possible compensation, but money is deducted for each missed response. Adult subjects will lose $4.76 for each missed survey. Child subjects will lose $0.79 for each missed survey.
11039857|NCT04499937|Active Comparator|Flat-fee control status quo condition|Subjects will receive the maximum possible compensation at the end of the study regardless of response rate.
11039858|NCT04499937|Active Comparator|Flat-Fitbit control status quo condition|Subjects will be compensated by keeping the Fitbit at the end of the study regardless of response rate.
11039859|NCT04499924|Experimental|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
11039860|NCT04499924|Experimental|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
11039861|NCT04499924|Active Comparator|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
11039862|NCT04499924|Experimental|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
11039863|NCT04499911|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 5 ml). The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
11039864|NCT04499898|Experimental|carvedilol|Carvedilol
11039865|NCT04499898|Active Comparator|Band Ligation|Band Ligation
11039866|NCT04499885|Active Comparator|Paraffin oil gastric lavafe|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
11039867|NCT04499885|Active Comparator|Saline gastric lavage|Gastric lavage with saline and sodium bicarbonate
11039868|NCT04499872||Patient/family Participant|Advance Care Plan with the Trajectory Touchpoint Technique
11039869|NCT04499859|Experimental|ezetimibe 10 mg plus rosuvastatin 5 mg|Rosuzet 5/10 mg , once a day for 24 months
11039870|NCT04499859|Active Comparator|rosuvastatin 20 mg only|Any brand drugs of rosuvastatin 20mg, once a day for 24 months
11039871|NCT04499846||Diabetic patients following education|Patients will followed an educational intervention about physiopathology of diabetes and mechanisms of action of statins. A questionnaire will allow to measure compliance to the treatment.
11040279|NCT04497064||Athlete|those who identified as participating in athletic competitions at DI, intramural, club or competitive levels
11039872|NCT04499833|Experimental|"liver transplant outside the Milan Criteria"|"patients with hepatocellular carcinoma, outside the Milan Criteria, that complied with the proposed HepatoPredictTool, submitted to liver transplant"
11039873|NCT04499820|Experimental|NUTROF Group|vitamin and DHA supplementation
11039874|NCT04499820|Placebo Comparator|MERALUT Group|vitamin A, natural flavonoids, lutein and zeaxanthin and no DHA
11039875|NCT04499807|Other|Smart Watch|The patients will wear the Smart Watch to generate data to assess their rhythm as confirmed by the ILR done during the same time.
11039876|NCT04499794||FISH diagnosed EML4-ALK fusion positive NSCLC group|
11039877|NCT04499794||FISH diagnosed EML4-ALK fusion negative NSCLC group|
11039878|NCT04499781|Experimental|HIV-infected youth: Intervention|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).
~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
11039879|NCT04499781|Active Comparator|HIV-infected youth: control|"Sample population of perinatally and behaviorally, HIV-infected youth (ages 18-29 years).
~Characteristics of the target study population include ethnic minority, Black and Hispanic HIV+AYA; both males and females are eligible for participation."
11039880|NCT04499768||control|the age-related cataract patients
11039881|NCT04499768||DR group|the cataract patients with mild/moderate NPDR
11039882|NCT04499755|Experimental|Nucleo CMP forte|Nucleo CMP forte twice daily for 6 weeks with supportive treatment.
11039883|NCT04499755|No Intervention|Supportive treatment|Supportive treatment only.
11039884|NCT04499729|Active Comparator|Treatment as Usual (TAU)|TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
11039885|NCT04499729|Experimental|IntelliCare|Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
11039886|NCT04499716|Active Comparator|Arm 1: ITO group|Arm 1: IPACK combined with femoral triangle and obturator nerve blocks
11039887|NCT04499716|Experimental|Arm 2 : Quadri-block group|Arm 2 : Femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks
11039888|NCT04499703||Group 1|Subjects with normal macular thickness in one or both eyes.
11039889|NCT04499703||Group 2|Subjects with center-involving macular edema due to wAMD in one or both eyes
11039890|NCT04499703||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes
11039891|NCT04499690||Global CALM Training Program Clinicians|Clinicians engaging in the CALM Training Program.
11039892|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r)|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
11039893|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
11039894|NCT04499677|Experimental|Favipiravir placebo + Lopinavir/ritonavir (LPV/r)|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
11039895|NCT04499677|Placebo Comparator|Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
11039896|NCT04499664||Blood donors|Healhy young male bloddonors, aged 30-45
11039897|NCT04499651|No Intervention|Control|All people who are living with HIV who are currently in custody in the Los Angeles County Jail are provided with Transitional Case Management and may also receive Whole Person Care related services regardless of participation in this study. Participants recruited from clinics who do not enroll in the study will be offered HIV/HCV care that follows the national HIV/HCV care guidelines, as provided by participating study clinics. Participants recruited from non-medical community agencies who do not enroll in the study and do not have a regular provider will receive a referral list of HIV/HCV care facilities that follow the national HIV/HCV care guidelines.
11039898|NCT04499651|Active Comparator|Navigation|"Participants will be paired with a navigator and will complete the following didactic sessions in one-on-one format:
~Session 1: Intervention Overview and Basic HIV/HCV Knowledge and Skills Builder
~Session 2: Rapport Building
~Session 3: Society and Self and the Role of Disclosure
~Session 4: Accompaniment 1
~Session 5: Goal-Setting, Problem-Solving and a Disclosure Toolkit
~Session 6: Accompaniment 2
~Session 7: Accompaniment 3 (ONLY if needed)
~Weekly check-in calls following Session 2 for six months"
11039899|NCT04499638||Non type 2 diabetic patient|Tracking the catheter from insertion to removal. Collection of any patients complication associated with these devices and what different treatments has been administered
11039900|NCT04499638||Diabetic type 2 patient|Tracking the catheter from insertion to removal.Collection of any patients complication associated with these devices and what different treatments has been administered
11039901|NCT04499625|Other|Control - Lateral window|Standard surgical technique to access maxillary sinus for sinus floor augmentation procedure.
11039902|NCT04499625|Experimental|Test - Hydrodynamic transalveolar approach|Novel transalveolar approach (using an ultrasonic device) to access maxillary sinus for sinus floor augmentation procedure.
11039903|NCT04499612||"Group Single-chamber CIED (A1)"|50 patients with permanent atrial fibrillation and indications for cardiac implantable electronic device implantation (single-chamber system).
11039904|NCT04499612||"Group Dual-chamber CIED (A2)"|50 patients with atrioventricular block/sick sinus syndrome and indications for cardiac implantable electronic device implantation (dual-chamber system).
11040040|NCT04498715|Experimental|OSTEOSYNTHESIS+SYSTEMIC Alendronate|After osteosynthesis, systemic 1 tablet of Alendronate 70 mg will be given from day 7 postoperation then weekly.
11039905|NCT04499612||"Group Dual-chamber CIED + Atrial fibrillation (A3)"|50 patients with atrioventricular block/sick sinus syndrome, paroxysmal or persistent atrial fibrillation and indications for cardiac implantable electronic device implantation (dual-chamber system).
11039906|NCT04499612||"Group CIED Replace (B)"|50 patients with cardiac implantable electronic device implantation 6-12 years ago (single- or dual-chamber system).
11039907|NCT04499612||"Group Conservative (C)"|50 patients with atrioventricular block/sick sinus syndrome/atrial fibrillation and without indications for cardiac implantable electronic device implantation (conservative group).
11039908|NCT04499599|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
11039909|NCT04499599|Placebo Comparator|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
11039910|NCT04499599|Experimental|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
11039911|NCT04499586|Experimental|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Administration of Raltitrexed and Irinotecan weekly followed by a 2 week 'rest' period with no drug given. Raltitrexed is given by IV infusion at a dose of 3mg/m2. Irinotecan is given by IV infusion at a dose of 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7).Radiation: 45-55Gy/25-30Fx
11039912|NCT04499573|Experimental|intervention/treatment|
11039913|NCT04499560|Experimental|Intervention|Participants consume 2 ounces of the supplement each morning for 60 days.
11039914|NCT04499560|No Intervention|Control|Participants do not make any changes to their health related routines
11039915|NCT04499547|Experimental|Physical activity intervention|Will receive twice-weekly, YouTube-delivered aerobic and muscle-strengthening physical activity videos for 8 weeks.
11039916|NCT04499547|No Intervention|General health education control|Will receive twice-weekly, YouTube-delivered videos with general health education information for 8 weeks.
11039917|NCT04499508|Experimental|Treatment with Optima Balt Coils|The APPLY study is a single-arm prospective study which means that everyone enrolled in the clinical trial will be/has been treated with the Optima Balt Coils.
11039918|NCT04499482|Experimental|Foods containing 10 g soy flour|Participants will receive foods containing 10 g of soy flour to be consumed everyday for one week.
11039919|NCT04499482|Experimental|Foods containing 20 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week.
11039920|NCT04499482|Experimental|Foods containing 30 g soy flour|Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week.
11039921|NCT04499469|Experimental|Spreader Graft|Placement and attachment with 5.0 polydioxanone (PDS) suture 2 grafts in the middle third of the nose
11039922|NCT04499469|No Intervention|Without Spreader Graft|No engraftment in the middle third
11039923|NCT04499456|Active Comparator|Control|Waiting list control receiving the PNF after the last assessment
11039924|NCT04499456|Experimental|Single PNF|Receives PNF after the first assessment only
11039925|NCT04499456|Experimental|Boosted PNF|Receives PNF after every assessment
11039926|NCT04499443|Experimental|Single-dose experimental group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2，Day4 and Day6. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
11039927|NCT04499443|Placebo Comparator|Single-dose control group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
11039928|NCT04499443|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, Day8 and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
11039929|NCT04499443|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
11039930|NCT04499443|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
11039931|NCT04499443|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
11039932|NCT04499430||1|"Group 1: 29 weeks and six days of gestation and earlier
~Group 1a: complementary feeding began chronologically in the sixth month
~Group 1b: Complementary feeding corrected at sixth month"
11040413|NCT04495998|Other|Motor Neurological Soft Signs|motor test and an interview for the participants
11039933|NCT04499430||2|"Group 2: Those whose gestational age is between 30 weeks and 33 weeks and sixth days
~Group 2a: complementary feeding began chronologically in the sixth month
~Group 2b: complementary feeding started in the sixth month, corrected"
11039934|NCT04499430||3|"Group 3: Those whose gestational age is between 34 weeks and 37 weeks and sixth day
~Group 3a: complementary feeding began chronologically in the sixth month
~Group 3b: complementary feeding started in the sixth month, corrected"
11039935|NCT04499417|Experimental|Experimental-Condition|"8 weeks x weekly 20 minutes whole-body-workouts with simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
11039936|NCT04499417|Sham Comparator|Sham-Condition|"8 weeks x weekly 20 minutes whole-body-workouts without simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are not actually stimulated by EMS."
11039937|NCT04499404|Experimental|Intervention group|Participants receive breastfeeding-related information from WeChat
11039938|NCT04499404|Active Comparator|Control group|Participants receive non-breastfeeding information from WeChat
11039939|NCT04499391|Experimental|ECHO plus|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
11039940|NCT04499391|Active Comparator|ECHO|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 4 months (16 sessions total) at regularly scheduled times. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
11039941|NCT04499378||SARS-CoV-2|Patients with a positive SARS-CoV-2 PCR test upon admission to the emergency department.
11039942|NCT04499378||H1N1 influenza|Patients with a positive Influenza H1N1 PCR test upon admission to the emergency department.
11039943|NCT04499365|Experimental|Experimental: 68Ga-DOTA/NOTA-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
11039944|NCT04499352|Experimental|treatment arm A|
11039945|NCT04499352|Experimental|treatment arm B|
11039946|NCT04499339|Experimental|All eligible patients|
11039947|NCT04499326|Experimental|Intervention|Patients undergoing catheter ablation of VT
11039948|NCT04499326|Active Comparator|Comparator|Patients undergoing AAD therapy for VT
11039949|NCT04499313|Active Comparator|Group A: Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization, followed by a tapering dose according to the patient's condition.
11039950|NCT04499313|Active Comparator|Group B: Methylprednisolone|Methylprednisolone Sodium Succinate at a dose of 0.5mg/kg (Injectable solution)
11039951|NCT04499300||Covid positive|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection.
11039952|NCT04499300||Sub-group: deceased patients|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, with death as outcome.
11039953|NCT04499300||Sub-group: patients who survived|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, who survived the infection.
11039954|NCT04499287|Placebo Comparator|Control|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption.
11039955|NCT04499287|Active Comparator|Fiber|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. 9 grams of soluble viscous fiber from psyllium husk (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) was mixed with the apple juice. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption.
11039956|NCT04499287|Experimental|Walk|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes.
11039957|NCT04499274|Experimental|0 ng/ml|Blood specimen which was added 0 ul of ondansetron
11039958|NCT04499274|Experimental|100 ng/ml|Blood specimen which was added 0.10 ul of ondansetron
11039959|NCT04499274|Experimental|200 ng/ml|Blood specimen which was added 0.20 ul of ondansetron
11039960|NCT04499274|Experimental|300 ng/ml|Blood specimen which was added 0.30 ul of ondansetron
11039961|NCT04499261|Experimental|laparoscopic surgery|The laparoscopic view is caudal to cephalic, which is consistent with the direction of hepatic transection. In addition, the high-definition magnified view and ability to change perspectives with the laparoscope are conducive to subtle manipulation, and compression of the carbon dioxide pneumoperitoneum can reduce venous bleeding. Therefore, laparoscopic surgery may have certain advantages in the treatment of paracaval-originating lesions.
11039962|NCT04499261|Active Comparator|Open surgery|Open surgery is the traditional surgical method for resection of paracaval-originating lesions.
11039963|NCT04499248|Experimental|Cohort 1 -Dose A|Single dose of AGN-193408 SR Dose A administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
11039964|NCT04499248|Experimental|Cohort 1 - Dose B|Single dose of AGN-193408 SR Dose B administered in the study eye on Day 1. One drop of Lumigan 0.01% administered in the non-study eye once daily every evening starting on Day 1.
11039965|NCT04499248|Experimental|Cohort 2 - Dose A|AGN-193408 SR Dose A (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
11041903|NCT04485689|Experimental|Capsaicin - alone|5x7 cm2 capsaicin patch
11039966|NCT04499248|Experimental|Cohort 2 -Dose B|AGN-193408 SR Dose B (single dose on Day 1) + vehicle eye drops (once daily in the evening starting on Day 1) administered in the study eye. Lumigan (once daily in the evening starting on Day 1) + Sham AGN-193408 SR (single administration on Day 1) administered in the non-study eye.
11039967|NCT04499235|Experimental|Mometasone furoate + AKST4290|Subjects will receive mometasone furoate concurrently with AKST4290, 400 mg twice daily, until disease control is reached.
11039968|NCT04499235|Placebo Comparator|Mometasone furoate + Placebo|Subjects will receive mometasone furoate concurrently with placebo until disease control is reached.
11039969|NCT04499222|Experimental|Portex|usage of PORTEX POLAR [Smiths Medical International, Hythe, United Kingdom] nasotracheal tube
11039970|NCT04499222|Active Comparator|Mallinckrodt|usage of Mallinckrodt TaperGuard [Covidien, Ireland] nasotracheal tube
11039971|NCT04499209|Experimental|Period 1- XG005|XG005 capsule in 4 dose level
11039972|NCT04499209|Active Comparator|Period 2- Naproxen and Pregabalin|Combination of Naproxen and Pregabalin
11039973|NCT04499209|Placebo Comparator|Period 1- Placebo|XG005 matching placebo
11039974|NCT04499183|Experimental|non-digestible carbohydrates|fructo- and galacto-oligosaccharides
11039975|NCT04499183|Placebo Comparator|placebo|maltodextrin
11039976|NCT04499170|Experimental|Muscle energy technique (G1)|Group Elderly (G1)
11039977|NCT04499170|Active Comparator|Muscle energy technique (G2)|Group of young people (G2)
11039978|NCT04499157|Experimental|MEMOPTIC added to the usual treatment of glaucoma|MEMOPTIC added to the usual treatment of glaucoma
11039979|NCT04499157|Active Comparator|usual treatment of glaucoma|usual treatment of glaucoma
11039980|NCT04499144|Experimental|modified buccal flap and subepithelial connective palatal flap|
11039981|NCT04499131|Experimental|I: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and vaginal natural micronized progesterone 400mg/12h
11039982|NCT04499131|Experimental|II: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/24h
11039983|NCT04499131|Experimental|III: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and subcutaneous natural progesterone 25mg/12h
11039984|NCT04499131|Experimental|IV: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and a combination of subcutaneous natural progesterone 25mg/24h + vaginal natural micronized progesterone 400mg/24h
11039985|NCT04499131|Experimental|V: Artificial endometrial preparation cycle|Artificial endometrial preparation cycle with estrogens and intramuscular natural progesterone 50mg/24h
11039986|NCT04499131|Active Comparator|Natural menstrual cycle|Natural menstrual cycle (without any exogenous steroid hormone Treatment)
11039987|NCT04499118|Experimental|Arm a(HR+/HER2-,HRD-）|Participants receive AT regimen for neoadjuvant therapy
11039988|NCT04499118|Experimental|Arm b(TNBC, HRD-)|Participants receive TP regimen for neoadjuvant therapy
11039989|NCT04499118|Experimental|Arm c(HER2-,HRD+)|Participants receive AT regimen for neoadjuvant therapy
11039990|NCT04499118|Experimental|Arm d(HER2-, HRD+)|Participants receive TP regimen for neoadjuvant therapy
11039991|NCT04499105|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem cell + Nacl 0.9%
11039992|NCT04499092|Active Comparator|Multifunction treatment|Patients that will receive a simulataneous multifunction treatment
11039993|NCT04499092|Experimental|Sequential treatment|Patients will receive a sequential function by function treatment
11039994|NCT04499079||Control|Includes data pre-implementation of the Learning Health System
11039995|NCT04499079||Experimental|Includes data post-implementation of the Learning Health System
11039996|NCT04499053|Experimental|durvalumab (MEDI4736)|Durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
11039997|NCT04499040|Experimental|patients with SD/THE|
11039998|NCT04499040|Placebo Comparator|control group|
11039999|NCT04499014|Experimental|ultrasound|ultrasound : a frequency of 1 MHz and an intensity of 1 W/cm2, 5 days a week, a total of 10 sessions
11040000|NCT04499014|Experimental|phonophoresis|an intensity of 1 W/cm2 and a frequency of 1 MHz and phonophoresis with 0.1% dexamethasone pomade,5 days a week, a total of 10 sessions
11040001|NCT04499014|Placebo Comparator|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week, a total of 10 sessions
11040002|NCT04498988||Substance use disorder (SUD) group|In the substance use disorder (SUD) group, participants had a diagnosis of alcohol and/or tobacco use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) but no lifetime non-substance-related addictive disorder (ND).
11040003|NCT04498988||Non-substance-related addictive disorder (ND) group|In the non-substance-related addictive disorder (ND) group, participants were included who fulfilled two or more criteria for a DSM-5 gambling disorder or for an addictive behavior related to Internet use (not for gambling, gaming, or shopping), gaming, or shopping assessed with adapted criteria from DSM-5 substance use disorder (SUD). Participants in the ND group had no lifetime SUD.
11040004|NCT04498988||Control group|The control participants had no current or lifetime substance use disorder (SUD) or non-substance-related addictive disorder (ND).
11040005|NCT04498975||Patients with IHD|No intervention
11040006|NCT04498962|Experimental|chronic stable angina|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with chronic stable angina will be treated by Danzhu Fuyuan Granule in addtion to routine care
11040007|NCT04498962|Experimental|Vascular Dementia|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Vascular Dementia will be treated by Danzhu Fuyuan Granule in addtion to routine care
11040008|NCT04498962|Experimental|Idiopathic Membranous Nephropathy|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Idiopathic Membranous Nephropathy will be treated by Danzhu Fuyuan Granule in addtion to routine care
11040009|NCT04498962|No Intervention|Healthy population|Comparator: Healthy population with no treatment
11040041|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BVF|During osteosynthesis, cerament BVF is used for the augmentation of the screw.
11041904|NCT04485689|Placebo Comparator|Placebo - alone|5x7 cm2 placebo patch alone
11040010|NCT04498949|Experimental|Exprimental|"The unified protocol modules are as follows:
~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
11040011|NCT04498949|Active Comparator|Treatment as usual|Treatment as usual care, Recieve consulting not included unified protocol Recieve supportive cares
11040012|NCT04498936|Experimental|Sofosbuvir/Ledipasvir|This group will receive a fixed combination of Sofosbuvir/Ledipasvir (400 mg and 90 mg, orally) once daily for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
11040013|NCT04498936|Experimental|Nitazoxanide|This group will receive nitazoxanide (500 mg, orally) four times per day for 14 days, plus the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
11040014|NCT04498936|No Intervention|Standard care treatment|This group will receive only the standard care treatment regimen (SCT) for COVID-19 patients according to the Egyptian Ministry of Health (MOH) protocol.
11040015|NCT04498923||Bupivacaine with dexamethasone|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.
~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone was injected for one plexus or peripheral nerve."
11040016|NCT04498923||Bupivacaine with dexamethasone and epinephrine|"Ultrasound guided peripheral nerve block for upper or lower extremity was performed before orthopedic surgery using neurostimulator.
~Twenty milliliters solution of bupivacaine 0,375% with dexamethasone 0,02% and epinephrine 0,00018% was injected for one plexus or peripheral nerve."
11040017|NCT04498910|Experimental|LY3451838|LY3451838 given intravenously (IV)
11040018|NCT04498910|Placebo Comparator|Placebo|Placebo given IV
11040019|NCT04498897|Active Comparator|Test group|Vortioxetine + Acamprosate
11040020|NCT04498897|Placebo Comparator|Placebo Group|Placebo + Acamprosate
11040021|NCT04498884|Experimental|Rinsulin® mix 30/70|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
11040022|NCT04498884|Active Comparator|Humulin® M3|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
11040023|NCT04498858||Patient|
11040024|NCT04498845|Active Comparator|Basic intervention group|Participants in the basic intervention group will have a 1-hour in-home assessment plan and family educational session.
11040025|NCT04498845|Experimental|Intermediate intervention group|Participants in the intermediate intervention group will have a 1-hour in-home assessment plan and educational session and refer worker to a 1-hr worker take home prevention educational session.
11040026|NCT04498845|Experimental|Advanced intervention group|Participants in the advanced intervention group will have a 1-hour in-home assessment plan and educational session, refer worker to a 1-hr worker take home prevention educational session, and provision of D-LEAD all-purpose cleaner and laundry detergent.
11040027|NCT04498832|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
11040028|NCT04498832|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
11040029|NCT04498819|Experimental|Single Arm|Only one arm, one intervention; this is a feasibility study.
11040030|NCT04498806|Experimental|Intervention|Pre-op appointment, patient will receive Fitbit device to track physical activity.
11040031|NCT04498793|Experimental|PD-1 group|"Participants receive tislelizumab every 3 weeks (Q3W) + nab-paclitaxel weekly x 4 cycles, followed by tislelizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 14 cycles of tislelizumab Q3W plus capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.
~Each cycle is 21 days."
11040032|NCT04498793|Active Comparator|Control group|"Participants receive nab-paclitaxel weekly x 4 cycles followed by (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by capecitabine (TNBC subtype) or endocrine therapy (Luminal subtype) as adjuvant therapy post-surgery.
~Each cycle is 21 days."
11040033|NCT04498767|Active Comparator|Arm 1: Standard of Care + palliative RT|"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
~Systemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy."
11040034|NCT04498767|Experimental|Arm 2: Standard of Care + SBRT|"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size & location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
~Patients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation."
11040035|NCT04498754|Experimental|Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants assigned to this arm will receive eight sessions of a well-established, evidence-based therapy called cognitive behavior therapy for insomnia (CBT-I).
11040036|NCT04498754|Other|Minimal Contact Control Condition|Participants assigned to this condition will be contacted every week for eight weeks and monitored regarding their insomnia symptoms.
11040037|NCT04498741|Experimental|EDP-938 and tacrolimus interaction (Part 1)|
11040038|NCT04498741|Experimental|EDP-938 and dabigatran interaction (Part 2)|
11040039|NCT04498741|Experimental|EDP-938 and rosuvastatin interaction (Part 3)|
11056478|NCT04382716||PANS participants|
11040042|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BVF+LOCAL ZOLEDRONIC ACID|During osteosynthesis, cerament BVF mixed with 2 mg zoledronic acid is used for the augmentation of the screw.
11040043|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BVF+SYSTEMIC Alendronate|During osteosynthesis, cerament BVF is used for the augmentation of the screw. Then systemic 1 tablet of Alendronate 70 mg will be given day from 7 postoperation then weekly.
11040044|NCT04498702|Experimental|APL-1202 treatment|
11040045|NCT04498689|Experimental|camrelizumab + nab-paclitaxel + gemcitabine|PD-1 Monoclonal Antibody Camrelizumab at 200 mg on Day 1 and 15 nab-paclitaxel at 100 mg/m2 on Day 1, 8, and 15; gemcitabine at 1000 mg/m2 on Day 1, 8, and 15
11040046|NCT04498676|Experimental|Test product|
11040047|NCT04498663|Experimental|Therapeutic Interview Condition|The therapeutic interview for chronic pain will be a one-session interview lasting approximately 90 minutes. The goals of the therapeutic interview are to promote awareness of the role of trauma and interpersonal stress in pain, to encourage experience of emotions associated with interpersonal stressors and conflicts, and to encourage more adaptive interpersonal communication in current relationships.
11040048|NCT04498663|No Intervention|Waitlist Control Condition|Participants in the waitlist control condition will receive a delayed interview (after 5-week follow-up assessment), if they choose to do so.
11040049|NCT04498650|Placebo Comparator|Placebo|
11040050|NCT04498650|Experimental|300 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-24: 300 mg BID
11040051|NCT04498650|Experimental|600 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-12: 300 mg BID Dose in weeks 12-24: 600 mg BID
11040052|NCT04498637||Physiotherapy students|Students enrolled in the Physiotherapy Bachelor´s Degree of the University of Cadiz, Spain
11040053|NCT04498637||Nursing students|Students enrolled in the Nursing Bachelor´s Degree of the University of Cadiz, Spain
11040054|NCT04498624|Active Comparator|inverted flap|
11040055|NCT04498624|Active Comparator|peeling internal limiting membrane (ILM)|
11040056|NCT04498611|Experimental|breast DCIS patients|Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.
11040057|NCT04498598|Experimental|A/Z Airway|Patients under general anesthesia for surgical procedures who need airway management for ventilation.
11040058|NCT04498585|Experimental|Intervention|Participants who will be receiving standard ICU care and additionally the VR stimulation during their ICU stay.
11040059|NCT04498585|No Intervention|Control|Patients in the ICU who will be receiving standard ICU care during their ICU stay. Participants in this arm will not be receiving VR stimulation.
11040060|NCT04498572|Experimental|research group|active exercises and dry needling for the Gluteus medius muscle
11040061|NCT04498572|Sham Comparator|control group|active exercises and sham dry needling for the Gluteus medius muscle
11040062|NCT04498559||Patients undergoing total hip replacement|Patients at HSS Main Campus undergoing primary total hip replacement surgery, age range between 18 and 80 years old, and English speaking
11040063|NCT04498533|Active Comparator|B (brace) group|The patients in the B group were informed about the application of the forearm strap (counterforce brace). Patients were advised to wear the counterforce brace for three weeks continuously.
11040064|NCT04498533|Active Comparator|KT (kinesio tape) group|In the KT group, a standard 2-inch (5 cm) Kinesio®Tex tape (Kinesio Holding Corporation, Albuquerque, New Mexico, USA) was used with techniques of muscle inhibition and fascia correction. Kinesio tape was applied once a week for four weeks.
11040065|NCT04498520|Experimental|Treatment (abexinostat tosylate, palbociclib, fulvestrant)|Patients receive abexinostat PO BID on days 1-4, 8-11, and 15-18, palbociclib PO QD on days 1-21, and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11040066|NCT04498494||myocarditis|The diagnosis of acute myocarditis was confirmed by a recent history of gastrointestinal/upper respiratory tract infection and/or complaints of cardiac symptoms and increasing cardiac markers and/or presentation with a new abnormality of the 12-lead ECGcombined with at least one of the following: ⅰ) Active or borderline biopsy according to the Dallas criteria (13); ⅱ) positive infectious origin of ventricular dysfunction; ⅲ) delayed enhancement on cardiac MRI consistent with myocarditis; or ⅳ) serological tests, ECGs, ultrasonic cardiogram (UCG), coronary angiography and ventriculography to exclude acute myocardial infarction (AMI), stress cardiomyopathy, congenital heart disease, myocarditis secondary to sepsis, valve disease, hyperthyroidism, autoimmune disease and rheumatic fever
11040067|NCT04498494||fulminant myocarditis|In patients with acute myocarditis, a diagnosis of FM was determined upon identification of one or more of the following: Haemodynamic instability due to cardiogenic shock or arrhythmia; left ventricular dysfunction and low cardiac output syndrome requiring inotropes or mechanical circulatory support; mechanical ventilation; and/or cardiac arrest (CA)
11040068|NCT04498481||Breast cancer patients|HR+/HER2- advanced/metastatic breast cancer patients in the USA.
11040069|NCT04498468|Experimental|Treatment Arm|Commercially available Sustained Release Dexamethasone, 0.4 mg intracannalicular insert (DEXTENZA® - Ocular Therapeutix, Bedford, MA)
11040070|NCT04498468|Sham Comparator|Control Arm|Commercially available EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL) (Vera90™ - Elkridge, MD)
11040071|NCT04498455|Placebo Comparator|Placebo|Dietary Supplement: Placebo
11040072|NCT04498455|Active Comparator|Prebiotin|Dietary Supplement: Prebiotin (oligofructose enriched inulin)
11040073|NCT04498442|No Intervention|Yoga Practitioners|Yoga practitioners arm is the observational arm of the study, wherein participants who follow Isha school of yoga and have completed either of the three courses : Inner Engineering Online (IEO), Inner Engineering Completion (Shambhavi Mahamudra kriya) or Shakthi Chalana Kriya can be included in this group. The participant are advised to continue with their routine yoga practice with no change in the duration of practice or frequency of their practices. Participants of this group have expertise in yoga practice and have been practicing yoga for more than 6 weeks before study enrollment.
11040074|NCT04498442|Active Comparator|Control Yoga|"Control Yoga is the active comparator arm of the study. Participants who are randomly allocated to this group, practice Simha Kriya, a deep breathing exercise taught by the Isha School of yoga."
11056516|NCT04382456|Experimental|acacia gum|
11040075|NCT04498442|Placebo Comparator|Control Idle|Control Idle is the active comparator arm of the study. Participants who are randomly allocated to this group, are advised to either read a book for 15 minutes each day or sit idle for 15 minutes. This is the true control group for the study
11040076|NCT04498429|Experimental|Integrated Manual and Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Integrated/Manual Cueing intervention.
11040077|NCT04498429|Experimental|Verbal Cueing Group|A series of 40 training repetitions of sit to stand using the Verbal Cueing intervention
11040078|NCT04498416||Group 1 Post-Traumatic Stress Disorder (PTSD)|children with an identified traumatic history
11040079|NCT04498416||Group 2 Pathology|children with psychological follow-up treatment for a psychiatric disorder, without traumatic history;
11040080|NCT04498416||Group 3 Control|children without traumatic experience and without psychiatric or psychological follow-up treatment.
11040081|NCT04498403|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied twice daily (BID)
11040082|NCT04498390|Experimental|LY3493269|LY3493269 administered orally.
11040083|NCT04498390|Placebo Comparator|Placebo|Placebo administered orally.
11040084|NCT04498377|Experimental|F-652|
11040085|NCT04498377|Placebo Comparator|Placebo|
11040086|NCT04498364|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 8 hours of treatment.
11040087|NCT04498351|Placebo Comparator|cotrol group|patients who will undergo Spermatic Cord Block by 18 ml of Levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.
11040088|NCT04498351|Active Comparator|dexmedetomidine group|the patients who will undergo Spermatic Cord Block by 18 ml of Levobupivacaine 0.5% plus plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml .
11040089|NCT04498351|Active Comparator|dexmedetomidine and magnesium sulphate group|the patients who will undergo Spermatic Cord Block by received 18 ml of Levobupivacaine 0.5% plus plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .
11040090|NCT04498338|Experimental|Neural mobilization and conventional physical therapy|Neural mobilization combined with conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) were performed three times/week for 6 successive weeks.
11040091|NCT04498338|Active Comparator|Conventional physical therapy program|Conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) was performed three times/week for 6 successive weeks.
11040092|NCT04498325|Experimental|NT-I7 (Phase I)|"In the phase I study, 3 dose levels of NT-I7 are planned. Dosing will be staggered such that there will be a minimum of 72 hours between the dosing of one participant and the dosing of the next participant
~NT-I7 will be given by intramuscular injection on Day 0
~Participants will also be given standard of care treatment for COVID-19"
11040093|NCT04498325|Experimental|NT-I7 (Pilot)|"NT-I7 (dose determined by Phase I portion of study) will be given by intramuscular injection on Day 0
~Participants will also be given standard of care treatment for COVID-19"
11040094|NCT04498325|Placebo Comparator|Placebo (Pilot)|"Placebo will be given by intramuscular injection on Day 0
~Participants will also be given standard of care treatment for COVID-19"
11040095|NCT04498312|Experimental|Shock wave group|Received Extracorporeal shock wave therapy twice/week for 4 weeks
11040096|NCT04498312|Experimental|Manual lympharic group|Received manual lymphatic drainage twice a week for four weeks
11040097|NCT04498286||Amsterdam MS Cohort|
11040098|NCT04498273|Active Comparator|Apixaban 2.5mg|Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
11040099|NCT04498273|Active Comparator|Apixaban 5mg|Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
11040100|NCT04498273|Active Comparator|Aspirin|Antiplatelet agent: low dose aspirin 81mg po qd
11040101|NCT04498273|Placebo Comparator|Placebo|Placebo
11040102|NCT04498260|Experimental|Local steroid-triamcinolone acetonide|Local steroid (triamcinolone acetonide) injection to the ulcer immediately after ESD. Total amount of injected triamcinolone is 100 mg.
11040103|NCT04498260|Active Comparator|Oral steroid-predonisolone|(predonisolone) administration three days after ESD. Predonisolone is administered over 8 weeks, started at 30 mg/day and tapered 30, 30, 25, 25, 20, 15, 10 and 5 every 7 days, totaling 8 weeks of treatment.
11040104|NCT04498247|Experimental|Part 1: Panels A, B|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.
11040105|NCT04498247|Experimental|Part 2A: Panels C-E|Participants in this 18 to 55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.
11040106|NCT04498247|Experimental|Part 2A: Panel F|Participants in this 18 to 55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.
11040107|NCT04498247|Experimental|Part 2B: Panels G, H|Participants in this >55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.
11040108|NCT04498247|Experimental|Part 2B: Panels I, J|Participants in this >55 year old cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.
11040109|NCT04498247|Experimental|Part 2B: Panels K, L|Participants in this >55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.
11040110|NCT04498234|Experimental|GROUP(A) (CONTROL GROUP)|Patients will receive standard regimen of anesthesia .
11040111|NCT04498234|Experimental|Group B|Patients will receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4.
11040112|NCT04498234|Experimental|Group C|Patients will receive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
11040113|NCT04498221|Experimental|Imaging Phase|During routine examination under anaesthetic 4 x peritumoural injection of Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
11040114|NCT04498221|Experimental|Surgical Phase|Excision of contralateral nodes identified on imaging *(fhSPECT or SPECT/CT*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
11040115|NCT04498208|Experimental|Personalized prehabilitation|Patients will participate in a personalized health optimization program combining one-on-one coaching, tailored to each patient's physical, nutritional, well-being and cognitive status baseline. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before surgery
11041905|NCT04485689|Experimental|Capsaicin - ice|5x7 cm2 capsaicin patch - plus ice
11040116|NCT04498208|No Intervention|Standard prehabilitation|Patients in the control group will be provided with standard instructions in a hard-copy form specific to prehabilitation before surgery associating physical, nutritional, stress-reduction and cognitive recommendations without any personalized coaching for at least 21 days prior to surgery.
11040117|NCT04498195|Experimental|Increase physical activity and exercise|
11040118|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.0014%)|Low Dose
11040119|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.003%)|High Dose
11040120|NCT04498182|Placebo Comparator|Vehicle|AR15512 Ophthalmic Solution Vehicle
11040121|NCT04498169|Experimental|Once Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
11040122|NCT04498169|Experimental|Twice Daily Netarsudil Ophthalmic Solution|One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.
11040123|NCT04498156||CKD-Patients|Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
11040124|NCT04498156||Physicians treating CKD|Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
11040125|NCT04498143|Experimental|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|SAVE is a ~30-minute, self-administered, web-based program that uses components of cognitive behavior therapy and dialectical behavior therapy designed to decrease self-injurious behaviors in youth. The Project SAVE SSI has 4 general content sections: (1) explaining the science behind how changing your actions (i.e. decreasing self-injurious behaviors) can positively impact your emotions over time; (2) providing scientific evidence and testimonials from other teens that have successfully decreased their self-injurious behaviors and noticed positive change as a result; (3) evidence-based tips for overcoming common obstacles to decreasing self-injurious behaviors in day to day life; and (4) offering an opportunity for youth to share their own thoughts and advice on what they have learned with other teenagers who are facing similar challenges.
11040126|NCT04498143|Active Comparator|"Supportive Therapy (Share Your Feelings) SSI"|Supportive Therapy SSI (Schleider & Weisz, 2018): ~30-minute, self-administered, web-based program that uses components of supportive therapy to encourage feelings sharing. The supportive therapy SSI encourages participants in the control group to identify and express their feelings by (1) explaining why sharing feelings is natural, important, and helpful and (2) including testimonials from teens who have shared their feelings with close others.
11040127|NCT04498130|Active Comparator|Increase Moderate-Vigorous Physical Activity (MVPA)|Participants will partake in aerobic walking and/or running sessions which encourage them to reach a pre-determined heart rate range. Sessions will be held at an indoor track facility 3 times a week for 12 weeks. Session times will increase from 15 minutes to 50 minutes as participants build their aerobic fitness. Participants in this group will be instructed not to change any physical activity behavior outside of the exercise sessions.
11040128|NCT04498130|Experimental|Increase MVPA + Decrease Sedentary Behavior|In addition to the aerobic exercise sessions, participants in this group will receive an additional intervention aimed at reducing their daily sitting time. The structure of this arm will be designed using constructs from Social Cognitive Theory, with specific emphasis on increasing self-efficacy, outcome expectations and self-regulation to sit less and move more during the work day. Participants will receive a workbook and members of the research team will guide them through activities each week. All components of the sedentary reduction intervention will be delivered during the exercise sessions.
11040129|NCT04498117|Experimental|Cohort 1- Surgery Active|Six (6) 21-day cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
11040130|NCT04498117|Placebo Comparator|Cohort 1 - Primary Surgery Control|Six (6) 21-day cycles of chemotherapy with placebo comparator given with chemotherapy at four (4) cycles (Cycle 1, Cycle 3, Cycle 5, and Cycle 5 plus 12 weeks).
11040131|NCT04498117|Experimental|Cohort 2 - NACT + Interval Surgery Active|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with oregovomab given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
11040132|NCT04498117|Placebo Comparator|Cohort 2 - NACT + Interval Surgery Control|In Cohort 2 - NACT + Interval Surgery, subjects must already have received three (3) cycles of paclitaxel and carboplatin neoadjuvant therapy. Subjects in Cohort 2 - NACT + Interval Surgery will receive three (3) cycles of chemotherapy with placebo comparator given at four (4) cycles (Cycle 4, Cycle 6, Cycle 6 plus 6 weeks and Cycle 6 plus 18 weeks).
11040133|NCT04498104||Borderline Personality Disorder|Borderline personality disorder diagnosed participants
11040134|NCT04498104||Control|Healthy participants
11040135|NCT04498091||A|Type 2 MI with COVID-19
11040136|NCT04498091||B|Type 2 without COVID-19
11040137|NCT04498091||C|Type 2 MI with pneumonia without COVID-19
11040138|NCT04498091||D|Type 2 MI without pneumonia and without COVID-19
11040139|NCT04498078|Experimental|Creatine|Twenty grams per day b.i.d.
11040140|NCT04498065||A|COVID positive and Troponin positive
11040141|NCT04498065||B|COVID positive and Troponin negative
11040142|NCT04498052|Experimental|Patients eligible for LDCT lung cancer screening|"This population will consist of patients eligible for, or potentially eligible for, LDCT lung cancer screening according to USPSTF guidelines, who are seen by a pilot user of the intervention. The inclusion criteria are (i) >= 55 years and <= 80 years old at the time of the visit; (ii) does not already have lung cancer; and (iii) meets USPSTF smoking criteria for LDCT screening (30+ pack-year smoking history and current smoker or quit in the past 15 years) or may meet the criteria if a complete smoking history were taken.
~USPSTF guidelines may change during the study. In particular, it is anticipated that the guidelines may update during the study whereby the minimum age is reduced to 50 (from 55) and the minimum smoking history is reduced to 20 years (from 30). In the event that the USPSTF guidelines change, the intervention will be updated to match the change to the guidelines. We may also update the study evaluation to match the updated USPSTF guidelines."
11040206|NCT04497558|No Intervention|Control group|In the control group, those patients do not receive any treatment before next cycle of transfer. In the control group, no intervention will be performed.
11040143|NCT04498039|Experimental|Active|Electrical stimulation to the tongue is delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Active subjects will be able to feel the sensation.
11040144|NCT04498039|Sham Comparator|Control|Electrical stimulation to the tongue will be delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Control subjects will be informed that while they may not feel the electrotactile stimulation, they are in-fact receiving a low level signal.
11040145|NCT04498026|Experimental|Adherus Dural Sealant System|Device: Adherus Dural Sealant, In situ polymerizing sealant
11040146|NCT04498026|Active Comparator|DuraSeal Exact Dural Sealant System|Device: DuraSeal Exact (P080013b)
11040147|NCT04498013|Experimental|Treatment group|Patients will be treated with Cyclodynon 1 tablet per day 6 month in addition to lifestyle modification
11040148|NCT04498013|Other|Control group|Lifestyle modification only
11040149|NCT04497987|Experimental|LY3819253|LY3819253 administered intravenously (IV).
11040150|NCT04497987|Placebo Comparator|Placebo|Placebo administered IV.
11040151|NCT04497974|Active Comparator|Regular dietary sweetness exposure - Control|Regular dietary sweetness exposure (RSE) - The RSE group consumes a diet with 25 - 30 % energy from sweet tasting foods, for 6 months.
11040152|NCT04497974|Experimental|Low dietary sweetness exposure - Experimental|Low dietary sweetness exposure (LSE) - The LSE group consumes a diet with 10 - 15 % energy from sweet tasting foods, for 6 months.
11040153|NCT04497974|Experimental|High dietary sweetness exposure - Experimental|High dietary sweetness exposure (HSE) - The HSE group consumes a diet with 40 - 45 % energy from sweet tasting foods, for 6 months.
11040154|NCT04497961|Experimental|Lenalidomide maintenance|Those randomized to lenalidomide maintenance will receive a maintenance dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.
11040155|NCT04497961|Experimental|Daratumumab maintenance|Those randomized to receive daratumumab maintenance will receive 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.
11040156|NCT04497948|Other|Single Arm|Single Arm
11040157|NCT04497935||1LPEG|Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.
11040158|NCT04497935||2LPEG|Patients receiving 2LPEG who had a colonoscopy in the morning were asked to follow a similar day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, the first 1L dose was consumed over a 1-hour period, followed by the second dose at 11:00 pm. For 2LPEG patients with procedures in the afternoon, they took Dose 1 at 7:00 am and Dose 2 at 10:00 am. Any patient receiving 2LPEG was also told to consume 1L of clear liquids during the preparation procedure.
11040159|NCT04497922|Active Comparator|Treatment as usual in emergency department|Individuals triaged to a pod in the emergency department without rooms that are fitted with a virtual display screen
11040160|NCT04497922|Experimental|Virtual white board|Individuals triaged to a pod in the emergency department in a room that is fitted with a virtual display screen
11040161|NCT04497909|Experimental|Pre-clerkship cohort|First- and second-year medical students
11040162|NCT04497909|Experimental|Clerkship cohort|Third- and fourth-year medical students
11040163|NCT04497909|Experimental|Resident cohort|Medical residents
11040164|NCT04497883|Experimental|Cohort A: Non-Hispanic, Caucasian group|Non-Hispanic, Caucasian group participants will receive 400 milligram (mg) maribavir tablets orally once on Day 1 during treatment period 1.
11040165|NCT04497883|Experimental|Cohort B: Japanese Descent|Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1 followed by 200 mg or 800 mg maribavir tablets orally once on Day 1 during treatment period 2 followed by 800 mg or 200 mg maribavir tablets orally once on Day 1 during treatment period 3 in cross-over fashion. A washout period of 72 hours will be maintained between treatment period 1, 2, and 3.
11040166|NCT04497870|Active Comparator|540 mg|Peppermint oil at a dose of 180 mg thrice daily orally
11040167|NCT04497870|Experimental|900 mg|Peppermint oil at a dose of 180 mg five times daily orally
11040168|NCT04497857|Placebo Comparator|CSC-SD|Standard clinic-based CSC model treatment. Treatment will be delivered largely in clinic for 12 months.
11040169|NCT04497857|Experimental|CSC-TH|Telehealth based CSC model treatment. Treatment will be delivered largely through telehealth for 12 months.
11040170|NCT04497844|Experimental|Niraparib with Abiraterone Acetate plus Prednisone (AA-P)|Participants will receive the following in each 28- day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
11040171|NCT04497844|Experimental|AA plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
11040172|NCT04497831|Experimental|Study Drug|Morphine hydrochloride
11040173|NCT04497831|Placebo Comparator|Placebo|Placebo
11040205|NCT04497558|Experimental|ERA group|In the experimental group, those patients undergo endometrial receptivity array. According to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out.
11040276|NCT04497077|Experimental|double dose tart cherry juice|double dose tart cherry juice
11056870|NCT04379934|Other|Heart failure|Ejection fraction < 45%
11040174|NCT04497818||Netizens|Netizens of Al Qassim province of Saudi Arabia were the target population for this cross sectional study. Sample size is (n=385) estimated based on the population size in Al Qassim province (Confidence Interval 95%, Design effect 1 & hypothesized % frequency of outcome factor of 50%). Assessment of Fear of COVID-19 was estimated using FEAR OF COVID-19, a 5 item Likert Scale. Assessment of Dental Anxiety was estimated using Modified Dental Anxiety 5 item Likert Scale. An online Survey form (Arabic 7 English) was developed using Google form application. The Google form link was shared to the netizens of Al Qassim province, across all relevant Social media platforms. Statistical analysis is done using SPSS 22.00 software program.
11040175|NCT04497805|Experimental|ALLO-ASC-SHEET|ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
11040176|NCT04497805|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
11040177|NCT04497792|Experimental|Treatment group|The treatment group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will receive empagliflozin additionally to previously taken hypoglycemic treatment.
11040178|NCT04497792|No Intervention|Control group|The control group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will continue previously taken hypoglycemic treatment.
11040179|NCT04497779||Screening (biospecimen collection, medical record review, CCP)|"PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed.
~CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed.
~CCP RECIPIENTS: Patients undergo collection of blood samples at baseline, 12-24 hours after each CCP infusion, and 7 days after last CCP infusion. Patients' medical records are reviewed."
11040180|NCT04497766|Experimental|Nebulized magnesium sulphate|100mg of mgso4 in 20ml of normal saline via ultrasonic nebulizer
11040181|NCT04497766|Experimental|Intravenous magnesium sulphate|Magnesium sulphate according to weight will be given intravenously.
11040182|NCT04497753||Can't fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.
~Record whether the subject feels bitterness, if there is no feeling, the test is over."
11040183|NCT04497753||Can fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.
~Record whether the subject feels bitterness, If there is a sensation, put the adhesive strip on the upper edge of the subject's mask and put on the hood to carry out the above fitness test again.
~Record whether the subject feels bitterness, if not, the test is over. If there is any sensation, ask the subject to change to a medical surgical mask, and put an adhesive strip on the upper edge of the mask, and put on the hood to carry out the above fitness test again."
11040184|NCT04497727||Patients undergoing routine colonoscopy|Patients with and without hypertension who routinely undergo colonoscopy
11040185|NCT04497714||Cervical lymph nodes tuberculosis|The patients with Cervical lymph nodes tuberculosis
11040186|NCT04497714||Cervical lymphoma|The patients with
11040187|NCT04497714||Cervical lymph node metastasis|The patients with
11040188|NCT04497714||Cervical Reactive hyperplasia|The patients with
11040189|NCT04497701|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®)24~72 hours after the end of chemotherapy, 100µg/kg, once in each chemotherapy cycle.
11040190|NCT04497701|Active Comparator|rhG-CSF group|Patients received subcutaneous injection of rhG-CSF 24~72 hours after the end of chemotherapy, 100µg/kg/d, and stop using it until the ANC value exceeds the lowest value for 2 consecutive days> 0.5×10^9/L.
11040191|NCT04497688|Experimental|PEG-rhG-CSF group|Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®) 48 hours after the end of chemotherapy, 6mg for patients with body weight≥45kg and 3mg for patients with body weight less than 45kg, once per chemotherapy cycle
11040192|NCT04497675||Can't fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.
~Record whether the subject feels bitterness, if not, let the subject puts on the hood, carry out the fitness test again and record the results."
11040193|NCT04497675||Can fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.
~If the subject feels bitterness, stick the adhesive strip on the upper edge of the subject's mask and perform the direct spray test again. Record whether the subject feels bitterness, if not, ask the subject to put on the hood, carry out the fitness test again and record it. If there is a feeling, ask the subject to change to a medical surgical mask and put an adhesive strip on the upper edge of the mask, then conduct the direct spray test again, and record the test results."
11040194|NCT04497662|Experimental|KPL-404 (IV Administration)|
11040195|NCT04497662|Experimental|KPL-404 (SC Administration)|
11040196|NCT04497649|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir with standard of care treatment
11040197|NCT04497649|No Intervention|Standard of care treatment|Standard of care treatment
11040198|NCT04497623|Experimental|Intervention arm|Patients with indication for volume-controlled mechanical ventilation
11040199|NCT04497610||Positive TeraSystem test|Patients having positive PCR tests will undergo TeraSystem test
11040200|NCT04497610||Negative TeraSystem test|Patients having negative PCR tests will undergo TeraSystem test
11040201|NCT04497597||Participants receiving Upadacitinib|Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
11040202|NCT04497584|Experimental|Afatinib + Prednisone|"Afatinib 40 mg PO daily
~Prednisone 40 mg PO daily starting 7 days after Afatinib"
11040203|NCT04497571|Experimental|Piezoelectric osteotomy|Implant placement by piezoelectric osteotomy
11040204|NCT04497571|Active Comparator|Conventional drilling|Implant placement by conventional drilling
11056871|NCT04379934|Other|Non-heart failure|Ejection fraction > 45%
11040207|NCT04497545|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual therapy and 30 minutes of therapy on the Luna EMG device.
11040208|NCT04497545|Other|Control Group|A four-week rehabilitation program (Monday to Friday) involving one hour of individual therapy and 30 minutes on lower limb rotor
11040209|NCT04497532|No Intervention|Control|
11040210|NCT04497532|Experimental|Diet|
11040211|NCT04497506|Experimental|Self-affirmation and Incremental theory of personality|1 hour Wise intervention (based on SA and ITP) consisting on several tasks to be completed online individually.
11040212|NCT04497506|Other|Standard preventive intervention|1 hour educational intervention (about stress management) consisting on several tasks to be completed online individually.
11040213|NCT04497493|Experimental|tDCS group|participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
11040214|NCT04497493|Sham Comparator|Sham group|Participants receive sham stimulation that administered similarly, but with current turned off after 30s combine a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitors(SNRI)
11040215|NCT04497480|Experimental|experimental group|
11040216|NCT04497480|No Intervention|controlled group|
11040217|NCT04497454|Active Comparator|ARDSNet|ARDSNet protocol (low PEEP-FiO2 table). Ventilatory mode: volume-controlled ventilation Tidal volume (VT) will be adjusted to 4-6 mL/Kg of PBW and Plateau pressure < 30 cmH2O for the at least the first 12 hours after inclusion in the protocol pH should be maintained between 7.35-7.45 Oxygenation (SpO2) target ranges 90-95% Maximum respiratory rate = 35 breaths/min PEEP and FIO2 adjusted according to the low PEEP-FiO2 Table.
11040218|NCT04497454|Experimental|EIT-Group|The goal is to maintain driving pressure (DP) < 16 cmH2O. Ventilatory mode: pressure-controlled ventilation After a recruitment a maneuver, PEEP will be chosen according to a PEEP titration maneuver monitored with electrical impedance tomography Plateau pressure may exceed 30 cmH2O and VT may exceed 6 mL/Kg if DP < 16 cmH2O pH should be maintained between 7.15-7.40 Oxygenation (SpO2) target ranges 90 -95% Maximum respiratory rate = 50 bpm
11040219|NCT04497441||Netizens|Internet users in Al Qassim province region are the target study population for this study. This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms.
11040220|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to S1|Adaptation to Altered Sensory Feedback + cTBS to S1
11040221|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to A1|Adaptation to Altered Sensory Feedback + cTBS to A1
11040222|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + cTBS to M1|Adaptation to Altered Sensory Feedback + cTBS to M1
11040223|NCT04497428|Experimental|Adaptation to Altered Sensory Feedback + Sham cTBS|Adaptation to Altered Sensory Feedback + Sham cTBS
11040224|NCT04497415|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
11040225|NCT04497415|No Intervention|Assessment only|Control
11040226|NCT04497402||female COVID19 patients|
11040227|NCT04497402||male COVID19 patients|
11040228|NCT04497402||female matched COVID19-free patients|
11040229|NCT04497402||male matched COVID19-free patients|
11040230|NCT04497389|Experimental|Intervention|10ml intravenous hAF QD for 5 consecutive days
11040231|NCT04497389|No Intervention|Standard of Care|10 mL normal saline QD for 5 days
11040232|NCT04497376|Experimental|Upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo ethanol infusion in the vein of Marshall (EI-VOM) followed by the '2C3L' ablation step which includes bilateral circumferential PV antral ablation and linear ablations across the left atrial roof, mitral isthmus (MI), and cavo-tricuspid isthmus (CTI).
11040233|NCT04497376|Active Comparator|Pulmonary vein antral isolation (PVI)|Patients randomized to PVI arm will undergo right PV antrum ablation, followed by the left PVA ablation. Radio frequency should be applied 1 cm proximal to the PV ostia in a wide-area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished.
11040234|NCT04497363|Experimental|Focused Ultrasound|On the day of the ultrasound appointment, patients will undergo ten minutes of ultrasound targeting the anterior cingulate. The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
11040235|NCT04497350|Experimental|Transcranial Magnetic Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
11040236|NCT04497350|Experimental|Theta Burst Stimulation|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest.
11040237|NCT04497324|Experimental|Experimental group|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
11040238|NCT04497324|No Intervention|Control group|Standard of care
11040239|NCT04497311||SARS-CoV-2|Patients with a SARS-CoV-2 polymerase chain reaction positive test upon admission to the emergency department.
11040240|NCT04497311||H1N1 influenza|Patients with an influenza H1N1 polymerase chain reaction positive test upon admission to the emergency department.
11040241|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083) - Low dose|Volunteers will receive two administrations of the low dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28
11040277|NCT04497077|Experimental|single placebo capsule|single placebo capsule
11040278|NCT04497077|Experimental|single placebo juice|single placebo juice
11040242|NCT04497298|Experimental|COVID-19 vaccine candidate (TMV-083) - High dose|Volunteers will receive two administrations of the high dose COVID-19 vaccine candidate by intramuscular (i.m.) injection on day 0 and 28.
11040243|NCT04497298|Experimental|One COVID-19 vaccine candidate (TMV-083) - High and placebo|Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
11040244|NCT04497298|Placebo Comparator|Placebo|Volunteers will receive physiological saline solution (0.9% NaCl), administered by intra muscular (i.m.) injection
11040245|NCT04497272|Other|The metabolomic signature of COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
11040246|NCT04497259|Experimental|Interventional|Patients in the teleconsultation arm will benefit from a tele-evaluation (a questionnaire filled through a chatbot link) and teleconsultation (skype-like connection) at 6 and 9 months after surgery.
11040247|NCT04497259|Experimental|Control|Patients in the consultation arm will benefit from a tele-evaluation (a questionnaire filled at home after the file was sent by secured mail) and a classical face to face consultation at 6 and 9 months after surgery.
11040248|NCT04497246||Elderly patients|Elderly patients (over 65 years old) hospitalized for COVID-19 within the CHU Brugmann Hospital
11040249|NCT04497246||Health Care professionals|Health Care professionals working within the CHU Brugmann Hospital
11040250|NCT04497233||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
11040251|NCT04497220|Placebo Comparator|Nocebo Group|Participants in this group will receive the control treatment
11040252|NCT04497220|Experimental|Positive Connotation Group|Participants in this group will receive the experimental treatment.
11040253|NCT04497207||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:
~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
11040254|NCT04497207||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
11040255|NCT04497207||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
11040256|NCT04497181|Experimental|Experimental group|
11040257|NCT04497181|Sham Comparator|Control group|
11040258|NCT04497168|Experimental|Citalopram|20mg daily
11040259|NCT04497168|Placebo Comparator|Placebo|matching placebo pills
11040260|NCT04497155||Prehospital norepinephrine|Trauma patients that received norepinephrine in the prehospital setting.
11040261|NCT04497155||Prehospital no norepinephrine|Trauma patients that did not receive norepinephrine in the prehospital setting.
11040262|NCT04497142|Experimental|Perampanel|"Participants will take a predetermined first dose of perampanel on the day before their tumor surgery
~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).
~After surgery participants will take perampanel at a predetermined dose once a day for as long as they do not have serious side effects and their disease does not get worse, up to a maximum of 12 months. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone."
11040263|NCT04497142|Active Comparator|Standard of Care|"Participants will receive standard of care medication before surgery.
~During surgery, an approximately 4x6cm recording grid will be placed on the surface of the brain over the tumor, and brain activity around the tumor will be recorded for 10 minutes during surgery (Electrocorticography).
~After surgery participants will take standard of care medications as predetermined by their doctor. Participants will be provided a drug and seizure diary to document drug and seizure information and have monthly study visits either in clinic or by phone.
~Participants will be followed up to 12 months after completing surgery."
11040264|NCT04497129|Experimental|ROMTech PortableConnect|Rehabilitation Using the ROMTech PortableConnect Device
11040265|NCT04497129|Active Comparator|Traditional Rehabilitation & Continuous Passive Motion Device|Combination of OPPT and HHPT in conjunction with CPM device usage
11040266|NCT04497116|Experimental|RP-3500|"Phase 1:
~Multiple doses of RP-3500 for oral administration alone or in combination with a talazoparib"
11040267|NCT04497116|Experimental|Expansion cohorts with RP-3500|"Phase 2:
~Expansion cohorts with RP-3500"
11040268|NCT04497103|Active Comparator|control|The traditional rehabilitation program conducted for 40-min sessions, three times per week for 8 weeks for all children.
11040269|NCT04497103|Experimental|task oriented training|Task-oriented training TOT group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
11040270|NCT04497103|Experimental|Xbox kinect|Xbox training group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
11040271|NCT04497090|Active Comparator|Fixed-EPAP|EPAP was kept fixed at the prescribed level throughout the night
11040272|NCT04497090|Experimental|Auto-EPAP|EPAP was continuously adjusted using the experimental approach aimed at abolishing tidal expiratory flow limitation
11040273|NCT04497077|Experimental|single dose tart cherry capsule|single dose tart cherry capsule
11040274|NCT04497077|Experimental|double dose tart cherry capsule|double dose tart cherry capsule
11040275|NCT04497077|Experimental|single dose tart cherry juice|single dose tart cherry juice
11040280|NCT04497064||non-athletes|those who did not identify as participating in athletic competitions at DI, intramural, club or competitive levels
11040281|NCT04497051||Embolized patients|subjects receiving preoperative embolization for aggressive spinal debulking surgery
11040282|NCT04497038|Experimental|Cabozantinib|Cabozantinib 20-60 mg by mouth once daily.
11040283|NCT04497025|Experimental|Non-immersive virtual reality-based vestibular training.|"Subjects in this group will receive a total of 24 sessions of 45 minutes (3 sessions per week, 8 weeks). A specific vestibular training software named Looking for the treasure will be used for vestibular rehabilitation. This software has been developed by the Polytechnics University of Valencia (UPV). This game will be display on a television screen and will be connected with a Microsoft Kinect system. The adjustment of the content will be to reach objects in the scenario. A physical therapy with at least two years of expertise in vestibular rehabilitation will adjust the content and difficulty level of this software/game to each subject. The parameters setting difficulty levels are: time interval between trials, time duration displaying objects, number of trials, velocity and range of motion. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain)."
11040284|NCT04497025|Experimental|Immersive virtual reality-based vestibular training.|"Subjects in this group will receive the same intervention than Arm 1 but they will wear a 3D head mounted display (Oculus Quest glasses) and will receive real-time gaming feedback in terms of visual and audio output while using the training system.
~Same location, tailoring parameters and physical therapist supervision than Arm 1."
11040285|NCT04497025|Active Comparator|Conventional vestibular training.|"Subjects in the control group will receive a total of 24 sessions of 45 minutes (3 sessions per week, 8 weeks). They will receive traditional Cawthorne-Cooksey vestibular rehabilitation exercises which can be categorized into a series of 7 movements: eyeball movements, head movements, waist rotation movements, stooping down movements, shoulder rotation movements, body rotation movements with eyes closed and the ball throwing test.
~A physical therapy with at least two years of expertise in vestibular rehabilitation will adjust the difficulty level. The parameters setting difficulty levels are: time interval between trials, number of trials, velocity and range of motion. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain)."
11040286|NCT04497012|Active Comparator|Low Iron Sulfate Supplementation|Participants will be given 2 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
11040287|NCT04497012|Active Comparator|High Iron Sulfate Supplementation|Participants will be given 6 mg/kg/day total of elemental iron once a day when they are consuming 150-160 ml/kg/day of enteral feeds and are at least 14 days old. The total iron doses will be provided by fortification of feeds and liquid iron sulfate and will be weight adjusted once a week. The participants will receive the study iron dose until 36 week corrected gestational age or discharge, whichever comes first.
11040288|NCT04496999|Experimental|Midostaurin with HDM201 dose escalation.|Midostaurin 50mg bid d1-28 (morning, evening) and HDM201
11040289|NCT04496986||Cardiovascular Surgical Patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
11040290|NCT04496960|Placebo Comparator|Placebo group|Receiving placebo
11040291|NCT04496960|Experimental|Subjects with SS|Receiving tofacidinib
11040292|NCT04496947|Experimental|Stress Reduction|8 week stress reduction course
11040293|NCT04496947|No Intervention|Control|No intervention
11040294|NCT04496934|Experimental|Intervention|Exercise intervention
11040295|NCT04496934|Active Comparator|Control|The control group is a waiting list group. The participants will receive exercise intervention after twelve weeks of treatment as usual.
11040296|NCT04496921|Active Comparator|Vitamin K supplement, dose #1|Vitamin K supplementation with dose #1
11040297|NCT04496921|Active Comparator|Vitamin K supplement, dose #2|Vitamin K supplementation with dose #2
11040298|NCT04496908|Active Comparator|Early Amniotomy|Women in the Early AROM group will under amniotomy one hour from Foley Catheter expulsion. Labor augmentation will continue per study protocol. Refer to Appendix A for protocol regimen.
11040299|NCT04496908|Active Comparator|Delayed Amniotomy|Women in the Delayed AROM group will undergo amniotomy at the discretion of the obstetrician or labor provider. No specific instructions will be given.
11040300|NCT04496895|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
11040301|NCT04496895|Experimental|orange peel fermentation|consume 1 sachet per day for 2 months
11040302|NCT04496882|Experimental|Switching therapy cohort|single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks
11040303|NCT04496882|No Intervention|Historical continuing therapy cohort|By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)
11040304|NCT04496856|Experimental|Collagen|Participants of this arm are going to consume 30 g of collagen peptides daily for 30 days
11040305|NCT04496856|Experimental|Whey Protein|Participants of this arm are going to consume 30 g of whey protein daily for 30 days
11040306|NCT04496843||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings HWA09 Device and overnight PSG
11040307|NCT04496830|Experimental|Relapsing Remitting Multiple Sclerosis|"Blood sample collection
~Vital signs, weight, height and BMI.
~Complete neurological examination documented in NeurEx (recorded with an iPAD).
~Clinical data questionnaire
~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).
~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).
~Optical Coherence Tomography (OCT)
~CSF Analysis"
11040308|NCT04496830|Experimental|Progressive Multiple Sclerosis|"Blood sample collection
~Vital signs, weight, height and BMI.
~Complete neurological examination documented in NeurEx (recorded with an iPAD).
~Clinical data questionnaire
~25FW & non-dominant hand 9HPT (required for calculating CombiWISE & MS-DSS).
~Smartphone Apps (include 25FW, SDMT and tests that correlate highly w 9HPT - can be acquired in patient-autonomous manner with minimal assistance).
~Optical Coherence Tomography (OCT)
~CSF Analysis"
11040309|NCT04496830|Experimental|Non-Inflammatory Neurological Diseases|"Clinical data questionnaire
~CSF Analysis"
11057345|NCT04376567|Active Comparator|Two Stage BBAVF|comparison
11040310|NCT04496830|Experimental|Other Non-Inflammatory Neurological Diseases|"Clinical data questionnaire
~CSF Analysis"
11040311|NCT04496817|Experimental|Enriched Egg Group|Participants will consume 2 medium sized docosahexaenoic acid and lutein enriched eggs daily (at least 5 days per week) for 6 weeks.
11040312|NCT04496817|Placebo Comparator|Regular Egg Group|Participants will consume 2 medium sized non-enriched eggs daily (at least 5 days per week) for 6 weeks.
11040313|NCT04496804|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|The current behavioral intervention consists of two primary components; an Internet website and one-on-one video chats with a behavioral coach. The Internet website involves content delivered through interactive video courses. The interactive video courses are based on elements of social cognitive theory. Each courses consists of an introduction, the primary content, and a take home message. The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic. A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention, discussion of website material, supportive accountability, and reporting of adverse events/injuries. The chats are conducted face-to-face through Skype. The chats occur 7 times during the first 2 months, 4 times during the second 2 months, and twice during the final 2 months of the intervention.
11040314|NCT04496804|Sham Comparator|Wellness for MS (WellMS)|Provides an Internet website and one-on-one video chats that discuss materials about self-managing multiple sclerosis (MS) consequences and health indicators through methods other than physical activity. The materials are transformations of brochures provided by the National MS Society, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will not involve tracking steps and a pedometer with not be provided.
11040315|NCT04496791|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing instrument (HI) with modified precalculation.
11040316|NCT04496791|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent RIC device from Phonak which will be fitted to the participants individual hearing loss.
11040317|NCT04496778|Active Comparator|low level laser plus exercise|acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
11040318|NCT04496778|Placebo Comparator|sham laser plus exercise|placebo acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
11040319|NCT04496765||< 40 years|Patients with rectal cancer ageing 40 years or less
11040320|NCT04496765||> 40 years|Patients with rectal cancer ageing more than 40 years
11040321|NCT04496739|Active Comparator|Group I (educational materials)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website.
11040322|NCT04496739|Experimental|Group II (educational materials, decision support, interview)|Patients receive standard educational materials about breast cancer risk and chemoprevention in RealRisks via the patient portal or website. Patients receive patient-centered decision support within the patient portal via an action plan summarizing their breast cancer risk profile, their risks and benefits of SERMs and AIs, and personal preferences for chemoprevention. Health care providers receive decision support and action plans based on their patients' interactions with RealRisks via the BNAV provider-centered support tool within the EHR. A sample of patients participate in an audio-recorded interview via telephone or video conference over 45-60 minutes at 12 months after registration. A sample of health care providers participate in 3 audio-recorded interviews via telephone or video conference over 45-60 minutes each at baseline, within 12-36 months after study activation, and within 12 months after study closure to accrual.
11040323|NCT04496726|Experimental|Cranberry and Quillaja|one 450mg cranberry capsule and one 50mg quillaja capsule in the morning and evening for 14 days.
11040324|NCT04496713|No Intervention|Telemedicine - Phone|Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
11040325|NCT04496713|Experimental|Telemedicine - Audio/Video|Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
11040326|NCT04496700|Experimental|Group 1 - Shooting test|All participants in this group were tested for shooting abilities before and after blood donation. No variation within the group.
11040327|NCT04496700|Experimental|Group 2 - VO2max|"All participants in this group were tested for physical abilities before and after blood donation. Method: Bruce protocol.
~No variation of protocol within the group."
11040328|NCT04496700|Experimental|Group 3 - Feasability|"All participants in this group were tested for feasability before and after blood donation. Method: Hiking uphill with 20 kg backpack.
~No variation of method within the group."
11040329|NCT04496674|Experimental|Treatment with bispecific Ab CC-1|administration of bispecific PSAMxCD3 Ab CC-1.
11040330|NCT04496661|Experimental|tDCS over M1 and PES|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
11040331|NCT04496661|Experimental|tDCS over DLPFC and PES|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area . Duration: 30 minutes.
11040332|NCT04496661|Sham Comparator|Sham tDCS and PES|Sham tDCS and PES stimulation. Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and PES (20Hz and 330ms) placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. The currents will be turned off automatically after 30 seconds. Duration: 30 minutes.
11040333|NCT04496648|Active Comparator|Percutaneous Coronary Intervention|Conventional PCI and optimal medical therapy
11040334|NCT04496648|Placebo Comparator|Sham-percutaneous coronary intervention|Sham-PCI and optimal medical therapy
11040335|NCT04496635|No Intervention|Baseline phase|Patients included in the VINCat program, and operated on colorectal surgery between 2007 and 2015 in Catalonia
11040336|NCT04496635|Experimental|Implementation phase|Patients included in the VINCat program, and operated on colorectal surgery between 2016 and 2018 in Catalonia
11040337|NCT04496622|Experimental|Whole Body Vibration Technique|WBV training with the frequency of 16-25 Hz along with conventional treatment.
11040338|NCT04496622|Active Comparator|WBV Technique|WBV training with the frequency of 26-35 Hz along with conventional treatment.
11040339|NCT04496609|Experimental|Stimulation-automated rehabilitation/automated rehabilitation|"Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days
~Washout 30 days
~Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
11040340|NCT04496609|Experimental|Automated rehabilitation/Stimulation-automated rehabilitation|"Automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days
~Washout 30 days
~Stimulation and automated rehabilitation (2 sessions of 45 minutes per day) for 40 working days"
11040341|NCT04496596|Experimental|Suramin|
11040342|NCT04496596|Placebo Comparator|Placebo|
11040343|NCT04496583|Active Comparator|Fluid Balance Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a predetermined negative balance
11040344|NCT04496583|Experimental|Preload Responsiveness Depletive Strategy Group|Patients with fluid overload under a depletive strategy to attain a state of preload responsiveness
11040345|NCT04496570|Active Comparator|Periodontitis patients|gingival crevicular fluid and saliva collection were taken before and after nonsurgical periodontal treatment
11040346|NCT04496570|No Intervention|Healthy individuals|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
11040347|NCT04496557|Experimental|Patients diagnosed with PTSD|7-15 men and women with PTSD will be recruited from the community and from local clinical programs through a multi-modal outreach program.
11040348|NCT04496544||Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with drug-coated devices (drug-eluting stent ± drug-coated balloon, bare metal stent with drug-coated balloon, or drug-coated balloon alone)
11040349|NCT04496544||Non-Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with non-drug-coated devices (bare metal stent ± percutaneous transluminal balloon angioplasty or percutaneous transluminal balloon angioplasty alone)
11040350|NCT04496531|Experimental|Active|Active group members use a device providing perceivable electrical stimulation
11040351|NCT04496531|Sham Comparator|Sham|Group members use a device providing a non-perceivable stimulus
11040352|NCT04496518||Patients with ICD/CRT device with iATP programmed on|Patients implanted with an iATP-capable device with iATP on in at least one device detection zone will be enrolled in the iATP PAS. Patients must also be enrolled in the CareLink network for remote monitoring. All patients must have provided signed informed consent.
11040353|NCT04496505|Sham Comparator|Control Arm|Participants will use a sham SANA device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
11040354|NCT04496505|Experimental|Treatment Arm|Participants will use a SANA device twice per day for 16 minutes per day for 8 weeks. They will be assessed for symptoms of depression at baseline, along with symptoms every two weeks thereafter until the 8 week mark. Participants will also be assessed for anxiety, irritability, future orientation, quality of life, and rumination.
11040355|NCT04496492|Experimental|Tocotrienol|Subjects receiveTocotrienol 200 mg/twice daily before surgery
11040356|NCT04496479|Experimental|LYG-LIV0001|Open-Label allogeneic hepatocytes suspended in a cell preservation buffer solution with dose escalation based upon the number of target lymph nodes. Patients will also receive tacrolimus 1 mg capsules to follow the prescribed doses by their physicians.
11040357|NCT04496479|Experimental|Blinded-LYG-LIV0001|Selected allogeneic hepatocytes suspended in a cell preservation buffer solution with targeted number of lymph nodes for blinded phase. Blinded encapsulated tacrolimus 1 mg capsules to follow the prescribed doses by their physicians.
11040358|NCT04496479|Placebo Comparator|Placebo|Cell preservation buffer solution. Matching placebo for encapsulated tacrolimus 1 mg capsules to follow the prescribed doses by their physicians.
11040359|NCT04496453|Experimental|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
11040360|NCT04496440||Trial Group|Contracture correction therapy
11040361|NCT04496440||Control Group|No new intervention, patients continued with the previous treatment.
11040362|NCT04496401|Experimental|Tacrolimus then Envarsus|Tacrolimus will be started on the day of surgery. After a stable trough level is achieved (on postoperative day 7-10) the first PK profile will be measured. Subsequently, the switch to ENVARSUS® will be performed
11040363|NCT04496388|Experimental|Aerobic exercise|Aerobic exercise is lasting for nearly 50 minutes each time, including warm-up and stretching for 10 minutes after exercise.
11040364|NCT04496388|Experimental|Aerobic exercise combined with resistance exercise|Aerobic exercise is lasting for nearly 20 minutes each time, and add resistance exercise for 20 minutes. Additional warm-up 10 minutes and stretching for 5 minutes.
11040365|NCT04496388|Experimental|Aerobic exercise combined with interval training|Aerobic exercise is lasting for nearly 20 minutes each time, and add moderal intensity interval training for 10 minutes. Additional warm-up 10 minutes and stretching for 15 minutes.
11040366|NCT04496388|Placebo Comparator|Placebo|No exercise intervention.
11040367|NCT04496375||Institut Paoli Calmettes Outpatients|Patients with a solid tumor or an hematologic malignancy who will attend an appointement at IPC Outpatients clinic
11040368|NCT04496362|Experimental|subcutaneous heparin anticoagulation|Experimental arm
11040369|NCT04496362|No Intervention|systemic intravenous anticoagulation|SOC arm
11040370|NCT04496349|Experimental|APG115 100mg|APG115 100mg QD x 5 days
11040371|NCT04496349|Experimental|APG115 200mg|APG115 200mg QD x 5 days
11040372|NCT04496349|Experimental|APG115 150mg|APG115 150mg QD x 5 days
11040373|NCT04496349|Experimental|APG115 250mg|APG115 250mg QD x 5 days
11040374|NCT04496323||LOW|Golf Skill level high, handicap below 11.5
11040375|NCT04496323||HIGH|Golf Skill level low, handicap 18.5 - 26.4
11040376|NCT04496310|Experimental|Telemedicine|"Baseline: in office clinical assessment of all patients (collection of seizure diary).
~Followup: scheduled 6-month consultations through a telemedicine device providing remote outcome assessment, counselling and follow-up. If required, on call video consultations available by contacting a provider through telemedicine, 3-hr/week."
11040377|NCT04496310|No Intervention|Usual care|"Baseline: in office clinical assessment of all patients (collection of seizure diary).
~Followup: scheduled 6-month in-office consultations with outcome assessment, counselling and follow-up. On-call consultations are possible if needed by the patient, by contacting a clinician through an in-office phone call, 3-hr/week."
11040378|NCT04496284|Experimental|Vitrification via slush nitrogen|Blastocyst stage embryos will be vitrified via slush nitrogen
11040379|NCT04496284|No Intervention|Vitrification via liquid nitrogen|Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.
11040380|NCT04496271|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing aid with modified precalculation.
11040381|NCT04496271|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent Receiver In Canal hearing aid by Phonak which will be fitted to the participants individual hearing loss.
11040382|NCT04496258|Experimental|Positive VR Scene|Participants will explore a virtual reality (VR) environment of a beach scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
11040383|NCT04496258|Experimental|Neutral VR Scene|Participants will explore a virtual reality (VR) environment of a neutral office scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
11040384|NCT04496245|Active Comparator|Wait-list control|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
11040385|NCT04496245|Experimental|Initial treatment wtih OM85|One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
11040386|NCT04496232|No Intervention|Normal SDF|Using routine semen processing method
11040387|NCT04496232|Active Comparator|Physiological ICSI (PICSI)|Sperm selection using PICSI dishes for selecting sperm with lower DNA fragmentation index for ICSI
11040388|NCT04496232|Active Comparator|Second ejaculate|Using the second ejaculate as a way of reducing SDF in the semen sample used for ICSI
11040389|NCT04496219|Experimental|Arm I (acupuncture, BCG)|Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management.
11040390|NCT04496219|Active Comparator|Arm II (BCG, standard of care)|Patients receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management. Patients may undergo acupuncture therapy after completion of intravesical BCG therapy.
11040391|NCT04496193|Experimental|Group lower dose ropivacaine with dexamethasone|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + dexamethasone 0.8 ml (4mg) at the end of surgery
11040392|NCT04496193|Active Comparator|Group higher dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.5% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
11040393|NCT04496193|Placebo Comparator|Group lower dose ropivacaine with N/S|Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery
11040394|NCT04496180|Experimental|PREVENA (CiPNT)|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply all parts just after the surgical procedure.
~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.
~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.
~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.
~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
11040395|NCT04496180|Active Comparator|Simple dressing|Simple dressing; standard, waterproof dressing applied to wound
11040396|NCT04496167|Experimental|EN3835|EN3835 up to 1.74mg.
11040397|NCT04496167|Placebo Comparator|Placebo|Placebo
11040398|NCT04496154|Experimental|Omega-3 fatty acids|3 oral softgels (600 mg EPA and 300 mg DHA / softgel), Triple Strength Omega-3 from Webber Naturals
11040399|NCT04496141||With COVID-19 infection|Subjects with a positive SARS-CoV-2 PCR
11040400|NCT04496141||Without COVID-19 infection|Subjects with COVID-19 negative serum
11040401|NCT04496115|Experimental|Mindfulness Intervention|Mindfulness training
11040402|NCT04496115|No Intervention|Control|Standard of Care
11040403|NCT04496102|Active Comparator|Cemented TKA|Cemented TKA (Triathlon, Stryker) include patellar resurfacing
11040404|NCT04496102|Experimental|Cementless TKA|Cementless TKA (Triathlon Tritanium, Stryker) include patellar resurfacing
11040405|NCT04496089|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
11040406|NCT04496063|Experimental|Group 1 Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
11040407|NCT04496063|Placebo Comparator|Group 2 Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
11040408|NCT04496050||one|there is only one patient group. This group of patients, given the same dose and at the same time, is examined by ultrasonography to determine the thickness of the pyloric muscle.
11040409|NCT04496037||Standard of care (SOC)|See NCT03994783
11040410|NCT04496037||Rituximab + SOC (SOCR)|See NCT03994783
11040411|NCT04496011|Experimental|Experimental Group|In this group the exercise program will be based on the protocol of Control Group, without the exception of walking training, adding aerobic capacity training using the bicycle ergometer, model CBL11 Classic® from ACT®.
11040412|NCT04496011|No Intervention|Group Control|"In this group the exercise program is based on the standard physiotherapy protocol that is part of the care routines performed at the bone marrow transplant service.
~It includes essential components of a rehabilitation program: range of motion, balance training, gait and strength of the upper and lower limbs"
11040414|NCT04495985||Thyrogen (rh-TSH)|Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
11040415|NCT04495985||Withdrawal from thyroid hormone|Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
11040416|NCT04495972|Active Comparator|Experimental arm: Intestinimonas|Intestinimonas in capsules
11040417|NCT04495972|Placebo Comparator|Placebo arm: Placebo|Placebo in capsules
11040418|NCT04495959||F18-DCFPyL PET/MRI DWB scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
11040419|NCT04495946|Experimental|Sepsis Transition and Recovery (STAR) Program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
11040420|NCT04495946|Active Comparator|Usual Care|Standard of care received through Atrium Health facilities for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
11040421|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|SARS-CoV-2 Sclamp antigen 5 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart.(Cohorts 1 & 4)
11040422|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|SARS-CoV-2 Sclamp antigen 15 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 2 & 5)
11040423|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|SARS-CoV-2 Sclamp antigen 45 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 3 & 6)
11040424|NCT04495920|Experimental|Test product|
11040425|NCT04495907||Group I|Group I- Asymptomatic patients with SARS-CoV-2 Infection
11040426|NCT04495907||Group II|Group II-Symptomatic patients with SARS-CoV-2 Infection
11040427|NCT04495894|Experimental|Preoperative Ketorolac|Participants randomized to receive ketorolac prior to surgery for stage I/II NSCLC and stage III RCC. Participants will receive standard-of-care surgery. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered.
11040428|NCT04495894|No Intervention|Control Group|Participants randomized to the control group receiving the standard of care during surgery for stage I/II NSCLC and stage III RCC. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered. The concurrent control group is to obtain untreated biologic samples for biologic correlative studies and secondary endpoints.
11040429|NCT04495881|Experimental|sitagliptin|sitagliptin 100mg
11040430|NCT04495868|Experimental|Bacteriostatic Normal Saline then 1% Lidocaine|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of bacteriostatic normal saline followed by an intradermal administration of 1% lidocaine.
11040431|NCT04495868|Active Comparator|1% Lidocaine then Bacteriostatic Normal Saline|Participants undergoing a lumbar medial branch block who are randomized to receive an intradermal administration of 1% lidocaine followed by an intradermal administration of bacteriostatic normal saline.
11040432|NCT04495855||Visanne treatment|Patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis, who have been prescribed Visanne
11040433|NCT04495842|Experimental|Intervention|Participants receive an active essential oil blend to inhale for 15 minutes. The blend contains plant based oils sourced from flowers and citrus plants.
11040434|NCT04495842|Placebo Comparator|Control|Participants receive an inert comparison to inhale for 15 minutes.
11040435|NCT04495829||Phorcides|Both eyes of subjects eligible for Contoura(R) topography-guided ablation with the Wavelight excimer laser, with surgery planned using Phorcides software.
11040436|NCT04495816|Active Comparator|Omega-3|1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
11040437|NCT04495816|Sham Comparator|Placebo/Control|2 softgels per day for 6 weeks
11040438|NCT04495803|Experimental|Experimental|After an initial assessment to confirm eligibility, the experimental group will receive 8 weekly sessions (2 hours long) of our augmented group CBT for perinatal anxiety during a global pandemic (n=6 per group). Participants will be re-assessed at post-treatment and at a 3-month follow-up to determine the effectiveness of the treatment and whether these effects are maintained in the long-term.
11040439|NCT04495777||students|students were assessed in order to have a risk for TMD in order to their status of having parafunctional habits and neck pain
11040440|NCT04495751|Experimental|Muscadine Grape Extract Arm|Muscadine grape extract pill (12 week supply)
11040441|NCT04495751|Placebo Comparator|Placebo Arm|Placebo provided (12 week supply)
11040442|NCT04495738|Active Comparator|Control Feeding Group|Ready to feed milk-based product
11040443|NCT04495738|Experimental|Experimental Feeding Group|Ready to feed milk-based product with oligosaccharides
11040444|NCT04495738|Other|Human Milk (HM) Reference Group|HM from infant's own mother and as needed supplemental infant formula and toddler milk-based product
11040445|NCT04495725|Placebo Comparator|Voucher for a Discounted Placebo Product|Voucher for a Discounted Placebo Soft-Gel Capsule Product
11040446|NCT04495725|Experimental|Voucher for a Discounted High THC:Low CBD Product|Voucher for a Discounted 4.3mg THC/0.7mg CBD Soft-Gel Capsule Product
11040447|NCT04495725|Experimental|Voucher for a Discounted Equal THC:CBD Product|Voucher for a Discounted 2.5mg THC/2.5mg CBD Soft-Gel Capsule Product
11040448|NCT04495725|Experimental|Voucher for a Discounted Low THC:High CBD Product|Voucher for a Discounted 0.2mg THC/4.8mg CBD Soft-Gel Capsule Product
11040449|NCT04495712|Active Comparator|Spironolactone|Patients randomized to active therapy with spironolactone
11040450|NCT04495712|Placebo Comparator|placebo|patients randomized to placebo
11040451|NCT04495699||Observation|Patients who elect to have observation of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
11040452|NCT04495699||Stone treated|Patients who elect to have intervention of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
11040643|NCT04494334||Sarcoidosis,|Patients with sarcoidosis who will be having bronchoscopy as part of their clinical diagnostic work up
11040453|NCT04495686|Experimental|Caregiver PWD-ADRD TCCI|Participants in the Caregiver PWD-ADRD telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
11040454|NCT04495686|No Intervention|Caregiver for PWD-ADRD (BMT)|Participants in the Caregiver PWD-ADRD best medical treatment (BMT) group will not receive care coordination.
11040455|NCT04495686|Experimental|Caregiver for PWD-TBI TCCI|Participants in the Caregiver PWD-TBI telehealth care coordination intervention (TCCI) group will complete a 12-month telehealth-delivered care coordination program with an assigned dementia care coordinator.
11040456|NCT04495686|No Intervention|Caregiver for PWD-TBI (BMT)|Participants in the Caregiver PWD-TBI best medical treatment (BMT) group will not receive care coordination.
11040457|NCT04495673|Experimental|tDCS with Cognitive Training|DLPFC stimulation with tDCS with simultaneous cognitive training
11040458|NCT04495673|Active Comparator|Sham tDCS with Cognitive Training|Sham tDCS with simultaneous cognitive training
11040459|NCT04495660|Experimental|Severe/profoundly deaf children 10-24 months old|The cohort 1 includes patients aged 10-24 months old about to be implanted
11040460|NCT04495660|Experimental|Severe/profoundly deaf children 3-7 years old|The cohort 2 includes 3-7 years old cochlear implanted patients (implanted before 24 months of age)
11040461|NCT04495660|Other|Normally hearing children 10-24 months old|The cohort 1 includes patients aged 10-24 months matched in age and sex with normally hearing children
11040462|NCT04495660|Other|Normally hearing children 3-7 years old|The cohort 2 includes 3-7 years old matched in sex and age with cochlear implanted patients
11040463|NCT04495647|Experimental|WB-EMS_frail|
11040464|NCT04495647|Active Comparator|WB-EMS_robust|
11040465|NCT04495647|Active Comparator|WB-EMS_young|
11040466|NCT04495634|Experimental|Head Trauma or Brain Bleed|Medically stable patients who have undergone conventional head CT imaging undergo imaging within 24 hours using the s-HCT system.
11040467|NCT04495621|Experimental|MEN1611|MEN1611 + Cetuximab
11040468|NCT04495608|Experimental|fluconazole|Fluconazole 50mg capsule (1, 2, 3 or 4 pills to take daily during 18 weeks, corresponding respectively to 50, 100, 150 or 200 mg of fluconazole).
11040469|NCT04495608|Placebo Comparator|placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
11040470|NCT04495582||Non-Interventional Study group|Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
11040471|NCT04495569|Experimental|Group/Cohort A|A single intramuscular injection of SYN023 at 0.3mg/kg
11040472|NCT04495569|Experimental|Group/Cohort B|A single intramuscular injection of SYN023 at 0.3mg/kg combined with the Chinese licensed Vero Cell Rabies Vaccine (following the PEP (Post-exposure Prophylaxis) recommendation)
11040473|NCT04495556||Typical|Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
11040474|NCT04495556||Atypical|Patients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS.
11040475|NCT04495543|Experimental|Brief-Skills for Safer Living (Brief-SfSL)|Participants with current suicidal ideation (Beck Suicide Scale >10) will undergo Brief-SfSLtherapy
11040476|NCT04495530||Patient|Patients will be considering commencing or discontinuing parenteral nutrition, or will be receiving home parenteral nutrition
11040477|NCT04495530||Carer|Carers will be those caring for a patient with advanced cancer who is considering commencing or discontinuing parenteral nutrition, or already receiving parenteral nutrition. Carers will also be recruited if they previously cared for a person with advanced cancer receiving parenteral nutrition in the last 12 months
11040478|NCT04495504|Experimental|Ropivacaine group|Administration of a bolus dose of ropivacaine, followed by a continuous infusion of ropivacaine during the first 48 hours postoperatively.
11040479|NCT04495491||Pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
11040480|NCT04495491||plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
11040481|NCT04495491||mixed mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
11040482|NCT04495478|Experimental|Ramucirumab - Intravenous (IV)|Ramucirumab administered IV.
11040483|NCT04495478|Placebo Comparator|Placebo - IV|Placebo administered IV.
11040484|NCT04495478|Experimental|Ramucirumab - Subcutaneous (SC)|Ramucirumab administered SC.
11040485|NCT04495478|Placebo Comparator|Placebo - SC|Placebo administered SC.
11040486|NCT04495465|Experimental|Experimental group: manual therapy + shock waves|Manual Therapy: 10 minute massage to neck muscles Shock waves: 2000 shots of extracorporeal radial shock waves therapy on neck muscles at 4bars and 10 Hertzs
11040487|NCT04495465|Placebo Comparator|Control group: manual therapy + placebo shock waves|Manual Therapy: 10 minute massage to neck muscles Placebo Shock waves: 3 minutes of placebo extracorporeal radial shock waves therapy on painful points neck muscles.
11040488|NCT04495452||Study Participants|"We will be enrolling 200 participants, this will provide a large enough sampling to assure there are at least 25 patients with significant respiratory depression and 25 with insignificant respiratory depression.
~The genetic data from participants with the most respiratory depression defined as having a 20-40% decrease from initial respiratory parameters will be compared with genetic data from participants with the least respiratory depression defined as having no change or less than 10% decrease from initial respiratory parameters."
11040489|NCT04495439|Other|Treatment with ISS Sleeve|The biocompatible, resorbable ISS sleeve is used for augmentation to enhance screw anchorage. It is melted into the trabecular bone structure of the osteoporotic vertebra using ultrasound. A standard pedicle screw is inserted into the sleeve.
11040490|NCT04495439|Other|Treatment with PMMA|The bone cement Polymethylmethacrylat (PMMA) that is injected into the osteoporotic vertebra.PMMA augmentation of pedicle screws is done using standard cannulated and perforated pedicle screws. The cancellous bone surrounding the screw is enhanced with PMMA bone cement to increase screw anchorage.
11040491|NCT04495426||Presence of symptomatic ataxic disease|Presence of symptomatic ataxic disease with definite molecular diagnosis of SCA10 or whose first-degree relative has a molecular diagnosis of SCA10.
11040492|NCT04495426||Premanifest for SCA10|Asymptomatic participants of either sex aged ≥18 with definite molecular diagnosis of SCA10 (Premanifest carriers)
11040493|NCT04495426||At risk for SCA10|Asymptomatic participants of either sex, aged ≥18 whose first-degree relative has a molecular diagnosis of SCA10 (50%-at-risk relatives*).
11040494|NCT04495426||Non-carrier for SCA10 (Control)|At risk participants who test negative for the SCA10 mutation will serve as non-carriers. Exclusion criteria described above also applies to non-carrier subjects. If the number of non-carriers were less than 10, we will recruit additional participants from normal population to supplement the controls.
11040495|NCT04495400||Percutaneous Screw Fixation|Patients who have had a Percutaneous Screw fixation procedure.
11040496|NCT04495400||Open Fixation|Patients who have had an Open Fixation procedure.
11040497|NCT04495387||patients with colon cancer|
11040498|NCT04495387||patients with breast cancer|
11040499|NCT04495374|Placebo Comparator|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
11040500|NCT04495374|Experimental|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
11040501|NCT04495361|Experimental|Online learning portal|Final year medical students will use an online learning portal in which three case scenarios of under five pneumonia patients will be displayed each month. Based on history and examination, the user will diagnose and manage the patient.
11040502|NCT04495348||Open-label arm|Participants are switched to doravirine and then switched back to INSTI-based therapy.
11040503|NCT04495335|Experimental|Test Group (TG)|The study included test group with Photobiomodulation treatment after dental implant surgery
11040504|NCT04495335|Active Comparator|Control Group (CG)|The control group consisted of laser application without energy delivery to the tissue.
11040505|NCT04495322|Experimental|10 mg TG-1000|Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.
11040506|NCT04495322|Experimental|20 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.
11040507|NCT04495322|Experimental|40 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
11040508|NCT04495322|Experimental|80 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
11040509|NCT04495322|Experimental|120 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
11040510|NCT04495322|Experimental|160 mg TG-1000 or Placebo|Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.
11040511|NCT04495322|Experimental|X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.
11040512|NCT04495322|Experimental|X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)|Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.
11040513|NCT04495309|No Intervention|Standard|Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)
11040514|NCT04495309|Experimental|Experimental|Standard of care (standard systemic therapy) + study intervention
11040515|NCT04495296|Experimental|TST001 Injection|TST001 Injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
11040516|NCT04495283|Experimental|PGB and APAP administered IV (Group A)|Group A receives the first infusion of PGB plus APAP IV prior to surgery. All subsequent Group A combination infusions should be timed from the first pre-surgical infusion.
11040517|NCT04495283|Experimental|APAP IV infusion (Group B)|Group B receives first infusion prior to surgery then receives the first infusion from the last suture. All subsequent Group B APAP infusions should be timed from the first post-surgical infusion.
11040518|NCT04495283|No Intervention|Placebo (Group C).|Saline Solution
11040519|NCT04495270||Clinical observation|All study patients were examined by 1 endodontist clinically and radiographically at baseline and after follow up of endodontic treatment.
11040520|NCT04495257|Experimental|Dose Level 1 (DL1)|DL1 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.1mg/kg for the induction phase. After 4 cycles, participants will be treated with 360mg of nivolumab and APX005M every 3 weeks.
11040521|NCT04495257|Experimental|Dose Level 2 (DL2)|DL2 will include ipilimumab at 1mg/kg and nivolumab at 3 mg/kg with APX005M of 0.3mg/kg for the induction phase. After 4 cycles we will treat with 360mg of nivolumab and APX005M every 3 weeks.
11040584|NCT04494763|Experimental|Propanolol|Dose: 1 to 8 mg/kg/day in 1 to 2 divided doses adjusted to achieve target reduction in resting heart rate by 25% from baseline Frequency: once to Twice daily Route of Administration: Oral Duration: 18 months
11040522|NCT04495244||Investigational Population|"Suspected Invasive Breast Cancer (any size) or DCIS (pre-invasive) are of particular interest. Women with abnormal screening mammograms (R3-5) recalled for further investigation.
~Inclusion criteria
~Women with suspected Invasive Breast Cancer (tumours of any size and/or DCIS).
~Individuals with an abnormal or suspicious screening mammogram recalled for further evaluation.
~Suspected Invasive Breast Cancer (tumours of any size and/or DCIS).
~Willing to give written Informed Consent and provide whole blood samples
~Age 30-75 years
~Exclusion criteria
~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
~Inoperable (T4 category) or inflammatory breast cancer
~Previous history of cancer previously at any site
~Previous history of breast cancer
~Concomitant or other concurrent anti-cancer therapy
~Male
~No histopathological diagnosis"
11040523|NCT04495244||Borderline (Atypica and LCIS) Population|"Women with borderline pathological B3 lesions (suspected atypia Ductal or Lobular and benign proliferative disease without DCIS or invasion) Inclusion criteria
~Abnormal screening mammogram with suspected benign breast disease or proliferative changes
~Willing to give Written Informed Consent and provide whole blood samples
~Aged 30-75 years
~Exclusion criteria
~Existing cancer diagnosis
~Male
~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
~Previous history of any cancer
~Previous history of breast cancer
~Concomitant or other concurrent anti-cancer therapy"
11040524|NCT04495244||Control Population|"Healthy Controls Inclusion criteria
~Normal breast examination - No cancer detected/suspected by physical exam, diagnostic radiology or screening mammography
~Willing to give Written Informed Consent and provide whole blood samples
~Aged 30-75 years
~Exclusion criteria
~Cancer diagnosis
~Male
~Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy)
~Previous history of any cancer
~Concomitant or other concurrent anti-cancer therapy"
11040525|NCT04495218||Patient with a diagnosis of incomplete form of albinism|
11040526|NCT04495205|Experimental|Non-eugenol containing periodontal packs with PRF|Non-eugenol containing periodontal packs with PRF after gingival de-pigmentation
11040527|NCT04495205|Placebo Comparator|Non-eugenol containing periodontal packs|Non-eugenol containing periodontal packs after gingival de-pigmentation
11040528|NCT04495192||Patients affected by severe Acquired Brain Injury|All patients admitted in the participant IRU with a history of sABI and fulfilling our inclusion and exclusion criteria will be recruited.
11040529|NCT04495179|Experimental|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of 80 participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
11040530|NCT04495179|Experimental|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of 80 participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
11040531|NCT04495166|Experimental|Motherly app with brief psychotherapy|Participants in this arm will receive intervention via Motherly 1.0, an app that delivers behavioral activation strategies and psychoeducational content to promote changes in sleep, nutrition, and physical activity habits. It has also functionalities that help participants to engage in prenatal care, breastfeeding, and social support, and to stimulate child development. In addition will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
11040532|NCT04495166|Active Comparator|Educational app (Active control)|Participants in this arm will have access to a psychoeducational app (active control) which delivers content about gestation, maternal health and mental health, and child development. In addition, they will undergo will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
11040533|NCT04495153|Other|Cohorts|"Cohort 1 - persistent but stable disease at least 18 weeks after starting ICI treatment
~Cohort 2 - radiographic progressive disease at least 18 weeks after starting ICI treatment
~Cohort 3 - refractory disease defined as progressed by imaging at least 9 weeks after starting ICI treatment"
11040534|NCT04495140|Experimental|Oral [14C]PF-06882961, 50 mg|In this arm, a single oral dose of [14C]PF-06882961, 50 mg will be administered as a liquid formulation.
11040535|NCT04495140|Experimental|Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug|In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961, 100 ug, will be administered via intravenous infusion.
11040536|NCT04495127|Experimental|Selumetinib|
11040537|NCT04495114|No Intervention|Control Arm|Modern fasting guidelines without the carbohydrate load preoperatively.
11040538|NCT04495114|Experimental|Intervention Arm|40g carbohydrate load preoperatively.
11040539|NCT04495101|Experimental|Prolastin 120 mg/kg + Standard Medical Treatment|Subjects will receive Prolastin, two intravenous infusion (IV) doses of 120 milligram per kilogram (mg/kg), based upon the subject's body weight, on Day 1 and Day 8. Subjects will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11040540|NCT04495101|Active Comparator|Standard Medical Treatment|Subjects will receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11040541|NCT04495088|Experimental|A (experimental arm)|The experimental arm A starts with 6 cycles of mFOLFOX or 4 cycles of XELOX. Surgery is scheduled four or six weeks after day 1 of the last mFOLFOX or XELOX cycle, respectively. No postoperative chemotherapy is planned
11040542|NCT04495088|Active Comparator|B (control arm)|In the standard arm B, patients undergo surgical resection of the primary tumor followed by stage- (risk-)adapted adjuvant chemotherapy 4-8 weeks after surgery according to recommendations of the S3 guidelines in analogy to colon cancer. Details of the recommended protocols are provided in the protocol.
11040543|NCT04495075|Experimental|Visuomotor Therapy|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. A target sine wave with a maximum amplitude of 30% MVIC and a minimum amplitude of 5% MVIC and a frequency of 0.128 Hz was visually presented to the patient.31 The patient was instructed to match their torque to the presented target throughout the duration of testing. Each visuomotor therapy trial was 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes.
11040585|NCT04494763|Placebo Comparator|Placebo|Placebo in a similar manner
11040644|NCT04494321|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
11040544|NCT04495075|Active Comparator|Passive Motion|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. The dynamometer then passively moved the patient from 80º to 120º of knee flexion for 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes. The patient was provided visual feedback of their knee position throughout the trials. The patient was instructed to relax their knee throughout the intervention.
11040545|NCT04495036||dermatology patients|
11040546|NCT04495036||physicians and medical staff|
11040547|NCT04495023||Group 1 (Kidney transplanted patients)|Group 1: Kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy All kidney transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
11040548|NCT04495023||Group 2 (Non-transplanted patients)|Group 2 : Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy Non-transplanted patients requiring oncologic or non-oncologic left elective colectomy between 01 January 2004 and 31 December 2015.
11040549|NCT04495010|Experimental|Neoadjuvant treatment + Adjuvant treatment|
11040550|NCT04495010|Experimental|Adjuvant treatment|
11040551|NCT04495010|Experimental|Neo treat with patho response-driven Adju treat or observation|Neoadjuvant treatment with pathologic response-driven Adjuvant treatment or observation
11040552|NCT04494997||Dentists|Practicing Dental Health Professionals who are either General Dentists &/or Specialists Dentists are part of the Cohort. They should have held or currently hold Social Media account for their Professional purpose. They should have used or currently using their Social Media account for Professional purpose. The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media &/Or email to seek responses. The link will be available for single response for a single respondent.
11040553|NCT04494984|Active Comparator|Active|Subjects will receive a 1st intravenous dose of 4 mg/kg INM005 (Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM005. Each dose will be separated by 48 h (± 2 h).
11040554|NCT04494984|Placebo Comparator|Placebo|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 48 h (± 2 h).
11040555|NCT04494958|Experimental|Palbociclib + Binimetinib|
11040556|NCT04494945|Other|Screening (genetic testing)|Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
11040557|NCT04494932|Experimental|Biceps Tenodesis|
11040558|NCT04494932|Active Comparator|SLAP Repair (Control)|
11040559|NCT04494919||Ultrafine Endoscope Assisted|The self-expanding metal stent (SEMS) implantation was conducted using an ultrafine endoscope (UFE) (GIF-XP260NS; Olympus, Tokyo, Japan). The UFE researched the stricture, and a guidewire was inserted into the endoscopic working channel. The guidewire was left. And the endoscope was withdrawn. The normal colonoscope was exchanged under the reverse guidance of the guidewire. Finally, a metal, uncovered SEMS was placed along the guidewire.
11040560|NCT04494906|Experimental|Interactive stepping exercise group|Participants will execute interactive stepping exercise 2 times per week for 8 weeks (16 sessions).
11040561|NCT04494906|Active Comparator|Square stepping exercise group|Participants will execute square stepping exercise 2 times per week for 8 weeks (16 sessions).
11040562|NCT04494893||Cohort 1|Exposed to coronavirus disease
11040563|NCT04494893||Cohort 2|Active coronavirus disease
11040564|NCT04494893||Cohort 3|Recovered from coronavirus disease
11040565|NCT04494880|Experimental|Treatment Group (Marcaine 1 Breast)|Marcaine will be injected into one randomized breast and saline into the other in the treatment group.
11040566|NCT04494880|No Intervention|Control Group (Marcaine 2 Breasts)|Marcaine will be injected into both breasts as is currently the standard of care.
11040567|NCT04494867|Experimental|Core warming|Patients receive the Attune Medical Esophageal Heat Transfer Device (EnsoETM) and undergo core warming
11040568|NCT04494867|Active Comparator|Standard of Care|Patients receive standard temperature management and treatment
11040569|NCT04494841|Experimental|DuoTherm VibraCool Back Device|Patients will be offered a pain relief belt device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate. They will be able to choose from 8 patterns of vibration with the multiple motors (50, 100, 200Hz), and hot or cold, and will wear the device for 20 minutes.
11040570|NCT04494828|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/ kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
11040571|NCT04494828|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
11040572|NCT04494815|Experimental|Treatment A+Treatment B+Treatment C|"Treatment A: Single 20 mg oral suspension dose of SR419 + single active control placebo capsule.
~Treatment B: Single SR419 placebo oral suspension + single 300 mg oral capsule of active control.
~Treatment C: Single SR419 placebo oral suspension + single active control placebo capsule."
11040573|NCT04494815|Experimental|Treatment A+Treatment C+Treatment B|
11040574|NCT04494815|Experimental|Treatment B+Treatment A+Treatment C|
11040575|NCT04494815|Experimental|Treatment B+Treatment C+Treatment A|
11040576|NCT04494815|Experimental|Treatment C+Treatment A+Treatment B|
11040577|NCT04494815|Experimental|Treatment C+Treatment B+Treatment A|
11040578|NCT04494802|Placebo Comparator|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
11040579|NCT04494802|Experimental|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
11040580|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 24hrs|Receive 50mcg doses of fludrocortisone every 24hrs
11040581|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 12hrs|Receive 50mcg doses of fludrocortisone every 12hrs
11040582|NCT04494789|Active Comparator|Fludrocortisone dosing regime: 6hrs|Receive 50mcg doses of fludrocortisone every 6hrs
11040583|NCT04494789|Placebo Comparator|Control Arm|Receives standard treatment without fludrocortisone dosing regime
11040617|NCT04494503|Experimental|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 400mg, 600mg, 800mg dose levels respectively, every 28 days as a cycle.
11040586|NCT04494737|Active Comparator|Active Comparator: Program 1|Mindfulness Training program is based on mindfulness based stress reduction developed by Kabat-Zinn, but the didactic content is focused on attention training and meta-awareness. Participants will be taught formal open awareness meditation, gentle yoga, and a 'body scan' meditation during weekly classes. Importantly, there is no retreat day included in the program.
11040587|NCT04494737|Active Comparator|Active Comparator: Program 2|Stress Management Education (SME) is designed to control for non-specific factors such as contact hours, stress education, and gentle exercise. Stress education classes will consist of teaching about the effects of stress on health and optimizing one's personal health care, understanding positive coping behavior, optimizing nutrition to decrease stress, and exercise and strength training.
11040588|NCT04494724|Experimental|Clazakizumab|Clazakizumab - 25mg in 50 milliliters (mL) of 0.9% saline, IV infusion over 30 minutes.
11040589|NCT04494724|Placebo Comparator|Placebo|Placebo - 50 mL 0.9% saline, IV infusion over 30 minutes.
11040590|NCT04494711|Experimental|Physical functional literacy|5 week physical literacy program for adults with multiple chronic conditions
11040591|NCT04494698|Active Comparator|DuoTherm VibraCool Back Device|A low back pain relief device incorporating multiple speeds and patterns of vibration and optional heat, cold, or pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice daily for 20 minutes.
11040592|NCT04494698|Sham Comparator|Posture Plate|a sham placebo sculpted metal plate attached with a plain belt, without the pocket or potential for heat, cold, or pressure. No motors are attached to this unit, so while support is possible there are no active pain relief modalities. Patients will be instructed to use the Posture Plate twice a day for 20 minutes.
11040593|NCT04494685|Experimental|Robotic rehabilitation|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland).
11040594|NCT04494685|Active Comparator|Conventional physiotherapy|The protocol will be based on lower limb exercises, aiming at maintaining and gaining muscle strength through passive, assisted or active mobilization, when possible, on the affected side.
11040595|NCT04494672|Experimental|Intramedullary nailing with ADAPT system (arm-A)|A commercial product, namely ADAPT will be used as investigation product in arm-A
11040596|NCT04494672|Active Comparator|Intramedullary nailing without ADAPT system (arm-B)|No aid in performing intramedullary nailing for proximal femoral fractures will be implemented in arm-B
11040597|NCT04494659|Experimental|Single arm|single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16
11040598|NCT04494646|Experimental|Bardoxolone Methyl|
11040599|NCT04494646|Placebo Comparator|Placebo|
11040600|NCT04494633|Experimental|Intervention|Participants will complete the pre-assessments, use the intervention, complete the assessments, wait 4 weeks, and complete the assessment a 3/final time.
11040601|NCT04494633|Other|Wait Group|Participants will complete the pre-assessments, wait, complete the assessments, use the intervention, complete the assessment a 3/final time.
11040602|NCT04494620|No Intervention|Control Arm|Standard of Care
11040603|NCT04494620|Active Comparator|Intervention Arm|Visual Inspection of Oral Cavity for Precancers and Cancer
11040604|NCT04494607|Experimental|Test arm|Determination of Glycemic and Insulinemic curves under different alimentary intake
11040605|NCT04494594|Sham Comparator|Control|
11040606|NCT04494594|Active Comparator|Intervention|
11040607|NCT04494581||Pregnant and postpartum women|Pregnant and postpartum women over 18, meeting inclusion and exclusion criteria.
11040608|NCT04494581||healthcare workers|Health professionals over 18, working in maternity wards included.
11040609|NCT04494568|Experimental|HIFU intervention|patients will benefit of an HIFU Treatment of their rectal endometriosis
11040610|NCT04494555|Experimental|Adaptable Prosthetic Socket|Using measurements of limb-socket displacements from sensors embedded within the socket wall, adaptable sockets make small adjustments to socket size so as to maintain consistent displacements while prosthesis users are active. They do not require the user to stop activity or to touch or modify the prosthesis, and they do not distract users from their objectives.
11040611|NCT04494542|Experimental|Sustained Low Efficiency Dialysis|Sustained Low Efficiency Dialysis
11040612|NCT04494542|Active Comparator|Continuous Renal Replacement Therapy|continuous renal replacement therapy
11040613|NCT04494529|Placebo Comparator|Single-Dose (12 mg betamethasone + placebo)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.
~Participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection instead of the standard 2nd dose of 12 mg of betamethasone (i.e. they will receive the experimental single-dose regimen, total 12 mg of betamethasone only from the first injection)."
11040614|NCT04494529|Active Comparator|Double-Dose (12 mg betamethasone + 12 mg betamethasone)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.
~Participants randomized to the Double-Dose arm will receive the standard 2nd dose of 12 mg of betamethasone injected intramuscularly (i.e. they will receive the standard double-dose regimen, total 24 mg of betamethasone)."
11040615|NCT04494516||Pre-trial|This cohort of participants will be recruited preceding evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with design of the intervention and implementation strategy. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
11040616|NCT04494516||Post-trial|This cohort of participants will be recruited after evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with future scale up and dissemination of the intervention. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
11040618|NCT04494503|Experimental|APG-2575+Rituximab in Relapse/Refractory CLL/SLL|"Stage 1:APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg. Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1. Every 28 days as a cycle.
~Stage 2: APG-2575 MTD/RP2D combined with rituximab. Every 28 days as a cycle."
11040619|NCT04494503|Experimental|APG-2575+ibrutinib in Relapse/Refractory CLL/SLL|"Stage 1: APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg.Ibrutinib 420mg orally once daily during C1D8-28 and following cycles. Every 28 days as a cycle.
~Stage 2: APG-2575 MTD/RP2D combined with ibrutinib. Every 28 days as a cycle."
11040620|NCT04494490|No Intervention|Usual Care Condition|"During the usual care condition the therapists will be instructed to act as usual, that is, to read the guidelines on low back pain if they have read previous published guidelines and not read these guidelines if they have not read any other guidelines."
11040621|NCT04494490|Active Comparator|CPG+PIPT Condition|An active Clinical Practice Guidelines (CPG) implementation strategy will be utilized with an education component in Psychologically Informed Physical Therapy (PIPT) with peer opinion leaders and a monthly audit/feedback on CPG adherence rates and patient outcomes
11040622|NCT04494477|Experimental|The IN•clued program|The IN•clued program for youth consists of a three-hour in-person workshop for youth which includes lessons about safe sex practices and self-efficacy at healthcare centers, exam room roleplays, and a discussion on patient rights. Youth receive a Zine, or a magazine-style booklet, that they may take home. They also receive a list of local healthcare providers that highlights those that have participated in the IN•clued healthcare provider workshop or have had training on working with the LGBTQ population. Program youth can also receive text messages with health tips and reminders to visit a healthcare center.
11040623|NCT04494477|No Intervention|Control|"The youth control group receives a 10-minute presentation and a list of local sexual healthcare providers, with no indication of which providers have been trained to be more LGBTQ friendly and accepting. This 10-minute presentation is a part of a longer three-hour activity unrelated to sexual health or accessing sexual healthcare. During the three-hour session, the list of approved activities includes but is not limited to:
~Films by, and for, LGBTQ youth about sexual orientation and gender identity;
~Community scavenger hunts;
~Poetry slams;
~Discussions about relationships; and
~Activities related to the appreciation of individuals' unique strengths."
11040624|NCT04494464||Patients with LDL cholesterol ≥250 mg/dL|Patients older than 18 years old and have a serum LDL-C≥250 mg/dL between January 2010 and December 2016. Patients with a serum TSH≥10 mIU/mL, patients with glomerulonephritis or nephrotic syndrome, patients with ALT or AST higher than 3 times of normal limits and patients with serum triglyceride >400 mg/dL were excluded.
11040625|NCT04494451|Experimental|Vitamin C + Standard Medical Treatment|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol along with iv antibiotics
11040626|NCT04494451|Active Comparator|Standard Medical Treatment|iv antibiotics alone
11040627|NCT04494438|No Intervention|Steroid tapering.|
11040628|NCT04494438|Experimental|Rituximab|Single administration of Rituximab 375 mg/mq at a rate of 0.5 to 1.5 ml/min over approximately 6 hours, following the infusion of 2.5-5 mg of intravenous chlorfenamine maleate (based on the local protocol and patient tolerance), methylprednisolone (2 mg/Kg) in normal saline and oral paracetamol (8 mg/kg).
11040629|NCT04494425|Experimental|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
11040630|NCT04494425|Active Comparator|Standard of Care|Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
11040631|NCT04494412|Experimental|Hospitalized neonates and infants with influenza infection|Preterm neonates and infants who have reached Post-Menstrual Age (PMA) of at least 28 weeks and have a confirmed complicated influenza infection will be included. Participants will receive daily IV infusion of zanamivir for up to 5 days. This initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests warrant further treatment. The initial dose of IV zanamivir will be determined by PMA/corrected age and body weight. The maintenance dose and interval between the initial dose and subsequent twice-daily maintenance dose will be further determined by Principal Investigator based on renal function.
11040632|NCT04494399|Active Comparator|Treatment group|5-day course of daily subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and oral ribavirin 400mg twice daily plus standard care
11040633|NCT04494399|No Intervention|Control group|Standard care alone
11040634|NCT04494386|Experimental|ULSC in Phase 1 Open Label|"Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:
~In Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen."
11040635|NCT04494386|Experimental|ULSC in Phase 2a Randomized|"Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:
~In Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability."
11040636|NCT04494386|Placebo Comparator|Placebo in Phase 2a Randomized|"Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:
~In Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
11040637|NCT04494373|Experimental|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
11040638|NCT04494373|Active Comparator|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
11040639|NCT04494360||Healthy Participants|Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
11040640|NCT04494347|Experimental|Treatment Group|This is not a randomized study. Patients who are clinically indicated for both procedures will be offered the option to enroll in this registry for a combined procedure. Otherwise, they will undergo TMVr and LAAO in two separate session as clinically indicated (standard of care).
11040641|NCT04494334||Healthy Volunteers|These will be age matched healthy volunteers (n=15) who will not undergo bronchoscopy
11040642|NCT04494334||Probable Idiopathic Pulmonary Fibrosis|Patients with probable IPF, who will be having bronchoscopy as part of their clinical diagnostic work up
11040645|NCT04494321|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
11040646|NCT04494321|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
11040647|NCT04494308||exacerbated|COPD patients admitted to the hospital for an exacerbation occurred within the past 10 days.
11040648|NCT04494308||stable|COPD stable patients with no exacerbations in the past 3 months
11040649|NCT04494295||AURORA|Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma
11040650|NCT04494282|Active Comparator|Same day|The ERP will be performed the same day of the endoscopic drainage of PP
11040651|NCT04494282|Active Comparator|Other day|The ERP will be performed 6 weeks after the endoscopic drainage of PP.
11040652|NCT04494269|Active Comparator|Subjects with normal hepatic function|Single dose of Tegoprazan 50mg
11040653|NCT04494269|Experimental|Subjects with mild hepatic impairment|Single dose of Tegoprazan 50mg
11040654|NCT04494269|Experimental|Subjects with moderate hepatic impairment|Single dose of Tegoprazan 50mg
11040655|NCT04494269|Experimental|Subjects with severe hepatic impairment|Single dose of Tegoprazan 50mg
11040656|NCT04494256|Experimental|Cohort A|Participants with ALS will receive BIIB105 Dose 1, intrathecally (IT), as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040657|NCT04494256|Experimental|Cohort B|Participants with ALS will receive BIIB105 Dose 2, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040658|NCT04494256|Experimental|Cohort C1|Participants with ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040659|NCT04494256|Experimental|Cohort C2|Participants with polyQ-ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040660|NCT04494256|Experimental|Cohort D1|Participants with ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040661|NCT04494256|Experimental|Cohort D2|Participants with polyQ-ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040662|NCT04494256|Placebo Comparator|Cohorts A-D2|Participants with ALS and polyQ-ALS will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
11040663|NCT04494243|Experimental|AD-214/Rabeprazole|Period 1 : Test Drug(AD-214 10/600mg) Period 2 : Reference Drug(Rabeprazole 10mg)
11040664|NCT04494243|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole 10mg) Period 2 : Test Drug(AD-214 10/600mg)
11040665|NCT04494230||Attention deficit hyperactivity disorder (ADHD) only|the diagnosis of ADHD
11040666|NCT04494230||Attention deficit hyperactivity disorder (ADHD) andSpecificand|the diagnosis of ADHD and SLD
11040667|NCT04494230||ADHD and oppositional defiant disorder (ODD)|the diagnosis of ADHD and ODD
11040668|NCT04494230||ADHD and Anxiety Disorder|the diagnosis of ADHD and Ank. Dis.
11040669|NCT04494230||Typical Development Children|no mental symptoms described by their teachers or parents and showing healthy development
11040670|NCT04494204|Experimental|Intervention|2 tablets Immunofree 500 mg tablets thrice a day for 10 days and 1 capsule Reginmune 750 mg twice a day for 10 days
11040671|NCT04494204|Active Comparator|Comparator Agent|As per standard National Clinical Management Protocol for COVID-19 by Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services, (EMR Division), Version 3, 13.06.20
11040672|NCT04494191|Experimental|T test|Test drug (AphroFemine) 1 tablet contains 100 mg Flibanserin
11040673|NCT04494191|Active Comparator|B reference|Reference drug (Addyi) 1 tablet contains 100 mg Flibanserin
11040674|NCT04494178|Experimental|2.0g G-PUR® oral - Placebo|
11040675|NCT04494178|Experimental|Placebo - 2.0g G-PUR® oral|
11040676|NCT04494165|Experimental|Aromatherapy Group|In addition to the standard physical therapy session, 30 patients in this group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
11040677|NCT04494165|Placebo Comparator|placebo group|In addition to the standard physical therapy session, 31 patients in this group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
11040678|NCT04494165|No Intervention|control group|30 patients in this group received standard physical therapy sessions, and no massage was applied.
11040679|NCT04494152||Critically ill patients|Adult critically ill patients hospitalised in the intensive care unit.
11040680|NCT04494139|Active Comparator|Canteen Only|Train canteen staff and implement canteen intervention in the canteen space: interventions targeting food quality and quantity, intervention targeting food choice at point of sale, interventions target improved supply, interventions targeting price and promotional material.
11040681|NCT04494139|Experimental|Behavioral and Canteen intervention|The behavioral intervention will be comprised of a combination of intensive education sessions and goal setting and monitoring based on a validated worksite curriculum tailored to local needs. The curriculum includes 24 sessions: 16 core weekly sessions during the first four months of the intervention followed by 8 weekly maintenance sessions (text messages). Each session will be facilitated by a nutritionist/dietitian and a peer educator; and will last one hour. Broadly, the curriculum covers the subject matters of importance of healthy weight, eating a healthy diet, increasing physical activity, stress management, and challenges of lifestyle changes. Participants will be encouraged to keep food and activity diaries throughout the course of the study. During the maintenance period, the focus will be on overcoming declines in motivation and on maintaining long-term healthy behaviors.
11040682|NCT04494126|Experimental|Tranexamic acid|Experimental: TXA Group One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
11040806|NCT04493424|Experimental|Treatment group|Up to 260 weeks
11057842|NCT04373083|Experimental|Concomitant treatment|Treatment Group A
11040683|NCT04494126|Placebo Comparator|Placebo|Placebo Comparator: Control Group Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
11040684|NCT04494113|Experimental|Treatment (triapine, surgical resection)|Patients receive triapine IV over 2 hours on day 1 in the absence of unacceptable toxicity. Patients then undergo surgical resection 6-8 hours after completion of triapine infusion.
11040685|NCT04494100|Active Comparator|CONTROL|Troncular blocks using a long-acting LA + Tourniquet
11040686|NCT04494100|Experimental|WALANT|Troncular blocks using a long-acting LA + WALANT technique using a short-term LA with epinephrine a vasoconstrictor agent
11040687|NCT04494087|Active Comparator|Hernia video|The video of the intervention group will provide a short (< 5 min) summary explaining the basic principles of endoscopic extraperitoneal hernia repair, its possible complications and the postoperative course. After carefully watching the video, participants should be able to correctly answer to a multiple-choice test consisting of 12 questions related to the aforementioned topics.
11040688|NCT04494087|Placebo Comparator|Mock video|"This video is a general documentation of the typical day of surgery in the day clinic. The information is essentially limited to the pictorial representation of the individual wards which the patient will pass through during the operation (arrival at the clinic, admission, transport to the operating theatre, recovery room, discharge).
~The video explicitly does not transport any information that could be helpful for answering the quiz questions or for medical understanding of the operation itself."
11040689|NCT04494087|Sham Comparator|Control group|The link of the third group leads to a digital version of the information sheet, which has already been discussed with all patients during the informed consent discussion. The digital version of the informed consent form allows the patient to read the information again. The third group thus corresponds to the standard of care.
11040690|NCT04494074|Experimental|Fever Control by external cooling|External cooling during 48 hours to obtain normothermia
11040691|NCT04494074|No Intervention|Fever respected, no cooling|Fever respect without any antipyretic therapy
11040692|NCT04494061||HSCT - Hematopoetic Stem Cell Proliferation|Patients who received hematopoietic stem cell transplant
11040693|NCT04494061||IHSCP - Impaired HSC proliferation|Patients with impaired hematopoietic stem cell proliferation
11040694|NCT04494048||Endoscopic Bariatric Therapies (EBT).|patients undergoing Endoscopic Bariatric Therapies
11040695|NCT04494035|Experimental|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
11040696|NCT04494022|No Intervention|Cross-sectional image only|Image set which consists of a Cross-sectional image only.
11040697|NCT04494022|Active Comparator|Cross-sectional image with CEUS|The same participants with Arm1. But image set will consist of a Cross-sectional image and CEUS.
11040698|NCT04494009|Experimental|INCMGA00012 군|INCMGA00012 500 mg iv every 4 weeks for up to 12 months
11040699|NCT04494009|No Intervention|Observation arm|followed up every 12 weeks for up to 12 months
11040700|NCT04493996|Experimental|Cognitive training group|
11040701|NCT04493996|No Intervention|Control group|
11040702|NCT04493983|Other|Investigation|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
11040703|NCT04493957|Experimental|educational intervention|"Patients and caregivers included in the ACCOMPAGNE Education Program group will benefit from seven group workshops spread over three half-days (once a week over 3 consecutive weeks), animated in pairs, each lasting approximately one and a half hours. and using educational pedagogical methods."
11040704|NCT04493957|Active Comparator|Control group|"Patients and caregivers included in the Control group will receive the usual recommendations for driving, issued by their referring doctor in memory consultation during the diagnostic announcement process or during the follow-up of their illness."
11040705|NCT04493944|Experimental|Intervention group (with culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study, and will participate in a culinary workshop with a chef (3 hours).
11040706|NCT04493944|No Intervention|Control group (without culinary workshop)|This group will be composed of participants that will answer online questionnaires before and after the study.
11040707|NCT04493931|Experimental|Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg|This is a fixed sequence (Sequence AB) cohort. Participants will receive gepotidacin 1500 milligrams (mg) single dose (SD) on Day 1 of Period 1 (Treatment A); and Cimetidine 400 mg 4 times daily on Days 1 through 4 of Period 2 and gepotidacin 1500 mg single dose (Treatment B). Gepotidacin will be administered 1 hour after the first dose of cimetidine on Day 2 of Period 2. There will be a washout of at least 3 days between Treatment A and Treatment B, and a follow-up visit 5 to 7 days after the last dose of cimetidine.
11040708|NCT04493931|Experimental|Cohort 2: Gepotidacin 1500 mg + Rifampicin 600 mg|This is a fixed sequence (Sequence CDE) cohort. Participants will receive gepotidacin 1500 mg single dose on Day 1 of Period 1 (Treatment C), rifampicin 600 mg (administered in the evenings) once daily for 7 days (Days 1 through 7 of Period 2, to elicit maximal enzyme induction) (Treatment D); and gepotidacin 1500 mg single dose administered in the morning on Day 8 and rifampicin 600 mg administered in the evening on Days 8 and 9 of Period 2 (Treatment E). There will be a washout of at least 3 days between Treatment C and Treatment D, and a follow-up visit 7 to 10 days after the last dose of rifampicin.
11040709|NCT04493931|Experimental|Cohort 3: Digoxin 0.5mg+Midazolam 2mg then Gepotidacin 3000mg|Participants will receive digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 1 on Day 1 then gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 2 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G). There will be a washout of at least 10 days between treatments. In Sequence 2, these regimens are reversed. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
11040710|NCT04493931|Experimental|Cohort 3: Gepotidacin 3000mg then Digoxin 0.5mg+Midazolam 2mg|Participants will receive gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 1 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G) followed by digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 2 on Day 1. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
11057843|NCT04373083|Experimental|Sequential treatment|Treatment Group B
11040711|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fed then fasted then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
11040712|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fasted then fed then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fasted conditions in Period 1 (Treatment I), then a single dose of gepotidacin 1500 mg under fed conditions in Period 2 (Treatment H), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
11040713|NCT04493931|Placebo Comparator|Cohort 4: Placebo fed then fasted then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fed conditions in Period 1, then a single dose of placebo under fasted conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
11040714|NCT04493931|Placebo Comparator|Cohort 4: Placebo fasted then fed then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fasted conditions in Period 1, then a single dose of placebo under fed conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
11040715|NCT04493918|Experimental|MSC Group|Mesenchymal Stem Cell + NaCl 0,9% 2ml
11040716|NCT04493892|Experimental|Educational Intervention|All participants receive educational information on the potential health risk of endocrine disruptor chemicals in hair care products, specifically phthalates. Provide information on how to reduce exposure.
11040717|NCT04493879|Experimental|Bioptron Light Therapy (BLT) group|Received Bioptron Light Therapy (BLT) ten minutes every day for one month plus the routine medical treatment of oral mucositis(Analgesics, anti-inflammatory medication and antimicrobial therapy for any new mouth infections
11040718|NCT04493879|Experimental|Routine medical care group|Received only the routine medical care of oral mucositis for one month this consists of analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections
11040719|NCT04493853|Experimental|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
11040720|NCT04493853|Placebo Comparator|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
11040721|NCT04493840|Experimental|Shenfu Injection|
11040722|NCT04493840|Placebo Comparator|5% Glucose Injection|
11040723|NCT04493814||Cohort|All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
11040724|NCT04493801||with nasoseptal flap|patient who undergo a pituitary gland surgery with nasoseptal flap
11040725|NCT04493801||without nasoseptal flap|patient who undergo a pituitary gland surgery without nasoseptal flap
11040726|NCT04493788||PCOS group|
11040727|NCT04493788||Control group|
11040728|NCT04493762||PSO/PSA|Patients diagnosed with psoriasis or psoriatic arthritis
11040729|NCT04493762||RA|Patients diagnosed with rheumatoid arthritis
11040730|NCT04493749||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
11040731|NCT04493749||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
11040732|NCT04493736||Case|Any person receiving services from a mental health provider who is able to either consent or for whom parental consent is able to be obtained.
11040733|NCT04493723||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
11040734|NCT04493697|Active Comparator|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
11040735|NCT04493697|Placebo Comparator|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
11040736|NCT04493684|Experimental|Part 1: Cohort 1: Participants receiving GSK3739937|Eligible participants in part 1 cohort 1, will consist of approximately 9 healthy participants. Part 1 cohort 1 may contain up to 3 escalating doses ( Period 1- 10 milligram [mg], Period 2- 80 mg, and Period 3- 320 mg) of GSK3739937. In each escalating dose period, 6 participants will be randomized to receive GSK3739937.
11040737|NCT04493684|Placebo Comparator|Part 1: Cohort 1: Participants receiving Placebo|Eligible participants in part 1 cohort 1, will consist of approximately 9 healthy participants. In this cohort , 3 participants will be randomized to receive placebo.
11040738|NCT04493684|Experimental|Part 1: Cohort 2: Participants receiving GSK3739937|Eligible participants in part 1 cohort 2, will consist of approximately 9 healthy participants. Part 1 cohort 2 may contain up to 3 escalating doses ( Period 1- 30 mg, Period 2- 160 mg, and Period 3- 640 mg) of GSK3739937. In each escalating dose period, 6 participants will be randomized to receive GSK3739937.
11040739|NCT04493684|Placebo Comparator|Part 1: Cohort 2: Participants receiving Placebo|Eligible participants in part 1 cohort 2, will consist of approximately 9 healthy participants. In this cohort , 3 participants will be randomized to receive placebo.
11040740|NCT04493684|Experimental|Part 2: Cohort 3: Participants receiving GSK3739937|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of GSK3739937 for 14 days.
11040741|NCT04493684|Placebo Comparator|Part 2: Cohort 3: Participants receiving Placebo|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
11040742|NCT04493684|Experimental|Part 2: Cohort 4: Participants receiving GSK3739937|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of GSK3739937 for 14 days.
11040743|NCT04493684|Placebo Comparator|Part 2: Cohort 4: Participants receiving Placebo|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
11040744|NCT04493684|Experimental|Part 2: Cohort 5: Participants receiving GSK3739937|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of GSK3739937 for 28 days.
11040745|NCT04493684|Placebo Comparator|Part 2: Cohort 5: Participants receiving placebo|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 28 days.
11040746|NCT04493671|Active Comparator|SAD (Part 1): Cohort 1, TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 6 will receive TBAJ-876 10mg under fasting conditions.
11040747|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 1, placebo for TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 10mg under fasting conditions.
11040748|NCT04493671|Active Comparator|SAD (Part 1): Cohort 2, TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 6 will receive TBAJ-876 25mg under fasting conditions.
11040749|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 2, Placebo for TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 25mg under fasting conditions.
11040750|NCT04493671|Active Comparator|SAD (Part 1): Cohort 3, TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 6 will receive TBAJ-876 50mg under fasting conditions.
11040751|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 3, Placebo for TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 50mg under fasting conditions.
11040752|NCT04493671|Active Comparator|SAD (Part 1): Cohort 4, TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 6 will receive TBAJ-876 100mg under fasting conditions.
11040753|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 4, Placebo for TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 100mg under fasting conditions.
11040754|NCT04493671|Active Comparator|SAD (Part 1): Cohort 5, TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 6 will receive TBAJ-876 200mg under fasting conditions.
11040755|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 5, Placebo for TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 200mg under fasting conditions.
11040756|NCT04493671|Active Comparator|SAD (Part 1): Cohort 6, TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 6 will receive TBAJ-876 400mg under fasting conditions.
11040757|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 6, Placebo TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 400mg under fasting conditions.
11040758|NCT04493671|Active Comparator|SAD (Part 1): Food effect Cohort, TBAJ-876|In food-effect cohort with 10 subjects, n=8 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive the chosen dose of TBAJ-876 under fed conditions.
11040759|NCT04493671|Placebo Comparator|SAD (Part 1): Food effect Cohort, Placebo|In food-effect cohort with 10 subjects, n=2 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive matching placebo for the chosen dose of TBAJ-876 under fed conditions.
11040760|NCT04493671|Active Comparator|MAD (Part 2): Cohort 1, TBAJ-876 Dose 1|In cohort 1 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
11040761|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 1, Placebo|In cohort 1 with 12 subjects, n=3 is expected to receive the matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
11040762|NCT04493671|Active Comparator|MAD (Part 2): Cohort 2, TBAJ-876 Dose 2|In cohort 2 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
11040763|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 2, Placebo|In cohort 2 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
11040764|NCT04493671|Active Comparator|MAD (Part 2): Cohort 3, TBAJ-876 Dose 3|In cohort 3 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements
11040765|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 3, Placebo|In cohort 3 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
11040766|NCT04493658||Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and a diagnosis of Sjogren's syndrome made according to the 2016 revised criteria
11040767|NCT04493658||Non-Sjogrens syndrome dry eye|Patients with a previous diagnosis of dry eye made by an eye care specialist and no diagnosis of Sjogren's syndrome based on 2016 revised criteria.
11040768|NCT04493658||Control|Normal individuals with no previous diagnosis of dry eye or Sjogren's syndrome
11040769|NCT04493645|Active Comparator|Standard of Care (SOC)|Participants will be randomized to receive standard of care rehabilitation (SOC) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the SOC group for 24 months following completion of their assigned SOC intervention.
11040770|NCT04493645|Experimental|Foot Intensive Rehabilitation (FIRE)|Participants will be randomized to receive foot intensive rehabilitation (FIRE) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the FIRE group for 24 months following completion of their assigned SOC intervention.
11040771|NCT04493619|Experimental|PLX2853 Phase 2a Monotherapy|Up to 26 evaluable subjects with ARID1A mutation-positive advanced gynecological malignancies will be enrolled.
11040772|NCT04493619|Experimental|PLX2853 + Carboplatin Phase 1b/2a Combination Therapy|"Phase 1b (PLX2853 + carboplatin combination): Up to 15 evaluable subjects with platinum-resistant EOC will be enrolled.
~Phase 2a (PLX2853 + carboplatin combination): Up to 26 evaluable subjects with platinum-resistant EOC will be enrolled."
11040773|NCT04493606|Experimental|Intervention Patients|SCI patients receiving the physical activity coaching (Objective 1)
11040774|NCT04493606|No Intervention|Control Patients|SCI patients that did not want to receive physical activity coaching (Objective 1)
11040775|NCT04493606|Experimental|Intervention- Interventionists|Interventionists receiving physical activity coaching training (Objective 2)
11040776|NCT04493593|Experimental|Space for Sleep Group|SilverCloud internet-delivered CBT intervention for Insomnia
11040969|NCT04492137|Experimental|NKF group|Patients submitted to primary NKF in a consecutive fashion by an expert endoscopist
11040777|NCT04493580|Experimental|iDBT Treatments|15 weekly DBT sessions. During each session, participants will be sent 30-40 PowerPoint slides including general information on particular topic, overview of skills, and homework sheets to be completed and returned to therapists. Therapists involved will be a psychiatry resident, a psychologist, and a registered nurse who will also facilitate the in-person groups. The content and format of the online program will directly corresponded with that of the in-person group. Participants will be asked to send their homework sheets back to therapists by a specific day each week. The following day, the therapist will email feedback regarding the homework submitted and send next week's PowerPoint slides, information sheets, and homework. In order to be eligible to receive the materials, participants are required to send in homework prior to deadline. If homework was not returned, reminder email will be sent. If more than two sessions are missed, participants are excluded from the program.
11040778|NCT04493580|Active Comparator|In-Person DBT Treatments|Weekly skills-building groups titled Managing Powerful Emotions (MPE) includes Mindfulness, Distress Tolerance, Emotion Regulation, and Interpersonal Effectiveness. Personality Disorders Service offers more advanced therapy groups for individuals who have successfully completed MPE and wish to continue seeking treatment modalities. Chrysalis Day Treatment Program (CDTP) is for an individual who has progress through two prior phases. In phase one, individuals will participate in a DBT-informed skill-building group (MPE). Once completed, the individual will progress to phase two which includes attending a psychotherapy group, incorporating DBT skills-building. Finally, in phase three, individuals who wish to participate in a more advanced and complex psychological treatment program, apply to participate in CDTP. The CDTP is an intensive day treatment program integrating DBT skills-building, psychodynamic psychotherapy, and a range of other group therapy modalities.
11040779|NCT04493567|Experimental|Part A: 1 x BMS-986036 via auto-injector or pre-filled syringe|
11040780|NCT04493567|Experimental|Part B: 2 x BMS-986036 via auto-injector or pre-filled syringe|
11040781|NCT04493554|Experimental|Vasopressin|Vasopressin (24 IU) intranasally
11040782|NCT04493554|Placebo Comparator|Placebo|Placebo (24IU) intranasally
11040783|NCT04493541|Experimental|BMS-986256|
11040784|NCT04493541|Placebo Comparator|Placebo|
11040785|NCT04493528|Active Comparator|Needle Infiltration anesthesia|Patients received one needle injection of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040786|NCT04493528|Experimental|Needle-free infiltration anesthesia|Patients received one NFLJI (needle-free liquid jet injection) of infiltration anesthesia at left or right upper lateral incisors using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040787|NCT04493528|Active Comparator|Needle mental nerve block|Patients received one needle injection of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040788|NCT04493528|Experimental|Needle-free mental nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mental nerve block at left or right lower premolar region using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040789|NCT04493528|Active Comparator|Needle mandibular nerve block|Patients received one needle injection of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040790|NCT04493528|Experimental|Needle-free mandibular nerve block|Patients received one NFLJI (needle-free liquid jet injection) of mandibular nerve block at left or right mandibular foramen using 2 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040791|NCT04493528|Active Comparator|Needle infraorbital nerve block|Patients received one needle injection of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040792|NCT04493528|Experimental|Needle-free infraorbital nerve block|Patients received one NFLJI (needle-free liquid jet injection) of infraorbital nerve block at left or right canine fossa using 1 ml 2% lidocaine with 1:50,000 epinephrine (xylocaine).
11040793|NCT04493515|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
11040794|NCT04493515|Placebo Comparator|Oral Placebo|Placebo orally (24 IU, identical ingredients, except the active agent)
11040795|NCT04493502|Experimental|LY3041658|LY3041658 given intravenously (IV).
11040796|NCT04493502|Placebo Comparator|Placebo|Placebo given IV. Participants will switch to LY3041658 given IV after week 16.
11040797|NCT04493489|Placebo Comparator|BCG|After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
11040798|NCT04493489|Experimental|Propranolol plus BCG|After TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
11040799|NCT04493476|Active Comparator|Chineese Herbal formula|The study group will be given capsules containing Chinese herbal formula extract - Traditional Chinese MedicinalSubstances
11040800|NCT04493476|Placebo Comparator|placebo|The control group tested will receive placebo capsules. Containing starch.
11040801|NCT04493463|Experimental|methylprednisolone + ropivacaine + saline|The local infiltration solution in the methylprednisolone plus ropivacaine with saline group (treatment group) will consist of 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
11040802|NCT04493463|Active Comparator|ropivacaine + saline|The local infiltration solution in the ropivacaine plus saline group (control group) will consist of 15 ml of 1% ropivacaine and 15ml saline.
11040803|NCT04493450||Smartphone-users|Cancer patients who use smartphones
11040804|NCT04493437|Experimental|Telerehabilitation group A|Device: Telerehabilitation Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
11040805|NCT04493437|Experimental|Telerehabilitation group B|"Device: Telerehabilitation + rehabilitation at health care center Telerehabilitation: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
~Rehabilitation at health care center: The rehabilitation will consist of four closed group sessions focusing on patient education. The groups will consist of both patients and relatives. The program at the health care center will not include any psychological tests or data control. Duration is 4 x 2 hours sessions over a period of 1 month."
11040807|NCT04493411|Experimental|Multiple Myeloma Patients|Patients with pathologically confirmed myeloma scheduled to undergo induction therapy followed by bone marrow transplantation.
11040808|NCT04493398|Active Comparator|Titanium curette and ultrasonic.|Debridement of mandibular furcations with conventional ultrasonic/curette (control).
11040809|NCT04493398|Experimental|Erythritol air-polishing.|Treatment of mandibular furcations with erythritol powder/air-polishing system (test)
11040810|NCT04493372|Experimental|Individuals with spinal cord injury|
11040811|NCT04493372|Experimental|Individuals without spinal cord injury|
11040812|NCT04493359|Experimental|Switch therapy|Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
11040813|NCT04493359|No Intervention|Maintenance therapy|Renin-angiotensin system inhibitors will be kept during in-hospital stay
11040814|NCT04493333|Experimental|Vaginal Dehydroepiandrosterone|vaginal dehydroepiandrosterone 6.5 mg inserted nightly for 12 weeks
11040815|NCT04493333|Active Comparator|Polycarbophil|prefilled applicator of a polycarbophil vaginal moisturizing gel (2.5 g) into the vagina two times per week at night for 12 weeks
11040816|NCT04493320|Experimental|L-DOPA, Then Placebo|"Step 1 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.
~Participants will then enter a 1 week taper period.
~Step 2 (3 Weeks): Participants will receive L-DOPA matching placebo tablets daily.
~Participants will then enter a 1-week taper period."
11040817|NCT04493320|Experimental|Placebo, Then L-DOPA|"Step 1 (3 Weeks): Participants will receive 3 L-DOPA matching placebo tablets daily. Participants will then enter a 1-week taper period.
~Step 2 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 200 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.
~Participants will then enter a 1-week taper period."
11040818|NCT04493281|Experimental|MT-1186|Healthy subjects were administered a single dose of Edaravone oral suspension
11040819|NCT04493281|Active Comparator|MCI-186|Healthy subjects were administered a single dose of Edaravone intravenous formulation
11040820|NCT04493255|Experimental|E7090|Participants will receive 100 microcurie (μCi) of [14C]E7090 as a single 35 milligram (mg), capsule, orally on Day 1.
11040821|NCT04493242|Placebo Comparator|Placebo|
11040822|NCT04493242|Experimental|Dose 1|
11040823|NCT04493242|Experimental|Dose 2|
11040824|NCT04493229|Experimental|Oxytocin|Oxytocin IM injection will be given per randomization prior to first outpatient physical therapy session
11040825|NCT04493229|Active Comparator|Placebo|Placebo IM injection will be given per randomization prior to first outpatient physical therapy session
11040826|NCT04493216|Experimental|Blinded GSK3640254 100 mg + Open Label ABC/3TC or FTC/TAF|Participants will be randomized to receive blinded GSK3640254 100 mg and placebo in combination with open label abacavir 600 mg/lamivudine 300 mg or emtricitabine 200 mg/tenofovir alafenamide 25 mg until the last participant completes their Week 48 study visit. Thereafter, participants with HIV-1 RNA <50 c/mL will move into the Non-Randomized Phase and will be switched from their blinded dose to the open label optimal dose. Simultaneously, these participants will also be switched from their dual NRTI therapy to DTG. Participants who continue to derive benefit from the treatments will remain on study beyond Week 96.
11040827|NCT04493216|Experimental|Blinded GSK3640254 150 mg + Open Label ABC/3TC or FTC/TAF|Participants will be randomized to receive blinded GSK3640254 150 mg in combination with open label abacavir 600 mg/lamivudine 300 mg or emtricitabine 200 mg/tenofovir alafenamide 25 mg until the last participant completes their Week 48 study visit. Thereafter, participants with HIV-1 RNA <50 c/mL will move into the Non-Randomized Phase and will be switched from their blinded dose to the open label optimal dose. Simultaneously, these participants will also be switched from their dual NRTI therapy to DTG. Participants who continue to derive benefit from the treatments will remain on study beyond Week 96.
11040828|NCT04493216|Experimental|Blinded GSK3640254 200 mg + Open Label ABC/3TC or FTC/TAF|Participants will be randomized to receive blinded GSK3640254 200 mg and placebo in combination with open label abacavir 600 mg/lamivudine 300 mg or emtricitabine 200 mg/tenofovir alafenamide 25 mg until the last participant completes their Week 48 study visit. Thereafter, participants with HIV-1 RNA <50 c/mL will move into the Non-Randomized Phase and will be switched from their blinded dose to the open label optimal dose. Simultaneously, these participants will also be switched from their dual NRTI therapy to DTG. Participants who continue to derive benefit from the treatments will remain on study beyond Week 96.
11040829|NCT04493216|Active Comparator|Open Label DTG + Open Label ABC/3TC or FTC/TAF|Participants in this arm will receive open label Dolutegravir 50 mg in combination with open label abacavir 600 mg/lamivudine 300 mg or emtricitabine 200 mg/tenofovir alafenamide 25 mg. They will then continue unchanged into the Non-Randomized Phase. Later they will end their participation in the treatment phase as each individual participant reaches their Week 144 visit.
11040830|NCT04493203|Experimental|Nivolumab plus Axitinib|"Nivolumab 480mg, IV, every 4 weeks, for up to two years.
~Axitinib 5mg, PO, BID, for up to two years."
11040831|NCT04493190|Experimental|Scapular control training group|Participants in these group will be taught how to correctly movement arm overhead. And they will undergo series of movement tasks with mirror and also receive scapular-focused exercises. The difficulty of the movements protocol will increase weekly.
11040832|NCT04493190|Experimental|General exercise group|Participants in this group will receive a general strengthening exercise, focusing on the shoulder muscles. And the load will progressively increase weekly.
11040833|NCT04493190|No Intervention|Healthy subject group|No intervention.
11040834|NCT04493177|Experimental|Gestational diabetes intervention|All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
11040835|NCT04493177|Experimental|No diabetes intervention|Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
11040836|NCT04493177|Active Comparator|No diabetes no intervention|Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.
11040904|NCT04492579|Experimental|Supplementation of Gentle-UHT donor milk|Supplementation of Gentle-UHT donor milk in addition to mother's own milk, as recommended by the health care providers.
11041001|NCT04491877|Experimental|Cohort 1 (RSV vaccine formulation 1)|1 administration of RSV vaccine formulation 1 on Day 0
11040837|NCT04493164|Experimental|Treatment (CPX-351, ivosidenib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and ivosidenib PO QD on days 1-28. Patients who do not achieve complete remission may receive a second cycle of induction therapy in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission proceed to consolidation.
~CONSOLIDATION: Patients receive CPX-351 IV over 90 minutes on days 1 and 3, and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ivosidenib PO QD for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who are experiencing clinical benefit and who have not experienced excessive toxicity after completion of 2 years of maintenance may be eligible to continue therapy after discussion with the principal investigator."
11040838|NCT04493151|Experimental|Imipenem-Cilastatin-Relebactam|Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.
11040839|NCT04493138|Experimental|Treatment (azacitidine, quizartinib)|Patients receive azacitidine SC or IV over about 30 minutes on days 1-5 and quizartinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11040840|NCT04493125|Experimental|Mosapride group|Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
11040841|NCT04493125|Placebo Comparator|Placebo group|Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery
11040842|NCT04493099|Experimental|Treatment (decitabine, alvocidib hydrochloride, venetoclax)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10, or 1-14, and venetoclax PO QD on days 1-14 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive decitabine IV over 1 hour on days 1-5, alvocidib hydrochloride IV over 1 hour on days 1-3, 1-5, 1-7, 1-10 or 1-14, and venetoclax PO QD on days 1-10. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
11040843|NCT04493073|Active Comparator|Trabectulectomy with mitomycin|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India) 10 mg vial 2 mg/ml concentration
11040844|NCT04493073|Active Comparator|Trabectulectomy with Ologen implants|Ologen Collagen Implant (Aeon Astron Europe, Netherlands) - three-dimensional collagen- GAG implant >90% lyophilized porcine atelocollagen and <10% lyophilized porcine GAG 12 mm in diameter with 1 mm of thickness and 6 mm in diameter with 2 mm of thickness
11040845|NCT04493060|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-21. Patients also receive dostarlimab IV over 30 minutes on day 1 Q3W for cycles 1-4 and Q6W for subsequent cycles. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11040846|NCT04493047|Experimental|Counselling on pneumonia prevention|Recruited caregivers will be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject.
11040847|NCT04493034|Experimental|Art Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
11040848|NCT04493034|Experimental|Music Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
11040849|NCT04493034|No Intervention|Standard Of Care|A list of support services is provided. No requirement to attend sessions and no home assignments
11040850|NCT04493008|Other|MIU students and patents|Educational session
11040851|NCT04492995|Active Comparator|Radiotracer + TUMIR|TUMIR = transvaginal ultrsound-guided myometrial injection
11040852|NCT04492995|Experimental|(Radiotraces + ICG) + TUMIR|ICG =indocyanine green TUMIR = transvaginal ultrsound-guided myometrial injection
11040853|NCT04492982|Active Comparator|Yoga|60 minute sessions of guided yoga in small group format
11040854|NCT04492982|Active Comparator|Distress Tolerance|60 minutes sessions of guided didactic distress tolerance skill building in small group format
11040855|NCT04492982|No Intervention|Treatment as Usual|Those recruited through Student Health and Wellness will complete the university standard BASICS intervention.
11040856|NCT04492956|Experimental|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
11040857|NCT04492956|Placebo Comparator|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
11040858|NCT04492930|Active Comparator|Comparator|Time restricted eating
11040859|NCT04492930|Experimental|Intervention|Time restricted eating
11040860|NCT04492917|Experimental|Cranial Technique CV4|"All subjects received a combination of active technique (CV4) and the corresponding sham technique (shamCV4).
~CV4: the lateral angles of the occipital squama are manually approximated slightly exaggerating the posterior convexity of the occiput and taking the cranium into sustained extension.The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
~ShamCV4: sham intervention was performed placing the hands in the same position of the corresponding active technique, applying a light touch"
11040861|NCT04492917|Active Comparator|Sacral Technique ST|"All subjects received a combination of active technique (ST) and the corresponding sham technique (shamST).
~ST: The subject was lying in supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point.
~ShamST: sham intervention was performed placing the hands in the same position of the corresponding active technique, applying a light touch"
11040862|NCT04492904||COVID-19 Positive (Case)|Participants who were present for COVID-19 screening and their test results will later indicate positive of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
11040905|NCT04492566|Experimental|AID Evaluation|After completing a 1-2 week CGM run-in period, subjects will complete a 48-60 hour closed-loop (CL) session in a supervised outpatient environment with medical staff present.
11040863|NCT04492904||COVID-19 Negative/Other respiratory diseases (Control)|Participants who were present for COVID-19 screening and their test results will later indicate negative of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days
11040864|NCT04492891|Experimental|Arm A Cyclosporine|Neoral, N=50 Patients 2.5 mg/kg PO BID 7 days
11040865|NCT04492891|Other|Arm B Standard of Care|Standard of Care Treatment, N= 25 Patients 7 days
11040866|NCT04492878|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|
11040867|NCT04492852|Experimental|Interventional Arm 1|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
11040868|NCT04492852|Active Comparator|Interventional Arm 2|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
11040869|NCT04492839|Experimental|Intestial adsorbent arm|This is a single arm study, all participants will receive the class IIa intestinal adsorbent medical device
11040870|NCT04492826||Infected patients|patients with bone flap surgeries
11040871|NCT04492813|Experimental|Obese patients|Severe and morbidly obese patients (35²≤BMI <55)
11040872|NCT04492813|Active Comparator|Non Obese patients|Patients with normal weight or slightly overweight (19 <BMI <30).
11040873|NCT04492800|Other|Paxman Scalp Cooling Device|Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
11040874|NCT04492787|Experimental|Changkang Granules|Changkang Granules
11040875|NCT04492787|Placebo Comparator|Changkang Placebo Granules|Changkang Placebo Granules
11040876|NCT04492774|Experimental|GOLDIC serum|Epidural ultrasound guided injections
11040877|NCT04492774|Active Comparator|Steroid|Epidural ultrasound guided injections
11040878|NCT04492774|Active Comparator|Manual therapy|veno-lymphatic spinal drainage
11040879|NCT04492748|Experimental|Collagen and PRP injections|Ultrasound guided injections
11040880|NCT04492748|Active Comparator|Collagen injections|Ultrasound guided injections
11040881|NCT04492748|Active Comparator|PRP injections|Ultrasound guided injections
11040882|NCT04492722|Experimental|AZD5718 Dose 1 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 1 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
11040883|NCT04492722|Experimental|AZD5718 Dose 2 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 2 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
11040884|NCT04492722|Experimental|AZD5718 Dose 3 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 3 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
11040885|NCT04492722|Placebo Comparator|Placebo + Dapagliflozin 10 mg|Participants will receive once daily oral dose of placebo matched to AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
11040886|NCT04492709|Experimental|Treatment|The subjects will receive oral midazolam solution of 2 mg as a single dose on 2 occasions, 6 days apart (Days 1 and 7). The first dose will be prior to dosing with oral AZD5718 tablet and the second dose after five administrations of AZD5718 under fasted conditions.
11040887|NCT04492696|Active Comparator|Crashcourse|"CC uses an approach to providing concussion education informed by user-centered formative design research studies. The program features an interactive choose your own adventure approach to navigate the learner through the content, and is guided by near-peer Division I collegiate football athletes"
11040888|NCT04492696|Active Comparator|CDC Video|CDC-Vi is an online learning module developed by the CDC and the National Federation of State High School Associations Learning Center. Learners progress through the curriculum sequentially completing each unit before proceeding to the next. The primary narrator of CDC-Vi is Dr. Mick Koester, Chair of the NFHS Sports Medicine Advisory Committee
11040889|NCT04492696|Active Comparator|CDC Written|"CDC-Wr consists of educational PDFs available for download from the CDC website, as part of the CDC's Heads Up brain injury awareness initiative. The PDFs used for the CDC-Wr condition were specific to high school athlete concussion education"
11040890|NCT04492683|Experimental|Disease group|One active patch and one control patch applied to subjects with clinical symptoms suggestive of non-IgE mediated CMA
11040891|NCT04492683|Experimental|Control group|One active patch and one control patch applied to subjects without any history of allergic disease
11040892|NCT04492670|Experimental|Tui-na and oral Chinese medicine|8 sessions of 20 minutes Tui-na for 4 weeks and take study medication (Herbal granules) twice daily concomitantly for 4weeks
11040893|NCT04492670|Other|Tui-na|8 sessions of 20 minutes Tui-na for 4 weeks
11040894|NCT04492644||elderly inpatients|Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.
11040895|NCT04492631|Experimental|Probiotic|Powdered probiotic with a carrier.
11040896|NCT04492631|Placebo Comparator|Placebo|Carrier only.
11040897|NCT04492618|Experimental|Necrobiosis Lipoidica|Adults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
11040898|NCT04492605|Placebo Comparator|Placebo|Placebo
11040899|NCT04492605|Experimental|TCI378 Probiotics|TCI378 Probiotics
11040900|NCT04492605|Experimental|TCI507 Probiotics|TCI507 Probiotics
11040901|NCT04492592|Experimental|Workshop Only|2 session weekend face:face workshop for adolescent-mother pairs
11040902|NCT04492592|Experimental|Workshop + SMS/Texting|2 session weekend face:face workshop for adolescent-mother pairs followed by 8 weeks of supplementary text messages (NOTE: there was no 'SMS/texting-only' arm of this study)
11040903|NCT04492592|No Intervention|Control|No intervention provided.
11040967|NCT04492150|Experimental|study group|women who will receive 250 mL/hour of dextrose 5% with normal saline in a 1:1 ratio.
11040906|NCT04492553|Experimental|Testogel|All patients will be treated with Testogel. Starting dose is 1 sachet of gel daily applied to the skin of arms, thighs or abdomen. Dose adjustments are made after serum-levels of testosterone. All patients will be treated for a total of 52 weeks, unless they exit the study early because of side-effects or other reasons.
11040907|NCT04492540|Other|aerobic exercises and diet recommendations|the aerobic exercises in form of treadmill training intensity of exercises moderate intensity, target heart rate (THR) will be 50-60% of heart maximum (HR MAX), time of session 40 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
11040908|NCT04492540|Other|diet recommendations|the control group will receive diet recommendations for 12 weeks
11040909|NCT04492527|Experimental|Telehealth coaching sessions|Receives the Telehealth-delivered coaching sessions.
11040910|NCT04492514|Experimental|Mavrilimumab|Mavrilimumab treatment infusion
11040911|NCT04492514|Placebo Comparator|Placebo|Placebo infusion
11040912|NCT04492501|No Intervention|Supportive Arm|As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 < 80mmHg) and corticosteroids. All patients of Cytokine release storm (CRS) received either Methylprednisolone 1 mg/kg or Dexamethasone 6-12mg/day irrespective of disease severity.
11040913|NCT04492501|Experimental|TPE arm|addition to standard care TPE will be performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access will be achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume will be calculated as per Nadler's formula. Anticoagulant acid dextrose ratio will be 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation will be monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume will be removed during each procedure. Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures will be performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE will be continued till recovery.
11040914|NCT04492501|Experimental|TPE in combination with other investigational treatments|During TPE, Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively plus 200-400 ml of convalescent plasma. A predefined number of patients will also receive mesenchymal stem cell therapy and/or Remdesivir
11040915|NCT04492501|Experimental|Either alone or combination of MSC, Remdesivir and Tocilizumab|A predefined number of patients will receive either alone Tocilizumab, Remdesivir and Mesenchymal stem cell therapy or their combination
11040916|NCT04492488|Experimental|Solid Tumors|Phase I Dose Escalation: MRG002 will be administrated by an IV infusion of escalating doses (starting dose of 2.2 mg/kg, followed by 2.6 mg/kg, 3.0 mg/kg) on Day 1 of every 3 weeks (21-day cycle).
11040917|NCT04492488|Experimental|Locally Advanced or Metastatic Gastric/GEJ Cancer|MRG002 will be administrated by an IV infusion on Day 1 of every 3 weeks (21-day cycle).
11040918|NCT04492475|Experimental|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
11040919|NCT04492475|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
11040920|NCT04492462|Experimental|Formal Physical Therapy|
11040921|NCT04492462|Experimental|Self-directed Physical Therapy|
11040922|NCT04492449||Obese pregnants group|Obese pregnants exposure of coronavirus infection.
11040923|NCT04492449||Normal pregnants group|Normal pregnants exposure of coronavirus infection.
11040924|NCT04492449||children with congenital malformations|Child with congenital malformations
11040925|NCT04492449||children without congenital malformations|Child without congenital malformations
11040926|NCT04492436|Experimental|Low Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
11040927|NCT04492436|Experimental|High Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
11040928|NCT04492436|Placebo Comparator|Placebo|Reconstituted lyophilized placebo with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
11040929|NCT04492423||Prasugrel|Patients taking prasugrel
11040930|NCT04492423||Ticagrelor|Patients taking ticagrelor
11040931|NCT04492410|Experimental|Experimental arm|screening using a rapid serological test with a drop of blood from a finger prick.
11040932|NCT04492397|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
11040933|NCT04492397|Active Comparator|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
11040934|NCT04492384||inpatients|Patients treated from COVID-19 in hospital
11040935|NCT04492384||outpatients|Patients treated from COVID-19 at home
11040936|NCT04492358|Experimental|colchicine + prednisone|Prednisone should be administered for 3 consecutive days (60 mg/d) together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function) for 3 days and maintained for 14 days in total (0.5 mg/d).
11040937|NCT04492358|Active Comparator|Standard treatment|The standard treatment used in each site will be administered to the patients assigned to the control group.
11040938|NCT04492345|Experimental|Experimental|Patient with conventional rehabilitation session and isokinetic reeducation during 7 weeks
11040939|NCT04492345|Other|Control|Patient with conventional rehabilitation session during 7 weeks
11040968|NCT04492150|Active Comparator|control group|women who will receive 250 mL/hour of normal saline for the whole duration of induction
11040940|NCT04492332|Sham Comparator|normal controls with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
11040941|NCT04492332|Sham Comparator|normal controls without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
11040942|NCT04492332|Active Comparator|BTSS patients with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
11040943|NCT04492332|Active Comparator|BTSS patients without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
11040944|NCT04492319|Active Comparator|cotrol group|• Group (C) The patients will be receive 9.5 ml Levobupivacaine 0.5% plus 0.5 ml 0.9 normal saline in each side . a total volume of 20 ml 19 ml Levobupivacaine 0.5% plus 1 ml of normal saline
11040945|NCT04492319|Active Comparator|neostigmine group|Group N: The patients will be receive 9,5 ml Levobupivacaine 0.5% plus neostigmine 250 μg in each side . a total volume of 20 ml 19 ml ml Levobupivacaine 0.5% plus neostigmine 500μg in 1ml of normal saline .
11040946|NCT04492306|Active Comparator|3M single bond, etch and rinse adhesive|"O.I. will clean the labial surface of tooth with polishing paste and brush Roughening of the surface may be needed by diamond point The tooth will be isolated by rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 10 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist.
~Apply 2 to 3 consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Supreme, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 40 s. Light curing of all resin materials was performed using a LED device (Bluephase 20i, Ivoclare Vivadent, Schaan, Liechtenstein) delivering 1100 mW/cm2."
11040947|NCT04492306|Experimental|DMSO pre-treatment before 3M single bond application|The same steps of the comparator group with additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 1% DMSO/H2O solutions on etched-dentin followed by blot drying until paper filters no longer absorbed liquids from the bonding surface by capillarity then apply adhesive.
11040948|NCT04492293|Experimental|ICP-192|ICP-192
11040949|NCT04492280|Active Comparator|1. Group H|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®, E.I.P.I.co. under license of Pfizer) at dose 50mg every 6 hours by Intra venous route.
11040950|NCT04492280|Active Comparator|2. Group HF|These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®) at dose of 50mg every 6 hours by Intra venous route and Fludrocortisone (Cortilon®, Amoun) 50 Microgram once daily by nasogastric tube for one week
11040951|NCT04492280|Placebo Comparator|3. Group C|These patients will receive standard therapy for sepsis.
11040952|NCT04492254|Experimental|Enoxaparin|(40 mg o/d if < 100 kg, 40 mg b/d if ≥ 100 kg)
11040953|NCT04492254|No Intervention|Current standard of care (no enoxaparin)|Standard of care
11040954|NCT04492241|Experimental|Study Arm|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
11040955|NCT04492241|Placebo Comparator|Control Arm|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
11040956|NCT04492228|Experimental|Ketogenic diet group|patients with COVID-19 feeding with a ketogenic diet (4.1 formula)
11040957|NCT04492228|No Intervention|Standard diet group|patients with COVID-19 feeding with a standard diet
11040958|NCT04492215|Experimental|Physicians trained in motivational interviewing|Patients followed by general practitioners trained in motivational interviewing
11040959|NCT04492215|No Intervention|Physicians did not trainned in motivational interviewing|Patients followed by general practitioners who did not receive motivational interviewing.
11040960|NCT04492202||First group|Physiotherapists will be included in this group.
11040961|NCT04492202||Second group|Doctors will be included in this group.
11040962|NCT04492202||Third group|Nurses will be included in this group.
11040963|NCT04492202||Fourth group|Other health professionals will be included in this group.
11040964|NCT04492176|Experimental|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%，ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.
11040965|NCT04492176|No Intervention|before treatment|the patient did not receive laser treatment
11040966|NCT04492163|Experimental|Experimental: TTFields|Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays.
11040970|NCT04492137|No Intervention|Standard cannulation techniques group|Patients submitted to standard cannulation techniques in a consecutive fashion by an expert endoscopist
11040971|NCT04492111|Experimental|X-space group|Each patient of the experimental group will receive one X-space implant.
11040972|NCT04492111|Active Comparator|2P group|Each patient of the control group will receive one 2P implant. Bone System Cylindric implants. Surface Ecotek.
11040973|NCT04492098||study group|women with spontaneous miscarriage
11040974|NCT04492085||Primary hospital or clinics|
11040975|NCT04492085||Secondary hospital|
11040976|NCT04492085||Tertiary hospital|
11040977|NCT04492072|Experimental|Oxytocin with Mechanical Dilation|"If the patient is randomized to Cook Balloon and Oxytocin - The balloon inflated to 60cc will be placed and oxytocin 2 mu/min will be initiated, and increased incrementally by 2mu/min every 30 minutes. If the cook cannot be placed initially, it will be reattempted and placed within 6 hours of oxytocin starting. The Cook catheter will remain in place until spontaneously expelled, or if not, after 12 hours of placement.
~If a Cook Balloon is not available, a Foley catheter can be used in its place as alternate and equivalent form of mechanical dilation."
11040978|NCT04492072|Active Comparator|Misoprostol with Mechanical Dilation|If the patient is randomized to Misoprostol and Cook balloon - she will be given 25mcg of misoprostol orally or buccal and a Cook Balloon inflated to 60cc will be placed. She will subsequently receive 50mcg oral or buccal misoprostol every 4 hours up to 4 doses. If regular contractions occur (three or more contractions in a 10-minute period), the patient will be switched to Oxytocin 2 mu/min, and increased incrementally by 2mu/min every 30 minutes. If the cook balloon cannot be placed initially, it will be reattempted and placed within 6 hours of induction start. The Cook catheter will remain in place until spontaneously expelled, or at the fourth misoprostol administration. At this point, oxytocin will be started if not already initiated and artificial rupture of membranes will occur
11040979|NCT04492059|Experimental|Blood flow restriction augmented physical therapy|The group will undergo traditional physical therapy with the augment of blood flow restriction therapy under the supervision of trained physical therapists.
11040980|NCT04492059|Active Comparator|Traditional physical therapy|The group will undergo traditional physical therapy without the augment of blood flow restriction therapy under the supervision of trained physical therapists.
11040981|NCT04492046||Complex Decongestive physiotherapy|All participants included in the study were included in a treatment protocol consisting of Complex Decongestive physiotherapy.
11040982|NCT04492033|Experimental|Paclitaxel|
11040983|NCT04492033|Experimental|Irinotecan|
11040984|NCT04492020|Experimental|Treatment Sequence A|Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
11040985|NCT04492020|Experimental|Treatment Sequence B|Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
11040986|NCT04492007|Experimental|PRISMS|In addition to usual care, participants assigned to this arm will have access to our Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) program.
11040987|NCT04492007|No Intervention|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
11040988|NCT04491994|No Intervention|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
11040989|NCT04491994|Experimental|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
11040990|NCT04491981|Experimental|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using a high viscosity glass ionomer cement (RIVA Self Cure - SDI)
11040991|NCT04491981|Experimental|Composite resin|Repair of restorations in primary molars using a composite resin (Filtek Bulk Fill- 3M ESPE)
11040992|NCT04491968|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
11040993|NCT04491968|Other|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
11040994|NCT04491955|Experimental|1/Arm 1|CEA/ MUC1 Vaccines + M7824 + N-803 (Triple Therapy).
11040995|NCT04491955|Experimental|2/Arm 2A|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); dose escalation of NHSIL12.
11040996|NCT04491955|Experimental|3/Arm 2B|CEA/ MUC1 Vaccines + M7824 + N-803 + NHSIL12 (Quadruple Therapy); fixed dose of NHSIL12.
11040997|NCT04491942|Experimental|Arm I (cisplatin, BAY 1895344)|Patients receive cisplatin IV over 1-2 hours on day 1, and BAY 1895344 PO BID on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11040998|NCT04491942|Experimental|Arm II (cisplatin, gemcitabine, BAY 1895344)|Patients receive cisplatin IV over 1-2 hours on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and BAY 1895344 PO BID on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11040999|NCT04491916|Experimental|Iron Treatment|Treatment with iron sucrose with orginal guideline from ferritin>500ng/ml, or TSAT>20% to ferritin>800ng/ml, or TSAT>50%.
11041000|NCT04491903|Experimental|REBOA|
11041003|NCT04491877|Experimental|Cohort 2 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
11041004|NCT04491877|Placebo Comparator|Cohort 2 (Placebo)|2 administrations of placebo on Day 0 and Day 56
11041005|NCT04491877|Experimental|Cohort 3 (RSV vaccine formulation 2)|1 administration of RSV vaccine formulation 2 on Day 0
11041006|NCT04491877|Placebo Comparator|Cohort 3 (Placebo)|1 administration of placebo on Day 0
11041007|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
11041008|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 2)|2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56
11041009|NCT04491877|Placebo Comparator|Cohort 4 (Placebo)|2 administrations of placebo on Day 0 and Day 56
11041010|NCT04491851|Experimental|LM3 group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
11041011|NCT04491851|Experimental|NODAGA group|In this arm, patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
11041012|NCT04491838|Experimental|Process A|Randomized 1:1
11041013|NCT04491838|Experimental|Process B|Randomized 1:1
11041014|NCT04491825||Mycosis fungoides (MF)|
11041015|NCT04491825||Eczema (Atopic Dermatitis)|
11041016|NCT04491825||Chronic Plaque-Psoriasis|
11041017|NCT04491825||Healthy Control Skin|
11041018|NCT04491812|Experimental|Kinesiotaping|kinesiotaping of the triceps muscle applied to the study group alongside the physical therapy program
11041019|NCT04491812|Placebo Comparator|physical therapy program|the control group recieved only the physical therapy program
11041020|NCT04491799||Nosocomial diarrhea|Patients who are hospitalized and develop diarrhea after 72 hours of hospitalization.
11041021|NCT04491786|Experimental|GAPA|Participants will treated with preoperative 600 mg of gabapentin plus nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
11041022|NCT04491786|No Intervention|Non-GAPA|Participants will treated with nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
11041023|NCT04491773||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for more than 6 months
11041024|NCT04491773||Control Group|Healthy controls without previous surgery of radical prostatectomy.
11041025|NCT04491760|Experimental|Inspiratory muscle training|Inspiratory muscle training (IMT) will be perform for 15 minutes each time, twice a day, training every day from 12h to 24h after primary percutaneous coronary intervention (PCI) to 30 days since randomized.
11041026|NCT04491760|No Intervention|Control group|Participants will receive standard care according to the current guideline and clinical practice after primary PCI.
11041027|NCT04491734|Other|Tolerability Arm|Single arm study of active study product
11041028|NCT04491721||Rituximab Biosimilar HLX01 in Combination With CHOP|Rituximab Biosimilar HLX01 in Combination With CHOP,in Previously Untreated Subjects With CD20+ DLBCL.
11041029|NCT04491721||MabThera in Combination With CHOP|MabThera in Combination With CHOP，in Previously Untreated Subjects With CD20+ DLBCL.
11041030|NCT04491708|Experimental|Apparatus Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
11041031|NCT04491708|Experimental|Mat Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
11041032|NCT04491695|Experimental|Tirofiban+Oral antiplatelet therapy|Patients will receive Tirofiban in the first 72 hours and bridge to oral antiplatelet therapy thereafter.
11041033|NCT04491695|Active Comparator|Oral antiplatelet therapy|Patients will receive oral antiplatelet therapy alone.
11041034|NCT04491682|Active Comparator|MA alone|"Patients will receive MA 160 mg by mouth daily for at least 6 months.Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.
~Due to personal reasons, it may not be possible to accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
11041035|NCT04491682|Experimental|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months.Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.
~Due to personal reasons, it may not be possible to accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
11041036|NCT04491656|Active Comparator|7 minutes group|surgeries performed with this group would wait 7 minutes after lidocaine+epinephrine injection prior to skin incision
11041037|NCT04491656|Active Comparator|30 minutes group|surgeries performed with this group would wait 30 minutes after lidocaine+epinephrine injection prior to skin incision
11041144|NCT04490837||COVID-19 positive|Patients with clinical, radiological and/or PCR positive for COVID-19 infection
11058338|NCT04369391|Placebo Comparator|Placebo|matched placebo
11041038|NCT04491643|Experimental|MA + Rosuvastatin|"Patients will receive MA 160 mg and rosuvastatin 10 mg by mouth daily for at least 6 months. Then every 3 months, hysteroscopy will be used to evaluate the endometrial condition, and findings will be recorded.
~Due to personal reasons, patients may not accept hysteroscopic evaluation every three months, then the longest duration will be 8 months."
11041039|NCT04491630|Active Comparator|Self-Hypnosis (SH)|
11041040|NCT04491630|Active Comparator|Mindfulness meditation (MM)|
11041041|NCT04491630|Active Comparator|Christian prayer (CP)|
11041042|NCT04491630|No Intervention|Control condition (CN)|Participants in the CN condition will not be instructed to use any particular coping strategy to cope with the painful stimulation provided by the Cold Pressor Arm Wrap. Participants in the CN condition will listen to a 20-minute natural history audio recording. The option for this recording is supported by: (a) previous research showing that individuals who were asked to listen to it found it to be a neutral, yet relaxing, passage; (b) the use of this passage as an effective control condition in previous studies.
11041043|NCT04491617|Active Comparator|Standard Opioid Protocol (Control)|Standard postoperative medications (opioids and non-opioids) are prescribed upon discharge after surgery
11041044|NCT04491617|Experimental|Restrictive Opioid Protocol (Intervention)|Only non-opioid analgesics (i.e. ibuprofen and acetaminophen) are prescribed upon discharge after surgery. Patients are allowed to request an opioid prescription if they so desire
11041045|NCT04491604|Placebo Comparator|Placebo|Matching masked inactive topical gel
11041046|NCT04491604|Active Comparator|B-VEC-03|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
11041047|NCT04491591|Experimental|BREASTChoice|"After consent, the participant will be randomized
~Depending on the clinic work-flow, the patient will be sent the link to the BREASTChoice tool by email or MyChart message
~1) prior to their visit with the surgeon;
~2) at the time of their visit with the surgeon;
~3) after the surgeon appointment
~Will receive an online survey to complete after viewing the BREASTChoice tool assessing socio-demographics, knowledge, health literacy, decisional conflict, patient engagement, health-related quality of life, preferred decision role, and usability of the website.
~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
11041048|NCT04491591|Active Comparator|Attention Control Website|"After consent, the participant will be randomized
~Depending on the clinic work-flow, the patient will be sent the link to the website by email or MyChart message
~1) prior to their visit with the surgeon;
~2) at the time of their visit with the surgeon;
~3) after the surgeon appointment
~Will receive an online survey to complete after viewing the website assessing socio-demographics, knowledge, preferences, health literacy, decisional conflict, measure of patient engagement, health-related quality of life, preferred decision role, consult time, and usability of the website.
~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
11041049|NCT04491591|Experimental|Clinicians|"Will receive a brief virtual training on how BREASTChoice functions and the features, including placement of the patient tool summary in the electronic health record
~Will complete pre-post trial survey about shared decision making"
11041050|NCT04491578|Experimental|Advance care planning programme|
11041051|NCT04491578|Placebo Comparator|Attention control|
11041052|NCT04491565|No Intervention|standard education|
11041053|NCT04491565|Active Comparator|educational video|
11041054|NCT04491552||Patients monitored with TruGraf and TRAC testing|Subjects will have TruGraf and TRAC testing at study enrollment (Baseline) and thereafter every 3 months. In addition subjects will have TRAC testing at any time there is a suspicion of acute rejection.
11041055|NCT04491539|No Intervention|Adaptation|Site will inform the adaptation of the FRESH intervention.
11041056|NCT04491539|Experimental|First Receipt|Site will received the adapted FRESH intervention first.
11041057|NCT04491539|Experimental|Second Receipt|Site will received the adapted FRESH intervention second.
11041058|NCT04491526|Experimental|Tamsulosin Arm|p.o.
11041059|NCT04491526|Placebo Comparator|Placebo Arm|p.o.
11041060|NCT04491513||Overall cohort|Pateints that underwent both CTA and CAG in the work-up for TAVI
11041061|NCT04491500||study group|This is a self-control study. Subjects who plan togo to 4000m altitude to work for two weeks will be enrolled. And before and after they arrive high altitude, they will have visual acuity, OCTA, and intraocular pressure; blood pressure, blood oxygen measurement.
11041062|NCT04491487|Experimental|Experimental group|
11041063|NCT04491487|No Intervention|Control group|
11041064|NCT04491474|Active Comparator|Group 1|bilateral great occipital nerve blockade and bilateral isotonic injection into the supraorbital region.
11041065|NCT04491474|Active Comparator|Group 2|bilateral supraorbital nerve blockade and bilateral isotonic injection into the great occipital nerve region
11041066|NCT04491474|Active Comparator|Group 3|bilateral great occipital nerve blockade and bilateral supraorbital nerve blockade
11041067|NCT04491474|Sham Comparator|Group 4|saline injection to bilateral great occipital nerve and supraorbital nerve region
11041068|NCT04491461|Active Comparator|Herbal tea blend|1 cup of herbal tea blend containing Rosehip and other berry extracts.
11041069|NCT04491461|Sham Comparator|Warm water|1 cup of warm water.
11041070|NCT04491435|Experimental|Interventional|4 weeks use of mucin-based saliva substitute
11041071|NCT04491435|Placebo Comparator|Control|4 weeks use of xylitol-based mouthwash
11041072|NCT04491422|Active Comparator|Integrated Next Steps Counseling using poi|At quarterly visits, intervention arm participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine TFV levels <1000 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing.
11041073|NCT04491422|No Intervention|Standard adherence counseling|Control arm participants will receive standard adherence counseling.
11041074|NCT04491409||Observational (standard of care, medical chart review)|Patients undergo standard of care treatment and their medical records are reviewed at 30 days and at 1 year after surgery.
11041075|NCT04491396|Other|GYYB|This is a single-arm pre-post design.
11041076|NCT04491383|Experimental|Tocovid Suprabio|200mg, twice 1 day, 12 months
11041078|NCT04491370|Experimental|Polatuzumab vedotin|"Evaluable patients for safety Patients receiving 1 dose of Polatuzumab Vedotin will be evaluable for safety.
~Evaluable patients for response Only in patients who are in PR or SD prior to PV and received a minimum of 3 doses will be evaluable.
~Evaluable patients for EFS, PFS, OS All patients who have completed conditioning and autoSCT will be evaluable for EFS, PFS, and OS."
11041079|NCT04491357|Experimental|Intervention arm|Intervention arm will receive 1 ampoule of intravenous calcium gluconate within 4 hours of skin closure post total thyroidectomy
11041080|NCT04491357|Placebo Comparator|Placebo arm|Placebo arm will receive 100ml of normal saline within 4 hours of skin closure post total thyroidectomy
11041081|NCT04491344||Overweight and obese children|Overweight and obese children and adolescents visiting the adiposity outpatient clinic.
11041082|NCT04491331||Non-anesthetized volunteers|Hemodynamic parameters will be measured in supine position. Volunteers will be turned into prone position. After a five-minute stabilization phase will be monitored CI, MAP, heart rate (HR), stroke volume variation SVV, systemic vascular resistance index (SVRI) by non-invasive measurements using a ClearSight (Edwards) in two prone positions (lying on support system allowing a free abdomen and then lying flat without any device). Furthermore, the width of the inferior vena cava and vena jugularis interna, vena saphena and vena cephalica will be measured by ultrasound. The measurement will be performed in inspiration and in expiration phase.
11041083|NCT04491318||Experimental group|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
11041084|NCT04491305||Women with pathohistological confirmation|Women aged between 18 and 50 with surgically proven endometriosis.
11041085|NCT04491292||Observational (questionnaire)|Participants complete 2 online questionnaires over 10 minutes each at baseline and at 3 months after the pandemic ends.
11041086|NCT04491279|Experimental|Neuropilates class.|"Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (chartered physiotherapist and pilates instructor).
~Pitched at a beginner level focused on the core elements of neuropilates and progressing week on week as appropriate.
~Includes a warm up, cool down and neuropilates exercises in line with the teaching of APPI (the Australian Physiotherapy and Pilates Institute). Exercises may be completed on mats, chairs, gym balls, plinths and in standing, depending upon the ability level of the participant.
~Two classes running with 8 participants in each based on their initial assessment into the higher and lower functionally independent participants.
~Participants will be given a home exercise programme weekly based on exercises from the class and will be asked to complete these independently at home twice more during the week and to keep a training diary."
11041087|NCT04491279|Active Comparator|Generalised exercise class.|"Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility.
~Exercises will be more functional and generic than in the pilates classes and will be conducted in a circuit style, including mobility practice, sit to stand practice, cycling with the motomed, and general upper and lower limb strengthening. Warm up and cool downs will also be a feature of this class.
~Participants will be also be given a home exercise programme based on exercises completed in the class and will be asked to complete these exercises twice more during the week and to keep a training diary."
11041088|NCT04491266|Experimental|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
11041089|NCT04491266|Placebo Comparator|placebo|maltodextrins
11041090|NCT04491253|Experimental|Intervention|The intervention is defined as informational support (transmission of information for health care, knowledge of DM2, nutrition, physical activity), instrumental (physical care) and emotional (management of anxiety, empowerment and decision-making).
11041091|NCT04491253|No Intervention|Control|Control group will receive usual care treatment at the diabetes mellitus nursing consultation in primary care.
11041092|NCT04491240|Experimental|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
11041093|NCT04491240|Experimental|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
11041094|NCT04491240|Placebo Comparator|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
11041095|NCT04491227||Kidney disease in COVID-19|"Chronic Kidney Disease (CKD): Known diagnosis of chronic kidney disease; prior evidence of markers of kidney damage for 3 months (microalbuminuria, proteinuria >300mg/24 hrs or abnormalities in imaging tests) or the presence of glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months calculated with CKD-EPI equation, with or without other signs of kidney damage as described above.
~ESKD: Patients that are dialysis dependent.
~Suspected AKI: Oliguria (<200 mL/6 hours) and any AKI-related clinical signs or symptoms (see table 1) or urinalysis/dipstick abnormality. All suspected AKI cases must be confirmed prior to enrollment.
~Confirmed AKI: Meeting of at least one of the modified KDIGO Criteria
~Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours
~Increase or decrease in serum creatinine > 50% from reference in 7 days
~Urine output < 400 ml/day
~Functioning Kidney transplant:"
11041096|NCT04491188|Experimental|Probiotic|1 x10-9 CFU Bacillus subtilis DE111 was consumed daily for 28-days
11041097|NCT04491188|Placebo Comparator|Placebo|Maltodextrin placebo was consumed for 28-days
11041098|NCT04491175|Active Comparator|DuoTherm|A low back pain relief device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice a day for 20 minutes.
11041099|NCT04491175|Sham Comparator|Posture Plate|a sham placebo sculpted metal plate attached with a plain belt, without the pocket or potential for heat, cold, or pressure. No motors are attached to this unit, so while support is possible there are no active pain relief modalities. Patients will be instructed to use the Posture Plate twice a day for 20 minutes.
11041100|NCT04491162|Active Comparator|Conventional gait therapy|Conventional gait therapy.
11041101|NCT04491162|Experimental|BWST training|Conventional gait therapy + Body weight support treadmill training
11041102|NCT04491149|Experimental|women using virtual glass during amniocentesis/foeticide|
11041103|NCT04491149|No Intervention|women undergoing amniocentesis/foeticide|
11041145|NCT04490837||Normal|Normal human serum from blood donnors before COVID-19 pandemia
11041146|NCT04490837||Pathological controls|Patients with other positive virological serologies
11041104|NCT04491136|Experimental|ACEI/ARB treatment in 6 months/ARNI treatment in next 6 months|"Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers treatment in the first 6 months
~Angiotensin receptor neprilysin inhibitor treatment in next 6 months"
11041105|NCT04491110|Experimental|Experimental: Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
11041106|NCT04491110|Sham Comparator|Sham Comparator: Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
11041107|NCT04491097|Experimental|Experimental: Panavia V5 resin cement|Resin cement with non-MDP monomer
11041108|NCT04491097|Active Comparator|Experimental: Panavia F2.0 resin cement|Resin cement with MDP monomer
11041109|NCT04491084|Experimental|FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140), and SBRT|"Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease. Subjects on Arm 1 with extensive disease will initially receive SBRT to a single site of disease but may receive additional cycles of FLT3 ligand, anti-CD40 antibody, and SBRT at later time points."
11041110|NCT04491084|Active Comparator|Standard care|Subjects on either study arm with limited disease will receive SBRT to all evident sites of active disease.Subjects on Arm 2 with extensive disease are expected to receive some form of standard systemic therapy (e.g., docetaxel). Subjects on Arm 2 with limited disease may also receive standard systemic therapy following completion of SBRT to all sites of evident disease, at the discretion of the treating physicians.
11041111|NCT04491071||Volunteers|volunteers over 18 years of age
11041112|NCT04491058||Carpal tunnel syndrome patients|
11041113|NCT04491058||Healthy|
11041114|NCT04491045|Experimental|Community-Engaged Learning Collaborative (CELC)|The CELC arm is an integration of community engagement and learning collaborative approach which involves province-wide collaborative meetings for commune health stations (6 CHSs for each province) randomized into the CELC implementation condition. CELC CHSs will meet monthly for 6-9 months and use continuous quality improvement process, track implementation goals, problem solve implementation barriers, and engage in cross-site learning. This will be in addition to enhanced supervision, workshops, and toolkit.
11041115|NCT04491045|Experimental|Enhanced Supervision (ES)|This is an evidence-based training approach which involves 6-9 months of ongoing group supervision support from psychiatric hospital mental health specialist (psychiatrist, psychiatric nurse, or psychologist) for each community health station randomized to the ES condition. Supervision approach is structured and involves observation of sessions, feedback on fidelity and quality. Supervision support will be provided biweekly initially and monthly after completion of one practice case. This is in addition to usual implementation condition (workshops, technical assistance, and evidence-based toolkit)
11041116|NCT04491045|Active Comparator|Usual Implementation (UI)|"Usual Implementation (UI) Control intervention that will be enhanced usual implementation and includes basic implementation and training supports for Multicomponent Collaborative Care for Depression program, which is an evidence-based stepped collaborative care intervention for integrating depression care into primary care settings. It consists of six components: routine screening, diagnostic assessment, psychoeducation, antidepressant medication, adherence management, behavior activation therapy.
~This implementation and training supports includes three 3-day workshop on collaborative care for depression (MCCD), limited technical assistance, and toolkit."
11041117|NCT04491032|Active Comparator|Low Volume|Caudal anesthesia will be performed with 0.8 ml/kg of the local anesthetic solution
11041118|NCT04491032|Active Comparator|High Volume|Caudal anesthesia will be performed with 1.25 ml/kg of the local anesthetic solution
11041119|NCT04491019|Experimental|Balance exercise group|Balance exercises will be carried out with a physiotherapist.
11041120|NCT04491019|Experimental|Strengthening exercise group|Strengthening exercises will be performed with a physiotherapist.
11041121|NCT04491006|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
11041122|NCT04491006|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
11041123|NCT04491006|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
11041124|NCT04490993|Experimental|APL-1202 treatment|
11041125|NCT04490993|Placebo Comparator|Placebo|
11041126|NCT04490980|Experimental|Observed group|
11041127|NCT04490980|No Intervention|Control group|
11041128|NCT04490967|Experimental|Silymarin and salicylic acid|There will be one group of patients, that will use salicylic acid peeling on the right side of the face and topical Silymarin cream on the left side
11041129|NCT04490954|Other|Patients examined with MRI/CT|
11041130|NCT04490954|Other|Patients examined with biological electrical impedance|
11041131|NCT04490941|Experimental|Intervention group|
11041132|NCT04490941|Other|Control group|
11041133|NCT04490928||complete revascularization|All patients who underwent complete myocardial revascularization
11041134|NCT04490928||incomplete revascularization|All patients who did not complete myocardial revascularization
11041135|NCT04490928||without revascularization|All patients who were not revascularized
11041136|NCT04490915|Experimental|Crinecerfont|Capsule, administered orally, twice daily for 24 weeks, followed by active treatment for 1 year.
11041137|NCT04490915|Placebo Comparator|Placebo|Capsule, administered orally, twice daily for 24 weeks, followed by active treatment for 1 year.
11041138|NCT04490902|Active Comparator|Single graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from single donors.
11041139|NCT04490902|Experimental|Dual graft corneal transplantation|Limbal transplantation combined with central penetrating keratoplasty from different donors.
11041140|NCT04490889||Patients with PGT indication|Patients undergo in vitro fertilization with PGT-A or for PGT-SR indication
11041141|NCT04490876||Retinal Detachment with PVR|Proliferative vitreoretinopathy (PVR), a major complication of rhegmatogenous retinal detachment (RRD), is an abnormal process whereby proliferative, contractile cellular membranes form in the vitreous and on both sides of the retina, resulting in tractional retinal detachment with fixed retinal folds. Patients with RD complicated by PVR will be included, and the proposed intervention will be performed.
11041142|NCT04490863|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
11041143|NCT04490850|Experimental|Participants|Blood sample
11041147|NCT04490824|Active Comparator|Treated|This Arm includes half of the total participants in the study. The results in this Arm will be compared to the results in the control participants and also with the known natural history of Covid-19 infections
11041148|NCT04490824|Placebo Comparator|Control|This Arm includes half of the total participants in the study. Participants will receive water without an elevated level of KELEA
11041149|NCT04490798||Lumbar back pain|Patients with lumbar back pain treated following the Acupuncture Treatment Clinic Pathway.
11041150|NCT04490798||Musculoskeletal pain|Patients with musculoskeletal pain treated following the Acupuncture Treatment Clinic Pathway.
11041151|NCT04490798||Cervicalgia|Patients with cervicalgia treated following the Acupuncture Treatment Clinic Pathway.
11041152|NCT04490798||Knee osteoarthritis|Patients with knee osteoarthritis treated following the Acupuncture Treatment Clinic Pathway.
11041153|NCT04490798||Headache|Patients with headache treated following the Acupuncture Treatment Clinic Pathway.
11041154|NCT04490798||Shoulder pain|Patients with shoulder pain treated following the Acupuncture Treatment Clinic Pathway.
11041155|NCT04490785|Experimental|patients under aortic surgery with CPB|Patients under aortic surgery with CPB will have MRI and postoperative dosage of released troponin
11041156|NCT04490772||Patients with Covid-19|COVID-19 patients presented with gastrointestinal manifestations
11041157|NCT04490759||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System
11041158|NCT04490746||active|patients with active tuberculosis
11041159|NCT04490746||latent|patients with latent tuberculosis infection
11041160|NCT04490746||negtive control|healthy volunteers
11041161|NCT04490733|Experimental|Experimental group|Participants in the experimental group will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
11041162|NCT04490733|No Intervention|Control group|Participants in control group will receive usual care.
11041163|NCT04490720|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
11041164|NCT04490720|Experimental|Buckwheat husk extract|consume 1 sachet per day for 2 months
11041165|NCT04490707|Experimental|Azacitidine plus Lenalidomide (AZA+LEN)|"Arm 1(AZA+LEN): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA combined with LEN: AZA 50mg/m² per day for days 1-5 and LEN 10mg per day orally for days 6-26 , every 28 days for up to 12 cycles or progression.
~AZA -Azacitidine, LEN- Lenalidomide"
11041166|NCT04490707|Experimental|Azacitidine(AZA)|"Arm 2 (AZA): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter maintenance therapy with AZA 50mg/m² per day for days 1-5, every 28 days for up to 12 cycles or progression.
~AZA -Azacitidine"
11041167|NCT04490707|No Intervention|Observation|Arm 3(Observation): Elderly or unfit for intensive therapy AML patients who had achieved CR after remission-induction and consolidation chemotherapy enter observation.
11041168|NCT04490694|Experimental|TACE Combined with Lenvatinib|
11041169|NCT04490681|Experimental|Ertugliflozin|Ertugliflozin 5mg
11041170|NCT04490681|Placebo Comparator|placebo|Placebo
11041171|NCT04490668||Human albumin support|Patients who received intravenous human albumin after gastric cancer surgery
11041172|NCT04490668||No human albumin support|Patients who did not receive intravenous human albumin after gastric cancer surgery
11041173|NCT04490655|Experimental|Active somatosensory training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that focuses on the retraining of both motor and somatosensory functions, for a maximum of one hour per session.
11041174|NCT04490655|Active Comparator|Motor-based training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that is purely motor based, for a maximum of one hour per session.
11041175|NCT04490642||Concomitant bladder and bowel Dysfunction|25 patients with concomitant bladder and bowel dysfunction.
11041176|NCT04490642||Those without concomitant bladder and bowel dysfunction|25 patients without concomitant bladder and bowel dysfunction.
11041177|NCT04490629|Other|DURAFORM|DURAFORM was used in repairing cerebral dura mater.
11041178|NCT04490629|Experimental|Lyoplant Onlay|Lyoplant Onlay was used in repairing cerebral dura mater.
11041179|NCT04490616|Experimental|RR-GR|MCI patients with social cognition deficits will receive 4 weeks of rTMS stimulation
11041180|NCT04490616|Other|SR-GR|MCI patients with social cognition deficits will receive 2 weeks of placebo treatment, followed by 2 weeks of real rTMS stimulation
11041181|NCT04490603|No Intervention|Conventional group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided in the same way as the conventional method of injecting drugs in Seoul National University Hospital Pain Center.
11041182|NCT04490603|Experimental|VR group|Drug is injected to epidural space for a total of 50 minutes. The drug injection is provided with virtual reality experience. Conditions are the same in both arms except for virtual reality experience.
11041183|NCT04490590|Experimental|Chidamide+ Etoposide capsule|"Chidamide: 30mg, twice a week(BIW), PO.
~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle. Patients receive the other treatment of chidamide and etoposide capsule, and those who have achieved PD(progressive disease) will give the other treatment."
11041184|NCT04490577|Experimental|Pilates training group|"In the Pilates group, the exercises were performed with Reformer® for eight weeks, twice in a week, one hour per day."
11041185|NCT04490577|Experimental|Whole-body vibration (WBV) group|"In the WBV group, the training was given Power Plate® for eight weeks, twice in a week, and 30 minutes in a day."
11041186|NCT04490577|No Intervention|Control group|The control group did not receive any training.
11041187|NCT04490564||HNSCC, NSCLC, melanoma Patients|
11041188|NCT04490564||Healthy volunteers|In case of healhty volunteers, only peripheral blood samples will be collected.
11041189|NCT04490551|Experimental|Intervention group|This group will be screened with the risk-based model. The input of the model will be gathered with the FIT, a validated questionnaire, and from data of the Dutch general population registry. The threshold of the model will be set at a calculated risk of 0.10. To comply with ethical guidelines, all participants in this group with a FIT result of >=15 mcg Hb/g faeces and a calculated risk of <0.10 will also be offered a colonoscopy.
11041190|NCT04490551|Active Comparator|Control group|This group will be screened with the FIT. The threshold of the FIT will be set at >= 15 mcg Hb/g faeces.
11041191|NCT04490538||Critically ill patients|Critically ill patients hospitalised at the intensive care unit indicated to echocardiographic examination.
11041192|NCT04490525|Experimental|Intervention|The intervention group will participate in the telerehabilitation program (please see detailed description of telerehabilitation program and technologies). The two steps in the telerehabilitation program last up to six months depending on how fast the titration of medicine in step one will be conducted. The intervention group will spend 5-10 minutes every day on monitoring themselves. Every month, an online questionnaire has to be filled in which will take up to 5 minutes. At enrolment, after titration of medicine, and the end of rehabilitation, the patient will fill in an online questionnaire. This will take 5 minutes each time. Selected patients and relatives will be asked if they wish to participate in interviews after participation in the trial. Each interview will last less than one hour. Number of interviews will be decided when data saturation has been achieved.
11041193|NCT04490525|No Intervention|Control|The control group will follow a conventional rehabilitation program (Egstrup et al 2015). The control subjects will participate in medicine titration for 1- 3 months and conventional rehabilitation for 3 months. The participation in the control group will last up to six months. The exact period depends on how fast the titration of medicine is conducted. At enrolment, after titration of medicine, and end of rehabilitation, the patient will fill in a questionnaire. This will take 5 minutes each time.
11041194|NCT04490512|Experimental|FluBHPVE6E7|Multiple administration of FluBHPVE6E7
11041195|NCT04490512|Placebo Comparator|Placebo|Multiple administration of buffer solution
11041196|NCT04490499|Experimental|HBVAXPRO™|Healthy children vaccinated approximately 9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).
11041197|NCT04490486|Experimental|Group 1: (UCMSCs)|Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.
11041198|NCT04490486|Placebo Comparator|Group 2: (Placebo)|Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3.
11041199|NCT04490473|Other|volunteer group|Only volunteer participants will be included in the research. Survey forms will be sent to individuals online. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
11041200|NCT04490460|Placebo Comparator|First 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. Double blind 50% Placebo capsules identical to those containing WB-0031 and 50% WB-0031
11041201|NCT04490460|Active Comparator|Second 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. All participants receiving WB-0031.
11041202|NCT04490447||Bronchiectasis|"Patient meets diagnose of bronchiectasis refering to BTS guideline 2010 or Consensus of Chinese experts on bronchiectasis 2012will be included."
11041203|NCT04490447||Healthy control|Healthy volunteers will be included.
11041204|NCT04490434|Experimental|Cohort 1, A (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
11041205|NCT04490434|Experimental|Cohort 1, B (DWP14012/Celecoxib)|Patients treated with DWP14012, Celecoxib will be enrolled. DDI will be evaluated.
11041206|NCT04490434|Experimental|Cohort 2, C (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
11041207|NCT04490434|Experimental|Cohort 2, D (DWP14012/Naproxen)|Patients treated with DWP14012, Naproxen will be enrolled. DDI will be evaluated.
11041208|NCT04490434|Experimental|Cohort 3, E (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
11041209|NCT04490434|Experimental|Cohort 3, F (DWP14012/Meloxicam)|Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
11041210|NCT04490421|Experimental|Experimental|Experimental:Carillizumab combined with Apatinib, Etoposide and Cisplatin
11041211|NCT04490408|Active Comparator|long surgical bypass|long surgical bypass for multilevel lower limb ischemia
11041212|NCT04490408|Experimental|Hybrid approach|surgical bypass and endovascular treatment for multilevel lower limb ischemia
11041213|NCT04490395|Experimental|Engage PA|
11041214|NCT04490395|Other|Treatment as usual plus fitness tracker|
11041215|NCT04490382|Experimental|Patients undergoing Neuromodulation|Patients, who have had a lower limb amputation and undergoing neuromodulation as part of standard of care.
11041216|NCT04490369||Group 1- short interval|Less than or equal to six minutes between receiving sedation and the start of the procedure
11041217|NCT04490369||Group 2- long interval|Greater than or equal to seven minutes between receiving sedation and the start of the procedure
11041218|NCT04490356|Experimental|Legacy Intervention|Older adults who have successfully completed a lifestyle intervention (lost at least 3% body weight and increased short physical performance battery (SPPB) score by 1 point or 6-minute walk test (6MWT) by 50 meters) will be enrolled in a tele-nutrition and tele-exercise intervention.
11041219|NCT04490317||Acute CO poisoning|A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
11041220|NCT04490304|Other|posterior soft tissue repair durability|
11041221|NCT04490278|Experimental|Patients with PICS|
11041222|NCT04490265|Experimental|Problem-Solving Treatment|Our PST is 12-weeks and teaches patients strategies to address real-life problems.20 Sessions are once a week for one hour except for the first session, which is two hours. The treatment has four main goals: 1. Safety planning; 2. Problem-orientation-addressing how patients approach problems; 3. Planful problem-solving or a logical approach to address problems; 4. Behavioral activation of daily activities. Patients are provided weekly worksheets on problem-solving and receive weekly assessment of emotional state and suicidal ideation monitoring.
11041248|NCT04490109|Experimental|B244 Suspension O.D. 20.0|Second arm of 192 subjects will receive a dose of B244 O.D. 20.0 suspension
11041249|NCT04490109|Placebo Comparator|Placebo|Third arm of 192 subjects will receive a vehicle dosing.
11041274|NCT04489953|Active Comparator|Clinical and Immunologic criteria|In the clinical and immunologic monitoring criteria was based on the 2010 WHO guidelines. Whereby children were monitored using clinical presentation and CD4 count to define treatment failure.
11041906|NCT04485689|Placebo Comparator|Placebo - ice|5x7 cm2 placebo patch - plus ice
11041223|NCT04490265|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was … ) in order to help identify experiences for discussion in session. Participants will be informed that the control condition is supportive and non-directive, and that providers will not engage in problem-solving. Providers will be taught to use reflective listening, clarification, empathy, and validation. The control consists of 12 weekly sessions delivered via telephone or video."
11041224|NCT04490252|No Intervention|Free diet|Free diet
11041225|NCT04490252|Experimental|FMD|Fasting mimetic diet for 5 days, next cycle after 25 days of free diet
11041226|NCT04490239|Experimental|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.
~Acute phase:
~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.
~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.
~Chronic phase:
~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
11041227|NCT04490226|Experimental|fasting, active|36 hours fasting, PAL 1.6
11041228|NCT04490226|Experimental|ketogenic diet, active|24 hours of ketogenic diet (liquid meals), PAL 1.6
11041229|NCT04490226|Experimental|exogeneous ketone bodies, active|24 hours of ketone body supplements (Beta-Hydroxybutyrate as Ca-Mg-salt) additional to a normal diet (liquid meals), PAL 1.6
11041230|NCT04490226|Experimental|fasting, inactive|36 hours fasting, PAL 1.3
11041231|NCT04490213||hydrofibre, Aquacel|Study participants were previously treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
11041232|NCT04490213||polyurethane foam, Allevyn|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
11041233|NCT04490213||porcine xenograft, Mediskin|Study participants were previolsuy treated on their donor sites with these CE-marked dressing products (RCT study published in 2014) and are now compared regarding scar outcome at the donor sites
11041234|NCT04490200|Experimental|Novel chitosan semi facial respirator (VESTA)|VESTA is a semi facial respirator that follows the same technical specifications of a N95 class PFF2 respirator. However, the VESTA respirator has nanoparticles in the filtering element, which is manufactured with a product of 50 gsm melt blown polypropylene-treated with an electrostatic charge. This filtering element deposits nanoparticles of polymeric biodegradable material known as chitosan. Chitosan can act as a surface for adsorption and viral inactivation.
11041235|NCT04490200|Active Comparator|Conventional N95 semi facial respirator|The N95 PFF2 respirators are manufactured from TNT as defined in ABNT NBR 15052: 2004 and in the resolution of ANVISA RDC No. 356. The filtering element is usually formed by a layer of thin polypropylene fibers arranged at random. This configuration influences the particles (which constitute aerosols) to move along an extensive and tortuous path in relation to their size; thus, increasing the probability of them coming into contact with the fibers and being retained. A number of mechanisms influence the interception of particles by the fibers of the filter element. In addition to the mechanical interception mechanisms, the presence of charges on the surface of the filter material can enhance the association of particles with its fibers and optimize the efficiency of the respirator.
11041236|NCT04490187|Experimental|Active tDCS stimulation|tDCS will be applied over the left motor cortex at 1 mA for 30 min. The current will be ramped up to 1 mA over 45-60 s, held for 30 min, and ramped down to 0 mA over 45-60 s.
11041237|NCT04490187|Sham Comparator|Sham tDCS stimulation|tDCS will be ramped up and held for only 60 s before it is slowly ramped down. This procedure, called the Fade-in-Short Stimulation-Fade out, has shown its reliability as an effective sham technique through making the same tolerability and transient scalp sensation as active stimulation in both adults (Ambrus 2012) and children (Ciechanski 2017).
11041238|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
11041239|NCT04490161|Experimental|Interventional|Subjects will receive reinstallation of CSF intravenously.
11041240|NCT04490161|No Intervention|Observational|Subjects will not receive study intervention; CSF will be sampled and analyzed in comparison to the Interventional arm,
11041241|NCT04490148|Active Comparator|remote PFT (rPFT) longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment.
11041242|NCT04490148|Experimental|remote PFT (rPFT) + Nurse Coaching longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment, and receive monthly coaching from an ALS nurse.
11041243|NCT04490135|Experimental|Carers group intervention|caregivers entered into the 8 week CARERS intervention (N=264) Group intervention, 8 x 2 hour sessions. Session 1-4 PST training, session 5-8 Simulation with standardized patients training Pre- post evaluations completed
11041244|NCT04490135|No Intervention|Wating list control|Caregivers waiting for entry into active arm of CARERS intervention.During this time usual care allowed with no other intervention. Study measures administered at intake and immediately prior to starting the CARERS group. (N=83)
11041245|NCT04490122||Inhalational|will receive inhalational anesthesia
11041246|NCT04490122||Total intravenous|will receive total intravenous anesthesia with propofol infusion(100-150 mcg/kg/min) and dexmedetomedine 0.3mcg/kg/h.
11041247|NCT04490109|Experimental|B244 Suspension O.D. 5.0|One arm of 192 Subjects will be receiving a dose of B244 O.D. 5.0 suspension
11041250|NCT04490096|Other|[11C]-PBR28 ALS|Neuroinflammatory pathways have been implicated in a variety of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), but the vast majority of this evidence is from animal or ex vivo human studies. In vivo measurement of the 18 kDa translocator protein (TSPO) has become possible with [11C]-PBR28 PET imaging. Briefly, TSPO expression is increased when microglial are activated. Cross-sectional studies have demonstrated that [11C]-PBR28 uptake is elevated in ALS compared to controls, is correlated with upper motor neuron severity, and that microglial activation is associated with more severe upper motor neuron disease and faster disease progression. We are only aware of a single 6-month study of 10 patients evaluating longitudinal change of [11C]-PBR28 in ALS. We hypothesize that we will observe increased [11C]-PBR28 uptake over a 6-month period in motor cortex and prefrontal cortex in ALS. This portion of the study will be performed at UPenn only.
11041251|NCT04490057|Experimental|12 wks NRT+CM / 12 wks NRT+CM|Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.
11041252|NCT04490057|Experimental|12 wks NRT+CM/ 12 wks VAR+CM|Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline combined with contingency management for second 12 weeks.
11041253|NCT04490057|Experimental|12 wks NRT+CM/12 wks NRT+CM plus|Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.
11041254|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT|Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.
11041255|NCT04490057|Experimental|12 wks NRT/ 12 wks VAR|Nicotine replacement therapy alone. Non-responders switch to varenicline alone for second 12 weeks.
11041256|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT+CM|Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.
11041257|NCT04490044|Active Comparator|1|Participants in Arm 1 will be posted the Under & Over study pack (1) and asked to complete the Under & Over tool daily for up to 30 minutes per day, 5 days per week for 3 months. They will be instructed to follow the instruction booklet and complete each pattern in the specific order described in the booklet.
11041258|NCT04490044|Active Comparator|2|Participants in Arm 2 will be posted the Under & Over study pack (2) and asked to complete the Under & Over tool daily for as long or short as they choose or are able to. They will be asked to complete 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to complete. They will also be encouraged to create their own patterns. These participants will have access to a section of the study website where they will be able to upload photographs of their patterns and see other participants' patterns over the 3-month period.
11041259|NCT04490044|Placebo Comparator|3|Participants in Arm 3 will be posted the Under & Over study pack (3). For the first three months of the study they will be asked to complete the c9HPT 5 days a week. After three months, they will be able to complete the Under & Over tool daily for as long or short as they choose. Similar to Arm 2, They will be asked to do this 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to
11041260|NCT04490031|No Intervention|Midazolam group|Standard sedation for ERCP in UKMMC
11041261|NCT04490031|Experimental|Ketamine group|
11041262|NCT04490018|Experimental|Group 1 (investigational group - sequential administration)|MenACYW conjugate vaccine on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
11041263|NCT04490018|Active Comparator|Group 2 (control group - sequential administration)|Nimenrix® on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
11041264|NCT04490018|Experimental|Group 3 (investigational group - concomitant administration)|MenACYW conjugate vaccine + 9vHPV* + Tdap-IPV vaccines on Day 01: n=116
11041265|NCT04490005||Acute brain injury|"Intensive care unit (ICU) admission after ABI, including traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH)
~• Age 18 years old."
11041266|NCT04489992||Standard radiology studies with AI|"The experiment is conducted on three types of studies:
~Chest Computed tomography and Low-Dose Computed Tomography for lung cancer detection (hereinafter referred to as CT/LDCT) with artificial intelligence results;
~Chest X-ray for lung pathology detection (hereinafter referred to as XR) with artificial intelligence results;
~Mammography for breast cancer detection (hereinafter referred to as MG) with artificial intelligence results;"
11041267|NCT04489992||Standard radiology studies without AI|"The experiment is conducted on three types of studies:
~Chest Computed tomography and Low-Dose Computed Tomography for lung cancer detection (hereinafter referred to as CT/LDCT) without artificial intelligence results;
~Chest X-ray for lung pathology detection (hereinafter referred to as XR) without artificial intelligence results;
~Mammography for breast cancer detection (hereinafter referred to as MG) without artificial intelligence results;"
11041268|NCT04489979||Analgetics only|Children with epididymitis / orchitis treated by analgetics only.
11041269|NCT04489979||Analgetics and antibiotics|Children with epididymitis / orchitis treated by analgetics and antibiotics.
11041270|NCT04489966|Experimental|Aerobic training group|The aerobic training group was performed 3 times/week for 60 minutes/session(including 5 minutes of warm-up, 50 minutes aerobic rhythmic exercise and 5 minutes to relax) for moderate(60 to 70% of participants' HRmax) aerobic rhythmic exercise. All patients received an open class, relate to diabetes health education. The intervention lasted for 6 months.
11041271|NCT04489966|No Intervention|Control group|Patients in control group remained the original lifestyle unchanged. All patients received an open class, relate to diabetes health education.
11041272|NCT04489966|Experimental|Intervention group|The intervention was aerobic rhythmic exercise, with intensive training under the guidance and supervision of a professional.The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 5-10 minutes flexibility exercises). Participants were educated on aerobic exercises (aerobic dancing) with music.The intervention lasted for one year.
11041273|NCT04489966|No Intervention|Compared group|The control group was instructed to maintain their usual habits and received no structured exercise intervention. But the form, frequency and time of movement of each participant must be recorded.Participants receive an open diabetes health education class once a month, which is taught by a specially trained diabetes nurse.
11041399|NCT04488978|Experimental|Irbesartan high/Amlodipine high|Irbesartan high & Amlodipine high, once daily for 8 weeks
11041275|NCT04489953|Active Comparator|Clinical, Immunologic and Virologic criteria|In the Clinical, Immunologic and Virologic criteria was based on a confirmed viral load of > 1000 HIV RNA copies/ml; as well as clinical and immunologic criteria
11041276|NCT04489940|Experimental|Bintrafusp alfa|
11041277|NCT04489901|Experimental|Extra Virgin Olivei oil group|The women in the experimental (olive oil) group were asked to apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
11041278|NCT04489901|No Intervention|Control group|The women in the control group did not undergo any intervention.
11041279|NCT04489888|Experimental|Pembrolizumab + Carboplatin + Paclitaxel|Participants will receive pembrolizumab plus carboplatin plus paclitaxel. Pembrolizumab will be administered via intravenous (IV) infusion at a dose of 200 mg on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Carboplatin will be administered via IV infusion at area under curve (AUC) 5 mg/mL/minute on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months). At investigator's choice, paclitaxel will be administered via IV infusion at a dose of 100 mg/m^2 on Day 1 and Day 8 of each 21-day cycle for up to 6 cycles (up to ~4 months) or at a dose of 175 mg/m^2 on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months).
11041280|NCT04489875|Experimental|Chewing gum|the patients in this arm will receive the post-operative oral feeding along with chewing gum which they'll be required to chew for at least 15 minutes before their meal 3 times a day
11041281|NCT04489875|No Intervention|No chewing gum|The patients in this arm will only receive the post-operative oral feeding
11041282|NCT04489862|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
11041283|NCT04489849|Experimental|Apixaban|Apixaban 2.5mg BID
11041284|NCT04489849|Active Comparator|Control|Other treatment except oral anticoagulant
11041285|NCT04489836|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
11041286|NCT04489836|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
11041287|NCT04489823|Experimental|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
11041288|NCT04489810|Placebo Comparator|Meal A + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal A
11041289|NCT04489810|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
11041290|NCT04489810|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
11041291|NCT04489810|Experimental|Meal B + Placebo|350 mg Placebo capsule, taken by mouth, once, with Meal B
11041292|NCT04489797|Experimental|Arm A|Participants will receive single oral dose of acalabrutinib capsule with 100 mL of water.
11041293|NCT04489797|Experimental|Arm B|Participants will receive single oral dose of acalabrutinib capsule taken with 100 mL of COCA-COLA along with 20 mg rabeprazole.
11041294|NCT04489784|Experimental|Treatment|Laser treatment on ballerina's feet.
11041295|NCT04489771|Experimental|Dose A (standard dose)|Participants receive Dose A (standard dose) of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.
11041296|NCT04489771|Experimental|Dose B (higher dose)|Participants receive Dose B (higher dose) of belzutifan by oral administration, QD, until disease progression or discontinuation.
11041297|NCT04489758|Experimental|Constrictive Bronchiolitis|Veterans with surgical lung biopsy-proven constrictive bronchiolitis
11041298|NCT04489758|Active Comparator|Controls|Control patients with minimal smoking history and no chronic lung disease or respiratory symptoms
11041299|NCT04489745|Experimental|SBRT and ADT|Patients undergo SBRT to a dose of 40 Gy in 5 fractions to prostate, and optional 25 Gy in 5 fractions to SVs and Pelvic LNs, with 9 months of Androgen Deprivation Therapy
11041300|NCT04489732|Experimental|Treatment with MSCs|A single dose of MSCs injected into the submandibular glands of patients with radiation-induced xerostomia
11041301|NCT04489719||Observational (biospecimen collection)|Patients receive standard of care radium Ra 223 dichloride given by IV bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
11041302|NCT04489706|Experimental|P53 mutation arm|patients of recurrent and metastatic ovarian cancer and endometrial cancer associated with P53 mutation
11041303|NCT04489693|Active Comparator|Ambulatory Care Coordinator Team (ACCT)|Patients randomized to ACCT receive care from different doctors in clinic and in the hospital. ACCT patients who have been hospitalized twice, had 4 emergency department (ED) visits in the last year or are referred by their primary care physician are offered ACCT care coordination services (ACCT-CC) from nurses and social workers who manage their care with the larger clinical team. Patients are graduated from ACCT if the ACCT team thinks they are no longer high risk.
11041304|NCT04489693|Active Comparator|Comprehensive Care Physician (CCP)|Patients randomized to the CCP group are assigned to a Comprehensive Care Physician and are asked to see their assigned CCP for their primary care. The patients receive their care from the same CCP in the outpatient clinic and also if they were to be hospitalized.
11041305|NCT04489693|Active Comparator|Comprehensive Care, Community & Culture Program (C4P)|Patients randomized to C4P receive care from a CCP in both the hospital and the clinic as well as the following: 1) systematic screening of 17 domains of unmet social needs, 2) access to a community health worker and 3) access to community-based arts and culture programming.
11041306|NCT04489680|Experimental|Surgical Trainees undergoing Cleft Palate Training|26 UK specialty trainees performed a vomerine mucosal flap and intra-velar veloplasty in a one-hour workshop. Pre- and post-simulation questionnaires assessing cleft knowledge and surgical confidence were compared for statistical significance.
11041307|NCT04489667|Other|+STEP Implementation|All patients will receive +STEP as new standard of care at their clinic. This intervention will include staff training, PROs as part of routine care to screen for substance use and mental health disorders, and telemedicine for health care delivery.
11041308|NCT04489654|Active Comparator|study|Test group will receive immediate implant with modified socket shield and deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) put in the buccal gap
11041309|NCT04489654|No Intervention|control|Control group will receive an immediate implant with modified socket shield technique but without deproteinized bovine bone mineral (DBBM) OneXeno Graft. ( OneGraft, Germany) in the buccal gap
11041310|NCT04489641|Experimental|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau et al., 2010). This intervention is provided by clinical psychologist in primary care."
11041311|NCT04489641|Active Comparator|Treatment as usual (TAU)|Medication provided by a general practitioner.
11041312|NCT04489628|Active Comparator|Vitamin D|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
11041313|NCT04489628|Placebo Comparator|Placebo|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
11041314|NCT04489602||Intervention|Each patient complete ObsQoR-11F questionnaire 3 times (before delivery, on Day 1, on Day 2)
11041315|NCT04489589|Experimental|Midodrine|Midodrine 10mg PO/NG q8h
11041316|NCT04489589|Placebo Comparator|Placebo|Carboxmethylcellulose PO/NG q8h
11041317|NCT04489576|Active Comparator|Group (1): Treatment with keratin cure hair|Group (1): Patients will be treated with Keratin cure ® hair treatment. It will be applied once with use of a flat iron.
11041318|NCT04489576|Active Comparator|Group (2): Treatment with Qod max keratin hair|Group (2): Patients will be treated with QOD Max ® keratin hair treatment. It will be applied once with use of a flat iron.
11041319|NCT04489576|Placebo Comparator|Group (3): Treatment without keratin hair treatment|Group (3): Patients will be treated without keratin hair treatment, but the same steps of keratin application will be followed.
11041320|NCT04489563|Other|Aged persons|A feasibility test of 20-30 minutes in aged persons with an adapted Kinect-based system, i.e. i-ACT.
11041321|NCT04489537|Experimental|MarzAA|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route, administered on-demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis
11041322|NCT04489537|Active Comparator|Standard of Care|Standard of care administered on-demand during bleeding episodes
11041323|NCT04489524|Experimental|individualized counselor-led MI sessions and NRT|The intervention (4 individualized counselor-led MI sessions and nicotine replacement therapy [NRT]) consisted of four 60-min in-person sessions of AMI counseling and a packet of self-help smoking cessation materials. Participants were provided NRT packs and counseled on their use.
11041324|NCT04489524|Active Comparator|general health education, self-help materials, and NRT|Participants in this condition were provided with four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco. Strategies for quitting smoking were also provided to participants in this group as well as a supply of NRT and counseling on its use.
11041325|NCT04489511|Experimental|Dose 1|STG-001 given orally at Dose 1 once a day for 28 days
11041326|NCT04489511|Experimental|Dose 2|STG-001 given orally at Dose 2 once a day for 28 days
11041327|NCT04489498||Children with stiff cerebral palsy|Children with stiff cerebral palsy, aged 1 to 13 years
11041328|NCT04489498||Normal children|Normal children, aged 1 to 13 years
11041329|NCT04489485||Primary Care Providers (PCP)|20 PCP who provide well child care to teens 12-18. After randomization, 10 PCPs in the enhanced care group will use the Teen Depression Module for care.
11041330|NCT04489485||Standard care teens|All teens coming for routine well child care to the control group PCPs will have routine depression screening and Youth Health Questionnaire without goals to inform treatment as usual. They will be offered a goals text messaging conversation. Suicide screening will be at the discretion of the PCP.
11041331|NCT04489485||Enhanced care teens|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, as well as Youth Health Questionnaire with goals and then they will receive treatment guided by the Teen Depression Module and offered a depression text messaging conversation. Suicide screening will be conducted.
11041332|NCT04489485||Standard care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the control group PCPs will complete a Pediatric Symptom Checklist and Short Moods and Feelings Questionnaire, plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
11041333|NCT04489485||Enhanced care- caregivers|All caregivers of teens <18 years old coming for routine well child care to the enhanced group PCPs will complete a Pediatric Symptom Checklist plus a Youth Health Questionnaire- Parent version to inform treatment as usual. If the internalizing subscale is positive the caregiver will also complete the Short Moods and Feelings Questionnaire and 3, 6 and 11.5 month follow up report of Intervention received (Parent Intervention Questionnaire)
11041334|NCT04489472|Experimental|PCD Group|
11041335|NCT04489472|Placebo Comparator|Control Group|
11041336|NCT04489459|Active Comparator|colistin-tigecycline|this group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12h
11041337|NCT04489459|Active Comparator|colistin-meropenem|received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
11041338|NCT04489446|Experimental|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
11041400|NCT04488978|Active Comparator|Amlodipine low|Amlodipine low, once daily for 8 weeks
11058430|NCT04368728|Experimental|Mid dose, 18-55 years of age (2 doses)|
11041339|NCT04489446|Placebo Comparator|Control|Patients allocated to this arm will receive a placebo that will be similar in form to sildenafil pills in the interventional arm. These doses will be scheduled every 8 hours and wil be administered orally por up to seven consecutive days.
11041340|NCT04489420|Experimental|Intravenous IV ( Recurrent and Surgical ) GBM|Cohort 1A ( recurrent GBM) will receive CYNK-001 at a dose of 1.2 x 10^9 cells intravenous ( IV) on Days 0, 7, and 14 and will include up to 6 subjects. The subjects will be followed for a 42 day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose). No other treatment interventions are planned between the last day of CYNK-001. In the event of DLTs, Cohort 1C ( recurrent GBM dose-De escalation) will receive CYNK-001 at a dose of 600 x 10^6 cells (IV) on Days 0, 7, 14, and will include up to 6 subjects who will be followed for a 42-day DLT period from the initial CYNK-001 infusion (or 28 days after the last dose. Cohort 1B (surgical cohort) will receive CYNK-001 at the maximum safe dose (MSD) (either 1.2x10^9 cells or 600x10^6 cells) (IV) at Days 0, 7, 14, and will include up to 6 subjects. The tumor resection surgery will be performed after the last CYNK-001 infusion during the DLT period.
11041341|NCT04489420|Experimental|Intratumoral IT ( Recurrent and Surgical ) GBM)|The cohort 2A or cohort 2C (recurrent GBM) IT route of administration can be started only after the safety results were acceptable from the completion of cohort 1A or Cohort 1C (IV route of administration). The Treatment Period for the IT cohorts will begin with having the Ommaya catheter placement per institutional policy, which is planned to occur within one week prior to the CYNK-001 administration on Day 0. Cohort 2A will be treated with CYNK-001 IT at 200 x 10^6 ± 50 x 10^6 cells IT on Day 0, 7 and 14 includes up to 6 recurrent GBM subjects Cohort 2C ( dose de-escalation) will be treated with CYNK-001 200 x 106 ± 50 x 106 cells IT on Day 0, and Day 7 ( only two days dosing) and include up to 6 recurrent GBM subjects. Cohort 2B ( the surgical IT cohort) will be treated with CYNK-001 at the maximum safe dose ( MSD) (either 200 x 10^6 ± 50 x 10^6 cells on Days 0, 7 and 14 or at 200 x 10^6 ±50x10^6 cells on Days 0 and 7) and include up to 6 surgical GBM subjects
11041342|NCT04489407|Experimental|rPPG Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with the rPPG app.
11041343|NCT04489407|Other|Conventional Vital Sign Monitor Readings|Oxygen saturation, heart rate and respiratory rate obtained with conventional vital sign monitors and manual respiratory rate counts.
11041344|NCT04489381|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
11041345|NCT04489381|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
11041346|NCT04489368||Study Group|Patients undergoing NA-CCRT followed by Surgery
11041347|NCT04489355||CABG|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG)
11041348|NCT04489355||CABG with SVR|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR)
11041349|NCT04489355||CABG with mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with and mitral repair (MR)
11041350|NCT04489355||CABG with SVR and mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
11041351|NCT04489329|Experimental|Single Arm|Participant swallows and retrieves capsule in stool before and after ingestion of a probiotic. Capsule and stool samples are analyzed for presence of probiotic strain and compared to baseline.
11041352|NCT04489316|No Intervention|Control|Subjects in the Control group will proceed through the standard pediatric oncology curriculum. They will not receive any sessions in narrative medicine. They will take the pretest and the post-test.
11041353|NCT04489316|Experimental|Intervention|Subjects in the Intervention group will receive 2-3 sessions in narrative medicine. They will also take the pretest and the postest.
11041354|NCT04489303|Experimental|Virtual Patient Behavioral Response Training|Caring Response mobile app with a behavioral training.
11041355|NCT04489303|Active Comparator|Educational Training|Traditional educational program.
11041356|NCT04489290|Experimental|D005 Vaginal Mousse|
11041357|NCT04489290|Placebo Comparator|Placebo|
11041358|NCT04489277||Patients with Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure with silent brain infarction
11041359|NCT04489277||Patients without Silent Brain Infarction|treated with an aortic endoprosthesis deployed in Ishimaru zone 0 to 3 and brain diffusion-weighted magnetic resonance imaging (DW-MRI) within 7 days after the procedure without silent brain infarction
11041360|NCT04489264||ASCT group|patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
11041361|NCT04489264||Observation group|patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up
11041362|NCT04489251||PH subjects|"Pediatric subjects ages 2-17 years
~Subjects undergoing a clinically indicated cardiac catheterization.
~Subjects with proven or being evaluated for pulmonary hypertension in WHO classification group 1 or 3†
~Subjects will be categorized as PAH subjects if they meet the hemodynamic criteria: pulmonary artery pressure >20mmHg, pulmonary vascular resistance index >3 Woods units*m2, and wedge pressures <15mmHg."
11041363|NCT04489251||Control subjects|"Pediatric subjects ages 2-17 years
~Subjects undergoing a clinically indicated cardiac catheterization.
~Subjects can be categorized as control subjects if they do not have PH on catheterization and do not meet any exclusion criteria."
11041364|NCT04489238||Young onset Colorectal Cancer Participants|(Stool collection on newly diagnosed patients in this cohort) Participants will include patients under the age of 50 who are diagnosed with colorectal adenocarcinoma.
11041365|NCT04489238||Average onset Colorectal Cancer Participants|"(Stool collection cohort only) 166 colorectal cancer patients 50 year-old or older will serve as controls.
~Stool collection cohort only."
11041366|NCT04489225||Observational|This single arm observational study includes all patients implanted with a Medtronic Cobalt™ XT ICD or CRT-D MRI SureScan™ (with Attain StabilityQuad™ MRI SureScan™ Model 4798 Lead (ASQ)), who are enrolled in the Medtronic CareLink (CL) Network and Product Surveillance Registry (PSR). Patients will be followed per the standard of care practices of their care provider. All patients must provide a signed informed consent.
11041401|NCT04488978|Active Comparator|Amlodipine high|Amlodipine high, once daily for 8 weeks
11041402|NCT04488978|Active Comparator|Irbesartan low|Irbesartan low, once daily for 8 weeks
11041367|NCT04489212|Experimental|Treatment (follow-up, observation)|Patients who have recurrence or progression during treatment or observation have medical charts are reviewed every 6 months for 5 years. Patients who complete adjuvant treatment are followed for observation 3 days after radiation therapy, 1 month after radiation therapy, every 3 months after radiation therapy for 2 years, every 6 months for 1 year, and then annually for 2 years.
11041368|NCT04489199||Stroke patient|Patient included in the Dijon Stroke Registry.
11041369|NCT04489186|Experimental|All subjects|Single arm feasibility study with a wearable device intervention for cardiorespiratory and activity monitoring in subjects with cystic fibrosis.
11041370|NCT04489173|Experimental|Treatment|Treatment with TAS102
11041371|NCT04489160|Experimental|C1-inhibitor|One dose 6000 IU C1-inhibitor intravenously
11041372|NCT04489160|Placebo Comparator|Placebo|0.9% saline
11041373|NCT04489147|Active Comparator|metformin|Group A ( involve 200 patients ) will receive metformin 850 mg twice daily along the cycle of ICSI
11041374|NCT04489147|No Intervention|No Metformin|Group B ( involve 200 patients) will not receive metformin
11041375|NCT04489134|Experimental|A D B C|Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°03:Administration of a 2 mg dose of LCP-tacro Period n°04:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
11041376|NCT04489134|Experimental|B A C D|Period n°01: Administration of a 2 mg dose of LCP-tacro Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro
11041377|NCT04489134|Experimental|C B D A|Period n°01: Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro Period n°03:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
11041378|NCT04489134|Experimental|D C A B|Period n°01:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°02:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro
11041379|NCT04489121|Experimental|omalizumab preseasonal treatment|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season. Rescue medication could be used during pollen seasons.
11041380|NCT04489121|No Intervention|control|No preseasonal treatment was performed. Rescue medication could be used during pollen seasons.
11041381|NCT04489108|Experimental|Tranexamic Acid with Standard Medical Treatment|Arm A will Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours along with standard medical and interventional (Endoscopy) therapy.
11041382|NCT04489108|Active Comparator|Placebo + Standard Medical treatment|Arm B will receive similar volume of isotonic solution (saline) along with standard medical and interventional (Endoscopy) therapy.
11041383|NCT04489095|Experimental|Electrophysiology Study pre and Post TAVR|In all patient's undergoing TAVR after informed consent will undergo an electrophysiology study pre and post device deployment in order to determine the need for permanent pacemaker implantation or further testing/monitoring.
11041384|NCT04489082|Experimental|Near Infrared Laser Therapy|"On the days of each near-infrared therapy session, patients will undergo 10 minutes of transcranial infrared laser stimulation.
~The laser dose for all conditions will be a 3.4 W continuous laser wave, at a 1064 wavelength, with irradiance (power density) at 250 milli-Watts/cm2. All groups will have treatment once a week (10 minutes per session) for 5-6 weeks. For Alzheimer's, the site targeted will be the right prefrontal cortex. Parkinson's patients will have laser delivered to the brain stem, bilateral temporal lobes. TBI/CTE patients will have the laser stimulation site dependent on location of injury. Patients with depression/anxiety will have laser stimulation applied to the prefrontal area of the head."
11041385|NCT04489069|Other|Clinical, neuropsychological and MRI evaluations|
11041386|NCT04489056||Study group|This group will consist of 50 pregnant women, who experienced pPROM between 22+5 and 28+0 gestational weeks, either presenting at the primary study site, or being referred from other hospitals, and delivered at preterm by cesarean section.
11041387|NCT04489056||Control group|This group will consist of 50 pregnant women, who are scheduled for elective cesarean section at the outpatient department of the primary study site, between a 32+0 and 37+0 gestational weeks, and delivered at term by cesarean section.
11041388|NCT04489043|Experimental|Exercise and healthy life style recommendations|A planned exercise programme to test the impact of this treatment. An Oral Glucose Tolerant Test (OGTT) at intermediate time points in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
11041389|NCT04489017|Experimental|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day for 24 weeks
11041390|NCT04489017|Placebo Comparator|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day for 24 weeks
11041391|NCT04489004|Experimental|Driver ablation+CPVI|Driver ablation plus CPVI (circumferential pulmonary vein isolation)
11041392|NCT04489004|Active Comparator|Stepwise ablation|Stepwise ablation
11041393|NCT04488991||the woman who has just HPV infection|the woman who is between 30-65 years old, who is participate this research, and has just HPV infection in cervix.
11041394|NCT04488991||the woman who has just nabothian cyst|the woman who is between 30-65 years old, who is participate this research, and has just nabothian cyst in cervix.
11041395|NCT04488991||the woman who has both nabothian cyst and HPV infection|the woman who is between 30-65 years old, who is participate this research, and has both nabothian cyst in cervix.
11041396|NCT04488978|Experimental|Irbesartan low/Amlodipine low|Irbesartan low & Amlodipine low, once daily for 8 weeks
11041397|NCT04488978|Experimental|Irbesartan low/Amlodipine high|Irbesartan low & Amlodipine high, once daily for 8 weeks
11041398|NCT04488978|Experimental|Irbesartan high/Amlodipine low|Irbesartan high & Amlodipine low, once daily for 8 weeks
11041404|NCT04488965|Experimental|Autologous neural cell ecosystems - ANCE|The patient will undergo first surgery under general anesthesia for the collection of the cortical biopsy (5x5x5 mm biopsy of non-dominant frontal cortex). After the production of ANCE from the cortical biopsy, which last 8 to 12 weeks, the patient will undergo a second neurosurgery, for the stereotaxic reimplantation of ANCE under general anesthesia.
11041405|NCT04488952|Experimental|nerve block combined with general anesthesia group|Patients in this group receive nerve block combined with general anesthesia.
11041406|NCT04488952|Experimental|spinal anesthesia group|Patients in this group receive spinal anesthesia.
11041407|NCT04488952|Placebo Comparator|control group|This group is used to obtain the learning effect.
11041408|NCT04488926|Active Comparator|Group 1|Normast® MPS (mPEA and umPEA 300mg + 600mg) microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
11041409|NCT04488926|Placebo Comparator|Group 2|Placebo microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
11041410|NCT04488913|Other|Standard of Care Treatment|Exposure to traditional evaluation for suspected acute coronary syndrome (ACS) with ECG, 0- and 3-hour troponin testing using the 99th percentile as the upper reference limit, and application of the History, EKG, Age, Risk factors, and troponin (HEART) score.
11041411|NCT04488913|Active Comparator|RACE-IT pathway|Exposure to new protocol for suspected ACS, which includes the use of 0- and 1-hour ECG and high-sensitivity troponin testing and application of the HEAR score (a modification of the HEART score)
11041412|NCT04488900|Experimental|CKD-508 single dose|Single dose administration of CKD-508
11041413|NCT04488900|Experimental|CKD-508 multiple dose|Multiple dose administration of CKD-508
11041414|NCT04488900|Placebo Comparator|Placebo|Matching placebo
11041415|NCT04488887||Diabetic retinopathy Group|Patients with non-proliferative and proliferative diabetic retinopathy with clear media will be recruited.
11041416|NCT04488887||Myopia Group|Patients with different grades of myopia, with accurate segmentation will be recruited
11041417|NCT04488887||Choroidal neovascularization group|Patients with active choroidal vascularization without scarring will be recruited
11041418|NCT04488887||Healthy controls|Healthy individuals without retinal disorders will be included for comaprison
11041419|NCT04488874|Experimental|Sodium Lactate|Intravenous Molar Sodium Lactate is administered during the first surgical incision. The dose is 2.5mL/kg.
11041420|NCT04488874|Active Comparator|Mannitol 20%|Intravenous mannitol 20% is administered during the first surgical incision. The dose is 5mL/kg (1g/kg).
11041421|NCT04488861||IVF-conceived|Those who have conceived by IVF (for whatever indication); target 80 participants of which it is anticipated 20 would have conceived by frozen embryo transfer IVF.
11041422|NCT04488861||Spontaneously conceived|Those who have conceived spontaneously (within 12 months and without use of hormonal or other contraception); target 20 participants
11041423|NCT04488861||Ovulation induction-conceived|Those who have conceived by ovulation induction (after more than 12 months); target 20 participants.
11041424|NCT04488848|Placebo Comparator|continous glucose|continous glucose infusion (60 grams over 3 hours)
11041425|NCT04488848|Experimental|bolus (excursion)|3 x 20 grams of glucose as a bolus over 6 minutes at t0, 60 minutes and 120 minutes
11041426|NCT04488835|Experimental|TENS Therapy Group|patients in this group received TENS therapy in addition to routine physical therapy
11041427|NCT04488835|Experimental|PEMFT group|patients in this group received PEMFT therapy in addition to routine physical therapy
11041428|NCT04488822|Experimental|Pexidartinib|
11041429|NCT04488809|Experimental|Deep Water Running|Participants in this group will perform running in a vertical position in water. The sessions will be held in deep pool where the feet of the participants will not touch the ground.
11041430|NCT04488809|Active Comparator|Treadmill Running|Participants in this group will perform running on a treadmill.
11041431|NCT04488809|No Intervention|Control|Participants in this group will not interfere regular exercise for 8 weeks.
11041432|NCT04488796|Experimental|Assigned Strategies: Opt-in|"Participants in this group will be assigned two behavioural strategies under the theme of moving more and will be asked to Place a check in the box [agree] if you will breakup your sitting throughout your work hours by X this week. The strategy statement is followed up by; OR, click the next button at the bottom. Within the opt-in condition, the default is to not participate (by clicking next): participants are not required to explicitly state they do not want to do the strategy"
11041433|NCT04488796|Experimental|Assigned Strategies; Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Active choice condition, participants will be required to either, Place a check in one box: I will break up my sitting throughout my work hours by [strategy] this week or, I will not break up my sitting throughout my work hours by [strategy] this week."
11041434|NCT04488796|Experimental|Assigned Strategies; Enhanced Active Choice|"Participants in this group will be assigned two behavioural strategies under the theme of moving more. In the Enhanced Active Choice condition, participants will to required to choose between two alternatives: I will break up my sitting throughout my work hours this week by [strategy] to reduce my risk of diabetes, mental health issues and other detrimental health outcomes and I want to win the eGiftcard or, I will not break up my sitting time during my work hours by [strategy] this week even if it means I increase my risk of developing diabetes, mental health issues and other detrimental health outcomes and I don't care about winning an eGiftcard"
11041435|NCT04488796|Experimental|Choice of Assignment; Opt-in|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
11041504|NCT04488380|Experimental|high-viscosity glass ionomer restoration|One of the carious mandibular 2nd molar teeth (according to randomisation) will be restored with high-viscosity glass ionomer restoration (Equia, GC)
11041505|NCT04488380|Experimental|nano-hybrid composite resin|One of the carious mandibular 2nd molar teeth will be restored with nano-hybrid composite resin (GrandioSO, Voco)
11041436|NCT04488796|Experimental|Choice of Assignment; Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
11041437|NCT04488796|Experimental|Choice of Assignment; Enhanced Active Choice|"Those opting to be assigned strategies (Choice Strategy Assignment group) will be assigned two random strategies, just like the No Choice Strategy Assignment group; however, they remain different from the No Choice Strategy Assignment group because they were given and chose the option to be given strategies. Those selecting to choose and manage their own strategies Choice Strategy Self-Selection group will be presented the same ten strategies each week, in random order, and will have the option to choose two strategies. The strategies can remain the same or change from week to week."
11041438|NCT04488783|Experimental|Glioblastoma patients|newly diagnosed GB who underwent at least partial resection of the tumor surgically
11041439|NCT04488770|Experimental|Part 1 (SAD) Cohort 1:Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
11041440|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 1:Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
11041441|NCT04488770|Experimental|Part 1 (SAD),Cohort 2: Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 500 mg, 750 mg and 900 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
11041442|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 2: Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
11041443|NCT04488770|Experimental|Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg|In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.
11041444|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 3: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
11041445|NCT04488770|Experimental|Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg|GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
11041446|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 4: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
11041447|NCT04488770|Experimental|Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg|GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
11041448|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 5: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
11041449|NCT04488770|Experimental|Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg|GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.
11041450|NCT04488770|Placebo Comparator|Part 2(MAD),Cohort 6: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
11041451|NCT04488757|Other|Study Arm|All participants enrolled in the study will undergo baseline fMRI and baseline and follow-up (4-month post-baseline) assessment of stress physiology (i.e., allostatic load). Treatment as usual information will be gathered for all participants to assess observational intervention response.
11041452|NCT04488744|Experimental|nicotine infusion 0.2mg|"nicotine infusion
~0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) The day order will be randomized over 5 days."
11041453|NCT04488744|Experimental|nicotine infusion 2.0mg|0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries),
11041454|NCT04488744|Experimental|nicotine infusion 1.0mg|1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries)
11041455|NCT04488744|Experimental|nicotine infuison 1.0mg|1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
11041456|NCT04488744|Placebo Comparator|Saline|saline delivered over 2minutes ,2.5minutes,10 minutes
11041457|NCT04488731||NW/MCC|Normal body mass index (BMI) / with moderate coffee consumption
11041458|NCT04488731||NW/HCC|Normal body mass index (BMI) / with heavy coffee consumption
11041459|NCT04488731||OW/MCC|Overweight / with moderate coffee consumption
11041460|NCT04488731||OW/HCC|Overweight / with heavy coffee consumption
11041461|NCT04488718|Experimental|EnergieShake® Junior Powder Complete (test)|EnergieShake® Junior Powder Complete will be consumed by children, as a supplement to normal diet, over a period of 7 day period to determine its acceptability (liking, compliance) and tolerance (gastro-intestinal tolerance). The dose will be the same as currently consumed product (all children recruited to the study will be consuming an oral nutritional supplement).
11041462|NCT04488705|Experimental|Single ascending dose|
11041463|NCT04488705|Experimental|Repeat dose - 7 days|
11041464|NCT04488705|Experimental|Repeat dose - 14 days|
11041465|NCT04488692|Experimental|Model 1|Participants will receive 2 sessions of functional training per day, 15-min per session.
11041466|NCT04488692|Active Comparator|Model 2|Participants will receive 1 session of functional training and 1 session of sham intervention (therapist visiting and education) per day, 15-min per session.
11041467|NCT04488679|Experimental|PRF along with MTA|10 ml of the participant blood will be drawn into 10 ml test tubes without an anticoagulant and centrifuged immediately .centrifugation will be done using a tabletop centrifuge for 12 min at 2700 rounds per minute. The resultant product will exhibit three layers. platelet-poor plasma at the surface, PRF clot in the middle, and red blood cells at the bottom. Sterile tweezers inserted into a test tube to retrieve the PRF clot. The prepared fibrin membrane will be gently packed over the pulp
11041468|NCT04488679|Active Comparator|MTA direct pulp capping|MTA is primarily calcium oxide in the form of tricalcium silicate, dicalcium silicate and tricalcium aluminate. Bismuth oxide is added for radiopacity, MTA is considered a silicate cement rather than an oxide mixture, a so its biocompatibility is due to its reaction products. MTA elevates the expression of transcription factors, induces dentin bridge formation, possesses biocompatibility9, and sustains a high pH for a longer duration and a close physiochemical seal with dentin that forms an insoluble barrier to prevent microleakag
11041469|NCT04488653|Experimental|Oligopin®|Oligopin® contains French Maritime Pine Bark Extract
11041470|NCT04488653|Placebo Comparator|Placebo|Placebo is a mixture of different inert compounds
11041471|NCT04488640||Thyroid fine needle aspiration biopsy group|A group of 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis.
11041472|NCT04488640||Thyroid core needle aspiration biopsy group|A patient group with 760 people who had a thyroid nodule and who had a thyroid fine needle aspiration biopsy for diagnosis and who underwent a core needle biopsy again. A total thyroidectomy was performed in 88 of these patients. Surgical pathology results, core needle results and TIRADS scores were compared.
11041473|NCT04488627||Critically ill patients|Critically ill patients hospitalised in the intensive care unit indicated to echocardiographic examination.
11041474|NCT04488614||Early Stage Breast Cancer (Stage I and II)|Consecutive early stage breast cancer patients who are treated according to the national guidelines. Observation over 11 years.
11041475|NCT04488601|Experimental|Rapamycin 4.5|Rapamycin 1.5 mg/day on 3 days per week
11041476|NCT04488601|Experimental|Rapamycin 7.5|Rapamycin 2.5 mg/day on 3 days per week
11041477|NCT04488601|Experimental|Rapamycin 5|Rapamycin 5 mg/day once per week
11041478|NCT04488601|Experimental|Rapamycin 10|Rapamycin 5 mg/day twice per week
11041479|NCT04488601|Placebo Comparator|Placebo 1|Placebo once per week
11041480|NCT04488601|Placebo Comparator|Placebo 2|Placebo twice per week
11041481|NCT04488601|Placebo Comparator|Placebo 3|Placebo three times a week
11041482|NCT04488575|Experimental|EDP1815|Patients will receive EDP1815 in addition to standard of care
11041483|NCT04488575|Placebo Comparator|Placebo|Patients will receive placebo in addition to standard of care
11041484|NCT04488562||Patients with COVID-19|Patients with proven COVID-19 and abnormalities on chest X-Ray/HRCT, admitted at the hospital. Patients are included around the time of discharge from the hospital or at their regular outpatient clinic visit 6 weeks after discharge, depending on the clinical status of the patient at time of discharge.
11041485|NCT04488536||Frail patients|Clinical Frailty Scale level 5-9
11041486|NCT04488536||Nonfrail patients|Clinical Frailty Scale level 1-4
11041487|NCT04488523|Experimental|Family-based Telehealth Treatment|A family-based telehealth intervention.
11041488|NCT04488497|Experimental|Peer coach guided online learning program|
11041489|NCT04488497|Placebo Comparator|Self-administered online learning program|
11041490|NCT04488484|Other|Arm|"Serology test results
~The Paris Saint- Joseph Hospital Group staff was submitted to a 2 times serology test: the 1st took place between April, 20th to May, 12th and the second, between May, 26th to June, 12th. The employees presenting positive antibodies titers to SARS-CoV-2 will be contacted and asked for a 12 month follow-up study organized by the Occupational Health Team and the team of COVID-19 Serology referents appointed to carry out and coordinate the procedure. Each enrolled member will receive a letter with containing an information letter describing the study with a written consent form and a questionnaire enabling the data to be collected individually on the COVID-19 infection."
11041491|NCT04488471||high-risk group|IBD patients who were high risk of infection and were shielding
11041492|NCT04488471||low-risk group|IBD patients who were low risk of infection and were following standard quarantine guidance
11041493|NCT04488471||young people from affiliated study|32 IBD patients from an affiliated study
11041494|NCT04488458|Experimental|MBEC and MIC susceptibility testing|"For all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin, fusidic acid, ciprofloxacin/levofloxacin and clindamycin.
~MBEC cut-off for replacement with 2nd or 3rd line antibiotic: RIF MBEC/MIC > 8; LEV MBEC/MIC > 5; FUS MBEC/MIC > 3; CLI MBEC/MIC > 4; LIN MBEC/MIC > 2; T/S MBEC > MIC
~Second line of treatment:
~RIF and Fusidic acid 500 mg TID (ter in die) RIF and Clindamycin 450 - 600 mg TID LEV and Fusidic acid 500 mg TID LEV and Clindamycin 450 mg TID
~Third line of treatment:
~Linezolid 600 mg BID (bis in die) Sulfamethoxazole/Trimethoprim 800/160 mg TID Clindamycin 450 mg TID and Fusidic acid 500 mg TID"
11041495|NCT04488458|Active Comparator|MIC susceptibility testing|If the causative bacterium is susceptible according to MIC diagnostics, the patient will follow the first line of treatment: Rifampicin 750-900 mg/day + Levofloxacin 750 mg BID
11041496|NCT04488445|Experimental|Strength Training|The intervention group performs a resistance training based on a resistance exercise of 3 sets of 3 to 5 repetitions (90% of an estimated 1 RM) and 3 minutes of resting time between sets.
11041497|NCT04488445|Placebo Comparator|Stretching|The control group performs 3 exercises of stretching and balance during one minute each and three sets. One minute of resting time between sets.
11041498|NCT04488419|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
11041499|NCT04488419|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
11041500|NCT04488419|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
11041501|NCT04488406||Graves' Orbitopathy|Graves' Orbitopathy patients who undergoing orbital decompressive surgery
11041502|NCT04488406||Control Patients|Patients undergoing eye surgery for unrelated reasons
11041503|NCT04488393||Pregnancies with multiple gestations|
11058431|NCT04368728|Experimental|Low dose, 65-85 years of age (2 doses)|
11041506|NCT04488367|Experimental|Early TXA|Experimental group will receive 10 mg/kg IV TXA while in the Emergency Department, and repeat preoperative and postoperative doses.
11041507|NCT04488367|Other|Control|Control group will receive 100 mL 0.9% normal saline in the Emergency Department, and 10 mg/kg IV TXA before skin incision and again in post anesthesia care unit.
11041508|NCT04488354|Experimental|CLBR001 treated patients|Patients who have been administered with CLBR001
11041509|NCT04488341|Other|aerobic exercises in addition to diet|The study group will receive aerobic exercises in addition to diet recommendations
11041510|NCT04488341|Other|diet recommendations|control group will receive diet recommendations
11041511|NCT04488328|Experimental|Magnetic Therapy Group|patients received the routine medical treatment (Bisphosphonates, Calcium, and Vitamin D) in addition to pulsed magnetic therapy on the pelvic region for 12 weeks
11041512|NCT04488328|Experimental|Exercise group|patients received the routine medical treatment in addition to moderate-intensity aerobic exercise for 12 weeks
11041513|NCT04488328|Experimental|Combined Magnetic Therapy and Exercise Therapy group|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks
11041514|NCT04488315|Experimental|The dexamethasone plus ropivacaine group|
11041515|NCT04488315|Experimental|The dexamethasone lipid microsphere plus ropivacaine group|
11041516|NCT04488315|Active Comparator|The ropivacaine group|
11041517|NCT04488302||Implant group|Patients with 1 or more implants with CBCT, ultrasound and open-bone images
11041518|NCT04488289|Other|Parallel measurement of blood pressure|Office blood pressure, self-directed and ambulatory blood pressure measurement.
11041519|NCT04488276||Pregnant women|Non smoking pregnant and post-partum women
11041520|NCT04488276||Smoking fathers|Expectant or new fathers who smoke
11041521|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
11041522|NCT04488250|Other|Low-to-mid functioning HIV/AIDS patients|Low-to-mid functioning HIV/AIDS patients greater than 18 years of age with stroke co-morbidity.
11041523|NCT04488250|Other|Stroke survivors|Stroke survivors greater than 18 years of age with hemiplegia with and without HIV/AIDS.
11041524|NCT04488224|Experimental|Patients receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.
~Participants in this arm undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. These participants do not require an additional conventional CBCT as the SOC conventional CBCT images are used to benchmark the experimental Nano-X CBCT scans for evaluation of the primary outcome measure."
11041525|NCT04488224|Experimental|Patients not receiving CBCT Image Guidance during treatment|"On two separate occasions, CBCT images will be acquired while participants are rotated 360° about the horizontal axis on the Nano-X Patient Rotation System. The rotation will take approximately 72 seconds to complete. Psychometrically validated questionnaires will be completed by the participant before and after each Nano-X CBCT session.
~Participants in this arm do not undergo conventional CBCT for image guidance during standard of care (SOC) radiotherapy treatment. As such these participants will receive an additional conventional CBCT scan on standard equipment which used to benchmark the experimental NAno-X CBCT scans for evaluation of the primary outcome measure."
11041526|NCT04488211||Prospective survey respondents|Invitations to participate in the survey will be emailed on three occasions to selected fertility specialists worldwide who are affiliated to a public or private fertility clinic.
11041527|NCT04488198|No Intervention|Control group|20 CIBD patients do not receive acupuncture or placebo-acupuncture.
11041528|NCT04488198|Active Comparator|Acupuncture group|20 CIBD patients receive 8 sessions of acupuncture therapy with 0,3 x 30mm needles (asia-med special number 16).
11041529|NCT04488198|Placebo Comparator|Placebo group|20 CIBD patients receive 8 sessions of sham acupuncture with placebo-needles 0,3 x 30mm (Streitberger).
11041530|NCT04488185|Experimental|Secukinumab 300mg|Randomized in a 2:1 ratio to secukinumab or placebo
11041531|NCT04488185|Placebo Comparator|Placebo|Randomized in a 2:1 ratio to secukinumab or placebo
11041532|NCT04488172|Experimental|Epilepsy subjects|Receiving multi-vitamins supplementation (B6, B9, D, E, Q10) for 6 months trial
11041533|NCT04488159|Experimental|Immunoscore stratification|"Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly, standardised physical excise (stair walking excise twice a week for 12 weeks), which will be monitored by an electronic sports device.
~Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)
~Immunoscore high (I high; I4): no adjuvant treatment."
11041534|NCT04488159|Active Comparator|TNM stratification|"TNM-based low-risk (pT1, pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)
~TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)"
11041535|NCT04488133|Experimental|Nusinersen 12 mg|Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
11041536|NCT04488120|Experimental|Occlutech septal occluder ( Figulla Flex II)|Occlutech septal occluder (Figulla Flex II)
11041537|NCT04488120|Active Comparator|Amplatzer Septal Occluder (ASO)|St. Jude AGA septal occluder (Amplatzer ASO)
11041538|NCT04488107|Experimental|Dose escalation cohort of FCN-437c|"This study plans to start escalating from 50 mg QD, through 100 mg, 200 mg, 300 mg, 450 mg, to 600 mg.
~Participants will receive FCN-437c in sequential 28-day cycles which are made up of monotherapy QD for 21 days followed by a 7 day rest period.
~Participants must be histologically or cytologically diagnosed with ER+/ HER2- advanced breast cancer."
11042299|NCT04482920||Transgender females|Transgender females who are clinically ready to start estradiol
11041539|NCT04488107|Experimental|Dose expansion cohort of FCN-437c + letrozole|"The dose expansion stage will be initiated after escalating to MTD.
~Six patients will be treated with FCN-437c combined with letrozole.
~DLT assessment and PK blood collection will be completed in the first 28-day cycle.
~If DLT does not occur in the first three patients, 15 additional patients were enrolled to complete the expansion study of MTD group.
~If one DLT occurs in the first three patients, three additional patients will be enrolled onal patients were enrolled and completed the MTD group.
~Patients will be evaluated every 8 weeks until disease progression, intolerable toxicity, death, investigator's decision or patient's voluntary withdrawal from the study."
11041540|NCT04488094|Experimental|Heart transplantation|Patients suspected of having acute heart allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
11041541|NCT04488094|Experimental|Liver transplantation|Patients suspected of having acute liver allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
11041542|NCT04488081|Active Comparator|Remdesivir plus standard of care|"See the Full EUA Prescribing Information for complete dosage, administration, and preparation instructions.
~Remdesivir is available as a concentrated solution.
~The recommended dose for adults weighing 40 kg and higher is a single loading dose of 200 mg on Day 1 followed by once- daily maintenance doses of 100 mg from Day 2.
~The optimal duration of treatment for COVID-19 is unknown.
~For patients requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO), the recommended total treatment duration is 10 days.
~For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days.
~Administer remdesivir via IV infusion over 30 to 120 minutes."
11041543|NCT04488081|Experimental|Cenicriviroc (CVC) plus remdesivir|"150 mg immediate release tablets Oral (subjects should take CVC twice daily at approximately 12-hour intervals with food orally or through a feeding tube).
~Treatment will be administered to subjects while hospitalized as in-patients and will continue whether or not the patient is discharged from the hospital for 28-days or until discharge from the hospital, whichever comes first but with a minimum course of 14 days. CVC should be administered twice daily at approximately 12-hour intervals in fed condition and at approximately the same time each day (±2 hours). Patients may receive a larger dose (450 mg total) for their first day of treatment as a loading dose administered as a morning dose of 300 mg and an evening dose of 150 mg. Remdesivir will be dosed as described for the active comparator arm."
11041544|NCT04488081|Experimental|Icatibant plus remdesivir|A sterile, single-use, prefilled syringe solution for subcutaneous administration. Each syringe contains 3 mL of a sterile solution of icatibant 30 mg (as icatibant acetate). 30 mg in sterile, single-use syringe. Single-dose, single-use prefilled syringe with a hypodermic needle (25G) included in the package. Subcutaneous (SC) injection in the abdominal area over at least 30 seconds. 30 mg every 8 hours daily for 3 days. Treatment will be administered to subjects while hospitalized as inpatients. Remdesivir will be dosed as described for the active comparator arm.
11041545|NCT04488081|Experimental|Razuprotafib plus remdesivir|"Ready to dose sterile solution for subcutaneous injection. Razuprotafib (AKB-9778) Sterile Solution is supplied as a clear, colorless to slightly yellow isotonic, sterile, unpreserved solution. Strengths to be used in trial: 10 mg and 20 mg. Route: Subcutaneous (SC) injection in the 4 quadrants of the abdominal area is preferred.
~Standard Regimen: 10 mg every 8 hours for 7 days, advancing to 20 mg q8h for 7 days once the safety run-in confirms tolerability. Agent Preparation: Aseptic filling of syringes to desired dose is required. Pre-medication: Specific pre-medication is not required for routine treatment. Administration: Treatment will be administered to subjects while hospitalized as inpatients. Remdesivir will be dosed as described for the active comparator arm."
11041546|NCT04488081|Experimental|Apremilast plus remdesivir|"Single dose, film-coated tablet for oral administration. The Apremilast drug product used for clinical trials is supplied as a tablet for oral administration containing 30 mg of apremilast drug substance. The tablet formulation of apremilast will be provided in bottles.Route: Oral (subjects should take apremilast twice daily at approximately 12-hour intervals by swallowing or dissolved in water and administered through a feeding tube).
~Standard Regimen: 30 mg twice daily (BID). Treatment will be administered to subjects while hospitalized as inpatients for a 14 day course. Subjects should be administered apremilast twice daily at approximately 12-hour intervals without restriction of food or drink, and at approximately the same time each day (±2 hours). Remdesivir will be dosed as described for the active comparator arm."
11041547|NCT04488068|Experimental|Magnetic Stimulation|Patients will be subjected to TPMS.
11041548|NCT04488068|No Intervention|Sham TPMS|Patients will be subjected to sham TPMS
11041549|NCT04488055|Experimental|Crisis Line Facilitation (CLF)|This single-session intervention addresses the individuals' perceived barriers and facilitators of crisis line use during periods of suicidal crisis.
11041550|NCT04488055|Active Comparator|Enhanced Usual Care (EUC)|Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with the NSP Lifeline and a list of outpatient mental health and substance use resources and encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms.
11041551|NCT04488042|Experimental|Stapler-less|after the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
11041552|NCT04488042|Active Comparator|Conventional Stapler|no reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
11041553|NCT04488029|Experimental|Experimental Group|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Research staff will remotely setup a PCT account for the subjects, and provide instructions for logging into the PCT application. During the treatment period, patients will be instructed to use PCT for at least 30 minutes a day and at least 5 days a week. Performance data (accuracy and latency) will be reported by the PCT software to the treating clinician and will be used to modify task assignment over time. PCT tracks usage of the program so that research staff can access automated reporting of subject use to monitor participant adherence to the treatment program.
11041554|NCT04488029|Active Comparator|Control Group 1 [Conventional Workbook Therapy]|At the start of the study, subjects will be provided with a tablet with videoconferencing software and the PCT app pre-installed. Subjects in the control group will be told they will have access to 3-months of PCT after their participation in the study has concluded. Subjects in this group will be provided with a standard regime of paper workbooks and instructions to complete approximately 30 minutes a day at least 5 days a week.
11041555|NCT04488016|Experimental|Cohort 1 -Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
11041556|NCT04488016|Experimental|Cohort 2- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
11041557|NCT04488016|Experimental|Cohort 3- Part 1|Subjects will be randomized to one of 4 sequences ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
11041558|NCT04488016|Experimental|Cohort 4 - Part 1|Subjects will be randomized to one of 4 sequences: ABC, BAC, ABD, or BAD. Subjects will receive 100 mg acalabrutinib capsule, fasted state (>10 h) in Treatment A , 100 mg acalabrutinib tablet (Variant 1), fasted state (>10 h) in Treatment B, 100 mg acalabrutinib tablet (Variant 1), fed state in Treatment C, Rabeprazole 20 mg ×1 (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1)* and following prior administration of rabeprazole 20 mg BID (with meals) on Days -3, -2 and -1 in Treatment D.
11041559|NCT04488016|Experimental|Cohort 1- Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC. In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
11041560|NCT04488016|Experimental|Cohort 2 - Part 2|Subjects will be randomized to one of 2 sequences in a 2×4 crossover: ABCD or BADC.In Part 2, subjects will be receiving 100 mg acalabrutinib tablet (Variant 1), Variant 2, Variant 3, and 100 mg acalabrutinib solution.
11041561|NCT04488003|Experimental|Part A: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
11041562|NCT04488003|Experimental|Part B: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
11041563|NCT04488003|Experimental|Part B: Physician's choice of treatment|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice). If a patient progresses on physician's choice of treatment, crossover to the ulixertinib arm is permitted.
11041564|NCT04487990|No Intervention|Control group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l.
11041565|NCT04487990|Experimental|Intervention group|Patients on continuous hemodialysis (blood flow 150 ml / min, dose of 30 ml / kg / h) receiving anticoagulation with sodium citrate at 4 mmol / l associated with unfractionated heparin at 10U / Kg / h.
11041566|NCT04487977||Surveyed professionals|
11041567|NCT04487964|Active Comparator|the conventional therapy according to the MOH protocol.|Patients who are receiving conventional therapy according to the MOH protocol.
11041568|NCT04487964|Active Comparator|conventional therapy +Liquorice cap and Boswellia Serrata gum|Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy
11041569|NCT04487951||Moderate|Moderate: moderate COVID -19 pneumonia
11041570|NCT04487951||Severe|_severe COVID-19 pneumonia
11041571|NCT04487938||Tobacco use and/or alcohol consumption|
11041572|NCT04487938||No tobacco use and/or alcohol consumption|
11041573|NCT04487925|Experimental|Intervention group: up to 3 modified natural cycles|Patients will receive up to 3 modified natural cycles in stead of a conventional ovarian hyperstimulation
11041574|NCT04487925|No Intervention|Control group: conventional ovarian stimulation|Patients will receive a conventional ovarian stimulation with corifollitropin alfa.
11041575|NCT04487912|Active Comparator|Injection of 99m-Tc Tilmanocept|
11041576|NCT04487912|Active Comparator|Injection of 99m-Tc Nanocolloid|
11041577|NCT04487899||Instructors group|Group of flight instructors at the reactor school.
11041578|NCT04487899||Students group|Group of students at the reactor school.
11041579|NCT04487886|Experimental|Duvelisib|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.
11041580|NCT04487886|Placebo Comparator|Placebo|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.
11041581|NCT04487873||Bronchiectasis|Having been diagnosed with non-cystic fibrosis bronchiectasis
11041582|NCT04487873||Healthy individuals|Healthy individuals without chronic disease
11041583|NCT04487860|Experimental|AS012 dose regimen I|Oral
11041584|NCT04487860|Experimental|AS012 dose regimen II|Oral
11041585|NCT04487860|Experimental|AS012 dose regimen III|Oral
11041586|NCT04487860|Experimental|AS012 dose regimen IV|Oral
11041587|NCT04487860|Placebo Comparator|Placebo|Oral
11041588|NCT04487847|Experimental|PIRADS 1-2|25 patients with PIRADS 1-2 (probably benign) on mpMRI
11041589|NCT04487847|Experimental|PIRADS 3|25 patients with PIRADS 3 (equivocal scan) on mpMRI
11041590|NCT04487847|Experimental|PIRADS 4-5|25 patients with PIRADS 4-5 (probably malignant) on mpMRI
11041687|NCT04487197||Cohort 1|"Adult patients (age ≥ 18 years),
~kidney or pancreas or pancreatic islets transplantation
~transplanted patients (period: 01.01.2020 to 30.06.2020)"
11041591|NCT04487834|Active Comparator|Simethicone Solution|Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.
11041592|NCT04487834|Experimental|Multilac Baby|Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.
11041593|NCT04487821|Experimental|Experimental Group|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. This contained 4 types of progressive activities. Respectively every type contains 2 to 4 tasks, performed in sets of 10 repetitions for 4 weeks.
~Results were obtained by using Balance scoring system, and physical performance test for speed and agility"
11041594|NCT04487821|No Intervention|Control Group|"Control group: (Group B) Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment. They were asked to perform the regular drills.
~Results were obtained using Balance Error scoring system and physical performance test for speed and agility."
11041595|NCT04487808|Active Comparator|Average American Diet|Diet representative of average American intake in terms of diet quality measured by the Healthy Eating Index-2015.
11041596|NCT04487808|Active Comparator|Average American Diet + Pecans|Diet that approximates average American intake in terms of diet quality measured by the Healthy Eating Index-2015, but includes 2 oz./day of pecans.
11041597|NCT04487808|Active Comparator|Healthy Diet + Pecans|High diet quality, measured by Healthy Index-2015 score >95, and includes 2 oz./day of pecans.
11041598|NCT04487795||under 18 years old|
11041599|NCT04487795||18-40 years old|
11041600|NCT04487795||41-60 years old|
11041601|NCT04487795||over 60 years old|
11041602|NCT04487782||High SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be African-American/Black.
11041603|NCT04487782||High SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be Caucasian/White.
11041604|NCT04487782||Low SES / African-American Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be African-American/Black.
11041605|NCT04487782||Low SES / Caucasian Women|Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of lower socioeconomic status (SES) and will be Caucasian/White.
11041606|NCT04487756|Experimental|Atezo+DCvac|"- Induction (4 cycles, every 3 weeks): Carboplatin area under the curve (AUC) 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) or cisplatin (60 mg/m2) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle) Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)
~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks) DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33."
11041607|NCT04487743|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
11041608|NCT04487743|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
11041609|NCT04487730|Experimental|"Engage-S Psychotherapy"|"Engage-S, a modified adapted version of Engage. Its principal intervention is social reward exposure - facilitating engagement in rewarding and meaningful social activities with significant others. In Engage-S therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding social activities of their choice."
11041610|NCT04487730|Active Comparator|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
11041611|NCT04487717||Low risk|good prognosis
11041612|NCT04487717||Intermediate risk|moderate prognosis
11041613|NCT04487717||High risk|poor prognosis
11041614|NCT04487704|Other|Camrelizumab in the treatment of liver cancer|Camrelizumab intravenous infusion (no need for prophylactic administration), no less than 30 min
11041615|NCT04487691|Experimental|Platelet Lysate|Inhaled nebulized platelet lysate (PL), 2-ml 1x per day for 8 weeks.
11041616|NCT04487691|Active Comparator|Saline|Inhaled nebulized normal sterile saline, 2-ml 1x per day for 8-weeks.
11041617|NCT04487678|Experimental|Low-dose KE|141 mg/kg bodyweight of ketone esters
11041618|NCT04487678|Experimental|High-dose KE|282 mg/kg bodyweight of ketone esters
11041619|NCT04487665||positive COVID-19|patient diagnosed by nasopharyngeal positive COVID-19
11041620|NCT04487652|Placebo Comparator|Placebo spray|Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray
11041621|NCT04487652|Experimental|CoQ10 spray|The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.
11041622|NCT04487639|Experimental|Cohort : patients needing oncofertility preservation|
11041623|NCT04487626|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
11041624|NCT04487613|Active Comparator|Moringa oleifera leaf|Participants received Moringa oleifera leaf 450 mg capsule orally twice daily for 3 days.
11041625|NCT04487613|Placebo Comparator|Placebo|Participants received placebo capsule orally twice daily for 3 days.
11041688|NCT04487197||Cohort 2|"Adult patients (age ≥ 18 years),
~kidney or pancreas or pancreatic islets transplantation
~Transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020."
11041626|NCT04487600|Experimental|Active Voiding Trial|At the completion of surgery, a Foley catheter was left in place. When the patient was determined to be ambulatory by the recovery room nurse, the bladder was backfilled with 300cc of sterile normal saline. Voiding 200cc or (2/3) of the backfill amount was considered passing.
11041627|NCT04487600|No Intervention|Passive Voiding Trial|At the completion of surgery, a Foley catheter was removed in the operating room. Study participants were allowed six hours to void spontaneously, with 200cc being considered adequate consistent with institution standard practice. At the completion of six hours, if spontaneous voiding has not occurred, a bladder scan was performed and additional time was allowed based on bladder volume with criteria previously established as institution standards based on published practices.
11041628|NCT04487587|Active Comparator|Active|Cediranib 20mg tablet OD (5 days out of 7) and Olaparib 300mg tablet BD (continuous) + standard of care
11041629|NCT04487587|Placebo Comparator|Placebo|Placebo Cediranib 20mg tablet OD (5 days out of 7) and Placebo Olaparib 300mg tablet BD (continuous) + standard of care
11041630|NCT04487574|Experimental|XC221|"XC221 100 mg orally.
~1 tablet of XC221 100 mg 2 times a day during 14 days of treatment period."
11041631|NCT04487574|Placebo Comparator|Placebo|"Placebo orally.
~1 tablet of Placebo 2 times a day during 14 days of treatment period"
11041632|NCT04487561|Other|aspirative drainage|Drainage is the usual treatment after axillary lymphadenectoma for breast cancer
11041633|NCT04487561|Active Comparator|Hemopatch|The hemopatch group will be the group without drainage and with a product patch
11041634|NCT04487548|No Intervention|Control group|The control group will have their preadmission clinic visit booked as normal, which is usually less than 2 weeks before surgery.
11041635|NCT04487548|Experimental|Intervention group|The intervention group will have their preadmission clinic visit booked approximately 4-6 weeks preoperatively.
11041636|NCT04487535|Other|Standard Total Knee Arthroplasty Surgery|Surgery performed by one orthopedic surgeon
11041637|NCT04487522||Retromuscular ventral hernia repair|These subjects will undergo an open, a laparoscopic, or a robotic-assisted retromuscular ventral hernia repair.
11041638|NCT04487522||Retromuscular TAR ventral hernia repair|These subjects will undergo an open or a robotic-assisted retromuscular transversus abdominis release (TAR) ventral hernia repair.
11041639|NCT04487483|Experimental|Sleep App|"Participants in this condition will receive full free access to the Pro version of the sleep app and asked to use the app every day for three months."
11041640|NCT04487483|No Intervention|Control|Participants in this condition will be asked to continue their life as normal and abstain from downloading or using any sleep aid and/or sleep tracker app for three months.
11041641|NCT04487470|Experimental|Flavored Filtered Cigars|Half of the group will be randomized to start with flavored filtered cigars (FCs) at the second visit and cross over to unflavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
11041642|NCT04487470|Experimental|Unflavored Filtered Cigars|Half of the group will be randomized to start with unflavored FCs at the second visit and cross over to flavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
11041643|NCT04487457||Cancer|Patients receiving chemotherapy alone after immunotherapy for NSCLC or bladder cancer
11041644|NCT04487444|Experimental|Ta1 treatment arm|Ta1 at a dose of 1.6 mg will be administered SC in 1 mL of diluent daily for a total of 1 week, in addition to standard of care.
11041645|NCT04487444|No Intervention|Control arm|No treatment will be provided in addition to standard of care.
11041646|NCT04487431|Experimental|BAY1817080 Part A|Healthy male participants will receive BAY1817080 given as an oral solution (study Part A)
11041647|NCT04487431|Experimental|[14C]BAY1817080 Part B|Healthy male participants will receive BAY1817080 blended with [14C]BAY1817080 given as an oral solution (study Part B).
11041648|NCT04487418|Experimental|Surgery group with electro cautery|Surgery will be performed with electro cautery.
11041649|NCT04487418|Experimental|High level diode laser surgery|High power diode laser surgery will be performed.
11041650|NCT04487405||Group A|Symptomatic with adnexal mass
11041651|NCT04487405||Group B|Asymptomatic with adnexal mass
11041652|NCT04487405||Group C|Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant
11041653|NCT04487392|Active Comparator|Estrogen vaginal cream group (group A)|22 participants will be included in this group. The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home.
11041654|NCT04487392|Experimental|Photobiomodutation group (group B)|22 participants will be included in this group. The participants selected for group B will be undergo photobiomodulation with red LED.
11041655|NCT04487379||Group with edentulous ridge|This group had edentulous ridge planning to receive a dental implant and had ultrasound and cone-beam computed tomography images of the ridge.
11041656|NCT04487366|Active Comparator|Double Operator Ultrasound-Guided Regional Anesthesia|resident control block needle and ultrasound probe and asistant operator inject the solution. resident reach the target area created in the phantom model using a block needle with ultrasound guidance
11041657|NCT04487366|Active Comparator|Jedi Grip|resident control block needle, ultrasound probe and syringe independently with jedi grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject and aspirate the solution.
11041658|NCT04487366|Active Comparator|On-lock grip|resident control block needle, ultrasound probe and syringe independently with on-lock grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
11041659|NCT04487366|Active Comparator|Bedforth alternative grip|resident control block needle, ultrasound probe and syringe independently with bedforth's alternative grip; reach the target area created in the phantom model using a block needle with ultrasound guidance; inject the solution.
11041689|NCT04487184|Active Comparator|Facilitation|From origin to insertion
11041690|NCT04487184|Experimental|Relaxation|From insertion to origin
11041691|NCT04487184|Placebo Comparator|Cross|Cross the muscle fiber
11041692|NCT04487184|Sham Comparator|Control|No tape
11041693|NCT04487158|Active Comparator|Small Changes|
11041694|NCT04487158|Experimental|INSPIRE|
11042300|NCT04482907|Active Comparator|Group receiving dill|They took 3 meals a day, 3x300 mg dry dill powder by mouth. They bought dry dill powder for 90 days.
11041660|NCT04487353|Experimental|Experiment I Group|"After 4 hours of theoretical training, 35 students will be followed by a computer-aided and guided virtual birth practice. After 4 hours of theory training, the information form (DEDBF) to be prepared by the researchers for use in this research will be applied as the first test.
~After the virtual birth application is watched to the experimental groups, the DEDBF questions will be changed and the posttest will be done. Also, at this stage, Cognitive Load Scale and Feel of Inventory will be applied to the experimental groups after the application.
~In all three groups, DEDBF will be applied again after 6 weeks, and the effectiveness of the application of virtual birth will be examined in remembering and recalling the information."
11041661|NCT04487353|Experimental|Experiment II Group|"After 4 hours of theoretical training, 35 students will be shown a computer-free and non-guided virtual birth practice. After 4 hours of theory training, the information form (DEDBF) to be prepared by the researchers for use in this research will be applied as the first test.
~After the virtual birth application is watched to the experimental groups, the DEDBF questions will be changed and the posttest will be done. Also, at this stage, Cognitive Load Scale and Feel of Inventory will be applied to the experimental groups after the application.
~In all three groups, DEDBF will be applied again after 6 weeks, and the effectiveness of the application of virtual birth will be examined in remembering and recalling the information."
11041662|NCT04487353|No Intervention|Control Group|"Virtual birth practice will not be shown to 35 students who will only receive 4 hours of theory training. After 4 hours of theory training, the information form (DEDBF) to be prepared by the researchers for use in this research will be applied as the first test. No application will be made to the control group, The DEDBF questions will be replaced and a post-test will be done after 4 hours of theory training.
~In all three groups, DEDBF will be applied again after 6 weeks, and the effectiveness of the application of virtual birth will be examined in remembering and recalling the information."
11041663|NCT04487327|Experimental|Dry Needling within the Myofascial Trigger Point|Randomized to receive DN at the site of the MTrP
11041664|NCT04487327|Active Comparator|Dry Needling away from Myofascial Trigger Point Site|Randomized to receive DN 2 cm away from the site of the MTrP but within the same muscle
11041665|NCT04487314||Patients without Chronic Venous Disease|Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
11041666|NCT04487314||Patients with Chronic Veinous Disease|Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer).
11041667|NCT04487288|Experimental|CEUS with fusion|Control group: The historic cohort is used to compare the results of the biopsy using fusion only technique from 2013 to 2019.
11041668|NCT04487275|Experimental|Drug|MLC901 capsules three times per day over 6 months
11041669|NCT04487275|Placebo Comparator|Placebo|Placebo capsules three times per day over 6 months
11041670|NCT04487262|Active Comparator|Day O chest tube removal|"Chest tubes maybe removed ten hours after arrival at the intensive care provided standardized removal criteria are fulfilled:
~blood loss through chest tubes less than 200 ml during the last four hours
~no air leak
~the patient extubated and mobilized It remains at the discretion of the attending cardiac surgeon to postpone chest tube removal in cases of increased bleeding risk, due to circumstances which develop during the perioperative period"
11041671|NCT04487262|Active Comparator|Day 1 chest tube removal|"Chest tubes are removed in the early morning of the first postoperative day, provided standardized removal criteria are fulfilled:
~blood loss through chest tubes less than 200 ml during the last four hours
~no air leak
~the patient extubated and mobilized It remains at the discretion of both the attending surgeon and anestesiologist to remove chest tubes prematurely in cases of drain-induced, severe analgetic resistant, intractable pain resistant to analgetic treatment."
11041672|NCT04487249|Experimental|Vision Therapy|Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.
11041673|NCT04487249|No Intervention|Observation|Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.
11041674|NCT04487236|Experimental|ZN-A-1041 50mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
11041675|NCT04487236|Experimental|ZN-A-1041 100mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
11041676|NCT04487236|Experimental|ZN-A-1041 200mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
11041677|NCT04487236|Experimental|ZN-A-1041 400mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
11041678|NCT04487236|Experimental|ZN-A-1041 600mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
11041679|NCT04487236|Experimental|ZN-A-1041 800mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
11041680|NCT04487236|Experimental|ZN-A-1041 1000mg|"Phase 1a:
~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
11041681|NCT04487236|Experimental|ZN-A-1041 level 1+Capecitabine 1000 mg/m2|"Phase 1b:
~ZN-A-1041 level 1+Capecitabine 1000 mg/m2; ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.
~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle."
11041682|NCT04487236|Experimental|ZN-A-1041 level 2+Capecitabine 1000 mg/m2|"Phase 1b:
~ZN-A-1041 level 2+Capecitabine 1000 mg/m2; ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study.
~Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle."
11041683|NCT04487236|Experimental|ZN-A-1041 level 3 +Capecitabine|"Phase 1c:
~The actual dose levels of ZN-A-1041 to be used in the combination Capecitabine will be determined based on the MTD identified in the Phase 1b study."
11041684|NCT04487210|Experimental|Phase 1a (Low Dose)|15 subjects will be enrolled to receive Low-dose S-protein with adjuvant MVC-COV1901.
11041685|NCT04487210|Experimental|Phase 1b (Medium Dose)|15 subjects will be enrolled to receive Medium-dose S-protein with adjuvant MVC-COV1901.
11041686|NCT04487210|Experimental|Phase 1c (High Dose)|15 subjects will be enrolled to receive High-dose S-protein with adjuvant MVC-COV1901.
11042370|NCT04482530|Experimental|isomaltulose recipe|fruit pastes with some of the sugars will be replaced (25% min) by isomaltulose
11041695|NCT04487145|Experimental|HIV-infected children on EFV-based ART (E3)|30 HIV-infected children age 3 - 10 years on EFV-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
11041696|NCT04487145|Experimental|HIV-infected children on DTG-based ART (D3)|30 HIV-infected children age 11 - 17 years on DTG-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
11041697|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L1)|20 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take one oral dose DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
11041698|NCT04487145|Experimental|HIV-infected children on LPV/r-based ART (L3)|30 HIV-infected children age 3 - 10 years on LPV/r-based ART for at least 10 days will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used.
11041699|NCT04487145|Active Comparator|HIV-uninfected children (C1)|20 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 1st dose. Control group for L1.
11041700|NCT04487145|Active Comparator|HIV-uninfected children (C3a)|30 HIV-uninfected children age 3-10 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. PK samples are collected after the 3rd dose. Control group for E3 and L3.
11041701|NCT04487145|Active Comparator|HIV-uninfected children (C3b)|30 HIV-uninfected children age 11-17 years not on ART will take standard 3 consecutive once-daily oral doses of DP (20/120mg tablets) based on weight per 2015 WHO guidelines for DP. The brand name Duocotexin will be used. Control group for D3.
11041702|NCT04487132|Active Comparator|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan provided to the controlled group
11041703|NCT04487132|Active Comparator|Recess or lunch time activities|Preparing the playground by offering adequate spaces and games provided to the experimental group
11041704|NCT04487106|Experimental|Treatment (azacitidine, venetoclax, trametinib)|"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
11041705|NCT04487093|Experimental|neoantigen vaccine + EGFR-TKI|
11041706|NCT04487093|Experimental|neoantigen vaccine + anti-angioge|
11041707|NCT04487080|Experimental|Treatment Arm A (Open-label): Amivantamab and Lazertinib|Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.
11041708|NCT04487080|Active Comparator|Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.
11041709|NCT04487080|Experimental|Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib|Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
11041710|NCT04487067|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
11041711|NCT04487054|No Intervention|Usual care|Subjects in the ICU with a poor prognosis will receive usual care in time period one.
11041712|NCT04487054|Experimental|Usual care plus palliative care|Subjects in the ICU with a poor prognosis will receive usual care plus targeted pro-active palliative care intervention within 48 hours of ICU admission in time period two.
11041713|NCT04487041|Active Comparator|Young HIV negative group|HIV uninfected participants that are 18-35 years of age will receive the standard dose flu vaccine. Participants who did not respond to the standard dose flu vaccination, as defined by less than a four-fold increase in flu antibody titer from baseline, will then receive the high dose flu vaccination 1 year after initial standard dose flu vaccination. Participants who respond to the standard dose flu vaccination will not receive the high dose flu vaccination.
11041714|NCT04487041|Experimental|Young HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 18-35 years of age, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
11041715|NCT04487041|Experimental|Old HIV negative group|HIV uninfected participants that are 65 years and older will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
11041716|NCT04487041|Experimental|Old HIV positive group|HIV infected viral suppressed participants, who are on anti-retroviral therapy (ART) aged 65 years and older, will receive the standard dose flu vaccine first followed by the high dose flu vaccine 1 year after initial standard dose.
11041717|NCT04487028||Thoracic Surgical Patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
11041718|NCT04487015|No Intervention|Part I: Non-Digital (Control)|Participants who currently receive performance nutrition support, via a qualified practitioner as indicated by a member of the sports science team at their sporting organisation, will be assigned to the non-digital approach (control). These participants will not receive any intervention from the research team for the duration of this study (6 weeks).
11041719|NCT04487015|Experimental|Part I: MP+ Call + MesC [6 weeks]|For part one of study, participants who currently do not receive performance nutrition support, will be given access to an app-based menu planner (MP) for 6 weeks with coach support that gives ad-hoc messaging and calls.
11041748|NCT04486833|Active Comparator|Phase 2 Active Comparator|Patients will continue on monotherapy osimertinib 80 mg fixed dose oral daily tablet until second progression event (PFS2).
11041749|NCT04486820||Chordoma|Patients diagnosed with chordoma
11041720|NCT04487015|Experimental|Part II: Stage 1- MP [1week]|For the pilot SMART trial (part two of study), participants (not the same participants as part one) who currently do not receive performance nutrition support, will be given access to a menu planner app (MP) for 4 weeks. In the first 1 week, participants will only receive MP.
11041721|NCT04487015|Experimental|Part II: Stage 2 - R1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1week, this group of participants are considered responders (R1) so they continue with MP only for another 1 week.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
11041722|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP [1 week]|"For participants in Part II: Stage 1- MP [1week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to continue with MP only for another 1 week.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
11041723|NCT04487015|Experimental|Part II: Stage 2 - NR1-MP + Call + MesC [1 week]|"For participants in Part II: Stage 1- MP [1 week], after the first 1 week, this group of participants are considered non-responders (NR1) and are re-randomised to have MP and additional coach support for another 1 week. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
11041724|NCT04487015|Experimental|Part II: Stage 3 - R2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered responders (R2) so they continue with MP only for 2 weeks.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
11041725|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to use MP only for another 2 week.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
11041726|NCT04487015|Experimental|Part II: Stage 3 - NR2-MP + Call + MesC [2 weeks]|"After going through Part II: Stage 2, this group of participants are considered non-responders (NR2) and are re-randomised to have MP and additional coach support for another 2 weeks. The coach support consists of up to 3 coach-initiated messaging and ad-hoc calls to participant.
~Participants' response status is dependent on whether they are randomised to using the stringent or relaxed engagement criteria as described in study details."
11041727|NCT04487002|Experimental|group A|underwent localized resection
11041728|NCT04486989|Experimental|Cardiovascular Conditioning Protocol|Participants will complete a sub maximal cardiovascular training program twice per week for a period of 4 weeks.
11041729|NCT04486989|Active Comparator|Voice Production Exercises|Participants will complete voice production exercises twice per week for a period of 4 weeks.
11041730|NCT04486976|Experimental|Normal|
11041731|NCT04486976|Experimental|Glaucoma|
11041732|NCT04486976|Experimental|Cataract|
11041733|NCT04486963|Experimental|Sanhuangjingshimingwan group|Sanhuangjingshimingwan,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
11041734|NCT04486963|Placebo Comparator|Sanhuangjingshimingwan Placebo group|Sanhuangjingshimingwan placebo,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.
11041735|NCT04486950|Experimental|Cohort 1 (Low Dose): TAK-951 20 mcg Infusion Over 60 Minutes|TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.
11041736|NCT04486950|Experimental|Cohort 2 (High Dose): TAK-951 TBD Infusion Over 60 Minutes|TAK-951 to be determined (TBD) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
11041737|NCT04486950|Experimental|Cohort 3 (High Dose): TAK-951 TBD Infusion for <60 Minutes|TAK-951 TBD or TAK-951 placebo-matching, infusion, intravenously, over a period of less than (<) 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
11041738|NCT04486937|Experimental|SC10914|400mg TID，oral admination on an fasting state
11041739|NCT04486911|Experimental|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
11041740|NCT04486898|Experimental|Music group|Music group will be receiving music intervention 3 times a day for 30 minutes per session for the duration of five (5) weeks period.
11041741|NCT04486898|No Intervention|Usual care|Those who will be in this group will be ask to continue doing their actual activities and not to partake in any kind of music listening or therapy for the 5 week period.
11041742|NCT04486872|Experimental|anti-CD19 and anti-CD20 dual specific CAR-T Cells|
11041743|NCT04486859|Other|mechanical prevention|patients were managed with IPC
11041744|NCT04486859|Other|machanical plus anticoagulant drugs prevention|patients were managed with IPC, and LMWH was added 24h after surgery and followed by riaroxaban 5 days after surgery
11041745|NCT04486846|Experimental|eVisit|The study intervention will be an electronically performed surveillance program replacing face-to-face clinic follow-up visits. At 3 month intervals for 1 year, the patient will receive an email reminder generated by the patient portal to complete lab testing and eVisit questionnaire.
11041746|NCT04486833|Experimental|Phase 1|"Up to 3 sequential dose escalation cohorts will be treated with GPX-001 intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet.
~The first group will receive GPX-001 IV infusion at 0.06 mg/kg, the next group 0.09 mg/kg and the third will receive 0.12 mg/kg. Additional GPX-001 dose levels may be evaluated until RP2D is identified."
11041747|NCT04486833|Experimental|Phase 2 Combination|Patients will receive the RP2D of GPX-001 intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet starting on Day 10. The 21-day treatment cycle will continue until second progression event (PFS2) or unacceptable toxicity.
11041750|NCT04486794|Experimental|Treatment at baseline|
11041752|NCT04486781|Experimental|Combination Therapy|All study participants will receive Pembrolizumab + sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. Pembrolizumab will be given at Day 1 of each 3 week cycle. The study drug (sEphB4-HSA) will be given at Day 1, 8, and 15 of each 3 week cycle.
11041753|NCT04486755|Experimental|Dose Level 1|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
11041754|NCT04486755|Experimental|Dose Level 2|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
11041755|NCT04486755|Experimental|Dose Level 3|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
11041756|NCT04486742|Experimental|Itch CBT Arm|Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.
11041757|NCT04486742|No Intervention|Usual Care Arm|Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.
11041758|NCT04486716|Experimental|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
11041759|NCT04486703|Experimental|Exercise with music group|physical therapy program combined with music therapy
11041760|NCT04486703|Experimental|Exercise group|physical therapy program without music
11041761|NCT04486690|Experimental|propofol group|"Propofol infusion, 25-150mic/kg/min.
~Fentanyl infusion, 1-2 mcg/kg/h.
~Atracurium infusion, 3-12 mic/kg/min"
11041762|NCT04486690|Active Comparator|ketofol group|"Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.
~Fentanyl infusion, 1-2 mcg/kg/h.
~Atracurium infusion, 3-12 mic/kg/min"
11041763|NCT04486677|Other|Caring Cards Group|Group of Veteran card-makers.
11041764|NCT04486677|Other|Caring Cards Recipients|Group of Veteran card-recipients.
11041765|NCT04486664|Experimental|Mediterranean diet|Mediterranean diet twice per day for four weeks
11041766|NCT04486664|Placebo Comparator|Conventional diet|Conventional diet for four weeks
11041767|NCT04486651|Experimental|HX008 plus Irinotecan|Participants recieve HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
11041768|NCT04486651|Placebo Comparator|Placebo plus Irinotecan|Participants recieve placebo intravenous (IV) every 3 weeks (Q3W) plus irinotecan 160 mg/m², IV, Q2W.
11041769|NCT04486638||Pregnant women and their offspring(s)|Women and their offspring(s) exposed to Dengvaxia during pregnancy
11041770|NCT04486625|Experimental|Cohort 1|Normal renal function
11041771|NCT04486625|Experimental|Cohort 2|Severe renal impairment (not on dialysis)
11041772|NCT04486612||hypotension|
11041773|NCT04486612||non-hypotension|
11041774|NCT04486599|Experimental|Electromagnetic Navigation|The patient have to low Flow Vascular Abnormality diagnosed by Duplex Ultrasound and MRI. Decision of Ultrasound Guided Percutaneous Foam Sclerotherapy taken in multidisciplinary staff meeting
11041775|NCT04486586|Experimental|Active tDCS plus Speech-Language Therapy first|Active tDCS will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to sham tDCS after a washout period.
11041776|NCT04486586|Sham Comparator|Sham plus Speech-Language Therapy first|Sham will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to an active tDCS after a washout period.
11041777|NCT04486573|Other|CMRI|"Clinical data will be collected regarding cardiac risk factors, cancer type, and cancer treatment.
~CMRI will be performed:
~Within 2 weeks before the first fraction of radiation therapy (RT)
~Within 1 week of the final fraction of RT (before or after)
~Any patient with a pre-RT and post-RT MRI scan will be considered evaluable.
~Pre- and post-RT CMRI parameters will be compared.
~3D reconstructed CMR images will be co-registered with RT treatment plans to assess for spatial associations."
11041778|NCT04486560|Experimental|Single Arm: Cryoprobe|Everyone who enrolls in this study will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe.
11041779|NCT04486547|No Intervention|Follow up Posttest and HbA1c|56.0% of the adolescents with type 1 diabetes were aged 12-14 years and 52.0% were male in the control group (n=25)
11041780|NCT04486547|Experimental|Information Motivation Behavioral Skills Based Intervention|52.0% of the adolescents with type 1 diabetes were aged 15-18 years and 52.0% were female(n=25)
11041781|NCT04486534||Case group|36 patients between the ages of 18-65, who have been followed up for at least 3 months with the diagnosis of unilateral transtibial amputation and who have been using prostheses for at least 3 months
11041782|NCT04486534||Control group|36 age and body mass index (BMI)-matched healthy controls
11041783|NCT04486521||Experimental|anti-IL-6 drugs (tocilizumab and siltuximab)
11041784|NCT04486521||Active Comparator|Anti-IL-6 drugs (tocilizumab and siltuximab) and corticosteroids combination
11041785|NCT04486508|Experimental|Intermediate dose anticoagulation|Intermediate dose anticoagulation will be the the tested regimen. The anticoagulation regimen will be modified according to weight/ body mass index, and creatinine clearance level (Cl Cr). Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according to Cockcroft-Gault Formula.
11041786|NCT04486508|Active Comparator|Standard Prophylaxis|Standard prophylaxis dose anticoagulation will be the anticoagulation of choice in the control arm. Enoxaparin will be the primary agent for anticoagulation, with unfractionated heparin reserved only for patients with creatinine clearance of ≤15 mL/min according Cockcroft-Gault Formula.
11041787|NCT04486508|Experimental|Atorvastatin 20|Atorvastatin 20 mg daily will be the statin therapy of choice in the intervention arm
11041788|NCT04486508|Placebo Comparator|Atorvastatin 20 mg Matched placebo|Matching placebo will be used for the control arm
11041791|NCT04486469|Experimental|Subjects with Irritable bowel syndrome|Experimental group is formed with 24 patients diagnosed with IBS treated in the digestive system service of the Virgen de la Arrixaca and Reina Sofía General University Hospitals.
11041792|NCT04486443|Experimental|Intervention Group|Patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour. All forms were applied to the group before the music therapy, respectively. Prior to musical therapy, the patient's preferred classical music (Rast or Hejaz modes) was asked by the specialist and 10 minutes of music therapy was performed according to patient's choice. Clinical data and pain scores were obtained 5, 30 and 60 minutes after music therapy. 6 sessions of music therapy were applied on different days. Patient Follow-up Form was recorded before and after each therapy. The forms were evaluated 3 times, before the application, after the 3rd and 6th application.
11041793|NCT04486443|No Intervention|control group|The control group consisted of patients who only received analgesic treatment and underwent routine nursing care, and didn't have any interventions. All forms were assessed 3 times, before application, after the 3rd application and after the 6th application. The Patient Information Form and K-MASF were applied only once.
11041794|NCT04486430|Experimental|Neu2000KWL 2750mg dose group|Low dose group
11041795|NCT04486430|Experimental|Neu2000KWL 5250mg dose group|Middle dose group
11041796|NCT04486430|Experimental|Neu2000KWL 6000mg dose group|High dose group
11041797|NCT04486430|Placebo Comparator|Placebo|Placebo
11041798|NCT04486404||Group 1|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra and Ec.
11041799|NCT04486404||Group 2|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra, Ch and Ec.
11041800|NCT04486391|Experimental|Tislelizumab|Tislelizumab monotherapy for up to 45 months
11041801|NCT04486391|Experimental|Salvage chemotherapy|Salvage chemotherapy for up to 45 months
11041802|NCT04486378|Experimental|RO7198457|Participants will receive a recommended dose of RO7198457.
11041803|NCT04486378|Other|Observational Group|Observational group will undergo watchful waiting, which is the standard of care in this setting.
11041804|NCT04486378|Experimental|Biomarker Cohort|15 patients
11041805|NCT04486378|Experimental|Exploratory Cohort|20 patients
11041806|NCT04486365|Active Comparator|Bifocal bone transport|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
11041807|NCT04486365|Active Comparator|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments between osteotomy and defect.
11041808|NCT04486352|Experimental|Atezolizumab and Bevacizumab Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with no specified gene signatures will be enrolled in this cohort. Twenty patients will be enrolled. Once twenty patientsare enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
11041809|NCT04486352|Experimental|Atezolizumab and Ipatasertib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with PIK3CA/AKT1/PTEN-altered tumors will be enrolled in this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
11041810|NCT04486352|Experimental|Atezolizumab and Talazoparib Cohort|Following the submission of tumor tissue to Foundation Medicine for the FoundationOne® assay, patients with tumors that have a ≥16%genomic loss of heterozygosity (LOH) will be assigned to this cohort. Twenty patients will be enrolled. Once twenty patients are enrolled, the cohort will be closed to further enrollment. Patients in this study cohort will commence treatment as specified on Day 1 of each cycle.
11041811|NCT04486339|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.
11041812|NCT04486326|Experimental|crofelemer|125mg bid
11041813|NCT04486326|Placebo Comparator|placebo|bid
11041814|NCT04486313|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
11041815|NCT04486313|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
11041816|NCT04486300|No Intervention|Season of presentation|Comparison of number of presented cases in each season
11041817|NCT04486300|Active Comparator|Intervention|Surgical intervention of failed Pneumatic cases is done
11041818|NCT04486287|Experimental|Sintilimab Arm|Sintilimab after Stereotactic Ablation Brachytherapy.
11041819|NCT04486274|Experimental|non MOSE arm|Three needle passes will be performed for each mass
11041820|NCT04486274|Experimental|MOSE arm|The endoscopist will perform biopsy until a macroscopic visible core (MVC) will be obtained and specimen will be placed in a container (Container A-MOSE). If the needle passes performed are less than 3 (1 or 2 passes) the specimens acquired in the remnant passes to join standard care of 3 passes, according to ESGE guidelines, will be placed in a second container (Container B).
11041821|NCT04486261|Experimental|High-intensity strength training|"16 weeks of high-intensity strength training three per week.
~Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient)
~Interventions:
~Other: high-intensity strength training Drug: Usual care"
11041822|NCT04486261|No Intervention|Control|"Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient).
~Intervention:
~Drug: Usual care"
11041823|NCT04486235|Experimental|Intervention|Receive experiential pamphlet
11041824|NCT04486235|No Intervention|Control|No materials, usual care
11041825|NCT04486222|Experimental|Experimental Group|The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.
11041892|NCT04485767|Experimental|Progressive Resistance Training Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend structured progressive resistance exercise training sessions 2 times/week for six months.
11041826|NCT04486222|Active Comparator|Standard Treatment Group|The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.
11041827|NCT04486222|Sham Comparator|Sham Control|The sham control group would receive an rTMS course with sham high-frequency stimulation (10Hz) at left DLPFC (40 trains, 1600 pulses) followed by sham low-frequency (1Hz) inhibition at right DLPFC (10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't sham-R't sham-1.5 hr-L't sham-R't sham), five days a week, and two weeks in total.
11041828|NCT04486222|Experimental|Open-label Experimental Group|"Partial unblinding (control group or not control group, rather than experimental group, standard treatment group and sham control group) would be done at the end of the third week. If the participant were in control group and HAM-D 17 scores neither decreased for ≥ 50% nor were ≤ 7 points at the end of the third week, he or she would enter an extending open-label trial, that participants would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total."
11041829|NCT04486196|Experimental|Control (No Laser) Group|The final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water.
11041830|NCT04486196|Experimental|Laser Disinfection (LD) Group|After final irrigation was performed using 5ml 2.5% NaOCI, followed by 5 ml 17% EDTA for 3 min and 5 ml distilled water, root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle. This cycle was applied 4 times for each root canal. The optical fiber (Medency) was inserted 1 mm short of the apex and the root canals were slowly (at a speed of 2mm/s) irradiated from apical to coronal in continuous circling movements to treat all dentinal tubules in one cycle for each power.
11041831|NCT04486183|Experimental|Intervention|The data were collected by the researcher at the waiting room of the blood collection unit at a close distance to the lavatory. The capillary first and second blood drop values taken from the patients after fasting and at two hours following OGTT and capillary and venous blood glucose values were compared.
11041832|NCT04486170|No Intervention|Control group: Current hospital education practices|The control group will receive standard of care postpartum educational materials provided by the nursing and resident physician staff. The will be asked to complete a brief questionnaire to determine if they would be interested in receiving education in a video formal.
11041833|NCT04486170|Experimental|Intervention group: Standardized video and pamphlet|The subjects enrolled in the invention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room. They will also be provided with a pamphlet with similar information that was discussed in the video. They will also be asked to complete a brief, anonymous survey to assess patient satisfaction with the video shown, no patient identifiers will be collected.
11041834|NCT04486157|Experimental|IN-A012|Intravenous administration of IN-A012
11041835|NCT04486157|Active Comparator|Akynzeo capsules|Single oral administration of Akynzeo capsules
11041836|NCT04486144|Experimental|COVID19 Positive: Intervention Group (Receive extract)|These are patients that are COVID19 positive who elect to try the extract.
11041837|NCT04486144|No Intervention|COVID19 Positive: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 positive who do NOT elect to try the extract
11041838|NCT04486144|Experimental|COVID19 Exposed: Intervention Group (Receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to try the extract.
11041839|NCT04486144|No Intervention|COVID19 Exposed: Comparison Group (Do NOT receive extract)|These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to NOT try the extract.
11041840|NCT04486118|Active Comparator|CA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:
~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
11041841|NCT04486118|Placebo Comparator|nonCA-ACEi|"Enrolled subjects will begin treatment with a low dose of study drug (5 mg) Study drug will then be titrated up as follows, provided the increased dose is tolerated:
~Day 3-15 (dosing begins after completion of FIMR Visit 1.1): 5 mg Day 29: 10 mg Day 43: 20 mg Day 57: 40 mg if tolerated Subjects will be required to achieve and maintain a minimum dose of 20 mg daily to ensure adequate dosage of the ACE inhibitor."
11041842|NCT04486105|Placebo Comparator|control|vehicle only for one week
11041843|NCT04486105|Experimental|40g sucrose ingestion|40g sucrose treatment on top of habitual diet for one week
11041844|NCT04486105|Experimental|80g sucrose ingestion|80g sucrose treatment on top of habitual diet for one week
11041845|NCT04486105|Experimental|120g sucrose ingestion|120g sucrose treatment on top of habitual diet for one week
11041846|NCT04486092|Experimental|Valproic Acid|
11041847|NCT04486079|Experimental|Carbohyrate loading|Group A will receive 400ml of the carbohydrate rich drink, Nutricia preOp 2 hours before operation. This is the intervention group.
11041848|NCT04486079|No Intervention|Fasting|Group B will be prepared before the operation with a 24-hour fasting. This is the current clinical standard.
11041849|NCT04486066|Experimental|Mindfulness-Based Stress Reduction (MBSR)|In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
11041893|NCT04485767|Active Comparator|Flexibility and Balance Exercise|Men with prostate cancer who are about to begin androgen-deprivation therapy (ADT) will attend flexibility and balance exercises training sessions 2 times/week for six months.
11041894|NCT04485754|Experimental|Telemedicine FU|Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
11041850|NCT04486066|Experimental|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 sessions in a group format, while retaining all essential elements.
11041851|NCT04486066|Other|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
11041852|NCT04486053||Patients with flexor tendon injury|Patients between the ages of 5-16 who have applied to orthopedics emergency department due to hand injury and have been operated with flexor tendon injury, for the last 3 years, were retrospectively scanned from hospital record. Eligible patients for the study were informed about the study by telephone and requested to come hospital for further evaluations including sensory, motor and functional assessments.
11041853|NCT04486040|Active Comparator|Drainage group|Patients with drainage after hip revision arthroplasty
11041854|NCT04486040|Active Comparator|No-drainage group|Patients without drainage after hip revision arthroplasty
11041855|NCT04486027||Healthy|Healthy individuals not smoking, not using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, not receiving chemotherapy, not being hypothyroidic
11041856|NCT04486027||Active Rheumatoid Arthritis|Active Rheumatoid Arthritis meeting American College of Rheumatology (ACR) RA remission criteria
11041857|NCT04486027||Rheumatoid Arthritis in remission|Rheumatoid Arthritis in remission meeting American College of Rheumatology (ACR) RA remission criteria
11041858|NCT04486014|Experimental|Erector spinae plane block (ESP)|Patients would receive erector spinae plane block
11041859|NCT04486014|Experimental|Serratus anterior plane block (SAP)|Patients would receive serratus anterior plane block
11041860|NCT04486001|Experimental|Treatment Group|This is single arm study with only comparison to non-treated cohorts at site.
11041861|NCT04485988||No-beta blocker|
11041862|NCT04485988||beta blocker|
11041863|NCT04485962|Experimental|Fibroblasts and keratinocytes treated patients|Fibroblasts and keratinocytes treated patients
11041864|NCT04485949|Experimental|IGV-001|Participants will be implanted with 20 biodiffusion chambers of IGV-001 on Day 1 and explanted with IGV-001 on Day 3. After 6 weeks, participants will receive radiotherapy (RT) per institutional standards for 5 days per week along with temozolomide 75 mg/m^2 orally, once daily (QD) for up to Week 12 followed by temozolomide 150 to 200 mg/m^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 40).
11041865|NCT04485949|Placebo Comparator|Placebo|Participants will be implanted with 20 biodiffusion chambers of placebo on Day 1 and explanted with placebo on Day 3. After 6 weeks, participants will receive RT per institutional standards for 5 days per week along with temozolomide 75 mg/m^2 orally, QD for up to Week 12 followed by temozolomide 150 to 200 mg/m^2, orally, on Days 1 to 5 of each 28-day cycle for up to 6 cycles (Week 40).
11041866|NCT04485936|Experimental|Epitomee Device|the participants receive the device which is non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of early satiation and prolonged satiety
11041867|NCT04485910|Active Comparator|Single step media|Embryos cultured in single step media
11041868|NCT04485910|Active Comparator|Sequential media|Embryos cultured in sequential media
11041869|NCT04485897|Experimental|icare HOME|
11041870|NCT04485884|Experimental|Group A|IN-C005 dose A
11041871|NCT04485884|Experimental|Group B|IN-C005 dose B
11041872|NCT04485884|Experimental|Group C|IN-C005 dose C
11041873|NCT04485884|Experimental|Group D|IN-C005 dose D
11041874|NCT04485884|Experimental|Group E|IN-C005 dose E
11041875|NCT04485884|Experimental|Group F|IN-C005 dose F
11041876|NCT04485871|Experimental|Omega-3 fatty acids|3.6 g EPA:DHA / day (2:1)
11041877|NCT04485858|Experimental|CorNeat KPro|Intraocular implantation of the CorNeat KPro
11041878|NCT04485845|Active Comparator|metformin treated group|A group of patients treated with a daily dose of metformin
11041879|NCT04485845|Experimental|vildagliptin treated group|A group of patients treated with a daily dose of vildagliptin
11041880|NCT04485832|Active Comparator|Intervention|
11041881|NCT04485832|Active Comparator|Control|
11041882|NCT04485819||Cleavage stage transfer|Poor responders who transfer their embryos in cleavage stage on day 3
11041883|NCT04485819||Blast stage transfer|Poor responders who transfer their embryos on blast stage on day 5/6
11041884|NCT04485806|Other|GPS / LM versus SPL/LM|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with light mineral oil (LM).
11041885|NCT04485806|Other|GPS/PO versus SPL/PO|to determine the effect of micro droplet geometry in 3D dishes (GPS) or 2D dishes (SPL) in combination with paraffin oil (PO).
11041886|NCT04485806|Other|GPS/PO versus GPS/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 3D dishes (GPS).
11041887|NCT04485806|Other|SPL/PO versus SPL/LM|to determine the effect of oil overlay light mineral(LM) or paraffin oil (PO) in combination with paraffin oil 2D dishes (SPL).
11041888|NCT04485793|Active Comparator|Active Comparator|Dietary supplement
11041889|NCT04485793|Placebo Comparator|Placebo comparator|Placebo
11041890|NCT04485780|Placebo Comparator|Botulinum toxin injection during surgery|Patients in this group underwent Botulinum toxin injection during surgery
11041891|NCT04485780|Experimental|Botulinum toxin injection one week before surgery|Patients in this group underwent Botulinum toxin injection at the outpatient clinic one week before surgery
11041895|NCT04485754|Active Comparator|Office FU|Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
11041896|NCT04485728|Experimental|Sleep Improvement Intervention|
11041907|NCT04485676||Dalbavancin|"Patients to be included in this study have been treated with Dalbavancin according to clinician's judgement and clinical practice according national or international guidelines.
~Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Information about dosing treatment will be collected."
11041908|NCT04485663|Experimental|ALG-010133|Subcutaneous injections of ALG-010133 in HV or CHB subjects once every 7 days
11041909|NCT04485663|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects once every 7 days
11041910|NCT04485650|Experimental|Music group|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group. The number of participants:30
11041911|NCT04485650|Active Comparator|Sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
11041912|NCT04485650|Other|Non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
11041913|NCT04485637|Other|Communication with basic table|Blood pressure communication showing a basic table representing only the normal range of blood pressure readings
11041914|NCT04485637|Other|Communication with enhanced table|Communication showing an enhanced table (Fig 1B) with more reference information for interpreting blood pressure readings, including how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
11041915|NCT04485637|Other|Communication with enhanced graph|Communication showing an enhanced graph (adapted from Blood Pressure UK) for interpreting blood pressure readings, showing the same color-coded ranges as the enhanced table, with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
11041916|NCT04485624||Attendees at Paediatric Emergency Department 1 (PED1)|These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large district general hospital.
11041917|NCT04485624||Attendees at Paediatric Emergency Department 2 (PED2)|These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large children's hospital.
11041918|NCT04485611|Experimental|Prehabilitation|This pilot cohort will undergo an intervention and will be followed for up to 6 months. The study does not include a comparator group.
11041919|NCT04485585|Experimental|Sequence T/M/T+M|"A total of 36 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(T, M, T+M) assigned to on sequence group in Period 1, Period 2, and Period 3.
~Period 1(T): BR9006-1 (Tamsulosin HCL 0.2mg) - 1 capsule QD, five-day repeated-dose
~Period 2(M): BR9006-2 (Mirabegron 50mg) - 1 tablet QD, eleven-day repeated-dose
~Period 3(T+M): BR9006-1 (Tamsulosin HCL 0.2mg) 1 capsule + BR9006-2 (Mirabegron 50mg) 1 tablet QD, five-day repeated-dose
~Washout period between Period 1 and Period 2: five days
~Washout period between Period 2 and Period 3: none"
11041920|NCT04485572||Straight Leg Raise test and Bragard test|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
11041921|NCT04485572||Fajersztajn test (F) and Sicard test (S)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
11041922|NCT04485572||Passive Neck Flexion test (PNF)and Kernig test (K)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
11041923|NCT04485572||Slump test (ST) and Dejerine triad (DT)|Patients referred to the radiology department, allocated to undergo MRI scan and neurodynamic tension tests
11041924|NCT04485559|Experimental|Treatment (trametinib, everolimus)|Patients receive dosing per their assigned dose level. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11041925|NCT04485546|Experimental|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj|
11041926|NCT04485533|Experimental|VisuXL® Gel/HYLO®|Patients treated with VisuXL® ophthalmic gel for the first 30 days (1 treatment period) and with HYLO® for the second 30 days (2 treatment period).
11041927|NCT04485533|Active Comparator|HYLO®/VisuXL® Gel|Patients treated with HYLO® for the first 30 days (1 treatment period) and with VisuXL® ophthalmic gel for the second 30 days (2 treatment period).
11041928|NCT04485520|Experimental|Carica Papaya extract|Carica Papaya at 3%
11041929|NCT04485520|Active Comparator|Chlorhexidine|0.12% chlorhexidine mouthwash formulation (commercially available)
11041930|NCT04485507|Experimental|Nature-VR|Viewing 3D pictures of natural environments
11041931|NCT04485507|Active Comparator|Urban-VR|Viewing 3D pictures of urban environments
11041932|NCT04485494||Professional Rugby Athletes|These are the cohort of players that consent to the study and have a preseason baseline blood sample taken. If the participant from this cohort then receives a concussion they are assessed by the World Rugby's Head Injury Assessment (HIA) and then enter into the return to play (RTP) protocol which means they cannot play a competitive game for 6 days.
11041933|NCT04485481|Experimental|Experimental: Cohort 1:1 - 1:6 ADX-914|ADX-914 single SC dose
11041934|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 1:1 - 1:6 placebo|Placebo single SC dose
11041935|NCT04485481|Experimental|Experimental: Cohort 2:1- 2:3|ADX-914 multiple SC dose once every 2 weeks for 6 weeks
11041936|NCT04485481|Placebo Comparator|Placebo Comparator: Cohort 2:1- 2:3|Placebo multiple SC dose once every 2 weeks for 6 weeks
11041937|NCT04485468||Parkinson's disease patients|Parkinson's disease patients and over 18 years old
11041938|NCT04485455|Experimental|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
11041939|NCT04485429|Experimental|Methylprednisolone + Standard treatment|Participants will receive the standard treatment and methylprednisolone.
11041940|NCT04485429|Experimental|Full-dose heparin + Standard treatment|Participants will receive the standard treatment and full-dose heparin,
11041941|NCT04485429|Experimental|Methylprednisolone + Full-dose heparin + Standard treatment|Participants will receive the standard treatment, methylprednisolone and full-dose heparin
11041942|NCT04485429|No Intervention|Standard treatment|Participants will receive the standard treatment
11041943|NCT04485416|Experimental|Treatment group|Subjects will receive eltrombopag
11041944|NCT04485403|Experimental|Ibuprofen|Depending on body weight, patients will be divided into two groups. Women with a body weight <70 kg will be taking a daily dose of 800 mg ibuprofen orally. Women ≥ 70 kg will take a dose of 1200 mg ibuprofen orally. Before and after 3 weeks of treatment, all subjects will have a full hormonal, biochemical and clinical profile.
11041945|NCT04485390||First responder group|Cardiac arrest victims in remote areas resuscitated by the first responders before the arrival of the EMS.
11041946|NCT04485390||EMS groups|Cardiac arrest victims in remote areas resuscitated by the EMS.
11041947|NCT04485351||Diabetic patients from the University Hospital of Nancy|
11041948|NCT04485325|Active Comparator|Tofacitinib|Tofacitinib (Xeljanz®; 5 mg twice daily, p.o.)
11041949|NCT04485325|Active Comparator|Etanercept|Etanercept (Enbrel®; 50 mg once per week, s.c.)
11041950|NCT04485312|Active Comparator|caries preventive protocol|preventive protocol for special needs ( tooth brushing , topical fluoride and mouth wash)
11041951|NCT04485312|Other|chlorhexidine varnish added to the caries preventive protocol|chlorhexidine varnish preventive caries protocol for special needs
11041952|NCT04485299|Experimental|bifluorid 10 varnish|Bifluorid 10 (NaF and CaF) lead to reduce the dentin hypersensitivity, the sodium fluoride (NaF) dissociates and releases F ions, that diffuse through the tubules and then precipitates as calcium fluoride as a consequence of the high of calcium content in saliva and dentinal fluid ,The calcium fluoride (CaF) present in the varnish composition diffuses into the tubules and block the canal with a semi-permanent protective layer.The calcium fluoride is added to block the dentin tubules mechanically, by the combination with the calcium fluoride resulted from the sodium fluoride reaction to the calcium of dentin.
11041953|NCT04485299|Active Comparator|sodium fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
11041954|NCT04485286|Experimental|Lung Cancer Subjects Undergoing Radiation Therapy|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging 1) prior to radiation therapy and 2) 3-6 months after radiation therapy
11041955|NCT04485273|Active Comparator|Dexmedetomedine Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected, in addition to dexmedetomedine.
11041956|NCT04485273|Placebo Comparator|Control Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected.
11041957|NCT04485260|Experimental|Part A, Arm 1, Cohort 1|KRT-232 by mouth once daily for Days 1-7, off treatment for Days 8-28 (28 day cycle)
11041958|NCT04485260|Experimental|Part A, Arm 2, Cohort 1|KRT-232 by mouth once daily for Days 1-5, off treatment for Days 6-28 (28 day cycle)
11041959|NCT04485247|Active Comparator|Conventional group|conventional laparoscopic appendectomy with 3-ports
11041960|NCT04485247|Experimental|TULAA group|An operator extracts and ligates appendix through umbilical port.
11041961|NCT04485234||All patients|All lesions undergo assessment with coronary pressure sensor and either Doppler velocity or coronary thermodilution
11041962|NCT04485221||Children with a TECPR2 mutation|"Children with a TECPR2 mutation, age 18 months to 12 years old.
~Assessments will include collection of genetic mutation reports, functional assessments, and questionnaires. There will be a singular blood draw and skin biopsy."
11041963|NCT04485208|Experimental|Active|Patients will undergo ten to thirty minutes of transcranial ultrasound treatment. The sonification device will be aimed at the thalamus. Targeting will include reference to scalp fiducials based on the obtained MRI; confirmation of target accuracy will either be obtained by Doppler waveform confirmation or optical tracking technology which co-registers patient neuroimaging with real space.
11041964|NCT04485195|Active Comparator|Vernakalant|Patients randomized to this arm will receive an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump.82 For patients ≤ 100 kg the infusion is prepared by adding 25 mL of BRINAVESS 20 mg/mL to 100 mL of diluent creating a total volume of 125 mL at a concentration of 4 mg/mL. For patients > 100 kg the infusion is prepared by adding 30 mL of BRINAVESS 20 mg/mL to 120 mL of diluent creating a total volume of 150 mL at a concentration of 4 mg/mL. For patients weighing ≥ 113 kg, the maximum initial dose is 339 mg (84.7 mL of 4 mg/mL solution).
11041965|NCT04485195|Active Comparator|Procainamide|Patients randomized to this arm will receive a continuous infusion of IV procainamide with a dose of 15 mg/kg in 500 mL of normal saline given over 60 minutes (maximum dose 1,500 mg), by a pre-programmed pump. While the CAEP Best Practices Checklist suggests an infusion time of 30-60 minutes, we believe that a 60-minute period will avoid some adverse events.
11041966|NCT04485182||First|Patients receiving Transcutaneous Electrical Nerve Stimulation + underwater massage + spine gymnastics +
11041967|NCT04485182||controll group|Patients receiving Transcutaneous Electrical Nerve Stimulation + spine gymnastics
11041968|NCT04485169|Experimental|TPE Arm|In addition to standard care TPE was performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access was achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume was calculated as per Nadler's formula. Anticoagulant acid dextrose ratio was 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation was monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume was removed during each procedure. Replacement fluid was fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures were performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE was continued till recovery
11041969|NCT04485169|No Intervention|NON TPE arm|Only supportive treatment offered including Vit C, Zinc, Vit D, famotidine, Enoxaparin and Methylprednisolone
11041970|NCT04485156|Active Comparator|Arm 1 (Conventional treatment group)|"Will be treated as recommended by Korean Guidelines For Tuberculosis as well as WHO guidelines (e.g. isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months followed by isoniazid, rifampicin, (and ethambutol)) Duration of the treatment
~- 6 months in total"
11042004|NCT04484909|Experimental|Treatment (NBTXR3, radiation therapy)|Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity.
11041971|NCT04485156|Experimental|Arm 2 (High-dose rifampicin group)|"High-dose rifampicin, isoniazid, and pyrazinamide
~Rifampicin: 30mg/kg
~Isoniazid: 300mg/day
~Pyrazinamide: 1000mg/day (<50kg), 1500mg/day (50-70kg), 2000mg /day (>70kg), till culture conversion Duration of the treatment
~Till 12 weeks after culture conversion on liquid media"
11041972|NCT04485143||experimental group|Non-invasive Wearable Device
11041973|NCT04485130|Experimental|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
11041974|NCT04485130|Placebo Comparator|Placebo|This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
11041975|NCT04485117|Active Comparator|Sevoflurane Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane anesthesia under BIS monitoring.
11041976|NCT04485117|Active Comparator|Propofol Group|Laryngeal mask airway is inserted and anesthesia is maintained with propofol infusion under BIS monitoring.
11041977|NCT04485104|Experimental|Standard of care (SOC) plus GWP42003-P|
11041978|NCT04485104|Active Comparator|SOC|
11041979|NCT04485091|Experimental|Group A: 20% TCM and PBM|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with photobiomodulation (PBM) with red spectrum LED (660nm) on the back of the hands.
11041980|NCT04485091|Placebo Comparator|Group B: 20% TCM and PBM placebo|21 participants will be included in this group. Application of chemical peel of 20% trichloroacetic acid solution (TCM) in association with simulated photobiomodulation on the back of the hands.
11041981|NCT04485078||Axial spondyloarthritis patients|QST with clinical scales
11041982|NCT04485078||Healthy controls|QST
11041983|NCT04485065|Experimental|IBI188+azacitidine|
11041984|NCT04485052|Experimental|IBI188+azacitidine|Participants receive IBI188 every four weeks(Q4W) by intravenous(IV) and azacitidine daily in Day1-7 of each four weeks(Q4W) by subcutaneous(IH)
11041985|NCT04485039|Other|ABCDE|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet."
11041986|NCT04485039|Other|ACEBD|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate"
11041987|NCT04485039|Other|ADBEC|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 1334 mg calcium acetate
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 1600 mg sevelamer carbonate
~Single oral dose of TPOXX 600 mg co-administered with a single oral dose of 500 mg lanthanum carbonate chewable tablet
~Single oral dose of TPOXX 600 mg co-administered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet"
11041988|NCT04485039|Other|AEDCB|"Single oral dose of TPOXX 600 mg
~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 500 mg lanthanum carbonate chewable tablet.
~Single oral dose of TPOXX 600 mg coadministered with a single oral dose of 1334 mg calcium acetate
~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 500 mg sucroferric oxyhydroxide chewable tablet
~Single oral dose of TPOXX 600 mg coadministered with single oral dose of 1600 mg sevelamer carbonate"
11041989|NCT04485026|Experimental|Local Consolidative Radiation Therapy Arm|Definitive external beam radiation therapy will be delivered to all sites of progressive disease for all patients. The technique used to deliver radiation therapy will be determined by the treating radiation oncologist.
11041990|NCT04485026|Active Comparator|Standard of Care - Control Arm|Second line systemic therapy is at the discretion of the treating medical oncologist.
11041991|NCT04485013|Experimental|Monotherapy Dose Escalation|
11041992|NCT04485000|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1) in addition to receiving standard postnatal care.
11041993|NCT04485000|Other|Waitlist Cpntrol|The waitlist control group will receive standard postnatal care for 12 weeks and will participate in the online 1-day CBT-based workshop at T2 (12 weeks post baseline).
11041994|NCT04484987|Other|TRE group|Time-restricted eating group
11041995|NCT04484987|Other|Control group|Time-unrestricted eating group
11041996|NCT04484974|Experimental|Pecan snack condition|In this crossover condition, a mid morning snack consisting of 300 kcal of lightly salted roasted pecan nuts will be administered.
11041997|NCT04484974|Active Comparator|Pretzel snack condition|In this crossover condition, a mid morning snack consisting of 300 kcal of lightly salted pretzels will be administered.
11041998|NCT04484961|No Intervention|Control - Routine Rehab|Participants in this group received standard ACL rehab with no blood flow restriction therapy.
11041999|NCT04484961|Experimental|Experimental - BFR|Participants in this group received standard ACL rehab with the addition of blood flow restriction therapy.
11042000|NCT04484948|Experimental|Systemic sclerosis|Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria
11042001|NCT04484935|Experimental|Nirsevimab|"1st RSV season: 50mg nirsevimab
~st RSV season: 100mg nirsevimab
~nd RSV season: 200mg nirsevimab"
11042002|NCT04484922|Experimental|Dexmedetomidine|
11042003|NCT04484922|Placebo Comparator|Control|
11042117|NCT04484155|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
11042005|NCT04484896|Experimental|Gain-frame Message|"Short messaging service (SMS) message: Dear group O/A Rh-D negative blood donor:
~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to save lives. Thank you for your support.
~Please bring your identification (ID) card and show this message to our staff. Thank you."
11042006|NCT04484896|Experimental|Loss-frame Message|"SMS message: Dear group O/A Rh-D negative blood donor:
~Hello! The inventory of group O/A Rh-D negative blood product is low at present, but patients with such blood group are in urgent need of blood. If you can, please consider donating blood again to prevent the loss of life. Thank you for your support.
~Please bring your ID card and show this message to our staff. Thank you."
11042007|NCT04484896|Experimental|Information Message|"SMS message: Dear group O/A Rh-D negative blood donor:
~Hello! The inventory of group O/A Rh-D negative blood product is low at present, if you can, please consider donating blood again. Thank you for your support.
~Please bring your ID card and show this message to our staff. Thank you."
11042008|NCT04484896|No Intervention|Control group|Donors in this group were not received SMS reminders.
11042009|NCT04484870|Experimental|Danshu capsule group|The patients in Danshu group were treated with Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets)，The course of treatment was 6 months
11042010|NCT04484870|Active Comparator|ursodeoxycholic acid group|UDCA group, 250mg/ was taken orally twice a day (0.25g/, Losan Pharma GmbH company). The course of treatment was 6 months
11042011|NCT04484857|Experimental|Roxadustat|
11042012|NCT04484844|Experimental|Shield Force Plus Varnish|Shield force plus (SFP), Self-reinforcing (SR) monomer technology supplied in the form of one component self-etching light-cured dental adhesive, which is characterized by an SR monomer component that penetrates the tooth substrate. Multi-point interactions with apatite calcium and three-dimensional cross-linking occur reactions.it forms a thin even, hard coating on the tooth surface that gives the tooth substrate a superior binding power.
11042013|NCT04484844|Active Comparator|Sodium Fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
11042014|NCT04484831|Experimental|ABT Weight Loss Intervention|Adolescent participants will attend sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
11042015|NCT04484831|Placebo Comparator|Enhanced Care|Adolescent participants will receive handouts on elements of a healthy lifestyle and will participate in a midpoint one-on-one nutrition consultation with a registered dietitian.
11042016|NCT04484818|Active Comparator|Arm A (ADT, placebo)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive a placebo four times daily (QID) for 52 weeks in the absence of disease progression or unacceptable toxicity.
11042017|NCT04484818|Experimental|Arm B (ADT, darolutamide)|Patients receive goserelin acetate, leuprolide acetate, or triptorelin via injection every 3 months for 12 months (4 injections), every 4 months for 12 months (3 injections), or every month for 12 months (12 injections) in the absence of disease progression or unacceptable toxicity. Patients also receive darolutamide QID for 52 weeks in the absence of disease progression or unacceptable toxicity.
11042018|NCT04484805|No Intervention|Baseline|The subject wears their usual socket with an ambient temperature sensor and step counter for approximately one month.
11042019|NCT04484805|Experimental|ICE Unit|"The subject wears the experimental socket with an ICE Unit, which includes a TEC and will be actively cooling the leg whenever the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
11042020|NCT04484805|Sham Comparator|Sham Unit|"The subject wears the experimental socket with a Sham Unit, which excludes a TEC and will not be actively cooling the leg when the device is powered on. An ambient temperature sensor and step counter is attached to the socket. The subject is only informed that each condition is a different level of cooling to reduce bias. This condition should last approximately one month."
11042021|NCT04484792|Experimental|Group A|
11042022|NCT04484792|Experimental|Group B|
11042023|NCT04484792|Placebo Comparator|Group C|
11042024|NCT04484779|Experimental|IIM System|The IIM system is comprised of an insulin lispro pen and/or an insulin glargine pen (both U-100), an investigational mobile medical application (MMA) that transmits data to cloud storage, an investigational Bluetooth Low Energy® (BLE)-paired insulin data transmission (IDT) module and a compatible commercially available BLE-paired blood glucose meter (BGM).
11042025|NCT04484766||Patient after pre-eclampsia|Patients with pre-eclampsia who were treated at the University Hospital of Jena between 1999-2009.
11042026|NCT04484766||Patients after PETN treatment|Patients of the PETN pilot study, with PETN and patients who received PETN as an individual therapy trial
11042027|NCT04484753|Other|Home Exercise Sheet|The participant took the sheet with the description of the exercises to his address.
11042028|NCT04484753|Other|Ipelvis mobile application|The participant received the app and performs home exercises guided by the app.
11042029|NCT04484753|Active Comparator|Home exercise sheet + Pelvic Physiotherapy|The participant did group physical therapy and used the exercise sheet at home on other days.
11042030|NCT04484753|Active Comparator|Ipelvis mobile application + Pelvic Physiotherapy|The participant did group physical therapy and used the mobile application on other days.
11042031|NCT04484740|Experimental|Gepotidacin|
11042032|NCT04484727||ICU-patients in ventilator treatment|Directly after intubation and start of mechanical ventilation a procedure of small PEEP steps is performed, 2 cmH2O at a time, while collecting data on airway pressure and tidal volume changes. The data is transferred into a dedicated software and lung elastance calculated. The procedure is repeated when clinical events such as disconnection of the tube, posture changes, suction, inhalation, CO2 insufflation etc. is performed, and repeatedly during the whole period of ventilator treatment.
11058432|NCT04368728|Experimental|Low-mid dose, 65-85 years of age (2 doses)|
11042033|NCT04484727||Surgery-patients during general anaesthesia|Directly after intubation and start of mechanical ventilation a procedure of small PEEP steps is performed, 2 cmH2O at a time, while collecting data on airway pressure and tidal volume changes. The data is transferred into a dedicated software and lung elastance calculated. The procedure is repeated when clinical events such as disconnection of the tube, posture changes, suction, inhalation, CO2 insufflation etc. is performed, and repeatedly during the whole period of ventilator treatment.
11042034|NCT04484714|Experimental|Behavioural: Exercise|"Participants will take part in a twelve week resistance and aerobic exercise program twice per week delivered virtually.
~Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises"
11042035|NCT04484701||PSMA-11 PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
11042036|NCT04484675|Active Comparator|Group IH(inhaled milrinone)|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
11042037|NCT04484675|Active Comparator|Group Iv(Intravenous milrinone)|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
11042038|NCT04484662|Other|Potted Mint Plants Intervention|We will measure 2 indoor environments (living room and bedroom) for placing potted plants. We will analyze the effect of potted mint plants on indoor air quality, fungal and bacterial concentration, and explore the correlation between the intervention of potted mint plants and cardiovascular health.
11042039|NCT04484649|Experimental|Intervention|Sleeping Healthy/Living Healthy
11042040|NCT04484649|Active Comparator|Control|Attention Control
11042041|NCT04484636|Other|Hepatocellular Cancer|molecular profiling - hepatocellular cancer (HCC)
11042042|NCT04484636|Other|Cholangiocarcinoma|molecular profiling - intra- and extrahepatic cholangiocellular carcinoma (CCA)
11042043|NCT04484636|Other|Gallbladder Cancer|molecular profiling - gallbladder carcinoma (GBCA)
11042044|NCT04484636|Other|Pancreatic Cancer|molecular profiling - pancreatic cancer (PanCa)
11042045|NCT04484636|Other|Oesophageal Cancer + Stomach Cancer|molecular profiling - esophagogastric cancer (EC/GC)
11042046|NCT04484623|Experimental|Arm A:Belantamab mafodotin plus Pomalidomide and Dexamethasone|
11042047|NCT04484623|Experimental|Arm B:Bortezomib plus Pomalidomide and Dexamethasone|
11042048|NCT04484610|Experimental|Appropriate Opioid Quantities|Pharmacists in the intervention regions are invited to complete an eLearning program to promote the practice change intervention of assessing and dispensing appropriate quantities of opioids prescribed for acute pain.
11042049|NCT04484610|No Intervention|Usual Practice|Pharmacists in the comparison regions are not targeted for the practice change intervention (they are not invited nor provided access to the eLearning program).
11042050|NCT04484584||Complex Decongestive Therapy Group (CDT)|"Complex Decongestive Therapy Group: The treatment was applied by a specialist therapist who received CDT training. The study group rehabilitation and CDT application is 1 hour. CDT Treatment Protocol:
~Deep abdominal technique application Neck region CDT application (supraclavicular fossa circular motion-Eflöraj) Circular movements on ipsilateral Axillar lymph nodes Circular movements on bottle neck cubital fossa Front arm bucket pumping pump push MLD application of dorsal and palmar face of the hand to ulnar and radial bundles
~Bandage Treatment (Fingers and hand and forearm bandage): Patients can stay for 6-8 hours or until the next day.
~Patients can do exercises in bandages. The patient is given home education.
~The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home. Orthopedic rehabilitation is the same as the control group."
11042051|NCT04484584||Orthopedic Rehabilitation Group (OR)|"Orthopedic Rehabilitation Group: The treatment was made for approximately 30-45 minutes. Patients were given exercise training at home.
~Orthopedic Rehabilitation Treatment Protocol:
~Exercises to be done at 4 to 6 weeks: Wrist NEH (at the pain limit),active exercise,Grasp exercise
~Exercises to be done at 6 to 8 weeks: Wrist NEH (at the pain limit),Active assistive / active exercise, Grasp exercise,Supination-pronation exercise. (Opposite baths and classical massage are recommended from orthopedics)
~Exercises to be done at 8 to 10 weeks: Stretching exercises,Finger strengthening spring with Digiflex spring, Power web combo hand finger arm amplifier, Msd theraflex hand exercise dough, Theraband flevbar exercise bar.
~Exercises to be done at 10 to 12 weeks Wrist strengthening exercises, Resistant exercises to all muscles."
11042052|NCT04484571|Experimental|Robotic treatment|Patients receive 4 weeks of elbow rehabilitation treatment provided by the NEEM robotic elbow exoskeleton
11042053|NCT04484571|Active Comparator|Conventional treatment|Patients receive 4 weeks of elbow conventional rehabilitation treatment matched in time
11042054|NCT04484545||Alive or Dead with COVID-19 diagnosis|Patients selected in phase 1 of study according to Health Protection Scotland criteria for diagnosis of COVID-19 infection Patients selected for phase 2 (validation phase) by PCR result
11042055|NCT04484532||Observational (trivalent influenza vaccine)|Within 14 days of baseline influenza titer, patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time, patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course, and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.
11042056|NCT04484519||Cognitively unimpaired|
11042057|NCT04484506|Experimental|Stage I/II nasal ENKTL|2-3 cycles of induction pegaspargase-COEP chemotherapy followed by concurrent chemoradiotherapy, then by 1-2 cycles of pegaspargase-COEP chemotherapy as consolidation
11042058|NCT04484506|Experimental|Stage III/IV or primary extra-nasal ENKTL|6-8 cycles of pegaspargase-COEP chemotherapy with or without local radiotherapy and/or consolidative autologous stem cell transplantation
11042059|NCT04484493|Experimental|mometasone nasal spray|Patients will receive topical corticosteroid nasal spray (mometasone furoate nasal spray) in appropriate dose of 2 puff in each nostril (100 µg once daily) beside olfactory training.
11042060|NCT04484493|No Intervention|control|Patients will not receive topical corticosteroid nasal spray but only olfactory training.
11042061|NCT04484480|Experimental|Balance training|Patients included in the study group, who received 3-month proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
11042062|NCT04484480|No Intervention|Control group|Patients included in the control group who did not received any intervention
11042063|NCT04484467|Experimental|Food supplement Standart Zdorovya GASTRO|"In the intervention group (Group 1), the supplement Standart Zdorovya GASTRO (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days."
11042064|NCT04484467|Placebo Comparator|Placebo|In the control group (Group 2), placebo (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days.
11042065|NCT04484454|Experimental|Omega 3 Oil Supplementation|Following all necessary screening, patients will be provided with the ProdromeNeuro Omega-3 oil supplement and instructed to consume the equivalent of 1 cc of the oil supplement per day for the first month, followed by 2 cc of the supplement/day for the second month, and finally ending with 4 cc/day of the supplement for the third month. Neurocognitive assessment and serology testing will take place at baseline, end of month 1, end of month 2, end of month 3, and one month post intervention-termination.
11042066|NCT04484441||Fetal surgical intervention group|Pregnant adult women carrying a fetus with a diagnosed congenital anomaly and scheduled to undergo fetal surgical intervention at Mayo Clinic.
11042067|NCT04484441||Control group - normal pregnancy|Pregnant adult women with normal ultrasound findings. These women will be matched with the subjects enrolled in the intervention cohort for parity, maternal age, ethnicity, fetal sex and gestational age at time of surgical intervention.
11042068|NCT04484428|Experimental|Treatment Arm A|K-285
11042069|NCT04484428|Active Comparator|Treatment Arm B|Menthol
11042070|NCT04484415|Experimental|Cevira® treatment|The Cevira® treatment is an integrated combination of drug and device
11042071|NCT04484415|Placebo Comparator|Placebo ointment|The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.
11042072|NCT04484402|Experimental|mesenchymal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells
11042073|NCT04484402|Experimental|limbal stem cells|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells
11042074|NCT04484402|Active Comparator|control|Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment
11042075|NCT04484389|Experimental|Study Group|Individual exercises will be applied to individuals with Chronic disease.
11042076|NCT04484389|Active Comparator|Control Group|Group to be given an exercise brochure
11042077|NCT04484376||Other invasive candida infection|Patients with invasive candida infection due a Candida specie othr than Candida Auris.
11042078|NCT04484376||Candida Auris related invasive infection|Candida Auris related invasive candida infection.
11042079|NCT04484350|Experimental|Intensive Blood Pressure management|Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
11042080|NCT04484350|Active Comparator|Standard Blood Pressure management|Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
11042081|NCT04484337|Experimental|Part 1:Cohort 1: CAB 400 mg/mL IM gluteal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via IM gluteal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via IM gluteal injection at Week 4.
11042082|NCT04484337|Active Comparator|Part 1:Cohort 1: CAB 200 mg/mL IM gluteal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 3 mL CAB 200 mg/mL via IM gluteal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 2 mL CAB 200 mg/mL via IM gluteal injection at Week 4.
11042083|NCT04484337|Experimental|Part 1:Cohort 2: CAB 400 mg/mL SC abdominal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via SC abdominal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via SC abdominal at Week 4.
11042084|NCT04484337|Active Comparator|Part 1:Cohort 2: CAB 200 mg/mL SC abdominal|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 300 mg as 1x 1.5 mL CAB 200 mg/mL via SC abdominal injection. Participants will receive a second injection of CAB 200 mg as 1 x 1 mL CAB 200 mg/mL SC abdominal at Week 4.
11042085|NCT04484337|Experimental|Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via IM (lateral thigh) injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via IM (lateral thigh) at Week 4.
11042086|NCT04484337|Active Comparator|Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 600 mg as 1 x 3 mL CAB 200 mg/mL via IM (lateral thigh) injection. Participants will receive a second injection of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (lateral thigh) at Week 4.
11042087|NCT04484337|Experimental|Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive injection 1 and injection 2 consisting of CAB 400 mg/mL formulation (to a maximum of 1200 mg/3 mL if given IM or 600 mg/1.5 mL if given SC). The determination of the dose and dosing schedule will be governed by the Study Team safety and PK Review (STR).
11042118|NCT04484142|Experimental|DS-1062a 6.0 mg/kg|Participants will receive 6.0 mg/kg of DS-1062a
11042890|NCT04478955||eyeliner and mascara|three days a week at least for 6 months
11042088|NCT04484337|Active Comparator|Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive CAB 200 mg/mL matched to the volume of CAB 400 mg/mL if administered subcutaneously. Should injection 1 be administered via the IM route, active control participants will receive CAB 200 mg/mL matched on dose to CAB 400 mg/mL. The determination of the dose and dosing schedule will be governed by the STR.
11042089|NCT04484337|Experimental|Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of up to 1400 mg of CAB 400 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.
11042090|NCT04484337|Active Comparator|Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of CAB 200 mg/mL formulation matched to the volume of CAB 400 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.
11042091|NCT04484337|Experimental|Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of <=2000 mg of CAB 400 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.
11042092|NCT04484337|Active Comparator|Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)|Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of CAB 200 mg/mL formulation matched to the volume of CAB 400 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.
11042093|NCT04484324|Experimental|60 seconds|60 seconds stretching group Stretching exercises for upper Trapezius and Levator the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times.
11042094|NCT04484324|Experimental|30 seconds|The same procedures while the therapist will maintain the stretch for 30 seconds.
11042095|NCT04484324|Experimental|15 seconds|The same procedures while the therapist will maintain the stretch for 15 seconds.
11042096|NCT04484324|Placebo Comparator|control|The therapist maintains the same manual contact without stretching force
11042097|NCT04484298|Experimental|reference group|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.
~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
11042098|NCT04484298|Experimental|TRINITRINE|0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered sublingually and CO was evaluated.
11042099|NCT04484285|Active Comparator|Younger Cohort|Healthy individuals aged 18 - 40
11042100|NCT04484285|Active Comparator|Older Cohort|Healthy individuals aged 65 - 85
11042101|NCT04484272|Active Comparator|Control Group|
11042102|NCT04484272|Experimental|Experimental Group|
11042103|NCT04484259|Experimental|Ticagrelor|ticagrelor 60 mg bid monotherapy
11042104|NCT04484259|Active Comparator|Aspirin plus Clopidogrel|aspirin 81 mg qd plus clopidogrel 75 mg qd
11042105|NCT04484259|Active Comparator|Aspirin plus Ticagrelor|aspirin 81 mg qd plus ticagrelor 60 mg bid
11042106|NCT04484233||Control Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management.
11042107|NCT04484233||Clinical Decision Support Group|Anesthesiologists would have to respond to an online questionnaire about 10 hypotheticals clinical situations regarding patient blood management helped by dedicated clinical decision support systems for patient blood management (iAnemia, Intelligence Anesthesia).
11042108|NCT04484220|Experimental|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients who have chronic kidney disease requiring dialysis.
11042109|NCT04484207|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
11042110|NCT04484207|Experimental|vignette intervention|A brief vignette about coping with COVID-19 stress presented to the participants
11042111|NCT04484207|No Intervention|Control|Only assessment, no intervention arrm
11042112|NCT04484194|Experimental|eHA Screening|Patients receiving eHA screening tool.
11042113|NCT04484181|Experimental|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
11042114|NCT04484181|Active Comparator|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer was based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
11042115|NCT04484168|Active Comparator|Terminal Interruption of the Reflux Source (TIRS|These patients will have foam sclerotherapy of the veins in the immediate vicinity of their venous ulcer and thereafter be managed in compression bandaging and followed up fro 6 months or until the ulcer has healed
11042116|NCT04484168|Active Comparator|Axial Ablation|These patients will undergo endovenous ablation of the great or small saphenous veins, or other large superficial veins exhibiting significant reflux
11042119|NCT04484129||Close contacts of MDR-TB patients|"Close contacts of MDR-TB who met the inclusion and exclusion criteria were enrolled. Routine follow-up is scheduled at week 8, 20, 32, and 80. During the visit, participants with suspected tuberculosis symptoms will have detailed clincial assessent, weight measurement, sputum smear, sputum culture and drug sensitivity examination, imaging examinations, etc. For patients diagnosed with TB, the trial ends. Proper treatment will be started. For all paricipants who are not diagnosed with tuebrculosis in previous follow-up, the last follow-up of this study is all face-to-face visits. Sputum smear, sputum culture and chest imaging screening will be performed when necessary to exclude the possibility of tuberculosis infection. In addition, If the participants has suspected TB symptoms or is diagnosed with TB in another hospital, the researchers can be contacted for follow-up at any time."
11042120|NCT04484116||Succesful surgery|PTH 24 hours after surgery <150pg/mL
11042121|NCT04484116||Unsuccessful surgery|PTH 24 hours after surgery >150pg/mL
11042122|NCT04484103||251 patients from the MRI-FIRST trial|The mpMRIs were performed at 16 centers with 1.5T or 3T MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging and dynamic contrast-enhanced imaging.
11042123|NCT04484090|Experimental|OhhMed|Treatment with OhhMed device for improving erectile function for men with erectile dysfunction
11042124|NCT04484077|Experimental|hCT-MSC infusion|A single, intravenous infusion of hCT-MSCs. Targeted dose is 2x10^6 cells/kg with a maximum dose of 10 x 10^7 cells/kg.
11042125|NCT04484064|No Intervention|Standard care|"Patients in the standard care arm will use an electronic adherence monitor (MEMS®) without any feedback (electronic data will be blinded to patients, clinicians and investigators until the analysis)"
11042126|NCT04484064|Experimental|Adherence program|"Patients in the adherence program will use the MEMS® and the pharmacist will provide an electronic feedback on medication adherence since the last visit. The identified determinants of medication adherence will be discussed with the patient."
11042127|NCT04484051|Active Comparator|Active comparator: Genotropin|Subcutaneous injections Genotropin, 0.6-0.8 mg/day. Participants start with 0.2 mg/day and the dose increases with 0.2 mg/day per month to a maximum dose of 0.6-0.8 mg/day.
11042128|NCT04484051|Placebo Comparator|Placebo comparator: Placebo|Placebo for 12 months.
11042129|NCT04484038|Other|IMRT, any mode|"External radiation therapy with 6-18 MV photons on the 62.5 Gy prostate bed in 25 2.5 Gy fractions (EQD2 71 Gy).
~Serving per fraction: 2.5 Gy Total fractions: 25 No. fractions / week: 5 Total treatment time: 5 weeks Total nominal dose: 62.5 Gy EQD3 (TRT): 68.75 Gy EQD1.5 (CaP): 71.43 Gy EQD2 (CaP): 68.75 Gy EQD10 (TRA): 65.10 Gy"
11042130|NCT04484025|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up
11042131|NCT04484025|Experimental|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up
11042132|NCT04484025|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 7 days, with 30-day follow-up
11042133|NCT04484012|Experimental|Treatment (CD19 CAR T cells, acalabrutinib)|Patients receive acalabrutinib PO BID on days -5 to 28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive CD19 CAR T cells IV on day 0. Treatment with acalabrutinib repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not attained CR after the first disease assessment and tolerated the initial CAR T cell infusion may receive a second CAR T cell infusion in cycle 2.
11042134|NCT04483986|Active Comparator|Study group|This arm is going to include the patients who are performed rectus reapproximation.
11042135|NCT04483986|No Intervention|Control group|This arm is going to include the patients who are not performed rectus reapproximation.
11042136|NCT04483973|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up
11042137|NCT04483973|Experimental|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 14 days, with 30-day follow-up
11042138|NCT04483973|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 14 days, with 30-day follow-up
11042139|NCT04483960|No Intervention|Antiviral - Standard of care|Standard of care without LPV/r or hydroxychloroquine
11042140|NCT04483960|Active Comparator|Antiviral - LPV/r|Lopinavir (400mg) / ritonavir (100mg) (LPV/r) twice daily for 10 days
11042141|NCT04483960|Active Comparator|Antiviral - LPV/r + hydroxychloroquine|Lopinavir (400mg) / ritonavir (100mg) (LPV/r) twice daily for 10 days + hydroxychloroquine (800mg twice a day for 1 day, followed by 400mg two times a day for 6 days)
11042142|NCT04483960|No Intervention|Antibody - Standard of care|No convalescent plasma
11042143|NCT04483960|Experimental|Antibody - convalescent plasma|Convalescent plasma (one unit) on day 1 and day 2
11042144|NCT04483947|Experimental|Cohort 1|9 participants will receive AZD2693 dose 1 and 3 participants will receive placebo
11042145|NCT04483947|Experimental|Cohort 2|16 participants will receive AZD2693 dose 2 and 8 participants will receive placebo
11042146|NCT04483947|Experimental|Cohort 3|16 participants will receive AZD2693 dose 3 and 8 participants will receive placebo
11042147|NCT04483934|Experimental|Patients treated with dermal fibroblasts|Cultured dermal fibroblasts and LED phototherepy
11042148|NCT04483921|Experimental|Exercise|Participants will complete a prescribed exercise bout.
11042149|NCT04483921|No Intervention|Sedentary|Participants will rest quietly in a seated position for the equivalent amount of time prescribed for the exercise condition.
11042150|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test > 12days (d) ago and no symptoms (~250 participants).
~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
11042151|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (~100 participants).
~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
11042152|NCT04483908||Cohort 3|Subjects with PCR negative test > 5d (~100 participants). Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
11042184|NCT04483700|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
11042153|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (~100 participants).
~Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
11042154|NCT04483895|Active Comparator|The OHL method|the ETT insertion depth was estimated according to the OHL method.
11042155|NCT04483895|Active Comparator|The 7-8-9 method|the ETT insertion depth was estimated according to the 7-8-9 method.
11042156|NCT04483882|Sham Comparator|Phase I- Visually Obscured Healthy Subjects|Tactile label to be evaluated by healthy subjects without visual defect. Subjects in visually obscuring lenses but without peripheral neuropathies or other tactile deficits will evaluate the tactile labeling product for efficacy in drug identity and dosing definition. .
11042157|NCT04483882|Active Comparator|Phase II- Low Vision Over 50 years of age|Subjects with documented Low Vision of 20/70 or less or visual field less than 20 degrees will be asked to evaluate tactile labeling product for efficacy in drug identity and dosing definition.
11042158|NCT04483856|Experimental|DermoRelizema cream|The treatment will be applied since about 7 (±3) days prior to RT start and will continue until 14 days post RT end
11042159|NCT04483856|Active Comparator|Dexeryl|The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
11042160|NCT04483843||CPE patients|All patients prehospitally treated for cardiogenic pulmonary edema in the pre-hospital emergency setting in the Central Bohemian region, Czech Republic.
11042161|NCT04483830|Placebo Comparator|group A|patient with the early stages of COVID-19 to received an oral dose of placebo twice a day for 21 days
11042162|NCT04483830|Active Comparator|group B|patient in the early stages of COVID-19 to received an oral dose of 500LRU of sulodexide twice a day for 21 days.
11042163|NCT04483817|Experimental|A: Transcutaneous tibial nerve stimulation|The transcutaneous electrostimulation of the posterior tibial nerve (ETNTP) will be applied to group A: place two surface electrodes, one 32 mm in diameter, 5 cm cephalad of the internal malleolus and 1 cm medial posterior of the tibia; and another 50x50 mm electrode in the calcaneous. The flexion of the first toe will indicate the correct placement of the electrodes. Stimulation is performed according to the Stoller method with a stimulator programmed at 20Hz and 200 µs, with a continuous current, 12 sessions, 2 weekly are completed. The intensity of the current will be tolerance by the subject.
11042164|NCT04483817|Active Comparator|B: Percutaneous tibial nerve stimulation|The percutaneous electrostimulation of the posterior tibial nerve (EPNTP) will be applied to group B: inserting a 0.25x30mm surgical steel needle at a 60º angle, 5 cm cephalad to the malleolus and 1 cm posterior of the tibia , and a surface electrode of 50x50 mm in the calcaneous. The flexion of the first finger will indicate its correct placement. The stimulation parameters will also follow the Stoller method.
11042165|NCT04483804||disease free survival|Time from randomization to relapse or death due to disease progression
11042166|NCT04483804||non-disease free survival|Time of metastasis or death
11042167|NCT04483778|Experimental|SCRI-CARB7H3(s)|Autologous CD4+ and CD8+ T-cells genetically modified to express an B7H3-specific CAR
11042168|NCT04483778|Experimental|SCRI-CARB7H3(s)x19|Autologous CD4+ and CD8+ T-cells genetically modified to a bispecific B7H3xCD19 CAR
11042169|NCT04483765||post-spinal hypotension|Patients with a fall in SBP by 25% of the preoperative baseline or an absolute value <90 mm of Hg; MAP ≤65 mmHg after spinal anesthesia
11042170|NCT04483765||post-spinal normotension|Patients with Fall of SBP<%25 of the preoperative value or absolute value >90 mm Hg, MAP>65 mmHg
11042171|NCT04483752|Other|Patients hospitalised for SARS CoV-2 infection.|
11042172|NCT04483739|Experimental|Krd Induction|4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
11042173|NCT04483739|Experimental|Isa-KRd induction|"Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4.
~Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22"
11042174|NCT04483739|Experimental|KRd post ASCT consolidation|4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
11042175|NCT04483739|Experimental|Isa-KRd post ASCT consolidation:|4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
11042176|NCT04483739|Experimental|KRd light consolidation|12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
11042177|NCT04483739|Experimental|Isa-KRd light consolidation|Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
11042178|NCT04483726|Experimental|MIDP|minimally invasive distal pancreatectomy
11042179|NCT04483726|Sham Comparator|ODP|open distal pancreatectomy
11042180|NCT04483713|Active Comparator|Educational Workshop|Will receive theoretical and practical training in EBP through a workshop in a structured model with themes related to the introduction to EBP, with the final proposal of a practical class that aims to structure and describe an individual case through an exercise formulated to go through the phases of a project of EBP, to base this exercise we will use a finished and consolidated project, this will be used as a template of the exercise, the description of this exercise is in the programmatic content.
11042181|NCT04483713|Active Comparator|Educational Workshop plus J. H. N. EBP Guide Tools|"Will receive the same training as group Educational Workshop, plus the presentation and availability of the Johns Hopkins Nursing Evidence-based Practice guide tools to be used in the practice class for the structuring and individual description of the EBP exercise case. The same theme of the case will be used in both groups."
11042182|NCT04483700|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
11042183|NCT04483700|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
11042185|NCT04483700|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.
~After study-wide unblinding, participants will receive filgotinib 200 mg."
11042186|NCT04483700|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.
~After study-wide unblinding, participants will receive filgotinib 100 mg."
11042187|NCT04483687|Experimental|Filgotinib 200 mg (Main Study - Blinded)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
11042188|NCT04483687|Experimental|Filgotinib 100 mg (Main Study - Blinded)|Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.
11042189|NCT04483687|Placebo Comparator|Placebo (Main Study - Blinded)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
11042190|NCT04483687|Experimental|Filgotinib 200 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg.
~After study-wide unblinding, participants will receive filgotinib 200 mg."
11042191|NCT04483687|Experimental|Filgotinib 100 mg (LTE)|"Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg.
~After study-wide unblinding, participants will receive filgotinib 100 mg."
11042192|NCT04483674|Experimental|Biktarvy|Patients will recive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks
11042193|NCT04483648|Experimental|Exercise Group|A progressive home-based cervical stabilization exercise program was delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) in a weekly basis.
11042194|NCT04483648|No Intervention|Control Group|Patients in control group did not receive any exercise intervention.
11042195|NCT04483635|Placebo Comparator|Placebo|"10 placebo tablets taken orally at baseline, followed by 1 placebo tablet once a week for 16 weeks
~Note that the study may be prolonged according to the overall infection rate monitored monthly."
11042196|NCT04483635|Experimental|Vitamin D3|"10 tablets containing 10,000 IU (total : 100,000 IU) of Vitamin D3 taken orally at baseline, followed by 10,000 IU once a week for 16 weeks.
~Note that the study may be prolonged according to the overall infection rate monitored monthly."
11042197|NCT04483609||pre-test Group|10 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
11042198|NCT04483609||Validation and Reliability Group|80 people with multiple sclerosis. The eligibility criteria were: (1) age 18-65; (2) definitive diagnosis of MS according to McDonald criteria; (3) ability to read and write in Turkish. The exclusion criteria are: (1) acute attacks of MS (within 3 months); (2) cognitive impairment (Mini Mental test result 24 points and below); (3) any chronic disease other than MS; (4) active malignant tumors; (5) symptomatic urinary tract infections; (6) patients who changed treatment within the test-retest period.
11042199|NCT04483596||M|will receive 5 mg melatonin orally at 9 p.m. the night before surgery and another 5 mg melatonin with 15 ml of plain water 30 min before operation and 5 mg melatonin at 9 p.m. in the day of operation and for the first three postoperative days
11042200|NCT04483596||C|received a placebo in the form of one tablet of 500 mg paracetamol that packaged the same way as melatonin at the same times
11042201|NCT04483583|Active Comparator|ABCD-GENE >10 - Clopidogrel|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
11042202|NCT04483583|Experimental|ABCD-GENE >10 - Ticagrelor|Patients with an ABCD-GENE>10 score will be randomized in a 1:1 fashion to ticagrelor (60 mg/bid) or clopidogrel (75 mg/qd). Treatment will be maintained for 30 days.
11042203|NCT04483583|Active Comparator|ABCD-GENE <10 - Clopidogrel|Patients with an ABCD-GENE<10 will be treated with clopidogrel (75 mg/qd) for 30 days.
11042204|NCT04483570||Secondary Tethered Cord Syndrome|Children with signs of progressive deterioration in urological or neuroorthopedic system, and suspected Secondary Tethered Cord Syndrome (STCS) following primary untethering surgery.
11042205|NCT04483557|Other|Neo-adjuvant chemotherapy (NACT)|The patients will be given NACT using combination of cisplatin/paclitaxel or carboplatin/paclitaxel on a weekly or 3-weekly regimen for a total of 3 cycles as per local standard of care for patients with cervical cancer.
11042206|NCT04483544|Experimental|Treatment|PD-1 inhibitor pembrolizumab, in combination with the PARP inhibitor olaparib
11042207|NCT04483518||HBV patients|HBV patients with HBsAg positive and/or HBV DNA positive
11042208|NCT04483505|Experimental|Rogaratinib + palbociclib + fulvestrant|
11042209|NCT04483492||1|newborns under 32 weeks with respiratory support if they are decided to start caffeine treatment
11042210|NCT04483479|Experimental|Active Treatment|Orally Administered ENT-01 25mg Tablet Once Daily (Dose dependent on ENT-01-030 dose level stratification)
11042211|NCT04483466|Experimental|Treatment with methotrexate|134 participants will be treated with methotrexate
11042212|NCT04483466|Placebo Comparator|Placebo methotrexate|76 will receive placebo
11042213|NCT04483453|Experimental|EXPL feeding regimen|Lower protein / lower estimated glycemic index regimen
11042214|NCT04483453|Active Comparator|CTRL feeding regimen|Standard protein / standard glycemic index regimen
11042215|NCT04483440|Experimental|4D-110 Dose 1|4D-110 IVT injection
11042216|NCT04483440|Experimental|4D-110 Dose 2|4D-110 IVT injection
11042217|NCT04483427|Experimental|OSA patients after multilevel surgery|
11042218|NCT04483414|Experimental|Patients with suspected BCR or metastatic prostate cancer|Patients with suspected BCR or metastatic prostate cancer
11042219|NCT04483401|No Intervention|Waitlist|"Waitlist Participants are first allocated to a waitlist condition. After the first MRI scan, participants wait for 12 weeks and have a second MRI scan."
11042297|NCT04482933|Experimental|Experimental: HSV G207|All subjects will receive G207 at 1 x 10^8 plaque-forming units (pfu), intratumorally via controlled rate infusion through up to 4 silastic catheters over a 6 hour period. The subject will then receive a single 5 Gy dose of radiation to the tumor within 24 hours of virus inoculation.
11042220|NCT04483401|Experimental|Treatment arm|Upon completion on the waitlist time of 12 weeks, participants then are allocated to the treatment group. Participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a third MRI scan.
11042221|NCT04483388|Other|Group AB|After randomization, 6 children composed the AB sequence were initially submitted to experimental training with virtual reality and after a week, a period considered washout, the conventional training.
11042222|NCT04483388|Other|Group BA|After randomization 6 children composed the BA sequence were initially submitted to conventional training and after a week, a period considered washout, the experimental training with virtual reality.
11042223|NCT04483375|Experimental|anti-SARS-CoV-2 monoclonal antibody(SCTA01)|SCTA01: single dose on Day0
11042224|NCT04483375|Placebo Comparator|Placebo|Placebo: single dose on Day0
11042225|NCT04483362|Experimental|Physical Activity|Behavioural change techniques to promote physical activity
11042226|NCT04483349||Observational (survey administration)|Patients and healthcare providers complete a survey over 10-15 minutes.
11042227|NCT04483336|Experimental|Virtual reality Distraction.|Subjects watched a video cartoon using virtual reality goggles as a distraction technique during the administration of local anesthesia.
11042228|NCT04483336|Active Comparator|TV screen Distraction|Subjects watched a video cartoon on a regular TV screen as a distraction technique during the administration of local anesthesia.
11042229|NCT04483323|Active Comparator|Group I: Intraarticular group ( IA )|Patients will receive 20 ml of 0.25% bupivacaine intra-articularly through the surgical port
11042230|NCT04483323|Experimental|Group II: Erector Spinae Plane Block group ( ES )|Patients will receive an ultrasound guided erector spinae plane block using 20 ml of 0.25% bupivacaine at the level of T2 transverse process
11042231|NCT04483310|Experimental|MR therapy|MR therapy is a psychological treatment for SP, comprised of the following steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
11042232|NCT04483310|Active Comparator|Control intervention|The control intervention was identical, except participants engaged in deep breathing; entailing slow deep breaths, while repeatedly counting from 1-10. This is an active control (breathing-distraction exercise) rather than a placebo.
11042233|NCT04483297|Experimental|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation
11042234|NCT04483297|Other|Control|Local Autologous Bone + Posterior Fixation
11042235|NCT04483284|Experimental|TACE combined with Camrelizumab|Camrelizumab（200mg q3w ivgtt）combined with TACE,the interval between TACE treatment and Carilizumab is not less than 7 days.
11042236|NCT04483271|Experimental|n-3FA group|Dietary Supplement: 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA for 2 months.
11042237|NCT04483271|No Intervention|Control group|No intervention was given
11042238|NCT04483258|Active Comparator|Sedation with Insufflation|Sedation induction via oxygen mask %8 sevoflurane and reducing %3 concentration after rediotherapy start
11042239|NCT04483258|Active Comparator|İntravenous sedation|Midazolam+ Ketamine sedation
11042240|NCT04483245||controls|persons free of hemorrhage or haemostasis disorder
11042241|NCT04483245||Haemorrhagic|Acute hemorrhagic patient
11042242|NCT04483245||ECMO|ECMO surgery patient with hemorrhagic complication
11042243|NCT04483245||polytrauma|
11042244|NCT04483245||Platelet disorder|Patient with an identified platelet disorder or treated with antiplatelet agents
11042245|NCT04483232||Healthy Subjects|
11042246|NCT04483232||Patients with ear infections|
11042247|NCT04483219|Experimental|TKI ± anti-PD-1 antibody|According to response to TKI, the combination of anti-PD-1 treatment would be determined.
11042248|NCT04483206|Experimental|Treatment (Melphalan-based autologous transplant)|Patients receive high dose (100 mg/m2) melphalan IV over 30 minutes on day -3 and PK-directed melphalan IV over 30 minutes on day -1 to achieve set cumulative melphalan exposure levels. Patients then undergo stem cell infusion on day 0.
11042249|NCT04483193||Critically ill patients|Critically ill patients hospitalised at the intensive care unit.
11042250|NCT04483180|Placebo Comparator|Control|Beverage containing a sucrose solution. Same aspect and flavor than the experimental beverages. About 1/4 of participants will start with this beverage first.
11042251|NCT04483180|Experimental|Sucralose / acesulfame K|Beverage containing a blend of sweeteners based on sucralose and acesulfame K. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
11042252|NCT04483180|Experimental|Stevia rebaudioside A / thaumatin|Beverage containing a blend of sweeteners based on stevia rebaudioside A and thaumatin. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
11042253|NCT04483180|Experimental|Mogroside V / stevia rebaudioside M|Beverage containing a blend of sweeteners based on mogroside V and stevia rebaudioside M. Same aspect and flavour than the control beverage. About 1/4 of participants will start with this beverage first.
11042254|NCT04483167|Experimental|99mTccAbVCAM1-5|"Healthy volunteers and asymptomatic patients
~Pré-screening of the volunteers by the CIC or the Vascular Surgeon and sending or handing over the newsletter
~Visit 0 Selection: Validation of IC / NIC + Consent collection + additional exams
~Visit 1 Inclusion: J0 Scintigraphic imaging following injection 99mTc-cAbVCAM1-5 (370 MBq - 550 MBq - 750 MBq depend of the SAE or AE )
~Visit 2: Follow-up visit (Day 14 +/- 7 days post injection)
~Visit 3: End of the study, follow-up visit (70 days +/- 10 days post injection)"
11042255|NCT04483141||non-communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (hetero-assessment of pain).
11042256|NCT04483141||communicant stroke patients|Patients suffering from stroke, and unable to efficient communication. They will be assessed for pain through several tools (including hetero-assessment and auto-assessment of pain)
11042257|NCT04483128|Sham Comparator|Sham IFC therapy: Control group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).
~IFC parameters:
~Carrier frequency of 4000 Hz
~Amplitude modulated frequency of 65 Hz (AMF)
~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.
~NO intensity (0 mA)
~Session duration: 25 minutes"
11042258|NCT04483128|Experimental|IFC therapy: Experimental group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).
~IFC parameters:
~Carrier frequency of 4000 Hz
~Amplitude modulated frequency of 65 Hz (AMF)
~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.
~Intensity will depend on subjet's tolerance but without generating visible muscle twitches.
~Session duration: 25 minutes"
11042259|NCT04483115|Experimental|TPN171H 2.5mg group|TPN171H 2.5mg tablet + Placebo 10mg tablet
11042260|NCT04483115|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg tablet
11042261|NCT04483115|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet
11042262|NCT04483115|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg tablet
11042263|NCT04483115|Active Comparator|tadalafil 20mg group|tadalafil tablet 20mg
11042264|NCT04483115|Active Comparator|tadalafil 40mg group|tadalafil tablets 20mg *2
11042265|NCT04483102|Experimental|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
11042266|NCT04483102|Active Comparator|Standard cold preservation of liver|This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.
11042267|NCT04483076|Experimental|Arm A|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm A will receive three more cycles of SOX (six cycles of neoadjuvant chemotherapy with SOX in total) followed by D2 gastrectomy.
11042268|NCT04483076|Active Comparator|Arm B|Patients will be pre-enrolled and receive three cycles of SOX. After randomization, patients in Arm B will receive D2 gastrectomy (three cycles of neoadjuvant chemotherapy with SOX in total).
11042269|NCT04483063|Experimental|Extended shoulder group|2% chlorhexidine gluconate skin cleanser over the not only the operative shoulder and axilla but also the chest, back, neck, and face
11042270|NCT04483063|Experimental|Shoulder group|2% chlorhexidine gluconate skin cleanser over the operative shoulder and axilla
11042271|NCT04483063|No Intervention|Control group|Skin prepare with soap as usual
11042272|NCT04483050|Experimental|experimental group|
11042273|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the morning|routine bowel preparation before colonoscopy in the morning
11042274|NCT04483037|Active Comparator|split dose, day before, colonoscopy in the afternoon|routine bowel preparation before colonoscopy in the afternoon
11042275|NCT04483037|Experimental|two dose in the same day, colonoscopy in the afternoon.|experimental group
11042276|NCT04483024|Placebo Comparator|Placebo|Maltodextrin
11042277|NCT04483024|Active Comparator|Glucosamine|Glucosamine hydrochloride
11042278|NCT04483024|Experimental|Collagen hydrolysate|2g of hydrolyzed collagen II
11042279|NCT04483024|Experimental|Collagen hydrolysate + chicken extract|2g of hydrolyzed collagen II with chicken extract
11042280|NCT04483011|Experimental|RiaGev|RiaGev, 2000mg, BID
11042281|NCT04483011|Active Comparator|Comparator|Comparator matched to RiaGev, BID
11042282|NCT04482998||Steroids only - early|treatment was initiated within 7 days of acoustic trauma.
11042283|NCT04482998||Early combined steroid and hyperbaric oxygen therapy|treatment was initiated within 7 days of acoustic trauma.
11042284|NCT04482998||Delayed combined steroid and hyperbaric oxygen therapy|treatment was initiated after 7 days of acoustic trauma.
11042285|NCT04482998||Early sequential steroid followed by HBO therapy|treatment was initiated within 7 days of acoustic trauma.
11042286|NCT04482998||Delayed sequential steroid followed by HBO therapy|treatment was initiated after 7 days of acoustic trauma.
11042287|NCT04482998||Hyperbaric oxygen therapy only|
11042288|NCT04482998||No treatment|
11042289|NCT04482998||Steroid only - delayed|treatment was initiated after 7 days of acoustic trauma.
11042290|NCT04482985|Active Comparator|Meclizine responders|
11042291|NCT04482985|Active Comparator|Meclizine non responders|
11042292|NCT04482972||DCB|DCB group: Patients treated with drug coated balloon (DCB) only angioplasty (all-comers: STEMI, NSTEMI, Stable angina)
11042293|NCT04482972||DES|DES group: Patients treated with drug eluting stent (DES) angioplasty (all-comers:STEMI, NSTEMI, Stable angina)
11042294|NCT04482959|Experimental|Carbetocin group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of carbetocin (100 mcg/ml) IV over 1 minute.
11042295|NCT04482959|Placebo Comparator|• Control group|This group will contain 20 patients having single type 0 or I submucous uterine myomas according to International Federation of Gynecology and Obstetrics classification system with a largest diameter ≤ 4 cm and myometrial free margin of at least 10 mm.After induction of general anesthesia, immediately before the operation, participants will receive either 1 ml of sodium chloride 0.9% IV over 1 minute.
11042296|NCT04482946|Experimental|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
11042298|NCT04482920||Transgender males|Transgender males who are clinically ready to start testosterone
11042301|NCT04482907|Placebo Comparator|Group receiving placebo|They took 3 meals a day and 3 cellulose placebo capsules by mouth. They took placebo capsules for 90 days.
11042302|NCT04482894|Experimental|Palliative Care Intervention|Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.
11042303|NCT04482894|No Intervention|Standard Clinical Care|Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.
11042304|NCT04482881|Active Comparator|women receiving isosorbide mononitrates lower dose|women who will receive isosorbide mononitrates lower dose
11042305|NCT04482881|Active Comparator|women receiving isosorbide mononitrates higher dose|women who will receive isosorbide mononitrates higher dose
11042306|NCT04482881|Active Comparator|Women receiving misoprostol|Women who will receive misoprostol
11042307|NCT04482868|Placebo Comparator|open reduction group|
11042308|NCT04482868|Experimental|percutaneous group|
11042309|NCT04482855|Experimental|Group 1 (laser group)|Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.
11042310|NCT04482855|No Intervention|Group 2 (wait-list control group)|Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.
11042311|NCT04482842|Experimental|Gene-guided Warfarin|
11042312|NCT04482842|Other|Routine use|
11042313|NCT04482829|Experimental|Experimental Group|On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.
11042314|NCT04482829|Other|Control Group|All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.
11042315|NCT04482816|Experimental|Physiological pacing|"Lead placed in the His-Purkinje system (his or branch) in order to achieve QRS shortening and physiologic pacing. A backup lead will be implanted in the right ventricle.
~If hisian pacing is not achieved (QRS is not shortened > 20% or QRS is not <130ms), the left bundle branch will be paced according to the criteria established in the literature (right branch block and intrinsic deflection <85ms).
~Crossover from physiological pacing to right ventricular pacing will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria or left bundle branch pacing criteria."
11042316|NCT04482816|Active Comparator|Right ventricular pacing|Lead placed in the right ventricle (conventional pacing).
11042317|NCT04482803|Experimental|Carbon nanoparticles labelled lymph nodes group|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes before NST.
11042318|NCT04482790|Active Comparator|Conventional celluloid matrix|Conventional celluloid matrix technique in management of black triangle
11042319|NCT04482790|Experimental|Bioclear cervical matrix|Bioclear cervical matrix with injection molding technique in management of black triangle
11042320|NCT04482764|Other|cyanotic breath holding spells|drug, valproic acid: 5mg/kg/d for 6 months
11042321|NCT04482751||Infertile women|the group consists of 80 infertile patients undergoing IVF
11042322|NCT04482738||Lean subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
11042323|NCT04482738||Obese subjects|24 hours before the study visit, participants will be asked to refrain from alcohol and strenuous exercise. Patients will be asked to remain fasted 10 hours before the study visit takes place. On the day of the study visit, patients will be admitted to the hospital and, after intake of the study meal, blood samples will be taken.
11042324|NCT04482725|Experimental|S1|"Day 1: Trial products 1-2-12-3-11-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 10-5-9-6-8-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042325|NCT04482725|Experimental|S2|"Day 1: Trial products 2-3-1-4-12-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 11-6-10-7-9-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042326|NCT04482725|Experimental|S3|"Day 1: Trial products 3-4-2-5-1-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 12-7-11-8-10-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042327|NCT04482725|Experimental|S4|"Day 1: Trial products 4-5-3-6-2-7 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 1-8-12-9-11-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042328|NCT04482725|Experimental|S5|"Day 1: Trial products 5-6-4-7-3-8 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 2-9-1-10-12-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042329|NCT04482725|Experimental|S6|"Day 1: Trial products 6-7-5-8-4-9 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 3-10-2-11-1-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042330|NCT04482725|Experimental|S7|"Day 1: Trial products 7-8-6-9-5-10 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 4-11-3-12-2-1-given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042369|NCT04482530|Experimental|fructose recipe|fruit pastes in which some of the simple sugars in the recipe (25% min) will be replaced by fructose
11044176|NCT04469998|Experimental|AXR-270 Low Dose|AXR-270 Low Dose administered once daily
11042331|NCT04482725|Experimental|S8|"Day 1: Trial products 8-9-7-10-6-11 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 5-12-4-1-3-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042332|NCT04482725|Experimental|S9|"Day 1: Trial products 9-10-8-11-7-12 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 6-1-5-2-4-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042333|NCT04482725|Experimental|S10|"Day 1: Trial products 10-11-9-12-8-1 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 7-2-6-3-5-4 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042334|NCT04482725|Experimental|S11|"Day 1: Trial products 11-12-10-1-9-2 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 8-3-7-4-6-5 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042335|NCT04482725|Experimental|S12|"Day 1: Trial products 12-1-11-2-10-3 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen.
~Day 2: Trial products 9-4-8-5-7-6 given as subcutaneous injections (s.c., under the skin) on alternate sides of the abdomen."
11042336|NCT04482712|Placebo Comparator|Placebo|Administration of placebo daily during hospitalization
11042337|NCT04482712|Active Comparator|Rapamycin|Administration of rapamycin (sirolimus) 1mg daily during hospitalization
11042338|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 1)|Dose level 1 is 40 x 10^6
11042339|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 2)|Dose level 2 is 160 x 10^6
11042340|NCT04482699|Active Comparator|RAPA-501 cells|RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)
11042341|NCT04482699|Placebo Comparator|Placebo-control Cohort|Placebo
11042342|NCT04482686|Experimental|Active Arm|Patients will be treated with a combination of Ivermectin, Doxycycline, Zinc, Vitamin D3 and Vitamin C
11042343|NCT04482686|Placebo Comparator|Placebo|Placebo and Vitamin D3, Vitamin C, and Zinc
11042344|NCT04482673|Experimental|COVID-19 Negative Active Treatment|Participants will be randomized to vitamin D3 (6000 IU) per day for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
11042345|NCT04482673|Placebo Comparator|COVID-19 Negative Placebo|Participants in this arm would receive placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
11042346|NCT04482673|Experimental|COVID-19 Positive Active Treatment|Participants will be randomized to vitamin D3 as a bolus (20,000 IU) per day for 3 days followed by high dose vitamin D (6000 IU) per dayfor 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
11042347|NCT04482673|Placebo Comparator|COVID-19 Positive Placebo|Participants in this arm would receive placebo as a bolus followed by daily placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
11042348|NCT04482660|Experimental|PET|
11042349|NCT04482647|Experimental|Supportive Care (video, breathing techniques, meditation)|Patients view an instructional video on breathing techniques and meditation. Patients then perform breathing techniques over 3 minutes and meditation over 2 minutes BID for 28 days.
11042350|NCT04482634|Active Comparator|Tele-rehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection.
11042351|NCT04482634|Active Comparator|Home exercise group|This group will perform the exercises at their home on their own, the first exercise program will be given at hospital and the patients will be followed up regular weekly by phone call.
11042352|NCT04482621|Active Comparator|Decitabine + Standard of Care (SOC)|Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
11042353|NCT04482621|Placebo Comparator|Standard of Care (SOC) + Placebo|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
11042354|NCT04482608||pMMR/MSS mCRC patients|The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
11042355|NCT04482608||dMMR/MSI-H mCRC patients|The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
11042356|NCT04482595|Experimental|BIO 300 Oral Suspension (genistein 1500 mg)|BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
11042357|NCT04482595|Placebo Comparator|Placebo|BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
11042358|NCT04482582|Experimental|Image-guided percutaneous ICN (pICN): Group A|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to percutaneous image-guided cryoneurolysis (pICN) group within 72 hours of presentation.
11042359|NCT04482582|Active Comparator|Standard-of Care : Group B|Patients who were admitted after a traumatic injury, with rib fractures identified, who are >= 65 years of age will be randomized to standard-of-care group within 72 hours of presentation.
11042360|NCT04482569|Experimental|Single Ascending Dose Study|Six XNW4107 doses ( 50-1250 mg ), each administered as a single dose with 60-minute IV infusion
11042361|NCT04482569|Experimental|Multiple Ascending Dose Study|Three XNW4107 doses (167-500 mg), each administered as 60-minute IV infusion every 6 hours for 7 days
11042362|NCT04482569|Experimental|Multiple Dose Study of XNW4107 +Imipenem/Cilastatin|500 mg XNW4107 co-administered with imipenem/cilastatin as 60-minute IV infusion every 6 hours for 14 days
11042363|NCT04482556|Other|Q-NRG+ Indirect Calorimetry Device|Q-NRG+ device will be compared to current V(max) device in each enrolled patient in subsequent, alternating fashion.
11042364|NCT04482556|Other|V(max) Encore Indirect Calorimetry Device|V(max) Encore device, currently institution's standard device, will be compared to Q-NRG+ device in each enrolled patient in subsequent, alternating fashion.
11042365|NCT04482543|Active Comparator|Intra-silicone oil injection of 250 µg methotrexate|
11042366|NCT04482543|No Intervention|No intra-silicone oil injection of methotrexate|
11042367|NCT04482530|Experimental|Original recipe|Normal fruit paste
11042368|NCT04482530|Experimental|maltodextrin recipe|fruit pastes in which some of the simple sugars in the recipe will be replaced by maltodextrin with a low glycemic index (DE12).
11042371|NCT04482530|Experimental|mixed recipe|fruit pastes with some of the sugars will be replaced (25% min) by fructose / isomaltulose
11042372|NCT04482517|Other|Density Gradient Centrifugation (DGC)|Using the routine DGC sperm processing only
11042373|NCT04482517|Active Comparator|Physiological ICSI (PICSI)|Using PICSI dish for selecting sperm with lower sperm DNA fragmentation
11042374|NCT04482517|Active Comparator|Magnetic Activated Cell Sorting (MACS)|Using MACS for selecting sperm with lower sperm DNA fragmentation
11042375|NCT04482517|Active Comparator|Testicular sperm (Testi)|Using testicular sperm not ejaculated sperm
11042376|NCT04482504||healthy pregnant women|"200 healthy pregnant women in 36.-38. Week of pregnancy. The investigators involve every healthy pregnant woman in 36.-38. week of pregnancy.
~Exclusion criteria:
~Unwilling to participate
~Minors (under 18 years old)
~e) Unfamiliar with slovak language f) Multiple pregnancy g) Musculoskeletal and neurological abnormalities"
11042377|NCT04482504||non-pregnant women|"30 non-pregnant healthy control women The investigators involve every healthy non-pregnant woman.
~Exclusion criteria:
~Unwilling to participate
~Minors (under 18 years old)
~e) Unfamiliar with slovak language f) Pregnancy g) Musculoskeletal and neurological abnormalities"
11042378|NCT04482478|Experimental|EDL(Extract of Dolichos lablab Linne)|The randomly assigned target was given a Extract of Dolichos lablab Linne (EDL) 715 mg/day for 12 weeks.
11042379|NCT04482478|Placebo Comparator|Placebo comparator|The randomly assigned target was given a placebo for 12 weeks.
11042380|NCT04482465|Other|pilot study 1 arm|50 subjects with no AMD or early AMD, aged over 55, at moderate-to-high risk for AMD based on a simplified AMD risk assessment scale score > or = 10, not taking vitamin D or trace nutriënt containing supplements
11042381|NCT04482439|Experimental|Vivity mini-monovision|Subjects will have bilateral Vivity IOL implanted, with a target of slight myopia in the non-dominant eye.
11042382|NCT04482413|Experimental|Treatment|treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10^8 cells / 20 mL of saline with 30% auto-serum.
11042383|NCT04482413|Active Comparator|Active Control|Active control group will receive 5 mg of Donepezil and AstroStem Placebo.
11042384|NCT04482400|Experimental|NEAT!2|Participants randomized to this arm will use the NEAT!2 app and receive biweekly coaching calls during weeks 4-12 after surgery, and monthly maintenance calls between months 3-6.
11042385|NCT04482400|Active Comparator|MyKneeGuide|Participants randomized to this arm will use the MyKneeGuide app/website and receive biweekly coaching calls during week 4-12 after surgery, and monthly maintenance calls between months 3-6.
11042386|NCT04482387|Other|subjects recruited to visual acuity testing|All recruited subjects will have the intervention (Digivis visual acuity self-testing) and the standard clinical visual acuity assessment in clinic.
11042387|NCT04482374||Transgender females|Transgender females who plan to start a gonadotropin releasing hormone agonist clinically in the next 2 months
11042388|NCT04482374||Cisgender males|Cisgender male controls
11042389|NCT04482348|Active Comparator|the mind is a great story teller-positively framed|explanations for more pain than expected
11042390|NCT04482348|Active Comparator|the mind is a great story teller-negatively framed|explanations for more pain than expected
11042391|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-positive frame|explanations for more pain than expected
11042392|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-negative frame|explanations for more pain than expected
11042393|NCT04482348|Active Comparator|"mixed emotion and cognition (mind and body work together)"|explanations for more pain than expected
11042394|NCT04482348|Active Comparator|"physically based explanations over-excited state"|explanations for more pain than expected
11042395|NCT04482348|Active Comparator|"physically based explanations overstimulated"|explanations for more pain than expected
11042396|NCT04482335||Main Study|Participants complete questionnaires and agree to have their retrospective and prospective medical data used as part f this research project. All participants will take part in this arm.
11042397|NCT04482335||Biosample Sub-Study|A subset of the participants will take part of this. Participants will agree to have blood samples taken at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to provide urine samples.
11042398|NCT04482335||Synovial Biopsy and Synovial Fluid Sub-Study|A subset of the participants will take part of this. Participants will agree to synovial biopsies at regular intervals or at the point of a flare or when their treatment changes. They might also be asked to donate waste synovial fluid.
11042399|NCT04482322|Other|Vitamin D plus blue light PDT|All patients will receive oral 10,000 IU Vitamin D3 daily, for a period of time based upon their baseline serum 25-OH D3 levels, immediately prior to blue light PDT. Patients with a normal 25-OH D3 level (31 mg/dL or higher) will take oral D3 supplements for 5 days. Patients with a low 25-OH D3 level (<31 mg/dL) will take oral D3 for 14 days.
11042400|NCT04482309|Experimental|Arm 1|Cohort 1: Biliary tract cancer
11042401|NCT04482309|Experimental|Arm 2|Cohort 2: Bladder cancer
11042402|NCT04482309|Experimental|Arm 3|Cohort 3: Cervical cancer
11042403|NCT04482309|Experimental|Arm 4|Cohort 4: Endometrial cancer
11042404|NCT04482309|Experimental|Arm 5|Cohort 5: Ovarian cancer
11042405|NCT04482309|Experimental|Arm 6|Cohort 6: Pancreatic cancer
11042406|NCT04482309|Experimental|Arm 7|Cohort 7: Rare tumors
11042407|NCT04482296|No Intervention|SSRI with placebo|50 patients who will receive placebo with SSRIs for 8 weeks
11042408|NCT04482296|Active Comparator|SSRI with zinc sulfate|50 patients who will receive SSRIs with zinc sulfate for 8 weeks
11042409|NCT04482270|Experimental|Fezolinetant: Mild Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11042410|NCT04482270|Experimental|Fezolinetant: Moderate Hepatic Impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11042411|NCT04482270|Experimental|Fezolinetant: Normal Hepatic Function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11042412|NCT04482257|Experimental|T-R|Subjects will receive Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV
11042518|NCT04481438|No Intervention|control group|control group will maintain the regular activities of their original daily lives
11042413|NCT04482257|Experimental|R-T|Subjects will receive Irinotecan Liposome Injection (Ipsen) 70mg/m2 plus 5-FU/LV, followed by Irinotecan Liposome Injection (CSPC) 70mg/m2 plus 5-FU/LV
11042414|NCT04482244|Experimental|Cannabidiol|"After screening procedures confirm participation in the research study, participants will be randomized one of two groups:
~Participants in the experimental arm will complete questionnaires and then receive a single dose of CBD prior to diagnostic CT scan.
~Cannabidiol: Oral, per protocol dosage, single dose
~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
11042415|NCT04482244|Placebo Comparator|Placebo|"After the screening procedures confirm participation in the research study, participants will be randomized one of two groups:
~Participants in the placebo arm will complete questionnaire and then receive a single dose of placebo prior to diagnostic CT scan.
~Placebo: Oral, per protocol dosage, single dose
~Additional questionnaires 2 hours post scan and follow up via phone call 1 week regarding experience"
11042416|NCT04482205||precovid group|those who were operated from fJanuary first to March 15
11042417|NCT04482205||covid|those operated from March 16, to May 31, 2020
11042418|NCT04482192|Active Comparator|Thoracic paravertebral block group|Continuous thoracic paravertebral block with 1% lidocaine infusion for 3 postoperative days through a paravertebral catheter inserted intraoperatively by the surgeon.
11042419|NCT04482192|Active Comparator|Systemic analgesia group|patients in this group will receive paracetamol and ketorolac by intravenous infusion every 6 hours for 3 postoperative days
11042420|NCT04482179|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
11042421|NCT04482179|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
11042422|NCT04482166|Experimental|Candidates|Training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
11042423|NCT04482140||Genta-Foil resorb|Genta-Foil resorb® is a transparent collagen foil that forms a temporary barrier between the functional structures during the critical phase of wound healing. As a result, the ability of the tissue layers to slide against each other is retained. The absorbability of equine collagen means the foil can be left in place and does not require removal. The addition of the antibiotic Gentamicin is for self-protection since collagen implants are prone to bacterial contamination.
11042424|NCT04482127|Experimental|SubEpithelial connective graft|"SCTG harvested from palatal tissue by single line incision technique, blade will be oriented perpendicular to the palatal tissue surface. A single incision will be made down to the bone in a horizontal direction approximately 2 to 3 mm apical to the gingival margin of the maxillary teeth. A partial thickness dissection will then be made within the single incision, leaving an adequate thickness of the palatal flap intact to minimize the chance of sloughing of the overlying tissue. Careful manipulation of the graft with tissue forceps will be required and care must be taken to prevent compression or tearing of the graft.
~The fatty tissue (yellow in color) will be eliminated and some contouring of the graft will be done to fit the prepared envelope. The harvested SCTG will be placed at the extraction sites in a supra-periosteal partial dissection (pouch II technique) prepared at the buccal aspect without using vertical incisions and without flap elevation."
11042425|NCT04482127|No Intervention|Atraumatic extraction|Extraction with Periotomes and Luxators keeping the buccal plate of bone intact
11042426|NCT04482114|Other|ultra-low dose CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
11042427|NCT04482101|Experimental|Ah-Plus sealer|"Root canal sealer which is a resin-based formula with excellent radiopacity , low shrinkage , low solubility and outstanding flow characteristics .
~It features a 1:1 , paste-to-paste mixing system for fast , easy preparation and less waste . It is biocompatible and silver free ."
11042428|NCT04482101|Experimental|Endosequence BC sealer|"It is a root canal sealer which is premixed ready-to-use injectable bioceramic cement paste developed for permanent root canal filling and sealing applications.
~It is insoluble , radiopaque and aluminum-free material based on calcium silicate composition , which requires the presence of water to set and hardens . It does not shrink during setting and demonstrate excellent physical properties ."
11042429|NCT04482088|Experimental|OTC & OTEE|Every participant will receive 10 weeks of occupational therapy in a clinic environment (OTC) followed by 10 weeks of occupational therapy in an equine environment
11042430|NCT04482075|Other|SEGMENTAL STABILISATION TRAINING (SST)|Segmental Stabilisation Training is an established treatment technique for chronic low back pain
11042431|NCT04482062|Experimental|Edwards EVOQUE System & OMT|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation
11042432|NCT04482062|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
11042433|NCT04482062|Experimental|Single-Arm Registry|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
11042434|NCT04482036|Placebo Comparator|Dementia Collaborative Care|"Patient and caregivers assigned to the three in-person assessments and no mobile application group will complete the following:
~The caregiver will be asked to complete three in-person assessments that involve answering survey questions and an interview.
~Some of the questions asked will be related to Behavioral and/or Psychological Symptoms the patient experiences.
~The caregiver will be asked to answer questions about the patient, the patient's experience with the research study and the caregiver's own experience with the research study.
~If the patient's symptoms or the caregiver's distress answers reach a high enough level, a member of the research study team and clinical team will contact the caregiver to ask more questions and check in on the patient and caregiver's safety.
~The research study team will also notify Dr. Bateman (the person responsible for the research)."
11042435|NCT04482036|Active Comparator|Dementia Collaborative Care Plus BrainCare Notes Application|"Patient and caregivers assigned to the three in-person assessments and mobile application group will complete the same tasks that Group 1 (control group) will complete with the addition of the following:
~The caregiver will be asked to monitor the patient and complete 5 to 10-minute long surveys (the neuropsychiatric inventory questionnaire) sent to the caregiver through the mobile application or in-person at each follow-up visit.
~The caregiver will be asked to monitor and complete these surveys at different times for a period of 6 months."
11042436|NCT04482023||Nurses COVID 19|Nurses from any unit of the Consortium Parc Taulí Corporation who have been in direct care of patients diagnosed with COVID 19 between March 9, 2020 and May 15, 2020
11042437|NCT04482010|No Intervention|Classic HIV care|Participants diangosed HIV positive at the time of the community-based activities conducted by ARCAD Santé PLUS. They will be referred to the referral centers (CSRéf) for the classic HIV care in the Malian public health system.
11042438|NCT04482010|Other|Community-based HIV care|Participants diagnosed HIV positive at the time of the community-based activities by ARCAD Santé PLUS. They will receive community-based HIV care by the NGO at the gold-mining site.
11042439|NCT04481997||Diabetic patients with CAD submitted to PCI|Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI
11042440|NCT04481984|Experimental|Exercise group|The training including isometric and stretching hand exercise was applied once by a physiatrist. A hand exercise ball was used for isometric exercise. Patients performed both stretching exercises and isometric exercises according to the training and printed materials. The home-based exercise program was implemented 7 days per week during an 8-week period. In addition, patients received recommendations such as avoiding cold exposure and trauma.
11042441|NCT04481984|Other|Control group|Patients received care advice including avoiding cold exposure and trauma.
11042442|NCT04481971|Experimental|40 mg|
11042443|NCT04481971|Experimental|20 mg|
11042444|NCT04481971|Placebo Comparator|Placebo|
11042445|NCT04481958|Experimental|I-PROTECT model|The I-PROTECT model is an end-user-driven intervention including evidence-based, theory-informed, and context-specific injury prevention training for youth handball, and an associated implementation strategy.
11042446|NCT04481945|Active Comparator|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
11042447|NCT04481945|Experimental|bioceramic sealer and silver nanoparticles|silver nanoparticles are antibacterial ions that can interact with multiple targets in the bacterial cell
11042448|NCT04481945|Experimental|bioceramic sealer and chitosan|chitosan has an excellent antibacterial, antiviral and antifungal properties, as an antibacterial, it works better on gram negative than gram positive
11042449|NCT04481932|Experimental|Trastuzumab combined with Pyrotinib and chemotherapy|The dosage of the above drugs can be adjusted according to the adverse reactions of the subjects. The subject continued to use the drug until the full cycle or the disease progressed or the toxicity was intolerable or withdrawn, or the researcher judged that the medication must be terminated.
11042450|NCT04481919|Active Comparator|Protocolized spot urine sodium guided diuretic therapy|Patients will have a spot urine sodium and urine creatinine obtained. The urine and creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance. Performed 3 times per day, diuretic dosing will be individualized based on the proportion of 24-hour diuresis achieved since the prior IV diuretic dose. Every 24 hours new goals for urine output and net negative fluid balance are established based on the study and treatment team's assessment of residual congestion until protocol completion.
11042451|NCT04481919|No Intervention|Guideline-based care|Patients will be placed on guideline-based diuretic dosing consistent with usual practice. The initial dose will be two times their home dose and will be subsequently adjusted by the treating team based on renal function and symptom severity. The treating team can increase or decrease the frequency and dose of diuretic based on urine output and clinical assessment. Patients in this arm also have urine collected 3 times per day by the bedside nurse to mirror the intervention arm.
11042452|NCT04481906||Women 20 years and older with cystocele|Women 20 years and older with cystocele
11042453|NCT04481893|Experimental|using a virtual reality headset|
11042454|NCT04481867|Active Comparator|intervention arm :densah bur group|at the maxillary molar area for implant placement ,,just after making initial drilling perforation close to the sinus floor, the direction of the drill is reversed and the cutting speed is raised to 1200 rpm, then 2 successive densah burs are used to elevate sinus membrane 2 mm and to prepare implant hole to the selected implant size .for both groups the selected implant size, 4.2 mm width and 10 mm. length
11042455|NCT04481867|Other|control group :osteotome group|at the maxillary molar area for implant placement .a set of concave osteotomes with different dimensions sequentially used to widen the osteotomy site by surgical mallet. Osteotome 2.5 mm is inserted into the osteotomy firstly to a depth of 1 mm away from the sinus floor with light malleting by the nylon cap mallet then 3 mm osteotome is used to fracture up the sinus floor and finally 3.5 mm osteotome is tapped gently to elevate the sinus floor to the desired depth of the implant in the maxillary sinus.
11042456|NCT04481854|Experimental|Cricoid pressure group|Patients of this group will recieve cricoid pressure during direct laryngoscopy.
11042457|NCT04481854|Experimental|left paratracheal pressure group|Patients of this group will recieve left paratracheal pressure during direct laryngoscopy.
11042458|NCT04481841|Experimental|experimental group|"On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
11042459|NCT04481841|Active Comparator|control group|oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
11042460|NCT04481828||open gastrectomy|The first group (Group 1; n: 30) consisted of patients who underwent open surgery
11042461|NCT04481828||laparoscopic gastrectomy|The second group (group 2; n:30) consisted of patients who underwent laparoscopic gastrectomy
11042514|NCT04481477||Patients COVID-19|Patients over the age of 18 who were admitted with a diagnosis of COVID-19 to any CCSPT unit between March 13, 2020 and April 30, 2020 and were discharged with a recovery result
11042462|NCT04481815|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
11042463|NCT04481815|Sham Comparator|R-MTX|Control arm will be treated with R-MTX regimen(Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved CR or PR with additional WBRT, they processed to Lenalidomide maintenance for 4 cycles.
11042464|NCT04481802|Experimental|RadiaAce gel|RadiaAce Gel is a clear, non-oily Hydrogel wound dressing for the management of Radiation Dermatitis which provides optimal moist wound environment necessary to the healing process. RadiaAce gel contains Acemannan, a high molecular polysaccharide obtained from the inner gel of Aloe Vera leaves and it is considered the main functional component of Aloe vera (Sahu et al. 2013).
11042465|NCT04481802|Active Comparator|Biafine|one of the standard skin care in radiation oncology, this treatment was chosen as the comparator.
11042466|NCT04481789|Experimental|Rosuvastatin, Sildenafil, and MT-1186|"Group 1 of Cohort 1:
~A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively."
11042467|NCT04481789|Experimental|Furosemide and MT-1186|"Group 2 of Cohort 1:
~A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6."
11042468|NCT04481789|Experimental|MT-1186|"Cohort 2:
~A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule."
11042469|NCT04481776|Experimental|Breakfast consumption|Participants will be asked to consume a standardised breakfast at home before 09:00 for seven consecutive days. The energy content of the breakfast will be 25% of individual measured resting metabolic rate. Prior to the experimental conditions, the participants will select one wholegrain, high-fibre ready-to-eat cereals (with the option of adding raisins) and fruit juice from a limited selection. Thus, breakfast composition will be controlled within participants, but not between participants to account for individual preferences. To ensure that the correct amount of each breakfast item is consumed, food items will be provided to the participants in pre-packaged containers and the participants will be provided with a marked beaker to measure their milk and juice each morning. The only exception is that parents will be asked to provide the 1.8% milk.
11042470|NCT04481776|Experimental|Breakfast omission|Participants were asked to abstain from all energy-providing nutrients before 10:30 for seven consecutive days.
11042471|NCT04481763|Other|camrelizumab + radiotherapy|This is a open-labeled, single-arm, Investigator-initiated clinical trial ,Compared with historical data
11042472|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S1)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
11042473|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S2)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
11042474|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S3-1)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
11042475|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S3-2)|Healthy Japanese male subjects receive doses of MT-1186 or matching placebo.
11042476|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S4)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
11042477|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S5)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
11042478|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S6)|Healthy Japanese male subjects receive a single dose of MT-1186 or matching placebo.
11042479|NCT04481750|Experimental|A single dose MT-1186 (Part 1, Cohort S7)|Healthy Caucasian male subjects receive a single dose of MT-1186 or matching placebo.
11042480|NCT04481750|Experimental|Multiple doses MT-1186 (Part 2, Cohort M1)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo.
11042481|NCT04481750|Experimental|Multiple doses MT-1186 (Part 2, Cohort M2)|Healthy Japanese male subjects receive multiple doses of MT-1186 or matching placebo
11042482|NCT04481737|Experimental|PDTA-IIMR|
11042483|NCT04481737|Active Comparator|Peer support|
11042484|NCT04481724|Experimental|gamma-linolenic acid (GLA) supplementation|Sonova GLA safflower oil (840 mg GLA per day)
11042485|NCT04481724|Placebo Comparator|placebo control|1500 mg 'light' olive oil per day
11042486|NCT04481711|Experimental|Study group|Twenty-nine patients (female/male: 24/5) with grade 4 osteoarthritis were included in the study group. These patients underwent total knee arthroplasty
11042487|NCT04481711|No Intervention|Control group|Twenty-two patients (female/male:13/9) with <grade 4 osteoarthritis were included in the control group.
11042488|NCT04481698||Mesoglycan|All patients received the standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy)
11042489|NCT04481698||Control|standard post-operative therapy (a recommended oral dose of ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not exceeding 5 post-operative days according to the indications for short-term management of moderate/severe acute post-operative pain and stool softeners)
11042490|NCT04481685|Active Comparator|ATI-450|Treated with 50 mg dose of ATI-450, orally, twice daily for 14 days
11042491|NCT04481685|Placebo Comparator|Placebo|Treated with matched placebo, orally, twice daily for 14 days
11042515|NCT04481451|Experimental|Erector spinae supplemental block|Single-shot T9/T10 operative side erector spinae block using ropivacaine 0.2%, 0.5ml/kg.
11042516|NCT04481451|Active Comparator|Quadratus lumborum supplemental block|Single-shot T9/T10 operative side quadratus lumborum (type 1) block using ropivacaine 0.2%, 0.5ml/kg.
11042492|NCT04481672|Experimental|Magnesium Sulfate|"Starting the night before surgery participants will receive intravenous infusion of magnesium over approximately 36 hours. Dosage amounts will vary among participants as the study is determining the highest dose of magnesium that can be administered safely without severe or unmanageable side effects. The first 5 participants of the study will all receive the same dose of magnesium. The decision to test other doses of magnesium in 5 additional participants will depend on magnesium levels and dose tolerance outcomes in the first 5 participants.
~Participants will be followed for 4 days and undergo blood test to measure magnesium levels at the time of hospital admittance, the morning prior to the surgery, twice immediately after surgery, and twice a day for 3 days after the surgery."
11042493|NCT04481659|Experimental|A group|Patients who are initially staged as T1-2, according to MRI and intraluminal ultrasound, are assigned to the direct surgery group (determined by the multidisciplnary team [MDT] group)
11042494|NCT04481659|Experimental|B group|Patients who are initially staged as T3M0, according to MRI and intraluminal ultrasound, should undertake preoperative chemoradiotherapy (determined by the MDT group). The operation was performed 8-12 weeks after the end of the chemoradiotherapy.
11042495|NCT04481646||1|Patients admitted to hospital with COVID-19 symptoms will be approached to undertake a face mask sample and nasopharyngeal swab at two time points 12 hours apart on a single day whilst in hospital. Medical records will be accessed for basic clinical, demographic and microbiological data.
11042496|NCT04481646||2|Healthcare workers who have report COVID-19 symptoms will be asked to undertake a face mask sample and nasophayngeal swab on days 1,3,5,7,10,14 and 21 of the study, for part of which they will be quarantined at home.During this time they will complete a simple symptom diary. Medical records will be accessed for basic clinical, demographic and microbiological data.
11042497|NCT04481646||3|Healthcare workers from different areas of the hospital will be approached as part of a screening programme. They will be asked to undertake a single face mask and swab sample. Basic clinical and environmental data will be collected about each participant so they exposure risk can be stratified.
11042498|NCT04481633|Other|Patient treated with Hydroxy-chloroquine|patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)Azathioprine or Methotrexate (HC+ group, n=400)
11042499|NCT04481633|Other|Patient without treatment with Hydroxy-chloroquine|patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants
11042500|NCT04481607|Experimental|TQB3454 tablets|TQB3454 tablets administered orally once. Then TQB3454 tablets administered orally, once daily in 28-day cycle after 7 days of first administration.
11042501|NCT04481594|Experimental|HPN-01|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01. One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01.
~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 once daily for a consecutive 14 days."
11042502|NCT04481594|Placebo Comparator|Placebo|"Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01 placebo.
~Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 placebo once daily for a consecutive 14 days."
11042503|NCT04481581|Experimental|Intervention arm- Oxygen titration with electronic alerts|Oxygen titration will be done based on electronic alerts and decisions support tool by Respiratory Therapists, if FiO2=> 0.4 and SpO2 =>94% for more than 45 minutes
11042504|NCT04481581|No Intervention|Control Arm- Oxygen titration by one time physician orders|Oxygen titration will be done ventilator management guidelines for the medical intensive care unit. Titration is done by one-time orders.
11042505|NCT04481568|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and nurse assistants who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff: mental health assistants with high school level education, who receive training in de-escalation and crisis prevention techniques and provide direct personal care to psychiatric patients. On the intervention unit, these PES purposefully engage patients with BPSD. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients. IV. Staff Training (please refer to NCT# 04179721 for more details on staff support and training).
11042506|NCT04481568|Active Comparator|The attention control condition|The attention control condition will consist of a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 nursing assistants (1:8 ratio), that primarily cohorts older patients with geriatric syndromes.
11042507|NCT04481555|No Intervention|"Eosinophil_Control/Azithro_Control"|"Azithromycin: patients are given placebo
~ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose."
11042508|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Control:"|"a. Azithromycin: placebo b. ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months): i. If blood eosinophil ≥ 300 cells/μL, ICS in usual dose next 3 months. Blood eosinophils are measured every 3 months.
~ii. If blood eosinophil <300 cells/μL, ICS is discontinued."
11042509|NCT04481555|Experimental|"Eosinophil_Control/Azithro_Active group"|Azithromycin: 250 mg azithromycin three times weekly. b. ICS: The patients are given the usual LAMA/LABA/ICS product in the usual dose, where the medical treatment for severe COPD is unchanged throughout the entire project period
11042510|NCT04481555|Experimental|"Eosinophil_Active/Azithro_Active:"|"Azithromycin: 250 mg azithromycin three times weekly.
~ICS: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months):"
11042511|NCT04481516||Yoga|Single arm only representing cohort of NHS health care workers with possible Covid-19 related stress and anxiety disorder. Participants act as their own controls pre and post regular practice of yoga technique.
11042512|NCT04481490||Home-based|Cardiac rehabilitation (including exercise training) delivered in a home-based setting, facilitated remotely by Mayo Clinic staff.
11042513|NCT04481490||Center-based|Cardiac rehabilitation (including exercise training) delivered in a center-based setting, facilitated in person by Mayo Clinic staff.
11042517|NCT04481438|Experimental|exercise group|exercise group will receive acupunch exercise
11042519|NCT04481425|Other|intervention group|Text messages will be sent to the subjects through the system, including reminding the patients to take medicine on time, returning to the hospital regularly, and giving popularization of psychiatric knowledge and coping skills.Three times a week for three months.
11042520|NCT04481425|No Intervention|control group|Subjects also collected in the outpatient department and the ward were randomly divided into the control group and regularly followed up.
11042521|NCT04481412|Experimental|Study group|(30) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
11042522|NCT04481412|Active Comparator|Control group|(30) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
11042523|NCT04481399|Experimental|FSI-ECD|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. The FSI-ECD will be delivered in weekly 90-minute home visiting sessions for 12 consecutive weeks.
11042524|NCT04481399|Other|Control|The control is standard maternal and child health home visiting delivered by community health workers. Families will receive three 90-minute home visiting educational sessions focused on nutrition, hygiene, and post-natal care.
11042525|NCT04481386|Experimental|Active arm|Participants with a diagnosis of retinal detachment or vitreous haemorrhage, who are scheduled for vitrectomy surgery with a vitreous substitute
11042526|NCT04481373|Experimental|THRIVE|Acceptance and Commitment Therapy plus Education about HIV A master's level mental health professional will provide the 4-5 hour intervention for out-of-care PWH during a hospitalization. There are two important components to the intervention: Acceptance and Commitment Therapy (ACT) content, targeting avoidance with acceptance-based coping and active engagement in values-based living, and HIV education.
11042527|NCT04481373|Other|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
11042528|NCT04481360||patients with covid 19 pneumonia|clinical presentation & outcome of covid 19 pneumonia
11042529|NCT04481347||Patients undergoing general anesthesia|Patients eligible for interventional neuroradiology or surgery performed under general anesthesia. Patients will be included if they are admitted for a non-emergency scheduled procedure.
11042530|NCT04481334|Experimental|One group|One group pre-test, post-test design
11042531|NCT04481321||Patient with benign gynaecologic disease|Patients consulting for endometriosis, pelvic pain, abnormal uterine bleeding and/or infertility, or for a pelvic mass,
11042532|NCT04481295|Active Comparator|High SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 94-96%, and a flow of 10 L/min).
11042533|NCT04481295|Active Comparator|Low SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 84-86%, and a flow of 10 L/min).
11042534|NCT04481282|Experimental|Terbutaline plus Danazol group|Terbutaline 2.5mg tid po plus danazol 200mg bid po for 12weeks
11042535|NCT04481269|Experimental|Research Group|Research group uses surface-modified composite coated orthopedic implants
11042536|NCT04481269|Active Comparator|Controls Group|Controls group uses conventional orthopedic implants
11042537|NCT04481256|Experimental|1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy|"Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
~External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy"
11042538|NCT04481243|Experimental|Experimental|Children will receive Pneumovax 23 vaccination.
11042539|NCT04481230|Experimental|99mTc-NTP 15-5 (level 1)|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
11042540|NCT04481230|Experimental|99mTc-NTP 15-5 (level 2)|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
11042541|NCT04481230|Experimental|99mTc-NTP 15-5 (level 3)|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
11042542|NCT04481217|Experimental|Schizophrenia|Patients included will be diagnosed with schizophrenia or schizoaffective disorder, and experience AVH at the time of the inclusion (n= 350). All will be inpatients.
11042543|NCT04481204|Active Comparator|Control arm GroupI(mFOLFIRINOX)|Patients receive mFOLFIRINOX for 3 months before and after surgery in the absence of disease progression or unacceptable toxicity.
11042544|NCT04481204|Active Comparator|Control arm GroupII(chemotherapy, FOLFIRINOX)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for up to 4 months in the absence of disease progression or unacceptable toxicity.
11042545|NCT04481204|Active Comparator|Control arm GroupIII(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
11042546|NCT04481204|Active Comparator|Control arm GroupIV(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
11042547|NCT04481204|Active Comparator|Control arm GroupV(FOLFIRINOX, radiation therapy)|Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
11042548|NCT04481204|Active Comparator|Control arm GroupVI(chemotherapy,FOLFIRINOX,radiation therapy)|Patients receive gemcitabine, gemcitabine and nab-paclitaxel, gemcitabine and cisplatin, or FOLFIRINOX for 6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors
11042549|NCT04481191|Experimental|Concomitant RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular [IM] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 [Day 1]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
11042550|NCT04481191|Active Comparator|Staggered RotaTeq and IPV|Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).
11042551|NCT04481178||patients with nevus of Ota|patients with nevus of Ota who had been treated with laser at Siriraj hospital
11042552|NCT04481165||Adolescents with anorexia nervosa|Adolescents from 12 to 25 year old, cared for anorexia nervosa at the Maison de Solenn (Cochin hospital, Paris, France) et for whom antidepressive agents have been prescribed
11042553|NCT04481139|Experimental|SHR0302 dose1|SHR0302 dose1 for 24 weeks
11042554|NCT04481139|Experimental|SHR0302 dose2|SHR0302 dose2 for 24 weeks
11042555|NCT04481139|Experimental|SHR0302 dose3|SHR0302 dose3 for 24 weeks
11042556|NCT04481139|Placebo Comparator|Placebo|Placebo for 12 weeks
11042557|NCT04481113|Experimental|Treatment (abemaciclib, niraparib)|Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
11042558|NCT04481100|Experimental|Experimental Group|Itraconazole capsule 100mg twice daily for 6 weeks concurrent with chemoradation.
11042559|NCT04481087|Experimental|Clearfil Universal Bond Quick, self-etch mode (CU-SE)|
11042560|NCT04481087|Experimental|Clearfil Universal Bond Quick, selective etch mode (CU-SLE)|
11042561|NCT04481087|Experimental|Clearfil Universal Bond Quick, etch&rinse mode (CU-ER)|
11042562|NCT04481087|Experimental|Clearfil SE Bond (CSE)|
11042563|NCT04481087|Experimental|Tetric N-Bond (TB)|
11042564|NCT04481074|Experimental|Inspiratory muscle training group|Group intervention: home-based interval inspiratory muscle training during 8 weeks, two sessions with two sets of 30 breaths with one minute rest between them. Load set is determinated weekly, aiming 50% of actual PImax and according to Borg Score.
11042565|NCT04481061|Other|Decision Making About Genetic Results|Adolescents between 13-21 and parent (if applicable) will make decisions about learning results using an electronic decision tool. Results that match their choices will be returned.
11042566|NCT04481048|Experimental|N-Acetylcysteine (NAC)|"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.
~Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg
~*Max dose not to exceed 2700mg/day (1350mg BID)"
11042567|NCT04481048|Placebo Comparator|Placebo|Each subject will be dosed with placebo for 8 weeks.
11042568|NCT04481035|Experimental|N-Acetylcysteine|Participants will be dosed with 70 mg/kg/dose (max dose 900 mg) three times per day of N-Acetylcysteine (NAC) for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
11042569|NCT04481035|Placebo Comparator|Placebo|Participants will be dosed three times per day with a placebo for eight (8) weeks. This is a double-blind study, neither study participant nor study team members will know whether the participant is given study drug or placebo until after all data is collected.
11042570|NCT04481022|Other|group will receive proximal control exercises|
11042571|NCT04481009|Experimental|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
11042572|NCT04481009|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
11042573|NCT04481009|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
11042574|NCT04480996||Road traffic accidents with medicines|Road traffic accidents cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Drugs Responsible for Cognitive and Psychomotor Side Effects
11042575|NCT04480970|Experimental|Nasogastric tube placement|
11042576|NCT04480957|Experimental|Escalation Cohort dose 1 of ARCT-021, 21 - 55 years|Escalation Cohort dose 1 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042577|NCT04480957|Experimental|Escalation Cohort dose 2 of ARCT-021, 21 -55 years|Escalation Cohort dose 2 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042578|NCT04480957|Experimental|Escalation Cohort dose 3 of ARCT-021, 21 - 55 years|Escalation Cohort dose 3 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042579|NCT04480957|Experimental|Escalation Cohort dose 4 of ARCT-021, 21 - 55 years|Escalation Cohort dose 4 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042580|NCT04480957|Experimental|Expansion cohort dose regimen 1, 21 - 55 years.|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042581|NCT04480957|Experimental|Expansion cohort dose regimen 2, 21 - 55 years.|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042582|NCT04480957|Experimental|Expansion cohort dose regimen 1, 56 - 80 years|Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042583|NCT04480957|Experimental|Expansion cohort dose regimen 2, 56 - 80 years|Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.
11042584|NCT04480931|Experimental|mHealth Intervention Group|This group will be provided with the mobile health app (including introductory videos on how to use its features).
11042585|NCT04480931|Sham Comparator|Control Group|This group will receive an educational brochure about physical activity during pregnancy.
11042586|NCT04480918||Major Depressive Episode|After referral to the University of Iowa's Interventional Psychiatry Clinic, the patient will be clinically evaluated and, if appropriate, commence the procedural-based treatment course.
11042830|NCT04479410||Drug resistant epilepsy patients|Patients with drug resistant epilepsy underwent epilepsy surgery
11042587|NCT04480905|Sham Comparator|Sham tape group|in supine, full knee extension position, apply the sham tape from the anterior inferior iliac crest to the middle of the lower leg
11042588|NCT04480905|Experimental|Dynamic tape group|in supine, full knee extension position, apply the dynamic tape from the anterior inferior iliac crest to the middle of the lower leg
11042589|NCT04480879|Experimental|AZD8154 nebuliser suspension|The study subjects will receive 1 mg delivered dose of AZD8154 nebuliser suspension
11042590|NCT04480879|Experimental|AZD8154 Monodose|The study subjects will receive 1 mg capsule delivered dose of AZD8154 Monodose DPI formulation
11042591|NCT04480879|Placebo Comparator|AZD8154 Placebo Monodose DPI|The study subjects will receive AZD8154 placebo Monodose DPI formulation dosed to correspond to 1 mg delivered dose AZD8154 Monodose DPI formulation
11042592|NCT04480866|Other|First-void urine collection|Women self-collect three first-void urine samples (random order) at home.
11042593|NCT04480853|Experimental|Fingolimod|Open label Fingolimod 0.5 mg capsule taken once daily, oral.
11042594|NCT04480840|Placebo Comparator|Placebo|
11042595|NCT04480840|Experimental|PLN-74809 Dose Level 1|
11042596|NCT04480840|Experimental|PLN-74809 Dose Level 2|PLN-74809 Dose Level 2 following safety review of PLN-74809 Dose Level 1
11042597|NCT04480840|Experimental|PLN-74809 Dose Level 3|PLN-74809 Dose Level 3 following safety review of PLN-74809 Dose Level 1
11042598|NCT04480827|Experimental|Part 1: Mild Hepatic Impairment (Cohort A)|8 mild hepatic impaired subjects
11042599|NCT04480827|Experimental|Part 1: Moderate Hepatic Impairment (Cohort B)|8 moderate hepatic impaired subjects
11042600|NCT04480827|Experimental|Part 1: Severe Hepatic Impairment (Cohort C)|8 severe hepatic impaired subjects
11042601|NCT04480827|Experimental|Part 1: Healthy Volunteers (Cohort D)|up to 24 matched healthy volunteers
11042602|NCT04480827|Experimental|Part 2: Hepatic Impairment cohort|up to 8 hepatic impaired subjects (mild, moderate or severe)
11042603|NCT04480827|Experimental|Part 2: Healthy Volunteers cohort|up to 8 matched healthy volunteers
11042604|NCT04480814||Metastatic Breast Cancer|
11042605|NCT04480814||Healthy volunteers|
11042606|NCT04480801|Experimental|thermal evaluation and foot care|Participants in the experimental group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone. Thermal evaluation will be done. The application of the thermal evaluation, the foot areas to be applied and how to record the results of the application will be taught to the patient and / or their relatives. In addition, the thermal evaluation video will be uploaded to the phone of the patient and / or their relative. While the participants in the experimental group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions, Thermal evaluation registration form, Daily step number registration form will be provided and participants will be invited to check every 2 months.
11042607|NCT04480801|Other|foot care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone.While the participants in the control group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions will be provided and participants will be invited to check every 2 months.
11042608|NCT04480788|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
11042609|NCT04480775|Experimental|bupivacaine group|28 Patients will receive 18 ml of bupivacaine 0.5 % plus 1ml 0.9% saline in TAP block divided equally on both sides
11042610|NCT04480775|Active Comparator|triamicinolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (20 mg of triamcinolone in 1ml 0.9% saline divided equally on both sides in TAP block
11042611|NCT04480775|Active Comparator|methylprednisolone group|28 Patient will receive 18 ml of bupivacaine 0.5 % plus (40 mg of methylprednisolone in 1ml 0.9% saline ) on both sides in TAP block.
11042612|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 1|A single subcutaneous injection of SHR-1703 (Dose 1) or Placebo
11042613|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 2|A single subcutaneous injection of SHR-1703 (Dose 2) or Placebo
11042614|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 3|A single subcutaneous injection of SHR-1703 (Dose 3) or Placebo
11042615|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 4|A single subcutaneous injection of SHR-1703 (Dose 4) or Placebo
11042616|NCT04480762|Experimental|SHR-1703-Subcutaneous administration of Dose 5|A single subcutaneous injection of SHR-1703 (Dose 5) or Placebo
11042617|NCT04480749|Other|Routine Testing|Among men in the control group, they will receive a list of local clinics that can provide free syphilis testing.
11042618|NCT04480749|Experimental|Self-Testing|In the intervention arm we will provide a treponemal rapid syphilis test kit to all individuals in the intervention arm of the pilot, delivered through MSM community facilitators. This is similar to existing rapid treponemal test kits that are available at many clinical facilities. Kits will be accompanied by simplified pictorial instructions on finger prick blood sample collection.
11042619|NCT04480736|Placebo Comparator|Placebo|Participants will receive matching placebo of JNJ-64281802 orally.
11042620|NCT04480736|Experimental|JNJ-64281802 High dose|Participants will receive high dose of JNJ-64281802 orally.
11042621|NCT04480736|Experimental|JNJ-64281802 Medium dose|Participants will receive medium dose of JNJ-64281802 orally.
11042622|NCT04480736|Experimental|JNJ-64281802 Low dose|Participants will receive low dose of JNJ-64281802 orally.
11042623|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen X|Participants will receive dosing regimen X of JNJ-64281802 orally.
11042624|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Y|Participants will receive dosing regimen Y of JNJ-64281802 orally.
11042625|NCT04480736|Experimental|JNJ-64281802 Dosing Regimen Z|Participants will receive dosing regimen Z of JNJ-64281802 orally.
11042670|NCT04480424|Experimental|GAMUNEX-C + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of GAMUNEX-C on Day 1 up to a total net dose of 2 grams per kilogram (g/kg), based on participant's body weight (maximum dose = 160 g for participants over 80 kg), administered in divided doses as infusions of 500 milligrams per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11042626|NCT04480723|Other|Participants with Low or Intermediate Probability of PH|Participants who underwent a work-up for the suspicion of PH that includes transthoracic echocardiography (TTE) and who were considered to have a low or intermediate probability of PH according to TTE (local interpretation) will be enrolled. Blood samples will be taken and a cardiac magnetic resonance imaging (MRI) will be performed to evaluate the presence of Pulmonary Hypertension (PH). The TTEs that were performed by local standards will be collected and undergo central interpretation using European society of Cardiology / European respiratory society (ESC/ERS) guidelines to confirm the local interpretation.
11042627|NCT04480710|Experimental|CRV431|CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions
11042628|NCT04480710|Placebo Comparator|Placebo|Placebo, softgel capsule, QD, 28 days, fasted conditions
11042629|NCT04480697|Experimental|SAD 10mg|A single oral dose of 10 mg
11042630|NCT04480697|Experimental|SAD 20mg|A single oral dose of 20 mg. Food effect will also be assessed at the same dose level.
11042631|NCT04480697|Experimental|SAD 40mg|A single oral dose of 40mg
11042632|NCT04480697|Experimental|SAD 80 mg|A single oral dose of 80 mg
11042633|NCT04480697|Experimental|SAD 120 mg|A single oral dose of 120 mg
11042634|NCT04480697|Experimental|SAD 150 mg|A single oral dose of 150 mg
11042635|NCT04480697|Experimental|MAD 10mg|Dose regimen is once daily 10 mg for 14 consecutive days.
11042636|NCT04480697|Experimental|MAD 30mg|Dose regimen is once daily 30 mg for 14 consecutive days.
11042637|NCT04480697|Experimental|MAD 90 mg|Dose regimen is once daily 90mg for 14 consecutive days.
11042638|NCT04480671|Other|Sacrocolpopexy|This group will only receive the sacrocolpopexy for their pelvic organ prolapse repair.
11042639|NCT04480671|Active Comparator|Sacrocolpopexy and concomitant level III support procedure|This randomized group will receive an additional vaginal repair for level III support at the conclusion of the sacrocolpopexy.
11042640|NCT04480658|Experimental|Bryophyllum pinnatum|Bryophyllum pinnatum (BP) muscle relaxing substance
11042641|NCT04480645|Experimental|Treatment|Radioactive bandage applied to surface of the body worn for approximately one week.
11042642|NCT04480632|Experimental|ABO compatible convalescent plasma|A 500 ml dose of convalescent plasma (from a single donor or two 250 ml units from one or two donations) collected by apheresis will be administered. In case of plasma storage, plasma unit will be thawed following parameters of blood bank. Administration will take place slowly and over the course of four hours. When two 250 ml units are administered, second unit must be administered after the first unit in a period not exceeding 12 hours.
11042643|NCT04480632|No Intervention|Usual care|Usual medical care for critically ill patients at ICU
11042644|NCT04480619|Experimental|Ga-68 AIP-301 Positron Emission Tomography|Companion Ga-68 PET diagnostic for tumor targeted therapy
11042645|NCT04480606|Experimental|Home exercise group|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group.
11042646|NCT04480606|No Intervention|Control Group|The control group will be asked to remain isolated as they are and the exercise program will not be implemented.
11042647|NCT04480593|Active Comparator|Control|standard care.
11042648|NCT04480593|Experimental|EPP-AF 400mg/day|Green propolis extract (EPP-AF) at a dose of 400mg / day in addition to the standard treatment.
11042649|NCT04480593|Experimental|EPP-AF 800mg/day|Green propolis extract (EPP-AF) at a dose of 800mg / day in addition to the standard treatment.
11042650|NCT04480580||Hospitalized patients|
11042651|NCT04480567|Experimental|Dose 1 of BMN 307|
11042652|NCT04480567|Experimental|Dose 2 of BMN 307|
11042653|NCT04480567|Experimental|Dose 3 of BMN 307|
11042654|NCT04480554|Experimental|Methadone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
11042655|NCT04480554|Experimental|Buprenorphine/naloxone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
11042656|NCT04480554|Experimental|XR-Naltrexone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
11042657|NCT04480541|Experimental|Roadmap 2.0 + Fitbit Charge 3|"Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.
~Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
11042658|NCT04480528|Experimental|BFRT Group|This group will receive physical therapy plus active BFRT.
11042659|NCT04480528|Sham Comparator|Standard of Care Group|This group will receive physical therapy plus sham BFRT.
11042660|NCT04480502|Experimental|Envafolimab|Patients treated with 300 mg of single agent envafolimab every three weeks
11042661|NCT04480502|Experimental|Envafolimab + Ipilimumab|Patients treated with envafolimab in combination with ipilimumab. Envafolimab will be given at 300 mg every three weeks. Ipilimumab will be given at 1 mg/kg every three weeks for a total of four doses.
11042662|NCT04480489|Experimental|Group A|In Group A, students will first perform Task 1 (walk from anesthesia lounge to the day surgery unit) using intervention 1 (using the virtual reality video) first, then Task 2 (walk from anesthesia lounge to the pre-operative clinic) using intervention 2 (using the traditional 2D video).
11042663|NCT04480489|Active Comparator|group B|In Group B, students will first perform Task 1 (follow route 1: walk from anesthesia lounge to the day surgery unit) using intervention 2 (using the traditional 2D video) first, then Task 2 (follow route 2: walk from anesthesia lounge to the pre-operative clinic) using intervention 1 (using the virtual reality video).
11042664|NCT04480463|Experimental|SCD411|
11042665|NCT04480463|Active Comparator|Aflibercept|
11042666|NCT04480450|Active Comparator|IVIg/SCIg < 12 Months Arm|Patients with CIDP successfully treated with IVIg/SCIg for under 12 months.
11042667|NCT04480450|Active Comparator|IVIg/SCIg > 12 Months Arm|Patients with CIDP successfully treated with IVIg/SCIg for more than 12 months.
11042668|NCT04480450|Active Comparator|Corticosteroid Arm|Patients with CIDP successfully treated with corticosteroids.
11042669|NCT04480437|Experimental|Study Intervention|mp-BUS data collection
11042671|NCT04480424|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
11042672|NCT04480411|Experimental|COVID-19 Patients|Patients that are admitted to the hospital with COVID 19.
11042673|NCT04480398||Ayurveda|Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol.
11042674|NCT04480398||Control|Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines.
11042675|NCT04480385|Experimental|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last 7 days through post-operative monitoring room (continuous comparison with reference monitor), general ward (comparison with spot-check monitoring) and patient's home
11042676|NCT04480372|Experimental|NSCLC (cohort 1) and inoperable MPM (cohort 2)|"Cohort 1 consists of NSCLC patients. Cohort 2 consists of MPM patients.
~Patients will be treated with gemcitabine at the dose of 1000 mg/m2 i.v. on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
~The trial treatments will be continued for max. 2 years or until discontinuation criteria are met (see Ch. 9.3), whichever occurs first. The follow-up phase will last up to 5 years from treatment start."
11042677|NCT04480359|Active Comparator|Bawei Shenqi group|participants should administrate both Bawei Shenqi Pill and Meloxicam tablets
11042678|NCT04480359|Placebo Comparator|placebo group|participants should administrate both Bawei Shenqi Pill placebo and Meloxicam tablets
11042679|NCT04480346|Experimental|CHP treatment|Participants assigned to this arm received the treatment described in another section.
11042680|NCT04480346|No Intervention|Community Care|Participants randomly assigned to this condition received information about service providers in the community, but no services from the investigators.
11042681|NCT04480333|Experimental|Drug: NA-831 - 0.10 mg/kg|3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
11042682|NCT04480333|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
11042683|NCT04480333|Experimental|Drug: NA-831 - 0.20 mg/kg|6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
11042684|NCT04480333|Placebo Comparator|Comparable Placebo- 0.20 mg/kg|3 subjects will take inhaled formulation of placebo once a day for 5 days
11042685|NCT04480333|Experimental|Drug: GS-5734 - 1.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
11042686|NCT04480333|Placebo Comparator|Comparable Placebo- 1.00 mg.kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
11042687|NCT04480333|Experimental|Drug: GS-5734 - 2.00 mg/kg|6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
11042688|NCT04480333|Placebo Comparator|Comparable Placebo - 2.00 mg/kg|3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
11042689|NCT04480333|Experimental|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
11042690|NCT04480333|Placebo Comparator|Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg|3 Subjects - inhaled formulation of placebo once/day for 5 days
11042691|NCT04480333|Experimental|Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)|6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
11042692|NCT04480333|Placebo Comparator|Placebo- 0.20 mg/kg + 2.00mg/kg|3 Subjects- inhaled formulation of placebo once/day for 5 days
11042693|NCT04480320|Experimental|Pericapsular nerve group block|
11042694|NCT04480320|Placebo Comparator|Saline placebo group|
11042695|NCT04480307|Experimental|temelimab 18 mg/kg|Monthly IV repeated dose
11042696|NCT04480307|Experimental|temelimab 36 mg/kg|Monthly IV repeated dose
11042697|NCT04480307|Experimental|temelimab 54 mg/kg|Monthly IV repeated dose
11042698|NCT04480307|Placebo Comparator|Placebo|Monthly IV repeated dose
11042699|NCT04480294|Experimental|Part 1a Treatment group 1|Intervention: Drug1: HRS5091, dose 1; Drug2: Placebo Healthy subjects
11042700|NCT04480294|Experimental|Part 1a Treatment group 2|Intervention: Drug1: HRS5091, dose 2; Drug2: Placebo Healthy subjects
11042701|NCT04480294|Experimental|Part 1a Treatment group 3|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects
11042702|NCT04480294|Experimental|Part 1a Treatment group 4|Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo Healthy subjects
11042703|NCT04480294|Experimental|Part 1a Treatment group 5|Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo Healthy subjects
11042704|NCT04480294|Experimental|Part 1b Treatment group 3|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects Food effect
11042705|NCT04480294|Experimental|Part 1c Treatment group 6|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects
11042706|NCT04480294|Experimental|Part 2 Treatment group 7|Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo CHB subjects
11042707|NCT04480294|Experimental|Part 2 Treatment group 8|Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo CHB subjects
11042708|NCT04480294|Experimental|Part 2 Treatment group 9|Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo CHB subjects
11042709|NCT04480281|Active Comparator|Lidocaine Group|Bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
11042710|NCT04480281|Placebo Comparator|Placebo Group|Equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
11042711|NCT04480255|Active Comparator|Group 1: Standard of Care|Parents of infants born from date July 2020-December 2020
11042712|NCT04480255|Active Comparator|Group 2: NICU2HOME+ app|Parents of infants born from mid Jan 2021-May2021
11042713|NCT04480242||Asthma Research in Children and Adolescents - Spanish Cohort|Groups defined according to treatments prescribed during regular clinical practice and to the exposure to inhalation techniques monitoring
11042774|NCT04479852|Experimental|SP-624|Daily oral capsule, 20 mg/day
11042775|NCT04479852|Placebo Comparator|Placebo|Daily oral capsule
11042714|NCT04480229|Experimental|Intervention Group|After the first treatment, every week the patients were called and consulted by telenursing. During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled. The study ended with the fourth cycle chemotherapy. A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients. Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
11042715|NCT04480229|No Intervention|No Intervention: Control Group|"During their first treatment the Patient Identification Form was filled and they were trained, which is the routine practice of the clinic. Patients were informed about the Symptom follow-up form, asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom. When the patients came to the second treatment, the first follow-up of the patients was done. The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews. The Symptom Follow-up Form given to the patients in the previous chemotherapy treatment was collected and the same new form was given. They were requested to bring this form in their next treatment. The same protocol was followed during the third and fourth chemotherapy treatment"
11042716|NCT04480203|Active Comparator|Cognitive based stress management (CBSM)|Cognitive based digital intervention (Stressproffen cognitive arm, Stressproffen 2A)
11042717|NCT04480203|Active Comparator|Mindfulness based intervention (MBI)|Mindfulness based digital intervention (Stressproffen mindfulness arm, Stressproffen 2B)
11042718|NCT04480203|Placebo Comparator|Control|Control arm
11042719|NCT04480190|Experimental|Research Treatment|Gemcitabine/Cisplatin/ChemoRT
11042720|NCT04480177|Other|insole group|the control group receives insole only.
11042721|NCT04480177|Experimental|exercise group|the experimental group receives exercise and insole.
11042722|NCT04480164|Experimental|NDMC 40 mg/day|Oral administration of two NDMC 20mg capsules per day over 6 weeks
11042723|NCT04480164|Experimental|NDMC 60 mg/day|Oral administration of three NDMC 20mg capsules per day over 6 weeks
11042724|NCT04480164|Experimental|NDMC 120 mg/day|Oral administration of six NDMC 20mg capsules per day over 6 weeks
11042725|NCT04480164|Placebo Comparator|Placebo|Oral administration respectively, according to the experimental arm considered, of two, three or six placebo capsules per day over 6 weeks
11042726|NCT04480151||IMPELLA™ alone as bridge to LVAD|patients assisted by IMPELLA™ pump alone during the days preceding the implantation of long term LVAD (at least 48 hours for patients for whom an ECLS was previously used)
11042727|NCT04480151||ECLS alone or with IMPELLA™ as bridge to LVAD|patients assisted by ECLS (ExtraCorporeal life support) alone or simultaneously with IMPELLA™ until the implantation of LVAD
11042728|NCT04480138|Experimental|Pegylated Interferon-α2b + Standard of care|"Test :- Pegylated Interferon-α2b + Standard of care (SOC)
~Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial."
11042729|NCT04480138|Active Comparator|Standard of Care|"Control: Standard of care
~Standard of care treatment will be provided as per regulatory recommendation and approval."
11042730|NCT04480125|Experimental|Aza+Chida|Azacitidine ivgtt D1-7 Chindamide 30mg,PO,twice a week Every 21 days for total 6 courses
11042731|NCT04480112|Experimental|Group A Intervention|Participants in Group A will receive an intervention designed to provide participants with more social interaction during a time of social distancing and highly limited in-person social interactions
11042732|NCT04480112|Active Comparator|Group B Control|Participants in Group B will not receive any new interventions.
11042733|NCT04480099|Active Comparator|CHOP|Patients in this arm will receive conventional CHOP regimen for 6 cycles
11042734|NCT04480099|Experimental|CHOP+X|Patients in this arm will receive targeted drug in combination with conventional CHOP regimen for 6 cycles, based on NGS results
11042735|NCT04480086|Experimental|Segment A: Mivebresib Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of mivebresib to identify the safe dosing regimen and schedule.
11042736|NCT04480086|Experimental|Segment A: Mivebresib Monotherapy|Participants will receive the identified safe dosing regimen of mivebresib as monotherapy.
11042737|NCT04480086|Experimental|"Segment B: Ruxolitinib + Mivebresib Add-on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and mivebresib as add-on therapy."
11042738|NCT04480086|Experimental|Segment C: Mivebresib + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive mivebresib and navitoclax.
11042739|NCT04480086|Experimental|Segment D: Mivebresib + Ruxolitinib|Participants who have never received JAKi will receive mivebresib and ruxolitinib.
11042740|NCT04480073|Other|edentulous patients with atrophic jaws|patients presenting with severely atrophic edentulous sites in the upper and lower jaw, and requesting implant-supported prosthetic restorations, will be enrolled in this study.
11042741|NCT04480047|Experimental|Tetranite Stabilized Dental Implants with Provisional Crown|Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.
11042742|NCT04480034||Group Pisa|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Bariatrica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy (Head Prof. Marco Anselmino) will be collected in a prospective database, to monitor the postoperative course.
11042743|NCT04480034||Group Padova|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOSD Week Surgery, Azienda Ospedaliera, Università di Padova, Italy (Head Dr. Mirto Foletto) will be collected in a prospective database, to monitor the postoperative course.
11042744|NCT04480034||Group Bologna|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Chirurgia Bariatrica, Azienda Ospedaliera Universitaria di Bologna, Italy (Head Dr. Paolo Bernante) will be collected in a prospective database, to monitor the postoperative course.
11042745|NCT04480034||Group Bergamo|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale e Oncologica, Policlinico San Marco di Zingonia, Bergamo, Italy (Head Prof. Stefano Olmi) will be collected in a prospective database, to monitor the postoperative course.
11042746|NCT04480034||Group Tor Vergata|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit U.O.S.D. Chirurgia Mininvasiva e dell'Apparato Digerente, Università Tor Vergata, Rome, Italy (Head Prof. Paolo Gentileschi) will be collected in a prospective database, to monitor the postoperative course.
11042747|NCT04480034||Group Torino|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria Citta della Salute e della Scienza, Università di Torino, Italy (Head Prof. Mario Morino) will be collected in a prospective database, to monitor the postoperative course.
11042748|NCT04480034||Group Milano|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Milano, Italy (Head Dr. Giuseppe Marinari) will be collected in a prospective database, to monitor the postoperative course.
11042749|NCT04480034||Group Rome|All the bariatric cases (all laparoscopic bariatric procedures) performed during the period July/December 2020 in the unit UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, University La Sapienza of Rome, Italy (Head Prof. Gianfranco Silecchia) will be collected in a prospective database, to monitor the postoperative course.
11042750|NCT04480021|Experimental|Multiuser Interactive Health Response Application (MITHRA)|Randomization is at the level of the Community Based Organization (CBO). CBOs randomized to MITHRA will have access to the MITHRA app on tablets. MITHRA app will include depression screening and behavioral activation modules.
11042751|NCT04480021|Placebo Comparator|Enhanced Usual Care (EUC)|CBOs randomized to EUC will receive standardized monthly group education (45 min) regarding the symptoms of depression
11042752|NCT04480008|Experimental|Resilient Living Program|All participants will be in the Resilient Living Program arm. Study participation involves participating in a 12-week stress management and resilience training program. This will involve four virtual sessions (video or phone) and answering questions about their health, well-being, and quality of life. There will also be online modules to watch and an accompanying journal (with prompts) to keep.
11042753|NCT04479995|Experimental|Horizon Program|"Eight weekly, audio recorded telehealth videoconferencing sessions. Sessions are 90 minutes.
~Questionnaire assessments at 8 and 16 weeks after end of videoconferencing sessions"
11042754|NCT04479995|Experimental|Usual Care|"Standard medical visits to address chronic GVHD, with an additional standardized booklet, in electronic or paper format, containing information on the management of chronic GVHD and stem cell transplant survivorship recommendations.
~Questionnaire assessment at 8 weeks and 16 weeks after Horizons Program group starts"
11042755|NCT04479969|Other|Intervention|This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing.
11042756|NCT04479956|Experimental|Surgical Ligation|Conventional surgical procedures will carried out through a 3-4 cm incision in the groin. The trunk of GSV and the tributaries will be ligated and divided.
11042757|NCT04479956|Experimental|Microwave group|The microwave treating wire (Microwave Intracavity Coagulation System; Shanghai Medical Electronics, Shanghai, China) will be inserted into the GSV until it reached the medial aspect of ankle, guided by a light that illuminated the tip of the wire. Then, GSV will be ablated using pulse mode at 20-30 W. The treating wire will be withdrawn at 2-4 mm/s, with the ablation time lasting 2 s (energy delivery to the GSV was estimated at around 80 J/cm); the treatment parameters will be based on a previous report. Tumescence will be used in all patients with 0.9% saline containing 20 mL 2% lidocaine with 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L 0.9% saline.
11042758|NCT04479956|Experimental|Laser ablation group|"Endovenous Laser Ablation (EVLA) uses a laser Fiber, which is inserted into the abnormal vein via a small skin puncture.using 1470 nm laser and a radial fiber for less discomfort. Two weeks later the branch vessels have reduced in size"
11042759|NCT04479956|Experimental|Radiofrequency ablation group|inserts a small catheter into the diseased vein through a small incision, using ultrasound guidance for an accurate and live view. Consistent and uniform heat is delivered to contract the collagen in the vein walls, causing them to collapse and close. After the vein is closed the treated vein is gradually absorbed into surrounding tissue.
11042760|NCT04479943|No Intervention|Pre-intervention/control|160 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months prior to implementation of the unit-based MOVIN intervention.
11042761|NCT04479943|Experimental|Post-intervention|160 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months after MOVIN has been implemented on the unit.
11042762|NCT04479930|Experimental|HappyAir Group|The HappyAir app comprises two main parts: an educational program providing patients useful information and advice about their illness and data collection related to physical activity and disease.
11042763|NCT04479930|No Intervention|Control group|The control group only underwent the scheduled check-ups
11042764|NCT04479917|Experimental|TPN171H 5mg group|TPN171H 5mg tablet + Placebo 10mg 2 tablets
11042765|NCT04479917|Experimental|TPN171H 10mg group|TPN171H 10mg tablet + Placebo 5mg tablet+ Placebo 10mg tablet
11042766|NCT04479917|Experimental|TPN171H 20mg group|TPN171H 10mg 2 tablets + Placebo 5mg tablet
11042767|NCT04479917|Placebo Comparator|Placebo group|Placebo 5mg tablet+ Placebo 10mg 2 tablets
11042768|NCT04479904|Experimental|famitinib|
11042769|NCT04479891|Experimental|pyrotinib alone, pyrotinib + itraconazole|Sequential treatments of pyrotinib alone followed by pyrotinib + itraconazole, with a washout period in between.
11042770|NCT04479865|Experimental|Sequence 1|Period 1, Aricept 5mg → DA-5207 150mg; Period 2, Aricept 5mg → Aricept 10mg
11042771|NCT04479865|Experimental|Sequence 2|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 150mg
11042772|NCT04479865|Experimental|Sequence 3|Period 1, Aricept 5mg → DA-5207 170mg; Period 2, Aricept 5mg → Aricept 10mg
11042773|NCT04479865|Experimental|Sequence 4|Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg →DA-5207 170mg
11042778|NCT04479813|Experimental|No conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
11042779|NCT04479813|Experimental|No conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
11042780|NCT04479813|Experimental|Remote pre-conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
11042781|NCT04479813|Experimental|Remote pre-conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
11042782|NCT04479800|Experimental|Treatment A - Fasting|No food prior to dosing
11042783|NCT04479800|Experimental|Treatment B - Fed|High-fat/high-calorie meal prior to dosing
11042784|NCT04479800|Experimental|Treatment C - Fed|Low-fat/low-calorie meal prior to dosing
11042785|NCT04479787|Active Comparator|Spinal Cord Stimulation (SCS)|An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
11042786|NCT04479787|Active Comparator|Comprehensive Medical Management (CMM)|CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
11042787|NCT04479774|Experimental|Experimental Group (Group A)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.
~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
11042788|NCT04479774|Other|Control group: (Group B)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.
~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
11042789|NCT04479761|Experimental|Virtual Reality|Participants will be wearing a virtual reality headset and observing 2 types of scenes: abstract (a display of stars) or contextual (a subway station).
11042790|NCT04479748|Other|Dextenza insert|Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).
11042791|NCT04479748|Other|Fellow-eye|The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.
11042792|NCT04479735|Experimental|VR goggle with venipuncture|Virtual reality goggles SamsungGearVR supplied by KindVR will be placed on patients at least 2 min prior to venipuncture. All patients will also receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture.
11042793|NCT04479735|No Intervention|no VR goggle with venipuncture|Patients will receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture but NO virtual reality goggles.
11042794|NCT04479722|Experimental|Microport CardioAdvance LAAC system|Subject implant Microport CardioAdvance LAAC system to occlude LAA through percutaneous intervention.
11042795|NCT04479722|Active Comparator|Watchman LAAC system|Subject implant Watchman LAAC system to occlude LAA through percutaneous intervention.
11042796|NCT04479696|Experimental|Arm I (NIRS)|Patients receive standard of care verbal and written education materials. Patients also receive a customized video which includes a description of each of their tumor, functional areas of the brain affected, and possible symptoms from the tumor and radiation treatment based on the neuro-imaging features. Patients and their caregivers watch the video together or separately over 1.5-3 minutes before the end of the first week of radiation treatment. Within 2 weeks after watching the NIRS video, patients complete an optional survey over 5-10 minutes.
11042797|NCT04479696|Active Comparator|Arm II (standard of care)|Patients receive standard of care verbal and written education materials.
11042798|NCT04479683|Other|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
11042799|NCT04479683|Experimental|FTH (full-time hospitalisation) then day hospitalization)|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.
~During this phase, all children are evaluated once a week on a somatic level."
11042800|NCT04479657|Experimental|QingFei Granule+Cefuroxime group|Cefuroxime：30mg/kg/d,bid QingFei Granule: tid
11042801|NCT04479657|Active Comparator|Cefuroxime group|Cefuroxime：30mg/kg/d,bid
11042802|NCT04479644|Experimental|Cohort 1|BRII-198 dose level 1 or placebo
11042803|NCT04479644|Experimental|Cohort 2|BRII-198 dose level 2 or placebo
11042804|NCT04479644|Experimental|Cohort 3|BRII-198 dose level 3 or placebo
11042805|NCT04479631|Experimental|Cohort 1|BRII-196 dose level 1 or placebo
11042806|NCT04479631|Experimental|Cohort 2|BRII-196 dose level 2 or placebo
11042807|NCT04479631|Experimental|Cohort 3|BRII-196 dose level 3 or placebo
11042827|NCT04479436|Experimental|Cohort 2: HER3 Low/Negative (IHC 1+, 0)|Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen.
11042828|NCT04479423|Experimental|Soda water|400ml soda water was drunk to obtain good vision before undergoing MCE examination.
11042808|NCT04479618|Active Comparator|Usual practice (negative control)|After a member of the UHWI surgical team performs the initial cleansing/debriding, the control group (1) will have their ulcer dressed as usually done at UHWI. Wounds are dressed with saline-soaked gauze, covered with dry gauze. One wrap of stretch gauze will hold the dressing in place. Patients will clean the wound by vigorously wiping with gauze soaked in homemade normal saline (1 tsp salt/500ml water bottle), center to edges, at each dressing change, unless already very clean. Clean wounds will simply be irrigated with normal saline at each dressing change. Patients experienced with using papaya for debridement of their ulcers may apply it only to the open wound, avoiding contact with the periwound, to remove slough or eschar. If patients observe green exudate, they are permitted to add one teaspoon of vinegar to their bottle of saline. Dressings in group (1) will be changed daily. The dressings will be soaked off if they become adherent.
11042809|NCT04479618|Experimental|improvised dressings (experimental)|After initial cleansing/debriding, patients in the improvised dressing group (2) will then have a thin layer zinc oxide paste applied to the dried periwound, carefully avoiding the open wound. A piece of a clean new plastic bag (food-grade World Star 1 mil LD bags, or the equivalent, purchased from the Papine Market across John Golding Road from the University of the West Indies), cut slightly larger than the ulcer will be gently conformed to the moist wound contours and sealed onto the zinc oxide paste. The bag will be fenestrated with a small slit using a number 11 scalpel or clean scissors prior to placing it on the ulcer in order to allow excess fluid to escape. The edges of the slit will be approximated. Clean gauze will be placed lightly over the slit to capture escaping fluid. One wrap of stretch gauze will hold the dressing in place. Patients will be instructed to change the dressings daily, irrigating with normal saline at each dressing change.
11042810|NCT04479618|Active Comparator|advanced dressings (positive control)|"After initial cleansing/debriding, the advanced dressing group (3) will have a cut piece of a 4x24 standard (pink) polymeric membrane dressing roll large enough to extend at least 0.5 cm beyond all open and closed (inflamed or damaged) wound edges applied as per the Instructions for Use (the periwound is blotted dry, but the wound bed remains moist from the final saline rinse). One wrap of stretch gauze will hold the polymeric membrane dressing in place. The approximate open wound edges will be marked on the dressing backing. As per the manufacturer's instructions for use, patients will change the dressings when saturation reaches any of the wound edges, as indicated by a change in color on the backing of the dressing, visible through the stretch gauze. Routine rinsing will not be performed; the wounds will be rinsed at dressing changes only if visible loose debris is present."
11042811|NCT04479605||Patients with advanced cancer|Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E & F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G & H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
11042812|NCT04479605||Caregivers|Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
11042813|NCT04479605||Oncologists|The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
11042814|NCT04479579|Experimental|Apixaban|apixaban for extended prophylaxis against VTE after discharge
11042815|NCT04479566|Experimental|lithium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
11042816|NCT04479566|Placebo Comparator|calcium carbonate|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
11042817|NCT04479553||Qizhi Tongluo Capsules|Qizhi Tongluo Capsules will be given to the patients, and the investigators will record all the information including ADR, application of Qizhi Tongluo Capsules and the combined medications, etc.
11042818|NCT04479540|Experimental|Hospitalized SARS Cov-2|Hospitalized patients diagnosed with SARS Cov-2 infection
11042819|NCT04479514|Experimental|Preventative Skin Care Routine|"Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.
~Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment."
11042820|NCT04479501||Asthma group|Patients with asthma
11042821|NCT04479488||Hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection need hospitalization.
11042822|NCT04479488||Non-hospitalized patients|Patient who are suspected or confirmed SARS-CoV2 infection non-hospitalized.
11042823|NCT04479475|Experimental|Supportive care through community support persons|Participants will attend 2-hour weekly group sessions for four weeks to build social support systems. Participants will also report back on social activities that they participated in with their partner each week for the four-week intervention.
11042824|NCT04479449|Experimental|SP-8203|SP-8203 80 mg (40 mg/dose twice a day for three days)
11042825|NCT04479449|Placebo Comparator|Placebo|Placebo group: twice a day for three days
11042826|NCT04479436|Experimental|Cohort 1: HER3 High (IHC 3+, 2+)|Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen.
11042829|NCT04479423|No Intervention|water|900ml clear water(100 ml water of simethicone solution was not included) was drunk to obtain good vision before undergoing MCE examination.
11042831|NCT04479397|Active Comparator|Sling Arm|This arm of the study will receive a sling for 3 weeks in postoperative care.
11042832|NCT04479397|Experimental|No Sling Arm|This arm of the study will not receive a sling during the postoperative care,
11042833|NCT04479384|Experimental|Intervention group|Thoracic manipulation T1-T5 if somatic dysfunction. Intrathoracic fascia stretch x 3. Recoil sternum x 3. Cranial base release - 4 steps.
11042834|NCT04479384|No Intervention|Control group|Supine position 10 minutes on the bench.
11042835|NCT04479371|Experimental|Liposomal bupivacaine|a penile block administered with novel liposomal bupivacaine during hypospadias repair
11042836|NCT04479371|Active Comparator|Standard Penile Block|Standard weight based bupivacaine penile block during hypospadias repair
11042837|NCT04479358|Active Comparator|Sub-study A, Tocilizumab-Free Standard of Care|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive no tocilizumab.
11042838|NCT04479358|Experimental|Sub-study A, Tocilizumab 40mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 40mg.
11042839|NCT04479358|Experimental|Sub-study A, Tocilizumab 120mg|Patient assigned to Sub-study A by primary treating physicians. Patient enrolled on trial sub-study A and randomized to receive tocilizumab 120mg.
11042840|NCT04479358|Active Comparator|Sub-study B, Tocilizumab 400mg or 8mg/kg Standard of Care|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab dose (400mg or 8mgkg).
11042841|NCT04479358|Experimental|Sub-study B, Tocilizumab 40mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 40mg.
11042842|NCT04479358|Experimental|Sub-study B, Tocilizumab 120mg|Patient assigned to Sub-study B by primary treating physicians. Patient enrolled on trial sub-study B and randomized to receive standard of care tocilizumab 120mg.
11042843|NCT04479332|Experimental|Resuscitation Area|Critical patient is assigned to the resuscitation area for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1-2 licensed physicians, 2-3 nurses (1 for preparing intubation materials and acts as the assist, 1-2 for administering medications and documentation); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside resuscitation area, 1 at nurses' station), 4 nurses (2 inside resuscitation area, 2 at the sterile area)
11042844|NCT04479332|Experimental|Negative Pressure Isolation Room|Critical patient is assigned to the negative pressure isolation room for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1 licensed physician, 2 nurses (1 for preparing intubation materials, acts as the assist, and for administering medications; 1 for documentation at the anteroom); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside negative pressure isolation room, 1 at nurses' station), 5 nurses (2 inside negative pressure isolation room, 1 at the anteroom, 2 at the sterile area)
11042845|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT
~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-
~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
11042846|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT
~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
11042847|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19
~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-
~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
11042848|NCT04479306|Experimental|Arm A (osimertinib, alisertib)|Patients receive osimertinib PO QD on days 1-28 and alisertib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm B.
11042849|NCT04479306|Experimental|Arm B (osimertinib, sapanisertib)|Patients receive osimertinib PO QD on days 1-28 and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm A.
11042850|NCT04479280||Covid19 positive patients|
11042851|NCT04479280||Covid19 negative patients|
11042852|NCT04479267|Experimental|Treatment (polatuzumab vedotin, R-CHP)|Patients receive prednisone PO, prednisolone IV, or methylprednisolone IV on days 1-5. Patients also receive rituximab IV, polatuzumab vedotin IV over 30-90 minutes, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11042853|NCT04479254|Experimental|Indirect Calorimetry- Directed Nutrition|Enteral Nutrition (EN) will be the preferred route of nutrition, and will be initiated within the first 24-48 hours of ICU admission. Caloric requirements will be measured by indirect calorimetry IC as soon as possible after recruitment and will be repeated in every 24 hrs. The amount of delivery is gradually increased to avoid the possibility of gastrointestinal intolerance. If EN fails to reach caloric goals or not feasible supplementary Parenteral nutrition(PN) will be initiated after 5-7days
11042854|NCT04479254|Active Comparator|Standard weight-based equation- Directed Nutrition|Enteral Nutrition (EN) will be initiated within the first 24-48 hours of ICU. Admission. Enteral nutrient delivery is gradually increased to avoid the possibility of gastrointestinal intolerance so that a few days are required to achieve the caloric target. PN will be started after 5-7 days if EN is not feasible. Energy and protein goals will be calculated by the standard weight-based equation of 25 kcal/kg BW body weight and 1.2-2.5 g/kg body weight, respectively.
11042855|NCT04479241|Experimental|PVSRIPO|
11042882|NCT04478994|Active Comparator|TEPEZZA 20mg/kg|Approximately 15 participants will receive 8 infusions of TEPEZZA q3W for a total of 21 weeks. TEPEZZA 10mg/kg will be administered on Day 1 and TEPEZZA 20mg/kg will be administered q3W for the remaining 7 infusions.
11042883|NCT04478994|Placebo Comparator|Placebo|Approximately 10 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
11042884|NCT04478981||SELENON- or LAMA2-related muscular dystrophy|Participants diagnosed with congenital myopathy/muscular dystrophy due to mutations in the SEPN1 (SELENON) or LAMA2 gene
11042885|NCT04478968||Active AVF|Patients after kidney transplantation with functioning AVF
11042856|NCT04479228|Experimental|NAGI bi-flanged metal stent (BFMS)|The WON will be punctured using a standard 19-gauge FNA needle and the aspirate was sent for biochemical and microbial analysis. A 0.025-inch (Visiglide; Olympus Corporation, Tokyo, Japan) or 0.035-inch stiff guidewire (Jag Wire; Boston Scientific) passed through the needle into the cyst cavity to form at least 1 to 2 loops under fluoroscopic guidance. A 6F cystotome (Endo-flex GmbH Dusseldorf, Germany) will be passed over the guidewire for creating a fistula. Subsequently, a 6-mm balloon dilator (Hurricane; Boston Scientific Corporation or Titan balloon, Wilson Cook) will be used to further dilate the fistula tract. After this, the stent delivery catheter is advanced over the guidewire across the PFC wall and the BFMS (Nagi; Taewoong Medical, Gyeonggi-do, South Korea) deployed using sonographic, fluoroscopic and endoscopic visualization.
11042857|NCT04479228|Experimental|Plastic stents|Double-pigtail plastic stents will be used. A minimum of one 10Fr pigtail plastic stent will be placed. After initial EUS-guided access, the ostomy will be dilated first, using a cystotome, and secondly with a balloon dilation. The plastic stent will be inserted and delivered following the routine technique of each interventional endoscopist. The number of the plastic stents and the size of the balloon used to dilate the ostomy will depend on the WON size and content.
11042858|NCT04479202|Experimental|berberine group (B group)|Patients in the B group were given berberine hydrochloride tables 0.3g tid orally or tube feed daily, until the 14th day of the study. Other treatments include general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support.
11042859|NCT04479202|Sham Comparator|control group (C group)|Patients in the C group were given montmorilonite orally if they presence of diarrhea. The other treatments were the same as in B group.
11042860|NCT04479176||Intranasal Drip Method|After the patient is placed in supine position, Two ml of 2% mepivacaine is placed in a syringe with sheath of 16 gauge vinca. Sheath of vinca is inserted through the nostril and 2% mepivacaine is dripped into nostril in the supine position. The mepivacaine dripped on the nasal pharynx is held for 10 minutes. Drip of 2% mepivacaine is performed in one nostril which pain is dominant. In cases of bilateral pain, drip of mepivacaine is performed in one nostril at random.
11042861|NCT04479176||Cotton Stick Method|The posture is supine position. Cotton tip applicator soaked with 2% mepivacaine is inserted vertically into the nostril. After the cotton tip applicator touched the posterior wall of the middle turbinate, the cotton tip applicator is fixed and removes after 10 minutes later. Cotton tip applicator is inserted in one nostril which pain is dominant. In cases of bilateral pain, one applicator is inserted in one nostril at random.
11042862|NCT04479163|Experimental|Plasma|Convalescent plasma with an IgG titer against SARS-CoV2
11042863|NCT04479163|Placebo Comparator|Placebo|Normal Saline 0.9%
11042864|NCT04479150||Pandemic Covid-positive cohort|All Covid-positive patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
11042865|NCT04479150||Pandemic Covid-negative cohort|All Covid-negative patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
11042866|NCT04479150||Control cohort|Pre-pandemic cohort: all patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2019.
11042867|NCT04479111|Experimental|LISRH group|Following the principle of complete mesocolic excision(CME), Ileocecus-Sparing Right colectomy refers to the resection of the most portion of the ascending colon, hepatic flexure and mid to distal transverse colon. The extent of lymph node dissection and length of distal resection margin are similar to conventional right hemicolectomy. The length of proximal resection margin varies.
11042868|NCT04479098|Experimental|Exercise training|Postmenopausal breast cancer survivors undergoing tamoxifen treatment, who will do the evaluations before the beginning and after 12 weeks of exercise training and subsequently 12 weeks of detraining.
11042869|NCT04479085|Experimental|experimental group|The nursing attempt to organize the home environment for the experimental group will take 4 months. During this period, two home visits and two telephone calls will be made. During the first home visit, training will be organized to regulate the home environment. Temperature and humidity changes of the houses will be monitored during the operation with the heat-moisture meter device. During the first home visit, a temperature-humidity meter device, symptom log and temperature-humidity log tracking chart will be provided. Children in this group will be given an anti-allergic duvet cover. After 4 months, mothers' home environment arrangements, children's allergic rhinitis symptoms and quality of life changes will be examined.
11042870|NCT04479085|Other|control group|The nursing initiative to regulate the home environment for the control group will take 4 months. During this time, two home visits will be made. During the first home visit, temperature-humidity meter device, symptom log and temperature-humidity log monitoring chart will be provided. After 4 months, mothers' home environment arrangements, children's allergic rhinitis symptoms and quality of life changes will be examined.
11042871|NCT04479072|Active Comparator|Intervention Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of aspirin 81 mg.
11042872|NCT04479072|Placebo Comparator|Placebo Arm|60 subjects will be randomly assigned to this arm. The subjects in this arm will receive a daily dose of a placebo pill
11042873|NCT04479072|No Intervention|Observational Arm|60 subjects will be placed in the observational arm. These subjects will not receive any intervention but will be followed and asked to return at the same time interval as the other 2 groups.
11042874|NCT04479059|Experimental|İntracavitary fluid flushing|
11042875|NCT04479059|No Intervention|Control group|
11042876|NCT04479046|Active Comparator|Stainless steel crowns|3M ESPE
11042877|NCT04479046|Experimental|Zirconia crowns|Nu Smile
11042878|NCT04479046|Experimental|PMMA crowns|Dental Direkt
11042879|NCT04479033|No Intervention|Control|Participants assigned to the control group had screened positive for cognitive impairment but refused the intervention. They were provided with a GP referral letter and information on helplines and caregiver support. Follow-up interviews were scheduled at week 24.
11042880|NCT04479033|Experimental|Intervention|Weekly meeting/communication sessions with members of intervention team for a total of 24 weeks.
11042881|NCT04479007||Mechanically ventilated patients|Critically ill patients of 18 years or older who receive invasive mechanical ventilation for acute respiratory failure and have an indication for an intervention in the airways.
11042886|NCT04478968||No AVF|Patients after kidney transplantation without AVF (thrombosed AVF, history of HD with catheter, history of PD, preemptive transplantation)
11042891|NCT04478942|Active Comparator|oral misoprostol|At time of delivery, participants randomly assigned to either oral misoprostol will receive 50 mcg of Misoprostol every 4 hours up to 6 doses, OR until simplified Bishop score >6 (whichever is achieved first).
11042892|NCT04478942|Active Comparator|intravenous oxytocin|At time of delivery, participants randomly assigned to intravenous oxytocin, will be administered the drug per standard of labor and delivery titrations.
11042893|NCT04478929||gastroscopy clinic patients|NBT gastroscopy clinic invited participants. Patients are already due to attend the clinic, and we are inviting them to share their gastroscopy data with our research study.
11042894|NCT04478916||Geriatric evaluation Group|Geriatric evaluation of the proportion of elderly patients in which the treatment is modified based on the complete geriatric assessment (CGA)
11042895|NCT04478916||Control Group|
11042896|NCT04478903||primary caregiver of patients aged 70 and over|
11042897|NCT04478890||Observational Group|Characterize right ventricular function while undergoing LVAD implantation
11042898|NCT04478851|Experimental|Intervention|All participants will be involved in group exercise classes, twice a week for 12 weeks.
11042899|NCT04478838|Experimental|Extended Dosing Group|Participants taking olanzapine or risperidone will be switched to an alternate day dosing schedule.
11042900|NCT04478838|No Intervention|Treatment as Usual group|Participants will continue to take their olanzapine or risperidone following the same prescribed daily schedule.
11042901|NCT04478825|Experimental|BBT-401-1S|BBT-401-1S, rectal administration
11042902|NCT04478812|Experimental|Single Group Assignment|
11042903|NCT04478799|Experimental|Group A (Transcutanous Posterior Tibial Nerve Stimulation)|Patients belonging to the group A received Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
11042904|NCT04478799|Sham Comparator|Group B (Sham Control)|Patients belonging to the group B received Sham Transcautanoues posterior tibial nerve stimulation plus diet and Kegel exercises
11042905|NCT04478786||Focus Groups 1-4|An anticipated 3-8 participants who meet the inclusion criteria of being aged 18 or over, a employee of the local ambulance service, are employed as an operational ambulance crew member, irrespective of title and to have had experienced an out of hospital resuscitation where MCCD was used, irrespective of the type of device or their level of involvement, and who also volunteer and agree to take part in the online focus group.
11042906|NCT04478773|Experimental|Experimental|Patient will receive MRI
11042907|NCT04478760||Masculinising therapy|Healthy transgender (including non-binary) adults who are on testosterone-containing hormone therapies.
11042908|NCT04478760||Feminising therapy|Healthy transgender (including non-binary) adults who are on oestrogen-containing hormone therapies.
11042909|NCT04478747|Active Comparator|Transvaginal mesh|BSC mesh (A.M.I., Feldkirch, Austria) is attached to the sacrospinosus ligaments and to the apical part of the vagina.
11042910|NCT04478747|Active Comparator|Colposacropexy with the apical fixation only|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina.
11042911|NCT04478747|Active Comparator|Colposacropexy with the apical and the levator fixation|EndoGYNious (A.M.I.) CSP mesh is attached laparoscopically to the apical part of the vagina with fixation reaching to the level of the levator planes.
11042912|NCT04478734|Experimental|Moderate doses|moderate doses of combination therapy applying the minimum average dosage of thiamine and biotin used in patients with BTBGD
11042913|NCT04478734|Experimental|High doses|high doses of the combination therapy applying the average standard dosage of thiamine and biotin used in patients with BTBGD.
11042914|NCT04478721|Experimental|Temocillin|Patients enrolled in this arm, will receive 2g each 8 hours of intravenous temocillin.
11042915|NCT04478721|Active Comparator|Meropenem|Patients enrolled in this arm, will receive 1g each 8 hours of intravenous meropenem.
11042916|NCT04478708|Experimental|AMG 133|Up to 6 single ascending dose cohorts.
11042917|NCT04478708|Placebo Comparator|Placebo|Up to 6 single ascending dose cohorts.
11042918|NCT04478695|Experimental|Cohort 1|
11042919|NCT04478695|Experimental|Cohort 2|
11042920|NCT04478682|Experimental|WhatsApp Messaging Application|Continuous breastfeeding support will be provided for the first 6 months through WhatsApp messaging application. Mothers will be contacted once a week through WhatsApp and feedback will be received on the breastfeeding process. The questions of the mother regarding breastfeeding will be answered by text / voice message or video call.
11042921|NCT04478682|No Intervention|Standard breastfeeding support|She will receive standard breastfeeding support after delivery. Breastfeeding will not receive continuous breastfeeding support for the first 6 months after discharge.
11042922|NCT04478656|Experimental|BBV121-2.5 µg|BBV121: Each 0.5ml vial contain purified10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
11042923|NCT04478656|Placebo Comparator|Placebo|Each 0.5ml vial contain purified 2.5 µg, 5 µg or 10 µg inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
11042924|NCT04478656|Experimental|BBV121-5 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5mL
11042925|NCT04478656|Experimental|BBV121-10 µg|BBV121: Each 0.5ml vial contain purified inactivated Zika virus, alum, 2-PE and phosphate buffered saline qs to 0.5ml
11042926|NCT04478643|Placebo Comparator|PLACEBO|"Collection of microbiological samples from the two deepest sites in two different quadrants.
~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).
~Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
11042927|NCT04478643|Experimental|PROBIOTIC (L. Reuteri)|"Collection of microbiological samples from the two deepest sites in two different quadrants.
~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).
~Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
11042972|NCT04478305|Other|Intervention group|Patient will be provided with study medication. To be taken once a day for 16 weeks (112 days). Active drug brand name - Duavive/Duavee. Dose consisting of 1 pill of 0.45mg conjugated estrogens and 20mg bazedoxifene as bazedoxifene acetate.
11044177|NCT04469998|Experimental|AXR-270 High Dose|AXR-270 High Dose administered once daily
11042928|NCT04478630|Active Comparator|Peppermint Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of peppermint essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4).The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening).The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
11042929|NCT04478630|Active Comparator|Ginger Essential Oil|Usual care plus a personal pocket diffuser prepared with 14 drops of ginger essential oil. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy.The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
11042930|NCT04478630|Placebo Comparator|Pure Vanilla Extract (placebo-control)|Usual care plus a personal pocket diffuser prepared with 1 drop of pure vanilla extract (placebo). Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). The subjects will complete a Pre-treatment Assessment form before cycle of chemotherapy (total of 2), as well as 24 and 72 hours after each cycle of chemotherapy. The exact same procedures will be repeated during the participant's next cycle of chemotherapy, which is likely two or three weeks after the first one.
11042931|NCT04478617|Experimental|Metronidazole|
11042932|NCT04478617|No Intervention|Control|
11042933|NCT04478604||pregnant women|last trimester pregnant women and gave birth in the same hospital
11042934|NCT04478591||Patients with multiple sclerosis using ocrelizumab.|Patients with multiple sclerosis using ocrelizumab for a minimum of one year.
11042935|NCT04478578||Patients with febrile illness|Participants from approximately 520 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study.
11042936|NCT04478552|Experimental|Intervention group|
11042937|NCT04478552|Placebo Comparator|Control group|
11042938|NCT04478539|Experimental|COVID-19 patients admitted to the ICU|"COVID-19 patients will be treated with the Prismaflex® oXiris® system in the ICU.
~Treatment will be initiated within 4 - 12 hours after admission upon establishing control of the haemostasis, ACT = Activated Coagulation Time of 180 seconds"
11042939|NCT04478526|Experimental|e-CBT|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session were designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
11042940|NCT04478526|Experimental|Pharmacotherapy|Biweekly meeting with psychiatrist with GAD-7, DASS-42 and Q-LES-SF. Pharmacotherapy class decided according to protocol developed in accordance with Canada's best practice guidelines for GAD treatment. At second appointment, medication will be maintained and optimized, regardless of response. At third appointment, optimized if partial response or switched according to protocol if no response. Partial response is improvement of 20% or more in GAD-7. If switched, 6-week protocol will recommence with new medication. At fourth appointment, dosage optimized if responding well to medication and improvement greater than 50% within primary arm, or 20% if secondary arm, patient will remain on said medication for remainder of 12-week study. If not improving more than 20%, medication switched according to protocol and 6-week protocol will recommence. If primary arm and 20-50% improvement after six weeks on new medication, augmented with olanzapine, risperidone or benzodiazepines.
11042941|NCT04478526|Experimental|e-CBT + Pharmacotherapy|Participants will commence both treatments described above simultaneously.
11042942|NCT04478513|Experimental|Smokers|Pre-specified group of participants.
11042943|NCT04478513|Experimental|Non-smokers|Pre-specified group of participants.
11042944|NCT04478500|Active Comparator|Minocycline Group|Subjects will be randomized to receive Minocycline 100mg twice daily
11042945|NCT04478500|Placebo Comparator|Placebo Group|Subjects will be randomized to receive placebo.
11042946|NCT04478487|Experimental|Study Participants|all preterm infants ≤ 32 weeks and 0 days gestational age (GA) with a birth weight 700 g to 1500 g at the hospital, who are enterally fed human milk in the neonatal intensive care unit (NICU) for at least 7 days. Various blending ratios of the fortifier with either the mother's expressed milk or donor milk will be used to deliver macro and micronutrients based on established guidelines to be adjusted according to the infant's tolerance for volume and calories. The estimated time for each subject's participation is approximately from 1 week through 8 weeks, depending on the weight and age at enrollment. Historic control cases treated by another human milk based human milk fortifier will be obtained from medical records, matched on birth weight and gender, with sample size twice (n=80) that of the study population.
11042973|NCT04478292|No Intervention|Cisplatin (CDDP) Group B1, Resectable|"Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.
~Patients will receive Cycles 3-6 of chemotherapy post-operatively."
11043363|NCT04475432|Experimental|Active|TP-03 ophthalmic solution 0.25%, administered topically twice a day for approximately 43 days
11042947|NCT04478474||Eligible|Retrospective chart review of all pediatric patients who underwent allogeneic stem cell transplant between June 29, 2011 and December 31, 2019 at Westchester Medical Center (WMC). Children, adolescent, and young adult patients, ages 0-≤26 years, who have received an allogeneic stem cell transplantation on the pediatric bone marrow transplant service including matched unrelated donor, matched sibling donor, haploidentical donor, umbilical cord donor, who received ganciclovir prophylaxis for ≥14 days.
11042948|NCT04478461|Experimental|MW11 injection|1, 3, 10 mg/kg and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W.
11042949|NCT04478448|Experimental|T test|Test drug (Flupirava) 1 tablet contains 200 mg Favipiravir
11042950|NCT04478448|Active Comparator|B reference|Reference drug (Avigan) 1 tablet contains 200 mg Favipiravir
11042951|NCT04478435|Active Comparator|1 Hour post intervention|Ultrasound assessment done 1 hour after ingestion of glucose loaded drink
11042952|NCT04478435|Placebo Comparator|2 hours post intervention|Ultrasound assessment done 2 hour after ingestion of glucose loaded drink
11042953|NCT04478422|Experimental|Muscle strengthening with vascular occlusion|Quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, with partial occlusion to blood flow. The occlusion equipment will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017).
11042954|NCT04478422|Active Comparator|Conventional muscle strengthening|Conventional quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, without occlusion to blood flow.
11042955|NCT04478409||Children or adult with Familial Mediterranean fever|"Considering 5 clearly pathogenic (homozygous) genotypes, 15 possibly pathogenic genotypes (5 pathogenic mutations in the heterozygous state, 10 possibly pathogenic mutations in the homozygous or heterozygous state), a number of 80 patients will be necessary to cover the correlation analysis genotype / phenotype.
~The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients."
11042956|NCT04478409||Healthy blood donor|Healthy blood donor
11042957|NCT04478370|Experimental|An. minimus|"This arm will be divided into 2 groups; the low-exposure groups and the high-exposure group.
~In the low-exposure group, participants will be exposed to 5 mosquito bites at weekly intervals from day 14 to day 56 (seven challenges with 5 mosquito bites/challenge over six weeks, yielding a total of 35 mosquito bites).
~In the high-exposure group, participants will be exposed to 5 mosquito bites on day 14 and then to 50 mosquito bites at weekly intervals from day 21 to day 56 (one challenge with 5 mosquito bites and six challenges with 50 mosquito bites/challenge over 6 weeks, yielding a total of 305 mosquito bites)."
11042958|NCT04478370|Experimental|An. maculatus|Same as above
11042959|NCT04478370|Experimental|An. dirus|Same as above
11042960|NCT04478370|Experimental|Ae. aegypti|Same as above
11042961|NCT04478370|Experimental|Ae. albopictus|Same as above
11042962|NCT04478357|Other|Treatment A|4 mg fesoterodine ER tablet manufactured at Zwickau.
11042963|NCT04478357|Other|Treatment B|4 mg fesoterodine ER tablet manufactured at Freiburg
11042964|NCT04478357|Other|Treatment C|8 mg fesoterodine ER tablet manufactured at Zwickau
11042965|NCT04478357|Other|Treatment D|8 mg fesoterodine ER tablet manufactured at Freiburg.
11042966|NCT04478344|Experimental|Ultrasound guided hydrodissection to superior cluneal nerve|Ultrasound guided perineural injection with 5% dextrose 4 c.c. + 1% xylocaine 1 c.c. to superior cluneal nerve of affected side.
11042967|NCT04478331|No Intervention|CONTROL|The Control group will receive the usual care. In the physical activity (PA) field, this includes two individual motivational interviews with a PA professional, and a group workshop during the first year after BS. PA recommendations will be explained to each participant, and their achievement will be encouraged and supported during these sessions. No face-to-face PA sessions will be offered as part of the usual care.
11042968|NCT04478331|Experimental|ACTI-VISIO|The two PA sessions per week will be delivered via videoconferencing (developed by Mooven™). The PA program consists in tailored adapted PA sessions led by a professional specialized in adapted PA. These sessions were specifically designed to be appropriate for the population and were developed in collaboration with the authors to ensure standardization of the recommended volume of PA. The PA sessions will be given live, individually at the beginning and then in groups of four women. During sessions, the professional and the participants will interact simultaneously, and the execution of the exercises will be monitored and adapted live by the professional. To ensure the safety of the PA, a rating of perceived exertion will be requested after each session on a 10-point scale. If the RPE exceed 7, the professional specialized in adapted PA will adjust the training load. In addition to the exercises, the sessions will also include advice and tips for reaching the recommended PA level.
11042969|NCT04478331|Experimental|ACTI-MOBIL|The PA sessions will be delivered by an eHealth platform (developed by BePatient™) associated with an activity bracelet. The researchers enrich PA content on the platform and ensure standardization of the recommended volume of PA. The platform consists of tips for reaching the PA level, PA questionnaires, PA feedback measured by the activity bracelet, and a video demonstration of PA sessions performed by a peer. The PA sessions are automatically broadcasted twice a week for 12 weeks. To ensure the safety of the PA, the sessions were designed to be appropriate for this population and the RPE will be measured after each session on a 10-point scale. If the RPE exceeds 7 for 3 consecutive sessions, the training load will be adjusted. The platform will also include a variety of content, including dietary tips, obesity-related facts, information about surgery, and frequently asked questions.
11042970|NCT04478318|Experimental|uEXPLORER/mCT|Each patient will undergo a scan on a total-body PET/CT scanner (uEXPLORER) and then undergo an additional scan on a conventional PET/CT scanner (mCT). The first scan will take place 90 minutes after injection with 18F-FDG and the second scan will be 120 minutes after injection with 18F-FDG.
11042971|NCT04478318|Experimental|mCT/uEXPLORER|Each patient will undergo a scan on a conventional PET/CT scanner (mCT) and then undergo an additional scan on a total-body PET/CT scanner (uEXPLORER) . The first scan will take place 90 minutes after injection with 18F-FDG and the second scan will be 120 minutes after injection with 18F-FDG.
11043397|NCT04475185|Experimental|MakAir|
11042974|NCT04478292|Experimental|CDDP plus STS Group B3, Resectable|"Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.
~Patients will receive Cycles 3-6 of chemotherapy post-operatively."
11042975|NCT04478292|No Intervention|CDDP Group B2, Unresectable|"Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectability evaluation will be scheduled after 4 cycles of chemotherapy.
~Resection of the primary tumor will be performed after completing the 4th cycle of chemotherapy if excellent response achieved at the 2nd evaluation timepoint.
~Patients resected after 4 cycles of chemotherapy will receive Cycles 5-6 of chemotherapy post-operatively.
~For those patients whose tumors after 4 cycles do not meet criteria for definitive surgical, it is recommended that such patients be evaluated by a surgeon team with a liver transplant expert while proceeding with Cycles 5 and 6."
11042976|NCT04478292|Experimental|CDDP plus STS/Group B4, Unresectable|"Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectability evaluation will be scheduled after 4 cycles of chemotherapy.
~Resection of the primary tumor will be performed after completing the 4th cycle of chemotherapy if excellent response achieved at the 2nd evaluation timepoint.
~Patients resected after 4 cycles of chemotherapy will receive Cycles 5-6 of chemotherapy post-operatively.
~For those patients whose tumors after 4 cycles do not meet criteria for definitive surgical, it is recommended that such patients be evaluated by a surgeon team with a liver transplant expert while proceeding with Cycles 5 and 6."
11042977|NCT04478292|No Intervention|C5VD/Group C1, Resectable|"Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.
~Patients will receive Cycles 3-6 of chemotherapy post-operatively."
11042978|NCT04478292|Experimental|C5VD plus STS/Group C3, Resectable|"Resection of the primary tumor will be performed after completing the 2nd cycle of chemotherapy.
~Patients will receive Cycles 3-6 of chemotherapy post-operatively."
11042979|NCT04478292|No Intervention|C5VD/ Group C2, Unresectable|"Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectability evaluation will be scheduled after 4 cycles of chemotherapy.
~Resection of the primary tumor will be performed after completing the 4th cycle of chemotherapy if excellent response achieved at the 2nd evaluation.
~Patients resected after 4 cycles of chemotherapy will receive Cycles 5-6 of chemotherapy post-operatively."
11042980|NCT04478292|Experimental|C5VD plus STS/Group C4, Unresectable|"Those patients whose tumors after 2 cycles do not meet criteria for definitive surgical, 2nd resectability evaluation will be scheduled after 4 cycles of chemotherapy.
~Resection of the primary tumor will be performed after completing the 4th cycle of chemotherapy if excellent response achieved at the 2nd evaluation.
~Patients resected after 4 cycles of chemotherapy will receive Cycles 5-6 of chemotherapy post-operatively."
11042981|NCT04478279|Experimental|Dose Escalation|This cohort only patients diagnosed with locally advanced or metastatic melanoma, carcinoma or sarcoma of any tumor type who are refractory or intolerant to all available therapies. ST101 will be administered intravenously (IV), initially once per week.
11042982|NCT04478279|Experimental|Dose Expansion HR+ Breast|This cohort must have progressed after 1-2 hormone based therapies. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
11042983|NCT04478279|Experimental|Dose Expansion Melanoma|This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
11042984|NCT04478279|Experimental|Dose Expansion GBM|Primary (de novo) GBM that has recurred or progressed (per modified RANO criteria) after 1 standard treatment regimen. Standard therapy is defined as maximal surgical resection, radiotherapy, and concomitant temozolomide with radiotherapy or adjuvant chemotherapy with temozolomide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
11042985|NCT04478279|Experimental|Dose Expansion CRPC|CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
11042986|NCT04478266|Experimental|SAR439859 with Letrozole-matching placebo Arm|"Participants in SAR439859 with Letrozole-matching placebo Arm will be administered: SAR439859 dose, once daily, continuously. Letrozole-matching placebo, once daily, continuously. Palbociclib dose once daily, days 1-21 of every 28-day cycle.
~Goserelin once every 4 weeks in pre/peri menopausal women and men."
11042987|NCT04478266|Active Comparator|Letrozole with SAR439859-matching placebo Arm|Participants in Letrozole with SAR439859-matching placebo Arm will be administered: Letrozole dose, once daily, continuously. SAR439859-matching placebo, once daily, continuously. Palbociclib dose once daily, days 1-21 of every 28-day cycle Goserelin once every 4 weeks in pre/peri menopausal women and men.
11042988|NCT04478253|Experimental|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
11042989|NCT04478253|No Intervention|Usual care|Insertion of the drain according to the usual management protocol
11042990|NCT04478240|Experimental|Intervention (access to PeerLearning.net)|Teachers and students in intervention schools will be given access to PeerLearning.net software for the purposes of instruction for the 2021-2022 school year.
11042991|NCT04478240|No Intervention|Passive Control (no intervention)|Teachers and students in control schools will conduct instruction as usual without PeerLearning.net.
11042992|NCT04478227|Experimental|Arm A|"Arm A will include acquired bone marrow failure (BMF) disorders including aplastic anemia, refractory cytopenia of childhood/Myelodysplastic Syndrome(MDS) without monosomy 7 and 5q deletion abnormalities, toxin induced myelosuppression due to infection and inherited cytopenia with or without involvement of other cell lines who are transfusion dependent and or showing progression to bone marrow failure.
~Arm A: Start at 5 microgram/kg/dose per week along with standard of care and escalate with 2.5 microgram/kg/dose increments (per week at physician's discretion depending on the clinical and laboratory response) (Maximum: 20 microgram/kg/dose) based on response for at least 24 weeks or until hematopoietic response is seen, whichever comes first. If patient shows response, therapy will be continued for a total of 52 weeks."
11058433|NCT04368728|Experimental|Mid dose, 65-85 years of age (2 doses)|
11042993|NCT04478227|Experimental|Arm B|"Arm B will include children with chemo and or radiotherapy induced thrombocytopenia/cytopenia and children undergoing stem cell transplantation (SCT).
~Arm B: Starting dose 2 microgram/kg/dose per week with increments at 1 microgram/kg/dose (Maximum: 10 micrograms/kg/dose) depending on the laboratory response."
11042994|NCT04478201|Experimental|Back lying sleep position|sleep on the back
11042995|NCT04478201|Experimental|Side lying sleep position|sleep on the side
11042996|NCT04478188||Cardiogenic Shock Patients Needing TMCS|Heart failure patients who undergo TMCS insertion for acute decompensated heart failure and cardiogenic shock.
11042997|NCT04478175|Other|Patients with advanced gastrointestinal (GI) cancers|"All patients will receive usual care including:
~Chemotherapy at the investigator's choice,
~Outpatient clinical visits according to the regular schedule,
~Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8 weeks.
~Nutritional support will consist of:
~A nutrition assessment by a dieticianat W2, W4 and W8 (plus additional visits if required),
~Nutritional intervention ± oral supplementation, enteral tube feeding, and/or parenteral nutrition).
~Physical activity support will consist of:
~A physical condition assessment by a APA profesional including physical tests (6-minute walking test, handgrip test, chair stand fitness test, get-up and go test, balance in single-leg and bipodal stance) at baseline, at W2, W4 and W8,
~Personalized unsupervised home-based program combining aerobic (e.g. walking, nordic walking) and resistance exercises."
11042998|NCT04478162|Experimental|Experimental|Newborn to be premature (28-34 Gestation Weeks), The baby is admitted to the neonatal intensive care unit,sleeps for at least 7 days, Any screened newborn gastrointestinal, neurological, and Genetic the absence of disease, Mother and father being open to communication and cooperation, Mother and father volunteering to participate in the research, Being a literate mother and father, The mother has primiparous and first maternity experience, Having the first parenting experience in your father, Your mom and dad being 19 and over, Participation of parents in the initiative group in training and practices for the FICare model, Participation in routine care in parents in the NICU to the parents in the control group, Baby nurses in charge of a 4-hour training on the Family Integrated Care model, Mothers and fathers in the venture group stay at least 6-8 hours a day in hospital, Mothers and fathers in the intervention group to perform at least 3 treatments a day with a nurse,
11042999|NCT04478162|No Intervention|Control Groups|Babies in the control group will be monitored in routine service care. There will be no intervention
11043000|NCT04478149|Experimental|Active Cameras|active cameras in the room
11043001|NCT04478149|Sham Comparator|Inactive Cameras|camera in the room, not activated
11043002|NCT04478136||Major bleeders (MB)|Additional blood to be drawn from patients on ECMO who have a major bleeding event.
11043003|NCT04478136||Non-major bleeders (NMB)|
11043004|NCT04478123|Experimental|romiplostim|"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.
~Regardless of the conditioning regimen received, all patients will receive romiplostim 3.0 mcg/kg SC on Day +1 and romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated until platelet count is >50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. No patient will receive more than six doses of romiplostim, even if platelets have not corrected by Day +42."
11043005|NCT04478110|Experimental|Interactive education with linkage to care|Main intervention components included interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care
11043006|NCT04478110|Active Comparator|general health education|Receive a group education session focused on general health education and primary prevention issues.
11043007|NCT04478097|Experimental|Reference-Reference-Test|
11043008|NCT04478097|Experimental|Reference-Test-Reference|
11043009|NCT04478097|Experimental|Test-Reference-Reference|
11043010|NCT04478084|Experimental|Group 1: pediatric participants; VRVg-2|VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
11043011|NCT04478084|Active Comparator|Group 2: pediatric participants; Verorab|Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
11043012|NCT04478084|Experimental|Group 3: adult participants; VRVG-2 + ERIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
~+ ERIG at D0"
11043013|NCT04478084|Active Comparator|Group 4: adult participants; Verorab + ERIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
~+ ERIG at D0"
11043014|NCT04478071|Experimental|vadadustat|
11043015|NCT04478071|Placebo Comparator|placebo|
11043016|NCT04478058|Experimental|e-CBT|Weekly e-CBT sessions will occur through Online Psychotherapy Tool (OPTT) and consist of slides and interactive therapist videos. Content and format mirrors live CBT. Slides will highlight a different topic each week and include general information, overview of skills, and homework. Homework will be submitted through OPTT and reviewed by administrators with personalized feedback within three days. Weekly homework submission will be mandatory before beginning the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment. After each cycle of e-CBT, patients and healthcare providers involved in e-CBT will be recruited for focus groups once they have completed their 12-week program. Qualitative data will be gathered through 10 focus groups. The focus group prompts will pertain to experience and expectations of service. Patients will be contacted six months after treatment to complete DASS 21 and Q-LES-Q-SF questionnaires.
11043017|NCT04478058|Active Comparator|Live CBT|The content and format of live CBT will be mirrored by the e-CBT group over the course of 12 weeks. The sessions will highlight a different topic each week and include general information, an overview of skills, and homework on that topic. Live CBT homework will be reviewed by the CBT group organizer and provided at the beginning of the next CBT session. Weekly homework submission for feedback will be mandatory before being eligible for the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment for both live and e-CBT. All live and e-CBT patients will be contacted six months after the completion of their CBT to complete final DASS 21 and Q-LES-Q-SF questionnaires. This will allow for the examination of the longevity of e-CBT compared to live CBT.
11043018|NCT04478032|Sham Comparator|sham stimulation|20 patients will be randomly allocated into this group,they will receive sham stimulation.
11058434|NCT04368728|Experimental|Mid dose, ≥12 years of age (2 doses)|
11043019|NCT04478032|Active Comparator|real stimulation dTMS targeting the ACC|20 patients will be randomly allocated into this group,they will receive real stimulation.
11043020|NCT04478019|Other|Control > Active Intervention|Treatment is 3 weeks of standard personal protective equipment without any povidone-iodine (PI) or chlorhexidine gluconate (CHG) intervention (control), followed by a 2 weeks washout period, and 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures.
11043021|NCT04478019|Other|Active Intervention > Control|Treatment is 3 weeks of nasal (10% povidone-iodine swab sticks in each nostril) and CHG oral decolonization (swish and spit 15 ml 0.12% CHG oral rinse for 30 seconds, four times/day) procedures, followed by 2 weeks of washout, and 3 weeks of standard personal protective equipment without any PI or CHG intervention (control).
11043022|NCT04478006||Childhood Leukemia|Peripheral blood and bone marrow samples are collected for genetic analysis, invitro drug sensitivity test and animal experiment.
11043023|NCT04477993|Experimental|Experimental Group - ruxolitinib|Ruxolitinib 5 mg PO b.i.d. for 14 days
11043024|NCT04477993|Placebo Comparator|Placebo Group|
11043025|NCT04477980||Culture positive empyema|Patients with empyema confirmed by a positive pleural fluid culture, irrespective of its gross fluid appearance
11043026|NCT04477980||Culture negative empyema|Patients with empyema confirmed by a gross pus appearance AND a negative pleural fluid culture
11043027|NCT04477954|Experimental|Experimental HBOT|Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
11043028|NCT04477954|No Intervention|Standard care|
11043029|NCT04477928||Newborn/Delayed Entry Group|Children 0-5.99 years old
11043030|NCT04477928||DGE- Opt In Group|36 weeks gestation up until onset of active labor
11043031|NCT04477915|Experimental|Core stabilization Exercise|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises. Exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
11043032|NCT04477915|Experimental|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles. exercises will be carried out under the supervision of a physiotherapist 3 days in a week separate time periods. Our study will take 6 weeks.
11043033|NCT04477915|No Intervention|Control|Control Group
11043034|NCT04477889||COVID-19 Cohort|Patients treated at MHS facilites for COVID-19
11043035|NCT04477850|Experimental|Luspatercept Administration|Starting dose of 1.0mg/kg subcutaneous injection every 3 weeks
11043036|NCT04477837||direct oral anticoagulant (DOAC) No.1|Apixaban 5mg, oral, twice daily for at least four months
11043037|NCT04477837||direct oral anticoagulant (DOAC) No.2|Rivaroxaban 20mg, oral, once daily for at least four months
11043038|NCT04477837||direct oral anticoagulant (DOAC) No.3|Edoxaban 60mg, oral, once daily for at least four months
11043039|NCT04477837||direct oral anticoagulant (DOAC) No.4|Dabigatran 150mg, oral, twice daily for at least four months
11043040|NCT04477811|Active Comparator|vitamin k1|vitamin k1 will be given 10 mg thrice a week for 3 months
11043041|NCT04477811|Active Comparator|vitamin k2|vitamin k2 (menaquinone) will be given 90 ug per day orally
11043042|NCT04477811|Placebo Comparator|placebo|placebo will be given daily per oral for 3 months
11043043|NCT04477798|Experimental|PCT-DIA/MS|PCT-DIA/MS protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules
11043044|NCT04477785||Clinical Observation|Up to 4500 participants will be followed clinically once identified, over the course of 5-8 years.
11043045|NCT04477772|Experimental|1mg/kg, Q3W until to 2 years|
11043046|NCT04477772|Experimental|3mg/kg, Q3W until to 2 years|
11043047|NCT04477772|Experimental|10mg/kg, Q3W until to 2 years|
11043048|NCT04477759|Experimental|50 Gray (Gy) Radiation Therapy|50 Gy of ionizing radiation therapy will be administered in 15 fractions.
11043049|NCT04477759|Experimental|55 Gray (Gy) Radiation Therapy|55 Gy of ionizing radiation therapy will be administered in 15 fractions.
11043050|NCT04477759|Experimental|60 Gray (Gy) Radiation Therapy|60 Gy of ionizing radiation therapy will be administered in 15 fractions.
11043051|NCT04477733|Experimental|Butorphanol group|
11043052|NCT04477733|Placebo Comparator|control group|
11043053|NCT04477707||Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO or FIGARO.
11043054|NCT04477707||Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO or FIGARO.
11043055|NCT04477694||type II diabetic patients|
11043056|NCT04477694||non-diabetic patients|
11043057|NCT04477681||Patients in therapeutic failure or relapse|Any child, adolescent or young adult, treated for a pediatric tumor or leukemia, in therapeutic failure or relapse without standard treatment option, not eligible / refusal of inclusion in a clinical study open on the territory and treated with an innovative drug within the framework of an ATU or outside AMM, in one of the centers of the SFCE (Société Française Cancer Enfant)
11043058|NCT04477668|Experimental|Helmet group|Patients will be allocated to helmet non-invasive ventilation
11043059|NCT04477668|No Intervention|Control group|Patients will be allocated to standard of care
11043060|NCT04477655|Active Comparator|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Continuous monitoring of vital signs. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%. Prone positioning will be allowed as a rescue therapy.
11043061|NCT04477655|Experimental|Awake prone positioning|Oxygen therapy through high flow nasal cannula (HFNC). Patients will be asked to remain in prone position throughout the day as long as possible, with breaks according to tolerance. Pillows will be offered for maximizing comfort at chest, pelvis and knees. Monitoring of vital signs will not be suspended. Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%.
11043062|NCT04477642|Experimental|AbataceptTreatment Arm|Enrolled patients who will receive treatment with abatacept
11043098|NCT04477343|Experimental|Experimental: SX-682 and Nivolumab|"SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill
~Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion"
11043063|NCT04477629|Experimental|Belatacept|Belatacept will be given as per the FDA approved product monograph (10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks) along with an upfront tacrolimus taper (trough level at month 1, 10-12ng/mL; month 2, 8-10ng/mL; month 3, 6-8ng/ml; month 4-6, 3-5ng/mL; months 7-9 taper off). Participants will also receive mycophenolate mofetil (MMF) 1000mg twice a day (BID) and corticosteroids (CS).
11043064|NCT04477616|Experimental|Experimental: Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 6 (chemotherapy day was record as day 1).
11043065|NCT04477616|Active Comparator|Comparator: Comparator/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 (chemotherapy day was record as day 1).
11043066|NCT04477603|Experimental|Subjects receiving the Impella ECP|
11043067|NCT04477590|No Intervention|NO EXERCISE TRAINING|25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
11043068|NCT04477590|Experimental|EXERCISE TRAINING FED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
11043069|NCT04477590|Experimental|EXERCISE TRAINING FASTED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
11043070|NCT04477577|Experimental|New Parent Intervention|
11043071|NCT04477577|Active Comparator|Safety Control|
11043072|NCT04477564||Unprovoked proximal deep vein thrombosis|
11043073|NCT04477564||Provoked distal deep vein thrombosis|
11043074|NCT04477551|Experimental|Diode laser (device) with scaling and root planing|Diode laser (device) with conventional scaling and root planing
11043075|NCT04477551|Active Comparator|Conventional scaling and root planing|Conventional scaling and root planing
11043076|NCT04477538||Participants with prepectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
11043077|NCT04477538||Participants with postpectoral reconstruction|-Participants will complete the post-mastectomy breast reconstruction physical well-being survey
11043078|NCT04477525|Experimental|ESP nerve block|
11043079|NCT04477525|No Intervention|Standard of Care|Standard of care includes IV opioids, NSAIDs (commonly ketorolac), +/- acetaminophen. No regional anesthesia will be given to control patients.
11043080|NCT04477512|Experimental|Level 1: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 20 mg.
11043081|NCT04477512|Experimental|Level 2: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 40 mg.
11043082|NCT04477512|Experimental|Expansion: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be dependent on recommended dose found in first part of study
11043083|NCT04477486|Experimental|Ibrutinib + Venetoclax|Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.
11043084|NCT04477473||Vulnerable subjects|Patients under long-term non-invasive ventilation (respiratory support) at home for chronic respiratory failure
11043085|NCT04477460||Infants with BRUE receiving thickened feeds|
11043086|NCT04477460||Infants with BRUE not receiving thickened feeds|
11043087|NCT04477421|Active Comparator|FS-LASIK Group|100 eyes of 50 patients underwent bilateral FS-LASIK (Femtosecond laser Insitu Keratomileusis)
11043088|NCT04477421|Experimental|FS-SMILE|100 eyes of 50 patients who underwent bilateral FS-SMILE (femtosecond small incision lenticule extraction)
11043089|NCT04477408|Other|plantar exercise group|"plantar sensitive exercises
~Plantar sensitive exercises:
~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
11043090|NCT04477395|Experimental|SRP plus fish oil|Patients will receive scaling and root planing (SRP) supplemented with the dietary fish oil rich in omega-3 PUFAs: 2.6 g of EPA and 1.8 g DHA daily for 6 months.
11043091|NCT04477395|Active Comparator|SRP alone|Patients will receive scaling and root planing (SRP) only.
11043092|NCT04477369|Other|Sequence A|7 subjects assigned to Sequence A will receive a single dose of 300mg DWJ1439 in period 1, 300mg DWC202003 in period 2 and 300mg DWJ1464 in period 3.
11043093|NCT04477369|Other|Sequence B|7 subjects assigned to Sequence B will receive a single dose of 300mg DWJ1464 in period 1, 300mg DWC202004 in period 2 and 300mg DWC202003 in period 3.
11043094|NCT04477369|Other|Sequence C|7 subjects assigned to Sequence C will receive a single dose of 300mg DWC202003 in period 1, 300mg DWJ1439 in period 2 and 300mg DWC202004 in period 3.
11043095|NCT04477369|Other|Sequence D|7 subjects assigned to Sequence D will receive a single dose of 300mg DWC202004 in period 1, 300mg DWJ1464 in period 2 and 300mg DWJ1439 in period 3.
11043096|NCT04477356|Active Comparator|Swim-up technique (SU)|The SU method's principle is that the normal and highly motile sperm will move against the gravity and separate from the dead or abnormal sperms to swim up to the upper media culture layer.
11043097|NCT04477356|Active Comparator|Density gradient centrifugation technique (DG)|The DG method is based on the density in which mature and normal sperms are capable of passing through filtration layer to be isolated from dead or abnormal sperms in semen.
11043609|NCT04473729|Experimental|Children with an autism spectrum disorder|The intervention as described above with children with an ASD.
11043099|NCT04477330|Experimental|Priming+HIISTT|Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
11043100|NCT04477330|Sham Comparator|Sham+HIISTT|Sham tDCS before high intensity interval speed based treadmill training
11043101|NCT04477317|Experimental|Experimental|4% Articaine Hydrochloride with 1:100,000 Adrenaline (Alexadricaine, Alexandria Co., Egypt).
11043102|NCT04477317|Active Comparator|Control|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin (Mepicaine-L, Alexandria Co., Egypt)
11043103|NCT04477304|Experimental|Behavioral Intervention Arm|Clinicians in clinics randomized to the intervention group will be prompted with an EHR nudge when the prescribing history for the patient falls into one of the following three categories: Opioid naïve, opioid refill, or chronic high-dose opioids. These EHR-based nudges include elements of accountable justification, defaults and precommitments. Clinicians will also receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
11043104|NCT04477304|No Intervention|Control|Clinicians in clinics randomized to the control group will receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
11043105|NCT04477291|Experimental|Dose Escalation and Expansion|Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.
11043106|NCT04477278|Experimental|Audio-Guided Mindfulness Intervention|Brief, 8-minute, audio-guided mindfulness intervention delivered prior to osteopathic manipulation.
11043107|NCT04477278|Active Comparator|History of Osteopathy|Brief, 8-minute, audio-guided history of osteopathy delivered prior to osteopathic manipulation.
11043108|NCT04477265|Experimental|combination of drug and exercise|Participant will be prescribed with oral medication in combination with biofeedback-assisted pelvic floor muscle training (PFMT) during the first month, participant will continue to have biofeedback assisted PFMT for another 2 months
11043109|NCT04477265|Active Comparator|drug only|Participant will be prescribed with oral medication for 3 months
11043110|NCT04477265|Active Comparator|exercise only|Participant will be doing biofeedback-assisted pelvic floor muscle training for 3 months
11043111|NCT04477252|Experimental|App group|Use of the Mobile App for the daily performance (Monday to Friday) of lumbopelvic stability exercises apart from the usual physiotherapy treatment for 3 months.
11043112|NCT04477252|Active Comparator|conventional physiotherapy|usual physiotherapy treatment for 3 months
11043113|NCT04477239|Placebo Comparator|Placebo|Oral administration of one capsule of Placebo
11043114|NCT04477239|Active Comparator|Purified gluten (10 mg)|Oral administration of capsules containing 10 mg of purified gluten.
11043115|NCT04477239|Active Comparator|Purified gluten (50 mg)|Oral administration of capsules containing 50 mg of purified gluten.
11043116|NCT04477239|Active Comparator|Purified gluten (100 mg)|Oral administration of capsules containing 100 mg of purified gluten.
11043117|NCT04477239|Active Comparator|Purified gluten (500 mg)|Oral administration of capsules containing 500 mg of purified gluten.
11043118|NCT04477239|Active Comparator|Purified gluten (1000 mg)|Oral administration of capsules containing 1000 mg of purified gluten.
11043119|NCT04477200|Experimental|Phase 0|Mycophenolate mofetil, administered at 4 dose levels (2 participants will be assigned to each dose level): 500mg, 1000mg, 1500mg and 2000mg, orally, twice daily for one week prior to re-resection or biopsy. The re-resection or biopsy of tumor is part of standard of care.
11043120|NCT04477200|Experimental|Phase 1|Mycophenolate mofetil, 250-2000mg orally twice daily, for one week prior to and concurrent with re-irradiation. Radiation therapy of 40.5 Gy in 15 fractions.
11043121|NCT04477187|Experimental|Single Group|All subjects will undergo a single treatment for skin laxity in the submentum with a dermal handpiece.
11043122|NCT04477174||Group A|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores. After 2 weeks, the participants match again.
11043123|NCT04477174||Group B|Twelve health professionals randomised assign to as equally count. The participants match between the images with scale scores.
11043124|NCT04477161|Experimental|Ketone Intervention|Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
11043125|NCT04477148|Active Comparator|Metallic Reusable(MR)|Patients in this group were intubated with reusable metallic blades
11043126|NCT04477148|Active Comparator|Metallic Disposable(MD)|Patients in this group were intubated with disposable metallic blades
11043127|NCT04477148|Active Comparator|Plastic Disposable(PD)|Patients in this group were intubated with disposable plastic blades
11043128|NCT04477135|Other|perinatologists|perinatologists working actively and performing ultrasonography every day
11043129|NCT04477122|Experimental|Blue|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes (2000 shots approximately) of extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles at 2 bars and 10 Hertzs. Participants will wear splint 23 hours/day
11043130|NCT04477122|Placebo Comparator|Red|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on temporal, masseter and pterygoid muscles and 5 minutes of joint passive mobilization) and 3 minutes of placebo extracorporeal radial shock waves therapy on painful points of masseter and temporal muscles. Participants will wear splint 23 hours/day
11043164|NCT04476875|Active Comparator|Open outpatient clinic programme (OOCP)|OOCP patients had no scheduled appointments but were allowed acute appointments with their rheumatologist, and had access to nurse-led consultations and telephone helpline.
11043610|NCT04473729|Experimental|Children with Hearing Loss|
11043131|NCT04477109|Active Comparator|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and a relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. the device will be applied on specific acupuncture points (N acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time, once per day, 3 times per week for three months
11043132|NCT04477109|Sham Comparator|sham laser application in addition to diet recommendations|while the control group will stick to the same line of treatment but with sham laser application
11043133|NCT04477096|Other|single arm for each part: two arms|"PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.
~PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days."
11043134|NCT04477083|Active Comparator|inhalable hydroxychloroquine (HCQ).|supportive and symptomatic treatment and inhalable hydroxychloroquine (HCQ).
11043135|NCT04477083|Placebo Comparator|Placebo|supportive and symptomatic treatment
11043136|NCT04477070|Experimental|Air-polishing with ultrasonic debridement|Air-polishing with ultrasonic debridement
11043137|NCT04477070|Active Comparator|Conventional scaling and root planing.|Conventional scaling and root planing.
11043138|NCT04477057|Other|one arm|one arm
11043139|NCT04477044|No Intervention|No GoPro|No GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
11043140|NCT04477044|Experimental|GoPro|GoPro Hero4 to be mounted on the participant's head while he/she performs intubation on a manikin.
11043141|NCT04477018|Experimental|Iron and Vitamin C|28 mg iron bis-glycinate chelate and 240 mg vitamin C
11043142|NCT04477018|Active Comparator|Iron|28 mg iron bis-glycinate chelate
11043143|NCT04477018|Placebo Comparator|Placebo|Matched placebo tablets
11043144|NCT04476992|Active Comparator|NO High Concentration|Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
11043145|NCT04476992|Experimental|NO High Concentration + Continuous Low Concentration|"Nitric oxide will be delivered twice a day with a non-rebreathing system that allows a safe administration of Nitric Oxide gas at high concentrations limiting the amount of NO2 delivered to the patient.
~This arm will receive in addition a continuous low flow of Nitric Oxide at 20 ppm among the high concentration treatments."
11043146|NCT04476979|Active Comparator|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
11043147|NCT04476979|Experimental|Dexamethasone + Tocilizumab|"Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
~+Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3"
11043148|NCT04476966|Experimental|T test|Test drug (Bladogra)1 extended release tablet contains 25 mg Mirabegron
11043149|NCT04476966|Active Comparator|B reference (first dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (first dose)
11043150|NCT04476966|Active Comparator|B reference (second dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (second dose)
11043151|NCT04476953|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
11043152|NCT04476953|Placebo Comparator|Placebo Group|Subjects will receive placebo
11043153|NCT04476940|Experimental|COVID BF-Support|COVID-19 breastfeeding guideline education and support for pregnant women.
11043154|NCT04476927|Experimental|DiaNose procedure|all subjects will be required to undergo the DiaNose exhalation test.
11043155|NCT04476914||Family Member|Family members of ICU patients admitted with respiratory failure from COVID-19
11043156|NCT04476901|Placebo Comparator|Genotype A administered with placebo Group|Participants whose blood genotyping resulted with Genotype A (absence of pathogenic mutation) and randomized to the placebo group will receive the placebo intervention.
11043157|NCT04476901|Experimental|Genotype A administered with hMSC Group|Participants whose blood genotyping resulted with Genotype A (absence of pathogenic mutation) and randomized to the treatment group will receive the hMSC intervention.
11043158|NCT04476901|Placebo Comparator|Genotype B administered with placebo Group|Participants whose blood genotyping resulted with Genotype B (variance of uncertain determinance) and randomized to the placebo group will receive the placebo intervention.
11043159|NCT04476901|Experimental|Genotype B administered with hMSC Group|Participants whose blood genotyping resulted with Genotype B (variance of uncertain determinance) and randomized to the treatment group will receive the hMSC intervention.
11043160|NCT04476901|Placebo Comparator|Genotype C administered with placebo Group|Participants whose blood genotyping resulted with Genotype C (pathogenic variance) and randomized to the placebo group will receive the placebo intervention.
11043161|NCT04476901|Experimental|Genotype C administered with hMSC Group|Participants whose blood genotyping resulted with Genotype C (pathogenic variance) and randomized to the treatment group will receive the hMSC intervention.
11043162|NCT04476888|Experimental|Treatment arm/CP recipient|"Patients with severe/critical COVID 19 who will receive 500 ml of Convalescent plasma (CP), obtained from donors who have been recovered from SARS-CoV-2 infection.
~These patients may or may not get other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
11043163|NCT04476888|Other|Control arm|"Patients with severe/critical COVID 19 who will not receive Convalescent plasma (CP). These will be those who were recruited during the period before CP becomes available or for whom no compatible CP is available.
~These patients will receive one or more of the other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
11043165|NCT04476875|No Intervention|Traditional scheduled routine follow up (TSRF)|Appointments for the TSRF group were scheduled according to routine procedures.
11043166|NCT04476862||Cerliponase alfa patients|Patients who are currently on or plan to start taking cerliponase alfa within 60 days of signing the study informed consent form.
11043167|NCT04476849|Experimental|Fezolinetant: Mild renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11043168|NCT04476849|Experimental|Fezolinetant: Moderate renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11043169|NCT04476849|Experimental|Fezolinetant: Severe renal impairment|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11043170|NCT04476849|Experimental|Fezolinetant: Normal renal function|Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.
11043171|NCT04476836|Experimental|AAT group|Animal-assisted therapy will be provided one 1-hour session per week for 48 weeks.
11043172|NCT04476836|No Intervention|control group|routine care
11043173|NCT04476810|Experimental|combined (phaco-kdb)|Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Consecutive patients with medically-treated glaucoma and visually-significant cataract underwent combined surgery. Subgroup analysis of glaucoma subtypes was performed.
11043174|NCT04476797|Experimental|Arm A Active GC4711|
11043175|NCT04476797|Placebo Comparator|Arm B Placebo|
11043176|NCT04476771|No Intervention|TAU + waiting list|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
11043177|NCT04476771|Experimental|TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
11043178|NCT04476758||Fungal Infection Group|Have had a fungal species isolated from sputum and/or BAL culture on >= 2 separate occasions in the 18 months preceding study visit and do not have a diagnosis of ABPA (N=10).
11043179|NCT04476758||Control Group|Have never previously isolated fungus from sputum, BAL, or OP swab (N=10).
11043180|NCT04476758||ABPA Group|"Previous diagnosis of ABPA as defined by CFF guidelines, regardless of the amount of fungal infection or history thereof.
~• ABPA Minimum diagnostic criteria per CFF: Acute or subacute deterioration, total serum IgE > 500 IU per mL, immediate cutaneous reactivity to Aspergillus or in vitro IgE antibody to A. fumigatus, and either a new or recent chest imaging change that has not responded to antibiotics and standard physiotherapy OR precipitin to A. fumigatus or IgG antibody to A. fumigatus1 (N=5). Culture positive sputum is not required for ABPA diagnosis and is not taken into account for the diagnosis per CFF guidelines."
11043181|NCT04476745|Experimental|Experimental: VD3 group|Dietary Supplement: Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks Other Names: cholecalciferol,
11043182|NCT04476745|No Intervention|Control group|Control group No intervention was given
11043183|NCT04476732|Experimental|Paraben-free then Paraben-containing|Paraben free facial lotion is applied twice a day for 1 week and measurements are taken. Then, paraben-containing facial lotion is applied twice a day for 1 week and measurements are taken.
11043184|NCT04476719|Experimental|Atafenovir 200 mg Kapsül|Capsules containing 207.009 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride (Atabay-Turkey).
11043185|NCT04476719|Active Comparator|Arbidol 100 mg Kapsül|Capsules containing 103.504 umifenovir hydrochloride monohydrate equivalent to 100 mg umifenovir hydrochloride (OTC-Pharma Russia).
11043186|NCT04476693|Experimental|Breakfast Consumption (BC)|"The consumption of a standardised breakfast followed by a standardised lunch 3-h after the last mouthful of breakfast meal. All the ingredients of the breakfast and lunch provided will be weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period will be provided to avoid carry-over effects between conditions.
~The standardised lunch will consist of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
11043187|NCT04476693|Experimental|Breakfast omission (BO)|"Participant will consume water, the individual volume of which was calculated based on the liquid content of the breakfast. A standardised lunch will be consumed 3-h after the last mouthful of water. All the ingredients of the breakfast and lunch provided were weighed, with the portion sizes calculated based on individual resting metabolic rate (RMR). The participants were instructed to consume the meals provided within 15 min. A minimum of seven days washout period was provided to avoid carry-over effects between conditions.
~The standardised lunch consists of white bread without crust (Tesco), margarine 'Butter Me Up Spread' (Tesco), strawberry jam (Tesco), salted crisps (Walkers) and sparkling glucose drink (Lucozade Energy Original). This carbohydrate-rich high glycameic index lunch was designed to trigger quick and exaggerated glucose and insulin response."
11043188|NCT04476680|Experimental|1000 I.U. Vitamin D supplement per day|The 1000 I.U. vitamin D supplement will be manufactured by Pure Encapsulations, Sudbury, Massachusetts, USA.
11043189|NCT04476680|Placebo Comparator|Placebo|The placebo will be manufactured by the same manufacturer as the interventional supplement and will be identical in size and appearance.
11043217|NCT04476433|No Intervention|Control Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
11043288|NCT04475926||LGMD2E Cohort|Patients with LGMD2E will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
11043611|NCT04473729|Experimental|Typically developing children with normal hearing acuity|
11043190|NCT04476667|Experimental|e-Psychotherapy|Participants will receive a 9-week program with CBT, mindfulness, and problem-based therapy, in addition to TAU. The content will be customized to reflect challenges faced through the COVID-19 pandemic and developed into interactive and engaging modules. All sessions and interactions will occur through Online Psychotherapy Tool (OPTT), a secure online platform. Participants will be assigned to a team of psychiatrists and social workers (SWs). The SW working with each patient will assign a pre-designed therapy module to that patient on a specific day of the week through OPTT. Participants will then be able to access the therapy content at any time throughout the week. Each module will highlight a different topic and include general information, an overview of skills, and homework that is to be completed by a specific day that week. This homework will be directly submitted through OPTT to the clinician who will provide personalized feedback to the patient.
11043191|NCT04476667|No Intervention|Treatment as Usual|The control group will receive treatment as usual during the first 9 weeks; if they still present significant symptoms (less than 50% response to treatment from baseline), they will be offered the e-psychotherapy program.
11043192|NCT04476654|No Intervention|Fact Sheet Arm|Komen print materials about genetic counseling and testing will be given to women.
11043193|NCT04476654|Active Comparator|YouTube Video Arm|Participants in this arm will receive the culturally tailored video either via a Youtube link or a DVD.
11043194|NCT04476641|Experimental|DC-CIK|
11043195|NCT04476628|Other|Budesonide 5MR then 1MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.
~st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~nd time period: 5MR administration method once daily for 8 weeks in duration.
~rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~th time period: 1MR administration method once daily for 8 weeks in duration."
11043196|NCT04476628|Other|Budesonide 1MR then 5MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.
~st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~nd time period: 1MR administration method once daily for 8 weeks in duration.
~rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.
~th time period: 5MR administration method once daily for 8 weeks in duration."
11043197|NCT04476615|Experimental|FMD|Fasting-Mimicking diet (ProLon®)
11043198|NCT04476615|Placebo Comparator|Placebo|Low-energy bars (L-Nutra®) supplementation
11043199|NCT04476602||COVID-19 (SARS-CoV-2) patients|adults 18 or older, ambulatory , with COVID-19 (SARS-CoV-2)
11043200|NCT04476589||COVID-19 Disorders of Consciousness|Patients with COVID-19 and disorders of consciousness
11043201|NCT04476576|Experimental|Aerobic|3 months program, 3 times/week aerobic ambulatory program.
11043202|NCT04476576|Active Comparator|Flexibility|3 months program, 3 times/week flexibility ambulatory program
11043203|NCT04476563||ChILI|Patients who are already on CPI therapy and have developed liver injury
11043204|NCT04476563||Control|Patients with cancer who are starting on checkpoint inhibitors
11043205|NCT04476537|Experimental|Intervention Arm|Individuals who meet the eligibility criteria based on their provided tissue sample will be followed by the investigators to obtain medical information every 4 weeks. This follow-up will consist of a review of medical records, contact with the participant's treating physician, or personal contact between the participant and the investigators at Columbia University Irving Medical Center (CUIMC). During the study, their tumor tissue will be evaluated to identify medications that may help treat the cancer. The results of these tests will be reviewed by experts on a Precision Medicine Tumor Board (PMTB) and these experts may recommend a specific treatment to the participant or participant's physician.These participants will continue to be followed until death or withdrawal of consent from the study.
11043206|NCT04476537|No Intervention|Observation Arm|Individuals who do not meet the eligibility criteria based on their provided tissue sample will be provided follow-up with their treating physicians up to every 4 weeks to gather clinical information related to their disease.
11043207|NCT04476524||Study Arm|Patients who present with AF as the primary diagnosis to the ER will have their chart reviewed
11043208|NCT04476524||Historical Cohort|Historical control arm will be selected from chart review of emergency department prior to the commencement of this study after propensity matching with age and sex.
11043209|NCT04476511|Active Comparator|Slower Loading Dose|30.000IU cholecalciferol once weekly for ten weeks
11043210|NCT04476511|Active Comparator|Moderate Loading Dose|30.000IU cholecalciferol twice weekly for five weeks
11043211|NCT04476498|No Intervention|Standard pull-PEG|"Standard pull-PEG
~In this group the participants receive a conventional pull-PEG as firstly described by Ponsky and Gauderer."
11043212|NCT04476498|Active Comparator|Pull-PEG with gastropexy|"Pull-PEG with gastropexy
~In this group the participants firstly receive a gastropexy with the Funada style gastropexy device. Afterwards a conventional pull-PEG will be inserted."
11043213|NCT04476485||experimental group|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy.
11043214|NCT04476472|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
11043215|NCT04476459|Experimental|camrelizumab in combination with apatinib|Apatinib should be given at a fixed time. On the day of camrelizumab infusion, Apatinib should be taken 30 minutes after the end of camrelizumab infusion
11043216|NCT04476446|Experimental|Intranasal Esketamine|Induction Phase: Participants will self-administer esketamine intranasally 56 milligram (mg) on Day 1 followed by 56 mg or 84 mg (as a flexible dose regimen) twice per week for 4 weeks. Participants greater than or equal to (>=) 65 years old will start at a dose of 28 mg on Day 1. Maintenance Phase: Participants will self-administer esketamine 56 mg or 84 mg intranasally once per week from Week 5 to Week 9. Subsequently from Week 9, based on the investigator's clinical judgment, participants will self-administer esketamine 56 mg or 84 mg intranasally once or twice a week.
11058435|NCT04368728|Placebo Comparator|Placebo, 18-55 years of age|
11043218|NCT04476433|Experimental|Experimental Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.
11043219|NCT04476420|Active Comparator|Group 1|Participants in group 1 will be given corticosteroid lotion (Betamethasone valerate 0.1%) and will be advised to apply it topically (0.5 ml) on the buccal mucosa thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
11043220|NCT04476420|Experimental|Group 2|Group 2 will be given commercially available, cold pressed N.sativa (Black seed) oil and will be advised to apply it topically over the buccal mucosa (1 ml) thrice a day along with physiotherapy using ice cream sticks three times a day for the duration of 10 minutes (3-5minutes on each side).
11043221|NCT04476407|Experimental|G1|subjects with nomal renal function
11043222|NCT04476407|Experimental|G2|subjects with mild renal impairment
11043223|NCT04476407|Experimental|G3|subjects with moderate renal impairment
11043224|NCT04476394|Experimental|1|Administered orally once
11043225|NCT04476381|Experimental|Dry needling of a trigger point in the infraspinatus muscle|Insertion a a acupuncture type needle into a trigger point in the infraspinatus muscle on the painful side to decrease the stiffness and tone and increase the elasticity
11043226|NCT04476368|Experimental|yoga|Participants in yoga group will be recruited during prenatal yoga classes at two locations: Maribor and Ljubljana. Women will be instructed to attend one class per week. Classes will consist of pregnancy-adapted yoga practices according to the system Yoga in Daily Life. They will be 90 min in duration and will consist of initial relaxation (10 to 15 min), followed by yoga postures (asanas) and stretching exercises (45 to 60 min), and final breathing (pranayama), concentration (dharana), and meditation (dhyana) techniques (20 to 30 min). Two certified yoga instructors will lead yoga classes. Measurements will be performed before and after yoga session.
11043227|NCT04476368|Active Comparator|control|Control group will consist of healthy pregnant women attending regular prenatal visits at the departments of perinatology of the university medical centers Maribor and Ljubljana. Only women not attending any formal prenatal exercise program will be offered entrance in the study. Measurements in this group will be performed before and after a 20-30 minute walk.
11043228|NCT04476355|No Intervention|control group|In the same ICU, the former(2019-12~2020-12) patients were the control group, data collected through case system.
11043229|NCT04476355|Experimental|experimental group|In the same ICU, the patients in the study period were the experimental group
11043230|NCT04476342|Experimental|MICPB group|The experimental group is minimal invasive cardiopulmonary bypass (MICPB) group, with built-in micro-thrombotic oxygenator and mini cardioplegia (MP) formula (15ML15% KCl+10ml compound potassium, calcium and magnesium +25ml normal saline).
11043231|NCT04476342|No Intervention|CCPB group|The control group was conventional cardiopulmonary bypass (CCPB) group, using ordinary oxygenator, microemboli filter, and 4:1 cardioplegia solution.
11043232|NCT04476329|Active Comparator|A|"Arm A: Regorafenib Cycle 1:
~80 mg daily Week 1
~120 mg daily Week 2
~160 mg daily week 3 then 1 week off followed by Cycle 2+ (160 mg for 21 days/1 week off) Subsequent Treatment Cycles
~160 mg daily for 21 days, then 1 week off."
11043233|NCT04476329|Active Comparator|B|"Arm B: Regorafenib Cycle 1:
~160 mg daily for 21 days/then 1 week off Subsequent Treatment Cycles
~160 mg daily for 21 days, then 1 week off"
11043234|NCT04476303|Experimental|SAD (#6 Cohort)|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo once.
11043235|NCT04476303|Experimental|SAD (#1 Cohort) - Food effect evaluation|Drug: BEY2153 or placebo subjects will receive single ascending dose of BEY2153 or placebo for two periods at 7 days interval, with both fasting and after high fat meal.
11043236|NCT04476303|Experimental|MAD (#4 Cohort)|Drug: BEY2153 or placebo subjects will receive multiple ascending dose of BEY2153 or placebo for 7 days.
11043237|NCT04476277|Experimental|1|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
11043238|NCT04476264||transscleral IOL fixation|the use of a novel adjustable single 8-0 polypropylene suture for scleral fixation without conjunctival dissection
11043239|NCT04476251|Experimental|Arm 1|E7 TCR T Cell Therapy
11043240|NCT04476238|Experimental|Inosine|2 grams of inosine dissolved in 250 ml of tap water
11043241|NCT04476238|Placebo Comparator|Water|250 ml of tap water only
11043242|NCT04476225||Individuals with Hirschsprung Disease|Individuals with Hirschsprung disease
11043243|NCT04476225||Unaffected Relatives|Unaffected relatives of individuals with Hirschsprung disease
11043244|NCT04476212|Experimental|Intervention|In the experimental arm, the surgical wound will be irrigated using an antibiotic solution (amoxicillin-clavulanate) for topical prophylaxis
11043245|NCT04476212|No Intervention|Control|In the control arm, the surgical wound will be irrigated with saline, which is our routine at present.
11043246|NCT04476199|Experimental|Treatment with VEN-DEC|Venetoclax will be given with a 3-day ramp up beginning with 100 mg dose on Day 1, with 200mg on Day 2, to reach the final dose of 400 mg on Day 3 of Cycle 1. Venetoclax will be continued at 400 mg daily. Tumor lysis prophylaxis will be administered from day -4, cycle 1 (oral uric acid reducing agent and hydration with at least 1.5 L/day).Decitabine will be administered at the dose of 20 mg/sqm intravenously from day 1 to day 5 every 28 days (VEN-DEC) for 2 cycles.
11043247|NCT04476186|Active Comparator|treatment group|200 mg of oral acyclovir 5 timed per day for 5 days per week for maximum 1 month
11043248|NCT04476186|Placebo Comparator|controlled group|KOH 10 % solution local application with apiece of cotton 2 time per day maximum for 1 month
11043249|NCT04476173|Experimental|Methoxyflurane|Patients treated with inhaled methoxyflurane (3 mg)
11043250|NCT04476173|Active Comparator|Morphine|Patients treated with intravenous morphine (5 mg)
11043251|NCT04476160|Experimental|Cinnamon|In this group, children will receive an intervention with 3000mg / day cinnamon along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
11043252|NCT04476160|No Intervention|Control|In this group, children will receive a placebo intervention along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
11043253|NCT04476147||Participates|This is an observational study
11043254|NCT04476134||patients with adverse events|patients underwent adverse events after cardiac surgery
11043255|NCT04476121|Experimental|Study group|Patients with alveolar osteitis in which PRF application was performed.
11043256|NCT04476121|Active Comparator|Control group|Patients with alveolar osteitis in which Nipas was used.
11043257|NCT04476108|Experimental|LY3016859|LY3016859 administered intravenously (IV).
11043258|NCT04476108|Placebo Comparator|Placebo|Placebo administered IV.
11043259|NCT04476095|Experimental|Active PBMT|Active PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
11043260|NCT04476095|Placebo Comparator|Placebo PBMT|Placebo PBMT will be performed twice a week (at the same time of the day), with intervals of three or four days between sessions, during three-week period (a total of 6 sessions).
11043261|NCT04476082||Initial Diagnosis|Patients with initial diagnosis of a malignant condition of the gastrointestinal tract planned to receive cytostatic treatment.
11043262|NCT04476082||Ongoing Cytostatic Treatment|Patients with a malignant condition of the gastrointestinal tract already receiving cytostatic treatment.
11043263|NCT04476069|Experimental|Ibuprofen|30 minutes before extraction, once/day orally
11043264|NCT04476069|Placebo Comparator|Placebo|30 minutes before extraction, once/day orally
11043265|NCT04476056|Experimental|Chronic Pancreatitis + Malnutrition|Malnourished patients with chronic pancreatitis will receive intensified nutritional therapy for 6 months.
11043266|NCT04476043|Experimental|INCB054707 Dose A|Participants will receive INCB054707 Dose A for 16 weeks (Period 1) followed by INCB054707 Dose C for 36 weeks (Period 2).
11043267|NCT04476043|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 16 weeks (Period 1) followed by INCB054707 Dose C for 36 weeks (Period 2).
11043268|NCT04476043|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2)
11043269|NCT04476043|Placebo Comparator|Placebo followed by INCB054707 Dose C|Participants will receive placebo for 16 weeks (Period 1) followed by INCB054707 Dose C for 36 weeks (Period 2).
11043270|NCT04476030|Experimental|SAGE-217 + Sertraline|Participants will receive SAGE-217 capsules, orally, once daily with sertraline tablets, orally, once daily from Day 1 through 14, followed by sertraline tablets, orally, once daily up to 42 days, with fat-containing food.
11043271|NCT04476030|Active Comparator|Placebo + Sertraline|Participants will receive SAGE-217-matching placebo capsules, orally, once daily with sertraline tablets, orally, once daily from Day 1 through 14 followed by sertraline tablets, orally, once daily up to 42 days, with fat-containing food.
11043272|NCT04476017|Experimental|SAGE-718|Participants will receive SAGE-718 tablets, once daily with food in the morning for 14 days.
11043273|NCT04476004|Experimental|experimental group|EMG group
11043274|NCT04476004|Active Comparator|control group|exercise group
11043275|NCT04475991|Active Comparator|Currently used therapy (CT) only|"Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present."
11043276|NCT04475991|Experimental|Maraviroc+CT|"Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
11043277|NCT04475991|Experimental|Favipiravir+CT|"Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
11043278|NCT04475991|Experimental|Maraviroc+Favipiravir+CT|"Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients"
11043279|NCT04475978|Experimental|IVUS group|
11043280|NCT04475978|Placebo Comparator|Angio group|
11043281|NCT04475965|Experimental|Group 1 20% maximal voluntary isometric contraction|Patients in group 1 received a five-series Isometric Contraction of shoulder external rotators at 20% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
11043282|NCT04475965|Active Comparator|Group 2 80% maximal voluntary isometric contraction|Patients in group 2 received a five-series Isometric Contraction of shoulder external rotators at 80% of maximal voluntary isometric contraction. Each series of Isometric Contraction was done until exhaustion or up to a maximum of 5 minutes. Patients received five sessions of treatment during a two-week period.
11043283|NCT04475952||Oropharyngeal squamous cell carcinoma|
11043284|NCT04475952||Oesophageal squamous cell carcinoma|
11043285|NCT04475952||Control|
11043286|NCT04475939|Experimental|Participants receiving niraparib plus pembrolizumab|Participants will be administered pembrolizumab at a dose of 200 milligrams (mg) via an intravenous infusion over 30 minutes on Day 1 of each treatment cycle (each cycle of 21 days). Niraparib will be administered orally once a day, continuously throughout the 21-day cycle starting on Cycle 1 (Day 1).
11043287|NCT04475939|Placebo Comparator|Participants receiving placebo plus pembrolizumab|Participants will be administered pembrolizumab at a dose of 200 mg via an intravenous infusion over 30 minutes on Day 1 of each treatment cycle (each cycle of 21 days). Placebo will be administered orally once a day, continuously throughout the 21-day cycle starting on Cycle 1 (Day 1).
11043327|NCT04475718|Other|Fourth Trimester Mobile Tool|Fourth Trimester Mobile Tool
11058436|NCT04368728|Placebo Comparator|Placebo, 65-85 years of age|
11043289|NCT04475926||LGMD2D Cohort|Patients with LGMD2D will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
11043290|NCT04475926||LGMD2C Cohort|Patients with LGMD2C will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to <8 years age range, 8 to <14 years age range, and ≥14 years age range through the course of the study.
11043291|NCT04475913|Active Comparator|(CIG Axial)|received 4 axial implants and conventional impression
11043292|NCT04475913|Experimental|(DIG Axial)|received 4 axial implants and digital impression
11043293|NCT04475913|Active Comparator|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
11043294|NCT04475913|Experimental|(DIG Tilted)|received two anterior axial implants and two distal tilted implants, and digital impression
11043295|NCT04475900||Healthy|Healthy eyes without any signs of ocular diseases
11043296|NCT04475900||Ectasia|ectasia suspects early, moderate and advanced keratoconus
11043297|NCT04475900||Glaucoma|Normal Tension glaucoma Primary Open-Angle Glaucoma
11043298|NCT04475887|Active Comparator|Group A|IV administration of iron-III-carboxymaltose according to iron deficit every 4 weeks.
11043299|NCT04475887|Placebo Comparator|Group B|IV administration of 1000ml 0.9% NaCl every 4 weeks.
11043300|NCT04475874|Active Comparator|supervised stretching exercises :group A|The intervention group A practiced a 30 to 45-minute supervised active stretching program three times a week for four weeks
11043301|NCT04475874|Active Comparator|non-supervised active stretching home program: group B|practiced non-supervised active stretching home program
11043302|NCT04475874|No Intervention|Standard of care: group c|control group
11043303|NCT04475861|Experimental|L-arginine supplements|The enrolled subjects will then be randomized into two groups. Study Group: will take a supplementation pill containing 5 g L-arginine (0.5g/ pill, GNC, USA) All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
11043304|NCT04475861|No Intervention|nutritional supports|"The enrolled subjects will then be randomized into two groups. Control group: will take a supplementation pill containing 5 g whey protein (5g/ pack, Santosa,Taiwan).
~All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians."
11043305|NCT04475848|Experimental|Part 1: SAD/FE|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of RO6953958 while fasted. Participants in the fed (FE) cohort will return to receive the same single oral dose of RO6953958 repeated in the fed state.
11043306|NCT04475848|Placebo Comparator|Part 1: SAD placebo|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of a placebo while fasted/fed.
11043307|NCT04475848|Experimental|Part 2: MAD|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 once daily (QD) for 10 days.
11043308|NCT04475848|Placebo Comparator|Part 2: MAD placebo|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 QD for 10 days.
11043309|NCT04475835|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during PCI
11043310|NCT04475835|Active Comparator|Heparin|Heparin 100U/kg
11043311|NCT04475822|Experimental|Intermittent fasting|During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
11043312|NCT04475822|Experimental|Low carb diet|According to the definition of low carbon diet given by R. D. Feinman et al. (Nutrition, 2015), the daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
11043313|NCT04475822|Experimental|Low carbon diet and intermittent fasting group|Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
11043314|NCT04475809|Placebo Comparator|Group C|high intra-abdominal pressure
11043315|NCT04475809|Active Comparator|Group L|low intra-abdominal pressure
11043316|NCT04475809|Active Comparator|Group LR|low intra-abdominal pressure with pulmonary recruitment maneuver group
11043317|NCT04475809|Active Comparator|Group LS|low intra-abdominal pressure with intraperitoneal saline infusion group
11043318|NCT04475796|Active Comparator|Early group|
11043319|NCT04475796|Active Comparator|Delayed group|
11043320|NCT04475783|Experimental|Sirolomus DCB group|Intervention with Sirolimus-coated balloon catheter
11043321|NCT04475783|Active Comparator|Paclitaxel DCB group|Intervention with Paclitaxel-coated balloon catheter
11043322|NCT04475770|Experimental|Real SNAGs|Real SNAGs group consists of 16 participants, where the Mulligan concept lumbal SNAGs is applied and evaluations are made before and after.
11043323|NCT04475770|Sham Comparator|Sham SNAGs|The Sham SNAGs group consists of 16 participants who performed the same positioning as the Real SNAGs group and evaluated twice with a similar interval without any intervention to the spine.
11043324|NCT04475744|No Intervention|Control arm|POI women radomized to control arm will undergo a 3-month follow up for: AFC, AMH, FSH and E2 determinations.COS will be initiated if growing antral follicles detected. In the second phase, POI women allocated to control group after completed the follow up period will undergo the 4-step ASCOT technique, as described in the previous phase but only one ovary will be injected, then they will undergo a 6-month follow up period as described above.
11043325|NCT04475744|Experimental|4-step ASCOT arm|POI women randomized to the 4-step ASCOT technique will receive a direct ovarian injection of G-CSF mobilized and activated PRP. For each patient, both ovaries will be directly injected with the G-CFS activated PRP (4-step ASCOT). Follow up (AFC, AMH, FSH and E2 determinations) will be developed for 6 months and COS initiated if growing antral follicles detected.
11043326|NCT04475731|Experimental|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).
~Patients will receive the study drug until disease relapse or progression."
11043328|NCT04475705|Active Comparator|Sevoflurane group|patients in this group will receive inhalation anaesthesia with sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
11043329|NCT04475705|Active Comparator|propofol group|patients in this group will receive intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60. Other anaesthetic management will be standardised.
11043330|NCT04475692|Experimental|Intervention|"Conventional care will continue.
~Participants (and proxy, where relevant) will be trained to use the intervention platform (GripAble). Participants will be loaned a GripAble device and advised to continue a self-selected training dose throughout the intervention period.
~Weekly follow-up phone calls will be conducted, remote tech support will be available. Adherence with the intervention will be remotely monitored via an inbuilt data capture system.
~At 3months post stroke, the intervention period will conclude, outcome measures will be implemented. Participants will be invited to complete a post intervention survey and interview. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.
~At 6months post stroke, follow-up outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
11043331|NCT04475692|Active Comparator|Control|"Baseline data collection and outcome measures will be completed.
~Conventional care will continue, no restrictions/specifications will be placed on this.
~At 3months post stroke, UL outcome measures will be implemented. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.
~At 6months post stroke, follow-up UL outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
11043332|NCT04475679|Experimental|Adhese Universal DC|
11043333|NCT04475679|Active Comparator|Adhese Universal|
11043334|NCT04475666|Active Comparator|Replenish protein group|The subjects randomized to this group will receive the standard amount of proteins (maximum 1.2 g/kg/day) from the primary polymeric formula AND supplemental protein at 1.2 g/kg/day
11043335|NCT04475666|Active Comparator|Standard protein group|The subjects randomized to this group will receive standard prescription without supplemental proteins (maximum1.2 g/kg/day) from the primary polymeric formula. No supplemental protein will be allowed
11043336|NCT04475653|Active Comparator|Group coaching|Performing physical activities with Activity tracker, coaching included
11043337|NCT04475653|Active Comparator|Group Independant|Performing physical activities with Activity tracker, coaching NOT included
11043338|NCT04475653|Other|Controls|Controls from former study (see Study description)
11043339|NCT04475640|Other|Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood or saliva sample for genetic testing.
11043340|NCT04475627||Participants randomised to 1.5T then 3T|Participants randomized to be scanned at 1.5T first followed by 3T
11043341|NCT04475627||Participants randomised to 3T then 1.5T|Participants randomized to be scanned at 3T first followed by 1.5T
11043342|NCT04475614|No Intervention|informative|The patients in this group received only verbal and written information about their condition.
11043343|NCT04475614|Experimental|oral probiotics|The patients in this group, beside verbal and written information about their condition, received also oral probiotics. They were instructed to melt one lozenge in the mouth in the evening, after tooth brushing and flossing, for one month.
11043344|NCT04475614|Experimental|low level laser treatment|The patients in this group, beside verbal and written information about their condition, received a total of ten low level laser treatments, for ten days consecutively excluding weekends.
11043345|NCT04475614|Experimental|B-vitamin injections|The patients in this group, beside verbal and written information about their condition, received a total of nine B vitamin injections, every other day, intra muscular.
11043346|NCT04475601|Experimental|Enzalutamide+Standard of Care|Up to 5 days with 4x40 mg enzalutamide tablets orally once daily
11043347|NCT04475601|No Intervention|Standard of Care|Standard of care
11043348|NCT04475588|Experimental|Best supportive care with Itolizumab|
11043349|NCT04475588|Active Comparator|Best supportive care|
11043350|NCT04475575|Other|COVID-19 suspected|Participants where included if an oropharyngeal and nasopharyngeal swab was collected for RT-PCR and serology testing had been performed, or if participants have had a confirmed COVID-19 diagnosis in the previous days or weeks with an indication for re-testing via PCR and serology testing at the moment of inclusion
11043351|NCT04475562|Other|COVID-19 suspected|Participants were recruited at the outpatient clinic for MUMC+ employees with COVID-19 symptoms or at the nursing unit where a SARS-CoV-2 patient was admitted.
11043352|NCT04475549|Experimental|IW-6463|
11043353|NCT04475536||Coronary Artery Disease (CAD)|
11043354|NCT04475523|Experimental|CI-8993 dose escalation|Patients will be administered CI-8993 intravenously at a planned infusion rate over 2 hours at planned step-doses and subsequent full doses. The planned schedule of administration is every 2 weeks. The MTD of full doses of CI-8993 will be determined based on the occurrence of DLTs 28 days from the first full dose. Eligible patients may receive CI-8993 at the dose and schedule, according to their assigned cohorts, until disease progression or unacceptable toxicity.
11043355|NCT04475510|Experimental|Antiplatelet treatment discontinuation|At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
11043356|NCT04475497|Experimental|Blood mangement group|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels <11.0. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
11043357|NCT04475497|Active Comparator|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
11043358|NCT04475484||School-age children|School-age children from primary school to high school (about age 6 to 18) in the Academy of Lyon
11043359|NCT04475458||LANDMARK|The children who underwent circumcision received general anesthesia plus dorsal penis nerve block performed by the surgeon with a landmark technique.
11043360|NCT04475458||ULTRASOUND|The children who underwent circumcision received sedation (in spontaneous breathing) plus ultrasound-guided dorsal penis nerve block.
11043361|NCT04475445|Experimental|Ultrasound guided transforaminal epidural steroid injection|
11043364|NCT04475432|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
11043365|NCT04475419|Active Comparator|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe)
11043366|NCT04475419|Active Comparator|preformed metal crowns|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
11043367|NCT04475406|Sham Comparator|Control group|Standard implant, intra-bone length ≥8 mm (30 implants)
11043368|NCT04475406|Active Comparator|Test group|Extra Short implant, intra-bone length ≤6 mm (30 implants)
11043369|NCT04475393|Experimental|Carmat TAH|Subjects implanted with Carmat TAH
11043370|NCT04475380||All-comer patients requiring PCI|All-comer patients requiring percutaneous coronary intervention (PCI) for the treatment of significant coronary artery of bypass graft lesions that are suitable for treatment with Xience Sierra DES
11043371|NCT04475367|Experimental|hypertensive patients using HyperCrossApp|"Interdisciplinary health care
~+ HyperCross App"
11043372|NCT04475367|Active Comparator|hypertensive patients without using HyperCrossApp|Interdisciplinary health care
11043373|NCT04475354||Cervical cancer patients and their partners|520 cervical cancer patients will complete questionnaires, online food diary and wear a fitbit after diagnosis, after 6 months, and after 1, 2, 5 and 10 years. In addition, a subsample (n=116) will donate blood samples and a scalp hair sample after diagnosis and 6, 12 and 24 months. We expect 312 partners of cervical cancer patients to included in the study and complete questionnaires after diagnosis, after 6 months, and after 1, 2, 5 and 10 years
11043374|NCT04475341|Active Comparator|BMS without BMAC|
11043375|NCT04475341|Experimental|BMS with BMAC|
11043376|NCT04475328|Experimental|AngongNiuhuang|Drugs : AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
11043377|NCT04475328|Placebo Comparator|Placebo of AngongNiuhuang|Drugs : Placebo of AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
11043378|NCT04475315|Experimental|Papillary Muscle Sling Group|Participants in the papillary muscle sling group will receive the sling technique performed in conjunction with their standard of care (SOC) Coronary Artery Bypass Grafting (CABG) surgery.
11043379|NCT04475315|Active Comparator|Controls Group|Participants in the control group will receive their SOC CABG surgery only, without any additional intervention.
11043380|NCT04475302|Experimental|Intervention arm|In the identified hotspots, BCG vaccine will be offered to all the elderly between 60 - 80 years of age. Those who get vaccinated will be followed for a period of 6-months.
11043381|NCT04475302|No Intervention|Control arm|"in the hotspots, those who do not agree for vaccination, will be considered as controls. They will have an entry and exit interview at baseline and end of study period
~in situations where we are unable to enrol the required number of controls from the vaccination hotspot zones, then hotspots in the neighbouring area / wards where BCG is not offered will be taken as control sites. Elderly between 60-80 years in those areas would be considered as control sites for the study. The elderly participants will be approached for an entry and exit interview, if they agree. If they do not agree for an exit interview at the end of 6-months, then the status of those in the control group would be collected either from the corporation records / other medical database."
11043382|NCT04475289||Patients with an coronary artery anomaly (focus on ACAOS)|Patients eligible for study participation have a CAA and a prior, clinically indicated testing (noninvasive and/or invasive measurement) at our institution to evaluate the hemodynamic significance of this coronary anomaly. They will be approach either after start of this study (retrospective inclusion) or before their testing (prospective inclusion).
11043383|NCT04475276|Placebo Comparator|Placebo|Life style modification with the placebo will be given for 12 weeks
11043384|NCT04475276|Experimental|Alphalipoic acid|Life style modification with Alpha lipoic acid in a dose of 600mg twice daily will be prescribed orally for 12 weeks
11043385|NCT04475263||Carbon monoxide exposure|Confirmed exposure to carbon monoxide
11043386|NCT04475250|Experimental|Tetragraph|
11043387|NCT04475237||Healthy mandibles|Belgian adults (between 20 and 60 years old), 50/50 male/female, with no major mandibular problems/deformities
11043388|NCT04475224|Other|Open-label|
11043389|NCT04475198|Experimental|Part A Single Ascending Dose: Cohort 1|7 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
11043390|NCT04475198|Experimental|Part A Single Ascending Dose: Cohort 2|20 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
11043391|NCT04475198|Experimental|Part A Single Ascending Dose: Cohort 3|50 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
11043392|NCT04475198|Experimental|Part A Single Ascending Dose: Cohort 4|100 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
11043393|NCT04475198|Experimental|Part A Single Ascending Dose: Cohort 5|200 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
11043394|NCT04475198|Experimental|Part B Multiple Ascending Dose: Cohort 6|ST-2427 (n=4) or placebo (n=2) administered over a 60-minute intravenous (IV) infusion, twice daily for 3 days. Dose of ST-2427 will be determined after review of safety, tolerability and pharmacokinetic data from Cohorts 1-5.
11043395|NCT04475198|Experimental|Part B Multiple Ascending Dose: Cohort 7|ST-2427 (n=4) or placebo (n=2) administered over a 60-minute intravenous (IV) infusion, twice daily for 3 days. Dose of ST-2427 will be determined after review of safety, tolerability and pharmacokinetic data from Cohorts 1-5.
11043396|NCT04475198|Experimental|Part B Multiple Ascending Dose: Cohort 8|ST-2427 (n=4) or placebo (n=2) administered over a 60-minute intravenous (IV) infusion, twice daily for 3 days. Dose of ST-2427 will be determined after review of safety, tolerability and pharmacokinetic data from Cohorts 1-5.
11043398|NCT04475172|Experimental|Fusio™ Flowable Self-Adhesive Flowable Composite|"2-Cavity preparation steps:
~patients will be given local anesthesia as required,the operative field will be isolated with rubber dam before starting.
~Conventional design Class V cavity will be prepared on the buccal surface of tooth by No. #330 bur (0.8 mm in diameter and 1.6 mm in length) , tooth surfaces will be kept moist to protect them against dehydration.
~2% chlorhexidine gluconate disinfecting solution .
~wash the dentin surface with water spray and air dry with maximum air pressure for 5 s.
~A) Intervention: Fusio™ Flowable (Self adhesive flowable composite):
~Simply syringe into the preparation 1 mm increments, agitate with tip or brush for 20 s, and light-cure.No need for an etchant or an adhesive."
11043399|NCT04475172|Active Comparator|Conventional flowable composite [Tetric Evo Flow (FF)].|"Tetric Evo Flow (Conventional flowable composite):
~After cleaning cavities, apply conditioning material (phosphoric acid etching 37% ) and apply bonding agent (ExciTE® F) according to the instructions for use of the product.
~Apply Tetric EvoFlow in layers of 1mm. Polymerize each layer separately following the instructions for use of this product. . Hold the light emission window as closely as possible to the surface of the restorative material.
~All 20 Class V restorations will be prepared, restored, finished, and polished by one operator. Each of the 10 patients had one (FL) restoration and the other restoration will be filled with (FF)."
11043400|NCT04475159|Experimental|PIPAC arm|Together with neoadjuvant systemic therpay PIPAC will be performed twice and regional chemotherpay will be administered before planned CRS/HIPEC
11043401|NCT04475146||Standard information and video visualization|Standard information and video visualization
11043402|NCT04475146||Standard information, no video|Standard information, no video
11043403|NCT04475133|Experimental|Low-frequency and high-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.
~The parameters are continuous stimulation of low frequency (2 hz) and high intensity (slightly painful) during 16 minutes."
11043404|NCT04475133|Experimental|High-frequency and low-intensity|"The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve.
~The parameters are high frequency (100 hz) and low intensity trains. There are 5 trains, 5 second active current and 55 second without current per train.
~The current is off on the first 11 minutes and the next 5 minutes it will be on. The total time is 16 minutes."
11043405|NCT04475133|Sham Comparator|Control group|The intervention of ultrasound guided percutaneous neuromodulation is applied over the median nerve without current during 16 minutes.
11043406|NCT04475120|Experimental|Group 1a (COVID-19 mild to moderate patients)|Group 1a received liposomal lactoferrin in 200 mg cps (equal to 100 mg of lactoferrin), 10 capsules per day for patients weighing less than or equal to 70 kg divided into 5 capsules in the morning and 5 capsules in the evening for 30 days for a total of 1 g of lactoferrin / day; patients with body weight over 70 kg, 15 capsules per day divided into 3 administrations / day for 30 days for a total of 1.5 g of lactoferrin per day; intra-nasal spray: 2 sprays per nostril 3 times a day, inhaling deeply during administration.
11043407|NCT04475120|Experimental|Group 2a (COVID-19 asymptomatic patients)|Group 2a received liposomal lactoferrin in 200 mg tablets (equal to 100 mg of lactoferrin), 5 capsules per day, 3 of which in the morning and 2 in the evening for 30 days (total dosage 500 mg of apo-lactoferrin per day); intra-nasal spray: 2 sprays per nostril 3 times a day, inhaling deeply during administration. Before administration, it was recommended to carefully clean the nasal cavity.
11043408|NCT04475120|No Intervention|Group 1b|15 mild-to-moderate symptomatic patients in hospitalization regimen were enrolled in the control group 1b to be paired by age group and gender to the aforementioned experimental group (1a)
11043409|NCT04475120|No Intervention|Group 2b|15 asymptomatic patients were enrolled as a control group (group 2b) to be paired by age group and gender to the aforementioned experimental group (2a)
11043410|NCT04475107|Experimental|Arm A|Pyramax (Pyronaridine 180mg/ Artesunate 60mg)
11043411|NCT04475107|Placebo Comparator|Arm B|Placebo
11043412|NCT04475094||COHORT|All patients will have had a clinically-indicated PET revealing at least one reversible perfusion defect followed by a research-indicated cardiac PET study between 3 and 8 weeks post-successful coronary artery stenting.
11043413|NCT04475081|Experimental|MMR vaccination|Subjects will be randomized to receive the MMR Vaccine subcutaneously
11043414|NCT04475081|Placebo Comparator|Placebo control|Subjects will be randomized to receive sterile saline given subcutaneously
11043415|NCT04475068||Moderate to severe ARDS patients due to COVID-19 infection|Mechanically ventilated patients with moderate to severe ARDS due to COVID-19 infection admitted to the COVID Intensive Care Unit of Rebagliati Hospital.
11043416|NCT04475055||Community sample|Participants will take part in the DIPS-interview and in an online survey.
11043417|NCT04475042|Active Comparator|Group A|Dapagliflozin - washout period - placebo
11043418|NCT04475042|Active Comparator|Group B|Placebo - washout period - Dapagliflozin
11043419|NCT04475029|Experimental|Methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
11043420|NCT04475029|Active Comparator|Morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and and study drug will be administered as intravenous bolus dose (0.15 mg/kg treatment weight (height (cm) - 100)). The study drug will be administered 1 hour prior to expected extubation.
11043421|NCT04475016|Experimental|Neoadjuvant Therapy|TIP (Paclitaxel + Ifosfamide + Cisplatin) & Nimotuzumab & Triprilimab
11043422|NCT04474964|Experimental|Low Dose Craniospinal Irradiation|WNT subgroup medulloblastoma patients accrued in the study will be treated with Low-dose Craniospinal Irradiation (18Gy/10fx) plus focal conformal tumor-bed boost (36Gy/20fx) for total primary-site dose of 54Gy/30fx over 6-weeks. Followed by adjuvant multi-agent systemic chemotherapy which will be initiated 4-6 weeks after completion of radiotherapy provided the ANC >1500 and platelet count >1,00,000. A total of 6 cycles of alternating chemotherapy every 4-weekly will be planned as per our standard practice using CET protocol.
11043423|NCT04474951|Experimental|Anemia|Metastatic patients with grade 1 anemia and on treatment with anti-CDK 4/6 or PARP Inhibitors (10 patients) or on adjuvant therapy with hormonal therapy (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; hemoglobin levels will be assessed every 4 weeks for a maximum period of 6 months.
11044178|NCT04469998|Placebo Comparator|AXR-270 Vehicle|AXR-270 Vehicle administered once daily
11043424|NCT04474951|Experimental|Fatigue|Patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing fatigue not associated to anemia or with anemia grade 1 (10 patients) or associated to anemia grade 2 (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; the assessment of fatigue will be performed at every chemotherapy cycle, for a maximum period of 6 months.
11043425|NCT04474951|Experimental|Nausea|20 patients on treatment with Epirubicin and Cyclophosphamide or Carboplatin and Taxane and showing nausea of any grade (without vomiting) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Peppermint Fluid Extract, associated to antiemetic therapy prescribed as per clinical practice; the assessment of nausea will be performed at every chemotherapy cycle, for a maximum period of 6 months.
11043426|NCT04474938|Experimental|Dara-BD|Daratumumab combined with bortezomib and dexamethasone
11043427|NCT04474925|Active Comparator|Surgical Resection followed by SRS (Non-Experimental)|Surgical Resection followed by SRS within 3 weeks of surgery date.
11043428|NCT04474925|Experimental|SRS followed by Surgical Resection (Experimental)|SRS followed by surgery within 1 week of radiotherapy end date.
11043429|NCT04474912||Control group|Healthy volunteers with no symptoms or signs of rheumatoid arthritis or osteoarthritis
11043430|NCT04474912||Rheumatoid arthritis group|Rheumatoid arthritis (RA) patients fulfilled 2010 American college of rheumatology (ACR) classification criteria. A patient is considered having definite RA if he/she scores at least 6 points in the established classification system
11043431|NCT04474912||Osteoarthritis group|Osteoarthritis (OA) patients fulfilled 1990 ACR criteria for the classification and reporting of osteoarthritis of the hand. A patient is considered having hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands
11043432|NCT04474899|Experimental|Phase 1|Moxonidine 0.4mg/daily
11043433|NCT04474899|Experimental|Phase 2|Amlodipine 5mg
11043434|NCT04474886|Experimental|Fresubin® powder fibre|2 servings of Fresubin® powder fibre per day as supplement to normal diet
11043435|NCT04474886|No Intervention|Usual diet|Maintain usual diet
11043436|NCT04474873|No Intervention|Group 1:Conventional intravenous analgesia|Conventional intravenous analgesia applied according to surgeon's preference
11043437|NCT04474873|Active Comparator|Group 2:ESPB|A 6-13 MHz linear probe was used for ultrasound-guided ESPB (Logiq e, General Electric, USA,) performed at the T11 level. The transverse process was detected by sliding the transducer 3-4 cm laterally from the midline, and after identification of the transverse process, a 20-gauge 100mm insulated echogenic needle (Vygon locoplex, France) was used
11043438|NCT04474860||Malignant Hyperthermia|Samples from Chinese whose malignant hyperthermia susceptibility had been confirmed after a positive clinical manifestation of malignant hyperthermia and samples from their blood relations will receive genetic testing.
11043439|NCT04474847|Experimental|Blinded Abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
11043440|NCT04474847|Placebo Comparator|Blinded Placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission.
11043441|NCT04474834||PRS|Providing polygenic risk score (PRS)
11043442|NCT04474821|Experimental|Prevention (HPV educational program)|Patients receive educational materials on HPV and are asked of their willingness to proceed with the first HPV vaccination. Patients who express interest in receiving the HPV vaccination, then receive the first dose of the HPV vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.
11043443|NCT04474808|Experimental|L-arginine-containing foot cream|The participants apply one foot (randomized assignment) with the L-arginine-containing foot cream twice a day (morning and evening) over a period of six weeks.
11043444|NCT04474808|Active Comparator|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the Urea-containing foot cream twice a day (morning and evening) over a period of six weeks.
11043445|NCT04474795|Placebo Comparator|Patients - Usual Care|Patient participants with gestational diabetes receiving usual care at community health center
11043446|NCT04474795|Experimental|Patients - Intervention Group|Patient participants with gestational diabetes receiving usual care at community health center plus patient-centered educational curriculum and support from a community health worker.
11043447|NCT04474795|Experimental|Staff - Educational training|Nurses and community health workers
11043448|NCT04474769|Experimental|Educational intervention|Intervention group's preceptors is given an eight-hour education entity about orientation and preceptorship. The objective is to enhance preceptors' knowledge and skills about the orientation and to give preceptors means to precept new graduate nurses better.
11043449|NCT04474769|No Intervention|No intervention|Nursing units at the control group continue to precept as before.
11043450|NCT04474756|Experimental|Mandibular Advancement Devices Narval™|The tested device Narval™ will be a custom-made adjustable bi-block mandibular advancement device, that is made with semi-rigid plastic materials (bio-compatible polymer) and customized using a high-precision computer-aided design (CAD)/computer-aided manufacturing (CAM) ) (ResMed, Narval CC™). The Mandibular Advancement Devices will be gradually adjusted to provide mandibular advancement over a 15-mm range. Each Mandibular Advancement Device will be ﬁtted by a dental specialist with an initial advancement of about 60 % of maximal jaw protrusion. During titration, mandibular advancement will be adjusted at the discretion of the dental specialist.
11043528|NCT04474210|Experimental|Part B: Group 4 (Optional)|Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379.
11043529|NCT04474210|Experimental|Part B: Group 5 (Optional)|Participants with kidney failure (eGFR: <15 mL/minute or dialysis patients on non-dialysis days) will receive a single oral dose of JNJ-56136379.
11043530|NCT04474197|Experimental|VX-864|Subjects will be randomized to receive different dose levels of VX-864.
11043451|NCT04474756|Active Comparator|Mandibular Advancement Devices TALI ™|"The control device TALI ™ is a mandibular advancement orthesis, customized and manufactured by the laboratoire TALI, of the bi-bloc type consisting of rigid gutters thermo-formed on the plaster dental arches and articulated by two links of variable size allowing to adjust the advance in steps of 1 millimeter. This orthesis is manufactured on molding from bio-compatible plastic materials. The different sizes of rods proposed allow mandibular advances of 4 mm to 16 mm. Two clinical studies evaluated the effectiveness of the AMC / AMO orthosis (initial version of the TALI orthesis, with non-curved links) in patients with OSA. They have already demonstrated the effectiveness of the TALI orthesis by decreasing AHI and drowsiness; most patients preferred to use the orthesis (76.4% vs. 9.1%)11."
11043452|NCT04474743||Liver Cirrhosis|Patients diagnosed with liver cirrhosis.
11043453|NCT04474743||Chronic Pancreatitis|Patients diagnosed with chronic pancreatitis.
11043454|NCT04474743||Short Bowel Syndrome|Patients diagnosed with short bowel Syndrome.
11043455|NCT04474743||Control Patients|Otherwise healthy patients visiting hospital with other non-severe diseases.
11043456|NCT04474743||Healthy Controls|Healthy subjects recruited from the general population.
11043457|NCT04474730|Active Comparator|Watch Only|
11043458|NCT04474730|Experimental|Watch+App|
11043459|NCT04474717|Other|The natural history of COPD|Monitoring risk factors, chronic respiratory symptoms and respiratory function in the natural history of chronic obstructive pulmonary disease
11043460|NCT04474717|Experimental|Study of systemic inflammation and molecular mechanisms|Study of systemic inflammation and molecular mechanisms underlying the comorbid course of COPD and atherosclerosis
11043461|NCT04474717|Other|non-coding miRNAs|Investigation of the role of non-coding miRNAs in the epigenetic regulation of signaling pathways involved in the pathogenesis of COPD and atherosclerosis
11043462|NCT04474717|Other|Exhaled breath condensate|A study of the clinical and biochemical COPD phenotype with systemic inflammation and comorbidity
11043463|NCT04474704|Experimental|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 36 hours postpartum.
11043464|NCT04474704|Other|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
11043465|NCT04474691|Experimental|Visual-acoustic biofeedback|
11043466|NCT04474691|Active Comparator|Traditional articulation treatment|
11043467|NCT04474678|Other|All Patients|Since this is a single-group study, all patients are within the same arm
11043468|NCT04474665|Other|Implant placement accuracy|Blueprint planning software will be used to plan reverse shoulder replacement surgery. Accuracy of the placement compared to the plan will be assessed post-surgery.
11043469|NCT04474639||with diastolic dysfunction|patients with diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e' >=8, and lateral e'>=10 and left atrium <34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
11043470|NCT04474639||without diastolic dysfunction|patients without diastolic dysfunction of the left ventricle confirmed by the results of the echocardiography (septal e'<8, and lateral e'<10 and left atrium >=34 ml/m2) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS_E, T_E, TP_E, BETA, BETA_S, BAD_T, QRS_D1_ons, QRS_D1_offs, QRS_D2, QRS_Ei (i = 1,2,3,4), T_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA).
11043471|NCT04474626|Experimental|ISOQUERCETIN|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits
~- ISOQUERCETIN: Oral Study Drug, 1 time per day, per predetermined dosed per 28 treatment cycle.
~This will continue for up to 337 days."
11043472|NCT04474613|Experimental|Liquid biopsy|A liquid biopsy is a test will be done on a sample of blood to look for cancer cells
11043473|NCT04474600|Experimental|TIVA group|Patients receiving the total intravenous anesthesia using propofol
11043474|NCT04474600|Active Comparator|Inhalation group|Patients receiving inhalation anesthesia using desflurane
11043475|NCT04474587||OHS-NIV|Patients with obesity-hypoventilation syndrome (OHS) treated with non-invasive ventilation (NIV).
11043476|NCT04474561|Other|Reduced sulfur diet intervention (INT)|"The INT group will receive conventional management plus a reduced sulfur diet and diet counselling by an RD. Implementation of the diet will be delivered directly by the RD and will provide each patient with an individualized plan. A reduced sulfur diet includes reducing foods, additives and beverages high in sulfate/sulfur.
~The reduced sulfur diet eating plan, resources on reduced sulfur eating, and RD counselling session will be designed and reviewed by experts in nutrition, dietary design, education resources and dietary behaviour change"
11043477|NCT04474561|No Intervention|Conventional management (CM)|The CM group will receive one session with RD on reduced sulfur diet at the end of 8 weeks.CM groups will receive conventional management .
11043478|NCT04474548|Experimental|Ultrasound|"For participants randomly assigned to ultrasound use, a bedside ultrasound will be performed using the trans-abdominal probe during and/or immediately after placement of the IUD. The distance from the IUD arms to the fundus will be measured with the ultrasound, and the IUD will be defined as being in place when the distance from the top of the IUD to the fundus is measured to be 3mm or less. If the distance is greater than 4mm, the provider may reposition the IUD manually or with a ring forceps."
11043479|NCT04474548|No Intervention|No ultrasound|For participants randomly assigned to no ultrasound use, provider will insert the IUD with a ring forceps and will use palpation of the fundus to determine whether or not the IUD is likely in place.
11043480|NCT04474522|Active Comparator|intervention group using morphology and NIPGT-A|
11043481|NCT04474522|No Intervention|control group based on morphology alone|
11043531|NCT04474197|Placebo Comparator|Placebo|Subjects will receive placebo matched to VX-864.
11043532|NCT04474184|Experimental|Aim 1 (focus group)|Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
11043482|NCT04474509|Experimental|FACT Module Engagement|During this module, patients will have the opportunity to increase their motivation to change and encourage the engagement in committed actions, consistent with their life values. Patients are invited to reflect on what is important in their lives, which values make their life worth living, and which actions they could take to live a meaningful life, in accordance with personal values. The use of metaphors and experiential exercises will facilitate the process of exploring personal values, identifying life directions and related behaviors. For example, the 80th Birthday Party metaphor requires participants to imagine there is a party in honor of their birthday and the time comes when people are starting to give speeches and try to answer the question about what they want to hear people at the party say. This exercise help patients in wondering what person they want to be with themselves and others.
11043483|NCT04474509|Experimental|FACT Module Openness|"Participants attending this module are guided to recognize and distancing themselves to stressful thoughts, feelings and sensations. They will learn to read suffering as part of human experience, without self-judgment and self-condemnation. Rather, therapist will encourage the patient's assumption of an open and acceptable approach to internal experiences. Throughout the module, therapist will help patients to reflect on their usual, but ineffective efforts to solve personal problems, and encourage the adoption of new responsive strategies based on acceptance and defusion from personal distress.
~An example of metaphor used during the Module is The Passenger on a bus. In this metaphor patient have to imagine to be a driver bus and his every thought is a passenger that gets on and off the bus. This exercise help patients to accept, defuse from, and reduce the power of their thoughts."
11043484|NCT04474509|Experimental|FACT Module Awareness|The module comprises meditation exercises and experiences aimed to learn how to act intentionally with awareness about personal thought and sensations without automatically reacting. Participants are supported to recognize their actions and the context where they occur and learn to choose to respond with action consistent with their values and not automatically. Therapist will propose breathing exercises, body scan and others mindfulness experiences. Participants will be encouraged to sitting comfortably, close the eyes, feel themselves in contact with the present moment they are living, paying attention to their breath, noticing the rhythm and any other aspect of the experience of breathing. Then, the therapist guides the participant's attention on the body, noting any part of their body from the head to feet. Then, the sounds around, any noises that could distract their attention on themselves.
11043485|NCT04474496||Marshallese in the U.S.|Marshallese persons 18 years of age or older residing in the United States
11043486|NCT04474483|Placebo Comparator|Control|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
11043487|NCT04474483|Experimental|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
11043488|NCT04474470|Experimental|Dose escalation of NT219 as a single agent|
11043489|NCT04474470|Experimental|Dose escalation of NT219 in combination with ERBITUX®|
11043490|NCT04474470|Experimental|Expansion cohort of NT219 in combination with ERBITUX®|
11043491|NCT04474457||COVID-19/Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
11043492|NCT04474444||Hear and treat|phone call, treatment, not attended
11043493|NCT04474444||See and treat|Ambulance crew attended
11043494|NCT04474431|Other|Patients admitted in the ICU of hospital of Rouen|Patients admitted in the intensive care unit (ICU) of the teaching hospital of Rouen.
11043495|NCT04474405|Experimental|Brain flortaucipir PET scan|Subjects receiving a brain PET scan after flortaucipir administration
11043496|NCT04474405|Experimental|Whole body flortaucipir PET scan|Subjects receiving a whole body PET scan after flortaucipir administration
11043497|NCT04474405|Other|MRI and Amyloid Extension Cohort|Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
11043498|NCT04474392||At-Risk (N=180)|"No evidence of inflammatory arthritis on clinical examination AND
~At elevated risk for RA based on familial or serologic risk
~Familial risk includes having a first degree relatives (FDRs) with RA
~Serologic risk includes asymptomatic serum ACPA positivity
~There will be 1 study visit per year for 3 years; for a subset of 30 of these participants, there will be an additional 3 quarterly visits in one year.
~Study Procedures (Baseline & Follow-up):
~Questionnaires
~Physical and joint exam
~Measurement of participants' height, weight
~Blood and sputum collection"
11043499|NCT04474392||Healthy Controls (N=120)|"No history of RA
~No FDRs with RA
~No systemic use of immunosuppressants for autoimmune disease
~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.
~Study Procedures (Baseline & Follow-up):
~Questionnaires
~Physical and joint exam
~Measurement of participants' height, weight
~Blood and sputum collection"
11043500|NCT04474392||RA Diagnosis (N=40)|"Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR
~Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)
~Participants will return for 1 follow-up visit, approximately 1 year after their baseline visit.
~Study Procedures (Baseline & Follow-up):
~Questionnaires
~Physical and joint exam
~Measurement of participants' height, weight
~Blood and sputum collection"
11043533|NCT04474184|Experimental|Aim 2 (vaginal kit)|Participants receive a tampon kit for collection of vaginal samples.
11043551|NCT04474067||Mild COVID-19|"Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging.
~According to NIH classification"
11043552|NCT04474067||Moderate COVID-19|COVID-19 patients who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2) ≥94% on room air at sea level.
11043645|NCT04473560||Catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with catheter-directed thrombectomy along with anticoagulation therapy
11043501|NCT04474379|Experimental|Strategy Training|Consists of 8-90 minute sessions over 4 weeks. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the therapist teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based) and instructs in their use before and during the training games. In sessions 3-8, the tester tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. After completing the training games, the therapist and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the therapist helps the participant develop written action plans to do so. Plans and goals are reviewed and modified, if necessary, at each session.
11043502|NCT04474379|No Intervention|Process Training|Consists of 8, 90 minute sessions over 4 weeks. In sessions 1 and 2, the therapist teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3-8, the tester tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the therapist. Feedback on accuracy is provided after each training game. This is typical of a process training approach and expects that practice of the training tasks will improve prospective memory ability per se or that participants will develop effective strategies for completing prospective memory tasks on their own. At the end of each session, the therapist reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Goals are reviewed and modified if necessary.
11043503|NCT04474366|Sham Comparator|Saline|Control group will receive an injection of 20ml of saline between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of saline between the pectoralis minor and pectoralis major muscles bilaterally.
11043504|NCT04474366|Experimental|Ropivacaine|Intervention group will receive an injection of 20ml of 0.2% Ropivacaine between the pectoralis minor and serratus anterior muscles bilaterally and 10ml of 0.2% Ropivacaine between the pectoralis minor and pectoralis major muscles bilaterally (Not to exceed 225mg or 3.5mg/kg).
11043505|NCT04474353|Experimental|Novo-TTF|"Day 1: Subjects will wear the Optune (TTFields device) for ≥ 18 hours/day. They will take off the device when receiving stereotactic radiosurgery and brain MRI scans.
~Days 1 to 8: Subjects will take oral temozolomide 75 mg/m2/day Days 2 to 8: Subjects will receive stereotactic radiosurgery (total of 35 Gy) divided equally over 5 days
~• After the interventional treatment, subjects will receive standard of care adjuvant chemotherapy and routine surveillance brain MRI scans."
11043506|NCT04474340|Experimental|CCP patients|"Patient has to fulfil the inclusion/exclusion criteria of the ward or the ICU
~Valid consent.
~Request the CCP from the central blood bank (200-250 ml/dose - can be repeated again in 12 hours) this is through the local hospital blood bank.
~How to transfuse CCP:
~Dose required is 200-250 ml/hr (one dose, can be repeated in 12 hrs), max total 500ml.
~Premedication prior to administration of CCP (Acetaminophen, diphenhydramine,steriods) or according to hospital guidelines."
11043507|NCT04474340|No Intervention|Control|Standard COVID-19 treatment.
11043508|NCT04474327|Experimental|Intervention group|"The intervention group will receive Montelukast Sodium for 10 days in addition to the conventional antibiotic therapy regimen and other supportive measures according to the policy of neonatal units and patients' needs. Montelukast sodium will be given at a dose according to body weight (1.5 kg to 2 kg, will be given 1.5 mg; greater than 2 kg, 2 mg will be given) this dose was calculated according to ( Kim et al. (2015). Four mg of the drug will be dissolved in four ml milk and 1.5 - 2 ml milk only will be given once daily at 9 pm via an orogastric tube or by oral administration for 10 days and patients of this group will be closely observed for development of Montelukast side effects as diarrhea, colic, vomiting, fever and cough (Adelsberg et al. 2005)."
11043509|NCT04474327|No Intervention|Control group|The control group will receive antibiotics and other supportive measures according to the policy of neonatal units and patients' needs.
11043510|NCT04474314|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
11043511|NCT04474314|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
11043512|NCT04474314|Placebo Comparator|Placebo|Oral administration of once daily Placebo
11043513|NCT04474301||Observational (survey administration)|Patients complete a survey over 10 minutes.
11043514|NCT04474288||Person Under Investigation (PUI)|PUI's are subjects who were admitted to the hospital with symptoms suspicious for COVID-19.
11043515|NCT04474288||Asymptomatic Person under Screening (APS)|APS's are those patients who do NOT meet the criteria to be a suspect COVID- 19 patient but are being tested because they are being admitted, are required for testing by state mandate, or are having a procedure, etc.
11043516|NCT04474275||Study group 1|Primiparous women who gave birth with ceserean section
11043517|NCT04474275||Study group 2|Primiparous women who gave birth with vaginal route delivery without episiotomy
11043518|NCT04474275||Study group 3|Primiparous women who gave birth with vaginal route delivery with episiotomy
11043519|NCT04474275||Control group|Nulliparous women
11043520|NCT04474262|Active Comparator|Albumin with placebo|Group A will be given albumin 8g/l of ascitic tap along with placebo for 7 days. Standard albumin therapy will continue (40gm/week)
11043521|NCT04474262|Experimental|Albumin with Midodrine|GROUP B will be given midodrine 7.5 mg to 10 mg tds (keeping the target MAP above 70 mmhg)for 7 days plus albumin same as in other group.
11043522|NCT04474249||COVID-19|Patients with PCR-confirmed COVID-19 who were treated in the intensive care unit.
11043523|NCT04474236||COVID-19 patients|Adult (> 18 years) with Proven COVID-19 (specific PCR from respiratory track sample)
11043524|NCT04474223|Experimental|Mothers with Fetuses Who Have 2° AVB or AV interval > 170ms|
11043525|NCT04474210|Experimental|Part A: Group 1|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliter[mL]/minute) will receive a single oral dose of JNJ-56136379.
11043526|NCT04474210|Active Comparator|Part A: Group 2|Healthy participants with normal renal function (eGFR greater than or equal to [>=] 90 mL/minute), will receive a single oral dose of JNJ-56136379.
11043527|NCT04474210|Experimental|Part B: Group 3 (Optional)|Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379.
11046127|NCT04456049|Experimental|Enzalutamide (Xtandi®)|Interventional treatment
11043534|NCT04474171|Experimental|SCI&U Intervention|The SCI&U online platform has a resource library, secure videoconferencing, and tools to support one-on-one health coaching. Health coaches are certified in motivational interviewing and have lived in the community with SCI for more than five years. In the first session, participants identify priority issues related to their health and target management of secondary conditions specific to SCI. They will work through goal setting, problem solving activities and create action plans for behaviour change, which will be securely stored. The intervention will be a maximum of 14 sessions over 6 months. Each session will cover a health-related topic (bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression) and a self-management skill topic (action planning, goal setting, problem-solving, mood management, navigating the health care system and communicating with health care providers) with an expected duration of 30 to 45 minutes.
11043535|NCT04474171|No Intervention|Waitlist Control|Usual health care and be offered the SCI&U program at the end of the 12-month follow-up period (wait-list control)
11043536|NCT04474158|Experimental|Creating Peace|Creating Peace uses a group discussion format with activities that explore race, gender, sexual identity, and social class. Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
11043537|NCT04474158|Active Comparator|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
11043538|NCT04474145|Active Comparator|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.
~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
11043539|NCT04474145|Active Comparator|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
11043540|NCT04474132|Other|single group|binary: positive or negative result
11043541|NCT04474119|Experimental|Experimental arm|KN046 plus Carboplatin and Paclitaxel
11043542|NCT04474119|Placebo Comparator|Control arm|Placebo plus Carboplatin and Paclitaxel
11043543|NCT04474106|Experimental|ESWT|The extracorporeal shockwave therapy is applied once at the level of lesion and 5 segments above and below; or below the occiput (in lesions higher than C6) and above the sacrum (in lesions lower than T12). In addition, the ESWT is applied to the soles of both feet on the medial side of the plantar surface. The ESWT is applied as soon as possible within 48 hours post-injury.
11043544|NCT04474106|Sham Comparator|Control|In the control group, the same procedure is performed, but without the device emitting extracorporeal shock waves using a dummy head.
11043545|NCT04474093|Active Comparator|Zirconium-reinforced glass ceramics (ZRGC)|12 posterior single tooth crowns made from monolithic zirconium-reinforced glass ceramics(ZRGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
11043546|NCT04474093|Active Comparator|Lithium disilicate glass ceramics (LGC)|Group 2: 12 posterior single tooth crowns made from monolithic lithium disilicate glass ceramics(LGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
11043547|NCT04474093|Active Comparator|Resin infiltrated glass ceramics (RIGC)|12 posterior single tooth crowns made from monolithic resin infiltrated glass ceramics(RIGC). Restorations were evaluated prosthetic and periodontal criteria at baseline, after 6 and 12 months. While prosthetic evaluation was performed according to Modified US Public Health Service criteria; probing depth(PD), clinical attachment level(CAL), gingival bleeding time index(GBTI), gingival(GI) and periodontal index(PI) were used in periodontal evaluation.
11043548|NCT04474080|Experimental|Virtual Peer Support Platform|"The intervention program content will be informed by the BASICS-a guide for supporting resilience against burnout, developed by the Ontario Medical Association Physician Health Program, as well as the Person-Environment-Occupation (PEO) model, a transactive approach to modelling occupational performance issues in the field of Occupational Therapy. The BASICS highlights six fundamental domains will underly the focus of group therapy sessions, where participants will be encouraged to consider how they may incorporate healthy physical and emotional practices both on their own (Person), and during the practice of medicine (Occupation), in addition to identifying barriers to adopting these practices within the healthcare environment (Environment)."
11043549|NCT04474080|Active Comparator|Control period|Residents receive a 30 minutes break during their weekly academic half-day.
11043550|NCT04474067||• Asymptomatic or Pre-symptomatic Infection|Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms.
11043553|NCT04474067||Severe COVID-19|COVID-19 patients who have respiratory frequency >30 breaths per minute, SpO2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, or lung infiltrates >50%
11043554|NCT04474067||Critical COVID-19|COVID-19 patients who have respiratory failure, septic shock, and/or multiple organ dysfunction.
11043555|NCT04474067||Sepsis|A control group of patients with sepsis-related cytokine storm
11043556|NCT04474067||CAR-T CRS|A control group of patients with cytokine release syndrome due to CAR-T therapy
11043557|NCT04474041|Experimental|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
11043558|NCT04474028||Hood group|The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood.
11043559|NCT04474028||Direct spray group|The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively.
11043560|NCT04474015|Active Comparator|Part A, Group 1|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 1 will receive forearm stimulation at 0.75 Hz with an oscillating direct current (DC) waveform while awake.
11043561|NCT04474015|Active Comparator|Part A, Group 2|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 2 will receive forearm stimulation at 0.75 Hz with a modified alternating current (AC) waveform while awake.
11043562|NCT04474015|Active Comparator|Part A, Group 3|Forearm stimulation during wake (study PART A) - electrode placement = volar surface of forearm, 2 electrodes (cathode and anode): Group 3 will receive forearm stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform while awake.
11043563|NCT04474015|Active Comparator|Part B, Group 4|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). roup 4 will receive scalp stimulation at 0.75 Hz with an oscillating direct current (DC) waveform during sleep.
11043564|NCT04474015|Active Comparator|Part B, Group 5|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 5 will receive scalp stimulation at 0.75 Hz with a modified alternating current (AC) waveform during sleep.
11043565|NCT04474015|Active Comparator|Part B, Group 6|Scalp stimulation during sleep (study PART B) - bilateral electrode pairs placed on the upper forehead near the midline (F3 and F4) and adjacent to the ear in the mastoid region (M1 and M2). Group 6 will receive scalp stimulation at 3.0 Hz with an alternating current (AC) sinusoidal waveform during sleep.
11043566|NCT04474015|Active Comparator|Part C, Group 7|Pulsed Stimulation: Group 7 (Part C)will receive a series of brief stimulations of up to 500 millisecond duration and of up to 5 milliamperes of current, using either metal electrodes or sponge electrodes as stimulating electrodes.
11043567|NCT04474002|Active Comparator|4L Klean Prep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl and aspartame 0.0494g
11043568|NCT04474002|Experimental|1L Klean prep® and 2 sachets Picoprep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl, aspartame 0.0494g, sodium picosulfate 0.01g, magnesium oxide 3.5g, citric acid 12.0g
11043569|NCT04473989|Placebo Comparator|Placebo|Injection product without active teriparatide
11043570|NCT04473989|Experimental|PTH 40ug/w|Injection product with active teriparatide
11043571|NCT04473963|Experimental|EGF-Guided Ablation Therapy|"Subjects randomized to therapy will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software)."
11043572|NCT04473963|No Intervention|Control - No Ablation Therapy|"Subjects randomized to control will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end."
11043573|NCT04473950|Experimental|Pain Group|Patients with chronic pain who are maintained on methadone for opioid use disorder
11043574|NCT04473950|Placebo Comparator|No Pain Group|Patients who are maintained on methadone for opioid use disorder but who do not have chronic pain.
11043575|NCT04473937|Experimental|Radiotherapy|"Participants must have received CAR-T infusion within the last 90 days prior to completing a study screening and enrollment process.
~Participants will be enrolled within 28 days after screening is complete and radiotherapy will occur within 14 days after study enrollment.
~Radiotherapy will be administered based on a dose and schedule pre-determined by the study doctor."
11043576|NCT04473924|Experimental|Body surface area-based mycophenolate dosing|Intervention group will receive mycophenolate mofetil 750 mg/m^2/day divided into twice daily dosing.
11043577|NCT04473924|Active Comparator|Standard (fixed) dosing|Active comparator group will receive standard fixed dosing of mycophenolate mofetil 1000 mg twice daily.
11043578|NCT04473911|Experimental|Regimen 1: Fludarabine, Cyclophosphamide, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician
~Pre- stem cell transplant:
~Fludarabine predetermined dose, intravenously, 4 times per cycle
~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
~Total body irradiation (TBI) once during treatment cycle
~Post stem cell transplant:
~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.
~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
11043604|NCT04473768||Other causes of febrile illness requiring hospital admission|"Current Pf malaria infection: see above
~Recent Pf malaria infection: see above
~Non-confirmed bloodstream infection without Pf malaria: no growth in blood culture and negative results in all Pf malaria tests
~If feasible, severe bacterial localized infections such as pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection, will be assessed and clinically defined"
11043605|NCT04473755||ADHD|This group will include participants who meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
11043579|NCT04473911|Experimental|Regimen 2: Fludarabine, Melphalan, and TBI|"-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician
~Pre- stem cell transplant:
~Fludarabine predetermined dose, intravenously 3 times per cycle
~Melphalan, infusion, determined dosage, once per cycle
~Total body irradiation (TBI) once per cycle.
~Post stem cell transplant
~Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
~Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:
~Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
~RGI-2001: IV, predetermined dose, weekly to 6 total doses"
11043580|NCT04473898|Sham Comparator|Patient Education Group|Information training about COViD-19 and its symptoms, hygiene education, family education
11043581|NCT04473898|Experimental|Aerobic Training Group|Teaching and regular follow-up of aerobic exercises shown online
11043582|NCT04473898|Experimental|Aerobic + Respiratory Training Group|Teaching and regular follow-up of aerobic and respiratory exercises shown online
11043583|NCT04473885|Experimental|Perturbation-based balance training group|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
11043584|NCT04473885|No Intervention|Control group|Participants in the control group will remain their regular activity without additional training.
11043585|NCT04473872|Active Comparator|Neurodevelopmental treatment program group|"When applying NGT, which is described as a problem solving approach, the treatment program appropriate for their functional levels will be determined for each patient, taking into account the individual needs and wishes of the patient. Principles to be considered while applying the treatment program:
~Inhibition of normal / ineffective movements
~Facility of normal / effective movements Sensory-motor stimulation
~Correct placement of body segments Neurodevelopmental treatment physiotherapy session for 5-days in a week, over 6-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities."
11043586|NCT04473872|Experimental|diaphragmatic breathing|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises. Diaphragmatic breathing; To give the patient a supine position, a pillow is placed under his knees and head. The patient is asked to place his right hand on the upper abdomen and his left hand on the upper part of his chest. The patient is told to take a slow and deep breath through the nose until four counts, and to hold the air in for the time it has inhaled, and then the patient shrinks her lips like a whistle and exhales from using her breath for a long time. Exercises are performed two hours after meals, in short, 2-3 minutes in the beginning, in 10 of the patients, on average 30 minutes per day.
11043587|NCT04473872|Experimental|respiratory muscle training with the THRESHOLD IMT device|The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and respiratory muscle training with the THRESHOLD IMT device. T-IMT is an instrument that provides the same pressure in each breath for the strength and endurance of the inspiratory muscles, regardless of the patient's rapid or slow breathing. This device provides a constant pressure in inspiration with its flow-free one-way valve. It also has an adjustable device pressure. The tool consists of pressure section, mouthpiece and nose clip. During application, constant pressure is applied to the inspiration phase. The training group is started from 40% of MIP and inspiratory muscle training is given. In practice, patients are asked to sit in a loose position on the upper chest and shoulders. After eight breathing cycles, 1-2 respiratory controls are requested
11043588|NCT04473859|Experimental|FSR Peptide 20 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
11043589|NCT04473859|Experimental|FSR peptide 50 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
11043590|NCT04473859|Experimental|FSR peptide 100 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
11043591|NCT04473859|Experimental|FSR peptide 200 μM|Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.
11043592|NCT04473859|Placebo Comparator|Placebo only|Each subject will have two punch biopsies. Placebo will be applied to both punch biopsies.
11043593|NCT04473846|Experimental|PF group|The first group will undergo general anesthesia using Fentanyl and Propofol.
11043594|NCT04473846|Experimental|PFK group|The second group will receive a mixture that consists of Fentanyl, Propofol, and Ketamine. In addition, Lidocaine will be added to reduce the pain on injection caused by Propofol.
11043595|NCT04473833|Experimental|Participants in the Kentucky Ovarian Cancer Screening Program|Participants from the Kentucky Ovarian Cancer Screening Program who choose to participate in this trial will undergo further serial transvaginal ultrasonography (TVS) screening.
11043596|NCT04473820|Active Comparator|Vapocoolant spray|
11043597|NCT04473820|Active Comparator|Lidocaine-Prilocaine cream|
11043598|NCT04473807|Other|DASH-AF|Patients with history of highly symptomatic persistent or paroxysmal AF who are scheduled for sotalol therapy once in sinus rhythm will be enrolled in this study.
11043599|NCT04473781|Experimental|Treatment (interstitial brachytherapy)|Patients undergo interstitial brachytherapy for 1-2 fractions in the absence of disease progression or unacceptable toxicity. Patients who undergo 2 fractions may receive both fractions in the same day or on 2 separate days over 2 weeks.
11043600|NCT04473768||NTS bloodstream infection|growth of NTS in blood culture
11043601|NCT04473768||NTS/Pf malaria co-infection|concurrence of current Pf malaria infection and NTS bloodstream infection
11043602|NCT04473768||Other pathogen bloodstream infections|growth of a pathogen other than NTS in blood culture
11043603|NCT04473768||Severe Pf malaria mono-infection|defined according to WHO-criteria
11043606|NCT04473755||Non-ADHD|This group will include participants who do not meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
11043607|NCT04473742|Experimental|Patients exposed to silica|
11043608|NCT04473742|Active Comparator|Patients exposed to asbestos fibres|
11046128|NCT04456049|Active Comparator|Standard of care (SOC)|Supportive treatment
11043612|NCT04473716|Experimental|Inductive therapy with Toripalimab, Paclitaxcel and Cisplatin|Pre-operative inductive therapy will be used with the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of paclitaxcel and cisplatin in patients with locally advanced OSCC. After inductive therapy, the patients will receive radical surgery and post-operative radiotherapy/chemoradiotherapy.
11043613|NCT04473703||observation group|A total of 300 patients are expected to include in this group. And the cardiac adverse reactions related to immune checkpoint inhibitor will be observed.
11043614|NCT04473690|Experimental|Low Dose KBP-COVID-19|"Two age groups.
~Part A (18-49 years).
~Part B (50-70 years).
~All subjects in these groups will receive the low dose of KBP-COVID-19"
11043615|NCT04473690|Experimental|High Dose KBP-COVID-19|"Two age groups.
~Part A (18-49 years).
~Part B (50-70 years).
~All subjects in these groups will receive the high dose of KBP-COVID-19"
11043616|NCT04473690|Placebo Comparator|Placebo|"Two age groups.
~Part A (18-49 years).
~Part B (50-70 years).
~All subjects in these groups will receive placebo"
11043617|NCT04473677||Fecal Occult Blood Test|People in this group will detect hemoglobin in stool before colonoscopy by the new qFIT and other 3 kind of FIT.
11043618|NCT04473664|Experimental|Hepatic-impaired Participants|Participants with moderate HI as defined by NCI-ODWG criteria.
11043619|NCT04473664|Experimental|Healthy Control Participants|Healthy participants with normal hepatic function matched as a group by sex, age (±10 years), and weight (±20%).
11043620|NCT04473651|Experimental|Part A: Single dose of Lu AG06479 or Placebo|
11043621|NCT04473651|Experimental|Part B: Repeated dose of Lu AG06479 and Food interaction|"Sequence B1: Fed - Fasting- Fasting
~Sequence B2: Fasting- Fed - Fasting
~Sequence B3: Fasting- Fasting - Fed"
11043622|NCT04473638||Arthroscopic|Deltoid Arthroscopic Repair in Ankle Fractures
11043623|NCT04473625||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043624|NCT04473625||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043625|NCT04473625||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043626|NCT04473625||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043627|NCT04473625||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043628|NCT04473625||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043629|NCT04473625||Kidney/Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043630|NCT04473625||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043631|NCT04473625||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043632|NCT04473625||Pancreas|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043633|NCT04473625||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043634|NCT04473625||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
11043635|NCT04473612||Neuromuscular low physical status group|Patients diagnosed of Neuromuscular disease with low physical status
11043636|NCT04473612||Neuromuscular high physical status group|Patients diagnosed of Neuromuscular disease with high physical status
11043637|NCT04473612||Control group|Healthy subjects
11043638|NCT04473599|Active Comparator|Uniform Random|Participants will receive supportive text-messages for a period of 2 months. These text-messages have two categories: behavioral activation (BA) and coping skills. In this arm, participants will receive one of these types of messages daily on a random schedule in random time periods throughout the day.
11043639|NCT04473599|Experimental|Reinforcement Learning|In this arm we will test a reinforcement learning (RL) algorithm with a learned decision mechanism for the timing and type of text-messages. The algorithm learns from previous data (which messages were sent, what was the participants' mood) to maximize an increase in participants' mood.
11043640|NCT04473586|Other|Sample tested in less than one-hour|Buccal samples will be collected and analyzed on the Spartan Cube CYP2C19 System immediately (<1hr). The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
11043641|NCT04473586|Other|Samples tested greater than 24 hours|Buccal samples will be collected, stored and then analyzed on the Spartan Cube CYP2C19 System greater than 24 hours after collection. The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
11043642|NCT04473573|Other|Lot to Lot Reproducibility|The purpose of this arm is to provide evidence to support that each lot of manufactured reagents for the Spartan Cube CYP2C19 Test produce the same result. Each participant, over the course of the study at the various sites, will be tested using 3 different lots of manufactured Spartan CYP2C19 Test Kits.
11043643|NCT04473573|Other|Site to Site Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when tested at different locations, produce the same result.
11043644|NCT04473573|Other|Operator Reproducibility|The purpose of this arm was to provide supporting evidence that showed the same samples (subjects), when collected and tested by different operators, produce the same result.
11043646|NCT04473560||No catheter-directed thrombectomy group|Patients with acute pulmonary embolism treated with anticoagulation therapy alone
11043647|NCT04473534|Experimental|Arm of CBT-I treatment|Web cognitive behavioral therapy was administered before starting CPAP use by a psychologist expert in behavioral sleep medicine and expert in CBT-I. CBT-I was administered according to the same model and standard visual approach in patients with insomnia. Five sessions are scheduled: sleep psycho-education, sleep restriction, stimulus control, sleep hygiene and challenging beliefs and perception of sleep.
11043648|NCT04473534|Experimental|Arm of psycho-education session|Single session of psycho-education about sleep, OSA, insomnia and interaction among them will be administered by web before beginning CPAP use
11043649|NCT04473534|No Intervention|Arm of control TAU (Treatment As Usual)|The control group will receive TAU. Each patient will start to use CPAP after the diagnosis according to AASM (American Academy of Sleep Medicine) guideline.
11043650|NCT04473521|No Intervention|No Adhesive|No adhesive will be applied.
11043651|NCT04473521|Active Comparator|Super Poligrip Free (SPF)|The denture adhesive of 1.00grams (g) +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilised using this adhesive up to 2 times (maximum [max] 3 adhesive applications per day) at examiner's discretion.
11043652|NCT04473521|Experimental|Investigational Adhesive|The denture adhesive of 1.00g +/- 0.05g will be applied only to the maxillary denture only in long, continuous strips manner that is controlled by weight for the maxillary dentures. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
11043653|NCT04473521|Experimental|Investigational Adhesive + Hot drink|The denture adhesive of 1.00g +/- 0.05g will be applied to only the maxillary denture in long, continuous strips manner that is controlled by weight for the maxillary dentures. Hot drinks will be provided within 1 hour of completing lunch and dinner and must be consumed within 30 minutes. Mandibular denture will be stabilized using SPF adhesive up to 2 times (max 3 adhesive applications per day) at examiner's discretion.
11043654|NCT04473508|Experimental|Treated|active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)
11043655|NCT04473508|Placebo Comparator|Control|Local administration of Placebo ( Saline Solution)
11043656|NCT04473495||video|patients who enjoyed an educational video
11043657|NCT04473495||control|patients who didn't enjoy any educational video
11043658|NCT04473482|Experimental|MAIN-ART Behavior Tool|The Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Tool (MAIN-ART) behavioral intervention is an online web application with two modules: misconception correction and tailored, preference-sensitive alcohol use disorder (AUD) treatment matching.
11043659|NCT04473482|No Intervention|Routine care|Patients randomized to usual care will receive a pamphlet for alcohol treatment referral to the University of Michigan Addiction Treatment Services, but will receive no further education from the research team.
11043660|NCT04473469|Experimental|Cystometrogram|The bladder will be filled to different volumes and electrical stimulation will be applied to the pudendal nerve via the implanted neurostimulator.
11043661|NCT04473456|No Intervention|Serial arm|In the serial group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
11043662|NCT04473456|Active Comparator|Simultaneous arm|In the simultaneous group, all colonoscopies will be performed by the same endoscopist. EGDs are performed by the attending endoscopist on the day of the procedure.
11043663|NCT04473443||Cohort A|Patients with a challenging anatomy, including bicuspid aortic valve, severely calcified aortic valves or small aortic roots
11043664|NCT04473443||Cohort B|Consecutive patients eligible for TAVI with Acurate TM and Lotus Edge TM valve
11043665|NCT04473430|Experimental|Dexcom G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia < 55 mg/dL within the preceding 20 minutes)."
11043666|NCT04473430|Active Comparator|Point-Of-Care Blood Glucose (POC BG) monitoring|Patients will receive conventional/point-of-care blood glucose monitoring
11043667|NCT04473417|Experimental|Part A, Sequence I|Period I: Forxiga® 10mg → DA-2811, Period II: DA-2811 → Forxiga® 10mg
11043668|NCT04473417|Experimental|Part A, Sequence II|Period I: DA-2811 → Forxiga® 10mg, Period II: Forxiga® 10mg → DA-2811
11043669|NCT04473417|Experimental|Part B, Sequence I|Period I: DA-2811 under fasting state → DA-2811 under fed state, Period II:DA-2811 under fed state → DA-2811 under fasting state
11043670|NCT04473417|Experimental|Part B, Sequence II|Period I: DA-2811 under fed state → DA-2811 under fasting state, Period II: DA-2811 under fasting state → DA-2811 under fed state
11043671|NCT04473404|Experimental|Probiotic - low dose|Powdered probiotic with a carrier.
11043672|NCT04473404|Experimental|Probiotic - high dose|Powdered probiotic with a carrier.
11043673|NCT04473404|Placebo Comparator|Placebo|Carrier only.
11043674|NCT04473391|Experimental|Robot-assisted Rehabilitation|Participants will receive Functional Electrical Stimulation (FES) training with a lower extremity cycle-ergometer (MOTOmed Viva 2, Reck GmbH., Germany) and a 6-channel FES Device (TrainFES, Biomedical Devices SpA, Chile). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 3 sessions per week for 8 weeks, each lasting about 45 minutes.
11043675|NCT04473378||FreeStyle Libre sensor cohort|Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
11043676|NCT04473352||Single Group|Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.
11043677|NCT04473339|Experimental|HRR mt 1|Patients are HRR mutated type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
11043956|NCT04471428|Active Comparator|Docetaxel|Participants will receive docetaxel on Day 1 of each 21-day cycle.
11043678|NCT04473339|Experimental|HRR mt 2|Patients are HRR mutated type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
11043679|NCT04473339|Experimental|HRR wt 3|Patients are HRR wild type, will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
11043680|NCT04473339|Experimental|HRR wt 4|Patients are HRR wild type, will undergo CRS and then go on to receive standard platinum-based combination doublet intravenous chemotherapy.
11043681|NCT04473326|Experimental|Reinforcement Learning Intervention Arm|Up to daily, tailored text messages.
11043682|NCT04473326|No Intervention|Control Arm|Up to daily, untailored text messages.
11043683|NCT04473287|Experimental|intervention group|Reflexology was applied to the intervention group during the procedure for 45 minutes.
11043684|NCT04473287|No Intervention|control group|Reflexology was not applied to the control group during the procedure. The control group received standard care and treatment.
11043685|NCT04473274|Experimental|Pioglitazone group|Participants will receive pioglitazone 15mg to 30mg daily oral or enteral during hospitalization for up to 30 days in addition to standard of care
11043686|NCT04473274|No Intervention|Matching cohort group|Participants will standard of care
11043687|NCT04473261|Experimental|Iodine Complex (Capsule form)|Renessans (Iodine Complex) capsule (200mg) will be given three times a day
11043688|NCT04473261|Experimental|Iodine Complex (Syrup form)|Renessans (Iodine Complex) syrup form (40ml) will be given three times a day
11043689|NCT04473261|Placebo Comparator|Standard Care Alone|Placebo as empty capsule.
11043690|NCT04473248|Experimental|Method 1- Nasopharyngeal Swab in transfer liquid|A nasopharyngeal swab will inoculate a proprietary solution which will be transferred to the Spartan COVID-19 System for analysis
11043691|NCT04473248|Experimental|Method 2- Dipping of specialized swab in VTM|A nasopharyngeal swab will inoculate VTM solution. A modified traditional Spartan Swab will be dipped into the inoculated VTM solution and then transferred to the Spartan COVID-19 System for analysis.
11043692|NCT04473248|Experimental|Method 3: Direct input of VTM|Using the VTM from Method 2, pipette 10uL of VTM, inoculated with sample, into the Spartan COVID-19 System for analysis.
11043693|NCT04473248|Experimental|Method 4: Collection of nasal sample.|Using a modified tip of the Spartan swab, a nasal sample will be taken from the patient and directly placed into the Spartan COVID-19 System for analysis.
11043694|NCT04473235|Experimental|Literacy training|The basic-literacy training will be given for two hours/day for four days/week for 6 months. At baseline, participants will be randomized into four classes of 30. An expert in adult education will oversee the classes and meet the teachers periodically, and each class will count with a certified and experienced lead teacher and teacher aid. The intervention group will receive literacy training based on analytical and phonemic methods for enabling reading and writing
11043695|NCT04473235|Active Comparator|Non-literacy training|The comparator group will have access to non-literacy classes offered at the adult school, including geography, history, informatics, and sciences, but no literacy-training, for two hours/day for four days/week for 6 months. After 6 months, the groups switch, so the comparator receives the specific reading and writing training, and the intervention group receives the lessons on other themes.
11043696|NCT04473222|Experimental|Sleep Well! Intervention|Participants in this condition will begin the Sleep Well! intervention after initiating baseline, daily diary, and actigraph procedures. Sleep Well! will be provided over approximately 6-8 weeks and will include 3 sessions. Intervention sessions will typically last about an hour, but session length may vary.
11043697|NCT04473222|Other|Enhanced Usual Care|The enhanced usual care condition will occur between 6 and 8 weeks. At randomization to this condition, participants will be provided with an evidence-based sleep guidelines for young children from the CHOP Parent Family Education manual. Participants in this condition will also be able to consult with their primary care physician for management of child sleep. Consistent with usual care in the CHOP system, the primary care physician may manage the sleep concern or choose to make a referral to the CHOP sleep center or to other behavioral health services internal or external to the CHOP system. Of note, the CHOP Parent Family Education handouts provide contact information for the CHOP Sleep Center and direct readers to follow-up with their primary care provider for further guidance.
11043698|NCT04473209|Active Comparator|diabetic group|diabetic patients with chronic periodontitis
11043699|NCT04473209|Active Comparator|non-diabetic group|non diabetic patients with chronic periodontitis
11043700|NCT04473196|Active Comparator|Weightbearing|Immediate weightbearing after surgery
11043701|NCT04473196|Active Comparator|Non weightbearing|nonweightbearing x 6 weeks post surgery
11043702|NCT04473183||General Healthy Population|Participants in this group are part of the general healthy population of adults 18 years-of-age and older, not known to be exposed to the virus as reported by potential participants and who have not sought medical help in the previous 4 months.
11043703|NCT04473183||Medical School Residents|Participants in this group are medical school residents.
11043704|NCT04473183||Individuals who are HIV positive|Participants in this group are HIV positive.
11043705|NCT04473170|Experimental|Group A|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
11043706|NCT04473170|Active Comparator|Group B|COVID-19 Standard care.
11043707|NCT04473144|No Intervention|Control|Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery.
11043708|NCT04473144|Sham Comparator|Ulistin|"In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
~Anesthesia induction and maintenance and postoperative recovery management were performed according to the standard anesthesia protocol for off pump coronary artery bypass surgery."
11043709|NCT04473131||COVID-19 positive|"Inclusion criteria:
~Male or female aged over 18 years
~Admitted patients to ICU with a suspicious COVID19 infection
~Tested positive for SARS-CoV-2
~Exclusion criteria:
~Burn and trauma
~Any immunological diseases, or immunosuppressive medications
~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)
~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
11044167|NCT04470050|Experimental|Cohort 4- 120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
11043710|NCT04473131||COVID-19 negative|"Inclusion criteria:
~Male or female aged over 18 years
~Admitted patients to ICU
~Tested negative for SARS-CoV-2
~Exclusion criteria:
~Burn and trauma
~Any immunological diseases, or immunosuppressive medications
~Other immune-related conditions (cancer, hematological malignancies, bone marrow diseases or transplant)
~Sample collection time points: 4 to 5 (day 1-3, day 7, day 14, day 21, discharge day from ICU -between day 30-60- if possible)"
11043711|NCT04473131||Heathy volunteers|"Inclusion criteria:
~Male or female aged over 18 years
~Normal clinical examination
~Exclusion criteria:
~Person with an infectious syndrome during the last 90 days
~Extreme physical stress within the last week
~Person receiving within the last 90 days, a treatment based on: antivirals; antibiotics; antiparasitics; antifungals; non-steroidal anti-inflammatory drugs; immunosuppressive therapy; corticosteroids; therapeutic antibodies; chemotherapy
~Person with history of: innate or acquired immune deficiency; hematological disease; solid tumor; severe chronic disease; surgery or hospitalization within the last 2 years; pregnancy within the last year; participation to a phase I clinical assay during the last year; participation to a phase I clinical assay during the last year; pregnant or breastfeeding women; a person with restricted liberty or under legal protection
~Sample collection time points: 1 (day of blood sample donation)"
11043712|NCT04473118||Healthcare workers|All healthcare workers exposed directly or not to suspected or infected COVID-19 patients such as nurse; paramedic; senior physician; resident/ trainee physician; respiratory therapist; perfusionist; physiotherapist; dietitian; technician lab; technician imaging; pharmacist; occupational therapist; speech therapist
11043713|NCT04473079|Experimental|Experimental group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus probiotic formulation (commercially-available as Lacidofil) for 12 weeks.
11043714|NCT04473079|Placebo Comparator|Placebo group|These participants will receive the standard treatment for H. pylori eradication (proton-pump inhibitor and antibiotics) plus placebo for 12 weeks.
11043715|NCT04473066||Adenotonsillectomy (AT)|Children diagnosed with moderate-to-severe OSA (OAHI ≥3/h) and tonsillar hypertrophy (tonsil grade ≥2) at the age of 5-12 years old and underwent AT since 2012.
11043716|NCT04473066||Refused AT|Children diagnosed with moderate-to-severe OSA and tonsillar hypertrophy but refused AT in the same period.
11043717|NCT04473066||Normal control|Children reported to have no habitual snoring (less than 3 nights per week) and confirmed to have no OSA (OAHI <1/h) by overnight sleep study in the same period.
11043718|NCT04473053|Experimental|Nafamostat|It is intended that the licensed dose (0.2mg/kg/hr) in Japan will be used. Patients randomised to Nafamostat will receive a continuous intravenous infusion at 0.2 mg/kg/hr for 7 days. If a participant is discharged from hospital or can no longer receive this treatment, the treatment will be stopped.
11043719|NCT04473053|Experimental|TD139|"Patients will inhale 5mg x 2 (10 mg) twice daily for the first 48 hrs and then subsequently 5mg x 2 (10 mg) once daily for the remaining 12 days. Unless a participant is discharged from hospital or can no longer use an inhaler - in which case treatment will be stopped at such time.
~CE marked inhalers will be provided by the Manufacturer. All patients will receive guidance on how to use the inhaler by an appropriately trained member of the research team. Two individual inhalers will be used by each patient over the course of the 14 day study period (each inhaler will be used by one patient for 7 days) and will be thoroughly cleaned with an antiseptic wipe before and after each use."
11043720|NCT04473053|Active Comparator|Standard of Care|All treatment arms will be compared to the Standard of Care arm.
11043721|NCT04473027||Patients with advanced melanoma|Patients receiving anti-PD-1 monotherapy (Nivolumab or Pembrolizumab) in the first-line setting
11043722|NCT04473014||Positive Mood|This group will be exposed to a positive mood induction prior to heat pain.
11043723|NCT04473014||Negative Mood|This group will be exposed to a negative mood induction prior to heat pain.
11043724|NCT04473014||Neutral Mood|This group will be exposed to a neutral mood induction prior to heat pain.
11043725|NCT04473001||Surgical patients|Adult patients admitted for major abdominal-, orthopedic or arterial vascular surgery.
11043726|NCT04472988|Experimental|Eye Movement Desensitization and Reprocessing|"30 participants will be randomly allocated to the EMDR group. They will receive a 90 minutes session of EMDR each week for twelve weeks. The sessions will be conducted by clinicians or psychotherapists specialized in EMDR, and the participants will be randomly allocated to them.
~EMDR is a structured, goal-oriented, short-term intervention organized around traumatic or stressful memories. This method was discovered in 1981 by F. Shapiro and represented an evidence-based treatment, one of the two first-line trauma treatment recommended for use with adults (NICE, 2005; World Health Organization, 2013). EMDR proved effective by hundreds of researches and has also been shown to be useful in alleviating physical symptoms such as pain or increased autonomic activity. But to our knowledge, research on EMDR efficacy in the treatment of autoimmune thyroiditis has not been previously reported."
11043727|NCT04472988|Placebo Comparator|Placebo|30 participants will be randomized to the placebo group. The placebo goup will receive an intervention that does not include working on past traumatic memories, it will be more focused on present and future.
11043728|NCT04472988|Active Comparator|Treatment as Usual|30 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
11043729|NCT04472975||Multiple sclerosis (MS) cohort|Individuals with multiple sclerosis without any exposure to disease-mofidying drugs (DMDs) and with exposure to one or more DMDs.
11043730|NCT04472962|Active Comparator|Low-carbohydrate-high-protein pre-exercise meal|
11043731|NCT04472962|Active Comparator|High-carbohydrate-low-protein pre-exercise meal|
11043732|NCT04472949|Experimental|Durvalumab & thoratic radiotherapy|"Patients will start with an induction phase (part 1). Patients with CR; PR or SD after the induction phase, will transfer to the maintenance phase (part 2). Patients with PD after the induction phase will transfer to the follow-up phase.
~Induction phase (part 1):
~Patients will receive durvalumab in combination with carboplatin and etoposide for 4 cycles of 21 days:
~Maintenance phase (part 2):
~Patients will receive durvalumab treatment up to PD or max. 2 years, i.e. 26 maintenance cycles, in combination with tRT:
~Follow up phase:
~Patients will be followed up for 24 months, every 8 weeks."
11043733|NCT04472936|Active Comparator|Group A|Double venous femoral access will be obtained. A duodecapolar catheter placed around tricuspid annulus will be used to prove isthmus block after CTI ablation.
11044168|NCT04470050|Experimental|Cohort 5- 180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
11043734|NCT04472936|Experimental|Group B|Ablation will be performed similar as described in the Group A. After the ablation line is over, PRI on the surface ECG will be used to prove isthmus block after CTI ablation.
11043735|NCT04472923|Active Comparator|Control group|Patients belonging to the control group received conventional physical therapy program in the form of diet and Kegel exercises.
11043736|NCT04472923|Experimental|Study group|Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training
11043737|NCT04472910|Experimental|Neo-adjuvant mFFX|Neo-adjuvant mFFX up to 6 cycles, surgery, adjuvant chemotherapy for up tp 6 cycles, follow up
11043738|NCT04472897|Experimental|Part A: Participants receiving GSK2556286|Participants will be randomized to receive one of the ascending doses of GSK2556286 in any of the 8 cohorts (Cohort 1A to 8A). In each dosing cohort, 6 participants will receive a single oral dose of GSK2556286 on Day 1 under fasting conditions (Cohort 1A to 6A) and under fed conditions (Cohort 7A and 8A). The starting dose in Part A will be 25 milligrams (mg) and no dose escalation to the next dose will be higher than 3-folds. One cohort (Cohort 7A) will investigate the effect of food administration (high fat meal) on safety, tolerability and PK after a single dose of GSK2556286. Based on emerging data, a second food effect cohort (Cohort 8A) may also be included using a higher dose of GSK2556286.
11043739|NCT04472897|Placebo Comparator|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 8 cohorts (Cohort 1A to 8A). In each dosing cohort, 2 participants will receive a single oral dose of matching placebo on Day 1 under fasting conditions (Cohort 1A to 6A) and under fed conditions (Cohort 7A and 8A).
11043740|NCT04472897|Experimental|Part B: Participants receiving GSK2556286|Participants will be randomized to receive one of the multiple-ascending doses of GSK2556286 in any of the 4 cohorts (Cohort 1B to 4B). In each dosing cohort, 6 participants will receive a single oral dose of GSK2556286 on Day 1 up to 14 days under either fasting or fed conditions, dependent on the results from Part A. Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B.
11043741|NCT04472897|Placebo Comparator|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts (Cohort 1B to 4B). In each dosing cohort, 2 participants will receive a single oral dose of matching placebo on Day 1 up to 14 days under either fasting or fed conditions, dependent on the results from Part A.
11043742|NCT04472884|Experimental|mWACh-PrEP|
11043743|NCT04472884|Other|Standard of Care|
11043744|NCT04472871||patients with atrial fibrillation and heart failure|Patients with cardiac function ejection fraction less than 35% and underwent Left atrial appendage closure in the period covered by the study
11043745|NCT04472871||patients with atrial fibrillation without heart failure|Patients with cardiac function ejection fraction more than 35% and underwent Left atrial appendage closure in the period covered by the study
11043746|NCT04472858|Experimental|Phase I arm|advanced solid tumors
11043747|NCT04472858|Experimental|Phase II arm|Subjects with tumor of specific types. Arm A: Patients with hepatocellular carcinoma(HCC) ; Arm B: Patients with head and neck squamous cell carcinoma(HNSCC); Arm C: Patients with endometrial carcinoma.
11043748|NCT04472845|Experimental|1 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be of 26Gy in 5 fractions over 1 week in the study arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 34Gy.Supraclavicular fossa(SCF) and axilla level III will be treated in patients with T3-4 disease with lymphovascular invasion, grade 3 or N2 disease and T3-4 disease treated with neoadjuvant chemotherapy after adequate axillary dissection. Level I and II axilla will only be irradiated in patients with inadequate axillary dissection(<10 lymph nodes). Internal mammary node (IMNs) radiation will be done in T3-4 central and inner quadrant lesions and patients with N2 disease. IMNs will be irradiated with a separate single field. The first five intercostal spaces will be included in the IMN target volume.
11043749|NCT04472845|Active Comparator|3 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be 40Gy in 15 fractions over 3 weeks in the control arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 48 Gy.
11043750|NCT04472832|Placebo Comparator|Treatment A|Participants will receive a single oral dose of mitapivat-matching placebo under fasted conditions on Day 1 of each of 4 periods.
11043751|NCT04472832|Experimental|Treatment B|Participants will receive a single oral dose of mitapivat 100 milligrams (mg) and placebo under fasted conditions on Day 1 of each of 4 periods.
11043752|NCT04472832|Experimental|Treatment C|Participants will receive a single oral dose of mitapivat 100 mg and placebo under high-fat meal conditions on Day 1 of each of 4 periods.
11043753|NCT04472832|Experimental|Treatment D|Participants will receive a single oral dose of mitapivat 300 mg under fasted conditions on Day 1 of each of 4 periods.
11043754|NCT04472819|Experimental|SHR2285 Part 1A|Participant received one of 5 dose levels of SHR2285 tablet as single-dose oral administration
11043755|NCT04472819|Placebo Comparator|Placebo Part 1A|Single ascending doses of placebo orally
11043756|NCT04472819|Experimental|SHR2285 Part 1B|Participant received one dose of SHR2285 tablet as single-dose oral administration
11043757|NCT04472819|Placebo Comparator|Placebo Part 1B|Single doses of placebo orally
11043758|NCT04472819|Experimental|SHR2285 Part 2|Participant received one of 3 dose levels of SHR2285 tablet as multi-dose oral administration
11043759|NCT04472819|Placebo Comparator|Placebo Part 2|Multiple ascending doses of placebo orally
11043760|NCT04472806|Experimental|chemotherapy+Endostar+Toripalimab(JS001)|
11043761|NCT04472793||Full-Time CCHMC Employees|
11043762|NCT04472780|Experimental|HBOT Group|will benefit from HBOT
11043763|NCT04472780|No Intervention|Control group|will benefit from the conventional treatment
11043764|NCT04472767|Experimental|Cabozantinib with Ipilimumab/Nivolumab and TACE|"Subjects receive Cabozantinib 40 mg daily on days 1-28 of a 28 day cycle, this is to be started 7-14 days after the last TACE procedure.
~Nivolumab 480 mg IV on day 1 of a 28 day cycle (cycle 2 and beyond), this is to be started 7-14 days after the last TACE procedure.
~Nivolumab: 3mg/kg IV on day 1 of a 21 day cycle x 1 dose.
~Ipilimumab: 1 mg/kg on day 1 of a 21 day cycle x 1 dose
~TACE: Within 3-4 weeks of cycle 1 day 1; may be done every 2 weeks up to 3 times (6-8 weeks total)"
11043765|NCT04472754||A(healthy control group)|patients who did not have ischemic stroke and whose TCM constitution was dialectically peaceful;
11043766|NCT04472754||B|Patients with no ischemic stroke and whose TCM constitution was dialectical with damp phlegm constitution
11043767|NCT04472754||C|patients with ischemic stroke diagnosed with phlegm dampness syndrome
11043768|NCT04472754||D|patients with ischemic stroke diagnosed as non-phlegm dampness syndrome
11043769|NCT04472741|Other|FUSE|wide angle colonoscope
11043770|NCT04472741|Other|HD Pentax i10 colonoscopes|SFV instrument
11043771|NCT04472741|Other|Endocuff|Cuff on SFV
11043772|NCT04472728|Experimental|BIO101|BIO101 350 mg bid
11043773|NCT04472728|Placebo Comparator|Placebo|Placebo
11043774|NCT04472715|Experimental|follicular unit extraction|extraction of hair follicle unit from donar area and tranplant it into recepient bald area
11043775|NCT04472715|Experimental|foolicular unit extraction and platelet rich plasma|the same procedure mentioned above coupled with seeion pf plateley rich plasma before and after transplantation
11043776|NCT04472702|Experimental|Subjects with knee OA using ultrasound for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to ultrasound (N=45) cRFA treatment arm.
11043777|NCT04472702|Experimental|Subjects with knee OA using fluoroscopy for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to fluoroscopic (N=45) cRFA treatment arm.
11043778|NCT04472689|Active Comparator|Lidocaine group|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
11043779|NCT04472689|Placebo Comparator|Control group|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation.
11043780|NCT04472676|Experimental|LY3473329 (Part A)|LY3473329 administered orally.
11043781|NCT04472676|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
11043782|NCT04472676|Experimental|LY3473329 (Part B)|LY3473329 administered orally.
11043783|NCT04472676|Experimental|Placebo (Part B)|Placebo administered orally.
11043784|NCT04472663||Cohort 1|Retrospective Long-term Chart Review
11043785|NCT04472663||Cohort 2|Prospective-Retrospective Chart Review and Humanistic Burden
11043786|NCT04472650|Experimental|Sitravatinib Free Base + Malate Salt|"Period 1: sitravatinib free base capsule on Day 1 of the 15 day cycle
~Period 2: sitravatinib malate salt capsule on Day 1 of the 15 day cycle"
11043787|NCT04472650|Experimental|Sitravatinib Malate Salt + Free Base|"Period 1: sitravatinib malate salt capsule on Day 1 of the 15 day cycle
~Period 2: sitravatinib free base capsule on Day 1 of the 15 day cycle"
11043788|NCT04472637|Experimental|Atorvastatin|They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.
11043789|NCT04472637|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 24 weeks.
11043790|NCT04472624|Experimental|Fasting arm|Participants will be fasting during 72 hours
11043791|NCT04472624|Experimental|Diet arm|Participants will be using ketogenic diet for 14 days
11043792|NCT04472611|Experimental|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
11043793|NCT04472611|No Intervention|Standard of care (SOC)|Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization
11043794|NCT04472598|Experimental|Navitoclax + Ruxolitinib|Participants will receive Navitoclax in combination with Ruxolitinib
11043795|NCT04472598|Active Comparator|Placebo for Navitoclax + Ruxolitinib|Participants will receive placebo for Navitoclax and Ruxolitinib
11043796|NCT04472585|Active Comparator|Ivermectin|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly plus standard care
11043797|NCT04472585|Active Comparator|Ivermectin with Nigella Sativa|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 80mg/Kg/day Nigella Sativa plus standard care
11043798|NCT04472585|Active Comparator|Ivermectin with Zinc|Sub-cutaneous injection ivermectin 200ug/kg body weight once every 48 hourly with 20mg Zinc Sulphate 8 hourly plus standard care
11043799|NCT04472585|Placebo Comparator|Placebo|Placebo drug plus standard care
11043800|NCT04472559|Experimental|Self-acupressure|
11043801|NCT04472559|No Intervention|Control|
11043802|NCT04472546|Other|Control subject group|"Divided in 5 subgroups :
~A': associated to acne of the face subgroup
~B' : associated to atopic dermatitis of the upper limb subgroup
~C' : associated to vulgar plaque psoriasis subgroup
~D' : associated to telangiectasic erythrocouperosis papule of the face (rosacea) subgroup
~E' : associated to seborrheic dermatitis of scalp subgroup"
11043803|NCT04472546|Other|Subject group with dermatitis|"Divided in 5 subgroups :
~A : acne of the face subgroup
~B : Atopic dermatitis of the upper limb subgroup
~C : Vulgar plaque psoriasis subgroup
~D : Telangiectasic erythrocouperosis papule of the face (rosacea) subgroup
~E : Seborrheic dermatitis of scalp subgroup"
11043804|NCT04472533||CTEPH|Patients diagnosed with chronic thromboembolic pulmonary hypertension
11043805|NCT04472533||CTED|Patients diagnosed with chronic thromboembolic disease but no evidence of pulmonary hypertension
11043806|NCT04472533||Control|Healthy control subjects
11043807|NCT04472520|Experimental|Subject getting an ECG|Subjects getting an ECG will have AliveCore tracings obtained in 3 configurations; between right hand and left hand, between left hand and left lower leg (thigh, calf, and foot) and between right hand and left lower leg (thigh, calf, and foot).These configurations will be obtained with the participant lying in bed and in a sitting position.
11043808|NCT04472494|Experimental|Abatacept + Standard of care|
11043809|NCT04472494|Placebo Comparator|Placebo infusion + Standard of care|
11043810|NCT04472481|Other|group II|50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months
11043811|NCT04472468|Experimental|Treatment (pericardiotomy)|"Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.
~An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.
~Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.
~Standard pericardiocentesis with prolonged drainage is performed afterwards.
~Pericardial drain is removed when output is less than 100cc/day"
11043812|NCT04472468|No Intervention|Control (standard pericardiocentesis)|"Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.
~Pericardial drain is removed when output is less than 100cc/day"
11043813|NCT04472455||Screen Negative Group|All women who screen negative at Visit 1.
11043814|NCT04472455||Screen Positive Group|All women who screened positive at Visit 1 and were invited to Visit 2
11043815|NCT04472455||10% Of Screen Negative Group|10% of women who screened negative at Visit 1 and were invited to Visit 2
11043816|NCT04472442|Experimental|High Intensity Training with Intermittent Hypoxia|The primary goal will be provide acute intermittent hypoxia (9% PO2; 1 min on 1 min off) prior to stepping training while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
11043817|NCT04472442|Sham Comparator|High Intensity Training with Sham Hypoxia|The primary goal will be provide sham intermittent hypoxia (20% PO2) prior to performing continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
11043818|NCT04472429|Placebo Comparator|Group A : carboplatin+paclitaxel+placebo|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle
11043819|NCT04472429|Experimental|Group B : carboplatin+paclitaxel+retifanlimab|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle
11043820|NCT04472416|No Intervention|Standardized analgesic protocol alone|Abdominal VAC dressing change using an standardized analgesic protocol alone.
11043821|NCT04472416|Experimental|VRD + standardized analgesic protocol|Abdominal VAC dressing change using standardized analgesic protocol + virtual reality device
11043822|NCT04472403||PFLL Group|"Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/m2) on day 1 and day 28, every 60 days.
~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
11043823|NCT04472403||Non-PFLL Group|"Patients were treated with other platinum-based chemotherapy every 21 days including:
~PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.
~GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1.
~TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1.
~TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5.
~Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed."
11043824|NCT04472390||Tapering|TNF-α inhibitors
11043825|NCT04472390||Discontinuing|TNF-α inhibitors
11043826|NCT04472377|Experimental|study population|"We enroll a total of 1,200 women, as follows,
~120 cases with no history or current cervical intraepithelial lesion or malignancy.
~180 cases with a history of abnormal Pap test including ASCUS, CIN1, or atypical glandular cell.
~240 cases with a history of atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.
~240 cases with current ASCUS, CIN1, or atypical glandular cell.
~420 cases with current abnormal Pap test as atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma."
11043827|NCT04472364|Experimental|HemoPill|All participants will receive the blood detection capsule HemoPill Acute ®.
11043828|NCT04472351|Experimental|ASCEND-I|Computerized WM training with Rehacom will be implemented in daily 30-minute sessions that are scheduled prior to the participant's occupational therapy (OT) session as an adjunct to routine rehabilitation. Tasks are tailored to the participant's current ability level and are adaptive to performance changes. During these sessions, the study staff member will use guided questioning to help the participant anticipate challenges, reflect on performance, and link computerized exercises to the Multicontext sessions. The Multicontext treatment sessions will be delivered within the participant's OT session by an OT. The Multicontext approach helps individuals to self-discover WM-related error patterns and learn to anticipate WM performance challenges through repeated practice using functionally-relevant activities. The OT conducts guided questioning pre- and post-task to help the participant anticipate challenges and self-discover WM strategies.
11043829|NCT04472351|No Intervention|Enhanced Usual Care|The control condition will account for the time spent with rehabilitation therapists and study staff and provide more general cognitive stimulation. The control group will receive usual, standard of care occupational therapy during OT by inpatient rehabilitation staff who are not trained in the Multicontext approach. The standard OT session often focuses on cognition in a non-standardized and non-targeted manner without the targeting of WM and guided self-discovery of the Multicontext approach. To control for the cognitive training element of ASCEND, individuals randomized to the control condition will meet with a study staff member for 30 minutes of general cognitive stimulation that includes word-searches, crossword puzzles, and/or jigsaw puzzles.
11043857|NCT04472130||Multiple System Atrophy|100 patients with Multiple System Atrophy based on Second consensus statement on the diagnosis of MSA
11058437|NCT04368728|Placebo Comparator|Placebo, ≥12 years of age|
11043830|NCT04472338||Screening (biospecimen collection)|Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.
11043831|NCT04472325||Atypical Parkinson's Disease patients|This group consists of patients includes 35 patients with Progressive Supranuclear Paralysis (PSP), 35 patients with Multiple System Atrophy (MSA), and 35 patients with Cortico-Basal Degeneration (CBD).
11043832|NCT04472325||Idiopathic Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD)
11043833|NCT04472325||Healthy volunteers|"The 96 healthy volunteers should meet the following criteria:
~Between 50-80 years old
~Right-handed
~MMSE score greater than or equal to 26
~Able to understand study requirements and give informed consent"
11043834|NCT04472312||Cirrhotic patients undergoing a liver transplantation|The investigators aim to conduct a prospective observational, non-interventional study including all cirrhotic patients undergoing a liver transplantation with a planned use of vasopressin during the surgery.
11043835|NCT04472299|Experimental|Experimental|Participants in this group will receive the intervention.
11043836|NCT04472299|No Intervention|Control|Participants in this group will receive no intervention.
11043837|NCT04472286||Pediatric Cancer Survivors|Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.
11043838|NCT04472273||high-flow nasal cannula group|Group 1
11043839|NCT04472273||classic nasal cannula group|Group 2
11043840|NCT04472260|Other|Sequence 1: PP->PP->V->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.
~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
11043841|NCT04472260|Other|Sequence 2: PP->V->V->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.
~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
11043842|NCT04472260|Other|Sequence 3: V->PP->PP->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.
~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
11043843|NCT04472260|Other|Saquence 4: V->V->PP->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.
~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
11043844|NCT04472247||Critical Care Patients|Critical care patients requiring mechanical ventilation via an endotracheal tube, with invasive hemodynamic monitoring via an arterial line, and receiving intravenous sedation by continuous infusion (propofol, midazolam).
11043845|NCT04472234|Other|BPA level|BPA (Bisfenol A) in urine, blood and follicle fluid samples
11043846|NCT04472221|Experimental|Vascular Access Venous Hypertension|Swollen upper limb with synthetic Arteriovenous graft
11043847|NCT04472208|Experimental|Ambulatory Monitoring Solution|The evaluable device is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
11043848|NCT04472195|Experimental|Experimental|The experimental group will review a pre-induction airway management plan for their upcoming case and undergo a scripted 10-minute RCDP session with an airway coach within 1 hour of patient intubation. The intubation approach (DL vs. video assisted DL) will be chosen by the primary case attending and communicated to the airway coach to simulate the planned laryngoscopy attempt. The experimental group will then proceed with their scheduled case with a member of the research team observing the laryngoscopy attempt(s) to capture data.
11043849|NCT04472195|No Intervention|Control|The trainees in the control group will have no interventions by the research team, only observation of the intubation and documentation of the same details.
11043850|NCT04472182|Experimental|Fluoride varnish with xylitol coated calcium and phosphate|
11043851|NCT04472182|Active Comparator|Conventional Fluoride varnish|
11043852|NCT04472169||Severe haemophila A patients with or without inhibitors|
11043853|NCT04472156|Experimental|Transfer of mosaic embryo|Women will have a mosaic embryo transferred to their uterus after in vitro fertilization (IVF) with pre implantation genetic testing completed at Colorado Center for Reproductive Medicine.
11043854|NCT04472143|Experimental|Granisetron Transdermal Delivery System|The patch will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days
11043855|NCT04472130||Early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset less than 5 years
11043856|NCT04472130||Non-early idiopathic Parkinson's Disease|200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset more than 5 years
11058438|NCT04368728|Experimental|High dose, 18-55 years of age (2 doses)|
11043858|NCT04472130||Progressive Supranuclear Palsy|100 patients with Progressive Supranuclear Palsy based on Clinical research criteria for diagnosis of PSP
11043859|NCT04472130||Alzheimer's Disease|100 patients with Alzheimer's Disease by Diagnostic and Statistical Manual of Mental disorder, Fifth edition (DSM-5) criteria
11043860|NCT04472130||Motor Neuron Disease|200 patients with Motor Neuron Diseases by revised El Escorial criteria or Awaji ALS criteria
11043861|NCT04472130||Small Vessel Disease|200 patients with cerebral Small Vessel Diseases
11043862|NCT04472130||Frontotemporal Dementia|100 patients with Frontotemporal Dementia by International consensus criteria for behavioral variant FTD (FTDC) or Primary Progressive Aphasia by Gorno-Tempini
11043863|NCT04472130||Healthy Control|200 age and sex matched healthy controls
11043864|NCT04472117|Experimental|Usual care and usual care plus video|Phase I: A sample of patients in phase I will complete a qualitative interview prior to or after surgery. Twenty-five patients (15 pre-operatively and a separate 10 post-operatively) will be selected to participate in an in-person/phone interview. Phase II: A separate group of women will compose phase II. All patients (N = 100) in phase II will complete discrete-choice surveys and will then be randomized to receive either standard preoperative counseling or standard preoperative counseling with the addition of an educational video,
11043865|NCT04472104|Active Comparator|MBCT-S|Mindfulness-Based Cognitive Therapy for sexuality (MBCT-S) which incorporates several empirically supported therapeutic approaches, integrating elements of education, mindfulness meditation skills, and sex therapy.
11043866|NCT04472104|Active Comparator|SexEd|Sexuality education on sexual desire, sexual distress, and sexual pain.
11043867|NCT04472091|Experimental|Genicular artery embolization|"Participants will undergo the genicular artery embolization (GAE) procedure for the treatment of moderate to severe knee osteoarthritis. A total of 30 patients will be enrolled in the single treatment arm of the study.
~The study will involve a screening period in which patient eligibility is determined. Once eligibility is confirmed, patients will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ). Following treatment, patients will undergo follow-up at 1, 6, 12, and 24 months post GAE."
11043868|NCT04472065|Active Comparator|Subjects receiving Probiotic Dietary Supplement|
11043869|NCT04472065|Placebo Comparator|Subjects receiving Placebo|
11043870|NCT04472052||Appendectomy|Patients who required appendectomy for suspected acute appendicitis
11043871|NCT04472039||Studygroup|Retrospective analysis of OCT, IOP and distance corrected visual acuity from the patients history.
11043872|NCT04472026|Experimental|Intervention group|Counseling using the electronic conversation aid
11043873|NCT04472000|Experimental|Vitamin C|Patients who are assigned to the experimental treatment group will be given extended release capsules with 500 mg of ascorbic acid orally two times daily, packed in PET/PP-bottles identical as used for the licenced product.
11043874|NCT04472000|Placebo Comparator|Placebo|The control intervention of this study consists of treatment with no active substance (placebo) but in the same schedule as the experimental treatment (verum).
11043875|NCT04471987|Experimental|Treatment|"The study will take place in two stages:
~In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.
~Following successful identification of the RD, the study will proceed with a dose expansion part and 40 patients will be treated at the RD dose level."
11043876|NCT04471974|Experimental|Safety Cohort|Patients receive 96mg pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11043877|NCT04471974|Experimental|Cohort A: Transdifferentiated mCRPC|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11043878|NCT04471974|Experimental|Cohort B: mCRPC without evidence of transdifferentiation|Patients receive pembrolizumab IV over 30 minutes on day 1, BET bromodomain inhibitor ZEN-3694 PO QD and enzalutamide PO QD on days 1-21. Patients not on enzalutamide prior to study enrollment or have previously discontinued enzalutamide receive BET bromodomain inhibitor ZEN-3694 beginning on day 1 of cycle 2. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11043879|NCT04471961|Experimental|Children with cancer (Proband) with theirs parents|
11043880|NCT04471948|Experimental|Fractional picosecond laser 1,064 nm laser|1 arm The subjects with enlarged pores were treated with fractional picosecond laser 1,064 nm laser
11043881|NCT04471935|Other|At home Speech Hero therapy|
11043882|NCT04471922|Experimental|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
~"
11043883|NCT04471922|Placebo Comparator|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
11043884|NCT04471922|Active Comparator|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
11043885|NCT04471909|Experimental|Chronic Dissection|
11043886|NCT04471909|Experimental|Aneurysm|
11043887|NCT04471909|Experimental|Penetrating Aortic Ulcer and/or Intramural Hematoma|
11043888|NCT04471896|Experimental|Treatment Arm|Participants will receive an infrared therapy device for use at home for 60 days. Participants will use the device every day for 10-20 minutes during the intervention period.
11043889|NCT04471857|Experimental|Hypnosis|A brief session of hypnosis just before child starts with anorectal manometry
11043890|NCT04471857|No Intervention|Control|No hypnosis session, standard care
11043891|NCT04471844|Experimental|Optune® + RT + TMZ for 6 weeks|Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment could be maintained up to 24 months without tumor progression.
11043892|NCT04471844|Active Comparator|RT +TMZ for 6 weeks|RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment could be maintained up to 24 months without tumor progression.
11043893|NCT04471831|Experimental|Stroke survivors with COVID19|The active intervention group
11043894|NCT04471831|Placebo Comparator|Non-stroke individuals with COVID19|Matching for age, sex and co-morbid status with the stroke survivors
11043895|NCT04471818|Experimental|Ketamine|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
11043896|NCT04471818|Placebo Comparator|Placebo|Patients allocated to the ketamine arm will receive 0.5 mg/kg of ketamine every week administered intravenously for 4 weeks.
11043897|NCT04471805|Sham Comparator|Women Sham 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
11043898|NCT04471805|Experimental|Women tDCS 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
11043899|NCT04471805|Sham Comparator|Women Sham 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (4 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
11043900|NCT04471805|Experimental|Women tDCS 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
11043901|NCT04471805|Sham Comparator|Men Sham 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
11043902|NCT04471805|Experimental|Men tDCS 2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
11043903|NCT04471805|Sham Comparator|Men Sham 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (4 mA) for the 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time.
11043904|NCT04471805|Experimental|Men tDCS 4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
11043905|NCT04471792|Experimental|Creatine monohydrate|Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.
11043906|NCT04471792|Placebo Comparator|Cellulose|These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.
11043907|NCT04471779|Experimental|Disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.
11043908|NCT04471779|No Intervention|Non-disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.
11043909|NCT04471766|Experimental|Certified cloth face mask plus preventive information|Certified cloth face mask
11043910|NCT04471766|Active Comparator|Information on COVID-19 prevention|Advice on how to prevent COVID-19 according to the government´ policy.
11043911|NCT04471753||Patients with disorders of consciousness|Patients with medical diagnosis of prolonged disorders of consciousness (≥28 days) were included in neurosurgery, neurology, and neurorehabilitation units.
11043912|NCT04471740|Experimental|Normal-pressure hydrocephalus only|Patients suffering from normal-pressure hydrocephalus with NO sleep apnea
11043913|NCT04471740|Active Comparator|Normal-pressure hydrocephalus with sleep apnea|Patients suffering from normal-pressure hydrocephalus with sleep apnea
11043914|NCT04471727|Experimental|Part 1 (Dose Escalation)|HPN328 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
11043915|NCT04471727|Experimental|Part 2 (Dose Expansion)|HPN328 is IV administered once weekly for about 1 hour at the recommended phase 2 dose (2) established in Part 1.
11043916|NCT04471714|Experimental|Control|Control participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
11043917|NCT04471714|Experimental|Spinal Cord Injury|Participants with a spinal cord injury will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
11043918|NCT04471688||patients|Preoperative patients needing transfusions
11043919|NCT04471675|Experimental|Experimental: solid tumors|Albumin-bound docetaxel by intravenous infusion.Patients receive albumin-bound docetaxel once every three weeks (a Cycle), starting at a dose of 50mg/m2.
11043920|NCT04471649||Experimental|Patient with rheumatoid arthritis using hydroxychloroquine as a part of their treatment regimen.
11043921|NCT04471649||Active Comparator|Patient with rheumatoid arthritis not using hydroxychloroquine as a part of their treatment regimen
11043922|NCT04471636|Experimental|Telemedicine Care|Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.
11043955|NCT04471428|Experimental|Atezolizumab + Cabozantinib|Participants will receive atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on days 1-21 of each cycle.
11043923|NCT04471636|No Intervention|Control|Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.
11043924|NCT04471623|Experimental|DeTAP Study App and Home Devices|Monitoring of OAC administration, OAC adherence, and clinical status through combined decentralized technologies
11043925|NCT04471610|No Intervention|Control group|Group A: Patients allocated to the control group will undergo the measurements at inclusion and discharge visit. The control group conduces to compare the NT-proBNP and HF medication changes under therapy monitoring with serial NT-proBNP measurements to the NT-proBNP and HF medication changes with sign and symptom guided HF therapy. The diagnostic and therapeutic decisions in the control Group and in the Intervention group will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal. At discharge, the same measurements as at the inclusion visit will be repeated in all patients to monitor the effects associated with the participation in this trial.
11043926|NCT04471610|Experimental|POC-available group|Group B:Patients allocated to the intervention group (POC-available group) will undergo serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day. The blood collection (10 ml of Lithium Heparin blood) for these tests will be done in the morning together with the regularly blood collection. The study team does the the analysis on the study devices. The result of the test will be provided directly to the responsible physician. Treatment changes are at the discretion of the responsible physician. The physician will be alerted by a phone call of a study member if the NT-proBNP hasn't decreased by 10% or more between two measurements. But no specific recommendations with regards to therapy will be provided by the investigator or his team. However, diagnostic and therapeutic decisions will be based on the current 2016 ESC guidelines on the diagnosis and therapy of HF as established at the KSBL Liestal.
11043927|NCT04471597|Placebo Comparator|Control group|patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.
11043928|NCT04471597|Active Comparator|bupivacaine group|patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.
11043929|NCT04471584|Active Comparator|Abbott Confirm Rx|All patients randomized to this group will be implanted Abbott Confirm RX
11043930|NCT04471584|Active Comparator|Medtronic Reveal LINQ|All patients randomized to this group will be implanted Medtronic Reveal LINQ
11043931|NCT04471584|Active Comparator|Biotronik Biomonitor|All patients randomized to this group will be implanted Biotronik Biomonitor
11043932|NCT04471571|Active Comparator|Resin infiltration group|Enamel lesions for this group will be treated only by resin infiltration.
11043933|NCT04471571|Experimental|Microabrasion + resin infiltration group|Enamel lesions for this group will be treated first by microabrasion followed by resin infiltration.
11043934|NCT04471558||Music group|A part of the care is realized with music.
11043935|NCT04471558||Control group|The entire care is realized without music.
11043936|NCT04471545|Experimental|Interventional group|Intervention arm: PECS II block with ropivacaine
11043937|NCT04471545|Placebo Comparator|Control group|Control arm: PECS II block with placebo (saline)
11043938|NCT04471532|Experimental|Behavior change intervention|A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
11043939|NCT04471532|No Intervention|Control|No attention
11043940|NCT04471519|Experimental|BBV152A - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
11043941|NCT04471519|Experimental|BBV152B - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
11043942|NCT04471519|Experimental|BBV152C - Phase I|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152C], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 14
11043943|NCT04471519|Active Comparator|Placebo - Phase I|0.5 mL of Placebo will be administered intramuscularly twice at Day 0 and Day 14.
11043944|NCT04471519|Experimental|BBV152A - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152A], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28.
11043945|NCT04471519|Experimental|BBV152B - Phase II|0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine [BBV152B], is a liquid vaccine administered intramuscularly twice at Day 0 and Day 28
11043946|NCT04471506|Other|study group will receive aerobic exercises and diet|The study group will receive aerobic exercises in addition to diet recommendations while . the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be70-80% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercises on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
11043947|NCT04471506|Other|diet recommendations|the control group will receive diet recommendations.he volunteers will follow diet recommendations for 12 weeks
11043948|NCT04471480|Experimental|group A，TCCA|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +anlotinib 10mg, PO, d1-14, q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab plus anlotinib for maintenance therapy until PD or intolerable toxicity
11043949|NCT04471480|Experimental|group B，TCC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab for maintenance therapy until PD or intolerable toxicity
11043950|NCT04471480|Other|group C，TC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w
11043951|NCT04471467||group F|Using tracheal tube fixation method （According to the needs of the surgery, the surgeon who did not participate in the trial）
11043952|NCT04471467||group N|No tracheal tube fixation （According to the needs of the surgery, the surgeon who did not participate in the trial）
11043953|NCT04471441|Experimental|CertiroBell Tablet|De novo liver transplant recipients will be randomized after liver transplant operation.
11043954|NCT04471441|Active Comparator|Mycophenolate mofetil Tablet/Capsule|De novo liver transplant recipients will be randomized after liver transplant operation.
11043957|NCT04471415|Experimental|Part 1|Single-agent dose escalation of DRP-104 to define the MTD (up to approximately 50 patients) starting at Dose Level 1 of 3.3 mg/m2
11043958|NCT04471415|Experimental|Part 2|"Cohort 1: Phase 1 single-agent safety expansion at the of DRP-104 in patients with advanced solid tumors (N=14 patients);
~Cohort 2: Phase 2a expansion at the of DRP-104 in patients with locally advanced or metastatic NSCLC whose tumors contain a KEAP1 mutation, NFE2L2 mutation and/or STK11 mutation (N=55 patients)
~Cohort 3: Phase 2a expansion at the MTD of DRP-104 in recurrent, unresectable or metastatic SCCHN (N=15-25 patients)."
11043959|NCT04471415|Experimental|Part 3|Dose escalation of DRP-104 at 1 dose level below declared MTD in combination with atezolizumab in patients with advanced solid tumors previously treated with an anti-PD-1, anti PD-L1, and/or anti-CTLA-4 antibody (up to approximately (N=12 patients).
11043960|NCT04471415|Experimental|Part 4|Dose expansion at the MTD of DRP-104 with atezolizumab (N=14 patients).
11043961|NCT04471402||All subjects recruited|"All subjects recruited will be given 3mcg/kg intranasal Precedex through an atomiser, divided equally between two nostrils. They will be observed and sedation score will be recorded every 5 minutes according to the University of Michigan Sedation Scale (UMSS). Pulse oximetry and Blood pressure cuff will be applied whenever they accept these monitoring.
~A buccal swab sample will be taken from all children and the identified genes will be analysed and compared between the different responders (fast, normal, slow or non-responders)."
11043962|NCT04471389||Hanzhong adolescent hypertension cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas was recruited in 1987. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
11043963|NCT04471389||Mei county adult salt-sensitive hypertension cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
11043964|NCT04471376|Active Comparator|Sugammadex group|
11043965|NCT04471376|No Intervention|control group|
11043966|NCT04471363||Cancer Specific Exercise Education|This subsample of participants will watch an audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
11043967|NCT04471363||Control|All participants will be asked to indicate their exercise knowledge, self-efficacy, beliefs and intentions.
11043968|NCT04471337|Experimental|Arm A: Moderately impaired renal function|Participants with moderately impaired renal function will receive multiple doses of BAY1817080.
11043969|NCT04471337|Experimental|Arm B: Normal renal function matched to Arm A|Participants with normal renal function matched to Arm A will receive multiple doses of BAY1817080.
11043970|NCT04471337|Experimental|Arm C: End stage renal disease on dialysis|Participants with ESRD requiring dialysis will receive single dose of BAY1817080.
11043971|NCT04471337|Experimental|Arm D: Normal renal function matched to Arm C|Participants with normal renal function matched to Arm C will receive single dose of BAY1817080.
11043972|NCT04471324|Experimental|EBUS cryo probe|Patients receive a transbronchial cryobiopsy using an eBUS cryo probe
11043973|NCT04471311|No Intervention|Primary closure of midline laparotomy|Primary closure of midline laparotomy
11043974|NCT04471311|Experimental|Sub-lay mesh supported closure|Sub-lay permanent mesh supported the closure
11043975|NCT04471298|Active Comparator|Active dosage group 1|Qishenyiqi dripping pills, 3.12g, oral, three times a day
11043976|NCT04471298|Active Comparator|Active dosage group 2|Qishenyiqi dripping pills, 4.68g, oral, three times a day
11043977|NCT04471298|Active Comparator|Active dosage group 3|Qishenyiqi dripping pills, 6.24g, oral, three times a day
11043978|NCT04471298|Placebo Comparator|Control dosage group 1|Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day
11043979|NCT04471298|Placebo Comparator|Control dosage group 2|Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day
11043980|NCT04471298|Placebo Comparator|Control dosage group 3|Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day
11043981|NCT04471285|Active Comparator|true acupuncture|patient will get treatment according to the point the will help the symphysiolysis according to the Alternative medicine
11043982|NCT04471285|Sham Comparator|Sham acupuncture|patient will get treatment according to the point the will NOT help the symphysiolysis according to the Alternative medicine
11043983|NCT04471272|Experimental|RFA using gradual RF energy delivery mode|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
11043984|NCT04471259||Patients' injured side|The Biodex, AOFAS, VAS were tested on the patients' injured side
11043985|NCT04471259||Patients' uninjured side|The Biodex, AOFAS, VAS were tested on the patients' uninjured side
11043986|NCT04471246|Experimental|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
11043987|NCT04471246|Active Comparator|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
11043988|NCT04471233|Experimental|Multimodal analgesia regimen including pregabalin|For the pregabalin group, patient will be provided with an oral preoperative pregabalin dose of 150mg on the day of surgery. Patient will continue pregabalin 75mg two times a day, for two weeks postoperatively. For both the intervention and control groups, the operative technique and additional perioperative analgesic modalities will follow a standard protocol
11043989|NCT04471233|Active Comparator|Multimodal analgesia regimen not including pregabalin|For the non-pregabalin group, patient will be undergo total knee arthroplasty with the same operative technique and additional perioperative analgesic modalities will follow a standard protocol
11043990|NCT04471220|Active Comparator|Low FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 10 L/min).
11043991|NCT04471220|Active Comparator|Low FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 40-50 L/min).
11043992|NCT04471220|Active Comparator|High FIO2 and low flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 10 L/min).
11043993|NCT04471220|Active Comparator|High FIO2 and high flow rate under HFNC|In this condition, patients have undergone 6MWT under the HFNC (FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 40-50 L/min).
11043994|NCT04471207|Experimental|Intelligent Biometrics - Prolonged Exposure (Therapist Guided)|In the therapist-guided group, Study Therapists will use actionable data during IVEs (e.g., HR, GSR) to modify the assignments in real time. Study Therapists will virtually accompany patients to three IVEs; after that Study Therapists will receive a system notification each time a patient completes an IVE, along with a summary report from that assignment (e.g., total time, x̅ and peak GSR).
11043995|NCT04471207|Active Comparator|Intelligent Biometrics - Prolonged Exposure (Record Only)|In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.
11043996|NCT04471194|Experimental|Self-Sampling Intervention|Participants in this group will receive cervical and colorectal cancer self-sampling kits, instructions for completing the self-sampling kits, and educational materials about cervical and colorectal cancer.
11043997|NCT04471194|No Intervention|Control|Participants in this group will receive a standardized letter informing them that they are out-of-date for both cervical and colorectal cancer screenings and should schedule an appointment with their provider to receive these screenings.
11043998|NCT04471181||All patients with ruptured abdominal aortic aneurysms|"All patients will undergo CTA to confirm the diagnosis. The use of balloon for aortic clamp in case of haemodynamic instability can be used.
~All patients included in the research study must undergo standard EVAR with a bifurcated graft or an aorto-uni-iliac and a femoral to femoral crossover. In aneurysms with short proximal neck down to 4mm, or in cases where completion angiography indicates type Ia endoleak, the Heli-FX EndoAnchor system is recommended to be used, as indicated. All patients will have plain abdominal x-rays on discharge. Participants will undergo CTA in 3months and annually post-op.. In case of an adverse event before the 3 months follow up CTA, a more urgent imaging might be requested and proceed to appropriate action according to the findings."
11043999|NCT04471168|Experimental|Cryo-Auriculotherapy|Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
11044000|NCT04471168|Sham Comparator|Control group|Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
11044001|NCT04471155|Active Comparator|Holep|patient underwent laser prostatectomy
11044002|NCT04471155|Active Comparator|open prostatectomy|patient underwent open prostatectomy
11044003|NCT04471142|Experimental|Group A|Intervention group with preventive application of compressive bandages in addition to suction drain (routine adopted at the institution).
11044004|NCT04471142|No Intervention|Group B|Group control. The patient will follow the institution's routine with only the suction drain.
11044005|NCT04471129|Other|High-Flow Oxygen Therapy, followed by Non-Invasive Ventilation|oxygenation first by High-Flow Oxygen Therapy, then by O2C, then by Non-Invasive Ventilation
11044006|NCT04471129|Other|Non-Invasive Ventilation, followed by High-Flow Oxygen Therapy|oxygenation first by Non-Invasive Ventilation, then by O2C, then by High-Flow Oxygen Therapy
11044007|NCT04471116|Active Comparator|Therapy group|Patients in the therapy group took 1 sachet of OMNi-BiOTiC® FLORA plus + (= 2 g) dissolved in 1/8 l of water once a day
11044008|NCT04471116|No Intervention|Control group|Patients in the control group received no additional medication.
11044009|NCT04471103|Experimental|Real-Time Delphi Method|The Real-Time Delphi Method involves a single-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant once they have rated an outcome. They can then modify how they rated the outcome based on this feedback if they wish. Participants can also re-visit and re-rate outcomes as many times as they wish when the survey is live. Duration will span approximately 5 weeks.
11044010|NCT04471103|Active Comparator|Multi-round Delphi Method|The Multi-Round Delphi Method involves a three-round Delphi survey rating the importance of outcomes for neonatal encephalopathy. Feedback on each outcome (participant's own rating score, rating of the outcome by stakeholder group and overall consensus results for that outcome) will be provided to the participant at the end of Round 1 and the end of Round 2. Participants can then modify how they rated the outcome based on feedback, in Rounds 2 and 3, if they wish. Each survey Round will run for 3 weeks approximately. In between survey Rounds, there will be a downtime of approximately 10 days before providing feedback and a further 7 days before starting the next round. Duration will span approximately 14 weeks.
11044011|NCT04471077||Favorable outcome of bariatric surgery|Excess weight loss above 50%
11044012|NCT04471077||Unfavorable outcome of bariatric surgery|Excess weight loss below 50%
11044013|NCT04471064|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg; multiple dose phase
11044014|NCT04471064|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg; multiple dose phase
11044015|NCT04471064|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg; multiple dose phase
11044016|NCT04471064|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg; multiple dose phase
11044017|NCT04471064|Experimental|XY0206-150mg|Drug:XY0206;Dosage form:Tablet;Dosage：150mg; multiple dose phase
11044018|NCT04471064|Experimental|XY0206-200mg|Drug:XY0206;Dosage form:Tablet;Dosage：200mg; multiple dose phase
11044019|NCT04471064|Experimental|XY0206-250mg|Drug:XY0206;Dosage form:Tablet;Dosage：250mg; multiple dose phase
11044020|NCT04471051||COVID19 Convalescent Plasma Treatment|Hospitalized COVID19 patients who receive COVID19 Convalescent Plasma under Expanded Access protocol NCT04372368.
11044021|NCT04471038|Experimental|Cohort 1|1 mg/mL SAB-176 in normal (0.9%) Saline; concentration 1 mg/mL (0.1%)
11044022|NCT04471038|Experimental|Cohort 2|10 mg/kgSAB-176 in normal (0.9%) Saline; concentration 4 mg/mL (0.4%)
11044023|NCT04471038|Experimental|Cohort 3|25 mg/kgSAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
11044024|NCT04471038|Experimental|Cohort 4|50 mg/kg SAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
11044025|NCT04471038|Placebo Comparator|Cohort 5|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
11044026|NCT04471025|Active Comparator|Group I|USG guided infraclavicular block with single operator jedi grip technique
11044027|NCT04471025|Active Comparator|Group 2|USG guided infraclavicular block with conventional double operator technique
11044028|NCT04471012|Experimental|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.
~The experimental group was given a Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet during their first counseling session."
11044029|NCT04471012|No Intervention|Standard Care|The progress of the participants in the control group was tracked routinely without any specific implementation. At the end of the study, the control group was also given the same booklet.
11044030|NCT04470999|Experimental|Single arm|Venous blood and apheresis collection will be conducted
11044031|NCT04470973||Cefuroxime/Amikacin|20 patients will be included in the cefuroxime cohort and 20 patients in the amikacin cohort.
11044032|NCT04470960|Experimental|participating community centers|Training course for the community center health coordinators Professional guidance for the CC health coordinators
11044033|NCT04470947||Next generation functional drug screening|
11044034|NCT04470947||Comprehensive genomic profiling|
11044035|NCT04470947||Physician's choice|
11044036|NCT04470921||Choice for Opportunistic Salpingectomy|Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.
11044037|NCT04470908|Experimental|Zanubrutinib + Rifabutin|"Day 1: zanubrutinib
~Days 3 to 10: rifabutin
~Day 11: zanubrutinib and rifabutin"
11044038|NCT04470895||Usual falling patients|"a group enrolling the patients who completed the inclusive criteria and have had at least one fall in the last 12 months in addition to the possible fall causing the index fracture.
~These patients must answer positively the following question Have you fallen in the last 12 months, regardless of the current fracture?"
11044039|NCT04470895||Unusual falling patients|"a group enrolling the patients who also completed the inclusive criteria, but are defined as unsual falling patients. These patients must answer negatively the following question: Have you fallen in the last 12 months, regardless of the current fracture?"
11044040|NCT04470882|Experimental|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
11044041|NCT04470882|Active Comparator|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
11044042|NCT04470882|Experimental|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
11044043|NCT04470869|Experimental|OLAF group|The interventional group (OLAF) benefit from a psychiatric follow up, from virtual visiting of the patient and video interview with ICU team.
11044044|NCT04470869|Placebo Comparator|Control|The control group contains the relatives of patients hospitalized after the confinement measure but before the OLAF intervention. This group benefit from phone contact with the ICU team at the admission in ICU then two contact per week minimum to one contact per day maximum during the stay, excepting the specific phone calls associated with favorable or unfavorable evolution.
11044045|NCT04470856|Experimental|septic shock patients|"Intubated patients with septic shock receive an end-expiratory occlusion test (EEOT) and, after the test, they receive a 500 ml-fluid challenge.
~During these phases the carotid doppler changes will be recorded."
11044046|NCT04470843|Active Comparator|Acetazolamide|Group 1 (acetazolamide): Patients undergoing RALP with the peri-operative use of one-time 250 mg dose of acetazolamide
11044047|NCT04470843|Placebo Comparator|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
11044048|NCT04470830||Participants With Essential Hypertension|Participants diagnosed with essential hypertension who have been treated with azilsartan medoxomil/chlorthalidone FDC as an early therapy for participants whose blood pressure is not properly controlled by monotherapy or who require administration of multiple drugs in order to reach the target blood pressure, will be observed prospectively over a period of 5 years.
11044049|NCT04470817||Participants With Essential Hypertension|Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
11044050|NCT04470804|Experimental|Sirolimus on newly diagnosed primary acquired PRCA|A prospective research of the sirolimus efficiency on newly diagnosed primary acquired PRCA patients. Sirolimus dosage: 2mg QD with plasma concentration 4-15ng/mL. Medication time should last at least 6 months
11044051|NCT04470804|Active Comparator|Cyclosporine A on newly diagnosed primary acquired PRCA|Cyclosporine A (CsA) efficiency on newly diagnosed primary acquired PRCA patients. CsA dosage: 4mg/kg QD. Medication time should last at least 6 months
11044052|NCT04470791|Experimental|F(ab')2 antivenom plus local cryotherapy.|Group A: patients with a Crotalus snakebite, and grade II envenomation received F(ab')2 antivenom therapy and application of local cryotherapy.
11044053|NCT04470791|Active Comparator|F(ab')2 antivenom.|Group B: patients who received only F(ab')2 antivenom therapy.
11044054|NCT04470778|Experimental|BMS-986256|
11044055|NCT04470778|Experimental|BMS-986256 + Famotidine|
11044056|NCT04470765|Active Comparator|Active Treatment|Active Zida device to be delivered for use by patient
11044057|NCT04470765|Sham Comparator|Sham Treatment|Identical Sham device to be delivered for use by patient
11044058|NCT04470752|Placebo Comparator|Placebo|InOrpha solution/ml, three times daily with meals for the Treatment period, 7 or 30 days.
11044059|NCT04470752|Experimental|Capsaicin|InOrpha solution plus 1 mcg Capsaicin/ml, three times daily with meals for the Treatment period of 7 or 30 days.
11044169|NCT04470050|Placebo Comparator|Cohort 6- Placebo|Sublingual placebo film
11044060|NCT04470739|Active Comparator|Infants born to COVID-19 positive mothers|Infants, born to COVID-19 positive mothers, will be evaluated for cardiothymic index in their first chest X-ray.
11044061|NCT04470739|No Intervention|Infants born to COVID-19 negative mothers|Infants, born to COVID-19 negative mothers, will be evaluated for cardiothymic index in their first chest X-ray.
11044062|NCT04470726|Experimental|AIV001 Treatment Dose 1|Intradermal/intratumoral, Dose 1
11044063|NCT04470726|Experimental|AIV001 Treatment Dose 2|Intradermal/intratumoral, Dose 2
11044064|NCT04470713||Group A - Retrospective data collection|Participants with a confirmed diagnosis, either deceased patients or patients whose survival status is not known at enrollment.
11044065|NCT04470713||Group B - Prospective data collection|Participants who are alive at enrollment. Data collection is retrospective for the time between birth and enrollment visit, and data collection is prospective from the enrollment visit onwards. Visits are performed as per local standard of care.
11044066|NCT04470700||subjects with greater than 3years delay|Subjects with delay in treatment of Urinary incontinence greater than three years
11044067|NCT04470700||subjects with less than three years delay|Subjects with delay in treatment of Urinary incontinence lesser than three years
11044068|NCT04470687|Experimental|Carotid plaque or stenosis ultrasound enhanced UF assesment|symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy
11044069|NCT04470674|Active Comparator|Arm A (Durvalumab)|Durvalumab 1500 mg IV every 4 weeks for 13 cycles.
11044070|NCT04470674|Experimental|Arm B (Durvalumab plus chemotherapy)|Durvalumab 1500 mg IV plus carboplatin AUC 5 IV and pemetrexed 500 mg/m2 IV every 3 weeks for 4 cycles followed by durvalumab and pemetrexed every 3 weeks for 13 more cycles.
11044071|NCT04470648||hosted in the center and HCWs at the epidemic period|people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time
11044072|NCT04470635||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
11044073|NCT04470635||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
11044074|NCT04470635||Healthy children with gingivitis|Systemically healthy children with gingivitis
11044075|NCT04470635||Healthy children and healthy gingiva|Systemically healthy children with healthy gingiva
11044076|NCT04470622|Experimental|Treatment Group 1|Aprepitant injectable emulsion.
11044077|NCT04470622|Placebo Comparator|Treatment Group 2|Saline placebo.
11044078|NCT04470609|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
11044079|NCT04470609|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
11044080|NCT04470609|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
11044081|NCT04470609|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
11044082|NCT04470583||Mild/moderate COVID-19 affected pregnant and postnatal women|Pregnant and postnatal women who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-50 years old.
11044083|NCT04470583||Severe/Critical COVID-19 affected pregnant and postnatal women|"Pregnant and postnatal women who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-50 years old.
~These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards."
11044084|NCT04470583||Mild/moderate COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who contracted COVID-19 and recovered without the need for ventilation will be classified as mild to moderate. Participants will be aged between 18-60 years old.
11044085|NCT04470583||Severe/Critical COVID-19 affected non-pregnant participants|Both male and non-pregnant female participants who are admitted to hospital after contracting COVID-19 and received ventilatory support before recovering will be classified as severe to critical. Participants will be aged between 18-60 years old. These participants will be identified from Intensive Treatment Unit (ITU), and standard COVID-19 wards.
11044086|NCT04470570|No Intervention|Control Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder only.
11044087|NCT04470570|Experimental|Cross-Education Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side.
11044088|NCT04470570|Experimental|Cross-Education + Blood-Flow Restriction Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side with blood-flow restriction simultaneously.
11044089|NCT04470557||Patients with COVID-19|The patients will be subjected to to laboratory analyses, a number of hematological, immunological and biochemical parameters like total leucocytic count and differential count of CBC, ESR, D- dimer levels in plasma, CRP, serum urea and creatinine levels, serum levels of AST, ALT liver enzymes, serum ferritin levels Also, CT scan of chest, clinical assessment and the severity and course of the disease.
11044090|NCT04470544|Placebo Comparator|Placebo + Standard of Care|Standard of Care will be defined by the investigators in collaboration with the sponsor on the basis of the best available evidence at the time of study initiation with placebo.
11044091|NCT04470544|Experimental|Camostat + Standard of Care|Patient will receive SOC tablets and Camostat mesilate 200 mg four times a day after each meal with Standard of Care treatment.
11044092|NCT04470531|No Intervention|Control|"Arm A :No Intervention/control: Standard treatment
~Antibiotics for secondary bacterial infection as per institutional guidelines
~Supplemental oxygen (to keep saturations between 90% to 96%)
~Intravenous hydration (to maintain euvolumia)
~Thrombo-prophylaxis as per local guidelines
~Paracetamol (oral or I/V 1gram QDS as required or regular)
~To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
11044170|NCT04470037|Experimental|DAAOI-P|DAAOI-P 250-1500mg
11044171|NCT04470037|Placebo Comparator|Starch pill|
11044172|NCT04470024|Experimental|Arm 1|Vax + delayed anti-PD-1
11044173|NCT04470024|Experimental|Arm 2|Vax + anti-GITR + delayed anti-PD-1
11044093|NCT04470531|Experimental|intervention /experimental|"Arm B: Experimental Arm received oral co-trimoxazole + standard therapy
~The following treatments are recommended as standard therapy:
~Antibiotics for secondary bacterial infection as per institutional guidelines
~Supplemental oxygen (to keep saturations between 90% to 96%)
~Intravenous hydration (to maintain euvolumia)
~Thrombo-prophylaxis as per local guidelines
~Paracetamol (oral or I/V 1gram QDS as required or regular)
~To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)"
11044094|NCT04470518|Active Comparator|Intervention: Diagnostic algorithm|diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
11044095|NCT04470518|No Intervention|Usual care|"In the control arm, patients will receive 'usual care' left at the discretion of the treating physician.
~Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools.
~They are expected (but not forced) to follow the Belgian guidelines (as described in BAPCOC National guidelines and the RIZIV consensus meeting Rational use of antibiotics in children)."
11044096|NCT04470492|Experimental|Experiment|
11044097|NCT04470492|Other|Control|
11044098|NCT04470479|Experimental|Pilocarpine Hydrochloride|Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
11044099|NCT04470479|Placebo Comparator|placebo|Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks
11044100|NCT04470466|Active Comparator|short pulse and Q-switched ND-YAG laser with topical carbon|
11044101|NCT04470466|Active Comparator|Fractional CO2 Laser|
11044102|NCT04470453|Experimental|Patients with active rheumatoid arthritis|30 patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
11044103|NCT04470453|Experimental|Patients with rheumatoid arthritis into remission|30 patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
11044104|NCT04470427|Experimental|mRNA-1273|Participants will receive 1 intramuscular (IM) injection of 100 microgram (ug) mRNA-1273 on Day 1 and on Day 29.
11044105|NCT04470427|Placebo Comparator|Placebo|Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.
11044106|NCT04470414||Recovered COVID-19 patients|Patients recovered from COVID-19 infection within three months before the start of the study.
11044107|NCT04470401|Placebo Comparator|Placebo|Abobotulinumtoxina 400 IU in 2cc of saline solution
11044108|NCT04470401|Experimental|Abobotulinumtoxina - 400IU|placebo (2cc of saline solution)
11044109|NCT04470388|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 capsule Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days.
11044110|NCT04470388|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days.
11044111|NCT04470362|Placebo Comparator|Control group|The control group will receive an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing quadriceps power and strength.
11044112|NCT04470362|Experimental|Study group|"Participants in the study group will perform the same exercise parameters used in the control group but in a different manner.
~The isokinetic exercise will be done with a closed eye to improve the proprioception function. This exercise will be performed for 6 sets.
~Additional training will be performed by the application of three vibrators above and on both sides of the knee joint to improve the function of the Pacinian and Meissner corpuscles which is one of the included receptors in the sensation of the fatigue."
11044113|NCT04470349||LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
11044114|NCT04470349||Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
11044115|NCT04470336|Active Comparator|Native CT-II®|Three capsules post-breakfast Three capsules post-dinner
11044116|NCT04470336|Other|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
11044117|NCT04470336|Placebo Comparator|Placebo|Three capsules post-breakfast Three capsules post-dinner
11044118|NCT04470323||COVID19 patients|Patients admitted to Assiut university Hospitals diagnosed as COVID19 positive patients by PCR.
11044119|NCT04470323||healthy volunteer|as negative control for each sample
11044120|NCT04470310|Active Comparator|glimepiride|glimepiride 1mg monotherapy and glimepiride 2mg monotherapy
11044121|NCT04470310|Active Comparator|alogliptin|alogliptin 25mg monotherapy
11044122|NCT04470310|Active Comparator|alogliptin - pioglitazone|Alogliptin 25mg+pioglitazone 15mg combination
11044123|NCT04470297|Placebo Comparator|Placebo|A placebo with the same physical characteristics of the experimental drug pill will be administered at the same time and daily schedule as the experimental intervention for 10 days.
11044124|NCT04470297|Experimental|Ramelteon|A pill containing ramelteon 8mg will be administered daily at bedtime for 10 days.
11044125|NCT04470284|Active Comparator|SMBP_only|Standard treatment with SMBP
11044126|NCT04470284|Experimental|SMBP_mobile_app|SMBP with mobile App based feed-back algorithm
11044127|NCT04470271||Patients under routine hepatitis C care|Patients who are routinely followed at the treating institution. Investigators will evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
11044128|NCT04470271||Patients with hepatitis C lost of follow-up|Patients who were lost of follow-up. Participants will be contacted to evaluate if the continued HCV care at another institution, were not routinely followed by a liver-specialist or if they died. Investigators will also evaluate baseline demographic, liver fibrosis stage, liver-related complications, and antiviral therapy.
11044174|NCT04470011||Patients who initiated HIV treatment|
11044175|NCT04470011||Service providers at study facilities|
11044129|NCT04470258|Other|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|A realistic simulation will be carried out, centered on the heuristic evaluation, by a multiprofessional team (N= 6), to evaluate the performance of the new equipment in the execution of the pre-defined skills. The prototype will be tested on a mannequin by the research team and on healthy volunteers by health professionals, where physiological parameters and interface comfort will be evaluated.
11044130|NCT04470258|Other|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The second phase will consist of a clinical trial, in the application of the non-invasive respiratory device in 10 patients with respiratory failure by COVID-19, to assess its clinical effectiveness, through the analysis of the physiological variables and patient comfort.
11044131|NCT04470245|Active Comparator|Healthy volunteers|
11044132|NCT04470245|Active Comparator|Patients undergoing surgery|We will include adults (over 18 years of age) undergoing surgical decompression of the ulnar nerve at the elbow for cubital tunnel syndrome.
11044133|NCT04470232||Patients with coxofemoral pathologies|"For the transcultural validation, a french version of the 2 self-assessment questionnaires, SUSHI-score and the HOOs-12 score will be produced.
~For the psychometric validation, 120 patients with coxofemoral pathologies will pass the two questionnaires. The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
11044134|NCT04470219|Experimental|intervention group|Participants receive rehabilitation as usual and training how to use RemindMe by personnel from the research group and an occupational therapist working at the rehabilitation clinic. The participants will use RemindMe for two months. The participants choose activities that he/she wishes to remember to carry out with support by RemindMe. An individual follow-up session will be conducted once a week by the occupational therapist to evaluate if the chosen activities were performed and discuss strategies for the continued use of RemindMe. After two months the participants decide if he/she wants to continue to use RemindMe.
11044135|NCT04470219|No Intervention|control group|The control group receive treatment as usual by the rehabilitation personnel, for example, occupational therapists give interventions that provide support for memory, it could be a paper calendar or other memory devices or strategies.
11044136|NCT04470193|Experimental|MyChildCMC Intervention Group|Parents/patients randomized into the MyChildCMC Intervention Group will use the MyChildCMC app to monitor their child's daily symptoms for the duration of the study period (3 months). The MyChildCMC app includes a daily form consisting of 12 questions assessing child's vitals, pain, seizures, mood, and feeding as well as caregiver worry for the day. Daily reminders are sent to the parent to fill out the vitals form in the app. Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
11044137|NCT04470193|No Intervention|Standard of Care Group|Parents/patients randomized into the Standard of Care Group do not use the MyChildCMC app to monitor their child's daily symptoms and are instructed to continue with regular care for their child and to continue monitoring their child's symptoms on their own without the use of the app for the duration of the study period (3 months). Parents/participants will also fill out a quality of life survey at baseline, 1 month, and 3 months as well as a caregiver satisfaction survey at 3 months.
11044138|NCT04470180|Experimental|Virtual Teach-to-Goal (V-TTG)|They will be randomized to receive education via a virtual learning module.
11044139|NCT04470180|Active Comparator|standardized brief intervention|Intervention that mimics usual care to deliver inhaler technique education.
11044140|NCT04470167|Experimental|TPX-115|Subjects receive Ultrasound-guided intratendinous injection of TPX-115
11044141|NCT04470167|Placebo Comparator|Placebo|Subjects receive Ultrasound-guided intratendinous placebo injection
11044142|NCT04470154|Experimental|Stage I: HSK21542 0.05 μg/kg,0.15 μg/kg,0.30 μg/kg|
11044143|NCT04470154|Placebo Comparator|Stage I: Placebo 0.05 μg/kg,0.15 μg/kg,0.30 μg/kg|
11044144|NCT04470154|Experimental|Stage II: HSK21542|
11044145|NCT04470154|Placebo Comparator|Stage II: Placebo|
11044146|NCT04470141|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
11044147|NCT04470128|Experimental|Stage I: HSK21542 0.5 μg/kg|
11044148|NCT04470128|Experimental|Stage I: HSK21542 1 μg/kg|
11044149|NCT04470128|Experimental|Stage II : HSK21542 0.5 μg/kg|
11044150|NCT04470128|Experimental|Stage II : HSK21542 1 μg/kg|
11044151|NCT04470128|Active Comparator|Stage II : fentanyl 1 μg/kg|
11044152|NCT04470115|Active Comparator|General anesthesia|Patients will receive general endotracheal anesthesia with propofol, fentanyl, sevoflurane and rocuronium.
11044153|NCT04470115|Experimental|Regional anesthesia|Patients will receive femoral and lateral femoral cutaneous nerves block under ultrasonographical guidance before operation.During surgical procedure they will receive deep sedation with propofol.
11044154|NCT04470102|Other|isolated septal myectomy|Isolated extended septal myectomy
11044155|NCT04470102|Active Comparator|"Septal myectomy+ edge-to-edge"|advanced septal myectomy in combination with mitral valve repair using the edge-to-edge technique
11044156|NCT04470089|Experimental|Myramistin 0.005%|
11044157|NCT04470089|Experimental|Myramistin 0.01%|
11044158|NCT04470089|Experimental|Myramistin 0.02%|
11044159|NCT04470089|Placebo Comparator|Placebo|
11044160|NCT04470076|Experimental|neoadjuvant afatinib combination with chemotherapy|"Neoadjuvant treatment (chemotherapy+afatinib) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment (including dynamic 18F-FDG PET/CT) will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) Adjuvant treatment (afatinib): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the first week (+ 7 days) from surgery and up to 2 years."
11044161|NCT04470063|Experimental|group A|
11044162|NCT04470063|Experimental|group B|
11044163|NCT04470063|Experimental|group C|
11044164|NCT04470050|Experimental|Cohort 1- 30 Micrograms|Sublingual film containing 30 Micrograms Dexmedetomidine
11044165|NCT04470050|Experimental|Cohort 2- 60 Micrograms|Sublingual film containing 60 Micrograms Dexmedetomidine
11044166|NCT04470050|Experimental|Cohort 3- 90 Micrograms|Sublingual film containing 90 Micrograms Dexmedetomidine
11044179|NCT04469972|Experimental|Implementation in the intervention group|This group of elderly were subjected to a pursed-lip breathing exercise (using a windmill toy), a diaphragmatic breathing exercise and a coughing exercise three times a week (Mondays, Tuesdays and Thursdays) for 12 weeks in groups of 5-6 individuals (2 groups of 6 persons, and 4 groups of 5 persons: 6 groups in total) between 10:00 and 15:30, at the same time of the day for each group in 30-minute sessions. All breathing exercises were taught to the elderly individuals on the first day of implementation and demonstrated again prior to practice by the researcher throughout the implementation phase.
11044180|NCT04469972|No Intervention|Implementation in the control group|None of the elderly in the control group were subjected to breathing exercises. They continued their daily lives as normal.
11044181|NCT04469959|Experimental|L-Dopa First / Placebo Second|"STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and placebo tablets at 1pm and 5pm. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, with placebo at 1pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2.
~Step 2 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets at 9am, 1pm, and 5pm over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn."
11044182|NCT04469959|Placebo Comparator|Placebo First / L-Dopa Second|"Step 1 (3 Weeks): Participants will receive matching placebo tablets daily. Participants take placebo tablets at 9am, 1pm, and 5pm over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2.
~Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and placebo tablets at 1pm and 5pm. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa tablets) at 9am and 5pm, with placebo at 1pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued."
11044183|NCT04469946|Experimental|Exploratory|Participants were fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Pre-intervention measures were obtained within one week of the hearing aid fit and post-intervention measures were obtained after two months of daily hearing aid use.
11044184|NCT04469920|Experimental|Group 1- mild hepatic impairment without evidence of PHT|Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
11044185|NCT04469920|Experimental|Group 2- mild hepatic impairment with evidence of PHT|Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
11044186|NCT04469920|Experimental|Group 3-moderate hepatic impairment|Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
11044187|NCT04469920|Experimental|Group 4- severe hepatic impairment|Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
11044188|NCT04469920|Experimental|Group 5-cholestatic liver disease|Subjects with cholestatic liver disease
11044189|NCT04469920|Experimental|Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH|Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
11044190|NCT04469920|Experimental|Group 7- normal hepatic function|Subjects with normal hepatic function
11044191|NCT04469907|Experimental|Treatment - AZD9977|There are 4 cohorts in this arm based on renal function (mild, moderate, severe, and normal). Each cohort will have 8 participants.
11044192|NCT04469894||Niemann-Pick Type A|Also referred to as Infantile Neurovisceral ASMD
11044193|NCT04469894||Niemann-Pick Type A/B|Also referred to as Intermediate form or Chronic Neurovisceral ASMD
11044194|NCT04469894||Niemann-Pick Type B|Also referred to as Chronic Visceral ASMD
11044195|NCT04469894||Niemann-Pick Type C (Early Infantile)|Onset at less than 2 years of age
11044196|NCT04469894||Niemann-Pick Type C (Late Infantile)|Neurodegenerative form (late-infantile) onset at 2-6 years of age
11044197|NCT04469894||Niemann-Pick Type C (Juvenile)|Neurodegenerative form (juvenile) onset at 6-15 years of age
11044198|NCT04469894||Niemann-Pick Type C (Adult)|Psychiatric neurodegenerative form (adult) onset at greater than 15 years of age
11044199|NCT04469881|Experimental|Virtual Reality|Wear VR glasses and watch movies during surgery
11044200|NCT04469868|Experimental|No opioids prescriptions|
11044201|NCT04469855||Ozempic®|Japanese people with type 2 diabetes being treated in normal clinical practice conditions
11044202|NCT04469842|Experimental|Immunosuppression with Extended-Release Tacrolimus|"LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).
~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
11044203|NCT04469842|Active Comparator|Immunosuppression with Intermediate Release Tacrolimus|"IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).
~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
11044204|NCT04469829|Experimental|secukinumab|patients with psoriasis and metabolic syndrome candidate for treatment with secukinumab standard doses
11044205|NCT04469829|Active Comparator|methotrexate|patients with psoriasis and metabolic syndrome candidate for treatment with methotrexate dosed 15 mg/week
11044206|NCT04469816|Experimental|Behavioral: Family Check-Up 4 Health|Families will receive the FCU4Health program 3 times annually in a health maintenance model. The FCU4Health coordinator reviews the assessment results with the parents, using motivational interviewing strategies to create a tailored plan to address family needs. This plan may include referrals to community resources or parenting modules that focus on family management.
11044207|NCT04469816|Experimental|Control-Services as Usual|"Families will continue with their medical standard of care and referrals for services as appropriate from the healthcare staff in their respective FQHCs or primary healthcare clinics.
~Families will receive brochures about the community programs to which families in the FCU4Health arm are referred."
11044208|NCT04469803|Experimental|No nap, brief nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
11044209|NCT04469803|Experimental|No nap, longer nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
11044210|NCT04469803|Experimental|Brief nap, no nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
11044211|NCT04469803|Experimental|Brief nap, longer nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
11044212|NCT04469803|Experimental|Longer nap, brief nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
11044213|NCT04469803|Experimental|Longer nap, no nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
11044214|NCT04469790||SIT|Continuous sitting for 3 hours
11044215|NCT04469790||SIT+WALK|Interrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
11044216|NCT04469790||EX|Perform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
11044217|NCT04469777|Experimental|Intravitreal erythropoietin|10 patients with Intravitreal injection of 2000 IU EPO in 0.2 ml of commercially available sterile EPREX 4000 solution.
11044218|NCT04469777|Active Comparator|Intravenous erythropoietin|10 patients with 20000 IU intravenous EPO injections
11044219|NCT04469764|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Patients with tumors that are hormone receptor positive also receive and anastrozole or letrozole per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11044220|NCT04469751|Experimental|patients undergoing neurosurgery|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
11044221|NCT04469738|Experimental|SCS off|
11044222|NCT04469738|Experimental|SCS on|
11044223|NCT04469725|Experimental|Thymic carcinoma|enrolled subjects will receive KN046 every 2 weeks.
11044224|NCT04469712||SASI Bipartition|Subjects submitted to SASI Bipartition
11044225|NCT04469712||Roux-en-Y gastric bypass|Subjects submitted to gastric bypass
11044226|NCT04469699|Experimental|Treatment arm|Stereotactic biopsy followed by stereotactical photodynamic therapy
11044227|NCT04469699|Other|Control arm|Stereotactic biopsy
11044228|NCT04469686|Experimental|Twice Daily - Active|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure suppository applicator
11044229|NCT04469686|Experimental|Once Daily - Active|Once daily 90 mg hydrocortisone acetate and once daily placebo suppository administered with Sephure suppository applicator
11044230|NCT04469686|Placebo Comparator|Placebo|Twice daily placebo suppository administered with Sephure suppository applicator
11044231|NCT04469673|Experimental|JS002|Participants received one of 3 dose regimens of JS002 administered as multiple subcutaneous doses.
11044232|NCT04469673|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
11044233|NCT04469647||High-risk|Employees at high-risk of Coronavirus exposure areas (physicians, nurses, respiratory therapists, radiology technologists, lab technologists, housekeepers)
11044234|NCT04469647||Low-risk|Employees working at lower risk areas such as (administration, HR, Public relations)
11044235|NCT04469634|Experimental|antibody response and memory B-cell|Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
11044236|NCT04469621|Experimental|SAR443122|SAR443122 dose 1, twice daily for 14 days
11044237|NCT04469621|Placebo Comparator|Placebo|matching placebo
11044238|NCT04469608|Experimental|TCM clinical daycare model for depression patients|Tai Chi and Acupuncture and Yoga and Mindfulness
11044239|NCT04469608|No Intervention|Depression patients|Tai Chi and acupuncture and yoga and mindfulness are not added
11044240|NCT04469595|Active Comparator|ILUVIEN Arm|Intravitreal ILUVIEN
11044241|NCT04469595|Active Comparator|Aflibercept Arm|Intravitreal aflibercept
11044242|NCT04469569|Other|Delayed Intervention|Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPVIQ-PedOnc intervention in Year 3, and to the sustainability condition in Year 4
11044243|NCT04469569|Other|Early Intervention|Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPVIQ-PedOnc intervention in Year 2, and to the sustainability condition in Years 3 and 4
11044244|NCT04469556|Active Comparator|Modified Folfirinox|"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.
~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
11044245|NCT04469556|Active Comparator|Gemcitabine/nab-Paclitaxel|"Gemcitabine/nab-Paclitaxel administered intravenously.
~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
11044246|NCT04469543||MTHFR polymorphism|
11044247|NCT04469530|Experimental|Maintenance regimen|"Maintenance chemotherapy regimen administered as a 12-month course of continuous sirolimus with celecoxib and low-dose oral etoposide alternating every 21 days with low-dose oral cyclophosphamide following the completion of standard therapy"
11044248|NCT04469530|No Intervention|Observation|"Observation alone following the completion of standard therapy"
11044249|NCT04469517||HHT|patients with HHT
11044250|NCT04469517||control|persons age- and sex matched who do not suffer from HHT nor their first or second degree relatives
11044251|NCT04469504|Experimental|PREHAB|
11044252|NCT04469504|Active Comparator|control group|
11044253|NCT04469491|Experimental|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; + appropriate O2 support)
11044254|NCT04469491|Active Comparator|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics; + appropriate O2 support).
11044255|NCT04469478|Experimental|Virtual Reality for imaging review|Each participant (patient and caregiver(s)) will undergo standard 2D imaging review on a computer screen, followed by 3D imaging review in virtual reality during their radiation oncology consultation
11044256|NCT04469465|Experimental|Danicopan + C5 Inhibitor|Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
11044257|NCT04469465|Placebo Comparator|Placebo + C5 Inhibitor|Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).
11044258|NCT04469452||Healthy Adults (19-99yrs)|Healthy adults already enrolled in separate studies using indirect calorimetry to measure RMR within our lab will be recruited for this study. Fifty participants (25 male, 25 female) will be heterogeneous in age, body composition, and physical activity based on the inclusion and exclusion of their respective studies. To test reliability, 25 of the 50 participants will repeat RMR measurements within 1 week of initial measurements.
11044259|NCT04469439||Surgical group|Individuals with cystic fibrosis and chronic rhinosinusitis who undergo endoscopic sinus surgery
11044260|NCT04469439||Medical group|Individuals with cystic fibrosis and chronic rhinosinusitis who do not undergo endoscopic sinus surgery
11044261|NCT04469426|Experimental|Informational online app group|Participants will have access to an interactive online peer support app developed by the research team.
11044262|NCT04469426|No Intervention|Booklet only|Participants will only have access to the educational booklet on LARS developed by the colorectal research team.
11044263|NCT04469413||standard IV intermittent bolus infusion group|
11044264|NCT04469413||continuousIV intermittent bolus infusion group|
11044265|NCT04469400|No Intervention|Group1|Researchers conduct health education on patients, including dietary guidance, physical activity guidance, psychological behavior counseling, etc.
11044266|NCT04469400|Experimental|Group2|In addition to education, the subjects will consume 2 composite protein solid drinks per day, in conjunction with the three-meal diet to increase satiety and intake of sufficient nutrients
11044267|NCT04469400|Experimental|Group3|In addition to education, the subjects will consume 2 nutrition bars daily to replace the staple food of daily lunch and dinner to help reduce carbohydrate intake and intake of sufficient nutrients
11044268|NCT04469387|Active Comparator|NS Group|NS Group includes patients who simply receive responsible segments fused (L4-S1).
11044269|NCT04469387|Experimental|LD Group|LD Group includes patients who receive responsible segments fused (L4-S1) plus limited decompression at adjacent segment (L3/4).
11044270|NCT04469374|Experimental|Jumping exercise|10 rest-inserted jumps performed three times per week
11044271|NCT04469374|Sham Comparator|Balance exercise|Single-leg balances for 60 seconds on each leg
11044272|NCT04469361||Ballerinas|Balerina students who have trained at least for 4 years
11044273|NCT04469361||Female students|Female students with sedentary lifestyle
11044274|NCT04469348|Experimental|Healthy volunteers|"Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus.
~If contamination of S. Aureus: they will have 12 follow-up visits (1 per month)
~If no contamination of S. Aureus: their participation stops"
11044275|NCT04469335|Experimental|mobile neurofeedback|
11044276|NCT04469335|Sham Comparator|sham control|
11044277|NCT04469335|Experimental|medication +mobile neurofeedback|
11044278|NCT04469335|Sham Comparator|medication + sham control|
11044279|NCT04469322|Experimental|Pharmacogenetic Test Guided|Treating physician for this group receives a detailed pharmacogenetic report for the patient, prioritizing 53 psychoactive medications into 4 use categories: preferential use, use as directed, may have significant limitations, and may have severe adverse reactions.
11044280|NCT04469322|Sham Comparator|Treatment As Usual|Treating physician receives a sham report listing the names of all drugs and treats patients according to standard of care.
11044281|NCT04469309|Experimental|Group I|Group I will receive Brandoff Exercises
11044282|NCT04469309|Active Comparator|Group II|Group II will receive Somersault exercises
11044283|NCT04469296|No Intervention|control arm|In the control arm, patients will continue their usual diet without further recommendation.
11044284|NCT04469296|Experimental|"specific diet arm Ketogenic arm"|In the specific diet arms, the study diet will be calculated with a dietician, for the ketogenic diet, an iso-caloric ketogenic will be proposed and explained to the patient Each diet will be respected by the patient during 9 days +/- 1 day.
11044285|NCT04469296|Experimental|"specofoc diet arm protein restricted diet"|"In the specific diet arms, the study diet will be calculated with a dietician, for the protein restricted diet, a 20% protein restriction as compared to the usual diet will be calculated and the diet will be explained to the patient.
~Each diet will be respected by the patient during 9 days +/- 1 day."
11044286|NCT04469283||caffeine efficacy|Collection of preliminary data on caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
11044287|NCT04469270|Experimental|Engensis|16 (ea) 0.25mg (0.5 mL) injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
11044288|NCT04469270|Placebo Comparator|Placebo|16 0.5 mL injections in each of the right and left gastrocnemius muscles on Days 0, 14, 90, and 104.
11044289|NCT04469257|Experimental|Sunbathing|During the activities for the intervention group, the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open. Sunbathing sessions were held between 10:30 and 11:30 to prevent elderly individuals from being affected by extreme temperatures, and UV index values were monitored during the time and duration of the event at WHO website (http://www.who.int/uv/resources/link/indexlinks/en/, Access date: July 1, 2018). During the hours of the day when UV index was > 6-7, elderly individuals were not taken out. After each sunbathing session, elderly individuals in the intervention group were evaluated for sensitivity and erythema that may occur in the exposed body areas
11044290|NCT04469257|No Intervention|Control|Elderly individuals in the control group were not invited to the activities held in the nursing home garden. There were no restrictions on them for not going out in the sun or spending time inside the nursing home
11044291|NCT04469231|Experimental|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restoring kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a single level discectomy for intractable radiculopathy and/or myelopathy.
11044292|NCT04469205|Experimental|Intervention Group|intervention group that will receive return-to-work coaching sessions. The intervention consists of 3 individual coaching sessions with a certified professional coach. This personalized accompaniment will complete the standard accompaniment offered to all patients.
11044293|NCT04469205|No Intervention|Control Group|"control group who will receive the current care which consists of a psychosocial care.
~This care consists in offering the patient regular information meetings organized with social workers of the Health Insurance, to consult a psychologist and to access patients' homes at the frequency of their choice and according to their need."
11044294|NCT04469192|Experimental|cryotherapy + education|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
11044295|NCT04469192|Active Comparator|education alone|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
11044296|NCT04469179|Experimental|Cohort 1|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
11044297|NCT04469179|Experimental|Cohort 2|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
11044298|NCT04469179|Experimental|Cohort 3|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
11044299|NCT04469179|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
11044300|NCT04469166|Active Comparator|Tourniquet|Group of tourniquet
11044301|NCT04469166|Active Comparator|No tourniquet|Group of no tourniquet
11044302|NCT04469153||SARS-COV 2 positive patient|57 SARS-COV-2 positive patients followed during the SARS-COV 2 epidemic in the internal medicine department of the Croix-Rousse hospital. For each patient ferritin and glycosylated ferritin was analysed one time (biological analysis) at the entry of the hospitalization.
11044303|NCT04469140||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
11044304|NCT04469140||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
11044305|NCT04469140||Cohort 3|Subjects with GA enrolled in another trial
11044306|NCT04469127|Experimental|Arm 1|Single Arm study
11044307|NCT04469114|Experimental|Tofacitinib|Tofacitinib 10mg twice daily for 14 days or until hospital discharge
11044308|NCT04469114|Placebo Comparator|Placebo|Placebo twice daily for 14 days or until hospital discharge
11044309|NCT04469101|Experimental|Left Uterine Displacement|Supine with left tilt for uterine displacement
11044310|NCT04469101|Experimental|Left Lateral|Left lateral decubitus position
11044311|NCT04469101|Experimental|Right Lateral|Right lateral decubitus position
11044312|NCT04469101|Experimental|Upright|Upright seated position
11044313|NCT04469088|Experimental|Dry Needling Group|
11044314|NCT04469088|Active Comparator|Manual Therapy Treatment|
11044315|NCT04469075|Experimental|topical clindamycin and triamcinolone|Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%. Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
11044316|NCT04469062|Experimental|Mirikizumab|Mirikizumab administered intravenously (IV) and subcutaneously (SC).
11044317|NCT04469062|Active Comparator|Vedolizumab|Vedolizumab administered IV.
11044318|NCT04469062|Placebo Comparator|Placebo|Placebo administered SC and IV.
11044319|NCT04469049|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 90-minute weekly group sessions.
11044320|NCT04469036|No Intervention|Telephone consultation|Telephone consultation to a pediatric trauma specialist
11044321|NCT04469036|Experimental|Virtual Pediatric Trauma Center|The Virtual Pediatric Trauma Center (VPTC), uses live video, or telehealth, to bring the expertise of a Level I pediatric trauma center virtually to patients at a hospital emergency department.
11044322|NCT04469023|Experimental|TS-142 2.5 mg|Period in which participants received multiple-dose of 2.5 mg TS-142 prior to bedtime
11044323|NCT04469023|Experimental|TS-142 5 mg|Period in which participants received multiple-dose of 5 mg TS-142 prior to bedtime
11044324|NCT04469023|Experimental|TS-142 10 mg|Period in which participants received multiple-dose of 10 mg TS-142 prior to bedtime
11044325|NCT04469023|Experimental|Placebo|Period in which participants received single placebo prior to bedtime
11044326|NCT04469010|Experimental|Iron and Vitamin C|28mg iron bis-glycinate chelate and 240mg vitamin C
11044327|NCT04469010|Active Comparator|Iron|28mg iron bis-glycinate chelate
11044328|NCT04469010|Placebo Comparator|Placebo|Matched placebo tablets
11044329|NCT04468997|Experimental|601 dose level 1 treatment|
11044330|NCT04468997|Experimental|601 dose level 2 treatment|
11044331|NCT04468997|Experimental|601 dose level 3 treatment|
11044332|NCT04468997|Experimental|601 dose level 4 treatment|
11044333|NCT04468997|Experimental|601 dose level 5 treatment|
11044334|NCT04468997|Experimental|601 dose level 6 treatment|
11044335|NCT04468984|Experimental|Arm A: Navitoclax + Ruxolitinib|Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
11044336|NCT04468984|Active Comparator|Arm B: Best Available Therapy (BAT)|Participants will receive one of the BAT options, per the investigator's discretion.
11044337|NCT04468971|Placebo Comparator|Arm 1|Excipient
11044338|NCT04468971|Experimental|Arm 2|CK0802: 1x10^8 cells
11044339|NCT04468971|Experimental|Arm 3|CK0802: 3x10^8 cells
11044340|NCT04468958|Experimental|10mg/kg SAB-185|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
11044341|NCT04468958|Experimental|25mg/kg SAB-185|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
11044342|NCT04468958|Experimental|25mg/kg SAB-185 x 2 doses|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%). Cohort 3 will receive a second 25mg/kg dose of SAB-185 7 days (+/-2) after the first treatment.
11044343|NCT04468958|Experimental|50mg/kg SAB-185|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
11044344|NCT04468958|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
11044345|NCT04468945|Experimental|mirror box therapy|The objects use for task-specific mirror therapy are duster, glass, the wooden block of different sizes and shapes, beads, coin, paper cards and spongy ball. In all these activities shoulder horizontal flexion-extension, adduction-abduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed automatically.
11044346|NCT04468945|Experimental|Repetitive Facilitation Exercise|Treatment involved rapid passive stretching of the muscles of the targeted joints in conjunction with tapping and rubbing the skin to assist in the generation of a contraction.Shoulder horizontal flexion-extension , adduction-abduction ,elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, finger flexion-extension, abduction, adduction, opposition, are performed
11044347|NCT04468932|Experimental|Active TMS first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week TMS intervention. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week sham TMS period prior to their final assessment.
11044348|NCT04468932|Experimental|Sham treatment first|After completing their baseline assessment, participants randomized to this arm will initially take part in a 2-week sham TMS period. After the midpoint assessment and subsequent a 1-month washout, these participants will then complete a 2-week TMS intervention prior to their final assessment.
11044349|NCT04468919|Experimental|BCI-FIT multi-modal configuration|For this single case research design with alternating treatments with baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with their existing alternative access method (baseline) and then with the multi-modal configurations optimized from the BCI-FIT algorithms (experimental). Outcome measures are typing accuracy, typing speed and user experience.
11044350|NCT04468919|Experimental|Adaptive signal modeling|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks when the BCI-FIT adaptive modeling is on and when the BCI-FIT adaptive modeling is off. Outcome measures are typing accuracy, typing speed and user experience.
11044351|NCT04468919|Experimental|Active querying techniques|For this single case research design with alternating treatments with baseline, 5 healthy control volunteers and 5 participants with severe speech and physical impairment who have AUC scores between 79-80% will complete copy spelling tasks with BCI-FIT active querying technique on and with BCI-FIT active querying technique off. Outcome measures are typing accuracy, typing speed and user experience.
11044352|NCT04468919|Experimental|Language modeling|For this single case research design with alternating treatments, 5 healthy control volunteers and 5 participants with severe speech and physical impairment, each with a healthy-control partner for partner input will complete a story retell task with BCI-FIT language modeling features on and with BCI-FIT language modeling features off. Outcome measures are information transfer rate and user experience.
11044353|NCT04468906|Experimental|"Biceps self-locking T tenotomy"|
11044354|NCT04468906|Active Comparator|Biceps tenodesis (control)|
11044355|NCT04468893|Experimental|Positive Psychology Intervention with chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression with the support of a chat service provided by therapists.
11044356|NCT04468893|Active Comparator|Positive Psychology Intervention without chat|Participants in this group will receive from 15 sessions of a Positive Psychology focused on the increase of wellbeing and sleep quality and decrease of anxiety and depression without the support of the chat service.
11044357|NCT04468880|Other|Group (A1 → A2)|Group (A1 → A2) receiving control milk A1A2 in period 1 then the milk evaluated A2A2 in period 2
11044358|NCT04468880|Other|Group (A2 → A1)|Group (A2 → A1) receiving the milk evaluated A2A2 in period 1 then the control milk A1A2 in period 2
11044359|NCT04468867|Experimental|Patient group|
11044360|NCT04468854|Experimental|Experimental intervention|In the experimental phase we will administer 500 mg Luteolin (2x250 mg capsules) per day formulated for oral administration for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning). The last intake on visits 2 resp. 4 is important as the participants then have to recall the learned material from visits 1 resp. 3 during a steady-state status of Luteolin.
11044361|NCT04468854|Placebo Comparator|Control Intervention|Control intervention consists of identical looking placebo capsules containing mannitol formulated for oral administration to be taken twice daily (e.g. every morning and evening) for 7.5 days (first intake: visit 1/3 in the morning; last intake: visit 2/4 in the morning) with water.
11044362|NCT04468841|Experimental|Prospective Group|Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
11044363|NCT04468841|Experimental|Retrospective Group|Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of ctDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
11044364|NCT04468815|Experimental|Treatment A: BMS-986278 suspension, fasted|
11044365|NCT04468815|Experimental|Treatment B: BMS-986278 tablet, fasted|
11044366|NCT04468815|Experimental|Treatment C: BMS-986278 tablet, fed|
11044367|NCT04468815|Experimental|Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted|
11044368|NCT04468789||Comparison group|Patients eligible for six-month dispensing receiving care at comparison sites.
11044369|NCT04468789||Intervention group|Patients eligible for six-month dispensing receiving care at intervention sites.
11044370|NCT04468776|Active Comparator|Zolpidem|Zolpidem, as prescribed by physician
11044371|NCT04468776|Active Comparator|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|Internet-based CBT-I program
11044372|NCT04468776|Experimental|Combination|Zolpidem as prescribed by physician and Internet-based CBT-I program
11044373|NCT04468750|Experimental|Kinesiotape|Kinesiotape (Nasara, Korea) was applied for three times a week (Monday, Wednesday, and Friday) for three weeks.
11044374|NCT04468724|Experimental|IMMEDIATE|People who are included in the Immediate Arm receive the Makasi intervention right away or in a six-week time if they are not available on the spot
11044375|NCT04468724|Other|DIFFERED|People who are included in the Differed Arm receive the Makasi intervention three months after inclusion
11044376|NCT04468711|Active Comparator|treatment group|vitamin D plus topical 1% hydrocortisone cream twice daily
11044377|NCT04468711|Placebo Comparator|placebo group|placebo plus plus topical 1% hydrocortisone cream twice daily
11044378|NCT04468698||Global cohort|A global cohort is built merging data from three studies
11044379|NCT04468685|Experimental|Ondansetron|Ondansetron intraperitoneal in the gall bladder bed
11044380|NCT04468685|Placebo Comparator|Saline|Normal saline intraperitoneal in the gall bladder bed
11044381|NCT04468672|Active Comparator|Day worker|Men and women who work only day shift for at least 3 consecutive days of the week
11044382|NCT04468672|Active Comparator|Night worker|Men and women who work only night shift for at least 3 consecutive days of the week
11044383|NCT04468659|Experimental|A45 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 milligram per kilogram (mg/kg), administered as intravenous (IV) infusion, every two weeks through 8 weeks, then 10 mg/kg, administered as IV infusion, every two weeks through 96 weeks, and 10 mg/kg, administered as IV infusion, every four weeks through 216 weeks.
11044384|NCT04468659|Placebo Comparator|A45 Trial: Placebo|Participants will receive placebo (0.9 percent [%] sodium chloride solution), administered as IV infusion, every two weeks through 96 weeks then every four weeks through 216 weeks.
11044385|NCT04468659|Experimental|A3 Trial: Lecanemab 5 mg/kg + 10 mg/kg|Participants will receive lecanemab 5 mg/kg, administered as IV infusion, every four weeks through 8 weeks, then 10 mg/kg, administered as IV infusion, every four weeks through 216 weeks.
11044386|NCT04468659|Placebo Comparator|A3 Trial: Placebo|Participants will receive placebo (0.9% sodium chloride solution), administered as IV infusion, every four weeks through 216 weeks.
11044387|NCT04468646|Placebo Comparator|Placebo|matching placebo drug
11044388|NCT04468646|Experimental|NK-1R antagonist group|80 mg daily
11044389|NCT04468633|Active Comparator|Baerveldt 350 implant|
11044390|NCT04468633|Active Comparator|Ahmed ClearPath 350 implant|
11044391|NCT04468620|Experimental|ASSET Intervention|13-session group intervention
11044392|NCT04468607|Experimental|Dose-Escalation Stage|Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD).
11044393|NCT04468607|Experimental|Dose-Expansion Stage|Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial.
11044394|NCT04468594|Experimental|rigid tape|the rigid tapping technique using zinc oxide tape and protective tape (reference). With the participant assuming a relaxed standing position, the tape was applied bilaterally starting from the first to the last thoracic vertebra. A second tape was then applied to form a position of scapular depression and retraction. This tape was applied bilaterally and extended from the midpoint of the spine of the scapula to the last thoracic vertebra (figure ). This taping was applied for 12 weeks and changes every 3 days
11044429|NCT04468347|Experimental|Alzheimer's disease (AD)|Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
11044395|NCT04468594|Experimental|scapular stabilizing exercises|scapular stabilizing exercises in the form of (1)wall slides with squat, (2) Wall push-ups with ipsilateral leg extension, (3) lawnmower with diagonal squat, (4) resisted retraction to scapula with opposite leg squat (5) robbery with squat. ten repetitions / exercises/ session were perform
11044396|NCT04468594|Active Comparator|control|a standard physical therapy protocol will be introduced. This protocol consisted of (1) progressive strengthening exercises for rotator cuff muscles. The resistance was applied first by a red-colored elastic Thera-band. Then progressed, using the green-colored band. Each exercise was performed 10 times /session, (2) Self-stretching exercises for levator scapula, posterior deltoid, pectoralis minor, and latissimus dorsi muscles. Five repetitions of stretching were performed for each muscle per session
11044397|NCT04468581||Community sample|We plan to recruit a representative sample of the Singapore population.
11044398|NCT04468568|Experimental|Experimental|Intravenous Atosiban.
11044399|NCT04468568|Active Comparator|Control|Intravenous Terbutaline.
11044400|NCT04468555|Experimental|Global postural reeducation|Patients completed 3 sessions of global postural reeducation for 3 weeks.
11044401|NCT04468555|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
11044402|NCT04468542|Experimental|Bupivacaine/triamcinolone injection|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
11044403|NCT04468542|Placebo Comparator|Saline injection|2-cc injection of normal saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
11044404|NCT04468529|Experimental|Investigational drug group|Injectable Neucardin + standard basic therapeutic medication
11044405|NCT04468529|Placebo Comparator|Placebo group|placebo + standard basic therapeutic medication
11044406|NCT04468516|Experimental|Treatment|Intervention is applied to the C1 of the spine.
11044407|NCT04468516|Placebo Comparator|Placebo|Intervention is applied in reduced intensity to the trapezius muscle.
11044408|NCT04468516|No Intervention|Waitlist period|Participants will have a 1 month waitlist period where no intervention takes place.
11044409|NCT04468503|Active Comparator|1 g per kg body weight per day|"Protein will be receive by patients that is 1g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.
~Base line characters(BMI, nitrogen Balance, Protein biomarker, LFTs, RFTs, GCS)"
11044410|NCT04468503|Active Comparator|2 g per kg body weight per day|"Protein will be receive by patients that is 2g per kg per day, Patients will be assess and according to patient actual dry weight 1 g per kg of that weight protein will provided, energy will be provided according to ASPEN guideline 2016.
~Base line characters(BMI, nitrogen Balance, Protein bio marker, LFTs. , RFTs, GCS)"
11044411|NCT04468490||GROUP A: Patients adherent to BTcP European Guidelines|
11044412|NCT04468490||GROUP B: Patients non Adherent to BTcP European Guidelines|
11044413|NCT04468477|Active Comparator|Patients attending cardiac outpatient clinic|
11044414|NCT04468464|Active Comparator|Control Group|Occlusal Splint
11044415|NCT04468464|Experimental|Study Group|Osteopathic Manuel Therapy
11044416|NCT04468451|Experimental|ROC-48 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 48 hours for a total of 12-week intervention.
11044417|NCT04468451|Active Comparator|ROC-24 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 24 hours for a total of 12-week intervention.
11044418|NCT04468451|Active Comparator|Control group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. The participant's clinical occupational therapist will be responsible for the regular therapy. The dosage will be their regular dosage for a total of 12-week intervention.
11044419|NCT04468438||50 patients with LN with regular menstrual cycle|1- First group of50 patients with regular menstrual cycle
11044420|NCT04468438||50 patients with LN with amenorrhea|2- Second group of 50 patients with amenorrhea.
11044421|NCT04468425|Experimental|Pharmacokinetic Study|"Period 1 (Day 1) and 2 (Day 8 - Day 21) separated by 7-day washout period. Period 1: A single 5 mg tofacitinib tablet will be administered orally on Day 1.
~Period 2: Repeat dosing of Tofacitinib Citrate Topical Gel 3.2% to approximately 10% BSA in the morning of Day 8 and twice daily from Day 9 to Day 20 with the last dose in the morning of Day 21."
11044422|NCT04468399||Patients who initiated HIV treatment|
11044423|NCT04468399||Service providers at study facilities|
11044424|NCT04468373|Experimental|WA-NG (NG-IMT) Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
11044425|NCT04468360|Experimental|IV Allopregnanolone (Allo) for Extinction Retention (Expt. 1)|Arm 1 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after completion of extinction training.
11044426|NCT04468360|Placebo Comparator|IV Placebo for Extinction Retention (Expt. 1)|Arm 2 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after completion of extinction training.
11044427|NCT04468360|Experimental|IV Allo for Reconsolidation Blockade (Expt. 2)|Arm 1 of Expt. 2 will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
11044428|NCT04468360|Placebo Comparator|IV Placebo for Reconsolidation Blockade (Expt. 2)|Arm 2 of Expt. 2 will include will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
11046211|NCT04455373||traumatic surgery group|Patients with traumatic vascular injury
11044430|NCT04468347|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
11044431|NCT04468347|Experimental|Subjective memory complainers (SMC)|Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
11044432|NCT04468347|Experimental|Cognitively normal (CN)|Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
11044433|NCT04468334|Experimental|LARIAT + PVI Treatment Group|"Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
~Subgroup 1: Radiofrequency (RF) PVI catheter ablation treatment (n<65) Subgroup 2: Cryoballoon PVI catheter ablation treatment (n<20)"
11044434|NCT04468321|Experimental|Apple Watch|Patients will be provided with the Apple Watch Series 5 with Irregular Rhythm Detection and ECG capabilities.
11044435|NCT04468321|Placebo Comparator|Fitbit Inspire|Patients will be provided with the Fitbit Inspire with activity tracking.
11044436|NCT04468308||Senile Cataract|Patient with senile cataract, whose cataract surgery was postponed in the COVID-19 pandemic
11044437|NCT04468295|Experimental|0.018-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.018-inch slot orthodontic bracket system.
11044438|NCT04468295|Active Comparator|0.022-inch slot orthodontic bracket system|En-masse retraction using frictionless mechanics with 0.022-inch slot orthodontic bracket system.
11044439|NCT04468282|Experimental|VGB-ST|"Name of the compound: Vigabatrin ORPHELIA Pharma (VGB-ST) Pharmaceutical form: Soluble tablet Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.
~Batch N°: 16.92.042 (expiry date: 31.05.2017)"
11044440|NCT04468282|Active Comparator|Sabril|"Name of the compound: Sabril (vigabatrin) Pharmaceutical form: granules (sachet) Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.
~Batch N°: 6810 (expiry date: 31.05.2019)"
11044441|NCT04468269|Experimental|balance training with sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group. For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability.
11044442|NCT04468269|Experimental|balance training without sensory integration group|Conventional treatment: Static stretching exercises such as trunk rotation, flexion, and extension; hip flexors stretch, standing hamstring stretch; plantar flexors stretch, shoulder, elbow and wrist flexors and supinators stretch. Stretching will be applied for 30-sec hold with 30-sec rest. 3-5 times for each muscle group.For 40 min/day and 3 days/week for 6 weeks to improve balance and postural stability
11044443|NCT04468256||Cardiomyopathy|Heart Hive registered participants with self-reported cardiomyopathy
11044444|NCT04468256||Participants without Heart Disease|Heart Hive registered participants without cardiomyopathy or other heart disease.
11044445|NCT04468243|Experimental|Nurse-led|Nurse-led (group A). Patients randomized to group A will be taken to an available consultation room within the clinic and provided brief diabetes education which includes understanding what it means to have diabetes, healthy eating, and physical activity. Patients will also receive instructions on how to use a glucometer and how to take Metformin.
11044446|NCT04468243|No Intervention|Usual Care|Usual Care (Control; group B). Patients randomized to usual care will be informed of their HbA1c value, will continue to receive usual cancer care, and will be encouraged to follow-up with their PCP for T2D management. The RA will ensure that oncology visit clinic notes and the results of the HbA1c testing are relayed to the patient's PCP office. Patients who do not have a PCP identified will be referred to an appropriate provider.
11044447|NCT04468230|Experimental|Nicotine Transdermal Patch Administration|Each patient will complete two 14-day treatment conditions, one each for 7 mg and 14 mg nicotine transdermal patch administration with a washout period in between (≥ 14 days and up to 21 days).
11044448|NCT04468217||Subjects with positive test to SARS-COV2|Employees of critical services companies and healthcare workers with a positive test to SARS-COV2.
11044449|NCT04468217||Subjects with negative test to SARS-COV2|Employees of critical services companies and healthcare workers with a negative test to SARS-COV2.
11044450|NCT04468204|Experimental|SinuSonic Device|SinuSonic device used for 1 min three times a day for 8 weeks.
11044451|NCT04468204|Sham Comparator|Sham|Sham SinuSonic device used for 1 min three times a day for 8 weeks.
11044452|NCT04468191|Experimental|Experimental, then sham|Patients with ALS in the experimental, then sham arm will undergo an expiratory muscle strength training (EMST) session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 0% resistance.
11044453|NCT04468191|Experimental|Sham, then experimental|Patients with ALS in the sham, then experimental arm will undergo an expiratory muscle strength training (EMST) session with a device set to 0% resistance during their first study visit. Then, during their second study visit, patients with ALS will undergo an EMST session with a device set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment.
11044454|NCT04468178|Experimental|Shoulder prosthesis system GLOBAL ICON from DePuy|The GLOBAL ICON stemless is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
11044455|NCT04468178|Active Comparator|SIMPLICITY shoulder prosthesis system from Wright Medical|The SIMPLICITY is a shaftless shoulder prosthesis system for anatomical reconstruction of the shoulder joint in cases of total or hemiarthroplasty in the shoulder. The base plate consists of titanium coated with hydroxyapatite, the head of cobalt-chrome.
11044456|NCT04468152|Experimental|Case|
11044457|NCT04468152|No Intervention|Control|
11044458|NCT04468139|Experimental|Quercetin|Quercetin 500 g of quercetin Quercetin will be administered orally once daily, in the morning before breakfast for 5-10 days or patient improves or discharged
11044459|NCT04468126|Active Comparator|standard oxygen group|In order to obtain a SpO2>92%
11046750|NCT04451863|Active Comparator|Low THC + Low BCP|5 mg THC, 0 mg myrcene, 0.5 mg BCP
11044460|NCT04468126|Experimental|high-flow nasal cannula oxygen group|At least 50 L/min, adjusted in order to obtain a SpO2>92%
11044461|NCT04468113||US-guided core biopsy and clip placement|Female patients with sonographically suspicious, intramammary foci, scheduled for ultrasound-guided core biopsy and marking of the lesion with the Tumark® Vision Clip
11044462|NCT04468100|Experimental|Tigerase®|Dornase alfa
11044463|NCT04468100|Active Comparator|Pulmozyme®|Dornase alfa
11044464|NCT04468087|Experimental|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
11044465|NCT04468087|Experimental|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
11044466|NCT04468087|Experimental|Sofusbuvir + Daclatasvir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofosbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
11044467|NCT04468087|Placebo Comparator|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
11044468|NCT04468087|Placebo Comparator|Placebo Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
11044469|NCT04468087|Placebo Comparator|Placebo Sofusbuvir + Daclatasvir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
11044470|NCT04468074|Experimental|Therapy Group|"Therapy Group participants start the treatment period with three 1 ½ hour introductory sessions:
~An education session on the science behind chronic pain and a basic overview of the VR therapy.
~A session to customize the VR experience to match the participant's own pain experience.
~A training session on the use of the VR hardware and software.
~Upon completion, participants begin using the VR therapy app at home once a day, 5 times a week (minimum), for a total of 8 weeks. The VR app contains different training exercises. A workbook provides a schedule and background on each of the training sessions.
~Therapy Group participants may continue their other pain treatment regimes, and are asked to notify the research team of any changes."
11044471|NCT04468074|No Intervention|Standard of Care (SOC) Group|The SOC Group (no-intervention) completes a daily pain survey. SOC Group participants are asked to maintain their pain treatment regimes, and are asked to notify the research team of any changes.
11044472|NCT04468061|Experimental|Sacituzumab Govitecan + Pembrolizumab|"Participants will receive Sacituzumab Govitecan + Pembrolizumab at a pre-determined dose during a 21 day cycle.
~Sacituzumab Govitecan will be given on days 1 and 8 of the 21 day cycle Pembrolizumab will be given on day 1 of the 21 day cycle."
11044473|NCT04468061|Experimental|Sacituzumab Govitecan|"Participants will receive Sacituzumab Govitecan at a pre-determined dose during a 21 day cycle.
~Sacituzumab Govitecan will be given on days 1 and 8 of a 21-day cycle"
11044474|NCT04468061|Experimental|Retreatment|"Participants randomized to the combination arm (Sacituzumab Govitecan + Pembrolizumab) who stop with CR after at least 24 weeks of treatment may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment. This is termed the Second Course Phase and is only available if the study remains open and the subject meets conditions:
~."
11044475|NCT04468048||Music|"Subjects will put on headphones containing music from the album Nada Himalaya performed by S. G. Sachchidananda. The music will start playing 10 minutes before the colonoscopy procedure and will stop once subjects have woken up from sedation. Subjects will be instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure."
11044476|NCT04468048||Control|Subjects will put on headphones, but there will be no music playing. Subjects are instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure.
11044477|NCT04468022|Active Comparator|Toric Trifocal IOL|Twenty patients (20) underwent Toric Trifocal IOL surgery (first group)
11044478|NCT04468022|Active Comparator|Toric Trifocal IOL RELEX SMILE|Twenty patients (20) underwent Toric Trifocal IOL and RELEX SMILE surgery (second group)
11044479|NCT04468009|No Intervention|Standard of care|Standard of care for Covid-19
11044480|NCT04468009|Experimental|PCC-19|Treatment with convalescent plasma
11044481|NCT04467996|Active Comparator|6 hour IUBT placement|
11044482|NCT04467996|Active Comparator|18 hour IUBT placement|
11044483|NCT04467983|Active Comparator|Denosumab alone|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
11044484|NCT04467983|Active Comparator|Combination therapy|3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
11044485|NCT04467970|Experimental|Unicompartmental Knee Replacement|
11044486|NCT04467970|Experimental|High Tibial Osteotomy|
11044487|NCT04467957|Experimental|CF Cohort|16 Cystic Fibrosis Patients will undergo MRI imaging before and 6 months after initiation of triple-combination modulator therapy. Initiation of triple -combination modulator therapy will be determined by clinician and family prior to study enrollment. Hyperpolarized Xenon 129 will be administered through inhalation at two MRI imaging study visits.
11044488|NCT04467957|Experimental|Control Cohort|10 Healthy control study participants matched for age and gender will undergo one MRI imaging study visit. Hyperpolarized Xenon 129 will be administered through inhalation at one MRI imaging study visit.
11044489|NCT04467944||NS Group|Patients without pre-existing degeneration at L3/4 segment will be classified into control group (NS group).
11044490|NCT04467944||D Group|Patients with pre-existing disc factors (Pfirrmann grade≥3, Hiz or vacuum sign) at L3/4 segment will be classified into group D.
11044491|NCT04467944||C Group|Patients with pre-existing canal stenosis factors (cerebrospinal fluid occlusion≥1) at L3/4 segment will be classified into group C.
11044522|NCT04467762||Meningoencephalitis (ME-PED)|"pediatric patients between 0 and 17 years of age
~admission to hospital with suspected meningoencephalitis
~confirmed meningoencephalitis within 24 hours after admission"
11044492|NCT04467931||1.1 Outpatient SARS-CoV-2 Positive, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
11044493|NCT04467931||1.2 Outpatient SARS-CoV-2 Positive, ACEI vs. ARB|Among Veterans with treated hypertension who test positive for SARS-CoV-2, compare all-cause hospitalization and all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
11044494|NCT04467931||2.1 COVID-19 Hospitalized, ACEI/ARB vs non-ACEI/ARB|Among Veterans with treated hypertension and without compelling indications who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI/ARB- vs. non-ACEI/ARB-based regimens.
11044495|NCT04467931||2.2 COVID-19 Hospitalized, ACEI vs. ARB|Among Veterans with treated hypertension who are hospitalized for COVID-19, compare all-cause mortality rates between current users of a range of doses of ACEI- vs. ARB-based regimens.
11044496|NCT04467918|Experimental|Cannabidiol (CBD)|50 cases in the CBD group plus pharmacological and clinical measures. Patients in the investigational treatment group will receive CBD within 24 hours after randomization, with a daily dose of 300mg / day (two 150mg doses; 1mL of the formulation) for 14 days.
11044497|NCT04467918|Placebo Comparator|Placebo (PLB)|50 in the placebo group plus pharmacological and clinical measures. Patients in the placebo group will also receive, within 24 hours after randomization, 1mL of the same investigational medication vehicle (medium / coconut chain triglyceride oil - MCT) for 14 days
11044498|NCT04467905|Placebo Comparator|Placebo|Patients will receive a total of 200 μL of placebo ((i.e. 100 μL in each nostril) via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
11044499|NCT04467905|Experimental|Etripamil|Patients will receive a total of 200 μL of etripamil Nasal spray 70 mg via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
11044500|NCT04467892|Active Comparator|Group A|. Group A 120 patients, received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
11044501|NCT04467892|Active Comparator|Group B|group B 120 patients, included received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
11044502|NCT04467879|Experimental|Zona Plus|Using the Zona Plus device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day . After an initial handgrip strength assessment(the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip,or rest,session between each isometric routine.
11044503|NCT04467879|Placebo Comparator|Control Device|Using the Zona Placebo Control Device the patient will perform a twelve-minute isometric handgrip therapy session at approximately the same time each day. After an initial handgrip strength assessment(the calibration), a two-minute isometric routine is performed four times, two sessions per hand, with a one-minute non-grip,or rest,session between each isometric routine.
11044504|NCT04467866|Experimental|ROC-Stand(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
11044505|NCT04467866|Experimental|ROC-Stand(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
11044506|NCT04467866|Active Comparator|Control(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. The other occupational therapist will be responsible for regular therapy.
11044507|NCT04467866|Active Comparator|Control(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. The other occupational therapist will be responsible for regular therapy.
11044508|NCT04467853|Experimental|chimeric Antigen Receptor T cell LCAR-C18S Cells|
11044509|NCT04467840|Experimental|Opaganib|In addition to standard of care, opaganib will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. When required this may be made into a suspension form and may be administered by nasogastric tube.
11044510|NCT04467840|Placebo Comparator|Placebo|In addition to standard of care, a matching placebo will be administered orally with 2 x 250 mg capsules (500 mg) every 12 hours. Where required this may be made into a suspension form and may be administered by nasogastric tube.
11044511|NCT04467827||Group A1 male|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
11044512|NCT04467827||Group A2 female|back shape neutral - a vertical line applied to the back of the body meets at the level of the thoracic segment and buttocks
11044513|NCT04467827||Group B1 male|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
11044514|NCT04467827||Group B2 female|round back shape - a vertical line applied to the back of the body contacts only at the level of the thoracic segment
11044515|NCT04467827||Group C1 male|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
11044516|NCT04467827||Group C2 female|round back shape - a vertical line applied to the back of the body only touches the level of the buttock section
11044517|NCT04467814|Experimental|Intervention|
11044518|NCT04467814|Active Comparator|Usual Care|
11044519|NCT04467801|Experimental|Treatment|"Ipatasertib, 400 mg once daily, Oral, Days 1-14 of each 21 day cycle (2 weeks on and 1 week off).
~Docetaxel, 75 mg/m2, Intra-venous, Day 1 of each 21 day cycle."
11044520|NCT04467788|Active Comparator|Computer-aided session|Training on ergonomic principles in dentistry will be given to the participants through Computer-Aided sessions, including explaining videos on proper postures in dental practice .
11044521|NCT04467788|Active Comparator|Clinical Simulation Session|Training on ergonomic principles in dentistry will be given to the participants through clinical simulation sessions showing the proper postures in dental practice.
11046751|NCT04451863|Active Comparator|Low THC + High BCP|5 mg THC, 0 mg myrcene, 7.5 mg BCP
11044523|NCT04467762||Sepsis-associated encephalopathy (SAE-PED)|"pediatric patients between 0 and 17 years of age
~admission to hospital with suspected sepsis
~confirmed sepsis within 24 hours after admission or time of diagnosis"
11044524|NCT04467762||Control group (CON-PED)|"pediatric patients between 0 and 17 years of age
~exclusion of neurocognitive impairment
~admission to hospital for minor surgery (e.g. herniotomy, adenoidectomy, fractures treated by osteosynthesis) or for hemangioma treated by propranolol"
11044525|NCT04467749|Experimental|Suspension Wheel|Participants will be given a set of in-wheel suspension wheels to use in their normal daily routine for three months.
11044526|NCT04467736|No Intervention|Control|No further treatment after alveolar ridge preservation
11044527|NCT04467736|Active Comparator|Test|In case the test group comes out, instructions for the daily application of hyaluronic acid (Gengigel Forte©) will be given. Hyaluronic acid will be administered by the patient 3 times per day during 7 days.
11044528|NCT04467723|Experimental|Treatment|"Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.
~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:
~Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID"
11044529|NCT04467710||Success of LCBDE|Patients with a fully laparoscopic surgical treatment of common bile duct stones
11044530|NCT04467710||Failure of LCBDE|Patients with a laparoscopic cholecystectomy but an endoscopic treatment of common bile duct stone with an ERCP performed intra, per or postoperatively
11044531|NCT04467697|Experimental|SOV2012-F1-treated|Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 600 mg SOV2012-F1 per day (300 mg in the morning and 300 mg in the evening) based on plasma T after 14 and 42 days of treatment.
11044532|NCT04467684|Experimental|Cohort 1|Cohort 1: 100 mg CB-0406 (n=6)
11044533|NCT04467684|Experimental|Cohort 2|Cohort 2: 200 mg CB-0406 (n=6). Dose initiated following review of all safety data from Cohort 1 by a Safety Review Committee
11044534|NCT04467684|Experimental|Cohort 3|Cohort 3: 400 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 2 by a Safety Review Committee.
11044535|NCT04467684|Experimental|800 mg|Cohort 4: 800 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 3 by a Safety Review Committee.
11044536|NCT04467684|Experimental|1000 mg|Cohort 5: 1000 mg CB-0406 (n=6). Dose initiated following review of all safety data and PK data from Cohort 4 by a Safety Review Committee
11044537|NCT04467684|Placebo Comparator|Matched placebo|Two subjects in each Cohort (1, 2, 3, 4, 5) are randomized to matched placebo
11044538|NCT04467671|Experimental|Tissue Engineered Vascular Grafts|
11044539|NCT04467658||ADHD|
11044540|NCT04467658||NT NeuroTypical|
11044541|NCT04467658||ADHD NOS|
11044542|NCT04467645|Experimental|Reflexology|Reflexology Application: A total of twelve 30-minute reflexology sessions (2 per week)were administered to each patient.
11044543|NCT04467645|No Intervention|No intervention|No intervention was applied to the postmenopausal women in the control group.
11044544|NCT04467632|Experimental|Patients affected with idiopathic Parkinson Disease|
11044545|NCT04467619|Active Comparator|Early Illusory Movements|"Phase 1: A patient enrolled in group A will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist from the start of the study (Day 1), and also FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 15).
~Phase 2: From Day 16 onwards, the patient will undergo standard rehabilitation only according to the instructions of the attending surgeon and performed by an independent physiotherapist for 14 days (Day 30)."
11044546|NCT04467619|Active Comparator|Deferred Illusory Movements|"Phase 1: A patient enrolled in group B will have standard rehabilitation according to the instructions of the attending surgeon and performed by an independent physiotherapist, from the start of the study (Day 1) for 14 days (Day 15).
~Phase 2: Then, from Day 16 onwards, in addition to standard physiotherapy, FPS performed by a study nurse will take place for 30 minutes twice a day, 2 hours or more after the end of standard rehabilitation, for 14 days (Day 30)."
11044547|NCT04467606|Experimental|Experimental|The experimental group will receive a discharge planning which use the strategy of motivational interviewing.
11044548|NCT04467606|No Intervention|Control|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
11044549|NCT04467593|Experimental|Cohort A1|Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)
11044550|NCT04467593|Experimental|Cohort A2|The highest whole-body hyperthermia duration with acceptable side effects from cohort A1 will be applied to three additional patients with advanced solid cancer, once a week and for 15 days in total.
11044551|NCT04467593|Experimental|Cohort B1|Three pancreatic cancer patients will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15) using the device and in combination with the standard of care chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nab-paclitaxel or gemcitabine alone).
11044552|NCT04467593|Experimental|Cohort B2|The highest whole-body hyperthermia duration with acceptable side effects from cohort B1 will be applied in combination with chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nabpaclitaxel or gemcitabine alone) to three additional pancreatic cancer patients, once a week and for 15 days in total.
11044553|NCT04467580|Experimental|Patients with stenosing CD|Patients with stenosing CD will be recruited in each investigation center, during a preoperative consultation for an already decided and planned intestinal resection (digestive surgery or hepato-gastro department) -enterology).
11044554|NCT04467567|Experimental|patients treated with lutathera|Patients undergoing treatment with Lutathera® and who accept to participate in the study, regardless of the cycle of treatment, 1, 2, 3 or 4.
11044555|NCT04467554|Experimental|Measurements and T-chair training|This group will receive three measurements sessions and training with a new developed device (15 therapy sessions in total).
11044556|NCT04467554|No Intervention|Measurements|This group will receive three measurements sessions.
11044625|NCT04467060|Experimental|Anaprazole Sodium enteric-coated tablet|Single ascendinng dose (2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg), fasting oral administration.
11044557|NCT04467541|Experimental|Inactivated enterovirus type 71 vaccine|Inactivated enterovirus type 71 vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
11044558|NCT04467528|Experimental|Electroacupuncture combined with conventional drug therapy|"Conventional drug therapy:
~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial
~For participants with abdominal distension:
~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min
~For participants with post-operative ileus:
~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min
~32# acupuncture needle used and twice daily for three days"
11044559|NCT04467528|Active Comparator|Conventional drug therapy|"Conventional drug therapy:
~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
11044560|NCT04467515|Experimental|Dose Escalation and Expansion|"The dose escalation phase of the study will be an open label 3 + 3 design, where at least 3 patients are treated at each dose level. Dose escalation will be done via increases of the nominal activity of CAM-H2 in cohorts of 3 to 6 patients.
~In the dose expansion phase of the study, the patients will be given the RDP2 determined in the dose escalation phase. Similar to the dose escalation phase, all patients will receive at least 1 cycle of CAM-H2."
11044561|NCT04467502|Experimental|CBT with VRET|
11044562|NCT04467502|Active Comparator|CBT with imaginal ET|
11044563|NCT04467489||CA (non-CASH)|Cavernous Angioma (CA) without symptomatic hemorrhage cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
11044564|NCT04467489||CA (CASH)|Cavernous Angioma (CA) with Symptomatic Hemorrhage (SH) cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
11044565|NCT04467489||Young with seizure|Young (<30 years old) healthy control cohorts with seizures in the prior year
11044566|NCT04467489||Young without seizure|Young (<30 years old) healthy control cohorts without seizures in the prior year
11044567|NCT04467489||Older with HMA|Older (>50 years old) with hemorrhagic microangiopathy (HMA)
11044568|NCT04467489||Older without HMA|Older (>50 years old) without hemorrhagic microangiopathy (HMA)
11044569|NCT04467476|Active Comparator|tDCS (anodal)|tDCS: 20 minutes, 2mA, over the motor cortex representation of lower limbs.
11044570|NCT04467476|Sham Comparator|tDCS (sham)|tDCS: 20 minutes (but 30s ON), 2mA, over the motor cortex representation of lower limbs.
11044571|NCT04467463|Experimental|GPN|administrated bilateral greater palatine nerve block using levobupivacaine 0.25%
11044572|NCT04467463|Experimental|SMN|administrated bilateral suprazygomatic nerve block using levobupivacaine 0.25%.
11044573|NCT04467450|Experimental|Botox injection|half of the hemiplegic patients will be injected by botulinum toxin A in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
11044574|NCT04467450|Active Comparator|methyl prednisolonate injection|the other half of the hemiplegic patients will be injected by methylprednisolonate in the inflamed subacromial-subdeltoid bursa guided by musculoskeletal ultrasound
11044575|NCT04467437|Active Comparator|Intensive Training Only|Physical and gait training that targets rehabilitation of walking function.
11044576|NCT04467437|Active Comparator|Intensive Training Combined with Spinal Stimulation|Transcutaneous spinal stimulation combined with physical and gait training that targets rehabilitation of walking function.
11044577|NCT04467424|Experimental|Pediatric anesthesia with ketofol|ketamine, propofol
11044578|NCT04467424|Experimental|Pediatric anesthesia with ketofol plus lidocaine|ketamine, propofol, lidocaine
11044579|NCT04467411||Breast Cancer Group|Breast Cancer Group
11044580|NCT04467411||Healthy Volunteer|Healthy Volunteer Group
11044581|NCT04467398||Tuohy needle group|The participants who undergo the trigeminal nerve block using 22 guage Tuohy needle.
11044582|NCT04467398||Quincke needle group|The participants who undergo the trigeminal nerve block using 22 guage Quincke needle.
11044583|NCT04467385|Experimental|Experimental Group|Virtual Reality training(VR) + Sensory Integration therapy + conventional therapy
11044584|NCT04467385|Experimental|Control Group|VR training + conventional therapy
11044585|NCT04467372|Experimental|Tart cherry juice concentrate|tart cherry juice
11044586|NCT04467372|Experimental|Freeze dried tart cherry powder|tart cherry capsules
11044587|NCT04467372|Experimental|Juice placebo|kool-aid
11044588|NCT04467372|Experimental|Capsule placebo|maltodextrin
11044589|NCT04467359|Experimental|The experimental group|ERAS intervention group
11044590|NCT04467359|Placebo Comparator|The control group|Sports medicine rehabilitation nursing group
11044591|NCT04467346|Experimental|Ped-TMZ|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
11044592|NCT04467346|Active Comparator|Temodal capsule|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition
11044593|NCT04467333||All lung cancer patients|There will not be an intervention.
11044594|NCT04467320|Experimental|Intervention Group|Receiving the Teaching Recovery Techniques intervention.
11044595|NCT04467320|Active Comparator|Care-As-Usual Group|Receiving care-as-usual.
11044596|NCT04467307|Active Comparator|Foreign body aspiration.|Patients undergoing bronchoscopy with suspicion of foreign body aspiration. There is a foreign body in the bronchoscopy performed on these patients and it is the treated group.
11044597|NCT04467307|Active Comparator|Group with no foreign body aspiration|Patients undergoing bronchoscopy with suspicion of foreign body aspiration, but there is no foreign body in bronchoscopy.
11044626|NCT04467060|Placebo Comparator|Placebo|single dose, fasting oral administration
11044627|NCT04467047|Experimental|Intervention|Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
11044628|NCT04467034|Experimental|Receives Stanford tobacco education curriculum|Stanford Tobacco Prevention Toolkit is administered.
11044629|NCT04467034|No Intervention|Does not receive Stanford tobacco education curriculum|Receives another curriculum or no tobacco education.
11044598|NCT04467281|Experimental|89Zr-DFO-daratumumab PET/CT|"Pre treatment evaluation: 1) Standard of Care (SoC) labs, imaging, blind bone marrow biopsy. 2) Baseline research 89 Zr DFO daratumumab PET/CT 3) Possible biopsy of 89 Zr DFO daratumumab avid lesion Treatment: Daratumumab containing combination therapy (up to 12 cycles, 4 weeks/cycle). SoC labs, imaging, and blind bone marrow biopsies until complete response (CR) is suspected or 12 cycles are completed.
~Post treatment evaluation:1) SoC labs, imaging, and blind bone marrow biopsy 2) SoC minimal residual disease (MRD) analysis by next generation sequencing 3) Follow up research 89 Zr DFO daratumumab PET/CT 4) Possible biopsy of 89 Zr DFO daratumumab avid lesion"
11044599|NCT04467268|Experimental|Sleep extension intervention|"Intervention group participants met with an experienced sleep scientist to discuss and agree changes to their sleep and personal schedules. Discussions lasted 60-90 minutes, were informed by actigraphic sleep assessments from the baseline period, and aimed to increase TST by ≥1 hour/night. The structure and content of the About Sleep, Sleep Hygiene and Thoughts and Sleep components of the online Sleepful application, a self-help sleep management programme. Advice was supported by the provision of self-help booklets addressing sleep hygiene and the management of pre-sleep cognitions which had been successfully trailed in an intervention for insomnia symptoms. Finally, to capitalize on the participant's motivation at recruitment, and optimize adherence, the newly agreed sleep schedule was written into an agreement which the participant was asked to sign, simulating a 'therapeutic contract'. Schedules were reviewed by telephone at the end of the first week and revised if required."
11044600|NCT04467268|No Intervention|Control group|Participants in the control group were asked to continue with their habitual sleep schedule.
11044601|NCT04467255|Active Comparator|group a|aerobic training
11044602|NCT04467255|Active Comparator|group b|endurance training
11044603|NCT04467242||COPD patients|COPD patients with severe emphysema and right heart dysfunction
11044604|NCT04467229|Experimental|Focus group with chronically painful adolescents|Adolescents with chronic pain
11044605|NCT04467216|Experimental|Intervention group|This arm will undertake VR simultaneous motor-cognitive training in 30 minutes session, twice a week for 8 weeks
11044606|NCT04467216|No Intervention|Control Group|This arm will be doing existing forms of motor-cognitive training in 30 minutes session, twice a week for 8 weeks
11044607|NCT04467203|Experimental|Fadanafil fast to fat meal|"Seven subjects in group A will receive treatment in the following order:
~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-> At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal"
11044608|NCT04467203|Experimental|Fadanfil fat meal to fat|"Seven subjects in group B will receive treatment in the following order:
~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
11044609|NCT04467177|Experimental|Glucose group|Neonates will receive 30% oral glucose
11044610|NCT04467177|Placebo Comparator|Placebo group|Neonates will receive sterile water
11044611|NCT04467164|Experimental|Exhalatory-gated tVNS|exhalatory-gated tVNS on the left auricle
11044612|NCT04467164|Active Comparator|Inhalatory-gated tVNS|inhalatory-gated tVNS on the left auricle
11044613|NCT04467151|Experimental|anti-SARS-CoV-2 plasma|Patients receive one dose (250-300ml) of anti-SARS-CoV-2 convalescent plasma
11044614|NCT04467151|Placebo Comparator|Placebo|Patients receive one dose (250-300ml) of placebo (albumin 5%)
11044615|NCT04467138||Inflammatory bowel disease|Patients with either Crohn's disease (CD, n=22), and Ulcerative colitis (UC, n=19).
11044616|NCT04467138||Chronic intestinal failure|Patients with intestinal failure (CIF, n=20)
11044617|NCT04467125|Experimental|EMLA|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
11044618|NCT04467125|Active Comparator|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.
11044619|NCT04467099||Os Trigonum Excision with Tear|Participants with flexor hallucis tendon tear
11044620|NCT04467099||Os Trigonum Excision without Tear|Participants without flexor hallucis tendon tear
11044621|NCT04467086|No Intervention|Control Arm - Usual Care|"Participants in the control group will receive usual intravenous sedation according to practices already in place at each participating site (3 quaternary hospitals). The choice of agent, route of delivery, method of monitoring, and target levels of sedation will be determined by the treating team; however, we will recommend best practice clinical guidelines be followed. Current guidelines recommend analgesia first sedation titrated to relief of pain and dyspnea and sedative infusions if need for anxiety or agitation titrated to a prescribed level of sedation using a validated sedation scale. Patients may receive adjunct sedative/analgesic medications (e.g., enteral benzodiazepines) but propranolol use in the control group will be considered a protocol violation."
11044622|NCT04467086|Experimental|Intervention Arm - Propranolol hydrochloride|"Participants in the control arm will received sedation as described for the control arm, but with the addition of propranolol hydrochloride (titrated up as described under Intervention Description) and a corresponding reduction in sedatives as appropriate and described under Intervention Description."
11044623|NCT04467073|Experimental|Stepped-Care Online Reciprocal Imitation Training (Online RIT)|"Participants completed four telehealth modules over a period of 5 weeks (~1 per week, 1 week to practice). Two variables were selected as tailoring variables for this stepped-care model. Fidelity (RIT-PFF) and self-efficacy (EIPSES) at 5 weeks were used to determine which participants were in need of a step up in care, in the form of remote parent coaching.
~Parents who demonstrated ≥80% on the RIT-PFF, and who reported gains on the EIPSES continued to have access to Online RIT and practiced on their own for the next 5 weeks, but did not receive any remote coaching. Parents who demonstrated <80% fidelity on the RIT-PFF and/or who didn't report increases in the EIPSES were directed into coaching. Coaching involved videoconferences once per week (wks. 6-10) with a parent coach (PI), and followed the occupational performance coaching model. Sessions included review of successes and challenges, parent practice with feedback, problem solving, and planning."
11044624|NCT04467073|No Intervention|Wait List Control|Participants provided with information about available community resources after randomization. These participants were given the opportunity to engage in the stepped-care format of Online RIT after the post-intervention data collection time point; however their data was included exclusively in control group analyses.
11044630|NCT04467021|Experimental|Arm A (intensive systolic blood pressure management)|Patients receive intensive systolic blood pressure management for 6 months. Patients receive increased blood pressure medication every 2 weeks while systolic blood pressure is 120 mmHg or higher. Patients also monitor blood pressure at home 1 day a week (4 times in 1 day) every 2 weeks, and upload the recorded blood pressure readings to the provider and to a central blood pressure monitoring team. Patients with changes in blood pressure medications monitor blood pressure readings on 3 days in 1 week (4 times in 1 day).
11044631|NCT04467021|Active Comparator|Arm B (usual blood pressure management)|Patients receive standard blood pressure management for 6 months. Patients receive blood pressure medications per doctor's instruction. Patients also monitor blood pressure at home 1 day (4 times in 1 day) every 2 weeks, and upload the recorded blood pressures to a central monitoring team.
11044632|NCT04467008||One group of patients|
11044633|NCT04466995|Experimental|laparoscopic gynecologic surgery|25 laparoscopic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
11044634|NCT04466995|Other|laparotomic gynecologic surgery|25 laparotomic surgery to endotracheal cuff pressure 5., 15., 30., 45. min will be measured, values will be recorded
11044635|NCT04466969||HF|"Patients with HF with reduced Ejection Fraction (HFrEF) is enrolled if patients meet following criteria within 6 months:
~Ejection Fraction ratio（EF） ≤40%
~New York Heart Association(NYHA) class II-IV"
11044636|NCT04466969||stages of CKD (stage 3b)|"CKD is diagnosed based on the following e Glomerular Filtration Rate (eGFR) categories:
~Stage 3b: 30 mL/min/1.73m2 ≤ eGFR <45 mL/min/1.73m2"
11044637|NCT04466969||Stages of CKD (stage 4)|"CKD is diagnosed based on the following eGFR categories:
~15 mL/min/1.73m2 ≤ eGFR <30 mL/min/1.73m2"
11044638|NCT04466969||stages of CKD (stage 5)|"CKD is diagnosed based on the following eGFR categories:
~eGFR <15 mL/min/1.73m2"
11044639|NCT04466969||Treated by potassium binders|Patients who have been treated by Potassium Binders
11044640|NCT04466956|Active Comparator|Virtual reality for reduction of pain and anxiety during MVA|15 participants randomised to use VR headset during MVA and complete questionnaire and short interview regarding experience
11044641|NCT04466956|No Intervention|Control group- no VR|15 participants randomised to not use VR headset during MVA and complete questionnaire and short interview regarding experience
11044642|NCT04466943|Experimental|group A|Moderate neuromuscular blockade (NMB) , defined as a 1±2 twitch response to the train-of four (TOF) by stimulation of the ulnar nerve. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
11044643|NCT04466943|Experimental|group B|Deep NMB, defined by (0 twitch count in the TOF, 1±2 twitch responses in the post-tetanic count. The device which will be used is neuromuscular transmission monitor (NMT) to test the depth of muscle relaxation after giving rocuronium which is a muscle relaxant during general anesthesia.
11044644|NCT04466917|Experimental|ABP 215|"Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles.
~All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles."
11044645|NCT04466917|Active Comparator|Bevacizumab|"Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles.
~All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles."
11044646|NCT04466904|Experimental|IBI362 low dose cohort|Participants receive low dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection.
11044647|NCT04466904|Experimental|IBI362 medium dose cohort|Participants receive medium dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
11044648|NCT04466904|Experimental|IBI362 high dose cohort|Participants receive high dose level of IBI362, matched placebo or Dulaglutide administrated by multiple subcutaneous injection
11044649|NCT04466891|Experimental|ZW25 (Zanidatamab) Monotherapy|
11044650|NCT04466865|Experimental|Best Case/Worst Case communication tool|The participant's enrolled nephrologist will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the participant.
11044651|NCT04466865|No Intervention|Usual Care|"Usual care conversations are typically focused on mode and timing of dialysis, management of electrolytes and scheduling of laboratory testing. Conservative management or a treatment option of no dialysis is rarely mentioned."
11044652|NCT04466852|Active Comparator|cardio-relay Family Clinic|Patients discharged from INC hospital and identified as belonging to a Family Clinic randomized to cardio-relay receive instruction for telemedicine consultations. These are based on their own devices, when available, or provided by their local community agents associated in the study.
11044653|NCT04466852|No Intervention|control Family Clinic|Patients discharged from INC hospital and identified as belonging to a Family Clinic randomized to the control group or belonging who consent to participate in follow-up
11044654|NCT04466852|Active Comparator|cardio-relay Basic Clinic|Patients discharged from INC hospital and identified as belonging to a Basic Clinic randomized to cardio-relay receive instruction for telemedicine consultations. These are based on their own devices, when available, or provided by their local community agents associated in the study.
11044655|NCT04466852|No Intervention|control Basic Clinic|Patients discharged from INC hospital and identified as belonging to a Basic Clinic randomized to the control group or belonging who consent to participate in follow-up
11044656|NCT04466839||parkinsonian patients|Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.
11044657|NCT04466826|Experimental|Minors with chronic migraines|
11044658|NCT04466813|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
11044659|NCT04466813|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
11044660|NCT04466800|Experimental|Intervention group_rehabilitation program|multidisciplinary and personalized rehabilitation program
11044698|NCT04466540|Experimental|Hydroxychloroquine (HCQ)|HCQ group participants will receive a dose of 400mg twice daily (BID) in the first day, and a dose of 400 mg once daily (OD) from the second day of treatment, in a total of 7 days.
11044699|NCT04466540|Placebo Comparator|Placebo|The placebo group will follow the same regimen of administration
11044661|NCT04466800|No Intervention|Control group|Usual care of each site, including delivery of an information sheet concerning recommended physical activity (based on WHO recommendations) and nutrition. One month after inclusion, patients of this group will be offered a rehabilitation program (as described in the intervention group, but with only one session with a physical activity educator at home) and one dietitian consultation.
11044662|NCT04466787|Experimental|Spectral Photon Counting Computed Tomography (SPCCT)|The randomized SPCCT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
11044663|NCT04466787|Active Comparator|Dual Energy CT (DECT)|The randomized DECT patient will have this CT scan and an MRI before surgery. The plaque carotid will be collected for histological analysis
11044664|NCT04466774|Experimental|Dip Home-Based Dipstick Analyzer|Each participant will test their urine sample using the HBDA. device
11044665|NCT04466761|Experimental|Experimental: Cohort 1-4|60% of subjects per cohort will consume 30-90 grams of dietary supplement daily for 4 weeks, with each successive cohort dosage increasing according to a Fibonacci dose escalation.
11044666|NCT04466761|Placebo Comparator|Placebo: Cohort 1-4|40% of subjects per cohort will consume 30-90 grams of daily placebo for 4 weeks with each successive cohort dosage increasing in parallel to the experimental arm.
11044667|NCT04466748|Experimental|Anaprazole Sodium enteric-coated tablet|"Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration."
11044668|NCT04466748|Placebo Comparator|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
11044669|NCT04466735|Experimental|Active group|Participants will be on the active intervention for 6 months
11044670|NCT04466735|Placebo Comparator|Placebo Group|Participants will be on the placebo intervention for 6 months
11044671|NCT04466735|Active Comparator|Open phase on active product|At the end of the 6-month randomized controlled phase, participants will be unblinded and invited to continue on the active product for an additional 3 months.
11044672|NCT04466696||t4 colorectal cancer treated with ERAS protocol|prospective from January 2016 to May 2020
11044673|NCT04466696||t4 colorectal cancer treated with standards of care|retrospective from January 2010 to December 2015
11044674|NCT04466683|Experimental|Low radiation arm|A single dose of 35 cGY delivered to the whole thorax
11044675|NCT04466683|Experimental|High radiation arm|A single dose of 100 cGY delivered to the whole thorax
11044676|NCT04466683|No Intervention|Control arm|Patients will receive no radiation therapy but will have research samples collected and best supportive care
11044677|NCT04466670|No Intervention|phase 1|
11044678|NCT04466670|Experimental|phase 2A|
11044679|NCT04466670|Experimental|phase 2B|
11044680|NCT04466670|Experimental|phase 2C|
11044681|NCT04466657|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
11044682|NCT04466657|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus daily antioxidant supplement composed of two proprietary formulations that include reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
11044683|NCT04466644||The regulars of IVF clinics in the USA|Mainly asymptomatic individuals composed by patients who are attending their regular medical consultation and/ clinic staff of the participant sites, located in two areas of the USA with different pandemic status, and undergoing PCR and ELISA tests for diagnosis of COVID-19 before initiating the work after the lockdown.
11044684|NCT04466631||Observative longitudinal|The participants won't receive any support during the post surgery period.
11044685|NCT04466618|Placebo Comparator|Saline|Saline infusion
11044686|NCT04466618|Active Comparator|Exendin-9,39|Exendin-9,39 infusion
11044687|NCT04466618|Active Comparator|Saline + Intralipid/Heparin|Induction of acute insulin resistance during Saline infusion
11044688|NCT04466618|Active Comparator|Exendin-9,39 + Intralipid/Heparin|Induction of acute insulin resistance during Exendin-9,39 infusion
11044689|NCT04466605|Experimental|Tele-Yoga Therapy|All patients randomized to the intervention group had one to one yoga sessions with yoga therapist twice a week for 45 minutes on secure virtual platform. Patients were encouraged with home practice to follow everyday at least for 30-mins.
11044690|NCT04466605|Active Comparator|Usual Care|Patients randomized to usual care continued to receive care for their chronic musculoskeletal pain from their primary care physician. There was no attempt by to influence clinical management unless an emergency arose
11044691|NCT04466592|Experimental|Supportive intervention|A research psychologist will support participants, promoting their competences in the recover of work and social activities, such as the compliance.
11044692|NCT04466579|Experimental|BIS monitoring|Study subjects randomized in this study arm will have the depth of anesthesia controlled with the BIS monitor.
11044693|NCT04466579|Active Comparator|Standard care|Study subjects randomized in this study arm will receive standard anesthesiology care according to the usual procedures used at the study centre.
11044694|NCT04466566|Placebo Comparator|Saline|Saline will be infused during the study
11044695|NCT04466566|Active Comparator|Exendin-9,39|Exendin-9,39 will be infused during the study
11044696|NCT04466553||NICO BrainPath™ Patients|"50 patients will be enrolled in Group A NICO BrainPath™ system.
~The NICO BrainPath™ System has been proposed to reduce high morbidity and mortality associated with ICH through minimally invasive clot evacuation. Previous, single-center trials concluded evacuation of ICH using the BrainPath™ system as being safe and effective. Additionally, previous studies concluded that lesser ICH removal was correlated with mortality benefit and that the NICO BrainPath™ system approach was shown to be safe and effective with a high rate of clot evacuation and functional independence. This system warrants further research because of the need to optimize clinical outcome in these patients and to better define the role of hematoma evacuation in the care of these patients."
11044697|NCT04466553||Standard of Care|50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care (e.g. no surgical intervention). These patients will be matched to the surgical patients based on age, gender, and location of hemorrhage.
11046752|NCT04451863|Active Comparator|High THC + Low BCP|15 mg THC, 0 mg myrcene, 0.5 mg BCP
11044700|NCT04466527|Experimental|Treatment|Subjects in this arm will undergo laser treatment on their active acne vulgaris lesions. Subjects will serve as their own control.
11044701|NCT04466514|Experimental|Treatment A - Fasting|Fasting conditions
11044702|NCT04466514|Experimental|Treatment B - Fed|High-fat/high-calorie breakfast
11044703|NCT04466514|Experimental|Treatment C - Fed|Low-fat/low-calorie breakfast
11044704|NCT04466501|Experimental|ACR LAB for Professional User|
11044705|NCT04466488|No Intervention|Standard of care study arm|"The standard TPT implementation is for a clinician to screen for TB and to consider TPT for those who do not have presumptive TB. Clinicians in the study district (and most districts in South Africa) have received training and job aids to assist in appropriate application of the TPT initiation algorithm. Prescribing for TPT and ART is done by writing, by hand, the prescription in the patient's paper file. As part of this study, all study clinic providers will have access to standard Department of Health printed material and clinical training."
11044706|NCT04466488|Experimental|Choice Architecture study arm|"In the choice architecture implementation strategy, all opt-out clinic providers and pharmacists will be trained on the approach. The fundamental tenant of this approach is that TPT will be prescribed with any ART initiation and any ART re-prescribing for 3-12 months of TPT (adherent to current guidelines) if TPT has not been previously prescribed. This will be facilitated by co-prescribing ART and TPT. That is when ART is being prescribed TPT is meant to be prescribed at the same time of the clinic visit.
~The simultaneous prescribing will be facilitated through the introduction of an ink stamp or pre-printed sticker to use for quick entry of the ART prescription along with TPT and cotrimoxazole. The stamp/sticker for ART prescription, the prescription for TPT and for cotrimoxazole will be automatically included. Active canceling of these prescriptions (and indicating the reasons) will be needed to not have TPT dispensed."
11044707|NCT04466475|Experimental|Treatment (211At-OKT10-B10, melphalan, PBSC transplantation)|Patients receive 211At-OKT10-B10 IV continuously on days -7 to -4 and melphalan via infusion on day -2. Patients then undergo PBSC transplantation on day 0.
11044708|NCT04466436||CABG group|
11044709|NCT04466436||spine group|
11044710|NCT04466423|Experimental|Small group intervention|Those randomized to the immediate intervention arm will be asked to meet approximately every other week for 6 months, covering 12 sessions. We will ask each group to meet in a relatively private setting (e.g., a restaurant near campus or a reserved meeting room), rather than more public spaces (e.g. river room, cafeteria) where interruptions are more likely.
11044711|NCT04466423|Placebo Comparator|Control|"Participants randomized to Arm 2 (delayed intervention) will be wait listed to begin sessions 6 months after the start of the study. This participation will be optional."
11044712|NCT04466410|Experimental|Low Dose XT-150|Lowest dose of XT-150. Cohort 1 of the study
11044713|NCT04466410|Experimental|Middle dose XT-150|Middle dose of XT-150. Cohort 2 of the study
11044714|NCT04466410|Experimental|High Dose XT-150|Highest dose of XT-150. Cohort 3 of the study
11044715|NCT04466410|Placebo Comparator|Placebo|PBS for injection. 4 of 16 subjects randomly assigned in each experimental drug cohort
11044716|NCT04466397||3D printed implants reconstruction group|The patients with large bone defects who treated by 3D printed individualized porous implants
11044717|NCT04466384|Other|Propofol|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Propofol will be started at a concentration of 0.5 µg/ml followed by incremental increases in the target effect-site concentrations of 1.5, 2, 2.5, 3, 4, 6, and 8 µg/ml until a MOAA/S score less than 2 is reached.
11044718|NCT04466384|Other|Propofol with Remifentanil|Subjects will be sequentially assigned to start with propofol or propofol with remifentanil. Approximately 2 minutes before starting propofol, to attain an effect-site targeted concentration of remifentanil of 4 ng/ml, remifentanil will be given by a continuous infusion. Within approximately 7 minutes, the infusion rate of Remifentanil may be adjusted to maintain the effect-site concentration of remifentanil of 4 ng/ml throughout the study.
11044719|NCT04466371||MIU students and staff members|All students and staff members in MIU
11044720|NCT04466358|Experimental|Modified CLOSE protocol|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol, confirmed with multipolar circular mapping catheter.
11044721|NCT04466358|Active Comparator|High density mapping guided pulmonary vein isolation|Width antral circumferential pulmonary vein isolation guided according to CLOSE protocol and confirmed with high density mapping of each pulmonary vein antrum, with additional ablation lesions at sites of gap or dormant conduction.
11044722|NCT04466345|Experimental|Semaglutide|Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
11044723|NCT04466345|Placebo Comparator|Placebo|Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
11044724|NCT04466332|Experimental|Saline ECG with Pilot Tip Location System|PICC insertion using electrocardiographic guidance Pilot Tip Location System (TLS), ECG signal transmission is with saline water
11044725|NCT04466332|Experimental|Guidewire ECG with Sherlock Tip Confirmation System|PICC insertion using electrocardiographic guidance Sherlock 3CG Tip Confirmation System (TCS), ECG signal transmission is with guidewire
11044726|NCT04466319|Experimental|intervention arm|The individuals in the intervention group in the rocking chair three times a day, 20 minutes, a total of 60 minutes after the first day after surgery.They did this intervention until they first defecation .
11044727|NCT04466319|No Intervention|Control arm|The individuals in the control group sat in a standard chair in the same time as the intervention group in the non-rocking chair.
11044728|NCT04466293|No Intervention|Standard of care study arm|"Providers will receive training on benefits, indications, and contra-indications for TPT. Providers will use the standard approach of the default being to not prescribe. Only if providers specifically write for TPT will it be dispensed by a pharmacy or the provider."
11044761|NCT04466085|Experimental|Population Ⅳ|In population Ⅳ, there were 150 subjects who injected with 3 doses of low-dose test vaccine in the upper arm deltoid muscle according to the 0, 1, and 2 month immunization schedule.
11044762|NCT04466085|Experimental|Population Ⅴ|In population Ⅴ, there were 150 subjects who injected with 3 doses of high-dose test vaccine into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
11044729|NCT04466293|Experimental|Choice Architecture study arm|"Clinic staff will be responsible for strategy delivery for all patient interactions. Research staff will provide training and guidance for the choice architecture arm. Research staff will also work with the clinics to develop appropriate clinical stationary, ink stamps, stickers, or EMR modifications for prescribing, and reminder systems (e.g. written by pharmacy in clinic file, post-it on clinic file, post-it on lab results). The goal of this approach is for TPT prescribing to occur routinely and as part of ART prescribing. This is in contrast to considering prescribing only at the end of a long algorithm that includes TB and other assessments. With this approach, a patient will automatically be prescribed TPT unless the clinician specifically decides patients are not candidates due to active TB treatment or other clinical reasons."
11044730|NCT04466280|Active Comparator|Control Group|Participants in this group use personal protective equipment in the face of patients with COVID-19
11044731|NCT04466280|Experimental|Intervention Group 1|In this group, participants will receive 200 mg of hydroxychloroquine tablets daily in addition to personal protective equipment.
11044732|NCT04466280|Experimental|Intervention Group 2|In this group, participants, while observing and using complete personal protective equipment, will apply a thin layer of Dentol gel to the vestibular area of the mouth daily, every 6 to 8 hours.
11044733|NCT04466254|Experimental|Arm A|CPGJ602 325mg/m2 IV Q2W； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks.
11044734|NCT04466254|Experimental|Arm B|CPGJ602 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
11044735|NCT04466254|Active Comparator|Arm C|cetuximab 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
11044736|NCT04466241|Active Comparator|Lopinavir/ritonavir|Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
11044737|NCT04466241|Experimental|Lopinavir/ritonavir + telmisartan|"Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
~Telmisartan 40 mg : 1 tablet daily from Day 1 to Day 10"
11044738|NCT04466241|Experimental|Lopinavir/ritonavir + atorvastatin|"Lopinavir boosted by ritonavir 200mg/50mg: 2 tablets morning and evening from Day 1 to Day 10
~Atorvastatin 20 mg : 1 tablet daily from Day 1 to Day 10"
11044739|NCT04466228|Experimental|Stim1 high dose|This group will receive high dose non-invasive transcranial electrical stimulation
11044740|NCT04466228|Experimental|Stim2 low dose|This group will receive low dose non-invasive transcranial electrical stimulation
11044741|NCT04466228|Sham Comparator|Sham control|This group will receive sham control non-invasive transcranial electrical stimulation
11044742|NCT04466215|Active Comparator|CORT118335|900 mg (6 x 150 mg) tablets daily taken orally for one week
11044743|NCT04466215|Placebo Comparator|Placebo|Six placebo tablets taken orally for one week
11044744|NCT04466202|Experimental|Music Group with Structured Verbal Training|Music with structured verbal training was applied during transrectal ultrasound guided prostate biopsy.
11044745|NCT04466202|No Intervention|Control Group|The control group did not listen to music during the procedure, and they received routine training.
11044746|NCT04466189||Pancreatic Cancer Patients Treated With Proton Beam Therapy|Pancreatic Cancer Patients Treated With Proton Beam Therapy
11044747|NCT04466176|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11044748|NCT04466176|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
11044749|NCT04466163|Experimental|Schema Therapy and the Healthy Adult|For this study the ST-HA protocol outlined by Broersen & Claassen (2019) will be followed, consisting of ten one-and-a-half hour individual sessions across ten weeks with daily homework assignments (30-60 minutes). The ST-HA protocol is based on three pillars, aimed at improving self-compassion, well-being and positive affect. First psycho-education about compassionate affect regulation is given and patients learn to recognize the importance of self-caring behavior in stimulating the soothing- affect system to buffer against stress. The second pillar of the ST-HA protocol concerns the development of personal values and committed action as well as getting insight in values of important others. The third pillar concerns developing self-compassion
11044750|NCT04466163|No Intervention|Baseline|Outcome variables will be measured repeatedly in a pre-treatment baseline condition (2-5 weeks). Patients are randomly assigned to a pre-treatment/baseline phase. In the present study a restricted randomisation is chosen (Heyvaert & Onghena, 2014a). A minimum length of the phases is decided a priori in order to prevent for the assignment of too few measurements per phase and to ensure that the full treatment protocol can be offered
11044751|NCT04466150|Active Comparator|Ocrelizumab treated|Participants age 18-50 with a first clinical presentation of MS or high-risk CIS diagnosed within 90 days of screening will be treated with ocrelizumab (300 mg IV x 2 doses given 2 weeks apart) at disease origin and with maintenance ocrelizumab 600 mg every 6 months through 30 months with a final study visit at 3 years
11044752|NCT04466150|No Intervention|Observational study cohort|Subjects enrolled into an observational study matched for the same disease duration and who are either untreated or treated with alternate MS disease modifying therapies will serve as a parallel reference group
11044753|NCT04466137|Experimental|YPEG-rhG-CSF 2mg|YPEG-rhG-CSF 2mg
11044754|NCT04466137|Experimental|YPEG-rhG-CSF 33μg/kg|YPEG-rhG-CSF 33μg/kg
11044755|NCT04466137|Active Comparator|Positive Control Group|rhG-CSF/PEG-rhG-CSF
11044756|NCT04466098|Experimental|Mesenchymal Stromal Cells|Three fixed doses of MSC approximately 48 hours apart.
11044757|NCT04466098|Placebo Comparator|Placebo|Three fixed doses of placebo control approximately 48 hours apart.
11044758|NCT04466085|Experimental|Population I|In population I, there were 150 subjects who injected with 2 doses of low-dose test vaccine into the deltoid muscle of the upper arm according to the 0 and 1 month immunization schedule.
11044759|NCT04466085|Experimental|Population II|In population II, there were 150 subjects who injected with 2 doses of high-dose test vaccine in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
11044760|NCT04466085|Placebo Comparator|Population Ⅲ|In population Ⅲ, there were 150 subjects who injected with 2 doses of placebo in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.
11044883|NCT04465110|Experimental|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 7 days
11044763|NCT04466085|Placebo Comparator|Population Ⅵ|In Population Ⅵ, there were 150 subjects who injected with 3 doses of placebo into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.
11044764|NCT04466072||High Ventricular Arrhythmia burden group|"Inclusion criteria for all groups:
~age >18 years-old
~competent and willing to provide consent
~presence of implantable cardioverter-defibrillator
~diagnosis of cardiomyopathy
~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment
~Inclusion criteria for high ventricular arrhythmia burden group:
~• at least one episode of sustained VT/VF or VT/VF requiring ICD therapies within the preceding 3 months as assessed on device interrogation at the time of study enrollment
~Both groups will have stool sample collected for microbial analysis. This is anticipated twice for the high ventricular arrhythmia (VA) burden group. Once at the time of diagnosis of VA and later after the clinically indicated treatment for the VA."
11044765|NCT04466072||Control group|"Inclusion criteria for all groups:
~age >18 years-old
~competent and willing to provide consent
~presence of implantable cardioverter-defibrillator
~diagnosis of cardiomyopathy
~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment
~Inclusion criteria for control group:
~• no VT/VF on device interrogation for a period of at least 3 months preceding study enrollment
~Both groups will have stool sample collected for microbial analysis. This is anticipated only once for the control group."
11044766|NCT04466046|Active Comparator|midazolam with ramosetron (MR)|Midazolam 0.05mg/kg is given to the patients intravenously before anesthesia induction and ramosetron 0.3mg is received 10 minutes before surgery.
11044767|NCT04466046|Active Comparator|midazolam with palonosetron (MP)|Midazolam 0.05mg/kg is given to the patients intravenously before anesthesia induction and palonosetron 0.075mg is received immediately before anesthesia.
11044768|NCT04466033|Experimental|Magneto Microcatheter|
11044769|NCT04466020||Patients with Chronic Breathlessness|Patients with Chronic Breathlessness
11044770|NCT04466007|Placebo Comparator|Control arm|0.9% physiological saline
11044771|NCT04466007|Experimental|Low dose treatment arm|Low dose allogeneic mesenchymal stem cells derived from adipose tissue
11044772|NCT04466007|Experimental|High dose treatment arm|High dose allogeneic mesenchymal stem cells derived from adipose tissue
11044773|NCT04465994||primary repair|Patients with acute achilles tendon ruptures who received the treatment of primary repair.
11044774|NCT04465994||gastrocnemius turn-down flaps|Patients with acute achilles tendon ruptures who received the treatment of gastrocnemius turn-down flaps.
11044775|NCT04465981||COVID-19|Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
11044776|NCT04465981||PUI|Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
11044777|NCT04465968|Experimental|CRT + Durvalumab ± Surgery + Durvalumab|Concurrent chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy)+2 courses of durvalumab followed by Surgery and adjuvant durvalumab for resectable SST or chemoradiotherapy (cisplatin+S-1+radiotherapy 66Gy) followed by maintenance durvalumab for unresectable SST.
11044778|NCT04465955|Experimental|NGM621 Treatment Group A (every 4 weeks)|NGM621 single IVT injection
11044779|NCT04465955|Experimental|NGM621 Treatment Group C (every 8 weeks)|NGM621 single IVT injection
11044780|NCT04465955|Sham Comparator|Sham Group B (every 4 wks) & D (every 8 wks)|Sham
11044781|NCT04465916|Experimental|Experimental Arm|Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
11044782|NCT04465916|Placebo Comparator|Control Arm|Control Arm: Placebo + NA daily (12 patients)
11044783|NCT04465903||Dysphagia patients|The first group consists of 85 dysphagia patients who have at least six months of dysphagia complaints. The participants will given the Turkish version of Sydney Swallow questionnaire (SSQ-T), consisted of 17 questions, eating assessment tool-10 and two scales evaluated with FEES. After the two weeks, 30 participants will given the SSQ-T for sampling.
11044784|NCT04465903||Healthy adults|The second group consists of 85 healty participants will given the SSQ-T consists of 17 questions, eating assessment tool-10.
11044785|NCT04465890|Experimental|Single dose ASC22 injection 0.3mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,0.3mg/kg dose of the drug once.
11044786|NCT04465890|Experimental|Single dose ASC22 injection 1.0mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,1.0mg/kg dose of the drug once.
11044787|NCT04465890|Experimental|Single dose ASC22 injection 2.5mg/kg|Single dose ASC22 Injection; Specification: 200mg/1ml/1bottle; Subcutaneous injection; once administration,2.5mg/kg dose of the drug once.
11044788|NCT04465890|Experimental|Multiple dose ASC22 injection 1.0mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks
11044789|NCT04465890|Experimental|Multiple dose ASC22 injection 2.5mg/kg|Multiple dose ASC22 injection; Specification: 200mg/1ml/1bottle; Subcutaneously administered once every 2 weeks , 4 received 2.5mg/kg, up to 24 weeks
11044790|NCT04465890|Placebo Comparator|Placebo sodium chloride injection 1.0mg/kg|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (1.0mg/kg).After 2 weeks ASC22 injection subcutaneously administered once every 2 weeks , 4 received 1.0mg/kg, up to 24 weeks.
11044791|NCT04465890|Placebo Comparator|Placebo sodium chloride injection 2.5mg/kg|Placebo saline injection; Specification: 90mg/10ml/1 bottle; Subcutaneously administered every 2 weeks (Q2W, known as one drug administration cycle), duration: once every 2 weeks (Q2W), up to 12 weeks. Based on the weight of the patients, an equal dose of placebo was administered according to the incoming dose group (2.5mg/kg). After 2 weeks ASC22 injection subcutaneously administered once every 2 weeks , 4 received 2.5mg/kg, up to 24 weeks.
11044792|NCT04465877|Experimental|JTT-662 Dose 1|JTT-662 Tablets Dose 1 by mouth once daily from Day 1 to Day 28
11044793|NCT04465877|Experimental|JTT-662 Dose 2|JTT-662 Tablets Dose 2 by mouth once daily from Day 1 to Day 28
11044794|NCT04465877|Experimental|JTT-662 Dose 3|JTT-662 Tablets Dose 3 by mouth once daily from Day 1 to Day 28
11044795|NCT04465877|Placebo Comparator|Placebo|Placebo Tablets by mouth once daily from Day 1 to Day 28
11044796|NCT04465864|Other|Insertion visit 4 days prior|Intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
11044797|NCT04465864|Other|Surgical 1 visit day 0|Intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
11044798|NCT04465851|Active Comparator|FS65_Curc|Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day
11044799|NCT04465851|Placebo Comparator|FS65_Plac|Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose])
11044800|NCT04465851|Placebo Comparator|FS0_Plac|Placebo (Ferrous Sulphate placebo [cellulose]) and Placebo (Curcumin placebo [cellulose])
11044801|NCT04465851|Placebo Comparator|FS18_Plac|Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo [cellulose])
11044802|NCT04465851|Active Comparator|FS18_Curc|Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day
11044803|NCT04465838||Psoriasis|This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
11044804|NCT04465825|Active Comparator|Interspersing HITT in exercise|We will test whether introducing HITT into an acute exercise bout will increase overall energy expenditure or time to fatigue.
11044805|NCT04465825|No Intervention|Acute exercise bout with no HITT|Exercise will occur at 50% peak without introducing HITT.
11044806|NCT04465812|No Intervention|Standard health counseling at baseline|Standard health counseling at baseline
11044807|NCT04465812|Experimental|Self-monitoring and personalized feedback on smartphone app|"Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;
~Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index > 15 to assess detail clinical status and recommend outpatient visit if necessary;
~Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS>49 or SDS>52 to assess detail clinical status and recommend outpatient visit if necessary;
~Patients will complete cognitive training games every week on app;
~Medical staff will send health information on app"
11044808|NCT04465799|Experimental|ENTREN Programme|This intervention consists in a total of 12 biweekly sessions: 9 sessions of 2-hr only for children, with a further three 3-hr sessions attended by both families and children together: nutrition, physical activity sessions, and a closing event session. Children content was developed based a cognitive-behavioural perspective, and included motivational interviewing tools. The aim of the children's programme is, to promote healthy eating habits, problem awareness, motivation to change unhealthy behaviours, health commitment, emotional regulation, social skills and self-esteem. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
11044809|NCT04465799|Experimental|ENTREN-F Programme|ENTREN-F has the same children's intervention than ENTREN. It has extra 6 2-hr sessions to work on family environment and communication, plus three 2-hr sessions attended by both families and children together. One 2-hr session at 6, 12 and 18-month follow-up was provided to refresh skills, their physical activity, and nutritional behaviours.
11044810|NCT04465799|Other|Control group|The intervention of this group consists in usual treatment in Primary Care provided by Endocrinology Services. 3 monthly face-to-face consultations and continuous online monitoring are provided to these families, oriented to promote healthy habits of nutrition and physical activity for 6 months. It works from an exclusively behavioural perspective. A token economy is used with the families as a system of contingency management based on the systematic reinforcement of target behaviour.
11044811|NCT04465773|Experimental|pupillometry|General anesthesia for scheduled gynecological surgery Propofol target concentration adjusted to maintain bispectral index between 45 and 55 for 10 minutes Remifentanil target concentration 1 ng/ml for 10 minutes Tetanic stimulations of 10-20-30-40-50-60 milliamps (5 seconds per stimulation, 2 minutes between stimulations) Continuous pupillometry VideoAlgesiGraph
11044812|NCT04465760|Experimental|Supportive Care (xisomab 3G3)|Patients receive xisomab 3G3 IV at the time of PICC line placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.
11044813|NCT04465734|Experimental|A (treatment group)|HLX10 in combination with HLX04
11044814|NCT04465734|Sham Comparator|B (control group)|sorafenib
11044815|NCT04465721|Active Comparator|HABIT|Participants randomized to the HABIT group will maintain their habitual eating schedule (≥14-h).
11044816|NCT04465721|Experimental|TRE|Participants randomized to TRE will reduce their eating window to a self-selected eating window (≤10-h).
11044817|NCT04465708|Other|Homework, Organization, and Planning Skills (HOPS)|"The Homework, Organization, and Planning Skills (HOPS) intervention is delivered through a series of 16 frequent but brief sessions between the school professional and student. For the purposes of this study, the school professional will be called a school partner. Each session is approximately 20 minutes. The three main skill areas covered as part of the program are: (1) school materials organization, (2) homework management and (3) time management and planning. A reward system is utilized in effort to change behavior patterns by making rewards available when a student engages in productive organizing and planning behaviors. The intervention also includes two parent meetings and one teacher meeting."
11044818|NCT04465708|No Intervention|Treatment-As-Usual Waitlist (WL-TAU)|The Treatment-As-Usual Waitlist (WL-TAU) will be enacted for study participants attending the enrolled schools assigned to this arm. After providing post data (and in some cases, follow-up data as well), participants will then receive the HOPS intervention.
11044819|NCT04465695|Experimental|IFN beta-1b and clofazimine|A 3-day course of 3 doses of subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) consecutively on day 1 to day 3 and oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
11044820|NCT04465695|Active Comparator|Clofazimine|A 3-day course of oral clofazimine 100mg twice daily on day 1, then 100mg daily for 2 days plus standard care
11044821|NCT04465695|No Intervention|Control|Standard care alone
11044822|NCT04465682|Experimental|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm. Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user
11044823|NCT04465669|Active Comparator|Orsiro|Implantation of a Orsiro® biolimus a9 eluting coronary stent (drug-eluting stent, DES)
11044824|NCT04465669|Active Comparator|Resolute Integrity|Implantation of a Resolute Integrity® zotarolimus eluting coronary stent (drug-eluting stent, DES)
11044825|NCT04465656||[PCR-COVID 19-Pos] group|Having a microbiological diagnosis confirming COVID-19 infection (ie positive RT-PCR on nasopharyngeal swab) and/or clinical/CT signs
11044826|NCT04465656||[PCR-COVID 19-Neg] group|Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
11044827|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Pos] group|"Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
~Having been tested positive in a serological test for COVID-19 at M3"
11044828|NCT04465656||[PCR-COVID 19-Neg & Sero-COVID 19-Neg] group|"Having a microbiological diagnosis confirming the absence of COVID-19 infection (ie negative RT-PCR on nasopharyngeal swab) and absence of clinical /CT signs
~Having been tested negative in a serological test for COVID-19 at M3"
11044829|NCT04465643|Other|Immunotherapy with Nivolumab and Ipilimumab|Nivolumab 4.5 mg/kg every 3 weeks (Q3W) x 2 Ipilimumab 1 mg/kg Q3W x 2 Nivolumab monotherapy 4.5mg/kg Q3W concurrent with standard therapy Nivolumab monotherapy should be held for at least 2 weeks before and 2 weeks after surgery
11044830|NCT04465630|Other|Pseudophakic eyes with Open Angle Glaucoma|Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.
11044831|NCT04465591||Myocardial infarction|Recruited patients with STEMI or NSTEMI and elevated Troponin T
11044832|NCT04465591||Myocardial injury|Recruited patients with myocardial injury based on elevated Troponin T and associated with renal failure, severe infection, strenouos exercise, atrial fibrillation, myocarditis, takotsubo cardiomyopathy or other similar conditions
11044833|NCT04465578|Active Comparator|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
11044834|NCT04465578|Active Comparator|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
11044835|NCT04465565|Experimental|Intravenous fluid administration|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will be treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 60 minutes. The fluids treatment will be initiated 90 minutes after the stimulation test will begin
11044836|NCT04465565|No Intervention|Control Group|This arm will include 20 children who received Testoviron or Estrofem prior to the the stimulation test and 40 children who did not receive preparation prior to the stimulation test. Participants in this arm will not receive fluids intravenously during the stimulation test, unless it will be required due to safety reasons
11044837|NCT04465552||Hospitalized COVID-19 Patients|
11044838|NCT04465539|Placebo Comparator|control group|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
11044839|NCT04465539|Experimental|Hydroxyethyl starch group):|Patients will start therapy with Hydroxyethyl starch instead of normal saline (6% hetastarch 600/0.75 in 0.9% sodium chloride) with a dose of 500 cc in 6 hours. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
11044840|NCT04465539|Experimental|Combined Hydroxyethyl starch and hydrocortisone group|Patients will start therapy with combined Hydroxyethyl starch (Voluven®, fresenius kabi, Germany) and hydrocortisone (SOLU-CORTEF 100 mg ampoule) instead of normal saline of normal saline as follow: Hydroxyethyl starch dose is 6% hetastarch 600/0.75 in 0.9% sodium chloride with a dose of 500 cc in 6 hours. Hydrocortisone dose is 200-300 mg /day intravenously until normalization of blood pressure. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
11044841|NCT04465513|Active Comparator|Best Standard of Care + CARDIO|Combination of CARDIO and Best Standard of Care
11044842|NCT04465513|Placebo Comparator|Best Standard of Care|Placebo and Best Standard of Care
11044843|NCT04465500|Other|Treatment|
11044844|NCT04465487|Experimental|REGN6569+cemiplimab|REGN6569 lead-in
11044845|NCT04465461|Experimental|Treatment|Patients exhibiting baseline collateral ventilation by Chartis® balloon catheter assessment who undergo video-assisted thoracoscopic surgery (VATS) fissure completion surgery, confirmation of fissure completion by computerized tomography (CT) scan and confirmation of conversion to collateral ventilation negative by Chartis® balloon catheter assessment post VATS surgery and subsequent Zephyr Valve insertion.
11044846|NCT04465448||healthy volunteers|
11044847|NCT04465448||group case|
11044848|NCT04465435||SUN-participants|"University students enrolled in a selected university in Stockholm, studying on a full-time educational program with at least one academic year left before graduation.
~There is no intervention. The exposures are repeated measures, 5 times (every three months), using web-based self-report questionnaires during one academic year. Also weekley SMS are used to measure depression, anxiety and pain intensity."
11044849|NCT04465422|Experimental|Intervention Group|We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.
11044850|NCT04465422|Active Comparator|Control Group|We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.
11044851|NCT04465409|Experimental|Presbyopic adults|"Presbyopic adults, male or female between 40-65 years of age who need from +1.25 D to +3.50 D of reading addition in the non-dominant eye to improve near visual acuity by at least one line or more.
~In this investigation, CorVision® will be implanted in the non-dominant eye to improve near vision and the dominant eye is left intact or corrected by a standard refractive surgery to emmetropia. In brief, subjects will undergo laser corneal surgery on their non-dominant eye to create an anterior stromal pocket into which the investigational device will be implanted."
11044852|NCT04465396|Experimental|Sequence AB|Cohort 1 participants will receive 3 milligram (mg) of Teduglutide and Cohort 2 participants will receive 4 mg of Teduglutide subcutaneous (SC) injection using syringe on Day 1 of treatment period I (Sequence A) followed by SC pen injector on Day 1 of treatment period II (Sequence B). A washout period of 7 days will be maintained between the treatment period I and II.
11044853|NCT04465396|Experimental|Sequence BA|Cohort 1 participants will receive 3 mg of Teduglutide and Cohort 2 participants will receive 4 mg of Teduglutide SC pen injector on Day 1 of treatment period I (Sequence B) followed by SC injection using syringe on Day 1 of treatment period II (Sequence A). A washout period of 7 days will be maintained between the treatment period I and II.
11044854|NCT04465383|Experimental|Digital Sedation|Digital Sedation with rescue intravenous sedation (propofol) if needed upon patient request
11044855|NCT04465383|Active Comparator|Intravenous sedation|Control arm with conventional Intravenous sedation
11044856|NCT04465357|Experimental|Erenumab-Aooe 140 MG/ML [Aimovig]|Participants received 140 mg/mL administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for three months (12 weeks).
11044857|NCT04465344|Experimental|IOL implantation experimental|Experimental arm: Trifocal intraocular lens Isatis TF
11044858|NCT04465344|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens Isatis
11044859|NCT04465331||patients with knee arthrosis|Painful Knee Osteoarthritis with presence of osteophytes on radiography
11044860|NCT04465318|Experimental|E-cigarettes (EC)|EC + Counseling
11044861|NCT04465318|Active Comparator|Nicotine Replacement Therapy (NRT)|NRT + Counseling
11044862|NCT04465305|Experimental|enraped group|patients with a new treatment of tarlov cysts
11044863|NCT04465305|Active Comparator|plasty group|patients with traditional treatment of tarlov cysts
11044864|NCT04465292|Experimental|Intervention|Participants will receive Tildrakizumab 100mg at Weeks 0, 4, 16; three doses; a 16-week treatment course and 24-week followup
11044865|NCT04465279|Experimental|Trifocal Diffractive Intraocular Lens (FineVision)|36 eyes having implantation of trifocal diffractive IOL (FineVision)
11044866|NCT04465266|Experimental|50 mg Tolperisone|50 mg tablets (2 days SD, 2 days TID)
11044867|NCT04465266|Experimental|100 mg of Tolperisone|100 mg tablets (2 days SD, 2 days TID)
11044868|NCT04465266|Experimental|200 mg Tolperisone|200 mg tablets (2 days SD, 2 days TID)
11044869|NCT04465253|Experimental|Health services research (discussion, interview)|Patients participate in a discussion with an occupational therapist via videoconferencing over 15 minutes QW for 4 weeks about their experience with lymphedema and the occupational services they received. After 4 weeks, some patients may also participate in an interview with an occupational therapist via videoconferencing over 60 minutes. During the first week of the study, patients also receive occupational therapy per standard of care.
11044870|NCT04465240|Experimental|Virtual reality simulation of neighborhood disadvantage|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood representative of disadvantage they were assigned to. Then they will watch a video again during a recovery period.
11044871|NCT04465240|Active Comparator|Virtual reality simulation of neighborhood affluence|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood, representative of affluence they were assigned to. Then they will watch a video again during a recovery period.
11044872|NCT04465214||1/Cohort 1|Patients with histologically or cytologically proven cancer under active treatment at the NCI.
11044873|NCT04465201|Experimental|Subjects receiving the Impella/Impella® Hemodynamics platform|
11044874|NCT04465188|Experimental|Experimental arm|Surgical procedure to prevent retinal detachment in the unaffected eye
11044875|NCT04465188|No Intervention|Control arm|Standard procedure of clinical practice without any surgical procedure for the unaffected fellow eye.
11044876|NCT04465175|Active Comparator|Second dose magnesium sulphate|Second dose magnesium sulphate 50 mg/kg infused over one hour
11044877|NCT04465175|Placebo Comparator|Placebo|Normal saline (2.5 ml/kg) infused over one hour
11044878|NCT04465162|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy QD 5 times weekly over 3.5-5 weeks.
11044879|NCT04465149|Experimental|Patients|Patients who required germectomy of mandibular third molars. Each patient received local anaesthesia on one side with articaine inoculated with plexus technique while on the other side with mepivacaine using inferior alveolar nerve block technique.
11044880|NCT04465136|Experimental|Received CES intervention|CES with the frequency of 0.5 Hertz; current of 100~600micro-ampere, for 60 minutes, 3 days per week for 3 weeks, total 9 sessions intervention
11044881|NCT04465123|Experimental|Furosemide with spironolactone or hydrochlorothiazide|"IV furosemide dosage will be adjusted according to the protocol as follows. Level 1: previous oral furosemide dose ≤80 mg/day; furosemide 80 mg IV bolus every 6 hours Level 2: previous oral furosemide dose 81-160 mg/day; furosemide 160 mg IV bolus every 6 hours Level 3: previous oral furosemide dose >160 mg/day; furosemide 250 mg IV bolus every 6 hours Furosemide dosage will be adjusted to keep urine output between 3,000 and 5,000 ml/day and >600 ml during 6 hours after furosemide administration.
~If the urine output <3,000 ml/day or <600 ml per 6 hours, furosemide dosage will be increase 1-level up per protocol above.
~If the urine output >5,000 ml/day, furosemide dosage will be reduced 1-level down per protocol above.
~Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels."
11044882|NCT04465123|Active Comparator|Furosemide with placebo|"IV furosemide dosage will be adjusted according to the pre-defined protocol as shown in the experimental group.
~Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels."
11044884|NCT04465110|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 7 days
11044885|NCT04465097|Experimental|Tucidinostat and Exemestane|Patients receive exemestane from week 1 to week 26 and Tucidinostat BIW from week 3 to week 26. Courses continue in the absence of disease progression or unacceptable toxicity. If the patient is premenopausal, leuprorelin or goserelin will be prescribed.
11044886|NCT04465084|Other|Case|Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.
11044887|NCT04465084|Other|Witness|"Person matched to a case on age (+/-3 years) and education level"
11044888|NCT04465071|No Intervention|Standard Treatment|Post-Cataract surgery standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
11044889|NCT04465071|Other|Standard Treatment plus lubricating drops|Lubricant eye-drops (0.3% cross linked sodium hyaluronate, AEONTM Protect Plus and phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vita-mins A and E (AEONTM Repair) for 6 weeks post-Cataract surgery, in addition to the standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
11044890|NCT04465045||Unique cohort|All women, 18 to 43 years, operated from laparoscopy-hysteroscopy for unexplained infertility in montpellier university hospital
11044891|NCT04465032|Active Comparator|Autologous gut microbiome transplantation|Three autologous (own) fecal transplantations (at baseline, 3 and 6 weeks)
11044892|NCT04465032|Experimental|Allogenic gut microbiome transplantation|Three allogenic (lean donor) fecal transplantations (at baseline, 3 and 6 weeks)
11044893|NCT04465019||TBI Group|Subjects in the TBI group included patients who suffered a TBI and who used the EKSO® bionic exoskeleton during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
11044894|NCT04465019||CVA Group|Subjects in the CVA group included all patients in the hospital that used the EKSO® during their rehabilitation process during their rehabilitation treatment from 01/01/2017 to 04/30/2020.
11044895|NCT04465006|Experimental|Hippotherapy Simulator Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
11044896|NCT04465006|Experimental|Conventional Exercise Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
11044897|NCT04464993|Experimental|CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
11044898|NCT04464993|Experimental|CORE + text|CORE components + The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV app) that will provide simple adaptive content based upon length of most recent SST bout, time of day, and time since last 10 min bout of MVPA. These prompts will specifically target outcome expectations around SST and MVPA.
11044899|NCT04464993|Experimental|CORE + Lockout|CORE components + Lockout component will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided with a planning tool for planning SST on a daily basis in order to reach their over 50% reduction goal.
11044900|NCT04464993|Active Comparator|CORE + Earn|CORE components + the investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits from the StandUPTV app to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be provided a planning tool for planning SST. on a daily basis in order to reach their over 50% reduction goal.
11044901|NCT04464993|Active Comparator|CORE + Text + Earn|"Intervention components will be delivered as described in simpler factorial conditions.
~App shows progress toward SST goal or if goal is exceeded. Can earn additional SST through exercise (10min per 30min), simple adaptive content (by SST bout, time of day, and last 10 min bout of MVPA)"
11044902|NCT04464993|Active Comparator|CORE + Text + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...
~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Simple adaptive content (by SST bout, time of day, and last 10 min bout of MVPA)"
11044903|NCT04464993|Active Comparator|CORE + Earn + Lockout|"Intervention components will be delivered as described in simpler factorial conditions, and...
~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise (10min MVPA for 20min SST)."
11044904|NCT04464993|Active Comparator|CORE + Earn + Lockout + Text|"Intervention components will be delivered as described in simpler factorial conditions, and...
~If exceeded, the limits feature will restrict screen time through the end of the week (Monday-Sunday) so cannot exceed limit. Can earn additional SST through exercise (10min MVPA for 20min SST). Simple adaptive content (by SST bout, time of day, and last 10 min bout of MVPA)"
11044905|NCT04464980|Experimental|SL-BUP standard dose + MM|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044906|NCT04464980|Experimental|SL-BUP high dose + MM|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11059342|NCT04362514|Active Comparator|CIW|Control-in-Wait Group
11044907|NCT04464980|Experimental|XR-BUP + MM|Extended-release injection buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044908|NCT04464980|Experimental|XR-NTX + MM|Extended-release injection naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044909|NCT04464980|Experimental|SL-BUP standard dose + MMR|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus reSET-O, a technology-based behavioral component, to support retention and abstinence.
11044910|NCT04464980|Experimental|SL-BUP high dose + MMR|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus reSET-O, a technology-based behavioral component, to support retention and abstinence.
11044911|NCT04464980|Experimental|XR-BUP + MMR|Extended-release injection buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus reSET-O, a technology-based behavioral component, to support retention and abstinence.
11044912|NCT04464980|Experimental|XR-NTX + MMR|Extended-release injection naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus reSET-O, a technology-based behavioral component, to support retention and abstinence.
11044913|NCT04464980|Experimental|Discontinue SL-BUP with SL-BUP + MM|Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044914|NCT04464980|Experimental|Discontinue SL-BUP with XR-BUP + MM|Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044915|NCT04464980|Experimental|Discontinue XR-BUP with XR-BUP + MM|Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044916|NCT04464980|Experimental|Discontinue XR-NTX with XR-NTX + MM|Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
11044917|NCT04464980|Experimental|Discontinue SL-BUP with SL-BUP + MMD|Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
11044918|NCT04464980|Experimental|Discontinue SL-BUP with XR-BUP + MMD|Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
11044919|NCT04464980|Experimental|Discontinue XR-BUP with XR-BUP + MMD|Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
11044920|NCT04464980|Experimental|Discontinue XR-NTX with XR-NTX + MMD|Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling plus Connections, an app-based behavioral component to support discontinuation and recovery.
11044921|NCT04464967|Experimental|Phase 1, Cohort 1|SNK01 (low dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
11044922|NCT04464967|Experimental|Phase 1, Cohort 2|SNK01 (high dose) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
11044923|NCT04464967|Experimental|Phase 1, Cohort 3|SNK01 (low dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
11044924|NCT04464967|Experimental|Phase 1, Cohort 4|SNK01 (high dose) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
11044925|NCT04464967|Experimental|Phase 2, Expansion Cohort 1|SNK01 (TBD RP2D) administered once every three weeks in combination with trastuzumab (loading dose of 8 mg/kg on Cycle 1, Day 1, followed by a 6 mg/kg on Cycle 2, Day 1 once every three weeks)
11044926|NCT04464967|Experimental|Phase 2, Expansion Cohort 2|SNK01 (TBD RP2D) administered once every week in combination with cetuximab (loading dose of 400 mg/m2 on Cycle 1, Day 1, followed by a 250 mg/m2 on Cycle 2, Day 1 once every week)
11044927|NCT04464954|Experimental|Auricular semi-permanent (ASP gold) needles|
11044928|NCT04464954|Experimental|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|
11044929|NCT04464954|Experimental|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|
11044930|NCT04464941|Experimental|oral health promotion program|"The oral health promotion program was a composite intervention with both group and individual components. The group intervention consisted of:
~1. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:
~1. Instruction in the Bass tooth-brushing method 2. Individual behavioral modification method"
11044931|NCT04464941|No Intervention|Usual care group|
11044932|NCT04464928||User interests|Facebook advertisements arm
11044933|NCT04464928||User characteristics|Google advertisements arm
11044934|NCT04464915|Experimental|Isopropyl alcohol swab every 10 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes for a total of one hour.
11044935|NCT04464915|Experimental|Isopropyl alcohol swab every 20 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 20 minutes for a total of one hour.
11044936|NCT04464915|No Intervention|No treatment arm|No intervention administered.
11044937|NCT04464902|Other|knee extension constraint rehabilitation group|
11044938|NCT04464902|Other|placebo group|
11044939|NCT04464902|Other|control group|
11044940|NCT04464889|Experimental|MDG1021|Dose-escalation part of the study to investigate 3 MDG1021 doses. Dose-expansion part of the study to investigate the selected optimal MDG1021 dose.
11044941|NCT04464876|Experimental|Treatment|SATURN TA TMVR Device implanted
11044942|NCT04464863||Cases|Acute stroke patients during the first week of evolution
11044943|NCT04464863||Control|Age and sex 1:1 healthy participants
11044944|NCT04464850|Experimental|Intravenous iron|Iron sucrose 200 mg every 2 weeks Folic acid 5 mg/day B6 10 mg/day
11044945|NCT04464850|Active Comparator|Oral iron|Ferrous fumarate 600 mg/day Folic acid 6.5 mg/day B6 15 mg/day
11044946|NCT04464824||patient over 75 years of age with an emergency room visit|Patients over 75 years of age, with a visit to the emergency department between April 1, 2019 and September 30, 2019, with a non-hospitalization at the end of their visit to the emergency department.
11044947|NCT04464811||Heart failure with diuretic resistance|This group includes acute heart failure patients who has diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have received oral furosemide before. Diuretic resistance was defined as urine output <250 hr at 2 hours after furosemide administration.
11044948|NCT04464811||Heart failure without diuretic resistance|This group includes acute heart failure patients who do not have diuretic resistance from furosemide stress test. Furosemide stress test will be performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide before. Patients will be defined not to have diuretic resistance if their urine output ≥250 hr at 2 hours after furosemide administration.
11044949|NCT04464798|Experimental|Cohort A- Monotherapy in R/R lymphoma subjects|Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
11044950|NCT04464798|Experimental|Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects|"Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.
~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.
~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
11044951|NCT04464798|Experimental|Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects|"Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.
~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6."
11044952|NCT04464798|Experimental|Cohort D - Monotherapy in other lymphomas subtype subjects|"Subjects with other lymphoma subtype who have been allocated to Cohort D will receive CC-220 monotherapy (MonoT).
~- Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles."
11044953|NCT04464798|Experimental|Cohort E - CC-220 and rituximab in B-cell lymphoma subjects|"Subjects with aggressive B-cell lymphoma who have been allocated to Cohort E will receive CC-220 in combination with rituximab
~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
11044954|NCT04464798|Experimental|Cohort F - CC-220 and rituximab in FL and MZL subjects|"Subjects with follicular lymphoma (FL) (1 to 3a) and marginal zone lymphoma (MZL) who have been allocated to Cohort F Part 2 will receive CC-220 in combination with rituximab.
~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2"
11044955|NCT04464798|Experimental|Cohort G -CC-220 and obinutuzumab in FL and MZL subjects|"Subjects with FL (1 to 3a) and MZL who have been allocated to Cohort G will receive CC-220 in combination with obinutuzumab.
~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.
~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15 and on D1 of every 28-day cycle from C2 to C6."
11044956|NCT04464785|Experimental|Treatment|Subjects who receive the CentriMag Circulatory Support System
11044957|NCT04464759|Experimental|Phase 1a: Nivolumab and Hydroxychloroquine (HCQ)|"Dose escalation:
~Dose Level 1: HCQ 400 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks
~Dose Level 2: HCQ 600 mg orally every 12 hours and nivolumab 480 mg IV every 4 weeks
~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
11044958|NCT04464759|Experimental|Phase 2: Nivolumab and Hydroxychloroquine (HCQ)|"HCQ 400-600 mg (maximum tolerated dose from Phase 1a) orally every 12 hours and nivolumab 480 mg IV every 4 weeks
~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
11044959|NCT04464759|Experimental|Phase 1b: Nivolumab + Ipilimumab +Hydroxychloroquine (HCQ)|"HCQ 400-600 mg orally every 12 hours and nivolumab 3 mg/kg IV plus ipilimumab 1 mg/kg IV every 3 weeks x4 cycles
~Then 6 weeks after the last dose of ipilimumab/nivolumab begin maintenance nivolumab 480 mg IV every 4 weeks
~Continue protocol treatment for up to 24 months until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
11044960|NCT04464746|No Intervention|Control|usual medical follow-up
11044961|NCT04464746|Active Comparator|Intervention|Implementation of a specific program to improve therapeutic adherence
11044962|NCT04464733|Experimental|Treatment group A|
11044963|NCT04464733|Experimental|Treatment group B|
11044964|NCT04464733|Experimental|Treatment group C|
11044965|NCT04464733|Experimental|Treatment group D|
11044966|NCT04464733|Experimental|Treatment group E|
11044967|NCT04464733|Experimental|Treatment group F|
11044968|NCT04464733|Experimental|Treatment group C-|
11044969|NCT04464733|Experimental|Treatment group G|
11044970|NCT04464733|Experimental|Treatment group H|
11044971|NCT04464733|Experimental|Treatment group I|
11044972|NCT04464733|Experimental|Treatment group J|
11044973|NCT04464720|Other|Intervention after One Week|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for one week prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional two weeks.
11045034|NCT04464304|Sham Comparator|Smartphone|Patients will be provided with a commercially-available smartphone device for use up to 15 minutes at bedside.
11044974|NCT04464720|Other|Intervention after Two Weeks|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for two weeks prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional one week.
11044975|NCT04464707|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
11044976|NCT04464707|Placebo Comparator|Placebo|Matching placebo
11044977|NCT04464694|Experimental|Ranibizumab|Single intravitreal injection of ranibizumab (0.5 mg) 3~7 days before vitrectomy
11044978|NCT04464694|Sham Comparator|Sham injection|Sham injection 3~7 days before vitrectomy
11044979|NCT04464681|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
11044980|NCT04464681|Placebo Comparator|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
11044981|NCT04464668||Wave 1 Only: Clinics using CARES Intervention|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics to implement the Colorectal Cancer Awareness, Research, Education & Screening (CARES) intervention.
11044982|NCT04464668||Wave 1 Only: Control Clinics|Based on a stratified (rural vs urban) procedure, investigators will randomly select 7 clinics as control (usual care) clinics.
11044983|NCT04464668||All Clinics|For Wave 2, the 7 clinics in the control group will roll out as intervention clinic, thus, all 14 clinics will be exposed to the intervention by year 2.
11044984|NCT04464655||Healthy Volunteers|Age: >18 y, No known current or pre-existing medical conditions that would affect the cardiovascular or respiratory system.
11044985|NCT04464655||Patients|Age: > 18y, Clinically indicated CMR exam
11044986|NCT04464642|Experimental|group A|"group A is a control arm who will get conventional drug (methotrexate). 25 mg subcutaneous weekly . at 3 months if DAS-28 not fall by at least 1.2, drug is to be changed and regarded as therapy failure. if at least 1.2 improvement of DAS-28 occur,then therapy is continued for 6 monyhs"
11044987|NCT04464642|Experimental|group B|"group B will get tofacitinib 10 mg weekly. if DAS-28 not improved at least 1.2 at 3 months, it is regarded as therapy failure. if improved at least 1.2, then therapy continued for 6 months"
11044988|NCT04464629|Experimental|Intracanalicular Sustained Release Dexamethasone, 0.4 mg|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of post-surgical inflammation and pain associated with ocular surgery.
11044989|NCT04464629|Active Comparator|topical prednisolone acetate 1%.|
11044990|NCT04464616|Placebo Comparator|control group|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + normal saline (0.5 ml).
11044991|NCT04464616|Experimental|Dexmedetomidine group):|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 5 μg dexmedetomidine in a volume of (0.5 ml).
11044992|NCT04464616|Experimental|Dexamethasone group|spinal anaesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 2 mg dexamethasone in a volume of 0.5 ml).
11044993|NCT04464603|Experimental|Arm A (InterFACE)|"Participants that will use the mHeath InterFACE tool during the simulation-based pediatric scenario.
~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
11044994|NCT04464603|Active Comparator|Arm B (Conventional methods)|"Participants that will use conventional methods during the simulation-based pediatric scenario.
~Each participant will have to do 2 consecutive scenarios (PALS, ATLS)."
11044995|NCT04464577|Experimental|Arm A: BMS-986235+Fluconazole|
11044996|NCT04464577|Experimental|Arm B: BMS-986235+ Bupropion|
11044997|NCT04464577|Experimental|Arm C: BMS-986235+ Itraconazole|
11044998|NCT04464564|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
11044999|NCT04464564|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
11045000|NCT04464551|Experimental|[14C]D-0316|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (75mg, 50µCi) of [14C]D-0316 to healthy Chinese male subjects
11045001|NCT04464538|Placebo Comparator|Health information|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
11045002|NCT04464538|Experimental|Group education session and individualised coaching (online)|Participants assigned to the WALC-R intervention will attend a virtual baseline educational group session which will include a maximum of five people. The aim of the sessions will be to introduce the basics of the benefits of walking for exercise and why exercise is beneficial, as well as to give information, support and motivation to help participants to independently walk more in their daily routines.The group session will also include goal setting, in which participants will be encouraged to set their own daily walking targets to increase their habitual levels of walking. All participants will be given a pedometer to self-monitor how far they walk and a diary to record activity context throughout the intervention daily. Participants will meet briefly (20-30 minutes) via the internet with an assigned coach every 2 weeks.
11045003|NCT04464525|Experimental|Omecamtiv mecarbil|All subjects will be assigned to OM
11045004|NCT04464512|No Intervention|Standard (control) treatment|"The control group receives 1mcg/kg fentanyl followed by fentanyl 0.5-1mcg/kg q10 minute PRN, ketorolac 0.5mg/kg up to 30mg max IV, and acetaminophen 1000mg IV for pain control intraoperatively. The patient is then treated with hydromorphone 0.005mg/kg q10minutes the post-anesthesia recovery. The patient would then receive hydromorphone 0.005 mg/kg q1hr PRN, 1 gram acetaminophen IV scheduled q6hr, and methocarbamol 750mg QID following discharge from the PACU and transfer to the hospital floor. The patient is converted to oxycodone 10mg (Roxicodone) q4hr PRN and 975 mg PO APAP scheduled for pain control on postoperative day number 1 or when appropriate for PO intake. The patients receives their home dose of suboxone onpostoperative day number 1 or when appropriate for PO intake.
~On postoperative day number 2 number 3, patients are transitioned to an increased dose of their Suboxone for pain control in preparation for discharge."
11046753|NCT04451863|Active Comparator|High THC + High BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
11045005|NCT04464512|Active Comparator|Treatment Group|Buprenorphine-sufentanil group receives sufentanil 0.03mcg/kg followed by sufentanil 0.01-0.03 mcg/kg q10 min PRN, IV ketorolac 0.5mg/kg up to 30mg max and IV acetaminophen 15mg/kg up to 1000mg for pain control intraoperatively. In the PACU, IV buprenorphine 0.3mg IV q30 minutes would be given as the first line choice for pain control for 3 doses. IV PCA sufentanil is used as a second line therapy if patient comfort is not achieved by IV buprenorphine alone. The patient receives 0.3 mg buprenorphine IV Q6hr PRN, scheduled IV acetaminophen 1 gram for 24 hrs and methocarbamol 750mg QID after discharge from the PACU and transfer to the floor. The patient is converted to buprenorphine2mg q6hr PRN and 975 gram PO APAP scheduled for pain control on postoperative day 1. The patient receives their home dose of Suboxone starting on postoperative day 1 if tolerating PO intake. On postoperative day 2, patients would be transitioned to an increased dose of their Suboxone.
11045006|NCT04464499||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
11045007|NCT04464499||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
11045008|NCT04464486|Experimental|COVID-19 Symptom Augmented SCH Intervention|The SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants receive automated self-management support messages for symptoms reported and a Nurse Practitioner monitors and responds to alerts for COVID-19 symptoms and poorly controlled or worsening cancer symptoms. Participants in this group complete baseline and monthly measures.
11045009|NCT04464486|No Intervention|Enhanced Usual Care|Participants in the control group are given information by research staff reviewing COVID-19 symptoms, home precautions, and instructions on what to do to address concerns that arise. Participants in this group complete baseline and monthly measures.
11045010|NCT04464473|Experimental|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold.
11045011|NCT04464473|Experimental|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
11045012|NCT04464473|Active Comparator|S1-TMS|Transcranial magnetic stimulation to primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
11045013|NCT04464460|Experimental|Cohort 1: TAK-671 Low Dose|TAK-671 low dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
11045014|NCT04464460|Experimental|Cohort 2: TAK-671 High Dose|TAK-671 high dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
11045015|NCT04464447|Other|Group-based Acceptance and Commitment Therapy|Group-based Acceptance and Commitment Therapy (ACT) for adolescents presenting with multiple functional somatic syndromes.
11045016|NCT04464434|Experimental|Upfront autologous HSCT|
11045017|NCT04464434|Active Comparator|Immunosuppressive therapy|"12 monthly i.v. pulses CYC 750 mg/m2 (= 9 g/m2 cumulative) followed by at least 12 months of oral MMF daily (3 grams as maximum daily dosage).
~Hyperhydration, alkalinisation of the urine and mesna is recommended, and will be given according to local protocols in order to prevent haemorrhagic cystitis."
11045018|NCT04464421|Experimental|Contingency management (CM)|Participants will receive physical rewards urine toxicology results are positive for buprenorphine (i.e., they are adherent to Medication-Assisted Treatment (MAT)) during their first four visits after initiation of MAT.
11045019|NCT04464421|Experimental|BSM|BSM (Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion) participants will have one-on-one behavioral intervention sessions at each of the first four visits after initiation of MAT.
11045020|NCT04464408|Experimental|Favipiravir|Favipiravir: 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (Maximum days of therapy is 7 days)
11045021|NCT04464408|Placebo Comparator|Placebo|9 tablets by mouth twice daily for one day, followed by 4 tablets twice daily (Maximum days of therapy is 7 days).
11045022|NCT04464395|Experimental|CPI-006 Dose Escalation|CPI-006 + Standard of Care
11045023|NCT04464395|Other|Control Arm|Standard of Care Only
11045024|NCT04464382|Experimental|Outpatient appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.
~Patients after surgery will go to the anesthetic recovery room without requiring hospital admission. The degree of satisfaction of the quality of the service and the care that must be completed before discharge and after surgery will be recorded.
~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
11045025|NCT04464382|Active Comparator|Hospitalization appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.
~Patients after surgery will go to the anesthetic recovery room and then be admitted to hospital beds, to be discharged within approximately 12 hours.
~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
11045026|NCT04464369|Placebo Comparator|Placebo|Placebo t.i.d.
11045027|NCT04464369|Active Comparator|Itopride|Itopride co 100 mg t.i.d.
11045028|NCT04464343||Posterior cruciate ligament injury group|According to the previous clinical diagnosis, volunteers who has never suffered the Posterior cruciate ligament injury.
11045029|NCT04464343||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
11045030|NCT04464330||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, patients who has suffered the Anterior Cruciate Ligament injury.
11045031|NCT04464330||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
11045032|NCT04464317||Patient who has had cardiovascular surgery|Undergone an elective, urgent, and/or emergent cardiovascular surgery via endovascular or open (sternotomy and/or extended thoracotomy) technique at the University of Florida Health.
11045033|NCT04464304|Active Comparator|Virtual Reality|Patients will be provided with a commercially-available VR device for use up to 15 minutes at bedside.
11047435|NCT04446858||Without TIPS|Prospective cohort that did not receive TIPS
11045035|NCT04464291|Experimental|Patients with pneumococcal infection|There will be assessing the prevalence of Streptococcus pneumoniae serotypes in the nasopharynx in healthy people; in middle ear liquid in patients with acute otitis media; in sputum and epithelial lining fluid in patients with community-acquired pneumonia; in spinal fluid in patients with invasive pneumococcal indection
11045036|NCT04464278||Case group: weight loss ≥ 5%|
11045037|NCT04464278||Control group: weight loss ≤ 5%|
11045038|NCT04464265|Experimental|Functional Magnetic Resonance Imaging|"While music is played Noninvasive functional magnetic resonance (fMRI) imaging will be performed at the University of Michigan Health System, University Hospital, Department of Radiology.
~The fMRI is done under anesthesia using propofol. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations of 1.2, 1.6, 2.0, and 2.4 μg/ml in a stepwise fashion."
11045039|NCT04464239|Experimental|Part A: Cohort 1: TS-142 10 mg|Single dose of TS-142 10 mg or placebo in a fasted condition
11045040|NCT04464239|Experimental|Part A: Cohort 2: TS-142 30 mg|Single dose of TS-142 30 mg or placebo in a fasted condition. The dose level may be changed after the interim review of safety results.
11045041|NCT04464239|Experimental|Part A: Cohort 3: TS-142 90 mg|Single dose of TS-142 90 mg or placebo in a fasted condition. The dose level may be changed after the interim review of safety results.
11045042|NCT04464239|Experimental|Part B: Cohort 4: TS-142 30 mg|Daily doses of 30 mg TS-142 or placebo for 7 days before bedtime. The dose level may be changed after the interim review of safety results from Cohorts 1 and 2 in Part A, and will not exceed the maximum dose evaluated in Part A (up to 90 mg daily).
11045043|NCT04464226|Experimental|Darolutamide (BAY1841788)|Participants enrolled in the current study will use the dose they were assigned to in the feeder study they come from.
11045044|NCT04464213|Experimental|Single dose experiments|
11045045|NCT04464213|Experimental|Multi-dose experiments|
11045046|NCT04464200|Experimental|19(T2)28z1xx CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the RP2D. There are 5 planned flat-dose levels: 25x10^6, 50 x 10^6, 100 x 10^6, 150 x 10^6, and 200 x 10^6 CAR T cells and one de-escalation dose: 12.5 x 10^6 CAR T cells. A standard 3+3 dose escalation design will be implemented starting from dose 1.
11045047|NCT04464187||Participants exposed to Orilissa|Pregnant participants exposed to Orilissa from 14 days after last menstrual period (LMP) or at any point during pregnancy.
11045048|NCT04464187||Participants not exposed to Orilissa|Pregnant participants with endometriosis or other conditions based on approved indications and prescribing patterns of Orilissa not exposed to Orilissa from 14 days after LMP or at any point during pregnancy.
11045049|NCT04464174|Experimental|Ipatasertib plus capecitabine|Arm A: Ipatasertib (GDC-0068) 400 milligrams (mg) tablets administered orally once a day (noon) on Days 1-14 of each 21-day cycle plus capecitabine 1000 mg/m2 tablets orally twice a day (morning and evening; equivalent to 2000 mg/m2 total daily dose), for 14 days (followed by a 7-day rest period) every 21-day cycle.
11045050|NCT04464174|Experimental|Ipatasertib plus Eribulin|Arm B: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle.
11045051|NCT04464174|Experimental|Ipatasertib plus carboplatin plus gemcitabine|Arm C: Ipatasertib (GDC-0068) 400 mg tablets administered orally once a day on Days 1-14 of each 21-day cycle plus carboplatin AUC5 on Day 1 administered intravenously plus gemcitabine 1000 mg/m2 administered intravenously over 30 minutes on Days 1 and 8, every 21-day cycle.
11045052|NCT04464161|Experimental|Arm 1|The treatment arm will receive 6 week supply of daily Ensure protein drinks, while the control arm will be instructed to continue their current diet. This includes 2 weeks pre-operatively and 4 weeks post-operatively.
11045053|NCT04464161|No Intervention|Arm 2|The control group will be instructed to continue to their regular diets.
11045054|NCT04464148|Experimental|Pregnenolone 250 BID > Pregnenolone 400 BID|For week 0-5 participants will receive pregnenolone 250 mg twice a day (total 500 mg/day). For weeks 6-8 participants will receive 400 mg twice a day (800 mg/day), if the drug is well tolerated.
11045055|NCT04464135|Experimental|WE+AA group|Water containing 1% of AA was used during insertion of colonoscopy using water exchange method.
11045056|NCT04464135|Active Comparator|WE group|Water exchange colonoscopy was used for standard screening or surveillance colonoscopy.
11045057|NCT04464122||Neuroendocrine toumor group|30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.
11045058|NCT04464122||Control group|Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)
11045059|NCT04464109|Active Comparator|Retro-scleral placement of the implant|"Surgical steps;
~Two anterior scleral relaxing incisions
~A 360° scleral incision around the optic nerve to disinsert it
~Two posterior scleral relaxing incisions
~The implant is inserted posterior to posterior scleral edges
~The posterior sclera is closed then the anterior sclera is overlapped and closed.
~The implant is completely seated in the intraconal space"
11045060|NCT04464109|Active Comparator|Intrascleral placement of the implant|"Anterior and posterior sclerotomies with the implant partly in the scleral shell and partly in the intraconal space.
~Anterior relaxing sclerotomies not reaching the optic nerve
~A 360° scleral incision around the optic nerve.
~The anterior sclera flaps are overlapped and closed
~Part of the implant remains in the scleral shell, while the remaining part is sitting in the intraconal space."
11045061|NCT04464070|Experimental|niacin|"Blood (10 ml) will be drawn from the subject. Immediately before or after the blood draw the subject will collect a urine (3-10 ml) sample. After the baseline blood draw and the urine sample is collected the subject will take 500 mg of niacin. The niacin will not be an extended release formulation. Subjects will be encouraged to drink plenty of water during the study. Subjects are instructed to collect urine 1, 2, 4, 6, 8, and 10 hours after niacin administration. Subjects will collect their urine in separate plastic tubes that will be provided to them.
~Approximately 1-2 h after niacin administration a second blood sample (10 ml) will be drawn from the subject."
11045119|NCT04463576||Experimental|A total of 5 676 hospital discharge prescriptions, defined as the list of medications prescribed at discharge from hospital or after a hospital visit, whether new or renewed, will be selected.
11045062|NCT04464070|Experimental|niacin + low-dose aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of low-dose aspirin (81 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
11045063|NCT04464070|Experimental|niacin + regular-strength aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of regular-strength aspirin (325 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
11045064|NCT04464070|Experimental|deuterated PGD2|"Volunteers will come to the clinical research center. Volunteers will provide a urine sample. The volunteers will be fitted to record an electrocardiogram (ECG) and blood pressure. ECG will be recorded continuously. Blood pressure will be taken at baseline and every 10 minutes thereafter for one hour. The solution with deuterated PGD2 (10 microgram) will be infused over the course of 30 min. Volunteers will be monitored for 1 h after the end of the infusion, and volunteers will start collecting urine in intervals up to 10 h.
~Infusion of the deuterated PGD2 solution will be performed in the presence of a physician. The injection solution will be prepared by Vanderbilt University Medical Center (VUMC) Investigational Drug Services. The solution will be sterile and pyrogen free."
11045065|NCT04464057|Experimental|experimental group|The patients in the experimental group would be given early oral feeding within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
11045066|NCT04464057|No Intervention|control group|The control group would be given early oral feeding within 4-5 days after intestinal anastomosis. Start taking it at 4-5 days after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
11045067|NCT04464044|Experimental|DDT2 Toric|Verofilcon A toric contact lenses worn in both eyes
11045068|NCT04464031|Experimental|Alert group|
11045069|NCT04464031|No Intervention|Control group|
11045070|NCT04464018|Experimental|Working group|Working group (hybrid simulation method) after the theoretical lecture, the application with hybrid simulation method is made by videotaping. Repeat the same practice after 1 Week
11045071|NCT04464018|No Intervention|Control group|Control group (Low reality simulation method) after the theoretical lecture, the application with low reality simulation method is made. Repeat the same practice after 1 Week Control group received only general care
11045072|NCT04464005|Experimental|Pads with cold magnesium sulfate 33% solution|
11045073|NCT04464005|Placebo Comparator|Pads with cold water|
11045074|NCT04463992|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
11045075|NCT04463992|Active Comparator|Behavioral:Program participants|The control group arm will receive usual care as provided by their local oncologists.
11045076|NCT04463979||Cerebellar Tumors|Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection.
11045077|NCT04463979||Brain Tumors|Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
11045078|NCT04463966|Active Comparator|Study|Tranexamic acid 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
11045079|NCT04463966|No Intervention|Control|control group will not be given tranexamic acid
11045080|NCT04463953|Experimental|ZID regimen|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15.
11045081|NCT04463940||Umbilical cord arterial blood|participant's umbilical cord arterial blood will be obtained
11045082|NCT04463940||Umbilical cord venus blood|participant's umbilical cord Venus blood will be obtained
11045083|NCT04463940||Maternal blood|participant's blood will be obtained
11045084|NCT04463927|Experimental|Intervention Group|The non-nutritive sucking is applied to the group during the examination for retinopathy of prematurity
11045085|NCT04463927|No Intervention|Control Group|The non-nutritive sucking is not applied to the control group.
11045086|NCT04463914|Other|Group A- Treatment as Usual|Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
11045087|NCT04463914|Experimental|Group B- Moodivate|Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
11045088|NCT04463914|Experimental|Group C- Moodivate + EHR|Participants randomized to the Moodivate + EHR condition will receive similar instructions as those randomized to Moodivate, but will also be instructed that their PCP will have access to metrics related to their app utilization and may choose to follow-up with them regarding treatment utilization and response. The PCP for each participant randomized to this condition will be provided EHR access to Moodivate metrics which will include metrics related to change in mood, frequency of app utilization, and frequency of activity completion. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
11045089|NCT04463901|Active Comparator|Group CAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then conjunctival autograft without limbal tissue will be used to cover the bare sclera.
11045090|NCT04463901|Active Comparator|Group LCAG|After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft will be used to cover the bare sclera.
11059407|NCT04362020|Active Comparator|Group-2|ACT-guided anticoagulation
11045091|NCT04463888|Experimental|Robot training with Smart Home-based Exoskeleton Robot System|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based robot assisted tenodesis-grip training per day, 5 days a week, for 4 weeks .
11045092|NCT04463888|Active Comparator|control group|In addition to receiving hospital occupational therapy training twice a week, the participants will receive 60 minutes of home-based specific motor task training per day, 5 days a week, for 4 weeks .
11045093|NCT04463849|Experimental|COVID-19 positive patients|Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
11045094|NCT04463849|Other|Healthy volunteers|Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
11045095|NCT04463797|Experimental|Square-stepping exercise group|Square-stepping exercise
11045096|NCT04463797|Active Comparator|Control group|Whole-body stretching and upper extremity strengthening
11045097|NCT04463784|Experimental|Efavirenz 400MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 400mg per day as antiretroviral treatment.
11045098|NCT04463784|Active Comparator|Efavirenz 600MG Oral Tablet|Recruited treatment-naive HIV infected patients will be given Lamivudin 300mg per day, tenofovir 300mg per day and efavirenz 600mg per day, per standard dose.
11045099|NCT04463771|Experimental|Group A - retifanlimab|Select participants will be administered retifanlimab intravenously
11045100|NCT04463771|Experimental|Group B - retifanlimab|Select participants will be administered retifanlimab intravenously
11045101|NCT04463771|Experimental|Group C - retifanlimab + epacadostat|Participants will be administered retifanlimab intravenously in combination with oral epacadostat (IDO1 inhibitor)
11045102|NCT04463771|Experimental|Group D - retifanlimab + pemigatinib|Select participants will be administered retifanlimab intravenously in combination with oral pemigatininb (FGFR 1,2,3 inhibitor)
11045103|NCT04463745||Liver Transplant Recipients|adult patients undergoing liver transplantation
11045104|NCT04463732||Healthy group|Subjects are above 20 years old. Their condition is healthy with no history of inspiratory disease. They can cooperate with the measurements of this study.
11045105|NCT04463719|Experimental|Intervention group|Counseling using the electronic conversation aid
11045106|NCT04463719|Active Comparator|Control Group|Routine counseling only
11045107|NCT04463706||COVID19 REDISSEC|Patients admitted (confirmed cases) by CoVid-19, excluding paediatric population. No losses are expected. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene [RdRp or S gene] or PCR positive for at least 2 genes used for screening [E or N gene].
11045108|NCT04463706||COVID19 Basque Country|All people from thw Basque Country positive to CoVid-19. A case of SARS-CoV-2 infection is defined as one that meets the laboratory criteria: PCR positive for a specific gene [RdRp or S gene] or PCR positive for at least 2 genes used for screening [E or N gene], or, as well and in the general population of the Basque Country, by detection of COVID-19 IgM or IgG antibodies.
11045109|NCT04463693|Experimental|Intervention|Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula
11045110|NCT04463680|Experimental|Intervention|Will receive 2 week regimen of rifampin 600mg per day
11045111|NCT04463667|Experimental|The effects of exercise intervention on fatty liver|The effects of exercise intervention on fatty liver and the improvement of the above-mentioned various metabolic indicators, including improvement of sleep patterns and changes of intestinal microflora.
11045112|NCT04463654|Experimental|Zero Self-Harm|When randomized to the Zero Self-Harm app the participants will receive an introduction to the app through videos in the app, which explains, amongst others, how to review previous crisis situations and possible strategies for future crisis. This will ensure the navigation and knowledge of the technicalities of the app, in addition to ensure the app can be used privately without personal guidance from e.g a therapist.
11045113|NCT04463654|No Intervention|Treatment as usual|The control group will continue their present course of treatment and/or counseling at non-profit organizations, service centers in the municipalities, at outpatient treatment services for psychiatric disorders and/or care, attention at emergency departments. They will receive no treatment on the nature of NSSI. Participants in the control group will be offered a possibility to download the Zero Self-Harm app after they have completed the last questionnaire at six months, which will be stressed at the initial appointment as well as after collection of all data.
11045114|NCT04463641|Experimental|Axone 4LV Lead|Subjects implanted with the Axone 4LV Lead
11045115|NCT04463628||Questionnaire and/or interview|An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences).
11045116|NCT04463615|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
11045117|NCT04463602|Experimental|Desidustat + Standard of Care|"Test: Desidustat + Standard of care
~Desidustat 100 mg for the duration of 14 days along with the recommended standard of care at the time of conduct of trial."
11045118|NCT04463602|Active Comparator|Standard of Care|"Control: Standard of care
~Standard of care treatment for the duration of 14 days at the time of conduct of trial."
11045120|NCT04463563|Active Comparator|NIRS group. Brain oxygen saturations group.|A monitor by means of non-invasive stickers will display cerebral oximetry (brain oxygen saturations) throughout the heart surgery.This gives a direct reading of brain frontal lobe oxygen levels. The baseline is recorded before the patient goes to sleep (anaesthetised) and throughout the surgery and time on cardiopulmonary bypass if the brain oxygen levels fall below baseline then various physiological changes are made to restore oxygen to baseline.
11045121|NCT04463563|No Intervention|Standard Patient Monitoring|No cerebral monitoring. Standard patient monitoring according to normal practice at Castle Hill Hospital apply.
11045122|NCT04463550||Patients GFAP-IgG positive in serum and/or CSF|Patients developing clinical autoimmune encephalitis or meningoencephalomyelitis with anti-GFAP antibodies, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis or the National Reference Center for Centre de référence for Neuro-inflammatory diseases of the brain and the spinal cord at the Neurological Hospital of Bron.
11045123|NCT04463537|Experimental|experiment group|"Firstly, patients selected with convenience sampling. In the sampling method, the order of the patients' enrollment to the emergency room was used. Then, patient's age, sex and presence of otitis media were recorded in the Personal Information Form.
~After recording, measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.
~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale. The auricle on the same side was used during both measurements."
11045124|NCT04463524||Test|They will receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
11045125|NCT04463524||Control|They will not receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
11045126|NCT04463511|Experimental|PB BCC: Polyethylene Bag Before Cord Clamping|Immediately after delivery, while still attached to placental circulation, infants will be placed in a PB. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire for ongoing care. In the case of caesarean section a sterile bag will be used and prepared observing sterile techniques. A member of the neonatal team donned in sterile gown and gloves will assist the obstetrician in placing the infant in the PB.
11045127|NCT04463511|No Intervention|PB ACC: Polyethylene Bag After Cord Clamping|Infants will not be placed in a PB immediately after birth. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire where they will be placed in a PB.
11045128|NCT04463498|Experimental|n=20, Sleep-school 8 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
11045129|NCT04463498|Experimental|n=20, Sleep-school 8 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
11045130|NCT04463498|Active Comparator|n=40 8-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
11045131|NCT04463485|Experimental|Delayed Clamping|The intervention group was waited 60 seconds for umbilical cord clamping in the second stage of labor.
11045132|NCT04463485|No Intervention|Early Clamping|No interventions have been assigned.
11045133|NCT04463472|Experimental|Low-dose group|
11045134|NCT04463472|Experimental|High-dose group|
11045135|NCT04463459|No Intervention|Chemotherapy + Placebo|Patients receiving chemotherapy This group will be received chemotherapy and placebo
11045136|NCT04463459|Active Comparator|Chemotherapy + Vitamin C + Vitamin E|Patients receiving vitamin C and E with Chemotherapy This group will be received vitamin C (500 mg) twice daily and vitamin E (400 mg) once daily with chemotherapy for 6 weeks
11045137|NCT04463446|Experimental|The app arm|Use of CHD app
11045138|NCT04463446|Active Comparator|Nurse-led intervention arm|Nurse-led intervention
11045139|NCT04463433|Experimental|Parent-child Relationship Intervention|The intervention involves five 2h weekly group sessions in which exercises in mindfulness are practiced and associated ABCDE theory is taught to improve emotional regulation and parent-child communication under COVID-2019.
11045140|NCT04463433|Experimental|Couple Relationship Intervention|The intervention involves four 2h weekly group sessions in which express feelings and wants clearly are practiced and associated Satir communication model is taught to improve couple conflict resolution and communication under COVID-2019.
11045141|NCT04463420|Experimental|Test Group|Intervention group: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days / PHR160 spray one hour oral puff with Demyar ten times a day for ten days in a row, for ten days.
11045142|NCT04463420|Placebo Comparator|Control Group|Control group: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days Daily / 25 mg prednisolone daily for 5 days / placebo spray one hourly oral puff ten times a day for ten days in a row, for ten days
11045143|NCT04463407|No Intervention|Control group|Participants keep their normal routine without intervention.
11045144|NCT04463407|Experimental|Experimental group|Participants receive a single nutritional intervention previous to a critical period.
11045145|NCT04463394|Experimental|Vasopressin|Participants undergoing cardiac catheterization
11045146|NCT04463381||Group 1|sharp choledochotomy by a scalpel or scissor
11045147|NCT04463381||Group 2|choledochotomy by a diathermy hook
11045148|NCT04463381||Group 3|choledochotomy by an ultrasonic device
11045149|NCT04463368|Experimental|Arm A|Patients will be treated with IHP followed by 4 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
11045150|NCT04463368|Experimental|Arm B|Patients will be treated with 1 course of ipilimumab 3mg/kg and nivolumab 1mg/kg followed by IHP after 3 weeks and then another 3 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
11045151|NCT04463355|No Intervention|Control group: usual verbal instructions|In this group, caregivers receive, after completing the test and prior to discharge, the usual verbal information and recommendations about AGE following the guidelines of the Spanish Society of Pediatric Emergencies. The instructions are always given by one of the main investigators to provide homogeneity in the information
11045152|NCT04463355|Experimental|Intervention group: video discharge instructions|Additionally to the verbal information, patients are shown a short 2-minute video providing the same information about AGE that would be given by verbal information.
11045153|NCT04463342|Experimental|Non Coated Glass Ionomer|A faster, easier procedure is great, but you want assurance that reducing chair time doesn't mean compromising on performance. KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.This advancement is the latest in 3M's 30-year history of developing proven and trusted glass ionomers.
11045154|NCT04463342|Active Comparator|Conventional Glass Ionomer with Coat|"A bulk-fill, packable and fast-setting conventional glass ionomer. Because it's less technique sensitive than a composite it's ideal for difficult-to-isolate posterior restoration. High compressive strength and marginal integrity make it a glass ionomer of choice for posterior restorations.Ketac Conditioner Dentin Pretreatment is required; Ketac Glaze Light-Cured Varnish applied on the top of the restoration to avoid moisture contamination."
11045155|NCT04463329|Active Comparator|Group C|conventional two-operator axillary brachial plexus blockage
11045156|NCT04463329|Active Comparator|Group J|axillary brachial plexus block with single operator using Jedi grip
11045157|NCT04463303||group 1|patient who will develop weaning induced pulmonary adema
11045158|NCT04463303||group 2|patient who will nor develop weaning induced pulmonary adema
11045159|NCT04463290||Knee Osteoarthritis Patients Group|Patients suffering from primary knee osteoarthritis
11045160|NCT04463290||Control Group|Healthy people without suffering from primary knee osteoarthritis
11045161|NCT04463277|Experimental|Calorie Restriction|
11045162|NCT04463277|Experimental|Time Restricted Feeding|
11045163|NCT04463277|Experimental|Time Restricted Feeding with Calorie Restriction|
11045164|NCT04463277|No Intervention|Control|
11045165|NCT04463264|Experimental|NTX active treatment|Intervention: NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
11045166|NCT04463264|Placebo Comparator|Intervention: placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
11045167|NCT04463251|Experimental|RPH-104 80 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites
11045168|NCT04463251|Experimental|RPH-104 160 mg|subjects will receive subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites
11045169|NCT04463251|Placebo Comparator|Placebo|subjects will receive subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites
11045170|NCT04463238|Experimental|Cartilage membrane surgery|"The test group applied the guidance provided by Shaanxi Baiao Regenerative Medicine Co., Ltd.
~Cartilage regeneration membrane combined with microfracture surgery."
11045171|NCT04463238|Other|Microfracture|The control group was treated with microfractures widely recognized at home and abroad.
11045172|NCT04463225|Other|Intervention condition|Participants assigned to the intervention condition will be invited to engage with an internet-based intervention three times during the course of the study.
11045173|NCT04463225|No Intervention|Control|The control group will not be offered the internet-based intervention.
11045174|NCT04463212||Patient|Diagnosis of probable SVCR evoked, faced with a single or repeated episode of unusual thunderclap or rapidly progressive headache, and demonstration of diffuse vasospasms via sectional imaging (angiography, angio-MRI or cerebral arteriography) or an increase in transcranial doppler speeds
11045175|NCT04463212||Subject control|Subject without SVCR (current and history)
11045176|NCT04463199|Experimental|Experimental|Experimental group received craniocervical flexion training for 4 weeks and postural advice
11045177|NCT04463199|No Intervention|Control Group|Control group received only postural advice
11045178|NCT04463186|Experimental|Experimental|subjects participated in three experimental trials: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Strength was measured before (pre), immediately after (post), and at 10- and 20- minutes post stretching.
11045179|NCT04463173|Experimental|High fat food oral administration|Anaprazole 40mg, single dose, oral administration 30 minutes after breakfast with high fat food.
11045180|NCT04463173|Experimental|Fasting oral administration|Anaprazole 40mg, single dose, oral administration before breakfast.
11045181|NCT04463160|Experimental|"prevention program for prediabetes Say No to Diabetes"|
11045182|NCT04463160|No Intervention|No prevention program|
11045183|NCT04463147|Other|new residents|new residents in ultrasound-guided central vascular catheterization.
11045184|NCT04463147|Other|experienced residents or ICU practitioners|experienced residents or ICU practitioners in ultrasound-guided central vascular catheterization.
11045185|NCT04463134||Treatment group|They will start pharmacological treatment according to guidelines and sensitivity
11045186|NCT04463134||Observation group|They will not start pharmacological treatment. They will be monitored on symptoms, sputum conversion and radiological progression
11045226|NCT04462796|Experimental|Magnesium Citrate|Magnesium Citrate given orally taken once daily for 8 weeks
11045227|NCT04462783|Experimental|Patient's symptom data without pulse oximeter|Some patients may not be given a pulse oximeter to enter heart rate and O2 saturation into the CovidX application.
11045289|NCT04462289|No Intervention|Usual Care|Randomly assigned sample who will receive usual care for tobacco cessation treatment
11045187|NCT04463121|Experimental|Acute CNT pacing signals testing|"Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals.
~Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well.
~A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions."
11045188|NCT04463108||Participants with MDD and Active Suicidal Ideation with Intent|Participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent as defined/confirmed by Investigator will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical records of each participant.
11045189|NCT04463082|Experimental|Weight category 10-20kg|Pediatric patients with a weight of 10-20kg will be enrolled in this arm.
11045190|NCT04463082|Experimental|Weight category 20-30kg|Pediatric patients with a weight of 20-30kg will be enrolled in this arm.
11045191|NCT04463082|Experimental|Weight category 30-50kg|Pediatric patients with a weight of 30-50kg will be enrolled in this arm.
11045192|NCT04463069|Experimental|intervention group|Participants in the intervention group participated in the APA intervention consisting of simple and fun endurance and strength-building exercise at a frequency of two sessions per week.
11045193|NCT04463069|No Intervention|control group|Participants in the control group received no intervention in the study time period.
11045194|NCT04463056|Experimental|Elizaria®|International nonproprietary name: eculizumab
11045195|NCT04463056|Active Comparator|Soliris®|International nonproprietary name: eculizumab
11045196|NCT04463043|Experimental|SelfBACK app|The selfBACK app in addition to usual care
11045197|NCT04463043|Active Comparator|e-Help webpage|The e-Help webpage in addition to usual care
11045198|NCT04463043|Active Comparator|Usual care|Usual care only
11045199|NCT04463030|Active Comparator|Liposomal vitamin C, 1 gram|Participants will consume 1 gram on study day
11045200|NCT04463030|Active Comparator|Liposomal vitamin C, 2 grams|Participants will consume 2 grams on study day
11045201|NCT04463030|Active Comparator|Liposomal vitamin C, 5 grams|Participants will consume 5 grams on study day
11045202|NCT04463030|Placebo Comparator|Placebo|Participants will consume placebo on study day
11045203|NCT04463017|Active Comparator|Active Treatment: HU6|Planned doses of HU6; N = 74
11045204|NCT04463017|Placebo Comparator|Placebo Comparator|Non-active study drug N = 14
11045205|NCT04463004|Active Comparator|Intervention|Treatment infusion
11045206|NCT04463004|Placebo Comparator|Control|Placebo infusion
11045207|NCT04462978||Non IgE-mediated food allergy|Children with non IgE-mediated food allergy
11045208|NCT04462965|Experimental|Test group|Toripalima Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
11045209|NCT04462965|Placebo Comparator|Placebo group|Placebo Combined with Temozolomide and Cisplatin. Toripalima3 mg/kg intravenous infusion, administered once every 2 weeks (1 treatment cycle every 2 weeks) for a maximum of 1 year. Temozolomide, Oral 200mg/m2 1-5 days and Cisplatin, Iv infusion 25 mg/m2/d for a period of 1 to 3 days, 28 days for 1 cycle, lasting 6 cycles;
11045210|NCT04462952|Experimental|Adavosertib monotherapy|Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
11045211|NCT04462939|Experimental|Healthy lactating women - Supplement|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
11045212|NCT04462939|Placebo Comparator|Healthy lactating women - Placebo|At randomization (Visit 2), from four to six weeks after delivery, eligible actating women will be equally randomized to one of the study arms (supplementation arm or placebo arm) and will assume the supplement or placebo once daily for a duration of 12 weeks.
11045213|NCT04462926|Experimental|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
11045214|NCT04462913||Healthy control|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
11045215|NCT04462913||Patients with sports injuries|According to the previous clinical diagnosis, patients who has suffered the sports injuries(including hip, knee, and ankle joint diseases).
11045216|NCT04462913||Patients with degenerative osteoarthritis|According to the previous clinical diagnosis, patients who has suffered the degenerative osteoarthritis.
11045217|NCT04462887|Experimental|Nursing intervention program|The nursing intervention program consisting of 3 parts: (1) Structural Informational (SI) booklet, (2) Nursing Telephone Support (NTS) protocol, and (3) Nurse Pager 24/7.
11045218|NCT04462887|No Intervention|Usual Care Group|Usual care participants received treatment as usual from their health care providers.
11045219|NCT04462861|Experimental|CVAD securement device|Patients with a pre-existing CVAD who will trial the new securement dressing
11045220|NCT04462848|Experimental|anti-SARS-CoV-2 human convalescent plasma|single transfusion of human convalescent plasma
11045221|NCT04462822|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11045222|NCT04462822|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
11045223|NCT04462809|Experimental|Cohort A, Malignant pleural mesothelioma|Malignant pleural mesothelioma
11045224|NCT04462809|Experimental|Cohort B1:Malignant peritoneal mesothelioma non-resected|Malignant peritoneal mesothelioma with non-resected or incompletely resected disease
11045225|NCT04462809|Experimental|Cohort B2:Malignant peritoneal mesothelioma (resected)|Malignant peritoneal mesothelioma with completely resected disease.
11047499|NCT04446377|Placebo Comparator|Placebo|(microcrystalline cellulose) in 5 capsules BID for 10 days
11045228|NCT04462783|Experimental|Patient's symptom data with a pulse oximeter|Some patients will be given (or may have) a pulse oximeter in order to enter heart rate and O2 saturation data into the CovidX application.
11045229|NCT04462770|Active Comparator|Active arm with EPX-100 (Clemizole HCl)|EPX-100 oral solution 5mg/mL starting at 2.0 mg/kg/day increasing 1 mg/kg/day every 7 days until the maximum tolerated dose is found. Those intolerant of the 2.0 mg/kg/day starting dose will drop to a dose of 1.0 mg/kg/day and increasing by 0.5 mg/kg every 7 days or to MTD.
11045230|NCT04462770|Placebo Comparator|Placebo arm|Color- and taste-matched placebo oral solution dosed to match the active arm at 2.0 mg/kg/day increasing 1 mg/kg/day for every 7 days until the maximum tolerated dose is found.
11045231|NCT04462757|Active Comparator|Subcutaneous Arm|100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
11045232|NCT04462757|Active Comparator|Intravenous Arm|100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.
11045233|NCT04462731|Experimental|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
11045234|NCT04462731|Active Comparator|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
11045235|NCT04462718|Active Comparator|CONTROL GROUP:|You will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks.
11045236|NCT04462718|Experimental|EXPERIMENTAL GROUP|"After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
~The treatment is administered with a pulsatile short-wave equipment and inductive electrodes of 100 W peak power, with a frequency of application of twice daily with a dose submitis (grade I), for 10 min, with a frequency of repetition of the impulses of 46 Hz and a pulse duration of 0.2 ms."
11045237|NCT04462705|Active Comparator|Usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.
~- At D + 1 post-surgical:
~- First lift with verticalization.
~- A session with the Cliniflo® in a seated position.
~- Walk at least 100 m with the help of the physiotherapist.
~At- D+2 and D+3 post-surgical Same session as on D+1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3"
11045238|NCT04462705|Experimental|abdominal massage and usual physiotherapeutic intervention|"the usual physiotherapeutic intervention (respiratory and walking exercices). Each patients will be treated following the ERAS Guideline.
~- At D + 1post-surgical:
~- First lift with verticalization.
~- A session with the Cliniflo® in a seated position.
~- Walk at least 100 m with the help of the physiotherapist.
~At- D + 2 and D + 3 post-surgical Same session as on D + 1 with progressive increase in the walking perimeter. Add up and down stairs on D+ 3
~In this experimental arm, a abdominal massage will be performed in addition to the usual physiotherapeutic intervention (respiratory and walking exercices).
~The sessions take place on D+1, D+2 and D+3 post-surgical The first session is performed at least 20 hours after surgery (incision begins) Never within an hour of a meal. The session is timed."
11045239|NCT04462679|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
11045240|NCT04462666|Experimental|HZG intervention|During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.
11045241|NCT04462666|Active Comparator|Etoricoxib intervention|During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.
11045242|NCT04462666|Placebo Comparator|Placebo intervention|During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.
11045243|NCT04462653|Experimental|use two kinds of device successively|the same participant use a Wearable Dynamic ECG Recorder and 12-lead ECG to record heart rate and atrial fibrillation
11045244|NCT04462640||regurgitation|45 infants aged 0 to 5 months suffering from regurgitation
11045245|NCT04462640||colic|45 infants aged 0 to 5 months suffering from colic
11045246|NCT04462627|Experimental|Covid 19 positive patients|
11045247|NCT04462627|Experimental|Covid 19 negative patients|
11045248|NCT04462627|Experimental|Untested healthy volunteers|
11045249|NCT04462614|Experimental|single-arm study|Chronic hemodialysis patients for at least 3 months at Reims University Hospital, treated by long-term anticoagulation with VKA and dialysed with the HeprAN ™ membrane
11045250|NCT04462601||Patients with Sjögren Syndrome|
11045251|NCT04462588||Medical Treatment Group|Medical treatment group of uncomplicated acute appendisitis
11045252|NCT04462588||Surgery|Operated group of uncomplicated acute appendisitis
11045288|NCT04462302|No Intervention|Pain Education Only|If you are in this group, in addition to your usual care, you will be provided pain education at your initial clinic visit. After you have completed the 6-month follow up assessment, you will be provided a secure log-in code and invited to complete the 8 sessions of this Internet-based pain program on your own.
11045253|NCT04462575|Experimental|Onlay bone block covered using collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block) covered by collagen membrane, stabilized by resorbable suture and fixed by tacs.
11045254|NCT04462575|Active Comparator|Onlay bone block without collagen membrane|The onlay bone block (harvested from mandibular intra oral sites) on top of a mixture of particulate autogenous bone and particulate xenogenic bone (assembly going to be fixed by at least 2 micro screws of diameter 1.5 mms and length 13 mms, to avoid micro movements of onlay bone block).
11045255|NCT04462562|Experimental|quantitative ultrasound imaging parameters|"quantitative ultrasound imaging parameters
~tissue attenuation imaging (TAI) parameter
~tissue scatter-distribution imaging (TSI) parameter
~Hepatorenal index (semi-auto, EzHRI)"
11045256|NCT04462549|Experimental|Resource Facilitation|This group is receiving Resource Facilitation
11045257|NCT04462549|No Intervention|Control|Not receiving Resource Facilitation
11045258|NCT04462536|Placebo Comparator|Placebo|Vehicle only
11045259|NCT04462536|Experimental|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
11045260|NCT04462523|Experimental|Group 1 Pre-surgery Dextenza insert|Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
11045261|NCT04462523|Experimental|Group 2 Surgery Day Dextenza insert|Ten patients will receive dexamethasone intracanalicular insert on the day of surgery. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
11045262|NCT04462523|Experimental|Group 3 Post op Day 1 Dextenza insert|Ten patients will receive DEXTENZA insert Day 1 post-operatively. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops
11045263|NCT04462523|Active Comparator|Group 4 Topical steroid|Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
11045264|NCT04462510|Experimental|Illioinguinal/Illiohypogastric Block|A single shot 20ml of 0.25% Ropivacaine was used to block illioinguinal/illiohypogastric nerves using ultrasound right before incision was given
11045265|NCT04462510|Experimental|Wound infiltration|Surgeon infiltrated the wound using 20ml of 0.25% Ropivacaine right after the skin was closed.
11045266|NCT04462497|No Intervention|Control Group|Participants will receive the existing method of head support (sponge and towel stack) intraoperatively.
11045267|NCT04462497|Experimental|Study Group|Participants will receive the prototype head and neck support device intraoperatively.
11045268|NCT04462484|No Intervention|Control group|No intervention
11045269|NCT04462484|Experimental|Intervention group|Videoconference
11045270|NCT04462471|Experimental|Participants with thyroid cancer|Eligible participants will have a diagnosis of BRAF mutant RAIR thyroid cancer
11045271|NCT04462445|Experimental|pazopanib|Pazopanib 800 mg (2x400mg ) taken orally daily as per clinical practice
11045272|NCT04462432||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
11045273|NCT04462432||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
11045274|NCT04462419||Diagnostic (18F-fluciclovine, PET/MRI imaging)|Patients receive fluciclovine IV and undergo brain dynamic PET/MRI imaging over 50 minutes.
11045275|NCT04462406|Experimental|Arm A (active surveillance)|Patients with a negative FDG-PET/CT scan or a positive FDG-PET/CT scan but with a negative biopsy for viable tumor discontinue the anti-PD-1 therapy and undergo active surveillance.
11045276|NCT04462406|Active Comparator|Arm B (nivolumab, pembrolizumab, ipilimumab)|Patients with a positive FDG-PET/CT scan and positive biopsy for viable tumor or a positive FDG-PET/CT scan and biopsy not performed continue their standard of care anti-PD-1 therapy for 12 months in the absence of disease progression or unacceptable toxicity.
11045277|NCT04462406|Other|Standard of Care (nivolumab, pembrolizumab, ipilimumab)|Patients continue their standard of care anti-PD-1 therapy. Treatment may consist of the following regimens: 1) nivolumab IV over 30 minutes Q2W or Q4W; 2) pembrolizumab IV over 30 minutes Q3W or Q6W; 3) nivolumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by nivolumab IV over 30 minutes Q2W or Q4W; or 4) pembrolizumab IV over 30 minutes and ipilimumab IV Q3W for 4 doses followed by pembrolizumab IV over 30 minutes Q3W or Q6W. Treatment continues until 52 weeks from start of standard of care anti-PD-1 therapy in the absence of disease progression or unacceptable toxicity.
11045278|NCT04462354|Active Comparator|Pancreatogastric anastomosis.|
11045279|NCT04462354|Experimental|Blumgart Anastomosis|
11045280|NCT04462341|Active Comparator|Manual brushing only|Participants brushed with a manual toothbrush and fluoridated toothpaste twice a day for 6 weeks
11045281|NCT04462341|Experimental|Manual brushing + water flossing|Participants brush twice a day and water flossed once a day for 6 weeks.
11045282|NCT04462328|Experimental|Phase I Dose Level 1: Durvalumab + Acalabruitinib|"Acalabrutinib 100 mg twice per day by mouth on days 1-28
~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
11045283|NCT04462328|Experimental|Phase I Dose Level 2: Durvalumab + Acalabruitinib|"Acalabrutinib 200 mg twice per day by mouth on days 1-28
~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
11045284|NCT04462328|Experimental|Expansion Cohort: Durvalumab + Acalabrutinib|"Acalabrutinib 100 mg or 200 mg (depends on tolerable dose found in Phase I portion of study) twice per day by mouth on days 1-28
~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
11045285|NCT04462315||Everolimus Arm|Everolimus Eluting Coronary Stent System
11045286|NCT04462315||Non-drug eluting stent Arm|Cobalt chromium balloon-expandable stent
11045287|NCT04462302|Experimental|Internet-based program + Pain Education|If you are in this group, in additional to your usual care, you will be provided access to the 8-session Internet-based pain program plus pain education. You will need to complete your sessions within 10 weeks of being provided your log-in code. You will be allowed to revisit sessions that you have completed during this 10 weeks. After completion of the study, you will still be provided access to the 8-session Internet-based pain program.
11045290|NCT04462289|Experimental|Proactive Outreach|Randomly assigned sample who will receive a proactive offer of tobacco treatment
11045291|NCT04462276|Experimental|Arm A: Atezolizumab + thoracic radiotherapy|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W) Thoracic radiation therapy (TRT), 30 Gy in 10 fractions
11045292|NCT04462276|Experimental|Arm B: Atezolizumab|Atezolizumab at a fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
11045293|NCT04462263|Experimental|Single Dose HTL0014242|The study consists of up to 5 dosing groups, with 2 to 3 subjects per dosing group. Each subject will receive a single oral dose of HTL0014242 in the form of solid suspension capsules (1, 5, 10, and 30mg) as required. HTL0014242 will be administered in up to 5 single dose groups, with 120mg administered in the first dosing group.
11045294|NCT04462250|Active Comparator|Control|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points but there will be no reward provided.
11045295|NCT04462250|Active Comparator|Contingency Management - Virtual Pet|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which can be used in the care of a virtual pet.
11045296|NCT04462250|Active Comparator|Contingency Management - Monetary|Subjects will use the smartphone app to manage use of prescribed opioid medications to earn points, which will be paid out at the end of the one-week trial in the form of a monetary reward.
11045297|NCT04462237|Experimental|collagen matrix + platelet-derived growth factor|Root coverage procedure using collagen matrix + platelet-derived growth factor for the treatment of multiple adjacent gingival recessions
11045298|NCT04462237|Active Comparator|collagen matrix alone|Root coverage procedure using collagen matrix alone (without the use of the platelet-derived growth factor) for the treatment of multiple adjacent gingival recessions
11045299|NCT04462211|Experimental|Management pharmacological protocol and bundle's|"The elaboration of the protocol according to the evidence-based approach, updated evidence found from both search engines such as MEDLINE, EMBASE, Cochrane Library, OVID and ScIELO will be used through the research question using the PICO method (Patient interest, Intervention, Comparation and Outcome).
~the ready-made protocol will be adjusted to the pharmacological options that are available in the hospital."
11045300|NCT04462198|Experimental|PIPE-505|
11045301|NCT04462198|Placebo Comparator|Diluent alone|
11045302|NCT04462185||Prospective Cohort|This is a prospectively enrolling cohort study and 3000 patients (1500 GGO and 1500 solid / semi solid nodules) with radiologic diagnosis of indeterminate pulmonary nodule (5-30 mm) will be recruited. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, a genomic and transcriptomic landscape analysis, at each visit.
11045303|NCT04462172|Experimental|Synthes Femoral Neck System (FNS)|Synthes Femoral Neck System (FNS) was developed with the intention to combine advantages of DHS (dynamic hip screw) and MCS (multiple cancellous screw). The FNS implants consist of plates, bolts, locking screws and antirotating-screws. The plate consists of a small base plate with one or two locking holes and a barrel portion. The barrel allows for gliding of the head elements while restricting rotation around the head-neck axis, so FNS is a fixed-angle gliding fixation device that allows for controlled collapse of the femoral neck, like DHS. The FNS was also designed to minimize implant footprint on the bone with its compact design, like MCS. Furthermore, the FNS was designed to reduce the length of incision necessary for implant insertion when compared to DHS. This new concept of femoral neck fracture fixation still emphasizes the biology of fracture healing by initial fracture compression.
11045304|NCT04462172|Active Comparator|Multiple cancellous screws (MCS)|Multiple cancellous screws (MCS) fixation is the most common and classic method to deal with femoral neck fractures which is less invasive and retains more viable bone, compared with dynamic hip screw (DHS) fixation that appears biomechanically more stable. In this study, three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
11045305|NCT04462159|Experimental|Risk Reduction Program|All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component.
11045306|NCT04462146|Experimental|Internet-based intervention|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
11045307|NCT04462146|Active Comparator|Face-to-face Intervention|Face-to-face Intervention applied by a therapist: Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
11045308|NCT04462133|Active Comparator|Empirical therapy for H. pylori infection|The empirical group receives triple therapy of 7 or 14 days for H. pylori eradication
11045309|NCT04462133|Experimental|Tailored therapy for H. pylori infection|The tailored therapy group receives eradication regimens based on their DPO-PCR results. Triple therapy of 7 or 14 days for clarithromycin sensitive patients based on DPO-PCR and bismuth quadruple therapy of 7 or 14 days for clarithromycin resistant patients based on DPO-PCR.
11045310|NCT04462107||Surveys|All participants will complete questionnaires at several time points, ranging from baseline to 3 months post partum.
11045311|NCT04462094|Active Comparator|End-of-surgery|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at the end of surgery
11045312|NCT04462094|Placebo Comparator|Induction|Low-dose ketamine (0.3 mg/kg) in 3 ml normal saline solution given at induction
11045313|NCT04462042|Active Comparator|Photon radiotherapy|Conventional photon radiation is delivered by volumetric arc therapy/intensity modulated radiotherapy/helical tomotherapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases >2 cm is 57.5 Gy in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy.
11045442|NCT04461197|Experimental|ESWT + orthotic insole|(shock waves + orthotic insole +Stretches of the posterior muscle chain)
11045314|NCT04462042|Experimental|Proton radiotherapy|Proton radiation is delivered by spot scanning. Proton plans will be produced by single field optimisation/single field uniform dose or multifield optimisation/intensity modulated proton therapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases >2 cm is 57.5 Gy(RBE) in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy(RBE) in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy(RBE).
11045315|NCT04462029|Other|sequence 1|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 1: R - T1 - T2"
11045316|NCT04462029|Other|sequence 2|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 2: R - T2 - T1"
11045317|NCT04462029|Other|sequence 3|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 3: T1 - R - T2"
11045318|NCT04462029|Other|sequence 4|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 4: T1 - T2 - R"
11045319|NCT04462029|Other|sequence 5|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 5: T2 - R - T1"
11045320|NCT04462029|Other|sequence 6|"A total of 18 subjects will be randomized into 6 sequence groups. The investigational products (IPs) will be administered according to the treatment groups (R, T1, and T2) assigned to each sequence group in Period 1, Period 2, and Period 3. In between each period, there will be a washout period (28 days) long enough for the administered IP to be metabolized and eliminated.
~R(Reference): BR4002-1 (oral intake) 5mg single-dose
~T1(Test1): BR4002 (patch) 5mg single-dose (using the applicator)
~T2(Test2): BR4002 (patch) 5mg single-dose (not using the applicator)
~sequence 6: T2 - T1 - R"
11045321|NCT04462016|Active Comparator|Reference drink|Healthy volunteers' blood glucose response to reference drink (glucose)
11045322|NCT04462016|Experimental|Test drink|Healthy volunteers' blood glucose response to test drink (calamansi)
11045323|NCT04462003|Active Comparator|Apixaban|50 patients with DVT with malignancy were randomized to apixaban 10 mg twice daily dose for 7 days followed by apixaban 5 mg twice daily
11045324|NCT04462003|Active Comparator|Enoxaparin|50 patients with DVT with malignancy were randomized to enoxaparin (1mg/Kg/SC every 12 h)
11045325|NCT04461990||Luminal|"Luminal A：ER+ and/or PR+,HER2- Luminal B：ER+ and/or PR+,HER2+
~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
11045326|NCT04461990||HER2 overexpression|"ER- PR-,HER2+
~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
11045327|NCT04461990||Triple negative|"ER- PR-,HER2-
~* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2"
11045328|NCT04461977|Experimental|A - true acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen 2011) and on previous studies (Jeong, 2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment."
11045329|NCT04461977|Sham Comparator|B - sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet."
11045330|NCT04461964|Experimental|treatment group|Eligible participants will be identified by their treating physician and referred to the study research coordinator for enrollment. NYU standard practice in relation to pre-operative and intra-operative imaging studies will be explained. The role of the MvIGS system in this study will then also be explained. In each subject, they will perform posterior instrumentation utilizing the MvIGS spine navigation system for pedicle screw guidance and record data for intraoperative study endpoints
11045331|NCT04461951||Community dwelling seniors|Participants are visited at the research facility in their residence town by a trained team. Informed consent form is completed at the research facility prior to data collection. In those individuals without capacity to give full informed consent, proxy consent is collected from relatives or caregivers. This 2-hours interview includes a face-to-face administration of a neuropsychological battery of tests and questionnaires to inquire about socio-demographic, occupational, and social-economic data, education, medical conditions and drug use, lifestyle habits, functional status, and dietary behaviours.
11045332|NCT04461938|Other|Fasting|All study participants follow the same dietary intervention; thus, no randomization will take place.
11045443|NCT04461197|Placebo Comparator|ESWT + flat insole|(shock waves + flat insole + Stretches of the posterior muscle chain)
11045333|NCT04461925|Experimental|Experimental group|"On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day 1, Day 4, Day 7."
11045334|NCT04461925|Active Comparator|Control Group|Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies
11045335|NCT04461912|Experimental|Cataract|Participants with diverse types and severities of cataract, that should realize phacoemulsification surgery
11045336|NCT04461912|Placebo Comparator|Control|Participants on which the presence of cataract have been excluded
11045337|NCT04461899|Other|sclerotherapy|a sclerotherapy will be done in patients
11045338|NCT04461886|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
11045339|NCT04461873|Experimental|Reiki|Reiki was applied to this arm by the researcher who completed her second level education according to the Usui method, for 45 minutes once a week for 6 weeks and by touching the 9 main points in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again. After the 6-week Reiki application, all the caregivers of the intervention group were asked about their experience and opinions regarding the application by the individual in-depth interview method during the home visit.
11045340|NCT04461873|Placebo Comparator|Sham Reiki|Four student nurses who did not receive Reiki training and were trained about application by the investigator applied sham by gesturing and mimic imitation through touching 9 points for 45 minutes/week for 6 weeks in line. A saliva sample was taken from the participants in order to determine the stress level through cortisol and Caregiver Stress Scale (CSS) was applied in the first week of Reiki application. Systolic and diastolic blood pressures and pulse rates were measured for six weeks before and after each application. At the end of six weeks, saliva samples were collected and CSS was applied again.
11045341|NCT04461847|Experimental|patients underwent ESM|
11045342|NCT04461847|Active Comparator|patients underwent SM|
11045343|NCT04461821||obstructive bronchitis/bronchiolitis|
11045344|NCT04461821||pneumonia|
11045345|NCT04461821||asthma|
11045346|NCT04461821||neurological diseases|
11045347|NCT04461821||type 1 diabetes (T1D)|
11045348|NCT04461821||pharmacotherapy with bronchodilators|
11045349|NCT04461821||pharmacotherapy with antibiotics|
11045350|NCT04461821||pharmacotherapy with antiviral medication|
11045351|NCT04461821||pharmacotherapy with antifungal medication|
11045352|NCT04461821||pharmacotherapy with antiepileptic medication|
11045353|NCT04461821||pharmacotherapy with immuno suppressants and immune-modulati|
11045354|NCT04461821||pharmacotherapy with anesthesia (including sedating, analges|
11045355|NCT04461808|Experimental|Tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.
~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
11045356|NCT04461808|Active Comparator|Digital Mammography|"Women will be screened for digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.
~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
11045357|NCT04461795|Experimental|AJOVY (fremanezumab-vfrm)|Participants received 225 mg/1.5 mL solution via single-dose prefilled syringe administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for 12 weeks.
11045358|NCT04461782|Experimental|Lactobacillus plantarum|"Oral intake 1 cap daily
~1E+09 cfu/cap of Lactobacillus plantarum"
11045359|NCT04461769|Experimental|Slow Oscillation Synchronization with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
11045360|NCT04461769|Sham Comparator|Sham Control|No current delivered.
11045361|NCT04461756|Experimental|inhaled THC/CBD (PPP001)|
11045362|NCT04461743||Patients with normal lac|
11045363|NCT04461743||Patients with abnormal lac|
11045364|NCT04461730||Parkinson disease|
11045365|NCT04461730||essential tremor|
11045366|NCT04461730||dystonia|
11045367|NCT04461730||OCD|
11045368|NCT04461730||healthy volunteers|
11045369|NCT04461717||MicroNet covered stenting (interventional)|MicroNet covered stent implantation for increased risk arterial lesions beyond the carotid bifurcation
11045370|NCT04461691|Other|Heart Failure|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
11045371|NCT04461691|Other|Normal cardiac function|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
11045372|NCT04461678|Experimental|screening population|
11045373|NCT04461665|No Intervention|Control|Enroll 6 months old breast feeding infant, who have not supplement vitamin D at pediatric clinic.
11045374|NCT04461665|Experimental|VitD supplement|Enroll 4 months old breast feeding infant, and provide 10 μg vitamin D daily for 2 months.
11045375|NCT04461652|Experimental|New method|One thoracic tube (28fr drainage tube) was inserted through intercostal incision, and one microtubule (7fr × 20cm) was punctured through the middle line of clavicle
11045376|NCT04461652|Placebo Comparator|Traditional method|Two conventional chest tubes (28fr or 24fr) were placed through intercostal incision
11045377|NCT04461639||Damoctocog alfa pegol|Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.
11045378|NCT04461626||Persona fixed bearing knee system|Persona fixed bearing knee system (All patients will received Persona fixed bearing knee system)
11045526|NCT04460651|Active Comparator|Active treatment|Participants in this arm will receive study medication icosapent ethyl (IPE) with a specific dose scheme.
11045379|NCT04461613|Experimental|Group 1|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 1 will receive an original International Physical Activity Questionnaire short form (IPAQ-sf). Group 1 will be asked to fill it out with information about physical activities in the last 7 days.
~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 1 will be asked to fill a revised version of IPAQ-sf to describe physical activities in the last 7 days."
11045380|NCT04461613|Experimental|Group 2|"In the first week, this group will receive a physical activity diary and be required to fill it out for 7 days. After completion of the activity diary, group 2 will receive a revised version of International Physical Activity Questionnaire short form (IPAQ-sf). Group 2 will be asked to fill it out with information about physical activities in the last 7 days.
~In the second week, the group will need to fill another physical activity diary for 7 days. After the completion of this, group 2 will be asked to fill an original IPAQ-sf to describe physical activities in the last 7 days."
11045381|NCT04461600|Experimental|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
11045382|NCT04461587|Experimental|Pirfenidone [Esbriet]|"Pirfenidone recommended daily dose for patients is 801 mg three times a day with food, for a total of 2403 mg/day. Upon initiating treatment, the dose should be titrated to the recommended daily dose of 2403 mg/day over a 14day period as follows:
~Days 1 to 7: a dose of 267 mg administered three times a day (801 mg/day)
~Days 8 to 14: a dose of 534 mg administered three times a day (1602 mg/day)
~Day 15 onward: a dose of 801 mg administered three times a day (2403 mg/day) It will be provided in 267mg capsules. Treatment will be for a minimum of 12 months. Treatment duration will continue until last patient enrolled received 12 months of treatment."
11045383|NCT04461574|Placebo Comparator|Cervex Brush|
11045384|NCT04461574|Active Comparator|Orcellex Brush|
11045385|NCT04461561|Experimental|ELNEC-PPC WBT pluss usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
11045386|NCT04461561|No Intervention|Usual care only|Participants nurses deliver usual care as his/her role appropriate to neonates, infants, toddlers, preschoolers, school age, also to adolescents in selected unit of perinatal, neonatal, and settings which can be pediatric.
11045387|NCT04461548|Experimental|Experimental group 1: Best Possible Self|Participants are asked to think and write about their best possible future self and to imagine this positive future subsequently.
11045388|NCT04461548|Experimental|Experimental group 2: Best Possible Self + next steps|Participants are asked to think and write about their best possible future self and what the next steps could be to reach that best possible future. Subsequently, participants are asked to imagine this positive future.
11045389|NCT04461548|Experimental|Experimental group 3: Self-compassion|Participants are asked to think and write about a self-compassion exercise and to imagine this content subsequently.
11045390|NCT04461548|Active Comparator|Active control group|Participants are asked to think and write about a neutral task that is comparable to the experimental groups.
11045391|NCT04461535|Experimental|AVS with ACTH stimulation|Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.
11045392|NCT04461535|No Intervention|AVS without ACTH stimulation|Patients divided into AVS without ACTH stimulation group take the same procedure of AVS except for continuous cosyntropin infusion.
11045393|NCT04461522||Exposed group|
11045394|NCT04461522||Control group|
11045395|NCT04461509|Experimental|18F-PSMA|10 mCi ±20% F18-PSMA injection
11045396|NCT04461496|Active Comparator|Hybrid revascularization|50 hybrid procedure
11045397|NCT04461496|Experimental|Full metall jacket|50 total endovascular interventions
11045398|NCT04461483|Experimental|Part 1, Cohort 1; TAK-935 200 mg|Part 1, Cohort 1; TAK-935 200 mg, tablets, orally once on Days 1 in fasted state.
11045399|NCT04461483|Experimental|Part 1, Cohort 2; TAK-935 600 mg|Part 1, Cohort 2; TAK-935 600 mg, tablets, orally once on Days 1 in fasted state.
11045400|NCT04461483|Experimental|Part 1, Cohort 3; TAK-935 1200 mg|Part 1, Cohort 3; TAK-935 1200 mg, tablets, orally once on Days 1 in fasted state.
11045401|NCT04461483|Placebo Comparator|Part 1, Cohort 1-3; Placebo|Part 1, Cohort 1-3; TAK-935 placebo-matching tablets, orally once on Days 1 in fasted state.
11045402|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 100 mg|Part 2, Cohort 4: TAK-935 100 mg, tablets, orally twice on Days 1-7 in fasted state with multiple doses with titration.
11045403|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 200 mg|Part 2, Cohort 4: TAK-935 200 mg, tablets, orally twice on Days 8-14 in fasted state with multiple doses with titration.
11045404|NCT04461483|Experimental|Part 2, Cohort 4: TAK-935 300 mg|Part 2, Cohort 4: TAK-935 300 mg, tablets, orally twice on Days 15-21 in fasted state with multiple doses with titration.
11045405|NCT04461483|Placebo Comparator|Part 2, Cohort 4: Placebo|Part 2, Cohort 4: TAK-935 placebo-matching tablets, orally twice on Days 1-21 in fasted state.
11045406|NCT04461470||London|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
11045407|NCT04461470||All United Kingdom|pulsed electro resonance hz 4, hz 3, hz 2, hz 3.5 and residual hz 5
11045408|NCT04461457|Experimental|Intraperitoneal Radioimmunotherapy boost|Four groups of 3 patients with recurring ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one IP dose of 211astatine-MX35 F(ab'2). Starting at 50 MBq/L. Dose escalation 100 Mbq/L, 200 MBq/L and finally 300 MBq/L.
11045409|NCT04461444|Other|Group ALMS et BBS|
11045410|NCT04461431|Experimental|Knee joint lateral reconstruction group|
11045411|NCT04461418|Active Comparator|Dexamethasone|Dose starting at 4 mg daily (for patients randomized to the Dexamethasone arm).
11045412|NCT04461418|Active Comparator|Prednisone|Dose starting at 25 mg/day (a calculation of equipotent steroid equivalencies will be used).
11045484|NCT04460885|Active Comparator|Insulin glargine|Insulin glargine + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
11045485|NCT04460872|Experimental|testosterone enanthate|Testosterone enanthate via i.m. injection (100 mg/week)
11045413|NCT04461405|Experimental|Intervention Arm|INTEGRATE-D is a step-by-step blueprint that will assist practices with employing American Diabetes Association recommendations for integrating medical and psychosocial care. INTEGRATE-D consists of a set of implementation strategies that enable clinical teams to put evidence-based care in place. The intervention consists of training and education; audit and feedback materials; a facilitation implementation protocol; and health information technology support materials.
11045414|NCT04461405|No Intervention|Control Arm|Usual care
11045415|NCT04461392|Experimental|Oncology patients|Patients diagnosed with cancer and treated with chemotherapy and/or radiotherapy
11045416|NCT04461379|Experimental|BCG Vaccine|A single dose BCG vaccine intradermally 0.1 ml.
11045417|NCT04461379|Placebo Comparator|Placebo|A single dose intradermally 0.1 ml of NaCl 0.9% solution
11045418|NCT04461366|Experimental|monopolar radiofrequency (MRF) group|Monopolar Radiofrequency Diathermy (LVT-250, Korea) was used at average energy160-180 W, main power 50/60 Hz, 40˚C ~ 45˚C Temperature, RF output 470 kHz, 20 mm electrode size.
11045419|NCT04461366|Active Comparator|Pulsed dye laser (PDL) group|Flash lamp pulsed dye laser; Candela SPTL-1 (Candela Corp., Wayland, Mass.) with the following parameters: (585nm wavelength, 450 msec pulse duration, 6.5 to 7.5 J/cm² energy density and 5or 7mm spot size).
11045420|NCT04461353|Active Comparator|Hydroxychloroquine Sulfate|The study drug AHCQ will be administered by inhalation through the mouth. The starting dose will be 20 mg (Cohort A1) with a proposed subsequent dose of 50 mg (Cohort A2). At each dose level 8 participants (including at least 3 female participants and 3 participants older than 50 years old) will be enrolled. Six participants will receive the active study drug and 2 participants will receive placebo.
11045421|NCT04461353|Placebo Comparator|Placebo|Placebo will be administered by inhalation through the mouth. It will be administered in both Cohort A1 and Cohort A2. Six participants will receive the active study drug and 2 participants will receive placebo.
11045422|NCT04461340|Experimental|Group A|20 patients will receive sirolimus ( oral dose of 6 mg on day 1 followed by 2 mg daily for 9 days) plus national standard of care therapy against COVID 19
11045423|NCT04461340|No Intervention|Group B|20 patients will receive only national standard of care therapy against COVID 19
11045424|NCT04461327|Experimental|Major Depressive patients|"3 groups:
~Women having recently attempted suicide (less than 72 hours).
~Women having a past suicide attempt (more than 72 hours).
~Women without lifetime history of suicidal behaviour."
11045425|NCT04461314|Other|Peer-led counselling|"About 50 university students trained as peer telephone counsellors through a structured training programme.
~About 200 Drug-abusing youth and young adults received telephone-based, Peer-led Brief Motivational Interviewing (BMI)"
11045426|NCT04461301|Experimental|Intervention|Patients that meet the inclusion criteria will be randomised and scheduled for surgery at least 2 weeks after the diagnosis/decision to proceed to surgery. This timeframe allows the implementation of a minimal 2 weeks (up to 4 weeks) multidisciplinary prehabilitation program. Prehabilitation program is composed of 4 elements: exercise training, nutritional intervention, correction of anaemia and smoking cessation. An individual treatment strategy will be proposed to the patient by a multidisciplinary team consisting of surgeon, anesthesiologist, dietitian and physiotherapist.
11045427|NCT04461301|No Intervention|Control|Perioperative care of the control group will be based on standardized, multi-element, ERAS recommendations as already implemented in the different participating clinics.
11045428|NCT04461288|Experimental|Pride Posts|This six month intervention will be conducted on the Facebook platform. Participants will receive regular social media posts tailored to the sexual and gender minority communities (LGBTQ+). Weekly live sessions with a tobacco expert will be available. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
11045429|NCT04461288|Experimental|Pride Posts Plus|This six month intervention will include all elements of the Pride Posts arm. In addition, the intervention will include gamification, gaming elements designed to encourage participation in the program and behavior change. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
11045430|NCT04461288|Active Comparator|Usual Care Condition|Participants in this arm will be provided with a referral to smokefree.gov, a federally-funded website which provides support and digital-based interventions to assist in smoking cessation activities. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
11045431|NCT04461275|Experimental|ERAS 2.0 group|Patients included in the ERAS 2.0 group will follow the ERAS 2.0 accelerated care protocol.
11045432|NCT04461262|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
11045433|NCT04461262|Other|Standard Care|Foley catheter, uncoated
11045434|NCT04461249||Latanoprost group|Latanoprost 0.005 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
11045435|NCT04461249||Travoprost group|Travoprost 0.004 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
11045436|NCT04461249||Tafluprost group|Tafluprost 0.0015 % eye drops was given once by night for 3 months for newly diagnosed primary open-angle glaucoma patients.
11045437|NCT04461236|Experimental|Isoleucine|Type 2 Diabetics randomized to isoleucine group
11045438|NCT04461236|Placebo Comparator|Placebo|Type 2 Diabetics randomized to placebo group
11045439|NCT04461236|No Intervention|Healthy|gender-, age-, BMI-matched controls for baseline measurements only. No supplementation provided.
11045440|NCT04461210||Vulvodynia|Women with localized, provoked vulvodynia
11045441|NCT04461210||Health Controls|Women without vulvar pain or other vulvar disorders.
11045444|NCT04461184|Experimental|Internet wellness intervention for aging|Feasibility components will be evaluated with a 5-point Likert scale may include open ended items for more detailed feedback. Participants will be asked to visit NDSU at the beginning and end of the intervention, and at 1-month follow-up. After written informed consent, each participant will complete a descriptive questionnaire at the beginning of the intervention period, and a health-related questionnaire at the beginning and end of the intervention, and at follow-up that includes self-rated health, current smoking status, smoking history, alcohol use, morbid conditions, functional disability, and depression status. Standing height and waist circumference will be collected with a tape measure. Body weight and composition will be measured with the InBody 570. Anthropometric and body composition assessments will be collected pre, post, and follow up.
11045445|NCT04461171|Experimental|ERAS|Administration of a perioperative non-narcotic, multimodal pain management pathway.
11045446|NCT04461171|No Intervention|Non-ERAS (Conventional)|Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
11045447|NCT04461158|Experimental|Interventional Group|
11045448|NCT04461145|Other|ACL group|
11045449|NCT04461132|Active Comparator|Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included manual lymphatic drainage on the leg, skin care, bandaging and exercise.
11045450|NCT04461132|Sham Comparator|Shame Manual Lymphatic Drainage Group|All patients were treated 3 times a week for 4 weeks. The treatment program of these patients included shame manual lymphatic drainage on the leg, skin care, bandaging and exercise. Shame manual lymphatic drainage include light touches instead of real manual lymphatic drainage techniques
11045451|NCT04461119|Experimental|Evenamide 7.5 mg bid|
11045452|NCT04461119|Experimental|Evenamide 15 mg bid|
11045453|NCT04461119|Placebo Comparator|Placebo|
11045454|NCT04461106|Active Comparator|Social Marketing Campaign|Select egg hubs will receive social marketing campaign which aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (<5yrs) and pregnant/lactating women.
11045455|NCT04461106|No Intervention|No Social Marketing Campaign|Other egg hugs will not receive social marketing campaign.
11045456|NCT04461093|Experimental|Group I|"Group I (n=45)
~Acupressure wristband
~IV Dexamethasone 8mg
~IV Ondansetron 4mg"
11045457|NCT04461093|Active Comparator|Group II|"Group II (n=45)
~1. IV Palonosetron 0.075mg"
11045458|NCT04461080|Experimental|Community Health Worker|Patients who are randomized to the intervention group will be connected with a trained Community Health Worker. The CHW could have a background as a social worker, health promoter or community worker. All CHWs will receive 1 week of training to assist participants with social needs.
11045459|NCT04461080|Active Comparator|Information on community resources|Patients randomized to the control group will receive a list of tailored written information.
11045460|NCT04461041|Active Comparator|Empagliflozin|Single 10 mg tablet, administered orally once daily for 6 months
11045461|NCT04461041|Placebo Comparator|Placebo|Single 10 mg tablet, administered orally once daily for 6 months
11045462|NCT04461028|Other|GROUP 1 liposomal Bupivacaine|Will receive a 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
11045463|NCT04461028|Other|GROUP 2 Bupivacaine with dexamethasone|Will receive 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
11045464|NCT04461015|Other|0.4mU Insulin|During the euglycemic clamp insulin will be infused at 0.4mU/Kg/Min
11045465|NCT04461015|Other|0.8mU Insulin|During the euglycemic clamp insulin will be infused at 0.8mU/Kg/Min
11045466|NCT04461002||Cohort|Retrospective cohort
11045467|NCT04460989||standard implant|arthroplasty with a standard implant
11045468|NCT04460989||personalized implant|arthroplasty with a customized implant
11045469|NCT04460976|Experimental|Experimental group|Experiment group that receives the psychoeducation direct after the baseline measurement.
11045470|NCT04460976|Other|Control group|Standard care / treatment as usual. Comparison group alos receives Prisma psychoeducation after the three-month follow-up time period.
11045471|NCT04460963|Other|Biological evaluation|Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up
11045472|NCT04460937|Experimental|Treatment (radiation therapy, adavosertib)|Patients undergo radiation therapy QD 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive adavosertib PO QD for 2-5 days (depending on dose level) during weeks 1 and 3 of radiation therapy in the absence of disease progression or unacceptable toxicity.
11045473|NCT04460924||MSM HIV-uninfected and ART naïve|Men who have sex with men without HIV infection, not receiving ART
11045474|NCT04460924||MSM HIV-infected starting ART|Men who have sex with men with HIV infection, starting ART
11045475|NCT04460924||MSM HIV-infected on ART with >500 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with >500 CD4 T cells/uL
11045476|NCT04460924||MSM HIV-infected on ART with <350 CD4 Tcells|Men who have sex with men with HIV infection, on ART and with <350 CD4 T cells/uL
11045477|NCT04460924||MSM HIV negative patients starting PEP with INST|Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir
11045478|NCT04460911||Cohort 1a (Pb-AI)|Patients who initiated treatment with an aromatase inhibitor (letrozole, exemestane, or anastrozole) palbociclib combination therapy as first-line treatment in the advanced or metastatic setting.
11045479|NCT04460911||Cohort 1b (Pb-FUL)|Patients who initiated palbociclib-fulvestrant combination therapy as first-line or beyond therapy in the advanced or metastatic setting.
11045480|NCT04460911||Cohort 2a (AI mono)|Patients who initiated treatment with an aromatase inhibitor (letrozole, exemestane, or anastrozole) as a monotherapy as first-line treatment in the advanced or metastatic setting.
11045481|NCT04460911||Cohort 2b (FUL mono)|Patients who received fulvestrant monotherapy as first-line or beyond therapy in the advanced or metastatic setting.
11045482|NCT04460898||Breast Cancer Patients|HR+/HER2- metastatic breast cancer patients in the US.
11045483|NCT04460885|Experimental|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
11045486|NCT04460872|Experimental|locomotor training, testosterone enanthate|Treadmill and overground walking training and testosterone enanthate via i.m. injection (100 mg/week)
11045487|NCT04460872|No Intervention|non-interventional control|Non-interventional control group
11045488|NCT04460859||Intubated mechanically ventilated ARDS patients|Intubated mechanically ventilated patients with moderate to severe ARDS according to the Berlin definition
11045489|NCT04460846|Active Comparator|Alkaline water|Participants will consume 1.5 liters per day
11045490|NCT04460846|Placebo Comparator|Reverse osmosis water|Participants will consume 1.5 liters per day
11045491|NCT04460833|Experimental|Test group|All children will have the 6 feedback modalities + the control given randomly
11045492|NCT04460820|Experimental|Doxorubicin Hydrochloride Liposome Injection|50mg/m2 ,IV on Day 1 of each cycle
11045493|NCT04460820|Active Comparator|Doxorubicin Hydrochloride Liposome Injection(Caelyx®)|50mg/m2 ,IV on Day 1 of each cycle
11045494|NCT04460807|Experimental|Exemestane|"Standard chemotherapy: paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.
~+
~Exemestane: single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
11045495|NCT04460807|Placebo Comparator|Placebo|"Standard chemotherapy : paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.
~+
~Placebo: single oral tablet until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
11045496|NCT04460794|Experimental|Ballet-inspired workout programme (Group A)|Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
11045497|NCT04460794|Other|Usual care (Group B)|Control participants will continue their usual activities and exercises during the study period. In addition, they will be provided with an information sheet about recommendations with pictorial demonstrations on basic stretching and leg exercises for stroke survivors.
11045498|NCT04460781||1|Pregnant women from the VAP00003 Study and their offspring - Pregnant women from the VAP00003 Study (NCT03694392) between September 2018 and May 2020 (2 influenza seasons), and infants born from this cohort of pregnant women
11045499|NCT04460755|Active Comparator|Control group|A group of participants that will be using toothpaste without tooth whitening ingredients.
11045500|NCT04460755|Experimental|Whitening toothpaste 1|A group of participants that will be using urea peroxide whitening toothpastes.
11045501|NCT04460755|Experimental|Whitening toothpaste 2|A group of participants that will be using hydrogen peroxide whitening toothpastes.
11045502|NCT04460755|Experimental|Whitening toothpaste 3|A group of participants that will be using whitening toothpastes that contain abrasive ingredients.
11045503|NCT04460755|Experimental|Whitening toothpaste 4|A group of participants that will be using whitening toothpastes that contain enzymes as whitening ingredients.
11045504|NCT04460755|Experimental|Whitening toothpaste 5|A group of participants that will be using toothpastes that contain an activated charcoal.
11045505|NCT04460742|Experimental|CAPABLE Transitions|Older adults admitted to University of Rochester Medicine Home Care with and without dementia will receive care as usual as well as CAPABLE-trained occupational therapy, registered nurse, and handyman services delivered over 3-4 months.
11045506|NCT04460742|Active Comparator|Care As Usual|Older adults admitted to University of Rochester Medicine Home Care (a Medicare-certified home health agency) with and without dementia will receive care as usual.
11045507|NCT04460729|Experimental|Cohort 1|Participants who are asymptomatic and without prior brain therapy
11045508|NCT04460729|Experimental|Cohort 2|Participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease
11045509|NCT04460703|Sham Comparator|Control|Control message about birdfeeding
11045510|NCT04460703|Active Comparator|Baseline message|These participants will be assigned a message about the benefits of vaccination. All other treatment arms include this baseline language.
11045511|NCT04460703|Experimental|Personal freedom|Experimental message arm.
11045512|NCT04460703|Experimental|Economic freedom|Experimental message arm.
11045513|NCT04460703|Experimental|Social benefit, self-interest|Experimental message arm.
11045514|NCT04460703|Experimental|Social benefit, community interest|Experimental message arm.
11045515|NCT04460703|Experimental|Economic benefit|Experimental message arm.
11045516|NCT04460703|Experimental|Social pressure- guilt|Experimental message arm.
11045517|NCT04460703|Experimental|Social pressure- embarrassment|Experimental message arm.
11045518|NCT04460703|Experimental|Social pressure- anger|Experimental message arm.
11045519|NCT04460703|Experimental|Trust in science|Experimental message arm.
11045520|NCT04460703|Experimental|Not bravery arm|Experimental message arm.
11045521|NCT04460690|Experimental|Rapid Onsite COVID-29 Testing|Community participants provide a saliva sample for a simple test to detect high concentrations of SARS-CoV-2 in saliva with assays that require no specialized equipment and can be completed in one hour.
11045522|NCT04460677|Experimental|Emotional Support Plan (ESP) + Weekly Monitoring|This will involve weekly assessments without prompting to use the plan.
11045523|NCT04460677|Experimental|Emotional Support Plan (ESP) + 4x Daily Monitoring|Participants in this arm will be prompted on their phones 4x/day randomly, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt
11045524|NCT04460664||Subjects admitted to floor|COVID-19 patients admitted to the floor as initial place of hospitalization
11045525|NCT04460664||Subjects admitted or transferred to ICU|COVID-19 patients admitted to the ICU as initial place of hospitalization or transferred to ICU from floor
11045527|NCT04460651|Placebo Comparator|Placebo|Participants in this arm will receive Placebo with the same dose scheme as the active comparator:
11045528|NCT04460638||Covid+ hospitalization group|Patients hospitalized with SARS-CoV2 infection
11045529|NCT04460638||Covid+ outpatient group|Patients or caregivers followed on an outpatient basis for an SARS-CoV2 infection
11045530|NCT04460638||Covid- group|Caregivers not infected with an SARS-CoV2
11045531|NCT04460638||Non-SARS pathology group|Individuals not infected with SARS-CoV2 but with another acute and/or infectious non-SARS pathology
11045532|NCT04460612|Placebo Comparator|Placebo Sock|Placebo Socks will be placed on participants feet first for 60 minute
11045533|NCT04460612|Active Comparator|Active IR Sock|Active IR socks will be placed on participants feet following first part of study and a rest period.
11045534|NCT04460586|Experimental|Omadacycline IV followed by PO|Omadacycline 100mg IV, Omadacycline 300 mg tablet
11045535|NCT04460573|Active Comparator|MOTUS boot irremovable|MOTUS boot rendered irremovable with cohesive bandage; no feedback on adherence.
11045536|NCT04460573|Active Comparator|MOTUS boot removable|MOTUS boot, removable, without feedback on adherence.
11045537|NCT04460573|Experimental|MOTUS boot removable+reinforcement|MOTUS boot with, removable, with reinforcement of adherence via smart watch and smart phone as well as remote patient monitoring.
11045538|NCT04460547||Completed Interventional studies|Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
11045539|NCT04460547||Completed Observational studies|Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
11045540|NCT04460534|Experimental|COHORT|Cohort
11045541|NCT04460521|Experimental|NAC Group|Participants in this group will given an N-acetylcysteine 500mg oral tablet daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
11045542|NCT04460521|Placebo Comparator|Placebo Group|Participants in this group will be given a placebo table to be taken orally daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
11045543|NCT04460508|Experimental|Mecapegfilgrastim|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle.
11045544|NCT04460508|Active Comparator|rhG-CSF|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle.
11045545|NCT04460495|Experimental|Feasibility (ASL,pH-Weighted amine CEST, O2-Weighted SAGE-EPI)|Participants undergo ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI , while breathing normal room air (21% oxygen). Patients then undergo another ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI while breathing medical grade air (100% oxygen). Total ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI imaging scan time is 60 minutes.
11045546|NCT04460482|Active Comparator|NIRS-guided PCI|Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
11045547|NCT04460482|Active Comparator|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
11045548|NCT04460456|Experimental|SBT6050 Monotherapy|Escalating doses of SBT6050 in Part 1 followed by expansion in Part 2 at the recommended dose determined in Part 1.
11045549|NCT04460456|Experimental|SBT6050 and pembrolizumab|Escalating doses of SBT6050 in combination with pembrolizumab in Part 3 followed by expansion in Part 4 at the recommended dose determined in Part 3.
11045550|NCT04460443|Experimental|Sofosbuvir and Ribavirin|Sofosbuvir and Ribavirin plus standard of care treatment.
11045551|NCT04460443|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir plus standard of card treatment..
11045552|NCT04460443|No Intervention|Standard treatment|Standard treatment alone
11045553|NCT04460430|Experimental|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
11045554|NCT04460417|Experimental|Enhanced care|Participants will take part in an approximate one-hour health and smoking feedback session at the University of Chicago in Dr. King's Clinical Addictions Research Laboratory (CARL). The session will follow the Courage to Quit™ (CTQ) Roadmap program (developed by Dr. King with the Respiratory Health Association). This roadmap shorter version of the larger CTQ program has been specifically designed as an inpatient bedside or outpatient brief intervention guide to assess smoking cessation motivation, consequences of smoking, facts and myths about smoking, barriers to making a change, approved medications, de-bunking myths about medications or treatments without scientific evidence (e-cigarette, laser treatments, herbals, etc.), and gaining social support.
11045555|NCT04460417|Active Comparator|Treatment as Usual|"Participants will receive the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information."
11045556|NCT04460391|Experimental|experimental group|Early standing training and routine rehabilitation
11045557|NCT04460391|Active Comparator|control group|Conventional rehabilitation，Muscle training and breathing training
11045558|NCT04460378|Experimental|Cognitive Behavioral Therapy|Manualized Cognitive Behavioral Therapy starting at the patients' home.
11045559|NCT04460365|Active Comparator|Active|Softgel capsules: 10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin once a day with a meal for 18 months
11045560|NCT04460365|Placebo Comparator|Placebo|Identical capsule containing no active ingredients
11045561|NCT04460352|Active Comparator|Control arm (A)|"Neoadjuvant chemoradiotherapy followed by esophagectomy.
~Radiotherapy: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
~Chemotherapy: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting on the first day of radiotherapy.
~Esophagectomy: Within 8 weeks of termination of chemoradiotherapy,"
11045588|NCT04460092|Experimental|"GroupB"|"In the first three days, participants in group B will inject 90-degree insulin injections using 8-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 5mm to inject insulin."
11045589|NCT04460066|Experimental|PD-L1 group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
11045562|NCT04460352|Experimental|Experimental arm (B)|"Definitive chemoradiotherapy followed by surveillance, and esophagectomy only in case of residual or recurrent locoregional cancer.
~Radiotherapy: Two alternative schemes:
~1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.
~2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.
~Chemotherapy: Three alternative regimens:
~1. Platin-Taxane Regimen: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy.
~2a. Platinum-Fluoropyrimidine Regimen: Cisplatin 75mg/m2 weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion weeks 1 and 5.
~2b. FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion weeks 1, 3 and 5."
11045563|NCT04460326|Active Comparator|Group 1 insulin glargine and Novolog|Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal BG is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
11045564|NCT04460326|Experimental|Group 2 insulin glargine and Fiasp|Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
11045565|NCT04460313|Other|prospective cohort|Nasopharyngeal sample for each enrrolled children
11045566|NCT04460300|Experimental|Aromatherapy-inhalation group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.
~In this method, 5 drops of lavender oil is dropped directly on a sterile gauze and individuals is allowed to breathe from a distance of 10 cm for 5 minutes."
11045567|NCT04460300|Experimental|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.
~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
11045568|NCT04460300|No Intervention|Control group|Interviews is held with the control group while performing the routine treatment and care of the clinic. No intervention is made by the researchers to the control group during the interview.
11045569|NCT04460287|Placebo Comparator|Milk Drink Unfortified (Negative Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days.
11045570|NCT04460287|Active Comparator|Milk Drink Unfortified Plus Fish Oil (Positive Control)|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
11045571|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Wet Mixing Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
11045572|NCT04460287|Experimental|Milk Drink Fortified with DHA Used Dry Blending Method|Children will get the product (packed for its individual portion) that must be consumed once a day for 30 days
11045573|NCT04460274||Model Building|Number of Covid-19 cases from December 31, 2019 to June 1, 2020 were used to build ARIMA model using Hyndman-Khandakar algorithm.
11045574|NCT04460274||Model Validation|Number of Covid-19 cases from June 2, 2020 to June 15, 2020 were used to forecast cases using the ARIMA model
11045575|NCT04460261|Experimental|COPD Group|Patients with COPD
11045576|NCT04460261|Experimental|Non-COPD Group|Non-COPD
11045577|NCT04460248|Experimental|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|
11045578|NCT04460235||Vaccination|All patients will be vaccinated
11045579|NCT04460222|Experimental|Rotational Thromboelastometry (ROTEM)|To prevent bleeding during invasive procedure, cirrhotic children in the ROTEM group will receive prophylactic transfusion based on the following protocol:- EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg
11045580|NCT04460222|Active Comparator|Conventional Transfusion|"To prevent bleeding during the procedure, cirrhotic children in the conventional group will receive prophylactic transfusion if either FFP, Platelet or Cryoprecipitate is deranged based on the following protocol
~If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg
~If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg
~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
11045581|NCT04460183|Experimental|Investigational arm|Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.
11045582|NCT04460183|Active Comparator|Control arm|Participants will receive institutional SOC for the treatment of COVID-19
11045583|NCT04460118||screw group|coracoid bone block fixed by the screw
11045584|NCT04460118||button group|coracoid bone block fixed by the suture-button
11045585|NCT04460105|Experimental|Lanadelumab|Participants receive 300 milligram (mg) of lanadelumab intravenous (IV) infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
11045586|NCT04460105|Placebo Comparator|Placebo|Participants will receive placebo matching IV infusion on Day 1 during Cohort 1 (single dose cohort) and on Day 1 and Day 4 during Cohort 2 (repeat-dose cohort).
11045587|NCT04460092|Experimental|"Group A"|"In the first three days, participants in group A will inject 90-degree insulin injections using 5-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 8 mm to inject insulin."
11045806|NCT04458415|Active Comparator|Silk Tape Arm|Surgeon will use silk tape to retract the panniculus during cesarean section.
11047500|NCT04446364|Experimental|Aloe vera group|Gel cavity disinfection
11045590|NCT04460066|Placebo Comparator|placebo group|All patients will receive 6 cycles of placebo ( IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
11045591|NCT04460053|Experimental|Neurofilament light protein measurement|Neurofilament light protein measurements in peripheral blood pre- peri- and postoperatively.
11045592|NCT04460040|Experimental|Intervention|Exercise in moderate intensity tailored individually to 20 kcal/kg/week (range 1500-2000 kcal/week) with a free choice to exercise at home/gym on a treadmill or outdoors.
11045593|NCT04460027|Experimental|W-SUDs|
11045594|NCT04460027|No Intervention|Wait List Control|
11045595|NCT04460014|Experimental|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.
~Options to engage in self-administered/guided booster sessions per intrusive memory."
11045596|NCT04460014|Placebo Comparator|Attention placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
11045597|NCT04460001|Active Comparator|Ranibizumab|intravetreal injection of Ranibizumab alone for treatment of patients with macular oedema after CRVO once per month and follow up
11045598|NCT04460001|Active Comparator|Ranibizumab and triamcinolone acetate|intravetreal injection of Ranibizumab and triamcinolone acetate for treatment of patients with macular oedema after CRVO once per month and follow up
11045599|NCT04459988||Patients with MS|Patients with MS who have been newly prescribed Ocrevus
11045600|NCT04459988||Healthy Controls|Healthy Controls
11045601|NCT04459975||AKI (-)|patients treated in ICU for COVID-19 infection and without occurrence of AKI (define as creatinine > 1,5x baseline according with KDIGO guidelines)
11045602|NCT04459975||AKI (+)|"patient treated in ICU for COVID-19 infection and with occurrence of AKI among which:
~• Severe AKI patients (define as creatinine > 3x baseline or need for renal replacement therapy according with KDIGO guidelines) who will participate to biocollection and to post-mortem biopsy (if death)."
11045603|NCT04459962|Experimental|Study Arm|Breath Test and Cheek Swab collection
11045604|NCT04459949|Active Comparator|Sharkskin Arm|
11045605|NCT04459949|Placebo Comparator|Grieshaber Arm|
11045606|NCT04459936|Experimental|Management by Rheumatologist|Treatment of modifiable risk factors for cardiovascular disease managed by the Rheumatologist according to national guideline.
11045607|NCT04459936|Active Comparator|Management by General Practitioner|Treatment of modifiable risk factors for cardiovascular disease managed by the General Practitioner according to national guideline.
11045608|NCT04459923|Active Comparator|Epidural Catheter Group|Patients will be applied with epidural catheter at T 5-6 level and the patient will be injected with an epidural solution containing 15 ml 0.125% bupivacaine through this epidural catheter
11045609|NCT04459923|Active Comparator|Erector Spina Block Catheter Groups|Patients will be applied with an erector spina plane block catheter at the T 5-6 level, erector spina plane block will be applied by ultrasound guidance and when the first local anaesthetic dosage block needle is identified under the erector spina muscle 30 ml 0.25% bupivacaine (15 ml bupivacain + 15 ml saline) will be injected.
11045610|NCT04459910||Multidirectional|Arthroscopic lateral ligament repair combined with deltoid arthroscopic ligament repair.
11045611|NCT04459897||diagnosed or treated for granulomatous hepatitis fol|The cohort is composed by patient diagnosed or treated for granulomatous hepatitis followed in the internal medicine and / or Hepato-gastroenterology departments (Croix-Rousse Hospital, Edouard-Herriot Hospital, Lyon Sud Hospital Center).
11045612|NCT04459871|Experimental|The experimental group|The topical recombinant human thrombin(rhThrombin) was prepared into 1000IU/mL solution with 10ml normal saline and used in combination with absorbable gelatin spongeat at appropriate bleeding evaluation site(s).
11045613|NCT04459871|Placebo Comparator|The control group|The placebo was prepared into a solution with 10mL normal saline and used in combination with absorbable gelatin sponge at appropriate bleeding evaluation site(s).
11045614|NCT04459858||rotator cuff lesion|patients treated for traumatic or degenerative rotator cuff lesion
11045615|NCT04459845|Active Comparator|Parent Child Interaction Therapy|Parents and children will receive 12 weekly sessions of PCIT.
11045616|NCT04459845|Active Comparator|Child Parent Psychotherapy|Parents and children will receive 12 weekly sessions of CPP
11045617|NCT04459832|Experimental|15 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 15 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
11045618|NCT04459832|Experimental|30 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 30 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
11045619|NCT04459832|Experimental|60 second stretch|Stretching of the hamstring muscles was performed by the primary researcher for 60 seconds. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
11045620|NCT04459832|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end
11045621|NCT04459780|Experimental|Group 1 : 20 subjects with plaque psoriasis|Intervention: skin biopsies and blood sample
11045622|NCT04459780|Experimental|Group 2 : 10 subjects with atopic dermatitis|Intervention: skin biopsies
11045623|NCT04459767|Experimental|Vupanorsen 80 milligram (mg)|Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
11045624|NCT04459767|Experimental|Vupanorsen 160 mg|Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
11045625|NCT04459767|Placebo Comparator|Placebo|"Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water.
~Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water."
11045626|NCT04459754|Experimental|Fuzheng Yiliu group|
11045627|NCT04459754|No Intervention|control group|
11060551|NCT04353882||patients with-out tumor recurrence|
11045628|NCT04459741|Experimental|HIV+ Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
11045629|NCT04459741|Other|HIV+ Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
11045630|NCT04459741|Experimental|HIV- Hypertensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
11045631|NCT04459741|Other|HIV- Normotensive|Participants receive 4 grams of dietary salt (equivalent of 1, 560 mg sodium) everyday for seven days followed by 9 grams (equivalent of 3, 510 mg sodium) of dietary salt for the following seven days
11045632|NCT04459728|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
11045633|NCT04459715|Experimental|Debio 1143|"Participants will receive:
~Concomitant chemo-radiation therapy period (Cycles 1-3):
~Radiotherapy
~Cisplatin
~Debio 1143
~Monotherapy period (Cycles 4-6):
~• Debio 1143"
11045634|NCT04459715|Active Comparator|Placebo|"Participants will receive:
~Concomitant chemo-radiation therapy period (Cycles 1-3):
~Radiotherapy
~Cisplatin
~Matched placebo
~Monotherapy period (Cycles 4-6):
~• Matched placebo"
11045635|NCT04459702|Experimental|Dual Therapy|Dual Therapy utilizing hydroxychloroquine and azithromycin.
11045636|NCT04459702|Experimental|Quadruple Therapy|Quadruple therapy utilizing hydroxychloroquine, lopinavir, ritonavir, and azithromycin
11045637|NCT04459676|Active Comparator|ANG-3777 + SOC|"ANG-3777 Administered IV for 30 min and SOC
~Repeat within 24 hours after previous dosing for a total of 4 days"
11045638|NCT04459676|Placebo Comparator|Standard of Care + Placebo|Standard of Care + Placebo
11045639|NCT04459663|Experimental|JS001 combined with Axitinib|JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy
11045640|NCT04459650|Experimental|Female Breast Cancer Pts|Participants include female breast cancer patients who either receive endocrine therapy and suffer from endocrine induced alopecia or suffer from post chemotherapy induced alopecia.
11045641|NCT04459637||Asymptomatic group|Definition of asymptomatic disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
11045642|NCT04459637||Mild group|Definition of mild disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
11045643|NCT04459637||general-type group|Definition of general-type disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
11045644|NCT04459637||severe group|Definition of severe disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
11045645|NCT04459637||critical group|Definition of critical disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
11045646|NCT04459624|Active Comparator|ESP block|Intervention: Erector Spina Plane Block will administer with 20 ml of % 0.25 bupivacaine
11045647|NCT04459624|Active Comparator|QLB 2 block|Intervention: Quadratus Lumborum Block 2 will administer with 20 ml of % 0.25 bupivacaine
11045648|NCT04459611|Experimental|sintilimab+chemotherapy(2 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the second dose of sintilimab; Followed by 2 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
11045649|NCT04459611|Experimental|sintilimab+chemotherapy(3 cycles of neoadjuvant chemotherapy)|Patients with nonsquamous NSCLC (including adenocarcinoma, large cell carcinoma and unspecified type) : sintilimab + pemetrexed + carboplatin; Patients with squamous NSCLC : sintilimab + albumin-bound paclitaxel + carboplatin; Followed by surgery within the 4th week after the third dose of sintilimab; Followed by 1 cycles of adjuvant chemotherapy, the researcher will decide whether to radiotherapy or not according to the clinical situation and pathological stage of the patient; Followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients.
11045650|NCT04459598|Experimental|Efavirenz 600 mg + Quizartinib 60 mg|Participants who are randomized to receive efavirenz 600 mg once daily (QD) for 34 days and a single, oral dose of quizartinib 60 mg will be administered on Day 15 concurrently with efavirenz.
11045651|NCT04459598|Active Comparator|Quizartinib 60 mg|Participants who are randomized to receive a single, oral dose of quizartinib 60 mg.
11045652|NCT04459585|Experimental|Dabigatran+Quizartinib|Participants who will receive a single oral dose of dabigatran etexilate mesylate 150 mg on Day 1 and Day 8 (Period 1: Substrate treatment period), with a single oral dose of quizartinib 60 mg being administered 2 hours prior to dabigatran on Day 8 (Period 2: Drug-drug interaction treatment period).
11045653|NCT04459572|Other|Sepsis and sepstic shock|The study consists patients and healty-control group. Patients divided into 3 groups based on severity: sepsis, severe sepsis and septic shock
11045654|NCT04459559|Experimental|Intervention|Using the Tactile Cueing Device
11045655|NCT04459546|Experimental|Study group|Study group intervention consists patient education, training booklet and 3 month follow-up.
11045656|NCT04459546|No Intervention|Control group|Control group received only general care
11045657|NCT04459533||TOF group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, for whom a NMB monitor use (TOF) was reported in the electronic health records (EHR).
11045658|NCT04459533||Control group|COVID-19 patients admitted to the ICU, receiving mechanical ventilation and NMB agents, with no NMB monitor use reported in the EHR
11045807|NCT04458402|Experimental|Hypofractionated Whole-Pelvis Radiotherapy|Hypofractionated WPRT Cohort 1: 41.25 Gy in 15 fx Cohort 2: 38 Gy in 10 fx
11045659|NCT04459520|Experimental|Testing Unavailable Group|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, but that COVID-19 testing is not available. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
11045660|NCT04459520|Active Comparator|Positive Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a positive COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
11045661|NCT04459520|Placebo Comparator|Negative Test Result|This arm will complete an online survey where they will be presented a vignette asking them to imagine they have symptoms consistent with COVID-19, a physician telling them they likely have COVID-19, and a negative COVID-19 test result. All arms will then be asked to fill out the same questions regarding behavior intentions and demographic questions. All participants will have completed five construct questions based off of Theory of Planned Behavior/Reason Action Approch during the pre-test survey.
11045662|NCT04459507||Participants With Palmoplantar pustulosis (PPP)|Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
11045663|NCT04459494|Experimental|Test group|Patients undergoing dental implant treatment without flap removal (Test Group)
11045664|NCT04459494|Active Comparator|Control group|Patients who will receive dental implants by removing conventional full thickness flaps (Control group)
11045665|NCT04459481|Experimental|70-degree bending angle group|
11045666|NCT04459481|Experimental|90-degree bending angle group|
11045667|NCT04459468||HCC for Lipiodol TACE|These patients will standard of care Lipiodol TACE treatment. No research intervention is planned
11045668|NCT04459468||Healthy controls|Healthy controls from public database
11045669|NCT04459468||HCC patients|HCC patients will be used for biomarker validation.
11045670|NCT04459455|Experimental|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people from the US who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
11045671|NCT04459455|Placebo Comparator|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
11045672|NCT04459442|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
11045673|NCT04459442|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth.
11045674|NCT04459429|Experimental|NHF by smaller cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the smaller cannula
11045675|NCT04459429|Experimental|NHF by larger cannula|Nasal High Flow will be applied at 8 L/min (AIRVO 2) through the larger cannula
11045676|NCT04459416|Experimental|Usual Care plus Acupuncture|Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. to prevent severe pain. If acupuncture does not prevent severe pain, the participant will receive opioid medication as backup pain relief.
11045677|NCT04459416|Active Comparator|Usual Care|Will receive only the usual pain management approach, which includes opioid medication when needed for severe pain, according to the routine guidelines for their care.
11045678|NCT04459390||COVID19 with comorbidities|"Patients with COVID19 with at least one of the following comorbidities:
~Hypertension
~Diabetes
~Cardiovascular disease
~Chronic pulmonary disease
~Obesity
~Chronic liver disease
~Chronic kidney disease
~Collagen vascular disease
~Autoimmune disease
~Malignancy"
11045679|NCT04459390||COVID19 without comorbidities|Patients with COVID19 without any of the previously mentioned comorbidities
11045680|NCT04459377|Placebo Comparator|Placebo|Sodium Chloride solution (9mg / ml) 0.2ml / kg slow intravenous injection (2ml / min).
11045681|NCT04459377|Active Comparator|K1|S-Ketamine (0.125 mg / kg body weight). (0.625mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
11045682|NCT04459377|Active Comparator|K2|S-Ketamine (0.25 mg / kg body weight). (1.25mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
11045683|NCT04459338|Placebo Comparator|Saline|Saline infused during the hyperglycemic clamp with escalating doses of glucagon
11045684|NCT04459338|Active Comparator|Exendin-9,39|Exendin-9,39 infused during the hyperglycemic clamp with escalating doses of glucagon
11045685|NCT04459325|Experimental|Study drug and best available care|Best available care and Tigerase®/nebulised dornase alfa [2.5 mg BID] for 7 days
11045686|NCT04459325|Other|Control group (best available care)|Patients will receive the usual care in accordance with good practice.
11045687|NCT04459299||STEMI patients with clinical indication for primary PCI|Subjects with a clinical indication of STEMI.
11045688|NCT04459286|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive SOC alone, which will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
11045689|NCT04459286|Experimental|SOC plus Intervention|Participants in this arm will receive SOC plus study intervention composed of orally administered nitazoxanide and atazanavir/ritonavir tablets
11045690|NCT04459273|Experimental|Basic science (68GA-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV then 20-90 minutes later undergo PET/CT.
11046207|NCT04455386||stable|The anterior drawer test and/or talar tilt test are negative and the ankle joint is stable.
11045691|NCT04459260|Experimental|Cognitive Behavior Therapy|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on cognitive behavior therapy and includes both cognitive interventions, e.g., cognitive restructuring and behavioral experiments, and behavioral interventions, behavioral activation. The treatment was manualized by Egan et al. (2016) and has been tested in several clinical trials, both via the Internet and face-to-face.
11045692|NCT04459260|Active Comparator|Unified Protocol|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on a transdiagnostic approach derived from cognitive behavior therapy called Unified Protocol, focusing on the shared emotional aspects underlying depression and anxiety disorders. The treatment was manualized by Ellard et al. (2010) and has been tested in several clinical trials, but so far not over the Internet.
11045693|NCT04459247|Experimental|Intervention|Vitamin D high dose
11045694|NCT04459247|No Intervention|Control arm|No Vitamin D supplementation
11045695|NCT04459221|Experimental|Facilitating access to HPV vaccination|
11045696|NCT04459221|No Intervention|promotion of HPV vaccination|
11045697|NCT04459208|Active Comparator|Manta|plug-based vascular closure
11045698|NCT04459208|Active Comparator|ProGlide|suture-based vascular closure
11045699|NCT04459195|Experimental|2 Minute Static stretching|Stretching applications will be applied to the first group for 2 minutes .
11045700|NCT04459195|Experimental|5 Minute Static stretching|Stretching applications will be applied to the first group for 5 minutes.
11045701|NCT04459182|Active Comparator|Endothelial dysfunction (DE+)|obsese patient with OSA (AHI>15) and endothelial dysfunction
11045702|NCT04459182|Sham Comparator|No endothelial dysfunction (DE-)|obsese patient with OSA (AHI>15) and no endothelial dysfunction
11045703|NCT04459156|Experimental|Healthy Participants|healthy control subjects
11045704|NCT04459156|Experimental|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
11045705|NCT04459130|Experimental|Child Obesity Program|"Firstly, overweight and obese students will be determined by measuring their height and weight. While selecting children for the experimental group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Experiment group. Child Obesity Program (COP) will be applied to students in the experimental group for 10 weeks. Before the program is implemented, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed.
~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales
~- Children's Dietary Self- Efficacy Scale-CDSS
~- Food Behavior Scale
~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)
~-Daily Food Consumption Form
~-Drink Consumption Form
~Health Perception Form
~Follow-ups will be performed in the 6th and 12th months after the intervention"
11045706|NCT04459130|No Intervention|Control Grup|"Firstly, overweight and obese students will be determined by measuring their height and weight. When selecting children for the control group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Control group. First, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed. The control group will be trained for a daily healthy diet and physical activity.
~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales
~- Children's Dietary Self- Efficacy Scale-CDSS
~- Food Behavior Scale
~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)
~-Daily Food Consumption Form
~-Drink Consumption Form
~Health Perception Form
~Follow-ups will be performed in the 6th and 12th months after the intervention"
11045707|NCT04459117|Active Comparator|Acetaminophen|The active product is a 10 ml polyethylene ampoule of acetaminophen containing 100 mg of acetaminophen, solution for infusion, B BRAUN.
11045708|NCT04459117|Placebo Comparator|NaCL 0.9%|The placebo product is a polyethylene ampoule of 10ml of NaCL 0.9%, B BRAUN. Polyethylene ampoule of active and placebo products are with the same appearance, in accordance with Good Manufacturing Practices Drugs for Clinical Trials.
11045709|NCT04459104|Experimental|chronic low back patients|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
11045710|NCT04459104|Experimental|breast cancer survivors having chronic pain|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
11045711|NCT04459104|Active Comparator|healthy pain-free controls|Participants will be given two beverages, (isomaltulose or sucrose) in a random order (one of each on each of the two test dates).
11045712|NCT04459091|Experimental|Amino essential acids|oral supplementation with a mixture of amino essential acids 8 gr die in two administrations for six weeks
11045713|NCT04459091|Placebo Comparator|Placebo|placebo consisting in isocaloric product containing maltodextrins in two administrations for six weeks
11045714|NCT04459078|Experimental|Camrelizumab combined with Albumin Paclitacxel and Apatinib.|Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days,, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity.
11045715|NCT04459065|Experimental|Low dose intermediate time|Participants will receive an i.v. infusion of 50 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
11045716|NCT04459065|Experimental|High dose intermediate time|Participants will receive an i.v. infusion of 100 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
11045810|NCT04458363|Experimental|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria) convalescent plasma will be administered
11047501|NCT04446364|Active Comparator|Chlorohexidine group|2% cavity disinfection
11045717|NCT04459065|Experimental|Optimal dose early time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on results from cohorts 1 and 2). Participants will undergo lung cancer resection surgery 1-3 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
11045718|NCT04459065|Experimental|Optimal dose late time|Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on cohorts 1 and 2). Participants will undergo lung cancer resection surgery 7+ days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration
11045719|NCT04459052|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered). Oral NAC will be taken for approximately 6 months.
11045720|NCT04459052|Other|Waitlist Control Cohort|Standard of Care Treatment
11045721|NCT04459039|Experimental|Fluid restriction|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
11045722|NCT04459039|Placebo Comparator|Non-fluid restriction|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously
11045723|NCT04459026|Experimental|group A - combination|Group A patients will receive intra-abdominal instillation 0.75% Ropivacaine 2 mg / kg in 200 ml of NaCl through the trocars and 2) Infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 1 mg / kg in 20 ml of NaCl
11045724|NCT04459026|Experimental|Group B - infiltration|Group B patients will receive infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 3 mg / kg in 20 ml of NaCl.
11045725|NCT04459026|Active Comparator|Group C - instillation|Group C patients will receive intra-abdominal instillation 0.75% Ropivacaine 3 mg / kg in 200 ml of NaCl through the trocars.
11045726|NCT04459013||Patient of the orthodontic consultation|
11045727|NCT04459000|Active Comparator|STARs Only|Consenting research participant who receive prenatal care services in the STAR clinic, but are not randomized to receive mABC home visiting services.
11045728|NCT04459000|Experimental|STARS + mABC|Consenting research participant who receive prenatal care services in the STAR clinic, and are randomized to receive mABC home visiting services.
11045729|NCT04459000|No Intervention|Control Group/CHOUM Only|These are research participants who were eligible to receive care in the STAR clinic, but did not opt to receive that care.
11045730|NCT04458987|Experimental|Expert patient in addictology|before/ after comparison, each patients being its own control
11045731|NCT04458974|Experimental|Experimental group (Exp)|Active tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation)
11045732|NCT04458974|Sham Comparator|Sham-tDCS (Sham)|Sham tDCS + conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation
11045733|NCT04458974|Other|Control group (Control)|Conventional rehabilitation therapy (physiotherapy and neuropsychological rehabilitation) without tDCS.
11045734|NCT04458961|Active Comparator|One-stage|
11045735|NCT04458961|Active Comparator|Two-stage|
11045736|NCT04458948|Experimental|Hydroxychloroquine and Azithromycin|All subjects receive Hydroxychloroquine and Azithromycin.
11045737|NCT04458935||Participants|Participants with retinal hemangioblastoma (RH) managed with trans-scleral cryotherapy at the NIH.
11045738|NCT04458922|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11045739|NCT04458909|Experimental|Arm I (nivolumab, gemcitabine, cisplatin, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 30-60 minutes or carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 4 weeks, patients then receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11045740|NCT04458909|Active Comparator|Arm II (gemcitabine, cisplatin, carboplatin)|Patients receive gemcitabine and cisplatin or carboplatin as in Arm I.
11045741|NCT04458896|Experimental|Stand When You Can|The intervention is grounded in Social Cognitive Theory and the Social Ecological Model (SEM). Multiple levels of the SEM will be targeted (individual, environmental, and organizational) over 6 weeks.
11045742|NCT04458883|Experimental|Myocardial Infarction Group|Patients diagnosed with a myocardial infarction
11045743|NCT04458883|Experimental|Healthy Volunteers|Healthy Volunteers
11045744|NCT04458870|Experimental|Acceptance and Commitment Therapy|
11045745|NCT04458857|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
11045746|NCT04458857|Placebo Comparator|Placebo|Matching placebo
11045747|NCT04458844|Experimental|Fundamental Movement Skill (FMS) Training|Exercise 2 x per week focusing on Fundamental Movement Skill Development
11045748|NCT04458844|Experimental|FMS and strength|Replacement of 50% FMS training with integrated strength training.
11045749|NCT04458844|No Intervention|Control|No intervention.
11045750|NCT04458831||Cohort 1|Patients with multiple myeloma (MM) who received at least one prior line of therapy and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
11045751|NCT04458818|Experimental|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
11045808|NCT04458389|Experimental|TY101|"Dose escalation：Humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg (fix dose) until disease progresses or unacceptable tolerability occurs.
~Dose expansion：After completion of the DLT observation, the sponsor and principal investigator will select a possible dose（RP2D）for dose expansion to further confirm the efficacy and safety of RP2D."
11045752|NCT04458805|Experimental|NX-13 250mg|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
11045753|NCT04458805|Placebo Comparator|Placebo|Dose escalation in Part A will be conducted in 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg and increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A. The starting dose level in Part B will be determined by the SRC based on safety and tolerability data obtained in Part A. A dose level will only be evaluated in Part B if determined to be safe and tolerable in Part A. It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days. NX-13 dose levels to be evaluated in Part B will be in the range of 500 to 4000 mg.
11045754|NCT04458792|Experimental|Experimental: Biological collection|"For all the patients include in the study :
~Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue)
~MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery
~circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery
~radiotherapy toxicity : Blood samples collected before the radiotherapy
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11045755|NCT04458779|Experimental|CPAP group|Subjects will receive CPAP treatment in addition to optimal standard therapy for acute stroke.
11045756|NCT04458779|No Intervention|Usual-care group|Subjects will receive optimal standard therapy for acute stroke.
11045757|NCT04458766|Experimental|Interventions|"All subjects in this trial will receive the following interventions:
~Pre-Intervention (Days 0-14): Subjects given access to Wellth application reminders, no incentives provided. A virtual check in with the study team will occur at the end of the pre-intervention period (14 days).
~Intervention (Days 15-74): Subjects will use Wellth app for 60 days, with incentives provided at the 30- and 60-day mark. At the end of the intervention period (Day 60), the subject will attend a clinic visit with the medical provider and a fasting lipid panel and MMAS will also be collected at this time.
~Post-intervention (Days 74-134): Subjects will continue to use the Wellth app and receive reminders, but with no incentives provided, for 60 days. A clinic visit, fasting lipid profile, and MMAS will also be collected following the post-intervention period."
11045758|NCT04458753|Experimental|Lumbar focused + knee focused exercise group|Will receive strengthening of back , abdominal, and quadriceps muscles, and stretching if calf and Hamstring muscles
11045759|NCT04458753|Active Comparator|Knee focused exercise group|Will receive strengthening of quadriceps and stretching of calf and Hamstring muscles
11045760|NCT04458740||Patient|Patients with a diagnosis of colorectal cancer after 65 years.
11045761|NCT04458740||The spouse and /or children and /or parents|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
11045762|NCT04458727||Patients who used supportive measures during home training|
11045763|NCT04458727||patients who did not use supp. measures during home training|
11045764|NCT04458714|Active Comparator|CO2 group (treatment arm)|This arm included 32 patients who were randomized for using CO2 as the contrast medium for aortoiliac angiolplasty.
11045765|NCT04458714|Active Comparator|ICM group (control arm)|This arm involved 32 patients who were randomized for using iodine contrast medium (ICM) for aortoiliac angiolplasty.
11045766|NCT04458688||African Americans with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as African American.
11045767|NCT04458688||Caucasian American with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as Caucasian American.
11045768|NCT04458675|Experimental|Active|Activr capsule
11045769|NCT04458675|Placebo Comparator|Placebo|Placebo capsule
11045770|NCT04458662||Eumenorrheic women|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).
~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.
~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.
~In both studies, eumenorrheic participants were evaluated at three specific moments of the menstrual cycle: Early-follicular phase (EFP), late-follicular phase (LFP) and mid-luteal phase (MLP);"
11045771|NCT04458662||Oral contraceptive users|"The project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).
~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.
~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.
~Oral contraceptive users performed the trial at two moments: Withdrawal phase (WP) and active pill phase (APP)."
11045809|NCT04458376|Experimental|Follows the internet-based self-help program|
11047550|NCT04446026|Experimental|teneligliptin|
11045772|NCT04458662||Postmenopausal women|"he project consisted on two sections carrying out at the same time: Iron physiology (Study I) and Muscle damage (Study II).
~For the study I, the exercise protocol consisted on an interval running test. 5 min warm-up at 60% of the vVO2peak followed by 8 bouts of 3 min at 85% of the vVO2peak with 90 secs recovery at 30% of the vVO2peak between bouts. Finally, a 5 min cool down was performed at 30% of the vVO2peak.
~The study II protocol was based on an eccentric-based resistance exercise protocol consisted on 10 sets of 10 reps of plate-loaded parallel back squats at 60% of their previously calculated 1RM with 2 mins recoveries between sets.
~Postmenopausal women were tested only once, since their hormonal status does not fluctuate."
11045773|NCT04458649||No increased risk of hypoglycemia|Infants born with no obvious risk factors for hypoglycemia in the neonatal period.
11045774|NCT04458649||Increased risk of hypoglycemia|"Infants considered at increased risk for hypoglycemia after birth including the following criteria:
~Infant born to a diabetic mother
~Very large for gestational age (VLGA) infant with weight >97%"
11045775|NCT04458636|Active Comparator|Standard care|Blinded prednisolone 30mg orally once per day for 14 days
11045776|NCT04458636|Placebo Comparator|Biomarker care|Blinded prednisolone 30mg orally once per day for 14 days if peripheral eosinophil count is equal or greater than 2%. Placebo equivalent if peripheral blood eosinophil count is <2%.
11045777|NCT04458623|Active Comparator|positive air test|Before induction patients received supplemental oxygen through a venture mask with a jet and flow adjusted to a theoretical fio2 of 100% for 10 min. The Air-Test was then performed by removing the oxygen mask and leaving the patients breathing room air for 10 min while continuously monitoring SpO2 with a pulse oximeter finger probe. The Air-Test result was considered positive when the recorded SpO2 was ≤96%.The same test will be done postoperatively in the recovery room.
11045778|NCT04458623|Active Comparator|negative air test|negative when SpO2 was >96 %.
11045779|NCT04458584||Ligament Reconstruction - Tendon Interposition (LRTI)|Patients undergoing thumb basal joint arthroplasty using LRTI procedure as treatment of osteoarthritis.
11045780|NCT04458584||Suture Suspensionplasty (SS)|Patients undergoing thumb basal joint arthroplasty using suture suspensionplasty (SS) procedure as treatment of osteoarthritis.
11045781|NCT04458584||Simple Trapeziectomy (ST)|Patients undergoing thumb basal joint arthroplasty using trapeziectomy (ST) procedure as treatment of osteoarthritis.
11045782|NCT04458558|Experimental|Medical abortion patients|Oral mifepristone 200 mg followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone).
11045783|NCT04458545|Placebo Comparator|Placebo Vaccine|
11045784|NCT04458545|Experimental|Low Dose Vaccine (100 μg)|
11045785|NCT04458545|Experimental|High Dose Vaccine (400 μg)|
11045786|NCT04458532|Experimental|(A) breast cancer after completion of chemo|300 min/wk for 16 weeks, followed by 16 weeks of usual care.
11045787|NCT04458532|Experimental|(B) breast cancer after completion of chemo|150 min/wk for 32 weeks.
11045788|NCT04458532|Experimental|(C) breast cancer after completion of chemo|300 min/wk for 32 weeks.
11045789|NCT04458532|Active Comparator|(D) breast cancer after completion of chemo|150 min/wk for 16 weeks, followed by 16 weeks of usual care.
11045790|NCT04458519|Experimental|Probiorinse|Nasal irrigations with Probiorinse (2.4 Billion CFU (Colony-Forming Units) of Lactococcus Lactis W136, (NPN: 80085895)) twice-daily for a period of fourteen days
11045791|NCT04458519|Active Comparator|Saline solution|Nasal irrigations with saline (NeilMed Sinus Rinse, (NPN: 80027142)) twice-daily for a period of fourteen days
11045792|NCT04458506|Experimental|Rapid Maxillary Expander (RME)|36 patients will be treated with RME in order to correct their unilateral posterior cross bite
11045793|NCT04458506|Active Comparator|Quad Helix (QH)|36 patients will be treated with QH in order to correct their unilateral posterior cross bite
11045794|NCT04458493|Experimental|control|no supplement will be provided on the day of the experiment
11045795|NCT04458493|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 400ml, 20% solution)
11045796|NCT04458480||Exposed Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
11045797|NCT04458480||Control Group|Both exposed group and control group are undertaken TKA surgery and routine postoperative management for 2 days in orthopedics department. Exposed group patients are transferred from orthopedics department to rehabilitation department on 2nd day after TKA, and accept fast inpatient rehabilitation for 1 week before hospital discharge, while control group patients continue to accept routine peri-operative management and conventional oral instructions of exercises in orthopedics department until hospital discharge.
11045798|NCT04458467|Active Comparator|Continuous Infusion|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout).
11045799|NCT04458467|Experimental|Automated Boluses|Patients will receive intermittent boluses of Ropivacaine 0.2% (8 mL automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).
11045800|NCT04458454||Examination of relaxin levels|This is a pilot study of 1 group of patients. The analysis of relaxin levels in serum and follicular fluid obtained on the day of puncture of the follicles in patients undergoing treatment in the IVF protocol is carried out.
11045801|NCT04458441|Active Comparator|warm skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be heated sterile to 38 degrees with a ben-mari method and its temperature will be controlled by degrees. When it reaches the appropriate degree, the skin cleaning of the baby will be done sterile.
11045802|NCT04458441|No Intervention|cold skin desenfection group|Povidion iodine will be used as a skin cleanser. povidion iodine will be used in the skin cleaning of the baby without any heating procedure.
11045803|NCT04458428|No Intervention|Control|No other non-standard of care activities will be performed
11045804|NCT04458428|Experimental|Intervention|Will be signed up for the automated short message service (SMS)
11045805|NCT04458415|Experimental|TPR Arm|Surgeon will use the Traxi Panniculus Retractor to retract the panniculus during cesarean section.
11045811|NCT04458350|Experimental|Digital Promotions Group|Eligible zip codes (n=96) will be randomized using stratified randomization at the state level. The intervention will last 13 weeks (Summer 2020 market season) and consist of receiving digital ads on the Fresh EBT app and Facebook for SNAP fruit and vegetable incentive programs at farmers' markets.
11045812|NCT04458350|No Intervention|Control Group|No intervention administered. Eligible zip codes (n=96) will be randomized using stratified randomization at the state level.
11045813|NCT04458337||SARS-CoV-2 patients undergoing a surgical procedure|The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery.
11045814|NCT04458324|Experimental|NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving NIV and taking Buspar.
11045815|NCT04458324|Placebo Comparator|NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving NIV and taking placebo.
11045816|NCT04458324|Sham Comparator|sham NIV + Buspar|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking Buspar.
11045817|NCT04458324|Active Comparator|sham NIV + placebo|Subjects will perform 6 months of FES-row-training while receiving sham NIV and taking placebo.
11045818|NCT04458311|Experimental|Phase I|Increasing doses of tildrakizumab in combination with a fixed dose of abiraterone to establish the recommended phase II dose in patients with metastatic castration resistant prostate cancer..
11045819|NCT04458311|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
11045820|NCT04458298|Experimental|Cohort A: OP-101 2 mg/kg|Participants will receive a single intravenous (IV) infusion of OP-101 2 milligram per kilogram (mg/kg) on Day 1.
11045821|NCT04458298|Experimental|Cohort B: OP-101 4 mg/kg|Participants will receive a single IV infusion of OP-101 4 mg/kg on Day 1.
11045822|NCT04458298|Experimental|Cohort C: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Day 1.
11045823|NCT04458298|Placebo Comparator|Cohort D: Placebo|Participants will receive a single IV infusion of matching placebo on Day 1.
11045824|NCT04458285|Experimental|Sacubitril/valsartan|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous angiotensin converting enzyme inhibitor(ACEI), ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
11045825|NCT04458285|Active Comparator|Valsartan|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
11045826|NCT04458272|Experimental|DS-1001b|
11045827|NCT04458259|Experimental|Dose Level 1|Participants will receive PF-07265807 at 25 mg once a day (QD) 2 weeks on/1 week off
11045828|NCT04458259|Experimental|Dose Level 2|Participants will receive PF-07265807 at 50 mg QD 2 weeks on/1 week off
11045829|NCT04458259|Experimental|Dose Level 3|Participants will receive PF-07265807 at 100 mg QD 2 weeks on/1 week off
11045830|NCT04458259|Experimental|Dose Level 4|Participants will receive PF-07265807 at 200 mg QD 2 weeks on/1 week off
11045831|NCT04458259|Experimental|Dose Level 5|Participants will receive PF-07265807 at 300 mg QD 2 weeks on/1 week off
11045832|NCT04458246|Experimental|Intervention|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will receive an online home-based aerobic training, three times a week, during 3 months.
11045833|NCT04458246|No Intervention|Control|10 patients from each chronic diseases conditions (1- Inflammatory bowel disease; 2- autoimmune hepatitis; 3- liver transplant; 4- renal transplant; 5- systemic lupus erythematosus; 6- juvenile dermatomyositis; 7- juvenile idiopathic arthritis) will be advised to maintain their daily routine.
11045834|NCT04458233|Active Comparator|long axis|
11045835|NCT04458233|Active Comparator|short axis|
11045836|NCT04458220||difficult airway|Meet one of the following conditions：Mask ventilation≥Ⅱgrade，C-L≥ⅢorⅣgrade，LEMON≥2 score，IDS≥1 score.
11045837|NCT04458220||none difficult airway|Meet none of the following conditions：Mask ventilation≥Ⅱgrade，C-L≥ⅢorⅣgrade，LEMON≥2 score，IDS≥1 score.
11045838|NCT04458207|Experimental|Experimental group (EG), the immediate rehabilitation group|The experimental group will begin with the rehabilitation immediately after the first measurement of cognitive tests (pre-test). Three months after complete rehabilitation the first post-test (post-test 1) will be conducted on all participants. Participants will be recalled after about a year for a long-term follow up (post-test 2). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at different time points (i.e., pre-test, post-test 1 and post-test 2).
11045839|NCT04458207|Active Comparator|Control group (CG), the test-retest group|The control group will be tested with the cognitive tests two times (pre-test + post-test 1) at an interval of about three months or more inbetween tests and before the onset of the prosthodontic rehabilitation. Three months after complete rehabilitation the post-test (post-test 2) will be conducted on all participants. Further, participants will be recalled after about a year for a long-term follow up (post-test 3). The OHIP-14, chewing function test, saliva samples, neuropsychological assessments together with MRI assessments will also be recorded at these time points (i.e., pre-test, post-test 1, post-test 2 and post-test 3).
11045840|NCT04458194|Active Comparator|Standard of Care|
11045841|NCT04458194|Experimental|Partnered yoga|
11045842|NCT04458194|Experimental|Non-partnered yoga|
11045843|NCT04458181|Experimental|Treatment Group|Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.
11045844|NCT04458181|No Intervention|Control Group|There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.
11045845|NCT04458168|Experimental|Recently completed treatment|25 women who have just completed treatment
11045846|NCT04458168|Experimental|No recurrence of ovarian cancer for at least one year|25 women who have not experienced a recurrence of their ovarian cancer at least one year after their initial diagnosis
11045847|NCT04458168|Experimental|Recurrence of ovarian cancer|25 women who have experienced a recurrence of their ovarian cancer after primary treatment
11045848|NCT04458155||Chest pain patients|"Patients are eligible for participation if they are admitted to:
~The cardiac emergency department (ED) because of chest pain for ruling out acute coronary syndrome by troponin analysis
~The Coronary Care Unit (CCU) with a NSTEMI or post-percutaneous coronary intervention (PCI) STEMI.
~Troponin analysis will be performed according to standard protocol. From every included patient two capillary blood samples and an extra venous blood sample will be drawn during regularly ordered blood work to evaluate HS cTnI levels obtained with the POC instrument."
11045849|NCT04458142|Experimental|Single buccal infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine).
~Injecting by a small amount of solution in the superficial mucosa. After a few seconds, the needle was slowly advanced in the mucobuccal fold toward the apex of the molar and 1.8 ml of 4% articaine using short 30-gauge needle was slowly given.
~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed by inquiring about the area of numbness from the participant, no pain during pricking the palatal mucosa. The cases in which palatal anesthesia will not be reported by the patient will be given supplemental palatal infiltration with 0.2 to 0.3 mL articaine.
~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
11045850|NCT04458142|Active Comparator|Buccal and intrapapillary infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine) Injecting a small amount of solution in the superficial mucosa,then needle will slowly advanced in the mucobuccal fold toward the apex of the molar and 1.5 ml of 4% articaine was slowly given. The remaining 0.3ml solution will be given equally into the distal, mesial intrapapillary and palatal sites respectively until blanching of the palate is observed extending more than halfway along the palatal gingival margin.
~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed.
~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
11045851|NCT04458129|Experimental|Polyethylene glycol treatment|Study participants will take a 3-month laxative treatment with polyethylene glycol for 3 months.
11045852|NCT04458116|Experimental|Tumeric Group|participants will receive capsules containing 1.5 grams of turmeric 95% curcumin
11045853|NCT04458116|Placebo Comparator|Placebo Group.|will receive capsules containing corn starch.
11045854|NCT04458103|Experimental|prospective interventional cohort|The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
11045855|NCT04458103|No Intervention|retrospective control cohort|The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.
11045856|NCT04458090|Experimental|Intervention|Receive hospice patient decision aid
11045857|NCT04458090|No Intervention|Control|Does not receive hospice decision aid
11045858|NCT04458077|Experimental|Mobile-phone-based SEIL Intervention|This group will receive the Discover Learning 10-session intervention through a mobile-phone based platform over the course of 10 weeks (1 session per week).
11045859|NCT04458064|Active Comparator|i gel|I gel LMA was inserted for all patients
11045860|NCT04458064|Active Comparator|Air Q LMA|Air Q LMA was inserted for all patients
11045861|NCT04458051|Experimental|SAR442168|Dose 1 of oral SAR442168 daily
11045862|NCT04458051|Placebo Comparator|Placebo|Placebo to match the SAR442168 daily
11045863|NCT04458038|Experimental|intervention arm|
11045864|NCT04458025|Active Comparator|Standard rehabilitation program|Standard postoperative 4 weeks immobilization rehabilitation program with a sling in adduction and internal rotation
11045865|NCT04458025|Experimental|Early rehabilitation program|Early rehabilitation program will start passive mobilization during second week after surgery, including controlled external rotation movements
11045866|NCT04457999|Experimental|Lipiflow treatment|Lipiflow thermal pulsation prior to cataract surgery
11045867|NCT04457986|Experimental|Erector spina plane block (ESP)|Patients will receive Erector spina plane block (ESP) with bupivacaine for postoperative analgesia
11045868|NCT04457986|Experimental|Modified thoracolumbar interfacial plane block (MTI)|Patients will receive Modified thoracolumbar interfacial plane block (MTI) with bupivacaine for postoperative analgesia
11045869|NCT04457986|Active Comparator|Intravenous patient controlled analgesia (IV-PCA)|Patients will receive Intravenous patient controlled analgesia (IV-PCA) with tramadol for postoperative analgesia
11045870|NCT04457973|Experimental|Active tDCS|
11045871|NCT04457973|Placebo Comparator|Sham tDCS|
11045872|NCT04457960|Experimental|JNJ-66525433|Participants will receive JNJ-66525433 in increasing dose level 1 to dose level 4 in Parts 1, 2, and dose level 3 in part 3.
11045873|NCT04457960|Placebo Comparator|Placebo|Participants will receive matching placebo in Parts 1, 2 and 3.
11045874|NCT04457934||IBD patients|"Patients with IBD will undergo preparation for Standard endoscopy with PLENVU, since it is considered to be less affecting for patients. IBD patients have to undergo endoscopy often and mostly suffer from non-efficient preparation.
~Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and will follow the Guidelines for preparation of endoscopy.
~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
11045875|NCT04457934||Screening patients|"Screening patients will undergo Standard endoscopy to prevent colon Cancer. Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy and nd will follow the Guidelines for preparation of endoscopy.
~The only Change from Standard care is that patients will receive Plenvu instead of Movicol."
11045876|NCT04457921|Experimental|Deep tissue massage|deep tissue massage applied group
11045877|NCT04457921|No Intervention|Standard of care|group without deep tissue massage
11045878|NCT04457908|Other|intelligent|receive the neurological function assessment by artificial intelligence
11045879|NCT04457908|No Intervention|manual|receive the neurological function assessment by doctor
11045913|NCT04457596|Experimental|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
11045880|NCT04457895|Experimental|Experimental arm|"For experimental arm patients, there will be a 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga. Starting the first day of the yoga practice there will be one daily 15 min session at home with My Yoga Guide and the audio guide during 12 weeks."
11045881|NCT04457895|Placebo Comparator|control arm|The control arm patients will have standard care. They will be proposed to participate in the physical therapy - yoga - educational program after the end of the study.
11045882|NCT04457882|Experimental|Without Drainage Tube|No place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
11045883|NCT04457882|Active Comparator|With Drainage Tube|Place the drainage tube after the intraperitoneal laparoscopic radical prostatectomy
11045884|NCT04457869|Experimental|Single arm|
11045885|NCT04457856|Experimental|TJ003234|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
11045886|NCT04457856|Placebo Comparator|Placebo|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
11045887|NCT04457843||COPD patients|
11045888|NCT04457830|Experimental|Single arm|
11045889|NCT04457817|Experimental|CRI Monitoring/Management|These patients are COVID-19 positive; ages > 18 and < 70 years old; require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.
11045890|NCT04457817|No Intervention|Standard of Care|These patients are COVID-19 positive; ages > 18 and < 70 years old; require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). This cohort will receive the standard of care.
11045891|NCT04457804|Experimental|Online ACT workshop for Emotional Eating|All participants will be assigned to 2, 1.5 hour interventions using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
11045892|NCT04457791|Experimental|Intervention phase|From week 5-8, participants will receive the intervention, namely personalized dietary advice.
11045893|NCT04457791|No Intervention|Observational phase|From week 1-4, participants will not receive any intervention, but just will be observed, to form as their own control
11045894|NCT04457778|Experimental|Part 1A: M6223 Monotherapy|
11045895|NCT04457778|Experimental|Part1B: M6223 + Bintrafusp alfa|
11045896|NCT04457765|Experimental|group 1|All participants will have PVP-I at 1.25% administered as an intranasal topical preparation prior undergoing rhinoplasty
11045897|NCT04457752|Active Comparator|Dual Layer Amniotic Membrane (DLAM) + SOC|DLAM (Up to 10 weekly DLAM applications) + Standard of Care (sharp debridement, offloading, and proper moisture balance).
11045898|NCT04457752|No Intervention|Standard of Care|Standard of Care: sharp debridement, offloading, and proper moisture balance.
11045899|NCT04457726|Experimental|Recipients with severe COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have severe COVID-19.
11045900|NCT04457726|Experimental|Recipients with mild to moderate COVID-19|Recipients who are confirmed positive by SARS-CoV-2 testing and have mild to moderate COVID-19.
11045901|NCT04457700||Triple-negative and HER2 Positive breast cancer|Patients with triple-negative or HER2 Positive breast cancer, axillary lymph node metastasis who underwent NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis. CT-based radiomics will be uesd in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.
11045902|NCT04457674|Other|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.
11045903|NCT04457674|Other|Sleep Hygiene Education (SHE)|SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.
11045904|NCT04457661|Experimental|TCI711 probiotic|Taking one capsule (containing 10^10 of Bacillus coagulans TCI711) daily for one month
11045905|NCT04457648|Placebo Comparator|Conventional|
11045906|NCT04457648|Active Comparator|Manuka Honey|
11045907|NCT04457635|Experimental|Brief psychotherapy (brief PsT)|The focus was on normalizing, accepting and coping with their present mental health complaints and their hindrance for work participation. Primarily, there was no intention to process previous pathogenic experiences. The standard duration was set on six sessions.
11045908|NCT04457635|Active Comparator|Short psychotherapy (short-PsT)|With more extended focus, there was besides coping of mental health and challenges concerning WP, an emphasis on both an extensive anamnesis and possibility to establish a so-called central theme based on previous or current challenging issues such as trauma, difficult childhood conditions, and personality-related issues. Additional aims of the intervention could include reducing symptoms and problematic behaviour and an improvement of home situation, with deeper focus on cognitive maladaptive coping strategies or dynamic repetitions. The number of sessions was aimed to be 20 on average
11045909|NCT04457622|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses
11045910|NCT04457609|Placebo Comparator|Control Group|Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin
11045911|NCT04457609|Experimental|Experiment Group|Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment
11045912|NCT04457596|Active Comparator|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
11046043|NCT04456647||Parenteral nutrition|
11045914|NCT04457583|Experimental|Intervention|Procedure: Inspiratory muscle training with powerbreathe with a linear pressure resistance using an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, 30 exercises daily for 12 weeks.
11045915|NCT04457583|No Intervention|Control|Procedure: Training with the same equipment but without load-generating resistance.
11045916|NCT04457570||exposed patients|"The exposed patients are patients with cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection. A patient will be considered as an exposed patient if he/she had a surgical procedure or a medical treatment for cancer in the past 5 years preceding the SARS-CoV-2 infection."
11045917|NCT04457570||control patients|"The control patients  are all of the patients without cancer that are hospitalized in one of the participating centers for a SARS-CoV-2 infection"
11045918|NCT04457557|Experimental|Low concentration|Interscalene block with 0.15% ropivacaine 15 ml
11045919|NCT04457557|Active Comparator|Usual concentration|Interscalene block with 0.5% ropivacaine 15 ml
11045920|NCT04457544||Retrospective patients|The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
11045921|NCT04457544||Prospective patients|Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.
11045922|NCT04457531|Experimental|LiuWeiLuoBi Group|Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.
11045923|NCT04457531|Other|Control Group|Patients will receive the standard medical treatment for 12 weeks.
11045924|NCT04457492|Experimental|Acute Facial Nerve Injury with Intact Facial Nerve|"40 sessions of FES (in a 14 week period)
~Assessments will be taken during the beginning, middle, and end of each study arm."
11045925|NCT04457492|Experimental|Facial Nerve Grafting After Surgical Excision|"40 sessions of FES (in a 14 week period)
~Assessments will be taken during the beginning, middle, and end of each study arm."
11045926|NCT04457492|No Intervention|Standard of Care Group|"No FES
~Assessments will be taken at the same intervals as the interventions group."
11045927|NCT04457466||Healthy musicians|Men and women aged 18-60, who must be enrolled in a music conservatory performance program or be professionally active, and must speak and understand English.
11045928|NCT04457466||Healthy non-musicians|Men and women aged 18-60, must speak and understand English and not have any kind of musical training.
11045929|NCT04457466||Musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must be enrolled in a music conservatory performance program or be professionally active and must speak and understand English.
11045930|NCT04457466||Non-musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must not have any kind of musical training and must speak and understand English.
11045931|NCT04457453|Active Comparator|control group|intubation with direct laryngoscope in sniffing position
11045932|NCT04457453|Experimental|direct laryngoscope in Trendelenburg and Sellick position|intubation with direct laryngoscope in Trendelenburg and Sellick position
11045933|NCT04457453|Experimental|video laryngoscope in Trendelenburg and Sellick position|intubation with video laryngoscope in Trendelenburg and Sellick position
11045934|NCT04457440|Active Comparator|Intensive Lifestyle Intervention (ILI)|The ILI will consist of 8 group-based 90-min sessions focusing on modifying dietary and exercise habits with the goal of reducing 450kcal of daily calories and increasing physical activity to 150 minutes of exercise per week.
11045935|NCT04457440|Experimental|ILI enhanced with cognitive behavioral sleep intervention|The ILI+Sleep intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session.
11045936|NCT04457427|No Intervention|Tracheostomy, no DPS|5 patients undergoing tracheostomy for failure to wean will receive no additional intervention.
11045937|NCT04457427|Experimental|Trachesotomy with immediate DPS stimulation and monitoring|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate stimulation and monitoring.
11045938|NCT04457427|Active Comparator|Trachesotomy with DPS monitoring, stimulation on day 5|5 patients undergoing tracheostomy for failure to wean will have DPS implanted concurrently and receive immediate monitoring followed by stimulation on day 5 post-procedure.
11045939|NCT04457401|Experimental|Probiotic|1 capsule daily for 8 weeks, containing 3 x 10^9 colony forming units/capsule of a Bifidobacterium strain
11045940|NCT04457401|Placebo Comparator|Placebo|1 capsule daily for 8 weeks containing the same carrier material and is similar in size, shape and taste to probiotic
11045941|NCT04457388|Experimental|Tele-Yoga Therapy|Individualised Yoga therapy based on participant's clinical condition and personal needs. Twice a week sessions were carried out by trained and experienced Yoga therapist via video conference with each therapy for individualized based on each participant.
11045942|NCT04457375||Healthy Adults|Healthy
11045943|NCT04457362|Experimental|Experimental Cohort|Patients with clinically diagnosed wrist pathology undergoing wrist arthroscopy
11045944|NCT04457349|Experimental|Therapeutic Plasma Exchange (TPE)|Each patient will undergo two sessions. TPE will be done through filtration technique using a plasma filter at a dose of (1-1.5) plasma volume/session. Fresh frozen plasma or albumin 5% will be used to replace plasma.
11045945|NCT04457336|Experimental|Tildacerfont Group 1|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1.
11045946|NCT04457336|Experimental|Tildacerfont Group 2|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2.
11045947|NCT04457336|Experimental|Tildacerfont Group 3|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 3.
11045948|NCT04457336|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 12 weeks.
11045949|NCT04457323|Experimental|Test|S-Metoprolol XR 25 mg Film Coated Tablets (first four weeks) S-Metoprolol XR 50 mg Film Coated Tablets (second four weeks)
11047551|NCT04446026|Placebo Comparator|placebo|
11045950|NCT04457323|Active Comparator|REFERENCE|Beloc® (Metoprolol) Zok 50 mg Controlled Release Film Tablets (first four weeks) Beloc® (Metoprolol) Zok 100 mg Controlled Release Film Tablets (second four weeks)
11045951|NCT04457310|Experimental|PF-06412562 1 mg|Each subject will complete 5 test visits each involving the administration of PF-06412562 (at different doses) or placebo. Subjects will be randomized to the order of doses of PF-0612562 (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
11045952|NCT04457310|Experimental|PF-06412562 4 mg|Each subject will complete 5 test visits each involving the administration of PF-06412562 (at different doses) or placebo. Subjects will be randomized to the order of doses of PF-0612562 (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
11045953|NCT04457310|Experimental|PF-06412562 15 mg|Each subject will complete 5 test visits each involving the administration of PF-06412562 (at different doses) or placebo. Subjects will be randomized to the order of doses of PF-0612562 (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
11045954|NCT04457310|Experimental|PF-06412562 25 mg|Each subject will complete 5 test visits each involving the administration of PF-06412562 (at different doses) or placebo. Subjects will be randomized to the order of doses of PF-0612562 (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
11045955|NCT04457310|Placebo Comparator|Placebo|Each subject will complete 5 test visits each involving the administration of PF-06412562 (at different doses) or placebo. Subjects will be randomized to the order of doses of PF-0612562 (1 mg, 4 mg, 15 mg, or 25 mg) or placebo for the next 5 visits. The randomization will assign 75% of patients to the highest dose on the last visit and 25% would receive the highest dose on one of the other four visits. Only the highest dose (25 mg) will be subject to this pseudo-randomization strategy; all other doses will be randomly distributed.
11045956|NCT04457297|Experimental|trifluridine and tipiracil|
11045957|NCT04457297|Placebo Comparator|Placebo|
11045958|NCT04457284|Experimental|temozolomide, cisplatin and nivolumab|Subjects will receive oral TMZ at 150-200 mg/m2 day 1 to 5 every 4 weeks, cisplatin via IV infusion at 40 mg/m2 every two weeks (Q2W), and nivolumab via IV infusion at 480 mg every four weeks (Q4W).
11045959|NCT04457271|Experimental|Goal Management Training (GMT)|Participants in this arm will attend 9 weekly, 2-hour group GMT appointments.
11045960|NCT04457271|No Intervention|Wait List|Participants in this arm will receive no treatment for approximately 21 weeks (at which point, they will be offered the same, standard GMT treatment).
11045961|NCT04457258|Experimental|Diagnostic (68Ga-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV, and then undergo PET/CT over 20-90 minutes.
11045962|NCT04457245|Active Comparator|Arm I (dRT)|150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
11045963|NCT04457245|Experimental|Arm II (18F-DCFPyL, PET/CT, dRT)|162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.
11045964|NCT04457232|Experimental|Basic Science (68Ga-FAPi-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.
11045965|NCT04457219|Active Comparator|Conventional dressing with 120 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 2 hours, as per protocol. This is the standard radial care currently in use at Liverpool Heart and Chest Hospital.
11045966|NCT04457219|Experimental|Conventional dressing with 60 minutes external compression|A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
11045967|NCT04457219|Experimental|Haemostatic dressing with 60 minutes external compression|A haemostatic absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. This consists of a mineral-based dressing that accelerates local haemostasis. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 1 hour, as per protocol.
11045968|NCT04457193||post-ablation Barrett's patients|The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
11045969|NCT04457180|Experimental|Treament|"In phase A, subjects receiving a single dose of Repaglinid orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16
~# In addition, In phase B, subjects receiving a single dose of Repaglinid (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13."
11045970|NCT04457167|Experimental|Robotic surgery|Robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
11046044|NCT04456634|Experimental|AL&RUX|"Oral administration of:
~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
11045971|NCT04457167|Active Comparator|Non robotic surgery|Non-robotic surgery for breast mastectomy with conservation of areolo-nipple plate and immediate or delayed reconstruction by latissimus dorsi flap,
11045972|NCT04457154||Registry Population|Pediatric subjects (age 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation System for the treatment of moderate to severe obstructive sleep apnea (OSA)
11045973|NCT04457141|Other|first:shod ,second:minimalist shoes|"The first group will race with conventional shoes and then minimalist shoes. The group run 5 minutes for warming and then 30 seconds at 9km/h, 30 seconds at 11km/h and 30 seconds at 13km/h.
~They have a washout period of 10 minutes between both interventions."
11045974|NCT04457141|Other|first:minimalist shoes ,second:shod|"The second group will race with minimalist shoes and then conventional shoes. The group run 5 minutes for warming and then 30 seconds at 9km/h, 30 seconds at 11km/h and 30 seconds at 13km/h.
~They have a washout period of 10 minutes between both interventions."
11045975|NCT04457128|Experimental|Secular Image|Secular Image
11045976|NCT04457128|Experimental|Non-secular image|non-secular images
11045977|NCT04457128|Experimental|Secular message|secular messages
11045978|NCT04457128|Experimental|Non-secular message|non-secular messages
11045979|NCT04457115|Experimental|TPV Block|Thoracic paravertebral block performed at thoracic level T2-T3 and T4-T5 with administration of Ropivacaine 0.7% 8 ml for each level.
11045980|NCT04457115|Experimental|ESP Block|Erector spinae plane block performed at thoracic level T2 and T5 with administration of Ropivacaine 0.5% 12 ml for each level.
11045981|NCT04457102|Active Comparator|Arm N°1 - Standard treatment-Breast DIBH|Patients will be treated during spontaneous breath hold wich is considered as the gold-standard radiotherapy treatment for left breast cancer.
11045982|NCT04457102|Experimental|Arm N°2 - Interventional -Breast MANIV DIBH|Irradiation will take place during DIBH induced by MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 40-50 seconds to allow the complete delivery of a treatment beam.
11045983|NCT04457102|Experimental|Arm N°3 - Interventional -Liver/Lung MANIV DIBH|Irradiation will take place during DIBH induced by the MANIV (Bellavista 1000, IMTMedical®) with SL mode. Oxygen will be added (FiO2 60%) to safely and easily prolong the DIBH duration up to 40-50 seconds to allow the complete delivery of a treatment beam [13]. Prior to treatment, a radio-opaque fiducial will be implanted in the tumor by an interventional radiologist, to facilitate the tumor position monitoring from onboard imaging. Residual tumor baseline shift and motion will thus be measured during beam delivery, and used to recompute the optimal safety margins that ensure an adequate dose coverage of at least 90% of tumors, according to literature recommendations [24]. We will also compare these safety margins computed under MANIV condition with those routinely applied in free-breathing condition (from a matched retrospective cohort) to estimate the gain in terms of margin reduction.
11045984|NCT04457102|Experimental|Arm N°4 - Interventional -Liver/Lung MANIV VC|Patients will be ventilated by VC mode during their treatment. For each fraction, the treatment time, the number of reconstructions of the tracking model and the correlation errors of the model will be collected. The same information will be extracted from a matched retrospective cohort treated by tracking in spontaneous breathing.
11045985|NCT04457102|Other|Arm N°5 -Liver/Lung MANIV DIBH for PT|Data on tumor position and its residual motion from patients included in the arm n°3 will be used to compute the planned and in silico delivered dose distribution with PBS PT. The MIRO lab (UCLouvain - IREC) has developed comprehensive tools for simulating treatment delivery on patients CT images using the Monte Carlo dose engine MCsquare [25], coupled with log-file acquisitions [26]. In this way, we will be able to validate our approach in silico in collaboration with IBA, as a first step before conducting prospective trials for the clinical validation of this approach.
11045986|NCT04457089|Experimental|Simvastatin|
11045987|NCT04457076|Experimental|LevoCept|LevoCept™ Intrauterine Contraceptive
11045988|NCT04457063|Experimental|penetrating keratoplasty|A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction
11045989|NCT04457050|Experimental|Non-Diabetic Hepatitis C infected patients|"clinical examination,
~measurement of weight (Kg), height (meter), and waist circumference (cm).
~Calculation of the body mass index.
~Ultrasound abdominal examination.
~Laboratory Investigations including Complete blood count, Serum aspartate and alanine aminotransferases, serum albumin, serum bilirubin, serum gamma-glutamyl transpeptidase, and international normalization ratio. HCV-RNA quantification before treatment and 12 weeks after the end of therapy.. Serum lipid profile, fasting and post-prandial blood sugar, glycated hemoglobin A1c also included.
~Treatment of all patients with the available generic direct antivirals in Egypt (sofosbuvir/ledipasvir ± ribavirin or sofosbuvir plus daclatasvir ± ribavirin).
~Evaluation of insulin resistance using the homeostasis model assessment of insulin resistance before and 12 weeks after end of treatment.
~measurement of serum levels of resistin before and at 12 weeks after treatment."
11045990|NCT04457037|Experimental|MSC|Patients with trophic ulcers received standard treatment and MSC
11045991|NCT04457011|Experimental|High dose group|High dose Susu Xiao'er Zhike Granules, 1 bag, bid
11045992|NCT04457011|Experimental|Middle dose group|Middle dose Susu Xiao'er Zhike Granules, 1 bag, bid
11045993|NCT04457011|Placebo Comparator|Extremely-low dose group|Extremely-low dose Susu Xiao'er Zhike Granules, 1 bag, bid
11045994|NCT04456998|Experimental|GB002|GB002 inhaled orally twice per day (BID) over 24 weeks
11045995|NCT04456998|Placebo Comparator|Placebo|Placebo inhaled orally BID over 24 weeks
11045996|NCT04456985|Active Comparator|Intervention group|Before the operation, the patient took 20ml of brown sugar aqueous solution containing folic acid and VitB12 for 3 days (folic acid concentration is 0.4mg / d for 2 year old children + 1.2μg / d of VitB12, dissolved in 20ml brown sugar water once a day). Postoperatively, PAED scores were performed at the time of awakening, extubation and every 10min within 30min after extubation. 10 points is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
11046045|NCT04456634|Placebo Comparator|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
11046046|NCT04456621|Experimental|PBT arm|
11046047|NCT04456608|Experimental|Low and High n-3 PUFA|Individuals with low or high n-3 PUFA RBC concentration will be given aspirin (81 mg of aspirin once a day, for 6 days)
11045997|NCT04456985|Placebo Comparator|Placebo group|The patients in the placebo group took 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation. Postoperatively, PAED scores were performed at the time of recovery, extubation, and every 10 minutes within 30 minutes after extubation. The PAED scores of all children were measured by the same person. (The total score is 0-20, and the score ≥10 is defined as delirium during the recovery period). Long-term neurobehavioral changes were evaluated using the Gesell scale, followed up every six months until the age of three
11045998|NCT04456972|Experimental|One arm only|
11045999|NCT04456959||Adult R/R ALL patients who have received InO|Relapsed/refractory ALL patients who are 18 years and over and initiated InO between 1st of June 2016 and date of data collection (to be confirmed). They will have accessed InO treatment via NHS commissioning, via the CUP, or via private purchase and will have at least 3 months follow up from the index date unless death occurs within that time.
11046000|NCT04456946|Experimental|Group of Low Level Laser Therapy|
11046001|NCT04456946|Experimental|Group of Occlusal Splint Treatment|
11046002|NCT04456920|Experimental|Experimental group 1|PRO (Patient Reported Outcomes) gathered via a phone consultation
11046003|NCT04456920|Experimental|Experimental group 2|e-PRO self-completed via connected objects (tablet/phone)
11046004|NCT04456920|No Intervention|Control group|group without e-PROs (standard care)
11046005|NCT04456907|Experimental|PPR group|Receive PRP injection
11046006|NCT04456907|Sham Comparator|Saline group|Receive saline injection
11046007|NCT04456881|Experimental|anatomical reconstruction group of Patellofemoral ligament|
11046008|NCT04456868|Active Comparator|Healthy volunteers|Healthy volunteers at least 18 years old and without a history of psychiatric or neurological disorders
11046009|NCT04456868|Experimental|Anhedonic drug-resistant bipolar depression patient|Adult patients at least 18 years old with drug-resistant bipolar depression of the anhedonic type
11046010|NCT04456868|Active Comparator|Non-anhedonic drug-resistant bipolar depression Pat|Adult patients at least 18 years old with drug-resistant bipolar depression of the non-anhedonic type
11046011|NCT04456868|Active Comparator|Mild to moderate Parkinson's disease patient|Adult patients at least 18 years of age with mild to moderate Parkinson's disease
11046012|NCT04456855||Locoregional surgery|
11046013|NCT04456855||No surgery|
11046014|NCT04456829|Experimental|Resveratrol drink|Taking one bottle of a resveratrol drink (30 mL) for two months
11046015|NCT04456829|Placebo Comparator|Placebo drink|Taking one bottle of a placebo drink (30 mL) for two months
11046016|NCT04456816|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
11046017|NCT04456816|Experimental|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
11046018|NCT04456803|Experimental|Ferric citrate tablet|Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.
11046019|NCT04456803|Active Comparator|Sevelamer carbonate tablet|Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.
11046020|NCT04456777|Experimental|1group|patients with vortioxetine
11046021|NCT04456777|Placebo Comparator|2 group|patients without vortioxetine
11046022|NCT04456764|Experimental|SaFTiE|The SaFTiE intervention includes: [a] real-time text-message assessments of fatigue and sleep during and between scheduled shift work; [b] tailored text-message alerts that promote adopting evidence based strategies for mitigating fatigue when high levels of fatigue or sleepiness are reported; [c] a mobile app that delivers goal setting, summary data of sleep/fatigue indicators from all study participants, and video interviews of EMS clinicians focused on sleep and fatigue.
11046023|NCT04456764|Placebo Comparator|Attention Placebo Control|The attention placebo control includes: [a] real-time text-message assessments of teamwork during and between scheduled shift work; [b] text-message alerts that promote techniques for mitigating poor teamwork when episodes of poor teamwork are reported; [c] a mobile app that delivers goal setting, summary data of teamwork indicators from all study participants, and video interviews of EMS clinicians focused on teamwork.
11046024|NCT04456751||No redo op|Patients with a single cardiac operation under extracorporeal bypass
11046025|NCT04456751||Redo op|Patients with a redo cardiac operation under extracorporeal bypass
11046026|NCT04456738|Experimental|Parent Training|16 weeks of parent training in a group context with 5 to 10 relative and non-relative foster caregivers
11046027|NCT04456738|No Intervention|Services as Usual|Foster care services as usual
11046028|NCT04456725|Active Comparator|Control|Usual care group
11046029|NCT04456725|Experimental|Intervention|Intensive management utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring.
11046030|NCT04456712|Experimental|ciprofloxacin for diabetic patients|50 diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
11046031|NCT04456712|Experimental|levofloxacin for diabetic patients|50 diabetic patients received intravenous levofloxacin 750mg/24 hours.
11046032|NCT04456712|Experimental|ciprofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.
11046033|NCT04456712|Experimental|levofloxacin for non-diabetic patients|50 non-diabetic patients received intravenous levofloxacin 750mg/24 hours.
11046034|NCT04456699|Experimental|Olaparib + Bevacizumab|Olaparib (300 mg twice daily [BID] oral) + Bevacizumab (5 mg/kg intravenous [IV] once every 2 weeks [Q2W]) until progressive disease or end of study
11046035|NCT04456699|Experimental|Olaparib|Olaparib (300 mg BID) oral, until progressive disease or end of study
11046036|NCT04456699|Active Comparator|Bevacizumab + 5-FU|Bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W) until progressive disease or end of study
11046037|NCT04456686|Experimental|LY3016859|LY3016859 given intravenously (IV).
11046038|NCT04456686|Placebo Comparator|Placebo|Placebo given IV.
11046039|NCT04456673|Experimental|Dupilumab|Dupilmab administered every 2 weeks
11046040|NCT04456673|Placebo Comparator|Placebo|Placebo dose administered every 2 weeks
11046041|NCT04456660|No Intervention|Control group|
11046042|NCT04456660|Active Comparator|sFlt-1 & Doppler group|
11046048|NCT04456595|Experimental|Adult - Vaccine|Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
11046049|NCT04456595|Experimental|Elderly - Vaccine|Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
11046050|NCT04456595|Placebo Comparator|Adult - Placebo|Participants aging 18-59 years receiving two doses with 14-days interval of placebo
11046051|NCT04456595|Placebo Comparator|Elderly - Placebo|Participants aging 60 years or above receiving two doses with 14-days interval of placebo
11046052|NCT04456582|Experimental|Amyloidosis transthyretin with cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
11046053|NCT04456582|Experimental|Amyloidosis transthyretin without cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
11046054|NCT04456582|Placebo Comparator|Healthy subjects|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
11046055|NCT04456569|Experimental|GAE + Standard of Care|Participants in this arm will receive geniculate artery embolization and standard of care.
11046056|NCT04456569|No Intervention|Standard of Care|Participants in this arm will receive standard of care only.
11046057|NCT04456543|Experimental|Pressure monitoring group|In the pressure monitoring group, garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg for 2 months. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
11046058|NCT04456543|Active Comparator|conventional treatment group|In the conventional treatment group, non-surgical standard treatment of burn scars except for pressure monitoring was performed in the same manner. Subjects were instructed to wear the garment 23 hours per day, removing them only for bathing.
11046059|NCT04456530|Experimental|Testosterone Group|Participants receiving two IM Testosterone injections.
11046060|NCT04456530|Placebo Comparator|Control Group|Participants receiving two IM Normal Saline Injections.
11046061|NCT04456517|Experimental|Ranolazine, Then Placebo|- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
11046062|NCT04456517|Experimental|Placebo, Then Ranolazine|- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
11046063|NCT04456504|Experimental|Healthcare worker|Healthcare worker who has previously received at least 5 doses of hepatitis B vaccine with aluminum adjuvant (Recombivax B or Engerix B) and has an antibody to the hepatitis B surface antigen (antiHBs) that is less than 10 mIU/ml.
11046064|NCT04456491||Asthma|Patients with Asthma
11046065|NCT04456491||COPD|Patients with COPD
11046066|NCT04456491||Control group|Healthy volunteers
11046067|NCT04456478|Active Comparator|pH 7.38 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02
11046068|NCT04456478|Experimental|pH 7.22 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.22 ± 0.02
11046069|NCT04456452|Experimental|Ampion|Ampion
11046070|NCT04456452|Other|Standard of Care|Standard of Care
11046071|NCT04456426||Patients treated with COVID-19|All populations of patients admitted with COVID-19 in healthcare institutions involved. No intervention but standard care designed by national guidelines will be provided.
11046072|NCT04456413|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
11046073|NCT04456413|Active Comparator|Best Supportive Care|Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.
11046074|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.
~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.
~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
11046075|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
11046076|NCT04456387|Experimental|Arm 1-on demand treatment|Part A-Participants will receive on-demand treatment with Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection for 6 months.
11046077|NCT04456387|Experimental|Arm 2- prophylaxis treatment|"Part B-Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.
~12 Participants of them will receive PK assessment at ED1 and ED35(Participants will be tested for PK assessment at timepoints throughout the study based on exposure days (ED). One ED is equivalent to a 24 hours period in which drug is dosed.)，measured by one-stage assay, they would not be given prophylaxis treatment until the completion of PK blood collection."
11046078|NCT04456374||Under-12 (U12) players|
11046079|NCT04456374||Under-14 (U14) players|
11046080|NCT04456374||Under-16 (U16) players|
11046081|NCT04456374||Under-18 (U18) players|
11046082|NCT04456361|Experimental|COVID-19 patients|Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
11046083|NCT04456348||positive|Subjects have gait disorder according to intelligent gait assessment at baseline.
11046084|NCT04456348||negative|Subjects don't have gait disorder according to intelligent gait assessment at baseline.
11046085|NCT04456335||Caries-free|Caries-free children
11046086|NCT04456335||Early childhood caries|Children with early childhood caries
11046124|NCT04456088|No Intervention|Phase 2- Group 2- control|Standard of Care
11046087|NCT04456322|Experimental|RT plus Nimotuzumab|Patients with pretreatment plasma EBV DNA<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy ( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
11046088|NCT04456322|Active Comparator|RT plus Cisplatin|Patients with pretreatment plasma EBV DNA<1500 copy/ml and up to CR/PR according to RECIST and the EBV DNA reduced to undectable(0 copy/mL ) after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-FU 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
11046089|NCT04456309||Atrial fibrillation|stroke patients with atrial fibrillation
11046090|NCT04456309||Intracardiac thrombus|stroke patients with intracardiac thrombus
11046091|NCT04456296|Active Comparator|Testosterone undecanoate injection (AVEED)|Fixed dosage level of 750mg/3mL
11046092|NCT04456296|Active Comparator|Testosterone gel (FORTESTA)|40mg once daily
11046093|NCT04456296|Active Comparator|Testosterone gel (TESTIM)|50mg once daily (titrated)
11046094|NCT04456283||Incomplete pathological response with less than 12 LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
11046095|NCT04456283||Incomplete pathological response with 12 or more LN.|Patients with incomplete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
11046096|NCT04456283||Complete pathological response with less than 12 LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and less than 12 lymph nodes
11046097|NCT04456283||Complete pathological response with 12 or more LN.|Patients with complete pathological response after Chemoradiation theraphy for Rectal Cancer and 12 lymph or more nodes
11046098|NCT04456270||Primary care patients with current asthma|Male and female primary care patients aged ≥18 years of age with clinically diagnosed asthma.
11046099|NCT04456257|Experimental|Fractional Picosecond 1,064 nm laser|The subjects with abdominal striae alba were treated with a fractional picosecond 1,064 nm laser
11046100|NCT04456244||Group 1:Transtibial Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
11046101|NCT04456244||Group 2:Transfemoral Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
11046102|NCT04456231||QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. In Addition, this Group will receive a health app for better preparation and more Information regarding preparation and endoscopy itself.
11046103|NCT04456231||no QR Code|Patients will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy Guidelines. This Group will have no app and will have to receive Information in traditional ways.
11046104|NCT04456218|Experimental|Biliary stone|Participants who meet the criteria of biliary stone enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
11046105|NCT04456218|Experimental|Biliary stricture|Participants who meet the criteria of biliary neoplasm enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
11046106|NCT04456205||Dual Therapy|Dual Therapy (long-acting muscarinic antagonist [LAMA] + long-acting beta-agonist [LABA])
11046107|NCT04456205||Triple Therapy|Triple Therapy (inhaled corticosteroid [ICS]/ long-acting beta-agonist [LABA] + long-acting muscarinic antagonist [LAMA])
11046108|NCT04456192|Experimental|Women with Obesity|23 healthy, obese (BMI ≥ 30 kg/m2; waist circumference > 80) women, aged 34-62, screened at the outpatient clinic of the Department of Internal Medicine, Metabolic Disorders, and Hypertension, University of Medical Sciences, Poznań, Poland were enrolled based on the inclusion criteria and the willingness to participate in the research.
11046109|NCT04456192|Active Comparator|Normal-weight Women|"8 healthy, normal-weight (≤ 24.9 and ≥ 18.5 kg/m2) women, aged 34-62 were enrolled to intervention from the announcement.
~Random selection for groups was not applicable due to the planned body mass difference in the studied groups."
11046110|NCT04456166||Patient who received carbohydrate loading|Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting
11046111|NCT04456153|Experimental|standard of care therapy with atovaquone|The first treatment group will receive continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days.
11046112|NCT04456153|Placebo Comparator|standard of care therapy with matching placebo|The second treatment group will receive continued standard of care therapy together with matching placebo.
11046113|NCT04456140|Experimental|Prevention (pre-genetic test counseling, genetic testing)|Patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. Patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.
11046114|NCT04456127|No Intervention|Standard of Care|Scar section does not receive CO2 laser therapy.
11046115|NCT04456127|Experimental|Factional CO2|Scar section receives fractional CO2 laser therapy.
11046116|NCT04456114|Experimental|Acid etched brackets|Stainless steel bracket base etched with 10% Hydrofluoric acid for 1 minute
11046117|NCT04456114|Active Comparator|Sandblasted brackets|Stainless steel bracket sandblasted base
11046118|NCT04456101||Control group|healthy volunteers without COVID-19
11046119|NCT04456101||Severe/Critical COVID-19 rehabilitation group|Patients recovering from severe/critical COVID-19
11046120|NCT04456101||mild/moderate COVID-19 rehabilitation group|Patients recovering from mild/moderate COVID-19;
11046121|NCT04456101||asymptomatic COVID-19 rehabilitation group|Asymptomatic COVID-19 patients with laboratory test for SRARS-COV2 turning negative
11046122|NCT04456088|Experimental|Phase 1- Nitric oxide treatment- 80ppm|
11046123|NCT04456088|Experimental|Phase 2- Group 1- Nitric oxide treatment- 150ppm|
11046129|NCT04456023|Experimental|Tisagenlecleucel|All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.
11046130|NCT04456010||Infertile couple|Infertile couple who had a fertility treatment prescribed during the past 9 months which was not completed yet.
11046131|NCT04455984||Neoadjuvant chemoradiotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery
11046132|NCT04455984||Neoadjuvant chemotherapy|Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery
11046133|NCT04455971||OM Group|People who participate in the practice of orgasmic meditation (OM)
11046134|NCT04455958|Experimental|Group I (lopinavir/ritonavir)|Patients receive lopinavir/ritonavir PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
11046135|NCT04455958|Placebo Comparator|Group II (placebo)|Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
11046136|NCT04455945||Open|Patients with open surgery for rectal cancer planned in our department.
11046137|NCT04455945||Laparoscopic|Patients with laparoscopic surgery for rectal cancer planned in our department.
11046138|NCT04455932|Experimental|HCC surveillance with US and aNC-MRI|
11046139|NCT04455919|Experimental|Yoga|Yoga classes once a week for eight weeks
11046140|NCT04455919|Other|Wait-list control|The delayed intervention group was to benefit from the intervention after week 8.
11046141|NCT04455893|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
11046142|NCT04455893|Experimental|Combined 2: Stratified only|Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
11046143|NCT04455880|Active Comparator|GDM with insulin therapy|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
11046144|NCT04455880|Active Comparator|GDM treated with only diet (without any medical therapy)|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
11046145|NCT04455880|Active Comparator|Non-diabetic Controls|Singleton non diabetic healthy pregnancies above 36 gestational weeks
11046146|NCT04455867||UHN Toronto Rehab|Participants with prediabetes of T2DM undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as per the site's standard protocol (Diabetes Exercise and Healthy Lifestyle Program).
11046147|NCT04455867||Sunnybrook Health Sciences Centre|Participants with prediabetes or T2DM receiving care from an outpatient service at Sunnybrook Health Sciences Centre.
11046148|NCT04455841|Experimental|Treatment Group A (TGA)|INCB000928 will be administered once daily( QD).
11046149|NCT04455841|Experimental|Treatment Group B (TGB)|INCB000928 will be administered in combination with ruxolitinib.
11046150|NCT04455828||Hospitalized Heart Failure subjects|Subjects hospitalized for heart failure exacerbation will be enrolled, prior to discharge from hospital, to wear the WHOOP device for 90 days.
11046151|NCT04455828||Non-hospitalized Heart Failure subjects|Subjects who have not been hospitalized in the past 1 year, but have a diagnosis of heart failure, will be enrolled during routine outpatient care to wear the WHOOP device for 90 days.
11046152|NCT04455815|Experimental|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
11046153|NCT04455815|No Intervention|Control arm|Patient to receive best supportive care.
11046154|NCT04455802|Active Comparator|Morphine|Infants randomized to the morphine arm will start at a dose of 0.06 mg/kg/dose every 4 hours. A buprenorphine placebo will also be given at the same frequency as a faux drug.
11046155|NCT04455802|Experimental|Buprenorphine|"Infants randomized to the buprenorphine arm will be started on a dose of 10 mg/kg/dose every 8 hours. A morphine placebo will also be given at the same frequency as a faux drug.
~Patients can only be randomized to only one arm."
11046156|NCT04455789|Experimental|conventional mechanical ventilation|routine mechanical ventilation will be adjusted based on conventional mechanical ventilation settings with tidal volume of 8 ml/kg and PEEP level of 5
11046157|NCT04455789|Experimental|mechanical ventilation adjusted according to driving pressure|routine mechanical ventilation adjusted based on driving pressure during lateral position. After patients are put to lateral position incremental increase in PEEP will be applied and the driving pressures will be recorded for each PEEP level and the patients will be ventilated with this PEEP during anesthesia. the other setting will be same with conventional group. tidal volume of 8 ml/kg
11046158|NCT04455763|Experimental|SVF|Thumb carpometacarpal injection with adipose-derived SVF combined with splinting
11046159|NCT04455763|Active Comparator|Splint|Thumb carpometacarpal osteoarthrosis treated with splinting only
11046160|NCT04455750|Experimental|Arm I (enzalutamide, rucaparib)|Patients receive enzalutamide PO QD and rucaparib PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11046161|NCT04455750|Active Comparator|Arm II (enzalutamide, placebo)|Patients receive enzalutamide PO QD and placebo PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11046162|NCT04455737||Patients with indigo carmine stained specimen|Specimen which underwent pathologic work-up after ex vivo indigo carmine injection into the inferior mesenteric artery after transanal total mesorectal excision.
11046163|NCT04455737||Patients with unstained specimen|Specimen which underwent pathologic work-up after transanal total mesorectal excision without indigo carmine dyeing.
11046208|NCT04455386||slightly instable|The anterior drawer test and/or talar tilt test are slightly positive and the ankle joint is partially instable.
11046209|NCT04455386||obviously instable|The anterior drawer test and/or talar tilt test is significantly positive, with significantly instable. The ankle joint is completely instable and can featured with dimple sign.
11046210|NCT04455373||orthopedic surgery group|Planned tumor resection
11046164|NCT04455724|Experimental|Negative Pressure Incisional Woundth Therapy|A PREVENA™ PEEL & PLACE™ system kit will be applied to the surgical wound and assembled in the operating room following closure by primary intent. The system will be set for a negative pressure of -125mmHg. The dressing will be left in place for 7 days post-operation, during which the patient may be discharged from hospital. The dressing will only be removed or changed if the treating physician has suspicion of one of the complications included in the primary composite outcome or is planning re-intervention on the surgical site.
11046165|NCT04455724|Active Comparator|Standard sterile dressing|A sterile island dressing will be applied to the surgical wound in the operating room following closure by primary intent, which will be removed on post-operative day 2 and left open to air unless there is ongoing discharge.
11046166|NCT04455711|Placebo Comparator|Remifentanil group|Emerge with continuous infusion of remifentanil 1.5 ng/ml
11046167|NCT04455711|Experimental|Lidocaine group|Emerge with continuous infusion of remifentanil 1.5 ng/ml with IV bolus of lidocaine 1.5 mg/kg
11046168|NCT04455698|Experimental|Remote Telegenetics: TELEPHONE (ARM A)|"Remote Phone Telegenetics:
~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - TELEPHONE."
11046169|NCT04455698|Experimental|Remote Telegenetics: VIDEOCONFERENCING (ARM B)|"Remote Videoconferencing Telegenetics:
~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - VIDEOCONFERENCING."
11046170|NCT04455698|Experimental|USUAL CARE (ARM C)|"Usual Care:
~Participants will receive referrals to genetic counseling providers, initiating services on their own. At 6 months, if participants have not sought and received genetic counseling services, they will be offered randomization to ARM A/ARM B."
11046171|NCT04455672|Experimental|interventional group|patient using two types of splints (3d Anterior Rrepositioning Splint then printed stabilizing splint)
11046172|NCT04455672|Active Comparator|control group|patient using two types of splints (3d printed stabilizing splint then Anterior Rrepositioning Splint)
11046173|NCT04455659|Experimental|TENS + Conventional physical therapy exercise|
11046174|NCT04455659|Active Comparator|conventional physical therapy exercise|
11046175|NCT04455633|Experimental|LX9211 low dose|LX9211, once daily
11046176|NCT04455633|Experimental|LX9211 high dose|LX9211, once daily
11046177|NCT04455633|Placebo Comparator|Placebo|Placebo, once daily
11046178|NCT04455620|Experimental|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
11046179|NCT04455607|Experimental|experimental group|Random perturbation training
11046180|NCT04455607|Active Comparator|control group|Block perturbation training
11046181|NCT04455594|Experimental|Almonertinib|Almonertinib 110mg QD
11046182|NCT04455594|Active Comparator|Investigator-choice therapy (Erlotinib or Chemotherapy)|Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
11046183|NCT04455581|Experimental|Treatment group|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
11046184|NCT04455568||experimental group|Non-invasive Wearable Device, use ECG Wisdom bracelet
11046185|NCT04455555|Experimental|rotigotine treatment group|rotigotine sustained release microspheres therapy by injection
11046186|NCT04455555|Placebo Comparator|placebo comparator|placebo comparator/null microspheres
11046187|NCT04455542||LMND-ALS|The main clinical manifestations were muscle weakness with atrophy and bundle fibrillation, the pyramidal tract sign was relatively mild, and extensive neurogenic damage with CMAP amplitude decreased could be seen in patients with electromyography.
11046188|NCT04455542||UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
11046189|NCT04455542||FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy
11046190|NCT04455529||ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
11046191|NCT04455516||repair group|The first operation in these patients was meniscus repair
11046192|NCT04455516||nonfailure group|These patients had a successful first operation
11046193|NCT04455516||failure group|In these patients, the first meniscus repair operation failed
11046194|NCT04455503|Experimental|Cohort A: Nivolumab and EVX-02A|EVX-02A administered IM.
11046195|NCT04455503|Experimental|Cohort B: Nivolumab and EVX-02B|EVX-02B administered IM.
11046196|NCT04455503|Experimental|Cohort C: Nivolumab and EVX-02A OR Nivolumab and EVX-02B|The selected delivery methodology either EVX02A or EVX-02B.
11046197|NCT04455490||Delayed wound healing|Patients with delayed wound healing after Achilles tendon suture who were treated at Peking University Third Hospital
11046198|NCT04455464|Experimental|Midodrine|Midodrine will be given 10 mg for one time only. HVPG will be done at baseline and after 3 hours
11046199|NCT04455438|Experimental|SBRT Level 1|The starting dose level will be SBRT 30 Gy in 5 fractions (level 1 or L1).
11046200|NCT04455438|Experimental|SBRT Level 2|If the starting dose is tolerated in the first 5 patients, the next dose will be SBRT 40 Gy in 5 fractions (level 2 or L2)
11046201|NCT04455438|Experimental|SBRT Level 3|If the second dose is tolerated in the next 5 patients, the next dose will be SBRT 50 Gy in 5 fractions (level 3 or L3)
11046202|NCT04455412|No Intervention|control group|Conventional ICSI procedure was done for first portion of sibling oocytes
11046203|NCT04455412|Experimental|Study group 1|Laser assisted drilling ICSI procedure was done for second portion of sibling oocytes
11046204|NCT04455412|Experimental|Study group 2|Laser assisted thinning ICSI procedure was done for Third portion of sibling oocytes
11046205|NCT04455399|Other|Intravitreal injection guide|Single use, combination ocular surface caliper to determine point of intravitreal injection and set-depth injection guide to limit injection needle entry into the eye
11046206|NCT04455399|Other|Dual blade eyelid speculum|Dual blade eyelid speculum to open eyelids followed by Castroviejo surgical caliper to measure injection point 3.5 mm from limbus
11061110|NCT04349800|Experimental|Single Ascending Dose - 80 mg|
11046212|NCT04455360|Experimental|EMDR R-TEP intervention|Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.
11046213|NCT04455360|No Intervention|Standard care|Patients will receive standard post-hospital discharge care.
11046214|NCT04455334|Other|healthy|year 1 study
11046215|NCT04455334|Other|stroke|year 1 study
11046216|NCT04455334|Active Comparator|active control group|year 2 study
11046217|NCT04455334|Experimental|Error-augmented treadmill training|year 2 study
11046218|NCT04455334|Experimental|Error-augmented concept combined physical therapy group|year 3 study
11046219|NCT04455334|Active Comparator|conventional physical therapy group|year 3 study
11046220|NCT04455321|Active Comparator|Vicryl|Single layer locked uterine closure with vicryl suture material
11046221|NCT04455321|Experimental|rapide vicryl|Single layer locked uterine closure with rapide vicryl suture material
11046222|NCT04455308|Experimental|Subjects with chilblains|
11046223|NCT04455308|Active Comparator|Subjects without chilblains|
11046224|NCT04455295|Experimental|Active Stimulation 0.5|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
11046225|NCT04455295|Placebo Comparator|Lobe Control|0.5mA, 30Hz intermittent transdermal vagus nerve stimulation of the earlobe. Stimulation 30 second on/30 seconds off for five cycles.
11046226|NCT04455295|Placebo Comparator|Sham Stimulation|0.5mA, 5Hz intermittent transdermal vagus nerve stimulation of the auricle vagus. Stimulation 30 second on/30 seconds off for five cycles.
11046227|NCT04455295|Placebo Comparator|Nonstimulation|Placement of electrode without any stimulation.
11046228|NCT04455269|Experimental|Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)|"The quadrants allocated to FM-EPAPT underwent the following steps:
~Decontamination of soft tissues with air-polishing and erythritol powder;
~Supra-gingival removal biofilm with air-polishing and erythritol powder;
~Sub-gingival removal of biofilm with air-polishing and erythritol;
~Calculus removal with a piezoceramic scaler."
11046229|NCT04455269|Active Comparator|Ultrasonic debridement and abrasive paste (US+P)|"The quadrants allocated to US+P treatment underwent the following steps:
~Full-mouth ultrasonic debridement with piezoceramic scaler;
~Plaque removal and polishing with soft rubber cup and low-RDA polishing paste"
11046230|NCT04455256||recurrent pregnancy loss group|Women between the ages of 18 and 45 who had a history of miscarriage under 3 weeks and above 22 weeks were included in this group.
11046231|NCT04455256||women who had healthy birth|Women between the ages of 18-45 who have not had a history of pregnancy loss and who have had at least one healthy birth and no known chronic diseases are included in this group.
11046232|NCT04455243|Experimental|Intervention group|
11046233|NCT04455243|Placebo Comparator|Control group|
11046234|NCT04455230|Experimental|Participants who have received gene therapy vector (FLT190)|
11046235|NCT04455204||non-pregnant women (group 1)|20 non-pregnant women who serve as a control group (group 1)
11046236|NCT04455204||pregnant women (group 2)|20 pregnant women with normal pregnancy at their third trimesters (group 2)
11046237|NCT04455204||pregnant women with Preeclampsia (group 3)|20 pregnant women with Preeclampsia in their third trimester (group 3) will be screened to fit the inclusion and exclusion criteria.
11046238|NCT04455191|Experimental|Thawing Embryos in Advance|Thawing embryos one day in advance (16:00), 18h before embryos transfer (10:00).
11046239|NCT04455191|Experimental|Thawing Embryos on the Day of Transfer|Thawing embryos on the day of transfer (8:00), 2h before embryos transfer (10:00).
11046240|NCT04455178|Experimental|Spironolactone|Spironolactone 20mg once daily
11046241|NCT04455178|Active Comparator|Indapamide|Indapamide 1.5mg once daily
11046242|NCT04455165||RVAo MITAVA|Patient operated since 2009 for aortic valve replacement through right anterior minithoracotomy approch in Dijon Burgundy University Hospital
11046243|NCT04455152|Experimental|Self-control|two-week period of practicing self-control (attempting to avoid eating sweet foods) and self-monitoring success in doing so
11046244|NCT04455152|No Intervention|wait list|waiting 2 weeks after baseline assessment before gaining access to web-based self-help
11046245|NCT04455139|Active Comparator|Treatment 1a|IVitC melphalan (randomized) in case of vitreous relapse only
11046246|NCT04455139|Experimental|Treatment 1b|IVitC topotecan (randomized) in case of vitreous relapse only
11046247|NCT04455139|Active Comparator|Treatment 2a|IAC melphalan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
11046248|NCT04455139|Experimental|Treatment 2b|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with no prior intra-arterial treatment
11046249|NCT04455139|No Intervention|Treatment 2c|IAC melphalan and topotecan (randomized) in case of retinal/diffuse subretinal relapse with prior intra-arterial treatment
11046250|NCT04455139|No Intervention|Treatment 3a|sequential administration of IVitC melphalan and IAC melphalan in case of combined vitreous and retinal/diffuse subretinal relapse, if no pretreatment with intra-arterial treatment
11046251|NCT04455139|No Intervention|Treatment 3b|sequential administration of IVitC melphalan and IAC melphalan and topotecan, in case of combined vitreous and retinal/diffuse subretinal relapse, if prior pretreatment with intra-arterial treatment
11046252|NCT04455126|Experimental|Preservative-free tafluprost|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
11046253|NCT04455113||Normo-phosphatemia|238 patients included in this group. Phosphorus level >2.5 mg/dl
11046254|NCT04455113||Hypophosphatemia|79 patients included in this group. Phosphorus level <2.5 mg/dl
11046255|NCT04455100|Experimental|SHR1459|Following a 10-hour overnight fast, subjects will be administered one dose of SHR1459 orally with 240 mL of ambient temperature water on Day 1. D2-D3 was the cleaning period. Itraconazole will be administered orally 200 mg/time/day form D4 to D8 after meal. On D7 following a 10-hour overnight fast, subjects will be administered SHR1459 and itraconazole 200 mg with 240 mL of ambient temperature water.
11046256|NCT04455087||before intervention|1000 patients befor sensitization
11046257|NCT04455074|Experimental|PD patients with motor fluctuations|FN scale is an autoquestionnaire consisting of 20 questions, to be answered in On-med and OFF-med condition
11046258|NCT04455048|Experimental|Intervention Group|A single-session manipulation with a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied.
11046259|NCT04455048|Sham Comparator|Control Group|A sham manipulation without a high-speed low-amplitude thrust technique in the cervicothoracic transition region will be applied.
11046260|NCT04455035|Active Comparator|Retrospective Group(Control)|
11046261|NCT04455035|Experimental|Prospective Group|
11046262|NCT04455022||Any infant who will have a blood culture collected.|During the study period educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
11046263|NCT04455009|Experimental|100mg Caffeine Formula|10kcal drink containing a total of 100 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
11046264|NCT04455009|Experimental|140mg Caffeine Formula|10kcal drink containing a total of 140 mg of caffeine from a proprietary blend of caffeine, guarana, ginger, and green tea extract containing epigallocatechin gallate
11046265|NCT04455009|Placebo Comparator|Placebo Formula|non-caloric/non-caffeinated drink
11046266|NCT04454996|Experimental|Non-erosive reflux disease test group|
11046267|NCT04454996|Placebo Comparator|Non-erosive reflux disease control group|
11046268|NCT04454996|Experimental|Diarrhea-type irritable bowel syndrome test group|
11046269|NCT04454996|Placebo Comparator|Control group with diarrheal irritable bowel syndrome|
11046270|NCT04454996|No Intervention|Healthy control group|
11046271|NCT04454983|Experimental|Lipiflow - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
11046272|NCT04454983|Experimental|iLux - All Subjects|Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
11046273|NCT04454970|Experimental|Urethral catheterisation device (UCD)|First attempt of urethral catheterisation using the Urethrotech(R) Urethral catheterisation device (UCD)
11046274|NCT04454970|Active Comparator|Bardia Aquafil Foley catheter|First attempt of urethral catheterisation using the Bardia Aquafil Foley catheter
11046275|NCT04454957|Experimental|Mastering Diabetes|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
11046276|NCT04454957|No Intervention|Usual care|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen not to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
11046277|NCT04454944|No Intervention|Control|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. Participants in the control arm will receive no other intervention.
11046278|NCT04454944|Experimental|No subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm will receive an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
11046279|NCT04454944|Experimental|Subsidy, no distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas (LPG) purchases.
11046280|NCT04454944|Experimental|Subsidy, distance variation|All individuals in each arm will have a well-functioning LPG cookstove and gas cylinder. This intervention arm receives a price subsidy on liquefied petroleum gas) (LPG) purchases an assigned depot where they have to make liquefied petroleum gas (LPG) purchases.
11046281|NCT04454931||Intensive care patients who underwent neurosurgery|Cerebral oxygenation status will be monitored during and after endotracheal suctioning in each patient included in the study. Non-invasive regional oximetry probes are placed in the frontal region of the patient and the patient will be positioned at the head height of 15 degrees with a 3-motor angle determining bearing system. Then, when the patient's need for endotracheal suctioning arises, endotracheal suctioning will be performed and the cerebral oxygenation status before the procedure, 1 minute, 5 minutes and 30 minutes after the procedure will be recorded on the monitor of the non-invasive regional oximeter device operating with NIRS technology. The same procedure will be applied to the patient at head heights of 30 and 45 degrees. Cerebral oxygenation status measured at each head height will be compared with appropriate statistical methods and the most appropriate head height will be determined.
11046282|NCT04454918|Experimental|TAK-906 50 mg + [14C]-TAK-906 100 mcg + [14C]-TAK-906 50 mg|TAK-906 50 mg, capsule, orally, once on Day 1, followed by [14C]-TAK-906 100 mcg (approximately 1 mcCi), infusion, intravenously, once on Day 1 of Period 1, followed by a washout period of at least 7 days, further followed by [14C]-TAK-906 50 mg (approximately 100 mcCi), solution, orally, once on Day 1 of Period 2.
11046283|NCT04454905|Experimental|Camrelizumab combination with Apatinib|Camrelizumab 200mg, every 3 weeks, intravenous infused. Apatinib 250mg, once a day, orally. Until progression or unacceptable toxicity events develop.
11046284|NCT04454892||Amyotrophic lateral sclerosis patients|Although previous studies have provided reference for the diagnosis and treatment of ALS, the etiology of ALS is still unknown, and the relevant clinical features and natural history of ALS still lack the verification of large samples. Therefore, the research on the natural history of ALS is of great significance to further increase the understanding of ALS and provide new evidence for the diagnosis and treatment of ALS
11046285|NCT04454879|Experimental|standard roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
11046286|NCT04454879|Experimental|lower roxadustat dosage group|Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.
11047552|NCT04446013|Experimental|Group General Anesthesia|C-Section under general anesthesia
11046287|NCT04454866|Placebo Comparator|Control group|For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
11046288|NCT04454866|Experimental|Single injection group|For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
11046289|NCT04454866|Experimental|Continuous infusion group|For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
11046290|NCT04454853||Lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in lung cancer.
11046291|NCT04454853||Lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in lung cancer.
11046292|NCT04454853||Suspected lung cancer with positive methylated DNA|Blood DNA methylation abnormalities are found in suspected lung cancer.
11046293|NCT04454853||Suspected lung cancer with negative methylated DNA|Blood DNA methylation abnormalities are not found in suspected lung cancer.
11046294|NCT04454840|Experimental|Biological+Riluzole|Plasma from healthy young people treatment + Riluzole
11046295|NCT04454840|Active Comparator|Riluzole|Riluzole
11046296|NCT04454814|Active Comparator|Rotary Engine-driven Instruments|The instrumentation protocol with Protaper Universal rotary files was began with an S1 file with a brushing movement to the two thirds of the working length and then an SX file was introduced to the two thirds of the working length with a brushing movement Afterwards, S1, S2, F1, F2 files in mesial roots and F4 files in distal roots were used to the working length, respectively. Protaper F2 instrument was then used to complete the canal preparation in mesial roots and Protaper F4 instrument was used to complete the canal preparation in distal roots.
11046297|NCT04454814|Active Comparator|Reciprocal Engine-driven Instruments|The instrumentation of the root canal in the Reciproc Blue group began with a R25 instrument with a slow in-and-out pecking movement.According to the manufacturer instructions, a #10 K-file was inserted to the canal to check the canal is free to 1 mm beyond the prepared canal section. After each 3 pecks or when a resistance was encountered the instrument was pulled out of the canal. Afterward, the R25 instrument was inserted in to root canal until approximately two thirds of the working length.RB R25 instrument was then used to complete the canal preparation in mesial roots and RB R40 instrument was used to complete the canal preparation in distal roots.
11046298|NCT04454788|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
11046299|NCT04454788|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
11046300|NCT04454775||group I|50 cases who received raloxifene and calcium therapy
11046301|NCT04454775||group II|30 cases who received only calcium therapy
11046302|NCT04454762|Experimental|Cabozantinib|40 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 20 mg daily.
11046303|NCT04454749||Stimulated cycles|Ovarian stimulation will be performed by standard protocols. Stimulation medication dosage will be individualised prior to stimulation start according to the ovarian reserve parameters and during ovarian stimulation according to the ovarian response and the measured levels of E2 and progesterone (P4), in order to avoid progesterone elevation during late follicular phase. Final oocyte maturation will be achieved by administration of either 10.000 IU of hCG, 0.3 mg of GnRH agonist (Triptorelin) or dual trigger (hCG and GnRH-analogue), as soon as ≥ 3 follicles ≥ 17 mm are present. Oocyte retrieval will be carried out 36 hours after administration of the trigger. Embryos will undergo PGT-A at blastocyst stage and be vitrified thereafter.
11046304|NCT04454749||Artificial (HRT) Cycles|"Start of estradiol valerate 4mg on day 2 of the cycle for three days. Increase E2 to 6mg on day 4 of E2 treatment. E2 dose may be increased according to clinician discretion based on endometrial thickness. Maximum time of E2 exposure will be 14 days. Transvaginally scan to monitor endometrial development and to exclude the presence of a dominant follicle. Serial measurements of serum LH, estradiol and progesterone levels. Commence the initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance. Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue estradiol administration 6mg (3 tablets daily).
~Blastocyst transfer is scheduled on the 5th full day of progesterone administration, following the initial initiation of progesterone."
11046305|NCT04454749||Spontaneous natural cycles|"Ultrasound scans to monitor follicular growth and serial measurements of serum LH, estradiol and progesterone levels to determine the timing of ovulation. The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter.
~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/ml confirming ovulation (day 0). This is considered as day 0 with initiation of vaginal progesterone 100mg (vaginal suppository) at 2200H. The following day (day 1) increases progesterone administration to 100mg vaginally three times daily (8 hourly) and continues this regime until 7 weeks gestation as per clinic protocol.
~Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
11046306|NCT04454736|Experimental|SBGmentdis|Children and adolescents with mental disorders at the Department of Child and Adolescents Psychiatry in Salzburg, Austria
11046307|NCT04454736|Experimental|SBGhealthy|Healthy children and adolescents from schools in Salzburg, Austria
11046308|NCT04454736|Experimental|VIEhealthy|Members from the Vienna Boys Choir, Austria
11046309|NCT04454723|Experimental|Tranfusions and blood collection|"Patients enrolled will receive one unit each of blood and/or platelet transfusions once a week based on trigger symptoms of anemia and/or thrombocytopenia, along with blood sample collections.
~Data on patient demographics, disease, and length of hospice stay will also be collected."
11046310|NCT04454710|Active Comparator|Real Pulsed Radiofrequency|The participant will receive real pulsed radiofrequency for 2 minutes at a frequency of 2 pulses per second (2Hz) while lie in the supine position with their leg of interest partially flexed about 45 degrees and externally rotated. The full procedure will take eight minutes, composed of four sessions of 2 minutes in which the temperature was maintained below 42°C.
11046311|NCT04454710|Sham Comparator|Sham Pulsed Radiofrequency|Identical to the real pulsed radiofrequency, except the participants will only receive the initial 2 seconds of ramp-up, after which the device will switch-off for the rest of the session and will turn-on again at the end of the session.
11046312|NCT04454697|Experimental|Intervention|Patient receive personalized 3D-printed GWR
11046313|NCT04454697|Active Comparator|Control|Patient receive standardized radiation protection tooth splints
11046314|NCT04454684|Experimental|AN-R: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
11046315|NCT04454684|Experimental|BED: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
11046316|NCT04454684|Experimental|Caregivers: Psychotherapy|Psychotherapy alone
11046317|NCT04454671|Experimental|ultrasound-guided percutaneous neuromodulation|Technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor point. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
11046318|NCT04454671|Placebo Comparator|Ultrasound-guided dry needling|Dry needling technique applied by ultrasound-guided but without electrical stimulation of a peripheral nerve.
11046319|NCT04454658|Experimental|Segment A: ABBV-744 Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.
11046320|NCT04454658|Experimental|Segment A: ABBV-744 Monotherapy|Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.
11046321|NCT04454658|Experimental|"Segment B: Ruxolitinib + ABBV-744 Add on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as add-on therapy."
11046322|NCT04454658|Experimental|Segment C: ABBV-744 + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.
11046323|NCT04454658|Experimental|Segment D: ABBV-744 + Ruxolitinib|Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.
11046324|NCT04454645|Experimental|Modified ABC|12-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
11046325|NCT04454645|Active Comparator|Modified DEF|12-session home visiting intervention designed to increase parental playful interactions that stimulate infant cognitive and motor development
11046326|NCT04454632|Experimental|Mirror therapy group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the mirror therapy group bilateral exercised with the affected arm behind the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation.
11046327|NCT04454632|Experimental|Visual feedback group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the visual feedback group bilateral exercised by seeing both arms in the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
11046328|NCT04454632|No Intervention|Control group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the control group bilateral exercised without a mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
11046329|NCT04454619|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propanolol-1 60% as control
11046330|NCT04454619|Experimental|Hand antisepsis with Clorhexidina and solution|chlorhexidine gluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.
11046331|NCT04454606|Experimental|Fit test|All the subjects will be tested for fit test
11046332|NCT04454593||Lateral patellar compression syndrome|Patients diagnosed with lateral patellar compression syndrome between February 2016 and April 2019
11046333|NCT04454593||patellar dislocation|Patients diagnosed with patellar dislocation between February 2016 and April 2019
11046334|NCT04454593||meniscus tear|Patients diagnosed with meniscus tear between February 2016 and April 2019
11046335|NCT04454580||treated patients|hypomethylating agent (azacitidine or decitabine) in combination with venetoclax
11046336|NCT04454567|Experimental|ABI-H0731 + SOC NrtI|Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).
11046337|NCT04454567|Placebo Comparator|Placebo + SOC NrtI|Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.
11046663|NCT04452266||case group|Women with Lynch Syndrome and endometrial Cancer matched on age of endometrial cancer diagnosis
11046338|NCT04454541|Active Comparator|Greater occipital nerve block with ultrasound|A-Greater occipital nerve block The ultrasound-guided GONB was performed to more accurately locate the nerve. The patient was asked to lie prone on the table. To locate the nerve, we searched for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp was cleaned with iodine. After that, the skin was sterilized, and the probe was sheathed in a sterile plastic package GONB was performed by applying the injection to the medial of the artery. A 22-gauge needle was advanced beneath the lateral border of the probe using real-time ultrasound guidance and an in-plane technique. In all patients the occipital nerve was seen medial to the artery. The injected side was determined by the patients' clinical symptoms and according to the painful side reported in their headache diaries. The patients were required to lie down for 30 minutes after the injection to avoid dizziness.
11046339|NCT04454541|Experimental|Multifidus cervicis plane block with ultrasound guided|Patients placed in a lateral position with their affected side upwards. Several gel cushions were placed under their head, neck, and arm to put the neck in a stable and slightly anterior flexion position spinal level was determined by identifying the transverse process of the seventh and sixth cervical vertebrae (C7 and C6). The seventh cervical transverse process (C7) differs from the levels above by having a rudimentary anterior tubercle and a prominent posterior tubercle. After aseptic preparation of the injection area, lidocaine 1% was used to anesthetize the skin. Under continuous ultrasound guidance, the needle (22-G, 0.7 mm × 60 mm, Plexufx, B-BRAUN, Tokyo, Japan) was introduced in-plane through the skin and advanced into the fascial plane between the multifidus cervicis and semispinalis cervicis muscles for the MCP block.
11046340|NCT04454528|Active Comparator|Arm 1|Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
11046341|NCT04454528|Active Comparator|Arm 2|Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
11046342|NCT04454528|Active Comparator|Arm 3|Arm 3 will receive pembrolizumab on day -14. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
11046343|NCT04454528|Other|Arm 4|Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
11046344|NCT04454515|Experimental|dexmedetomidine|patient recieving dexmedetomidine
11046345|NCT04454515|Placebo Comparator|placebo|patients receiving placebo
11046346|NCT04454502|Experimental|Experimental|"In the first stage of data collection, the information in the Mother-Preterm Introductory Information Form study and control groups before colostrum administration, and the information in Preterm Follow-up Form including questions related to physiological parameters, body measurements and nutrition will be obtained. In the second stage, oral colostrum, will be administered once every 3 hours and for at least 5 days until the newborn begins oral feeding. In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered in approximately 1 minute for infants weighing between 1001-1500 g. The third stage, the effectiveness of the first breastfeeding will be evaluated by the observers in experimental group using the Bristol Breastfeeding Assessment Tool. In the last stage, one week after the first breastfeeding sucking / breastfeeding experience will be evaluated again."
11046347|NCT04454502|No Intervention|Control Groups|The infants in the control group will be followed up by oral care with sterile physiological saline in routine care of the service
11046348|NCT04454489|Experimental|Quad-shot palliative radiotherapy and Immunotherapy|Systemic therapy (ICI) and radiotherapy will be administered according to the standard of care, according to the treating medical oncologist and radiation oncologist, respectively
11046349|NCT04454476|Experimental|Trametinib treatment|
11046350|NCT04454463||Adult patients with NAFLD|1500 patients 18 years and older at the time of enrollment.
11046351|NCT04454463||Pediatric patients with NAFLD|750 patients 2 years or older and up to 17 years old at the time of enrollment.
11046352|NCT04454450|Experimental|Imaged prior to primary debulking surgery|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection. Concretely, in patients triaged to primary debulking surgery (PDS), PET/MRI will be obtained within 30 days preceding multi-region tissue collection at the time of PDS (already being done under IRB# 06-107).
11046353|NCT04454450|Experimental|Imaged pre/postneoadjuvant chemotherapy (NACT)|In patients triaged to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), PET/MRI will be obtained at two time points, i.e. first within 30 days preceding NACT/ multi-region laparoscopic tissue sampling (already being done under IRB# 06-107) and, second, any time after completion of NACT and before multi-region tissue collection at the time of interval debulking surgery (already being done under IRB# 06-107).
11046354|NCT04454437|Other|Arm A|
11046355|NCT04454424|Experimental|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
11046356|NCT04454424|Experimental|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
11046357|NCT04454424|Experimental|Arm C: Child-Pugh C|Participants with severely impaired hepatic function (Child-Pugh C)
11046358|NCT04454424|Experimental|Arm D: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
11046359|NCT04454424|Experimental|Arm E: Normal hepatic (Matched to C)|Participants with normal hepatic function matched to Arm C
11046360|NCT04454411|Experimental|Buprenorphine|Participants assigned to treatment with extended-release buprenorphine
11046361|NCT04454411|Active Comparator|Naltrexone|Participants assigned to treatment with extended-release naltrexone
11046362|NCT04454398|Experimental|COVI-GUARD|COVI-GUARD (STI-1499) administered via a single IV push injection at a dose of 10 mg, 30 mg, 100 mg, or 200 mg, in addition to standard of care
11046363|NCT04454398|Placebo Comparator|Placebo|Placebo administered via a single IV push injection, in addition to standard of care
11046364|NCT04454359|Experimental|EXP|EXP group will ingest a supplement consisting of 1) flavored whey protein isolate with added pure leucine (3 g) diluted in water, twice daily, before breakfast and before bedtime; doses are adjusted per body weight as follows: 20 g, 25 g or 30 g per category of <65 kg, 65-75 kg and >75 kg of body weight respectively. 2) fish oil containing vitamin D, provided as 7.5 mL liquid oil providing 1500 IU vitamin D3 + 1125 mg EPA + 750 mg DHA, to be ingested once daily.
11046365|NCT04454359|Placebo Comparator|CTR|Control will ingest an isocaloric placebo consisting of 1) 30 g maltodextrin, twice daily, following the same schedule, and 2) 7.5 mL corn oil, once daily.
11046366|NCT04454346|Experimental|double Foley Catheter|
11046367|NCT04454346|Experimental|Single Foley Catheter|
11046368|NCT04454346|Experimental|Cook Baloon|
11046369|NCT04454333||Hospitalized caused by COVID-19|A total of 466 patients hospitalized with the diagnosis of SARS-COV-2 at the University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital were retrospectively screened. 212 of these patients did not answer the calls, 34 of them could not be reached because they gave the wrong phone number beforehand. 4 of the patients called by the phone had communication problems due to language problems and 10 people did not want to fill the questionnaire. 206 of them were contacted by the phone and their pain and myalgia in the head, neck-back, waist, shoulder and hip regions before, during and after SARS-COV-2, their anxiety and depression levels after SARS-COV-2, and their quality of life were questioned.
11046370|NCT04454307|Experimental|Tramadol|tramadol 100 mg twice daily for 10 days
11046371|NCT04454307|Active Comparator|standard care|standard care plus (placebo twice daily for 10 days).
11046372|NCT04454294|Experimental|Control|The first method; There is no application in maintaining the drain opening, but if there are necessary medical indications such as clot formation, blood accumulation in the drainage connections, lack of drainage, this group is intervened by milking method. In our study, this group will be taken as a control group, there will be a situation that requires intervention in the first 6 hours, and if the milking method is used, it will be excluded from the sample.
11046373|NCT04454294|Experimental|Experimental Group (Absorption Group)|The second method used to maintain the drain opening is the suction method. In this study, this group will be taken as the first experimental group. The suction method is a continuous use until the patient's drainage requirement and the physician's request is terminated by ensuring that the pressure is between 5 and 15 kPa (kilopascals) or 10-20 cm H20 after the appropriate negative pressure tracking system of the patient, who is accepted with intensive care under water drainage system, is established. system.
11046374|NCT04454294|Experimental|Experimental Group (Milking Group)|The third method is milking. In our study, this group will be taken as the 2nd experimental group. In the milking method, the process starts from the area close to the drain entry point. The latex tube is folded into 12 cm long pieces and gripped with two hands. The nurse repeats the process 3 times by compressing the parts gripped by the hand. This process is then used at intervals every hour to repeat the distal part.
11046375|NCT04454281|Experimental|Naloxone HCl Low dose: 0.02 mg|This arm will receive 0.02 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
11046376|NCT04454281|Experimental|Naloxone HCl High dose: 0.08 mg|This arm will receive 0.08 mg naloxone hcl on the experimental visit and balance salt solution on the control visit.
11046377|NCT04454268|Other|hydatid cyst|
11046378|NCT04454255|Experimental|Primo-FunSpeech|Participants will begin the study by a period using FunSpeech (45 days) followed by a control period without the game (45 days). This sequence will be repeated once.
11046379|NCT04454255|Experimental|Primo-control|Participants will begin the study by a control period without the game (45 days) followed by a period using FunSpeech (45 days). This sequence will be repeated once.
11046380|NCT04454242|Experimental|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 8 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.
~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
11046381|NCT04454242|Active Comparator|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 8 weeks will be trained with a 1-minute rest cycle in 5 breaths.
~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
11046382|NCT04454229|Experimental|Direct oral antibiotic challenge|Direct oral antibiotic (penicillin) challenge in patients with PEN-Fast less than 3.
11046383|NCT04454229|Active Comparator|Standard of care|Standard of care: skin testing and, if negative, oral challenge.
11046384|NCT04454203|Experimental|Mepivacaine Block Group|Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.
11046385|NCT04454203|Placebo Comparator|Saline Sham Group|Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.
11046386|NCT04454190||Glaucoma - Slow progressors|Rates of MD change slower than -0.50 dB/year Rates of global RNFL thickness change slower than -1.0 µm/year
11046387|NCT04454190||Glaucoma - Fast progressors|Rates of MD change faster -0.50 to -2.00 dB/year Rates of global RNFL thickness change -1.0 to -4.0 µm/year
11046388|NCT04454190||Glaucoma - Catastrophic progressors|Rates of MD change faster than -2.00 dB/year Rates of global RNFL thickness change faster than -4.0 µm/year
11046389|NCT04454177||SMART watch|Medical records from patients aged 18 years or older undergoing Transcatheter Aortic Valve Replacement
11046390|NCT04454164|Experimental|PRP group|Intraarticular 5 ml single PRP injection
11046391|NCT04454164|Placebo Comparator|Saline group|Intraarticular 5 ml single saline injection
11046392|NCT04454164|Experimental|Multiple PRP group|Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)
11046393|NCT04454164|Placebo Comparator|Multiple saline group|Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)
11046394|NCT04454151|Experimental|Azithromycin|1x250
11046395|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
11046396|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
11046397|NCT04454125|Active Comparator|Routine Care|
11046398|NCT04454125|Experimental|AQI Intervention|
11046428|NCT04453800|Experimental|Group A ：low dose sofadil|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
11046664|NCT04452266||control group|Women with Lynch Syndrome, without Cancer at Lynch Syndrome Diagnostic matched on their age at Lynch Diagnostic
11046399|NCT04454112|Experimental|24-hour esophageal pH monitoring|24-hour esophageal pH monitoring was conducted using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands). This system consists of a portable data logger (MMS Investigation and Diagnostic Software®) and a disposable catheter which contains two pH electrodes (Unisensor, Attikon, Switzerland). Before recording, the pH electrode was calibrated in the special buffer solutions at pH values of 1 and 2.
11046400|NCT04454099||Fecal Occult Blood Test|People in this group will use four kind of fecal occult blood test, including quantitative and qualitative method, to detect Hb in stool before colonoscopy.
11046401|NCT04454086|Experimental|Supportive care (exercise program, counseling)|Patients undergo aerobic exercise over 10-30 minutes and resistance exercise comprising 1-3 sets of 8-12 repetitions of 10 different exercises over 1 hour for 24 weeks. Patients also receive behavioral activity counseling once a week and nutritional counseling over 30 minutes for 10 sessions after center-based exercise sessions during months 1-2.
11046402|NCT04454073||Bipolar patients|In euthymic state or with mild to moderate symptoms
11046403|NCT04454060||Extracapsular method group|consecutive 43 patients who received extracapsular method treatment for refractory tennis elbow
11046404|NCT04454047||Extracapsular method group|50 patients with refractory tennis elbow who received extracapsular arthroscopic surgery.
11046405|NCT04454034||Group1|The refractory elbow RA who undergo arthroscopic synovectomy
11046406|NCT04454008|Experimental|Intervention|The intervention group will receive 12 sessions of executive function family training, including executive function training for children and parenting guidance for parents.
11046407|NCT04454008|Active Comparator|waiting|The waiting group will receive routine clinical intervention, including health education, family support and guidance from outpatient clinic.
11046408|NCT04453982||Human milk donors|
11046409|NCT04453969||Breastfeeding mothers positive for COVID-19|
11046410|NCT04453956|Sham Comparator|Control group|Patients will receive colonoscopy without assistance of EndoAngel's any function.
11046411|NCT04453956|Experimental|Polyp detection function group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection function.
11046412|NCT04453956|Experimental|Quality monitoring function group|Patients will receive colonoscopy with the assistance of EndoAngel's quality monitoring function.
11046413|NCT04453956|Experimental|Polyp detection plus quality monitoring functions group|Patients will receive colonoscopy with the assistance of EndoAngel's polyp detection plus quality monitoring function.
11046414|NCT04453943|Experimental|Group A - SCI|Ten individuals with SCI at the T1-T10 level will be recruited (Group A). These individuals can have incomplete or complete paraplegia.
11046415|NCT04453943|Experimental|Group B - Subjects without disability|Twenty individuals without disability will be recruited (Group B). Individuals with SCI who have experience in using some kind of walking assistive devices in the recent past will be preferably recruited.
11046416|NCT04453930|Experimental|Camrelizumab+Irinotecan+Platinum→Camrelizumab+apatinib|Participants received intravenous infusions of Camrelizumab 200 mg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) or Cisplatin 30 milligrams per square meter (mg/m^2) followed by Irinotecan 65 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4/5/6). On Days 8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6), Cisplatin 30 mg/m^2 and Irinotecan 65 mg/m^2 was administered. Thereafter, participants received maintenance (Cycle onward) Camrelizumab 200 mg on Day 1 of every 21-day cycle with Apatinib 250mg until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
11046417|NCT04453917|Experimental|Patients with active PML|Patients with neurological symptoms (< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV
11046418|NCT04453904|Experimental|"sequential radiochemotherapy in a sanwich mode"|Two courses of TC regimen chemotherapy (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) will be given first, followed by external pelvic radiation (± vaginal brachytherapy), and then four courses of the same regime consolidation chemotherapy.
11046419|NCT04453904|Active Comparator|concurrent chemoradiotherapy followed by chemotherapy|External pelvic radiation (± vaginal brachytherapy) will be given after operation. On the first day and the 29th day of radiotherapy, concurrent intravenous cisplatin (50mg/m2) will be given. After the concurrent radiochemotherapy, four courses of TC regimen (paclitaxel 135-175mg / m2; carboplatin AUC = 5; once every 21 days) chemotherapy will be given.
11046420|NCT04453865|Experimental|Project BRAVE|"Project BRAVE is a web-based, self administered SSI for parents that takes about 30 minutes to complete. The program includes 5 elements, based on current best-practices in SSI design (Schleider, Dobias, Sung, & Mullarkey, in press) and existing, therapist-delivered interventions targeting accommodation (Lebowitz & Omer, 2014): (1) an introduction to the program's rationale; (2) psychoeducation around child anxiety and avoidance, along with how parental accommodation can inadvertently maintain child anxiety; (3) information on how parents can better identify children's patterns of avoidance and encourage brave behavior instead; (4) facilitating parents' creation of an action plan for promoting brave behavior and reduce avoidance in their own child; (5) a vignette exercise in which parents read about another family's difficulty managing their child's anxiety; parents identify the elements of the anxiety cycle and provide possible solutions to these parents based on what they learned."
11046421|NCT04453865|Other|Online Resources and Referrals (ORR)|Online Resources and Referrals (ORR) is an information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment. ORR does not include any psychoeducational components regarding parental accommodation.
11046422|NCT04453852|Experimental|Group A|Spike antigen (25ug) + 15 mg Advax-2 adjuvant
11046423|NCT04453852|Placebo Comparator|Group B|Saline
11046424|NCT04453826|Experimental|Camrelizumab plus chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.
11046425|NCT04453826|Active Comparator|Chemo-radiotherapy arm|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy.
11046426|NCT04453813|Experimental|Toripalimab plus concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.
11046427|NCT04453813|Active Comparator|Concurrent chemo-radiotherapy arm|Concurrent chemo-radiotherapy alone.
11046429|NCT04453800|Experimental|Group B: Medium dose group|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
11046430|NCT04453800|Experimental|Group C: high dose group|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
11046431|NCT04453800|Placebo Comparator|Group D: placebo group|Saline was administered intravenously
11046432|NCT04453787|Experimental|Arch support orthoses with forefoot medial wedge|The intervention of this group include orthoses with arch support and added forefoot medial wedge.
11046433|NCT04453787|Experimental|Arch support orthoses|The intervention of this group include orthoses with arch support.
11046434|NCT04453787|Sham Comparator|Flat insole|This group will wear a flat insole. It is made from ethylene-vinyl acetate copolymer with 4mm thickness. It only provide shock absorbtion.
11046435|NCT04453774|Experimental|Covi19 patients receiving intervention|We will collect self-reported symptoms via a questionnaire, temperature and oxygen saturation will be entered by the patient and passive near continuous sensing of heart rate, audio for cough detection, respiratory rate, cough and physical activity from a smart watch. The smart watch then transmits this sensor data to the paired smartphone.
11046436|NCT04453761|Experimental|Drugs Group|Thiamine IV
11046437|NCT04453761|Placebo Comparator|Placebo|NaCl IV
11046438|NCT04453748||COVID-19 convalescents|People who recovered from COVID-19: have no symptoms and no SARS-Cov2 RNA in PCR
11046439|NCT04453735|Active Comparator|Intervention|Atorvastatin mylan 40 mg once daily
11046440|NCT04453735|No Intervention|Control|No statin therapy
11046441|NCT04453722||Oxalert in monitor only mode|Randomization will be to Oxalert in monitor-only mode
11046442|NCT04453722||Oxalert in monitor in normal mode|Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.
11046443|NCT04453709|Experimental|Problem Management Plus for Immigrants at family settings|PMP-I intervention aims to develop skills in coping adaptively in a new culture, seeking help and support for mental health problems, and other life skills opportunities that can help to improve their quality of life. PMP-I intervention includes stress management through breathing exercises and yoga, problem solving, behavioral activation, and skills to strengthen social support.
11046444|NCT04453709|Active Comparator|Talk program with Community Support Service Pamphlet (CSS)|Family receives pamphlet including list of community support service institutions that provide various health and well-being services.
11046445|NCT04453696||Communication before operation|Communication was established before the operation.
11046446|NCT04453696||Communication after operation|Communication was established after the operation.
11046447|NCT04453696||Communication before and after operation|Communication took place both before and after the operation.
11046448|NCT04453696||No communication|No communication.
11046449|NCT04453683|Active Comparator|Group I ( Air Q)|nsertion of proper size Air-Q. ILA
11046450|NCT04453683|Active Comparator|Group II (ILMA)|nsertion of proper size ILMA
11046451|NCT04453670||COVID-19 non-survivors|ICU adults who died from severe COVID-19 and in whom autopsy could be performed
11046452|NCT04453657|Experimental|Intervention|There is only one arm in this study. All recruited and consented participants will fill out a pre-survey, engage with the digital toolkit for 15 weeks, then fill out a post-survey.
11046453|NCT04453644|Experimental|Group A (Hamstrings)|Hamstring stretching would be done then isometric strength would be measured.
11046454|NCT04453644|Experimental|Group B (Calf)|Calf stretching would be done then isometric strength would be measured.
11046455|NCT04453631|Experimental|active tDCS + CBT-UP|Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
11046456|NCT04453631|Active Comparator|sham tDCS + CBT-UP|Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
11046457|NCT04453631|Active Comparator|active tDCS + Psychoeducation|Active tDCS combined with psychoeducation (control condition for CBT-UP).
11046458|NCT04453631|Placebo Comparator|sham tDCS + Psychoeducation|Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
11046459|NCT04453618|Experimental|Food effect|Healthy subjects receive a single dose of SYHA1402 (100mg) in either a fasted state or with a meal.
11046460|NCT04453618|Experimental|Multiple doses 25mg|Healthy subjects receive multiple doses of SYHA1402 (25mg) or Placebo(25mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
11046461|NCT04453618|Experimental|Multiple doses 50mg|Healthy subjects receive multiple doses of SYHA1402 (50mg) or Placebo (50mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
11046462|NCT04453618|Experimental|Multiple doses 150mg|Healthy subjects receive multiple doses of SYHA1402 (150mg) or Placebo (150mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
11046463|NCT04453605||Patients with neo-diagnosed type 2 diabetes|Patients referring for the first time to the outpatient diabetes clinic in the department of Internal Medicine between January 2008 and December 2015 and matching the inclusion criteria.
11046464|NCT04453579||116 patients completed a survey|116 patients were assessed during the Italian lockdown by means of a telephone interview performed by a trained researcher. The interview was composed of socio-demographic items (e.g. employed before and during the lockdown, own accommodation during lockdown etc.) and questions about physical and mental health in relation to the COVID-19 emergency
11046465|NCT04453566||Elite Athletes|Elite Athletes
11046466|NCT04453553|Active Comparator|Standard of care|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
11046467|NCT04453553|Experimental|Near Patient Testing|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
11046468|NCT04453514|Experimental|Trauma-informed yoga video recording|Participants will complete a single trauma-informed yoga practice using a 45-minute guided video recording.
11046469|NCT04453501||Azithromycin or non-azithromycin group|Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
11046588|NCT04452838|Other|Cohort 2 Sequence 1 (Part B)|Treatment Sequence E, F, G, and H
11046470|NCT04453488|Experimental|RUTI® vaccine|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
11046471|NCT04453488|Placebo Comparator|Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
11046472|NCT04453475|Experimental|Partial digital group: depression|"Burg
~Online depression session as a flipped classroom"
11046473|NCT04453475|Experimental|Partial digital group: social work (social medicine)|"NOR
~Online lecture with socio-medical content"
11046474|NCT04453475|Experimental|Partial digital group: depression + social work|"JUL
~Online depression session as a flipped classroom and an online lecture with socio-medical content"
11046475|NCT04453475|Active Comparator|Control group: only digital training before rehabilitation|"MOE
~Does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups)"
11046476|NCT04453475|No Intervention|No Treatment Control Group|"Paracelsus Clinic
~does not provide any of the interventions"
11046477|NCT04453462|Active Comparator|Local direct median nerve block|
11046478|NCT04453462|Active Comparator|Brachial plexus block|
11046479|NCT04453449||No sedation|Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).
11046480|NCT04453449||Sedation|Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).
11046481|NCT04453436||Virologic failure|Viral load above detection limits at window period
11046482|NCT04453436||Virologic Success|Viral load bellow detection limits at window period
11046483|NCT04453423|Other|First-line Treatment|
11046484|NCT04453423|Experimental|Maintenance Treatment A|
11046485|NCT04453423|Experimental|Maintenance Treatment B|
11046486|NCT04453423|Experimental|Maintenance Treatment C|
11046487|NCT04453384|Experimental|Treatment arm|"Administrations of XAV-19
~Phase 2a: XAV-19 at 0.5 mg/kg (Group 1) or at 2 mg/kg (Group 2)
~Phase 2b: Selected dose from Phase 2a"
11046488|NCT04453384|Placebo Comparator|Placebo arm|"same administration as treatment arm
~Phase 2a: two administrations of placebo on day 1 and day 5
~Phase 2b: two administrations of placebo on day 1 and day 5"
11046489|NCT04453371|Experimental|Study group|Thrombolysis
11046490|NCT04453371|Placebo Comparator|Control group|Ringer's solution infusion
11046491|NCT04453358|Active Comparator|Interactive coaching|Airway clearance therapy using goal setting and interactive feedback.
11046492|NCT04453358|Active Comparator|Standard of care coaching|Standard of care airway clearance therapy.
11046493|NCT04453345|Experimental|TPM regimen|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
11046494|NCT04453332|Active Comparator|Oral hormone therapy|Estradiol 1mg and micronized natural progesterone 200mg 14 days a month (oral)
11046495|NCT04453332|Active Comparator|Non-oral hormone therapy|Percutaneous estradiol gel 1.5mg and micronized progesterone 200mg vaginal 14 days a month (non-oral)
11046496|NCT04453319|Experimental|Application of the device (PICO)|PICO® is a disposable, single-use pump without a canister that generates an effective, non-adjustable, negative pressure of -80 mmHg and that can be used for up to 7 days.(-1113) It incorporates leak detection and low battery indicators and is connected to a 4-layer absorbent dressing that primarily removes wound exudates through evaporative loss. The mechanism of action has been postulated to occur because of the combined effects of a reduction in the frequency of dressing changes, a reduction in stress concentration in the tissue surrounding the incision, and an enhancement in the appositional strength of the incision line, thus reducing dead space and minimizing the risk of wound contamination.(14) PICO® has also been demonstrated to enhance lymphatic clearance and decrease the risk of hematomas or seromas
11046497|NCT04453319|No Intervention|Conventional Dressing of the femoral wound|Conventional Dressing of the femoral wound
11046498|NCT04453306|Placebo Comparator|placebo|"Patients with the same characteristics as the intervention group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.
~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
11046499|NCT04453306|Experimental|intervention|"Patients with the same characteristics as the placebo group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.
~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
11046500|NCT04453293|Experimental|BCG vaccine|Freeze-dried Glutamate Bacillus Calmette-Guérin (BCG) (Tokyo 172) vaccine
11046501|NCT04453293|Placebo Comparator|Placebo|Vaccine diluent [sodium glutamate]
11046502|NCT04453280||Cohort 1 - Prague and Central Bohemian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - Prague and Central Bohemian Region population
11046503|NCT04453280||Cohort 2 - South Moravian Region|A population cohort of cured patients based on epidemiologically defined demographic parameters - South Moravian Region population.
11046504|NCT04453267||Patient Arm.|"Consecutive patients undergoing elective percutaneous coronary intervention (PCI) or isolated coronary artery bypass grafting (CABG) for symptomatic stable angina (SA) despite optimal medical therapy at the University Hospital Southampton NHS Foundation Trust will be prospectively enrolled (n=86).
~No interventions administered. 40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
11046505|NCT04453267||Age and gender matched controls|"Age and gender-matched patients being investigated for chest pain with unobstructed coronary arteries, defined as coronary stenosis ≤ 30% in any major epicardial vessel on CT or invasive coronary angiography, will also be recruited as controls (n=86).
~40ml of whole blood in EDTA vials to be taken for cellular separation and analysis."
11046506|NCT04453254|Active Comparator|Whole Food Meal|A whole meal consisting of 1 cup 2% milk, 1 cup Kashi Go Lean Original cereal, ¼ cup of almonds, ¼ cup of strawberries, and ¼ cup of raspberries.
11046507|NCT04453254|Active Comparator|Supplement Food Meal|A supplemental meal equivalent consisting of 1 cup 2% milk, 20 g whey protein, ½ EAS Myoplex bar, and ½ Balance bar.
11046508|NCT04453241|Experimental|NBP615|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
11046509|NCT04453241|Active Comparator|GARDASIL|Adult : 3 doses of vaccination Adolescent :2 doses of vaccination
11046510|NCT04453228||2017-2018 snow season|Injured skiers in the 2017-2018 snow season
11046511|NCT04453228||2018-2019 snow season|Injured skiers in the 2018-2019 snow season
11046512|NCT04453215|Experimental|mild group|patients with mild systemic lupus erythematosus
11046513|NCT04453215|Experimental|moderate group|patients with moderate systemic lupus erythematosus
11046514|NCT04453215|Experimental|severe group|patients with severe systemic lupus erythematosus
11046515|NCT04453202|Experimental|Cohort 1 Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an Ad26-based RSV vaccine on Day 1.
11046516|NCT04453202|Experimental|Cohort 1 Group 2: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 1) on Day 1.
11046517|NCT04453202|Experimental|Cohort 1 Group 3: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 2) on Day 1.
11046518|NCT04453202|Experimental|Cohort 1 Group 4: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 3) on Day 1.
11046519|NCT04453202|Placebo Comparator|Cohort 1 Group 5: Placebo|Participants will receive IM injection of placebo on Day 1.
11046520|NCT04453202|Experimental|Cohort 2 Group 6: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
11046521|NCT04453202|Experimental|Cohort 2 Group 7: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 1) on Day 1.
11046522|NCT04453202|Placebo Comparator|Cohort 2 Group 8: Placebo|Participants will receive IM injection of placebo on Day 1.
11046523|NCT04453202|Experimental|Cohort 3 Group 9: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
11046524|NCT04453202|Experimental|Cohort 3 Group 10: RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 2) on Day 1.
11046525|NCT04453202|Experimental|Cohort 3 Group 11: Placebo|Participants will receive IM injection of placebo on Day 1.
11046526|NCT04453189|Experimental|Treatment Sequence: AB(Part 1) followed by C(Part 2-Optional)|Participants will received Treatment A (single dose of JNJ-64417184 in fed condition on Day 1) in period 1 followed by Treatment B (lansoprazole on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5) in period 2 of part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
11046527|NCT04453189|Experimental|Treatment Sequence: BA(Part 1) followed by C(Part 2-Optional)|Participants will receive Treatment B in period 1 followed by Treatment A in period 2, Part 1. There will be a washout period of 7 days between each treatment. Participants will receive Treatment C: optional (famotidine under fasted conditions administered 12 hours before and 12 hours after a single dose of JNJ-64417184 under fed conditions on Day 1) in Part 2, Period 3.
11046528|NCT04453176||"operating block admission on foot"|Patient going to the oparating block on foot
11046529|NCT04453176||standard operating block admission|Patient going to the operating room in a conventional way (stretcher)
11046530|NCT04453163|Experimental|RAAC program|"If the patient is under the RAAC group, he/she will then be received in consultation by a RAAC specialist nurse, between the anesthesia / radiology consultation and the intervention. This RAAC nurse will explain the procedure and show him/her an information video on vertebroplasty. Information about managing anxiety and pain will also be provided. In addition, the day after the patient leaves the clinic, the RAAC nurse will call him/her to inquire."
11046531|NCT04453163|Other|Standard management program|"If the patient is under the control group, he/she will be taken care of according to the standard protocol after a surgery in percutaneous vertebroplasty. The patient will not have a consultation with the specialized nurse."
11046532|NCT04453150|Experimental|Standard hypocaloric diet|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits 3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
11046533|NCT04453150|Experimental|Intermittent fasting 16/8 (early fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 12 am. to 8 pm.), maintaining 16 fasting hours (from 8 pm. to 12 am. the following day).
11046534|NCT04453150|Experimental|Intermittent fasting 16/8 (late fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
11046535|NCT04453150|Experimental|Alternate-day fasting|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
11046536|NCT04453150|Experimental|Ketogenic diet|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein.
11046589|NCT04452838|Other|Cohort 2 Sequence 2 (Part B)|Treatment Sequence E, F, H and G
11046590|NCT04452838|Other|Cohort 2 Sequence 3 (Part B)|Treatment Sequence F, E, G, and H
11046591|NCT04452838|Other|Cohort 2 Sequence 4 (Part B)|Treatment sequence F, E, H, and G
11046537|NCT04453137|Active Comparator|Humira 40 mg/mL (Adalimumab Originator)|During the LeadIn Period, patients will receive Humira (initial dose of 80 mg [2 × 40 mg] administered subcutaneously [SC], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index [PASI] ≥ 75 [PASI75]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.
11046538|NCT04453137|Active Comparator|IC - Humira 40 mg/mL (Adalimumab Originator)|patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)
11046539|NCT04453137|Experimental|IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)|"patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:
~Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections),
~Sw2-Humira (40 mg every other week) for 4 weeks (2 injections),
~Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections)."
11046540|NCT04453137|Experimental|AVT02 40 mg/mL (Adalimimab Biosimilar)|At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 [PASI50]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.
11046541|NCT04453124|No Intervention|Soap and Water|Standard of care using soap and water
11046542|NCT04453124|Experimental|Ficus Septica Sap|Ficus Septica Sap, topical cream, 50ul, daily, for 2 days
11046543|NCT04453124|Active Comparator|Chlorhexidine (Topical)|Chlorhexidine, topical solution, 50ul, daily, for 2 days
11046544|NCT04453111|Experimental|Hyaluronic Acid (HA) + P-MMSCs|Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
11046545|NCT04453111|Experimental|Hyaluronic Acid (HA) + BM-MMSCs|Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients
11046546|NCT04453111|Active Comparator|Hyaluronic Acid (HA)|Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients
11046547|NCT04453098|Experimental|Re group|high-Resistance-moderate-endurance, participants performed 10 repetitions at 70% of one maximal repetition in resistance and 30% of VO2-peak for endurance training
11046548|NCT04453098|Experimental|rE group|moderate-resistance (30%) - high-Endurance (70%)
11046549|NCT04453098|Experimental|re group|moderate-resistance (30%) - moderate-endurance (30%).
11046550|NCT04453098|No Intervention|control group|no intervention
11046551|NCT04453085|Experimental|JR-171|Until the dose determination, subjects will intravenously receive either the low dose or high dose of JR-171 (the same dose as at Week 12 of the JR-171-101 study). Thereafter, all subjects will receive the optimal dose of JR-171 determined based on the results of JR-171-101 study.
11046552|NCT04453072|Experimental|Supportive Care (app, scales, coaching, questionnaire)|Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.
11046553|NCT04453046|Experimental|Hemopurifier and Pembrolizumab|In this clinical trial, the exosome-depleting device, the Hemopurifier, will be combined with standard of care therapy, Pembrolizumab. The purpose of the combination is to more effectively reduce immune suppression and provide a combined benefit of immune restoration for patients with recurrent/metastatic HNSCC. Therapy with the Hemopurifier will be initiated on the same day as and prior to Pembrolizumab infusion. The Hemopurifier treatment will be 4h. The subject treated with the Hemopurifier will remain in the Hemopurifier treatment area for the duration of the treatment. Pembrolizumab infusion will take place shortly after Hemopurifier treatment and may take place through the next day if needed.
11046554|NCT04453033|Active Comparator|Investigational Device|The Celeste device resembles a large tablet. It has a protective cover that folds into a stand and is magnetically attached to the back of the device. It produces a low intensity of specific bandwidths of light believed to be responsible for circadian and alerting responses in humans. The overall emission produces a pleasing soft glow of light.
11046555|NCT04453033|Sham Comparator|Control Device|The Control device is identical in appearance to Celeste. When turned on, the device emits a soft diffused light that is indistinguishable in color from the Active Device. However, this device produces a different amount of the specific wavelengths thought to be effective in the Active Device.
11046556|NCT04453020|Experimental|LHA DBS|Subjects will receive bilateral DBS of the LHA
11046557|NCT04453007|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Any follow-up emails sent to them later contain only a reminder to participate in follow-up surveys.
11046558|NCT04453007|Active Comparator|Intervention plus 2-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 2 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
11046559|NCT04453007|Active Comparator|Intervention plus 6-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 6 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
11046560|NCT04453007|Active Comparator|Intervention plus 10-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 10 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
11046561|NCT04453007|Active Comparator|Intervention plus 14-week feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the feedback booster email 14 weeks later. It contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
11046562|NCT04453007|Active Comparator|Intervention plus repeated feedback boosters|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receive the multiple feedback booster emails, 2, 6, 10, and 14 weeks later. Each time, the email contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant-reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies.
11046563|NCT04452981|Active Comparator|Active|The active device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
11046564|NCT04452981|Sham Comparator|Sham|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
11046565|NCT04452968|Experimental|intermittent fasting|"Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
~Women were told about timed restricted feeding. They were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours."
11046566|NCT04452968|Active Comparator|caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
11046567|NCT04452955|Experimental|PRL3-zumab|All patients will receive PRL3-zumab until clinical progression per RECIST v1.1 criteria, or unacceptable toxicity, or withdraws consent.
11046568|NCT04452929|Active Comparator|Randomized treatment phase: Erenumab|Erenumab 140 mg single subcutaneous injection at baseline
11046569|NCT04452929|Placebo Comparator|Randomized treatment phase: Placebo|Saline placebo single subcutaneous injection at baseline
11046570|NCT04452929|Other|Open-label extension treatment phase: Erenumab|Erenumab 140 mg monthly subcutaneous injection for six months after completion of the randomized, double-blinded, placebo-controlled study phase during the open-label extension
11046571|NCT04452916|Active Comparator|Fasting|Starts immediately with 5 days of Buchinger fasting
11046572|NCT04452916|Placebo Comparator|Waiting list control|Starts with 5 days of Buchinger fasting after a waiting period of 12 weeks
11046573|NCT04452903|Experimental|Reassurance intervention|The physiotherapist in the intervention group (n=15) will participate in a 3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
11046574|NCT04452903|No Intervention|Control|The physiotherapist in the control group (n=15) receives no training.
11046575|NCT04452890|Experimental|Sonourethrography|Ultrasound of the urethra (Sonourethrography - SUG): In this procedure, a Foley catheter is inserted into the top of the urethra and physiological serum is instilled into the urethra while a linear 7.5 MHz ultrasound probe is placed sagitally on the course of the urethra to detect a narrowing of the urethra.
11046576|NCT04452877|Experimental|Dabrafenib in combination with trametinib|Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
11046577|NCT04452864|Experimental|Study Intervention|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
11046578|NCT04452864|Active Comparator|Active Control Group|This control study arm will watch documentaries at home for three months (each day for 20 minutes) , instead of performing the CCT and serve as active control group. This group will also train with the CCT tasks after these three months.
11046579|NCT04452864|Other|Wait-List Control|This control study arm will start with the CCT with a delay of three months and serve as wait-list control group.
11046580|NCT04452851|Experimental|Treadmill test with BREATHE|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).
11046581|NCT04452851|Active Comparator|Treadmill test with BiPAP|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).
11046582|NCT04452851|Placebo Comparator|Treadmill test with placebo inhaler|Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).
11046583|NCT04452851|Experimental|Activity of Daily Living with BREATHE|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
11046584|NCT04452851|Experimental|Activity of Daily Living with BREATHE during recovery|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
11046585|NCT04452851|No Intervention|Activity of Daily Living|Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).
11046586|NCT04452838|Other|Cohort 1 Sequence 1 (Part A)|Treatment Sequence A,B,C and D
11046587|NCT04452838|Other|Cohort 1 Sequence 2 (Part A)|Treatment Sequence B, A,C and D
11046592|NCT04452825||Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
11046593|NCT04452825||Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
11046594|NCT04452812|Experimental|Convalescent plasma|"Best available treatment + convalescent plasma
~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.
~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
11046595|NCT04452812|Placebo Comparator|Best available treatment|"Best available treatment + Placebo (0.9% saline solution)
~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.
~Placebo will consist on 2 doses of 200 ml of 0.9% saline solution separated on a 12 hour interval."
11046596|NCT04452799|Experimental|expermintal|1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days
11046597|NCT04452799|Active Comparator|standard|standard care therapy in quarantine hospitals
11046598|NCT04452786|Other|Endoscopic sleeve gastroplasity operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
11046599|NCT04452786|Other|Laparoscopic sleeve gastrectomy operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
11046600|NCT04452773|Experimental|Manremyc|Participants will receive daily oral administration of a capsule of Manremyc for 14 days in the morning with breakfast
11046601|NCT04452773|Placebo Comparator|Placebo|Participants will receive daily oral administration of a capsule of Placebo for 14 days in the morning with breakfast
11046602|NCT04452760|Active Comparator|Control group|Only testing sessions
11046603|NCT04452760|Experimental|Progressive resistance training group|10-weeks of progressive resistance training group. Leg press, leg extension, calf raises, hip extension exercises.
11046604|NCT04452747|Active Comparator|Dino-first|Labour will be induced by the use of the vaginal Dinoprostone system (Propess®) first.
11046605|NCT04452747|Active Comparator|Balloon-first|Labour will be induced by the use of a cervix dilatation balloon first.
11046606|NCT04452734|Active Comparator|Control Group|
11046607|NCT04452734|Experimental|Study Group|
11046608|NCT04452721||Retrospective cohort|340 to 400 patients
11046609|NCT04452721||Validation cohort|120 patients
11046610|NCT04452708||HFNC at 30-60L/min|HFNC at 50-60L/min with humidification at 37C (Airvo 2, Fisher & Paykel, Auckland, New Zealand) will be applied for patients with moderate type 1 respiratory failure
11046611|NCT04452708||NIV|NIV (Respironics V60) via oronasal mask (Quattro, ResMed) will be reserved for patients with type 2 respiratory failure
11046612|NCT04452708||Conventional nasal oxygen|Oxygen 1-5 L/min via nasal cannula for those with mild type 1 respiratory failure
11046613|NCT04452695||Intervention arm|Patients presenting to the emergency department are triaged using a novel robotic telehealth triage system. Once triage is complete, patients complete a quantitative assessment to measure their acceptance and willingness to interact with the robotic telehealth system.
11046614|NCT04452682||Era of COVID 19|Total number of cases admitted during first six months of 2020
11046615|NCT04452682||Era of Non COVID 19|Total number of cases admitted the first six months of 2019
11046616|NCT04452669|Experimental|Study Treatment|Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
11046617|NCT04452669|Placebo Comparator|Placebo Control|Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.
11046618|NCT04452656|Active Comparator|bilateral erector spinae plane block plus fentanyl infusion|The patient WILL receive bilateral erector spinae plane block in addition to fentanyl infusion
11046619|NCT04452656|Active Comparator|fentanyl infusion only|The patient will receive continous intravenous infusion of fentanyl
11046620|NCT04452643|Active Comparator|Bacmune (MV130)|Subject included in the active group will receive Bacmune. The dose consists on 2 spray puff every 12 hours for 45 days.
11046621|NCT04452643|Placebo Comparator|Placebo|Subject included in the placebo group will receive placebo. The dose consists on 2 spray puff every 12 hours for 45 days.
11046622|NCT04452630||Covid 19 Patients|patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
11046623|NCT04452591|Experimental|Single Arm|"Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease.
~CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments.
~Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter."
11046624|NCT04452578|Experimental|Experimental: Recipient of HCV positive heart graft|A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.
11046625|NCT04452565|Active Comparator|Active Comparator: NA-831 alone|Arm 1: NA-831 30 mg orally twice a day for one day, followed by 30 mg once day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule
11046626|NCT04452565|Active Comparator|Active Comparator: NA-831 plus Atazanavir Sulfate|"Arm 2: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.
~AND Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets."
11046627|NCT04452565|Active Comparator|Active Comparator: NA-83 plus Dexamethasone|"Active Comparator: NA-831 30 mg capsule plus Dexamethasone 4 mg Arm 3: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.
~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
11046628|NCT04452565|Active Comparator|Active Comparator: Atazanavir and Dexamethasone|"Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets.
~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
11046629|NCT04452552|Experimental|ultra-sound cavitation|cavitation40 KHz applied for 30 min, once time weekly for 8 weeks.
11046630|NCT04452552|Experimental|radiofrequency|radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks
11046631|NCT04452539||Paediatric cardiac surgery patients|All patients undergoing paediatric cardiac surgery
11046632|NCT04452526|Experimental|ARM I (EARLY INTERVENTION) (educational material, reminders)|Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
11046633|NCT04452526|Experimental|ARM II (DELAYED INTERVENTION)(education, reminder, usual care)|Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
11046634|NCT04452500|Experimental|CORT108297|CORT108297- 180mg daily for 7 days
11046635|NCT04452500|Placebo Comparator|Placebo|Placebo- 180mg daily for 7 days
11046636|NCT04452487||Patient 2019|Patients hospitalized in selected centers during march and june 2019
11046637|NCT04452487||Patient 2020|Patients hospitalized in selected centers during march and june 2020 (during COVID-19 pandemia)
11046638|NCT04452487||Patient 2021|Patients hospitalized in selected centers during march and june 2021
11046639|NCT04452474|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
11046640|NCT04452474|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy
11046641|NCT04452461|Other|Single Arm Intervention|"Chemotherapy: 6 cycles (three months) of IV combination chemotherapy with mFOLFIRINOX on day 1 followed by one week of rest (14-day cycle). Alternatively, patients will receive three months of gemcitabine / nab-paclitaxel.
~Re-staging CT scan with Carbohydrate Antigen (CA) 19-9 serum test.
~Radiation therapy with SBRT for 5 days.
~Re-staging CT scan with CA 19-9 serum test one week following the last day of SBRT . Staging laparoscopy to rule out occult metastatic disease is optional based on surgeon's preference.
~Pancreatectomy 4 weeks following the last day of SBRT as per standard of care.
~Adjuvant chemotherapy: as per standard of care.
~Clinical assessment and CT scan with CA 19-9 serum test at 4-month intervals until identification of cancer recurrence.
~Follow up of patients after 2 years every six months for up to 5 years following the initiation of treatment will be performed off-protocol as per standard of care."
11046642|NCT04452448|Experimental|Laser in situ keratomileusis|A prospective clinical study including 20 eyes of 10 cases undergoing laser in situ keratomileusis (LASIK)
11046643|NCT04452435|Experimental|C21|
11046644|NCT04452435|Placebo Comparator|Placebo|
11046645|NCT04452409|Active Comparator|study (low level laser plus Mediterranean diet)|Active infra -red laser in addition to diet
11046646|NCT04452409|Other|control (Mediterranean diet only)|diet
11046647|NCT04452396|Experimental|patients|patients undergoing CGM monitoring
11046648|NCT04452383|Active Comparator|propofol (P)|patients will receive only propofol intravenous for sedation
11046649|NCT04452383|Active Comparator|propofol ketamine (pk)|patients will receive ketamine in addition to propofol intravenous for sedation
11046650|NCT04452370|Experimental|oral Etoposide+Anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
11046651|NCT04452357|Experimental|PLDR Chemoradiation|"Patients will receive pulse-low-dose rate radiation, along with gemcitabine chemotherapy.
~6 patients each will be accrued at two dose levels. PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows: Dose level 1: 56 Gy; Dose level 2: 66 Gy"
11046652|NCT04452344|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.
11046653|NCT04452344|Active Comparator|Non-Opioid|Combination of ibuprofen 400 mg/acetaminophen 500 mg
11046654|NCT04452331|Experimental|OAA Intervention|Visit recorded, both patient and provider aware, both patient and provider have access to audio post-visit
11046655|NCT04452331|Sham Comparator|OAA Physician Aware Control|Visit recorded, both patient and provider aware, neither patient nor provider have access to audio post-visit
11046656|NCT04452331|Placebo Comparator|OAA Physician Unaware Control|Visit recorded, patient aware but provider unaware, neither patient nor provider have access to audio post-visit
11046657|NCT04452318|Experimental|REGN10933 + REGN10987|
11046658|NCT04452318|Placebo Comparator|Placebo|
11046659|NCT04452305|Experimental|Spermatogonial Stem Cell Transplant & Testicular Tissue Graft|Stem cell transplantation Testicular tissue grafting
11046660|NCT04452292|Active Comparator|No TP53/Rb1 Co-Mutation|HG-LCNEC tumor lacking the TP53/Rb1 co-mutation (non-small cell-like).
11046661|NCT04452292|Experimental|TP53/Rb1 Co-Mutation Present|HG-LCNEC tumor with the TP53/Rb1 co-mutation.
11046662|NCT04452279|Experimental|Ocular Surface Disease post-stenting|Eyes will undergo phacoemulsification cataract surgery combined with iStent or iStent inject implantation according to standard clinical practice. From baseline through 3 months postoperatively, participants will complete subjective and objective assessments of ocular surface disease.
11046665|NCT04452253|Active Comparator|PS128|"The PS128, which belongs to Lactobacillus plantarum subsp. plantarum, 2 caps daily use.
~Sub-project for IT specialists also take the same probiotics."
11046666|NCT04452253|Active Comparator|PS23 live|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use.
11046667|NCT04452253|Active Comparator|PS23 heat-treated|PS23 heat-treated, 2 caps daily use.
11046668|NCT04452253|Placebo Comparator|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
11046669|NCT04452227||eumenorrheic healthy women|women with a regular menstrual cycle for three months, predictable, and a period between 24-38 days that lasts less than 8 days.
11046670|NCT04452214|Experimental|CAN04 and pembrolizumab|Subjects will receive weekly doses of CAN04 in combination with pembrolizumab given as standard regimen
11046671|NCT04452201|Experimental|Guided Participation (GP)|A GP intervention is participatory formal and informal education to support learning of a practice beyond what could occur as efficiently and effectively without guidance. GP uses strategies for teaching-learning that make best use of the family's situation and opportunities, tailored to the parents' needs. The overall goal of the GP intervention is to support parent couples in effectively communicating for parenting work, including care-giving and maintaining the couple's relationship
11046672|NCT04452201|No Intervention|Usual Care (UC)|The UC group will receive standard of care
11046673|NCT04452188|Experimental|Normoxia|"On bypass, goal PaO2 on cardiopulmonary bypass of 60-100 mm Hg using lower fraction of inspired oxygen (FiO2) (blended sweep gas) via oxygenator
~Post-bypass, goal of PaO2 <100 mm Hg by anesthesia and in ICU via oxygen titration via mechanical ventilator for 24 hours post-op."
11046674|NCT04452188|Active Comparator|Standard of care|Frequent blood gases will be checked per protocol on bypass and correlated with the blood parameter monitoring system to maintain a PaO2 of 200-300 per standard practice
11046675|NCT04452175|Experimental|HIGH 5%|
11046676|NCT04452175|Active Comparator|LOW 1.7%|
11046677|NCT04452162|Other|Salivary Gland Tumor|
11046678|NCT04452149|Other|Observation Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 7 months.
11046679|NCT04452149|Experimental|Intervention Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed using an integrated device diagnostic-based risk stratification algorithm combined with a clinical medication plan.
11046680|NCT04452123|Experimental|Argon plasma|Patients with endometrioma treated with laparoscopic argon plasma energy.
11046681|NCT04452123|Experimental|Stripping and suture/coagulation|Patients with endometrioma treated with laparoscopic excision with suture or gentle coagulation of the rest of ovary.
11046682|NCT04452110||Group I|For volunteers in group 1 with previously taken MRI (Magnetic Resonance Imaging), USG (Ultrasonography) and MRI findings will be compared.
11046683|NCT04452110||Group II|In volunteers in group 2, the values obtained using different probes (linear, hockey stick) will be compared.
11046684|NCT04452110||Group III|In the third group of volunteers, the values to be obtained by using the USG probe at different angles (horizontal / longitudinal) will be compared.
11046685|NCT04452110||Group IV|In volunteers in group 4, the megahertz values of the probe are changed and the findings obtained by examining them separately will be compared.
11046686|NCT04452097|Experimental|Phase 1 Low-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.
11046687|NCT04452097|Experimental|Phase 1 Middle-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.
11046688|NCT04452097|Experimental|Phase 1 High-dose Group|Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.
11046689|NCT04452097|Experimental|Phase 2a Treatment Group|Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.
11046690|NCT04452097|Placebo Comparator|Phase 2a Control Group|Eligible subjects will receive a single infusion of placebo control and standard of care treatment.
11046691|NCT04452084|Active Comparator|Control|
11046692|NCT04452084|Experimental|Experimental Procedure|
11046693|NCT04452071||prepubertal|patients born in 2012-2011
11046694|NCT04452071||pubertal|patients born in 2010-2009-2008-2007
11046695|NCT04452071||postpubertal|patients born in 2006-2005-2004-2003
11046696|NCT04452058||Internal cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to December 31,2019. Patients with single pulmonary lesion underwent preoperative chest CT scan and histologically confirmed precancerous lesions or early stage lung adenocarcinoma after thoracic surgery was included.
11046697|NCT04452058||External cohort 1|The same inclusion/exclusion criteria were applied for another independent centers, Sun Yat-sen Memorial Hospital ,Guangdong Province, China, forming an external validation cohort of 73 patients
11046698|NCT04452058||External cohort 2|The same inclusion/exclusion criteria were applied for another independent centers, Zhoushan Lung Cancer Institution, Zhejiang Province, China, forming second external validation cohort of 30 patients
11046699|NCT04452058||Immune Cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to May 31,2020. Patients with advanced lung cancer underwent preoperative chest CT scan and histologically confirmed NSCLC before receiving immunotherapy was included.
11046700|NCT04452045|Experimental|SweetDreams|Access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
11046701|NCT04452045|No Intervention|Waitlist Control|Wait list condition with future access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
11046746|NCT04451863|Active Comparator|Low THC + Low myrcene|5 mg THC, 0.5 mg myrcene, 0 mg BCP
11046747|NCT04451863|Active Comparator|Low THC + High myrcene|5 mg THC, 12.0 mg myrcene, 0 mg BCP
11046748|NCT04451863|Active Comparator|High THC + Low myrcerne|15 mg THC, 0.5 mg myrcene, 0 mg BCP
11046749|NCT04451863|Active Comparator|High THC + High myrcene|15 mg THC, 12.0 mg myrcene, 0 mg BCP
11046702|NCT04452032|Experimental|Single arm|"The first phase of the study will consist of an evaluation of the initial dental state of each subject based on stomatological examination, orthopantomogram, bitewing radiographs, evaluation of potential risks of caries and fractures. Dental decalcification, dental care and/or avulsion if necessary, and afterwards, a dental splint will be performed before the start of RT treatment.Based on our predictive model, every tooth which potentially will receive more than 40 Gy and for which long term survival is compromised will be avulsed at least 2 weeks before the start of RT.
~After RT, the subject will have clinical follow-up with dental evaluation every 6 months for 36 months in order to identify possible dental events. At each consultation, a stomatological examination will be performed as well as bitewing radiographs. Orthopantomogram will be done once a year. Periapical X-rays will be performed if there is a dental complain or to refine a lesion visible on orthopantomogram."
11046703|NCT04452019|Active Comparator|Standing frame|Use of standard standing frame
11046704|NCT04452019|Experimental|Innowalk|Use of a new Device; Innowalk Pro
11046705|NCT04452006|Experimental|Part A (SAD) - A1, ACT-541478 10 mg fasted|SAD = single ascending dose
11046706|NCT04452006|Experimental|Part A (SAD) - A2, ACT-541478 30 mg fasted|SAD = single ascending dose
11046707|NCT04452006|Experimental|Part A (SAD) - A3 (Period 1), ACT-541478 100 mg fasted|SAD = single ascending dose
11046708|NCT04452006|Experimental|Part A (SAD) - A3 (Period 2), ACT-541478 100 mg fed|SAD = single ascending dose
11046709|NCT04452006|Experimental|Part A (SAD) - A4, ACT-541478 300 mg fasted|SAD = single ascending dose
11046710|NCT04452006|Experimental|Part A (SAD) - A5, ACT-541478 1000 mg fasted|SAD = single ascending dose
11046711|NCT04452006|Experimental|Part B - B1-3, ACT-541478 low or high dose|
11046712|NCT04452006|Experimental|Part C (MAD) - C1, ACT-541478 30 mg, fasted|MAD = multiple ascending dose
11046713|NCT04452006|Experimental|Part C (MAD) - C2, ACT-541478 100 mg, fasted|MAD = multiple ascending dose
11046714|NCT04452006|Experimental|Part C (MAD) - C3, ACT-541478 300 mg, fasted|MAD = multiple ascending dose
11046715|NCT04452006|Experimental|Part C (Elderly) E1, ACT-541478, fasted|
11046716|NCT04451993||OSAS PATIENTS|mild, moderate and severe OSAS patients
11046717|NCT04451993||HEALTHY INDIVIDUALS|healthy individuals without chronic disease
11046718|NCT04451980||HIV+ non-diabetics|HIV-infected participants with hemoglobin A1c (HbA1c) <5.7% or fasting glucose <100 mg/dl.
11046719|NCT04451980||HIV+ pre-diabetics|HIV-infected participants with HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dl.
11046720|NCT04451980||HIV+ diabetics|HIV-infected participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
11046721|NCT04451980||HIV-negative diabetics|HIV-negative participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
11046722|NCT04451967||Transfer after thrombolysis|
11046723|NCT04451967||Transfer after DAPT|
11046724|NCT04451967||Direct transfer|
11046725|NCT04451954|Experimental|Group 1: Quadrivalent RIV with H3 strain 1, without adjuvant|1 injection of quadrivalent RIV containing H3 strain 1, without adjuvant, in participants ≥ 50 years old
11046726|NCT04451954|Experimental|Group 2: Quadrivalent RIV with H3 strain 1, with adjuvant|1 injection of quadrivalent RIV containing H3 strain 1, with adjuvant, in participants ≥ 50 years old
11046727|NCT04451954|Experimental|Group 3: Quadrivalent RIV with H3 strain 2, without adjuvant|1 injection of quadrivalent RIV containing H3 strain 2, without adjuvant, in participants ≥ 50 years old
11046728|NCT04451954|Experimental|Group 4: Quadrivalent RIV with H3 strain 2, with adjuvant|1 injection of quadrivalent RIV containing H3 strain 2, with adjuvant, in participants ≥ 50 years old
11046729|NCT04451954|Active Comparator|Group 5: Quadrivalent RIV Control, without adjuvant|1 injection of quadrivalent RIV containing 2018-19 Northern Hemisphere (NH) recommended H3 strain, without adjuvant, in participants ≥ 50 years old
11046730|NCT04451954|Active Comparator|Group 6: Quadrivalent RIV Control, with adjuvant|1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, with adjuvant, in participants ≥ 50 years old
11046731|NCT04451954|Active Comparator|Group 7: Quadrivalent RIV Control, without adjuvant|1 injection of quadrivalent RIV containing 2018-19 NH recommended H3 strain, without adjuvant, in participants 18-30 years old
11046732|NCT04451941|Experimental|RecoveriX with individual EEG calibration|RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
11046733|NCT04451941|Sham Comparator|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
11046734|NCT04451928||Preterm delivery|Pregnant women who give birth before 37th gestational week
11046735|NCT04451928||Term delivery|Pregnant women who will give birth 37th and after gestational week
11046736|NCT04451915|Experimental|Early management GDM group|defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
11046737|NCT04451915|Experimental|Late management GDM group|early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
11046738|NCT04451889|Experimental|Confocal laser endomicroscopy diagnostic study|"Cohort 1: COVID-19 patients. Cohort 2: patients with lung diseases unrelated to COVID-19.
~All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special Alveoflex miniprobe during the hospitalisation period. Records will be done and analysed prospectively with the included software for the endomicroscopic system.
~Using Alveoflex is a minimally invasive intervention."
11046739|NCT04451863|Placebo Comparator|Placebo|0 mg THC, 0 mg myrcene, 0 mg BCP
11046740|NCT04451863|Active Comparator|Low strength THC|5 mg THC, 0 mg myrcene, 0 mg BCP
11046741|NCT04451863|Active Comparator|Higher strength THC|15 mg THC, 0 mg myrcene, 0 mg BCP
11046742|NCT04451863|Active Comparator|Low strength myrcene|0 mg THC, 0.5 mg myrcene, 0 mg BCP
11046743|NCT04451863|Active Comparator|High strength myrcene|0 mg THC, 12.0 mg myrcene, 0 mg BCP
11046744|NCT04451863|Active Comparator|Low strength BCP|0 mg THC, 0 mg myrcene, 0.5 mg BCP
11046745|NCT04451863|Active Comparator|High strength BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
11046754|NCT04451837|Active Comparator|semaglutide|Patients randomized to add semaglutide (Ozempic) will receive injection training at the study site and inject 0.25 mg subcutaneously once weekly during the first four weeks, followed by 0.5 mg weekly for the subsequent four weeks and finally 1.0 mg weekly throughout the study.
11046755|NCT04451837|Active Comparator|dapagliflozin|Those randomized to dapagliflozin will receive 10 mg orally once daily in addition to metformin.
11046756|NCT04451824|Experimental|Intervention with Routine Use of Red Light|Routine Use of red light (635nm) for 30 minutes on patients is to be observed in relation to its effect(s) in achieving circumferential reduction of the thighs, hips and waist of the patient, and a contour reduction of any protrusion of fat.
11046757|NCT04451811|Experimental|OPL-002 SDD 20 mg|20 mg SDD formulation of OPL-002
11046758|NCT04451811|Experimental|OPL-002 5 mg Tablet|5 mg tablet formulation of OPL-002
11046759|NCT04451811|Experimental|OPL-002 20 mg Tablet|20 mg tablet formulation of OPL-002
11046760|NCT04451798|Experimental|Intervention|Impella implantation and hemodynamic measurement
11046761|NCT04451785|Active Comparator|Healthy individuals|20 healthy subjets aged 6 years minimum will be included in this study. This is the control group.
11046762|NCT04451785|Experimental|Patients with hereditary spherocytosis|60 patients with hereditary spherocytosis will be included in this study.
11046763|NCT04451772|Experimental|Part 1: Elsubrutinib Dose A and Upadacitinib Dose A|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose A once daily (QD).
11046764|NCT04451772|Experimental|Part 2: Elsubrutinib Dose A and Upadacitinib Dose B|Participants will receive Elsubrutinib Dose A and Upadacitinib Dose B QD.
11046765|NCT04451772|Experimental|Part 3: Elsubrutinib Dose A and Upadacitinib Placebo|Participants will receive Elsubrutinib Dose A and Upadacitinib placebo QD.
11046766|NCT04451772|Experimental|Part 4: Elsubrutinib Placebo and Upadacitinib Dose A|Participants will receive Elsubrutinib placebo and Upadacitinib Dose A QD.
11046767|NCT04451759|Active Comparator|healthy controls|
11046768|NCT04451759|Experimental|Anorexia|
11046769|NCT04451759|Experimental|Obesity|
11046770|NCT04451746|Other|Tableted hormonal drugs for contraception|Tableted hormonal drugs for contraception, 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
11046771|NCT04451720|Experimental|Risankizumab|In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.
11046772|NCT04451720|Experimental|Placebo|In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.
11046773|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
11046774|NCT04451694||Covid-19 unit outgoing patients|nutritional evaluation and intervention
11046775|NCT04451681|Other|Ankylosing spondylitis|A total of 42 patients, who were diagnosed with AS with modified New York Criteria, and who agreed to participate in the study, will be included in this group.
11046776|NCT04451681|Other|Control|A total of 42 control participants between the ages of 18-65 who agreed to participate in the study will be included in this group.
11046777|NCT04451668|Experimental|FT218|once nightly sodium oxybate extended release oral solution (FT218)
11046778|NCT04451655|Experimental|Interventional|
11046779|NCT04451642||Peripheral nerve block Group|Every patient scheduled during 2011-2019 for the surgery needed a peripheral nerve block were enrolled.
11046780|NCT04451629|Experimental|Exercises group|intervention group çalışma grubundaki kadın öğrencilere 8 hafta süresince haftada 4 kez 40 dakika boyunca pelvik taban ve core egzersizleri uygulatılacak
11046781|NCT04451629|No Intervention|control group|students will be watched without any intervention
11046782|NCT04451616||Group A - study group - patients with metabolic syndrome|"Patients with metabolic syndrome will be included.
~Procedures:
~blood sample collection
~hair sample collection
~urine sample collection
~body composition analysis
~questionnaires
~blood pressure, pulse and blood oxygen saturation measurement"
11046783|NCT04451616||Group B - control group - patients without metabolic syndrome|"Patients without metabolic syndrome will be included.
~blood sample collection
~hair sample collection
~urine sample collection
~body composition analysis
~questionnaires
~blood pressure, pulse and blood oxygen saturation measurement"
11046784|NCT04451603||Surgical resection|
11046785|NCT04451603||Y-90 therapy|
11046786|NCT04451603||Systemic Therapy|
11046787|NCT04451590|Experimental|VR-based Simulation (Intervention)|Students will receive training on traumatic airway management using VR-based simulation.
11046788|NCT04451590|Other|Mannequin-based Simulation (Control)|Students will receive training on traumatic airway management using mannequin-based simulation.
11046789|NCT04451577||EMPLOYEES WITHOUT COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.
~Negativity to COVOD-19 will be tested by peripheral blood samples every month for 6 months (or until seroconversion). If they are positive for anti- covid 19 antibodies, a test for positivity of the virus will be carried out. T"
11046790|NCT04451577||EMPLOYEES WITH COVID-19 INFECTION|"Humanitas group employees (including ICH, Humanitas University and Gavazzeni), and two validation cohorts.
~employees that are Sars-Cov-2 positive both symptomatic and asymptomatic, there will be at least 2 peripheral blood samples (5 and 3 ml) at every control visit until ascertained negativity. They will also undergo a pharyngeal swab for viral titers and microbiota analysis at enrollment and at negativity. In addition, a sample of saliva/sputum will be collected for most of the employees at positivity and at every control visit.
~For employees hospitalized but not requiring intensive care the following samples will be collected:
~an aliquot of samples from the respiratory tract (e.g., bronchial aspirate, bronchoalveolar lavage) residual from the normal clinical practice
~saliva/sputum
~pharyngeal swab not used for diagnosis both at admission and at the first check up
~blood sample in EDTA for plasma and peripheral blood mononuclear cell (PBMC)"
11046791|NCT04451564|Experimental|MORE Mindfulness oriented recovery enhancement group|MORE Mindfulness oriented recovery enhancement group
11046792|NCT04451564|No Intervention|Control|wait-list
11047553|NCT04446013|Experimental|Grup Spinal Anesthesia|C-Section under spinal anesthesia
11046793|NCT04451538|Experimental|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g [12 spoon, 500 kcal]/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoon, 440 kcal]/day, twice a day).
11046794|NCT04451538|Placebo Comparator|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
11046795|NCT04451525||Patients with Acute Ischemic Stroke|
11046796|NCT04451512||CSP|
11046797|NCT04451512||HSP|
11046798|NCT04451499|Experimental|Intervention group -smartphone app|"All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
~All the participants will get access to our study's smartphone app site."
11046799|NCT04451499|No Intervention|Control group|All the participants will receive the standard care of 3-6 preparation to bariatric surgery meetings with a dietitian.
11046800|NCT04451486|Experimental|Treatment dose 1|1x10*5 CD61-Lin- cells /0.25mL DPBS
11046801|NCT04451486|Experimental|Treatment dose 2|1x10*6 CD61-Lin- cells /0.25mL DPBS
11046802|NCT04451486|Experimental|Treatment dose 3|1x10*7 CD61-Lin- cells /0.25mL DPBS
11046803|NCT04451473|Experimental|ERAS- Group|Patients underwent surgery for lung cancer accepted the enhanced recovery after surgery (ERAS).
11046804|NCT04451473|Other|Control- Group|Patients underwent surgery for lung cancer without enhanced recovery after surgery (ERAS).
11046805|NCT04451460||Hyponatremia|Hyponatremic small cell cancer patients
11046806|NCT04451460||Normonatremia|Normonatremic small cell cancer patients
11046807|NCT04451447|Experimental|white test arm|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
11046808|NCT04451447|Other|Saline test arm|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
11046809|NCT04451434|Experimental|Danicopan 200 mg Fasted|Fasting participants will receive a single dose of 200 mg danicopan.
11046810|NCT04451434|Experimental|Danicopan 200 mg Fed|Fed participants will receive a single dose of 200 mg danicopan.
11046811|NCT04451434|Experimental|Danicopan 400 mg Fed|Fed participants will receive a single dose of 400 mg danicopan.
11046812|NCT04451421|Experimental|Standing Angle|Assist the electric hospital bed to conduct different Angle standing training, starting from 20 degrees, every five minutes to rise 5 degrees, the maximum rise to 80 degrees
11046813|NCT04451408|Experimental|LY3372993|LY3372993 administered intravenously (IV).
11046814|NCT04451408|Placebo Comparator|Placebo|Placebo administered IV.
11046815|NCT04451395|Experimental|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet..The supplement is provided within the parent trial.
~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
11046816|NCT04451395|No Intervention|Standard of care|Daily iron and folic acid supplementation provided through the existing public health system.
11046817|NCT04451382||OnabotulinumtoxinA (BoNTA)|DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
11046818|NCT04451382||Percutaneous tibial nerve stimulation (PTNS)|DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.
11046819|NCT04451369|No Intervention|Control group|Group without prehabilitation program before surgery
11046820|NCT04451369|Experimental|Prehabilitation group|Group will follows a prehabilitation program before surgery
11046821|NCT04451343||Patients|Patients with a diagnosis of colorectal cancer before 65 years.
11046822|NCT04451343||Family|The spouse and /or children and /or parents of a patient 's diagnosis of colorectal cancer before 65 years.
11046823|NCT04451330|Experimental|Trifarotene (CD5789) Cream + Doxycycline|Participants will apply trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.
11046824|NCT04451330|Placebo Comparator|Trifarotene Vehicle + Doxycycline Placebo|Participants will apply vehicle trifarotene 50 mcg/g cream topically once daily in the evening on the face and will receive one tablet of placebo doxycycline hyclate delayed-release 120 mg orally in the evening on Day 1, 2, 3 for 12 weeks and one tablet in the morning on Day 2.
11046825|NCT04451317||Experimental|Patients involved in a Sport-Health initiative Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
11046826|NCT04451317||Control|Healthy sport subjects. Visit once by telephone and then ask to fill in 3 questionnaires on a digital platform within 48 hours after the telephone interview.
11046827|NCT04451291|Experimental|Decidual Stromal Cells (DSC)|Participants will receive one dose of DSC at 1x10^6/kg. A second dose may be given sometime between Day 5 and Day 8 if the participant's condition improves.
11046828|NCT04451239|Other|COVID-19 keratoconjunctivitis|cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
11046829|NCT04451226|Experimental|Fezolinetant|Participants will receive fezolinetant once daily for 52 weeks.
11046830|NCT04451213|Experimental|experimental|
11046831|NCT04451200|Experimental|busulfan treatment|Personalized BU administration
11046866|NCT04450927||1|Data collection and treatment according to guidelines of standard of medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
11046832|NCT04451187|Experimental|Treatment Sequence CADB|Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
11046833|NCT04451187|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3 followed by Treatment D in Period 4. There will be a washout period of 5 to 21 days between each period.
11046834|NCT04451187|Experimental|Treatment Sequence BDAC|Participants will receive Treatment B in Period 1 followed by Treatment D in Period 2 followed by Treatment A in Period 3 followed by Treatment C in Period 4. There will be a washout period of 5 to 21 days between each period.
11046835|NCT04451187|Experimental|Treatment Sequence DCBA|Participants will receive Treatment D in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3 followed by Treatment A in Period 4. There will be a washout period of 5 to 21 days between each period.
11046836|NCT04451174|Experimental|Treatment|Prednisone 40 mg days 1 to 4. Then Prednisone 20 mg days 5 to 8.
11046837|NCT04451174|No Intervention|Control|
11046838|NCT04451161|Other|BASIS with TF-CBT|"Implementation intervention: experimental arm (Beliefs and Attitudes for Successful Implementation in Schools)
~Clinical Intervention: experimental arm (Trauma-Focused CBT)"
11046839|NCT04451161|Other|AC with TF-CBT|"Implementation intervention: control arm
~Clinical Intervention: experimental arm (Trauma-Focused CBT)"
11046840|NCT04451161|Other|Enhanced Treatment as Usual|"Implementation intervention: non-applicable
~Clinical Intervention: control arm (Enhanced TAU)"
11046841|NCT04451148||Obese subjects|Subjects with obesity
11046842|NCT04451148||Obese plus metabolic syndrome subjects|Subjects with obesity and metabolic syndrome
11046843|NCT04451148||Healthy controls|Otherwise healthy subjects
11046844|NCT04451135|Experimental|Patients with Treatment-Resistant Depression|
11046845|NCT04451122|Other|Treatment of ocular demodicosis|
11046846|NCT04451109||Cases in which Dilapan-S was used for cervical ripening.|Every participating site will select 50 cases of pregnant women who underwent cervical ripening by Dilapan-S prior to induction of labor. These cases has to fulfill inclusion/exclusion criteria defined in the protocol.
11046847|NCT04451096|Active Comparator|Probiotic with prebiotic|Drug: Probiotic sachet containing granulated multiple strains of Lactobacillus and Bifidobacterium, granulated fermented milk, lactose, fructo-oligosaccharide (FOS) with orange flavouring.
11046848|NCT04451096|Placebo Comparator|Placebo|Drug : Placebo sachet of granulated milk, lactose and orange flavouring, without FOS or microbial cells which appeared similar to the probiotics
11046849|NCT04451083|Experimental|FOY-305|
11046850|NCT04451070||Family Medicine resident physicians|Family Medicine resident physicians at David Grant Medical Center who started their Family Medicine residency at David Grant Medical Center between June 2018 - June 2019 and are scheduled to graduate from Family Medicine residency between June 2021 - June 2022.
11046851|NCT04451057|Experimental|high flow nasal nasal cannula|Patients allocated for this arm are received high flow nasal cannula therapy after extubation.
11046852|NCT04451057|Active Comparator|low flow nasal cannula|Patients allocated for this arm are received conventional oxygen therapy after extubation.
11046853|NCT04451044|Experimental|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
11046854|NCT04451044|Active Comparator|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
11046855|NCT04451031|Experimental|LiFT Program|LiFT is a two-module curriculum workshop for youth and their parenting adults. Topics for youth include communication skills, condom use, and skill building to access sexual healthcare resources. For parenting adults, topics include building a climate of trust and open communication with youth about sexual health. Trained and certified facilitators deliver each 2.5 hour module over one or two sessions. Youth and parents participated in simultaneous but separate programming in community locations such as schools or health care settings. They received participant guides that encourage communication between them. They could opt-in to receive 12 weekly texts that offered additional resources. Parenting adults received a phone call from the facilitator a month after the workshop to reinforce the skills learned during the program.
11046856|NCT04451031|No Intervention|Comparison Group|The comparison group received business as usual. The youth and parents enrolled in the study could receive the existing services available within the broader community, which may have included sexual education delivered in the local school system. Study staff collected data throughout the study to track access to other TPP programming offered at the study sites.
11046857|NCT04451005||Elderly patients with sarcopenia|Elderly patients with sarcopenia
11046858|NCT04450979|Active Comparator|Bioactive hydrolysate|20 g of hydrolysed rice protein
11046859|NCT04450979|Placebo Comparator|Placebo|20 g micro crystalline cellulose
11046860|NCT04450966|No Intervention|Usual Care|Clinicians randomized to this arm will not receive training in delivery of cSBI until study completion, and their participating patients will receive usual care.
11046861|NCT04450966|Experimental|Computer-facilitated screening and brief intervention|Clinicians randomized to this arm will receive training in delivery of cSBI and their participating patients will then receive the experimental intervention.
11046862|NCT04450953|Experimental|Eplerenone group A (cross over design)|Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 2-month wash-out period, then a 6-month period without eplerenone, until the end of the study.
11046863|NCT04450953|Active Comparator|Eplerenone group B (cross over design)|Eplerenone-free for 6 months, followed by a 2-month wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
11046864|NCT04450940|Experimental|PACV|The PACV arm received the PACV survey at baseline in order to assess the impact of administration on vaccine hesitancy. All participants received the PACV at 6-month follow up.
11046865|NCT04450940|Sham Comparator|Placebo|The placebo arm received a placebo survey on general childhood health topics at baseline. All participants received the PACV at 6-month follow up.
11046867|NCT04450914|Other|Health Systems - First Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the first step, health systems will be assigned to usual care (passive implementation of CV Prevention Choice).
11046868|NCT04450914|Other|Health Systems - Second Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the second step, health systems (in an order to be determined by randomization and staggered over time) will move into active implementation.
11046869|NCT04450914|Other|Health Systems - Third Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions.In the third step, all health systems will move to maintenance implementation.
11046870|NCT04450901|Experimental|Cohort A1 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 0.5 mg/kg
11046871|NCT04450901|Experimental|Cohort A2 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 2 mg/kg
11046872|NCT04450901|Experimental|Cohort A3 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 5 mg/kg
11046873|NCT04450901|Experimental|Cohort A4 group|YBL-006 will be administered once every 2 weeks (Q2W). Dose: 10 mg/kg
11046874|NCT04450888|Other|Model A|Total cardiovascular disease (CVD)-free life expectancy gain in one's remaining life.
11046875|NCT04450888|Other|Model B|Average CVD-free life expectancy gain per year.
11046876|NCT04450888|Other|Model C|Total CVD-free life expectancy loss that can be reclaimed in one's remaining life.
11046877|NCT04450888|Other|Model D|Average CVD-free life expectancy loss that can be reclaimed per year.
11046878|NCT04450875|Experimental|Experimental group (with diet)|It consisted in the administration of nutritional therapy with foods high in methionine according to the National Nutrient Database For Standard Reference (USDA) and adapted to the consumption and usual cost in the Mexican diet.
11046879|NCT04450875|No Intervention|Control|The control group continued with their usual diet for the same period of 3 months as the experimental group.
11046880|NCT04450862|Experimental|Intervention arm|Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky & Mooney, 1990).
11046881|NCT04450862|No Intervention|Control arm|A waiting-list will be used as a control condition. If the self-management intervention is found to be acceptable and not associated with any risk, then participants in the control condition will receive the intervention.
11046882|NCT04450849|Experimental|collagen membrane associated to anorganic bone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio) associated to anorganic bovine bone matrix + collagen (Bio-Oss® Collagen) . The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
11046883|NCT04450849|Active Comparator|collagen membrane alone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio). The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
11046884|NCT04450836|Experimental|Arm A (R-TT)|Regorafenib followed by trifluridine-tipiracil.
11046885|NCT04450836|Experimental|Arm B (TT-R)|Trifluridine-tipiracil followed by Regorafenib.
11046886|NCT04450810||Control|Evaluation of serum and salivary ET-1
11046887|NCT04450810||Periodontitis|Evaluation of serum and salivary ET-1
11046888|NCT04450810||Diabetes|Evaluation of serum and salivary ET-1
11046889|NCT04450810||Periodontitis + diabetes|Evaluation of serum and salivary ET-1
11046890|NCT04450797|Active Comparator|US -G VPS placement|
11046891|NCT04450797|Active Comparator|Stereotactic navigation for VPS placement|
11046892|NCT04450784||Secondary Acute Myeloid Leukemias (AML) of the child|
11046893|NCT04450771|Experimental|Family-based Treatment for ARFID(FBT-ARFID)|FBT-ARFID is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior. Early sessions focus on inciting parents to make changes and include a family meal that allows therapists to observe & consult directly to mealtime behaviors. FBT-ARFID for children 12 and under is manualized and consists of 2 phases. The first phase is focused on parents taking charge & changing the eating behaviors of their child that are maintaining ARFID. The second phase focuses on the child taking up in an age-appropriate way managing their eating consistent with the changes the parents have employed in phase 1. Fourteen 1-hour sessions will be conducted approximately weekly over 4 months. Throughout medical monitoring and weekly dietary consultation are available to the family.
11046894|NCT04450771|Active Comparator|Manualized Non-Specific Usual Care for ARFID(NSC)|A manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model that has been used in other RCTs with eating disorders as a comparison. NSC consists of sessions with the child alone and 7 parent only meetings. Sessions are 1-hour. NSC matches FBT-ARFID for time and therapist attention. The focus of the NSP intervention is psychoeducation about health & social impacts of restrictive eating and supporting parent & child exploration of motivation to change eating patterns & choices they make about changes to eating. The therapist does not initiate behavioral or cognitive interventions. Feelings about eating and making changes are explored in both the child and parent sessions. Medical and dietary advice are provided weekly.
11046895|NCT04450758||resection|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with acute resection.
11047022|NCT04449887|Experimental|The treatment group|The subjects in this group were treated with Xiangsha Liujunzi granule for 4 weeks
11046896|NCT04450758||bridge to sugery|Patients who present with obstruction due to colon cancer with a need for urgent intervention who are treated with bridge to surgery i.e. either stent or stoma and resection later on.
11046897|NCT04450745|Experimental|Exercise in hypoxia|Patients randomized to this arm will have training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above see level( indoor air composition: 15,4% of O2 and 84,7% of N)
11046898|NCT04450745|Experimental|Exercise in normoxia|Patients randomized to this arm will have the same training program in normoxic conditions
11046899|NCT04450732|Experimental|GQ1001 1.2 mg/kg|Administered intravenously every 21 days.
11046900|NCT04450732|Experimental|GQ1001 2.4 mg/kg|Administered intravenously every 21 days.
11046901|NCT04450732|Experimental|GQ1001 3.6 mg/kg|Administered intravenously every 21 days.
11046902|NCT04450732|Experimental|GQ1001 4.8 mg/kg|Administered intravenously every 21 days.
11046903|NCT04450732|Experimental|GQ1001 6.0 mg/kg|Administered intravenously every 21 days.
11046904|NCT04450719||Group 1: Patients with lung cancer|Exercise capacity [6-minute walk test (6-MWT)], pulmonary functions [spirometry], respiratory [maximal inspiratory and expiratory pressures (MIP-MEP), mouth pressure device] and peripheral muscle strength [dynamometer], physical activity level [metabolic holter], dyspnea [Modified Medical Research Council dyspnea scale (MMRC)] and quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] were evaluated in patients with lung cancer. Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
11046905|NCT04450719||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were performed in healthy individuals.
11046906|NCT04450706|Experimental|Treatment: all patients|"Blood will be collected, and a biopsy will be performed prior to starting the first systemic therapy (triple-negative) or first chemotherapy (hormone receptor-positive). If enough tumor is collected, the patient is eligible for the trial. Malignant tissue collected from this biopsy will be used for genomic sequencing and for the development of organoid models for drug screening. Drugs selected for sensitivity testing will be guided by the results of the genome analysis and NCCN guidelines. Following tissue acquisition, the patient will begin therapy as selected by the treating physician. This line of therapy, either standard-of-care or investigational in the context of another existing active clinical trial, will be defined as the first uninformed line of therapy.
~Patient response is tracked for up to two uninformed lines of therapy. The first line of the therapy started after the biopsy will count as the first uniformed line."
11046907|NCT04450706|Experimental|Physician Questionnaire|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician. Prior to and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
11046908|NCT04450693|Experimental|TTAX01|TTAX01 plus standard of care
11046909|NCT04450693|Other|Control|Standard care alone
11046910|NCT04450667|No Intervention|Fasting|"Patient will be nil per os from midnight before their cesarean section"
11046911|NCT04450667|Active Comparator|Rehydration|Patient will receive 400 mL of Nutricia Preop ® 2 hours before their cesarean section
11046912|NCT04450654|Experimental|Gamunex-C IVIG|Gamunex-C IVIG dosed at 2g/kg will be given on week 0 and week 4.
11046913|NCT04450654|Placebo Comparator|Placebo|Albumin in a 1% solution at an equivalent volume to the corresponding Gamunex-C IVIG dose will be given at week 0 and week 4.
11046914|NCT04450641|Experimental|Treatment|Treatment group used GuessWhat during the 4 week intervention period.
11046915|NCT04450641|Other|Control|Participants in control group received standard treatment as usual.
11046916|NCT04450628|No Intervention|Surgeon blinded|"During blinded cases no adjustment will be made to the surgical procedure based on EndoFLIP results, as the operating surgeon will not be informed of the measured values.
~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
11046917|NCT04450628|Experimental|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.
~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
11046918|NCT04450615|Experimental|Training group|"The first part of the program aims in pelvic and hip mobility and includes the following exercises, glute bridge, single-leg glute bridge, side-lying clam, side plank and side plank with hip abduction, on stable surface.
~The second part consists of exercises for deep and superficial trunk muscles. In the first exercise the participants learn to activate the transversus abdominis muscle from the crook-lying position, by performing abdominal hollow. Other exercises include the front plank, trunk curl-up, trunk curl-up on stable surface and curl-up on unstable surface (Swiss ball).
~The third part of the program consists of exercises for strengthening the lumbar multifidus muscle. The participants will perform prone trunk extension, superman exercise, quadruped diagonal arm and leg lift, single leg supine bridge and supine bridge on unstable surface (Swiss ball)."
11046919|NCT04450615|No Intervention|Control group|The participants of this group will follow their typical daily routine
11046920|NCT04450602|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR (Patent Pending) active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
11046921|NCT04450602|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
11046922|NCT04450589|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
11046923|NCT04450589|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
11046924|NCT04450563|Active Comparator|Placebo + closed-loop insulin system|
11046925|NCT04450563|Experimental|Empagliflozin 2.5 mg + closed-loop insulin system|
11046926|NCT04450563|Experimental|Empagliflozin 5 mg + closed-loop insulin system|
11046927|NCT04450550|Active Comparator|Active|
11046928|NCT04450550|Sham Comparator|Sham|
11046929|NCT04450537|Experimental|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
11046930|NCT04450537|No Intervention|Sun Safety Control|Participants will be exposed 10 sun safety messages
11046931|NCT04450524|Experimental|Hypnosis|Hypnosis formed from hypnotic induction (an adapted version from Harvard Group Scale of Hypnotic Susceptibility) together with hypnotic suggestions about a future where they will control their eating behaviors by choosing the low-calorie food instead of dense calorie one.
11046932|NCT04450524|Experimental|Food Inhibition Training|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press or not a button when the pictures are framed in a bold frame (dense calorie food).
11046933|NCT04450524|Placebo Comparator|Control|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press the button to indicate the position of the picture - left or right.
11046934|NCT04450511|Active Comparator|Group 1: Bladder Training (BT)|BT, consisting of four stages, did not contain any PFMT programs in all groups. In these stages, including urgency supression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women were encouraged to pause/stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
11046935|NCT04450511|Experimental|Group 2: Bladder Training+Magnetic Stimulation|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is in serted by this magnetic ﬁeld, an eddy current ﬂow is generated. This eddy current stimulates nerve or muscle of the pelvic ﬂoor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
11046936|NCT04450498|Experimental|Walvax MPV ACYW® vaccine group|
11046937|NCT04450498|Active Comparator|Sanofi Pasteur Menactra® vaccine group|
11046938|NCT04450485|Active Comparator|Medial para-patellar approach|Fast track protocol applied total knee arthroplasty patients operated by using medial para-patellar approach
11046939|NCT04450485|Active Comparator|Mini mid-vastus approach|Fast track protocol applied total knee arthroplasty patients operated by using mini mid-vastus approach
11046940|NCT04450446||cerebral hemorrhage|
11046941|NCT04450446||thromboembolism|
11046942|NCT04450446||no thromboembolism and cerebral hemorrhage|
11046943|NCT04450433||Baseline table of patients|
11046944|NCT04450433||Differential metabolites of two groups of control patients|
11046945|NCT04450433||Functional verification of differential metabolites|
11046946|NCT04450420|Experimental|Simulation based curriculum|"Three phases:
~Self-study of an eBook - Participating trainees will be required to learn material pertaining to tunnel construction and general surgical principles during SICS from an eBook that has been developed by HelpMeSee.
~Instructor led teaching - didactic training, lab activities to gain familiarity with instruments, simulator based training through deliberate practice, and debriefing with instructor.
~Instructor supervised performance of surgery on patients in the operating room."
11046947|NCT04450420|Active Comparator|Standard training|Current standard curriculum for resident training.
11046948|NCT04450407|Experimental|LY3209590 Algorithm 1|LY3209590 administered subcutaneously (SC).
11046949|NCT04450407|Experimental|LY3209590 Algorithm 2|LY3209590 administered SC.
11046950|NCT04450407|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
11046951|NCT04450394|Experimental|LY3209590 Algorithm 1|LY3209590 administered subcutaneously (SC).
11046952|NCT04450394|Experimental|LY3209590 Algorithm 2|LY3209590 administered SC.
11046953|NCT04450394|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
11046954|NCT04450381|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
11046955|NCT04450368||Cases with Air Trapping|20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
11046956|NCT04450368||Cases without Air Trapping|20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
11046957|NCT04450368||Healthy Controls|Non COPD patients and non-smokers
11047181|NCT04448717||Children and adolescents|Children and adolescents in primary and secondary schools (aimed sample size: 2500)
11046958|NCT04450355|Experimental|Nefopam group|At the end of induction, the nefopam group will receive intravenous nefopam 20mg mixed with 50ml of normal saline, and at the end of surgery, this group will receive intravenous nefopam 60mg mixed with 50ml of normal saline at a rate of 2ml/hr.
11046959|NCT04450355|Placebo Comparator|Control group|The control group will receive intravenous normal saline 50ml at the end of induction and receive intravenous normal saline 50ml at a rate of 2ml/hr at the end of surgery.
11046960|NCT04450342|Experimental|ARCR augmented with REGENETEN™ Bioinductive Implant|During the ARCR procedure, the REGENETEN™ Bioinductive Implant is covering the tendon and attached to the bone and the tendon with small anchors.
11046961|NCT04450342|Sham Comparator|ARCR alone|The rotator cuff is repaired during arthoscopic standard procedure. No product is added for healing
11046962|NCT04450342|Other|ARCR revision group|ARCR revision group allows treatment of subjects having recurrent tears, ARCR supplemented with REGENETEN
11046963|NCT04450329|Experimental|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
11046964|NCT04450329|Active Comparator|Eylea (Aflibercept)|"Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
~At Week 32, subjects in Eylea group will re-randomized into SB15 or Eylea group. After re-randomization, subjects transited to SB15 group will receive SB15 2 mg (0.05 mL) once every 8 weeks until Week 48 and subjects remaining in Eylea group will continue to receive Eylea 2 mg (0.05 mL) once every 8 weeks until Week 48."
11046965|NCT04450316|Active Comparator|Low-dose naltrexone|4.5mg of naltrexone to be taken one hour prior to bedtime nightly for 8 weeks.
11046966|NCT04450316|Placebo Comparator|Placebo|Placebo tablet (sugar-pill) to be taken one hour prior to bedtime nightly for 8 weeks.
11046967|NCT04450303|Experimental|Telehealth Therapy|
11046968|NCT04450290|Experimental|single arm - treatment|All subjects will be implanted with the investigational device.
11046969|NCT04450264|Other|Breast Cancer Education Program|
11046970|NCT04450251||Pregnant women, at least 24 weeks gestation|
11046971|NCT04450238||Study Group|"All participants are inpatients at the clinic Stillachhaus in Germany. They are receiving treatment for a variety of psychological disoders, mostly depressive disoders."
11046972|NCT04450212|Experimental|Phase I, Buccal Swab Collection for DNA Isolation|Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
11046973|NCT04450212|Experimental|Phase II, Vitamin K (Vitacost) Supplementation|Subjects from Phase I with a homozygous CYP4F2*1 (n=14) or CYP4F2*3 (n=14) genotype are selected to receive daily vitamin K supplementation, for 10-days. Blood and urine samples are collected sequentially, at baseline, and during the supplementation period.
11046974|NCT04450199|Active Comparator|Vitamin D|12 over encapsulated 50,000 IU Vitamin D2
11046975|NCT04450199|Placebo Comparator|Placebo|12 over encapsulated placebo tablets
11046976|NCT04450186|Experimental|EEG/fMRI neurofeedback|Healthy volunteers
11046977|NCT04450173|Experimental|Treatment (obinutuzumab, venetoclax, ibrutinib)|Patients receive obinutuzumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, and 24. Patients also receive venetoclax PO QD on days 1-28 (days 4-28 of cycle 1) and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11046978|NCT04450160|Placebo Comparator|Standard of Care|Current GBM Treatment of surgery, radiation and chemotherapy with temozolomide.
11046979|NCT04450160|Experimental|AEO with Standard of Care|Anhydrous Enol-Oxaloacetate added to the Standard of Care (surgery, radiation and chemotherapy with temozolomide).
11046980|NCT04450147|Experimental|Tai Chi and Qigong|50mins x 12 weeks of virtually-delivered group tai chi/qigong
11046981|NCT04450147|Active Comparator|Walking and Stretching|50mins x 12 weeks of virtually-delivered group walking and stretching
11046982|NCT04450134|Placebo Comparator|Placebo|6 weeks high-intensity interval training + placebo intake
11046983|NCT04450134|Experimental|Blockade|6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
11046984|NCT04450121|Active Comparator|GA (n =22)|Patients will be intubated using Air-Q airway
11046985|NCT04450121|Active Comparator|GF (n =22)|Patients will be intubated using Fekry airway
11046986|NCT04450095|Active Comparator|Treated group|Tab. Volibris 10mg given once a day for 5 days, starting 48 hours before surgery (in addition for the standard treatment for partial nephrectomy)
11046987|NCT04450095|No Intervention|Control group|Treated with the standard treatment for partial nephrectomy
11046988|NCT04450082||One anastomosis gastric bypass|One anastomosis gastric bypass in Sleeve Gastrectomy failure
11046989|NCT04450069|Experimental|Dose Escalation|CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
11046990|NCT04450056||Mother-infant pairs|Mothers with a term-born (>37 weeks gestation) infant whom they are exclusively or predominantly breastfeeding at 1 month postpartum. Mothers must be enrolled in the MaPPS Trial (ClinicalTrials.gov Identifier: NCT03287882).
11046991|NCT04450043|Experimental|Run In|"Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study.
~Participants will receive Sessions 1-5 of the psychoeducational intervention condition and will complete both assessments and a semistructured interview about the intervention.
~Session 1 with a study interventionist, focused on identifying participant's goals, expectations and wishes for post-treatment quality of life, as well as a handout listing local and national support resources.
~Session 2-5 is focused on teaching skills to enhance post-treatment quality of life, with attention to (a) managing expectations about life after cancer treatment, (b) managing uncertainty (e.g., fears of cancer recurrence), (c) enhancing self-management of residual symptoms and (d) strengthening social support"
11047023|NCT04449874|Experimental|Dose-escalation (Stage I), Dose Expansion (Stage II)|"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a safety threshold is observed.
~Participants with select solid tumors will be treated with GDC-6036 PO QD in Stage II."
11047182|NCT04448717||Parents|Parents of participating children (aimed sample size: 3000)
11046992|NCT04450043|Experimental|Intervention=Study Sessions|"Participants randomized to this arm will receive Sessions 1-5
~Session 1 with a study interventionist, focused on identifying participant's goals, expectations and wishes for post-treatment quality of life, as well as a handout listing local and national support resources.
~Session 2-5 is focused on teaching skills to enhance post-treatment quality of life, with attention to (a) managing expectations about life after cancer treatment, (b) managing uncertainty (e.g., fears of cancer recurrence), (c) enhancing self-management of residual symptoms and (d) strengthening social support"
11046993|NCT04450043|No Intervention|Control=Session 1 and No Additional Study Sessions|Participants randomized to this arm will receive Session 1 with a study interventionist, focused on identifying participant's goals, expectations and wishes for post-treatment quality of life, as well as a handout listing local and national support resources.
11046994|NCT04450030||Intravenous methyl prednisolone|Patients receiving an additional course of intravenous methyl prednisolone for treatment of a steroid-refractory MS relapse
11046995|NCT04450030||Immunoadsorption|Patients receiving 6 courses of immunadsorption treatment for treatment of a steroid-refractory MS relapse
11046996|NCT04450017||Clinical Features of Severe Patients With COVID-19|Critical ill patients with COVID-19 admitted to the ICU. The demographic, clinical data, laboratory data, and Instrumental data will be analysed.
11046997|NCT04450004|Experimental|Vaccine (3.75 µg) unadjuvanted|• Group 1: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine
11046998|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with CpG 1018|• Group 2: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
11046999|NCT04450004|Experimental|Vaccine (3.75 µg) adjuvanted with AS03|• Group 3: 3.75 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
11047000|NCT04450004|Experimental|Vaccine (7.5 µg) unadjuvanted|• Group 4: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
11047001|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with CpG 1018|• Group 5: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
11047002|NCT04450004|Experimental|Vaccine (7.5 µg) adjuvanted with AS03|• Group 6: 7.5 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
11047003|NCT04450004|Experimental|Vaccine (15 µg) unadjuvanted|• Group 7: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine unadjuvanted
11047004|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with CpG 1018|• Group 8: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with CpG 1018
11047005|NCT04450004|Experimental|Vaccine (15 µg) adjuvanted with AS03|• Group 9: 15 µg of the Coronavirus-Like Particle COVID-19 Vaccine adjuvanted with AS03
11047006|NCT04449991|Experimental|Intervention arm: Repeat kidney biopsy at M12|Patients will undergo repeat kidney biopsy at month 12 from baseline.
11047007|NCT04449991|No Intervention|Control arm: No repeat kidney biopsy|Patients will not undergo repeat kidney biopsy at month 12 from baseline.
11047008|NCT04449965|Experimental|PVP-I sinus rinses and throat gargles|Participants will dilute 7 mL of 10% PVP-I into 300 mL of saline for a final concentration of 0.23% available iodine. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
11047009|NCT04449965|Placebo Comparator|Placebo sinus rinses and throat gargles|Participants will dilute 7 mL of PVP-I placebo into 300 mL of saline. They will be instructed to rinse each nostril with 120ml (total 240mL) in a NeilMedTM sinus rinse bottle, and gargle with 60 mL of the solution.
11047010|NCT04449965|Experimental|PVP-I gel forming nasal spray|0.6% PVP-I gel forming nasal spray will come prepared and ready for participants to use. They will be instructed to use two sprays to each nostril each time they administer the spray.
11047011|NCT04449952|Experimental|AFEO-Containing Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive AFEO-containing mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 milliliter (mL) of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
11047012|NCT04449952|Experimental|Listerine Cool Mint Mouth Rinse (Marketed product)|Participants with Diabetes (Type 1 and 2) will be randomized to receive Listerine cool mint mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
11047013|NCT04449952|Experimental|5 Percent (%) Hydroalcohol Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
11047014|NCT04449939|Experimental|Group 1|Single dose of KY1005 by i.v. infusion
11047015|NCT04449939|Experimental|Group 2|Single lower dose KY1005 by s.c. injection
11047016|NCT04449939|Experimental|Group 3|Single higher dose KY1005 by s.c. injections
11047017|NCT04449926|Experimental|BCG Vaccinated|"Experimental: BCG Group FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area. A follow up booster dose will be given one month after the initial dose."
11047018|NCT04449913|Experimental|Active group|10 days intensive meditation retreat
11047019|NCT04449913|Other|Control group|Waiting for a 10 days intensive meditation retreat
11047020|NCT04449900||The exudative CCH group|Treatment naïve patients with exudative CCH which caused subfoveal retinal detachment and/or intraretinal fluid
11047021|NCT04449900||The healthy eye control group|In the healthy eye control group, all eyes should have no ocular diseases and the best-corrected visual acuity (BCVA) should be 20/20 or better.
11047024|NCT04449861|Experimental|Durvalumab plus 4-6 cycles chemotherapy|Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
11047025|NCT04449848|Experimental|Sitting after intra tympanic injection|Patients with Sudden hearing loss sitting after intra tympanic injection of steroids
11047026|NCT04449822|Active Comparator|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
11047027|NCT04449822|Active Comparator|Colonic stenting|The colonic stent placement
11047028|NCT04449809|Experimental|Exercise|Exercise program
11047029|NCT04449783||study patients|Patients undergoing elective cancer surgery, who will receive pre-operative screening including reporting symptoms and nose and throat swabbing 48 hours prior to surgery
11047030|NCT04449757|Experimental|bicarbonated ringer's solution|We apply bicarbonated ringer's solution as resuscitation fluid to patients with septic shock.
11047031|NCT04449757|Experimental|lactated ringer's solution|We apply lactated ringer's solution as resuscitation fluid to patients with septic shock.
11047032|NCT04449744|Active Comparator|MySafeRx Group A-(coaching + medication dispenser)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
11047033|NCT04449744|Experimental|MySafeRx Group B-(coaching + dispenser based on clinical need)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a manual lockbox, and a standardized protocol for supervising self-administration of medication via videoconferencing. Participants will be assessed bi-weekly by their clinical team for substance abuse, coaching and medication adherence, compliance with urine drug screen policies, safety/ risk or mental health concerns, and diversion. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study.
11047034|NCT04449731||Adult population (> 18 years old)|Around 30000 adults (> 18 years old) from 22 different countries.
11047035|NCT04449718|Experimental|Experimental|Patients will receive 200,000 IU of vitamin D3 on admission + conventional care
11047036|NCT04449718|Placebo Comparator|Placebo|Patients will receive an equivalent amount of a placebo solution on admission + conventional care
11047037|NCT04449692|Experimental|80 µg s.c. dasiglucagon|80 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
11047038|NCT04449692|Experimental|120 µg s.c. dasiglucagon|120 µg of dasiglucagon will be administered subcutaneously when plasma glucose levels reach 4.5 mmol/l
11047039|NCT04449692|Active Comparator|15 g oral carbohydrate (dextrose tablets)|15 g of oral carbohydrate (dextrose tablets) will be administered when plasma glucose levels reach 4.5 mmol/l
11047040|NCT04449679|Experimental|Health Services Research (RT-CAMSS)|Patients receive RT-CAMSS over 2 months or until chemotherapy is discontinued, whichever is earlier. RT-CAMSS consists of text messages addressing knowledge about specific cancer type and chemotherapy, side-effect prevention, suggestions of lifestyle behavioral changes and emotional support, and preparation for surgery. Patients then record their symptoms through answering a series of questionnaires and receive tailored feedback according to their answers, including a consultation with a nurse.
11047041|NCT04449666||Experimental group|Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage
11047042|NCT04449666||Control group|Healthy adults controlled for age, gender and educational status
11047043|NCT04449653||Lupus Cases|Individuals who are diagnosed with System Lupus Erythematosus and consent to the study will be placed in this cohort. Upon enrollment they will be given the opportunity to invite a non-SLE-diagnosed friend to enroll in the study as a healthy control. These individuals will answer weekly questions and receive a smartwatch to measure their physical activity.
11047044|NCT04449640||Uterine rupture|Women who had uterine rupture during pregnancy.
11047045|NCT04449627||Naturalistic cohort|Patients who were hospitalised between March and June from Covid19, who did not require treatment in intensive care, who at 8 weeks post discharge have symptoms of anxiety or depression. All patients are offered access to an audio based self help programme based on applied relaxation and mindfulness based cognitive therapy.
11047046|NCT04449614||1|"Inclusion criteria: All consenting Infants and children who have had A Congenital Pulmonary Airway Malformation (CPAM) surgically removed by thoracoscopy over a 10 year period (2008-2017) in a regional centre.
~Exclusion criteria: Non consenting participants"
11047047|NCT04449601||Group 1 (with hypertension )|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
11047048|NCT04449601||Group 2( without hypertension)|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
11047049|NCT04449588|Experimental|Treatment group|
11047050|NCT04449588|Experimental|Control group|
11047051|NCT04449575||Health care workers with hand eczema|Swabs will be taken from eczema lesions on dominating hand (if possible) and nostril
11047052|NCT04449575||controls (health care workers without hand eczema)|swabs will be taken from healthy skin on dominating hand and nostril
11047053|NCT04449549|Experimental|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28- day cycles.
11047054|NCT04449536|Experimental|Mesna|Administration of a single oral dose of 400 mg, 800 mg, 1200 mg or 1600 mg
11047055|NCT04449510|Other|E-liquid pH 5, 7, or 9|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned e-liquid pH.
11047056|NCT04449510|Other|1 of the other 2 remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
11047691|NCT04445220|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
11047057|NCT04449510|Other|Remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining assigned e-liquid pH.
11047058|NCT04449497||Bereaved caregivers|Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
11047059|NCT04449497||Country experts|Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
11047060|NCT04449497||Patients|Patients with life-limiting or life-threatening illness or condition associated with serious health-related suffering who have undergone or are undergoing palliative care
11047061|NCT04449484|Experimental|MEDI1341|3 doses given at 4 week intervals
11047062|NCT04449484|Placebo Comparator|Placebo|3 doses given at 4 week intervals
11047063|NCT04449471|Experimental|Naproxen Tablet|Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
11047064|NCT04449458|Experimental|Positively Me|Positively Me is a 12-session (8 [1.5] hour main sessions plus four booster sessions) intervention guided by Social Cognitive Theory to promote smoking cessation in people with certain health conditions.
11047065|NCT04449458|Sham Comparator|Positively Living|Positively Living is a modified updated version of a healthy living intervention based on Social Cognitive Theory that is designed for people with certain health conditions and attention-matched to the experimental condition (8 [1.5] hour main sessions plus four booster sessions).
11047066|NCT04449445|Other|Standard enteral tube feeds|Patients will be instructed to continue a normal diet before surgery. Post-operatively, patients will receive standard of care isocaloric and iso-nitrogenous standard enteral tube feeds
11047067|NCT04449445|Experimental|Nestle IMPACT AR|Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
11047068|NCT04449432|Experimental|GROWell (Interactive Obesity Treatment Approach)|With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
11047069|NCT04449432|Active Comparator|Attention Support Control|The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
11047070|NCT04449419||very severe COPD|Patients diagnosed with COPD and FEV1 less than 30
11047071|NCT04449419||Severe COPD|Patients diagnosed with COPD and FEV1 less than 50
11047072|NCT04449419||Moderate COPD|Patients diagnosed with COPD and FEV1 less than 80
11047073|NCT04449419||Mild COPD|Patients diagnosed with COPD and FEV1 80 or more.
11047074|NCT04449419||CONTROL|Non-copd control group
11047075|NCT04449419||Exacerbated Patients|Patients 48 hours after hospital admission for COPD exacerbation.
11047076|NCT04449406||Individuals at risk of developing PDAC|"Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study)
~Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry)
~Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available)."
11047077|NCT04449393|Experimental|Emdogain® FL|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation. EDTA gel will be applied for 2 minutes in the respective pockets, followed by rinsing with saline, drying and application of Emdogain® FL.
11047078|NCT04449393|Placebo Comparator|Control group|Non-surgical periodontal therapy in terms of scaling and root planing will be applied at sites with remaining periodontal pockets at reevaluation, followed by rinsing with saline.
11047079|NCT04449380|Experimental|IFNβ 1a|
11047080|NCT04449380|Active Comparator|Standard care|
11047081|NCT04449367||Randomized and Single-Arm Trials|a sham comparator (no intervention)
11047082|NCT04449354|Other|Quality of Life assessment|HidraWear AX Garment
11047083|NCT04449341|Experimental|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
11047084|NCT04449341|No Intervention|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
11047085|NCT04449328|Experimental|Patient with first stroke causing hemiplegic|"Patient with first stroke causing hemiplegic will be included.
~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:
~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))
~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
11047114|NCT04449107|Experimental|Intervention Arm|The intervention arm in addition to the standard counselling will include receiving text messages, voice messages, pictorial messages and video messages regarding vaccination once a week till the child turns 14 weeks
11047183|NCT04448717||School personnel|School personnel (teaching, administrative, maintenance, etc.) (aimed sample size: 2500)
11061111|NCT04349800|Experimental|Single Ascending Dose - 160 mg|
11047086|NCT04449328|Sham Comparator|healthy subjects|"Healthy subjects will be included.
~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:
~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))
~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
11047087|NCT04449315|Experimental|Peppermint and Lavender Essential Oil|Young Living Essential oil of Peppermint and Lavender will be used to patients who meet the inclusion criteria.
11047088|NCT04449302|Experimental|Immediate molar implant with customized healing abutment|Patients will receive an immediate mandibular molar implant with customized healing abutment
11047089|NCT04449302|Active Comparator|Immediate molar implant with submerged healing|Patients will receive an immediate mandibular molar implant with submerged healing
11047090|NCT04449289|Active Comparator|Intravenous lidocaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
11047091|NCT04449289|Active Comparator|Epidural ropivacaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
11047092|NCT04449276|Experimental|Dose Escalation CVnCoV|"Participants will be vaccinated with CVnCoV at escalating dose levels on Day 1 and Day 29. Safety data will inform the decision to continue enrolling at the current dose level, or to proceed to dose escalation. Initially, dose levels of 2, 4 and 8 μg will be evaluated.
~Dose levels of 2, 4, 6, 8 and 12µg will be evaluated with potential increase to dose levels up to 20 μg"
11047093|NCT04449276|Placebo Comparator|Dose Escalation Placebo|Participants will be given placebo on Day 1 and Day 29.
11047094|NCT04449263|Experimental|Lens A (Test) then Lens B (Control)|Subjects will be randomized to wear Lens A (test) then Lens B (control) for 3 weeks in this randomized, cross-over bilateral dispensing study.
11047095|NCT04449263|Active Comparator|Lens B (Control) then Lens A (Test)|Subjects will be randomized to wear Lens B (control) then Lens A (test) for 3 weeks in this randomized, cross-over bilateral dispensing study.
11047096|NCT04449250|Active Comparator|CTx-1301 Fasted|Subjects will receive CTx-1301 in a fasted state.
11047097|NCT04449250|Active Comparator|CTx-1301 Fed|Subjects will receive CTx-1301 in a fed state (high fat meal).
11047098|NCT04449237|Other|volunteer|40 volunteer will not accept any treatment
11047099|NCT04449237|Placebo Comparator|patients with unmodified music group|40 participants in this group will listen to music without any modification
11047100|NCT04449237|Experimental|patients with modified tinnitus relieving music|40 participants in this group will listen to the music modified according to the matched dominant tinnitus pitch
11047101|NCT04449224||RA patients who start bDMARD|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a biologic disease modifying antirheumatic drug (bDMARD) including Adalimuab, Etanercept, Tocilizumab or Abatacept after shared-decision making.
11047102|NCT04449224||RA patients who start small molecule inhibitor|The efficacy and safety of targeted therapy will be evaluated in RA patients who are treated with a small molecular inhibitor including Tofacitinib or Baricitinib after shared-decision making.
11047103|NCT04449211|Experimental|Participants with massive bone defect|"Adult participants with health insurance regardless of sex having bone defect greater than 5cm due to trauma or tumour resection agree to participate the research.
~The customised 3D-Printed implant is manufactured and undergoes post-processing treatment before being ready for implantation surgery."
11047104|NCT04449198|Experimental|Individuals with type 1 diabetes|Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
11047105|NCT04449198|No Intervention|Healthy Controls|Healthy individuals who participate will receive no intervention and serve as controls.
11047106|NCT04449185|Experimental|HP eradication group|"HP eradication group
~Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days"
11047107|NCT04449159|Placebo Comparator|Placebo|
11047108|NCT04449159|Experimental|Vinh Wellness Collagen|
11047109|NCT04449146|Experimental|shoulder localizer ultrasound|The localizer ultrasound of the shoulder is performed on an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer. The Protocol plans to acquire different landmarks on the scapula: lower angle, coracoid, scapula spine and bilateral acromioclavicular joint (definition of the coronal plan). These acquisitions are carried out by the probe connected to a Tablet (Microsoft surface Pro 3) which allows to locate the probe and by extension of the probe the location of the points selected by ultrasound.
11047110|NCT04449133|Experimental|Treatment Group 1|AD128 for 7 days, then, after a wash-out period of 7-10 days, placebo for 7 days
11047111|NCT04449133|Experimental|Treatment Group 2|Placebo for 7 days, then, after a wash-out period of 7-10 days, AD128 for 7 days
11047112|NCT04449120|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one-month. Three visits will be scheduled for participants assigned to this group:
~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
11047113|NCT04449120|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group received the written nutrition educational information as well as four online cooking classes (one cooking class per week) during the one-month intervention period. Three visits will be scheduled for participants assigned to this group:
~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected.
~Participants will attend 4 culinary workshops between visit 2 and 3. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
11047115|NCT04449107|No Intervention|Control Arm|The control group will receive one-time standard verbal counselling at the time of initial visit for on-time EPI vaccines at 10 and 14 weeks of age as recommended by EPI, government of Pakistan.
11047116|NCT04449068||Evaluation of patients with Tourette's Gilles Syndrome|Neurological and neuropsychological evaluations of patients with Tourette's Gilles syndrome treated with high frequency bilateral stimulation of the anterior part of the internal pallid globus
11047117|NCT04449055|Experimental|Study arm|Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TBS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use.
11047118|NCT04449042||COVID19 positive|a recently performed test which is positive for coronavirus infection
11047119|NCT04449042||COVID19 negative|a recently performed test which is negative for coronavirus infection
11047120|NCT04449042||COVID19 presumed positive|patients who do not have testing or who have negative testing but whose symptoms, history, physical exam, laboratory and imaging findings are consistent with infection with COVID19 and are treated as positive
11047121|NCT04449042||COVID19 presumed negative|patients who do not have testing, but based on symptoms, history, physical exam, laboratory and imaging findings are deemed to be low risk for COVID19 infection and are treated as negative
11047122|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD|Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.
11047123|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
11047124|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
11047125|NCT04449029|Experimental|Cohort 1: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
11047126|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.
11047127|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
11047128|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
11047129|NCT04449029|Experimental|Cohort 2: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
11047130|NCT04449016|Experimental|Caucasian|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
11047131|NCT04449016|Experimental|Hispanic|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
11047132|NCT04449003||Adolescents with Tourette Syndrome|Adolescents with Tourette Syndrome
11047133|NCT04448990|Experimental|tVNS|Stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) bilaterally at the cymba conchae of the auricles for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
11047134|NCT04448990|Sham Comparator|Sham|Same stimulation will be applied using TENS device eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany) to bilaterally to the earlobes for 20 minutes. Current intensity (1-max. 10 mA) will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.
11047135|NCT04448977||Multiple Sclerosis group 1|Individuals with Multiple Sclerosis who are going to be starting Ocrevus as determined by Neurologist as part of clinical care.
11047136|NCT04448977||Multiple Sclerosis group 2|Individuals with Multiple Sclerosis who are going to be starting Copaxone as determined by Neurologist as part of clinical care.
11047137|NCT04448977||Healthy Controls|Healthy individuals who are age, gender and education matched to the other groups.
11047138|NCT04448964|Experimental|Part 1: Treatment Sequence ABC|Participants will receive a single dose of JNJ-70033093 spray-dried dispersion (SDD) tablet under fasted conditions (Treatment A) in Treatment Period 1, followed by JNJ-70033093 SDD tablet in fed conditions (Treatment B) in Treatment Period 2, and then JNJ-70033093 SDD granule capsule under fasted conditions (Treatment C) in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047139|NCT04448964|Experimental|Part 1: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047140|NCT04448964|Experimental|Part 1: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047179|NCT04448730||Group 1 (normal weight with PCOS )|35 cases
11047180|NCT04448730||overweight PCOS|38 cases
11047141|NCT04448964|Experimental|Part 1: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047142|NCT04448964|Experimental|Part 1: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment C in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047143|NCT04448964|Experimental|Part 1: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047144|NCT04448964|Experimental|Part 2: Treatment Sequence DE|Participants will receive Treatment D (single dose of JNJ-70033093 SDD tablet in fed conditions) in Treatment Period 1, and then Treatment E (single dose of JNJ-70033093 SDD granule capsule under fasted conditions) in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047145|NCT04448964|Experimental|Part 2: Treatment Sequence ED|Participants will receive Treatment E in Treatment Period 1, and then Treatment D in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
11047146|NCT04448951||sepsis/septic shock|target population
11047147|NCT04448951||non-septic critically ill|demographically-matched control group
11047148|NCT04448951||healthy control|control group
11047149|NCT04448938||optic neuritis|
11047150|NCT04448938||control|
11047151|NCT04448925|Experimental|Recovery duration 15 seconds|Resting for 15 sec
11047152|NCT04448925|Experimental|Recovery duration 30 seconds|Resting for 30 sec
11047153|NCT04448925|Experimental|Recovery duration 45 seconds|Resting for 45 sec
11047154|NCT04448912||Open-abdomen treatment|Patients with non-traumatic abdominal emergencies undergoing surgery with open-abdomen treatment.
11047155|NCT04448912||Primary abdominal closure|Patients with non-traumatic abdominal emergencies undergoing surgery with primary abdominal closure.
11047156|NCT04448899|Active Comparator|Ivabradine|
11047157|NCT04448899|Placebo Comparator|Control|
11047158|NCT04448886|Experimental|Sacituzumab Govitecan + Pembrolizumab|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits. Each Cycle =21 Days
~Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle
~Pembrolizumab (iv) fixed dose administered once per cycle"
11047159|NCT04448886|Experimental|Sacituzumab Govitecan|"The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.
~- Sacituzumab Govitecan (iv) fixed dose, administered twice per cycle"
11047160|NCT04448886|Experimental|Retreatment|"Participants randomized to the combination arm (sacituzumab govitecan + pembrolizumab) may elect to stop pembrolizumab and/or sacituzumab govitecan with confirmed CR after at least 24 weeks of treatment. These participants would still be required to undergo regular disease restaging every 9-12 weeks.
~Participant who stop pembrolizumab and/or sacituzumab govitecan with CR may be eligible for additional pembrolizumab and/or sacituzumab govitecan therapy if they progress after stopping study treatment.
~This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the subject meets the following conditions"
11047161|NCT04448873|Active Comparator|Maintenance treatment group|After at least 2 years of remission of KHE, the participant receives sirolimus as usual. The serum concentration is supposed to be 5-7 ng/ml. If the effect or side effects of sirolimus require discontinuation, it is allowed to modify intervention, and if so, the patient stays in the maintenance group.
11047162|NCT04448873|Experimental|Guided discontinuation group|"After at least 2 years of remission of KHE, the discontinuation measurement should be guided by the clinician with the following principles:
~10% monthly reduction of the previous dose at most.
~At least 5 half-lives between each reduction (2 weeks).
~Blood concentration should be monitored monthly. Adjustment can be suggested according to the linear relationship between the dose and the blood concentration.
~At least 6 months for the duration of guided discontinuation.
~Regular assessments and evaluations should be done.
~If the condition relapses or worsens during this process, dose of sirolimus should be adjusted to the previously effective dose. After a 3-month stabilization phase, 5% monthly reduction of the previous dose could be considered."
11047163|NCT04448860|Experimental|Retinitis Pigmentosa patients|Patients with Retinitis Pigmentosa (RP) at different stages of impairment of the visual field, acuity and sensitivity to contrasts 15 patients will be included in phase 1 versus 36 in phase 2 (15 in step 1 and 21 in step 2).
11047164|NCT04448860|Other|healthy volunteers patients|36 patients will be included just in phase 2 (15 in step 1 and 21 in step 2).
11047165|NCT04448847|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
11047166|NCT04448847|Experimental|Bif195 arm|Active trial product with minimum 100 billion CFU daily dose
11047167|NCT04448834|Experimental|Treatment|A single cycle of blinatumomab which includes 4 weeks of CIVI of blinatumomab followed by a 2 week treatment free interval
11047168|NCT04448821|Experimental|Sequence A|Period 1: metformin; Period 2: metformin + nilotinib
11047169|NCT04448821|Experimental|Sequence B|Period 1: metformin + nilotinib; Period 2: metformin
11047170|NCT04448808|Experimental|BX-1 (dronabinol)|BX-1
11047171|NCT04448808|Placebo Comparator|Placebo|Placebo of BX-1
11047172|NCT04448769|Other|Anti-SARS-CoV-2 IgT seropositivity|Analysis of the serology result: The ELISA method allows semi-quantitative detection of total IgT antibodies. A positive sample will be defined by a ratio ≥ 1.0.
11047173|NCT04448756|Experimental|M5049 100 mg|
11047174|NCT04448756|Experimental|M5049 200 mg|
11047175|NCT04448756|Placebo Comparator|Placebo|
11047176|NCT04448743||Covid-19 patients|
11047177|NCT04448743||patients with coronary artery disease|
11047178|NCT04448743||healthy volunteers|
11047184|NCT04448691|Other|CCTA|Suspected coronary disease patients enrolled in EVINCI trial with CCTA where recalled for follow up CCTA and blood sampling
11047185|NCT04448678|Experimental|HIEP intervention|Participants will be randomized to receive the insurance navigation intervention from patient navigators, which includes four, one hour long, educational learning sessions. Randomization will be done by age at diagnosis and site.
11047186|NCT04448678|Active Comparator|Usual Care|"Participants will be randomized to receive standard navigation provided by patient navigators (usual care)."
11047187|NCT04448665||patients with suspected infection|The hospitalized patients in whom, based on clinical signs and symptoms, an infection is suspected, and an administration of antimicrobial agents as empiric therapy is necessary.
11047188|NCT04448652||+NSAIDs|Patients undergoing elective colorectal cancer resection before april 1st 2016 were treated with paracetamol tablets 1000 mg and ibuprofen tablets 400 mg four times a day from the day of the operation and until discharge.
11047189|NCT04448652||-NSAIDs|Patients undergoing elective colorectal cancer resection from april 1st 2016 were only treated with paracetamol tablets 1000 mg four times a day from the day of the operation and until discharge.
11047190|NCT04448639||STEMI|Patients with ST-elevation myocardial Infarction (STEMI) (TS) who undergo urgent coronary angiography within 12 hours of symptom onset.
11047191|NCT04448639||TS|Patients with Takotsubo Syndrome (TS) who undergo urgent coronary angiography within 12 hours ofsymptom onset.
11047192|NCT04448626||Healthy subject|Healthy subject
11047193|NCT04448626||Stable COPD patients|Stable COPD patients
11047194|NCT04448626||Exacerbation COPD patients|Exacerbation COPD patients
11047195|NCT04448587|Experimental|Sitagliptin|
11047196|NCT04448561|Experimental|ASP8062 in combination with morphine|Participants will receive multiple oral doses of ASP8062 on days 1 through 10. On day 10, participants will also receive a single oral dose of morphine immediately after the ASP8062 dose.
11047197|NCT04448561|Placebo Comparator|Placebo ASP8062 in combination with morphine|Participants will receive multiple oral doses of placebo on days 1 through 10. On day 10, participants will also receive a single oral dose of morphine immediately after the placebo dose.
11047198|NCT04448535|Experimental|Gingko Biloba|oral intake of gingko biloba for 4 weeks
11047199|NCT04448522|Experimental|Reduced dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 63.6 Gy
11047200|NCT04448522|Active Comparator|Conventional dosage IMRT group|3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent cheomtherapy with IMRT dosage of 69.96 Gy
11047201|NCT04448509|Other|Healthy donor|Healthy donor
11047202|NCT04448496|Experimental|Arms|Diabetic macular edema Dexamethasone 0.7mg is injected into the vitreous cavity. Center-involved macular edema secondary to diabetic retinopathy for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
11047203|NCT04448483|Experimental|Group A|Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
11047204|NCT04448483|Experimental|Group B|Patients belonging to group B will follow an observation period (max. 3 months) before starting intervention I. We will recruit about 15 patients for group B (randomization will take into account the two to one study design) in order to have about 10 patients in Group B that will complete the study.
11047205|NCT04448470||patients with a clinical suspicion of sleep apnea (n=150)|patients with a clinical suspicion of sleep apnea
11047206|NCT04448470||healthy subjects (n=10)|healthy subjects
11047207|NCT04448457|Experimental|SSTS group|Patients received sufentanil nanotab patient controlled analgesia (PCA) system (Zalviso) 15 mcg with 20 min of lockout interval during 48 hours postoperatively
11047208|NCT04448457|Active Comparator|Oxycodone group|Patients received oxycodone extended-release tablet (OxyContin) 10 mg every 12 hours systematically plus Oxycodone 5 mg every 6 hours if numeric rating scale is above 3 during the 48 hours postoperatively
11047209|NCT04448444|Experimental|Motor Program Activating Therapy (MPAT)|The MPAT was chosen for our clinical experience - it was developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centred. Then somatosensory (manual and verbal) stimuli are applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when the patient is lying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to use the acquired motor skills automatically in daily life.
11047210|NCT04448444|Experimental|Vojta Reflex Locomotion (VRL)|VRL was developed by prof. Vojta and is standardly used in the Czech Republic. In this therapy, patients should be set up into the precisely given initial position with defined angular setting of extremities. In each position (supine, prone, lying on the side, and low kneeling position), activation points (zones) are stimulated with precise localization and pressure direction. Such stimulation activates one of the global movement patterns (reflex turning and reflex creeping) corresponding to the initial position. In addition to motor involuntarily reaction, also sensory and autonomic response is activated.
11047211|NCT04448444|No Intervention|healthy controls|sex and age matched healthy controls
11047212|NCT04448431|Experimental|Vortioxetine|8 weeks treatment
11047213|NCT04448431|Active Comparator|Desvenlafaxine|8 weeks treatment
11047214|NCT04448405||Patients followed by the CRIAVS|Patients followed by the CRIAVS (resource center for workers working with authors of sexual violence) in CHU Motpellier from June to October 2020
11047215|NCT04448392|Other|Neonatal HSV disease requiring suppressive therapy|All subjects enrolled in the study will receive 2 (up to 7) days of valacyclovir 20 mg/kg every 8 hours after completion of standard of care treatment course with acyclovir.
11047216|NCT04448379|Experimental|Dose Escalation Cohort|"Two dose levels of JMT101 combined with afatinib or osimertinib will be tested according to the 3 + 3 dose-escalation design.
~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
11047217|NCT04448379|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
11047218|NCT04448366|Experimental|Cognitive behavioral therapy group|Patients in this group will undergo a total of 7 sessions of CBT in 5 months in addition to usual care.
11047219|NCT04448366|No Intervention|Usual care|Patients in this group will undergo usual care only.
11047220|NCT04448353||Development / training|Selected by stratified partitioning
11047221|NCT04448353||Sequestered / test|Selected by stratified partitioning
11047222|NCT04448340||Parkinson Disease Dementia|the PDD group comprised of 58 patients fulfilling the Criteria for probable PDD of the Movement Disorders Society
11047223|NCT04448340||Dementia with Lewy Bodies|the DLB group comprised of 40 patients, according to the recent revised criteria for probable DLB
11047224|NCT04448327|Experimental|Active tVNS|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
11047225|NCT04448327|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
11047226|NCT04448301|Experimental|PointCheck Cohort|
11047227|NCT04448288|Experimental|Hamstring Group|Pretest-posttest experimental design. Subjects participated in three experimental trials on three different days. On day-I for static-stretching for 2 minutes (SS2), day-II for 4 minutes (SS4), and day-III for 8 minutes (SS8). Testing was conducted before (pre), immediately after (post), and at 10 and 20 min post stretching. MVCF was measured using strain gauze as main outcome measure. The SS trials involved varied repetitions of 30-s static-stretches and 20-s relax period. MVC force was assessed.
11047228|NCT04448275|Experimental|study group|received conventional selected exercise program and in addition to Neurodynamics Nerve flossing for femoral nerve
11047229|NCT04448275|Experimental|control group|received conventional selected exercise program in form of: Ultrasound therapy The flexibility exercises for iliopsoas & quadriceps in heamophilic patient The iliopsoas & quadriceps muscles strength exercise
11047230|NCT04448262||G1|Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
11047231|NCT04448262||G2|Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
11047232|NCT04448262||G3|Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
11047233|NCT04448249|Experimental|Interventional group|After inclusion, eligible patients are randomly assigned to one of the following groups: the control group of patients keeps a traditional follow-up (AH then consultation with a MD within approximately two to six months) and the interventional group meets an APN between the AH and the MD consultation, within one to three months
11047234|NCT04448249|No Intervention|Control group|After inclusion, eligible patients are randomly assigned to one of the following groups: the control group of patients keeps a traditional follow-up (AH then consultation with a MD within approximately two to six months) and the interventional group meets an APN between the AH and the MD consultation, within one to three months
11047235|NCT04448236|Experimental|BFR-RE intervention group|"The participants will have the standardised 2 week resistance training with BFR-device with details as follows:
~Cuff size: medium
~Restriction time: 5- 10 mins (stop after finishing 4 sets of training or terminating by Physiotherapists)
~Applied location: alternate quadriceps in consecutive day
~Applied pressure: 80% limb occlusion pressure (LOP)"
11047236|NCT04448236|No Intervention|Control group|"Same standardized 2-week in-patient rehabilitation and same amount of the above-mentioned resistance training without the BFR device."
11047237|NCT04448223|Experimental|CKD-351|CKD-351
11047238|NCT04448223|Active Comparator|Latanoprost+Dorzolamide|Latanoprost(50ul/ml) Dorzolmamide(20mg/ml)
11047239|NCT04448210|Experimental|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
11047240|NCT04448210|No Intervention|Wait-list control|
11047241|NCT04448184|No Intervention|Prophylactic Platelet Transfusion|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
11047242|NCT04448184|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.
11047243|NCT04448171|Active Comparator|Activated TENS Unit with standard pain control measures|Activated TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
11047244|NCT04448171|Placebo Comparator|Sham TENS Unit with standard pain control measures|Sham TENS Unit with standard pain control measures during Office Based Cystoscopic Intra-detrusor Onabotulinumtoxin A Injection
11047245|NCT04448158||5 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 5 years
11047246|NCT04448158||10 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 10 years
11047247|NCT04448145||COVID-19|Participants who have been diagnosed with COVID-19 or experienced symptoms of COVID-19 for more than 7 days.
11047248|NCT04448132|Experimental|IPV-Al AJV|One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.
11047249|NCT04448119|Experimental|Chemoprophylaxis|Participants of LTCH units allocated to the chemoprophylaxis arm receive favipiravir for 25 days. Residents in the LTCH unit diagnosed with COVID- 19 at enrollment will be offered treatment with favipiravir for 14 days.
11047250|NCT04448119|Placebo Comparator|Placebo|Participants of LTCH units allocated to the control arm receive placebo for 25 days. Residents in the LTCH unit diagnosed with COVID-19 at enrollment will be offered treatment with placebo for 14 days.
11047251|NCT04448106|Experimental|Phase 2 Arm 1 - OA Knee|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.
~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
11047252|NCT04448106|Active Comparator|Phase 2 Arm 2 OA Knee|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
11047431|NCT04446884|Active Comparator|control|Patients with Stress urinary incontinence receiving standard treatment
11047253|NCT04448106|Experimental|Phase 2 Arm 3 - OA Hip|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.
~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
11047254|NCT04448106|Active Comparator|Phase 2 Arm 4 - OA Hip|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
11047255|NCT04448106|Experimental|Phase 2 Arm 5 - OA Shoulder|"50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.
~On day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint."
11047256|NCT04448106|Active Comparator|Phase 2 Arm 6 - OA Shoulder|Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion
11047257|NCT04448093|Experimental|Treatment group|Treated group (53) that answered quality of life questionnaires before, after and with 45 days of treatment.
11047258|NCT04448093|No Intervention|Group control|Untreated group (68) that answered quality of life questionnaires before, after and with 45 days of treatment.
11047259|NCT04448080|Experimental|Topical Anesthesia|topical tetracaine eye drops (3 times, given in 1 minute intervals) followed by topical Xylocaine 2% Gel (alcohol-free formulation), given in 1 minute intervals for a total of 5 minutes
11047260|NCT04448080|Active Comparator|Analgosedation|Remifentanil 1mg i.v., and, Thiopental i.v., adapted to patients' weight, age, and hepatic and renal function; usually, a bolus of 150-250mg
11047261|NCT04448067|Experimental|LOW Lentil Intake|Consumption of meals containing 60 g of lentils 5 out of 7 days per week for 8 weeks.
11047262|NCT04448067|Experimental|HIGH Lentil Intake|Consumption of meals containing 120 g of lentils 5 out of 7 days per week for 8 weeks
11047263|NCT04448067|Sham Comparator|CONTROL|Consumption of meals matched in total energy and protein to the lentil meals but containing 0 g of lentils 5 out 7 days per week for 8 weeks
11047264|NCT04448041||Ghana|
11047265|NCT04448041||India|
11047266|NCT04448041||Philippines|
11047267|NCT04448041||Zambia|
11047268|NCT04448028|Placebo Comparator|Intervention group|Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esomeprazole 20mg on day 2, 4, 6, 8, 11, 14, to minimize the risk for gastric acid rebound symptoms.
11047269|NCT04448028|Active Comparator|Control group|Patients randomized to the control group continue their pre-existing PPI therapy with esomeprazole 20mg/day (day 15 to 360). During the first 14 days (dose tapering phase) patients in the control group receive esomeprazole 20mg/day on day 1 to 14.
11047270|NCT04448015|Experimental|Enhanced Perinatal Care|Pregnant women enrolled in the study will receive enhanced perinatal care from community healthcare providers that have participated in the perinatal OUD education curriculum.
11047271|NCT04448002|Experimental|AIM2ACT|AIM2ACT is the experimental arm for the trial. AIM2ACT is a dyadic mHealth intervention designed to sustain caregiver involvement and monitoring as well as guide dyads through collaborative asthma management.
11047272|NCT04448002|Active Comparator|mHealth Attention Control Condition|The mHealth attention control condition is the active comparator arm in the trial that accounts for staff attention and novelty of technology based asthma management intervention.
11047273|NCT04447989|Active Comparator|Cohort 1, sildenafil|Sildenafil (0.5 mg/kg IV or 1 mg/kg enteral) every 8 hours for 28 days
11047274|NCT04447989|Placebo Comparator|Cohort 1, placebo|Placebo (IV or enteral) every 8 hours for 28 days
11047275|NCT04447989|Active Comparator|Cohort 2, sildenafil|Sildenafil (1 mg/kg IV or 2 mg/kg enteral) every 8 hours for 28 days
11047276|NCT04447989|Placebo Comparator|Cohort 2, placebo|Placebo (IV or enteral) every 8 hours for 28 days
11047277|NCT04447989|Active Comparator|Cohort 3, sildenafil|Sildenafil (2 mg/kg IV or 4 mg/kg enteral) every 8 hours for 28 days
11047278|NCT04447989|Placebo Comparator|Cohort 3, placebo|Placebo (IV or enteral) every 8 hours for 28 days
11047279|NCT04447976||Patients undergoing ERCP by formally trained Endoscopists|No intervention has been used and this is an observational study of evaluation of a TIP duodenoscope performance overall.
11047280|NCT04447963|Experimental|Non-invasive treatment of wrinkles and rhytids|"The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete three (3) treatment visits and two follow-up visits.
~At the baseline visit health status will be assessed and, if needed, additional tests will be performed. Inclusion and exclusion criteria will be verified and informed consent will be signed.
~The treatment administration phase consists of three (3) treatment visits, delivered 1 week apart.
~At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device."
11047281|NCT04447950|Experimental|Study group|Posterior QL block with 20-40 cc of Bupivocaine in posterior border of Quadratum Lumborum muscle at the end of the operation.
11047282|NCT04447950|Placebo Comparator|Placebo group|Posterior QL block with 40 cc of Saline in posterior border of Quadratum Lumborum muscle at the end of the operation.
11047283|NCT04447937||Multiple Sclerosis and Related Diseases|Individuals with one or more immunoglobulin level results and medical histories available for data collection will be included. Subjects will be 18 years of age or older at the time of data collection.
11047284|NCT04447924|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
11047285|NCT04447924|Experimental|Bif195 arm|Active trial product with minimum 15 billion CFU daily dose
11047286|NCT04447911|Experimental|Empagliflozin|Empagliflozin (Jardiance)® 25mg per os once daily for 30 days
11047287|NCT04447911|Placebo Comparator|Placebo|Placebo (Lactose tablet) per os once daily for 30 days
11047288|NCT04447898|Experimental|Low dose|10 μg + Montanide™ ISA 51 VG
11047289|NCT04447898|Experimental|High dose|50 μg + Montanide™ ISA 51 VG
11047290|NCT04447885|Experimental|Experimental blanket|This blanket is the weight being tested which cannot be disclosed without unblinding participants.
11047291|NCT04447885|Active Comparator|Control blanket|This blanket is the control weight which cannot be disclosed without unblinding participants.
11047430|NCT04446884|Experimental|mesenchymal stem cells|Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
11047292|NCT04447872|Active Comparator|Luteal phase ovarian stimulation (LPOS)|Patients will present in the luteal phase, and will begin 150 IU hMG and 300 IU recombinant FSH daily, as well as oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH can then be titrated per patient response. Gonadotropin releasing hormone antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started per criteria. Once patients are ready for ovulation trigger, 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU), will be administered. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
11047293|NCT04447872|Active Comparator|Luteal estradiol priming protocol|In the luteal phase, the patient will begin Estradiol patches 0.1mg QOD. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for three days. With menses, she will begin 150 IU hMG, 300 IU recombinant FSH daily, and oral Clomiphene citrate 100mg qd (for five days). FSH can be titrated per patient response. GnRH antagonist will be started per criteria. 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU) will be administered for ovulation trigger. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.
11047294|NCT04447859|Active Comparator|label recommended titration|eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy)
11047295|NCT04447859|Experimental|Slow semaglutide titration|A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached)
11047296|NCT04447846|Experimental|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
11047297|NCT04447833|Experimental|Mesenchymal Stromal Stem Cell Treatment|Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg.
11047298|NCT04447820|Experimental|K-877-ER Dose A|K-877-ER dose A administered once daily
11047299|NCT04447820|Experimental|K-877-ER Dose B|K-877-ER dose B administered once daily
11047300|NCT04447820|Experimental|K-877-IR|K-877-IR administered twice daily.
11047301|NCT04447807|Experimental|Group A: Metacognitive Training Intervention|"Participants of this group will under go Metacognitive Training (MCT) in group format for the duration of 8 weeks. The intervention will be helf once a week, with an estimate duration of 1-2 hours. The MCT intervention focuses on rehabilitating Social Cognition and teaching skills of inter-personal relations, as well as functional remediation aspects.
~We estimate a total of 45 participants in this group."
11047302|NCT04447807|Experimental|Group B: Treatment as Usual|Participants of this group will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School, although they will not be part taking in any group rehabilitation format We estimate a total of 45 participants in this group.
11047303|NCT04447794|Active Comparator|Step Away App|Participants randomly assigned to this arm will access the Step Away smartphone-based mobile application immediately upon enrollment.
11047304|NCT04447794|Experimental|Step Away Chatbot|Participants randomly assigned to this arm will access the Step Away mobile, text-based, interactive AI chatbot immediately upon enrollment.
11047305|NCT04447794|No Intervention|Step Away App Delay|Participants randomly assigned to this arm will be provided access to the Step Away smartphone-based mobile application three months after enrollment.
11047306|NCT04447781|Experimental|Group 1 (Part A)|"Number of Subjects: 20 subjects
~ID Injection of INO-4800 1mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
11047307|NCT04447781|Experimental|Group 2 (Part A)|"Number of Subjects: 20 subjects
~ID Injection of INO-4800 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
11047308|NCT04447781|Experimental|Group 3 (Part B)|"Number of Subjects: 90 subjects
~ID Injection of INO-4800 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
11047309|NCT04447781|Placebo Comparator|Group 4 (Part B, Placebo)|"Number of Subjects: 30 subjects
~ID Injection of Placebo (SSC) 1mg or 2mg/dose + EP using CELLECTRA® 2000 (dosing at Day 0 and Week 4)"
11047310|NCT04447768|Experimental|Venetoclax and Obinutuzumab|All patients will receive a minimum of 12 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 12 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
11047311|NCT04447755|Experimental|Lenvatinib|Participants receive lenvatinib 14 mg/m^2 once daily (QD) orally until progressive disease or unacceptable toxicity (up to approximately 1 year).
11047312|NCT04447729|Experimental|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
11047313|NCT04447716|Experimental|Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)|Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11047314|NCT04447703|Experimental|Aim I (Interview)|Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinical for 2 weeks. After 2 weeks, provides discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
11047359|NCT04447365||control|10 patients who have had no device-monitored for ventricular tachycardia/ ventricular fibrillation the 3 months prior to recruitment will comprise a group of controls
11047315|NCT04447703|Active Comparator|Aim II: Arm I (Genetic Counseling, Genetic Testing)|Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
11047316|NCT04447703|Experimental|Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)|Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
11047317|NCT04447664|Experimental|Telemedicine arm|
11047318|NCT04447664|No Intervention|Control arm|
11047319|NCT04447651||Patients with SF3B1 mutation|Metastatic breast cancer patients that have a SF3B1 mutation
11047320|NCT04447625|Active Comparator|CE patients receiving OAA|Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
11047321|NCT04447625|Experimental|CE patients receiving OAA and IAI|Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
11047322|NCT04447612|Experimental|Durvalumab arm|"Induction phase: Durvalumab 1500mg via intravenous infusion every 4 weeks, with chemotherapy gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.
~Concurrent phase: Durvalumab 1500mg via intravenous infusion every 4 weeks for 2 cycles, with cisplatin 100mg/m2 via intravenous infusion every 3 weeks for 3 cycles.
~Maintenance phase: Durvalumab 1500mg daily via intravenous infusion every 4 weeks for 8 cycles."
11047323|NCT04447612|Active Comparator|Standard of care arm|"Induction phase: Chemotherapy with gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.
~Concurrent phase: Cisplatin 100mg/m2 on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles."
11047324|NCT04447599|Experimental|Photographs|Photographs
11047325|NCT04447586|Active Comparator|Patients following Command A and B|This group of patients followed the Commands A and B with this specific order, and performed 3 exhalation attempts for each command.
11047326|NCT04447586|Active Comparator|Patients following Command B and A|This group of patients followed the Commands B and A with this specific order, and performed 3 exhalation attempts for each command.
11047327|NCT04447586|Active Comparator|intervention group|"Intervention group was requested to exhale as indicated by the right command, performing 3 sets of 10 repetitions."
11047328|NCT04447586|No Intervention|control group|"Did not perform exhalation attempts by the right command."
11047329|NCT04447573|Experimental|BCMA CAR-T cells|Patients will be treated with BCMA CAR-T cells
11047330|NCT04447560|Experimental|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol before and after the plane block and two researchers will measure the radius and area of those vessels separately.
11047331|NCT04447547|Experimental|SL1904B CAR-T|Patients will be treated with CD19 CAR-T cells
11047332|NCT04447534|Experimental|Chloroquine|Chloroquine alone
11047333|NCT04447534|Experimental|Chloroquine with zinc|Chloroquine with zinc
11047334|NCT04447508|Experimental|Exercise class and motivational interviewing|Patients receiving the intervention will be enrolled in an online instructor led group exercise class and five online one on one motivational interviewing sessions.
11047335|NCT04447508|No Intervention|Usual care|Participants in the control group will receive an exercise booklet and educated on the benefits of exercise for low back pain. They will be advised to exercise for the duration of the study
11047336|NCT04447495||SARS-CoV-2 positive|We will enroll patients within a larger clinical validation study of the iAMP® test against the gold standard (the CDC-recommended test) until we have prospectively collected a total of 100 positive cases.
11047337|NCT04447495||Controls|Current SARS-CoV-2 positivity in the region is approximately 20%, therefore, approximately 400 negative control samples will be needed.
11047338|NCT04447482|Experimental|Treatment Group|4D electromagnetic navigation bronchoscopy (4D-ENB) for lung biopsy. Guidance based on tip tracked surgical tools and images calculated from CT.
11047339|NCT04447482|Active Comparator|Control Group|Bronchoscopic lung biopsy taken while using X-ray fluoroscopy.
11047340|NCT04447469|Active Comparator|10 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
11047341|NCT04447469|Active Comparator|6 mg/kg (Cohort 1)|Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
11047342|NCT04447469|Placebo Comparator|Placebo (Cohort 1)|Non-mechanically ventilated participants administered placebo as a single IV infusion
11047343|NCT04447469|Active Comparator|10 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
11047344|NCT04447469|Active Comparator|6 mg/kg (Cohort 2)|Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
11047345|NCT04447469|Placebo Comparator|Placebo (Cohort 2)|Mechanically ventilated participants administered placebo as a single IV infusion
11047346|NCT04447456||Surgery|
11047347|NCT04447456||Radiotherapy|
11047348|NCT04447443|Experimental|Prebiotic Fiber|
11047349|NCT04447443|Placebo Comparator|Maltodextrin|
11047350|NCT04447430|Experimental|bright light group|treat patients with bright light (10000 lux)
11047351|NCT04447430|Placebo Comparator|dim red light group|treat patients with dim red light (100 lux)
11047352|NCT04447417|Experimental|Dupilumab|Double dose on Day 1 and followed by single dose every 14 ±2 or 3 days through week 14. - Type: Experimental
11047353|NCT04447417|No Intervention|Healthy volunteers|Healthy volunteers are matched by age, gender, body location and study site to AD patients. They will receive no treatment with dupilumab but will be monitored in the same way as atopic dermatitis patients during the study.
11047354|NCT04447404|Experimental|DUR-928|
11047355|NCT04447404|Placebo Comparator|Placebo|
11047356|NCT04447391|Experimental|Exercise group|Exercise group who performed a combined exercise and 300 kcal/day deficit diet during 12 weeks.
11047357|NCT04447391|Placebo Comparator|Control group|Control group who performed 300 kcal/day deficit diet during 12 weeks.
11047358|NCT04447378|Experimental|Fondaparinux|Subcutaneous injection of fondaparinux 2.5 mg once daily would be given over 10 days for post partum thromboprophylaxis
11047360|NCT04447365||high burden of ventricular arrhythmias|. 20 patients will comprise a group of patients with high burden of ventricular arrhythmias, defined as patients with at least one sustained episode of VT/VF requiring ICD therapies in the 3 months preceding study enrollment.
11047361|NCT04447352|Active Comparator|Arm A - FLOT|"Patients randomized to treatment Arm A already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
11047362|NCT04447352|Experimental|Arm B - FLOT/HIPEC|"Patients randomized to treatment Arm B already received 3-6 cycles of FLOT in 2-week treatment cycles prior to undergoing surgery including Intraoperative Hyperthermic IntraPEritoneal Chemoperfusion (HIPEC) during gastric-/ esophagogastric resection using Cisplatin 75mg/m². Following surgery, patients will receive four further 2-week cycles FLOT. FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
~FLOT = Docetaxel 50 mg/m², Oxaliplatin 85 mg/m², Leucovorin 200 mg/m², 5-FU 2600 mg/m²."
11047363|NCT04447339||Open|Prophylactic NSM cases by Open approach
11047364|NCT04447326|Experimental|IC＋CCRT＋Toripalimab＋Endostar|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.
11047365|NCT04447326|Active Comparator|IC＋CCRT|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w.
11047366|NCT04447313|Experimental|Arm I (ACT)|Participants receive ACT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
11047367|NCT04447313|Active Comparator|Arm II (SBT)|Participants receive SBT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
11047368|NCT04447300|Active Comparator|Standard power application|
11047369|NCT04447300|Active Comparator|High power application|
11047370|NCT04447287|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants will receive multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. Titration may be extended based on a participants tolerability; however, participants must be on a stable dose of buprenorphine/naloxone by day 5. Participants will be on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants will receive a single oral dose of ASP8062 concomitantly with buprenorphine/naloxone and undergo repeat intensive safety assessment on day 12 with continued safety and pharmacokinetic assessments up to day 23. The stable dose of buprenorphine/naloxone will be down titrated from days 19 through 26.
11047371|NCT04447287|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive multiple sublingual doses of buprenorphine/naloxone on days 1 through 26. Titration may be extended based on a participants tolerability; however, participants must be on a stable dose of buprenorphine/naloxone by day 5. Participants will be on a stable daily dose of buprenorphine/naloxone on days 5 through 18. After randomization on day 12, participants will receive a single oral dose of placebo ASP8062 concomitantly with buprenorphine/naloxone and undergo repeat intensive safety assessment on day 12 with continued safety and pharmacokinetic assessments up to day 23. The stable dose of buprenorphine/naloxone will be down titrated from days 19 through 26.
11047372|NCT04447274|Experimental|Camrelizumab and Apatinib|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11047373|NCT04447261|Experimental|BI 1356225|
11047374|NCT04447261|Placebo Comparator|Placebo|
11047375|NCT04447235|Placebo Comparator|ARM A: Placebo|Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
11047376|NCT04447235|Experimental|ARM B: Ivermectin plus losartan|Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days
11047377|NCT04447222||Observational (survey)|Participants complete a survey online over 35-45 minutes about their experiences regarding the COVID-19 pandemic.
11047378|NCT04447209||Child Health Clinic (CHC)|"Children attending CHC for routine vaccinations and follow-up in a tertiary center Parents will be counselled on food groups based on Infant and Young Children feeding practices.
~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.
~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
11047379|NCT04447209||Community Children|"Children of urban poor families living in low-cost flats around Kuala Lumpur. Parents will be counselled on food groups based on Infant and Young Children feeding practices.
~Monthly telephone calls to collect data on dietary diversity - 4 telephone calls in total.
~Anthropometric measurements and Blood investigations for hemoglobin and iron status at the start and end of study - optional"
11047380|NCT04447196||CCHS|20 patients presenting with central hypoventilation syndrome during spontaneous breathing and with Non Invasive Ventilation
11047381|NCT04447183|Experimental|Test group|The test group of patients who took thyroid hormone medicine and were euthyroid [i.e. their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
11047382|NCT04447183|Experimental|Control group|The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e. their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
11047383|NCT04447170||Laparoscopic repair|Patients undergoing laparoscopic treatment
11047384|NCT04447170||Open repair|Patients undergoing open treatment
11047385|NCT04447157||Microspherophakia|This is a non-interventional study(NIS). All the patients diagnosed as microspherophakia are included in the study and recieved intraocular lens implantation
11047429|NCT04446897|Active Comparator|standard treatment|standard treatment according to clinical protocols
11047386|NCT04447144||COVID-19 mild severity|"Definition of mild cases according to MOH:
~Age < 60
~Temperature <38.5
~arterial oxygen saturation (SaO2) >92%
~Heart Rate <110
~Respiratory Rate <25 /min.
~Neutrophil / lymphocyte ratio on complete blood count (CBC) < 3.1
~No co-morbidities that necessitates hospital admission: Pregnancy, severe uncontrolled Diabetes, Chronic lung disease, Chronic kidney disease, Chronic liver disease, Serious heart diseases (arrythmia, Ischemic heart disease, uncontrolled hypertension), immunocompromised: prolonged use of corticosteroids and other immunosuppressive drugs/ organ transplantation/ HIV/ Immunodeficiency, Obesity (BMI > 40)"
11047387|NCT04447144||COVID-19 moderate severity|Any patient not fulfilling the above mild criteria is considered having moderate disease as well as any positive pulmonary imaging findings
11047388|NCT04447131||COVID-19|Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
11047389|NCT04447131||Healthy Individuals|Asymptomatic and with negative SARS-CoV-2 serology
11047390|NCT04447131||Influenza|Positive for influenza vírus. Negative for SARS-CoV-2.
11047391|NCT04447131||Respiratory symptoms but negative for influenza or COVID-19|Negative for influenza vírus. Negative for SARS-CoV-2. But with respiratory symptoms
11047392|NCT04447118|Experimental|Study treatment Arm|Pyrotinib maleate tablet, 400 mg, once daily (QD)
11047393|NCT04447118|Active Comparator|Control Arm|Docetaxel injection, 75 mg/m2, once every 3 weeks (Q3W)
11047394|NCT04447105|Experimental|TIVA group|Patients receiving total intravenous anesthesia with propofol.
11047395|NCT04447105|Active Comparator|Desflurane group|Patients receiving inhalation anesthesia with desflurane.
11047396|NCT04447092|Experimental|Gemcitabine/Nab-paclitaxel|Gemcitabine/Nab-paclitaxel + pembrolizumab
11047397|NCT04447092|Experimental|FOLFIRINOX|FOLFIRINOX + pembrolizumab
11047398|NCT04447079||'Before' and 'After' Arm|"Before Arm - This refers to the rate of Emergency Department visits in the pre-intervention period (12 months).
~After Arm - This refers to the rate of Emergency Department visits in the post-intervention period (12 months) following the START of intervention."
11047399|NCT04447066||Patients hospitalized at the rehabilitation department|
11047400|NCT04447053|Experimental|Belimumab + SOC|Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.
11047401|NCT04447053|No Intervention|SOC only|Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.
11047402|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
11047403|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
11047404|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
11047405|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
11047406|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
11047407|NCT04447040|Placebo Comparator|Placebo|Placebo tablets administered as a single two-tablet dose.
11047408|NCT04447027|Experimental|1- Experimental Treatment: Dose Escalation|Lenalidomide by oral intake at escalating doses of 5, 10, 15, or 20 mg/day on days -7 to 10 of each 21-day cycle (max 6 cycles) with 5-azacitidine at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle, to determine MTD
11047409|NCT04447027|Experimental|2 - Experimental Treatment: Dose Expansion|Lenalidomide by oral intake at MTD on days -7 to 10 of each 21-day cycle (max 6 cycles) with 5-azacitidine at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle
11047410|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
11047411|NCT04447001|Experimental|Tai Chi Prime (TCP)-session 1|This arm will receive Tai chi prime as an intervention. TCP is a combination of two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
11047412|NCT04447001|No Intervention|Wait list control-session 2|Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time. At week 7, pre-test measures from wait-list group will be used as a control and compared with the post intervention measures of the experimental group.
11047413|NCT04446988|Experimental|Ultrasound(US)|Sacroiliac joint injection using ultrasound
11047414|NCT04446988|Experimental|Fluoroscopy(FL)|Sacroiliac joint injection using fluoroscopy
11047415|NCT04446975|No Intervention|BPA Off|No BPA message is displayed to providers.
11047416|NCT04446975|Experimental|BPA On|BPA message is displayed to providers based on patient opioid intake as reported in the EHR.
11047417|NCT04446962|Active Comparator|Arm A: R-MPV with Lenalidomide|Lenalidomide in association with R-MPV as a targeted induction treatment
11047418|NCT04446962|Active Comparator|Arm B: R-MPV with Ibrutinib|Ibrutinib in association with R-MPV as a targeted induction treatment
11047419|NCT04446949||Undocumented migrants|
11047420|NCT04446949||Immigrants with Norwegian ID|
11047421|NCT04446949||Norwegian residents|
11047422|NCT04446936||Propeller flaps|Patients who undergone propeller flap surgery
11047423|NCT04446936||Random flaps|Patients who undergone random flap surgery
11047424|NCT04446923|Experimental|Hand antisepsis by scrub|Hand antisepsis by scrub using propan-ol-1 60%
11047425|NCT04446923|Active Comparator|Hand antisepsis by rub|Hand antisepsis by rub using propan-ol-1 60%
11047426|NCT04446910|Experimental|Text-messaging|SMS text messaging intervention for a period of 90 days to remind of community-based substance use treatment appointments and to provide motivational texts.
11047427|NCT04446910|Active Comparator|Standard of care engagement practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
11047428|NCT04446897|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
11047432|NCT04446871|Placebo Comparator|Standard care|Placebo
11047436|NCT04446845|Experimental|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|"A first stimulation Stimulation will initiate in the luteal phase of the menstrual cycle On day 21 of the previous cycle150mcg of corifollitropin alfa (Elonva, Merck Sharp & Dohme (MSD), Spain) will be administrated and from day 8 of the stimulation when necessary, r-FSH of 250 IU per day will start until the day of ovulation trigger in a flexible gonadotropin-releasing hormone (GnRH) antagonist protocol. The first ovulation triggering will be induced with GnRH-agonist (triptorelin 0.2 ml). The embryos obtained from the first stimulation will be cryopreserved in a freeze-all approach.
~A second stimulation will start on day 2 of bleeding after the first oocyte retrieval.
~This time will correspond to a conventional COS where corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of Recombinant Human Chorionic Gonadotropin (rhCG)"
11047437|NCT04446845|Active Comparator|Conventional Stimulation (Elonva+rFSH) in follicular phase|A conventional COS where Corifollitropin alfa will be administered on the beginning of the follicular phase, in a flexible antagonist protocol, and the second ovulation will be triggered with 250μg of rhCG
11047438|NCT04446832||Liver transplantation candidates|
11047439|NCT04446819|Other|Cohort|Patients diagnosed with solid tumors who are about to received albumin-binding paclitaxel monotherapy are recruited. Dominant hands and non-dominant hands are treated with small-size compression gloves and suitable-size compression gloves, respectively, during the administration of albumin-binding paclitaxel.
11047440|NCT04446780||Women who underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery with mediolateral episiotomy
11047441|NCT04446780||Women who did not underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery without mediolateral episiotomy
11047442|NCT04446767|Experimental|Bioptron light therapy and medical care|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks plus medical care in the form of Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
11047443|NCT04446767|Active Comparator|medical care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
11047444|NCT04446741||Acute Myeloid Leukemia (AML)|Newly diagnosed or relapsed/resistant AML
11047445|NCT04446728|Active Comparator|Stategy I.Training|Sites randomized to Strategy I will receive a three hour training webinar in preparing for implementation of the PAT in their center.
11047446|NCT04446728|Active Comparator|Strategy II.Training+Implementation Enhanced Resources (TIER)|Sites randomized to Strategy II will identify a Champion for screening and will participate in a monthly consultation call in addition to completing the three hour training webinar for implementing the PAT in their center.
11047447|NCT04446715|Experimental|Sufentanil Group|Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia
11047448|NCT04446715|Experimental|Meperidine Group|Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia
11047449|NCT04446689|Active Comparator|Biofeedback|The intervention group will develop an activity with self-monitoring called Cardiovascular Biofeedback or Cardiac Frequency Variability (CFV). This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph. This photoplethysmograph verifies blood flow alterations through an optical method. Cardiac frequency oscillations may be estimated both by the quantity of blood infrared lights absorbed or reflected, and by variations in blood volume and pressure. Captured physiological signs will be recorded during ten minutes by the Software Emwave Pro Plus®, which is adapted to biofeedback training.
11047450|NCT04446689|No Intervention|activity without self monitoring|"The placebo group will develop an activity without self monitoring. In order to keep blindness between the groups the activities will be processed by an electronic device - the on line app Jigsaw Puzzles. This app consists of a puzzle with different levels of difficulties, and is played in a tablet.
~Each participant will be performing in the study during four weeks, with two encounters each week (total: four weeks). While the participant will be performing its activity he/she will be monitored by the researchers through CFV (Cardiac Frequency Variability) - with no visualization of the computer monitor.
~The control group will answer the research protocol in two moments (D1 and D8), to evaluate"
11047451|NCT04446676|Active Comparator|Stem stabilization|Group of patients with stem endoprosthesis stabilization
11047452|NCT04446676|Active Comparator|Sleeve stabilization|Group of patients with sleeve endoprosthesis stabilization
11047453|NCT04446663|Experimental|Toripalimab+induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.
~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT .
~Toripalimab 240mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy"
11047454|NCT04446663|Active Comparator|induction chemotherapy +CCRT|"Patients will receive induction chemotherapy with Albumin-bound paclitaxel (260 mg/m2, d1 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiotherapy.
~Then patients will receive definitive intensity-modulated radiotherapy (IMRT) of ≥66 Gy（2-2.2Gy/fx）.Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT ."
11047455|NCT04446650|Experimental|Fedratinib Administration|The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.
11047456|NCT04446637|Experimental|Ipratropium/Levosalbutamol|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
11047457|NCT04446637|Active Comparator|Salbutamol + Ipratropium|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
11047458|NCT04446624|No Intervention|Treatment as usual (TAU)|Patients in the TAU group will receive the treatment routinely offered to patients undergoing RT for breast cancer.
11047459|NCT04446624|Experimental|Music therapy intervention (PSY)|Patients in the PSY group will participate to a short-term group psychotherapy with elements of music therapy; meetings will be 1 / week, for a total of 6 weeks. Beginning of psychotherapy intervention will be 1-2 weeks after recruitment at T0 and will therefore cover the entire duration of the RT cycle.
11047460|NCT04446611|Experimental|Test at 1st ANC + Test-of-Cure (Treatment 1)|Single point-in-time diagnostic screening plus test-of-cure three weeks post-treatment
11047461|NCT04446611|Experimental|Test at 1st ANC + 30-34 gestation (Treatment 2)|Repeated diagnostic screening at first antenatal care and 30-34 weeks gestation
11047462|NCT04446611|No Intervention|Syndromic Management (Control)|Syndromic management (standard of care) at every antenatal care visit per South African National Guidelines.
11047463|NCT04446598|Experimental|Laser group|In the laser group, the patients received two sessions of Er:YAG intraurethral laser in non-ablative SMOOTH™ mode, with 1 month interval between sessions.
11047464|NCT04446598|Active Comparator|Tadalafil group|The tadalafil group was treated with daily oral administration of tadalafil, at a dose of 5 mg/day, which lasted consecutively for two months.
11047465|NCT04446585|No Intervention|Control sites|"For all 1-1-2 calls with suspected cardiac arrest to the emergency dispatch center will activate a two-tiered response consisting of dispatch of an ambulance with an emergency medical technician, a physician-staffed mobile emergency care unit, and citizen first responders through the Heart Runner app.
~The medical dispatcher offers telephone assisted cardiopulmonary resuscitation (CPR) to bystanders. Furthermore, if more than two bystanders are present and an AED is accessible within 1½ minute travel distance (depending on the type of terrain), then one bystander is guided to localize and retrieve the AED."
11047466|NCT04446585|Experimental|Intervention sites|"As a supplement to the standard care as described in the control arm, the following will be supplied:
~Strategical deployment of AEDs with 24:7 availability and 1½ minute walking distance to every residence within the area. The AEDs will be registered with the AED network and thus linked to the emergency dispatch center.
~The emergency dispatch center will retrieve data from used AEDs.
~For each interventional area, approximately 120 residents will receive a course in CPR and AED use and subsequently be recruited as citizen responders so that they can be activated through the HeartRunner app in case of a nearby cardiac arrest."
11047467|NCT04446572|Experimental|Repetitive Abortion (RA) group|Starting at day 0, women of the RA (n=21) group consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
11047468|NCT04446572|Experimental|Infertility (INF) group|Starting at day 0, women of the INF group (n=23) consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
11047469|NCT04446572|No Intervention|Control group|The control group (n = 14) included fertile women having at least two children after uncomplicated term pregnancies.
11047470|NCT04446559|Experimental|Sitting in a chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
11047471|NCT04446559|No Intervention|Semi-recumbent in bed position|The patient will benefit from conventional positioning techniques in the ICU bed. With the help of the medical monitoring software present in the wards, we will note the different nursing care given to the patient during the 3 hours following the morning arterial gasometry.
11047472|NCT04446546||Cold Stored Allograft Vascular Access|
11047473|NCT04446533|Experimental|Hydrogen Peroxide and Hyaluronic acid (BMG0703)|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.
~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.
~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.
~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
11047474|NCT04446533|Active Comparator|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.
~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.
~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.
~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
11047475|NCT04446533|Placebo Comparator|Placebo product|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.
~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.
~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.
~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
11047476|NCT04446520|Experimental|autogenic drainage and traditional physiotherapy|autogenic drainage technique plus traditional physiotherapy (localized breathing exercise, diaphragmatic breathing and splinted coughing)
11047477|NCT04446520|Active Comparator|traditional physiotherapy|traditional physiotherapy (localized breathing exercise, diaphragmatic breathing, and splinted coughing)
11047478|NCT04446507|Experimental|Group 1|Subjects in severe renal impairment group will be enrolled and dosed consecutively (i.e. first 8 subjects of group 1 will receive 2 mg dose, followed by another 8 subjects who will receive 4 mg dose).
11047479|NCT04446507|Experimental|Group 2|Subjects (Normal renal function eGFR ≥90) will be matched according to age (± 10 years), sex, and weight (± 10 kg) with participants in Group 1 (Severe renal impairment not on HD) on a one to one basis based on demographic characteristic. Here, 8 participants will be administered single dose of 2 mg Saroglitazar Magnesium and 8 participants will be administered single dose of 4 mg Saroglitazar Magnesium.
11047480|NCT04446494|Experimental|Axillary dissection with DEPART technique|In the experimental group, 1 ml (2.5 mg) indocyanine green (ICG) and methylene blue (MB) was intradermally injected into the internal bicipital sulcus of ipsilateral arm. During axillary dissection, the identified arm sentinel nodes were carefully injected with 0.1 ml methylene blue (MB) using a 1-cc syringe with a 32-gauge needle. MB could then flow from the nodes along several lymphatic channels toward the infraclavicular nodes. Subsequent-echelon nodes and lymphatics were identified. Sentinel lymph nodes (SLNs) were removed after the identification of the arm sentinel nodes and the procedure of MB injection. When patients harbored positive SLNs, axillary lymph node dissection (ALND) was performed subsequently. All discernible arm lymphatics and lymph nodes were preserved, except that gross arm lymph nodes (major axis larger than 10 mm or node firm on palpation) were sent for immediate partial frozen section (pFS) to determine their resection during ALND.
11047481|NCT04446494|No Intervention|Standard axillary dissection|In the control group (no intervention), ALND was performed with complete resection of at least Berg's levels I and II. Resection of level III was performed only in cases with gross disease in level II and/or III
11047482|NCT04446481|Experimental|MCI patients|Vets with mild cognitive impairment
11047483|NCT04446481|Active Comparator|NC|Normal healthy Veterans
11047484|NCT04446468|Experimental|PEACE|The PEACE intervention will be delivered by a trained mental health staff member, such as a study psychologist, mental health nurse, social worker, or psychiatrist. The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide. Patients in this arm will also continue to receive standard post-discharge psychiatric care.
11047485|NCT04446468|Experimental|Control|Those randomized to the control arm will receive standard psychiatric hospital discharge care alone. Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
11047486|NCT04446455|Experimental|Functional Power + Cognitive Training|Training sessions began with approximately 30 minutes of cognitive training using a desktop computer followed by 40 minutes of functional power training.
11047487|NCT04446455|Active Comparator|Functional Power Training|Training sessions began with 40 minutes of functional power training.
11047488|NCT04446442|Experimental|Full Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1 mA will be administered over 20 minutes to the right crusI/II area of the cerebellum with a 15 second fade in period at the beginning and a 15 second fade out period at the end. During the tDCS administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
11047489|NCT04446442|Sham Comparator|Sham Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1mA increased over 15 seconds and immediately decreased over 15 seconds to provide sensation associated with tDCS. During the sham administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
11047490|NCT04446429|Experimental|Dutasteride + Standard Care|Ivermectin+ Azythromycin + Dutasteride
11047491|NCT04446429|Active Comparator|Standard Care|Ivermectin + Azythromycin
11047492|NCT04446429|Experimental|Proxalutamide + Standard Care|Ivermectin+ Azythromycin + Proxalutamide
11047493|NCT04446416|Experimental|Bevacizumab plus NaviFUS System|"Device: NaviFUS System BBB Disruption by FUS in recurrent GBM Microbubbles (MB) (SonoVue®) 0.1 mL/kg and optimal ultrasound exposure doses (based on the acoustic emission feedback FUS power control algorithm) generated from the NaviFUS System every 2 weeks to transiently open the BBB.
~Drug: Bevacizumab 10 mg/kg every 2 weeks for up to 36 weeks or until evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent."
11047494|NCT04446403|Experimental|circumflex|patients will undergo ultrasound guided SSN+circumflex
11047495|NCT04446403|Experimental|posterior cord|patients will undergo ultrasound guided SSN+circumflex
11047496|NCT04446390|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care). Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash,0.12% concentration) for one minute per day; such the regimen will be repeated one week every month.
~Chew xylitol gum 2 pieces four times per day for 5 minutes after meals."
11047497|NCT04446390|Active Comparator|preventive regimen using Fluoride based toothpaste(colgate)|preventive regimen using Fluoride based toothpaste (colgate cavity protection). Participants will be using a fluoride-based toothpaste (colgate cavity protection), (1450 ppm sodium fluoride) Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash, 0.12% concentration) for one minute per day; such a regimen will be repeated for one week every month. hew xylitol gum 2 pieces four times per day for 5 minutes after meals.
11047498|NCT04446377|Experimental|LAM-002A|LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
11047502|NCT04446351|Experimental|Participants receiving GSK6097608 (Arm A)|Participants will be administered an IV infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
11047503|NCT04446351|Experimental|Participants receiving GSK6097608 plus dostarlimab (Arm B)|Participants will be administered an IV infusion of GSK6097608 every 3 weeks in escalating doses followed by an IV infusion of dostarlimab (every 3 weeks for 4 doses and every 6 weeks thereafter).
11047504|NCT04446338||Healthcare Worker|Staff of the Department of Ophthalmology, University Tuebingen, Germany
11047505|NCT04446312|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
11047506|NCT04446312|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
11047507|NCT04446299|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
11047508|NCT04446299|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
11047509|NCT04446273|Experimental|PRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The PRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist).
11047510|NCT04446273|Active Comparator|DRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The DRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).
11047511|NCT04446260|Experimental|Part 1 Dose escalation|
11047512|NCT04446260|Experimental|Part 2 Indication expansion|
11047513|NCT04446234|Experimental|Risperidone|Risperidone tablet
11047514|NCT04446234|Experimental|Aripiprazole|Aripiprazole tablet
11047515|NCT04446234|Experimental|Ziprasidone|Ziprasidone tablet
11047516|NCT04446234|Experimental|Amisulpride|Amisulpride tablet
11047517|NCT04446234|Experimental|Quetiapine|Quetiapine tablet
11047518|NCT04446195|No Intervention|Control group|The control group received routine intestinal preparation education.
11047519|NCT04446195|Active Comparator|Experimental group|The experimental group was treated with routine intestinal preparation education and individualized intervention.
11047520|NCT04446182|Experimental|Treatment: all patients|Patients will self-administer itacitinib every morning regardless of food. ECP will be administered twice weekly on consecutive days for 8 weeks per institutional standards. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule and itacitinib will be continued at the assigned dose level. After six cycles of therapy, itacitinib may be tapered at the treating investigator's discretion as described below.
11047521|NCT04446169||SARS-CoV 2 Patients|Patients with previous nasopharyngeal swab positive for SARS-CoV-2, subsequently negativeized in two detections
11047522|NCT04446143|Other|Application of mindfulness meditation prior to UDS|Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete.
11047523|NCT04446143|Active Comparator|No meditation prior to UDS|The control group will be seated in a quiet empty room where they wait for 10 min.
11047524|NCT04446130|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed T-ALL/LBL and T/M-MPAL patients.
11047525|NCT04446117|Experimental|Experimental Arm|Subjects with mCRPC will receive cabozantinib 40mg oral, qd + atezolizumab 1200mg infusion, q3w
11047526|NCT04446117|Active Comparator|Control Arm|Subjects with mCRPC will receive active comparator of EITHER abiraterone 1000mg oral, qd + prednisone 5 mg oral, bid; OR enzalutamide 160mg oral, qd as designated by the Investigator prior to randomization
11047527|NCT04446104|Experimental|Hydroxychloroquine|Participants will receive hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
11047528|NCT04446104|Experimental|Ivermectin|Participants will receive ivermectin tablet 12mg single dose
11047529|NCT04446104|Experimental|Zinc/ Vitamin C|Participants will receive zinc tablet 80 mg/vitamin C 500mg daily for 42 days
11047530|NCT04446104|Experimental|Povidone-iodine throat spray|Participants will receive povidone-iodine throat spray (3 times daily) for 42 days
11047531|NCT04446104|Active Comparator|Vitamin C|Participants will receive vitamin C tablet 500mg daily for 42 days
11047532|NCT04446091|Experimental|Two-drug group|Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
11047533|NCT04446091|Experimental|Three-drug group|Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
11047534|NCT04446078|Experimental|PEEK - All-on-4|Patients rehabilitated with a PEEK-acrylic resin prosthesis supported by immediate function dental implants inserted through the All-on-4 concept
11047535|NCT04446065|Experimental|Previfenon®|Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
11047536|NCT04446065|Placebo Comparator|Placebo|Participants will receive coded non-transparent bottles of placebo, each containing 90 starch capsules (250 mg plus excipients) under the same dosage, frequency and duration that Previfenon@ arm.
11047537|NCT04446052|Placebo Comparator|Placebo|
11047538|NCT04446052|Active Comparator|GM-CSF priming|
11047539|NCT04446039||1. Escitalopram Cohort|
11047540|NCT04446039||2. Paroxetine Cohort|
11047541|NCT04446039||3. Fluoxetine Cohort|
11047542|NCT04446039||4. Mirtazapine Cohort|
11047543|NCT04446039||5. Duloxetine Cohort|
11047544|NCT04446039||6. Sertraline Cohort|
11047545|NCT04446039||7. Venlafaxine Cohort|
11047546|NCT04446039||8. Tianeptine Cohort|
11047547|NCT04446039||9. Vortioxetine Cohort|
11047548|NCT04446039||10. Desvenlafaxine Cohort|
11047549|NCT04446039||11. Bupropion Cohort|
11047554|NCT04446000|Experimental|CSL730 (dose 1 with premedication)|administered as a single dose by subcutaneous (SC) injection or by SC infusion
11047555|NCT04446000|Experimental|CSL730 (dose 2 with premedication)|administered as a single dose by SC injection or by SC infusion
11047556|NCT04446000|Experimental|CSL730 (dose 3 with premedication)|administered as a single dose by SC injection or by SC infusion
11047557|NCT04446000|Experimental|CSL730 (dose 1 without premedication)|administered as a single dose by SC injection or by SC infusion
11047558|NCT04446000|Experimental|CSL730 (dose 2 without premedication)|administered as a single dose by SC injection or by SC infusion
11047559|NCT04446000|Experimental|CSL730 (dose 3 without premedication)|administered as a single dose by SC injection or by SC infusion
11047560|NCT04446000|Experimental|CSL730 (dose 4 without premedication)|administered as a single dose by SC injection or by SC infusion
11047561|NCT04446000|Experimental|CSL730 (dose 5 without premedication)|administered as a single dose by SC injection or by SC infusion
11047562|NCT04446000|Experimental|CSL730 (dose 6 without premedication)|administered as a single dose by SC injection or by SC infusion
11047563|NCT04446000|Experimental|CSL730 (dose 7 without premedication)|administered as a single dose by SC injection or by SC infusion
11047564|NCT04446000|Placebo Comparator|Placebo|A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion
11047565|NCT04445987|Experimental|Long-term safety of ARQ-154|Open-label, Long-term Safety of ARQ-154
11047566|NCT04445974|Active Comparator|Expand Your Horizons: More than my skin|Participants allocated to the intervention condition will be asked to follow the adapted instructions for 'Expand Your Horizon'. Participants will be asked to complete three 15 min writing exercises over approximately six days. Participants who complete the first exercise on Qualtrics will be sent links to and asked to complete the second and third writing exercises.
11047567|NCT04445974|Experimental|Control writing activity|Participants in the control condition will be asked to complete three 15 minute creative writing exercises online via Qualtucs over approximately six days. Participants completing the first writing exercise will be sent links to the second and third writing exercises.
11047568|NCT04445948|Active Comparator|Triple Therapy|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days.
11047569|NCT04445948|Active Comparator|Sequential Therapy|Received the sequential therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 g tablets twice daily for 5 days, then esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus metronidazole 500 milligrams tablets twice daily plus clarithromycin 500 milligrams tablets twice daily after meal for another 10 days.
11047570|NCT04445948|Active Comparator|Triple Therapy plus Lactoferrin|Received triple therapy in the form of esomeprazole 40 milligrams tablets once daily 30 minutes before breakfast plus amoxicillin 1 gram tablets twice daily and clarithromycin 500 milligrams tablets twice daily after meal for 14 days. in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner for 14 days.
11047571|NCT04445948|Active Comparator|Sequential Therapy plus Lactoferrin|Received the sequential therapy in the form of esomeprazole 40 milligrams once daily 30 minutes before breakfast plus amoxicillin 1 gram twice daily for 5 days, then esomeprazole 40 mg once daily 30 minutes before breakfast plus metronidazole 500 milligrams twice daily plus clarithromycin 500 milligrams twice daily after meal for another 10 days in addition to 200 milligrams of bovine lactoferrin sachets twice daily 30 minutes after breakfast and dinner throughout the 15 days.
11047572|NCT04445935|Active Comparator|Standard treatment|"In this arm the patients will be treated according to our standard anticoagulation protocol.
~The patients will not be treated with Bivalirudin (the investigational drug)."
11047573|NCT04445935|Experimental|Bivalirudin arm|The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
11047574|NCT04445922|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
11047575|NCT04445922|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
11047576|NCT04445909||VA-ECMO patients|VA-ECMO support because of low cardiac output.
11047577|NCT04445896||Study Participants|Patients with a diagnosis of a life-limiting illness who have previosuly had a discussion with a healthcare professional about the care they would want at the end of life
11047578|NCT04445883|Experimental|Study Group A|Study group A will include patients from the medical unit on 6S100 in addition to the Rehab units on 6N400/500. Participants in Study Group A will be receiving mealtime assistance from volunteers via the Eating Matters Program.
11047579|NCT04445883|No Intervention|Control Group B|Control Group B will include participants from the Rehab Unit on 4N400 and the Medical unit on 6S200.
11047580|NCT04445857|Active Comparator|Group 1|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.
11047581|NCT04445857|Active Comparator|Group 2|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.
11047582|NCT04445857|Placebo Comparator|Group 3 (control group)|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.
11047583|NCT04445844|Experimental|Treatment (pelareorep, retifanlimab)|Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11047584|NCT04445831|Placebo Comparator|Placebo|Placebo administered at predefined time points over a 48-week period.
11047585|NCT04445831|Experimental|ACI-35.030 - Low dose|Active vaccine administered at predefined time points over a 48-week period.
11047586|NCT04445831|Experimental|ACI-35.030 - Medium dose|Active vaccine administered at predefined time points over a 48-week period.
11047587|NCT04445831|Experimental|ACI-35.030 - High dose|Active vaccine administered at predefined time points over a 48-week period.
11047588|NCT04445831|Experimental|JACI-35.054|Active vaccine administered at predefined time points over a 48-week period.
11047589|NCT04445818|Experimental|More Appreciation|"A 6-minute engaging video will be shown, illustrating examples where a mother initially withholds her appreciation for her son's effort in school and later express it. The video will also capture the effect on the child and the family. Attributional discussion questions will follow to elicit positive outcomes of expressing appreciation and the negative outcomes of withholding appreciation (e.g., What may be the long-term effects of showing appreciation on your child, family, or on yourself?). Key points will be summarised and reinforced to enhance behavioural intention (Schwarzer & Luszczynska, 2008). Then the participants will be asked to plan by indicating when (e.g., Saturday afternoon), what (e.g., child helping a younger sibling prepare for a dictation test), and how (e.g., I can see that you gave up your leisure time to help your sister with the spelling. Thank you!) they would express appreciation to their children."
11047590|NCT04445818|Experimental|Less Criticism|"Participants will watch a 6-minute video showing examples of a father criticising his son, which will be replaced by positive communication later, and the different reactions evoked in the child and the family. Then, participants will have an attributional discussion on the negative effects of criticism (e.g., negative effect on self-worth and motivation) and positive outcomes of using constructive feedback (e.g., promptly identifying undesirable behaviours without relating to personal traits or abilities). In small groups, they will work out alternatives (i.e., constructive feedback; termed positive reminder in the intervention) to criticism, and each plan and write down when (e.g., after school), what (e.g., low test marks), and how (e.g., How do you prepare for the tests?)"
11047591|NCT04445818|Experimental|Fruit and Vegetable|This workshop will emphasise the importance of consuming at least 5 portions of fruit and vegetable daily for a healthy diet, and aim to boost participants' self-efficacy in achieving this. Participants will be presented with examples of one portion of fruit or vegetable, and then create their own recipes. They will also consider how to overcome obstacles of consuming more portions. Each participant will set goals and write down plans on when, where, what, and how they would increase their fruit and vegetable intake of their children and family as a whole.
11047592|NCT04445805|Active Comparator|CBTI Treatment Group|Telemedicine Cognitive Behavioral Therapy for Insomnia (CBTI)
11047593|NCT04445805|Experimental|MBTI Treatment Group|Telemedicine Mindfulness Based Therapy for Insomnia (MBTI)
11047594|NCT04445805|Placebo Comparator|Attention Control Treatment Group|Minimal intervention control
11047595|NCT04445792|Experimental|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
11047596|NCT04445792|Other|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
11047597|NCT04445792|Experimental|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
11047598|NCT04445792|Other|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
11047599|NCT04445792|Experimental|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
11047600|NCT04445792|Other|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
11047601|NCT04445779|Experimental|CoQ10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure.
11047602|NCT04445779|Placebo Comparator|Placebo|Patients will receive per-orally placebo in three divided doses.
11047603|NCT04445753|Experimental|Tai Chi program|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
11047604|NCT04445753|Other|Control group|Individuals in the control group will be trained on heart failure. The only attempt to be made to the control group will be education.
11047605|NCT04445740|Experimental|Intervention|Participants will receive an intervention and will participate in assessments
11047606|NCT04445740|No Intervention|Control|Participants will not receive an intervention, but will participate in assessments
11047607|NCT04445727|Experimental|vitamin c|daily dose of 1000 mg vitamin c in order to regenerate collagen
11047608|NCT04445727|Experimental|spinal manipulation|Spinal manipulation in cervical and dorsal with high speed and short amplitude techniques
11047609|NCT04445727|Experimental|Transcutaneous electrical nerve stimulation (TENS)|electrotherapy for an analgesic purpose
11047610|NCT04445727|Experimental|manual therapy|manual muscle treatment for epicondyl musculature
11047611|NCT04445714|Other|dapagliflozin and saxagliptin|Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
11047612|NCT04445701|Experimental|AO-176 Dose Escalation Monotherapy|The dose escalation monotherapy cohorts will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
11047613|NCT04445701|Experimental|AO-176 + DEX Expansion Cohort|Once the monotherapy RP2D has been established, an expansion cohort of AO-176 + dexamethasone will be enrolled.
11047614|NCT04445701|Experimental|AO-176 + DEX + BORT Dose Escalation|Following evaluation of AO-176 + dexamethasone, dose escalation cohorts of AO-176 + dexamethasone + bortezomib will be enrolled. Each dose escalation cohort will initially recruit 3 patients in a standard 3+3 design; cohorts will be expanded in the event of a DLT. The Phase 2 portion of the study will further evaluate the RP2D of AO-176 + DEX + BORT.
11047615|NCT04445688|Experimental|AD036|AD036 oral capsule administered before sleep
11047616|NCT04445688|Active Comparator|Atomoxetine|Atomoxetine oral capsule administered before sleep
11047617|NCT04445688|Placebo Comparator|Placebo|Placebo oral capsule administered before sleep
11047661|NCT04445389|Placebo Comparator|GX-19: Dose C|Dose C of GX-19 will be intramusculary administered via PharmaJet® Needle Free Delivery on day 1 and day 29.
11047618|NCT04445675|Experimental|Experimental|The support for breastfeeding and the feeding of infants' with breast milk will be conducted in one stage for the experimental group. (1) breastfeeding support education. The content of the support for breastfeeding and the feeding of infants' with breast milk and the materials used were determined by the researchers in accordance with the literature. The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding. Breastfeeding support will be provided in the postpartum service and lactation outpatient clinic of the relevant hospital.
11047619|NCT04445675|No Intervention|Control Groups|The infants in the control group will be followed up in routine service. No intervention will be made.
11047620|NCT04445662|Active Comparator|Control (N=200)|"Transdermal nicotine patch
~In-person smoking cessation counseling"
11047621|NCT04445662|Experimental|Financial Rewards (N=200)|"Transdermal nicotine patch
~In-person smoking cessation counseling
~Contingent financial rewards for smoking abstinence"
11047622|NCT04445649||ICU patients|Patients with impaired consciousness admitted to intensive care unit after severe brain injury
11047623|NCT04445636|Experimental|Dexmedetomidine group|A group which will receive dexamedetomidine as an adjunct to bupivacaine used in caudal anesthesia.
11047624|NCT04445636|Experimental|Morphine group|A group which will receive morphine as an adjunct to bupivacaine used in caudal anesthesia.
11047625|NCT04445623|Active Comparator|prasugrel hydrochloride|film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
11047626|NCT04445623|Placebo Comparator|placebo|film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
11047627|NCT04445610||A|mild
11047628|NCT04445610||B|moderate
11047629|NCT04445610||C|severe
11047630|NCT04445597|Other|COVID-19 normosmia|Surgical sampling of tissue from the nasal cavity and olfactory bulb.
11047631|NCT04445571|Active Comparator|INSURE|Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.
11047632|NCT04445571|Active Comparator|LISA|Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.
11047633|NCT04445558|Experimental|Membrane PEPA®|Patient will use the membrane PEPA® for the dialysis
11047634|NCT04445558|Active Comparator|Standard membrane of dialysis|Patient will use a standard membrane for the dialysis
11047635|NCT04445545|Experimental|Experimental group 1 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in continuous emission (duty cycle 100%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
11047636|NCT04445545|Experimental|Experimental group 2 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 50 J / cm2 in continuous emission (duty cycle 100%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
11047637|NCT04445545|Experimental|Experimental group 3 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in pulsed emission (duty cycle 25%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
11047638|NCT04445545|Experimental|Experimental group 4 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in pulsed emission (duty cycle 25%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
11047639|NCT04445545|Active Comparator|Control group|The group will receive only passive static stretching exercises of 5 sets of 30 seconds.
11047640|NCT04445532||hepatobiliary tumor patients|benign or malignant hepatobiliary tumors patients
11047641|NCT04445532||Benign Hepatobiliary Disease|chronic hepatitis, cirrhosis, and healthy control
11047642|NCT04445519|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes
11047643|NCT04445519|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
11047644|NCT04445519|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
11047645|NCT04445506||SARS-CoV2 patients that received dexamethasone|
11047646|NCT04445493||Device: MindRhythm Harmony|Passive recording of the head pulse
11047647|NCT04445480|Experimental|Popliteal block group|
11047648|NCT04445480|Active Comparator|Control group|
11047649|NCT04445467|Experimental|Favipiravir|1800 mg Favipiravir twice daily on Day 1 followed by 800 mg Favipiravir twice daily for the next 13 days.
11047650|NCT04445467|Placebo Comparator|Placebo|Matched Placebo
11047651|NCT04445454|Experimental|MSC therapy for severe COVID-19 infection|After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.
11047652|NCT04445428|Experimental|Intervention|Standard dose bivalent oral polio vaccine, 0.1ml, and information regarding prevention of COVID-19
11047653|NCT04445428|Other|Control|Information regarding prevention of COVID-19
11047654|NCT04445402||Heme/Non-Sickle Cell Disease|Subjects with a diagnosis of hemoglobinapathy except Sickle Cell Disease
11047655|NCT04445402||Heme/Sickle Cell Disease|Subjects with a diagnosis of Sickle Cell Disease
11047656|NCT04445402||Neuro-Oncological Disease|Oncology diagnosis with involvement of the neurological system
11047657|NCT04445402||Oncology/Non-Neuro-Oncological|Subjects with any oncology diagnosis except those that involve the neurological system.
11047658|NCT04445402||Transplant patients|Subjects who have received or are intending to have a stem cell transplant for treatment of disease.
11047659|NCT04445389|Experimental|GX-19: Dose A|Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
11047660|NCT04445389|Experimental|GX-19: Dose B|Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
11061112|NCT04349800|Experimental|Single Ascending Dose - 300 mg|
11047662|NCT04445389|Placebo Comparator|Placebo: Dose A, B, or C|Placebo will be intramusculary administered on day 1 and day 29 via EP or PharmaJet® Needle Free Delivery
11047663|NCT04445376|Experimental|Intervention Group (Ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
11047664|NCT04445376|Experimental|Intervention (Non ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
11047665|NCT04445363|Experimental|Cohort 1,0.5% Bid|Jacatinib hydrochloride cream 0.5% concentration, twice daily
11047666|NCT04445363|Experimental|Cohort 1,1.5% Bid|Jacatinib hydrochloride cream 1.5% concentration, twice daily
11047667|NCT04445363|Experimental|Cohort 1,2.5% Qd|Jacatinib hydrochloride cream 2.5% concentration, once daily
11047668|NCT04445363|Experimental|Cohort 1,2.5% Bid|Jacatinib hydrochloride cream 2.5% concentration, twice daily
11047669|NCT04445363|Placebo Comparator|Dose extension: Placebo|Placebo, twice daily
11047670|NCT04445363|Experimental|Dose extension: 1.5% Bid|Jacatinib hydrochloride cream 1.5% concentration, twice daily
11047671|NCT04445363|Experimental|Dose extension: 2.5% Bid|Jacatinib hydrochloride cream 2.5% concentration, twice daily
11047672|NCT04445350|Experimental|External focus of attention training program|The intervention group receives a strength and neuromuscular training program. The training instructions have an external focus of attention.
11047673|NCT04445350|Active Comparator|Internal focus of attention training program|The control group receives a strength and neuromuscular training program. The training instructions have an internal focus of attention.
11047674|NCT04445337|Experimental|Open Label SGB|Initial perineural bolus injection - clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml will be used for SGB block.
11047675|NCT04445324|Experimental|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
11047676|NCT04445324|Active Comparator|Control Group (pharmacotherapy and/or psychotherapy N=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
11047677|NCT04445311|Experimental|Ivermectin group|group that will receive ivermectin plus standard of care ttt
11047678|NCT04445311|No Intervention|Control group|group that will receive standard of care ttt
11047679|NCT04445298||Pregnant women with expected delivery in the fall or winter|We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February). We will then follow their infant offspring.
11047680|NCT04445298||Pregnant women with expected delivery in the spring or summer|We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August). We will then follow their infant offspring.
11047681|NCT04445298||Infants born in the fall or winter|The infants born to the enrolled mothers will be followed. These are infants born in the fall (September, October, November) or winter (December, January, February).
11047682|NCT04445298||Infants born in the spring or summer|The infants born to the enrolled mothers will be followed. These are infants born in the spring (March, April, May) or summer (June, July, August).
11047683|NCT04445285|Experimental|Treatment Arm|Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
11047684|NCT04445285|Placebo Comparator|Placebo Arm 0.9% sodium chloride|Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
11047685|NCT04445272|Experimental|Tocilizumab|"Patients will receive IV tocilizumab as per clinical practice and at the discretion of treating investigator, following the posology indicated in the SmPC, or the recommendations proposed by the Spanish Ministry of Health:
~The recommended posology by the SmPC is 8 mg per kg in patients weighing greater than or equal to 30 kg or 12 mg per kg in patients weighing less than 30 kg. If no clinical improvement in the signs and symptoms up to 3 additional doses of tocilizumab may be administered. The interval between consecutive doses should be at least 8 hours.
~The recommendations of the Spanish Ministry of Health:
~Patients more than 80 kg: first dose 600 mg; second dose 600 mg. Patients less than 80 kg: first dose 600 mg; second dose 400 mg.
~A third dose might be considered 16 to 24 hours after if: fever persists or a worsening of the laboratory parameters
~Given the exceptionality of the situation modification of doses according to the physician experience will be allowed."
11047686|NCT04445259||Critically Ill Patients with COVID-19|We plan to recruit patients who are admitted to intensive care units with COVID-19 diagnosis.
11047687|NCT04445246|Experimental|Inhaled Iloprost therapy|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization
11047688|NCT04445233||COV Participants|COVID-positive index cases (COV): Participants who are greater than or equal to 18 years of age who test positive for COVID-19 by positive NP swab
11047689|NCT04445233||COV-HC Participants|Household contact of COVID-positive index case (COV-HC): Household contacts greater than 1 year of age currently living in the same home as the COVID-positive index case
11047690|NCT04445220|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
11047692|NCT04445220|No Intervention|Case controls|Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.
11047693|NCT04445194|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
11047694|NCT04445194|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
11047695|NCT04445194|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
11047696|NCT04445181||Patients with T2D|Active patients (defined as patients seen by an LMC endocrinologist between January 1, 2019 and December 31, 2019) with T2D (Type 2 Diabetes). Among the patients with T2D, those identified with CKD will be included in the renal registry.
11047697|NCT04445181||Healthcare providers|Healthcare providers caring for patients with CKD and T2D.
11047698|NCT04445168|No Intervention|Usual Care|Participants assigned to usual care may receive advice from their primary care physician to increase their physical activity. They will receive handouts about every 6 weeks on general health topics.
11047699|NCT04445168|Experimental|Intervention|Participants assigned to the intervention arm will receive telephone-based motivational interviews with trained interventionists to encourage increases in physical activity.
11047700|NCT04445155|Experimental|Modified DECIDE|DECIDE has two primary components: 1) three parent training sessions designed to help patients effectively ask questions and participate in decisions about care: and 2) a 12-hour workshop and up to 4 individual coaching sessions for providers to improve perspective-taking, reduce attributional errors, and increase receptivity to parent participation
11047701|NCT04445155|No Intervention|Usual Care|Usual Care consists of standard outpatient mental health care, including individual treatment for the adolescent (i.e., therapy, and/or medication) or family treatment for adolescents and parents, delivered in a variety of settings (e.g., clinics, schools, homes).
11047702|NCT04445142||epiretinal membrane group|Patients developed secondary fovea epiretinal membrane
11047703|NCT04445129||Narcolepsy Type 1 Participants|Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
11047704|NCT04445129||Healthy Participants|Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
11047705|NCT04445116|Experimental|Endeavor group|25 participants will fill out questionnaires and complete a neuropsychological evaluation. During study participation, participants will target using Endeavor™ action video game to complete 25-30 minutes at-home sessions 5 days a week for a total of 8 weeks via an iOS application.
11047706|NCT04445103||History of malaria|Individuals with a history of malaria infection
11047707|NCT04445103||Controls|Individuals without a history of malaria infection
11047708|NCT04445103||Symptomatic malaria|Patients with symptomatic malaria infection (complicated and uncomplicated)
11047709|NCT04445090|Experimental|Single Rising Dose part: BI 1569912|
11047710|NCT04445090|Placebo Comparator|Single Rising Dose part: Placebo|
11047711|NCT04445090|Experimental|Bioavailability and Food effect part: BI 1569912|This part follows the SRD part; open-label, randomised, single-dose, intraindividual, six-sequence, three-way crossover
11047712|NCT04445077|Experimental|Intervention group|The education will be delivered weekly with 60-90 minutes per lecture for eight lectures. Multiple teaching methods will be used, including lectures, structured handouts, video, role play, case study and discussion. During the study period, the research team will provide ongoing support and consultation through electronic communication and bimonthly field visits.
11047713|NCT04445077|Other|Control group|Printed materials will be given to the participants in the control group for their self-study.
11047714|NCT04445064|Experimental|IO102 vaccine|
11047715|NCT04445064|No Intervention|Control group|
11047716|NCT04445051|Active Comparator|Standard of care|SpeediCath® standard Male and Female
11047717|NCT04445051|Experimental|New intermittent catheter variation 1 for male and female|New intermittent catheter variation 1 for male and female
11047718|NCT04445051|Experimental|New intermittent catheter variation 2 for male and female|New intermittent catheter variation 2 for male and female
11047719|NCT04445038|Experimental|610 group|Participants will be administered with 0.03mg/kg, 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg of 610 by subcutaneous injection. Subjects will be followed for 84 days.
11047720|NCT04445038|Placebo Comparator|controll group|Participants will be administered with 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg placebo once by subcutaneous injection. Subjects will be followed for 84 days.
11047721|NCT04445025|Experimental|Test group|Subjects will receive the medication elagolix
11047722|NCT04445025|Active Comparator|Control group|Subjects will receive leuprolide acetate
11047723|NCT04445012||Aortic Valve Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
11047724|NCT04445012||Mitral Valve Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral regurgitation, using the BSE gradings [Wharton 2014].
11047725|NCT04445012||Aortic Regurgitation (Adults)|30 patients with mild, 30 with moderate, and 30 with severe aortic regurgitation, using the BSE gradings [Wharton 2014].
11047726|NCT04445012||Mitral Stenosis (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mitral stenosis, using the BSE gradings [Wharton 2014].
11047727|NCT04445012||Mixed Valve Disease (Adults)|30 patients with mild, 30 with moderate, and 30 with severe mixed valve disease. Overall classification based on the most severe disease using the BSE gradings [Wharton 2014].
11047728|NCT04445012||Ventricular Septal Defects (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe ventricular septal defects, using gradings from [Samaan 1970].
11048009|NCT04443101||Group（MI60）|Group（MI60）：Implant MI60 intraocular lens
11047729|NCT04445012||Aortic Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe aortic stenosis
11047730|NCT04445012||Pulmonary Stenosis (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe pulmonary stenosis.
11047731|NCT04445012||Patent Ductus Arteriosus (Paediatric Patients)|36 paediatric patients with mild, 37 with moderate, and 36 with severe patent ductus arteriosus, graded using ductal size [Arlettaz 2017].
11047732|NCT04445012||No Disease (Paediatric Patients)|264 paediatric patients with no heart disease. Note that we are only taking recordings from those who have been referred for an echocardiogram with a suspected heart condition but are subsequently found to have no heart disease.
11047733|NCT04444999|Experimental|Endovascular abdominal aortic aneurysm repair|a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA).
11047734|NCT04444986|Experimental|FAVIR then AVIGAN|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
11047735|NCT04444986|Experimental|AVIGAN then FAVIR|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
11047736|NCT04444973||Invasive RV assessment|RV conductance catheter assessment of RV performance
11047737|NCT04444960||Intracoronary physiology and imaging-guided group|
11047738|NCT04444960||Angiography-guided group|
11047739|NCT04444934||Patients with not-surely pathologic diaphragmatic peritoneum|The definition of not-surely pathologic diaphragmatic peritoneum was given in association with the presence of flat dyschromic areas.
11047740|NCT04444934||Patients with certainly pathologic diaphragmatic peritoneum|The definition of certainly pathological diaphragmatic peritoneum was given when isolated or confluent thick nodules were visualized at the intra-operative inspection.
11047741|NCT04444921|Active Comparator|Arm A (carboplatin, paclitaxel)|Patients receive carboplatin IV on day 1, and paclitaxel IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11047742|NCT04444921|Experimental|Arm B (carboplatin, paclitaxel, nivolumab)|Patients receive carboplatin on day 1, paclitaxel IV on days 1, 8 and 15, and nivolumab IV over 30 minutes on days 1 and 15 of cycle 1, and then on day 1 only of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for carboplatin and paclitaxel, and up to 2 years for nivolumab in the absence of disease progression or unacceptable toxicity.
11047743|NCT04444895|Experimental|Lanadelumab|Rollover participants from SHP643-303 (NCT04206605) will receive 300 milligram (mg) of lanadelumab solution in prefilled syringe subcutaneously (SC) for 26 weeks once every 2 weeks (Q2W) or once every 4 weeks (Q4W) if well controlled during SHP643-303 (NCT04206605) with up to 13 doses.
11047744|NCT04444869|Other|Open label single-arm study|All patients will receive concurrent cisplatin and radiation therapy with radiation dose de-escalation to clinically and radiologically uninvolved lymph nodes.
11047745|NCT04444856||NovoSeven|Women with severe postpartum haemorrhage treated with NovoSeven
11047746|NCT04444856||Standard of care|Women with severe postpartum haemorrhage treated with other standard of care
11047747|NCT04444843|Other|Mycophenolate Mofetil Capsules|The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring. It is not allowed to switch to other MPAs. When MMF is discontinued but is not switched to other MPA, the patients will be followed until the end of study.
11047748|NCT04444830|No Intervention|Standard|"To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed a standard postoperative regimen of Acetaminophen 650 mg PO q 6-8 hours + Ibuprofen 600 mg PO q 6-8 hours + rescue narcotics (Oxycodone 5-10 mg PO q 4-6 hours or if allergic to Oxycodone, Norco 5-10mg/325mg PO q 4-6 hours) for breakthrough pain"
11047749|NCT04444830|Experimental|Sprix|To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed regimen of Sprix 30.5mg Intranasal q 6-8 hour up to 4 times daily + Acetaminophen 650 mg PO q 6- 8 hours + rescue narcotics (as above) for breakthrough pain during the day of surgery and the following 4 postoperative days.
11047750|NCT04444817||Tacrolimus-based immunosuppression|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started.
11047751|NCT04444804||Rivaroxaban|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
11047752|NCT04444804||Low-molecular-weight heparin (LMWH) and Phenprocoumon|The source population of this study will include all insured members of more than 60 German statutory health insurances (SHIs) contributing data to the InGef database.
11047753|NCT04444791||Cohort|This cohort study only set up one group. The habits and health status of mothers and their offspring will be followed up and observed. The participants will be divided into more than one group according to the variables (e.g. age, physical activity, dietary patterns, sleep quality.).
11047754|NCT04444778|Active Comparator|Continuous positive airway pressure|Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
11047755|NCT04444778|No Intervention|Conservative treatment|Diet and general life style recommendations.
11047756|NCT04444765||Patients with bicarbonate-based intermittent dialysis|Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).
11047757|NCT04444765||Patients with acetate free biofiltration dialysis|Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification
11047758|NCT04444752|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection
11047759|NCT04444752|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection
11047760|NCT04444752|Experimental|CBP-201 Dose 3|CBP-201 Dose 3 subcutaneous (SC) injection
11047761|NCT04444752|Placebo Comparator|placebo|subcutaneous (SC) injection
11047762|NCT04444726|Experimental|"Phototherapy PUVA +traditional medical treatmentn"|"patient sock his hands in a bath containing water with the constitution of psoralen meladinine  capsule for 20 minutes then irradiated at the UVA device for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
11047763|NCT04444726|Experimental|Tap Water Iontophoresis + Traditional medical treatment|"Tap-water iontophoresis was given 3 times weekly for 10 min The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30mA. Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
11047764|NCT04444726|Active Comparator|traditional medical treatment|"Traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
11047765|NCT04444700|Experimental|Therapeutic anticoagulation|"Therapeutic anticoagulation with enoxaparin 1 mg/Kg BID will be administered until discharged from the hospital or after 7 days, whichever is longer, or death.
~If the patient is admitted to the ICU or requiring ventilatory support, we recommend the continuation of the allocated treatment as long as the treating physician is in agreement."
11047766|NCT04444700|No Intervention|Standard care|"Standard care will be administered until discharged from the hospital or after 7 days, whichever is longer, or death.
~If BMI less than 40 Kg/m², the treating physician may select one of the following options considered appropriate and available in Brazil:
~Enoxaparin 40 mg once daily, enoxaparin 60 mg once daily, UFH 5,000 twice daily, UFH 5,000 thrice daily.
~If BMI equals to or greater than 40 Kg/m², the treating physician may select one of the following options considered appropriate and available in Brazil:
~Enoxaparin 40 mg BID, UFH 7,500 TID."
11047767|NCT04444687||SARS-CoV-2-positive 01|SARS-CoV-2-positive patient, no symptoms, low viral load in tracheal aspirate, RNAemia not detectable
11047768|NCT04444687||SARS-CoV-2-positive 02|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia not detectable
11047769|NCT04444687||SARS-CoV-2-positive 03|SARS-CoV-2-positive patient, symptoms, high viral load in tracheal aspirate, RNAemia detectable
11047770|NCT04444687||Control|Control patients, SARS-CoV-2-negative
11047771|NCT04444674|Experimental|Group 1- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
11047772|NCT04444674|Placebo Comparator|Group 1- placebo|Participants (HIV-negative) will receive two doses of Normal saline (0.9%) in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
11047773|NCT04444674|Experimental|Group 2a- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
11047774|NCT04444674|Placebo Comparator|Group 2a- placebo|Participants (HIV-negative) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
11047775|NCT04444674|Experimental|Group 2b- IP|Participants will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
11047776|NCT04444674|Placebo Comparator|Group 2b- placebo|Participants will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
11047777|NCT04444674|Experimental|Group 3- IP|Participants (HIV-positive) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
11047778|NCT04444674|Placebo Comparator|Group 3- placebo|Participants (HIV-positive) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
11047779|NCT04444661||HIT-resistance exercise|High Intensity Resistance Exercise
11047780|NCT04444661||Non exercising control|Control group that maintained life style and physical activity habits
11047781|NCT04444648||One groupe without distinction of age, sexe, and pathology.|"Patients with strok in coma, with or without wake up, and with disorder of consciousness. No limit in age (maybe give the younger age).
~We obtain this data from medical record. Every assessment was made of clinical purposes.
~We use the Glasgow coma recovery scale for assessment of behavior to check the variation of wakefulness. The scale was performed by the nursing staff every 2 to 8 hours depending on the severity of the medical condition.
~The continuous analysis of neurophysiologic data was based on EEG with a bipolar montage composed of the less noisy electrodes per recording period.
~The EEG features will include: spectral analysis (relative and absolute power in 4 canonical bands: Delta/Theta/Alpha/Beta) and complexity analysis (DFA, determinism, SVD entropy and permutation entropy).
~The patient outcome at the ICU and hospital discharges were collected from the medical files."
11047782|NCT04444635|Active Comparator|Serratus Anterior Plan block plus fentanyl infusion|The patients will receive serratus anterior block in addition to continous intraoperative fentanyl infusion.
11047783|NCT04444635|Active Comparator|Fentanyl infusion only|The patient will receive fentanyl infusion only.
11047784|NCT04444622|Experimental|AlloStim|"AlloStim is administered in three cycles:
~Cycle 1 Day 0: 0.5ml ID AlloStim® Day 7: 0.5ml ID AlloStim® Day 14: 0.5ml ID AlloStim® Day 21: 0.5ml ID AlloStim® Day 28: 0.5ml ID AlloStim®
~Cycle 2 Day 42: 0.5ml ID AlloStim® Day 49: 0.5ml ID AlloStim® Day 56: 0.5ml ID AlloStim® Day 63: 0.5ml ID AlloStim® Day 70: 0.5ml ID AlloStim® + 3ml IV AlloStim®
~Cycle 3 Day 84: 0.5ml ID AlloStim® Day 91: 0.5ml ID AlloStim® Day 98: 0.5ml ID AlloStim® Day 105: 0.5ml ID AlloStim® Day 112: 0.5ml ID AlloStim® + 3ml IV AlloStim®"
11047828|NCT04444284|Placebo Comparator|Dosage Group 2: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
11047785|NCT04444609||COVID -19 with chronic lung disease|"Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)
~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
~Mild/Moderate ( n =30) (absence of severe criteria)"
11047786|NCT04444609||COVID-19 without chronic lung disease|"Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)
~Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
~Mild/Moderate ( n =30) (absence of severe criteria)"
11047787|NCT04444609||Chronic Lung disease|"Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)
~Asthma (defined as severe) - (n=20)
~CF (FEV1% predicted baseline <50%) - (n=20)
~COPD (FEV1% predicted baseline <50%) - (n=20)
~Idiopathic Pulmonary Fibrosis (n=20)"
11047788|NCT04444609||Healthy volunteers|Healthy subjects with no COVID-19 (n=30)
11047789|NCT04444596|Other|Swab|Conjunctival swab and nasopharyngeal swab for SARS-COV 2
11047790|NCT04444583||HFpEF|HF patients with preserved ejection fraction (HFpEF)
11047791|NCT04444583||HFrEF|HF patients with reduced ejection fraction (HFrEF)
11047792|NCT04444570||Control group|14 days before the date of the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom)
11047793|NCT04444570||Study group|Right after the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
11047794|NCT04444557||Turkish hemodialysis patients|Turkish patients undergoing in-center hemodialysis
11047795|NCT04444557||Temporarily protected Syrian hemodialysis patients|Temporarily protected Syrian patients undergoing in-center hemodialysis
11047796|NCT04444531||Ozone autohemotherapy plus standard treatment|
11047797|NCT04444531||Standard treatment alone|
11047798|NCT04444518|Experimental|VAX-MOM Intervention|
11047799|NCT04444518|Active Comparator|Standard of Care|
11047800|NCT04444492|Experimental|Ranibizumab+Laser-arm|Ranibizumab injections and additional targeted laser
11047801|NCT04444492|Active Comparator|Ranibizumab-arm|Only Ranibizumab injections
11047802|NCT04444479|Experimental|PICC catheter placement|Study subjects in whom placement of the PICC catheter is indicated
11047803|NCT04444466|Experimental|UCB8600|Study participants randomized to this arm will receive various single doses and multiple doses of UCB8600 administered to various cohorts.
11047804|NCT04444466|Placebo Comparator|Placebo|Study participants randomized to this arm will receive various single doses and multiple doses of Placebo administered to various cohorts.
11047805|NCT04444453|Experimental|Pedometer|Admitted patients who receive a pedometer to wear during their hospital stay to measure steps ambulated
11047806|NCT04444453|No Intervention|Control|Patients admitted to hospital who do not receive a pedometer, but receive all other usual standard of care
11047807|NCT04444440|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
11047808|NCT04444440|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
11047809|NCT04444427|Experimental|Part 1: Dose Escalation|Dose escalation cohorts are planned to determine the maximum tolerated dose or recommended phase 2 dose of GLR-2007, as well as expansion cohorts and a Phase 2 cohort.
11047810|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort A|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their non-small cell lung cancer (NSCLC) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
11047811|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort B|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their brain metastases of breast or NSCLC origin will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
11047812|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort C|Participants experiencing their first recurrence glioblastoma multiforme (GBM) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
11047813|NCT04444414|Experimental|Manual Therapy group|Bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
11047814|NCT04444414|Other|Control group|They received no treatment, they just went to the evaluations.
11047815|NCT04444388|Experimental|Cocoa group|5 g/day of flavonoid-rich defatted cocoa for 10 weeks
11047816|NCT04444388|Placebo Comparator|Placebo group|5 g/day of maltodextrin for 10 weeks
11047817|NCT04444375||obese, non-obese|obese and non-obese diabetic patients
11047818|NCT04444362|Experimental|Inspiratory Muscle Training|The Inspiratory Muscle Training group received respiratory muscle training, in addition to routine preparation, including laboratory and radiological examinations and preoperative education.
11047819|NCT04444362|No Intervention|Control|The control group received routine preparation, including laboratory and radiological examinations and preoperative education.
11047820|NCT04444349|Experimental|Coenzyme Q10 group|Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
11047821|NCT04444349|Sham Comparator|Control|Participants in the experimental group will be given 10mg of placebo each time (3 times a day).
11047822|NCT04444323|Experimental|3D Telemedicine|Single arm. All patient seen face-to-face and then with 3D telemedicine.
11047823|NCT04444297|Active Comparator|2D telemedicine|2D telemedicine first, followed by crossover to 3D telemedicine with no washout period
11047824|NCT04444297|Experimental|3D Telemedicine|3D telemedicine first, followed by crossover to 2D telemedicine with no washout period
11047825|NCT04444284|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
11047826|NCT04444284|Placebo Comparator|Dosage Group 1: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
11047827|NCT04444284|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
11047829|NCT04444284|Experimental|Dosage Group 3: RSV Vaccine Dosage 3|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
11047830|NCT04444271|Experimental|Mesenchymal stem cells|10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
11047831|NCT04444271|Placebo Comparator|Placebo|Only supportive care will be given to 10 patients
11047832|NCT04444258|Experimental|Experimental I Group|After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
11047833|NCT04444258|Experimental|Experiment II Group|Following the Fetal Development Assessment Information Form (FEGBF), the computer-aided and unguided virtual reality application prepared by the researchers including the fetal development week by week will be monitored, and then FEGBF will be applied again by changing the locations of the questions.
11047834|NCT04444258|No Intervention|Control Group|FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
11047835|NCT04444245|Experimental|ARM 1 Platelet Rich Plasma|Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. (Emcyte II Pure PRP) Endovaginal ultrasound guided intra-ovarian placement into ovarian parenchyma, preferably both if accessible.
11047836|NCT04444245|Experimental|ARM 2 emulsified tSVF and PRP|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue into tSVF (Tulip Nanofat device). Blending of Nanofat with PRP at a 3:1 ratio.
~Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible."
11047837|NCT04444245|Experimental|ARM 3 emulsified tSVF and PRP, enriched with cSVF|"Blood draw, processing of PRP, white blood cell poor, high platelet multiple >/= 4, e.g. Emcyte PRP tSVF preparation: Lipoaspiration utilizing closed microcannula harvesting of small volume (Tulip tumescent fluid infiltrator and Tulip Harvester). Decanting of free lipid. Emulsification of adipose tissue (Tulip Nanofat device).
~cSVF preparation: lipoaspiration as above. Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocol. Quantification of viable nucleated cell count with flow cytometry. Addition of pellet of viable nucleated cells to tSVF.
~Blending of tSVF/cSVF emulsion with PRP at a 3:1 ratio. Endovaginal ultrasound guided intra-ovarian placement into ovary, preferably both if accessible.
~Intervention:"
11047838|NCT04444245|Experimental|ARM 4 Intra-ovarian guided placement|Specifically designed 23 gauge modified oocyte harvester needle for ultrasound guided placement
11047839|NCT04444232|Experimental|Health services research (educational video, survey)|Participants view an educational video on cancer and cancer screening options over 12 minutes. Participants also complete a phone survey over 10-15 minutes before attending the video session and 2 months after the video session.
11047840|NCT04444219|Other|Breakfast meal_1|14g bread, 40g cheese and 15g dry mushrooms (meal 1)
11047841|NCT04444219|Other|Breakfast meal_2|114g bread, 40g cheese and 200g tomatoes
11047842|NCT04444206|Experimental|CL and CCI screening|The Cervical lenght (CL) and the Consistence Cervix Index (CCI) will be evaluated by transvaginal ultrasound. CL and CCI measurements will be expected in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy, in accordance with current national guidelines.
11047843|NCT04444206|No Intervention|No CL and CCI screening|The investigators collect data of these pregnant women without any additional ultrasound examination
11047844|NCT04444193|Experimental|Durvalumab and Lenvatinib|Combination therapy of Lenvatinib 80-120mg daily orally and durvalumab 1500mg by IV infusion every 4 weeks
11047845|NCT04444180||Clinical high risk for psychosis (CHR)|No intervention. Just use virtual hand illusion (VHI) paradigm to observe the outcome of individuals with CHR at one-year follow-up node and analyze the predictive role of self-representation in transition into psychosis.
11047846|NCT04444180||First episode of schizophrenia (FES)|In contrast to FES, it is anticipated to observe CHR individuals with similar behavioral performance to FES may presented higher risk of transition.
11047847|NCT04444180||Healthy control (HC)|In contrast to HC, it is anticipated to observe CHR individuals with similar behavioral performance to HC may presented lower risk of transition.
11047848|NCT04444167|Experimental|AK104 and Lenvatinib|AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
11047849|NCT04444154|Active Comparator|Control group|oral hygiene advice given orally
11047850|NCT04444154|Active Comparator|Group with active participation|oral hygiene advice given orally and demonstration of brushing methods in the sink with active participation
11047851|NCT04444154|Experimental|Group with video and quizz|oral hygiene advice given orally and an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
11047852|NCT04444141|Experimental|AK104|AK104 450mg IV every 2 weeks (Q2W)
11047853|NCT04444102|No Intervention|Control group (CG)|Those subjects randomized to the CG will be offered reading options that do not evoke high emotional distress. They will spend an hour reading.
11047854|NCT04444102|Experimental|Stretching protocol 1, Mild Stretching Group (MSG)|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 50% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch and then corrected to 50%. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 50% with some feedback from the instructor.
11047855|NCT04444102|Experimental|Stretching protocol 2, Intense Stretching Group (ISG):|The protocol starts with 5 minutes of instruction about finding a range of stretching representing approximately 100% of the range of motion and pain-free. The instructor will also wear wrist and ankle reflective bands as body-marks to show a posture with 100% stretch. Once the participant grasps the concept the routine will begin with 5 minutes of warm-up, followed by stretching exercises targeting 10 anatomical groups. Each posture will last 1 minute divided in 30 seconds of settling into each posture and 30 seconds of holding. Each session will be video recorded to analyze the stretching range, only if the participant agrees at the informed consent visit. Participants will be encouraged to find their own 100% with some feedback from the instructor.
11047856|NCT04444089|Experimental|conventional group, CG|receives Ringer's lactate solution at a rate of 4 ml/kg/h for the first-10 kg of body weight, 2 ml/kg/h for the second-10 kg of body weight, and 1 ml/kg/h for each further kg of body weight. The deficit volume is calculated as the maintenance volume multiplied by fasting hours and given as follows: 50% of the volume in the first hour, 25% of the volume in the second hour, and 25% of the volume in the third hour, in addition to the aforementioned maintenance volume
11047857|NCT04444089|Experimental|restricted group, RG|Patients in the RG receives Ringer's lactate solution at a rate of 3 ml/kg/h from the start to the end of surgery.
11047858|NCT04444076|Experimental|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a bovine mesh that will be implanted following supraspinatus tendon repair.
11047859|NCT04444076|No Intervention|Standard of Care|Supraspinatus tendon repair.
11047860|NCT04444063|Experimental|NIPSA technique with Allograft plus PRF|Non-incised papilla preservation technique to treat intraosseous bony defects with the addition of Allograft plus PRF
11047861|NCT04444063|Active Comparator|NIPSA technique|Non-incised papilla preservation technique to treat intraosseous bony defects without the addition of Allograft plus PRF
11047862|NCT04444050|Experimental|Part 1 Single Ascending Dose (SAD): Panel 1|
11047863|NCT04444050|Experimental|Part 1 SAD: Panel 2|
11047864|NCT04444050|Experimental|Part 1 SAD: Panel 3|
11047865|NCT04444050|Experimental|Part 1 SAD: Panel 4|
11047866|NCT04444050|Experimental|Part 1 SAD: Panel 5|
11047867|NCT04444050|Experimental|Part 1 SAD: Panel 6|
11047868|NCT04444050|Experimental|Part 1 SAD: Optional Split-dose Panel|
11047869|NCT04444050|Experimental|Part 2 Multiple Ascending Dose (MAD): Panel 1|
11047870|NCT04444050|Experimental|Part 2 MAD: Panel 2|
11047871|NCT04444050|Experimental|Part 2 MAD: Panel 3|
11047872|NCT04444050|Experimental|Part 2 MAD: Panel 4|
11047873|NCT04444050|Experimental|Part 2 MAD: Optional (to be determined) Panel|
11047874|NCT04444050|Experimental|Part 3 MAD in Japanese Participants (J-MAD): Panel 1|
11047875|NCT04444050|Experimental|Part 3 J-MAD: Panel 2|
11047876|NCT04444050|Experimental|Part 3 J-MAD: Panel 3|
11047877|NCT04444050|Experimental|Part 3 J-MAD: Optional (to be determined) Panel|
11047878|NCT04444037||OCT-guided PCI|PCI procedure was done with intra-coronary imaging OCT.
11047879|NCT04444037||Angiography-guided PCI|PCI procedure was done without any intra-coronary imaging assistance, guided by angiography alone
11047880|NCT04444024||NTC/-HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to normal TC/ none hypertension(NTC/-HTN) group.
11047881|NCT04444024||NTC/+HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to normal TC/ hypertension(NTC/+HTN) group.
11047882|NCT04444024||BHTC/-HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to borderline-high TC/ none hypertension (BHTC/-HTN) group.
11047883|NCT04444024||BHTC/+HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to borderline-high TC/ hypertension (BHTC/+HTN) group.
11047884|NCT04444024||HTC/-HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to high TC/ none hypertension(HTC/-HTN) group.
11047885|NCT04444024||HTC/+HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 80 mmHg belong to high TC/ hypertension(HTC/+HTN) group.
11047886|NCT04444011|Experimental|Anaprazole Sodium enteric-coated tablet|Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), one tablet each time.
11047887|NCT04444011|Experimental|Amoxicillin capsules|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 capsules each time."
11047888|NCT04444011|Experimental|Clarithromycin tablet|"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 tablets each time."
11047889|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin|"Cohort 1: Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods ( only once on the morning of D5 of treatment periods).
~Cohort 2: Administered orally on an empty stomach once on the morning of D1 of treatment periods"
11047890|NCT04444011|Experimental|Anaprazole + Amoxicillin +Clarithromycin+Bismuth|Administered orally on an empty stomach once on the morning of D1 of treatment periods in cohort 2
11047891|NCT04443998|Experimental|Bone reduction forceps|
11047892|NCT04443972|Experimental|PD VitalOs cement® alone|class II furcation defects that will be treated with PD VitalOs cement® alone
11047893|NCT04443972|Experimental|PD VitalOs cement® plus Bone graft and membrane|PD VitalOs cement® and Hydroxyapatite bone graft and biodegradable collagen membrane in the treatment of class II furcation defects.
11047894|NCT04443959|Experimental|MBTI Treatment|Telemedicine-assisted digital mindfulness-based therapy for insomnia (MBTI).
11047895|NCT04443946|Active Comparator|Group-P|Group-P: (Propofol group): 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
11047896|NCT04443946|Experimental|Group-PAS|Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 2.5 mg kg-1 h-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
11047897|NCT04443946|Experimental|Group-PS|Group-PS: (Propofol and Sevoflurane group): 2.5 mg kg-1 h-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time.
11047898|NCT04443946|Experimental|Group-S|Group-S: (Sevoflurane group): 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
11047899|NCT04443946|Experimental|Group-PSu|Group-PSu: (Propofol and Sufentanil group): 5 mg kg-1 h-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
11047900|NCT04443933||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
11047901|NCT04443933||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
11047902|NCT04443920|Active Comparator|Tranexamic acid (TXA)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of 15 mg/kg of Tranexamic acid (TXA) before the release of the tourniquet. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
11047903|NCT04443920|Placebo Comparator|Placebo Normal Saline (NS)|"All patients will receive 15 mg/kg Tranexamic acid (TXA) IV prior to skin incision. This arm will receive a second intravenous dose of placebo (Normal Saline) in the volume calculated to be equal to the volume of 15 mg/kg of TXA. The medication is delivered from the pharmacy in a masked syringe labeled as study medication."
11047904|NCT04443907|Experimental|OTQ923 or HIX763|Single intravenous infusion of either OTQ923 or HIX763, Part A - Adults treated with OTQ923; Part B - Adults treated with HIX763 Part C - Children age 2-17 - either OTQ923 or HIX763 based on review of data from Part A and/or Part B by Health agency after a formal interim analysis.
11047905|NCT04443894|Active Comparator|PECS block|
11047906|NCT04443894|Active Comparator|local infiltration|
11047907|NCT04443881|Experimental|Anakinra Arm|Standard of care plus Anakinra (100mg) administered as 4-times daily i.v. infusions for a maximun of 15 days
11047908|NCT04443881|No Intervention|Control Arm|Standard of care
11047909|NCT04443868|Experimental|Nitric Oxide Releasing Solution|Daily nasal irrigation (240mL) 14.4ppm
11047910|NCT04443868|Placebo Comparator|Placebo Isotonic Saline|Daily nasal irrigation (240mL) 0.9% saline
11047911|NCT04443855|Active Comparator|Water quality|90 clusters, approx. 720 newborns
11047912|NCT04443855|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
11047913|NCT04443855|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
11047914|NCT04443855|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
11047915|NCT04443855|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
11047916|NCT04443855|Active Comparator|Nutrition+ Combined WASH|90 clusters, approx. 720 newborns
11047917|NCT04443855|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
11047918|NCT04443842|Experimental|Intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentive, social incentives and weekly feedback on performance for 6 months.
11047919|NCT04443842|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
11047920|NCT04443829|Experimental|CD19CAR T-cells|Treatment with the ATIMP: CD19CAR T-cells
11047921|NCT04443790|Active Comparator|Obesecure Capsules (Test Group)|A dose of 500mg capsule twice daily of Polyherbal formulation Obesecure was given in the test group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
11047922|NCT04443790|Placebo Comparator|Plasicure (Control Group)|A dose of 500mg capsule twice daily of Placebo as Plasicure was given in the control group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
11047923|NCT04443777|Active Comparator|Sulphonylurea Group|Gliclazide 60 mg (Diamicron® MR) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
11047924|NCT04443777|Placebo Comparator|Placebo Group|Placebo (starch, sodium lauryl sulfate and Aerosil) will be orally administered as matched capsules (same color, flavor, smell and size) 8 hours before the beginning of exercise session.
11047925|NCT04443751|Experimental|SHR-1702 monotherapy|SHR-1702 monotherapy, given intravenously (IV); dose escalation and dose expansion.
11047926|NCT04443725|Experimental|Hydroxychloroquine plus Sofosbuvir/Daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days, Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days
11047927|NCT04443725|Active Comparator|Standard of care|Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days
11047928|NCT04443686|Experimental|ALA / Fractions of Radiotherapy|Subjects will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed.
11047929|NCT04443673|Experimental|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
11047930|NCT04443673|No Intervention|Control|Participants will receive the habitual treatment for their severe condition.
11047931|NCT04443660||Group A|without medical history or risk factors, with a normal pregnancy
11047932|NCT04443660||Group B|without medical history or risk factors, developing a pregnancy complication
11047933|NCT04443660||Group C|with risk of complication, having a normal pregnancy
11047934|NCT04443660||Group D|with a risk of complication, developing a pregnancy complication
11047935|NCT04443647|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
11047936|NCT04443647|Placebo Comparator|Placebo|Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
11047937|NCT04443634|Experimental|Adductor 20|Ultrasound guided adductor canal block will be performed with injection of 20 ml bupivacaine
11047938|NCT04443634|Experimental|Adductor 30|Ultrasound guided adductor canal block will be performed with injection of 30ml bupivacaine
11047939|NCT04443634|Experimental|Adductor /Saphenous|Ultrasound guided adductor canal block will be performed by injection of 20 ml bupivacaine , combined with ultrasound guided saphenous nerve block at the distal third of the thigh in the intermuscular plane between Vastus Medialis and Sartorius muscle with injection of 10ml bupivacaine 0.5%.
11047940|NCT04443621||participants with early stage dementia|Subjects with diagnosed any type of dementia at an early phase (MMSE score 20 - 25 points) - for longitudinal study (three phasis).
11047941|NCT04443621||participants without dementia|Subjects without dementia with MMSE score 26 - 30 points (for validation of ACE-III).
11047942|NCT04443608|Active Comparator|Veltassa|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
11047943|NCT04443608|Placebo Comparator|Placebo|3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
11047944|NCT04443595|Experimental|Experimental|Treatment of Acute Severe Pancreatitis with DPN
11047945|NCT04443569|Experimental|Lidocaine Patch Group|This group will be women who were randomized to receive a lidocaine patch for postoperative pain following cesarean delivery in addition to routine postoperative pain management.
11047946|NCT04443569|No Intervention|Control Group|This group will be women randomized to routine postoperative pain management following cesarean delivery.
11047947|NCT04443556|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|Standart postoperative analgesia + Continue Rhomboid Intercostal and Subserratus Plane Block
11047948|NCT04443556|Other|Control Group|Standart postoperative analgesia
11047949|NCT04443543|Experimental|Arm 1|"Arm 1 includes patients with MSS/pMMR. In this arm, patients receive consolidation chemotherapy after neoadjuvant chemoradiation (nCRT). The chemotherapy regimens either XELIRI or FOLFIRINOX, and the cycles of chemotherapy depend on patient tumor responses. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
11047950|NCT04443543|Experimental|Arm 2|"Arm 2 includes patients with MSI-H/dMMR status. In this arm, patients receive consolidation immunotherapy of 3 cycles of tislelizumab after nCRT. For patients who reach cCR will enter the W&W cohort and omit radical surgery, while those without cCR will receive radical surgery."
11047951|NCT04443530||Coronary artery stenosis|Patients with coronary artery disease
11047952|NCT04443517|Experimental|Maintenance-Alpha Optimization / Wake from Propofol|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive individualized titration of anesthetic gas and opioid. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
11047953|NCT04443517|Active Comparator|Maintenance-Alpha Optimization / Wake from Volatile|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive real-time monitoring of alpha recordings and individualized titration of desflurane and opioid. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
11047954|NCT04443517|Active Comparator|Maintenance-Routine Care / Wake from Propofol|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
11047955|NCT04443517|No Intervention|Maintenance-Routine Care / Wake from Volatile|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
11047956|NCT04443504|Experimental|Intervention Group|
11047957|NCT04443504|No Intervention|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
11047958|NCT04443478||Laparoscopic Surgery|Lower Mediastinal Lymphadenectomy should be finished via laparoscopic method.
11047959|NCT04443478||Open Surgery|Lower Mediastinal Lymphadenectomy should be finished via open method.
11047960|NCT04443452||Prevalent Central Sensitisation|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
11047961|NCT04443452||Non-prevalent Central Sensitisation|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
11047962|NCT04443439||No related neurological symptoms and transient ischemic attack|Mild stenosis group: CTA suggested carotid stenosis < 30%; Moderate stenosis group: CTA suggested carotid stenosis of 30-69%; Severe stenosis group: CTA indicated carotid stenosis ≥70%;
11047963|NCT04443426|Experimental|3-Hydroxybutyrate followed by Placebo treatment (one month)|Cross-over study in 20 HFrEF-patients. Investigated by right heart catherization, echocardiography, cardiopulmonary exercise test and whole-body substrate metabolism.
11047964|NCT04443426|Experimental|Placebo followed by 3-Hydroxybutyrate treatment (one month)|Cross-over study in 20 HFrEF-patients. Investigated by right heart catherization, echocardiography, cardiopulmonary exercise test and whole-body substrate metabolism.
11047965|NCT04443426|Experimental|Single dose placebo or oral 3-hydroxybutyrate|Cross-over pilot study in 8 patients receiving single-dose oral 3-hydroxybutyrate and placebo.
11047966|NCT04443413|Experimental|Arm I (x-ray therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 since the last chemotherapy, patients undergo x-ray therapy over 25 fractions in the absence of disease progression or unacceptable toxicity. Patients may receive a sequential boost of x-ray therapy after breast conserving surgery.
11048006|NCT04443114|Other|Early Arm|The early arm will receive the experimental organ donation workshop first, followed by the control workshop on end-of-life care.
11048007|NCT04443114|Other|Late Arm|The late arm will receive the control workshop on end-of-life care first, followed by the experimental organ donation workshop.
11047967|NCT04443413|Experimental|Arm II (proton beam radiation therapy)|Within 12 weeks of the last breast cancer surgery or last dose of adjuvant chemotherapy and no sooner than 14 since the last chemotherapy, patients undergo proton beam radiation therapy over 5 fractions in the absence of disease progression or unacceptable toxicity. Patients may receive a sequential boost of proton beam radiation therapy after breast conserving surgery.
11047968|NCT04443387|Active Comparator|Asthmatic low vitamin D on treatment|asthmatic patient low vitamin D level received treatment for Vitamin D 50000IU weekly
11047969|NCT04443387|Placebo Comparator|Asthmatic low vitamin D on placepo|asthmatic patient low vitamin D level received placepo
11047970|NCT04443348|Experimental|Group A (No RT Boost)|No RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy.There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
11047971|NCT04443348|Experimental|Group B (Low Dose RT Boost)|Low-dose RT boost plus pembrolizumab, followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
11047972|NCT04443348|Experimental|Group C (High Dose RT Boost)|High-dose RT boost plus pembrolizumab followed by pembrolizumab plus paclitaxel, doxorubicin and cyclophosphamide chemotherapy. There will be up to a total of 8 cycles of pembrolizumab (4 cycle before surgery and 4 cycles after surgery at the discretion of the study doctor).
11047973|NCT04443335|Sham Comparator|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
11047974|NCT04443335|Experimental|sequential feeding|This feeding mode utilizes a combination of continuous feeding in the beginning, time-restricted feeding in the second stage and oral feeding in the last stage
11047975|NCT04443322|Experimental|Durvalumab and Lenvatinib|"Participants receive intravenous (IV) durvalumab at 1500mg on Day 1 of each 28-day cycle. Number of cycles: until unacceptable toxicity develops or >42 days before liver transplantation (If patients with locally advanced HCC would undergo liver transplant).
~Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation(If patients with locally advanced HCC would undergo liver transplant)."
11047976|NCT04443309|Experimental|Lenvatinib plus Camrelizumab|"Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
11047977|NCT04443296|Experimental|CCRT+TIL|Cisplatin based concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
11047978|NCT04443296|Active Comparator|CCRT|Cisplatin based concurrent chemoradiotherapy(CCRT) only
11047979|NCT04443283||LTBI Group|IGRA(+)
11047980|NCT04443283||No LTBI Group|IGRA(+)
11047981|NCT04443270|Experimental|Chloroquine phosphate prophylactic group|"Drug: Chloroquine phosphate
~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
11047982|NCT04443270|No Intervention|Control group|Health personnel who want to be included voluntary in the study and meet the inclusion criteria without Chloroquine use.
11047983|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 24Units|Botulinum Toxin Type A (Botulax®) 24Units total dose administered intramuscularly to the bilateral masseter muscles.
11047984|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 48Units|Botulinum Toxin Type A (Botulax®) 48Units total dose administered intramuscularly to the bilateral masseter muscles.
11047985|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 72Units|Botulinum Toxin Type A (Botulax®) 72Units total dose administered intramuscularly to the bilateral masseter muscles.
11047986|NCT04443244|Experimental|Botulinum Toxin Type A(Botulax®) 96Units|Botulinum Toxin Type A (Botulax®) 96Units total dose administered intramuscularly to the bilateral masseter muscles.
11047987|NCT04443244|Placebo Comparator|Placebo(Normal Saline)|Placebo(Normal saline) administered intramuscularly to the bilateral masseter muscles.
11047988|NCT04443205||no macrosomy|pregnant women whose child is not macrosomal
11047989|NCT04443205||screened macrosomy|pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
11047990|NCT04443205||no screened macrosomy|pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
11047991|NCT04443192|Active Comparator|Part A Cohort 1 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
11047992|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874|Single oral dose of placebo by mouth in the fasted state
11047993|NCT04443192|Active Comparator|Part A Cohort 2 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
11047994|NCT04443192|Active Comparator|Part A Cohort 3 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
11047995|NCT04443192|Active Comparator|Part A Cohort 4 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
11047996|NCT04443192|Active Comparator|Part B - ZF874|ZF874 once daily by mouth for 28 days.
11047997|NCT04443192|Placebo Comparator|Part B - Placebo to ZF874|Placebo once daily by mouth for 28 days. Dose Level to be determined following Part A.
11047998|NCT04443179||Infants a family history of ASD/ADHD|
11047999|NCT04443179||Infants without a family history of ASD/ADHD|
11048000|NCT04443166|Experimental|Group A|At the beginning of the study (T0), group A will receive one course of PRP+HA program and group B will receive one HA course (a single HA injection (Hyajoint) weekly for 3 weeks). The PRP+HA program includes 3 HA injections and a single PRP injection (Arthrex double syringe system).
11048001|NCT04443166|Active Comparator|Group B|In the 6th month, alternately, group B will receive one PRP+HA program and group A will receive one HA course.
11048002|NCT04443153|Experimental|De-escalation|Subjects randomized to this arm will proceed from DSS to PF to SAP
11048003|NCT04443153|Experimental|Escalation|Subjects randomized to this arm will proceed from SAP to PF to DSS
11048004|NCT04443127|Experimental|Game-Based Rehabilitation|
11048005|NCT04443127|Placebo Comparator|Conventional Rehabilitation|
11048008|NCT04443101||Group（SN6CWS）|Group（SN6CWS）：Implant SN6CWS intraocular lens
11048010|NCT04443101||Group（Aspira-aA）|Group（Aspira-aA）：Implant Aspira-aA intraocular lens
11048011|NCT04443088|Other|Dose Escalation|Subjects will receive escalating doses of INV-1120 orally once a day until un-acceptable toxicity or disease progression. Three to six patients will be enrolled per cohort to evaluate the safety and pharmacokinetics for each dose level. After the last patient in each cohort completes Cycle 1 (DLT observation period of 28 days), the Safety Evaluation Team (SET) will evaluate the safety data and pharmacokinetic collected from Cycle 1, and make the decision whether to escalate the dose before opening the second cohort.
11048012|NCT04443075||exposed group|The exposed group consists of the frontline medical workers who take part in the medical team to support Wuhan.
11048013|NCT04443075||non-exposed group|This group includs medical workers who didn't join in the medical team to support Wuhan.
11048014|NCT04443062|Experimental|Interventional arm: 177Lu-PSMA radioligand therapy|Two cycles of 7.4 GBq 177Lu-PSMA 6 weeks apart
11048015|NCT04443062|No Intervention|Standard of care|Deferred androgen deprivation therapy. However, the control arm can receive the study drug (177Lu-PSMA) in case of disease progression (defined in the study protocol).
11048016|NCT04443049|Active Comparator|Lenvatinib +Placebo|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
11048017|NCT04443049|Experimental|Lenvatinib and mebendazole|Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
11048018|NCT04443036|Experimental|Albumin-bound Paclitaxel Combined With Toripalimab|"Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W
~Toripalimab：240 mg，IV d1，Q3W
~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months"
11048019|NCT04443023|Active Comparator|Sapien|Patients randomized to treatment
11048020|NCT04443023|Active Comparator|Myval|Patients randomized to treatment
11048021|NCT04443010|Experimental|Phase 1 part: Dose Finding|Patients will be treated in cohorts according to a 3+3 study design with standard treatment (consisting of radiotherapy of 60 Gy/30 fractions for 6 weeks plus 75 mg/m2 TMZ (temozolomide) daily (chemoradiotherapy), followed by 4 weeks of treatment break, followed by maintenance treatment with 6 maintenance cycles of TMZ 150-200 mg/m2 on Days 1 to 5 q28) combined with L19TNF at different dose levels on Day 1, 3, 5, 22, 24 and 26 of chemoradiotherapy and on Day 1, 3 and 5 of each 28-day chemotherapy maintenance cycle.
11048022|NCT04443010|Experimental|Phase 2 part: Signal Seeking|32 patients will receive standard chemoradiotherapy and L19TNF at RD and with the administration scheme established in phase I part of the study.
11048023|NCT04443010|Active Comparator|Phase 2b part: Activity Evaluation_control arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).
~- Arm 2: Patients will receive radiotherapy and TMZ (temozolomide)."
11048024|NCT04443010|Experimental|Phase IIb part: Activity Evaluation_treatment arm|"Patients will be randomized 1:1 and treated with either standard chemoradiotherapy and L19TNF as established in phase I part and the phase II part of this study or only chemoradiotherapy (control).
~- Arm 1: Patients will receive radiotherapy, TMZ (temozolomide) and L19TNF."
11048025|NCT04442984|Active Comparator|FOLFOX6|5FU 400mg/m2 iv bolus d1, 5-FU 2400 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
11048026|NCT04442984|Experimental|mFOLFIRINOX|Irinotecan 180mg/m2 d1, 5FU 250mg/m2 iv bolus d1, 5-FU 2200 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles
11048027|NCT04442971|Experimental|Music Stimulation|Patients preferred music is presented via headphones.
11048028|NCT04442971|Active Comparator|Alternative Auditory Stimulation|An audio book is presented via headphones.
11048029|NCT04442971|Sham Comparator|No Auditory Stimulation|Silence is presented via headphones.
11048030|NCT04442958|Experimental|Convalescent Plasma Therapy Group|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
11048031|NCT04442958|No Intervention|Non-Plasma Therapy Group|Standart critical care treatment group
11048032|NCT04442945|Experimental|ANAVEX3-71 Oral|Up to four single ascending doses of ANAVEX3-71 administered orally
11048033|NCT04442945|Placebo Comparator|Placebo arm Oral|Placebo administered orally
11048034|NCT04442932||Interventions|Per test, a minimum of 40 atopic subjects for a given allergy and a total of at least 100 non-atopic subjects. To ensure that sufficient subjects with valid results are enrolled, the atopic enrollment goal per allergy is approximately 50 subjects. For each allergen, approximately 20% of the samples must be in the range of 0.70 to 3.5 IUA/mL and the remainder must cover a measuring range that is representative of the target population. Results from a single positive subject can be used in the analyses of more than one allergen if the subject is sensitized for more than one allergen.
11048035|NCT04442919|Experimental|Ticagrelor followed with methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
11048036|NCT04442919|Active Comparator|Ticagrelor followed with morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
11048037|NCT04442919|Active Comparator|Ticagrelor|patients who received ticagrelor without any analgesia due to unstable angina
11048038|NCT04442906|Active Comparator|group B|IGroup B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline
11048039|NCT04442906|Active Comparator|group BD|. Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
11048040|NCT04442906|Active Comparator|group BF|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug).
11048041|NCT04442893|Experimental|Experimental group|The experimental group would be provided with a 6- session RFCBT program for 12 weeks (60-90 mins, once every two weeks).
11048042|NCT04442893|Other|Control group|The control group would receive a 6- session Health Education program for 12 weeks (60-90 mins, once every two weeks)
11048110|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type IIII, Male
11048111|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IVVI, Female
11048043|NCT04442867|Experimental|Intervention group|Subjects will receive nurse-led case management supported by a social service team.The nurse, functioning as a case manager, is involved in the initial assessment of the participant using the Omaha system. After the initial assessment, the NCM will equip participants with the skills required to perform self-care in health maintenance, including self-monitoring of vital signs, medication adherence, and sources of help if needed.
11048044|NCT04442867|Other|Control group|Participants in the control group will receive a monthly social control call from a trained research assistant
11048045|NCT04442854|Experimental|cognitive behavioral group therapy|A cognitive behavioral group prevention program An 8-session, cognitive behavioral group prevention program, featuring cultural appropriateness. One session per week, 3 hours for each session. The program contents include psychoeducation, cognitive skills training to identify and challenge maladaptive cognitions, and behavioral skills training. Each session contains mood check and homework. Participants' own examples are used in the group to demonstrate the CBT skills.
11048046|NCT04442854|No Intervention|Wait-list control group|No immediate intervention No intervention was provided when the experimental group was receiving services, but the same cognitive behavioral group prevention program was delivered to the wait-list control group after that.
11048047|NCT04442841|Experimental|Single arm (vaccine)|No further description
11048048|NCT04442828||Primary mitral regurgitation|Patients with mitral regurgitation due to mitral valve disease
11048049|NCT04442828||Secondary mitral regurgitation|Patients with mitral regurgitation due to ventricular or atrial disease
11048050|NCT04442802|Experimental|Long time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 6 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
11048051|NCT04442802|Active Comparator|Short time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 3 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
11048052|NCT04442776|Experimental|Intervention group|The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.
11048053|NCT04442776|No Intervention|Control group|The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication
11048054|NCT04442763|Experimental|Densah burs|Osseodensification using Densah burs
11048055|NCT04442763|Active Comparator|Standard drills|conventional drilling using standard drills
11048056|NCT04442750|Experimental|A (0.5%) group|patients will receive a single shot erector spinae block with 30 ml 0.5% bupivacaine followed by general anesthesia
11048057|NCT04442750|Experimental|B (0.375%) group|patients will receive a single shot erector spinae block with 30 ml 0.375% bupivacaine followed by general anesthesia
11048058|NCT04442750|Experimental|C (0.25%) group|patients will receive a single shot erector spinae block with 30 ml 0.25% bupivacaine followed by general anesthesia
11048059|NCT04442737|Experimental|D/C/F/TAF FDC Arm (Immediate Switch)|Participants will be immediately switched to a regimen of darunavir 800 milligram (mg)/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily for 48 weeks.
11048060|NCT04442737|Active Comparator|INI + TAF/FTC Arm (Delayed Switch)|Participants will continue to receive current baseline integrase (INI)-based regimen plus Tenofovir Alafenamide/Emtricitabine (TAF/FTC) antiretroviral (ARV) regimen for 24 weeks. After 24 weeks participants will switch to a regimen of D/C/F/TAF FDC once daily for an additional 24 weeks.
11048061|NCT04442724|Experimental|Single Arm - Bladder Chemo-Radiotherapy|Fiducial marker placement & cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
11048062|NCT04442711||PFBIO-EXA|All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.
11048063|NCT04442698||Diabetic MGB post op patients|Diabetic MGB post op patients
11048064|NCT04442672|Experimental|compartment syndrome model group(CSM group)|
11048065|NCT04442672|Sham Comparator|sham group|
11048066|NCT04442646|Experimental|ASG|"experimental asthma school group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day"
11048067|NCT04442646|No Intervention|CG|Control group will attend control visits every three months.
11048068|NCT04442633|Active Comparator|conventional therapy|topical corticosteroid plus antifungal
11048069|NCT04442633|Experimental|Glutamine with a topical corticosteroid plus antifungal|Glutamine therapy in combination with a topical corticosteroid plus antifungal
11048070|NCT04442620|Experimental|1st group: Physical Activity and Mediterranean Diet (PA-MD)|"A first group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 35-40% fat, 20% proteins, and 40-45% carbohydrates. Healthy fats (a maximum of 8-10% from saturated fats, >20% from monounsaturated fats, >10% from polyunsaturated fats and <300 mg/day of cholesterol) and low glycaemic index foods rich in fibre (not less than 30-35g /day) are strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Such diet reflects the traditional Mediterranean Diet described in the PREDIMED (Primary Prevention of Cardiovascular Disease with a Mediterranean Diet)-Plus study.
~As for physical activity, patients the participants will be recommended a 35 minutes interval training session three times a week. Physical activity sessions of 35 minutes will consist of 5 minutes warm-up, 20 minutes interval training, and 10 minutes breathing and stretching."
11048112|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IVVI, Male
11048113|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type IIII, Female
11048114|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type IIII, Male
11048115|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IVVI, Female
11048071|NCT04442620|Experimental|2nd group: High Meal Frequency of Mediterranean Diet (HMF-MD)|A second group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30-35% fat, 25% proteins, and 40-45% carbohydrates. Healthy fats and low glycaemic index foods will be strongly advised, together with foods rich in antioxidants, namely fruits and vegetables. Participants will be advised to consume 7 meals a day, gradually reducing the caloric content at each main meal, and to walk 10.000 steps a day.
11048072|NCT04442620|Active Comparator|3rd group: Control diet (CD)|A third group of participants will be advised to reduce their caloric intake by 25-30% with a macronutrients distribution of 30% fat, 15% proteins, and 55% carbohydrates, and maintain an adequate fibre (25g/day) and cholesterol (<250mg/day) intake. Meal frequency will be of 3-5 meals a day. Moreover, the participants will be advised to walk 10.000 steps a day.
11048073|NCT04442607|Experimental|AI arm|Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
11048074|NCT04442594|Experimental|personalized video|Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
11048075|NCT04442594|Active Comparator|generic vidéo|The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.)
11048076|NCT04442581|Experimental|Treatment (cabozantinib S-malate, pembrolizumab)|Patients receive cabozantinib S-malate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11048077|NCT04442568|Active Comparator|ERAS|all patients in this group will be performed LSG under a specified anesthesia protocol. This protocol includes non-opioid analgesia and sedation. Also short-acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the second hour postoperatively, also will be started oral intake between second and fourth hours.
11048078|NCT04442568|No Intervention|no ERAS|all patients in this group will be performed LSG under a conventional anesthesia protocol which is depended on the anesthesiologist . This protocol includes opioid analgesia and sedation. Also short and long acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the fourth hour postoperatively, also will be started oral intake in the next day morning after surgery.
11048079|NCT04442555|Experimental|3-Hydroxybutyrate treatment|HVMN Ketone Ester 0,5 g / kg
11048080|NCT04442555|Placebo Comparator|Placebo Treatment|Maltodextrin-base isocaloric placebo
11048081|NCT04442542|Experimental|Respiratory exercises plus method JaPer|Respiratory exercises plus the new intervention protocol with an inspirometer (JaPer Method)
11048082|NCT04442542|Active Comparator|Protocol of use of inspirometer in a conventional way|Respiratory exercises plus conventional use of the inspirometer.
11048083|NCT04442529|No Intervention|Control|Pregnant women will receive prenatal care as usual.
11048084|NCT04442529|Experimental|Intervention|Pregnant women will receive the 12-session Mothers and Babies intervention
11048085|NCT04442516||Adults receiving Cisplatin as part of their cancer therapy|
11048086|NCT04442516||Children receiving Cisplatin as part of their cancer therapy|
11048087|NCT04442503|Experimental|SAGE-217|Participants will receive SAGE-217 capsules, once daily for 14 days.
11048088|NCT04442503|Placebo Comparator|Placebo|Participants will receive SAGE-217 matched-placebo capsules, once daily for 14 days.
11048089|NCT04442490|Experimental|SAGE-217|Participants will receive SAGE-217 capsules, once daily for 14 days. The dose may be decreased based on safety and tolerability.
11048090|NCT04442490|Placebo Comparator|SAGE-217 Matched Placebo|Participants will receive SAGE-217 matched-placebo capsules, once daily for 14 days.
11048091|NCT04442477||Experimental: Enriched Protein Fractions|This group was given Infant formula with enriched protein fractions
11048092|NCT04442477||Active Comparator: Protein Fractions|This group was given Infant formula with protein fractions
11048093|NCT04442464|Experimental|Study Eye|One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
11048094|NCT04442464|No Intervention|Control Eye|Non-lens wearing eye
11048095|NCT04442451|Experimental|Control Exercise|Low-load knee extension resistance training (20% of 1-RM) without blood flow restriction. A 10-cm wide inflatable cuff will be placed around the upper portion of the thigh but not inflated.
11048096|NCT04442451|Experimental|Blood Flow Restriction Exercise|Low-load knee extension resistance training (20% of 1-RM) with blood flow restriction using a 10-cm wide inflatable cuff placed around the most proximal part of the exercising thigh. Blood flow will be restricted in the BFR leg at above the limb occlusion pressure of the and this will be determined prior to the exercise while the participant is seated in the knee extensor machine. The cuff pressure during the BFR protocol will be 10 mmHg above limb occlusion pressure.
11048097|NCT04442438|Experimental|Intensive care unit 1|Receives of intervention consisting of monthly moral case deliberation (ethical decision-making) meetings, planned and set up by ICU professionals which have received the task of being more attentive to ethical situations during work.
11048098|NCT04442438|Other|Intensive care unit 2|First non-intervention, then flips to experimental arm type after six months.
11048099|NCT04442438|Other|Intensive care unit 3|First non-intervention, then flips to experimental arm type after six months.
11048100|NCT04442438|Other|Intensive care unit 4|First non-intervention, then flips to experimental arm type after twelve months.
11048101|NCT04442438|Other|Intensive care unit 5|First non-intervention, then flips to experimental arm type after twelve months.
11048102|NCT04442438|Other|Intensive care unit 6|First non-intervention, then flips to experimental arm type after Eighteen months.
11048103|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IVVI, Female
11048104|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IVVI, Male
11048105|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
11048106|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
11048107|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IVVI, Female
11048108|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IVVI, Male
11048109|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type IIII, Female
11048116|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IVVI, Male
11048117|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type IIII, Female
11048118|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type IIII, Male
11048119|NCT04442412|Experimental|Arm B (Experimental):|"Patients randomized to Arm B will receive a prephase with oral prednisone and a prephase therapy with VitD according to the below reported schedule followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.
~Schedule for VitD supplementation: 25,000 U/day starting on day -6:
~daily loading dose for 7 days if 25 VitD baseline level 20-40 ng/ml daily loading dose for 14 days if 25 VitD baseline level < 20 ng/ml followed by weekly maintenance supplementation of 25,000 U for the entire duration of immunochemotherapy (6 courses every 21 days - 18 weeks), regardless of the baseline level of 25 VitD."
11048120|NCT04442412|Other|Arm A (Standard arm)|"Patients randomized to Arm A will receive a prephase with oral prednisone followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.
~If patients randomized to arm A are already on VitD, they are allowed to continue receiving VitD supplementation at a dose that can be considered part of the standard of care and does not exceed the maximum standard VitD dose recommended for general adult and elderly population , up to 10,000 U/week VitD"
11048121|NCT04442399|Experimental|Intervention|The intervention was based on the WHO-endorsed manual entitled Positive Connections: Leading Information and Support Groups for Adolescents Living with HIV. For Family Connections, a caregiver companion guide was developed. In brief, adolescent/caregiver pairs attended 10 intervention sessions held every other Saturday at their HIV clinic over a six-month period.
11048122|NCT04442399|No Intervention|Comparison|The comparison arm consisted of standard of care for adolescents as offered at the HIV clinics.
11048123|NCT04442373||Patients undergoing THR with no known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment in THR patients
11048124|NCT04442373||Patients undergoing THR with known bone neoplasm|Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
11048125|NCT04442347|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
11048126|NCT04442347|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
11048127|NCT04442334||The LITMUS Study Cohort|Prospectively recruited NAFLD patients, recruited according to The European NAFLD Registry study protocol.
11048128|NCT04442334||The LITMUS Metacohort|Collated data and biological samples on patients with histologically characterised NAFLD prospectively recruited at contributing academic centres across Europe.
11048129|NCT04442334||EFPIA Clinical Trial Cohort|Collated data and biological samples on patients with histologically characterised NAFLD that have participated in phase 2 and phase 3 trials of IMPs for NAFLD.
11048130|NCT04442321|Active Comparator|PENS plus exercise group|Experimental: PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently . It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
11048131|NCT04442321|Sham Comparator|Sham PENS plus exercise group|Sham Comparator: Sham PENS plus exercise group 4-week intervention program with 1 weekly treatment session, one of percutaneous electrical stimulation. In addition, self-management loaded exercise, prescribed by the physical therapist but completed by the patient independently. It involved isometric exercises, eccentric exercise, eccentric-concentric with weight or resistive therapeutic band.
11048132|NCT04442295|Experimental|Cohort 1: STK-001 dose level 1|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age. There will be an option to dose up to 3 additional patients at the same level.
11048133|NCT04442295|Experimental|Cohort 2: STK-001 dose level 2|Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age. There will be an option to dose up to 3 additional patients at the same level.
11048134|NCT04442269|Experimental|dupilumab|Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
11048135|NCT04442269|Experimental|Placebo|Matching dupilumab without active substance
11048136|NCT04442256|Other|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a monthly fashion. Observation period will be 30 minutes after injection
11048137|NCT04442230|Experimental|NasoVAX|Participants will receive a single intranasal dose of NasoVAX on Day 1 (enrollment).
11048138|NCT04442230|Placebo Comparator|Placebo|Participants will receive a single intranasal dose of placebo on Day 1 (enrollment).
11048139|NCT04442191|Experimental|Convalescent plasma|This study will utilize convalescent plasma from donors recovered from infection with SARS-CoV-2 (which causes COVID-19) with neutralizing antibody titers >1:64.
11048140|NCT04442191|Placebo Comparator|Placebo|Placebo utilized in this study will include Fresh Frozen Plasma collected before the COVID-19 pandemic began. As an extra control, some of this plasma will be saved and tested for COVID-19 antibodies to ensure they are not present.
11048141|NCT04442178|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
11048142|NCT04442178|Placebo Comparator|Placebo|Intramuscular (IM) administration of Saline twice a week for 3 weeks
11048143|NCT04442152|Experimental|Intervention|See intervention description
11048144|NCT04442152|No Intervention|Control|Participants who were randomized into the control arm were and will be surveyed at the same time point as intervention participants, but did not receive any intervention.
11048145|NCT04442139||Mini-Gastric Bypass|Patients reported completing survey following Mini-Gastric Bypass
11048146|NCT04442126|Experimental|NM21-1480 Treatment arm|
11048147|NCT04442113|Active Comparator|Control group|Pulmonary vein isolation alone (by catheter ablation)
11048148|NCT04442113|Experimental|STAR guided ablation group|Pulmonary vein isolation plus ablation guided by STAR MappingTM
11048149|NCT04442100|Experimental|bioprosthesis|"prosthetics of heart valves with dentures MedEng-Bio"
11048150|NCT04442074||Stroke Patients|These patients were hospitalized in the neurology / neurovascular department of the Paris Saint-Joseph Hospital Group, for the management of a transient ischemic infarction or accident for which the diagnosis of ipsilateral carotid diaphragm was accepted, between April 2017 and April 2020.
11048151|NCT04442061|Active Comparator|Active transcranial magnetic stimulation|excitatory TMS will be applied to the right posterior STS
11048152|NCT04442061|Sham Comparator|Sham transcranial magnetic stimulation|The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
11048153|NCT04442048|Experimental|IMM-101|The treatment regimen with IMM-101 will be one 1.0 mg (= 0.1 mL) dose given on Day 0, followed by a second dose of 0.5 mg (= 0.05 mL) on Day 14 (-2/+5 days), and a third Dose of 0.5 mg (= 0.05 mL) on Day 45 (+/-14 days)
11048154|NCT04442048|Active Comparator|Observation|
11048155|NCT04442035|Experimental|The teatment group|5-element misic therapy
11048156|NCT04442035|Experimental|The control group|health education
11048157|NCT04442022|Experimental|Phase 2: Selinexor 40 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1, and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
11048158|NCT04442022|Experimental|Phase 2: Selinexor 60 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
11048159|NCT04442022|Active Comparator|Phase 2: R-GDP|Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
11048160|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
11048161|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
11048162|NCT04442022|Placebo Comparator|Phase 3: Placebo + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
11048163|NCT04442009|Active Comparator|Group S = SCPB group|"US-guided SCPB will be performed at the end of the surgery before extubation, with patients in the supine position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the high frequency linear probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath and a 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used.
~Sternocleidomastoid (SCM) muscle will be visualized. The 22 G needle will be inserted between the SCM and the prevertebral fascia by using in plane technique horizontally. The needle tip will be corrected with injecting 2 ml of normal saline. Then a 20 mL dose of 0.25% bupivacaine will be injected here. The same procedure will be performed for the opposite site (totally 40 mL dose of 0.25% bupivacaine)."
11048164|NCT04442009|No Intervention|Group C = Control group|Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11048165|NCT04441996|Experimental|Therapeutic plasma exchange (TPE)|Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
11048166|NCT04441996|Active Comparator|Standard of care|Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
11048167|NCT04441970|Active Comparator|Neutral position|General anesthesia will be induced and nasotracheal tube will be placed through the patient's nose. After 30 seconds, the cuff pressure will be measured using a cuff manometer. Inspiratory tidal volume, expiratory tidal volume, peak inspiratory pressure, and end-tidal carbon dioxide waveform will be recorded three times according to breathing. Whether ventilation is not adequate and air is leaking will be recorded.
11048168|NCT04441970|Experimental|Head extension position|After changing the posture of the head and neck into head extension, cuff pressure will be recorded.
11048169|NCT04441970|Experimental|Head flexion position|After changing the posture of the head and neck into head flexion, cuff pressure will be recorded.
11048170|NCT04441970|Experimental|Head rotation position|After changing the posture of the head and neck into head rotation, cuff pressure will be recorded.
11048171|NCT04441957||Group A, MOCA-group|Procedure/Surgery: MOCA Mechano-Chemical Ablation plus Elastic Compression
11048172|NCT04441957||Group B, Elastic Compression only group|Treatment: Elastic Compression only
11048173|NCT04441944||Telemedicine Cases|Patients presenting to rural emergency departments who had real-time provider-to-provider telemedicine used to supplement their emergency department care.
11048174|NCT04441944||Non-Telemedicine Cases|Patients presenting to rural emergency departments who did not have real-time provider-to-provider telemedicine used to supplement their emergency department care.
11048175|NCT04441931|Experimental|LY3832479|LY3832479 administered intravenously (IV).
11048176|NCT04441931|Placebo Comparator|Placebo|Placebo administered IV.
11048177|NCT04441918|Experimental|Test group|
11048178|NCT04441918|Experimental|Control group|
11048179|NCT04441905|Experimental|Cohort 1|0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
11048180|NCT04441905|Experimental|Cohort 2|1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
11048181|NCT04441905|Experimental|Cohort 3|3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
11048444|NCT04440163|Experimental|4-Immuno Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
11048182|NCT04441905|Experimental|Cohort 4|10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
11048183|NCT04441905|Experimental|Cohort 5|20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
11048184|NCT04441892|Experimental|QTc Meter|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device
11048185|NCT04441892|Experimental|QTc Meter - Healthy Controls|Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.
11048186|NCT04441879|Experimental|Blended Be a Mom|Women will receive a blended intervention (integrating face-to-face and online sessions) for the treatment of postpartum depression.
11048187|NCT04441879|Active Comparator|Control (treatment as usual)|Women will receive intervention provided by primary healthcare units (treatment as usual).
11048188|NCT04441866|Active Comparator|Automated algorithms|
11048189|NCT04441866|Placebo Comparator|Standard technique|
11048190|NCT04441853|Experimental|YouTube video group|The intervention group attended five sessions of weekly-based tutorial, by watching YouTube videos on older people's and their caregivers' lived experience. On each session, they would joined post-video group discussion.
11048191|NCT04441853|Active Comparator|No YouTube video group|The control group were offered for five sessions of tutorial with same content without YouTube or other audio-visual tools. They also needed to join for group discussion in each tutorial.
11048192|NCT04441840|Active Comparator|Active Probiotic Culture|Active culture of Bacillus Coagulans Dose: 1 x 10^9 colony forming units (CFU)
11048193|NCT04441840|Active Comparator|Inactive Probiotic Culture|"Inactive culture of Bacillus Coagulans (GBI-30, 6086) - Marked as StaImune Dose: 1 x 10^9 colony forming units (CFU)"
11048194|NCT04441827|No Intervention|Control|Usual care
11048195|NCT04441827|Experimental|Pranayama|Pranayama breathing exercise
11048196|NCT04441827|Experimental|Deep breathing exercise|Deep breathing exercise
11048197|NCT04441814||Lung cancer screening subjects|Subjects enrolled in SMILE lung cancer screening trial
11048198|NCT04441801|Experimental|15 seconds|Stretching of the hamstring muscles will be performed by the primary researcher. A straight-leg-raising technique will be used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible, each subject's knee will be maintained in extension with the ankle at 90 degrees without medial (internal) or lateral (external) rotation of the lower extremity, and the extremity was raised until the subject reported discomfort. The subject was asked to relax the lower extremity in an effort to prevent contracting muscles from affecting the stretch and to allow for a slow stretch. stretching will continue for 15 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
11048199|NCT04441801|Experimental|30 seconds|the same stretching technique will continue for 30 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
11048200|NCT04441801|Experimental|60 seconds|the same stretching technique will continue for 60 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
11048201|NCT04441801|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end.
11048202|NCT04441788|Experimental|ION-827359|Single-dose of ION-827359 will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks
11048203|NCT04441788|Placebo Comparator|Placebo|Single-dose of placebo will be administered by oral inhalation via nebulizer, once every week for up to 13 weeks
11048204|NCT04441775||All patients for enrollment and analysis|Patients previously treated with RT for prostate cancer who are now being enrolled into this study for data analysis and incorporation into Artificial Intelligence (AI) models
11048205|NCT04441762|Active Comparator|intravenous|30 mg intravenous ketorolac in 10 ml syringe + 1 mL Normal Saline 9% using an intranasal device (0.5 ml in each nostril).
11048206|NCT04441762|Experimental|Intranasal|30 mg intranasal ketorolac in 1 ml intranasal device (0.5 ml in each nostril) + 10 ml Intravenous Normal Saline 9%.
11048207|NCT04441749||nCLE Analysis|Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis
11048208|NCT04441736|Active Comparator|High flow nasal cannula|A device og high flow nasal cannula giving 60 litres / min
11048209|NCT04441736|Placebo Comparator|Conventional oxygen|Nasal cannula giving oxygen up to 10 litres / minute
11048210|NCT04441723|Active Comparator|lag screw with dynamic mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
11048211|NCT04441723|Active Comparator|lag screw with static mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
11048212|NCT04441710||Caregivers|Staff of university hospitals
11048213|NCT04441710||Primary care caregivers|Population of professional caregivers such as general practitioner or freelance nurse.
11048214|NCT04441710||Patients|
11048215|NCT04441697||continuous apomorphine delivery|apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day
11048216|NCT04441697||continous levodopa/carbidopa delivery|levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day
11048217|NCT04441697||deep brain stimulation|bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings
11048218|NCT04441684|Experimental|PCR+ group|This group includes any symptomatic person with a positive COVID result, with a RT-PCR test carried out at least 10 days before inclusion.
11048219|NCT04441684|Experimental|PCR- group|This group includes any symptomatic person with a negative RT-PCR COVID 19 test carried out at least 10 days before inclusion.
11048220|NCT04441684|Experimental|No PCR|This group includes any person, for which no COVID 19 RT- PCR testing was performed.
11048221|NCT04441671|Experimental|Open label|Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00
11048222|NCT04441658|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.
11048223|NCT04441658|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
11048224|NCT04441645|Experimental|the acupoint-on-head group|pressing acupoints only on head
11048225|NCT04441645|Experimental|the acupoint-on-body group|pressing acupoints only on body
11048226|NCT04441645|Experimental|the acupoint-on-head-and-body group|pressing acupoints on head and body
11048227|NCT04441645|No Intervention|the control group|routine care
11048228|NCT04441632|Other|Positive feedback|Participants in the study will provide consistent positive feedback to the colleagues they work with in the medical ICU (MICU) over a 4 week duration.
11048229|NCT04441619|Active Comparator|Repeated exposure|Participants will complete four exercise sessions designed to induce delayed onset muscle soreness in the biceps
11048230|NCT04441619|Active Comparator|Single exposure|Participants will complete one exercise session designed to induce delayed onset muscle soreness
11048231|NCT04441619|No Intervention|Natural history|Participants will complete all sensory testing and imaging but not perform any exercise sessions.
11048232|NCT04441606|Experimental|gastric and pancreatic cancers|"The study population will include 25 patients with one of the following indications:
~Exocrine Pancreatic cancer.
~Gastric carcinoma, either with low-FDG uptake or known to be mucin-producing or signet-ring carcinoma.
~The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff."
11048233|NCT04441593|Experimental|Intervention|Videoconferencing Intervention for Heavy Drinking and Chronic Pain
11048234|NCT04441593|Active Comparator|Control|Treatment as Usual
11048235|NCT04441580|Experimental|Artificial intelligence arm|Patients undergoing colonoscopy with artificial intelligence.
11048236|NCT04441580|Active Comparator|standard colonoscopy arm|Patients undergoing colonoscopy with standard colonscopy
11048237|NCT04441567|No Intervention|Phase 1|Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2
11048238|NCT04441567|Experimental|Phase 2|Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.
11048239|NCT04441541|Experimental|Treadmill with auditory feedback group|
11048240|NCT04441541|Experimental|Treadmill with visual feedback group|
11048241|NCT04441541|Experimental|Treadmill with auditory and visual feedback group|
11048242|NCT04441541|Active Comparator|Treadmill training group|
11048243|NCT04441528|Experimental|Lid wipes containing terpinen-4-ol and sodium hyaluronate|The lid wipes will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
11048244|NCT04441528|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
11048245|NCT04441515|Experimental|Music|music supplied by ipod
11048246|NCT04441515|Active Comparator|oral books|Listening to books on ipod
11048247|NCT04441515|Placebo Comparator|usual care|Usual care
11048248|NCT04441476||ICU staff|
11048249|NCT04441463|Experimental|cohort|Mother-child couple
11048250|NCT04441450|Experimental|[14C]ICP-022|Subjects will take a single of 150mg 100μCi of [14C]ICP-022.
11048251|NCT04441437|Experimental|Splint Group|1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
11048252|NCT04441437|Placebo Comparator|No-Splint Group|1-hour task-oriented training without wearing a customized dynamic hand splint, totally 15 times in a duration of one month.
11048253|NCT04441424|Experimental|Convalescent plasma group|21 critically-ill COVID-19 patients were given convalescent plasma: 400 ml of convalescent plasma from COVID-19 recovered subjects. The plasma infusion lasts for one hour.
11048254|NCT04441424|Other|Control group|"This group is 28 critically-ill COVID-19 patients who are at the same disease stage to those of experimental group that were treated with conventional therapy without taking convalescent plasma.
~The conventional therapy: 400 mg once PO Hydroxychloroquine/day with 250mg once PO Azithromycin."
11048255|NCT04441411|Other|NEMOST-AIS|This study is designed as a cohort study.
11048256|NCT04441398|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
11048257|NCT04441398|Placebo Comparator|Placebo|Subjects will receive placebo TID.
11048258|NCT04441385|Experimental|Test arm|100 subjects will be randomly assigned to this arm. Patients in the test group will receive 300 mg of maraviroc BID for 14 days (added to standard care).
11048259|NCT04441385|Other|Control arm|100 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health has issued detailed guidelines for the management of COVID-19. Local Institutional Guidelines and Protocols for supportive management will also be implemented.
11048260|NCT04441359|Experimental|supplemented formula|Standard formula supplemented with prebiotic inulin-type fructans
11048261|NCT04441359|Placebo Comparator|standard formula|Standard Formula not supplemented with prebiotic inulin-type fructans
11048262|NCT04441346||patients with recent hemodialysis(less than 6 month|
11048263|NCT04441346||patients on hemodialysis more than 6 months and l|
11048264|NCT04441346||patients on hemodialysis more than 5 years|
11048265|NCT04441333|Experimental|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum.
11048266|NCT04441320|Experimental|CMUS group|Coated metal ureteral stent is indwelled.
11048267|NCT04441320|Other|DJS group|Double-J stent is indwelled
11048268|NCT04441307|Active Comparator|Healthy Foundations|A community-based parenting education program with individual family check ins will be implemented to all participants assigned to this arm.
11048515|NCT04439630|Sham Comparator|reference|Test product without the active components
11048269|NCT04441307|Experimental|Family Foundations|An adapted Family Foundations parenting program for expecting first time parents with individual family check ins will be implemented to all participants assigned to this arm.
11048270|NCT04441294|Experimental|ACE-Plus|"ACE-Plus is a one-on-one dual-session intervention for males aged 16 to 20 within foster care or preventive services settings which promotes condom use and knowledge of dual methods of contraception. The goal of ACE-Plus is to promote correct and consistent condom use of male latex condoms during penile-vaginal sex and to promote male engagement (e.g., discussion, decision-making) with their female partners in the use of female-centered contraception methods.
~Session one focuses on correct and consistent condom use for purposes of HIV/STD prevention including information and activities that address teen pregnancy prevention. Session two, which occurs within 10 to 14 days of the first session, promotes dual-method contraceptive use. Both sessions are one hour."
11048271|NCT04441294|No Intervention|On Track|On Track was the alternative program provided to males randomly assigned to the control group. On Track seeks to assist participants in identifying their aptitudes and preferences regarding their careers and their values associated with employment, and to provide tools to prepare them for the work setting and future job interviews. Participants learn how to identify attitudes, values, preferences, and challenges surrounding a career path, receive an understanding of the documents required for employment, and develop an initial employment strategy and action plan. Trained foster care agency staff deliver the curriculum to participating youth in two one-on-one sessions at agencies. Each session is one hour in length. Session two occurs 10 to 14 days after session one.
11048272|NCT04441281|Active Comparator|Single-tooth tenaculum (Pozzi forceps)|In the control arm, a single-tooth tenaculum, Pozzi forceps, used during routine IUD insertion, is employed to hold and stabilize the cervix.
11048273|NCT04441281|Experimental|AspivixTM cervical vacuum tenaculum|In the experimental arm, the investigational AspivixTM cervical vacuum tenaculum is employed to hold and stabilize the cervix.
11048274|NCT04441255|Experimental|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
11048275|NCT04441255|Experimental|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
11048276|NCT04441242|Placebo Comparator|Retrospective: Low lighting during screening colonoscopy|Screening colonoscopies performed with low lighting conditions.
11048277|NCT04441242|Active Comparator|Prospective: Ambient lighting during screening colonoscopy|Screening colonoscopies performed with ambient lighting conditions.
11048278|NCT04441229|Experimental|Treatment Group|Patients age 12-24 diagnosed with pediatric-onset Multiple Sclerosis
11048279|NCT04441216|No Intervention|Consultation only|Review by Chinese Medicine practitioner only
11048280|NCT04441216|Active Comparator|JinQi JiangTang Fang|JinQi JiangTang Fang (Rhizoma Coptidis, Radix Astragali and Flos Lonicerae)
11048281|NCT04441216|Active Comparator|JM-ELD|JQJT plus extra low dose Ophiopogonis Radix
11048282|NCT04441216|Active Comparator|JM-LD|JQJT plus low doses Ophiopogonis Radix
11048283|NCT04441203|No Intervention|Control|Heart failure clinic follow up
11048284|NCT04441203|Active Comparator|CardioMems|The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.
11048285|NCT04441190|Experimental|Digital Action Observation Therapy (Digital AOT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
11048286|NCT04441190|Experimental|Digital Mirror Therapy (Digital MT)|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
11048287|NCT04441190|Active Comparator|Conventional Occupational Therapy|The common categories of motor actions and tasks will be selected and included in this group: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-limb functional tasks.
11048288|NCT04441177|Experimental|Study group|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
11048289|NCT04441177|No Intervention|Control group|Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays.
11048290|NCT04441164|Experimental|Observation of Virtual Actions (steps 1 and 3)|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
11048291|NCT04441164|Placebo Comparator|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
11048292|NCT04441164|Other|Patients|It will be offered to patients hospitalized in these 2 services and presenting post-resuscitation ICU-weakness, especially in the aftermath of COVID infection, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
11048293|NCT04441164|Other|Caregivers|It will be offered to caregivers of the ICU of the Rennes University Hospital, to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
11048294|NCT04441164|Experimental|Relaxation (step 3)|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
11048295|NCT04441164|Experimental|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
11048296|NCT04441164|Placebo Comparator|Observation of Virtual Actions|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
11048297|NCT04441164|Experimental|Haptic stimulation|Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
11048298|NCT04441164|Placebo Comparator|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
11048299|NCT04441151|Experimental|Experimental group|Pulmonary rehabilitation therapy
11048300|NCT04441151|No Intervention|Control group|Routine medical treatment
11048301|NCT04441138|Experimental|Concurrent, Split Course Chemoradiation Followed by Durvalumab|Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
11048302|NCT04441125||Experimental|The mothers in the experimental group will receive oxytocin induction before and after delivery(n:35).
11048303|NCT04441125||No Intervention|The mothers in the control group will not receive any oxytocin induction before delivery, and will receive oxytocin induction in the end of delivery(n:35)
11048304|NCT04441112|Experimental|Ketorolac Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with ketorolac.
11048305|NCT04441112|Active Comparator|Triamcinolone Intraarticular Hip Injection|Patients will receive an intraarticular hip injection with triamcinolone.
11048306|NCT04441112|Experimental|Ketorolac Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with ketorolac.
11048307|NCT04441112|Active Comparator|Triamcinolone Intraarticular Knee Injection|Patients will receive an intraarticular knee injection with triamcinolone.
11048308|NCT04441099|Experimental|Dose-escalation Cohort (DEC)|Escalating doses of NBE-002 depending on cohort at enrollment.
11048309|NCT04441099|Experimental|Safety-expansion Cohort (SEC)|Dose to be determined based on DEC.
11048310|NCT04441099|Experimental|Expansion Cohort 1 (EC1)|Dose to be determined based on DEC and SEC.
11048311|NCT04441099|Experimental|Expansion Cohort 2 (EC2)|Dose to be determined based on DEC and SEC.
11048312|NCT04441086|Experimental|eMotion|The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for aging rural adults following a first cardiac event in tandem with usual cardiac rehabilitation. The intervention helps patients recognize their emotions, balance emotional and physical wellbeing, and implement emotion regulation strategies effectively.
11048313|NCT04441086|Active Comparator|Healthy living active control|
11048314|NCT04441086|No Intervention|Usual care|
11048315|NCT04441073|Experimental|Lignocaine|preoperative nebulization of lignocaine
11048316|NCT04441073|Placebo Comparator|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
11048317|NCT04441060|Experimental|distress intervention subject group|Distress intervention program will be developed, and applied to the subject group, and they will be assessed before and after the intervention program with several tools.
11048318|NCT04441060|No Intervention|distress intervention control group|No intervention will be applied to the control group. They will be assessed before and after the intervention program with same tools with subject group.
11048319|NCT04441047|Experimental|Vaccination|ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
11048320|NCT04441034|Experimental|Anti-convulsant medication|The participants will be randomized to receiving an anti-convulsant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
11048321|NCT04441034|Experimental|Anti-depressant medication|The participants will be randomized to receiving an anti-depressant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
11048322|NCT04441021||Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
11048323|NCT04441008|Experimental|aiTBS arm|aiTBS treatment as lead-in phase to ECT standard of care treatment.
11048324|NCT04441008|Active Comparator|ECT arm|ECT as clinically indicated.
11048325|NCT04440995|Experimental|PECS block(P) group|PECS group (P) received general anesthesia and pectoral nerve block(PECS block) with 025% ropivacaine after surgical resection of breast by operator.
11048326|NCT04440995|No Intervention|Control(c) group|only received general anesthesia
11048327|NCT04440982|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015
11048328|NCT04440982|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
11048329|NCT04440969|Experimental|Intervention|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks. (Week 1 - 24)
11048330|NCT04440969|Experimental|Wait-list control|Intervention administered is bi-weekly dual-task exercises, small group acitivites and computerised cognitive training for a total of 24 weeks after Intervention Group has completed intervention. (Week 25 - 48)
11048331|NCT04440956|Experimental|Intervention|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection."
11048332|NCT04440943|Experimental|CDX-527|"Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.
~Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase."
11048333|NCT04440930|Experimental|White tea|
11048334|NCT04440930|Active Comparator|Salt water with soda|
11048335|NCT04440917|Experimental|Study group|Inductive therapy with Camrelizumab and Apatinib
11048336|NCT04440904||Characteristic of aortic length and body surface mark|The diameters and lengths of blood vessels and the distances on the body surface were measured by three-dimensional reconstruction using related Software on CT Workstation
11048337|NCT04440891|Experimental|TMS-Stimulation with X-Torp task|TMS with VR 1 experimental arm
11048338|NCT04440891|Experimental|TMS-Stimulation with MindMotion Go|TMS with VR 2 experimental arm
11048339|NCT04440891|Sham Comparator|TMS-Sham with X-Torp task|TMS sham control with VR 1
11048340|NCT04440891|Sham Comparator|TMS-Sham with MindMotion Go|TMS sham control with sham VR 2
11048341|NCT04440878|Experimental|Static stretching|Static stretching will be administered to the hamstring muscles in the first group.
11048342|NCT04440878|Experimental|Mulligan TSLR technique|The Mulligan TSLR technique will be administered on the same muscle in the second group.
11048343|NCT04440865|Active Comparator|Arm 1- Standard colonoscopy|Standard colonoscopy is performed
11048344|NCT04440865|Active Comparator|Arm 2- Colonoscopy assisted by Genius|Colonoscopy assisted by Genius artificial intelligence system is performed
11048345|NCT04440852|Experimental|TEACCH intervention|TEACCH intervention for ASD
11048346|NCT04440852|No Intervention|conventional rehabilitation group|Other conventional interventions
11048347|NCT04440839|Experimental|Intervention|Telemedicine specialty consultation for patients
11048348|NCT04440839|No Intervention|Standard Care|Standard in person referral to a specialist
11048349|NCT04440826|Active Comparator|Whole Food Meal|Whole foods meal - grilled cheese and drink meal
11048350|NCT04440826|Experimental|Processed Food Meal|Highly processed foods - grilled cheese and drink meal
11048351|NCT04440826|Experimental|Gluten-Free and Lactose-Free Meal|Gluten-free and lactose-free foods - grilled cheese and drink meal
11048352|NCT04440813|Active Comparator|Clinician Training|Traditional healers randomized to the control arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by trained medical personnel.
11048353|NCT04440813|Experimental|Healer + Clinician Training|Traditional healers randomized to the intervention arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by both healers who already use PPE regularly and trained medical personnel.
11048354|NCT04440800||Study participants|All patients will receive the intervention
11048355|NCT04440787||Three point cuff palpation and Blck mark line technique|"In Three point cuff palpation technique the cuff will be palpated just below the cricothyroid membrane,at the level of suprasternal notch and below the suprasternal notchand the tube is re-positioned in case of any discrepancy between the black mark line technique and three point cuff at three different over the trachea."
11048356|NCT04440774|Experimental|CHIK low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048357|NCT04440774|Experimental|CHIK mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048358|NCT04440774|Experimental|CHIK high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048359|NCT04440774|Experimental|ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048360|NCT04440774|Experimental|ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048361|NCT04440774|Experimental|ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048362|NCT04440774|Experimental|CHIK ZIKA low dose|Volunteers will receive a single dose of 5x10^9 vp ChAdOx1 Chik and 5x10^9 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048363|NCT04440774|Experimental|CHIK ZIKA mid dose|Volunteers will receive a single dose of 2.5x10^10 vp ChAdOx1 Chik and 2.5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048364|NCT04440774|Experimental|CHIK ZIKA high dose|Volunteers will receive a single dose of 5x10^10 vp ChAdOx1 Chik and 5x10^10 vp ChAdOx1 Zika delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11048365|NCT04440774|Placebo Comparator|Placebo|Volunteers will receive a single dose of isotonic saline solution (0.9%) delivered intramuscularly. Volunteers will be blinded and will not know if they have received the IMP or the placebo comparator
11061113|NCT04349800|Experimental|Single Ascending Dose - 600 mg|
11048366|NCT04440761||Troponin rise/ diagnosis of MINOCA|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease.
11048367|NCT04440748|Experimental|Experimental Group|Participants in the experimental group will perform additional high-intensity therapy on the T-Chair 2.0, which is a newly developed non-CE-marked prototype to train trunk control and sitting balance. This they will do in addition to their normal rehabilitation program.
11048368|NCT04440748|Active Comparator|Control Group|Participants in the control group will execute their normal rehabilitation program.
11048369|NCT04440735|Experimental|DSP107 monotherapy|DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. The study will include up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
11048370|NCT04440735|Experimental|DSP107 in combination with atezolizumab|DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion.
11048371|NCT04440722||Transgender individuals|All transgender individuals referred to center of gender identity Odense
11048372|NCT04440709|Experimental|Brain/neural hand exoskeleton (B/NHE)|
11048373|NCT04440696|Experimental|group 1:dose 1.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
11048374|NCT04440696|Experimental|group 2:dose 3g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
11048375|NCT04440696|Experimental|group 3:dose 4.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
11048376|NCT04440696|Experimental|group 4:dose 6g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
11048377|NCT04440683||Antler plate group|Antler plate group
11048378|NCT04440670|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after birth. Cell dose for all patients was targeted at 5×107 cells per kilogram.
11048379|NCT04440670|Placebo Comparator|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume.
11048380|NCT04440657|Experimental|Immigrant parents|All enrolled parents will be included in the parenting program
11048381|NCT04440644||Patients|patients with amyotrophic lateral sclerosis
11048382|NCT04440644||Healthy control|healthy control participants
11048383|NCT04440631||Antibiotic therapy including rifampicin|
11048384|NCT04440631||Non-rifampicin antibiotic therapy|
11048385|NCT04440631||Control group (healthy volunteers)|
11048386|NCT04440605||cI|clincal TNM stage I
11048387|NCT04440605||cII|clinical TNM stage II
11048388|NCT04440605||cIII|clinical TNM stage III
11048389|NCT04440592|Experimental|MT-7117|Oral tablet of MT-7117 once a day.
11048390|NCT04440592|Placebo Comparator|Placebo|Oral tablet of placebo once a day.
11048391|NCT04440579|Active Comparator|Standard Cystoscopy|Patients will undergo a standard of care cystoscopy
11048392|NCT04440579|Experimental|PTNS and Cystoscopy|Patients will undergo PTNS while undergoing cystoscopy
11048393|NCT04440579|Sham Comparator|Sham PTN and Cystoscopy|Patients will undergo a sham PTNS procedure while undergoing cystoscopy
11048394|NCT04440566|Experimental|Systemic lupus erythematosus (SLE)|
11048395|NCT04440553|Active Comparator|Uniform random|In this arm the types of messages were sent out randomly, i.e. with a uniform random distribution.
11048396|NCT04440553|Experimental|Reinforcement learning|In this arm the types of messages were chosen by a reinforcement learning algorithm. The decision about which message to send was based on several contextual variables, including data for the pedometer app, and consecutive days since messages from different categories were sent.
11048397|NCT04440540|Experimental|lifestyle modification program group|
11048398|NCT04440540|Experimental|usual care group (control)|
11048399|NCT04440527|Experimental|Microshunt|Patients will be treated with Preserflo / Innfocus Microshunt (Santen Pharmaceutical Co., Ltd.).
11048400|NCT04440527|Active Comparator|Trabeculectomy|Patients will be treated with trabeculectomy.
11048401|NCT04440501|No Intervention|Control|Standard education regarding the gluten free diet by the nutritionist will be provided.
11048402|NCT04440501|Experimental|Virtual Reality Program to teach gluten free diet|"Virtual Reality Goggles and education regarding the gluten free diet will be provided.
~This group will receive VIRTUE, and watch a VR educational video, and play Chaos Café, which will be administered by a research team member. This group will be prescribed to take home the VIRTUE headset and play modules for 15 minutes per week until the 6-8 month follow up.
~The VIRTUE technology will track frequency of game playing to control for adherence to the prescription."
11048403|NCT04440488|Experimental|ARALAST NP 120 mg/kg|Participants will receive 120 mg/kg BW of ARALAST NP intravenous (IV) infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
11048404|NCT04440488|Experimental|ARALAST NP 60 mg/kg|Participants will receive 60 mg/kg BW of ARALAST NP IV infusion once in a week for a total of 104 weeks which will be compared with an external placebo arm.
11048405|NCT04440475|Experimental|Tap Block|"TAP block at the end of the surgery, in addition to conventional postoperative oral medication as needed
~postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours"
11048406|NCT04440475|No Intervention|Conventional postoperative oral medication|postoperative conventional oral medication as needed: Acetaminophen 650 mg Q 6 hours Ibuprofen 600 mg Q 6 hours Tramadol 50 mg Q 6 hours
11048407|NCT04440462|Experimental|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
11048408|NCT04440462|Active Comparator|Sterile water|2 ml of sterile water
11048516|NCT04439630|Experimental|Nopal fraction 1|Fraction one out of two possible
11048409|NCT04440449|Active Comparator|Group A|This group will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
11048410|NCT04440449|Active Comparator|Group B|This group will receive a behavior lifestyle intervention with a smartphone-based self-monitoring of diet and physical activity. This group will also have an individual, face-to-face session at the beginning of the study and monthly follow-up phone calls.
11048411|NCT04440436|Experimental|IM19 CAR-T cells|IM19 CAR-T cells be administrated in two dose level
11048412|NCT04440423|Experimental|Clotiazepam Test Product|
11048413|NCT04440423|Active Comparator|Clotiazepam Reference Product|
11048414|NCT04440410||Hidradenitis suppurativa|Subjects with active mild, moderate, or severe HS disease using the HS-PGA assessment
11048415|NCT04440410||Atopic Dermatitis|Subjects with active moderate or severe AD disease using the PGA assessment
11048416|NCT04440371|Active Comparator|Tacrolimus|Phototherapy NBUVB will be given 3 times per week and Tacrolimus 0.1% ointment will be applied twice a day
11048417|NCT04440371|Active Comparator|calcipotriol / betamethasone|Phototherapy NBUVB will be given 3 times per week and calcipotriol & betamethasone containing cream will be applied once a day
11048418|NCT04440358|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
11048419|NCT04440345|Experimental|IBI362|"Participants received low dose level of IBI362 administered as multiple subcutaneous doses.
~Participants received medium dose level of IBI362 administered as multiple subcutaneous doses.
~Participants received high dose level of IBI362 administered as multiple subcutaneous doses."
11048420|NCT04440345|Placebo Comparator|placebo|Participants received matching placebo dose regiments by subcutaneous injection
11048421|NCT04440319|Experimental|Intervention groups (4 PHC/clinics)|Intervention group are individual with T2DM who will receive DM nutrition counseling at selected Public Health Care (PHC). There are 75 subjects in Intervention group at selected 2 districts by randomly and 4 PHC which is selected based on cluster. DM nutrition counseling will be delivered by a selected nutritionist at each PHC. Nutritionist will educate the subjects following DM nutrition education module properly. DM nutrition education will be delivered for 3 months and 30 minutes for each meeting.
11048422|NCT04440319|Experimental|Control groups (4 PHC/clinics)|As the same with intervention group, the control group will have 75 subjects but at the different districts and PHC to avoid contaminant. Control group will follow conventional DM nutrition education. Therefore, there is a selected nutritionists will deliver DM counseling at each PHC.
11048423|NCT04440293|Experimental|Group BBAT / CT|Group BBAT / CT started treatment with BBAT and received 2 days a week for 6 weeks. After the interval of 5-week, group BBAT / CT was treated with CT twice a week for 6 weeks.
11048424|NCT04440293|Experimental|Group CT / BBAT|Group CT / BBAT started treatment with CT and received 2 days a week for 6 weeks. After the interval of 5-week, group CT / BBAT was treated with BBAT twice a week for 6 weeks.
11048425|NCT04440280|Active Comparator|NAC 10% group|Subjects in this group will be treated with eye drops containing a 10% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
11048426|NCT04440280|Active Comparator|NAC 20% group|Subjects in this group will be treated with eye drops containing a 20% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
11048427|NCT04440280|Placebo Comparator|Placebo group|Subjects in this group will be treated with a placebo (Visine Tears Dry Eye Relief artificial tears ophthalmic solution.)
11048428|NCT04440267|Experimental|single arm|Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) in CR. Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors.
11048429|NCT04440254|Other|ONE|One single group of patients
11048430|NCT04440241|Experimental|Test group|submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
11048431|NCT04440241|Experimental|Control group|non submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.
11048432|NCT04440228|Experimental|Schools implementing TeamSTEPPS|Select schools will take a participatory approach to collaboratively identify solutions to challenges in collocated school-based mental health services based upon the feedback of stakeholders and use TeamSTEPPS to support mental health team-school collaboration.
11048433|NCT04440215|Other|Control|Usual rehabilitation care (no telerehabilitation, interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals)
11048434|NCT04440215|Experimental|Telerehabilitation|A mix of home or rehabilitation center visits, telerehabilitation and interprofessional shared decision making process.
11048435|NCT04440202|Active Comparator|Conventional sea bream group|This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.
11048436|NCT04440202|Experimental|Enriched sea bream group|This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.
11048437|NCT04440189|Placebo Comparator|Placebo|Subjects will receive an injection of Lactated Ringers in their index knee
11048438|NCT04440189|Experimental|Stromal Vascular Fraction (SVF)|Subjects will receive an injection of Stromal Vascular Fraction in their index knee
11048439|NCT04440176|Experimental|Group 1 (MenABCWY 0-, 24-months)|MenABCWY administered at Month 0 and Month 24
11048440|NCT04440176|Experimental|Group 2 (MenABCWY 0-, 48-months)|MenABCWY administered at Month 0 and Month 48
11048441|NCT04440163|Experimental|1-Immuno Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
11048442|NCT04440163|Experimental|2-Immuno Subset (ACWY Naive, Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
11048443|NCT04440163|Experimental|3-Immuno Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
11048445|NCT04440163|Experimental|5-Safety Subset (ACWY Naive,MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
11048446|NCT04440163|Experimental|6-Safety Subset (ACWY Naive,Trumenba/MenACWY-CRM)|ACWY Naive subjects, Trumenba/MenACWY-CRM
11048447|NCT04440163|Experimental|7-Safety Subset (ACWY Experienced,MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
11048448|NCT04440163|Experimental|8-Safety Subset (ACWY Experienced,Trumenba/MenACWY-CRM)|ACWY Experienced subjects, Trumenba/MenACWY-CRM
11048449|NCT04440150|Other|Complicated Acute Appendicitis|The patients were assigned to the complicated acute appendicitis group (Group C) based on the preoperative imaging findings (periappendiceal abscess formation or significant periappendiceal fat tissue contamination in ultrasonography and computed tomography), intraoperative exploration findings (presence of gangrenous appendicitis, perforation or abscess formation), and pathological examination findings (acute phlegmonous appendicitis, acute gangrenous appendicitis or acute perforated appendicitis).
11048450|NCT04440150|Other|Uncomplicated Acute Appendicitis|The patients were assigned to the uncomplicated acute appendicitis group (Group UC) based on the increased diameter and wall thickness of the appendix and detection of minimal contamination in the surrounding fat tissue in the imaging tests; the presence of edema and the absence of gangrene, perforation or abscess in the the exploratory surgery of appendix, and confirmation of the diagnosis of acute appendicitis by the pathological examination findings
11048451|NCT04440137|No Intervention|Control Group|Mother of children will receive a brochure with a standard of care info (with only essential information regarding the harmful effect of bottle feeding) and kid toothbrush and toothpaste (1000ppm of fluoride).
11048452|NCT04440137|Experimental|Intervention group|Mother of the children will be provided with intervention brochure (which include detailed information regarding the harmful effect of bottle feeding), kid toothbrush and toothpaste (1000ppm of fluoride) and a sippy cup.
11048453|NCT04440111|Active Comparator|Control group|One year basic life support training
11048454|NCT04440111|Sham Comparator|Experimental group|Two years basic life support training
11048455|NCT04440098||Isolated Observational group|All participants socially restricted as a result of COVID-19
11048456|NCT04440085|Active Comparator|Intervention group|Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
11048457|NCT04440085|Placebo Comparator|Control group|By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) > 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.
11048458|NCT04440059|Experimental|ICP-022|Subjects will take ICP-022 150mg once daily (QD).
11048459|NCT04440046|Experimental|Real manual therapy|Real manual therapy directed to the thoracic spine and glenohumeral joint added to a therapeutic exercise program
11048460|NCT04440046|Sham Comparator|Sham thoracic manual therapy|Sham manual therapy directed to the thoracic spine with real manual therapy directed to the glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
11048461|NCT04440046|Sham Comparator|Sham manual therapy|Sham manual therapy directed to the thoracic spine and glenohumeral joint added to the same therapeutic exercise program performed in the real manual therapy group
11048462|NCT04440033|Experimental|Parkinson's Disease group|Patients with stage 3 idiopathic Parkinson's Disease
11048463|NCT04440033|Active Comparator|Healthy control group|Age and sex-matched healthy adults
11048464|NCT04440020|Experimental|Beverage of Olive Oil Leaves|50 patients Beverage of Olive Oil Leaves
11048465|NCT04440020|Active Comparator|Mediterranean dietary protocol Intervention|50 patients Dietary Supplement: Dietary Supplement:Mediterranean Diet
11048466|NCT04440007|Experimental|Abivertinib with Standard of Care|STI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge if sooner, in addition to standard of care
11048467|NCT04440007|Active Comparator|Standard of Care|Standard of care treatments for COVID-19 as determined appropriate by the Investigator
11048468|NCT04439994|Active Comparator|Hypertonic saline|Each participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
11048469|NCT04439994|Placebo Comparator|Isotonic Saline|Each participant will be given i.d. in 0.1 mL volumes of a isotonic saline solution. The subject will be blinded to the hypertonic/isotonic administration.
11048470|NCT04439981|Placebo Comparator|Control Group|treated by ice cream without any Curcuma extract supplementation
11048471|NCT04439981|Experimental|Treatment Group|treated by ice cream supplemented by Curcuma extract
11048472|NCT04439968|Active Comparator|Targeted Csats|Subjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
11048473|NCT04439968|No Intervention|Non-targeted Csats|Subjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
11048474|NCT04439955|Experimental|CBD|At the end of the one month run-in period, all trial subjects will continue on individual Standard of case plus increasing doses of CBD during the first six weeks of the study. Dosage of CBD will start at 25 mg twice a day and will be increased once every 14 days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day CBD respectively. Treatment will be given with food. If the 300 mg CBD dose level is deemed safe for two weeks patients will continue receiving 300 mg CBD +for an additional follow-up period of three months
11048475|NCT04439929|Experimental|Adalimumab-TUR01|
11048476|NCT04439929|Active Comparator|Adalimumab-EU|
11048477|NCT04439903|Experimental|Web-based Simulation Tool (WST)|
11048512|NCT04439656||Absence Seizures|Participants with absence seizures will have their eye movements compared to the EEG recording.
11048513|NCT04439643||Development / training|Selected by stratified partitioning
11048478|NCT04439890|Experimental|Anlotinib hydrochloride capsule + chemotherapy|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
11048479|NCT04439890|Placebo Comparator|Placebo + chemotherapy|Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).
11048480|NCT04439864|Experimental|MyIDEA|Research Participants interacted with MyIDEA program both in the hospital and in the follow up cardiology appointment.
11048481|NCT04439864|No Intervention|Treatment as normal|The research participants were given the chance to play games on the tablet and received normal clinical education.
11048482|NCT04439838|Experimental|Treatment group|
11048483|NCT04439838|Placebo Comparator|Placebo group|
11048484|NCT04439825|Active Comparator|Botox|
11048485|NCT04439825|Placebo Comparator|Placebo|
11048486|NCT04439812||R=0|Patients without positive margins after gastrectomy for gastric cancer
11048487|NCT04439812||R=1|Patients with positive margins after gastrectomy for gastric cancer
11048488|NCT04439799|Active Comparator|Testosterone Cypionate Group|Participants in this group will receive the intramuscular Testosterone Cypionate intervention for four months
11048489|NCT04439799|Active Comparator|Natesto Group|Participants in this group will receive the intranasal testosterone (Natesto) intervention for four months.
11048490|NCT04439786|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
11048491|NCT04439786|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
11048492|NCT04439773|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
11048493|NCT04439773|Experimental|lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
11048494|NCT04439760|No Intervention|control study.|No intervention
11048495|NCT04439760|Active Comparator|superior cervical block.|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
11048496|NCT04439747||Control|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, neutrophil- gelatinase assosiated lipocalin-2 (NGAL), adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, antibodies to thyroid peroxidase (Ab-TPO), Ab--R-TSH, Ab-Tg, parathyroid hormone (PTH), vitamin D, osteocalcin, b-cross-laps, prolactin)
11048497|NCT04439747||CKD 1-2|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps, prolactin)
11048498|NCT04439747||CKD 3-5|Ultrasound examination of the thyroid gland and parathyroid glands, osteodensitometry (DXA), biochemical analysis, general blood count, NGAL, adiponectin, urine albumin / creatinine ratio, hormonal tests (TSH, free T4 and T3, total T4 and T3, Tg, Ab-TPO, Ab--R-TSH, Ab-Tg, PTH, vitamin D, osteocalcin, b-cross-laps,prolactin)
11048499|NCT04439734|Experimental|Whole-Body Electromyostimulation|WB-EMS once per week for for 16 week (85 Hz, 350 µs, bipolar, duty cycle 4s-4s)
11048500|NCT04439734|No Intervention|Non WB-EMS control|No WB intervention, but maintained physical activity and habitual exercise habits
11048501|NCT04439721|Experimental|γδT|γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.
11048502|NCT04439708||Group 1|Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy
11048503|NCT04439708||Group 2|Control group : patients without choroidal neovascularization
11048504|NCT04439695|Experimental|Low Dose KBP-V001|Subjects in this group will receive the low dose of KBP-V001.
11048505|NCT04439695|Experimental|Intermediate KBP-V001|Subjects in this group will receive the intermediate dose of KBP-V001.
11048506|NCT04439695|Experimental|High Dose KBP-V001|Subjects in this group will receive the high dose of KBP-V001.
11048507|NCT04439695|Placebo Comparator|Placebo|Subjects in this group will receive placebo
11048508|NCT04439682|Experimental|Study group|Aerobic exercise will be performed for a single session
11048509|NCT04439682|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
11048510|NCT04439669|Active Comparator|Starts with active stimulation|"Active nrTMS is given to S2 at the right side (10 sessions in a three week period). Thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to M1 contralateral to the side of pain. After 5 stimulation sessions the response is evaluated. If pain is still ≥510, the investigators change the target to the S2 on the left side for five sessions. If there is response with pain relief, a maintenance therapy with this target is offered for 6 months with gradually reducing stimulation sessions."
11048511|NCT04439669|Placebo Comparator|Starts with sham stimulation|"Sham nrTMS will be targeted to the S2 on the right side, but using a sham box/coil. Stimulation period is similar than for the active comparator. Similarly, thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to S2 at the right side. After 5 stimulation sessions the response is evaluated. If pain is still ≥5/10, the investigators change the target to M1 on the contralateral side of the pain and furthermore to S2 at the left side after 5 stimulation sessions, if pain is still ≥5/10."
11048517|NCT04439630|Experimental|Nopal fraction 2|Fraction two out of two possible
11048518|NCT04439617||sepsis patient|
11048519|NCT04439617||Sepsis-free patient|
11048520|NCT04439604||patient undergoing surgery under general anaesthesia|
11048521|NCT04439591|Experimental|Intervention group|Intervention group undergoes computerised brain training programme first.
11048522|NCT04439591|Other|Control group|Waitlist control group: control group undergoes programme after intervention group has completed it in a crossover design.
11048523|NCT04439578|Experimental|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then rifampicin capsules 600 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
11048524|NCT04439552||CXL group|Patients who are about to undergo a corneal cross-linking (CXL) surgery to treat keratoconus.
11048525|NCT04439552||Control group|Healthy volunteers age and sex matched to the CXL group.
11048526|NCT04439539|Experimental|JNJ-73763989 + JNJ-56136379 + NA (with PegIFN-α2a)|Participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with nucleos(t)ide analog (NA) (tenofovir disoproxil tablets orally) treatment. During initiating the consolidation phase, participants will be randomized to receive pegylated interferon alpha-2a (PegIFN-α2a subcutaneously. According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
11048527|NCT04439539|Experimental|JNJ-73763989 + JNJ-56136379 + NA (without PegIFN-α2a)|Participants will receive JNJ-73763989 subcutaneously along with JNJ-56136379 tablet orally with nucleos(t)ide analog (NA) (tenofovir disoproxil tablets orally) treatment. During initiating the consolidation phase, participants will be randomized not to receive pegylated interferon alpha-2a (PegIFN-α2a subcutaneously. According to predefined criteria NA treatment may be continued during the follow up (FU) phase.
11048528|NCT04439526||Participants with Facial Psoriasis|Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
11048529|NCT04439526||Participants with Genital Psoriasis|Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
11048530|NCT04439513|Experimental|Dual Artery Compression|time to hemostasis and incidence of radial artery occlusion will be monitored while using a dual artery compression device (Terry-2-band) to achieve hemostasis.
11048531|NCT04439513|Active Comparator|Radial Artery-Only|time to hemostasis and incidence of radial artery occlusion will be monitored while using the device currently approved by the institution (Hemo-Stop) and following institutional protocols for hemostasis.
11048532|NCT04439500|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
11048533|NCT04439500|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
11048534|NCT04439487||Obese patients requiring general anesthesia|Group consists of consecutive, adult, obese patients undergoing elective surgical procedures requiring general anaesthesia, direct laryngoscopy and intubation. All patients undergo general anesthesia according to a standardised protocol. They are preoxygenated with 100% oxygen breathed through a face mask for 3-5 minutes. Induction of general anaesthesia is achieved with propofol 1,5-2 mg·kg-1 (of Ideal Body Weight) and 0,1mg fentanyl or sufentanil 10µg. Muscle relaxation is accomplished with rocuronium 0.6 mg ·kg-1 (of Ideal Body Weight). Depth of muscular blockade is monitored using Train of Four (TOF) method. The first laryngoscopy attempt is performed at TOF 0. The patient is placed in an optimal, sniffing or ramped position as appropriate and a #3 or #4 Macintosh blade is used. Successful intubation is confirmed with bilateral auscultation and capnography.
11048535|NCT04439474|Experimental|Patients with vitamin D deficiency|This group receives 50,000 units of vitamin D3 daily for up to 8 days until the serum level of vitamin D reaches above 30 ng/ml.
11048536|NCT04439474|Active Comparator|Patients without vitamin D deficiency|Participants in this group receive only their usual treatments
11048537|NCT04439448||HIV+ non-obese|HIV+ adults on antiretroviral therapy with a body mass index <30 kg/m2
11048538|NCT04439448||HIV+ obese|HIV+ adults on antiretroviral therapy with a body mass index >=30 kg/m2
11048539|NCT04439448||HIV-negative obese|HIV-negative adults on antiretroviral therapy with a body mass index >=30 kg/m2
11048540|NCT04439422|Experimental|SAINT|
11048541|NCT04439422|Active Comparator|Self-help material|
11048542|NCT04439409||Patients with Cluster Headache (CH)|Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.
11048543|NCT04439396|Placebo Comparator|Control|Saline injection administered during surgical procedure
11048544|NCT04439396|Experimental|Low Dose (15mg) Toradol|15mg ketorolac (toradol) administered during surgery
11048545|NCT04439396|Experimental|High Dose (30mg) Toradol|30mg ketorolac (toradol) administered during surgery
11048546|NCT04439370||Aim 1: Postmenopausal Women|Participants in this group are postmenopausal women.
11048547|NCT04439370||Aim 1: Premenopausal Women|Participants in this group are premenopausal women.
11048548|NCT04439370||Aim 2: Premature/Early Menopause|Participants in this group women who experienced premature or early menopause.
11048549|NCT04439370||Aim 2: Typical-Age Menopause|Participants in this group are women who experienced menopause at a typical age.
11048550|NCT04439357|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048551|NCT04439344|Experimental|Treatment (binimetinib)|Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048552|NCT04439331|Experimental|Treatment (defactinib)|Patients receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048553|NCT04439318|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048554|NCT04439305|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048555|NCT04439292|Experimental|Treatment (dabrafenib, trametinib)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048556|NCT04439279|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048557|NCT04439266|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
11048558|NCT04439253|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048559|NCT04439240|Experimental|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048560|NCT04439227|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11048561|NCT04439214|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048562|NCT04439201|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
11048563|NCT04439188|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048564|NCT04439175|Experimental|Treatment (taselisib)|Patients receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048565|NCT04439162|Experimental|group A|antegrade cardioplegia
11048566|NCT04439149|Experimental|Treatment (GSK2636771)|Patients receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048567|NCT04439136|Experimental|Treatment (afatinib dimaleate)|Patients receive afatinib dimaleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048568|NCT04439123|Experimental|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11048569|NCT04439110|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11048570|NCT04439097|Experimental|Experimental Group|"Patients allocated to the intervention group will perform a MPEP during 6 months, with a frequency of 3 sessions per week, and approximately 45-50 minutes of duration each session. In addition, they will have a Mediterranean Diet.
~The patients in the MPEP will be carried out in small groups of 5-8 people. Structure of sessions: 3 different parts: an initial warm-up, a main part and a final cool-down and relaxation."
11048571|NCT04439097|Active Comparator|Control Group|Participants allocated to the control group will receive usual care and continue with their life normally, without participating in a standardized exercise program. They will be instructed to maintain their current physical activity level.
11048572|NCT04439084||Chronic Liver Disease Group|COVID-19 patients with Chronic Liver Disease.
11048573|NCT04439084||Control Group|COVID-19 patients without Chronic Liver Disease.
11048574|NCT04439071|Experimental|PTC299 + Standard of Care (SOC)|"Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.
~SOC will also be administered according to local, written policies or guidelines."
11048575|NCT04439071|Placebo Comparator|Placebo + SOC|"Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.
~SOC will also be administered according to local, written policies or guidelines."
11048576|NCT04439058|Active Comparator|Bupivacaine+lignocaine|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with10 ml of bupivacaine 0,25%+ 5ml lignocaine 1%(20 patients).
~Under complete aseptic precautions an ultrasound guided left stellate ganglion block (paratracheal technique ) The patient placed in the supine position with the head in the neutral position and slightly extended.
~The US probe placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia anterior to the C6 vertebral body and deep to the carotid artery. skin infiltration with local anesthetic, the needle inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
11048577|NCT04439058|Other|Normal saline|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with 15 ml of normal saline (20 patients).
~US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland"
11048578|NCT04439045|Experimental|VPM1002|A single dose of 0.1 mL of the reconstituted vaccine containing VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU), administered via intradermal injection.
11048579|NCT04439045|Placebo Comparator|Placebo|A single dose of 0.1 mL of the 0.9% sodium chloride injection, administered via intradermal injection.
11048580|NCT04439032||Spine Fusion using NanoBone|All patients in the study will be drawn from the individual surgeons' practice. Patients will be candidates for spinal fusion surgery after having failed conservative treatment or will have had spinal fusion surgery but have not completed their standard of care follow-up as determined by the surgeon's practice. In addition, the surgeon has determined that the use of a NanoBone product is or was clinically necessary for the patient.
11048581|NCT04439019|Experimental|All patients referred to the Alberta Hip and Knee Clinic|All patients who are diagnosed with severe osteoarthritis undergoing total hip/knee replacement surgery and show interest to be part of the study.
11048582|NCT04439006|Experimental|Arm A (ibrutinib)|Patients receive ibrutinib PO QD on days 1-7. Treatment repeats every 7 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who remain hospitalized or are re-admitted after 2 cycles may receive an additional 2 cycles per physician's discretion.
11061114|NCT04349800|Experimental|Formulation Screen|
11048583|NCT04439006|Active Comparator|Arm B (usual care)|Patients receive usual care.
11048584|NCT04438980|Experimental|Methylprednisolone Arm|Standard of care plus Methylprednisolone
11048585|NCT04438980|Placebo Comparator|Placebo Arm|Standard of care plus placebo
11048586|NCT04438928|Experimental|Healthy pregnant women - Supplement|"Supplementation with micronutrients plus docosahexaenoic acid (DHA) preparation (Multimicronutrients and docosahexaenoic acid (MMS) soft gel capsules) during 2nd and 3rd trimesters of pregnancy.
~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
11048587|NCT04438928|Other|Healthy pregnant women - Non-Supplement|"Control study group
~Subgroup: Healthy pregnant women with Caesarean section [A subset of subjects (approximately 10 subjects per study arm) undergoing elective Caesarean section (for reasons independent from the study)]"
11048588|NCT04438915|No Intervention|Average weight .control group|Average weight BMI (18.5_25)
11048589|NCT04438915|Active Comparator|Overweight|Overweight BMI ( 25_30 )
11048590|NCT04438915|Active Comparator|Mild obese|Mild obese BMI (30_35 )
11048591|NCT04438902|Experimental|osimertinib combined with anlotinib|
11048592|NCT04438889||AML|Patients with WHO 2016 diagnosis of AML
11048593|NCT04438889||MDS|Patients with WHO 2016 diagnosis of MDS
11048594|NCT04438889||CMML|Patients with WHO 2016 diagnosis of CMML
11048595|NCT04438889||PMF|Patients with WHO 2016 diagnosis of PMF
11048596|NCT04438876|Experimental|Function power training|12-week structured FPT program, conducted by a certified trainer from a community service provider. Sessions were held twice weekly at the respective community senior activity centers, each lasting 60 minutes in duration.
11048597|NCT04438876|Active Comparator|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
11048598|NCT04438850|Experimental|I_600|ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo
11048599|NCT04438850|Experimental|I_1200|ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
11048600|NCT04438850|Placebo Comparator|Placebo|placebo
11048601|NCT04438837|No Intervention|control group|no intervention
11048602|NCT04438837|Active Comparator|intervention group|participants will recieve hydroxychloroquine in a dosage regimen of 400mg BID in the first day followed by 200mg BID for overall 10 days.
11048603|NCT04438824|Experimental|Palbociclib and INCMGA00012|"One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib on Day 1 and INCMGA00012 on day 15 (+/- 7 days) of each cycle at the following dose schedule:
~INCMGA00012: 500 mg IV (flat dose) q28 days Palbociclib: 125 mg PO daily for 21 days, followed by 7 days off, q28 days Palbociclib will be taken on Day 1 of each cycle for 21 consecutive days followed by 7 days off (days 22-28 of each Cycle). INCMGA00012 will be administered on Day 15 of (+/- 7 days) each cycle and repeat every 28 days."
11048604|NCT04438811|Other|Consultant Anesthetist|Patients who are randomized to this arm will receive their spinal anesthesia froma consultant anesthetist
11048605|NCT04438811|Other|Medical Officer|Patients randomized to this arm will receive their spinal anesthetic from a medical officer. There will be a consultant anesthetist immediately available if needed but they will not be a direct participant in this arm. Any involvement by the consultant will result in the label of failure for this patient.
11048606|NCT04438798|Placebo Comparator|face mask group|Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
11048607|NCT04438798|Active Comparator|THRIVE group|High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
11048608|NCT04438785|Experimental|INTERVENTION (AirwayGym) GROUP|Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
11048609|NCT04438785|No Intervention|CONTROL GROUP|Patients newly diagnosed with severe OSAHS do no therapy for 90 days.
11048610|NCT04438772|Experimental|LPEC|
11048611|NCT04438772|Sham Comparator|Sham procedure|
11048612|NCT04438759|Experimental|investigational group|Virtual Reality
11048613|NCT04438759|No Intervention|reference group|standard of care
11048614|NCT04438746|Experimental|Group receiving CBAT|
11048615|NCT04438746|Placebo Comparator|Group receiving general emotion training|
11048616|NCT04438733|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
11048617|NCT04438733|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
11048618|NCT04438720|Active Comparator|Extended Release Nifedipine Tablets（Adalat® GITS）|Extended Release Nifedipine reference formulation at a single dose of 30 mg
11048619|NCT04438720|Experimental|Extended Release Nifedipine Tablets|Extended Release Nifedipine test formulation at a single dose of 30 mg
11048620|NCT04438707|Experimental|Experimental group|
11048621|NCT04438707|Active Comparator|Control group|
11048622|NCT04438694|Active Comparator|STANDARD OF COARE|Receiving SOC
11048623|NCT04438694|Experimental|STANDARD CP DOSE Adm (Two infusions)|Two infusions 48 hours apart
11048624|NCT04438668|Active Comparator|Standard Care|Standard care (SC) for screening for FGR is a healthcare provider auscultating the foetal heart rate with a standard stethoscope, palpation of foetal size by hand, and measuring the size of the woman's uterus with a tape measure, and comparing the measurement to the expected measurement for the gestational age of the foetus.
11048625|NCT04438668|Experimental|Standard Care and Centaflow|Centaflow uses sound-derived maternal intra-arterial turbulence as a marker of foetal growth restriction (FGR) and provides information on the foetal heart rate. Indication for use is as a screening device for FGR in women beyond 27 weeks of pregnancy with a singleton pregnancy.
11048626|NCT04438655|Experimental|Oral + Parenteral prophylaxis|"Oral antibiotic drugs:
~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.
~Systemic antibiotic drugs:
~Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.
~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
11048627|NCT04438655|Sham Comparator|Only parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.
~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
11048628|NCT04438642|Other|conventional ceramic onlay with shoulder finishline|tooth that need ceramic onlay restoration, a conventional cavity will be prepared with shoulder finishline.
11048629|NCT04438642|Experimental|conservative ceramic onlay preparation buttjoint with bevel|tooth that need ceramic onlay restoration, a conservative cavity will be prepared with butt joint with bevel finishline.
11048630|NCT04438629||Mild disease|COVID-19 hospitalized patients
11048631|NCT04438629||Severe disease|COVID-19 hospitalized patients in intensive care unit
11048632|NCT04438629||paucisymptomatic syndrome|Mild symptomatic patients in home quarantine
11048633|NCT04438616|Active Comparator|dome magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.
~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor
~We connect magnetic attachment(dome) for each groups on complete denture by pick up procedure at day of implant installation"
11048634|NCT04438616|Active Comparator|flat magnetic attachment|"A crestal incision is made using No. 15 c blade extending over the crest of anterior mandible and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge for implant installed.
~Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant in each group by the contra angle handpiece with special adaptor
~We connect magnetic attachment(flat) for each groups on complete denture by pick up procedure at day of implant installation"
11048635|NCT04438603||IgAN patients at low risk of disease progression|n = 30, incipient disease
11048636|NCT04438603||IgAN patients at high risk of disease progression|n = 60, incipient disease
11048637|NCT04438603||Long-term stable patients|n = 30, follow-up for at least 15 years
11048638|NCT04438603||Progressive IgAN patients|n = 30
11048639|NCT04438603||Healthy control|n = 30
11048640|NCT04438590|Experimental|Kelulut Honey|"Medical Grade Kelulut Honey which will be in 2 doses.
~The first would be diluted to 800 ml of water, and the second dose in 400ml of water."
11048641|NCT04438590|Active Comparator|Carborie|Carborie Load which will be 100g of carbohydrate in 800 ML of water and 50g of carbohydrate in 400ml of water.
11048642|NCT04438577|Experimental|Efficacy of Lidocaine mucilage-ICG|Efficacy of Lidocaine mucilage-ICG for intraoperative tumor delineation
11048643|NCT04438564|Other|cancer of breast, colorectal, ovarian and endometrial|Patient who diagnostic of Breast cancer, Colorectal cancer, cancer of Ovary, and cancer of Endometrial are can recruit.
11048644|NCT04438551|Active Comparator|Standard dietary counseling|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection.
11048645|NCT04438551|Experimental|Standard dietary counseling plus mobile app|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection. Subjects will use a mobile app to build their shopping lists prior to grocery shopping.
11048646|NCT04438538||Patients with Dizziness|All trial participants are within this group. All trial participants will either have a diagnosis or a suspected diagnosis of Ménière's Disease in order to take part.
11048647|NCT04438525|Active Comparator|early maintenance phase|patients who reached the maintenance dose of venom immunotherapy one week (max. +3 weeks) before recruitment will be sting challenged
11048648|NCT04438525|Active Comparator|maintenance phase|patients who reached the maintenance dose of venom immunotherapy one year (+/- 2 months) before recruitment will be sting challenged
11048649|NCT04438525|Active Comparator|after stopping VIT|patients who finished venom immunotherapy two years (+/- 6 months) before recruitment (duration of VIT: at least 3 years) will be sting challenged
11048650|NCT04438525|Other|blood donors|patients with confirmed vespid venom allergy who have not undergone venom immunotherapy (blood donation necessary to perform BAT Inhibition test)
11048651|NCT04438499|Experimental|Subjects Indicated for a UDS study|The investigational device, i.e. the eSense catheter will be used in all the subjects to assess primary and exploratory objectives. It is a single arm study with no comparative, placebo, sham or control arm.
11048652|NCT04438486|Active Comparator|dietary advice|
11048653|NCT04438486|Experimental|dietary advice+ Barely Green|
11048654|NCT04438473|Experimental|Pectin|
11048655|NCT04438473|Placebo Comparator|Control|
11048656|NCT04438460|Experimental|Patient group|150 children aged 1 month to 12 years with multi-visceral failure syndrome within 48 hours of hospitalization in pediatric resuscitation will be included in this study
11048657|NCT04438460|Other|Control group|60 children aged 1 month to 12 years hospitalized for simple elective surgery will be included in this study
11048658|NCT04438447|Experimental|ERAS plus artificial nutrition|"Patients randomised in the treatment arm will be treated with a full ERAS protocol that establishes oral food at will plus parenteral nutrition (PN) from postoperative day 1. A 3-bag compartment peripheral parenteral solution (mOsm < 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation. In case of the occurrence of any complication impairing the full or partial recovery of oral food, the treatment will be continued until clinically indicated"
11048659|NCT04438447|Active Comparator|Enhanced recovery protocol|"Patients randomised in the control arm will be treated with a full ERAS protocol that establishes oral food at will. In case of the occurrence of any complication impairing the full recovery of oral food within postoperative day 7, patients will receive parenteral nutrition as in the treated arm until clinically indicated"
11048673|NCT04438356|Experimental|wait list control|wait list control for 3 months and then use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
11048674|NCT04438343|Experimental|experimental group|
11048675|NCT04438343|Active Comparator|control group|
11048660|NCT04438434|Experimental|Hydrogen Peroxide and Hyaluronic acid mouthwash (BMG0703)|"The enrolled subjects will be examined and treated by specialized medical personnel.
~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.
~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.
~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).
~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
11048661|NCT04438434|Active Comparator|Chlorhexidine 0.2% mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.
~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.
~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.
~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).
~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
11048662|NCT04438434|Placebo Comparator|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.
~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.
~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.
~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).
~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
11048663|NCT04438421|Experimental|BMG0703|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
11048664|NCT04438421|Active Comparator|Chlorhexidine 0.2%|Subjects will then be given a 0.2% Chlorhexidine product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
11048665|NCT04438421|Placebo Comparator|Placebo Product|Subjects will then be given a placebo product, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be reevaluated after 3 days and after one month.
11048666|NCT04438408||severe asthma patient|Adult patients (≥ 18 years) with diagnosis of severe asthma for at least 12 months
11048667|NCT04438395||Enrolled AFL and AF Patients|All subjects that are enrolled are group one, as there is only one group of subjects in this study
11048668|NCT04438382|Experimental|Arm A (infliximab)|Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
11048669|NCT04438382|Experimental|Arm B (intravenous immunoglobulin therapy)|Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
11048670|NCT04438369|Active Comparator|Erector spinae block|"Group ESPB: Multimodal analgesia comprising of preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodon 1 mg/ml.
~Preoperatively positioned bilateral catheters at level T7 injected with ropivacaine 2,5 mg/ml, 30 ml on each side. Postoperative maintenance treatment with injection of 2 mg/ml ropivacaine 30 ml on each side every 6 hours postoperatively. Maximum allowed bolus preoperative ropivacaine dose is 3 mg/kg body weight (BW), while the maximum 24 hour dose postoperatively is 11 mg/kg to avoid local anesthesia systemic toxicity (LAST). The catheter will be discontinued 24 hours after the original procedure. The container with ropivacaine will be masked for blinding of the personnel on the ward."
11048671|NCT04438369|Placebo Comparator|Control|"Control group with standard multimodal analgesia: Preoperative paracetamol adjusted for weight (2000 milligrams (mg) >70 kilograms (kg) <70 years, 1500 mg <70 kg >70 years, 1000 mg <50 kg) and diclofenac adjusted for weight (100 mg >70 kg <70 years, 50 mg <70 kg >70 years). After the operation they receive paracetamol 1000 mg x4 and diclofenac 50 mg x3 a day, as well as PCA with iv oxycodone 1 mg/ml.
~Insertion of bilateral catheters preoperatively. Injection of 30 ml saline preoperatively and every 6 hours postoperatively. The catheter will be discontinued 24 hours after the original procedure. The container with saline will be masked for blinding of the personnel on the ward."
11048672|NCT04438356|Experimental|M-health|After the acute myocardial infarction, patients will be randomly assigned to the intervention group. Give the intervention group mobile health care programs and given Garmin monitoring hands ring. In order to give patients clear walking goals and exercise intensity, the intervention group will use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
11048676|NCT04438330|Experimental|Nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
11048677|NCT04438330|Active Comparator|non-nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
11048678|NCT04438317|Active Comparator|Seldinger Technique|Small bore chest tubes inserted by Seldinger technique. A needle is inserted into the intercostal space, and the aspiration of a fluid allows the confirmation the correct position, possibly after ultrasound tracking. A metal guidewire is inserted through the needle, which is then removed. A dilator is then inserted on the metal guidewire to dilate the skin and the subcutaneous tissues. The chest tube is finally inserted on the guide, which is finally removed, and the chest tube is connected to the aspiration system after fixation to the chest wall.
11048679|NCT04438317|Active Comparator|Surgical-like Technique|Large bore chest tube inserted by surgical-like technique. Progressive chest wall dissection is conducted with appropriate instruments (scissors, scalpel, clamps…) by a non-surgeon physician. Large bore drain with rigid introductor is blindly inserted in the pleural cavity, secured to the chest wall with suture fixation and further connection to the aspiration system.
11048680|NCT04438304|Experimental|Intervention|64Cu-SARTATE will be administered at a fixed administration dose of 200 MBq (5.4 mCi) given as a single bolus intravenous injection.
11048681|NCT04438291|Experimental|Intervention schools|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
11048682|NCT04438291|Other|Control schools|Control and usual care
11048683|NCT04438265|Other|quadratus lumborum|analgesic technique. The evaluation of the patient will consist of 2 stages. The first of these will consist of the evaluation consultation (clinical history, EVN evaluation, WOMAC) and initial treatment (QL2 block). In the second stage, the patient will be followed up with interviews at 3 weeks, 3 and 6 months.
11048684|NCT04438252|Experimental|Cariescan pro|device for early caries detection
11048685|NCT04438252|Experimental|ICDAS II|Index for caries detection
11048686|NCT04438239||Covid-19 discharged|Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
11048687|NCT04438226|Experimental|Posterolateral|Patients treated with a hemiarthroplasty using the posterolateral approach
11048688|NCT04438226|Experimental|Direct lateral|Patients treated with a hemiarthroplasty using the direct lateral approach
11048689|NCT04438213|Experimental|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
11048690|NCT04438213|Experimental|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
11048691|NCT04438213|Placebo Comparator|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
11048692|NCT04438200||Adolescents|Individuals aged 10-19 years
11048693|NCT04438200||Young Adults|Individuals aged 20-39 years
11048694|NCT04438200||Elderly Adults|Individuals aged 40+ years
11048695|NCT04438187|Other|Aggressive Arm|If an intubated patient is suspected of having an ICU-acquired HAP/VAP during the aggressive period, antimicrobials should be initiated immediately after quantitative or semi-quantitative endobronchial cultures are sent regardless of clinical status. This will include patients who, as determined by the attending intensivist, are in sepsis or septic shock. If, after 72 hours, cultures and other clinical data do not point to a pneumonia, the antimicrobials should be stopped in the absence of another source of infection.
11048696|NCT04438187|Other|Conservative Arm|If a patient is suspected of having an ICU-acquired HAP/VAP during the conservative period, quantitative or semi-quantitative endobronchial cultures should be sent. If the patient is in septic shock persistent hypotension requiring vasoactive medications to maintain mean arterial pressure (MAP) ≥65 mm HG or persistent lactic acidosis (>2 mmol/L) despite adequate resuscitation) antimicrobials will be initiated immediately. If the patient has new onset organ dysfunction that is presumed to be due to infection (sepsis) then antimicrobials will be initiated at the discretion of the attending intensivist. In the absence of septic shock or sepsis (intensivist discretion), antimicrobials will not be initiated unless objective evidence of pneumonia is present or another documented source of infection is identified mandating treatment with antimicrobials.
11048697|NCT04438174|Experimental|Amniotic Fluid Injection|Processed Amniotic Fluid. Dose is 1ml/5cm2; Route: injected directly into wound; Limited to two injections. The wound will then be dressed according to standard of care.
11048698|NCT04438174|Active Comparator|Standard of Care Wound Treatment Regimen|Primary dressings are variable and based on the moisture content and microorganism load. In general, wounds respond differently to various topical treatments. Through our clinical practice, we have found that wounds plateau with the same topical for greater than 4 weeks, hence changing antimicrobial topical helps to manage the bacterial overgrowth. We will start with our application of our slurry, a 1:1:1 ratio of Nystatin ointment, Mupirocin Ointment, and Bacitracin Ointment. This slurry will be applied directly to the cleansed wound, followed by silver gauze/foam product to all wounds. Types of silver product- site and comfort predict use of Restore, Mepilex-AG, or Mepitel-AG. If allergies to the above slurry occurs, we will use medical honey with or without bacitracin. If ointment related rash present with transition to silver product only or silver product plus medical honey.
11048699|NCT04438161|Active Comparator|Low Risk|"Low risk natural history study (n=250*)
~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families."
11048700|NCT04438161|Experimental|High Risk|"High risk families in prospective longitudinal study of newborns (n=150*).
~*Participants will be randomized 2:1 PERCCS:Control, and the randomization will be within successive sets of three families who fall in either high risk counts (n=105) families for child maltreatment or low risk counts (n=45) families.
~Participants in this arm will be randomized to:
~PERCCS (see attached figure and table for details)
~Care as Usual"
11048701|NCT04438135|Active Comparator|active test|
11048702|NCT04438135|Placebo Comparator|placebo test|
11048703|NCT04438122|Active Comparator|Red Wine group|Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.
11048704|NCT04438122|Active Comparator|Ethanol group|Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.
11048705|NCT04438122|No Intervention|Control group|Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks
11048706|NCT04438096|Experimental|100 mg|
11048707|NCT04438096|Experimental|200 mg|
11048710|NCT04438083|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
11048711|NCT04438070|Placebo Comparator|Daily active screening only|
11048712|NCT04438070|Experimental|Daily active screening and self-collected nasal swab|
11048713|NCT04438070|Experimental|Daily active screening and self-collected oral-nasal swab|
11048714|NCT04438070|Experimental|Daily active screening and nurse collected nasopharyngeal swab|
11048715|NCT04438057|No Intervention|Standard of Care|Patient will receive standard of care therapy.
11048716|NCT04438057|Active Comparator|Treatment Arm|Patient will receive convalescent plasma
11048717|NCT04438044|Experimental|ICP-022|150mg,QD
11048718|NCT04438031|Experimental|Navigation Intervention Prenatal|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
11048719|NCT04438031|Experimental|Navigation Intervention 12mo|This program recruits mothers in pediatricians' (12 months old) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
11048720|NCT04438031|Experimental|Navigation Intervention 24mo|This program recruits mothers in pediatricians' (24 months old) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
11048721|NCT04438031|Experimental|Navigation Intervention 36mo|This program recruits mothers in pediatricians' (36 months old) offices, provides up to three Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
11048722|NCT04438031|Other|Control Intervention Prenatal|Brief information will be provided about child development.
11048723|NCT04438031|Other|Control Intervention 12mo|Brief information will be provided about child development.
11048724|NCT04438031|Other|Control Intervention 24mo|Brief information will be provided about child development.
11048725|NCT04438031|Other|Control Intervention 36mo|Brief information will be provided about child development.
11048726|NCT04438031|Experimental|Virtual Navigation Intervention Prenatal|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three virtual Navigation visits, establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
11048727|NCT04438031|Other|Virtual Control Intervention Prenatal|Brief information will be provided about child development.
11048728|NCT04438018||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
11048729|NCT04438018||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
11048730|NCT04438018||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
11048731|NCT04438018||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
11048732|NCT04438005|Experimental|ICP-022|
11048733|NCT04437992||Pregnant women|"Pregnant women resident in the Emilia Romagna region who access the combined test at regional counseling centers and hospital prenatal clinics.
~Women able to understand the information, participate in pre-test counseling and provide informed consent."
11048734|NCT04437966|Experimental|Self-management Group|"The intervention consists of three levels - (1) chronic disease self-management workshops, (2) distribution of and teaching on the use of medication pill boxes and (3) use of social media (WhatsApp version 2.0) to encourage medication adherence.
~We combine the Stanford Chronic Disease Self-Management Curriculum, add medication adherence tools and social media use to develop a novel intervention aimed at better blood pressure control. The CDSMP focuses on enhancing skills through problem solving and brainstorming activities. In the workshop we discuss: blood pressure control, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control. Pill boxes will be distributed to all individuals in the intervention group. Post workshop, participants will be sent twice weekly reminders to use their high blood pressure medications via the social media tool WhatsApp. These will be sent for one month."
11048735|NCT04437966|No Intervention|Usual care group|Controls will receive educational material at baseline and one didactic session (on importance of medication adherence to hypertension control) lasting 1 hour delivered by a health care professional.
11048736|NCT04437953|Experimental|Avatrombopag|Patients will receive an initial dose of Avatrombopag 60 mg on Day 1.Starting on Day 2, the dose will be Avatrombopag 20 mg daily.
11048737|NCT04437940||Covid-19 positive women|Women with nasofarangeal Covid-19 PCR test is positive
11048738|NCT04437927||Prospective patients|30 consecutive patients with cardiac FDG PET prescribed
11048739|NCT04437927||Control|30 patients referred for cardiac FDG PET in the nuclear medicine department of the Centre Hospitalier Princesse Grace
11048740|NCT04437914||Group 1 - Smartwatch - single lead (D1)|To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
11048741|NCT04437914||Group 2 - conventional ECG|The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
11048742|NCT04437901||COVID-19 patients|Patients admitted at one of the participating centres with highly suspected/confirmed infection with SARS-CoV-2.
11048743|NCT04437888|Active Comparator|Racemic Ketamine|ketamine 0.5mg/kg bolus on induction of anesthesia and 10mcg/kg/min infusion initiated prior to incision and terminated at the completion of wound closure. Maximum ketamine dose will not exceed 500mg
11048744|NCT04437888|Placebo Comparator|Saline|saline in the same volume as the study drug, administered in the exact same format.
11048745|NCT04437875|Experimental|Component 1|rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene.
11048746|NCT04437875|Experimental|Component 2|rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene.
11048747|NCT04437875|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
11048748|NCT04437862|Experimental|Q Revascularization System|
11048749|NCT04437849|Experimental|Telemonitoring|
11048750|NCT04437849|No Intervention|Usual Care|
11048751|NCT04437836|Experimental|Control arm|Participants will receive standard treatment of rifampicin
11048752|NCT04437836|Experimental|First High dose|Participants will receive 30mg per kg body weight of rifampicin
11048753|NCT04437836|Experimental|Second high dose|Particpants will receive 40mg per kg body weight of rifampicin
11048754|NCT04437823|Experimental|Group 1 : Treatment|Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).
11048755|NCT04437823|No Intervention|Group 2: standard care|Five (5) subjects will be treated under Standard of Care (SOC) .
11048756|NCT04437810|Experimental|Albumin+ SMT|Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3) along with standard medical therapy
11048757|NCT04437810|Placebo Comparator|Placebo+SMT|- Patients in placebo arm will receive similar volume of isotonic fluid (saline) over same duration of time along with standard medical therapy
11048758|NCT04437797|Experimental|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
11048759|NCT04437797|Active Comparator|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
11048760|NCT04437784|Active Comparator|Laparoscopic Trans-Abdominal Pre-Peritoneal (Lap TAPP group))|Both hernias were treated by laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
11048761|NCT04437784|Active Comparator|Open Pre-Peritoneal Repair ( Open PP group)|Both hernias were treated by open pre-peritoneal single mesh repair with suture fixation
11048762|NCT04437784|Active Comparator|Bilateral Lichtenstein repair (LICHT group)|treated by bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
11048763|NCT04437771||Subjects with Fanconi Anaemia Subtype A (FA-A)|Subjects treated with ex vivo lentiviral gene therapy product in FANCOLEN-I trial and agree to participate in this long-term follow-up (LTFU) study
11048764|NCT04437758|Experimental|Hydrolyzed collagen and Vitamin C powder mix|20 g hydrolyzed collagen + 50 mg vitamin C (ascorbic acid) pre-packed powder diluted in 250 ml (8 oz) of water
11061115|NCT04349800|Experimental|Food Effect|
11048765|NCT04437758|Placebo Comparator|Maltodextrin powder|20 g maltodextrin pre-packed powder diluted in 250 ml (8 oz) of water
11048766|NCT04437745|Experimental|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
11048767|NCT04437745|No Intervention|Control|No Intervention
11048768|NCT04437732|Other|Apioc Lens|All subjects will wear either the Apioc-P or Apioc-PT contact lens design
11048769|NCT04437719|Experimental|Obvio-19 App|"If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. After enrollment, patients will be sent an invitation via email to download the Obvio-19 mobile app. After downloading the Obvio-19 app, patients will receive instructions as to how they may communicate with the study investigator. Communication may occur through the chat function of the app or live telephone conversations.
~Patients must log into the Obvio-19 app daily to complete the questionnaires. The Obvio-19 system is designed to identify responses that indicate the participant is at an increased risk for serious illness or exhibiting serious symptoms, such as coughing up blood. Such patients will be notified by the app of this status and prompted to seek medical attention."
11048770|NCT04437706||Participants|Participants completing COVID-19 testing
11048771|NCT04437693|Experimental|Hydroxychloroquine|400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks.
11048772|NCT04437693|Placebo Comparator|Placebo|2 tablets (Placebo White tablets) twice daily on day 1 followed by 2 tablets weekly for 7 weeks
11048773|NCT04437667|Experimental|Intervention Arm|Adolescents participants enrolled in the intervention arm will receive the intervention, Tumaini, loaded on a low-cost Android smartphone, during the long November-December school holidays for the first three years of the study.
11048774|NCT04437667|Active Comparator|Control Arm|Adolescent participants enrolled in the control arm will receive a commercially available age- and language-appropriate educational game or knowledge quiz loaded on a study-provided low-cost Android smartphone.
11048775|NCT04437654|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
11048776|NCT04437654|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
11048777|NCT04437641||Experimental|A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.
11048778|NCT04437602|Experimental|CEM|Patients in experimental arm will go through additional preoperative staging with contrast enhanced mammography
11048779|NCT04437602|No Intervention|No CEM|Patients in No intervention arm will go through no additional preoperative imaging
11048780|NCT04437589||Exposure group|In this group the treatment applied for postoperative pain involves Free-opioid anesthesia (LKDi).
11048781|NCT04437589||Control group|In this group the treatment applied for postoperative pain involves an opioid-based anesthesia.
11048782|NCT04437563|No Intervention|Control|('Standard' care). No intervention offered.
11048783|NCT04437563|Experimental|Intervention|('Standard' care +) The 'Herlev Hospital Empowerment of Relatives through More and Earlier information Supply' (HERMES) intervention.
11048784|NCT04437550|Experimental|high-intensity|
11048785|NCT04437550|Experimental|low-intensity|
11048786|NCT04437537||Pilot Group|Ten subjects with a DFU non-responsive to standard of care for a minimum of treatment period of 28 days.
11048787|NCT04437524|Active Comparator|balance-proprioception exercises group|balance-proprioception exercises group
11048788|NCT04437524|Active Comparator|aerobic exercises group|aerobic exercises group
11048789|NCT04437511|Experimental|Donanemab|Donanemab given intravenously (IV).
11048790|NCT04437511|Placebo Comparator|Placebo|Placebo given IV.
11048791|NCT04437498|Experimental|nVNS|non invasive vagal nerve stimulation
11048792|NCT04437498|Sham Comparator|sham|sham stimulation
11048793|NCT04437485|Experimental|eIMPACT-DM intervention|eIMPACT-DM is a 6-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for diabetes risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers (PCPs).
11048794|NCT04437485|Active Comparator|Active Control|Active Control (AC) consists of depression education (study staff), symptom monitoring (study staff), and primary care for depression (clinical staff).
11048795|NCT04437472||CareSignal|-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up.
11048796|NCT04437459|Experimental|Abbreviated Fat Tolerance Test|
11048797|NCT04437459|Active Comparator|Oral Glucose Tolerance Test|
11048798|NCT04437446|Experimental|Case Group|"The Case group corresponds to patients with glaucoma following the clinical criteria for glaucoma:
~papilla excavation> 5/10 with altered ISNT rule, or neuro-retinal rhyme characteristic of glaucoma, or fiber alterations characteristic of glaucoma.
~OCT with typical alterations (loss of the layer of nerve fibers or loss of these ganglion cells), loss of fibers typical of glaucoma.
~Humphrey 24: 2 visual fields produced, reliable and typical of glaucoma.
~The assignment to the Cas group will be carried out by an ophthalmologist specializing in glaucoma according to the following criteria:
~- The intraocular pressure must be increased before the start of treatment (21 mmHg or more), except in cases of normal pressure glaucoma.
~The additional examination corresponds to an OCTA alone leading to an extension of the duration of the consultation by 5 minutes."
11048907|NCT04436796|Active Comparator|Sensor Augmented Pump/Predictive Low Glucose Suspend|Subjects will continue use of home insulin pump with a study continuous glucose monitor (CGM) and study glucometer. Subject may use home pump in PLGS mode if this is supported and compatible with the study sensor.
11048799|NCT04437446|Experimental|Control Groupe|"The Control group corresponds to patients with no glaucoma, no suspicion or history of glaucoma, ocular hypertension, or alterations detected during the ophthalmological consultation.
~Witnesses will be matched to cases by age (+/- 5 years) and gender.
~For patients in this group, the additional examinations correspond to a visual field, an OCT and an OCTA leading to an extension of the duration of the consultation by 35 minutes."
11048800|NCT04437433|Experimental|Atogepant 60 mg|Taken once daily
11048801|NCT04437420||T-ALL|
11048802|NCT04437420||B-ALL|
11048803|NCT04437407|Other|Control|The first night will be a control night with infrared video recording where only the Ajuvia sleep monitor is worn in passive mode so that each participant can act as her own control for comparison of treatment effect on outcomes.
11048804|NCT04437407|Experimental|PB2-1|During this night, the PB2-1 prototype will be worn with the Ajuvia in passive mode.
11048805|NCT04437407|Experimental|PB2-2|During this night, the PB2-2 prototype will be worn with the Ajuvia in passive mode.
11048806|NCT04437407|Experimental|PB2-3|During this night, the PB2-3 prototype will be worn with the Ajuvia in passive mode.
11048807|NCT04437407|Experimental|PB2-4|During this night, the PB2-4 prototype will be worn with the Ajuvia in passive mode.
11048808|NCT04437407|Experimental|PB2-5|During this night, the PB2-5 prototype will be worn with the Ajuvia in active mode.
11048809|NCT04437394||Study group|Study group was performed on 30 patients who were diagnosed with ankylosing spondylitis using modified New York criterion.
11048810|NCT04437394||Control group|Control group was performed on 30 participants who were healthy.
11048811|NCT04437368|Experimental|GT005 Dose 1|Approximately 25 subjects are planned, with subjects randomised to GT005 Dose 1.
11048812|NCT04437368|Experimental|GT005 Dose 2|Approximately 25 subjects are planned, with subjects randomised to GT005 Dose 2.
11048813|NCT04437368|No Intervention|Untreated control|Approximately 25 subjects are planned, with subjects randomised to untreated control.
11048814|NCT04437355|Active Comparator|Control Group|Young and healthy Group of People (18-50 years) without any pathology of the lower limb
11048815|NCT04437355|Active Comparator|Ankle Fracture Type Weber B|Young and healthy patients with an operative treated fracture of the ankle (type Weber B)
11048816|NCT04437355|Active Comparator|Ankle Fracture Weber C and complex|Young and healthy patients with an operative treated fracture of the ankle (type Weber C or complex fracture)
11048817|NCT04437342||Maternal Group|Pregnant women in labour (vaginal delivery or caesarean section) that are admitted to the hospital. Pre-labour 3 different questionnaires are administered to evaluate depression, general anxiety disorder and the association to the covid-19 pandemic. 40 days post delivery via telephone contact 2 questionnaires are administered, one in order to assess the postpartum disorder the other to assess depression.
11048818|NCT04437329|Experimental|DNF-N|"Induction chemotherapy:
~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks
~Concurrent chemoradiotherapy:
~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy
~Radiotherapy: radical intense modulated radiation therapy"
11048819|NCT04437329|Active Comparator|DPF-P|"Induction chemotherapy:
~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous cisplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks
~Concurrent chemoradiotherapy:
~three cycles of 100 mg/m² cisplatin every 3 weeks, concurrently with intensity-modulated radiotherapy
~Radiotherapy: radical intense modulated radiation therapy"
11048820|NCT04437316|Active Comparator|Low Level Laser|therapeutic laser
11048821|NCT04437316|Placebo Comparator|Placebo Low Level Laser|non-therapeutic laser
11048822|NCT04437303|Active Comparator|Continuation of oral anticoagulants|
11048823|NCT04437303|Active Comparator|Interruption of oral anticoagulants|
11048824|NCT04437290||Alzheimer disease|The group is composed of individuals with a consensus diagnosis of amnestic mild cognitive impairment (MCI) or amnestic multimodal MCI or dementia primarily attributed to Alzheimer's disease (AD), as determined by the UW ADRC Clinical Core. They will have age of presentation > 55 years, sporadic onset, CDR (Clinical Dementia Rating Scale) score 0.5-1.0, and sufficient English competency to complete a standardized cognitive testing battery. All will have no contraindication to MRI and will have had an MRI scan in the UW ADRC Imaging and Biomarker Core. These participants will undergo PET scanning with the investigational tau tracer [18F] MK6240
11048825|NCT04437277|Experimental|Patients consenting|
11048826|NCT04437264|Experimental|Intermittent feed|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
11048827|NCT04437264|Experimental|Continuous feeds|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
11048828|NCT04437251|Experimental|Brain stimulation-induced improvements in leg skill learning|"To examine the degree of stimulation-induced improvements in learning capacity between three groups: stroke group, healthy young group, and healthy older group. Up to date, most studies have investigated the effects of brain stimulation on hand skill improvements in healthy young adults; little is known about stimulation-induced improvement in the leg skill improvement in stroke survivors as well as in older healthy adults. The investigators will answer the question: Do stroke survivors improve leg skill learning at a comparable rate as healthy young and older adults after brain stimulation transcranial direct current stimulation (tDCS)?"
11048829|NCT04437251|Experimental|Effects of brain stimulation on functional improvements|"To determine the effect of brain stimulation (tDCS) on functional improvements in stroke survivors. Specifically, the investigators will compare stepping reaction time, cortical neuronal activity, peripheral nerve activity, and walking function in the stroke survivors before and after tDCS, and also compared these findings with results from healthy adults. The investigators will answer the question: Do stroke survivors shorten stepping reaction time and improve leg muscle activation and gait performance after tDCS, and these improvements are at a similar rate as compared to data collected from healthy young and older adults?"
11048941|NCT04436523|Sham Comparator|Standard rehabilitation|The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.
11048830|NCT04437251|Sham Comparator|Effects of brain stimulation combined with stepping training|After enrolling to the study, participants with chronic stroke will be randomly assigned to one of two groups: anodal tDCS or sham tDCS groups. All subjects will then undergo a total of twelve training sessions over four weeks in which subjects will learn a novel visuomotor stepping task immediately after visuomotor learning training while 20-minute tDCS (anodal or sham stimulation) is delivered over the leg area of primary motor cortex.The investigators will measure changes in brain neuronal activity, peripheral nerve activity, and walking performance before and after a 12-session training program, and will follow up one week later.
11048831|NCT04437238|Experimental|Intervention - KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
11048832|NCT04437238|Placebo Comparator|Control|Participants allocated to the control condition will receive care as usual but will be asked to complete the health risk questionnaire at baseline, 3- and 6-month follow-up via an online survey to collect outcomes data. The control group will receive full access to KeepWell at the conclusion of the study.
11048833|NCT04437225|Experimental|Constant Infusion of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for the carbon 13 glycolate infusion which will occur at a constant rate for 6 hours, following a priming dose. From 7:30 am to 2:30 pm, urine collections will occur hourly, and from 8:30 am to 2:30 pm, IV blood collections will occur every half hour. Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
11048834|NCT04437225|Experimental|Single Intravenous Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for a single dose of carbon-13 glycolate to be administered. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, IV blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
11048835|NCT04437225|Experimental|Single Oral Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. At 8:30 am, subjects will ingest the carbon-13 glycolate, dissolved in to 50 ml (about 1/4 cup) of water. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, intravenous (IV) blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
11048836|NCT04437212|Experimental|Toripalimab Group|All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.
11048837|NCT04437199|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
11048838|NCT04437199|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
11048839|NCT04437186|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
11048840|NCT04437186|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
11048841|NCT04437173|Experimental|Virtual Reality Arm|Patients undergo interventional pain procedure with virtual reality distraction
11048842|NCT04437173|No Intervention|No Intervention Arm|Patients undergo interventional pain procedure without virtual reality distraction
11048843|NCT04437160|Experimental|Adjuvant chemotherapy|"Adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
~Adjuvant chemotherapy regiments: Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV + Cyclophosphamide 600mg/m2 IV, q21d*4cycles."
11048844|NCT04437160|No Intervention|Observation|No adjuvant chemotherapy for triple negative breast cancer with residual invasive disease (invasive breast tumor size≥1cm and/or positive axillary lymph nodes) after taxanes and platinum based neoadjuvant chemotherapy.
11048845|NCT04437147|Placebo Comparator|Placebo|a) Control placebo (P1) Component Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
11048942|NCT04436510|Experimental|Verdiperstat|Verdiperstat is administered twice daily p.o. for 24 weeks.
11049205|NCT04434794|Active Comparator|control|standard treatment according to clinical protocols
11048846|NCT04437147|Active Comparator|3 Billion CFU strains of probiotics|b) 3 Billion CFU (P2) Component Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
11048847|NCT04437147|Active Comparator|8 Billion CFU strains of probiotics|c) 8 Billion UFC (P3) Component Lactobacillus paracasei LPC 00 ID 1076 1 billion CFU;Bifidobacterium longum BL 03 ID 1152 1 billion CFU; Bifidobacterium lactis BS 01 ID 1195 1 billion CFU;Lactobacillus casei LC 03 ID 1872 1 billion CFU; Bifidobacterium animalis LMG 10508 1 billion CFU; Lactobacillus acidophilus LA 02 ID 1688 1 billion CFU,Bifidobacterium bifidum BB 01 ID 1722 1 billion CFU, Lactobacillus rhamnosus LR 04 ID 1132 1 billion CFU,Vitamin C (Ascorbic acid) 45 mg,Vitamin B1 (Thiamine) 1.1 mg, Vitamin B2 (Riboflavin) 1.1 mg,Vitamin D-3 40,000,000 IU / GR (Cholecalciferol) 34 mcg, Magnesium hydroxide 0.3 g, Calcium Carbonate 0.5 g, Natural Vanilla Flavor Powder 0.03 g,Fos (Fructooligosaccharides) qsp 3 g, for 30 days, once a day by sachet
11048848|NCT04437134||On-line exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-line. Patients attend both the exercise and educational sessions by logging on to virtual rooms using links sent out by e-mail. The sessions are led and supervised by GLA:D certified physiotherapists.
11048849|NCT04437134||On-site exercise and education|Exercise (12 sessions) and education (2-3 sessions) delivered on-site. Patients attend both the exercise and educational sessions at physiotherapy clinics in Denmark. The sessions are led and supervised by GLA:D certified physiotherapists.
11048850|NCT04437121||Parents of children aged 2-18 years|Parents of children aged 2-18 years during the lockdown due to the COVID-19 pandemic, following their informed consent form prior to their participation to the study.
11048851|NCT04437108|Active Comparator|Li-SWT (suprapubic approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through suprapubic approach.
11048852|NCT04437108|Active Comparator|Li-SWT (perineal approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through perineal approach.
11048853|NCT04437108|Active Comparator|Li-SWT (combined approach)|Patients will be treated by 8 sessions of Li-SWT with one week interval, applied through suprapubic and perineal approaches during each session.
11048854|NCT04437108|Sham Comparator|Sham treatment|Patients will be treated by 8 sessions of sham treatment with one week interval, applied through suprapubic and perineal approaches.
11048855|NCT04437108|Active Comparator|antimuscarinics|Patients will be treated by solifenacin 10 mg once daily for 6 months.
11048856|NCT04437095|Experimental|PSBPS Audiorecording|Thirty minute daily administration of audio recording containing messages of psychological support based on positive suggestion delivered via headphones
11048857|NCT04437095|No Intervention|Control|Standard of care
11048858|NCT04437082||Normal|no pre-existing conditions
11048859|NCT04437082||Glaucoma|diagnosis of glaucoma
11048860|NCT04437082||Retina|diagnosis of retina pathology
11048861|NCT04437082||Cornea|diagnosis of corneal condition
11048862|NCT04437069|No Intervention|Standard Care (Control)|Participants will receive standard care and will not view either the Decision Aid or the Values Clarification Exercise
11048863|NCT04437069|Experimental|Decision Aid|Participants view the Decision Aid only
11048864|NCT04437069|Experimental|Decision Aid & Values Clarification Exercise|Participants view both the Decision Aid and the Values Clarification Exercise
11048865|NCT04437056|Other|Stroke patients with upper limb spasticity|Patients with post-stroke upper limb spasticity will be operated for cognitive nerve transfers to spastic muscles to allow for volitional muscle reinnervation and disrupture of spasticity. Adequate healthy nerve donors from the ipsilateral arm will be determined clinically and electrophysiologically.
11048866|NCT04437043|Other|Laparoscopic ventral hernia repair with closure of the defect|In laparoscopic intraperitoneal onlay mesh or IPOM repair, the mesh is inserted intra-abdominally and fixed to the peritoneum / abdominal wall. The general steps include safe entry into the peritoneum, insufflation and placement of the trocars to gain access and visibility (via laparoscope) of the defect. Careful adhesiolysis is performed, which is the removal of scar tissue connecting tissues and organs. The content of the hernia, which may include intestine and fatty tissue, is returned into the abdominal cavity. After closure of the hernia defect, a wide intraperitoneal mesh is fixed over the defect. Desufflation releases the gas from the abdomen. The trocars will be removed and the incisions are closed.
11048867|NCT04437043|Other|Open ventral hernia repair with closure of the defect|An open retromuscular ventral hernia repair involves an incision through the abdominal wall. Adhesiolysis is performed and the content of the hernia is returned into the abdominal cavity. The posterior rectus sheath is separated from the rectus muscle and closed, which closes the abdominal cavity. The mesh is then placed behind the muscle and anterior to the re-approximated posterior rectus sheath. Preperitoneal mesh extension is allowed via transversus abdominis release (TAR). The anterior rectus sheath is closed over the mesh, which closes the hernia.
11048868|NCT04437043|Other|Robotic ventral hernia repair with closure of the defect|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar closure of the hernia defect and similar retromuscular mesh placement as for the open approach. Preperitoneal mesh extension is allowed via TAR. The da Vinci System is a robotic-assisted surgical device that allows the surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of the abdominal cavity. Rather than one long incision with open repair, four to six small incisions are made along the outer part of the abdomen between the rib cage and the hip.
11048869|NCT04437030|Active Comparator|Patient|Patient with Head and neck cancer
11048870|NCT04437030|Other|Healthy subjects|Healty subjects with not history of Tumor disease in the Head and neck region
11048871|NCT04437017|Experimental|Olanzapine+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists(a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
11048872|NCT04437017|Active Comparator|Dexamethasone+NK-1 RA+5-HT3 RA|Using one of the 5-HT3 receptor antagonists (a. Palonosetron: 0.25 mg d1 intravenous; b. Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally; c. Ondansetron: 8-16 mg d1 intravenous or oral. the specific agent is chosen by the primary clinician, and is only delivered on the first day) within 30 minutes before cisplatin. Using one of the NK-1 receptor antagonists (a. Aprepitant: 125 mg orally, d1, 80 mg orally, d2-3; b. Fosaprepitant: 150 mg intravenously, d1) within 1 hour before cisplatin. On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administered, and on day 2-4, the given dose of dexamethasone is 8 mg.
11048873|NCT04436991||Amoxicillin-clavulanate|Administration of amoxicillin-clavulanate as standard care therapy (4x or 6x 1g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
11048874|NCT04436991||Piperacillin-tazobactam|Administration of piperacillin-tazobactam as standard care therapy (4x 4g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
11048875|NCT04436991||Temocillin|Administration of temocillin as standard care therapy (2x or 3x 2g/d). Blood sampling in early and steady state dose (up to 5 samplings per dose). Collection of hemocultures, urine samples and sputum samples when possible.
11048876|NCT04436978|Active Comparator|Dual therapy|
11048877|NCT04436978|Active Comparator|Triple therapy|
11048878|NCT04436965|Experimental|Standard nutrition therapy|Dynamic nutrition assessment will be performed to patients. If malnutrion happened, patients would receive oral nutritional supplements (ONS) first, then feeded with nasal feeding tube or PEG when ONS wasn't enough. If all the these enteral nutrition methods couldn't make up for patient's nutritional deficiencies, parenteral nutrition would be considered.
11048879|NCT04436965|Active Comparator|Conventional nutrition therapy|Dynamic nutrition assessment will be performed to patients throughout whole treatment, and symptomatic treatment would be performed if needed.
11048880|NCT04436952|Experimental|H7 coil only|patients undergoing DTMS treatment using the H7 coil
11048881|NCT04436952|Active Comparator|Cool D-B80 coil only|20 patients undergoing rTMS treatment using the cool D-B80 coil
11048882|NCT04436952|Active Comparator|DTMS treatment using the H7 coil + ERP|20 patients undergoing DTMS treatment using the H7 coil + ERP
11048883|NCT04436952|Active Comparator|rTMS treatment using the cool D-B80 coil + ERP|20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP
11048884|NCT04436952|Active Comparator|ERP only|20 patients undergoing ERP only
11048885|NCT04436939|Experimental|PEEK healing abutment|Healing abutment made of polyetheretherketone (PEEK)
11048886|NCT04436939|Active Comparator|Ti healing abutment|Healing abutment made of titanium (Ti)
11048887|NCT04436926|Experimental|opioid approach bias training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of opioid approach bias modification taking place over two weeks.
11048888|NCT04436926|Sham Comparator|sham training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of sham training taking place over two weeks.
11048889|NCT04436913|Experimental|preventive regimen using Herbal toothpaste(Himalaya)|"The regimen includes herbal toothpaste containing Neem , Miswak , Babool and Pomegranate (Himalaya Complete Care).
~Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash, 0.12% concentration) for one minute per day; such a regimen will be repeated one week every month.
~Fluoride varnish (5% sodium fluoride) will be applied at baseline visit."
11048890|NCT04436913|Experimental|preventive regimen using Fluoride based toothpaste (Signal).|"Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) Participants will be instructed to use 10 ml of 0.12% chlorhexidine gluconate rinse (Hexitol Mouthwash, 0.12% concentration) for one minute per day; such a regimen will be repeated one week every month.
~Fluoride varnish (5% sodium fluoride) will be applied at baseline visit."
11048891|NCT04436913|Active Comparator|Fluoride toothpaste and fluoride varnish|Participants will be using fluoride-based toothpaste (Signal), (1450 ppm sodium fluoride) and fluoride varnish
11048892|NCT04436900|Experimental|Intervention group|20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
11048893|NCT04436887|No Intervention|Primary closure|Primary closure of midline laparotomy
11048894|NCT04436887|Experimental|Mesh closure|Sub-lay permanent mesh supported the closure
11048895|NCT04436874|Experimental|Han ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Han ethnic by endoscopy
11048896|NCT04436874|Experimental|Han ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Han ethnic by endoscopy
11048897|NCT04436874|Experimental|Dai ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Dai ethnic by endoscopy
11048898|NCT04436874|Experimental|Dai ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Dai ethnic by endoscopy
11048899|NCT04436848||PD patients positive for LRRK2 G2385R|
11048900|NCT04436848||PD patients negative for LRRK2 G2385R|
11048901|NCT04436848||Non-PD controls negative for LRRK2 G2385R|
11048902|NCT04436835|Experimental|Supportive care (ART)|Patients undergo ART over 60-90 minutes once a week for up to 5 sessions.
11048903|NCT04436822|Experimental|Subjects with diabetes wearing DS5|Subjects wearing DS5 over 7 days and participating in FSTs.
11048904|NCT04436809|Other|SNB only|"cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have disease-free sentinel nodes (pN0) after primary chemotherapy, are directed to SNB only: i.e. no further treatment to the axilla."
11048905|NCT04436809|Other|SNB + AD|cT2 patients scheduled for primary chemotherapy (with or without a clinically involved axilla - cN0/1) who have metastatic sentinel nodes (pN1) on sentinel node biopsy (SNB) will undergo axillary dissection (AD) i.e. surgical removal of most axillary lymph nodes.
11048906|NCT04436796|Experimental|Artificial Pancreas|Subjects will be provided the Interoperable Artificial Pancreas System (iAPS) which includes the iAPS phone platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This iAPS is designed to help control blood sugar in people living with type 1 diabetes.
11048943|NCT04436510|Placebo Comparator|Matching Placebo|Matching placebo is administered twice daily p.o. for 24 weeks.
11048908|NCT04436783|Experimental|Virtual Reality Epley Maneuver System - VREMS|Patients in the VREMS cohort will be provided with the VREMS device, which will help guide them through the Epley maneuver in a virtual reality environment. All participants will be asked to rate the severity of their symptoms before undergoing the Epley maneuver. Subsequently, patients will be supervised as they perform the Epley maneuver - VREMS assisted. In both groups, once the patient has performed the Epley maneuver (whether with VREMS assistance or with the IH), they will be asked to rate their symptom severity after undergoing the Epley maneuver
11048909|NCT04436783|Active Comparator|Instructional Handout (IH)|Those in the control cohort will be provided an instructional handout (IH) to help them perform the Epley maneuver. They will be given a chance to review the IH, and then they will have a chance to perform the Epley maneuver.
11048910|NCT04436770|Active Comparator|Control Group|Standard physiotherapy and OT
11048911|NCT04436770|Experimental|Experimental|Virtual Reality Therapy and OT
11048912|NCT04436757|Experimental|IPS (Self-image and body-representation program)|"The IPS program (Self-image and body representation) was designed by Dr PLAZAT and coll. for specific use with patients with severe mental disorders suffering of low self- and body-esteem and aiming at  reinsert themselves in the society."
11048913|NCT04436757|Active Comparator|TAU|Treatment As Usual : the usual care proposed by the health service (SUR/CL3R).
11048914|NCT04436744|Experimental|GDC-9545 + Palbociclib|
11048915|NCT04436744|Active Comparator|Anastrozole + Palbociclib|
11048916|NCT04436731|Experimental|Hypoxia Exposure|A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
11048917|NCT04436718|Experimental|Daily POCUS|Patients are assessed by facility experts with daily chest ultrasound and findings of interstitial syndrome and IVC measurement are reported to primary care providers.
11048918|NCT04436718|No Intervention|Usual care|Patients are assessed daily by primary care providers per usual care.
11048919|NCT04436705|Experimental|Progressive Muscle Relaxation (PMR) technique|Participants in intervention group continued Progressive Muscle Relaxation (PMR) technique daily for 20 minutes for a total of four weeks addition to usual care. The usual care consists of pharmacological interventions to manage Cancer-related pain.
11048920|NCT04436705|No Intervention|control|control group received only usual care for their pain during the study period. The usual care consists of pharmacological interventions to manage Cancer-related pain.
11048921|NCT04436692|Other|Improve dietary pattern|Nudging approach to test this methodological approach in persons with intellectual disabilitites with goal to improve dietary pattern and loss of weight
11048922|NCT04436666|Experimental|Ice Application|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
11048923|NCT04436666|Experimental|Virtual Reality|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
11048924|NCT04436666|No Intervention|control|No Intervention
11048925|NCT04436653|Experimental|Tricuspid Valve Replacement System|Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.
11048926|NCT04436640|Experimental|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
11048927|NCT04436627|Experimental|Mild severity:|Brunnstrom stage of distal part: 5-6
11048928|NCT04436627|Experimental|Moderate severity:|Brunnstrom stage of distal part: 4
11048929|NCT04436627|Experimental|severe severity:|Brunnstrom stage of distal part: 2-3
11048930|NCT04436614|Experimental|Aloe Vera and Crocus|50 patients Aloe Vera and Crocus (saffron) 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle Intervention: Dietary Supplement: Aloe Vera and Crocus (saffron) in a glass bottle 1L, per 15 days.
11048931|NCT04436614|Placebo Comparator|Aloe Vera|50 patients Aloe Vera (simple) in a glass bottle 1L, 1 bottle per 15 days. Dietary Supplement: Aloe Vera (simple) in a glass bottle Intervention: Dietary Supplement: Aloe Vera (simple) in a glass bottle in a glass bottle 1L, per 15 days.
11048932|NCT04436614|Other|Mediterranean Diet|50 patients Mediterranean dietary protocol Intervention:mediterranean diet
11048933|NCT04436601|Active Comparator|Lactulose|90 ml of Lactulose dissolved in 750 ml of water administered orally by mouth or nasogastric tube (three doses within 24 hrs) continued up to 72 hours or until patient discharge, whichever comes first.
11048934|NCT04436601|Experimental|PEG: Polyethylene Glycol|Three or four sachet of Movicol(PEG) will be dissolved in 750 ml of water and will be given over 24 hrs as 3 doses orally by mouth or Nasogastric tube and will continue up to 72 hours or until patient discharge, whichever comes first
11048935|NCT04436588||DDX3X|DDX3X
11048936|NCT04436562|Experimental|Poziotinib|A single oral dose of 8 mg poziotinib as a capsule formulation (as the hydrochloride salt) containing approximately 100 μCi of [14C]-poziotinib
11048937|NCT04436549||Patients with varicose veins|Patients with varicose veins and eligible to receive open surgery (stab avulsion of varicose veins) as routinely care.
11048938|NCT04436536|Experimental|training with random speed changes|Walking training on treadmill with random speed changes, that is, random sequence of several different walking speeds
11048939|NCT04436536|Active Comparator|training with blocked speed changes|Walking training on treadmill with blocked speed changes, that is a steady progression of faster walking speed.
11048940|NCT04436523|Experimental|Blood flow restriction|The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
11048944|NCT04436497|Experimental|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection
~Dosage: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight"
11048945|NCT04436497|Placebo Comparator|Matching Placebo|"Administration: Subcutaneous injection
~Dosage: Daily subcutaneous injection"
11048946|NCT04436471|Experimental|Component 1|"rAd26 Component, 1 vaccination
~Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type 26, containing the SARS-CoV-2 S protein gene"
11048947|NCT04436471|Experimental|Component 2|"rAd5 Component, 1 vaccination
~Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene."
11048948|NCT04436471|Experimental|Prime-Boost Immunization|Day 1 rAd26 Component Day 21 rAd5 Component
11048949|NCT04436458|Experimental|Niclosamide|Continued SOC therapy together with Niclosamide tablets for 14 days
11048950|NCT04436458|Placebo Comparator|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide
11048951|NCT04436445|Active Comparator|dry cupping|Dry cupping is considered to be a noninvasive and inexpensive technique, used worldwide to treating patients with pain syndromes It is in fact a type of physical therapy which is applied by the specialists of acupuncture or other individuals. It improves the subcutaneous blood flow and, as a result, stimulates the autonomic nervous system and reduces the pai
11048952|NCT04436445|Active Comparator|Life style modification|"lifestyle modifications in the form of dietary recommendations, exercises and sleep quality improvement for 8 weeks.The life style modification followed in the treatment: Avoid consumption of all kinds of alcohol beverages. Avoid consumption of spicy foods, pepper, chili and coffee Follow a correct diet assuming each day 50% carbohydrates,30% fats and 20% proteins Increase your intake of fruits, vegetables and foods rich of natural fibers (dark bred, vegetables, spinaches).
~8 hour sleep at night 40 minutes of walking 3time per week."
11048953|NCT04436432||Assessment|Children with ASD ages 3-5 years at baseline
11048954|NCT04436419|Placebo Comparator|Placebo|Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
11048955|NCT04436419|Active Comparator|ALA|Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
11048956|NCT04436406|Other|Arm 1: Non-small cell lung cancer|"Participants with non-small cell lung cancer as per inclusion/exclusion criteria undergo baseline and PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PDL1 single-domain antibody SPECT imaging at 0 and 9 weeks.
~FDG-PET/CT is also performed at baseline (0) and first follow-up (9) weeks scans, in addition to standard CT clinical imaging at 0, 9 and 18 weeks."
11048957|NCT04436406|Other|Arm 2: Melanoma|"Participants with malignant melanoma as per inclusion/exclusion criteria undergo baseline and PD-L1 expression testing by immunohistochemistry and [99m-Tc]-anti-PDL1 single-domain antibody SPECT imaging at 0 and 12 weeks.
~FDG-PET/CT is also performed as standard clinical imaging at baseline (0), first follow-up (12) weeks and 24 weeks."
11048958|NCT04436393||Advanced Breast Cancer|Patients with diagnosis of advanced breast cancer
11048959|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
11048960|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
11048961|NCT04436354|Experimental|vaginoscopic office hysteroscopy in the trendelenburg position|
11048962|NCT04436354|Experimental|vaginoscopic office hysteroscopy in lithotomy position|
11048963|NCT04436341||Patients with Alzheimer's disease|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
11048964|NCT04436341||Patients with Lewy body dementia|No treatment interventions. Investigations: physical examination, ear EEG, cranial MR, cognitive tests, blood samples
11048965|NCT04436341||Healthy controls|No treatment interventions. Investigations: physical examination, ear-EEG cranial MR, cognitive tests, blood samples
11048966|NCT04436328|Experimental|Surgical treatment|Surgical treatment of native vertebral osteomyelitis followed by antimicrobial therapy
11048967|NCT04436328|Active Comparator|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only
11048968|NCT04436315|Experimental|Intervention|Exergame intervention
11048969|NCT04436315|Sham Comparator|Control|Active control condition
11048970|NCT04436302|Experimental|Intervention|Dividat senso exergame device
11048971|NCT04436302|Active Comparator|Control|Listening to music
11048972|NCT04436289|No Intervention|Care-as-usual (CAU) study arm|Participants will receive standard discharge care as provided at Tshepong Hospital during the study. This currently includes discharge counseling from a trained discharge counselor and will be provided with a follow-up return date (usually two weeks post-hospital). Discharge counseling will include a review of discharge medications and instructions regarding follow-up care visits.
11048973|NCT04436289|Experimental|Home Link study arm|"The Home Link intervention will be delivered by a home visit team including a primary care nurse and counselor trained in patient-centered counseling. A rotating hospital-based doctor will be available for pre-home visit clinical file review and post-visit discussion, via cell phone, for decision making and input on patient care during a household visit. We have termed this individual a discharge officer. The discharge officer will be a Tshepong clinician who is working in the hospital. Supporting Home Link is expected to take <30 minutes of the physician's time during the day. For study-specific concerns, the team will consult with a GCP-trained, PHRU research doctor based at Tshepong Hospital."
11048974|NCT04436276|Experimental|Cohort 1a|Participants (healthy adults aged greater than or equal to (>=)18 to less than or equal to (<=) 55 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57.
11048975|NCT04436276|Experimental|Cohort 1b|Participants (healthy adults aged >=18 to <= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57.
11048976|NCT04436276|Experimental|Cohort 2a|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1, followed by booster vaccination at 6, 12 or 24 months with same dose or matching Placebo.
11062238|NCT04341870|Active Comparator|Sarilumab|Sarilumab only
11048977|NCT04436276|Experimental|Cohort 2b|Participants (healthy adults aged >=18 to <=55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57, followed by booster vaccination at 8 months, 14 months, and 26 months (that is, 6 months, 12 months, or 24 months after completion of the primary regimen) with same dose or matching Placebo.
11048978|NCT04436276|Experimental|Cohort 3|Participants (good or stable health adults aged >=65 years) will receive Ad26.COV2.S at 2 dose levels, as a single dose or 2 dose schedule with an 8-week interval or matching Placebo on Day 1 and Day 57.
11048979|NCT04436263|Experimental|Supplement|Ethanol-water extract of winery by-products
11048980|NCT04436263|Placebo Comparator|Placebo|Maltodextrin-based placebo
11048981|NCT04436250|Active Comparator|Placebo|Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
11048982|NCT04436250|Experimental|S-Ketamine Low dose|S-Ketamine at a dose of 0.2 mg/kg
11048983|NCT04436250|Experimental|S-ketamine High dose|S-ketamine at a dose of 0.4 mg/kg
11048984|NCT04436237|Experimental|Non-visual exproprioception training|The training requires the participant to place the foot at a target without visual cues of the foot in virtual environment.
11048985|NCT04436237|Active Comparator|Visual exproprioception group|The training requires the participant to place the foot at a target with visual cues of the foot in virtual environment.
11048986|NCT04436224|Experimental|hydromorphone|NS 40ML+ hydromorphone(10mg , 2mg:2ml），IV-Pump，maintenance dose 0.50mg/h
11048987|NCT04436224|Active Comparator|fentanyl|NS 40ML+ fentanyl(0.5mg, 0.1mg:2ml），IV-Pump，maintenance dose 0.08-0.2mg/h
11048988|NCT04436224|Active Comparator|Butorphanol|NS 40ML+ butorphanol(10mg, 1mg:1ml），IV-Pump，maintenance dose 0.7-10mg/kg/h
11048989|NCT04436211||TKA (mechanical alignment)|
11048990|NCT04436211||TKA (kinematic alignment)|
11048991|NCT04436198|Experimental|Treatment group: toric IOL plus capsular tension ring|
11048992|NCT04436198|Active Comparator|Control group: toric IOL only|
11048993|NCT04436185|No Intervention|Characteristics of newborns included|Characteristics of newborns included in the randomized controll
11048994|NCT04436185|Experimental|Intraclass Correlation between the NIPS Score of Parent, Nurse|Intraclass Correlation between the NIPS Score of Parent, Nurse
11048995|NCT04436185|Experimental|Comparisons of procedural pain scores among groups|Comparisons of procedural pain scores among groups
11048996|NCT04436172|No Intervention|pre intervention|Before intervention
11048997|NCT04436172|Experimental|post intervention|Received soinal anesthesia
11048998|NCT04436159|Active Comparator|Nissen fundoplication|Addition of 360 fundoplication after crural closure
11048999|NCT04436159|Active Comparator|Toupet fundoplication|Addition of 180 posterior fundoplication after crural closure
11049000|NCT04436146|Other|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
11049001|NCT04436133|Experimental|vaccine group|
11049002|NCT04436133|Active Comparator|Positive control group|
11049003|NCT04436120|Other|Tumor biopsy and blood draw|Tumor biopsy and blood draw
11049004|NCT04436107|Experimental|Part 1 : Zanubrutinib + Lenalidomide|"Zanubrutinib for up to 48 months
~Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months"
11049005|NCT04436107|Experimental|Part 1: Zanubrutinib+Rituximab+Lenalidomide|"Zanubrutinib for up to 48 months
~Rituximab on Day 1 of each 28-day cycle for 6 cycles
~Lenalidomide administered orally once daily (QD) at 4 dose levels of escalating doses on Days 1 - 21 of each 28-Day cycle for up to 48 months"
11049006|NCT04436107|Experimental|Part 2 : Zanubrutinib+Lenalidomide|"Zanubrutinib for up to 48 months
~Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months"
11049007|NCT04436094|Experimental|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.
~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
11049008|NCT04436094|Active Comparator|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
11049009|NCT04436081|Active Comparator|Hemp-based CBD oil Gelcaps|The intervention consists of 6 weeks oral administration of CBD oil Gelcaps, starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day. At any given dose, if participants develop side effects, the dosage will be reduced to the previous dose.
11049010|NCT04436081|Placebo Comparator|Oral placebo Gelcaps|Participants in the control group will receive oral placebo Gelcaps that are identical in appearance to the CBD oil Gelcaps. Dosing will be identical to the intervention arm.
11049011|NCT04436068|Experimental|Outpatients with known or suspected hydrocephalus|
11049012|NCT04436068|Experimental|Outpatients with other known or suspected neurological condition|
11049013|NCT04436055||All participants|All participants including cannabis users, other drug users, and non-drug users.
11049014|NCT04436042|Experimental|MyHand Treatment|Participants will use the MyHand device during repetitive grasp and release tasks.
11049015|NCT04436029|Experimental|Descartes 11|
11049103|NCT04435470||Critical ill children|Critial ill children admited in pediatric intensive care units 1-16 years old
11049104|NCT04435470||Control|Healthy children 1-16 years old
11049016|NCT04436016|Experimental|Ivabradine|"Ivabradine will be administered in an individualized regimen adapted to the subject's heart rate at each visit in a dosage ranging from 0-7.5mg twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:
~If heart rate is ≥101 bpm: capsule D (Ivabradine 7.5 mg);
~If heart rate is 86-100 bpm: capsule C (Ivabradine 5 mg);
~If HR is 71-85 bpm: capsule B (Ivabradine 2.5 mg);
~If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (placebo)."
11049017|NCT04436016|Placebo Comparator|Placebo|"Placebo will be administered twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:
~If heart rate is ≥101 bpm: capsule D (Placebo)
~If heart rate is 86-100 bpm: capsule C (Placebo)
~If HR is 71-85 bpm: capsule B (Placebo)
~If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (Placebo)."
11049018|NCT04436003|Experimental|Muscle and Articulation chains GDS method treatment|"Participants in the intervention Group are examined and treated according to the principles of Muscle and Articulation Chains GDS Method. They receive GDS treatment individually, up to 8 sessions of 1 hour."
11049019|NCT04436003|No Intervention|Control (treatment as usual)|The Control Group receives standard treatment from their RGP/ doctor. Some are prescribed physiotherapy or chiropractor treatment, or they choose their own alternatives.
11049020|NCT04435990|Experimental|Experimental:10,000 MM09|10,000 TU/mL of subcutaneous immunotherapy
11049021|NCT04435990|Experimental|Experimental: 30,000 MM09|30,000 TU/mL of subcutaneous immunotherapy
11049022|NCT04435990|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without any active ingredients.
11049023|NCT04435977|Experimental|Cabozantinib|Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
11049024|NCT04435964||Overall series|Patients treated with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule. No limitations to previous lines of treatment. ICI therapy may be either as single agent or in combination. Concomitant chemotherapy (CT) and radiotherapy (RT) is allowed.
11049025|NCT04435951||Group 1 (with TMJD)|Group 1, consists of 60 patients diagnosed with Temporomandibular Joint Dysfunction (TMJD) according to the Research Diagnostic Criteria for Temporomandibular Disorders by a specialist and experienced dentist in TMJD.
11049026|NCT04435951||Group 2 (without TMJD)|Group 2, consists of 60 individuals who did not exhibit TMJD symptoms and have not TMJD diagnosis.
11049027|NCT04435938|Experimental|Stereotactic Body Radiotherapy (SBRT)|The dose prescribed in the study will be 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days. (e.g. treatment given on Monday/Thursday/Mon/Thurs/Mon) (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues.)
11049028|NCT04435925|Active Comparator|Remifentanil|Patients assigned to this group will receive IV Remifentanil as an opioid for general anesthesia.
11049029|NCT04435925|Placebo Comparator|Fentanyl|Patients assigned to this group will receive IV Fentanyl as an opioid for general anesthesia.
11049030|NCT04435912|No Intervention|PS alone group|Patients received only Protamine Sulfate for reversal of Heparin
11049031|NCT04435912|Experimental|PS and HC group|Patients received Hydrocortisone pre-treatment then Protamine Sulfate for the reversal of Heparine
11049032|NCT04435899|Experimental|EFFECTS OF A CHAIR-YOGA EXERCISES ON STRESS HORMONE LEVELS.|assess the changes mediated by exercise on activities of daily life and falls (autonomy), physical fitness, salivary cortisol and alpha amylase in older adults living in social care givers centers. Methods: 35 women (83.81 ± 6.6 years old) were divided into two groups: chair-yoga exercises (CY, n=20) and control group (CG, n=15). All subjects were evaluated before and after 14-weeks of intervention. CY was involved in classes two times per week, while the GC did not participate in any exercise.
11049033|NCT04435899|Experimental|Physical fralty and health outcomes of fitness, sex hormones.|The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
11049034|NCT04435899|Experimental|physical fitness and frailty syndrome institutionalized older|"This study analyzed the relationship between old physical frailty syndrome (PF) and PhFi indicators and assessed how the latter might predict the former. Participants were 119 elderly women (81.96 ±7.89 years) recruited from four social and healthcare centers. PhFi was assessed through muscle strength tests of upper and lower limbs, endurance, agility-dynamic balance, flexibility and body composition.
~The following PF indicators were assessed: weight loss, exhaustion, weakness, slowness and low physical activity level."
11049035|NCT04435899|Experimental|THE RELATIONSHIP BETWEEN FUNCTIONAL DISABILITY OUTCOMES|The associations between functional disability activities of life activities and frailty have already been explored. The contribution of each component of physical frailty and their contribution to understanding the early physical decline of older individuals are poorly explored. The relationships between PF and functional disability and to identify the independent components of frailty that most influence on disability in older women. A cross-sectional study of 119 (81,96±7,89) older women aged 75 and over. Functional disability was assessed through Agility-dynamic and Static balance tests, Activities of daily life and Falls risk screen outcomes.
11049036|NCT04435886|Experimental|Probiotic group|A multi-strain probiotic
11049037|NCT04435886|Placebo Comparator|Placebo group|Identical placebo
11049038|NCT04435873||Mail Survey Participants|Approximately 1200 home patients will receive mail surveys. Of these, one thousand and twenty (1,020) patients will be asked to complete the survey once. One hundred and eighty (180) patients will be asked to complete the survey twice.
11049136|NCT04435301|No Intervention|No treatment group|No stimulation is applied.
11049039|NCT04435873||Telephone Survey Participants|Three hundred (300) home patients will be surveyed by phone. Of those, one hundred and twenty will be asked to complete the survey once. One hundred and eighty patients will be asked to complete the phone surveys on two separate occasions.
11049040|NCT04435860||Ankylosing Spondylitis|Patients with ankylosing spondylitis meeting the inclusion and exclusion criteria
11049041|NCT04435860||Healthy Controls|Healthy individuals meeting the exclusion criteria
11049042|NCT04435847|Experimental|HST 001|HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
11049043|NCT04435847|Placebo Comparator|Placebo - Phosphate Buffered Saline|Phosphate Buffered Saline
11049044|NCT04435834|Active Comparator|Randomized propofol|"Subject will receive propofol anesthesia during their MRI. Dosage form: injectable solution. Dosage: 100-300 mcg/kg/min, or as per clinical standard of care appropriate for specific subjects.
~Frequency and duration: continuous infusion while undergoing MRI."
11049045|NCT04435834|Active Comparator|Randomized sevoflurane|"Subject will receive sevoflurane anesthesia during their MRI. Dosage form: volatile liquid for inhalation Dosing: 0-1 month full term neonate (3.3% in oxygen), 1-6 months old (3% in oxygen), 6 months to <3 years old (2.8% in oxygen), or as per clinical standard of care appropriate for specific subjects.
~Frequency and duration: continuous infusion while undergoing MRI."
11049046|NCT04435821|Experimental|Pediatric Chronic Pain Patients|Individuals 11-18 years old, with chronic pain (lasting at least 2 months).
11049047|NCT04435808|Experimental|Hydroxychloroquine Arm|Group A: up to 275 health care workers who choose to take hydroxychloroquine. Will receive a 600 mg loading dose, followed by 200 mg daily (tablets).
11049048|NCT04435808|No Intervention|No Intervention Arm|Group B: Up to 75 health care workers who choose not to take hydroxychloroquine.
11049049|NCT04435795|Active Comparator|Ciclesonide inhaled and nasal|Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled cilcesonide 600mcg BID x 14 days
11049050|NCT04435795|Placebo Comparator|Placebo|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
11049051|NCT04435782|Experimental|JNJ-67896049|Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 26.
11049052|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on warfarin|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.
11049053|NCT04435769||Non-valvular Atrial Fibrillation (NVAF) on apixaban|The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.
11049054|NCT04435756||Observational (blood collection)|Patients undergo collection of blood every 3-6 months for up to 3 years.
11049055|NCT04435743||DLBCL|Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.
11049056|NCT04435743||FL/MCL/MZL|Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.
11049057|NCT04435743||Maintenance|B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.
11049058|NCT04435730||Group 1|45 patients with cutaneous psoriasis with no musculoskeletal manifestations.
11049059|NCT04435730||Group 2|45 patients with psoriatic arthritis fulfilling CASPAR criteria of PsA
11049060|NCT04435730||Group 3|45 patients with subclinical psoriatic arthritis (patients with cutaneous psoriasis and musculoskeletal manifestations but not fulfilling CASPARcriteria of PsA).
11049061|NCT04435730||Group 4|45 sex and age matched healthy controls
11049062|NCT04435717|Experimental|TCZ 8 mg / kg one dose|TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
11049063|NCT04435717|Experimental|TCZ 8 mg / kg in two|TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
11049064|NCT04435717|No Intervention|standard care treatment|Usual / standard care treatment
11049065|NCT04435704|Experimental|Oxytocin|Oxytocin will be administered at increasing and decreasing rates
11049066|NCT04435691|Experimental|Treatment (azacitidine, venetoclax, magrolimab)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-21 of cycle 1 (may be reduced to days 1-14 for subsequent cycles after principal investigator approval), and magrolimab IV over 2-3 hours on days 1, 4, 8, 11, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycle 2, and days 1 and 15 of cycle 3 and subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11049067|NCT04435678|Other|birch pollen allergy|"106 patients with suspicion of birch pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
11049068|NCT04435678|Other|grass pollen allergy|"106 patients with suspicion of grass pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
11049069|NCT04435678|Other|house dust mite allergy|"148 patients with suspicion of house dust mite allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)"
11049070|NCT04435678|Other|cat allergy|"106 patients with suspicion of cat allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
11049174|NCT04435041||RECAP early warning score|Development of disease specific early warning score, building on earlier work through literature review and NEWS2 score
11049071|NCT04435678|Other|bee venom allergy|"106 patients with suspicion of bee venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
11049072|NCT04435678|Other|vespid venom allergy|"106 patients with suspicion of vespid venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
11049073|NCT04435678|Other|non-allergic individuals|"148 non-allergic individuals will be included in the study. They should have no symptoms that could be related to inhalant allergy or Hymenoptera venom allergy, negative skin test results and undetectable IgE levels.
~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
11049074|NCT04435665|Experimental|NFX-179 Gel Low|NFX-179 Gel for topical administration, once daily for 28 days
11049075|NCT04435665|Experimental|NFX-179 Gel Mid|NFX-179 Gel for topical administration, once daily for 28 days
11049076|NCT04435665|Experimental|NFX-179 Gel High|NFX-179 Gel for topical administration, once daily for 28 days
11049077|NCT04435665|Placebo Comparator|Vehicle Arm|Vehicle Gel, for topical administration, once daily for 28 days
11049078|NCT04435652|Experimental|Experimental: Cohort A|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
11049079|NCT04435652|Experimental|Experimental: Cohort B-arm1|Participants receive QL1604 and nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle. If not disease progression after 4 cycles, participants receive QL1604 monotherapy until disease progression、unacceptable toxicity or up to 2 years.
11049080|NCT04435652|Experimental|Experimental: Cohort B-arm2|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
11049081|NCT04435639|Experimental|MLD + Adjustable Compression Sleeve.|Manual lymph drainage + Adjustable Compression Sleeve.
11049082|NCT04435639|Active Comparator|MLD + Coban Compression Bandage.|Manual lymphatic drainage + Coban compression bandaging.
11049083|NCT04435626|Experimental|Arm 1_BAY94-8862|Adult patients receive BAY94-8862
11049084|NCT04435626|Placebo Comparator|Arm 2_Placebo|Adult patients receive placebo
11049085|NCT04435600|Experimental|Part 1: Risankizumab Dose A|Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
11049086|NCT04435600|Experimental|Part 2: Ustekinumab Dose A or B then Risankizumab Dose A or B|"Participants age 12 to less than 18 will receive:
~Period A: Ustekinumab Dose A or Dose B based on body weight for 16 weeks (at Week 0 and Week 4).
~Period B: Risankizumab Dose A or B based on body weight for 24 weeks."
11049087|NCT04435600|Experimental|Part 2: Risankizumab Dose A or B|"Participants age 12 to less than 18 will receive:
~Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).
~Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare.
~Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4)."
11049088|NCT04435600|Experimental|Part 3: Risankizumab Dose A or B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
11049089|NCT04435600|Experimental|Part 4: Risankizumab Dose A or B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
11049090|NCT04435587|Experimental|ivermectin|oral ivermectin 600 mcg/kg/day once daily for 3 days
11049091|NCT04435587|Active Comparator|ART/hydroxychloroquine|"Combination of
~Day1 hydroxychloroquine 400mg bid, then 200mg bid on Day 2-5
~Darunavir/ritonavir (400/100mg) every 12 hours for 5 days"
11049092|NCT04435574|Experimental|Group A|group A is lactoferrin group, receiving 100mg sachet of lactoferrin once daily.
11049093|NCT04435574|Active Comparator|Group b|group B is the ferrous sulfate group, receiving 6mg/kg/ day single dose of ferrous sulfate.
11049094|NCT04435561|Experimental|Standard physiotherapy rehabilitation and dry needling|"In addition to the usual therapy, the experimental group will receive the application of dry needling technique in the hemiparetic limbs.
~Dry needling intervention will take place over a period of one and a half months (6 weeks), with a total of 6 sessions. Each session will be performed once a week, where a single puncture will be made in each muscle to be treated, using Hong´s technique and lasting 60 seconds per muscle (or until the muscle is release).
~The muscles that will receive dry needling are the following ones:
~Upper limb: infraspinatus, teres minor, pectoralis major, deltoid.
~Lower limb: gastrocnemius, soleus and anterior tibial muscles."
11049095|NCT04435561|Other|Standard physiotherapy rehabilitation|The control group will receive the usual therapy and treatment.
11049096|NCT04435535|Other|Positive expiratory pressure (PEP)|PEP 10 cmH2O 15 min
11049097|NCT04435522|Experimental|Maraviroc Treatment|Maraviroc 300 mg Twice Daily
11049098|NCT04435509|Experimental|Greek Mountain Tea|50 patients Greek Mountain Tea 50 grams one per 30 days. Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams Intervention:Greek Mountain Tea in a plastic bag.
11049099|NCT04435509|Placebo Comparator|Mediterranean Diet|50 patients same dietary habits and a Mediterranean dietary protocol Intervention: Mediterranean diet.
11049100|NCT04435496|Other|GYN-CS insertion|GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.
11049101|NCT04435483|Experimental|Treatment Sequence 1|Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
11049102|NCT04435483|Experimental|Treatment Sequence 2|Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
11049105|NCT04435444|Experimental|Masterful supportive care|This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
11049106|NCT04435444|Active Comparator|Attention control supportive care|This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
11049107|NCT04435431|Experimental|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
11049108|NCT04435431|Experimental|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
11049109|NCT04435431|Experimental|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
11049110|NCT04435431|Placebo Comparator|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
11049111|NCT04435405||Video microanalisys|Video footage analysis of group and individual behavioral processes.
11049112|NCT04435392|Experimental|Part 1: Cohort 1, 0.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 0.5% Cream will be applied topically twice daily.
11049113|NCT04435392|Experimental|Part 1: Cohort 2,1.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 1.5% Cream will be applied topically twice daily.
11049114|NCT04435392|Experimental|Part 1: Cohort 3, 2.5% Jaktinib Qd|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically Once daily.
11049115|NCT04435392|Experimental|Part 1: Cohort 4, 2.5% Jaktinib Bid|Subjects were randomly assigned to receive either jakatinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically twice daily.
11049116|NCT04435392|Placebo Comparator|Dose extension: Vehicle Control|the Vehicle Control cream will be applied topically twice daily
11049117|NCT04435392|Experimental|Dose extension: low-dose group, X%|X% based on results of part 1. The Jaktinib Hydrochloride X% Cream will be applied topically twice daily
11049118|NCT04435392|Experimental|Dose extension: high-dose group, Y%|Y% based on results of part 1. The Jaktinib Hydrochloride Y% Cream will be applied topically twice daily
11049119|NCT04435379|Experimental|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.
~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
11049120|NCT04435379|Placebo Comparator|Placebo|Physiological saline 0.1ml
11049121|NCT04435366|Experimental|Zimura Treatment Group|Monthly Zimura 2mg Intravitreal Injections, followed by monthly injections or every other month injections from Month 12 to Month 23
11049122|NCT04435366|Sham Comparator|Sham Treatment Group|Monthly Sham Administration until Month 23
11049123|NCT04435353|Active Comparator|Time-day of respiratory fail|Objective data
11049124|NCT04435353|Active Comparator|Oxygen status|Facultative data
11049125|NCT04435353|Active Comparator|Oxugen support|FiO2
11049126|NCT04435353|Active Comparator|Adverse outcomes|Complication
11049127|NCT04435340|Other|Retrospective|All patients in the retrospective cohort are contacted at least 1 year after surgery and/or 3 years after surgery via phone call or letter, informed about the study and asked to participate. In case of informed consent, they are invited to the study site. They are asked to complete the questionnaires and they undergo a Sonography of the ventral abdomen.
11049128|NCT04435340|Other|Prospective|All patients in the prospective cohort are informed about the study and asked to participate in the outpatient clinic before surgery. In case of informed consent, they are invited to the study site at least one year and three years, respectively, after surgery. They are asked to complete the questionnaires and they undergo an ultrasound of the ventral abdomen.
11049129|NCT04435327||Oxygen therapy|Patients who were hospitalised due to COVID-19 pneumonia and received only oxygen support therapy.
11049130|NCT04435327||Non invasive ventilation (NIV/CPAP)|Patients who were hospitalised due to COVID-19 pneumonia and received non invasive ventilation (NIV/CPAP) as maximum support therapy
11049131|NCT04435327||Invasive ventilation|Patients who were hospitalised due to COVID-19 pneumonia and received invasive mechanical ventilation (IMV)
11049132|NCT04435314|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
11049133|NCT04435314|Placebo Comparator|Placebo|Subjects will receive placebo TID.
11049134|NCT04435301|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator(NeuroConn, Germany). Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
11049135|NCT04435301|Experimental|Beta modulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). 40Hz acoustic stimuli and 40Hz electric stimuli are synchronously applied for 40min/day, for a total of 5 days.
11049137|NCT04435288|Active Comparator|TNFi-induction group|"The patients in the TNFi-induction group will receive golimumab at a standard dose of 50 mg subcutaneously (SC) every 4 weeks (with matching methotrexate (MTX)-placebo). In case of potential intolerance or toxicity to MTX-placebo, the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX-placebo will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
11049138|NCT04435288|Active Comparator|csDMARD-Step-up group|"The patients in the csDMARD-Step-up group will start with oral methotrexate (MTX) at a weekly dose of 15 mg for 4 weeks (with matching TNFi-placebo injections). In case of potential intolerance or toxicity to MTX , the dose will be gradually tapered to a minimum of 7.5 mg per week. When there are no tolerability/toxicity issues, the weekly dose of MTX will be increased to 20 mg at week 4. At week 12, a Patient Acceptable Signs & Symptoms Improvement ('PASSI') will be assessed by asking the question Taking into account both efficacy and side effects, did you experience over the past 12 weeks enough improvement in signs and symptoms of your' arthritis-enthesitis-dactylitis to consider continuation of the same treatment schedule for the next 12 weeks?. If yes, all study medication will be kept stable until week 24; if no, oral sulphasalazine at a dose of 2 g per day will be started (escape medication)."
11049139|NCT04435275|Active Comparator|Donning PPE using VA then doffing PPE using HC|Study subjects will receive VA guidance for donning first, then guidance from a human coach (HC) for doffing.
11049140|NCT04435275|Active Comparator|Donning PPE using HC then doffing PPE using VA|Study subjects will receive HC guidance for donning first, then VA guidance for doffing.
11049141|NCT04435275|Active Comparator|Intubation using VA then extubation using HC;|Study subjects will receive VA guidance for the intubation first , then HC guidance for extubation procedure
11049142|NCT04435275|Active Comparator|Intubation using HC then extubation using VA|Study subjects will receive HC guidance for the intubation first , then VA guidance for extubation procedure
11049143|NCT04435262||ILR Group followed with RM|Patients with unexplained syncope underwent ILR monitoring and followed with RM
11049144|NCT04435262||ILR Group followed with in-hospital visits|Patients with unexplained syncope underwent ILR monitoring and followed with in-hospital visits
11049145|NCT04435249|Experimental|Treatment Arm|Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula.
11049146|NCT04435236|Active Comparator|Cervical ESP block group|Cervical ESP block will be performed as described by Elsharkawy at al. (7).
11049147|NCT04435236|Sham Comparator|ISB Block group|ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
11049148|NCT04435223||COVID-19 severe pneumonia|
11049149|NCT04435223||Severe pneumonia due to other pathogene|
11049150|NCT04435210|Experimental|Nifedipine arm|Participants in this arm will be pregnant women with severe hypertension who will receive nifedipine
11049151|NCT04435210|Experimental|Hydralazine|Participants in this arm will be pregnant women with severe hypertension who will receive hydralazine
11049152|NCT04435197|Experimental|Arm A|"Arm 1:
~A: Pembrolizumab 200mg(100mg if weight less than 50kg) IV on days 1 and 22 B: Carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.
~D: Ivor-Lewis or McKeown esophagectomy
~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
11049153|NCT04435184|Experimental|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
11049154|NCT04435184|Active Comparator|Placebo Saline|0.9% saline 100 ml IV once.
11049155|NCT04435171||Open renal transplantation|Patients who were performed open renal transplantation due to end stage renal disease.
11049156|NCT04435171||robot assisted renal transplantation|Patients who were performed robot assisted renal transplantation due to end stage renal disease
11049157|NCT04435158|Experimental|Cohort 1：SHR-1222|Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
11049158|NCT04435158|Experimental|Cohort 2：SHR-1222|Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
11049159|NCT04435158|Experimental|Cohort 3：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
11049160|NCT04435158|Experimental|Cohort 4：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 biomonthly × 6 months
11049161|NCT04435158|Experimental|Cohort 5：placebo|Subcutaneous injection of placebo monthly
11049162|NCT04435145|Experimental|Intervention|Sugar-sweetened beverage warning label
11049163|NCT04435145|No Intervention|Control|No label
11049164|NCT04435132|Experimental|PCNL with the aid of the robotic device|Patients will undergo prone PCNL under fluoroscopic guidance and with the aid of the robotic device.
11049165|NCT04435106||Opaganib + Standard of Care|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
11049166|NCT04435106||Standard of Care|Study participants received Standard of Care
11049167|NCT04435093||MFM completion|
11049168|NCT04435080||Non-rehabilitation|The patients hospitalised in ICU who were provided all the intensive care managements except for rehabilitation interventions (discharged from intensive care unit before April 14, 2020)
11049169|NCT04435080||Rehabilitation|The patients hospitalised in ICU who were provided rehabilitation interventions in addition to all the intensive care managements. (discharged from intensive care unit after April 14, 2020)
11049170|NCT04435067||Cohort A|patients in whom lung metastasis were resected for therapeutic purposes
11049171|NCT04435067||Cohort B|patients in whom lung metastasis were removed for diagnostic purposes only
11049172|NCT04435054|Other|Non invasive tests|
11049173|NCT04435041||Remote assessment tools|Qualitative methods: semi-structured interviews for approx 40 front line clinical practitioners
11049175|NCT04435041||Implementation/Scale up case studies|Study of implementation and scale up of remote-by-default at four different UK sites
11049176|NCT04435041||Infrastructure strengthening|Theory and data driven change effort involving policymakers, regulators, professional bodies, industry, patients and citizens with a view to overcoming interacting issues impacting success of digital projects.
11049177|NCT04435028||control group|55 patients received their standard therapy (anthracycline-containing chemotherapy without ketotifen)
11049178|NCT04435028||ketotifen group|Ketotifen Group: 56 patients received anthracycline-containing chemotherapy plus ketotifen as a cardioprotective agent. Ketotifen will be given orally as one tablet (1 mg/tablet) 3 times daily, before and during the chemotherapeutic cycle for 6 cycles of treatment
11049179|NCT04435015|Experimental|Camostat mesylate 200 mg|Participants will be given Camostat mesylate three times daily.
11049180|NCT04435015|Placebo Comparator|Microcrystalline Cellulose|Participants will be given placebo three times daily.
11049181|NCT04435002|Experimental|Intervention Group|For 9 different points acupressure technique applied to this group for 4 weeks
11049182|NCT04435002|No Intervention|Control Group|
11049183|NCT04434989|Experimental|Stereotactic Body Radiation Therapy|SBRT is defined as a special radiotherapy technique. The high dose of radiotherapy is accurately injected into the tumor lesion in one to several times using external irradiation technique. Then the tumor is exposed to high dose and the surrounding normal tissue to low dose.
11049184|NCT04434989|Active Comparator|Radiofrequency Ablation|Percutaneous radiofrequency ablation to the tumor
11049185|NCT04434976||delayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is more than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
11049186|NCT04434976||undelayed diagnosis|The length from the first clinical visit date to the diagnosis confirmed date is equal or less than 14 days. Diagnosis is confirmed by any positive result of anti fast bacteria smear, culture, histological test, and molecular detection such as GeneXpert.
11049187|NCT04434950|Experimental|Intervention|Intervention group
11049188|NCT04434937|Experimental|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
11049189|NCT04434898||Ｍild cognitive impairment patients|"The patients with mild cognitive impairment have a Clinical Dementia Rating score of 0.5. First, we will evaluate the correlation between diffusion MRI and the clinical severity and cognitive decline of patients. Second, we will evaluate if diffusion MRI can predict if these patients will develop Alzheimer's Disease and hence be involved in the third year of the study. Patients with mild cognitive impairment should meet the following criteria:
~Between 50-80 years old
~Right-handed
~Clinical Dementia Rating score equal to 0.5
~For patients who have a CDR score of 0.5, should be diagnosed by clinician's judgement of clinical information, daily living activities, and extent of neuropsychological disorders
~Able to understand study requirements and give informed consent"
11049190|NCT04434898||Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD), 15 patients with Progressive Supranuclear Paralysis (PSP), 15 patients with Multiple System Atrophy (MSA), and 15 patients with Cortico-Basal Degeneration (CBD). In differential diagnosis in the first year of the study, diffusion MRI will be used for a retrospective study.
11049191|NCT04434898||Healthy volunteers|"The healthy volunteers should meet the following criteria:
~Between 50-80 years old
~Right-handed
~MMSE score greater than or equal to 26
~Able to understand study requirements and give informed consent"
11049192|NCT04434885||Psoriatic arthritis|Patients diagnosed with PsA and fulfilling the classification criteria for PsA with symptom duration of up to 10 years and not receiving biological or targeted synthetic disease modifying antirheumatic drugs (b or tsDMARDs).
11049193|NCT04434872|Active Comparator|FMT from a healthy donor|"Patients will undergo FMT 4 times during the study:
~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:
~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.
~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
11049194|NCT04434872|Placebo Comparator|FMT from a self donated stool sample|"Patients will undergo FMT 4 times during the study:
~first time, through a colonoscopy (sample volume: 250ml), and 3 more times (each sample volume: 100ml) during the following three days through:
~A Naso-jejunal feeding tube (that will be inserted through a gastroscopy) for patients suffering from colitis that involves more than 40 cm of the colon.
~Enemas, for patients suffering from colitis that involves the left colon up to 40 cm from the rectum."
11049195|NCT04434859||Patients with tinnitus|Patients (over 18 years old) seen at the medical center due to tinnitus, lasting at least 3 months.
11049196|NCT04434846||1|Adults ages 18-55 with ZIKV, DENV, and/or CHIKV seroprevalence.
11049197|NCT04434833||Extra nodal diseases|Patients with both lymph node and extra nodal involvement.
11049198|NCT04434833||Target drugs|Patients enrolled in clinical trials of novel target drugs.
11049199|NCT04434833||Relapse|Patients with high risk of relapse.
11049200|NCT04434820|No Intervention|standard dressing group|patients will receive sterile wound dressing of gauze and tape for 4 days.
11049201|NCT04434820|Active Comparator|External negative pressure dressing system group|patients will receive placement of a sterile dressing of gauze and occlusive adhesive over the closed incision. The dressing's tubing will then be attached to a compact, portable negative-pressure therapy unit (Yuwell 7E-A portable suction unit) that will deliver -80 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
11049202|NCT04434807|Experimental|Minimally invasive hematoma evacuation|Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.
11049203|NCT04434807|No Intervention|Standard care (medical therapy)|Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.
11049204|NCT04434794|Experimental|mesenchymal stem cells|standard treatment according to clinical protocols plus mesenchymal stem cells
11049206|NCT04434768|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke.
11049207|NCT04434755||health care professionals in palliative care|health care professionals in palliative care
11049208|NCT04434755||health care professionals in neurorehabiliation|health care professionals in neurorehabiliation
11049209|NCT04434742|Experimental|Intervention group|The subjects in this group receive complex interventions, including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team.
11049210|NCT04434742|Other|Control group|The control group received usual discharge care and community resources that were made available to them as appropriate. A monthly social call was made to each client in the control group in order to exclude social effects. The contents of the social call, such as asking about entertainment and clients' hobbies, were set in the protocol.
11049211|NCT04434729|Experimental|Fetal embolization of vein of Galen malformation|This is a single-arm study. Fetal subjects will undergo a one-time intervention of fetal embolization of vein of Galen malformation.
11049212|NCT04434716|Other|Feasibility of Wearing a Readiband|"Participants will wear the Fatigue Science Readiband for 42 consecutive day. On day one, every seventh day and at the end of the study each participant will complete the Dyspnea-Characteristic scale, BRICS NINR PROMIS Fatigue Short Form6a scale , Modified Pulmonary Functional Status, Dyspnea Questionnaire and the BRICS NINR PROMIS SF v1.0-Sleep Disturbance 6a scale.The Minnesota Living with Heart Failure Questionnaire and Self-Care of Heart Failure Index will be completed on day one and day 60. The purpose of this intervention is to assess the Feasibility of Wearing a Readiband.
~Semi-structured Interview will be conducted at the end of 42 days to assess patient comfort and challenges with wearing the Readiband."
11049213|NCT04434703|Active Comparator|Platelet rich fibrin (PRF)|Platelet rich fibrin is the secoond generation of platelet concentrates which is an autogenous biomaterial that is prepared from the patient's own blood
11049214|NCT04434703|Experimental|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin is the last modification of PRF which is expected to contain a relatively greater number of white blood cellsand growth factors
11049215|NCT04434703|Placebo Comparator|blood clot|normal healing of the wound without adding any biomaterial
11049216|NCT04434690|Experimental|Simultaneous|2 surgeons will perform simultaneous total knee arthroplasty in this group.
11049217|NCT04434690|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
11049218|NCT04434677|Active Comparator|Hypofractionation|Control arm:patients who will receive standard 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
11049219|NCT04434677|Experimental|Ultrahypofractionation|Experimental arm: Patients who will receive 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
11049220|NCT04434664|Active Comparator|Amlodipine besylate|Initial dose 5mg (1 capsule) daily, titrated up to 10mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
11049221|NCT04434664|Active Comparator|Metoprolol succinate|Initial dose 100mg (1 capsule) daily, titrated up to 200mg (2 capsules) daily for a home systolic BP ≥135 mmHg and heart rate ≥50 bpm after the first week of use
11049222|NCT04434651|Experimental|Block group (A)|"10 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed before induction of anesthesia.
~The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes."
11049223|NCT04434651|No Intervention|control group (B)|10 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] .The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes
11049224|NCT04434638|Experimental|Transitions of Care Coordinator Group|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
11049225|NCT04434638|Active Comparator|Usual Care Group|Patients in the usual care group, which served as the control, received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
11049226|NCT04434625|No Intervention|control group|Colonoscopy was performed in the control group directly.
11049227|NCT04434625|Experimental|model-based interference group|Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score<3 in IM group colonoscopy directly.
11049228|NCT04434612|Experimental|OXSIGHT smart glasses|Wearing OXSIGHT smart glasses
11049229|NCT04434599|Active Comparator|Fluoroscopically guided ablation|These patients will receive one catheter ablation of typical atrial flutter by fluoroscopically guided radiofrequency ablation catheters
11049230|NCT04434599|Active Comparator|Contact force guided ablation|These patients will receive one catheter ablation of typical atrial flutter by contact force guided radiofrequency ablation catheters using the CARTO 3D electroanatomic mapping system
11049231|NCT04434599|Active Comparator|Local impedance guided ablation|These patients will receive one catheter ablation of typical atrial flutter by local impedence guided radiofrequency ablation catheters using the Rhythmia Ultra-high density 3D electroanatomic mapping system
11049232|NCT04434586|Sham Comparator|angiography 2D|Control group: an arteriography will be performed on the entire treated segment to assess the quality of the result, the application or not an active balloon will be left to the discretion of the operator. In case of application of the active balloon, a new arteriography before decision or not the use of stenting will be practiced. In case of stenting, an arteriographic final is performed.
11049233|NCT04434586|Experimental|angiography 2D with OCT|Experimental group: an arteriography and OCT acquisition on the entire treated segment to ensure the quality of the result, the application or not of an active ball will be left. In case of application of the active balloon, a new arteriography and OCT acquisition before decision or not the use of stenting will be practiced. In case of stenting, a final arteriography and then OCT acquisition are performed.
11049234|NCT04434573||french-speaking digestive surgeons|french-speaking digestive surgeons are visceral and digestive surgeons that have a general surgical activity too. They can have or not an expertise on hernia pathology. They are questioned by survey on decisions about different patient asymptomatic hernia clinical situations.
11049235|NCT04434560|Experimental|Arm with checkpoint|Arm 1 (arm with checkpoint) will receive a single dose of neoadjuvant nivolumab and ipilimumab 7 days (± 3 days) prior to surgical resection.
11049236|NCT04434560|No Intervention|Arm without checkpoint|Arm 2 (control arm without checkpoint) will proceed straight to surgical resection with no nivolumab/ipilimumab given prior to surgery.
11049237|NCT04434547|Experimental|PRP group|In the PRP group autologous platelets rich plasma was prepared from the blood using the two step centifuge process .Under ultrasound guidance and complete aseptic procedure , 1 ml of PRP was infused inside the uterus while performing the mock embryo transfer
11049238|NCT04434547|No Intervention|Control group|In the control group mock embryo transfer was performed without injecting anything inside the uterus.
11049239|NCT04434534|Experimental|Hipocaloric Diet with Açaí Juçara|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories, including 200g of Açaí Juçara (2 pulps).
11049240|NCT04434534|Active Comparator|Hipocaloric Diet|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories.
11049241|NCT04434508|Active Comparator|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
11049242|NCT04434508|Active Comparator|open right hemicolectomy with CME and central v|open right hemicolectomy with CME and central v
11049243|NCT04434495|Experimental|PRP group|mock embryo transfer and PRP injection
11049244|NCT04434495|No Intervention|control group|only mock embryo transfer
11049245|NCT04434482|Experimental|IMP4297 and temozolomide|"IMP4297 and temozolomide
~The dose levels will be escalated following a modified 3+3 dose escalation scheme."
11049246|NCT04434469|Experimental|Phase I Dose-Escalation Stage: RO7297089|Cohorts of at least 3 participants each will be treated with escalating doses of RO7297089 to determine the MTD or maximum administered dose (MAD)
11049247|NCT04434469|Experimental|Phase I Expansion Stage: RO7297089|After dose escalation has been completed, approximately 30 patients will be enrolled in the expansion stage. Participants will receive RO7297089 at the recommended phase 2 dose (at or below the maximum tolerated dose).
11049248|NCT04434456||CGuard stenting (interventional)|CGuard implantation in the carotid artery with aneurysm requiring intervention
11049249|NCT04434443|Experimental|trunk exercise on unstable surface|trunk exercise training in supine and sitting positions, with unstable surfaces
11049250|NCT04434443|Sham Comparator|upper limb range of motion exercise|upper limb range of motion exercise in sitting with back fully supported
11049251|NCT04434430|Active Comparator|Gabapentin|Patient will receive preemptive oral gabapentin 600 mg
11049252|NCT04434430|Placebo Comparator|Placebo|Patient will receive oral placebo
11049253|NCT04434417||Cohort tested|The cohort will include patients or health professionals who patients who were suspected of being infected with 2019-nCoV
11049254|NCT04434404|Placebo Comparator|control group|33, patients in the control group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 without cardioprotective agents
11049255|NCT04434404|Active Comparator|L-carnitine group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine
11049256|NCT04434404|Active Comparator|Silymarin group|25 patients received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin140 mg
11049257|NCT04434391||QF-PCR for GBS screening|QF-PCR for vaginal-rectal samples in pregnant women
11049258|NCT04434378|Placebo Comparator|Placebo|Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
11049259|NCT04434378|Experimental|Interventional|Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.
11049260|NCT04434365|Experimental|Berberine+standard therapy Arm|In the Berberine Arm, patients will receive berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
11049261|NCT04434365|Active Comparator|Standard therapy Arm|In the Control Arm, patients will receive standard treatment, including aspirin (100mg/day), clopidogrel (75mg/day), statins, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, beta-blockers, and/or antidiabetic therapy (including insulin or oral medication) was decided on an individual basis by the attending physician for 12±1 weeks.
11049262|NCT04434352|Active Comparator|Baseline Erectile Dysfunction|The first arm of the study will be those men with erectile dysfunction as defined by IIEF score. These men will either have PDE5i refractory or responsive erectile dysfunction. Subjects will receive either Sham treatment (no ultrasound energy delivered via a Sham probe) or LiSWT for erectile dysfunction. Follow up will occur at 1 month, 3 months, and 6 months following the end of treatment. Effectiveness will be measured by change in IIEF/SHIM score and EHS score. Each questionnaire is described in the trial description with a higher score indicating improved function.
11049329|NCT04433897||Transdermal estrogen + oral progesteron|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + oral progesteron
11049263|NCT04434352|Active Comparator|Erectile Dysfunction-Penile Rehabilitation|The second population of patients will be those who are planning to undergo treatment for prostate cancer. In a similar manner, men will be randomized to either the Sham or active treatment groups. Men will be treated prior to undergoing definitive treatment for prostate cancer to assess the effectiveness in LiSWT as a means of erectile preservation prior to prostate cancer treatment.
11049264|NCT04434352|Active Comparator|Erectile Dysfunction Post-Prostate Cancer Treatment|The third population of patients will be those who have undergone treatment for prostate cancer. The investigators will compare IIEF scores and EHS scores in men who have undergone prostatectomy or radiation therapy. Again, there will be a sham and treatment group.
11049265|NCT04434339|Experimental|group 1|"ESP block group ,Patients received preoperative US guided ESP block on BOTH sides to be operated upon 30 minutes before being transferred to the OR"
11049266|NCT04434339|Experimental|group 2|"TAB group ,Patients received bilateral lower TAB 30 min before being transferred to the OR"
11049267|NCT04434339|No Intervention|group 3|"the control group, Patients will not receive any block."
11049268|NCT04434326|Experimental|[14C]CM082|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]CM082 to healthy Chinese male subjects
11049269|NCT04434313|Experimental|Delivery of iStride™ device gait treatment using telemedicine|"Treatment with the gait device will be adapted to remote delivery using the telemedicine platform. Participants and caregivers will be guided through an adapted treatment protocol remotely by physical therapists. Training will include platform navigation, device instruction, treatment guidelines, safety precautions, and assessment performance. Understanding will be verified through a caregiver quiz.
~Gait patterns will be monitored before, during, and after treatment using gait sensors and outcome measures. Assessments include the 10-Meter Walk Test, Six Minute Walk Test, Timed Up and Go Test, Geriatric Depression Scale, Activities-Specific Balance Confidence Scale, and Stroke Impact Scale-16. Treatment will consist of 12 sessions of walking on the device for a goal of 30 minutes per session. Assessments will be repeated one-week, one-month, three-months, six-months, and 12-months after treatment. Feasibility and safety of the delivery method will be measured throughout the trial."
11049270|NCT04434300|Other|Dapto SC-IV|"First stage :
~Subcutaneous injection of daptomycin 10mg/kg
~Subcutaneous injection of placebo (physiological serum)
~Second stage :
~- Intravenous injection of daptomycin 10mg/kg"
11049271|NCT04434300|Other|Dapto IV-SC|"First stage :
~- Intravenous injection of daptomycin 10mg/kg
~Second stage :
~Subcutaneous injection of daptomycin 10mg/kg
~Subcutaneous injection of placebo (physiological serum)"
11049272|NCT04434274||Group A, MPFF-group|MPFF [Detralex®, Servier, France] 1,000 mg OD for 30 days in the postoperative period.
11049273|NCT04434274||Group B|No venoactive drug prescribed in the postoperative period.
11049274|NCT04434261||Patients tested for SARS-CoV-2|Patients who underwent the preoperative screening program for SARS-CoV-2
11049275|NCT04434248|Experimental|Favipiravir, lower dose (pilot stage)|1600mg BID on the 1st day followed by 600mg BID for 13 days
11049276|NCT04434248|Experimental|Favipiravir, higher dose (pilot stage)|1800mg BID on the 1st day followed by 800mg BID for 13 days
11049277|NCT04434248|Active Comparator|Standard of care (pilot stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
11049278|NCT04434248|Experimental|Favipiravir, selected dose (pivotal stage)|The dose will be selected based on pilot study results.
11049279|NCT04434248|Active Comparator|Standard of care (pivotal stage)|Based on approved clinical recommendations for treatment of COVID-19 in the Russian Federation (but not Favipiravir). Might include hydroxychloroquine, chloroquine, lopinavir/ritonavir or other recommended schemes.
11049280|NCT04434235||Dynamic cervical stability|"The participant is asked to move the head in 6 directions in a sitting position and 30° leaning backward sitting position; lateral flexion (left / right), flexion, extension, and rotation (left / right). Results are to be taken for each direction and random at each axial load-level (0 kg, 1kg, 2 kg, and 3 kg). In total 24 measurements.
~The duration of all measurement will be 60 minutes."
11049281|NCT04434235||Cervical Stiffness|The participant is asked to move the head in 4 directions; flexion, extension, and rotation (left / right). Joint-Position Error measurements will be executed in neutral sitting position. Additionally, stiffness will be measured in neutral sitting position and neutral sitting position with 45° cervical flexion. All measurements will be performed with 0 kg and 3 kg axal loading. In total 18 measurements.The duration of all measurement will be 60 minutes.
11049282|NCT04434222|Active Comparator|Compressive stockings group|Group receives postoperatively compressive stockings for a period of 6 weeks.
11049283|NCT04434222|No Intervention|Control group|The control group is treated without compressive stockings.
11049284|NCT04434209|Experimental|NephroCheck-guided interventions|
11049285|NCT04434209|Active Comparator|Standard of Care|Standard of Care (SOC) assessment and treatment
11049286|NCT04434196|Experimental|CC-99282 + obinutuzumab|Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
11049287|NCT04434183|Active Comparator|isokinetic exercise|The group (isokinetic exercise group, n = 25) was given isokinetic exercise.
11049288|NCT04434183|Active Comparator|home exercise|The group(home exercise group, n=25) was given home exercise program.
11049289|NCT04434170||Heart failure|outpatients with heart failure with reduced ejection fraction in treatment with sacubitril/valsartan according to guidelines
11049290|NCT04434144||Group A:|Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days
11049291|NCT04434144||Group B|Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.
11049292|NCT04434131|Experimental|Single Arm|The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Vitalant from local and national donors following national blood donation guidelines. All subjects receive the convalescent plasma.
11049293|NCT04434118||Rheumatoid Arthritis with COVID-19|
11049294|NCT04434118||Rheumatoid Arthritis without COVID-19|
11049295|NCT04434105|Experimental|PRP group|patients received ultrasound-guided injection of 2 mL PRP into the affected carpal tunnel.patients will be injected twice with 2 weeks intervals
11049296|NCT04434105|Active Comparator|Steroid group|patients received ultrasound-guided injection of 2 mL steroids (40 mg triamcinolone acetonide). into the affected carpal tunnel. patients will be injected twice with 2 weeks intervals
11049297|NCT04434105|Placebo Comparator|Control group|patients received ultrasound-guided injection of 2 mL saline patients will be injected twice with 2 weeks intervals
11049298|NCT04434092|Experimental|Arm A (Crovalimab)|Participants will receive an initial intravenous (IV) loading dose on Week 1 Day 1, followed by 4 weekly crovalimab subcutaneous (SC) doses on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter, for a total of at least 24 weeks of study treatment.
11049299|NCT04434092|Active Comparator|Arm B (Eculizumab)|Participants will receive initial IV weekly doses for 4 weeks which will be followed by Q2W (every 2 weeks) IV administrations starting on Week 5.
11049300|NCT04434079||Included individuals|Adult patients consecutively admitted to the ICU from June to October 2018 are eligible if expected length of stay is superior to 24 hours and no oral nutritional has been offered.
11049301|NCT04434066|Experimental|Abdominal Morcellation|Abdominal morcellation will occur following completion of the hysterectomy. Route of incision will be either suprapubic or umbilical incision - based on surgeon preferences. All steps and instruments have been standardized for abdominal morcellation.
11049302|NCT04434066|Experimental|Vaginal Morcellation|Vaginal morcellation will occur following completion of the hysterectomy. All steps and instruments have been standardized for vaginal morcellation.
11049303|NCT04434053|Experimental|MIETHKE M.blue®|
11049304|NCT04434053|Active Comparator|MIETHKE proGAV 2.0® (with SA 2.0®)|
11049305|NCT04434040|Experimental|Atezolizumab and Ipatasertib|"Patients will receive the following treatment:
~Atezolizumab and Ipatasertib treatment will continue for 6 cycles (24 total weeks), with evaluations done at 12 and 24 weeks.
~Atezolizumab intravenously (IV) at a pre-determined dose on days 1 and 15 in a 28-day cycle
~Ipatasertib: Oral daily at a pre-determined dose daily on days 1-21, followed by one week off (3 weeks on, 1 week off) in a 28 day cycle (with daily prophylactic loperamide for first cycle)"
11049306|NCT04434014||males from 20 to above 65 y|will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
11049307|NCT04434014||female from 20 to above 65 y|will be sub divided into 4 groups according to age will be sub divided into 4 groups according to age sub group I from 20 - 35 sub group II from 36- 45 sub group III from 46- 65 sub group IV more than 65
11049308|NCT04434001|Experimental|ZEPLAST|"In case of bleeding and:
~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;
~MCF FIBTEM < 8 mm : give Fibrinogen Concentrate 30 mg/kg;
~CT EXTEM > 100 s : give Prothrombin Complex Concentrate 20 mg/kg."
11049309|NCT04434001|Active Comparator|Control|"In case of bleeding and:
~CT INTEM > CT HEPTEM by 25% : give protamine 0.25 mg/kg;
~fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg."
11049310|NCT04433988|Placebo Comparator|Control group|100 patients will receive standard treatment plus placebo
11049311|NCT04433988|Experimental|Pentoxifylline group|100 patients will receive standard treatment plus pentoxifylline 1200 mg/day
11049312|NCT04433975|Experimental|Psychosocial Pain Management (PPMI)|Eight Cognitive Behavioral Therapy-based individual telephone therapy sessions with research study therapist.
11049313|NCT04433975|Active Comparator|Enhanced Usual Care (EUC)|Two individual telephone educational sessions with research study therapist.
11049314|NCT04433962|Active Comparator|conventional rehabilitation group|the conventional rehabilitation group completed hip joint range of motion and muscle strengthening exercises
11049315|NCT04433962|Experimental|conventional rehabilitation + balance training group|The conventional rehabilitation + balance training group completed hip joint range of motion and muscle strengthening exercises and 12 balance exercises.
11049316|NCT04433949|Active Comparator|Arm I (physician choice)|Patients get best supportive care + physician choice of treatment
11049317|NCT04433949|Experimental|Arm II (LDRT)|Patients receive best supportive care + low dose RT (whole lung)
11049318|NCT04433936||Thyroid Gland Dysfunction|Patients with a recent diagnosis of TGD (the study group) were recruited from endocrinology outpatient clinic of Specialized Medical Hospital, Mansoura University. Diagnosis of TGD was based on précised history, clinical examination and laboratory investigations. In order to avoid bias, patients with history of intake of any thyroid-related medications (antithyroid medications or thyroxine replacement), radioactive iodine or thyroidectomy were excluded from the study.
11049319|NCT04433936||Control|fifty age and gender matched healthy subjects without known personal or family history of thyroid disease or any autoimmune diseases were recruited from candidates of refractive surgery referred to the outpatient clinic of Mansoura Ophthalmology Center for pentacam assessment and who were proved to have normal corneal pentacam parameters. They were further examined by the endocrinologist to exclude thyroid dysfunction; this was supported by normal thyroid function profile (serum TSH and free T4) and negative anti-TPO and antithyroglobulin antibodies.
11049320|NCT04433923|Active Comparator|GROUP1|Phototherapy with aluminum foil
11049321|NCT04433923|Placebo Comparator|GROUP2|Phototherapy without aluminum foil
11049322|NCT04433910|Experimental|Convalescent plasma|Convalescent plasma transfusion on day 1, 3 and 5.
11049323|NCT04433910|No Intervention|Best supportive care|Best supportive care, cross over for patients with progressive disease on day 14 with convalescent plasma transfusion on day 15, 17 and 19.
11049324|NCT04433897||Oral estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + IUD
11049325|NCT04433897||Oral estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + hysterectomy.
11049326|NCT04433897||Oral estrogen + oral progesterone|Women who opt to be treated for their postmenopausal symptoms using Oral estrogen + oral progesterone.
11049327|NCT04433897||Transdermal estrogen + IUD|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + IUD.
11049328|NCT04433897||Transdermal estrogen + hysterectomy|Women who opt to be treated for their postmenopausal symptoms using transdermal estrogen + hysterectomy.
11049330|NCT04433897||SERM|Women who opt to be treated for their postmenopausal symptoms using SERM's
11049331|NCT04433897||Aromatase inhibitor|Women who opt to be treated for their postmenopausal symptoms using aromatase inhibitor.
11049332|NCT04433897||Duavive|Women who opt to be treated for their postmenopausal symptoms using duavive.
11049333|NCT04433897||No treatment|Women who opt not to be treated for their postmenopausal symptoms.
11049334|NCT04433884|Experimental|Conventional MAC Laryngoscope|Patients in this group will undergo intubation using conventional macintosh laryngoscope
11049335|NCT04433884|Experimental|C-MAC Video laryngoscope|Patients in this group will undergo intubation using video C-Mac laryngoscope
11049336|NCT04433858|Experimental|Psilocybin|25mg of Psilocybin
11049337|NCT04433845|Experimental|Psilocybin|25mg of Psilocybin
11049338|NCT04433819||Cushing syndrome|Male and female patients diagnosed as Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
11049339|NCT04433819||Controls|Healthy controls matched for age, gender, and body mass index
11049340|NCT04433806|Experimental|Intervention|25 subjects, all referred to community based program for weight loss at ExercisAbilities
11049341|NCT04433793|Experimental|Yoga group|Patients in the yoga group will receive yoga therapy, one hour every week for eight weeks.
11049342|NCT04433793|No Intervention|Waitlist-control group|Patients in the waitlist-control group will receive no intervention at first, but nine weeks after IG, they will get the opportunity to also receive yoga therapy for 8 weeks.
11049343|NCT04433780|Experimental|Delstrigo|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
11049344|NCT04433767|Experimental|Transdermal Nicotine Patch|Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.
11049345|NCT04433754||patients with pancreatic injury|patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
11049346|NCT04433754||patients without pancreatic injury|patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
11049347|NCT04433741|Other|Oxytocin First, then Placebo|Oxytocin administered intravenously for the first half of the study and then will receive intravenous placebo for the second half.
11049348|NCT04433741|Other|Placebo, Then Oxytocin|Placebo administered intravenously for the first half of the study and then will receive intravenous oxytocin for the second half.
11049349|NCT04433728||Adults Phenylketonuric|Adults patients screened in neonatal period for PKU and treated
11049350|NCT04433715||patients with UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
11049351|NCT04433715||patients without UI symptoms|All participants completed all three questionnaires: ICIQ-SF, UDI-6 and IIQ-7.
11049352|NCT04433702|Experimental|Experimental Eye|10 mmHg of negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that only one goggle receives negative pressure.
11049353|NCT04433702|Placebo Comparator|Control Eye|The opposing eye serves as the intrasubject control for each participant. No negative pressure is applied to the periocular microenvironment. This is achieved by programming the Mercury™ Multi-Pressure Dial (MPD) such that the other goggle does not receive negative pressure.
11049354|NCT04433689||Pregnant women|Pregnant woman, age 18 to 38 yo, with uncomplicated singleton pregnancy and no ocular diseases.
11049355|NCT04433676||Patients with surgical procedures|Adult patients undergoing surgical procedures under general or regional anesthesia and with an admission to a recovery unit for the initial postoperative care.
11049356|NCT04433663|Experimental|Mentalization-based Intervention|Participants in the intervention group, received mentalization-based psychotherapy with the developed ECOSA axis. Therapist received mentalization-based supervision.
11049357|NCT04433663|Active Comparator|IPT-Inter Personal Therapy|The control group's participants received IPT - interpersonal psychotherapy that focused on resolving interpersonal problems and symptomatic recovery. The control group's therapist received regular supervision - with no emphasis on mentalization or tool's usage.
11049358|NCT04433650|Experimental|Group 1|"The child will firstly undergo phase A without the digital reporting and communication tool.
~The child will secondly undergo phase B with the digital reporting and communication tool (i.e., A, B)."
11049359|NCT04433650|Experimental|Group 2|"The child will firstly undergo phase B with the digital reporting and communication tool.
~The child will secondly undergo phase A without the digital reporting and communication tool (i.e., B, A)."
11049360|NCT04433637|Experimental|Nutrition Group|Pregnant women in the first experimental group were provided to consume cake and fruit juice 30 minutes before the NST procedure.
11049361|NCT04433637|Experimental|Video Group|The video, which contains information about the developments and changes occurring in the mother and the fetus during pregnancy, was watched for 15-20 minutes during the NST procedure, accompanied by music that provided relaxation.
11049362|NCT04433637|No Intervention|Control Group|No intervention was applied to the pregnant women in the control group.
11049363|NCT04433624|Active Comparator|Group (B)|will receive The bilateral ESP blocks before surgery
11049364|NCT04433624|Active Comparator|Group B MG|will receive bilateral ESP blocks performed by each side) before surgery
11049365|NCT04433611|Experimental|'lidocaine flushing' group|intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy
11049366|NCT04433611|Placebo Comparator|Placebo group|intrauterine infusion of 0.9 % normal saline (placebo group) just prior to HyFoSy.
11049367|NCT04433598|Experimental|Nutrition Education Intervention|the participants the intervention group under went to Nutrition Education Intervention program were received the developed educational materials (pamphlets).
11049368|NCT04433598|No Intervention|Treatment as usual|the participants in the control group were received the usual medical care at their respective Center.The developed educational materials (pamphlets) were distributed at the end of the study.
11049369|NCT04433585|Experimental|LY3471851 High Dose|LY3471851 administered subcutaneously (SC).
11049370|NCT04433585|Experimental|LY3471851 Mid Dose|LY3471851 administered SC.
11049371|NCT04433585|Experimental|LY3471851 Low Dose|LY3471851 administered SC
11049372|NCT04433585|Placebo Comparator|Placebo|Placebo administered SC.
11049373|NCT04433572|Active Comparator|Temsirolimus|Temsirolimus delivered to adventitia and perivascular tissue after primary revascularization
11049374|NCT04433572|Placebo Comparator|Placebo|Saline placebo delivered to adventitia and perivascular tissue after primary revascularization
11049375|NCT04433559|Active Comparator|Group Active Tadalafile|One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
11049376|NCT04433559|Placebo Comparator|Group Placebo|One oral tablet of placebo daily for 14 weeks of treatment.
11049377|NCT04433546|Experimental|High Dose (100 mg) Group|High: Pemziviptadil (PB1046) 100 mg subcutaneous (SC) weekly for 4 weeks or until hospital discharge
11049378|NCT04433546|Experimental|Middle Dose (40 mg) Group|Middle: Pemziviptadil (PB1046) 40 mg SC weekly for 4 weeks or until hospital discharge
11049379|NCT04433546|Placebo Comparator|Low Dose (10 mg) Control Group|Low Control: Pemziviptadil (PB1046) 10 mg SC weekly for 4 weeks or until hospital discharge
11049380|NCT04433533|Active Comparator|Rosuvastatin 20mg (Group 1)|
11049381|NCT04433533|Experimental|Rosuvamibe 10/10mg (Group 2)|
11049382|NCT04433507|Active Comparator|Sleeve Gastrectomy group|
11049383|NCT04433507|Experimental|Sleeve Gastrectomy + Hiatal Hernia repair group|
11049384|NCT04433494|Experimental|TY-302 ; TY-302 combine with Tamoxifen|"TY-302
~Find the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D) of TY-302, given orally.
~Increased dose cohorts from low dose to MTD, starting at 25mg daily.
~TY-302 combine withTamoxifen in dose-escalation stage
~TY-302: RP2D-1to RP2D daily for 28 days of each 28 day cycle.
~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle.
~TY-302 combine withTamoxifen in dose-expansion stage
~TY-302: RP2D daily for 28 days of each 28 day cycle.
~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle."
11049385|NCT04433481|Experimental|DABIGATRAN|150mg BD for 12 months
11049386|NCT04433481|Placebo Comparator|Placebo|Placebo
11049387|NCT04433468|Active Comparator|RIPC|
11049388|NCT04433468|No Intervention|Control|
11049389|NCT04433442||Participants with Moderate to Severe Plaque Psoriasis|Participants will receive risankizumab (prefilled syringe for injection) as prescribed by the physician in routine clinical practice.
11049390|NCT04433429||RYR plus CoQ|333 mg of red yeast rice (RYR, equivalent to 10 mg of Monacolin K) plus 30 mg of Coenzyme Q10 (CoQ10) in a single pill once daily
11049391|NCT04433416||hypertension|After admission, two or more of the three blood pressure measurements under the same period of calm state that met hypertension, and the patient reported that he had a history of hypertension and that the blood pressure reached the standard of hypertension in the previous non-medication state was included in the hypertension group
11049392|NCT04433416||non-hypertension|Patients who denied the history of hypertension and were not taking antihypertensive drugs after admission and had normal blood pressure measurements were included in the non-hypertensive group
11049393|NCT04433390|Experimental|Naloxegol group|naloxégol tablet by oral route
11049394|NCT04433390|Placebo Comparator|Placebo group|inert tablet by oral route
11049395|NCT04433377|Experimental|Suprascapular nerve block group|"Suprascapular nerve block will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the suprascapular fossa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 22 gauge 90-mm injector.
~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
11049396|NCT04433377|Experimental|Subacromial injection group|"Subacromial injection will be performed with a MyLab60 model a high resolution 7-12-MHz linear probe ultrasonography device. After the subacromial bursa will be observed by ultrasonography, a betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) will be injected with an in-plane technique using a 21 gauge 38-mm injector.
~Home exercise: The exercise program consists of passive and active-assistive ROM exercises (3 sets daily, 20 times in each set)."
11049397|NCT04433364||Screening group|"a general population of women giving birth, called screening group included at routine antenatal visits, their partners, and children"
11049398|NCT04433364||COVID-19 group|"group of women testing positive for SARS-CoV-2 or falling ill with COVID-19, called COVID-19 group, their partners, and children"
11049399|NCT04433351|Experimental|SE cohort|Patients in the SE cohort will carry out first the simple rehabilitation protocol (S, 4 weeks) followed by enriched rehabilitation (E, 4 weeks).
11049400|NCT04433351|Experimental|ES cohort|Patients in the ES cohort will carry out first the enriched rehabilitation protocol (E, 4 weeks) followed by simple rehabilitation (S, 4 weeks).
11049401|NCT04433338|Experimental|Intervention group|"Participants in the intervention group will follow a low-calorie diet during 14 days before undergoing surgery. The diet will consist of both meal replacements and regular foods.
~For women, the diet provides ± 900 kcal, 50 grams of carbohydrates, 85 grams of protein, 30 grams of fat and 25 grams of fibres.
~For men, the diet provides ± 1000 kcal, 55 grams of carbohydrates, 100 grams of protein, 30 grams of fat and 30 grams of fibres."
11049402|NCT04433338|No Intervention|Control group|Participants in the control group can eat according to the standard nutritional advices provided by their dietitian. These advices are intended to educate participants on the recommended eating pattern after surgery.
11049403|NCT04433325||Patients transferred|Patients transferred from Paris's Intensive Care Units
11049404|NCT04433325||Patients not transferred|Patients admitted in Intensive Care Units with no transfer from Paris
11049405|NCT04433299||low back pain patients|no intervention
11049406|NCT04433299||controls|no intervention
11049407|NCT04433273|No Intervention|Group A: Healthy control group|Neither placebo nor vestibular stimulation is administered
11049408|NCT04433273|Placebo Comparator|Group B: Placebo control group|Placebo stimulation along with regular treatment
11049409|NCT04433273|Active Comparator|Group C: Intervention group|Electrical vestibular nerve stimulation along with regular treatment
11049410|NCT04433260||Cases|Doctors, nurses and other healthcares ≥ 18 years of age in direct contact with patients potentially infected with COVID-19
11049411|NCT04433260||Internal Control|Healthcare /NHS Administrative staff who are working in the hospital, but not directly in contact with patients potentially infected with COVID-19.
11049412|NCT04433260||Population Control|Non-healthcare/non-NHS academic staff who are not working in the environment where patient exposure is expected.
11049413|NCT04433260||Follow-up cases|Doctors, nurses and other healthcare workers ≥ 18 years of age in direct contact with patients potentially infected with COVID-19 consenting to receive follow-up surveys (n ~ 400)
11049414|NCT04433260||Follow-up controls|Healthcare Administrative staff who are working in the hospital, not at risk of work-related exposure to patients potentially infected with COVID-19 (n~80)
11049415|NCT04433247|Experimental|Peer Led Group Intervention|In the virtual peer-led group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique and discuss the costs of pursuing the thin-ideal ideal. The intervention is 4 sessions long (1-hr each) and is administered by trained peer facilitators who use an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
11049416|NCT04433247|No Intervention|Wait-List Control|Participants will be placed on a wait list for four weeks, an equal span of time of participants in the peer led group intervention. At four weeks, participants will complete their post-test assessment, then receive the intervention.
11049417|NCT04433234|Experimental|DS-5141b 2.0 mg/kg|Participants who will receive DS-5141b 2.0 mg/kg once weekly.
11049418|NCT04433234|Experimental|DS-5141b 6.0 mg/kg|Participants who will receive DS-5141b 6.0 mg/kg once weekly.
11049419|NCT04433221|Experimental|Multiple sarcoma-specific CAR-T cells|Patients who have confirmed surface antigens including GD2, PSMA, Her2, CD276 or other markers
11049420|NCT04433208|Experimental|Cohort 1 (PPI + probiotic)|Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
11049421|NCT04433208|Experimental|Cohort 2 (Complex oligosaccharide + PPI)|Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
11049422|NCT04433208|Experimental|Cohort 3-6 (Complex oligosaccharide + PPI +probiotic)|Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43
11049423|NCT04433195|Active Comparator|Immediate NAA by clinician|Nucleic acid amplification test requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB
11049424|NCT04433195|Experimental|Immediate NAA as intervention|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, but Xpert MTB/RIF is performed as intervention in this study (intervention group)
11049425|NCT04433195|No Intervention|No immediate NAA|Nucleic acid amplification test not requested by clinicians as the initial diagnostic test for the diagnosis of pulmonary TB, and Xpert MTB/RIF is not performed as the initial diagnostic test in this study (control group). Nucleic acid amplification test may be ordered at a later point in time by clinicians as an add-on test after sputum smear microscopy
11049426|NCT04433182|Experimental|Single arm Copa-RB|Induction phase with Copanlisib, Rituximab and Bendamustina. Maintenance phase (for patients who reach at least SD after induction) with Copanlisib in monotherapy.
11049427|NCT04433169|Experimental|Experimental group|ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.
11049428|NCT04433169|Active Comparator|Control group|The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).
11049429|NCT04433156|Experimental|VR-CAP|Rituximab, 375 mg/m2, Intravenous administration on day 0, Bortezomib, 1.3 mg/m2 hypodermic injection on day 1 and 4, combined with regimen: Cyclophosphamide, Epirubicin, and Prednisone: repeated every 3 weeks, up to 6 cycles.
11049430|NCT04433143|Experimental|oral medication|just oral minocycline hydrochloride capsules (100mg/ time, once per day),
11049431|NCT04433143|Experimental|Intense Pulsed Light single filter|Intense pulsed Acne filter
11049432|NCT04433143|Experimental|Intense Pulsed Light two filters|Intense pulsed light Acne filter and another filter (560nm, 590nm or 640nm filter)
11049433|NCT04433117|Other|Control Group|Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
11049434|NCT04433117|Experimental|Test Group|The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
11049435|NCT04433104|Experimental|Treatment (UC-MSC trasnplatation)|1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure
11049436|NCT04433104|Other|control arm|drug therapy according to Vietnamese MOHS procedure
11049437|NCT04433091|Active Comparator|2-HOBA|2-Hydroxybenzylamine(2-HOBA) 250 mg three tabs TID (po) for seven days prior to ablation and 28 days post ablation.
11049438|NCT04433091|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for seven days prior to ablation and 28 days post-ablation
11049439|NCT04433078|Experimental|Doxycycline|Participants receive 100 MG BID for 21 days
11049440|NCT04433078|Placebo Comparator|Placebo|Participants receive Placebo BID for 21 days
11049441|NCT04433065|Experimental|Primary Cohort|Device: Intrepid TTVR System
11049442|NCT04433052|Experimental|Personalised prevention program (PPP)|Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.
11049443|NCT04433052|No Intervention|Usual care (UC)|"Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses.
~Randomized UC patients are invited to site visits twice over a three year period."
11049444|NCT04433013|Experimental|Treatment group|
11049446|NCT04432987|Experimental|Newly Diagnosed Patient Group (n=30)|"I. Dornase Alpha treated group (n=15)
~ii. Control group (n=15)"
11049447|NCT04432987|Experimental|Patient Group Monitored by Mechanical Ventilation (n=30)|"I. Dornase Alpha treated group (n=15)
~ii. Control group (n=15)"
11049448|NCT04432974|Experimental|ACTIVA|ACTIVA closed-loop anesthesia control system
11049449|NCT04432948||Maternal Group|Pregnant women administered into a maternity public hospital in labour (vaginal delivery, caesarean section)
11049450|NCT04432935|Experimental|Bovine Lactoferrin|Intervention group will receive bovine lactoferrin supplementation daily once a day from day 0 of birth to 6 weeks of life.
11049451|NCT04432935|Placebo Comparator|Glucon D|Control group will receive Glucon-D supplementation daily once a day from day 0 of birth to 6 weeks of life.
11049452|NCT04432909||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UroCAD analysis, the result will be compared with cytology and FISH test.
11049453|NCT04432909||Non-cancer participants|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD analysis.
11049454|NCT04432896|Experimental|4 weeks dietary Nickel free|"At the baseline time (T0) the pathological and physiological history and anthropometric data (weight, height, waist circumference, BMI) will be collected. The patients of the intervention group will be given dietetic indications by the reference dietitian, which must be followed for 8 weeks.
~In short, the indications provide for an exclusion period (4 weeks). At the end of this phase (T1) one group of foods per week will be reintroduced on the basis of their nickel content."
11049455|NCT04432896|Experimental|4 weeks reintroduction of Nickel in diet|"The reintroduction will begin with the group of foods with a lower nickel content and will proceed gradually for a period of 4 weeks (T1a, T1b, T1c, T2).
~In order to monitor the trend of gastroenteric symptoms, a diary of symptoms will be administered at baseline time (T0) which must be completed for the duration of the study (T1a, T1b, T1c, T2) and which will be delivered and evaluated by the dietician and the reference clinician."
11049456|NCT04432883|Active Comparator|Experimental: Active cathodal tDCS + Speech-language training|In this arm, 25 patients with stroke induced Aphasia will undergo 15 sessions of active tDCS (x 30 minutes of stimulation) combined with 1 hour simultaneous speech-language training on consecutive weekdays.
11049457|NCT04432883|Sham Comparator|Comparator: Placebo cathodal tDCS + Speech-language training|In this arm, 25 patients with stroke induced Aphasia will undergo 15 sessions of sham tDCS (x 30 minutes sham) combined with 1 hour simultaneous speech-language training on consecutive weekdays..
11049458|NCT04432870||MGH Patients|Patients aged 45-75 who had their screening or surveillance colonoscopy postponed or delayed due to the COVID pandemic at Massachusetts General Hospital
11049459|NCT04432857|Experimental|Ph1a: Urothelial carcinoma of the bladder and NSCLC|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
11049460|NCT04432857|Experimental|Phase 1b: Urothelial carcinoma of the bladder|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
11049461|NCT04432857|Experimental|Phase 1b: Non-Small Cell Lung Cancer (NSCLC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
11049462|NCT04432857|Experimental|Phase 1b: Triple-negative breast cancer (TNBC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
11049463|NCT04432857|Experimental|Phase 1b: Cervical|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
11049464|NCT04432857|Experimental|Phase 1b: Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Patients will receive AN0025 orally once daily (QD); Pembrolizumab, 200mg as an intravenous infusion over 30 minutes every 3 weeks.
11049465|NCT04432831|Experimental|Faricimab PTI|
11049466|NCT04432818|Experimental|Pack Health's digital life coaching (DLC)|Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
11049467|NCT04432805|Experimental|Pregnant women|Pregnant women suspected of COVID-19
11049468|NCT04432792|Experimental|Telehealth Arm|Participants will receive information and counseling via video chat.
11049469|NCT04432779||Women tested positive to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.
~Follow up end at 1 month post delivery."
11049470|NCT04432779||Women tested negative to SARS-CoV-2 during pregnancy|"All women who had a positive nasal swab or a positive serology during pregnancy or at delivery are included.
~No follow up after delivery."
11049471|NCT04432779||Newborns from women tested positive|"Newborns born to mothers who had a positive nasal swab or a positive serology during pregnancy or at delivery and who consented the follow up study.
~Follow up end at 3 years of age."
11049472|NCT04432779||Newborns from women tested negative|"Newborns born to mothers who had no COVID-19 infection during pregnancy or at delivery and who consented the follow up study. These control children will be matched with children from the other group for gestational age and ethnicity.
~Follow up end at 3 years of age."
11049473|NCT04432766|Experimental|Low dose|
11049474|NCT04432766|Experimental|Medium dose|
11049475|NCT04432766|Experimental|High dose|
11049476|NCT04432753|Experimental|Decision aid with incidental findings information|Participants in this arm will view a video decision aid that include information on incidental findings in lung cancer screening.
11049477|NCT04432753|Active Comparator|Decision aid without incidental findings information|Participants in this arm will view a video decision aid that does not include information on incidental findings in lung cancer screening.
11049478|NCT04432740|Active Comparator|Below Arm Cast Group|All the patients were prepared in the supine position at the emergency department. For analgesia, we used the hematoma block technique with 3 cc of 2% prilocaine hydrochloride®. In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, the standard below arm cast was applied. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
11049779|NCT04430920|Active Comparator|Intensive intraoperative blood pressure management|
11049479|NCT04432740|Active Comparator|Reverse Sugar Tong Group|In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, sugar tong splint made of 12 layers of plaster was performed by one person. The reverse sugar tong splint succeeds as a classic sugar tong splint by stabilizing the volar and dorsal aspects of the wrist and forearm, maintaining the same degree of immobilization. The splint fold is located distally at the first web space of the hand, which does not immobilize the elbow. In all the groups, the wrist immobilization position was the same; pronated forearm, 15-20° wrist flexion, ulnar deviation, and care was taken not to immobilize the metacarpophalangeal joints. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
11049480|NCT04432727|Experimental|ACTIVE FT-CC|Text message reminders will be sent if subject does not use the device for 2 consecutive days.
11049481|NCT04432727|Experimental|PASSIVE FT-CC|Text message reminders will not be sent to subjects.
11049482|NCT04432714|Experimental|R2-DA-EPOCH|
11049483|NCT04432701|Active Comparator|group A|children were extubated in a light plane of anesthesia, when they are still asleep or have swallowing reflex.
11049484|NCT04432701|No Intervention|group B|Tracheal extubation was performed when the patient regained consciousness, facial grimace, spontaneous eye opening, and purposeful arm movement.
11049485|NCT04432688||Latuda®|Chinese schizophrenia patients who are receiving Latuda® in the real world
11049486|NCT04432675|Experimental|hydroxyethl starch group|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
11049487|NCT04432675|Active Comparator|The control group|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
11049488|NCT04432662|Active Comparator|Erythropoietin|Administration of Erythropoietin (1000 U/kg) IV once a day x 5 doses along with cooling therapy
11049489|NCT04432662|Active Comparator|Darbepoetin Alpha|Administration of Darbepoetin Alpha (10 mcg/kg) IV single dose given less than 24 hours of age along with cooling therapy
11049490|NCT04432662|No Intervention|Standard of care|Standard of care: Cooling only
11049491|NCT04432649|Experimental|Effectiveness of 4SCAR-276 T cells|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
11049492|NCT04432636|Other|Prospective French population based cohort|"Data collection of environmental factors at the recruitment
~Collection of maternal feces
~Collection of infant feces:
~A food questionnaire completed by the mother the week after delivery, a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year and a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
~A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day
~The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up"
11049493|NCT04432623|Experimental|Low dose|A low dose, 1 mg/kg or 100 mg, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks
11049494|NCT04432623|Experimental|Middle dose|2 mg/kg, up to 200 mg/kg, by mouth once per day, on Monday, Wednesday, and Friday, for 12 weeks
11049495|NCT04432623|Experimental|High dose|5 mg/kg, up to 350 mg/kg, by mouth once per day, on Monday, Wednesday, and Friday, fpr 12 weeks
11049496|NCT04432623|Experimental|Expansion group|The highest and well-tolerated dose, once per day on Monday, Wednesday, and Friday, for 12 weeks
11049497|NCT04432610|Experimental|Bisoprolol first, Nebivolol Second|In this arm, patient will first receive bisoprolol, and after 1 week washout period, nebivolol
11049498|NCT04432610|Experimental|Nebivolol first, Bisoprolol second|In this arm, patient will first receive nebivolol, and after 1 week washout period, bisoprolol
11049499|NCT04432597|Experimental|1/Arm 1A|HPV vaccine at 1x10(11) Viral Particles (VP) (DL1) and at 5x10(11) VP (DL2)
11049500|NCT04432597|Experimental|2/Arm 1B|HPV vaccine at RP2D plus M7824 at 1200 mg
11049501|NCT04432597|Experimental|3/Arm 2A|HPV vaccine at RP2D given as neoadjuvant or induction therapy
11049502|NCT04432597|Experimental|A/Arm 2B|HPV vaccine at RP2D plus M7824 at 1200 mg given as neoadjuvant or induction therapy
11049503|NCT04432584|Experimental|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
11049504|NCT04432584|Active Comparator|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
11049505|NCT04432584|Experimental|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
11049506|NCT04432571|Active Comparator|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC)
11049507|NCT04432571|Experimental|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT)
11049508|NCT04432571|Experimental|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV)
11049509|NCT04432571|Experimental|E-NAV/SOC-OIC|Electronic Navigation/SOC-OIC
11049510|NCT04432571|Experimental|E-NAV/CCT|E-Nav/Conditional cash transfer
11049511|NCT04432571|Experimental|E-NAV/IP-NAV|E-Nav/In-Person Peer Navigation
11049512|NCT04432558||Preoperative anxiety level|
11049513|NCT04432558||Postoperative pain and analgesic consumption|
11049514|NCT04432532||Neuroendocrine Tumor|
11049515|NCT04432532||Adrenal Tumor|
11049516|NCT04432519|Experimental|Group CA|Customized healing abutment inserted in immediate implant placement.
11049517|NCT04432519|Active Comparator|Group CM|Resorbable Collagen Membrane for socket closure in immediate implant placement.
11049518|NCT04432506|Experimental|Treatment (cyclophosphamide, fludarabine, axi-cel, anakinra)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra SC on days 0-6 in the absence of disease progression or unacceptable toxicity.
11049519|NCT04432493|Experimental|Active TMS|Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses
11049520|NCT04432493|Placebo Comparator|Sham TMS|Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation
11049521|NCT04432480||Children|0-15 years old children undergoing surgery under general anesthesia
11049522|NCT04432467|Experimental|mesenchymal stem cells|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells
11049523|NCT04432467|Active Comparator|control|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment
11049524|NCT04432454|Experimental|Treatment|Women who have locally advanced or metastatic ER+/HER2- breast cancer and disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation
11049525|NCT04432441|Active Comparator|Scapular flexion exercise|
11049526|NCT04432441|Active Comparator|Scapular flexion exercise + Electrostimulation|
11049527|NCT04432428|Experimental|sufentanil sublingual tablet|sufentanil sublingual 15µg tablets
11049528|NCT04432415|Experimental|Group Silver Diamine Fluoride|Participants receive Annual applications of 38% SDF solution and semestral applications of artificial saliva and a personalized dental health education program.
11049529|NCT04432415|Experimental|Group Sodium Fluoride Varnish|Participants receive semestral applications of Sodium Varnish Fluoride and a personalized dental health education program.
11049530|NCT04432415|Placebo Comparator|Placebo|Participants receive semestral apllications of artificial saliva and a personalized dental health education program.
11049531|NCT04432402|Experimental|Lenalidomide in Combination With R-GemOx|Lenalidomide 10mg、15mg、20mg、25mg qd PO d1-7 Rituximab 375mg/m2 ivd d0 Gemcitabine 1g/m2 ivd d1 Oxaliplatin 100mg/m2 ivd d1 every14 days as a cycle
11049532|NCT04432389|Experimental|ALLOB|Single injection of ALLOB at fracture site (4 ml)
11049533|NCT04432389|Placebo Comparator|placebo|Single injection of Placebo at fracture site (4 ml)
11049534|NCT04432376|Active Comparator|Active treatment arm|Treatment with miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
11049535|NCT04432376|Placebo Comparator|Placebo treatment arm|Treatment with the vehicle oil, placebo, 5 drops into each ear twice daily for 14 consecutive days
11049536|NCT04432376|Other|Open-label treatment arm|Application of miconazole 2% oil, 5 drops into each ear twice daily for 14 consecutive days
11049537|NCT04432363|Active Comparator|M1 stimulation|A 20 minutes 1mA direct current stimulation over left M1.
11049538|NCT04432363|Active Comparator|M1+DLPFC stimulation|A 20 minutes 1mA direct current stimulation over left M1 and 1mA direct current stimulation over left DLPFC.
11049539|NCT04432363|Sham Comparator|Sham stimulation|A 20 minutes sham stimulation where the device only is working first 30s and last 30s of the intervention and have a 10 seconds fade out in intensity at each ramp.
11049540|NCT04432350||Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
11049541|NCT04432350||Not Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were not treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
11049542|NCT04432337|Experimental|Type 2 diabetes patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for TD2 patients after cardiac surgery with extracorporeal circulation .
11049543|NCT04432337|Active Comparator|Non-diabetic type 2 patients|The variation in the plasma concentration of the two pro-inflammatory cytokines IL-1β and IL18, between a baseline level measured the day before the operating room (D-1) and 24 hours (D1) for non-diabetic type 2 patients after cardiac surgery with extracorporeal circulation
11049544|NCT04432324|Experimental|Intravenous Immune Globulin + Standard Medical Treatment|Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
11049545|NCT04432324|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29
11049546|NCT04432311|Experimental|Binge Focused Therapy (BFT)|Guided self-help - Three online group sessions, homework, and self-guided check-ins to monitor continued progress and/or signs of relapse.
11049547|NCT04432311|Active Comparator|CBT Unguided Self Help (CBT USH)|Pure self-help - The use of the book Overcoming Binge Eating and its associated homework.
11049548|NCT04432298|Experimental|Pamrevlumab|
11049549|NCT04432298|Experimental|Placebo|
11049550|NCT04432285||Deep Brain Stimulation (GPi-DBS)|Patients with cervical dystonia (CD) who were operated at Oslo University Hospital between June 2004 and December 2017 with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years.
11049551|NCT04432285||Botulinum toxin treatment|CD patients who for a minimum of 3 years have received treatment with botulinum neurotoxin (BoNT) injections at regular intervals (minimum 12 injection cycles) and still are receiving them (Age- and gender matched to the GPi-DBS group)
11049552|NCT04432272|Experimental|Group A|Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain oxygen saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
11049553|NCT04432272|Experimental|Group B|Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
11049554|NCT04432259|Experimental|Arm B: Oral Dexamethasone|Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days
11049555|NCT04432259|Placebo Comparator|Arm A: Placebo|Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days
11049556|NCT04432246|Experimental|bilateral SMA|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
11049557|NCT04432233|Experimental|Intravenous therapy|Subjected enrolled will receive (a) a 10-day intravenous triple therapy containing esomeprazole 40 mg thrice a day, metronidazole 500 mg twice a day and levofloxacin 500 mg once a day and (b) esomeprazole 20 mg twice a day taken orally for 8 weeks.
11049558|NCT04432220|Experimental|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
11049559|NCT04432220|No Intervention|Nonanticoagulation group|Standard treatment except anticoagulant for 2 years
11049560|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 1|10 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
11049561|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 2|50 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
11049562|NCT04432207|Experimental|Dose Escalation: Monotherapy Cohort 3|100 μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection
11049563|NCT04432207|Experimental|Dose Escalation: Combination|In Part 1b combination dose escalation, participants receive MU-201 in combination with SOC treatment for NSCLC with the first dose cohort starting at one dose level below the monotherapy optimal biological dose (mOBD-1) established in part 1a monotherapy dose escalation.
11049564|NCT04432207|Experimental|Dose Expansion: Combination|In Part 2 dose expansion, participants will receive IMU-201 in combination with SOC treatment for NSCLC at the combination optimal biological dose determined in Part 1b combination dose escalation.
11049565|NCT04432194|No Intervention|Control group|The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
11049566|NCT04432194|Active Comparator|Pulmonary Rehabilitation Group|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
11049567|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus HMB (4g)|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
11049568|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus citrulline (3g)|Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
11049569|NCT04432181||Group 1, astigmatic patients with amblyopia|astigmatic children with amblyopia
11049570|NCT04432181||Group 2, astigmatic patients without amblyopia|astigmatic children without amblyopia
11049571|NCT04432168|Experimental|Fetoscopic Laser Surgery|fetoscopic laser coagulation of the vascular anastomoses at the placental surface
11049572|NCT04432168|Other|Standard Treatment|Expectant management, IUT (with or without PET), preterm delivery
11049573|NCT04432155|Experimental|NBTX-001|Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
11049574|NCT04432155|Placebo Comparator|Placebo|Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.
11049575|NCT04432142||Proton|Patients receiving proton therapy
11049576|NCT04432142||Photon|Patients receiving photon therapy in 4 fractions or less
11049577|NCT04432129|Experimental|IBBIS II|Integrated Mental Health Care and Vocational Rehabilitation
11049578|NCT04432129|Active Comparator|Service As Usual|Standard vocational rehabilitation and treatment
11049579|NCT04432116|Experimental|virtual reality 1|the subject is in a virtual room and is asked to emit a retrospective time duration judgement at the end of the session
11049580|NCT04432116|Experimental|virtual reality 2|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible while the background of the virtual environment is a starfield with standard speed vs. self-determined speed vs. static stars
11049581|NCT04432116|Experimental|virtual reality 3|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible.Asynchronous distracters vs. synchronous distracters, vs no distracters are displayed while the subjects wait for the target
11049582|NCT04432103|Experimental|Severe COVID-19 pneumonia|Hospitalized patients with SARS-CoV 2 severe infection will receive an anti SARS-CoV 2 Convalescent Plasma
11049583|NCT04432103|Experimental|Critical COVID- 19 pneumonia|Hospitalized patients with SARS-CoV 2 critical infection will receive an anti SARS-CoV 2 Convalescent Plasma
11049584|NCT04432090|Active Comparator|Volunteers with Type 1 diabetes|
11049585|NCT04432090|Active Comparator|Healthy Volunteers|
11049586|NCT04432077|Experimental|Treatment|All participants receive the DINOSAUR intervention
11049587|NCT04432064|Experimental|Phase 3 Active TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation. Participants will receive stimulation for 60 minutes on one day.
11049588|NCT04432064|Sham Comparator|Phase 3 Sham TI-NDBS|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds.
11049589|NCT04432064|Active Comparator|Phase 4 Traditional tDCS|Participants assigned to this condition will receive traditional transcranial direct current stimulation for 60 minutes for 5 days.
11062565|NCT04339543|Other|Longitudinal assessment|
11049590|NCT04432064|Experimental|Phase 4 TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation for 60 minutes for 5 days and will be compared to sham stimulation and tDCS.
11049591|NCT04432064|Sham Comparator|Phase 4 Sham stimulation|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds. Participants will be in the scanner for 60 minutes for 5 days. This will be used as the control condition and compared with TI-NDBS and tDCS.
11049592|NCT04432051|Placebo Comparator|GRUP Control|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis.
11049593|NCT04432051|Active Comparator|GRUP Ultrasonography|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis. However, the lung of the patient will be evaluated by ultrasound and the position to use the lung capacity most appropriately will be given.
11049594|NCT04432038||General population of adults from about 30 countries|Data will be collected in general population of adults from about 30 countries. Questionnaires contain also questions about the occurrence of chronic illnesses, being a professional athlete, etc. to control all such aspects.
11049595|NCT04432038||General population of adults from Poland|
11049596|NCT04432038||General population of adults from Germany|
11049597|NCT04432038||General population of adults from China|
11049598|NCT04432038||General population of adults from Vietnam|
11049599|NCT04432038||General population of adults from Spain|
11049600|NCT04432038||General population of adults from Brazil|
11049601|NCT04432038||General population of adults from Croatia|
11049602|NCT04432038||General population of adults from Ethiopia|
11049603|NCT04432038||General population of adults from France|
11049604|NCT04432038||General population of adults from Indonesia|
11049605|NCT04432038||General population of adults from Iran|
11049606|NCT04432038||General population of adults from Sri Lanka|
11049607|NCT04432038||General population of adults from USA|
11049608|NCT04432038||General population of adults from Italy|
11049609|NCT04432038||General population of adults from South Africa|
11049610|NCT04432038||General population of adults from Portugal|
11049611|NCT04432038||General population of adults from Norway|
11049612|NCT04432038||General population of adults from Lithuania|
11049613|NCT04432038||General population of adults from Romania|
11049614|NCT04432038||General population of adults from Pakistan|
11049615|NCT04432038||General population of adults from Ukraine|
11049616|NCT04432038||General population of adults from India|
11049617|NCT04432038||General population of adults from Japan|
11049618|NCT04432038||General population of adults from Russia|
11049619|NCT04432038||General population of adults from Bangladesh|
11049620|NCT04432038||General population of adults from Nigeria|
11049621|NCT04432025|Active Comparator|Control|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner
11049622|NCT04432025|Experimental|Intervention|Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids.
11049623|NCT04432012|Experimental|arm-A Intra-venous dexamethasone|9 mg of Intra-venous dexamethasone
11049624|NCT04432012|Experimental|arm-B intra-articular dexamethasone|9 mg of intra-articular dexamethasone
11049625|NCT04432012|No Intervention|arm-C routine|No steroid supplementation or other drugs will be added to the routinely performed anaesthesia protocol in the control group
11049626|NCT04431999|Experimental|Whole blood group|Damage control resuscitation for trauma care using whole blood.
11049627|NCT04431999|Active Comparator|Fractionated blood products group|Damage control resuscitation for trauma care using component therapy.
11049628|NCT04431986||NuAge participants|All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes
11049629|NCT04431973|Experimental|Shoulder prothesis|Evaluate the performance of the Medacta Shoulder System total reverse shoulder prothesis
11049630|NCT04431960|Active Comparator|low-BC Group|consume: 1) one tablet containing 450 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
11049631|NCT04431960|Active Comparator|high-BC Group|consume: 1) two capsules containing 450 mg BC extract per tablet (total 900 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
11049632|NCT04431960|Placebo Comparator|Control Group|consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
11049633|NCT04431947||Youth|Youth, between the ages of 2 and 17, with type 1 diabetes
11049634|NCT04431947||Parent|Parents of youth with type 1 diabetes
11049635|NCT04431934|No Intervention|CONTROL|No intervention arm
11049636|NCT04431934|Active Comparator|PROBIOTIC|
11049637|NCT04431934|Active Comparator|FMT REGIMEN|
11049638|NCT04431921||Lung cancer patients|Lung cancer survivors who had stable conditions and routine follow-up at Hacettepe University Oncology Hospital
11049639|NCT04431921||Healthy subjects|No health problems related or affect outcome measure parameters examined in this study.
11049640|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
11049641|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
11049642|NCT04431895|Experimental|tofacitinib 5mg twice a day|
11049643|NCT04431882|Experimental|optic nerve sheath fenestration|Leukemic patients mainly those suffering from acute lymphoblastic leukemia.
11049718|NCT04431349||ticagrelor|The patient with acute myocardial infarction received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
11049644|NCT04431869||Mothers that contract SARS-CoV-2 during pregnancy|"To evaluate evidence for in-utero vascular accidents that may manifest as intestinal atresias and limb abnormalities in the first 30 days of life as well as rates of preterm labor, fetal growth restriction and spontaneous abortions in pregnant females that contract the SARS-CoV-2 virus during gestation.
~A multidisciplinary approach in conjunction with maternal fetal medicine (MFM), neonatology, and pathology will identify, and recruit infants whom were exposed to COVID-19 while in-utereo. This project will run in parallel with the institution's COVID-19 in Pregnancy Biobank that intends to obtain needed epidemiological and clinical data linked to biosamples to provide insight into SARS-CoV-2 in pregnant women and their infants. This study will request access to enrolled women infected during gestation and their neonates to assess for the conditions suggestive of in-utero vascular accidents such as intestinal atresias or limb anomalies."
11049645|NCT04431869||Infants noted to have intestinal atresias or limb anomalies|"To evaluate children identified in the neonatal intensive care unit (NICU) as having evidence of intestinal atresias or limb anomalies for potential asymptomatic carriers of COVID-19 that could have contracted the disease during the pregnancy.
~Mothers of children identified will undergo SARS-CoV-2 antibody testing to identify the possibility of asymptomatic carriers which may have occurred during the pregnancy."
11049646|NCT04431856|Experimental|Immediate Condition|Participants in the Immediate Condition group will receive a total of 4 sessions of Unified Protocol for COVID-19 Parenting Stress (UP-COVID) intervention
11049647|NCT04431856|Active Comparator|Delayed Condition|Participants in the Delayed Condition group will receive the Self Help Guide (SHG) by the National Child Traumatic Stress Network (NCTSN). They will then receive the UP-COVID intervention following their week 6 assessment
11049648|NCT04431843|Experimental|Spirulina maxima extract|Spirulina maxima extract for 1.5 g/day
11049649|NCT04431843|Placebo Comparator|Placebo|Spirulina maxima extract for 0 g/day
11049650|NCT04431830|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery) for managing pain.
11049651|NCT04431830|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
11049652|NCT04431817||Left transtibial|Left below knee amputation- 25
11049653|NCT04431817||Right transtibial|Right below knee amputation- 25
11049654|NCT04431817||Left transfemoral|Left above knee amputation- 25
11049655|NCT04431817||Right transfemoral|Right above knee amputation- 25
11049656|NCT04431817||Provider|Provider- 15
11049657|NCT04431791||Regorafenib|
11049658|NCT04431791||Fruquintinib|
11049659|NCT04431778|Experimental|Ethosuximide|Patients with chronic peripheral neuropathic pain
11049660|NCT04431778|Placebo Comparator|Placebo|Patients with chronic peripheral neuropathic pain
11049661|NCT04431765|Active Comparator|Patient for Eye Movement desensitization Reprocessing therapy|Patient with post-traumatic Stress Disorder will receive Eye Movement Desensitization reprocessing therapy
11049662|NCT04431765|Placebo Comparator|patients for Trauma-Centred Cognitive and Behavioural Therapy|Patients with post-traumatic Stress Disorder will receive Trauma-Centred Cognitive and Behavioural Therapy
11049663|NCT04431752||Healthy Volunteer|10 healthy volunteers to undergo radiographic examinations of the knee joint.
11049664|NCT04431752||Kellgren-Laurence grading I Osteoarthritis Knee|10 patients in Kellgren-Laurence grading I to undergo radiographic examinations of the knee joint.
11049665|NCT04431752||Kellgren-Laurence grading II Osteoarthritis Knee|10 patients in Kellgren-Laurence grading II to undergo radiographic examinations of the knee joint.
11049666|NCT04431752||Kellgren-Laurence grading III Osteoarthritis Knee|10 patients in Kellgren-Laurence grading III to undergo radiographic examinations of the knee joint.
11049667|NCT04431752||Kellgren-Laurence grading IV Osteoarthritis Knee|10 patients in Kellgren-Laurence grading IV to undergo radiographic examinations of the knee joint.
11049668|NCT04431726|Experimental|Emicizumab|
11049669|NCT04431713|Experimental|Exenatide|
11049670|NCT04431713|No Intervention|Standard of care|
11049671|NCT04431700|Experimental|Anti-inflammatory whole food|Included food items will include a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., curcumin), fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be permitted or encouraged. Recommended portions of complex carbohydrates (50% - 60%) and lean proteins (20% - 30%) will form the basis of weight-based caloric needs. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Vegetables with high insoluble fiber content will be cooked instead of eaten raw.
11049672|NCT04431700|Active Comparator|Regular Diet|Patients in the control diet arm will be counseled to continue their regular diets and focus on recording all food intake.
11049673|NCT04431687|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.
~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
11049674|NCT04431687|Experimental|Sequence 2|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).
~Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days"
11049675|NCT04431687|Experimental|Sequence 3|"Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).
~Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets)."
11049676|NCT04431687|Experimental|Sequence 4|"Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).
~Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets)."
11049677|NCT04431674|Experimental|MRg-FUS MB Treatment|Patients with locally advanced breast cancer (LABC) and chest wall tumours will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
11049678|NCT04431648|Experimental|MRg-FUS MB Treatment|Patients with head and neck cancer will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
11049679|NCT04431635|Experimental|Arm A: Copanlisib, Nivolumab & Rituximab|Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
11049680|NCT04431622|Experimental|Effects of hearing aid algorithms|Neural processing and cognitive effort will be assessed in individuals who listen to stimuli generated with linear and fast-acting compression hearing aid algorithms and with actual hearing aids.
11049681|NCT04431609||CAROtid WEB associated with cerebral infarction|french multicentric cohort that collects retrospectively and prospectively purely observational data on patients with cerebral infarction associated with a carotid web. Diagnostic, therapeutic or follow-up strategies will be at the discretion of the Stroke Unit taking care of the patient.
11049682|NCT04431596|Active Comparator|Cooling|Participants will be actively cooled during rest breaks.
11049683|NCT04431596|No Intervention|No Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
11049684|NCT04431583||2008-2012 Participants|Participants who underwent bariatric surgery between 2008 and 2012 (inclusive).
11049685|NCT04431583||2013-2016 Participants|Participants who underwent bariatric surgery between 2013 and 2016 (inclusive).
11049686|NCT04431583||2017- 2018 Participants|Participants who underwent bariatric surgery between 2017 and 2018 (inclusive).
11049687|NCT04431570|Experimental|rTMS over M1 region|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is M1 region.
11049688|NCT04431570|Experimental|rTMS over supplementary motor area (SMA)|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is SMA region.
11049689|NCT04431570|Sham Comparator|sham stimulation|
11049690|NCT04431531|Active Comparator|yogatherapy-EMDR|one of the two groups will have yogatherapy treatment and Eye movement desensibilization reprocessing (EMDR)
11049691|NCT04431531|Active Comparator|waiting list and EMDR|The other group will have Eye movement desensibilization reprocessing
11049692|NCT04431518|Experimental|Hemodialysis Group|Receipt of JULUCA one pill per day up to 14 days
11049693|NCT04431518|Active Comparator|Normal Renal Function Group|Receipt of JULUCA one pill per day up to 14 days
11049694|NCT04431492||coronary artery bypass|
11049695|NCT04431492||thoracic surgery|
11049696|NCT04431479||Observational (questionnaire, biospecimen, chart review)|Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.
11049697|NCT04431466|Active Comparator|Standard treatment|Standard treatment for COVID-19
11049698|NCT04431466|Experimental|Ivermectin lower single-dose|Ivermectin 100mcg / kg PO single dose
11049699|NCT04431466|Experimental|Ivermectin lower repeated-dose|100mcg / kg PO on the first day, followed by 100mcg / kg PO after 72h
11049700|NCT04431466|Experimental|Ivermectin higher single-dose|Ivermectin 200mcg / kg PO single dose
11049701|NCT04431466|Experimental|Ivermectin higher repeated-dose|200mcg / kg PO on the first day, followed by 200mcg / kg PO after 72h
11049702|NCT04431453|Experimental|Remdesivir (RDV)|"Participants will receive RDV up to 10 days. The RDV dose administered in each cohort is as follows:
~Cohort 1: intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg daily
~Cohorts 2-5: IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily
~Cohorts 6-7: IV RDV at a dose to be determined based on RDV exposure data from Cohort 5
~Cohort 8: IV RDV 200 mg on Day 1 followed by IV RDV 100 mg daily"
11049703|NCT04431440||Methicillin resistant staphylococcus aureus|
11049704|NCT04431440||vancomycin resistent staphylococcus aureus|
11049705|NCT04431427|Active Comparator|Partially Covered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
11049706|NCT04431427|Active Comparator|Uncovered Metal Stent Arm|The patients who had extra-hepatic malignant biliary obstruction will be enrolled in our study. Enrolled patient will be randomized to two group (uncovered metallic stent vs. partially covered metallic stent). After metallic biliary stent insertion, enrolled patients will be followed until bilirubin values will be under 2 mg/dl.
11049707|NCT04431414||Group 1|Persons that are positive for SARS-CoV-2 and are asymptomatic
11049708|NCT04431414||Group 2|Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)
11049709|NCT04431414||Group 3|Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients
11049710|NCT04431401|Experimental|rTMS treatment group|The participants will be divided into the rTMS treatment group and the sham treatment group by means of randomized methods.The protocol of the treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
11049711|NCT04431401|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
11049712|NCT04431388||SIPB (block)|Patients undergone nephectomy and who received SIPB as analgesia
11049713|NCT04431388||QL block|Patients undergone nephectomy and who received QL as analgesia
11049714|NCT04431375|Experimental|plasma Exchange+Tenofovir+FMT|Subjects will receive Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir [antiviral] 300mg PO once a day .
11049715|NCT04431375|Active Comparator|Tenofovir|TabletTenofovir [antiviral] 300mg per oral once a day
11049716|NCT04431362|No Intervention|Baseline|Participants will not listen to music for 5 to 15 days based on the baseline duration they were assigned.
11049717|NCT04431362|Experimental|Intervention|Participants will listen to music for 3 weeks.
11062952|NCT04336449|Experimental|Cohort 1 100 mg eptinezumab|
11049719|NCT04431349||clopidogrel|The patient with acute myocardial infarction received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
11049720|NCT04431336||younger aortic dissection or aneurysm patients|this is an observation cohort study about younger aortic dissection or aneurysm patients without intervention.
11049721|NCT04431323|Experimental|biopsychosocial intervention|"Young adults with MS will receive an intervention (group setting) composed of physical activities (duration: 10-12 weeks; either dancing or walking) and psychosocial interventions (6-8 encounters).
~[The intervention will start as soon as 8-10 patients will have been enrolled. A waiting list will be then created and patients contacted when the subsequent group starts. This waiting list does not serve as control group.
~One or more groups, respectively for the psychological intervention and the physical activities, may start at the same time but on different days, considering also the results of the co-creation phase.]"
11049722|NCT04431310||Serial seroconversion measurements in hospital employees|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
11049723|NCT04431297|Other|Health Care Workers|Voluntary participation in the virtual presentations
11049724|NCT04431284||Obese patients with binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
11049725|NCT04431284||Obese patients without binge eating disorders|Severely obese patients (with or without binge eating disorders, Binge Eating Sclae >= 16) who have been hospitalized for obesity assessment before the start of the lockdown in the Endocrinology department of the Lyon Hospital
11049726|NCT04431271||Robot-assisted laparoscopy|Patients who underwent robot-assisted groin hernia repair
11049727|NCT04431271||Conventional laparoscopy|Patients who underwent conventional laparoscopic groin hernia repair
11049728|NCT04431258|Experimental|Arm A) ABTL0812 + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:
~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion, followed by
~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion, followed by
~fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
~ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease."
11049729|NCT04431258|Experimental|Arm B) PLACEBO + FOLFIRINOX|"FOLFIRINOX will be dosed according to the standard following regimen:
~oxaliplatin 85 mg/m2, administered as 2-hour iv infusion, followed by
~irinotecan 180 mg/m2, administered as 1.5-hour iv infusion, followed by
~fluorouracil 2400 mg/m2, administered as 46-hour iv infusion every 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
~Placebo will be administered at the same volume than ABTL0812 in arm A) FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued."
11049730|NCT04431245||Stop antiviral|HBeAg-negative non-cirrhotic CHB patients on long-term NA ≥3 years will be identified. Only those who have undetectable serum HBV DNA by the conventional assay (Cobas Taqman, Roche Diagnostics, Branchburg, NJ) which has a lower limit of detection (LLOD) of 10 IU/mL will be recruited. CHB patients were treated with potent oral NA (i.e. tenofovir or entecavir). All recruited patients will have written informed consent for participation of study. Patients with HCC, cirrhosis, history of liver transplantation, or on immunosuppressants, will be excluded.
11049731|NCT04431232|Experimental|Band Ligation|Band ligation of gastric body for weight loss
11049732|NCT04431219|Experimental|Ascending Dose Cohort|"The AD cohort will be first recruited and will include 5 patients: 1 patient per dose, sequentially recruited, the recruitment of the next dose level patient will be assessed by Data Safety Monitoring Board :
~Patient 1: 0.6 mg/Kg/day
~Patient 2: 1 mg/Kg/day
~Patient 3: 3 mg/Kg/day
~Patient 4: 6 mg/Kg/day
~Patient 5: 8 mg/Kg/day
~Once the 5 AD patients complete LIS1 treatment, the sponsor and the DSMB will rule on the LIS1 dose to obtain an optimal CD3+ cells depletion, with a good safety profile and will determine the therapeutic dose."
11049733|NCT04431219|Experimental|Therapeutic Dose Cohort|The TD cohort will be recruited once the therapeutic dose is defined. This cohort will be divided in 2 subgroups of respectively 2 and 3 patients sequentially recruited. The DSMB will evaluate the accuracy of the chosen therapeutic dose safety profile after the first two patients' treatment completion and will allow the recruitment of the 3 patients of the second subgroup at the same dose, or adapt LIS1 dose for the next three patients.
11049734|NCT04431206|Experimental|Oxytocin|Oxytocin administered by IV infusion
11049735|NCT04431193|Experimental|Oxytocin 4 picogram/millilitre|Oxytocin infused to maintain serum concentration of 4 picogram/millilitre
11049736|NCT04431193|Experimental|Oxytocin 16 picogram/millilitre|Oxytocin infused to maintain serum concentration of 16 picogram/millilitre
11049737|NCT04431193|Experimental|Oxytocin 64 picogram/millilitre|Oxytocin infused to maintain serum concentration of 64 picogram/millilitre
11049738|NCT04431193|Experimental|Oxytocin 256 picogram/millilitre|Oxytocin infused to maintain serum concentration of 256 picogram/millilitre
11049739|NCT04431180|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors'life saving donation during 2019-nCoV epidemic.
11049740|NCT04431180|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
11049741|NCT04431180|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
11049742|NCT04431180|Placebo Comparator|SMS with blood donor day greeting|SMS content in this group will be about SMS with blood donor day greeting.
11049743|NCT04431167|Experimental|Living well with Lupus Group|A newly developed intervention focused on promoting lifestyle change through recommendations for structured and unstructured physical activity and healthy eating.
11049744|NCT04431167|No Intervention|Usual Care Group|This group will receive all regular medical care and advice healthy
11049777|NCT04430933|Experimental|NC318 + Nab-paclitaxel/carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Nab-paclitaxel/carboplatin
11049778|NCT04430933|Experimental|NC318 + Docetaxel|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with Docetaxel
11049745|NCT04431154|Experimental|Experimental: Usual care|Participants randomized to this arm will receive the standard of care (SOC) following the STAR program protocol in various sites in Johannesburg. This will include a HIV self-screen test kit and the standard linkage officer follow-up call and an invitation to i) participate in study visit 1 to have their positive HIVSS result confirmed and complete blood collection for viral load PCR testing and to ii) participate in study visit 2 at 6 months for Viral Load PCR.
11049746|NCT04431154|Experimental|Experimental: Incentives and linkage promotion|Participants randomized to this arm will receive the same standard HIV self-screen test kit and linkage officer follow-up call including the invitation to i) participate in study visit 1 and ii) study visit 2. In addition, they will receive a financial incentive if they complete a confirmatory HIV test at visit 1 and if they demonstrate viral suppression at study visit 2, approximately 6 months after positive HIVSS result. They will also receive monthly reminders and incentives to pick up HIV medication.
11049747|NCT04431141|Experimental|Teneligliptin|
11049748|NCT04431141|Experimental|Empagliflozin|
11049749|NCT04431141|Experimental|Teneligliptin and Empagliflozin|
11049750|NCT04431128||study group|Adenoid hypertrophy
11049751|NCT04431128||Control group|UTI, GE, vomiting, diarrhea
11049752|NCT04431115||Stakeholders|"Academic experts, Politicians and officials of state ministries of health and education and teachers.
~Interviews will be conducted for academic experts, politicians and officials of state ministries of health and education.
~Headteachers and physical education teachers will be administered questionnaires."
11049753|NCT04431115||Parents|Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
11049754|NCT04431115||Primary school children aged 6-12 yrs.|"A cross sectional survey of the biographical data, socio economic status, physical activity level through appropriate questionnaires will be done.
~A pedometer will be attached to the waist of each of the participants for a consecutive 7 days to objectively determine the level of their physical activity."
11049755|NCT04431102|Experimental|PILATES METHOD|"It was intended the Pilates program were low supervision and easily realizable by all patients, which implied flexibility in the schedule. In this sense the sessions of Pilates was adjusted to these assumptions and the Pilates monitor offered several schedules on diferent days of the week.
~The pregnant women assigned to the intervention group were supervised by the midwifery of reference and trained by a Pilates monitor who explained the training program. The women received eight sessions of Pilates, given with a frequency of two classes per week and one hour of duration during a period of four weeks. The exercises for each session were determined beforehand. In addition, the participants maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.
~The therapeutic control were carried out by telephone call and clinical history review between the eighth and tenth day postpartum."
11049756|NCT04431102|No Intervention|MATERNAL EDUCATION|"The control group maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.
~Therapeutic control was carried out by phone call and review of the clinical history between the eighth and tenth day postpartum."
11049757|NCT04431089|Experimental|SHC014748M treatment|SHC014748M capsule, 200mg QD, 28 days for each cycle
11049758|NCT04431063|Experimental|Sutured Stump|The group consist of subject with distal stump suturing of perobeus longus agains peroneus brevis in ACL Reconstruction Case
11049759|NCT04431063|No Intervention|Unsutured Stump|The group consist of subject without distal stump suturing of peroneus longus agains peroneus brevis in ACL Reconstruction Case
11049760|NCT04431050||Suspected influenza or other respiratory viral infection.|"Any adult presenting to the Accident & Emergency department with influenza like illness or a febrile illness associated with symptoms such as cough, sore throat or rhinorrhoea, and for whom a respiratory viral screen is clinically indicated.
~For the purposes of this study one nasal swab will be taken from consenting adults."
11049761|NCT04431037|Experimental|Early oral feeding group(A)|Patients admitted in the HDU postoperatively.NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
11049762|NCT04431037|No Intervention|Traditional postoperative care group(B)|Patients in this group were managed traditionally
11049763|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
11049764|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
11049765|NCT04431011||Participants|Healthy right-handed participants aged 18-50
11049766|NCT04430998|Experimental|Zinc L-Carnosine mouth rinse|Using undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 60 seconds, 3 times daily
11049767|NCT04430998|Active Comparator|Chlorhexidine|Using undiluted 10 ml of Chlorhexidine mouth rinse, retain for 60 seconds, 3 times daily
11049768|NCT04430998|Placebo Comparator|Water|Mouth rinsing with 10 ml of water, retain for 60 seconds, 3 times daily
11049769|NCT04430985|Experimental|FOLFOX + Immunotherapy|"8 cycles of FOLFOX every 2 weeks with intrahepatic administration of oxaliplatin in cycles 1-4, thereafter (cycles 5-8) oxaliplatin i given i.v.; starting from cycle 3 this is combined with i.v. administration of nivolumab (cycle 3-8) and ipilimumab (cycle 3 + 6)
~Immunotherapy:
~Starting from cycle 3: Nivolumab 3 mg/kg i.v. on day 3 (every 2nd week, total of 6 administrations), Ipilimumab 1 mg/kg i.v. on day 3 (every 6th week, total of 2 administrations)"
11049770|NCT04430959|Experimental|Candesartan first then Placebo|4 weeks of candesartan with crossover to the other.
11049771|NCT04430959|Placebo Comparator|Placebo first then Candesartan|4 weeks of placebo with crossover to the other.
11049772|NCT04430946|Experimental|Lean patients with type 1 diabetes|Test meal consumed within 10 minutes
11049773|NCT04430946|Experimental|Obese patients with type 1 diabetes|Test meal consumed within 10 minutes
11049774|NCT04430946|Active Comparator|Lean healthy control subjects|Test meal consumed within 10 minutes
11049775|NCT04430946|Active Comparator|Obese healthy control subjects|Test meal consumed within 10 minutes
11049776|NCT04430933|Experimental|NC318 + Pemetrexed/Carboplatin|NC318 at various dose strengths administered on the first day of each 21 day cycle in combination with pemetrexed/carboplatin
11049780|NCT04430920|Placebo Comparator|Conventional intraoperative blood pressure management|
11049781|NCT04430907||Vaccine Accepting|This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
11049782|NCT04430907||Vaccine Rejecting|This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
11049783|NCT04430894|Experimental|Induction|"All participants will receive the same study drugs up to 8 cycles. Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone: Each cycle is 28 days in length.
~Stem cell collection after 4 cycles of therapy. Based on the recommendation participants may or may not proceed to an autologous stem cell transplant (SCT) as part of induction therapy.
~Up Front Autologous Stem Cell Transplant:
~--- 4 cycles of treatment, followed by stem cell collection, high-dose chemotherapy, and autologous SCT followed by 2 additional cycles of therapy (called consolidation) and then maintenance.
~Deferring Stem Cell Transplant:
~Deferring SCT following collection: 4 cycles of treatment, followed by stem cell collection followed by 4 additional cycles of therapy and then maintenance"
11049784|NCT04430894|Experimental|Maintenance-High Risk|"Experimental: Maintenance The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk.
~High Risk: All participants will receive study treatment for up to two years after induction until progressive disease (PD) or unacceptable toxicity
~Lenalidomide
~Carfilzomib
~Isatuximab"
11049785|NCT04430894|Experimental|Maintenance- Standard Risk|"The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk
~Lenalidomide - Standard of care All participants will receive study treatment for up to two years after induction until progressive disease (PD) or unacceptable toxicity"
11049786|NCT04430868|Experimental|LRP group|The participants in LRP group receive lifestyle redesign program plus treatment as usual. The LRP intervention consisted of one 90-minute session each week for 10 weeks
11049787|NCT04430868|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as LRP group.
11049788|NCT04430855|Experimental|Upadacitinib Dose A|Participants will receive Upadacitinib Dose A for 12 weeks (Period 1) followed by Upadacitinib Dose A for 36 weeks (Period 2).
11049789|NCT04430855|Experimental|Placebo followed by Upadacitinib Dose B|Participants will receive placebo for 12 weeks (Period 1) followed by Upadacitinib Dose B for 36 weeks (Period 2).
11049790|NCT04430842|Experimental|Dose escalation of QBS10072S|Intravenous administration of QBS10072S once every 4 weeks starting at 3mg/m2 and increasing dose levels in subsequent cohorts.
11049791|NCT04430816|Active Comparator|modified chevrel technique|22 participant with large midline incisional hernia underwent repair by double mesh modification of chevrel's technique
11049792|NCT04430816|Active Comparator|ON LAY mesh hernioplasty|21 participant with large midline incisional hernia underwent repair by online mesh hernioplasty
11049793|NCT04430803|Experimental|Hydrogen-rich water|"Hydrogen-rich water (Rejuvenation, HRW Natural Health Products Inc.)
~8 ppm of hydrogen
~Administered one dose two times per day on an empty stomach in the morning and at the evening"
11049794|NCT04430803|Placebo Comparator|Control water|"Tap water
~0 ppm of hydrogen
~Administered one dose two times per day on an empty stomach in the morning and at the evening"
11049795|NCT04430790|Experimental|Doxapram|Blinded doxapram (2mg/ml, in glucose 5%) loading dose of 2.0 to 2.5 mg/kg administered in 5 to 10 minutes, followed by a continuous infusion of 0.5 - 1.0 mg/kg/hr ('www.kinderformularium.nl') as long as needed. Therapy is down titrated or stopped based on the patients' respiratory condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons.
11049796|NCT04430790|Placebo Comparator|Placebo|Placebo (glucose 5%) will also be administered with a loading dose and continuous infusion (in equal amounts of fluid as in experimental arm) by intravenous or gastro-intestinal infusion. The treatment protocol will be equal to the protocol in the doxapram arm.
11049797|NCT04430777|Placebo Comparator|Placebo group|No use of tranexamic acid. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
11049798|NCT04430777|Experimental|Intravenous group|A single dose of 1 gr of tranexamic acid (10 ml) IV, thirty minutes previous to the initiation of the surgery. Subcutaneous infiltration of normal saline solution plus 1 mg of epinephrine as required for the procedure.
11049799|NCT04430777|Experimental|Subcutaneous group|"A single dose of 1 gr of tranexamic acid (10 ml) in the total of the infiltration mixture, as follow:
~4 liters of infiltration contents 2.5 ml of tranexamic acid plus 1 mg epinephrine 5 liters of infiltration contents 2 ml of tranexamic acid plus 1 mg epinephrine.
~6 liters of infiltration contents 1.6 ml of tranexamic acid plus 1 mg epinephrine."
11049800|NCT04430764|Experimental|smoker|
11049801|NCT04430764|Active Comparator|non-smoker|
11049802|NCT04430751|Active Comparator|Immediate start|
11049803|NCT04430751|Active Comparator|wait time control|
11049804|NCT04430738|Experimental|Single Arm|Tucatinib + trastuzumab + oxaliplatin + leucovorin + fluorouracil
11049805|NCT04430725||Observational (microwave ablation, wedge excision, CT)|Patients undergo standard care microwave ablation or wedge resection followed by contrast-enhanced CT imaging at 1, 6, 12, 18 and 24 months. Patients also complete questionnaires over 10-15 minutes at baseline up to 9 months.
11049806|NCT04430699|Experimental|Pembrolizumab, Cisplatin and Radiation Therapy|"Treatment period is 36 weeks with 21 day study cycles.
~Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.
~First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.
~Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks."
11049807|NCT04430673|Experimental|Home-School based VR trial|The VR system will be provided to each participant for a 2-week home- or school- based trial. No additional interventions.
11049808|NCT04430660|Other|Arm 1|Participants will have there glial acetate metabolism assessed via 13C MRS at baseline and then again 14 days later. Participants will wear blinded continuous glucose monitoring devices for ~4 weeks.
11050485|NCT04426032||Patients with RRI more than 0.7|High renal resistive index
11049809|NCT04430647|Experimental|phaco-UCP|Under peribulbar anesthesia, UCP was performed first, followed by phacoemulsification. UCP was performed using the same technique described before [18]. For all treatments, 2nd generation probe was used (EyeOP1, Eye Tech care; France) with the same parameters; Operating frequency was 21 MHz. Number of sectors activated was 6. Acoustic power was 2.45 W; duration of each shot was 8s; and the time between shots was 20s. The probe diameter (11, 12 or 13 mm) was determined according to the eye's biometric readings. The coupling cone was centered on the eye and kept in place with low vacuum suction, followed by introduction of the treatment probe inside the cone, then activation of the transducers by constantly pressing the foot switch. Once UCP treatment was finished, phacoemulsification was commenced
11049810|NCT04430647|Active Comparator|Phaco alone|A standard phacoemulsification was performed with 2.2 mm clear corneal incision, continuous curvilinear capsulorhexis, phacoemulsification and intrabagal implantation of foldable acrylic intraocular lens (AcrySof® IQ SN60WF monofocal; Alcon Laboratories Inc, Fort Worth, TX, USA) for all patients. Irrigation-aspiration was performed for at least 30 seconds to remove any viscoelastic from the anterior chamber. Reformation of the anterior chamber was done with balanced saline solution (BSS), followed by hydration of the corneal wound and side port.
11049811|NCT04430634|Experimental|Myblu flavor A 2.4|MybluTM e-cigarette with flavor A 2.4% nicotine
11049812|NCT04430634|Experimental|Myblu flavor B 3.6|MybluTM e-cigarette with flavor B 3.6% nicotine
11049813|NCT04430634|Experimental|Myblu flavor C 2.5|MybluTM e-cigarette with flavor C 2.5% nicotine
11049814|NCT04430634|Experimental|Myblu flavor D 4.0|MybluTM e-cigarette with flavor D 4.0% nicotine
11049815|NCT04430634|Experimental|Myblu flavor A 3.6|MybluTM e-cigarette with flavor A 3.6% nicotine
11049816|NCT04430634|Experimental|Myblu flavor B 2.4|MybluTM e-cigarette with flavor B 2.4% nicotine
11049817|NCT04430634|Experimental|Myblu flavor C 4.0|MybluTM e-cigarette with flavor C 4.0% nicotine
11049818|NCT04430634|Experimental|Myblu flavor E 3.6|MybluTM e-cigarette with flavor E 3.6% nicotine
11049819|NCT04430621|Experimental|FSH|FSH, 300 IU s.c.
11049820|NCT04430621|Placebo Comparator|Control|Placebo, s.c.
11049821|NCT04430608|Other|Fingerprick glucose|Standard care with fingerprick glucose + blinded CGM stratification on COVID-19 status
11049822|NCT04430608|Experimental|Open continous glucose monitoring (CGM)|Standard care with fingerprick glucose + un-blinded CGM stratification on COVID-19 status
11049823|NCT04430595|Experimental|Multiple 4SCAR T cells to treat breast cancer|Multiple 4SCAR T cells to treat breast cancer
11049824|NCT04430582||Hypoglycemia after upper gastrointestinal (GI) surgery|Participants with hypoglycemia after upper GI surgery, recruited from the Joslin Hypoglycemia Clinic and from other hypoglycemia studies at Joslin.
11049825|NCT04430582||Asymptomatic post-bariatric participants|Participants with a history of bariatric surgery, but without a diagnosis of hypoglycemia, or symptoms of hypoglycemia. They will be recruited by advertisement flyers at postoperative surgical clinics at local hospitals (e.g. Brigham and Women's and Beth Israel Deaconess Hospitals) and from other hypoglycemia studies at Joslin.
11049826|NCT04430582||Hypoglycemia no upper GI surgery & no diabetes (DM) or pre-DM|Participants with hypoglycemia and no history of upper gastrointestinal surgery, and NO current diagnosis of diabetes or pre-diabetes, recruited from the Joslin Hypoglycemia Clinic, or from other hypoglycemia studies at Joslin.
11049827|NCT04430582||Controls, no hypoglycemia or history of upper GI surgery|Participants without hypoglycemia or upper gastrointestinal surgery (controls), recruited by local advertisement. Some participants may be recruited from other hypoglycemia studies at Joslin.
11049828|NCT04430569|Experimental|Alteplase|
11049829|NCT04430569|Placebo Comparator|Placebo|
11049830|NCT04430556|Other|Volumetric changes in response to sertraline or escitalopram|
11049831|NCT04430543|Experimental|CBM Group|This group will receive Cognitive Bias Modification training
11049832|NCT04430543|Sham Comparator|Control Group|This group will receive Sham (control) training
11049833|NCT04430530|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20 infusion|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
11049834|NCT04430517|Experimental|Mild Cognitive Impairment and Alzheimer's Dementia|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
11049835|NCT04430504|Experimental|Telerehabilitation (TR)|Multidisciplinary, weekly video meetings, self-exercises at home, digital diary recordings, follow-up assessments
11049836|NCT04430491||Training dataset|No interventions
11049837|NCT04430491||Validation dataset|No interventions
11049838|NCT04430478|Experimental|Volume flow group|Consecutive patients undergoing sequential volume flow measurements using percutaneous DUS
11049839|NCT04430465|Experimental|High wholegrain then low wholegrain|Starting with high wholegrain intervention followed by low wholegrain intervention
11049840|NCT04430465|Experimental|Low wholegrain then high wholegrain|Starting with low wholegrain intervention followed by high wholegrain intervention
11049841|NCT04430452|Experimental|Arm I (hypofractionated RT, durvalumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11049842|NCT04430452|Experimental|Arm II (hypofractionated RT, durvalumab, tremelimumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
11049843|NCT04430439|Experimental|Psychosocial stress|Participants will complete the Trier Social Stress Test (TSST) immediately following consumption of their assigned meal type (low or high GI).
11049844|NCT04430439|Active Comparator|Control non-stress|Participants will complete a non-stress relaxed task immediately following consumption of their assigned meal type (low or high GI).
11049845|NCT04430426|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for five days and be administered an intravenous (IV) load of glycolate. Participants will provide urine and blood samples both before the glycolate load to establish baseline levels and after the glycolate load to measure oxalate levels afterwards.
11049846|NCT04430413|No Intervention|Group A|50 Participants who underwent a total excision of the pilonidal sinus and the wound remained open for secondary healing.
11049847|NCT04430413|Active Comparator|Group B|50 Participants who underwent the same operation with secondary healing intention but on postoperative days 4 and 12 the platelet rich plasma was injected to the surgical wound.
11049848|NCT04430387|Active Comparator|Group 1- The saliva ejector|
11049849|NCT04430387|Active Comparator|Group 2- The high-volume evacuator|
11049850|NCT04430387|Active Comparator|Group 3- The DryShield|
11049851|NCT04430361|Experimental|Megestrol|Palonosetron 2.5mg, Dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, Megestrol acetates 160mg orally every morning on the day of the beginning of chemotherapy for 10 days.
11049852|NCT04430361|Other|Control|Palonosetron 2.5mg, Dexamethasone12mg on the first day, 8mg on the 2nd-4th day
11049853|NCT04430348|Experimental|PTX-35 Dose Level 1|Dose Level 1: PTX-35 0.01 mg/kg
11049854|NCT04430348|Experimental|PTX-35 Dose Level 2|Dose Level 2: PTX-35 0.03 mg/kg
11049855|NCT04430348|Experimental|PTX-35 Dose Level 3|Dose Level 3: PTX-35 0.10 mg/kg
11049856|NCT04430348|Experimental|PTX-35 Dose Level 4|Dose Level 4: PTX-35 0.30 mg/kg
11049857|NCT04430348|Experimental|PTX-35 Dose Level 5|Dose Level 5: PTX-35 1.0 mg/kg
11049858|NCT04430335|Other|Telephone-Based Cognitive Behavioral Therapy|Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
11049859|NCT04430309|Experimental|Baduanjin exercise group|"The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.
~The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks"
11049860|NCT04430309|Active Comparator|Control group|The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks
11049861|NCT04430296|Active Comparator|High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU)|
11049862|NCT04430296|Active Comparator|MicroPulse cyclophotocoagulation (MP-CPC)|
11049863|NCT04430296|Active Comparator|Continuous Wave cyclophotocoagulation (CW-CPC)|
11049864|NCT04430283|Experimental|Experimental: FDY-5301 Low Dose|FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
11049865|NCT04430283|Experimental|Experimental: FDY-5301 High Dose|FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
11049866|NCT04430283|Placebo Comparator|Placebo|"Placebo will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
~Other Names:
~Saline"
11049867|NCT04430270||Comparison of Perceptions of X-ray, CT and 3D Model|The study group consisted of 11 orthopaedic residents of University Hospital. Selection criteria for the 4 cases was the involved patients who required orthopaedic surgery. 4 cases for orthopaedic procedures were determined with the consensus of experts. As data collection tool was used to evaluate the perceptions of each of these imaging methods in terms of their usefulness in seeing the surgical problem, their efficiency in differential diagnosis and presurgical planning. CT images were converted into in the 3D model was prepared. The survey utilized by our group, addressed the issues in understanding bone anatomy, seeing pathology, and preparation for unexpected events. A multi-item survey was prepared to assess fellow's perception of residency training. Residents who completed their examination in the stations answered the questions on a scale of 10. Descriptive statistics and Friedman test were used for comparison analysis using IBM SPSS Statistics, version 24.
11049868|NCT04430257|Experimental|PrEP for health|Participants in the PreEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.
11049869|NCT04430257|Active Comparator|Standard of care|Participants in the standard of care arm will receive PrEP information and referrals.
11049870|NCT04430244|Experimental|DALK using Dehydrated Corneas|Corneal transplantation of anterior lamellar grafts from dehydrated corneas.
11049871|NCT04430244|Active Comparator|DALK using Standard Organ Culture Stored Corneas|Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.
11049872|NCT04430231||Wait list time 0-2 weeks|Wait list time 0-2 weeks
11049873|NCT04430231||Wait list time 2-4 weeks|Wait list time 2-4 weeks
11049874|NCT04430231||Wait list time 4-6 weeks|Wait list time 4-6 weeks
11049875|NCT04430231||Wait list time > 6 weeks|Wait list time > 6 weeks
11049876|NCT04430218|Experimental|iSens|3 months trial with the iSens system
11049877|NCT04430218|No Intervention|State of the Art Prosthesis|3 months trial with their own prosthesis.
11049878|NCT04430192|Experimental|177Lu-PSMA-617 followed by prostatectomy|177Lu-PSMA-617 followed by prostatectomy
11049879|NCT04430179|Active Comparator|Active drug|Dupilumab initial dose 600 mg and 300 mg every other week for 24 weeks
11049880|NCT04430179|Placebo Comparator|Placebo|Placebo
11049881|NCT04430166|Experimental|PD-1 monoclonal antibody|
11049882|NCT04430153||Low match|A group with both low observed and perceived upper limb ability.
11049883|NCT04430153||Good match|A group with both good observed and perceived upper limb ability.
11049884|NCT04430153||Mismatch|A group with good observed but low perceived function.
11049885|NCT04430140||1|"CT Scan
~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
11049886|NCT04430127||Colorectal adenocarcinoma|patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging
11049887|NCT04430114|Experimental|TAAA spinal loop graft|
11049888|NCT04430101|Active Comparator|Negative WB radiographs and stress fluoroscopy|"Cohort 1
~Negative weight bearing radiographs:
~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.
~Negative stress fluoroscopy: the midfoot is tested stable"
11049889|NCT04430101|Active Comparator|Negative WB radiographs / positive stress fluoroscopy|"Cohort 2
~Negative weight bearing radiographs:
~Interval between medial cuneiform and base of the second metatarsal (C1-M2) are less than 2mm increased compared to the uninjured side.
~Positive stress fluoroscopy: manual testing reveals midfoot instability"
11049890|NCT04430101|Other|Surgical cohort (Cohort 3)|Patients with positive weightbearing radiographs will be operated on with minimally invasive technique and followed up as an independent cohort.
11049891|NCT04430088|Experimental|VVZ-149 Injections|
11049892|NCT04430088|Placebo Comparator|Placebo|
11049893|NCT04430062||Covid-19 patients operated (February 21st -April 10th)|
11049894|NCT04430049||restrictive visitation group|relatives cannot visit ICU patient during Covid pandemic period in France
11049895|NCT04430049||open visitation group|relatives can visit ICU patient during no Covid period in France
11049896|NCT04430036|Experimental|Safety Run-In|The safety run-in of the study will first enroll three patients who will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. These first 3 patients will be assessed for DLTs and there will be a pause in enrollment until all three complete the DLT period. If there are no DLTs in the first 3 patients, we will proceed to further accrual to stage I of phase II. If there is 1 DLT in the initial 3 patients, we will enroll 3 additional patients to the safety run-in. If > 2 DLTs are experienced in the initial 3 patients, the study will be terminated.
11049897|NCT04430036|Experimental|Phase II, Stage 1|In the first stage of phase II of this study, 17 patients will be enrolled. Patients will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. They will be evaluated with each cycle of therapy, with radiographic restaging assessment after 2 cycles of therapy and prior to the third cycle of treatment. If no disease progression is identified, patients will receive a third and fourth cycle of therapy. Following this neoadjuvant regimen, they will proceed to planned surgery following preoperative clearance within 10 weeks of the last dose of neoadjuvant therapy.
11049898|NCT04430036|Experimental|Phase II, Stage 2|If criteria are met to continue to the second stage of the Phase II portion of the study, 19 more patients will be enrolled for a total of 36 evaluable patients. Patients will be treated and endpoints evaluated.
11049899|NCT04430010|Experimental|Implementation|Teachers will implement the BEST in CLASS treatment in their classrooms
11049900|NCT04429997|Experimental|Removal of fibrosynovial tissue|Removal of fibrosynovial tissue in patellar non-resurfacing TKA
11049901|NCT04429997|Experimental|Non-removal of fibrosynovial tissue|Non-removal of fibrosynovial tissue in patellar non-resurfacing TKA
11049902|NCT04429984||Velaglucerase alfa (VPRIV)|Participants with Gaucher disease will receive VPRIV therapy according to the investigator's judgment for 12 months.
11049903|NCT04429971|Experimental|Immediate PreP initiation|"PreP screening program with immediate PrEP (iPrEP) initiation in the ED using a PrEP starter pack with facilitated linkage to care."
11049904|NCT04429971|Active Comparator|Out-patient care for PrEP initiation|PrEP screening program with referral to out-patient care for PrEP initiation
11049905|NCT04429971|Experimental|PreP Screening Program|Part 1: Targeted ED-based patients
11049906|NCT04429958||GDM|125 mothers with a history of GDM in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
11049907|NCT04429958||abnormal GCT group|125 mothers with an abnormal glucose challange test (GCT of 130mg/dl or more) in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
11049908|NCT04429958||normal group|125 mothers with both a normal GCT and OGT in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
11049909|NCT04429945|Experimental|Immersive Virtual Reality|A Virtual Reality headset will be used for 30 minutes twice per day outside of usual therapy times while in bed with bedrails raised. Virtual Reality games will be selected that will help with relaxation, pain, and arm and hand recovery after a stroke.
11049910|NCT04429932|Experimental|Myblu flavor 1_2.4|MybluTM e-cigarette with flavor n°1, 2.4% nicotine
11049911|NCT04429932|Experimental|Myblu flavor 2_2.4|MybluTM e-cigarette with flavor n°2, 2.4% nicotine
11049912|NCT04429932|Experimental|Myblu flavor 3_2.4|MybluTM e-cigarette with flavor n°3, 2.4% nicotine
11049913|NCT04429932|Experimental|Myblu flavor 4_2.4|MybluTM e-cigarette with flavor n°4, 2.4% nicotine
11049914|NCT04429932|Experimental|Myblu flavor 1_1.2|MybluTM e-cigarette with flavor n°1, 1.2% nicotine
11049915|NCT04429932|Experimental|Myblu flavor 2_1.2|MybluTM e-cigarette with flavor n°2, 1.2% nicotine
11049916|NCT04429932|Experimental|Myblu flavor 5_2.4|MybluTM e-cigarette with flavor n°5, 2.4% nicotine
11049917|NCT04429932|Experimental|Myblu flavor 6_2.4|MybluTM e-cigarette with flavor n°6, 2.4% nicotine
11049918|NCT04429919|Experimental|AP-325|25 mg capsule for oral use, 4 capsules (100 mg) once daily in the morning before meals
11049919|NCT04429919|Placebo Comparator|Placebo|4 capsules once daily in the morning before meals
11049920|NCT04429906||test group|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
11049921|NCT04429906||control group A|Pulse oximetry monitor/desktop ECG monitor with a medical device registration certificate was selected as reference device A. The mean value of qualified pulse oximetry measured by pulse oximetry monitor/desktop ECG monitor within 2 minutes of each successive measurement of the Huami Smart Wearable Device was used as control group A measurement.
11049922|NCT04429906||control group B|A carbon monoxide blood gas analyzer (CO-oximeter) was selected as reference device B. Arterial blood was sampled and arterial oxygen saturation (SaO2) was obtained from the blood gas analyzer as a control group B measurement.
11049923|NCT04429893|Experimental|Group BM|The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.
11049924|NCT04429893|Active Comparator|Group B|The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml
11049925|NCT04429880|Experimental|Oxytocin|Oxytocin 17 micrograms infusion over 10 minutes
11049926|NCT04429867|Experimental|Hydroxychloroquine|
11049927|NCT04429867|Placebo Comparator|Placebo|
11049928|NCT04429854|Experimental|Convalescent Plasma|"4 units of convalescent plasma:
~2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible
~2 units of plasma should be administered between 24h and 36h after the first infusion"
11049929|NCT04429854|Other|Standard of Care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive. Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
11049930|NCT04429841||D1 Gastrectomy|Patients are managed by radical gastrectomy with D1 lymphadenectomy
11049931|NCT04429841||D2 Gastrectomy|Patients are managed by radical gastrectomy with D2 lymphadenectomy
11049932|NCT04429828|Experimental|e-package: psychological wellbeing for healthcare workers|A COVID-19 educational package on psychological wellbeing for healthcare workers, accessible to all healthcare students.
11049933|NCT04429815||Active smokers.|Active smokers since October 2019.
11049934|NCT04429815||Smokers undergoing smoking cessation|Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.
11049935|NCT04429815||Non-smoking.|Person who's never smoked before.
11049936|NCT04429802|Placebo Comparator|Placebo|Placebo is an opaque empty gel capsule obtained from the UZ Gasthuisberg pharmacy. These capsules are composed of 100% gelatine that will rapidly dissolve (disintegration time is 15 minutes) in the stomach without affecting the gastric motor function.
11049937|NCT04429802|Experimental|Prucalopride|2 mg, Resolor®, Shire, Belgium Prucalopride (2 mg) is rapidly absorbed; after a single oral dose of 2 mg Cmax was attained in 2-3 hours. The absolute oral bioavailability is >90%. Concomitant intake of food does not influence the oral bioavailability of prucalopride.
11049938|NCT04429789|Experimental|Active-Alert Hypnosis|
11049939|NCT04429789|Experimental|Traditional Hypnosis|
11049940|NCT04429789|No Intervention|Wait-List Control|Participants in this arm will continue their usual care for fatigue. The therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their fatigue. The study therapist will emphasize the importance of completing the outcome assessments. Following the completion of their final assessment (3 month follow-up); these individuals will be offered their choice of the two hypnosis treatments.
11049941|NCT04429776|Experimental|Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results fed back to recruiting clinical team who can choose to use these to influence their tapering decisions.
11049942|NCT04429776|Active Comparator|No Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results not fed back to recruiting clinical team.
11049943|NCT04429763|Experimental|Experimental|Usual tratment for COVID-19 plus MSC
11049944|NCT04429763|Placebo Comparator|Control|Usual treatment for COVID-19
11049945|NCT04429750|Active Comparator|Immediate umbilical cord clamping|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH management procedure as described in the French national CDH management guidelines (Programme National de Soins).The resuscitation maneuvers are started after the umbilical cord is clamped."
11049946|NCT04429750|Experimental|Intact cord resuscitation|"This group includes newborn infants with isolated CDH who will benefit from the standardized CDH resuscitation maneuvers as described in the French national CDH management guidelines (Programme National de Soins) before the umbilical cord is clamped. The resuscitation maneuvers are started at birth while the umbilical cord still bridges mother and child."
11049947|NCT04429737|Experimental|Experimental|The prediabetes patients in this arm will receive Clam protein capsules or Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months.
11049948|NCT04429737|Placebo Comparator|placebo|The prediabetes patients in this arm will receive placebo with similar appearance of Clam protein capsules or Clam peptide plus Chlorella capsules.
11049949|NCT04429724|Experimental|health workers at hospital|Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
11049950|NCT04429711|Placebo Comparator|IVERMECTIN|
11049951|NCT04429711|Active Comparator|PLACEBO|
11049952|NCT04429698|Other|POCUS group|Patients in this group underwent POCUS after primary clinical evaluation with the knowledge of their primary physician. This procedure was performed in the first hour after the patients' primary clinical evaluations to evaluate the predetermined parameters in the study form for the heart, lungs, hepatobiliary, aortic and deep veins.
11049953|NCT04429698|No Intervention|Control group|All processes and results were followed without any intervention in the processes related to the patients in this group and the results were recorded in the study form
11049954|NCT04429685|Experimental|Low Dose Ketamine|
11049955|NCT04429685|Placebo Comparator|Saline (placebo)|
11049994|NCT04429464|Experimental|Non-randomized|All subjects will be treated using the Acutus Medical's AcQBlate Force Sensing Ablation Catheter in combination with the Qubic Force Sensing Module (AcQBlate Force Sensing System) to treat their arrhythmia.
11049995|NCT04429451|Experimental|4SCAR-PSMA Cell Therapy for PSMA positive tumor|Infusion of 4SCAR-PSMA T cells at 10^6 cells/kg body weight via IV
11049956|NCT04429672|Experimental|Experimental Group (EG)|"The participants of the Experimental Group receive as treatment the intervention called The Right to your Sexual Health, which is socio-educational and is composed of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Conduct and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of the opening, development and closing phase established in a manual for the facilitator, it should be noted that the intervention is applied by a multidisciplinary team in which the areas of medicine, nursing and psychology participate. In addition, Information and Communication Technologies (ICTs) are used through a Moodle platform that has available to participants digital support material as digital presentations on each of the thematic axes, as well as audiovisual material through the Podcast format of conversations concerning each of the axes."
11049957|NCT04429672|Active Comparator|Control Group (CG)|The participants of the Control Group receive the usual sexual health intervention applied by Secretary of Health consisting of six sessions (one a week) lasting 50 minutes each using illustrative material through rotating official secretary of health folios on reproductive health, sexually transmitted diseases and sexual violence.
11049958|NCT04429659||Group 1, patients with amblyopia and partially refractive ET|children with both amblyopia and partially refractive accommodative esotropia
11049959|NCT04429659||Group 2, patients with refractive ET|children with refractive esotropia
11049960|NCT04429646|Experimental|LAMax left atrial appendage occluder|Intervention device, LAMax left atrial appendage closure system
11049961|NCT04429646|Active Comparator|Watchman (control)|Intervention device, Watchman® LAA Closure Device
11049962|NCT04429633|Active Comparator|Conventional Cardiac intervention|Starting candesartan in patients with left ventricular ejection fraction (LVEF) between 45% and 50% by echocardiogram.
11049963|NCT04429633|Active Comparator|Early Cardiac intervention|Starting candesartan in patients with decreased myocardial strain below 18% regardless of LVEF by echocardiogram.
11049964|NCT04429620||Positive group|Subjects are diagnosed with SARS-CoV2 by qPCR assay.
11049965|NCT04429620||Negative group|Subject were 2 times proved negative SARS-CoV2 by qPCR assay.
11049966|NCT04429607|Active Comparator|Erbium:YAG Laser|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
11049967|NCT04429607|Active Comparator|PDL plus Nd:YAG|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
11049968|NCT04429607|Active Comparator|ED&C treatment|Solitary lesions will be randomized to a group, thus, a patient may receive all three treatments, each on different lesions. Patients will undergo two total treatment sessions at 2-6 week intervals.
11049969|NCT04429594|Other|volonteers|
11049970|NCT04429568|Other|Smoked Cannabis, Vaped Cannabis, or Tobacco Cigarette|"Abstinence from any product night before hospital admission
~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette
~6-hr abstinence and blood draws (PK)
~2 hr Free use session w/ video monitoring
~Free use of assigned product
~12-hr cardiovascular (CV) monitoring
~Circadian blood draws
~12-hr urine collection"
11049971|NCT04429568|Other|Either of the 2 remaining products|"Abstinence from any product night before hospital admission
~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette
~6-hr abstinence and blood draws (PK)
~2 hr Free use session w/ video monitoring
~Free use of assigned product
~12-hr CV monitoring
~Circadian blood draws
~12-hr urine collection"
11049972|NCT04429568|Other|Remaining product|"Abstinence from any product night before hospital admission
~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette
~6-hr abstinence and blood draws (PK)
~2 hr Free use session w/ video monitoring
~Free use of assigned product
~12-hr CV monitoring
~Circadian blood draws
~12-hr urine collection"
11049973|NCT04429555|Experimental|MN-166 (ibudilast)|MN-166 capsules, 50 mg twice daily, for 7 days.
11049974|NCT04429555|Placebo Comparator|Placebo|Placebo capsules, 50 mg twice daily, for 7 days.
11049975|NCT04429542|Experimental|BCA101 Monotherapy|Route: IV Infusion Frequency: QW Dose: 64mg, 240mg, 800mg, 1600mg
11049976|NCT04429542|Experimental|BCA101 + pembrolizumab|Route: IV Infusion Frequency: Q3W Dose: 200mg
11049977|NCT04429529|Experimental|TY027 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
11049978|NCT04429529|Placebo Comparator|Placebo 0.5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11049979|NCT04429529|Experimental|TY027 5mg/kg|Subject will be administered with 5 mg/kg of TY027 via IV infusion over a period of 30 minutes.
11049980|NCT04429529|Placebo Comparator|Placebo 5 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11049981|NCT04429529|Experimental|TY027 10 mg/kg|Subject will be administered with 10 mg/kg of TY027 via IV infusion over a period of 30 minutes.
11049982|NCT04429529|Placebo Comparator|Placebo 10 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11049983|NCT04429529|Experimental|TY027 20 mg/kg|Subject will be administered with 20 mg/kg of TY027 via IV infusion over a period of 30 minutes.
11049984|NCT04429529|Placebo Comparator|Placebo 20 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11049985|NCT04429529|Experimental|TY027 30 mg/kg|Subject will be administered with 30 mg/kg of TY027 via IV infusion over a period of 30 minutes.
11049986|NCT04429529|Placebo Comparator|Placebo 30 mg/kg|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11049987|NCT04429516|Experimental|Morphine Sulfate|
11049988|NCT04429516|Placebo Comparator|Placebo|
11049989|NCT04429503|Experimental|aflibercept Q8|Administered every 8 weeks after a loading phase
11049990|NCT04429503|Experimental|High-Dose aflibercept Q12|Administered every 12 weeks after a loading phase
11049991|NCT04429503|Experimental|High-Dose aflibercept Q16|Administered every 16 weeks after a loading phase
11049992|NCT04429490|Experimental|"Group Cases"|patients with pancreatic adenocarcinoma
11049993|NCT04429490|Other|"Group Controls"|patients without pancreatic adenocarcinoma
11050123|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
11049996|NCT04429438|Experimental|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.
11049997|NCT04429425|Other|EA group|patients with colorectal surgery that willl be performed epidural anesthesia
11049998|NCT04429425|No Intervention|non -EA group|patients with colorectal surgery that willl be performed only general anesthesia
11049999|NCT04429412|Experimental|Metacognitive Training (MCT+)|"MCT+ combines the process-oriented approach of metacognitive group training with elements of individual cognitive-behavioral therapy.
~The metacognitive training program is comprised of 10 modules targeting common cognitive errors in schizophrenia. (Moritz et al, 2013).
~The modules are: 1:Therapeutic alliance, 2: Introducyion to MCT+, 3:Disease model, 4: Attributional style, 5: Decision making, 6: Changing beliefs, 7: Empathizing, 8: Memory, 9: Depression and self-steem, 10: Relapse prevention.
~The treatment consist of 10 weekly sessions of 45-60 minutes."
11050000|NCT04429412|No Intervention|TAU|Treatment as usual.
11050001|NCT04429399|Other|High positive end-expiratory pressure Ventilation|patient ventilated fixing high level of positive end expiratory pressure
11050002|NCT04429399|Other|Low positive end-expiratory pressure Ventilation|patient ventilated fixing low level of positive end expiratory pressure
11050003|NCT04429373|Experimental|Implant installation with PRF|PRF membrane over the buccal aspect of implant site
11050004|NCT04429373|Active Comparator|Implant installation without PRF|Implant installation contralateral to the the experimental implant, without PRF membrane
11050005|NCT04429347|Experimental|Tizanidine 2mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
11050006|NCT04429347|Experimental|Gabapentin 300mg|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
11050007|NCT04429347|Placebo Comparator|Placebo|Friday night: 1 capsule Saturday night: 2 capsules Sunday night: Subject chooses 1-2 capsules
11050008|NCT04429334|Experimental|nangibotide|
11050009|NCT04429334|Placebo Comparator|placebo|
11050010|NCT04429321|Experimental|Ipilimumab +Nivolumab with Embolization|"Patients receive ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 3 mg/kg IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities.
~Patients will receive 2 cycles of systemic therapy followed by Lipiodol:ethanol embolization of their primary tumor and continue systemic therapy subsequently."
11050011|NCT04429308|Active Comparator|Photodynamic Therapy|One upper arm will be exposed to blue light therapy
11050012|NCT04429308|Active Comparator|Chemical Peels|One upper arm will be exposed to Jessner's Solution AND 35% Trichloroacetic acid peel
11050013|NCT04429295|Experimental|Group A - Intervention regimen|SHAN6™ + routine pediatric vaccines pneumococcal 13-valent conjugate vaccine [PCV] [Prevnar 13®] and oral rotavirus vaccine [ORV-1] [Rotarix™] at age of 2, 4 months; SHAN6™ + Prevnar 13® at age of 6 months; SHAN6™ administered alone as a booster dose at age of 18 months
11050014|NCT04429295|Active Comparator|Group B - Control regimen|SHAN5™ + bivalent oral polio vaccine (bOPV), co-administered with Prevnar 13® and Rotarix™ at 2, 4 months of age and with inactivated polio vaccine [IPV] at 4 months of age; SHAN5™ + bOPV, co-administered with Prevnar 13® at 6 months of age; SHAN6™ administered alone as a booster dose at 18 months of age
11050015|NCT04429282|Experimental|ibuprofen( 400mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 400 mg .
11050016|NCT04429282|Experimental|ibuprofen( 800mg group)|Patients were randomly divided into the group received respectively IV ibuprofen 800 mg.
11050017|NCT04429282|Placebo Comparator|placebo group|Patients were randomly divided into the group received respectively IV placebo,.
11050018|NCT04429269||mammography and ultrasound|mammography and ultrasound screening
11050019|NCT04429243||GORE® VIABAHN® Stent Graft|Participants will be examined 1, 3, 6, 12 and 24 months following the GORE® VIABAHN® Stent Graft installation.
11050020|NCT04429230|Active Comparator|Real tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
11050021|NCT04429230|Sham Comparator|Sham tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
11050022|NCT04429217|Experimental|Arm-A|experimental post-operative rehabilitation intervention consisting in immediate weight-bearing
11050023|NCT04429217|Active Comparator|Arm-B|control post-operative rehabilitation intervention consisting in delayed weight-bearing
11050024|NCT04429204|Experimental|Basic science (cryoablation, tissue collection)|At the time of standard of care pleural biopsy, patients undergo cryoablation over 30 minutes, then a sample of tissue from the ablated region and a non-ablated (tumor negative control) region are collected.
11050025|NCT04429191|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
11050026|NCT04429178||women in the 1st trimester of pregnancy.|
11050027|NCT04429178||women in the 2nd trimester of pregnancy.|
11050028|NCT04429178||women in the 3rd trimester of pregnancy.|
11050029|NCT04429178||non-pregnant women|
11050030|NCT04429165||ACL reconstruction|ACL reconstruction using an autologous hamstring tendon
11050031|NCT04429165||control group|knee-healthy, age-matched subjects as a control group
11050032|NCT04429152|Experimental|Doravirine|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
11050033|NCT04429139|Experimental|PDT treatment group|All the patients received once PDT with Visudyne® as the initial treatment. Rescue treatment with systemic chemotherapy would be given to patients if tumors were insensitive to PDT treatment, the tumors became larger, or disease relapse.
11050034|NCT04429126|Experimental|4-point acupressure group|"The 5-point acupressure group will be instructed on the following acupressure points: sanyinjiao (SP6), Zu San Li (ST36), shenmen (TF4), Yongquan (KI-1), and He Gu (LI4).
~Bilateral 1.5 min for each point, three times daily for 4 weeks."
11050035|NCT04429126|Active Comparator|4 -point acupressure group|"The 2-point acupressure group will be instructed on the following acupressure points: He Gu (LI4) and Tai Chong (LV3).
~Bilateral 1.5 min for each point, three times daily for 4 weeks."
11050036|NCT04429126|No Intervention|Usual care|The usual care group will be required to maintain their daily activities. Weekly telephone follow-up will be conducted by principle investigator.
11050037|NCT04429113||G1 or Early Group|Patients treated before age 7 (Quad Helix on decidual second molars)
11050038|NCT04429113||G2 or Late Group|Patients treated between 7 and 13 years old (Quad Helix on first permanent molars)
11050039|NCT04429100||liver fibrosis stage F0|
11050040|NCT04429100||early-stage liver fibrosis (F1-2)|
11050041|NCT04429100||late-stage liver fibrosis (F3-4)|
11050042|NCT04429087|Experimental|BI 764532|
11050043|NCT04429074||Group 1 (Registrar)|Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon)
11050044|NCT04429074||Group 2 (Consultant)|Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert)
11050045|NCT04429061|No Intervention|SOC Arm|Standard of care (SOC) SKILLZ-Girl Curriculum implemented with subsequent encouragement to be involved with pre-existing clubs at their school
11050046|NCT04429061|Active Comparator|Enhanced Arm|Enhanced SKILLZ-Girl Curriculum, including an enhanced event (including HIVST + access to family planning) with subsequent encouragement to be involved with SKILLZ-Clubs at their school
11050047|NCT04429048|Experimental|acupressure group|The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.
11050048|NCT04429048|Sham Comparator|control group|The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.
11050049|NCT04429035|Experimental|Vitamin K2|Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
11050050|NCT04429035|Placebo Comparator|Placebo|Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
11050051|NCT04429022|Experimental|Prospective cohort|"Pre-Op:
~Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op)
~Acetaminophen 1000mg PO x1 prior to surgery (in pre-op)
~Intra-Op:
~Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL
~Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL
~Will operate at <15mmHg intra-abdominal pressure, with goal of <12mmHg
~At end of procedure during closure of fascia, give 30mg ketorolac IV x 1
~Post-Op:
~Gabapentin 300mg PO BID for 7 days
~Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN
~Celecoxib 200mg PO q 12h x 7d
~Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge"
11050052|NCT04429022|Active Comparator|Historical Control|Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Perocets 12 x 5mg/325 (90MME) upon discharge
11050053|NCT04429009|Experimental|Active Study Group|"Participants in this group will be prescribed to use the ZEPHYRx RT device for incentive spectrometer once every hour during waking hours to perform a series of 10 deep breaths. The novel ZEPHYRx RT system consists three components:
~The Spirobank Smart Spirometer, which is a non-significant risk, FDA-cleared diagnostic spirometer made by Medical International Research (MIR) that connects via bluetooth to an Android tablet.
~A Samsung 10-inch tablet provided by Pad-in-Motion Inc. that will be connected to the hospital GuestWiFi network.
~The ZEPHYRx Respiratory Therapy video game application installed on the tablet. This application consists of seven games that have been created to combine traditional IS techniques with playing a breath controlled video game. The application will record data while playing the video games including date/time of use, game played, inhalation duration, and inhalation volume."
11050054|NCT04428996|Experimental|Arm AB|"A means SCIT program, and B means treatment as usual. Arm AB will receive a 60-minutes manual-guide SCIT session each week for 20 times first, then receive treatment as usual.
~Before the SCIT session, after the SCIT session and after 20 weeks treatment as usual, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.
~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
11050055|NCT04428996|Experimental|Arm BA|"A means SCIT program, and B means treatment as usual. Arm BA will first receive treatment as usual, then a 60-minutes manual-guide SCIT session each week for 20 times.
~At the first week, before and after the SCIT session, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.
~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
11050056|NCT04428983|Experimental|Hericium erinaceus mycelium|Hericium erinaceus capsules 1 table tid orally per day for 24 months
11050057|NCT04428983|Placebo Comparator|placebo|placebo capsules 1 table tid orally per day for 24 months
11050058|NCT04428970||TBI patients with ICP monitoring|Patients with severe TBI (GCS<9 on arrival) receiving invasive ICP monitoring
11050059|NCT04428957|Experimental|Telemonitoring group|3 months home-based telemonitoring
11050060|NCT04428957|No Intervention|Control group|3 months standard care
11050061|NCT04428944|Active Comparator|PV antral isolation alone (PVAI)|PV antral isolation alone (PVAI)
11050062|NCT04428944|Active Comparator|PV antral isolation plus ablation of drivers|PV antral isolation plus ablation of drivers (PVAI+drivers)
11050063|NCT04428944|Active Comparator|PV antral isolation plus isolation of posterior wall|PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
11050064|NCT04428931||PD patients|Patients with Asymmetric Parkinson's disease
11050065|NCT04428918||Cohort 1|Allogeneic HCT recipient or patient pending receipt of HCT
11050124|NCT04428489||Idiopathic cytopenia of undetermined significance (ICUS)|
11050125|NCT04428489||Clonal cytopenia of unknown significance (CCUS)|
11050126|NCT04428476|Other|Open-label arm|Open-label CAP-1002 will be administered to all subjects enrolled in the trial
11050066|NCT04428905|Experimental|Arm I (personalized care plan, telehealth sessions)|Patients receive a personalized care plan/resource manual. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) about self-management skills building, then 3 maintenance telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) for additional self-management skills building support. A copy of patient's care plan is also sent to their PCP.
11050067|NCT04428905|Active Comparator|Arm II (ASCO care plan, telehealth sessions)|Patients receive an ASCO care plan. Patients also participate in 5 telehealth sessions with a nurse over 60 minutes each for 4 months (months 1-4) to answer questions on a handbook about life after cancer treatment, then 3 monthly telehealth sessions with a nurse over 60 minutes each for 3 months (months 5-7) to answer questions about the handbook. A copy of the ASCO care plan is also sent to their PCP.
11050068|NCT04428892|Experimental|Clinical Simulation|The group denominated SP received a teaching strategy based on a class session with simulated practice for decision-making in clinical skills when caring for a person with LBP. Each session lasted approximately 120 minutes, and the clinical case used for the SP sessions was subjected to face validity with experts in the area of study.
11050069|NCT04428892|Active Comparator|Conventional Pedagogical strategy|"received a class session based on a role playing simulation strategy, structured for the same purpose established in the SP group. This session lasted approximately 120 minutes, and the learning environment was the classroom in which students assumed different roles to act out; some of them acted as people with LBP and others as physiotherapists"
11050070|NCT04428879|Experimental|Phase I single arm trial|
11050071|NCT04428866||Participants with post-bariatric hypoglycemia|Individuals with history of Roux-en-Y gastric bypass surgery, who have a history of hypoglycemia will be recruited from the Joslin Hypoglycemia Clinic.
11050072|NCT04428866||Asymptomatic participants with Roux-en-Y gastric bypass (RYGB)|Individuals with history of RYGB, without a history of or symptoms of hypoglycemia will be recruited from local postoperative surgical clinics and from the community.
11050073|NCT04428866||Control group|Individuals without a history of bariatric surgery will be recruited by local advertisement.
11050074|NCT04428853|Experimental|exercise|A schedule has designed by the researcher for group yoga therapy of the participant twice a week, each session lasting for 75- minutes for the duration of 8 weeks
11050075|NCT04428840|Experimental|on-day|Use of the self-measurement kiosk: measurement of vital signs + completion of short questionnaire
11050076|NCT04428840|No Intervention|Off-day|No use of the self-measurement kiosk
11050077|NCT04428827||Surgery|Patients treated with surgery
11050078|NCT04428827||Medications|Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism
11050079|NCT04428814|Experimental|CT-P43 (Part 1)|45mg single dose administration
11050080|NCT04428814|Active Comparator|EU-approved Stelara (Part 1)|45mg single dose administration
11050081|NCT04428814|Experimental|CT-P43 (Part 2)|45mg single dose administration
11050082|NCT04428814|Active Comparator|EU-approved Stelara (Part 2)|45mg single dose administration
11050083|NCT04428814|Active Comparator|US-licensed Stelara (Part 2)|45mg single dose administration
11050084|NCT04428801|Experimental|Phase 2 AdMSC group|"Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days
~Other Names: Celltex-AdMSCs Celltex-AdMSCs"
11050085|NCT04428801|Placebo Comparator|Phase 2 Placebo group|The control group- receive three doses of placebo via intravenously infusion every three days.
11050086|NCT04428788|Experimental|Administration of CC-94676|Escalating doses of CC-94676 administered orally (tablets) once daily.
11050087|NCT04428775|Experimental|Group I (Low Dose)|Group I (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 17.1 mg/twice a day (bid) (total of 34.2 mg/day)
11050088|NCT04428775|Experimental|Group II (High Dose)|Group II (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 34.2 mg/bid (total of 68.4 mg/day)
11050089|NCT04428762|Experimental|I-Port use arm|
11050090|NCT04428762|No Intervention|Regular injection arm|
11050091|NCT04428749||Study group|"Participants are screened using the Yale Swallow Protocol (YSP) 2-4 hours after extubation:
~Ability to swallow is assessed by an ICU nurse using the YSP. If the YSP is negative, the patient may start oral feeding and drinking. In case of a positive YSP, the screening may be repeated within the next 24 hours provided the patient improves clinically. If YSP continues to be positive the patient is referred to assessment by a speech language pathologist (SLP).
~Participants are screened within 24 hours:
~To evaluate YSP against the FEES, the patient undergoes 1) YSP performed by an ICU nurse followed by 2) FEES performed by a SLP (until PAS>6 (aspiration on any food consistency on the Penetration Aspiration Scale (20)). The SLP will be blinded to the assessment made by the ICU nurses. Patients will follow recommendations for oral feeding and drinking as given by the SLP."
11050092|NCT04428723||Hypoglycemia, no upper gastrointestinal (GI) surgery|Males or females with hypoglycemia with neuroglycopenia, but no history of upper GI surgery, diabetes or prediabetes
11050093|NCT04428723||Hypoglycemia, with history of upper GI surgery|Males or females with hypoglycemia with neuroglycopenia, with history of upper GI surgery
11050094|NCT04428723||Controls, without hypoglycemia or upper GI surgery|Males or females with no history of upper gastrointestinal surgery, hypoglycemia, or diabetes.
11050095|NCT04428710||patients admitted to cancer genetic counseling test|Participants were recruited from all consecutive patients referred to the Cancer Genetic Program at the Hospital Universitari i Politècnic la Fe.
11050096|NCT04428697|Experimental|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm. After identifying both the internal and external sphincters completely, under direct vision, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. This section was preserved during the operation in a standard fashion for all patients . Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter bundle was elevated with a right angle clamp, then cut with cautery . The operation was completed with meticulous hemostasis and additional suturing (3/0 absorbable suture) of the proximally dissected mucosal flap underlying the muscularis layer
11050327|NCT04427033||SSD (5 years and older)|SSD= single sided deaffness
11050097|NCT04428697|Active Comparator|Closed Lateral Internal Sphincterotomy|The sphincterotomy was performed through a new incision, guided by the surgeon's finger, as described by Boulos et al Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? The British journal of surgery 1984;71:360-2.
11050098|NCT04428684|Experimental|Pepti 3.6 treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
11050099|NCT04428684|Active Comparator|Zoladex 3.6 mg treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
11050100|NCT04428671|Experimental|Treatment (cemiplimab)|"NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~ADJUVANT PHASE: Within 2-6 weeks after standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity."
11050101|NCT04428658|Experimental|Home-based video visits|Participants in the intervention arm will receive home-based video visits with a pediatric endocrinologist every 12 weeks for the duration of 1 year in addition to usual care (which includes initial assistance with setting up secure platforms for diabetes data-sharing and usual quarterly in-person care at the UCD Pediatric Diabetes Clinic).
11050102|NCT04428658|Active Comparator|Standard of Care|The control group will receive usual care, which includes initial assistance with setting up secure platforms for diabetes data-sharing and usual quarterly in-person care at the UCD Pediatric Diabetes Clinic.
11050103|NCT04428645|Experimental|DailyDose Decision Support|Subjects will use DailyDose decision support for 8 weeks at home.
11050104|NCT04428619|Active Comparator|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|The PENFS device has a battery activated generator and wire harness. Four leads are attached to the generator, each with a sterile 2 mm, titanium needle. The patient's ear is trans-illuminated to identify neurovascular bundles that are avoided during needle placement. The generator is attached with adhesive to the skin behind the patient's ear. Needles are inserted into the dorsal and ventral aspects of the ear, within 1-1.5 mm of the vascular branches to create a field effect. The device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The device is worn for 5 days/week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will be asked to wear a SmartWatch during the study to monitor heart rate.
11050105|NCT04428619|Sham Comparator|Sham Device|The sham devices will be identical to the active devices but will not administer electrical charges. Per manufacturer design and patient anecdotal experience from previous studies, both active stimulation and sham are below detectable sensation threshold. Per report from previous studies, some patients may experience a sensation around the ear after percutaneous needle placement; however, this sensation can occur with equal likelihood in the active or sham device. The device is worn for 5 days a week for a total of 4 weeks. Patients remove devices at home on day 6 of each treatment cycle. Patients will also be asked to wear a SmartWatch as above.
11050106|NCT04428606|Experimental|Metabolic Rheostat™|Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
11050107|NCT04428606|Experimental|Butyrate Ultra|Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
11050108|NCT04428606|Placebo Comparator|Placebo|Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
11050109|NCT04428593|Experimental|Treamid 5 mg|Cohort 1 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 5 mg (4 subjects) or placebo (1 subject, see placebo arm).
11050110|NCT04428593|Experimental|Treamid 15 mg|Cohort 2 - 5 subjects were randomized in a 4:1 ratio to be treated either Treamid 15 mg (4 subjects) or placebo (1 subject, see placebo arm).
11050111|NCT04428593|Experimental|Treamid 50 mg|Cohort 3 - 5 subjects were randomized in a 8:2 ratio to be treated either Treamid 50 mg (8 subjects) or placebo (2 subjects, see placebo arm).
11050112|NCT04428593|Placebo Comparator|Placebo|Placebo comparator arm consists of 4 subjects (1 subject from Сohorts 1 and 2, 2 subjects from Cohort 3).
11050113|NCT04428580|Experimental|Online Training|10 lectures that are self-paced with a maximum of three months to complete with each lecture bundle comprising of 5-8 short (about 4 minutes in length), didactic videos that discuss the treatment model and provide mock therapy session video clips (modeling FBT with a typical adolescent AN case), as well as supplementary readings and videotaped role-plays. Enrollees complete each lecture bundle and complete the assignments as they move through the training at their own pace, but to have completed all within the 3-month time frame. When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
11050114|NCT04428580|Active Comparator|Webinar Training|1-hour weekly webinar lectures that essentially is the FBT training that is conducted in person, just recorded. There will be lectures discussing the scientific evidence supporting FBT, how therapists set up treatment for FBT, main interventions used in FBT during each phase, and recorded role-plays illustrating interventions throughout the 3 phases. Enrollees watch each webinar video as it is released weekly over a 12 week (3 month period). When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
11050115|NCT04428567|Experimental|Treadmill Exercise + Cognitive Training (Dual-Task)|The Dual-Task group will be provided with treadmill training with added simultaneous cognitive training during treadmill exercise training.
11050116|NCT04428567|No Intervention|Control Group|The control group will be assessed as the intervention group at the same time intervals without the intervention.
11050117|NCT04428554|No Intervention|Control arm|Observation
11050118|NCT04428554|Experimental|Experimental arm|
11050119|NCT04428541|Experimental|Questionnaire|Description : 18 items questionnaire, filled by the parents of the child
11050120|NCT04428528||Neoadjuvant Chemotherapy Monitoring|
11050121|NCT04428528||Breast Mass Characterization|
11050122|NCT04428515||Radiotherapy Response Monitoring|
11050486|NCT04426019|Experimental|CLS intervention|
11050127|NCT04428463|Active Comparator|tympanoplasty using fascia and cartilage|tympanoplasty under general anesthesia using fascia and cartilage witch is the gold standard for treating tympanic membrane perforations.
11050128|NCT04428463|Experimental|Tachosil|repair of tympanic perforations under local anesthesia using Tachosil patch.
11050129|NCT04428450|Experimental|Deprexis (unguided)|web-based self-help program without any support from a therapist during the 10-week treatment period
11050130|NCT04428450|Experimental|Deprexis (guided, with therapist)|web-based self-help program plus scheduled e-mail contact with a therapist during the 10-week treatment period
11050131|NCT04428450|No Intervention|Wait-list|Wait-list group (subjects receive access to Deprexis after 10 weeks)
11050132|NCT04428437||Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by lenvatinib.
11050133|NCT04428437||Non-Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by non-lenvatinib.
11050134|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
11050135|NCT04428411||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease
11050136|NCT04428398||No renal involvement|Patients with ANCA-vasculitis and no ANCA-associated renal involvement in disease history
11050137|NCT04428398||Renal remission|Patient with ANCA-vasculitis in renal remission
11050138|NCT04428385|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
11050139|NCT04428385|Experimental|Arm 2 (provider-directed intervention)|Providers receive a small payment (~25cents) for each RDT that they perform, RDTs available at study-recommended price
11050140|NCT04428385|Experimental|Arm 3 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
11050141|NCT04428385|Experimental|Arm 4 (consumer-directed and provider-directed in|providers receive a small payment (~25 cents) for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
11050142|NCT04428372|Experimental|Mannitol|intravenous 20% mannitol, 0.25g/kg/hour (maximum 25g/hour; maximum 75g per session; maximum volume 375mL/session) as a continuous infusion during dialysis
11050143|NCT04428372|Placebo Comparator|Placebo|0.9% saline at a rate of 1.25mL/kg/hour (maximum volume 375mL) as a continuous infusion during dialysis
11050144|NCT04428359|Experimental|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
11050145|NCT04428359|Experimental|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
11050146|NCT04428346|Active Comparator|Contigency Management (Intervention)|
11050147|NCT04428346|No Intervention|Standard of Care (Control)|
11050148|NCT04428333|Experimental|GSK3359609+ Pembrolizumab + 5-FU-platinum chemotherapy|
11050149|NCT04428333|Placebo Comparator|Placebo + Pembrolizumab + 5-FU-platinum chemotherapy|
11050150|NCT04428320|Experimental|Bupivicaine pelvic floor muscle injection|Five injections at pre-specified locations at pelvic floor muscle bilaterally after induction of general anesthesia for vaginal pelvic prolapse surgery
11050151|NCT04428320|No Intervention|Standard of care (no injection) preoperatively|No injection - standard analgesia
11050152|NCT04428307|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
11050153|NCT04428307|Experimental|Arm 2 (provider-directed intervention)|Providers receive a small payment (~10cents) for each RDT that they perform, RDTs available at study-recommended price
11050154|NCT04428307|Experimental|Arm 3 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
11050155|NCT04428307|Experimental|Arm 4 (consumer-directed and provider-directed intervention)|providers receive a small payment (~10 cents) for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
11050156|NCT04428281|Experimental|Cohort A1 RO7248824|Participants 5-12 Years
11050157|NCT04428281|Experimental|Cohort A2 RO7248824|Participants 5-12 Years
11050158|NCT04428281|Experimental|Cohort A3 RO7248824|Participants 5-12 Years
11050159|NCT04428281|Experimental|Cohort A4 RO7248824|Participants 5-12 Years
11050160|NCT04428281|Experimental|Cohort B1 RO7248824|Participants 1-4 Years
11050161|NCT04428281|Experimental|Cohort B2 RO7248824|Participants 1-4 Years
11050162|NCT04428281|Experimental|Cohort B3 RO7248824|Participants 1-4 Years
11050163|NCT04428281|Experimental|Cohort B4 RO7248824|Participants 1-4 Years
11050164|NCT04428281|Experimental|Cohort B5 RO7248824|Participants 1-4 Years
11050165|NCT04428268|Active Comparator|Chloroquine|Patients will receive chloroquine phosphate 450 mg every 12 hours orally
11050166|NCT04428268|Experimental|Chloroquine plus losartan|Patients will receive Chloroquine phosphate 450mg orally every 12hrs plus Losartan 25mg orally every 12hrs
11050167|NCT04428255|Experimental|HBM9161 Dose A|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
11050168|NCT04428255|Experimental|HBM9161 Dose B|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
11050169|NCT04428255|Placebo Comparator|Placebo|Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo
11050170|NCT04428242||Group 1|Subjects with normal macular thickness in one or both eyes.
11050171|NCT04428242||Group 2|Subjects with center-involving macular edema due to w/AMD in one or both eyes.
11050172|NCT04428242||Group 3|Subjects with center-involving macular edema due to DR or RVO in one or both eyes.
11050173|NCT04428216|Active Comparator|Group RIB = Rhomboid intercostal block group|In group RIB, RIB block will be performed with patients in the lateral decubitus position. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injected into the fascial plane.
11050487|NCT04426019|Active Comparator|No CLS intervention|
11050174|NCT04428216|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11050175|NCT04428203|Experimental|single arm|A Phase I/Ib on the Safety of Epidiolex in Patients with Prostate Cancer with Rising PSA after Localized Therapy with either Surgery or Radiation
11050176|NCT04428190|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.
~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have been shown to stimulate the production of short chain fatty acids, especially propionate. Propionate has been shown to be important in attenuating hypertrophy, fibrosis, vascular dysfunction and hypertension (Bartolomaeus H et al 2019Mar12) and extremely important for the gut kidney axis (Li L et al 2017Dec11)."
11050177|NCT04428190|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.
~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
11050178|NCT04428177|Experimental|Intrvascular Lithotripsy|Calcified coronary lesions will be treated with intrvascular lithotripsy
11050179|NCT04428177|Active Comparator|Standard therapy|Standard treatment of calcified coronary lesions: cutting, scoring or non-compliant balloon predilatation or rotational atherectomy
11050180|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
11050181|NCT04428151|Experimental|Pembrolizumab + Lenvatinib|Participants will be treated with the combination of pembrolizumab (200 mg 30-minute intravenous (IV) infusion on day 1 of each 21-day cycle for 35 cycles), plus lenvatinib (once daily 20 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib.
11050182|NCT04428151|Active Comparator|SOC Chemotherapy|Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
11050183|NCT04428151|Active Comparator|Lenvatinib Monotherapy|Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
11050184|NCT04428138||Patients with Inguinal hernia|Patients presenting with inguinal hernia will undergo vascular in-office visit and echo duplex of aorta, carotid arteries and lower limb arteries in order to detect any abnormalities related to arterial disease (aneurysm, stenosis, flow alteration).
11050185|NCT04428125||Healthy sporty subjects|Healthy sporty subjects that participate in the following sports: baseball, tennis, swimming, rowing, volleyball, rugby football, weightlifting.
11050186|NCT04428125||Healthy non-sporty subjects|Healthy subjects that do not partecipate in sport activities.
11050187|NCT04428112|Experimental|Building Better Caregivers Workshop Group|Building Better Caregivers Workshop is a 6-week online self-management and skills building workshop. Participants receive the online workshop as soon as possible after randomization.
11050188|NCT04428112|Active Comparator|Attention Control Group|Participants will be offered the online workshop after the 12 month trial is completed if they so desire.
11050189|NCT04428099|Experimental|Intervention|Lifestyle change promotion program
11050190|NCT04428099|Active Comparator|Control 1|MBCT program
11050191|NCT04428099|Placebo Comparator|Control 2|Usual care
11050192|NCT04428086|Experimental|Assess PK effects of Apatinib on Rosuvastatin|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.
11050193|NCT04428086|Experimental|Assess PK effects of Apatinib on Metformin|Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.
11050194|NCT04428073|Experimental|Low dose group|Subjects will receive 1.0 mL of low dose vaccine at week 0 and 2.
11050195|NCT04428073|Experimental|High dose group|Subjects will receive 1.0 mL of high dose vaccine at week 0 and 2.
11050196|NCT04428060|Experimental|PERSEUS CPR|Patients will be resuscitated according to the PERSEUS protocol
11050197|NCT04428060|Active Comparator|CONTROL|Patients will be resuscitated according to current Advanced Life Support guidelines
11050198|NCT04428047|Experimental|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
11050199|NCT04428034|Experimental|Learning Skills Together Intervention|Participants in the Learning Skills Together program will begin their participation with a one-on-one phone call with an interventionist, who will ensure the participant is prepared to to attend the group sessions (e.g., familiar with videoconference technology) and will help the participant to set individual goals. The caregiver participant will then attend 4, group-based sessions lasting approximately 1.5 hours each, to learn about common complex care tasks managed by family caregivers to someone with mid-stage Alzheimer's disease, such as managing behavioral symptoms of dementia, incontinence, nutrition, transferring, medication management, and more. Sessions will integrate interactive activities, such as videos, case studies, and discussions. Approximately four weeks later, caregivers will be asked to attend a group reflection session to discuss application of what was learned and progress in meeting individual goals.
11050200|NCT04428021|Active Comparator|Standard therapy protocol (STP)|STP is defined as the best evidence based therapy approved for treatment of COVID-19 patients by Regional Health System emergency committee. STP could be updated during the trial.
11050201|NCT04428021|Experimental|STP + Standard Plasma (SP)|STP + 3 units on day 1-3-5 of Standard Plasma collected in pre-COVID era (January-September 2019)
11050202|NCT04428021|Experimental|STP + COVID-19 Convalescent Plasma (CP)|STP + 3 units on day 1-3-5 of COVID-19 Convalescent Plasma containing neutralizing SARS-Cov-2 antibodies
11050203|NCT04428008|Experimental|Active arm|1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks
11050204|NCT04428008|No Intervention|Control arm|Standard care
11050328|NCT04427020|Experimental|Milk Protein + Probiotic|25 gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
11050329|NCT04427020|Active Comparator|Milk Protein|25 gram dose of milk protein concentrate
11050205|NCT04427995||Oen Angle Glaucoma|• Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.
11050206|NCT04427982|Experimental|Experimental Group|All participants will attend a 2-month weekly light-to-moderate intensity dance workshop followed by a brief diabetes education and discussion session.
11050207|NCT04427969||EPP|patients who applied early awake prone position for treatment with conventional oxygen supply
11050208|NCT04427969||non-EPP|patient who only get conventional oxygen therapy as respiratory supply
11050209|NCT04427956|Active Comparator|Isotonic riboflavin|CXL (UVA 9mW/cm2) treatment using isotonic riboflavin
11050210|NCT04427956|Active Comparator|Hypotonic riboflavin|CXL (UVA 9mW/cm2) using hypotonic riboflavin
11050211|NCT04427956|Active Comparator|Iontophoresis|Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).
11050212|NCT04427943||RIKA cohort|patients with periprosthetic knee joint infection scheduled for revision knee arthroplasty surgery
11050213|NCT04427930|Experimental|JOINTSTEM|Long Term Follow-up after Jointstem Transplantation
11050214|NCT04427930|Placebo Comparator|Saline|
11050215|NCT04427917|Experimental|PF-06835919|
11050216|NCT04427917|Placebo Comparator|Placebo|
11050217|NCT04427904|Experimental|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
11050218|NCT04427904|Active Comparator|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
11050219|NCT04427891||Group I|"Patients undergoing emergency surgery due to perforated diverticulitis with peritonitis.
~No intervention, samples from abdominal fluid, blood, tissue, feces"
11050220|NCT04427891||Group II|Patients with colorectal cancer undergoing elective surgery. No intervention. Samples as for Group I
11050221|NCT04427891||Group III|Patients with mild diverticulitis, not undergoing surgery. No intervention. Samples from blood and feces.
11050222|NCT04427878|Experimental|patients with Covid-19|
11050223|NCT04427865|Experimental|Lactoferrin prophylaxis|200 mg oral lactoferrin daily
11050224|NCT04427865|No Intervention|Control group|
11050225|NCT04427852|Experimental|30 day Beef consumption|One serving of beef is consumed each day for 30 days.
11050226|NCT04427852|Placebo Comparator|30 day Veggie Patty consumption|One serving (1 patty) of a vegetable based protein source is consumed each day for 30 days. The weight of the food, total calories, grams of protein, and total fat are the same as the beef serving.
11050227|NCT04427826|Experimental|Patient admitted for acute Exacerbation of Chronic Obstructive|Patient admitted for acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) and required NIV
11050228|NCT04427800||CKD G4|Chronic kidney disease stage (G4). (eGFR < 30 mL/min/1.73m2)
11050229|NCT04427800||CKD G5|Chronic kidney disease stage (G5). (eGFR < 15 mL/min/1.73m2) with imminent initiation of RRT
11050230|NCT04427800||ESRD on ICHD|End stage renal disease on in centre haemodialysis
11050231|NCT04427800||ESRD on HHD|End stage renal disease on home haemodialysis
11050232|NCT04427800||ESRD on PD|End stage renal disease on peritoneal dialysis
11050233|NCT04427800||Post-transplant|Participants post-transplant
11050234|NCT04427787|Experimental|Cabozantinib+lanreotide|Cabozantinib will be administered orally at a dose of 60 mg/day continuously in combination with Lanreotide 120 mg injection every 28 days. Both treatments will start the same day
11050235|NCT04427774|Experimental|Surufatinib plus Sintilimab|
11050236|NCT04427761||pancreatic cancer health-illness transition|In this prospective longitudinal correlational study, a convenience sample of patients with pancreatic cancer receiving chemotherapy will be asked to report on their health-illness transition experiences and their level of distress.
11050237|NCT04427748||congenital cataract group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and IOL implantation are perfomed ERG
11050238|NCT04427748||age-matched normal children group|age-matched normal children are perfomed ERG
11050239|NCT04427735||before COVID-19|Patients with myocardial infarction from January 24, 2019 to June 24, 2019
11050240|NCT04427735||after COVID-19|Patients with myocardial infarction from January 24, 2020 to June 24, 2020
11050241|NCT04427709|Other|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®) first then placebo injection.
11050242|NCT04427709|Other|Placebo, Then Oxytocin|Subjects in this arm will receive Intramuscular placebo injection first then oxytocin injection
11050243|NCT04427696|Active Comparator|Aerobic walking|The participants in this arm were obligated to carry out one hour aerobic walking (goal setting walking) daily. The goal of aerobic walking: 1. at least 60 steps per minute; 2. continuously walking for 10 minutes.
11050244|NCT04427696|Placebo Comparator|No aerobic walking|The participants in this arm were requested to maintain sedentary life, without joining other physical exercise programmes.
11050245|NCT04427683|Experimental|Brief mindful parenting program|The program will consist of a four-session and last for eight hours integrating mindfulness skills and psychoeducation in managing stress under social unrest and promoting strategies for emotion regulation, conflict management, and self-care.
11050246|NCT04427683|Other|Wait-list control group|A four-minute educational video will be distributed to the participants who accept the randomisation. It includes brief information on mental health. After the participants from experimental group complete the intervention, those in wait-list control group will receive the same intervention.
11050247|NCT04427670|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group.
11050248|NCT04427670|Other|Group intervention|Group intervention will be provided to the experimental group.
11050249|NCT04427657|Active Comparator|Controls|39 patients with knee osteoarthritis undergoing arthroscopic debridement
11050250|NCT04427657|Experimental|Cases|39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (Lipogems®).
11050488|NCT04426006|Other|PRO-SERO-COV|Blood sample and self-administered questionnaire
11062953|NCT04336449|Experimental|Cohort 2 300 mg eptinezumab|
11050251|NCT04427644||Complication positive|Patients with perioeprative complications after laparascopic sleeve gastrectomy before discharge (wound complications, thromboembolic events, staple line leakage, splenic infarction proven by imaging modalities, bleeding detected due to low hemoglobin and hematocrit values during follow-up, acute renal failure due to deterioration in biochemical parameters)
11050252|NCT04427644||Complication negative|Patients without perioeprative complications after laparascopic sleeve gastrectomy before discharge
11050253|NCT04427644||BMI 40 - 45 kg/m2|Operated patients preoperative BMI values between 40 - 45 kg/m2
11050254|NCT04427644||BMI 45 - 50 kg/m2|Operated patients preoperative BMI values between 45 - 50 kg/m2
11050255|NCT04427644||BMI over 50 kg/m2|Operated patients preoperative BMI values 45 - 50 kg/m2
11050256|NCT04427644||Clavien Dindo Major Complications|"Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy This grade also includes wound infections opened at the bedside
~Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included"
11050257|NCT04427644||Clavien Dindo Minor Complciations|3. Requiring surgical, endoscopic or radiological intervention 3a Intervention under regional/local anaesthesia 3b Intervention under general anaesthesia 4. Life-threatening complication requiring intensive care/intensive care unit management 4a Single-organ dysfunction 4b Multi-organ dysfunction 5. Patient demise
11050258|NCT04427631|Experimental|Single arm study|The family will complete questionnaires before and after each childs intervention. Therefore each child will act as their own control.
11050259|NCT04427618|Experimental|Intervention group|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision, and Intravenous oxytocin 5 units post delivery of the baby.
11050260|NCT04427618|Placebo Comparator|Control group|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision, and intravenous oxytocin 5 units post delivery of the baby
11050261|NCT04427605||ketamine group|ketamine intravenous infusion in pediatric patients refractory to conventional analgesic-sedative strategy lasted more than 12 hours (dose range 10-50 mcg/Kg/min)
11050262|NCT04427592|Experimental|pregnant women with placenta accreta spectrum|The participants were subjected to ultrasound to diagnose placenta accreta spectrum followed by new conservative surgical technique.
11050263|NCT04427566|Experimental|Radiation Arm|Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
11050264|NCT04427553|Experimental|Percutaneous Peripheral Nerve Stimulation|"Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve. We will apply a biphasic compensated electrical current at a frequency of 10 Hz, a pulse width of 240 µs and intensity allowed over a pain-free motor threshold (muscle contraction). Each participant will receive 10 repetitions of 10 seconds each one with 10 seconds rest- period between series (total treatment session 1.40 min).
~After that participants will walk during 3 minutes."
11050265|NCT04427553|Placebo Comparator|Control|Participants in the control group will walk during 5 minutes, without receiving any intervention
11050266|NCT04427540|Experimental|Oxytocin|Single IM injection Oxytocin 17 micrograms
11050267|NCT04427527|Experimental|Multi-level Intervention|Receives the project intervention first
11050268|NCT04427527|No Intervention|Delayed Multi-level Intervention|Offered the intervention later in the project
11050269|NCT04427514|Experimental|CAPD group|Standard CAPD therapy wtih telemedicine system
11050270|NCT04427501|Experimental|LY3819253|LY3819253 administered intravenously (IV)
11050271|NCT04427501|Experimental|LY3819253 + LY3832479|LY3819253 + LY3832479 administered IV
11050272|NCT04427501|Placebo Comparator|Placebo|Placebo administered IV
11050273|NCT04427488|Experimental|Aerobic Exercise Group|The first group will have a total of 12 weeks of aerobic exercise for the first 6 weeks in the morning and the next 6 weeks in the evening.
11050274|NCT04427488|Experimental|Strengthening Exercise Group|In the second group, 12 weeks strengthening exercises will be done in the first 6 weeks in the morning and 6 weeks in the evening
11050275|NCT04427475|Other|pabolizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
11050276|NCT04427475|Other|nafulizumab|Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
11050277|NCT04427449|Experimental|Experimental: Single arm 4SCAR-CD44v6 T cells to treat cancer|
11050278|NCT04427436||Patients|Mild Cognitive Impairment (clinical determination)
11050279|NCT04427436||Control|Healthy Elderly
11050280|NCT04427423|Experimental|Positional Distraction plus Stabilization Exercise group|The treatment group will receive positional distraction with stabilization exercises
11050281|NCT04427423|Active Comparator|Stabilization Exercise group|control group will be treated with stabilization exercises only.
11050282|NCT04427410||pregnancy|
11050283|NCT04427410||postpartum|
11050284|NCT04427397|Experimental|Sulcular Bristle Tip Technique (SBTT)|This test group will receive formal instruction on the Sulcular Bristle Tip Technique (SBTT).
11050285|NCT04427397|No Intervention|User manual of the electric toothbrush (DFU)|This control group will be asked to read and use the instructions found in the user manual of the electric toothbrush (DFU). No formal instruction will be provided. The DFU accompany the electric toothbrush regardless of the subject's participation in the research.
11050286|NCT04427384||GammaTile|Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.
11050287|NCT04427371||survivors|Improve or under treatment
11050288|NCT04427371||nonsurvivors|all-cause 28-day mortality
11050289|NCT04427345||Covid19 infection related patients|Patients admitted to COVID wards of the S. Gerardo Hospital of Monza, including Intensive Care wards.
11050330|NCT04427007|Experimental|Experimental Prosthetic Liner|Participants will test the experimental liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
11050290|NCT04427332||Covid19 infection related patients|"All subjects that had access to the nasopharyngeal swabs service of the hospital for the detection of the Sars-CoV-2 virus, both hospitalized and discharged from the hospital and not hospitalized, from mid-May to the end of June 2020, will be consecutively enrolled. It is assumed that 500 people will be recruited."
11050291|NCT04427319|Experimental|Experimental group|Product: β-Alanine Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
11050292|NCT04427319|Placebo Comparator|Placebo group|Product: wheat semolina Supplementation strategy: 5 g, four times a day with main meals, for 7 days after the initial evaluation and until the end of the study.
11050293|NCT04427306|Experimental|Treatment (talimogene laherparepvec)|
11050294|NCT04427293|Experimental|Open Label|All participants will receive one 21-day cycle of therapy prior to surgery, consisting of lenvatinib 12 mg daily, days 1 through 14, and pembrolizumab 200 mg IV on day 1
11050295|NCT04427267||Health workers|
11050296|NCT04427254|Experimental|Neurological biological samples|
11050297|NCT04427241|Active Comparator|Amantadine plus cerebrolysin|
11050298|NCT04427241|Active Comparator|Amantadine only|
11050299|NCT04427241|Active Comparator|Cerebrolysin only|
11050300|NCT04427228|Experimental|Arm A|
11050301|NCT04427228|Active Comparator|ARM B|
11050302|NCT04427215|Experimental|A - Music Therapy|Two section a week of music therapy
11050303|NCT04427215|Experimental|B - Art Therapy|Two section a week of Art therapy
11050304|NCT04427215|Experimental|C - Dance-Movement Therapy|Two section a week of Dance-Movement Therapy
11050305|NCT04427215|Experimental|D - Bibliotherapy|Two section a week of Bibliotherapy
11050306|NCT04427215|Experimental|E - Physical Activity|Two section a week of systematized physical activity
11050307|NCT04427202|Other|Referral to harm reduction services|Participants will be taken through the study survey and interview, blood and urine toxicology testing and given a referral to a harm reduction organization.
11050308|NCT04427176||Nurses|"Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne will be included.
~They will be wear ARFC mask."
11050309|NCT04427163||Genomic, transcriptomic, proteomic, metabolomic profiles|Determination of genomic, transcriptomic, proteomic, metabolomic profiles in subjects.
11050310|NCT04427150|Experimental|Auditory Training Group|12 hours of psychoacoustic training over 8 weeks
11050311|NCT04427150|Active Comparator|Other Training Group|12 hours of non-psychoacoustic training over 8 weeks
11050312|NCT04427150|No Intervention|TD Group|
11050313|NCT04427137|Experimental|Accelerated LFR|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients that have responded to treatment will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
11050314|NCT04427124||Prospective|Patients admitted into the hospital will receive care based on a multidisciplinary team approach and Institutional critical limb ischemia protocol.
11050315|NCT04427124||Retrospective|A retrospective analysis of all patients with CLI admitted to the hospital from 2017-2019 will serve as a baseline comparator for overall CLI care and long-term mortality out to 2 years will be analyzed in the retrospective cohort using the national death index. Patients will be identified by the following ICD codes: 440.22 (ASVD of extremities with rest pain), 440.23 (ulceration), and 440.24 (gangrene).
11050316|NCT04427111||Mild-moderate OSA patients for MAD treatment|Patients are classified as mild Obstructive Sleep Apnea (OSA) if they have between 5-15 Apnea-Hypopnea Index, moderate if they have between 15-30, and severe if they have >30, as measured by Polysomnography (Epstein LJ, Kristo D, Strollo PJ, et al. 2009). The principal treatment methodology for OSA patients is positive airway pressure. In patients with mild to moderate OSA, oral appliances such as mandibular advancement devices (MAD) is alternately indicated (Ramar K, Dort LC, Katz SG, et al. 2015) The American Academy of Dental Sleep Medicine (Ramar K, Dort LC, Katz SG, et al. 2015) recommended titratable-customized MADs for patient comfort and the ability to permit modifications in the amount of mandibular protrusion for treatment efficacy. However, Aarab et al (Aarab G, Lobbezoo F, Hamburger HL, Naeije M. 2010) demonstrated similar therapeutic efficiency of non-titratable-customized MADs in the treatment of OSA
11050317|NCT04427098|Active Comparator|a phase II single-arm interventional prospective study|"Patients included in the interventional study will receive subcutaneous enoxaparin in a single daily dose of:
~60 mg once daily in case of body weight of 45 to 60 kg
~80 mg per day in case of weight from 61 to 100 kg or
~100 mg once daily in case of bodyweight >100 kg
~Enoxaparin will be started on the first day of COVID19 diagnosis and continued for 14 days."
11050318|NCT04427098|Experimental|observational cohort study|Patients included in the observational cohort will will receive standard thrombo-prophylaxis with subcutaneous enoxaparin 40 mg/die
11050319|NCT04427085|Experimental|Obese group|body mass index≥ 30 kg/m2
11050320|NCT04427085|Active Comparator|Non-obese group|BMI < 30 kg/m2
11050321|NCT04427072|Experimental|Capmatinib|400mg of capmatinib tablets, administered orally twice daily
11050322|NCT04427072|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 solution administered by intravenous infusion on Day 1 of every 21-day cycle
11050323|NCT04427059|Experimental|Arm A - laparoscopic assisted TAP block|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.5%) is then injected for postoperative pain control according to the allocated procedure (TPA).
11050324|NCT04427059|Active Comparator|Arm B - PSI|Patients will undergo the planned bariatric intervention according to the standard of treatment. A solution of 20 ml of the local anesthetic Ropivacaine (0.5%) is then injected for postoperative pain control according to the allocated procedure (PSI).
11050325|NCT04427033||CHL & MHL (18 years and older)|CHL= conductive hearing loss MHL= mixed hearing loss
11050326|NCT04427033||CHL & MHL (5 to 17 years)|
11050331|NCT04427007|Other|Control Prosthetic Liner|Participants will test the control liner in combination with the active cooling socket (ICE System). Prosthetic liners and socket will be tested by walking on a treadmill.
11050332|NCT04426994||Case|Patients admitted with hypomagnesemia are evaluated for proton pump inhibitor use and likelihood of hypomagnesemia due to proton pump inhibitor use
11050333|NCT04426994||Control|Patients on long-term proton pump inhibitor without documented hypomagnesemia
11050334|NCT04426981|Experimental|Intervention arm|Consenting patients will be enrolled into a Behavioral Activation treatment arm. Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities.
11050335|NCT04426968|Experimental|Hepalatide 2.1mg+Pegylated Interferon|
11050336|NCT04426968|Experimental|Hepalatide 4.2mg+Pegylated Interferon|
11050337|NCT04426968|Experimental|Hepalatide 6.3mg+Pegylated Interferon|
11050338|NCT04426968|Active Comparator|placebo+Pegylated Interferon|
11050339|NCT04426955|Experimental|Arm A|Camrelizumb + Paclitaxel + Cisplatin + Radiotherapy.
11050340|NCT04426955|Placebo Comparator|Arm B|Placebo + Paclitaxel + Cisplatin + Radiotherapy.
11050341|NCT04426942||Spontaneous pregnancy|
11050342|NCT04426942||Assisted reproduction pregnancy|
11050343|NCT04426929|Experimental|Conventional Group|Electrotherapy program will be applied to all individuals. conventional exercise therapy will be applied to this group.
11050344|NCT04426929|Experimental|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
11050345|NCT04426929|Experimental|Video Based Exercise Group|Video based exercise program will be applied to the this group.
11050346|NCT04426916||normal lumbar spine|Patient without spondylolisthesis or significant spinal anatomic deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
11050347|NCT04426916||spondylolisthesis|Spondylolisthesis patients, with whom the deformity is at just one level. The patients should not have any other significant spinal deformity. (ex> severe spondylosis, spinal stenosis, scoliosis, etc..)
11050348|NCT04426903|Experimental|LLM Care|LLM Care training Participants use the webFitForAll exergaming computer platform as the physical training component (PT); Participants use the language adapted version of the BrainHQ Program as the cognitive training component (CT)
11050349|NCT04426903|Experimental|Physical Training (PT)|Physical training only. Participants use the webFitForAll exergaming computer platform as the physical training component (PT).
11050350|NCT04426903|Experimental|Cognitive Training (CT)|Cognitive training only. Participants use the language adapted Version of the BrainHQ Program as the cognitive training component (CT).
11050351|NCT04426890|Experimental|Arm 1|300 mg of CT-P39 as SC injections via PFS
11050352|NCT04426890|Active Comparator|Arm 2|300 mg of EU-approved Xolair as SC injections via PFS
11050353|NCT04426890|Experimental|Arm 2-1|300 mg of CT-P39 as SC injections via PFS
11050354|NCT04426890|Active Comparator|Arm 2-2|300 mg of EU-approved Xolair as SC injections via PFS
11050355|NCT04426890|Experimental|Arm 3|"Treatment period 1: 150 mg of CT-P39
~Treatment period 2: 300 mg of CT-P39"
11050356|NCT04426890|Active Comparator|Arm 4|"Treatment period 1: 150 mg of EU-approved Xolair
~Treatment period 2: 300 mg of EU-approved Xolair"
11050357|NCT04426877|Experimental|Experimental group|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
11050358|NCT04426877|Experimental|Control Group|The control group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
11050359|NCT04426864|Active Comparator|Supervised Aerobic Plus Stretching Exercises Group|The participants were instructed to perform the walking exercise at their target HR on a treadmill and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
11050360|NCT04426864|Experimental|Supervised Resistance Plus Stretching Exercises Group|The participants were instructed to perform resistance exercises using weight machines and stretching exercises before and after the exercise program in the Sports Rehabilitation Unit of Pamukkale University.
11050361|NCT04426864|Experimental|Home-based Stretching Exercises Group|The participants were instructed to perform the stretching exercises at home.
11050362|NCT04426851|Experimental|Part 2: BI 1358894 (Test 2-Reference 2)|BI 1358894
11050363|NCT04426851|Experimental|Part 2: BI 1358894 (Reference 2-Test 2)|BI 1358894
11050364|NCT04426851|Experimental|Part 1: BI 1358894 (Test 1-Reference 1)|BI 1358894
11050365|NCT04426838|Experimental|PLwD Face-to-Face Intervention|Persons living with dementia in a dyad randomized to receive the CBTi intervention in a face-to-face format.
11050366|NCT04426838|Experimental|Caregiver Face-to-Face Intervention|Caregivers in a dyad randomized to receive the CBTi intervention in a face-to-face format.
11050367|NCT04426838|Experimental|PLwD Videoconferencing Intervention|Persons living with dementia in a dyad randomized to receive the CBTi intervention in a videoconferencing format.
11050368|NCT04426838|Experimental|Caregiver Videoconferencing Intervention|Caregivers in a dyad randomized to receive the CBTi intervention in a videoconferencing format.
11050369|NCT04426825|Experimental|Atezolizumab plus Bevacizumab|Participants will receive atezolizumab plus bevacizumab intravenously on Day 1 of each cycle. Treatment will continue until progressive disease, unacceptable toxicity, or death.
11050370|NCT04426812||MTurk sample|Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
11050371|NCT04426812||KnowledgePanel|Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
11050372|NCT04426799|No Intervention|Control group|no application
11050373|NCT04426799|Experimental|Experimental group|application is done
11050374|NCT04426786|Active Comparator|Immediate intervention start: active exercise|Immediately starts the six month intervention of active exercise following the baseline scan.
11050481|NCT04426058|Active Comparator|Fascia iliaca|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
11050375|NCT04426786|Placebo Comparator|Delayed intervention start: passive exercise|Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.
11050376|NCT04426773|Experimental|tDCS treatment|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
11050377|NCT04426760||Women with submucosal leiomyoma(s)|Women with submucosal leimyomas undergoing hysteroscopical removal of the leiomyoma
11050378|NCT04426760||Women with intramural leiomyomas|Women with intramural leiomyomas undergoing myomectomy
11050379|NCT04426760||Infertility patients|Patients treated at the Department for Reproductive Medicine at the Oslo University hospital failing to conceive after 3 or more embryo transfers with good quality embryos.
11050380|NCT04426760||Fertile women|Healthy, volunteering women with proved fertility with 1 or more deliveries and no history of infertility
11050381|NCT04426734|Experimental|Dextenza|"Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.
~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
11050382|NCT04426734|Active Comparator|Topical Pred Forte 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of
~8x/day week 1 4x/day week 2 2x/day week 3
~1x/day week 4
~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
11050383|NCT04426721|Experimental|Ozone|Participant will receive an intraarticular injection of oxygen-ozone, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
11050384|NCT04426721|Active Comparator|Hyaluronic acid|Participant will receive an intraarticular injection of hyaluronic acid, once a week for three weeks. During procedure a clear ultrasound image is to be taken to document needle placement in the synovial space. The injector may choose the position of the knee (e.g., extended or bent) and the approach for the injection (e.g., medial or lateral).
11050385|NCT04426708|Experimental|Mild hepatic impaired subjects (A)|Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
11050386|NCT04426708|Experimental|Moderate hepatic impaired subjects (B)|Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
11050387|NCT04426708|Experimental|Healthy volunteers (C)|Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally
11050388|NCT04426695|Experimental|On Low-Flow Oxygen|Cohort 1 (C1): O2 saturation >93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device
11050389|NCT04426695|Experimental|With COVID-19 symptoms but not requiring supplemental O2|Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen
11050390|NCT04426695|Experimental|High O2 No Mechanical Ventilation|Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation
11050391|NCT04426695|Experimental|On Mechanical Ventilation|Cohort 3 (C3): On mechanical ventilation
11050392|NCT04426682||post-operative urinary incontinents|In patients who have previously had incontinence surgery due to stress incontinence, symptoms may return in the following years, and the patient may reapply with urinary incontinence. The first group will consist of postoperative urinary incontinence recurrent patients. Patients whose urodynamics are reperformed due to recurrence are the study group.
11050393|NCT04426682||without postoperative urinary incontinence|Patients who previously had incontinence surgery due to stress incontinence and who did not have postopertive urinary incontinence but whose urodynamics were repeated during the routine controls will constitute the control group.
11050394|NCT04426669|Experimental|CISH CRISPR TIL / Phase I Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin
11050395|NCT04426669|Experimental|CISH CRISPR TIL / Phase II Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of CISH inactivated TIL
11050396|NCT04426656|No Intervention|Part 2 Standard of Care|Participants will receive written HIV prevention materials including basic facts of PrEP, recommendations for HIV/STIs testing and referrals to local HIV/STIs testing sites and prevention services.
11050397|NCT04426656|Experimental|Part 2 mini-app|In addition to the standard of care, participants in the mini-app arm will have access to the mini-app (i.e. the intervention) during the whole study period.
11050398|NCT04426643|Experimental|mesenchymal stem cells|Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells
11050399|NCT04426643|Active Comparator|control|Patients with Urinary incontinence receiving standard treatment
11050400|NCT04426630|Other|mHealth|Heart failure patients enrolled in the mHealth program
11050401|NCT04426617|Experimental|fentanyle|: patients will receive US guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & fentanyl).
11050402|NCT04426617|Experimental|Midazolam|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25% & midazolam).
11050403|NCT04426617|Placebo Comparator|control|patients will receive us guided unilateral Transversus abdominis plane block (25 ml bupivacaine 0.25%).
11050404|NCT04426604|Experimental|Light induced fluorescence intraoral camera|
11050405|NCT04426604|Experimental|Laser-induced fluorescence device|
11050406|NCT04426604|Active Comparator|Visual-tactile assessment method according to FDI criteria|
11050407|NCT04426591|Experimental|Biotin labeled Red Blood Cells|Participants receiving a transfusion with biotin labeled RBCs. Samples will be taken for 12 weeks after the biotinylated transfusion. During this time participants will continue to receive regular monthly transfusions (non-biotinylated) as part of CTT.
11050408|NCT04426578|Experimental|Perhexiline|
11050409|NCT04426578|Placebo Comparator|Placebo|
11050410|NCT04426565|Other|the motivational enhancement interview|The motivational enhancement interview is a counseling approach developed in part by clinical psychologists William R. Miller and Stephen Rollnick. It is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
11050482|NCT04426045|Experimental|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
11050483|NCT04426045|Active Comparator|Supra-inguinal fascia iliaca compartment block|Participants receiving supra-inguinal fascia iliaca compartment block
11050411|NCT04426565|Other|the individual psychotherapy|The individual psychotherapy is the use of psychological methods, particularly when based on regular personal interaction with adults, to help a person change behavior and overcome problems in desired ways. Psychotherapy aims to improve an individual's well-being and mental health, to resolve or mitigate troublesome behaviors, beliefs, compulsions, thoughts, or emotions, and to improve relationships and social skills.
11050412|NCT04426565|Other|the group psychotherapy|The group psychotherapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including Art therapy, cognitive behavioural therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilised as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.
11050413|NCT04426565|Other|the family therapy|The family therapy is is a branch of psychotherapy that works with families and couples in intimate relationships to nurture change and development. It tends to view change in terms of the systems of interaction between family members.
11050414|NCT04426552|Experimental|Dexmedetomidine|have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
11050415|NCT04426552|Active Comparator|Sevoflurane|(sevoflurane) will be preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
11050416|NCT04426539||Amyloid PET-Positive|Those for whom a beta amyloid PET scan is consistent with underlying AD as causing or contributing to cognitive impairment
11050417|NCT04426539||Amyloid PET-Negative|Those for whom a beta amyloid PET scan has ruled out AD (i.e. not consistent with underlying AD as causing or contributing to cognitive impairment)
11050418|NCT04426526|Experimental|Biceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of biceps brachii.
11050419|NCT04426526|Experimental|Triceps circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of triceps brachii.
11050420|NCT04426526|Experimental|Lower limb circumference reduction|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of muscles in lower limbs.
11050421|NCT04426526|Experimental|Oblique muscles toning|This arm will evaluate the clinical efficacy and safety of the high power magnet system for toning and strengthening of oblique muscles.
11050422|NCT04426513|Active Comparator|Only kinesiotherapy|Patients have only kinesiotherapy of hand without steroid anti-inflammatory drugs and magnetotherapy.
11050423|NCT04426513|Experimental|Kinesiotherapy with bipolar magnetic field|Patients have kinesiotherapy of hand and bipolar magnetic field. All patients without steroid anti-inflammatory drugs.
11050424|NCT04426513|Experimental|Kinesiotherapy with unipolar magnetic field|Patients have kinesiotherapy of hand and unipolar magnetic field. All patients without steroid anti-inflammatory drugs.
11050425|NCT04426500|Placebo Comparator|Placebo/Local Anesthesia|Direct injection of 0.25% bupivacaine into surgical wounds
11050426|NCT04426500|Active Comparator|Ultrasound-guided transversus abdominus plane (UTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
11050427|NCT04426500|Experimental|Laparoscopic-guided transversus abdominus plane (LTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using laparoscopic guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
11050428|NCT04426487|Placebo Comparator|Control|Receiving conventional management for traumatic subarachinoid hemorrhage
11050429|NCT04426487|Active Comparator|progesterone group|Intramusculer progesterone therapy before and after craniotomy
11050430|NCT04426474|Experimental|LY3502970|LY3502970 administered orally.
11050431|NCT04426474|Placebo Comparator|Placebo|Placebo administered orally.
11050432|NCT04426461|Experimental|Behavioral activation|
11050433|NCT04426461|Experimental|Exposure-based therapy|
11050434|NCT04426461|Active Comparator|Supportive therapy|
11050435|NCT04426448|Experimental|Intervention group|Participants will receive the BREATHE intervention for three weeks
11050436|NCT04426448|No Intervention|Control group|The participants will receive treatment as usual
11050437|NCT04426435|Experimental|Intervention|Group A: patients receiving HB syrup, 10 cc three times daily
11050438|NCT04426435|Placebo Comparator|Placebo|Group B: patients receiving placebo, 10 cc three times daily
11050439|NCT04426422|Experimental|metformin group|all the patients were treated with metformin 1500-2000mg daily for 3 months.
11050440|NCT04426409|No Intervention|control group|
11050441|NCT04426409|Experimental|ointment group|Ointment group should apply a nasal ointment to both noses using a cotton swab the night before surgery and the morning of surgery.
11050442|NCT04426370||Case|100 rheumatoid arthritis patients (age from 20 to 70 years)
11050443|NCT04426370||Control|95 healthy volunteer
11050444|NCT04426357|Experimental|Group 1 (Participants with Renal impairment): JNJ-64417184|Participants with varying degrees of impaired renal impairment function (moderate renal impairment [optional], severe renal impairment, and end stage renal disease [ESRD] not requiring hemodialysis) will be enrolled and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
11050445|NCT04426357|Active Comparator|Group 2 (Healthy Participants): Control Group|Participants with normal renal function will be enrolled in controlled group and will receive a single oral dose of JNJ-64417184 as film coated tablet on Day 1.
11050446|NCT04426344|Experimental|Group A - core warming|Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).
11050484|NCT04426032||Patients with RRI between 0.6 and 0.7|Normal renal resistive index
11050447|NCT04426344|No Intervention|Group B - Control Group|Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature < 36°C) or antipyretic therapy for febrile patients, as requested by the treating physician.
11050448|NCT04426331|No Intervention|No Voucher|"Individuals being referred from screening events randomized to no intervention received the standard approach to offering free follow-up examinations (patient education, standard counseling, appointment information packet, reminder phone calls)."
11050449|NCT04426331|Experimental|Voucher Without Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher Without Value Information received a personal voucher."
11050450|NCT04426331|Experimental|Voucher With Value Information|"In addition to receiving the standard approach above, individuals being referred from screening events randomized to Voucher With Value Information received a personal voucher, which differed from the voucher in the second arm since it included a statement of value."
11050451|NCT04426318|Experimental|Healthy Minds Program Foundations Training|"Healthy Minds Program (HMP) Description:
~The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Richard Davidson, PhD. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose."
11050452|NCT04426318|No Intervention|Wait-list control|Participants assigned to the wait-list control will not receive treatment for the intervention and follow-up period. They will be provided access to the HMP Foundations training after completing follow-up testing.
11050453|NCT04426305|Experimental|Intervention arm|psychosocial support
11050454|NCT04426305|Active Comparator|control arm|care as usual
11050455|NCT04426292|Other|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
11050456|NCT04426279||patient with chronic inflammatory rheumatism|
11050457|NCT04426240|Active Comparator|Cyclosporine|Subject who use cyclosporine and hyaluronate artificial tear 1 month before cataract surgery
11050458|NCT04426240|No Intervention|non-Cyclosporine|Subject who use only hyaluronate eye drop 1 month before cataract surgery
11050459|NCT04426227|Experimental|Group Gaze|The gaze-trained group will be shown a video, derived from the eye tracker, of an expert's visual control whilst performing the ultrasound task. Participants will be made aware of the target-focused gaze strategy (lengthy and stable fixations on the needling target), and the manner in which the gaze shifted from target to tools (hands, needle and transducer) in a fast, smooth fashion. They will then be advised to try to mimic the gaze strategy of the expert while undertaking the needling task as their first training task. After completion of this training task, participants will be shown their own video data, as captured by the eye tracker. Participants will be asked to comment on differences between their own video and the expert video they had previously seen. This feedback process will be replicated a further four training task attempts. Participants in this group will therefore undergo a total of five training attempts of the needling task.
11050460|NCT04426227|Active Comparator|Group Discovery|The discovery learning group will be given no video feedback and will be instructed to perform five training attempts at the needling task without further training or feedback.
11050461|NCT04426214|Experimental|Active tDCS|
11050462|NCT04426214|Placebo Comparator|Sham tDCS|
11050463|NCT04426201|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
11050464|NCT04426201|Placebo Comparator|Saline control|Intramuscular (IM) placebo (normal saline) at the same frequency
11050465|NCT04426188|Sham Comparator|Without mouthguard|Heading series without mouthguard from machine-projected soccer balls at standardized speeds
11050466|NCT04426188|Experimental|With mouthguard|Heading series with mouthguard from machine-projected soccer balls at standardized speeds
11050467|NCT04426175|Experimental|2D LASIK|With the 2D method, the flap resection is created in a planar mode (xy-plane), without vertical cut, at the requested depth.
11050468|NCT04426175|Experimental|3D LASIK|With the 3D method, the flap resection is done in a three-dimensional mode, at the requested depth, with the requested diameter and the desired border (side cut) angle
11050469|NCT04426162|Experimental|Memory Boot Camp Participants|All subjects undergo a 12-week control period, followed by a multi-domain 12-week memory program.
11050470|NCT04426149|Experimental|interventional|supplement: trehalose
11050471|NCT04426136||1. WLE group|patients in this group receiving WLE merely
11050472|NCT04426136||2. other method group|patients in this group receiving any other surgical procedures except WLE
11050473|NCT04426123|Active Comparator|Botulinum toxin|Botulinum toxin type A
11050474|NCT04426123|Placebo Comparator|Saline solution|NaCl
11050475|NCT04426110||"Period 1 Control"|No Music. Wound stitches procedure conducted according to clinical practice.
11050476|NCT04426110||"Period 2 Music"|Music by headphones. Wound stitches procedure conducted according to clinical practice
11050477|NCT04426097|Experimental|Cervical Vagal Blockade|
11050478|NCT04426097|Placebo Comparator|Without Blockade|
11050479|NCT04426071||SCI, brain injury, stroke Participants|Those 18 years of age and older, diagnosed with a stroke, spinal cord injury (traumatic and non-traumatic), or acquired brain injury (of all severities, including concussion) living in the community will be included. Additionally, only those the cognitive capacity to understand and complete the measures will be included. Those who consent will complete an online survey on enrollment into the study, and subsequently at 3 and 6 months.
11050480|NCT04426058|Experimental|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
11050553|NCT04425512|Active Comparator|Thyroid Malignancy|Thyroidectomy
11050489|NCT04425993|Experimental|Rectal indomethacin and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.
~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
11050490|NCT04425993|Active Comparator|Rectal indomethacin and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.
~All patients without contraindications should receive rectal indomethacin within 30 min before ERCP."
11050491|NCT04425993|Active Comparator|Rectal placebo and sublingual nitrate|"All patients without contraindications should receive sublingual isosorbide dinitrate within 5 min before ERCP.
~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
11050492|NCT04425993|Placebo Comparator|Rectal placebo and sublingual placebo|"All patients without contraindications should receive sublingual placebo within 5 min before ERCP.
~All patients without contraindications should receive rectal placebo within 30 min before ERCP."
11050493|NCT04425980|Experimental|Modified Constraint-Induced Movement Therapy (test treatments)|A list of fine and motor activities consisted of the functional tasks or play activities such as school-education and sports activities, manipulative games, arts, and crafts, etc. to elicit the maximum capacity of the more affected upper limb was created according to the procedure of modified constraint-induced movement therapy (Gordon et al., 2005) and Bimanual training. In addition, specific activities were also chosen in terms of deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request. In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook a role as a dominant hand
11050494|NCT04425980|Active Comparator|Bimanual training|For the Bimanual training, skilled, repetitive, and structured bimanual activities (part or whole task practice) were used to promote bimanual hand use and improve movement deficits determined before the intervention. All targeted deficits of interest were addressed within the context of the selected activity. Specifically, symmetrical bilateral movements were utilized to augment neural input from both sides. Also, meaningful activities such as buttoning and zipping-up trousers, etc. were used to ensure a transition from structured setting to real-life activities
11050495|NCT04425928|Active Comparator|activity group|Participants received an activity-based home program that was performed for 4 weeks.
11050496|NCT04425928|Experimental|exercise group|Participants received an exercise-based home program was performed that was performed for 4 weeks.
11050497|NCT04425928|No Intervention|control group|No intervention
11050498|NCT04425915|Experimental|Convalescent Plasma with Standard of Care|Two doses of 250 ml Convalescent plasma from recovered COVID-19 patients + Standard of Care will be given to severely sick COVID-19 patients in the treatment arm
11050499|NCT04425915|Active Comparator|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
11050500|NCT04425902|Experimental|Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254|Participants will be administered a single dose of probe substrate drugs: caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg (2.5 milliliter [mL]), digoxin 0.25 mg, and pravastatin 40 mg on Day 1; followed by washout of 10 days. On Days 11 to 20, participants will be administered once daily doses of GSK3640254 200 mg followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.
11050501|NCT04425889||exposed Healthcare workers|Healthcare workers working for 8 weeks in a COVID-19 area
11050502|NCT04425876|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib combined with FOLFIRINOX followed by maintenance Fluzoparib monotherapy
11050503|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
11050504|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
11050505|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
11050506|NCT04425850||IVER+|Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
11050507|NCT04425850||IVER-|Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
11050508|NCT04425837|Active Comparator|Standard care alone|
11050509|NCT04425837|Experimental|SARS-CoV-2 convalescent plasma treatment plus standard care|
11050510|NCT04425824|Experimental|Toripalimab combine with Rituximab|"Experimental: Toripalimab combine with Rituximab
~Induction period:
~Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.
~Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles.
~Maintenance:
~Toripalimab 240mg administered intravenously (IV) and Rituximab 375mg/m² on Day 1 of each 56-day cycle for 6 cycles."
11050511|NCT04425811|No Intervention|No tape applied|Walking parameters were evaluated without any intervention.
11050512|NCT04425811|Experimental|Kinesiological Tape|Walking parameters were evaluated after kinesiological taping on the tibialis anterior muscle
11050513|NCT04425811|Sham Comparator|Sham taping|Walking parameters were evaluated after sham taping on the tibialis anterior muscle
11050514|NCT04425798||Patients with LEV application|LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
11050554|NCT04425512|Sham Comparator|Benign Thyroidal Goitor|Thyroidectomy
11050515|NCT04425798||Patients without LEV application|LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
11050516|NCT04425785|Experimental|Physical Exercise Group|A structured exercise program for 12 weeks
11050517|NCT04425785|Experimental|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy for 12 weeks
11050518|NCT04425785|No Intervention|Standard Clinical Care|Standard Clinical Care
11050519|NCT04425772|Experimental|Experimental Group|FNC+Standard of Care
11050520|NCT04425772|Placebo Comparator|Control Group|FNC dummy tablet+ Standard of Care
11050521|NCT04425746|Experimental|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
11050522|NCT04425746|Placebo Comparator|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
11050523|NCT04425733|Experimental|Panel A MK-5475 180 µg|Participants receive 180 µg of MK-5475 once daily (QD) via inhalation from Days 1-7.
11050524|NCT04425733|Placebo Comparator|Panel A Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
11050525|NCT04425733|Experimental|Panel B MK-5475 360 µg|Participants receive 360 µg of MK-5475 QD via inhalation from Days 1-7.
11050526|NCT04425733|Placebo Comparator|Panel B Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
11050527|NCT04425733|Experimental|Panel C MK-5475 ≤360 µg|Participants receive ≤360 µg of MK-5475 QD via inhalation from Days 1-7.
11050528|NCT04425733|Placebo Comparator|Panel C Placebo|Participants receive MK-5475-matching placebo QD via inhalation from Days 1-7.
11050529|NCT04425720|Active Comparator|Standard Of Care|Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
11050530|NCT04425720|Experimental|Monitored|Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary
11050531|NCT04425707|Experimental|A ivermectin alone|ivermectin will be administarted alone to COVID 19 patients
11050532|NCT04425707|Experimental|B standard care alone|standard care will be administarted alone
11050533|NCT04425707|Active Comparator|C ivermectin added to standard of care|ivermectin will be administarted in adition to standard care
11050534|NCT04425694||F3B ward staff|The e-EWS system will be implemented in a selected surgical ward (F3B ward) in Tuen Mun Hospital. All F3B ward staff will use the system and evaluate its effectiveness.
11050535|NCT04425681|Experimental|Osimertinib With Bevacizumab group|Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
11050536|NCT04425668|Active Comparator|Control Group|
11050537|NCT04425668|Experimental|Academic detailing intervention|
11050538|NCT04425655|Experimental|Fludarabine and CPX351|"Induction 1:
~Fludarabine 30 mg/m2/day IV on days 1-5 for 5 doses Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3, 5 (given 4 hours after fludarabine infusion) for 3 doses
~Induction 2 (residual leukemia after Induction 1):
~Fludarabine 30 mg/m2/day IV on days 1-3 for 3 doses
~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 44 mg/m2/day and cytarabine 100 mg/m2/day IV on days 1, 3 (given 4 hours after fludarabine infusion) for 2 doses
~Optional consolidation, up to 2 cycles:
~Daunorubicin and cytarabine liposome (CPX-351) daunorubicin 29 mg/m2/day and cytarabine 65 mg/m2/day IV on days 1, 3 for 2 doses"
11050539|NCT04425642|Experimental|Glucose/Amino acids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose and amino acids according age and weight
11050540|NCT04425642|Experimental|Glucose/Amino acids/Lipids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose, amino acids and lipid emulsions according age and weight
11050541|NCT04425629|Experimental|REGN10933+REGN10987 low dose|
11050542|NCT04425629|Experimental|REGN10933+REGN10987 high dose|
11050543|NCT04425629|Placebo Comparator|Placebo|
11050544|NCT04425616|Experimental|Universal Interventions|"The delivery of nutrition, exercise and psychological interventions delivered in the following structure:
~Month 1: Up to three times per week
~Months 2-3: Once per week
~Months 4 - 6: One session per month for the last 3 months"
11050545|NCT04425590|Experimental|Experimental Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily and DLBS1033 3 times daily (experimental group).
11050546|NCT04425590|Active Comparator|Control Group|standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily
11050547|NCT04425577|Other|Transabdominal Ultrasound|All patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
11050548|NCT04425564|Active Comparator|Classic (A)|patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)
11050549|NCT04425564|Experimental|metronomic (B)|patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.
11050550|NCT04425551|Active Comparator|Treated|"The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias.
~The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn.
~After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes."
11050551|NCT04425551|No Intervention|Untreated|The lateral eye was observed as control.
11050552|NCT04425538|Experimental|Infliximab|All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
11050555|NCT04425512|Other|Control Group|Selective lichtenstein procedure for inguinal hernia
11050556|NCT04425499|Placebo Comparator|Control group|On GEN (Gamified Educational Network), each student will view individually eight videos of an expert performing a running subcuticular suture correctly. The OSATS (Objective Structured Assessment of Technical Skills) Global Rating Scale (GRS) and Subcuticular Suture Checklist will be available beside each video and students will be required to fill them out for each video. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, students will view the same eight videos of an expert performing a running subcuticular suture, however, the videos will be shuffled in a different order. The order of the videos will be the same for all students.
11050557|NCT04425499|Experimental|Self-learning|Each student will view eight videos individually and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. The errors will be technical mistakes in the execution of a running subcuticular suture. For three days, students will have access to a distinct set of videos on GEN to learn running subcuticular sutures. Three days later, all students will repeat this activity. However, the same videos will be shuffled in a different order. The order of the videos will be the same for all students.
11050558|NCT04425499|Experimental|Peer-learning|Each student will view eight videos and complete the GRS and Subcuticular Suture Checklist for each video. Six videos will contain errors and two videos will not. After this initial test, students will interact with other medical students in their group on the GEN platform anonymously for three days. We will display distinct videos on GEN. Comments will be allowed in an interactive way to encourage exchanges. Students will be required to participate in the discussion of at least two videos. Students will not be able to modify their answers on the initial test. On the third day, students in this group will perform a post-test individually with the same eight initial videos but shuffled. The order of the videos will be the same for all students.
11050559|NCT04425499|Experimental|Peer-learning with expert feedback|"Same as group 3, the only difference is that an expert will actively participate in the discussion by commenting on each video on GEN, enhancing students' educational experience. Although anonymous, students will be able to identify the expert as the name expert will be used. The expert will answer any question and comment on the discussion in order to guide the students."
11050560|NCT04425473|Experimental|esketamine|
11050561|NCT04425473|Placebo Comparator|placebo|
11050562|NCT04425460|Experimental|Favipiravir|Favipiravir Tablets, 200 mg/tablet Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
11050563|NCT04425460|Placebo Comparator|Placebo|Placebo control group Favipiravir combined with supportive care recommended in the current National/Local guidelines
11050564|NCT04425447|Active Comparator|Group C|30 patients will receive bilateral tumescent local anesthesia as a control group
11050565|NCT04425447|Experimental|Group TPVB|30 patients will receive bilateral US guided thoracic paravertebral block.
11050566|NCT04425447|Experimental|Group TIPB|30 patients will receive bilateral US guided thoracic interfascial plane block
11050567|NCT04425408|Experimental|Positional pillow followed by vibrating belt|26 patients with positional sleep apnea will be randomized to spend 3 nights using a positional pillow followed by a vibrating belt. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
11050568|NCT04425408|Experimental|Vibrating belt followed by positional pillow|26 patients with positional sleep apnea will be randomized to spend 3 nights using a vibrating belt followed by a positional pillow. The time spend on supine position will be monitored on each device and a satisfaction questionnaire as well as a sleep quality questionnaire will be performed after the use of each device.
11050569|NCT04425395|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while producing vocalisations. Produced vocalisations will be audio recorded and physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
11050570|NCT04425382||Darunavir/Cobicistat|Patients received Darunavir/Cobicistat (Rezolsta®) as part of the treatment regimen for COVID-19 pneumonia
11050571|NCT04425382||Lopinavir/Ritonavir|Patient received Lopinavir/Ritonavir (Kaletra®) as part of the treatment regimen for COVID-19 pneumonia
11050572|NCT04425369|No Intervention|inner side approaches for iliac crest bone graft|An anterior approach was used to expose the inner table of the ilium.
11050573|NCT04425369|Experimental|two-sided approaches for iliac crest bone graft|both sides of the ilium were totally exposed of the ilium.
11050574|NCT04425356|Experimental|Intervention Group|This group will receive the LifeXT program
11050575|NCT04425356|No Intervention|Control Group|Wait-list control group that receives the LifeXT program after the conclusion of the study
11050576|NCT04425343|Experimental|Periodontitis, Adult|Plaque samples were taken from subgingival pocket and send to the lab for metagenomic analysis
11050577|NCT04425343|Experimental|Metgenomic analysis|Analysis for whole bacterial count
11050578|NCT04425330|Experimental|physiotherapy exercises + PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.
~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The irradiation will be with LED with a wavelength of 850 nm, energy per point of 25 J, 50 seconds per point and power of 200 mW.
~Treatment will be performed in 24 sessions 2 times a week"
11050623|NCT04425057|No Intervention|Control group|No physiotherapy
11050624|NCT04425044||AiM Covid|Self Monitoring of symptoms in AiM Covid App
11050625|NCT04425031|Experimental|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
11050626|NCT04425031|Active Comparator|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
11050664|NCT04424745|Active Comparator|Attention Bias Modification Training with real tDCS|
11050665|NCT04424745|Placebo Comparator|Attention Bias Modification Training with sham tDCS|
11050579|NCT04425330|Sham Comparator|physiotherapy exercises + SHAM PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.
~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The same LED device will be used in groups. However, in the placebo group (Sham), the device does not emit light.
~Treatment will be performed in 24 sessions 2 times a week"
11050580|NCT04425317|Other|Diagnostic arm|Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
11050581|NCT04425304|Active Comparator|Group counseling|
11050582|NCT04425304|Experimental|Group counseling + persuasive ICT support|
11050583|NCT04425304|Active Comparator|Intensive group counseling|
11050584|NCT04425304|Experimental|Intensive group counseling + persuasive ICT support|
11050585|NCT04425291|Experimental|4-valent HPV Vaccine|Participants in this arm would receive 4-valent Human Papillomavirus (Types 6, 11, 16 and18) Recombinant Vaccine (Hansenula Polymorpha)
11050586|NCT04425291|Experimental|9-valent HPV Vaccine|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
11050587|NCT04425291|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
11050588|NCT04425278|Active Comparator|Real Stimulation|The Real Stimulation of tDCS lasted 20 mins.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
11050589|NCT04425278|Sham Comparator|Sham Stimulation|The Sham Stimulation of tDCS lasted 20 minutes with no current. In particular, the current went up for the first 30 seconds and went down for the last 30 seconds.Behavior and ERPs dataset should be acquired before the first tDCS session and after the last tDCS session.
11050590|NCT04425278|No Intervention|Control|Behavior and ERPs dataset should be acquired before and after 14 days.
11050591|NCT04425265|Experimental|Plasma radiofrequency ablation arm|Plasma radiofrequency ablation at low temperature for localized recurrent nasopharyngeal carcinoma
11050592|NCT04425265|Active Comparator|Electrocautery block resection arm|Electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma
11050593|NCT04425252|Other|Standard of Care|Subjects are hospitalized for COVID-19 and will receive all supportive/interventional care per institutional guidelines.
11050594|NCT04425252|Experimental|Brequinar|Subjects will receive standard of care plus brequinar 100 mg daily (Study Days 1-5).
11050595|NCT04425239|Active Comparator|CONTINUOUS ARM:|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal.
11050596|NCT04425239|Experimental|INTERMITTENT ARM:|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
11050597|NCT04425226|Experimental|Pembrolizumab plus Lenvatinib|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle. Number of cycles: until >42 days before liver transplantation or unacceptable toxicity develops. Patients receive Lenvatinib 8-12mg(basing on weight), once a day, oral at least 38 days of each 6 weeks cycle until >7 days before liver transplantation.
11050598|NCT04425226|No Intervention|Comparator|Participants are advised to stay as healthy as possible and wait regularly
11050599|NCT04425213||Normal weight|BMI < 25 kg/m2
11050600|NCT04425213||Overweight|BMI : 25 - 29.9 kg/m2
11050601|NCT04425213||Moderate obesity|BMI : 30 - 39.9 kg/m2
11050602|NCT04425213||Severe obesity|BMI : > or = 40 kg/m2
11050603|NCT04425187|Active Comparator|gefitinib|
11050604|NCT04425187|Experimental|gefitinib&bevacizumab|
11050605|NCT04425174||QL|QL = 30 patients representing the case group receiving QL block.
11050606|NCT04425174||EP|EP = 30 patients representing the control group receiving epidural anesthesia.
11050607|NCT04425161||VO2 ≥15 %|This group is classified based on increased oxygen consumption (VO2) ≥15 % by volume expansion in fluid responders
11050608|NCT04425161||VO2 <15 %|This group is classified based on increased oxygen consumption (VO2) < 15 % by volume expansion in fluid responders
11050609|NCT04425148|Experimental|tACS|40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
11050610|NCT04425148|Sham Comparator|Sham tACS|Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions
11050611|NCT04425135|Experimental|Camrelizumab +apatinib mesylate+Pemetrixed + Carboplatin|Camrelizumab combined with apatinib mesylate,Pemetrixed and Carboplatin in the treatment（4-6 cycle）of effective (CR, PR, SD) patients continued to be treated with Camrelizumab combined with apadine mesylate until PD, toxicity intolerance, and other reasons that the researcher thinks need to stop the research treatment.
11050612|NCT04425122||Esophageal cancer|Patients with esophageal cancer (SCC)
11050613|NCT04425122||Non-cancer group|Non-cancer patients scheduled for upper endoscopy
11050614|NCT04425109|Experimental|tempeh steak|The subjects were received the tempeh steak meal with isocal diet containing energy 307.4Kcal
11050615|NCT04425109|Experimental|soybean steak|The subjects were received the soybean steak meal with isocal diet containing energy 307.4Kcal
11050616|NCT04425096|Experimental|Skin to skin contact|The mothers and their babies in the experimental group received a 30-minute skin to skin contact immediately after birth (n:32)
11050617|NCT04425096|No Intervention|Routine care|The babies in the control group received routine care (n:32)
11050618|NCT04425083||Polycystic Ovary Syndrome|Polycystic Ovary Syndrome women
11050619|NCT04425083||control|non- Polycystic Ovary Syndrome women
11050620|NCT04425070|Experimental|ATG-010 + ICE|ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11
11050621|NCT04425070|Experimental|ATG-010 + GEMOX|ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9
11050622|NCT04425057|Experimental|Interval training|Physiotherapy program during two months: Interval training at a high intensity, inlcuding a warm-up and a cool-down. Aerobic exercises, resistance exercises, stretching
11050627|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Margetuximab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days
~Paclitaxel- via IV, Day 1,8,15 of each cycle
~Margetuximab via IV, Day 1 of each cycle
~Pertuzumab via IV, Day 1 of each cycle"
11050628|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Trastuzumab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days
~Paclitaxel- via IV, Day 1,8,15 of each cycle
~Pertuzumab via IV, Day 1 of each cycle
~Trastuzumab via IV, Day 1 of each cycle"
11050629|NCT04425005|No Intervention|Control group|
11050630|NCT04425005|Experimental|Exercise training group|
11050631|NCT04424992||Covid19 infection related patients|The patients enrolled in the study are all patients with clinical and microbiological diagnosis of COVID-19 infection hospitalized since February 23, 2020 at San Gerardo Hospital (ASST-Monza).
11050632|NCT04424979|Experimental|High power prisms|Various configurations of high power prisms will be developed for each individual and custom fit into spectacles lenses.
11050633|NCT04424966|Experimental|Arm 1|"Phase 0: 125 mg of infigratinib administered orally for 7 days prior to surgical resection.
~Expansion Cohort: 125 mg of infigratinib administered orally for 21 days of a 28-day treatment cycles."
11050634|NCT04424953|Active Comparator|McGrath videolaryngoscope|Anesthetists randomized to this group will intubate patients using the McGrath videolaryngoscope
11050635|NCT04424953|Active Comparator|Direct laryngoscope|Anesthetists randomized to this group will intubate patients using the direct laryngoscope
11050636|NCT04424927|Experimental|PRV-015 Low Dose|PRV-015 Low Dose, sterile solution for subcutaneous administration
11050637|NCT04424927|Experimental|PRV-015 Medium Dose|PRV-015 Medium Dose, sterile solution for subcutaneous administration
11050638|NCT04424927|Experimental|PRV-015 High Dose|PRV-015 High Dose, sterile solution for subcutaneous administration
11050639|NCT04424927|Placebo Comparator|Placebo|Placebo, sterile solution for subcutaneous administration
11050640|NCT04424914|Other|ATTR-CM positive|Participants diagnosed with ATTR-CM by scintigraphy).
11050641|NCT04424914|Other|ATTR-CM negative|Participants who are scintigraphy negative for ATTR-CM
11050642|NCT04424901|No Intervention|Standard Care|"Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.
~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.
~Data collection ends on day 9."
11050643|NCT04424901|Experimental|Standard Care with Dipyridamole|"For this arm, Dipyridamole 100 mg, tid is given for 7 days. Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.
~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.
~Data collection ends on day 9."
11050644|NCT04424888|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 2 weeks
11050645|NCT04424888|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 2 weeks
11050646|NCT04424875|Experimental|study arm|patients will undergo surgery to remove impacted lower third molar and receive Melatonin (3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%) in the socket following removal of the impacted third molar
11050647|NCT04424875|Placebo Comparator|controlled arm|patients will undergo surgery to remove impacted lower third molar and patients will receive no melatonin (2 ml of hydroxyethyl cellulose gel 2 %).
11050648|NCT04424862|Experimental|Multitarget Therapy|The combined therapy with prednisone, ciclosporin and mycophenolate mofetil.
11050649|NCT04424862|Active Comparator|Control|Ponticelli Regimen
11050650|NCT04424849||COVID-19 patients|Patient tested positive for COVID-19 who had a CT scan
11050651|NCT04424836||H GROUP|patients get the oxygen supply with high flow nasal cannula . In group H, HFNC device settings the initial flow rate was 30 L/min and could be increased to 60. The Fio2 was adjusted to maintain oxygen saturation as indicated by a pulse oximetry reading of grater than or equal to %90.
11050652|NCT04424836||C GROUP|patients get the oxygen supply with conventional methods. In group C 6-15 L/min oxygen delivered to patients by conventional methods and targeted to maintain the oxygen saturation %90 or over.
11050653|NCT04424823|Experimental|LED|LED photobiomodulation therapy for the non-specific LBP working nurse
11050654|NCT04424823|Sham Comparator|Sham|Shame group. The all procedure was same as the LED group but the LED ped was upside down without direct treatment.
11050655|NCT04424810|Experimental|Video group|Patients selected to be in the intervention group will be asked to watch a high-quality, physician created video describing their condition and the operative treatment they are about to undergo.
11050656|NCT04424810|Placebo Comparator|Control group|Patients selected to be in the control group will not be asked to watch a video prior to surgery.
11050657|NCT04424797|Experimental|Prone Positioning|Prone positioning
11050658|NCT04424797|Other|Supine Positioning|Supine Positioning
11050659|NCT04424784|No Intervention|20% O2|In the control group, oocyte pickup will be performed in atmospheric oxygen environment (20% oxygen, 89% nitrogen, 6% carbon dioxide).
11050660|NCT04424784|Experimental|5% O2|In the experimental group, oocyte pickup will be performed in a low oxygen tension environment (5% oxygen, 89% nitrogen, 6% carbon dioxide). If time lapse embryo culture system is used, fertilization check and embryo grading will also be conducted under the low oxygen tension environment.
11050661|NCT04424771||Health workers|They include doctors, nurses, techinicians, biologists and other non technical inhospital workers
11050662|NCT04424758|Experimental|Intervention group|Receives information about mammography screening through a video. The video was developed with the goal of informing about mammography screening in a societal perspective using best available evidence.
11050663|NCT04424758|Placebo Comparator|Control group|Receives information about energy systems through a video. The video does not contain any information related to mammography screening.
11050666|NCT04424732|Other|Stereotactic Body Radiotherapy for Breast Bony oligometastases|Newly diagnosed bone only oligometastatic breast cancers with 1-3 bone metastases will be enrolled in this protocol. Patients will receive SBRT to all metastatic sites.
11050667|NCT04424719|Other|Patients with uveal melanoma|
11050668|NCT04424706||Normal people|No diabetes and atherosclerosis
11050669|NCT04424706||type 2 diabetes mellitus without atherosclerosis|Newly diagnosed type 2 diabetes without atherosclerosis
11050670|NCT04424706||type 2 diabetes mellitus with atherosclerosis|Newly diagnosed type 2 diabetes with atherosclerosis
11050671|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 28|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 28 will receive a placebo injection at week 36. Subject will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
11050672|NCT04424693|Active Comparator|Tdap vaccinations at gestational week 36|Pregnant women entering into this clinical research study and signing informed consent at week 12 will be randomized to either receive Tdap vaccination at week 28 or week 36. Subjects receiving Tdap vaccination at week 36 will receive a placebo injection at week 28. Subjects will be followed with routine standard of care throughout their pregnancy and have routine clinic visits from which study visits will include weeks 12, 20, 28, 36, and 2 weeks postpartum. Data will be collected at each of these visits with special attention to the development of preeclampsia and fetal health
11050673|NCT04424680|No Intervention|Control|"Patients will be followed in heart failure outpatients units according to the usual established protocol. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.
~Treatment for heart failure will be the same in both groups."
11050674|NCT04424680|Experimental|Intervention|"Patients will participate in the Advanced Care Planning Program. In the first visit, patients from both control and intervention groups will complete the questionnaires with the help of researchers. After one year of follow-up, the questionnaires will be submitted again to all patients and three new questionnaires will be proposed.
~Treatment for heart failure will be the same in both groups."
11050675|NCT04424667|Active Comparator|Holder pasteurization|Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
11050676|NCT04424667|Experimental|HTST pasteurization|Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
11050677|NCT04424654|Experimental|Bipolar Androgen Therapy (BAT)|Testosterone cypionate 400 mg IM every 28 days for 3 cycles
11050678|NCT04424641|Experimental|Treatment|Open Label, single arm where GEN1044 will be administered
11050679|NCT04424628|Active Comparator|Radiotherapy 3 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days).
~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again"
11050680|NCT04424628|Active Comparator|Radiotherapy 6 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days).
~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again"
11050681|NCT04424602|Experimental|cyclophosphamide|participants will receive intra venous cyclophosphamide 500mg once every two weeks for 6months.
11050682|NCT04424602|Active Comparator|mycophenolate|participants will receive oral mycophenolat 2 to 3mg/kg for 6 months.
11050683|NCT04424589|Experimental|Myofascial release|"Myofascial release or induction (MFR) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. Manual therapists often use their hands using their knuckles, elbows, or other instrumental tools to slowly penetrate the layers of the fascia, using applied pressure with a few kilograms of force that can strain the restricted fascia, this implies a guided gentle stretch.
~The experimental group will receive 1 examination session and 6 myofascial release sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for the spinal at the level of the quadratus lumborum, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks."
11050684|NCT04424589|Sham Comparator|Sham Therapy|The control group will receive 1 examination session and 6 simulated myofascial releasesessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial release, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
11050685|NCT04424576||Regular Menstrual Cycles|22 adolescents with regular menstrual cycles (i.e., once every 4-6 weeks) will be enrolled within 11 months of menarche.
11050686|NCT04424576||Irregular Menstrual Cycles|26 adolescents with irregular menstrual cycles (i.e., < 4 weeks or > 6 weeks between periods) will be enrolled within 11 months of menarche.
11050687|NCT04424563||Group A|Patients of group A include 40 patients, received aminocaproic acid at dose of 4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
11050688|NCT04424563||Group B|While patients of group B include 40 patients, received aFVII according to the following protocol, First dose 200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (>10 gm%) another 2 doses of aFVII received each dose 100microgram /kg 1 hour and 3 hours apart from the initial dose if needed.
11050689|NCT04424537|Placebo Comparator|Control|"A control group will consume 2 meal replacement beverages(MRBs) made with whey protein
~The control diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.
~No overall calorie reduction will be implemented for any group.
~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.
~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
11062954|NCT04336449|Placebo Comparator|Placebo|
11050690|NCT04424537|Active Comparator|Low protein(LP) diet|"This group will consume 2 meal replacement beverages(MRBs) containing low protein (goal to reduce total protein by 2/3rds).
~LP diet group will be provided with a protein powder which will provide all Amino Acids. Diets will be provided in unmarked containers, to ensure subjects will be blinded to the dietary group assignment.
~No overall calorie reduction will be implemented for any group.
~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.
~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
11050691|NCT04424537|Experimental|Low branched-chain amino acids (BCAA)|"The group on low-BCAA diet will consume 2 meal replacement beverages (MRBs) per day made with BCAD2 (branched chain amino acid) powder (lacking BCAAs).
~BCAD2 powder(Mead Johnson) is a fortified medical food powder that does not contain the BCAAs isoleucine, leucine, or valine, but provides all other essential and nonessential AAs, carbohydrates, fat, vitamins, and minerals.
~No overall calorie reduction will be implemented for any group.
~All subjects will receive recipes developed by clinical nutritionist in the study team. Theses recipes will maximize palatability and match energy density across all diets and total protein content.
~The subjects will be able to use multiple different recipes over the course of the study to prevent taste fatigue and dropout. Each subject is anticipated to replace 2 meals per day with a beverage."
11050692|NCT04424511|Placebo Comparator|Control|"Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age:
~Single-dose of 0.5 ml / kg child weight
~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture."
11050693|NCT04424511|Active Comparator|Azithromycin-biannually (Azi-biannual)|"Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age:
~Single-dose of 0.5 ml / kg child weight
~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug.
~Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg."
11050694|NCT04424511|Active Comparator|Azithromycin-quarterly|"Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age:
~Single-dose of 0.5 ml (20 mg) / kg child weight.
~Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin."
11050695|NCT04424485|Active Comparator|Thyroid carcinoma patients (biopsy-proven)-Total thyroidectomy|"Control group-Total thyroidectomy (TT) with central lymph node dissection (CLND) procedure for patients with papillary thyroid carcinoma (PTC)
~Standard TT+CLND procedure only"
11050696|NCT04424485|Experimental|Thyroid carcinoma patients (biopsy-proven)-Sentinel lymph node|"Experimental group- Sentinel lymph node dissection (SLND) after intratumoral indocyanine green (ICG) injection and visualization of all 4 parathyroid glands with infra-red (NIR) fluorescence after intravenous (iv) ICG injection, during total thyroidectomy and central lymph node dissection (CLND).
~TT+CLND with NIR fluorescence ICG"
11050697|NCT04424472|Experimental|Ultrasonography|Patient will be scheduled to undergo an additional US by a blinded sonographer within 4 weeks of their most recent cross-sectional imaging that indicated a recurrence
11050698|NCT04424459||Patients included from 10/01/19 to 12/31/19.|Patients included from 10/01/19 to 12/31/19. (the study will be extended to a larger number of patients according to the first results), continued according to the first results. DCNC patients treated at the Montpellier Pain Assessment and Treatment Center hospitalized during the period from 10/01/19 to 12/31/19, for misuse of opioid treatment.
11050699|NCT04424446||NIH staff|NIH staff undergoing standard NIH COVID-19 screening willing to donate additional research samples.
11050700|NCT04424433|Other|Normoxaemia First|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second.
11050701|NCT04424433|Other|Hyperoxia First|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second.
11050702|NCT04424420|Experimental|Paracetamol|Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.
11050703|NCT04424420|Active Comparator|Ibuprofen|Study phase 1 (single dosing): 800 mg once.
11050704|NCT04424420|Placebo Comparator|Placebo|Study phase 1 (single dosing): Once. Study phase 2 (multiple dosing): Twice daily for a minimum of 12 and a maximum of 14 days.
11050705|NCT04424407|Other|CBT-I|
11050706|NCT04424394|Experimental|DualStim Therapy with Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of umbilical cord-derived Wharton's Jelly formulation.
11050707|NCT04424394|Active Comparator|DualStim Therapy without Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of normal saline.
11050708|NCT04424381|Active Comparator|Rivaroxaban 20 MG Oral Tablet [Xarelto]|rivaroxaban oral tablet [Xarelto] at a single oral dose of 20 mg
11050709|NCT04424381|Experimental|Rivaroxaban 20 MG Oral Tablet|rivaroxaban oral tablet at a single oral dose of 20 mg
11050710|NCT04424368|Experimental|The remote monitoring system|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations and using remote monitoring system.
11050711|NCT04424368|No Intervention|Clinical recommendations|A group of patients, who had myocardial infraction and who has a very high risk of developing an unfavorable prognosis, which are followed up in the local outpatient department according to existing clinical recommendations.
11050712|NCT04424355||Patients with suspected pneumonia COVID-19|"Chest MRI findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
11050713|NCT04424355||Patients with suspected pneumonia with COVID -19|"Chest CT findings: bilateral, diffuse ground-glass opacity (GGO), consolidation, crazy paving pattern, pleuritis."
11050714|NCT04424329|Experimental|Nutrition intervention|Ingestion of fibers and probiotics daily for 22 days
11050715|NCT04424329|No Intervention|No intervention|No intervention
11050716|NCT04424316|Experimental|RSVpreF vaccine|RSVpreF
11050717|NCT04424316|Placebo Comparator|Placebo dose|Placebo
11050718|NCT04424303||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of moderate to severe ulcerative colitis initiating tofacitinib as per the French summary of product characteristics (SmPC).
11050719|NCT04424290|Experimental|BI 764524|Single rising dose part followed by a multiple dosing part.
11050720|NCT04424264|Experimental|Tenofovir Alafenamide|TAF 25 mg once-daily administered with RIF/INH 600*/300mg
11050721|NCT04424251|Experimental|HSK21542 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg
11050722|NCT04424251|Experimental|HSK21542 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg
11050723|NCT04424251|Experimental|HSK21542 2 μg/kg|Preoperative:2 μg/kg Postoperative:1 μg/kg
11050724|NCT04424251|Experimental|HSK21542|Preoperative:2 μg/kg Postoperative:1 μg/kg
11050725|NCT04424251|Placebo Comparator|Placebo 0.4 μg/kg|Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg
11050726|NCT04424251|Placebo Comparator|Placebo 1 μg/kg|Preoperative:1 μg/kg Postoperative:0.5 μg/kg
11050727|NCT04424251|Placebo Comparator|Placebo 2 μg/kg|Preoperative:2 μg/kg Postoperative:1 μg/kg
11050728|NCT04424251|Placebo Comparator|Placebo|Preoperative:2 μg/kg Postoperative:1 μg/kg
11050729|NCT04424238|No Intervention|Standard Clinic Prenatal Care (Control Group)|pregnancy's prenatal care appointment would be changed to once every two weeks when diagnosed with GDM. Doctors generally ask GDM women record their daily diet, exercise, weight, BG and blood pressure for at least three days between two visits and give lifestyle guidance according to the records. If they fail to show diaries, doctors would ask them come back with record next week. If BG control is poor, medicine intervention would be considered.
11050730|NCT04424238|Experimental|m-health group (Intervention Group)|participants were managed continuously through WeChat group chat.
11050731|NCT04424225|Experimental|Psilocybin First|Participants in this arm will receive psilocybin first, then niacin
11050732|NCT04424225|Experimental|Niacin First|Participants in this arm will receive niacin first, then psilocybin
11050733|NCT04424212|Experimental|Experimental: Intervention group CoronaCope|ICBT, were participants receive 8 out of 15 possible modules depending on their current problems and needs, 7 week long internet intervention for reducing mental health issues related to the coronavirus pandemic.
11050734|NCT04424212|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
11050735|NCT04424199||LBD patients R-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:
~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.
~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
11050736|NCT04424199||LBD patients L-PA|"A group of 10 left brain damaged (LBD) patients will attend two sessions:
~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.
~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
11050737|NCT04424199||RBD patients R-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:
~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.
~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
11050738|NCT04424199||RBD patients L-PA|"A group of 10 right brain damaged (RBD) patients will attend two sessions:
~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological test battery to assess cognitive abilities.
~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
11050739|NCT04424199||HC R-PA|"A group of 10 healthy controls (HC) will attend two sessions:
~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.
~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing rightward attentional shift (R-PA)."
11050740|NCT04424199||HC L-PA|"A group of 10 healthy controls (HC) will attend two sessions:
~First session - before prismatic adaptation (pre-PA): they will perform a computerized test battery to measure time abilities (Mental Time Travel and Time Estimation) and a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria.
~Second session - after prismatic adaptation (post-PA): they will perform the Mental Time Travel and Time Estimation tasks immediately after a single session of pointing with prismatic goggles inducing leftward attentional shift (L-PA)."
11050741|NCT04424186|Experimental|'Rehabilitation for Life'|Vital sign measurement and rehabilitation
11050742|NCT04424186|Active Comparator|Usual care and rehabilitation|Usual care and rehabilitation provided in primary and secondary sectors
11050743|NCT04424160|Experimental|Endometrial PRP|Patients in whom endometrial PRP was performed
11050744|NCT04424147|Experimental|HVA treatment|All patients with rrAML are treated with HVA regimen
11050745|NCT04424134|Experimental|Bromhexine And Spironolactone|
11050746|NCT04424134|Active Comparator|Base therapy|
11050960|NCT04422561|No Intervention|Control group|Contacts who will be only observed without prophylaxis
11050747|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing|Participants will be approached and randomized to receive standard care plus ECG-stress testing
11050748|NCT04424121|No Intervention|Standard of care plus ECG Stress Testing and CACS|Participants will be approached and randomized to receive standard care plus ECG-stress testing and coronary artery calcium scoring
11050749|NCT04424121|Active Comparator|Standard of care plus CCTA|Participants will be approached and randomized to receive standard care plus ≥ 64 multidetector coronary computed tomography angiography
11050750|NCT04424095||Pediatric patients|Recruited pediatric patients will undergo an in-office vascular visit and an echo duplex scan of lower limbs, in order to detect any symptoms or signs related to chronic venous disease.
11050751|NCT04424082|Other|dead space removal|external dead space will be removed and Vcap parameters (VCO2, PaCO2 and alveolar dead space) recorded before and after.
11050752|NCT04424069|Active Comparator|LASIK group|Patients will do excimer laser LASIK operation for correction of myopia with flap creation by mechanical keratome
11050753|NCT04424069|Active Comparator|SMILE group|Patients will do Femtosecond laser assisted corneal refractive surgery for correction of myopia
11050754|NCT04424069|Active Comparator|Photorefractive keratectomy group|Patients that will undergo photorefractive keratectomy for correction of myopia
11050755|NCT04424069|Active Comparator|Refractive lens exchange|Include eyes that will undergo refractive lens exchange
11050756|NCT04424069|No Intervention|Control group|Myopic control eyes with no surgical intervention
11050757|NCT04424056|Experimental|Anakinra +/- Ruxolitinib|"Anakinra +/- Ruxolitinib
~According to clinical stage (gradual strategy):
~Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib"
11050758|NCT04424056|Experimental|Tocilizumab +/- Ruxolitinib|"Tocilizumab +/- Ruxolitinib
~According to clinical stage (gradual strategy):
~Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib"
11050759|NCT04424056|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
11050760|NCT04424043|Experimental|neo-TACE-HAIC with surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
11050761|NCT04424043|Active Comparator|surgery alone|hepatic resection remove the liver tumors
11050762|NCT04424030||Multimodality imaging|Patients who have undergone echocardiography and cardiac MRI as part of their clinical management A research cardiac CT scan will be performed in eligible participants
11050763|NCT04424017||Healthcare workers (HCWs)|
11050764|NCT04424017||Healthy blood donors and healthy subjects in blood bank|
11050765|NCT04424017||Convalescents|
11050766|NCT04424004||MURDOCK Study Participants with valid email address|"Randomized for testing: 1.A randomly selected subset of individuals who consent to participate (N~300-500), will be invited to participate in COVID-19 polymerase chain reaction (PCR) viral testing by at-home collection and return of self-administered nasal swabs. Saliva specimens may replace the nasal swab specimen.
~2. The same randomly selected subset of individuals who collect at-home samples for COVID-19 PCR testing (N~300-500), will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies."
11050767|NCT04423991|Experimental|Exposed group|All patients were exposed to the algorithm and were characterized as being likely responders to hydroxychloroquine treatment. Treatment decisions regarding the administration of hydroxychloroquine were made independently by care providers.
11050768|NCT04423965|Experimental|mXELOXIRI|Patients receive 6 cycles of mXELOXIRI
11050769|NCT04423965|Experimental|Chemoradiotherapy(CRT)|Patients receive standard chemoradiotherapy
11050770|NCT04423952||Patients with chronic otitis media|Patients aged 7 to 15 years with chronic otitis media.
11050771|NCT04423952||Controls|Minors aged 7 to 15 years, with no and no history of chronic otitis.
11050772|NCT04423939|Experimental|Hematopoietic Stem Cell Transplantation (HCT) Patients|20 HCT patients at Duke
11050773|NCT04423939|Experimental|Caregivers|20 HCT patients caregivers at Duke
11050774|NCT04423926|Experimental|Lenalidomide+CHOP|
11050775|NCT04423913|Experimental|Patients undergoing transarterial embolization of the prostate|Three patients will undergo transarterial embolization of the prostate using unloaded beads.
11050776|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 2.5 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 2.5 mg of doxorubicin.
11050777|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 5.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 5.0 mg of doxorubicin.
11050778|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 10.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 10.0 mg of doxorubicin.
11050779|NCT04423900|Experimental|Plantar Fasciitis App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
11050780|NCT04423900|Experimental|Achilles Tendinopathy App Exercise Group|Video simulation of patient education (definition of the disease, risk factors, lifestyle modifications, prevention methods) will be performed to people via smart phone app application. Individuals will receive feedback after completing the training program and will then be included in the exercise program. The mobile application provides feedback so that the exercise program (stretching, strengthening, self-myofascial relaxation exercises) determined according to the diagnosis of the patients is performed by the patients at twice a day for eight weeks.
11050781|NCT04423900|Experimental|Plantar Fasciitis Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
11050961|NCT04422548|Active Comparator|AI-assisted Group|
11050962|NCT04422548|Active Comparator|Standard|
11050782|NCT04423900|Experimental|Achilles Tendinopathy Home Exercise Group|Patients will learn the exercises by the physiotherapist in the clinic. Patients will be included in the training program (stretching, strengthening, self-myofascial release exercises) -only once. Then, patients will do this program at their home twice a day for eight weeks.
11050783|NCT04423900|Experimental|Plantar Fasciitis Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
11050784|NCT04423900|Experimental|Achilles Tendinopathy Conventional Physiotherapy Group|In this group, patients will first be included in the patient education and exercises program in the clinic-only once. Mulligan Concept - Manual Therapy and Compressive myofascial relaxation methods will be applied to the individuals who have completed the patient training program by the physiotherapist. Patients will participate in the rehabilitation program twice a week for eight weeks. These patients will perform their home exercises twice daily and for eight weeks.
11050785|NCT04423887|Active Comparator|Control|
11050786|NCT04423887|Experimental|Creatine Supplementation|
11050787|NCT04423874|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while listening to vocalisations. Physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
11050788|NCT04423861|Experimental|nitazoxanide BID|Patients will receive nitazoxanide 600 mg BID for 7 days.
11050789|NCT04423861|Placebo Comparator|Placebo|Patients will receive matching placebo BID for 7 days.
11050790|NCT04423848|Experimental|Home Hospital for Lymphoma|The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
11050791|NCT04423835||lateral closing osteotomy for cubitus varus deformity|The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs.
11050792|NCT04423822||Firefighter|Firefighter with high cardiovascular risk
11050793|NCT04423809||caregivers of adult patients hospitalized in psychiatry|a face-to-face interview with a nurse and self-assessment scales.
11050794|NCT04423796|Experimental|Robotic assisted early mobilization|Robotic assisted early mobilization started within 72 hours of ICU admission.
11050795|NCT04423796|Active Comparator|Early mobilization|Early mobilization started within 72 hours of ICU admission without the use of a robotic assistance. Mobilization is done by personell.
11050796|NCT04423783|Experimental|Spider gamification app|Participants play the spider gamification app twice a day for 7 days
11050797|NCT04423783|Experimental|Online exposure + spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play the spider gamification app twice a day for 7 days
11050798|NCT04423783|Active Comparator|Online exposure + non-spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play a non-spider gamification app twice a day for 7 days
11050799|NCT04423770||U.S. dentists|Dentists in the United States
11050800|NCT04423757|Experimental|BI 1358894|
11050801|NCT04423757|Placebo Comparator|Placebo|
11050802|NCT04423744|Experimental|Intervention ABCD|"Intervention A:
~Day 1 and 2: Supra-therapeutic dose of BAY1817080, three times daily (tid) Day 3: Supra-therapeutic dose of BAY1817080 and placebo to moxifloxacin, once
~Intervention B:
~Day 1 and 2: therapeutic dose of BAY1817080 and placebo to BAY1817080, tid Day 3: therapeutic dose of BAY1817080, placebo to BAY1817080 and placebo to moxifloxacin, once
~Intervention C:
~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and moxifloxacin, once
~Intervention D:
~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and placebo to moxifloxacin, once
~Subjects will receive intervention A, B, C and D sequentially. The washing-out period between each intervention is at least 14 days"
11050803|NCT04423744|Experimental|Intervention BCDA|Subjects will receive intervention B, C, D and A sequentially. The washing-out period between each intervention is at least 14 days
11050804|NCT04423744|Experimental|Intervention CDAB|Subjects will receive intervention C, D, A and B sequentially. The washing-out period between each intervention is at least 14 days
11050805|NCT04423744|Experimental|Intervention DABC|"Subjects will receive intervention D, A, B and C sequentially. The washing-out period between each intervention is at least 14 days
~Note: the intervention sequences in this and above arms are examples, the actual order of intervention may differ from these examples"
11050806|NCT04423718|Active Comparator|Aflibercept 2q8|Aflibercept 2 mg administered every 8 weeks after a loading phase.
11050807|NCT04423718|Experimental|Aflibercept high dose (HD)q Interval A|Aflibercept high dose administered at a treatment interval A after a loading phase.
11050808|NCT04423718|Experimental|Aflibercept (HD)q Interval B|Aflibercept high dose administered at a treatment interval B after a loading phase.
11050809|NCT04423692||pregnant women with abnormal labs|Mothers who have abnormal labs during pregnancy with abnormal coagulation profile
11050810|NCT04423679||CIN2+|Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
11050811|NCT04423679||< CIN2|Non-cases will include those with <CIN2 on colposcopy/biopsy and women who did not have an indication for colposcopy (because of a negative screening test).
11050812|NCT04423666|Experimental|Intervention|"Will receive:
~education
~a wireless pedometer with set up
~nurse coaching via text message, email or telephone based on participant preference and at frequency determined by the participant"
11050813|NCT04423666|Experimental|Control|"Will receive:
~education
~a wireless pedometer with set up"
11050814|NCT04423653|Experimental|Tele-coaching group|This group will receive exercises videos, 2 sessions a week to be done on participant's own and the 3rd session will be live video conference session for training, supervision, and consultation purposes.
11051110|NCT04421508|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 125 mcg/kg IBW/hour
11050815|NCT04423653|Active Comparator|Self-monitored group|This group will receive exercises videos, 3 sessions a week to be done on participant's own with out any supervision.
11050816|NCT04423640||COVID Patients|Diagnosed patients with COVID-19 by PCR
11050817|NCT04423627|Experimental|Clonidine|0.2 mg/day oral
11050818|NCT04423627|Active Comparator|Hydrochlorothiazide|37.5 mg/day oral
11050819|NCT04423627|Placebo Comparator|Placebo|Placebo
11050820|NCT04423614|Experimental|Inspiratory Muscle Training (IMT)|Pre-operative inspiratory muscle training
11050821|NCT04423614|Experimental|Relaxation Breathing (RLX)|Relaxation breathing exercises
11050822|NCT04423601|Experimental|Treatment|subjects receiving a single oral dose of SHR6390 tablets, then itraconazole capsules 200 mg/day orally with a single oral dose of SHR6390 tablets co-administered.
11050823|NCT04423588|Other|Dexlansoprazole|The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.
11050824|NCT04423575|Experimental|Outpatients|Health care pathway: patient education, communication to liberal nurses, first-position surgical planning, bariatric surgery (bypass or sleeve) as outpatient procedure, follow-up by home nurse twice-a-day, standardized communication to surgeons, management of possible complications
11050825|NCT04423575|No Intervention|Inpatients|Standard care pathway with bariatric surgery (bypass or sleeve) as inpatient procedure (at least one night in the hospital)
11050826|NCT04423562||Durable LVAD recipient with post implant VO2|
11050827|NCT04423549||tested group|
11050828|NCT04423549||controlled group|
11050829|NCT04423536||tested group|
11050830|NCT04423536||controlled group|
11050831|NCT04423510||Recurrent pilonidal sinus|Postoperative recurrent pilonidal sinus disease
11050832|NCT04423484||Children with Nephroblastoma|All children coming into the participating units with suspected Nephroblastoma.
11050833|NCT04423471||Group 1|Psoriasis patients who will receive systemic treatment (mainly methotrexate)
11050834|NCT04423471||Group 2|Psoriasis patients who will receive a biological treatment
11050835|NCT04423471||Group 3|Patients with major depression who will receive an antidepressant treatment
11050836|NCT04423458||Transplanted kidney|No intervention is required. Routine Doppler assessment + 3D scan + Shear wave elastography + Angio-PL.U.S. mood will be immediately recorded afterwards
11050837|NCT04423445|Experimental|Laser acupuncture combined with acupressure (LAA)|A 4-week LAA intervention included low-level laser acupuncture and auricular acupressure. Six acupuncture points were selected, and three auricular points. Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. After five days, the seed was removed, and a new seed was taped on the other ear.
11050838|NCT04423445|No Intervention|Control group|Control participants received a similar intervention, but without laser energy output or acupressure.
11050839|NCT04423432|Active Comparator|Control|
11050840|NCT04423432|Experimental|Creatine Supplementation|
11050841|NCT04423432|Experimental|Glucoseamine/ Chondritin Sulfate Supplementation|
11050842|NCT04423419|Other|A|will undergo Peri -articular nerve group block for hip joint under ultrasound guide as analgesia post operative after hip arthroscopy
11050843|NCT04423419|Other|B|will undergo ultrasound guided fascia iliaca block as postoperative analgesia after hip arthroscopy
11050844|NCT04423419|Other|C|will receive ordinary IV analgesia during operation hip arthroscopy
11050845|NCT04423393|Experimental|VIR-3434|
11050846|NCT04423393|Placebo Comparator|Placebo|
11050847|NCT04423380|Experimental|SH3051 capsules treatment|Oral Twice Daily Administration of SH3051
11050848|NCT04423367|Experimental|bortezomib/dexamethasone|Enrolled patients will receive the combination therapy of bortezomib and dexamethasone.
11050849|NCT04423354|Experimental|Research group|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy.
11050850|NCT04423341|Active Comparator|Group A - active medication followed by placebo|
11050851|NCT04423341|Active Comparator|Group B - placebo followed by active medication|
11050852|NCT04423328|Experimental|acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Shenmen→Neiguan→Hegu acupoints.
11050853|NCT04423328|Sham Comparator|sham acupressure|Every day before going to sleep, massage acupoints for eight consecutive weeks, followed by Waiguan→Liangqiu→Tiaokou→ Chengshan acupoints
11050854|NCT04423315||patients with covid-19 pneumonia|patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
11050855|NCT04423302|Experimental|TOTUM-63 3 intakes per day|Experimental active diet supplement TOTUM-63 taken 3 times per day (blinded arm)
11050856|NCT04423302|Placebo Comparator|Placebo 3 intakes per day|Placebo comparator taken 3 times per day (blinded arm)
11050857|NCT04423302|Experimental|TOTUM-63 2 intakes per day|Experimental active diet supplement TOTUM-63 taken 2 times per day (open arm)
11050858|NCT04423289|Experimental|Farmalarm|Farmalarm app for the follow-up
11050859|NCT04423289|No Intervention|Control|Regular primary care follow-up
11050860|NCT04423276|Placebo Comparator|Control|
11050861|NCT04423276|Experimental|Donepezil|
11050862|NCT04423263|Experimental|Intervention|Receives bilateral internal iliac artery occlusion
11050863|NCT04423263|Active Comparator|Control|Does not receive bilateral internal iliac artery occlusion
11050864|NCT04423237||Severe Iron Overload (SIO)|Children affected by Severe Iron Overload who received DEFERASIROX
11050865|NCT04423237||Severe Iron Overload + Ductopenia (SIO+D)|Children affected by Severe Iron Overload + Ductopenia who received DEFERASIROX
11051111|NCT04421508|Sham Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
11063887|NCT04329910||class i obesity|BMI 30 -34.9
11050866|NCT04423224|Active Comparator|Control group|Control group Management of the hemodynamic status in the control group will be performed in the discretion of the attending anesthesiologist, with the aim of keeping mean arterial pressure (MAP) > 65mmHg. The type and amount of delivered fluids, and vasoactive or inotropic drugs will be recorded.
11050867|NCT04423224|Active Comparator|GDFM|Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position & before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.
11050868|NCT04423211|Active Comparator|Arm A (EBRT, goserelin, leuprolide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline.
~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT for 6 months. Patients also receive goserelin acetate SC or leuprolide acetate IM for 6 months starting up to 3 months prior to EBRT but no later than the first fraction of EBRT. All treatment continues for 6 months in the absence of disease progression or unacceptable toxicity."
11050869|NCT04423211|Experimental|Arm B (EBRT, goserelin, leuprolide, apalutamide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline.
~STEP 1: Patients who are PET negative for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD for 6 months in the absence of disease progression or unacceptable toxicity."
11050870|NCT04423211|Experimental|Arm C (EBRT, goserelin, leuprolide, apalutamide)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arm C undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.
~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A. Patients also receive apalutamide PO QD as in Arm B."
11050871|NCT04423211|Experimental|Arm D (EBRT, goserelin, leuprolide, apalutamide, RT)|"STEP 0: Patients receive fluciclovine F18 IV and undergo SOC PET/CT scan at baseline. NOTE: Patients randomized to Arm D undergo a repeat fluciclovine F18 PET/CT at time of second PSA recurrence or 12 months after completion of enhanced systemic therapy.
~STEP 1: Patients who are PET positive for extra pelvic metastases undergo SOC EBRT and receive goserelin acetate SC or leuprolide acetate IM as in Arm A and apalutamide PO QD as in Arm B. Patients also undergo SBRT or 3D CRT, IMRT (including VMAT), and IMPT over 3-5 fractions in the absence of disease progression or unacceptable toxicity."
11050872|NCT04423198||Target Condition|Subjects presenting to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma
11050873|NCT04423198||Trauma Control|Subjects presenting to the ED or UC requiring an Xray but do not have a head trauma
11050874|NCT04423198||Healthy Control|Subjects that are healthy and not taking any prescription medications
11050875|NCT04423185|Experimental|Almonertinib-EGFR mutation|Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
11050876|NCT04423185|Experimental|Dacomitinib-EGFR mutation|Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
11050877|NCT04423185|Experimental|Alectinib-ALK fusion|Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
11050878|NCT04423185|Experimental|Crizotinib-ALK fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
11050879|NCT04423185|Experimental|Vemurafenib-BRAF mutation|Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
11050880|NCT04423185|Experimental|Niraparib-BRCA mutation or HRD|Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
11050881|NCT04423185|Experimental|Pyrotinib-HER-2 overexpression/amplification|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
11050882|NCT04423185|Experimental|Imatinib-CKIT mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
11050883|NCT04423185|Experimental|Palbociclib-CDKN2A mutation|Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
11050884|NCT04423185|Experimental|Crizotinib-ROS-1 fusion|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
11050885|NCT04423185|Experimental|Crizotinib-C-MET amplification|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
11050886|NCT04423185|Experimental|Crizotinib-C-MET mutation|Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
11050887|NCT04423185|Experimental|Pyrotinib-HER-2 mutation|Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
11050888|NCT04423185|Experimental|Sintilimab-PD-1|Administration: 200mg q21d, to disease progression or intolerable adverse effects.
11050889|NCT04423185|Experimental|Combination ARM-Niraparib & Sintilimab|Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
11050890|NCT04423185|Experimental|Combination ARM-Vemurafenib & Atezolizumab|Vemurafenib (960 mg oral bid) & Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
11050891|NCT04423185|Experimental|Combination ARM-Palbociclib & Atezolizumab|Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
11050892|NCT04423172|Experimental|Using the New Tissue Containment System group|using the new tissue containment system during Laparoscopic Hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
11050893|NCT04423172|No Intervention|Open group|Without using any procteciton system during Laprascopic Hysterectomy.
11050894|NCT04423159|Experimental|OCV vaccine|Shanchol 1.5mL to be administered orally. Each dose contains V.cholerae O1 Inaba El Tor Strain, Inaba classical strain, ogawa classical strain and O139 strain. As well as Thiomersal and a buffer
11051112|NCT04421495|Experimental|delamanid containing regimen arm|the only one arm to be studied with delamid-containing regimen.
11050895|NCT04423146||Patients scheduled for elective scoliosis surgery|Patients scheduled for elective scoliosis surgery will be anesthetized in TIVA mode,combining propofol and remifentanil with titration to the target BIS value. Motor evoked potentials will be measured and evaluated by members of operating team perioperatively. The quality of evoked potentials (poor vs good quality) and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
11050896|NCT04423133|Experimental|Online Family Literacy Program|The Ready and Healthy for Kindergarten program is a bilingual family literacy program that uses anticipatory guidance on health routines (e.g., physical activity) to introduce language and literacy skills to children and their families delivered via an online video conference format.
11050897|NCT04423107|Active Comparator|No opioid|Acetaminophen every 6 hours and Ibuprofen every 6 hours
11050898|NCT04423107|Active Comparator|Opioid|Acetaminophen every 6 hours, Ibuprofen every 6 hours, and Oxycodone every 6 hours as needed for breakthrough pain for 10 doses.
11050899|NCT04423068|Experimental|Open trial of SexHealth II|
11050900|NCT04423055|Experimental|COC users or new starts|Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
11050901|NCT04423042|Experimental|Tocilizumab Arm|Tocilizumab 8 mg/kg IV up to a maximum of 800 mg with possible repetition of the same dosage within 28 hours (the optional second dose after 12 hours but before 28 hours following the first dose), based on the clinical judgement of the attending physician in consultation with the COVID-inflammation team.
11050902|NCT04423042|No Intervention|No Intervention Arm|No intervention arm patients will be identified from medical records, as being COVID-19 positive patients with hyperinflammation who did not receive any interleukin antagonist treatment.
11050903|NCT04423029|Experimental|DF6002 Monotherapy Dose Escalation|3+3 dose escalation of subcutaneous DF6002 as monotherapy in patients with solid tumors.
11050904|NCT04423029|Experimental|DF6002 Monotherapy Expansion (Melanoma)|Dose expansion of up to 40 patients with melanoma receiving subcutaneous DF6002 as monotherapy.
11050905|NCT04423029|Experimental|DF6002 Monotherapy Expansion (Renal Cell)|Dose expansion of up to 40 patients with renal cell carcinoma receiving subcutaneous DF6002 as monotherapy.
11050906|NCT04423029|Experimental|DF6002 In Combination with Opdivo Escalation|3+3 dose escalation of subcutaneous DF6002 in combination with intravenous Opdivo.
11050907|NCT04423029|Experimental|DF6002 in Combination with Opdivo Expansion (Urothelial)|Dose expansion of up to 40 patients with urothelial carcinoma receiving subcutaneous DF6002 in combination with intravenous Opdivo.
11050908|NCT04422977|Other|CoVID exposure|
11050909|NCT04422964|Experimental|Intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
11050910|NCT04422964|No Intervention|control group|The standard procedure without the 3D obturator.
11050911|NCT04422951|Experimental|Wise interventions plus family-based group behavioral Rx|
11050912|NCT04422951|Active Comparator|Family-based group behavioral Rx|
11050913|NCT04422938||Manuel compression|Manuel chest compressions will be handled by clinicians
11050914|NCT04422938||Mechanical compression|Mechanical chest compressions will be handled via mechanical chest compression device
11050915|NCT04422912|Experimental|DSG3-CAART|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (4 groups) administered as a single cycle.
~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (2 groups) administered as a single cycle.
~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle"
11050916|NCT04422899|Experimental|AIV007 Treatment Dose 1|Intravitreal, Dose 1
11050917|NCT04422899|Experimental|AIV007 Treatment Dose 2|Intravitreal, Dose 2
11050918|NCT04422899|Experimental|AIV007 Treatment Dose 3|Intravitreal, Dose 3
11050919|NCT04422886|Experimental|Physio+tDCS|Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
11050920|NCT04422886|Sham Comparator|Physio+sham|Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
11050921|NCT04422873||in-centre|Currently dialysing in-centre
11050922|NCT04422873||home|Currently dialysing at home
11050923|NCT04422860|Experimental|Gum Arabic varnish|Gum arabic (Acacia senegal) is an exudate obtained from Acacia senegal stems and roots, and other similar African Acacia species. It consists mainly of high molecular weight polysaccharides high concentrations of calcium, magnesium, and potassium salts which can potentially increase tooth remineralization.
11050924|NCT04422860|Active Comparator|Sodium Fluoride varnish|The gold standard remineralizing agent recommended by the guidelines.
11050925|NCT04422860|Active Comparator|10% w/v CPP-ACP, 5% sodium fluoride varnish|CPP-ACP is the most studied non fluoride remineralizing agent.
11050926|NCT04422847|Experimental|intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
11050927|NCT04422847|No Intervention|control group|The standard procedure without the 3D obturator.
11051153|NCT04421248||Typically developing controls (TDC)|Typically developing controls - 8 to 12 year old children
11050928|NCT04422834|Experimental|Health Professional Students|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
11050929|NCT04422821|Experimental|FreeStyle Libre™|FreeStyle Libre™ will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will receive subcutaneous sensor for glucose monitoring (FreeStyle Libre™; Abbott Diabetes Care, Alameda, CA) for 4 weeks.
11050930|NCT04422821|Active Comparator|iXell®|iXell® will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will monitor glycemia through use of standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) for 4 weeks.
11050931|NCT04422795|Experimental|External thermomechanical device delivering stimuli|The thermomechanical device is placed on the digit two centimeters proximally to the injection site with the ice wings frozen and the vibration mechanism switched on.
11050932|NCT04422795|Placebo Comparator|External thermomechanical device without delivering stimuli|The thermomechanical device is placed on the digit two centimeters proximally to the injection site with the ice wings at room temperature (unfrozen) and the vibration mechanism switched off.
11050933|NCT04422795|No Intervention|Nail injection without the external thermomechanical device|Nail injections will be performed without the use of external thermomechanical stimuli.
11050934|NCT04422782|Other|Single Arm|Single Arm
11050935|NCT04422743|Experimental|standard of care + citicoline plus homotaurine (CIT/HOMO)|CIT/HOMO was supplemented for 4 months to the standard of care (SOC, i.e. topical intraocular pressure, IOP, lowering medication)
11050936|NCT04422743|No Intervention|standard of care|only standard of care (SOC, i.e. topical IOP lowering medication) for 4 months
11050937|NCT04422730||pancreatectomy in cancer patients|
11050938|NCT04422730||pancreatectomy in non-cancer patients|
11050939|NCT04422730||mastectomy|
11050940|NCT04422730||Acute leukaemia|
11050941|NCT04422704|Experimental|Retired people|People who are either ordinarily or early retired and who have previously held a paid employment.
11050942|NCT04422691||Covid-19 suspected|Emergency department patients with suspected or diagnosed COVID-19 disease. All patients will be screened at triage and put into isolation if suspected disease. Ultrasound of the patients lungs will be performed after patient consent and findings will be recorded and categorized (Soldati et al., 2020). The use of ultrasound and registration of data will not affect the regular patient evaluation, treatment or logistics.
11050943|NCT04422678|Experimental|Imatinib Standard Dose|"Imatinib 400 mg oral tablet once daily for 21 days
~In addition for the treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
11050944|NCT04422678|Experimental|Imatinib Low Dose|"Imatinib 200 mg oral tablet once daily for 21 days.
~In addition to the treatment for COVID-19 Pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
11050945|NCT04422678|Active Comparator|Control|Treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH).
11050946|NCT04422665|Experimental|Single Exercise|Subjects allocated to this group will perform a single bout of one-legged resistance exercise. This bout will take place 1 day prior to the start of the bed rest. The resistance exercise will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
11050947|NCT04422665|Experimental|Multi Exercise|Subjects allocated to this group will perform 4 bouts of one-legged resistance exercise. These bouts will take place on alternate days the week leading up to the bed rest. Each resistance exercise bout will consist of 8 sets of leg extensions and 8 sets of leg curls. The non-exercising leg will serve as an internal control. The dominant leg will perform the exercise.
11050948|NCT04422652|Active Comparator|Strategy 1|Strategy 1: Single-blind Behavioral Activation Therapy plus placebo for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind bupropion (Phase 2) for another 8 weeks.
11050949|NCT04422652|Active Comparator|Strategy 2|Strategy 2: Double-blind bupropion plus single-blind Clinical Management (CM) attention control for 8 weeks (Phase 1), augmented in non-remitters at 8 weeks with single-blind BAT (Phase 2) for another 8 weeks.
11050950|NCT04422652|Placebo Comparator|Control|Control: Clinical management attention control plus placebo for 16 weeks
11050951|NCT04422639|Experimental|Arm I (pre-operative SRS/SRT)|Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
11050952|NCT04422639|Active Comparator|Arm II (post-operative SRS/SRT)|Patients undergo surgery within 15 days of randomization followed by standard-of-care SRS or SRT within 30 days of surgery. Patients may undergo additional SRS or SRT if disease returns after treatment.
11050953|NCT04422626||Critically ill COVID-19 patients, who receive CytoSorb therapy|Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) CytoSorb therapy on consultant's discretion.
11050954|NCT04422613|Experimental|characterization of pulmonary damage|This clinical trial will be characterized the pulmonary damage after COVID-19 pneumonia
11050955|NCT04422600||Mothers who report use of THC with or without CBD|Mothers who report THC and CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
11050956|NCT04422600||Mothers who report use of CBD only|Mothers who report CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
11050957|NCT04422600||Control Mothers|Recruitment of pregnant women who do not use THC or CBD will be conducted using the Epic MyChart research participant recruitment tool
11050958|NCT04422587||RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
11050959|NCT04422561|Experimental|Ivermectin group|Contacts who will receive prophylactic ivermectin
11050963|NCT04422535||Critical care patients|Patients admitted to critical care units for COVID-19, where ECG records and relevant clinical information are available to assess the impact of the disease and its concomitant treatment on electrocardiographic parameters of ventricular repolarization
11050964|NCT04422509|Experimental|lanadelumab|20 Patients will receive an intravenous dose of 300 mg lanadelumab on day 1, followed by a second dose of lanadelumab 300mg iv on day 4 (if needed).
11050965|NCT04422509|Other|controls|20 patients will received standard of care In additiona, for every index patient we will match one historical controls. Controls will be matched based on age, bodyweight and gender.
11050966|NCT04422496|Experimental|HEC96719 tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B: There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
11050967|NCT04422496|Placebo Comparator|placebo tablets|part A: There will be a total of 6 dose cohorts: 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg part B:There will be a total of 3 dose cohorts: 0.5 mg, 1 mg, 2 mg
11050968|NCT04422483||Service Model Level Case Studies|Realist Interviews. MONTHS 9-30 (N=6-8 sites, 12 people per site, 96 interviewees)
11050969|NCT04422483||Individual/family level interviews|Child Interviews. MONTHS 9-30 (N=6-8 sites, 6 people per site, max. 48 interviewees)
11050970|NCT04422483||Individual child/family Level Case Studies:|MONTHS 10-30 (N=6-8 sites, 78 people per model (x4), 312 participants, 156 per NU/SCFT depending on distribution of sites)
11050971|NCT04422483||Focus groups:|MONTHS 9-30 (N=6-8 sites, 6-8 focus groups of up to 8 parents) N= 64
11050972|NCT04422457|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans
11050973|NCT04422431|Experimental|ALXN1840|Participants will receive ALXN1840.
11050974|NCT04422405|Experimental|Patients undergoing OAGB|
11050975|NCT04422392|Experimental|Neoadjuvant PD-1 antibody puls chemotherapy|"Neoadjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3) Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of combinded adjuvant treatment (PD-1 antibody+carboplatin+pemetrexed or nab-paclitaxel ) will be administered. Five cycles of PD-1 antibody will start within day 21-24 days from day 1 of adjuvant cycle 2."
11050976|NCT04422392|Active Comparator|Neoadjuvant chemotherapy|"Neoadjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 4rd-6th week from day 1 cycle 3 of neoadjuvant treatment (day 29-43 after day 1 of cycle 3).
~Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Three cycles of adjuvant treatment (carboplatin+pemetrexed or nab-paclitaxel ) will be administered."
11050977|NCT04422366|Experimental|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52|Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
11050978|NCT04422366|Active Comparator|GARDASIL®|Participants in this arm would receive GARDASIL®
11050979|NCT04422353|Experimental|video Dance classes|"The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm.
~Classes will be divided into four stages: Joint warm-up and stretching on the chairs; strengthening, balance, and rhythm exercises with the support of the chair; exercises inspired by the samba and forró (Brazilian ballroom dance) basic steps; and Final cool down. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
~The video Dance classes will happen in the period of self-isolation and social distance during the Covid-19 pandemic."
11050980|NCT04422353|Active Comparator|Unsupervised physical activities|The unsupervised physical activity programs will happen in the period of self-isolation and social distance during the Covid-19 pandemic. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
11050981|NCT04422353|No Intervention|control group|The control group will be people with PD, engaged, before the Covid-19 pandemic, in the Dance, the Nordic Walk and the Aquatic Jogging extension projects at Federal University of Rio Grande do Sul but did not do any type of physical activity during the Covid-19 pandemic.
11050982|NCT04422327|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
11050983|NCT04422314||Cohort 1|Lyme disease testing cohort
11050984|NCT04422314||Cohort 2|Endemic, asymptomatic controls
11050985|NCT04422314||Cohort 3|Non-endemic, asymptomatic controls
11050986|NCT04422314||Cohort 4|Potential cross-reactive disease states
11050987|NCT04422314||Cohort 5|Lyme disease testing cohort for AV/Development studies
11050988|NCT04422301|Experimental|High intensity eccentric training|"High intensity eccentric training high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
~eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction."
11050989|NCT04422301|Experimental|High intensity eccentric training with blood flow restriction|High intensity eccentric training with blood flow restriction high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction
11050990|NCT04422301|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
11050991|NCT04422301|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week. eccentric exercise with blood flow restriction High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
11050992|NCT04422275|Active Comparator|Budesonide & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
11050993|NCT04422275|Active Comparator|Placebo & High-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different high-concentration (1 ml) essential oils for olfactory training twice daily.
11050994|NCT04422275|Active Comparator|Budesonide & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with budesonide (0.5mg/capsule) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
11050995|NCT04422275|Placebo Comparator|Placebo & Low-Concentration OLF|In this arm, subjects will perform nasal saline lavage (240 ml) with placebo (lactose monohydrate) and four different low-concentration (0.1 ml) essential oils for olfactory training twice daily.
11050996|NCT04422262||Moli-sani Study sub-cohort|A sample of 2,500 men and women from the Moli-sani Study cohort (2005-2010) who were re-examined in 2017-2020. Participants will be contacted by telephone by researchers of the Moli-sani Study recruitment team in order to collect dietary, lifestyle and psychosocial information and assess potential changes possibly occurred during Phase 1 lockdown.
11050997|NCT04422262||Italian general population|The project will retrospectively collect data through a web-based survey using Google form. The questionnaire consists of the same items used for the Moli-sani sub-cohort. The project aims at including as many subjects' records as possible.
11050998|NCT04422249|Experimental|laparoscopic middle hepatic vein guidance hemihepatectomy|In theory, the advantages of anatomical hemihepatectomy guided by middle hepatic vein are as follows: 1) correctly guiding the transecting plane of the liver parenchyma can reduce the cross-sectional area of the liver and avoid damaging the vascular ducts of the pre-cut liver. so as to reduce the residue of necrotic tissue without blood supply and reduce the occurrence of postoperative complications. 2) active anatomy and exposure of hepatic vein can avoid uncontrollable bleeding after passive injury of hepatic vein, and laparoscopic anatomy has obvious advantage in exposing hepatic vein. 3) it may reduce the early recurrence rate of hepatocellular carcinoma after operation.
11050999|NCT04422249|Active Comparator|laparoscopic traditional anatomic hemihepatectomy|According to textbooks and the views of some scholars at present, traditional anatomical hepatectomy (non-hepatic vein-guided anatomical hepatectomy) has the following advantages: 1) avoiding exposure of hepatic vein can reduce the probability of injury to the trunk of hepatic vein, thus reduce the risk of massive bleeding during operation; 2) the difficulty of operation is relatively low, and a better short-term and long-term effect can be obtained.
11051000|NCT04422236||Obese patients eligible for laparoscopic bariatric surgery|
11051001|NCT04422223||Cohort|Patients newly diagnosed with liver cirrhosis form the Gastro Unit, Amager Hvidovre Hospital, Denmark. All patients with clinically verified diagnosis, irrepsective of disease stage and etiology is included.
11051002|NCT04422210|Experimental|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, will be administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
11051003|NCT04422210|Experimental|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, will be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
11051004|NCT04422210|Experimental|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who have completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, will be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
11051005|NCT04422210|Experimental|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
11051006|NCT04422210|Experimental|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
11051007|NCT04422210|Experimental|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
11051271|NCT04420442|Active Comparator|Intervention Group|In addition to the comparison between arm 1 and 2, there will be an intraindividual comparison within arm 1.
11051008|NCT04422210|Experimental|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC will be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerate study treatment without excessive toxicity, and have not undergone disease progression will then proceed to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
11051009|NCT04422210|Experimental|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort will continue to test venetoclax in both induction and maintenance. Participants will be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction preclude identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax will only be investigated in dose-expansion in the maintenance setting. Participants will be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
11051010|NCT04422197|Active Comparator|Patients with ultrasound-guided botox injection|Effect of Botox injection on lateral abdominal wall muscles after major open abdominal surgery
11051011|NCT04422197|Active Comparator|Patients with no botox injection|Patients with major abdominal surgery without botox injection
11051012|NCT04422184|Experimental|SEN GROUP|Sensodyne Repair and Protect - NOVAMIN technology
11051013|NCT04422184|Experimental|REG GROUP|Dentalclean Daily Regenerator - REFIX technology
11051014|NCT04422184|Experimental|REGK GROUP|Dentalclean Daily Regenerator - REFIX technology + potassium citrate
11051015|NCT04422158|Experimental|Nuun Single strength|3 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
11051016|NCT04422158|Experimental|Nuun Double strength|6 Nuun electrolyte tablets will be dissolved in 1.4 liters of water. Subjects will drink one liter of the prepared solution over 30 min (250 mL every 7.5 min)
11051017|NCT04422158|Placebo Comparator|Control|Subjects will drink one liter of water over 30 min (250 mL every 7.5 min)
11051018|NCT04422145|Active Comparator|Interventional/intensive|Participants received a structured nurse led education programme surrounding hypoglycaemia. They were encouraged to use self monitoring of blood glucose (SMBG) and had their diabetes medications adjusted according to this. They also received information on how to avoid hypoglycaemia (including the effects of diet, exercise, alcohol and their medications) and how to treat hypoglycaemia should it occur.
11051019|NCT04422145|Placebo Comparator|Standard|Participants returned to their standard diabetes care provider with no intervention.
11051020|NCT04422145|No Intervention|Observational|Participants were happy to have baseline characteristics collected and be followed up using electronic records in a longitudinal fashion but did not wish to be randomized. The observational and standard groups therefore received the same diabetes care.
11051021|NCT04422132|Active Comparator|ARM 1 - 2 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
11051022|NCT04422132|Active Comparator|ARM 2 - 4 weeks|Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
11051023|NCT04422119|Experimental|Multi-layer foam dressing|Patients in experimental group will receive the application of a multi-layer foam dressing with Safetac in surgical wound
11051024|NCT04422119|Active Comparator|Usual care|Patients in control group will receive standard treatment with povidone-iodine and a gauze dressing with plaster.
11051025|NCT04422080||Keratoconus patient|Patient with keratoconus disease diagnosed on videotopography
11051026|NCT04422080||Healthy patient|Patient consulting for keratoconus screening with no keratoconus on videotopography
11051027|NCT04422067||Case group (Retrognatism)|All pregnant patients with one or more fetuses suffering from a microretrognathia, diagnosed prenatally and integrated into a Pierre Robin Sequence, were included. All cases were confirmed postnatally, either by a pediatric examination or by a fetopathological examination in the case of a medical termination of the pregnancy. We had 21 cases.
11051028|NCT04422067||Control group|47 pregnant patients with fetus without facial abnormalities
11051029|NCT04422054||Open Surgery Repair Group|In the open surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications, in the postoperative period, during follow up.
11051030|NCT04422054||Endovascular Repair Group|In the endovascular surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications in the postoperative period, during follow up.
11051031|NCT04422041|Active Comparator|Early discharge|Discharge between 24 and 48 hours
11051032|NCT04422041|Experimental|Very early discharge|Discharge in less than 24 hours
11051033|NCT04422028|Experimental|Desogestrel Test Product|Participants received two tablets of the test formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
11051034|NCT04422028|Active Comparator|Desogestrel Reference Product|Participants received two tablets of the marketed reference formulation containing Desogestrel 0.075 mg. The tablets were taken with water and in a fasting condition.
11051035|NCT04422002||Surgical treatment|
11051036|NCT04422002||Palliative treatment|
11051070|NCT04421794|Placebo Comparator|Control group|For the control group the one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will be used to apply a stimulation of 15 minutes considered by TENS at the lowest intensity detectable by the participant in order to not influence the outcomes of interest. Our aim is to strengthen IFM which is not the role of TENS. The two electrodes will be placed on the dominant foot, at the same place than those for the NMES group.
11051106|NCT04421534|Experimental|Standard of care in addition to 600 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily [three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
11051037|NCT04421989|Experimental|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
11051038|NCT04421989|Active Comparator|Support Group|Participants randomized to FBT + Support parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The parent support group facilitates parent discussion and support around a variety of topics central to treatment for pediatric AN including: understanding medical co-morbidities, levels of care for treatment, understanding expected body weight, navigating FMLA, and medications. The facilitator introduces each topic weekly and opens up discussion between parents. The facilitator's role is to ensure the group remains on topic and on time.
11051039|NCT04421976|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
11051040|NCT04421976|Experimental|Driving pressure (DP) guided-PEEP|PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
11051041|NCT04421963|Experimental|Olaparib|Treatment
11051042|NCT04421950|Active Comparator|Wild Blueberry Supplement|30 grams of wild blueberry powder per day in foods items provided to them
11051043|NCT04421950|Placebo Comparator|Placebo supplement|Food items will be provided to them without the wild blueberry power.
11051044|NCT04421937|Experimental|Neuromuscular Electrical Stimulation (NMES) with TDT|
11051045|NCT04421937|Active Comparator|Traditional Dysphagia Therapy (TDT)|
11051046|NCT04421924|Experimental|Thrombelastogram (TEG)|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm.
11051047|NCT04421924|Experimental|Standard of Care (SOC)|In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
11051048|NCT04421911|Experimental|ketoprofen|
11051049|NCT04421911|Active Comparator|Diclofenac|
11051050|NCT04421898||group 1|group 1 : infants with congenital muscular torticollis
11051051|NCT04421898||group 2|group 2 : healthy , without congenital muscular torticollis
11051052|NCT04421885|Experimental|A: TBPM-PI-HBr (Reference - fasted)|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
11051053|NCT04421885|Experimental|B: TBPM-PI-HBr (Test - fasted)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.
11051054|NCT04421885|Experimental|C: TBPM-PI-HBr (Test - fed)|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.
11051055|NCT04421872|Experimental|General anesthesia Group|
11051056|NCT04421872|No Intervention|Healthy control group|
11051057|NCT04421859|Experimental|EyeCU App|"Augmented reality mobile application called EyeCU which simulates glaucoma progression and enhances understanding about the disease and its course. It is a bilingual (English/Spanish) application that is free-to-download on the Android and Apple app store. It will be delivered on a hospital owned tablet device and patients will be instructed to complete two sections, taking approximately 10 minutes."
11051058|NCT04421846|Other|Group 1 : Status epilepticus|
11051059|NCT04421846|Other|Group 2 : Dysimmune encephalitis|
11051060|NCT04421846|Other|Group 3 : Control patients|
11051061|NCT04421833|Active Comparator|Group A|Participants will benefit from TOVERTAFEL activities for 6 weeks then the usual animation techniques for 6 weeks with a week of wash-out between the two periods.
11051062|NCT04421833|Sham Comparator|Group B|Participants will benefit from the usual animation techniques for 6 weeks then from TOVERTAFEL activities for 6 weeks with a week of wash-out between the two periods.
11051063|NCT04421820|Experimental|Gastric Cancer|
11051064|NCT04421820|Experimental|Pancreatic Cancer|
11051065|NCT04421820|Experimental|Colorectal Cancer|
11051066|NCT04421820|Experimental|Cholangiocarcinoma|
11051067|NCT04421807|Experimental|Exercise+Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
11051068|NCT04421807|Active Comparator|Only Complex decongestive therapy (CDT) group|The patients diagnosed with lymphedema with 18-65years of age followed by routine controls and who were volunteered will be included in the study
11051069|NCT04421794|Experimental|NMES group|For the NMES group one portable stimulator (Compex 2, Medicompex SA, Ecublens, Switzerland) will deliver NEMS (15 min; 75 EMS contractions completed during the training session; rise time = 0.25 s and descending time = 0.75 s). In order to maximize muscle tension without accompanying detrimental effects on fatigue onset, biphasic symmetric regular-wave pulsed currents (85 Hz) lasting 400 μs will be delivered. Each 4-s steady tetanic stimulation will be followed by pause lasting 8-s, during which subjects will be submaximally stimulated at 4 Hz on the medial arch muscles. According to the recommendations, the two electrodes are placed behind the head of the first metatarsal to stimulate the medial arch intrinsic muscles. The goal is to attain the highest tolerable level of muscle contraction without discomfort during the 15 minutes and to provide a full tetanic contraction of the intrinsic foot muscles during the contraction time.
11051107|NCT04421534|Active Comparator|Standard of care only|Standard of care treatment; as per MOHP protocol
11051108|NCT04421521|Experimental|Acupuncture Group|
11051109|NCT04421521|No Intervention|Standard Therapy Group|
11051071|NCT04421781||Salvage HIFU for local recurrence after prostatectomy and EBRT|Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
11051072|NCT04421768|Experimental|systematic cervical exam training--retrospective measures|Effects of systematic cervical exam training on Labor and Delivery Care The total number of exams per hour of labor or triage stay and exam discrepancy between 2 examiners who performed exams less than 30 minutes apart will be compared between the 6 month time period before the unit wide training and 6 months after completing training
11051073|NCT04421768|Experimental|systematic cervical exam training--prospective measures|Effects of systematic cervical exam training on Labor and Delivery care Patient will be approached to obtain consent for them to have 2 cervical exams performed one after the other when an exam is clinically indicated. The discrepancy between the 2 examiners will be compared between the 6 month time period before the unit wide training and 6 months after completion of the training.
11051074|NCT04421755|Experimental|Produce Only|Receives weekly home delivery of fresh fruits and vegetables
11051075|NCT04421755|Experimental|Produce + Cooking Classes|Receives weekly home delivery of fresh fruits and vegetables plus invitation to participate in a series of three small group culinary medicine cooking classes
11051076|NCT04421755|No Intervention|Control|Control group with no cooking classes or groceries
11051077|NCT04421742||43 COPD|COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks
11051078|NCT04421729|Active Comparator|Savvy Caregiver Program|Savvy Caregiver Program, 6 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
11051079|NCT04421729|Active Comparator|Savvy Express|Savvy Express, 3 weekly sessions, group treatment, addressing educational, informational, and psychosocial issues and community resources.
11051080|NCT04421716|Experimental|Ursolic Acid|Administration of Ursolic Acid twice a day for 2 weeks
11051081|NCT04421716|Experimental|Curcumin|Administration of Curcumin twice a day for 2 weeks
11051082|NCT04421716|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin. If subjects from Cohort 1 or 2 wish to continue in the study, they will undergo a washout period of at least 4 weeks before participating in Cohort 3
11051083|NCT04421703|Experimental|Distance Collaborative|For sites randomized to the distance arm, training will be delivered via web conference, and technical assistance and assessment and feedback will be delivered by phone.
11051084|NCT04421703|Experimental|Blended in-person/distance collaborative|For the QI collaborative arm, training will be delivered in two in-person collaborative meetings; and the remainder of the strategies will be delivered via web-conferencing.
11051085|NCT04421690|Experimental|Cognitive Training|8 week computerized cognitive training
11051086|NCT04421690|Active Comparator|Trivia Training|8 week computerized trivia training
11051087|NCT04421677|Experimental|Phenylbutyrate|Open-label phenylbutyrate
11051088|NCT04421664|Experimental|Treatment|Participants in this arm will receive the study drug, hydroxychloroquine.
11051089|NCT04421664|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
11051090|NCT04421651|Experimental|Treatment group|The participants in the treatment group were offered 20 Dance movement therapy sessions in addition to standard care.
11051091|NCT04421651|No Intervention|Control group|Participants in the control group continued treatment as usual in the health services.
11051092|NCT04421625|Experimental|Diagnostic test for SARS-Cov2 for patients and health staff|"Blood test (rapid serology (immediate analysis), ELISA serology (differed analysis on frozen sample), genotyping of FCGR2A and FCGR3A gens)
~Nasal swab test (only if the patient has symptoms)
~Questionnaires"
11051093|NCT04421612|Experimental|Intensive|This group recieve access to a new module every 3rd day.
11051094|NCT04421612|Experimental|Ordinary|This group recieve access to a new module every 5th day.
11051095|NCT04421599|Experimental|Experimental Group A|Experimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
11051096|NCT04421599|No Intervention|Control Group|Control Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
11051097|NCT04421599|Experimental|Experimental Group B|Experimental Group B who were not administered aspiration during IM injection.
11051098|NCT04421586|Experimental|Pregnant women receiving VISTA counseling|Up to 60 pregnant women are screened and counseled for vaccine concerns using VISTA
11051099|NCT04421586|No Intervention|Pregnant women receiving usual care|Up to 60 pregnant women receiving usual care
11051100|NCT04421573|Experimental|Bilateral cervical plexus hydrodissestion with D5W|Injection of 10 mL of 5% dextrose under the sternocleidomastoid muscle
11051101|NCT04421573|Placebo Comparator|Bilateral sternocleidomastoid muscle injection with D5W|Delayed/usual care treatment
11051102|NCT04421560|Experimental|Pembrolizumab + Ibrutinib + Rituximab|"Phase 1b
~Dose escalation will occur using a standard 3+3 dose-escalation approach, beginning at dose level I (560 mg daily) and potentially escalating to dose level 2 (840mg) with rules for escalation and de-escalation.
~Ibrutinib: orally 2x daily
~Pembrolizumab: 200 mg intravenously every 3 weeks
~Rituximab: 375mg/m^2 intravenously once per week for 4 weeks (4 total doses).
~Phase 2
~Participants will receive Pembrolizumab, Rituximab and Ibrutinib at the pre-determined dosage level established in Phase 1b.
~Ibrutinib: orally maximum tolerated dose from phase 1 daily (560 mg or 840mg)
~Pembrolizumab: 200 mg intravenously every 3 weeks
~Rituximab: 375 mg/m^2 intravenously once per week for 4 weeks (4 total doses)."
11051103|NCT04421547|Experimental|Letrozole|Letrozole 1 tablet (2,5 mg) orally once a day
11051104|NCT04421547|Active Comparator|Standard Chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
11051105|NCT04421534|Experimental|Standard of care in addition to 400 mg lactoferrin|Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily [two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
11051113|NCT04421482|Other|Very Low Birth Weight Preterm Infants|Very Low Birth Weight Preterm Infants (birth weight less than 1,500g and less than 32 weeks gestation) admitted to NYU Winthrop NICU. (n=42)
11051114|NCT04421469|Experimental|Comprehensive treatment|Patients with multiple metastatic NPC were given Triprilimab(JS001) and chemotherapy combined with local treatment.
11051115|NCT04421456|Experimental|GWP42003-P 300 mg|GWP42003-P 300 milligrams (mg) per day
11051116|NCT04421456|Placebo Comparator|Placebo|Matching placebo
11051117|NCT04421456|Experimental|GWP42003-P 1000 mg|GWP42003-P 1000 mg per day
11051118|NCT04421443|Active Comparator|3 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 3 days.
11051119|NCT04421443|Active Comparator|5 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 5 days.
11051120|NCT04421443|Active Comparator|8 days before intervention|Participants have to complete a pre-treatment assessment (baseline) for 8 days.
11051121|NCT04421430|Experimental|Distraction cards group|Distraction cards was applied to the children in this group during the venipuncture procedure.
11051122|NCT04421430|Experimental|Virtual reality group|Virtual reality intervention was applied to the children in this group during the venipuncture procedure.
11051123|NCT04421430|Experimental|Buzzy® group|Buzzy® was applied to the children in this group during the venipuncture procedure.
11051124|NCT04421430|No Intervention|Control group|The control group received the routine venipuncture procedure and did not receive any other non-pharmacological intervention.
11051125|NCT04421417|Active Comparator|Standard Arthroscopic Rotator Cuff Repair|
11051126|NCT04421417|Experimental|Microfracture and Arthroscopic Rotator Cuff Repair|
11051127|NCT04421404|Experimental|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
11051128|NCT04421404|Placebo Comparator|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
11051129|NCT04421391|Experimental|Treatment Arm|Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks
11051130|NCT04421378|Experimental|Arm A: Selinexor+Radiation Therapy|Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet QW in a 28-day cycle for 6 cycles and beyond until PD during adjuvant therapy period.
11051131|NCT04421378|Active Comparator|Arm A_Control: Temozolomide+Radiation Therapy|Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m^2) of Temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 of Temozolomide oral capsule daily for 5 days in a 28-day cycle during Cycles 2 to 7 for 6 cycles during adjuvant therapy period.
11051132|NCT04421378|Experimental|Arm B: Selinexor+Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1, 2 and 3 and 75 mg/m^2 of Temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 of Temozolomide oral capsule daily for 5 days in a 28-day cycle during Cycle 2 to 7 during adjuvant therapy period.
11051133|NCT04421378|Active Comparator|Arm B_Control: Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 75 mg/m^2 of Temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 of Temozolomide oral capsule daily for 5 days in a 28-day cycle during Cycles 2 to 7 for 6 cycles during adjuvant therapy period.
11051134|NCT04421378|Experimental|Arm C: Selinexor+Lomustine|Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m^2 of Lomustine capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
11051135|NCT04421378|Active Comparator|Arm C_Control: Lomustine|Participants with rGBM uMGMT or mMGMT will receive 110 mg/m^2 of Lomustine capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
11051136|NCT04421365|Active Comparator|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
11051137|NCT04421365|Sham Comparator|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
11051138|NCT04421352|Experimental|low-dose radiation+CS1001|low-dose radiation+CS1001
11051139|NCT04421339|Experimental|Melatonin|
11051140|NCT04421339|Placebo Comparator|Placebo|
11051141|NCT04421326||Patients with acute ischemic stroke|Patients undergoing Mechanical Thrombectomy for large vessel occclusion with acute ischemic stroke
11051142|NCT04421313|Experimental|Rhumatoid Arthritis|The patients with Rheumatoid arthritis receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
11051143|NCT04421313|Placebo Comparator|Control Subjects|The patients with Control Subjects receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
11051144|NCT04421300|Experimental|smile exercise|smile exercise, 4 times a day，8 weeks
11051145|NCT04421300|Active Comparator|0.1% Sodium Hyaluronate Eye Drops|0.1% sodium hyaluronate, 4 times a day, 8 weeks.
11051146|NCT04421287|Experimental|Zhenyuan capsule|
11051147|NCT04421287|Placebo Comparator|Zhenyuan capsule placebo|
11051148|NCT04421274|Experimental|BM-MSCs group|Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )
11051149|NCT04421274|Sham Comparator|Control group|Receive the best medication, percutaneous coronary intervention
11051150|NCT04421261||Air-Q Self Pressurized Airway Device with Blocker|
11051151|NCT04421261||I-Gel|
11051152|NCT04421248||Attention Deficit Hyperactivity Disorder (ADHD)|8 to 12 year old children diagnosed with ADHD
11051154|NCT04421235|Other|Childbirth Support|Women who enroll in the intervention portion of this study will receive the childbirth support elements for which they are eligible in and elect to participate. Possible program elements include prenatal education classes, support group, lactation program, doula support, and parenting classes.
11051155|NCT04421222|Active Comparator|Cohort 1|200 mg EPI-7386
11051156|NCT04421222|Active Comparator|Cohort 2|400 mg EPI-7386
11051157|NCT04421222|Active Comparator|Cohort 3|600 mg EPI-7386
11051158|NCT04421222|Active Comparator|Cohort 4|800 mg EPI-7386
11051159|NCT04421222|Active Comparator|Cohort 5|1000 mg EPI-7386
11051160|NCT04421209|Experimental|Propranolol treatment|"Subjects randomized to the propranolol treatment arm will be administered propranolol 40mg BID for three days prior to surgery, 40mg BID the day of surgery and on post-operative days 1 and 2. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.
~Patients will be evaluated for opioid usend pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.
~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers, and if this correlates to decreased opioid use and pain scores post-operatively.
~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
11051161|NCT04421209|Placebo Comparator|Placebo|"Subjects randomized to the placebo treatment arm will be administered placebo tablets with the same schedule as propranolol in the experimental arm. Subjects and researchers will be blinded and will not know if propranolol or placebo control is administered.
~Patients will be evaluated for opioid use and pain scores at 24 hrs, 48 hrs, 1 week, 4 weeks, and 12 weeks post-op.
~Blood will also be obtained pre-operatively, 8 hours and 24 hours post-operatively to measure the level of inflammatory markers. We will use these samples to evaluate if treatment with propranolol decreases the levels of inflammatory markers compared to placebo, and if this correlates to decreased opioid use and pain scores post-operatively.
~All other pre-, intra-, and post-operative interventions will be equivalent between the experimental and placebo groups, and this study's interventions will not affect surgical management."
11051162|NCT04421196|No Intervention|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.
~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) & Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
11051163|NCT04421196|Experimental|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.
~The modified multimodal analgesic regimen utilizes the following medications:
~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
11051164|NCT04421183||1|preeclampsia
11051165|NCT04421183||4|normal pregnancy without complication
11051166|NCT04421183||2|hellp
11051167|NCT04421183||3|eclampsia
11051168|NCT04421170|Experimental|Intervention Group|Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
11051169|NCT04421170|No Intervention|Control group|Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
11051170|NCT04421157|Experimental|Schroth group|The Schroth group received Schroth exercises in addition to traditional rehabilitation.
11051171|NCT04421157|Experimental|Stabilization group|The stabilization group received core stabilization in addition to traditional rehabilitation.
11051172|NCT04421144|Experimental|study group|using CAD/CAM surgical cutting guides for maxilla and mandible and customized titanium plates to guide all osteotomies and fixation of both arches.
11051173|NCT04421131|Experimental|mIVAA|Screened for cervical cancer with mIVAA in mobile units
11051174|NCT04421131|No Intervention|Historical controls|Screened for cervical cancer in mobile units using standard of care; Data from medical records of women screened in the year(s) prior to mIVAA implementation
11051175|NCT04421118||standard portal pressure gradient measurement and CT scan|"Procedure/Surgery:
~Portal pressure gradient measurement and CT imaging examination. Three-dimensional models reconstructing and fluid dynamics simulation."
11051176|NCT04421105|Experimental|Group 1 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
11051177|NCT04421105|Experimental|Group 2 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
11051178|NCT04421105|Experimental|Group 3 N=12|6 doses at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
11051179|NCT04421105|Placebo Comparator|Group 4 N=12|6 doses 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose.
11051180|NCT04421092|Experimental|Steroid-Lidocaine Mixture|Will receive numbing injection, which is a mixture of steroid and lidocaine
11051181|NCT04421092|Placebo Comparator|Placebo|Will receive saline injection as a placebo
11051182|NCT04421079|Placebo Comparator|Placebo|Comparable placebos
11051183|NCT04421079|Active Comparator|Low Dose BDPP|8 oz. Concord grape juice + 450 mg Grape seed polyphenol extract + 150 mg Trans-resveratrol
11051184|NCT04421079|Active Comparator|Medium Dose BDPP|16 oz. Concord grape juice + 900 mg Grape seed polyphenol extract + 300 mg Trans-resveratrol
11051185|NCT04421079|Active Comparator|High Dose BDPP|24 oz. Concord grape juice + 1200mg Grape seed polyphenol extract + 450mg Trans-resveratrol
11051186|NCT04421066||Peri-implantitis|Patients with at least one dental implant diagnosed with peri-implantitis undergoing treatment for peri-implantitis as their standard of care will be included in this study.
11051187|NCT04421066||Healthy|Patients with general good health and health gingiva undergoing extraction of wisdom tooth will be included in this study group.
11051188|NCT04421053||women with GDM|After participants enrollment, we conducted follow-up visit every two weeks. Blood glucose values, body weight, life style record and clinical information are collected. Blood samples and stool samples are collected from participants in Beijing.
11051189|NCT04421040|Experimental|Biomonitor 3|Placement of Biotronic 3 Device for a 6 month period. After the 6 month monitoring period, the patient will have the Biotronic 3 device removed.
11051190|NCT04421027|Experimental|Baricitinib|4 milligrams (mg) of baricitinib given orally with background therapy.
11051191|NCT04421027|Placebo Comparator|Placebo|Placebo given orally with background therapy.
11051192|NCT04421014|Active Comparator|HVMN Ketone Ester/ Arm 1|25 participants
11051193|NCT04421014|Placebo Comparator|Placebo/ Arm 2|25 participants
11051194|NCT04421001|Experimental|I-Port™*(Medtronic) use Arm|Patients will administer insulin via iport system. I-Port™* (Medtronic), infusion set, dedicated for insulin deliery for 72 hours.
11051195|NCT04421001|Active Comparator|Insulin Pen Injections|Patients will administer insulin via injections as usual
11051196|NCT04420975|Experimental|Treatment (BO-112, nivolumab)|Patients receive BO-112 intratumorally on days 1, 8, and 15 and nivolumab IV over 30-60 minutes on days 8 and 22 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
11051197|NCT04420962||Microbial Keratitis|Presence of a bacteria or fungal keratitis with ≥ 2mm stromal infiltrate
11051198|NCT04420962||Viral or Inflammatory Keratitis|Non-infectious inflammatory, Viral, Acanthamoeba, or other forms of keratitis
11051199|NCT04420949|Experimental|Healthy|Healthy adults with visually-induced dizziness with undergo the testing and treatment.
11051200|NCT04420949|Experimental|Vestibular-impaired|Adults with unilateral or bilateral, peripheral vestibular loss who also have visually-induced dizziness with undergo the testing and treatment.
11051201|NCT04420936|Experimental|Lifestyle coaching|
11051202|NCT04420936|Active Comparator|Control tracking|
11051203|NCT04420923|Experimental|Observe-and-Plan|Patients will follow the same protocol as described by dr. Mantel et al. (2014) in the first Observe-and-Plan study conducted in Lausanne.
11051204|NCT04420923|Active Comparator|Treat-and-Extend|Patients will follow the standard treatment protocol for Treat-and-Extend, used for several years in the participating clinics.
11051205|NCT04420910||Parkinson's disease group|being diagnosed with PD by a neurologist, being in Hoehn & Yahr Stage 1-3
11051206|NCT04420910||Healthy group|20 healthy volunteers with matching ages and genders.
11051207|NCT04420897||Normoxy: PaO2 = 80-120 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
11051208|NCT04420897||Moderate hyperoxemia: PaO2 =120-200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
11051209|NCT04420897||Severe hyperoxemia: PaO2 >200 mm Hg|Data collection explained below: Arterial blood samples from all groups shall be taken after induction, 5 minutes after graft perfusion, and end of surgery in the intraoperative period, in the operating room. The duration of the intensive care unit (ICU), the duration of mechanical ventilation in intensive care, Whether or not to re-intubate, hospital stay, intraoperative and postoperative laboratory data, immunosuppression regimen, postoperative complications (surgical site infection, ischemic vascular conditions, complications from respiratory) and interventions will be included for the study analysis. The survival of the patients will be enrolled, and the relationship between the obtained data and survival will be investigated. For early-stage graft survival, postoperatively; Data such as renal replacement therapy, the total amount of urine levels, creatinine values, presence of delayed graft function will be recorded.
11051272|NCT04420442|No Intervention|Control Group|No Intervention.
11051273|NCT04420429||Cohort|All patients
11051210|NCT04420884|Experimental|Monotherapy Dose Escalation Phase: TAK-676 SA|"Safety Lead-in: TAK-676 0.1 milligram (mg), infusion, intravenously, once weekly, on Days 1, 8 and 15 in 21-day treatment Cycles.
~TAK-676 SA Dose Escalation: TAK-676 SA, infusion, intravenously, once weekly on Days 1, 8 and 15 in each 21-days treatment cycles with escalating dose (0.2 mg and above), for up to 1 year. The dosing will be initiated in the TAK-676 SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in Phase."
11051211|NCT04420884|Experimental|Combination Dose Escalation Phase: TAK-676 + Pembrolizumab|"TAK-676, infusion, intravenously, once weekly on Days 1, 8 and 15 in each 21-days treatment cycles with escalating dose (0.2 mg and above) plus pembrolizumab 200 mg, infusion, intravenously, once on Day 1 in each 21-days treatment cycles for up to 1 year.
~The dosing will be initiated based on the available safety and tolerability data from the previous cohort."
11051212|NCT04420871|Active Comparator|capecitabine reference formulation at a single dose of 150 mg|150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
11051213|NCT04420871|Experimental|capecitabine test formulation at a single dose of 150 mg|The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.
11051214|NCT04420858|Other|Control|The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit.
11051215|NCT04420858|Experimental|Experimental|The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA).
11051216|NCT04420845|Other|Intervention|
11051217|NCT04420832|Active Comparator|Surgical treatment|Patients with a distance of 5 mm or more between tendon ends will be treated surgically and with physiotherapy
11051218|NCT04420832|Other|Non-surgical treatment|Patients with a distance of less than 5 mm between tendon ends will be treated non-surgically and with physiotherapy
11051219|NCT04420819|Experimental|IPC-LOP|this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
11051220|NCT04420819|Experimental|IPC-40%|this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
11051221|NCT04420819|Placebo Comparator|IPC-10mmHg:|this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
11051222|NCT04420819|No Intervention|CONTR|this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
11051223|NCT04420806|Active Comparator|HIT-exercise|13 months of high intensity endurance and resistance exercise - 3 months of exercise break
11051224|NCT04420806|Sham Comparator|control|no exercise intervention that affect the present study outcomes
11051225|NCT04420793||ECT and Voice Recorded Group|This is an add-on study of voice samples to be gathered during ECT clinical treatments. The ONLY research procedures are four tasks on an online form, one text task and three voice recording tasks. These voice recordings will take place in a private room on the 5th floor of the Institute of Psychiatry on the same day of a patient's ECT treatment. The questionnaire will take less than 10 minutes.
11051226|NCT04420780|Experimental|Xyl Group|Children will receive sugar-free gums containing 100% Xylitol as sweetener
11051227|NCT04420780|Active Comparator|Pol Group|Children will receive sugar-free gums containing a polyols mixture plus a low amount of Xylitol (22%).
11051228|NCT04420767|Experimental|tDCS and Go-No Go task|"Certain randomly assigned participants will receive tDCS to the DLPFC for 8 daily 20-minute sessions, with a TDCS amplitude of 2 mAmps.
~During the tDCS session, individuals will perform a 10-min computerized Go-No Go task"
11051229|NCT04420767|Sham Comparator|Sham brain stimulation and Go-No Go task|"Certain randomly assigned participants will receive Sham Stimulation to the DLPFC for 8 daily 20-min sessions. The Sham stimulation is an inactive form of stimulation.
~During the sham brain stimulation session, individuals will perform a 10-min computerized Go-No Go task"
11051230|NCT04420754|Experimental|Cohort -1|AIC100 Cell Dose Level -1 (Flat Dose): 1 x 10e6 CAR T cells
11051231|NCT04420754|Experimental|Cohort 1|AIC100 Cell Dose Level 1 (Flat Dose): 1 x 10e7 CAR T cells
11051232|NCT04420754|Experimental|Cohort 2|AIC100 Cell Dose Level 2 (Flat Dose): 1 x 10e8 CAR T cells
11051233|NCT04420754|Experimental|Cohort 3|AIC100 Cell Dose Level 3 (Flat Dose): 5 x 10e8 CAR Tcells
11051234|NCT04420741|Experimental|Iloprost|Patients randomized to active treatment (n=40 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
11051235|NCT04420741|Placebo Comparator|Isotonic saline|Patients randomized to placebo treatment (n=40 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
11051236|NCT04420728|Experimental|Early auto-mode enabled|Auto mode continuous glucose monitoring enabled 2-10 days post-partum
11051237|NCT04420728|Active Comparator|Delayed auto mode enabled|Auto mode continuous glucose monitoring enabled 12 weeks post-partum
11051238|NCT04420715|Experimental|Less-experienced group|The participant who has completed the number of PCI less than 200 before recruiting
11051239|NCT04420715|Experimental|Experienced group|The participant who has completed the number of PCI more than 200 before recruiting
11051240|NCT04420702|Experimental|Early Detection Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy
~Standard of care prostate biopsy will be performed within 12 weeks of MRI
~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
11051341|NCT04419961|Experimental|Intervention|Routine care plus participation in an educational program including a group discussion and a booklet.
11051241|NCT04420702|Experimental|Active Surveillance Cohort (MRI with DBSI)|"Magnetic resonance imaging (MRI) with DBSI analysis prior to prostate biopsy
~Standard of care prostate biopsy will be performed within 12 weeks of MRI
~Some participants may go on to receive standard of care radical prostatectomy and those participants may have their prostatectomy specimens scanned via MRI with DBSI imaging"
11051242|NCT04420689|Experimental|Dose Escalation/De-Escalation Cohorts|This arm of the study will include Dose Escalation/De-Escalation cohorts of ALM-488.
11051243|NCT04420689|Experimental|Dose Timing Cohorts|This arm of the study will include Dose Timing cohorts of ALM-488.
11051244|NCT04420676|Active Comparator|Probiotic|Group 1: receiving a probiotic mixture (Omni-Biotic® 10 AAD) twice a day
11051245|NCT04420676|Placebo Comparator|Placebo|Group 2: receiving a similar looking and tasting placebo without bacteria twice a day
11051246|NCT04420663|Experimental|Manometer Group|"Therapeutic thoracentesis will be performed in a sitting position. wide bore catheter as a pleural catheter will be inserted into the pleural cavity. simple water manometer will be connected to the pleural catheter via 3-way adapter.connected to the infusion lines with one draining into the drainage collection bottle and the other pre-flushed with normal saline hanging down till 40 cm below the puncture site and then rising up (forming a U) with the ascending arm taped to the IV stand. baseline pleural pressure will be registered before the beginning of pleural fluid withdrawal. Pleural pressure curve will subsequently be registered after the withdrawal of each 200 ml of pleural fluid up to a total volume of 1000 ml."
11051247|NCT04420663|No Intervention|Conventional Group|Therapeutic thoracentesis will be performed in a sitting position. The skin will be cleaned with betadine antiseptic solution. Pleural aspiration should take place in a clean area using full aseptic techniques. 5-10 cc Lidocaine 2% will be given as local anesthetic in the site of puncture. the IV cannula is advanced till fluid is aspirated. Then, the needle is withdrawn and the catheter is fixed to two 3-way adapters fixed in series placed in between. connected to the infusion lines with one draining into the drainage collection bottle.
11051248|NCT04420650|Active Comparator|Anodal tDCS|Anodal tDCS of the hypothalamus-cognitive network
11051249|NCT04420650|Active Comparator|Cathodal tDCS|Cathodal tDCS of the hypothalamus-cognitive network
11051250|NCT04420650|Sham Comparator|Sham Stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
11051251|NCT04420624|Experimental|Colchicine|colchicine and standard therapy
11051252|NCT04420624|No Intervention|Comparator|standard therapy
11051253|NCT04420598|Experimental|Trastuzumab deruxtecan (DS-8201a)|"Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);
~Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;
~Cohort 3: HER2-positive BC with progressing BMs after local treatment;
~Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;
~Cohort 5: HER2-positive or HER2-low expressing BC with LMC."
11051254|NCT04420585|Experimental|Treatment Group|Desmopressin 0.2mg tablets, dose titrated to effect
11051255|NCT04420572|Experimental|ozone injection group|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
11051256|NCT04420572|Experimental|steroid injection group|1ml betamethasone will be used for steroid injection.
11051257|NCT04420559|Experimental|Virtual Reality|
11051258|NCT04420559|Experimental|Distraction Card|
11051259|NCT04420559|No Intervention|Control|
11051260|NCT04420546|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to be more physically active (We want you to plan to increase your level of physical activity). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted not to be physically active and identifying ways to overcome those temptations had been shown to help people change their behaviour.
~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
11051261|NCT04420546|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.
~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
11051262|NCT04420533|Active Comparator|Behavior therapy alone|Behavior therapy alone
11051263|NCT04420533|Experimental|Behavior therapy plus mirabegron 50mg|Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
11051264|NCT04420507||GDM group|pregnant women who are diagnosed after 75g OGTT test between 24~27+6 gestational weeks
11051265|NCT04420507||health group|pregnant women who pass the 75g OGTT test and aren't diagnosed as GDM, and also don't have any other conditions, like hypertensive disorders, IBD, gastrointestinal ulcer, and so on.
11051266|NCT04420494|Experimental|Patients treated with umbilical cord blood|
11051267|NCT04420481|Active Comparator|Growth hormon group|A 12 month study, consisting of a 9 months growth hormone treatment phase followed by a 3 month growth hormone treatment-free period.
11051268|NCT04420481|Placebo Comparator|Control group|A 12 month study, consisting of a 9 month placebo treatment phase followed by a 3 month treatment-free period.
11051269|NCT04420468||Possible COVID-19 infection and acute myocarditis|"Children presented with an acute myocarditis, fever and shock with a possible COVID-19 infection cared between April 2020 till the end of the main SARS-Cov-2 outbreak in 4 AP-HP Parisian hospitals :
~Necker-Enfants Malades
~Armand Trousseau
~Robert Debré
~Kremlin Bicêtre"
11051270|NCT04420455|Experimental|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
11051274|NCT04420403|Experimental|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
11051275|NCT04420403|Active Comparator|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
11051276|NCT04420390|Experimental|Radiotherapy|
11051277|NCT04420377|Placebo Comparator|Placebo Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
11051278|NCT04420377|Experimental|Experimental Group|Participants will engage in a 5-week, whole-body, resistance training program 2 days per week will consuming a treatment condition (Carnipure™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. For week 5 of the study, participants will come in for 1 intense exercise training day.
11051279|NCT04420364|Experimental|Maintenance of Immunosuppression|Maintenance of immunosuppression (defined as no change to pre-admission immunosuppression, or reduction in anti-metabolite by up to 50% (to a minimum of MMF 500 mg per day or azathioprine 50 mg per day)
11051280|NCT04420364|Active Comparator|Reduction of Immunosuppression|Reduction of immunosuppression (defined as anti-metabolite withdrawal plus reduction of tacrolimus or cyclosporin, to a minimum target trough concentration of 3 ng/mL for tacrolimus and 50 ng/mL for cyclosporin).
11051281|NCT04420351|Experimental|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
11051282|NCT04420351|Other|Antiplatelet treatment|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
11051283|NCT04420338|Experimental|Chronic hemodialysis patients|
11051284|NCT04420338|Experimental|Caregivers of chronic hemodialysis patients|
11051285|NCT04420312||Group 1|Enrolled the Covid-19 patients with a negative CT Pulmonary Angiogram.
11051286|NCT04420312||Group 2|Enrolled the Covid-19 patients in whom only a CT was performed.
11051287|NCT04420299|Experimental|Experimental - therapeutic bemiparin dose|Sub-cutaneous dose of bemiparin at therapeutic dose for 10 days
11051288|NCT04420299|Experimental|Control - prophylactic bemiparin dose|Sub-cutaneous dose of bemiparin at prophilactic dose for 10 days
11051289|NCT04420286||Hospital having ICU beds|Hospital having ICU beds during COVID-19 outbreak in France
11051290|NCT04420273|Experimental|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
11051291|NCT04420273|Active Comparator|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
11051292|NCT04420273|Experimental|Home sample collection of of concerning moles|The participant will be given directions about taking a picture of the concerning mole. The picture will be reviewed by the physician, who determines if the pigmented lesion is concerning and sends an adhesive patch skin sample collection kit to the participant. The participant will receive directions about obtaining the sample, and returning it to the processing laboratory. The physician will obtain the results of the genomic analysis and provide them to the participant. If the test results indicate that the concerning mole requires a biopsy, then the participant will be advised to seek an appointment within the Northwestern Medicine Healthcare System.
11051293|NCT04420260|Experimental|Treatment oropharyngeal spray + immunostimulan|Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
11051294|NCT04420260|Experimental|Treatment immunostimulan|"Placebo oropharyngeal spray + Active principle immunostimulant taken PO.
~Placebo oropharyngeal spray + Placebo taken PO."
11051295|NCT04420260|Experimental|Treatment oropharyngeal spray|Active principle oropharyngeal spray + Placebo taken PO.
11051296|NCT04420260|Placebo Comparator|Placebo|Placebo oropharyngeal spray + Placebo taken PO.
11051297|NCT04420247|Experimental|Intervention|"Treatment with either Chloroquine or Hydroxychloroquine according to what was available in the hospital:
~Chloroquine - 900mg on the first day, followed by 450mg in the next 4 days. Hydroxychloroquine - 800mg on the first day, followed by 450mg in the next 4 days.
~+
~Standard treatment available and recomended by the Brazilian Guidelines for COVID-19."
11051298|NCT04420247|Active Comparator|Control|Standard treatment available and recomended by the Brazilian Guidelines for COVID-19.
11051299|NCT04420234|Experimental|Pharmacokinetics study of single and multiple administration|During the study session, 30 healthy subjects will be administered a single and multiple dose of narfurine hydrochloride orally disintegrating tablets 5 µg (2.5 µg/table) to evaluate the pharmacokinetic parameters and the safety profile.
11051300|NCT04420221|Experimental|Half dose non-adj Group 1a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1.
11051301|NCT04420221|Placebo Comparator|Placebo Group 1b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
11051302|NCT04420221|Experimental|Full dose non-adj Group 2a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1
11051303|NCT04420221|Placebo Comparator|Placebo Group 2b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
11051304|NCT04420221|Experimental|Half dose adj Group 3a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1.
11051305|NCT04420221|Placebo Comparator|Placebo Group 3b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
11051306|NCT04420221|Experimental|Full dose adj Group 4a|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61)
11051342|NCT04419948|Experimental|Control|100g white bread plus 40ml butter
11051307|NCT04420221|Placebo Comparator|Placebo Group 4b|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
11051308|NCT04420221|Experimental|Vaccine Group 5a|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61).
11051309|NCT04420221|Placebo Comparator|Placebo Group 5b|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
11051310|NCT04420208|Experimental|Intervention group|Adding a non-painful event after the most uncomfortable phase of Pap smear.
11051311|NCT04420208|No Intervention|Control group|Standard Pap-smear procedure.
11051312|NCT04420195|Experimental|Envarsus XR|Envarsus XR to be initiated once patient is tolerating oral medications
11051313|NCT04420195|Experimental|IR tacrolimus (historical control)|Historical cohort of patients maintained on IR tacrolimus following transplant
11051314|NCT04420182|Other|COVID-19 Virtual Care at Home|"VIRTUES COVID-19 Care at Home Platform
~The components of the platform will include:
~Vital sign monitoring, including O2 saturation with a home-based pulse oximeter, temperature and respiratory rate performed three times per day (a notification to do this will be sent from the app), with the option of doing assessments more frequently if needed. Study patients will be provided monitoring devices to collect this data.
~Symptom logs will be entered by the patients.
~Feedback to the patient by the local COVID-19 care team for any action:
~Two-way communication between the patient and the COVID-19 care team
~Ability for team members to see all prior notes in order to have continuity of care
~Reports of these interactions are transmitted to the patient's health record
~Current information on COVID-19 as per the Public Health Agency of Canada"
11051315|NCT04420169||PRE implementation communication protocol|
11051316|NCT04420169||POST implementation communication protocol|
11051317|NCT04420156||i-ROP cohort|Premature infants who are at risk of retinopathy of prematurity(ROP) at participating study sites. As standard of care, babies who are born less than 31 weeks gestational age or less than 1500 grams are routinely screened for ROP. Families are approached to participate in this study where finding from babies' eye exams and associated retinal images along with demographic and other health data are collected and coded with unique identifier. No intervention is administered. The ROP exams and images obtained are done as a standard of care and would be performed even if there is no consent provided.
11051318|NCT04420143||MLX - Medial Lateral Expandable Lumbar Interbody System|Patients who underwent lumbar interbody fusion with the MLX expandable interbody implant will be included in the MLX - Medial Lateral Expandable Lumbar Interbody System cohort.
11051319|NCT04420143||XLX ACR Interbody System|Patients who underwent lumbar interbody fusion with the XLX ACR expandable interbody implant will be included in the XLX ACR Interbody System cohort.
11051320|NCT04420130|Experimental|Camrelizumab combined with ablation and chemotherapy|First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.
11051321|NCT04420104|Experimental|esp block group|
11051322|NCT04420104|Active Comparator|control group|
11051323|NCT04420091|Experimental|Cartidyss|
11051324|NCT04420078||CA BrS|Symptomatic BrS patients who underwent catheter ablation of the BrS/VF substrate
11051325|NCT04420065|Active Comparator|Classical biventricular pacing|Commercially available LV-pacing capable CRT devices and quadripolar leads will be implanted. Right ventricular (RV) and right atrial (RA) leads will be placed according to standard practice. The LV lead will also be placed according to standard practice, targeting to a lateral, posterolateral, or anterolateral branch of the coronary sinus (CS). Interventricular delay programmed will be determined based on stroke volume maximization, and will be used as a criterion for BVP optimization. Atrioventricular delay optimization shall be automatically performed by the device.
11051326|NCT04420065|Experimental|Preferential left ventricular pacing|In G2 patients, an algorithm for preferential left ventricular pacing will be activated. Following selection of the dipole maximizing stroke volume during simultaneous LV-RV pacing, subsequent V-V delay optimization shall be delegated to the algorithm. Based on previous studies, a subgroup analysis of G2 will be performed, comparing those receiving ≥50% with those receiving <50% preferential LV pacing evaluated over the total duration of the study (12 months).
11051327|NCT04420052|Experimental|OMT group|
11051328|NCT04420052|Placebo Comparator|Placebo group|
11051329|NCT04420039||1- Single biliary LAMS|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent after failed ERCP cannulation or inaccessible papilla.
11051330|NCT04420039||2- Biliary LAMS plus Doublu-Pigtail plastic Etent|Unresectable/inoperable biliopancreatic cases with distal biliary obstruction who underwent EUS-BD with a single lumen-apposing stent (plus double-pigtail plastic stent) after failed ERCP cannulation or inaccessible papilla.
11051331|NCT04420026|Experimental|Experimental Arm|Hepatocellular tumours
11051332|NCT04420013||exposed group|for CRC patients with non-resectable hepatic metastases: surgery for CRC combined with RFA.
11051333|NCT04420013||no-exposed group|for CRC patients with resectable metastases: surgery only without RFA.
11051334|NCT04420000|Experimental|Interventional group|Patients having a Mindfulness program
11051335|NCT04420000|Placebo Comparator|Control group|Patients having a routinary managment
11051336|NCT04419987|Experimental|constitutional platelet patholog|Patient and relatives having a constitutional platelet pathology
11051337|NCT04419974||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
11051338|NCT04419974||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
11051339|NCT04419974||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
11051340|NCT04419961|No Intervention|Control|Routine care.
11051343|NCT04419948|Experimental|Positive control|100g white bread plus 40ml butter and 400mg ibuprofen
11051344|NCT04419948|Experimental|Refined olive oil|100g white bread plus 40ml refined olive oil
11051345|NCT04419948|Experimental|EVOO with moderate concentration of oleocanthal|100g white bread plus 40ml EVOO containing 250 mg/kg oleocanthal
11051346|NCT04419948|Experimental|EVOO with high concentration of oleocanthal|100g white bread plus 40ml EVOO containing 500 mg/kg oleocanthal
11051347|NCT04419922||Smartphone Contingency Management Arm|100 participants will be voluntarily recruited at BrightView's Colerain outpatient treatment center to participate in the Smartphone Contingency Management Intervention.
11051348|NCT04419909|Experimental|Retreatment with CTL019/CTL119|All subjects will receive retreatment with CTL019/CTL119 and be followed per the schedule of procedures.
11051349|NCT04419896||Retrospective|"Inclusion criteria for Retrospective Subjects:
~Men and women 18 years or older;
~Is or was a patient of a Participating Practice and was previously tested with Germline, Genomic, or other Biomarker Tests; and
~For Germline Genetic Test patients, have a diagnosis of cancer or pathogenic or likely pathogenic (P/LP) result."
11051350|NCT04419896||Prospective|"Inclusion criteria for Prospective Subjects:
~Men and women aged 18 years or older;
~Presents consecutively to a Participating Practice and who has previously been screened and tested (i.e., is a new patient scheduled for a visit at a Participating Practice or is an existing patient who returns to a Participating Practice);
~Receives or has received Germline, Genomic, or other Biomarker Testing, either through a prior healthcare provider or a Participating Practice; and
~Consents to be a part of the Registry."
11051351|NCT04419883||Anesthesia Providers|Anesthesia providers from 15 different health care facilities in the United States.
11051352|NCT04419870||Group 1|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
11051353|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
11051354|NCT04419857|Experimental|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
11051355|NCT04419857|No Intervention|Standard calorie formula|Infant randomly assigned to standard-calorie formula for 14 days
11051356|NCT04419844|Active Comparator|TAR with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect Botox injection .
11051357|NCT04419844|Active Comparator|TAR without Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect without Botox injection .
11051358|NCT04419831|Experimental|Healthy volunteers|
11051359|NCT04419831|Experimental|Binge Heavy drinkers|
11051360|NCT04419831|Experimental|Cannabis Use Disorder|
11051361|NCT04419831|Experimental|Alcohol Use Disorder|
11051362|NCT04419831|Experimental|Individuals with Moderate to Severe Pain|
11051363|NCT04419831|Experimental|Opioid Use Disorder in medication assisted treatment|
11051364|NCT04419818||Left brain damaged patients|"A group of 20 left brain damaged (LBD) patients will perform:
~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);
~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;
~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
11051365|NCT04419818||Right brain damaged patients|"A group of 20 right brain damaged (RBD) patients will perform:
~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);
~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;
~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
11051366|NCT04419818||Healthy controls|"A group of 40 (20 young and 20 elderly) healthy controls (HC) will perform:
~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);
~a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria;
~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
11051367|NCT04419805|Experimental|Single Palatal TAD|Single Palatal TAD for orthodontic molar intrusion
11051368|NCT04419805|Experimental|Two buccal TADs|Two buccal TADs for orthodontic molar intrusion
11051369|NCT04419792||Narcolepsy|
11051370|NCT04419779|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.
11051371|NCT04419779|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.
11051372|NCT04419766|Experimental|intervention|Community of Tambai: Indoors and outdoors spraying with IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester)
11051373|NCT04419766|No Intervention|Control|Community of Micheu 1: Without spraying.
11051374|NCT04419753|Active Comparator|No Attention Focus Walking Group (NAFWG)|In each training session, the NAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway without attention focus instruction (20 minutes) and cool down (5 minutes).
11051375|NCT04419753|Experimental|External Attention Focus Walking Group (EAFWG)|In each training session, the EAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with external attention focus instructions (20 minutes) and cool down (5 minutes).
11051376|NCT04419753|Experimental|Internal Attention Focus Walking Group (IAFWG)|In each training session, the IAFWG will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various levels of difficulties in a 40-meter walkway with internal attention focus instructions (20 minutes) and cool down (5 minutes).
11051418|NCT04419441||treated patients|patients with relapsed/refractory Hodgkin lymphoma who received a treatment with the combination of radiotherapy and an immune checkpoint inhibitor
11051419|NCT04419415|Experimental|Skipping breakfast and maintain habitual physical activity|Subject will skip breakfast and maintain habitual physical activity.
11063888|NCT04329910||class ii obesity|BMI 35 - 39.9
11051377|NCT04419740|Experimental|Mindfulness based psychological intervention|"Patients allocated to the intervention group will receive an email with a link to a video and a pdf document. The video and the pdf document will introduce them to the principles and the practice of mindfulness. They will also receive an access code to an e-tool valid for 1 month. On this e-tool the patient will have access to short guided meditations both general and specific to infertility. They will be instructed to follow the découverte (discovery) program of 8 meditations of 10 minutes and then the program désir de parentalité (wish to become a parent) of 13 minutes 15 meditations of 13 minutes each. Patients will be given access to all other meditations programs of PetitBambou and instructed to meditate with the program for at least 10-15 minutes on a daily basis."
11051378|NCT04419740|No Intervention|Standard care|The control group will have no additional intervention and will receive standard care in the institution. Women in all 3 study sites have access to counselling/psychological support with a trained professional before treatment initiation. During that consultation coping and stress reduction strategies are discussed.
11051379|NCT04419701|Experimental|periarticular infiltration group|will receive intraoperative periarticular infitration consisting of 89.5 mL of normal saline, 20 mL of 5% bupivacaine and 0.5 mL of adrenaline (4.5 ugm/ml) with a concentration 1:220000 (total volume: 110 mL)
11051380|NCT04419701|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% with adrenaline 2.5 µg/ml with a concentration 1:400000 in the immediate postoperative period.
11051381|NCT04419688|Experimental|STT-5058|
11051382|NCT04419688|Placebo Comparator|Placebo|
11051383|NCT04419662|Experimental|All patients included|
11051384|NCT04419649|Experimental|KER-050 Cohort 1|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
11051385|NCT04419649|Experimental|KER-050 Cohort 2|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
11051386|NCT04419649|Experimental|KER-050 Cohort 3|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
11051387|NCT04419649|Experimental|KER-050 Cohort 4|Escalating doses of KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
11051388|NCT04419649|Experimental|KER-050 Dose Confirmation Cohort|Participants to receive KER-050 administered subcutaneously (SC) every 4 weeks for up to 4 cycles
11051389|NCT04419636|Experimental|Part A Single doses|Lu AG06466 in fast and fed state
11051390|NCT04419636|Experimental|Part B Repeated doses|Lu AG06466 after light meal
11051391|NCT04419623|Experimental|Part 1 - Dose Finding|TL-895 orally BID at up to 3 dose levels taken continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
11051392|NCT04419623|Experimental|Part 2 - Arm 1 - TL-895 at recommended dose|TL-895 orally BID at the recommended dose continuously in 7-day cycles for 2 - 4 cycles with SAT for COVID-19 (14 - 28 days of treatment).
11051393|NCT04419623|Placebo Comparator|Part 2 - Arm 2 - Placebo at recommended dose|Placebo orally BID at the recommended dose continuously in 7-day cycles for 2 - 4 cycles with standard available treatment for COVID-19 (14 - 28 days of treatment).
11051394|NCT04419610|Experimental|Patients with confirmed/suspected C19 given intervention|Intravenous infusion of either placebo or TRV027 at 12mg/hr. Treatment will continue until discharge or for 7 days (whichever is sooner).
11051395|NCT04419610|Placebo Comparator|Patients with confirmed/suspected C19 given no intervention|Saline infusion.
11051396|NCT04419597|Experimental|HEMOPATCH Collagen Patch and PEG Haemostatic Sealant|Two units of the large patch are applied as reinforcement of the primary dural seal (HEMOPATCH 4,5x9cm, 1506253).
11051397|NCT04419597|Active Comparator|Standard of care treatment|Usual clinical practice techniques for reinforcing primary dural closure.
11051398|NCT04419584|Experimental|Modified Qing-Ying Decoction|Herbal granules, twice per day for 12 weeks
11051399|NCT04419584|Placebo Comparator|Identical looking placebo|Placebo granules, twice per day for 12 weeks
11051400|NCT04419571||Suspected or Confirmed COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) with clinically or radiologically suspected COVID-19, or with viral PCR confirmation; diagnosis made 7-days before and 30-days after date of surgery in accordance with the COVIDsurg study criteria (3).
11051401|NCT04419571||Negative or non-suspected COVID-19|All adult patients (>17 years) undergoing emergency (laparotomy) surgery at a single centre (Queens Hospital, Romford, UK) without clinically or radiologically suspected COVID-19, or without viral PCR (Polymerase Chain Reaction) confirmation.
11051402|NCT04419558|Experimental|Pamrevlumab|
11051403|NCT04419558|Experimental|Placebo|
11051404|NCT04419545||interstitial pneumonia cases|Chest x-ray diagnosis
11051405|NCT04419545||Negative controls|Chest x-ray Negative for pneumonia
11051406|NCT04419532|Experimental|Dose Escalation (DS-1055a)|Participants will receive escalating doses of DS-1055a (starting dose 0.3 mg/kg every 3 weeks).
11051407|NCT04419519|Experimental|Venetoclax monotherapy|
11051408|NCT04419519|Experimental|Venetoclax with anti-CD20 monoclonal antibody|
11051409|NCT04419506|Experimental|BI 1015550|
11051410|NCT04419506|Placebo Comparator|Placebo|
11051411|NCT04419493|Experimental|Test treatment (T)|
11051412|NCT04419493|Active Comparator|Reference treatment (R)|
11051413|NCT04419480|Experimental|CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge implantation of the CardioMEMS device will receive that device ≤14 days following discharge from the index hospitalization for Cardiogenic Shock, in addition to local standard of care medical therapy.
11051414|NCT04419480|No Intervention|Non-CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge standard of care will be treated according to local standard of care medical therapy following their index hospitalization for Cardiogenic Shock.
11051415|NCT04419467|Experimental|CSL346 (low dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
11051416|NCT04419467|Experimental|CSL346 (high dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
11051417|NCT04419467|Placebo Comparator|Placebo|Administered as a single IV loading dose followed by SC infusions
11052123|NCT04414345|Experimental|CNM-Au8|"Drug: CNM-Au8
~Administration: Oral
~Dosage: 30 mg or 60 mg daily"
11051420|NCT04419415|Experimental|High protein breakfast and maintain habitual physical activity|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and maintain habitual physical activity.
11051421|NCT04419415|Experimental|Skipping breakfast and exercising three times per week|Subject will skip breakfast and participate in organized exercise-training three times per week (and maintain habitual physical activity)
11051422|NCT04419415|Experimental|High protein breakfast and exercising three times per week|Subject will consume a high protein dairy breakfast (300 g high protein yoghurt (skyr)) and and participate in organized exercise-training three times per week (and maintain habitual physical activity)
11051423|NCT04419402|Experimental|Lu-PSMA + Enzalutamide|"Lu-PSMA - 7.5 GBq (± 10%): doses 1 and 2 (Days 15 and 57). Doses 3 and 4 (Days 113 and 169) will be given following result of PSMA PET/CT scans at Day 92.
~Enzalumatide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity."
11051424|NCT04419402|Active Comparator|Enzalutamide|Enzalutamide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity.
11051425|NCT04419389|Experimental|Safety Lead-In Cohort 1|Subjects with R/R TP53-mutant CLL.
11051426|NCT04419389|Experimental|Safety Lead-In Cohort 2|Subjects with R/R TP53-mutant CLL.
11051427|NCT04419389|Experimental|Expansion Cohorts|Subjects with R/R TP53-mutant CLL and/or MCL
11051428|NCT04419376||Patients with pARDS|Within 7 days of known clinical insult Respiratory failure not fully explained by cardiac failure or fluid overload chest imaging findings of new infiltrate(s) consistent with acute pulmonary parenchymal disease patients with an oxygenation index (OI) ([FIO2 × mean airway pressure × 100]/PaO2) above 4
11051429|NCT04419376||Patients with non-pARDS|non-pARDS patients who received mechanical ventilation support due to respiratory failure.
11051430|NCT04419363|Experimental|The whole cohort|Children affected with X-linked hypophosphatemia of average age of 9.8 years were switch from conventional therapy to burosumab
11051431|NCT04419350|Experimental|treatment|microneedling.
11051432|NCT04419350|No Intervention|No treatment|No treatment will be done to these hypopigmented lesions
11051433|NCT04419337|Experimental|Active arm|metformin+pioglitazone+an SGLT2 inhibitor
11051434|NCT04419337|Active Comparator|Control arm|metformin with or without combination with following oral antidiabetic drugs: DPP4 inhibitor, sulfonylurea, and acarbose.
11051435|NCT04419324|Other|esophago-gastroscopy endoscopy with narrow band imaging|a transoral flexible endoscope with magnifying narrow band imaging in nasopharyngeal examination
11051436|NCT04419311|Experimental|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
11051437|NCT04419311|Experimental|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
11051438|NCT04419298||Acute CO poisoning with myocardial injury|"A diagnosis of CO poisoning was made according to medical history and carboxyhaemoglobin >5% (>10% in smokers).
~Myocardial injury was defined as elevated high-sensitivity TnI level above the upper limit (> 0.046 ng/mL) when measured in the emergency department (ED) or repeatedly within 24 hours after ED arrival."
11051439|NCT04419285|Experimental|Retinitis Pigmentosa patients|50 patients with very severe Retinitis Pigmentosa
11051440|NCT04419272|Experimental|Methylphenidate|Subjects who will receive methylphenidate in the double-blinded period; when assigned to the active drug, the dosage of MPH will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 3 weeks.
11051441|NCT04419272|Placebo Comparator|Placebo|Subjects who will receive placebo in the double-blinded period; when assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 4 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
11051442|NCT04419259|Experimental|Erenumab|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
11051443|NCT04419246|Active Comparator|Group I|interscalene block + General anesthesia
11051444|NCT04419246|Active Comparator|Group T|Tranexamic acid +General anesthesia
11051445|NCT04419246|Sham Comparator|Group S|General anesthesia
11051446|NCT04419233||All Participants|Participants with 5q SMA and who were prescribed with nusinersen sodium injection in China according to the local marketing authorization.
11051447|NCT04419220||Observational|Doppler Ultrasound will be performed in all subjects.
11051448|NCT04419207||Patients with Surbery|Patients who with pulmonary nodules in computed tomography and planned to receive thoracic surgery will be included. And those who have other types of cancer, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
11051449|NCT04419207||Healthy Controls|Adult participants (>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
11051450|NCT04419194||Observation|Observation
11051451|NCT04419181|Experimental|Pathologic complete response (pCR)|Participants will receive four cycles of TCHP [docetaxel (Taxotere®), carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who achieve pathologic complete response will receive infusions of trastuzumab every 3 weeks for a total of 12 cycles/infusions.
11051452|NCT04419181|Experimental|Residual Disease|Participants will receive four cycles of TCHP [docetaxel (Taxotere®, carboplatin, trastuzumab (Herceptin®), pertuzumab], followed by surgery. Participants who have residual disease may be offered two more cycles of TCHP in the adjuvant settings (optional) per treating oncologist's discretion and then will receive infusion of Trastuzumab Emtansine (TDM1) plus pertuzumab every three weeks for a total of 12 cycles/infusions.
11051453|NCT04419168|Experimental|cCBT|Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
11063889|NCT04329910||class iii obesity|BMI >= 40
11051454|NCT04419168|Experimental|m-Education|Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
11051455|NCT04419168|No Intervention|Convenience Comparison|Not participating in the intervention. Participants will complete the baseline questionnaire battery only and we will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
11051456|NCT04419142|Experimental|Total infrapatellar fat pad excision group|Infrapatellar fat pad was totally excised during total knee arthroplasty in patients randomized to this group.
11051457|NCT04419142|Experimental|Partial infrapatellar fat pad excision group|Infrapatellar fat pad was partially excised during total knee arthroplasty in patients randomized to this group.
11051458|NCT04419129|Active Comparator|Mobile bearing unicompartmental knee arthroplasty|50 mobile bearing UKA
11051459|NCT04419129|Active Comparator|posterior stabilized fixed bearing total knee arthroplasty|50 posterior stabilized fixed bearing cemented total knee arthroplasty
11051460|NCT04419116|Experimental|tibial preservation bone cut|tibial preservation bone cut following mobile bearing UKA
11051461|NCT04419116|Experimental|tibial conventional bone cut|tibial conventional bone cut following mobilebearing UKA
11051462|NCT04419090|Experimental|Monogenic positive FH, direct contact|
11051463|NCT04419090|No Intervention|Monogenic positive FH, usual care|
11051464|NCT04419090|Experimental|Monogenic negative FH, direct contact|
11051465|NCT04419090|No Intervention|Monogenic negative FH, usual care|
11051466|NCT04419077|Other|Virtual reality exposure|Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
11051467|NCT04419038|Active Comparator|conjunctival autografting with MMC|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
11051468|NCT04419038|Active Comparator|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
11051469|NCT04419025|Active Comparator|NAC|Patients receiving N-acetylcysteine (NAC)
11051470|NCT04419025|No Intervention|Control|Patients not receiving N-acetylcysteine (NAC)
11051471|NCT04419012||Patients with AF treated with VKA|
11051472|NCT04419012||Patients with AF treated with NOAC|
11051473|NCT04418999|Experimental|Dexamethasone insert|
11051474|NCT04418999|Active Comparator|Loteprednol etabonate ophthalmic gel 0.38%|
11051475|NCT04418986|Sham Comparator|Control (CCI Group)|The Participants will undergo phacoemulsification with on-axis incision
11051476|NCT04418986|Active Comparator|Study (OCCI Group)|The Participants will undergo phacoemulsification with opposite clear corneal incisions
11051477|NCT04418973|Experimental|A - load/apnea|Threshold inspiratory load then apnea
11051478|NCT04418973|Experimental|B- apnea/load|apnea than threshold inspiratory load
11051479|NCT04418947|No Intervention|No intervention|
11051480|NCT04418947|Active Comparator|MPM control letter|
11051481|NCT04418947|Experimental|MPM intervention letter|
11051482|NCT04418947|Active Comparator|Mailed control letter|
11051483|NCT04418947|Experimental|Mailed intervention letter|
11051484|NCT04418934|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext One device.
11051485|NCT04418934|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
11051486|NCT04418921|Experimental|Experimental Group|"Intervention on self-regulation will be carried out through a non-immersive virtual reality platform, SR-Mrehab: Un colegio emocionante in which students must conduct a series of activities designed specifically for this purpose. These activities will be performed by the children using mainly their hands to manage the virtual objects showed in the screen. To do this, our system make use of a Kinect motion sensor connected to the computer to control the body movements of the children. Moreover, our system records some relevant data of the execution of these activities for further analysis of the children's performance.The exercises will be divided into two blocks, emotional regulation (ER) and cognitive regulation (CR), in a total of 10 sessions, once a week, performing an exercise of each block per session. Each session will consists of 60 minutes. ."
11051487|NCT04418921|Active Comparator|Control group|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom (5, 49). Each session will last 50 minutes, just like in the experimental group. The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation. The activities are similar for the experimental group, but the virtual reality system will not be used. It will be held in parallel in another room of the school, on the same day and time, carried out by occupational therapists and students from the students in the last year of occupational therapy degree.
11051488|NCT04418908|Active Comparator|GnRHant + E2|Participants in this arm received GnRHant and a transdermal estradiol patch (0.075 mg/day) for a period of 1 week.
11051489|NCT04418908|Placebo Comparator|GnRHant + PL|Participants in this arm received GnRHant and a placebo patch for a period of 1 week.
11051490|NCT04418895|Experimental|Single Arm: Standard of Care|Investigator's choice of total neoadjuvant therapy (TNT) comprised of neoadjuvant chemotherapy and chemoradiation followed by surgical resection; or neoadjuvant chemoradiation followed by surgical resection and then adjuvant chemotherapy.
11051491|NCT04418882||non septic open fracture|patients having had an open fracture without septic evolution
11051492|NCT04418882||septic open fracture|patients having had an open fracture with septic evolution
11051493|NCT04418869|Experimental|Exercise|All subject will perform three different exercise bouts and one control session.
11051494|NCT04418856|Experimental|Experimental light: Breast cancer surgery and chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
11051495|NCT04418856|Active Comparator|Comparison Light:Breast cancer surgery and chemotherapy|Exposed to comparison systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
11051496|NCT04418856|Experimental|Experimental light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
11051497|NCT04418856|Active Comparator|Comparison light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
11051498|NCT04418843|Experimental|Standard Endoscopic Mucosal Resection|Standard Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
11051499|NCT04418843|Experimental|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection, if necessary, multi-piece to resect large nonpedunculated homogeneous colorectal lesions (>20 mm)
11051500|NCT04418830||Base Interfixated System|
11051501|NCT04418830||Brigade Interfixated System|
11051502|NCT04418830||Coalesce TLIF Interbody System|
11051503|NCT04418830||Cohere XLIF Interbody System|
11051504|NCT04418830||CoRoent Ti PLIF Interbody System|
11051505|NCT04418830||CoRoent Ti TLIF Interbody System|
11051506|NCT04418830||MLX - Medial Lateral Expandable Interbody System|
11051507|NCT04418830||Modulus TLIF Interbody System|
11051508|NCT04418830||Modulus XLIF Interbody System|
11051509|NCT04418830||TLX Interbody System|
11051510|NCT04418830||XLX ACR Interbody System|
11051511|NCT04418830||CoRoent Ti XLIF Interbody System|
11051512|NCT04418817||Modulus XLIF Interbody System|
11051513|NCT04418804|Experimental|Healthy|Participants without an active diagnosis of pleural disease.
11051514|NCT04418804|Experimental|Pneumothorax|Participants diagnosed with pneumothorax during the past 24 hours.
11051515|NCT04418804|Experimental|Pleural effusion|Participants diagnosed with current pleural effusion during the past 48 hours.
11051516|NCT04418791|Experimental|MIF-regular|MIF-regular will start with modified intermittent fasting. After 12 weeks, this arm will return to regular diet with no fasting intervention.
11051517|NCT04418791|Experimental|Regular-MIF|Regular-MIF will start with regular diet with no fasting. After 12 weeks, this arm will start with modified intermittent fasting.
11051518|NCT04418778||BEAR intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma
11051519|NCT04418778||BEAR LifeMoves intervention group|BEAR Therapeutic group for women who have experienced interpersonal trauma who are currently living in transitional housing at LifeMoves
11051520|NCT04418778||Control Condition|Treatment as usual group, women participating in individual or group therapy but not taking the BEAR group
11051521|NCT04418765|Experimental|Eptinezumab 100 mg|
11051522|NCT04418765|Experimental|Eptinezumab 300 mg|
11051523|NCT04418765|Experimental|Placebo|
11051524|NCT04418752|Other|Psychological therapy|Narrative Exposure Therapy will be delivered to all participants in the study except carer participants recruited to complete informant measures.
11051525|NCT04418739|No Intervention|Control Arm|Standard intraoperative fluid regime
11051526|NCT04418739|Experimental|Treatment Arm|Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
11051527|NCT04418726|Experimental|Intensive Monitoring and Preemptive Intervention|In this group patients receive intensive monitoring and preemptive intervention. AVF surveillance refers to using non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa every month. Clinical assessment refers to monitoring for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V. Preemptive intervention is performed as long as problems are recognized, including health education and timely surgery.
11051528|NCT04418726|No Intervention|Traditional Monitoring and Intervention|In this group patient receive traditional AVF monitoring, includes clinical assessment for any presence of stenosis by (i) physical examination, by means of visual inspection and presence of abnormal thrill, bruit or pulse and (ii) checking for signs of access dysfunction during dialysis: difficult cannulation, increase in dynamic arterial or venous pressure, inability to achieve the prescribed dialysis blood pump flow (Qb), prolonged bleeding after needle removal, access recirculation or a drop in Kt/V.
11051529|NCT04418713|Experimental|exercise group with active video-games|exergaming exercise: A combination of traditional exercise and exercise through active video games performed 3 days a week for one hour during 7 months. As well, it will be including some session about nutritional advice.
11051530|NCT04418713|No Intervention|control group|no physical intevention will be provided, but it will be included some sessions on nutritional advice.
11051531|NCT04418700|Experimental|Breath Stacking technique|"The intervention group will receive routine physical therapy associated with the Breath Stacking technique in 2 daily sessions of up to 20 minutes.
~The technique consists of an Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes."
11051532|NCT04418700|No Intervention|Routine physical therapy|The control group will receive only routine physical therapy. Routine physiotherapy consists of breathing exercises, using techniques bronchial hygiene and pulmonary reexpansion, and motor physiotherapy through exercise passive, active-assisted or active mobilization, stretching, training activities of daily living, positioning and removal of the bed and guidelines for post-discharge.
11051533|NCT04418687|Active Comparator|Physiotherapy only|Standard treatment post Total Knee Arthroplasty
11051534|NCT04418687|Experimental|Physiotherapy + Orthoglide intervention|Standard treatment post TKA, with additional Orthoglide device provided.
11051535|NCT04418674|Experimental|Ketamine|Patient will be given Ketamine 0.3mg/kg intravenously before sitting positioning for subarachnoid block.
11051536|NCT04418674|Active Comparator|Fentanyl|Patient will be given Fentanyl 1.5mcg/kg intravenously before sitting position for subarachnoid block.
11051537|NCT04418661|Experimental|SAR442720|SAR442720 (also known as RMC-4630) will be administered orally with pembrolizumab which is given by IV once every 3 weeks (Q3W). The dose of SAR442720 will be escalated or de-escalated depending on the emerging safety data of the combination.
11063929|NCT04329637|No Intervention|usual care|usual care
11051538|NCT04418648|Experimental|Toripalimab Consolidation|Patients in experimental group will receive toripalimab consolidation (240 mg) via iv infusion Q3W.
11051539|NCT04418648|No Intervention|Observation|Patients in this group will receive observation.
11051540|NCT04418635|Experimental|Tamsulosin and Prosta-OK® Neo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo 707mg 2 tablets twice daily for 85 days
11051541|NCT04418635|Placebo Comparator|Tamsulosin and Prosta-OK® Neo-matched placebo|Tamsulosin 0.2mg once daily and Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days
11051542|NCT04418596||Elite Soccer Players|Adolescent male aged 12-16 years old elite athletes that are recruited from special sport school in Leuven-Belgium and play football at a high level.
11051543|NCT04418596||Recreational Soccer players (control)|Adolescent male aged 12-16 years old recruited from ordinary school in Flanders Belgium that play soccer or any other sport recreationally with no high intensity training
11051544|NCT04418583|Experimental|Three-dimensional imaging|Participants receive a three-dimensional image of their chest, just prior to and after application of the Crane technique.
11051545|NCT04418570|Experimental|Cognitive remediation|"Computerized cognitive remediation through Neuropersonal Trainer software, 1.5 h per session twice a week for 12 weeks (36 h of total duration).
~Participants will also attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled."
11051546|NCT04418570|Other|Treatment as usual|Participants will attend the Early Intervention Service for Psychosis with visits by a psychiatrist, clinical psychologist, social worker, or nurse as scheduled.
11051547|NCT04418557||Pregnant women without COVID-19 Infection|Women who are tested for COVID-19 at the time of admission for labor and delivery and test negative
11051548|NCT04418557||Pregnant women with a history of COVID-19 infection|Women who are tested for COVID-19 at any point during their pregnancy, including at the time of admission for labor and delivery, and test positive
11051549|NCT04418544||Control|Do not test positive for COVID
11051550|NCT04418544||COVID-19 Positive|Test positive for Covid using swab test.
11051551|NCT04418531|Experimental|Experimental antibodies (immunoglobulins) infusion|Anti-coronavirus obtained with double-filtration plasmapheresis (DFPP) from convalescent patients
11051552|NCT04418518|Experimental|Convalescent plasma|~500 mL ABO compatible convalescent apheresis plasma
11051553|NCT04418518|No Intervention|Standard of Care|Treated as per institutional standard of care.
11051554|NCT04418505|No Intervention|Standard of Care|This group will not receive Vielight RX Plus treatment. Instead, they will follow the COVID-19 standard of treatment recommended by Health Canada.
11051555|NCT04418505|Experimental|Standard of Care + Vielight RX Plus Treatment|The is group will receive Vielight RX Plus treatment and follow the COVID-19 standard of treatment recommended by Health Canada.
11051556|NCT04418492|Experimental|SAFE intervention|The single group received the SAFE intervention for 10 weeks.
11051557|NCT04418479|Active Comparator|Aspirin monotherapy arm|Patients will receive 100 mg of aspirin once daily.
11051558|NCT04418479|Experimental|Clopidogrel monotherapy arm|Patients will receive 75 mg of clopidogrel once daily.
11051559|NCT04418466|Experimental|DLP-114 alpha-4 (6-months)|2 360mg Risperidone Implants
11051560|NCT04418466|Experimental|DLP-114 alpha-7 (12-months)|2 435mg Risperidone Implants
11051561|NCT04418453||Integration of telemedicine in primary care settings for MOUD|Primary care providers may refer OUD patients to receive telemedicine for MOUD
11051562|NCT04418440|No Intervention|Control|Routine NHS care following traumatic brain injury
11051563|NCT04418440|Experimental|Treatment|Routine NHS care following traumatic brain injury plus daily dose of test compound (oral nutritional supplement)
11051564|NCT04418427|Experimental|1|6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT
11051565|NCT04418427|Experimental|2|2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT
11051566|NCT04418427|Active Comparator|3|Aflibercept 2mg IVT
11051567|NCT04418414|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.
11051568|NCT04418401|Experimental|Experimental group|Treatment with Donafenib 100mg PO BID，and anti-PD-1 antibody 3mg/kg ivgtt Q2W. Treatment will last 6 months, unless the tumor recurrence.
11051569|NCT04418388|Experimental|A|
11051570|NCT04418388|Experimental|B|
11051571|NCT04418388|Experimental|C|
11051572|NCT04418362|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home 4-6 times per week for 8 weeks. Each session consists of 6 blocks of 5 minute training with a one minute rest period between each block.
11051573|NCT04418336|Active Comparator|Endoscopic Pilonidal sinus treatment (EPSIT)|Endoscopic Pilonidal sinus treatment (EPSIT)
11051574|NCT04418336|Active Comparator|Sinus Laser Closure (SiLaC)|Sinus Laser Closure (SiLaC)
11051575|NCT04418336|Active Comparator|lay open technique|lay open technique
11051576|NCT04418323|Active Comparator|Video-assisted anal fistula treatment (VAAFT|Video-assisted anal fistula treatment (VAAFT) in the Management of anal fistula
11051577|NCT04418323|Active Comparator|Fistula-tract Laser Closure (filac)|Fistula-tract Laser Closure (filac)in the Management of anal fistula
11051578|NCT04418323|Active Comparator|Conventional seton|Conventional seton in the Management of anal fistula
11051579|NCT04418310|Active Comparator|Lay open and curettage|Lay open and curettage in Pilonidal sinus
11051580|NCT04418310|Active Comparator|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method in the treatment of sacrococcygeal pilonidal sinus disease
11051581|NCT04418297|Experimental|CT-G20|
11051582|NCT04418297|Placebo Comparator|Placebo|
11051583|NCT04418284||Veterinary Medical students|Veterinary Medical students who are studying anatomy during COVID-19 pandemic lockdown
11051584|NCT04418271|Experimental|Prehabilitation|Prefrail and frail patients receive prehabilitation (new form of care)
11051585|NCT04418271|No Intervention|Standard of Care|Prefrail and frail patients receive no prehabilitation, but receive standard of care
11051586|NCT04418258|Experimental|Capillary Aspiration Endoscopy Catheter group|Small intestine aspirate suction was carried out with a capillary aspiration endoscopy catheter
11051587|NCT04418258|Active Comparator|Aspiration endoscopy catheter group|Small intestine aspirate suction was carried out with an aspiration endoscopy catheter
11051588|NCT04418245||Patients positive for SARS-CoV-2|
11051589|NCT04418232|Experimental|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
11051590|NCT04418219|Experimental|Treatment (SV-BR-1GM, pembrolizumab)|Patients receive cyclophosphamide IV over 1-2 hours on day 1, SV-BR-1-GM ID on day 3, pembrolizumab IV over 30 minutes on day 5, and interferon-alpha-2b ID on days 5 and 7. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11051591|NCT04418206|Other|Samples With DNA|Nasopharyngal swab and blood samples
11051592|NCT04418180|Active Comparator|GROUP1|group receiving single dose fenofibrate
11051593|NCT04418180|Active Comparator|GROUP2|group receiving double dose fenofibrate
11051594|NCT04418180|Placebo Comparator|GROUP3|photo therapy only
11051595|NCT04418167|Experimental|Part A: JSI-1187 Monotherapy Dose Escalation|Locally advanced or metastatic solid tumors with confirmed with MAPK pathway mutation, refractory to or relapsed on prior therapy and received all available therapy known to confer clinical benefit
11051596|NCT04418167|Experimental|Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation|Locally advanced or metastatic solid tumors with confirmed BRAF V600 mutation, refractory to or relapsed on prior therapy and received all available therapy known to confer clinical benefit
11051597|NCT04418167|Experimental|Part C: JSI-1187 Plus Dabrafenib Expansion|"Cohort 1: BRAF V600-mutated metastatic melanoma after two prior therapies for metastatic disease, including anti-PD1 therapy, with or without ipilimumab, and BRAF/MEK inhibitor treatment.
~Cohort 2: BRAF V600-mutated metastatic melanoma after adjuvant therapy for Stage 3 disease followed by one prior therapy for metastatic disease, including anti-PD-1 therapy, with or without ipilimumab, or BRAF/MEK inhibitor treatment.
~Cohort 3: Either BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC), or BRAF V600-muated metastatic solid tumor, after 1 or 2 prior therapies."
11051598|NCT04418154|Experimental|EC-ABX/PD-1|Patients who are treated with epirubicin hydrochloride andcyclophosphamide followed by nanoparticlealbumin-bound paclitaxel and Toripalimab
11051599|NCT04418141|Experimental|Single Arm|"Five planned CN1 dose levels of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg.
~Subjects will receive CN1 by intravenous infusion (IV) on Day 1 (D1) of each cycle (once every 3 weeks per cycle)."
11051600|NCT04418128|No Intervention|Conventional therapy|The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
11051601|NCT04418128|Experimental|Conventional therapy + Nafamostat mesylate|"The conventional therapy comprised, as necessary, Lopinavir/ritonavir, Hydroxychlorquine, supplemental oxygen, Non-invasive and invasive ventilation, antibiotic agents, renal-replacement therapy (e.g.: CRRT, HD), extracorporeal membrane oxygenation (ECMO).
~Nafamostat mesylate injection day), taking into account the severity and underlying disease of the clinical trial patient.
~Method of administration: Nafamostat injection is mixed with 1,000 ml of 5% DW infusion, followed by continuous infusion over 24 hours.
~Duration of administration: The researcher administers for 10-14 days considering the severity and underlying disease of the clinical trial patient."
11051602|NCT04418115|Experimental|Acupuncture + usual care|Participants randomized to acupuncture treatment will receive 12 acupuncture treatments during 8-12 weeks.
11051603|NCT04418115|No Intervention|Usual care|"Our control group will receive business as usual. Hence, they will continue with their usual care for their CRF. By inclusion in the study and by the end of it, the participants in the control group will fill in the requested and similar instruments as the participants in the acupuncture group. Further, we will document any medical care they have received during the study period. This includes also life styles advice, and to which point they have followed such advices."
11051604|NCT04418102|Experimental|Palmitic acid rich interesterified fat|Snacks (muffins) and spread containing palmitic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
11051605|NCT04418102|Active Comparator|Stearic acid rich interesterified fat|Snacks (muffins) and spread containing stearic acid rich interesterified fat to replace habitual snacks and spreads, and provide 10% of total daily energy intake with the interesterified fat.
11051606|NCT04418089|Experimental|Simvastatin|The group received standard treatment with the oral administration of Simvastatin
11051607|NCT04418089|Experimental|Placebo|The group received standard treatment with the oral administration of Placebo
11051608|NCT04418076|Experimental|No feedback|For participants in the control group (Group A), no feedback from the TowerView Health® smart pill box or clinical nurse will be given.
11051609|NCT04418076|Experimental|Automated feedback|For participants in Group B (automated feedback), automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages.
11051610|NCT04418076|Experimental|Automated feedback + Clinician feedback|For participants in Group C, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, clinical nurse will also send personalized feedback and suggestions to the participants in this group.
11051611|NCT04418076|Experimental|Automated feedback + Social Network feedback|For participants in Group D, automated feedback will be generated from the TowerView Health® smart pill box and sent to participants' smartphone as text messages. In addition, a weekly text reminder will be sent to each participant from a social network designee chosen by the participant.
11051612|NCT04418037|Experimental|Single arm using the Digital Health Feedback System|This protocol is designed to evaluate a novel technology that employs an ingestible sensor to detect medication ingestion for use by persons initiating or restarting antiretroviral (ARV) treatment for HIV infection during a hospital admission.
11051613|NCT04418024|Experimental|AG10 800 mg|TTR stabilizer administered orally twice daily (BID)
11051614|NCT04418024|Placebo Comparator|Placebo|Placebo administered orally twice daily (BID)
11051748|NCT04417075|Active Comparator|Dejar de Fumar Asistente|This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto.
11051615|NCT04418011|Active Comparator|Active 10 Hz rTMS|Active treatment will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
11051616|NCT04418011|Active Comparator|Active iTBS|Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
11051617|NCT04418011|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS.
~For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation."
11051618|NCT04417998|Active Comparator|Motion Correction|Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. The purpose of this arm is to evaluate the effectiveness of motion correction software.
11051619|NCT04417998|Active Comparator|Parametric Imaging|Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
11051620|NCT04417985|Experimental|18F-FDG PET/CT with MRI and blood sampling|"The enrolled subjects received 18F-FDG PET/CT and MRI before, during, and after the primary definitive treatment.
~The blood sample was collected on the same day of PET/CT scan."
11051621|NCT04417972|Experimental|SHR7280 dose 1|oral administration for 21days,Phase I
11051622|NCT04417972|Experimental|SHR7280 dose 2|oral administration for 21days,Phase I
11051623|NCT04417972|Experimental|SHR7280 dose 3|oral administration for 21days,Phase I
11051624|NCT04417972|Experimental|SHR7280 dose 4|oral administration for 21days,Phase I
11051625|NCT04417972|Active Comparator|SHR7280 low dose|oral administration for 84days,Phase II
11051626|NCT04417972|Active Comparator|SHR7280 high dose|oral administration for 84days, Phase II
11051627|NCT04417972|Placebo Comparator|Placebo|oral administration for 84days, Phase II
11051628|NCT04417959|Other|Phaco-DSAEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's stripping automated endothelial keratoplasty.
11051629|NCT04417959|Other|Phaco-DMEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's membrane endothelial keratoplasty.
11051630|NCT04417946|Experimental|PrEP Messages|The peer leaders and the study staff will post PrEP related health messages
11051631|NCT04417946|Active Comparator|Health messages|The peer leaders and study staff will post general health messages that are not related to sexual health.
11051632|NCT04417933|Experimental|Tumor Electric Fields Treatment System|Patients have a histologically confirmed diagnosis of supratentorial glioblastoma that is recurrent. All patients will receive Tumor Electric Fields Treatment System.
11051633|NCT04417920|Active Comparator|group I (Express implant)|conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva
11051634|NCT04417920|Active Comparator|group II (trabeculectomy)|"Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.
~conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of sclerectomy and peripheral iridectomy and closed scleral flab and conjunctiva by nylon 10/0 sutures"
11051635|NCT04417907|Placebo Comparator|Placebo|Participants will take 2mg placebo PO QD for six weeks.
11051636|NCT04417907|Experimental|PER 1 Week Titration|Participants will take 2mg perampanel PO QD for one week, followed by 4mg perampanel PO QD for five weeks.
11051637|NCT04417907|Experimental|PER 2 Week Titration|Participants will take 2mg perampanel PO QD for two weeks, followed by 4mg perampanel PO QD for four weeks.
11051638|NCT04417907|Experimental|PER 4 mg|Participants will take 4mg perampanel PO QD for six weeks
11051639|NCT04417894|Experimental|Dupilumab|Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1
11051640|NCT04417894|Experimental|Matching Placebo|Administered SC Q2W, following a loading dose on Day 1
11051641|NCT04417881||patients with acurate heart failure|
11051642|NCT04417855||LDH|Group of symptomatic individuals with LDH confirmed in MRI.
11051643|NCT04417855||Control|Group of asymptomatic individuals with no LDH.
11051644|NCT04417829||Only one arm (intervention=TAVI)|There is not control group/arm for comparison.
11051645|NCT04417816|Experimental|Exercise training + adipose tissue cavitation|
11051646|NCT04417816|Sham Comparator|Exercise training + sham procedure|
11051647|NCT04417803|Other|diffuse large B-cell lymphoma|
11051648|NCT04417803|Other|follicular lymphoma|
11051649|NCT04417803|Other|Hodgkin's lymphoma|
11051650|NCT04417790||Study population|Children under 12 years of age, Undergoing elective cardiac surgery for cyanotic or acyanotic congenital heart disease, Aristotle score ≤9, Giving prior written informed consent.
11051651|NCT04417777||Polynesian patient|Patient with dilatation of idiopathic bronchi
11051652|NCT04417777||Relatives of polynesian patient|Healthy
11051653|NCT04417764|Experimental|TACE combined PD-1 knockout T cell treatment|
11051654|NCT04417751|Experimental|Intervention Group|Intervention group will receive 47 sessions of individual CS and participate in 3 evaluation sessions. The CS program will last 1 year and each individual CS session will last approximately 45 minutes.
11051655|NCT04417751|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
11051656|NCT04417738|Active Comparator|Active|Patients will receive the active treatment.
11051657|NCT04417738|Sham Comparator|Sham|Patients will receive the sham treatment (the identical LED covered by aluminum foil).
11051658|NCT04417725||Chronic kidney disease|
11051659|NCT04417725||Type 2 diabetes mellitus|
11051660|NCT04417725||Comorbid type 2 diabetes mellitus and chronic kidney disease|
11051661|NCT04417712||Patients with ventricular septal defect|"All patients who signed informed consent and are implanted with a KONAR-MF™ VSD Occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post-implant:
~Before discharge 1-3 months after the Procedure 6 months after the procedure 12 months after the procedure"
11051662|NCT04417699|Experimental|TAS102 plus Oxaliplatin|Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID
11051663|NCT04417686|Experimental|patient|
11051664|NCT04417673||Sickle Cell Disease|Individuals with sickle cell disease
11051665|NCT04417660|Experimental|Bintrafusp alfa (M7824)|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until diseaseprogression or development of intolerable adverse events.
11051666|NCT04417647|Experimental|Group 1|Proximal wound SoC treatment - Distal wound VZ application
11051667|NCT04417647|Experimental|Group 2|Distal wound SoC treatment - Proximal wound VZ application
11051668|NCT04417634|Experimental|RFR: resting full-cycle ratio|RFR will be used to drive PCI
11051669|NCT04417634|Active Comparator|FFR: fractional flow reserve|FFR will be used to drive PCI
11051670|NCT04417621|Experimental|LXH254 + LTT462|
11051671|NCT04417621|Experimental|LXH254 + trametinib|
11051672|NCT04417621|Experimental|LXH254 + ribociclib|
11051673|NCT04417595|Experimental|Fish Oil|Participants allocated to n-3 LCPUFA supplementation will be instructed to take four 1000 mg n-3 LCPUFA capsules (Metagenics™) daily. This will provide a total daily dose of 4000 mg n-3 LCPUFAs (2840 EPA and 1160 DHA).
11051674|NCT04417595|Placebo Comparator|Olive Oil|Oleic acid (olive oil) capsules have a similar texture, size, color, and consistency to EPA capsules. Participant will be instructed to take four 100mg olive oil capsules
11051675|NCT04417582||life syte modification only|obese patients followed with life style modification
11051676|NCT04417582||medical teatment with antiobesity drugs|patients prescribed antiobesity drugs
11051677|NCT04417582||bariatric surgery|patients undergone bariatric surgery
11051678|NCT04417569||stimulated cycles|Patients will have blood drawn on three separate occasions following hCG trigger on the day of final oocyte maturation
11051679|NCT04417569||spontaneous cycles|"Commencing on the second day of menses and intermittently throughout the patients' natural cycle ultrasound scans will be performed to monitor follicular growth.
~In conjunction with ultrasound monitoring the patient will undergo serial measurements of serum LH, estradiol and progesterone levels to accurately determine the timing of ovulation. These serum hormonal levels will be measured with an automated Elecsys® immunoanalyzer (Roche Diagnostics, Mannheim, Germany)."
11051680|NCT04417556|Experimental|Sleep Measurement|Sleep Measurement arm, sleep are simultaneously measured using polosomgraphy, actigraphy and Thai-version Richards Campbell Sleep Questionnaire.
11051681|NCT04417543|Active Comparator|Memantine hydrochloride group|included 50 patients who received memantine
11051682|NCT04417543|Placebo Comparator|Placebo group|included 50 patients who received placebo
11051683|NCT04417530|Experimental|Cohort 1 AU-011 & Laser|Single dose of 20 µg of AU-011 + 1 laser application
11051684|NCT04417530|Experimental|Cohort 2 AU-011 & Laser|Single dose of 40 µg of AU-011 + 1 laser application
11051685|NCT04417530|Experimental|Cohort 3 AU-011 & Laser|Single dose of 40 µg of AU-011 + 2 laser applications
11051686|NCT04417530|Experimental|Cohort 4 AU-011 & Laser|Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 2 treatments
11051687|NCT04417530|Experimental|Cohort 5 AU-011 & Laser|Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 3 treatments. Up to 2 cycles of this regimen may be administered.
11051688|NCT04417530|Other|Cohort 6 AU-011 & Laser or Sham Treatment|Subjects will be randomized in a 1:1 ratio to receive either AU-011 (maximum tolerated dose regimen from Cohorts 1-5) or sham treatment.
11051689|NCT04417517|Experimental|ALX148 + azacitidine|"Phase 1: Participants will receive escalating doses of ALX148 in combination with azacitidine (75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle)
~Phase 2: Participants will receive ALX148 at the recommended Phase 2 dose in combination with azacitidine (75 mg/m2 IV or subcutaneous daily for 7 days of a 28 day cycle)"
11051690|NCT04417504|Experimental|MobFood breakfast kit|
11051691|NCT04417504|Experimental|Control isocaloric breakfast|
11051692|NCT04417491|Experimental|Dry Needling|The intervention group will receive real dry needling (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
11051693|NCT04417491|Sham Comparator|Sham Needling|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
11051694|NCT04417478|Active Comparator|Normal weight|Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2.
11051695|NCT04417478|Experimental|class I Obesity|Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2.
11051696|NCT04417478|Experimental|class II Obesity|Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2.
11051697|NCT04417465|Experimental|ABBV-CLS-579 Monotherapy|Participants will receive escalating doses of ABBV-CLS-579
11051698|NCT04417465|Experimental|ABBV-CLS-579 And Programmed Cell Death-1 (PD-1) Inhibitor|Participants will receive escalating doses of ABBV-CLS-579 and PD-1 inhibitor.
11051777|NCT04416828||Suspected ganglion cyst of the wrist or hand|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging AND cart-based ultrasound imaging before surgery.
11051699|NCT04417452||Mothers / children after diabetes in pregnancy|The study collective is composed of mother-child pairs after gestational diabetes, which were supervised in the Competence Center for Diabetes and Pregnancy at the University Hospital of Jena. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
11051700|NCT04417452||Controls|The control collective is composed of mother-child pairs who were cared for at the same time as the study collective at the University Hospital Jena. This collective is status post singleton pregnancy and term birth. The patients can decide to fill in an online questionnaire. For all other parts of the study, only patients who have been informed individually or on behalf of their legal guardian about the nature of the study after a detailed and understandable explanatory discussion with an investigator and who have given written consent will be included in the study.
11051701|NCT04417439||flame burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
11051702|NCT04417439||scald burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
11051703|NCT04417439||electrical burns|The joint range of motion was assessed by a universal goniometer within the affected areas of burn patients. A tape measure with a width of 7 mm was used to evaluate the circumference measurement in individuals. The biochemical examination of CK (creatine kinase) was performed in the laboratories.
11051704|NCT04417400|Experimental|Intervention|Patients who received MUR at visit 1
11051705|NCT04417400|No Intervention|Control|Patients received standard care and MUR after visit 2 (upon completion of the study)
11051706|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2019|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2019
11051707|NCT04417374||Unvonluntary commitment from March 12th to April 09th 2020|Patients hospitalized with unvonluntary commitment procedure from March 12th to April 09th 2020
11051708|NCT04417361|Experimental|Galcanezumab|The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
11051709|NCT04417361|Placebo Comparator|Placebo|The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
11051710|NCT04417348|Active Comparator|Retinoic Acid|patients with melasma treated with 0.05% retinoic acid plus UV-Visible light filter
11051711|NCT04417348|Placebo Comparator|Sunscreen|patients with melasma treated with UV-Visible light filter alone
11051712|NCT04417335|Experimental|Treatment|BCG vaccine (Danish strain 1331, SSI, Denmark)
11051713|NCT04417335|Placebo Comparator|Placebo|0.9% NaCl
11051714|NCT04417322||Control|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
11051715|NCT04417322||Periodontitis|Observation of serum A.actinomycetemcomitans levels and correlation of plasma A.actinomycetemcomitans levels
11051716|NCT04417309|Experimental|Moderate Intensity Exercise|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
11051717|NCT04417309|Active Comparator|Control|"Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
~Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction"
11051718|NCT04417296||nonlaboring term singleton pregnancies|"All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at >37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications"
11051719|NCT04417283||Mother-infant dyads|Mother and/or infant participants will provide a series of biological specimens, including blood, urine, and microbiome samples. Additionally, each participant will wear a silicone wrist band each trimester to capture environmental exposures and will fill out study surveys related to diet, environmental exposures, and social factors.
11051720|NCT04417270|Other|Freestyle Libre 14-day CGM|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
11051721|NCT04417270|Other|Accuchek Inform II meter|ACCU-CHEK INFORM II system quantitatively measures glucose in fresh venous, arterial, neonatal heel stick and capillary whole blood from the finger and is used as an aid in monitoring the effectiveness of glucose control
11051722|NCT04417257|Experimental|LAU-7b|Active drug as LAU-7b capsules
11051723|NCT04417257|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
11051724|NCT04417231|Experimental|Apheresis group|"10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts at the latest 36 hours after infarction or, in case of an unclear time window, within 36 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is <10 mg/l or if the patient has been discharged from hospital.
~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours."
11051725|NCT04417231|No Intervention|Control group|10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.
11051933|NCT04415723|Experimental|intervention group|supportive care management programme
11051726|NCT04417218|Experimental|Normal Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the normal lysine diet, participants will be asked to adhere to a specific diet for 1 week. Each study subject will receive 3 meals and 1-2 snacks per day during the study period.
11051727|NCT04417218|Experimental|High Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the high lysine diet, participants will be asked to consume the same foods as in the normal lysine diet, but with the addition of lysine supplements (5g/day).
11051728|NCT04417205|Active Comparator|Carbohydrate rich breakfast|Participants will be provided with 28-days worth of pre-weighed carbohydrate rich breakfast materials to consume before 1000h daily.
11051729|NCT04417205|Experimental|Whey protein enriched breakfast|Participants will be provided with 28-days worth of pre-weighed whey protein enriched rich breakfast materials to consume before 1000h daily.
11051730|NCT04417205|No Intervention|Extended morning fast|Participants will be asked to remain fasted (i.e. to not consume breakfast) until 1200h daily for 28-days.
11051731|NCT04417192|Experimental|Olaparib or Olaparib Plus Pembrolizumab|Cohort 1 : Olaparib will be administered for 6 weeks before surgery. Cohort 2 : Olaparib and Pembrolizumab will be administered simultaneously for 2 cycles(6 weeks) before surgery.
11051732|NCT04417179|Experimental|TAP block group|"the TAP block will be given by a high frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .
~a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under direct ultrasound visualization, . After confirming the correct placement of the needle and the negative aspiration probe anaesthetic substance will be injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine(10) , and the dissection of the plane was observed. The block will be performed bilaterally."
11051733|NCT04417179|Experimental|ESP group|the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .A blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under strict aseptic precautions until the tip is deep to erector spinae muscle, The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally
11051734|NCT04417166|Experimental|Pembrolizumab and Radiotherapy|"Induction Phase:
~Standard Involved Field Radiation Therapy (IFRT) and pembrolizumab. Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 6 cycles. IFRT will start at first cycle of Pembrolizumab and will be delivered concurrently.
~Patients with complete remission (CR), partial response (PR) and stable disease (SD) after Induction Phase will continue with pembrolizumab maintenance.
~Maintenance Phase:
~Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle up to 34 cycles or until disease progression or unaccepted toxicity"
11051735|NCT04417153||Mindfulness based intervention, Non Emergency (MBI-NE)|"4 week Mindfulness foundation course face to face (MF-NE) or
~8 week Mindfulness Based stress reduction face to face (MBSR-NE)
~The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions. Participants will be provided handouts for the information covered during these talks and discussions.
~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together"
11051736|NCT04417153||Mindfulness based intervention, DORSCON Orange (MBI-Orange))|"4 week Mindfulness foundation course face to face (MF-Orange) or
~8 week Mindfulness Based stress reduction face to face (MBSR-Orange)
~The content of these courses are the same as in the non emergency ones, and consist of four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques. Participants will also be provided with the same handouts for the information covered during these talks and discussions.
~Classes are done at the Mindfulness centres providing the courses, with face to face sessions with the teacher and up to 30 participants together."
11051737|NCT04417153||Mindfulness based intervention, Partial lockdown (MBI-Covid)|"4 week Mindfulness foundation course online (MF-Covid) or
~8 week Mindfulness Based stress reduction online, partial lockdown situation (MBSR-Covid)
~The content of these courses are the same as in the non emergency ones. Participants will also be provided with the same handouts for the information covered during these talks and discussions.
~During the partial lockdown, classes can only be held online, using platform as zoom with the teacher and up to around 17 participants together."
11051738|NCT04417140|Experimental|Treatment Arm-dHACM|Patients enrolled in this arm will have a thin sheet of dHACM placed as an overlay over the length of the closed incisions. dHACM is Dehydrated Human Amniotic-Chorion Membrane. It is a FDA registered healing adjunct that has been applied in a broad range of diseases including wounds, plantar fasciitis and burns.
11051739|NCT04417140|No Intervention|Control Arm|Patients enrolled in this arm will have routine closure.
11051740|NCT04417127|Experimental|Microfinance with Integrated Community-based Care|20 microfinance groups with n=450 participants will be randomized to receive the ICB intervention.
11051741|NCT04417127|Active Comparator|Microfinance with Standard of Care|20 microfinance groups with n=450 participants will be randomized to continue to receive standard of care from an AMPATH-supported rural health facility.
11051742|NCT04417127|No Intervention|Standard of Care without Microfinance|n=300 participants who receive care at an AMPATH health facility and who are not involved in microfinance will serve as matched contemporaneous controls. These participants will be actively followed over the 18-months of the trial.
11051743|NCT04417114|Experimental|Single-Arm Open label|This is a single-arm open label mechanistic clinical trial. Subjects will be treated with rosuvastatin at a dose of 20mg/day and uptitrated as tolerated to a dose of 40mg/day.
11051744|NCT04417101|Experimental|JBT treatment|The participants will be instructed to take their Chinese herbal medicine formula (CHM), which named Juan Bi Tang, and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
11051745|NCT04417101|No Intervention|No treatment|Participants in the non-treatment period will receive conventional self-care management for myofascial pain syndrome.
11051746|NCT04417088|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to Carboplatin administration.
11051747|NCT04417075|Experimental|Impacto|This is the mobile app to be developed and evaluated in this project.
11051749|NCT04417062|Experimental|Olaparib-Ceralasertib|"Unresectable disease (can not be surgically removed) will be enrolled into Cohort 1 and Resectable disease (can be surgically removed) which is limited only to the lung parenchyma will be enrolled into Cohort 2.
~Olaparib at a predetermined dose orally 2 times a day on days 1-28
~Ceralasertib will be given at a predetermined dose orally once a day on days 1-7 in 28-day study cycles.
~Patients can remain on treatment for up to 2 years if disease progression has not occurred."
11051750|NCT04417049|Experimental|Pentoxifylline|
11051751|NCT04417036|Experimental|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
11051752|NCT04417036|Experimental|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
11051753|NCT04417036|Placebo Comparator|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
11051754|NCT04417036|Experimental|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
11051755|NCT04417036|Placebo Comparator|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
11051756|NCT04416997||Rheumatoid arthritis patients|Blood and serum samples
11051757|NCT04416984|Experimental|ALLO-501A, ALLO-647|
11051758|NCT04416971||mature AVF|Patients initiate HD with mature AVF.
11051759|NCT04416971||immature AVF|Patients initiate HD with immature AVF.
11051760|NCT04416958||CIED for cardiac resynchronisation|Patients implanted with an CIED for cardiac resynchronisation aiming to avoid pacing induced ventricular dyssynchrony, e.g. His bundle pacing, LBB-area pacing, CRT. These different implanted types of devices may be further analysed as subgroups.
11051761|NCT04416945|Experimental|RACD|Reactive case detection led by VMWs in response to cases in study area HCCA, with follow up testing with HS-RDTs/RDTs in both villages and forest workers; referrals for qualitative G6PD testing for P. vivax cases and 14-day PQ for G6PD non-deficient
11051762|NCT04416945|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMWs; village-based RACD conducted by district staff in some areas
11051763|NCT04416932||Post-operative patients who had total shoulder arthroplasty|Patients who have had a total shoulder replacement will be scheduled for an ultrasound at Duke Radiology. An ultrasound will be completed on the shoulder that has been replaced, which takes no more than an hour. This ends all study involvement.
11051764|NCT04416919|Other|Assembled Mask|Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences. The Fitted Mask will be attached to a bacterial/viral filter for fit testing. After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator. Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes. The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia. At the end, the mask will be removed.
11051765|NCT04416906|Experimental|Biktarvy|This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.
11051766|NCT04416893||Children under 15 years of age in a community|Children under 15 years of age in a community : kindergarten, school, college, holiday center, etc.
11051767|NCT04416880|Experimental|Press Tack Needle Acupuncture|Patients in this group were given seirin pyonex press tack needle treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
11051768|NCT04416880|Sham Comparator|Sham Control Press Tack Needle Acupuncture|Patients in this group were given sham treatment in the acupuncture points CV17 Danzhong and SI1 Shaoze bilateral for 7 days.
11051769|NCT04416867|Active Comparator|group-1 splint and home exercise|Patients in group 1 will be treated with splinting of the affected hand at night and a home exercise program. A wrist orthosis which held the wrist in the neutral position will be used for splinting at night time for a minimum of eight hours. Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
11051770|NCT04416867|Active Comparator|group 2 RESWT|Patients in group 2 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and a total of 3 sessions of RESWT at a frequency of one session per week using the Masterpuls ® mp200 radial shock wave therapy system (Elite-Storz Medical AG, Kreuzlingen, Switzerland). RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
11051771|NCT04416867|Active Comparator|group 3 physical therapy|Patients in group 3 will be treated with splinting of the affected wrist at night, a home exercise program similar to that of group one and two and 20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks.
11051772|NCT04416854|Experimental|Chemotherapy plus surgery|Chemotherapy plus surgery: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to surgery group. Patients receive palliative resection of Primary tumor. Then the rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
11051773|NCT04416854|Active Comparator|Chemotherapy alone|Chemotherapy alone: Four cycles of XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy accroding to gene testing. After 4 cycles, the patients are randomized to chemotherapy group. The rest four cycles XELOX or six cycles of mFOLFOX6 combined with or without targeted therapy are administrated.
11051774|NCT04416841|Experimental|Tai Chi Chuan Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour Tai Chi Chuan training per week for 24 weeks and standard diabetic care education.
11051775|NCT04416841|Active Comparator|Fitness Walking Group|In addition to conventional medical treatment, participants will receive 3 sessions of 1-hour fitness walking training per week for 24 weeks and standard diabetic care education
11051776|NCT04416841|Other|Control group|In addition to conventional medical treatment, participants will receive standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
11051778|NCT04416815|No Intervention|Usual care|The participants allocated to the control group received no intervention. However, they could, on their own initiative, approach the usual range of community or health services (e.g., home help services, rehabilitation, or medical care).
11051779|NCT04416815|Experimental|eHealth|The intervention will be delivered for 6 months on top of usual care.
11051780|NCT04416802|Experimental|PRP and Li-ESWT treatment|Participants diagnosed with erectile dysfunction will receive the combined treatment of platelet-rich plasma and low-intensity extracorporeal shockwave therapy.
11051781|NCT04416776||Eligible patients for AI test|Device: strabismus diagnostic system.
11051782|NCT04416750|Experimental|Treatment|Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
11051783|NCT04416737|Experimental|Upper Peritoneal, then Lower Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the upper peritoneum then lower peritoneum then subcutaneous space.
11051784|NCT04416737|Experimental|Lower Peritoneal, then Upper Peritoneal, then Subcutaneous|Ultra-fast acting insulin will be injected into the lower peritoneum then upper peritoneum then subcutaneous space.
11051785|NCT04416724|Experimental|Phacoemulsification|Main study intervention will be Phacoemulsification
11051786|NCT04416724|Experimental|SLT|Main study intervention will be Selective Laser Trabeculoplasty
11051787|NCT04416711|Active Comparator|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
11051788|NCT04416711|Experimental|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
11051789|NCT04416698||Youth smokers|Participants of Youth Quitline
11051790|NCT04416685|Other|Level 1|Those tumors located superior to the portal confluence were classified as Level I,
11051791|NCT04416685|Other|Level II|those tumors located on the confluence (involving the confluence) located on the portal confluence
11051792|NCT04416685|Other|Level III|those tumors located inferior to the portal confluence
11051793|NCT04416633|Other|Durvalumab|Single arm, Durvalumab , IV
11051794|NCT04416620|Active Comparator|The active group of Syria|"Participants in the active group received the 'pharmacist standard counseling' plus the 'pharmaceutical care service' designed by the research group. Both services were delivered by one female clinical pharmacist who has a Master's degree in pharmaceutical sciences, 5-year work experience in community pharmacies, and comprehensive knowledge of PCOS. The time it took to deliver the counseling and education to each participant in the active group was formally assessed. This time assessment excluded data collection and questionnaire filling time (which was planned to take around 15 min).
~Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise."
11051795|NCT04416620|No Intervention|The control group of Syria|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.
~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
11051796|NCT04416620|Active Comparator|The active group of Jordan|Participants in the active group received the usual care delivered at the community pharmacies plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise.
11051797|NCT04416620|No Intervention|The control group of Jordan|"Participants in the control group received the usual care only which is the 'pharmacist standard counseling' involved dispensing the prescribed medication (delivered by the pharmacist in charge), counseling on how to take the dispensed medications, and a brief reply to questions if asked by the participants. The 'pharmacist standard counseling' followed what was normally delivered to females with PCOS by pharmacists working at community pharmacies in both countries. This 'pharmacist standard counseling' was established based on what was observed and reported by the project research team after viewing the usual pharmacists' interaction with females with PCOS for two weeks in each country before the start of the study.
~Participants in the control group were informed that the educational intervention (the pharmaceutical care service) will be delivered to them after the end of the study (for ethical reasons)."
11051798|NCT04416607|Experimental|corifollitropin alpha|Ovarian stimulation protocol is performed with a single dose of 100 μg (<60 kg) or 150 μg (≥60 kg) of corifollitropin alpha (Elonva, Schering-Plough, Brazil), plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
11051799|NCT04416607|Active Comparator|menotropin|150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3, according to age, AMH level and AFC, plus gonadotropin-releasing hormone antagonist co-treatment (Ganirelix 25 mcg/day, Orgalutran, Schering-Plough, Brazil) in a flexible protocol (at least 1 follicle >14 mm or 3 or more follicles >12 mm).
11051800|NCT04416594||Factor XIII deficiency|Patients admitted to hospital with FXIII levels below 70% during their hospital stay
11051801|NCT04416581|Experimental|P-CAB 50mg group|"tegoprazan 50 mg + rabeprazole 20mg placebo + tegoprazan 25 mg placebo, once daily.
~Target enrollment: 1250"
11051802|NCT04416581|Active Comparator|PPI group|"rabeprazole 20mg + tegoprazan 50 mg placebo + tegoprazan 25 mg placebo, once daily.
~Target enrollment: 1250"
11051803|NCT04416581|Other|P-CAB 25mg group|"tegoprazan 25 mg + rabeprazole 20mg placebo + tegoprazan 50 mg placebo, once daily.
~Target enrollment: 500"
11051804|NCT04416568|Experimental|Solid Tumor (Stratum 1)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles
~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle
~Patients with INI1-negative relapsed or refractory extracranial solid tumors"
11051805|NCT04416568|Experimental|CNS (Stratum 2)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles
~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle
~Patients with INI1-negative relapsed or refractory CNS tumors"
11051806|NCT04416555|Placebo Comparator|VR googles using exposure sham program|The study groups will receive VR googles and the sham program
11051807|NCT04416555|Active Comparator|VR googles and the real VR program experience.|The study group will receive the VR googles and the real VR program experience.
11051808|NCT04416542|No Intervention|Control|Subjects in this group will be implanted with the Inspire UAS system and will undergo a standard in-lab PSG titration study at approximately 3 months post-activation and a 2-night HST at approximately 6 months post-activation
11051809|NCT04416542|Active Comparator|Home Monitoring|Subjects who have undergone implant of the Inspire UAS System and are randomized to this group will undergo a 2-night HST at 3 months post-activation. Depending on the results of the 2-night HST, the subject will either (a) undergo a PSG titration at 5 months post-activation and a 2-night HST at 6 months post-activation OR (b) undergo only a 2-night HST at approximately 6 months post-activation
11051810|NCT04416529|Experimental|Intervention (tele-MBCT) group|"Tele-MBCT was an 8-week program delivered to participants online via a videoconferencing program called Zoom by a tele-MBCT instructor. Tele-MBCT was delivered in three, 8-week rounds. Each round consisted of 8 weekly, 2-hour group sessions with 4-6 participants on Wednesdays from 2:00 to 4:00 pm. Participants were trained in mindfulness concepts and techniques including mindful eating, body scan, sitting meditation, breathing awareness, mindful walking and mindful movements. Participants were given a mindfulness a book called The Mindful Way Workbook and a practice log. The book was a guide for their daily practice at home and the practice log was a simple log for self-recording daily practices (number of minutes of daily MBCT practice) and a note pad for recording the reasons/obstacles for not practicing."
11051811|NCT04416529|No Intervention|Control Group|Participants in the control group continued their usual caregiving activities.
11051812|NCT04416516|Experimental|Arm 1, Patients with 1 Tumour|"Participants with 1 Target Tumour will receive 3 x ASN-002 1.0x10(11) Injections
~+ VISMODEGIB (150 mg) daily for 4 weeks."
11051813|NCT04416516|Experimental|Arm 2, Patients with 3 or more Tumours|Participants with 3 or more Target Tumours will receive 3 x ASN-002 1.0x10(11) Injections (per tumour) + VISMODEGIB (150 mg) daily for 4 weeks.
11051814|NCT04416503|Experimental|Intervention group|Foot reflexology was performed for 12 week in the intervention group, whereas the control group continued their routine treatment and follow-up.
11051815|NCT04416503|No Intervention|Control group|Usual follow-up was done to the control group.
11051816|NCT04416490||Patients|Patients with high-risk stage II or stage III primary colon cancer who have received curative resection
11051817|NCT04416464||Pneumonia due to SARS-CoV-2 infection|Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
11051818|NCT04416451|Experimental|Rituximab and Venetoclax|Patients will be treated with an Induction phase of rituximab 375 mg/m2 weekly for 4 weeks. Patients will undergo restaging imaging after the last of 4 weekly rituximab doses and before beginning venetoclax. Based on post-rituximab restaging studies, patients will be risk-stratified for risk of Tumor Lysis Syndrome (TLS) and treated in the appropriate setting with TLS prophylaxis per institutional TLS guide lines starting at week 5. Oral venetoclax will follow a ramp-up dosing schedule and will be taken daily after 4 weeks of rituximab therapy. Following the 4-week ramped-up phase of venetoclax, patients will begin their target dose of venetoclax and continue for a maximum of 24 months. In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months. Venetoclax may be continued after this period if patient has not achieved a complete remission
11051819|NCT04416425||Enrolled Cohort|200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.
11051820|NCT04416412||Open Fracture Cohort|"Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion.
~Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.
~Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
~Provision of informed consent."
11051821|NCT04416399|Experimental|Inhaled budesonide|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
11051822|NCT04416399|No Intervention|Standard of care|Standard of care
11051823|NCT04416360|Experimental|Interview by psychologists|Children and adolescent interview Parents interview Referring caregiver interview
11051824|NCT04416347||Workstream 1|Adult patients admitted to SGHFT (St. Georges Hospital Foundation Trust) with or without laboratory confirmed SARS- CoV-2.
11051825|NCT04416347||Workstream 2|Adult patients admitted to to SGHFT (St. Georges Hospital Foundation Trust) ITU with respiratory failure.
11051826|NCT04416334|Experimental|Colchicine plus symptomatic treatment (paracetamol).|"Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.
~All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice."
11051827|NCT04416334|Active Comparator|Symptomatic treatment|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
11051828|NCT04416321|Other|Device|All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.
11051829|NCT04416308|Other|Seroprevalence survey|NG Test + short self-questionnaire (except validation survey and detailed survey)
11051830|NCT04416308|Other|Validation test of the NG test survey|Blood test + NG test + detailed self-questionnaire
11051831|NCT04416308|Other|Detailed Survey|NG test + self-questionnaire complementary to the short questionnaire
11051832|NCT04416308|Other|Prevalence monitoring (2 population samples)|"Participants having presented a certain or probable COVID: acts of the validation test survey, + follow-up questionnaire,+ blood test + NG test, on D30 and D90
~Others Participants : drawn by lot: acts of the seroprevalence survey, + follow-up questionnaire + NG test, on D90"
11051833|NCT04416295|Active Comparator|Standard COPD care and a digital COPD support system|Device: LifePod The intervention group is testing LifePod on a digital communication platform between patient and healthcare provide
11051834|NCT04416295|Other|Control group Standard COPD Care|
11051835|NCT04416282|Experimental|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
11051836|NCT04416282|Active Comparator|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
11051837|NCT04416269|Experimental|Oral Anti-diabetes Drugs (OADs) alone|OADs will be continued at same outpatient dosage unless contraindicated
11051838|NCT04416269|Active Comparator|Basal bolus insulin|Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.
11051839|NCT04416256||France|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051840|NCT04416256||Spain|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051841|NCT04416256||Portugal|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051842|NCT04416256||Croatia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051843|NCT04416256||Germany|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051844|NCT04416256||Italy|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051845|NCT04416256||Netherlands|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051846|NCT04416256||Austria|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051847|NCT04416256||US|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051848|NCT04416256||Canada|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051849|NCT04416256||Mexico|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051850|NCT04416256||Brazil|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051851|NCT04416256||Uruguay|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051852|NCT04416256||Argentina|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051853|NCT04416256||Chile|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051854|NCT04416256||Australia|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051855|NCT04416256||Belgium|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051856|NCT04416256||Finland|All organs procured for transplantation and transplanted during the observation period. These include kidney, lung, liver, heart, and combined transplantations.
11051857|NCT04416243|Experimental|Recumbent Stepping, High-Intensity Interval Training|
11051858|NCT04416230|Experimental|Massage|Infants randomized to the massage intervention received a 30 minute massage daily for the 7 day study.
11051859|NCT04416230|Active Comparator|Quiet Time|Infants randomized to the Quiet Time intervention experienced a 30 minute time during which non-essential clinical caregiving tasks were restricted.
11051860|NCT04416217||Topical Steroid Treatment|Pediatric patients with eosinophilic esophagitis scheduled to begin topical steroid treatment for the treatment of their condition. The type of topical steroid is not limited and is at the discretion of the treating physician as are dosing and concomitant treatments.
11051861|NCT04416204|Experimental|Type 2 diabetes|
11051862|NCT04416204|Experimental|Participants without diabetes|
11051863|NCT04416191|Experimental|Limb immobilization|Participants will undergo a 2-week leg immobilization period
11051864|NCT04416178||Parents of children with SCD|Parent of child with HbSS, HbS/ β0thalassemia, or HbSC aged 12 months to 18 years at study initiation
11051865|NCT04416178||Adolescents with SCD|Patient aged 13-18 with HbSS, HbS/ β0thalassemia, or HbSC
11051866|NCT04416165|Experimental|Experimental: 68Ga-DOTA-FAPI-04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
11051867|NCT04416139|Active Comparator|Treated group|Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.
11051934|NCT04415723|No Intervention|control group|receive the usual care provided by the health care system of Cyprus
11051868|NCT04416139|No Intervention|Control Group|The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables.
11051869|NCT04416126|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
11051870|NCT04416126|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
11051871|NCT04416113|Active Comparator|photobiomodulation group|"Laser watch Patients will be subjected to low-level laser (diode laser 980nm) for 30 minutes, the recommended dose based on the previous study is 20 J for 3 to 7 days.
~The laser device:
~Laser watched applied at the wrist on the radial artery.
~Laser acupuncture"
11051872|NCT04416113|Active Comparator|photodynamic group|"Methylene blue injection USP 1% will be used as a photosensitizer in PDT.
~0.1 to 0.2 mL of 1% solution per kilogram of body weight Methylene Blue (methylene blue injection) will be injected intravenously very slowly over a period of several minutes to
~After one hour apply Light dose: 100 - 200 J/cm2 50-100 mW/cm2. (50 mW/cm2 increased the phototoxic response as well as the fractionated light application).
~The session will be done twice per week
~Laser watched applied at the wrist on the radial artery."
11051873|NCT04416113|Active Comparator|positive control|This group will include patients who are subjected to conventional treatment
11051874|NCT04416087|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
11051875|NCT04416074|Experimental|Group psychotherapy group|Students will be intervened by an online 5-week professional identity group psychotherapy.
11051876|NCT04416074|Other|Controlled message push group|Students will receive online messages of self-care knowledge forward by researchers.
11051877|NCT04416061||Subjects underwent COVID-19 test|Subjects who underwent COVID-19 test in HKSH during the study period
11051878|NCT04416048|Experimental|Rivaroxaban|Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
11051879|NCT04416048|Other|Standard of Care|Subjects will receive standard of care (SOC) treatment SOC including prophylactic LMWH or UFH, when considered appropriate according to the judgment of the treating physician.
11051880|NCT04416035|Experimental|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle，carboplatin will be administered at an AUC 6 mg/mL/ min by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
11051881|NCT04416035|Active Comparator|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Paclitaxel will be administered at a dose of 200 mg/m^2 by IV infusion Q3W on Day 1 of each cycle and carboplatin will be administered at an AUC 6 mg/mL/min (the maximum dose capped at 900 mg) by IV infusion Q3W on Day 1 of each cycle. Each cycle is 3 weeks. Treatments will continue until disease progression, death, intolerable toxicity, withdrawal of consent, investigator decision, or completion of 4-6 cycles of therapy. Maintenance therapy may be given at the discretion of the patient's primary oncologist.
11051882|NCT04416009||mild pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the ward
11051883|NCT04416009||severe pneumonia ECW|the covid 19 pneumonia patients who hospitalised to the intensive care unit
11051884|NCT04415996|Experimental|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.
~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.
~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
11051885|NCT04415996|Sham Comparator|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.
~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
11051886|NCT04415983|Experimental|Nitazoxanide group|Clarithromycin, Nitazoxanide and Proton pump inhibitor
11051887|NCT04415983|Active Comparator|Traditional group|Clarithromycin, Metronidazole and Proton pump inhibitor
11051888|NCT04415970|Experimental|Flotation Therapy|Participants will utilize flotation sensory deprivation tanks.
11051889|NCT04415970|Active Comparator|Sleep Pod|Participants will utilize sleep pods with partial sensory deprivation (no light and silence).
11051890|NCT04415957|Experimental|Elastic Tape Group (ETG)|The ET will be placed in the patient chest wall and abdomen for as long of 2 consecutive weeks.
11051891|NCT04415957|No Intervention|Control Group (CG)|The CG will be an education program in COPD and physical activity recommendations. Besides, after study ends they will be invited to place the ET.
11051892|NCT04415944|Experimental|Second Look Laparoscopy and HIPEC with Carboplatin|Laparoscopic assessment of disease status of the peritoneal cavity with lysis of adhesions as necessary noting either no gross residual disease or minimal residual disease prior to or after resection. This is performed prior to establishment of a peritoneal perfusion circuit and hyperthermic intraperitoneal chemotherapy.
11051893|NCT04415931|Experimental|Local infiltration analgesia group|This group of patients will receive local infiltration analgesia
11051894|NCT04415931|Active Comparator|Interscalene block group|This group of patients will receive interscalene block
11051895|NCT04415918|Experimental|Intervention group|Recruited patient according inclusion/exclusion criteria
11051896|NCT04415918|No Intervention|Historical control|Cohort of historical patients matched to study population to serve as control
11051897|NCT04415905|Experimental|group P|The participants in the group P are anesthetized with propofol.
11051898|NCT04415905|Active Comparator|group S|The participants in the group S are anesthetized with sevoflurane.
11051899|NCT04415892|Other|High-Low-Vehicle|Volunteers in group A will receive a high dose, low dose and vehicle solution of each compound on digit 2, 3 and 4, respectively.
11051935|NCT04415710||Group|Women with diagnosed Sjogren syndrome
11051900|NCT04415892|Other|Vehicle-High-Low|Volunteers in group B will receive a high dose, low dose and vehicle solution of each compound on digit 3, 4 and 2, respectively.
11051901|NCT04415892|Other|Low-Vehicle-High|Volunteers in group C will receive a high dose, low dose and vehicle solution of each compound on digit 4, 2 and 3, respectively.
11051902|NCT04415879|Active Comparator|No Mask|Individuals will perform a Modified Balke Treadmill test with no mask and their estimated VO2 peak will be calculated based off of peak workload.
11051903|NCT04415879|Experimental|N-95 Respirator|Individuals will perform a Modified Balke Treadmill test while wearing a N-95 Respirator and their estimated VO2 peak will be calculated based off of peak workload.
11051904|NCT04415879|Experimental|Cloth Mask|Individuals will perform a Modified Balke Treadmill test while wearing a cloth mask and their estimated VO2 peak will be calculated based off of peak workload.
11051905|NCT04415866|Experimental|Effects of PASAT on Sensory Testing|After baseline evaluation of light and pain sensitivity FM subjects and controls will undergo the PASAT task. This task consists of responding to a rapid presentation of numbers by ear phones. Subjects are asked to add each 2 consecutive numbers and provide a response each time the sum is equal to 13. This test will last several minutes and delivered at increasing speed.
11051906|NCT04415853|Experimental|Lerotinib Arm|350 mg,qd, orally about half an hour after a meal, continuous administration, every 21 days for a treatment cycle.
11051907|NCT04415853|Active Comparator|Active Comparator Arm|"Irinotecan: Intravenously administered at a dose of 180 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.
~Tegafur: 40-60mg po bid(d1-d14),every 21 days as a cycle, continuous drug administration from 1 to 14 days of each cycle, and then stopped 7 days."
11051908|NCT04415827|Experimental|Athletes with community-acquired pneumonia|man and women, athletes, age 17-25, patients with community-acquired pneumonia
11051909|NCT04415827|Experimental|Untrained people with community-acquired pneumonia|man and women, untrained people, age 17-25, patients with community-acquired pneumonia
11051910|NCT04415827|Experimental|Athletes with bronchitis|man and women, athletes, age 17-25, patients with bronchitis
11051911|NCT04415827|Experimental|Untrained people with bronchitis|man and women, untrained people, age 17-25, patients with bronchitis
11051912|NCT04415827|Experimental|Athletes with chronic obstructive pulmonary disease|man and women, athletes, age 17-25, patients with with chronic obstructive pulmonary disease
11051913|NCT04415827|Experimental|Untrained people with chronic obstructive pulmonary disease|man and women, untrained people, age 17-25, patients with with chronic obstructive pulmonary disease
11051914|NCT04415827|Experimental|Athletes with acute respiratory infections|man and women, athletes, age 17-25, patients with acute respiratory infections
11051915|NCT04415827|Experimental|Untrained people with acute respiratory infections|man and women, untrained people, age 17-25, patients with acute respiratory infections
11051916|NCT04415814|Experimental|Group 1 (Unilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed unilaterally, which means on one side of the spinous processes. The system will be fixed with standard rod and blockers.
11051917|NCT04415814|Active Comparator|Group 2 (Bilateral Pedicle Screw Fixation)|Patients will undergo stabilizing surgery on the lumbar spine for degenerative diseases of the spine. Pedicular screws will be installed bilaterally, which means on the both sides of the spinous processes. The system will be fixed with standard rods and blockers.
11051918|NCT04415801|Experimental|Implant abutments|implant abutments
11051919|NCT04415788|Experimental|Test of Incremental Respiratory Endurance - IMT|Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
11051920|NCT04415788|Experimental|Threshold - IMT|Subjects assigned to the Standard training regimen will receive a commonly used Threshold inspiratory muscle trainer. This device features a one-way spring-loaded valve at one end and a mouthpiece on the other through which subjects will be required to breathe in hard enough to overcome the resistance provided by the spring-loaded valve, allowing correct inspiration to happen. In other words, air flow is blocked until subjects generate sufficient inspiratory pressure to exceed the device pre-set pressure in cmH2O. The resistance will be set using the device's adjustable pressure setting which is fixed at 50% of the subject's MIP at the time of enrollment. The resistance will be readjusted as needed at week 4 to still reflect 50% of their inspiratory muscle strength at that time. Subjects will be coached to perform up to 36 breaths daily using the device. They will be also instructed to complete the training session within a 30-minute period.
11051921|NCT04415788|Sham Comparator|Sham IMT (Low resistence)|The Sham (Low Resistance) training regimen will use the same methods described above for the Standard IMT, except for the amount of resistance applied within the device. Subjects will receive a Threshold which has been set to its minimal resistance, which is 9 cmH2O. Again, subjects will be instructed to perform up to 36 breaths daily using the device within a 30-minute period.
11051922|NCT04415775|Experimental|Dual-task walking Intervention|
11051923|NCT04415775|Active Comparator|Conventional Gait Rehabilitation|
11051924|NCT04415775|No Intervention|Healthy Controls|
11051925|NCT04415749|Experimental|NasoShield One Dose in Position 1|NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
11051926|NCT04415749|Placebo Comparator|Placebo in Position 1|Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)
11051927|NCT04415749|Experimental|NasoShield Two Doses in Position 2|NasoShield on Day 1 and Day 29 in position 2 (Group 2)
11051928|NCT04415749|Placebo Comparator|Placebo in Position 2|Saline placebo on Day 1 and Day 29 in position 2 (Group 2)
11051929|NCT04415749|Experimental|NasoShield Two Doses in Position 3|NasoShield on Day 1 and Day 29 in position 3 (Group 3)
11051930|NCT04415749|Placebo Comparator|Placebo in Position 3|Saline placebo on Day 1 and Day 29 in position 3 (Group 3)
11051931|NCT04415736||Delayed cerebral ischemia|Patients with subarachnoid hemorrhage that develop delayed cerebral ischemia
11051932|NCT04415736||Non delayed cerebral ischemia|Patients with subarachnoid hemorrhage that do not develop subarachnoid hemorrhage
11051936|NCT04415697||Responders|Those who present complete response, partial response, or stable disease, according to RECIST 1.1.
11051937|NCT04415697||Not responders|Those who present progression disease according to RECIST 1.1.
11051938|NCT04415684|Experimental|Test Arm|
11051939|NCT04415671|Experimental|Part A- AD-214 SAD in Healthy Volunteers|
11051940|NCT04415671|Placebo Comparator|Part A-Placebo SAD in Healthy Volunteers|
11051941|NCT04415671|Experimental|Part B- AD-214 SAD in patients with ILD|
11051942|NCT04415671|Experimental|Part C-AD-214 MAD in patients with ILD|
11051943|NCT04415658|Experimental|Thyroxine|Intravenous thyroxine infusion
11051944|NCT04415658|Placebo Comparator|Saline Placebo|Intravenous saline infusion
11051945|NCT04415645|Experimental|VVZ-149 Injections|
11051946|NCT04415632|Experimental|LGI Diet|low glycemic index diet
11051947|NCT04415632|Other|HGI Diet|High glycemic index diet
11051948|NCT04415619|Experimental|Intervention group|10 patients will have immediate implant placement with buccal pad of fat free tissue
11051949|NCT04415606|Experimental|QuikClot Control+|QuikClot Control+
11051950|NCT04415606|Placebo Comparator|Standard gauze|Standard gauze per standard of care
11051951|NCT04415593|Experimental|high dose of peanut|20 patients
11051952|NCT04415593|Active Comparator|low dose of peanuts|20 patients
11051953|NCT04415580|Experimental|Vestibular Rehabilitation Group|
11051954|NCT04415580|Active Comparator|Conventional rehabilitation Group|
11051955|NCT04415567||lenvatinib|high-risk patients with HBV-related HCC who took lenvatinib as adjuvant therapy after liver transplantation
11051956|NCT04415567||control|high-risk patients with HBV-related HCC who received routine treatment and follow-up after liver transplantation
11051957|NCT04415554||exposure to aminoglicosides|preterm receiving aminoglycosides
11051958|NCT04415554||non exposure to aminoglycosides|preterm not receiving aminoglycosides
11051959|NCT04415541|Experimental|Psychodynamic Psychotheray|Following Coordinated Specialty Care, we will offer weekly psychodynamic psychotherapy and medication management sessions which will be conducted solely by the PI, Keith Gallagher, in the initial pilot period. Consent will be obtained to record audio and video of the sessions
11051960|NCT04415541|Active Comparator|Treatment as Usual|Following Coordinated Specialty Care, patients will be referred to general mental health providers in the community, which would typically include less intensive and frequent psychotherapy by a social worker or psychologist as well as medication management by a psychiatrist who may not be a specialist in psychotic disorders.
11051961|NCT04415528|Experimental|Intervention group|The intervention group will begin receiving the group intervention within one - two weeks of Time 1 assessment. This group will receive Time 2 assessments at the end of the group delivery. Time 3 assessments will be administered eight weeks after the completion of group delivery.
11051962|NCT04415528|Active Comparator|Wait listed control group|The wait listed control group will be assessed at Time 1, eight weeks before receiving the intervention. This group will receive Time 2 assessments at the beginning of their group delivery. This group will complete Time 3 assessments eight weeks after the completion of group delivery.
11051963|NCT04415515|Experimental|Treatment 1|RN Standard care coordination and disease management + RN Case Management
11051964|NCT04415515|Experimental|Control|RN Standard care coordination and disease management
11051965|NCT04415515|Experimental|Treatment 2|RN Standard care coordination and disease management + Community Health Worker Case Management
11051966|NCT04415502||Measuring of CTHRc1 , its correlation with RAdisease activity|Measuring of CTHRc1 levels and its correlation with RA disease activity
11051967|NCT04415489|Active Comparator|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
11051968|NCT04415489|No Intervention|Saline infusion sonography|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
11051969|NCT04415476|Other|Sirolimus and Tacrolimus and prednisone|Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
11051970|NCT04415476|Experimental|Standard of Care|"Arm1:) sirolimus and tacrolimus and prednisone group:
~Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml.
~Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if >40 kg / 1 mg/m²/day if <40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effects.
~Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effect"
11051971|NCT04415463|Experimental|FC-SEMS|Placement of multisegmented fully covered self-expandable metal stent
11051972|NCT04415450|Experimental|Nutrition Education Group|The experimental group is the group who received the intervention which is the nutrition education and counseling. Phase I of the data collection from the experimental group which is the pregnant women (baseline assessment) using a questionnaire immediately before receiving nutrition counseling from their ANC providers first took place. Health professionals then started providing nutrition education to pregnant women preselected and assessed before the intervention. Immediate post education evaluation of the pregnant women was done by the same questionnaire used to assess in the pretest. Phase II or post intervention data collection of pregnant women was done after the client was appointed for 6 weeks after the counseling session.
11051973|NCT04415437||healthy|Healthy participants
11051974|NCT04415437||mentally ill|Participants with mental disorders
11051975|NCT04415437||physically ill|Participants with organic disease
11051976|NCT04415437||mentally and physically ill|Participants with mental disorders and organic disease
11051977|NCT04415424|Experimental|Treatment arm A - 4CMenB vaccine|4CMenB vaccine will be administered as an intramuscular injection in 0.5 ml single-dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
11051978|NCT04415424|Placebo Comparator|Treatment arm B - placebo|Placebo will be administered as an intramuscular injection in 0.5 ml single dose pre-filled syringe in two doses with 3-month apart (at Baseline and Month 3 visit).
11051979|NCT04415411|No Intervention|Control group|Routine nursing care
11051980|NCT04415411|Experimental|Intervention group|Nursing care based on the Theory of Human Caring
11051981|NCT04415398|Experimental|Delivery of automated external defibrillators using drones|"Three drone systems are setup to be deployed in suspected OHCA cases as a complement to EMS. This is a single-arm intervention evaluating feasibility in:
~Operational feasibility (Legislation, Weather conditions, conflict in airspace)
~Participant feasibility (Failure to respond; Dispatcher, Drone-pilot, Air traffic controller)
~Technological feasibility (Drone technology, software, winch-system , 4G network, radio communication"
11051982|NCT04415385|Experimental|Camrelizumab + Apatinib|Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
11051983|NCT04415372||Cognitive Impairment|Adults diagnosed with MS that have evidence of cognitive decline.
11051984|NCT04415372||No Cognitive Impairment|Adults diagnosed with MS that have no evidence of cognitive decline.
11051985|NCT04415346|Experimental|HU-014 Inj(Phase 1|HU-014 Inj was given an injection to 5 Upper limb muscle(Total 360U/, IM)
11051986|NCT04415333|Experimental|Sodium Butyrate [5 mmol] first, then Sodium Butyrate [80 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-days washout period, they will return to testing office to self-administer the other enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
11051987|NCT04415333|Experimental|Sodium Butyrate [80 mmol] first, then Sodium Butyrate [5 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 ml total). After a 7-day washout period, they will return to the testing office to self-administer the other enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 ml total).
11051988|NCT04415333|No Intervention|Control|African Americans with normal blood pressure (control group) will not perform self-administration of the enema. They will submit to 1 blood draw and wear the 24-hour ambulatory blood pressure monitor for 1-day.
11051989|NCT04415320|Experimental|X-396(Ensartinib) Capsule|
11051990|NCT04415307|Experimental|Acupuncture|Acupuncture over acupoints.
11051991|NCT04415307|Experimental|Far-Infrared|Far-Infrared heat-patch attachment over acupoints.
11051992|NCT04415307|Experimental|Combination of Acupuncture and Far-Infrared|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
11051993|NCT04415307|Placebo Comparator|Placebo (no Acupuncture nor Far-Infrared)|Far-Infrared heat-patch attachment over acupoints without electric current passing.
11051994|NCT04415281|Experimental|Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
11051995|NCT04415281|Sham Comparator|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
11051996|NCT04415268|Experimental|Multitreatment|"Pharmacological treatment per standard of care (whole study length, starting on week 1).
~Supervised exercise protocol (phase 1, 8 weeks starting on week 9). Unsupervised exercise protocol (phase 2, 8 weeks starting on week 17)."
11051997|NCT04415255|Experimental|EPABI & IABPI|extrapleural autologous blood injection (EPABI) along with intraparenchymal autologous blood patch injection (IABPI)
11051998|NCT04415255|Active Comparator|IABPI-alone|intraparenchymal autologous blood patch injection (IABPI)
11051999|NCT04415242|Active Comparator|suspension group|Arm on the side operated at 90 ° abduction, 90 ° anti-drive, resting on an arm support.
11052000|NCT04415242|Experimental|supported group|Arm on the operated side at 0 ° abduction, 90 ° anti-pulsation, resting on an adjustable support arm support located opposite the patient's head.
11052001|NCT04415216||ISR PCI with thin-DES|
11052002|NCT04415216||ISR PCI with DEB|
11052003|NCT04415203|Experimental|TAES plus usual care|TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); Usual Care: usual medicine treatment for PVCs.
11052004|NCT04415203|Placebo Comparator|Sham-TAES plus usual care|"Sham-TAES on Neiguan (PC6), Shenmen (HT7), Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current.
~Usual Care: usual medicine treatment for PVCs."
11052005|NCT04415190||cholangiocarcinoma with early palliative care|
11052006|NCT04415190||cholangiocarcinoma without early palliative care|
11052007|NCT04415177|Experimental|VR Program A|Software with active intervention
11052008|NCT04415177|Active Comparator|VR Program B|Software without active intervention
11052009|NCT04415164|Experimental|Xueshuantong|Patients will receive intravenously administered Xueshuantong, combined with guidelines-based standard care.
11052010|NCT04415164|Placebo Comparator|Placebo|Patients will receive intravenously administered Xueshuantong placebo, combined with guidelines-based standard care.
11052011|NCT04415151|Experimental|Tofacitinib|Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
11052012|NCT04415151|Placebo Comparator|Placebo|Matching placebo will be administered.
11052013|NCT04415138||Robotic-assisted Group|
11052014|NCT04415138||Video-assisted Group|
11052045|NCT04414904||Case group|"Men 18-50 years of age
~Already attending hospital for another reason
~High risk of prior COVID-19 infection:
~EITHER Prior positive COVID-19 PCR test result
~OR history suggestive of COVID-19 illness"
11052015|NCT04415125|Experimental|elite male ice hockey players|The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
11052016|NCT04415112|Active Comparator|Mediterranean Diet|The MD diet is rich in plant based foods including vegetables, whole cereal and fruit with the main added fat being extra virgin olive oil. In addition, the diet emphasises, while consumption of legumes, nuts and fish is high, consumption of red meat and home-made desserts is low, and consumption of fermented milk and poultry is moderate. The MD diet had a target macronutrient composition of 35-40% fat (with <10% of energy as saturated fat), 40-44% carbohydrate and 20% protein.
11052017|NCT04415112|Active Comparator|Low Fat Diet|The Low Fat diet had a target macronutrient composition of 55% of energy from carbohydrate, 20-25% from fat (with <10% of energy as saturated fat) and 20-25% from protein. Nutrition education focused on choosing foods containing ≤3 grams of fat/serving, limiting added fats, and using low-fat meal preparation strategies. Parents were instructed to offer their children ample amounts of grains, vegetables, fruits, lean meats, low-fat dairy products and limit high-fat foods
11052018|NCT04415099|Experimental|One group|Only one group was assessed before and after performing muscle fatigue protocol.
11052019|NCT04415086|Sham Comparator|Group A|Participants will receive the standard of care treatment
11052020|NCT04415086|Active Comparator|Group B|Participants will receive the standard treatment and convalescent plasma in a volume of 200ml (150-300ml)
11052021|NCT04415086|Active Comparator|Group C|Participants will receive the standard treatment and convalescent plasma in a volume of 400ml (300-600ml)
11052022|NCT04415073|Active Comparator|Axatilimab (SNDX-6352)|Axatilimab on Days 1 and 15, IV + SOC
11052023|NCT04415073|Placebo Comparator|Placebo|Matching placebo on Days 1 and 15 + SOC
11052024|NCT04415060|Experimental|Inhaled - volatile anesthetic|The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
11052025|NCT04415060|No Intervention|Standard Care|The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
11052026|NCT04415060|No Intervention|Non-randomized|In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
11052027|NCT04415047|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System Intervention Device: JenaValve Pericardial TAVR System
11052028|NCT04415034||Pediculosis capitis|Subjects with pediculosis capitis based on the findings of eggs, larva, or an adult parasite on the scalp or in the hair
11052029|NCT04415021|Experimental|Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
11052030|NCT04415021|Sham Comparator|Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
11052031|NCT04415008|Experimental|treatment arm|prospective, open-label, multicenter,single arm
11052032|NCT04414995|Experimental|Paracetamol+Ibuprofen|Patients in Group 1 will receive a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation following by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.
11052033|NCT04414995|Experimental|Paracetamol+normal saline|Patients in Group 2 will receive 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation following by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.
11052034|NCT04414995|Experimental|Ibuprofen+normal saline|Patients in Group 3 will receive 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation following by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours.
11052035|NCT04414982|Experimental|Intervention Values Affirmation|Compare the effects of the values-affirmation exercise with a control exercise in AI/AN patients with hypertension.
11052036|NCT04414982|Active Comparator|Control Values Affirmation|Compare the effects of the values-affirmation exercise in AI/AN patients with its effects in white patients.
11052037|NCT04414969|Experimental|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1; PEG-ASP 2500U/m2 im d1; Chidamide, 30mg, PO, on d1，d5，d8，d12，d15，d19; repeat every 3 weeks.
11052038|NCT04414956|Other|Surveillance|All participants will be examined with three biomarker tests and sonography every six months and contrast-enhanced CT annually.
11052039|NCT04414943|Experimental|S-katamine group|For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
11052040|NCT04414943|Placebo Comparator|Placebo group|For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
11052041|NCT04414930|Placebo Comparator|TCT + PBO|
11052042|NCT04414930|Active Comparator|TCT + AMPH|
11052043|NCT04414917|Experimental|Twin Block local anesthetic|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s
11052044|NCT04414917|Sham Comparator|Control|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block injection but with no medication administered/dispensed from the syringe, on the side/s of their extraction/s
11052077|NCT04414722|Other|Amoxicillin-clavulanate|Amoxicillin-clavulanate 875 mg-125 mg oral tablet
11052046|NCT04414904||Control Group|"Men 18-50 years of age
~Already attending hospital for another reason
~Low risk of prior COVID-19 infection:
~EITHER Negative positive COVID-19 PCR test result within last 4 weeks
~OR no history suggestive of COVID-19 illness"
11052047|NCT04414891|Experimental|NAVA arm|"Delivery of NIV-NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.
~Subjects randomised to this arm will undergo placement of Edi catheter and will be initiated on NIV. Appropriate NAVA level will be selected based on the scalars corresponding to stable ventilation in pressure support mode. During NAVA, the NAVA level would be increased in multiples of 0.2 cm H2O/µV to attain favourable response (tidal volume 6-8mL/kg RR ≤25). Once the patient's clinical condition stabilises, and the Edi maximum starts declining or remains unchanged with stable tidal volumes, NAVA level will be decreased in steps of 0.2 cm H2O/μV every 2 hours. If response to new settings is not favourable earlier settings will be restored. If favourable response is attained the weaning is continued until peak pressure is <12cm H20 and PEEP requirement is <5cm H2O. NIV will be replaced by a venture mask to titrate SpO2 between 88-92%"
11052048|NCT04414891|Active Comparator|ASV arm|Patients randomised to the ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland). The patients will be ventilated with an initial setting of 100%-minute volume (MV%). Increments of 10% will be made every 15 minutes to achieve clinical response (relief of dyspnea, RR<30, and tidal volume 6-8mL/kg). The expiratory trigger sensitivity will be set at 35% and adjusted accordingly. PEEP will be commenced at 3-4 cm H2O and increased by 1 cm of H2O to achieve SpO2 between 89-92% and maximum PEEP of 10 cm of H2O. Weaning would be performed by reducing the MV% gradually in decrements of 10%/hour to a MV% of 60% after the peak inspiratory pressure decreases to <8 cm of H2O, and the respiratory rate is < 28 breaths per minute and patient is able to maintain SpO2 > 90% at FiO2< 30%. Once the patient is comfortable on these settings, NIV will be replaced with oxygen supplementation using a venturi mask to maintain SpO2 between 89 and 92%.
11052049|NCT04414878|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
11052050|NCT04414865||single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
11052051|NCT04414852|Experimental|mild renal impairment|
11052052|NCT04414852|Experimental|moderate remal impairment|
11052053|NCT04414852|Active Comparator|normal renal impairment|
11052054|NCT04414839|Active Comparator|Digital Intubation (Two-finger)|
11052055|NCT04414839|Active Comparator|Video Laryngoscopy|
11052056|NCT04414826|Active Comparator|Mindfulness + Compassion (MC) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching both mindfulness and compassion skills.
11052057|NCT04414826|Active Comparator|Mindfulness Alone (MO) Intervention|Subjects assigned to this condition will participate in an hour-long, one-session telehealth intervention teaching mindfulness skills alone.
11052058|NCT04414826|Placebo Comparator|Waitlist Control (WL)|Those in the wait-list control condition will wait one week and complete a one-week follow-up assessment before being randomized to one of the two intervention conditions.
11052059|NCT04414813|Experimental|hAESCs treatment|hAESCs of 50 million transplant to Parkinson's disease participants.
11052060|NCT04414800|Placebo Comparator|Control (Placebo+ Standard of Care))|
11052061|NCT04414800|Active Comparator|Ketamine + Standard of Care|
11052062|NCT04414800|Active Comparator|Fentanyl + Standard of Care|
11052063|NCT04414787|Active Comparator|Intervention|PCplanner intervention during hospitalization
11052064|NCT04414787|No Intervention|Usual care control|Usual care
11052065|NCT04414774|Experimental|using app first|The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
11052066|NCT04414774|Active Comparator|waiting list|During the first 15 days, the control group is inactive (T1). After 15 days (T2) the control group will start using GGSI app for additional 15 days (T3). Participants will fill questionnaires about suicide ideation and related risk factors three time during the study on: T1, T2 and T3.
11052067|NCT04414761|Active Comparator|Antagonist group|Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
11052068|NCT04414761|Experimental|PPOS group|Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger.
11052069|NCT04414748|Active Comparator|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
11052070|NCT04414748|Experimental|PPOS group|Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
11052071|NCT04414735|No Intervention|1- Control group (Standard immunosuppression)|1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.
11052072|NCT04414735|Experimental|2- Treatment group (ECP+Standard immunosuppression)|2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department
11052073|NCT04414722|Placebo Comparator|Concurrent control yogurt and amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
11052074|NCT04414722|Placebo Comparator|Control yogurt taken 4 hours after amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
11052075|NCT04414722|Active Comparator|Concurrent BB-12 yogurt and amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
11052076|NCT04414722|Active Comparator|BB-12 yogurt taken 4 hours after amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
11052078|NCT04414709|Experimental|Two short implants|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
11052079|NCT04414709|Active Comparator|Single short implant|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
11052080|NCT04414696|Experimental|Intervention|Participants will be asked to use a web-based (eHealth) exercise intervention for 3 months. This eHealth exercise intervention includes over 90, 10-minute exercise videos with options for exercise type, time, and intensity, customized to the weight of the infant. Users can either select up to three 10-minute videos to create a 10 to 30-minute workout or choose a 'Ready Made' workout that is either 10, 20, or 30-minutes long.
11052081|NCT04414696|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard care as suggested by their provider. Participants will complete the same assessments and incentives as the active intervention but will not receive the eHealth exercise intervention.
11052082|NCT04414644|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
11052083|NCT04414644|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
11052084|NCT04414631|Active Comparator|active treatment arm|treatment with conestat alfa in addition to standarf of care
11052085|NCT04414631|No Intervention|Standard of care treatment arm|Standard of care treatment established at the centers
11052086|NCT04414618|Active Comparator|opaganib|Study participants will receive opaganib 2 x 250 mg capsules (500 mg) every 12 hours
11052087|NCT04414618|Placebo Comparator|placebo|Study participants will receive placebo 2 x 250 mg capsules (500 mg) every 12 hours
11052088|NCT04414605|Experimental|Chinese herbal medicine in combination with secukinumab|Oral Chinese herbal medicine (Gu Ben Hua Yu Fang decoction) and secukinumab will be used concurrently. The treatment duration for both secukinumab and oral Chinese herbal medicine is up to 16 weeks. Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg). Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice a day. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
11052089|NCT04414592|Experimental|Human Umbilical Cord Mesenchymal Stem Cells|Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc
11052090|NCT04414579|No Intervention|No Intervention: Conventional Insulin Aspart (NovoLog®)|In the aspart group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
11052091|NCT04414579|Active Comparator|Faster Insulin Aspart (Fiasp®)|In the Fiasp group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Fiasp is put into their pump and delivered to their body through a small tube placed under their skin. In this Fiasp treatment group, the subject will take fiasp with each meal while their pump also gives them a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
11052092|NCT04414566|Experimental|IC plus RT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m^2) every three weeks for three cycles during radiotherapy.
11052093|NCT04414566|Active Comparator|IC plus CCRT|Patients receive GP(gemcitabine+cisplatin) or TPF(docetaxel+cisplatin+fluorouracil) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy.
11052094|NCT04414553|Experimental|Community-AHF|Participants in this arm will receive the 10 month Community Active and Healthy Families Intervention
11052095|NCT04414553|No Intervention|Wait List|Participants in this arm will receive routine primary care follow up for childhood overweight/obesity. After the 10 month experimental period they will be offered the Community Active and Healthy Families Intervention but participation is not required.
11052096|NCT04414540|Experimental|Arm 1: Metformin before Pembrolizumab|Metformin ER 1000mg daily D-14 to D-7. Metformin ER 2000mg daily D-7 to D1. D1 Begin Pembrolizumab 200mg every 3 weeks, while continuing Metformin ER 2000mg daily.
11052097|NCT04414540|Experimental|Arm 2: Metformin after Pembrolizumab|D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
11052098|NCT04414527|Other|Standard counseling|Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines. In the standard health care, pregnant women receive a minimum of four ante-natal care visits at the health centers during which they also receive iron and folic acid supplementation. They participate in monthly forums facilitated by nurses to answer questions and concerns regarding nutritional care.
11064301|NCT04326829|Experimental|QL1604 Injection|
11052099|NCT04414527|Experimental|Health-Video|Women in the Health-Video group will receive home visits for delivery of healthy nutrition messages using prepared video-based messages every two weeks. They will also participate in monthly forums facilitated by nurses using also videos for demonstration of nutritional care. During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show coordinated by a nurse/ health professional for any questions. During postnatal period, two counseling sessions will be delivered within two weeks of birth, and 12 sessions or twice every month till 6 months.
11052100|NCT04414514|Experimental|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
11052101|NCT04414501|Active Comparator|Tablet study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
11052102|NCT04414501|Active Comparator|VR study group|Anxiety at separation from caregiver was measured by the modified Yale Preoperative Anxiety Scale (mYPAS). Caregiver anxiety was measured using the State-Trait Anxiety Inventory for Adults (STAI), a validated self-evaluation questionnaire. Mask acceptance, a functional evaluation of stress at the time of induction, was determined using the Mask Acceptance Scale.
11052103|NCT04414488||Patient controlled analgesia|General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
11052104|NCT04414488||Thoracic paravertebral block and patient controlled analgesia|Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
11052105|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-40 BIW)|Participants will receive fixed dose of 40 milligram (mg) of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet twice weekly (BIW) on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle.
11052106|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-100 QW)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet followed by 40 mg of low-dose Dexamethasone oral tablet once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone may be given as 20 mg on days 1 and 2 of each week).
11052107|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-80 BIW)|Participants will receive fixed dose of 80 mg of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet BIW on Days 1, 3, 8, 10,15, 17, 22, and 24 of each 28-day cycle.
11052108|NCT04414475|Experimental|Selinexor + Bortezomib + Dexamethasone (SVd)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet on Days 1, 8, 15, 22, and 29 followed by 1.3 milligram per square-meter (mg/m^2) of Bortezomib subcutaneous (SC) injection on Days 1, 8, 15, and 22 and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, 22, and 29 of each 35-day cycle (Dexamethasone dose may be split to 20 mg on days 1 and 2).
11052109|NCT04414462|Experimental|Group I|Group I will receive following exergaming training: heading, tightrope tension,snowboard slalom and table tilt game
11052110|NCT04414462|Active Comparator|Group II|Group II will receive Habituation,wobble board exercises,double leg,single leg and tandem stance training.
11052111|NCT04414449|Experimental|Intervention group|During the tutoring time, the intervention program is carried out in the experimental group, through emoTIC. EmoTIC is an emotional education program focused on the development of social-emotional competences through an application that can be used in mobile devices and tablets. It takes place in the classroom.
11052112|NCT04414449|No Intervention|Control group|During the period in which the intervention program is conducted in the experimental group, the control group will carry out the activities established by the school during the tutoring time.
11052113|NCT04414436|Experimental|GYNEA- digital coping program|Participants randomized to this arm will receive active treatment after the inclusion
11052114|NCT04414436|No Intervention|Waiting list|6 weeks waiting list before crossing over to GYNEA- digital coping program
11052115|NCT04414423|Experimental|Bone marrow concentrate|Bone marrow concentrate combined with Autogenous bone graft
11052116|NCT04414423|Active Comparator|autogenous bone graft|grafting with autogenous bone graft
11052117|NCT04414397|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM VOLUMA® XC injectable gel in temple. Participants are eligible for touch up treatment.
11052118|NCT04414397|No Intervention|Control- No treatment|No treatment is administered. Optional treatment at month 3.
11052119|NCT04414384|Experimental|Abdominal Binder|During this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
11052120|NCT04414384|Other|Control|This group of patients will not wear abdominal binders, but during this time they will wear a step counter and track their steps. This step counter will be returned at the time of their two week visit.
11052121|NCT04414371|Experimental|Group 1 - Yoga Group|Learn online yoga practices and practice daily for 12-weeks
11052122|NCT04414371|Other|Group 2 - Control Group|waist-list control for 4-week, cross-over to yoga practice for 8-week
11052124|NCT04414345|Placebo Comparator|Matching Placebo|"Administration: Oral
~Dosage: 2 bottles daily"
11052125|NCT04414306|Experimental|Experimental Arm 1|Attendees at in-person events (e.g. health fairs) who meet eligibility criteria will be able to enroll and participate in-person, with some participating in online or telephone survey follow-up.
11052126|NCT04414306|Experimental|Experimental Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up.
11052127|NCT04414306|Experimental|Experimental Arm 3|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up. This arms will serve as an experimental arm for assessing study aim 2 and as a control arm for study aim 1.
11052128|NCT04414293|Experimental|Treatment|All the patients will be treated with low dose lung radiation
11052129|NCT04414280||type 1 diabetes patients using Medtronic MiniMedTM 670G|Patients with type 1 diabetes, aged 18 years or older, who start with the Medtronic MiniMedTM 670G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
11052130|NCT04414267|Experimental|BCG vaccine|One intradermal injection of 0.1ml of BCG (BCG vaccine Moscow strain 361-1; Serum Institute of India Pvt. Ltd)
11052131|NCT04414267|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
11052132|NCT04414254|Experimental|conference-Cefprozil for Suspension®|"Cefprozil for Suspension® (125mg/5ml, 50ml/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.)"
11052133|NCT04414254|Experimental|test-cefprozil granule|cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd)
11052134|NCT04414241|Experimental|Hydroxychloroquine|Hydroxychloroquine prophylaxis plus standard measures of personal protection.
11052135|NCT04414241|No Intervention|Control|Standard measures of personal protection.
11052136|NCT04414228|Active Comparator|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
11052137|NCT04414228|Active Comparator|ProAQT in guiding goal-directed hemodynamic therapy|Subjects randomized to the GDT group will be managed according to the ERAS algorithm utilizing ProAQT variables (mean arterial pressure, stroke volume variation and cardiac index) If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
11052138|NCT04414215|Experimental|Cognitive training|Emotional working memory training
11052139|NCT04414215|Placebo Comparator|Placebo training|Placebo working memory training
11052140|NCT04414202||1 GROUP|"Patient with an Invasive breast cancer with a good prognosis that is accessible to breast-conserving surgery.
~The treatment combines extended tumorectomy with axillary dissection (sentinel lymph node) in addition to 20 Gy of per-operative partial irradiation at the tumor Follow up after this treatment will scheduled 10 years"
11052141|NCT04414189||Arm A|Patients with suspected sepsis at the time of admission to the ICU
11052142|NCT04414189||Arm B|Patients not currently suspected but at high risk for sepsis.
11052143|NCT04414176||Case|Patients with coronary artery stenosis more than 75% (or left-main stenosis more than 50%) are defined as case group
11052144|NCT04414176||Control|Patients with normal angiography are considered as control group.
11052145|NCT04414163|Experimental|IMC-001|Single Dose level (IMC-001 20mg/kg, every 2 weeks)
11052146|NCT04414150|Experimental|SHR-1802|
11052147|NCT04414137||Eosinophilic pneumonia on daptomycin|patients having an osteoarticular infection treated with daptomycin and which developped eosinophilic pneumonia
11052148|NCT04414124|Other|KB109 + Self Supportive Care (SSC)|
11052149|NCT04414124|Other|Self Supportive Care (SSC) Alone|
11052150|NCT04414111||Kidney transplant recipient|Kidney transplant recipient
11052151|NCT04414072|Active Comparator|laparoscopic sleeve gastrectomy|
11052152|NCT04414072|Active Comparator|mini gastric bypass|
11052153|NCT04414072|Active Comparator|sleeve gastrectomy with loop bipartition|
11052154|NCT04414046|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
11052155|NCT04414033|Experimental|research group|
11052156|NCT04414020|No Intervention|Control|Control group receiving conventional treatment without progesterone
11052157|NCT04414020|Active Comparator|progesterone group|1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
11052158|NCT04414007|Experimental|Internet+ home-based cardiac rehabilitation group|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
11052159|NCT04414007|Active Comparator|conventional care group|The UC-assigned patients will maintain standard of care.The conventional rehabilitation group received routine medical care and traditional home-based cardiac rehabilitation based on the rehabilitation manual and exercise diary, followed up by telephone and outpatient.
11052160|NCT04413994|Active Comparator|Randomized study product group|"receiving study product (human milk fortifier Humavant) until a gestational age of 36 weeks"
11052161|NCT04413994|Active Comparator|Randomized control group|receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation
11052162|NCT04413994|No Intervention|Term control group|Term-born controls as a reference group for outcome parameters
11052163|NCT04413968|Experimental|Interventional|nasopharyngeal and blood sample
11052164|NCT04413942|Active Comparator|FB825|FB825
11052165|NCT04413942|Placebo Comparator|Placebo|Formulation buffer
11052166|NCT04413903|Active Comparator|Pressure controlled ventilation, Volum controlled ventilation|Undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled ventilation settings were adjusted to be 50% O2- 50% air, 8ml / kg TV (tidal volume) and PEEP 5.
11052167|NCT04413903|Active Comparator|Optic Nerve Sheath Diameter|In optic nerve diameter measurements; A layer of water-soluble sterile gel was applied to the closed upper eyelid. The linear 10-5 MHz ultrasound probe was carefully placed on the upper eyelid over the gel. The entrance of the optic nerve to the orbital globe in 2D mode was displayed on the monitor without applying too much pressure. After finding the optimal contrast between the retrobulbar echogenic fat tissue and vertical hypoechoic band 23, the diameter of the optic nerve sheath was measured 3 mm behind the optic disc using an electronic caliper.
11052168|NCT04413890|Active Comparator|Classical administration|One prostaglandin vaginal gel every 24 hours
11052169|NCT04413890|Experimental|Experimental administration|One prostaglandin vaginal gel every 12 hours
11052170|NCT04413877||Descriptive cohort study|"Prospective cohort study of community-dwelling adults ≥65-year-old living at home, with no other exclusion criteria than the inability to use the ICOPE Apps or communicate by telephone/video-call for any reason (cognitive or limited access to technologies like telephone/video-call).
~Cohort study, designed to determine the incidence of frailty in community-dwelling older people during 1-year follow-up, starting the recruitment at a certain point of the COVID-19 pandemic and beyond."
11052171|NCT04413864|Other|SARS-CoV-2 (Covid-19 positive)|Patients hospitalized in intensive care unit (ICU), infected with SARS-CoV-2
11052172|NCT04413851||Dementia|Subjects with a diagnosis of dementia who are experiencing agitation severe enough that it interferes with activities of daily living or social interaction.
11052173|NCT04413838|Experimental|NIVOLUMAB on top of routine standard of care|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND aspartate aminotransferase (AST) > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a NIVOLUMAB treatment and routine standard of care for COVID-19 infection at the time of study inclusion
11052174|NCT04413838|Other|Standard of care for COVID-19 infection|This correspond to COVID-19+ patients diagnosed upon biological testing (PCR Coronavirus SARS-CoV2), hospitalized, obese (BMI≥30kg/m²), with low lymphocyte counts, without high biological probability of macrophage activation syndrome (hemoglobin < 9.2 g/dl AND a blood platelets < 110000/mm3 AND AST > 30 U/l AND ferritin > 600 mg/l) and upon oxygen (either using mask or nasal cannula) but without criteria for ICU admission benefiting from a routine standard of care for COVID-19 infection at the time of study inclusion
11052175|NCT04413812|Experimental|Experimental Group|The experimental group will participate in a 3-months training programme focusing on health competence related outcomes.
11052176|NCT04413812|No Intervention|Control Group|The control group does not participate in the exercise programme but undergoes identical outcome assessments.
11052177|NCT04413799|Active Comparator|lidocaine/ ketamine infusion|Lidocaine/ ketamine infusion will be monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
11052178|NCT04413799|Active Comparator|paravertebral block with ropivacaine|Paravertebral block catheter will be placed by Anesthesiology led Acute Pain Service. Once the catheter is inserted, a ropivacaine bolus and infused with ropivacaine, monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
11052179|NCT04413786|Experimental|oxytocin group|male subjects with oxytocin treatment
11052180|NCT04413786|Placebo Comparator|placebo group|male subjects with placebo treatment
11052181|NCT04413773|Active Comparator|Treatment as usual|Treatment as Usual, Explanation of standard procedures before, during and after surgery by nurse
11052182|NCT04413773|Experimental|Treatment as usual + Video|Treatment as usual and additionally Video
11052183|NCT04413747|Experimental|Yoga-based breathing support|Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
11052184|NCT04413734|Experimental|Triprilumab in combination with chemotherapy of GP|Triprilumab, 240 mg, every 3 weeks (Q3W), Day 1 of each 3 week cycle PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity .
11052185|NCT04413734|Active Comparator|Mono-chemotherapy of GP|Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity.
11052186|NCT04413721|Experimental|Short-term storage RBCs (stored for ≤ 14 days)|patients in this group were transfused with short-term storage RBCs (stored for ≤ 14 days).
11052187|NCT04413721|Active Comparator|Longer-term storage RBCs (stored for ≥21 days)|patients in this group were transfused with longer-term storage RBCs (stored for ≥21 days).
11052188|NCT04413708|Experimental|P3-T PrEP adherence app|"Intended app use includes, at a minimum, participant completion of selected app activities (medication tracking, daily quest, social wall post) each day for the 3 month intervention period.
~Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit."
11052189|NCT04413708|No Intervention|Standard of Care|Participant completion of Standard of Care PrEP adherence and sexual risk behavior counseling at the 1-month post-prescription visit and the 4-month post-prescription visit.
11052190|NCT04413682|Experimental|Supervised Exercise Group|One session per day, 3 days per week over a 12-weeks structured exercise program under supervision of a physical therapist.
11052191|NCT04413682|Experimental|Telerehabilitation Group|One session per day, 3 days per week over a 12-weeks structured exercise program through Telerehabilitation
11052192|NCT04413669|Experimental|white light bronchoscopy and autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out for people at high risk for lung cancer with heavy smoking (smoking history> 400 years).Biopsy was taken for abnormal bronchial mucosa.
11052225|NCT04413435||Confirmed COVID-19 cases|Patients with PCR test positive were considered as the confirmed COVID-19 cases.
11052193|NCT04413656|Experimental|ablation group|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
11052194|NCT04413656|Experimental|surgery group|Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
11052195|NCT04413643|Experimental|Noninvasive Ventilation|Subjects will be introduced to NIV and educated on sleep disordered breathing. NIV will be initiated during hospitalization following resolution of acute respiratory failure. NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment. Initial settings will be set with goals of tolerance and acceptance of therapy. Minimum pressure difference between IPAP and EPAP settings will be 5cmH20. Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used. Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device. Data from the device will be reviewed the following day. Tolerance, mask comfort, and acceptance of therapy will be assessed. Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
11052196|NCT04413630|Experimental|Study group|family workshop
11052197|NCT04413617|Experimental|PF-06650833 + tofacitinib|
11052198|NCT04413617|Experimental|PF-06650833 + PF-06651600|
11052199|NCT04413617|Experimental|PF-06650833|
11052200|NCT04413617|Experimental|PF-06651600|
11052201|NCT04413617|Experimental|Tofacitinib|
11052202|NCT04413604|Experimental|YCM Group (1- <3) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
11052203|NCT04413604|No Intervention|Observation Group (1-<3) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
11052204|NCT04413604|Experimental|YCM Group (3-5) Years old|2 servings / day of the investigational (test) young children's milk (YCM) for 16 weeks
11052205|NCT04413604|No Intervention|Observation Group (3-5) Years old|Habitual diet, consume the same regular foods and drinks as the children would normally
11052206|NCT04413591|Experimental|Intervention Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
11052207|NCT04413591|No Intervention|Control Area|Participants are assigned to the intervention area or the control area based on the location they were recruited in.
11052208|NCT04413578|Experimental|Dexcom G6 (Intervention Group)|• Intervention group: CGM using a Dexcom G6 to measure glycosylated hemoglobin levels every five minutes. Patients will be asked to download the Dexcom G6 and Clarity applications (to have access to their real-time data) and be given a link to complete an exit survey in REDCap near the end of their study participation. Data will be sent via Bluetooth and then exported by the Intermountain research team into a Tableau (or similar) dashboard for data analysis/comparison
11052209|NCT04413578|Placebo Comparator|Contour NextOne (Standard of Care) Glucometer|• Control group: A standard finger-prick protocol that will require patients to continue with their daily fingerprick regimen established by their physician. This group will be given a Contour Next One meter to ensure that each patient is receiving the same level of accuracy by the same device. A review by Ekhlaspour et al of 17 glucose meters demonstrated wide variability, with only two devices achieving the 2013 ISO standard (with the most accurate being the Contour Next). Patients in the control group will be asked to download the Contour Next application which will send data via Bluetooth similar to above. Data will be aggregated, and protected health information removed prior to analysis (by Intermountain Healthcare and Savvysherpa). At the end of the study, patients will be asked to complete a short survey in REDCap about their willingness to participate in future studies.
11052210|NCT04413565|Experimental|Two surgeon bilateral TKA group|2 surgeons will perform simultaneous total knee arthroplasty in this group.
11052211|NCT04413565|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
11052212|NCT04413552|Experimental|Part I-Active arm|Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort
11052213|NCT04413552|Placebo Comparator|Part II-Placebo arm|Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort
11052214|NCT04413552|Experimental|Part II-Active arm-fed|Study medication will be administered after a high fat meal. Dose to be determine based on a well-tolerated dose studied in Part I.
11052215|NCT04413552|Experimental|Part II-Active arm-fasting|Study medication will be administered under fasted conditions. Dose to be determine based on a well-tolerated dose studied in Part I.
11052216|NCT04413526||radiofrequency-assisted liver resection|radiofrequency-assisted liver resection for intractable liver cancer
11052217|NCT04413526||TACE(transcatheter arterial chemoembolization)|temporary TACE for intractable liver cancer
11052218|NCT04413526||radiofrequency ablation plus TACE|radiofrequency ablation plus TACE for intractable liver cancer
11052219|NCT04413513|Experimental|Integrated Attention Training Program|"The intervention group (I) will receive integrated attention training program (IATP) on a variety of structured attention tasks by an intervention instructor. It is considered to be simple and safe but effective enough for cognitive health promotion."
11052220|NCT04413513|Placebo Comparator|Health Education|The control group (C) will receive health educational sessions on health concerns and physical diseases commonly found in old age during the invention period.
11052221|NCT04413500|Experimental|adaptive intervention|The patients will receive various adaptive digital interventions through mobile app.
11052222|NCT04413474||Study group|Unselected critically ill patients who met the inclusion criteria
11052223|NCT04413461|Experimental|TENS|
11052224|NCT04413461|Placebo Comparator|TENS Sham|
11052226|NCT04413435||Suspected COVID-19 cases|The suspected COVID-19 cases were defined as follows: those who were interpreted in favor of the suspected covid-19 on c-CT by radiologists in addition to the typical symptoms of the novel coronavirus disease such as cough, high fever (>38,5 °C), or dyspnea, and those with a history of contact with another confirmed COVID-19 patient in addition to typical symptoms.
11052227|NCT04413422||propofol|Those patients planned for general surgery, who received propofol as an induction agent for general anesthesia.
11052228|NCT04413422||etomidate|Those patients planned for general surgery, who received etomidate as an induction agent for general anesthesia.
11052229|NCT04413422||thiopental|Those patients planned for general surgery, who received thiopental as an induction agent for general anesthesia.
11052230|NCT04413409|Experimental|surgical group|The metastatic sites are firstly treated by surgery then followed by systemic treatment
11052231|NCT04413409|No Intervention|systemic group|After confirmation of puncture, receive systemic treatment
11052232|NCT04413396||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
11052233|NCT04413383|Active Comparator|Traditional Curved Iris Scissors|The traditional curved Iris scissors are used to during the dermatologic surgery. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
11052234|NCT04413383|Experimental|Modified Curved Iris Scissors|"The Wuennenberg modified curved Iris scissors are used during the dermatologic surgery.
~Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure."
11052235|NCT04413383|Other|Comparative Experience|Both the traditional and modified curved Iris scissors are used and patients are asked which they prefer. Patients complete a survey after the surgery on sights, sounds and smells experienced during the procedure.
11052236|NCT04413370||Referral Group (no MGD)|This group of subjects was diagnosed with dry eye (without meibomian gland dysfunction) and need to be a referral to the hospital for further treatments.
11052237|NCT04413370||Referral Group (MGD)|This group of subjects was diagnosed with meibomian gland dysfunction and need to be a referral to the hospital for further treatments.
11052238|NCT04413370||Artificial tears group|This group of subjects was diagnosed with dry eye but can use artificial tears instead of further treatment.
11052239|NCT04413370||Normal control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
11052240|NCT04413357|Active Comparator|Oral Nutrition Supplement|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition.
11052241|NCT04413357|Active Comparator|Oral Nutrition Supplement - DMA|The study interventions contain protein, carbohydrate and fat and are intended for use as retail Supplemental Nutrition for people living with diabetes.
11052242|NCT04413357|Active Comparator|Oral Nutrition Supplement - DMB|The study interventions contain protein, carbohydrate and fat and are intended for use as Supplemental Nutrition for people living with diabetes.
11052243|NCT04413344|Active Comparator|Active|
11052244|NCT04413344|Placebo Comparator|Placebo|
11052245|NCT04413331||Vasculitis|Those with systemic vasculitis
11052246|NCT04413318|Experimental|electronic device followed by pneumatic device|Children receive continuous control of tracheal cuff pressure with the electronic device (VBM©) for 6-hours followed by continuous control of tracheal cuff pressure with the pneumatic device (Nosten©) for 6-hours.
11052247|NCT04413318|Experimental|pneumatic device followed by electronic device|Children receive the reverse sequence (continuous control using the pneumatic device (Nosten©) for 6-hours followed by the electronic device (VBM©) for 6-hours
11052248|NCT04413305|Experimental|WGS-based screen and control group|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
11052249|NCT04413305|No Intervention|Non-intervention|Non-intervention
11052250|NCT04413292||Group A|21 patients with lung cancer
11052251|NCT04413292||Group B|21 patients with various benign lung diseases
11052252|NCT04413292||Group C|Healthy controls
11052253|NCT04413292||Group D|15 patients with malignant pleural mesothelioma (MPM)
11052254|NCT04413292||Group E|16 patients having various benign pleural diseases
11052255|NCT04413279|Active Comparator|Lipiflow Only Group|Patients with dry eye disease Lipiflow only
11052256|NCT04413279|Experimental|Lipiflow + Dextenza Group|Patients with dry eye disease Lipiflow + Dextenza
11052257|NCT04413266|Active Comparator|Curcumin for CKD|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
11052258|NCT04413266|Placebo Comparator|Placebo for CKD|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
11052259|NCT04413253|Active Comparator|Xiidra Only Group|Patients with dry eye disease Xiidra only
11052260|NCT04413253|Experimental|Xiidra + Dextenza Group|Patients with dry eye disease Xiidra + Dextenza
11052261|NCT04413240|Experimental|Telerehabilitation group|"Patients in this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain telerehabilitation (motor, speech and/or cognitive) with VRRS, K-Wand and Khymu connected to a workstation (Telecockpit)."
11052262|NCT04413240|Active Comparator|Conventional rehabilitation group|"The patients assigned to this group will undergo 20 sessions (1 hour a day, 5 days a week for 4 consecutive weeks) of multidomain rehabilitation (motor, speech and/or cognitive). It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated."
11052263|NCT04413227|Experimental|PEG-ENDO+Docetaxel|PEG-ENDO( 1 mg/kg or 2mg/kg or 4mg/kg or 6mg/kg or 8mg/kg）+Docetaxel 75 mg/m2，once every 3 weeks at day 1
11052301|NCT04412863|Experimental|Cohort 3d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
11052302|NCT04412863|Experimental|Cohort 1e|VIR-2218 given by subcutaneous injection
11052264|NCT04413214|Experimental|Test Group|The 3x3 dose escalation design will be adopted, including 200mg, 400mg and 600mg of Carrimycin; and three subjects at each dose level initially. If there is no DLT in the dose level of 200mg, the dose level of 400mg will be followed; if there is one DLT in the dose level of 200mg, another three patients will be added in the dose level of 200mg; if there is no DLT occurs in the another three patients, the dose level of 400mg will also be followed; if there is one DLT in the another three patients, the trial will be closed. The same condition to the dose level of 400mg and 600mg.
11052265|NCT04413201|Experimental|Afatinib|Afatinib followed by osimertinib or ICT depending on T790M status
11052266|NCT04413201|Active Comparator|Osimertinib|Osimertinib followed by ICT
11052267|NCT04413188|Experimental|A warm foot bath group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
11052268|NCT04413188|No Intervention|Control group|65years, relative independent in daily life activities and literate, having a PSQI score of 5 or more and no communication problems.
11052269|NCT04413175|Experimental|a music group|Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.
11052270|NCT04413175|No Intervention|control group|control group
11052271|NCT04413162|Other|measurement before and after capsular distention|
11052272|NCT04413136|Experimental|Web-ORLA|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.
~The participant is presented with 3-5 word (level 1) or 8-10 word (level 2) sentences, depending upon the severity of the aphasia. Each sentence is chosen by the software program at random from a group of 150 sentences. The participant is instructed to look, listen, and point to words spoken by the virtual therapist, read highlighted words aloud, and then read the sentence aloud, both chorally with the virtual therapist and independently."
11052273|NCT04413136|Placebo Comparator|Control|"Administered 90 minutes a day, six days a week ( i.e. nine hours of computer treatment per week) for a total of six weeks.
~A commercially available game, Bejeweled 2, by PopCap. Participants use loaned 13-in laptop computers to access the Bejeweled interface, which displays an 8 X 8 grid of gems of varying shapes and colors. The objective is to match three gems of the same color and shape to score points and advance to more difficult levels."
11052274|NCT04413123|Experimental|Cabozantinib|"Eligible patients will be enrolled and receive treatment with
~Cycle 1-4 (cycles of 21 days)
~Cabozantinib predetermined protocol dosage po daily
~Nivolumab predetermined protocol dosage via IV every 3 weeks
~Ipilimumab predetermined protocol dosage via IV every 3 weeks
~After the first four cycles of therapy,
~Cabozantinib determined protocol dosage po daily
~Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)"
11052275|NCT04413110||Non-subjective cognitive impaired|Cases of migraine and non-subjective cognitive impaired
11052276|NCT04413110||Subjective cognitive impaired|Cases of migraine and subjective cognitive impaired
11052277|NCT04413110||Control group|Age and sex matched healthy controls
11052278|NCT04413097|Active Comparator|DCC and Low Oxygen Concentration|During 60 seconds of delayed cord clamping and oxygen blender set at FiO2 .30, breathing assistance with CPAP of 5 cmH20 or positive pressure ventilation (starting PIP of 20 cmH20) is provided. The infant will remain on this support up until the umbilical cord is clamped. Once the cord is clamped, resuscitation will continue according to unit protocol.
11052279|NCT04413097|Experimental|DCC and High Oxygen Concentration|During 60 seconds of delayed cord clamping and oxygen blender set at FiO2 1.0, breathing assistance with CPAP of 5 cmH20 or positive pressure ventilation (starting PIP of 20 cmH20) is provided. The infant will remain on this support up until the umbilical cord is clamped. Once the cord is clamped, resuscitation will continue according to unit protocol.
11052280|NCT04413084|Experimental|Gaze stability exercises|Group I will receive Gaze stability exercises.
11052281|NCT04413084|Experimental|Brandt-Daroff Exercises|Group II will receive Brandt-Daroff Exercises.
11052282|NCT04413071||Health care workers|Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
11052283|NCT04413058||Female healthcare workers|Healthy female healthcare workers at Covid 19 clinic in Istanbul, Turkey
11052284|NCT04413045||C Group|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
11052285|NCT04413032|Experimental|Patients with MS|30 Patients with MS will use the DreaMS App over a study duration of 6 weeks.
11052286|NCT04413032|Experimental|Healthy Volunteers|30 Healthy Volunteers will use the DreaMS App over a study duration of 6 weeks.
11052287|NCT04413019||Group (D): Planned domiciliary care.|Patients within this group will be counseled for home care with self-monitoring for any symptoms suggestive of preterm labor, maternal or fetal distress.
11052288|NCT04413019||Group (H): Planned hospital care.|Patients within this group will be admitted at hospital for close monitoring of maternal & fetal wellbeing & finally the neonatal outcome
11052289|NCT04413006|Experimental|Treatment Arm|Participants who will receive the 6-session Group-Based Virtual Self-Compassion for Chronic Pain treatment
11052290|NCT04412967|Active Comparator|Standard Technique PVC placement|Standard PVC placement technique
11052291|NCT04412967|Experimental|DUST|Dynamic ultrasound-guided short-axis needle tip navigation (DUST)
11052292|NCT04412954|Experimental|Intervention|Health coach with Smartphone application for diet and physical activity
11052293|NCT04412954|No Intervention|Control|No intervention, using a Smartphone application for sleep monitoring
11052294|NCT04412941|Experimental|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
11052295|NCT04412941|Active Comparator|Control group|the rules of sleep hygiene
11052296|NCT04412889|Experimental|CAR-T treatment group|The patients will receive BCMA/CD19 dual-target CAR-T cell treatment. BCMA/CD19 dual-target CAR-T cell dosage ranges from 2×10^5 to 1×10^6 CAR+T/Kg.
11052297|NCT04412876|Experimental|Duloxetine|Receive Duloxetine 30 mg treatment per day
11052298|NCT04412876|Active Comparator|Imipramine|Receive Imipramine 25 mg treatment per day
11052299|NCT04412863|Experimental|Cohort 1d|VIR-2218 given by subcutaneous injection
11052300|NCT04412863|Experimental|Cohort 2d|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
11052303|NCT04412863|Experimental|Cohort 2e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
11052304|NCT04412863|Experimental|Cohort 3e|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
11052305|NCT04412863|Experimental|Cohort 1f|VIR-2218 and pegylated interferon-alfa 2a given by subcutaneous injection
11052306|NCT04412850|Experimental|Control group|Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
11052307|NCT04412850|Placebo Comparator|placebo group|Normal Saline in equal volume as the control group.
11052308|NCT04412837|Experimental|CBD Patch|Topical CBD patch to be worn for 24 hours and changed daily for the course of 4 weeks.
11052309|NCT04412837|Placebo Comparator|Control Patch|Control placebo patch to be worn for 24 hours and changed daily for the course of 4 weeks.
11052310|NCT04412824|Active Comparator|Alcohol Beverage Cues|Participants will complete an MRI with alcohol beverage visual cues and oral alcohol session.
11052311|NCT04412824|Placebo Comparator|Non-Alcoholic Beverage Cues|Participants will complete an MRI with non-alcoholic beverage cues and oral alcohol session.
11052312|NCT04412811||Patients with hematological disease|Adult and children allogenic Hematopoietic stem cell transplantation recipients
11052313|NCT04412798|Other|group 1|orange juice concentrate
11052314|NCT04412798|Other|Group 2|Sugar-sweetened orange-flavoured beverage
11052315|NCT04412798|Other|Group 3|Whole orange juice with skin removed
11052316|NCT04412785|Experimental|Single Arm|Cyclosporine; oral or IV route of administration, per investigator discretion. Duration of administration up to 14 days, as tolerated.
11052317|NCT04412772|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen.
11052318|NCT04412772|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
11052319|NCT04412759|No Intervention|Porcine xenograft|porcine xenograft derived from dermal porcine skin. Standard of care treatement for partila thickness burn at the specfic centre
11052320|NCT04412759|Experimental|Microbial cellulose|Novel dressing consisting of a biopolymer spun by the bacteria Acetobacter xylinum (later removed).
11052321|NCT04412733|Experimental|Pulsed Ultrasound Group|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2 ) 5-min daily session, 5 days per weeks, for a total of 15 sessions.
11052322|NCT04412733|Sham Comparator|Sham Group|Control group received sham ultrasound with the same protocol.
11052323|NCT04412720|Experimental|Aerobic and Breathing Exercises|The experimental intervention will be aerobic and breathing exercises.
11052324|NCT04412720|Active Comparator|Aerobic and Stretching Exercises|The active comparative intervention will be aerobic and stretching exercises.
11052325|NCT04412707|Active Comparator|Arm A|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a PVC and cycle 2 and onwards melflufen will be administered via a CVC.
11052326|NCT04412707|Active Comparator|Arm B|Melflufen 40 mg iv Day 1 of each 28 day cycle. Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle, if > 75 years of age 20 mg. Cycle 1 will be administered via a CVC and cycle 2 will be administered via a PVC. From cycle 3 and onwards melflufen will be administered via CVC.
11052327|NCT04412694|Experimental|supplementation group|Patients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
11052328|NCT04412694|Placebo Comparator|placebo group|Patients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
11052329|NCT04412681|Experimental|PE Enhanced Screening|"The PE screening program entails the following for all participants:
~provision of additional demographic and risk factors
~provision of mean arterial pressure
~standard nuchal translucency scan as part of their first trimester screening (FTS) with the addition of the measurement of the uterine artery Doppler by a certified sonographer
~standard blood sample (as part of the FTS)
~results of the PE screening (in the format of a screening report) will be provided to the study team and participant's healthcare provider"
11052330|NCT04412668|Experimental|ATYR1923 1 mg/kg|Single dose of ATYR1923 1 mg/kg
11052331|NCT04412668|Experimental|ATYR1923 3 mg/kg|Single dose of ATYR1923 3 mg/kg
11052332|NCT04412668|Placebo Comparator|Placebo|Single dose of Placebo
11052333|NCT04412655||STEMI patients treated in March April 2019|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
11052334|NCT04412655||STEMI patients treated in March April 2020|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
11052335|NCT04412642|Other|methoxyflurane|methoxyflurane
11052336|NCT04412629|Experimental|Cabozantinib|-Cabozantinib 60 mg by mouth daily on days 1-21
11052337|NCT04412616|Experimental|ZZ06 0.03 mg/kg dose group|ZZ06 0.03 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11052338|NCT04412616|Experimental|ZZ06 0.06 mg/kg dose group|ZZ06 0.06 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11064329|NCT04326595|Active Comparator|medical termination|
11052339|NCT04412616|Experimental|ZZ06 0.12 mg/kg dose group|ZZ06 0.12 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11052340|NCT04412616|Experimental|ZZ06 0.22 mg/kg dose group|ZZ06 0.22 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11052341|NCT04412616|Experimental|ZZ06 0.39 mg/kg dose group|ZZ06 0.39 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11052342|NCT04412616|Experimental|ZZ06 0.70 mg/kg dose group|ZZ06 0.70 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11052343|NCT04412616|Experimental|ZZ06 1.00 mg/kg dose group|ZZ06 1.00 mg/kg will be administered twice weekly.A cycle is defined as continuous treatment for 28 days, and the initial treatment course is 2 cycles. Patients can receive up to 6 additional cycles unless disease progression, unacceptable toxicity, or other protocol specified stopping criteria occur. After 6 cycles, additional cycles may be given upon request by the Investigator and approval by the Medical Monitor.
11052344|NCT04412603|Experimental|Conventional Mirror Therapy group|"Therapy:
~-With the affected upper limb into the mirror box, perform the exercise with the non-affected extremity which is reflected in the mirror box. -The affected side must perform the corresponding movement within its possibilities, according to the exercise that is being performed with the healthy arm. - It is very important to look at the mirror at all times, which reflects the non-affected side while doing the exercises."
11052345|NCT04412603|Experimental|Mirror Therapy Virtual Reality group|"Therapy:
~-Perform the exercises with the non-affected limb, which must be watched constantly with virtual reality glasses, to interpret that this limb corresponds to the affected side. - The affected side accompanies the movement within its possibilities (out of sight of the patient, it can be covered with a handkerchief). - It is very important to look at the non-affected side. The affected side should be out of the visual field to avoid confusion."
11052346|NCT04412590|Experimental|Vermont Family Based Approach|"The VFBA group was offered a variety of supports and services to help them achieve and maintain wellness and address emotional behavioral challenges.
~All families partnered with a Family Wellness Coach (FWC) to design and implement a comprehensive program of family health and wellness with an emphasis on nutrition, exercise, music training, mindfulness, decreasing screen time, and positive parenting.
~Families with a child or parent experiencing significant emotional and behavioral problems were also partnered with Focused Family Coaches (FFCs) and Family Based Psychiatrists (FBPs). FFCs and FBPs respectively provided evidence-based psychotherapy and psychiatric care from the family perspective.
~Families also were also offered health promotion programs, including music lessons for all family members, behavioral parent training, yoga and mindfulness training, and nutrition coaching."
11052347|NCT04412590|Active Comparator|Control|The Control Group received pediatric care as usual.
11052348|NCT04412577|Experimental|TQB3473 tablets|TQB3473 tablets administered once daily in 28-day cycle .
11052349|NCT04412564|Experimental|TQ-B3101 capsules|TQ-B3101 capsules 300mg bid administered orally in 28-day cycle.
11052350|NCT04412538|Experimental|Low dosage vaccine on a 0- and 28-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
11052351|NCT04412538|Experimental|Low dosage vaccine on a 0- and 14-day schedule|Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
11052352|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 28-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
11052353|NCT04412538|Experimental|Medium dosage vaccine on a 0- and 14-day schedule|Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
11052354|NCT04412538|Experimental|High dosage vaccine on a 0- and 28-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
11052355|NCT04412538|Experimental|High dosage vaccine on a 0- and 14-day schedule|Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14
11052356|NCT04412538|Placebo Comparator|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0, 28
11052357|NCT04412538|Placebo Comparator|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0, 14
11052358|NCT04412525|Experimental|27 gauge needle vitrectomy surgery|
11052359|NCT04412525|Experimental|larger than 27 gauge (23G or 25G) needle vitrectomy surgery|
11052360|NCT04412512|Experimental|VATS approach|patients treated by VATS technique.
11052361|NCT04412512|Active Comparator|Thoracotomy approach|patients treated by Thoracotomy technique
11052362|NCT04412499||Methylphenidate + parent-training programm|Methylphenidate and participation in a parent-training programme
11052363|NCT04412499||Methylphenidate alone|Methylphenidate alone
11052364|NCT04412486|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants with serious or life threatening complications from COVID-19 or are at high risk to develop serious complications.
11052387|NCT04412265||Covid 19 patients|The study will be conducted on all patients hospitalized in COVID+ departments of the S.Gerardo Hospital in Monza (Geriatrics Unit, First Aid Unit and Emergency Medicine, Gastroenterology Unit, Infectious Disease Unit) affected by pneumonia COVID related.
11052388|NCT04412252|Experimental|Tofacitinib|Participants will receive tofacitinib 10 mg twice per day for 14 days and standard of care therapy.
11052365|NCT04412447|Experimental|Subjects|"Phase V1: 1 month of home-based FES-training using isometric contractions of quadriceps and hamstring muscles (3 times a week).
~Phase V2: 2 months of home-based FES-training on an ergo-cycle with arm support (3 times a week)
~Phase V3: 1 month of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting.
~Optional (only for selected pilot):
~Phase V4: 2-4 months of home-based FES-training on an ergo-cycle with arm support (1-2 times a week) and FES-cycling training overground on a tricycle (1-2 times a week) in the clinical setting. This phase is focussing on optimizing the performance of the pilot and improving the mechanical efficiency of the tricycle.
~Phase V5: Participation on Cybathlon 2020"
11052366|NCT04412434|Other|patients with acute ischemic stroke|This open-label prospective study will be conducted in the single medical center (RAMBAM Medical Center) and will include at least 200 patients with acute ischemic stroke resulted from MCA or ICA occlusion.
11052367|NCT04412408|Experimental|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.
~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
11052368|NCT04412395|Active Comparator|Arm 01 (SOC + Lactoferrin 1200 mg QID)|Patients randomized to this group will receive two 600 mg Lactoferrin tablets QID plus the Standard of Care (SOC) treatment(s).
11052369|NCT04412395|Placebo Comparator|Arm 02 (SOC + Placebo QID)|Patients randomized to this group will receive two placebo tablets QID plus the SOC treatment(s).
11052370|NCT04412382||covid-19|Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
11052371|NCT04412382||control|Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer.
11052372|NCT04412369||Study group|Patients with COVID-19 and cardiac Troponin elevation
11052373|NCT04412356|Experimental|Early tracheotomy|Tracheotomy within 7 days after intubation.
11052374|NCT04412356|Active Comparator|Late tracheotomy|Tracheotomy after at least 10 days after intubation.
11052375|NCT04412343|Experimental|Virtual group exercise|Individuals in the (virtual) group-based exercise program, will have the opportunity to take part in (virtual) group exercise classes, delivered via videoconferencing, by experienced older adult exercise instructors. Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group. Classes will be offered multiple days a week at 9am PST (12 noon EST), and will last approximately 50 minutes. Classes include a warm-up component, moderate intensity exercises as the core component of the class, and a cool-down. At the end of classes participants will have the opportunity to connect in small groups (videoconferencing breakout groups) to socially connect over a beverage (coffee, water) from their own homes. Participants in the group condition will also be sent, by mail, a program t-shirt to foster a sense of distinctiveness.
11052376|NCT04412343|Experimental|Personal exercise|Each of the older adult instructors described above will also contribute to delivering pre-recorded exercise classes (involving the same exercises, intensity, music, and so forth as those described above for the group condition). However, in this instance, instructors will deliver those classes to each participant by referring to themselves as each participant's personal trainer/coach, with language directed to the individual and not the group. That is, no sense of 'groupness' or 'shared social identities/connectivity' will be primed. Also, participants in this condition will not have the opportunity to interact with other older adults after classes have ended and will not receive the same program t-shirts designed to foster a sense of group distinctiveness.
11052377|NCT04412343|No Intervention|Wait-list control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 12-week trial. They will be asked to complete the same questionnaires (and will be remunerated in the same way as those in the other two conditions via $10 per questionnaire completion). At the end of the 12-week trial, participants in this condition will have access to the personal exercise programming.
11052378|NCT04412330|Experimental|ICU followup + physical therapy|Patients surviving ICU admission for Covid-19 will receive ICU follow-up care in an ICU Recovery Clinic plus 8 weeks of physical therapy interventions. ICU Recovery Clinic is standard of care for patients surviving medical ICU admission at University of Kentucky with potential to attend in person or complete through telemedicine up to 5 appointments in the first year after hospital discharge. Physical therapy interventions completed at an outpatient pulmonary rehabilitation center or through telemedicine is not currently standard of care for patients in the short-term recovery phase (1-6 months after hospital discharge) after critical illness.
11052379|NCT04412317||Children < 15 years old|Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic
11052380|NCT04412304||thrombose prophylaxis|The dose used to prevent thromboembolic complication in critically ill
11052381|NCT04412304||double thrombose prophylaxis|Double the dose used to prevent thromboembolic complication in critically ill
11052382|NCT04412304||full dose anticoagulant|Dose used to treat thromboembolic event
11052383|NCT04412291|Active Comparator|Standard-of-care Treatment (SOC)|"SOC according to local recommendations at the Karolinska University Hospital:
~Oxygen supplementation so to achieve SpO2>93%. Antipyretic treatment (paracetamol) Thrombosis prophylaxis (Fragmin or Innohep) Antibiotics for seven days."
11052384|NCT04412291|Active Comparator|Anakinra + SOC|"Anakinra: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
~SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Antipyretic treatment (paracetamol) Thrombosis prophylaxis (Fragmin or Innohep) Antibiotics for seven days."
11052385|NCT04412291|Active Comparator|Tocilizumab + SOC.|Tocilizumab: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Antipyretic treatment (paracetamol) Thrombosis prophylaxis (Fragmin or Innohep) Antibiotics for seven days.
11052386|NCT04412278||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
11052487|NCT04411511||Lean children|Children between 4-18 years, living in the Netherlands.
11052389|NCT04412252|Placebo Comparator|Placebo|Participants will receive tofacitinib-matching placebo twice per day for 14 days and standard of care therapy.
11052390|NCT04412239|Experimental|Telephone Consultation in TB Patients|The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.
11052391|NCT04412213||children of possitive family history of stuttering|
11052392|NCT04412213||children of negative family history of stuttering|
11052393|NCT04412200|Experimental|Hyperbaric oxygen chamber Arm|Patients will be randomized at a ratio of 2:1, to hyperbaric chamber (100% oxygen at 2 ATA)
11052394|NCT04412200|Sham Comparator|Sham hyperbaric chamber Arm|Patients will be randomized at a ratio of 2:1, to Sham chamber (21% oxygen at 1 ATA)
11052395|NCT04412187|Other|TSPO PET imaging|All study participants will receive [18F]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
11052396|NCT04412174|Experimental|GC022F|The patients will receive GC022F CAR-T treatment. GC022F dosage ranges from 3×10^5 to 1×10^6 CAR+T/Kg.
11052397|NCT04412161||Extra-Malatya|Liver transplant patients with MTD>6 cm of HCC
11052398|NCT04412148|Active Comparator|Intralesional Steroids|
11052399|NCT04412148|Placebo Comparator|Control|
11052400|NCT04412122|Experimental|Kinesio Taping|Kinesio taping is thought to remove the barriers that slow the healing process, activate neurological suppression and reduce pain (El-Refayea, El Nahasa & Ghareebb, 2016; Kamali, Sinaei & Taherkhan, 2018). Kinesio tape stimulates cutaneous mechanoreceptors. Mechanoreceptors decrease sympathetic nervous system activity and increase parasympathetic activity, which can improve intestinal control (Azam, 2017; Szczegielniak, Krajczy, Bogacz, Luniewski & Sliwinski, 2007). Kinesio taping changes skin contours and accelerates blood flow. Increased blood flow brings more oxygen and nutrients to the area. This phenomenon contributes to the natural healing process (Kafa et al., 2015).
11052401|NCT04412122|Experimental|Breathing Exercise|Breathing exercise is accepted as a key to relaxation or cooling down (El-Refayea et al., 2016). It is stated that breathing exercises reduce anxiety by preventing the transmission of pain messages to the spinal cord (Rejeh et al., 2013), reducing the catecholamine response (Rakel & Herr, 2004) and muscle tension by distracting subjects (Kelle, Güzel & Sakallı, 2016).
11052402|NCT04412122|Experimental|Kinesio Taping and Breathing Exercise|According to the application protocols, two applications were made together.
11052403|NCT04412122|Other|Control Group|No intervention was performed to reduce pain in the control group.
11052404|NCT04412109|Active Comparator|injection of low volume of saline|low volume (5 cc) saline injection during thoracic epidural catheterization
11052405|NCT04412109|Active Comparator|injection of intermediate volume of saline|intermediate volume (10 cc) saline injection during thoracic epidural catheterization
11052406|NCT04412109|Active Comparator|injection of high volume of saline|high volume (20 cc) saline injection during thoracic epidural catheterization
11052407|NCT04412096|Experimental|Timolol 0.5%|To compare the variation in response to timolol between individuals
11052408|NCT04412096|Experimental|Latanoprost 0.005%|To compare the variation in response to latanoprost between individuals
11052409|NCT04412083|Other|PPA Tele-Savvy Pilot Intervention|The Tele-Savvy program is comprised of weekly, two-hour interactive classes, over seven consecutive weeks, the same duration as the proposed intervention. Tele-Savvy consists of educational instruction, video and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of contented involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
11052410|NCT04412070||Patient with Non-Muscle invasive Bladder Cancer|Patients in this group will be enrolled before the start of their treatment with BCG. This will start within 4 weeks after the transurethral bladder resection, in accordance with the guidelines
11052411|NCT04412070||Patient with Muscle Invasive Bladder Cancer|Patients in this group will be enrolled in the study before surgical treatment by radical cystectomy
11052412|NCT04412057|Experimental|CERC-002|
11052413|NCT04412057|Placebo Comparator|Placebo|
11052414|NCT04412044|Experimental|Asthmatics|Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment
11052415|NCT04412018|No Intervention|Usual Care|Participants in this arm will continue with usual care
11052416|NCT04412018|Experimental|Icosapent Ethyl|Participants in this arm will take icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
11052417|NCT04412005||Manhiça|Pregnant women attending the Manhiça District Hospital
11052418|NCT04412005||Ilha Josina|Pregnant women attending the Ilha Josina Health Center
11052419|NCT04412005||Magude|Pregnant women attending the Magude Health Center
11052420|NCT04411992|Experimental|Allocated to Vibration intervention (1) A|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
11052421|NCT04411992|No Intervention|Allocated to Control intervention (1) B|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
11052422|NCT04411992|Experimental|Allocated to Vibration intervention (2) B|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
11052423|NCT04411992|No Intervention|Allocated to Control intervention (1) A|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
11052424|NCT04411979|No Intervention|treatment-as-usual|
11052425|NCT04411979|Experimental|treatment-as-usual plus aerobic walking|
11052426|NCT04411966|Experimental|18F-fluorothymidine PET|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
11052427|NCT04411953|Active Comparator|Reference Product (Treatment A)|"Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
11052428|NCT04411953|Experimental|Test Product (Treatment B)|"Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
~A high-fat, high-calorie breakfast was served 30 minute before administration of the IMP."
11052429|NCT04411940|Active Comparator|Reference Product (Treatment A)|Subjects received Haloperidol Tablets 2 mg Reference Product (Mylan Pharmaceuticals Inc.). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
11052430|NCT04411940|Experimental|Test Product (Treatment B)|Subjects received Haloperidol Tablets 2 mg Test Product (Cycle Pharmaceuticals Ltd). Subjects also received as pre-medication Benztropine Mesylate Tablets, USP (1 mg every 10 to 12 hours), beginning 4 to 6 hours before dosing with IMP and continued for a total of 4 doses.
11052431|NCT04411927||control group|this group included 25 typically developed children
11052432|NCT04411927||on-heamodialysis group|this group included children with CKD on-heamodialysis treatment
11052433|NCT04411927||non-dialysis group|this group included children with CKD who don't require dialysis
11052434|NCT04411914|Experimental|Clavulanic Acid|9 Participants will receive 500 mg of CLAV at baseline. Subjects who can tolerate 500 mg/day for 3 days (or matched placebo) will have a dose escalation to 750 mg/day for 3 days. Subjects who can tolerate 750mg/day for three days will have a dose escalation to 1000mg for 4 days.
11052435|NCT04411914|Placebo Comparator|Placebo|"3 participants will receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
11052436|NCT04411901|Experimental|vitamin D 3|oral vitamin D3 drops and tablets
11052437|NCT04411875|Active Comparator|Amlodipine|amlodipine reference formulation at a single dose of 10 mg
11052438|NCT04411875|Experimental|Levamlodipine|levamlodipine test formulation at a single dose of 5 mg
11052439|NCT04411862|Experimental|Intervention Group|50 Participants with NAFLD that receive lifestyle modification by Clinical Pharmacist plus Phosphatidylcholine two soft capsules 3 times daily(2.1 g per day) for 6 month
11052440|NCT04411862|Active Comparator|Control Group|50 Participants with NAFLD that receive only lifestyle modification by Clinical Pharmacist
11052441|NCT04411849|Experimental|Group I (early intervention)|During year 2, participants receive the HPV self-testing intervention consisting of mailed HPV self-test devices. Participants also receive an information about cervical cancer. Participants who do not return their self-test within a few weeks receive telephone-based patient navigation. Participants then complete a satisfaction survey and have their medical record reviewed. During years 3-5, this intervention is repeated among women who remain unscreened/underscreened.
11052442|NCT04411849|Active Comparator|Group II (delayed intervention)|During year 2, participants receive usual care consisting of a reminder letter to get a clinic-based cervical cancer screening test and information about cervical cancer. During years 3-5, participants receive the HPV self-testing intervention described for Group I.
11052443|NCT04411836|No Intervention|Control|Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)
11052444|NCT04411836|Experimental|PQ Intervention|Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
11052445|NCT04411836|Experimental|TQ Intervention|Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)
11052446|NCT04411823|Experimental|Intervention arm|Undergo an upper endoscopy with EndoFLIP at baseline before sleeve gastrectomy
11052447|NCT04411810|Experimental|Participants with skin lesions|Participants who have up to 3 concerning skin lesions will be evaluated by both an in-person dermatologist and a team of three teledermatologists(board-certified dermatologists). The teledermatoogy team will deliver a consensus recommendation. If either the in-person dermatologist or teledermatologists are concerned that the skin spot(s) may be a skin cancer, a biopsy will be recommended and can be performed at no charge. Or if both agree that the spot(s) are not concerning for skin cancer, no biopsy will be needed.
11052448|NCT04411784||Main group|Patient with Acute Severe Ulcerative Colitis based on Modified Truelove and Witts Severity Index managed during the study period
11052449|NCT04411784||Control Group|Patients with ASUC managed in the unit from 1st Jan to 31st June 2019
11052450|NCT04411771|Experimental|Extended Assessment - Given shCBT|"The extended assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).
~In the primary analysis, only patients given shCBT are included"
11052451|NCT04411771|Active Comparator|Screening Assessment - Suitable for shCBT but given BI|"The screening assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.
~In the primary anaysis, only patients suited for shCBT are included, as decided from an algorithm based on data from their screening."
11052452|NCT04411771|Experimental|Extended Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomized to Extended Assessment are included, regardless of if they start shCBT or BI"
11052453|NCT04411771|Active Comparator|Screening Assessment - All patients|"Same as the other arm marked as Active comparator, but for the purpose of a secondary analysis all patients randomized to Screening Assessment are included, regardless of if they are suiteble for shCBT or not."
11052454|NCT04411758|Other|Control Group|The control group will not receive any intervention in those first two months, and then the groups will be crossed and will receive the same amount of propolis as the first group.
11052455|NCT04411758|Experimental|Propolis Group|The propolis will be instructed to use 20 drops of standardized green propolis alcohol extract (16% w / v) diluted in 1 glass of water, daily for 2 months before to sleep, and then the groups will be crossed and will not receive any intervention
11052456|NCT04411745||Parturition|Healthy women who are carrying a healthy singleton pregnancy, but have not yet gone to labor at 40 weeks of gestation or who are at term and admitted to hospital for any sign of labor.
11052457|NCT04411732||patients with neuromuscular disorder|cohort of patients with neuromuscular disorder
11052458|NCT04411732||healthy controls|cohort of healthy controls
11052459|NCT04411719|Experimental|Gamma modulation effect|40Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
11052460|NCT04411719|Experimental|Electric stimulation effect|28Hz current is applied by a battery-driven current stimulator. Two pairs of electrodes are attached to the bilateral superior orbital fissure and suborbital foramen to stimulate the ophthalmic nerve (V1) and the maxillary nerve (V2). The stimulation is applied for 40min/day, for a total of 5 days.
11052461|NCT04411719|No Intervention|No treatment group|No electric stimulation is applied.
11052462|NCT04411706|Experimental|Sintilimab+Apatinib+Capecitabine|=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）
11052463|NCT04411693|Active Comparator|Group A: Intravitreal Dexamethasone Implant|Subjects in this arm will be given intravitreal Dexamethasone implant injection at month 0. PRN intravitreal Dexamethasone implant injections will be given for persistent edema, if it has been 10 weeks or more since last implant injection. If it has been less than 10 weeks since last implant injection, subjects will receive PRN intravitreal Aflibercept for persistent edema.
11052464|NCT04411693|Active Comparator|Group B: Intravitreal Aflibercept|Subjects in this arm will be given Intravitreal aflibercept at month 0. PRN intravitreal Aflibercept will be given at months 1-6 for persistent edema.
11052465|NCT04411680|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
11052466|NCT04411680|Active Comparator|Control Arm|Standard of care for COVID-19
11052467|NCT04411667|Experimental|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
11052468|NCT04411667|No Intervention|Group B (SOC)|Standard of Care
11052469|NCT04411654|Experimental|PR001|
11052470|NCT04411641|Experimental|SAR442168|Dose 1 of oral SAR442168 once daily
11052471|NCT04411641|Placebo Comparator|Placebo|Placebo tablet to match SAR442168 once daily
11052472|NCT04411628|Experimental|LY3819253|LY3819253 administered intravenously (IV).
11052473|NCT04411628|Placebo Comparator|Placebo|Placebo administered IV.
11052474|NCT04411615|Experimental|Omega|Omega-3 re-esterified triglyceride form
11052475|NCT04411602|Experimental|Treatment with Convalescent Plasma|SARS-CoV-2 convalescent plasma from approved donors will be transfused into severely ill patients with confirmed COVID-19 severe respiratory distress. Plasma will be administered on days 0, 2,4, 6 and 8.
11052476|NCT04411589|Experimental|Magnifying endoscopy with optical enhancement system group|Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.
11052477|NCT04411589|Active Comparator|white light endoscopy group|Patients in this group go through gastroscopy under white light endoscopy.
11052478|NCT04411563||Group I-Mild|The patients who have these mild symptoms are low-grade fever (not more than 38 degrees celsius), dry cough, fatigue, sore throat, headache, the new loss of taste, and smell. Patients with normal or mild pneumonia findings of radiological imaging and blood lymphocyte count ≥800 / µl and serum CRP≤40 mg /l, ferritin ≤500ng/ml, D-Dimer ≤1000 ng/ml will be included in group I.
11052479|NCT04411563||Group II-Moderate|The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count <800 / µl or serum CRP> 40 mg / l or ferritin> 500ng / ml or D-Dimer> 1000 ng / ml will be included in group II.
11052480|NCT04411563||Group III-Severe|The patients who have these severe symptoms are all the common symptoms mentioned above along with shortness of breath, chest discomfort, confusion/unresponsiveness, bluish face/lips, possible gastrointestinal issues, like diarrhea or nausea. Patients with ICU (intensive care unit) admission criteria, such as confusion or tachycardia (> 125 / min) or respiratory distress or tachypnea (> 22 / min) or hypotension <90/60 mmHg or SPO2 <93%will be included in group III. Also, patients with the central nervous system and heart involvement will be directly included in the severe case group
11052481|NCT04411550|Experimental|HLX11 group|HLX11 are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
11052482|NCT04411550|Active Comparator|CN-Perjeta group|CN-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
11052483|NCT04411550|Active Comparator|EU-Perjeta group|EU-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
11052484|NCT04411550|Active Comparator|US-Perjeta group|US-Perjeta are given intravenous infusion at a single dose of 420 mg, and the administration time is 60 min (± 10 min).
11052485|NCT04411537|Experimental|Treatment Arm|A total of 50 MSS LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
11052486|NCT04411524|Experimental|Treatment Arm|A total of 50 MSI-H LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
11052682|NCT04410146|Active Comparator|No Embolization|Standard Management
11052488|NCT04411511||Children with overweight or obesity|Children between 4-18 years, living in the Netherlands. Besides inclusion from the general population, childhood expertise centres will contact their patients to pay attention to this study.
11052489|NCT04411498||Group of Systemic Sclerosis|Patients who were followed-up with the diagnosis of diffuse systemic sclerosis in the Hospital of Rheumatology Clinic were evaluated in terms of inclusion criteria. 44 female patients who met the inclusion criteria were included in the study. All patients were evaluated by a rheumatologist with detailed history and physical examination. Scleroderma patient group was evaluated for the presence of other rheumatic diseases that may accompany.
11052490|NCT04411498||Group of control|The healthy control group (96 female ) was evaluated for rheumatic diseases [undiagnosed connective tissue diseases and additional rheumatological diseases] that may accompany secondary FMS exclusion.
11052491|NCT04411485||Group of Ankylosing Spondylitis|Patient with ankylosing spondylitis diagnosed by a rheumatologist
11052492|NCT04411485||Group of control|Healthy volunteers of the same age and gender as patients
11052493|NCT04411472|Experimental|active|recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions
11052494|NCT04411472|Placebo Comparator|placebo|matching placebo
11052495|NCT04411459||COVID-19 pneumonia patients|Patients needing intubation and mechanical ventilation for COVID-19 related pneumonia without other primary causes of ICU admission
11052496|NCT04411446|Experimental|Vitamin D|5 capsules containing 100.000 UI of vitamin D each. The intervention will be 5 capsules given in one-time oral intake.
11052497|NCT04411446|Placebo Comparator|Placebo|5 capsules containing placebo. The intervention will be 5 capsules given in one-time oral intake.
11052498|NCT04411433|Experimental|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).
~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
11052499|NCT04411433|Experimental|Favipiravir (3600 mg + 1600 mg)|"Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).
~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
11052500|NCT04411433|Experimental|Favipiravir combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).
~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
11052501|NCT04411433|Experimental|Favipiravir combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).
~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
11052502|NCT04411433|Active Comparator|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).
~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
11052503|NCT04411433|Active Comparator|Hydroxychloroquine combined with Azithromycin|"Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).
~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).
~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
11052504|NCT04411420|Active Comparator|Integrated Care Pathway|The integrated care pathway provides both on-site physical therapy services and centrally-delivered services via telephone or video from study providers at the Durham VA.
11052505|NCT04411420|Active Comparator|Coordinated Care Management Pathway|The care management pathway involves a referral of patients from a physician to a pain navigator on site at the local VA who is knowledgeable in current recommended treatment guidelines for low back pain.
11052506|NCT04411407|Other|Group WT|PROM registration via the DANBIO WebApp and thereafter the outpatient touchscreen
11052507|NCT04411407|Other|Group TW|PROM registration via the outpatient touchscreen and thereafter the DANBIO WebApp
11052508|NCT04411394||Healthy Participants|There is no intervention
11052509|NCT04411394||Anxiety Participants|There is no intervention
11052510|NCT04411381|Active Comparator|Telemedicine-based model of care|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
11052511|NCT04411381|No Intervention|Traditional model of care|Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation
11052512|NCT04411355|No Intervention|control group patients|non intervention. only rutin care
11052513|NCT04411355|Experimental|intervention group patients|The intervention group was trained and monitored by a professional team in line with the components of the model. Life quality scale, hypertension information questions and chronic care assessment scale were applied to both groups at the beginning and in the sixth month of the study.
11052514|NCT04411342||patients with type 2 diabetes|patients with type 2 diabetes and have normal range of albumine in urine and decline in renal functions
11052515|NCT04411329|Active Comparator|group A|patients will receive 30 ml of 0.125% bupivacaine with 8 mg dexamethasone (20 ml before skin incision and 10 ml at end of surgery
11052516|NCT04411329|Active Comparator|group B|we will add 50µg dexmedetomidine to the previous mixture given to group A (20 ml before skin incision and 10 ml at end of surgery
11052517|NCT04411329|Active Comparator|group c|we will add 1500 IU hyalurodinase to the mixture given to group B. (20 ml before skin incision and 10 ml at end of surgery
11052518|NCT04411316|Experimental|Pharmacomechanical thrombolysis plus anticoagulation|"This group of patients will receive Pharmacomechanical catheter-directed thrombolysis (PCDT) plus Anticoagulation.
~PCDT will be AngioJet along with alteplase. Anticoagulation will be heparin only"
11052519|NCT04411316|Active Comparator|Anticoagulation|This group of patients will receive standard anticoagulation only. Anticoagulation will be Heparin only
11052520|NCT04411303|Experimental|Reducing interlimb asymmetry with biofeedback post-stroke|We will use a randomized crossover design to determine the performance and retention effects following single-day training sessions with biofeedback of three different gait variables (i.e., step length, propulsive force, and interlimb asymmetry) in 25 individuals with chronic stroke.
11052521|NCT04411303|Experimental|Evaluating capacity for biofeedback use at varied intensities|We will use a within-session randomized crossover design to test the capacity of persons post-stroke (second cohort; n=25) to reduce their interlimb asymmetry using the biofeedback variable found to be the most effective for the group in Aim 1 while walking in three aerobic intensity zones: low, moderate, and vigorous (30-40%, 50-60%, and 70-80% of heart rate reserve, respectively).
11052522|NCT04411290||Total Thyroidectomy (TT)-indicated patients|Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon
11052523|NCT04411277||T2DM Elderly on Insulin CGM|70 patients with type 2 diabetes > 65 years of age taking insulin as treatment. The sample size was calculated to estimate the minimal number of patients necessary to describe the mean TIR (minutes/day).
11052524|NCT04411264|No Intervention|Classic protocol for pain management|classic protocol for pain management during chronic wound dressing
11052525|NCT04411264|Experimental|Virtual reality for pain management|protocol associating virtual reality with the classic protocol for pain management during the treatment of chronic wound dressings
11052526|NCT04411251|Experimental|Outdoor|Nature-centered therapy in a near-natural area
11052527|NCT04411251|Active Comparator|Indoor|Conventional therapy in rooms mainly in a hospital building
11052528|NCT04411238||Patients|
11052529|NCT04411238||Caregivers|
11052530|NCT04411238||Home help|
11052531|NCT04411225|Experimental|Cannabidiol Augmentation|The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
11052532|NCT04411225|Placebo Comparator|Placebo Augmentation|Placebo will appear identical to the cannabidiol solution
11052533|NCT04411212|Active Comparator|Granulocyte colony-stimulating factor and platelet-rich plasma|
11052534|NCT04411212|Other|Control group|
11052535|NCT04411199|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
11052536|NCT04411199|Other|Standard of Care|The SoC for prophylactic antibiotic treatment is based on international guidelines
11052537|NCT04411186|Active Comparator|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Control for this study will be the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
11052538|NCT04411186|Experimental|ERAS and 5 Lung Protective Interventions|"The standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:
~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height)
~Positive end-expiratory pressure (PEEP) 7cm H2O5
~Immediately post intubation recruitment breath (30cm water for 30 seconds)
~Every 1 hour recruitment breath (30cm water for 30 seconds)
~40% FIO2 initially - titrate up as necessary to maintain SPO2 >94%"
11052539|NCT04411173|Active Comparator|Rice Protein|Rice Protein - 24 grams, chocolate, powder
11052540|NCT04411173|Active Comparator|Whey Protein|Whey Protein - 24 grams, chocolate, powder
11052541|NCT04411160||Group A|Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose.
11052542|NCT04411160||Group B|While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
11052543|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
11052544|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
11052545|NCT04411134|Experimental|Arm 1|Approximately 3x10^8 or 1.5x10^9 E7 TCR T cells will be injected on day 0 and 1.5x10^9 E7 TCR T cells on day 31 (2 escalating dose levels)
11052546|NCT04411134|Experimental|Arm 2|The MTD from among dose level 1 and dose level 2
11052547|NCT04411108|Active Comparator|Exercise Instruction by PT and written handout|
11052548|NCT04411108|Experimental|Exercise Instruction by Motion Coach Technology|
11052549|NCT04411095|Experimental|Stretching of intrathoracic fascia|A technique will be used to stretch the intrathoracic fascia. The subject lies in his/her back, and a flexion of the upper cervical spine is combined with a retraction movement of the lower cervical and upper thoracic spine, this in combination with inspiration.
11052550|NCT04411095|Placebo Comparator|Test without stretching|A placebo technique is performed by positioning the hands of the therapist on the thorax without pressure or performing a technique. Similar as the stretching technique, a deep inspiration is performed by the patient, for each of the intrathoracic cilinders. This without performing a retraction of the lower cervical and upper thoracic spine.
11052551|NCT04411082|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
11052552|NCT04411082|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
11052553|NCT04411082|Placebo Comparator|Placebo|Oral administration of once daily placebo
11052554|NCT04411069|No Intervention|Patients without previous CINV|Patients who didn't have chemotherapy or that didn´t have any nausea and/or vomiting induced by chemotherapy (CINV) before surgery
11052555|NCT04411069|Other|Patients with previous CINV|Patients who had previous nausea and vomiting induced by chemoterapy.
11052556|NCT04411056|Experimental|Barrier box|Participants will have a barrier box placed during intubation
11052557|NCT04411056|No Intervention|No Barrier box|Participants will have routine intubation with no barrier box
11052558|NCT04411030|Experimental|Part 1|Oral administration of ASTX660 and itraconazole at specific time points.
11052559|NCT04411030|Experimental|Part 2|Oral administration of ASTX660 and midazolam at specific time points.
11052560|NCT04411017|Active Comparator|1L PEG|
11052561|NCT04411017|Active Comparator|2L PEG|
11052562|NCT04411017|Active Comparator|2L sodium picosulfate|
11052563|NCT04411004||Women who underwent shaving for rectal endometriosis|
11052564|NCT04410991|Experimental|SAR442168|Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
11052565|NCT04410991|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
11052566|NCT04410978|Experimental|SAR442168|Dose 1 of oral SAR442168 + placebo to match the teriflunomide tablet once daily
11052567|NCT04410978|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
11052568|NCT04410965|Experimental|teriflunomide|daily oral administration of teriflunomide 14 mg for 24 weeks
11052569|NCT04410952||no EES|Patients with a Type-C pelvic ring fracture who underwent no external emergency stabilization (EES) for the posterior pelvic ring
11052570|NCT04410952||Pelvic binder|Patients with a Type-C pelvic ring fracture who received a pelvic binder for emergency stabilization of the posterior pelvic ring
11052571|NCT04410952||Pelvic C-clamp|Patients with a Type-C pelvic ring fracture who received a pelvic C-clamp for emergency stabilization of the posterior pelvic ring
11052572|NCT04410926|Placebo Comparator|control group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).
~Neuromuscular electrical stimulation The control group received placebo NMES with no current stimulation. In another words, the current intensity was set at 0mA while standing on both feet for 30 minutes."
11052573|NCT04410926|Experimental|intervention group|"Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).
~Neuromuscular electrical stimulation
~The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles. High-voltage pulsed current was set at frequency of 85 Hz with 5 seconds contraction time and 12 seconds rest time while the ramp-up and ramp-down time were 0.3 and 0.7 respectively. The current intensity was adjusted based on the individual tolerance without reporting pain or discomfort while standing on both feet. The stimulation time lasted each session for 30 minutes."
11052574|NCT04410913|Experimental|Visual Healing Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
11052575|NCT04410913|Active Comparator|Standard Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
11052576|NCT04410900|Experimental|Experimental (anti-rabies vaccine, collection of blood)|Patients receive anti-rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo collection of blood samples at baseline, and at approximately 1, 2, and 4 weeks after each vaccination. There will be an additional blood draw 6 months (+/- 14 days) after the first immunization.
11052577|NCT04410900|Active Comparator|Control (anti-rabies vaccine, collection of blood)|Patients receive anti-rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo collection of blood samples at baseline, and at approximately 1, 2, and 4 weeks after each vaccination. There will be an additional blood draw 6 months (+/- 14 days) after the first immunization.
11052578|NCT04410887|Experimental|PISOXO|"st cycle of PIPAC during 1st laparoscopic exploration Three cycles of SOX
~nd cycle of PIPAC during 2nd laparoscopic exploration Surgery Three cycles of SOX +/-OLAPARIB
~PIPAC Intraperitoneal chemotherapy for PIPAC is Docetaxel Neoadjuvant Chemotherapy Patients will receive three cycles of a standard dose of Tegafur gimeracil oteracil potassium capsule (TGO) plus oxaliplatin (SOX) +Olaparib prior to curative gastrectomy.
~Adjuvant chemotherapy Three cycles of SOX +/- OLAPARIB will be given as postoperative chemotherapy.
~Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule (TGO) 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg oral twice a day"
11052579|NCT04410874|Experimental|Imvamune|Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study
11052580|NCT04410861|Active Comparator|Minimal Micropulse Arm|"Wavelength 810 577 Power 0.75 W 0.15 W DC 5% 5% Spot size 125um 100um Duration 0.3 sec 0.3 sec Number of spots 100-120 100-120
~."
11052581|NCT04410861|Experimental|Panmacular Micropulse Arm|Wavelength 810 577 Power 1.7 W 0.425 W DC 5% 5% Spot size 500um 500um Duration 0.3 sec 0.3 sec Number of spots 400-450 400-450
11052582|NCT04410848||All patient with suspicion of choledocholithiasis|Patient with the suspect of common biliary duct stone for pain type colic in the right upper quadrant abdomen, the elevation of bilirubin, alkaline phosphatase, pancreatitis, dilated common bile duct and cholangitis. According to the criteria to assign the risk of choledocholithiasis. We are going to validate a scale based on intelligence artificial compared to the clinical predictor.
11052583|NCT04410835||Psychiatric patients|Psychiatric patients with ICD-10 (International Statistical Classification of Diseases and Related Health Problems) F2/F3/F4 diagnosis
11052584|NCT04410835||Healthy Controls|Participants who do not have a psychiatric disorder or a first degree relative with psychiatric disorder.
11052585|NCT04410822||Patients enrolled|an age older than 18 years old and symptoms of FI according to Rome IV criteria.
11052586|NCT04410809|Placebo Comparator|Placebo|The same composition as the active medication but without the active substance TA-46
11052587|NCT04410809|Experimental|TA-46|Decoy protein of the fibroblast growth factor receptor 3
11052588|NCT04410796|Experimental|Osimertinib alone|All patients will receive osimertinib 80mg orally daily.
11052589|NCT04410796|Experimental|Osimertinib plus Carboplatin and Pemetrexed|All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards.
11052590|NCT04410783|Other|Before group|Mechanically ventilated emergency department patients receiving standard post-intubation sedation prior to an educational initiative on the importance of ED-based targeted sedation
11052591|NCT04410783|Other|After group|Mechanically ventilated emergency department patients receiving post-intubation sedation after an educational initiative aimed at improving sedation practices in the ED
11052592|NCT04410770|Active Comparator|Active intervention|Participants assigned to the active treatment arm are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 6 week outcome. The participant is encouraged to continue completing the self-ratings, but does not receive any more support calls. After 6 more weeks, the 12 week outcome is assessed the participant's involvement with the study ends.
11052593|NCT04410770|No Intervention|Wait list|Wait list participants have no study activities for 6 weeks after completing the baseline assessment. After 6 weeks, list participants complete the 6 week assessment. After completing the assessment. wait list participants are trained to use the mood tracker app and instructed to complete multiple self-ratings each week. Each the participant receives a support call each week for 6 weeks to engage the participant in the study and to address any problems the participant may have in completing self ratings. After 6 weeks of self-ratings, the participant complete the 12 week outcome and the participant's involvement with the study ends.
11052594|NCT04410757||Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply POCUS examinations in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
11052595|NCT04410757||No Point of Care Ultrasound (POCUS) group|When the provider in charge of covering the post-anesthesia care unit, they would apply routine bedside examination techniques in their PACU assessment as per the study protocol of hypotensive and hypoxic events.
11052596|NCT04410731|Experimental|BM-MSC injections for low back pain|Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy
11052597|NCT04410718||The intensive care unit cohort|Patients (with or without diabetes) with COVID-19 admitted to the intensive care unit
11052598|NCT04410718||The hospitalisation cohort|Patients with diabetes and COVID-19 admitted to the medical ward
11052599|NCT04410705|Experimental|Tendinopathy patients|Patients with tendinopathy will be administered ESWT
11052600|NCT04410692|No Intervention|Control|Participants' COVID-19 predictions are elicited via a survey
11052601|NCT04410692|Experimental|Treatment|Participants' COVID-19 predictions are elicited via a prediction market
11052602|NCT04410679|Experimental|injectabl PRF for treatment of internal root resorption|
11052603|NCT04410666|Experimental|GREEN TEA MOUTH WASH|an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.
11052604|NCT04410666|Placebo Comparator|Placebo|distilled water, in sterile glass containers.
11052605|NCT04410653|Experimental|Arm 1 (KRASwt PDAC)|
11052606|NCT04410653|Experimental|Arm 2 (IMA)|
11052607|NCT04410653|Experimental|Arm 3 (other)|
11052608|NCT04410627|No Intervention|Standard of Care|
11052609|NCT04410627|Experimental|Standard of Care + HoPE|
11052610|NCT04410614|Experimental|Free epithelial graft|Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa
11052611|NCT04410601|Active Comparator|No dysphagia (after total thyroidectomy-TT)|"Patients s/p post-thyroidectomy without complication
~*will NOT be enrolled to standard dysphagia-rehabilitation treatment"
11052612|NCT04410601|Experimental|Dysphagia (with at least one more complication of TT)|"Patients s/p post-thyroidectomy with both dysphagia and other documented TT complication such as vocal cord paralysis/hypocalcemia/surgical site infection etc.
~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
11052613|NCT04410601|Experimental|Dysphagia (the only complication after TT)|"Patients s/p post-thyroidectomy dysphagia only.
~*will be enrolled to standard dysphagia-rehabilitation treatment for 6-week."
11052614|NCT04410588|No Intervention|saline|saline for pain for nasal packing
11052615|NCT04410588|Active Comparator|levobupivacaine|levobupivacaine for pain of nasal packing
11052616|NCT04410588|Active Comparator|fentanyl +levobupivacaine|fentanyle with levobupivacaine for pain of nasal packing
11052617|NCT04410575|Experimental|Intervention Group (Pharmacist Interventions)|Participants enrolled in the intervention group will receive pharmacist interventions, in addition to standard care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians), at enrollment (month 0) and at months 1, 3, and 6
11052618|NCT04410575|Active Comparator|Control Group (Standard Pharmacist Care)|Patients randomized to the usual care groups will receive standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians) and physician care with no specific interventions for the duration of 6 months
11052619|NCT04410562|Experimental|Hydroxychloroquine|Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
11052620|NCT04410562|Placebo Comparator|Placebo|Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
11052621|NCT04410549|Experimental|COVID-19 patient with pulmonary thrombosis|"patients with COVID-19, high D-dimer levels and contrast CT scan negative for pulmonary thrombosis
~patients with contrast CT scan positive for pulmonary embolism in areas where contrast CT scan was negative."
11052683|NCT04410133|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
11052684|NCT04410120||Asthma with recent (<4/52) asthma attack|
11052622|NCT04410536|Other|Symptomatic drugs - bridge theray - mindfu|"abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting;
~oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day);
~mindfulness practice daily with standard sessions by smartphone 6 minutes per day."
11052623|NCT04410523|Experimental|CSJ117 0.5 mg|0.5 mg
11052624|NCT04410523|Experimental|CSJ117 1 mg|1 mg
11052625|NCT04410523|Experimental|CSJ117 2 mg|2 mg
11052626|NCT04410523|Experimental|CSJ117 4 mg|4 mg
11052627|NCT04410523|Experimental|CSJ117 8 mg|8 mg
11052628|NCT04410523|Placebo Comparator|Placebo|0 mg
11052629|NCT04410510|Placebo Comparator|Control group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days Placebo capsule equivalent to 250mg of excipient every 12 hours for 14 days
11052630|NCT04410510|Experimental|Intervention group|Lopinavir / ritonavir * Capsules 200/50 mg 400/100 mg every 12 hours for 7 to 14 days Hydroxychloroquine * Tab 200 mg Tab Load 400 mg every 12 hours the first day, follow 200 mg every 12 hours for 10 days P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days
11052631|NCT04410497|Experimental|Porcine xenograft|Conformité Européenne/European Conformity (CE)-marked dressing product used in clinical practise (Standard of care).
11052632|NCT04410497|Active Comparator|Silver foam|Conformité Européenne/European Conformity (CE)- marked dressing product used in clinical practise
11052633|NCT04410484||1|Admitted patients with IBD (with IBD OR due to COVID) whether tested or not tested for COVID between 1st March and 30th June 2020
11052634|NCT04410484||2|Patients with IBD self-isolating with suggestive COVID19 symptoms (Fever or persistent Cough) or tested positive for COVID19 during same period
11052635|NCT04410484||3|Patients with active IBD identified during the same study period. (definition: increased symptoms suggestive of flare, raised calprotectin, raised CRP, endoscopy or imaging during the previous 6 weeks showing active disease and contacted/reviewed during the study period , admission with IBD ( These will be identified through your helpline/ virtual clinics/Hot clinics/flare lines
11052636|NCT04410484||Control Group|Consecutive patients with active IBD between 1st March 2019-30th June 2019
11052637|NCT04410471||Liver transplant patient after having Covid19|Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
11052638|NCT04410471||No immunosuppressed patient with previous Covid19|Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June
11052639|NCT04410458|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic.
11052640|NCT04410458|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
11052641|NCT04410458|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
11052642|NCT04410458|Placebo Comparator|SMS with thank-you note|SMS content in this group will be thank-you note for their previous donation(s) .
11052643|NCT04410445|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Arm A: Participants will receive bempegaldesleukin (NKTR-214) 0.006mg/kg IV in combination with nivolumab 360mg every 3 weeks.
11052644|NCT04410445|Active Comparator|Nivolumab|Arm B: Participants will receive nivolumab 480mg IV alone every 4 weeks.
11052645|NCT04410432||Patient|Patient hospitalized with SARS-Cov2 infection proven by virological sampling.
11052646|NCT04410419|No Intervention|Standard Care|Standard care for patients with diabetes pre-operatively .
11052647|NCT04410419|Experimental|Carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
11052648|NCT04410406|Active Comparator|IA (Ivermectin + Albendazole)|Participants will receive one oral dose of Ivermectin (IVM) 200 µg/kg + Albendazole (ABZ) 400 mg (IA) annually for 24 months.
11052649|NCT04410406|Active Comparator|MoxA (Moxidectin + Albendazole)|Participants will receive one oral dose of Mox 8 mg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxA at the same dosage.
11052650|NCT04410406|Active Comparator|IDA (Ivermectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of IVM 200 µg/kg + Diethylcarbamazine (DEC) 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with IDA at the same dosage.
11052651|NCT04410406|Active Comparator|MoxDA (Moxidectin + Diethylcarbamazine + Albendazole)|Participants will receive one oral dose of Mox 8 mg + DEC 6mg/kg + ABZ 400 mg. Participants who are Mf positive at 24 months will be retreated with MoxDA at the same dosage.
11052652|NCT04410393||sacrocolpopexy patients|Patients who underwent sacrocolpopexy for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
11052653|NCT04410393||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
11052654|NCT04410380|Experimental|Electronic tablet|Spanish-speaking parents receive electronic tablet and teaching about use
11052655|NCT04410367|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
11052656|NCT04410354|Active Comparator|MMPD + remdesivir|Study subjects will receive MMPD oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
11052685|NCT04410107||Severe Pneumonia|"Presence of fever or suspected lower respiratory infection, plus one of the following criteria:
~1) respiratory rate> 30 movements / min; 2) severe respiratory distress 3) Pulse oximetry (SpO2) ≤93% in room air; and/or 3) Pulmonary infiltrates> 50% on chest imaging within 24-48hrs of symptom onset."
11052657|NCT04410354|Placebo Comparator|Placebo + remdesivir|Study subjects will receive matching placebo oral solution 3 times per day for 10 days unless discontinued early. Study subjects will also receive remdesivir infusion once a day for 5 days. If a subject does not demonstrate clinical improvement, remdesivir treatment may be extended for up to 5 additional days (for a total of up to 10 days).
11052658|NCT04410341|Placebo Comparator|Placebo group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet once daily for 12 weeks
11052659|NCT04410341|Experimental|Vildagliptin group|Escitalopram 20 mg tablet once daily for 12 week plus Vildagliptin 50mg tablet once daily for 12 weeks
11052660|NCT04410328|Experimental|Participants receiving Dipyridamole and Aspirin|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally plus standard care. Participants will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily starting on the day of enrollment for a total of 2 weeks.
11052661|NCT04410328|Other|Participants receiving standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
11052662|NCT04410315||Tumorcraniotomy patients|
11052663|NCT04410302||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue samples during standard of care tumor biopsy or surgical resection to establish PDXs. Patients may also undergo collection of blood, saliva, and urine samples to compare DNA abnormalities to noncancer cells in order to determine if they were present before the cancer started or developed with it.
11052664|NCT04410289|Experimental|Intervention Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the intervention group were positioned using props horizontally aligning the external auditory meatus (EAM) with the sternal notch (SN) and the chin with the sinciput. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
11052665|NCT04410289|Active Comparator|Control Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the control group were positioned freely according to the provider's preference. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
11052666|NCT04410276||Patients with enterococcal bloodstream infections|Adult patients (≥ 18 years of age) with ≥ 1 positive blood cultures with Enterococcus during hospitalization and who have repeat blood culture(s) within 7 days from the first positive culture will be included.
11052667|NCT04410263||COVID-positive ICU patients|The collective of COVID-positive patients on the ICU
11052668|NCT04410250|Active Comparator|Oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 1 will be instructed to clean the child's oral cavity by massaging the gingival rods with gauze and filtered water once a day at night.
~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
11052669|NCT04410250|Experimental|Absence of oral hygiene before tooth eruption|"The mothers of the newborns allocated to Group 2 will be advised not to perform any type of oral cavity cleaning of the newborn.
~Following the eruption of the child's first tooth, mothers will be instructed to brush twice a day with fluoride toothpaste (1100 ppm fluoride) in a minimum amount, equivalent to one grain of raw rice, using the Fones technique. circular movements in the buccal and lingual faces of all teeth (FONES, 1934)."
11052670|NCT04410237|Experimental|Med-Jet|"The Med-Jet injector is a novel needle-free drug-delivery system, which we believe may be a solution to the impracticalities of ILTA for mild-to-moderate psoriasis. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region.12 The drug-delivery device is highly configurable allowing adjustable depth and volume parameters.12 In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas"
11052671|NCT04410237|Active Comparator|Traditional Syringe|TAC will be injected on a half-plaque while the control half of the plaque will be untreated. A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
11052672|NCT04410224|Experimental|ASN004 ascending doses|Patients will receive escalating doses of ASN004 to identify the best dose for further study.
11052673|NCT04410211|Active Comparator|Group S (inhalational Sevoflurane sedation)|"The inhalational anaesthetic agent and oxygen will be delivered via an anaesthetic circuit with a vaporizer (Sevotec 3, Ohmeda, Streeton UK) with a nasal mask.
~Patients who are allocated for Sevoflurane will be given initial oxygen flow of 8L/min and then Sevoflurane was introduced at a concentration of 0.2% and was increased stepwise by 02% for every 30s up to a maximum of 1.0 minimum alveolar concentration (MAC; 2.05% end tidal). Patient's deepest sedation was recorded and adjusted to achieve optimal Observer's Assessment of Alertness/ Sedation Scale (OAAS) score of 3.
~Inadequate or over sedation was treated by reducing or increasing the Sevoflurane concentration dial by 0.2 - 0.6% until the desired effect is reached.
~Full vital signs monitoring are done for every participant"
11052674|NCT04410211|Active Comparator|Group M (Intravenous Midazolam sedation)|"Patients who are allocated for Midazolam will be given the similar nasal mask delivering 8L/min oxygen. However, Sevoflurane will not be introduced to these patients.
~Midazolam is titrated slowly to achieve OAAS score of 3 but no more than 2.5mg is to be given within 2 minutes period to patients selected to be in Midazolam group.
~Inadequate sedation is treated by giving slow titration of the medication based on the unblinded observer's judgement. Over sedation is treated by withholding the midazolam and continuing oxygen supplementation until the patient returned to the desired sedation level. No other sedative agents are allowed to be given to the patient or else patient will be excluded from this study."
11052675|NCT04410198|Experimental|Roxadustat|
11052676|NCT04410185|Experimental|MEDITATION|Meditation sessions will take place over 12 weekly sessions of 1.5 hours. A retreat (3 hours) will be realized after the 9th session
11052677|NCT04410159|Experimental|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
11052678|NCT04410159|Experimental|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
11052679|NCT04410159|Experimental|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
11052680|NCT04410159|No Intervention|Control|This group will receive the standard treatment protocol without any additional intervention
11052681|NCT04410146|Experimental|Embolization|Middle Meningeal Artery (MMA) embolization
11052686|NCT04410107||Acute respiratory distress syndrome (ARDS)|"Onset: acute, i.e. within 1 week of known clinical insult or new or worsening respiratory symptoms; and
~Chest imaging (e.g. X-ray or CT scan): bilateral opacities, not fully explained by effusions, lobar/lung collapse or nodules; and
~Origin of pulmonary edema: respiratory failure not fully explained by cardiac failure or fluid overload; and
~Degree of hypoxemia: arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O."
11052687|NCT04410094|Experimental|Cohort 1: Lazertinib plus Itraconazole|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by itraconazole capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
11052688|NCT04410094|Experimental|Cohort 2: Lazertinib plus Rifampin|Participants will receive a single oral dose of lazertinib tablets in Treatment Period 1 followed by rifampin capsules orally along with a single oral dose of lazertinib tablet in Treatment Period 2.
11052689|NCT04410081|Experimental|14C-lazertinib|Participants will receive a single oral dose of 14C-lazertinib on Day 1.
11052690|NCT04410068|Experimental|Electrical heating pad|"Electrical heating pad (WARMTAC device). Patients will be randomized to one arm.
~In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down."
11052691|NCT04410068|Experimental|forced-air warming device|Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down.
11052692|NCT04410055|Active Comparator|Sitting|Three hours of sitting condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
11052693|NCT04410055|Active Comparator|Static standing|Four hours of static standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
11052694|NCT04410055|Active Comparator|Dynamic standing|Four hours of dynamic standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
11052695|NCT04410042|Experimental|Tranexamic Acid|At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
11052696|NCT04410042|Placebo Comparator|Placebo|At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
11052697|NCT04410029|Experimental|Intervention|Standard counseling + Healthwise Decision Aid
11052698|NCT04410029|Active Comparator|Control|Standard counseling + a control informational handout.
11052699|NCT04410016|Experimental|Staff Wellbeing Centre|Wellbeing Centres are rooms where staff employed at the hospital trust can go for a break, rest, relaxation, quiet time out, advice support or signposting. They are manned by Wellbeing Buddies who are support workers who offer advice and signposting services. The Centres are accessible to all staff at the Trust.
11052700|NCT04410003|Placebo Comparator|Placebo|Cellulose capsules, cloxacillin, electrolyte purgative (Peglyte)
11052701|NCT04410003|Active Comparator|Active|Capsules of stool from Protected donors, cloxacillin, electrolyte purgative (Peglyte)
11052702|NCT04409990|Other|Shear Wave Elastography|SWE value measurement will be added during the ERUS examination.
11052703|NCT04409977||Patient group|Patients suffering from cluster headache will be included in this group. When analysing the data, the investigators will distinguish those in the in-bout period from those in the out-bout period. People in this group may participate twice: once in the in-bout and once in the out-bout period.
11052704|NCT04409977||Control group|Participants not suffering from cluster headache will be included in this group.
11052705|NCT04409964|Experimental|opioid-free anesthesia|The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
11052706|NCT04409964|Active Comparator|opioid anesthesia|The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.
11052707|NCT04409938|Experimental|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention.
11052708|NCT04409938|Experimental|Progressive Muscle Relaxation with Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds.
11052709|NCT04409938|No Intervention|Standard Practice|The standard practice of the lab was made.
11052710|NCT04409925|Experimental|rhDNase1 (Pulmozyme, Roche/Genentech)|Single Arm: rhDNase1 (Pulmozyme, Roche/Genentech) 2.5 mg inhaled nebulisations BID, for a maximum of 14 consecutive days.
11052711|NCT04409912|Experimental|Sirolimus coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
11052712|NCT04409912|Placebo Comparator|Plain balloon|The plain balloon or placebo will not be coated. The plain balloon will be inflated at 2 minutes at rated burst pressure (typically 12 to 14 ATM). Plain balloon will be applied to all the narrowed segment of the dialysis circuit
11052751|NCT04409639|Experimental|Treatment: all patients|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
11052752|NCT04409626||Cases|
11052753|NCT04409626||Controls|Matched (5 controls per case) by date of birth +/- 180 days.
11052713|NCT04409899||Urological surgical patients during COVID-19 pandemic|During the COVID-19 pandemic, the urological patients in the need of a surgical intervention have been screened on the basis of the underline conditions, the priority of surgery, and risk-benefit assessment. A pre-surgical work-out was performed in the selected patients, with some of them being detected of COVID-19 at RT-PCR or suspected for it according to the risk-assessment survey. Enhanced blood tests and X-rays of the thorax were performed as baseline assessments. In case of development of post-surgical unspecific symptoms, clinical and laboratory work-out were performed before to expedite a new RT-PCR, which would have required preventive isolation of a patient in a COVID-19 ward. We evaluated the impact of COVID-19 in this selected cohort and the complications eventually associated with the viral infection.
11052714|NCT04409886|Experimental|HBOT (Hyperbaric Oxygen Therapy)|
11052715|NCT04409886|Experimental|NBOT (Normobaric Oxygen Therapy)|
11052716|NCT04409873|Placebo Comparator|Control (Distilled Water)|Over the counter: Distilled water
11052717|NCT04409873|Experimental|Oral-B Mouth Sore (H2O2) mouthwash|Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
11052718|NCT04409873|Experimental|Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash|Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
11052719|NCT04409873|Experimental|CloSYS (ClO2) mouthwash|Over the counter: CloSYS (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
11052720|NCT04409873|Experimental|Listerine Mouthwash|Over the counter: Listerine (Zero Alcohol)(Johnson and Johnson, USA)
11052721|NCT04409860|Active Comparator|control group|In this group, observation is given after CCRT.
11052722|NCT04409860|Experimental|trial group|In this group, adjuvant chemotherapy is given after CCRT.
11052723|NCT04409847||COVID+ PCR|Subjects who are SARS-CoV-2 PCR+ve and/or have diagnostic CXR or CT chest features of COVID -19
11052724|NCT04409847||COVID- PCR|subjects admitted with COVID-19 like symptoms but are SARS-CoV-2 PCR-ve and have CXR or CT chest that show low probability of COVID-19 will form the control group
11052725|NCT04409834|Experimental|Full-dose anticoagulation + antiplatelet therapy|"• Full-dose anticoagulation: Unfractionated heparin IV continuous targeting aPTT of 1.5-2.5X control, or Enoxaparin 1 mg/kg SC Q12h
~• Anti-platelet therapy: Clopidogrel 300 mg PO x1, followed by clopidogrel 75 mg PO QD"
11052726|NCT04409834|Experimental|Full-dose anticoagulation + no antiplatelet therapy|• Full-dose anticoagulation: Unfractionated heparin IV continuous targeting aPTT of 1.5-2.5X control, or Enoxaparin 1 mg/kg SC Q12h
11052727|NCT04409834|Experimental|Prophylactic anticoagulation + antiplatelet therapy|"• Standard prophylactic anticoagulation: Enoxaparin 40 mg SC QD or Unfractionated heparin 5,000 IU SC TID
~• Antiplatelet therapy: Clopidogrel 300 mg PO x1, followed by clopidogrel 75 mg PO QD"
11052728|NCT04409834|Active Comparator|Prophylactic anticoagulation + no antiplatelet therapy|• Standard prophylactic anticoagulation: Enoxaparin 40 mg SC QD or Unfractionated heparin 5,000 IU SC TID
11052729|NCT04409821|Experimental|Tele-delivered psychological intervention|Weekly tele-delivered psychological intervention
11052730|NCT04409808|Experimental|IRIS vitrectomy device|all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device
11052731|NCT04409795|Other|HLA+ Group|Participants who are high-risk HLA-DR3 and/or DR4 (+); monogenic variant (+) with rare exome variant ensemble learner (REVEL) score>0.75; and both glutamic acid decarboxylase (GAD65) and islet antigen (IA2) autoantibody (-)
11052732|NCT04409795|Other|HLA- Group|Participants who are high-risk HLA-DR3 and DR4 (-); with known or yet unknown monogenic variants with REVEL score>0.75; and either GAD65 and IA2 autoantibody (-), or autoantibody (+) with titers close to the cutoff
11052733|NCT04409782|Experimental|Arm 1|Attendees at in-person events (e.g. infusion suites, waiting rooms) who meet eligibility criteria will be able to enroll and participate in-person, with some participating in online survey.
11052734|NCT04409782|Experimental|Arm 2|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via a geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
11052735|NCT04409782|Active Comparator|Arm 3: Control|People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via a geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online follow-up.
11052736|NCT04409769||Description of use of ceftaroline and ceftobiprole|description of patients and their PJI/BJI,conditions of use, adverse event
11052737|NCT04409756|Other|postassessment of the SRQ-T test|the SRQ -T will be obtained to all patients three days after the first assessment
11052738|NCT04409743|Active Comparator|Immediate Treatment|The sleep treatment is Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants randomized to this arm will begin treatment immediately after randomization.
11052739|NCT04409743|Other|Waitlist|The subjects assigned to the Waitlist condition will receive the same CBT-I treatment 7 months after randomization.
11052740|NCT04409730|Experimental|Children with Cerebral Palsy|"Aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of I, II, III according to GMFCS"
11052741|NCT04409717||Patients treated for type II endoleaks|Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
11052742|NCT04409704|Experimental|10 Hz|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 4-6 weeks
11052743|NCT04409691|Active Comparator|prednison group|
11052744|NCT04409691|Experimental|prednison+sirolimus group|
11052745|NCT04409678|Experimental|activity|
11052746|NCT04409678|No Intervention|bed rest|
11052747|NCT04409665|Experimental|Ketamine sedated group|30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA
11052748|NCT04409665|Active Comparator|Glucose sedated group|30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA
11052749|NCT04409652|Placebo Comparator|Control group|The endotracheal extubation is performed in head on bed without pillow.
11052750|NCT04409652|Active Comparator|Head elevation group|The endotracheal extubation is performed in head elevation on pillow (slight flextion of neck on chest) .
11064402|NCT04325997|No Intervention|Video laryngoscopy intubation|
11052754|NCT04409613|Active Comparator|Clinical pharmacist-provided services+standard care group|that receive clinical pharmacist-provided services at the Warfarin Counseling Clinic plus standard medical care
11052755|NCT04409613|No Intervention|Standard care group|that will receive standard medical care
11052756|NCT04409600|Active Comparator|Home Based Gait Retraining + Saline Injection|
11052757|NCT04409600|Experimental|Home Based Gait Retraining + Botulinum Toxin Injection|
11052758|NCT04409600|Active Comparator|Supervised Gait Retraining + Saline Injection|
11052759|NCT04409600|Experimental|Supervised Gait Retraining + Botulinum Toxin Injection|
11052760|NCT04409587|No Intervention|NovoLog®-only|In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
11052761|NCT04409587|Active Comparator|Novolog® and Tresiba® Group|This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.
11052762|NCT04409561||Interventions|This patient pool shall be representative of the US population in term of the relative proportion of race/ethnicities. In addition, the population shall be enriched with patients above 60 year old as the target population of the PSP test is mostly the elderly.
11052763|NCT04409548|Active Comparator|Lumbar Disc Hernaition Group|The number of participants in this group is anticipated to be 154. The pain intensity of the patients was recorded by a Visual Analog Scale (VAS) immediately before performing the analysis. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
11052764|NCT04409548|Active Comparator|Healthy Control Group|The number of participants in this group is anticipated to be 54. The participants were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day.
11052765|NCT04409548|Active Comparator|Preoperative and Postoperative Group|The number of participants in this group is anticipated to be 60. The patients were asked to continuously walk barefoot for ten times as straight as possible without any assistance on the Win-Track platform within the same day, before and 15 days after surgery.
11052766|NCT04409535||Rural Living Community Member|Adult residents of a New Mexico rural county (as federally designated)
11052767|NCT04409535||Urban/Suburban Living Community Member|Comparison group: adult resident of a New Mexico urban/suburban city or town (as federally designated)
11052768|NCT04409522|Experimental|Test Group|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
11052769|NCT04409522|Active Comparator|Control Group|Participants in this group will receive the usual treatment of COVID-19
11052770|NCT04409509|Experimental|CSL312|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
11052771|NCT04409509|Placebo Comparator|Placebo|CSL312 diluent administered intravenously
11052772|NCT04409496|Experimental|Intervention group|Chat-based instant messaging support + Self-help booklet
11052773|NCT04409496|Active Comparator|Control group|SMS message support + Self-help booklet
11052774|NCT04409483|Active Comparator|Standard Care|Standard care for COVID-19 according to the national guidelines of Niger
11052775|NCT04409483|Experimental|Standard Care plus lopinavir/ritonavir|Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir
11052776|NCT04409470||Indication for blood gas sampling|To be eligible, patients will need to be classified as critically ill and there has to be a clear clinical indication for an arterial blood gas sampling. Enrollment will be performed in a consecutive manner at all hours.
11052777|NCT04409457|Other|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:
~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.
~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
11052778|NCT04409457|Other|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:
~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.
~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
11052779|NCT04409444||Data (main study)|This study group is for any individual that attends and has a lung health check. The data collected for this study group is to evaluate the uptake and performance of a community-based lung health check / lung screening programme.
11052780|NCT04409444||Biomarker (sub-study)|This sub-study is for participants that are determined to require a CT scan through their lung health check and have also signed up to the data part of the study. This part of the study is to evaluate the potential for biomarkers to improve the early detection of lung cancer.
11052781|NCT04409431|Experimental|Adrenal Artery Ablation|Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol.
11052782|NCT04409431|No Intervention|Spironolactone|Patients in this group will be treated with aldosterone 20-80mg daily according to blood pressure
11052783|NCT04409418|Experimental|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
11052934|NCT04408248||COVID-19 patients with acute respiratory disease|Adult patients with COVID-19 and moderate or severe respiratory disease
11052784|NCT04409418|Active Comparator|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
11052785|NCT04409405||Cured population|• Age ≥ 5 year old
11052786|NCT04409405||Contact population|"Age ≥ 5 year old
~Contact of a participant included in cured-population cohort
~Not diagnosed with EVD"
11052787|NCT04409392||Prothestic joint infection due to Staphylococcus lugdunensis|Patients having had a prosthetic joint infection with Staphylococcus lugdunensis
11052788|NCT04409379||acute leukemia group|300 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
11052789|NCT04409366|Active Comparator|Conventional Crown Lengthening; CCL|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days.
11052790|NCT04409366|Experimental|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan
11052791|NCT04409353|Experimental|Virtual Reality Program A|This arm will include software that provides immersive skills-based content for pain reduction.
11052792|NCT04409353|Active Comparator|Virtual Reality Program B|This arm will include software that provides immersive distraction based content for pain reduction.
11052793|NCT04409353|Sham Comparator|Virtual Reality Program C|This arm will include software that provides nonimmersive distraction based content for pain reduction.
11052794|NCT04409340||Training cohort|"All patients enrolled will undergo:
~Magnetic Resonance Viscoelastography
~Quantitative ultrasound (QUS)"
11052795|NCT04409340||Validation cohort|"All patients enrolled will undergo:
~• Quantitative ultrasound (QUS)"
11052796|NCT04409327|Experimental|10 mg daily RTB101|TORC1 inhibitor
11052797|NCT04409327|Placebo Comparator|Placebo|Placebo
11052798|NCT04409314||Diagnostic (18F-FAZA PET scan)|Prior to CAR T-cell therapy, patients receive 18F-FAZA IV. Beginning 2 hours after injection, patients undergo PET scan over 30-45 minutes.
11052799|NCT04409301|Experimental|MSAD Intervention|Children receiving cancer treatment in a hospital randomized to the My Special Aflac Duck (MSAD) intervention.
11052800|NCT04409301|Active Comparator|Control Group|Children receiving cancer treatment in a hospital randomized to be a control hospital. Children in the control hospitals will receive the My Special Aflac Duck (MSAD) at the end of the intervention period.
11052801|NCT04409288|Experimental|Group A|Apalutamide followed by Enzalutamide Study participants will receive 12 weeks of oral apalutamide (240mg) daily, followed by five weeks of washout period, and then 12 weeks of oral enzalutamide (160mg) daily.
11052802|NCT04409288|Experimental|Group B|Enzalutamide followed by Apalutamide Study participants will receive 12 weeks of oral enzalutamide (160mg) daily, followed by five weeks of washout period, and then 12 weeks of oral apalutamide (240mg) daily.
11052803|NCT04409262|Experimental|Remdesivir + Tocilizumab (RDV+TCZ)|Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
11052804|NCT04409262|Active Comparator|Remdesivir + Placebo (RDV+Placebo)|Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
11052805|NCT04409236|Experimental|Arm I (Quit2Heal app)|Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
11052806|NCT04409236|Active Comparator|Arm II (QuitGuide app)|Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.
11052807|NCT04409223|Experimental|Famitinib|
11052808|NCT04409223|Active Comparator|Sunitinib|
11052809|NCT04409210|Experimental|Intervention Group|The intervention group will receive establishment of individual health records, cardiovascular risk assessment, popularization of medical knowledge, personalized reminders and routine treatment.
11052810|NCT04409210|Other|Control Group|The control group just receive routine treatment and routine management.
11052811|NCT04409184||Convalescent subjects|Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection
11052812|NCT04409184||Healthy controls|
11052813|NCT04409171||PD|pancreaticoduodenectomy
11052814|NCT04409171||DP|distal pancreatectomy
11052815|NCT04409145|Experimental|VT30|VT30 is a PI3K-inhibitor prodrug, formulated as a topical gel and dispensed from a metered dose pump; administration is once or twice daily, applied to target-treatment area(s) on the skin. One pump action dispenses 250 µL of gel, intended to treat an area of 140 cm2.
11052816|NCT04409132|Experimental|Triferic AVNU infusion pre-dialyzer|Patients will receive one (1) 6.75 mg Fe dose of Triferic AVNU by continuous infusion over 3 hours into the predialyzer blood line.
11052817|NCT04409132|Experimental|Triferic AVNU for injection at T=0 and T= 3 hours|Patients will receive two (2) doses of Triferic AVNU 3.4 mg IV (2.25 mL) at T=0 and T=3 hours of hemodialysis into the venous drip chamber.
11052818|NCT04409132|Experimental|Triferic AVNU for injection at T=0|Patients will receive one (1) dose of Triferic AVNU 0.08 mg/kg IV, up to 6.75 mg Fe, at T=0 of hemodialysis into the venous drip chamber.
11052819|NCT04409132|Experimental|Triferic AVNU for injection at T=0, T=1.5 and T= 3 hours|Patients will receive three (3) doses of Triferic AVNU 2.25 mg Fe (1.5 mL) at T=0, T=1.5 and T=3.0 hours of hemodialysis into the venous drip chamber.
11052820|NCT04409119|Experimental|HIS/LBB pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.
11052821|NCT04409119|Active Comparator|LV pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.
11052822|NCT04409093|Experimental|Nail bed repair with eponychial sent|
11052823|NCT04409093|Active Comparator|Nail bed repair without eponychial stent|
11052824|NCT04409080|Experimental|Part A and Part B|Part A: Single ascending dose Part B: Preferred dose
11052825|NCT04409067||TMD-pain group|The TMD-pain group consisted of 30 children aged between 7.1 and 12.3 with a pain-related TMD diagnosis. All the patients in the TMD-pain group had myogenous or arthrogenous TMD according to the RDC/TMD protocol.
11052826|NCT04409067||pain-free TMD group|The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
11052827|NCT04409067||non-TMD group|The non-TMD group comprised 30 children aged between 7.2 and 12.5 without any recognised TMD based on RDC/TMD, Axis I.
11052828|NCT04409054||Patients undergoing the cough and Valsalva protocol|Patients over 18 years old, consulting in neuro urology departement, undergoing ano rectal manometry in order to explore ano rectal disorders
11052829|NCT04409028|Active Comparator|indirect restoration|
11052830|NCT04409028|Active Comparator|direct restoration|
11052831|NCT04409002|Experimental|Niraparib+Dostarlimab + Radiation|"Each study treatment cycle lasts 21 days
~Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
~Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
~Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1"
11052832|NCT04408989|Experimental|MB02-SP (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
11052833|NCT04408989|Experimental|MB02-DM (Bevacizumab Biosimilar)|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
11052834|NCT04408989|Active Comparator|US licenced Avastin®|Sterile vial 100mg/4ml, single-dose 1mg/kg administered as 90-minute infusion on day 1.
11052835|NCT04408976||Software practices|Patients with urinary tract infection in practices using the clinical decision support software
11052836|NCT04408976||Control practices|Patients with urinary tract infection in practices not using the clinical decision support software
11052837|NCT04408963|Experimental|Group 1|5 mg/kg IV
11052838|NCT04408963|Experimental|Group 2|5 mg/kg SC
11052839|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
11052840|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
11052841|NCT04408937|Experimental|tropifexor A|LJN452/placebo
11052842|NCT04408937|Experimental|tropifexor B|placebo/LJN452
11052843|NCT04408924|Experimental|Abemaciclib|Abemaciclib given orally.
11052844|NCT04408911||Midazolam|Critically ill intensive care unit patients receiving midazolam
11052845|NCT04408911||Lormetazepam|Critically ill intensive care unit patients receiving lormetazepam
11052846|NCT04408898|Experimental|ADP-A2M4 T cells in combination with pembrolizumab|
11052847|NCT04408872|Active Comparator|EGD|SUBJECT WILL UNDERGO ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)
11052848|NCT04408872|Experimental|EUS|SUBJECT WILL UNDERGO ENDOSCOPIC ULTRASOUND (EUS)
11052849|NCT04408859||NACS|The patients with advanced gastric cancer who received neoadjuvant chemotherapy followed by surgery（NACS）.
11052850|NCT04408859||SA|The patients with advanced gastric cancer who received surgery alone.
11052851|NCT04408846|Other|Minimally invasive lumbar fusion|
11052852|NCT04408846|Other|Open posterior lumbar fusion|
11052853|NCT04408820||Roxadustat|Participants will receive oral dose of roxadustat.
11052854|NCT04408807|Experimental|Study Group|ROPEE screening with speculum-free fundoscopy
11052855|NCT04408807|Active Comparator|Control Group|ROPEE screening with speculum fundoscopy
11052856|NCT04408794|Experimental|Vazegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
11052857|NCT04408781|Experimental|Ridge expansion by osseodensifcation|Ridge expansion and osteotomy drilling by osseodensifcation in conjunction with simultaneous implant placement in narrow ridges
11052858|NCT04408781|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
11052859|NCT04408768||Normal RBS|Normal RBS on ICU admission and controlled blood sugar within 24 hours
11052860|NCT04408768||High RBS|High RBS on ICU admission and uncontrolled blood sugar during first 24 hours
11052861|NCT04408755|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
11052862|NCT04408755|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
11052863|NCT04408742||females with Multiple Sclerosis|patients with a confirmed diagnosis of MS according to the McDonald criteria, physician-administered Expanded Disability Status Scale (EDSS) range of 1-3.5, having regular menstrual cycle (between 21-35 days), and cognitive levels to give history and following the instructions
11052935|NCT04408235|Active Comparator|Low-Dose LMWH|Enoxaparin 4000 IU daily
11052936|NCT04408235|Experimental|High-Dose LMWH|Enoxaparin 70 IU/kg twice daily
11052864|NCT04408729|Experimental|PrEP My Way intervention|PrEP My Way is an intervention that involves peer-delivery of a kit containing PrEP and other sexual health services. Participants will be offered PrEP if HIV-negative per a point-of-care test, pregnancy testing, vaginal swabs for gonorrhea and chlamydia testing, condoms, and/or self-injection medroxyprogesterone, as desired.
11052865|NCT04408729|No Intervention|Control|These participants will continue to receive PrEP at the clinic.
11052866|NCT04408716|Experimental|Ablation Index Guided High-Power Short-Duration Group|For patients assigned to undergo AF ablation with ablation index guided high-power short-duration strategy, point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
11052867|NCT04408716|Active Comparator|Standard Radiofrequency Ablation Group|For patients assigned to undergo AF ablation with standard radiofrequency ablation group, point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
11052868|NCT04408703||Ulcerative colitis in clinical remission|Clinical remission with SCCAI <3 at baseline and stable remission for the last 3 months
11052869|NCT04408690|Experimental|Rehabilitation and optional delayed ACL reconstruction|
11052870|NCT04408690|Active Comparator|Immediate ACL reconstruction + rehabilitation|
11052871|NCT04408664|Experimental|Sodium Cromoglycate|Patients will take Sodium Cromoglycate (SCG) (Lomudal®) 4 times daily during 6 months: SCG 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
11052872|NCT04408664|Placebo Comparator|Sodium Chloride 0.9%|Patients will take Sodium Chloride 0.9% 4 times daily during 6 months: Sodium Chloride 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
11052873|NCT04408651|Experimental|Acceptance and Commitment Therapy|
11052874|NCT04408651|Experimental|Compassion-Focused Therapy|
11052875|NCT04408638|Experimental|Glofit-GemOx|Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
11052876|NCT04408638|Experimental|R-GemOx|Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
11052877|NCT04408625|Experimental|Low dose|
11052878|NCT04408625|Experimental|Medium dose|
11052879|NCT04408625|Experimental|High dose|
11052880|NCT04408612||Dyspnea in stable coronary artery disease|Stable patients with dyspnea and coronary artery disease
11052881|NCT04408599|Experimental|NC410|NC410 for injections of various dose strengths administered in 14 day dosing cycles
11052882|NCT04408586|Active Comparator|Phentermine - Topiramate Extended Release group|
11052883|NCT04408586|Placebo Comparator|Placebo Group|
11052884|NCT04408573|No Intervention|Regular Continuous High Frequency|Patient remains 2 weeks in the currently chosen stimulation protocol.
11052885|NCT04408573|Experimental|Cycling High Frequency|Patient is stimulated with the same polarity, voltage/current, pulse width and frequency as the currently chosen stimulation protocol, but with cycling stimulation: 40sec On - 02 sec OFF
11052886|NCT04408573|Experimental|Continuous Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
11052887|NCT04408573|Experimental|Cycling Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
11052888|NCT04408560|Active Comparator|Groupe A with homéopathic treatment|Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
11052889|NCT04408560|Sham Comparator|Groupe B without homeopathic treatment|Conventional treatment : paracetamol (drug analgesic class1)
11052890|NCT04408547||soft catheter|Patients who underwent embryo transfer with a soft catheter
11052891|NCT04408547||stiff catheter|Patients who underwent embryo transfer with a stiff catheter because soft couldn't pass
11052892|NCT04408534|Active Comparator|continuous positive airway pressure|Patients receive continuous positive airway pressure as a mode of noninvasive ventilation
11052893|NCT04408534|Experimental|bilevel positive airway pressure|Patients receive bilevel positive airway pressure as a mode of noninvasive ventilation
11052894|NCT04408521|Experimental|NEUROFEEDBACK|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. Self-regulation of alpha rhythm is reflected in the dynamically varying opacity of the video replay window, i.e. the window would turn lighter/darker and reveal/obscure video content during episodes of low/high alpha amplitude, respectively.
11052895|NCT04408521|Placebo Comparator|CONTROL|Participants undergo individual at home sessions of 45-minute video-replay of popular TV series while recording their 1-channel EEG using a portable system. The recording is passive without real-time EEG neurofeedback (i.e. constant brightness and volume).
11052896|NCT04408508|Other|Amoxicillin administration|Oral amoxicillin administered to study patients
11052897|NCT04408495|Experimental|Intervention group_MRA|Recruitment maneuvers and high PEEP
11052898|NCT04408495|Active Comparator|Control group|No recruitment maneuvers and low PEEP
11052899|NCT04408482|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy performed in difficult cannulation
11052900|NCT04408482|Active Comparator|Pancreatic sphincterotomy + pancreatic stent|Pancreatic sphincterotomy performed in difficult cannulation + pancreatic stent placement
11052901|NCT04408469|Experimental|Online EQuIP|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
11064403|NCT04325997|Experimental|Video laryngoscope with mouth opener|
11052902|NCT04408469|Placebo Comparator|Self-Monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
11052903|NCT04408456|Active Comparator|Post Exposure Prophylaxis (PEP) Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
11052904|NCT04408456|Other|Control Group|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
11052905|NCT04408443|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
11052906|NCT04408443|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
11052907|NCT04408430|Experimental|Transseptal ViMAC|100 MAC patients treated with transseptal Valve-in-MAC.
11052908|NCT04408430|No Intervention|Registry of untreated patients|100 MAC patients not eligible for transseptal ViMAC, treated with conservative management including medications.
11052909|NCT04408417|Experimental|Harnessing Sequence A|Participants will harness their child into the 2 different child safety seats in the following order: control, prototype, prototype, control.
11052910|NCT04408417|Experimental|Harnessing Sequence B|Participants will harness their child into the 2 different child safety seats in the following order: prototype, control, control, prototype.
11052911|NCT04408417|Experimental|Harnessing Sequence C|Participants will harness their child into the 2 different child safety seats in the following order: control, control, prototype, prototype.
11052912|NCT04408417|Experimental|Harnessing Sequence D|Participants will harness their child into the 2 different child safety seats in the following order: prototype, prototype, control, control.
11052913|NCT04408404||Type A aortic dissection|Patient operated for type A acute aortic dissection between 01 January 2007 and 31 December 2017 in Dijon Burgundy University Hospital
11052914|NCT04408391||COVID-19 patients with anosmia|Patients reporting loss of smell and scoring < 30 on a VAS 0-100 for ability to detect n-Butanol diluted 1/1000
11052915|NCT04408391||COVID-19 patients without anosmia|Patients reporting no loss of smell and scoring > 80 on a VAS 0-100 for ability to detect n-Butanol diluted 1/16000
11052916|NCT04408378||mild pneumonia|The patients who has followed in the ward
11052917|NCT04408378||severe pneumonia|The patiens who has followed in the intensive care unit
11052918|NCT04408378||control group|patients who has not covid 19 pneumonia
11052919|NCT04408365||COVID-19 patients|Adult COVID-19 patients admitted to intensive care units
11052920|NCT04408352|Active Comparator|Treatment Arm|A compatible standard cystoscopy lens (30°) will be inserted into the Hologic trigone RF Device. The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Ablations at the trigone will be created using the Hologic trigone RF ablation device together with the compatible standard commercially available RF cannula and generator. It is expected that a subject would receive between 4-6 ablations to completely treat the appropriate area of the trigone. At the completion of the procedure, 200 ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge.
11052921|NCT04408352|Sham Comparator|Sham Arm|"The sham procedure will mimic the Hologic trigone RF ablation device procedure to maintain subject blinding and provide the most accurate assessment of control data while minimizing risk to the subject.
~The bladder will be emptied of urine and saline infused into the bladder to allow adequate visualization and working space. Suction will be applied to the bladder wall and the cannulas (needles) will be introduced into the bladder wall. Energy will not be delivered to the tissue when each sham ablation is started. In order to maintain blinding of the subject, the typical sounds that Hologic trigone RF ablation device makes during actual ablation/fulguration will be replicated. The simulated ablation procedure will be repeated as many times as necessary to cover the area of the trigone. 4 to 6 sham ablations would be required. At the completion of the procedure, 200ml of saline is instilled into the bladder to allow for assessment of voiding function prior to discharge."
11052922|NCT04408326||Angiotensin II|Patients with COVID-19 and acute respiratory distress syndrome who received angiotensin II as an add-on vasopressor will be collected
11052923|NCT04408326||Anakinra|Patients with COVID-19 and acute respiratory distress syndrome who received Anakinra (interleukin 1 receptor antagonist) will be collected
11052924|NCT04408326||Angiotensin II control|Patients with COVID-19 and acute respiratory distress syndrome who also received vasopressor support will be matched to angiotensin II group by date of intensive care unit admission, age, history of hypertension, history of angiotensin converting enzyme inhibitor/angiotensin receptor blocker, respiratory support
11052925|NCT04408326||Anakinra control|Patients with COVID-19 and acute respiratory distress syndrome will be matched to Anakinra group by matching age and date of intensive unit care admission
11052926|NCT04408313|Experimental|XR-B|Extended-release buprenorphine
11052927|NCT04408313|Active Comparator|XR-NTX|Extended-release naltrexone
11052928|NCT04408300|Experimental|Ophthalmological exam|
11052929|NCT04408287|Experimental|Intervention|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
11052930|NCT04408274|Experimental|Computerized Tests|
11052931|NCT04408274|Placebo Comparator|Placebo Control|
11052932|NCT04408261|Experimental|Buqitongluo Granule|Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
11052933|NCT04408261|Placebo Comparator|Placebo|Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
11065012|NCT04321837|Active Comparator|Ibandronate and vitamin D|
11052937|NCT04408222||Awake Proning|COVID-19 patients with hypoxemic respiratory failure with awake prone positioning, as tolerated, up to 24 hours daily.
11052938|NCT04408209|Experimental|Convalescent Plasma|Convalescent Plasma - early treatment of patients with severe COVID-19
11052939|NCT04408196||Patients|100 patients admitted to an inpatient rehabilitation facility
11052940|NCT04408196||Caregivers|100 caregivers of patients admitted to an inpatient rehabilitation facility
11052941|NCT04408183|Experimental|GLS-1200|1 mL of GLS-1200 per nostril, TID
11052942|NCT04408183|Placebo Comparator|0.9 %Saline|1 mL of 0.9% Saline per nostril, TID
11052943|NCT04408157|Experimental|Self-management booklet|Self-management booklet: developed drawing on existing evidence and work conducted by researchers at the Health Psychology section at KCL, tailored to the current circumstances in response to the COVID-19 pandemic.
11052944|NCT04408157|No Intervention|Education only (waiting-list)|Participants allocated to the waiting-list control arm will receive a link via email to educational materials related to COVID produced by King's College London for an online event and will be provided with the self-management booklet after completing the T2 assessment and qualitative interview. The topics covered in the online event are the same as the ones included in the self-management booklet, without structured guidance and behaviour change techniques to facilitate behaviour change.
11052945|NCT04408144|Experimental|StudyGroup|Patients will receive an addition of dydrogesterone (Duphaston) to the standard treatment for luteal phase support
11052946|NCT04408144|No Intervention|Control Group|Patients will receive the standard treatment for luteal phase support without Dydrogesterone
11052947|NCT04408131|Experimental|Homeless people|Blood sample
11052948|NCT04408118|Experimental|Atezolizumab + Paclitaxel + Bevacizumab (Avastin®)|"All eligible patients will be treated with atezolizumab (840 mg) intravenously on days 1 and 15, Paclitaxel (90 mg/m2) on days 1, 8 and 15 via IV infusion and Bevacizumab (Avastin® 10mg/kg) intravenously on days 1 and 15.
~Treatment cycles and patient visits are organized in scheduled cycles of 28 days."
11052949|NCT04408105||Primary Care Providers|400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
11052950|NCT04408105||Gastroenterologists|100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.
11052951|NCT04408105||Patients|500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.
11052952|NCT04408092|Experimental|GM-CSF treatment at second-look surgery arm|Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
11052953|NCT04408092|Experimental|GM-CSF treatment at recurrence arm.|"EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients.
~Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician"
11052954|NCT04408079|Experimental|TQB3558 Tablets|TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
11052955|NCT04408066|Experimental|Arm A:Suspected COVID-19 patients|Arm A: Suspected COVID-19 Patients - SARS-CoV-2 viral antigen test swab and blood sample for SARS-CoV-2 IgG/IgM
11052956|NCT04408066|Experimental|Arm B: Previously positive COVID-19 patients|Arm B: Previously Positive COVID-19 patients - SARS-CoV-2 IgG/IgM blood sample. Capillary fingerstick samples will additionally be collected in Stage 2.
11052957|NCT04408053|Experimental|Preventive fixation of the contralateral femoral neck|Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
11052958|NCT04408053|No Intervention|No fixation|
11052959|NCT04408040|Other|Critical Patients|
11052960|NCT04408040|Other|Severe Patients|
11052961|NCT04408040|Other|High Risk|
11052962|NCT04408040|Other|Health Care Providers|
11052963|NCT04408027|Experimental|Virtual-Care Cognitive Behavioural Therapy|
11052964|NCT04408014||HC-USP|Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
11052965|NCT04408014||CORAS|Refugees living in the city of São Paulo
11052966|NCT04408014||Hemocenter|Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
11052967|NCT04408014||CPP - Butantan Penitentiary Progression Center|Participants of the CPP - Butantan Penitentiary Progression Center
11052968|NCT04408014||CHSP - Penitentiary System Hospital Center|Participants of the CHSP - Penitentiary System Hospital Center
11052969|NCT04408014||SABE (Health, Wellness and Aging)|Participants of the SABE Project (Health, Wellness and Aging)
11052970|NCT04408014||ILPI - Long-Term Care Institution for the Elderly|Residents of the Long-Term Care Institution for the Elderly of Botucatu
11052971|NCT04408014||ICR-USP - Children's Institute of HCFMUSP|Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
11053003|NCT04407741|Experimental|SHR1701|Drug: SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
11053594|NCT04403386||Smokers|Participants who currently smokes and has smoked for at least 5 years
11052972|NCT04408001||Symptomatic individuals|"Hospital staff identified by the COVID-19 case census cell :
~who have been infected (confirmed by a positive RT-PCR result on a nasopharyngeal swab)
~OR who have displayed clinical signs compatible with COVID-19 despite a negative RT-PCR result."
11052973|NCT04408001||Asymptomatic individuals|Hospital staff who have not been identified by the COVID-19 case census cell.
11052974|NCT04407988|Experimental|Pyrotinib plus Letrozole|
11052975|NCT04407975|Experimental|Betamethasone|Patients will receive 14 mg (2 ml) intramuscular betamethasone
11052976|NCT04407975|Placebo Comparator|Placebo|Patients will receive an equivalent volume of normal saline
11052977|NCT04407962|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
11052978|NCT04407962|No Intervention|Control group|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
11052979|NCT04407949|Other|event detection|
11052980|NCT04407936||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention
11052981|NCT04407910|Experimental|Air-powder polishing device|
11052982|NCT04407910|Experimental|Rubber-cup+paste|
11052983|NCT04407897|Experimental|Radiotherapy|Patients with oligometastatic lesions, fulfilling the inclusion/exclusion criteria's will be assigned to SABR.
11052984|NCT04407884|Experimental|study arm|Subjects will receive an active study device.
11052985|NCT04407871|Experimental|acupuncture and CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after embryo transfer (ET). They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
11052986|NCT04407871|Placebo Comparator|acupuncture and placebo CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
11052987|NCT04407871|Placebo Comparator|control acupuncture and CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
11052988|NCT04407871|Placebo Comparator|control acupuncture and placebo CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
11052989|NCT04407832|Active Comparator|low dose PPI|40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
11052990|NCT04407832|Active Comparator|high dose PPI|40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
11052991|NCT04407819||diabetes mellitus type 2|36 patients with diabetes mellitus type 2, aged 20-80 years, attending endocrinology outpatient clinics were studied for the assessment of muscle mass and function compared to controls.
11052992|NCT04407819||CONTROLS|14 community people who visited the endocrinology outpatient hospital clinic for a routine checkup, or with a non-related to diabetes disease.
11052993|NCT04407806|Active Comparator|Continuous Pulse Oximetry Monitoring of Oxygen Saturation|Continuous pulse oximetry to measure oxygen saturation
11052994|NCT04407806|Active Comparator|Intermittent Pulse Oximetry Monitoring of Oxygen Saturation|Intermittent pulse oximetry to measure oxygen saturation, measured every 4 hours
11052995|NCT04407793||Diverticulitis Group|Patients with acute diverticulitis episode
11052996|NCT04407793||Diverticulosis group|Patients diagnosed with diverticulosis without any acute diverticulitis episode
11052997|NCT04407793||Non-diverticulosis|Patients without diverticulosis
11052998|NCT04407767|Experimental|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
11052999|NCT04407767|Active Comparator|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
11053000|NCT04407754|Placebo Comparator|Control Arm|This group will receive placebo powder twice daily.
11053001|NCT04407754|Active Comparator|Inositol Arm|This group will receive myo-inositol (2,000mg) plus d-chiro-inositol (50mg) supplement powder twice daily.
11053002|NCT04407741|Experimental|SHR2554+ SHR1701|Drug: SHR2554 recommended dose from phase Ⅰstudy, PO, twice a day, every 3 weeks SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
11053004|NCT04407728|Experimental|precocious EchoMorpho-T1|Women whose fetus is at high risk of congenital heart disease after the 1st trimester screening echo (EchoT1), will benefit from an early morphological ultrasound centered on the heart (EchoMorpho-T1) by a sonographer referent between 11 and 14 weeks +/- of an early fetal heart ultrasound (EchoCoeur-T1) between 11 and 15 weeks by a cardio-pediatrician in the event of an abnormality with the EchoMorpho-T1.
11053005|NCT04407715|Placebo Comparator|High Flow Anesthesia, Low Flow Anesthesia|. The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow. Group 1 (n = 40) was operated under high flow anesthesia with 50% O2 - 50% air at 2 L/min and desflurane at 1.1 MAC for the duration of the surgery. For anesthesia maintenance, Group 2 (n=40) was administered 50% oxygen - 50% air at 2 L/min and desflurane for 10-15 minutes. After reaching 1.1 MAC, it was switched to minimal flow with 50-60% oxygen- 40-50% air at 0.5 L/min and desflurane. 10 minutes before the end of the surgery, it was switched to high flow with 50% oxygen -50% air at 2 L/min.
11053006|NCT04407715|Active Comparator|Peroperetive Optic Nerve Sheath Diameter|Optic nerve sheath diameter measurements were performed by an experienced and the same anesthetist. In the measurements, the GE Healthcare Logiq e series USG device and 12-MHz linear probe were used. Longitudinal and transverse axis images were obtained on both eyelids while the patient was in the supine position. Measurements were taken 3 mm behind the optic nerve head
11053007|NCT04407702|Experimental|Control Group|The volunteers in this group will receive the same hygiene instructions as the other groups and will undergo both treatments, except that water will be used instead of the sealant and the laser device will be set to a power of 0 W. In other words, the same irradiation procedure will be performed but without the emission of light.
11053008|NCT04407702|Experimental|Sealant Group|The volunteers in this group will receive treatment with sealant (Permaseal - Ultradent), which is a photopolymerizable methacrylate-based resin.
11053009|NCT04407702|Experimental|Low-Level Laser Group|The volunteers in this group will receive irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation.
11053010|NCT04407702|Experimental|Low Level Laser + Sealant Group|The volunteers in this group will receive the same irradiation administered to Low-level Laser Group. During the last session, these volunteers will also receive the same sealant applied in Sealant Group.
11053011|NCT04407689|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
11053012|NCT04407689|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
11053013|NCT04407676|Experimental|Experimental|Patients eligible for an investigator initiated trial are given the standard PIS by email, and are also emailed a summary PIS and access to an online set of 10 video educational modules. They are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They then present for their standard of care consent visit.
11053014|NCT04407676|Placebo Comparator|Control|Patients eligible for an investigator initiated trial are given the standard PIS by email and are then administered a demographic data collection form, the Quality of Informed Consent Questionnaire Parts A and B, and a user feedback survey form. They will then be emailed and are also emailed a summary PIS and access to an online set of 10 video educational modules. They will then perform the QuIC-A and QuIC-B again. They will then present for their standard of care consent visit.
11053015|NCT04407663||Bariatric Patient|Inclusion criteria were as follows: obese adults (> 18 years of age, BMI> 40 or > 35 with comorbidities) older than 18 years; patients undergoing bariatric surgery within 6 months; patients who required clinical and instrumental control; presence of a caregiver in case of subject with cognitive impairment; patients with a history of bariatric surgery who requested a first outpatients access or established patients who requested an outpatients' visit for an emerging problem.
11053016|NCT04407650|Active Comparator|Metformin|Oral 1000 mg BD
11053017|NCT04407650|Experimental|Ursodeoxycholic acid|Oral 500 mg BD
11053018|NCT04407637||neck pain patients|Patients with acute non-specific neck pain were consecutively recruited from a private manual physiotherapy center as sample of convenience. Inclusion criteria were acute (<3months) non-specific neck pain with a neck disability index (NDI) > 8% and a Numerical Pain Rating Scale (NPRS) >3 . Patients were excluded if they reported any of the following: a history of neck surgery, dizziness caused by neck or head movements and cervical radiculopathy diagnosed by a physician.
11053019|NCT04407637||healthy|Healthy control participants were included if they reported a NDI < 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
11053020|NCT04407624|Experimental|Intermittent Exercise Group|Warm-up, loading (walking, squat, sitting down on a chair, limb movements with weights, stepping on steps, walking on different floors), cooling and relaxation exercises
11053021|NCT04407624|Active Comparator|Control Group|Warm-up, loading (brisk walking at 60-85% of maximum heart rate), cooling and relaxation exercises
11053022|NCT04407611|No Intervention|Conventional modality|Control arm. Conventional modality entails telephone disclosure of genetic results by a licensed genetic counselor.
11053023|NCT04407611|Experimental|Online modality|Online self-guided modality entails return of genetic results directly to participants, with optional genetic counselor follow-up via telephone.
11053024|NCT04407598||Glenfield Complex COPD Clinic Cohort|Patients previously seen in the complex COPD clinic at the Glenfield Hospital.
11053025|NCT04407585||Covid-19 Symptom Study app-user|UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
11053026|NCT04407559||Groupe 1|Group 1: Rheumatoid arthritis seropositive for RF (+)
11053027|NCT04407559||Groupe 2|Group 2: Rheumatoid arthritis seronegative for RF (-)
11053028|NCT04407546||Families with Children|Families containing an immunocompromised individual that have children in the family setting.
11053029|NCT04407546||Famlies without children|Families containing an immunocompromised individual that do not have children in the family setting.
11053030|NCT04407520||Adult patients with intellectual and/or physical disabilities|Adult patients with intellectual and/or physical disabilities requiring dental treatment under general anesthesia
11053219|NCT04406064|Experimental|Viral Specific T-cells (VSTs)|
11053031|NCT04407507|Experimental|Ivermectin|Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
11053032|NCT04407507|Placebo Comparator|Placebo|Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
11053033|NCT04407494||COVID-19|Healthcare workers and adult outpatients attending the COVID-19 screening center of the University Hospital of Montpellier, France.
11053034|NCT04407481||Adults with autosomal dominant polycystic kidney disease|All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
11053035|NCT04407481||Healthy Controls|Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).
11053036|NCT04407468||COVID|Patients with or without prone position
11053037|NCT04407455||Children with cerebral palsy|Children who will be referred to pediatric dentistry above the age of 2 years.
11053038|NCT04407455||Children with typical development|Children who will be referred to pediatric dentistry above the age of 2 years.
11053039|NCT04407442|Experimental|Treatment (azacitidine, dexamethasone, daratumumab)|"PRE-INDUCTION (CYCLE 0): Patients receive azacitidine IV on days -7 to -3 in the absence of disease progression or unacceptable toxicity.
~INDUCTION PHASE (CYCLES 1-2): Patients receive azacitidine IV on days 22-26 and dexamethasone IV or PO and daratumumab IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION PHASE (CYCLES 3-6): Patients receive azacitidine IV on days 22-26 of cycle 3 and on days 1-5 of cycles 4-6 and dexamethasone IV or PO and daratumumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE (CYCLES 7+): Patients receive azacitidine IV on days 1-5 and dexamethasone IV or PO and daratumumab IV over 30-60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11053040|NCT04407429||Health care workers|Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
11053041|NCT04407429||Patients|Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples.
11053042|NCT04407416|Active Comparator|Healthy subjects|The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
11053043|NCT04407416|Active Comparator|Colorectal Cancer patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
11053044|NCT04407416|Active Comparator|Colonic Polyps patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
11053045|NCT04407403|Experimental|Tai Chi tailored for lowering blood pressure (PRESSURE)|During the 12-week Tai Chi intervention, participants in the PRESSURE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the PRESSURE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
11053046|NCT04407403|Experimental|Tai Chi tailored for improving balance (BALANCE)|During the 12-week Tai Chi intervention, participants in the BALANCE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the BALANCE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
11053047|NCT04407403|No Intervention|control group (CONTROL)|During the 12-week Tai Chi intervention, participants in the CONTROL group performed their regular daily activities. In addition, participants in the CONTROL group were instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed. Of note, both PRESSURE and BALANCE were offered to participants assigned in the CONTROL group after data collection was completed.
11053048|NCT04407390|Placebo Comparator|Control|Patients receiving placebo.
11053049|NCT04407390|Experimental|NR|Patients receiving nicotinamide riboside (NR-E)
11053050|NCT04407377|Experimental|Tolperisone 200 mg|Study Drug, Tolperisone 200mg TID
11053051|NCT04407377|Experimental|Tolperisone 400 mg|Study Drug, Tolperisone 400mg TID
11053052|NCT04407377|Active Comparator|Cyclobenzaprine|Active Comparator, Cyclobenzaprine 10mg TID
11053053|NCT04407377|Placebo Comparator|Placebo|Placebo, TID
11053054|NCT04407364||Intervention Cohort|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
11053055|NCT04407364||Historical Cohort|Primary and Revision total hip arthroplasty patients between 18-85 years of age
11053056|NCT04407351|Other|Arm Green LED light - Red LED light|Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks, the rest of the time indoors is not limited by light. Then crossover to red light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks.
11053057|NCT04407351|Other|Arm Red LED light - Green LED light|Every morning between 7-8 o'clock, participants receive 50 Lux of Red LED light (dim light) at their own homes and illuminate at a distance of 80-100 cm at a 45-degree angle for 30-60 minutes for 12 weeks, and the rest of the time indoors is not restricted by light. Then crossover to green light after 2 weeks for wash out. Every morning between 7-8 o'clock, participants will receive 7,500 Lux at home at 470 nm as a full-band (bright light) light-emitting diode (Green LED light) luminaire with a distance of 80-100 cm at a 45-degree angle Light exposure for 30-60 minutes for 12 weeks.
11053058|NCT04407338|Experimental|B-DYN Device|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
11053059|NCT04407338|Active Comparator|Conventional bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
11053060|NCT04407325|Experimental|AeoNose|the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
11053061|NCT04407312|Experimental|CILO group|"Intervention:
~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.
~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.
~For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).
~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.
~Drug:
~Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
11053062|NCT04407312|Placebo Comparator|Placebo group|"Intervention:
~Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room.
~After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence.
~In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily).
~Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial.
~Drug:
~Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily."
11053063|NCT04407299||1|180 patients diagnosed with autoimmune rheumatic disease. Patients are RA SLE Rhupus AS Behcet Sjogren Vasculitis FM Polymyalgia APA Sarcoidosis IBD Scleroderma DM PSA Mixed
11053064|NCT04407299||2|control group composed of 180 healthy individuals (matched for age and sex)
11053065|NCT04407286|Experimental|Treatment Group|"This group will receive vitamin D.
~The dosage for the first two weeks will be 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+)
~After two weeks of taking vitamin D, if vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation."
11053066|NCT04407273||with statins|Covid-19 infected patients with statins
11053067|NCT04407273||without statins|Covid-19 infected patients without statins
11053068|NCT04407260||Intervention|Patients on oxygen hoods who have fail conventional high-flow oxygen delivery systems.
11053069|NCT04407260||Control|Patients maintained on conventional high-flow oxygen delivery systems (such as non-rebreather masks, high-flow nasal cannula, BiPAP, CPAP) or who have failed on these conventional symptoms and were subsequently mechanically ventilated.
11053070|NCT04407247|Active Comparator|Arm I (infliximab)|Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
11053071|NCT04407247|Experimental|Arm II (vedolizumab)|Patients receive vedolizumab IV over 1 hour at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.
11053072|NCT04407234|Experimental|Tirzepatide + Acetaminophen|Tirzepatide administered subcutaneously (SC) and acetaminophen administered orally.
11053073|NCT04407208|Experimental|Convalescent plasma recipient|Recipients receive 3 times of each 100 ml convalescent plasma on day 0, 3, and 6
11053074|NCT04407195||Healthcare Providers|Healthcare workers (physicians and nurses) who have interacted with patients with known or suspected COVID-19.
11053075|NCT04407182|Experimental|Viusid Plus Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.
~A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.
~Treatment duration: 21 days."
11053076|NCT04407182|No Intervention|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.
~Treatment duration: 21 days."
11053077|NCT04407169||Patients without chronic respiratory disease|All patients hospitalized for severe CoVid-19 without chronic respiratory disease
11053078|NCT04407169||Patients with chronic respiratory diseas|Patients hospitalized for severe CoVid-19 with one chronic respiratory disease
11053079|NCT04407143||lung cancer+COVID-19|Lung cancer patients infected by COVID-19
11053080|NCT04407130|Active Comparator|Tab Ivermectin +Cap Doxycycline|"200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)
~+ Placebo one tablet D2-5"
11053081|NCT04407130|Active Comparator|Tab Ivermectin|"Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5
~+ Placebo two tablets D1 followed by Placebo one tablet D2-5"
11053082|NCT04407130|Placebo Comparator|Placebo|"Drug: Placebo
~3 Placebo tablets D1 followed by 2 tablets D2-5"
11053083|NCT04407091|Experimental|[14C]AZD4831 Oral Solution|One 10 mg dose of [14C]AZD4831 Oral Solution
11053084|NCT04407078|Experimental|Sugammadex group|Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
11053085|NCT04407078|Placebo Comparator|Neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
11053086|NCT04407065|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
11053087|NCT04407065|Active Comparator|HCG|HCG is used to trigger ovulation
11053088|NCT04407052|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
11053089|NCT04407052|Active Comparator|HCG|HCG is used to trigger ovulation
11053090|NCT04407039||Glioma molecular subtype: G-CIMP-low|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053091|NCT04407039||Glioma molecular subtype: G-CIMP-high|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053092|NCT04407039||Glioma molecular subtype: codel|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053093|NCT04407039||Glioma molecular subtype: classic-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053094|NCT04407039||Glioma molecular subtype: mesenchymal-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053095|NCT04407039||Glioma molecular subtype: LGM6-GBM|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053096|NCT04407039||Glioma molecular subtype: PA-like|one of molecular subtypes according to gene expression, DNA copy number, DNA methylation, exome sequencing and protein expression of glioma
11053097|NCT04407026||Healthy|Healthy control group (n=25) consisted of the volunteers having clinically healthy gingiva, PD≤3 mm, BOP<10% and no sign of clinical attachment loss and radiographic alveolar bone destruction.
11053098|NCT04407026||Gingivitis|Gingivitis group (n=25) had PD≤3 mm with BOP>50% in the entire mouth, and no clinical attachment loss or alveolar bone loss.
11053099|NCT04407026||Stage 3 periodontitis|Stage 3 periodontitis group included the patients exhibiting PD ≥6 mm and interdental CAL ≥5 mm at %30 or more teeth. They had no more than four teeth loss.
11053100|NCT04407013|Experimental|A|Experimental group with application of the standardized care pathways and symptom management education
11053101|NCT04407013|Other|B|Control group with usual care
11053102|NCT04407000|Experimental|Test Drug|Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)
11053103|NCT04407000|Active Comparator|Reference drug|Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)
11053104|NCT04406987||decompression|patients treated with decompression for lumbar spinal stenosis
11053105|NCT04406987||fusion|patients treated with decompression with fusion for lumbar spinal stenosis
11053106|NCT04406974||Patients with local recurrence|
11053107|NCT04406974||Patients with advanced colorectal cancer|
11053108|NCT04406961|Active Comparator|Standard sphincterotomy.|"Standard retrograde sphincterotomy is performed on 750 patients using a standard sphincterotome. After deep bile duct cannulation, the standard sphincterotome, the Erlangen pull-type model, retrogradely cuts all layers of the wall of the duodenum and sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve insert standard sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis."
11053109|NCT04406961|Active Comparator|Antegrade sphincterotomy. ASD.|750 patients underwent a new antegrade sphincterotomy using the new sphincterotome design developed by Dr. Dovbenko (ASD). After deep bile duct cannulation, the new design of sphincterotome, antegradely cuts only circular muscle layer of the sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve cannulation new design sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis.
11053110|NCT04406948|Experimental|MGCND00EP1|"Participants who will assigned to receive add on MGCND00EP1 will receive carrier oil containing THC and CBD in ratio 20:1, (10% of cannabidiol and 0.5 % and (-)-trans-Δ9-tetrahydrocannabinol) .
~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).
~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.
~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
11053111|NCT04406948|Placebo Comparator|PLACEBO|"Participants who are assigned to receive add on PLACEBO will be administered the carrier oil (without the active ingredients).
~Titration Dose: 1 to 2 mg/kg body weight/day. dose will be increased every week by 2 mg/kg body weight/day up to a maximum 25 mg/kg body weigh/day or maximum daily dose 800 mg (the smaller of those 2 values) (divided into two daily doses).
~After titration, patients will be receiving a stable maintenance dose of IMP (up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller)) for 6 weeks period.
~During forth treatment period participants will commence a 2 weeks down-titration taper period, followed by 4 weeks observational follow up period of previous standard AE treatment without IMP."
11053112|NCT04406935|Active Comparator|475 KHz|NuEra device treatment using 475 KHz
11053113|NCT04406935|Active Comparator|1 MHz|Arm 2: NuEra device treatment using 1 MHz
11053114|NCT04406935|Active Comparator|2 MHz|NuEra device treatment using 2 MHz
11053115|NCT04406922|Experimental|Intervention group|Cold exposure in the morning and evening.
11053116|NCT04406909|Experimental|Training|Access to training at membership training facility
11053117|NCT04406909|No Intervention|No training|No access to training at membership training facility
11053118|NCT04406896|Experimental|Participants with mild hepatic impairment (Group 1)|Participant with Child-Pugh Grade A Score of 5-6.
11053119|NCT04406896|Experimental|Participants with moderate hepatic impairment (Group 2)|Participant with moderate hepatic impairment with a Child-Pugh Grade B Score of 7-9.
11053120|NCT04406896|Experimental|Healthy participants (Group 3)|
11053121|NCT04406883|Active Comparator|A (Simavastatin 10 mg with gelatin sponge graft)|A group: After atraumatic extraction, filled the tooth socket with Simvastatin10 mg solution impregnated gelatin sponge.
11053122|NCT04406883|Active Comparator|B(Gelatin sponge graft )|B group: Following atraumatic extraction, put in the tooth socket with gelatin sponge.
11053123|NCT04406870|Experimental|Intervention|patients with propranolol-resistant IHHE are given propranolol combined with sirolimus
11054426|NCT04397939||Patients without cardiac injury|Patients without cardiac injury
11053124|NCT04406857|Experimental|Treatment (ropidoxuridine, capecitabine, radiation therapy)|Patients receive ropidoxuridine PO BID over 7 days per week and capecitabine PO BID over 6 days per week for 6 weeks. Patients also undergo radiation therapy over 1 fraction per day for 5 days per week (Monday-Friday) during weeks 1-5 and for 3 days during week 6 in the absence of disease progression or unacceptable toxicity. Approximately 8-12 weeks after completion of treatment with ropidoxuridine, capecitabine, and radiation therapy, patients undergo standard of care surgery.
11053125|NCT04406831||New Unresectable Pancreatic Cancer|Individuals with biopsy-proven adenocarcinoma of the pancreas, classified as locally advanced or metastatic disease
11053126|NCT04406831||Control|Healthy individuals without cancer diagnoses to provide reference microRNA
11053127|NCT04406818|Active Comparator|Healthy Control|
11053128|NCT04406818|Active Comparator|Sickle Cell Anemia|
11053129|NCT04406805||Severe aortic stenosis|Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation
11053130|NCT04406792|Experimental|ALIVE Program|"Post-partum doulas for in home support and BP/glucose screening via telehealth visits after hospital discharge
~Weekly community sponsored agriculture (CSA) boxes/ gardening lessons by a local farmer and virtual culturally sensitive recipe demonstrations.
~Assess DNA methylation to identify differentially methylated genes important in the pathogenesis of Type 2 DM and chronic hypertension (CHTN)"
11053131|NCT04406792|Active Comparator|Diabetes Prevention Program (DPP) online|Diabetes Prevention Program (DPP) curriculum as outlined by the Centers for Disease Control and Prevention (CDC) using an online platform. Enrolled participants randomized to DPP only will be enrolled into the Fruit street program at www.fruitstreet.com for one year. As a member of Fruit street, they are provided with a wireless scale, a Fitbit activity tracker and have access to a video chat with a licensed dietitian and online support from other Fruit street participants. They will also sign a medical release and be followed 12 weeks post-partum up to 2 years to assess if they have completed recommended screening and whether or not they developed Type 2 DM or CHTN as defined above.
11053132|NCT04406792|Other|Standard of Care|1 week post-partum followup for blood pressure check and 6 weeks post-partum follow-up and screening for Type 2 DM CHTN.
11053133|NCT04406779||Patients with breast cancer|Patients with breast cancer
11053134|NCT04406779||Control|Healthy patients without breast cancer
11053135|NCT04406766|Experimental|Connected nutrition pump system|
11053136|NCT04406753|Experimental|Manual Therapy + Exercise Group|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
11053137|NCT04406753|Active Comparator|Exercise Group|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.
~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
11053138|NCT04406740||All Participants|Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia in the MHealth East Bank operating rooms in which the administration of a nondepolarizing neuromuscular blocking drug (rocuronium or cisatracurium) is anticipated.
11053139|NCT04406727|Experimental|UB-421|"2-arm Comparison Phase: UB-421(25 mg/kg, every 2 weeks) in combination with ARV
~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
11053140|NCT04406727|Active Comparator|Placebo|"2-arm Comparison Phase: Placebo in combination with ARV
~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
11053141|NCT04406714|Experimental|Mailed FIT|Patients randomized to this arm will receive mailed FIT plus up to two reminder letters to complete and return the FIT. Patients with a positive (abnormal) FIT result will be offered patient navigation to facilitate follow-up colonoscopy.
11053142|NCT04406714|No Intervention|Usual Care|Patients randomized to this arm will receive usual care. Current usual care at the participating community health centers consists of a visit-based FIT distribution approach.
11053143|NCT04406675|Other|Patients Amyotrophic Lateral Sclerosis|
11053144|NCT04406675|Other|Control subjects|
11053145|NCT04406649|Experimental|STS101|STS101 (dihydroergotamine nasal powder), low dose
11053146|NCT04406623|Experimental|SL-172154|Intravenous administration
11053147|NCT04406610|Experimental|GD2 CAR-T|Treated by GD2 CAR-T therapy intravenously
11053148|NCT04406610|No Intervention|Control|With no medical intervention
11053149|NCT04406597|Experimental|the New Tissue Containment System group|Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy
11053150|NCT04406597|No Intervention|Open group|Without any protection system during Laparoscopic Ovarian Cystectomy
11053151|NCT04406584|Placebo Comparator|Saline|Injection of 1cc saline into olfactory cleft x4
11053152|NCT04406584|Experimental|Platelet Rich Plasma|Injection of 1cc patient's own platelet rich plasma (PRP) into olfactory cleft x4
11053153|NCT04406571||"pancreatic adenocarcinoma before COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.
11053154|NCT04406571||"pancreatic adenocarcinoma after COVID-19 containment  group"|patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.
11053155|NCT04406545||healthy volunteers|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
11053156|NCT04406545||cardiovascular disease and COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
11053157|NCT04406545||cardiovascular disease without COVID-19 infection|skin laser Doppler perfusion monitoring before and after local thermal hyperemia
11053158|NCT04406532|Experimental|PT-Pal|Participants randomized to the 14-day intervention arm will receive exercise instructions via PT-Pal. The Pt-Pal is a mobile health technology used to facilitate communication between the Care Team and patients, by allowing the team to send from their web-portal, exercise routines, surveys and educational material to the patient's mobile device. The PT-Pal app then captures the patient activity adherence, and reports those results back to the team including a graphical summary about patients' condition and activity. Clinicians can send/receive HIPAA-secure messages with patients. The app was designed to work with intermittent data connectivity typically found in mobile networks by switching between store-and-forward and real-time mode of connectivity to ensure data delivery.
11053159|NCT04406532|Active Comparator|Self-guided exercises|Participants randomized to the 14-day control arm will be instructed by research staff on how to use the exercise manual provided at the time of their screening.
11053160|NCT04406519||Hemophilia Group|The inclusion criteria in the hemophilia group were as follows; patients aged 6 to 18 years who developed HA in at least one of the lower limb joints due to severe haemophilia (total lower limb HJHS ≥3); to be receiving prophylaxis but have no major bleeding that could affect the musculoskeletal system in the past two weeks; and who did not perform regular physical activity and sports.
11053161|NCT04406519||Control Group|The control group was consisted of healthy peers. The exclusion criteria in the control group were as follows: who had any auditory and visual impairment; who underwent orthopedic injuries including lower limb; and who had any neurological or cognitive impairment that could affect balance.
11053162|NCT04406506||Group A|Group A received nasogastric feeding (NG), insure through ngt pump
11053163|NCT04406506||Group B|"receive feeding throughThe nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.
~Patients were placed in right lateral position"
11053164|NCT04406493|Experimental|COVID 19 patients|"COVID 19 patients are admitted to the Infectious Diseases Unit, will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.
~During the hospitalization each patient will undergo this examination twice a day until discharged.
~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need for mechanical ventilation will be measured."
11053165|NCT04406480|Other|90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)|
11053166|NCT04406454||Heathy volunteers|Patients has healthy skin at 5 anatomical locations including face, back, dorsal forearm, volar forearm, calf and at least a nevus without superficial scales and crusting.
11053167|NCT04406441|No Intervention|Standard of Care|Participants will attend regularly scheduled well child visits (WCV) that follow standard clinical guidelines. Well child visits will include review of history, age-appropriate measurements (height/length, weight, body mass index (BMI), blood pressure), sensory and developmental screenings, physical exam, immunizations, oral health review, and anticipatory guidance (preventive counseling).
11053168|NCT04406441|Active Comparator|Patient Reported Outcome|Arm 2 builds on the standard of care WCV by adding a patient reported outcome measure, the Family Nutrition and Physical Activity risk assessment, to inform family-centered preventative counseling during clinical care.
11053169|NCT04406441|Active Comparator|Patient Reported Outcome + Food Care|Participants will receive all Arm 2 components, in addition to be referred to both the Geisinger Wellness Program for a Parent Training Program and a grocery store nutritionist for a tour aligned with the Cooking Matters program.
11053170|NCT04406428|Experimental|NKI followed by EBD|
11053171|NCT04406428|No Intervention|Standard EBD|
11053172|NCT04406415|Experimental|10 mg|10 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
11053173|NCT04406415|Experimental|50 mg|50 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
11053174|NCT04406415|Experimental|100 mg|100 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
11053175|NCT04406415|Experimental|200 mg|200 mg nafamostat three times a day (t.i.d., approximately q8h) for up to 5 days
11053176|NCT04406415|Placebo Comparator|Placebo|Placebo administered three times a day (t.i.d., approximately q8h) for up to 5 days
11053177|NCT04406402|Experimental|Acute glucose tolerance test|A standard oral glucose tolerance test (75 grams of dextrose in 180 cc of water)
11053178|NCT04406402|Experimental|Acute protein load test|A protein-rich, vanilla-flavored powder (Pro-gym, Telpharma, Is
11053179|NCT04406402|Experimental|Acute fat load test|a 100-gram portion of sweet cream containing 300 Kacls, of which 94% of the ingested calories were fat
11053180|NCT04406402|Experimental|Acute alcohol load test|Vodka (100 cc, 40% alcohol)
11053181|NCT04406402|Experimental|Acute exercise|30 minutes of supervised graded walking on a treadmill according to each subject's individual ability. A goal heart rate was calculated as 70% of the age-adjusted maximal allowable heart rate.
11053182|NCT04406402|Experimental|Lifestyle modification program - 12 weeks|12 weeks of weight-loss dietary program constructed according to the guidelines of the American Diabetes Association. Based on weight, gender, and age, daily dietary allowance varied at 1200-1800 Kcal, 50% carbohydrates, 20% protein, and 30% fat. Participants were also asked to engage in moderate physical activity comprised of a 40-minute walk three times a week. A weekly clinic visit alternating with a weekly telephone contact was also required.
11053183|NCT04406389|Active Comparator|Intermediate Dose Prophylaxis|"Subjects will receive one of the following interventions, at their physician's discretion:
~Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min
~Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min
~If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.
~Fondaparinux (if history of heparin-inducted thrombocytopenia [HIT]) 2.5 mg daily subcutaneously"
11053220|NCT04406051|Active Comparator|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive colloid preloading (5 mL/kg)
11054501|NCT04397289|Sham Comparator|Control group|No preventive intervention measures.
11053184|NCT04406389|Experimental|Therapeutic Dose Anticoagulation|"Subjects will receive one of the following interventions, at their physician's discretion:
~Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).
~Enoxaparin 1 mg/kg subcutaneously every 12 hours
~Argatroban (if heparin-induced thrombocytopenia [HIT]), dosed according to institutional protocol.
~Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:
~≥100 kg: 10 mg daily
~<100 kg but ≥50 kg: 7.5 mg daily
~<50 kg: 5 mg daily"
11053185|NCT04406376|Active Comparator|Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)
11053186|NCT04406376|Active Comparator|No Tapering Down of Steroids|Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)
11053187|NCT04406350|Experimental|Study group - MRI CO2 and O2 stress test|Pilot Study of Feasibility of tight control of end-tidal respiratory gases during conduct of anesthesia
11053188|NCT04406337|Experimental|Low intensity pulsed ultrasound|Participants in this arm will receive low intensity pulsed ultrasound therapy on the affected knees for 20 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
11053189|NCT04406337|Active Comparator|High intensity continuous ultrasound|Participants in this arm will receive high intensity continuous ultrasound therapy on the affected knees for 10 minutes per day, 5 days a week for 4 weeks. Conventional physiotherapy of quadriceps muscle exercise and health education about life style will also be given.
11053190|NCT04406324||SARS-CoV-2 patients|Patients infected by SARS-CoV-2
11053191|NCT04406298|Experimental|Small Quantity Paracentesis|Intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days.
11053192|NCT04406298|Active Comparator|Large Volume Paracentesis|Large Volume Paracentesis > 5 litres
11053193|NCT04406285|Active Comparator|Leukemia Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
11053194|NCT04406285|Experimental|Leukemia Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
11053195|NCT04406285|Active Comparator|Lymphoma Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
11053196|NCT04406285|Experimental|Lymphoma Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
11053197|NCT04406272|Experimental|Before and After Surgery|"VB-111 will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.
~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
11053198|NCT04406272|Experimental|After Surgery|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.
~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
11053199|NCT04406272|Experimental|After Surgery Standard of Care|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.
~Upon recovery from surgery, participants will receive standard of care treatment every 6 weeks until tumor growth is evidenced a two consecutive time points."
11053200|NCT04406259|Other|Verapamil|administration of verapamil to treat cluster headache
11053201|NCT04406246|Experimental|Nitazoxanide early treatment|Health workers with symptoms of COVID-19 not requiring hospitalization will receive an early treatment with nitazoxanide.
11053202|NCT04406220|Active Comparator|Small clog size|
11053203|NCT04406220|Active Comparator|Large clog size|
11053204|NCT04406207||Patients|Patients relapsing or not after hematopoietic stem cell transplantation.
11053205|NCT04406194|Experimental|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
11053206|NCT04406194|Experimental|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
11053207|NCT04406181|Other|operation deferred|Adult patients whose operation date has been deferred due to the pandemic
11053208|NCT04406181|Other|no operation date|Patients who did not have had an operation date and who were told to need cardiac surgery before the pandemic started
11053209|NCT04406181|Other|postoperative consultation deferred|Patients who have been operating on during the month before the pandemic
11053210|NCT04406155||Patients with suspicion of rectosigmoid endometriosis|
11053211|NCT04406142|Experimental|treatment feasibility|feasibility, safety and effectiveness assessment
11053212|NCT04406129|Experimental|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
11053213|NCT04406129|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
11053214|NCT04406116|Experimental|patients receiving microwave therapy using the HS1 Instrument|
11053215|NCT04406103|Experimental|Sleepwell|Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)
11053216|NCT04406103|Active Comparator|Empower|Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)
11053217|NCT04406103|No Intervention|TAU|Treatment-as-usual group: no mailed intervention package.
11053218|NCT04406077|Experimental|Intervention|Patients suffering from hydrocele, underwent treatment using Ligasure device.
11053221|NCT04406051|Active Comparator|norepinephrine infusion and crystalloid co-loading (NOR-CRYS)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive crystalloid co-loading (10 mL/kg)
11053222|NCT04406038||Healthy adults|Healthy adults randomly sampled from the population of Saint Petersburg
11053223|NCT04406025||participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have attended a Regional Anesthesia Seminar taking place once a year
11053224|NCT04406025||no participation in Regional Anesthesia Seminar|this group consists of anesthesiologists that have not attended a Regional Anesthesia Seminar taking place once a year
11053225|NCT04406012|Active Comparator|block group|Paravertebral group at Thoracic 9-10 vertebrae level with an in-plane technique advanced ultrasound guided 10 ml bupivacaine hydrochloride (Marcaine 0.5%, Astra Zeneca) in 20 ml volume was enjected in the paravertebral area with real-time visualisation It was observed that the local anesthetic drug spread on the pleura and the pleura was pushed. All blocks were performed by the same experienced anaesthesiologist.
11053226|NCT04406012|No Intervention|Control group|Conventional analgesia methods were applied to the control group. Control group was relieved by dexketoprofen 50mg intravenously. If the patient was not relieved with dexketoprofen and VAS score >4, tramadol 1 mg kg-1 was administered intravenously.
11053227|NCT04405999|Experimental|Treatment group|medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride
11053228|NCT04405999|No Intervention|Control group|medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride
11053229|NCT04405986|Experimental|Electrophysiological procedure|Brainstem reflexes and neural conduction will be explored using Auditory Evoked Potentials (AEP) and blink and Masseter Inhibitory Reflex (MIR) in hospitalised patients with COVID infection
11053230|NCT04405973||COVID-19 ARDS, vv-ECMO|All patients in the study centers with diagnosed COVID-19 infection (PCR proven) and treatment with vv-ECMO
11053231|NCT04405960|Experimental|Intervention group|Individuals in intervention group were given oral Vitamin D supplements (Alphacalcidol 1 µg) once daily
11053232|NCT04405960|Placebo Comparator|Control Group|Individuals in control group were given placebo once daily
11053233|NCT04405947|Other|deltopectoral|deltopectoral surgical approach
11053234|NCT04405947|Other|antero-superior|antero-superior approach
11053235|NCT04405934|Other|Genomic-sequence informed IPC measures|Cohort follow baseline (no report receipt), then rapid vs standard sequencing report receipt phase, then return to baseline phase (no report receipt)
11053236|NCT04405921|Experimental|Hydroxychloroquine associated to azithromycin|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. Azithromycin: 500 mg at day 1 then 250 mg/day for 4 days. with standard of care in association to treatments.
11053237|NCT04405921|Active Comparator|Hydroxychloroquine with placebo|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. with standard of care in association to treatments.
11053238|NCT04405908|Active Comparator|Adult Group 1|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg.
11053239|NCT04405908|Active Comparator|Adult Group 2|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
11053240|NCT04405908|Active Comparator|Adult Group 3|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
11053241|NCT04405908|Active Comparator|Adult Group 4|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg .
11053242|NCT04405908|Active Comparator|Adult Group 5|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
11053243|NCT04405908|Active Comparator|Adult Group 6|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
11053244|NCT04405908|Active Comparator|Adult Group 7|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg .
11053245|NCT04405908|Active Comparator|Adult Group 8|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
11053246|NCT04405908|Active Comparator|Adult Group 9|Adult healthy subjects (18 to 54 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
11053247|NCT04405908|Active Comparator|Elderly Group 10|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with AS03 adjuvant.
11053248|NCT04405908|Active Comparator|Elderly Group 11|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 3 µg with CpG 1018 plus Alum adjuvant.
11053249|NCT04405908|Active Comparator|Elderly Group 12|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with AS03 adjuvant.
11053250|NCT04405908|Active Comparator|Elderly Group 13|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 9 µg with CpG 1018 plus Alum adjuvant.
11053251|NCT04405908|Active Comparator|Elderly Group 14|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with AS03 adjuvant.
11053252|NCT04405908|Active Comparator|Elderly Group 15|Elderly healthy subjects (55 to 75 years of age, inclusive) receive SCB-2019 30 µg with CpG 1018 plus Alum adjuvant.
11053253|NCT04405895|Experimental|Breakfast Diet (3Mdiet)|The Breakfast Diet (3Mdiet) will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
11053254|NCT04405895|Active Comparator|Allday Diet (6Mdiet)|The Allday Diet (6Mdiet) will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% in each of the three snacks.
11053255|NCT04405843|Experimental|Ivermectin|Ivermectin, 300 micrograms / kg, once daily for 5 days
11053256|NCT04405843|Placebo Comparator|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
11053257|NCT04405804|Experimental|Ivabradine|Eligible patients will be given treatment with ivabradine during a titration period which will last from a minimum of 3 days to a maximum of 15 days. This will be followed by a maintenance period of another 14 days. At the end of maintenance period, primary endpoint will be assessed. After maintenance period, the patient will continue ivabradine at the same dosage during a follow-up period that will last 4 months.
11053321|NCT04405297||Knee Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected knee joint.
11053258|NCT04405791|Experimental|Active stimulation group|"low intensity transcranial focused ultrasound (tFUS) stimulationThe acoustic intensity output of the FUS transducer was validated at the maximum intensity area using a calibrated needle hydrophone (HNR-500, Onda). The incident acoustic intensity and pressure at the FUS focus were 3W/cm2 spatial-peak pulse-average acoustic intensity (Isppa) and a peak negative pressure (Pr) of 300 kPa. The incident acoustic intensity and pressure at the FUS focus were 3W/cm2, and tone burst duration was 1 ms at 50 % duty cycle (thus, pulse repletion frequency was 500 Hz) for the duration of 300 ms, according to the studies in humans. Each sonication was delivered every 6 s for the duration of 20 min (a total FUS stimulation per each session was therefore 200 times). With a derating factor of 55% reduction in pressure transmission by the human skull, estimated in situ Pr was ~135 kPa with an in situ acoustic intensity of 600 mW/cm2 Isppa ."
11053259|NCT04405791|Sham Comparator|Sham stimluation group|"sham stimulation In case of sham stimulation, the same procedure was repeated without providing actual sonication. No subjects in FUS condition hear/feel any tangible somatosensory phenomena; therefore, the sham condition was indistinguishable."
11053260|NCT04405778|Experimental|TAK-102 Cohort 1|TAK-102, 1 × 10^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 30 minutes.
11053261|NCT04405778|Experimental|TAK-102 Cohort 2|TAK-102, 1 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 30 minutes.
11053262|NCT04405778|Experimental|TAK-102 Cohort 3|TAK-102, 1 × 10^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 30 minutes.
11053263|NCT04405765|Active Comparator|Lyopreserved Stravix|Treated with NPWT and lyopreserved Stravix
11053264|NCT04405765|Active Comparator|Cryopreserved Stravix|Treated with NPWT and cryopreserved Stravix
11053265|NCT04405752||12-mm diameter metallic billiary stent|
11053266|NCT04405752||10-mm diameter metallic billiary stent|
11053267|NCT04405739|Experimental|EIDD-2801 twice daily (BID) for 5 days|Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
11053268|NCT04405739|Placebo Comparator|placebo (PBO) twice daily (BID) for 5 days|
11053269|NCT04405713|Active Comparator|from the onset of symptoms within the first 3 days (group 1)|ELC for ACC from the onset of symptoms within the first 3 days (group 1)
11053270|NCT04405713|Active Comparator|from the onset of symptoms within the 4-7 days|ELC for ACC from the onset of symptoms within the4-7 days (group II)
11053271|NCT04405713|Active Comparator|from the onset of symptoms beyond 7 days|ELC for ACC from the onset of symptoms beyond 7 days (group III)
11053272|NCT04405700||Cohort 1 (C1)|Prospective recruitment of pregnant women enrolling in ANC at the site. All HIV+ pregnant women and a 1:1 systematic sample of HIV- pregnant women enrolling in antenatal clinic at the site will be prospectively enrolled in the study. In addition, medical record data for the mother and infant will be collected at the time of delivery for all women who deliver at the site and as such will contribute to a subset of C2 (below). Women enrolled in C1 who do not deliver at the site will be contacted by phone and through field follow-up to ascertain their pregnancy and infant outcomes. Infants born to women enrolled in this component who are suspected of having CAs will be enrolled as outlined in C3 (below) if their mothers deliver at the site. If their mothers do not deliver at the site these infants will be enrolled in the field. Photos/videos of infants with CAs will also be taken for review and classification by a panel of experts (see C3 below).
11053273|NCT04405700||Cohort 2 (C2)|Cross-sectional data collection for deliveries at the site. Data will be collected retrospectively from medical records for all women who deliver at the site (including the women enrolled in C1 above), as well from the medical records of all newborn infants and stillbirths delivered at the site. Missing or incomplete information in the woman or her infant's medical record will be clarified by contacting the woman to provide this information.
11053274|NCT04405700||Cohort 3 (C3)|Photos/videos of infants with CAs. All newborn infants and stillbirths ≥ 24 weeks gestational age delivered at the site, as well as all infants born to women enrolled in C1, will be assessed by surface exam for the presence of CAs. Video and photographs will be taken of CAs identified on surface exam. These images will be reviewed and classified by panel of experts in genetics, dysmorphology and teratology. Mothers of infants with major CAs will be contacted by phone at 1, 6, and 12 months post-delivery to ascertain their infants' vital status and care engagement status.
11053275|NCT04405687||Severe head and face deformity|
11053276|NCT04405674|Experimental|Tislelizumab plus chemotherapy|Tislelizumab plus Carboplatin/Nab-paclitaxel as induction treatment and followed by Tislelizumab plus pemetrexed as maintenance treatment.
11053277|NCT04405622|Experimental|Toripalimab plus gemcitabin arm|Subjects receive gemcitabine and toripalimab.
11053278|NCT04405609|Experimental|ArmAssist group|"The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage).
~Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months.
~The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians."
11053279|NCT04405596|Experimental|Ambroxol|Participants randomized to the 1350 mg/day group will begin with a dose of 450 mg, increasing bi-weekly to a dose of 1350 mg/day.
11053280|NCT04405596|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
11053281|NCT04405570|Experimental|EIDD-2801 twice daily (BID) for 5 days|Dose A, Dose B, Dose C, Dose D, Dose E
11053282|NCT04405570|Placebo Comparator|placebo (PBO) twice daily (BID for five days|
11053283|NCT04405544|Other|Main|patients with COVID-19 and Acute Encephalopathy
11053284|NCT04405544|Other|Control|patients with COVID-19 without Acute Encephalopathy
11053318|NCT04405310|Experimental|EXP-PC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
11053319|NCT04405310|Placebo Comparator|EXP-NONPC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
11053320|NCT04405297||Hip Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected hip joint.
11053285|NCT04405531|Experimental|task-oriented training(TOT)|The first phase of the TOT, functional activity analysis, was performed for the activities, for which performance problem was determined by Canadian Occupational Performance Measure (COPM) and Functional Independence Measure for Children (WeeFIM). In the second phase, the occupational performance, fatigue and functional independence levels that prevent the realization of the activity were determined by functional activity analysis. These designated occupational performance, fatigue and functional independence levels constitute the task of this study, as we aim to improve children's functionality. In the third phase, various functional activities including these tasks were executed. The TOT was practiced by following the above mentioned steps for each performance area. All the activities were designed for the inpatient settings of children.
11053286|NCT04405531|Experimental|conventional occupational therapy (COT)|The treatment efficacy determined by the therapist was provided by considering the functional level in order to achieve the desired goal by the participant. The COT included functional activities based on the client-centered principles of the neuro-developmental approach. All the sessions started with relaxation training combined with breathing exercises. At the end of approximately 10 minutes of application time, individualized functional activities were implemented.
11053287|NCT04405518|Active Comparator|Control group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.
~Formula: 8mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
11053288|NCT04405518|Experimental|intervention group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.
~Formula: 11mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
11053289|NCT04405505|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11053290|NCT04405505|Active Comparator|Paclitaxel for injection (albumin bound)|Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.
11053291|NCT04405492|Experimental|Population 1 : Patients|Hospitalized patients, positive or suspected of SARS-CoV-2 infection
11053292|NCT04405492|Experimental|Population 2 : Hospital caregivers exposed to SARS-CoV-2|Longitudinal study of a hospital caregiver cohort
11053293|NCT04405492|Experimental|Population 3 : Lay users|Suitability of rapid test in view of its intended purpose for self-testing
11053294|NCT04405479||Patients with multiple sclerosis|MS patients will be chosen by an independent neurologist.
11053295|NCT04405479||Healthy volunteers|Healthy controls will be paired by age and sex with MS patients.
11053296|NCT04405466||Group 1|Workers working within a production area
11053297|NCT04405466||Group 2|Workers working within a laboratory area
11053298|NCT04405466||Group 3|Workers working within other areas
11053299|NCT04405453|Active Comparator|Trapezius Muscle İnjection (TMI) group|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
11053300|NCT04405453|Active Comparator|Erector Spina Plane Block (ESPB) group|ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
11053301|NCT04405440||Healthy controls|The healthy control group will perform a well-validated avoidance (behavioral) task and will fill in some questionnaires about eating behaviors, emotions, and feelings.
11053302|NCT04405440||Anorexia Nervosa patients|As the healthy controls, the participants of the anorexia nervosa group will perform the same behavioral task and will fill in the same questionnaires
11053303|NCT04405427|Experimental|head acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the head
11053304|NCT04405427|Active Comparator|body acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the body
11053305|NCT04405401|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
11053306|NCT04405401|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
11053307|NCT04405388|Other|Spermidine first|First treatment period (8 weeks) will be 4 mg spermidine per day orally. Afterwards 4 weeks of wash-out followed by 8 weeks of placebo treatment.
11053308|NCT04405388|Other|Placebo first|First treatment period (8 weeks) will be placebo. Afterwards 4 weeks of wash-out followed by 8 weeks of 4 mg spermidine per day orally.
11053309|NCT04405375|Experimental|treatment arm|gemcitabine 1.25g/㎡ d1, pegaspargase 2500IU/㎡ d1 (max dose =<3750IU) etoposide 75mg/㎡ d1-3 dexamethasone 20mg d1-4 repeated every 21 days, up to 6 cycles.
11053310|NCT04405349|Experimental|Combination Therapy|VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
11053311|NCT04405336|Active Comparator|giving tab block|giving patients tab block
11053312|NCT04405336|Active Comparator|giving PCA|Giving PCA to patients
11053313|NCT04405336|No Intervention|Patients who will not receive PCA or tab block|No tab block or PCA
11053314|NCT04405323|Experimental|Lu AG06466 - Sequence 1|Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.
11053315|NCT04405323|Experimental|Lu AG06466 - Sequence 2|Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.
11053316|NCT04405310|Experimental|EXP-PC-F2|Patients with Pneumonia due to SARS-COV-2 phase 2 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
11053317|NCT04405310|Placebo Comparator|EXP-NONPC-F2|20 Patients with Pneumonia due to SARS-COV-2 phase 2 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
11065013|NCT04321837|Active Comparator|Coral calcium complex|
11053322|NCT04405297||Ankle Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected ankle joint.
11053323|NCT04405297||Shoulder Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected shoulder joint.
11053324|NCT04405297||Wrist Osteoarthritis|Subjects will receive autologous adipose-derived regenerative stem cells into their affected wrist joint.
11053325|NCT04405271|Experimental|FTC/TAF|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks.
11053326|NCT04405271|Placebo Comparator|Placebo|Identical tablets to the active experimental tablets with the same characteristics and packaging. A dose of 1 tablet per day will be administered for a total of 12 weeks
11053327|NCT04405258|Active Comparator|PVI alone|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
11053328|NCT04405258|Active Comparator|PVI and PWI|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
11053329|NCT04405245|Experimental|AKB-9778 QD + Latanoprost|• AKB-9778 QD (AM) and placebo for AKB-9778 ophthalmic solution QD (PM) plus latanoprost QD (PM) for 28 days
11053330|NCT04405245|Experimental|AKB-9778 BID + Latanoprost|• AKB-9778 BID (AM & PM) plus latanoprost QD (PM) for 28 days
11053331|NCT04405245|Placebo Comparator|Placebo BID + Latanoprost|• Placebo for AKB-9778 ophthalmic solution BID (AM & PM) plus latanoprost QD (PM) for 28 days
11053332|NCT04405219|Sham Comparator|smokers (S)|
11053333|NCT04405219|Active Comparator|non smokers (NS)|
11053334|NCT04405206||Group A:Clinical complete response (cCR)|Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
11053335|NCT04405206||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
11053336|NCT04405206||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation
11053337|NCT04405193|Experimental|Treatment|2 capsules, each containing 600 mg N-acetylcysteine administered once daily every morning.
11053338|NCT04405193|Placebo Comparator|Placebo|2 capsules of matching placebo administered once daily every morning
11053339|NCT04405180|Experimental|20 mg Sodium Nitrite TID Arm|Subject is to receive active study drug three times per day during treatment (12 weeks +/- 5 days) period and then after the treatment period (up to 16 weeks total).
11053340|NCT04405180|Placebo Comparator|Placebo Control Arm|Subject is to receive placebo three times per day during treatment period (12 weeks +/- 5 days) and then after the treatment testing period (up to 16 weeks total).
11053341|NCT04405167|Experimental|A1: Tasquinimod single agent dose escalation|There are up to 5 planned dose levels, with 3 de-escalation dose levels available in case dose level 1 is determined to exceed the MTD. This arm will enroll 15-30 subjects if all dose levels are explored.
11053342|NCT04405167|Experimental|A2: Tasquinimod single agent expansion|Additional subjects will enroll in arm A2 at the MTD and optimal schedule, so that 12 subjects total who are evaluable for response will have received the MTD/optimal schedule of single agent tasquinimod. Enrollment in arm A2 will not begin until enrollment in arm A1 has been completed and a single agent MTD/optimal schedule has been established.
11053343|NCT04405167|Experimental|B1: Tasquinimod+IRd dose escalation|Dose levels will be defined according to the same tasquinimod doses as in the single agent (Arm A1) dose escalation. Enrollment in arm B1 will not begin until enrollment in arm A1 has been completed and an MTD/optimal schedule has been established for single agent tasquinimod. Initial subjects in arm B1 will be enrolled at the lower of dose level 1 or one dose level below the single agent MTD . If this initial dose level is determined to exceed the combination MTD, further subjects will be enrolled at one dose level lower. Enrollment is not planned in arm B1 at doses higher than the single agent MTD. There are 9-12 planned subjects if all dose levels are explored.
11053344|NCT04405167|Experimental|B2: Tasquinimod+IRd expansion|Additional subjects will enroll in arm B2 at the MTD and optimal schedule, so that 12 subjects total who are both evaluable for response and previously refractory to their most recent Imid/PI combination will have received the MTD/optimal schedule of tasquinimod in combination with ixazomib, lenalidomide, and dexamethasone. Enrollment in arm B2 will not begin until enrollment in arm B1 has been completed and a combination MTD/optimal schedule has been established.
11053345|NCT04405154|Experimental|Investigational Arm|Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
11053346|NCT04405115|No Intervention|No intervention arm|routine care only; will not be scheduled for comprehensive geriatric assessment
11053347|NCT04405115|Active Comparator|Active comparator arm|those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician
11053348|NCT04405102|Experimental|Ozanimod + standard of care|During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).
11053349|NCT04405102|Active Comparator|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
11053350|NCT04405089|Experimental|Active tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over right frontal cortex, cathode over left frontal cortex; 2 mAmps for 26 minutes).
11053351|NCT04405089|Sham Comparator|Sham tDCS with cognitive training|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
11053352|NCT04405076|Experimental|mRNA-1273: Dose 50 mcg - Adults Aged 18-54|Groups: Adults aged 18-54 years Dose: 50 mcg Intervention: Biological/Vaccine: mRNA-1273 50 mcg
11053353|NCT04405076|Experimental|mRNA-1273: Dose 50 mcg - Adults Aged 55+ years|Groups: Adults aged 55+ years Dose: 50 mcg Intervention: Biological/Vaccine: mRNA-1273 50 mcg
11053354|NCT04405076|Experimental|mRNA-1273: Dose 100 mcg - Adults Aged 18-54|Groups: Adults aged 18-54 years Dose: 100 mcg Intervention: Biological/Vaccine: mRNA-1273 100 mcg
11053355|NCT04405076|Experimental|mRNA-1273: Dose 100 mcg - Adults Aged 55+ years|Groups: Adults aged 55+ years Dose: 100 mcg Intervention: Biological/Vaccine: mRNA-1273 100 mcg
11053356|NCT04405063|Experimental|Genoss® DCB|Drug Coated Balloon Catheter(Genoss® DCB)
11053357|NCT04405063|Active Comparator|SeQuent® Please|Drug Coated Balloon Catheter(SeQuent® Please)
11053358|NCT04405050|Active Comparator|Restrata|Treated with Restrata
11053359|NCT04405050|Active Comparator|NPWT|Treated with NPWT (Negative Pressure Wound Therapy)
11053360|NCT04405037|Experimental|Alvimopan Group|"Patients randomized to the study group will be given a maximum of 3 doses of Alvimopan 12mg orally, 12 hours apart. Alvimopan will be given from the time of diagnosis of postoperative ileus to the time of return of bowel function or the maximum 3 doses. Subsequent Alvimopan doses will be given if there is no return of bowel function or if symptoms of distension and/or nausea persist despite some return of bowel function.
~All patients will follow a standard ERAS pathway after surgery, with early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol."
11053361|NCT04405037|No Intervention|Control Group|Control patients will follow a standard ERAS pathway after surgery, including NPO status, IV fluid rehydration, and nasogastric decompression, early feeding and ambulation, along with opioid minimizing measures as is our standard postoperative protocol.
11053362|NCT04405024|Other|Hepatitis C testing|"If the patient is included in the study, HCV serology (2 x 5 ml tubes) will be taken at the time of admission as part of the routine entry assessment.
~These two tubes will be used for HCV screening. The patient is informed of the HCV serology result during hospitalization by an investigator."
11053363|NCT04405011|Experimental|Entecavir 0.5mg daily for 24 weeks|Entecavir will be delivered for 24-week and will be the experimental arm
11053364|NCT04405011|Active Comparator|Entecavir 0.5mg daily for 12 weeks|12-week entecavir will be served as active comparator
11053365|NCT04405011|No Intervention|Control|Control group does not receive prophylactic ETV
11053366|NCT04404998|Experimental|Lower Energy Density & Lower Satiation|Test meal with lower energy density and lower satiation information
11053367|NCT04404998|Experimental|Lower Energy Density & Higher Satiation|Test meal with lower energy density and higher satiation information
11053368|NCT04404998|Experimental|Higher Energy Density & Lower Satiation|Test meal with higher energy density and lower satiation information
11053369|NCT04404998|Experimental|Higher Energy Density & Higher Satiation|Test meal with higher energy density and higher satiation information
11053370|NCT04404985|Active Comparator|Surgical AVFs|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an Surgical AVF intervention group that will undergo a routine surgical AVF creation.
11053371|NCT04404985|Experimental|Endo-vascular AVF|Participants who initiated dialysis with a catheter or have advanced chronic kidney disease ,these patients who an endo-vascular AVF intervention group that will undergo a per-cutaneous AVF creation.
11053372|NCT04404959|Active Comparator|fascia iliaca compartment block with ropivacaine|in this arm, the fascia iliaca compartment block will be performed with 40 mL ropivacaine 0.25%
11053373|NCT04404959|Placebo Comparator|fascia iliaca compartment block with placebo|in this arm, the fascia iliaca compartment block will be performed with 40 mL normal saline
11053374|NCT04404946|Active Comparator|phenylephrine infusion|fixed-rate phenylephrine infusion
11053375|NCT04404946|Active Comparator|norepinephrine infusion|fixed-rate norepinephrine infusion
11053376|NCT04404946|Placebo Comparator|placebo infusion|normal saline infusion
11053377|NCT04404894||Prolaris tested patients with Prostate Cancer|Recently diagnosed patients with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites who have undergone Prolaris testing.
11053378|NCT04404881|Experimental|Bevacizumab|"The research study procedures include: screening for eligibility, pretreatment period, study treatment, end-of-study visit, and follow-up visit. Each period consists of 12 weeks, for a total of 36 weeks.
~Pretreatment Period:Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.
~Induction Period (first 3 months of bevacizumab treatment):
~Hematologic Support: iron transfusions and red cell transfusions as determined by study doctor.
~Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.
~Maintenance Period (second 3 months of bevacizumab treatment):
~Hematologic Support: Iron transfusions and red cell transfusions as determined by study doctor.
~Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
11053379|NCT04404868||Enrolled patients|"Each patient (whether hospitalized or outpatient) included in the study underwent to a baseline evaluation in which near and remote pathological history were recorded (main concomitant pathologies, drug therapy in progress, previous major surgery) and the following evaluation scales were administered: modified Ashworth scale (MAS), MI (motricity index), FMA (Fughl Meyer assessment) and Modified Rankin' scale (MRS).
~Each patient will subsequently undergo to a follow-up evaluation at 4, 12 and 24 weeks after the date of inoculation through the execution of a specialist visit (physiatric/neurological) and the administration of the following evaluation scales: MAS, MI, FMA and MRS. For the duration of the study, each patient may undergo integrated rehabilitation treatment at the discretion of each of the investigators of each centre involved in the study according to the guidelines and common clinical practice."
11053380|NCT04404855|Other|Intervention Group (NGS + Antibiotic Recommendation)|Next Generation Sequencing results along with Infectious Disease Pharmacist will be shared with clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
11053381|NCT04404855|Other|Control Group|NGS results will not be shared with the clinical provider at time of standard of care urology stone procedure. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
11053382|NCT04404842||EvidenceQ Cohort|Adult subjects, aged over 18 years, male and female.
11053383|NCT04404829|Experimental|Informational Manual Therapy|It is an integral no orthopedic and very soft manual therapy
11053384|NCT04404816|Experimental|Group 1|premature infants born < 33 G.A. enrolled in the first 72 hours after birth, with respiratory distress syndrome, requiring non-invasive ventilation with FiO2 <0.4
11053385|NCT04404816|Experimental|Group 2|premature infants born < 33 G.A. with respiratory insufficiency requiring mechanical ventilation, after more than 1 failed extubation attempt
11053386|NCT04404790|Experimental|Anfibatide 5 IU/60kg|Ten subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes.
11053387|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
11053388|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
11053389|NCT04404790|Experimental|Anfibatide 5 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 5 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
11053390|NCT04404790|Experimental|Anfibatide 7 IU/60kg|Ten subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes.
11053391|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.002 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours.
11053392|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.004 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours.
11053393|NCT04404790|Experimental|Anfibatide 7 IU/60kg+0.008 IU/kg/h|Four or fourteen subjects will injected with the dose of 7 IU/60kg of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours.
11053394|NCT04404777||Patients with local recurrence|
11053395|NCT04404764||Treated with nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III treated with nusinersen in the Brazilian Unified Public Health System
11053396|NCT04404764||With indication to receive nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III with indication, but not yet receiving nusinersen treatment in the Brazilian Unified Public Health System
11053397|NCT04404751|Active Comparator|Arm 1|
11053398|NCT04404751|Active Comparator|Arm 2|
11053399|NCT04404751|Sham Comparator|Arm 3|
11053400|NCT04404738|Experimental|MicroPort® Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using MicroPort® surgical system
11053401|NCT04404738|Active Comparator|da Vinci Surgical System|robot-assisted surgeries, for instance, prostatectomy, cystectomy or nephrectomy will be performed using da Vinci surgical system
11053402|NCT04404725|Experimental|comfilcon A then samfilcon A|Subjects were randomized to wear comfilcon A for one month then Samfilcon A for one month in this randomized, bilateral cross-over study.
11053403|NCT04404725|Active Comparator|samfilcon A then comfilcon A|Subjects were randomized to wear samfilcon A for one month then comfilcon A for one month in this randomized, bilateral cross-over study.
11053404|NCT04404712|Experimental|[11C]MK-3168 PET Scan|
11053405|NCT04404686|Experimental|Indomethacin group|Group of patients receiving Indomethacin for preterm labor treatment.
11053406|NCT04404686|Active Comparator|Nifedipine group|Group of patients receiving Nifedipine for preterm labor treatment.
11053407|NCT04404673||Open rectal resection|
11053408|NCT04404673||Laparoscopic rectal resection|
11053409|NCT04404673||Robotic rectal resection|
11053410|NCT04404673||Trans-anal TME (Ta-TME)|
11053411|NCT04404660|Experimental|AUTO1|
11053412|NCT04404647|Experimental|Intervention|Selected patients who choose to participate will undergo ablation of the target lesion using irreversible electroporation.
11053413|NCT04404621|Experimental|Cross-Over Sequence A|Participants in this arm will be randomized to receive the 18 week program first and be in treatment as usual comparison condition in the following 18 weeks.
11053414|NCT04404621|Experimental|Cross-Over Sequence B|Participants in this arm will be randomized to remain in treatment as usual during the first 18 week period and then receive the 18 week program during the following 18 weeks.
11053415|NCT04404608||Asymptomatic or mild symptoms patients patients|Patients with no or mild symptoms and need no respiratory support.
11053416|NCT04404608||Severe symptoms patients|Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.
11053417|NCT04404608||Critically ill patients|Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients
11053418|NCT04404595|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Phase 1 will include two parts, a dose escalation part to determine the recommended dose for the expansion part. During expansion patients will be treated with the recommended dose determined in the expansion part.
11053419|NCT04404582||Klebsiella pneumoniae|patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients.
11053420|NCT04404569|Experimental|Continued Treatment|"Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study.
~The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose."
11053487|NCT04404075||Group 1 patients|"Age 18 and above
~Eczema Area and Severity Index (EASI) score ≥ 10
~Investigator Global Assessment (IGA) ≥ 3"
11053488|NCT04404075||Group 2 patients|"Age 18 and above
~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10
~Investigator Global Assessment (IGA) 1 or 2"
11053421|NCT04404556|Experimental|Diabetes Journey|Diabetes Journey is a web-based intervention to address key adherence barriers. Participants randomized to this arm will first receive the mandatory Introduction and Problem-Solving Module. Based on their elevations on the Barriers to Diabetes Adherence measure, participants will receive up to 7 modules in total. Participants will navigate through the web-based theme park map and complete modules independently and then will have accompanying Zoom telehealth sessions with a therapist.
11053422|NCT04404556|Active Comparator|Enhanced Standard of Care|Participants randomized to Enhanced Standard of Care will receive general education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) from each site across 12-weeks. Content to address adherence barriers were modified and or newly developed for the Enhanced Standard of Care group via the T1DToolkit website.
11053423|NCT04404543|Experimental|Escalation Cohort|"Five dose levels will be tested according to the 3 + 3 dose-escalation design.
~The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1807 to the end of the first cycle (28 days)."
11053424|NCT04404543|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 12~40 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D.
11053425|NCT04404530||Palynziq Therapy for PKU|Participants with PKU who are starting Palynziq therapy.
11053426|NCT04404517|Active Comparator|40mg1w|Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks
11053427|NCT04404517|Active Comparator|80mg2w|Adalimumab at an administration of 80 mg every two weeks
11053428|NCT04404491|Active Comparator|PD-1 and Concurrent chemoradiotherapy|Camrelizumab: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
11053429|NCT04404491|Placebo Comparator|placebo and Concurrent chemoradiotherapy|placebo: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
11053430|NCT04404478|Experimental|B-SWELL|Participants in the B-SWELL intervention will receive information about stress and goal setting in addition to healthy lifestyle behaviors. The intervention will take place weekly for eight weeks in groups of 11 to 13 midlife Black women for peer support. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
11053431|NCT04404478|Active Comparator|WE|The attention control group (WE), will include education about healthy lifestyle behaviors and peer support. The attention control groups will also have weekly sessions for eight weeks in groups of 11 to 13 midlife Black women. Outcome measures will include perceived general health, depressive symptoms, life's simple 7 (LS7) score, and number of unhealthy days. Data collections will occur at baseline, 8 weeks, and 12 weeks.
11053432|NCT04404465||Control Group|Participants undergoing electrophysiologic (EP) study or ablation for supraventricular tachycardia (SVT) with no history of AF and does not meet criteria of At Risk Group or AF Group
11053433|NCT04404465||At Risk Group|"Participants with no prior diagnosis of AF and have:
~two or more of the following criteria:
~Age >65 years of age
~A diagnosis of hypertension
~A diagnosis of diabetes
~A diagnosis of sleep apnea
~A body mass index (BMI) ≥30
~Stable heart failure (HF) with preserved or reduced ejection fraction (New York Heart Association Class I, II or III)
~Chronic kidney disease (CKD) not requiring dialysis
~AND/ OR
~More than 5% premature atrial complex (PAC) burden on ambulatory ECG monitoring (e.g. holter, ZioPatch, Lifewatch, etc.)"
11053434|NCT04404465||AF Group|Participants who have a history of non-valvular AF or Atrial Flutter (AFL) documented on ECG or ambulatory monitoring within 1 year of enrollment
11053435|NCT04404439|Experimental|Nortriptyline + topiramate|Nortriptyline (7.5 mg) plus topiramate (10 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 7.5mg weekly (to a maximum of 60mg) for nortriptyline, and by 10mg weekly (maximum 80mg) for topiramate.
11053436|NCT04404439|Experimental|Verapamil + paroxetine|Verapamil (30 mg) plus paroxetine (4 mg) in a single pill initially taken once daily. Dose may be increased as directed by care provider by 30mg weekly (to a maximum of 240mg) for verapamil, and by 4mg weekly (maximum 32mg) for paroxetine.
11053437|NCT04404439|Placebo Comparator|Placebo|Placebo pill.
11053438|NCT04404426|Experimental|L-citrulline|Administration of citrulline enterally for 7 days
11053439|NCT04404426|Placebo Comparator|Placebo|Administration of placeboenterally for 7 days
11053440|NCT04404413|Experimental|PARTICIPANTS|A single-group crossover design was used to compare the effects of 2x8 weeks of high-intensity interval training without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance. There were two weeks in the middle of both phases in which they did not carry out programmed activity, in order not to alter the experimental phase.
11053441|NCT04404400|Experimental|Active|For CIRCI patients: hydrocortisone + fludrocortisone therapy.
11053442|NCT04404400|Placebo Comparator|Placebo|For CIRCI patients: hydrocortisone placebo + fludrocortisone placebo
11053443|NCT04404387|Experimental|Experimental arm|vitamin C 50 mg/kg every 6 hours for 96 hours.
11053444|NCT04404387|Placebo Comparator|Control arm|Placebo administration
11053445|NCT04404374|Active Comparator|A-PRF|Advanced Platelet-Rich Fibrin
11053446|NCT04404374|Active Comparator|EMD|Enamel Matrix Derivatives
11053447|NCT04404361|Experimental|Pacritinib and SOC|Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC
11053448|NCT04404361|Placebo Comparator|Placebo and SOC|4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC
11053449|NCT04404348|Experimental|Intervention|Three times per week for four weeks, participants will complete a computerized cognitive training session (approximately 30 minutes long).
11053450|NCT04404348|Placebo Comparator|Control|Three times per week for four weeks, participants will complete a computerized session (approximately 30 minutes long) that consists of inert computer games.
11053451|NCT04404335||Healthy (control group)|"This group will include a total of 30 patients free of periodontitis Samples of crevicular fluid to quantity levels of antimicrobial peptide LL-37 will be taken at baseline
~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
11053452|NCT04404335||Periodontitis (test group)|"60 Periodontal patients (subdivided in 2 groups of 30, depending of the severity of their disease):
~30 patients with Stage I-II periodontitis (mild/moderate)
~30 patients with Stage III-IV periodontitis (severe).
~Two sets of samples of crevicular fluid will be obtained before and after receiving a course of routine basic periodontal treatment (root scaling and planing).
~A reevaluation visit to re-assess clinical periodontal parameters will take place at 4-6 weeks after treatment. New samples of crevicular fluid will then be taken at this stage to compare the level of LL-37 before and after the treatment.
~ELISA analysis of all samples will be performed by using a specific ELISA kit commercially available for human LL-37 (HyCult Biotechnology, Uden, the Netherlands)."
11053453|NCT04404322|Experimental|IPT A SCI|The IPT-A SCI follows the intervention protocol, which includes an intensive phase of 5 weekly 50-minute sessions and 3 follow up personal emails.
11053454|NCT04404322|Active Comparator|Treatment as usual|TAU patients receive an integrative combination of psychodynamic, supportive and cognitive behavioural therapy, usually lasting between 10-30 weeks.
11053455|NCT04404322|No Intervention|wait list|WL patients are monitored by a trained clinician during their waiting period and complete the study questionnaire battery at the parallel time intervals.
11053456|NCT04404309||Population 1|Any patient admitted to a psychiatric ward with a clinical diagnosis of (unipolar) major depression
11053457|NCT04404309||Population 2|Any patient with a clinical diagnosis of a moderate or severe unipolar depressive disorder with suicidal tendencies that persist for at least 48 hours after admission
11053458|NCT04404309||Population 3|Patients with moderate or severe unipolar depressive episodes validated by research interviews and suicidal tendencies that persist for at least 48 hours after admission who will be followed up for 6 months
11053459|NCT04404296|Other|25-gauge PPV|Eyes will undergo pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
11053460|NCT04404283|Experimental|Experimental Arm|Brentuximab vedotin + lenalidomide + rituximab
11053461|NCT04404283|Active Comparator|Control Arm|Placebo + lenalidomide + rituximab
11053462|NCT04404257|Experimental|ControlRad System|Participant will undergo Cardiac catheterization with the ControlRad system installed in Cath lab room 5
11053463|NCT04404257|Active Comparator|Without ControlRad System|Participant will undergo the cardiac catheterization per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
11053464|NCT04404231|Sham Comparator|No infrared light therapy|This arm does not receive any phototherapy
11053465|NCT04404231|Active Comparator|810 nm|Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
11053466|NCT04404231|Experimental|945nm|This wavelength has been chosen as a comparison to 810, to see if it works better.
11053467|NCT04404231|Experimental|random frequency|A wavelength between 650-1100nm which is picked at random
11053468|NCT04404218|Experimental|Açaí palm berry extract|Açaí palm berry extract is a powerful antioxidant with no known side-effects and is widely consumed in Brazil. Açaí palm berry chemical composition has been established and includes several antioxidants - gallic acid, catechin, chlorogenic acid, caffeic acid, p-coumaric acid, epicatechin, orientin, cyanidin-3-0-glucoside, luteolin and apigenin. Orientin is the most concentrated compound (7,96mg/g) and this compound is able to modulate the NLRP3 inflammasome.
11053469|NCT04404218|Placebo Comparator|Placebo arm|This study will be double-blinded and placebo-controlled. To ensure double-blinding, placebo and active compound capsules will be over-encapsulated with DBCAPS® capsules, which were developed with a tamper-evident design to address the clinical trial challenges of testing without bias. These capsules are made of gelatin and have no interaction with bioavailability.
11053470|NCT04404205||Adult patient with cochlear implant|Adult patients who had cochlear implant surgery before will be included. We will call patients from our cochlear implant list.
11053471|NCT04404192|Experimental|PH94B|Intranasal spray 3.2 micrograms up to four times a day as needed for anxiety for 14 days.
11053472|NCT04404179||CASE|59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
11053473|NCT04404166|Experimental|PINGS 2|
11053474|NCT04404166|No Intervention|Standard of Care|
11053475|NCT04404153|Experimental|Active tDCS|The active tDCS will involve 30-minutes of direct current at intensity of 2 milliamperes (mA).
11053476|NCT04404153|Sham Comparator|Sham tDCS|Sham stimulation consists of the direct current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining application period.
11053477|NCT04404140|Experimental|Ipatasertib + Atezolizumab + Docetaxel|"Part A (Safety Run-In): 12 Participants will be administered Ipatasertib orally once a day [QD] from Day 1 to Day 14 in combination with Atezolizumab administered by intravenous (IV infusion) every 3 weeks (Q3W) on Day 1 of each cycle (a cycle being 21 days) and Docetaxel administered by IV infusion (Q3W) on Day 1 of each cycle. Docetaxel will be administered for a maximum of 10 cycles (approximately 7 months), after which Atezolizumab and Ipatasertib will be administered as a doublet until disease progression. During Part A, a staggered recruitment will be applied to the first and potentially first 6 participants to enrol a participant only once the former one has safely overcome the safety time window (Cycle 1).
~Part B (Expansion): 38 Participants will be administered Ipatasertib, Atezolizumab and Docetaxel as described above, though without a staggered enrolment or safety assessment window."
11053478|NCT04404127|Placebo Comparator|No induction Arm|
11053479|NCT04404127|Active Comparator|Induction with basiliximab|
11053480|NCT04404114||Normal renal function|Normal renal function
11053481|NCT04404114||Acute kidney injury in normal kidney|Acute kidney injury in normal kidney
11053482|NCT04404114||Acute kidney injury in chronic kidney disease|Acute kidney injury in chronic kidney disease
11053483|NCT04404114||Chronic kidney disease|Chronic kidney disease
11053484|NCT04404101|Experimental|1). EUS-FNA plus MFB|A 19-G needle plus micro-forceps will be used for FNA plus MFB.
11053485|NCT04404101|Active Comparator|2). EUS-FNA Alone|A 19-G needle will be used for FNA alone.
11053486|NCT04404088|Experimental|Treatment (acalabrutinib, lenalidomide, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21 and rituximab IV on days 1, 8, 15, and 22 of cycle 2 and day 1 of subsequent cycles. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
11065059|NCT04321460|Experimental|LRG-002|LRG-002 once daily for 14 days
11053489|NCT04404075||Group 3 patients|"Age 12 to 17
~Eczema Area and Severity Index (EASI) score ≥ 10
~Investigator Global Assessment (IGA) ≥ 3"
11053490|NCT04404075||Group 4 patients|"Age 12 to 17
~Eczema Area and Severity Index (EASI) score ≥ 1 but < 10
~Investigator Global Assessment (IGA) 1 or 2"
11053491|NCT04404062||Trial Participants|Male and female participants aged 18-70 years
11053492|NCT04404049|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
11053493|NCT04404049|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
11053494|NCT04404049|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
11053495|NCT04404036|Experimental|SinuSonic Device|"Aim 1: SinuSonic device used once a day over a 2 day period.
~Aim 2: SinuSonic device used twice daily for 3 minutes in the home setting for 6 weeks.
~Aim 3: SinuSonic device used twice daily for 3 minutes in the home setting for 4 weeks."
11053496|NCT04404023|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
11053497|NCT04404023|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
11053498|NCT04404023|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
11053499|NCT04404023|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
11053500|NCT04404023|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
11053501|NCT04404010|Active Comparator|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
11053502|NCT04404010|Other|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
11053503|NCT04403997|Active Comparator|Chromoendoscopy with methylene blue 0.1%|Once the cecum is reached, a spray catheter is introduced through the working channel and the dye, a 0.1% methylene blue solution, is applied.
11053504|NCT04403997|Experimental|Virtual Chromoendoscopy with NBI with HQ190 endoscopes|Intubation is done with normal white light. Once the cecum is reached, the removal will be done in NBI mode
11053505|NCT04403984||Patients with Luminal A breast cancer|Patients confirmed with Luminal A breast cancer sub type
11053506|NCT04403984||Patients with Luminal B breast cancer|Patients confirmed with Luminal B breast cancer sub type
11053507|NCT04403971|Experimental|0.12% chlorhexidine|Participants will be randomized to Chlorhexidine solution group, applied twice a day by care givers.
11053508|NCT04403971|Sham Comparator|Listerine|Participants will be randomized to Listerine solution group, applied twice a day by care givers.
11053509|NCT04403971|Placebo Comparator|Normal saline|Participants will be randomized to Normal saline group, applied twice a day by care givers.
11053510|NCT04403958|Experimental|PRC|Total wrist arthrodesis with PRC and dorsal plate
11053511|NCT04403958|Active Comparator|TWA|Total wrist arthrodesis with dorsal plate
11053512|NCT04403945||Group 1|healthy volunteers with normal fasting blood glucose and HbA1c, without hypertension, kidney diseases, or taking drugs that affects microcirculation
11053513|NCT04403945||Group 2|type 2 diabetic patients without microvascular complications like Diabetic nephropathy, diabetic retinopathy, diabetic foot or diabetic peripheral neuropathy
11053514|NCT04403945||Group 3|type 2 diabetic patients with diabetic nephropathy diagnosed by clinic or pathology.
11053515|NCT04403919|Active Comparator|Revision total knee arthroplasty: control|
11053516|NCT04403919|Experimental|Revision total knee arthroplasty: active|
11053517|NCT04403919|Active Comparator|Revision Total Hip Arthroplasty: control|
11053518|NCT04403919|Experimental|Revision Total Hip Arthroplasty: active|
11053519|NCT04403906|Experimental|PCL Rapid Antigen Test arm|Single arm trial design. Only patients undergoing standard clinical testing (SARS-CoV-2 PCR test) and consenting for additional testing with the PCL rapid antigen test will be included
11053520|NCT04403880||Group 1|"Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3
~1A: Persons with asymptomatic infection, ages 18 through 55, inclusive
~1B: Persons with asymptomatic infection, age > 55
~1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55
~1D: Persons with symptomatic infection (ie, COVID-19), age > 55"
11053521|NCT04403880||Group 2|"Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3
~2A: Persons 18 through 55 years of age
~2B: Persons > 55 years of age"
11053522|NCT04403880||Group 3|Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)
11053523|NCT04403867||Endometrial cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
11053524|NCT04403867||Cervical cancer patients|Patients submitted to Sentinel Lymph Node (SLN) procedure. Patients with lymph nodal disease (macrometastasis, micrometastasis, isolated tumor cells).
11053525|NCT04403854||ME/CFS patients|Patients diagnosed according to Canada Criteria 2003
11053526|NCT04403854||Healthy Controls|Age and sex matched healthy controls
11053527|NCT04403841|Other|Intervention|The intervention of group education on type 2 diabetes, including, in addition to usual diabetes care
11053528|NCT04403841|Other|Control|Patients meeting the inclusion criteria assigned to usual diabetes care alone
11053529|NCT04403815||right radial access|"diagnostic coronary angiography and/or PCI performed through right wrist and distal (snuffbox) radial access"
11053530|NCT04403815||left distal radial access|"diagnostic coronary angiography and/or PCI performed through left distal (snuffbox) radial access"
11053531|NCT04403802|Experimental|Arm A: Voxx socks followed by placebo socks|Continuous wear of Voxx Human Performance Technology Socks for 2 weeks, followed by continuous wear of placebo socks for 2 weeks (separated by a 2-week washout period)
11053532|NCT04403802|Experimental|Arm B: Placebo socks followed by Voxx socks|Continuous wear of placebo socks for 2 weeks, followed by continuous wear of Voxx Human Performance Technology Socks for 2 weeks (separated by a 2-week washout period)
11053593|NCT04403386||Non-smokers|Participants who have never smoked or do not currently residing with a smoker
11053533|NCT04403789|Experimental|Intervention Group|During the intervention period they will receive 2 hours per week of group exercise sessions during working hours for 12 weeks. However, after the intervention period, there will be no change in working hours
11053534|NCT04403789|Active Comparator|Delayed Intervention Group (Control group)|During the intervention period there will be no change in working hours. However, after the intervention period they will receive 2 hours of exercise time during working hours per week for 4 weeks
11053535|NCT04403776|Experimental|Treatment A, separated washout phase, followed Treatment B.|"Treatment A:
~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
~washout phase: no later than 72 hours
~Treatment B:
~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
11053536|NCT04403776|Experimental|Treatment B, separated washout phase, followed Treatment A.|"Treatment A:
~Single oral dose of tofacitinib MR 11mg, administered as 1xMR 11mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
~Washout phase: no later than 72 hours
~Treatment B:
~Two separate oral doses (12 hours apart) of tofacitinib IR 5mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."
11053537|NCT04403763|Experimental|AGN-241622 Dose 1|Administered as single drop in one eye or a single drop in each eye
11053538|NCT04403763|Placebo Comparator|Placebo Dose|Administered as single drop in one eye or a single drop in each eye
11053539|NCT04403763|Experimental|AGN-241622 Dose 2|Administered as single drop in one eye or a single drop in each eye
11053540|NCT04403763|Experimental|AGN-241622 Dose 3|Administered as single drop in one eye or a single drop in each eye
11053541|NCT04403763|Active Comparator|AGN-190584|Administered as single drop in each eye
11053542|NCT04403750|Experimental|Combined laser-surgical technology|"Combined laser-surgical technology includes 3 steps:
~Nd-YAG laser excision of the vitreoretinal traction zone
~Pneumatic retinopexy (10% C3F8)
~Barrier laser photocoagulation around retinal break after retinal attachment."
11053543|NCT04403737|No Intervention|Usual Care|Patients in the control arm will have a Rothman Index calculated but this will not be visible to providers.
11053544|NCT04403737|Experimental|Intervention|Patients in the intervention arm will have a Rothman Index calculated and will be visible to providers. Providers will be given a set of clinician-specific recommended-use protocols that they will be encouraged to follow based on the RI thresholds achieved by patients.
11053545|NCT04403724|Active Comparator|premixed injection|will receive an intrathecal injection of 2.4 ml hyperbaric bupivacaine 0.5%, 20 µg fentanyl, and 100 µg preservative-free morphine mixed together.
11053546|NCT04403724|Active Comparator|sequential injections|will receive an intrathecal injection of 2,4 ml hyperbaric bupivacaine 0.5% followed immediately by the opioid mixture by two separate syringes.
11053547|NCT04403711|Active Comparator|local anesthetic and dexmedetomidine|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL dexmedetomidine
11053548|NCT04403711|Placebo Comparator|local anesthetic and placebo|ultrasound-guided transversus abdominis plane block with 25 mL ropivacaine 0.5% and 2 mL normal saline
11053549|NCT04403698|Experimental|24 weeks|Subject receiving alendronate treatment for 24 weeks (n = 20)
11053550|NCT04403698|Experimental|48 weeks|Subject receiving alendronate treatment for 48 weeks (n = 20)
11053551|NCT04403685|Experimental|Tocilizumab|Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
11053552|NCT04403685|No Intervention|Control arm|Best supportive care.
11053553|NCT04403672||COVID-19 positive|ideSHi (CRO) investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
11053554|NCT04403672||COVID-19 Negative|"ideSHi investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
~In addition, 60 fresh specimens which will be tested at IEDCR will also be tested at ideSHi using RealDetect on a real time basis. These samples will also be blinded by IEDCR and sent to the testing laboratory (ideSHi). Of these 60 samples, 30 will be COVID-19 positive and 30 COVID- 19 negative samples. These fresh samples will be provided to ideSHi for testing and analysis for performance evaluation of RealDetect COVID-19 RT-PCR kit."
11053555|NCT04403659|Experimental|Intervention|Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care
11053556|NCT04403659|No Intervention|Control|Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines
11053557|NCT04403646|Experimental|TREATED|"Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.
~Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
11053558|NCT04403646|Placebo Comparator|CONTROL|"Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.
~Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy."
11053559|NCT04403633|Experimental|Receiving Educational Tool|Patients in this arm will receive the educational tool after the pretest in addition to usual care.
11053560|NCT04403633|No Intervention|Receiving Usual Care|Patients in this arm will receive usual care after the pretest.
11053561|NCT04403620|Active Comparator|Conventionally fractionated radiotherapy|60 Gy in 30 fractions, 5 fractions/week
11053562|NCT04403620|Experimental|Hypofractionated radiotherapy|"Dose and fractionation determined by Phase I:
~Level 1: 44.4 Gy in 12 fractions, 4 fractions/week
~Level 0: 46.5 Gy in 15 fractions, 5 fractions/week
~Level -1: 52 Gy in 20 fractions, 5 fractions/week
~Level -2: 50 Gy in 20 fractions, 5 fractions/week"
11053563|NCT04403594||MS with spasticity of one lower extremity|A person diagnosed with Multiple Sclerosis and spasticty of one lower extremity. The person must be able to walk 25 feet and cannot have had Botox in the lower extremity on the last 6 months.
11053564|NCT04403568|Experimental|Ursolic Acid|Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy
11053565|NCT04403568|Experimental|Curcumin|Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy
11053566|NCT04403568|Experimental|Ursolic Acid and Curcumin|Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy
11053567|NCT04403555|Experimental|Ivermectin and doxcycline|Ivermectin and doxycycline treatment
11053568|NCT04403555|Active Comparator|chloroquine|Chloroquine treatment
11053569|NCT04403529|Experimental|Traditional Chinese Medicine|"60 days of oral Traditional Chinese Medicine (prescription for breast cancer Traditional Chinese Medicine formulation)"
11053570|NCT04403529|Placebo Comparator|Placebo|"60 days of oral placebo (placebo contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler)"
11053571|NCT04403516|Experimental|DEXTENZA Group|Patients with Pterygium DEXTENZA Group
11053572|NCT04403516|Experimental|Topical Prednisolone Acetate 1% Group|Patients with Pterygium Topical Prednisolone Acetate 1% Group
11053573|NCT04403503|Active Comparator|Gelatine Sponge|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA)
11053574|NCT04403503|Active Comparator|Gelatine sponge +Cyanoacrylate|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group)
11053575|NCT04403490|Experimental|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
11053576|NCT04403490|Active Comparator|Conventional intervention|Conventional physical and occupational therapy
11053577|NCT04403477|No Intervention|Standard treatment|Standard supportive treatment (Oxygen, Enoxaparine, antibiotic, fluid, immune modulator (Steroid) and or antiviral (favipiravir or ramdesivir or lopinavir + ritonavir)
11053578|NCT04403477|Experimental|Standard treatment + 200 ml plasma|Standard supportive treatment + 200 ml apheretic convalescent plasma single transfusion
11053579|NCT04403477|Experimental|Standard treatment + 400 ml plasma|Standard supportive treatment + 400 ml apheretic convalescent plasma single transfusion
11053580|NCT04403464|Experimental|HABIT-ILE with REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities with an interactive device
11053581|NCT04403464|Active Comparator|HABIT-ILE without REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
11053582|NCT04403451|Experimental|Phase 1/Cohort 1|True North Love Notes, Financial Stability, Jobs
11053583|NCT04403451|Experimental|Phase 2/Cohort 2|True North Love Notes, Financial Stability, Jobs
11053584|NCT04403451|Experimental|Phase 3/Cohort 3|True North Love Notes, Financial Stability, Jobs
11053585|NCT04403438||patients with behçet's or fmf|
11053586|NCT04403425||Emergency laparotomy, obstruction|Patients undergoing emergency laparotomy for intestinal obstruction in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
11053587|NCT04403425||Emergency laparotomy, perforation|Patients undergoing emergency laparotomy for perforated ventricle or intestine in need of intraoperative Noradrenaline infusion to maintain predefined normotension.
11053588|NCT04403412|Experimental|Left atrial appendage closure group|
11053589|NCT04403412|Experimental|Radiofrequency ablation group|
11053590|NCT04403412|Experimental|LAAC combined with radiofrequency ablation group|
11053591|NCT04403399|Experimental|Varenicline then Placebo|Participants in this arm of the experiment are given varenicline for several weeks, then after a 3 week washout period they are given placebo for several weeks. Measurements of walking speed and balance, as well as cognitive testing are used to assess brain function throughout both treatment periods. There are no PET scans done in experiment 3. Walking speed is measured by how quickly a person can walk down a corridor. Balance is measured by ability to maintain a normal standing stance. Safety monitoring with clinical assessments of severity of PD and cognition are performed.
11053592|NCT04403399|Experimental|Placebo then Varenicline|Participants in this arm of the experiment are given placebo for several weeks, then after a 3 week washout period they are given varenicline for several weeks. Measurements of walking speed and balance, as well as cognitive testing are used to assess brain function throughout both treatment periods. There are no PET scans done in experiment 3. Walking speed is measured by how quickly a person can walk down a corridor. Balance is measured by ability to maintain a normal standing stance. Safety monitoring with clinical assessments of severity of PD and cognition are performed.
11053595|NCT04403373|Placebo Comparator|Waitlist control group|Participants in this group receive no intervention during the 12-week period.
11053596|NCT04403373|Experimental|Moderate-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a moderate intensity (~3.5 METs). The training will be conducted outdoors. Each training session lasts for 50 minutes.
11053597|NCT04403373|Experimental|Vigorous-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a vigorous intensity (~7 METs). The training will be conducted outdoors. Each training session lasts for 25 minutes.
11053598|NCT04403360|Experimental|Erector Spinae plane Block (ESPB) group|The ultrasound-guided ESPB was realized at T12 level (levo bupivacaine 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)after the induction of anesthesia but before the start of the surgery.
11053599|NCT04403360|Active Comparator|Local anesthesia infiltration by the surgeon|The surgeon infiltrates the surgical site after skin incision with local anesthetics (Levo Bupivacaïne 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)
11053600|NCT04403347|Experimental|Innovative Dietary Formulation|In addition to regular diets and usual care of hypertension, additional innovative dietary formulation will be orally taken 3 times per day.
11053601|NCT04403347|Active Comparator|Antihypertensive Medication|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
11053602|NCT04403347|No Intervention|Usual Care|Usual Care (Guideline-based patient education and lifestyle recommendations)
11053603|NCT04403334|Experimental|Intracameral levofloxacin|0.5% unpreserved solution
11053604|NCT04403334|Experimental|Intracameral moxifloxacin|0.5% unpreserved solution
11053605|NCT04403321|Placebo Comparator|Eltrombopag|Eltrombopag and the placebo would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day.
11053606|NCT04403321|Experimental|Eltrombopag + Tacrolimus|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. Tacrolimus will be given at 1mg bid with the target concentration to be 5-10 ng/ml throughout the study.
11053607|NCT04403321|Experimental|Eltrombopag + Cyclosporin A|Eltrombopag and tacrolimus would be applied. Eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. Cyclosporin A will be given started with 100mg bid with the target concentration to be 100-150 ng/ml throughout the study.
11053608|NCT04403308|Experimental|ONO-7913 as a Single Agent|
11053609|NCT04403295|Experimental|collaborative specialty care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
11053610|NCT04403295|Active Comparator|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
11053611|NCT04403282|Active Comparator|Paired(right and left neck) comparison group eflornithine|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
11053612|NCT04403282|Placebo Comparator|Paired(right and left neck) comparison group placebo|randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
11053613|NCT04403269|Experimental|IgIV|The experimental arm is human immunoglobulins. 2 infusion at D1 and D2. (0.8 g / kg by IV infusion)
11053614|NCT04403243|Experimental|1. Colchicine|30 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
11053615|NCT04403243|Experimental|2. Ruxolitinib|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
11053616|NCT04403243|Experimental|3.Secukinumab|10 Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
11053617|NCT04403243|Active Comparator|4.Standard treatment|-30 patients Patients with mild and severe COVID 19 Patients will get investigated therapy for ten days. Patients will be follow-up during 45 days after randomization
11053618|NCT04403230|Experimental|Clinical behaviour on teeth prepared without finish line|Evaluate the clinical behavior of restorations placed on teeth prepared without finish line, monitoring periodontal status as well as the prostheses to assess stability and treatment predictability.
11053619|NCT04403217|Experimental|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
11053620|NCT04403204||Established SSI Fracture Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
11053621|NCT04403204||Closed Fracture Cohort|"Patients 18 years of age or older Closed extremity fracture Planned definitive fracture management with external fixation, internal fixation, or joint fusion.
~Provision of informed consent"
11053622|NCT04403204||Established SSI Fracture Cohort Subset (DCE-MRI)|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
11053623|NCT04403191||Group A|received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours
11053624|NCT04403191||Group B|received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours
11053625|NCT04403191||Group C|received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours.
11053626|NCT04403178||Children who develops hip displacement|Patient group 1 includes children who developed a Migration Percentage of > 40 % in either hip over a follow-up period of three years.
11066652|NCT04310098||Asymptomatic carriers of CADASIL|
11053627|NCT04403178||Children who do not develops hip displacement|Patient group 2 includes children who did not develop a Migration Percentage of > 40 % on either hip over a follow-up period of three years
11053628|NCT04403165|Experimental|Locus-coeruleus functioning group|The study will conduct brain scans of 30 people between the age of 60-75 as well as clinical and neuropsychological evaluations to test the locus-coeruleus (LC) functioning affects their sleep and thinking ability.
11053629|NCT04403152|Experimental|Rehabilitation group|This is the study group in whom post-operative rehabilitation was provided for 5 days.
11053630|NCT04403152|Active Comparator|Mobilization group|This is the control group in whom post-operative mobilization was provided for 5 days.
11053631|NCT04403139|Other|Cohort 1: 30-40 year of age|
11053632|NCT04403139|Other|Cohort 2: 70 years of age or older|
11053633|NCT04403126|Experimental|Forgiveness curriculum for 5th grade|"Classrooms randomly assigned to the experimental group will receive the forgiveness intervention. The forgiveness intervention will follow the curriculum - The Journey Toward Forgiveness -A Guided Curriculum for Children Ages 10-12 (Grade 5 in the US). The Forgiveness Curriculum Guide consists 14 lessons over 12 weeks. Each class meets weekly for 40 to 60 minutes to complete one lesson (in two of the weeks, there will be two lessons)."
11053634|NCT04403126|No Intervention|Regular school instruction|Classrooms randomly assigned to the control group will have instruction as usual.
11053635|NCT04403113|Experimental|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
11053636|NCT04403113|Placebo Comparator|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
11053637|NCT04403100|Active Comparator|Hydroxychloroquine Sulfate|Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
11053638|NCT04403100|Active Comparator|Lopinavir/ Ritonavir|Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days
11053639|NCT04403100|Active Comparator|Hydroxychloroquine plus Lopinavir/ Ritonavir|"Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days
~Plus
~Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days"
11053640|NCT04403100|Placebo Comparator|Placebo|"Placebo
~Twice a day from day 1 through day 10."
11053641|NCT04403087|Experimental|Trimebutine add group|Addition of Trimebutine on the Bismuth-containing quadruple regimen
11053642|NCT04403087|No Intervention|Control group|Bismuth-containing quadruple regimen
11053643|NCT04403074||Chronic Pancreatitis Patients|Patients that have Chronic Pancreatitis and the current treatment with Celiac Plexus Blocks (CPB) are providing minimal relief of pain (CPB provide less than one month of pain relief). These patient will then receive a Celiac Plexus Neurolysis.
11053644|NCT04403048|Active Comparator|Patients in which standard provisional approach is preformed|Detailed technique is described in the Detailed study description paragraph
11053645|NCT04403048|Experimental|Patients in which provisional DCB approach is preformed|Detailed technique is described in the Detailed study description paragraph
11053646|NCT04403035||ID NOW vs. Acccula arm|Each patient serves as his or her own control. The ID NOW test is the one that is being currently used (i.e. the control) and the Accula test is the newer test being evaluated.
11053647|NCT04403022|Other|Single arm|Colorectal procedure will be performed by da Vinci SP® Surgical System
11053648|NCT04403009||the nonsevere Coronavirus Disease 2019 Patients|
11053649|NCT04403009||the severe Coronavirus Disease 2019 Patients|
11053650|NCT04402996||Healthy|Individuals with Periodontally Healthy
11053651|NCT04402996||Gingivitis|Individuals with Gingival Inflammation
11053652|NCT04402996||Periodontitis|Individuals with Periodontitis
11053653|NCT04402983|Experimental|Telerehabilitation Group|Physiotherapy will be carried out by conducting online conference method. Program content; Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
11053654|NCT04402983|No Intervention|Control group|Information and exercise brochure will be provided
11053655|NCT04402970|Experimental|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
11053656|NCT04402970|No Intervention|Standard of care|Standard of care provided for ARDS.
11053657|NCT04402957|Placebo Comparator|Placebo|100 mL drug-free IV saline infusion over 2 hours daily
11053658|NCT04402957|Experimental|LSALT|100 mL of 5 mg IV LSALT peptide infusion over 2 hours daily
11053659|NCT04402944|Experimental|Study Drug|Study drug
11053660|NCT04402944|Placebo Comparator|Placebo|Placebo
11053661|NCT04402931|Other|Transcatheter Valve-in-Valve Intervention|Transcatheter Valve-in-Valve Intervention
11053662|NCT04402931|Other|Redo Surgery|Surgical Mitral valve replacement
11053663|NCT04402918|Other|pregnancy patients diagnosed with SARS Cov2 during pregnancy|Delivery day biological samples from the mother and the newborn will be performed
11053664|NCT04402892|Active Comparator|Patients hospitalized for SARS-CoV-2|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
11053665|NCT04402892|Active Comparator|Patients who have recovered from CoV-2-SARS|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
11053666|NCT04402879|Experimental|Prone Positioning (PP)|The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.
11053667|NCT04402879|No Intervention|Control - usual management|The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.
11053668|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose A|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose A
11053669|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose B|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose B
11053670|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose C|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose C
11053671|NCT04402866|Experimental|Part 1: Placebo for MAD|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
11053672|NCT04402866|Experimental|Part 2: TD-0903|99 subjects will be randomized to receive TD-0903
11053673|NCT04402866|Experimental|Part 2: Placebo|99 subjects will be randomized to receive Placebo
11053674|NCT04402853||COVID 19 Patients|hospitalized patients with COVID 19
11053675|NCT04402840|Experimental|Stellate Ganglion Block (SGB)|Clinical Stellate ganglion block
11053676|NCT04402827||Cases|HCW highly exposed (defined as more than 15 days of continued personal attention in ICU, anaesthesia, or Infectious Diseases wards) to patients with a diagnosis of COVID-19 (PCR confirmed), who remained asymptomatic and with a negative serology (IgM and IgG negative). Transient entry or stay in the zone (kitchen personnel, rehab members,...) will be not included.
11053677|NCT04402827||Controls|HCW highly exposed to PCR-confirmed patients with a diagnosis of COVID-19, as defined above, matched by age and sex, who had suffered confirmed SARS CoV-2 disease (positive PCR or after, positive IgG)
11053678|NCT04402814||Arm A (positive for COVID-19)|"One or two samples of your blood that were previously collected for routine care will be obtained from the hospital laboratory and will be tested for the antibodies against COVID-19 virus.
~First blood sample obtained: 7 to 12 days following onset of symptoms; and/or
~Second blood sample obtained: 12 to 40 days following the onset of symptoms."
11053679|NCT04402814||Arm B (negative for COVID-19)|One sample of blood that was collected for routine care at any point during hospitalization will be obtained from the hospital laboratory and will be tested for the antibodies.
11053680|NCT04402801||Standard of Care Telemedicine Cohort|This cohort will have telemedicine visits in lieu of in-person clinic visits
11053681|NCT04402801||Standard of Care In-Person Cohort|
11053682|NCT04402788|Active Comparator|Arm I (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11053683|NCT04402788|Experimental|Arm II (atezolizumab, radiation therapy)|Patients receive atezolizumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy QD on days 1-5 during weeks 1-5 only.
11053684|NCT04402775|No Intervention|Vascular clamps|Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
11053685|NCT04402775|Experimental|Tourniquet|Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.
11053686|NCT04402762|Experimental|TR treatment sequence|Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma. Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France.
11053687|NCT04402762|Active Comparator|RT treatment sequence|Period 2-Reference Treatment: Porcine enoxaparin sodium 60 mg SC injection (Lovenox), manufactured by Sanofi, France. Period 1-Test Treatment: Ovine enoxaparin sodium 60 mg SC injection, manufactured by Metiska Farma.
11053688|NCT04402749||Nephrectomy|Patients underwent nephrectomy
11053689|NCT04402736|Experimental|Modified Barthel Index-based rehabilitation nursing program|Patients received the Modified Barthel Index based rehabilitation nursing from qualified nurses.
11053690|NCT04402736|Other|Usual care|Patients received the usual care.
11053691|NCT04402723|Experimental|Donafenib, 0.2g|Donafenib,0.2g,bid,Combination with Cytarabine and Daunorubicin.
11053692|NCT04402723|Experimental|Donafenib,0.3g|Donafenib,0.3g,bid,Combination with Cytarabine and Daunorubicin
11053693|NCT04402710|Active Comparator|Control Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. Ideal Care will involve: Session 2: Introductions and Goal setting/planning. Session 3: Action-Coping Planning and Monitoring Physical Activity Session 4: Goal re-visitation and adjustment and building self-efficacy. Session 5: Physical Activity Enjoyment and Barriers/Solutions. Session 6: Relapse prevention and commitment to exercise. The last 30 minutes of sessions 2-6, control participants will receive 30-minutes of non-self-compassion or physical activity related health education (i.e., sleep, screen time, antibiotic use, oral health, osteoporosis and vitamin D).
11053694|NCT04402710|Experimental|Intervention Group|Session 1: Participants will meet individually with a research assistant to discuss their type 2 risk and discuss benefits of engaging in 150 minutes of moderate-to-vigorous physical activity per week. First 30 minutes of each subsequent session will be ideal care (as described above in the control group). Last 30 minutes of sessions 2-6, self-compassion condition participants will learn to apply self-compassion to their prediabetes experience and physical activity. Session 2: Learn about fear of self-compassion and the benefits of self-compassion. Session 3: Yin and Yang of self-compassion. Session 4: Mindfulness. Session 5: Dealing with difficult emotions, loving Kindness and Self-Compassionate motivation. Session 6: Living deeply, self-appreciation and stages of progress.
11053695|NCT04402697|No Intervention|Normal-weight (NW)|Individuals with BMI<25 kg/m2
11053696|NCT04402697|Experimental|Overweight-Obese (OW-OB)|Individuals with BMI>25 kg/m2, submitted to a nutritional intervention (hypocaloric balanced diet) during 6 months and prescription of physical activity to achieve weigh loss
11053697|NCT04402697|Experimental|Metabolically obese normal-weight (MONW)|Individuals with BMI<25 kg/m2, with metabolic alterations related to obesity (hypertriglyceridemia, hypercholesterolemia, hyperglycaemia, hypertension or high waist-hip ratio), submitted to an intervention to improve dietary habits and physical activity in order to achieve a better body composition and metabolic health. Mediterranean diet will be and aerobic and strength exercises will be advised to these individuals.
11053698|NCT04402671|Active Comparator|non-crosslinked collagen membrane group|2 patients (1 male, 1 female)
11053699|NCT04402671|Active Comparator|glutaraldehyde cross-linked collagen membrane|2 patients (2 females)
11053757|NCT04402216|Experimental|Child Life-led preparation|Participants will meet with a child life specialist who will provide psychological preparation utilizing photos, MRI sounds, verbal discussion of MRI process, and discuss various coping strategies such as deep breathing or stress ball and option to watch a movie for alternative focus/distraction during the scan.
11066653|NCT04310098||Relatives of CADASIL patients and carriers|
11053700|NCT04402658|Experimental|Physical performance test|After performing measurements of lung function by spirometry, participants will inhale either salbutamol or placebo. After 15 minutes of rest, a second spirometry will be performed before the participants warm-up by 10 minutes cycling. The exercise protocol will consist of 60 minutes of cycling at 70% of maximal oxygen consumption (VO2max) on the cycle ergometer followed by an all-out sprint. Several times during the exercise test, 30-second Wingate tests will be conducted. Participants will be blinded to feedback such as power (W), distance covered, and heart rate. Strong verbal encouragement will be given to each participant for them to perform their best. Measurements of lung function (spirometry), heart rate, arterial oxygen saturation and Borg ratings of perceived exercising will be recorded throughout the trials, as well as capillary blood sampled for analysis of [La-] and [Glucose].
11053701|NCT04402645||Chronic pulmonary hypertension|Diagnosis on echocardiography at 36 weeks CGA using standard criteria (flat interventricular septal motion or right ventricular dilatation)
11053702|NCT04402645||No chronic pulmonary hypertension|Confirmed on echocardiography at 36 weeks CGA
11053703|NCT04402632|Active Comparator|Interventional Cohort: Control Arm|Control
11053704|NCT04402632|Experimental|Interventional Cohort: Treatment Arm|Treatment
11053705|NCT04402632|Active Comparator|Observational Cohort: Control Arm|Control
11053706|NCT04402632|Experimental|Observational Cohort: Treatment Arm|Treatment
11053707|NCT04402619|Experimental|Online CBT|Ten modules with minimum therapist guidance
11053708|NCT04402606|Experimental|Evaluation on skin toxicities|This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
11053709|NCT04402593|Experimental|Modified Heidelberg Model of Neuro-Music Therapy (mHNMT)|The mHNMT for Tinnitus program was modified based on participant feedback of the original HNMT. This study will include 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
11053710|NCT04402580|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells)
~How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
~Where: in Hospital
~When and how much: once; diluted in 1000 ml of normal saline."
11053711|NCT04402580|Active Comparator|Mycophenolate Mofetil|"Drug Name: Mycophenolate Mofetil (MMF)
~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis
~Procedures: MMF 1,200 mg/1,73 sqm orally divided in 2 daily doses"
11053712|NCT04402541|Experimental|CB-5339|Orally administered CB-5339
11053713|NCT04402528|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will use the mehealth for ADHD web-based software and have access to a module that allows parents and teachers/childcare providers to develop and implement behavioral interventions such as daily report cards online.
11053714|NCT04402515||Tiotropium plus Olodaterol treatment regimen|
11053715|NCT04402515||Inhaled corticosteroids-containing treatment regimen|
11053716|NCT04402502|Experimental|Healthy Population|Healthy Individuals with no presence of neurological disorders, rheumatoid arthritis or comorbid health conditions, and are not pregnant.
11053717|NCT04402489|Placebo Comparator|Placebo Comparator|Oral tablet of placebo once a day.
11053718|NCT04402489|Experimental|MT-7117 Low Dose|Oral tablet of MT-7117 Low Dose once a day.
11053719|NCT04402489|Experimental|MT-7117 High Dose|Oral tablet of MT-7117 High Dose once a day.
11053720|NCT04402476|Experimental|Device and Control|"Device:
~Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, Tested for use with Chemotherapy Drugs.
~Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
~Positive Control:
~0.4% Sodium Lauryl Sulfate (SLS) Dose. 0.2 ml"
11053721|NCT04402463|Experimental|GPR Group|"Global Postural Reeducation with 2 parts in each session:
~st: 2 postures in lying position - without gravity load (15 minutes each posture): The aim of these postures is to achieve and maintain postural balance and to stretch the posterior muscle chain. In order to achieve this, specific exercises in the lying position are used. That exercises involve a precise use of contractions, stretch reflexes, light and controlled manual tractions and sustained elongations.
~The maintenance of alignment during posture will be achieved by verbal commands and manual contact of the therapist, guaranteeing the active engagement of patient to reach the correct posture.
~st: Standing posture - integration under gravity load (10 minutes): With the participant standing the physiotherapist makes final corrections for postural integration."
11053722|NCT04402463|Experimental|Exercise Group|"Therapeutic exercises. That they will be divided into 3 phases:
~The exercises in these phases will consist in active exercises of the cervical spine and shoulder girdle, motor control exercises, and finally strength and endurance of the cervical flexors and extensors and of the musculature of the shoulder girdle."
11053723|NCT04402450|Active Comparator|suprainguinal fascia iliaca block|Forty mL of levobupivacaine 0.25% with epinephrine 5 ug/mL will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
11053724|NCT04402450|Experimental|Pericapsular nerve group block|Twenty mL of levobupivacaine 0.5% with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle.
11053725|NCT04402437|Active Comparator|Receives LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
11053726|NCT04402437|Active Comparator|Receives QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
11053727|NCT04402424||Two-Week Rule Colorectal Patients|Patients that the GP has referred to two-week rule colorectal clinics at Royal Surrey County Hospital with bowel symptoms or found to be anaemic
11053728|NCT04402411|Active Comparator|Control Group|Patients will receive general anesthesia with intravenous opioid
11053729|NCT04402411|Experimental|Quadratus lumborum|Patients will receive bilateral quadratus lumborum block
11053730|NCT04402411|Experimental|Transversus abdominis plane|Patients will receive bilateral transversus abdominis plane block
11053731|NCT04402385|Experimental|Aspirin|Participants randomized to 81 mg of Aspirin daily
11053732|NCT04402385|Placebo Comparator|Placebo|Participants randomized to placebo daily
11053733|NCT04402372||Group 1|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F bidirectional (BiflowTM, LivaNova, Italy) for femoral artery cannulation
11053734|NCT04402372||Group 2|30 patients undergoing aortic valve replacement with minimally invasive technique prospectively randomized to receive 19 F conventional (HLS, Maquet, Germany cannula with downstream line (6F) for femoral artery cannulation
11053735|NCT04402359||Group A|Patients of Group A received meropenem one gram slowly IV infusion every 8 hours for 14 days and gentamicin 7 milligram (mg)/ Kilogram body weight per day slowly IV infusion once daily only for one week after ventilator for 2 weeks
11053736|NCT04402359||Group B|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution). The solution for injection should be administered over 120 minutes.after ventilator for 2 weeks
11053737|NCT04402346|Experimental|Radiofrequency-assisted|
11053738|NCT04402346|Active Comparator|Stapler|
11053739|NCT04402333||Robotic interval debulking surgery|Surgery will commence with an initial assessment with a camera inserted though the belly button. This visual assessment will be used to determine whether it is feasible to proceed with surgery robotically or whether full debulking surgery to zero macroscopic residual disease would be best carried out through an open surgical approach. If an open surgical approach is considered the optimum treatment for the patient and they have consented for this, then this will be done. If there is disease that cannot be removed Robotically after starting by this route, but can be removed via an open incision the surgery will be converted to an open procedure if it is safe to do so. If there are any complications, we may also need to convert to open surgery. The aim of the surgery whether by robotic or open is to remove all visible disease safely.
11053740|NCT04402333||Open interval debulking surgery|Standard Care. Following initial laparoscopic assessment patients not deemed suitable for minimally invasive robotic surgery will proceed with standard open interval debulking surgery through an extended midline incision. These patients will also be followed up to assess recovery, complication rate and quality of life.
11053741|NCT04402320||Control group|extubated and weaning from the ventilator and followed our routine protocol of management post extubation without mechanical ventilation or BIPAP machine
11053742|NCT04402320||Invasive ventilation group|reconnected to mechanical ventilator before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use of NIV.
11053743|NCT04402320||non invasive ventilation group|following the same previous protocol done after extubation with immediate connection to NIV with BIPAP mode for 1 hour and repeated every 12hours for 48 hours, BIPAP adjusted in our study by FIO2 40%, PEEP 8 cmH2O, Pressure support of 15 cmH2O.
11053744|NCT04402307|No Intervention|Usual care|Usual care to patients with dysphagia
11053745|NCT04402307|Experimental|Training|Chin Tuck Against Resistance to patients with dysphagia
11053746|NCT04402281|Placebo Comparator|suPAR algoritm control|Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.
11053747|NCT04402281|Experimental|suPAR algoritm intervention|"Intervention arm (Jorvi Hospital).
~According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question
~Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician.
~If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question
~Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician."
11053748|NCT04402268||Low risk|Low risk of sudden cardiac death according to HCM Risk-SCD Calculator
11053749|NCT04402268||Intermediate risk|Intermediate risk of sudden cardiac death according to HCM Risk-SCD Calculator
11053750|NCT04402268||High risk|High risk of sudden cardiac death according to HCM Risk-SCD Calculator
11053751|NCT04402255|Experimental|behcet group|this group includes 16 patients with behçet
11053752|NCT04402255|Experimental|fmf group|this group includes 16 patients with fmf
11053753|NCT04402255|Active Comparator|healty control|this group includes 16 healthy control
11053754|NCT04402242|Sham Comparator|Standard Care|Control : bispectral index guided anesthesia
11053755|NCT04402242|Experimental|NOL monitoring|Intervention : NOL index guided anesthesia
11053756|NCT04402216|No Intervention|Current standard of care, no formal preparation|Participants in this group will receive the standard of care with no formal preparation. MRI technologist will meet patient prior to scan introducing role of patient, role of MRI technician, and give verbal discussion of MRI process. MRI technologist will offer opportunity for patient to watch a movie as alternative focus/distraction during MRI scan. The child life specialist will not meet with the caregiver or child during their visit.
11053758|NCT04402216|Experimental|MRI preparation video|Participants will be shown an MRI preparation video by the research coordinator in the MRI dressing room prior to MRI scan. The MRI preparation video will walk the patient through the MRI experience with a mock patient explaining all the steps of MRI process from check in to discharge. The child life specialist will not meet with the caregiver or child during their visit.
11053759|NCT04402216|Experimental|Child Life preparation with VR|Participants will be provided MRI preparation with a child life specialist using the Kind VR device. The VR (virtual reality) session will consist of an audio and visual MRI experience designed to serve as an opportunity for the patient to practice their scan prior to MRI. The VR session will take place once during the Radiology admission and will be approximately 15 minutes in duration. The VR software was developed by Kind VR and was designed specifically for the purpose of preparation for brain MRI. The interactive VR experience walks patients through each step of an MRI. Patients can practice holding still for the MRI and will get feedback from the VR headset when they are moving their head. Along with VR practice session CCLS will discuss various coping strategies such as deep breathing and/or stress ball and option to watch a movie for alternative focus/distraction during the scan.
11053760|NCT04402203|Experimental|Favipiravir + Standard Treatment|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
11053761|NCT04402203|Placebo Comparator|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
11053762|NCT04402177|Experimental|Hypersensitivity Pneumonitis patients showing lung fibrosis|hypersensitivity Pneumonitis patients that shows lung fibrosis after CT scan ( fibrotic patients ) methyl prednisolone 0.5mg/kg /day orally for 8 weeks
11053763|NCT04402177|Active Comparator|hypersensitivity Pneumonitis patients without lung fibrosis|hypersensitivity Pneumonitis patients that doesn't show lung fibrosis after CT ( non-fibrotic patients ) will be given also methyl prednisolone 0.5mg/kg /day orally for 8 weeks
11053764|NCT04402164|Active Comparator|Dentally anchored Herbst group|Herbst appliance will be anchored on the mandibular dentition
11053765|NCT04402164|Active Comparator|Skeletally anchored Herst group|Herbst appliance will be anchored on mini-plates placed in the para symphesial areas
11053766|NCT04402151|Other|Single Arm|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.
~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.
~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
11053767|NCT04402138|Experimental|Acalabrutinib|Acalabrutinib will be self-administered orally for up to approximately 2 years post-BMT.
11053768|NCT04402125|Experimental|Intervention|Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up
11053769|NCT04402125|Other|Waitlist|Participants randomized to waitlist for 6 months, then offered the intervention for 6 months
11053770|NCT04402086||Biorepository|Participants with rheumatic diseases who contributed biospecimen samples (blood, saliva, urine, stool, tissue).
11053771|NCT04402073|Other|standard arms|"Criteria: Adult SHH (p53wt) M0-1, adult WNT M0-1, adult Group 4 M0-1.
~Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
~Criteria: Post pubertal < 18 y SHH (p53wt) M0.
~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy."
11053772|NCT04402073|Experimental|experimental arms|"Radiotherapy Criteria: Adult and post-pubertal SHH (p53wt) M0; adult WNT M0, adult Group 4 M0.
~Radiotherapy to the cranio-spinal axis of 23.4 Gy in 13 daily fractions of 1.8 Gy, followed by an additional boost to the tumour site of 30.6 Gy in 17 daily fractions of 1.8 Gy, summing up to a total dose of 54.0 Gy in 30 daily fractions of 1.8 Gy.
~SMO-inhibitor Criteria: Adult and post-pubertal SHH (p53wt) M0.
~Sonidegib 200 mg/day (daily) from first day of radio-chemotherapy until end of maintenance chemotherapy, including 6w chemotherapy break."
11053773|NCT04402060|Experimental|180 mg APL-9 IV plus SOC|
11053774|NCT04402060|Placebo Comparator|Isotonic saline|
11053775|NCT04402047|Experimental|Electroacupuncture group|
11053776|NCT04402047|Active Comparator|Topical DSG group|
11053777|NCT04402034|Experimental|Application of tele-rehabilitation|Individuals that will perform the protocol of virtual reality intervention.
11053778|NCT04402021|Experimental|Aerobic Exercise|Participants randomized to the aerobic exercise group will complete 30 minutes of outdoor walking at a moderate intensity, defined as 50% heart rate reserve from the American College of Sports Medicine (ACSM) exercise prescription recommendations. A 5-minute warm-up and cool-down will occur before and after the 30-minute bout. A Polar H10 heart rate monitor will continuously monitor exercise intensity during the session. Ratings of Perceived Exertion (RPE) will be assessed using the Borg scale (i.e., 6-20 rating system) to indicate perceived exercise effort every 5 minutes during the exercise session. Each session will last approximately 50 minutes.
11053779|NCT04402021|Other|Quiet Rest|Participants randomized to this condition will be instructed to watch a nature documentary void of topics related to sleep or exercise. A Polar H10 heart rate monitor will continuously monitor heart rate during the session to mimic the aerobic exercise condition. Participants will not be permitted to complete homework or work during the allotted time to reduce the chance of unintended stimuli. The quiet rest sessions will be 50 minutes in length.
11053780|NCT04402008|Experimental|Phase 1: Once Daily Dosing|Dose finding at 8 mg, 12 mg, or 16 mg of poziotinib once daily in 28-day treatment cycles.
11053781|NCT04402008|Experimental|Phase 1: Twice Daily Dosing|Dose finding at 4 mg, 6 mg, or 8 mg of poziotinib twice daily in 28-day treatment cycles.
11053782|NCT04402008|Experimental|Phase 2: Once Daily Dosing or Twice Daily Dosing|"Once Daily or Twice Daily Dosing as determined in Phase 1 in 28-day treatment cycles.
~Cohort 1: EGFR exon 20 insertion mutations
~Cohort 2: HER2 exon 20 insertion mutations"
11054761|NCT04395261||Group 3|Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation
11053783|NCT04401995|Experimental|Nivolumab and CMP-001 Combination with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2,4,6) for 6 weeks in combination with CMP-001 5mg subcutaneous 1st dose, and the remaining injections, 10mg intra-tumorally will be administered Weeks 2-7. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 5.
~Boost Phase - Nivolumab 480mg IV, every 4 weeks and CMP-001 5mg subcutaneous every 4 weeks up to 48 weeks."
11053784|NCT04401995|Experimental|Nivolumab with [18F]F-AraG PET/CT|"Prime Phase - Nivolumab 240mg IV, every 2 weeks starting with Cycle 2 (Cycles 2, 4, 6) for 6 weeks. [18F]F-AraG PET/CT, single bolus injection of 5 (±10%) mCi IV into a vein, Screening and at Week 5.
~Boost Phase - Nivolumab 480mg IV, every 4 weeks starting from the time of surgery recovery for up to 48 weeks."
11053785|NCT04401969||Patients with eumycetoma lesions|Patients with eumycetoma lesions
11053786|NCT04401969||Patients with actinomycetoma lesions|Patients with actinomycetoma lesions
11053787|NCT04401969||Patients with lesions of unknown causality|Patients with lesions of unknown causality
11053788|NCT04401956|Active Comparator|Gluten free bread with added gluten|Bread will be eaten by the participants for 4 consecutive days.
11053789|NCT04401956|Active Comparator|Gluten free bread with added FODMAPs|Bread will be eaten by the participants for 4 consecutive days.
11053790|NCT04401956|Experimental|Traditional manufactured wheat bread|Bread will be eaten by the participants for 4 consecutive days.
11053791|NCT04401956|Experimental|Traditional manufactured spelt bread|Bread will be eaten by the participants for 4 consecutive days.
11053792|NCT04401956|Experimental|Conventional manufactured wheat bread|Bread will be eaten by the participants for 4 consecutive days.
11053793|NCT04401956|Experimental|Conventional manufactured spelt bread|Bread will be eaten by the participants for 4 consecutive days.
11053794|NCT04401943|Experimental|Fatigue intervention|the Fatigue intervention is a 6 week intervention delivered using video teleconferencing
11053795|NCT04401930||Free-living elderly|"Free-living elderly over the age of 65 living in Metropolitan Area of Milan, in apparent good health conditions.
~Male and Female"
11053796|NCT04401917|Other|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD)|
11053797|NCT04401917|Other|HIV negative (HIV-) subjects with OUD|
11053798|NCT04401917|Other|HIV Positive (HIV+) subjects with OUD negative|HIV+ subjects who may have been opioid-exposed but do not have current or past OUD
11053799|NCT04401917|Other|Healthy volunteer|HIV-, OUD- healthy controls who have been opioid-exposed but do not have current or past OUD
11053800|NCT04401904|Experimental|Dapagliflozin|10 participants with pre-diabetes will be randomized to the experimental group to receive dapagliflozin 10mg by mouth daily for 12 weeks.
11053801|NCT04401904|Other|Nutritional Counseling|10 participants with pre-diabetes will be randomized to receive nutritional counseling weekly for 12 weeks
11053802|NCT04401891|No Intervention|Routine Pre-Operative Education in MD office prior to surgery|
11053803|NCT04401891|Experimental|Formal Pre-operative education/therapy prior to surgery|
11053804|NCT04401878|Experimental|the treatment group (A)|Patients who have PDPH are manged by SPGB, they are assessed by NRS before the block, at 30 mins, 2h, 4h, 6h, 12h, and 24hours after block. The patients are also examined by TCD before and after the block.
11053805|NCT04401878|Experimental|control group (B)|The control group (B) of 60 patients with no PDPH were examined by TCD
11053806|NCT04401865|Experimental|Pulsed, Accelerated|5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
11053807|NCT04401865|Active Comparator|Conventional|4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
11053808|NCT04401852|Active Comparator|MgSO4 group|will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose
11053809|NCT04401852|Placebo Comparator|placebo group|will receive an equal volume of isotonic 0.9% saline over 15-20 minutes
11053810|NCT04401839|Active Comparator|Control group|153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
11053811|NCT04401839|Active Comparator|Study group|156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.
11053812|NCT04401826|Experimental|The conventional approach|Conventionnal ECL using piezosurgery and microsurgical tools
11053813|NCT04401826|Active Comparator|The intervention approach:|Conventionnal ECL with tunneling using piezosurgery and microsurgical tools
11053814|NCT04401813|Experimental|IBI310|An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
11053815|NCT04401800|Experimental|Part 1: Safety Run-in|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
11053816|NCT04401800|Experimental|Part 2: Lenvatinib|Lenvatinib at the recommended phase 2 dose (RP2D) determined from Part 1 + tislelizumab in 21-day cycles for up to 12 months
11053817|NCT04401787|Active Comparator|laparoscopic anterior resection (LAR)|LAR group included 88 patients, 17 patients converted to open
11053818|NCT04401787|Active Comparator|open anterior resection|Open anterior resection for 56 patients
11053846|NCT04401566|Experimental|External Myofascial Release Group|Eksternal myofascial trigger point release therapy consists of 30 minutes massage to the abdominal wall, gluteal area and abductors, and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and the lower extremity of the muscle.
11053847|NCT04401566|Other|Control Group|The Control group will have a video about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breathing, pelvic floor muscle stretching, and releasing.
11066654|NCT04310098||Unrelated healthy controls|
11053819|NCT04401774|Experimental|Nivolumab Maintenance|All patients will undergo cerebrospinal fluid (CSF) and blood collection as well as MRI imaging as standard of care prior to (- 21 days) first-line treatment initiation, during first-line therapy (before initiation of the 5th methotrexate dose (+/- 7 days)), at completion of first-line chemotherapy therapy (+/- 7 days) as well as 60, 180, and 360 days after enrollment into maintenance or observation (+/- 7 days). Those patients with persistent cfDNA in the CSF after completion of first-line chemotherapy and either complete or partial response on imaging will be enrolled into the nivolumab maintenance treatment arm. All other patients (no persistent cfDNA in the CSF and either complete or partial response on imaging) are followed with observation. Patients who do not respond to first-line therapy are not eligible for nivolumab maintenance and will no longer be followed in the biospecimen and clinical data collection cohort.
11053820|NCT04401761||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Brazil, Europe, Russia, Saudi Arabia, Asia and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid.
11053821|NCT04401748|Experimental|Arm 1: Venetoclax + Azacitidine (AZA)|Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (Days 1-7) of each 28 day cycle.
11053822|NCT04401748|Active Comparator|Arm 2: Placebo + Azacitidine|Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (Days 1-7) of each 28 day cycle.
11053823|NCT04401735|Experimental|Polydeoxyribonucleotide|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml
11053824|NCT04401735|Experimental|Polydeoxyribonucleotide, Placebo|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)
11053825|NCT04401735|Placebo Comparator|Placebo|Placebo (Normal saline)
11053826|NCT04401722|Active Comparator|PD in normal altitude|PD underwent in the area at the level of the sea, normal altitude region
11053827|NCT04401722|Active Comparator|PD in high altitude region.|PD underwent in high altitude region.
11053828|NCT04401709|Experimental|Gemcitabine/Capecitabine|gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
11053829|NCT04401709|Active Comparator|Capecitabine|capecitabine 2,500 mg/m2 D1-14
11053830|NCT04401696|Experimental|Group A|Use of Bubble CPAP for management of respiratory distress
11053831|NCT04401696|Active Comparator|Group B|Use of Oxygen via nasal cannula for respiratory distress
11053832|NCT04401683|Experimental|Digital Rehabilitation|Standard medical treatment + Fully remote rehabilitation program with a digital therapist
11053833|NCT04401683|Active Comparator|Conventional Rehabilitation|Standard medical treatment + Home-based rehabilitation program
11053834|NCT04401670|Other|Triage with different options|"Self-Collection: hrHPV and Biomarkers Testing (among hrHPV+)
~ThinPrep Specimen: Liquid-Based Cytology (LBC), hrHPV Testing, and Biomarker Testing (among hrHPV+)
~Visual Inspection after Acetic Acid (VIA)"
11053835|NCT04401657|Experimental|FFR Measurement|Myocardia ischemia evaluation during adenosine stress testing
11053836|NCT04401644|Experimental|primary arm|There will only be one set of participants with each participants samples and results as the comparator groups. There will be within group comparison of methods of detection of virus by two test methodologies. Post hoc validation of test performance against reference set.
11053837|NCT04401631||Interventions|"A minimum of 20 subjects with targeted levels of total IgE are needed to participate in the Operator-to-Operator whole blood study.
~A minimum of 20 subjects with targeted levels of allergen-specific and total IgE are needed to participate in the capillary whole blood between-run imprecision study in the POL environment.
~A minimum of 40 subjects with targeted levels of Fel d 1-specific IgE and total IgE are needed to participate in the sample type comparison study. These subjects will be recruited, and their samples analyzed at 1 POL.
~A minimum of 300 subjects (approximately 100 subjects enrolled and evaluated at each of three sites) and with targeted levels of total IgE are needed to participate in the method comparison study."
11053838|NCT04401618|Active Comparator|Resin-modified glass ionomer - Fuji 2 LC|Resin-modified glass ionomer material, Fuji 2 LC, was used to restore cervical carious and non-carious class V lesions in adult patients of Schulich dental clinic by 3rd and 4th-year dental students.
11053839|NCT04401618|Other|Glass ionomer - Fuji 9|Glass ionomer material, Fuji 9, was used to restore cervical carious and non-carious class V lesions in adult patients of Schulich dental clinic by 3rd and 4th-year dental students.
11053840|NCT04401605|Experimental|Fermented Food-Supplemented Diet|Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
11053841|NCT04401605|Placebo Comparator|Regular Diet Control Arm|Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.
11053842|NCT04401592||disease and control|
11053843|NCT04401579|Experimental|Remdesivir plus Baricitinib|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
11053844|NCT04401579|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
11053845|NCT04401566|Experimental|Internal Myofascial Release Group|Internal myofascial trigger point release therapy consists of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial release techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point. Releasing pelvic muscle tension includes applying varying amounts of pressure, sometimes gradually stroking and strumming the muscle region while systematically contracting and relaxing the affected muscles to aid in a trigger point release.
11053848|NCT04401553|Experimental|First Tier Antibiotic|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
11067478|NCT04304391|No Intervention|Group D|Negative Control Group
11053849|NCT04401553|Active Comparator|Second Tier Antibiotic|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam
11053850|NCT04401527|Active Comparator|Sodium Nitrite|Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.
11053851|NCT04401527|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.
11053852|NCT04401514|Experimental|Experiemntal intervention|The experimental intervention is a 20 min. long rocking chair with music therapy.
11053853|NCT04401514|Active Comparator|Control intervention|Control intervention is also transferred to the rocking chair, but the therapy program will not be turned on.
11053854|NCT04401501|Experimental|Manual Therapy + Exercise Group|Combination of manual therapy and exercises for cervicogenic headache
11053855|NCT04401501|Active Comparator|Exercise Group|Only exercises for cervicogenic headache
11053856|NCT04401475|Experimental|Stage 1|"Stage 1 (Phase II Study) Based on these response rates, a 4:1 ratio of patients treated with EB05 vs. Placebo, a two-sided alpha of 0.05, and 80% power, a total of 295 evaluable patients will be required for Stage 1 (Phase II study), 236 treated with EB05 and 59 treated with Placebo. Allowing for 20% attrition, a total of 355 patients will be enrolled in this Stage.
~There will be one blinded, non comparative Interim Analysis during the Phase II study when 50% of the patients (148 evaluable) have reached the 28-day follow-up time point. There will be no between comparisons conducted for this interim analysis; therefore, there is no need for multiplicity considerations. The purpose of the interim analysis will be to validate the assumptions used in the sample size calculations and to assess the inclusion / exclusion criteria as well as the study outcome. Based on the results of this interim analysis, outcome measures and sample size of the Phase II study can be changed."
11053857|NCT04401475|Experimental|Stage 2|"Based on the above-mentioned response rates, a 4:1 ratio of patients treated with EB05 vs. Placebo, >90% power, and a two-sided alpha of 0.05 using a z-test, a total of 425 evaluable patients will be required for Stage 2 (Phase III study), 340 treated with EB05 and 85 treated with Placebo. Allowing for 20% attrition, a total of 510 patients will be enrolled in this Stage.
~During the Phase III study there will be one blinded, comparative interim analysis when approximately 50% (213) of the evaluable patients have reached the 28-day follow up time period. The results of the interim analysis during the Phase III study will be used to determine whether the study should continue or be terminated early for futility or proven efficacy."
11053858|NCT04401462|Active Comparator|Operative group|tension band wiring or plate fixation
11053859|NCT04401462|Active Comparator|Non-operative group|conservative treatment
11053860|NCT04401449||Acutely illl subjects|COVID-19 subjects treated at the Clinical Center, followed through recovery and intoconvalescence
11053861|NCT04401449||Recovered subjects|COVID-109 subjects who were treated at other hospitals, followed through recovery and into convalescence
11053862|NCT04401436||COVID 19 patients|Study participants will be adults who either have COVID-19 or who have recently recovered from the disease(recovered per Centers for Disease Control and Prevention guidelines).
11053863|NCT04401423|Experimental|TXA127|Participants will receive one 3-hour dosage (0.5 mg/kg), intravenously, for 10 days consecutively.
11053864|NCT04401423|Placebo Comparator|Placebo|Participants will receive one 3-hour dosage (0.5 mg/kg), intravenously, for 10 days consecutively.
11053865|NCT04401410|Experimental|Dose Finding Phase|"This phase is designed to evaluate the maximum tolerated dose (MTD) of partially HLA-matched SARS-CoVSTs administered to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.
~The dose finding phase is a standard 3+3 safety study design. The 3 dose levels are:
~DL1: 1x107 cells (flat dose) DL2: 2x107 cells (flat dose) DL3: 4x107 cells (flat dose)"
11053866|NCT04401410|Experimental|Randomized Pilot - SARS-CoVSTs|Partially HLA-matched Virus Specific T cells (VSTs) will be given by intravenous injection.
11053867|NCT04401410|Active Comparator|Randomized Pilot - Routine Care|Hospitalized patients with COVID-19 will be treated per current institutional guidelines.
11053868|NCT04401397|Experimental|Early mobilization group|Immediately after ICU extubation, enrolled patients will receive an intensive 30-45 minutes, implemented twice a day early mobilization protocol containing psychological empowerment, detailed informative education of patients and close relatives, close monitoring of the recovery course, frequent parameter protocol configuration, high intensity active progressive pulmonary and musculoskeletal exercises and mobility techniques, close monitoring for early identification and measures for prevention and treatment of complications.
11053869|NCT04401397|Active Comparator|Standard care group|Enrolled patients will receive the standard hospital mobilization protocol after their admission to the ward, containing standardized basic pulmonary and mobilization techniques of 15 minutes, once a day.
11053870|NCT04401384|Experimental|Diclectin and active acupuncture|Diclectin (combination of doxylamine succinate and pyridoxine hydrochloride, 2 tablets/day at bedtime) + active acupuncture(30min once every other day). Participants will receive active acupuncture or sham acupuncture treatment every other day (or once every day if the symptoms are unrelieved (PUQE≧6)) for 2 consecutive weeks, 7-14 times in total, and receive Diclectin or placebo treatment every day (2 tablets at bedtime for the first day, if the symptoms are unrelieved (PUQE≧6), add one tablet in the morning, if the symptoms are still unrelieved (PUQE≧6), add another one tablet at three o 'clock in the afternoon) for 2 consecutive weeks, 28-56 tablets in total.
11053871|NCT04401384|Placebo Comparator|Diclectin and sham acupuncture|Diclectin (2 tablets/day at bedtime) + sham acupuncture (30min once every other day); Participants will receive active acupuncture or sham acupuncture treatment every other day (or once every day if the symptoms are unrelieved (PUQE≧6)) for 2 consecutive weeks, 7-14 times in total, and receive Diclectin or placebo treatment every day (2 tablets at bedtime for the first day, if the symptoms are unrelieved (PUQE≧6), add one tablet in the morning, if the symptoms are still unrelieved (PUQE≧6), add another one tablet at three o 'clock in the afternoon) for 2 consecutive weeks, 28-56 tablets in total.
11053913|NCT04401085||Population area cohort - Control Cohort|A population cohort of asymptomatic individuals (only adults). This is a representative sample of the population, which are part of the research project of Institute for Clinical and Experimental Medicine and Czech Academy of Sciences. The second subsample included individuals from the official household survey of Czech Statistical Office. This cohort allowed better comparative analysis of other population cohorts from specific geographical areas.
11068761|NCT04295161|Active Comparator|Reference|
11053872|NCT04401384|Placebo Comparator|Diclectin Placebo and active acupuncture|Diclectin Placebo (2 tablets/day at bedtime) + active acupuncture(30min once every other day). Participants will receive active acupuncture or sham acupuncture treatment every other day (or once every day if the symptoms are unrelieved (PUQE≧6)) for 2 consecutive weeks, 7-14 times in total, and receive Diclectin or placebo treatment every day (2 tablets at bedtime for the first day, if the symptoms are unrelieved (PUQE≧6), add one tablet in the morning, if the symptoms are still unrelieved (PUQE≧6), add another one tablet at three o 'clock in the afternoon) for 2 consecutive weeks, 28-56 tablets in total.
11053873|NCT04401384|Placebo Comparator|Diclectin Placebo and sham acupuncture|Diclectin Placebo (2 tablets/day at bedtime) + sham acupuncture (30min once every other day). Participants will receive active acupuncture or sham acupuncture treatment every other day (or once every day if the symptoms are unrelieved (PUQE≧6)) for 2 consecutive weeks, 7-14 times in total, and receive Diclectin or placebo treatment every day (2 tablets at bedtime for the first day, if the symptoms are unrelieved (PUQE≧6), add one tablet in the morning, if the symptoms are still unrelieved (PUQE≧6), add another one tablet at three o 'clock in the afternoon) for 2 consecutive weeks, 28-56 tablets in total.
11053874|NCT04401345|Experimental|Experimental Group (GP)|Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.
11053875|NCT04401345|Placebo Comparator|Placebo Group(NS)|patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min
11053876|NCT04401332|Experimental|Intervention|
11053877|NCT04401332|No Intervention|Usual Care|
11053878|NCT04401319|Sham Comparator|Sham Stimulation Group for Crossover Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the crossover study.
11053879|NCT04401319|Active Comparator|DLPFC Stimulation Group for Crossover Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the crossover study.
11053880|NCT04401319|Active Comparator|AG Stimulation Group for Crossover Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the crossover study.
11053881|NCT04401319|Sham Comparator|Sham Stimulation Group for Parallel Study|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the parallel study.
11053882|NCT04401319|Active Comparator|DLPFC Stimulation Group for Parallel Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the parallel study.
11053883|NCT04401319|Active Comparator|AG Stimulation Group for Parallel Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the parallel study.
11053884|NCT04401306|Experimental|Self-regulated simulation training|
11053885|NCT04401306|Active Comparator|Instructor-regulated simulation training|
11053886|NCT04401293|Experimental|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.
11053887|NCT04401293|Active Comparator|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
11053888|NCT04401280|Active Comparator|BiominF®|Test group
11053889|NCT04401280|Active Comparator|Novamin®|Test group
11053890|NCT04401280|Active Comparator|GC Tooth Mousse|Control group
11053891|NCT04401267|Experimental|Intensive Antihypertensive Therapy|Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
11053892|NCT04401267|Active Comparator|Conventional Antihypertensive Therapy|Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
11053893|NCT04401228||covid ICU patients|
11053894|NCT04401228||covid conventionnal ward|
11053895|NCT04401215|Other|Technology Augmented Treatment group|Intervention Group
11053896|NCT04401215|No Intervention|Control group|After the baseline visit the control arm participants will receive no additional follow-up beyond usual care until the 30 days' end. Surveys at the end of 30 days.
11053897|NCT04401202|Experimental|NS|
11053898|NCT04401202|No Intervention|Control|
11053899|NCT04401189||Breast cancer patients|
11053900|NCT04401189||Healthy controls|
11053901|NCT04401176|Active Comparator|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
11053902|NCT04401176|Active Comparator|Intradetrusor Onabotulinumtoxin A Injection|100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.
11053903|NCT04401150|Experimental|Vitamin C|Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
11053904|NCT04401150|Placebo Comparator|Control|Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
11053905|NCT04401137|Placebo Comparator|Placebo|
11053906|NCT04401137|Experimental|QDX 25|
11053907|NCT04401137|Experimental|QDX 50|
11053908|NCT04401137|Experimental|QDX 100|
11053909|NCT04401137|Experimental|QDX 200|
11053910|NCT04401124||patients treated at surgical emergency rooms|
11053911|NCT04401124||patients receiving surgeries (both elected and emergency)|
11053912|NCT04401111||Survivors of Intensive care unit patients|Survivors of severe COVID-19 pneumonia after intensive care unit
11054762|NCT04395261||Group 4|Control group. Subjects with no otitis media with effusion
11053914|NCT04401085||Population cohort from specific geographical areas|"This cohort is based on epidemiologically defined demographic parameters. These are populations from the following geographical areas:
~Brno and the South Moravian Region; Praha; Olomouc; Litoměřice; Litovel and Uničov."
11053915|NCT04401085||Chronically ill patients cohort|A cohort of chronically ill people enrolled by Institute for Clinical and Experimental Medicine with chronic cardiovascular problems, hypertension, or diabetes.
11053916|NCT04401059|Experimental|Elemene plus First-generation EGFR-TKIs|Elemene Injectable Emulsion sequentially with Elemene Oral Emulsion plus First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib).
11053917|NCT04401059|Active Comparator|First-generation EGFR-TKIs only|First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib).
11053918|NCT04401046|Experimental|Post traumatic stress and anxiety evaluation|
11053919|NCT04401033||Endoscopic cohort|Endoscopic examinations: They will be carried out according to the recommendations of the Spanish society for digestive endoscopy (SEED). In summary, the patient will perform a hand wash with hydroalcoholic solution before entering the endoscopy room, and will put on a surgical mask and gloves. Personnel close to the patient will wear an FFP2 mask, exceptionally a surgical mask, a gown (waterproof in high-risk examinations as established in the SEED guidelines), a cap, nitrile gloves and face shield or safety glasses (reusable) and shoe covers. The examinations will be performed by endoscopist-guided sedation in accordance with current clinical guidelines.
11053920|NCT04401033||Ultrasonography cohort|Abdominal ultrasound: They will be carried out according to international clinical guidelines (12). The explorer will wear an FFP2 mask, exceptionally a surgical mask, a gown, a hat, nitrile gloves, and a face shield or safety glasses (reusable) and shoe covers. The gel bottle, transducer, and stretcher will be washed prior to each scan with low-level disinfectant
11053921|NCT04401033||Telephonic cohort|The patient will be telephonically contacted for a medical visit.
11053922|NCT04401020|Experimental|Dose escalation|SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by twice weekly until week 4 (Cycle 1) and twice weekly for each subsequent cycle(s).
11053923|NCT04401007|Experimental|Group 20/30|Two different local anesthetic volumes will be investigated: 20 mL of 1.5% lidocaine (300 mg lidocaine) at one study visit and 30 mL of 1.5% lidocaine (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit
11053924|NCT04401007|Experimental|Group 30/20|(2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. This crossover design allows subjects to serve as their own control.
11053925|NCT04400994|Active Comparator|Rituximab only|"Rituximab infusion 375mg/m2 body surface area (BSA) weekly for 4 weeks from baseline (week 0, 1, 2, 3)
~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 24 (week 24, 25, 26, 27)
~Rituximab infusion 375mg/m2 BSA weekly for 2 weeks at week 52 (week 52, 53)
~Rituximab infusion 375mg/m2 BSA weekly for 4 weeks at week 76 (week 76, 77)
~A total of 12 doses of rituximab will be given in 55 weeks"
11053926|NCT04400994|Experimental|Rituximab and IVIG|"Rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 1, 2, 3);
~Week 4: Rituximab + IVIG 2g per kg
~Week 5, 6, 7: Above treatment repeated for 2nd cycle, infusion of rituximab (375 mg/m2 BSA) once a week for 4 weeks (week 5, 6, 7);
~Week 8: Rituximab + IVIG 2g/kg
~In months 3, 4, 5, 6, patients received a single infusion of rituximab (375 mg/m2 BSA) plus infusion of 2g/kg IVIG
~Thus in 6-month period patients received a total of 12 infusions of rituximab and 7 infusions of IVIG
~If a patient was clinically free of disease at end of 6 months, additional infusions of IVIG will be given at week 30, 38, 48, 60 and 76
~A total of 12 doses of rituximab and 12 cycles of IVIG will be given"
11053927|NCT04400981|Experimental|Intervention arm: RIC plus standard medical therapy|"Remote ischemic conditioning (RIC) will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
~Patients randomized to remote ischemic post conditioning will also receive standard medical therapy"
11053928|NCT04400981|Active Comparator|Control arm: Standard medical therapy alone|"Standard medical therapy will be administered immediately after randomization in the Emergency Department. Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.
~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
11053929|NCT04400968|Experimental|Auricular therapy group|The auricular therapy group received an intervention based on the bilateral application of 7 adhesive tapes with vaccaria seeds. The points were located with a retractable 250 gr. pressure palpator (Sedatelec®). An experienced health professional trained on acupuncture techniques applied the vaccaria seeds.
11053930|NCT04400968|Sham Comparator|Auricular therapy Placebo group|The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.
11053931|NCT04400968|Experimental|Kinesio tape group|The kinesio tape group received an intervention that consisted on the standard application of three elastic bandages. An experienced kinesio tape certified physical therapist applied the taping.
11053932|NCT04400968|Sham Comparator|kinesio tape Placebo group|The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area.
11053933|NCT04400968|No Intervention|Control group|The control group did not receive any treatment. The participants continued with their routine medical treatment. However, the controls completed all the questionnaires to collect the information regarding their symptoms in order to observe their progress with no intervention.
11053934|NCT04400942||Women with uterine myomas undergoing hysteroscopic myomectomy|
11054859|NCT04394559|No Intervention|Usual care|inpatient pharmacists as available; standard discharge orders; standard follow up visit.
11053935|NCT04400929|Experimental|Group A: Treatment Group|Day 1 - 5: Receive study medication Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
11053936|NCT04400929|Placebo Comparator|Group B: Placebo Group|Day 1 - 5: Receive normal saline 0.9% daily (via infusion into the vein) in addition to standard of care treatments
11053937|NCT04400929|Experimental|Group C|Day 6 - 10: Subjects in Group A who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
11053938|NCT04400929|Experimental|Group D|Day 6 - 10: Subjects from Group B to receive study medication (based on the treating physician's assessment), Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
11053939|NCT04400929|Experimental|Group E|Day 11 - 15: Subjects in Group D who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
11053940|NCT04400916|Experimental|Topical tranexamic acid|
11053941|NCT04400916|Placebo Comparator|Topical BSS|
11053942|NCT04400903||Observational (HRV monitoring, questionnaire)|Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.
11053943|NCT04400890|Active Comparator|Plant Polyphenol (supplement)with Vitamin D3|Plant Polyphenol (Supplement) for 15 days. Vitamin D3 100,000 IU on day 1
11053944|NCT04400890|Placebo Comparator|Placebo with Vitamin D3|Placebo for 15 days. Vitamin D3 100,000 IU on day 1
11053945|NCT04400877||SARS-CoV-2 pos|Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
11053946|NCT04400877||SARS-CoV-2 neg|Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
11053947|NCT04400864|Experimental|Mediterranean Diet|Nutritional guidelines based on the principals of the Mediterranean Diet
11053948|NCT04400864|Experimental|Paleolithic Diet|Nutritional guidelines based on the principals of thePaleolithic Diet
11053949|NCT04400851|Experimental|Sintilimab in advanced childhood cancer patients|
11053950|NCT04400838|Experimental|Group 1 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
11053951|NCT04400838|Experimental|Group 1 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
11053952|NCT04400838|Experimental|Group 1 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost (4-6 weeks apart)
11053953|NCT04400838|Experimental|Group 2 a1|Volunteers will receive a single dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260)
11053954|NCT04400838|Experimental|Group 2 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks apart
11053955|NCT04400838|Experimental|Group 2 b1|.Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
11053956|NCT04400838|Experimental|Group 3|Volunteers will receive a single low dose of 2.5x10^10vp ChAdOx1 nCoV-19 (qPCR)
11053957|NCT04400838|Experimental|Group 4 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp (Abs 260)
11053958|NCT04400838|Experimental|Group 4 b1|Volunteers will receive two dose ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs 260) prime and 2.2x10^10vp (qPCR) boost 4-6 weeks apart
11053959|NCT04400838|Experimental|Group 4 c1|Volunteers will receive two doses of ChAdOx1 nCOV19 vaccine, 5x10^10vp (Abs260) prime and 2.2x10^10vp (qPCR) boost*, at least 4 weeks apart
11053960|NCT04400838|Experimental|Group 5 a1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (Abs 260)
11053961|NCT04400838|Experimental|Group 5 a3|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine: 5x10^10vp (Abs 260) prime and 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260) boost, minimum 4 weeks from prime
11053962|NCT04400838|Experimental|Group 5 b1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x1010vp, (qPCR)
11053963|NCT04400838|Experimental|Group 5 c1|Volunteers will receive a single dose ChAdOx1 nCoV19 vaccine, 5x10^10vp, (qPCR)
11053964|NCT04400838|Experimental|Group 5 d1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
11053965|NCT04400838|Experimental|Group 6 a1|Volunteers will receive a single dose ofChAdOx1 nCoV19 vaccine, 5x1010vp (qPCR)
11053966|NCT04400838|Experimental|Group 6 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 5x1010vp (Abs260) prime and 0.5mL (3.5 - 6.5 × 1010 vp, Abs 260)* boost* at least 4 weeks apart
11053967|NCT04400838|Experimental|Group 7 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
11053968|NCT04400838|Experimental|Group 7 b1|Volunteers will receive two doses of ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)* 4-6 weeks apart
11053969|NCT04400838|Experimental|Group 8 a1|Volunteers will receive a single dose ChAdOx1nCOV19 vaccine, 5x10^10vp (qPCR)
11053970|NCT04400838|Experimental|Group 8 b1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
11053971|NCT04400838|Experimental|Group 9 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
11053972|NCT04400838|Experimental|Group 10 a1|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
11053973|NCT04400838|Experimental|Group 11|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
11053974|NCT04400838|Experimental|Group 12|Volunteers will receive two doses of ChAdOx1 nCoV19 vaccine, 0.5mL (3.5 - 6.5 × 10^10 vp, Abs 260)* 4-6 weeks apart
11053975|NCT04400838|Active Comparator|Single dose MenACWY|Groups 1 a2, 2 a2, 3 a, 4 a2, 5 a2, 5 b2, 5 c2, 6 a2, 7 a2 & 8 a2 will receive a standard single dose of MenACWY vaccine
11053976|NCT04400838|Active Comparator|Two dose MenACWY 4 - 6 weeks|Groups 1 b2, 2 b2, 4 b2, 5 d2, 7 b2, 8 b2, 9 a2 & 10 a2 will receive two doses of MenACWY 4-6 weeks apart
11055151|NCT04392349|Other|NORMAL|Normal group includes eyes with healthy cornea.
11053977|NCT04400838|Active Comparator|Two dose MenACWY minimum 4 weeks|Groups 1 a4, 2 a4, 4 c2, 5 a4, 6b2 will receive two doses of MenACWY at least 4 weeks apart
11053978|NCT04400825|Experimental|Dry needling|Dry needling of 3 active MTrPs at most.
11053979|NCT04400825|Active Comparator|Stretching|Stretching of the main hip flexors (rectus femoris, iliopsoas and tensor fasciae latae)
11053980|NCT04400799|Experimental|Test Group|Enoxaparin (Clexane®) will be given at the recommended dose of 4,000 IU antiXa activity (40 mg/0.4 ml) once daily by SC injection for 14 days.
11053981|NCT04400799|No Intervention|Control Group|No study drug
11053982|NCT04400786|Experimental|On-demand treatment|This group of 98 ankylosing spondylitis patients is prescribed with intermittent Imrecoxib (100mg.prn.po) according to the feeling of pain till 24 weeks. The sulfasalazine (500mg.tid.po) is used.
11053983|NCT04400786|Active Comparator|Continuous treatment|This group of 98 ankylosing spondylitis patients is prescribed with continuous Imrecoxib (100mg.bid.po) for 24 weeks. The sulfasalazine (500mg.tid.po) is used.
11053984|NCT04400773|Experimental|Plyometric Group|This group will receive a 6-week upper body plyometric exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
11053985|NCT04400773|Experimental|Strength Group|This group will receive a 6-week upper body strength exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
11053986|NCT04400760|Other|DAPA Tx|This arm will comprise the participants who are administered Dapagliflozin 10mg per oral once daily for 2 weeks.
11053987|NCT04400747|Experimental|weekly treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 50,000 IU of vitamin D weekly for 8 weeks.
11053988|NCT04400747|Experimental|daily treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 6,000 IU of vitamin D daily for 8 weeks.
11053989|NCT04400747|No Intervention|control group|20 patients with high calcium (Ca) values in blood tests, patients with kidney and urinary stones, as well as patients who refuse to use vitamin D supplements will be included in the control group
11053990|NCT04400721|No Intervention|PCIA arm|Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)
11053991|NCT04400721|Active Comparator|ESP block arm|ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin [Ropivacaine])
11053992|NCT04400721|Active Comparator|IC block arm|3 ml of 0.5% solution of Naropin [Ropivacaine] per intercostal space, up to a maximum of 30ml
11053993|NCT04400708|Sham Comparator|control group|normal saline injection
11053994|NCT04400708|Experimental|test group|0.5% ropivacaine injection
11053995|NCT04400695|Experimental|RC48-ADC|RC48-ADC common name：Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form：Lyophilized powder injection specification：60 mg / piece Medication plan：Every 2 weeks Expiration date：18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
11053996|NCT04400695|Active Comparator|Physician's Choice|"Physician's Choice:
~HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
~Physician's choice from the following options:
~Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets"
11053997|NCT04400682|Experimental|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
11053998|NCT04400682|Experimental|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
11053999|NCT04400669|Experimental|Mechanical Bowel Preparation|Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
11054000|NCT04400669|Active Comparator|Low fibre diet|Patients will be given detailed instructions about the pre-operative diet (total daily Fibre intake inferior to 10 g) to be used for 3 days prior to surgery.
11054001|NCT04400669|Active Comparator|MBP plus low fibre diet|This group will receive both mechanical bowel preparation and 3-days low fibre diet.
11054002|NCT04400669|No Intervention|Control|Control subjects will receive no instructions about the pre-operative diet (free diet).
11054003|NCT04400630|No Intervention|Control (TAU)|patients without any intervention + treatment as usual (TAU)
11054004|NCT04400630|Experimental|PE intervention+TAU|Physical exercise (PE) intervention + treatment as usual (TAU)
11054005|NCT04400617||Assisted-living residents|The target population will be inactive men and women residents of the Brenda Strafford Foundation (> 50 yrs. old). We expect the participants to be classified as inactivity, which will be defined as an engagement in < 3 sessions/week of 20 min or more of vigorous exercise. Participants should be able to move independently without the assistance of a wheelchair.
11054006|NCT04400617||Control group|Volunteers from the Brain in Motion II (BIM II) study (NCT03035851). The BIM II study aims to examine the mechanisms whereby exercise may improve sleep and cognition in men and women aged 50 to 80 years old. As the baseline measurements of the BIM II study are similar to the assessments proposed in this study, the assisted living residents will be matched with older individuals of the same age and cognitive performance who live independently to answer the last research question.
11054007|NCT04400604||1: Patients with minimal risk of extensive fibrosis|TE < 5.8kPa; rule out cut-off value)
11054008|NCT04400604||2: Patients with intermediate risk of fibrosis|
11054009|NCT04400604||Patients with high risk of extensive fibrosis|
11054010|NCT04400604||Patients with compensated cirrhosis biopsy-proven|
11054011|NCT04400604||Patients with a first decompensation|patients with a first decompensation event of cirrhosis after exclusion of HCC.
11054012|NCT04400578|Experimental|TRICIN|"If a patient is eligible
~local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application
~Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application
~Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application"
11054013|NCT04400565|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
11054014|NCT04400565|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
11054015|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op|Oral nutrition supplementation (ONS) pre-operatively and post-operatively up to being discharged from hospital
11054016|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Oral nutrition supplementation (ONS) pre-operatively, post-operatively up to being discharged from hospital and an extended oral nutrition supplementation post-operatively up to 3 months
11054017|NCT04400552|Active Comparator|Usual intake Pre-op + ONS Post-op|Follow a meal plan of 2000 kcal / day using conventional foods and oral nutrition supplementation (ONS) post-operatively up to being discharged from hospital
11054018|NCT04400539|Experimental|Malignant Pleural Mesothelioma patients|
11054019|NCT04400526|Other|Phase 1: A video competition for anti-drug abuse|Phase 1 aims to increase the public awareness of hazardous effects of drug abuses and existing resources available for drug abusers through a video competition. We will co-organize a video competition for anti-drug abuse with C.H.O.I.C.E. The competition will appeal to the participation of all children (aged 13-18) living in the four targeted districts.
11054020|NCT04400526|Other|Phase 2: Developing a community-based network|Phase 2 aims to develop a community-based network through training anti-drug ambassadors (ADAs). We target to recruit a total of 150 children aged 13 - 18 as ADAs through secondary schools and community centres in the four targeted districts by sending invitation letters. The content of the workshop will be designed by our expert panel. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
11054021|NCT04400526|Other|Phase 3: A mass promotional campaign|Phase 3 aims to engage the public to join the community-based network through anti-drug activities organized by anti-drug ambassadors. They are encouraged to design their own promotional activities for community members in the targeted districts.Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites.
11054022|NCT04400513||Aortic Stenosis|Subjects with echo-confirmed AS graded moderate-to-severe or worse
11054023|NCT04400513||Mitral Regurgitation|Subjects with echo-confirmed MR graded moderate-to-severe or worse
11054024|NCT04400513||Tricuspid Regurgitation|Subjects with echo-confirmed TR graded moderate-to-severe or worse
11054025|NCT04400513||Innocent Murmur|Subjects with echo-confirmed trace/trivial valve disease severity
11054026|NCT04400513||Diastolic Murmur|Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS)
11054027|NCT04400513||Continuous Murmur|Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA)
11054028|NCT04400500||Suspected NSTEACS|Patients urgently admitted to the CCU with suspected NSTEACS
11054029|NCT04400487|Experimental|Voxelotor|Participants will receive voxelotor at 1500 mg
11054030|NCT04400474|Experimental|Cabozantinib 40 mg + Atezolizumab 1200 mg|"Cabozantinib 40 mg tablets, oral administration, once daily, continuously.
~Atezolizumab 1200 mg administered intravenously, every three weeks (cycle)."
11054031|NCT04400422|Experimental|Lipano MCT formula|Kanso Lipano will be consumed daily for 3 months each to assess tolerability and compliance
11054032|NCT04400409|Active Comparator|Intervention A + site 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.
~6-Minute Walk Test (6MWT) will be administered by site staff."
11054033|NCT04400409|Active Comparator|Intervention B + site 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.
~6-Minute Walk Test (6MWT) will be administered by site staff."
11054034|NCT04400409|Active Comparator|Intervention A + CPC EQuIP 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.
~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
11054035|NCT04400409|Active Comparator|Intervention B + CPC EQuIP 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.
~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
11054036|NCT04400396||target HM fortification|Contemporary cohort fed HM with target fortification
11054037|NCT04400396||standard HM fortification|Historical cohort fed HM with standard fortification
11054038|NCT04400383|Experimental|AB011 Injection|AB011 Injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
11054039|NCT04400370||Pediatric patients undergoing lung resection|
11054040|NCT04400357|Experimental|Robotic pancreaticoduodenectomy|Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy.
11054041|NCT04400357|Active Comparator|Open pancreaticoduodenectomy|Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy.
11054342|NCT04398368|Experimental|Prevention (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.
11054042|NCT04400344||Survey Respondents|Respondents are members of the American Association of Diabetes Educators recruited via an introductory email sent out by the AADE on behalf of Podimetrics.
11054043|NCT04400331|Experimental|Valbenazine|Capsule, administered orally once daily.
11054044|NCT04400318|Experimental|Dupilumab|2 x loading dose on Day 1, followed by 1 x maintenance dose every 2 weeks (Q2W) during 24 weeks
11054045|NCT04400318|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 24 weeks
11054046|NCT04400305|No Intervention|Control|No Intervention: Control Group This group will complete baseline and final questionnaires (online). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 6 week period following the study.
11054047|NCT04400305|Other|Intervention|Participants will complete a baseline questionnaire, and receive access to the our online platform for 6 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 3 weeks, a check-in session will occur over the phone. At 6 weeks the participant will be contacted to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
11054048|NCT04400292|Experimental|SLN mapping by NIR with ICG|Patients will undergo ICG injection and NIR imaging for lymphatic mapping. Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy. The SLN biopsy procedure will be performed as described below. Although NIR with ICG is used to assess conduit perfusion in all esophagectomies performed at MSK, its use for lymphatic mapping is considered experimental in esophageal cancer.
11054049|NCT04400279|Experimental|Yoga Exercise group|Using the Down Dog app, this group will be given access to an at-home personalized yoga practice, unique every time the participants complete it. Asked to complete yoga practice 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
11054050|NCT04400279|Experimental|High Intensity Interval Training group|Using the Down Dog app, this group will be given access to at-home bodyweight high intensity interval training (HIIT) workouts. Asked to complete these HIIT workouts 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
11054051|NCT04400279|Experimental|Combination Yoga & HIIT group|Using the Down Dog app, this group will be given access to both the unique yoga practice and bodyweight HIIT workouts. Asked to complete 2 yoga and 2 HIIT workouts per week. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
11054052|NCT04400279|No Intervention|Control group|This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
11054053|NCT04400266|Experimental|Buspirone and Melatonin|Buspirone 15mg and Melatonin 3mg
11054054|NCT04400253|Experimental|Intervention group|The intervention group will receive a 18-week in-person program. The program includes the following components: multi family group counseling, group exercise classes, mother group discussion, daughter group discussion and Fitbit.
11054055|NCT04400253|No Intervention|Control group|The group group will receive print materials about physical activity.
11054056|NCT04400240|Experimental|Intervention|complete questionnaires and phone sessions
11054057|NCT04400240|No Intervention|Control|complete questionnaires only
11054058|NCT04400227|Experimental|Youth-Parent Dyads|Participants will receive the Family Talk intervention and followup.
11054059|NCT04400214|Experimental|Food Allergy Superheroes Training (FAST) Program|Participants enrolled in this arm of the study will receive 5, 20 minutes skills training sessions designed to promote adherence to food allergy safety guidelines. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
11054060|NCT04400214|Active Comparator|Food Allergy Knowledge (FAK) Intervention|Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
11054061|NCT04400201|Experimental|Remimazolam Tosilate|
11054062|NCT04400201|Active Comparator|Propofol|
11054063|NCT04400188|Experimental|Experimental A (part 1) : Fluzoparib + temozolomide|
11054064|NCT04400188|Experimental|Experimental B (part 2) : Fluzoparib + temozolomide + SHR-1316|
11054065|NCT04400175|Experimental|B-ESP|B-ESP group will be fed with a feeding system with a valved ergonomic teat.
11054066|NCT04400175|Sham Comparator|B-STD|B-STD will be fed with a standard feeding system.
11054067|NCT04400162|Active Comparator|CCT (standard)|This arm consists of the CCT in a standard variant that provides the basic training experience without any added gaming elements.
11054068|NCT04400162|Experimental|CCT (game)|This arm consists of the same CCT as the standard version, however pre-defined gaming elements that are thought to increase usability as well as interest in the intervention have been added.
11054106|NCT04399889|No Intervention|Standard of care|Subjects on this arm will not receive any hCT-MSCs (study product). They will receive standard of care treatment for COVID19, as clinically indicated by their care provider.
11054182|NCT04399356|Active Comparator|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally on day 1 and daily for 6 more days (total 7 days of treatment)
11054183|NCT04399356|Placebo Comparator|Control|Participants in the control group will receive identical-appearing placebo by mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment)
11054069|NCT04400149||1|amniotic fluid progesterone (this group will be evaluated by the amniotic fluid which was received via amniocentesis). This group consisted of pregnant women who had high risk in the antenal test and give consent to perform amniocentesis. Notwithstanding, amniocentesis detects chromosome abnormalities, neural tube defects, and genetic disorders for the fetuses. İn a routine amniocentesis, 1-2 ml amniotic fluid which was taken in the first place was discarded in order to prevent maternal contamination. Then 15-20 ml amniotic fluid was taken from all of the patients to diagnose genetic disorders of the fetuses. İn this study we evaluate the amniotic fluid progesterone in this 1-2 ml amniotic fluid which was discarded and throw away. Therefore, we are not performing an extra invasive procedure for pregnant women
11054070|NCT04400149||2|serum progesterone (this group consisted of the pregnant women who have amniocentesis procedure and blood samples were taken in the same procedure )
11054071|NCT04400136|No Intervention|GROUP A - no PPI|no PPI treatment (control group)
11054072|NCT04400136|Experimental|GROUP B PPI 1/day for 6 months|(standard dose-long term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months
11054073|NCT04400136|Experimental|GROUP C PPI 1/day for 3 months|(standard dose-short term): Lansoprazole oral tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months
11054074|NCT04400123|Experimental|Treatment group TR|Intervention: Drug: famitinib malate, new formulation; Intervention: Drug: famitinib malate, old formulation.
11054075|NCT04400123|Experimental|Treatment group RT|Intervention: Drug: famitinib malate, old formulation; Intervention: Drug: famitinib malate, new formulation.
11054076|NCT04400110|Experimental|Short treatment group|Amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 5 consecutive days
11054077|NCT04400110|Active Comparator|Standard treatment group|amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 10 consecutive days
11054078|NCT04400097|Experimental|hidden-knot group|
11054079|NCT04400097|Active Comparator|two-knot group|
11054080|NCT04400097|Active Comparator|multi-knot group|
11054081|NCT04400084||Pregnant mothers|Pregnant mothers who have a normal pregnancy
11054082|NCT04400071|Experimental|Active Music Engagement|See intervention description.
11054083|NCT04400071|Active Comparator|Audio Storybooks|See intervention description.
11054084|NCT04400058|Experimental|Octagam 10%|Octagam 10%
11054085|NCT04400058|Placebo Comparator|Placebo|Placebo
11054086|NCT04400045|Experimental|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0
11054087|NCT04400032|Experimental|Panel 1|25 million cells/unit dose (cumulative dose: 75 million MSCs)
11054088|NCT04400032|Experimental|Panel 2|50 million cells/unit dose (cumulative dose: 150 million MSCs)
11054089|NCT04400032|Experimental|Panel 3|up to 90 million cells/unit dose (cumulative dose: up to 270 million MSCs)
11054090|NCT04400019|No Intervention|Tracking control|"According to the randomization process described, those nursing homes assigned to the control arm of the trial will receive the same treatment as those assigned to the intervention group, except for the medication, which will be a masked placebo.
~The study is triple blind, so neither the professionals who carry out the follow-up, nor the patients, nor the person in charge of analyzing the data, know to which group each nursing home belongs."
11054091|NCT04400019|Experimental|Intervention|The dose to be used as chemoprophylaxis will be 800mg of Hydroxychloroquine (HCQ) on the first day and 400mg during the subsequent four days. Participating subjects will be followed up at 6, 14 and 28 days.
11054092|NCT04399993|Experimental|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.
~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.
~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
11054093|NCT04399993|Sham Comparator|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.
~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.
~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
11054094|NCT04399980|Active Comparator|Intervention|Treatment infusion
11054095|NCT04399980|Placebo Comparator|Control|Placebo infusion
11054096|NCT04399967|Experimental|Intervention Group|Personalized instant messaging (PIM) + COVID-19 specific advice + AWARD advice + COVID-related health warning leaflet + referral card + COSH booklet
11054097|NCT04399967|Experimental|Control Group|Regular instant messaging (RIM) + AWARD advice + warning leaflet + referral card + COSH booklet
11054098|NCT04399954|Experimental|Ketoflo|Ketoflo to be incorporated into each participant's usual ketogenic diet for 28 days. Amount taken and frequency of intake to be determined by the dietitian.
11054099|NCT04399941|Experimental|IVUS and venography group|Participants in the this group will receive venography/fistulogram, intravascular ultrasound (IVUS), and image processing.
11054100|NCT04399915||Hyperoxalemia/Hyperuricemia Group|
11054101|NCT04399915||Hyperoxalemia/Hyperuricemia-free Group|
11054102|NCT04399915||Healthy Subjects|
11054103|NCT04399902|Experimental|Study blanket|Upon activation of a massive hemorrhage protocol, a standard warmed hospital blanket will be placed on top of the patient and the study blanket(s) on top of the standard warmed blanket. The blanket will remain on the patient through their path of care, and removed from the patient at arrival to the ICU/final phase of care, or if the patient temperature exceeds 38˚C at any point.
11054104|NCT04399889|Experimental|Open Label infusion of hCT-MSC|The first 10 consecutive patients will all receive investigational product.
11054105|NCT04399889|Other|Randomized infusion of hCT-MSC|An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 20 patients will be randomized in a 1:1 fashion between treatment with MSCs and standard of care.
11054107|NCT04399876|Experimental|Surgery Cohort|"Participant eligibility for intervention and selection of lesion for device placement
~- Surgery Cohort will undergo percutaneous placement of several microdevices in a selected tumor(s) prior to surgery. The microdevice in the surgery cohort will dwell in the tumor tissue for approximately 48 hours to allow time for tissue effects of the drugs in the microdevice reservoirs.
~Placement of at least 1, and up to 6, microdevices depending on the number of lesions, size and accessibility
~Extirpative surgery will proceed according to standard-of-care procedures. The microdevice(s) will be removed surgically along with surrounding tumor tissue.
~Standard of care treatment and follow-up of clinical course"
11054108|NCT04399876|Experimental|Ex-Vivo Cohort|"Each participant will undergo a screening process to determine their eligibility for microdevice placement, consisting of the following items:
~Routine standard of care for radical prostatectomy.
~Placement of implantable microdevice with multiple miniature drug reservoirs but no drug in prostate that have been removed
~Ex vivo image guided removal using retrieval device
~Standard of Care Treatment and follow-up of clinical course"
11054109|NCT04399863|Experimental|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
11054110|NCT04399850|Experimental|Patients who receive hypnosis|Patients who receive hypnosis during procedure by experiment physician
11054111|NCT04399850|No Intervention|Control arm|Patient with conventional pain management
11054112|NCT04399837|Experimental|Spesolimab, treatment arm 1|
11054113|NCT04399837|Experimental|Spesolimab, treatment arm 2|
11054114|NCT04399837|Experimental|Spesolimab, treatment arm 3|
11054115|NCT04399837|Placebo Comparator|Placebo|
11054116|NCT04399824|Experimental|Arm I (SBRT)|Patients undergo SBRT in 5 fractions over 14 days in the absence of disease progression or unacceptable toxicity.
11054117|NCT04399824|Experimental|Arm II (HDR brachytherapy)|Patients undergo HDR brachytherapy on day 1 and a second fraction within 14 days in the absence of disease progression or unacceptable toxicity.
11054118|NCT04399798|Experimental|Baricitinib active treatment|Baricitinib 4 mg/day
11054119|NCT04399785|Experimental|Arm 1|
11054120|NCT04399772|Experimental|Cognitive Functional Therapy+|The CFT+ intervention includes treatment performed by a CFT trained physiotherapists and a psychologist in the Pain Center. Each patient receives a maximum of 10 consultations over a period of 3 months. The first two sessions is combined with the physiotherapist and psychologist who investigates potential maintaining factors for pain and disability in the patient's everyday life. Remaining sessions are primarily run by the physiotherapist, and the treatment is individually tailored to the needs of the individual patient, aiming to provide the patient with skills in dealing with his / her own situation via information, reflection, change of movement and training of functions and physical level. The psychologist provide extra support for 2-3 sessions focusing on coping strategies to reinforce the physiotherapist work.
11054121|NCT04399772|Active Comparator|Interdisciplinary pain management|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.
~Treatment can be diverse, but based on an individual assessment it consists of a combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects) AND (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs. On average patients in the pain center receives 9-10 sessions."
11054122|NCT04399759|Experimental|A-IADL Group|Approach-Instrumental Activities of Daily Living in home
11054123|NCT04399759|Active Comparator|Control group|Home health education
11054124|NCT04399746|Experimental|Combination|Ivermectin (6mg once daily in day 0,1,7 and 8) plus Azithromycin (500mg once daily for 4 days) plus Cholecalciferol (400 IU twice daily for 30 days).
11054125|NCT04399746|No Intervention|Control|No intervention
11054126|NCT04399733||Ethnicity|Patients will be segmented on a 1:1:1 ratio similar to the EMPOWER-1 study based on ethnicity (White, Black, South Asian).
11054127|NCT04399720||BPS group|patients under Bisphosphonate therapy for at least 24 months
11054128|NCT04399720||healthy patients|healthy patients not assuming with no previous Bisphosphonate assumption
11054129|NCT04399707|Active Comparator|Active TENS Unit|
11054130|NCT04399707|Placebo Comparator|Placebo TENS Unit|
11054131|NCT04399707|No Intervention|No TENS Unit|
11054132|NCT04399681|Other|Suspected COVID-19 Group|Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
11054133|NCT04399642|Active Comparator|Standard|Patients receiving single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision
11054134|NCT04399642|Experimental|Vanco|Patients receiving a single dose of IV cefazolin (2 grams if < 120kg; 3 grams if >120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure
11054135|NCT04399629|Active Comparator|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
11054136|NCT04399629|Experimental|Parenting Wisely|Online parenting training
11054174|NCT04399421||Cement-augmented pedicle screw fixation|Patients undergoing pedicle screw fixation augmented with bone cement.
11054175|NCT04399408|Experimental|Study group|Device users
11054176|NCT04399395|Active Comparator|Lifestyle and naltrexone/bupropion|
11054177|NCT04399395|Other|Lifestyle|
11054178|NCT04399382||Non-radiographic group|Participants with non-radiographic axial SpA
11054179|NCT04399382||Radiographic group|Participants with radiographic axial SpA (a.k.a. ankylosing spondylitis)
11054180|NCT04399369|Experimental|SDF|38% silver diamine fluoride solution
11054181|NCT04399369|Active Comparator|NaF|5% sodium fluoride varnish
11054343|NCT04398355|No Intervention|control|basic treatment+Swallowing rehabilitation training
11054137|NCT04399616|Experimental|Experimental|"The intervention consists of the availability in the patient's medical history of the visual risk map. The patients in the intervention group will have a risk map in their medical history similar to the one presented in image (annex 2), and any care provider will have immediate access to this map which we think will help them to prioritize the implementation of the relevant practices. safe (in relation to the areas that appear in red).
~Areas of risk:
~Other independent variables will be the areas of risk:
~Identification of the patient
~Functional autonomy and quality of life
~Caregiver
~Safe management and use of medicines
~Risk of falls
~Risk of injuries and pressure ulcers
~Symptom control
~Risk of infection associated with health care
~Patient and family values and beliefs
~Social risk
~Unplanned hospital admissions / proactive monitoring
~Continuity of care 7X24 h
~Transfers (between care levels)
~Safety culture
~Nursing work environment"
11054138|NCT04399616|No Intervention|No intervention|The patients in the control group will have in their medical records the usual records of the comprehensive geriatric assessment.
11054139|NCT04399603||COVID critically unwell patients|
11054140|NCT04399603||Non-Covid critically unwell Patietns|
11054141|NCT04399577|Experimental|Wart Patients|Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
11054142|NCT04399564|Active Comparator|temporary hemodialysis catheters|one arm-temporary hemodialysis catheter
11054143|NCT04399564|Experimental|long-term hemodialysis catheters|another arm-long term hemodialysis catheter
11054144|NCT04399551|Experimental|Participants with HIV infection|HIV-infected participants receiving CAB+RPV LA will be included in this arm. Participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
11054145|NCT04399551|Other|Staff study participants (SSP)|Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
11054146|NCT04399538|Placebo Comparator|Placebo|Participants will receive medication for 6 weeks
11054147|NCT04399538|Experimental|DGAT2i (25 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
11054148|NCT04399538|Experimental|DGAT2i (100 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
11054149|NCT04399538|Experimental|DGAT2i (300 mg QD) + ACCi (20 mg QD)|Participants will receive medication for 6 weeks
11054150|NCT04399538|Experimental|DGAT2i (300 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
11054151|NCT04399525|Experimental|Sequence 1|Desloratadine 5 mg Levocetirizine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
11054152|NCT04399525|Experimental|Sequence 2|Desloratadine 5 mg Levocetirizine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
11054153|NCT04399525|Experimental|Sequence 3|Levocetirizine 5 mg Desloratadine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
11054154|NCT04399525|Experimental|Sequence 4|Levocetirizine 5 mg Desloratadine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
11054155|NCT04399512|Active Comparator|Patients with liver cirrhosis|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis and change in MELD(model for end stage liver disease) will be checked after treatment.
11054156|NCT04399512|Active Comparator|Normal healthy patients|prevalence of apical periodontitis will be checked and non-surgical root canal treatment will be given to the patients with apical periodontitis
11054157|NCT04399486|Experimental|Aquatic Physical Therapy|
11054158|NCT04399486|Active Comparator|Land-based Physical Therapy|
11054159|NCT04399473||Control group: Usual PT Care|
11054160|NCT04399473||Experimental group: PNE + Usual PT Care|Participants in this arm will receive PNE education in addition to Usual PT Care
11054161|NCT04399460|Experimental|Low Dairy Energy Restrictive Diet|Low-dairy (<1 serving/day) and 500kcal/deficit per day energy restrictive diet
11054162|NCT04399460|Experimental|3 Servings of Full-Fat Dairy with Energy Restrictive diet|Energy-restrictive diet (500 kcal/deficit per day) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
11054163|NCT04399460|Experimental|3 Servings of Full-Fat Dairy but no energy restriction|Normal diet (no energy restriction) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
11054164|NCT04399447||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
11054165|NCT04399447||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
11054166|NCT04399447||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
11054167|NCT04399447||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
11054168|NCT04399447||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
11054169|NCT04399447||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
11054170|NCT04399434||normal pregnancy|pregnancy with a normal fetal size
11054171|NCT04399434||fetal growth restriction|fetal birth weight is below two standard deviations of the average weight for the same gestational age, or below the 10th percentile of normal weight for the same age
11054172|NCT04399434||fetal macrosomia|fetal birth weight ≥ 4000g
11054173|NCT04399421||Conventional pedicle screw fixation|Patients undergoing conventional pedicle screw fixation without the use of bone cement.
11054184|NCT04399343|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
11054185|NCT04399343|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
11054186|NCT04399317|Experimental|Group A|This is the treatment group. Patients will be ventilated using the new device (Evone) applying flow controlled ventilation for 48 hours. Ventilation parameters will be assessed every 6-8 hours. All other treatment will be unchanged and according to institutional standards.
11054187|NCT04399317|No Intervention|Group B|These patients will be treated according to institutional standards. Only data will be collected. This is the control group.
11054188|NCT04399304||Simultaneous|One-stage bilateral high tibial osteotomy
11054189|NCT04399304||Staged|Two-stage bilateral high tibial osteotomy
11054190|NCT04399291||Residential care facility residents|Older adults recruited from care homes in Northern Ireland
11054191|NCT04399278|Other|Group A|The EEO test will be applied first over 15 seconds and secondly over 30 seconds (each EEO test separated by 1 minute wash-out period)
11054192|NCT04399278|Other|Group B|The EEO test will be applied first over 30 seconds and secondly over 15 seconds (each EEO test separated by 1 minute wash-out period)
11054193|NCT04399265|Experimental|Trehalose|Trehalose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
11054194|NCT04399265|Placebo Comparator|Maltose placebo|Isocaloric maltose powder form to be dissolved in water, to be consumed by mouth, every day for 3 months.
11054195|NCT04399252|Experimental|LGG Arm|Participants in this arm will be given LGG for 28 days.
11054196|NCT04399252|Placebo Comparator|Placebo|Participants in this arm will be given a placebo for 28 days.
11054197|NCT04399239|Experimental|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
11054198|NCT04399213|Experimental|Group A|From cubital fossae to wrist: 50 - 15 - 5 µg histamine dihydrochloride
11054199|NCT04399213|Experimental|Group B|From cubital fossae to wrist: 15 - 5 - 50 µg histamine dihydrochloride
11054200|NCT04399213|Experimental|Group C|From cubital fossae to wrist: 5 - 50 - 15 µg histamine dihydrochloride
11054201|NCT04399200||Sleep-disordered breathing group|Sleep-disordered breathing (SDB) patients (AHI>15/h, measured by polysomnography performed 3 months after stroke)
11054202|NCT04399200||Control group|Control patients with no SDB (AHI<15/h, measured by polysomnography performed 3 months after stroke)
11054203|NCT04399187|Experimental|scaling and root planing, Sodium hypochlorite gel application|Periodontal pockets > 5 mm in patients of test group were treated by scaling and root planing and Sodium hypochlorite gel application
11054204|NCT04399187|Placebo Comparator|scaling and root planing alone|scaling and root planing alone was performed
11054205|NCT04399161|Experimental|Child Participants|Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
11054206|NCT04399161|Experimental|Elderly Participants|Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
11054207|NCT04399148|Experimental|Sequence 1|Desloratadine - Aprepitant - Ketotifen
11054208|NCT04399148|Experimental|Sequence 2|Aprepitant - Ketotifen - Desloratadine
11054209|NCT04399148|Experimental|Sequence 3|Ketotifen - Desloratadine - Aprepitant
11054210|NCT04399135|Active Comparator|Normal Patients|All patients admitted to Qassim dental clinics, who need root canal treatment would be screened for possible involvement in this study
11054211|NCT04399135|Active Comparator|Periodontitis Patients|All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. the periodontitis patients would be categorized according to the new periodontitis classification 2017 world workshop.
11054212|NCT04399122|Active Comparator|Acetaminophen with codeine|codeine 30mg/acetaminophen 300mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
11054213|NCT04399122|Active Comparator|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
11054214|NCT04399109|Active Comparator|TCC-COVID mHealth solution|TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms, connected to a back-end clinical database with inbuilt data analytics.
11054215|NCT04399109|No Intervention|Control|Propensity matched and synthetic control groups will be utilised from another local health district not participating in the ReCOVER study. The control group will not be actively recruited at the same time as the intervention. The control group will be matched via data linkage at the completion of the trial. However, it is not a historical control, as the control standard of care treatment will be provided simultaneously as our intervention
11054216|NCT04399096||General population|The general public attending exhibitions of the artworks who wish to complete the on-line questionnaire and feedback
11054217|NCT04399083|Experimental|Single Arm|
11054218|NCT04399070|Placebo Comparator|Propofol group|patients were treated with propofol 1 mg/kg and saline bolus infusion before ECT
11054219|NCT04399070|Active Comparator|Ketamine group|patients were treated with propofol 1 mg/kg and ketamine 0.5 mg/kg bolus infusion before ECT
11054220|NCT04399070|Experimental|S-ketamine group|patients were treated with propofol 1 mg/kg and S-ketamine 0.25 mg/kg bolus infusion before ECT
11054344|NCT04398355|Experimental|treatment|basic treatment+Swallowing rehabilitation training+Chinese traditional rehabilitation
11054221|NCT04399057||andrological patients|shear wave elastosonography of the corpora cavernosa was performed to all patients who went to our clinic for andrological problems. in addition, the International Index of Erectile Function short form (IIEF5) questionnaire and the Erectile Hardness Score (EHS) questionnaire were administered.
11054222|NCT04399044|No Intervention|Group 1: No flap|Participants will undergo the scheduled vascular surgery procedure without involvement of the plastic surgery team and use of muscle flaps for graft coverage.
11054223|NCT04399044|Experimental|Group 2: Prophylactic muscle flap|Participants will undergo the scheduled vascular surgery procedure and then a muscle flap will be used to cover the vascular graft by a plastic surgeon in the same setting.
11054224|NCT04399031|Experimental|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
11054225|NCT04399031|Experimental|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
11054226|NCT04399031|Experimental|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
11054227|NCT04399031|Experimental|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
11054228|NCT04399031|Experimental|E-cigarette e-liquid 5|Participants will self-administer an e-cigarette e-liquid.
11054229|NCT04399031|Experimental|E-cigarette e-liquid 6|Participants will self-administer an e-cigarette e-liquid.
11054230|NCT04399031|Experimental|E-cigarette e-liquid 7|Participants will self-administer an e-cigarette e-liquid.
11054231|NCT04399031|Experimental|E-cigarette e-liquid 8|Participants will self-administer an e-cigarette e-liquid.
11054232|NCT04399031|Experimental|E-cigarette e-liquid 9|Participants will self-administer an e-cigarette e-liquid.
11054233|NCT04399031|Experimental|E-cigarette e-liquid 10|Participants will self-administer an e-cigarette e-liquid.
11054234|NCT04399031|Experimental|E-cigarette e-liquid 11|Participants will self-administer an e-cigarette e-liquid.
11054235|NCT04399031|Experimental|E-cigarette e-liquid 12|Participants will self-administer an e-cigarette e-liquid.
11054236|NCT04399031|Experimental|E-cigarette e-liquid 13|Participants will self-administer an e-cigarette e-liquid.
11054237|NCT04399031|Experimental|E-cigarette e-liquid 14|Participants will self-administer an e-cigarette e-liquid.
11054238|NCT04399031|Experimental|E-cigarette e-liquid 15|Participants will self-administer an e-cigarette e-liquid.
11054239|NCT04399031|Experimental|E-cigarette e-liquid 16|Participants will self-administer an e-cigarette e-liquid.
11054240|NCT04399031|Experimental|E-cigarette e-liquid 17|Participants will self-administer an e-cigarette e-liquid.
11054241|NCT04399031|Experimental|E-cigarette e-liquid 18|Participants will self-administer an e-cigarette e-liquid.
11054242|NCT04399031|Experimental|E-cigarette e-liquid 19|Participants will self-administer an e-cigarette e-liquid.
11054243|NCT04399031|Experimental|E-cigarette e-liquid 20|Participants will self-administer an e-cigarette e-liquid.
11054244|NCT04399005|Experimental|daily room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
11054245|NCT04399005|Experimental|after-each-case room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. After-each-case room disinfection was defined as after completing each case.
11054246|NCT04398966|Experimental|PAE Procedure|This will be a single arm, uncontrolled, non-blinded study of PAE using HydroPearl Beads in a small population of 30 subjects with benign prostate hyperplasia (BPH)
11054247|NCT04398953|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
11054248|NCT04398940|Experimental|TQ-B3139 capsules|TQ-B3139 capsules administered orally.
11054249|NCT04398927|Experimental|Folfirinox plus PD1|Patients treated with systemic chemotherapy(regimen: Folfirinox) plus PD1
11054250|NCT04398914|Experimental|Pyrotinib, trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: pyrotinib, trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).
~After surgery：
~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.
~if tpCR: chemotherapy 0-4 cycles according to physician's choice, followed with pertuzumab and trastuzumab up to 1 year total."
11054251|NCT04398914|Active Comparator|Trastuzumab, pertuzmab and paclitaxel|"Prior to surgery: trastuzumab, pertuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days).
~After surgery：
~if non-tpCR：chemotherapy with epirubicin and cyclophosphamide (EC), followed with pertuzumab and trastuzumab up to 1 year total; or T-DM1 for 14 cycles.
~if tpCR: chemotherapy 0-4 cycles according to physician's choice; followed with pertuzumab and trastuzumab up to 1 year total."
11054252|NCT04398901||Colombia ZIKV-exposed|Children in Colombia were previously enrolled as part of a fetal-neonatal neuroimaging study in 2016-2017 and were from Department of Atlantico, Colombia on the Caribbean coast. Eligible children had prior normal fetal MRI and fetal US, normal birth head circumference, normal clinical exam, no more than mild non-specific postnatal imaging findings, and are thus without findings of CZS.
11054253|NCT04398901||Colombia Non-ZIKV exposed control|We will enroll 70 non-ZIKV exposed children, age 4 years, in Department of Atlántico, Colombia with birth dates prior to August 31, 2015. Based on the arrival of ZIKV to Colombia in November 2015, this date would ensure a control cohort without congenital ZIKV exposure or infection in the first 3 months of age.
11054254|NCT04398901||United States ZIKV-exposed|The US cohort either presented during pregnancy or after birth and sought clinical care with the Children's National Congenital Zika Program in Washington, DC and were ZIKV-exposed.
11054255|NCT04398901||United States Non-ZIKV exposed control|We will enroll 32 non-ZIKV exposed children, age 4 years, in Washington, DC.
11054282|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
11054283|NCT04398719|Active Comparator|CBD|
11054284|NCT04398719|Placebo Comparator|Placebo|
11054256|NCT04398888|Experimental|BXD|"Participants will be diagnosed and treated by Chinese medicine practitioners (CMPs) with at least 5 years of clinical experience. CMPs will differentiate syndrome and prescript herbs in a semi-standardized protocol, which consists of a base Chinese medicine decoction, BXD, and the additional syndrome-specific herbs.
~The modified decoction will be prepared in a conventional decocting method at the Chinese medicine pharmacy in the clinic (HKBA-HKU CMCTR) and will be packaged into bags by the auto-decocting machines. Participants will take the decoction twice per day, 5 days per week, for 3 weeks."
11054257|NCT04398888|No Intervention|Waitlist|Participants in the waiting list control group will be observed for a three-week waiting period. Rescue medication is not restricted.
11054258|NCT04398875|Experimental|ASC|Traditional manual acupuncture with standard care (ASC) will be provided. Subjects in the ASC group will receive 9 sessions of acupuncture and standard care for 3 weeks. A semi-standardized acupuncture treatment protocol (combined fixed acupoints with additional acupoints by symptom differentiation) will be employed. The fixed acupuncture points including, Guanyuan (CV4), Xuanzhong(GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Zusanli (ST36), Yingtang (EX-HN3), Baihui (GV20), and Qihai (CV6) will be used in every session.
11054259|NCT04398875|Sham Comparator|SSC|Sham acupuncture plus standard care (SSC) will be provided. Subjects in the SSC group will receive 9 sessions of sham acupuncture and standard care for 3 weeks. The Streitberger sham acupuncture will be employed. The selection of acupoints is the same as ASC.
11054260|NCT04398875|Placebo Comparator|SC|Standard care alone (SC) will be provided. Subjects in the SC group will standard care for 3 weeks.
11054261|NCT04398862||Children with Down syndrome and aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
11054262|NCT04398862||Children with Down syndrome without aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
11054263|NCT04398849||14-19 year olds residing in the Northern Territory|All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
11054264|NCT04398836|Active Comparator|Malnourished patients - EEN|patiens will receive EEN for 4 week prior surgery
11054265|NCT04398836|Other|Malnourished patients - enriched diet|patiens will receive an enriched high energy and protein diet.
11054266|NCT04398836|Other|Well nourished patients|Patient will receive a standard nutrition
11054267|NCT04398823|Active Comparator|Foam sclerotherapy,FS|Participants in this arm will receive the enteroscopic treatment with the sclerosing foam of lauromacrogol.
11054268|NCT04398823|Placebo Comparator|Liquid sclerotherapy,Ls|Participants in this arm will receive the enteroscopic treatment with the liquid of lauromacrogol.
11054269|NCT04398810|Experimental|the low-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery
~Cholelithiasis
~Chronic cholecystitis
~Gallbladder polyps
~Gallbladder adenoma
~Porcelain gallbladder
~The experimental group controls the CO2 flow that is injected into the abdominal cavity during surgery and maintains the pressure in the abdominal cavity at a low level of 5 mmHg to perform the surgery."
11054270|NCT04398810|Experimental|the standard-pressure pneumoperitoneum during surgery|"A. Inclusion criteria Patients who underwent elective gallbladder surgery
~Cholelithiasis
~Chronic cholecystitis
~Gallbladder polyps
~Gallbladder adenoma
~Porcelain gallbladder
~In the case of the control group, surgery is performed while maintaining the pressure in the abdominal cavity at 12 mmHg as generally performed during surgery."
11054271|NCT04398797|Experimental|Intervention|Use of notification algorithm and nurse follow-up
11054272|NCT04398797|No Intervention|Control|Standard regime (usual care)
11054273|NCT04398784|Other|1-Blueberry First/Placebo First|Participants will be randomly assigned into either blueberry-first treatment or placebo-first group.
11054274|NCT04398784|Other|2-Crossover|Participants who received blueberry treatment will switch to placebo and vice versa.
11054275|NCT04398771||Treatment|Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)
11054276|NCT04398758|Experimental|Treatment group|"Children of the treatment group receive the cream SanaCutan Basiscreme. The cream's main ingredients are white soft paraffin and liquid paraffin and it is already approved for the treatment of several skin diseases due to its skin care effect."
11054277|NCT04398758|No Intervention|Control group|Children of the control group should avoid regular skincare applications. Skincare is not prohibited, however, it is recommended to use products only in urgent cases.
11054278|NCT04398745|Experimental|Part 1: Participants with normal/mild impaired renal function|Participants with normal or mildly impaired renal function (Normal: estimated glomerular filtration rate [eGFR]: >=90 milliliter per minute per 1.73 meter square [mL/min/1.73 m^2]; Mild impairment: eGFR: 60-89 mL/min/1.73 m^2) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
11054279|NCT04398745|Experimental|Part 1: Participants with severe renal impairment|Participants with severely impaired renal function (eGFR: 15-29 mL/min/1.73 m^2) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
11054280|NCT04398745|Experimental|Part 2: Participants with ESRD (not on dialysis)|"Participants with ESRD (eGFR:
~<15 mL/min/1.73 m^2) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, dose will be decided after evaluation of pharmacokinetic and safety data of Part 1."
11054281|NCT04398745|Experimental|Part 2: Participants with ESRD (on hemodialysis)|Participants with ESRD (eGFR: <15 mL/min/1.73 m^2) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
11054285|NCT04398706|Experimental|Group 1|One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
11054286|NCT04398706|Experimental|Group 2|One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
11054287|NCT04398706|Experimental|Group 3|One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
11054288|NCT04398706|Active Comparator|Group 4|One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
11054289|NCT04398706|Experimental|Group 5|Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine and hepatitis B vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months
11054290|NCT04398706|Experimental|Group 6|Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine and hepatitis B vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months
11054291|NCT04398706|Experimental|Group 7|Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine and hepatitis B vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months
11054292|NCT04398706|Active Comparator|Group 8|Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine and hepatitis B vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months
11054293|NCT04398693|No Intervention|Normotensive Patients|40 normotensive patients with systolic BP (SBP) < 140 mmHg and diastolic BP (DBP) < 90 mmHg at the office, without the use of antihypertensive drugs and evaluated through ambulatory blood pressure monitoring (ABPM) to confirm normotension (BP < 130/80 mmHg) and the exclusion of possible masked hypertension.
11054294|NCT04398693|No Intervention|Controlled Hypertensive Patients|40 controlled hypertensive patients using up to three antihypertensive drugs with SBP < 130 mmHg and DBP < 80 mmHg evaluated through 24 hours ambulatory blood pressure monitoring (ABPM).
11054295|NCT04398693|Active Comparator|Resistant Hypertensive Patients|The study will be double-blinded, randomized, placebo-controlled crossover Initially, 20 individuals of the resistant hypertensive group will take prebiotic for 4 weeks, while other 20 individuals this group will use placebo. After a washout period of 4 weeks, the study protocol will be repeated in the other arm.
11054296|NCT04398680|Experimental|Part 1: Participants with normal hepatic function|Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase [AST] <= Upper limit of normal [ULN]) will be administered with Belantamab mafodotin 2.5 mg/kg intravenous infusion over 30 minutes on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
11054297|NCT04398680|Experimental|Part 1: Participants with moderate hepatic impairment|Participants with moderate hepatic impairment (Serum bilirubin >1.5 - 3 × ULN and any AST) will be administered with Belantamab mafodotin 2.5 mg/kg intravenous infusion over 30 minutes on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
11054298|NCT04398680|Experimental|Part 2: Participants with severe hepatic impairment|Participants with severe hepatic impairment (Serum bilirubin >3 × ULN and any AST) will be administered with Belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other lower adjusted dose) intravenous infusion over 30 minutes on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
11054299|NCT04398654|No Intervention|Control Group|Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.
11054300|NCT04398654|Active Comparator|Intervention Group|As in control group. In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.
11054301|NCT04398641||Nerve and vessel sparing segmental resection (NVSSR)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of nerve and vessel sparing segmental resection (NVSSR)
11054302|NCT04398641||Transanal disc excision (TADE)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of transanal disc excision (TADE)
11054303|NCT04398628||Hemophilia|"This cohort includes three Arms:
~PUPs Arm:
~This Arm is for previously untreated patients (PUPs) with congenital hemophilia A or B. This is a longitudinal, observational, prospective and retrospective Arm of PUPs with moderate or severe congenital hemophilia. Participants will be followed to assess inhibitor development within 50 exposure days (ED).
~Hemophilia Natural History Arm:
~This Arm is investigating a natural history of the safety, effectiveness, and practice of treatment for people with hemophilia. It is a longitudinal, observational, prospective Arm for participants with acquired or congenital hemophilia A or B.
~Hemophilia Gene Therapy Outcomes Arm:
~This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. It is a longitudinal, observational cohort Arm following participants prospectively and retrospective for 15 years after vector infusion."
11054304|NCT04398628||Von Willebrand Disease|The Severe VWD Natural History Arm is investigating the natural history of the safety, effectiveness, and practice of treatment for people with severe von Willebrand disease (VWD). It is a longitudinal, observational cohort Arm following participants every 6 months for at least 2 years.
11054305|NCT04398628||Congenital Platelet Disorders|No Arms or Modules at this time.
11054306|NCT04398628||Rare Bleeding Disorders|No Arms or Modules at this time
11054307|NCT04398628||Bleeding NOS|No Arms or Modules at this time
11054308|NCT04398628||Thrombosis/Thrombophilia|No Arms or Modules at this time
11054309|NCT04398628||Non-Neoplastic Hematologic Conditions|No Arms or Modules at this time
11054310|NCT04398615|Experimental|Intervention|Single arm, receiving the experimental device
11054311|NCT04398589|Experimental|SSNB and ANB c DEX|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.
11054312|NCT04398589|Placebo Comparator|SSNB and ANB c saline|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.
11054341|NCT04398394|Experimental|Group 5|Patients with other retinopathies than AMD, over the age of 18.
11054313|NCT04398576|No Intervention|Support as usual|"There will be no interventions, only support as usual. All GPs receive an information package by post or via e-mail containing:
~Belgian guidelines on the management of hazardous and harmful alcohol use
~A summary card about EIBI for hazardous and harmful alcohol consumption.
~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).
~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider."
11054314|NCT04398576|Active Comparator|Training and support|"All GPs receive an information package by post or via e-mail containing:
~Belgian guidelines on the management of hazardous and harmful alcohol use
~A summary card about EIBI for hazardous and harmful alcohol consumption.
~Internet links to documentation of the medical association and the Flemish centre of expertise on alcohol and drugs(31).
~An EHR-update allows the use of an extra e-form permitting standardised introduction of screening results from the Alcohol Use Disorders Identification Test (-Consumption) (AUDIT(-C)), alcohol-related diagnoses and actions including provision of oral brief advice/intervention, referral to a digital-based system for advice and/or referral to another health care provider.
~There shall be tailored training and support for the general practioners. At the start of the study, this group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months."
11054315|NCT04398576|Active Comparator|Training and support and community actions|In this group, GPs receive the same training and support as in the second arm (training and support). There will also be embedded community-based actions within a local strategy.
11054316|NCT04398550|Experimental|Specific Carbohydrate Diet|Exclusive consumption of the specific carbohydrate diet for 6 weeks
11054317|NCT04398550|Experimental|Mediterranean Diet|Exclusive consumption of the Mediterranean diet for 6 weeks
11054318|NCT04398537|Experimental|5mm retraction of clip deployment apparatus|The participants in this group will have clip placement 5mm in front of the biopsy site site.
11054319|NCT04398537|Active Comparator|no retraction of clip deployment apparatus|These participants will the clip delivered at the biopsy site.
11054320|NCT04398524|Experimental|single arm|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
11054321|NCT04398511|Experimental|L brevis|Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
11054322|NCT04398511|Placebo Comparator|Placebo|Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
11054323|NCT04398498||Cohort A: Clinical Practice|Subjects more than 60 days post-transplant
11054324|NCT04398498||Cohort B: Long Term Follow-Up|Subjects who are at least 2 years post transplant up to 5 years post-transplant
11054325|NCT04398485|Experimental|ION251|In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion.
11054326|NCT04398472|Active Comparator|Challenge|"Participants in the challenge will be asked to complete four activities over the next four weeks to address loneliness and social isolation in their communities.
~The activities will involve doing an activity with people in their neighbourhood. These activities have been selected based on being positive, engaging and feasible to the average individuals. An example of the type of activities is having a conversation with a neighbour on the phone or via video chat and safely checking in on someone who is elderly or living alone. All activities will adhere to the relevant country or states health department's safety recommendations and laws during COVID-19."
11054327|NCT04398472|No Intervention|Waitlist|
11054328|NCT04398459|Experimental|IBRIAN|
11054329|NCT04398446|Experimental|Hemp-based CBD|
11054330|NCT04398446|Placebo Comparator|Placebo Oral Tablet|
11054331|NCT04398433|Experimental|Cohort A and Cohort B|Cohort A: Participants with Juvenile-Onset RRP (J-O RRP; age at first diagnosis <12 years) will be administered one injection of INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9. Cohort B: Participants with Adult-Onset RRP (A-O RRP; age at first diagnosis ≥ 12 years) will be administered one injection of INO-3107 intramuscular (IM) injection followed by EP using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
11054332|NCT04398420|Active Comparator|TVERP|
11054333|NCT04398420|Active Comparator|TURis|
11054334|NCT04398420|Active Comparator|HoLEP|
11054335|NCT04398407|Experimental|Coaching and Achievement of Peer Providers (CAPP)|"CAPP will consist of 16 individualized, one-on-one sessions using Zoom or Skype and occurring over a 4-month period. Coaching meetings will take approximately one hour per week. The coach will tailor and individualize the modules and time spent on modules to meet the goals of each peer provider.
~Modules:
~Module 1: Establishing and solidifying the working alliance, understanding the work setting and role Module 2: Understand Generic drivers of burnout and role stress Module 3: Discuss specific sources of role stressors and burnout Module 4: Set SMART Goals Module 5: Overcome challenges for workplace success Module 6: Develop Skills for Workplace Success Module 7: Managing co-worker and supervisory relations in the workplace Module 8: Wrap-up sessions
~During the first stage of research, the CAPP intervention will be further developed and refined, prior to the RCT."
11054336|NCT04398407|Active Comparator|Enhanced control|"The enhanced control condition will include 1 generic informational session conducted by a CAPP coach.During that session, the coach will introduce the key concepts under study and provide information about the drivers of burnout and role stress. The CAPP coach will discuss the need to set goals to overcome these challenges and will provide one article via email describing burnout and role stressors that is suitable for a lay person."
11054337|NCT04398394|Experimental|Group 1|Individuals with healthy retina, 18 to 50 years old.
11054338|NCT04398394|Experimental|Group 2|Individuals with healthy retina and presenting with myopia, 18 to 50 years old.
11054339|NCT04398394|Experimental|Group 3|Individuals with healthy retina, over the age of 50.
11054340|NCT04398394|Experimental|Group 4|Patients with early and intermediate AMD, over the age of 50.
11054345|NCT04398342||Children with Cerebral Palsy in Denmark|Children diagnosed with cerebral palsy born 2003 - 2020 and registered in the Danish Cerebral Palsy Follow-up Program.
11054346|NCT04398329|Experimental|Phase 1b (Cohort 1)|Single dose level of HTX-034.
11054347|NCT04398329|Experimental|Phase 1b (Cohort 2)|Individualized doses of HTX-034.
11054348|NCT04398329|Experimental|Phase 2 (Optional)|Dose of HTX-034 selected from Phase 1b.
11054349|NCT04398329|Active Comparator|Phase 1b and Phase 2|Bupivacaine HCl.
11054350|NCT04398316|Experimental|Intravenous Lidocaine|Administered at a dose of 2 mg/kg over 5 minutes
11054351|NCT04398316|Active Comparator|Intravenous Hydromorphone|Administered at a dose of 1 mg over 5 minutes
11054352|NCT04398303|Experimental|ACT-20-MSC in ACT-20-CM|Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
11054353|NCT04398303|Experimental|ACT-20-CM|Conventional treatment plus ACT-20-CM administered intravenously
11054354|NCT04398303|Placebo Comparator|Placebo|Conventional treatment plus placebo (MEM-α) administered intravenously
11054355|NCT04398290|Experimental|iNOpulse Treatment Group|Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days.
11054356|NCT04398290|Active Comparator|Placebo Group|Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days
11054357|NCT04398277|Active Comparator|Initial Low dose|Participants will receive only one daily positive emotion prompt in the first seven days of the toolkit use.
11054358|NCT04398277|Active Comparator|Initial high dose|Participants will receive two daily positive emotion prompts in the first seven days of use.
11054359|NCT04398251|Experimental|Uric acid drug control group|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week
11054360|NCT04398251|Active Comparator|Non-drug control group|They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
11054361|NCT04398238||Pre-PBM|patients screened for surgery before the implementation of PBM program: pre-operative evaluation and treatment according to usual care
11054362|NCT04398238||post-PBM|patients screened for surgery after the implementation of PBM program (3 months allowed for training/optimization): all patients with pre-operative hemoglobin < 13g/dl undergo screening for causes and treatment as needed.
11054363|NCT04398225|Experimental|Cohort 1 (9-12 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
11054364|NCT04398225|Experimental|Cohort 2 (9-12 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
11054365|NCT04398225|Experimental|Cohort 3 (9-12 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
11054366|NCT04398225|Experimental|Cohort 4 (4-8 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
11054367|NCT04398225|Experimental|Cohort 5 (4-8 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
11054368|NCT04398225|Experimental|Cohort 6 (4-8 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
11054369|NCT04398212|Placebo Comparator|Non-complaining group|the students in this group are not complaining of CVS symptoms but will be examined to diagnose CVS or exclude it
11054370|NCT04398212|Experimental|Complaining group|the students in this group are complaining of CVS symptoms but will be examined to document their complains and correlate to clinical findings
11054371|NCT04398199|Experimental|Hypofractionated Radiation Therapy|Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.
11054372|NCT04398186||Study group 1|Hiperandrogenism + ultrasonographic PCO
11054373|NCT04398186||Study group 2|Menstruel cycle irregular + ultrasonographic PCO
11054374|NCT04398186||Study group 3|Menstruel cycle irregular + ultrasonographic PCO + hyperandrogenism
11054375|NCT04398186||Control group|Do not have PCOS
11054376|NCT04398173||Group A (previous negative biopsy)|Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI
11054377|NCT04398173||Group B (biopsy naive)|Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI
11054378|NCT04398160|Experimental|HVLA manipulation|"In the intervention of the experimental group, the investigator will be primarily on the right side of the volunteer and identify C3 through the cervical reference of jaw angle, which is at the disc level between C2/C3 and then contact with the phalanges of third metacarpal in the left transverse of this vertebra.
~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
11054379|NCT04398160|Sham Comparator|Sham technique|"The investigator will be primarily on the right side of the volunteer and identify the C3 vertebra, having as anatomical reference the angle of the jaw, which is at the disc level between C2/C3 and then contact, with the phalanges of the third metacarpal, the left transverse apophysis of this vertebra.
~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
11054380|NCT04398160|No Intervention|No intervention group|The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally.
11054381|NCT04398147|Experimental|phase ⅠLow single dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
11054382|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (18-<55)|6 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
11054383|NCT04398147|Experimental|phase ⅠLow 2 dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
11054384|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (18-<55)|6 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
11054385|NCT04398147|Experimental|phase ⅠLow single dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
11054386|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
11054387|NCT04398147|Experimental|phase ⅠLow 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
11054388|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
11054389|NCT04398147|Experimental|phase ⅠMedium single dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
11054390|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
11054391|NCT04398147|Experimental|phase ⅠMedium 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
11054392|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
11054393|NCT04398147|Experimental|Phase II Low single dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
11054394|NCT04398147|Placebo Comparator|Phase II placebo low single dose (18-<55)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
11054395|NCT04398147|Experimental|Phase II Low 2 dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
11054396|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (18-<55)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
11054397|NCT04398147|Experimental|Phase II Low single dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
11054398|NCT04398147|Placebo Comparator|Phase II placebo low single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
11054399|NCT04398147|Experimental|Phase II Low 2 dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
11054400|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
11054401|NCT04398147|Experimental|Phase II medium single dose (55-<85)|50 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
11054402|NCT04398147|Placebo Comparator|Phase II placebo medium single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
11054403|NCT04398147|Experimental|Phase II medium 2 dose (55-<85)|50 subjects，Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
11054404|NCT04398147|Placebo Comparator|Phase II placebo medium 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
11054405|NCT04398147|Experimental|Phase II Low 1 or 2 dose (18-<55)|100 subjects，Ad5-nCoV containing 5E10 vp, 1or2 dose, Intramuscular administration ，according to the Previous trial results
11054406|NCT04398147|Placebo Comparator|Phase II placebo 1 or 2 dose (18-<55)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
11054407|NCT04398147|Experimental|Phase II Low or medium dosage 1 or 2 dose (55-<85)|100 subjects，Ad5-nCoV containing 5E10 vp or 10E10vp, 1or2 dose, Intramuscular administration，according to the Previous trial results
11054408|NCT04398147|Placebo Comparator|Phase II placebo Low or medium,1 or 2 dose (55-<85)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
11054409|NCT04398134|Experimental|ABI-H2158 plus ETV|ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
11054410|NCT04398134|Placebo Comparator|Placebo plus ETV|Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
11054411|NCT04398108|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
11054412|NCT04398095|Experimental|Radiotherapy with hyperthermia in resectable sarcomas|12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
11054413|NCT04398095|Experimental|Radiotherapy with hyperthermia in non-resectable sarcomas|12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
11054414|NCT04398069|No Intervention|Standard Group|standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.
11054415|NCT04398069|Experimental|personalized hemodynamic goals Group|Personalized hemodynamic goals and catecholamin infusion to achieve normal cerebral perfusion assessed by transcranial doppler: PI < 1,2.
11054416|NCT04398056|Experimental|Chemotherapy plus radiotherapy and Toripalimab|Patients were treated with PF chemotherapy for a maximum of six cycles followed by loco-regional radiotherapy combined with toripalimab.
11054417|NCT04398030|Experimental|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
11054418|NCT04398030|Active Comparator|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
11054419|NCT04398017|Active Comparator|Standard support|
11054420|NCT04398017|Experimental|Hypnosis|
11054421|NCT04398004|Experimental|Clarithromycin arm|Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.
11054422|NCT04397991|Experimental|Furosemide|Patients will receive nebulised furosemide
11054423|NCT04397991|Placebo Comparator|Placebo|Patients will receive nebulised 0.9% saline
11054424|NCT04397965|Experimental|Experimental: Continuous Monitoring|Intervention: Device: Cascade Continuous Glucose Monitoring System
11054425|NCT04397939||Patients with Cardiac Injury|Patients with cardiac injury
11054427|NCT04397926|Experimental|neoantigen vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
11054428|NCT04397913||Treatment(paracetamol or ibuprofen)|Paracetamol and ibuprofen are administered at standard dose for children with PDA.
11054429|NCT04397887|Experimental|Men with Azoospermia and varicocele|In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods
11054430|NCT04397822||COVID-19 GROUP Intensive care unit|Patients suffering from COVID-19 hospitalized in intensive care unit
11054431|NCT04397822||COVID-19 GROUP Standard care unit|Patients suffering from COVID-19 hospitalized in standard care unit.
11054432|NCT04397809||Acute Pulmonary Exacerbation (APE)|Those subjects presenting with APE will be treated with at least two pathogen specific I.V. antibiotics, as dictated by their treating physician and compliant with standard guidelines for care of an APE.
11054433|NCT04397809||Baseline Health|Those subjects presenting at baseline health will be identified by their treating physician as such and will not be starting on any treatments for APE.
11054434|NCT04397796|Experimental|BM-Allo.MSC|Subjects in the experimental arm will be administered BM-Allo.MSC
11054435|NCT04397796|Placebo Comparator|Placebo|Subjects in the control arm will be treated with placebo
11054436|NCT04397783|No Intervention|Cruciate incision|the classic cruciate incision in the colostomy construction
11054437|NCT04397783|Experimental|longitudinal incision|longitudinal incision with two proline sutures
11054438|NCT04397770|Experimental|Camre+Apa+TMZ|
11054439|NCT04397757|Experimental|COVID-19 Convalescent plasma|COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
11054440|NCT04397757|No Intervention|Standard care|Standard care alone
11054441|NCT04397744|Experimental|Unidas por Vida y Salud prevention program|Unidas por Vida y Salud (United for Life and Health) prevention program
11054442|NCT04397744|No Intervention|No intervention control|The control arm will not receive the Unidas por Vida y Salud (United for Life and Health) prevention program during the study analysis period (though, the control arm will receive the intervention after study has been completed).
11054443|NCT04397718|Placebo Comparator|Placebo + BSC|No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
11054444|NCT04397718|Experimental|Degarelix + BSC|Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
11054445|NCT04397705|Experimental|Ambulatory monitoring|Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
11054446|NCT04397692|Experimental|Inhaled NO delivered using LungFit™ in addition to SST|Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
11054447|NCT04397692|No Intervention|Standard of care|Control - Standard of care
11054448|NCT04397679|Experimental|Treatment (radiation therapy, temozolomide, chloroquine, TTF)|"Patients undergo 30 fractions of 3D CRT or Intensity-modulated radiation therapy (IMRT) and receive temozolomide by mouth (PO) and chloroquine PO daily from day 1 for the duration of radiation therapy up to day 49. Treatment continues in the absence of disease progression or unacceptable toxicity.
~ADJUVANT TREATMENT: Beginning 4 weeks after the last day of radiation therapy, patients receive temozolomide PO QD on days 1-5 and chloroquine PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients demonstrating continued benefit may continue to receive temozolomide and chloroquine for up to 12 cycles. Patients also undergo TTF therapy over 18 hours or longer per day."
11054449|NCT04397666|Experimental|1|
11054450|NCT04397653|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
11054451|NCT04397653|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
11054452|NCT04397640|Other|Sonovue|ICU patients with sepsis and septic shock who are eligible for myocardial contrast echocardiography with sulphur hexafluoride microbubbles contrast Sonovue (Bracco, Milan, Italy) injection.
11054453|NCT04397614||No Elevated Risk for COVID-19 Detected|Continue daily mHealth assessments
11054454|NCT04397614||Elevated Risk for COVID-19 Detected|Daily mHealth assessments and telemedicine/nurse triage. If non-emergent intervention, enhanced symptom monitoring will occur.
11054455|NCT04397601||A|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
11054456|NCT04397601||B|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
11054457|NCT04397562|Experimental|LVL group|Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy
11054458|NCT04397562|Placebo Comparator|Placebo group|Single subcutaneous administration of placebo in combination with standard therapy
11054459|NCT04397549|Active Comparator|Block group|Cervical Erector Spinae Plane Block administered group
11054460|NCT04397549|Sham Comparator|Control group|Control group
11054461|NCT04397536||Cohort|Patients diagnosed with MDR-TB
11054462|NCT04397523|Other|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
11054463|NCT04397510|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
11054464|NCT04397510|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days
11054465|NCT04397497|Experimental|Mavrilimumab|Single dose of IV Mavrilimumab
11054466|NCT04397497|Placebo Comparator|Placebo|Single dose of matching IV placebo
11054467|NCT04397484|Active Comparator|Levobupivacaine|0.5% levobupivacaine (0.5% Chirocaine) 30ml (150mg) will be injected once for regional anaesthesia before surgery
11054468|NCT04397484|Active Comparator|Xylocaine + adrenaline|2% Xylocaine with adrenaline 1:200,000 30ml (450mg) will be injected once for regional anaesthesia before surgery
11068762|NCT04295161|Experimental|Prototype 1|
11054469|NCT04397471||Healthy Volunteer|A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests.
11054470|NCT04397458|Active Comparator|Control Group|no quadratus lumborum block
11054471|NCT04397458|Experimental|quadratus lumborum block (type1)|0.25% bupivacaine with dexamethasone
11054472|NCT04397458|Experimental|quadratus lumborum block (type 2)|0.25% bupivacaine and liposomal bupivacaine
11054473|NCT04397445|Experimental|Ranitidine and Low Nitrite/NDMA Meals|Single dose of ranitidine (300 mg) plus low nitrite/NDMA meals
11054474|NCT04397445|Placebo Comparator|Placebo and Low Nitrite/NDMA Meals|Single dose of placebo plus low nitrite/NDMA meals
11054475|NCT04397445|Experimental|Ranitidine and High Nitrite/NDMA Meals|Single dose of ranitidine (300 mg) plus high nitrite/NDMA meals
11054476|NCT04397445|Placebo Comparator|Placebo and High Nitrite/NDMA Meals|Single dose of placebo plus high nitrite/NDMA meals
11054477|NCT04397432||Elemene plus TKIs|This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
11054478|NCT04397432||TKIs only|This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
11054479|NCT04397419|Experimental|Intervention group|This group is administered a total of 750 ml Red Bull® Energy Drink at defined time-intervals.
11054480|NCT04397419|Placebo Comparator|Placebo group|This group is administered a total of 750 ml still water at defined time-intervals.
11054481|NCT04397406|Active Comparator|Group C (Control group)|pidural analgesia with levobupivacaine alone
11054482|NCT04397406|Experimental|Group D (Dexmedetomidine group)|Epidural analgesia with levobupivacaine and dexmedetomidine
11054483|NCT04397406|Experimental|Group F (Fentanyl group)|Epidural analgesia with levobupivacaine and fentanyl
11054484|NCT04397393||non-camel milk consumption|non-camel milk consumption over life time
11054485|NCT04397393||camel milk consumption|camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).
11054486|NCT04397380||ED Patients|Patients Presenting in Emergency Department
11054487|NCT04397367|Experimental|Ruxolitinib10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
11054488|NCT04397367|Experimental|Ruxolitinib5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
11054489|NCT04397367|Experimental|Ruxolitinib5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
11054490|NCT04397367|Experimental|Ruxolitinib 2.5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
11054491|NCT04397354|Active Comparator|Group 1|intracochlear dexamethasone application during cochlear implantation
11054492|NCT04397354|Active Comparator|Group 2|intratympanic dexamethasone application during cochlear implantation
11054493|NCT04397354|Sham Comparator|Group 3|No drugs during cochlear implantation
11054494|NCT04397341|Experimental|biweekly TPF induction|Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2
11054495|NCT04397328|Experimental|Hydroxychloroquine 200mg|Regular Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg twice a day for 4 consecutive days (5 days in total) Modified Dose 400mg orally once, followed in 8 hours by 400mg, then 200mg once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
11054496|NCT04397328|Placebo Comparator|Placebo Arm|The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
11054497|NCT04397315|Active Comparator|Complete Pulpotomy|In case of complete pulpotomy procedure the exposed pulp tissue will be amputated using sterile bur in high speed hand piece to the level of canal orifices.
11054498|NCT04397315|Active Comparator|Partial Pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece to a depth of 2-3 mm.
11054499|NCT04397289|Experimental|Heparin group|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
11054500|NCT04397289|Experimental|Rivaroxaban group|Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
11054502|NCT04397276|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
11054503|NCT04397276|Experimental|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
11054504|NCT04397263|Experimental|Guselkumab|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
11054505|NCT04397250|Experimental|High-intensity interval training|Participants will be asked to perform four 30 minutes bouts of high-intensity interval exercise per week.
11054506|NCT04397250|No Intervention|Control|Participants will be asked to continue their habitual lifestyle
11054507|NCT04397237||Systemic Lupus Erythematosus|Consecutive Systemic Lupus Erythematosus patients followed-up in each service
11054508|NCT04397237||Sjogren's Syndrome|Consecutive Sjogren's Syndrome patients followed-up in each service
11054509|NCT04397237||Axial Spondyloarthritis|Consecutive Axial Spondyloarthritis patients followed-up in each service
11054510|NCT04397237||Rheumatoid Arthritis|Consecutive Rheumatoid Arthritis patients followed-up in each service
11054511|NCT04397237||Giant Cell Arteritis|Consecutive Giant Cell Arteritis patients followed-up in each service
11054512|NCT04397224||CRT responder|
11054513|NCT04397224||CRT non-responder|
11054514|NCT04397211|Active Comparator|Angiography-derived FFR-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by Angiography-derived FFR-guided strategy
11054515|NCT04397211|Active Comparator|IVUS-guided PCI group|Percutaneous coronary intervention using drug-eluting stent(s) will be performed by IVUS-guided strategy
11054516|NCT04397198||HIBRIDH-SG 01|Study subjects with documented ST segment Elevation Myocardial Infarction
11054517|NCT04397185|Experimental|Breast Cancer Locator (BCL)|Subject randomized to BCL surgical guidance to perform partial mastectomy
11054518|NCT04397185|Active Comparator|Wire Localization (WL)|Subject randomized to WL surgical guidance to perform partial mastectomy
11054519|NCT04397159|Experimental|Combination Exercise|Flywheel resistance exercise plus aerobic exercise
11054520|NCT04397159|No Intervention|Standard-of-care|Participants will maintain standard-of-care and current activity levels during the course of the study.
11054521|NCT04397146|Experimental|Single-blind sensory and satiety evaluation|In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
11054522|NCT04397133|Experimental|intervention 1|in this group patients will get 4 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
11054523|NCT04397133|Experimental|intervention 2|in this group patients will get 8 week of inspiratory muscle training exercise 30 minutes every weekday ( 15 minutes of two session in each day)
11054524|NCT04397133|Sham Comparator|control group|this group will get sham intervention with 0 to 5 cmH2O resistance
11054525|NCT04397107|Experimental|Recombinant Human Interleukin-2|Induced remission period,recombinant human IL-2(500,000 unit per square meter) infusions five days;Maintenance treatment period,recombinant human IL-2 infusions five days then once every two weeks for 6 months.
11054526|NCT04397107|No Intervention|Traditional therapy|Patients were treated with glucocorticoid and/or immunosuppressor.
11054527|NCT04397094|Experimental|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
11054528|NCT04397094|Active Comparator|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
11054529|NCT04397081||Control Group|Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
11054530|NCT04397081||Study group|"Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed atopic disease (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
~Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded."
11054531|NCT04397068|Other|macular pucker wherefore vitrectomy|one eye phaco-vitrectomy and other eye only phaco. No other involvement of drug or device. Standard of care procedure
11054532|NCT04397055|Experimental|Cottonseed Oil|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
11054533|NCT04397055|Active Comparator|Olive Oil|Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
11054534|NCT04397042||recurrent pregnancy loss|Group 1 included thirty women admitted to our clinic for termination of pregnancy due to absence of fetal cardiac activity or absence of fetal pole on ultrasonographic examination. Patients with a history of two or more unexplained first trimester miscarriages and no live births were included in the study
11054535|NCT04397029|Experimental|Subjects without messes|Subjects who are believed to be free of masses.
11054536|NCT04397029|Experimental|Subjects with known masses|Subjects with known masses.
11054537|NCT04397016|No Intervention|Arm 1: Usual Care|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.
~Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure."
11054538|NCT04397016|Experimental|Arm 2: Option Grid|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.
~Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure."
11054539|NCT04397003|Experimental|Arm A: neoantigen DNA vaccine+durvalumab+tremelimumab|"Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks
~Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab, patients on Arm A will then receive four cycles of durvalumab 1500 mg and tremelimumab 75 mg with the polyepitope neoantigen DNA vaccine, with each cycle given every 4 weeks. Patients on Arm A will then receive an additional two doses of vaccine given with 1500 mg of durvalumab q4wk (to complete a series of 6 total doses of vaccine). Patients on Arm A are then eligible to receive durvalumab every 4 weeks to complete a total course of therapy of 2 years.
~In the event that after biopsy a vaccine cannot be produced for a patient randomized to Arm A, that patient will be eligible to cross over to Arm B."
11054540|NCT04397003|Active Comparator|Arm B: durvalumab+tremelimumab|"Patients will receive durvalumab (1500mg Q3W) in combination with standard of care carboplatin and etoposide for a total of 4 cycles given every 3 weeks.
~Beginning 4 weeks following Cycle 4 of carboplatin/etoposide/durvalumab,patients will receive durvalumab (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 4 doses/cycles each, followed by durvalumab 1500mg every 4 weeks for a maximum of 2 years"
11054541|NCT04396990|Experimental|Group A Dextenza|
11054542|NCT04396990|Active Comparator|Group B Topical Prednisolone|
11054543|NCT04396977|Other|Histamine and placebo skin pricks|Each subject will receive the same histamine (10 mg/ml) and control (saline) skin prick on the right and left forearm on both study visits, to allow an intra-individual comparison
11054544|NCT04396964||surgery|subjects undergoing multilevel lumbar fusion
11054545|NCT04396951|No Intervention|Passive external overheating|"Passive external overheating in the environmental temperature control adjusted to thermal comfort.
~Measure during 6 hours with indirect calorimetry"
11054546|NCT04396951|Active Comparator|Active external overheating with heating plate|Combination of passive and active external heating with heating plate Measure during 6 hours with indirect calorimetry
11054547|NCT04396951|Active Comparator|Active external overheating with air blanket|Combination of passive and active external heating with convective air blanket Measure during 6 hours with indirect calorimetry
11054548|NCT04396938|Experimental|Lamotrigine|Single dose of Lamotrigine (300mg - capsule). In healthy volunteers.
11054549|NCT04396938|Placebo Comparator|Placebo|Placebo capsule: identical appearance to experimental capsule. In healthy volunteers.
11054550|NCT04396912||Control, s/p TT, without complication|Control (status/post-s/p total thyroidectomy-TT, without complication- demographics and BMI matched)
11054551|NCT04396912||Experimental, s/p TT with only VCP|Experimental (s/p TT, with only vocal cord paralysis-VCP, uni or bilateral)
11054552|NCT04396912||Experimental, s/p TT with only H|Experimental (s/p TT, with only hypocalcemia-H, transient or permanent)
11054553|NCT04396912||Experimental, s/p TT with both VCP+H|"Experimental (s/p TT, with both vocal cord paralysis-VCP and hypocalcemia-H);
~Subgroups:
~4.1. VCP (Permanent) + H (Permanent) 4.2. VCP (Transient) + H (Transient) 4.3. VCP (Permanent) + H (Transient) 4.4. VCP (Transient) + H (Permanent)
~Please answer:
~Improvement in hypocalcemia also make a positive effect on voice? (any objective sign? Ca? PTH?)
~Return of voice is parallel with the improvement in hypocalcemia? (any objective sign? Ca? PTH?"
11054554|NCT04396899|Other|EHM Implantation|All patients will receive EHM implant
11054555|NCT04396886|Experimental|Bintrafusp Alfa|Single group assignment of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) nonkeratinizing nasopharyngeal carcinoma (NPC)
11054556|NCT04396873|Other|Only one arm|All subjects receive the same tests
11054557|NCT04396860|Active Comparator|Arm I (radiation therapy, temozolomide)|Patients undergo radiation therapy over 30 fractions for 5 days per week (Monday-Friday) and receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity.
11054558|NCT04396860|Experimental|Arm II (radiation therapy, ipilimumab, nivolumab)|Patients undergo radiation therapy over 30 fractions for 5 days per week (Monday-Friday) for 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression.
11054559|NCT04396847|Experimental|Lorcaserin|Lorcaserin (10mg BID)
11054560|NCT04396847|Placebo Comparator|Placebo|Placebo pill (BID)
11054561|NCT04396834|Experimental|Lorcaserin|Lorcaserin (10mg BID)
11054562|NCT04396834|Placebo Comparator|Placebo|Placebo pill (BID)
11054563|NCT04396821|Experimental|Part A Q2W|Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, 5 dose levels will be tested.
11054564|NCT04396821|Experimental|Part A Q3W|Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg,, and 4 dose levels will be tested.
11054565|NCT04396821|Experimental|Part B Cohort 1|Participants with gastric or gastroesophageal junction cancers CLDN18.2 expression, dosed Q2W IV with the Part A Q2W recommended dose.
11054566|NCT04396821|Experimental|Part B Cohort 2|Participants with solid tumors other than gastric or gastroesophageal junction cancers with CLDN18.2 expression dosed Q2W IV with TST001 as above.
11054567|NCT04396821|Experimental|Part B Cohort 3|Participants with any kind of advanced or metastatic solid tumors with CLDN 18.2 expression, dosed Q3W with the Part A Q3W recommended dose of TST001
11054568|NCT04396808|Active Comparator|Standard of care (no pre-treatment genomics testing)|Provider will discuss askMUSIC results with patient prior to deciding on a management strategy (standard of care).
11054569|NCT04396808|Active Comparator|Standard of care + pre-treatment genomics testing|Provider will discuss askMUSIC and Gene Expression Classifier (GEC) results with patient prior to deciding on a cancer management strategy. Patients' biopsy tissue will be analyzed using one of the following GECs: Decipher, Prolaris or Oncotype Dx.
11054570|NCT04396795|Experimental|PRP group|Participants in this group will receive 2 sessions of autologous PRP penile injection, each administered 1 month apart ± 7 days
11054571|NCT04396795|Placebo Comparator|Placebo group|Participants in this group will receive 2 sessions of placebo injection, each administered 1 month apart ± 7 days.
11054572|NCT04396782|Experimental|physiotherapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
11054573|NCT04396782|Active Comparator|standard physiotherapy rehabilitation|static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.
11054574|NCT04396769|Experimental|FLOW-PA|Participants received the physical activity component of FLOW five days a week during participants' 45-minute long physical education (PE) class period for six months. Intervention activities were designed to promote moderate-vigorous physical activity through circuit-based stations with both aerobic and strength exercises. Trained research staff partnered with PE teachers to facilitate lessons and undergraduate college students were trained to complete activities with participants.
11054575|NCT04396769|Active Comparator|PE class as usual|Participants had PE class as usual 5 days a week for 45 minutes.
11054576|NCT04396756|Experimental|Placebo|Placebo
11054577|NCT04396756|Experimental|PLN-74809 Dose Level 1 (Part A)|PLN-74809 Dose Level 1 (Part A) - 4 weeks
11054578|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part A)|PLN-74809 Dose Level 2 (Part A) - 4 weeks
11054579|NCT04396756|Experimental|PLN-74809 Dose Level 2 (Part B)|PLN-74809 Dose Level 2 (Part B) - 12 weeks
11054580|NCT04396756|Experimental|PLN-74809 - Dose Level 3 (Part C)|PLN-74809 Dose Level 3 (Part C) - 12 weeks
11054581|NCT04396756|Experimental|PLN-74809 - Dose Level 4 (Part C)|PLN-74809 Dose Level 4 (Part C) - 12 weeks
11054582|NCT04396743|Active Comparator|Periapical surgery with placement of prf high clots|Patients will undergo periapical surgery and PRF-high clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
11054583|NCT04396743|Active Comparator|Periapical surgery with placement of prf medium clots|Patients will undergo periapical surgery and PRF-medium clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
11054584|NCT04396730|Placebo Comparator|Placebo + OCP|Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily.
11054585|NCT04396730|Experimental|Cannabidiol + OCP|Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily.
11054586|NCT04396717|Experimental|Pritumumab|"Dose Escalation phase (3+3 patients):
~Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity.
~Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity."
11054587|NCT04396704||Botox|all eligible subjects, in a reverse consecutive order, initiated on onaBoNT-A from 01 March 2015 to 29 May 2017.
11054588|NCT04396704||Dysport|all subjects meeting inclusion/exclusion criteria and initiated on aboBoNT-A from 30 May 2017 to 30 March 2019.
11054589|NCT04396691||Instructors group|Group of flight instructors at the reactor school.
11054590|NCT04396691||Students group|Group of students at the reactor school.
11054591|NCT04396678|No Intervention|PrEP Standard of Care|PrEP standard of care, administered through the Baltimore City Health Department
11054592|NCT04396678|Experimental|PrEP standard of care+behavioral intervention|PrEP standard of care, administered through the Baltimore City Health Department, and the behavioral intervention.
11054593|NCT04396665|Experimental|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
11054594|NCT04396665|No Intervention|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
11054595|NCT04396652|Experimental|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
11054596|NCT04396652|Experimental|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.
~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
11054597|NCT04396652|Experimental|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
11054598|NCT04396639|Experimental|Treatment Arm|Fifty eligible male subjects will be enrolled in the treatment arm to receive Moroctocog alfa (AF-CC) until 24 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
11054599|NCT04396626||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
11054600|NCT04396613|Active Comparator|Running Subcuticular Suture|
11054601|NCT04396613|Active Comparator|Interrupted Vertical Mattress Suture|
11054602|NCT04396613|Active Comparator|Staple Closure Techniques|
11054603|NCT04396600||Healthcare Workers Already Starting Peer Support Program|
11054604|NCT04396600||Healthcare Workers Starting Peer Support Program Later|
11054605|NCT04396574|Experimental|Lasmiditan Dose 1|Lasmiditan administered orally.
11054606|NCT04396574|Experimental|Lasmiditan Dose 2|Lasmiditan administered orally.
11054607|NCT04396561|Experimental|Paravertebral group (group P):|After induction of general anesthesia and stabilization of the patients, they were positioned in lateral decubitus position with the side to be blocked uppermost.
11054608|NCT04396561|Experimental|Control group (group C):|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia (IV fentanyl 2 μcg/kg at induction and 1 gm of IV paracetamol).
11054609|NCT04396548|Active Comparator|Group A (midodrine group)|Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
11054610|NCT04396548|Placebo Comparator|Group B (placebo group):|Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
11054611|NCT04396535|Experimental|Arm I (docetaxel, bintrafusp alfa)|Patients receive docetaxel IV over 1 hour and bintrafusp alfa IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bintrafusp alfa IV over 60 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11054612|NCT04396535|Active Comparator|Arm II (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone.
11054613|NCT04396509||women giving birth by normal vaginal delivery|100 women delivered vaginally. . They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
11054614|NCT04396509||women giving birth by c-section|100 delivered with cesarean section. They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
11054615|NCT04396496|Experimental|Daratumumab Injection|"Up to 12 four-week cycles of Daratumumab (DARA), in combination with the immunomodulatory drug (IMiD) lenalidomide.
~DARA is injected. Dosage calculated by weight.On Cycles 1 and 2, DARA is given on Days 1, 8,15 and 22. On Cycles 3-6,DARA is given on Days 1 and 15. On Cycles 7-12, DARA is given on Day 1.
~Lenalidomide is taken by mouth. 15 mg on Days 1-21 of each cycle."
11054616|NCT04396483|Experimental|"Tubal sterilization Pomeroy's method"|
11054617|NCT04396483|Active Comparator|Salpingectomy|
11054618|NCT04396470|Experimental|tVNS treatment|
11054619|NCT04396470|Sham Comparator|tVNS sham treatment|
11054620|NCT04396457|Experimental|Pembrolizumab+Pemetrexed|"200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1.
~500 mg/m^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1.
~*Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed.
~And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met."
11054621|NCT04396444|Experimental|Lavender Aromastick Group|The aromastick is a plastic tube, similar in size to a lipstick. A study team member will prepare the aromastick by infusing ten drops of lavender essential oil onto a blank cotton wick inside the tube and sealing the cap.
11054622|NCT04396444|Placebo Comparator|Blank Aromastick Group|A study team member will prepare the blank aromastick by placing a blank cotton wick inside the aromastick tube and sealing the cap.
11054623|NCT04396431|Other|2|The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy.
11054624|NCT04396418|Experimental|Intervention arm|A 16-week blended learning programme targeting stroke prevention and rhythm control therapy at the healthcare professional level, with controlled assessments, a commitment to change plan, and reinforcement actions
11054625|NCT04396418|Other|Control arm|No added education of healthcare professionals
11054626|NCT04396392|Experimental|VR-based training|receiving only VR intervention
11054627|NCT04396392|Active Comparator|text-based training|receiving only text-based intervention
11054628|NCT04396392|Experimental|VR- and text-based training|receiving both VR intervention and text-based intervention
11054629|NCT04396392|No Intervention|waiting list|waiting list in phase 1 and text-based training after 3 weeks
11054630|NCT04396379|Experimental|Device Implantation|To epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy) using an epicardial implant.
11054631|NCT04396366|Placebo Comparator|placebo|Placebo controlled arm
11054632|NCT04396366|Active Comparator|QBW251|Active comparator drug arm
11054633|NCT04396353||Physically active|Those who receive regular amounts of physical activity. Those who participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen as recommended by the health organizations. Additionally, a person who spend less time sitting (i.e. watching television, surfing the web, playing video games).
11054634|NCT04396353||Sedentary|Those who do not receive regular amounts of physical activity. Where physical inactivity is considered the failure to meet the recommendations of the health organizations, stating that an individual should participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen. Sitting about 70-85% of the time (i.e. watching television, surfing the web, playing video games) is also considered a person living a sedentary lifestyle.
11054635|NCT04396340|Experimental|Dose Escalation|XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.
11054636|NCT04396340|Experimental|Confirmation of Dose|New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose
11054637|NCT04396327|Active Comparator|Active Comparator: 2-Drug Combination|50 mg diphenhydramine and 0.5 mg lorazepam
11054638|NCT04396327|Experimental|Active Treatment: SM-1 3-Drug Combination|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
11054639|NCT04396314|Experimental|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources, is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits. BBAT consists of a broad scope of movements in the following positions: lying, sitting, standing and walking. Relational movements are practiced in therapy with components such as rhythm, form, elasticity, flow, intention and voice
11054823|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
11054640|NCT04396314|Active Comparator|Control|The control group will be treatment for usual for PTSD. Pharmacological treatment is based in fluoxetine, paroxetine, sertraline and venlafaxine. Regarding non-pharmacological treatment the strongly recommendations are cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
11054641|NCT04396301|Active Comparator|Fydrane group|Fydrane is injected intracamerally at the beginning of cataract surgery after the first incision, at a dose of 0.2 ml of solution, in only one injection. Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). No preoperative topical eye drops are used.
11054642|NCT04396301|No Intervention|Reference group:|not injected with intracameral Fydrane. Pupillary dilatation in this group is achieved using preoperative topical eye drops: cyclopentolate hydrochloride 1% and tropicamide 1 % one drop every 15 min for 1 hour preoperatively.
11054643|NCT04396288|Experimental|Healthy volunteers|
11054644|NCT04396275|Experimental|Cooked whole navy beans|A meal consisting of cooked navy beans
11054645|NCT04396275|Experimental|Cooked whole yellow split peas|A meal consisting of cooked yellow peas
11054646|NCT04396275|Experimental|Cooked rice (control)|A meal consisting of cooked rice
11054647|NCT04396262|Experimental|HTD-blueberry beverage with white bread|The beverage prepared using hydro-thermodynamic processing of whole wild blueberries.
11054648|NCT04396262|Experimental|Sweetened water (control) with white bread|The water control of the same volume and with the same amount of available carbohydrate as HTD-blueberry beverage.
11054649|NCT04396249|Experimental|Active tVNS group|The active tVNS group will be stimulated with 10 sessions of active transcutaneous vagal nerve stimulation (tVNS)
11054650|NCT04396249|Sham Comparator|Sham tVNS group|The sham tVNS group will be stimulated with 10 sessions of sham transcutaneous vagal nerve stimulation (tVNS)
11054651|NCT04396236|Experimental|Lasmiditan High Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
11054652|NCT04396236|Experimental|Lasmiditan Mid Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
11054653|NCT04396236|Experimental|Lasmiditan Low Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
11054654|NCT04396236|Placebo Comparator|Placebo|Placebo administered orally.
11054655|NCT04396223|Experimental|Avelumab combined with methotrexate and folinic acid|Avelumab administration at 800 mg every 2 weeks and methotrexate administration at 1mg/kg/day during 4 months ½ (median)
11054656|NCT04396197||COVID-19|Observations taken of standard physiotherapy practice. All patients are assessed daily and receive respiratory care and rehabilitation as deemed appropriate by the treating therapist
11054657|NCT04396184|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 288 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once every two weeks for 3 times.
11054658|NCT04396184|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
11054659|NCT04396171||Probable bruxism(+)|
11054660|NCT04396171||Probable bruxism(-)|
11054661|NCT04396158|Experimental|intervention|
11054662|NCT04396145||Surgery group|Subjects who will have chronic otitis media surgery will be included in the study.
11054663|NCT04396132|Experimental|Virtual SVV|The subjects will be tested by virtual SVV. The deviation angle will be measured at 15, 30 and 45-degree head tilt to the left and right side while they are standing
11054664|NCT04396106|Active Comparator|AT-527 + SOC|
11054665|NCT04396106|Placebo Comparator|Placebo + SOC|
11054666|NCT04396080|Experimental|Onlays behaviour depending on materials|Patients who require it as treatment option will be treated with posterior partial restorations, and will have clinical follow-up to obtain a comparison of the behavior of subsequent restorations based on the material.
11054667|NCT04396067|Active Comparator|Aerosolized 13 cis retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
11054668|NCT04396067|Active Comparator|All trans retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days
11054669|NCT04396067|Placebo Comparator|Placebo Comparator|4 Placebo tablets twice daily by mouth for 2 weeks
11054670|NCT04396054|Active Comparator|Lag Screws|Group 1: underwent open reduction and internal fixation using two lag screws.
11054671|NCT04396054|Active Comparator|Double Y-shaped plates|Group 2: underwent open reduction and internal fixation using double Y-shaped plates.
11054672|NCT04396041||Patients treated for Pulmonary Arteriovenous Malformation|All participants in the study will be patients who have been treated for Pulmonary Arteriovenous Malformation using Microvascular Plugs, Amplatzer Vascular Plugs or Detachable coils.
11054673|NCT04396015|Placebo Comparator|medium chain triglyceride (MCT) vs placebo|MCT or placebo (olive oil) for 4 months. Crossover at 4 months
11054674|NCT04396015|Other|open label extension|6 months of MCT oil.
11054675|NCT04396002||Primary Open-Angle Glaucoma|Patients diagnosed with primary open-angle glaucoma.
11054676|NCT04396002||Control|Participants with healthy eyes.
11054677|NCT04395989|Experimental|LAR-HER2+|If patients were LAR subtype with HER2 gene activated mutation
11054678|NCT04395989|Experimental|LAR-PAM+|If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
11054679|NCT04395989|Experimental|IM|If patients were IM subtype (CD8 positive T cell more than 20%)
11054680|NCT04395989|Experimental|BLIS|If patients were BLIS subtype or MES subtype and without PI3K/AKT/mTOR pathway activation
11054681|NCT04395989|Experimental|MES-PAM+|If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
11054682|NCT04395976|No Intervention|Control Group|Participants randomised into the control group receive conventional standard care given by recommended guideline.
11054763|NCT04395248|Active Comparator|Risk factors of difficult intubation|Appearance anpalpationpalpationpalpationd ultrasound features for predicting difficult laryngoscopy intubation
11054683|NCT04395976|Experimental|Ayurveda|Treatment includes a tailored combination of herbs based on individual constitution (based on Ayurveda) nutritional advice, specific consideration of selected food items, specific lifestyle advice, yoga advice along with standard recommendations.
11054684|NCT04395950|Active Comparator|PF-0522130|PF-05221304 10 mg daily (two 5mg tablets daily in the morning).
11054685|NCT04395950|Placebo Comparator|Placebo|Placebo (two tablets daily in the morning).
11054686|NCT04395937|Active Comparator|respiratory physiotherapy|exercises to improve the way of breathing
11054687|NCT04395937|Experimental|respiratory physiotherapy and physical exercises|intensity determined by the VO2max measured during ergospirometric measure
11054688|NCT04395924||Pregnant women COVID-19 positive by RT-PCR|Pregnant women COVID-19 positive by RT-PCR on nasopharyngeal swabs and/or by serology or with previous history of SARS-Cov-2 positive during the pregnancy coming to the maternity to deliver
11054689|NCT04395911|Other|SCD|Cytopheretic device
11054690|NCT04395885||study group|health care staff, regardless of gender, who is actively working during the outbreak
11054691|NCT04395885||control group|age matched group of non-health worker individuals.
11054692|NCT04395872||COVID-19|Among patients who were confirmed as COVID-19 and admitted to the COVID-19 management ward of Daegu Catholic University Hospital, patients who were consulted by the Department of psychiatry was selected as participants. Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R). were collected from participants. It evaluates whether there is a difference in the psychological scale according to the difference in participants' sociodemographic status and medical severity, and evaluates the effectiveness of psychiatric counseling by comparing clinical psychological measures before and after referral to department of psychiatry.
11054693|NCT04395859||Patients treated with IVT before COVID19 pandemia|Treatment started at least 6 months before the French confinement for COVID19 (15th march 2020)
11054694|NCT04395820||Cystic Fibrosis|
11054695|NCT04395820||Healthy|
11054696|NCT04395807|Active Comparator|Helmet CPAP|Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
11054697|NCT04395807|Active Comparator|HFNC|High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)
11054698|NCT04395794||Medical Employees|Asymptomatic medical employees in high-volume cardiovascular center.
11054699|NCT04395781||Control cases|Children who suspected COVID-19 cases but tested negative for COVID-19
11054700|NCT04395781||Confirmed cases|Children who tested positive for COVID-19
11054701|NCT04395768|Experimental|Vitamin C|"Participants will receive vitamin C in addition to active comparator treatment:
~Inpatients: IV Vitamin C (Sodium Ascorbate) 50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x per day; 400mg/kg/day) for 7 days (average 28g/day; maximum dose of 50g/24hrs for those weighing more than 125kg). Can be converted to 1 gram three times per day PO on hospital discharge) Outpatients: Vitamin C Outpatient trial: 200mg/kg x1 IV, then 1 gram PO three times per day for 7 days;
~Plus Active Comparator treatment:
~Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days"
11054702|NCT04395768|Active Comparator|Control|Hydroxychloroquine Hydroxychloroquine 400mg (2x200mg) PO for 1 day, followed by 200mg PO per day for 6 days Azithromycin 500 mg PO on day 1 followed by 250 mg PO once daily for 4 days Zinc Citrate 30mg elemental zinc PO daily Vitamin D3 5,000iu PO daily for 14 days Vitamin B12 (Methylcobalamin) 500mcg PO daily for 14 days
11054703|NCT04395755||Infertile women who had the IVF treatment postponed or delayed|
11054704|NCT04395742||Coffee:1,3,7-trimethylxanthine|
11054705|NCT04395742||Tea and hot chocolate with milk|
11054706|NCT04395716|Experimental|Treatment Group|This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
11054707|NCT04395703||Maternity staff|Interviews with maternity staff working within a maternity unit including midwifery managers and infant feeding lead staff members.
11054708|NCT04395703||Neonatal unit staff|Staff working within a local maternity unit.
11054709|NCT04395690|Active Comparator|Inferior Alveolar Block Nerve (IABN)|When a participant surgeon had a patient to place implants in the posterior mandible, phoned to a person not participating in the study, to obtain the method of anesthesia to be used in this particular patient thirty minutes before intervention started.
11054710|NCT04395690|Experimental|Infiltration (INF)|When a participant surgeon had a patient to place implants in the posterior mandible, phoned to a person not participating in the study, to obtain the method of anesthesia to be used in this particular patient thirty minutes before intervention started.
11054711|NCT04395677|Experimental|AB-106 （DS-6051b）|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
11054712|NCT04395638|Experimental|Weekly Vitamin D group|
11054713|NCT04395638|Experimental|Daily Vitamin D group|
11054714|NCT04395625|Experimental|Group 1|Patients had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding.
11054715|NCT04395625|Experimental|Group 2|Patients had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
11054716|NCT04395612|Experimental|Treatment arm|niraparib200mg，brivanib600mg
11054717|NCT04395599|Experimental|COVID19 patients undergoing visceral surgery|
11054718|NCT04395586||Culture-proven infected patients|
11054719|NCT04395547|Placebo Comparator|Placebo|
11054720|NCT04395547|Experimental|JointAlive™|
11054721|NCT04395521|Experimental|Facebook group arm|Access to a diabetic foot self-management support program via a Facebook group platform for three months plus the standard care.
11054722|NCT04395521|No Intervention|Standard care arm|Carry on with the routine diabetes care offered to the participants in their health facilities.
11054820|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
11068763|NCT04295161|Experimental|Prototype 2|
11054723|NCT04395495||Neurofibromatosis 1 (NF1)|Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.
11054724|NCT04395495||Noonan Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054725|NCT04395495||Noonan Syndrome with Multiple Lentigines|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054726|NCT04395495||Noonan Neurofibromatosis Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054727|NCT04395495||Cardiofaciocutaneous Syndrome|Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054728|NCT04395495||Costello Syndrome|Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054729|NCT04395495||Legius Syndrome|Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054730|NCT04395495||Smith-Kingsmore Syndrome|Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
11054731|NCT04395495||GATOR-1 Mutation|Individuals with a suspected or known mutation of GATOR-1.
11054732|NCT04395495||SYNGAP1-Related Intellectual Disability|Individuals with a suspected or known mutation of SYNGAP1.
11054733|NCT04395495||DLG4 Mutation|Individuals with a suspected or known mutation of DLG4.
11054734|NCT04395495||MAPK1 Gene Mutation|Individuals with a suspected or known mutation of MAPK1.
11054735|NCT04395495||MTOR Gene Mutation|"Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.
~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway."
11054736|NCT04395495||RAS Mutation|"Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.
~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway."
11054737|NCT04395482||covid-19 pneumonia related patients|The study aims to collect the highest number possible of lung CT scan images performed in patients with COVID-19, in order to obtain a large sample size that will allow us to characterize the extent of lung injury, the presence of specific patterns of lung alteration, and their potential association with the outcome of patients - in view of assisting the medical staff in better understanding the grade of the severity impairment in these patients which might be potentially candidates to more intensive therapeutic strategies.
11054738|NCT04395456|Experimental|AMY-101|
11054739|NCT04395456|Placebo Comparator|Placebo|
11054740|NCT04395443|Experimental|patients admitted to emergency department|the intervention is the medication reconciliation
11054741|NCT04395430|Active Comparator|Information Group|Subjects randomized to the Information Group will receive standard care and age appropriate reading books.
11054742|NCT04395430|Experimental|Intervention Group|Subjects randomized to the Intervention Group will receive standard care plus invitation to participate in the online KKH Sports Singapore programme.
11054743|NCT04395417|Experimental|Hyaluronic acid injection group|This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
11054744|NCT04395417|Active Comparator|Prolotherapy injection group|This is the control group in whom prolotherapy injection was given at lateral epicondyle site.
11054745|NCT04395404|Experimental|Single arm|
11054746|NCT04395378||Flying pilots|Flying pilots holding class 1 and class 2 certificates
11054747|NCT04395365|Experimental|Co-trimoxazole|Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 24 months
11054748|NCT04395365|Placebo Comparator|Placebo|Placebo, 960mg capsule oral tablet, to be taken daily for 24 months
11054749|NCT04395352||Pre-ECV|Patients having undergone colonoscopy prior to the introduction of ECV (November 1 2018 to April 30 2019).
11054750|NCT04395352||ECV|Patients having undergone colonoscopy after the introduction of ECV (June 1 2019 to November 30 2019).
11054751|NCT04395339|Experimental|Experimental arm(GM1)|This arm will be treated with GM1.
11054752|NCT04395339|Placebo Comparator|Control arm|This arm will be treat with blank placebo.
11054753|NCT04395326||24 months follow-up|"Single-group study Patients have been included for up to 4 weeks after the initiation of Second Generation Antipsychotic (SGA) treatment (baseline)
~Patients under 18 years of age, previously naïve of antipsychotics, starting an SGA or who started an SGA treatment for less than 4 weeks, followed longitudinally at one of the selected recruiting centers, regardless of the diagnosis that motivated the prescription. Comedications and combination of APs are allowed, as this is an observational study.
~The exclusion criteria are the following: participants diagnosed before or at the baseline with diabetes, dyslipidemia, high blood pressure, thyroid dysfunction, hepatic disease, a disorder that can lead to hyperprolactinemia or another disorder that may interfere with the development of the side effects studied in this research, participants taking a drug intended to treat one of the conditions mentioned above before starting the SGA treatment, and pregnancy."
11054754|NCT04395300||Healthcare workers|Physicians, Nurses, Laboratory workers, radiology technicians
11054755|NCT04395287||Preschool children|Attending public preschools in Svendborg, Denmark, at the time of recruitment
11054756|NCT04395274||Current E-Cigarette Users|Monitoring current e-cigarette users
11054757|NCT04395274||Never E-Cigarette / Tobacco Users|Monitoring never users of any tobacco or e-cigarette products.
11054758|NCT04395261||Group 0|Patients were divided into groups according to observation in surgery Empty ear in operation
11054759|NCT04395261||Group 1|Patients were divided into groups according to observation in surgery Serous fluid in operation
11054760|NCT04395261||Group 2|Patients were divided into groups according to observation in surgery Mucoid fluid in operation
11068764|NCT04295161|Experimental|Prototype 3|
11054764|NCT04395248|Active Comparator|Radial artery cannulation using ultrasound or blind palpation|In the ultrasound group, a linear vascular probe in the frequencies 5 to 13 MHz (GE 12L-RS, GE Healthcare, Chicago, IL, USA) of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image.
11054765|NCT04395248|Active Comparator|Preoxygenation using high-flow nasal cannula or facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs.
11054766|NCT04395248|Active Comparator|Type of volatile anesthetics and M-Entropy guidance|Patients will be randomized by a computer-generated list into one of the four groups, desflurane with usual care (N=20), desflurane with M-Entropy guidance (N=20), sevoflurane with usual care (N=20), and sevoflurane with M-Entropy guidance (N=20).
11054767|NCT04395235|Experimental|Targeted Surgical Therapy Plan|This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
11054768|NCT04395222|Experimental|ATG Group I|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen.
~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
11054769|NCT04395222|Experimental|ATG Group II|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen.
~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
11054770|NCT04395222|Experimental|ATG Group III|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen.
~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
11054771|NCT04395222|Experimental|ATG Group IV|"Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)
~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.
~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.
~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
11054772|NCT04395209|Experimental|stroke individuals|
11054773|NCT04395209|Active Comparator|healthy individuals|
11054774|NCT04395196|Active Comparator|High-dose choline supplementation|2 g choline cation
11054775|NCT04395196|Placebo Comparator|Placebo|Placebo identical to active treatment in appearance, taste, and smell.
11054776|NCT04395183|Active Comparator|5-HTP + Placebo|5-hydroxytryptophan 100mg PO BID plus placebo matched to creatine monohydrate
11054777|NCT04395183|Active Comparator|Creatine + Placebo|Creatine 5g PO qday plus placebo matched to 5-HTP
11054778|NCT04395183|Active Comparator|Creatine + 5-HTP|Creatine 5g PO qday plus 5-hydroxytryptophan 100mg PO BID
11054779|NCT04395170|Experimental|Convalescent plasma|Plasma from patients recovering from COVID-19.
11054780|NCT04395170|Experimental|Anti-COVID-19 human immunoglobulin|Anti-COVID-19 human immunoglobulin to be administered intravenously.
11054781|NCT04395170|Active Comparator|Standard (specific) therapy|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.
~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
11054782|NCT04395157||Veterans engaged in VA mental health rehabilitation/recovery|Veterans must receive services in a VA Healthcare System psychosocial rehabilitation and recovery center (PRRC) or mental health residential rehabilitation treatment program (RRTP).
11054783|NCT04395144|Experimental|Awake prone positioning|Prone positioning of patients on nasal high-flow oxygen therapy
11054784|NCT04395144|Active Comparator|Standard care|Standard decubitus positioning of patients on nasal high-flow oxygen therapy
11054785|NCT04395131|Other|Clearum HF Dialysis Subjects|All subjects enrolled in the study and treated with the Clearum HF hemodialyzer
11054821|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2[AOA2]).
11054822|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
11054858|NCT04394572||colorectal cancer|Patients with and without colorectal cancer
11054786|NCT04395118|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
11054787|NCT04395118|Active Comparator|Mailed Outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
11054788|NCT04395105|Experimental|High dose Dexamethasone|16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
11054789|NCT04395105|No Intervention|Usual care with Low dose Dexamethasone|Usual treatment without using up to 6 mg qd of dexamethasone for 10 days.
11054790|NCT04395092|Experimental|K-NK002|
11054791|NCT04395079|Experimental|Arm I (durvalumab, brachytherapy)|Patients receive durvalumab IV on day 1. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
11054792|NCT04395079|Experimental|Arm II (tremelimumab, brachytherapy)|Patients receive tremelimumab IV on day 1. Treatment repeats every 28 days for 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
11054793|NCT04395053|Experimental|Treatment group TR|Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
11054794|NCT04395053|Experimental|Treatment group RT|Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
11054795|NCT04395040||Patients|Elderly patients with digestive cancer or breast cancer.
11054796|NCT04395027|No Intervention|Usual care|These patients will not have their iatrogenic septal defect closed.
11054797|NCT04395027|Experimental|Device|These patients will have their iatrogenic septal defect closed after the mitral intervention is completed.
11054798|NCT04395001|Experimental|behavioral intervention, nurse support plus medication|Subjects randomized to this arm will receive duloxetine, web-based Cognitive Behavioral Therapy (CBT) and nurse support.
11054799|NCT04395001|Experimental|behavioral intervention plus medication|Subjects randomized to this arm will receive duloxetine and web-based Cognitive Behavioral Therapy (CBT).
11054800|NCT04395001|Active Comparator|medication only|Subjects randomized to this arm will receive duloxetine only.
11054801|NCT04394975|Experimental|Test group|Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orally twice daily.
11054802|NCT04394975|Active Comparator|Control group|Sunitinib monotherapy. Participants receive sunitinib 50mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
11054803|NCT04394962|No Intervention|Control group|Patients who will be randomized to the control group will be waiting for the ET procedure without any intervention and without any deviation from the standard of care
11054804|NCT04394962|Experimental|Study group|Exposure to virtual reality environment exposure
11054805|NCT04394949|Active Comparator|Business as Usual Arm|Consumers will usual care
11054806|NCT04394949|Experimental|Experimental Arm|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
11054807|NCT04394936|Experimental|Guselkumab|Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.
11054808|NCT04394936|Placebo Comparator|Placebo|Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.
11054809|NCT04394936|No Intervention|Healthy volunteers|Healthy volunteer cohort (observational)
11054810|NCT04394923|Experimental|"Intervention group or PRINT group"|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print, which is the zone where the atrioesophageal distance is shorter. The maximal distance and the area between the original line and the modified line will be noted. In cases when ablation through the red layer is unavoidable, the delivered energy can be lowered to an ablation index (AI) of 300 regardless of the local wall thickness. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
11054811|NCT04394923|Other|Control group|The ablation line will not be modified from the original one drawn before randomization and RF applications will follow the regular path. If the temperature rises above 39℃, ablation will be immediately stopped, and energy will be reduced.
11054812|NCT04394910|Experimental|Pomegranate Juice|Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
11054813|NCT04394910|Placebo Comparator|Placebo Juice|Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
11054814|NCT04394897||TIVA|TIVA either with remifentanil and propofol infusions separately
11054815|NCT04394897||MIXTIVA 2/1000|MIXTIVA infusion that had remifentanil/propofol proportion 2/1000
11054816|NCT04394897||MIXTIVA 3/1000|MIXTIVA infusion that had remifentanil/propofol proportion 3/1000
11054817|NCT04394884||COVID-19 -|will receive BTK therapy for other reasons
11054818|NCT04394884||COVID-19 + BTK|will receive BTK therapy
11054819|NCT04394884||COVID-19 + No BTK|will not receive BTK therapy
11054824|NCT04394858|Experimental|Arm I (temozolomide, olaparib)|Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11054825|NCT04394858|Active Comparator|Arm II (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
11054826|NCT04394845|Experimental|[18F]GTP1|Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).
11054827|NCT04394832|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.
~In the intervention phase the participant was offered around five intervention sessions with a researcher. Each session the participant chose which intrusive memory they would like to focus on and the cognitive task was completed. The intervention included a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants were given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) were collected in a pen-and-paper diary."
11054828|NCT04394819||experimental and control groups|"Task-oriented EMG-triggered ES treatment will be applied to the experimental group 2 days a week for 5 weeks and will continue with conventional physiotherapy.
~The control group will only continue conventional physiotherapy treatment."
11054829|NCT04394793|Experimental|Study Arm|
11054830|NCT04394780|No Intervention|Peritoneal dialysis at 37 C|Patients underwent peritoneal dialysis with the standard temperature.
11054831|NCT04394780|Active Comparator|Peritoneal dialysis at 32 C|Patients started on continuous ambulatory peritoneal dialysis using a peritoneal dialysate cooled to between 32-33 degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour duration treatment.
11054832|NCT04394754|No Intervention|Control|Patients will receive usual care and no digital health device.
11054833|NCT04394754|Experimental|BodyPort|Patients will receive the BodyPort device.
11054834|NCT04394754|Experimental|Noom|Patients will receive a subscription to the Noom platform.
11054835|NCT04394754|Experimental|Conversa|Patients will receive a subscription to the Conversa platform.
11054836|NCT04394741|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
11054837|NCT04394741|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
11054838|NCT04394715|Experimental|Intervention|Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
11054839|NCT04394715|No Intervention|Control|Providers will not see an electronic alert for any patients and will provide usual care. Silent alerts will be generated that will be sent to study team members.
11054840|NCT04394702|Experimental|One Shape Single-file rotary system|
11054841|NCT04394702|Active Comparator|Manual stainless steel K-file|
11054842|NCT04394689|Active Comparator|MRV-SC|A standard, single dose of Measles Rubella vaccine delivered subcutaneously with a needle and syringe
11054843|NCT04394689|Experimental|MRV-MNP|A single dose of Measles Rubella vaccine delivered intradermally with a microneedle patch
11054844|NCT04394676|Experimental|Reduction in Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
11054845|NCT04394676|Active Comparator|Standard Amount of Pressure|This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
11054846|NCT04394663|Experimental|High-dose oral PPI|Omeprazole 80 mg/day (40 mg twice a day) per oral route for 72 hours
11054847|NCT04394663|Active Comparator|Standard IV PPI|Pantoprazole 8 mg/hour IV continuous drip for 72 hours
11054848|NCT04394650|Experimental|CC-98633|Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
11054849|NCT04394637||PROSe-ICD|PROSe-ICD [NCT00733590/ Institutional Review Board (IRB) NA_00045142], a large prospective cohort study of patients who received an ICD for primary prevention.
11054850|NCT04394637||Reynolds study|Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.
11054851|NCT04394624|Experimental|Ramucirumab + SAR408701|Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.
11054852|NCT04394611||Fetal Growth Restriction (FGR)|FGR will be defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. Hadlock I formula will be used to calculating estimated fetal weight percentiles
11054853|NCT04394611||Control|healthy pregnancies will be selected for the control group.
11054854|NCT04394598|Experimental|CRT with Dendrobium Huoshanense|"Dendrobium Huoshanense Granules: 3g tid per day for 5weeks
~Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
11054855|NCT04394598|Placebo Comparator|CRT with Placebo|"Placebo: 3g tid per day for 5weeks
~Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
11054856|NCT04394585|Experimental|Smart phone app group|Patients used smart phone app based human coaching program for 3 months postoperatively.
11054857|NCT04394585|Active Comparator|Nutritional consultation group|Patients have two consulting with clinical nutritionist at 1 month and 3 months postoperatively.
11054860|NCT04394559|Experimental|Intervention|Discharge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app.
11054861|NCT04394546|Experimental|Device Group|Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
11054862|NCT04394546|Active Comparator|Control Group|Randomized to non-vitamin K oral anticoagulant (NOAC)
11054863|NCT04394533|Experimental|Prilocaine (Intervention) Group|Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
11054864|NCT04394533|Active Comparator|Bupivacaine (Control) Group|Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
11054865|NCT04394520|No Intervention|Control|No change will be made to the introduction content or the consent mode (active opt-in and active opt-out) from other related trials
11054866|NCT04394520|Experimental|Modified Intro, Standard Consent|Modified introductory language will be used, but the consent structure (active opt-in and active opt-out) will remain the same.
11054867|NCT04394520|Experimental|Modified Intro, Active Opt-in|Modified introductory language will be used, and the consent mode will be changed to active opt-in only.
11054868|NCT04394520|Experimental|Modified Intro, Active Opt-out|Modified introductory language will be used, and the consent mode will be changed to active opt-out only.
11054869|NCT04394520|Experimental|Modified Intro, Passive Opt-in|Modified introductory language will be used, and the consent mode will be changed to passive opt-in only.
11054870|NCT04394507||Fontan Patients|Fontan patients operated at the two centres between 1991 and 2014.
11054871|NCT04394507||Control Group|Age, gender and weight matched healthy controls.
11054872|NCT04394494|Experimental|Motor Imagery|Patients are instructed in a motor imagery protocol of imaging extension exercises (similar to the CG), without doing the actual extension exercises. Patients will be instructed in visualizing them moving into extension and back as well as common sensations they may experience (as if doing the actual exercise). They will repeat the visualization process 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 visualization exercises.
11054873|NCT04394494|Active Comparator|Control|Patients are instructed in extension exercises and actually, physically doing the actual extension exercises. Patients will physically repeat the extension exercises 10 times while in the clinic, after which they will be instructed in a home program containing the same treatment - every 2 hours, perform 10 exercises.
11054874|NCT04394481|Experimental|DMD|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)
11054875|NCT04394481|Active Comparator|Control|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection
11054876|NCT04394468|Other|patient group|Data is collected from women (18-45y) with endometriosis (superficial and / or deep infiltrating endometriosis) where the preferred treatment is a laparoscopic intervention at UZ Gent.
11054877|NCT04394455|Experimental|Brief cognitive behavioral therapy|Medical staff (medical doctors and residents) who will receive brief cognitive behavioral therapy through telepsychiatry.
11054878|NCT04394455|Active Comparator|Crisis intervention therapy|Medical staff (medical doctors and residents) who will receive 3 sessions of crisis intervention therapy through telepsychiatry.
11054879|NCT04394442|Experimental|Hydroxycholoroquine group|
11054880|NCT04394442|No Intervention|Control group|
11054881|NCT04394416|Experimental|Imatinib|Imatinib oral 400 mg daily for 14 days.
11054882|NCT04394416|Active Comparator|Placebo|Placebo oral for 14 days
11054883|NCT04394403|Experimental|immediate guided self-help|In this condition, individuals will be given access to material and exercises based on CBT to reduce their stress
11054884|NCT04394403|No Intervention|waitlist|Individuals in this condition will wait 6 weeks before they are provided access to the guided self-help program
11054885|NCT04394377|Other|Group 1|"The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):
~Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);
~Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation)."
11054886|NCT04394377|Other|Group 2|Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.
11054887|NCT04394364||BIS monitor group|Patients under monitoring of BIS
11054888|NCT04394351|Experimental|Part A - Dupilumab or Placebo|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight once every 2 weeks (Q2W).
11054889|NCT04394351|Experimental|Part B - Dupilumab|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight once every 2 weeks (Q2W).
11054890|NCT04394338|Active Comparator|plastic sheath covering|plastic sheath was prepared with the standard 9 cmx15cm self-gripping mesh. Then the meshe were folded and unfolded over or under the plastic sheaths in different directions.
11054891|NCT04394338|No Intervention|mesh placement without plastic sheath|self-gripping mesh were placed without plastic sheath.
11054892|NCT04394325|Experimental|Group A) Intervention group|Group A) an intervention group (n=80) who will receive the standard care and information (oral and written) + the digital information tool.
11054893|NCT04394325|No Intervention|Group B) Control group|Group B) a control group (n=80) who will receive standard care and information (oral and written).
11054894|NCT04394312|Experimental|Intervention|Participants will attended a 75 minute physical literacy workshop (Parent PLAYSHOP). A questionnaire will be completed at the beginning of the workshop and the end of the workshop to measure if there is a difference in parent's knowledge and confidence levels in regard to engaging in meaningful physical activity with their children.
11055005|NCT04393467|Sham Comparator|sham tSMS|A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.
11054895|NCT04394312|No Intervention|Control|Participants will complete the 2 questionnaires online, one week or more apart. Once questionnaires are completed they will be invited to attended the 75 minute physical literacy workshop. The workshop content and delivery will be the same as the intervention group but will not include questionnaires.
11054896|NCT04394286|Experimental|Cohort 1|Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).
11054897|NCT04394286|Experimental|Cohort 2|Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).
11054898|NCT04394286|Experimental|Cohort 3|Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).
11054899|NCT04394273||Long- Term Exercise Group|They will exercise one an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).In this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
11054900|NCT04394273||Short-Term Exercise Group|They will exercise half an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).n this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
11054901|NCT04394273||Home Program|Pregnant women who choose the home program group are told to continue their home program until the 32nd week, which includes posture and body mechanics training, increase their physical activity levels and be as active as possible and take daily walks.
11054902|NCT04394260|Active Comparator|Savvy Caregiver Program (SCP)|The SCP program is comprised of weekly, two-hour interactive classes, over six consecutive weeks, the same duration as the proposed intervention. The SCP consists of educational instruction and in-class exercises that engage participants on a functional level. Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
11054903|NCT04394260|Experimental|Modified LGBT Savvy Group program|LGBT-friendly SCP is designed to assess the stressors and unique needs of LGBT caregivers of PLWD, not reflected in the existing SCP. Modifications to the SCP include themes of physical, interpersonal, financial, social, and environmental stressors specific to LGBT caregivers.
11054904|NCT04394247||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
11054905|NCT04394234||Treatment Group|Participants data who are new users of rivaroxaban, apixaban and dabigatran with prior Non-valvular atrial fibrillation/Venous thromboembolism/Total hip replacement (NVAF/VTE/THR) or Total knee replacement (TKR) in a nationally representative population of insured participants in the United States (US) will be compared pairwise.
11054906|NCT04394234||Comparator Group|Participants data who are new users of warfarin, apixaban, and dabigatran with prior NVAF/VTE/THR or TKR in a nationally representative population of insured participants in the US will be compared pairwise.
11054907|NCT04394208|Placebo Comparator|Group 1|Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo
11054908|NCT04394208|Experimental|Group 2|patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses
11054909|NCT04394195||patients with COVID-19 infection|patients with COVID-19 infection
11054910|NCT04394182|Experimental|An experimental group receiving radiotherapy|an experimental group with a poor or no response to standard medical treatment and without invasive mechanical ventilation (IMV) will receive ultra low-dose lung radiotherapy (0.8 Gy single dose)
11054911|NCT04394169|Experimental|Intervention arm|The intervention is a program that includes early patient care, therapeutic education, and psychological intervention. It will be performed through three medical visits and a psychological intervention that requires seven face-to-face sessions.
11054912|NCT04394169|No Intervention|Standard care arm|Standard medical practice: patient follow-up is carried out by their referring physicians (primary care physicians or specialists) who are outside the study.
11054913|NCT04394156|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.
~In the intervention phase the participant will be offered around five intervention sessions with a researcher. Each session the participant will choose which intrusive memory they would like to focus on and the cognitive task will be completed. The intervention includes a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants will be given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary."
11054914|NCT04394143|Experimental|AD128|The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.
11054915|NCT04394143|Placebo Comparator|placebo|Two placebo capsules (Mannitol) will be administered for the control intervention once daily, just before light outs, for one week.
11054942|NCT04393922|Experimental|Aim 1|"To accomplish this aim, we will conduct one experiment in two sessions separated by 2- 3 days using a crossover design. Participants will be assigned into one of three groups: spastic SCI, non-spastic SCI, and controls. We expect that people enrolled in Aim 1 will complete 2 visits within 1 week.
~Visit 1 Measurements:
~MVCs
~MEP Recruitment Curves
~iMEPs
~StartReact
~Visit 2 Measurements:
~Participant Reported Spasticity
~MAS
~PSAD
~KINARM
~MRI of brain and spinal cord"
11055081|NCT04392830|Placebo Comparator|Placebo|Placebo
11055394|NCT04390542|Experimental|Psychoeducation intervention|Psychoeducatoinal intervention
11054916|NCT04394130|Experimental|CI group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.
~Then a continuous infusion of ropivacaine 0.2% at a flow rate of 6 ml.h-1 will be running for 48h after the bolus administration.
~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
11054917|NCT04394130|No Intervention|SS group|"Patients will have a preoperative ultrasound-guided interscalene brachial plexus block with 20 ml of lidocaïne 1% and epinephrine 1:100,000, followed by the insertion of a catheter. In the post-operative period, after clinical assessment of motor recovery in the operated limb (flexion of the forearm possible) in order to exclude any neurological damage of surgical origin, ropivacaine 0.5% 20 ml will be injected through the catheter.
~After the injection, the catheter will be removed.
~During surgery, patients will also receive multimodal analgesia inclusive of iv dexamethasone 8 mg, iv magnesium sulfate 40 mg.kg-1, iv ketorolac 30 mg, and iv acetaminophen 1000 mg, according to the current practice in our institution."
11054918|NCT04394117|Active Comparator|Standard Care + Angiotensin Receptor Blocker (ARB)|Participants will receive an Angiotensin Receptor Blocker on top of the standard care provided by their institution.
11054919|NCT04394117|No Intervention|Standard Care|Participants will receive on the standard care provided by their institution.
11054920|NCT04394104||COVID-19 Survey Group|Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.
11054921|NCT04394091||PET CT and ultrasensitive PET CT|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .
11054922|NCT04394078||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
11054923|NCT04394065||Ultrasensitive PET CT|Newly diagnosed NPC patients will undergo ultrasensitive PET CT before treatment
11054924|NCT04394052||Soft-tissue tumors|Benign and malignant soft tissue masses
11054925|NCT04394052||Bone tumors|Benign and malignant bone focal bone lesions
11054926|NCT04394039|Experimental|public sp exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
11054927|NCT04394013|Experimental|Mindfulness Arm|The content of the approximately 20 minutes video is recorded in advance of the intervention by a certified teacher with teaching experience. The 20 minutes session consists of a series of body stretching exercises (around 17 different gentle and simple stretches from head to toe) with the incorporation of breathing technique (i.e. when to breathe in and breathe out). The whole body stretching exercise is performed with a sitting position, ideally on an exercise mat. As mentioned above, the participants are required to conduct the stretching exercise by following the guidance video for at least 5 days weekly for at least 2 weeks duration. The video will be uploaded onto a webpage which requires participants to log in and view the video. The webpage and video will be accessible through computers and mobile phones.
11054928|NCT04394013|Active Comparator|Non-mindfulness Arm|In this study, for control group, the participants are instructed with a similar video content as the intervention group, minus the incorporation of breathing technique, as breathing technique is hypothesised to be a key component of mindfulness.
11054929|NCT04394000||Before or control group|All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
11054930|NCT04394000||After or intervention group|On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
11054931|NCT04393987|Experimental|Arms|Treatment Compliance Training The treatment compliance training consists of five sessions in total and was given individually. Each session of the treatment compliance training given once a week took 45 minutes on average.
11054932|NCT04393987|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
11054933|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
11054934|NCT04393961|Other|Past Positive COVID-19 confirmed|Invited participants who Radish Health has completed a positive COVID-19 test who have recovered from all symptoms for more than 14 days.
11054935|NCT04393961|Other|Physician Diagnosed: Not Tested|Individuals who self report that a medical professional has told them they likely have COVID-19 (and have since recovered), but did not get a confirmatory test.
11054936|NCT04393961|Other|Self-Diagnosed Not Tested|Participant suspects they contracted (and have since recovered) from COVID-19, but they do not have a medical diagnosis or confirmatory test.
11054937|NCT04393961|Other|Likely Exposed, No Symptoms. Not Tested|Participant suspects that they've been exposed to COVID-19, but have not shown symptoms and wonder if they have antibodies so they may return to some normalcy.
11054938|NCT04393948|Experimental|No irradiation|
11054939|NCT04393948|Experimental|100 cGy single lung irradiation|100 cGy single lung radiation
11054940|NCT04393948|Experimental|100 cGy bilateral lung irradiation|100 cGy bilateral lung radiation
11054941|NCT04393935|Experimental|Pharmacy delivered PrEP Intervention|Customers of the study pharmacies who participate in the intervention to receive PrEP through the pharmacy.
11054976|NCT04393662||Tenodesis group|Tenodesis as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
11054977|NCT04393662||Tenotomy group|Tenotomy as surgical treatment option for a lesion of the long head of the biceps tendon (LHBT)
11055395|NCT04390542|No Intervention|Usual care|Information from healthcare providers
11054943|NCT04393922|Experimental|Aim 2|"To accomplish this aim, we will use a randomized crossover design study with spastic SCI participants receiving a single intervention combining non-invasive acoustic stimuli (Startle) or sham-Startle with motor training to enhance cortico- and reticulo-spinal contribution, separated by ~2 weeks.
~Visit 1 and Visit 2
~Single intervention of:
~Startle + exercise training OR sham-Startle + exercise training
~Pre and post measurements:
~MVCs
~MEP recruitment curves
~iMEPs
~StartReact
~Participant reported spasticity
~MAS
~PSAD
~KINARM
~Neuromechanical hand and/or leg testing
~GRASSP
~TRI-HFT
~10-meter walk test
~Pendulum Test"
11054944|NCT04393909|Active Comparator|Control group|Patients do not have access to the Patient Dx Questionnaire.
11054945|NCT04393909|Active Comparator|Patient Dx Questionnaire User group|Patient enrollees will be randomized to receive the Patient Dx Questionnaire administered by the research staff at the bedside.
11054946|NCT04393896|Experimental|intervention group|Participants in the intervention group will receive the usual financial benefits of the Reward Policy as well as the WIFI program which will include three key components: psycho-education through WOA publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call.
11054947|NCT04393896|No Intervention|control group|Participants in the control group will receive the usual financial benefits of the Reward Policy and receive payment from the Changsha psychiatric hospital. However, they will not have access to the WIFI program since they cannot scan the WeChat barcode for the research.
11054948|NCT04393883|Experimental|Standard maintenance programme group|pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
11054949|NCT04393883|Experimental|Improvement maintenance programme group,|pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
11054950|NCT04393870|Experimental|Maryam's Flower Group|Maryam's flower was placed in a bowl of water and left in the room of the pregnant women who were at 1 cm cervical dilatation and in the first phase of the labor. It was explained to the pregnant women that the leaves of the plant would open up in the water, and they were asked to imagine that the birth canal would simultaneously open up. In effect, they were told to focus on the opening of these leaves during the course of the labor
11054951|NCT04393870|No Intervention|Control Group|All the pregnant women, those in the control group, were provided with standard midwifery care.
11054952|NCT04393857||Oocyte donors|Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory.
11054953|NCT04393844|Placebo Comparator|with obturator|A group using an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
11054954|NCT04393844|Experimental|without obturator|A group that does not use an obturator when performing peripherally inserted central venous catheterization in children under 18 years of age under general anesthesia.
11054955|NCT04393831|Active Comparator|Retzius sparing|Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
11054956|NCT04393831|No Intervention|Conventional (non-Retzius) nerve sparing|A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
11054957|NCT04393818|Experimental|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep), work environment, and social support.
11054958|NCT04393818|Sham Comparator|Control App|Participants allocated to the control App will receive access to a a fully operational mobile phone App with limited contents about management and prevention of mental health problems. Although this group will also receive psychoeducation, the content will be reduced to general, written recommendations.
11054959|NCT04393805||MED-Cohort|Patients hospitalized for SARS-COVID-2 infection in a medical ward
11054960|NCT04393805||ICU-Cohort|Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
11054961|NCT04393792|Active Comparator|Povidone-Iodine|0.23% sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
11054962|NCT04393792|Placebo Comparator|Normal Saline|sinus rinse and mouthwash three times daily (tds) for days 1-3 of study
11054963|NCT04393779|Other|HARPOON™ MVRS|Subjects who were treated with the HARPOON MVRS.
11054964|NCT04393766|Experimental|normal saline|
11054965|NCT04393766|Placebo Comparator|non normal saline|
11054966|NCT04393753|Experimental|domatinostat and avelumab|Single arm study of Domatinostat tablets in combination with avelumab infusion
11054967|NCT04393727|Experimental|Intervention|Patients in the intervention group will receive 200 cc of convalescent plasma
11054968|NCT04393727|No Intervention|Control|Patients will continue to receive standard therapy
11054969|NCT04393714|Experimental|autogenous dentin graft treated with nitric acid|
11054970|NCT04393714|Active Comparator|autogenous dentin graft treated with hydrochloric acid|
11054971|NCT04393701|Experimental|neonates tested in Normandie, France|All neonates will be tested in Normandie
11054972|NCT04393688|Experimental|Experimental: Tri-wire Peripheral Balloon Dilatation Catheter|Percutaneous transluminal angiography (PTA) will be performed using the Tri-wire Peripheral Balloon Dilatation Catheter. Interventions: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter; Procedure: Percutaneous Transluminal Angiography.
11054973|NCT04393688|Active Comparator|Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.|Percutaneous transluminal angiography (PTA) will be performed using OHICHO Ⅱ PTA Balloon Catheter, a commercially available high-pressure PTA balloon. Multiple balloons, inflations and/or prolonged inflation may be used. Interventions: Device: OHICHO Ⅱ PTA Balloon Catheter. Procedure: Percutaneous Transluminal Angiography.
11054974|NCT04393675|Active Comparator|LT5001|Administered twice daily (maximum 6 g per time, morning and evening respectively)
11054975|NCT04393675|Placebo Comparator|Placebo|Administered twice daily (maximum 6 g per time, morning and evening respectively)
11055396|NCT04390516|Other|COViage|Machine learning intervention
11054978|NCT04393649||Older patients / community dwellers|"The inclusion criteria are:
~Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria
~Living and staying at home because of physical and social distancing
~Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)
~Agree to participate in the study
~The exclusion criteria are:
~A concomitant participation to another medical trial
~Living in semi-autonomous residence or CHSLD"
11054979|NCT04393636|No Intervention|Control arm|Participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes.Additional to known risk factors a Covid-19 module will be used as well.
11054980|NCT04393636|Active Comparator|Intervention arm|All participants will receive at the different time intervals through our custom-made Digital Cardiac Counseling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants in the intervention group will receive through the Digital Cardiac Counseling platform different modules with E-counseling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.
11054981|NCT04393623|Experimental|Cognitive Reappraisal Microintervention|"The CR microintervention (session 1) is drawn from Barlow & colleagues empirically supported treatment for emotional disorders (the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders). The microintervention consist of four sections: (1) Introduction to cognitive appraisal; (2) Introducing the idea of thinking traps that prevent reappraisal and maintain negative emotion; (3) Describing cognitive reappraisal as a strategy that can help the participant get out of such thinking traps; (4) Providing an example of this process (situation> negative appraisal > negative emotion > thinking trap > opportunity for cognitive reappraisal) and have participants provide a personalized example."
11054982|NCT04393623|Active Comparator|Psychoeducation (Control)|The manualized psychoeducational control module, serving as an attentional control, is derived from two sources: 1. The first session of the Women's Health Education Manual, which provides psychoeducation about the basic body systems and their function, with focus on components of the immune system and 2. Fact sheets published by the American College of Obstetricians and Gynecologists(ACOG), providing female-specific facts about cancer and heart health. None of this psychoeducation discusses potential relevancy of alcohol use, nor will any behavior changes be suggested during the control microintervention.
11054983|NCT04393610|Active Comparator|Group (L)|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group)
11054984|NCT04393610|Active Comparator|Group M|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
11054985|NCT04393610|Active Comparator|Group F|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
11054986|NCT04393597|Experimental|Group 1|Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.
11054987|NCT04393597|Experimental|Group 2|Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.
11054988|NCT04393584|Experimental|FOLFIRINOX|Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
11054989|NCT04393584|Active Comparator|FLOT|d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP
11054990|NCT04393571|Experimental|conventional follow up patients|
11054991|NCT04393571|Experimental|Mobile app follow up patients|
11054992|NCT04393558||COVID-19|Individuals experiencing COVID-19 like symptoms.
11054993|NCT04393558||Healthy Controls|Individuals without any known significant health problems
11054994|NCT04393545|Active Comparator|HV night splint (SP) group|
11054995|NCT04393545|Active Comparator|exercise (EX) group|
11054996|NCT04393545|Active Comparator|high-voltage galvanic stimulation (EL) group|
11054997|NCT04393532|Experimental|Laparoscopic hernia repair using Su2ura Approximation Device|"Surgery will be performed under general anesthesia. Standard antibiotic prophylaxis will be administered at induction of anesthesia. A single surgeon, the PI, will perform the procedure. A surgical assistant will be selected by the PI from the surgical staff of the department.
~The procedure will involve placement of laparoscopic ports, reduction of the hernia sac, closure of the defect with the Su2ura Approximation device and fixation of mesh with tacks over the closed defect.
~Study follow up visits: at post operation discharge, 14 days, 3 months, 6 months."
11054998|NCT04393519||Prospective|Prospective cohort that received TIPS from 05/12/2020 onwards
11054999|NCT04393506|Other|Inductive therapy|Inductive therapy with Camrelizumab and Apatinib, followed by radical surgery and post-operative radiotherapy/chemoradiotherapy.
11055000|NCT04393493|Experimental|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:
~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution
~Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution
~Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution
~Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
11055001|NCT04393493|Experimental|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:
~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.
~Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.
~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.
~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
11055002|NCT04393480|Active Comparator|Robotic therapy|Robotic rehabilitation and conventional rehabilitation
11055003|NCT04393480|Sham Comparator|Conventional therapy|Conventional rehabilitation
11055004|NCT04393467|Experimental|real tSMS|tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.
11055152|NCT04392349|Other|IRREGULAR|Irregular goup includes eyes with irregular astigmatism or corneal scarring.
11055006|NCT04393454|Experimental|Sirolimus|Participants will be instructed to take 2 mg every day for 28 days (1 cycle). They will be evaluated in the oncology clinic every 2 weeks to make sure they are tolerating the medication well.
11055007|NCT04393441|Active Comparator|Systane Ultra Multidose|Participants will administer 1 to 2 drops in each eye 3 times daily
11055008|NCT04393441|Experimental|New Artificial Tear Formulation|Participants will administer 1 to 2 drops in each eye 3 times daily
11055009|NCT04393428||COVID-19 patients with urinary samples|COVID-19 patients with urinary samples
11055010|NCT04393415|Active Comparator|patients receiving LGF|
11055011|NCT04393415|No Intervention|patients not receiving LGF nor PRP|
11055012|NCT04393415|Active Comparator|patients receiving Platelet rich plasma|
11055013|NCT04393402||Patients with Covid-19 and admitted in critical care unit|
11055014|NCT04393389||non-CLI group|Rutherford Clinical Category (RCC) 2-3
11055015|NCT04393389||CLI group|critical limb ischemia，Rutherford Clinical Category (RCC) 4-6
11055016|NCT04393350|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11055017|NCT04393337|Experimental|Gestational Age Chart Method|In this method, the endotracheal tube insertion depth is obtained from the gestational age chart provided in the 7th edition textbook of neonatal resuscitation program (adapted from Kempley et al. PubMed identifier number: 18372092)
11055018|NCT04393337|Active Comparator|Nasal-Tragus Length Method|In this method, the endotracheal tube insertion depth is calculated based on the formula-the distance from nasal septum tip to ear tragus+1 cm
11055019|NCT04393324||Transferred patients|A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds
11055020|NCT04393324||Matched Non-transferred patients|A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables
11055021|NCT04393311|Experimental|Ulinastatin|Patients will receive ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
11055022|NCT04393311|Placebo Comparator|Placebo|Patients will receive placebo to match ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
11055023|NCT04393298|Experimental|UCB6114 iv infusion|Study participants assigned this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels.
11055024|NCT04393285|Experimental|Abemaciclib and Letrozole|Study treatment will consist of abemaciclib 150mg orally twice a day and letrozole 2.5mg orally once a day.
11055025|NCT04393259||Participants|Women attending an antenatal service using the Rainbow Clinic model of care.
11055026|NCT04393246|Active Comparator|Standard of care|Standard of care
11055027|NCT04393246|Experimental|EDP1815|1.6 x 10^11 cells dosage-in-capsule orally twice per day for up to 7 days (with the option to extend up to 14 days), on top of standard of care
11055028|NCT04393246|Experimental|Dapagliflozin and Ambrisentan|Ambrisentan 5mg tablet orally once per day for up to a maximum of 14 days and Dapagliflozin 10mg tablet orally once per day for up to a maximum of 14 days, on top of standard of care
11055029|NCT04393220|Experimental|Bevacizumab and anti-PD-1 therapy|
11055030|NCT04393220|Active Comparator|Bevacizumab|
11055031|NCT04393220|Active Comparator|anti-PD-1|
11055032|NCT04393207|Sham Comparator|Control group|Patient will receive intrathecal morphine and a Sham TAP block.
11055033|NCT04393207|Experimental|Liposomal Bupivacaine|Patient will receive intrathecal morphine + TAP block with Liposomal bupivacaine and bupivacaine 0.25%
11055034|NCT04393207|Active Comparator|Bupivacaine|Patient will receive intrathecal morphine + TAP block with only bupivacaine.
11055035|NCT04393194|Experimental|Vaginal estrogen cream|subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
11055036|NCT04393194|Placebo Comparator|vaginal placebo cream|Subjects will be treated with the prescribed vaginal medication, 1g per time, q d for the first 2 weeks and then 1g per time, twice a week.
11055037|NCT04393181||recipients of hearts with impaired function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with impaired function
11055038|NCT04393181||recipients of hearts with normal function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with normal function
11055039|NCT04393168|Experimental|Patients with unilateral arm or leg lymphedema|
11055040|NCT04393155||COVID-19+|Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
11055041|NCT04393103|Other|Follow up|Follow Up of 30 patients after administration of atropine.
11055042|NCT04393103|Experimental|intralipid 20% adjuvant|30 patients will receive atropine and intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
11055043|NCT04393077|No Intervention|Control|Participants will complete the pre-tests of the introductory features form, SUD, STAI-I, and burnout scales sent via Survey Monkey. The participants (n=40) will be given 15 minutes of free time and asked to be in a position where the individuals were comfortable, in the quietest and most tranquil environment possible. At the end of this period, post-test SUD, STAI-I, and burnout scales will be sent to the participants and they will be asked to fill in the scores.
11055044|NCT04393077|Experimental|Intervention|Firstly, people in the entire group fill out the introductory features form on the online questionnaire form. The time of the meeting will be determined by collaborating with the participants in the experimental group. During the interview, they will be asked to be in a position that was comfortable for the individuals, in the quietest and calm environment possible. At the beginning of the meeting, they will be asked to fill in the pre-test SUD, STAI-I, and burnout scales sent via SurveyMonkey. Then, the EFT session (20 minutes) will be conducted once mutually with the researcher, who is an expert in their field. At the end of the session, they will be filled the post-test SUD, STAI-I and burnout scales
11055045|NCT04393064|Other|full term and preterm|75 preterm and 75 fullterm will be recruited in this study; all will be hemodynamically stable on discharge doing FEES
11056093|NCT04385420|Experimental|ATR-002 600 mg (MAD)|600 mg ATR-002 once daily (morning) for 7 days
11055046|NCT04393051|Experimental|BAR group|"Patients who will be assigned (after a computerized randomization) to the BAR group will. receive baricitinib as adjunctive therapy.
~Baricitinib will be administered at 4 mg daily via oral route for 14 days as add-on therapy or 2 mg daily via oral route (eGFR between 30 and 60 ml/min and for patients with age >75 years old) for 14 days as add-on therapy"
11055047|NCT04393051|No Intervention|Control group|Patients in the control group will continue to receive standard therapy.
11055048|NCT04393038|Experimental|ABX464|ABX464 - Capsules + Standard of Care (SOC)
11055049|NCT04393038|Placebo Comparator|Placebo|Placebo - Capsules + Standard of Care (SOC)
11055050|NCT04393025|Other|Intracranial Stenting|25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS
11055051|NCT04393025|Active Comparator|Aspirin+Clopidogrel|25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment
11055052|NCT04393012|Experimental|Noddle Group|Patients who received noddle to allow access to the nurse call system.
11055053|NCT04392999|Experimental|Platelet Rich Plasma|One time injection of 1.5-6cc of platelet rich plasma prepared from a blood sample into cervical facet joints. There is no trade/generic name
11055054|NCT04392999|Active Comparator|Xylocaine and Dexamethasone Sodium Phosphate|Corticosteroid: A mixture of 1 mL 2% lidocaine and 0.5 mL of 10 mg/mL dexamethasone per facet joint (up to 6 mL total volume for 4 facet injections)
11055055|NCT04392986|No Intervention|Baseline|Baseline measurement
11055056|NCT04392986|Experimental|Intervention|Sunlight intervention
11055057|NCT04392973|Experimental|Intervention|Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
11055058|NCT04392973|No Intervention|Control|Standard of Care Treatment for COVID-19 Infection
11055059|NCT04392960|Experimental|18F-florbetaben PET-CT scans|
11055060|NCT04392947|Active Comparator|combined iTBS/cTBS|"Combined theta burst stimulation (TBS) of the left (intermittent TBS, iTBS) and right (continuous TBS, cTBS) dorsolateral prefrontal cortex (dlPFC; F3 and F4 according to EEG10/20 system). Each stimulation session will comprise 2 trains of 600 stimuli each applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s. In the same session, stimulation with cTBS will be applied continuously for 40 s. Intensity of TBS will be standardized at 120 % of the resting motor threshold (rMT).
~Additionally, patients receive an electrical co-stimulation of the forehead. One electrode is fixed to FZ and the 2nd one is either fixed to the left forehead (iTBS) or the right forehead (cTBS), rectangular aligned to the upper edge of the FZ-electrode with a distance of 0.5 cm. Intensity of the co-stimulation is applied with 50% of TBS-intensity."
11055061|NCT04392947|Sham Comparator|sham stimulation|Setup is identical to combined active iTBS/cTBS but TBS is not actively delivered
11055062|NCT04392934|Experimental|flat shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
11055063|NCT04392934|Experimental|curved shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
11055064|NCT04392934|Experimental|hooked shape acromion group|a conservative physiotherapy protocol was applied for 4 weeks
11055065|NCT04392921|Experimental|Intervention Arm|Patients randomized to amiodarone treatment
11055066|NCT04392921|Placebo Comparator|Control Arm|Patients randomized to placebo treatment
11055067|NCT04392908||Patients|Pediatric patients from 12 to 17 with cancer diagnosis only taken by Meyer Children's Hospital prior consent. Knowledge of fluent Italian language is required
11055068|NCT04392908||Parents|Parents of pediatric patients prior consent. Knowledge of fluent Italian language is required
11055069|NCT04392908||Medical Staff|Medical staff including doctor, psychologist and nurse
11055070|NCT04392895||Patients with locally advanced cervical cancer|Patients with locally advanced cervical cancer, who had undergone a PAL
11055071|NCT04392882|Experimental|Legume enriched diet group|"Replacing 1/3 refined rice intake with legumes three times per day
~Regular 30-min walk after dinner each day"
11055072|NCT04392882|No Intervention|Usual diet group|"Maintaining usual diet with sufficient vegetable intakes (30-70 g/unit per day)
~Regular 30-min walk after dinner each day"
11055073|NCT04392869|Experimental|CRAFT group|This arm will instruct the students on an adapted and extended version of the CRAFT program. This is a mindfulness based program which is a systematic combination of practices derived from ancient philosophies, such as yoga and Buddhism, in conjunction with more recent disciplines such as mindfulness, emotional intelligence and positive psychology. The contents are structured along in five consecutive modules aimed at cultivating and enhancing consciousness, relaxation and regulation, attention, bliss and transcendence.
11055074|NCT04392869|Experimental|MBSR group|This arm will instruct the students on an adapted and extended version of the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
11055075|NCT04392869|No Intervention|No intervention group|This group does not receive any instruction. The aim of this arm is to determine if there are any differences in outcomes between the two groups that receive intervention and this one.
11055076|NCT04392856|Experimental|Unified Protocol Transdiagnostic Treatment Emotional Disorders|"An adaptation of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to women in a homeless situation will be implemented in public shelters setting in Madrid, Spain.
~The UP adaptation is an intervention based protocol for emotional disorders, consisted of 12 treatment sessions of one and a half hours of duration each, at a rate of one per week."
11055077|NCT04392856|Other|Waitlist Control condition|The participants assigned to the waitlist control condition will not immediately receive the intervention. They will wait for 3 months, which is the duration of the intervention in the experimental group. After that time, they will be offered the same psychological treatment as those assigned to the UP (experimental condition).
11055078|NCT04392843|Other|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
11055079|NCT04392843|Active Comparator|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
11055080|NCT04392830|Experimental|ALZ002 DS|"SAD: 6 cohorts of subjects are planned to be orally dosed, ranging from 15 mg - 800 mg.
~MAD: 3 cohorts of subjects are planned to be orally dosed once daily for 7 consecutive days, ranging from 300 mg - 800 mg."
11055082|NCT04392817|Experimental|the participating group in the intervention|patient complaining of seppch rerrors due t ovelopharyngeal insufficiency and underwent the intervention
11055083|NCT04392804|Experimental|0.1 ml 4% articaine|single dose of 0.1 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
11055084|NCT04392804|Experimental|0.2 ml 4% articaine|single dose of 0.2 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
11055085|NCT04392804|Experimental|0.3 ml 4% articaine|single dose of 0.3 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
11055086|NCT04392791|Active Comparator|Treated group|The participants received thermal water therapy
11055087|NCT04392791|No Intervention|Control group|The participants haven't received thermal water therapy
11055088|NCT04392778|No Intervention|Untreated|Group 1: patients that are not on a ventilator (n=10) No extra intervention will be done.
11055089|NCT04392778|Sham Comparator|Saline Control|Group 2: patients that are on a ventilator and will receive saline injections (n=10) as control for MSC transplantation group (3).
11055090|NCT04392778|Experimental|Experimental UC-MSCs|Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10)
11055091|NCT04392765|Other|Therapy arm|Six week use of Snoozeal device. Once daily for 20 minutes.
11055092|NCT04392752|Experimental|Participants|The participants are recruited via the University of Jyväskylä and Finnish Fitness Sports Association web page and social media channels. An online pre-study questionnaire are sent to randomly chosen athletes and control group candidates who claim to fulfill the inclusion criteria and volunteer for the study. The participants selected for the study filled an additional questionnaire which is subsequently reviewed by the physician of the study to confirm that they will meet inclusion criteria relating to health.
11055093|NCT04392752|No Intervention|Control|The target is 15 male ja 15 female participants for both the control and intervention groups. To be included, participants need to be with two or more years of resistance training experience, similar to our previous study in females (Hulmi et al. 2017). If more than 15+15 control participants sign up for the study, the final group will be matched to the intervention group based on age, height, weight, and training experience reported on the pre-study questionnaire. The control group maintain their normal nutrition and training during the study.
11055094|NCT04392739|Other|TPOXX|TPOXX 600 mg BID x 7 days
11055095|NCT04392726||patients with suspected DPLD|
11055096|NCT04392726||patients with known DPLD|
11055097|NCT04392713|Active Comparator|Ivermectin arm|Participants will be administered Ivermectin with standard chloroquine regimen
11055098|NCT04392713|No Intervention|Control arm|This arm will only receive chloroquine as per existing policy of hospital
11055099|NCT04392700|Experimental|group A|drugs：tenofovir disoproxil fumarate, dose：300mg/d
11055100|NCT04392700|Active Comparator|group B|drugs：entecavir dose： 0.5 mg/d
11055101|NCT04392674|Experimental|using the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
11055102|NCT04392661||Laparoscopic Sleeve Gastrectomy (group I)|111 morbid obese females underwent LSG (group I). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
11055103|NCT04392661||Laparoscopic Roux-en-Y Gastric Bypass (group II)|86 morbid obese females underwent LRYGB (group II). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
11055104|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone|TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
11055105|NCT04392648|Experimental|Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone|TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
11055106|NCT04392648|Experimental|Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone|TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
11055107|NCT04392648|Experimental|Expansion: TAK-573 + Bortezomib + Dexamethasone|TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
11055108|NCT04392648|Experimental|Expansion: TAK-573 + Pomalidomide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
11055149|NCT04392362|Active Comparator|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
11055109|NCT04392648|Experimental|Expansion: TAK-573 + Cyclophosphamide + Dexamethasone|TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
11055110|NCT04392635|Experimental|Trocar Placement Assist Device (TPAD)|Participants will receive investigational TPAD device during laparoscopic surgery
11055111|NCT04392622|Experimental|d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
11055112|NCT04392622|Experimental|d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
11055113|NCT04392622|Experimental|d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
11055114|NCT04392622|Experimental|d-limonene -8gram|8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation
11055115|NCT04392622|Experimental|de-escalation dose d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
11055116|NCT04392622|Experimental|de-escalation dose d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
11055117|NCT04392622|Experimental|de-escalation dose d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
11055118|NCT04392596|Experimental|patients|40
11055119|NCT04392583||Device: ENTACT Septal Staple|Septoplasty
11055120|NCT04392570||Fasting group|patients with type 2 diabetes who prefer to fast during Ramadan
11055121|NCT04392570||Non-fasting group|patients with type 2 diabetes who are otherwise healthy and have no contraindications for fasting but prefer not to fast
11055122|NCT04392557|Active Comparator|metformin/alogliptin|metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
11055123|NCT04392557|Active Comparator|metformin/pioglitazone|metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
11055124|NCT04392557|Active Comparator|triple therapy|metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
11055125|NCT04392544||Pediatric|Pediatric CF population age 10-18 years.
11055126|NCT04392544||Adult|Adult CF population age ≥ 18 years.
11055127|NCT04392531|Active Comparator|Group A (control)|The control group will consist on the standard treatment that patients will receive according to hospital standard of care protocol.
11055128|NCT04392531|Experimental|Group B (experimental)|The experimental group will consist on cyclosporine added to the standard treatment that patients will receive according to hospital standard of care protocol.
11055129|NCT04392518|Active Comparator|Hospital based rehabilitation group|This group will perform the exercises in the hospital under the supervision of a physiotherapist
11055130|NCT04392518|Active Comparator|Telerehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection
11055131|NCT04392505|Experimental|The whole study population|All patients will receive durvalumab for up to 1 months after standard treatment With chemoradiotherapy.
11055132|NCT04392492||Patients undergoing transfemoral TAVI with MANTA closure|Patients undergoing transfemoral transcatheter aortic valve replacement with femoral access site closure using the novel plug-based vascular closure device (MANTA, Teleflex/Essential Medical Inc., Malvern, Pennsylvania, USA).
11055133|NCT04392479|Active Comparator|Aflibercept-FOLFIRI (arm 1)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),
~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),
~Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min (+ 2-minute window),
~5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min (+ 2-minute window),
~5-fluorouracile (D1 to D3): H+3.5: 2400mg/m² IV infusion over 46 hours (+ 1hour window)
~H+49.5: End of treatment administration"
11055134|NCT04392479|Experimental|Aflibercept-mFOLFIRI3 (arm 2)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),
~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),
~Irinotecan (D1 and D3) H+1 and H+49: 75mg/m² IV infusion over 60min (+ 2-minute window) on cycles 1 and 2, then 90mg/m² at cycle 3 and furthers in absence of AEs grade ≥2,
~5-fluorouracile (D1 to D3) H+3: 2400mg/m² IV infusion over 46 hours (+ 1hour window)
~H+50: End of treatment administration"
11055135|NCT04392466||Transtibial amputees|People who use transtibial prosthesis.
11055136|NCT04392466||Transfemoral amputees|People who use transfemoral prosthesis.
11055137|NCT04392466||Healty individuals|Healty individuals
11055138|NCT04392453|Experimental|Robotic therapy|Upper limb robotic rehabilitation by means of the portable robot Icone.
11055139|NCT04392440|Experimental|intervention|
11055140|NCT04392440|Other|control|Usual care
11055141|NCT04392427|Active Comparator|INTERVENTION|"*Intervention:
~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :"
11055142|NCT04392427|No Intervention|CONTROL|"B) Control group: will not receive nothing
~Data collection will include: sociodemographic data, clinical history, results of follow up (daily or according to clinical situation )
~Follow-up: to record any side effects of drugs, swab will be taken for PCR"
11055143|NCT04392414|Experimental|COVID-19 convalescent hyperimmune plasma|Moderately and severely ill COVID-19 patients treated with convalescent hyperimmune plasma. Patients will be infused with two units of 300 ml
11055144|NCT04392414|Placebo Comparator|Non-convalescent fresh frozen plasma (Standard plasma)|Moderately and severely ill COVID-19 patients treated with non-convalescent fresh frozen plasma (standard plasma). Patients will be infused with two units of 300 ml
11055145|NCT04392401||Cohort|Patients over 18 years with a confirmed diagnosis of COVID 19 hospitalized in intensive care unit
11055146|NCT04392388||SAPRIS-SERO|SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
11055147|NCT04392375|Active Comparator|Nifedipine 30MG|Oral administration of 30mg Nifedipine XL q24 hours until delivery
11055148|NCT04392375|Placebo Comparator|Placebo|Matching placebo group q24hrs until delivery
11055150|NCT04392362|Active Comparator|Control group|Giving adenosine Ising the recommended AHA two syringe method
11055153|NCT04392336|Experimental|Trust/Respect feedback|Clinicians with consumers in this arm receive feedback on trust/respect in addition to symptom feedback.
11055154|NCT04392336|No Intervention|No Trust/Respect feedback|Clinicians with consumers in this arm do not receive feedback on trust/respect and only receive symptom feedback.
11055155|NCT04392323|Experimental|Study Group|Patients will be recruited as an outpatient prior to their surgical procedure or during their hospital admission. If they consent, they will provide signed informed consent and will receive testing with serology and PCR for COVID-19 infection at pre-surgical testing 24-48 hours prior to their scheduled procedure. If they consent while inpatient postoperatively, signed informed consent will be procured after they have completed their pre-operative COVID-19 testing. PCR for COVID entails obtaining a nasopharyngeal swab to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital.
11055156|NCT04392297||Patients with CMV infection|
11055157|NCT04392284|Experimental|In-Person/Community Fitness/Metformin|In-person delivery of weight loss intervention with community fitness membership and metformin prescription.
11055158|NCT04392284|Experimental|In-Person/Community Fitness/No Metformin|In-person delivery of weight loss intervention with community fitness membership.
11055159|NCT04392284|Experimental|In-Person/No Community Fitness/Metformin|In-person delivery of weight loss intervention with metformin prescription.
11055160|NCT04392284|Experimental|In-Person/No Community Fitness/No Metformin|In-person delivery of weight loss intervention.
11055161|NCT04392284|Experimental|Telehealth/Community Fitness/Metformin|Online delivery of weight loss intervention with community fitness membership and metformin prescription.
11055162|NCT04392284|Experimental|Telehealth/Community Fitness/No Metformin|Online delivery of weight loss intervention with community fitness membership.
11055163|NCT04392284|Experimental|Telehealth/No Community Fitness/Metformin|Online delivery of weight loss intervention with metformin prescription.
11055164|NCT04392284|Experimental|Telehealth/No Community Fitness/No Metformin|Online delivery of weight loss intervention.
11055165|NCT04392271|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.
11055166|NCT04392258||Status post resuscitation|Patients or dataset that underwent resuscitation
11055167|NCT04392232|Experimental|Convalescent Plasma|
11055168|NCT04392219|Experimental|EIDD-2801|
11055169|NCT04392219|Placebo Comparator|Placebo|
11055170|NCT04392206|Experimental|Adipose Derived Mesenchymal Stem Cells|Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment.
11055171|NCT04392193|Experimental|Proton Particle Therapy for Cardiac Arrhythmia|Subjects who have an ICD with recurrent VT, VF, or VT storm who have failed one prior standard catheter-based ablation after device implantation, will subsequently undergo particle-based extracorporeal ablation.
11055172|NCT04392180||Caregivers|"Caregivers who care for a child that is both under 3 years of age and has experienced acute pain.
~This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child."
11055173|NCT04392167|Experimental|a/LCI-OCT Imaging of the Esophagus|
11055174|NCT04392154|Experimental|Lebrikizumab Q2W|Participants randomized to Lebrikizumab Q2W arm will receive investigational product on a once every 2 week schedule.
11055175|NCT04392154|Experimental|Lebrikizumab Q4W|"Participants randomized to Lebrikizumab Q4W arm will receive investigational product on a once every 4 week schedule.
~Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms."
11055176|NCT04392141|Experimental|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
11055177|NCT04392141|Experimental|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
11055178|NCT04392128|Experimental|Treatment arm|Patients enrolled in the experimental arm will receive hydroxychloroquine (200mgx3 tablets per day during 10 days) and azithromycine (500 mg at day 1 (2 capsules taken at the same time) then 250mg per day (1 capsule per day) during 4 days).
11055179|NCT04392128|Placebo Comparator|Control arm|Patients enrolled in the control arm will receive a placebo of hydroxychloroquine (3 tablets per day during 10 days) and a placebo of azithromycine (2 capsules taken at the same time at day 1, then 1 capsule per day during 4 days)
11055180|NCT04392115|Experimental|Exercise Group|"The home-based exercise program called the PREPARE program.
~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
11055181|NCT04392115|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
11055182|NCT04392102|Experimental|ZL-2306(Niraparib)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
11055183|NCT04392089||COVID-19|Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation
11055184|NCT04392076||Radiofrequency Ablation (RFA) of RCC|Patients following image guided radiofrequency ablation (RFA) of renal cell carcinoma (RCC)
11055185|NCT04392076||Microwave Ablation (MWA) of RCC|Patients following image guided microwave ablation (MWA) of renal cell carcinoma (RCC)
11055186|NCT04392076||Cryoablation (CRYO) of RCC|Patients following image guided cryoablation (CRYO) of renal cell carcinoma (RCC)
11055187|NCT04392063|Other|Cerebral palsy|Not included
11055188|NCT04392037|Experimental|Iberdomide plus low-dose cyclophosphamide and dexamethasone|"Iberdomide 1.6mg on days 1-21
~Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle
~Dexamethasone 40 mg once weekly (20 mg in patients aged > 75 years)"
11055189|NCT04392024|Other|Triumf|Subjects who have cataract surgery with Triumf IOL
11055293|NCT04391296|Active Comparator|II (Subpectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
11069502|NCT04289662|Experimental|K-924 LD|K-924 LD once daily
11055190|NCT04392011|Experimental|Arm 1|"Six non-naive* subjects (3 men, 3 women) will be administered a single low dose of a well-characterized kratom product (2 g) by mouth as a tea. These subjects may or may not choose to participate in Arms 2a and 2b. For subjects who will participate in Arms 2a and 2b, a washout period of 7 days will separate Arm 1 and Arm 2. Plasma will be collected from 0-120 hours and during the washout period. Urine will be collected from 0-120 hours.
~*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks."
11055191|NCT04392011|Experimental|Arm 2|"Arm 2 is divided into Arms 2a and 2b. Twelve non-naive subjects (6 men and 6 women) will participate in Arm 2a. Subjects who participate in this study arm will be administered an oral probe drug cocktail of dextromethorphan HBr (2 x 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-24 hours. Urine will be collected from 0-24 hours. A washout period of 7 days will separate Arms 2a and 2b.
~For Arm 2b, the same 12 subjects will be administered a combination of a well-characterized kratom product (2 g) by mouth as a tea with an oral probe drug cocktail consisting of dextromethorphan HBr (2, 15 mg liquid capsules; 30 mg total) and midazolam HCl (1.25 mL of 2 mg/mL syrup; 2.5 mg total). Plasma will be collected from 0-12 hours and during a midpoint collection within 5 days of the 24-hour blood collection. Urine will be collected from 0-24 hours."
11055192|NCT04391998|Active Comparator|Anemia without parasitic infection|women with anemia without parasitic infection will receive iron treatment
11055193|NCT04391998|Active Comparator|parasitic infection treated with iron|women with anemia with parasitic infection will receive oral iron treatment
11055194|NCT04391998|Active Comparator|parasitic infection treated with iron and antihelmemsic|women with anemia with parasitic infection will receive oral iron treatment and antihelminsic treatment in the form of metronidazole 500mg tab twice daily for 5 days in cases with Entamoeba or Giardia or albendazol 200mg tab
11055195|NCT04391985|Active Comparator|Cirrhotic Participants|The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
11055196|NCT04391985|Active Comparator|Non-cirrhotic Participants|The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
11055197|NCT04391972|Other|SAV multifocal IOL|Subjects who have cataract surgery with SAV multifocal IOL
11055198|NCT04391959|Experimental|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to twice weekly.
11055199|NCT04391959|Experimental|AZR-MD-001 Active|AZR-MD-001 Active will be dosed up to twice weekly.
11055200|NCT04391933|Other|MRI colon cancer|MRI scan of patients with colon cancer
11055201|NCT04391920||COVID-19 ICU Patients|
11055202|NCT04391907|Active Comparator|IPL group|Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery
11055203|NCT04391907|No Intervention|Non-IPL group|Subject who do not have intense pulsed light (IPL) laser before cataract surgery
11055204|NCT04391894|Experimental|ECF843 0.45 mg/mL TID or vehicle (Part 1)|Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
11055205|NCT04391894|Experimental|ECF843 0.15 mg/mL TID or vehicle (Part 1)|Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
11055206|NCT04391894|Placebo Comparator|ECF843 vehicle TID (Part 1)|Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
11055207|NCT04391894|Experimental|ECF843 0.15 mg/mL BID or vehicle (Part 1)|Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
11055208|NCT04391894|Placebo Comparator|ECF843 vehicle BID (Part 1)|Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
11055209|NCT04391894|Experimental|ECF843 -Part 2 (concentration/frequency TBD from Part 1)|Randomized in a 1:1 ratio in Part 2. Topical ocular eye drops. Exploratory Arm only.
11055210|NCT04391894|Active Comparator|Xiidra® -Part 2 (5% lifitegrast BID)|Randomized in a 1:1 ratio in Part 2. Topical ocular eye drops. Exploratory Arm only.
11055211|NCT04391868|Active Comparator|Viagra tablet|Subjects receive a single dose of 50 mg Viagra tablet followed by plasma sampling for 14 hours.
11055212|NCT04391868|Experimental|Sildenafil citrate ODF without water|Subjects receive a single dose of 50 mg sildenafil ODF without water followed by plasma sampling for 14 hours.
11055213|NCT04391868|Experimental|Sildenafil citrate ODF with water|Subjects receive a single dose of 50 mg sildenafil ODF with water followed by plasma sampling for 14 hours.
11055214|NCT04391855|Experimental|Tramadol with ropivacaine|Tramadol 2mg/kg with ropivacaine 0.5% 100mg for wound infiltration
11055215|NCT04391855|Experimental|Dexmedetomidine with ropivacaine|Dexmedetomidine 1μg/kg with ropivacaine 0.5% 100mg for wound infiltration
11055216|NCT04391855|Experimental|Magnesium with ropivacaine|Magnesium sulfate 10 mg/kg with ropivacaine 0.5% 100mg for wound infiltration
11055217|NCT04391855|Placebo Comparator|Placebo with ropivacaine|Ropivacaine 0.5% 100mg with 2ml isotonic saline 0.9% for wound infiltration
11055218|NCT04391842|Experimental|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
11055219|NCT04391829|Experimental|SARS-CoV-2 positive men|Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.
11055220|NCT04391816||Study Participants|Participants that were previously enrolled in the NIAAA Screening Protocol.
11055221|NCT04391803|Experimental|Pipeline™ Flex Embolization Device with Shield Technology™|This is a prospective, single-arm study in which subjects have consented and deployment of the Pipeline™ Flex Embolization Device with Shield Technology™ is attempted.
11055222|NCT04391790|Active Comparator|Control|Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker
11055223|NCT04391790|Experimental|Intervention|Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit
11055224|NCT04391777|Experimental|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.
~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.
~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
11055225|NCT04391777|Sham Comparator|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.
~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.
~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
11055226|NCT04391764|Experimental|Naltrexone|Naltrexone at a dose of 50 mg per day.
11055227|NCT04391764|Placebo Comparator|Placebo|Placebo tablets will be identical in size, colour, shape, and taste and will be given in a similar manner.
11055228|NCT04391751|Experimental|Single incision|Carpal tunnel release and basal joint arthroplasty through a single radial approach
11055229|NCT04391751|Active Comparator|Double incision|Double approach: carpal tunnel release through palmar approach and basal joint arthroplasty through radial approach
11055230|NCT04391738||BMI SARS-CoV-2|Patients admitted to Intensive Care Unit with SARS-CoV-2
11055231|NCT04391725|Experimental|Periapical surgery with guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and the defect is filled with mixture of iPRF and type 1 collagen granules before flap closure.
11055232|NCT04391725|Active Comparator|Periapical surgery without any guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and flap closure done.
11055233|NCT04391712|Experimental|Experimental|Participants will receive MLS laser treatment along with regular inpatient medical care.
11055234|NCT04391712|Active Comparator|Control Group|Participants will receive regular inpatient medical care.
11055235|NCT04391699|Experimental|CPAP + Heated humidification|CPAP + Heated humidification
11055236|NCT04391699|No Intervention|CPAP alone|CPAP
11055237|NCT04391686||COVID intensive care unit|
11055238|NCT04391686||intensive care unit|
11055239|NCT04391686||obesity|
11055240|NCT04391673||Dizzy group|Patients attending the dizziness and balance exercise programme at Guy's Hospital, London. Patients data will be included if they complete at least 4 sessions.
11055241|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution|
11055242|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution and 70% ethanol|
11055243|NCT04391647||HPV vaccinated group|"Women (18-25 years old) whom are previously fully vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.
~No intervention/drug to be administered."
11055244|NCT04391647||HPV unvaccinated group|"Women (18-25 years old) whom are not previously vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.
~No intervention/drug to be administered."
11055245|NCT04391634|Other|Mechanical ventilation|Preterm infants on mechanical ventilation
11055246|NCT04391621|Experimental|Adipose Derived Stem Cell(ADSC) arm|In this arm, the participant selected keloid will receive a single dose intra-lesional Adipose derived Stem cells infiltration. This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6).
11055247|NCT04391621|Active Comparator|Triamcinolone Acetanoide (TAC) arm|"This arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid.
~This will be a single dose infiltration of 40mg/cubic centimetres."
11055248|NCT04391608|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25 mg/day
11055249|NCT04391608|No Intervention|TDF dose reduction|TDF dose reduction
11055250|NCT04391595|Experimental|Arm 1|400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
11055251|NCT04391582|Experimental|Test - Tilapia Skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage.
11055252|NCT04391582|Active Comparator|Control - Silver sulfadiazine|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and band
11055253|NCT04391569|Placebo Comparator|IV Placebo|Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
11055254|NCT04391569|Experimental|IV ganaxolone active|Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
11055255|NCT04391556|Experimental|Firmagon|120 mg Firmagon subcutaneous injection after a TEP-PSMA
11055256|NCT04391543|Experimental|Experimental Arm|"4 experimental session (baseline, after treatment, 6 month post treatment and 12 months post treatment) with :
~comprehensive interview
~cognitive tests
~anthropometric measures
~postural balance test
~critical force test
~Astrand-Ryhming test
~self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)
~actimetry
~clinical and biological characteristics
~determination of inflammatory markers
~skeletal muscle index"
11055257|NCT04391530|Experimental|emotional freedom technique group|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
11055258|NCT04391530|Experimental|Breathin therapy group|Breathing therapy: the basic recipe After applying pre-test forms to students, the hall will be quiet and dim. In this study, breathing exercise application will be performed in three stages as (1) relax, (2) deep breath and (3) feel yourself.
11055259|NCT04391530|No Intervention|Control group|No intervention was made to the students in the control group.
11055260|NCT04391517|Experimental|Study Population|Included patients will be evaluated by an anaesthesiologist according to national and international guidelines as it is routine at the pre-operative clinic. In addition, all included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
11055261|NCT04391504|Experimental|transesophageal echocardiography guidance|
11055262|NCT04391504|Experimental|intracardiac echocardiography guidance|
11055316|NCT04391075||Exposed|Pudendal nerve block provided
11055263|NCT04391491||Heart failure with preserved ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFpEF (Symptoms of HF (NYHA II-IV); LVEF >50%; Elevated levels of natriuretic peptides (NT-pro BNP > 300 pg/ml in sinus rhythm, >600 pg/ml in AF);Relevant structural heart disease (Left ventricle hypertrophy (LVH) and/or Left atrium enlargement (LAE); left atrial volume index (LAVI) >34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females)
11055264|NCT04391491||Microvascular angina|Patients of both sexes and > 18 years with a confirmed diagnosis of MVA (Angina-like chest pain: signs of exercise-induced ischemia (ST-depression on exercise ECG (>1 mm down-sloping or rectilinear ST-segment depression in >2 leads)); No fixed stenosis (>50%) in epicardial coronary arteries or branches at baseline coronary arteriography)
11055265|NCT04391491||Pulmonary hypertension|Patients of both sexes and > 18 years with a confirmed diagnosis of secondary PH due to left heart disease (Left ventricular systolic dysfunction, left ventricular diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow obstruction and congenital cardiomyopathies) or chronic thromboembolic pulmonary hypertension defined by echo when peak tricuspid regurgitation velocity =2.8 m/s and presence of other echo 'PH signs'
11055266|NCT04391491||Heart failure with redused ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFrEF (Symptomatic HF (NYHA class II-IV), left ventricular ejection fraction ≤ 35% (at any time in the past))
11055267|NCT04391478|Active Comparator|milrinone|Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
11055268|NCT04391478|Active Comparator|sildenafil|Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.
11055269|NCT04391465|Experimental|Patients Scheduled for Elective Electrophysiological Study|"High right atrial pacing will occur at the following rates for 60 seconds each, with a rest period of at least 60 seconds between pacing runs:
~600 msec (100 bpm)
~500 msec (120 bpm)
~400 msec (150 bpm)
~350 msec (171 bpm)"
11055270|NCT04391452|Experimental|Dietary supplement group|Group 1:50 stressed subjects who will have a 28-day intake of dietary supplement. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam. Dietary supplement is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg).
11055271|NCT04391452|Placebo Comparator|Placebo group|Group 2 (Placebo comparator (lactose)): 50 stressed subjects who will have a 28-day intake of placebo. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam.
11055272|NCT04391439||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
11055273|NCT04391426||Patients who will undergo ERCP (case group)|
11055274|NCT04391426||Living liver transplantation donors (control group)|
11055275|NCT04391413|Experimental|OCT group|"OCT will be performed after initial coronary angiography and at the end of the procedure. Several OCT runs can be performed. The operator may change procedural strategy, and use additional interventions. The operator must evaluate the following parameters, based on OCT data:
~Before angioplasty: reference diameter and reference area of distal main vessel; lesion length; presence and extent of thrombus or calcification.
~Stent implantation: Stent should be sized according to distal reference diameter, and should allow for expansion to the reference diameter of the proximal main vessel.
~After stent implantation: minimal and reference lumen diameter, minimal and reference lumen area, minimal stent area, presence of thrombus, presence of edge dissection, tissue protrusion, optimal lesion coverage, malapposition, suboptimal stent deployment."
11055276|NCT04391413|No Intervention|Control group|Angioplasty will be guided by traditional fluoroscopy alone, performed before and after stent implantation. The recommendation for angioplasty of left main stenosis is to use main vessel (MV) stenting with a proximal optimisation technique (POT) and provisional side branch (SB) stenting as a preferred approach. Predilatation of the side branch (SB) may be considered, but is recommended in the following circumstances: extensive ostial SB involvement, heavy calcification, etc. even with a provisional SB stenting approach.
11055277|NCT04391387|Active Comparator|16-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour after prone position
11055278|NCT04391387|Experimental|24-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour, 24- hour after prone position
11055279|NCT04391374||Conservative treatment|Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.
11055280|NCT04391374||Peripheral artery bypass grafting|Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position
11055281|NCT04391374||Peripheral artery balloon angioplasty and stenting|Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position
11055282|NCT04391361|Experimental|trial group|
11055283|NCT04391361|Placebo Comparator|control group|
11055284|NCT04391348|Experimental|PET-TDM|PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine
11055285|NCT04391335||Group 1|Participants who meet the screening criteria for the development of bronchiolitis obliterans syndrome (BOS) according to the NIH criteria
11055286|NCT04391335||Group 2|Participants who may or may not have abnormal spirometry; however they do not fulfill the NIH criteria for the development of BOS
11055287|NCT04391322||Group 1|Healthy participants without lung disease
11055288|NCT04391322||Group 2|Participants with stable cystic fibrosis
11055289|NCT04391322||Group 3|Participants with cystic fibrosis, anticipated to receive treatment with CFTR-modulator therapy. Please note: treatment is determined by your physician as part of your normal therapy plan.
11055290|NCT04391309|Experimental|IC14, monoclonal antibody to CD14|150 patients randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously
11055291|NCT04391309|Placebo Comparator|Placebo|150 patients randomized to Placebo diluent on Days 1-4 intravenously
11055292|NCT04391296|Experimental|I (Prepectoral)|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
11055294|NCT04391270|Experimental|web-based intervention group|"Except Library, the participants in this group will also have access to the Intervention sub-section of the website. It will consist of six sessions delivered every two weeks following the same time schedule as the essay delivery in Library."
11055295|NCT04391270|Experimental|blended intervention group|"Except visiting Library and Intervention of the website, the participants in this group will also receive three face-to-face workshops (40 min per session) held at their workplaces."
11055296|NCT04391270|No Intervention|Control group|"The participants in the control group will have access to the Library sub-section of the website. General information of MVPA, health and work productivity will be provided with 18 short essays, which can be downloaded and printed out. The information will be factual and non-personally tailored."
11055297|NCT04391257|Other|Main|gekoTM neuromuscular electrostimulation device (NMES) briefly used on patients with cardiac pacemakers to check if pacemakers detect the gekoTM electrical pulses as interference.
11055298|NCT04391231|Experimental|Pentoxifylline Arm|Pentoxifylline (in suspension with SyrSpend SF)
11055299|NCT04391231|Placebo Comparator|Placebo Arm|Placebo (SyrSpend SF only)
11055300|NCT04391218|Experimental|Multidisciplinary Approach Group|Multidisciplinary medication review and reconciliation during hospitalization involving geriatricians, nurses, pharmacists and supported by a Clinical Decision Support System, followed by an end-user App to support patients/caregivers in the correct drug intake after discharge.
11055301|NCT04391218|No Intervention|Control Group|Medication review and reconciliation will be performed by geriatricians according to Good Clinical Practice and usual habits, that might also include digital and printed supports for medication appropriateness and drug interaction. Drug therapy will be listed and explained to the patient/caregiver at discharge. Patients/caregivers will be allowed to use any tools to support medication adherence, according to their habits and preferences (i.e. calendars, alarms, pill boxes).
11055302|NCT04391192|Experimental|Participants|All participants will be given the phone number and encouraged to call any time they plan to use substances alone
11055303|NCT04391179|Experimental|Dipyridamole 100 Milligram(mg)|100 milligrams (mg) by mouth (PO) four times a day (QID)
11055304|NCT04391179|Placebo Comparator|Placebo|Placebo given by mouth four times a day
11055305|NCT04391153|Active Comparator|conventional samplig|"Patients with biliary strictures udergo ERCP or EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods.
~Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology."
11055306|NCT04391153|Active Comparator|Fluorescence in situ Hybridization (FISH)|Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
11055307|NCT04391140|Experimental|Experimental|Combination of prone position and HFNC
11055308|NCT04391140|No Intervention|Control|Standard care: HFNC set for a SpO2 90-95% if unless indication for intubation is present.
11055309|NCT04391127|Experimental|Hospitalized patients with COVID-19 QTc < 500 mseg|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc < 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
11055310|NCT04391127|Experimental|Hospitalized patients with COVID-19 infection with QTc >500ms|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc > 500 ms could be randomized to ivermectin or placebo.
11055311|NCT04391114|Active Comparator|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to Transurethral Resection of the Prostate (TURP) and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay [4]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low [5]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay [6].
11055312|NCT04391114|Active Comparator|Top-Down HoLEP|"The Top-Down HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve, with anticipated improved continence [8]. A variation of this method is also being explored in Japan (termed the en-bloc technique with anteroposterior dissection HoLEP) [9]. The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique."
11055313|NCT04391101|Experimental|Intervention group|Administration of two units of fresh frozen plasma (between 400 and 500 ml) obtained from convalescent patients from infection by SARS-CoV-2. Convalescent plasma is defined as the plasma of patients who had PCR confirmed SARS-CoV-2 infection, who have recovered clinically, and who have positive antibodies against SARS-CoV-2.
11055314|NCT04391101|No Intervention|Control group|Subjects assigned to the control group will receive support treatment in the intensive care unit based on institutional management guidelines. The use of antiviral, antimalarial or anti-inflammatory drugs is allowed in both groups according to the ICU protocols.
11055315|NCT04391088||hospitalized people living with diabetes|hospitalized people living with diabetes
11055321|NCT04391049|Experimental|Treatment (OBP-301, carboplatin, paclitaxel, radiation)|Patients receive OBP-301 by intratumoral injection on days -3, 12, and 26. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
11055322|NCT04391036|Experimental|High Eudragit® Film, then Low Eudragit® Film|High (12.8%) Eudragit® content vaginal film, then low (6.4%) Eudragit® content vaginal film
11055323|NCT04391036|Experimental|Low Eudragit® Film, then High Eudragit® Film|Low (6.4%) Eudragit® content vaginal film, then high (12.8%) Eudragit® content vaginal film
11055324|NCT04391023|Sham Comparator|Sham tDCS|The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
11055325|NCT04391023|Experimental|2 mA tDCS|The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
11055326|NCT04391023|Experimental|4 mA tDCS|The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
11055327|NCT04391010|Other|Health care providers with beard|
11055328|NCT04391010|Other|Health care providers without beard|
11055329|NCT04390997|No Intervention|Periodontally Healthy|20 participants with bleeding on probing less than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
11055330|NCT04390997|No Intervention|Gingivitis|20 participants with bleeding on probing greater than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
11055331|NCT04390997|Other|Periodontitis|20 participants with bleeding on probing greater than or equal to 30%, probing depths greater than or equal to 5mm at least non-adjacent two teeth in each quadrant of the dentition, and clinical attachment loss greater than or equal to 4mm which was measured by six sites per tooth, and radiographic bone loss on the coronal third of root or severe (vertical/ horizontal) bone loss.
11055332|NCT04390984|Experimental|1|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
11055333|NCT04390971|Experimental|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.
11055334|NCT04390958|Experimental|Neoadjuvant chemotherapy group|Total 6 perioperative chemotherapy composed of nab-paclitaxel, cisplatin and capecitabine every 21 days
11055335|NCT04390945|Experimental|Camrelizumab combined with chemotherapy|Camrelizumab (200mg Q2W, continuous medication until disease progression, intolerable toxicity, or withdrawal due to other reasons) simultaneous radiotherapy (50-50.4Gy / 1.8-2Gy / 25-28F), chemotherapy (Capecitabine, 625mg/m2, bid, oral, d1-5, qw, total 5 weeks.
11055336|NCT04390932|Experimental|Enhanced TA|Therapeutic exercise protocol accompanied by an enhanced TA.
11055337|NCT04390932|Active Comparator|Neutral therapeutic alliance|Therapeutic exercise protocol accompanied by an limited TA
11055338|NCT04390919||high group|high group: monocyte count≥0.445×10*9 cells/L
11055339|NCT04390919||low group|low group: monocyte count<0.445×10*9 cells/L;
11055340|NCT04390906||All participants|Participants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist
11055341|NCT04390893|Experimental|ultrasound positioning group|
11055342|NCT04390893|Active Comparator|leak test positioning group|
11055343|NCT04390880|Experimental|PEt/CT arm|Subjects receive a PET/CT scan.
11055344|NCT04390867|Experimental|TOPS1 DBS|Participants receive TOPS1 for one week, followed by one week each of TOPS2, TOPS3, and Standard in random order.
11055345|NCT04390867|Experimental|TOPS2 DBS|Participants receive TOPS2 for one week, followed by one week each of TOPS1, TOPS3, and Standard in random order.
11055346|NCT04390867|Experimental|TOPS3 DBS|Participants receive TOPS3 for one week, followed by one week each of TOPS1, TOPS2, and Standard in random order.
11055347|NCT04390867|Active Comparator|Standard DBS|Participants receive Standard for one week, followed by one week each of TOPS1, TOPS2, and TOPS3 in random order.
11055348|NCT04390854|Active Comparator|Induced blood clot scaffold|
11055349|NCT04390854|Experimental|Induced blood clot scaffold combined with Platelet rich fibrin|
11055350|NCT04390841|Experimental|Single Arm ( Qubic Stim Cardiac Stimulator )|There is only one Arm in this trial, the subjects who meet the inclusion and exclusion criteria will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
11055351|NCT04390828|Experimental|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
11055352|NCT04390828|No Intervention|Usual care|usual care
11055392|NCT04390555||CV involvement|Patients with COVID-19 and preexisting cardiovascular diseases and/or cardiovascular risk factors (diabetes mellitus, arterial hypertension and/or dyslipidaemia).
11055393|NCT04390555||Control|Patients with COVID-19 without preexisting cardiac involvement.
11055353|NCT04390815|Experimental|Intervention|"Before starting the therapeutic procedure, all wounds will be fully washed with normal saline.
~Group A patients will receive 10 units (0.1 mL) of regular insulin (manufactured by novo nordisk) in solution with 1 cc of normal saline 0.9% for each 10 cm of wound. The solution will be sprayed on the wound surface with an insulin syringe needle, once daily.
~The patients in this arm will receive conventional therapy."
11055354|NCT04390815|Placebo Comparator|Control|Before starting the therapeutic procedure, all wounds will be fully washed with normal saline Group B patients will receive conventional topical application without insulin
11055355|NCT04390789|Experimental|single visit retreatment|nonsurgical root canal retreatment will be carried out in single visit.
11055356|NCT04390789|Active Comparator|multi visit retreatment|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
11055357|NCT04390776|Experimental|Treatment Sequence 1|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).
11055358|NCT04390776|Experimental|Treatment Sequence 2|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).
11055359|NCT04390776|Experimental|Treatment Sequence 3|PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).
11055360|NCT04390776|Experimental|Treatment Sequence 4|PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).
11055361|NCT04390763|Experimental|Safety Run-in|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
11055362|NCT04390763|Experimental|Randomized Arm 1|Combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel
11055363|NCT04390763|Experimental|Randomized Arm 2|Combination of NIS793 + gemcitabine + nab-paclitaxel
11055364|NCT04390763|Active Comparator|Randomized Arm 3|gemcitabine + nab-paclitaxel
11055365|NCT04390750|No Intervention|Treatment Group 1|Treatment Group 1 will receive a standard educational booklet, a clinical oral health evaluation and a smart electronic toothbrush with no instruction on oral hygiene technique. The study coordinator will download the toothbrush data for data collection. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided. The hygienist will provide basic instruction on proper use of the smart electronic toothbrush.
11055366|NCT04390750|Experimental|Treatment Group 2|Treatment Group 2 will receive a standard educational booklet, a smart electronic toothbrush, a clinical oral health evaluation with tailored instruction on oral hygiene technique and care partner coaching. The study coordinator will download the toothbrush data for data collection. The dental hygienist and interventionist will work together to fulfill the following intervention components: tailored instruction and coaching.
11055367|NCT04390750|No Intervention|Control Group|The Control group will receive a standard educational booklet and a clinical oral health evaluation with no instruction on oral hygiene technique. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided.
11055368|NCT04390737|Experimental|Dose escalation study of HH2853|To determine MTD and/or RP2D and to evaluate the safety, tolerability of HH2853
11055369|NCT04390724||Patient Group 1: Y90 Standard-of-Care|The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
11055370|NCT04390724||Patient Group 2: Y90 Dose determined by results from Group 1|The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1
11055371|NCT04390711||Healthy subjects|We included 40 age- and gender-matched healthy subjects to serve as the control group, who had normal blood pressure, serum fasting glucose, lipid profile, and renal function.
11055372|NCT04390711||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. All patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
11055373|NCT04390711||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association.T2DM without CAD was diagnosed if no luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
11055374|NCT04390698|Experimental|nerve block+opioid-free general anesthesia|Paravertebral block with an ultrasound-guided technique; opioid-free general anesthesia
11055375|NCT04390698|Sham Comparator|sham bock+opioid general anesthesia|Sham block by local infiltration at the same site of paravertebral block; opioid based general aneshesia
11055376|NCT04390685|Experimental|Tacrolimus ointment|Apply whole arm, in a thin layer, once daily for one year
11055377|NCT04390685|No Intervention|Control|
11055378|NCT04390672|Experimental|SUPRAFLEX Cruz|Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
11055379|NCT04390672|Active Comparator|SYNERGY|Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.
11055380|NCT04390646|Active Comparator|Pulsatile GnRH pump treatment|
11055381|NCT04390646|Placebo Comparator|Pulsatile placebo pump treatment|
11055382|NCT04390620||MUCODA|DAFILON - sterile, monofilament, non-absorbable surgical suture material produced from Polyamide
11055383|NCT04390607||Subjects undergoing revision joint surgery|
11055384|NCT04390594|No Intervention|Standard of Care|The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
11055385|NCT04390594|Experimental|Standard of Care + Nafamostat mesilate|"The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
~Nafamostat mesilate"
11055386|NCT04390581|Experimental|Juvéderm® VOLIFT with Lidocaine|All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.
11055397|NCT04390503|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Participants randomized to the experimental arm will receive 1 unit (approximately 200 to 250 mL) of convalescent plasma that was collected from a volunteer who recovered from COVID-19 disease.
11055398|NCT04390503|Active Comparator|Control (albumin 5%)|Participants randomized to the control arm will receive 250 mL of albumin (human) 5% infusion. The albumin will be prepared in bags that are identical to the bags used for plasma. The similar appearance of albumin and plasma will facilitate maintaining the blinded status of subjects and most of the study staff.
11055399|NCT04390490|No Intervention|control|Automatic chemiluminescence analyzer will be used for dectecting the concentration of cardiac troponin I as control group.
11055400|NCT04390490|Experimental|Photoelectrochemical immunosensor|Photoelectrochemical immunosensor will be used for dectecting the concentration of cardiac troponin I as test group.
11055401|NCT04390477|Experimental|Probiotic|1 pill od containing 1x10E9 cfu of the probiotic
11055402|NCT04390477|No Intervention|Control|No treatment
11055403|NCT04390464|Active Comparator|Standard of care|Standard of care
11055404|NCT04390464|Experimental|Ravulizumab + Standard of care|Ravulizumab IV (adjusted to weight, Day 1 only)
11055405|NCT04390464|Experimental|Baricitinib + Standard of care|Baricitinib PO OD (4mg, Days 1-14)
11055406|NCT04390451|Experimental|Whole Health STEPS|Participants will immediately receive Whole Health STEPS.
11055407|NCT04390451|Other|Waitlist|Participants will receive Whole Health STEPS after a defined waiting period.
11055408|NCT04390438|Experimental|High-Intensity short time percutaneous electrolysis|Application of a 0,66uA galvanic current in the active TrP through a needle during 10 seconds. During the 20 seconds left necessary to blind the patient and the examiner, the needle was inside but with no electrical current
11055409|NCT04390438|Experimental|Low-Intensity long time percutaneous electrolysis|Application of a 0,22uA galvanic current in the active TrP through a needle during 30 seconds
11055410|NCT04390438|Active Comparator|Dry needling|One acupuncture needle was placed in the active TrP to produce a local twitch response during 30 seconds
11055411|NCT04390425|No Intervention|Control - Standard pneumatic tourniquet pressure|This group receives the standard pneumatic tourniquet pressure during surgery like they would during standard of care.
11055412|NCT04390425|Experimental|Experimental - Limb occlusion pressure|This group receives a slightly lower tourniquet pressure than they would during standard of care. This lowered limb occlusion pressure is determined by the tourniquet device.
11055413|NCT04390412|Experimental|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA fashion
11055414|NCT04390399|Active Comparator|Cohort A Control Treatment Arm|SBRT + gemcitabine + nab-paclitaxel
11055415|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 1|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803
11055416|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 2|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
11055417|NCT04390399|Active Comparator|Cohort B Control Treatment Arm|Irinotecan liposome + 5-FU/leucovorin
11055418|NCT04390399|Experimental|Cohort B Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
11055419|NCT04390399|Experimental|Cohort C Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK
11055420|NCT04390360|Other|Protective ventilation with HME|Protective ventilation + HME
11055421|NCT04390360|Other|Protective ventilation with Heated humidifier|Protective ventilation + HH
11055422|NCT04390360|Other|Implementation of protective ventilation|Protective ventilation implementation
11055423|NCT04390360|Other|Tidal Volume reduction|Tidal volume reduction
11055424|NCT04390347|Experimental|Intervention|The intervention product (Yakult) (supplied as fermented milk) and placebo will be delivered in sealed pots of 65 mL with date stamped expiry. Yakult contains Lactobacillus casei Shirota (a minimum of 6.5 × 109 live cells of Lactobacillus casei Shirota are contained in each pot).
11055425|NCT04390347|Placebo Comparator|Placebo|The placebo will be indistinguishable (identical in taste and colour but will not contain Lactobacillus casei Shirota) to both participants and trial investigators. It will be stored and provided in exactly the same manner as the intervention product.
11055426|NCT04390334|Experimental|Treatment A: Daridorexant|Single dose of 50 mg daridorexant
11055427|NCT04390334|Experimental|Treatment B: Famotidine & daridorexant|Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant
11055428|NCT04390334|Experimental|Treatment C: Efavirenz|600 mg efavirenz once daily in the evening from Day 5 to Day 14
11055429|NCT04390334|Experimental|Treatment D: Daridorexant & efavirenz|Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16
11055430|NCT04390321|Experimental|Down Syndrome LLMcare|Individuals with Down Syndrome which are able to execute the LLMcare physical and cognitive training intervention
11055431|NCT04390308||Intervention|The cortex of selected ovary will be punctured up to ten times. In the surgical report, the surgeon will state how many punctures have been done.
11055432|NCT04390308||Control|No intervention
11055433|NCT04390295|Experimental|SHR3824+Metformin, Placebo+Metformin|once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks
11055434|NCT04390295|Experimental|SHR3824 5 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
11055435|NCT04390295|Experimental|SHR3824 10 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
11055475|NCT04390074||Control|Age- and sex-matched controls are drawn from all residents of Sweden by Statistics Sweden.
11055476|NCT04390061|Experimental|tofacitinib+HYQ|Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days
11055477|NCT04390061|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200mg cp three times a day for 14 days
11055478|NCT04390048|Experimental|Anodal tDCS and Balance Training (BT) Group|Participants will undergo 4 weeks of BT under anodal tDCS treatment.
11055479|NCT04390048|Sham Comparator|Sham tDCS and BT Group|Participants will undergo 4 weeks of BT under sham tDCS.
11055480|NCT04390048|Active Comparator|BT only Group|Participants will undergo BT only.
11069503|NCT04289662|Experimental|K-924 HD|K-924 HD once daily
11055436|NCT04390282|Experimental|Application-based support system Lifepod®PAD|Patients in the experimental group will be introduced to and use Lifepod®PAD, a web-based application designed to support adherence to lifestyle advice and medication for three months. Lifepod®PAD is built as a two-side system. One side is the patient interface, the web-based application, accessible through a smartphone or tablet. The patients can log information about their lifestyle, symptoms and medication and review their data in relation to recommended targets. They get positive feedback, recommendations about healthy behaviours and receive notifications as short messages depending on their individual health status. The other side is the medical interface managed by the health care professionals. All information the patient is reporting into the app can be accessed by the treating nurse and the system ranks the patients, thus gives high priority to patients who have the greatest needs.
11055437|NCT04390282|No Intervention|Life style advice according to usual practice|Patients in the control group will receive usual care meaning advice about lifestyle changes and medication from the physician at the visit in the vascular open clinic.
11055438|NCT04390269||Infected group|The infected group will be classified according to the severity whether mild ,moderate or severe
11055439|NCT04390269||susceptible (non infected|This group either exposed and not infected .
11055440|NCT04390269||control group|normal control subject
11055441|NCT04390256|Active Comparator|Egg shell powder nanoparticles|
11055442|NCT04390256|Experimental|Clove water extract|
11055443|NCT04390256|Experimental|Carbopol|
11055444|NCT04390256|Experimental|Carboxymethyle cellulose|
11055445|NCT04390243|Experimental|Treatment (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
11055446|NCT04390230||Patient with peniale implantation|All patients who underwent implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France.
11055447|NCT04390217|Experimental|LB1148|LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
11055448|NCT04390217|Placebo Comparator|Placebo|Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
11055449|NCT04390204|Experimental|Experimental|Motor control exercises are performed on foam mats. The physiotherapist instructs them, and gives a description on paper, as well as a USB key allowing to view the exercises on video. A supervised home self-rehabilitation program on foam mats is implemented.
11055450|NCT04390204|No Intervention|control|According to the recommendations of learned societies, patients are offered voluntary MPP contraction work, in strength and endurance, in increasing complexity, under manual endocavitary control and under biofeedback. A supervised program of self-rehabilitation at home by voluntary contraction of MPP is set up.
11055451|NCT04390191|Experimental|Continuous Positive Airway Pressure (CPAP)|Patients will be given CPAP at fixed pressure of 8-10 cm water pressure for 72 hours continuously
11055452|NCT04390191|No Intervention|Control|Patients in this arm will be not be given any intervention and will be monitored for 72 hours continuously, and then daily for a total of 14 days.
11055453|NCT04390178|Experimental|Convalescent plasma treatment|All participants will receive a bag of convalescent plasma. The bag volume will be 180-200 ml. The first 10 patients will receive 1, 5, 10, 50 and 134 ml of plasma at 30 minute intervals while being closely monitored for adverse events, especially allergic reactions. The remaining twenty patients will receive the convalescent plasma as a slow infusion according to normal routines.
11055454|NCT04390165||Malaysian COVID-19 Cohort|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
11055455|NCT04390152|Experimental|Mesenchymal stem cell|WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
11055456|NCT04390152|Active Comparator|Control group|Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo
11055457|NCT04390139|Experimental|Treatment A|Wharton-Jelly mesenchymal stromal cells on D1 and D3
11055458|NCT04390139|Placebo Comparator|Treatment B|Placebo on D1 and D3
11055459|NCT04390126||Register of haematological malignancies|
11055460|NCT04390126||Idiopathic Pulmonary Fibrosis and PAH Cohort|
11055461|NCT04390126||Giant Cell Arteritis Cohort|
11055462|NCT04390126||AMD and Macular Edema Cohort|
11055463|NCT04390126||Multiple Sclerosis Cohort|
11055464|NCT04390126||Myocardial Infarction Observatory RICO|
11055465|NCT04390126||Heart Failure Cohort|
11055466|NCT04390126||Hemophilia Cohort|
11055467|NCT04390113|Placebo Comparator|Placebo|Administered as 2-4 milliliter infusion, visually identical to Viralym-M
11055468|NCT04390113|Experimental|Viralym-M|Administered as 2-4 milliliter infusion, visually identical to placebo
11055469|NCT04390100|Active Comparator|PRF|PRF membrane is placed in the area where the free gingival graft was taken from the palate
11055470|NCT04390100|Active Comparator|hyaluronic acid|hyaluronic acid gel is placed in the area where the free gingival graft was taken from the palate and the patient is instructed to place the gel 3 times per day
11055471|NCT04390100|Active Comparator|Gel foam|Gel foam is placed in the area where the free gingival graft was taken from the palate
11055472|NCT04390087|Experimental|Exercise|Upper-body rowing performed up to 30 min, 3 times per week with moderate-to-vigorous intensity
11055473|NCT04390087|No Intervention|Control|The participants allocated to the control group will be asked to maintain their normal lifestyle throughout the intervention period
11055474|NCT04390074||COVID-19|Patients with COVID-19 who have received or are receiving Intensive Care in Sweden. Patients are identified in the Swedish Intensive care registry, to which all Swedish intensive care units (ICU) are reporting all intensive care patients.
11055481|NCT04390035|No Intervention|Control|Participants in the control arm will follow the standard-of-care treatment exercises for the 6 months following ACL reconstruction surgery.
11055482|NCT04390035|Experimental|Test (BFRT)|Participants in the test arm will follow the identical physical therapy exercises as the control arm but will perform the exercises with BFRT during the first 16 weeks post-surgery. After reaching the 16-week mark, participants will complete the identical standard-of-care rehabilitation between weeks 16-24.
11055483|NCT04390022|Active Comparator|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
11055484|NCT04390022|Placebo Comparator|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
11055485|NCT04390009|Other|Siemens Biograph Vision PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
11055486|NCT04390009|Other|United Imaging uEXPLORER PET-CT scans|Parallel study arms defined by PET-CT scanners by different manufacturer and model
11055487|NCT04389996||Patients with cancer|Survey
11055488|NCT04389983|Active Comparator|Healthy, under 65 years|Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)
11055489|NCT04389983|Active Comparator|Healthy, over 65 years|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.
~(All MCT doses administered as a single dose at time 0)"
11055490|NCT04389983|Active Comparator|Alzheimer's Disease subjects|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.
~(All MCT doses administered as a single dose at time 0)"
11055491|NCT04389970|Experimental|Time Restricted Feeding|Participants will be asked to follow a time-restricted meal pattern (8:16 protocol)
11055492|NCT04389957||Providers|The quantitative surveys will be delivered to the identified local quality stewards (N=73) and providers (N=657) for each enrolled site via the Research Electronic Data Capture (REDCap) platform at baseline (prior to VA-EQuIP) and 12 months following completion of the VA-EQuIP intervention. We will incorporate established methods of maximizing web survey responses, including multiple, carefully-timed, integrated email contacts.
11055493|NCT04389957||Patients|We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
11055494|NCT04389944|Experimental|convalescent plasma treatment|"After confirmation of negative SARS-CoV-2 polymerase chain reaction (PCR) in two consecutive nasal swabs or 28 days after resolution of symptoms, donor check is performed and plasma donation occurs by apheresis. The plasma is photochemically pathogen reduced using the INTERCEPT Blood System.
~In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up."
11055495|NCT04389931|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
11055496|NCT04389931|Experimental|Periodontal treatment, Omega 3|Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.
11055497|NCT04389918|Experimental|Tality|Participants will receive TalityTM as their sole intake for nutritional purposes for a 4 week period.
11055498|NCT04389905|Experimental|Motivational Interviewing Oral Health Education Group|The intervention group focused on the mothers from before birth until their child reached the age of 3 years. They received repeated questionnaires and repeated oral health education using the Motivational Interviewing (MI) technique.
11055499|NCT04389905|No Intervention|Local Control Group|The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
11055500|NCT04389905|No Intervention|Similar Socio-economics Control Group|This control group is from a Public Dental Clinic with similar socioeconomics (among the families in the catchment area of the clinic) as in the intervention group. This control group included mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
11055501|NCT04389892|Experimental|study participants|After a careful endoscopic ultrasound examination in B mode of the entire pancreas, contrast enhancement was administrated to the participants. The uptake and the wash-out of the agent were followed and then a morphological diagnose was established. EUS-fine needle aspiration of the cyst wall, septa or solid components was guided by the enhancing pattern.
11055502|NCT04389879|Experimental|CAD/CAM|CAD/CAM custom-cut Nickel Titanium (NiTi) FR
11055503|NCT04389879|Active Comparator|Conventional multistranded|Conventional multistranded Stainless Steel (SS) FR
11055717|NCT04388254|Experimental|Sumifilam (PTI-125), 100 mg tablets|Sumifilam (PTI-125), 100 mg oral tablets administered twice daily (BID)
11056094|NCT04385420|Placebo Comparator|Placebo (MAD)|Placebo once daily (morning) for 7 days
11055504|NCT04389866|Experimental|Both Jawline and Lateral (Zygomatic) Cheek Area Injections|JUVÉDERM VOLUMA™ XC 1-3 syringes (each syringe is 1 cc) will be injected into the lateral cheek (zygomatic) area plus JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation)
11055505|NCT04389866|Experimental|Jawline Injections|JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation)
11055506|NCT04389853|Active Comparator|Flexible ureteroscopy (fURS)|Retrograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
11055507|NCT04389853|Active Comparator|Mini-percutaneous nephrolithotomy (mini-PCNL)|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs)4
11055508|NCT04389840|Experimental|Dociparstat sodium (DSTAT)|Dociparstat 4 mg/kg IV bolus on Day 1, followed by Dociparstat by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])
11055509|NCT04389840|Placebo Comparator|Placebo|Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for 7 days (starting on Day 1 and ending on Day 8 [168 hours])
11055510|NCT04389827||Incident & Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
11055511|NCT04389801|Experimental|Desferal|An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours
11055512|NCT04389801|Placebo Comparator|control group|Will receive glucose 5% over 4 hrs infusion
11055513|NCT04389788|Active Comparator|Rt Eye|The right eye of the patients received carboxy therapy for 6 sessions every 2 weeks. The used device is locally manufactured by a national company for esthetic and dermatological devices. Carbon dioxide gas was subcutaneously injected at the lateral one-third of each eye lid (5 cc gas in each puff according to standardized flowmetry) using insulin syringe. Compression of the injected area will be avoided to prevent rapid leakage of the gas.
11055514|NCT04389788|Active Comparator|Lt Eye|The left eye of the same patients received microneedling with topical glutathione for 6 sessions every 2 weeks. Microneedling was done with Derma pen which is automatic and rechargeable device (vibrating frequency : 6500-10000 r/m , vibration speed level 5 , model :Ultima A6 , company : Dr ,pen and country : Korea). Needle length is adjustable from 0.25 mm to 0,5 mm.Needles number : 36 .Then, Patient was subjected to topical glutathione about 0.25 ml (vial : 600mg/5ml).
11055515|NCT04389775|Active Comparator|Drug|Subcutaneously administer a single dose of XW003, ranging from 0.03mg to 2.0mg, every cohort by the body weight.
11055516|NCT04389775|Placebo Comparator|placebo|Subcutaneously administer a single dose of volume-matching placebo, ranging from 0.03mg to 2.0mg, every cohort by the body weight.
11055517|NCT04389762|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
11055518|NCT04389749|Experimental|CPM|The experimental group will have a CPM applied in the PACU immediately post-op and it will be utilized while the patient is awake in bed for 2 hours on and 2 hours off, when not mobilizing with Physical Therapy (PT). The experimental group will also have traditional PT, including sessions 1 to 3 times a week.
11055519|NCT04389749|No Intervention|No CPM|The control group will have typical care, including working with physical therapy 1 to 3 times a week.
11055520|NCT04389736|Experimental|SIT|Sitting
11055521|NCT04389736|Experimental|STAND|Standing
11055522|NCT04389736|Experimental|NMES|Self-selected maximal intensity of neuromuscular electrical stimulation
11055523|NCT04389723|Other|Placebo→ Qualia Mind|Subjects are first administered the placebo then crossover to the investigational product
11055524|NCT04389723|Other|Qualia Mind→ Placebo|Subjects are first administered the investigational product then crossover to the placebo
11055525|NCT04389710|Experimental|Intervention Group|Participants included in the experimental group will receive 200-600 milliliters of convalescent plasma, administered at a rate of 100-250 mL/hr
11055526|NCT04389697|Experimental|Intervention arm|Clear fluids and food up to up to 1 hour before the procedure
11055527|NCT04389697|No Intervention|Control arm|Fasting for solids for up to 6 hours and fluids up to 2 hours before the procedure
11055528|NCT04389671|Experimental|Lyophilized Lucinactant|Lyophilized lucinactant reconstituted with water for injection
11055529|NCT04389658||Asymptomatic population|Subjects who underwent PCR and ELISA tests for the diagnosis of COVID-19: mainly asymptomatic individuals from three main areas of Spain (Madrid, Barcelona and Valencia) with high impact of COVID-19 that have performed the PCR and ELISA test for the diagnosis of COVID-19 before initiating the work immediately after Spanish lockdown.
11055530|NCT04389632|Experimental|SGN-B6A|
11055531|NCT04389619|Experimental|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
11055600|NCT04389138|No Intervention|Comparison|In this arm participants will attend 3 study visits to complete study questionnaire and assessments. In between these visits, participants will be asked to wear an activity monitor and record an activity diary for one week. Other than this, participants will continue to receive only standard of care treatment.
11069504|NCT04289649|Experimental|K-924 LD|K-924 LD tablet once daily
11055532|NCT04389619|Active Comparator|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
11055533|NCT04389606|Experimental|Study Formula (SF)|New infant formula for term infants
11055534|NCT04389606|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
11055535|NCT04389606|No Intervention|Human Milk Reference Group|Human milk
11055536|NCT04389593||Single arm|This is a single arm study in which all partiipants have one MRI
11055537|NCT04389580|Active Comparator|13 cis retinoic acid doses orally plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
11055538|NCT04389580|Active Comparator|13 cis retinoic acid doses Aerosolized plus Tamoxifen orally|80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
11055539|NCT04389580|No Intervention|No Intervention:|No study treatment Arm No Isotretinoin or Tamoxofien treatment
11055540|NCT04389567||Patients with COVID-19 taking Famotidine|Use of any dose of oral Famotidine during period of COVID-19
11055541|NCT04389554||Control Group|Healthy pregnant women
11055542|NCT04389554||Study Group|Pregnant women with COVID-19
11055543|NCT04389528|Experimental|tDCS active arm|
11055544|NCT04389528|Placebo Comparator|tDCS placebo|
11055545|NCT04389502|Experimental|CaPtyVa app group|Those assigned to the CaPtyVa app group will receive a tutorial video describing its operation and will have to complete 10-item clinical vignette quiz according to the app recommendations based on local current CRC screening and surveillance guidelines on every question. Physicians in this group will download a free of charge application (CaPtyVa CCR APP, Digital Means, Argentina) on their iOs or Android device.
11055546|NCT04389502|Active Comparator|Control group|The ones assigned to the control group will be asked to complete the 10-item clinical vignette quiz according to their current knowledge on local current CRC screening and surveillance guidelines
11055547|NCT04389476||Medical staff in high contact with patients|
11055548|NCT04389476||Other personnel in low contact with patients|
11055549|NCT04389476||Patients|
11055550|NCT04389476||Community residents|
11055551|NCT04389463||Cardiac or thoracic surgery in COVID-19 positive patients|
11055552|NCT04389463||Cardiac/thoracic surgery in COVID-19 negative patients|
11055553|NCT04389450|Experimental|PLX-PAD interval high dose|PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.
11055554|NCT04389450|Experimental|PLX-PAD low dose|PLX-PAD 300, single administration, second administration of placebo after 1 week.
11055555|NCT04389450|Placebo Comparator|Control Group A|Placebo, two administrations, 1 week apart
11055556|NCT04389450|Experimental|PLX-PAD high dose|PLX-PAD, single administration
11055557|NCT04389450|Placebo Comparator|Control Group B|Placebo, single administration
11055558|NCT04389437|Experimental|NCD patients (case)|Patient diagnosed with Alzheimer's disease or parkinsonian dementia / Lewy body dementia or other mild or severe NCD defined by international criteria.
11055559|NCT04389437|Other|Control patients with memory complaint|Normal neuropsychological evaluation during assessment
11055560|NCT04389437|Other|Control patients without memory complaint|MMS score and / or the Montreal Cognitive Assessment grid (MoCA) ≥26 / 30, No memory complaint
11055561|NCT04389424||Anastrozole|Breast cancer women with anastrozole treatment
11055562|NCT04389424||Tamoxifen|Breast cancer women with tamoxifen treatment
11055563|NCT04389424||Exemestane|Breast cancer women with exemestane treatment
11055564|NCT04389424||Basal|Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
11055565|NCT04389424||Recurrence|Breast cancer women luminal type with recurrence of disease during endocrine therapy
11055566|NCT04389411|Experimental|Montelukast|10mg Oral Montelukast once daily for 60 days
11055567|NCT04389411|Placebo Comparator|Placebo|Placebo.
11055568|NCT04389398|Experimental|Pocket compression fixation belt|Pocket compression belt is used to compress the bleeding vessels and reduce bleeding after implantation.
11055569|NCT04389398|Active Comparator|Sand bag compression|Sand bag compression is used to compress the bleeding vessels and reduce bleeding after implantation.
11055570|NCT04389385|Experimental|COVID-19 STCs -Exo therapy|"In addition to the best available treatment, participants will receive inhaler COVID-19 STCs -Exo therapy *.
~Biological: Inhaler CSTH-Exo treatment will be applied daily x 5 times (2.0 x 108 nano vesicle / 3 ml; on day 1 to day 5).
~* If the improvement contribution is observed in the parameters, this application period could be extended"
11055571|NCT04389372|Experimental|Mindfulness by Smartphone|mindfulness therapy by smart phone
11055572|NCT04389359|Experimental|HCQ group (dialysis)|"Dialysis patients will receive Hydroxychloroquine sulfate 200 mg capsules or tablets (oral administration), as 600mg weekly in divided doses, given as 200mg after each dialysis session.
~Non-dialysis patients will receive Hydroxychloroquine sulfate, 400mg twice daily for two days, then 400mg weekly.
~Maximum treatment duration will be 26 weeks (6 months)."
11055573|NCT04389359|No Intervention|Control|Patients will continue with their usual medicines and clinical care without additional HCQ.
11055574|NCT04389346|Active Comparator|Periapical surgery with PRF group|Autologous platelet aggregate (PRF) will be placed over the denuded root surface, following apicoectomy and before flap repositioning.
11055575|NCT04389346|Placebo Comparator|Control group without PRF|Flap will be repositioned following apicoectomy without placement of any autologous platelet aggregate.
11055713|NCT04388280|Other|Imaging|Echocardiography combined with coronary flow reserve (CFR) and strain imaging, or computed tomography (CT) angiography with direct visualization of coronary arteries.
11055576|NCT04389333|Experimental|Non-contact MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination. In order to simplify the examination procedure, the data recorder was put on the examination bed. The patient lay down after swallowing the capsule under the remote guidance of the endoscopist.
11055577|NCT04389333|Active Comparator|MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of an endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient was instructed to assume the supine or left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist face to face, the subject turned over on the bed to complete the examination.
11055578|NCT04389320||Rheumatoid patients receiving hydroxychloroquine|immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics
11055579|NCT04389307|Other|Group 1: Bladder Training - Control group|
11055580|NCT04389307|Active Comparator|Group 2: Bladder Training+Intra Vaginal Electrical Stimulation|
11055581|NCT04389281|Experimental|X-PACT Treatment|Single arm consisting of a six-week treatment period with X-PACT (phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) administered as an intra-tumoral injection. Intra-tumoral injections will be given on D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6. After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart.
11055582|NCT04389268||HCV patients|Patients with uncomplicated newly diagnosed hepatitis C virus
11055583|NCT04389268||Control group|Age and sex matched with patients
11055584|NCT04389255||Healthy people|65 people will be included.
11055585|NCT04389242|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
11055586|NCT04389242|Experimental|app-based cognitive behavioral intervention|"Application-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
11055587|NCT04389242|Other|Wait-list control group|No intervention will be provided when the experimental groups are receiving services, but the access to the App-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
11055588|NCT04389229|Experimental|UTIL-01|Single dose autologous unmodified tumour infiltrating lymphocytes
11055589|NCT04389229|Experimental|CoTIL-01|Single dose autologous gene modified tumour infiltrating lymphocytes
11055590|NCT04389216|Experimental|Radiofrequency|Radiofrequency Ablation of breast cancer tumour by Cool-tip electrode.
11055591|NCT04389203|Experimental|Study group|Unilateral tubal disconnection and waiting for pregnancy for 2 years after laparoscopy
11055592|NCT04389203|Experimental|Control group|Unilateral tubal disconnection and ICSI
11055593|NCT04389190|Active Comparator|Standard Protocol|This is the fluoroscopy protocol used routinely in most catheterization labs in the region. This includes fluoroscopy and cine image acquisition at 15 frames per second (FPS) at 8-inch mode. Virtual collimation and last image hold (LIH) will be used as needed. This protocol will be implemented for 6 weeks.
11055594|NCT04389190|Experimental|Low frame rate protocol|This will have fluoroscopy and cine image acquisition at 7.5 FPS at 8-inch mode with all other settings on factory default. Virtual collimation and LIH will be used as needed. This protocol will be implemented for 6 weeks as well.
11055595|NCT04389190|Experimental|Customized Protocol|This will have varying settings based on three weight based groups. Small (<60 kg), medium (60-85 kg), large (>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
11055596|NCT04389177|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin|Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks
11055597|NCT04389164|Experimental|Tissue engineering method|The thickness of scar tissue in the middle of the dermis is removed by a roller cutter with a thickness of about 0.01 -- 0.02mm. After cleaning, the dermis can be used for punching and mesh drawing in the dermal rolling machine.Autologous epidermal basal cell suspension was prepared according to the description of autologous epidermal basal cell extraction box.The size of the remaining skin should be the same as the wound surface. After washing with normal saline, the wet yarn should be wrapped for later use.The autogenous scar dermal scaffold was prepared and transplanted onto the wound surface. The autoepidermal basal cells prepared were sprayed or coated between the mesh and the dermal scaffold. Autologous skin slices were transplanted onto the wound surface and fixed with pressure bandaging.
11055598|NCT04389164|Active Comparator|Conventional therapy|Autologous skin was grafted onto the wound surface and fixed with pressure bandage
11055599|NCT04389151|Other|The experimental group|
11055714|NCT04388280|No Intervention|Observation|No imaging for the estimation of coronary artery disease
11055715|NCT04388267||Septic shock|Patients with septic shock, according to the Sepsis 3 definition, regardless of the origin
11055601|NCT04389138|Experimental|Intervention arm|In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
11055602|NCT04389125|Experimental|Improvement of Blood Flow group|One packet once a day, after breakfast (1.5 g/day, 1.5 g/day as an Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures)
11055603|NCT04389125|Placebo Comparator|Placebo group|One packet once a day, after breakfast (1.5 g/day)
11055604|NCT04389112|Experimental|Patients with actinic keratoses|
11055605|NCT04389112|Experimental|patients with squamous cell carcinoma in situ|
11055606|NCT04389112|Experimental|patients with squamous cell carcinomas|
11055607|NCT04389112|Experimental|patient with invasive metastates|
11055608|NCT04389099||Healthy placenta (control)|Pregnant women without preeclampsia and/or fetal growth restriction
11055609|NCT04389099||Pathological placenta|Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia without fetal growth restriction ; fetal growth restriction without preeclampsia.
11055610|NCT04389086|Experimental|Induction chemotherapy + chemoradiotherapy + surgery|Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery
11055611|NCT04389086|Active Comparator|Neoadjuvant chemotherapy + surgery|Neoadjuvant chemoradiotherapy followed by surgery
11055612|NCT04389073|Active Comparator|Arm 1 (PD-1+NVB)|"The treatments received are:
~Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])."
11055613|NCT04389073|Experimental|Arm 2 (PD-1+NVB+Bev)|"The treatments received are:
~Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Bevacizumab (15 mg/kg every 3 weeks, intravenously [IV])."
11055614|NCT04389073|Experimental|Arm 3 (PD-1+NVB+DDP)|"Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Cisplatin (50mg/m2 every 3 weeks, intravenously [IV])."
11055615|NCT04389073|Experimental|Arm 4 (PD-1+VEX)|"Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Cyclophosphamide (50 mg/day, qd, per os)
~Capecitabine (500 mg, tid, per os)"
11055616|NCT04389073|Experimental|Arm 5 (PD-1+NVB+Radiation)|"Vinorelbine (40 mg/day, tiw, per os)
~Toripalimab (240 mg every 3 weeks, intravenously [IV])
~Hypofractionated radiotherapy"
11055617|NCT04389060|Active Comparator|GSE group|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing
11055618|NCT04389060|Placebo Comparator|Placebo group|Subjects took a single dose of 600 mg starch in capsule form through ingestion 2 hours prior to testing
11055619|NCT04389034||Adults|Patients with IgE-induced Rhinitis, Conjunctivitis and/or asthma due to tree- and/or grass pollen induced allergy
11055620|NCT04389021|Experimental|VR|The intervention group will receive VR support upon the standard of care during the procedure.
11055621|NCT04389021|No Intervention|Control|The control group will have standard care without the VR support.
11055622|NCT04389008||Postoperative death|
11055623|NCT04389008||Postoperative non-death|
11055624|NCT04388995|Experimental|observed patients|
11055625|NCT04388982|Experimental|MSCs-Exos Dosage 1|MSCs-Exos. low-dose group
11055626|NCT04388982|Experimental|MSCs-Exos Dosage 2|MSCs-Exos mid-dose group
11055627|NCT04388982|Experimental|MSCs-Exos Dosage 3|MSCs-Exos high-dose group
11055628|NCT04388969||Gaucher disease patients|Patients with type 1,2,3 Gaucher disease.
11055629|NCT04388969||GBA carriers with Parkinson disease|Patients with Parkinson disease GBA related (carriers)
11055630|NCT04388943||1|
11055631|NCT04388930||Kidney transplant live-donor|Participants that will be a planned live renal transplant donor
11055632|NCT04388930||Kidney transplant recipient|Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
11055633|NCT04388917||Clip Group|Use of Hemo-lock hemostatic clips during tumor resection to prevent bleeding
11055634|NCT04388917||No Clip group|No Hemo-lock hemostatic clips used during tumor resection
11055635|NCT04388904|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
11055636|NCT04388891|Experimental|Minimally supervised therapy|This group will undergo minimally supervised therapy with the robot ReHapticKnob.
11055637|NCT04388878|Experimental|PF-07054894|Participants will receive single or multiple ascending doses of oral PF-07054894
11055638|NCT04388878|Placebo Comparator|Placebo|Participants will receive matching placebo
11055639|NCT04388865|Experimental|Control|Usual Care
11055640|NCT04388865|Experimental|Clinical Hovering|Remote monitoring with feedback to social support
11055641|NCT04388852|Experimental|Treatment (valemetostat, ipilimumab)|Patients receive valemetostat PO QD on days 1-21 and ipilimumab IV over 90 minutes on day 1 of cycles 1 and 3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11055642|NCT04388839|Experimental|Arm A - First Strike|Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
11055643|NCT04388839|Experimental|Arm B - Second Strike - Maintenance|Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
11055644|NCT04388839|Experimental|Arm C - Adaptive Therapy|Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
11055645|NCT04388839|Active Comparator|Arm - D Conventional Therapy|Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
11055646|NCT04388826|Experimental|Veru-111 18 mg|Veru-111 18mg capsules
11055647|NCT04388826|Placebo Comparator|Placebo|Placebo capsules
11056131|NCT04385199|No Intervention|Control|Standard therapy for COVID-19 disease as defined by institutional protocols
11055648|NCT04388800|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist."
11055649|NCT04388800|Experimental|app-based cognitive behavioral intervention|"App-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.
~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist"
11055650|NCT04388800|No Intervention|Wait-list control group|No intervention will be provided when the experimental group is receiving services, but the access to the app-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
11055651|NCT04388774|Experimental|Ketamine|Total dose administration or 0.5 mg/kg of ketamine
11055652|NCT04388761|Experimental|Intra parenchymal injection|5 subjects will receive AMSCs via direct injection into the kidney parenchyma only
11055653|NCT04388761|Experimental|Intra-arterial infusion|5 subjects will receive AMSCs via intra-arterial infusion only
11055654|NCT04388761|Experimental|Intra parenchymal injection & Intra-arterial infusion|5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion
11055655|NCT04388748|Experimental|SMART-D Intervention Group|Subjects will participate in Stress Management and Resiliency Training for Depression (SMART-D) therapy as well as treatment as usual which consists of any ongoing medication or psychotherapy based treatments that are currently in place.
11055656|NCT04388748|No Intervention|Standard of Care Group|Treatment as usual will consist of any ongoing medication or psychotherapy based treatments that are currently in place.
11055657|NCT04388735||Newly Diagnosed MM 1st Line and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.
~Both patients with or without identified caregivers will complete a one time series of questionnaires.
~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete."
11055658|NCT04388735||MM receiving 1-3 prior lines of therapy and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.
~Both patients with or without identified caregivers will complete a one time series of questionnaires.
~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
11055659|NCT04388735||MM patients receiving ≥ 4 lines of therapy and Cargivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.
~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.
~Both patients with or without identified caregivers will complete a one time series of questionnaires.
~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
11055660|NCT04388709|Experimental|Peginterferon lambda-1a|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
11055661|NCT04388709|No Intervention|Best supportive care|Best supportive care
11055662|NCT04388696|Experimental|Sisterhood 2.0|"Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period.
~Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care."
11055663|NCT04388696|Active Comparator|Job Skills Training|The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.
11055664|NCT04388683|Experimental|Intervention|Will receive study drug treatment.
11055665|NCT04388683|No Intervention|Control|Will receive standard of care.
11055666|NCT04388657||Covid Intensive arm|Patients included in intensive care admission by one of the principal investigators from the 3 selectioned centers.
11055667|NCT04388631||Exposed group|Male patient discharged with COVID-19
11055668|NCT04388631||Control group|Healthy male volunteers without COVID-19
11055669|NCT04388618||covid19 positive patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested positive
11055670|NCT04388618||covid19 negative patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested negative
11055671|NCT04388592|Experimental|Nurse practitioner (NP)-led care arm|The patient randomized to the NP intervention arm will be contacted by the NP to be scheduled for an NP appointment within 4 to 6 weeks from the date of the referral. The NP consultation will include patient history, physical examination, symptomatic management strategies as appropriate (eg: bladder and bowel management strategies, fatigue management, depression, anxiety, spasticity etc), discussion of mental and physical health resources for symptomatic treatment, support, physical and mental health resources to optimize functioning (eg: home care, physical/occupational therapy referral) and quality of life. There will be NP followup, in person or by phone or videoconferencing at 3 months, and 6 months. The NP will be using the electronic medical record offered by Alberta Health Services.
11055716|NCT04388267||Major vascular surgery|Patients who underwent elective or emergent major vascular surgery abdominal aortic surgery (open or endovascular surgery)
11055672|NCT04388592|No Intervention|Usual Care Arm|Those patients randomized to the usual care arm (community neurologist and registered nurses) will be contacted by the NP to be scheduled for an NP appointment in 6 months, so that every participant is given the opportunity to meet with the NP, after their involvement in the study has concluded. During the six-month period, patients randomized to the control group will receive usual care from community neurologists and MS registered nurses or family physicians. The care will be delivered according to standard practices, and follow-up visits will be conducted according to the various neurologists' or family physicians' practices.
11055673|NCT04388553|Experimental|Treatment|lumbar ESP block is performed. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.
11055674|NCT04388553|No Intervention|Control|no regional anaesthesia is performed nor saline is injected into the ESP
11055675|NCT04388540||Jamaica|School aged children 6 - 12 years living in Jamaica
11055676|NCT04388540||Trinidad and Tobago|School aged children 6 - 12 years living in Trinidad and Tobago
11055677|NCT04388540||Belize|School aged children 6 - 12 years living in Belize
11055678|NCT04388540||Barbados|School aged children 6 - 12 years living in Barbados
11055679|NCT04388540||St. Lucia|School aged children 6 - 12 years living in St. Lucia
11055680|NCT04388540||Grenada|School aged children 6 - 12 years living in Grenada
11055681|NCT04388540||St. Vincent & the Grenadines|School aged children 6 - 12 years living in St. Vincent & the Grenadines
11055682|NCT04388540||Antigua|School aged children 6 - 12 years living in Antigua
11055683|NCT04388540||Dominica|School aged children 6 - 12 years living in Dominica
11055684|NCT04388540||St. Kitts and Nevis|School aged children 6 - 12 years living in St. Kitts and Nevis
11055685|NCT04388527|Experimental|Treatment|Penn COVID-19 convalescent plasma
11055686|NCT04388514|Experimental|Blood ozonization|Blood ozonization plus BAT
11055687|NCT04388514|No Intervention|Standard of Care|"BAT only
~To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days."
11055688|NCT04388501|Experimental|Treatment Sequence ABC|Participants will receive JNJ-70033093 capsule once daily (qd) for 5 days (Treatment A) in Period 1 followed by Atorvastatin tablets qd for 5 days (Treatment B) in Period 2 followed by JNJ-70033093 capsules qd and atorvastatin tablets qd for 5 days (Treatment C) in Period 3. Each period is separated by a washout period of 7 days.
11055689|NCT04388501|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
11055690|NCT04388501|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
11055691|NCT04388501|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Period 1 followed by Treatment B in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
11055692|NCT04388501|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Period 1 followed by Treatment C in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
11055693|NCT04388501|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Period 1 followed by Treatment A in Period 2 and Treatment C in Period 3. Each Period is separated by a washout period of 7 days.
11055694|NCT04388488|Experimental|CONNECT TF|Trans-femoral amputees currently using a conventional handmade socket will be fitted with the CONNECT TF adaptable socket system for 6 weeks and their current existing conventional socket for 6 weeks, data collection on both sockets will be performed and outcomes compared.
11055695|NCT04388475|Experimental|All patients|All patients enrolled in this study
11055696|NCT04388462||locked plating with predicted distribution of loc|
11055697|NCT04388462||unlocked plating with predicted distribution of loc|
11055698|NCT04388462||Interlocking nail +/- blocking screws|
11055699|NCT04388423|Experimental|Group S|
11055700|NCT04388423|Experimental|Group C|
11055701|NCT04388410|Experimental|convalescent plasma|Convalescent plasma obtained from volunteers who have recovered from COVID 19. Enclosed with a similar material as the control
11055702|NCT04388410|Placebo Comparator|Normal saline|Normal saline solution in 200 ml plasma bags enclosed with with a similar material as the plasma
11055703|NCT04388397|Experimental|Immediate-access Arteriovenous Grafts|Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
11055704|NCT04388397|Active Comparator|Standard Arteriovenous Grafts|Standard Arteriovenous Grafts as a vascular access for hemodialysis patients
11055705|NCT04388371|Experimental|Prior to subject taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
11055706|NCT04388371|Experimental|subjects taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
11055707|NCT04388358|Other|mixed Chinese herb formula|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
11055708|NCT04388332||Retrospective|20 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
11055709|NCT04388332||Prospective|20 patients who are receiving Tritanium C as standard of care.
11055710|NCT04388319|Experimental|Combination zonisamide and bupropion with e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.
11055711|NCT04388306||Study Group|Thirty-two participants with undergone arthroscopic Rotator Cuff repair
11055712|NCT04388306||Control Group|Thirty-two healthy participants
11056220|NCT04384536|No Intervention|Control group|Control group used thumb spica splint and had rest
11055718|NCT04388241|Experimental|Behavioral Intervention|Children and adolescents with SCD between the ages of 8 and 17 years old (n=20) will be recruited to complete a four-week behavioral intervention designed to reduce pain-related impairment in SCD.
11055719|NCT04388228|Experimental|Extended audit and feedback|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.
~This extended feedback report consists of:
~Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.
~A low cognitive load of the feedback where the results will be presented with the help of graphs.
~Action plans to improve the quality of registration
~A push system to minimize the effort the GP must make to consult the feedback."
11055720|NCT04388228|Active Comparator|Basic feedback|In the past, all GPs received basic feedback on the level of registration in the EHR and this form of feedback will still be provided in the control group. By providing all GPs a basic level of feedback, we do not change the former protocol and all GPs will receive the opportunity to improve their registration performance. Only the way of receiving feedback is more straightforward, the GP needs to login to HealthStat.be.
11055721|NCT04388215|Experimental|Treatment group|"Drug: CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg
~- CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
11055722|NCT04388215|Active Comparator|Comparator group 1|"Drug: CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D013(placebo) 80mg
~- CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D337(placebo) 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
11055723|NCT04388215|Active Comparator|Comparator group 2|"Drug: CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg
~- CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg, orally, 1 tablet once a day for 8 weeks"
11055724|NCT04388202|Experimental|Sertraline|Sertraline 100-200 mg daily for 8 weeks
11055725|NCT04388202|Active Comparator|Escitalopram|Escitalopram 10-20 mg daily for 8 weeks
11055726|NCT04388189|Experimental|Duloxetine|Duloxetine 60 mg daily for 8 weeks
11055727|NCT04388189|Active Comparator|Bupropion|Bupropion 150-450 mg daily for 8 weeks
11055728|NCT04388176|Experimental|C21 followed by placebo|
11055729|NCT04388176|Experimental|Placebo followed by C21|
11055730|NCT04388163|Experimental|Gentian Violet Treatment|A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
11055731|NCT04388137||infants aged 0-3|No intervention.
11055732|NCT04388137||children aged 4-18|No intervention.
11055733|NCT04388124|Placebo Comparator|Placebo|Patient will receive placebo for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
11055734|NCT04388124|Experimental|Bosentan|Patient will receive Bosentan for 56 days: 2 capsules of 62.5 mg per day for 27 days +/-1 day, 2 capsules of 125 mg per day for 27 days +/-1 day.
11055735|NCT04388111|No Intervention|Control Group|Patient receives an intraosseous injection of antibiotics into the tibia as per the standard of care for primary total knee arthroplasty under the study providers.
11055736|NCT04388111|Experimental|Intarosseous Morphine|Patient receives an intraosseous injection of antibiotics + 10mg of morphine into the tibia during their total knee arthroplasty.
11055737|NCT04388098||Asthmatic children|Asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
11055738|NCT04388098||Non-asthmatic children|Non-asthmatic children were clinically examined to assess their dental caries experience and periodontal health condition. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
11055739|NCT04388059||Transection at 2 cm from the pylorus|the effect of transection at 2 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
11055740|NCT04388059||Transection at 5 cm from the pylorus|the effect of transection at 5 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
11055741|NCT04388046|Experimental|skeletal class 2 malocclusion|10 patients treated with type IV Herbst appliance. The appliance was connected directly to the mandible by a bilateral reconstruction bone plates to provide a skeletal anchorage and avoid any mandibular teeth involvement
11055742|NCT04388033|Experimental|Safety Evaluation Group|"Basic treatment phase:
~The patients have surgery followed by concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days).
~Immunotherapy phase:
~Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle. Fusion cells will be suspended in 0.5 mL normal saline and then injected intradermally close to a cervical lymph node. IL-12 will be injected subcutaneously at the same side at dose of 6ug twice for interval of one hour."
11055743|NCT04388020|Experimental|Test Arm|
11055744|NCT04387981|Experimental|[14C]-orvepitant|[14C]-orvepitant administered as 30mg single dose in oral solution
11055745|NCT04387968||agents in contact with the public|patients working with children, policemen, desk office
11055746|NCT04387968||agents with no contact with the public|administrative workers
11055747|NCT04387955|Other|Acrovid|Cohort
11055748|NCT04387942|Experimental|Recombinant Human Interleukin-2|patients were treated with IL-2.
11055749|NCT04387942|No Intervention|Traditional therapy|patients were treated with dipyridamole and/or glucocorticoid，immunosuppressor.
11055750|NCT04387929||IgG negative|No intervantion. Only antibody mesurment from blood sample
11055751|NCT04387929||IgG positive, viral load negative|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
11055752|NCT04387929||IgG positive, viral load positive|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
11055753|NCT04387916|Experimental|KC1036|Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
11056221|NCT04384523|Experimental|OsrHSA 20 mg/kg IV|
11056222|NCT04384523|Experimental|OsrHSA 40 mg/kg IV|
11055754|NCT04387903||Reoperation group|The group of patients who underwent pancreaticduodenectomy for management of periampullary tumors and required surgical reintervention afterwards for management of procedure-related complications as pancreatic fistula, bleeding, abdominal collection, biliary fistula, gastric fistula.
11055755|NCT04387903||No reoperation group|The group of patients who underwent pancreaticoduodenectomy for management of periampullary tumors and did not require surgical reintervention.
11055756|NCT04387890||Serologic Screening|Participants will be screened for IgM and IgG SARS-CoV-2 antibodies at baseline and every 2 weeks. Participants showing symptoms compatible with COVID-19 will undergo nasopharyngeal swab for PCR testing for diagnosis. Participants recovered from COVID-19 will have to have 2 negative and consecutive nasopharyngeal swab PCR tests in order to return to work.
11055757|NCT04387877|Experimental|Graston Group|Graston technique will be applied on the lateral and posterior myofascial chain area tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
11055758|NCT04387877|Sham Comparator|Sham Group|"Sham graston technique will be applied on lateral and posterior myofascial chain area (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.
~(Sham graston technique will be applied to the patient by partially touching the muscle or fascia region via ultrasound gel with the flat part of the Graston tool so as not to provide the activity of the fascia)"
11055759|NCT04387864|Experimental|Whole-body Vibration Exercise Group|"The patients in the WBV exercise group underwent WBV exercise sessions 2 days a week (72 hours in between) for a total of 6 weeks. Each exercise session was performed under the supervision of a physician.
~The patients received support from both hands on the WBV platform and both knees were positioned statically at 40-60 degree flexion (high squat position). All patients stood on the platform with sports socks (without shoes) to avoid the shoes absorbing vibration. Vibration was given by a Power Plate® device where a three-plane oscillation occurs (most vertical, Z axis). In all vibrations, 30 Hz frequency and 2 mm amplitude (low amplitude) were used. The vibration time was set to be 30 seconds in the first two weeks, 45 seconds in the next two weeks and 60 seconds in the last two weeks. The repetition of vibration was increased by 1 repetition every week, starting with 5, and 10 repetitions were given in the last week. A 1-minute rest period was given between each repetition."
11055760|NCT04387864|No Intervention|Home Exercise Group|The home program, which included isometric and isotonic exercises, was followed at home for 6 weeks. Three sets of quadriceps setting as 5 repetitions, 5-second contractions, and three sets of isotonic quadriceps exercise in seating position with weights as 12 repetitions were administered to be performed two days a week. While the patients included in the study group came for TVT exercise two days a week, the patients in the control group performed quadriceps setting exercises also on those days. The patients were invited to the physician follow-up on Wednesday every week for motivation and follow-up. The patients were asked to write their complaints during and after the exercise, if any. In addition, they were asked to note the number of repetitions and sets of their exercises on exercise booklets prepared for the patient.
11055761|NCT04387851||Placebo|Placebo effects are defined as the positive effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive effects.
11055762|NCT04387851||Nocebo|Nocebo effects are defined as the negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have negative effects.
11055763|NCT04387838||Anti-SARS-CoV2 serological status|"At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
~For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60.
~For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped."
11055764|NCT04387825|Experimental|Experimental group|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
11055765|NCT04387825|No Intervention|Control|Evolution and medical therapy effects were observed in the control group.
11055766|NCT04387812|Experimental|Xtrodes home PSG system|Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
11055767|NCT04387799||Negative PCR Covid associated Pneumonia|Patients with pneumonia who test negative to RT-PCR
11055768|NCT04387799||Positive PCR Covid associated Pneumonia|Patients with pneumonia from Covid 19
11055769|NCT04387773|Experimental|GOCOVRI Treatment|Participants will receive GOCOVRI over a total of 7 weeks and do two gait and balance testing visits -- one prior to starting GOCOVRI and one after 5 weeks of taking GOCOVRI. The first gait and balance visit is followed by 7 days of home monitoring with wearable sensors, and there are 7 days of home monitoring prior to the second gait and balance visit.
11055770|NCT04387760|Experimental|Hydroxychloroquine|Hydroxychloroquine is widely used to treat autoimmune diseases, due to its immunomodulatory properties, such as systemic lupus erythematosus and rheumatoid arthritis, with an excellent safety profile. In vitro studies have suggested that their mode of action in COVID-19 disease is blockade of SARS-CoV-2 transport from endosomes to endolysosomes, which appears to be a requirement to release the viral genome.
11055771|NCT04387760|Experimental|Favipiravir|Favipiravir is an antiviral drug that it is a pyrazinecarboxamide derivative with activity against influenza viruses, west nile virus, yellow fever virus, foot and mouth disease virus as well as against flaviviruses (i.e. arenaviruses, bunyaviruses and alphaviruses).
11055772|NCT04387760|Active Comparator|Standard clinical care|Supportive care according to local guidelines
11055773|NCT04387734|Experimental|Ocrevus|
11055774|NCT04387734|Active Comparator|Platform therapies|Platform therapies consist of the following injectable disease modification treatments: IFNb-1a, IFNb-1b, and glatiramer acetate.
11055775|NCT04387721||Trifocal IOL(Finevision IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted First group: FineVision
11055776|NCT04387721||Trifocal toric IOL (Finevision Toric IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted: Second group: FineVisionToric
11055777|NCT04387695|Experimental|SBRT + TACE + Sorafenib|SBRT sequential TACE combined with Sorafenib
11055778|NCT04387695|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
11055779|NCT04387682|Other|OSCC subjects with β-glucan supplement|Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan
11055780|NCT04387682|No Intervention|Healthy donors|healthy donors without pre-surgical administration of whole glucan particle β-glucan
11055781|NCT04387682|No Intervention|OSCC subjects without β-glucan supplement|Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan
11055782|NCT04387656||Observational Cohort (data collection, biospecimen collection)|Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 9 times for adults and up to 6 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
11055783|NCT04387630|Experimental|metformin group|"metformin 850 mg once daily increased within 3 weeks to a maximum dose of 2550 mg on three divided daily doses.
~Neoadjuvant cytotoxic chemotherapy as per MDT (multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization."
11055784|NCT04387630|Placebo Comparator|Placebo group|placebo. Neoadjuvant cytotoxic chemotherapy as per MDT(multi-disciplinary team) decision. Patients scheduled for AC-T (adriamycin, Cyclophosphamide, paclitaxel) or AC (adriamycin, cyclophosphamide) will be eligible to randomization.
11055785|NCT04387617|Experimental|CBD Oil Group|
11055786|NCT04387617|Placebo Comparator|Control Group|
11055787|NCT04387604||non vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
11055788|NCT04387604||vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
11055789|NCT04387591|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
11055790|NCT04387591|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
11055791|NCT04387578|Experimental|Group A singlestrand NiTi arch wires|in which 10 patients (5 males and 5 females) were treated with round singlestrand NiTi arch wires in a sequence of 0.012, 0.014, and 0.016 inch.
11055792|NCT04387578|Experimental|Group B Gummetal arch wires|in which 10patients (6 males and 4 females) were treated with niobium-titanium-tantalum-Zirconium arch wires (Gummetal arch wires) in a sequence of 0.014, 0.016, and 0.018 inch.
11055793|NCT04387578|Experimental|Group C multistrand NiTi arch wires|in which 10 patients (4males and 6females) were treated with multistrand NiTi arch wires in a sequence of 0.016, 0.018, and 0.020 inch.
11055794|NCT04387565||Preeclampsia|The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe.
11055795|NCT04387565||control pregnant group|These participants with normal healthy pregnancies at the third trimester (before birth)
11055796|NCT04387565||control non-pregnant group|A volunteer group of healthy women who visited the gynaecology clinic for routine examinations and women who were admitted for pre-pregnancy tests were invited randomly to this research as a control group.
11055797|NCT04387552|Experimental|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
11055798|NCT04387552|Experimental|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
11055799|NCT04387552|Experimental|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
11055800|NCT04387552|Experimental|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
11055801|NCT04387539|Active Comparator|Non-Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks
11055802|NCT04387539|Active Comparator|Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks
11055803|NCT04387526|Active Comparator|SOF/DCV|"Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.
~This arm included non-cirrhotic treatment-naïve patients"
11055804|NCT04387526|Active Comparator|SOF/DCV/RBV + Cirrhosis|This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
11055805|NCT04387526|Active Comparator|SOF/DCV/RBV + Non-Cirrhosis|This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
11055806|NCT04387500|Experimental|Sintilimab injection combined with Inlyta|"Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.
~Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.
~In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs."
11055807|NCT04387487|Experimental|Video Group|"Video Group
~multimedia video information of 4.5 mins regarding procedure, indication and complications related to spinal anesthesia will be shown to patients in intervention group , patient will be allowed to ask questions."
11055808|NCT04387487|No Intervention|Placebo|patients in control group will be given verbal information regarding procedure, indication and complication, patient will be allowed to ask questions.
11055809|NCT04387474|Experimental|Experimental group|brain-computer interface rehabilitation training and traditional rehabilitation training.
11055810|NCT04387474|Other|Control group|traditional rehabilitation training.
11055811|NCT04387461|Experimental|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.
~Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.
~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years."
11055812|NCT04387448|Experimental|GFB-887 multiple ascending dose (MAD) active|GFB-887 active once-daily dosing
11055813|NCT04387448|Placebo Comparator|GFB-887 MAD placebo|GFB-887 placebo once-daily dosing
11055814|NCT04387422|Experimental|150 mg/dL|Hyperglycemia target of 150 mg/dL
11055815|NCT04387422|Experimental|225 mg/dL|Hyperglycemia target of 225 mg/dL
11055816|NCT04387422|Experimental|300 mg/dL|Hyperglycemia target of 300 mg/dL
11055817|NCT04387409|Active Comparator|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.
~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
11055818|NCT04387409|Placebo Comparator|Placebo|Physiological saline 0.1ml
11055819|NCT04387396|Experimental|Physiotherapy|Exercise intervention will be applied to this arm.
11055820|NCT04387396|No Intervention|Control|No intervention will be made to this arm, only evaluations will be made.
11055821|NCT04387383|Experimental|Acupuncture group|Electro-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
11055822|NCT04387383|Placebo Comparator|sham-acupuncture group|Sham-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
11055823|NCT04387357||Control|Neurologically healthy older adults above the age of 50
11055824|NCT04387357||Experimental|Older adults above the age of 50 with Mild Cognitive Impairment or Dementia
11055825|NCT04387318|Experimental|Multimodal training|"IMT + NMES + Pulmonary Rehabilitation
~IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).
~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).
~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
11055826|NCT04387318|Experimental|IMT + Pulmonary Rehabilitation|"IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).
~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
11055827|NCT04387318|Experimental|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).
~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
11055828|NCT04387318|Placebo Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise.
11055829|NCT04387305|Experimental|Tranexamic acid 15 mg/kg bolus|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 30 minutes followed by a 2 mg/kg/h infusion over 8 hours. This represents 31 mg/kg total dose of TXA.
11055830|NCT04387305|Experimental|Tranexamic acid 30 mg/kg bolus|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 30 minutes followed by a 4 mg/kg/h infusion over 8 hours. This represents 62 mg/kg total dose of TXA.
11055831|NCT04387305|Experimental|Tranexamic acid 45 mg/kg bolus|Subjects will receive a 45 mg/kg bolus of tranexamic acid over 30 minutes followed by a 6 mg/kg/h infusion over 8 hours. This represents 91 mg/kg total dose of TXA. This dosing arm will only open if a dose-effect is determined based on accumulating data.
11055832|NCT04387305|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours
11055833|NCT04387292|Experimental|Ophthalmologic exam|
11055834|NCT04387279||Inflammatory bowel disease|Patients with inflammatory bowel disease who live in COVID-19 hyperemic area
11055835|NCT04387266||Modified reduce-volume target IMRT|Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
11055836|NCT04387240|Experimental|intervention group|this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
11055837|NCT04387240|Placebo Comparator|placibo|this group will receive a placebo of the same shape and picture of the study drug
11055838|NCT04387227|Experimental|Treatment (carboplatin, pembrolizumab)|Patients receive carboplatin IV over 30 minutes on day -2 of cycle 1 only. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11055839|NCT04387214||Veterinary students and researchers|
11056223|NCT04384523|Experimental|OsrHSA 80 mg/kg IV|
11055840|NCT04387201|Experimental|Dulaglutide, then Cyanocobalamin|Dulaglutide is experimental, cyanocobalamin is inactive placebo comparator
11055841|NCT04387201|Experimental|Cyanocobalamin, then Dulaglutide|Cyanocobalamin is inactive placebo comparator, dulaglutide is experimental
11055842|NCT04387175|Experimental|Carriere Motion 3D Class III Appliance|
11055843|NCT04387175|Active Comparator|Facial mask|
11055844|NCT04387162|Experimental|Immediate|Participants will enter treatment after one week baseline
11055845|NCT04387162|Experimental|Delayed|Participants will enter treatment after two week baseline
11055846|NCT04387149||CSA-AKI|Patients that developed cardiac surgery-associated Acute Kidney Injury
11055847|NCT04387149||non CSA-AKI|Patients that did not developed cardiac surgery-associated Acute Kidney Injury
11055848|NCT04387136|Experimental|Sublingual Sufentanil|Participants in this arm will receive the intervention.
11055849|NCT04387136|No Intervention|Control|Participants in this arm will not receive an intervention.
11055850|NCT04387123|Active Comparator|Conventional vaginoscopy|Vaginoscopy without vulvar tightness
11055851|NCT04387123|Active Comparator|Tight vaginoscopy|Vaginoscopy via Darwish sheet
11055852|NCT04387110||Ocrelizumab|Women receiving treatment for multiple sclerosis with ocrelizumab infusion between 2 and 36 weeks postpartum.
11055853|NCT04387097||gradual withdrawal following by drip-infusion of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated. Following by drip-infusion of remifentanil for 30 minutes was administered immediately after tracheal extubation.
11055854|NCT04387097||gradual withdrawal of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated.
11055855|NCT04387084|Experimental|Treatment (STF, PD-1/PD-L1 inhibitor)|Patients undergo STF for 47-48 hours prior to immunotherapy and for 24 hours after immunotherapy with standard of care pembrolizumab given IV over 30 minutes, nivolumab IV over 30 minutes, cemiplimab IV over 30 minutes, avelumab IV over 60 minutes, atezolizumab IV over 60 minutes, or durvalumab IV over 60 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11055856|NCT04387071|Experimental|Treatment (CMP-001, INCAGN01949)|Patients receive CMP-001 SC on day 1 of weeks 1 and 2 and IT on day 1 of weeks 3-6 in the absence of disease progression or unacceptable toxicity. Patients also receive INCAGN01949 IT on day 1 of weeks 3-6 in the absence of disease progression or unacceptable toxicity.
11055857|NCT04387058|Other|patients with cirrhosis and and portal hypertension|All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
11055858|NCT04387045|Experimental|Guilty feelings|Write for 20 minutes about a situation that in the participant's past life has caused feelings of guilt.
11055859|NCT04387045|Placebo Comparator|Neutral feelings|Write for 20 minutes about a situation that in the participant's past life has caused neutral feelings.
11055860|NCT04387032|Experimental|Experimental group|Experimental group (students with hypomobile SIJs)
11055861|NCT04387032|Sham Comparator|Control group|control group (students without hypomobile SIJs)
11055862|NCT04387019||I|30 with uncontrolled type 2 DM patients
11055863|NCT04387019||II|30 controlled type 2 DM patients
11055864|NCT04387019||III|30 healthy subjects as a control group
11055865|NCT04387006|Experimental|Osteopatic Manipulative Treatment (OMT)|
11055866|NCT04387006|Placebo Comparator|Manual Placebo (MP)|
11055867|NCT04386993|Experimental|IMRT|-Five 5-Gy fractions of IMRT will be given to the pelvis with elective simultaneous boost to any suspicious lymph node or residual disease to 30 Gy.
11055868|NCT04386980|Experimental|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume administered once intra-articularly
11055869|NCT04386980|Placebo Comparator|Placebo|5 mL of diluent in normal saline administered once intra-articularly
11055870|NCT04386967|Experimental|Dose expansion|Dose expansion trial comprises of 2 cohorts. In cohort 1, OH2 injection will be administered at 1x10e7CCID50/mL . In cohort 2, OH2 injection will be administered at 1x10e7CCID50/mL in combination with Keytruda injection, an anti-PD-1 antibody, and the first doses of the two anti-tumor agents will be administered on the same day.
11055871|NCT04386941|Active Comparator|Greenlight XPS Vaporization|Greenlight 532nm laser photoselective vaporization of the prostate (PVP) is an appealing treatment modality with hemoglobin as tissue target chromophore and relatively short learning curve. The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser. It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibres required in these situations.
11055872|NCT04386941|Active Comparator|Xpeeda Fibre Laser Vaporesection|Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue. Moreover, hemostasis would be improved by the pulse reshaping technology with a wider pulse width, activated by a dedicated footswitch. Therefore, the Lumenis Pulse™ 100W will make prostate vaporesection procedures more precise, faster and efficient, with excellent hemostasis. Consequently, bleeding is minimal, tissue is easier to remove and patients can have their catheter removed faster.
11055873|NCT04386928||Elderly patients with hematological disease|older than 60 years who received hematopoietic stem cell transplantation (HSCT)
11055874|NCT04386915|Experimental|Single-dose experimental group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2 and Day4. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
11056224|NCT04384523|Experimental|OsrHSA 140 mg/kg IV|
11056225|NCT04384523|Experimental|OsrHSA 200 mg/kg IV|
11055875|NCT04386915|Placebo Comparator|Single-dose control group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
11055876|NCT04386915|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
11055877|NCT04386915|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
11055878|NCT04386915|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
11055879|NCT04386915|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
11055880|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
11055881|NCT04386889|Other|SLE Vasculitis|20 SLE Female patients will subjected to study of the all vasculitic pattern that may occur.
11055882|NCT04386876|Experimental|Lopinavir/ritonavir Test|Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine Ilaç San. ve Tic., Turkey.
11055883|NCT04386876|Active Comparator|Lopinavir/ritonavir Reference|Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH & Co. -Germany
11055884|NCT04386850|Experimental|Treatment|Infected patients with acute respiratory tract infection symptoms (e.g. fever, cough, dyspnea) with no other etiology that fully explains the clinical presentation accompanied by chest computed tomography (CT) scan findings compatible with Covid-19 or with a COVID-19 positive test by the polymerase chain reaction (PCR)
11055885|NCT04386850|Experimental|Prevention|This arm of study includes the health care providers and hospital workers with a negative test for COVID-19 and a close patient relative with a negative test for COVID-19 who lives with the infected patients.
11055886|NCT04386837||Aphasics|Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.
11055887|NCT04386824||Behçet's disease|Male patients who arediagnosed as Behçet's disease according to International Study Group Classification Criteria
11055888|NCT04386811|Experimental|Calcitriol|
11055889|NCT04386811|Placebo Comparator|Placebo|
11055890|NCT04386798|Other|survey application to mothers|In the neonatal intensive care, the information form, postpartum specific anxiety scale, and neonatal intensive care unit parent-father stress scale will be filled in for the mothers who have a baby.
11055891|NCT04386772|Experimental|PVE with coils plus TAGM|PVE with coils proximally plus TAGM distally and subsequent major hepatectomy
11055892|NCT04386772|Active Comparator|PVE with multiple coils|PVE with multiple coils and subsequent major hepatectomy
11055893|NCT04386759||Healthcare workers|"Filling when including a first self-survey concerning the period of the last fifteen days. The following questionnaires will be completed online every week until the end of the study.
~For healthcare worker who have already presented a symptomatic infection at the time of inclusion, only the self-survey inclusion will be completed, it will relate to the period of fifteen days preceding the diagnosis."
11055894|NCT04386746|Experimental|Intravesical Gemcitabine/Docetaxel|
11055895|NCT04386733||Cancelled|all adult patients whose surgery was cancelled on the day of the planned procedure
11055896|NCT04386733||Non-cancelled|all adult patients whose surgery was not cancelled on the day of the planned procedure
11055897|NCT04386707|Experimental|Experimental Vaccine-lot 1|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
11055898|NCT04386707|Experimental|Experimental Vaccine-lot 2|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
11055899|NCT04386707|Experimental|Experimental Vaccine-lot 3|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
11055900|NCT04386707|Active Comparator|Control Vaccine|Wild strain IPV (wIPV）manufactured by Sanofi Pasteur S.A.
11055901|NCT04386694|Experimental|PBMT/sMF|"Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.
~PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT."
11055952|NCT04386343|Active Comparator|167% dose level arm - Phase I|4 healthy volunteer will use 167% dose level for Phase I in the left hand side and use placebo in the right hand side
11055953|NCT04386343|Placebo Comparator|Placebo arm - Phase II|20 Breast cancer patients will use Placebo in the radiation affected area right after radiation
11056769|NCT04380675|Active Comparator|Music during ESWL|Patients listen to music during ESWL
11055902|NCT04386694|Placebo Comparator|Placebo PBMT/sMF|"Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.
~The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator."
11055903|NCT04386681|Experimental|RCBI|Receiving RCBI intervention, including BICS, ICAN, and RF.
11055904|NCT04386681|No Intervention|Treatment as usual- Control group|Not receiving the RCBI intervention
11055905|NCT04386668|Experimental|LIO-C|Participants receive LIO-C writing intervention
11055906|NCT04386668|Placebo Comparator|Neutral writing control|Participants receive neutral writing control intervention
11055907|NCT04386655|Experimental|Telemedicine Group|BICS-T is the intervention that will take place over telemedicine software on the iPad provided to participants
11055908|NCT04386655|Active Comparator|In-Person Group|Participants a part of the in-person BICS group will then come to the NRC for the following BICS sessions. This group is the traditional, in-person, BICS group
11055909|NCT04386642|Experimental|Experiment group|Each ampule contains TXA 250 mg. TXA preparation is 2000 mg dilute in normal saline 50 ml to get the concentration of 40 mg/ml. TXA will be administered 20 mg/kg loading over 20 min before skin incision followed by a maintenance infusion of 0.025 ml/kg/h (1 mg/kg/h) until the end of operation.
11055910|NCT04386642|Placebo Comparator|Control group|Normal saline solution 50 ml is prepared in a clear 50 ml syringe similar to the experiment group.
11055911|NCT04386616|Experimental|MSTT1041A|Participants randomized to this arm will receive MSTT1041A. Study treatment will be given in combination with standard of care.
11055912|NCT04386616|Placebo Comparator|MSTT1041A-matched Placebo|Participants randomized to this arm will receive MSTT1041A-matched placebo. Study treatment will be given in combination with standard of care.
11055913|NCT04386616|Experimental|UTTR1147A|Participants randomized to this arm will receive UTTR1147A. Study treatment will be given in combination with standard of care.
11055914|NCT04386616|Placebo Comparator|UTTR1147A-matched Placebo|Participants randomized to this arm will receive UTTR1147A-matched placebo. Study treatment will be given in combination with standard of care.
11055915|NCT04386603||shoulder-tip pain group|The patients in this group have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
11055916|NCT04386603||non-shoulder-tip pain group|The patients in this group don't have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
11055917|NCT04386590|Sham Comparator|'Sham' manual therapy plus Pulmonary Rehabilitation (PR)|Treadmill walking, upper body exercise machine, light weight training and bicycle. These exercises are supervised. In addition to the standard exercise therapy, all participants will undergo a 20-minute session consisting of discussion with the patient and 11 minutes of detuned ultrasound, which has been used in previous studies to account for time and attention for the patient. The detuned ultrasound procedure is to apply the ultrasound gel and turn the machine on, but set the intensity at zero (0) W/cm2
11055918|NCT04386590|Experimental|Manual therapy plus Pulmonary Rehabilitation (CMT+|Manual therapy is made up of gentle Effleurage and cross-fibre friction massage applied to the muscles of the posterior chest wall. Manual Therapy consists of two separate manipulations (Grade V mobilization). Each manipulation involves the delivery of a high-velocity low amplitude (HVLA) posterior to anterior force directed at the inter-vertebral, costo-vertebral and costo-transverse joints. The first manipulation is delivered at the level of the upper/middle thoracic spine while the second is at the level of the middle/lower thoracic spine. In addition to the MT, the participant will also undergo Pulmonary Rehab as previously described.
11055919|NCT04386577|Active Comparator|Vitamin D + fish oil|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Each capsule contains 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA).
11055920|NCT04386577|Active Comparator|Vitamin D + fish oil placebo|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary supplement: Fish oil placebo
11055921|NCT04386577|Active Comparator|Vitamin D placebo + fish oil|Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Dietary supplement: Vitamin D3 placebo
11055922|NCT04386577|Placebo Comparator|Vitamin D placebo + fish oil placebo|Dietary supplement: Vitamin D3 placebo Dietary supplement: Fish oil placebo
11055923|NCT04386564||Mild COVID-19|Pneumonia without respiratory failure
11055924|NCT04386564||Moderate COVID-19 up to 60 years|Respiratory frequency ≥30/minute, blood oxygen saturation≤93%
11055925|NCT04386564||Moderate COVID-19 over 60 years old and severe COVID-19|Pneumonia with respiratory distress syndrome
11055926|NCT04386538|Experimental|Low Starch Diet (LSD)|Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
11055927|NCT04386538|Active Comparator|Control|Participants will receive dietary counselling based on general recommendations for healthy eating.
11055928|NCT04386525|Experimental|Omega-3|Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly
11055929|NCT04386525|No Intervention|Controle|for comparison with interventional arm
11055930|NCT04386499|Experimental|Resveratrol|A nutraceutical formulation (trade mark Genante) composed of resveratrol, REVIFAST, folic acid, Vitamin D
11055931|NCT04386499|Active Comparator|Folic acid|Folic Acid 400 ug
11055932|NCT04386486|Experimental|bathe group|The patients were divided into two equal groups randomly first group is BATHE anamnesis group.
11055933|NCT04386486|Sham Comparator|standart anamnesis group|The patients were divided into two equal groups randomly second group is standart anamnesis group.
11055934|NCT04386473||Left Bundle Branch Pacing|
11055935|NCT04386473||Right Ventricular Outflow Tract Septal Pacing|
11055954|NCT04386343|Placebo Comparator|50% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 50% of the expected dose level in the radiation affected area right after radiation
11056770|NCT04380675|No Intervention|ESWL without music|Patients don't listen to music during ESWL
11055936|NCT04386447|Experimental|Oxytocin 40 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
11055937|NCT04386447|Experimental|Oxytocin 25 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
11055938|NCT04386447|Other|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:
~Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%
~Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.
~Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted
~Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine
~Prophylaxis for deep vein thrombosis
~Steroids are not routinely recommended but may be considered in selected patients."
11055939|NCT04386434|Experimental|Active for Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
11055940|NCT04386421|Experimental|video group|Group A: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed Appliance Treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions. Participants in this group will also receive the same video graphic educational material through their Whats app once weekly for a total duration of 3 months.
11055941|NCT04386421|Experimental|Plaque disclosing tablet|Group B: Plaque-disclosing tablets will be taken by patients on chair-side showing the location of the biofilm. The patients will be given plaque disclosing tablets to be used once weekly for 3 months to evaluate their oral hygiene at home. They will be given written information in the form of leaflets on importance of cooperation and compliance. Participants in this group will receive a reminder log fill, and tablets that are not used will be asked to return to the investigator by the participants to check the compliance.
11055942|NCT04386421|No Intervention|Control. verbal instructions|Control Group C: Controls will be given only routine verbal OHI and will be briefed on the importance of cooperation and compliance at every orthodontic visit for a period of 3 months study. They will receive a reminder log that they will return at the end of the study to check compliance.
11055943|NCT04386408|Experimental|Combination of plant extracts (BSL_EP027)|Volunteers will dissolve in water a sachet per day with the Combination of plant extracts (BSL_EP027), and maltodextrin.
11055944|NCT04386408|Placebo Comparator|Placebo|Volunteers will dissolve in water a sachet per day with maltodextrin.
11055945|NCT04386395||Immuno Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations:
11055946|NCT04386382|Experimental|ridge splitting flapless technique using interchangeable guide|"Fabrication of interchangeable surgical guide stent:
~Optical scanning of the dental casts was done using Ceramill map 400
~The treatment plan and the surgical stent were designed using Mimics Innovation Suite 19 ™ software
~Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique."
11055947|NCT04386369||Airway Pressure Release Ventilation|Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.
11055948|NCT04386356|No Intervention|Orotracheal intubation with macintosh laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
11055949|NCT04386356|Active Comparator|Orotracheal intubation with Airtraq Video Laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
11055950|NCT04386343|Placebo Comparator|50% dose level arm - Phase I|4 healthy volunteer will use 50% dose level for Phase I in the left hand side and use placebo in the right hand side
11055951|NCT04386343|Placebo Comparator|100% dose level arm - Phase I|4 healthy volunteer will use 100% dose level for Phase I in the left hand side and use placebo in the right hand side
11055955|NCT04386343|Placebo Comparator|100% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 100% of the expected dose level in the radiation affected area right after radiation
11055956|NCT04386343|Placebo Comparator|167% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 167% of the expected dose level in the radiation affected area right after radiation
11055957|NCT04386330|Experimental|Narrative Exposure Therapy|Firefighters will receive distance-delivered NET administered by a paraprofessional.
11055958|NCT04386317|Experimental|terazosin therapy|
11055959|NCT04386304|Experimental|Dose escalation of (+)-epicatechin|Subjects will receive escalating doses of (+)-epicatechin starting at 75 mg/day and progressing to 150 mg/day and 225 mg/day with 2 months treatment duration for each dose. Subjects will continue treatment on the individual's maximum tolerated dose for another 6 months.
11055960|NCT04386291|Active Comparator|Anxiety Reduction Training (A.R.T.)|Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
11055961|NCT04386291|Experimental|ART and Kundalini Yoga|This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
11055962|NCT04386291|Experimental|ART and Meditation|This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.
11055963|NCT04386278|Experimental|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
11055964|NCT04386278|Experimental|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
11055965|NCT04386278|Experimental|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
11055966|NCT04386278|Experimental|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
11055967|NCT04386278|Experimental|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
11055968|NCT04386278|Experimental|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
11055969|NCT04386278|Experimental|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
11055970|NCT04386278|Experimental|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
11055971|NCT04386252|Experimental|Phase 1 Antigen Dose Exploration|AV-COVID-19 consisting of autologous DC loaded with 0.1 mg, 0.33 mg or 1.0 mg SARS-CoV-2 spike protein, with or without GM-CSF
11055972|NCT04386252|Experimental|Phase 2|Separate cohorts of patients who have 0 or >1 risk factor related to poor outcome for COVID-19 infection will receive AV-COVID-19 consisting of optimal antigen and GM-CSF formulation.
11055973|NCT04386239|Experimental|Covid-19|Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
11055974|NCT04386226|Experimental|2 grams Ambrotose LIFE|2 grams daily for 8 weeks
11055975|NCT04386226|Experimental|4 grams Ambrotose LIFE|4 grams daily for 8 weeks
11055976|NCT04386226|Active Comparator|2 grams Advanced Ambrotose|2 grams daily for 8 weeks
11055977|NCT04386226|Active Comparator|4 grams Advanced Ambrotose|4 grams daily for 8 weeks
11055978|NCT04386226|Placebo Comparator|Placebo|4 grams Maltodextrin daily for 8 weeks
11055979|NCT04386213|Experimental|Paclitaxel Drug-coated Balloon|
11055980|NCT04386213|Active Comparator|SeQuent® Please Paclitaxel Drug-coated Balloon|
11055981|NCT04386200|Experimental|WEB GROUP|Traditional approach integrated with web-based technologies.
11055982|NCT04386200|Other|TRADITIONAL GROUP|Traditional educational approach
11055983|NCT04386187|Experimental|Arm 1: Experimental Feeding|Small glutathione-rich meals will be prepared and delivered to participants for 12 weeks.
11055984|NCT04386187|Active Comparator|Arm 2: Education Control|Standard of care medical nutrition education for type 2 diabetes will be provided in the form of electronic handouts and web-based resources.
11055985|NCT04386174|Other|Group A|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
11055986|NCT04386174|Other|Group B|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
11055987|NCT04386161|Experimental|Children with dyslexia|Children, aged between 8 and 11 years, with clinical dyslexia diagnosed by a child and adolescent psychiatrist
11055988|NCT04386148||laparoscopic colorectal surgery|Patients undergoing laparoscopic colorectal surgery with use of Obsidian ASG® during primary anastomosis.
11055989|NCT04386122|Experimental|FABALOFEN 60|Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition
11055990|NCT04386122|Active Comparator|JAPROLOX TABLET|Subjects will receive a single dose of 1 JAPROLOX® TABLETS tablet under fed condition
11055991|NCT04386109||Neonates COVID-19 positive|1. Neonatal COVID-19 in babies (<29 days old) in neonatal units, paediatric intensive care units and other in-patient locations.
11055992|NCT04386109||Neonates born to COVID-19 positive mothers|2. Neonates (<29 days old) born to COVID-19 positive mothers requiring neonatal care
11055993|NCT04386096|Experimental|Mehealth for ADHD software with medication continuity tools|
11055994|NCT04386096|Active Comparator|Mehealth for ADHD software with no medication continuity tools|
11055995|NCT04386083||COVID-19 patients with neurologic manifestations|Patients with confirmed COVID-19 disease who presented with neurological symptoms or new-onset neurological disorders/complications
11055996|NCT04386083||COVID-19 patients without neurologic manifestations|Patients with confirmed COVID-19 disease who did not present with neurological symptoms or new-onset neurological disorders/complications
11055997|NCT04386070|No Intervention|Control (normal practice; neither trial drug)|Treatment without the trial drugs. Patients will be treated as per hospital routine practice without receiving any of the drugs given in the intervention arms.
11056090|NCT04385420|Placebo Comparator|Placebo (SAD)|Placebo once (morning)
11055998|NCT04386070|Experimental|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth every 12 hours. Started on the morning of surgery, given for 10 days or until discharge, whichever occurs first.
11055999|NCT04386070|Experimental|Hydroxychloroquine|Hydroxychloroquine 400mg BD day 1; then 400mg daily day 2-5. Started on the morning of surgery, given until day 5 postoperatively or until discharge, whichever occurs first.
11056000|NCT04386070|Experimental|Lopinavir-Ritonavir and Hydroxychloroquine|Lopinavir 400mg-Ritonavir 100mg by mouth every 12 hours for 10 days or until discharge, whichever occurs first AND Hydroxychloroquine 400mg BD day 1; then 400mg daily day 2-5 or until discharge, whichever occurs first.
11056001|NCT04386057|Experimental|Safety Lead-In Cohort|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis.
~Test the safety of study drugs in combination and define dose levels.
~LY3214996
~HCQ"
11056002|NCT04386057|Experimental|LY3214996 and HCQ Combination|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days. Treatment will be administered on an outpatient basis. Combined dosage per determined Lead-In Cohort
~LY3214996
~HCQ"
11056003|NCT04386057|Experimental|LY3214996-Monotherapy|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits. A treatment cycle will be defined as 28 consecutive days.Treatment will be administered on an outpatient basis.
~-LY3214996"
11056004|NCT04386057|Experimental|Cross Over Arm|"Participants who are enrolled to Arm 2 who experience radiologic disease progression on monotherapy will have the option to cross-over to receive treatment with the combination. Crossover will occur at the treating investigator's discretion following consultation and approval from the overall principal investigator. Combined dosage per determined Lead-In Cohort
~LY3214996
~HCQ"
11056005|NCT04386044||Hospital in-patients|Cross-sectional study of hospital in-patients admitted with COVID-19 n=200
11056006|NCT04386044||Controls (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
11056007|NCT04386044||Cases (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
11056008|NCT04386031||group with antifungal drug|
11056009|NCT04386031||A control group|A control group will be taken ,patients undergoing thyroidectomy or parotidectomy
11056010|NCT04386005|Experimental|Continuous Glucose Monitoring|All participants will have the continuous glucose monitoring device placed.
11056011|NCT04385992|Experimental|All enrolled patients|Enrolled patients following inclusion criteria
11056012|NCT04385979|Active Comparator|Curcumin|%2 Curcumin gel
11056013|NCT04385979|Active Comparator|Nanocurcumin|%1 NanoCurcumin gel
11056014|NCT04385966|Active Comparator|Standard Volume Dose|24 patients will be included in the Standard Volume Dose arm. 20 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
11056015|NCT04385966|Experimental|Low Volume Dose|24 patients will be included in the Low Volume Dose arm. 10 ml Levobupivacaine Hydrochloride 2.5 MG/ML will be administered in the Interscalene brachial plexus block before the arthroscopic shoulder surgery.
11056016|NCT04385953||Trauma patients|Subject experiencing major trauma
11056017|NCT04385953||Obstetric patients|Obstetric patient with postpartum hemorrhage
11056018|NCT04385940|Experimental|High dose vitamin D|Ddrops® products,Vitamin D3, 50,000 IU, Oral
11056019|NCT04385940|Active Comparator|Low dose vitamin D|Vitamin D3 1000IU
11056020|NCT04385927|Experimental|Immediate e-NET Group|Parents of neurodiverse children with PTSI will receive e-NET immediately after the baseline survey
11056021|NCT04385927|Experimental|Wait List Control Group|Parents of neurodiverse children with PTSI will receive e-NET 3 months after the baseline survey
11056022|NCT04385914||COVID positive patients|
11056023|NCT04385914||COVID negative patients|
11056024|NCT04385901|No Intervention|Standard of Care|These are patients who were diagnosed with COVID19 and recovered with usual care prior to implementation of the rehabilitation program developed by MUHC therapists. These patients will be selected in such a way as to match the approximate demographics that exist within the treatment group. These patients received education and supportive care only.
11056025|NCT04385901|Experimental|Rehabilitation Group|These are patients who were diagnosed with COVID19 and participated in the physical and pulmonary rehabilitation program developed at MU Healthcare as described in the study design.
11056026|NCT04385888|Experimental|Low-calorie sweetened beverage restriction|Participants will be instructed to avoid low-calorie sweetened beverages and instead consume unsweetened plain or sparkling water for 12 weeks.
11056027|NCT04385888|No Intervention|Usual consumption/control|Participants will continue low-calorie sweetened beverage consumption, as usual.
11056028|NCT04385875|Experimental|Vaccine group|ATI_extension will keep allocation from AELIX-002 for a separate description of the results.
11056029|NCT04385875|Placebo Comparator|Placebo group|ATI_extension will keep allocation from AELIX-002 for a separate description of the results.
11056030|NCT04385849|Experimental|Experimental Arm|
11056031|NCT04385849|Placebo Comparator|Placebo Arm|
11056032|NCT04385836|Active Comparator|alpha one antitrypsin group|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) add to 2cm of normal saline solution as nebulizer every 12 hours for 5 days
11056033|NCT04385836|Placebo Comparator|placebo group|we will give 8 ml of normal saline as nebulizer every 12 hours for 5 days
11056034|NCT04385810|Experimental|Ophthalmologic exam|
11056035|NCT04385797||Dyads|Community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers
11056036|NCT04385784|Experimental|Sedentary Intervention Group (SIG)|Group of sedentary older adults who perform the intervention and a home-based exercise program.
11056037|NCT04385784|Experimental|Active Intervention Group (AIG)|Group of active older adults who perform the intervention and a home-based exercise program.
11056038|NCT04385784|Active Comparator|Control Group (CG)|Group of sedentary older adults who perform a home-based exercise program.
11069505|NCT04289649|Experimental|K-924 HD|K-924 HD tablet once daily
11056039|NCT04385771|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
11056040|NCT04385771|Other|vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
11056041|NCT04385758|Experimental|Diabetes-REM Program|
11056042|NCT04385745|Experimental|Elastic Stable Intramedullary Nailing|BIN (biodegradable intramedullary nailing) method will be compared with the ESIN (elastic stable intramedullary nailing)
11056043|NCT04385745|Experimental|Biodegradable intramedullary nailing|BIN method will be compared with the ESIN.
11056044|NCT04385732|Experimental|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography.
11056045|NCT04385732|No Intervention|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
11056046|NCT04385719|Experimental|Study A Sequence 1|"Single dose remdesivir 150mg IV on Day 1
~Wash out period Day 2-7
~TDF/3TC 300/300mg tablets OD from Day 8-14 single dose remdesivir 150mg IV on Day 14"
11056047|NCT04385719|Experimental|Study A Sequence 2|"TDF/3TC 300/300mg tablets OD from Day 1-7 single dose remdesivir 150mg IV on Day 7
~Wash out period Day 8-14
~Single dose remdesivir 150mg IV on Day 15"
11056048|NCT04385719|Experimental|Study B|TDF/3TC/ATV/r 300/300/300/100mg tablets OD from Day 1-7 single dose remdesivir 150mg IV infusion on Day 7
11056049|NCT04385693|Experimental|Pulpotomy|Group A: The patient will benefit from an experimental treatment: a Pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
11056050|NCT04385693|Active Comparator|Control Group|Group B: Extracted teeth will serve as controls, and information regarding the need or not of space maintenance, and the impact on the occlusion and eruption of the succedaneous permanent tooth will be noted.
11056051|NCT04385680|Experimental|Chlorhexidine vaginal prep.arm|"Women in labor who will receive vaginal cleaning immediately before cesarean section using 50 ml of chlorhexidine gluconate 0.05% solution and standard abdominal scrub with chlorhexidine gluconate 4%. This concentration is indicated within the British National Formulary for swabbing in obstetrics. A swab soaked in the antiseptic will be used to clean the vagina for 30 seconds prior to CS at the time of urinary catheter insertion by long forceps.
~After the CS procedure, the vagina is always cleaned of excess blood as with a dry swab."
11056052|NCT04385680|No Intervention|No vaginal antiseptic arm|Women in labor who will receive abdominal scrub with chlorhexidine gluconate 4% only. Vaginal preparation is not including antiseptic or using normal saline only.
11056053|NCT04385667|Active Comparator|levonorgestrel intrauterine system (LNG-IUD)|"levonorgestrel intrauterine system (LNG-IUD) applied.
~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.
~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.
~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
11056054|NCT04385667|Active Comparator|Megestrol acetate (MA)|"Megesterol arm will receive 160 mg daily
~Follow up endometrial sampling will be scheduled for all study patients in 3 months manner for at least one year. Specimens will be reviewed by single expert pathologist.
~Patients with persistent atypical hyperplasia in specimens done after 6 months of start of therapy will be considered resistant to therapy and hysterectomy will be done.
~Primary and secondary outcome data will be collected in tables with the other demographic data. All will be processed in tables for statistical analysis."
11056055|NCT04385654|Experimental|Neoadjuvant toripalimab plus axitinib|Toripalimab (240 mg,ivgtt,q3w) combined with Axitinib (5 mg,po,bid) was treated for 6 weeks and underwent surgery within 2-4 weeks
11056056|NCT04385641|Experimental|Dose-finding (Group A)|"In this study, the dose was explored according to the 3+3 mode, in which group A was divided into three dose groups: 1.5*10＾9 group, 2*10＾9 group and 3*10＾9 group. If DLT occurs in one of the first three subjects in each dose group within four weeks after cell infusion, three subjects will continue to be included. If more than 1/6 cases of DLT appear in 6 subjects with 1.5*10＾9 dose, the dose level and/or cell infusion frequency and method will be reduced after discussion between the investigator, the collaborator and DMC. If DLT did not occur in the first 3 subjects within 4 weeks after receiving 1.5*10＾9 cell infusion，another three subjects were enrolled into the group received 2*10＾9 cell infusion. DLT did not occur within 4 weeks after cell infusion, it will increase to 3*10＾9 dose group. That is to say, the first three subjects were included for observation for 4 weeks in the 3*10＾9 dose group, if DLT did not occur, there will be another 3 cases, reaching to 6 subjects."
11056057|NCT04385641|Experimental|Extended research (Group B)|If DLT≤1/6, the dose will not be increased. This dose will also be used as the treatment dose of group B. If DLT is more than 1/6 in the 3*10＾9 dose group, three subjects will be added in 2*10＾9 dose group. If DLT ≤1/6 in 4-week observation, the 2*10＾9 will be the maximum tolerable dose, and will be used as the treatment dose of group B. The subjects in group A were enrolled first, after at least 4 weeks of observation for all subjects, six subjects will be included in group B.
11056058|NCT04385628||Relatives of patients hospitalized in the intensive care unit|Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
11056059|NCT04385615|Experimental|FMD Group|Participants will be requested to follow a Fasting Mimicking Diet, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
11056091|NCT04385420|Experimental|ATR-002 100 mg (MAD)|100 mg ATR-002 once daily (morning) for 7 days
11056092|NCT04385420|Experimental|ATR-002 300 mg (MAD)|300 mg ATR-002 once daily (morning) for 7 days
11056060|NCT04385615|No Intervention|Control Group|Participants will be requested to continue with their habitual eating habits, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
11056061|NCT04385602|Placebo Comparator|CON group|placebo
11056062|NCT04385602|Active Comparator|DT group|Intratracheal dexmedetomidine
11056063|NCT04385589|Active Comparator|Dapagliflozin group|50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.
11056064|NCT04385589|Placebo Comparator|Placebo group|50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.
11056065|NCT04385576|Active Comparator|Aerosol Box|Intubation using the Taiwan model Aerosol Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
11056066|NCT04385576|Active Comparator|Intubation Box|Intubation using the UMMC model Intubation Box to assess the duration of time needed for successful endotracheal intubation of an airway manikin.
11056067|NCT04385563|Experimental|TQ-B211 + docetaxel|Participants will be administered TQ-B211 plus docetaxel once every three weeks(Q3W) in cycles up to cycle 8.
11056068|NCT04385563|Active Comparator|Herceptin®+docetaxel|Participants will be administered Herceptin® plus docetaxel Q3W in cycles up to cycle 8.
11056069|NCT04385550|Experimental|Anlotinib hydrochloride capsule + AK105 injection|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
11056070|NCT04385550|Active Comparator|Standard Second-line Chemotherapy|Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.
11056071|NCT04385537|No Intervention|Control|Participants in this group avoid all nuts for 4-weeks
11056072|NCT04385537|Experimental|PECAN|Participants in this group consume 68 g of pecans/d with no other changes to their habitual diet and avoid all other nuts.
11056073|NCT04385524|Other|Vaccination|"Heplisav B vaccine will be administered to subjects demonstrating completion of two prior series of standard 3-dose Hepatitis B vaccine but still without evidence of seroconversion.
~One dose (20 mcg) of vaccine will be administered intramuscularly followed by Hepatitis B quantitative antibody titer 30-60 days later.
~If still Hepatitis B antibody negative, a second dose (20 mcg) of vaccine will be administered intramuscularly followed by a Hepatitis B quantitative titer 30-60 days later.
~If still no evidence of Hepatitis B immunity (10iU antibody or greater), will be deemed a non-responder to this vaccine"
11056074|NCT04385511|Experimental|supraglottic jet ventilation group|Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
11056075|NCT04385511|No Intervention|mask pressurized ventilation group|"Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will give them 1 min mask pressure respiration, by pressure control V - E technique after muscle relaxant. Check blood gas,stomach-ultrasound after 2 min, then do the tracheal intubation guided by visual laryngoscope."
11056076|NCT04385498|Experimental|BREATHE Intervention|Five session program, with additional sessions provided based on the individual's learning style and needs. Sessions are designed to be 20 to 30 minutes long, to accommodate the needs of the primary health care centers. Sessions will ideally be conducted once per week, but may be conducted as infrequently as once per month.
11056077|NCT04385498|Active Comparator|Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm.
11056078|NCT04385485|Experimental|Active rehabilitation|The patient see an occupational therapist 1-3 days after surgery. A splint is made to immobilise the wrist and work as a extension block for the MCP-joints. This splint has to be worn day and night for 4 weeks. Another splint that immobilise the DIP- and PIP-joints are worn whenever the patient is not exercising. During active exercise the patient follows a strict protocol with both active and passive training and increasing number of repetitions. The rehabilitation is proceeding for 3 months.
11056079|NCT04385485|Active Comparator|Passive rehabilitation|1-3 days after surgery the patient gets a new plaster that immobilise the wrist and work as an extension block for the MCP-joints. The occupational therapist attach rubberbands to the nails of all the fingers and the training is done passively with active hold according to a strict protocol. The training with rubberbands is done during 4 weeks. After that the rehabilitation is active. The rehabilitation is proceeding for 3 months.
11056080|NCT04385459||Patients without coronary artery disease|No prior coronary intervention and no significant stenosis noted during coronary angiography.
11056081|NCT04385459||Patients with coronary artery disease|"Our definition of coronary artery disease is:
~Prior coronary artery bypass grafting or percutaneous coronary intervention
~Significant stenosis or occlusion noted during coronary angiography"
11056082|NCT04385446|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material in the area where the pterygium tissue was removed during the surgery.
11056083|NCT04385446|No Intervention|conjnctival autograft.|Conjunctival autograft was used as a covering material in the area where the pterygium tissue was removed during the surgery.
11056084|NCT04385433|Experimental|EXPERIMENTAL GROUP|RADIOTHERAPY + PRAVASTATIN
11056085|NCT04385433|Placebo Comparator|CONTROL GROUP|RADIOTHERAPY + PLACEBO
11056086|NCT04385420|Experimental|ATR-002 100 mg (SAD)|100 mg ATR-002 once (morning)
11056087|NCT04385420|Experimental|ATR-002 300 mg (SAD)|300 mg ATR-002 once (morning)
11056088|NCT04385420|Experimental|ATR-002 600 mg (SAD)|600 mg ATR-002 once (morning)
11056089|NCT04385420|Experimental|ATR-002 900 mg (SAD)|900 mg ATR-002 once (morning)
11056095|NCT04385407|Active Comparator|SOF + RBV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
11056096|NCT04385407|Active Comparator|SOF + RBV (Experienced)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
11056097|NCT04385407|Active Comparator|SOF + SMV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
11056098|NCT04385407|Active Comparator|SOF + SMV (Expereined)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
11056099|NCT04385381|Experimental|URECA CTO device|investigate the safety and efficacy of the URECA CTO device in facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature.
11056100|NCT04385368|Experimental|Durvalumab + SoC chemotherapy|Intravenous administration of Experimental and Standard of Care Therapy
11056101|NCT04385368|Placebo Comparator|Placebo + SoC chemotherapy|Intravenous administration of Placebo and Standard of Care Therapy
11056102|NCT04385355|Other|Control Group|Control group will receive an intermediate transmucosal abutment with conventional diameter and 3mm height, once the implants are placed.
11056103|NCT04385355|Experimental|Test Group|Test group will receive an intermediate transmucosal abutment with a TCP design, narrower than the conventional one, of 3mm height, once the implants are placed
11056104|NCT04385342|Active Comparator|FSH then HP-hMG|Women will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering
11056105|NCT04385342|Active Comparator|FSH + HP-hMG|Women will receive 150 IU FSH plus 75IU HP-hMG from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm 150 IU HP-HMG till day of triggering
11056106|NCT04385329|Experimental|Experimental group:shock waves extended to gastrocnemius TrP|Focused shock wave therapy was extended from the plantar fascia to the gastrocnemius-soleus trigger points.
11056107|NCT04385329|Active Comparator|Control group: shock waves not extended to gastrocnemius TrP|A standard focused shock wave therapy exclusively targeted at the plantar fascia
11056108|NCT04385316||Gastric Cancer|
11056109|NCT04385316||Colorectal Cancer|
11056110|NCT04385316||Bladder Cancer|
11056111|NCT04385303|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
11056112|NCT04385303|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
11056113|NCT04385290|Experimental|MODULE trial: dose escalation|Phase I (Trial part MODULE): The treatment plan combines increasing doses levels of midostaurin (25/50 mg BID) and gemtuzumab ozogamicin (3 mg/m^2 i.v. max 4.5 mg on day(s) 1, (4, 7)) with 7+3 standard chemotherapy scheme using cytarabine (200 mg/m^2 cont. inf. i.v. on days 1 to 7) and daunorubicin (60 mg/m^2 i.v. on days 1 to 3).
11056114|NCT04385290|Experimental|MAGNOLIA-trial: conventional chemotherapy+GO and midostaurin|Phase II (Trial part MAGNOLIA): midostaurin (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
11056115|NCT04385290|Placebo Comparator|MAGNOLIA-trial: conventional chemotherapy+GO and placebo|Phase II (Trial part MAGNOLIA): placebo is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus GO (recommended phase II dose, RP2D) in CBF AML
11056116|NCT04385290|Experimental|MAGMA-trial: conventional chemotherapy+midostaurin and GO|Phase II (Trial part MAGMA): GO (recommended phase II dose, RP2D) is combined with treatment standard (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v.) plus Midostaurin (recommended phase II dose, RP2D) in FLT3 mutated AML
11056117|NCT04385290|Active Comparator|MAGMA-trial: conventional chemotherapy+midostaurin|Phase II Trial (MAGMA): treatment standard of FLT3 mutated AML (7+3 standard chemotherapy scheme using cytarabine 200 mg/m^2 cont. inf. i.v. and daunorubicin 60 mg/m^2 i.v plus midostaurin). No additional GO is given.
11056118|NCT04385277|Experimental|Treatment (temozolomide, irinotecan, dinutuximab)|Patients receive temozolomide PO or via enteral tube daily and irinotecan IV over 90 minutes daily on days 1-5, dinutuximab IV over 10-20 hours daily on days 2-5, sargramostim SC or IV over 2 hours daily on days 6-12, and isotretinoin PO BID on days 8-21. Treatment repeats every 28 days for 5 cycles (6 cycles for isotretinoin only) in the absence of disease progression or unacceptable toxicity.
11056119|NCT04385264|Placebo Comparator|Placebo|Placebo (Mannitol), oral capsules Day 0: 4 capsules PO OD Days 1-5: 2 capsules PO OD
11056120|NCT04385264|Experimental|Hydroxychloroquine|Hydroxychloroquine 200mg (HCQ, Plaquenil), oral capsules Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
11056121|NCT04385251||SARS-CoV-2 infection/COVID-19|Adults who present for SARS-CoV-2 testing will be consented for this study. Participants who are enrolled will be informed that if they have SARS-CoV-2 infection/COVID-19, they will be followed for 28 days in an observational cohort study, and that if they do not have SARS-CoV-2 infection, there will be no further follow-up.
11056122|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
11056123|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
11056124|NCT04385225|Other|Healthy controls|Age-matched controls with normal hearing or mild sensorineural hearing loss: 40 decibel or less in better hearing ear, and normal vestibular function
11056125|NCT04385225|Other|Moderate Sensorineural hearing loss|Moderate Sensorineural hearing loss: 41-60 decibel in the better hearing ear
11056126|NCT04385225|Other|Severe Sensorineural hearing loss|Severe Sensorineural hearing loss: 61-80 decibel in the better hearing ear
11056127|NCT04385225|Other|Bilateral Vestibulopathy|Bilateral vestibulopathy: half with normal hearing, half with severe to profound sensorineural hearing loss
11056128|NCT04385225|Other|Mild Cognitive Impairment|Mild Cognitive Impairment
11056129|NCT04385225|Other|Alzheimer's Disease|Alzheimer's Disease
11056130|NCT04385199|Experimental|Intervention|Convalescent plasma 200mL transfusion
11056872|NCT04379921|No Intervention|Control|Participants will receive standard care.
11056132|NCT04385186|Experimental|Convalescent plasma+Support treatment selected by the hospital|Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.
11056133|NCT04385186|Active Comparator|Support treatment selected by the hospital|The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.
11056134|NCT04385173|Experimental|B7-H3 CAR-T|Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval. 3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment. Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
11056135|NCT04385147||ERCP|Patients who will have endoscopic retrograde cholangiopancreatography
11056136|NCT04385147||EUS|Patients who will have endoscopic ultrasound
11056137|NCT04385134||General parturient|Observe the enterovirus infection in general parturients and their neonates.
11056138|NCT04385134||Puerpera with fever|Observe the enterovirus infection in puerpera with fever and their neonates.
11056139|NCT04385134||Febrile newborns|Observe the enterovirus infection in neonates
11056140|NCT04385108|Experimental|hospitalized patients|"very well-defined population of COVID-19 patients with the following outcomes:
~Patients with severe disease requiring on admission ICU management for ARDS,
~Non-severe hospitalized patients with secondary clinical worsening requiring ICU management,
~Non-severe hospitalized patients without clinical worsening requiring ICU management."
11056141|NCT04385108|Experimental|healthcare workers|mildly symptomatic patients among healthcare workers attending outpatient dedicated clinics will be recruited
11056142|NCT04385095|Active Comparator|SNG001|inhalation using the I-neb device.
11056143|NCT04385095|Placebo Comparator|Placebo|inhalation using the I-neb device.
11056144|NCT04385082|Placebo Comparator|Placebo|Smoked Cannabis (~0% THC)
11056145|NCT04385082|Experimental|Low strength cannabis|Smoked Cannabis (~4% THC)
11056146|NCT04385082|Experimental|Higher strength cannabis|Smoked Cannabis (~10% THC)
11056147|NCT04385056|Experimental|Low Dose MSCTC-0010|Participants will receive low-dose cell administration
11056148|NCT04385056|Experimental|Medium Dose MSCTC-0010|Participants will receive medium-dose cell administration
11056149|NCT04385056|Experimental|High Dose MSCTC-0010|Participants will receive high-dose cell administration
11056150|NCT04385043|Experimental|plasma-hyperimmune|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy
11056151|NCT04385043|Active Comparator|standard therapy|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy
11056152|NCT04385030|Active Comparator|ETCC Active associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
11056153|NCT04385030|Sham Comparator|ETCC simulated associated with Mirror Therapy (TE)|The study will consist of 12 sessions, being carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
11056154|NCT04385017|Other|DNA from monocytes|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
11056155|NCT04384991|Experimental|HU007 Eye drop|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.
~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
11056156|NCT04384991|Active Comparator|Restasis Eye drop 0.05% (Cyclosporine)|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.
~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
11056157|NCT04384978|Active Comparator|Control Group|Control Group: Group 2 users will play solitary games (word puzzles) and activities but will have no interaction with Ryan.
11056158|NCT04384978|Experimental|Active Group|Active Group: Group 1 users will play games with and administered by Ryan, 2-3 times a week and 30-minutes per day.
11056159|NCT04384965|Experimental|Accelerated iTBS|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
11056160|NCT04384952|Experimental|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeated reading with feedback from the parent and time control.
11056161|NCT04384952|Active Comparator|Dyslexic's Holliday Workbook.|Use of a special Dys holiday book, no parent-guided training.
11056162|NCT04384939|Experimental|Double-J ureteral stent|Pediatric patient with an uropathy or kidney graft need the insertion of Double-J ureteral stent in a routine care
11056163|NCT04384926||Cohort 1|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery completed during the COVID-19 pandemic
11056164|NCT04384926||Cohort 2|Adult patients (aged ≥18 years), planned for curative cancer surgery, that have surgery delayed or cancelled during the COVID-19 pandemic
11056226|NCT04384510||Patients with placenta accreta spectrum (PAS)|This cohort presents patients who were suspected or diagnosed either antenatal or intrapartum with placenta accreta spectrum
11070447|NCT04283175|Other|Hemiparetic subjects|
11056165|NCT04384913||MA (mechanical alignment)|Patients in group MA (mechanical alignment) will be operated according to mechanical implantation technique. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation.
11056166|NCT04384913||KA (kinematic alignment)|Patients in group KA (kinematic alignment) will be operated according to kinematic implantation technique. The kinematic cutting blocks will be designed to resurface the femoral and tibial bones to restore each patient´s pre-arthritic anatomy and Joint line. Based on a available CT dat the prearthritic anatomy is reconstructed by compensating bone defects and restoring the physiological cartilage height of 1,7mm. Femoral Flexion is evaluated by the anterior Cortex of the distal femur, tibia slope is defined to 3° due to ACL (Anterior Cruciate Ligament) loss, but cab be adapted during surgery.
11056167|NCT04384900|Experimental|Accelerated prone position|Prone position ventilation initiated as soon as possible following intubation. The patients are maintained in a prone position for 12-16 hrs daily for 5 days, unless one of the following criteria are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption. Following the five day intervention period, prone position ventilation will be continued according to the intervention in the control group
11056168|NCT04384900|Active Comparator|Standard prone position|Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) < 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
11056169|NCT04384874|Active Comparator|Silbernagel combined concentric-eccentric program|A graduated rehabilitation program using exercises with concentric and eccentric contractions and progressing to plyometric training. The exercises are performed daily with progression guided by pain symptoms. There is no specificity in prescribed exercise loading.
11056170|NCT04384874|Experimental|SSC6|A multi-stage rehabilitation program with focus on strength and reactive strength targets, as well as running gait re-training. These exercises will be initially carried out 3 days per week for the first 6 weeks with specific load targets prescribed.
11056171|NCT04384861|Experimental|ACTIVE|The ACTIVE arm of the project received the Mayo Clinic SMART training (1 two-hour in-person workshop) and access to the Mayo Clinic's SMART eLearning Support study modules (4 x 45 minute modules in weeks 1-4; 20 x 10 minute modules weeks 5-24)
11056172|NCT04384861|No Intervention|CONTROL|The CONTROL did not receive any interventions.
11056173|NCT04384848||Chronic myeloid leukemia (CML) patients|CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy
11056174|NCT04384835||Mild to moderate asthma|low or medium dose of inhaled steroids according to GINA guidelines
11056175|NCT04384835||Severe asthma|criteria described by the ATS / ERS guidelines (for the recruitment of severe patients)
11056176|NCT04384822|Experimental|Tai Chi Group|Subjects will participate in a tai chi program conducted in small groups (10 subjects per group) delivered by qualified instructors, who have experience in teaching tai chi to older adults. The tai chi intervention will be prescribed as a 3-month program with two 1-hour sessions weekly. Tai chi forms will be taught for 2 months followed by 1 month of consolidation. The 24-form simplified Yang-style tai chi will be adopted, as it is the most popular form of tai chi and older adults can manage to learn this simplified form of tai chi within 2-3 months. The instructors will introduce the safety issues, proper training principles, and skills to the subjects in their first class to minimize any avoidable adverse events due to improper skill/practice. The appropriate intensity will be individually determined for each subject by the attending instructors to achieve the training principle of progressive adaptation regarding the exercise intensity.
11056177|NCT04384822|Active Comparator|CBT-I Group|Subjects will participate in a conventional CBT-I program conducted in small groups (10 subjects per group) delivered by trained personnel. The CBT-I will be prescribed as a 3-month program with two 1-hour sessions weekly. The CBT-I components will be delivered for 2 months, which is consistent with the duration of the majority of CBT-I treatments, followed by 1 month of consolidation.
11056178|NCT04384809|Experimental|Leukocyte rich platelet rich plasma injection|Patients will be injected with leukocyte rich platelet rich plasma in their common extensor tendon
11056179|NCT04384809|Experimental|Percutaneous tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
11056180|NCT04384783||GH group|GH group: Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
11056181|NCT04384783||NGH group|NGH (non-GH) group: Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
11056182|NCT04384770||Group I (CT-SBRT)|Patients undergo 5 fractions of CT-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
11056183|NCT04384770||Group II (MRI-SBRT)|Patients undergo 5 fractions of MRI-guided SBRT over 14 days in the absence of disease progression or unacceptable toxicity.
11056184|NCT04384757|Active Comparator|Open distal gastrectomy|An incision of 15~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth II method was used for gastric reconstruction for most cases
11056227|NCT04384497|Experimental|Convalescent plasma treatment|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 7 CP infusions. CP will be given as a slow infusion over 1 hour. Patients will be monitored for adverse events, especially allergic reactions.
11056284|NCT04384068||Chinese RA patients|Chinese RA patients who used tocilizumab in real world clinical practice
11056285|NCT04384055||Covid-19 Positive Patients|This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx
11070448|NCT04283175|Other|Healthy subjects|
11056185|NCT04384757|Experimental|Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.
~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.
~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.
~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.
~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.
~As a general rule, Billroth II method was used for gastric reconstruction for most cases"
11056186|NCT04384744||GH-POR|Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
11056187|NCT04384744||NGH-POR|Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
11056188|NCT04384744||NGH-NOR|Participants with normal ovarian reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
11056189|NCT04384731|Experimental|Surfactant arm|patient receiving the surfactant
11056190|NCT04384731|No Intervention|Control arm|patient not receiving the surfactant
11056191|NCT04384718||Medea Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at IRCCS Medea
11056192|NCT04384718||Asur Group|Group of children with Developmental Dyslexia treated with Tachidino protocol at Asur Marche
11056193|NCT04384718||Waiting list Group|Group of children with Developmental Dyslexia on a waiting list for treatment with Tachidino protocol at IRCCS Medea or Asur Marche
11056194|NCT04384705||caregivers|caregivers
11056195|NCT04384692|Experimental|Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)|See detailed description.
11056196|NCT04384679|Experimental|Hydrophilic polymer and potassium ferrate powder|Hydrophilic polymer with potassium ferrate powder is applied to the surgical wound with pressure until hemostasis is achieved
11056197|NCT04384679|No Intervention|Direct pressure with sterile gauze|Direct pressure with sterile gauze is applied to the surgical wound until hemostasis is achieved
11056198|NCT04384666|Experimental|LY03003|LY03003 28 mg
11056199|NCT04384666|Active Comparator|Neupro 4Mg/24Hr Transdermal Patch|Neupro 4 mg / 24 Hr. Transdermal Patch
11056200|NCT04384653|Experimental|Treatment A|Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
11056201|NCT04384653|Experimental|Treatment B|IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
11056202|NCT04384640||Patients seated after Intra-Tympanic injection|
11056203|NCT04384627|Active Comparator|Pre-IC GTV|The gross tumor volume (GTV) is delineated according to the pretreatment tumor extension
11056204|NCT04384627|Experimental|Post-IC GTV|The gross tumor volume (GTV) is delineated according to the post-IC tumor extension
11056205|NCT04384614||COVID (+)|Patients COVID19(+) confirmed by PCR
11056206|NCT04384614||COVID (-)|Patients COVID19 (-) who had been in contact with COVID-19 (+) confirmed by PCR
11056207|NCT04384601|Experimental|SOX Chemotherapy|"Three preoperative and three postoperative cycles of SOX chemotherapy
~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)
~Repeated every 21st day"
11056208|NCT04384601|Active Comparator|FLOT Chemotherapy|"Four preoperative and four postoperative cycles of FLOT chemotherapy
~A cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous
~Repeated every 15th day"
11056209|NCT04384588|Experimental|Cancer patients with COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
11056210|NCT04384588|Experimental|Cancer patients with COVID 19 infection and risk factors|All patients will be treated with 1 or more convalescent plasma units
11056211|NCT04384588|Experimental|Non-Cancer patients COVID 19 infection and severity criteria|All patients will be treated with 1 or more convalescent plasma units
11056212|NCT04384588|Experimental|Non-cancer patients COVID 19 (+) and risk factors|All patients will be treated with 1 or more convalescent plasma units
11056213|NCT04384562|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 20 mg methylphenidate 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
11056214|NCT04384562|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 4 mg reboxetine 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
11056215|NCT04384562|Experimental|Cholinergic receptor agonist|Participants in the cholinergic receptor agonist group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a gum with 2 mg of nicotine.
11056216|NCT04384562|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
11056217|NCT04384549|Experimental|BCG Arm|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
11056218|NCT04384549|Placebo Comparator|PLACEBO Arm|One intradermal placebo injection.
11056219|NCT04384536|Experimental|Neural therapy group|Neural therapy group underwent local anesthetics injections by the same physician. Local injections, segmental injections and injection of trigger points of the forearm are done. The patients are evaluated at the beginning of the study and after 4 weeks of follow-up. Pre and post-treatment visual analog scale and Duruöz Hand Index scores are obtained.
11056228|NCT04384484|Experimental|Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Part 1 consists of a non-randomized safety run-in period evaluating the study drug for the first 20 participants.
~Participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 every 3 weeks (Q3W) for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles."
11056229|NCT04384484|Experimental|Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)|Randomized participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 every 3 weeks (Q3W) for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles.
11056230|NCT04384484|Active Comparator|Part 2: Standard Immunochemotherapy (R-GemOx)|Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2 every 2 weeks (Q2W) for up to 8 cycles.
11056231|NCT04384471||People living with Type 1 Diabetes|People from all ages living with type 1 diabetes in the Province of Quebec
11056232|NCT04384458|Active Comparator|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with with 20 milligrams twice on day of active zinc for 45 consecutive days
11056233|NCT04384458|Active Comparator|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
11056234|NCT04384445|Experimental|Zofin Plus Standard Care|Participants in this group will receive standard of care plus Zofin on day 0, day 4 and day 8.
11056235|NCT04384445|Placebo Comparator|Placebo Plus Standard Care|Participants in this group will receive standard of care plus placebo (Saline) on day 0, day 4 and day 8.
11056236|NCT04384432|Experimental|Routine Physical Therapy with Thoracic mobility exercise|Combination of Routine Physical Therapy with Thoracic mobility exercise.
11056237|NCT04384432|Active Comparator|Routine Physical Therapy|Routine Physical Therapy exercise
11056238|NCT04384393|Experimental|ThisCART19 cells injections|In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.
11056239|NCT04384380|Experimental|HCQ in adult Patients with COVID-19|The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
11056240|NCT04384380|No Intervention|standard of care treatment (SOC)|The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
11056241|NCT04384367|Experimental|Rizatriptan 10mg+ Naproxen 550mg|Rizatriptan 10mg+ Naproxen 550mg
11056242|NCT04384367|Active Comparator|Maxalt 10mg|Rizatriptan10mg
11056243|NCT04384367|Active Comparator|Flanax 550mg|Naproxen 550mg
11056244|NCT04384367|Placebo Comparator|Placebo|Placebo
11056245|NCT04384341|Experimental|Haemophilic patients|Blood sampling Bone Densitometry (BMD)
11056246|NCT04384341|Other|Healthy volunteers|Bone Densitometry (BMD)
11056247|NCT04384328|Experimental|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
11056248|NCT04384328|No Intervention|Standard Care|Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.
11056249|NCT04384315||EVRF|Patients that have undergone Endovenous Radio Frequency® (EVRF®) from F Care Systems (Belgian) for the treatment of primary great and short saphenous vein reflux.
11056250|NCT04384302|Experimental|Visual training|"Pre-specidied visual training methods that use: the Marsden ball, tables that uses green-red visual stimuli, physical reation in response to the visual stimuli that uses the flippers or the preselected distances.
~One set of exercises per week was prepared.
~Each visual training will last for 15 minutes and should be performed by the participant in their home (using the telemedicine devices to control the conduction of each exercise) 3 times a week."
11056251|NCT04384289|No Intervention|''Standard Care''|''Standard Care'' group were given standard care services.
11056252|NCT04384289|Experimental|"Transitional Care Model"|"Transitional Care Model group were given care based on the Transitional Care Model until the post discharge 9th week starting from date of hospitalization."
11056253|NCT04384276|Experimental|Prospective Weigh Easy|"Patients enrolled onto this arm of the study will use the Weigh Easy system for weight tracking in the first three months of life. Weights will be measured in home using the Weigh Easy scale and transmitted to the study team via the Weigh Easy eClipboard message. A notification scheme will be activated for weights found to have plateaued or decreased to ensure that the infant's standard of care nutritionist and provider are able to follow up and recommend additional interventions to counteract the weight change.
~After three months, families will complete a satisfaction survey to determine if the Weigh Easy system was preferable or if there are any improvements that could be made.
~All other aspects of the patients' care will follow the standard of care for cleft and craniofacial diagnoses and will be guided by the nutritionists specializing in cleft and craniofacial care."
11056254|NCT04384276|Other|Retrospective Control Arm|Patients enrolled onto the control arm will have retrospectively presented to the Cleft and Craniofacial Clinic from January 1, 2016 to December 31, 2018 as infants. These patients were treated with the standard of care for cleft and craniofacial diagnoses and were followed by the nutritionists specializing in cleft and craniofacial care.
11056278|NCT04384107|Experimental|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.
11056279|NCT04384094||Test subjects|Test subjects according to the inclusion / exclusion criterias.
11056280|NCT04384081|Experimental|Dose group 1|
11056281|NCT04384081|Experimental|Dose group 2|
11056255|NCT04384263|Experimental|Tai Chi group|"During the 12-week Tai Chi intervention, participants in the Tai Chi group will attend supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 50 minutes/session for 12 weeks. The participants will also practice Tai Chi at home between sessions using print out material that will be given to them at the end of each supervised Tai Chi session.
~Participants in the Tai Chi group will be instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions and home Tai Chi exercise, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
11056256|NCT04384263|No Intervention|control|"Participants in the control group will perform only their regular habitual daily activities throughout the 12 weeks of intervention period.
~Participants in the control group will be instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
11056257|NCT04384237|Experimental|Er,Cr:YSGG laser-aided CSF|Experimental: Er, Cr: YSGG laser-aided Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment of the orthodontic treatment by inserting the laser tip at an angle of 10-15º to the radicular surface
11056258|NCT04384237|Active Comparator|Conventional CSF|Fiberotomy comparator: this arm is going to receive a blade conventional Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment by inserting a surgical blade into the gingival sulcus at an angle like that in the laser-aided CSF.
11056259|NCT04384224|Placebo Comparator|sham acupuncture + placebo tablet group|sham acupuncture point + placebo tablet
11056260|NCT04384224|Experimental|true acupuncture + placebo tablet group|true acupuncture point + placebo tablet
11056261|NCT04384224|Experimental|true acupuncture + antihistamine group|true acupuncture point + Dexchlorpheniramine (4 mg)
11056262|NCT04384224|Sham Comparator|sham acupuncture + antihistamine group|sham acupuncture point + Dexchlorpheniramine (4 mg)
11056263|NCT04384211||Radiologists|A computer search of CT scans (2010.01.01-2018.09.30) was performed in Wan Fang Hospital. These CT images were retrospectively reviewed by an experienced radiologist who classified and marked with annotations of vertebral fractures by the Genant's semiquantitative method.
11056264|NCT04384211||Smart Bone|The same CT images were separately reviewed and processed by the artificial intelligence system (Smart Bone) by Quanta for compression fractures. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
11056265|NCT04384198|Experimental|Sonolysis group|Cerebral hemisphere with sonolysis during MitraClip implantation.
11056266|NCT04384198|No Intervention|Control group|Cerebral hemisphere without sonolysis during MitraClip implantation.
11056267|NCT04384185|Experimental|Group A: Exercise therapy|Group A: will perform an exercise protocol to improve the stability of the spine muscle of low-back
11056268|NCT04384185|Experimental|Group B. Manual therapy and exercises|Group B: Will be treated with manual therapy in the diaphragm muscle and the same protocol of therapeutic exercise applied in group A
11056269|NCT04384172|Experimental|Tibial e-stim followed by genital e-stim|Tibial e-stim followed by genital e-stim
11056270|NCT04384172|Experimental|Genital e-stim followed by tibial e-stim|Genital e-stim followed by tibial e-stim
11056271|NCT04384146|Experimental|Quad Shot Radiation|In this trial, patients with centrally located lung tumors will be treated with up to 3 cycles of Quad Shot Radiation. Radiation treatment will be given within 1 week of administration of chemotherapy. Quad Shot radiation will involve: 3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break. The first group of patients will be treated with 2 cycles of quad shot radiation, followed by a 3-month observation period post-RT to allow a complete evaluation of acute toxicity. The next group of patients will be treated with either 1 cycle or 3 cycles of quad shot radiation. The minimum accrual is 4 patients with an expected accrual of 16 patients. Twenty additional patients will be recruited to an expansion cohort.
11056272|NCT04384133|Other|COPD group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. To assess symptom control in patients with COPD, a dyspnea scale of mMRC will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All participants will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD.
11056273|NCT04384133|Other|Healthy control group with a history of smoking|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
11056274|NCT04384133|Other|Healthy control group with no smoking history|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
11056275|NCT04384120|Experimental|Rotator Cuff Rehabilitation Using BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation using blood flow restriction cuffs.
~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy using blood flow restriction cuffs.
~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy using blood flow restriction cuffs."
11056276|NCT04384120|Active Comparator|Rotator Cuff Rehabilitation Without BFR|"Patients with rotator cuff tears who plan for either nonoperative treatment with physical therapy or operative treatment with arthroscopic rotator cuff repair (RCR) surgery will be randomized to undergo rehabilitation without using blood flow restriction cuffs.
~Patients who elect for nonoperative treatment of their rotator cuff tear will undergo traditional therapy without using blood flow restriction cuffs.
~Patients who elect for RCR will undergo preoperative and postoperative traditional therapy without using blood flow restriction cuffs."
11056277|NCT04384107|Experimental|V114|Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.
11056282|NCT04384081|Experimental|Dose group 3|
11056283|NCT04384081|Placebo Comparator|Placebo group|
11071159|NCT04278131|Experimental|Cohort 3|BS01 Cohort 3 dose
11056286|NCT04384055||Covid-19 Negative Patients|This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx.
11056287|NCT04384042||Malaysian COVID-19 Cohort (Cases)|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
11056288|NCT04384042||Healthy Volunteers (Controls)|A cohort of age and sex-matched healthy volunteers will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
11056289|NCT04384016|Experimental|Evaluating the Safety of Skyvaricella Inj.|"The main target:
~• Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection"
11056290|NCT04384016|Experimental|Evaluating the Immunogenicity of Skyvaricella Inj.|"Secondary target
~• Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
11056291|NCT04384003|Active Comparator|Shear Wave Ultrasound Elastography|Shear Wave Ultrasound Elastography (SWUE, AplioTM 300 Platinum, Toshiba Medical System Corp, Japan, 6I) to examine the morphology and mechanical properties (μ = ρVs2, μ is the shear modulus of the tissue, ρ is the density of muscle (1000 kg m-3), Young's modulus )
11056292|NCT04384003|Active Comparator|The 3-D Motion Analysis|
11056293|NCT04384003|Active Comparator|EMG acquisition system|
11056294|NCT04384003|Active Comparator|Foot intrinsic muscle assessment and training device|"Schematic diagram of the novel modified foot intrinsic muscle (FIM) assessment and training device, which consists of one controller unit (signal generators, amplifier and A/D converter; signal generators provide noise-enhanced vibration to facilitate the muscle activation), 2 voice coil motor & server, 2 optical rulers, 2 rail scale, and 7 load cells.
~The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing and kicking."
11056295|NCT04383990|Active Comparator|Early Glargine|To take insulin Glargine at 6-7 pm
11056296|NCT04383990|Active Comparator|Late Glargine|To take insulin Glargine at 10-12 pm
11056297|NCT04383977|Experimental|Apatinib-Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
11056298|NCT04383977|Active Comparator|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
11056299|NCT04383964|Experimental|Transport distraction osteogenesis|"Locally made and designed submerged monodirectional in the vertical (Y) axis distractor was used.
~A transport disc is created at the remaining stump of the RCU with an L shaped osteotomy.
~The prepared disc is to be wide enough to fit the upper portion of the distrcator.
~The submerged distractor will be placed in a position to guide the transport disc moving up and backwards toward the glenoid fossa.
~The length of the distractor is determined according to the amount of distraction planned to reach the glenoid fossa."
11056300|NCT04383951|Active Comparator|Ketogenic diet|For participants randomized to the ketogenic diet arm, a consultation with the providers of medically supervised weight loss clinic of Indiana University Health will be arranged. Subjects will be educated on the concepts of ketosis, symptoms associated with it, and dietary manipulation to achieve ketosis. Participants in this arm will use the suggested recipes in combination with strict carbohydrate monitoring though checking for urine ketone bodies. These recipes were gathered and vetted by the dietitian at the medically supervised weight loss clinic. We anticipate that this approach will allow for more calorie intake and easier carbohydrate restriction. The follow up visits will be determined by the providers of the medically supervised weight loss clinic based on the symptoms reported and subject's compliance with carbohydrate restriction.
11056301|NCT04383951|Sham Comparator|Standard of Care|For participants randomized to this arm, a consultation with the providers of medically supervised weight loss clinic will be arranged. The discussion will focus on portion control using a balanced diet. A follow up visit will be at 16 weeks. This is the extent of interventions received for participants in this arm.
11056302|NCT04383938|Experimental|Safety Lead In|Patients with advanced solid tumors. Up to 3 dose levels evaluated.
11056303|NCT04383938|Experimental|Expansion 1|Patients with advanced gastric cancer.
11056304|NCT04383938|Experimental|Expansion 2|Patients with advanced urothelial/bladder cancer.
11056305|NCT04383938|Experimental|Expansion 3|Patients with advanced NSCLC.
11056306|NCT04383925|Experimental|BCG-Japan|Infants randomized to receive BCG-Japan at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Japan (Tokyo BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination.
11056307|NCT04383925|Active Comparator|BCG-Russia|Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
11056308|NCT04383912|Experimental|onabotulinum toxin A group (brow)|"Product name: Onabotulinum toxin A (Botox A, Allergan), 50 unit vials Product code: 93094EC
~Description: The side randomized to treatment will receive an injection of 20 units of onabotulinum toxin A as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
11056309|NCT04383912|Placebo Comparator|placebo group (brow)|"Product name: normal saline
~Description: The side randomized to placebo will receive an injection of normal saline as the final step of a direct brow lift surgery. The surgeon will visually divide the surgical incision in half, and divide the volume of the injection evenly between the two sides. This will be a one time administration."
11056310|NCT04383899||Case patient|Patients from the cohort with severe coronavirus infection necessitating intensive care (artificial ventilation) with ulterior recovery or fatal outcome.
11056311|NCT04383899||Control patient|All patients from the cohort with non-severe coronavirus infection, who were not admitted to hospital or who were admitted to hospital but without the need for intensive care, and who recovered.
11056312|NCT04383886||Emergency department staff|
11071308|NCT04277104|Sham Comparator|At risk sham|No stimulation
11056313|NCT04383873|Experimental|Intervention|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
11056314|NCT04383873|Active Comparator|Control|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
11056315|NCT04383860|Experimental|5-0 suture|5-0 suture administration during surgery
11056316|NCT04383860|Active Comparator|4-0 suture|4-0 suture administration during surgery
11056317|NCT04383847|Experimental|Main study|There is only 1 arm because this is a feasibility and acceptability pilot.
11056318|NCT04383821|Experimental|Double-Trunk Mask|The oxygen delivery system is the DTM
11056319|NCT04383821|Active Comparator|Non-Rebreather Mask|The oxygen delivery system is the NRM
11056320|NCT04383808|Experimental|Arm-1|20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
11056321|NCT04383808|Experimental|Arm-2|20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical. These subjects wont receive an additional injection of radiopharmaceutical.
11056322|NCT04383795||Graves' disease patients|First diagnosed Graves' disease patients volunteered for stool collection
11056323|NCT04383782|Active Comparator|Expectancy Challenge|The expectancy challenge intervention will involve two brief videotaped testimonials in which former smokers discuss their experiences with smoking-related health conditions. Participants will be encouraged to reflect back on the content of each video once per week leading up to the follow-up assessment.
11056324|NCT04383782|Experimental|Expectancy Challenge + Behavioral Activation|In addition to the expectancy challenge intervention (see Expectancy Challenge condition), participants in the Expectancy Challenge + Behavioral Activation group will also receive a novel behavioral activation intervention. Participants will be presented with brief psychoeducation about behavioral activation, several examples of possible functions of cigarette smoking, and several suggestions of behavioral strategies. All participants will receive the same information, but they will be encouraged to apply the information to their personal circumstances and to consider additional examples of rewarding activities they may engage in over the next four weeks. Participants will also be encouraged to engage in at least one behavioral activation activity each week leading up to the follow-up assessment.
11056325|NCT04383782|Placebo Comparator|Neutral Reading|The control group will receive neutral reading materials related to the components and structure of a cigarette. The content will be strictly curated so as to avoid inadvertently encouraging or discouraging smoking among participants.
11056326|NCT04383769||5,000 participants:|"2,500 are PLHIV receiving standard care in the hospital and 2,500 are PLHIV receiving care in DSD-ART model
~Inclusion criteria:
~Thai citizenship
~Age ≥ 18
~HIV positive
~Received ART for at least 6 months at a participating hospital (Except for After hour ART clinic model that will allow participants who receive ART less than 6 months into service)
~One of the following:
~Accept DSD-ART, OR
~Already receiving DSD-ART, OR
~Decline DSD-ART and will continue standard ART service at the hospital."
11056327|NCT04383756|Experimental|Donor Blood|Between 2-4 units of donor leukoreduced whole blood (each unit will contain up to 350mL) transfused as needed in Liver transplantation participants
11056328|NCT04383756|Active Comparator|Banked Blood|Standard of Care - Up to 350mL Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets) transfused as needed in Liver transplantation participants
11056329|NCT04383743|Experimental|Treatment (pembrolizumab, aMVAC)|Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.
11056330|NCT04383730||Usual practice of intravenous sedation|The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
11056331|NCT04383730||Usual practice of inhaled sedation|The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
11056332|NCT04383717|Active Comparator|Proposed treatment group|Levamisole and isoprinosine
11056333|NCT04383717|Active Comparator|Control group|hydroxychloroquine and azithromycin
11056334|NCT04383704|Experimental|calorie-restricted modified MIND diet|This arm received instruction in modifying the content of their diet to meet MIND pattern guidelines.
11056335|NCT04383704|Active Comparator|calorie-restricted standard control diet|They instructed to calorie-restricted diet alone.
11056336|NCT04383691|Experimental|Lurasidone|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
11056337|NCT04383691|Placebo Comparator|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
11056338|NCT04383678||COVID-19 positive patients|
11056339|NCT04383665|Sham Comparator|STN DBS off|
11056340|NCT04383665|Experimental|STN DBS 10Hz|
11056341|NCT04383665|Active Comparator|STN DBS 130Hz|
11056342|NCT04383652||Adult cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)
~Age 16 years or older
~Have provided informed consent
~Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
11056343|NCT04383652||Paediatric cohort|"Diagnosed with SARS-CoV-2 infection (COVID-19; by a registered diagnostic facility)
~Age less than 16 years
~Parent or caregiver has provided informed consent Blood samples and clinical data related to COVID19 diagnosis, symptoms, and outcomes will be collected."
11056344|NCT04383639|Active Comparator|1|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
11056345|NCT04383639|Experimental|2|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
11071587|NCT04275310|Experimental|Microeconomic intervention|
11056346|NCT04383639|Experimental|3|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
11056347|NCT04383613|Experimental|PRONE POSITIONING|Patients in this arm will be instructed to lie on their stomach while they are in bed for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome.
11056348|NCT04383613|No Intervention|STANDARD OF CARE|Patients in this arm are not specifically instructed to lie on their stomach while they are in bed.
11056349|NCT04383600|No Intervention|Conventional side|Canine retraction was commenced without micro-osteoperforations.
11056350|NCT04383600|Experimental|Mops side|Canine retraction was commenced with micro-osteoperforations.
11056351|NCT04383587|Other|Serologic Arm|Enrolled participants will have COVID19 IgG antibody testing performed.
11056352|NCT04383574|Experimental|Experimental Vaccine-low dosage|low dosage inactivated SARS-CoV-2 vaccine
11056353|NCT04383574|Experimental|Experimental Vaccine-medium dosage|medium dosage inactivated SARS-CoV-2 vaccine
11056354|NCT04383574|Experimental|Experimental Vaccine-high dosage|high dosage inactivated SARS-CoV-2 vaccine
11056355|NCT04383574|Placebo Comparator|Placebo|No active ingredient in the placebo
11056356|NCT04383561|Active Comparator|stage 3 periodontitis|GCF and serum samples were collected before and after treatment from periodontitis patients.
11056357|NCT04383561|Placebo Comparator|Periodontally healthy controls|GCF and serum samples were collected from periodontally healthy controls at baseline for once.
11056358|NCT04383548|Experimental|Hyper immunoglobulins have anti-Corona VS2 immunoglobulin|safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients
11056359|NCT04383535|Experimental|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma, in addition to standard care.
11056360|NCT04383535|Placebo Comparator|Placebo|Single infusion of saline solution, in addition to standard care.
11056361|NCT04383509|Experimental|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
11056362|NCT04383509|Active Comparator|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
11056363|NCT04383496|Experimental|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
11056364|NCT04383483||CoVID patients admitted to ICU|Patients admitted to the intensive care unit with the diagnosis of COVID
11056365|NCT04383470||General population, during COVID pandemic|General population during COVID-19 pandemic. Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
11056366|NCT04383470||General population, 6 months after COVID pandemic|General population, 6 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
11056367|NCT04383470||General population, 12 months after COVID pandemic|General population, 12 months after COVID pandemic Adults, adolescents, and children aged 6 years or older. People working in health-care, police, fire-, and military-service vs others. People with physical illness vs others. People with mental illness vs others. Different continents, countries, and regions.
11056368|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
11056369|NCT04383431|Experimental|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
11056370|NCT04383431|Experimental|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
11056371|NCT04383418|Experimental|High dose group|In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.
11056372|NCT04383418|Experimental|Low dose group|In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.
11056373|NCT04383418|Placebo Comparator|Placebo group|In the placebo group，36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
11056374|NCT04383405|Experimental|Sequential Preparotory Approach|
11056375|NCT04383405|Active Comparator|Conventional|
11056376|NCT04383392|Experimental|Rate adaptive pacing|Turn on Rate adaptive pacing
11056377|NCT04383392|Active Comparator|No Rate adaptive pacing|Turn off Rate adaptive pacing
11056378|NCT04383379|Experimental|Intervention group|6 NICUs in the intervention group . The participating units of the intervention group determine the improvement items (one or more) in each quarter from the list of best practices of breast feeding quality improvement of Jiangsu Province, and report the improvement plan to the supervision unit, and recommend the application of PDSA (plan-do-study-act) for the implementation of quality improvement loop. Report the implementation of quality improvement to the supervision unit on a quarterly basis.
11056379|NCT04383379|No Intervention|control group|Continue current practices
11056380|NCT04383366||Patients with keratoconus|
11056436|NCT04382989||Mothers of moderate and late preterm infants|(gestational age 32 - 36 weeks)
11056381|NCT04383353||Cancer arm|Participants with new diagnosis of cancer, from whom a blood sample and contemporaneous tissue samples will be collected.
11056382|NCT04383353||Benign disease arm|Participants with benign diseases corresponding to the tumor types in the cancer arm, from whom a blood sample and contemporaneous tissue samples will be collected.
11056383|NCT04383353||Non-tumor arm (Healthy)|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
11056384|NCT04383340|Experimental|Mother-Infant Transaction Program|Four sessions were delivered to the mothers one-on-one based on a manualized protocol while the infants were still in the neonatal intensive care units. These coaching sessions included psychological care for the mother and topics on recognizing premature infant's characteristics, understanding and recognizing signs of infant stress and infant's engagement and disengagement cues, principles of graded stimulation, and how to optimize interactions and avoid over-stimulating the infant.
11056385|NCT04383340|Active Comparator|Treatment as usual|For this group, infants and mothers received standard hospital care following the initial baseline assessment; these mothers were invited to ask questions about recommended ways to take care of their infants, but no specific knowledge or skills targeted by the adapted MITP program were taught
11056386|NCT04383327|Experimental|ParentCorps-Professional Development (PD)|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs
~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
11056387|NCT04383327|Experimental|ParentCorps-Professional Development (PD) + T-Wellness|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs
~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
11056388|NCT04383327|No Intervention|Control|"n = 6 Schools in Kampala, Uganda (Urban) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs
~+ n = 6 Schools in Hoima, Uganda (Rural) - 90 Teachers, 6 PTAs, 330 Parent-Child Pairs"
11056389|NCT04383314|Experimental|Exercise Program Group|Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
11056390|NCT04383301|Active Comparator|Intra corneal ring segment|Intra corneal ring segment implantation for moderate keratoconus patients
11056391|NCT04383301|Active Comparator|Corneal Wavefront-guided TPRK and ACXL|Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months
11056392|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Poor response|"If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.
~BEFORE SURGERY TREATMENT:
~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)
~AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)
~All the product are used as commercial formulation
~Other Names:
~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
11056393|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Good response|"If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.
~BEFORE SURGERY TREATMENT:
~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
~AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)
~All the product are used as commercial formulation
~Other Names:
~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
11056394|NCT04383288||No overexpression of ABCB1 / P-glycoprotein|"If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.
~BEFORE SURGERY TREATMENT:
~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
~AFTER SURGERY TREATMENT:
~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
~Total length 34 weeks
~All the product are used as commercial formulation
~Other Names:
~methotrexate cisplatin doxorubicine"
11056395|NCT04383275|Experimental|IRIS-A|
11056396|NCT04383275|Experimental|IRIS-B|
11056397|NCT04383262|Experimental|Lexiva|Lexiva/fosamprenavir at the FDA approved and manufacturers recommended dose (1,400mg twice daily) for 12 weeks
11056398|NCT04383262|Placebo Comparator|Placebo|standard of care
11056399|NCT04383249||Pathology result|Pathology result of the hernia sac
11056400|NCT04383236|Experimental|ChocBalls|(L. acidophilus containing lozenges, PharmaCare Europe Ltd; West Sussex, RH10 9NQ, UK)
11056401|NCT04383236|Active Comparator|Oracure oral gel (15 gm, Amun pharmaceutical company, Egypt)|"Each 100 g contains:
~Lidocaine HCI 2.0g. Cetylpyridinium chloride 0.1 g."
11056402|NCT04383223|No Intervention|YLH Historical Control Group|"Participants in this group will have the following phases:
~Screening
~Single visit assessment"
11056403|NCT04383223|Experimental|YLH iTransition Intervention Group|"Participants in this group will have the following phases:
~Screening
~Baseline Visit
~Follow-Up visits at 6, 12 and 18 month
~Interview visits for selected YLH around 3 and 9 month"
11056404|NCT04383223|Experimental|Provider Group|"Participants in this group will have the following phases:
~Screening
~Baseline Visit
~Follow-Up visits at 6, 12 and 18 month
~Interview visits for selected YLH around 3, 9 and 15 month"
11056405|NCT04383223|Experimental|Transition Champion Group|"Participants in this group will have the following phases:
~Screening
~Baseline Visit and Follow-Up visits at 6, 12 and 18 month
~Interview visits for selected YLH around 3, 9 and 15 month"
11056406|NCT04383210|Experimental|Cohort 1|"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.
~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
11056437|NCT04382989||Mothers of term infants|(gestational age ≥ 37 weeks)
11056474|NCT04382755|Placebo Comparator|Group B (control)|Standard of Care (SoC) + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
11056475|NCT04382742|Experimental|Exercise|
11056407|NCT04383210|Experimental|Cohort 2|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.
~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
11056408|NCT04383210|Experimental|Cohort 3|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.
~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
11056409|NCT04383197|Experimental|Semaglutide treatment|3 months of therapeutic semaglutide treatment
11056410|NCT04383197|Experimental|Semaglutide and Endurance exercise|12 weeks of endurance exercise concomitant to semaglutide treatment
11056411|NCT04383197|Experimental|Endurance exercise|12 weeks of endurance exercise
11056412|NCT04383184||TRACHEAL FORMING GROUP|Left pulmonary artery transplantation and slide tracheoplasty
11056413|NCT04383184||NON-TRACHEAL FORMING GROUP|only Left pulmonary artery transplantation
11056414|NCT04383158|Active Comparator|PRGF extraction sockets (Test)|Immediately after dental extraction, the socket will be filled with Plasma Rich in Growth Factors (ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16))
11056415|NCT04383158|No Intervention|Unassisted extraction sockets (Control)|Dental extraction sockets to be left to heal spontaneously unassisted.
11056416|NCT04383132|Experimental|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
11056417|NCT04383132|Sham Comparator|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
11056418|NCT04383119|Experimental|Arm A|Trabectedin at the dose of 1.5 mg/m2-1.3 mg/m2 with a top-dose of 2.6 total mg per cycle (according the clinical practice in pretreated patients and in all our ISG studies) will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles
11056419|NCT04383119|Active Comparator|Arm B|Gemcitabine 800-1000 mg/m2 will be administered via a central venous catheter on days 1,8 every 21 days
11056420|NCT04383093||Combination Therapy|"Patients initial assessment included age, waist circumference, blood pressure, clinical laboratory parameters, digital rectal examination. LUTS were evaluated with total IPSS, focusing also on storage, voiding IPSS sub-scores, and IPSS QoL, and Overactive Bladder questionnaire (OAB-q), while ED with IIEF-515. Each patient underwent uroﬂowmetry and postvoid residual volume (PVR) was measured with abdominal ultrasound immediately after voiding. All patients reporting any intake of therapies for LUTS or ED underwent a 4 weeks treatment-free washout period.
~All subjects were treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. The medications were self-administered every day at the same time, before the night rest, without any limitations or variations of sexual activity timing or food intake. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5"
11056421|NCT04383080|Experimental|Low-level laser therapy|Low-level laser irradiation on specific acupuncture points
11056422|NCT04383080|Active Comparator|Acupuncture therapy|Dry needle inserting specific acupuncture points
11056423|NCT04383080|Placebo Comparator|Placebo low level laser therapy|Low-level laser irradiation on specific acupuncture points for placebo control
11056424|NCT04383067|Experimental|Tumor Infiltrating Lymphocytes (TIL)|
11056425|NCT04383054|Experimental|Long PA intervention group|The long PA intervention will be a MI (motivational interview) exploring the participant's knowledge and concerns about PA. An MI involves a semi-structured discussion between an investigator and the participant. The MI initially explores the participant's knowledge of the benefits of PA and their concerns about PA. The MI will then explore the participant's confidence in increasing their PAL, help the participant come up with a plan to increase their PAL and finally the participant will be signposted to further support and local opportunities for PA. The investigator will use a Moving Medicine 'more minutes' conversation tool of a chronic health condition that the patient has to facilitate every MI. Where possible the investigator will discuss the chronic condition that most relates to the participant's current admission to hospital. For patients with no health conditions the primary prevention section will be used.
11056426|NCT04383054|Active Comparator|Short PA intervention group|The short PA intervention will involve a short (1 min) discussion between an investigator and a participant. A Moving Medicine 'one minute' intervention appropriate to the participant's health conditions will be used to guide every short intervention. The short intervention will firstly involve the investigator asking whether the participant knew that doing PA was beneficial for their health. The investigator would then explain to be more PA they could try to build more PA into their daily routine and that this was often enough to meet the current PA recommendations. The investigator will also offer the participant a patient information sheet about PA.
11056427|NCT04383041||Patients with Type 2 Diabetes|Patients with Metformin containing prescription drugs will be eligible for participation and consecutively invited to study participation in their pharmacy.
11056428|NCT04383028|Experimental|MELD-assisted SEEG trajectory planning|Following routine clinical planning, the MELD algorithm will be run on the enrolled patient's scans. Up to 3 extra electrodes may be used to target lesion clusters identified by the algorithm such that the investigators will record from the top 3 clusters, with the aim of improving the rate of identification of a focal seizure onset zone in patients undergoing SEEG.
11056429|NCT04383015|Other|Carbohydrate (CHO)-only|Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
11056430|NCT04383015|Other|50 Percent Basal Rate Reduction (BRR)|A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
11056431|NCT04383015|Other|Combo|The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
11056432|NCT04383002|No Intervention|Standard of Care (control)|Patients will receive standard of care therapy
11056433|NCT04383002|Experimental|Inhaled Nitric Oxide|
11056434|NCT04382989||Mothers of extremely preterm infants|(gestational age < 28 weeks)
11056435|NCT04382989||Mothers of very preterm infants|(gestational age 28 - 31 weeks)
11056438|NCT04382963|Other|High Risk- intense coaching|"age ≥ 55 with MORE than three of the following risk factors:
~History of TIA/Stroke
~History of Coronary Artery disease
~History of Hypertension and/or current elevated blood pressure
~History of Diabetes
~Current smoker
~BMI ≥30"
11056439|NCT04382963|Other|High Risk - standard care|"age ≥ 55 with MORE than three of the following risk factors:
~History of TIA/Stroke
~History of Coronary Artery disease
~History of Hypertension and/or current elevated blood pressure
~History of Diabetes
~Current smoker
~BMI ≥30"
11056440|NCT04382963|Other|Low risk - control|"age ≥ 55 with LESS than three of the following risk factors:
~History of TIA/Stroke
~History of Coronary Artery disease
~History of Hypertension and/or current elevated blood pressure
~History of Diabetes
~Current smoker
~BMI ≥30"
11056441|NCT04382950|Experimental|Experimental: rbACE2 group plus Aerosolized Isotretinoin|rbACE2 0.4 mg/kg IV BID for 7 days (unblinded) plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
11056442|NCT04382950|No Intervention|No Intervention: Control group|Standard of care; no placebo
11056443|NCT04382937|Experimental|P1101 + Ribavirin|P1101 400 µg SC Q2W
11056444|NCT04382937|Active Comparator|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W
11056445|NCT04382924|Experimental|Treatment Arm A|NP-120 (Ifenprodil) 20 mg TID + Standard of Care
11056446|NCT04382924|No Intervention|Control Arm|Standard of Care only
11056447|NCT04382924|Experimental|Treatment Arm B|NP-120 (Ifenprodil) 40 mg TID + Standard of Care
11056448|NCT04382911|Experimental|18F-fluoroestradiol PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
11056449|NCT04382898|Experimental|Part 1 (mCRPC) - dose titration|W_pro1 monotherapy
11056450|NCT04382898|Experimental|Part 2 Arm 1 (mCRPC) - expansion cohort|W_pro1 monotherapy
11056451|NCT04382898|Experimental|Part 2 Arm 2 (LPC) - expansion cohort|W_pro1 in combination with cemiplimab and goserelin acetate
11056452|NCT04382898|Experimental|Part 2 Arm 3 (LPC) - expansion cohort|W_pro1 in combination with goserelin acetate
11056453|NCT04382885|Experimental|Cohort 1 (10-17 years)|"10 to 12 years: 0.75 mg/day cariprazine oral solution
~13 to 17 years: 1.5 mg/day cariprazine oral solution"
11056454|NCT04382885|Experimental|Cohort 2 (10-17 years)|"10 to 12 years: 1.5 mg/day cariprazine oral solution
~13 to 17 years: 3.0 mg/day cariprazine oral solution"
11056455|NCT04382885|Experimental|Cohort 3 (5-9 years)|0.5 mg/day cariprazine oral solution
11056456|NCT04382885|Experimental|Cohort 4 (5-9 years)|1.5 mg/day cariprazine oral solution
11056457|NCT04382859|Active Comparator|TAP block with liposomal bupivacaine|Active comparator
11056458|NCT04382859|Other|TAP block with 0.25% bupivacaine|Standard comparator
11056459|NCT04382846|Experimental|Nitazoxanide and Azithromycin|Nitazoxanide and Azithromycin as combined treatment.
11056460|NCT04382846|Experimental|Ivermectin and chloroquine|Ivermectin and chloroquine for treatment of COVID-19
11056461|NCT04382846|Experimental|Ivermectin and Nitazoxanide|Ivermectin and Nitazoxanide for covid treatment.
11056462|NCT04382846|Experimental|Nitazoxanide, Ivermectin and Azithromycin|Nitazoxanide, Ivermectin and Azithromycin for COVID treatment.
11056463|NCT04382833|Experimental|HOT APPLICATION GROUP|Thermoforming, one of the dry hot application methods, was performed on the sacral (S1-S4) vertebrae region of pregnant women in the hot application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). Thermoforming was applied by wrapping it with a towel to protect pregnant women from the direct effect of its hot surface. The mean water temperature used in thermoforming was 50C. The water temperature was measured using a liquid thermometer. When 50°C water was subjected to hot application, the surface temperature reached around 40°C. The hot application was carried out continuously for 20 min.20 The body temperature of the pregnant women was evaluated before the application.
11056464|NCT04382833|Experimental|MASSAGE GROUP|Massage using effleurage and friction techniques was applied to the 4-5 cm right and left lateral parts of the midline on the sacral (S1-S4) vertebrae region of pregnant women in the massage application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). The massage application was carried out continuously for only 10 min because it was thought to cause irritation to the area where it was practiced.
11056465|NCT04382833|No Intervention|CONTROL GROUP|
11056466|NCT04382820||Families of rare chronically ill children|Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf due to a rare pediatric surgical disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
11056467|NCT04382820||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-21 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
11056468|NCT04382807||Subjective, chronic tinnitus|Tinnitus patients who received internet-based psycho-educational counseling
11056469|NCT04382794||DMT2 COVID19 positive patients treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
11056470|NCT04382794||DMT2 COVID19 positive patients not treated with Sitagliptin|The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
11056471|NCT04382781||COVID-19 infection|Consecutive patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who showed clinical and analytical data suggestive of macrophage activation syndrome during admission until March 30, 2020 .
11056472|NCT04382768|Experimental|Luarprofen|Inhaled Hypertonic ibuprofen 50 mg tid
11056473|NCT04382755|Active Comparator|Group A (active)|Standard of Care (SoC) + subcutaneous Zilucoplan® + prophylactic antibiotics until 14 days after last Zilucoplan®
11056479|NCT04382703|Experimental|Intervention|Given the associated questionnaire which has the embedded self-affirmation exercise.
11056480|NCT04382703|Active Comparator|Control|Given the associated questionnaire without the embedded self-affirmation exercise.
11056481|NCT04382690||India|People residing in India
11056482|NCT04382690||United Kingdom|People residing in the United Kingdom
11056483|NCT04382690||China|People residing in China
11056484|NCT04382690||Australia|People residing in Australia
11056485|NCT04382690||South Africa|People residing in South Africa
11056486|NCT04382690||Indonesia|People residing in Indonesia
11056487|NCT04382690||Saudi Arabia|People residing in Saudi Arabia
11056488|NCT04382677|Experimental|Promoting First Relationships|The PFR program designed for birth families being reunited after foster care placement consists of a manualized 12-session intervention delivered in the home by trained providers.
11056489|NCT04382677|Other|Resource & Referral|The service consists of a needs assessment conducted by phone, followed by a personalized resource packet and referrals, and 3 monthly check-in phone calls.
11056490|NCT04382664|Experimental|UV1 vaccination + nivolumab and ipilimumab|UV1 vaccination + nivolumab and ipilimumab
11056491|NCT04382664|Active Comparator|Nivolumab and ipilimumab|nivolumab and ipilimumab
11056492|NCT04382651|Experimental|MAS825 + SoC|Single dose of MAS825 by i.v. infusion, in addition to Standard of Care (Soc)
11056493|NCT04382651|Placebo Comparator|Matching placebo + SoC|Single dose of Matching Placebo by i.v. infusion, in addition to Standard of Care (Soc)
11056494|NCT04382638|Experimental|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
11056495|NCT04382638|Active Comparator|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
11056496|NCT04382625|Experimental|Hydroxychloroquine (HCQ)|Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
11056497|NCT04382625|No Intervention|Usual Care|The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.
11056498|NCT04382612|Other|HARPOON MVRS|Subjects who were treated with the HARPOON MVRS.
11056499|NCT04382599|Experimental|Added sugar warning message|"Message displayed on warning labels is: WARNING: High in added sugar."
11056500|NCT04382599|Experimental|Weight gain warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to weight gain."
11056501|NCT04382599|Experimental|Type 2 diabetes warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to type 2 diabetes."
11056502|NCT04382599|Experimental|Heart damage warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to heart damage."
11056503|NCT04382599|Active Comparator|Neutral message|"Message displayed on control label is: Please refrain from littering."
11056504|NCT04382586|Experimental|Cohort 1: Zanubrutinib + Supportive Care|Participants not requiring mechanical ventilation (Cohort 1) will receive zanubrutinib plus supportive care
11056505|NCT04382586|Active Comparator|Cohort 1: Placebo + Supportive Care|Participants not requiring mechanical ventilation (Cohort 1) will receive placebo plus supportive care alone
11056506|NCT04382586|Experimental|Cohort 2: Zanubrutinib+Supportive Care|Participants who have been on mechanical ventilation for ≤ 24 hours (Cohort 2) will receive zanubrutinib plus supportive care alone for respiratory distress due to COVID-19 infection for up to 28 days
11056507|NCT04382573||CDK13|CDK13 intragenic pathogenic variant
11056508|NCT04382560|Experimental|Intervention group|The intervention group will receive a Deep Breathing Training and a Compassion Intervention. Deep Breathing Training and Compassion Intervention will be administered once, on two consecutive days, and will last for 30 minutes.
11056509|NCT04382560|No Intervention|Wait-list control group|The waiting list group will receive the intervention at the end of the study.
11056510|NCT04382547|Experimental|mesenchymal stem cells|Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
11056511|NCT04382547|Active Comparator|control|Patients with Covid-19 associated pneumonia receiving standard treatment
11056512|NCT04382534||Rehabilitation guidance group|1 to 2 times of rehabilitation instruction according to the rehabilitation instruction program, either online or in person.According to the rehabilitation instruction, the patient performed self-rehabilitation exercises in the isolation point.
11056513|NCT04382534||Systematic rehabilitation treatment|According to the systematic rehabilitation treatment program, the rehabilitation therapist entered the home for one-to-one rehabilitation treatment, once a day, for a total of 10 days.
11056514|NCT04382521|Experimental|Text Message Intervention (TMI)|Participants in the TMI condition will receive daily text messages through an adaptive algorithm plus separate twice-weekly tailored messages focused on a specific health goal.
11056515|NCT04382521|Other|Wait-list Control Group (WLC)|Waitlist Control group participants will begin to receive the full 12-week Text Message Intervention (with all components, e.g., phone check-ins) after completing follow-up assessments at Weeks 12 and 24. Participants in this group will receive no text messages or other study-specific interventions during the first 24 weeks of the study.
11056517|NCT04382443|Experimental|Oral Colchicine +BMS implantation|This group will receive after BMS and Colchicine, at the time of PCI, 0,5 mg twice a day during the first three months after stent implantation
11056518|NCT04382443|No Intervention|Second generation Drug eluting stent (DES)|"This group will receive DES at the moment of randomization and will be treated as standard of care.
~All second generation DES should be approved by ANMAT for clinical use."
11056519|NCT04382430|Experimental|US Guided Axillary venous access|Physician/ provider will perform 2 unassisted & 10 solo Ultrasound (US) guided venous access and pocket creation cardiac device implant. First 2 device implant will be done to educate physicians about ultrasound guided venous access. Subsequent subject will be randomized to 2:1 in ultrasound vs. conventional technique.
11056520|NCT04382430|Active Comparator|Conventional technique|Physician/ provider will perform 5 cardiac device implant using conventional technique for venous access and pocket creation.
11056521|NCT04382417||Covid-19|Patients with verified or highly suggestive Covid-19 diagnosis and Intensive Care treatment.
11056522|NCT04382404|Experimental|Sofosbuvir-Velpatasvir|Sofosbuvir-Velpatasvir
11056523|NCT04382391|Experimental|gammaCore Sapphire® (nVNS) plus standard of care|Subjects will be administered study treatment with the nVNS device 3 times per day (prophylaxis) and also as needed for acute respiratory symptoms.
11056524|NCT04382391|Active Comparator|standard of care alone|Will receive standard of care therapies to treat CoViD-19 infection and symptoms
11056525|NCT04382378|No Intervention|control group|Group that will receive a standard care from physiotherapy staff not involved in delivering the intervention whenever feasible.
11056526|NCT04382378|Experimental|50 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 50 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
11056527|NCT04382378|Experimental|100 electrically evoked contractions|Group that will receive a standard care from physiotherapy staff plus neuromuscular electrical stimulation with the following parameters: pulsed current; freqeuncy 50Hz; pulse witdh 400 us, current intensity that get level 4/5 of evoked contractions proposed by Segers et al; on/off time and duration of therapy that allow 100 ellectrically evoked contractions with surface electrodes positioned on the quadriceps femoris.
11056528|NCT04382365|Other|Internet-Based Insomnia Intervention|"2 weeks of online sleep diaries. Participants will also wear an Actiwatch at night, which records measurements of movements of a limb, providing an estimation of sleep duration, sleep pattern and disturbed sleep.
~9 week interveition period, subjects complete the internet based CBT-I program, consisting of six Cores (Getting Ready, Sleep Scheduling, Sleep Practices, Thinking Differently, Sleep Hygiene, and Moving On).Each Core takes approximately 45-60 minutes to review online, and most participants spend an additional 30-45 minutes per week on recommended exercises.
~Participant will then be instructed to complete a post-Assessment, consisting of one online questionnaire and two weeks of Daily Sleep Diaries. The Actiwatch is worn as before during this two week period."
11056529|NCT04382352|Experimental|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection|Registration number: CTR20181455 Indications: HER2-positive recurrent or metastatic breast cancer Experimental popular topic: Phase Ia clinical study of recombinant anti-HER2 humanized monoclonal antibody composition
11056530|NCT04382339|Active Comparator|Treatment-naive|"Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks
~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
11056531|NCT04382339|Active Comparator|Treatment-experienced|"Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks
~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
11056532|NCT04382326|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
11056533|NCT04382326|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
11056534|NCT04382313|Experimental|the adequate hydration group guided by Vigileo|The rehydration speed is adjusted according to SVV.
11056535|NCT04382313|Active Comparator|the control group|The hydration method is perioperative saline ≤500 ml.
11056536|NCT04382300|Experimental|Treatment arm|pyrotinib 400mg p.o. qd, combined with thalidomide 200mg p.o. qd
11056537|NCT04382287|Experimental|REMIN paste|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
11056538|NCT04382287|Experimental|MI PASTE PLUS|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
11056539|NCT04382287|Active Comparator|COLGATE Total|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
11056572|NCT04382053|Active Comparator|Standard of Care (SoC)|Standard of Care will be used as a comparator arm.
11056573|NCT04382040|Experimental|ArtemiC|Active study treatment + Standard care
11056574|NCT04382040|Placebo Comparator|PLACEBO|Placebo + Standard care
11056944|NCT04379440||" At home  cohort"|Outpatients at risk of SARS-CoV-2 infection
11056540|NCT04382274|Experimental|Quadratus Lumborum Block|the transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized, leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial then placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
11056541|NCT04382274|Experimental|Dual block|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
11056542|NCT04382261|Placebo Comparator|Periodontitis quadrant|Patients undergo non surgical quadrant scaling and root planing
11056543|NCT04382261|Active Comparator|Periodontitis full mouth|Patients undergo non surgical full mouth scaling and root planing
11056544|NCT04382248|Experimental|Interventional Group|An app for tracking medications, receiving personal coaching and educational material
11056545|NCT04382248|Active Comparator|Control Group|An app for tracking medications
11056546|NCT04382235||Covid-19 related Pneumonia patients|The cohort is defined by subjects with a diagnosis of COVID 19-related pneumonia requiring non-invasive ventilatory support.
11056547|NCT04382209|Active Comparator|Erector Spinae plane block group|Erector spinae plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively.
11056548|NCT04382209|Sham Comparator|Control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
11056549|NCT04382196||Health care workers|Health care workers at university hospital
11056550|NCT04382183|Experimental|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
11056551|NCT04382183|Experimental|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the standard Norwegian Health Directorate recommendations for 1 year.
11056552|NCT04382170|Active Comparator|20 mcg|Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
11056553|NCT04382170|Experimental|60 mcg|Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
11056554|NCT04382157|Experimental|Mablet|Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
11056555|NCT04382157|Placebo Comparator|Placebo|Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
11056556|NCT04382144|Active Comparator|Levobupivacaine arm|Patients will receive a single injection of 10 mL of 0.5% (5 mg/mL) levobupivacaine into the common extensor origin.
11056557|NCT04382144|Experimental|Liposomal Bupivacaine arm|Patients will receive a single injection of 10 mL (133mg) of liposomal bupivacaine into the common extensor origin.
11056558|NCT04382131|Experimental|Hypertonic saline nasal irrigation and gargling|Participants in the intervention arm will be asked to perform hypertonic saline nasal irrigation and gargling up to 12 times daily for a maximum of 14 days or until they report that they feel well.
11056559|NCT04382131|No Intervention|Standard Care|Participants in the control arm will be given standard NHS guidance for the management of their symptoms and household hygiene.
11056560|NCT04382118||OWDFO: Open Wedge Distal Femoral Varus osteotomy|
11056561|NCT04382118||CWDFO: Closed Wedge Distal Femoral Varus osteotomy|
11056562|NCT04382105||Control|observation of salivary IL-6 levels
11056563|NCT04382105||Periodontitis|observation of salivary IL-6 levels
11056564|NCT04382092|Experimental|Intervention COVID-19|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
11056565|NCT04382079|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.
~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
11056566|NCT04382079|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).
~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
11056567|NCT04382079|No Intervention|control|Routine care to encourage oral care three times a day.
11056568|NCT04382066|Experimental|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
11056569|NCT04382066|Experimental|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
11056570|NCT04382066|Experimental|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
11056571|NCT04382053|Experimental|DFV890 + SoC|DFV890 will be administered for 14 days in addition to Standard of Care (SoC). SoC will be used as an active comparator.
11056996|NCT04378998|No Intervention|Usual care|
11056575|NCT04382027|Experimental|Monoacylglycerol|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
11056576|NCT04382027|Active Comparator|Ethyl ester|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in ethyl ester form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
11056577|NCT04382014|Experimental|MAG fish oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
11056578|NCT04382014|Active Comparator|Rice bran oil + Curcumin|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
11056579|NCT04382014|Active Comparator|Curcumin extract|The participant will arrive fasted at he research center. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 400 mg curcumin. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
11056580|NCT04381988|Experimental|Hydroxychloroquine|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of hydroxychloroquine 400mg daily.
11056581|NCT04381988|Placebo Comparator|Placebo|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of placebo 400mg daily.
11056582|NCT04381975|Experimental|Move in Mind Program|The Move in Mind Program is a 6-week Rolfing®-based intervention program shortened from ten to six sessions and adapted to a group setting by Rolfing® instructor Monica Canducci.
11056583|NCT04381975|Other|6 Week Waitlist Control|Participants will be crossed over to the Move in Mind program following the 6-week waitlist control. Participants of the waitlist control group will be asked to complete follow-up questionnaires both at the same time as the intervention group (after week six) as well as after their own program.
11056584|NCT04381962|Experimental|Azithromycin|Azithromycin 2x250mg capsules to be taken orally once daily for 14 days. The first dose will be within 4 hours of randomisation. This is in addition to standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
11056585|NCT04381962|No Intervention|Usual standard care|Standard care as per local hospital advice for those patients with suspected COVID who are not admitted: i.e. symptomatic relief with rest, as-required paracetamol (where appropriate) and advice to seek further medical attention if significant worsening of breathlessness.
11056586|NCT04381949|No Intervention|Standard extubation Arm|
11056587|NCT04381949|Experimental|Positive pressure extubation arm|
11056588|NCT04381936|No Intervention|Standard Care|Patient receives usual hospital care
11056589|NCT04381936|Active Comparator|Low dose corticosteroids|First (main) randomisation part A [This arm is now closed to adult recruitment]
11056590|NCT04381936|Active Comparator|Hydroxychloroquine|First (main) randomisation part A [This arm is now closed to recruitment]
11056591|NCT04381936|Active Comparator|Lopinavir-Ritonavir|First (main) randomisation part A [This arm is now closed to recruitment]
11056592|NCT04381936|Active Comparator|Azithromycin|First (main) randomisation part A
11056593|NCT04381936|Active Comparator|Convalescent plasma|First (main) randomisation part B
11056594|NCT04381936|Active Comparator|Tocilizumab|Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo an optional subsequent randomisation between Tocilizumab and no additional treatment.
11056595|NCT04381936|Active Comparator|Intravenous Immunoglobulin|First (main) randomisation part A (open to children only)
11056596|NCT04381936|Active Comparator|Synthetic neutralising antibodies|First (main) randomisation part B
11056597|NCT04381936|Active Comparator|Aspirin|First (main) randomisation part C
11056598|NCT04381923|Active Comparator|Helmet Continuous Positive Airway Pressure (CPAP)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC, helmet CPAP will be applied unless a specific contraindication is present.
11056599|NCT04381923|Active Comparator|High Flow Nasal Oxygen (HFNO)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC , HFNO (≥ 40 LPM) will be applied unless a specific contraindication is present
11056631|NCT04381676||Traditional Classroom|Residents in the traditional classroom were assigned a pre-class reading assignment followed by a 44-minute lecture that was delivered in-person using PowerPoint.
11056632|NCT04381663||conservative treatment|In study A this group will be treated conservatively (stenosis). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
11056771|NCT04380662||COVID+ patients WITH worsening of the disease|COVID+ patients WITH worsening of the disease (case group)
11056600|NCT04381910|Experimental|LY01610|LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
11056601|NCT04381897|Experimental|Group A: NAC 1800mg then Placebo|NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
11056602|NCT04381897|Experimental|Group B: Placebo then NAC 1800mg|NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
11056603|NCT04381884|Experimental|IVERMECTIN (IVER P®)|Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.
11056604|NCT04381884|No Intervention|CONTROL|Patients in this group will receive standard care.
11056605|NCT04381871|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
11056606|NCT04381871|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose
11056607|NCT04381858|Experimental|Severe pneumonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:
~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]
~Requiring invasive mechanical ventilation."
11056608|NCT04381858|Active Comparator|Severe pnemonia due to COVID-19|"Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:
~Severe respiratory failure [respiratory rate> 25 - <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)]
~Requiring invasive mechanical ventilation."
11056609|NCT04381845|Other|psychiatric patient|patients who are hospitalized in psychiatric department
11056610|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + enzalutamide|Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab and standard oral enzalutamide
11056611|NCT04381832|Active Comparator|Stage 2: enzalutamide|Participants will receive standard oral enzalutamide
11056612|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + docetaxel|Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel
11056613|NCT04381832|Active Comparator|Stage 2: docetaxel|Participants will receive standard dose of IV docetaxel
11056614|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab|Oral etrumadenant in combination IV zimberelimab
11056615|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + AB680|Participants will receive oral etrumadenant in combination with IV zimberelimab and IV AB680
11056616|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + AB680|Participants will receive oral etrumadenant in combination with IV AB680
11056617|NCT04381832|Experimental|Stage 1: Etrumadenant + zimberelimab PK Sub-Study|Participants will receive oral etrumadenant in combination with IV zimberelimab
11056618|NCT04381806|Experimental|5-ALA|orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)
11056619|NCT04381793|Experimental|Assessing clinical efficacy|Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects
11056620|NCT04381780|Experimental|Assessing clinical outcomes|Nutritional support with Recovery Factors
11056621|NCT04381767||Concussion Evaluation|Adult athletes receiving a clinical evaluation for a suspected concussion after head injury
11056622|NCT04381754||AVG/AVF Treated with Passeo-18 Lux|Patients with failing dialysis access, treated lesions located between the anastomosis to the axillary-subclavian vein junction.
11056623|NCT04381741|Experimental|CD19-7×19 CAR-T plus PD1 monoclonal antibody|
11056624|NCT04381728|Experimental|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.
~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.
~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
11056625|NCT04381715||YY1|YY1 intragenic pathogenic variant
11056626|NCT04381702||Patients with an open approach|Patients requiring pancreatoduodenectomy and operated with an open approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology before the first laparoscopic pancreaticoduodenectomy.
11056627|NCT04381702||Patients with a laparoscopic approach|Patients requiring pancreatoduodenectomy and operated with a laparoscopic approach : All consecutive patients requiring pancreato-duodenectomies for benign or malignant pathology operated with a laparoscopic approach.
11056628|NCT04381689|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
11056629|NCT04381689|Active Comparator|GSK PFS|Fluarix Tetra Pre-filled Syringe
11056630|NCT04381676||Flipped Classroom|Residents in the flipped classroom were assigned a pre-class video lecture prior to completing the flipped classroom in-class case-based activity in groups of 2-3 each.
11057867|NCT04372914|Experimental|BRB Lozenges|Oral lozenges that contain 1 gram of BRB freeze-dried powder
11056633|NCT04381663||surgical treatment (stenosis and myelopathy).|In study A this group that will be treated surgically (stenosis and myelopathy). Study B is a single centre longitudinal study where the same patient groups will be followed up during the course of their treatment
11056634|NCT04381650|Experimental|Dose Escalation: TAK-981 + Pembrolizumab (fixed dose)|Escalating doses of TAK-981 with starting dose of 40 mg, intravenous (IV) infusion, on Days 1, 4, 8 and 11 in each 21-day Treatment Cycle and pembrolizumab 200 mg, IV infusion, as a fixed dose every 3 weeks in 21-day Treatment Cycle until RP2D is determined (for a maximum of 24 months).
11056635|NCT04381650|Experimental|Dose Expansion Phase: Non-squamous NSCLC|TAK-981 at RP2D as IV infusion in participants with non-squamous non-small cell lung cancer (NSCLC) on Days 1, 4, 8 and 11 in each 21-day Treatment Cycle up to disease progression or 12-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
11056636|NCT04381650|Experimental|Dose Expansion Phase: Cervical Cancer|TAK-981 at RP2D as IV infusion in participants with cervical cancer on Days 1, 4, 8 and 11 in each 21-day Treatment Cycle up to disease progression or 12-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
11056637|NCT04381650|Experimental|Dose Expansion Phase: MSS-CRC|TAK-981 at RP2D as IV infusion in participants with microsatellite stable colorectal cancer (MSS-CRC) on Days 1, 4, 8 and 11 in each 21-day Treatment Cycle up to disease progression or 12-months and pembrolizumab 200 mg IV infusion as a fixed dose every 3 weeks in 21-day Treatment Cycle for a maximum of 24 months.
11056638|NCT04381637|Experimental|NIPE|
11056639|NCT04381624|Experimental|Transcutaneous Vagal Stimulation|TVS will be applied through a portable electrostimulation equipment during the whole session in each of the treatment sessions. The electrodes will be placed in the left ear, specifically in the auricular concha. The device will be programmed with a biphasic square current at an intensity that produces a clear tingling sensation that is neither uncomfortable nor painful, with pulses of 300 microseconds, at 25 Hertz, the stimulus will be present for 30 seconds and will be followed by a 30-second rest period repeating this for approximately one hour.
11056640|NCT04381624|Placebo Comparator|Placebo Transcutaneous Vagal Stimulation|In the application of this placebo, the device will be configured with the same parameters and intensity of the real TVS. However the device will be located in the left ear lobe.
11056641|NCT04381611||Primary Glaucoma|
11056642|NCT04381611||Glaucoma Surgery|
11056643|NCT04381611||Glaucoma Laser|
11056644|NCT04381611||Glaucoma Surgery Combined|
11056645|NCT04381611||Glaucoma treatment|
11056646|NCT04381611||Glaucoma imaging|
11056647|NCT04381611||Glaucoma co-morbidity|
11056648|NCT04381611||Glaucoma untreated|
11056649|NCT04381611||Glaucoma Suspect|
11056650|NCT04381611||Secondary Glaucoma|
11056651|NCT04381598|Experimental|stevia rebaudiana bertoni|Randomly in all subjects one quadrant will be allotted as test site for placing stevia gel in the gingival sulcus having probing depth ≥ 5mm after performing thorough scaling and root planing.
11056652|NCT04381598|Placebo Comparator|placebo|Other quadrant will be allotted as a control site for placing placebo in the gingival sulcus having PD≥ 5mm after performing thorough scaling and root planing.
11056653|NCT04381585|Experimental|Distraction osteogenesis using mini distractor|"A mini distractor will be used to move bone. Distraction osteogenesis originally developed for the severe craniofacial malformations has been adapted to correct vertical defects of the oral bone to improve bone volume for dental procedures.
~However, the design of the distractor
~has not evolved to adapt to a much smaller surgical site such as bone ridge in the oral cavity which necessitates a smaller screw.
~are bulky, cumbersome to place, and cause significant discomfort to the patient.
~has an extraoral component jutting out of the mouth to which a key (blue object) is attached to turn the screw to move bone fragments. Our Solution and the Innovation is to remove the extra-oral component by reducing the size and permitting an atraumatic placement of the screw under the gingiva (gum) thereby lessening irritation for the patient."
11056654|NCT04381572||High fidelity simulation training|Group consisting of medical students scheduled to undergo high fidelity medical simulation as a part of standard scholastic program.
11056655|NCT04381559|Experimental|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
11056656|NCT04381559|Active Comparator|Applied Relaxation|In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response. AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety. This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition. Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety. However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
11056681|NCT04381429|Active Comparator|Groupe 2: F-A-F-A|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.
~All patients will test both insulin treatments (A and F) in alternating periods.
~The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP)."
11056728|NCT04381000|Experimental|Intervention|The intervention group will participate in an exercise program for 6 weeks/ 2 sessions per week, for a total of 12 sessions of 30-45 minutes each.
11056729|NCT04380987||Predicovid|
11058039|NCT04371718|Placebo Comparator|Placebo|Matched placebo, daily for 104 weeks
11056657|NCT04381546|Experimental|FES in patients with hemiplegia|Patients will be equipped with 5 inertial measurement units. Two wireless bluetooth pressure insoles will be connected to the Raspberry. Electrical stimulation will be delivered via a wireless stimulator to the quadriceps and hamstrings via surface electrodes. Insoles will be used to online analyze Paretic Foot Support to discriminate between stance and swing phases. Stimulation will also be delivered just before initial contact at the end of swing phase. In stance phase, stimulation will be triggered either to quadriceps or hamstrings, depending on the paretic knee angle estimation relatively to the knee angle setpoint defined by the practitioner as the optimal flexion during stance phase (around 5°).
11056658|NCT04381533|Experimental|I-A-CRA|Internet-delivered Adolescent Community Reinforcement Approach: The treatment program consists of 8 extensive treatment modules delivered over 10 weeks with continuous therapist support and guidance. There are two separate treatments for the young adult and the caregiver/significant other.
11056659|NCT04381533|Active Comparator|Psychoeducation alcohol use|Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
11056660|NCT04381520|Experimental|Heat-sensitive moxibustion plus antihypertensive drugs|
11056661|NCT04381520|Active Comparator|Antihypertensive drugs|
11056662|NCT04381494|Other|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
11056663|NCT04381481|Experimental|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
11056664|NCT04381481|Experimental|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
11056665|NCT04381481|Experimental|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
11056666|NCT04381481|Experimental|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
11056667|NCT04381481|Experimental|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
11056668|NCT04381481|Experimental|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
11056669|NCT04381481|Experimental|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
11056670|NCT04381481|Experimental|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
11056671|NCT04381481|Experimental|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
11056672|NCT04381481|Experimental|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
11056673|NCT04381481|Experimental|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
11056674|NCT04381481|Experimental|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
11056675|NCT04381468|Experimental|pepinemab 40mg/kg|The study drug, pepinemab, will be administered via monthly intravenous infusions.
11056676|NCT04381468|Experimental|pepinemab 20mg/kg|The study drug, pepinemab, will be administered via monthly intravenous infusions.
11056677|NCT04381468|Placebo Comparator|Placebo|.A placebo control will be administered via monthly intravenous infusions.
11056678|NCT04381442|Experimental|Buccal &palatal low level laser therapy|In group I,low level laser therapy was delivered at 10 points; 5 from buccal and 5 from palatal aspects with a total dose of 8 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
11056679|NCT04381442|Active Comparator|Buccal low level laser therapy|In group II, low level laser therapy was delivered at 5 points; from buccal palatal aspects only with a total dose of 4 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
11056680|NCT04381429|Active Comparator|Group 1: A-F-A-F|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.
~All patients will test both insulin treatments (A and F) in alternating periods.
~The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid).
~Each treatment period will last 3 months."
11056767|NCT04380688|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
11056682|NCT04381416|Experimental|Cohort I: SEAD treatment|Following the first SEAD™ treatment, women who experience a sub-optimal treatment response (at least 3 months after the first treatment) will be eligible to receive a second SEAD™ treatment (see re-treatment criteria below), which will be performed during the first 1-3 days following the cessation of their menses immediately following decision to retreat.
11056683|NCT04381416|Experimental|Cohort II: Repeted SEAD treatment 1m post op|Following the first SEAD™ treatment, women will undergo a second SEAD™ treatment during the first 1-3 days following the cessation of their next menses.
11056684|NCT04381403|Experimental|Bio-descaling D-Tart toothpaste|Bio-descaling D -Tart is a bio-descaler toothpaste that is manufactured at Du-Var laboratories (1460 Graham Bell, Boucherville, Québec, Canada J4B 6H5)
11056685|NCT04381403|Active Comparator|Crest®|anti-tartar toothpaste, Complete Whitening plus Scope, tartar control produced by Procter & Gamble, Cincinnati, OH),
11056686|NCT04381390|Experimental|Whole egg consumption|This arm involved whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
11056687|NCT04381390|Experimental|Egg whites consumption|This arm involved egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
11056688|NCT04381377|Experimental|Polyoxidonium|Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
11056689|NCT04381377|Placebo Comparator|Placebo|Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
11056690|NCT04381364|Experimental|Medical treatment|Treatment with ciclesonide
11056691|NCT04381364|No Intervention|Standard of Care|Standard Medical Care
11056692|NCT04381338|Experimental|Rehabilitation in COVID-19 patients in ICU|"Every person admitted to ICU for ARDS with a confirmed diagnosis of COVID-19 Motor program
~Intubated patient GCS >8: passive mobilization; postural positioning GCS< 8: passive and active-assist mobilization; postural positioning
~Extubated patient
~If strength < 3 MRC: passive and/or active-assist; functional retraining
~If strength ≥3 MRC: active-assist and active; strength training; functional retraining Pulmonary Rehabilitation
~Intubated patient GCS >8: postural positioning GCS< 8: postural positioning, cautious inspiratory muscle training
~Extubated patient
~If strength < 3 MRC: postural positioning, positive pressure expiration exercise,inspiratory muscle training
~If strength ≥3 MRC: postural positioning, positive pressure expiration exercise, inspiratory muscle training The intensity of exercise will prescribed based on the results of the PFIT. and modified Borg Scale.
~Frequency of sessions: 3×15 min/day"
11056693|NCT04381338|No Intervention|COVID-19 in ICU without Rehabilitation|Standard of care without rehabilitation in ICU
11056694|NCT04381325|Experimental|MSB0254 Injection|This experiment will start from 4mg/kg with a dose increase of 3+3, and is planned to be carried out in 5 dose groups, namely 4mg/kg, 8mg/kg (100% increase), 12mg/kg (50% increase), 16mg/kg (33% increase) and 20mg/kg (25% increase).MSB0254 injection was administered intravenously on day 1 and day 15 every 28 days.To collect pharmacokinetic blood samples after repeated administration, MSB0254 injection was not administered on day 1 of the third cycle (C3D1).The observation period of DLT was 28 days after the first administration.
11056695|NCT04381299||Intervention|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
11056696|NCT04381299||Control|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
11056697|NCT04381260||2016-2019 STEMI Registry|Retrospective data will be collected to develop a well-characterized registry of patients treated from 2016-2019 by any of 14 local rural EMS agencies and transported to a facility capable of performing Percutaneous Coronary Intervention. This registry will be used to determine the time to PCI performance for each of the EMS agencies. Time will be adjusted for patient distance from a PCI center using a linear mixed model with a random effect for center and a fixed effect for distance. This process will allow qualitative methods to identify organizational culture, structure, and clinical processes that impact STEMI care from the two highest and lowest performing rural EMS agencies. (n=750)
11056698|NCT04381260||Key Informant Interviews|After identifying the two highest and lowest performing rural EMS agencies in the 2016-2019 STEMI Registry, key employees from each of those agencies will be recruited to participate in semi-structured key informant interviews. The interviews will assess current clinical care, organizational culture and opportunities for improvement. (n=32)
11056699|NCT04381260||Stakeholder Surveys|Employees at all local EMS agencies will be invited to participate in stakeholder surveys to quantify each agency's use of the care strategies identified during Key Information Interviews. (n=240)
11056700|NCT04381234|Experimental|ATA plus citrate|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan) in combination with citrate (1 mM) containing dialysate
11056701|NCT04381234|Active Comparator|ATA plus predilution hemodiafiltration|1.9 m2 ATA membrane (Solacea™-19H, Nipro Corp., Japan), in combination with high volume predilution hemodiafiltration
11056702|NCT04381208||Sacroiliac joint pain|Patients diagnosed with sacroiliac joint pain on the basis of history, physical examination and diagnostic sacroiliac joint block
11056703|NCT04381208||Lumbar pain|Patients diagnosed with other chronic lumbar pathologies on the basis of history, physical examination and radiographic studies
11056724|NCT04381013|Experimental|Phase 1: Routine surgery|As part of routine cardio-thoracic surgery, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 1 minute.
11056725|NCT04381013|Experimental|Phase 2: ECHO treatment|During care with Extracorporeal Membrane Oxygenation (ECMO) for non-SARS-CoV-2, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 24 hours.
11056726|NCT04381013|Experimental|Phase 3: COVID-19 treatment|Endotracheal tubes split from ventilator delivering oxygen independently to two patients with COVID-19 disease for up to 1 hour.
11056727|NCT04381000|No Intervention|Control Group|The control group will not participate in any exercise program.
11056768|NCT04380688|No Intervention|Arm 2|Best Supportive Care
11056704|NCT04381195||Aim 1|"Item Drafting and Revising (Aim 1). Together with a stakeholder panel of adults with ASD and parents/caregivers, the study investigators will generate an item pool based on the conceptual model. The measure will utilize the capability scale response options from the PROMIS preferred response sets (4 = without any difficulty, 3 = with a little difficulty, 2 = with some difficulty, 1 = with much difficulty, 0 = unable to do). To increase the reliability of ratings, a visual response scale with objective benchmarks and anchors will be developed for each response option.
~Cognitive Interviews (Aim 1). A battery of assessments will be completed to describe the sample. The investigators will monitor these results to ensure that the sample is representative of the range of functioning in ASD, and will enrich the sample as needed. The assessment battery will be the same as the battery for the calibration sample (see battery in Aim 2)."
11056705|NCT04381195||Aim 2|"Item Calibration (Aim 2). Measures will be completed online. To be conscious of participant burden, the minimum needed measures were selected to describe the sample, enable differential item functioning (DIF) analyses, and support IRT co-calibration.
~The battery will include:
~measures to characterize the sample (demographics, medical/psychiatric history, treatment and education, history, employment, parent- and self-reported IQ/verbal ability, 2) the online version of the Wide Range Achievement Test- Reading;
~measures related to functional outcomes for IRT co-calibration (Vineland Scale of Adaptive Behavior -3; Wisconsin Activities of Daily Living, Specific Levels of Functioning Scale, PROMIS Social Participation, PROMIS Emotional Support, World Health Organization Quality of Life); and
~symptom measures (Emotion Dysregulation Inventory, Adult Behavior Checklist/Adult Self-Report of psychiatric symptoms, and Social Responsiveness Scale - 2 of ASD symptoms)."
11056706|NCT04381182|Other|Biostrap/Apollo Device Use|Participants wear a Biostrap wearable device which measures steps, heart rate, heart rate variability, sleep metrics, and quantitative data in typical day-to-day activities of residents. Participants then again wear Biostrap except now also with the Apollo device which is worn around the ankle and is suggested to modulate heart rate variability and perceived stress of participants.
11056707|NCT04381169|Experimental|Aggressive fluid resuscitation|"Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h.
~At 12(±4) hours:
~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped
~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours
~Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours"
11056708|NCT04381169|Experimental|Moderate fluid resuscitation|"At recruitment:
~A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h.
~B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus).
~At 12(±4) hours:
~A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped
~Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours
~Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours"
11056709|NCT04381143|Active Comparator|Aspirin|Aspirin tablet 100mg daily
11056710|NCT04381143|Placebo Comparator|Matching Placebo|Placebo tablet 1 pill daily
11056711|NCT04381130|Experimental|EF-009|In both the Phase I and Phase IIa portions of the study, subjects will be evaluated for response every 8 weeks after EF-009 wafer implantation for up to 2 years, by CT, PET/CT or MRI (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be assessed based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST v1.1). The total study duration for each subject consists of screening, treatment, and extended follow-up period and survival follow-up period.
11056712|NCT04381117||No Treatment|Subjects who participated in and completed study EN3835-201 and had composite improvement of at least 2-levels on both the Clinician Reported-Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient Reported-Photonumeric Cellulite Severity Scale (PR-PCSS) in EN3835-201 study will be eligible for this study. The study will consist of a single day evaluation approximately 4 years after the first dose of the study drug was received in the EN3835-201 study.
11056713|NCT04381104|Active Comparator|Paracetamol|Capsule Paracetamol 1000 mg 1 hour before the mammography procedure
11056714|NCT04381104|Placebo Comparator|Placebo|The control arm will receive 2 capsules of placebo.
11056715|NCT04381078|Experimental|Intervention|Standardised Verbal Instructions Standardised Written Instructions Audiovisual Guide
11056716|NCT04381078|No Intervention|Control|Standardised Verbal Instructions Standardised Written Instructions
11056717|NCT04381065|Experimental|PKG+ Group|For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is in the target range or out of the target range based on scores provided by the PKG.
11056718|NCT04381065|Placebo Comparator|PKG- Group|For subjects in the PKG- Group, participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
11056719|NCT04381052|Experimental|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
11056720|NCT04381052|Placebo Comparator|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
11056721|NCT04381039|Experimental|customized insole group|
11056722|NCT04381026|Placebo Comparator|Placebo Group|Pill of 500 mg containing filler agent, two pills daily for eight weeks.
11056723|NCT04381026|Experimental|Treatment Group with botanical extracts|Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.
11056730|NCT04380974|Experimental|OCTA plus OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization, OCTA and OCT in the extension treatment period.
11056731|NCT04380974|Active Comparator|OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization and OCT in the extension treatment period.
11056732|NCT04380961|Experimental|Sirukumab|Participants will receive single intravenously (IV) dose infusion of sirukumab 5 milligram per kilogram (mg/kg) on Day 1 along with standard of care treatment.
11056733|NCT04380961|Placebo Comparator|Placebo|Participants will receive IV single dose infusion of placebo on Day 1 along with standard of care treatment.
11056734|NCT04380935|Experimental|convalescent plasma and standard of care|
11056735|NCT04380935|Active Comparator|standard of care|
11056736|NCT04380922||Active IBD|"Active Inflammatory Bowel Diseases defined as :
~For Crohn's disease :
~Harvey Bradshaw Index ≥ 4
~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis
~Partial Mayo score ≥ 2
~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months"
11056737|NCT04380922||Non-active IBD|Non-active Inflammatory Bowel Diseases
11056738|NCT04380909|Experimental|Internet-based self-help|The self-help program consists of six text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
11056739|NCT04380909|Other|Waiting control group|Access to internet-based intervention after 3 weeks.
11056740|NCT04380896||SARS-CoV-2 Seropositive Cases|"It will be formed of approximately N= 200 to 350 staff members
~Core Group of PCR Confirmed Cases N ~ 150 to 250:
~A) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Positive N ~ 150 to 250 OR
~Other SARS-CoV-2 Sero-positives N ~ 50 to 100:
~B) Symptoms consistent with SARS-CoV-2 infection and SARS-CoV-2 PCR Negative cases. OR C) No symptoms consistent with SARS-CoV-2 infection and PCR Not Tested cases"
11056741|NCT04380896||SARS-CoV-2 Seronegative Comparison Group|"It will be formed of approximately N= 800 to 900 staff members
~Core Comparison Group N ~ 800 A) Have not had clinical symptoms consistent with SARS-CoV-2 infection OR
~Other Seronegatives N ~ 100 B) Have had sympoms of SARS-CoV-2 infection but have been tested and were PCR positive or negative but have not developed antibodies at 21 days"
11056742|NCT04380883|Experimental|InnoSEAL+TRB|InnoSEAL is a hemostatic patch which will be applied along with TRB to control bleeding from access site
11056743|NCT04380883|Active Comparator|TRB alone|
11056744|NCT04380870||Chinese Herbal Medicine|Chinese Herbal Medicine for suspected COVID-19 symptoms.
11056745|NCT04380857|Experimental|Dexamethazone ophthalmic insert 0.4 mg|Dexamethazone ophthalmic insert 0.4 mg
11056746|NCT04380857|Experimental|topical prednisolone acetate ophthalmic drops|topical prednisolone acetate ophthalmic drops
11056747|NCT04380844|Active Comparator|Beprevent|10 will become part of the intervention group. Each of the participants in the intervention group is selected. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
11056748|NCT04380844|No Intervention|patients only evaluated|10 will be included in the control group. During the period of the study, we will pass the same questionnaires in the participants assigned to the control group, also leaving a time interval of two weeks, and no device will be installed, nor will any monitoring be carried out in their homes.
11056749|NCT04380831|Experimental|Treatment (TBI using IMRT, cyclophosphamide, HSCT)|Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.
11056750|NCT04380818|Active Comparator|Control group|a control group only receive pharmacological treatment
11056751|NCT04380818|Experimental|Experimental group|an experimental group will receive low-dose lung irradiation
11056752|NCT04380805|Experimental|AK104|AK104 monotherapy
11056753|NCT04380766||Pre-COVID|All patients with pancreatic cancer diagnosis before COVID-19 pandemic
11056754|NCT04380766||COVID|All patients with pancreatic cancer diagnosis during COVID-19 pandemic
11056755|NCT04380753|Experimental|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
11056756|NCT04380740|Placebo Comparator|Standard GVHD Prophylaxis + Abatacept + Placebo|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 4 doses of Abatacept (investigational product) + 4 doses of Placebo.
11056757|NCT04380740|Experimental|Standard GVHD Prophylaxis + Abatacept Extended dosing|Standard GVHD prophylaxis of calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate + 8 doses of Abatacept.
11056758|NCT04380727||Almitrine|Administration of 4 mcg/kg/min iv almitrine bismesylate (Vectarion®, Servier Laboratory, France), over 30-45 min followed by 12 mcg/kg/min infusion rate. Because of a shortage of drug store at national level, a protocol using continuous infusion was not considered. Some patients may receive the drug for 36 hours depending on availability..
11056759|NCT04380727||Control|To eliminate the eventuality of a spontaneous evolution of hypoxia, these patients were matched to control COVID-19 patients treated without almitrine (time control).
11056760|NCT04380701|Experimental|BNT162a1 (P/B) - Part A 18-55 years of age|Escalating dose levels
11056761|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 18-55 years of age|Escalating dose levels
11056762|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 18-55 years of age|Escalating dose levels
11056763|NCT04380701|Experimental|BNT162c2 (P/B) - Part A 18-55 years of age|Escalating dose levels
11056764|NCT04380701|Experimental|BNT162c2 (prime only) - Part A 18-55 years of age|Single dose
11056765|NCT04380701|Experimental|BNT162b1 (P/B) - Part A 56-85 years of age|Escalating dose levels
11056766|NCT04380701|Experimental|BNT162b2 (P/B) - Part A 56-85 years of age|Escalating dose levels
11056772|NCT04380662||COVID+ patients WITHOUT worsening of the disease|COVID+ patients WITHOUT worsening of the disease (control group)
11056773|NCT04380649|Experimental|ALS people with severe disability|
11056774|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo|Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.
11056775|NCT04380636|Experimental|pembrolizumab+chemoradiation→pembrolizumab+olaparib|Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.
11056776|NCT04380636|Active Comparator|chemoradiation→durvalumab|Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.
11056777|NCT04380623|Experimental|Mobile Phone-Based Web-Page: HPV vaccine|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit, tailored education information on the HPV vaccine via a text message with a website link.
11056778|NCT04380623|Active Comparator|Mobile Phone-Based Web-Page: Healthy Lifestyles|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit education information on an unrelated topic (e.g., healthy eating and physical activity) via a text message with a website link.
11056779|NCT04380610||Pediatric SCA|We will develop a novel eGFR equation in 200 pediatric participants
11056780|NCT04380610||Adult SCA|We will develop a novel eGFR equation in 200 adult participants
11056781|NCT04380597||Patients with nail psoriasis|Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
11056782|NCT04380584||I|30 patients with type 2 DM with nephropathy
11056783|NCT04380584||II|30 type 2 DM without nephropathy
11056784|NCT04380584||III|30 non DM as control group
11056785|NCT04380571|Experimental|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
11056786|NCT04380571|Experimental|Electrical Stimulation|Bilateral (TPTNS); was applied with an electrode above the medial malleolus A second electrode) was applied just below the same malleolus. Electrical stimulation with a low-frequency current (10 Hz), and adjustable intensity. The procedure was done for 20-30 minutes, three times per week for 3 months together with the conventional maneuvers applied in the control group.
11056787|NCT04380571|Active Comparator|Control group|were managed by conventional methods through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
11056788|NCT04380558||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.
~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
11056789|NCT04380545|Experimental|Treatment (fluorouracil, interferon alpha 2b, nivolumab)|Patients receive fluorouracil IV continuously on days 1-7 and 15-21 and recombinant interferon alpha 2b-like protein SC on days 1, 3, 5, 15, 17, and 19. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 3, patients receive nivolumab IV over 30 minutes on day 1, fluorouracil IV continuously on days 1-7 and 15-21, and recombinant interferon alpha 2b-like protein interferon alpha 2b SC on days 1, 3, 5, 15, 17, and 19. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11056790|NCT04380532|Experimental|V-SARS recipients|Single arm having at least 20 volunteers administered once-per-day pill of V-SARS
11056791|NCT04380519|Experimental|RPH -104 80 mg|Subject randomized to receive subcutaneous single injection of 2 ml solution of RPH-104 on Day 1, in addition to standard therapy
11056792|NCT04380519|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
11056793|NCT04380519|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 2 ml solution of Placebo on Day 1, in addition to standard therapy
11056794|NCT04380506|Experimental|Drain removal|Patients that fulfill criteria for surgical drains removal
11056795|NCT04380480|Experimental|Experiment|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.
~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
11056796|NCT04380467|Experimental|Vitamin D Group|Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.
11056797|NCT04380467|No Intervention|Control|No vitamin D given
11056798|NCT04380454|Experimental|Fast treadmill walking with functional electrical stimulation|Fast treadmill walking with functional electrical stimulation (FastFES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. FES is delivered only to the paretic ankle muscles, enhancing afferent ascending as well as descending corticomotor drive. Increased corticomotor drive in lesioned corticomotor circuits in turn promotes improved timing and intensity of muscle activation in the paretic plantar- and dorsi-flexor muscles, increasing plantarflexor moment and propulsion from the paretic ankle.
11056832|NCT04380194||healthy witnesses|fourteen healthy witnesses who have never been in contact with lightning, matched on age and sex
11056799|NCT04380454|Active Comparator|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention that provides similar structure, dose, and intensity of stepping practice as FastFES, but does not include FES, and no specific instructions are provided to target practice to the paretic leg or specific ankle deficits
11056800|NCT04380428||Cross section of the student body.|Matriculated students at Portuguese medical and dental faculties.
11056801|NCT04380415|Active Comparator|Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist. ECG will be collected from a single lead ambulatory ECG patch worn on the chest. The data from both the commercial wrist-worn device and the ECG patch are not analyzed real-time.
11056802|NCT04380415|No Intervention|Non Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist.
11056803|NCT04380402|Experimental|Treatment|40 mg
11056804|NCT04380402|No Intervention|Control|Standard care
11056805|NCT04380389|Other|profound hypoxia|
11056806|NCT04380376|Experimental|Melphalan inhalations|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 7-10 consequent days
11056807|NCT04380376|Other|Standard of care group|Patients assigned to the standard of care group will not receive any additional therapy.
11056808|NCT04380363|Experimental|Honda Walk Assist (HWA) Group|Participants utilize HWA device at home for 2 months according to prescribed settings.
11056809|NCT04380363|Active Comparator|Control Group|Participants complete prescribed exercise program at the Shirley Ryan AbilityLab gym for 2 months.
11056810|NCT04380337|Experimental|Radiation/FOLFOXIRI|Treatment will comprise 6 daily fractions of radiotherapy at 5 Gy per fraction followed by 4 months of FOLFOXIRI. Patients who have performance status or conditions that may preclude use of FOLFOXIRI may be treated with FOLFOX or XELOX. Those who achieve a clinical complete response will be considered for organ preservation approach. All other patients will receive standard of care total mesorectal excision (TME).
11056811|NCT04380324|Experimental|LY3471851|Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
11056812|NCT04380324|Placebo Comparator|Placebo|Healthy participants in each cohort will receive the placebo comparator.
11056813|NCT04380311|Experimental|Precision Tacrolimus|Participants in this arm of the study will have their tacrolimus dose determined using a precision medicine decision support software tool. The participant's transplant physician will consider the recommended dose from the decision support tool in combination with the physician's expertise and experience to determine the proper tacrolimus dose for the participant.
11056814|NCT04380298|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
11056815|NCT04380298|Active Comparator|The control group|In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
11056816|NCT04380285|Active Comparator|Group 1. Custom heel pads and modified soft molded orthotics|Modified soft custom orthotics supported in the medial longitudinal arches and medial shock absorbing heel pads with customized cutout at the point corresponding to the heel pain
11056817|NCT04380285|Active Comparator|Group 2. Custom hard orthotics|Custom hard orthotics made from a positive mold of a foot in neutral position, with arch support and medial heel postings.
11056818|NCT04380272||Brodsky tonsil staging system|An oropharynx examination of all participants will be performed and tonsil size will be evaluated according to the Brodsky staging system. According to this staging system, tonsil sizes will be classified as stage I when the tonsils fill less than 25% of the transverse oropharyngeal space measured between the anterior tonsillar pillars; stage II when they fill between 25% and 50%, stage III when they fill between 50% and 75%, and stage IV when they fill more than 75%.
11056819|NCT04380272||The ultrasonographic data|The submental ultrasonography will be performed on all participants. Ultrasonographic examinations will be performed blinded to the physical examination results. All measurements will be performed by the same radiologist with experience in the field of ultrasonography. A GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) device will be used in the ultrasonography examination. The participants will be viewed using a 2-9 MHz linear probe from the submental region. The examination will be performed while the patient was lying in a supine position with a support placed under the neck.
11056820|NCT04380259|Experimental|MBTR-R (Mindfulness-Based Trauma Recovery for Refugees)|Mindfulness-based group intervention consisting of nine 2.5-hour weekly sessions.
11056821|NCT04380259|No Intervention|Waitlist-Control|Following the 9-week waitlist period and 1-week post-intervention assessment, participants randomized to waitlist-control were offered an equivalent group intervention (i.e., 22.5 total hours, group instructor and cultural mediator, psychoeducation and low-intensity cognitive behavior therapy skill training, relaxation techniques).
11056822|NCT04380246||Clinicians|"Clinicians who care for pediatric patients >50% of their time, who treat pediatric patients who are in acute pain and between 0 and 3 years of age. May include physicians, clinical pharmacists, nurse practitioners, physician assistants, and/or nurses.
~This cohort will complete a qualitative interview about pain and distress in infants and young children."
11056823|NCT04380233|Experimental|Investigational Drug Group|A 8-weeks double-blind treatment period with a Proprietary Chinese Medicine (consists of 4 kinds of Chinese herbs at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
11056824|NCT04380233|Placebo Comparator|Placebo Group|A 8-weeks double-blind treatment period with Placebo Capsules (at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
11056825|NCT04380220||Relapsing MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.
11056826|NCT04380220||Remitting MS patients|Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.
11056827|NCT04380220||Healthy controls|Age- and sex-matched healthy control subjects.
11056828|NCT04380207|Experimental|QPX7728|antibiotic
11056829|NCT04380207|Placebo Comparator|Placebo|Matched placebo
11056830|NCT04380207|Experimental|QPX2014|antibiotic
11056831|NCT04380194||victims|thirteen patients affected by lightning in collective fulguration
11056833|NCT04380181||Dobutamine|Weaning from cardiopulmonary bypass using dobutamine as inotrope.
11056834|NCT04380181||Milrinone-epinephrine|Weaning from cardiopulmonary bypass using milrinone and epinephrine as inotropes.
11056835|NCT04380168|Active Comparator|Modified pec 11 trunk block using ketamine additive|Ultasound guided modified pec 11 trunk block using ketamie hydrochoride 1mg/kg in 2ml volume added to 30ml bupivacaine 0.25% for trunk analgesia
11056836|NCT04380168|Active Comparator|Modified pec 11trunk block using dexmedetomidine additive|Ultasound guided modified pec 11 trunk block using dexmedetomidine 1ug/kg in 2ml volume added to 30ml bupivacaine 0.25%
11056837|NCT04380168|Active Comparator|Modified pec 11trunk block without additive|Ultasound guided modified pec 11 trunk block using bupivacaine 0.25% added to 2ml saline
11056838|NCT04380155|Experimental|Participants|All participants will perform three moderate intensity cycling trials of different duration (30, 60 and 120 min) in an energy replete state.
11056839|NCT04380142|Experimental|ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks
11056840|NCT04380142|Active Comparator|Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951|Participants will receive oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks
11056841|NCT04380129|Experimental|Μusic therapy-conversation sessions|
11056842|NCT04380129|Active Comparator|Discussion sessions|
11056843|NCT04380116|Experimental|Sb+Aware|Patients will access to the Soberlink device and receive treatment with Aware Recovery Care
11056844|NCT04380116|No Intervention|Aware|Patients will only have access to Aware Recovery Care
11056845|NCT04380103|Experimental|XELOXIRI/Bevacizumab|drugs: Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7, administered every 2 week for 12 cycles, after 12 cycles, administer bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy.
11056846|NCT04380090|Active Comparator|Drug: Docusate Sodium|Docusate sodium one pill to be taken twice a day by mouth for 28 days
11056847|NCT04380090|Experimental|Drug: Propylene Glycol|One standard dose (17 grams) of propylene glycol by mouth on postoperative day one
11056848|NCT04380077|Experimental|SF6|
11056849|NCT04380077|Active Comparator|Fluid|
11056850|NCT04380064|Experimental|Study Group|Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment
11056851|NCT04380064|Active Comparator|Control Group|Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
11056852|NCT04380051|Experimental|Arm 1 : skin-to-skin contact associated with a sensory-tonic s|skin-to-skin contact left free for parents associated with a sensory-tonic stimulation five times a week during 15 minutes at each time
11056853|NCT04380051|Active Comparator|Arm 2 : skin-to-skin contact only|skin-to-skin contact left free for parents
11056854|NCT04380038|Active Comparator|Dupilumab|The dupilumab dose regimen selected for this study (300 mg q2w after an initial loading dose of 600 mg)
11056855|NCT04380038|Placebo Comparator|Placebo|A harmless substance that looks like the study drug, but which should have no effect. The placebo formulation used in this study contains all the ingredients present in the active drug, except the active ingredient (IL-4α antibody). Therefore, the risk related to this formulation should be no greater than the risk associated to the active drug.
11056856|NCT04380025|Experimental|Mirtogenol|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) the experimental group will also take Mirtogenol. Mirtogenol is a dietary supplement composed of bilberry and pycnogenol which are botanical compounds with antioxidant properties. The active components of bilberry are flavonoid anthocyanosides (anthocyanins). Anthocyanosides are the only flavonoids able to reach the eye as a target organ in experimental animals. Unchanged anthocyanosides demonstrated after oral administration that it is absorbed and distributed into ocular tissues, showing its ability to pass through the blood-aqueous and blood retinal barriers.6
11056857|NCT04380025|Placebo Comparator|Lactose based Placebo|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) this control group will also take an identical placebo. This placebo is a inactive lactose based product of the same color and size capsule.
11056858|NCT04380012||Single drug group|Single drug group: Pyrotinib treatment dose: 400mg, po, qd, 21d for a treatment cycle
11056859|NCT04380012||Dual-targeted drug group|Dual-targeted drug group: Pyrotinib treatment dose: 400mg, po, qd, 21d for one treatment cycle; Trastuzumab: first dose 8mg/kg, then 6mg/kg, iv, q3w, 21d for one treatment cycle
11056860|NCT04379999|Active Comparator|Atorvastatin|Atorvastatin (LIPITOR) 20 milligram tablet daily for 6 weeks
11056861|NCT04379999|Active Comparator|Atorvastatin and Aspirin|Atorvastatin (LIPITOR) 20 milligram tablet and Aspirin 325 mg tablet daily for 6 weeks
11056862|NCT04379986|Experimental|Standardized measures in the cardiac catheterization laborator|Immediately after coronary angiography, intra-arterial BP waveforms will be recorded using a fluid-filled catheter via right femoral or radial access. The catheter will be flushed before any waveform recordings is made. At first, the catheter will be positioned in the aorta for 3 minutes of stable BP waveforms recording. Intracoronary nitroglycerin will be administered at a dose of 300 µg, newly preceding 3 minute of recording. At the end of the coronary angiography, additional 3 minutes of recording will be performed in the aorta.
11056863|NCT04379986|Experimental|Standardized measures in the intensive care unit|Invasive BP monitoring is a commonly used technique in the ICU and is used to guide many intensive care unit therapies. Enrolled patients must have had an arterial catheter in place at the time of inclusion to the study. Arterial catheterization will be performed by the intensive care team according to current medical guidelines. No arterial catheters were placed for the sole purpose of this study. The Senbiosys device will be placed on the opposite arm of the arterial catheter for simultaneous measurements.
11056864|NCT04379973|Experimental|Tubal flush with Lipiodol Ultra Fluide® after Hyfosy|
11056865|NCT04379973|No Intervention|No tubal flush after Hyfosy|
11056866|NCT04379960||Peptides|PBMCs will be incubated with peptides.
11056867|NCT04379960||W/o peptides|PBMCs will be incubated without peptides.
11056868|NCT04379947||FFR-CABG|Patients with at least one intermediate stenosis that received a preoperative FFR evaluation before being referred for CABG
11056869|NCT04379947||Angio-CABG|Patients with at least one intermediate stenosis that did not received a preoperative FFR evaluation before being referred for CABG
11056873|NCT04379921|Experimental|Apple Watch and App|Participants will receive standard care, and an Apple Watch to record activity through the App.
11056874|NCT04379895|Active Comparator|Heated RF ablation|Patients with OA that will undergo heated RF of the genicular nerves
11056875|NCT04379895|Active Comparator|Pulsed RF ablation|Patients with OA that will undergo pulsed RF of the genicular nerves
11056876|NCT04379882|Experimental|Digital sedation|30 minutes Silva module
11056877|NCT04379869|Experimental|NNZ-2591 SAD Cohort 1|Single Ascending Dose (SAD) of oral NNZ-2591 in healthy volunteers
11056878|NCT04379869|Experimental|NNZ-2591 SAD Cohort 2|Single Ascending Dose (SAD) of oral NNZ-2591 in healthy volunteers
11056879|NCT04379869|Experimental|NNZ-2591 SAD Cohort 3|Single Ascending Dose (SAD) of oral NNZ-2591 in healthy volunteers
11056880|NCT04379869|Experimental|NNZ-2591 MAD Cohort 1|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
11056881|NCT04379869|Experimental|NNZ-2591 MAD Cohort 2|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
11056882|NCT04379856|Experimental|Dose 1|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
11056883|NCT04379856|Experimental|Dose 2|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
11056884|NCT04379856|Experimental|Dose 3|NM-002 will be administered at the indicated dose by subcutaneous injection on Days 1 and 15.
11056885|NCT04379830|Experimental|Very Low Energy Diet|VLED in its entirety is composed of the following for 3-weeks preoperatively: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
11056886|NCT04379804|Active Comparator|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery. The tissue between the carotid artery and the trachea was dissected gently parallel to the direction of the nerve until the nerve is identified visually and,or by hand held stimulation probe. After the identification of RLN, the vessels of inferior thyroid lobe was ligated. The nerve was dissected along its course to the entry point, and then the thyroid lobe was totally dissected from the trachea and the lobectomy was completed. If adverse EMG changes were encountered during lateral approach, traction was released immediately and waited for recovery.
11056887|NCT04379804|Active Comparator|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN nerve was identified at the point of entry both visually and with hand held stimulation probe. The RLN dissection was proceeded craniocaudally by the division of the suspensory ligaments of the berry through the level of inferior thyroid artery. After the identification and visualitzation of the RLN through its whole course, the medial and inferior vessels of the thyroid gland were dissected and ligated. Then, the lobe was dissected from the trachea and lobectomy was completed.
11056888|NCT04379791||case cohort|Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
11056889|NCT04379791||control cohort|Patients without a surgical site infection or a wound complication (normal wound-healing and suture or staple removal) after surgical treatment of an ankle fracture.
11056890|NCT04379778|Experimental|Aerobic exercise|Moderate to high intensity aerobic exercise for 24 weeks.
11056891|NCT04379778|No Intervention|Standard care|Habitual lifestyle including standard care.
11056892|NCT04379765||Grup 1: Exercise and physical therapy programme|30 patients with lumbar spinal stenosis will receive hot pack, transcutaneous electrical nerve stimulation and deep warming as a physical therapy modality , and lumber flexion and strengthening exercises were performed for 7 times/week for 3 weeks.
11056893|NCT04379765||Grup 2: Surgical procedure programme|30 patients with lumbar spinal stenosis underwent decompression operation of the relevant level.
11056894|NCT04379752|Experimental|Cold-atmospeheric pressure plasma activated solution|Treatment arm subjects receive the trial intervention
11056895|NCT04379739|Experimental|camrelizumab + apatinib|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.
~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.
~Adjuvant treatment stage: according to the NCCN guidelines."
11056896|NCT04379739|Experimental|camrelizumab + platinum-based chemotherapy|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.
~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.
~Adjuvant treatment stage: according to the NCCN guidelines."
11056897|NCT04379726||patients with CFRD|Patients with diagnosis of CFRD, after OGTT
11056898|NCT04379726||patients without CFRD|Patients without diagnosis of CFRD, after OGTT
11056899|NCT04379713|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
11056900|NCT04379713|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
11056901|NCT04379700|Experimental|Embolization Group|23 participants who are aged between 30 to 75 years old, with grade 2 or 3 knee OA on the most recent knee radiographs obtained within 6 months of intervention. Each individual participant will be enrolled for approximately 13 months to complete all study visits from the initial screening visit to last follow up at 12-months post intervention.
11056902|NCT04379687|Experimental|Virtual reality|"st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control. 15 minutes
~nd part: Experimental training program for static and dynamic balance in sitting and standing by immersive Virtual Reality. 15 minutes"
11056903|NCT04379687|Active Comparator|Control group|"st part: Conventional physiotherapy treatment program aimed at achieving functional improvement and increased postural control.15 minutes
~nd part: Training program for static and dynamic balance in sitting and standing, according to Bayouk. 15 minutes"
11056904|NCT04379674|Experimental|Grup 1- Facilitation|It consists of cases that start with the taping of the facilitation.
11071588|NCT04275310|No Intervention|Waitlisted control|
11056905|NCT04379674|Experimental|Grup 2- İnhibition|It consists of cases that start with the taping of the inhibition.
11056906|NCT04379674|Placebo Comparator|Grup 3- Plasebo|It consists of cases that start with the taping of the placebo.
11056907|NCT04379661|Experimental|Online support group|Online weekly 1-hour moderated support group sessions for 12-weeks; participants complete surveys at baseline and 12-week follow-up
11056908|NCT04379661|No Intervention|Treatment as usual|Inactive control group of participants who complete surveys at baseline and 12-weeks later
11056909|NCT04379648|Other|Posttraumatic stress disorder|cohort of patients with Posttraumatic stress disorder PTSD
11056910|NCT04379635|Experimental|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Tislelizumab|Tislelizumab + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium on Day 1 of each cycle for up to a total of 12 cycles
11056911|NCT04379635|Placebo Comparator|Neoadjuvant chemotherapy + Neoadjuvant/Adjuvant Placebo|Placebo + cisplatin/carboplatin + paclitaxel or Pemetrexed Disodium on Day 1 of each cycle for up to a total of 12 cycles
11056912|NCT04379609||Employees and students|The control group was selected from among the employees and students of the faculty of dentistry to represent the general population without any temporomandibular disorder (TMD).
11056913|NCT04379609||Patients|Patients who were referred to the Ondokuz Mayıs University Faculty of Dentistry Department of Prosthodontics with a complaint of pain in the chewing muscles were enrolled in this study.
11056914|NCT04379596|Experimental|Arm 1A|T-DXd and 5-fluorouracil (5-FU)
11056915|NCT04379596|Experimental|Arm 1B|T-DXd and capecitabine
11056916|NCT04379596|Experimental|Arm 1C|T-DXd and durvalumab
11056917|NCT04379596|Experimental|Arm 1D|T-DXd and 5-FU or capecitabine and oxaliplatin
11056918|NCT04379596|Experimental|Arm 1E|T-DXd, durvalumab and 5-FU or capecitabine
11056919|NCT04379596|Active Comparator|Arm 2A|Trastuzumab, 5-FU/capecitabine, and cisplatin/oxaliplatin
11056920|NCT04379596|Experimental|Arm 2B|T-DXd monotherapy
11056921|NCT04379596|Experimental|Arm 2C|T-DXd, 5-FU or capecitabine, and oxaliplatin
11056922|NCT04379596|Experimental|Arm 2D|T-DXd, 5-FU or capecitabine, and durvalumab
11056923|NCT04379583||Subjects|Female subjects providing DNA saliva sample
11056924|NCT04379570|Experimental|Arm I (TMR)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
11056925|NCT04379570|Experimental|Arm II (MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
11056926|NCT04379570|Experimental|Arm III (TMR + MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
11056927|NCT04379570|Active Comparator|Arm IV (enhanced usual care)|Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
11056928|NCT04379557|Experimental|High power ablation|Ablation Index guided high power ablation (radio frequency energy: Left atrium anterior segment and roof: 40W, Left atrium inferior/posterior: 30W, near esophagus: 25W)
11056929|NCT04379557|Active Comparator|Conventional ablation|Conventional ablation applying 30-35W strategy for Left atrium anterior segments.
11056930|NCT04379544||COVID-19 Positive Patients Receiving CPUS|Adult patients (18 years) presenting to the ED or ICU with highly suspected diagnosis or confirmed diagnosis of COVID-19 in whom the clinician deems a CPUS (cardiopulmonary ultrasound) is indicated.
11056931|NCT04379531|Active Comparator|Standard Chest CT|
11056932|NCT04379531|Experimental|Low-dose Chest CT|
11056933|NCT04379518|Experimental|Supportve Care (rintatolimod, recombinant interferon alpha-2b)|Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on Day 3 or 4, in the absence of disease progression or unacceptable toxicity.
11056934|NCT04379505|Experimental|Quad shot radiation|-Radiotherapy will consist of Quad shot radiation delivered on the Ethos ring gantry kV-CBCT combined with linear accelerator system to a dose of 14 Gy in four, twice-daily fractions of 3.5 Gy delivered at least 6 hours apart over two consecutive days for a possible total of 3 cycles delivered in 3 to 4 intervals for a cumulative dose of of 42 Gy in 12 fractions. Cycle 2 and 3 of treatment is not mandated per protocol but may be given at the discretion of the treating physician.
11056935|NCT04379492|Experimental|Arm A - hydroxycholoroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
11056936|NCT04379492|Placebo Comparator|Arm B - placebo|Participants will receive placebo
11056937|NCT04379479|Experimental|Dialyzable Leukocyte Extract|"Oral administration 2 mg/5 mL every 24 hours for 14 days, following by 2 mg/5 mL twice a week for 3 weeks.
~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
11056938|NCT04379479|Placebo Comparator|Placebo|"Oral administration 5 mL every 24 hours for 14 days, following by 5 mL twice a week for 3 weeks.
~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
11056939|NCT04379453|Experimental|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
11056940|NCT04379440||" Acute Ward Patients  care setting cohort"|Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
11056941|NCT04379440||" Nursing Homes (RSA)  care setting cohort"|Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
11056942|NCT04379440||" Home and Outpatients' Care  cohort"|Outpatients at risk of SARS-CoV-2 infection
11056943|NCT04379440||" Dementia Outpatients  cohort"|Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
11056945|NCT04379440||" Outcomes  cohort"|Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
11056946|NCT04379427|Experimental|Optimization and control 1|The first study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
11056947|NCT04379427|Experimental|Optimization and control 2|The second study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
11056948|NCT04379427|Other|Precision and accuracy|During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.
11056949|NCT04379414|Experimental|Newly Diagnosed Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
11056950|NCT04379414|Experimental|Newly Diagnosed Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
11056951|NCT04379414|Experimental|Metastatic Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
11056952|NCT04379414|Experimental|Metastatic Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.
~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.
~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.
~Surveys will be sent once every 6 months for the first 3 years, then annually.
~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
11056953|NCT04379401|Other|Biventricular Pacing deactivated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
11056954|NCT04379401|Other|Biventricular Pacing activated|The primary objective of the study is to determine, whether short term activation/deactivation of biventricular pacing (BivP) of the CRT (during routine CRT interrogation) has an effect on vascular function
11056955|NCT04379388|Experimental|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
11056956|NCT04379388|No Intervention|Usual care control|Participants will receive referral to a quit smoking hotline
11056957|NCT04379375|Active Comparator|Inertia|"Participants simply receive and subsequently have default access (i.e., readily and immediately available) to handwashing (HW) materials. This condition will functionally serve as a control comparison. As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment."
11056958|NCT04379375|Experimental|Anchoring|"Involves once again providing default access to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser. The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that overshoots a desired target rate of 10+ daily HWs."
11056959|NCT04379362|Experimental|Low or intermediate grade prostate cancer|
11056960|NCT04379349|Experimental|Active SMS|Weekly interactive SMS text messaging check-ins.
11056961|NCT04379349|Sham Comparator|Sham SMS|Weekly minimally interactive SMS text messages.
11056962|NCT04379336|Experimental|Bacille Calmette-Guérin (BCG)|Participants will receive an intradermal injection of 0.1ml of the suspended BCG vaccine which accounts for 0.075mg of attenuated Mycobacterium bovis. BCG-Vaccin SSI [Statens Serum Institut], Danish strain 1331.
11056963|NCT04379336|Placebo Comparator|Placebo|The placebo used for this study is 0.9% Sodium Chloride (NaCl). Participants that are randomized to the control arm will receive a placebo injection of 0.1ml 0.9% NaCl, which is the same volume and has the same colour as the suspended BCG vaccine.
11071657|NCT04274751||Transfemoral|TAVI, transfemoral approach
11056964|NCT04379323|Experimental|YuWell YE900 and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE900 Electronic Sphygmomanometer (YuWell YE900) and with Desk Mercury Sphygmomanometer.
11056965|NCT04379310||covid-19 pneumonia|diagnosed with covid-19 by using PCR and computed tomography scans
11056966|NCT04379284||Pregnant women - positive COVID19 test|Pregnant women of any gestational age 8 weeks through delivery with a positive COVID19 test, with or without physical symptoms
11056967|NCT04379284||Pregnant women - negative or unknown COVID19 test|Pregnant women experiencing any respiratory or other physical symptoms of COVID19 at onset of labor, with negative or uncertain COVID19 test results
11056968|NCT04379271|Experimental|IMU-838|twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
11056969|NCT04379271|Placebo Comparator|Placebo|twice-daily (BID) oral placebo (+ SoC)
11056970|NCT04379219|Active Comparator|surgery|"Valid consent
~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )
~Laparotomy transverse incision (pfannenstiel incision)
~Exploration of the abdominal cavity
~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.
~Surgical repair of the uterine incision, and the abdomen"
11056971|NCT04379219|Active Comparator|methotrexate before surgery|"Valid consent
~patient will receive 50 mgm /m2 of methtrexate after full investigation ( CBC, serum creatinie, AlT, AST), 1 week before surgery.
~Anathesia , (regional may br converted into general ). IV antibiotic ( cefotaxime 1 gm I.V )
~Laparotomy transverse incision (pfannenstiel incision)
~Exploration of the abdominal cavity
~Identification of the uterus, dissection of the bladder, incision of the uterus and excision of the CSP mass.
~Surgical repair of the uterine incision, and the abdomen"
11056972|NCT04379206||Men who have sex with men|MSM receiving a self-test kit with optional assistance
11056973|NCT04379193|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
11056974|NCT04379193|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
11056975|NCT04379180||Treatment(bosentan, sildenafil and tadalafil)|
11056976|NCT04379167|Experimental|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma.
11056977|NCT04379154|Experimental|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air in patients hospitalised for COVID-19 infection
11056978|NCT04379141||hypotension|Patients with hypotension after induction of anesthesia
11056979|NCT04379141||non-hypotension|Patients without hypotension after induction of anesthesia
11056980|NCT04379128||patients with epilepsy|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
11056981|NCT04379128||Normal controls|Attentional tasks : D2-R task and TAP battery (sustained attention, alertness, divided attention) executive task : digit span, incompatibility and flexibility task (TAP battery), verbal fluencies depression score (NDDI-E scale) and anxiety score (GAD-7 scale)
11056982|NCT04379115|Active Comparator|Active (tDCS) + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS)
11056983|NCT04379115|Sham Comparator|Sham (tDCS) + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
11056984|NCT04379102||IUD patients|80 patients who matched the inclusion criteria and received IUDs
11056985|NCT04379089||Children <18|"Infants, children, and young adults age < 18 years
~Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)"
11056986|NCT04379076|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
11056987|NCT04379076|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
11056988|NCT04379063||Canadian physicians during COVID-19 pandemic|Any physician who is practicing in Canada during the COVID-19 pandemic, whether they hold a full, provisional, or post-graduate in-training license.
11056989|NCT04379050|Experimental|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for 96 weeks.
11056990|NCT04379037|Experimental|Intervention Arm|Adults over 18 years of age hospitalized because of COVID-19 infection will be treated with transcutaneous auricular vagus nerve stimulation (taVNS).
11056991|NCT04379024|Experimental|Immediate active agent|Duavee. One capsule daily for 6 months (+/- 1 month) of Duavee (Bazedoxifene 20 mg plus conjugated estrogens 0.45 mg)
11056992|NCT04379024|Other|Delayed active agent|No intervention for first 6 months. Then option to receive daily Duavee for 6 months.
11056993|NCT04379011|Experimental|Brivaracetam Group|Participants in this arm will receive the investigational drug, Brivaracetam.
11056994|NCT04379011|Placebo Comparator|Control Group|Participants in this arm will receive a placebo.
11056995|NCT04378998|Experimental|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Ying Tang were used.
11056997|NCT04378985|Experimental|Wearing a wearable device (the smart watch) for 8 weeks|The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.
11056998|NCT04378972||TREATED GROUP|25 portions of vitreous samples from 25 eyes of patients operated on vitrectomy for complications from diabetic retinopathy, incubated with curcumin, homotaurine and vitamin D3. The substances will be used individually and in triple association, to evaluate a possible synergistic effect on the expression of inflammatory cytokines and endothelial growth factors.
11056999|NCT04378972||CONTROL GROUP|The same fractions of vitreous samples (n = 25) evaluated for the expression of oxidative biomarkers, inflammatory cytokines and metalloproteinases, without prior incubation with the substances of the treated group.
11057000|NCT04378959|Experimental|Lidocaine patch first|This group will receive up to 3 lidocaine patches for 4 weeks, followed by placebo patches after a 1-3 week washout period.
11057001|NCT04378959|Placebo Comparator|Placebo patch first|This group will receive up to 3 placebo patches for 4 weeks, followed by lidocaine patches after a 1-3 week washout period.
11057002|NCT04378946|Experimental|Experimental - Error Augmented feedback (Restricted area)|Error augmented feedback. Random targets always INSIDE of workspace area.
11057003|NCT04378946|Active Comparator|Control - General feedback (Full area)|General feedback about task success. Random target INSIDE or OUTSIDE of workspace area.
11057004|NCT04378933|Experimental|Amber Glasses and Fixed Wake|Participants will wear glasses with amber lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will also be required to wake up at the same time (±30 mins).
11057005|NCT04378933|Active Comparator|Clear glasses and Free Wake|Participants will wear identically appearing glasses with clear lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will not be given instructions regarding sleep schedule.
11057006|NCT04378920|Experimental|4L6715|exploring various doses of LEAF-4L6715
11057007|NCT04378907|Active Comparator|Cigarette Smokers: 0 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
11057008|NCT04378907|Experimental|Cigarette Smokers: 4 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 4 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
11057009|NCT04378907|Experimental|Cigarette Smokers: 15 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
11057010|NCT04378907|Experimental|Cigarette Smokers: 30 mg/ml nicotine concentration|"ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration
~During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout."
11057011|NCT04378894|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
11057012|NCT04378894|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Families in the wait-listed control group will participate in a special awareness program but not MOCEP. Although the families in the wait-listed control group will start as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
11057013|NCT04378868|Active Comparator|Surgery within 8 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
11057014|NCT04378868|Experimental|Surgery within 24 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
11057015|NCT04378868|Experimental|Surgery within 8 hours, antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
11057016|NCT04378868|Experimental|Surgery within 24 hours, antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
11057017|NCT04378829||ambulatory follow-up|
11057018|NCT04378829||hospital follow-up|
11057019|NCT04378829||intensive care unit follow-up|
11057020|NCT04378816|Experimental|QPL intervention group|Using shared decision making support tool(Question Prompt List) for intervention
11057021|NCT04378816|No Intervention|Usual care group|No intervention, just continue using usual care
11057022|NCT04378803|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
11057023|NCT04378803|Experimental|Wait-list control (WLC) group|Receives 4 weeks of no-training interval followed by a testing session. Then, 4 weeks of mindfulness training followed by a testing session.
11057024|NCT04378790|Active Comparator|Sequential treatment|full-time spectacle correction first, with subsequent patching for 2 hours per day/7 days per week only if needed (no improvement (stable/worsening) and residual)
11057025|NCT04378790|Experimental|Simultaneous treatment|full-time spectacle correction and part-time patching for 2 hours per day/7 days per week
11057026|NCT04378777||Surveillance cohort|Cohort descriptive data will include demographic variables (e.g. age, sex, race, ethnicity), clinical information on enrollment and key aspects of medical history (e.g. concomitant medications, for example). Patients will be longitudinally followed, up to 12 months.
11057027|NCT04378751|Other|Decision aid video|Participants receiving the intervention will complete a pretest, watch the decision aid video, and complete posttest via tablet computer facilitated by Patient Navigators.
11057028|NCT04378751|Other|Genetic counseling informational brochure|Participants receiving the control will complete pretest, review a genetic counseling brochure with the Patient Navigators, and complete posttest via tablet computer facilitated by a Patient Navigator.
11057029|NCT04378738|Other|Cohort|the healthy people who accepted to participate in the study
11057030|NCT04378725|No Intervention|Control School|"When a student is screened as a smoker. The student will only be receiving Brief Intervention Advice from the dentist.
~Brief Intervention advice: delivered to all schoolchildren regardless of smoking status by the dentist. Brief information of dangers of smoking was embedded in the generic lecture of Dental Health Education given to the whole school in large group."
11057031|NCT04378725|Experimental|Intervention School|The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
11057032|NCT04378712|Experimental|Intervention Group|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
11057033|NCT04378712|Other|Control Group|Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.
11057034|NCT04378699|Experimental|SMR Sensory Motor Rhythm (12-15 Hz)|3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
11057035|NCT04378699|Experimental|the alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
11057036|NCT04378686||ESKD|Patients with ESKD and on treatment with any form of dialysis
11057037|NCT04378673||parental involvement group|n=46
11057038|NCT04378673||parental presence group|n=42
11057039|NCT04378673||parental absence group|control group, n=32
11057040|NCT04378660|Experimental|Intervention arm|Colonoscopy with AI
11057041|NCT04378647|Active Comparator|Induction ESHAP|3 Cycles ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4]
11057042|NCT04378647|Experimental|Induction BV-ESHAP|3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4] Brentuximab Vedotin [1.8 mg/kg IV, D1]
11057043|NCT04378634|Experimental|ME/CFS Exercise|Patients undergoing exercise first and the mental stress task after wash-out
11057044|NCT04378634|Experimental|Patients Stress|Patients undergoing the mental stress task first and exercise after wash-out
11057045|NCT04378634|Active Comparator|Healthy Exercise|Healthy controls undergoing exercise first and the mental stress task after wash-out
11057046|NCT04378634|Active Comparator|Healthy Stress|Healthy controls undergoing the mental stress task first and exercise after wash-out
11057047|NCT04378621|Experimental|Pharmacological anti-inflammatory treatment|Use of anti-rheumatic treatment with TNF-α inhibitor (subcutaneous injection given once or twice a week) or JAK inhibitor (per oral tablet once or twice a day)
11057048|NCT04378621|Experimental|Physical hand training|Physical hand training 10 min twice daily while on stable treatment
11057049|NCT04378608|Other|2 DAA (OBV/PTV/r) ± ribavirin (RBV)|Administering Ombitasvir/Paritaprevir/Ritonavir/ tablets plus RBV tablets to HCV GT4 in the treatment of Egyptian naïve patients
11057050|NCT04378595||During Pandemic|During Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. If a positive response is given, the investigators will ask if the food insecurity began or worsened during the pandemic in the past 1 to 2 months.
11057051|NCT04378595||Post-Pandemic|Post-Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. The investigators will assess if food insecurity has stopped or lessened after the pandemic.
11057052|NCT04378582||COVID-19 confirmed|Patients with confirmed COVID-19 by RT-PCR or serological test
11057053|NCT04378582||COVID-19 suspected|Patients suspected COVID-19, as defined by clinical history and course, who have negative RT-PCR or serological test but where treated and cared for as COVID-19 patients
11057054|NCT04378569|Active Comparator|ARQ-252 cream 0.3% QD (once daily)|Active Comparator
11057055|NCT04378569|Active Comparator|ARQ-252 cream 0.3% BID (twice daily)|Active Comparator
11057056|NCT04378569|Active Comparator|ARQ-252 cream 0.1% QD (once daily)|Active Comparator
11057057|NCT04378569|Placebo Comparator|Vehicle cream BID (twice daily)|Placebo Comparator
11057058|NCT04378569|Placebo Comparator|Vehicle cream QD (once daily)|Placebo Comparator
11057059|NCT04378556|Other|Nutrition|All participants received diet coaching, nutrition education and a per-meal protein prescription.
11057060|NCT04378543|Experimental|ART252-L|local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion
11057061|NCT04378530|Experimental|Personalized Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be asked to select a cue to use to remember to meditate.
11057062|NCT04378530|Active Comparator|Study control|Participants in the control group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive non-anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day.
11057096|NCT04378231|Experimental|standard dose group|patients take dry suspension of amoxicillin clavulanate potassium 30 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
11057097|NCT04378218|Experimental|HIIT Intervention|
11057063|NCT04378530|Experimental|Fixed Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be given a specific cue (i.e. leaving the bathroom in the morning) to use to remember to meditate.
11057064|NCT04378517|Experimental|ADHD family support|Psychoeducational support that consist of weekly parents support group meetings a total of three times and two interviews for parents of each adolescent.
11057065|NCT04378504||ACS|All patients admitted in the ICU for ACS after coronary angiography evaluation between May 2019 and May 2020
11057066|NCT04378465||ERP group|A prospective series of consecutive patients undergoing elective colorectal surgery completing a standardized Enhanced Recovery Program (ERP) protocol at the S. Anna University Hospital in Ferrara (Italy) in 2013-2015
11057067|NCT04378465||Non-ERP group|A retrospective series of consecutive patients operated at the same hospital (S. Anna University Hospital in Ferrara), in the same period of time (2013-2015), but with a traditional perioperative care protocol.
11057068|NCT04378452||COM-COVID cohort|Individuals of >16 years old evaluated during the COVID-19 outbreak by an anonymous survey and willing to respond. Expected timeframe for the collection of completed surveys: March 31th, 2020-September 30th, 2020]
11057069|NCT04378439|Active Comparator|intervention group|7 community health leaders; 56 social network members
11057070|NCT04378439|Active Comparator|delayed-intervention|7 community health leaders; 56 social network members
11057071|NCT04378426|Experimental|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50%nitrous oxide and 50% oxygen plus intravenous saline
11057072|NCT04378426|Active Comparator|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
11057073|NCT04378413|Experimental|The Effect of Aquatic Exercises on Pain, quality of life|Water-based exercise program was conducted in the second group of 15 patients in an indoor swimming pool. Temperature of mineral water was 36 °C. The program included warming up by walking forwards, sideways and backwards through the water in the pool; active range of motion of the joints of the lower extremities; stretching lower extremities; strengthening exercises for hips, knees, arms, elbows and wrists; and cooling down (slow walking, squatting and standing).
11057074|NCT04378413|Experimental|The Effect of Land Exercises on Pain, Quality of life|Land-based exercise program included abdominal and back strengthening exercises.
11057075|NCT04378374|Experimental|Baked food made of lentil flour|Food prepared with 100% lentil flour
11057076|NCT04378374|Experimental|Baked food made of lentil flour and wheat flour|Food prepared with a mixture of lentil flour and wheat flour
11057077|NCT04378374|Experimental|Baked food made of wheat flour|Food prepared with 100% wheat flour
11057078|NCT04378374|Experimental|Water|Potable water (energy and carbohydrate-free control)
11057079|NCT04378348|Experimental|Motivational Interview|
11057080|NCT04378348|Experimental|Participatory Group Activity|
11057081|NCT04378348|Placebo Comparator|Control Condition|
11057082|NCT04378335|Experimental|one arm|oral disorder
11057083|NCT04378322|Active Comparator|Nutrition and food purchasing tool + telenutrition|Participants will use an online nutrition and food purchasing tool in addition to telenutrition.
11057084|NCT04378322|Active Comparator|Nutrition and food purchasing tool|Participants will use an online nutrition and food purchasing tool.
11057085|NCT04378322|Active Comparator|Nutrition education tool|Participants will be exposed to an online nutrition education materials.
11057086|NCT04378309|Experimental|ePrep|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
11057087|NCT04378296|Experimental|Teledermatology|The 221 patients who are included in this group will be monitored from the Primary Care centers.
11057088|NCT04378296|No Intervention|Conventional monitoring|The 221 patients included in this group will have to visit the dermatologist at the hospital.
11057089|NCT04378283|Experimental|LET as topical anesthetic for wound repair.|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%) is a topical anesthetic that is routinely used before laceration repair.
11057090|NCT04378283|Active Comparator|EMLA plus infiltration as anesthetic for wound repair.|"EMLA (eutectic mixture of local anesthetics) with subsequent lidocaine infiltration. EMLA is a mixture of lidocaine (2.5%) and prilocaine (2.5%) in a cream base."
11057091|NCT04378270|Experimental|PopSole™ offloading device|This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.
11057092|NCT04378257|Experimental|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform. The sessions will be conducted in the Arabic or English languages.
~Following sessions would focus on psychological first aid based on the following interventional tools:
~Cognitive Behavior Therapy (CBT)
~Acknowledging emotions and normalizing current stress
~Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)
~Behavioral Activation Acceptance and Commitment Therapy (ACT)
~Grounding, Breathing, Acceptance of emotions, and de-fusion"
11057093|NCT04378257|Active Comparator|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice.
11057094|NCT04378244|Experimental|DeltaRex-G|"Escalating doses of DeltaRex-G i.v daily for 7 days as follows:
~Dose Level I: 3-6 patients will receive 1 x 10e11 cfu/dose Dose Level II: 3-6 patients will receive 2 x 10e11 cfu/ dose Dose Level III: 3-6 patients will receive 3 x 10e11 cfu/dose"
11057095|NCT04378231|Experimental|high-dose group|patients take dry suspension of amoxicillin clavulanate potassium 45 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
11057438|NCT04375982|Other|Blood collection|Venepuncture and fingerstick to obtain venous blood and capillary blood respectively
11057098|NCT04378205|Experimental|0.014/0.018 NiTi arch wire|0.014-inch NiTi on one side /0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
11057099|NCT04378205|Experimental|0.016/0.018 NiTi arch wire|0.016-inch NiTi on one side / 0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
11057100|NCT04378192|Active Comparator|Face mask ventilation|Use of face mask ventilation technique after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
11057101|NCT04378192|Active Comparator|Laryngeal mask ventilation|Use of laryngeal mask airway LMA for ventilation after induction of anaesthesia and administration pf muscle relaxant till the insertion of the endotracheal tube in a morbidly obese patient undergoing sleeve gastrectomy
11057102|NCT04378179||HFpEF|HF patients with preserved ejection fraction (HFpEF)
11057103|NCT04378179||HFrEF|HF patients with reduced ejection fraction (HFrEF)
11057104|NCT04378179||PAH|Patients with Pulmonary arterial hypertension (PAH)
11057105|NCT04378179||Control|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF but meet other inclusion criteria and non of the exclusion criteria.
11057106|NCT04378166|Experimental|Smart glasses|Application of smart glasses for ultrasound-guided central venous catheterization
11057107|NCT04378166|No Intervention|Control|Conventional ultrasound-guided central venous catheterization
11057108|NCT04378153|Experimental|HS-Discontinue (Study A)|Discontinuation of current hypertonic saline (HS) therapy in Study A
11057109|NCT04378153|Active Comparator|HS-Continue (Study A)|Continuation of current hypertonic saline (HS) therapy in Study A
11057110|NCT04378153|Experimental|Dnase-Discontinue (Study B)|Discontinuation of current dornase alfa (dnase) therapy in Study B
11057111|NCT04378153|Active Comparator|Dnase-Continue (Study B)|Continuation of current dornase alfa (dnase) therapy in Study B
11057112|NCT04378127|Experimental|educational program + traditional medical care|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
11057113|NCT04378127|No Intervention|traditional medical care|traditional medical care
11057114|NCT04378114|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one FST.
11057115|NCT04378101||Anorexia Nervosa Case|Participants in this group have a life-time history of anorexia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
11057116|NCT04378101||Bulimia Nervosa Case|Participants in this group have a life-time history of bulimia nervosa as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa.
11057117|NCT04378101||Binge-Eating Disorder Case|Participants in this group have a life-time history of binge-eating disorder as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders. These participants do not have a history of anorexia nervosa or bulimia nervosa.
11057118|NCT04378101||Control|Participants in this group have no history of disordered eating behaviors as determined by an algorithm applied to their responses to an eating disorders screening questionnaire (ED100K) that is based on the Structured Clinical Interview for Axis 1 Disorders.
11057119|NCT04378088||Group 1 - experts|"Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).
~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
11057120|NCT04378088||Group 2 - mix experts/trainee|"If intra and interobserver rates in group 1 are >0.7 proceed to group 2 evaluation with the same intervention.
~Evaluation of 15 images for each of the proposed 3 grade scale (45 images in total), randomly distributed to validate de scale; images will be assessed twice by the participants with a two-week interval in both study phases (the random distribution will vary between both evaluations).
~Together with the assessment of each image the participant is invited to choose one of possible three clinical actions (do nothing, wash with water and wash with simethicone)"
11057121|NCT04378075|Experimental|Vatiquinone|15 milligrams/kilogram (mg/kg) if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, 3 times per day (TID) or up to 72 weeks
11057122|NCT04378075|Placebo Comparator|Placebo|Vatiquinone-matching placebo, administered orally, TID for up to 24 weeks followed by vatiquinone 15 mg/kg if body weight <13 kg, and 200 mg if body weight ≥13 kg, administered orally, TID for up to 48 weeks.
11057123|NCT04378062|Active Comparator|Traction Neurectomy|Traction neurectomy - of digital sensory nerves at the time of amputation.
11057124|NCT04378062|Experimental|Targeted Muscle Reinnervation|Targeted Muscle Reinnervation - of digital sensory nerves at the time of amputation
11057125|NCT04378062|Experimental|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface - of digital sensory nerves at the time of amputation
11057126|NCT04378049|Active Comparator|Standard total knee arthroplasty|Participants who are randomized to the control group will undergo TKA according to local standard of care. The choice of implant and use of bone cement will be recorded but left to the surgeon's discretion according to their standard practice.
11057155|NCT04377867||LRBA deficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
11072188|NCT04270994|Experimental|Misoprostol|
11057127|NCT04378049|Experimental|Robot-assisted partial knee arthroplasty|Participants with isolated medial or isolated lateral compartment OA who are randomized to the intervention group and have one affected knee compartment will receive a robot-assisted unicompartmental knee arthroplasty (UKA). If the patient has medial or lateral OA plus patellofemoral OA they will receive a bicompartmental knee arthroplasty (BiKA) consisting of a two simultaneous UKAs. The partial knee replacement procedures will be performed using the Mako RIO robotic arm (Stryker) according to the manufacturer's instructions. The choice of implant and use of bone cement will be recorded but will be left to the surgeon's discretion. Surgeons will resurface the patella if the patellar cartilage meets Outerbridge grade 3 or 4 criteria
11057128|NCT04378036|Active Comparator|Neurodevelopmental Therapy Group|The number of participants in this group is 30. All participants were included in the rehabilitation program using only the Neurodevelopmental Therapy approach for 16 sessions (8 weeks x 2 days x 45 minutes).
11057129|NCT04378036|Active Comparator|Hippotherapy Simulator Group|The same participants were taken into a rehabilitation program in which 16 sessions (8 weeks x 2 days a week) the Hippotherapy Simulator device (30 minutes) and Neurodevelopmental Therapy (NDT) (15 minutes) (HS + NDT method) were used together.
11057130|NCT04378023|Other|Study group|Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
11057131|NCT04378010|Experimental|EDP-305 1.5 mg|Once a day orally for 72 weeks
11057132|NCT04378010|Experimental|EDP-305 2 mg|Once a day orally for 72 weeks
11057133|NCT04378010|Placebo Comparator|Placebo|Once a day orally for 72 weeks
11057134|NCT04377997|Experimental|Therapeutic Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.
~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.
~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation (LMWH for most subjects but UFH for those with morbid obesity or moderate to severe renal dysfunction as noted below) or standard of care anticoagulation. Those assigned to the therapeutic anticoagulation group will receive a higher dose of heparin."
11057135|NCT04377997|Active Comparator|Standard of Care Anticoagulation Group|"Patients identified as eligible through discussions with the primary care team and review of the electronic medical record will be approached and consented as described above in Subject Enrollment and Procedures for obtaining consent.
~For research purposes, 20ml of blood will be drawn and stored for biobanking at the following timepoints: at baseline (i.e., after enrollment and before randomization), 5-7 days post-randomization, and on the day of discharge. The blood sample taken at baseline will also be used to conduct a pregnancy test for women of childbearing age.
~After enrollment and blood collection, patients will then be randomized to therapeutic anticoagulation or standard of care anticoagulation. Those assigned to the standard of care anticoagulation group will receive the normal dose of heparin as per the Mass General guidelines."
11057136|NCT04377971|Experimental|Ask-tell-ask method|Study team will provide participant education using the ask-tell-ask method. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
11057137|NCT04377971|Active Comparator|Standard of Care (SOC)|Participants will receive SOC education from the researcher. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
11057138|NCT04377958|Other|Asthmatics|Asthmatic group from which serum samples will be collected for analysis
11057139|NCT04377945|Experimental|Part 1, JM-010 component Group A|Part 1, JM-010 component Group A
11057140|NCT04377945|Experimental|Part 1, JM-010 component Group B|Part 1, JM-010 component Group B
11057141|NCT04377945|Experimental|Part 1, JM-010 component Group C|Part 1, JM-010 component Group C
11057142|NCT04377945|Placebo Comparator|Part 1, Placebo Group|Part 1, Placebo Group
11057143|NCT04377945|Experimental|Part 2, JM-010 combination Group A|Part 2, JM-010 combination Group A
11057144|NCT04377945|Experimental|Part 2, JM-010 combination Group B|Part 2, JM-010 combination Group B
11057145|NCT04377945|Placebo Comparator|Part 2, Placebo Group|Part 2, Placebo Group
11057146|NCT04377945|Experimental|Part 2, JM-010 component Group C|Part 2, JM-010 component Group C
11057147|NCT04377932|Experimental|AGAR T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 (AGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
11057148|NCT04377919|Active Comparator|Cranberry|Administration of 2 capsules with 500mg (Miralys Ltda) of cranberry extract per day, for 8 weeks
11057149|NCT04377919|Placebo Comparator|Placebo|Administration of 2 capsules with 500mg of maize starch per day, for 8 weeks
11057150|NCT04377906|Experimental|High Protein-Fiber and Exercise|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day and exercise : aerobic and resistance training for 5x/week, 45 minute each sesion
11057151|NCT04377906|Experimental|High Protein-Fiber|give 1200 Kcal with 25% protein from fish and tempeh and 30g fiber from vegetable and fruit, 3 times/day
11057152|NCT04377906|Experimental|Exercise|aerobic and resistance training for 5x/week, 45 minute each sesion
11057153|NCT04377906|No Intervention|control|regular diet
11057154|NCT04377893|Experimental|Treatment arm|Participants will receive eye-gaze AT intervention
11057198|NCT04377542|Active Comparator|Parks|Modified Parks technique
11057199|NCT04377542|Active Comparator|Seton|Two-stage seton placement
11057251|NCT04377256|Experimental|Radiological assessement|Two CBCTs were recorded and compared, one at the baseline and the other at 4 months post-op. The bone resorption was quantified and analyzed using ITK-SNAP software
11072215|NCT04270773|Other|Only arm|Single arm, Receiving treatment
11057156|NCT04377867||CTLA4 haploinsufficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
11057157|NCT04377867||Control group|Age matched healthy control group will be used during the study to determine the reference values of the immunological assays.
11057158|NCT04377854||MCS recipient|All recipients of durable MCS will be followed up on a yearly basis with collection of blood sample and clinical data for 25 years.
11057159|NCT04377841||Facial Demodicosis|"Clinical presentation of facial skin matches any of the followings:
~Pityriasis folliculorum.
~Papulopustular lesion.
~Rosacea.
~Demodex infestation detected by direct microscopic examination ≥ 5 mites/cm2."
11057160|NCT04377841||Ocular Demodicosis|"Clinical presentation of ocular region matches any of the followings:
~Chronic blepharitis.
~Eyelash abnormalities: trichiasis, distichiasis, madarosis.
~Meibomian gland dysfunction.
~Recurrent chalazion.
~Ocular rosacea.
~Demodex infestation detected by cilia epilation test ≥ 1 mite/eyelid."
11057161|NCT04377828|Experimental|Laser intervention|1 to 2 sessions of pigment laser1
11057162|NCT04377815||General Public cohort|General Public
11057163|NCT04377815||Hospital cohort|Medical records of patients hospitalised due to COVID-19
11057164|NCT04377789|No Intervention|non-quercetin group|Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
11057165|NCT04377789|Active Comparator|quercetin prophylaxis group|Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
11057166|NCT04377789|Active Comparator|quercetin treatment group|Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
11057167|NCT04377776||Transplanted patients|Transplanted Kidney, Pancreas or Pancreatic Islet patients at MedicineTransplant Unit - San Raffaele Scientific Istitute
11057168|NCT04377750|Experimental|Tocilizumab treatment group|Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.
11057169|NCT04377750|Placebo Comparator|Placebo group|Placebo. intravenous administration of 100 ml of normal saline.
11057170|NCT04377737|Other|RT-PCR Covid-19|
11057171|NCT04377724||ETH cohort|employees or students at ETH Zurich, Switzerland
11057172|NCT04377711|Active Comparator|Group 1|Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI
11057173|NCT04377711|Placebo Comparator|Group 2|Participants receive Placebo matching Alvesco , twice daily for 30 days via pMDI
11057174|NCT04377698|Active Comparator|Platelet Rich Fibrin group(PRF)|Following apicoectomy PRF gel was prepared and placed in the osseous defect followed by placement of PRF membrane
11057175|NCT04377698|Active Comparator|Freezed Dried Bone Allograft group(FDBA)|Following apicoectomy FDBA graft were prepared and placed in the osseous defect followed by placement of PRF membrane
11057176|NCT04377685||COVID19 patients|Patient tested positive for SARS-CoV-2 who had a CT scan
11057177|NCT04377672|Experimental|Anti- SARS-CoV-2 Plasma|Human Convalescent Plasma
11057178|NCT04377659|Experimental|Intubation/Mechanical Ventilation|Progression of respiratory failure in cohort #1 will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation
11057179|NCT04377659|Experimental|Respiratory Support|In cohort #2 progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)
11057180|NCT04377646|Active Comparator|Hydroxychloroquine & Zinc|"Will receive:
~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.
~Zinc 15 mg at daily dose up to 2 months"
11057181|NCT04377646|Active Comparator|Hydroxychloroquine|"Will receive:
~Hydroxychloroquine 400 mg at day 1 and day 2, then a weekly dose of 400 mg up to 2 months.
~Placebo of Zinc"
11057182|NCT04377646|Placebo Comparator|Placebo|Will receive a double placebo (Hydroxychloroquine and Zinc) up to 2 months
11057183|NCT04377633|Sham Comparator|Pre-intervention|Anesthesia handover during surgery will be performed as usual, i.e., a verbal exchange of pertinent clinical information.
11057184|NCT04377633|Experimental|Post-intervention|Anesthesia handover during surgery will be performed according to a structured checklist.
11057185|NCT04377620|Placebo Comparator|Placebo + Standard of Care (SoC)|Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
11057186|NCT04377620|Experimental|Ruxolitinib 5mg + Standard of Care (SoC)|Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
11057187|NCT04377620|Experimental|Ruxolitininb 15mg + Standard of Care (SoC)|Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
11057188|NCT04377607||Group OP|outpatients with asymptomatic or uncomplicated or mild pneumonia
11057189|NCT04377607||Group H|hospitalized patients
11057190|NCT04377607||Group IC|patients admitted to intensive care unit
11057191|NCT04377594|Experimental|Pulmonary vein isolation plus substrate modification|Pulmonary vein isolation plus ablation of low voltage areas in the left atrium
11057192|NCT04377594|Active Comparator|Pulmonary vein isolation|Pulmonary vein isolation
11057193|NCT04377568|Experimental|Convalescent Plasma + Standard of Care (C19-CP + SoC)|Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.
11057194|NCT04377568|No Intervention|Standard of Care (SoC)|Participants will receive standard of care while being hospitalized for COVID-19.
11057195|NCT04377555|Experimental|All Participants|Participants in the main study will be evaluated at baseline, monitored, and followed for a 1-year period with the option to continue in the study for a second year of treatment.
11057196|NCT04377555|Experimental|CSF-Substudy Participants|Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.
11057197|NCT04377542|Active Comparator|LIFT|Ligation of intersphincteric fistula tract
11057200|NCT04377529|Experimental|Back Skills Training Champion|In additional to access to the online provider Back Skills Training course, participants in clusters randomised to this arm will receive additional support from a local champion. The local champion will have received additional training and support on the implementation of the Back Skills Training intervention from the study team.
11057201|NCT04377529|Active Comparator|No Champion|Participants in clusters randomised to this arm will not receive any additional training or support beyond access to the online provider Back Skills Training course.
11057202|NCT04377516|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
11057203|NCT04377516|Active Comparator|Exercise group|pelvic floor muscle training
11057204|NCT04377516|Placebo Comparator|Control group|pelvic girdle education
11057205|NCT04377516|Other|Health group|pelvic girdle education
11057206|NCT04377503|Experimental|Tocilizumab|Patients will receive Tocilizumab, 8 mg / kg diluted in 100 ml of saline and administered IV for 60 minutes. The dose will be repeated only once 12 hours after the first dose.
11057207|NCT04377503|Active Comparator|Methylprednisolone|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days in two daily doses. Finally 0.5 mg / kg / day for another 7 days.
11057208|NCT04377477|Experimental|Lung low dose radiotherapy|Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
11057209|NCT04377464||COVID-19 Survivors|Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points.
11057210|NCT04377451|No Intervention|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
11057211|NCT04377451|Experimental|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age <16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
11057212|NCT04377425||Patients with acute neurological symptoms|Consecutive patients with acute neurological disease admitted at the Neurology departments will be tested with a nasopharyngeal swap for SARS-COVID-19 RNA according to standard operating procedures at the department (if estimated hospital stay is >24hours). Medical and clinical characteristics will be collected
11057213|NCT04377425||Stroke patients|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.
~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
11057214|NCT04377425||Seizure/epilepsy|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.
~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
11057215|NCT04377412||Albania|
11057216|NCT04377412||Australia|
11057217|NCT04377412||Czech Republic|
11057218|NCT04377412||France|
11057219|NCT04377412||Germany|
11057220|NCT04377412||Hong Kong|
11057221|NCT04377412||Israel|
11057222|NCT04377412||Italy|
11057223|NCT04377412||Lebanon|
11057224|NCT04377412||Norway|
11057225|NCT04377412||Poland|
11057226|NCT04377412||Russia|
11057227|NCT04377412||Spain|
11057228|NCT04377412||Sweden|
11057229|NCT04377412||Taiwan|
11057230|NCT04377412||Ukraine|
11057231|NCT04377412||United States|
11057232|NCT04377399|Active Comparator|high dose|vitamin D (40,000 IU weekly) for 24 weeks
11057233|NCT04377399|Active Comparator|Low dose|vitamin D (5,000 IU weekly) for 24 weeks
11057234|NCT04377386|Experimental|Intervention group: 1000 IU DV|The 75 participants assigned to the intervention group will take 1 DV capsule of 1000 IU daily for 15 weeks.
11057235|NCT04377386|Placebo Comparator|Control group: 200 IU DV|The 75 participants of the control group will take 1 DV capsule of 200 IU daily for 15 weeks, this dose being the minimum recommended for children. The above, considering that it is ethical for the control group to receive a minimum dose of supplementation.
11057236|NCT04377360|Experimental|Diffusing Alpha-emitter Radiation Therapy (DaRT)|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Tumor response to DaRT will be assessed periodically 3 months after removal.
11057237|NCT04377347||Confirmed spontaneous subarachnoid haemorrhage|"Patients, minimum 18 years of age, identified with the diagnosis in the Danish National Patient Register. The diagnosis is verified by medical record review.
~All patients were initially admitted to a hospital in the Capital Region of Denmark.
~In a national labour marked register and the civil registration register the patients are then followed for four years."
11057238|NCT04377334|Experimental|MSC Treatment|
11057239|NCT04377334|No Intervention|control|
11057240|NCT04377321||group 1 on cochicine|The first group patients received colchicine 0.5 twice daily for 6 months
11057241|NCT04377321||group 2 on glucophage 1 gm twice daily|second group received glucophage 1gm twice daily for 6 months
11057242|NCT04377321||group 3 control|the third group patients were on diet only for 6 months
11057243|NCT04377308|No Intervention|Treatment As Usual|Participants may choose to not take fluoxetine and remain in the study
11057244|NCT04377308|Active Comparator|Fluoxetine|Participants will take fluoxetine 20 mg initially, increasing as tolerated to a maximum of 60 mg until symptoms abate, then will be tapered by 20 mg per week off the fluoxetine Participants will be on fluoxetine for 2 weeks to 2 months depending on symptom duration
11057245|NCT04377282|Experimental|Buckwheat|Cooked buckwheat
11057246|NCT04377282|Experimental|Couscous|Cooked couscous
11057247|NCT04377282|Experimental|Water|Potable water
11057248|NCT04377269|Experimental|Taping Group|33 participants, received ankle taping
11057249|NCT04377269|Experimental|Bandaging|33 participants, received ankle bandaging
11057250|NCT04377269|Placebo Comparator|Placebo Taping (Control) Group|34 participants, received ankle placebo taping
11057252|NCT04377256|Experimental|Histomorphometric analysis|During implant placement (4 months after the bone grafting), a bone biopsy is collected and stained with several colorants to analyze the biological bone healing
11057253|NCT04377243|Experimental|V8 850 mg|Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8
11057254|NCT04377243|Placebo Comparator|Placebo 850 mg|Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo
11057255|NCT04377230|Experimental|Biliopancreatic limb 60cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
11057256|NCT04377230|Active Comparator|Biliopancreatic limb 100cm|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
11057257|NCT04377217|Experimental|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months.
11057258|NCT04377204|Active Comparator|Lidocaine Group|Local injection of 1% lidocaine with 1:100,000 epinephrine one time pre-operatively prior to general anesthesia
11057259|NCT04377204|Active Comparator|Lidocaine with Bupivacaine|Local injection of 1% lidocaine with 1:100,000 epinephrine mixed 1:1 with 0.5% marcaine bupivacaine with 1:200,000 epinephrine, one time pre-operatively prior to general anesthesia
11057260|NCT04377191|Experimental|VR 1 Group|In this group, participants received standard exercise and exergame training with Microsoft Xbox 360 Kinect for 2 days per week for 6 weeks.
11057261|NCT04377191|Experimental|VR 2 Group|In this group, participants received standard exercise and exergame training with ALDA balance gear for 2 days per week for 6 weeks.
11057262|NCT04377191|Active Comparator|Control Group|In this group, participants received only standard exercise for 2 days per week for 6 weeks.
11057263|NCT04377178|Experimental|Dentin chips group from automated mill|Dentin particles prepared from dentin grinder will be placed in extraction socket immediately after extraction
11057264|NCT04377178|Active Comparator|Manually milled Dentin chips|Dentin particles prepared from bone mill will be placed in extraction socket immediately after extraction.
11057265|NCT04377165|Active Comparator|Newsfeed|This will provide you with reliable accurate information on the pandemic.
11057266|NCT04377165|Experimental|Gamification|The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.
11057267|NCT04377139||Prophylaxis|Those LTR receiving prophylaxis against CMV
11057268|NCT04377139||Preemptive therapy|Those LTR receiving preemptive therapy against CMV
11057269|NCT04377126|Active Comparator|Unacylated ghrelin|Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).
11057270|NCT04377126|Placebo Comparator|Placebo|Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.
11057271|NCT04377113||RCC patients|"RCC patients (30 pts) will include patients with kidney cancer (renal cell cancer).
~Investigators will collect and analyze:
~blood sample,
~urine sample,
~kidney tissue sample (healthy tissue, carcinomatous tissue and borderline tissue between them)."
11057272|NCT04377113||Healthy patients|"In this group (30 patients) will be recruiting healthy patients (volunteer).
~Investigators will collect and analyze:
~blood sample."
11057273|NCT04377100|Other|Single arm study|Descriptive behavioral health survey
11057274|NCT04377087|Experimental|Olaparib|Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
11057275|NCT04377061||NCWS retrospective and prospective patients|"The clinical charts of NCWS patients, diagnosed by DBPC gluten/wheat challenge, between January 2001 and December 2019, attending the Department of Internal Medicine at the University Hospital of Palermo, the Department of Internal Medicine of the Hospital of Sciacca, and the Department of Medical and Surgical Sciences of the University of Bologna, will be reviewed retrospectively. The investigators prospectively will also survey patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS by DBPC gluten/wheat challenge. The patients will be recruited between January 2019 and January 2022 at the same centers, and at the Internal Medicine Division of the Cervello-Villa Sofia Hospital of Palermo, Palermo."
11057276|NCT04377061||CD retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of a control group of CD patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of CD patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
11057277|NCT04377061||IBS retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of another control group of IBS patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of IBS patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
11057278|NCT04377048|Experimental|Nivolumab/GS|"Part-1: GS Induction
~Patients will receive GS for 1 cycle.
~S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle
~BSA < 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day
~Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle
~After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.
~Part-2: Nivolumab Add-On
~Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle
~S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle
~Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle
~The treatment will be continued until disease progression, intolerance to study treatment or death."
11057279|NCT04377022|No Intervention|Conventional Therapy|In this group, Patients receive Conventional Therapy for 40 minutes daily and 5 days in a week. The training period was 5 week after the recruitment of patients.
11057280|NCT04377022|Experimental|Combined Therapy|In this group, Patients receive Aerobic exercise training in addition to conventional Physical Therapy. Patients undergoes Aerobic exercise training for 25 minutes and 3 days in a week. A total of 15 session of aerobic exercise training session was given to patient.
11057281|NCT04377009|Experimental|Active CBT-I|Internet-guided cognitive behavioral therapy
11057282|NCT04377009|Other|Control|Education control program
11057283|NCT04376996||General cohort|General population cohort aged 0-100 years from Slovenia
11057284|NCT04376983|No Intervention|Control|Patients will get no intervention
11057285|NCT04376983|Experimental|Intervention|Patients will transmit their CRT data every week (first 6 weeks) and then every two week to the Heart Centre Hasselt. The physical activity data will be used to deliver a tailored motivational message to the patient to increase physical activity in this group.
11057286|NCT04376970|Active Comparator|Fluorometholone group|This group included 38 patients treated with topical fluorometholone 0.1% (FLUCON®) 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
11057287|NCT04376970|Active Comparator|Cyclosporine A group|This group included 34 patients treated with cyclosporine A 0.5% eye drops prepared in Ricin oil by the pharmacy of Tunis Military Hospital and prescribed 4 times a day for one month then 3 times a day for one month and 2 times a day for four months.
11057288|NCT04376957|Active Comparator|Counselled with Current Standard Care|Standard of care consists of standard counselling and written materials provided by the oncologist or pharmacy (e.g. instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered).
11057289|NCT04376957|Experimental|Counselled with MASCC Oral agent Teaching Tool (MOATT)|This group will receive counselling using the MASCC Oral Agent Teaching Tool and be compared with the standard of care counselling.
11057290|NCT04376944||Exposed group|Caregivers and agents working directly in COVID units compared to those living.
11057291|NCT04376944||Control group|caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
11057292|NCT04376931|Experimental|Iscador®P as intravenous infusion|"Investigational therapy will be administered in six Dose Groups (DG):
~10 mg, 20 mg, 40 mg, 90 mg, 140 mg and 200 mg Iscador®P. The initial dose group of the study is set to 40 mg Iscador®P. The two lower dose groups (20 or 10 mg) will only be used in case of intolerance at 40 mg Iscador®P. Once per week patients receive intravenous infusions of Iscador®P dissolved in 250 ml of sodium chloride solution (0.9 %). After the 4-week period of the MTD estimation phase each subject will immediately be included into a follow up observation in which he/she receives the last well tolerated dosage they had or the next lower dosage than the currently investigated DG in the running phase Ib study depending on the current estimate of the MTD at that time."
11057293|NCT04376918|Active Comparator|Begin with BVGA|"After initial anesthesia induction, anesthetized volunteers will be ventilated through through the BVGA for 2 minutes and then through the face-mask for 2 minutes. The normal anesthesia procedures will then be resumed.
~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
11057294|NCT04376918|Active Comparator|Begin with Face-mask|"After initial anesthesia induction, anesthetized volunteers will be ventilated through the face mask for 2 minutes and then through the BVGA for 2 minutes. The normal anesthesia procedures will then be resumed
~The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation The Mask is a classic face mask"
11057295|NCT04376892||Group 1|Exercise capacity under 149 meter
11057296|NCT04376892||Group 2|Exercise capacity between 150 and 249 meter
11057297|NCT04376892||Group 3|Exercise capacity between 250 and 349 meter
11057298|NCT04376892||Group 4|Exercise capacity above 340
11057299|NCT04376879||Step 1: creation of the score|Cohort for the creation of clinical-biological score to predict the risk of intubation in COVID-19
11057300|NCT04376879||Step 2: validation of the score|Cohort for the validation of clinical-biological score to predict the risk of intubation in COVID-19
11057301|NCT04376866|Experimental|Toripalimab+CCRT|"Toripalimab 240mg, and Cisplatin 100mg/m2 (every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT), followed by Toripalimab 240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy.
~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
11057302|NCT04376866|No Intervention|CCRT alone|"Cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy (IMRT).
~IMRT: total dose 60-66Gy, 1.8-2.0Gy/f"
11057303|NCT04376853||COVID-19|Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
11057304|NCT04376840|Experimental|adults with severe SARS-CoV2 pneumonia|adult with severe SARS-CoV2 pneumonia
11057305|NCT04376827|Experimental|Guselkumab+Standard of Care|Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids.
11057306|NCT04376827|Placebo Comparator|Placebo+Standard of Care|Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids.
11057307|NCT04376814|Experimental|Test Group|In this group, Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days, plus 200mg of Hydroxychloroquine two times per day will be given to patients for 7 days.
11057308|NCT04376814|Active Comparator|Control Group|In this group, Patients will be given a stat dose of 400mg Hydroxychloroquine tablets plus 200/50 mg of Lopinavir/Ritonavirtwo times per day for seven days.
11057309|NCT04376801||Tension-band Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed tension-band fixation after olecranon osteotomy were classified into Tension-band Fixation Group.
11057344|NCT04376567|Active Comparator|One stage BBAVF|comparison
11057310|NCT04376801||Plate Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed plate fixation after olecranon osteotomy were classified into Plate Fixation Group.
11057311|NCT04376788|Experimental|Exchange transfusion|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up
11057312|NCT04376788|Experimental|Methylene blue with plasma|Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
11057313|NCT04376788|Experimental|Exchange transfusion and methylene blue with plasma|Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.
11057314|NCT04376775||Transplant patient|This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.
11057315|NCT04376762|Experimental|Fibrinogen Concentrate|Fibrinogen Concentrate (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM).
11057316|NCT04376762|Active Comparator|Cryoprecipitate|. Cryoprecipitate (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM).
11057317|NCT04376749||preterm infants received caffeine|preterm infants aged between 28 to 34 weeks gestational age who received caffeine therapy either for prophylaxis or treatment
11057318|NCT04376749||preterm infants received no caffeine|preterm infants aged between 28 to 34 weeks gestational age who received no caffeine therapy
11057319|NCT04376736|No Intervention|Control arm|Patients are reminded about their appointments
11057320|NCT04376736|Experimental|Intervention arm|Patients are offered a one-time home visit by providers in lieu of their upcoming in-person visit
11057321|NCT04376723|Experimental|Self-guidance|Participants will be asked to use the app for five weeks without the input of a clinician or researcher.
11057322|NCT04376723|Experimental|Assisted self-guidance|Participants will be asked to use the app for five weeks and will be contacted via telephone once a week by a researcher to provide a rationale for using the app, or to offer any information about the app itself. This will not be used to provide therapeutic intervention.
11057323|NCT04376710||Surgeons|
11057324|NCT04376710||Patients|
11057325|NCT04376697|Experimental|Active rTMS|Treatment will be delivered daily (weekdays) rTMS treatments, for up to 10 daily sessions and up to 75 sessions in total.
11057326|NCT04376684|Experimental|Participants receiving otilimab|Participants will receive a single dose of otilimab administered as an IV infusion in addition to standard of care.
11057327|NCT04376684|Placebo Comparator|Participants receiving placebo|Participants will receive a single dose of placebo administered as an IV infusion in addition to standard of care.
11057328|NCT04376671||temporal lobe epilepsy|Group of patients with temporal lobe epilepsy
11057329|NCT04376671||Extra-temporal lobe epilepsy|Group of patients with extra-temporal lobe epilepsy
11057330|NCT04376658||Cohort 1|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with up to 4L/minute oxygen supply through nasal catheter.
11057331|NCT04376658||Cohort 2|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection needing oxygen supplementation > 4L/min on nasal catheter or HFNC or NIV or MV or ECMO.
11057332|NCT04376658||Cohort 3|Adult hospitalized patients with proven or suspected SARS-Cov-2 infection with moderate or severe ARDS according to the Berlin definition
11057333|NCT04376645|Experimental|Group 1|Group 1: - Class III patients with increased vertical relationship These patients were scheduled for bimaxillary surgical procedures (Maxillary advancement and mandibular setback with posterior maxillary impaction) to correct the antero-posterior and vertical skeletal discrepancies.
11057334|NCT04376645|Experimental|Group 2|Group 2: - Class III subjects with normal vertical relationship These patients were scheduled for mandibular setback surgical procedure (with no posterior maxillary impaction) to correct the antero-posterior skeletal discrepancy.
11057335|NCT04376632|No Intervention|Control|Participants in this group avoid all nuts for 8 weeks.
11057336|NCT04376632|Experimental|Pecan ADD|Participants in this group consume 68 g of pecans/d with no additional dietary instructions and avoid all other nuts.
11057337|NCT04376632|Experimental|Pecan SUB|Participants in this group consume 68 g of pecans/d with instructions to substitute pecans with isocaloric foods in the habitual diet. They are also instructed to avoid all other nuts.
11057338|NCT04376619|Experimental|KDIGO guidelines|Part 1 of study, those identified as high risk for AKI then will have Kidney Disease Global Improving outcomes guideline implemented to see if this reduces incidence of AKI
11057339|NCT04376619|Experimental|RIPC|part 2 of study, those identified as high risk of AKI will have Kidney Disease Improving Global Outcomes guidelines and RIPC implemented to see if this reduces incidence of AKI compared to part 2 of study
11057340|NCT04376606|Experimental|Left atrial appendage closure group|
11057341|NCT04376606|Experimental|Radiofrequency ablation group|
11057342|NCT04376606|Experimental|LAAC combined with radiofrequency ablation group|
11057343|NCT04376593|Experimental|18F-αvβ6-BP|Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
11057346|NCT04376554|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
11057347|NCT04376554|Active Comparator|amoxicillin-clavulanate|Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or for 10 days.
11057348|NCT04376541||early extubation|the patients extubated in O.R or within 2 hours in the ICU
11057349|NCT04376541||late extubation|the patients extubated after 2 hours from O.R
11057350|NCT04376528|Experimental|Cyclosporin A|
11057351|NCT04376528|Active Comparator|Mycophenolate Mofetil|
11057352|NCT04376515|Experimental|HOPE Intervention|HOPE peer-led intervention
11057353|NCT04376515|No Intervention|Control|Control group- online community without peer leaders
11057354|NCT04376502|Other|radiation therapy (RT)|RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
11057355|NCT04376489|Experimental|Brief cognitive/behavioral strategies|
11057356|NCT04376489|Experimental|Effortful self-regulatory activities|
11057357|NCT04376489|No Intervention|No activities|
11057358|NCT04376476|Experimental|Adult group A1|Adults with confirmed pauci-symptomatic COVID-19 infection recruited through the blood collection centers set up by the occupational health services. Hospital visits (for clinical examination, biology, immunology, virology measurements) are scheduled at day 0, day 3, day 7, day 14, day 21; phone call is scheduled at day 10.
11057359|NCT04376476|Experimental|Adult group A2|Adults with confirmed COVID-19 infection of moderate clinical severity recruited within participating units. Follow-up visits (for clinical examination, biology, immunology, virology measurements) are scheduled at day 0, day 3, day 7, day 14, day 21, and in case of worsening; a day 10 visit will be performed by phone or onsite if the patient is still hospitalized.
11057360|NCT04376476|Experimental|Adult group A3|Adults with confirmed non-COVID-19 viral infection pauci-symptomatic recruited through the blood collection centers set up by the occupational health services. Hospital visits (for clinical examination, biology, immunology, virology measurements) are scheduled at day 0, day 3, day 7, day 14, day 21; phone call is scheduled at day 10.
11057361|NCT04376476|Experimental|Children group E1|Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
11057362|NCT04376476|Experimental|Children group E2|Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
11057363|NCT04376476|Experimental|Children group E3|Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
11057364|NCT04376463|Experimental|Mood state and aminoacids supplementation|The aim of this study was to analyse the isolated and combined effects of BCAA supplementation and exercise on physical frailty status and mood states in pre-frail institutionalized older women.
11057365|NCT04376463|Experimental|Physical Tests|Through the combination of bcaa supplementation and physical exercise is able to improve the functional capacity of the elderly, through the SPPB test battery, short performance physical battery.
11057366|NCT04376463|Experimental|Psychometrics evaluated|Through the combination of bcaa supplementation and physical exercise, it is able to improve moods and cognition of the elderly.
11057367|NCT04376463|Experimental|Fried Scale Phenotype|Primary outcomes include Physical Frailty evaluated according to Fried's Frailty Phenotype2): Shrinking assessed by self-report of unintentional weight loss of four kilograms or more in the last six months; Self-reported exhaustion evaluated by concordance of two questions (7 and 20) of the Center for Epidemiology-Depression (CES-D) scale; Weakness analyzed using the handgrip strength test; Slowness measured by the 4.6 meters walking test; levels of Physical Activity assessed by the (IPAQ).
11057368|NCT04376450|Experimental|Nonincised Papillae Surgical Approach|Nonincised papillae surgical approach is a papillae preservation technique, where an apical approach is carried out, without incisions or disinsertion of tissues at the level of the papillae or marginal tissues.
11057369|NCT04376450|Active Comparator|Entire Papilla Preservation Technique|Entire Papilla preservation technique is a tunnel-like procedure to preserve the defect associated papilla
11057370|NCT04376437|Experimental|medical cannabis|All patients will start with 250mcg cannabis flos BID and will follow the titration plan of dose modification according to CIPN relief and adverse events. Maximum dose of 2,000mcg per day is prescribed at the end of titration period, which is continuous for 15 days (about 2 weeks).On 10 weeks visit all patients will be discontinued from the treatment. In case of worsening of neuropathy at any point during the 4 weeks of FU, patients might be able to restart with inhaled MC treatment for no more than 4 weeks. Total treatment in this study will be for no more than 14 weeks.
11057371|NCT04376424|Experimental|Ultra Sound Guided Therapy Group|Hand carried ultrasound will be used in this group to measure IVCd, collapsibility along with internal jugular vein collapsibility. The results of the ultrasound will be unblinded to the treating team.
11057372|NCT04376424|No Intervention|Conventional Therapy Group|Conventional therapy will occur the use of hand carried ultrasound. The results will be blinded to the treating team. The managing team will analyze the data at the end of the study.
11057373|NCT04376411||patients with Behcet disease|Flow-cytometric assay Detailed 2 Di mention Echocardiographic analysis Two-Dimensional speckle tracking echocardiography
11057374|NCT04376411||Healthy control subjects|Flow-cytometric assay
11057375|NCT04376398||COVID-19|Any pediatric or adult patient with COVID-19 or suspected of COVID-19 scheduled for any intervention
11057376|NCT04376385|Experimental|Treatment condition - 9 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
11057377|NCT04376385|Experimental|Treatment condition - 12 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
11057378|NCT04376385|Experimental|Treatment condition - 15 days wait|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
11057379|NCT04376372||TD_lefthanders|Typical developing lefthanded children and adolescents Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
11057380|NCT04376372||F_lefthanders|Forced left handed NBPP children Assessment : sensibility, strength,writing,manual dexterity,degree of lefthandedness, body representation, movement analysis, motor control, quality of life, participation
11057381|NCT04376359|Experimental|hyperbaric oxygen therapy|Patients with stroke will receive the hyperbaric oxygen therapy (HBOT) for 40 times, which were completed on 40 business days over a 2-month period and each session lasted 90 minutes at 100% oxygen concentration and 2 atmospheres.
11057382|NCT04376359|No Intervention|Control|Stroke patients were not treated with HBOT except for the same routine treatment as the experimental group.
11057383|NCT04376346|Experimental|Intervention Arm|Participants in the intervention arm will complete the AIY-C curriculum that has been translated for mHealth delivery. This includes completing various activities such as completing their own risk assessment when it comes to AEP and setting goals for themselves.
11057384|NCT04376346|No Intervention|Control Arm|Participants in the control arm will complete activities that are carefully designed under different topics than the intervention arm. In this regard, participants will complete various activities such as quizzes, interactive games and videos. The investigators will ensure that participants in both arms will spend similar time on completing the activities.
11057385|NCT04376333|Active Comparator|STD+CBT|Standard conservative dental orofacial pain care + cognitive-behavioral coping skills treatment
11057386|NCT04376333|Experimental|STD+IATP|Standard conservative dental orofacial pain care + Individualized Assessment and Treatment Program; a highly individualized coping skills training procedure.
11057387|NCT04376320|Active Comparator|Group 1(ceramic membrane)|using customized ceramic membranes for augmentation of vertical mandibular ridge defects in preparation for implant placement
11057388|NCT04376320|Active Comparator|Group 2 (modified sausage technique)|using tenting titanium screws in conjunction with particulate bone graft and collagen membrane (modified sausage technique) for augmentation of vertical mandibular ridge defects in preparation for implant placement
11057389|NCT04376307|Experimental|minimal flow anesthesia|the patiennts who have thoracic sugery with one lung ventilaiton
11057390|NCT04376294|Experimental|Study group|This group received Extracorporeal Shockwave Therapy(ESWT) + conservative Physical Therapy Treatment (eccentric training + stretching exercise)
11057391|NCT04376294|Active Comparator|Control group|This group received conservative physical therapy treatment(eccentric training + stretching exercise) only.
11057392|NCT04376281|Experimental|Noradrenaline group|
11057393|NCT04376268|Active Comparator|Chlorhexidine gluconate|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects.
11057394|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057395|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057396|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057397|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057398|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057399|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057437|NCT04375995|Other|Healthy control group|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
11072216|NCT04270760|Active Comparator|Arm 1 AMG 890 Dose 1|
11057400|NCT04376268|Active Comparator|Boric acid mouthwash (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
11057401|NCT04376255|Experimental|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
11057402|NCT04376255|Active Comparator|Conventional Simulation|Participants in the control arm will be introduced to workplace training modules using standard in person training.
11057403|NCT04376242|Experimental|virtual reality then standard technology|patients randomized to this arm will first use virtual reality (VR) during and oral food challenge and then use standard technology during a second oral food challenge
11057404|NCT04376242|Active Comparator|standard technology then virtual reality|patients randomized to this arm will first use standard technology during and oral food challenge and then use virtual reality during a second oral food challenge
11057405|NCT04376229||Cancer patients receiving proton radiation therapy|Registry of cancer patients who receive proton radiation therapy to track disease and toxicity outcomes.
11057406|NCT04376216|No Intervention|Control|No treatment
11057407|NCT04376216|Active Comparator|Prednisone|Oral prednisone. Starting dose of 60 mg with tapering for 2 months
11057408|NCT04376203||Control|any patient with indications for thyroidectomy other than confirmed preoperative cancer
11057409|NCT04376203||Thyroid microcarcinoma|either preoperative detection or random finding after thyroidectomy of another indication.
11057410|NCT04376190|No Intervention|control group|12 patients treated with twin block functional appliance without low-level laser application for 9 month
11057411|NCT04376190|Experimental|laser group|12 patients treated with twin block functional appliance with low-level laser application with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. The laser was applied at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points. Laser application was repeated weekly for three months according to a standard protocol
11057412|NCT04376177||Patients with Thoracic outlet syndrome|Patients referred to the University Hospital of Angers for the diagnostis or follow-up of thoracic outlet syndrome
11057413|NCT04376164|No Intervention|control group|was treated without laser intervention
11057414|NCT04376164|Experimental|laser group|received low level laser therapy
11057415|NCT04376151|Experimental|Intervention|Participants will work through an Acceptance and Commitment Therapy informed self-help bibliotherapy over a period of eight weeks. The bibliotherapy is called 'Get Out of Your Life and Into your Mind' written by Steve. C. Hayes.
11057416|NCT04376138|Experimental|Motor Imagery|A Brain-Computer Interaction (BCI) based intervention while receiving conventional therapy. Use of motor imagery training, allied with brain-computer interaction, as a solution to promote motor and cognitive gains in stroke survivors.
11057417|NCT04376138|Active Comparator|Conventional Therapy|Extra Occupational Therapy sessions while receiving conventional therapy. Use of conventional therapy techniques and tools for motor rehabilitation, following the original therapeutic intervention plan of the participants.
11057418|NCT04376125|Experimental|Suboccipital inhibition in tension headache|"Two groups of patients suffering from tension headache associated with cervicalgia are selected.
~The control group performs conventional therapy. The experimental group performs conventional therapy plus the technique of suboccipital inhibition"
11057419|NCT04376125|Active Comparator|study of results|We compared data from both groups
11057420|NCT04376112|Active Comparator|Standard of Care|
11057421|NCT04376112|Experimental|Pharmacist Intervention|
11057422|NCT04376099||Exercise oximetry|Patients complaining claudication and referred for exercise diagnostic oximetry. Exercise oximetry are performed on treadmill (3.2km/h, 10% slope)
11057423|NCT04376086|Active Comparator|General anesthesia|Patients will receive general anesthesia
11057424|NCT04376086|Active Comparator|Epidural anesthesia|Patients will receive epidural anesthesia
11057425|NCT04376073|Experimental|Treatment group|"Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh <77 kg) po QD day1~21, Anlotinib 12mg po QD day1~14.
~Starting dose of anlotinib changed to 10mg from 2020-11-13."
11057426|NCT04376060|Experimental|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
11057427|NCT04376047|Experimental|Reverse Trendelenburg position group|Obese critically ill patients who are positioned in reverse Trendelenburg position
11057428|NCT04376047|Active Comparator|Semi-recumbent position group|Obese critically ill patients who are positioned in semi-recumbent position which is the routine ICU position
11057429|NCT04376034|Other|Mild Severity|Eligible to enroll in study and will be monitored for progression. Will not initially receive plasma.
11057430|NCT04376034|Active Comparator|Moderate Severity|"Adult patients will be treated with 1 unit (200mL) of convalescent plasma
~Pediatric patients will be treated with 10mg/kg up to 1 unit of convalescent plasma."
11057431|NCT04376034|Active Comparator|Severe or Critical Severity|"Adult patients will be treated with up to 2 units of convalescent plasma
~Pediatric patients will be treated with 10mg/kg up to 2 units of convalescent plasma."
11057432|NCT04376021|Experimental|Physical Contact|Baby carrier (and education) provided to mother to increase physical contact with baby
11057433|NCT04376021|No Intervention|Control|No intervention
11057434|NCT04376008|Experimental|PI-RADS 1-2|Standard prostate biopsy
11057435|NCT04376008|Experimental|PI-RADS 3-5|Targeted and standard prostate biopsy
11057436|NCT04375995|Other|Asthma group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed to all asthmatic patients.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. Asthma control test (ACT) and asthma quality of life scale (AQLQ) will be applied. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma.
11057439|NCT04375969|Experimental|whole body cryostimulation treatment|WBC will be performed at the Pomeranian Rheumatologic Centre in Sopot. The centre is equipped with an electric cryochamber Zimmer Medicine System, Cryochamber ELECPOL, located in a temperature- and humidity-controlled room. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
11057440|NCT04375969|Experimental|Connection WBC treatment and HIIT training|This group will perform HIIT protocol and WBC sessions . HIIT will be performed after 1h WBC.
11057441|NCT04375969|Active Comparator|Control Group|Control group who will be investigated (meanwhile at baseline and after the interventions)
11057442|NCT04375969|Experimental|HIIT training group|This group will perform only HIIT protocol without cryo-sessions
11057443|NCT04375956|Experimental|Pembrolizumab|Pembrolizumab 200 mg d1 q 21 iv infusion, until disease progression of disease, unacceptable toxicity or patient's refusal. Pembrolizumab will be administered for a maximum of 2 years.
11057444|NCT04375943||diabetic HF-pEF patients|It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (>45%).
11057445|NCT04375943||diabetic HF-rEF patients|It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
11057446|NCT04375930|Experimental|Experimental|The patient will be trained with STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION. The patient will be follow up at 2nd, 6th and 12th weeks.
11057447|NCT04375930|Active Comparator|control|The patient will be trained only skills and discharge education. The patient will be follow up at 2nd, 6th and 12th weeks.
11057448|NCT04375917|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
11057449|NCT04375917|No Intervention|control|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
11057450|NCT04375904|Experimental|Radiation|Treatment will be delivered via image-guided (IG)-SABR in 8 fractions of 7.5Gy. OAR constraints must be respected but minimum dose coverage of 77% to 95% of the PTV will be allowed and minimum dose of 87% to 99% of the GTV will be allowed. The minimums are chosen to represent at least an equivalent BED to the RT standard fractionation of 60Gy in 30 fractions based on actual treatment dose of 7.5Gy in 8 fractions. In stage 1 there will be 91 evaluable patients. If there are 35 or less ≥G3 TxR-AEs in these 91 evaluable patients, the study will be stopped, and concluded that the regime is not unsafe. If there are 43 or more ≥G3 TxR-AEs in these 91 patients, the study will be stopped, and the conclusion will be made that the regime is not safe. Otherwise, the study will proceed to stage 2 and 87 additional evaluable patients will be accrued (178 evaluable patients total). The conclusion will be made that the regime is not safe if 78 or more TxR-AEs are observed in 178 evaluable patients.
11057451|NCT04375891|Other|Radiotherapy|Radiotherapy alone
11057452|NCT04375891|Other|Radiotherapy plus radiofrequency ablation|Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)
11057453|NCT04375878|Active Comparator|MS1819 2240 mg/day vs PERT arm,|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
11057454|NCT04375878|Active Comparator|MS1819 4480 mg/day vs PERT arm|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
11057455|NCT04375865|Experimental|Treatment A|Period1: Celecoxib 200mg Period2: Tramadol 150mg Period3: Celecoxib 200mg + Tramadol 150mg
11057456|NCT04375865|Experimental|Treatment B|Period1: Celecoxib 200mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Tramadol 150mg
11057457|NCT04375865|Experimental|Treatment C|Period1: Tramadol 150mg Period2: Celecoxib 200mg Period3: Celecoxib 200mg + Tramadol 150mg
11057458|NCT04375865|Experimental|Treatment D|Period1: Tramadol 150mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Celecoxib 200mg
11057459|NCT04375865|Experimental|Treatment E|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Celecoxib 200mg Period3: Tramadol 150mg
11057460|NCT04375865|Active Comparator|Treatment F|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Tramadol 150mg Period3: Celecoxib 200mg
11057461|NCT04375852|Experimental|1|consecutive cases diagnosed with APS-1associated keratitis
11057462|NCT04375839|Experimental|Main treatment group|Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.
11057463|NCT04375839|Active Comparator|Control group|Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.
11057464|NCT04375826|Active Comparator|Epidural analgesia|Only Epidural analgesia is used for this group
11057465|NCT04375826|Active Comparator|Preperitoneal analgesia and IV-PCA|This group is given with both preperitoneal analgesia and Intravenous Patient Controlled Analgesia (IV-PCA)
11057466|NCT04375813|Active Comparator|Active Study Drug Group|Patients will be given 0.5mg eRapa (encapuslated rapamycin) orally each weekday (Monday-Friday) for one year.
11057467|NCT04375813|Placebo Comparator|Placebo Group|Patients will be given a placebo (visually identical to the eRapa (encapsulated rapamycin)) orally each weekday (Monday-Friday) for one year.
11057468|NCT04375800|Experimental|Doravirine + 2 NRTIs|Participants receive DOR (3.2 mg to 40 mg based on weight) in combination with 2 NRTIs (based on local label) for 96 weeks.
11057469|NCT04375787|Active Comparator|Statin group|100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention
11057470|NCT04375787|Placebo Comparator|Placebo group|100 patients received placebo
11057471|NCT04375774|Other|FFP2|
11057472|NCT04375774|Other|Facial mask|
11057473|NCT04375774|Other|Modified full-face snorkeling|
11057474|NCT04375761||SARS-CoV-2 Surveillance: Total Group|"Participants either currently or in the past, enrolled in National Institutes of Health (NIH)-funded cohort studies, and their families (household contacts).
~Active surveillance for detection of SARS-CoV-2 for 6 months, beginning with enrollment. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed at the time that biological samples are collected."
11057616|NCT04374708||homosexual cisgender men|fMRI: body morph test and neurocognitive testing
11057475|NCT04375748||Patients treated for symptoms of acute myocarditis.|Patients treated in intensive coronary care unit (ICCU) or intensive care unit (ICU), in one of the participating hospitals, for symptoms of acute myocarditis confirmed by a myocardial MRI and/or a CT scan and/or a myocardial biopsy.
11057476|NCT04375735|Experimental|BLES treatment|For patients randomized to the treatment arm, exogenous BLES will be administered as soon as possible and within 48 hours of intubation. BLES will be administered daily for up to 3 doses, or until the patient is liberated from the ventilator.
11057477|NCT04375735|No Intervention|Control|Patients will receive standard treatment and will not receive surfactant.
11057478|NCT04375722|Experimental|tACS 10 Hz low frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
11057479|NCT04375722|Experimental|tACS 40 Hz high frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
11057480|NCT04375722|Sham Comparator|tACS sham|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.
11057481|NCT04375696|Experimental|Product|60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
11057482|NCT04375696|Placebo Comparator|Placebo|60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
11057483|NCT04375683|Experimental|Ph-positive ALLs|Subjects aged 60 years or older are received flumatinib and dose-adjusted VDCP or prednisone regimen. Subjects younger than 60 years are received flumatinib and hyper-CVAD regimen
11057484|NCT04375657|Experimental|TRIIM Treatment|
11057485|NCT04375657|Active Comparator|Active Control|
11057486|NCT04375631|Experimental|Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)|"Patients receive filgrastim SC daily on days -9 to -4, cladribine IV over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If WBC > 20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients undergo TBI and HCT on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4, cyclosporine IV over 1-2 hours BID on days 5-60, and mycophenolate mofetil IV or PO BID on days 5-28 (transplant with related donors) or TID on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive cyclosporine tapered through day 180 at the discretion of the treating physician in the absence of GVHD."
11057487|NCT04375618|Experimental|EGF impregnated in collagen membrane|EGF impregnated in collagen membrane is placed in gingival recession defects
11057488|NCT04375618|Active Comparator|plain collagen membrane|plain collagen membrane is placed in gingival recession defects
11057489|NCT04375605|Active Comparator|Arm A (control arm)|Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, leucovorin 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
11057490|NCT04375605|Experimental|Arm B (experimental arm)|Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, leucovorin 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
11057491|NCT04375566||IT specialist|20 IT Specialist will evaluate the usability and patient-friendliness of the tool
11057492|NCT04375566||Doctors|13 doctors will evaluate the information in the tool
11057493|NCT04375566||Patients|10-20 patients will evaluate the utility and the contribution of the tool in decision making proces.
11057494|NCT04375553|Active Comparator|Exercise group|Intradialytic aerobic exercise, 3 times a week, for 12 weeks.
11057495|NCT04375553|No Intervention|Non-exercise group|Without intradialytic aerobic exercise for 12 weeks.
11057496|NCT04375540|Experimental|Upper first premolars extraction|Included 24 patients (7 males,17 females) with a mean age of 21.56±3.19years who were treated with fixed orthodontic appliance for 2.22±0.31years.
11057497|NCT04375540|Experimental|Upper second premolars extraction|Included 26 patients (8 males,18 females) with a mean age of 22.16±3.59years who were treated with fixed orthodontic appliance for 2.25±0.30 years.
11057498|NCT04375540|No Intervention|No intervention|Included 26 subjects (10 males, 16 females) with a mean age of 20.45±3.29years.This group was included to observe any changes in the vertical gingival display over the 2 years' observation period (1.65±0.17 years).
11057499|NCT04375527|Experimental|Treatment (binimetinib, nivolumab)|Patients receive binimetinib PO BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11057500|NCT04375514|Experimental|ARO-ENaC|ARO-ENaC Inhalation
11057501|NCT04375514|Placebo Comparator|Placebo|Sterile normal saline (0.9% NaCl)
11072217|NCT04270760|Active Comparator|Arm 2 AMG 890 Dose 2|
11057502|NCT04375501||COVID-19 positive|All patients admitted with fractured neck of femur during specified time period testing POSITIVE for COVID-19
11057503|NCT04375501||COVID-19 negative|All patients admitted with fractured neck of femur during specified time period testing NEGATIVE for COVID-19
11057504|NCT04375488|Experimental|Resistance Exercise Training Group|Resistance exercise training for 8 major muscle groups and 150 min per week walking suggestions were given
11057505|NCT04375488|Experimental|Inspiratory Muscle Training Group|Resistance exercise training for 8 major muscle groups and inspiratory muscle strength training and 150 min per week walking suggestions were given
11057506|NCT04375488|No Intervention|Control Group|150 min per week walking suggestions were given.
11057507|NCT04375475|Experimental|Bright Changyou probiotic flavored yogurt|Bright Changyou probiotic flavored yogurt contains 5.0×10^8cfu/g of probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum ST-Ⅲ (7mg/kg), and 1.5% of inulin
11057508|NCT04375475|Active Comparator|Bright Changyou lactobacillus flavored yogurt|Bright Changyou flavored yogurt contains probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum ST-Ⅲ (7mg/kg)
11057509|NCT04375475|Active Comparator|Bright flavored yogurt|Bright flavored yogurt contains Lactobacillus bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus casei LC2W (0.1 mg/kg)
11057510|NCT04375462|Experimental|AspireAssist|"Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days, and the AspireAssist group will have a clinic visit at 7 days to have the skin-port placed.
~All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube"
11057511|NCT04375462|Active Comparator|Standard PEG|Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube
11057512|NCT04375449|Active Comparator|Pep2dia- dosage 1|700mg of whey protein hydrolysates single dose
11057513|NCT04375449|Active Comparator|Pep2Dia - dosage 2|1400mg of whey protein hydrolysates single dose
11057514|NCT04375449|Placebo Comparator|Placebo|maltodextrin single dose
11057515|NCT04375436|Active Comparator|NTRX-07-SDD|NTRX-07-SDD at 0.3-8mg/kg; single dose
11057516|NCT04375436|Placebo Comparator|Control|Placebo control
11057517|NCT04375423|Experimental|Intervention|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. In response to the behaviors they report, they receive messages on their smartphones supporting ongoing healthy behaviors or suggesting alternative behaviors to limit risks. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
11057518|NCT04375423|Active Comparator|Control|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
11057519|NCT04375397|Experimental|Ibrutinib|Participants will receive Ibrutinib along with supportive care.
11057520|NCT04375397|Placebo Comparator|Placebo|Participants will receive Placebo along with supportive care.
11057521|NCT04375384|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.
11057522|NCT04375371|Active Comparator|Obese patients who have received a bariatric surgery|Obese patients who have undergone a bariaric surgery as part of routine clinical management within the indication of this intervention.
11057523|NCT04375371|No Intervention|Obese patients without a bariatric surgery|Obese patients who have not undergone bariaric surgery.
11057524|NCT04375332|Experimental|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
11057525|NCT04375319|Experimental|OCT guided 3-month follow-up group|OCT guided the operation, and OCT reexamined 3 months after the operation to evaluate the vascular repair
11057526|NCT04375319|No Intervention|3-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 3 months after operation to evaluate vascular repair
11057527|NCT04375319|No Intervention|6-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 6 months after operation to evaluate vascular repair
11057528|NCT04375306|Active Comparator|angiography guided CABG|angiography guided CABG
11057529|NCT04375306|Experimental|RFR guided CABG|RFR guided CABG
11057530|NCT04375293|Experimental|AERD|Patients suffering from AERD
11057531|NCT04375293|Sham Comparator|Healthy|Healthy Controls
11057532|NCT04375293|Active Comparator|CRSwNP|Patients suffering from CRS with nasal polyps
11057533|NCT04375293|Active Comparator|CRSsNP|Patients suffering from CRS without nasal polyps
11057534|NCT04375280|Experimental|Cohort 1|Participants will be involved in a long-term evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 5 years with evaluations taking place at inclusion, 6 months, at 1, 2 and 5 years
11057535|NCT04375267|Experimental|177Lu-DOTA-TATE and olaparib|
11057536|NCT04375254||Intervention group|Medical students during psychiatry clerkship who received NbN psychopharmacology training
11057537|NCT04375254||Control group|Medical students during psychiatry clerkship who received standard psychopharmacology training
11057538|NCT04375241||Screening with Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
11057539|NCT04375228|Experimental|Rituximab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Rituximab.
11057540|NCT04375228|Experimental|Tocilizumab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Tocilizumab.
11057541|NCT04375215|Active Comparator|Selective caries removal to soft dentin (one step)|In selective caries removal to soft dentine, after caries excavation application of liner will be done on pulpal floor. Teeth will then be filled with composite resin material.
11057542|NCT04375215|Active Comparator|Stepwise caries removal (two step)|The stepwise caries removal is a two step procedure. The first step is similar to selective caries removal to soft dentin group. In the second step, after 6 months lesion will be re-entered to remove remaining carious tissue till firm dentin is encountered. Once all the caries is removed from floor of cavity a liner followed by final restoration with composite will be performed.
11057543|NCT04375202|Experimental|Colchicine plus current care|Colchicine 0.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to discharge. Reduce based on gastrointestinal symptoms appearance at discretion of the Investigator.
11057544|NCT04375202|No Intervention|Current care alone|Current care
11057545|NCT04375189|No Intervention|Standard Care|
11057546|NCT04375189|Experimental|Complex Clinic Arm|
11057547|NCT04375176||Tested positive for SARS-CoV-2|"Patients, tested positive for SARS-CoV-2, will be recruited in E.R. of the Ospedale Di Circolo - ASST Settelaghi Teaching Hospital in Varese."
11057548|NCT04375163|Experimental|Massage group (ME)|A sport massage was applied between the sets of an intense isokinetic exercise protocol for knee extensor muscles
11057549|NCT04375163|Active Comparator|Control|the break between the sets of an intense isokinetic exercise protocol for knee extensor muscles was passive
11057550|NCT04375150||Patients with advanced renal cell carcinoma (RCC)|
11057551|NCT04375137||Severe COVID|patients with positive PCR or compatible CT admitted in ICU or intubated
11057552|NCT04375137||Non-severe COVID-19|patients with positive PCR or compatible CT admitted in ward without hypoxia
11057553|NCT04375137||Healthy Controls|Healthy controls with negative IgM/IgG for COVID-19
11057554|NCT04375124|No Intervention|non-peptide group|This group will receive routine treatment and care for COVID-19.
11057555|NCT04375124|Active Comparator|peptide group|This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
11057556|NCT04375111|Active Comparator|SAP block for management of post-mastectomy pain|the patients in this group shall undergo Serraturs anterior plane block for management of post-mastectomy pain.
11057557|NCT04375111|Active Comparator|TTP block combined with SAP block for post-mastectomy pain|the patients in this group shall undergo combined Serraturs anterior plane block, and Transversus thoracic plane block for management of post-mastectomy pain.
11057558|NCT04375098|Experimental|Early COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 at admission after confirmation of eligibility
11057559|NCT04375098|Experimental|COVID-19 convalescent plasma|COVID-19 convalescent plasma 200 ml day 1 and 2 only if worsening of respiratory function or persistence of COVID symptoms for >7 days after enrolment
11057560|NCT04375085|Other|DESyne X2 Novolimus Eluting Coronary Stent System|
11057561|NCT04375072|Experimental|active tDCS paired with active MBM,|
11057562|NCT04375072|Active Comparator|sham tDCS paired with active MBM|
11057563|NCT04375072|Active Comparator|active tDCS paired with sham MBM|
11057564|NCT04375072|Sham Comparator|sham tDCS paired with sham MBM|
11057565|NCT04375059|Active Comparator|Study group|3 months of interactive attention training programs, 2 times per week, 15 min per session, a total of 24 sessions, with conventional rehabilitation programs
11057566|NCT04375059|No Intervention|Control group|3 months of conventional rehabilitation programs without interactive attention training programs
11057567|NCT04375046|Experimental|Experimental: rbACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
11057568|NCT04375046|No Intervention|No Intervention: Control group|Standard of care; no placebo
11057569|NCT04375033|Experimental|Sublingual Arm|"The sublingual buprenorphine contains naloxone in a ratio of 4:1 and will be prescribed. Consistent with the SAMHSA TIP 40 guidelines 75, before SL-BUP/NLX is prescribed, participants will be evaluated for recent (within 24 hours) drug use and associated symptoms.
~The randomization dose will be determined based on the maintenance dose identified during the induction period, with a target dose of 16-24mg that is standard practice. While the target dose is 16-24mg, doses may go as low as 8mg as occasionally patients prefer lower doses. SL-BUP/NLX will be prescribed at the randomization visit (28-day supply), then every 4 weeks until week 48."
11057570|NCT04375033|Experimental|Injectable Arm|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit. The target dose is 300mg, there is the option to use 100mg dose. The final study dose of injectable buprenorphine will be given at Week 48.
11057571|NCT04375020||group1 on GABA|The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.
11057572|NCT04375020||group 2 on just insulin|The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.
11057573|NCT04374994|Active Comparator|intervention group|Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks
11057574|NCT04374994|Placebo Comparator|control group|Males with sexual dysfunction who received daily placebo tablets for four weeks
11057575|NCT04374981|Experimental|Celecoxib|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
11057576|NCT04374981|Experimental|Montelukast|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
11057617|NCT04374708||homosexual cisgender women|fMRI: body morph test and neurocognitive testing
11057618|NCT04374708||cisgender women|fMRI: body morph test and neurocognitive testing
11057619|NCT04374708||cisgender men|fMRI: body morph test and neurocognitive testing
11057656|NCT04374409|Experimental|High-flavanol Cocoa powder|Dietary supplement: single serving of a high-flavanol cocoa powder containing 150 mg of (-)-epicatechin and 35.5 mg of (+)-catechin
11057577|NCT04374968|Experimental|BFR Treatment|Patients will be recruited following ACL tear and medical screening for history of DVT/PE. Patients allocated to the BFR intervention group will undergo physical therapy with the use of a blood flow restriction cuff. Rehabilitation will consist of a structured home exercise program prior to surgery. We will instruct patients on how to perform home BFR and test them in the office to ensure competence. Following surgery patients will immediately be started in physical therapy. Therapy will consist of a structured program progressing from range of motion, to strength training and then functional tests. Both arms will use the same protocol with the only difference being use of BFR.
11057578|NCT04374968|No Intervention|Control|The control arm will undergo the same pre and post operative physical therapy as the BFR group. They will undergo a structure home therapy program prior to surgery and an outpatient physical therapy program under the guidance of a therapist following surgery.
11057579|NCT04374955|Experimental|interventional|Mothers of babies diagnosed with infantile colic in the intervention group will start taking probiotic products after the first stool of the babies and blood is taken for intestinal permeability and will continue for 15 days.
11057580|NCT04374955|Placebo Comparator|Control|Mothers of babies diagnosed with infantile colic in the control group will receive routine care for 15 days after blood is taken for the first stool and intestinal permeability of the babies.
11057581|NCT04374942|Experimental|Study drug arm|50% of participants will be randomized to the study drug arm, and will take 400mg hydroxychloroquine orally once a day for three months (Day 1-90).
11057582|NCT04374942|Placebo Comparator|Placebo arm|50% of participants will be randomized to the placebo arm, and will take placebo orally once a day for three months (Day 1-90).
11057583|NCT04374929|Active Comparator|Negative Pressure Wound Therapy|
11057584|NCT04374929|Active Comparator|Anti-Inflammatory Glucocorticoid|
11057585|NCT04374929|Active Comparator|Increased Electrode Spacing|
11057586|NCT04374929|Other|Control|
11057587|NCT04374916|Experimental|Partosure® test + Premaquick® test|All patients will have the same 2 tests.
11057588|NCT04374903|Experimental|Study Arm A (HCQ & AZ)|Subjects will receive HCQ 600mg PO X 10 days and AZ PO 250mg DAILY X 10 days.
11057589|NCT04374903|Experimental|Study Arm B (HCQ+SIR)|Subjects will receive HCQ 600mg PO X 10 days and SIR 4mg PO X 1 day then 2mg PO DAILY X 9 days
11057590|NCT04374890|Experimental|Experimental|
11057591|NCT04374877|Experimental|Part A Monotherapy Expansion|The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as monotherapy in up to 42 patients with advanced solid tumors.
11057592|NCT04374877|Experimental|Part B Indication-specific SRF388 Monotherapy Expansion|Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRF388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC (any clear cell component in the histologic definition) and up to 40 patients with HCC.
11057593|NCT04374864|Experimental|Trilaglibtin 50 mg|Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg trilagliptin. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.
11057594|NCT04374851|Experimental|New Device|The new Hearing aid is essentially the same as the current device (i.e., hardware, use) but with an improved digital signal processing (DSP).
11057595|NCT04374851|Active Comparator|Current Device|The current device is the Hearing aid that is currently sold on the market. It is used as a normal Hearing aid that is worn daily to amplify sounds for Hearing-impaired people.
11057596|NCT04374825|Experimental|Acceptance and Commitment Therapy (ACT)|Weekly video conference groups led by a trained facilitator introducing key concepts of ACT
11057597|NCT04374825|Active Comparator|Cognitive Behavioral Stress Management (CBSM)|Weekly video conference groups led by a trained facilitator introducing key concepts of CBSM
11057598|NCT04374825|No Intervention|Usual care|Patients' usual health care as received over the duration of the pilot trial
11057599|NCT04374799|Active Comparator|Low dose heparin|heparin (25 IU/Kg -maximal dose 3,000 IU)
11057600|NCT04374799|Active Comparator|High dose heparin|heparin 50 IU/kg -maximal dose 5,000 IU
11057601|NCT04374799|Placebo Comparator|Placebo|Normal saline 0.9%.
11057602|NCT04374786|Experimental|Intervention Group|"Will receive a 30-day are trial of the mobile meditation app Calm on study day 0"
11057603|NCT04374773|Experimental|Estradiol|1 week treatment with 0.3 mg/24 hr transdermal estradiol
11057604|NCT04374773|Experimental|Cortisol|1 week treatment with 30 mg hydrocortisone daily, administered in 2 divided doses
11057605|NCT04374760|No Intervention|in-person control|Usual care, initial screening measures conducted in-person in the Emergency Department.
11057606|NCT04374760|No Intervention|Self-Administered Control|Usual care, initial screening measures conducted on their own via an iPad.
11057607|NCT04374760|Experimental|In-person Treatment|Treatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department.
11057608|NCT04374760|Experimental|Self-Administered Treatment|Treatment group (receives text messages), initial screening measures conducted on their own via an iPad.
11057609|NCT04374747|Experimental|Dietary Intervention|Intensive dietary counseling and fruit and vegetable box delivery.
11057610|NCT04374747|No Intervention|Information|Control condition of information on healthy eating during breastfeeding
11057611|NCT04374721|Experimental|Patients with Adrenal Insufficiency|Patients with Adrenal Insufficiency established or newly diagnosed, under glucocorticoid replacement therapy.
11057612|NCT04374721|Experimental|Patients with Cushing's Syndrome|patients with adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent Cushing's Syndrome diagnosis during active disease (new diagnosis or recidivating) at enrollment.
11057613|NCT04374721|Experimental|Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by Adrenal Insufficiency or Cushing's Syndrome.
11057614|NCT04374708||trans men|fMRI: body morph test and neurocognitive testing
11057615|NCT04374708||trans women|fMRI: body morph test and neurocognitive testing
11057655|NCT04374422||2|same population during pandemic
11057620|NCT04374695||patients with COVID-19|Patients with positive RT-PCR for SARS-CoV-2, and patients with négative RT-PCR for SARS-CoV-2 but clinical presentation highly suggestive of COVID-19, and typical COVID-19 abnormalities on chest CT-Scan.
11057621|NCT04374695||patients without COVID-19|Patients with négative RT-PCR for SARS-CoV-2 and chest CT-Scan or chest X-ray not suggestive of COVID-19
11057622|NCT04374669||patients with lumbar spinal stenosis|Patients with lumbar spinal stenosis will be scheduled for neuroplasty.
11057623|NCT04374643||Confined patients|General population
11057624|NCT04374630|Experimental|Arm 1|Arm 1 is afuresertib 125 mg PO QD + paclitaxel 80 mg/m2 intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 3 week cycle.
11057625|NCT04374630|Active Comparator|Arm 2|Arm 2 is paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15 of a 3 week cycle
11057626|NCT04374617||Venous thromboembolism|Patients at risk of venous thromboembolism (deep venous thrombosis and/or pulmonary embolism)
11057627|NCT04374604||Paturients with preeclampisia|The participants will be pregnant women with late-onset pre-eclampsia
11057628|NCT04374591|Other|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
11057629|NCT04374591|Placebo Comparator|Control|placebo
11057630|NCT04374565|Experimental|Study participants|A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.
11057631|NCT04374552|Experimental|Hydroxychloroquine & Azithromycin|Hydroxychloroquine sulfate 400 mg po BID for day one and then 400 mg QD for 4 days Azithromycin 500 mg po on day one, followed by 250 mg po QD X 4 days
11057632|NCT04374552|Placebo Comparator|Placebo|Placebo for Hydroxychloroquine sulfate (2 pills bid day one and then 2 tablets QD for 4 days) Placebo for Azithromycin (2 pills on day one and followed by 1 pill po QD x 4 days)
11057633|NCT04374539|Experimental|Plasma exchange|Plasma exchange with human serum albumin + Polyclonal immunoglobulin + standard medical treatment
11057634|NCT04374539|Active Comparator|Standar medical treatment|Standar medical treatment
11057635|NCT04374526|Experimental|Convalescent plasma|Patients receive COVID-19 Convalescent Plasma (CCP) in addition to standard therapy
11057636|NCT04374526|No Intervention|Standard therapy|Patients receive standard therapy alone
11057637|NCT04374500|Experimental|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and blood flow was measured. The other forearm was used as the control.
11057638|NCT04374500|Experimental|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
11057639|NCT04374500|Experimental|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse. The other forearm was used as the control.
11057640|NCT04374487|Experimental|Test Arm|50 subjects will be randomized in this arm. Patients in the test group will receive convalescent plasma.
11057641|NCT04374487|Other|Control Arm|50 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.
11057642|NCT04374474|Sham Comparator|Control Group|The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.
11057643|NCT04374474|Experimental|Olfactory Retraining Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.
11057644|NCT04374474|Experimental|Olfactory Retraining_Budesonide Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.
11057645|NCT04374461|Experimental|mechanically ventilated &/or managed in a critical-care|"This arm is closed to accrual as of September 2020. Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.
~Patients will receive treatment for a maximum of 3 weeks or until one of the following:
~Arm A:
~Transfer out of the critical-care unit
~Extubation
~Toxicity
~Death"
11057646|NCT04374461|Experimental|non-mechanically ventilated, non-critical-care|"Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.
~Patients will receive treatment for a maximum of 3 weeks or until one of the following:
~Arm B:
~Discharge from hospital
~Admission to a critical-care unit
~Intubation
~Toxicity
~Death"
11057647|NCT04374448|Other|Sinus Tumor Resection|Those who are undergoing endoscopic sinonasal surgery for benign and malignant tumor removal.
11057648|NCT04374448|Other|Skull Base Surgery|Those who are receiving Endoscopic Skull Base Surgery (ESBS) for minimally-invasive access for removal of skull base tumors, most commonly for ones of pituitary origin.
11057649|NCT04374448|Other|Endoscopic Sinus Surgery|Individuals with chronic rhinosinusitis (CRS) with or without polyposis that are to have endoscopic sinus surgery, a minimally invasive procedure to open the sinuses.
11057650|NCT04374448|Other|Epistaxis Management|Those who have severe nose bleeds and requires going into the operating room for management.
11057651|NCT04374435|Experimental|MKTP with Surgical Blade|The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
11057652|NCT04374435|Experimental|MKTP with Negative Pressure Instrument|Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
11057653|NCT04374435|Experimental|Suction blister grafting without cell dissociation|In this arm, transplanting the blisters without dissociation of the cells will be conducted.
11057654|NCT04374422||1|study group pre-pandemic time interval
11057657|NCT04374409|Active Comparator|Low-flavanol Cocoa powder|Dietary supplement: single serving of a low-flavanol cocoa powder intervention containing < 4 mg of (-)-epicatechin and (+)-catechin and matched as best as possible for macronutrients and micronutrients, such as caffeine and theobromine.
11057658|NCT04374396|Sham Comparator|Group 1|patients in this group will receive sham ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery without injection of local anesthetics
11057659|NCT04374396|Experimental|Group 2|patients in this group will receive real ipsilateral ultrasound-guided single shot erector spinae block at L2 after induction of anaesthesia and before the start of surgery with injection of 0.3 ml/kg of 0.25% of plain bupivacaine.
11057660|NCT04374383|Experimental|main treatment group|LASER assisted SRP followed by antimicrobial photodynamic therapy with a novel photosensitizer dye Phthalocyanine
11057661|NCT04374383|Placebo Comparator|control group|LASER assisted SRP
11057662|NCT04374344||Medical professionals|Medical professionals including cardiologists, electrophysiologists, cardiac nurses, and general practitioners.
11057663|NCT04374331|Experimental|Video-Assisted Training Group|The patients in the VAT group watch a training video in the patient rooms before RCR in addition to the routine treatment and care in the unit.
11057664|NCT04374331|No Intervention|control group|The control group received the routine treatment and care in the unit. The routine treatment and care of the unit includes verbal briefing by physicians and nurses about the surgical procedure before RCR, cold application and analgesic application for pain control after RCR, using arm sling, verbal discharge training (e.g., drug use, exercises, follow-up time, etc.) and discharge on the first post-operative day in the absence of complications. In addition, patients are invited to weekly controls to explain how to do the exercises and, if necessary, they are referred to physiotherapy.
11057665|NCT04374318|Active Comparator|IT intrathecal|administration of intrathecal dexmedetomidine in addition to bupivacaine for lower limb surgeries
11057666|NCT04374318|Active Comparator|IV intravenous|administration of intravenous dexmedetomidine in addition to spinal anaesthesia for lower limb surgeries
11057667|NCT04374305|Experimental|Brigatinib Sub-Study|Subjects treated in this arm will receive brigatinib 90 mg by mouth daily for 7 days and then increased to 180 mg by mouth daily if the drug is tolerated.
11057668|NCT04374292|Experimental|Intervention group|"Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.
~The key message was that healthy dietary habits and health risks are acquired at home and that opportunities for change can be identified in the processes that surround meal times. It begins with selecting and purchasing food, followed by preparation and consumption behaviors. Mothers were encouraged to participate in the sessions which involved the use of food models, videos, slides, and, in some cases, real food. Upon completing each session, mothers were given printed material to add to a home consultation manual.
~Upon concluding consultations and group sessions, mother/child pairs from both groups were asked to return for monthly follow-ups over the next three months."
11057669|NCT04374292|Active Comparator|Control group|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. Similarly, CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
11057670|NCT04374279|Active Comparator|Standard of care and bicalutamide|Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care
11057671|NCT04374279|No Intervention|Standard of care only|Randomized participants receive standard of care only.
11057672|NCT04374253|Experimental|Group 1|Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 104 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
11057673|NCT04374253|Experimental|Group 2|Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
11057674|NCT04374240|Experimental|AdNRGM followed on day 2 by CB1954|The proposed dose levels for AdNRGM are 10^10, 3x10^10, 10^11, 3x10^11, 10^12 vp while the prodrug CB1954 will be given at a standard dose of 24 mg/m^2
11057675|NCT04374227|Experimental|Treatment Group|The treatment group received three osteopathic manipulative treatments once a week for three weeks. The osteopathic manipulative treatment was a full body treatment based upon Dr. Zink's model of a common compensatory pattern.
11057676|NCT04374227|No Intervention|Control Group|This group received an osteopathic structural exam once a week for three weeks without any treatment performed.
11057677|NCT04374214|Active Comparator|Complete Pulpotomy using mineral trioxide aggregate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Mineral Trioxide Aggregate.
11057678|NCT04374214|Active Comparator|Complete Pulpotomy using Simvastatin-alphatricalcium phosphate|Twenty-eight patients with curiously exposed permanent molars will be treated with complete pulpotomy by using Simvastatin -alphatricalcium phospahte.
11057679|NCT04374201||2 zirconia FDPs|11 patients received 2 zirconia fixed dental prostheses
11057680|NCT04374201||1 zirconia FDP|26 patients received 1 zirconia FDP
11057681|NCT04374188|Active Comparator|ciprofloxacin|ciprofloxacin tablets
11057682|NCT04374188|Active Comparator|levofloxacin|levofloxacin tablets
11057683|NCT04374175||Adenocarcinoma group|Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
11057684|NCT04374175||Control group|Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
11057685|NCT04374162|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
11057686|NCT04374162|Experimental|Driving pressure (DP) guided-PEEP|"DP is calculated as plateau pressure - PEEP. 10 min after pneumoperitoneum， PEEP is increased from 5 to 15 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
11057757|NCT04373694|Active Comparator|Standard hysteroscopy|morcellation hysteroscopy with intravenous sedation and paracervical bloc
11057687|NCT04374149|Experimental|1 - TPE Alone|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
11057688|NCT04374149|Experimental|2 - TPE Plus Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
11057689|NCT04374136|Experimental|AL001|AL001 every 4 weeks
11057690|NCT04374136|Placebo Comparator|Placebo|Placebo every 4 weeks
11057691|NCT04374110||Hospitalized patients with COVID-19|Hospitalized patients with COVID-19 will be included in the study in centers around Poland.
11057692|NCT04374110||Infected SARS-CoV-2 patients|patients with SARS-CoV-2 infection not requiring hospitalization
11057693|NCT04374110||Controls|structure-matched and co-existing disease matched control group from the general population.
11057694|NCT04374084|Experimental|Moxibustion plus Cupping|"Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas:
~A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6)."
11057695|NCT04374084|No Intervention|Basic therapy|Basic therapy: rehabilitation direction and basic breathing exercise.
11057696|NCT04374071||Pre-Corticosteroid protocol|Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
11057697|NCT04374071||Corticosteroid Protocol|"As a result of observed poor outcomes, clinical rationale based upon immunology, clinical course of COVID-19, and more recently best available evidence, the HFHS corticosteroid protocol was developed. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the institutional standard on March 20, 2020. Patients with confirmed influenza infection were not recommended to receive corticosteroids.
~Patients with moderate COVID-19 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days."
11057698|NCT04374058||Two Times|The treatment group consists of selected patients that, based on their mean ultrafiltration rate, are switched from thrice-weekly to twice-weekly hemodialysis sessions
11057699|NCT04374058||Three times|Usual thrice-weekly hemodialysis schedule
11057700|NCT04374045||Patients with SARS-CoV-2|patients having a continuous recording of the heart rhythm during their hospitalization
11057701|NCT04374032|Experimental|ENKORTEN|
11057702|NCT04374032|Other|The standard of care treatment|The usual therapeutically established protocol for the treatment of patients with moderate to severe COVID-19 infection
11057703|NCT04374019|Experimental|Arm C: Ivermectin|Ivermectin
11057704|NCT04374019|Experimental|Arm D: Camostat Mesilate|Camostat Mesilate
11057705|NCT04374019|Experimental|Arm E: Artemesia annua|Artemesia annua tea or coffee
11057706|NCT04374019|Experimental|Arm F: Artesunate|Artesunate
11057707|NCT04374006|Experimental|propolis 50|we do sonde everyday to the rat that given treatment of 50mg/kg propolis for 2, 4, and 6 weeks
11057708|NCT04374006|Experimental|propolis 100|we do sonde everyday to the rat that given treatment of 100mg/kg propolis for 2, 4, and 6 weeks
11057709|NCT04374006|Active Comparator|dienogest|we do sonde everyday to the rat that given treatment of 25mg/kg dienogest for 2, 4, and 6 weeks
11057710|NCT04374006|Placebo Comparator|water|we do sonde everyday to the rat that given 0,2 ml water placebo for 2, 4, and 6 weeks
11057711|NCT04374006|Sham Comparator|sham group|after the 2nd laparotomy, we do nothing about sonde, just giving food and drink everyday
11057712|NCT04373993||Nordlandssykehuset HF|
11057713|NCT04373993||Akershus universitetsssykehus|
11057714|NCT04373993||Helgelandssykehuset|
11057715|NCT04373993||Basel University Hospital|
11057716|NCT04373980|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
11057717|NCT04373980|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
11057718|NCT04373980|No Intervention|Control group|
11057719|NCT04373967|Experimental|TQZ2451+metformin hydrochloride|TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
11057720|NCT04373967|Active Comparator|Victoza®+metformin hydrochloride|Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
11057721|NCT04373954|Experimental|Forgiveness Therapy|6-month Forgiveness Therapy; Participants meet once per week, in group setting.
11057722|NCT04373954|Active Comparator|Carey Guides|6-month Carey Guides; Participants meet once per week, in group setting.
11057723|NCT04373941|Experimental|Kasai GCSF|The Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously by day 3 post Kasai surgery
11057724|NCT04373941|No Intervention|Kasai no GCSF|The no GCSF group will not receive GCSF and receives the standard of care
11057758|NCT04373694|Experimental|Vaginoscopy|morcellation hysteroscopy with only intravenous sedation
11057725|NCT04373941|Experimental|No Kasai GCSF|The No Kasai GCSF group will receive the standard of care PLUS 3 consecutive daily doses of 10 ug/kg of GCSF to be administered subcutaneously once the diagnosis of BA is established
11057726|NCT04373941|No Intervention|No Kasai No GCSF|The No Kasai No GCSF group will receive the standard of care and will not receive GCSF
11057727|NCT04373928|Experimental|Drug guided by Mini-PDX/PDX|Procedure: The tumor tissue is used for drug sensitivity test by Mini-PDX, building PC PDX, and acquiring the genetic information by the second genetic sequence or RNA-sequence. PC patients will accept personalized treatment guided by the experimental results of mini-PDX and sequencing.
11057728|NCT04373928|No Intervention|Drug according to guideline|The drugs (gemcitabine, Nab-paclitaxel, S-1) are used ccording to NCCN pancreatic cancer guideline。
11057729|NCT04373915|No Intervention|Standard Bedside Rounding|
11057730|NCT04373915|Experimental|Remote Bedside Rounding|Parents of infants on one care team will have the opportunity to participate in rounds via secure remote video software.
11057731|NCT04373902|Experimental|Physiological-based cord clamping|In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate >100 bpm and preductal oxygen saturation >85%, while using an fraction of inspired oxygen (FiO2) of <0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.
11057732|NCT04373902|No Intervention|Immediate cord clamping|In the immediate cord clamping group, the cord will be clamped immediately after birth. The infant will then be transferred to the standard neonatal resuscitation table. After cord clamping, all infants will be managed according to the standardised neonatal management protocol for infants with a CDH, which is a consensus of current clinical guidelines by the CDH EURO consortium.
11057733|NCT04373850|Experimental|Home visit group|Will receive a home visit after discharge in addition to the standard discharge planning.
11057734|NCT04373850|No Intervention|Control group|Will receive only the standard discharge planning.
11057735|NCT04373837|Experimental|Group 1: Without pre - With post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + Virtual Reality (VR) task (5 sessions).
~Second week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic adaptation (PA) + VR task (5 sessions)."
11057736|NCT04373837|Experimental|Group 2: With pre - Without post|"Patients will perform two weeks treatment (10 sessions in total). First week: 5 days/week for 1 week, a daily session of pointing with prismatic goggles inducing prismatic (PA) + Virtual Reality (VR) task (5 sessions).
~Second week: 5 days/week for 1 week, a daily session of pointing with neutral goggles inducing no-adaptation (NA) + VR task (5 sessions)."
11057737|NCT04373824|Experimental|Group I- Ivermectin|First group with 25 confirmed cases of COVID 19 shall be treated with Ivermectin 200 to 400mcg per kg body weight on day 1 and day 2 along with standard treatment of the hospital protocol
11057738|NCT04373824|No Intervention|Group II- standard treatment|The second group with 25 confirmed cases of COVID 19 shall be treated with standard treatment as per hospital protocol for COVID 19.
11057739|NCT04373811||Principal cohort|"Quality of life, autonomy and survival will be assessed at six months and one year on 50 patients.
~Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization."
11057740|NCT04373811||Lung cohort|Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.
11057741|NCT04373811||Muscle cohort|Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.
11057742|NCT04373798||Suspected COVID-19|Individuals with symptoms who are seen at covid19 check points for covid19 diagnosis.
11057743|NCT04373785|Experimental|NG101m and standard treatment|"Concomittant therapy:
~Radiation therapy, oral temozolomide, and oral NG101m
~Adjuvant therapy:
~Oral temozolomide and oral NG101m"
11057744|NCT04373772|Experimental|abdominal massage group|the abdominal massage group received a total of 30 minutes of massage, 15 minutes every morning and evening, until the first defecation.
11057745|NCT04373772|No Intervention|control group|Routine care for the control group
11057746|NCT04373759||Unexpected in-intensive care unit cardiac arrest patients|ICUCA Patients admitted in intensive care unit for a confirmed COVID-19 and presenting an unexpected in-intensive care unit cardiac arrest
11057747|NCT04373759||In-hospital cardiac arrest patients|IHCA Patients admitted in intensive care unit for an in-hospital cardiac arrest with a confirmed Covid-19
11057748|NCT04373759||Out-of-hospital cardiac arrest|OHCA Patients admitted in intensive care unit for an out-hospital cardiac arrest with a confirmed Covid-19
11057749|NCT04373746|Experimental|10-20 kg|Patients undergoing major surgery that weigh between 10-20 kg.
11057750|NCT04373746|Experimental|20-40 kg|Patients undergoing major surgery that weigh between 20-40 kg.
11057751|NCT04373746|Experimental|40-80 kg|Patients undergoing major surgery that weigh between 40-80 kg.
11057752|NCT04373733|Experimental|Favipiravir & Standard of Care|Favipiravir: Day 1 1800mg twice per day, Days 2-10 800mg twice per day
11057753|NCT04373733|Other|Standard of care|No trial intervention
11057754|NCT04373720|Experimental|Diagnostic (MRE, standard of care MRI)|Patients undergo MRE over 10 minutes and then undergo standard of care MRI of the brain with and without contrast at baseline. Within 4 weeks after the initial MRI and MRE scans, patients may undergo standard of care biopsy to check the status of the disease. Within 48 hours after biopsy, patients undergo standard of care MRI to check the status of the disease. Patients who do not undergo biopsy undergo standard of care MRI 4-8 weeks after MRE scan to check the status of the disease.
11057755|NCT04373707|Active Comparator|Low Prophylactic Dose of Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
11057756|NCT04373707|Experimental|Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
11057759|NCT04373668|No Intervention|Control, optimised usual care|Treatment delivered as usual in the care home
11057760|NCT04373668|Experimental|Hypnotic Drug Review|Care homes to receive the Hypnotic Drug Review intervention
11057761|NCT04373668|Experimental|Structured Sleep Hygiene|Care homes to receive the Structured Sleep Hygiene intervention
11057762|NCT04373668|Experimental|Night Time Care Activities Programme (NightCAP)|Care homes to receive the Night Time Care Activities Programme (NightCAP) intervention
11057763|NCT04373668|Experimental|Hypnotic Drug Review and Structured Sleep Hygiene|Care homes to receive the Hypnotic Drug Review and Structured Sleep Hygiene interventions
11057764|NCT04373668|Experimental|Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP|Care homes to receive all three interventions: Hypnotic Drug Review, Structured Sleep Hygiene and NightCAP interventions
11057765|NCT04373668|Experimental|Hypnotic Drug Review and NightCAP|Care homes to receive the Hypnotic Drug Review and NightCAP interventions
11057766|NCT04373668|Experimental|Structured Sleep Hygiene and NightCAP|Care home to receive the Structured Sleep Hygiene and NightCAP interventions
11057767|NCT04373642|Experimental|Pembrolizumab + QUADSHOT Radiotherapy|"Combination Treatment
~Pembrolizumab by IV once on day 1 of 21 day cycle, begin 7 days before the first round of QUAD SHOT radiotherapy.
~QUAD SHOT radiotherapy twice a day for two days, begin 7 days after the first dose of pembrolizumab; repeat every 28 days for up to 3 rounds.
~Maintenance Treatment
~Pembrolizumab by IV once on day 1 of 21 day cycle
~On day 21, if the medical oncologist feels that the patient may safely continue treatment, patient will receive a new 21 days cycle of treatment with pebrolizumab."
11057768|NCT04373629||Men and women with body dysmorphic disorder|fMRI: visual modulation
11057769|NCT04373629||Men and women with subclinical body dysmorphic disorder|fMRI: visual modulation
11057770|NCT04373629||Control men and women|fMRI: visual modulation
11057771|NCT04373616|Experimental|ACI-24|
11057772|NCT04373616|Placebo Comparator|Placebo|
11057773|NCT04373603|Experimental|Intervention: HA plus TXA|HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
11057774|NCT04373603|Placebo Comparator|Control: HA plus Saline|HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
11057775|NCT04373590|Experimental|Decision aid (DA)|a one-page DA for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics.
11057776|NCT04373590|No Intervention|Treatment as usual (TAU)|Treatment as usual without the DA
11057777|NCT04373577|Experimental|ESP group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected beneath the erector spinae muscle sheath at the level of the transverse process of the second lumbar vertebrae
11057778|NCT04373577|Experimental|PENG group|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) plain bupivacaine 0.25%with adrenaline 2.5 µg/ml injected as the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
11057779|NCT04373564|Experimental|Linear GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan) prior to MRI. Each participant will receive the same GBCA throughout the study.
11057780|NCT04373564|Experimental|Macrocyclic GBCAs|Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI. Each participant will receive the same GBCA throughout the study.
11057781|NCT04373564|Other|No GBCA (Control arm)|Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms. They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g. unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).
11057782|NCT04373551|Experimental|Cultural adaptation of a patient-provider communication tool|Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
11057783|NCT04373538|Experimental|Memory Support Intervention|
11057784|NCT04373512|Experimental|Low Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermitent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
11057785|NCT04373512|Experimental|High Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
11057807|NCT04373356|Experimental|Resin Infiltration|The interproximal surface with initial dental caries that are selected for this group will be treated using the resin infiltration ICON (DMG, Germany) and 5% Sodium Fluoride Varnish
11057808|NCT04373356|Active Comparator|Sodium Fluoride Varnish|The interproximal surface with initial dental caries that are selected for this group will be treated using topical application of 5% Sodium Fluoride Varnish.
11057841|NCT04373096|Experimental|Group H (enhanced PPE group )|Will use modified IPAC-UHN PPE including the prototype hood as described under assigned intervention:
11057786|NCT04373499|Experimental|Virtual Teach-to-Goal (V-TTG)|"The RA will show the patient how to use the tablet to access the education module and be available for questions about the technology / tablet but not about the content. Within the module, the child will:
~answer questions about how to use the inhaler as part of a pre-video assessment.
~watch a video about how to correctly use a Metered Dose Inhaler (MDI) and spacer.
~answer questions on the tablet to assess how well they understand how to use the inhaler.
~If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions."
11057787|NCT04373499|Active Comparator|Brief Intervention (BI)|The RA will give the patient a handout about inhaler technique and read the steps to the child.
11057788|NCT04373473|Experimental|Patients with UC will receive FMT capsules|Patients with ulcerative colitis will receive fecal microbiota capsules from 3 healthy donors
11057789|NCT04373473|Placebo Comparator|Patients with UC will receive placebo|Patients with ulcerative colitis will receive matching placebo capsules. Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
11057790|NCT04373460|Experimental|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; ~200-250 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
11057791|NCT04373460|Active Comparator|Standard Control plasma|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
11057792|NCT04373447|Active Comparator|fundus-calot laparoscopic cholecystectomy|use laparoscopic fundus first then calot dissection cholecystectomy
11057793|NCT04373447|Active Comparator|open cholecystectomy|open cholecystectomy
11057794|NCT04373434|Experimental|HH/HF in 2-1-1|"The intervention will be delivered weekly alternating between phone and text/e-mail contact. The Coach will contact participants one week after baseline to review the home environment profile and select the first healthy action. The Coach will review the profile, then present a list of low-cost healthy actions that target possible environmental changes to make in the home. Using a series of open-ended questions, the coach guides participants to select a healthy action to work on. This will be followed at weekly intervals by text/e-mail check-ins to reinforce progress. More healthy actions are added in future calls, for a total of three healthy actions across three months. Participants will document the selected healthy actions on a family contract. The coaching calls, text messages and intervention materials are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention."
11057795|NCT04373434|Active Comparator|Control|Participants in the control condition will receive two mailings on healthy eating. They will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes as HH/HF in 2-1-1, but without the home environment emphasis. Participants will be sent their home environment profile with a list of healthy actions upon completion of the study.
11057796|NCT04373421|Active Comparator|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
11057797|NCT04373421|Active Comparator|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
11057798|NCT04373421|Active Comparator|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
11057799|NCT04373408||ACL rupture without indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL only
11057800|NCT04373408||ACL rupture with indication for ALL surgery|Patients with an ACL rupture undergoing surgical repair of the ACL and the ALL
11057801|NCT04373395|Experimental|D-CLAG|Administration of D-CLAG regimen (Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor)
11057802|NCT04373382|Experimental|Peer Resilience Champion Support|The clusters that receive this intervention will receive support from a Peer Resilience Champion.
11057803|NCT04373382|No Intervention|No Peer Resilience Champion Support|The clusters in this arm of the study will not receive the Peer Resilience Champion support until they cross-over into the Peer Resilience Champion support arm.
11057804|NCT04373382|Experimental|Enriched Feedback|This arm of the study encompasses individuals who will receive feedback from the survey that will hopefully help provoke self-reflection.
11057805|NCT04373382|No Intervention|Express Feedback|This arm of the study encompasses individuals who will not receive feedback from the survey.
11057806|NCT04373369|Experimental|Vorolanib + Atezolizumab|Consenting and eligible participants who have no evidence of tumor progression after 3 to 4 cycles of standard-of-care induction therapy will receive atezolizumab intravenously (IV) every 3 weeks and vorolanib by mouth daily. Participants can continue to receive treatment up to two years.
11057809|NCT04373343|Other|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
11057810|NCT04373330|Experimental|Intensive lifestyle intervention|The intensive lifestyle intervention used in HELP PD and that will be used in HELP-VM was a modification of the successful Diabetes Prevention Program (DPP) core curriculum adapted for use in groups. The 16-session core curriculum used in DPP, covering key concepts related to energy balance, nutrition, and physical activity, was expanded to include regular sessions focused on group problem-solving of barriers and issues specific to the members and to incorporate presentations from local community groups on topics relevant to healthy living (exercise resources, etc.) The same intervention will be used in HELP-VM and will target moderate intensity physical activity (goal ≥180 min/wk). A DVD series was developed in HELP PD to standardize this core content, improve fidelity of intervention delivery, and to allow the CHWs to focus on group facilitation and problem-solving. This DVD series will also be used in HELP-VM.
11057811|NCT04373330|No Intervention|Medical Treatment as Usual|Subjects randomized to MTAU will be encouraged to continue engaging in medical treatment as per their usual. The MTAU group will complete baseline and 6-month follow-up assessments, and participants will complete daily symptom self-monitoring on the same schedule as HELP-VM participants.
11057812|NCT04373317|Active Comparator|Pimavanserin 34mg|All participants assigned to pimavanserin will receive the FDA-approved dose of 34mg (equivalent to 40 mg pimavanserin tartrate) daily without titration; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability.
11057813|NCT04373317|Active Comparator|Quetiapine|"Quetiapine extended release will be titrated as shown in the following table. During the 8-week treatment phase, there is a maximum of 6 weeks for titration.
~Titration Schedule
~Visit/call Quetiapine Dose (Flexible)Quetiapine Notes Baseline visit (Visit 00)25 mg IR QHSAll participants must be up-titrated to at least 50 mg/day at week 1 Week 1 call (Visit 01)50 mg XR QHSUp-titration Week 3 visit (Visit 03)100 mg XR QHS (requiring two 50-mg quetiapine XR capsules)Up- or down-titration as appropriate based on psychosis symptoms and tolerability Week 5 visit (Visit 05)150 mg quetiapine XR QHSUp- or down-titration as appropriate based on psychosis symptoms and tolerability Week 6 call (Visit 06)200 mg quetiapine XR QHSUp- or down-titration as appropriate based on psychosis symptoms and tolerability"
11057814|NCT04373304|Experimental|low FODMAP diet|
11057815|NCT04373291|Active Comparator|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.
~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
11057816|NCT04373291|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine.
11057817|NCT04373278||description of infection of free fibula flap reconstruction|
11057818|NCT04373265|Experimental|Relacorilant in Combination with Pembrolizumab|Relacorilant dose escalation starting with 100 mg once daily in Cycle 1, followed by 200 mg once daily in Cycle 2, followed by 300 mg once daily in Cycle 3, followed by 400 mg (or highest tolerated dose) once daily in subsequent cycles up to 24 months treatment. The relacorilant dose can be reduced if not tolerated and subsequently increased if tolerated. Pembrolizumab 200-mg IV infusion on Day 1 of each cycle. Cycle duration is 3 weeks.
11057819|NCT04373252|Experimental|Fecal Microbiota Transplant|All participants will receive two fecal microbiota transplants one week apart. The transplant will occur via antegrade enema and the enema transplant material will be provided by OpenBiome, the product used is FMT Lower Delivery (FMP 30).
11057820|NCT04373239||Women in BC conceiving by ART|All women in BC registered in the Perinatal Services BC database having undergone Assisted Reproductive Technology. Assisted Reproductive Technology will consist of in vitro fertilization (+/-ICSI). Data from April 1, 2008 to March 31 2018 will be analyzed for live birth rate.
11057821|NCT04373239||Women in BC conceiving spontaneously|he comparison group will be all women in BC registered in the Perinatal Services BC database with spontaneously conceived pregnancies between April 1, 2008 to March 31 2018.
11057822|NCT04373226|Experimental|22q11.2DS|Children aged from 4 to 11 years old with 22q11.2 deletion syndrome
11057823|NCT04373226|Active Comparator|NON22q11.2DS|Children aged from 4 to 11 years old without developmental disease
11057824|NCT04373213||Pleth variability index|Patients undergoing fluid management with Pleth variability index
11057825|NCT04373213||hemodynamic|Patients undergoing fluid management with hemodynamic findings
11057826|NCT04373200|Experimental|COVID-19 patients with associated ARDS|
11057827|NCT04373200|Active Comparator|COVID-19 patients without associated ARDS|
11057828|NCT04373200|Active Comparator|Patients with ARDS from other causes|
11057829|NCT04373187|Experimental|CC-93538, 180mg/mL|26 healthy subjects will receive one injection of 2mL, 180mg/mL CC-93538
11057830|NCT04373187|Experimental|CC-93538, 150mg/mL|26 healthy subjects will receive 2 injections of 1.2mL, 150mg/mL CC-93538
11057831|NCT04373174|Active Comparator|Group E|Thoracic Epidural block + Regional oximetry probe will be placed in the frontal area of the head
11057832|NCT04373174|Sham Comparator|Group P|Regional oximetry probe will be placed in the frontal area of the head
11057833|NCT04373161|Experimental|Suspected COVID-19 patients being discharged to home|Patients will be given a portable, fingertip pulse oximeter to take home. Patients will monitor their resting home oxygen saturation three times per day.
11057834|NCT04373148||COVID-19|Participants diagnosed with COVID-19
11057835|NCT04373148||Controls|Participants not diagnosed with COVID-19
11057836|NCT04373135|Experimental|Experimental|Subjects will be provided a brief educational intervention prior to completing follow up survey about SRA attitudes and knowledge
11057837|NCT04373135|No Intervention|Control|Subjects will not be provided any prior to completing follow up survey about SRA attitudes and knowledge
11057838|NCT04373122|Experimental|REBOA|Insertion of the ER-REBOA Catheter during ongoing CPR
11057839|NCT04373109||Single-group study|Assessment of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
11057840|NCT04373096|Active Comparator|Group C (Control)|Will use current IPAC-UHN PPE as described under assigned intervention:
11057844|NCT04373070|Experimental|chatbot-based intervention programme (intervention)|"Participants randomised to the intervention group will receive a CAir desk and a chatbot-based intervention programme for a period of 12 weeks. The CAir desk is supplied to assess HrQoL, physical activity, and spirometry data. The first week is equal to the procedure in the control group (for details see paragraph below) and serves for baseline measurements of daily physical activity. Starting in week 2 of the study duration, participants receive feedback on their daily physical activity through the CAir chatbot application and aim to increase their daily step count by 15% from baseline. Furthermore, the CAir chatbot provides several components of the Living well with COPD programme (e.g. educational content, information on exercise training) to the patient."
11057845|NCT04373070|Other|Usual care group (control)|Participants randomised to the control group receive usual care and a CAir desk for a period of 12 weeks. The CAir desk is supplied to assess daily symptom burden, physical activity, and spirometry data. In contrast to the intervention group, participants do not receive feedback or scores of the daily reported CAT and daily physical activity.
11057846|NCT04373057|Experimental|Galacto-oligosaccharide|"Phase I: Subjects will receive GOS, at dose levels 0.75g, 1.5g, and 2.9 g/day administered once daily. GOS will be dosed per the following schedule using a modified 3+3 design: 0.75g x 4 days, followed by 1.5g x 4 days, followed by 2.9g for the duration of the study starting from about 30 days before transplant to about 4 weeks after transplant.
~Phase II: Subjects will receive GOS, at dose levels 0.25*MTD, 0.5*MTD, and MTD with MTD determined by the phase 1 of the study, once daily from about 30 days before transplant to about 4 weeks after transplant."
11057847|NCT04373057|Placebo Comparator|Maltodextrin|Phase II: Subjects will receive maltodextrin at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
11057848|NCT04373044|Placebo Comparator|Arm II (placebo, antiviral therapy)|Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
11057849|NCT04373044|Experimental|Treatment (baricitinib, antiviral therapy)|Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
11057850|NCT04373031|Experimental|Control|Control Arm: (Pembro + ACT): Pembrolizumab induction (single-dose 200mg IV), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
11057851|NCT04373031|Experimental|Arm A|• Arm A: (Pembro + IRX-2 + ACT): Pembrolizumab (single-dose 200mg IV) + cyclophosphamide (single-dose 300 mg/m2 IV) + IRX-2 induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab Q3W + paclitaxel (T) weekly x 4 cycles, followed by IRX-2 re-induction (1mL SQ x 2 daily, x 10 days), followed by pembrolizumab + doxorubicin + cyclophosphamide (AC) Q3W x 4 cycles as neoadjuvant therapy prior to surgery.
11057852|NCT04373018|Active Comparator|Sodium hypochlorite|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Sodium hypochlorite during biomechanical preparation.
11057853|NCT04373018|Active Comparator|Chlorhexidine|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Chlorhexidine during biomechanical preparation.
11057854|NCT04373018|Experimental|Chlorhexidine + Hydrogen peroxide|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using a combination of Chlorhexidine + Hydrogen peroxide during biomechanical preparation.
11057855|NCT04373005||Nasopharyngeal (NP) swabs|"NP swabs:
~At the time of consent
~3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment)
~Optional 3 months after second swab"
11057856|NCT04372992|Experimental|Early stoma closure|Ileostomy closure between 30 and 40 day after rectal resection
11057857|NCT04372992|Active Comparator|Delayed stoma closure|Ileostomy closure 15 days from the end of adjuvant therapy (up to 60 days)
11057858|NCT04372979|Experimental|SARS-CoV-2 patients treated with convalescent plasma|Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
11057859|NCT04372979|Active Comparator|SARS-CoV-2 patients treated with standard plasma|Subjects will receive an intravenous injection of standard Plasma.
11057860|NCT04372966|Active Comparator|Cemented|This group will receive a cemented Exeter stem and contemporary acetabular component (Stryker).
11057861|NCT04372966|Active Comparator|Uncemented|This group will receive an uncemented Corail stem and uncemented acetabular component (Depuy).
11057862|NCT04372953|Active Comparator|Static PEEP Group|Delivery of PEEP at 5-6 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). FiO2 and other aspects of respiratory care are then titrated using a standardised resuscitation algorithm.
11057863|NCT04372953|Experimental|Dynamic PEEP Group|"Dynamic delivery of PEEP at 8 cmH2O via a T-piece resuscitator using an initial fraction of inspired oxygen (FiO2) of 0.30 via local standard interface (facemask, nasopharyngeal tube or nasal prong). PEEP levels increased step-wise to 10 and/or 12 cmH2O if FiO2/respiratory care needs to be escalated as per a standardised resuscitation algorithm.
~If an infant shows evidence of respiratory improvement during resuscitative care, PEEP will be reduced in a stepwise method by 2 cmH2O each reduction, but to no lower than 8 cmH2O."
11057864|NCT04372940|Experimental|Intervention Side: TXA Irrigation|2.5% tranexamic acid will be applied directly to the wound via bulb irrigation and left in place for 5 minutes in the wound bed
11057865|NCT04372940|Placebo Comparator|Control Side: Saline Irrigation|Contralateral side will serve as a control
11057866|NCT04372927|Experimental|Treatment (chemotherapy, durvalumab, radiation therapy)|Patients with squamous cell cancer receive standard of care chemotherapy consisting of cisplatin on days 1, 8, 29, and 36, and etoposide on days 1-5 and 29-33. Cycles repeat every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell cancer receive standard of care chemotherapy consisting of cisplatin and pemetrexed on days 1, 21, and 42. Cycles repeat every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. All patients receive durvalumab IV over 1 hour Q4W. Radiation to the primary tumor will be given over 8-15 fractions during weeks 1-3 of chemotherapy. For patients who have residual disease in the mediastinal lymph nodes at week 9, radiation will be given to the lymph nodes starting week 11. Durvalumab is given for 2 years after completion of radiationin the absence of disease progression or unacceptable toxicity.
11057868|NCT04372901|Experimental|digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
11057869|NCT04372901|Active Comparator|digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement
11057870|NCT04372888|Other|rare genetic disease|Hypothetical scenario 1: rare, life-altering genetic condition (congenital hypogonadotropic hypogonadism)
11057871|NCT04372888|Other|common genetic disease|Hypothetical scenario 2: common, life-threatening genetic condition (hereditary breast and ovarian cancer)
11057872|NCT04372875|Experimental|SHS-derived CDS|All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
11057873|NCT04372875|No Intervention|Usual care|All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
11057874|NCT04372862|Active Comparator|Serratus anterior plane block|Serratus anterior plane block was performed in the supine position placing the ipsilateral upper limb in abduction 90 degrees position. Aiming to find the serratus anterior muscle the investigator identified the fifth rib in the mid-axillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) were detected using ultrasound. The investigator penetrated the serratus anterior muscle by a 25 GA, 90 mm spinal needle in-plane concerning the ultrasound probe from superoanterior to posteroinferior to inject deep to it.
11057875|NCT04372862|Active Comparator|Erector spinae plane block|Erector spinae plane block was performed at lateral decubitus with the operation site up, the vertebrae were counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe was placed vertically 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle.
11057876|NCT04372849|Active Comparator|Nasal insulin spray|
11057877|NCT04372849|Placebo Comparator|Placebo spray|
11057878|NCT04372836|No Intervention|Control arm|During laparoscopic enucleation of unilateral endometrial cyst, no intervention is added to subjects allocated to control arm.
11057879|NCT04372836|Experimental|Study arm (with vasopressin injection)|During laparoscopic enucleation of unilateral endometrial cyst, diluted vasopressin is injected into the interface between endometrioma and ovarian parenchyma of patients allocated to study arm.
11057880|NCT04372823||Comparison|Comparison children within family child care homes not exposed to policy/program
11057881|NCT04372823||Intervention|Intervention children within family child care homes exposed to policy/program
11057882|NCT04372810|Experimental|Intervention Group|Intervention group, assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention and again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).
11057883|NCT04372810|Sham Comparator|Sham Group|Sham group, evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up).
11057884|NCT04372797|Experimental|Mild Traumatic Brain Injury Participants|Males and females from 18-50 years of age who present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria: 1) clear mechanism of injury (i.e., direct or indirect impact to head), 2) Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and 3) neurosensory symptoms.
11057885|NCT04372797|Active Comparator|Control Participants|Age- and sex-matched control subjects with minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mild traumatic brain injury will be recruited from the same study sites.
11057886|NCT04372784|Active Comparator|EGD with Balloon Dilatation|Esophagogastroduodenoscopy with balloon dilatation
11057887|NCT04372784|Experimental|EGD with Balloon Dilatation and Cryotherapy|Esophagogastroduodenoscopy with balloon dilatation and cryotherapy
11057888|NCT04372771|No Intervention|Control|No diet or exercise intervention
11057889|NCT04372771|Experimental|Curves Program|The Curves group will follow the high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 7-days at 1,200 kcals/day and then 1,500 kcals/day for the remaining 21-days of the 30-day diet period. The participants will then consume a normal maintenance diet (2,200 kcals/d; 45% carbohydrate, 30% protein, 25% fat) for 30-days. During the maintenance period, participants will diet for 2-days at 1,200 kcals/day if they gain 3 pounds of weight.
11057890|NCT04372771|Experimental|Weight Watchers Momentum Program|"This program is based on the Weight Watchers four pillar approach (food, exercise, behavior and support). The Momentum Program uses POINTS values to help keep track of what you eat. A POINTS budget will be personalized for you at the weekly meetings."
11057891|NCT04372732||Study group|All participants will be detected for antoantibodies and then treated with PD-1 blockade.
11057892|NCT04372719|Experimental|H3N2 10EXP5 TCID50/mL|A/Belgium/4217/2015 (H3N2) (SGS Code: SGS 421-7), Wild-type, influenza A (H3N2) human challenge strain
11057893|NCT04372706|Experimental|Part 1: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors.
11057894|NCT04372706|Experimental|Part 2: RTX-240 Solid Tumor Expansion|Phase 2: RTX-240 administered intravenously on Day 1 of each cycle.
11057895|NCT04372706|Experimental|Part 3: RTX-240 Dose Escalation|Phase 1: RTX-240 monotherapy dose escalation in AML
11057896|NCT04372693|Experimental|group of students who are learning by Online Distance|"The following principals implemented while online learning will be processing;
~Address and consider the students' differences in online learning application as a new experience.
~Allow for Individual Locus of Control.
~Motivate the student:
~Avoid information overload,
~Create A real-life context,
~Encourage social interaction,
~Provide hands-on activities,
~Encourage student reflection."
11057897|NCT04372693|No Intervention|students who were learned by Traditional Classroom-Based|
11057898|NCT04372680|Experimental|CTUS strategy group|CTUS examination will be performed until the day of patient extubation. CTUS examination will consist on a fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
11057899|NCT04372680|No Intervention|standard strategy group|from the day of patient's inclusion and beyond every day, the clinical team in charge of patients will decide to perform or not an SBT following current recommendations2. These criteria are mainly based on clinical data and do not include any specific ultrasound assessment.
11057900|NCT04372667|Experimental|Post intervention|Community score card approach
11057901|NCT04372654|Experimental|Radial group|Use of Electroducer Sleeve on radial route
11057902|NCT04372654|Experimental|femoral group|Use of Electroducer Sleeve on femoral route
11057903|NCT04372641|Experimental|Treatment (p97 inhibitor CB-5339 tosylate)|Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11057904|NCT04372628|Active Comparator|Group 1 - Lopinavir/Ritonavir|Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
11057905|NCT04372628|Placebo Comparator|Control Group|Placebo unmatched orally twice daily for 14 days
11057906|NCT04372615|Active Comparator|Inebilizumab|"Approximately 58 patients will receive Inebilizumab in addition to first line immunotherapy.
~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).
~All participants will also receive a 3 day course of IVIg."
11057907|NCT04372615|Placebo Comparator|Placebo|"Approximately 58 patients will receive placebo in addition to first line immunotherapy.
~(Approximately 116 participants will be randomized in a 1:1 ratio to 2 treatment groups; approximately 58 participants to each treatment group).
~All participants will also receive a 3 day course of IVIg."
11057908|NCT04372602|Experimental|Duvelisib|-Duvelisib 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.
11057909|NCT04372602|Sham Comparator|Placebo|-Placebo 25 mg twice daily for up to 10 days. Patients who have significant clinical improvement prior to day 10 and are going to be discharged from the hospital may discontinue the treatment early with investigator permission.
11057910|NCT04372589|Experimental|Investigational arm|Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.
11057911|NCT04372589|No Intervention|Control arm|Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.
11057912|NCT04372563||healthy|Healthy patients with normal aortic dimensions
11057913|NCT04372563||ascending aortic dilation 45-55, operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves operated on
11057914|NCT04372563||ascending aortic dilation 45-55, non operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves non operated
11057915|NCT04372550|Active Comparator|Standard of Care|"Standard of care treatment:
~- including passive / assisted / active movements, stretching, functional exercise, scar treatment
~Duration: 6-12 weeks"
11057916|NCT04372550|Experimental|Exercise|"Standard of care + added exercises
~Exercise type: resistance and aerobic exercise
~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)
~Duration: 6-12 weeks"
11057917|NCT04372537|Experimental|Hypnosis|"Patients will benefit from formal hypnosis (trance induction, hypno analgesia, comfort suggestions) and/or conversational hypnosis (confusion, distraction, use of chosen words, goodwill using verbal and non verbal languages).
~They will also get to be informed of the proceedings of the performed examination as the standard procedure group."
11057918|NCT04372537|Active Comparator|Standard procedure group.|"Patients will be informed of the proceedings of the performed examination, without using any hypnosis technique.
~This corresponds to the standard clinical procedures used while performing an electroneuromyogram."
11057919|NCT04372524||Allogeneic HSC Transplant recipients|"Five possible patient scenarios are anticipated to occur in those who underwent allogeneic HSCT:
~Early event (e.g. death, non-engraftment) occurring before day 100.
~No late-acute or chronic GvHD ever develops at any time point in the first year post-transplant (regardless of whether or not classical acute GvHD develops in the first 100 days after transplant).
~Early-onset chronic GvHD (including overlap syndrome) occurred before day 60.
~Early-onset chronic GvHD (including overlap syndrome) occurred between day 60 and day 100.
~Chronic GvHD after Day 100, Late-acute GvHD (de-novo or recurrent) after day 100, or cases of overlap syndrome occurred after day 100."
11057920|NCT04372511|Experimental|Binaural Beats|Group A : use of stereo headphones that generate sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
11057921|NCT04372511|No Intervention|No sounds|Group B : use of stereo headphones with a white background noise
11057922|NCT04372498|Experimental|Treatment|This is a pivotal trial in members of the same family carrying the V282M nutation in the Gardos channel (KCNN4), which leads to hyperactivation of the channel and red cell dehydration. Up to 6 members of the family are eligible to enroll in this study, which will assess effectiveness based on individual changes of primary endpoints over individually established baselines.
11057923|NCT04372485|Other|mHealth|Adolescents enrolled in this arm will receive treatment-related text messages.
11057924|NCT04372485|No Intervention|Usual care|Adolescents in this arm will receive usual care.
11057925|NCT04372459|Experimental|Online integrated and stepped psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the online integrated and stepped psychosocial care group
11057926|NCT04372459|Experimental|Usual psychosocial care|A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the usual psychosocial care group
11057927|NCT04372433|Experimental|Dose Escalation|Dose cohorts treated with intravenous (IV) IO-202 monotherapy, in ascending doses Q2wks.
11057928|NCT04372433|Experimental|Dose Expansion|IV IO-202 monotherapy at the recommended Phase 2 dose and frequency
11057929|NCT04372420|Active Comparator|RhBMP-2|RhBMP-2 belongs to TGF-β super family with osteoinductive property which is capable of promoting bone formation
11058080|NCT04371419|Experimental|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
11057930|NCT04372420|Placebo Comparator|PLATELET RICH FIBRIN|Platelet rich fibrin(PRF) is a healing biomaterial with a great potential for bone and soft tissue regeneration, without any inflammatory reactions
11057931|NCT04372407|Experimental|Treatment Crossover Arm|All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2
11057932|NCT04372394|Experimental|Fed/Fasted|surufatinib with food on Day 1 and surufatinib without food on Day 8
11057933|NCT04372394|Experimental|Fasted/Fed|surufatinib without food on Day 1 and surufatinib with food on Day 8
11057934|NCT04372381|Active Comparator|Supra-Annular transcatheter heart valve|Medtronic Evolut Pro Valve implantation
11057935|NCT04372381|Active Comparator|Annular transcatheter heart valve|Edwards Sapien 3 Ultra implantation
11057936|NCT04372355|Experimental|Chlorite-based drug WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five
11057937|NCT04372342|Experimental|nalbuphine|
11057938|NCT04372342|Placebo Comparator|remifentanil|
11057939|NCT04372329|Experimental|CPAP4HealthySleep: System 1 (ABAB)|Participants in this group will first receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A). Next, they will receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B), re-introduction of type A for another two weeks, followed by re-introduction of type B for two weeks.
11057940|NCT04372329|Experimental|CPAP4HealthySleep: System 2 (BABA)|Participants in this group will first receive weekly feedback messages only (one message per week) notifying participants of their CPAP usage for two weeks (type B). Next, they will receive six tailored educational messages per week and weekly feedback messages notifying participants of their CPAP usage on the seventh day for two weeks (type A), re-introduction of type B for another two weeks, followed by re-introduction of type A for two weeks.
11057941|NCT04372329|No Intervention|Control Condition|Control patients will not receive any educational and/or feedback messages.
11057942|NCT04372316|Active Comparator|methylcobalamin injection|
11057943|NCT04372316|Active Comparator|methylcobalamin tablet|
11057944|NCT04372303|Experimental|Short-term Compassion Fatigue Resiliency Program|Experimental I received a short-term program (five hours per day for two days, ten hours in total).
11057945|NCT04372303|Experimental|Long-term Compassion Fatigue Resiliency Program|Experimental II received a long-term program (five weeks, two hours per week, ten hours in total).
11057946|NCT04372303|No Intervention|Control|No intervention was applied to the control group.
11057947|NCT04372290|Experimental|Product usage order ABECD|Subjects will use each of the 5 products sequentially (ABECD) during an evaluation period, followed by a 6 hour Test Session.
11057948|NCT04372290|Experimental|Product usage order BCADE|Subjects will use each of the 5 products sequentially (BCADE) during an evaluation period, followed by a 6 hour Test Session.
11057949|NCT04372290|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products sequentially (CDBEA) during an evaluation period, followed by a 6 hour Test Session.
11057950|NCT04372290|Experimental|Product usage order DECAB|Subjects will use each of the 5 products sequentially (DECAB) during an evaluation period, followed by a 6 hour Test Session.
11057951|NCT04372290|Experimental|Product usage order EADBC|Subjects will use each of the 5 products sequentially (EADBC) during an evaluation period, followed by a 6 hour Test Session.
11057952|NCT04372290|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products sequentially (DCEBA) during an evaluation period, followed by a 6 hour Test Session.
11057953|NCT04372290|Experimental|Product usage order EDACB|Subjects will use each of the 5 products sequentially (EDACB) during an evaluation period, followed by a 6 hour Test Session.
11057954|NCT04372290|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products sequentially (AEBDC) during an evaluation period, followed by a 6 hour Test Session.
11057955|NCT04372290|Experimental|Product usage order BACED|Subjects will use each of the 5 products sequentially (BACED) during an evaluation period, followed by a 6 hour Test Session.
11057956|NCT04372290|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products sequentially (CBDAE) during an evaluation period, followed by a 6 hour Test Session.
11057957|NCT04372277|Experimental|Enstilar|Enstilar foam
11057958|NCT04372264|Experimental|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
11057959|NCT04372264|Experimental|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
11057960|NCT04372264|Experimental|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
11057961|NCT04372251|Active Comparator|Sinus tarsi approach (STA)|Patients randomized to this arm are operated with plate osteosynthesis via the sinus tarsi approach
11057962|NCT04372251|Active Comparator|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Patients randomized to this arm are operated with percutaneous reduction of the fracture and osteosynthesis with screws, assisted by subtalar arthroscopy
11057963|NCT04372238|Experimental|RAPIDS intervention|Participants randomized to receive the RAPIDS intervention will receive a fentanyl specific behavioral intervention and a brief behavioral intervention to increase willingness to use fentanyl test strips and engage in overdose risk reduction behaviors, in addition to standard OEND.
11057964|NCT04372238|Active Comparator|Standard OEND|In the control arm participants will receive standard overdose education and naloxone distribution (OEND).
11057965|NCT04372225||477 patients|the biological tests of 477 patients undergoing total thyroidectomy were analyzed
11058007|NCT04371939|Experimental|I (Romiplostim)|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.
~Patients failing to achieve a complete platelet response cross over to arm II."
11058008|NCT04371939|Experimental|II (Eltrombopag)|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (>6 years) for at least 1 month depending on their response to study drug.
~Patients failing to achieve a complete platelet response switch to arm I."
11058169|NCT04370743||Group 1|
11057966|NCT04372212|Active Comparator|Inversion and Snaring|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.
~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
11057967|NCT04372212|Active Comparator|Inversion and Ligation|"Vertical trans umbilical 5-mm incision [Point A] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.
~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
11057968|NCT04372186|Placebo Comparator|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
11057969|NCT04372186|Experimental|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
11057970|NCT04372160||Younger school age children|Equal ratio of boys and girls, age range 7-13 years (68 subjects)
11057971|NCT04372160||Older school age children|Equal ratio of boys and girls), age range 14-17 years (68 subjects)
11057972|NCT04372160||Adults|Equal ratio of adult men and women, age range 18-65 years (68 subjects).
11057973|NCT04372147|Experimental|intervention group|MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
11057974|NCT04372147|No Intervention|control group|standard medical care
11057975|NCT04372134|Active Comparator|real rTMS group|motor incomplete traumatic SCI patients receiving real repetitive transcranial magnetic stimulation therapy
11057976|NCT04372134|Sham Comparator|sham r TMS|motor incomplete traumatic SCI patients receiving sham repetitive transcranial magnetic stimulation therapy
11057977|NCT04372121|Experimental|Linzagolix 75 mg|
11057978|NCT04372121|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
11057979|NCT04372108||Ustekinumab New User Cohort|Participants with crohn's disease (CD) with no prior exposure to ustekinumab, at least 1 year of enrollment records immediately prior to the new use will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
11057980|NCT04372108||Other Biologics Comparator Cohort|Participants with CD with no prior exposure to the individual drugs (for example, infliximab, adalimumab, or vedolizumab) in question, at least 1 year of enrollment records immediately prior to the new use of the comparator biologic will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
11057981|NCT04372095||group 1: Exposed to CPA + Meningioma|"Meningioma diagnosed in women by medical imaging examination and confirmed histologically if surgery is performed.
~Cyproterone acetate taken for at least 6 months."
11057982|NCT04372095||group 2: Exposed to CPA without Meningioma|Women exposed to Cyproterone acetate without developing any meningioma Absence of meningioma assessed by a normal cerebral MRI . Cyproterone acetate taken for at least 5 years.
11057983|NCT04372095||group 3: Not exposed to CPA, Meningioma diagnosed|"Meningioma in women not exposed to cyproterone acetate. Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery was necessary.
~Never exposed to cyproterone acetate."
11057984|NCT04372095||group 4: General population|Subjects (women) never diagnosed with meningioma and not exposed to cyproterone acetate.
11057985|NCT04372082|Placebo Comparator|standard of care (SOC)|
11057986|NCT04372082|Experimental|SOC + Hydroxychloroquine|
11057987|NCT04372082|Experimental|SOC + Diltiazem-Niclosamide|
11057988|NCT04372043||Lebanese population|"The Sleep Hygiene Index with other demographic questions will be applied to the Lebanese population."
11057989|NCT04372030|Other|General population|There is only one arm wishing to participate
11057990|NCT04372017|Experimental|Cohort A: Healthcare worker (hydroxychloroquine)|
11057991|NCT04372017|Placebo Comparator|Cohort A: Healthcare worker (placebo)|
11057992|NCT04372017|Experimental|Cohort B: High-Risk participant (hydroxychloroqine)|
11057993|NCT04372017|Placebo Comparator|Cohort B: High-Risk participant (placebo)|
11057994|NCT04372004|Active Comparator|Viral RNA test using nasopharyngeal swab|
11057995|NCT04372004|Active Comparator|Viral RNA test using sputum|
11057996|NCT04372004|Active Comparator|Serology test using blood|
11057997|NCT04371991||Group 1|Ectopic pregnancy
11057998|NCT04371991||Group 2|Early viable pregnancy
11057999|NCT04371991||Group 3|incomplete miscarriage
11058000|NCT04371991||Group 4|Healthy women
11058001|NCT04371978|Experimental|DPP-4 inhibition|Participants in the Dipeptidyl Peptidase-4 (DPP-4) inhibition group will receive linagliptin in addition to standard of care insulin regimen as per hospital protocol during their entire hospitalization.
11058002|NCT04371978|No Intervention|Control|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during their entire hospitalization.
11058003|NCT04371965|Experimental|Decolonization|1% Povidone iodine mouthwash (95 mL), gargle, and nasal spray (2,5 mL by nostril), and 10% nasal gel (one drop). All four time a day for five days.
11058004|NCT04371965|No Intervention|Control|Absence of local decolonization
11058005|NCT04371952|Experimental|Doxycycline 100mg|Doxycycline capsule containing 2 tablets doxycycline 100mg over-encapsulated. Doxycycline is given at 200 mg once a day and administered per os during 2 weeks
11058006|NCT04371952|Placebo Comparator|Doxycycline placebo|Doxycycline Placebo capsule 200 mg, containing 1 capsule of a marketed placebo = RODAEL placebo ( lactose, 380 mg / capsule). Doxycycline placebo is given once a day and administered per os during 2 weeks
11058038|NCT04371718|Experimental|JKB-122 High dose|JKB-122 35 mg daily for 104 weeks
11058009|NCT04371926|Active Comparator|HCQ arm|"COVID-19 positive cases will receive receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
~Staff randomized to this group will receive HCQ sulfate 400 mg/week for 4 weeks"
11058010|NCT04371926|No Intervention|No-HCQ arm|Will receive standard treatment as needed, but no HCQ
11058011|NCT04371913|Other|Radiation Therapy|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT).
11058012|NCT04371900|Experimental|Experimental Group|Mothers randomized to receive a voucher to be used at Planned Parenthood to cover the cost of contraceptives
11058013|NCT04371900|No Intervention|Control Group|Mothers randomized to NOT receive a voucher. Mothers in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
11058014|NCT04371887|Experimental|Local Tailoring|The intervention arm will consist of six KPSC service areas randomly assigned to the intervention arm. Immediately after primary HPV screening opens at KPSC, the intervention arm will receive the local tailoring interventions. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
11058015|NCT04371887|No Intervention|Hybrid Usual Care|The hybrid-usual care arm will consist of six KPSC service areas randomly assigned to this arm. The hybrid usual care arm will receive regional educational activities for the transition (as will the intervention arm) before the roll out of primary HPV testing. However, they will not receive any research-led intervention or adaptation guidance after primary HPV screening opens at KPSC. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
11058016|NCT04371874|No Intervention|Control|Hypertension of patients in the control group was managed with the original protocol including lifestyle by doctors in village clinic.
11058017|NCT04371874|Experimental|Treatment with Ten Dollars Project (TDP)|"Hypertension of patients in the TDP group were managed with the protocol of Ten Dollars Project (TDP) by doctors in village clinic."
11058018|NCT04371861||Treatment of lower extremity lesion via transradial access.|Interventions performed are standard of care for treatment of a peripheral lesion.
11058019|NCT04371822|Active Comparator|5 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days
11058020|NCT04371822|Active Comparator|7mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days
11058021|NCT04371822|Active Comparator|9 mg SnPP dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days
11058022|NCT04371822|Active Comparator|5mg TPPS dose plus sunlight exposure|7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days
11058023|NCT04371822|Placebo Comparator|placebo|No intervention
11058024|NCT04371809||control subjects|
11058025|NCT04371809||subjects with Atrial Fibrillation|
11058026|NCT04371809||subjects with Acute Coronary Syndrome|
11058027|NCT04371809||subjects with Acute Coronary Syndrome and Atrial Fibrillation|
11058028|NCT04371796|Experimental|Sintilimab injection|"Drugs: Eligible patients received two doses of intravenous sintilimab (200 mg) every 3 weeks (Q3W). Each infusion time is 30-60min.
~Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 6-8 weeks after the first dose."
11058029|NCT04371783|Other|Immediate FET group|FET will be performed in the first menstrual cycle following the stimulated IVF cycle
11058030|NCT04371783|Other|Delayed FET group|FET will be performed in the second menstrual cycle following the stimulated IVF cycle
11058031|NCT04371757|Experimental|Aerobic exercise session|The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
11058032|NCT04371757|Experimental|Resistance exercise session|The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
11058033|NCT04371757|Experimental|Combined exercise session|The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
11058034|NCT04371731|Experimental|Active Arm|Active cohort will use the Care4today platform to help manage their heart failure
11058035|NCT04371731|No Intervention|Control arm|Control arm will contain standard of care heart failure treatment
11058036|NCT04371718|Experimental|JKB-122 Low dose|JKB-122 5 mg daily for 104 weeks
11058037|NCT04371718|Experimental|JKB-122 Medium dose|JKB-122, 15 mg daily for 104 weeks
11058040|NCT04371705|Experimental|ESPB group|31 patients Will undergo ultrasound guided ESP block with 40 ml bupivacaine 0.25% (20 ml on each side).
11058041|NCT04371705|Placebo Comparator|control group|31 patients anesthetized with the protocol followed by Minia University Hospital
11058042|NCT04371692||High-risk|staff working in a unit specifically for patients infected or suspected of being infected with SARS-Cov2
11058043|NCT04371692||Medium- risk|staff working in a unit that can accommodate patients infected or suspected of being infected with SARS-Cov2, i.e., all care services that do not fall into the high-risk group.
11058044|NCT04371692||Low-risk|off-patient staff
11058045|NCT04371679||Endotracheal intubation and ventilation|Patients admitted at ICU that are intubated and ventilated
11058046|NCT04371679||Non-Invasive Ventilation|Patients admitted at ICU who are non-invasively ventilated
11058047|NCT04371666|Experimental|Arm A|pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
11058048|NCT04371666|Experimental|Arm B|matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
11058049|NCT04371653|Experimental|Active group|Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors
11058050|NCT04371653|Placebo Comparator|Placebo group|Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria
11058051|NCT04371640|Active Comparator|Sirolimus|Sirolimus + standard medical care Day 1: 10mg Days 2-7: 5mg
11058052|NCT04371640|Placebo Comparator|Placebo|Placebo + standard medical care Day 1: 10mL Days 2-7: 5mL
11058053|NCT04371614|Active Comparator|Prime Time Sister Circle Intervention|The women in this arm participate in a Prime Time Sister Circle (PTSC). The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group. PTSC addresses three key modifiable health risk factors for chronic disease: unmanaged stress, physical inactivity, and unhealthy nutritional choices. It also addresses additional risk factors that contribute to unhealthy lifestyles: lack of knowledge or misinformation about major illnesses-cardiovascular disease (CVD), hypertension, diabetes, cancer, stress and depression-and the failure of African American women to prioritize their health and take proactive steps to manage their health and health outcomes. PTSC gives African American women the information, motivation, tools, skills, and consultative support they need to improve and maintain their health.
11058054|NCT04371614|No Intervention|Usual Care|The women in the arm do not receive the intervention but provide data at baseline, 3 months, 9 months and 15 months.
11058055|NCT04371601|Active Comparator|Control group|conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies
11058056|NCT04371601|Experimental|Experimental group|On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission
11058057|NCT04371588||Deep neuro-muscular blockade|
11058058|NCT04371588||Moderate neuro-muscular blockade|
11058059|NCT04371549|Active Comparator|Glue|Skin closure after cesarean section using glue
11058060|NCT04371549|Active Comparator|Monocryl|Skin closure after cesarean section using running subcuticular sutures using synthetic monofilament
11058061|NCT04371536|Active Comparator|Arm A: Oral iron therapy|Arm A is standard oral iron therapy for 3 months.
11058062|NCT04371536|Experimental|Arm B: Oral iron therapy plus IRONCHILD web-based intervention|Oral iron therapy as per Arm A plus the IRONCHILD web-based intervention aimed at promoting oral iron adherence. This web-based intervention was developed specifically for caregivers of young children with nutritional iron deficiency anemia to promote oral iron adherence.
11058063|NCT04371523|Experimental|Intervention - Hydroxychloroquine|
11058064|NCT04371523|Placebo Comparator|Control|
11058065|NCT04371510|Other|Covid-19 patients with moderate symptoms|Whole blood, culture supernatant, serum
11058066|NCT04371484||children from 0 to 5 years old, hospitalized|
11058067|NCT04371471||Patient with Covid-19|Patient with clinical signs of CoV-2-SARS infection and signs of severity
11058068|NCT04371458|Experimental|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
11058069|NCT04371445|Experimental|Intracanalicular dexamethasone insert group|This arm will receive the DEXTENZA® insert within minutes after the completion of the surgery.
11058070|NCT04371445|Active Comparator|Topical steroid drop group|This arm will receive the prescription for daily prednisolone acetate 1% eye drops 4 times a day for the first week following the procedure, starting on the day of surgery.
11058071|NCT04371432||Sample Group 1 (NIHCC)|Existing NIH Clinical Center patients /participants tested positive for SARS-CoV-2 invited to participate by their NIH study team
11058072|NCT04371432||Sample Group 2 (OMS &amp; ClinSeq)|Individuals recruited through NIH Occupational Medical Services (OMS) invited to participateby OMS or ClinSeq participants, tested positive for SARS-CoV-2 with mild manifestations ofCOVID-19 disease
11058073|NCT04371419|Experimental|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
11058074|NCT04371419|Experimental|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
11058075|NCT04371419|Experimental|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
11058076|NCT04371419|Experimental|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
11058077|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
11058078|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
11058079|NCT04371419|Experimental|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
11072218|NCT04270760|Active Comparator|Arm 3 AMG 890 Dose 3|
11058081|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messanger
11058082|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messanger
11058083|NCT04371419|Experimental|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
11058084|NCT04371419|Experimental|Control- MGH-MaskS (antiStigma) discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
11058085|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Concordan|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
11058086|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Discordan|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
11058087|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
11058088|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
11058089|NCT04371419|Placebo Comparator|Info later - Pure Control|This group will not receive the videos but will receive information later.
11058090|NCT04371406|Experimental|Experimental Arm|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
11058091|NCT04371406|Sham Comparator|Control Arm|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
11058092|NCT04371393|Experimental|Remestemcel-L Plus Standard of Care|Intravenous infusion of remestemcel-L 2x10^6 MSC/kg of body weight plus standard of care
11058093|NCT04371393|Placebo Comparator|Placebo Plus Standard of Care|Placebo (Plasma-Lyte) plus standard of care
11058094|NCT04371380|Experimental|OLI phase followed by Injection phase|Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.
11058095|NCT04371367|Experimental|avdoralimab|"Biological/Vaccine: avdoralimab intravenous administration of avdoralimab
~Other Names:
~• IPH5401"
11058096|NCT04371367|Placebo Comparator|Placebo|intravenous administration of Placebo
11058097|NCT04371341|Experimental|E1|will receive erector spinae block with 0.25% bupivacaine volume of 2.5 ml/segment
11058098|NCT04371341|Experimental|E2|will receive erector spinae block 0.25% bupivacaine with volume of 3.4ml/segment
11058099|NCT04371341|Experimental|E3|will erector spinae block receive 0.25% bupivacaine with volume of 6.6 ml/segment
11058100|NCT04371341|No Intervention|C|will not receive erector spinae block
11058101|NCT04371315||Positive COVID-19|"Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
~Monthly follow-up until Covid-19 is negative: Respiratory and Whole Blood Samples Collected"
11058102|NCT04371315||Negative COVID-19|Baseline and Day 28: Respiratory and Whole blood Samples Collected, Days 7 and 14: Respiratory Samples Collected
11058103|NCT04371302||Intensive Care Unit nurses|Nurses working in the Intensive care Unit of an exclusive Covid-19 hospital in Malaysia, during the Covid-19 pandemic
11058104|NCT04371289||COVID-19 outpatients|Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)
11058105|NCT04371289||COVID-19 inpatients|Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)
11058106|NCT04371250||Youth|Assessed group
11058107|NCT04371237|Experimental|Intermittent pneumatic compression|IPC sleeve device on leg
11058108|NCT04371237|Experimental|Heat therapy|Custom water-circulating garment on leg
11058109|NCT04371224|Experimental|NaliCap|nal-IRI/Capecitabine
11058110|NCT04371224|Active Comparator|NAPOLI|nal-IRI/5-FU/LV
11058111|NCT04371198|Experimental|Organoid|
11058112|NCT04371185|Experimental|BAT2206 injection|45mg; subcutaneous injection
11058113|NCT04371185|Active Comparator|Stelara(US-licensed)|45mg; subcutaneous injection
11058114|NCT04371185|Active Comparator|Stelara(EU-licensed)|45mg; subcutaneous injection
11058115|NCT04371172||Patients with TAVI|cognitive research battery, MRI, laboratory values
11058116|NCT04371159|Experimental|Velieve U.S.|Each participant will test their urine sample using the Velieve U.S. device
11058117|NCT04371146|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 35 mg methylphenidate 1.5 hours before performing the tasks.
11058118|NCT04371146|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 8 mg reboxetine 1.5 hours before performing the tasks.
11058119|NCT04371146|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before performing the tasks.
11058120|NCT04371133||Endometrioma|Endometrioma (n=23)
11058121|NCT04371133||Healthy controls|Healthy controls Healthy volunteers n=25
11058122|NCT04371120||Brain Injury Survivors|Traumatic or acquired brain injury survivors, patients of RHI
11058123|NCT04371107|Experimental|azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
11058124|NCT04371107|Active Comparator|symptomatic treatment|continuation of symptomatic treatment
11058125|NCT04371094|Active Comparator|stylet|The stylet is a device that is put inside the endotracheal tube to facilitate its insertion into the trachea
11058126|NCT04371094|Active Comparator|bougie|The bougie is a device that is inserted into the trachea and an endotracheal tube is loaded over it and is slide into the trachea
11058127|NCT04371081||Amplatzer Piccolo Occluder|Amplatzer Piccolo Occluder device implant
11058128|NCT04371068||Patients suspected of low-grade PJIs|Adult patients suspected of low-grade PJIs, who have a scheduled prosthesis removal or change and who meet the inclusion criteria
11058170|NCT04370730|Other|prospective cohort|prospective monitoring of children and adolescents with schizophrenia and related psychotic disorders
11058129|NCT04371055|Experimental|Risk-adapted ECG monitoring for atrial fibrillation|"Intervention Group with high Risk for AF:
~Continuous Rhythm Monitoring using an implantable cardiac Monitor
~Intervention group with low risk for AF:
~7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation"
11058130|NCT04371055|Other|Standard of Care|Standard of care rhythm monitoring
11058131|NCT04371029|Experimental|Experimental|A Polysomnography (PSG) will be performed in all patient the night before extubation, the day prior discharge and 3 month after. Recording will consist in EEG, EOG et EMG of the chin. We will record NIM EMG. We will also performed an actimetry during hospitalization in the post ICU ward. A quality of sleep questionnaire (Pittsburgh questionnaire) will be completed by the patients during the visit at 3 month.
11058132|NCT04371016|Experimental|Verticalization group|"After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed :
~insertion of an esophageal balloon catheter (Nutrivent®, Sidam)
~installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger)
~insertion of a Swan-Ganz catheter
~continuous recording of digital and analogic data
~After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected."
11058133|NCT04371003||WNND|40 subject with West-Nile Neuroinvasive Disease will be recruited
11058134|NCT04371003||WNF|40 subject with West-Nile Fever will be recruited
11058135|NCT04371003||controls|20 control will be recruited. These controls will be aged matched to the cases.
11058136|NCT04370990|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
11058137|NCT04370990|No Intervention|controle|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
11058138|NCT04370977|Active Comparator|Artemether-Lumefantrine|4 sites, namely Massinga, Mopeia, Moatize and Montepuez
11058139|NCT04370977|Active Comparator|Amodiaquine-Artesunate|3 sites, namely Massinga, Mopeia and Montepuez
11058140|NCT04370964|Other|Family with young aged people|The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments
11058141|NCT04370951|Active Comparator|Erector Spinae Plane Block|Patients will receive a ESP block with 20mls 0.25% Levobupivicaine bilaterally, pre incision plus standardised multimodal analgesia
11058142|NCT04370951|No Intervention|Control|no ESP block, standardised multimodal analgesia
11058143|NCT04370938|Experimental|Coping strategies video|Individuals will be asked to watch a 1 hour long video that discusses strategies helpful in coping with stress during the COVID-19 pandemic.
11058144|NCT04370938|No Intervention|Control|No additional requests will be made of individuals in the control arm.
11058145|NCT04370925|Active Comparator|Matched control|Patients undergo radical resection of primary colorectal cancer and receive standard adjuvant systemic chemotherapy
11058146|NCT04370925|Experimental|HIPEC|Patients undergo radical resection of colorectal cancer and HIPEC simultaneously or within 2 days after primary tumor resection. Followed by standard adjuvant systemic chemotherapy
11058147|NCT04370899||Familial hypercholesterolaemia children|FH diagnostic criteria were as follows: a positive genetic test or, if no genetic test results were available, LDL-C >160 mg/dL and one parent with a DLCN score >8.
11058148|NCT04370899||Unaffected children|The children evaluated for suspected FH who did not meet the FH criteria were included in the non-FH control group
11058149|NCT04370886|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic
11058150|NCT04370886|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation
11058151|NCT04370886|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation
11058152|NCT04370886|Placebo Comparator|SMS with holiday greeting|SMS content in this group will be about holiday greeting of Labour Day.
11058153|NCT04370873|Experimental|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7
11058154|NCT04370873|Placebo Comparator|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7
11058155|NCT04370873|Experimental|Part 2: MK-5475|Participants receive MK-5475 380 μg QD via inhalation from Days 1-28
11058156|NCT04370873|Placebo Comparator|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28
11058157|NCT04370847||Lung Ultrasound (LUS) Examination|Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
11058158|NCT04370834|Experimental|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a >= 1-category worsening on the 7-category ordinal scale from nadir.
11058159|NCT04370808||Mild to severe disease|Mild to severe disease (admission to isolation room)
11058160|NCT04370808||Critical patients|Critical patients (admission to ICU)
11058161|NCT04370795|Active Comparator|Group 1|Patients will be treated with Total Body Irradiation (TBI)
11058162|NCT04370795|Active Comparator|Group 2|Patients will not be treated with Total Body Irradiation (TBI)
11058163|NCT04370782|Experimental|Experimental Arm 1|"Hydroxychloroquine
~Azithromycin
~Zinc sulfate"
11058164|NCT04370782|Experimental|Experimental Arm 2|"Hydroxychloroquine
~Doxycycline
~Zinc sulfate"
11058165|NCT04370769||Women with Kidney Disease|Women with kidney disease
11058166|NCT04370756|Active Comparator|Ex only|Participants will perform 8 weeks of supervised exercise training (EX).
11058167|NCT04370756|Placebo Comparator|EX + PL|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of placebo (PL) beetroot juice (deplete of nitrate).
11058168|NCT04370756|Experimental|EX + BR|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of beetroot juice (BR).
11058171|NCT04370704|Experimental|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
11058172|NCT04370704|Experimental|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
11058173|NCT04370704|Experimental|Phase 2|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
11058174|NCT04370691||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
11058175|NCT04370691||Limb Ischemia|Patients presenting with limb ischemia
11058176|NCT04370691||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
11058177|NCT04370691||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than deep vein thrombosis, limb ischemia or thrombosed hemodialysis access for treatment
11058178|NCT04370665|Experimental|Open label single arm|Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.
11058179|NCT04370639|Experimental|AccuFlow Sensor|These 50 patients will wear the AccuFlow sensor device during their surgery, and will complete the post-procedural survey. The data will be reviewed after 25 patients, and the pilot study may be stopped at that point if it is felt that the device feasibility and tolerability have been adequately established.
11058180|NCT04370626|Active Comparator|Screw Fixation|Patients with a clinically diagnosed purely ligamentous perilunate injury requiring an isolated repair to the scapholunate ligament. These subjects will be treated with open reduction and internal fixation using a Kirschner-wire (k-wire).
11058181|NCT04370626|Active Comparator|K-Wire Fixation|Patients with a clinically diagnosed purely ligamentous perilunate injury requiring an isolated repair to the scapholunate ligament. These subjects will be treated with open reduction and internal fixation using a stainless steel smooth shafted headless compression screw.
11058182|NCT04370600|Active Comparator|Group A|These patients will receive ketone supplementation between visits 1 and 2 and will receive placebo drink between visits 2 and 3 (after the washout period).
11058183|NCT04370600|Active Comparator|Group B|These patients will receive ketone supplementation between visits 2 and 3 (after the washout period) and will receive placebo drink between visits 1 and 2
11058184|NCT04370587|Experimental|Escalating doses of T3011 Injection|Dose escalation study of T3011 with 4 cohorts from 1E+6 pfu/mL to 1E+8 pfu/mL
11058185|NCT04370587|Experimental|Dose expansion of T3011 with recommended dose|Does expansion with MTD or SRC recommended dose from Arm 1
11058186|NCT04370561|Active Comparator|1/3 tubular plate|"Standard care according to AO guidelines using the Implant 1/3 tubular plate"
11058187|NCT04370561|Active Comparator|Active ankle plate|"Actual care using the new implant using the Implant Active ankle plate"
11058188|NCT04370548|Experimental|Clindamycin phosphate vaginal gel, 2%|
11058189|NCT04370548|Placebo Comparator|Placebo vaginal gel (Universal HEC Placebo Gel)|
11058190|NCT04370535|Placebo Comparator|Control group + cellulose (Group A)|healthy subjects (control group) receive placebo (cellulose) as powder
11058191|NCT04370535|Active Comparator|Control group + PMA-zeolite(Group B)|healthy subjects (control group) receive PMA-zeolite as powder
11058192|NCT04370535|Placebo Comparator|UCD-group + Cellulose (Group C)|subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder
11058193|NCT04370535|Active Comparator|UCD-group + PMA-zeolite (Group D)|subjects with uncontrolled Crohn disease receive PMA-zeolite as powder
11058194|NCT04370522||Cohort A: hormone-sensitive disease|"Patients who initiate ET in first line of advanced disease, they could be patients de novo with no previous ET or patients who received adjuvant ET and experience disease recurrence more than one year after its completion.
~Patients will be divided in two subgroups according to having or not received previous ET."
11058195|NCT04370522||Cohort B: hormone-resistant disease|"Patients in progression who are starting a first or second line of ET for advanced Breast Cancer (BC) and showing one of following the hormone-resistance criteria to any ET:
~For first line:
~Primary hormone-resistance: disease recurrence occurs within the first two years of adjuvant ET.
~Secondary hormone-resistance: disease recurrence occurs after the first two years of adjuvant ET or during the first year after its completion.
~For second line:
~Primary hormone-resistance: disease progression occurs within the first 6 months of ET for advanced disease.
~Secondary hormone-resistance: disease progression occurs after the first 6 months of ET for advanced disease.
~Patients will be divided in two subgroups according to having primary or secondary hormone-resistance."
11058196|NCT04370509|Experimental|Cohort A (Pembrolizumab monotherapy)|"Preoperative treatment consists of 200mg pembrolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles.
~Within 14-21 days following the end of treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.
~Within 21-42 days after surgery, patients with R0 resection or R1 resection receive 400 mg pembrolizumab every 21 days for up to 9 cycles (1 year) and patients with R2 resection receive pembrolizumab every 21 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
11058197|NCT04370509|Experimental|Cohort B (Pembrolizumab + VEGF-TKI)|"Preoperative treatment consists of 200 mg pembrolizumab IV on day 1 of each cycle, and 5mg axitinib (a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)) PO BID on days 1-21 of each cycle. Axitinib maybe titered in select patients after cycle 1. Treatment repeats every 21 days for up to 3 cycles
~Within 14-21 days following the end of pre-operative treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.
~Within 21-42 days after surgery, patients with an R0 or R1 resection receive 400 mg pembrolizumab and 1, 3, 5, 7 or 10 mg axitinib PO BID every 21 days for up to 9 cycles (1 year), and patients with an R2 resection receive pembrolizumab IV and axitinib PO BID every 21 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
11058198|NCT04370496|Experimental|SOLUTION group|Patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.
11072219|NCT04270760|Active Comparator|Arm 4 AMG 890 Dose 4|
11058199|NCT04370483|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11058200|NCT04370457|Experimental|Experimental arm|
11058201|NCT04370457|No Intervention|Standard care arm|
11058202|NCT04370444|Experimental|Experimental (PLR)|Participants will be given the OhNut Phallus Length Reducer (PLR) for use during the study period.
11058203|NCT04370444|Other|Control (Waitlist)|Participants will not have a PLR during the study period. They will be placed on a waitlist to receive the PLR at the end of the study period.
11058204|NCT04370431|Experimental|PartA: TTYP01 single ascending doses|In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.
11058205|NCT04370431|Placebo Comparator|Part A: Placebo|Placebo control for Part A of the study
11058206|NCT04370431|Experimental|Part B: TTYP01 (oral edaravone) first then IV edaravone|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.
11058207|NCT04370431|Experimental|Part B: IV edaravone first then TTYP01 (oral edaravone)|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.
11058208|NCT04370431|Experimental|Part C: TTYP01: fasted dosing first then fed dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.
11058209|NCT04370431|Experimental|Part C: TTYP01: fed dosing first then fasted dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.
11058210|NCT04370418||neoadjuvant chemo-radiation|"Short-course RT: 5 fractions of 5 Gy to a total dose of 25 Gy over 5 consecutive days. IMRT plans are generated with 6 MV photons.
~Dose-escalated concurrent 5-FU: The 3 doses levels of 5-FU are 100, 150, and 200 mg/m2/d. 5-FU will be given by continuous infusion for 20 hours every day starting on the morning of radiation.
~mFOLFOX: will be given 2 weeks after concurrent chemoradiation for a total of 4 cycles, with each cycle being 14 days. Surgery will be omitted in patients with complete pathological response and proceed to adjuvant chemotherapy. If patient develops progressive or metastatic disease, he/she will be omitted from the investigators study.
~The surgery will be considered 4-8 weeks after end of therapy. Adjuvant mFOLFOX6: 6 cycles chemotherapy will begin between 4 weeks and 8 weeks after surgery.
~Toxicities assessment: be using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0."
11058211|NCT04370405|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
11058212|NCT04370392|Active Comparator|control group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
11058213|NCT04370392|Experimental|IV dexmedetomidine group|intraperitoneal local anesthetic instillation (40 ml bupivacaine 0.25%) through the trocar with intravenous infusion of 50 ml normal saline containing dexmedetomidine 1 ug/kg over 10 minutes.
11058214|NCT04370392|Experimental|IP dexmedetomidine group|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25% with dexmedetomidine 1 ug/kg) through the trocar with intravenous infusion of 50 ml normal saline over 10 minutes.
11058215|NCT04370379|Experimental|low dose of IBI302|
11058216|NCT04370379|Experimental|high dose of IBI302|
11058217|NCT04370379|Active Comparator|2mg aflibercept|
11058218|NCT04370353|Placebo Comparator|Placebo|Placebo supplement, each capsule containing: 0mg total flavanols, matched for caffeine and theobromine content as experimental supplement (2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM after mixed meal for 7 days.
11058219|NCT04370353|Experimental|Cocoa Flavanols|Experimental supplement, each capsule containing: 316 mg CocoActiv (Naturex, Netherlands: 100mg total cocoa flavanols, 2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM) for 7 days.
11058220|NCT04370340|No Intervention|control|
11058221|NCT04370340|Active Comparator|intervention|
11058222|NCT04370327|Active Comparator|Pain Free Exercise (PF)|Patients will be randomised to twice weekly for 24 weeks of pain free exercise in a supervised exercise programme
11058223|NCT04370327|Active Comparator|Moderate Claudication Pain Exercise (MOD-P)|Patients will be randomised to twice weekly for 24 weeks of moderate claudication pain exercise in a supervised exercise programme
11058224|NCT04370327|Active Comparator|Maximal Claudication Pain Exercise (MAX-P)|Patients will be randomised to twice weekly for 24 weeks of maximal claudication pain exercise in a supervised exercise programme
11058225|NCT04370314|Experimental|Zirconia implant-supported crown|Full zirconia implant-supported crown
11058226|NCT04370301|Experimental|Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.
~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1.
~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.
~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is > 1,500/mm^3."
11058227|NCT04370288|No Intervention|Control group|Covid-19 patients treated with standard medical therapy (supportive therapy).
11058228|NCT04370288|Experimental|Intervention group|Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).
11072220|NCT04270760|Placebo Comparator|Arm 5 Placebo Dose 5|
11058229|NCT04370262|Active Comparator|SOC/Famotidine|Subjects in this study arm will receive a combination of Standard of Care (SOC) treatment and intravenous famotidine. Famotidine Injection, 10mg/mL mixed with Normal Saline is given intravenously at 120mg (30% of 400 mg oral dose). The total daily dose proposed is 360mg/day famotidine IV for a maximum of 14 days, or hospital discharge, whichever comes first. SOC will be administered as per the current clinical protocol for COVID-19.
11058230|NCT04370262|Placebo Comparator|SOC/Placebo|Subjects in this arm will receive the current Standard of Care treatment for COVID-19; plus placebo infusion three times daily.
11058231|NCT04370249||Patient with suspected COVID-19 infection|Patients admitted and managed in an emergency department under suspicion of COVID-19 infection who received a pleuro-pulmonary ultrasound on admission
11058232|NCT04370236|Placebo Comparator|Placebo + Standard of Care|Patients will receive placebo + standard medical care
11058233|NCT04370236|Experimental|INB03 + Standard of Care|Patients will receive INB03 + standard medical care
11058234|NCT04370223|Experimental|Ozone auto-hemotherapy plus standard treatment|Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.
11058235|NCT04370223|No Intervention|Standard treatment alone|Standard treatment will be the one used in each hospital participating in the trial.
11058236|NCT04370210||Child without follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
11058237|NCT04370210||Child with follow-up in child psychiatry|Child enrolled, and their parents, must complete online questionnaires
11058238|NCT04370171||Group TC: Diabetic patients followed by Teleconsultation|Teleconsultation group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.
11058239|NCT04370171||Group P: Diabetic patients with conventional follow-up|Conventional group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was differed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients and not available
11058240|NCT04370145|Experimental|moderate cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q12h; Tinidazole injection, iv. drip,20mg/Kg,Qd.
11058241|NCT04370145|Experimental|severe cholangitis|Meropenem injection, iv. drip,20mg/Kg，Q8h; Teicoplanin injection, iv. drip,10mg/Kg,Qd; Tinidazole injection, iv. drip,20mg/Kg,Qd.
11058242|NCT04370145|Active Comparator|control group|Sulperazon, iv.,drip,100mg/Kg,Bid; Tinidazole injection, iv. drip,20mg/Kg,Qd
11058243|NCT04370132||Group of patient with liver venous deprivation|Group of patient with liver venous deprivation
11058244|NCT04370132||Group of patient with portal embolization|Group of patient with portal embolization
11058245|NCT04370119||Healthcare workers|Healthcare workers at University Medicine Greifswald
11058246|NCT04370106|No Intervention|Control|Usual care for participants with existing VLU in the CG is defined as visiting the outpatient wound clinic/visits by the community care nurse as prescribed by the physician. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses.
11058247|NCT04370106|Other|Social leg Program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
11058248|NCT04370093|Experimental|Pioglitazone Drug (including Placebo)|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
11058249|NCT04370093|Experimental|Weight Loss, Behavioral|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
11058250|NCT04370093|Other|Pioglitazone + Weight Loss|Pioglitazone 45 mg/day + Weight Loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
11058251|NCT04370080|Experimental|Silver Diamine Fluoride|Topical application of one drop of silver diamine fluoride 38% to active untreated roof surface caries, lesions at the furcation, or lesions at crown margins. Application was repeated once each six months.
11058252|NCT04370054|Experimental|PF-07055480|Single administration of PF-07055480
11058253|NCT04370041|Experimental|Dokimos Plus aortic valve implantation|Dokimos Plus aortic valve implantation in all included patients.
11058254|NCT04370015|Experimental|Treatment group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
11058255|NCT04370015|Placebo Comparator|Control group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
11058256|NCT04370002||No Intervention|This is an observational study. There is no active treatment that is examined.
11058257|NCT04369989||Hydroxychloroquine - NO|Did not receive / are not receiving any Hydroxychloroquine
11058258|NCT04369989||Hydroxychloroquine - YES - started before|Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
11058259|NCT04369989||Hydroxychloroquine - YES - started same|Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
11058260|NCT04369989||Hydroxychloroquine - YES - started after|Hydroxychloroquine date started was after the date recorded for signs of respiratory distress
11058261|NCT04369976|Experimental|SHORT ARM HUMAN CENTRIFUGE|SHORT ARM HUMAN CENTRIFUGE IN COMBINATION WITH EXERCISE INTERMITTENT CENTRIFUGATION TOTAL TIME 30 MINUTES
11058262|NCT04369950|Active Comparator|2 percent Lidocaine with epinephrine and epidural morphine|
11058263|NCT04369950|Experimental|3 percent 2-Chloroprocaine and epidural morphine|
11058264|NCT04369937|Experimental|IMRT + Pembrolizumab + Cisplatin + ISA101b|"IMRT (Intensity Modulated Radiotherapy) of 70 Gy in 35 fractions over 7 weeks (5 fractions per week).
~Pembrolizumab will be administered at 200 mg (fixed dose) IV every 3 weeks (+/- 3 days), beginning beginning one week (week -1) prior to concurrent cisplatin-IMRT.
~Cisplatin will be administered at 100 mg/m2 IV on days 1(Week 0) and 22 (Week 3).
~ISA101b will be administered as three rounds of vaccination 3-4 weeks apart via two SC injections per vaccination round at 100ug/peptide, before pembrolizumab treatment. Vaccination #1 will be administered 1 week before pembrolizumab."
11058265|NCT04369924|Experimental|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
11058266|NCT04369924|Experimental|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
11058267|NCT04369911|Experimental|Low Dose|Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
11058268|NCT04369911|Experimental|High Dose|Acupuncture treatment twice per week for 5 weeks. Ten total acupuncture treatments completed.
11058269|NCT04369885|Experimental|Home Telemedicine Device|This arm will receive the intervention of the home telemedicine device for three months.
11058270|NCT04369872|Experimental|Microwave Ablation|Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
11058271|NCT04369859||pregnant women with COVID-19|Pregnant women who have tested positive for COVID-19
11058272|NCT04369846|Experimental|Test drug group|The arm applies the test drug of GM-XANTHO
11058273|NCT04369846|Placebo Comparator|Placebo group|The arm applies the placebo
11058274|NCT04369833||continuous glucose monitoring group|all participants wearing a continuous glucose monitoring device
11058275|NCT04369820|Experimental|COVID-19 PATIENTS|"Two blood samples (40mL) at 2 different points in time:
~Within the first 72 hours of medical care in resuscitation unit or department.
~Between the 5th and the 10th day of medical care (ideally at the end of the first week) or on the day of discharge of patient if it is earlier, or of death if it takes place earlier."
11058276|NCT04369794|Active Comparator|BCG vaccine|BCG Group (n = 500): 0.1 ml of lyophilized, live and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
11058277|NCT04369794|Placebo Comparator|Placebo|Placebo group (n = 500): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
11058278|NCT04369781||Suspected critical limb ischemia|Patients referred for transcutaneous oxygen pressure measurements due to a clinical suspicion of critical limb ischemia
11058279|NCT04369768|Active Comparator|direct composite restorations|
11058280|NCT04369768|Active Comparator|preformed metal crowns|
11058281|NCT04369755|Other|MRI|A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)
11058282|NCT04369742|Experimental|Hydroxychloroquine|N= 313
11058283|NCT04369742|Placebo Comparator|Placebo|N= 313
11058284|NCT04369729||Post-Traumatic Headache|Individuals who have post-traumatic headache attributed to mild traumatic brain injury according to ICHD-3 diagnostic criteria
11058285|NCT04369729||Healthy Control|Healthy controls will have no history of traumatic brain injury and no history of migraine or other headaches
11058286|NCT04369716|Active Comparator|Whole fruit 1|Oranges
11058287|NCT04369716|Active Comparator|Whole fruit 2|Apples
11058288|NCT04369716|Experimental|Juice 1 + pomace|Orange Juice + orange pomace
11058289|NCT04369716|Experimental|Juice 2 + pomace|Apple Juice + apple pomace
11058290|NCT04369716|Active Comparator|Juice 1 alone|Orange Juice
11058291|NCT04369716|Active Comparator|Juice 2 alone|Apple Juice
11058292|NCT04369677||First-Episode Psychosis|Twenty individuals with FEP will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
11058293|NCT04369677||Healthy|Twenty age-matched individuals with no psychotic disorder will complete a 24-hour continuous assessment of core body temperature using a CorTemp ingestible sensor (HQInc., Palmetto, FL).
11058294|NCT04369664|Experimental|Type 2 Diabetes group|All participants with type 2 diabetes will be given cholesterol-lowering medicine (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
11058295|NCT04369664|Other|Control group|The participants in the control group are subjects with elevated cholesterol who do not have diabetes. All participants will be given cholesterol-lowering medicines (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
11058296|NCT04369638|Experimental|3D NAM|
11058297|NCT04369638|Active Comparator|Traditional NAM|
11058298|NCT04369625|Experimental|CHIMPS-T|(Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents. CHIMPS-T is based on a theory model, needs analyses and the pioneering studies of Williams Beardslee. The CHIMPS approach was tested, evaluated and manualized in an initial project (2007-2011).
11058299|NCT04369625|Experimental|CHIMPS-P-single|"CHIMPS-P-single is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention. The sessions will be carried out by a social worker (based on the Finnish model Let's talk about children (Solantaus), but in a family setting Let's talk WITH children)."
11058336|NCT04369404|Experimental|Patient Decision Aid|Providers have access to patient decision aids to review and discuss during the visit.
11058300|NCT04369625|Experimental|The CHIMPS-P-group|The CHIMPS-P-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families: preliminary talk, one additional session with the family (if needed), multifamily group with three to six other families, concluding session.
11058301|NCT04369625|Experimental|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included. Overall, 8 consecutive online modules as well as elective modules will be included. These modules (e.g., dealing with difficult situations, emotion regulation, taboos and shame, self-worth) will be provided based on the specific constellation of children and adolescents of mentally ill parents. iCHIMPS will be completed by 2 booster session within a six months follow-up.
11058302|NCT04369625|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
11058303|NCT04369612|Active Comparator|Standard of care|Standard follow-up after kidney transplantation during the first 7-8 post-transplant weeks
11058304|NCT04369612|Experimental|Home-based monitoring|Every second visit will be performed without patients actually visiting the hospital. They take a capillary blood sample themselves, send it to the lab and get a telecom follow-up by treating physician the same day.
11058305|NCT04369599|Experimental|V/Q Vest|Participants with acute respiratory failure due to COVID-19 will undergo therapy with the V/Q Vest.
11058306|NCT04369586|Experimental|meplazumab dose 1|0.06mg/kg for single dose
11058307|NCT04369586|Experimental|meplazumab dose 2|0.12mg/kg for single dose
11058308|NCT04369586|Experimental|meplazumab dose 3|0.2mg/kg for single dose
11058309|NCT04369586|Experimental|meplazumab dose 4|0.3mg/kg for single dose
11058310|NCT04369586|Experimental|meplazumab dose 5|0.42mg/kg for single dose
11058311|NCT04369586|Experimental|meplazumab dose 6|0.56mg/kg for single dose
11058312|NCT04369586|Experimental|meplazumab multiple dose|0.3mg/kg for double doses, 1 dose/week
11058313|NCT04369573|Active Comparator|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
11058314|NCT04369573|Other|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20
11058315|NCT04369560|Experimental|Magnetic Resonance Imaging|Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
11058316|NCT04369547|Experimental|Roflumilast|Participants will ingest a capsule containing 100mcg of the phosphodiesterase-4 inhibitor roflumilast. Their baseline TMS evoked potentials (TEP) will be recorded over 100 single TMS pulses prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the left dorsolateral prefrontal cortex (DLPFC). TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
11058317|NCT04369547|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however, this capsule will be contain a placebo. Their baseline TEP will be recorded over 100 single TMS pulses prior to receiving TBS to the left DLPFC. TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
11058318|NCT04369534|Active Comparator|First group|The patients randomized into the first group will be given the newer P2Y12 receptor inhibitor ticagrelor during the 12 months.
11058319|NCT04369534|Active Comparator|Second group|The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
11058320|NCT04369521|Experimental|Intervention|low free sugar diet with nutrition and exercise recommendation
11058321|NCT04369521|No Intervention|control|regular diet with nutrition and exercise recommendation
11058322|NCT04369495||Cyclophosphamide|Patients with induction therapy for lupus nephritis with cyclophosphamide
11058323|NCT04369495||Mycophenolate|Patients with induction therapy for lupus nephritis with mycophenolate
11058324|NCT04369482|Active Comparator|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
11058325|NCT04369482|Active Comparator|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
11058326|NCT04369469|Experimental|Ravulizumab plus Best Supportive Care|
11058327|NCT04369469|Other|Best Supportive Care|
11058328|NCT04369456|Other|Covid-19 kidney transplant patients with moderate symptoms|
11058329|NCT04369443|No Intervention|MANH|
11058330|NCT04369443|Experimental|LANH|
11058331|NCT04369430|Experimental|AKST4290|Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.
11058332|NCT04369430|Placebo Comparator|Placebo|Subjects will receive placebo, twice daily, for 12 weeks.
11058333|NCT04369417|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
11058334|NCT04369417|Active Comparator|Active Comparator: Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
11058335|NCT04369404|No Intervention|Usual care|In the usual care group, the providers do not have access to the decision aids.
11058337|NCT04369391|Experimental|SEP363856 150 mg|SEP363856 tablet 150 mg
11058339|NCT04369391|Active Comparator|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
11058340|NCT04369378|Experimental|Meditation app group|Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
11058341|NCT04369378|No Intervention|Control group|Participants will be in the no intervention period for 30 days. Two days before the end of the 30 day no intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. After this 30 day no intervention period, participants are invited to use the Insight Timer app if they so choose. Two months after the conclusion of the 30 day no intervention period (90 days after study began), participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
11058342|NCT04369365|Active Comparator|Arm A: Azithromycin|weekly oral azithromycin 1500mg for a maximum of 8 weeks
11058343|NCT04369365|Placebo Comparator|Arm B: Placebo|weekly oral placebo for a maximum of 8 weeks
11058344|NCT04369339|Experimental|Other High Risk HPV Positivity|Colposcopy performed to women with High risk HPV positive ,negative for intraepithelial lesions or malignancy cytology
11058345|NCT04369339|Active Comparator|HPV16/18|Colposcopy performed to women with HPV 16/18 positive ,negative for intraepithelial lesions or malignancy cytology
11058346|NCT04369326|Experimental|Community-Based TPT Initiation|All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children <15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
11058347|NCT04369326|No Intervention|Facility-Based TPT Initiation|Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.
11058348|NCT04369313|Experimental|delayed cord clamping|clamping the cord at least 30s at birth
11058349|NCT04369313|Other|early cord clamping|umbilical cord clamping before 15 seconds
11058350|NCT04369287||IDH1-mutated AML|Patients affected with AML and carryng IDH1 mutations
11058351|NCT04369287||IDH2-mutated AML|Patients affected with AML and carryng IDH2 mutations
11058352|NCT04369287||IDH1/2 unmutated AML|Patients affected with AML without IDH1/2 mutations
11058353|NCT04369274|Experimental|Interventional|All subjects will briefly be placed on the automated BVM compressor device. Measurements obtained while on this device will be compared to those obtained in the same subject prior to mechanical ventilation and while on a conventional ventilator.
11058354|NCT04369248||Control group|30 healthy women with BMI < 30 between 18 and 35 years old
11058355|NCT04369248||Non-obese PCOS|2003 Rotterdam ESHRE/ASRM PCOS Consensus Criteria were used to diagnose PCOS that fulfilled at least two of the followings: chronic oligo-anovulation, clinic or biochemical hyperandrogenism and presence of polycyctic ovary by ultrasound (Rotterdam). Oligo-anovulation is defined as periods lasting more than 35 days and/or amenorrhea. Clinic or biochemical hyperandrogenism is defined as the presence of acnes and/ or Ferriman-Galleway modified score >8 and/ or hyperandrogenemia defining the testosterone level > 0.6 ng/ml (2 nmol/l) and/or dehydroepiandrosterone level > 3 ng/ml (10.5 nmol/l). Polycyctic ovaries are defined as the presence of more than 12 follicules 2-9 mm in diameters or ovarian volume >10 cm3 under transvaginal or abdominal ultrasound. non-obese group are the women BMI < 30 between age of 18 and 35.
11058356|NCT04369248||Obese PCOS|Obese group are the women with BMI > 30 between age of 18 and 35.
11058357|NCT04369235|Experimental|tCES & upper extremity rehabilitation|The experiment group will receive tCES combined with upper extremity rehabilitation of affected side.
11058358|NCT04369235|Sham Comparator|Sham tCES & upper extremity rehabilitation|The sham control group will receive sham tCES combined with upper extremity rehabilitation of affected side.
11058359|NCT04369222||Controls|Children born from mothers with no consumption of mild analgesics 3 months before or during pregnancy
11058360|NCT04369222||Exposed|Children born from mothers with consumption of mild analgesics 3 months before or during pregnancy
11058361|NCT04369183||Study Group|Patients with primary focal segmental glomerulosclerosis or minimal change disease who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to or relapse after at least one set of prior therapies including corticosteroids, calcineurin inhibitors or mycophenolic acid derivatives.
11058362|NCT04369170|Other|Group A - Control Group|Control group where an intermediate abutment is placed in between the CAD-CAM dental prostheses an the dental implant.
11058363|NCT04369170|Experimental|Group B - Test Group|Test group where the CAD-CAM dental prostheses is connected directly to the dental implant
11058364|NCT04369157||Elective surgery group|Patients undergoing hip/knee replacements or colorectal surgery will be recruited and tested on 3 occasions: pre-op, post-op and at follow-up. POCD status will be determined at post-op and follow up. Cognitive function, zinc status, POCD biomarkers and inflammatory markers will be measured on all 3 occasions.
11058365|NCT04369144|Experimental|Intervention group|The dynamic scapular recognition exercise + rigid taping with 50%-75% tension.
11058366|NCT04369144|Placebo Comparator|Control|The dynamic scapular recognition exercise + placebo taping
11058396|NCT04368949|Active Comparator|TELE Group|The initial telephone session will be 20-30 minutes, with subsequent weekly calls will be approximately 10 minutes.
11058578|NCT04367532|Experimental|Tissue flossing|Tissue flossing of cuff muscles.
11058367|NCT04369131|Experimental|Intervention|All participants will receive intervention in four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominals only FES, and (d) calves, quads, and abdominals FES. Session-by-session alternation among conditions will occur in a unique, predetermined, randomized order for each participant.
11058368|NCT04369118|Experimental|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
11058369|NCT04369118|Active Comparator|conventional postoperative follow-up|Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
11058370|NCT04369092|Other|without swallowing problem|patients without swallowing problem
11058371|NCT04369092|Other|mild swallowing problem|patients with mild swallowing problem
11058372|NCT04369092|Other|severe swallowing problem|patients with severe swallowing problem
11058373|NCT04369079|Experimental|TREATMENT GROUP|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side. The exact sequence and number of procedures differed in each patient according to need as determined by prior functional examination. Before or after every of the treatment procedure treatment group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
11058374|NCT04369079|Other|CONTROL GROUP|Treatment duration was a mean of 4 weeks. Therapy was performed daily excluding weekends and consisted of 45 minutes of individual work with an oncological physiotherapist. The control group underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area. Before or after every of the treatment procedure control group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
11058375|NCT04369066|Other|Subjects who are not showing active SARS-Cov2 infection|
11058376|NCT04369040|Other|High-flow nasal oxygen therapy|Ventilation with High-flow nasal oxygen therapy
11058377|NCT04369040|Experimental|Flow Controlled Ventilation|Ventilation with laryngeal tri-tube with Flow Controlled Ventilation technique
11058378|NCT04369027||preload responders|patients who increase their delta VTI by more than 10% during PLR
11058379|NCT04369027||preload unresponders|patients who do not increase their delta VTI by more than 10% during PLR
11058380|NCT04369014|Experimental|etomidate|
11058381|NCT04369014|Experimental|propofol|
11058382|NCT04369001|Experimental|Intervention Group|(Program ACTIVE n=20) Participants randomized into the Program ACTIVE group will receive a gym membership to a local, Detroit-based community recreation facility where they will complete 150 minutes of exercise per week for 12 weeks and will receive 10 sessions (once weekly) of CBT therapy sessions. Exercise per week will be documented using exercise logs. Exercise logs will be given to research staff at the end of the 12-week timeframe; all exercise logs will be kept organized respective to the participant identification number and related documents (questionnaires and surveys). To ensure treatment fidelity, three CBT and three physical activity sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
11058383|NCT04369001|No Intervention|Enhanced Usual Care|(EUC n=20) Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Participants will not be required to report any use of resources offered or change their course of treatment in any way. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, gym access and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
11058384|NCT04368988|Placebo Comparator|Placebo - Phase 1|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
11058385|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.
11058386|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
11058387|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
11058388|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.
11058389|NCT04368988|Placebo Comparator|Placebo - Phase 2|3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.
11058390|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
11058391|NCT04368988|Experimental|SARS-CoV-2 rS - Alternating 5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
11058392|NCT04368988|Experimental|SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
11058393|NCT04368988|Experimental|SARS-CoV-2 rS - Alternating 25/5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
11058394|NCT04368962||MMF group|Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.
11058395|NCT04368949|Experimental|Stepping-Up Group|Participants will attend one 2-hour session (1-hour exercise and 1-hour SM) per week. Each class of 10-12 participants is supervised by a Physiotherapist (PT) and kinesiologist who will individually tailor the exercises for each participant.
11058397|NCT04368949|Placebo Comparator|STRETCH Group|Participants will attend 2x/week for 1 hour each time to ensure this group is matched for attention to STEPPING-UP.
11058398|NCT04368936||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 1-14 years
11058399|NCT04368936||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
11058400|NCT04368936||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
11058401|NCT04368936||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
11058402|NCT04368936||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed Epilepsia
11058403|NCT04368936||EFS: group of individuals with Epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
11058404|NCT04368923|Experimental|Oxygen Therapy Group|
11058405|NCT04368923|Experimental|Physical Therapy Group|
11058406|NCT04368910|Experimental|Pyronaridine - artesunate|"Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
11058407|NCT04368910|Active Comparator|Chloroquine|"Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
11058408|NCT04368897||COVID-19 Male Patients|Males with laboratory confirmed SARS-CoV-2 infection
11058409|NCT04368884||Healthcare workers|The healthcare workers who are being tested for COVID-19 would be included in this group
11058410|NCT04368884||OPD patients|Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group
11058411|NCT04368884||IPD COVID-19 cases|Admitted positive cases of COVID-19 in the hospital will be included in this group
11058412|NCT04368858|Experimental|Cohort 1 : experimental group|Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
11058413|NCT04368845|Active Comparator|Experimental Intervention Arm: Telerehabilitation|The treatment arm will be given up to 1-hour resistive training exercises, breathing exercises and aerobic exercises administered by an expert physiotherapist via teleconference (telerehabilitation). Every ten days one physiotherapist will record the individualized exercise program, will reevaluate the magnitude of exercise for each patient and reinforce to continue or increase exercise magnitude.
11058414|NCT04368845|No Intervention|No Intervention: Conventional teleconference|The usual care arm will receive standard communication via teleconference every ten days for a six-month period without any specific recommendations and exercise prescription for home training. The control arm will be subject to the same assessments as the experimental arm at the start, and at the 3 and 6 months period.
11058415|NCT04368832||Experimental group|During prenatal monitoring, at least one consultation by remote consultation (phone or teleconsultation)
11058416|NCT04368832||Control group|"Prenatal monitoring by face-to-face consultations adapted to confinement (absence of clinical signs or notion of travel, occupation, contact, clustering (TOCC), no attendant, limited movements inside the hospital and precautions of droplet and contact type)"
11058417|NCT04368819|Active Comparator|Allopurinol|Allopurinol 300mg P.O. once daily for four weeks followed by allopurinol 300mg P.O. twice daily for 12 weeks.
11058418|NCT04368819|Placebo Comparator|Placebo|Placebo pills indistinguishable from the active comparator given P.O. once daily for four weeks, followed by twice daily for 12 weeks.
11058419|NCT04368806|Experimental|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
11058420|NCT04368806|Placebo Comparator|Placebo|Normal Saline with Autologous Serum
11058421|NCT04368793||Discharged COVID-19 patient cohort|All enrolled participants will be given 8 weeks (online 2 weeks + offline 6 weeks) pulmonary rehabilitation intervention, and will be followed up for at least one year, to assess their adherence and efficacy of the rehabilitation program.
11058422|NCT04368780|No Intervention|Control group|Individuals who provide home care to an elderly person who is dependent on the bed
11058423|NCT04368780|Experimental|Experimental group|Individuals who provide home care to an elderly person who is dependent on the bed. It is planned that the exercises will be conducted two days a week with the researcher and on the other days by the caregiver herself for a total of eight weeks.
11058424|NCT04368767|No Intervention|Usual Care: Incubator|The infant will remain in the incubator and stress biomarkers will be collected per protocol
11058425|NCT04368767|Experimental|Intervention: Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, 30 minutes after feeding. SSC will usually occur in the afternoon between 11:30-12:30 pm or 14:30-15:30pm. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. The room will be monitored to maintain a temperature of 72-77 degrees Fahrenheit during SSC. Stress biomarkers will be collected per protocol.
11058426|NCT04368741|Experimental|Experimental group|SANZ®KINGWILL
11058427|NCT04368741|Other|Control group|GLUCERNA SR®
11058428|NCT04368728|Experimental|Low dose, 18-55 years of age (2 doses)|
11058429|NCT04368728|Experimental|Low-mid dose, 18-55 years of age (2 doses)|
11058439|NCT04368715|Experimental|2780 nm Er:Cr;YSGG laser treated group|Patients treated with Er:Cr;YSGG laser for labial frenectomy
11058440|NCT04368715|Experimental|940 nm Diode laser treated group|Patients treated with 940 nm Diode laser for labial frenectomy
11058441|NCT04368702|Experimental|Phase I - Gastric Cancer|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
11058442|NCT04368702|Experimental|Phase I - Breast Cancer|"The research study procedures include:
~Screening for eligibility
~Study treatment including evaluations
~MR-image guided radiation will be administered per disease site standards.
~Follow up visits
~Questionnaires"
11058443|NCT04368689|Experimental|Floating|Participants have 3 Floatation sessions that last up to 90 minutes. Each spaced about a week apart.
11058444|NCT04368676|Experimental|Sudarshan Kroya Yoga (SKY)|Sudarshan Kriya Yoga (SKY) will be delivered using the Hospital approved Cisco WebEx platform. The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 3 hours. Phase I will consist of 5 self-paced online modules of 4-10 minutes each to learn the breath control techniques. In Phase II, 2 interactive online sessions of 1 hour each will be held on consecutive days with a certified SKY teacher, during which participants will learn the fast, medium and slow breaths. For ease of scheduling, multiple time windows will be offered for Phase II. Phase I and Phase II will be completed in the first week of the trial. Weekly follow up sessions will be offered to participants for 30 minutes each for 4 weeks in both study arms.
11058445|NCT04368676|Active Comparator|Health Enhancement Program (HEP)|The Health Enhancement Program (HEP) will be delivered using the Hospital approved Cisco WebEx platform. The active control arm, HEP, will consist of time-matched online self-paced modules for Phase I, comprised of de-stressing guided exercises such as gentle stretch and yoga asanas and progressive muscle relaxation. Phase II will consist of mindfulness-based meditation sessions delivered by Dr. Paris Lai, co-investigator and senior psychiatry resident, and backed up by Ms. Victoria Mills and Ms. Kasha Herba, MSWs, mental health social workers. They all have previous research experience in our Geriatric Mood Disorders Lab. They will be supervised by the PI and Dr. Imants Baruss to deliver the HEP intervention. Weekly follow up sessions will be offered to all recruited participants for 30 minutes each for 4 weeks in both study arms.
11058446|NCT04368663|Active Comparator|TJ-134 group|The traditional Japanese medicine, Keishi-ka-shakuyaku-daio-to（TJ-134, 7.5g/day), which consists of a mixture of a compound of peony root (6 g), cinnamon bark (4 g), jujube (4 g), glycyrrhiza (2 g), rhubarb (2 g), and ginger (1 g) is administered to enrolled patients for 8 weeks.
11058447|NCT04368663|Placebo Comparator|Lactomin group|Lactomin (3g/day) is administered to enrolled patients for 8 weeks.
11058448|NCT04368650|Experimental|Main treatment group|The in situ BMP-2 gel was prepared to a concentration of approximately 0.5 μg/ml and were stored at 4oC. The gel was then dispensed at site of interest in the study.
11058449|NCT04368650|Active Comparator|Control|In patients selected for control group, after degranulation, sticky bone was used to fill the defect. The surgical site was protected and covered using a periodontal dressing.
11058450|NCT04368624||Participants with PKU|"Patients with classical PKU phenotype (serum phenylalanine concentration > 10 mg/dL on a normal diet at diagnosis) # ~25
~Patients with hyperphenylalaninemia (serum phenylalanine concentration < 10 mg/dL on a normal diet at diagnosis) # ~15
~Patients with PKU on therapy with Kuvan # ~10"
11058451|NCT04368624||Non-PKU Control|Study Controls: Up to 50 children and adults without a known metabolic disorder.
11058452|NCT04368611|Active Comparator|fundus first cholecystectomy|start with fundus dissection then complete the dissection
11058453|NCT04368611|Active Comparator|Calot first dissection|start and complete the dissection by dissection of Calot triangle
11058454|NCT04368598|Experimental|High-dose Dexamethasone plus Acetylcysteine|For all patients in this arm, DXM was administered intravenously at 40 mg daily for 4 consecutive days and then stopped. If platelet count remained below 30×10^9/L or there were bleeding symptoms by day 10 to 14, an additional 4-day course of DXM (40 mg daily) was given. Besides, all patients received Acetylcysteine orally at 0.4g three times a day for 4 consecutive weeks in the first month.
11058455|NCT04368585|Experimental|TBPM-PI-HBr Alone (Period 1)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
11058456|NCT04368585|Experimental|TBPM-PI-HBr and Antacid (Period 2)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
11058457|NCT04368585|Experimental|TBPM-PI-HBr and Omeprazole (Period 3)|40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.
11058458|NCT04368572|Experimental|lumbar puncture under hypnosis|Hypnosis is the only act added by protocol to patients receiving a lumbar puncture as part of the etiological assessment of cognitive disorders
11058459|NCT04368572|Active Comparator|lumbar puncture without hypnosis|Lumbar puncture is performed by a physician assisted by a nurse or a psychologist who reassure the patient during the installation and the procedure.
11058460|NCT04368559|Experimental|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-PCP prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo.
11058461|NCT04368559|Active Comparator|Group 2: Oral Antifungal|Subjects in SAR treatment group will receive 400 mg oral fluconazole once daily for 13 weeks. Fluconazole may be switched, due to acute clinically significant GVHD, to 300 mg oral posaconazole twice daily on the first day of the medication switch and 300 mg once daily, thereafter. However, subjects who are switched to posaconazole cannot be switched back to fluconazole. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from daily oral therapy to daily IV therapy at the discretion of the Investigator. In addition, subjects in the SAR group will receive anti-PCP prophylaxis with oral TMP/SMX (80 mg TMP/400 mg SMX) once daily.
11058579|NCT04367532|No Intervention|Control group|Without any intervention.
11058462|NCT04368546||Patients|Metastatic cell carcinoma patients before sunitinib treatment, after 4 week on, after 2 week off and finally again 4 week on medication.
11058463|NCT04368546||Healthy controls|Age-matched subjects without known disease.
11058464|NCT04368533|Experimental|Livionex Dental Gel|Children assigned to this arm will brush/clean teeth with Livionex Dental Gel twice a day for 9 months.They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, and 9 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience at each study visit. A monthly phone call will be made to assess compliance with the study protocol, and to answer any questions or concerns. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
11058465|NCT04368533|Active Comparator|A standard children's toothpaste containing 1500 ppm fluoride|Children assigned to this arm will brush/clean teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for 9 months. They will undergo a dental exam by a trained dentist including caries assessment (at baseline, 1, 3, 6, and 9 months), dental plaque photograph, (at baseline, 1, 3, 6 and 9 months), and swab samples for dental plaque and saliva will be collected at all study visits. A questionnaire will be given to address dentifrice and brushing experience at each study visit. A monthly phone call will be made to assess compliance with the study protocol, and to answer any questions or concerns. Data on compliance and side-effects of toothpastes will be collected at each of the calls.
11058466|NCT04368520|Placebo Comparator|Placebo|
11058467|NCT04368520|Experimental|Low dose vitamin D3|
11058468|NCT04368520|Experimental|High dose vitamin D3|
11058469|NCT04368507|Experimental|YYB101+Irinotecan|"b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks
~a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks"
11058470|NCT04368494|No Intervention|Control|Continue with normal activity.
11058471|NCT04368494|Experimental|Exercise|12-weeks of home based exercise involving 30 minutes of brisk walking on 5 days per week.
11058472|NCT04368455|Experimental|Primary Care Clinic|Physician participants will receive the self-directed app based curriculum. The physician participants will engage in the VR simulations independently.Next, we will implement VICTORI with staff including nurses and medical assistants in groups of up to 15-20 participants (phase II; secondary outcome). Staff will watch a 5-minute video on evidence-based practices in recommending the HPV vaccine and observe a facilitator and clinician participating in the VICTORI VR simulations, and then engage in a 5-minute debriefing.
11058473|NCT04368455|Active Comparator|Control Primary Care Clinic|Physician participants will receive the self-directed app based curriculum component of VICTORI though will not undergo the VR simulations.
11058474|NCT04368429|Experimental|Group 1: MenACYW conjugate vaccine|MenACYW conjugate vaccine: single injection at Day 0
11058475|NCT04368429|Active Comparator|Group 2: Menactra® vaccine|Menactra® vaccine: single injection at Day 0
11058476|NCT04368403|Experimental|KHK4827|
11058477|NCT04368377|Experimental|Tirofiban|"Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0.15 microgram/kg/minute for 48 hours.
~Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75 mg daily for 30 days.
~Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75 mg daily for 30 days
~Patents will receive concurrent fondaparinux 2.5 mg s/c per day for the duration of the hospital stay"
11058478|NCT04368364|Active Comparator|Group 1 (Control group)|
11058479|NCT04368364|Experimental|Group 2(Bupivacaine hydrochloride group)|
11058480|NCT04368364|Experimental|Group 3 (ropivacaine hydrochloride group)|
11058481|NCT04368351||Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
11058482|NCT04368351||bacteriotherapy|Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
11058483|NCT04368325||Study group|Total of 46 patients with low serum creatinine levels whose values were obtained from the central laboratory with inclusion criteria (< 40mmol/L)
11058484|NCT04368325||Control group|A total of 61 consecutive patients were obtained who were treated in ICU CHC Osijek, according to the date of admission.
11058485|NCT04368312||Health care providers/hospital staff|The targeted group are doctors and nurses (hospital stuff) of a large university hospital directly confronted with patients with Cov-19
11058486|NCT04368299|Experimental|Telemedicine|Telemedicine group will receive scheduled follow-ups via videoconferencing.
11058487|NCT04368299|Active Comparator|Standard care|Standard care group patients will continue conventional standard in-person outpatient care.
11058488|NCT04368286|Experimental|Rehabilitation group|To conduct a comprehensive pulmonary rehabilitation assessment and treatment
11058489|NCT04368286|No Intervention|Conventional medical group|Conventional medical treatment
11058490|NCT04368273|Experimental|treatment|PD-1 antibody combined CCRT for patients with local advanced cervical cancer.
11058491|NCT04368260|Active Comparator|Control swab|FDA cleared swab
11058492|NCT04368260|Experimental|Prototype swab|Injection molded polypropylene flocked nylon NP swab
11058493|NCT04368247||Nevi undergoing biopsy per SOC|Subjects with Nevi who will as part of their standard of care, will undergo biopsy.
11058494|NCT04368234||COVID-19 Patients|Any Duke patient that is being treated for COVID-19.
11058495|NCT04368195|No Intervention|Control group|This group will not receive any regional block
11058496|NCT04368195|Experimental|Erector spinae block group|This group will receive erector spinae block
11058497|NCT04368182|Experimental|Treatment group|Autologous C-TCR055 administered by intravenous (IV) infusion
11058498|NCT04368169|Experimental|Aromatic Extract|Participants receive the aromatic botanical extract orally every 4-6 waking hours for 3 days.
11058721|NCT04366596|Experimental|DEB group|angioplasty with paclitaxel eluting balloon
11058499|NCT04368169|Placebo Comparator|Placebo|Participants receive the placebo matching the botanical extract orally every 4-6 waking hours for 3 days.
11058500|NCT04368156|No Intervention|Control|
11058501|NCT04368156|Experimental|Gammacore treatment|
11058502|NCT04368130|Experimental|SIGNAL|"Program to explore the feasibility and acceptability of a smartphone-based real-time behavioral anomaly detection system (SIGNAL).
~Patients will download the adapted Beiwe app onto their smartphones for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
11058503|NCT04368117|Active Comparator|Standard Therapy (ST)|Patients randomized to the ST group will receive standard of care, routine burn physical therapy.
11058504|NCT04368117|Experimental|Active Therapy (STAT)|Patients randomized to the STAT group will receive an intensive, quantifiable, activity-based physical therapy prescription emphasizing four of the most active components of therapy: mobilization, strength training, aerobic training and functional training.
11058505|NCT04368104||Group A|women using any form of minipills
11058506|NCT04368104||Group B|women subjected to office hysteroscopy for different indications but not using any form of hormones or systemic or local hormonal contraception.
11058507|NCT04368091||All-comers, real-world registry|Subjects requiring infrainguinal revascularization with the Xtreme Touch - Neo (Magic Touch PTA)
11058508|NCT04368078|Experimental|Toripalimab plus Lenvatinib|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
~Toripalimab is a recombinant anti-human PD-1 monoclonal antibody."
11058509|NCT04368052|Other|Observation|preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
11058510|NCT04368039|Experimental|Normobaric Oxygen Therapy (40% FiO2)|4 weeks of nightly normobaric oxygen therapy (40% FiO2)
11058511|NCT04368039|Placebo Comparator|Placebo Condition|4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)
11058512|NCT04368026||Group 1|"Responders currently working in a COVID-19-dedicated hospital, which was transformed by Polish Ministry of Health during SARS-CoV-2 pandemic into institution designated only for SARS-CoV-2 patients, including those developing symptoms and quarantined."
11058513|NCT04368026||Group 2|"Responders currently working in non-COVID-19-dedicated hospital."
11058514|NCT04368013|Experimental|Experimental|The difference from the standard of care is extended sample collection and study related procedures during the study.
11058515|NCT04368000|Experimental|Prone Positioning|
11058516|NCT04368000|Active Comparator|Usual care|
11058517|NCT04367987||Patients undergoing colorectal surgery|
11058518|NCT04367974||1|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，they were given intraperitoneal twice daily in the first bag and the fourth bag for 5 days，and given 1g once daily in the fourth bag for 9 days. Total treatment duration was 2 weeks.
11058519|NCT04367974||2|The dose of cefazolin and Ceftazidime co-administered were 20 mg /kg，and were given once daily in the fourth bag. Total treatment duration was 2 weeks.
11058520|NCT04367948|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
11058521|NCT04367948|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
11058522|NCT04367935|Active Comparator|Intervention|Pentoxifylline tablets 400mg three times daily for 2 months
11058523|NCT04367935|No Intervention|Control|Control Group receiving placebo tablets three times daily for 2 months
11058524|NCT04367922|Experimental|Positive emotion skills invervention|Participants will go through a 6-week positive emotion skills course where 1 new skill opens each week.
11058525|NCT04367909|Experimental|Nimotuzumab plus TC Regimen chemotherapy|Nimotuzumab (200 mg) plus TC Regimen chemotherapy every 3 weeks
11058526|NCT04367909|Active Comparator|TC Regimen chemotherapy|TC Regimen chemotherapy every 3 weeks
11058527|NCT04367883||CST Hospital Incomes|"Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.
~No intervention is performed."
11058528|NCT04367870||Non immune patient|Patients with a negative SARS-CoV-2 immunoassay
11058529|NCT04367870||Immune patient|Patients with a positive SARS-CoV-2 immunoassay
11058530|NCT04367857||Prior Positive polymerase chain reaction (PCR) and Recovered|Prior Positive PCR result, fully recovered, back at work and symptom free for greater than or equal than 14 days.
11058531|NCT04367857||Never tested, history of COVID-19 Symptoms and Recovered|Never tested and history of COVID-19 symptoms and symptom-free for more than 14 days
11058532|NCT04367857||Never tested and current COVID-19 Symptoms|Never tested and current COVID-19 Symptoms (e.g. referred by a provider or clinic)
11058533|NCT04367857||Never tested and asymptomatic|Never tested and asymptomatic for COVID-19 symptoms, including asymptomatic health care worker
11058534|NCT04367831|Experimental|Intervention arm: intermediate-dose anticoagulation|"If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily or unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1-0.3 U/mL.
~If eGFR <30 mL/min or acute kidney injury or CRRT: Unfractionated heparin infusion at 10 units/kg/hour (minimum 500 units/hour if CRRT) with goal anti-Xa 0.1-0.3 U/mL"
11058535|NCT04367831|Active Comparator|Control arm: prophylaxis|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):
~If eGFR ≥30 mL/min (stable kidney function):
~BMI < 40 kg/m2: Enoxaparin 40 mg SC daily
~BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h
~BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h
~If eGFR < 30 mL/min or acute kidney injury:
~50-120 kg: Unfractionated heparin 5000 units SC q8h
~>120 kg: Unfractionated heparin 7500 units SC q8h
~If CRRT: Unfractionated heparin infusion pre-filter at 500 units/hour"
11058536|NCT04367818|Active Comparator|Peri-anal local anaesthetic infiltration|
11058537|NCT04367818|Active Comparator|caudal anaesthesia|
11058538|NCT04367792||Patients died with Covid-19 disease|Sample of patients died with Covid-19 disease and pulmonary disease
11058722|NCT04366596|Placebo Comparator|POB group|Angioplasty with plain old balloon
11058539|NCT04367792||Patients died with Covid-19 and cardiovascular disease|Sample of patients died with Covid-19 disease and pulmonary disease with clear cardiovascular involvement
11058540|NCT04367792||Patient died with myocarditis|Sample of patient died with different types of myocarditis without Covid-19 disease. These samples are used as control and are part of database of previously collected samples of CVPath Institute Inc.
11058541|NCT04367779||A : High Grade Sarcoma|Pediatric and adult patients with High Grade Sarcoma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
11058542|NCT04367779||B : Brain tumors|Pediatric and adult patients with Brain Tumors treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
11058543|NCT04367779||C : Meningioma|Pediatric and adult patients with Meningioma treated or to be treated with Proton Beam Therapy (PBT) and not candidate to surgery before PBT.
11058544|NCT04367766|Active Comparator|Immediate Implant Placement|prosthetically driven immediate implant placement (WinSix, Biosafin) with bone substitute (BioOss Collagen, Geistlich) filling the gap between the buccal socket wall and the implant surface and a collagen matrix (Fibrogide, Geistlich) positioning at the vestibular aspect to increase soft tissue volume, with immediate (non occlusal loading) prosthetic provisionalization.
11058545|NCT04367766|Active Comparator|Alveolar Ridge Preservation (ARP) + Delayed Implant Placement:|ARP performed with bone substitute (BioOss Collagen, Geistlich) and a collagen matrix placed to seal the socket entrance (Mucograft Seal, Geistlich). After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm
11058546|NCT04367766|Active Comparator|Spontaneous Healing + Delayed Implant Placement|extraction socket will be left to heal spontaneously. After 4 months of healing a prosthetically driven implant (WinSix, Biosafin) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm, and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm .
11058547|NCT04367753||Fulfilled contract|The contract before the epiphysiodesis has been fulfilled with the wanted limb length at the final analysis
11058548|NCT04367753||Failed contract|The contract before the epiphysiodesis hasn't been fulfilled with the wanted limb length at the final analysis
11058549|NCT04367740||Serum Antibodies|Blood samples to be obtained assess for IgG antibodies against SARS-CoV2
11058550|NCT04367727|Experimental|5 minutes before 1|Light emitting diode applied 5 minutes before fatiguing task
11058551|NCT04367727|Placebo Comparator|5 minutes before 2|Light emitting diode applied 5 minutes before fatiguing task
11058552|NCT04367727|Experimental|1 hour before 1|Light emitting diode applied 1 hour before fatiguing task
11058553|NCT04367727|Placebo Comparator|1 hour before 2|Light emitting diode applied 1 hour before fatiguing task
11058554|NCT04367727|Experimental|5 hours before 1|Light emitting diode applied 5 hours before fatiguing task
11058555|NCT04367727|Placebo Comparator|5 hours before 2|Light emitting diode applied 5 hours before fatiguing task
11058556|NCT04367701||Thalassemia group|"16 pediatric patients with thalassemia major undergoing surgery for repair of congenital heart disease.
~Authors measure hemolysis by free plasma hemoglobin concentration."
11058557|NCT04367701||Control group|"25 pediatric patients with demographic data related to those in thalassemia group, undergoing surgery for repair of congenital heart disease.
~Authors measure hemolysis by free plasma hemoglobin concentration"
11058558|NCT04367675|Experimental|INO-5401|Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
11058559|NCT04367675|Experimental|INO-5401 and INO-9012|Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
11058560|NCT04367662|Experimental|Patient with COVID-19 infection|Patient with COVID-19 infection hospitalized in a COVID unit
11058561|NCT04367649|Experimental|Hall technique|
11058562|NCT04367649|Active Comparator|Atraumatic restorative treatment|
11058563|NCT04367649|Sham Comparator|Conventional restorative treatment|
11058564|NCT04367636|Active Comparator|Active Comparator: PSE + OCAT-sham|Psycho-education video + an active placebo training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected scrambled sentences task with online contingent feedback.
11058565|NCT04367636|Experimental|Experimental: PSE + OCAT|Psycho-education video + an attention training, consisting of 10 sessions of ±15 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed scrambled sentences task with online contingent feedback.
11058566|NCT04367623|Active Comparator|Control|Patients receiving conventional hand therapy, time matched to the duration of total intervention in the Active group
11058567|NCT04367623|Active Comparator|Active|Patients receiving BCI FES prior to the conventional therapy
11058568|NCT04367610||Study Group|Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
11058569|NCT04367597|Experimental|Active NMES|
11058570|NCT04367597|Sham Comparator|Modified NMES sham|
11058571|NCT04367584||Subjects with inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
11058572|NCT04367584||Subjects with non inflammatory AV lesions|Clinical examination Laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
11058573|NCT04367571|Experimental|Osteopathic Manipulative Treatment|
11058574|NCT04367571|Placebo Comparator|Manual Placebo|
11058575|NCT04367558|Experimental|Interventional|Patient suffering from OSA, and found to suffer from obstruction of one or more of the following areas - Lower turbines, Soft Palate, Tonsils, Base-of-tongue.
11058576|NCT04367545|Experimental|Patient with COVID-19 infection suspicion|Patient with COVID-19 infection suspicion are tested using standard diagnosis method
11058577|NCT04367532|Experimental|Foam rolling|Foam rolling of cuff muscles.
11058580|NCT04367506|Experimental|BecomeAnEX|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital.
11058581|NCT04367506|Active Comparator|Usual Care|Brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
11058582|NCT04367493|Experimental|1. Group 55% cocoa intervention|55% cocoa intervention
11058583|NCT04367493|Experimental|2. Group White Chocolate|White chocolate
11058584|NCT04367493|No Intervention|3. Control Group|Control Group
11058585|NCT04367480|Experimental|Group I (TENS)|Patients wear an active wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
11058586|NCT04367480|Placebo Comparator|Group II (placebo TENS)|Patients wear a placebo wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
11058587|NCT04367467||Individuals with solid tumors receiving PARPi|"Kidney function will be assessed by serum creatinine, serum cystatin C, and urine creatinine clearance calculation for patients who opt-in to 24 hour urine collection.
~These laboratory measures will be completed by patients at the following time points:
~Timepoint A: Baseline (prior to PARP inhibitor initiation, at the time of standard of care clinical testing)
~Timepoint B: On-treatment (within 3-9 weeks of PARP inhibitor initiation, at the time of standard of care clinical testing)
~Timepoint C: Post-treatment (within 4 weeks of PARP inhibitor discontinuation, only for those patients with clinically significant changes in GFR based on serum creatinine, cystatin C, or 24 hour urinalysis at Timepoint B"
11058588|NCT04367454|Experimental|Personal Protective Equipment|"Wearing: Tyvek pro-tech® C gear (Bonetti, Milano, Italy), a full visor SGE 400 mask (EN 136:98 CL3) connected to an A2B2E2K2-P3 R filter (Spasciani, Milano, Italy), and well-fitting, non-sterile Mapa Ultranitril 480 gloves (Mapa SAS, Colombes, France)."
11058589|NCT04367454|No Intervention|NO-Personal Protective Equipment|only wearing well-fitting, medical examination nitrile gloves.
11058590|NCT04367441|Experimental|608|8mg, 20mg, 40mg, 80mg, 120mg, 160mg, 200mg
11058591|NCT04367441|Placebo Comparator|Placebo|20mg, 40mg, 80mg, 120mg, 160mg, 200mg
11058592|NCT04367428|Experimental|Probiotics|Patients will receive the previously mentioned combination of probiotics pre- and postoperatively
11058593|NCT04367428|No Intervention|No probiotics|Patients will not receive probiotics
11058594|NCT04367415||Normal uterine cavity on office hysteroscopy|If the uterine cavity is normal the patient will be allocated as group A.
11058595|NCT04367415||uterine cavity shown one or more polyps on office hysteroscopy|If there is one or more polyp(s) the patient will be allocated as group B. Localization and size estimation of the polyp(s) is mandatory.
11058596|NCT04367402||Symptomatic Patients|Patients who had symptoms related to COVID-19 infection
11058597|NCT04367402||Health people|Healthy people who never had syntomps related to COVID-19 infection
11058598|NCT04367402||Asyntomatic Individuals|Asyntomatic people to recruit after the restriction have ended
11058599|NCT04367389|Experimental|Intervention|Participants receive a physical activity promotion intervention as well as an individualized exercise plan.
11058600|NCT04367389|No Intervention|Control|
11058601|NCT04367376|Experimental|manual therapy|The control group will receive central postero-anterior grade III mobilization through the pisiform grip method at the level of pain in the lumbar spine.
11058602|NCT04367376|Experimental|instrumental manual therapy|the intervention groub rcieved central postero-anterior mobilization with a force of 20-30 N through physiotherapy instrument mobilization at the level of pain in the lumbar spine.
11058603|NCT04367363||Community sample|We plan to recruit a representative sample of the Singapore population.
11058604|NCT04367337||Poland|Adults, general population, N = 400
11058605|NCT04367337||Australia|Adults, general population, N = 400
11058606|NCT04367337||Canada|Adults, general population, N = 400
11058607|NCT04367337||China|Adults, general population, N = 400
11058608|NCT04367337||France|Adults, general population, N = 400
11058609|NCT04367337||Gambia|Adults, general population, N = 400
11058610|NCT04367337||Germany|Adults, general population, N = 400
11058611|NCT04367337||Israel|Adults, general population, N = 400
11058612|NCT04367337||Italy|Adults, general population, N = 400
11058613|NCT04367337||Malaysia|Adults, general population, N = 400
11058614|NCT04367337||Portugal|Adults, general population, N = 400
11058615|NCT04367337||Romania|Adults, general population, N = 400
11058616|NCT04367337||Singapore|Adults, general population, N = 400
11058617|NCT04367337||Switzerland|Adults, general population, N = 400
11058618|NCT04367324||Low level laser therapy|Applied the low-level laser irradiation
11058619|NCT04367324||Control|No low-level laser application
11058620|NCT04367311|Experimental|NSC: Non-squamous cell tumors|Atezolizumab 1200mg, Pemetrexed 500 mg/m^2, Cisplatin 60-75 mg/m^2
11058621|NCT04367311|Experimental|SC: Squamous cell tumors|Atezolizumab 1200mg, Docetaxel 60-75 mg/m^2, Cisplatin 60-75 mg/m^2
11058622|NCT04367298||Chronoprevention in hospital falls|Implementation of a hospital preventive measures program: adjusted to the identification of temporal patterns of falls and relative risk factors of falls.
11058623|NCT04367285|Experimental|Sensor-based Training|
11058624|NCT04367285|Active Comparator|Upper limb motor training|
11058625|NCT04367272|Active Comparator|First Knee|The first knee is the knee where the surgery will begin to be applied.
11058626|NCT04367272|Experimental|Second Knee|The second knee is the knee where the surgeon will apply secondly.
11058627|NCT04367259|Active Comparator|Single puncture arthrocentesis (SPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with single puncture arthrocentesis
11058628|NCT04367259|Active Comparator|Double puncture arthrocentesis (DPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with double puncture arthrocentesis
11058629|NCT04367246||Affected Patients|Eligible subjects have a confirmed germline TP53 mutation or variant, OR have a family history of LFS and clinically managed as a LFS patient, OR meet LFS diagnostic criteria including Classic, Chompret, and LFL (Birch and Eeles) criteria. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a blood sample for plasma and a stool sample every six months, as well as access to their residual clinical tissues.
11058630|NCT04367246||Family Members|Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
11058631|NCT04367246||Household Members|Household member of subjects with germline TP53 mutation or variant (LFS), sharing a living space (apartment or free-standing home) for at least 6 months prior to study enrollment. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time stool sample.
11058632|NCT04367233|Active Comparator|Placebo group|General anesthesia with fentanyl, propofol and remifentanyl
11058633|NCT04367233|Experimental|Transverse block group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive transverse plan block, with levobupivacaine 0,25% 0,2 ml/kg.
11058634|NCT04367233|Experimental|Quadratus lumborum group|At the end of general anesthesia with fentanyl, propofol and remifentanil, the patient will receive quadratus lumborum block with levobupivacaine 0,25% 0,2 ml/kg.
11058635|NCT04367220||Patients with known or suspected cardiovascular disease|All patients with known or suspected cardiovascular disease are studied with a-priori stratification of specific disease-based cohorts.
11058636|NCT04367207||Adult patients with COVID-19 referred to intensive care|Prospective observational cohort study of adult (≥18 years) patients referred to intensive care or high-care units in Africa with suspected or known COVID-19 infection in Africa
11058637|NCT04367194|Experimental|BPPV intervention|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
11058638|NCT04367194|No Intervention|BPPV controll|After the patient survey, patients received only basic treatment.
11058639|NCT04367194|No Intervention|Healthy controll|They do not perform therapy, they function only as a control group.
11058640|NCT04367181|Experimental|ELGA group|"*Less than 29 weeks Gestational Age (GA) preemies (100)
~DCS monitoring will be performed for up to 72 hours starting within 2 days after birth. In a subgroup of infants, we will also perform additional measurements with aEEG and FDNIRS. At a second stage we will add Transcranial Doppler Ultrasound (TCD)"
11058641|NCT04367168|Active Comparator|Colchicine|Colchicine PO
11058642|NCT04367168|Placebo Comparator|Placebo|Placebo PO
11058643|NCT04367155|Active Comparator|tranexamic acid local|tranexamic acid inside the irrigation fluid
11058644|NCT04367155|Active Comparator|tranexamic acid IV|tranexamic acid injection
11058645|NCT04367142||positive SARS-Cov2|100 patients with a positive diagnosis of SARS-CoV-2
11058646|NCT04367142||negative SARS-Cov2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
11058647|NCT04367116|Experimental|spinal cord stimulation|the spinal cord stimulation was performed and operated
11058648|NCT04367103|Active Comparator|NEP group|Norepinephrine infusion of 0.025 µg/kg/min and 6 µg bolus will be used if BP is reduced 20 % below baseline.
11058649|NCT04367103|Placebo Comparator|PHE group|Phenylephrine will be started at 25µg/min immediately after the intrathecal local anaesthetic injection and titrated according to blood pressure and pulse rate.
11058650|NCT04367090|Experimental|Pyrotinib and docetaxel plus trastuzumab|
11058651|NCT04367077|Experimental|MultiStem|
11058652|NCT04367077|Placebo Comparator|Placebo|
11058653|NCT04367051|Experimental|Withdrawal group|Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.
11058654|NCT04367051|Active Comparator|Continuation group|Spironolactone will be continued during the study period with other medical therapy in combination.
11058655|NCT04367038|Experimental|Warm Acupressure Procedure Group|"Latent phase Visual Analog Scale and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first warm acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.
~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second warm acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
11058656|NCT04367038|Experimental|Cold Acupressure Procedure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first cold acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.
~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second cold acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
11058657|NCT04367038|Experimental|Conventional Acupressure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase Conventional acupressure was performed for 30 minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated twice more at one-hour intervals.
~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second conventional acupressure procedure was performed twice at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
11072598|NCT04268017|Experimental|Healthy volunteer|
11058658|NCT04367038|No Intervention|Control Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous sample taken Active phase
~No procedure other than the routine clinical practices were carried out. Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase No procedure other than the normal clinical routines was conducted Visual Analog Scale III and Verbal Category Scale III were performed. Second venous blood sample taken"
11058659|NCT04367025|Active Comparator|SOX|SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 2-4 cycles
11058660|NCT04367025|Experimental|Camrelizumab+ SOX|Camrelizumab:200mg,iv drip for 1h,d1,q3w SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy+ Camrelizumab for 2-4 cycles, adjuvant chemotherapy + Camrelizumab for 2-4 cycles.
11058661|NCT04367012||group 1 NAFLD and group 2 Non NAFLD|study from 20-60 years old.Subjects will be evaluated clinically by abdominal examination for evaluation of fatty liver and grades it into 3 grades .evaluation of fatty pancreas and grade it into 3 grades ,measuring blood pressure and physically by calculating body mass index (BMI) weight/height2
11058662|NCT04367012||Group1 NAFLD & Group 2 Non NAFLD|As the study is randomized cross sectional , all subjects whom have fatty liver by abdominal ultrasound included in group 1 NAFLD , and whom do not have fatty liver by abdominal ultrasound included in group 2.both groups was age and sex matched
11058663|NCT04366999||LSG|In this group, the bariatric procedure is laparoscopic sleeve gastrectomy (LSG), all operations follow the same standard operating procedure.
11058664|NCT04366999||LRYGB|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass (LRYGB), all operations follow the same standard operating procedure.
11058665|NCT04366999||OAGB-MGB|In this group, the bariatric procedure is one anastomosis gastric bypass-mini gastric bypass(OAGB-MGB), all operations follow the same standard operating procedure.
11058666|NCT04366986||Pregnant Women|Women who are currently pregnant
11058667|NCT04366986||Post-partum women|Women who have been pregnant in the past 6 months
11058668|NCT04366973||Participants with Hepatitis C Virus With or Without Treatment|"This study includes 3 populations for analysis:
~Target Population (TP): Defined as all participants enrolled in the study regardless of whether treated for HCV or not.
~Core Population (CP): Defined as all participants of the TP who have been prescribed glecaprevir/pibrentasvir (G/P) and started treatment.
~Safety Population (SP): Defined as all participants who received at least one dose of G/P."
11058669|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin o.d.|Effects of 40 mg subcutaneous enoxaparin o.d.
11058670|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin b.i.d|Effects of 40 mg subcutaneous enoxaparin b.i.d
11058671|NCT04366947|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
11058672|NCT04366947|Experimental|Experimental: IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
11058673|NCT04366934||COVID-19 patients|Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection
11058674|NCT04366934||Control subjects|Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia
11058675|NCT04366908|Active Comparator|Control - best available therapy|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
11058676|NCT04366908|Experimental|Treatment|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be
~Start: 2 capsules
~Days 3, 7, 14, 21, 28: 1 capsule"
11058677|NCT04366895|Experimental|control|Participants in control group (Group-A) received conventional manufactured implant overdenture
11058678|NCT04366895|Experimental|intervention|participants in intervention group (Group-B) received CAD-CAM manufactured implant overdenture.
11058679|NCT04366869|Active Comparator|control|traditional approach of removing denture at night
11058680|NCT04366869|Experimental|intervention 1|occlusal splint
11058681|NCT04366869|Experimental|intervention 2|Botox
11058682|NCT04366856|Experimental|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
11058683|NCT04366856|Other|2: No instruction regarding positioning|the control group will get no instruction regarding positioning
11058684|NCT04366843|Experimental|The chair massage group|chair massage 15 min,, 2 x week; measurement before and after each treatment
11058685|NCT04366843|Experimental|The exercise program group|excercises 15 min., 2 x week; measurement before and after each treatment
11058686|NCT04366843|No Intervention|The control group|control 2 measurements, 4 weeks apart
11058687|NCT04366817|Experimental|women in postpartum period|
11058688|NCT04366804||Patients with neuropsychiatric fluctuations|PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)
11058689|NCT04366804||Patients without neuropsychiatric fluctuations|PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)
11058690|NCT04366791|Experimental|Supportive care (low-dose radiation therapy)|Patients undergo 1 fraction of low-dose radiation therapy.
11058691|NCT04366778||patients hospitalized for Covid-19|Patients with Covid-19 infection hospitalized in Lyon University Hospitals
11058692|NCT04366778||patients hospitalized for Covid-19 who present thrombosis|Patients with Covid-19 infection hospitalized in Lyon University Hospitals who present thrombosis during hospitalization
11058693|NCT04366765||COVID-19 suspects|Patients presenting with suspected COVID-19 to the emergency department of the University Hospital Basel.
11058694|NCT04366739|Experimental|CHLORPROMAZINE (CPZ)|Standard of Care (SOC) plus CHLORPROMAZINE (CPZ)
11058695|NCT04366739|Active Comparator|standard of care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparator arm"
11058696|NCT04366726|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide.
11058697|NCT04366713|Experimental|Neratinib|Neratinib with loperamide prophylaxis, and capecitabine for participants treated for metastatic breast cancer
11058698|NCT04366700|Active Comparator|Bone replacement substitute and membrane|periapical surgery will be done and defect will be filled with a mixture of autograft and prf and over the defect and denuded root surface collagen membrane will be placed before closure of flap
11058699|NCT04366700|Active Comparator|membrane|periapical surgery will be done and defect will be filled with blood clot and over the defect and denuded root surface collagen membrane will be placed before closure of flap
11058700|NCT04366687|Active Comparator|PAT-AU|Parents randomized to this arm (i.e., group) receive Parents as Teachers (PAT) services as usual (AU).
11058701|NCT04366687|Experimental|PAT+CSA|Parents randomized to this arm (i.e., group) receive the added CSA-focused session (Smart Parents - Safe and Healthy Kids) added to typical Parents as Teachers (PAT).
11058702|NCT04366674|Active Comparator|Langerbeck's repair|Langerbeck's repair of cleft palate,without specific restoration of levator veli palatini or tensor veli palatini. Incisions along the margins of the cleft at the junction of oral and nasal mucosa. Lateral relaxing incisions were performed and the mucoperiosteal flap of hard palate were elevated on both sides except the ones with only soft palate cleft. The anterior end of the mucoperiosteal flap may be cut off for the purpose of tension relieving and would be resutured to the anterior area during closing. In the soft palate, the division was made between the oral mucous layer and the palatal musculature layer. Hamulus were broken for closing the cleft without tension. Closing was done by two seperated layers, one layer of nasal mucosa-palatal muscle, and one layer of oral mucosa.
11058703|NCT04366674|Active Comparator|restoration of levator veli palatini|The incision was made similar to Langerbeck's repair. During disection, the levator veli palatini was identified after the elevation of flap. The levator veli palatini was separate from the oral and nasal mucosa. During closing, the anterior end of levator veli palatini was rotated towards the midline and the two muscle bundle from the two sides were sutured in the midline. In this process, the tensor veli palatini was not intentionally identified or dissected.
11058704|NCT04366674|Experimental|mordified restoration of tensor veli palatini|Incision was made similar to Langerbeck's repair. During disection, the tensor veli palatini was identified after flap elevation. Its tendinous fibers was released from but still connected to the pterygoid process without breaking the hamulus or cutting off the tendinous fibers. If the tension is too strong during suturing, the tensor tendon could be partly dissected laterally meanwhile be kept continuity medially so that the tensor veli palatini could be rotated more medially. The levator veli palatini, tensor veli palatini, together with the palatine aponeurosis and the nasal mucosa from two sides were sutured in the middle line. The tensor veli palatini may not be jointed to the contralateral one directly.
11058705|NCT04366661|Experimental|screening|Participants undergo low dose CT of the chest
11058706|NCT04366648|Experimental|50mg/m2|Starting dose, administered once only
11058707|NCT04366648|Experimental|75mg/m2|Second dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
11058708|NCT04366648|Experimental|100mg/m2|Third dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
11058709|NCT04366648|Experimental|125mg/m2|Forth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
11058710|NCT04366648|Experimental|150mg/m2|Fifth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
11058711|NCT04366648|Experimental|180mg/m2|Sixth dose level, administered at least twice, first two cycles of drug delivery accompanied with PK analyses.
11058712|NCT04366648|Active Comparator|175mg/m2|CPT-11, given every 14 days, first 2 cycles of drug delivery will accompanied with PK test,
11058713|NCT04366635|Experimental|Mineralised Plasmatic Matrix Group|Mineralized Plasmatic Matrix (MPM) is a product of mixing of two phases: the mineral phase and the plasma phase. After centrifugation, the white blood cells are recovered and mixed with the mineral phase of bone graft that can be autogenic, allogeneic bone, or a bone substitute like Xenogeneic Bone Synthetic. We will use Beta-tricalcium phosphate as a graft material. The result of this mixture is a homogeneous single component, which is compact and stable, containing the graft, the dense fibrin network, and the promoting healing. And then we are planning to place MPM material to extraction socket of impacted third molar tooth to improve periodontal healing at the distal aspect of second molar tooth. Additional after MPM places to extraction socket, Once the MPM has been placed, it will be covered with a Platelet Rich Fibrin (PRF) membrane and sutured as a primer.
11058714|NCT04366635|Experimental|Beta-tricalcium phosphate Group|Beta-tricalcium phosphate graft will place in the extraction socket and cover with a PRF membrane.
11058715|NCT04366635|Active Comparator|Control Group|In the control group, after removal of impacted third molar tooth no material will be placed on the extraction socket. Only the extraction socket was primarily closed with non-resorbable sutures.
11058716|NCT04366622|Experimental|Riociguat, Child Pugh A|Participants with liver cirrhosis and mild hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11058717|NCT04366622|Experimental|Riociguat, Child Pugh B|Participants with liver cirrhosis and moderate hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11058718|NCT04366622|Experimental|Riociguat, control A|Healthy age-, weight-, and gender- matched participants to Child Pugh A group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11058719|NCT04366622|Experimental|Riociguat, control B|Healthy age-, weight-, and gender- matched participants to Child Pugh B group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11058720|NCT04366609||ADHD patients|Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.
11058723|NCT04366583|Experimental|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
11058724|NCT04366583|Active Comparator|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
11058725|NCT04366570||The 1st group|(n=511; 36,45%) included patients with extra-articular injury of the proximal humerus (rotator cuff tear, anatomical and surgical neck fracture)
11058726|NCT04366570||The 2nd group|(n=309; 22,04%) included patients with intra-articular injury of the proximal humerus (contracture of the shoulder joint and shoulder instability, humeral head fracture, including Hill-Sachs lesion)
11058727|NCT04366570||The 3rd group|(n=582; 41,51%) - patients with injury of subacromial (suprahumeral) space (soft tissue injury, acromioclavicular and sternoclavicular joint injury, diaphyseal and distal end clavicle fracture)
11058728|NCT04366557|Experimental|Body posture correction|Subjects from study group had an education about pelvic floor and additional a six week body posture therapy.
11058729|NCT04366557|Other|Without correction of body posture|Subjects form control group had only an education about pelvic floor.
11058730|NCT04366544|Other|Time Point 1: Baseline/Pre-preparatory Samyama|"Survey link for participant
~Survey link for spouse/ control
~Stool collection from home
~Blood sample at home provided by at home phlebotomy services or at Isha Center group meditation by study personnel."
11058731|NCT04366544|Other|Time point 2: Post-Preparatory/Pre-Samyama|"Online Surveys
~Participant
~Spouse
~Stool collection from IIIS/home
~Blood sample collection: on site at IIIS/home EEG and fMRI"
11058732|NCT04366544|Other|Timepoint 3: Immediate Post-Samyama|"Online survey to be completed
~Survey link for participant
~Survey link for spouse
~Blood sample collection: on site at IIIS o Participant only - Not spouse/significant other. EEG and fMRI"
11058733|NCT04366544|Other|Timepoint 4: 3 months Post Samyama|"Blood draw at home by at home phlebotomist
~Post program online survey follow up to be completed
~Survey link for participant
~Survey link for spouse: https
~Stool collection from home"
11058734|NCT04366531|No Intervention|Monitoring/Treatment as usual|Veterans will not receive any study related interventions.
11058735|NCT04366531|Active Comparator|Reentry Program|Veterans will receive the START-VET reentry program
11058736|NCT04366518|Experimental|Physostigmine vs Saline|
11058737|NCT04366518|Placebo Comparator|Scopolamine vs. saline|
11058738|NCT04366505|Experimental|NFB + (MBRP)|Neurofeedback (NFB) from target region or control region plus Mindfulness-based relapse prevention (for some)
11058739|NCT04366505|Active Comparator|TAU and sham NFB|TAU + Neurofeedback (NFB) from control region
11058740|NCT04366492|Other|persons in prison|
11058741|NCT04366479|Experimental|intervention group|The study lasted for 5 weeks (1 month 7 days). During the research process, we monitor closely, especially the training schedule, implementation, and evaluation, directly and indirectly. Directly assisting participants to do endurance training activities, not directly monitoring via telephone or WhatsApp.
11058742|NCT04366466|Other|suicide attempt patient who will receive sanitory supervision|The control group will establish the health monitoring
11058743|NCT04366466|Experimental|Suicide attempt patient who will participate to PEPS Program|The intervention group will test the program of Promotion of Commitment to Care for the Prevention of Suicidal Recidivism.
11058744|NCT04366453|Other|Echocardiography|"• Echocardiography performed by the evaluator 1: 2 LVEF visual evaluations 2 LVEF automatic evaluations
~• Echocardiography performed by the evaluator 2: 2 LVEF visual evaluations 2 LVEF automatic evaluations"
11058745|NCT04366440|Other|Order set review and modification|The antimicrobial stewardship program will review and change order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
11058746|NCT04366440|Other|Order Set review and Modification plus facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
11058747|NCT04366427|Experimental|Low-pressure hyperbaric oxygenation (L-HBO)|Low-pressure hyperbaric oxygen administration at 1.45 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 sessions (3-4 per week).
11058748|NCT04366427|Experimental|Standard-pressure hyperbaric oxygenation (HBO)|Standard pressure hyperbaric oxygen administration at 2.5 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 non-consecutive sessions (3-4 per week).
11058749|NCT04366427|No Intervention|Control|Control group of athletes, no intervention.
11058750|NCT04366427|Experimental|30% O2|Administration of air mixture with 30% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
11058751|NCT04366427|Experimental|50% O2|Administration of air mixture with 50% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
11058752|NCT04366414|Active Comparator|hook breathing removing nose-clip|"It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
~During that training, only this group will perform an experimental breathing protocol consisted of removing nose-clip previous to surface and then perform hook breathing during 20 seconds. This protocol was applied at the end of each of the 8 submaximes-dynamic apnoeas and after the maximal-dynamic apnoea"
11058783|NCT04366258|Experimental|t-PBM at Middle, High Irradiance, Sham, Low Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 770 mW/cm2, then 0 mW/cm2, and then 50 mW/cm2
11058753|NCT04366414|Active Comparator|usual breathing (UB)|It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
11058754|NCT04366401|Active Comparator|Conventional Dietary Advice|"The control group will consist of participants diagnosed on the schizophrenic spectrum who will receive conventional dietary counseling (n=25) on an individual basis.
~In the control group, data will be collected on the psychopathological state (PANSS and PSP scales), and blood analysis (hemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
11058755|NCT04366401|Experimental|Prebiotic/Probiotic Dietary Modulation|"In the intervention group (n=25), individual dietary counseling will be established through intensive nutritional counseling to provide a high prebiotic and probiotic food pattern.
~In the experimental group, data will be collected on psychopathological status (Positive and Negative Syndrome Scale -PANSS- and Personal and Social Functioning Scale -PSP-), and blood tests (haemogram, lipid profile, etc.). The measurements will be taken at the beginning (basal), at three and six months. The estimation of the intestinal microbiota and the usual nutritional pattern will also be evaluated at the beginning and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, GI participants will fill in a specific weekly record of the main dishes/foods consumed. At least, anthropometric parameters will also be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter)."
11058756|NCT04366388||Frail hospitalized old adults|Over than 65-years of age Admitted into Acute Unit Nonambulatory
11058757|NCT04366375||TLH+BSO|Total Laparoscopic Hysterectomy + Bilateral Salpingo-Oophorectomy N=20
11058758|NCT04366375||TAH + BSO|Total Abdominal Hysterectomy + BSO N=20
11058759|NCT04366362|Active Comparator|Convetional reconstruction group|Patients will undergo ACL reconstruction based on conventional ACL surgery
11058760|NCT04366362|Experimental|Individualised reconstruction group|Patients will undergo ACL reconstruction based on their special anatomical and functional characteristics and with the use of a navigation system
11058761|NCT04366349|Experimental|Participants receiving GSK3772847 70 milligram (mg)|Participants will receive a single dose of GSK3772847 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
11058762|NCT04366349|Experimental|Participants receiving GSK3772847 140 milligram (mg)|Participants will receive a single dose of GSK3772847 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
11058763|NCT04366349|Placebo Comparator|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
11058764|NCT04366336|Experimental|Blood Flow Restriction Training|"Blood flow restriction training (BFRT) uses a specialized tourniquet system to restrict arterial inflow and venous outflow to the limb during low-load resistance exercise.
~BFRT involves placing the pressure cuff before the start of therapeutic exercises.
~Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching"
11058765|NCT04366336|Active Comparator|Standard Physical Therapy|Subjects will receive American College of Sports Medicine guided-strength training Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
11058766|NCT04366323|Experimental|Experimental|
11058767|NCT04366323|No Intervention|Control|
11058768|NCT04366310||capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
11058769|NCT04366297|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
11058770|NCT04366297|Experimental|IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
11058771|NCT04366284|Active Comparator|NOCTEM only (NOCTEM)|No external or internal facilitation
11058772|NCT04366284|Active Comparator|External Facilitation (NOCTEM+EF)|External facilitation only
11058773|NCT04366284|Active Comparator|External and Internal Facilitation (NOCTEM+EF/IF)|External and internal facilitation
11058774|NCT04366271|Experimental|Mesenchymal cells|Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
11058775|NCT04366271|Active Comparator|Standard of care|Standard of care
11058776|NCT04366258|Experimental|t-PBM at High, Middle, Low Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 300 mW/cm2, then 50 mW/cm2, and then 0 mW/cm2.
11058777|NCT04366258|Experimental|t-PBM at High, Middle Irradiance, Sham, Low Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 300 mW/cm2, then 0 mW/cm2, and then 50 mW/cm2.
11058778|NCT04366258|Experimental|t-PBM at High, Low, Middle Irradiance Sham|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 50 mW/cm2, then 300 mW/cm2, and then 0 mW/cm2
11058779|NCT04366258|Experimental|t-PBM at High, Low Irradiance, Sham, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 50 mW/cm2, then 0 mW/cm2 and then 300 mW/cm2
11058780|NCT04366258|Experimental|t-PBM at High Irradiance, Sham, Middle, Low Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 0 mW/cm2, then 300 mW/cm2, and then 50 mW/cm2
11058781|NCT04366258|Experimental|t-PBM at High Irradiance, Sham, Low, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 770 mW/cm2, then 0 mW/cm2, then 50 mW/cm2, and then 300 mW/cm2
11058782|NCT04366258|Experimental|t-PBM at Middle, High, Low Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 770 mW/cm2, then 50 mW/cm2, and then 0 mW/cm2
11058784|NCT04366258|Experimental|t-PBM at Middle, Low, High Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 50 mW/cm2, then 770 mW/cm2, and then 0 mW/cm2
11058785|NCT04366258|Experimental|t-PBM at Middle, Low Irradiance, Sham, High Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 50 mW/cm2, then 0 mW/cm2, and then 770 mW/cm2
11058786|NCT04366258|Experimental|t-PBM at Middle Irradiance Sham High Irradiance Low Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 0 mW/cm2, then 770 mW/cm2, and then 50 mW/cm2
11058787|NCT04366258|Experimental|t-PBM at Middle Irradiance, Sham Low, High Irradiance|Participants first receive t-PBM at irradiance doses of 300 mW/cm2, then 0 mW/cm2, then 50 mW/cm2, and then 770 mW/cm2,
11058788|NCT04366258|Experimental|t-PBM at Low High Middle Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 770 mW/cm2, then 300 mW/cm2, and then 0 mW/cm2
11058789|NCT04366258|Experimental|t-PBM at Low, High Irradiance, Sham Middle Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 770 mW/cm2, then 0 mW/cm2, and then 300 mW/cm2
11058790|NCT04366258|Experimental|t-PBM at Low, Middle, High Irradiance, Sham|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 300 mW/cm2, then 770 mW/cm2, and then 0 mW/cm2
11058791|NCT04366258|Experimental|t-PBM at Low, Middle Irradiance, Sham High Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 300 mW/cm2, then 0 mW/cm2, and then 770 mW/cm2
11058792|NCT04366258|Experimental|t-PBM at Low Irradiance, Sham High, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 0 mW/cm2, then 770 mW/cm2, and then 300 mW/cm2
11058793|NCT04366258|Experimental|t-PBM at Low Irradiance, Sham Middle, High Irradiance|Participants first receive t-PBM at irradiance doses of 50 mW/cm2, then 0 mW/cm2, then 300 mW/cm2, and then 770 mW/cm2
11058794|NCT04366258|Experimental|t-PBM at Sham, High, Middle, Low Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 770 mW/cm2, then 300 mW/cm2, and then 50 mW/cm2
11058795|NCT04366258|Experimental|t-PBM at Sham, High, Low, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 770 mW/cm2, then 50 mW/cm2, and then 300 mW/cm2
11058796|NCT04366258|Experimental|t-PBM at Sham, Middle, High, Low Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 300 mW/cm2, then 770 mW/cm2, and then 50 mW/cm2
11058797|NCT04366258|Experimental|t-PBM at Sham Middle, Low, High Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 300 mW/cm2, then 50 mW/cm2, and then 770 mW/cm2
11058798|NCT04366258|Experimental|t-PBM at Sham Low, High, Middle Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 50 mW/cm2, then 770 mW/cm2, and then 300 mW/cm2
11058799|NCT04366258|Experimental|t-PBM at Sham Low, Middle, High Irradiance|Participants first receive t-PBM at irradiance doses of 0 mW/cm2, then 50 mW/cm2, then 300 mW/cm2, and then 770 mW/cm2
11058800|NCT04366245|Experimental|Experimental|
11058801|NCT04366245|Active Comparator|Comparator|
11058802|NCT04366232|Experimental|Anakinra +/- Ruxolitinib|"According to clinical stage (gradual strategy):
~Stage 2b or 3 : Anakinra 300 mg IV
~Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2"
11058803|NCT04366232|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
11058804|NCT04366219||2019|Data collection on patients with Lung cancer diagnosed between March 13, 2019 and August 28, 2019.
11058805|NCT04366219||2020|Data collection on patients with Lung cancer diagnosed between March 13, 2020 and August 28, 2020.
11058806|NCT04366206||Patients exposed to the study variable|Depending on the studied variable (treatment or risk factor)
11058807|NCT04366206||Patients not exposed to the study variable|Depending on the studied variable (treatment or risk factor)
11058808|NCT04366180|Experimental|Probiotic|Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day).
11058809|NCT04366180|Placebo Comparator|Control|Control group who will receive a daily placebo capsule consisting of maltodextrin
11058810|NCT04366167||Cardiac surgery patients|Patients undergoing adult cardiac surgery during the Covid-19 pandemic
11058811|NCT04366154||Patients|
11058812|NCT04366154||Caregivers|
11058813|NCT04366141|Experimental|COVID-19 barrier box intervention group|Attending anesthesiologists will use a COVID-19 barrier box for intubating the patient participants of this group.
11058814|NCT04366141|No Intervention|Control group|Attending anesthesiologists will use standard intubation procedures.
11058815|NCT04366128|Experimental|CAPA indution immunotherapy|CAPA regimen, repeat every 3 week for 4 cycles.
11058816|NCT04366115|Experimental|AVM0703|supra-pharmacologic dexamethasone sodium phosphate
11058817|NCT04366115|Placebo Comparator|Placebo|GMP excipients
11058818|NCT04366102|Experimental|Group A|Combined Multisensory stimulation and soft tissue therapy
11058819|NCT04366102|Experimental|Group B|Multisensory stimulation only
11058820|NCT04366102|Experimental|Group C|Soft tissue therapy only
11058821|NCT04366102|Active Comparator|Group D|Routine hospital care
11058822|NCT04366089|Active Comparator|Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
11058823|NCT04366089|Experimental|Oxygen-ozone and probiotic|"Oxygen-ozone therapy, probiotic supplementation plus standard of care
~Oxygen-ozone therapy: systemic autohemotherapy (twice a day).
~Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day)."
11058824|NCT04366076||nonlaboring term singleton pregnancies|A total of 51 nonlaboring term singleton pregnancies were enrolled.
11058825|NCT04366063|Experimental|Two MSC infusion|Intervention Group1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) intravenously plus Conventional treatment.
11058826|NCT04366063|Experimental|Two MSC infusion Plus two EVs infusion|Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), intravenously plus two doses of EVs plus Conventional treatment
11058827|NCT04366063|No Intervention|Control|Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control.
11058828|NCT04366050|Experimental|Ramipril 2.5mg orally daily|"Total 2.5 mg Ramipril per day once a day orally for 14 days
~Intervention: Ramipril"
11058829|NCT04366050|Placebo Comparator|Placebo|Placebo in the form of a capsule, taken orally for 14 days
11058830|NCT04366037|Experimental|Control group|This group performed their routine training
11058831|NCT04366037|Experimental|Experimental 1|This group performed their routine training plus proprioceptive exercises in the warm-up.
11058832|NCT04366037|Experimental|Experimental 2|This group performed their routine training plus proprioceptive exercises in the cool-down
11058833|NCT04366024||Observed group|COVID-19 disease patients who were detected by RT-PCR and CT imaging.
11058834|NCT04366011|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is a twelve-week therapeutic intervention based on the theory that maladaptive thoughts contribute to symptom development and maintenance of PD/A.
11058835|NCT04366011|Experimental|Capnometry Assisted Respiratory Training (CART)|Capnometry-assisted respiratory therapy is a five-week treatment based on the theory that hyperventilation causes or maintains panic disorder.
11058836|NCT04365998|Experimental|BUBOLight® Device|
11058837|NCT04365985|Placebo Comparator|Placebo|Placebo by mouth 1 time per day for patients with stage I or stage 2A COVID-19
11058838|NCT04365985|Experimental|Naltrexone|Naltrexone 4.5 mg by mouth 1 time per day for patients with stage I or stage 2A COVID-19.
11058839|NCT04365985|Experimental|Ketamine|Ketamine IV infusion (0.15 mg/kg based on total body weight for maximum 20 mg every 6 hours) for patients with stage 2B or stage 3 COVID-19; may be increased to 0.3 mg/kg based on total body weight for a maximum of 30 mg every 6 hours if needed. Patients entering this arm from the placebo or naltrexone arms remain on those medications as well.
11058840|NCT04365972|Experimental|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 5 sessions using a variant of the dot-probe task in which the target probe always replaces neutral rather than threat (health-related) stimuli to induce diversion of attention away from threat.
11058841|NCT04365959||covid-19 pneumonia related patients|This study will be conducted on all patients admitted to the Infectious Diseases and UTIR units of the S. Gerardo Hospital in Monza with the diagnosis of related COVID pneumonia requiring oxygen support or CPAP.
11058842|NCT04365946||Complete type|Patients with complete-type intestinal metaplasia
11058843|NCT04365946||Incomplete type|Patients with incomplete-type intestinal metaplasia
11058844|NCT04365946||Controls|Healthy subjects
11058845|NCT04365933|Experimental|Arm 1|EYP001a Dose A QD + ETV 0.5 mg QD + peg-IFN 180 µg QW
11058846|NCT04365933|Experimental|Arm 2|EYP001a Dose A QD + peg-IFN 180 µg QW
11058847|NCT04365920|No Intervention|Re-Entry as Usual|The type and level of services provided to individuals at re-entry will vary across jails and will be carefully documented. For the most part, individuals released to the community will receive a referral to an opioid treatment provider (OTP) for treatment with MOUD, and a subset may potentially be mandated to participate in community based treatment and/or recovery programs such as recovery coaching, and/or sentenced to varying levels of probation.
11058848|NCT04365920|Experimental|Recovery Management Checkups (RMC)|In the RMC condition, participants will have access to services provided as a part of re-entry as usual. In addition, checkups will be provided on a fixed schedule that includes face-to-face monthly checkups for the initial 3 months, and quarterly for the rest of the two years. Participants will have access to referrals and services provided by the jail and linkage to an OTP as part of their usual re-entry procedures. Individuals will meet with a Linkage Manager (LM) upon study enrollment and during each quarterly checkup, during which they will complete a Brief Treatment Needs Assessment, receive motivational interviewing, linkage assistance, or a check-in on continuing care and recovery support. The priority is to engage the individual into treatment with MOUD as soon as possible at the time of release, however, if individuals express a preference for another form of SUD treatment, the LM will work with that individual to link, engage, and retain them in that form of treatment.
11058849|NCT04365920|Experimental|RMC-Adaptive|In the RMC-Adaptive condition, checkups will be provided based on the participant's current need for treatment and will be adapted in three ways. First, the interval between RMC-A check-ups will vary (in 1-month increments) depending upon the individual's assessed need for treatment at the prior check-up. Second, in cases where participants have 3 consecutive checkups in which they need treatment, the LM and treatment provider will discuss how to better meet the participant's needs, e.g., a different treatment provider, different type of MOUD or other types of treatment, and/or additional services. Third, if RMC-A participants are re-incarcerated at the time of their checkup, the LM will meet with the individual while incarcerated to discuss a recovery plan, which may include initiation of treatment with MOUD while incarcerated and re-linkage to an OTP upon release.
11058850|NCT04365907|Experimental|Omarigliptin 12.5 mg|Drug: Omarigliptin 12.5 mg Once weekly new anti-diabetic drug approved only in Japan Other Name: Zafatek tablets
11058851|NCT04365894|No Intervention|Control|The study was applied in 2nd grade nursing students' disability health course. The control group was taught with the traditional method.
11058852|NCT04365894|Experimental|Intervention|The intervention group with learning activities based on the transformative learning theory.
11058853|NCT04365868|Experimental|belapectin 2 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)
~Phase 3: The patient will be switched to the optimal dose"
11058854|NCT04365868|Experimental|belapectin 4 mg/kg lean body mass (LBM)|"Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)
~Phase 3: The patient will be switched to the optimal dose"
11058855|NCT04365868|Placebo Comparator|Placebo|"Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)
~Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)"
11058856|NCT04365855|Other|Subjects at risk for NAFLD|Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
11058857|NCT04365842|Experimental|Digital exercise group|"After the 6-week digital intervention, 1) qualitative interviews have done with 6-15 patients from intervention group to assess the feasibility of digital intervention.
~2) The primary outcomes are hand pain and function and exercise adherence will be evaluated for all participants"
11058858|NCT04365842|Active Comparator|Waiting list conrol|A hand rehabilitation home program will be given to the patients in the group through the telephone messages with brochures.
11058859|NCT04365829|Experimental|Virtual reality|
11058860|NCT04365816||Prospective cohort University Hospital, Grenoble|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058861|NCT04365816||Prospective cohort University Hospital, Toulouse|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058862|NCT04365816||Prospective cohort University Hospital, Nancy|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058863|NCT04365816||Prospective cohort University Hospital, Rennes|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058864|NCT04365816||Prospective cohort Hospices Civils de Lyon|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058865|NCT04365816||Prospective cohort Assistance Publique Hôpitaux de Paris|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058866|NCT04365816||Prospective cohort University Hospital, Rouen|Semi-structured survey administered on the phone, once, one month after discharge from hospital. The interview will not be recorded.
11058867|NCT04365803||patient with radiological complete response|patient with radiological complete response after neoadjuvant chemotherapy
11058868|NCT04365790||Patients with triple-negative breast cancer|Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
11058869|NCT04365790||Patients with HER2+ positive breast cancer|Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
11058870|NCT04365777||Awake group|
11058871|NCT04365777||Mild sedation group|
11058872|NCT04365777||Deep sedation group|
11058873|NCT04365764||Exposed to the treatment|Exposure variable will be studied treatment
11058874|NCT04365764||Not exposer to the treatment (control group)|
11058875|NCT04365751|Experimental|Percutaneous microwave ablation group|MWA (Microwave) is an ultrasound-guided, minimally invasive technique that implants ablation electrodes into target tissue to rapidly generate high temperatures and rapidly develop coagulative necrosis in tumor tissue, thereby achieving the goal of local tumor treatment.
11058876|NCT04365751|Other|Laparoscopic hepatectomy|Laparoscopic hepatectomy is a widely used surgical technique in the treatment of benign (malignant) liver diseases
11058877|NCT04365738|Experimental|Pulmonary Rehabilitation|The patients who applied pulmonary rehabilitation were checked, motivated and followed-up regularly with video calls every day. Pulmonary rehabilitation program consists of patient education, breathing, in-house mobilization and range of motion exercises.
11058878|NCT04365738|Placebo Comparator|Control|As a patient education, information was given about the disease and treatment process, listening to the patient during this process and getting regular sleep, balanced nutrition and taking a break from smokers.
11058879|NCT04365712|Active Comparator|Oscillating saw|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by common oscillating saw
11058880|NCT04365712|Experimental|Piezoelectric tool|Patients treated for hallux valgus with 1st metatarsal osteotomy obtained by piezoelectric tool
11058881|NCT04365699|No Intervention|Registry: Hospitalized Patients with COVID-19 Infection|All subjects hospitalized with COVID-19 infection in the four NYU hospitals will be enrolled in the registry.
11058882|NCT04365699|Experimental|Interventional Patients: AT-001|Patients enrolled in registry from NYU Langone Tisch Hospital with history of diabetes mellitus and/or acute hyperglycemia (any glucose measurement >200 mg/dl) and evidence of acute or chronic heart disease. This subset will receive Standard of Care + AT-001.
11058883|NCT04365686|Active Comparator|Group K|Ketofol group
11058884|NCT04365686|Active Comparator|Group P|propofol group
11058885|NCT04365673||Readmitted|Patients that were readmitted within 30 days post hospital discharge
11058886|NCT04365673||Not readmitted|Patients that were not readmitted within 30 days post hospital discharge
11058887|NCT04365660|Experimental|18-F-FTC 146 PET/CT|For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).
11058888|NCT04365647||1|Patient's in whom there is increase in tumor size after craniotomy
11058889|NCT04365647||2|Patient's in whom there was either no increase in tumor size or decrease in tumor size after craniotomy
11058890|NCT04365634||Diabetes|Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
11058891|NCT04365634||Non-diabetes|Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
11058892|NCT04365634||Survivors|COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
11058893|NCT04365634||Non-survivors|COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
11058894|NCT04365621|Other|ultra-high risk of psychosis patient|patient with ultra -high risk of psychosis will be enrolled to the study
11058895|NCT04365608|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy. The standard intubation procedure is to use a styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the guidelines on difficult airway management.
11058896|NCT04365608|Active Comparator|Vie Scope laryngoscopy|Intubation will be done using Vie Scope laryngoscopy
11058970|NCT04365088|Placebo Comparator|Sugar pill|Placebo is an inert substance or treatment which is designed to have no therapeutic value. Patients took sugar pill for plasebo once one hour before operation.
11074042|NCT04257851|Active Comparator|Group S (n=30)|Sumatriptan group
11058897|NCT04365595||SARS-CoV-2 associated respiratory failure|Participants will receive a daily HrQoL questionnaire on their personal smartphone using the docdok health application during 3 months. A selection of participants will furthermore receive a custom-built home disease monitoring device during 1 month. Both procedures start at least 4 weeks after hospital discharge.
11058898|NCT04365582|Experimental|Azithromycin|Azithromycin
11058899|NCT04365582|Experimental|Hydroxychlororquine|Hydroxychlororquine
11058900|NCT04365582|Experimental|Lopinavir/Ritonavir|Lopinavir/Ritonavir
11058901|NCT04365582|No Intervention|standards of care|SoC
11058902|NCT04365569|Experimental|Individualized, nutrition and physical activity intervention|Initial in-person consult with a registered dietitian, with further in-person follow-ups and monthly telephone consults
11058903|NCT04365556|Experimental|TASC Intervention|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
11058904|NCT04365556|No Intervention|Treatment as Usual|Participants will not receive any intervention.
11058905|NCT04365543|Experimental|UP-C/A for Misophonia|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
11058906|NCT04365543|Experimental|Psychoeducation and Relaxation Therapy|Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
11058907|NCT04365517|Active Comparator|Treatment group|patients will be treated with sitagliptin add on to nutritional therapy with o without insulin treatment. The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
11058908|NCT04365517|No Intervention|Control group|Patients who will be prescribed nutritional therapy with or without insulin treatment
11058909|NCT04365504||Osteoporotic|Post menopausal females with Lumbar T score <-2.5 as determined by dual energy X ray absorbitometry
11058910|NCT04365504||Osteopenic|Post menopausal females with Lumbar T score -1 to -2.5 as determined by dual energy X ray absorbitometry
11058911|NCT04365504||Normal|Post menopausal females with T score >-1 as determined by dual energy X ray absorbitometry
11058912|NCT04365478|Experimental|rSWT group|Radial Extracorporeal Shock Wave Therapy on spastic muscles of upper limb
11058913|NCT04365478|Active Comparator|Control group|conventional physiotherapy
11058914|NCT04365465|Experimental|Active device|Participants in this arm will receive an active NSS-Bridge device placed immediately following their cesarean section.
11058915|NCT04365465|Sham Comparator|Placebo device|Participants in this arm will receive an inactive (sham) NSS-Bridge device placed immediately following their cesarean section.
11058916|NCT04365465|Active Comparator|Active Control|Participants in this arm will receive no device, only the standard postpartum pain control.
11058917|NCT04365452|Experimental|Invia Motion Arm|
11058918|NCT04365439|Experimental|Convalescent plasma|Convalescent plasma from patients after COVID-19
11058919|NCT04365426|Experimental|Oral contraceptive (OC)|Oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
11058920|NCT04365426|Experimental|No oral contraceptive (No OC)|No oral contraceptive patients will be tested to mechanical (cephalic and extracephalic) stimulus and cold pain stimulus.
11058921|NCT04365413|Experimental|Imaging of Tumor or Lymph node|"Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery.
~The temperature of their skin prior to and after MSOT imaging will also be measured."
11058922|NCT04365400|Experimental|DS102 2000mg|Participants in this group will receive 1000mg DS102 capsules twice daily.
11058923|NCT04365400|Experimental|DS102 4000mg|Participants in this group will receive 2000mg DS102 capsules twice daily.
11058924|NCT04365400|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules twice daily.
11058925|NCT04365387|Experimental|Nemolizumab|Participants will receive a loading dose of nemolizumab (60 milligram [mg]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) will then be administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.
11058926|NCT04365387|Placebo Comparator|Placebo|Participants will receive a placebo via 2 SC injections at baseline. Placebo will then be administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
11058927|NCT04365374|Experimental|Surgical Resection and GammaTile Therapy|
11058928|NCT04365374|Active Comparator|Surgical Resection and Stereotactic Radiation Therapy|
11058929|NCT04365322||Severe COVID-19 infection|
11058930|NCT04365322||Light to moderate COVID-19 infection|
11058931|NCT04365322||Cancer patients with COVID-19 infection|
11058932|NCT04365309|No Intervention|the NCP standard treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment).
11058933|NCT04365309|Experimental|the NCP aspirin treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge.
11058934|NCT04365296|Experimental|Aerobic group|This group will include 30 burned patients who will receive aerobic exercises 8 weeks (3times/week) in form of treadmill exercise in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
11058935|NCT04365296|Experimental|Resistance group|This group will include 30 burned patients who will receive resistance exercises 8 weeks (3times/week) by using dumbbells and sand bags in addition to their physical therapy program (splinting, stretching ex. and ROM ex.) and medical treatment (medications as cataflam, alphintern, zinetac and hemacaps and wound dressings).
11058936|NCT04365283|Experimental|New Bioactive Restorative Material|ACTIVA Presto restorative material
11058937|NCT04365283|Active Comparator|High Viscosity Glass Hybrid Reinforced Glass Ionomer|EQUIA Forte restorative material
11058938|NCT04365270|Experimental|Chitosan Glass ionomer|"purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid to be used to modify the stock liquid provided with the glassionomer Fuji IX to have 10% v/v chitosan.
~will be placed in the prepared cavity over the last layer of caries"
11058939|NCT04365270|Experimental|Chitosan/Titanium dioxide nanoparticles Glass ionomer|"The stock liquid provided with the glassionomer Fuji IX will be modified with 10%v/v purified low molecular weight and viscosity chitosan will be dissolved in 0.1 mol/L acetic acid.
~The Powder will be modified with 3% titanium dioxide nanoparticles will be placed in the prepared cavity over the last layer of caries"
11058940|NCT04365270|Active Comparator|Chlorhexidine glass ionomer|Chlorhexidine Diacetate will be added to the powder of Fuji IX with 0.5% v/v
11058941|NCT04365270|Placebo Comparator|Glass ionomer|Stock powder and liquid Fuji IX from GC japan
11058942|NCT04365257|Experimental|Prazosin|"Prazosin 1mg given to observe if medication is tolerated or if signs or symptoms of hypotension develop (e.g. dizziness, lightheadedness).
~If the patient remains asymptomatic and BP >110/60 mmHg, prazosin is continued at 1mg every 8 hours (q8h).
~Day 3: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 2mg q8h.
~Day 6: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 5mg q8h.
~If the BP is <100/60 mmHg at any time, the next dose should be held, and patient continues with the highest previously tolerated dose 8 hours later.
~If the patient did not tolerate dose escalation to 5mg q8h, one attempt is made to increase dose to 3mg q8h. If this is not tolerated, the patient continues with the highest previously tolerated dose 8 hours later.
~If BP monitoring is not available, repeated occurrences of postural dizziness should trigger drug dose reduction or BP monitoring."
11058943|NCT04365257|Active Comparator|Standard of care|Subjects randomized to this arm will receive standard of care.
11058944|NCT04365231|Experimental|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.
~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
11058945|NCT04365231|Active Comparator|conventional management of patients|Regular management of patients
11058946|NCT04365218|Experimental|Cohort 1 (Dose A)|6 subjects will be randomized to receive MEDI8367 Dose A and 2 subjects will be randomized to receive placebo.
11058947|NCT04365218|Experimental|Cohort 2 (Dose B)|6 subjects will be randomized to receive MEDI8367 Dose B and 2 subjects will be randomized to receive placebo.
11058948|NCT04365218|Experimental|Cohort 3 (Dose C)|6 subjects will be randomized to receive MEDI8367 Dose C and 2 subjects will be randomized to receive placebo.
11058949|NCT04365218|Experimental|Cohort 4 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D and 2 subjects will be randomized to receive placebo.
11058950|NCT04365218|Experimental|Cohort 5 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 2 subjects will be randomized to receive placebo.
11058951|NCT04365218|Experimental|Cohort 6 (Dose D)|15 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 15 subjects will be randomized to receive placebo.
11058952|NCT04365205||severe asthma|"Diagnosis of severe asthma according to the American Thoracic Society / European Respiratory Society task force.
~Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in Forced expiratory volume forced expiratory volume at one second (FEV1) within 12 months before enrollment.
~Documented blood eosinophils ≥ 300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1."
11058953|NCT04365205||non-severe asthma|• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA).
11058954|NCT04365205||non-asthmatic controls|"No prior history of any chronic respiratory disease including asthma.
~No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.
~No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.
~Normal lung function with FEV1 > 90%."
11058955|NCT04365192||I-gel|
11058956|NCT04365192||Self-pressurized air-Q|
11058957|NCT04365179|Experimental|NEROFE|"Dose Level - Nerofe Dose
~-1 - 6mg/m2
~- 12 mg/m2
~- 24 mg/m2
~- 48 mg/m2
~- 96 mg/m2
~- 150mg/m2"
11058958|NCT04365153|Active Comparator|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients </= 40 kg)
11058959|NCT04365153|Active Comparator|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients </= 40 kg)
11058960|NCT04365153|Placebo Comparator|Control|Placebo
11058961|NCT04365140||positive ACD to nickel|Patients with positive epicutaneous patch test to nickel
11058962|NCT04365140||negative ACD to nickel|Patients with negative epicutaneous patch test to nickel
11058963|NCT04365127|Experimental|Progesterone plus SOC|Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
11058964|NCT04365127|No Intervention|SOC only|Subjects will receive institutional standard of care only
11058965|NCT04365114||Single reading|Only one clinician examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
11058966|NCT04365114||Double reading|Two clinicians examined the woman's mammograms for signs of cancer and recommended whether to recall her for further tests or not.
11058967|NCT04365101|Experimental|Phase I|CYNK-001 infusions on Days 1, 4, and 7
11058968|NCT04365101|Active Comparator|Phase II|Randomized, open label; CYNK-001 infusions on Days 1, 4, and 7 compared to Control Group: Best Supportive Care
11058969|NCT04365088|Experimental|Deflazacort|Deflazacort is a glucocorticoid used as an anti-inflammatory drug. We used deflazacort 30 mg tablet. Patient took a pill once preoperatively (1 hour ago) in third molar surgery.
11059003|NCT04364867|Experimental|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
11058971|NCT04365075|Experimental|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
11058972|NCT04365075|Active Comparator|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
11058973|NCT04365062|Experimental|Intervention: Excimer laser and drug coated balloon|Intervention: Excimer laser and drug coated balloon group
11058974|NCT04365062|Active Comparator|Excimer laser and plain balloon|Excimer laser and plain balloon group
11058975|NCT04365062|Active Comparator|plain balloon and drug coated balloon|plain balloon and drug coated balloon group
11058976|NCT04365049||Treatment|Patients in treatment group will receive anti-PD-1 antibody intravenously every three weeks and apatinib 250mg per day until disease progression, unacceptable toxicity, death or withdrawal. Concurrent external beam radiation will be initiated after one course of anti-PD-1 treatment. The total radiation dose is over 40Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed.
11058977|NCT04365049||Gemcitabine+cisplatin|Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
11058978|NCT04365036|Experimental|toripalimab with P-GemOx|Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
11058979|NCT04365036|Active Comparator|P-GemOx|Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
11058980|NCT04365023||1|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive first line platinum based chemotherapy
11058981|NCT04365023||2|Well-differentiated grade 3 gastrointestinal neuroendocrine tumors patients who receive receiving first line non-platinum chemotherapy
11058982|NCT04365010|Experimental|Sodium Bicarbonate Ringer's Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.
~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
11058983|NCT04365010|Active Comparator|0.9% Sodium Chloride Injection|"administration route and dosage：Intravenous infusion, 500~1000 ml/time. The dosage can be increased or decreased according to the age, weight and symptoms.
~rate: according to the the routine rate of fluid resuscitation of septic shock in the ICUs of Zhongda Hospital, School of Medicine, Southeast University."
11058984|NCT04364997|Experimental|Desvenlafaxine Succinate Sustained-Release|
11058985|NCT04364997|Active Comparator|Duloxetine Hydrochloride Enteric-coated|
11058986|NCT04364984||ARB group|Hypertensive patients with COVID-19 who received ARBs
11058987|NCT04364984||ACEi group|Hypertensive patients with COVID-19 who received ACEis
11058988|NCT04364984||DRi|Hypertensive patients with COVID-19 who received DRis
11058989|NCT04364971|Experimental|singleradius|Single Radius(SR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Single Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
11058990|NCT04364971|Experimental|Multiradius|Multi Radius(MR) femoral design will be perfomed to patients who is going to total knee arthroplasty. Multi Radius femoral design is one of knee prosthesis' pattern which shows variation in knee kinematics
11058991|NCT04364958|Experimental|Intervention group|Patients who agree participant and will sign the informed consent, will complete the baseline assessment. Then, those allocated to the intervention group will review the web-based PtDA, with the help of a researcher if necessary, and then will fill the questionnaires assessing the outcome measures in the same web interface.
11058992|NCT04364958|Active Comparator|Control group|Patients allocated to the control group will receive a fact sheet with general information on mental health as a part of usual care, and they will also complete the same questionnaires.
11058993|NCT04364945|Placebo Comparator|Control group|General anesthesia is maintained using sevoflurane only. Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
11058994|NCT04364945|Experimental|Dexmedetomidine-remifentanil(DEX-R) group|General anesthesia is maintained using sevoflurane, dexmedetomidine (1 mcg/kg/hr) and remifentanil (0.1-0.2 mcg/kg/min). Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
11058995|NCT04364919|Experimental|aerobic exercise intervention|The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
11058996|NCT04364919|No Intervention|control group|The control group received routine prenatal care only.
11058997|NCT04364906|Active Comparator|Quadratus Lumborum Block 2|Quadratus Lumborum Block 2 (QLB 2) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
11058998|NCT04364906|Active Comparator|Quadratus Lumborum Block 3|Quadratus Lumborum Block 3 (QLB 3) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively
11058999|NCT04364893|Other|Group 1|Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
11059000|NCT04364893|Other|Group 2|Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
11059001|NCT04364880|Experimental|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
11059002|NCT04364880|Sham Comparator|Sham controlled intervention|The sham-TBS coil produced a similar sound without a magnetic pulse.
11059004|NCT04364867|Active Comparator|Pain pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the PACU infusing at 4cc/hr. The patient will go home with that device until it runs out.
11059005|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 3 weeks|
11059006|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 4.5 weeks|
11059007|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 6 weeks|
11059008|NCT04364854|Other|No Therapy 6 weeks|
11059009|NCT04364828|Other|Host Genome Analysis|For 150 patients from the extreme phenotypes - complementary to Whole Genome Analysis of each patient also Whole Transcriptome will performed Analysis; DNA methylation analysis using EPIC arrays will be performed in the pilot study (phase 1). Identically, in phase 2 starting from month 4, will be generated WGS, Whole transcriptome sequencing (WTS), and methylation data of the 500 patients. Epigenetic changes are likely to occur upon Corona infection. Subsequently, genome and epigenome data with RNA expression pattern will be correlated.
11059010|NCT04364828|Other|Host Response to SARS-CoV-2 Infection|Focus on longitudinal analysis of TCR repertoire of CD4+ and CD8+ T cells from blood samples (PBMCs) from clinically characterized patients (n = 24). The bulk- T-cell receptor (TCR) sequencing will be performed at different time points during the course of disease progression and recovery.
11059011|NCT04364828|Other|Viral Sequence Composition|The Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) viral composition is determined by Next Generation sequencing (different protocols for enrichment are available, and are currently being tested to successfully analyse the virus from different isolates). It is known that SARS-CoV-2 sequence is changing at least one position every second passing from person to person. Numerous variants have been described deriving from 3 different ancestral viruses (named A, B, and C) reflecting different distributions in East Asia, Europeans and Americans. At it is anticipated that other (super)infections may add to the severity of the infection and disease course, the entire metagenome of the throat is being sequenced and analyzed as well.
11059012|NCT04364815|Experimental|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine oral loading dose of 400mg two times per day on Day 1 then 400 mg once a day for Day 2-10 plus standard preventive measures as defined by PGH Hospital Infection Control Unit (HICU)
11059013|NCT04364815|Placebo Comparator|Placebo plus standard preventive measure|Placebo tablet plus standard preventive measures as defined by PGH-HICU
11059014|NCT04364802|No Intervention|Healthcare Workers - Control|Front-line healthcare workers (FLCHW) who are negative for COVID will receive standard PPE and a pre- and post-study test for COVID-19.
11059015|NCT04364802|Experimental|Healthcare Workers - PVP-I|Front-line healthcare workers (FLCHW) who are negative for COVID-19 will receive standard PPE and a pre- and post-study test for COVID-19. Additionally, they will receive PVP-I spray and gargle.
11059016|NCT04364802|No Intervention|Inpatients - Control|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test.
11059017|NCT04364802|Experimental|Inpatients - PVP-I|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays that will be applied shortly after admission or perioperatively.
11059018|NCT04364802|No Intervention|Community - Control|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test.
11059019|NCT04364802|Experimental|Community - PVP-I|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays.
11059020|NCT04364789|Experimental|SAD|"For the SAD part, there will be 5 cohorts (including 1 cohort for food effect assessment).To assess the safety, tolerability, and PK profile. The starting dose will be 50 mg.In each cohort, TT-00920 will be administered to 6 subjects and placebo will be administered to 2 subjects.Safety, tolerability, and PK data for each cohort will be reviewed by the Safety Review Committee (SRC) before the dose escalation in the next cohort.
~One of the 5 cohorts (Cohort X) will be crossed-over to the fed condition to assess the effect of food. Subjects will receive a TT-00920/placebo single oral regimen on Day 1 of each period."
11059021|NCT04364789|Experimental|MAD|MDA will comprise of at least 3 cohorts. The dose in each cohort will be decided by the SRC, based on safety, tolerability, and PK data from Part 1 and/or any preceding dose cohorts from Part 2.Subjects will receive TT-00920 or placebo for 7 consecutive days, once or twice daily based on the PK profile of Part 1.
11059022|NCT04364763|Experimental|RBT-9 (90 mg)|RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.
11059023|NCT04364763|Placebo Comparator|Placebo|0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.
11059024|NCT04364750|Experimental|Group A|"Participants in group A will undergo challenges in the order:
~High-FODMAP beverage + placebo probiotic + L-Histidine
~Low-FODMAP beverage + placebo probiotic + L-Histidine
~High-FODMAP beverage + probiotic + L-Histidine
~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
11059025|NCT04364750|Experimental|Group B|"Participants in group A will undergo challenges in the order:
~Low-FODMAP beverage + placebo probiotic + L-Histidine
~High-FODMAP beverage + probiotic + L-Histidine
~High-FODMAP beverage + placebo probiotic + L-Histidine.
~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
11059026|NCT04364750|Experimental|Group C|"Participants in group A will undergo challenges in the order:
~High-FODMAP beverage + probiotic + L-Histidine
~High-FODMAP beverage + placebo probiotic + L-Histidine
~Low-FODMAP beverage + placebo probiotic + L-Histidine.
~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
11059027|NCT04364737|Active Comparator|Convalescent donor plasma|
11059028|NCT04364737|Placebo Comparator|Lactated ringer's solution or sterile saline solution|
11059029|NCT04364724||Study group|"All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented.
~Eligible consenting patients will sign informed consent."
11074534|NCT04254757|Other|Open decompression and fusion surgery group|
11059030|NCT04364685|Active Comparator|Normal Walking|The participants performed 30 minutes on levelled surface on the track and field ground. Participants performed moderate intensity walking, self paced.
11059031|NCT04364685|Experimental|Sand Walking|The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
11059032|NCT04364672|Experimental|Women with stage 1-4 newly diagnosed breast cancer|
11059033|NCT04364659|Experimental|Food-specific ICT + TAU|Participants in the Food-specific ICT + TAU group will be encouraged to complete the FoodT phone app (a food-specific go/no-go task) and a food diary daily for four weeks. After four weeks, they will be asked to complete a post-intervention questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
11059034|NCT04364659|No Intervention|TAU|Participants in the TAU group will not receive the Food-specific ICT. After four weeks, they will be asked to complete a 'post-intervention' questionnaire. After eight weeks, they will be asked to complete a follow-up questionnaire.
11059035|NCT04364646|Active Comparator|Usual Care|Women in the usual care group receive medications and/or talk therapy. Sleep and light levels are monitored at home with wrist actigraphy during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and18 after the baby is born (postpartum weeks 2-6 and 18).
11059036|NCT04364646|Experimental|Personalize Integrated Chronotherapy|Women in the integrated chronotherapy group receive usual care (medications and/or talk therapy, as above) and also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor.
11059037|NCT04364633||Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
11059038|NCT04364633||Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
11059039|NCT04364620|Experimental|Arm AB-16B5 and Docetaxel|AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1.
11059040|NCT04364607|Active Comparator|Neostigmine group|After surgery, in the postoperative care unit, participants will receive 0.5 mg IM neostigmine
11059041|NCT04364607|Placebo Comparator|Placebo group|After surgery, in the postoperative care unit, participants will receive IM NaCl 0.9% as a placebo
11059042|NCT04364594|Experimental|affected individual|Patients affected by Coronavirus 19 admitted to the hospital setting
11059043|NCT04364581|Active Comparator|Letrozole group|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
11059044|NCT04364581|Placebo Comparator|Placebo group|Women will be treated with placebo for 10 days before hysteroscopic intervention
11059045|NCT04364568|Experimental|Symptomatic group at three month|"Rivermead Post-Concussion Syndrome >= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview
~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
11059046|NCT04364568|Experimental|Asymptomatic group at three month|"Rivermead Post-Concussion Syndrome < 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview
~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
11059047|NCT04364555|Active Comparator|Active/active|The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.
11059048|NCT04364555|Active Comparator|Placebo/active|The bottle for use in the morning cantains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.
11059049|NCT04364555|Placebo Comparator|Placebo/placebo|Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.
11059050|NCT04364542|Experimental|Suprascapular nerve block (SSNB)|Single shot using the blind block technique with 10 ml 0.75% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
11059051|NCT04364542|Active Comparator|Interscalene Nerve Block (ISB)|Single shot using US-guided interscalene brachial plexus block with 15 ml 0.5% ropivacaine and arthroscopic portals infiltration with 5 ml 0.75% diluted in 15 ml of distilled water.
11059052|NCT04364529|Experimental|Pit crew model|13 groups being taught the pit crew model
11059053|NCT04364529|No Intervention|no pit crew model (traditional ALS education)|13 groups being taught without the pit crew model (traditional ALS simulation)
11059054|NCT04364490|Experimental|Experimental VF group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.
~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform advanced gait training sessions by the computerized BWS system without visual feedback; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
11059055|NCT04364490|Experimental|Experimental VF+ group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.
~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform the same advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
11059056|NCT04364490|Active Comparator|Control group|"Inpatients with a diagnosis of first-ever ischemic stroke in post acute phase, admitted for rehabilitation to S.Anna rehabilitation Institute.
~The intervention consist of 2-h of rehabilitation daily sessions, five weekly over 6 weeks. During one hour of treatment, this group perform conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation; during second hour of treatment, during the second hour of treatment patients are treated according to conventional therapy consisting of exercises for passive and active mobilization of lower limbs, trunk control, standing, deambulation."
11059057|NCT04364477|Active Comparator|Tap block Group|Tap Block group :(Group 1) After General anestehesia At the end of the operation, TAP blocks were placed to the 1st group patients.
11059058|NCT04364477|Placebo Comparator|Control Group|No block applied. only General anesthesia was applied.
11059059|NCT04364464|Experimental|Riociguat, healthy participants|Participants with creatinine clearance (CLCR) >80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11059060|NCT04364464|Experimental|Riociguat, mild renal impairment|Participants with CLCR 50-80 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11059061|NCT04364464|Experimental|Riociguat, moderate renal impairment|Participants with CLCR 30-<50 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11059062|NCT04364464|Experimental|Riociguat, severe renal impairment|Participants with CLCR <30 mL/min received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
11059063|NCT04364438|No Intervention|Control Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises
11059064|NCT04364438|Experimental|EMS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Electric Muscle Stimulation (EMS)
11059065|NCT04364438|Experimental|TENS Group|Patients will be treated with conventional medical treatment for overactive bladder including anticholinergic drugs and pelvic floor muscle exercises along with Transcutaneous Electric Nerve Stimulation (TENS)
11059066|NCT04364425|Experimental|low dose steroid|patient received ultrasound-guided 40mg triamcinolone + 4cc xylocaine + 12cc NS
11059067|NCT04364425|Active Comparator|high dose steroid|patient received ultrasound-guided 10mg triamcinolone + 4cc xylocaine + 15cc NS
11059068|NCT04364399|Experimental|Experimental group|Mumps vaccine, one dose
11059069|NCT04364399|Active Comparator|Control group|measles, mumps and rubella combined vaccine, live, one dose
11059070|NCT04364386|Experimental|InPress|Treatment with InPress Device for Postpartum Hemorrhage
11059071|NCT04364373|Active Comparator|D2 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed.
~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed.
~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed.
~For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed."
11059072|NCT04364373|Experimental|D3 lymph node dissection|"For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed.
~For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed.
~For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed.
~For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed."
11059073|NCT04364360|Experimental|Sulforaphane supplementation|Daily (2 capsules) consumption of BroccoMax (Jarrow Formulas Los Angeles, CA) for 3-weeks.
11059074|NCT04364334||Knee registry patients|
11059075|NCT04364321|Experimental|Single dose Clonazepam|Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)
11059076|NCT04364321|Active Comparator|Intermittent oral diazepam|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.
11059077|NCT04364295||Implanted with SeaSpine spinal or orthobiologics product|
11059078|NCT04364282||Parent-Child Dyads Taking Part in Weight-Management Programs|Participants in this study will be children and their parents taking part in existing pediatric weight-management programs at participating sites. All participants will be seen at baseline and 6-months for data collection visits.
11059079|NCT04364269|Experimental|VIT-2763 Once a day (QD)|"Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight.
~The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind."
11059080|NCT04364269|Experimental|VIT-2763 Twice a day (BID)|Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
11059081|NCT04364269|Placebo Comparator|Placebo|Participants will be assigned to receive Placebo, Twice a day.
11059082|NCT04364256|Active Comparator|Active NMES|"asymmetric biphasic waveforms at 71 pulses per second frequency (Hz), 400 s pulse duration, 5:10s on:off time (50% duty cycle), and 1.5s ramp-up time. Participants will be in control of the muscle stimulator devices at all times and will be instructed to perform all sessions in the supine position. Bilateral NMES will be delivered via asymmetric, biphasic using four cutaneous parallel channels delivered simultaneously using 2x4 or 3x5 self-adhesive electrodes. For the active NMES group, participants will be encouraged to increase the amplitude to a level of moderate discomfort, such as that experienced during conventional exercise, but not to induce pain. At minimum, the amplitude should induce visible muscle contraction."
11059083|NCT04364256|Sham Comparator|Sham NMES|The amplitude of the muscle stimulators for the Sham group will be capped at 15 milliamperes so patients will only feel cutaneous sensation without achieving muscle contraction.
11059084|NCT04364243|Experimental|Patients exercise|Low back pain patients Next to basic medical physical training therapy group A receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
11059085|NCT04364243|No Intervention|Patients control|Low back pain patients Group B will receive basic medical physical training therapy
11059086|NCT04364243|Experimental|Non-patients exercise|non-patients Groups C will receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
11059087|NCT04364243|No Intervention|Non-patients control|non-patients Group D will receive no intervention
11059108|NCT04364139|Experimental|Lower BP goal and Metoprolol|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
11059109|NCT04364139|Experimental|Usual BP goal and Metoprolol|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
11059088|NCT04364230|Experimental|Arm A|6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 for both arms (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given at the primary site at days 1, 8, 16, 38, 67, and 78 and at the replicate site at day 1. A vaccine that contains all components except for CDX-1140 will be given at the replicate site at days 8 and 16. The vaccine will be given subcutaneously/intradermally.
11059089|NCT04364230|Experimental|Arm B|6MHP (200mcg of each peptide) and 300mcg of NeoAg-mBRAF will be co-administered locally with 0.9mg of polyICLC and CDX-1140. There will be a dose escalation of CDX-1140 for both arms (50mcg, 200mcg, 800mcg, 3.0mg). A vaccine containing all of these components will be given at the primary site at days 1, 38, 67, and 78 and at the replicate site at days 1, 8, and 16. A vaccine that contains all components except for CDX-1140 will be given at the primary site at days 8 and 16. The vaccine will be given subcutaneously/intradermally.
11059090|NCT04364217|Other|Treatment|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz
11059091|NCT04364204|Experimental|Kangaroo mother care with bracelet|
11059092|NCT04364204|Active Comparator|Kangaroo mother care|
11059093|NCT04364191|Experimental|Intervention Arm|Meaningful activity protocol during the day and Assistive Relaxation Therapy (ART) at night; includes 1) Sleep Hygiene Education; 2) Meaningful Activity Modules a) Physical Activity b) Cognitive Activity and c) Social engagement; 3) ART, a breath-based relaxation intervention that is coupled with a physical anchoring task. Participants will complete a daily sleep diary, use the activity modules daily as pre-determined times personalized to the participant, use the ART software when they get in bed to help with insomnia symptoms, and wear an actiwatch for a four-week period. Participants will have biweekly phone consultation with the research nurse.
11059094|NCT04364191|Active Comparator|Control Arm|Study participants in the control group will also receive a tablet and watch, but the meaningful activity modules and ART software will not be accessible to them. The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education. This approach provides staff and technology interaction/attention that is comparable to the intervention arm, and thereby promotes adherence; it has been used as a placebo comparator for many insomnia treatment studies and has low attrition rates. Control subjects will also be asked to complete electronic sleep diaries and wear the actiwatch on the non-dominant wrist to monitor sleep/wake patterns. For both arms, participants will be asked to complete baseline assessments, 1 month (post-intervention) and follow-up (3 month).
11059095|NCT04364178|Experimental|Viral Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
11059096|NCT04364165|Experimental|Standard of care messaging|Participants randomized into this arm will receive standard invitation cards distributed at the Tutu Tester containing basic information encouraging HIV testing. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the standard invitation card and share a brief script including the standard Tutu Tester message that free HIV testing is available at the Tutu Tester, with no further information or motivation to test.
11059097|NCT04364165|Experimental|U=U messaging|Participants randomized into this arm will receive the U=U invitation cards distributed at the Tutu Tester that will seek to assuage the fears of testing HIV positive by conveying the message that HIV treatment makes it possible for HIV positive people to be untransmittable and to live normal lives. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the U=U invitation card and share a brief script asking people if they knew they could control HIV and that pills exist that can keep them healthy and ensure they don't transmit the virus to their sex partners, and that free HIV testing is available at the Tutu Tester.
11059098|NCT04364152|Experimental|PD patients with freezing of gait, internal strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
11059099|NCT04364152|Experimental|PD patients with freezing of gait, external strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
11059100|NCT04364152|Experimental|PD patients without freezing of gait, internal strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
11059101|NCT04364152|Experimental|PD patients without freezing of gait, external strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
11059102|NCT04364152|Experimental|Healthy elders, internal strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
11059103|NCT04364152|Experimental|Healthy elders, external strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
11059104|NCT04364139|Experimental|Lower BP goal and Ramipril|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Ramipril 2.5 to 10 mg/d
11059105|NCT04364139|Experimental|Usual BP goal and Ramipril|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and participants assigned to Receive Ramipril 2.5 to 10 mg/d
11059106|NCT04364139|Experimental|Lower BP goal and Amlodipine|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
11059107|NCT04364139|Experimental|Usual BP goal and Amlodipine|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
11059110|NCT04364126|Active Comparator|Standard of care|Clinical blood pressure measured at regular visits
11059111|NCT04364126|Experimental|Home blood pressure monitoring|Home blood pressure measured daily for 1 week before regular clinical visits
11059112|NCT04364113|Active Comparator|Study A Usual Protein Usual Pressure|Study A Usual Protein and Usual Pressure
11059113|NCT04364113|Experimental|Study A Usual Protein Low Pressure|Study A Usual Protein and Low Pressure
11059114|NCT04364113|Experimental|Study A Low Protein Usual Pressure|Study A Low Protein and Usual Pressure
11059115|NCT04364113|Experimental|Study A Low Protein Low Pressure|Study A Low Protein and Low Pressure
11059116|NCT04364113|Active Comparator|Study B Low Protein Usual Pressure|Study B Low Protein and Usual Pressure
11059117|NCT04364113|Experimental|Study B Low Protein Low Pressure|Study B Low Protein and Low Pressure
11059118|NCT04364113|Experimental|Study B Very Low Protein Usual Pressure|Study B Very Low Protein and Usual Pressure
11059119|NCT04364113|Experimental|Study B Very Low Protein Low Pressure|Study B Very Low Protein and Low Pressure
11059120|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
11059121|NCT04364074|Experimental|GoodBelly Probiotic|Subjects randomized to this arm consume one serving of the Goodbelly lactobacillus plantarum 299v probiotic
11059122|NCT04364074|Placebo Comparator|Placebo|Subjects randomized to this arm consume one serving of the Goodbelly that does not contain lactobacillus plantarum 299v
11059123|NCT04364061|Experimental|Women with overweight or obesity|
11059124|NCT04364048|Experimental|Induction durvalumab, chemoradiation, consolidation durvalumab|Induction durvalumab at 1500 mg intravenously (IV) on Day 1 of a four week cycle for 1 cycle, followed by concurrent definitive chemoradiation, followed by consolidation durvalumab at 1500 mg IV Day 1 of every 4 week cycle for up to 12 cycles.
11059125|NCT04364035|Experimental|CCMM+GS-9620|ChAdOx1.HTI 2 doses, MVA.HTI 2 doses, GS-9620 10 doses.
11059126|NCT04364035|Placebo Comparator|PLACEBO|ChAdOx1.HTI placebo 2 doses, MVA.HTI placebo 2 doses, GS-9620, placebo 10 doses.
11059127|NCT04364022|Active Comparator|Lopinavir/Ritonavir|
11059128|NCT04364022|No Intervention|Active surveillance|
11059129|NCT04364009|Active Comparator|Optimized Standard of Care (oSOC)|The control group will receive optimized standard of care alone, including all treatments authorized for COVID-19 by the French Health Ministry and/or the center COVID-19 therapeutic committees at inclusion and during the follow-up.
11059130|NCT04364009|Experimental|Anakinra plus Optimized Standard of Care (oSOC)|The experimental group will receive Anakinra plus optimized Standard of Care. The patients will receive Intravenous injection (IV) of Anakinra 400mg/day (100mg IV every 6 hours) at Day 1, 2 and 3. From Day 4 to Day 10, the patient will receive IV injection of Anakinra 200mg/day (100mg every 12 hours). The total duration of Anakinra is 10 Days
11059131|NCT04363996|Experimental|New Bioactive Restorative Material|Activa Presto Bioactive restorative material
11059132|NCT04363996|Active Comparator|Resin Modified Glass Ionomer|Fuji II
11059133|NCT04363983|Active Comparator|Located/resected colorectal cancer|
11059134|NCT04363983|Active Comparator|Advanced colorectal cancer|
11059135|NCT04363983|Active Comparator|Located/resected pancreatic cancer|
11059136|NCT04363983|Active Comparator|Advanced pancreatic cancer|
11059137|NCT04363983|Active Comparator|Located/resected biliary tract cancer|
11059138|NCT04363983|Active Comparator|Advanced biliary tract cancer|
11059139|NCT04363983|Active Comparator|Located/resected gastroesophageal cancer|
11059140|NCT04363983|Active Comparator|Advanced gastroesophageal cancer|
11059141|NCT04363983|Active Comparator|Located/resected neuroendocrine cancer|
11059142|NCT04363983|Active Comparator|Advanced neuroendocrine cancer|
11059143|NCT04363970||group A- early catheter removal)|in group A, we will remove the catheter after 24 h.
11059144|NCT04363970||Group B- delayed catheter removal|In group B, we will remove the catheter after 48 h.
11059145|NCT04363957|Other|Standard Consent|Patients only receive the standard brachytherapy consent process
11059146|NCT04363957|Experimental|Standard Consent and Video Intervention|Patients receive the standard brachytherapy consent process and the addition of an informational video about brachytherapy
11059147|NCT04363944|Experimental|mRehab|Use of mRehab in a home program
11059148|NCT04363931|Experimental|Manual Therapy|Manual Therapy is a widely used physiotherapy modality which is known to be effective in the management of musculoskeletal problems . Manual Therapy is a passive, therapeutic approach used to target a variety of anatomical structures with the intent to create beneficial changes in the amount of pain a patient experiences. Manual Therapy includes joint mobilization, manipulation, or treatment of the soft tissues and is widely used to break fibrous adhesions, restore normal range of motion, reduce local ischemia, stimulate synovial fluid production, and reduce pain .
11059149|NCT04363931|Experimental|Kinesio Taping|Kinesio tape is a type of elastic therapeutic tape that was developed which is used in many different situations with various aims. Advocates of Kinesio Tape state that it may promote different therapeutic objectives such as; improved circulation and lymphatic drainage, pain inhibition, reduction of delayed onset of muscle soreness or improvement in performance and coordination .
11059150|NCT04363918|Active Comparator|intervention (IG1)|
11059151|NCT04363918|Active Comparator|intervention (MyoStim group)|
11059152|NCT04363918|Sham Comparator|control (CG)|
11059153|NCT04363905|Placebo Comparator|Placebo|100 mg lactose capsule
11059154|NCT04363905|Experimental|Ferrous sulfate|20 mg ferrous sulfate and lactose capsule
11059155|NCT04363892|Experimental|Receiving optical and infrared imaging|This is the only arm of the study. All patients will have optical and infrared images acquired of skin on the treated and contralateral sides.
11059156|NCT04363879|Active Comparator|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
11059157|NCT04363879|Experimental|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
11059158|NCT04363866|Experimental|Hydroxychloroquine|400 mg bid (PO) Day 1, followed by 200 mg bid (PO) Day 2 through Day 5
11059159|NCT04363866|Placebo Comparator|Placebo|Placebo pill bid (PO) Day 1 through Day 5 of the treatment period
11059160|NCT04363853|Experimental|Tocilizumab tratment|
11059161|NCT04363840|No Intervention|Observation|
11059162|NCT04363840|Experimental|Aspirin 81 mg|
11059163|NCT04363840|Experimental|Aspirin + vitamin D|Offered to COVID-19 patients who are vitamin D deficient AND randomized to aspirin
11059164|NCT04363827|Experimental|Group 1: Hydroxychloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
11059165|NCT04363827|No Intervention|Group 1: Observation|observation only
11059166|NCT04363827|Experimental|Group 2: Hydroxycloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
11059167|NCT04363827|No Intervention|Group 2: Observation|Observation only
11059168|NCT04363814|Experimental|Bactek-R|Subject included in the experimental group will receive Bactek- R.The dose consists on 3 spray puff every 6 hours for 2 weeks.
11059169|NCT04363814|No Intervention|Control|Subject included in the control group will receive standard therapy for COVID-19.
11059170|NCT04363801|Experimental|Part A First Line Treatment|Part A patients will receive IV DKN-01 (300 mg) on Days 1 and 15, IV tislelizumab (200 mg) on Day 1, IV oxaliplatin (130 mg/m2) on Day 1, and oral capecitabine (1000 mg/m2 twice daily [BID]) on Days 1-15 of each 21-day cycle. Part A is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
11059171|NCT04363801|Experimental|Part B1 Second Line Treatment|"Part B patients will receive IV DKN-01 (300 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.
~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
11059172|NCT04363801|Experimental|Part B2 Second Line Treatment|"Part B patients will receive IV DKN-01 (600 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.
~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
11059173|NCT04363788||Cardiopulmonary resuscitation|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
11059174|NCT04363775|Experimental|Regurgitation|intubation in regurgitation condition
11059175|NCT04363775|Experimental|Tongue edema|intubation in Tongue edema condition
11059176|NCT04363762|Experimental|Internet-based multimodal pain program|The iMPP is based on CBT and self-management principles that help patient cope with chronic TMD pain. The iMPP translates a face-to-face therapy to a software platform program.
11059177|NCT04363762|Active Comparator|Occlusal splint|Participants randomized to active control received a hard Michigan-type stabilization splint placed in the upper jaw by one of two calibrated general dentists {Ramfjord, 1994 #276}. The occlusal splint was chosen as the control treatment because it is a conventional and reversible treatment of TMD pain, and it has a known moderate efficacy {Welfare, 2011 #266}.
11059178|NCT04363749|Experimental|15 COVID positive patients|dyspnea rating to various dyspneic stimulus
11059179|NCT04363749|Active Comparator|15 healthy controls|dyspnea rating to various dyspneic stimulus
11059180|NCT04363736|Active Comparator|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
11059181|NCT04363736|Experimental|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
11059182|NCT04363723||patients with an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that developed an acute exacerbation during a pulmonary Rehabilitation program but continued the Rehabilitation program
11059183|NCT04363723||patients without an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that did not develop an acute exacerbation during a pulmonary Rehabilitation program and completed the Rehabilitation program regularly.
11059184|NCT04363710|Experimental|Intervention group|Participants in this arm were advised intervention of Low Calorie Diet (800-1000 Kcal/day) for 8 weeks without any anti diabetic medication
11059185|NCT04363710|No Intervention|Control Group|Participants in this arm were kept on their standard medical treatment
11059186|NCT04363697|Experimental|Dapagliflozin|Dapagliflozin 10 mg administered orally once daily for 2 months
11059187|NCT04363697|Placebo Comparator|Placebo|Matching placebo administered orally once daily for 2 months
11059188|NCT04363684||Longitudinal Arm|Annual clinic visits throughout the length of the study.
11059189|NCT04363684||Biofluid-Focused Arm|Single clinic visit.
11059190|NCT04363645|Experimental|Multicontext approach (Intervention) Arm|Participants received 30-minute sessions of strategy and self-monitoring practice within the context of everyday activities. These sessions were delivered either daily or twice a day. The total number of sessions varied depending on the participant's length of stay in acute rehabilitation.
11059191|NCT04363619|Placebo Comparator|Controls|
11059192|NCT04363619|Experimental|ICH|
11059193|NCT04363619|Experimental|aSAH|
11059194|NCT04363606|Experimental|"Non-fatigued patients who have been in intensive care units"|
11059195|NCT04363606|Experimental|"Fatigued patients who have been in intensive care units"|
11059196|NCT04363606|Experimental|patients who have not been in intensive care units|
11059197|NCT04363593|Other|prospective group COVID|New patients consulting for suspected or diagnosed COVID(+)
11059302|NCT04362826|Placebo Comparator|Placebo|Placebo plus normal standard of care for breast cancer.
11059198|NCT04363593|Other|retrospective group COVID|Patients already diagnosed with COVID(+) or with a suspicion of unconfirmed COVID or at a date before the apparition of the COVID infection (April-March 2019)
11059199|NCT04363593|Other|Hospital staff|All hospital staff including those already diagnosed at COVID(+)
11059200|NCT04363580||Patients|Children consulting for an assessment of central auditory skills
11059201|NCT04363567||CKD 1|"Patients with Chronic kidney disease stage 1: Normal kidney function but urine findings or structural abnormalities or genetic trait point to kidney disease. eGFR :90+.
~20 patients, maximun 4 patients with diabetes."
11059202|NCT04363567||CKD 2|"Patients with Chronic kidney disease stage 2: Mildly reduced kidney function, and other findings (as for stage 1) point to kidney disease. eGFR: 60-89.
~20 patients, maximun 4 patients with diabetes."
11059203|NCT04363567||CKD 3|"Patients with Chronic kidney disease stage 3: Moderately reduced kidney function. eGFR: 30-59.
~20 patients, maximun 4 patients with diabetes."
11059204|NCT04363567||CKD 4|"Patients with Chronic kidney disease stage 4: Severely reduced kidney function. eGFR: 15-29.
~20 patients, maximun 4 patients with diabetes."
11059205|NCT04363567||CKD 5|"Patients with Chronic kidney disease stage 5: Very severe kidney function. eGFR: <15.
~20 patients, maximun 4 patients with diabetes."
11059206|NCT04363567||Dialysis|Patients with end stage renal disease in dialysis. 20 patients, maximun 4 patients with diabetes.
11059207|NCT04363567||Healthy|20 healthy people. Control group
11059208|NCT04363554|Other|Urine dilution test|Urine dilution test
11059209|NCT04363554|Other|Urine concentration test|Urine concentration test
11059210|NCT04363541|Experimental|Thermotherapy|"Electric heat pad applied in the thorax for 90 minutes, twice daily, for 5 days.
~+ Usual in-hospital care"
11059211|NCT04363541|No Intervention|Control|Usual in-hospital care
11059212|NCT04363528|Other|Doppler Echo|patients will have a Doppler Echo when they enter ICU (within 48 hours) and a second Doppler Echo 7 days later
11059213|NCT04363515|No Intervention|Usual Pre-Transplant Counseling Intervention|Subjects in the control arm will undergo usual pre-transplant counseling as per the standard of care.
11059214|NCT04363515|Experimental|Social Support Network Counseling Intervention|Subjects in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks between 2-12 weeks after their initial transplant evaluation and counseling
11059215|NCT04363502|Experimental|clazakizumab at a dose of 25 mg|A first dose of 25 mg of clazakizumab will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25mg clazakizumab (an identical dose to the day 1 dose) will be given no later than day 3
11059216|NCT04363502|Placebo Comparator|placebo|A first dose of placebo will be given. No premedications will be given prior to the investigational product. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab or placebo administration to assess response. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo (an identical dose to the day 1 dose) will be given no later than day 3
11059217|NCT04363476|Experimental|Intervention|8-week exercise and education intervention. Two 60-minute physiotherapist-lead group exercise classes with education incorporated will be delivered weekly for 8 weeks (16 classes). In addition, participants will complete a 30-minute home exercise session once a week for 8-weeks (8 sessions). After the intervention, the group will enter a 16-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
11059218|NCT04363476|Other|Control|The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
11059219|NCT04363463|No Intervention|Conventional positioning|semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).
11059220|NCT04363463|Experimental|Interventional positioning : prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
11059221|NCT04363450|Experimental|Hydroxychloroquine|Hydroxychloroquine loading dose will be given as 400mg for two doses 12 hours apart. This will then be followed by maintenance dosing of 200mg twice weekly for the remainder of the trial.
11059222|NCT04363450|Placebo Comparator|Placebo|An identical placebo will be administered on an identical dosing interval and frequency.
11059223|NCT04363437|Active Comparator|Colchine|
11059224|NCT04363437|Active Comparator|Usual Care|
11059225|NCT04363424||Validation cohort|Patients with alcoholic cirrhosis with reliable self-reported alcohol use.
11059226|NCT04363424||Clinical application cohort|Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.
11059227|NCT04363411|Experimental|drug use|
11059228|NCT04363398|Experimental|Comprehensive|Coaches from schools randomized to the comprehensive follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a trained research team member will monitor the team weekly for injuries, participation, and adherence, and provide support to the school coaches regarding the warm-up.
11059229|NCT04363398|Active Comparator|Standard|Coaches from schools randomized to the standard follow-up receive a workshop outlining a neuromuscular training program to be used as a warm-up for 10 minutes at the beginning of each basketball practice and game. Throughout the season, a research team member will monitor the team weekly for injuries, participation, and adherence, however will not provide support to the school coaches regarding the warm-up.
11059230|NCT04363385|Other|Collection of blood sample|
11059231|NCT04363372|Experimental|MRx-4DP0004|Patients receiving standard of care will add MRx-4DP0004 to their treatment. MRx-4DP0004 is taken as 2 capsules, twice a day for 14 days. Daily dose is 4 x 10^9 to 4 x10^10 colony forming units.
11059232|NCT04363372|Placebo Comparator|Placebo|Patients receiving standard of care will also take 2 placebo capsules, twice a day for 14 days.
11059233|NCT04363359|Experimental|Quadrivalent influenza vaccine HD|Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
11059234|NCT04363359|Experimental|Quadrivalent influenza vaccine LD|Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.
11059235|NCT04363359|Active Comparator|Trivalent influenza vaccine Victoria|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.
11059236|NCT04363359|Active Comparator|Trivalent influenza vaccine Yamagata|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.
11059237|NCT04363346|Experimental|Dose Strategy 1|"Dose Strategy 1:
~Day 1 - FT516 is given at 9x107 cells/dose (low)"
11059238|NCT04363346|Experimental|Dose Strategy 2|"Dose Strategy 2:
~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid)"
11059239|NCT04363346|Experimental|Dose Strategy 3|"Dose Strategy 3:
~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid) + Day 7 - FT516 is given at 9x108 cells/dose (high)"
11059240|NCT04363333||High Probability of OSA|Based on a sleep questionnaire
11059241|NCT04363333||Low Probability of OSA|Based on a sleep questionnaire
11059242|NCT04363320|Experimental|High-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~4-hour onsite visit (NIATx Training)
~11 monthly (one-hour) NIATx coaching calls
~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
11059243|NCT04363320|Experimental|Low-Dose NIATx Coaching & ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~One-hour conference call with Executive Sponsor
~Two-hour NIATx webinar training with Change Leader/Team
~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team
~Prescribers participate in 12 monthly (one-hour) ECHO video conference calls"
11059244|NCT04363320|Experimental|High-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~4-hour onsite visit
~11 monthly (one-hour) NIATx coaching calls"
11059245|NCT04363320|Experimental|Low-Dose NIATx Coaching & No ECHO|"Attend an in-person Kick-Off Meeting with Study Team & Coaches
~One-hour conference call with Executive Sponsor
~Two-hour NIATx webinar training with Change Leader/Team
~Three (one-hour) coaching calls at months 4, 8, and 12 with Change Leader/Team"
11059246|NCT04363307||Adult participants|Adult participants ages 18 and older with AF
11059247|NCT04363294|Other|Participants|Patients who had TAVR and underwent evaluation for ATTR with PYP scan
11059248|NCT04363255|Experimental|Maintenance group|After 4-6 cycles of EP/EC chemotherapy regiment, maintenance therapy with toripalimab and anlotinib was followed and continued until disease progression.
11059249|NCT04363242|Experimental|Part A|Dose escalation of SYN125. Each dose level will be tested in a cohort of 3 patients. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next SYN125 dose level.
11059250|NCT04363242|Experimental|Part B|Dose escalation of SYN125 administered with a fixed-dose of SYN004 (SYN004 will be administered immediately after SYN125 infusion is complete, if tolerated). Each dose level of SYN125 will be tested in a cohort of 3 patients following that level of SYN125 being cleared in Part A. If no dose-limiting toxicity (DLT) is observed in the 3 patients, dose escalation will continue to the next level after that single SYN125 dose level has been cleared in Part A.
11059251|NCT04363216|Experimental|Treatment|Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
11059252|NCT04363216|No Intervention|Routine care|These subject will follow routine care and their clinical courses will be recorded only.
11059253|NCT04363203|Active Comparator|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg capsule in the AM and 200 mg in the PM on Days 2-5
11059254|NCT04363203|Active Comparator|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM followed by 250mg PO every day on days 2-5
11059255|NCT04363203|Placebo Comparator|Placebo|The pills packs for the 3 arms are identical.
11059256|NCT04363190||Cases|
11059257|NCT04363190||Controls|
11059258|NCT04363177|Experimental|Web-based psychosocial peer-to-peer support|"Web-based psychosocial peer-to-peer support, using Thinking Healthy two times during pregnancy"
11059259|NCT04363177|Active Comparator|Standard perinatal care|Perinatal standard care in Hong Kong, Shanghai
11059260|NCT04363164|Experimental|Arm A: Enzalutamide|Patients randomized to Arm A will receive continuous therapy with standard dose Enzalutamide (160 mg oral daily).
11059261|NCT04363164|Experimental|Arm B: Testosterone cypionate or Testosterone enanthate|Patients randomized to Arm B will receive intramuscular injection with testosterone cypionate or testosterone enanthate at a dose of 400 mg every 56 days
11059262|NCT04363151||Hydatid cyst patients|patients who underwent surgery for liver hydatid cyst from 2004 to 2018 in two major university-affiliated hospitals in Fars Province, southern Iran
11059263|NCT04363138||bacterial infection|Patients with bacterial infection
11059264|NCT04363138||No bacterial infection|Patients without bacterial infection
11059265|NCT04363112|Other|study with just one arm|"All of participants are in this arm. Mini Kid II and CBCL score are administered between day 3 and 7. Moreover, salivary test will be remove to evaluate cortisol secretion, 4 time per day during 2 consecutive days.
~Psychologic aftercare will be propose if children have psychologic troubles (results of Mini Kid II)"
11059266|NCT04363099||outpatients COVID 19 positive|
11059267|NCT04363086|Experimental|TAU|
11059268|NCT04363086|Experimental|iFD|
11059269|NCT04363086|Experimental|iFD + weekly phone calls|
11059270|NCT04363073|Experimental|Anaabella|Milk will be expressed using Annabella breast pump.
11059271|NCT04363073|Active Comparator|Control pump|Milk will be expressed using a control breast pump.
11059341|NCT04362514|Experimental|IG|Intervention Group
11059272|NCT04363060|Experimental|Azithromycin with amoxicillin/clavulanate|Combination of azithromycin during 4 days with amoxicillin/clavulanate during 7 days.
11059273|NCT04363060|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/clavulanate every day during 7 days.
11059274|NCT04363047||Healthy Volunteers|"These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.
~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.
~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
11059275|NCT04363047||Rheumatoid Arthritis|"These people will have already provided at least one sample as part of the BRAGGSS Study.
~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.
~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
11059276|NCT04363021||cases|Cases will be defined as women with systemic sclerosis, specific vascular complications (digital ulcers, specific cardiac involvement of systemic sclerosis including pulmonary arterial hypertension, renal crisis) and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
11059277|NCT04363021||controls|Controls will be defined as women with systemic sclerosis, no specific vascular complication and with a previous pregnancy longer than 6 months before systemic sclerosis diagnosis.
11059278|NCT04362995||SARS-CoV-2 Infection|St. Jude Children's Research Hospital employees with SARS-CoV-2 infection
11059279|NCT04362995||Controls|St. Jude Children's Research Hospital employees uninfected with SARS-CoV-2 infection
11059280|NCT04362982|Experimental|ADHD|In the first part of the clinical trials, ADHD cohorts are going to undergo a neuropsychological assessement. Moreover, they will interact with the serious game twice (30-45 minutes/each time). In the second part, participants will interact with game two or three times per week (30-45 minutes/each time). Finally, a neuropsychological assessment will be administered following the procedures of the first one.
11059281|NCT04362982|Active Comparator|non-ADHD|Non-ADHD group will follow the same procedures as the experimental one.
11059282|NCT04362943||Complete sample|"Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the Perpetuo Socorro Hospital of Albacete (Spain)"
11059283|NCT04362943||Baricitinib|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.
11059284|NCT04362943||Anakinra|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.
11059285|NCT04362930||Neurological and psychiatric impact of COVID-19|Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
11059286|NCT04362930||Impact of Covid-19 in patients with neurological pathology|patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
11059287|NCT04362917||FDR-|"Adults with a first degree relative with T1D, who have tested negative for islet autoantibodies.
~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
11059288|NCT04362917||FDR+|"Adolescents and adults with a first or second degree relative with T1D, who has tested positive for at least one islet autoantibody.
~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
11059289|NCT04362917||Control|"Adults with no family history of Type 1 Diabetes, who have tested negative for islet autoantibodies
~There is no intervention. Each group will get a MMTT and a clamp to evaluate beta cell function, identify elevations in circulating biomarkers of β cell stress or death, as well as their associations with measures of β cell function, and compare advantages of hyperglycemic clamps in identifying β cell dysfunction in this setting, relative to the mixed meal tolerance test (MMTT). They will repeat both the MMTT and the clamp once, to assess inter-test variability."
11059290|NCT04362904|Experimental|acupressure|In accordance with the acupressure protocol, each day for four weeks, taking into account the awakening and sleep periods of the individuals, acupressure applied for a total of 3 min to the each acupuncture points (one session 18 minutes) twice a day between 07:00 and 10:00 and 19:00 to 22:00 in the morning patients were asked to perform acupressure by their caregivers or on their own.
11059291|NCT04362904|No Intervention|control|No intervention was applied to the control group.
11059292|NCT04362891|Experimental|Juvéderm®|Cross-linked hyaluronic acid dermal filler product brand A (1,0 mL at baseline and 0,2 mL touch-up at 3-week follow-up).
11059293|NCT04362891|Experimental|Restylane®|Cross-linked hyaluronic acid dermal filler product brand B (1,0 mL at baseline and 0,2 mL touch-up at 3-week follow-up).
11059294|NCT04362891|Experimental|Belotero®|Cross-linked hyaluronic acid dermal filler product brand C (1,0 mL at baseline and 0,2 mL touch-up at 3-week follow-up).
11059295|NCT04362891|Experimental|Stylage®|Cross-linked hyaluronic acid dermal filler product brand D (1,0 mL at baseline and 0,2 mL touch-up at 3-week follow-up).
11059296|NCT04362865||COVID-19 infection|Patients with confirmed or suspected COVID-19 infections
11059297|NCT04362865||No COVID-19 infection|Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
11059298|NCT04362852||Lung Cancer|No intervention
11059299|NCT04362852||Atopic Dermatitis/Eczema|No intervention
11059300|NCT04362839|Experimental|Treatment (regorafenib, nivolumab, ipilimumab)|Patients receive regorafenib PO QD on days 1-21, nivolumab IV over 30 minutes Q2W, and ipilimumab IV over 30 minutes Q6W. Cycles repeat every 28 day for up to 2 years in the absence of disease progression or unacceptable toxicity.
11059301|NCT04362826|Experimental|Novel probiotic|Investigational novel probiotic plus normal standard of care for breast cancer.
11059303|NCT04362813|Experimental|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
11059304|NCT04362813|Placebo Comparator|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
11059305|NCT04362800|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
11059306|NCT04362800|Placebo Comparator|Control|10 days of care and classic activities
11059307|NCT04362787||High pressure _ low pressure non-invasive ventilation|"In the high-pressure NIV,52 patients will undergo pressure-limited NPPV at a higher IPAP level. IPAP is initially set at 20 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (up to 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 15 mL/kg of IBW.
~2- EPAP for patients with COPD will be started at EPAP 5 and will be increased till 7 and for the patients with hypoventilation syndrome will be increased up to EPAP 8.
~3-Respiratory rate 10-12 b/min."
11059308|NCT04362761|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
11059309|NCT04362748|Experimental|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
11059310|NCT04362748|Experimental|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
11059311|NCT04362748|Experimental|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
11059312|NCT04362735||Study group|All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)
11059313|NCT04362722|Experimental|Single arm|"40 patients will be enrolled and treated with a mixture of 6.5 Mio IU (~1.08 mg) L19IL2 and 200 µg L19TNF once weekly for 4 consecutive weeks. The dose will be distributed among the lesions via multiple intralesional injections.
~New lesions occurring during the treatment phase will also be treated as described but the treatment period for new lesions will not be extended beyond the previously defined 4 weeks treatment period with clock-start at the time of the first intralesional L19IL2/L19TNF injection.
~After the Tumor Assessment/Safety visit, patients may receive surgery in a curative intention within 6 weeks, in order to assess the pathological response with estimation of percent of residual viable tumor cells."
11059314|NCT04362709||Postoperative complications|
11059315|NCT04362709||No postoperative complications|
11059316|NCT04362696|Experimental|active stimulation|
11059317|NCT04362696|Sham Comparator|sham stimulation|
11059318|NCT04362683||High Power Atrial Fibrillation Ablation|"In our center, routine medical care for atrial fibrillation ablation includes:
~Multidirectional high-density mapping
~High power - short duration settings
~Contact force sensing ablation catheter"
11059319|NCT04362670|Experimental|OTX-CSI-Cohort 1|Formulation 2A-.36 mg
11059320|NCT04362670|Experimental|OTX-CSI-Cohort 2|Formulation 1- .36 mg
11059321|NCT04362670|Placebo Comparator|HV|"Cohort 2:
~Formulation 2B"
11059322|NCT04362670|Experimental|OTX-CSI- Cohort 2|Formulation 2A- .36 mg
11059323|NCT04362670|Placebo Comparator|HV-2|"Cohort 2:
~Formulation 3"
11059324|NCT04362657|Experimental|Computer aided diagnosis|Using CAD to assist in completeness of the examination during OGD
11059325|NCT04362644|Experimental|PET/CT using PET ligands [18F]FDG and [18F]DPA-714|
11059326|NCT04362631||Adults|Adults 18 years or older
11059327|NCT04362618|Experimental|Muscle Strengthening Training (MST)-group|Subjects allocated to the MST group (n=30) will perform a muscle strengthening training program of 12 weeks.
11059328|NCT04362618|Experimental|Behavioral Graded Activity (BGA)-group|Subjects allocated to the BGA group (n=30) will perform a rehabilitation program according to the principles of behavioural graded activity for a period of 12 weeks.
11059329|NCT04362618|No Intervention|Control group|Subjects allocated to the control group (n=30) have to maintain their current life-style and treatment (if any) and to refrain from other new interventions during 24 weeks.
11059330|NCT04362605|Experimental|intervenional group|ENPT
11059331|NCT04362592|Experimental|Percutaneous Technique|The percutaneous technique uses endoscopic scopes through the maternal skin and uterus to perform the surgery.
11059332|NCT04362592|Experimental|Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique consists of performing a laparotomy (incision into the abdominal cavity), exteriorizing the uterus, and using endoscopic scopes through the uterus to perform the correction.
11059333|NCT04362579||Subjects seen in hospital|Subjects will be recruited from Prentice Women's Hospital inpatient antepartum and labor and delivery services, and the outpatient Obstetrics and Gynecology practice, located within Galter tower with the assistance of staff.
11059334|NCT04362579||Home Study subjects|Subjects will be prescreened by an IRB approved staff and recruited from Prentice Women's Hospital's Department of Obstetrics and Gynecology.
11059335|NCT04362566|Active Comparator|Bupivicaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
11059336|NCT04362566|Placebo Comparator|Placebo saline|Saline in the same volume as described above for bupivicaine
11059337|NCT04362553||Adults|Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)
11059338|NCT04362540||Pregnant women with GDM|Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)
11059339|NCT04362527|Experimental|Milrinone|The patients randomized to this arm will have Milrinone (Laboratoires STRAGEN, France)
11059340|NCT04362527|Placebo Comparator|Placebo|The patients randomized to this arm will have Saline solution
11059343|NCT04362501|Experimental|dupilumab treatment group|dupilumab treatment group
11059344|NCT04362501|Placebo Comparator|placebo group|placebo group
11059345|NCT04362488|Experimental|Patients with chronic post-traumatic lateral ankle instability|"The study population consists in patients affected by chronic post-traumatic lateral ankle instability who must undergo surgical intervention of ankle external ligament reconstruction.
~The patients will be analyzed pre and postoperatively using differents tests, questionnaires, instrument and clinical evaluation:
~Delos system (computerized oscillating platform)
~Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires
~modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
11059346|NCT04362475|Active Comparator|Family Youth Intervention (FYI)|The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
11059347|NCT04362475|Active Comparator|ESPI Environment: Social and Physical Intervention (ESPI)|ESPI will enroll 500 community members to examine the effect of blight elimination through lot recovery on primary outcomes of improved social interaction, social cohesion around common neighborhood norms, and collective efficacy to effect change in the neighborhoods . Neighborhood residents will select a cluster of lots (2-3) for lot recovery that are highly visible in the neighborhood (e.g. on a main thoroughfare). The community residents will lead the neighborhood projects. In some cases, neighborhood residents will personally undertake all or part of the greening projects.
11059348|NCT04362475|Other|Wait-List Control|The two communities will get ESPI, upon completion of the study.
11059349|NCT04362475|Active Comparator|FYI and ESPI|Two of the eight neighborhoods will receive both FYI and ESPI intervention.
11059350|NCT04362449|Experimental|Shortened hydration time with dispensary of Akynzeo|ABC-02 regime - gemcitabine and cisplatin with a shortened hydration time and administration of a newer antiemetic
11059351|NCT04362449|Active Comparator|Standard of care|ABC-02 regime - gemcitabine and cisplatin with currently approved hydration time and administration of the current choice of antiemetic
11059352|NCT04362436|Experimental|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
11059353|NCT04362423||propofol+fNIRS|During data collection, only propofol is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
11059354|NCT04362423||sevoflurane+fNIRS|During data collection, only sevoflurane is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
11059355|NCT04362423||neuro-stimulator+fNIRS|During data collection, we use neuro-stimulator to give the stimulation.
11059356|NCT04362410|Experimental|Tezepelumab: Low dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
11059357|NCT04362410|Experimental|Tezepelumab: Medium dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
11059358|NCT04362410|Experimental|Tezepelumab: High dose|Tezepelumab: Tezepelumab single dose subcutaneously injection.
11059359|NCT04362410|Placebo Comparator|Placebo|Placebo single dose subcutaneously injection.
11059360|NCT04362397|Experimental|A (first group to receive the intervention)|This arm will receive the attention, care, and self-care training first.
11059361|NCT04362397|Experimental|B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive it after this period.
11059362|NCT04362384|Experimental|Vitamin E ovules|Endoanal Vitamin E ovules will be prescriped during 14 days
11059363|NCT04362384|Active Comparator|Prednisolone ointment|Endoanal Prednisolone ointment will be prescriped during 14 days
11059364|NCT04362371|Experimental|Ainara|"Ainara is a class II medical device, already marketed in several EU countries. The product is a mucoadhesive moisturising gel for vulvovaginal use, indicated for the relief of symptoms of vaginal atrophy and dryness, and related discomfort. In each packaging there is a tube containing the gel (sterile and viscous with about 87% water) and a syringe-like plastic applicator with cannula and plunger.
~Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration)."
11059365|NCT04362358|Experimental|7 sessions of the online CBT programme|
11059366|NCT04362358|Active Comparator|Bibliotherapy|
11059367|NCT04362332|Active Comparator|chloroquine|1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
11059368|NCT04362332|Active Comparator|hydroxychloroquine|2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
11059369|NCT04362332|No Intervention|Supportive care only|3. Supportive care only.
11059370|NCT04362319||Anaesthesiology clinicians|Including Consultants, Specialists and Medical officers serving in the Department of Anaesthesiology and Intensive Care
11059371|NCT04362306|Experimental|Planned Intervention|Patients will be scheduled for CT (computed tomography ) simulation for radiation treatment planning. Prior to simulation, patients will be asked to complete anxiety and patient satisfaction questionnaires. Following completion of the questionnaires, each patient will receive the first intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic. The patient will then be asked to complete a second set of anxiety and patient satisfaction questionnaires and will then undergo the planned simulation.
11059372|NCT04362306|Active Comparator|No Planned Intervention|After patients are enrolled into this study, they will be scheduled for CT simulation for radiation treatment planning. Prior to simulation, patients will receive anxiety and patient satisfaction questionnaires to complete
11059373|NCT04362293|Experimental|Matched Sibling Donor (MSD)|Patients with a suitable HLA matched sibling donor (MSD) will be enrolled on the MSD arm.
11059374|NCT04362293|Experimental|Haploidentical (HAPLO)|Patients without an eligible MSD who have a suitable haploidentical (HAPLO) donor available will be enrolled on the HAPLO arm of the study.
11059375|NCT04362280|Experimental|ReCHARGE|intervention intensity is increased through: the creation of family groups, greater involvement of school staff, separate lessons for females, health screeners will be home and families are invited to a nutrition counseling session with a registered dietitian.
11059376|NCT04362280|Active Comparator|Treatment as Usual (TAU)|PE class as usual which consisted of choice time.
11059377|NCT04362254|Experimental|Spesolimab arm|
11059378|NCT04362241|Experimental|Dextenza|Sustained release Dexamethasone 0.4mg
11059379|NCT04362241|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate Ophthalmic drops
11059380|NCT04362228|Experimental|Whole-body exercise|
11059381|NCT04362215||High AA group|Group 1 consisted of those having an AA level of 3.57-4.16 D (high AA group; those who had near clear vision between 24-28 cm). .
11059382|NCT04362215||Low AA group|Group 2 consisted of those having an AA level of 3.44-3.03 D (low AA group; those who had near clear vision between 29-33 cm)
11059383|NCT04362202|Experimental|experimental|8 individual experimental rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
11059384|NCT04362202|Active Comparator|control|8 individual of standard aquatic rehabilitation sessions as outpatients (2 days/week, 4 weeks), in a rehabilitation pool at Fondazione Santa Lucia Neurorehabilitation hospital. Each session lasted 45minutes. The water temperature was between 30°C and 32°C.
11059385|NCT04362189|Experimental|HB-adMSCs|Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.
11059386|NCT04362189|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.
11059387|NCT04362176|Experimental|pathogen reduced SARS-CoV-2 convalescent plasma|Transfusion of convalescent plasma will be administered by clinical or research personnel while the participant is hospitalized on Study Day 0. Plasma will be administered at a rate of 500 mL/hour and will be administered within 12 hours of randomization.
11059388|NCT04362176|Placebo Comparator|Placebo|Participants randomized to the control group will receive 250mL of Lactate Ringers containing multivitamins intravenously on Day 1 as a placebo.
11059389|NCT04362150||COVID-19 positive, recovered|Individuals with positive test for COVID-19 who have recovered from acute infection (21 days after symptom onset + improvement in symptoms + resolution of fever for 72 hours without fever reducing medicines).
11059390|NCT04362137|Experimental|Ruxolitinib 5 mg|Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
11059391|NCT04362137|Placebo Comparator|Placebo|Matching-image placebo for 14 days with possible extension of treatment to 28 days
11059392|NCT04362124|Experimental|vaccine BCG|"A single dose intradermal application of 0.1 ml of between 1 x 105 to 33 x 105 CFU of BCG, in the deltoid of the non-dominant arm.
~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
11059393|NCT04362124|Placebo Comparator|Placebo|"A single dose intradermal application of 0.1ml of normal saline solution, in the deltoid of the non-dominant arm.
~Follow-up of the participant up to day 360. The frequency and intensity of possible Adverse Events, reactions, and symptoms that appear, and other reactions stipulated in the protocol will be documented in the subject's diary."
11059394|NCT04362111|Experimental|Anakinra Group|The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 10 days. For subjects meeting complete response criteria at 5 days, dosing will be decreased to 100 mg twice daily for the remaining 5 days.
11059395|NCT04362111|Placebo Comparator|Control Group|The control group will receive normal saline placebo subcutaneously every 6 hours for period of 10 days. For subjects meeting complete repsonse criteria at 5 days, dosing wll be decreased to twice daily for the remaining 5 days.
11059396|NCT04362098|Experimental|Nurse home visits|Nurse home visits biweekly.
11059397|NCT04362098|No Intervention|Usual care|Usual care.
11059398|NCT04362085|Experimental|Therapeutic Anticoagulation|Therapeutic anticoagulation with LMWH or UFH (high dose nomogram). The choice of LMWH versus UFH will be at the clinician's discretion and dependent on local institutional supply. Therapeutic anticoagulation will be administered until discharged from hospital, 28 days or death. If the patient is admitted to the ICU or requiring ventilatory support, we recommend continuation of the allocated treatment as long as the treating physician is in agreement.
11059399|NCT04362085|No Intervention|Standard Care|In Canada and the US, administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is considered standard care.
11059400|NCT04362072|Experimental|Lorlatinib|Participants will take 100 mg (four, 25 mg tablets) once daily.
11059401|NCT04362059|Experimental|Treatment Arm|Patients will be administered surfactant via COVSurf Drug Delivery System
11059402|NCT04362059|Active Comparator|Control Arm|Patients shall receive regular Standard of Care treatment
11059403|NCT04362046|Experimental|Hysteroscopic uterine resection|This is a prospective single-arm surgical intervention trial.
11059404|NCT04362033|Experimental|PLR group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:
~In PLR arm, patients will be submitted to the PLR maneuver (patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grade) firstly, then PEEP increment maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
11059405|NCT04362033|Experimental|PEEP group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:
~In PEEP arm, patients will be submitted to the PEEP maneuver (consisted in increase the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position) firstly, then PLR maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
11059406|NCT04362020|Experimental|Group-1|No anticoagulation
11059408|NCT04362007|Experimental|Phase 1 dose-escalation part|Subjects with r/r PTCL and r/r CTCL will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RD is determined.
11059409|NCT04362007|Experimental|Phase 1 ATLL expansion part|Subjects with r/r ATLL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
11059410|NCT04362007|Experimental|Phase 2|Subjects with r/r PTCL will receive ASTX660 at RD obtained from the Phase 1 part (dose-escalation part) once a day for 7 consecutive days every other week of each 28-day cycle.
11059411|NCT04361981||Cases|COVID-19 infection patients with a Deep Venous Disease event
11059412|NCT04361968|Experimental|Animal-assisted placebo condition|Participants receive verbal information that they are receiving an analgesic cream. Additionally, and before getting the dog, participants will get a therapeutic rationale for the presence of the dog.
11059413|NCT04361968|Experimental|Placebo condition|Participants receive verbal information that they are receiving an analgesic cream.
11059414|NCT04361968|Experimental|Dog only condition|Before meeting the dog, participants will get a therapeutic rationale for the presence of the dog.
11059415|NCT04361968|Other|Control condition|Participants in this condition will receive no intervention.
11059416|NCT04361955|Other|PD with DBS on|intervention is EEG while at rest and performing tasks, on anti PD medications and off anti PD medications
11059417|NCT04361955|Other|PD with DBS off|intervention is EMG while at rest and performing tasks, on anti PD medications and off anti PD medications
11059418|NCT04361955|Other|ET with DBS on|intervention is EEG while performing tasks and at rest
11059419|NCT04361955|Other|ET with DBS off|intervention is EEG while performing tasks and at rest
11059420|NCT04361942|Experimental|Experimental|Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline
11059421|NCT04361942|Placebo Comparator|Placebo|Intravenous injection of 100 ml of saline containing no cells
11059422|NCT04361916|Experimental|home care with active monitoring|home care with active monitoring conducted by health workers with daily visit to patients.
11059423|NCT04361903||Patients treated with ruxolutinib|SARS-CoV-2 COVID-19 patients with rapid worsening of respiratory parameters in the last 12 hours treated with ruxolutinib, dosage of at least 20 mg x 2 / day in the first 48 hours.
11059424|NCT04361890|Other|women with predominant SUI|All women with predominant SUI will be referred to a physiotherapist for PFMT as usually. They will have an ultrasound evaluation before and after the session
11059425|NCT04361864||RUTI|patients with at least 3 episodes of UTI during 2019
11059426|NCT04361864||UTI|patients with one or two episodes of UTI during 2019
11059427|NCT04361851|Experimental|1|Pembrolizumab and Daratumumab
11059428|NCT04361838|Active Comparator|Prayer|Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
11059429|NCT04361838|No Intervention|No Prayer|Patients will receive standard of care treatment while in the ICU.
11059430|NCT04361825|Experimental|Durvalumab(MEDI4736) and AZD6738 combination|
11059431|NCT04361812|Experimental|HS632|HS632 150mg for a single subcutaneous injection
11059432|NCT04361812|Active Comparator|Omalizumab (Xolair®)|Omalizumab 150mg for a single subcutaneous injection
11059433|NCT04361799|Experimental|Closed-loop insulin therapy|
11059434|NCT04361799|Active Comparator|Standard insulin therapy|
11059435|NCT04361773|Active Comparator|Photobiomodulation group|In this group, PBM will be applied daily using LED devices until the lesion presents healthy granulation tissue, absence of necrosis and purulent secretion and, therefore, is suitable for primary closure, closure by flap or graft or for healing by second intention. At this point, the protocol will be finalized.
11059436|NCT04361773|Sham Comparator|Sham group|Sham group participants will receive the application of the disconnected device, for the same period. The characteristic sound of the device will be activated by means of recording.
11059437|NCT04361760|Experimental|Healthy younger participants (20-30y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
11059438|NCT04361760|Experimental|Healthy older participants (65-75y)|Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.
11059439|NCT04361747|Experimental|nursing counseling intervention|The nursing counseling intervention was implemented by a maternity nursing instructor. During the 12-week prenatal genetic testing evaluation period, experimental-group participants received three nursing consultation sessions plus regular care, while their control-group peers received regular care only. The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
11059440|NCT04361747|No Intervention|control group|control group participants received regular care only
11059441|NCT04361734||Juvenile onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
11059442|NCT04361734||Adult onset Systemic Lupus Erythematosus (SLE) patients|All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
11059517|NCT04361136|Experimental|Delgocitinib cream 1 mg/g|Single topical occlusive administration
11059443|NCT04361734||Matching healthy volunteers|Healthy volunteers, matched by age and gender, will be used as a control group
11059444|NCT04361721||Chronic migraine patients|Three monthly administration of erenumab 70 mg subcutaneously.
11059445|NCT04361708|Experimental|High Risk UGT1A1 genotype|
11059446|NCT04361708|Experimental|Intermediate Risk UGT1A1 genotype|
11059447|NCT04361708|Experimental|Low Risk UGT1A1 genotype|
11059448|NCT04361695|Active Comparator|Ketoprophenum|A tablet with 10 mg Ketoprophenum is taken per os 2 hours before surgery
11059449|NCT04361695|Placebo Comparator|Placebo|A tablet containing starch is taken per os 2 hours before surgery
11059450|NCT04361669||Intervention|Patients that receive pharmacist-delivered services in the pilot program
11059451|NCT04361669||Control|Patients that do not receive pharmacist-delivered services in the pilot program
11059452|NCT04361656||Current standard of care preparation|Current Standard of Care for inpatient colonoscopy: The dose of PEG-ELS will be large-volume (4-Liter) administered as either single-dose if colonoscopy is scheduled BEFORE 11 a.m. (250 mL orally every 15 minutes between 6 p.m. and midnight the day prior to procedure), or split-dose if the colonoscopy is scheduled AT or AFTER 11 a.m. (First dose: 2-Liters; 250 mL orally every 15 minutes between 6-8 p.m. the day prior to procedure. Second dose: 2-Liters; 250 mL orally every 15 minutes to be completed 5 hours before the scheduled time of the procedure).
11059453|NCT04361656||Lubiprostone Intervention|"The study entails giving two doses of Lubiprostone in addition to the standard large-volume polythene glycol-electrolytes solution (PEG-ELS) according to the time of the procedure as follow: If the colonoscopy is scheduled BEFORE 11a.m. the patient will receive in addition to the PEG-ELS: Lubiprostone 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy.
~If the colonoscopy is scheduled AT or AFTER 11a.m. the patient will receive in addition to PEG-ELS: Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS"
11059454|NCT04361643|Experimental|Experimental|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
11059455|NCT04361643|Placebo Comparator|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3, and 5.
11059456|NCT04361630|Experimental|Main treatment group|Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.
11059457|NCT04361617|Active Comparator|Epigenetic age knowledge arm|Half of the intervention participants will be randomly selected to be informed of their epigenetic age before the intervention.
11059458|NCT04361617|Active Comparator|No epigenetic age knowledge arm|The other half of intervention participants will not be informed of their epigenetic age before the intervention.
11059459|NCT04361604||250 Patients co infected HIV and SRAS-CoV2|Cohort of Patient co infected HIV AND SRAS-CoV2
11059460|NCT04361604||20 patients infected HIV without COVID-19|Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
11059461|NCT04361591||COVID-19|Liver Transplant recipients
11059462|NCT04361578||Patients|All patients enrolled in the study will be in this group.
11059463|NCT04361565||Individuals diagnosed for COVID-19|
11059464|NCT04361552|Experimental|Arm I (tocilizumab, standard of care)|Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
11059465|NCT04361552|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
11059466|NCT04361539||Elite adolescent badminton players|The population was all the elite adolescent badminton players from a high-level club. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed from September 2018 to May 2019.
11059467|NCT04361526|No Intervention|Control|standard intensive care alone
11059468|NCT04361526|Experimental|Cytokine Adsorption|cytokine adsorption plus standard intensive care
11059469|NCT04361513|Active Comparator|Nerve block group|3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.
11059470|NCT04361513|Other|intra-articular steroid injection|1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.
11059471|NCT04361500||COVID-19 patients with Seraph 100 therapy|
11059472|NCT04361487||Horizontal Cleavage Meniscal Tear|Participants with horizontal cleavage meniscal tears
11059473|NCT04361487||Complex Meniscal Tear|Participants with complex meniscal tears
11059474|NCT04361474|Experimental|Experimental group|Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
11059475|NCT04361474|Placebo Comparator|Control group|Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.
11059476|NCT04361461|Experimental|Group 1|Hydroxychloroquine (400 mg)
11059477|NCT04361461|Experimental|Group 2|Hydroxychloroquine (400 mg) + azithromycin (500 mg)
11059478|NCT04361448|Other|Health Care Workers with Covid-19 symptoms|3 samples (2 nasopharyngeasl swabs, 1 oropharyngeal swab) willl be taken from each volunteer
11059479|NCT04361435|Other|NIOD first|In this arm, we will apply for NIOD first which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses. This arm of patients will receive standard CPT at least 3 hours after the NIOD intervention.
11059480|NCT04361435|Other|CPT first|In this arm, we will apply for CPT first which will be performed by physiotherapists. This arm of patients will receive NIOD procedures which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses at least 3 hours after the CPT intervention.
11059481|NCT04361422|Active Comparator|Isotretinoin|13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
11059482|NCT04361422|Sham Comparator|Standard COVID-19 therapy|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
11074921|NCT04252001|Experimental|Group T|Group receives transition-toolkit
11059483|NCT04361422|Active Comparator|Standard COVID-19 therapy+ isotretinoin|Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.
11059484|NCT04361409|Experimental|Rituximab plus chemotherapy|"Drug:Rituximab
~Drug:Cisplatin
~Drug:Gemcitabine"
11059485|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy).
11059486|NCT04361383|Placebo Comparator|Control group|patients will be operated under general anesthesia.
11059487|NCT04361383|Active Comparator|QLB group|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
11059488|NCT04361383|Active Comparator|ESPB group|patients will receive ultrasound-guided erector spinae plane block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
11059489|NCT04361370|Experimental|Treatment group|BRCA mutation wild type, non-mucinous , platinum-sensitive recurrent ovarian cancer
11059490|NCT04361357|Experimental|Experimental group|whey protein powder was added on the basis of standardized enteral nutrition preparation.
11059491|NCT04361357|No Intervention|Control group|standardized enteral nutrition preparation only.
11059492|NCT04361331|Other|Toripalimab combined with lenvatinib|"Toripalimab: 240 mg, intravenous infusion, Q3W;
~Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd;"
11059493|NCT04361331|Other|Lenvatinib combined with gemox|"Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd
~Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses"
11059494|NCT04361318|Experimental|Hydroxychloroquine plus Nitazoxanide|200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
11059495|NCT04361318|Active Comparator|Standard care|Standard care delivered in the COVID-19 isolation hospitals.
11059496|NCT04361305|Experimental|tadalafil combined with dapoxetine|
11059497|NCT04361305|Active Comparator|tadalafil mono group|
11059498|NCT04361292|Active Comparator|Group A: one day abstinence period|Patients allocated into group A had an ejaculatory abstinence period of one day
11059499|NCT04361292|Active Comparator|Group B: three days abstinence period|Patients allocated into group B had an ejaculatory abstinence period of three days
11059500|NCT04361279|Experimental|SIBP-02|"Biological: SIBP-02, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.
~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.
~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.
~Treatment cycle: 6 cycles, each cycle is 3 weeks."
11059501|NCT04361279|Active Comparator|Rituximab|"Biological: Rituximab, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.
~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.
~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.
~Treatment cycle: 6 cycles, each cycle is 3 weeks."
11059502|NCT04361266|Experimental|Rotium patch recipient|Subjects with Rotium nano scaffold patch included in rotator cuff repair construct
11059503|NCT04361266|Active Comparator|Control|Subjects undergoing non-patch augmented rotator cuff repair
11059504|NCT04361253|Experimental|Arm A|Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
11059505|NCT04361253|Placebo Comparator|Arm B|Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)
11059506|NCT04361240||Ancillary Cohort|No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
11059507|NCT04361214|Experimental|Leflunomide|"Leflunomide 300 mg once daily administered for three days followed by 30 mg once daily administered for two days or until fevers abate (maximum ten days of treatment allowed).
~If patients report symptoms attributed to the medication, the dose will be administered at 50 mg once daily for the loading dose followed by 20 mg once daily."
11059508|NCT04361201||Ligament plastic surgery ankle|Patient treated priorly by ligament plastic surgery of lateral ankle plane under arthroscopy
11059509|NCT04361201||Control group|Controlateral ankle
11059510|NCT04361188|Experimental|MAC anesthesia group|Parkinson's disease patients receiving deep brain stimulation under MAC anesthesia.
11059511|NCT04361188|Active Comparator|AAA anesthesia group|Parkinson's disease patients receiving deep brain stimulation under AAA anesthesia.
11059512|NCT04361175|Experimental|letrozole group|letrozole group, Patients will receive 5 mg of letrozole oral tablets daily from day 2 of the cycle for 5 days for three successive cycles
11059513|NCT04361175|Experimental|Clomiphene Citrate group|Clomiphene Citrate group, Patients will receive 100 mg : Clomiphene Citrate daily starting on cycle day 2 for 5 days for three successive cycles
11059514|NCT04361162|Experimental|Nivolumab + Ipilimumab + Radiation|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, (Study cycles are 6 weeks.)
~Nivolumab via iv, at predetermined dose every 2 weeks for duration of study.
~Ipilimumab via iv at a predetermined dose on day 1 of 4 study cycles.
~Radiation treatments will be administered every other weekday or 2 days during week 1 of cycle 1."
11059515|NCT04361149|Placebo Comparator|Placebo Topical|The cream was a lipobase cream, applied topically to the participants upper back, on their left side.
11059516|NCT04361149|Active Comparator|Capsaicin Topical|Capsaicin Cream (0.075%), applied topically to the participants upper back, on their left side.
11059518|NCT04361136|Experimental|Delgocitinib cream 3 mg/g|Single topical occlusive administration
11059519|NCT04361136|Experimental|Delgocitinib cream 8 mg/g|Single topical occlusive administration
11059520|NCT04361136|Experimental|Delgocitinib cream 20 mg/g|Single topical occlusive administration
11059521|NCT04361136|Placebo Comparator|Delgocitinib cream vehicle|Single topical occlusive administration
11059522|NCT04361123||Clients of Atrium Health|daily syndromic surveillance, monthly serologic IgM/G test
11059523|NCT04361123||Health care workers of Atrium Health|daily syndromic surveillance, monthly serologic IgM/G test
11059524|NCT04361110||Acute intestinal ischaemia|Abdominal CT scan within 48 hours preoperative.
11059525|NCT04361110||Controls|Abdominal CT scan within 48 hours preoperative.
11059526|NCT04361097|Experimental|Faecal microbiota transplant|This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
11059527|NCT04361097|Placebo Comparator|Placebo|This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
11059528|NCT04361084|Active Comparator|traditional training|Participants will undertake the Community simulation using traditional methods, physical items to recreate the community environment. Training will be in pairs and will play the role of their own profession when undertaking simulated scenarios. Medium to low fidelity traditional simulation techniques involving scenarios played out using actors as (standardised patients) to participants. Following a briefing, the participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results and are anonymous. They will also complete their pre-questionnaire which will anonymous. Afterwards participants undertake a post-questionnaire and then asked if they wish to take part in a semi-structured interview.
11059529|NCT04361084|Experimental|mixed reality simulation training|Participants will undertake a mixed reality (MR) simulation training session set in two home situations; involving immersive virtual reality equipment. Participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results. The participants will then undertake the simulation watched via live camera by the simulation technician, simulation fellow and a community specialist. Participants will undertake a post simulation questionnaire and then asked if they wish to take part in a semi-structured interview (optional).
11059530|NCT04361071|Active Comparator|Stent|Stent group
11059531|NCT04361071|Active Comparator|Atherectomy|Atherectomy group
11059532|NCT04361058|Experimental|Arm A - HLA-matched unrelated donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with an HLA-matched unrelated donor will be separated into Arm A and treated with Nivolumab post-SCT
11059533|NCT04361058|Experimental|Arm B - HLA-haploidentical donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with a HLA-haploidentical donor will be separated into Arm B and treated with Nivolumab post-SCT
11059534|NCT04361045|Experimental|Intervention Condition|Participants in this condition were delivered 8 weeks of online intervention modules and then were invited to complete a posttest survey.
11059535|NCT04361045|No Intervention|Waitlist Condition|Participants in this condition received no intervention content nor communications for 8 weeks and then were invited to complete a posttest survey.
11059536|NCT04361032|Experimental|Tocilizumab|ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
11059537|NCT04361032|Active Comparator|Deferoxamine|DESFERAL: 500 mg, powder, and solvent for IV solution
11059538|NCT04361006|Active Comparator|Radiofrequency (RF)|Twenty patients will be allocated to this group, which will be treated using radiofrequency (RF) ablation technique.
11059539|NCT04361006|Active Comparator|Cryotherapy (CRYO)|Twenty patients will be allocated to this group, which will be treated using Cryotherapy (CRYO) ablation technique.
11059540|NCT04360993||Patients underwent PET/CT & PET/MRI|Patients with head and neck cancer were underwent PET/CT and PET/MRI for staging, assessment and follow up
11059541|NCT04360980|Active Comparator|Intervention|40 RT-PCR positive COVID-19 patients without hypoxemia administered Colchicine plus standard treatment
11059542|NCT04360980|No Intervention|Standard treatment|40 RT-PCR positive COVID-19 patients without hypoxemia receiving vitamin C 3grams daily , 400 mg Tiamine, Selenium , Omega-3 500 mg daily, Vit A , Vit D, Azithromycine, Ceftriaxone, Kaletra 400 BID 10 days
11059543|NCT04360967|Experimental|Randomized Standard Formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
11059544|NCT04360967|Experimental|Randomized Nutrient-enriched formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
11059545|NCT04360967|No Intervention|Non-randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
11059546|NCT04360967|No Intervention|Non-Randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
11059547|NCT04360954||Acute COVID infection|Active infection with positive RT-PCR
11059548|NCT04360954||Convalescent COVID|Recent documented infection. Now asymptomatic and RT-PCR negative.
11059549|NCT04360954||US Controls|Human samples pre-COVID.
11059550|NCT04360954||LMIC Controls|Samples from LMIC pre-COVID.
11059551|NCT04360941|Experimental|Two-part phase 1b trial of induction palbociclib with avelumab|"Recruitment to Part A will be conducted at the Royal Marsden Hospital only. Up to 18 patients will be recruited for dose escalation of palbociclib in combination with fixed dose avelumab.
~Part B will recruit at up to 8 high volume centres. Up to 27 patients will be recruited to treatment with the maximum tolerated dose and schedule established in part A. In Part B of the study, additional selection by triple negative histology and positive androgen receptor status will define the study population."
11059552|NCT04360928|Experimental|Lake Effect Zero Degree Splinting Group|These patients will be randomized to receive the Lake Effect Zero Degree Splint. Patients will follow the same standardized postoperative rehabilitation protocol.
11059578|NCT04360733||asymptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR but no clinical symptoms
11059553|NCT04360928|Sham Comparator|Standard Hinged Knee Brace|These patients will be randomized to receive a standard hinged knee brace. Patients will follow the same standardized postoperative rehabilitation protocol.
11059554|NCT04360915|Experimental|ASK120067 in fast condition|Take ASK120067 tablets orally once in the first day at 160mg in fast condition.
11059555|NCT04360915|Experimental|ASK120067 in fed condition|Take ASK120067 tablets orally once in the first day at 160mg in fed condition.
11059556|NCT04360902|No Intervention|Standard of Care Group|Subjects in the standard of care group will continue to receive anemia management in the same way they normally do as part of their routine dialysis care. For the purposes of this study, this means the use of the clinic's established Mircera® anemia management algorithm. Participation in this study will not affect the anemia management of subjects in the control group.
11059557|NCT04360902|Experimental|Intervention Group|"For subjects randomized into the intervention group, our erythropoiesis model will be used to identify each subject's individual values for several physiological determinants of erythropoiesis based on his/her sex, body height and history of body weights, Hgb concentrations and Mircera® administrations over the preceding 150 to 180 days.
~For subjects in the intervention group, their current method of anemia management will be discontinued. From this point on, Mircera® dose recommendations will be generated by the Anemia Controller software based on our erythropoiesis model and each subject for the duration of their 26-week participation in this study. The Anemia Controller computes the Mircera® doses required to attain the target Hgb level of 10.5 g/dL. Controller-generated Mircera® recommendations will be communicated to the respective clinics' anemia managers on a standardized report."
11059558|NCT04360889|Experimental|Tocopherol|patients with lower limb lymphedema who will receive conservative therapy with elastic compression and an antioxidant (Tocopherol-400 IU/day) - 90 days
11059559|NCT04360889|Experimental|Micronised purified flavonoid fraction|patients with lower limb lymphedema who will receive conservative therapy with Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)-1000mg/day) in addition to elastic compression - 90 days
11059560|NCT04360889|Other|Elastic compression|patients with lower limb lymphedema who will be treated with elastic compression - 90 days
11059561|NCT04360889|No Intervention|Healthy volunteers|healthy volunteers with no history or clinical signs of venous or lymphatic disease - 90 days
11059562|NCT04360876|Experimental|Dexamethasone|Patients assigned to the dexamethasone arm will receive an intravenous dose of 20 mg once daily from day 1 to day 5 which will be reduced to 10mg once daily from day 6 to day 10. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The time from randomization to time for first medication administration will be 4 hours or less. All infusions - dexamethasone and placebo - will be manufactured by the investigational pharmacy at the University of Colorado.
11059563|NCT04360876|Placebo Comparator|Placebo|Participants randomized to the control group will received placebo intravenously for 10 days, one dose per day. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The placebo infusion bags will be as similar as possible to the dexamethasone infusion bags to ensure blinding.
11059564|NCT04360863||Youth smokers|Participants of Youth Quitline
11059565|NCT04360837|Experimental|PEEP incremental-decremental alveolar recruitment|"installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters
~implementation of recruitment:
~increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O
~decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20
~end inspiratory hold manoeuvre at every PEEP level
~recording closing parameters
~Repeating the above detailed intervention once daily as long as the patient is controlled ventilation."
11059566|NCT04360824|Active Comparator|Standard of Care|1) Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI <30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30kg/m2).
11059567|NCT04360824|Other|Interventional|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI<30 kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
11059568|NCT04360811|Other|Unexposed group : COVID 19 negatif pregant woman|COVID-19 negative women (not immunize
11059569|NCT04360811|Other|Exposed group : COVID 19 positif pregant woman|Women positive for COVID-19 (symptomatic and asymptomatic) COVID-19 negative women with long-standing immunity
11059570|NCT04360798|Experimental|Unilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will only be applied to the affected lower extremities of the participants.
11059571|NCT04360798|Experimental|Bilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will be applied to the both lower extremities of the participants.
11059572|NCT04360785|Experimental|Methotrexate + Adalimumab|Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
11059573|NCT04360785|No Intervention|Adalimumab|Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
11059574|NCT04360759|Experimental|Arm 1: Chloroquine or hydroxychloroquine|Loading dose of 4 tablets (150 mg chloroquine base per chloroquine salt tablet; 155 mg chloroquine base per hydroxychloroquine tablet) at time 0 and 6 hours, followed by a maintenance dose of 2 tablets at time 12 hours, and then twice daily for a total of 7 days.
11059575|NCT04360759|No Intervention|Arm 2: Standard of care|This does not include specific therapy under current guidelines.
11059576|NCT04360746|Active Comparator|Clinical pharmacist intervention group|"all hip fractured patients admitted to D1 subunit in Beit rivka geriatric rehabilitation center. This group will get a clinical pharmacist review of their medication and a pharmaceutical counseling to the medical staff in the first few days of admission (1-5 days post admission)"
11059577|NCT04360746|Other|control group|"The control group will include all hip fractured patients admitted to D2 subunit in Beit rivka geriatric rehabilitation center. This group will not receive any pharmacist intervention during their rehabilitation."
11075039|NCT04251143||Ectasia|Keratoconus, Keratoconus suspects
11059579|NCT04360733||symptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR and light clinical symptoms
11059580|NCT04360733||severe Covid-19|Patients with confirmed SARS-CoV2 PCR and severe clinical symptoms with ICU admission
11059581|NCT04360733||healthy controls|Persons with negative SARS-CoV2 PCR
11059582|NCT04360720|No Intervention|DAPT-Dual antiplatelet therapy|"Subjects randomized to DAPT Control Group will be categorized as high risk of bleeding (see above) and treated with a regimen of ASA combined with ticagrelor for at least 6 months, and after such period ticagrelor may be discontinued (ASA will be continued) at the discretion of the local investigator.
~Subjects randomized to DAPT Control Group who are not categorized as high risk of bleeding (see above) will be treated with a regimen of ASA combined with prasugrel until the end of the study, at Month 12.
~ASA (100 mg/day) + ticagrelor (90 mg twice daily)(pts at high risk of bleeding) Or ASA + prasugrel (10 mg once daily)(pts at no high risk of bleeding)"
11059583|NCT04360720|Experimental|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have ASA discontinued immediately after randomization.
~Subjects randomized to Monotherapy Group who are categorized as high risk of bleeding (see above) will be treated with ticagrelor alone until the end of the study, at Month 12. Subjects randomized to Monotherapy Group who are not categorized as high risk of bleeding (see above) will be treated with prasugrel alone until the end of the study, at Month 12.
~Ticagrelor alone (90 mg twice daily)(pts at high risk of bleeding) Or Prasugrel alone (10 mg once daily)(pts at no high risk of bleeding)"
11059584|NCT04360694|Experimental|Incremental hemodialysis|Procedure: Incremental hemodialysis. It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
11059585|NCT04360694|Active Comparator|Conventional hemodialysis|Procedure: Conventional hemodialysis. It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
11059586|NCT04360681|Experimental|Lofexidine (LFX)|LFX starting dosage is two 0.2 mg LFX tablet taken orally 2 times daily (i.e., 0.8 mg/day). At study visit 2 (Day 3), the dosage is increased to 1.2mg/day (3 tablets, BID). At visit 3 (Day 5), the dose is increased to the target dose of 1.6mg/day (4 tablets, BID). Participants enter the flexible dosing period at visit 4, at which point the LFX dose can be maintained at 1.6 mg/day or decreased to 1.2 mg/day based on symptoms and the clinical judgement of the investigator. The flexible dosing period extends through to visit 6, however, doses will be adjusted during the study as needed.
11059587|NCT04360681|Placebo Comparator|Placebo (PLB)|A placebo drug will be employed as the comparison group to active study drug.
11059588|NCT04360668|Experimental|Muscle Energy Technique combined with Trigger Point Therapy|For this group of participants, combined therapy (Muscle Energy Technique with Trigger Point Therapy) will be used
11059589|NCT04360668|Active Comparator|Muscle Energy Technique|For this group of participants, a single method (Muscle Energy Technique) will be used
11059590|NCT04360668|Active Comparator|Trigger Point Therapy|For this group of participants, a single method (Trigger Point Therapy) will be used
11059591|NCT04360655|Active Comparator|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
11059592|NCT04360655|Experimental|combined with bronchoscopic microwave intervention|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
11059593|NCT04360642|Other|singing arm|"Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.
~Lung function, frailty and health-related quality of life will be assessed by Spirometry, CRQ (chronic respiratory questionnaire), MRC breathlessness scale, Rockwood frailty and Warwick-Edinburgh Mental Well-being Scale (WEMWBS). Participants will be assessed at baseline and then again at completion of the 12-week course.
~Written feedback from participants to capture qualitative experience using narrative and Patient Reported Outcome Measures (PROMs). The attrition and attendance rate will also be recorded for later review."
11059594|NCT04360629|Experimental|high dose TXA|TXA will be given as a 20mg/kg bolus followed by infusion of 5mg/ kg/hr per our anesthesia protocol
11059595|NCT04360629|Experimental|low dose TXA|TXA will be given as a 10mg/kg bolus followed by infusion of 1mg/ kg/hr per our anesthesia protocol
11059596|NCT04360629|Placebo Comparator|normal saline|saline will be given as a 4ml/kg bolus followed by infusion of 1ml/ kg/hr per our anesthesia protocolprotocol4ml/kg
11059597|NCT04360616||MG+|the lesion could detected by mammography
11059598|NCT04360616||US+|the lesion could detected by breast ulrtasound
11059599|NCT04360603|Experimental|27 gauge system|study group, using 27G vitrectomy system
11059600|NCT04360603|Active Comparator|25 gauge system|control group, using 25G vitrectomy system
11059601|NCT04360577|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
11059602|NCT04360577|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (one cycle of chemotherapy) for 9 weeks (3 cycles of chemotherapy)
11059603|NCT04360577|No Intervention|Usual care|Chemotherapy without acupuncture
11059604|NCT04360564||Recurrent pregnancy loss|All women with >/=2 pregnancy loss before 20 weeks gestational age
11059605|NCT04360564||Primary recurrent pregnancy loss|Primary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age before the first birth
11059606|NCT04360564||Secondary recurrent pregnancy loss|Secondary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age occurring after the first birth
11059607|NCT04360564||No history of recurrent pregnancy loss|Those with 0 or 1 previous spontaneous pregnancy loss.
11059608|NCT04360551|Experimental|Telmisartan|Telmisartan 40 mg po daily x 21 days
11059609|NCT04360551|Placebo Comparator|Placebo|Placebo
11059610|NCT04360538||COVID19 positive|ICU patients coronavirus positive
11059611|NCT04360538||non-COVID19|ICU patients without coronavirus
11059612|NCT04360525||Elderly patients|Elderly patients (60≤ age) with sigmoid volvulus
11059613|NCT04360525||Young patients|Young patients (<60 age) with sigmoid volvulus
11059614|NCT04360512|Experimental|One session|One session of talus posteriorization
11059615|NCT04360512|Experimental|Two sessions|Two sessions of talus posteriorization
11059616|NCT04360512|Experimental|Three sessions|Three sessions of talus posteriorization
11059617|NCT04360512|Experimental|Four sessions|Four sessions of talus posteriorization
11059618|NCT04360499|Experimental|Low-weight-high-repetitions training|Low-weight-high-repetitions (LWHR) refer to a specific form of resistance exercise which utilizes low weights and very high repetitions. Participants will be exercised 3 times per week for 3 months in small groups.
11059619|NCT04360499|Active Comparator|Pilates Training|Pilates exercises focused on breathing, concentration, control and precision. Participants will be exercised 3 times per week for 3 months in small groups
11059620|NCT04360473|Active Comparator|Placebo group|The patients in this group will receive general balanced anesthesia
11059621|NCT04360473|Experimental|Ketamine group|The patients in this group will receive 0.3 mg / kg of ketamine in saline (total volume of 100 ml) 15 min before general balanced anesthetic induction
11059622|NCT04360473|Experimental|Magnesium sulfate group|The patients in this group will receive 40 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
11059623|NCT04360473|Experimental|Magnesium / ketamine group|The patients in this group will receive 0.15 mg / kg of ketamine + 20 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
11059624|NCT04360460|Experimental|Experimental|Virtual reality followed by translation into related functional tasks in a real life setting for 2 weeks + conventional therapies
11059625|NCT04360460|Active Comparator|Control|Virtual reality followed by translation into non-related functional tasks in a real life setting for 2 weeks + conventional therapies
11059626|NCT04360447|Experimental|Reformer pilates group|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
11059627|NCT04360447|Active Comparator|Home exercise group|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
11059628|NCT04360434|Experimental|NI006|Dose escalation in up to 6 dose cohorts. Subjects will be administered a single dose of NI006 in the SAD, multiple doses of NI006 in the MAD and OLE phases.
11059629|NCT04360434|Placebo Comparator|Placebo|"Subjects will be administered a single dose of placebo in the SAD phase and multiple doses of placebo in the MAD phase.
~In the OLE phase, all subjects will be administered multiple doses of NI006."
11059630|NCT04360421|Experimental|Intraoperative liposomal bupivacaine field block|
11059631|NCT04360408|Experimental|Intervention|Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.
11059632|NCT04360408|No Intervention|Control|Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers
11059633|NCT04360395|No Intervention|Neurotypical Youth/Young Adults|No intervention administered. The controls will only undergo initial baseline assessments.
11059634|NCT04360395|Experimental|Cerebral Palsy Youth/Young Adults|Baseline and 8 week assessments; 8 week gait therapy
11059635|NCT04360382||Enhanced recovery|"Part I: Preoperative evaluation and preparation:
~Part II: Postoperative daily intervention:
~Part III: Expected daily outcome :
~Phase three: Implementing enhanced recovery program:
~The established pathway will implement on the study group by researcher from admission till discharge as conventional care group assessment in phase one.
~Phase four: Evaluating enhanced recovery program outcomes:
~The efficacy of enhanced recovery program will be determined by comparing outcomes for patients of both control and study groups"
11059636|NCT04360382||Regular care|usual care for all cases of cesarean section at our hospital.
11059637|NCT04360369|Active Comparator|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
11059638|NCT04360369|Active Comparator|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
11059639|NCT04360369|Experimental|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
11059640|NCT04360356|Experimental|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
11059641|NCT04360356|Active Comparator|Standard care|Oxygen via ventilators
11059642|NCT04360343|Experimental|LC51-0255 film-coated tablet|Drug: LC51-0255
11059643|NCT04360343|Active Comparator|LC51-0255 uncoated tablet|Drug: LC51-0255
11059644|NCT04360330|Experimental|Preoperative SABER|"Experimental: Preoperative Stereotactic Ablative Breast Radiotherapy (SABER). Phase I study testing up to 4 dose levels.
~Non-experimental: Participants will undergo standard partial mastectomy and axillary surgery as per discretion of treating physician 4 to 6 weeks (+ at most 1 week delay) after preoperative SABER is completed."
11059645|NCT04360317|Experimental|Experimental group|
11059646|NCT04360304|Experimental|Study group|
11059647|NCT04360291||Healthy volunteers|Healthy volunteers
11059648|NCT04360291||Retinopathy pigment|Patients with retinopathy pigment
11059649|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
11059650|NCT04360265||ABO-102|Participants from prior interventional trials involving the administration of ABO-102.
11059651|NCT04360252|Experimental|Gracie Diet|Patients will have a nutritional consultation and will follow the Gracie diet for a month.
11059652|NCT04360239|Experimental|Fish Oil|Fish-Oil naïve subjects will be started on fish oil 4 weeks prior to surgery and continued until the 6 week follow up. Subjects already taking fish oil will be switched to the study fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
11059653|NCT04360239|No Intervention|Control|No fish oil supplementation
11059654|NCT04360213||Children with Asthma|"Patients ages 1 to 17 years old
~Patients in the Emergency Department or admitted to the hospital for asthma exacerbation."
11059655|NCT04360213||Children with allergy|"Patients ages 1 to 17 years old
~Patients scheduled to do an oral food challenge"
11059656|NCT04360200||Normal Aging|Normal Aging with normal cognitive function
11059657|NCT04360200||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
11059658|NCT04360187|Experimental|Crisaborole ointment|Crisaborole ointment application twice daily for 28 days
11059659|NCT04360187|Placebo Comparator|Crisaborole Placebo Vehicle|Vehicle Ointment application twice daily for 28 days
11059660|NCT04360174|Experimental|OTX-TIC-Cohort 1|15 µg (formulation1) implant
11059661|NCT04360174|Experimental|OTX-TIC-Cohort 2|26 µg (formulation1) implant
11059662|NCT04360174|Experimental|OTX-TIC-Cohort 3|15 µg (formulation 2) implant
11059663|NCT04360174|Experimental|OTX-TIC-Cohort 4|5 µg (formulation 3) implant
11059664|NCT04360161|Experimental|Healthy participants|Swept-source optical coherence tomography A device testing TM/SC and Lens morphology
11059665|NCT04360148|Experimental|Very-low-calorie-ketogenic-diet|Very-low-calorie-ketogenic-diet (VLCKD) for 12 weeks; hypocaloric-balanced-diet (HBD)
11059666|NCT04360148|Active Comparator|Hypocaloric-balanced-diet|Hypocaloric-balanced-diet (HBD)
11059667|NCT04360135|Experimental|Preemptive acetominophen|Acetaminophen 975mg BID the day before surgery and again 30-60 minutes preoperatively
11059668|NCT04360135|Placebo Comparator|Standard of care|Placebo the day before surgery and acetaminophen 30-60 minutes preoperatively
11059669|NCT04360122|Active Comparator|Levamisole|Oral Levamisole 150 mg/day for two days per week for two months
11059670|NCT04360122|Active Comparator|Isoprinosine|Oral Isoprinosine 1 g 3 times per day daily for two months
11059671|NCT04360122|Active Comparator|Levamisole and Isoprinosine|Oral Levamisole 150 mg/day for two days per week and Oral Isoprinosine 1 g 3 times per day daily for two months
11059672|NCT04360122|No Intervention|Non-interventional group|No-intervention
11059673|NCT04360096|Experimental|Moderate COVID-19 RLF-100|Patients with Moderate COVID-19 to be treated with inhaled RLF-100 (aviptadil) by mesh nebulizer 100μg 3x daily
11059674|NCT04360096|Experimental|Moderate COVID-19 Placebo|Patients with Moderate COVID-19 to be treated with inhaled placebo 3x daily
11059675|NCT04360096|Experimental|Severe COVID-19 RLF-100|Patients with Severe COVID-19 to be treated with inhaled RLF-100 (aviptadil) by mesh nebulizer 100μg 3x daily
11059676|NCT04360096|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
11059677|NCT04360083||Overweight and obese children|Overweight and obese children included in RéPPOP care programs between 2007 and 2010.
11059678|NCT04360070|Experimental|Ketamine Arm|Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
11059679|NCT04360070|No Intervention|Control Arm|Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
11059680|NCT04360057|Other|Hand Hygiene education|
11059681|NCT04360044|Experimental|THC ~5%|4 puffs of cannabis flower containing THC ~5% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
11059682|NCT04360044|Experimental|THC ~5%/CBD ~12%|4 puffs of cannabis flower containing THC ~5% and CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
11059683|NCT04360044|Experimental|CBD ~12%|4 puffs of cannabis flower containing CBD ~12% administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
11059684|NCT04360044|Sham Comparator|Sham Cannabis|4 puffs of cannabis flower from which the THC and CBD have been extracted administered by vaporizer using Foltin Uniform Puff Procedure for treatment of a moderate-severe migraine attack. The flower is from the United States National Institute on Drug Abuse (NIDA).
11059685|NCT04360031||Tacrolimus / Mycophenolate Mofetil|All patients receive maintenance immunosuppressive treatment of tacrolimus in combination with Mycophenolate Mofetil.
11059686|NCT04360018|Active Comparator|arm one|participants receive alcohol beverage
11059687|NCT04360018|Placebo Comparator|arm two|Placebo
11059688|NCT04359979|Experimental|tamsulosin treatment|patients will receive 0.4mg/day of Tamsulosin tablet for 3 months
11059689|NCT04359966|Active Comparator|First line therapy for H pylori infection|Tripple 14 day first line therapy Esomeprazole 40 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg, all BID 14 days
11059690|NCT04359966|Experimental|First line therapy for H pylori infection second arm|"Bismuth quadruple first line therapy
~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
11059691|NCT04359966|Active Comparator|Second line therapy for H pylori infection|"Bismuth quadruple second line therapy for those treated with Tripple first line therapy
~Bismuth subcitrat 120 mg , Amoxicillin 500 mg, Metronidazole 400 mg, all QID, Esomeprazole 40 mg BID, 14 days."
11059692|NCT04359966|Experimental|Second line therapy for H pylori infection second arm|"Tripple second line therapy
~Esomeprazol 40 mg BID Amoxicillin 1000 mg BID, Levofloxacin 500 mg OID, 14 days or"
11059693|NCT04359953|Experimental|Hydroxychloroquine|Patient will take 200mg of Hydroxychloroquine twice a day during 14 days
11059694|NCT04359953|Experimental|Azithromycin|Patient will take 250mg of Azithromycin twice a day during 14 days
11059695|NCT04359953|Experimental|Telmisartan|Patient will take 40mg of Telmisartan twice a day during 14 days
11059696|NCT04359953|No Intervention|Usual Care|No intervention
11059697|NCT04359940||Repaired Tetralogy of Fallot|Patients undergoing routine clinical aand CMR surveillance
11059698|NCT04359927||SARS-CoV2/Covid-19 (cases)|Patients with detectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
11059699|NCT04359927||No SARS-CoV2/Covid-19 (controls)|Patients with undetectable real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2/Covid-19.
11059700|NCT04359914||NCoV-A-COVID|"adult patients of every age
~admission to hospital with suspected COVID-19 disease
~confirmed SARS-CoV-2 infection within 48 hours after admission"
11059701|NCT04359914||NCoV-A-CONTROL|"adult patients of every age
~admission to hospital with suspected COVID-19 disease
~exclusion of SARS-CoV-2 infection within 48 hours after admission"
11059702|NCT04359914||NCoV-P-COVID|"pediatric patients
~admission to hospital with suspected COVID-19 disease
~confirmed SARS-CoV-2 infection within 48 hours after admission"
11075710|NCT04246489|Experimental|Bintrafusp alfa|
11059703|NCT04359914||NCoV-P-CONTROL|"pediatric patient
~admission to hospital with suspected COVID-19 disease
~exclusion of SARS-CoV-2 infection within 48 hours after admission"
11059704|NCT04359901|Active Comparator|Standard of care plus subcutaneous sarilumab|Standard of care as directed by the treating clinicians, plus sarilumab 400 mg subcutaneous injection. Sarilumab is provided in prefilled syringes/pens containing 200 mg each as is used clinically, and both injections will be given as soon as is convenient after the patient has decided to enroll.
11059705|NCT04359901|No Intervention|Standard of care|Standard of care as directed by the treating clinicians.
11059706|NCT04359888||MCET Group|Multi-Component Exercise Training (MCET) Group
11059707|NCT04359888||BRT Group|Balanced Reach Training Group
11059708|NCT04359875|Experimental|Management by a student/general practitioner tandem|Patients will receive a phone call from the medical student who will inquire about their health. The medical student will then transmit this information to the general practitioner who will decide on the most suitable management for the patient.
11059709|NCT04359875|No Intervention|Usual care|"Usual care, i.e. patients will call their general practitioner when needed, up to 1 month, which corresponds to the estimated time for the intervention to be delivered to all patients in the intervention group.
~At the end of the intervention at 1 month, patients in the usual care group will also receive a phone-call from the medical student/general practitioner tandem."
11059710|NCT04359862|Experimental|SEVOFLURANE Group|
11059711|NCT04359862|Active Comparator|PROPOFOL Group|
11059712|NCT04359836||General Population|The general population will have their microbiome sequenced from stool samples provided.
11059713|NCT04359823|Experimental|Statin/Cholesterol Combination Group|This arm will utilize 2% cholesterol and 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
11059714|NCT04359823|Experimental|Statin Alone Group|This arm will utilize 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
11059715|NCT04359810|Experimental|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent plasma (1 unit; ~200-250 mL) collected from a volunteer who recovered from COVID-19 disease
11059716|NCT04359810|Active Comparator|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (1 unit; ~200-250 mL) of standard plasma collected prior to December 2019
11059717|NCT04359797|Active Comparator|Usual Care|Participants randomized to this arm will remain in their natural choice of position, which is anticipated to favor a supine, semi-recumbent position.
11059718|NCT04359797|Active Comparator|Prone|Participants randomized to this arm will be encouraged to lay in a completely prone position for as much time as is tolerable during hospitalization.
11059719|NCT04359784|Experimental|Prevention (anakinra, axicabtagene ciloleucel)|Patients receive anakinra SC daily on days 0-13 and axicabtagene ciloleucel via infusion on day 0.
11059720|NCT04359771|Active Comparator|Yellow MPL|
11059721|NCT04359771|Active Comparator|Diode MPL|
11059722|NCT04359758|Experimental|Proactive Streamlined Genetic Education and Testing|Participants randomized to this arm will proactively receive genetic education print materials and the option to proceed directly with genetic testing.
11059723|NCT04359758|Active Comparator|Usual Care|Participants in this arm will be sent a referral letter recommending that they schedule a genetic counseling session and providing them with contact information to do so.
11059724|NCT04359732|Other|Hybrid PET/MRI|For the purposes of the study, in addition to standard imaging (EUS and CT scan), a fully integrated hybrid PET/MRI (PET/MRI) study with FDG will replace the Standard PET (pre-surgical evaluation) used for evaluating distant metastases and will be considered as the add-on procedure at three time points. The additional evaluation for patients is that during nCRT treatment.
11059725|NCT04359719||Group mild melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.
~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.
~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
11059726|NCT04359719||Group Moderate-severe melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.
~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.
~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
11059727|NCT04359706||Covid-19 group|Critically ill patients with SARS-CoV-2 infection
11059728|NCT04359706||control group|Historical critically ill patients with no SARS-CoV-2 infection
11059729|NCT04359693||SARS-CoV2 group|Patients receiving invasive mechanical ventilation for more than 48h with SARS-CoV-2 infection
11059730|NCT04359693||Flu group|Patients receiving invasive mechanical ventilation for more than 48h with influenza infection
11059731|NCT04359693||No viral infection group|Patients receiving invasive mechanical ventilation for more than 48h with no viral infection at ICU admission
11059732|NCT04359680|Active Comparator|Nitazoxanide|Two NTZ 300 mg tablets orally twice daily for 6 weeks.
11059733|NCT04359680|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks.
11059734|NCT04359667||tocilizumab|one infusion of TCZ 8 mg/kg i.v., with a maximum dose of 800 mg, and SOC treatment according to local guidelines (hydroxychloroquine or/and lopinavir/ritonavir or/and remdesivir).
11059735|NCT04359654|Experimental|Dornase alfa treatment|Best available care and nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure
11059736|NCT04359654|No Intervention|Best available care|Best available standard of care
11059737|NCT04359641|Experimental|CoMET Display|Display of Continuous Monitoring of Event Trajectories (CoMET) predictive monitoring score, with standard CoMET device training.Risk scores will also be presented daily during rounds to members of the care team.
11059738|NCT04359641|No Intervention|No Display|Standard CoMET device training but no display or presentation of predictive monitoring score.
11059739|NCT04359628||BOA|Patients with osteoarthritis registered in the Better BOA register
11059740|NCT04359628||Swedankle|Patients who underwent ankle replacement, fusion or osteotomies and registered in the Swedish ankle registry
11059741|NCT04359628||xBase|Patients with cruciate ligament injuries who received surgical treatment and were registered in the Anterior Cruciate Ligament Register
11059742|NCT04359628||SFR|Patients who received treatment in the Swedish Fracture Register
11059743|NCT04359628||SHAR|Patients who underwent hip replacement therapy and registered in the Swedish Hip Arthroplasty Register
11059744|NCT04359628||SKAR|Patients with knee osteoarthritis and other diagnoses who underwent knee replacement or osteotomies and were registered in the Swedish Knee Arthroplasty Register
11059745|NCT04359628||Bipolär|Patients with Bipolar disorder receiving treatment and were registered in the Swedish National Register for Bipolar Disorder
11059746|NCT04359628||Swedevox|Patients with respiratory failure receiving technical respiratory assistance and were registered in the Swedish National Registry for Respiratory Failure
11059747|NCT04359628||PsoReg|Patients receiving systemic treatment for psoriasis and were registered in the Swedish Registry for Systematic Psoriasis Treatment
11059748|NCT04359628||SRQ|Patients with rheumatic disease receiving medical treatment and rehabilitation and were registered in the Swedish Rheumatology Quality Register
11059749|NCT04359628||SwedeHF|Patients who received treatments of different types in the Swedish Heart Failure Registry
11059750|NCT04359628||Swespine|Patients with spinal stenosis, disc hernia and related diagnoses receiving surgical spine treatment and were registered in the Swedish Spine Register
11059751|NCT04359628||Population health survey|Data of members of the general population who answered population surveys using the EQ-5D-3L instrument
11059752|NCT04359615|Experimental|Favipiravir|
11059753|NCT04359615|Active Comparator|Control|
11059754|NCT04359589||Acute myocardial infarction (AMI) group|"700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases."
11059755|NCT04359589||Acute ischemic stroke group|"500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
11059756|NCT04359589||Acute lower limb ischemia group|"500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
11059757|NCT04359589||Control group|200 healthy volunteers were included as controls
11059758|NCT04359576||FET|Estrogen/progesterone substituted and natural cycles
11059759|NCT04359563|Experimental|Mindfulness-Based Intervention|The MBI programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on the investigator's ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
11059760|NCT04359550|Experimental|treatment group|ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
11059761|NCT04359550|Placebo Comparator|control group|placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
11059762|NCT04359537|Experimental|Arm 1|Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks
11059763|NCT04359537|Experimental|Arm 2|Hydroxychloroquine Sulphate will be admoinistered at a dose of 400 mg on day 1 followed by 400mg once every 3 weeks for at total of 12 weeks
11059933|NCT04358393|Experimental|APG115 150mg|APG115 150mg PO QD D1-5/every 28 days
11059764|NCT04359537|Experimental|Arm 3|Hydroxychloroquine Sulphate will be administered at a dose of 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
11059765|NCT04359537|Placebo Comparator|Arm 4|Control group will recieve Placebo 200mg on day 1 followed by Placebo 200mg every three weeks for 12 weeks
11059766|NCT04359524|Active Comparator|Intervention|Received vitamin D3 capsules (1200 IU/30µg).
11059767|NCT04359524|Placebo Comparator|Control|Received placebo (oil capsules).
11059768|NCT04359511|Experimental|corticosteroid + Optimized Standard of Care|"prednisone 0.7 mg/kg/day for 10 days, administered orally, once a day, or
~hydrocortisone hemisuccinate 3.5 mg/kg/day by continuous infusion for 10 days, administered by IV route if the patient cannot take drugs by oral route,
~standard of care"
11059769|NCT04359511|No Intervention|Optimized Standard of Care|standard of care
11059770|NCT04359498||LAR for rectal cancer|Retrospective chart review for surgical complications related to the LAR surgery, the stoma (diverting loop ileostomy) creation and the stoma reversal procedure after LAR for rectal cancer.
11059771|NCT04359485|Experimental|glycolic acid peel|
11059772|NCT04359485|Placebo Comparator|Saline|
11059773|NCT04359472|Other|Treatment Arm|Collection and reapplication of amniotic fluid.
11059774|NCT04359459||Mild COVID-19|Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
11059775|NCT04359459||Severe COVID-19|Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
11059776|NCT04359459||Very Severe COVID-19|Patients with very severe disease admitted to intensive care, who require mechanical ventilation.
11059777|NCT04359446|Other|Stent under-expansion with NC Balloon|
11059778|NCT04359446|Other|Stent under-expansion with Laser Excimer + NC Balloon|
11059779|NCT04359433|No Intervention|Standard group|The participates in this group would provide normal health education of scientific and rational diet.
11059780|NCT04359433|Experimental|Exercise intervention group|Besides normal health education of scientific and rational diet，the participates in this group would be suggested to carry out an anaerobic exercise named Tabata.
11059781|NCT04359420|Experimental|BC-Predict|"Women will be sent an invitation letter one to two days after their breast screening invitation letter, directing prospective participants to the online risk assessment platform. Once participants have consented to the study online, they will be directed to the BC-Predict risk assessment questionnaire. Assessment of the online questionnaire during the pilot phase estimated that most women would be able to complete this within 30 minutes.
~Women who complete the questionnaire will receive 10-year breast cancer risk estimates once they have screened negative for breast cancer, based on the Tyrer-Cuzick model, incorporating mammographic density, and for some women, SNPs (single nucleotide polymorphisms). Women who are identified as being at high (>8%) or moderate (5% and <8%) 10-year risk will be offered a consultation to discuss prevention options including prescription of chemoprevention drugs and/ or more frequent mammography as part of the NHS Breast Screening Programme."
11059782|NCT04359420|Active Comparator|NHS-Breast Screening Programme|Usual care in the NHS Breast Screening Programme, which involves mammography every 3 years for the majority of women
11059783|NCT04359394||PP patients|patients with active PP
11059784|NCT04359381|Experimental|kinesiotaping|by kinesiotaping during menstruation for 3 successive menstruation
11059785|NCT04359381|Experimental|pilate exercises|pilate exercises, 3 sessions per week for 3 months
11059786|NCT04359368||patients with hypersensitivity reactions to NDIPs|Patients with previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject) or to iron sucrose (Venofer)
11059787|NCT04359355||Artificial Intelligence|
11059788|NCT04359342|Experimental|HIIT + protein|High-intensity interval training (HIIT) combined with protein supplementation
11059789|NCT04359342|Placebo Comparator|HIIT + placebo|High-intensity interval training (HIIT) combined with placebo
11059790|NCT04359342|Experimental|HIIT and resistance training + protein|High-intensity interval training (HIIT) and resistance training combined with protein supplementation
11059791|NCT04359342|Placebo Comparator|HIIT and resistance training + placebo|High-intensity interval training (HIIT) and resistance training combined with placebo
11059792|NCT04359329|Experimental|Active|Estradiol Patch
11059793|NCT04359329|No Intervention|Control|No intervention
11059794|NCT04359316|Experimental|Azithromycin|
11059795|NCT04359316|Active Comparator|Hydroxychloroquine|
11059796|NCT04359303|No Intervention|CONTROL|Base WHO recommended treatment.
11059797|NCT04359303|Experimental|TREATMENT|Base WHO recommended treatment + Systemic indirect endovenous ozone therapy
11059798|NCT04359290|Experimental|Ruxolitinib treatment|Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days
11059799|NCT04359277|Experimental|Higher-dose anticoagulation|
11059800|NCT04359277|Experimental|Lower-dose prophylactic anticoagulation|
11059801|NCT04359264|Experimental|Cash transfer|
11059802|NCT04359264|No Intervention|Control|
11059803|NCT04359251|Experimental|Optimizing oxygenation|Best oxygenation during PEEP titration
11059804|NCT04359251|Experimental|Optimizing compliance|Best compliance during PEEP titration
11059805|NCT04359251|Experimental|ARDSnet|PEEP settings according to ARDSnet table
11059806|NCT04359238|Active Comparator|Intervention group with motivation messages|There are 100 patients in the intervention group with automated or observer initiated motivation messages. They receive an individualized training program with regular notifications about their training status via their SmartWatch.
11059807|NCT04359238|Active Comparator|Intervention group without motivation messages|There are 100 patients in the intervention group without automated or observer initiated motivation messages. They receive an individualized training program without regular notifications about their training status via their SmartWatch.
11059808|NCT04359238|No Intervention|Control group|100 patients are in the control group without an individualized training program.
11059809|NCT04359225|Active Comparator|3D telemedicine|3D telemedicine system
11059810|NCT04359225|Placebo Comparator|2D telemedicine|2D telemedicine system (standard care)
11059811|NCT04359212||Medical|subject with a confirmed infection for COVID-19 and needing admission to a medical division for a non-severe clinical disease
11059812|NCT04359212||Intensive|subject with a confirmed infection for COVID-19 and needing admission to an Intensive Cure Unit for a severe to critical disease
11059813|NCT04359199||Radiotherapy with chemotherapy|Patients treated with definitive RT and chemotherapy (cisplatin) or targeted therapy (cetuximab)
11059814|NCT04359199||Radiotherapy with immunotherapy|Patients treated with definitive RT and immunotherapy (pembrolizumab, nivolumab, or durvalumab)
11059815|NCT04359186|Experimental|Treatment Interruption Arm|
11059816|NCT04359173||Hypothermic machine perfusion (HMP)|patients who underwent kidney transplantation following HMP
11059817|NCT04359173||Static cold storage (SCS)|patients who underwent kidney transplantation following SCS
11059818|NCT04359160|Experimental|Mobile-app follow-up|The mobile app follow-up group will receive an email, to connect into a secure website. They will answer to periodical questions about their condition. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative. All of this information is submitted via the mobile application (Orthense, Digikare Inc. Blagnac, France).The surgeon will have an access to the answer of the patient in real time, and if the patient didn't answer.
11059819|NCT04359160|Active Comparator|Conventional follow-up|Patients in the conventional, questionnaire follow-up group will have the same periodical questions but on paper. They will have to stick personally with the schedule without any reminders. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative where they have to bring the questionnaire.
11059820|NCT04359147|Active Comparator|Yohimbine|10 mg
11059821|NCT04359147|Active Comparator|Hydrocortisone|10 mg
11059822|NCT04359147|Active Comparator|Yohimbine + Hydrocortisone|10 mg each
11059823|NCT04359147|Placebo Comparator|Placebo|
11059824|NCT04359121||Physicians|Questionnaires
11059825|NCT04359121||Medical staff|Questionnaires
11059826|NCT04359121||General public|Questionnaires
11059827|NCT04359121||Patients with psychiatric disorders|Questionnaires
11059828|NCT04359108|Experimental|Navigation system for users of a visual prosthesis|This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
11059829|NCT04359095|Active Comparator|I1 Emtricitabine + Tenofovir|Intervention 1: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days
11059830|NCT04359095|Active Comparator|I2 Colchicine + rosuvatatine|Intervention 2: Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
11059831|NCT04359095|Active Comparator|I3 Emtricitabine/ tenofobir + colchicine+ rosuvastatin|Intervention 3: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days + Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
11059832|NCT04359095|Other|I4 Standard Treatment|Intervention 4: Standard treatment. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient, might include Dexamethasone. No viral therapies are included.
11059833|NCT04359082|Placebo Comparator|Placebo|Placebo for 8 straight days
11059834|NCT04359082|Experimental|Bioflavanol|Bioflavanol supplementation for 8 days at 900 mg flavanol per day
11059835|NCT04359069|Experimental|Urinary catheter removal on postoperative day 1|
11059836|NCT04359069|Active Comparator|Urinary catheter removal on postoperative day 3|
11059837|NCT04359056|No Intervention|control|patients for the observational phase. This corresponds to usual cares where no clinical pharmacy activities will be performed
11059838|NCT04359056|Experimental|Interventional|patients for the interventional phase where clinical pharmacy activities will be performed at each step of the care pathway: from hospitalization to home care.
11059839|NCT04359043|Experimental|Mediational Intervention for Sensitizing Caregivers|Half of the child participants and the careworkers in the Community-based Organization taking care of them, received the Mediational Intervention for Sensitizing Caregivers.
11059840|NCT04359043|Other|Treatment as Usual|The other half of child participants and the careworkers in the Community-based Organization taking care of them, received Treatment as Usual which consists of the usual services delivered to children at the CBO: food, help with homework, registrations for birth certificates.
11059841|NCT04359030||Freestyle group|Patients treated with a Freestyle aortic valve bioprosthesis
11059842|NCT04359030||Perimount group|Patients treated with a Perimount aortic valve bioprosthesis
11059843|NCT04359017|Experimental|Lidocaine Hematoma Block|
11059844|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
11059845|NCT04358978|Active Comparator|posterior mesh no attachment|laparoscopic sacral colpopexy with no fixation of posterior mesh
11059846|NCT04358978|Active Comparator|posterior mesh attachment|laparoscopic sacral colpopexy with fixation of posterior mesh by suture
11059847|NCT04358965|Experimental|intravenous tranexamic acid|patients were given a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision plus one vaginal placebo tablet 1 hour before skin incision
11059848|NCT04358965|Active Comparator|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
11059849|NCT04358965|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
11075711|NCT04246476||Parkinson disease|People living with Parkinson disease.
11059850|NCT04358952||COVID + patients|Major patients hospitalized for respiratory criteria for SARS-Cov-2 infection confirmed by RT-PCR
11059851|NCT04358939|Experimental|Prone decubitus group|Prone positioning of patients on nasal high-flow oxygen therapy with usual care
11059852|NCT04358939|No Intervention|Control group|Patients on nasal high-flow oxygen therapy with usual care and positioned in supine
11059853|NCT04358926|Active Comparator|Hyperbaric oxygen therapy|8 sessions in 4 days hyperbaric oxygen therapy
11059854|NCT04358926|No Intervention|Control|Standard of care
11059855|NCT04358913|Experimental|MR Imaging on the Alberta linac-MR P3 system|All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
11059856|NCT04358900||Mood disorder group|Participants must meet criteria for one of the following disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 criteria (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, cyclothymia. Multiple mood disorders are employed, in line with the Research Domain Criteria (RDoC; (53)) framework and the relative imprecision of current symptom diagnostic clusters for tracking treatment responses and course of disease. To ensure adequate representation across diagnostic categories (including controls), the investigators will cap enrollment of major mood disorders (MDD, BD type I/II) to 50%, PDD and cyclothymia to 25% and recruit a healthy comparison group to comprise the remaining 25% of the sample.
11059857|NCT04358900||Control group|Participants who do not meet the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, or cyclothymia.
11059858|NCT04358887|Experimental|periapical surgery with piezo.|After flap reflection bone and root end cutting are done with US6 piezoelectric surgical insert
11059859|NCT04358887|Active Comparator|Periapical surgery with bur.|After flap reflection bone and root end cutting are done with surgical bur.
11059860|NCT04358874|Experimental|Active follow-up|Participants randomized to the active follow-up arm will have follow-up visits in the AKI follow-up clinic every 4 weeks after discharge for a total of 90 days after discharge
11059861|NCT04358874|Active Comparator|Usual follow-up|Participants randomized to the usual follow-up arm will be called at home 4 weeks after the baseline visit to collect information on primary and secondary outcomes.
11059862|NCT04358861|Experimental|Experimental group|Nonsurgical Root canal therapy was performed using dental operating microscope in the experimental group.
11059863|NCT04358861|Active Comparator|Control group|Nonsurgical Root canal therapy was performed without any magnification aid in control group.
11059864|NCT04358835|Experimental|Intubated patients with COVID-19 on a ketogenic diet only|4:1 ketogenic diet formula
11059865|NCT04358822|Active Comparator|30 second cord clamping|Infants in this group will receive delayed cord clamping for 30 seconds.
11059866|NCT04358822|Active Comparator|120 second cord clamping|Infants in this group will receive delayed cord clamping for 120 seconds.
11059867|NCT04358809|Experimental|Suspension of Mw + Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days + Standard therapy of COVID-19
11059868|NCT04358809|Placebo Comparator|Placebo|0.3 ml (0.1ml x 3 Injection) of intradermal Placebo for 3 consecutive days + Standard therapy of COVID-19
11059869|NCT04358796|Experimental|HBOT environment|Cognitive testing in 2ATA, 100% oxygen in breathing-masks
11059870|NCT04358796|Sham Comparator|Control environment|Cognitive testing in 1ATA, air in breathing-masks
11059871|NCT04358783|Experimental|Plasma|Convalescent plasma from cured COVID-19 patients y Supportive management depending on individual needs
11059872|NCT04358783|Experimental|Best Available Therapy|Will receive supportive management depending on individual needs including.
11059873|NCT04358770|Experimental|Test|Clocortolone Pivalate Cream, 0.1%
11059874|NCT04358770|Active Comparator|Reference|Cloderm® (clocortolone pivalate) Cream, 0.1%
11059875|NCT04358757||Cesarean patients|participants undergoing elective cesarean will have measures of recovery assessed (patient-reported outcome measures and activity data from watch)
11059876|NCT04358731|Experimental|NmCV-5|"A total of 1640 subjects 18 to 85 years of age will be accrued contemporaneously across three age groups - 18 to 29 years, 30 to 60 years, and 61 to 85 years.
~Within each age group subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.
~The NmCV-5 subjects in 18-29 year age group will be further randomized 1:1:1 into three different lots (Lot A, B & C) of NmCV-5.
~Total 1230 subjects will be enrolled in NmCV-5 arm."
11059877|NCT04358731|Active Comparator|Menactra|"Subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.
~In Menactra arm, total 410 subjects will be enrolled."
11059878|NCT04358718|Active Comparator|general anesthesia|Patients in this group will receive general anesthesia with intraoperative and postoperative intravenous opioid-based analgesia.
11059879|NCT04358718|Experimental|general analgesia combined with epidural analgesia|Patients in this group will receive combined epidural and general anesthesia with intraoperative and postoperative epidural ropivacaine-based analgesia.
11059880|NCT04358705||Young Cigarillo User (YCU) Sample|Aim 1: Online survey Aim 2: Eye tracking activity Aim 3: Online Experimental Marketplace
11059881|NCT04358705||Aim 2 - Non-cigarillo users|Aim 2: Eye tracking activity
11059882|NCT04358692|Experimental|Surgical Aortic Valve Replacement|Patients with aortic stenosis
11059883|NCT04358692|Other|Reference|Coronary bypass patients without hypertrophic left ventricular remodeling or sequelae of myocardial infarction
11059884|NCT04358679|Active Comparator|Conventional Treatment|Conventional Treatment: Deep breathing, Assisted coughing, Sustained stretching, Splinting, Bracing and Functional mobility
11059885|NCT04358679|Experimental|Upper Limb ergometer training|Conventional Treatment + Upper Limb (UL) ergo-meter exercise
11059886|NCT04358666|Active Comparator|surgery and focal radiosurgery of the surgical site|
11059887|NCT04358666|Active Comparator|hypofractionned radiosurgery|
11059888|NCT04358653|Experimental|fall prevention exercise program|The experimental group was designed to undergo supervised exercise 2 days a week for 8 consecutive weeks for 45-50 min/session. The intervention program was implemented at the nursing home facilities.
11059889|NCT04358653|No Intervention|Control Group|The control group did not receive any intervention during that period and were instructed to pursue their habitual daily life activities.
11059890|NCT04358640||Employees of Nîmes University Hospital (France)|Employees of Nîmes University Hospital (France)
11059891|NCT04358627||DEXMEDETOMIDINE|Patients receiving dexmedetomidine continuous infusion since their admittance to ICU. Continuous checking of the primary and secondary outcomes
11059892|NCT04358627||No-DEXMEDETOMIDINE|Historical Control patients matched for ICU admittance diagnosis, age, and concomitant disease and medication state. No Dexmedetomidine. CONtinuous checking of primary outcomes
11059893|NCT04358614|Active Comparator|Case patients|Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
11059894|NCT04358614|Other|Controls|Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.
11059895|NCT04358601|Experimental|All-polyethylene tibial components|Triathlon PS Knee System with all-polyethylene tibial components
11059896|NCT04358601|Active Comparator|Metal-backed modular components|Triathlon PS Knee System with metal-backed modular components
11059897|NCT04358575|Experimental|All-polyethylene tibial components|Triathlon CS Knee System with all-polyethylene tibial components
11059898|NCT04358575|Active Comparator|Metal-backed modular components|Triathlon CS Knee System with metal-backed modular components
11059899|NCT04358562|Experimental|Gefitinib with Anlotinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily and Anlotinib 10mg oral d1-14, every 3 weeks
11059900|NCT04358562|Experimental|Gefitinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment, Gefitinib 250mg oral daily
11059901|NCT04358549|Experimental|Favipiravir Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC
11059902|NCT04358549|Other|Standard of Care Arm|Standard of Care for 14 days
11059903|NCT04358536||COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from COVID-19 patients"
11059904|NCT04358536||Non COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from subsets of non COVID-19 patients"
11059905|NCT04358523|Experimental|ASC18 (D1,D4-13）;RDV + SOF(D27,D30-39)|ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
11059906|NCT04358523|Experimental|RDV + SOF (D1,D4-13）;ASC18(D27,D30-39)|RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 1 and day 4 to 13. ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 27 and day 30 to 39.
11059907|NCT04358510||COViage|Machine learning intervention
11059908|NCT04358497|Experimental|Interventional treatment plus best chronic medical treatment|Sandwich embolization ( 2% polidocanol + Coils) Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
11059909|NCT04358497|Active Comparator|Best chronic medical treatment alone|Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
11059910|NCT04358484|Experimental|Intervention Group|Participants attend The Incredible Years - ASLD parenting intervention and continue to receive usual care at their healthcare center
11059911|NCT04358484|No Intervention|Treatment As Usual (TAU) Group|Participants continue to receive usual care at their Healthcare Center
11059912|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection|Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0
11059913|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection|Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0
11059914|NCT04358471|Sham Comparator|Sham Intravitreal Injection|Intravitreal Sham injection administered once on Day 0
11059915|NCT04358458|Experimental|Treatment Administered|
11059916|NCT04358445|No Intervention|Historical control group|The patients were treated by aneurysm clipping in our hospital in the previous nine months, and normal saline (0.9% Sodium Chloride Injection) had applied as intraoperative perfusion solution in operation of the historical control group. All of the 35 patients selected should meet the inclusion and exclusion criteria of this study.
11059917|NCT04358445|Experimental|MACSF group|Use Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) in the operation, and the remaining treatments should strictly follow the guidelines as same as the historical control group.
11059918|NCT04358432|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
11059919|NCT04358432|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
11059920|NCT04358432|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
11059921|NCT04358432|Experimental|AK102 75 mg|Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
11059922|NCT04358432|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
11059923|NCT04358432|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
11059924|NCT04358419||PA proven/probable/possible|15 patients with proven, probable or possible PA
11059925|NCT04358419||PA suspected, not confirmed|15 patients as the PA patients, but where the diagnosis of PA is rejected.
11059926|NCT04358419||Healthy controls (PA)|15 subjects of same gender and age as an included patient with proven/probable/possible PA as healthy controls.
11059927|NCT04358419||Pneumocystis pneumonia positive|Four patients with confirmed pneumocystis pneumonia
11059928|NCT04358419||Pneumocystis pneumonia negative|If the diagnosis of pneumocystis pneumonia is not confirmed in a patient with suspected pneumocystis pneumonia, the patient will be included as negative control. Four such patients will be included as healthy controls.
11059929|NCT04358419||Healthy controls (pneumocystis pneumonia)|Four subjects of same gender and age as an included patient with verified pneumocystis pneumonia as healthy controls.
11059930|NCT04358406|Placebo Comparator|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
11059931|NCT04358406|Active Comparator|Rhu-pGSN|Recombinant human plasma gelsolin reconstituted for slow bolus injection.
11059932|NCT04358393|Experimental|APG115 100mg|APG115 100mg PO QD D1-5/ every 28 days
11059934|NCT04358393|Experimental|APG115 200mg|APG115 200mg PO QD D1-5 /every 28 days
11059935|NCT04358393|Experimental|APG250mg|APG115 250mg PO QD D1-5 / every 28 days
11059936|NCT04358380||Patients without Liver Injury|Hospitalized patients with COVID-19 disease who did not develop liver injury
11059937|NCT04358380||Patients with Liver Injury|Hospitalized patients with COVID-19 disease who develop liver injury
11059938|NCT04358367|Active Comparator|Dexmedetomidine|spinal anesthesia and intravenous dexmedetomidine(1µg/kg)
11059939|NCT04358367|Placebo Comparator|Saline|spinal anesthesia and placebo (saline).
11059940|NCT04358354|Experimental|FOLFOXiri group|Irinotecan 150 mg/m2 iv drip d1; Oxaliplatin 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
11059941|NCT04358354|Active Comparator|FOLFOX group|Oxaliplatin: 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
11059942|NCT04358341|Active Comparator|Irinotecan alone|150 mg/m2 iv drip d1; Repeat every 14 days.
11059943|NCT04358341|Experimental|Pegliposomal Doxorubicin and 5-FU|Pegliposomal Doxorubicin: 25mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h d1; Repeat every 14 days.
11059944|NCT04358328|Experimental|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
11059945|NCT04358328|Active Comparator|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
11059946|NCT04358315||Observational (smell or puff e-liquids)|Non-user panelists smell and user panelists puff flavored e-liquids and answer questions about the products.
11059947|NCT04358302|Experimental|Device use|"All participants will be provided with the electronic pill bottle cap called Pillsy to use with their regular HCQ prescription bottles at the start of the study."
11059948|NCT04358289|No Intervention|Arm 1: Control group|For commune health center and community
11059949|NCT04358289|Other|Arm 2: Basic antimicrobial stewardship education|For commune health center and community
11059950|NCT04358289|Other|Arm 3: 3. Basic AS education + community education|For commune health center and community
11059951|NCT04358289|Other|Arm 4: Education + participatory action research|For commune health center and community
11059952|NCT04358289|Other|Hospital intervention|For hospital: The hospital interventions will use quality improvement using a participatory action research approach to improve antibiotic stewardship. These activities will be evaluated through a before and after knowledge, attitudes and practice (KAP) survey, to assess whether or not the engagement activities had a measurable impact on knowledge and behaviour. There are not sufficient hospitals in the area to conduct a cluster randomized evaluation, so we will conduct a before and after survey, patient record review, and overall antibiotic use data from the Pharmacy Department
11059953|NCT04358276|Experimental|Group I (PAE)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
11059954|NCT04358276|Experimental|Group II (PAE, physician)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
11059955|NCT04358276|Experimental|Group III (PAE, physician, dermatoscope)|"Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and mimickers common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice."
11059956|NCT04358263|Experimental|rtCGM|Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).
11059957|NCT04358263|Experimental|isCGM|Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
11059958|NCT04358250|Experimental|direct superior approach|Direct superior approach 25 patients
11059959|NCT04358250|Active Comparator|posterolateral approach|posterolateral approach 25 patients
11059960|NCT04358237|Experimental|Experimental: lurbinectedin (PM01183) + pembrolizumab|"During the phase I stage, patients will start receiving pembrolizumab at a fixed dose of 200 mg as a 30-min intravenous (IV) infusion followed by lurbinectedin at a starting dose of 2.4 mg/m2 as a 1-h IV infusion on Day 1, both every 3 weeks (Q3W). Lurbinectedin dose will be escalated from the starting dose in successive cohorts of patients, with a pre-established fixed dose increase (in mg/m2) of approximately 30%.
~During the phase II stage, patients will receive pembrolizumab at a fixed dose of 200 mg as a 30-min IV infusion followed by lurbinectedin as a 1-h IV infusion on Day 1 Q3W at the redommended dose (RD) determined during the phase I stage. A cycle is defined as an interval of 3 weeks. No dose escalation will be allowed during the phase II stage."
11059961|NCT04358224|Other|open-label|open-label
11059962|NCT04358198|Experimental|GIM patient|The patients with GIM will be assessed at both GIM and normal mucosa during endoscopy.
11059963|NCT04358185|Experimental|Itacitinib|Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
11059964|NCT04358172|Experimental|Mobile app|Participants in this group is educated using the mobile application
11059965|NCT04358172|No Intervention|Control|Participants in this group is educated using the conventional method practised in the Faculty of Dentistry, National University of Malaysia (verbal instructions accompanied by demonstrations on dental models)
11059966|NCT04358159|Experimental|Ventralex|Repair with Ventralex patch in sublay position
11059967|NCT04358159|Active Comparator|Progrip|Repair with Progrip in Onlay position
11059968|NCT04358146|Experimental|Test|new thickened infant formula containing fibres
11059969|NCT04358146|Active Comparator|Control|infant formula thickened with locust bean
11059970|NCT04358133|Experimental|Chlorhydrate de morphine|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
11059971|NCT04358133|Placebo Comparator|NaCl 0,9%|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
11059972|NCT04358120|Other|Hyaluronic Acid Combined With Chondroitin Sulfate|The treatment consists of 3 intra articular injections of Hyaluronic Acid With Chondroitin Sulfate administered one per week for 3 consecutive weeks: the 1st at Visit 1 (Week 0), the 2nd at Visit 2 (Week 1) and the 3rd at Visit 3 (Week 2)
11059973|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
11059974|NCT04358094|Experimental|Conversational hypnosis script|Patient who received conversational hypnosis script during peripherical veinous access set up
11059975|NCT04358094|Other|Standard script|Patient who received standard script during peripherical veinous access set up
11059976|NCT04358081|Experimental|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d to be initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZI) placebo o.d.
11059977|NCT04358081|Experimental|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. to be initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
11059978|NCT04358081|Placebo Comparator|Arm 3; hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
11059979|NCT04358068|Experimental|Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|"Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:
~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days)."
11059980|NCT04358068|Placebo Comparator|Arm B: Placebo for Hydroxychloroquine and Azithromycin|"Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:
~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days)."
11059981|NCT04358055|Experimental|WET® gel|"At the screening/baseline visit (Visit 1, Day 1), eligible patients will be assigned to treatment with WET® gel, at the dose of 3-4 nasal applications/day (according to necessity), 1or 2 puff/nostril, for maximum 14 days.
~Treatment will be administered according to patient's need without any relation with the time of the day (i.e. day time or night time administration), however within a maximum of 4 applications/day, which must include one administration in the morning upon awakening and one administration in the evening before retiring to bed."
11059982|NCT04358029||COVID-19 patients|Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital
11059983|NCT04358016|Experimental|terlipression|terlipression 1mg；once every 6 hours；5days
11059984|NCT04358016|Active Comparator|Control|Somatostatin，3mg， once every 12 hours; 5 days
11059985|NCT04358003|Experimental|Plasma Adsorption Cartridge|Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.
11059986|NCT04357990|Experimental|Viruxal Oral and Nasal Spray|The Device will be administered to the oral and nasal passages, three times per day.
11059987|NCT04357990|Placebo Comparator|Placebo|The placebo will be administered to the oral and nasal passages, three times per day.
11059988|NCT04357977||Covid +|Laboratory obtained Covid+ specimen results will be compared to saliva specimen
11059989|NCT04357964||obese and lean individuals|obese and lean individuals
11059990|NCT04357951|Experimental|Behavior Therapy + DCS|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the d-cycloserine pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
11059991|NCT04357951|Active Comparator|Behavior Therapy + Placebo|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the placebo pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
11059992|NCT04357912|Experimental|Experimental group|
11059993|NCT04357912|Active Comparator|Control Group|
11059994|NCT04357873|Experimental|pembrolizumab + vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations
~Vorinostat: 400 mg once daily, until progression"
11059995|NCT04357860|Experimental|Sarilumab 200 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 200 mg single dose.
11059996|NCT04357860|Experimental|Sarilumab 400 mg|Subjects treated with the best available treatment up to 14 days plus Sarilumab 400 mg single dose.
11059997|NCT04357860|Active Comparator|Control|Subjects treated with the best available treatment up to 14 days.
11059998|NCT04357834||Smartwatch group|
11059999|NCT04357821|Experimental|Combination intervention arm|All volunteers will receive the combination intervention outlined above.
11060000|NCT04357808|Experimental|Sarilumab plus standard of care|Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed
11060001|NCT04357808|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
11060002|NCT04357795|Experimental|CequaTM (Cyclosporine 0.09%) ophthalmic solution|
11060003|NCT04357782|Active Comparator|Mild hypoxemia|S/F ratio >250 prior to Vitamin C infusion
11075712|NCT04246476||Controls|Age-matched controls.
11060004|NCT04357782|Active Comparator|Severe Hypoxemia|S/F ratio ≤250 prior to Vitamin C infusion
11060005|NCT04357769||Patients|Individuals aged 18-70 years with a diagnosis of severe mental disorder (schizophrenia or psychosis spectrum disorder; bipolar disorder; major depressive disorder) who were in a condition of psychopathological compensation, had their last clinical evaluation at the University of Naples Federico II outpatient unit of Psychiatry during January-February 2020, were not positive or suspected positive for COVID-19, and were under strict quarantine
11060006|NCT04357769||Controls (General Population)|Individuals aged 18-70 years who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine (e.g. not getting out for work)
11060007|NCT04357769||First-degree Relatives|Individuals aged 18-70 years who were first-degree relatives and caregivers of an individual included in the Patients group, who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine
11060008|NCT04357756|Experimental|YH001 combined with Toripalimab|All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
11060009|NCT04357743|Experimental|Chin supported Arm ergometry with pursed lip breathing|Chin supported along with Arm ergometry with pursed lip breathing
11060010|NCT04357743|Active Comparator|Arm ergometry with pursed lip breathing|Arm ergometry with pursed lip breathing
11060011|NCT04357730|No Intervention|Control|Patients randomized to Control arm will receive no study medication; the treatment will be standard of care according to the institution's protocol for ARDS.
11060012|NCT04357730|Experimental|Alteplase-50 bolus|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Re-bolusing of Alteplase, at the same dose, is permitted in those patients who show an initial transient response. The repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
11060013|NCT04357730|Experimental|Alteplase-50 bolus plus drip|Patients randomized to Alteplase-50 plus drip group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Immediately following this initial Alteplase infusion, a drip of 2 mg/hr of Alteplase will be initiated over the ensuing 24 hours (total 48 mg infusion).
11060014|NCT04357704|Experimental|bilateral cochlear implant recipients|
11060015|NCT04357704|Active Comparator|normal hearing listners|
11060016|NCT04357691|Other|Healthy individuals (low-high-mod)|Participants will undergo the calibration phase beginning with low intensity training, followed by high, and moderate intensity training. Each training intensity will be performed 3 days a week for 2 weeks
11060017|NCT04357691|Other|Healthy individuals (mod-high-low)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by high, and low intensity training. Each training intensity will be performed 3 days a week for 2 weeks
11060018|NCT04357691|Other|Healthy individuals (mod-low-high)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by low, and high intensity training. Each training intensity will be performed 3 days a week for 2 weeks.
11060019|NCT04357678|Experimental|Qi Gong Programme|Qi Gong Programme
11060020|NCT04357678|Experimental|Short Form Sun Style Tai Chi|Short Form Sun Style Tai Chi
11060021|NCT04357665|Active Comparator|Lap TAPP Group|Patients treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
11060022|NCT04357665|Active Comparator|Open PP Group|Patients treated by open preperitoneal single mesh repair fixated using sutures
11060023|NCT04357665|Active Comparator|Bilateral LICHT Group|Patients treated by standard bilateral Lichtenstein repair using 2 separate meshes fixed by sutures
11060024|NCT04357639||Protease inhibitor exposed|HIV patients treated with antiretroviral drugs including a protease inhibitor
11060025|NCT04357639||Protease inhibitor non exposed|HIV patients treated with antiretroviral drugs without a protease inhibitor
11060026|NCT04357626||Completed discharged hospital rehabilitation electronic record|Completed discharged hospital rehabilitation electronic record of patients who underwent inpatient rehabilitation as part of routine clinical care.
11060027|NCT04357613|Experimental|Expérimental ARM|800mg/d IMATINIB during 14days
11060028|NCT04357613|No Intervention|Comparator ARM|Standard of care
11060029|NCT04357600|Experimental|intravenous injection of UC-MSC|The dosage of the intravenous route is 100 million MSCs for each subject.
11060030|NCT04357587|Experimental|Pembrolizumab|Experimental pembrolizumab and SOC external beam radiation and capecitabine
11060031|NCT04357574||Radiation Oncology Providers|Faculty physicians, residents and advanced practice providers in the Radiation Oncology Department in Duke University Health System (DUHS)
11060032|NCT04357561|Experimental|Exercise group (Schroth best practice)|Exercise program will consists of scoliosis-specific exercises (schroth best practice), which is a pattern specific scoliosis rehabilitation concept and provide three dimensional improvements and include patient education for maintaining corrected posture in daily life. In addition, these exercises provide improvements in neuromuscular control and the endurance of the postural muscles.
11060033|NCT04357561|No Intervention|Control group|Due to there is not a standard preoperative exercise protocol, additional exercise program will not be applied in control group. The patients will wait for the surgery in their routine daily life. Measurements will be performed at the same time frame in experimental group.
11060034|NCT04357548||Feedback system|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
11060035|NCT04357535||Primary Cohort|"Patients enrolled in this study will have data collected from the beginning of their hospital stay until discharge.
~Data collected will include:
~Patient demographics (age, sex, weight, and height)
~Indication for ACE-I, ARB therapy, duration and doses
~Use of any a non ACE-I/ ARB sntihypertensive agents
~Comorbidities, and COVID19 related markers: Including WBC, plateltes, ferritin, CRP, CK, and LD
~CT scan reports
~First positive COVID19 PCR
~Admission to the intensive care unit (ICU) and data relating to ICU stay."
11060036|NCT04357522|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine(experimental vaccine), 0.5 ml/dose
11060037|NCT04357522|Active Comparator|Positive control group|Received Vaccine: 13-valent pneumococcal Conjugate Vaccine(positive control vaccine), 0.5 ml/dose
11060038|NCT04357509|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
11060039|NCT04357496||Participants with SARS-COV-2|Participants tested positive for SARS-COV-2 aged 60 years or older
11060040|NCT04357483|Experimental|Collastat|Patients who were applied flowable thrombin containing collagen hemostat matrix after pancreatectomy
11060041|NCT04357483|Active Comparator|Collaseal|Patients who were applied thrombin coated L-dopa contained collagen patch after pancreatectomy
11060042|NCT04357470|Active Comparator|USF Group|DRF with ulnar styloid fracture
11060043|NCT04357470|Active Comparator|NON-USF Group|DRF without ulnar styloid fracture
11060044|NCT04357457|Experimental|Almitrine|
11060045|NCT04357457|Placebo Comparator|Placebo|
11060046|NCT04357444|Experimental|1: ILT101|ILT-101 in Subcutaneous route
11060047|NCT04357444|Placebo Comparator|2: Placebo Comparator|Placebo in subcutaneous injections every day during 10 days
11060048|NCT04357431||study group|Health care providers include physicians, nurses, and health officers both medical and nursing subjects.
11060049|NCT04357418||hospital staff|
11060050|NCT04357418||close relatives.|
11060051|NCT04357405||Experimental arm|This group consists of 100 EHPAD which will benefit from ECG teletransmission. all data will be collected
11060052|NCT04357405||Control arm|This arm consists of 50 EHPAD that have not benefited from ECG teletransmission. Only the global death occurrence data will be analyzed, no individual data will be collected.
11060053|NCT04357392|Experimental|Glucocorticoid intervention group|prednisone
11060054|NCT04357392|Placebo Comparator|Placebo control group|placebo
11060055|NCT04357379|Experimental|IQOS group|
11060056|NCT04357366|Experimental|Anakinra|Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.
11060057|NCT04357353|Sham Comparator|Placebo|All arms will have phlebotomy (blood drawn). This group will receive saline injection only.
11060058|NCT04357353|Experimental|PRP|All arms will have phlebotomy (blood drawn). This group will receive PRP injection only.
11060059|NCT04357340|Experimental|Pulmonary Physiotherapy Techniques group|Pulmonary physiotherapy techniques, 6 sessions during 3 days and incentive spirometer.
11060060|NCT04357340|No Intervention|Control group|Incentive spirometer only
11060061|NCT04357327|Experimental|Symptomatic patients|Patients with symptoms associated with COVID-19, i.e., dyspnea, cough, fever, etc.
11060062|NCT04357327|Active Comparator|Asymptomatic subjects|Asymptomatic patients with low risk phenotype, that means patients with a previous negative swab, no relatives affected by COVID-19 and with reduced social interaction within the last two weeks.
11060063|NCT04357314||Patients with STEMI in 2019|Patient with acute myocardial infarction between March 17, 2019 and April17, 2019
11060064|NCT04357314||Patients with STEMI in 2020|Patient with acute myocardial infarction between March 17, 2020 and April17, 2020.
11060065|NCT04357301|Experimental|Closed-loop|Closed-loop administration of norepinephrine
11060066|NCT04357288|Experimental|Patient Decision Aid|Participants in this arm will use the Patient Decision Aid (PDA), an online education tool about atrial fibrillation designed for patient use, prior to the encounter with their provider.
11060067|NCT04357288|Experimental|Encounter Decision Aid|Participants in this arm will use the Encounter Decision Aid (EDA), an online educational tool about atrial fibrillation designed for patient-provider use, during the encounter with their provider.
11060068|NCT04357288|Experimental|Patient & Encounter Decision Aids|Participants in this arm will use both the PDA & EDA as described above.
11060069|NCT04357288|No Intervention|Standard Care|Participants in this arm will receive standard care, that is they will not use either the PDA or EDA.
11060070|NCT04357275||ICU admissions due to COVID-19|
11060071|NCT04357262|No Intervention|Control|No other non-standard of care activities will be performed
11060072|NCT04357262|Experimental|Intervention|Will be signed up for the automated text messaging program (StreaMD)
11060073|NCT04357236||Experimental Group|The experimental group received 18F-FDG PET examination
11060074|NCT04357236||Control Group|The control group received 18F-FDG PET examination
11060075|NCT04357223|Experimental|Experimental|
11060076|NCT04357223|Placebo Comparator|Placebo|
11060077|NCT04357210||primary sphincteroplasty|end-to-end primary sphincteroplasty with interrupted sutures
11060078|NCT04357210||muco-muscular advancement flap|A U-shaped muco-muscular flap was mobilized and fixed to the anoderm with one-row interrupted absorbable sutures
11060079|NCT04357210||full-thickness low rectum posterior semicircular mobilization|Proximal parts of the internal sphincter and the longitudinal muscle were carefully separated from the underlying external sphincter and puborectalis muscle, moving further in the cranial direction, the Waldeyer's fascia was exposed and incised. Full-thickness posterior semicircular flap was fixed to anoderm
11060080|NCT04357197|Experimental|Closed-loop|Closed-loop administration of norepinephrine in critically ill patients
11060081|NCT04357184|Experimental|BFRT with 4 exercises and low resistance loads|Blood flow resistance training will be performed with a standard blood pressure cuff that is placed and inflated by a clinician. The patient will perform 4 exercises with low resistance loads that will produce a muscle burn to enhance promotion of strength. Training will be supervised in the clinic. The cuff is deflated between exercises.
11060082|NCT04357171|Active Comparator|Ileostomy|Loop protective ileostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
11060083|NCT04357171|Active Comparator|Colostomy|Loop protective transverse colostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
11060084|NCT04357158|Other|Patients referred for colonoscopy|
11060085|NCT04357145|Active Comparator|Standard Exercise Group|Exercise training is given to patients in the form of a home exercise program.
11075713|NCT04246463||Thoracic - TEVAR|
11060086|NCT04357145|Experimental|High Dosage Exercise Group|The high dosage exercise training group will implement the recommended exercise program 3 times more than the standard exercise group.
11060087|NCT04357132|Other|VR-Biofeedback|
11060088|NCT04357132|Other|VR-Distraction|
11060089|NCT04357119|Active Comparator|CL measured from Treitz ligament|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 200 cm distal to the ligament of Treitz with the same stapler using a 60 mm blue cartridge
11060090|NCT04357119|Active Comparator|CL measured from ileocecal valve|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 300 cm proximal to the ileocecal valve with the same stapler using a 60 mm blue cartridge
11060091|NCT04357106|Experimental|Convalescent Plasma|200 ml of convalescent plasma, single dose.
11060092|NCT04357093|Experimental|Grape seed extract mouthwash|Grape seed extract mouth wash 15% concentration
11060093|NCT04357093|Active Comparator|Sodium fluoride mouthwash|Sodium fluoride mouthwash 1000 ppm
11060094|NCT04357080||Case|Patients with urethral stricture recurrence
11060095|NCT04357080||Control|Patients with normal, patent urethra
11060096|NCT04357067|Experimental|Lingual brackets|Patients with moderate crowding without extraction treated with Incognito lingual bracket (3M Unitek, Bad Essen, Germany)
11060097|NCT04357067|Experimental|Labial brackets|Patients with moderate crowding without extraction treated with labial bracket (3M Unitek, Ca, USA
11060098|NCT04357054|Active Comparator|Normal uterus|Darwish test
11060099|NCT04357054|Active Comparator|Myomatous uterus|Darwish test
11060100|NCT04357028|Experimental|MMR vaccine|0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm
11060101|NCT04357028|Placebo Comparator|Control|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
11060102|NCT04357015|Experimental|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
11060103|NCT04357015|Active Comparator|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
11060104|NCT04357015|Placebo Comparator|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
11060105|NCT04357002|Experimental|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
11060106|NCT04357002|Active Comparator|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
11060107|NCT04357002|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
11060108|NCT04356989||Rivaroxaban|Adult NVAF patients with renal impairment, who are prescribed with rivaroxaban to prevent stroke or non-central nervous system (CNS) systemic embolism (SE).
11060109|NCT04356976|Experimental|Ventralex|Repair with Ventralex hernia patch in sublay position
11060110|NCT04356976|Active Comparator|Stratafix|Repair with Stratafix suture
11060111|NCT04356963|Experimental|Virtual Reality Sessions|All participants will participate in virtual reality sessions.
11060112|NCT04356963|Active Comparator|Comparator Sessions|All participants will participate in tablet-based sessions to content-less sessions wearing the virtual reality headset
11060113|NCT04356937|Experimental|Tocilizumab|"Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.
~Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures."
11060114|NCT04356937|Placebo Comparator|Standard of care plus placebo|Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.
11060115|NCT04356924|Experimental|Psychological treatment|The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
11060116|NCT04356924|Active Comparator|Cognitive training|Like the experimental group, the active control group also consists of 11 sessions (55 minutes per occasion), once a week. At those occasions, the patient will meet a psychology student under training or a MSc in psychology that coaches the patients during the cognitive training. In between sessions, patients are supposed to take 2 walks (45 minutes per occasion to meaningfully match the home exercises in the experimental group).
11060117|NCT04356924|No Intervention|Treatment as usual|This group receives no intervention. They receive regular health information that is given after the extended cognitive examination at the Cognitive Centers.
11060118|NCT04356911|Placebo Comparator|PLACEBO (Negative Control)|The dental elements of this group had no desensitizing treatment. After whitening therapy, a water-soluble placebo gel (KY®, Johnson & Johnson, SP, Brazil) was applied to dental oral surfaces, then the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of Low Level Laser Therapy (LLLT).
11060119|NCT04356911|Experimental|FBM|The group received the application of a placebo gel associated with LLLT after office bleaching.
11060120|NCT04356911|Experimental|ESTRÔNCIO|After whitening in-office bleaching, the group was treated with desensitization to 10% strontium chloride. Subsequently, a laser tip was positioned at two points (apical and cervical), without emitting light (placebo).
11060297|NCT04355650|Experimental|Clinical decision tool|Launch of clinical decision support tool at baseline visit with study clinician.
11060121|NCT04356911|Experimental|FBM+ESTRÔNCIO|After whitening in the office, the group received a 10% strontium chloride desensitizer associated with low level light therapy.
11060122|NCT04356898||Diabetes fasting|Diabetes patients who decided to fast during the month of Ramadan
11060123|NCT04356898||Diabetes non-fasting|Diabetes patients who decided to not fast during the month of Ramadan
11060124|NCT04356898||Healthy|Healthy volunteers that decided to fast during the month of Ramadan
11060125|NCT04356872|Experimental|treatment|The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.
11060126|NCT04356859|No Intervention|Crystalloid|Subjects in the crystalloid group will receive fluid resuscitation with Lactated Ringer's titrated each hour to achieve a urine output of 0.5-1mL/kg predicted body weight.
11060127|NCT04356859|Active Comparator|Colloid|Subjects in the colloid group will receive fluid resuscitation with Lactated Ringer's and 5% human albumin solution introduced no earlier than 8 hours post burn and no later than 12 hours post burn in a ratio by volume of 1/3 albumin to 2/3 Lactated Ringer's, and titrated each hour to achieve a urine output of 0.5-1mL/kg (milliliter/kilogram) predicted body weight.
11060128|NCT04356846|Experimental|R/R CLL|Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
11060129|NCT04356846|Experimental|R/R NHL|Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Patients, including SLL, FL, MZL, MCL, DLBCL, WM.
11060130|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA)|For patients in the rt-PA group, 10 mg of rt-PA dissolved in 5 ml of diluent will be given every 6 hrs for 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). 6 patients will be receiving Invasive mechanical ventilation and another six will be receiving Non Invasive ventilation.
11060131|NCT04356833|No Intervention|Standard of care|Standard of care for COVID-19 acute respiratory distress syndrome (ARDS). 6 patients will be receiving Invasive mechanical ventilation and another six will be receiving Non Invasive ventilation.
11060132|NCT04356820|Experimental|acupressure|
11060133|NCT04356820|Experimental|music|
11060134|NCT04356820|No Intervention|control|
11060135|NCT04356807|Experimental|Reflex Locomotion Therapy|during 15 minutes once a day five days a week
11060136|NCT04356807|Experimental|Passive Joint Mobilizations|during 15 minutes once a day five days a week
11060137|NCT04356807|Placebo Comparator|Massage|during 15 minutes once a day five days a week
11060138|NCT04356794|Experimental|Medical electroacupuncture(EA)|EA were treated for 4 weeks, 2 times per week.
11060139|NCT04356794|Sham Comparator|Sham electroacupuncture|"Sham acupuncture was performed without stimulation and manipulation to avoid eliciting De Qi sensations.It were treated for 4 weeks, 2 times per week."
11060140|NCT04356755|Experimental|autologous cultured ASC|Subcutaneous injections of autologous cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
11060141|NCT04356755|Placebo Comparator|Placebo|Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
11060142|NCT04356742|Experimental|Dapagliflozin 10mg + Evogliptin 5mg + Metformin|
11060143|NCT04356742|Placebo Comparator|Dapagliflozin Placebo + Evogliptin 5mg + Metformin|
11060144|NCT04356729|Experimental|Atezolizumab and Bevacizumab|"The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.
~Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks
~Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
~Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment"
11060145|NCT04356716|Active Comparator|Standard of Care Sildenafil|Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
11060146|NCT04356716|Active Comparator|Sildenafil|Participants are prescribed sildenafil 40-80 mg daily.
11060147|NCT04356703||Children submitted to fetoscopic surgery|Children submitted to fetoscopic in utero myelomeningocele repair using the SAFER (Skin-over-biocellulose for Anternatal FEtoscopic Repair) technique will evaluate the neuropsicomotor development at 30 months of chronological age or older
11060148|NCT04356690|Experimental|Cohort 1 - Etoposide|"Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4
~If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
11060149|NCT04356690|Experimental|Cohort 2 - Etoposide|"Participants that are NOT on ventilation Etoposide 150 mg/m2 daily days 1 and 4
~Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4. If the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard HLH etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators."
11060150|NCT04356690|No Intervention|Cohort 1 - Control|Standard of care therapy in participants that are on ventilation
11060151|NCT04356690|No Intervention|Cohort 2 - Control|Standard of care therapy in participants that are NOT on ventilation.
11060152|NCT04356677|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
11060153|NCT04356677|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
11060154|NCT04356664|No Intervention|Frozen embryo transfer with Hormonal Replacement Therapy (HRT)|Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
11060298|NCT04355637|No Intervention|Control|patients receiving standard of care to treat their pneumonia
11060155|NCT04356664|Experimental|Frozen embryo transfer with HRT and GnRH agonist|Patient will received 1 or 2 injection of GnRH agonist priori to usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.
11060156|NCT04356651|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
11060157|NCT04356651|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
11060158|NCT04356638|Active Comparator|The sedative pre-medication oral Midazolam|
11060159|NCT04356638|Active Comparator|The sedative pre-medication intranasal Dexmedetomidine|
11060160|NCT04356638|Placebo Comparator|Placebo|
11060161|NCT04356638|No Intervention|No Sedative Pre-medication|
11060162|NCT04356625|Other|MEPic|"Ready for extubation (pass SBT)
~Measurement of maximum expiratory pressure during the induced cough (MEPic)"
11060163|NCT04356612||Achilles Tendon Rupture|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
11060164|NCT04356599|Experimental|Intervention Group|All participants will receive study intervention
11060165|NCT04356573|Placebo Comparator|Gold kiwifruit|Subjects ate 2 gold kiwifruit with midday meal for 2 weeks.
11060166|NCT04356573|Active Comparator|Green Hayward kiwifruit|Subjects ate 2 green Hayward kiwifruit with midday meal for 2 weeks.
11060167|NCT04356560||healthcare workers|Actively working at Department of Otorhinolaryngology Head and Neck Surgery & Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark. During 2020 COVID 19 pandemic
11060168|NCT04356560||Patients|Patients presenting with complications to upper respiratory tract infections and patients undergoing surgery involving airway mucosa During 2020 COVID 19 pandemic
11060169|NCT04356547|Active Comparator|Fiberoptic intubation using laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
11060170|NCT04356547|Active Comparator|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator. Will be evaluated the success rate at the first attempt and other secondary outcomes
11060171|NCT04356534|Active Comparator|Control group|local standard of care which include antivirals and supportive care
11060172|NCT04356534|Experimental|Intervention group|convalescent patient plasma 400ml given as 200ml over 2 hours in 2 consecutive days, plus routine local standard of care
11060173|NCT04356521|Active Comparator|Group LS|Ultrasound-guided infraclavicular block - lateral sagittal approach (20 ml 0.5% bupivacaine)
11060174|NCT04356521|Active Comparator|Group CC|Ultrasound-guided infraclavicular block - costoclavicular approach (20 ml 0.5% bupivacaine)
11060175|NCT04356508|Experimental|Intervention (n=10)|Nivolumab + best supportive care
11060176|NCT04356508|No Intervention|Non-intervention (n=5)|Best supportive care
11060177|NCT04356495|Sham Comparator|Vitamins|"Patients in this arm will receive a vitamin supplement (AZINC forme et vitalité®) during 10 days"
11060178|NCT04356495|Experimental|Telmisartan|Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days
11060179|NCT04356482|Experimental|single arm|"Determine the convalescent plasma dose to be administered to two groups: one severely ill (not intubated) and one very severely ill (intubated).
~Second phase: safety and efficacy of the plasma dose found in the same two types of patients."
11060180|NCT04356469|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
11060181|NCT04356456|Experimental|Lumenato Supplement|Lumenato oleoresin
11060182|NCT04356456|Placebo Comparator|Placebo|paraffin oil
11060183|NCT04356430|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
11060184|NCT04356430|Experimental|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
11060185|NCT04356391|Active Comparator|Connective Tissue Graft harvest from Palate|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Technique. The tooth assigned to the CTG technique will receive the graft harvested from the palate.
11060186|NCT04356391|Experimental|collagen resorbable membrane material|In each participant, a tooth will be assigned to the Connective Tissue Graft (CTG) technique and another tooth to the Pinhole Surgical Technique (PST). The tooth assigned to the PST technique will receive the collagen resorbable membrane material.
11060187|NCT04356378||"infection with coronavirus SARS-CoV2 group"|"SARS-CoV2 infected patients group: in-patient in the acute phase then requiring rehabilitation."
11060188|NCT04356352|Active Comparator|Lidocaine|1 mg/kg lidocaine to a max of 100 mg
11060189|NCT04356352|Active Comparator|Esmolol|0.5 mg/kg esmolol to a max of 50 mg
11060190|NCT04356352|Placebo Comparator|Placebo|Saline water
11060191|NCT04356339||BETASERON|Participants with Multiple Sclerosis treated with BETASERON using BETACONNECT autoinjector and myBETAapp will be enrolled
11060192|NCT04356326|Experimental|Aspirin 150 mg|Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening
11060193|NCT04356326|Placebo Comparator|Placebo|Placebo taken in the evening
11060194|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & HGB|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and the Hipogastric component (HGB)
11060342|NCT04355338||60-69 years|Participants aging 60-69 years
11060195|NCT04356313||GORE® EXCLUDER® Iliac Branch Endoprosthesis & VBx|Patients with Aorto-Iliac Aneurysm with implantation of a Iliac Branch device (IBE) and Viabahn Balloon Expandable ( VBx)
11060196|NCT04356300|Experimental|The exosome of MSC arm|Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.
11060197|NCT04356300|No Intervention|The control arm|Patients in the control arm will not be given exosome of MSC.
11060198|NCT04356287|Experimental|One infusion of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of placebo at months 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A. Each placebo infusion will consist of a similar volume of PlasmaLyte A.
11060199|NCT04356287|Experimental|Two infusions of UCMSC|Patients receive one intravenous infusion of UCMSC at month 0 and one intravenous infusion of UCMSC at month 3. Each experimental infusion will consist of 1 million UCMSC/kg suspended in 50 ml of PlasmaLyte A.
11060200|NCT04356287|Placebo Comparator|Placebo infusions|Patients receive intravenous placebo infusions at months 0 and 3. Each placebo infusion will consist of 50 ml of PlasmaLyte A.
11060201|NCT04356274|Experimental|Participatory System Dynamics (PSD)|12 clinics assigned to PSD
11060202|NCT04356274|Experimental|Audit and Feedback (AF)|12 clinics assigned to AF
11060203|NCT04356261|Placebo Comparator|Control PNF|Personalized Normative Feedback on non-alcohol/health related topics delivered in all weekly rounds (active control)
11060204|NCT04356261|Active Comparator|Light Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 33% of weekly rounds
11060205|NCT04356261|Active Comparator|Heavy Dose of Alcohol PNF|Personalized Normative Feedback on Alcohol Use delivered in 67% of weekly rounds
11060206|NCT04356248|Experimental|High-intensity interval training + energy management education|"High-intensity interval training (HIIT): physiologically defined heart rate-controlled cycling with 80-100 rounds per minute (rpm) at 95-100% of maximum heart rate (HRmax). Participants will perform 5 × 1.5-min high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 min with the aim to achieve 60% of HRmax.
~Energy management education (IEME): face-to-face education sessions of 6.5 h in duration over a 3-week period, all conducted by a trained occupational therapist. Participants acquire knowledge and understanding about factors that influence energy and the consequences of fatigue on their habits and lifestyle. Six weeks after returning home, the participants will receive a reinforcement letter in the form of information material to remember the content of the IEME and to reinforce the implementation of the behaviour change in managing energy."
11060207|NCT04356248|Active Comparator|Low-intensity training + progressive muscle relaxation|"Low-intensity training (ST): participants will exercise for 24 min continuously at 65% of participants' HRmax (60-70 rpm).
~Progressive muscle relaxation (PMR): The aim of PMR is to achieve enhanced mental relaxation by reducing muscle tension. Participants will attend six 1-h group sessions over the 3-week intervention period, instructed by a trained physical therapist. Six weeks after returning home, the participants will receive a reinforcement letter with information material for remembering the content of the PMR techniques and to reinforce the implementation of the exercises at home."
11060208|NCT04356235||A:Exp-impl-mastopexy|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
11060209|NCT04356235||B: exp-impl-mastopexy+mesh|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
11060210|NCT04356235||C: exp-impl-mastopexy+implant|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
11060211|NCT04356235||D: exp-impl-mastopexy+implant+mesh|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
11060212|NCT04356235||E: simple masectomy|unilateral simple mastectomy
11060213|NCT04356235||F: bilateral exp-impl|after bilateral SSM, ASM, NSM, expander-implant exchange
11060214|NCT04356222|Experimental|Leptomeningeal Metastasis|Durvalumab + Intrathecal chemotherapy
11060215|NCT04356209|Experimental|EXPERIMENTAL GROUP|ePRO intervention + PRAVASTATINE treatment
11060216|NCT04356209|Other|CONTROL GROUP|PRAVASTATINE treatment ( without ePRO)
11060217|NCT04356196|Experimental|Verapamil group|45 patients will receive 80 mg oral verapamil 3 hours pre-operative
11060218|NCT04356196|Experimental|Bisoprolol group|45 patients will receive Bisoprolol 5mg PO 3 hours preoperative
11060219|NCT04356196|Experimental|placebo group|45 patients will receive placebo tablet PO 3 hours preoperative .
11060220|NCT04356183|Other|Counseling Health As Treatment (CHAT)|CHAT is a control arm designed to reflect traditional clinical counselling.
11060221|NCT04356183|Experimental|Supervised Weight loss and Exercise Training (SWET)|SWET includes supervised aerobic (3x/w) and resistance (2x/w) training plus a weekly weight loss session.
11060222|NCT04356170|Active Comparator|TPF (docetaxel, cisplatine, 5-FU)|Docetaxel, cisplatine, 5-FU administered, every 3 weeks for a total of 3 cycles
11060223|NCT04356170|Experimental|TPFm (docetaxel, cisplatine, 5-FU) modifié|Docetaxel, cisplatine, 5-FU administered, every 2 weeks for a total of 6 cycles
11060224|NCT04356157|Other|Special day|The special day takes place with an extraordinary opening of the clinical centre once a month on a pre-festive day (Saturday). During this day, access will be reserved exclusively for men, including those who are not on treatment for HIV. The centre will offer free health promotion services to all participants.
11060225|NCT04356157|Other|Male Champions|"The male champion is a figure present in a few settings which carries out home visits with men and couples and follows up with men who did not accompany their partners to Antenatal Care visits. Usually, this role is covered by the female Expert Clients, namely HIV+ patients working in the organization as volunteers after appropriate training. Some men among patients who are on treatment will be identified and trained to cover this role."
11060226|NCT04356157|Other|Nudge|The intervention based on the use of incentives (nudge) to men who follow the prevention and treatment program aims to evaluate whether this action is effective in guiding behaviour change towards the test, treatment, involvement and adherence to therapy approach.
11060227|NCT04356157|Other|No intervention|No intervention will be carried out in a center.
11060228|NCT04356144||Critical infection|Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU
11060343|NCT04355338||70-79 tears|Participants aging 70-79 years
11060229|NCT04356131|Experimental|experimental group|Students in the experimental group were taught about massage and progressive relaxation exercises (PRE). The phases of the massage and PRE trainings were first explained by being demonstrated by the author on herself. In the meantime, the trainings were video-taped and uploaded to the mobile phones of the students. After the author, each student was made to perform massage and PRE. Both the exercises and massage techniques were daily performed 3 times a day after pain had started and relaxation exercises lasted 30 minutes whereas massage was performed for 15 minutes consecutively
11060230|NCT04356131|No Intervention|control group|The students in the control group continued their routines during the study.
11060231|NCT04356118|Experimental|Endostatin Therapy for NSCLC of LM|"Recombinant Human Endostatin + intrathcal methotrexate+Targeted drugs for non-small cell lung cancer
~Recombinant Human Endostatin:15mg/endostatin;The dose is 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles.
~intrathcal methotrexate :Intrathecal chemotherapy specified dose on specified days.
~Targeted drugs for non-small cell lung cancer:
~EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs ."
11060232|NCT04356105|Active Comparator|Minimal Stimulation Group|Minimal dose stimulation ovarian induction protocol given to poor responders, involving letrozole, low dose recombinant FSH and GnRH antagonist
11060233|NCT04356105|Active Comparator|Microflare Group|Microflare ovarian induction protocol given to poor responders, involving OCP, GnRH agonist, high dose recombinant FSH
11060234|NCT04356092|Experimental|Perfusion|Consecutive patients scheduled to undergo infrapopliteal angioplasty or stenting, or both, as part of their standard treatment for Rutherford-Becker class 5 and 6 chronic limb-threatening ischemia, were included in the study. All procedures were performed using local anesthesia. An antegrade access was used in all patients followed by the deployment of a 5 or 6 Fr arterial sheaths. A semi-lateral foot projection was preferred and the pre-revascularization DSA of the foot was performed via a 5 Fr angiographic catheter placed at the distal third of the popliteal artery. Following revascularization of one or more tibial arteries, the catheter was placed at the same popliteal segment and post-procedural DSA of the foot was performed following the exact pre-revascularization injection protocol at the same semi-lateral projection. The 2D-perfusion imaging and analysis of the DICOM files was performed after revascularization.
11060235|NCT04356079||Migraine patients|
11060236|NCT04356079||Control|
11060237|NCT04356066|Other|Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise|"History taking: age, sex, disease duration, history of present illness, drug intake, past and family history.
~Physical examination including thorough clinical examination.
~Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018)."
11060238|NCT04356040|Experimental|Main Study|
11060239|NCT04356040|Experimental|HSP Sub-Study|
11060240|NCT04356027|Other|Standard of Care: Angiography, OCT, FFR, and VFR|Participants will have an Angiography (prior procedure), an OCT pullback, a Fractional Flow Reserve measurement and a virtual flow reserve offline calculated.
11060241|NCT04356001|Experimental|Socket preservation group|"Extraction sockets filled with a one-piece dual tissue graft harvested from the tuberosity using an adjusted trephine."
11060242|NCT04355988|Active Comparator|Well controlled diabetics|Nonsurgical root canal treatment
11060243|NCT04355988|Active Comparator|Poorly controlled diabetics|Nonsurgical root canal treatment
11060244|NCT04355988|Active Comparator|Healthy control group|Nonsurgical root canal treatment
11060245|NCT04355975||Medical Therapy / Anticoagulation|
11060246|NCT04355975||Systemic Lysis|
11060247|NCT04355975||Interventional Therapy for PE|
11060248|NCT04355975||Surgical Embolectomy|
11060249|NCT04355962|Experimental|Sevoflurane Sedation|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
11060250|NCT04355962|Active Comparator|Intravenous|No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine
11060251|NCT04355949|Experimental|Patients with premature ejaculation|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
11060252|NCT04355949|Experimental|Normal subjects|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
11060253|NCT04355936|Experimental|TELMISARTAN|Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
11060254|NCT04355936|No Intervention|CONTROL|Patients in this group will receive standard care.
11060255|NCT04355910|Experimental|Intermittent fasting mimic-diet (IFD)|Restrict 75% energy on two non-consecutive days each week.
11060256|NCT04355910|Active Comparator|Continuous calorie restriction (CCR)|A daily 25% energy-restricted Mediterranean-type diet
11060257|NCT04355910|No Intervention|Control|No advice to restrict energy
11060258|NCT04355897|Experimental|Convalescent COVID 19 Plasma|Subjects will receive and intravenous infusion of 500 mls of Convalescent COVID 19 Plasma.
11060259|NCT04355858|Experimental|NF1 mutated|If a patient were NF1 mutated, she would receive SHR7390(MEK1/2 inhibitor) and Faminitib.
11060260|NCT04355858|Experimental|gBRCA mutated|If a patient were gBRCA mutated, she would receive SHR3162 (PARP inhibitor)and SHR6390(CDK4/6 inhibitor) .
11060261|NCT04355858|Experimental|HER2 activated mutated|If a patient were HER2 activated mutated and had not previously used capecitabine, she would receive Pyrotinib and Capecitabine , while if the patient have previously used capecitabine, she would only use pyrotinib as a single agent.
11060262|NCT04355858|Experimental|PDGFRb mutated|If a patient were PDGFRb mutated, she would receive Faminitib.
11060263|NCT04355858|Experimental|CD8 ≥20%|If a patient's IHC showed CD8 ≥20%, she would receive SHR1210(PD-1 antibody ) ,nab-paclitaxel and Faminitib.
11060264|NCT04355858|Experimental|PAM pathway mutated|If a patient had any PAM pathway mutation, she would receive Everolimus(mTOR inhibitor) combined with nab-paclitaxel.
11060265|NCT04355858|Experimental|AR≥10%|If a patient's IHC showed AR≥10% , she would receive SHR2554(EZH2 inhibitor) and SHR3680(AR inhibitor).
11060266|NCT04355858|Experimental|Epigenetic Cohort|In this cohort, a patient would receive SHR2554(EZH2 inhibitor) and SHR3162 (PARP inhibitor).
11060344|NCT04355338||80+ years|Participants aging 80 years or more
11060267|NCT04355858|Experimental|Combined Immunity Cohort|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1701(anti-PD-L1/TGF-βRII bifunctional fusion protein) .
11060268|NCT04355845|Experimental|Sumatriptan and PF-06651600 DDI|In Period 1, participants will receive a single oral 25 mg dose of sumatriptan on Day 1 in the morning. In Period 2 on Day 1, participants will receive a single oral 25 mg dose of sumatriptan and a single 400 mg oral dose of PF-06651600 in the morning. In Period 3 participants will receive a single 400 mg oral dose of PF-06651600 in the evening of Day 1, and then a single oral 25 mg dose of sumatriptan in the morning of Day 2.
11060269|NCT04355832|Placebo Comparator|Placebo 1|The participants will be randomized to placebo infusion.
11060270|NCT04355832|Placebo Comparator|Placebo 2|The participants will be randomized to placebo infusion.
11060271|NCT04355832|Experimental|GLP-1|The participants will be randomized to Glucagon-like peptide-1 infusion.
11060272|NCT04355819|Experimental|Disclosure before|Patients will be told that a hernia was found on CT before the follow-up survey is administered.
11060273|NCT04355819|Experimental|Disclosure after|Patients will be told that a hernia was found on CT after the follow-up survey was administered.
11060274|NCT04355806||Vaccinated NSCLC group|This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
11060275|NCT04355806||Vaccinated Health group|This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
11060276|NCT04355806||Unvaccinated NSCLC group|This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
11060277|NCT04355780||Subgroup 1|Composed of HCT patients with respiratory failure requiring intubation and mechanical ventilation.
11060278|NCT04355780||Subgroup 2|Composed of oncology patients (solid tumor or leukemia patients) who have not undergone HCT and who have respiratory failure requiring intubation and mechanical ventilation.
11060279|NCT04355780||Subgroup 3|Composed of chimeric antigen T-cell receptor infusion recipients who have respiratory failure requiring intubation and mechanical ventilation.
11060280|NCT04355767|Experimental|Convalescent Plasma|Participants receive 1 unit of convalescent plasma.
11060281|NCT04355767|Placebo Comparator|Placebo|Participants receive 1 unit of saline with multivitamin.
11060282|NCT04355754|Experimental|mechanically ventilated patients|"Adult ICU patients who are mechanically ventilated and who do not require complex modes of ventilation.
~A designated flow divider (Ventil) will be used to divide inspiratory gas flow from ventilator in two separate streams - one to the patient and the second to the artificial lung"
11060283|NCT04355741||Ambulatory|Patients that are self-isolated at home
11060284|NCT04355741||Ward|Patients that are in an isolated room at the hospital
11060285|NCT04355741||ICU|Patients that are in the ICU of the hospital
11060286|NCT04355728|Experimental|UC-MSCs Group|Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
11060287|NCT04355728|Placebo Comparator|Control Group|Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
11060288|NCT04355702||Lupus patients treated by hydroxychloroquine|Lupus patients treated by hydroxychloroquine
11060289|NCT04355702||Lupus patients not treated by hydroxychloroquine|Lupus patients not treated by hydroxychloroquine
11060290|NCT04355689|Experimental|NPI-001|NPI-001 Tablet, 250 mg, BID
11060291|NCT04355689|Placebo Comparator|Placebo|Placebo Tablet, BID
11060292|NCT04355676|Experimental|Selinexor 40mg|Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
11060293|NCT04355676|Experimental|Selinexor 20mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
11060294|NCT04355663|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
11060295|NCT04355663|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
11060296|NCT04355663|Experimental|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
11075714|NCT04246463||Abdominal - EVAR|
11060299|NCT04355637|Experimental|Intervention|patients receiving standard of care to treat their pneumonia + inhaled budesonide
11060300|NCT04355624||ICU patients|COVID-19 patients admitted in Intensive Care Units
11060301|NCT04355624||Non ICU patients|COVID-19 patients admitted in conventional units
11060302|NCT04355611||Patients with MS or NMO|Cohort study evaluating the epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
11060303|NCT04355598|Experimental|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
11060304|NCT04355598|Active Comparator|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
11060305|NCT04355598|Placebo Comparator|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
11060306|NCT04355585|Experimental|Male|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
11060307|NCT04355585|Experimental|Female|Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.
11060308|NCT04355572|Experimental|Vitamin D Supplement|Patients will take vitamin D tablet with 4,000IU daily for 6 months.
11060309|NCT04355572|Placebo Comparator|Placebo|Patients will take placebo for 6 months
11060310|NCT04355559||conventional oxygen therapy|Continuous use of current oxygen therapy
11060311|NCT04355559||high flow nasal cannula|change the oxygen therapy to high flow nasal cannula
11060312|NCT04355559||Noninvasive ventilation|change the oxygen therapy to noninvasive ventilation
11060313|NCT04355546||COPD patients|Trimbow 87/5/9 pMDI for COPD prescribed according to licensed indication
11060314|NCT04355533|Experimental|Children|
11060315|NCT04355533|Experimental|Parents|
11060316|NCT04355533|Experimental|Family|
11060317|NCT04355520|Experimental|TQ-B3525 tablets combined with fulvestrant injection|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
11060318|NCT04355507||Patients with suspicions of COVID-19 pneumonia|Patients with suspicions of COVID-19 pneumonia
11060319|NCT04355468||Control group|General anaesthesia was induced with midazolam 0.1 mgkg-1, propofol 2 mgkg-1 and cisatracurium 0.15 mgkg-1. Anaesthesia was maintained with one minimal alveolar concentration (MAC1) sevoflurane. Patients awoke from anaesthesia in the postanaesthesia care unit (PACU) where extubation was performed by an anaesthetist after administration of incremental doses of atropine and neostigmine, as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia or until side effects occurred. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
11060320|NCT04355468||Opioid Free Aneasthesia group|General anaesthesia was induced with midazolam 0.1 mgkg-1, propofol 2 mgkg-1 and cisatracurium 0.15 mgkg-1. Anaesthesia was maintained with one minimal alveolar concentration (MAC1) sevoflurane. Patients awoke from anaesthesia in the postanaesthesia care unit (PACU) where extubation was performed by an anaesthetist after administration of incremental doses of atropine and neostigmine, as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia or until side effects occurred. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
11060321|NCT04355455|Active Comparator|Citalopram|Administration of citalopram to assess the esophageal sensitivity in HV
11060322|NCT04355455|Placebo Comparator|Placebo|Administration of placebo to assess the esophageal sensitivity in HV
11060323|NCT04355442||contained patients|contained patients
11060324|NCT04355442||Comparative patients|Comparative patients
11060325|NCT04355429|Experimental|CAPTOPROL|Inhalation administration by nebulization
11060326|NCT04355429|No Intervention|STANDARS CARE|According to surviving covid-Campaign guidelines
11060327|NCT04355416|Experimental|curcumin oral gel|
11060328|NCT04355416|Other|subgingival scaling and root planing|
11060329|NCT04355403|Experimental|Hyalo Gyn gel|Vaginal application of Hyalo Gyn gel in prefilled applicators
11060330|NCT04355403|No Intervention|No treatment|No treatment application
11060331|NCT04355377||Patients|
11060332|NCT04355364|Experimental|Experimental group|Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.
11060333|NCT04355364|Active Comparator|Control group|Patients will receive the usual care in accordance with good practice.
11060334|NCT04355351|Other|hospital staff exposed to SARS-Cov-2|
11060335|NCT04355351|Other|SARS-Cov-2 infected patient|
11060336|NCT04355338||0-9 years|Participants aging 0-9 years
11060337|NCT04355338||10-19 years|Participants aging 10-19 years
11060338|NCT04355338||20-29 years|Participants aging 20-29 years
11060339|NCT04355338||30-39 years|Participants aging 30-39 years
11060340|NCT04355338||40-49 years|Participants aging 40-49 years
11060341|NCT04355338||50-59 years|Participants aging 50-59 years
11060345|NCT04355325|Active Comparator|Experimental|modified monolithic zirconia crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
11060346|NCT04355325|Placebo Comparator|control|metal ceramic crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
11060347|NCT04355312|Experimental|Kysindo|Group of 45 patients with short-term desire for pregnancy who will undergo laparoscopic ovarian cystectomy with use of indocyanine green. Evaluation of the ovarian reserve preoperatively and longitudinal cohort follow-up after surgery at 6 months and 12 months. Analysis by a new imaging technique.
11060348|NCT04355299|Experimental|Intervention group|a mixed exercise program including aerobic, balance, and resistance exercises that were personally tailored.
11060349|NCT04355299|Other|control group|usual care
11060350|NCT04355286|Experimental|Part 1, one-arm open label pilot study|Part 1 is an open label, 1-arm pilot study to evaluate the systemic absorption and effects of multiple applications of a market-image topical sunscreen formulation containing BEMT (6%) under maximum use conditions in healthy adult subjects.
11060351|NCT04355273|Experimental|Heparin with a concentration of 2 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
11060352|NCT04355273|Experimental|Heparin with a concentration of 4 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
11060353|NCT04355273|Placebo Comparator|normal saline|normal saline is placed in a pressure bag with a pressure of 300 mmHg
11060354|NCT04355260|Experimental|Hypertrophic Obstructive Cardiomyopathy|
11060355|NCT04355247|Experimental|Single Arm|"Patients will be admitted to a regular room in the hospital (not ICU)
~They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.
~Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
11060356|NCT04355234|Experimental|all patients|
11060357|NCT04355234|Experimental|patients who presented a SARS-CoV-2 infection confirmed by PCR|
11060358|NCT04355221|Active Comparator|Group A|using the standard settings of pulsed radiofrequency technique (PRFT). two cycles, each one for 2 minutes at 45 Volts (V) with a pulse width of 10 milliseconds (ms) and a pulse frequency of 4 Hertz (Hz). The cut-off needle tip temperature is set at 420 Celsius (C).
11060359|NCT04355221|Experimental|Group B|using prolonged duration of PRFT. four cycles, each one for 2 minutes at 45V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
11060360|NCT04355221|Experimental|Group C|using higher voltage PRFT.. two cycles, each one for 2 minutes at 60V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
11060361|NCT04355208|Experimental|Intervention|Restoration of anterior teeth using monochromatic layering technique using body shade (filtek universal from 3m
11060362|NCT04355208|Active Comparator|comparator|Restoration of anterior teeth using polychromatic layering technique using Enamel and Dentin shades (filtek Z350 xt from 3m
11060363|NCT04355195||Cohort before training|500 patients should be asked to participate in the project in the phase of zero value measurement. The documentation of the routine data before the training phase relates to patients aged ≥70 years, male and female, who are undergoing surgery.
11060364|NCT04355195||Cohort after training|From October 1st, 2020, the documentation of the routine data will begin after the training phase: 1,700 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2023.
11060365|NCT04355169|Experimental|Naldemedine 1.25 mg|Participants will receive 1.25 mg naldemedine twice daily (BID) beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
11060366|NCT04355169|Experimental|Naldemedine 2.5 mg|Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
11060367|NCT04355169|Experimental|Naldemedine 5 mg|Participants will receive 5 mg naldemedine BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
11060368|NCT04355169|Placebo Comparator|Placebo|Participants will receive matching placebo BID beginning on the day of surgery and for up to a maximum of 10 days post-surgery.
11060369|NCT04355156|Experimental|Axitinib|small molecule multi-kinase inhibitor
11060370|NCT04355156|Placebo Comparator|Placebo|
11060371|NCT04355143|Experimental|Colchicine plus current care|Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians
11060372|NCT04355143|Active Comparator|Current care alone|Current care per UCLA physicians alone (control arm)
11060373|NCT04355117|Experimental|Treatment: TEV-48125|
11060374|NCT04355104|Experimental|Education+standard physical therapy|Consist of 37 patients will take education sessions in addition to standard physical therapy.
11060375|NCT04355104|Active Comparator|Standard physical therapy|Consist of 37 patients take just standard physical therapy.
11060376|NCT04355091|Experimental|Intervention Group|"The pregnant women in this group will be informed about the application of EFT with a written material.
~The pregnant women who have undergone EFT will be interviewed a week or two after the application, and how they feel and whether the problem still disturbs him. If a new issue is reported, similar actions will be repeated for this new issue. The number of EFT sessions was decided based on the condition of the pregnant woman. After all EFT sessions are completed, a re-evaluation (post-test) of Edinburgh Postpartum Depression Scale, Stress Coping Scale and State-Trait Anxiety Inventory will be done.
~The same participants will be asked to apply the other inventories and the postpartum interview form if she had birth three months and six months after the last application (follow-up). In the follow-up study performed three months after the last application, EFT will be applied to the pregnant women in need."
11060402|NCT04354948|Placebo Comparator|No pain (Hypotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 3 min wall squat exercise
11060403|NCT04354935|Active Comparator|Méthode 1 ( iTBS)|target region: Dorsolateral Prefrontal left Fréquence : 50 Hz Intensity of the stimulation : 120% SM duration : 3 minutes Number of pulses : 600
11060623|NCT04353284|Experimental|Camostat mesylate|Camostat mesylate 200mg taken 7 days.
11075715|NCT04246463||Custom Device|
11060377|NCT04355091|No Intervention|control group|"The participants in this group will be talked about the problems they should have in routine midwifery care, the problems they encounter during pregnancy or postpartum period and the subjects they want to receive information.
~If necessary, suggestions will be made for problems related to pregnancy, postpartum period or newborn care. Again, with these participants, after the depression risk determination (pre-test), after the interviews ended (post-test), three months and six months after the last application, Edinburgh Postpar All Depression Scale, Stressful Life Events List, Stress Coping Scale. If the pregnant woman has given birth, State-Trait Anxiety Inventory and postnatal interview form will be performed."
11060378|NCT04355078|Experimental|Neuromuscular Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks. The involved leg is used if nothing else is stated that includes Walking on a treadmill, Squatting exercises, Single leg stance exercise Balance reach leg and arm exercises, Lunge exercises: anterior, lateral and posterior, Step-up and step down exercises, Single leg standing on balance mat, appropriate knee and hip position, Backwards and sideways walking for 5 steps on each side 1, 1 leg and 2 leg Wobble board Exercise and progress after every two weeks
11060379|NCT04355078|Experimental|Strength Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks that includes straight leg raising exercises, Supine position-isometric quadriceps contraction, Supine position-knee flexion and extension ROM exercises, the heel in contact with the bench during the ROM, Prone position-straight leg raising exercises, Prone position-knee flexion & Extension ROM exercises, Stationary biking-before reaching 100 degrees of flexion(Progression: stair climbing and strength exercises), Standing-full weight-bearing, controlled balance double-limb support during parallel and diagonal stance, controlled knee extension, emphasis on full knee extension in weight-bearing position 3 10 reps Standing heel rising exercises both legs and one leg, 1 leg and 2 leg Wobble board Exercise, Step Up and down low height, Squatting exercises without bars/weight, Hamstrings, hip adductor and abductor strengthening exercises and progress after every two weeks
11060380|NCT04355065|Experimental|Cognitive Training with Virtual Reality Videogame|"The Secret trail of mon is a therapeutic video game that has been created for the cognitive training of patients with ADHD.
~Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: attention, memory, reasoning, planning and visuospatial ability.
~Patients have to go to the hospital once a week for training sessions of approximately forty minutes duration during 12 weeks."
11060381|NCT04355065|Experimental|Cognitive Training with Therapeutic chess|"The training in Therapeutic chess consists of four sections:
~Video tutorial: Weekly videos have been recorded in which a chess board and the image of the psychologist explaining the lesson appear. Each week a chess concept will be explained.
~Traditional chess exercises Therapeutic chess exercises: The exercises use the elements of chess but it is not necessary to know how to play chess to perform them. The purpose of the exercise is to work on a specific cognitive area each week.
~Playing online games: The patient must play a minimum of 2 online games on the chess platform chess24.es . The psychologist will follow the progress of each patient.
~At the end of the week, the patient should send an email to the psychologist with the completed exercises and then they will receive a personalised email. This group carries out all the treatment online from their home."
11060382|NCT04355065|Active Comparator|Control Group|This group corresponds to the control group. The control group continues with their prescribed pharmacological treatment without any cognitive intervention. The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects.
11060383|NCT04355052|Active Comparator|A - HCQ + AZT|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
11060384|NCT04355052|Experimental|B - HCQ + CAM|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Camostat mesylat 200 mg TID for 10 days
11060385|NCT04355052|No Intervention|C - NI|No Intervention
11060386|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 50 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
11060387|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 65 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
11060388|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 80 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
11060389|NCT04355026|Experimental|hydroxychloroquine and bromhexine|Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID
11060390|NCT04355026|Active Comparator|hydroxychloroquine alone|hydroxychloroquine 200 mg BID
11060391|NCT04355000|Active Comparator|Hall Technique|In Hall Technique, SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
11060392|NCT04355000|Active Comparator|RMGIC restoration|In RMGIC(Vitremer) filling, carious lesion will be completely removed from primary molars using air rotor and local anaesthesia according to need and filled with vitremer rmgic material.
11060393|NCT04354987|Experimental|Group A|R+R+T+T Period 1 : R Period 2 : R Period 3 : T Period 4 : T
11060394|NCT04354987|Experimental|Group B|R+T+R+T Period 1 : R Period 2 : T Period 3 : R Period 4 : T
11060395|NCT04354987|Experimental|Group C|T+R+T+R Period 1 : T Period 2 : R Period 3 : T Period 4 : R
11060396|NCT04354987|Experimental|Group D|T+T+R+R Period 1 : T Period 2 : T Period 3 : R Period 4 : R
11060397|NCT04354974|Active Comparator|Eco Program (Ecological Cognitive Training for Mood Disorders)|"Duration: four months, 16 sessions
~Frequency: One one-hour session and one hour of personal work per week
~Modalities: Paper and pencil exercises and manipulable tools
~Objective: Learning problem-solving strategies for use in daily life
~Modules: Psychoeducation, Information Processing, Memory, Concept Formation, Functional Disorders"
11060398|NCT04354974|Active Comparator|ThOR Program (Remission Oriented Therapy)|"Duration: four months, 16 sessions
~Frequency: One one-hour session and one hour of personal work per week
~Modalities: Paper tools and verbal exchange with the patient
~Objective: Improvement of the patient's quality of life
~Themes: Mood, social skills, autonomy, motivation, sleep"
11060399|NCT04354961|Experimental|Almonertinib 110mg PO once daily|
11060400|NCT04354961|Active Comparator|Paclitaxel (175mg/m2, iv) and carboplatin (AUC=5, iv)|
11060401|NCT04354948|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 3 min wall squat exercise
11060404|NCT04354935|Active Comparator|Méthode 2 (French touch)|target region : dorsolateral prefrontal cortex right Frequency:1HZ Intensity:120% SM duration : 8 Min 30 Sec Number of plulses : 360
11060405|NCT04354935|Active Comparator|Méthode 3 (FDA)|target region: Dorsolateral Prefrontal left Fréquence : 10HZ Intensity of the stimulation : 120% SM duration : 37 minutes Number of pulses : 3000
11060406|NCT04354922|Placebo Comparator|Attention control|Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period
11060407|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
11060408|NCT04354922|Active Comparator|Moderate-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
11060409|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×3/wk|Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
11060410|NCT04354922|Active Comparator|Vigorous-intensity walking exercise ×1/wk|Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period
11060411|NCT04354909||Biological samples|levels of s-CD95-L (ELISA test)
11060412|NCT04354896|Experimental|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.
11060413|NCT04354896|Placebo Comparator|Placebo|Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
11060414|NCT04354883|Active Comparator|Schmitz-Hinkelbein-Method|
11060415|NCT04354883|Active Comparator|Hinkelbein-Schmitz-Method|
11060416|NCT04354870|Experimental|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
11060417|NCT04354870|No Intervention|Control Group|approximately 50 HCW who choose not to be provided HCQ
11060418|NCT04354857||RT-PCR SARS-CoV-2 positive|
11060419|NCT04354857||RT-PCR SARS-CoV-2 negative|
11060420|NCT04354844||Cyanotic and acyanotic group|questinnaire
11060421|NCT04354831|Experimental|ICU Cohort|Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
11060422|NCT04354831|Experimental|Non-ICU Cohort|Patients who are NOT in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
11060423|NCT04354818||People living with HIV|
11060424|NCT04354818||Recipients of Solid Organ Transplants|
11060425|NCT04354818||People Living with Cancer|
11060426|NCT04354818||People with acquired immunodeficiency|Patients with acquired immunodeficiency associated with other immunosuppressive therapy.
11060427|NCT04354818||People with primary immunodeficiency|
11060428|NCT04354805|Experimental|Group A|The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
11060429|NCT04354805|No Intervention|Group B|A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
11060430|NCT04354779||AUVA HCW|health care workers in Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA)
11060431|NCT04354766||Convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary.
11060432|NCT04354766||Hospitalized convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization.
11060433|NCT04354740||Group A : Diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
11060434|NCT04354740||Group B: Non diabetic|group is subdivided into 2sub-groups: Group 1: Group: underwent PCI(Primary or Rescue) Group 2: underwent CABG Patients diagnosed as multivessel disease or left main coronary artery lesion will be included in the study
11060435|NCT04354727|Experimental|APG-1252|
11060436|NCT04354727|Experimental|APG-1252 + Ruxolitinib|
11060437|NCT04354714|Experimental|Ruxolitinib|-Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.
11060438|NCT04354688|Experimental|T3 Certain Tapered implant with DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
11060439|NCT04354688|Active Comparator|T3 Certain Tapered implant without DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
11060440|NCT04354675|Experimental|Artificial intelligence program|Will complete consult with the use of an artificial intelligence program Chatbot.
11060441|NCT04354675|Active Comparator|in-person genetic counseling|Will complete a traditional in-person genetic counseling. consult by meeting with a Genetics Counselor
11060442|NCT04354662|Experimental|Toripalimab combined with FLOT|In the perioperative period, patients with resectable gastric cancer is treated with flot regimen combined with Toripalimab to observe whether the 3-year disease-free survival (DFS) rate, pathological remission rate, R0 resection rate, D2 radical resection rate, 5-year DFS rate and 5-year OS rate could be improved.
11060443|NCT04354649|Experimental|Hydroxychloroquine, plus prednisone|Hydroxychloroquine 5mg/kg PO daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
11060444|NCT04354649|Placebo Comparator|Hydroxychloroquine-matching placebo, plus prednisone|Matching placebo daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose.
11060445|NCT04354636|Experimental|Silver modified atraumatic restorative treatment|Using silver diamine fluoride incorporated with atraumatic restorative treatment
11060446|NCT04354636|Active Comparator|Atraumatic restorative treatment|Using atraumatic restorative treatment without the application of silver diamine fluoride
11060447|NCT04354623||High Risk Subjects (n=50)|All subjects will be recruited from falls and geriatrics clinics at Vancouver General Hospital. These clinics see about 2500 patients per year and are currently used for research recruitment. Each clinic patient has gait speed measured, which will allow to recruit both high and low risk fallers. This test will allow us to recruit 50 subjects at marked risk for falls, providing us with prospectively gathered dataset of greater than 100 events, five times higher than any other sensor study.
11060448|NCT04354623||Low Risk Subjects (n=50)|We will use newspaper advertisements to recruit and then screen low risk subjects. All subjects will have a gait speed > 0.8 m/s and have had no falls in the last year.
11060449|NCT04354610|Other|Patients hospitalized for Covid-19 infection|"Patients hospitalized for Covid-19 infection will undergo the following evaluations:
~Clinical examination
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
11060450|NCT04354597|Experimental|Study Arm A (HCQ & AZ)|Subjects will receive weekly HCQ 400mg X 1 Day PO and AZ 500mg PO X 3 Days; weekly for 16 weeks.
11060451|NCT04354597|No Intervention|Study Arm B (No treatment)|Subjects will receive no treatment in this group and will be serving as control.
11060452|NCT04354571|Experimental|GROUP (Erector spinae block):|were given general anesthesia plus Erector spinae plane block
11060453|NCT04354571|Active Comparator|GROUP (caudal block):|were given general anesthesia plus caudal block
11060454|NCT04354558||survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
11060455|NCT04354558||non-survival patients|The cohort will be dichotomised in survival/non-survival groups according to the issue during ICU stay
11060456|NCT04354545||Group 1|Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
11060457|NCT04354532||209 patients were submitted to primary LBSG|All patients submitted to primary Laparoscopic Banded Sleeve Gastrectomy were examined. Collected data included demographic factors, pre-operative weight, pre-operative BMI, operative time, surgical complications, and clinical outcomes in terms of short and mid-term weight loss.
11060458|NCT04354519||Confirmed Cases|"Diagnosed by health professional / Covid-19 test
~Monitored through fortnightly questionnaires"
11060459|NCT04354519||Not Covid-19 cases|"Through self report no suspicion of COVID-19, tested by fortnightly questionnaire.
~non Covid Cases can become COVID cases through self report."
11060460|NCT04354519||Suspected Covid-19 Cases|"Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed.
~Fortnighly questionnaire"
11060461|NCT04354493|Experimental|Baseline and Training|This group consists of a baseline and training conditions only.
11060462|NCT04354493|Experimental|Baseline, Training, and Control|This group stops training condition sooner and returns to a control to evaluate carry-over effects.
11060463|NCT04354480|Experimental|RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
11060464|NCT04354480|Placebo Comparator|Placebo|Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
11060465|NCT04354467||Acute Kidney Injury due to Nephrotoxic medication|
11060466|NCT04354467||No Acute Kidney Injury due to Nephrotoxic Medications|
11060467|NCT04354454|Active Comparator|Fitbit|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit only group.
~-- Participants will track their daily steps for 4.5 months with use of a Fitbit
~The study interventions involved in this research are:
~Fitbit (also known as a wearable accelerometer or fitness tracker)
~Way to Health platform
~Actigraph GT9X Link (a research grade accelerometer)
~Surveys/Interviews"
11060468|NCT04354454|Experimental|Fitbit + Game + Support from a Teammate|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit + Game + Support from a Teammate.
~Participants will select a step goal, use a Fitbit to track daily activity, and select a teammate (e.g. family member or friend) who they think will help them achieve their goals.
~Participants will participate a 3-month game designed to increase activity and then followed for another 1.5 months to see if their increased activity can be maintained without the game.
~The study interventions involved in this research are:
~Fitbit (also known as a wearable accelerometer or fitness tracker)
~Help from a Teammate (i.e. friend or family member chosen to help reach goals, if applicable
~Way to Health Platform
~Actigraph GT9X Link (a research grade accelerometer)
~Surveys/Interviews"
11060469|NCT04354441|Experimental|hydroxychloroquine|10-day course of hydroxychloroquine 200 mg tablet twice a day. To be taken orally.
11060470|NCT04354441|Placebo Comparator|Placebo|An identical appearing placebo. To be taken orally twice a day for 10-days.
11060471|NCT04354428|Placebo Comparator|Ascorbic acid and Folic acid|Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
11060472|NCT04354428|Experimental|Hydroxychloroquine and Folic Acid|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5])
11060473|NCT04354428|Experimental|Hydroxychloroquine and Azithromycin|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
11060474|NCT04354428|Experimental|Lopinavir-ritonavir|LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
11060475|NCT04354428|Placebo Comparator|Ascorbic acid|Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days
11060476|NCT04354415|Active Comparator|Tourniquet Group|Tourniquet application during procedures
11060477|NCT04354415|Experimental|Non-Tourniquet group|No application of tourniquet for procedures
11060478|NCT04354389|Experimental|DAS181 b.i.d.+ standard local care for COVID-19|4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19
11060479|NCT04354389|Placebo Comparator|Placebo+ standard local care for COVID-19|nebulized inhalation for 10 consecutive days + standard local care for COVID-19
11060480|NCT04354389|Experimental|DAS181 q.d.+ standard local care for COVID-19|4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19
11060481|NCT04354376||Loop diuretics, thiazides, dihydropyridines|Reference group
11060482|NCT04354376||Telmisartan|Exposure group
11060483|NCT04354363|Active Comparator|PRP|women who will receive PRP before ICSI
11060484|NCT04354363|No Intervention|No PRP|women who willnot receive PRP before ICSI
11060485|NCT04354350||Ramipril|Reference group
11060486|NCT04354350||Telmisartan|Exposure group
11060487|NCT04354337|Experimental|Intervention Group|8-weeks online program with weekly modules for parents to learn about specific sleep topics and implement behavioral changes to improve their child's sleep.
11060488|NCT04354324|Experimental|The test group|Oral administration of 30mci once on an empty stomach.
11060489|NCT04354324|Active Comparator|The control group|Oral administration of 100mci once on an empty stomach.
11060490|NCT04354311|Experimental|Experimental|"Anesthetic induction : total target-controlled intravenous anesthesia d was used with propofol and remifentanil. The effect site was then gradually increased to obtain a satisfaction depth of anesthesia. Assisted ventilation was then started by facemask ventilation (Sat O2>95% and expired CO2 fraction normal, tidal volume of 8 mL/kg, a respiratory rate of 12 cycles per minute, with an FiO2 100% with no positive end expiratory pressure.
~After stabilisation period of 2 minutes and record of the patient's parameters, a standardized nociceptive stimulation was applied at the level of the ulnar nerve (PTC of 50 Hz at 70 mA). The variation of ANI score and hemodynamic parameters were collected during the 2 following minutes.
~After stabilization of ANI, orotracheal intubation was attempted. Maximal variation of heart rate (HR), blood pressure and the occurrence of somatic manifestations (intense cough, movement, tears) were recorded."
11060491|NCT04354298|Experimental|Fall 2019 ID Class|The ID group participated in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2019-December 2019.
11060492|NCT04354298|Experimental|Fall 2020 ID Class|The ID group will participate in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2020-December 2020.
11060493|NCT04354298|No Intervention|Control Group|Participants are pre- and post-tested 12-14 weeks apart after not having changed anything drastic in their daily life.
11060494|NCT04354272||Questionnaire|
11060495|NCT04354259|Experimental|Ambulatory Cohort - Treatment|to receive a single dose of peginterferon lambda 180µg SC at baseline (day 0).
11060496|NCT04354259|Placebo Comparator|Ambulatory Cohort - placebo|Patients in the arm will be given a single injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
11060497|NCT04354259|Experimental|Hospitalized Cohort - Treatment|To receive a dose of peginterferon lambda 180µg SC at baseline and a second dose on day 7.
11060498|NCT04354259|Placebo Comparator|Hospitalized Cohort - placebo|Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 7.
11060499|NCT04354246|Experimental|COM902 Monotherapy Dose Escalation Arm.|Monotherapy Dose Escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation Cohorts using a rules-based design. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
11060500|NCT04354233|Experimental|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
11060501|NCT04354233|No Intervention|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
11060502|NCT04354220||no shunt, no lung injury|ventilated newborns / infants / children with healthy lungs and without or corrected congenital heart disease and no intra-/extra-cardiac shunt
11060503|NCT04354220||mild lung injury|ventilated newborns / infants / children with mild lung injury (OI between 4 and 8)
11060504|NCT04354220||moderate-severe lung injury|ventilated newborns / infants / children with moderate or severe lung injury (OI above 8)
11060505|NCT04354220||shunt lesion|ventilated newborns / infants / children with cyanotic heart diseases and therefore existing intra-cardiac or extra- cardiac right-left shunt lesions
11060506|NCT04354207||Atopic dermatitis|
11060507|NCT04354207||Asthma|
11060508|NCT04354207||Healthy individuals|
11060509|NCT04354194|Experimental|Conventional Physiotherapy Group|This group will receive 15 sessions of conventional physiotherapy programme 5 times per week.
11060510|NCT04354194|Experimental|Osteopathic Manipulative Treatment Group|This group will receive 9 sessions of Osteopathic Manipulative Treatment programme 3 times per week.
11060511|NCT04354168|Experimental|Nthabi mHealth Application|Twenty women from each of the ten district hospitals will be recruited for a total of 200 participants. Each district hospital will have a separate administrative page on the Nthabi server where women will be enrolled with a unique username and password. Upon enrollment, the women will be asked to engage with Nthabi for two months to discuss the relevant content areas they are interested in learning more about.
11060512|NCT04354155|Experimental|Thromboprophylaxis|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 mg/kg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
11060513|NCT04354142|Experimental|iSpy|In addition to usual care, participants in the intervention group will receive the iSpy intervention.
11060550|NCT04353882||patients with tumor recurrence|
11060514|NCT04354142|No Intervention|Control|The control group participants will continue to use their usual method of carbohydrate counting for a 3-month period.
11060515|NCT04354129||PID/SID Cutaquig Treated Patients|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
11060516|NCT04354116|Experimental|MARPE|Maxillary expander anchored in mini-implants (MARPE)
11060517|NCT04354116|Active Comparator|Hyrax|Tooth-born anchored maxillary expanders, without mini-implants
11060518|NCT04354090|Experimental|Cohort 0.3-mg|Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort
11060519|NCT04354090|Experimental|Cohort 0.7-mg|Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22
11060520|NCT04354090|Experimental|Cohort 1.5-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22
11060521|NCT04354090|Experimental|Cohort 3.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22
11060522|NCT04354090|Experimental|Cohort 6.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30
11060523|NCT04354077|Experimental|NAc DBS|Subjects will receive bilateral DBS of the NAc
11060524|NCT04354064||Healthy Donor Samples|"Donation of blood and/or urine samples as often as monthly and as many as 12 times in total
~These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise."
11060525|NCT04354064||Samples from Repository and Banking Studies|"Healthy prostate and/or blood and/or urine samples from Genitourinary Repository
~Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies
~Tissue and/or blood samples from Esophageal Repository
~Tissue and/or blood samples from Genitourinary Repository
~Tissue and/or plasma from Sarcoma Tissue Bank
~Tissue and/or plasma from Breast Cancer Bank
~Tissue, plasma, and/or urine from GI Tissue and Blood Bank
~Tissue, blood, and/or urine from Solid Tumor Bank
~Tissue, blood, and/or urine from Lung Cancer Bank
~Tissue and/or blood from Skin Cancer Bank"
11060526|NCT04354051|Experimental|Sodium nitrite|
11060527|NCT04354025|Experimental|Recipient: FLAG + CIML NK Cells + IL-2|-The recipient will begin a chemotherapy regimen of fludarabine, cytarabine and GCSF starting on Day -7. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20 L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. CIML NK cells will be infused at maximum cell dose of 10 x 106/kg. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
11060528|NCT04354025|Other|Donor:|-On Day -1 (one day before the planned NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard apheresis over 4-5 hours (with a target volume of at least 20 L) from the identified haploidentical donor. The apheresis procedure will be done as per standard institutional procedures (which may include placement of a central line if necessary). If the goal minimum NK cell dose will not be met based on the initial assessment of the leukapheresis product, a second collection/procedure may be performed.
11060529|NCT04354012|Experimental|Treatment|methylene blue, gentian violet, and ovine forestomach wound dressings to HS lesions
11060530|NCT04353999|Experimental|980 nm diode laser photocoagulation|980 nm diode laser was used to coagulate the blood over the bone graft particles and achieve a socket seal after socket grafting
11060531|NCT04353999|Active Comparator|Dense polytetrafluroethylene membrane|dPTFE membrane was used to seal the socket after grafting
11060532|NCT04353986|Experimental|Beta thalassemia|HCV infected Beta thalassemia major adolescents
11060533|NCT04353986|Active Comparator|Control|HCV infected, otherwise healthy, sex and age matched to the thalassemia group serving as control group
11060534|NCT04353973|Experimental|ARM A|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).
~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing)."
11060535|NCT04353973|Experimental|ARM B|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).
~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
11060536|NCT04353973|Experimental|ARM C|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.
~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing)."
11060537|NCT04353973|Experimental|ARM D|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.
~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
11060538|NCT04353960||anticholinergic|Patients who receive anticholinergic medication before strabismus surgery
11060539|NCT04353960||non-anticholinergic|Patients who do not received anticholinergic medication before strabismus surgery
11060540|NCT04353947||Healthy older adults|Healthy older adults with 65 years or older
11060541|NCT04353947||Older adults with Alzheimer's disease|Older adults with Alzheimer's disease with 65 years or older
11060542|NCT04353947||Older adults with Parkinson's disease|Older adults with Alzheimer's disease with 65 years or older
11060543|NCT04353934||Respondents|All adults aged 18 or older who elect to respond to the online survey
11060544|NCT04353921||Single-Dose of Psilocybin|
11060545|NCT04353921||Niacin-Control|
11060546|NCT04353908|Active Comparator|kabat|Rehabilitation will be started in both groups of patients and it will be carried out according to Kabat et al., i.e. a proprioceptive neuromuscular facilitation procedure, twice a week for 8 weeks, by an experienced physioptherapist
11060547|NCT04353908|Experimental|collagen injection|Injections of an equally-balanced solution of MD Neural, MD Matrix and MD Muscle (Guna S.p.a., Milan-Italy), containing collagen of porcine origin, will be administered subcutaneously after applying lidocaine/prilocaine cream on the affected side, by a skilled otonaryngologist in the field of injection treatments, twice a week for 8 weeks
11060548|NCT04353895|Experimental|Robotic group (RG)|Patients in the RG group will be operated using the assistance of the Mazor X Stealth robot
11060549|NCT04353895|Active Comparator|O-arm navigation group (NV)|Patients in the NV group will be operated using the guidance of the Stealth navigation
11060552|NCT04353869||Group 1|"Patients with uncomplicated diabetes and low cardiovascular risk
~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA (Éthylènediaminetétraacétique) tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
11060553|NCT04353869||Group 2|"Patients with uncomplicated diabetes and high cardiovascular risk
~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
11060554|NCT04353869||Group 3|"Patients with complicated diabetes
~During a scheduled hospitalization or consultation as part of the follow-up of their diabetes additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
11060555|NCT04353869||Group 4|"Patients without diabetes and with a high cardiovascular risk
~Practical implementation During a scheduled hospitalization or consultation as part of the follow-up of their cardiological problems, additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
11060556|NCT04353869||Group 5|"Patients without diabetes and with a history of cardiovascular event
~Practical implementation During a scheduled hospitalization or consultation as part of the follow-up of their cardiological problems, additions of biological samples, which include:
~A unique venous blood sampling of 9 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes (total: 51 mL) at a single time during the study and collection of 2 monovettes of 1.6 ml urine (total: 3.2 mL)."
11060557|NCT04353856||twin pregnancy|Women followed for a twin pregnancy
11060558|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939|Participants will be treated with escalating doses of IBI939 to determine the MTD.
11060559|NCT04353830|Experimental|Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab|Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.
11060560|NCT04353830|Experimental|Phase Ib Expansion Stage:IBI939+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.
11060561|NCT04353817|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA in the morning and IVA in the evening.
11060562|NCT04353817|Placebo Comparator|Placebo|Subjects will receive placebo matched to ELX/TEZ/IVA in the morning and placebo matched to IVA in the evening.
11060563|NCT04353804|Experimental|Computerized Cognitive Rehabilitation|Computerized Cognitive Rehabilitation
11060564|NCT04353804|Active Comparator|Active Control computer games|Active Control computer games
11060565|NCT04353791|Active Comparator|Experimental arm OST-122 low dose|12 subjects will be randomized to receive low dose OST-122 orally daily for 28 days
11060566|NCT04353791|Active Comparator|Experimental arm OST-122 high dose|12 subjects will be randomized to receive high dose OST-122 orally daily for 28 days
11060567|NCT04353791|Placebo Comparator|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
11060568|NCT04353778|No Intervention|PLWH|People living with HIV (HIV)
11060569|NCT04353778|No Intervention|Healthy Controls|Healthy controls who do not have HIV
11060570|NCT04353778|Active Comparator|Pyridostigmine|PLWH on pyridostigmine 30mg PO TID
11060571|NCT04353778|Placebo Comparator|Placebo|PLWH on placebo
11060572|NCT04353778|Other|nVNS|PLWH to undergo non-invasive vagal nerve stimulation
11060573|NCT04353765||cabozantinib arm|
11060574|NCT04353765||non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm|
11060575|NCT04353739|Experimental|Immediate Treatment (IT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
11060576|NCT04353739|Active Comparator|Delay Treatment (DT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
11060577|NCT04353726|Experimental|Intervention group|Eligible participants will be in an intervention group led by a registered dietitian
11060578|NCT04353713|Experimental|Dextrose Gel|"Dextrose 40% gel will be given immediately following stabilisation (and/or resuscitation) at birth via buccal route. This will be prior to in-house transport from the Delivery Ward/Operating Room to the Neonatal Unit.
~A standard total dose of 1ml of dextrose gel will be administered to each participant. Prior to administration, a single brief oral suction will be given (using routine suction catheter) and 1 dry wipe of inside of both cheeks. This will only be performed if the clinician caring for the newborn considers it appropriate to do so.
~Half the dose of gel (0.5ml) will be squeezed onto the gloved finger (sterile gloves) of administering team member. This half dose will be given on one side of mouth. The remaining half dose (0.5ml) of gel will be administered to the other side of the mouth using a gloved finger. Administration is by massage into the buccal membrane."
11060579|NCT04353713|Placebo Comparator|Placebo|"2% carboxymethylcellulose gel will be given immediately following stabilisation (and/or resuscitation) at birth via buccal route. This will be prior to in-house transport from the Delivery Ward/Operating Room to the Neonatal Unit.
~A standard total dose of 1ml of placebo gel will be administered to each participant. Prior to administration, a single brief oral suction will be given (using routine suction catheter) and 1 dry wipe of inside of both cheeks. This will only be performed if the clinician caring for the newborn considers it appropriate to do so.
~Half the dose of gel (0.5ml) will be squeezed onto the gloved finger (sterile gloves) of administering team member. This half dose will be given on one side of mouth. The remaining half dose (0.5ml) of gel will be administered to the other side of the mouth using a gloved finger. Administration is by massage into the buccal membrane."
11060624|NCT04353284|Placebo Comparator|Placebo|Placebo taken for 7 days.
11060625|NCT04353271|Experimental|Treatment|Subjects in this arm will receive the study drug
11060580|NCT04353700|Active Comparator|Yoga group|A certified yoga instructor led the supervised yoga session. An exercise physiologist taught how to record your Rating of Perceived Exertion to monitor their exercise intensity during the in-home yoga intervention. During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks.
11060581|NCT04353700|No Intervention|Control group|If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
11060582|NCT04353687||Cohort 1 Open Surgeons|Primarily open inguinal hernia surgeon with no or limited previous robotic-assisted experience.
11060583|NCT04353687||Cohort 2 Laparoscopic Surgeons|Primarily laparoscopic inguinal hernia surgeon with no or limited previous robotic-assisted experience.
11060584|NCT04353674|Sham Comparator|Control|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo standard of care
11060585|NCT04353674|Active Comparator|SLEDD with a L-MOD|Patients diagnosed with severe COVID-19: Those admitted to the intensive care unit with evidence of severe respiratory distress syndrome will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
11060586|NCT04353661|Experimental|Arm A Open-label: azithromycin + SOC therapy|Participants will receive azithromycin and SOC theraphy for 52 weeks.
11060587|NCT04353661|Active Comparator|Arm A Open-label: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
11060588|NCT04353661|Active Comparator|Arm B Observational: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
11060589|NCT04353648||Duke ICU/Trauma Center Patients|Any patient admitted to the Duke Trauma Center or Duke ICU will be approached to participate in this study.
11060590|NCT04353635||Patients with class III dentofacial deformity|No intervention as it will be a retrospective study
11060591|NCT04353622|Active Comparator|Robot-assisted Treatment|Rehabilitation protocol was applied with robotic device (HOUSTONBIONİCS ExoRehab UE1).
11060592|NCT04353622|Active Comparator|Conventional Physiotherapy|Conventional physiotherapy program included neurophysiological approaches.
11060593|NCT04353596|Experimental|Stopping/replacing ACEI/ARB|Chronic treatment with ACEI or ARB will be stopped or replaced.
11060594|NCT04353596|No Intervention|Control|No intervention, which means further treatment with ACEI or ARB.
11060595|NCT04353583||ICU patients|Patients with COVID-19 requiring ICU care
11060596|NCT04353583||Non-ICU patients|In-hospital patients with COVID-19 not requiring ICU care
11060597|NCT04353544|Active Comparator|Immediate cord clamping|Immediate cord clamping was defined as clampingwithin 15 seconds of birth
11060598|NCT04353544|Experimental|delayed cord clamping|when the cord stopped pulsing, or five minutes
11060599|NCT04353518|Experimental|Suspension of Mw|"Intradermal suspension of Mw will be administered in two divided doses:
~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal Mw in two divided dose.
~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal Mw administered."
11060600|NCT04353518|Placebo Comparator|Placebo|"Placebo will be administered in two divided doses:
~Dose 1 at Day 0: 0.2 ml (0.1 ml x 2 injection) of intradermal placebo in two divided dose.
~Dose 2 at Day 15 after the first dose: 0.1 ml injection of intradermal placebo."
11060601|NCT04353505|Experimental|Intra-Arterial Delivery of Ketorolac and Dexamethasone|
11060602|NCT04353492|Experimental|Ofatumumab|Ofatumumab 20 mg subcutaneous injections every 4 weeks, following loading of 3 doses in the first 14 days
11060603|NCT04353479|Experimental|Camrelizumab(SHR-1210) Combined With Decitabine|Patients will be administered Camrelizumab(SHR-1210) at D1 and D15 and decitabine at D1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity.
11060604|NCT04353466|Experimental|Trial to asses impact of Elelyso on bone involvement in patien|The infusions will be administered at the selected medical center or in the home care setup. The dose of intravenous (IV) infusions of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months.
11060605|NCT04353427|Experimental|Faith based educational group|"A seven-session faith-based small group educational program using the The Seven Pathways to Healing, Health and Wellness curriculum will be delivered."
11060606|NCT04353414|Active Comparator|Pericapsular Injection (PCI) group|Subjects in PCI group will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
11060607|NCT04353414|Active Comparator|Transmuscular QL Block + Pericapsular Injection (PCI) group|Subjects in the TQLB group will receive the TQLB containing 30mL of 0.5% Bupivacaine Hydrochloride (HCL) plus PCI containing 20 mL of 0.25% of Bupivacaine Hydrochloride (HCL). For PCI, subjects will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
11060608|NCT04353388||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
11060609|NCT04353375|Experimental|HMPL-453|HMPL-453 150mg QD
11060610|NCT04353362|Experimental|Ofloxacin group|
11060611|NCT04353362|Active Comparator|Amoxicillin plus Metronidazole group|
11060612|NCT04353349||Patients operated with an open approach|
11060613|NCT04353349||Patients operated with minimally invasive robotic approach|
11060614|NCT04353349||Patients operated with VATS approach|
11060615|NCT04353336|Experimental|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine with standard of care treatment.
11060616|NCT04353336|No Intervention|No intervention|standard of care treatment alone.
11060617|NCT04353323||Covid area|
11060618|NCT04353323||Non-Covid area|
11060619|NCT04353310|Experimental|Curcumin|
11060620|NCT04353310|Placebo Comparator|Placebo|
11060621|NCT04353297|Experimental|BCI Group|(EEG-)BCI- assisted MI training delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
11060622|NCT04353297|Active Comparator|Control Group|MI training without BCI support delivered as add-on regimen (Standard physiotherapy-3 h/day, 5 day/week).
11060626|NCT04353271|Placebo Comparator|Control|Subjects in this arm will take placebo for 6 days
11060627|NCT04353258|Experimental|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
11060628|NCT04353258|Active Comparator|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
11060629|NCT04353245||Arm treatment (HCQ + Azithro)|Participants that used HCQ + Azithro in their treatment for COVID19
11060630|NCT04353245||Arm control (without HCQ + Azithro)|Participants that did not used HCQ + Azithro in their treatment for COVID19
11060631|NCT04353232||DANCAVAS I and II trials|Enrolment started September 2014 and ended in February 2019. Approx. 24 000 were invited, and approx. 15 000 were examined.
11060632|NCT04353232||VIVA screening trial|Enrolment started October 2008 and ended January 2011. In all, 18 749 men were screened.
11060633|NCT04353219|Experimental|research group|training program with compression stocking
11060634|NCT04353219|Active Comparator|control group|training program without compression stocking
11060635|NCT04353206|Experimental|Intubated COVID-19 patients in the ICU|Mechanically ventilated intubated patients with respiratory failure due to COVID-19
11060636|NCT04353193|Experimental|Terlipressin IV bolus|Terlipressin 1mg IV bolus
11060637|NCT04353193|Experimental|Terlipressin IV continuous infusion|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
11060638|NCT04353193|Experimental|Octreotide IV bolus plus continuous infusion|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
11060639|NCT04353180|Active Comparator|13 cis retinoic acid doses orally|Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
11060640|NCT04353180|Active Comparator|Aerosolized 13 cis retinoic acid|Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
11060641|NCT04353180|Sham Comparator|The standard therapy|Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days
11060642|NCT04353141||Pregnant patients with confirmed COVID-19 infection|
11060643|NCT04353141||Pregnant patients symptomatic for COVID-19|Symptomatic patients suspicious for COVID-19 infection (swab is taken on admission)
11060644|NCT04353141||Pregnant patients asymptomatic for COVID19|Patients asymptomatic for COVID19 with other feto-maternal diseases or who come for delivery or caesarean section
11060645|NCT04353128|Experimental|Melatonin|2 mg of melatonin orally before bedtime for 12 weeks
11060646|NCT04353128|Placebo Comparator|Placebo|Identically looking placebo orally before bedtime for 12 weeks
11060647|NCT04353115||Training with Serious Game|Trained group, 5 weeks training with the serious game; patients have a vestibular impairment.
11060648|NCT04353102|Experimental|YH002|All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.
11060649|NCT04353089||Basic Life Support Participants|All persons attending certified Basic Life Support Courses in Denmark from 2016 to 2019
11060650|NCT04353089||OHCA|Out-of-hospital cardiac arrest victims in Denmark from mid 2016 til mid 2019
11060651|NCT04353076|Experimental|Young adults|Young adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
11060652|NCT04353076|Experimental|Older adults (no cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
11060653|NCT04353076|Experimental|Older adults (cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity) with ambient cooling intervention (i.e., exposure to an air-conditioned room) for hours 5-6.
11060654|NCT04353063|No Intervention|control group|"The patients in the control group will not receive any walking exercise education until the 4-week intervention ends. They will then receive the same education material (How walking is beneficial to your health) and will be told about the benefits of walking."
11060655|NCT04353063|Experimental|experimental group|"Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials How walking is beneficial to muscle mass and your health. And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4."
11060656|NCT04353050|No Intervention|Cohort 1 (retrospective)|Only data from medical records and formalin-fixed paraffin-embedded tissue blocks will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
11060728|NCT04352530|Experimental|The Longest Mile|"Video of spoken word poem from The Bigger Picture Project, The Longest Mile by Tassiana Willis; images of African-American female poet interspersed with images of environment"
11060657|NCT04353050|No Intervention|Cohort 2 (retrospective)|Only data from medical records, formalin-fixed paraffin-embedded tissue blocks and cytologic slides will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
11060658|NCT04353050|Other|Cohort 3 (prospective)|Patients with pigmented lesions on the skin or mucosa who are referred for excisional biopsy will be offered to apply investigated non-invasive adhesive system on their lesion just before the excisional biopsy. After biopsy cytological slides and FFPE tissue blocks will be prepared. All three types of obtained samples will be investigated separately (adhesive patches, cytologic slides and FFPE tissue blocks) for genetic markers whereas cytologic slides and FFPE tissue blocks will be processed also routinely and regular cytologic and histopathologic report will be generated.
11060659|NCT04353037|Experimental|Sub Study 1 Patients|Patients tested for COVID-19 who meet symptomology and age requirements for eligibility
11060660|NCT04353037|Experimental|Sub Study 2 Health Care Workers|Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months
11060661|NCT04353024|Placebo Comparator|Placebo|Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min, resulting in a total dose of 0 mg DMT.
11060662|NCT04353024|Experimental|Low dose|Intravenous bolus of 0 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 54 mg DMT.
11060663|NCT04353024|Experimental|Low dose with bolus|Intravenous bolus of 15 mg DMT + perfusion of 0.6 mg/min DMT over 90 min, resulting in a total dose of 69 mg DMT.
11060664|NCT04353024|Experimental|High dose|Intravenous bolus of 0 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 90 mg DMT.
11060665|NCT04353024|Experimental|High dose with bolus|Intravenous bolus of 25 mg DMT + perfusion of 1 mg/min DMT over 90 min, resulting in a total dose of 115 mg DMT.
11060666|NCT04353011||patient with chronic painful|
11060667|NCT04352998|Active Comparator|One dose pre-workout supplement condition|One dose/serving of a multi-ingredient pre-workout supplement was administered to the subjects.
11060668|NCT04352998|Active Comparator|Two dose pre-workout supplement condition|Two doses/servings of a multi-ingredient pre-workout supplement was administered to the subjects.
11060669|NCT04352998|Placebo Comparator|Placebo condition|One dose/serving of a placebo was administered to the subjects.
11060670|NCT04352972|Active Comparator|Hospital-based rehabilitation program|
11060671|NCT04352972|Experimental|Tele-monitored home exercise program|
11060672|NCT04352959|Active Comparator|mouth rinse with antiviral|
11060673|NCT04352959|Placebo Comparator|mouth rinse without antiviral|
11060674|NCT04352946|Experimental|Hydrocholoroquine Pre-exposure prophylaxis|HCQ will be administered as 400mg orally once for 60 days.
11060675|NCT04352946|Placebo Comparator|Placebo|Placebo will be administered as 400mg orally once for 60 days.
11060676|NCT04352933|Active Comparator|Hydroxychloroquine - Daily dosing|"Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days.
~Route: Oral. Pharmaceutical form: Tablet"
11060677|NCT04352933|Active Comparator|Hydroxychloroquine - Weekly dosing|"Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days.
~Route: Oral. Pharmaceutical form: Tablet"
11060678|NCT04352933|Placebo Comparator|Placebo|"Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days.
~Route: Oral. Pharmaceutical form: Tablet"
11060679|NCT04352920|Experimental|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
11060680|NCT04352894|Experimental|fluorescence guided peritoneal exploration|Indocyanine green (ICG) intravenous injection and peritoneal exploration with technology able to detect fluorescence generated by ICG
11060681|NCT04352868|Active Comparator|Toric soft contact lens|Toric soft contact lens
11060682|NCT04352868|Experimental|Multifocal toric soft contact lens|A multifocal toric soft contact lens with a +2.00 D add.
11060683|NCT04352855||C/T|C/T cases: individuals fulfilling eligibility criteria and treated with ceftolozane-tazobactam
11060684|NCT04352855||C|C cases: individuals fulfilling eligibility criteria and treated with colomycine
11060685|NCT04352842||Non-survivors|Patients deceased during the study period
11060686|NCT04352842||Survivors|Patients survived during the study period
11060687|NCT04352829|Experimental|EXPERİMENTAL GROUP|"On the 1st day, patients were asked to use the sample of their MDI that did not contain active agent. At the same time, MDI Skill Evaluation Form was filled in and scores of the 1st measurement were found. Next, MDI use was explained through the video and the researcher had the video watched twice. After each video and explanation, patients were asked to use the sample of their MDI that did not contain active agent and this performance lasted for 10 minutes. Simultaneously, skill-steps were marked by the researcher through observation on MDI Skill Evaluation Form and scores of the 2nd measurement were found. The procedure was repeated on the 2nd day in the same way.
~On the 3rd day, patients were asked to use MDI used in their treatments. At the same time, MDI Skill Evaluation Form was marked and the final measurement was finished."
11060688|NCT04352829|No Intervention|CONTROL GROUP|This training included verbal explanation of MDI use. In line with ethical principles, the control group patients received training about MDI use and were made to watch the video once after the 5th measurement. After the study, internet links were given to those of the experimental and control group patients who wanted to watch the training-video again.
11060689|NCT04352816|Experimental|Control Group|Participants who do not receive an ICD therapy and have normal Echocardiogram findings and no evidence of arrhythmia will form this group. These participants will receive an MCG scan in addition to their standard care plan We will record the findings of any/all investigations participants receive as per their standard care plan, such as imaging providing left ventricular ejection fraction and usual care blood tests although their research activity/involvement in the trial will cease after the baseline observation. There will be no follow up. We aim to recruit 210 participants to this group to match the anticipated size of the group who receive an ICD but don't receive a shock.
11060690|NCT04352816|Experimental|Observation group|The participants who go on to receive an ICD therapy, as part of standard care, will constitute the 'Observation' group. These participants will undergo an MCG, lying and standing blood pressure and undertake a quality of life questionnaire. Participants in this group will undergo additional blood tests, circulating vascular biomarkers such as (High sensitivity Troponin, Nt pro BNP, CRP, High sensitivity CRP, mRNA, IL-6). All scans and tests that are conducted as part of standard care for evaluation of requirement of ICD implantation will be collected, for example; Echocardiographic, CMRI or MUGA measurements of the heart chambers and function. We will record these findings as this will enable us to substratify patients according to different degrees of cardiac dysfunction
11060691|NCT04352816|Experimental|Device in situ group|"To achieve the secondary objectives of exploring whether features consistent with arrhythmogenesis are extractable from MCG scans on participants with ICDS and pacemakers in situ, the investigators will recruit an additional 30 participants separate from the main trial. Twenty participants will be recruited from the ICD clinic. These participants, who have already had an ICD implanted will be selected with a 50:50 split as to whether they have had previous therapy from the ICD. The presence of an ICD can impact the analysis of MCGs in these patients due to the background signal noise subtraction required to obtain a usable signal. We will use these scans to trial different signal noise reduction strategies. These will be analysed to determine whether the features seen in the main trial can be extracted from this data set.
~10 participants will be recruited who have got an upgrade from a pacemaker to an ICD."
11060692|NCT04352803|Experimental|Autologous Adipose Derived Mesenchymal Cells|Conventional treatment plus MSC's IV
11060693|NCT04352803|No Intervention|Untreated|Conventional treatment only
11060694|NCT04352777|Active Comparator|Cohort 1|Fulvestrant plus abemaciclib
11060695|NCT04352777|Active Comparator|Cohort 2|Aromatase inhibitor plus abemaciclib (with or without ovarian suppression)
11060696|NCT04352751|Experimental|Single Arm|"Intervention: Convalescent plasma (Frozen Solution for infusion) obtained from COVID-19 recovered patients.
~The dosage depends upon the clinical situation and underlying disorder. Children: 15 ml/kg over 4-6 hours once in patients under 35 kg body weight. Adults: maximum 450 - 500 ml over 4-6 hours once in all adults patients."
11060697|NCT04352738||Healthy adults (group I)|
11060698|NCT04352738||Adults with type 1 diabetes (group II)|"T1D for ≥2 years or evidence of undetectable C-peptide (<100pmol/l with concomitant plasma glucose≥4.0mmol/l).
~HbA1c≤8.0mmol/l (64mmol/mol)."
11060699|NCT04352738||Adults after bariatric surgery (group III)|"Female.
~Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) ≥1 year ago.
~Lack of a history of diabetes or pre-diabetes (HbA1c≤5.6% in the absence of anaemia)."
11060700|NCT04352725|Experimental|experimental procedure|"end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat<28cmH2o
~incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
11060701|NCT04352712||Healthy Children|healthy children, untreated, donors of monocytes
11060702|NCT04352712||GHD children|GHD children, untreated, donors of monocytes
11060703|NCT04352699||Naive patients|Group of naive patients who have undergone elective or emergency surgery during the study period
11060704|NCT04352686|Active Comparator|Buspirone|Buspirone 20 mg per oral
11060705|NCT04352686|Placebo Comparator|Placebo|Placebo
11060706|NCT04352673||Healthy individuals|Healthy students 18 years and older
11060707|NCT04352660|Active Comparator|Injection group|MMC delivered by preoperative subconjunctival injection
11060708|NCT04352660|Active Comparator|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
11060709|NCT04352647||female athletes over the age of 18|the presence or absence of urinary incontinence in female athletes is studied. In addition, the quality of life and other aspects are evaluated
11060710|NCT04352634||Healthcare workers|Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)
11060711|NCT04352621|Experimental|Ketamine plus rTMS|Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.
11060712|NCT04352608|Experimental|Emergency schedule & Medium dosage vaccine|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
11060713|NCT04352608|Experimental|Emergency schedule & High dosage vaccine|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
11060714|NCT04352608|Placebo Comparator|Emergency schedule & Placebo|Two doses of placebo at the emergency vaccination schedule
11060715|NCT04352608|Experimental|Routine schedule & Medium dosage vaccine|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
11060716|NCT04352608|Experimental|Routine schedule & High dosage vaccine|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
11060717|NCT04352608|Placebo Comparator|Routine schedule & Placebo|Two doses of placebo at the routine vaccination schedule
11060718|NCT04352595|Experimental|1% Hemay808|
11060719|NCT04352595|Experimental|3% Hemay808|
11060720|NCT04352595|Experimental|7% Hemay808|
11060721|NCT04352595|Placebo Comparator|vehicle|
11060722|NCT04352582||1|Survey respondants
11060723|NCT04352569|Active Comparator|transcranial direct current stimulation|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the LTP, le cathode over L DLPFG.
11060724|NCT04352569|Sham Comparator|transcranial direct current stimulation sham|tDCS device allows sham stimulation. This technic give the same impression that active stimulation and allows optimum placebo stimulation.
11060725|NCT04352543|Experimental|Older adults group|Group of older adults >60 years old.
11060726|NCT04352530|Active Comparator|Rewind the Future|Fear appeal, video message to reduce sugar consumption or risk death
11060727|NCT04352530|Experimental|Hear No|"Video of spoken word poem from The Bigger Picture project, Hear No by Joshua Merchant; images of African-American male poet interspersed with images of environment"
11060765|NCT04352283|No Intervention|palpation|Usual method to determinate needle puncture site
11060729|NCT04352530|Experimental|A Taste of Home|"Video of spoken word poem from The Bigger Picture Project, A Taste of Home by Monica Mendoza; images of Hispanic female poet interspersed with images of environment"
11060730|NCT04352530|Experimental|Lost in Translation|"Video of spoken word poem from The Bigger Picture Project, Lost in Translation by Yosimar Reyes; images of Hispanic male poet interspersed with images of environment"
11060731|NCT04352530|Experimental|Bottled Up|"Video of spoken word poem from The Bigger Picture Project, Bottled Up by Eileen Torrez; images of Hispanic female poet interspersed with images of environment"
11060732|NCT04352530|Experimental|The Corner|"Video of spoken word poem from The Bigger Picture Project, The Corner by Jose Vadi; images of Hispanic male poet interspersed with images of environment"
11060733|NCT04352530|Experimental|Thin Line|"Video of spoken word poem from The Bigger Picture Project, Thin Line by Ivori Holson; images of African-American female poet interspersed with images of environment"
11060734|NCT04352504|Experimental|Almonds|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
11060735|NCT04352504|Active Comparator|Pretzels|Consume 2 oz. serving pretzels (216 calories) daily for 12 weeks
11060736|NCT04352491||Patients with liver disease|All people who have shown at Institute of Liver and Biliary Sciences (1st January 2018 - 31st March 2020), will be sent the SMS for participation.
11060737|NCT04352478||Elder|elderly (≥60 years old).
11060738|NCT04352478||Young|young (<60 years old)
11060739|NCT04352465|Experimental|A|Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
11060740|NCT04352465|Experimental|B|Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
11060741|NCT04352465|Experimental|C|Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
11060742|NCT04352452||RALS|Surgeons perform robot-assisted laparoscopic surgery
11060743|NCT04352452||CLS|Surgeons perform conventional laparoscopic surgery
11060744|NCT04352439|Experimental|Aspirin|Patients receive 81 mg aspirin daily while receiving neoadjuvant chemotherapy for ovarian cancer.
11060745|NCT04352413|Experimental|Cohort A: PLM60|20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle
11060746|NCT04352413|Experimental|Cohort B: PLM60|15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle
11060747|NCT04352400|Active Comparator|Nafamostat|Nafamostat mesylate on top of best standard of care.
11060748|NCT04352400|Placebo Comparator|Placebo|Placebo on top of best standard of care.
11060749|NCT04352387|Experimental|Montessori Method for Dementia|The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
11060750|NCT04352387|Active Comparator|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
11060751|NCT04352374|Experimental|Aerobic exercise group|"The therapist advised all participants of this group to drink a plenty of water before and after the exercise session to avoid excessive loss of body water during the session. Pregnant women were instructed to have a light meal about one hour before the performance of exercise and to wear comfortable clothes.
~Participants in this group were given a Low-Intensity Aerobic Exercise with Borg scale RPE at 11. Participants were asked to maintain this intensity of rate of perceived exertion throughout the 45 minutes' duration of the aerobic training.
~During the training session, the therapist stood near the patient to observe and detect signs of stopping the exercise. The therapist continuously asked the patient if she felt pain, dizzy or shortens of breath.
~No complications were observed during physical exercise sessions, for example, hypertensive crisis, hypotension, hyperthermia, musculoskeletal lesions, or other complications identified that demanded interruption of the exercise."
11060752|NCT04352374|Active Comparator|Device guided breathing group|"At the beginning the researcher explained the device and study procedures to every participant of this group .The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
~The participant is instructed to alter their breathing rate, aiming for up to 10 breaths per minute, in response to a melody played to them via the asked to use the device for at least 40 min per week, with each session lasting at least 10 min"
11060753|NCT04352361|Experimental|TVB-2640 tablets|
11060754|NCT04352361|Placebo Comparator|placebo|
11060755|NCT04352348|Other|COVID-19 negative|Patients with exclusion diagnosis for COVID-19 infection
11060756|NCT04352348|Other|COVID-19 positive, not severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and not requiring hospitalization
11060757|NCT04352348|Other|COVID-19 positive, severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and requiring hospitalization
11060758|NCT04352335||Cohort 1：ICI treatment with immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
11060759|NCT04352335||Cohort 2：ICI treatment without immunomodulator|Lung cancer patients received immunological checkpoint inhibitors (ICIs).
11060760|NCT04352322|Experimental|A+HA(tm)|20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
11060761|NCT04352322|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
11060762|NCT04352309||Participants Treated With Glecaprevir/Pibrentasvir (GLE/PIB)|Participants will receive GLE/PIB over 8 weeks of therapy as prescribed by their physicians.
11060763|NCT04352296|Experimental|Experimental group|Individualized BP management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit.
11060764|NCT04352296|Active Comparator|Control group|Standard BP management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure <140 mm Hg, and treatment of hypertension defined by a systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
11060766|NCT04352283|Experimental|Ultrasound|Ultrasound preprocedural exam used to determinate needle puncture site
11060767|NCT04352270|Active Comparator|Group 1- Printed educational materials|Parent-child dyads randomized to this group will receive printed educational materials in English or Spanish about atopic dermatitis.
11060768|NCT04352270|Experimental|Group 2- Educational videos|Parent-child dyads randomized to this group will receive an investigator developed educational video in English or Spanish about atopic dermatitis.
11060769|NCT04352257||ultrasonography|pelvic and transrectal ultrasound
11060770|NCT04352244||Surgical Participants|Individuals undergoing abdominal surgery or radiologically-guided biopsies for clinical indications will be recruited prior to the planned procedures.
11060771|NCT04352231|Experimental|High to Low Fiber Diet Intervention|Participants receive the high fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the low fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
11060772|NCT04352231|Experimental|Low to High Fiber Diet Intervention|Participants receive the low fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the high fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
11060773|NCT04352218|Active Comparator|PTA Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty of internal jugular vein non-thrombotic stenosis in patients with chronic headache
11060774|NCT04352218|Experimental|"PTA + Stenting using Petalo stent"|Percutaneous Transluminal Angioplasty + Stenting of internal jugular vein non-thrombotic stenosis in patients with chronic headache
11060775|NCT04352205|Experimental|Treatment (daratumumab-based treatment)|Patients receive daratumumab IV weekly of cycles 1-3 and on day 1 only of cycle 4, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV or PO on days 1-4 of cycle 1 and on day 1 of cycles 2-4 and PO on days 8 and 15 of all cycles. Beginning cycle 2, patients may also receive lenalidomide PO daily on days 1-14 or thalidomide PO QD on days 1-21. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
11060776|NCT04352192|Experimental|Kinesiotaping Group|The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
11060777|NCT04352192|No Intervention|Control Group|The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
11060778|NCT04352179|Experimental|Virtual Education Simulation|All participants will have access to the virtual education simulations.
11060779|NCT04352166|Experimental|extended-release buprenorphine (BXR)|Three extended-release buprenorphine (BXR) injections to be administered roughly 28 days apart. The first and second injection will be 300 mg and the third will be 100 mg.
11060780|NCT04352166|Active Comparator|sublingual buprenorphine (BSL)|sublingual buprenorphine (BSL) up to 24 mg will be administered once daily for 12 weeks or length of study participation.
11060781|NCT04352153|Experimental|Single-use group|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
11060782|NCT04352153|Experimental|Research group|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
11060783|NCT04352140|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand
11060784|NCT04352140|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand
11060785|NCT04352127|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand
11060786|NCT04352127|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand
11060787|NCT04352114|Experimental|LY3461767 - Subcutaneous (SC)|LY3461767 administered SC.
11060788|NCT04352114|Placebo Comparator|Placebo - SC|Placebo administered SC.
11060789|NCT04352114|Experimental|LY3461767 - Intravenous (IV)|LY3461767 administered IV.
11060790|NCT04352101|Experimental|Bupropion|Participants randomized to take bupropion for 8 weeks.
11060791|NCT04352101|Active Comparator|Escitalopram|Participants randomized to take escitalopram for 8 weeks.
11060792|NCT04352088||Allergic rhinitis patients|
11060793|NCT04352088||Allergic rhinitis and asthma patients|
11060794|NCT04352088||Healthy individuals|
11060795|NCT04352075|Experimental|Microfat + PRP 3M platelets|microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
11060796|NCT04352075|Experimental|Microfat + PRP 1M platelets|microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
11060797|NCT04352075|Experimental|Microfat|microfat (5 ml) and saline solution (5 ml)
11060798|NCT04352062|Experimental|Treatment Group|Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
11060799|NCT04352062|Placebo Comparator|Placebo|1 tablet twice daily (period 6 months)
11060800|NCT04352062|Other|Helicobacter pylori infected group|Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
11060801|NCT04352049|Active Comparator|3TV group|Patients were randomly assigned to receive either three minutes tidal volume (3TV) with a fresh gas flow (FGF 100% O2) via facemask of 5 L/min
11060802|NCT04352049|Active Comparator|8DB group|Or eight vital capacity breaths for 1 minute with FGF of 10 L/min
11060803|NCT04352036||patient|
11060804|NCT04352023|Experimental|A (IV-PCA group)|IV-PCA drug: Fentanyl 3000 mcg and Oxycodone 100 mg were mixed Normal saline 200 ml
11060918|NCT04351295|Experimental|Faviprevir|Faviprevir
11060805|NCT04352023|Experimental|B (PCEA group)|"PCEA drug: Morphine 5 mg and Ropivacaine 750 mg were mixed Normal saline 400 ml
~loading of preadministered Morphine 1 mg and Ropivacaine 11.25 mg"
11060806|NCT04352010|Experimental|"Online-Intervention Res-Up!"|Participants in the Res-Up! group get access to Res-Up! while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
11060807|NCT04352010|Experimental|"Online-Intervention REMOTION"|Participants in the REMOTION group get access to REMOTION while waiting for psychotherapy or in addition to psychotherapy. Participants will answer questionnaires after inclusion as well as six and twelve weeks later.
11060808|NCT04352010|Experimental|Wait-control group|Participants in the wait-control group will not get access to the online-tools while waiting for psychotherapy or while in psychotherapy. Participants will answer questionnaires after inclusion, six weeks later and twelve weeks later.They get access to one of the online-tools after 12 weeks.
11060809|NCT04351997|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
11060810|NCT04351997|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth,
11060811|NCT04351984||Severe Mitral Regurgitation|
11060812|NCT04351971|Experimental|Intervention Group|The dorsal sliding technique C0-C1 will be applied to this group.
11060813|NCT04351971|Sham Comparator|Placebo group|A placebo dorsal mobilization technique will be applied
11060814|NCT04351958|Experimental|Augmented Reality (FREEZE!)|
11060815|NCT04351945||Blood test|Patients will have a blood test to define hormone levels.
11060816|NCT04351932|Active Comparator|bone marrow mesenchymal stem cell|Bone marrow mesenchymal stem cells 10 cc by intra articular injection once
11060817|NCT04351932|Active Comparator|adipose mesenchymal stem cells|Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once
11060818|NCT04351932|Active Comparator|Bone marrow and Adipose mesenchymal stem cells|Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once.
11060819|NCT04351919|Experimental|HCQ Arm|
11060820|NCT04351906|Other|ECCO2R|ECCO2R in patients with mild to moderate ARDS with/without AKI requiring dialysis.
11060821|NCT04351880|Active Comparator|Meals - 2 weeks|Receive meal delivery for 2 weeks (1 meal per day for a total of 14 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
11060822|NCT04351880|Active Comparator|Meals - 4 weeks|Receive meal delivery for 4 weeks (1 meal per day for a total of 28 days). The medically tailored meal ordered for each participant will depend on their medical conditions.
11060823|NCT04351867|Experimental|experimental group|docetaxel plus oxaliplatin and capecitabine
11060824|NCT04351867|Active Comparator|control group|oxaliplatin plus capecitabine
11060825|NCT04351854||Patients with SARS-CoV-2-infection|Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED
11060826|NCT04351854||Control group|Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
11060827|NCT04351841|Placebo Comparator|control|15 g maltodextrin per day consumed in the morning
11060828|NCT04351841|Experimental|Active|15 g arabinogalactan per day consumed in the morning
11060829|NCT04351828||Celiac patients compliant to gluten-free diet (GFD)|People with celiac disease who compliant to gluten-free diet (GFD) when they accepted in the study
11060830|NCT04351828||Celiac patients non-compliant to gluten-free diet(NGFD)|People with celiac disease who noncompliant to the gluten-free diet (NGFD) group when they accepted in the study
11060831|NCT04351815|Experimental|Short prehabilitation|This arm will benefit from a 2 weeks prehabilitation program including a personalized dietetic and physical training program as well as psychological support.
11060832|NCT04351815|Other|No prehabilitation|This arm will not benefit from a prehabilitation program before surgery. Patients will be told to maintain a regular physical activity without support.
11060833|NCT04351789|Experimental|Intervention Group|Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. The intervention is based on psychoeducational theory and consists of both written and verbal information. A manual describing the content and procedures of the intervention will be developed to ensure that the intervention is both replicable and transparent. The intervention has a planned duration of 30 minutes and will be conducted by a designated study affiliated researcher, who has a background in healthcare (i.e. nurse or medical doctor).
11060834|NCT04351789|No Intervention|Control Group|Standard of Care at discharge of patients with COVID-19 from hospital is to inform the patients whom to contact in case of worsening of the physical condition, such as increasing e.g. shortness of breath, and of precautions regarding further isolation to avoid infection of household and other contacts, if relevant. Information regarding the patient´s psychological condition is not part of a standard conversation at discharge.
11060835|NCT04351776|Other|VR-Biofeedback|
11060836|NCT04351776|Other|VR-Distraction|
11060837|NCT04351776|Other|360 Video|
11060838|NCT04351763|Experimental|Amiodarone|"Amiodarone - administered intravenously
~Bolus of 150 mg is given over a minimum of 10 min, with subsequent continuous infusion of 1 mg/min for 6 h, next continuous infusion of 0.5 mg/min for 18 h, then switch to oral administration.
~Oral administration
~200 to 400 mg/day (adjust dosage based on cardiac response and age) up to discharge."
11060839|NCT04351763|Experimental|Verapamil|"Verapamil - administered intravenously
~Bolus of 0.075-0.15 mg/kg (5-10 mg) over at least 3 minutes, then switch to oral administration.
~Oral administration
~120 to 480 mg/day in divided doses every 6-8 hours (adjust dosage based on cardiac response and age) up to discharge."
11060840|NCT04351763|No Intervention|Usual Care|
11060919|NCT04351295|Placebo Comparator|Placebo|Placebo
11061008|NCT04350645|Active Comparator|Tranexamic acid group|Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)
11060841|NCT04351750|Experimental|high-intensity group|The participants will receive high-intensity general exercise and pelvic floor muscle training in high-intensity group. The intensity of aerobic exercise is 60 ~ 89% of heart rate reserve (HRR) or oxygen uptake reserve (VO2R), which is equivalent to the vigorous intensity exercise proposed in the American College of Sports Medicine (ACSM). The intensity of resistance exercise is 60~80% of 1 repetition maximum (RM), which is equivalent to the moderate-to-vigorous intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
11060842|NCT04351750|Experimental|low-intensity group|The participants will receive low-intensity general exercise and pelvic floor muscle training in low-intensity group. The intensity of aerobic exercise is 40~59% of HRR or VO2R, which is equivalent to the moderate intensity exercise proposed in ACSM. The intensity of resistance exercise is 40~50% of 1RM, which is equivalent to the very light-to-light intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
11060843|NCT04351750|Active Comparator|control group|The participants will only receive pelvic floor muscle training in control group.
11060844|NCT04351737|Experimental|Pterygium patients|patients with bilateral pterytium
11060845|NCT04351724|Experimental|(Hydroxy)Chloroquine|"Due to limited availability of the experimental substances, this arm will include both chloroquine and hydroxychloroquine treatment. However, both substances are similar chemically and also with regards to the mechanism of action comparable.
~Dosage: Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available"
11060846|NCT04351724|Experimental|Lopinavir/Ritonavir|Dosage: 200mg/50mg 2-0-2
11060847|NCT04351724|Other|Standard of Care|"patients will be treated with standard of care, which precludes treatment with lopinavir/ritonavir or (hydroxy-)chloroquine"
11060848|NCT04351724|Experimental|Rivaroxaban|
11060849|NCT04351724|Active Comparator|Thromboprophylaxis|according to local standard
11060850|NCT04351724|Experimental|RAS Blockade|Renin-Angiotensin-System-Blockade (RAS) by candesartan intake starting with 4mg once daily and titrated to normotension patients > 120/80 mmHG are eligible
11060851|NCT04351724|Active Comparator|non-RAS-Blockade|non-RAS blocking antihypertensive agents titrated to normotension Those with normal blood pressure may only be controlled without further treatment
11060852|NCT04351724|Experimental|Clazakizumab|patients with respiratory deterioration qualify for this treatment arm
11060853|NCT04351724|Placebo Comparator|Placebo|patients with respiratory deterioration qualify for this treatment arm
11060854|NCT04351711||Patients SARS-CoV-2 with respiratory failure|Patients in intensive care
11060855|NCT04351711||Patients SARS-CoV-2 without respiratory failure|Patients hospitalized in normal hospital wards
11060856|NCT04351711||HEALTHY VOLUNTEERS|HEALTHY VOLUNTEERS
11060857|NCT04351711||NON-COVID-19 PATIENTS|Patient hospitalized at the CHU of Nîmes for an infection by a virus other than SARS-CoV-2
11060858|NCT04351711||PAUCISYMPTOMATIC SARS-COV-2+ PATIENTS|Patient positive for SARS-CoV-2 by RT-PCR at the CHU of Nîmes and presenting at most moderate clinical signs without respiratory insufficiency (O2 saturation greater than or equal to 96%) during the confinement period
11060859|NCT04351698|Active Comparator|Investigation|Montelukast
11060860|NCT04351698|Placebo Comparator|Match Placebo|Matched Placebo
11060861|NCT04351685|Experimental|VPM1002|"Total 3470 subjects will be enrolled in VPM1002 arm.
~Single dose of VPM1002 will be administered."
11060862|NCT04351685|Active Comparator|BCG SII|"Total 3470 subjects will be enrolled in BCG SII arm.
~Single dose of BCG SII will be administered."
11060863|NCT04351672|Experimental|Early Time-Restricted Feeding|
11060864|NCT04351672|Experimental|Late Time-Restricted Feeding|
11060865|NCT04351659||Blood donors|Donors who had tested positive for SARS-CoV-2 in the past and have recovered from COVID-19 and are now suitable for blood donation.
11060866|NCT04351646||SARS-CoV-2 negative inpatients|Hospitalised adult patients with SARS-CoV-2 negative tests.
11060867|NCT04351646||SARS-CoV-2 positive inpatients|Hospitalised adult patients with SARS-CoV-2 positive tests.
11060868|NCT04351646||SARS-CoV-2 suspected or confirmed NHS staff|Suspected or proven SARS-CoV-2 positive cases amongst health care professionals and lab staff.
11060869|NCT04351633||osteoporosis patient|
11060870|NCT04351620|Experimental|Hydroxychloroquine|"Hydroxychloroquine 1200 mg daily administered as 600 mg BID for five days or until fevers abate (maximum ten days of treatment allowed).
~If patients report gastrointestinal discomfort, the dose will be administered as 400 mg TID."
11060871|NCT04351607|Experimental|Verum|oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand
11060872|NCT04351607|No Intervention|Control group|no intervention
11060873|NCT04351607|Other|Patient with menstral bleeding - subcollective A|verum or control
11060874|NCT04351607|Other|Patient without menstral bleeding - subcollective B|verum or control
11060875|NCT04351594|Experimental|Topical analgesia (+Menthol)|Biofreeze Topical Gel with active ingredient (Menthol 4%)
11060876|NCT04351594|Placebo Comparator|Topical analgesia (-Menthol)|Biofreeze Topical Gel with no active ingredient (Menthol 0%)
11060877|NCT04351581|Experimental|Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.
11060878|NCT04351581|Experimental|Discontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
11060879|NCT04351568||medical personel|
11060880|NCT04351568||non medical personel|
11060881|NCT04351555|Placebo Comparator|Arm 1: Placebo with platinum-based chemotherapy|Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
11061004|NCT04350684|Active Comparator|Control|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
11060882|NCT04351555|Experimental|Arm 2: Osimertinib with platinum-based chemotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
11060883|NCT04351555|Experimental|Arm 3: Osimertinib monotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
11060884|NCT04351542|Experimental|Ayurveda Care Group|Individualised ayurveda treatment was given to participants based on individual constitution.
11060885|NCT04351542|Active Comparator|Usual Care Group|Participants followed the usual care.
11060886|NCT04351516|Experimental|hydroxychloroquine|
11060887|NCT04351516|Placebo Comparator|Placebo|
11060888|NCT04351503||SARSCoV-infected patients (cases)|
11060889|NCT04351503||non-SARS-CoV-2 infected patients (control)|non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
11060890|NCT04351490|Experimental|Group supplementation|
11060891|NCT04351490|No Intervention|Group usual treatment|
11060892|NCT04351477|Experimental|Massage chair group|Use mechanical massage chair for 20 minutes/1 session, 3 sessions/week, for 3 weeks
11060893|NCT04351477|No Intervention|Control|No use of mechanical massage chair for 3 weeks
11060894|NCT04351464|Active Comparator|Physical therapy and Reflexology group|Received reflexology implementation for 20-30 minutes on the sole along with the physical treatment involving NDT approaches. Within the scope of the implementation, all the reflex points on the sole were stimulated. The pituitary gland, which is related to sleep and control of salivation, oromotor area and areas of muscular and skeletal system were stimulated with further repetitions.
11060895|NCT04351464|Experimental|Just Physical therapy group|The group received a 45-minute physical therapy program involving NDT approaches as the control group. Within the scope of this program, the children were treated with intramuscular stretching and soft tissue mobilization, exercises that improved balance and that supported the development of postural control, position shifts, and stretching and reinforcement exercises in the necessary muscle groups.
11060896|NCT04351438|Active Comparator|Centrifuge TPE with citrate|These participants were undergoing centrifuge TPE using citrate anticoagulant
11060897|NCT04351438|Active Comparator|Filter TPE with heparin|These participants were undergoing filter TPE using filter-based heparin anticoagulant
11060898|NCT04351438|Active Comparator|Filter TPE with citrate|These participants were undergoing filter TPE using filter-based citrate anticoagulant
11060899|NCT04351425|Experimental|study group|study group will be shifted from incubator to an unheated open cot a weight of 1400 grams
11060900|NCT04351425|Active Comparator|control group|control group will be shifted from incubator to an unheated open cot at a weight of 1600 grams
11060901|NCT04351412|Active Comparator|Tactile stimulus|The tactile stimulus was examined using an explorer (# 17/23), passing at a right angle to the bucco-cervical tooth surface of concern. Contributors evaluated participants' pain score on a 10-point visual analogue scale (VAS). The stimulus was used to assess dentine hypersensitivity at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
11060902|NCT04351412|Active Comparator|Air blast stimulus|For air blast stimuli, air was delivered by a three-way syringe from a typical dental unit air syringe at 40 psi (± 10 psi) and 70 °F (± 5 °F). The air flow was aimed at the tooth surface of concern, for 1 second, from a distance of 1 cm. The air blast stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for air blast stimuli at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
11060903|NCT04351412|Active Comparator|Cold stimulus|For cold hypersensitivity assessment, the tooth was isolated using cotton rolls; then, a few drops of extremely cold water were delivered to the tooth from a syringe that had previously been cooled. The cold stimulus scores were assessed by the Schiff Cold Air Sensitivity Scale 18. DH was assessed for cold stimulus at baseline and immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
11060904|NCT04351399||patient with chronic painful inflammatory rheumatism|
11060905|NCT04351386||Atrial Fibrillation (AF)|Patients diagnosed with AF during reference ECG
11060906|NCT04351386||Normal Sinus Rhythm (NSR)|Patients with NSR during reference ECG
11060907|NCT04351386||Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
11060908|NCT04351373|Experimental|Treatment|"At the time of tumor exposure, patients will be given intravenous fluorescein sodium. The timing and dose may vary. Maximum cumulative dose will not exceed 500 mg.
~• Initial dosing protocol will be 1 mg/kg intravenous FS.
~o If insufficient fluorescence is obtained or washout occurs, additional doses of 1 mg/kg may be administered
~The surgeon will use the YELLOW 560 nm microscope filter (YE560) to assist in visualizing the tumor during the resection."
11060909|NCT04351347|Experimental|Ivermectin|Ivermectin alone
11060910|NCT04351347|Experimental|Nitazoxanide with Ivermectin|Nitazoxanide with Ivermectin
11060911|NCT04351347|Experimental|Ivermectin with chloroquine|Ivermectin with chloroquine
11060912|NCT04351334||Patients with ALK-positive NSCLC|
11060913|NCT04351321|Experimental|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.
11060914|NCT04351321|Active Comparator|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.
11060915|NCT04351308|Experimental|API+apatinib|"AP = Doxorubicin (Adriamycin) 20 mg/m2/day * 2 day (total/cycle 40 mg/m²)
~+ Cisplatin 100 mg/m2/course (total/cycle 120 mg/m²);
~I = Ifosfamide 2000 mg/m2/day *5 day (total/cycle 10000 mg/m²);
~apatinib = 500 mg QD;"
11060916|NCT04351308|Experimental|MAPI+camrelizumab|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);
~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;
~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);
~camralizumab = 200mg ivgtt. Q2W;"
11060917|NCT04351308|Active Comparator|MAPI|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day * 2day (total/cycle 75 mg/m²)
~+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²);
~M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue;
~I = Ifosfamide 2400 mg/m2/day *5day (total/cycle 12000 mg/m²);"
11060920|NCT04351282|Experimental|SBRT|4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
11060921|NCT04351269||CanGaroo Envelope|Patients who received a CanGaroo envelope with their CIED implantation.
11060922|NCT04351269||Tyrx Envelope|Patients who received a Tyrx envelope with their CIED implantation.
11060923|NCT04351269||No Envelope|Patients who had their CIED implanted with no envelope.
11060924|NCT04351256|Experimental|Arm A (HYPO group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles
~Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)"
11060925|NCT04351256|Active Comparator|Arm B (CON group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles
~Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)"
11060926|NCT04351243|Experimental|Gimsilumab|Gimsilumab high dose on Day 1 Gimsilumab low dose on Day 8
11060927|NCT04351243|Placebo Comparator|Placebo|Normal saline on Day 1 Normal saline on Day 8
11060928|NCT04351230|Active Comparator|Arm A (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11060929|NCT04351230|Experimental|Arm B (trastuzumab emtansine, abemaciclib)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11060930|NCT04351217|Experimental|Music|Music was Indian Classical Flute music, 23 minutes long. It was played on a speaker at equal volume to ensure uniformity.
11060931|NCT04351217|Experimental|Progressive Muscle Relaxation|Progressive Muscle Relaxation was recorded for uniformity of delivery, and was 22 minutes in length. It was played on a speaker at equal volume to ensure uniformity.
11060932|NCT04351204|Other|MRL|radiotherapy on MR linac
11060933|NCT04351191|Active Comparator|HCQ Regular dose|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
11060934|NCT04351191|Experimental|HCQ Loading dose|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
11060935|NCT04351191|Active Comparator|CQ regular dose|Cholorquine 500 mg BID for 5 days plus standard of care
11060936|NCT04351191|Placebo Comparator|Placebo|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
11060937|NCT04351178|Experimental|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0)
11060938|NCT04351178|Active Comparator|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
11060939|NCT04351165|Experimental|Arm 1|"Period 1:
~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);
~Period 2:
~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);
~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
11060940|NCT04351165|Experimental|Arm 2|"Period 1:
~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);
~Period 2:
~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);
~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
11060941|NCT04351152|Experimental|Lenzilumab Arm|Participants will receive IV infusion of lenzilumab upon randomization at a pre-specified dosing interval and continued administration of standard of care
11060942|NCT04351152|Placebo Comparator|Placebo Arm|Participants will receive IV infusion of saline upon randomization matched to lenzilumab at same pre-specified dosing interval and continued administration of standard of care
11060943|NCT04351139||gynecological cancer|Patients over 18 with gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned during the period of COVID-19 pandemic during 2020
11060944|NCT04351139||control group|Patients over 18 with gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned outside the period of COVID-19 pandemic, on the end of the year 2019
11060945|NCT04351126|Other|Control group|patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
11060946|NCT04351126|Experimental|treatment group|patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
11060947|NCT04351126|Experimental|prevention group|patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis
11060948|NCT04351113|Experimental|MITO-AO|Healthy older adult subjects ages 65-75 will take the supplement MITO-AO during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (31P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
11060949|NCT04351113|Experimental|PB-125|Healthy older adult subjects ages 65-75 will take the supplement PB-125 during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
11060950|NCT04351113|Placebo Comparator|Placebo|Healthy older adult subjects ages 65-75 will take placebo during a 5 day bed rest and will be assessed for vascular function independent of metabolism with passive leg movement (PLM), skeletal muscle bioenergetics independent of vascular constraints (i.e. blood flow and O2 supply) with phosphorous magnetic resonance spectroscopy (P-MRS), and skeletal muscle bioenergetics under normal blood flow and O2 supply.
11060951|NCT04351100||Diacerein group|Osteoarthritis and dry eye patients treated with Diacerein
11061005|NCT04350671|Experimental|Interferon-β 1a|Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
11060952|NCT04351087|Active Comparator|Platelet Rich Plasma|157cc of whole blood will be harvested via standard venipuncture from the antecubital fossa and mixed with 24cc ACD-A (manufacturer recommends 8cc ACD-A per 52cc of whole blood). 156ml of whole blood will be processed in the FDA Cleared Angel cPRP system at 2% hematocrit. 1ml of whole blood and the resultant PRP will be analyzed in the Sysmex XN-350 for complete analysis (platelet, leukocyte, red blood cell counts). The remaining PRP will be injected under sterile technique using ultrasound-guidance through a superolateral approach. For patient comfort, 2cc of 1% lidocaine can be administered using a 26-gauge needle (into soft tissues only). PRP will then be injected using a 25-guage needle. A maximum of 6ml of PRP will be injected. Injection site will be cleaned and bandaged and patient will be dismissed with post-injection precautions and 1 month follow-up scheduled.
11060953|NCT04351087|Active Comparator|Microfragmented adipose tissue|Adipose is aspirated from the subcutaneous tissue of the buttock or abdomen. Aspiration site is injected with 10ml 1% lidocaine with epinephrine. A small poke incision is made with an 11-blade scalpel. Then 120ml of Klein solution is injected into the adipose tissue. Solution sits for 15 minutes to allow for adequate anesthesia. Aspiration cannula is inserted and moved in a back and forth motion for 2 minutes to allow for adipose aspiration. 30ml fat will be aspirated. Aspiration site is cleaned and bandaged. The aspirated fat is processed using the Lipogems system. 30ml of adipose is transferred to the device, saline is run through the device to remove oils and then approximately 5-7ml of adipose tissue is removed and ready for injection. The Microfragmented adipose tissue are then injected in identical fashion to the PRP above.
11060954|NCT04351074|Active Comparator|group A , LIFT|39 patients underwnt ligation of the intersphincteric track( LIFT) for treatment of transsphincteric fistula
11060955|NCT04351074|Active Comparator|group B fistulectomy|39 patients under went fistulectomy for treatment of transsphincteric fistula
11060956|NCT04351061|Experimental|Acetazolamide Arm|Participants in this arm will receive the Acetazolamide intervention for 7 consecutive days post standard of care endoscopic skull base surgery.
11060957|NCT04351048|Experimental|SW|stepwise excavation
11060958|NCT04351048|Experimental|OneS|one step excavation
11060959|NCT04351035||Children with CNS tumours|Patients newly diagnosed with CNS tumours in children younger than 18 y/o, who were under in-patient treatment, were labeled as candidate cases in the CNOG-MC001 cohort for reviewing.
11060960|NCT04351022|Experimental|CD38 positive relapsed or refractory acute myeloid leukemia|
11060961|NCT04351009|Experimental|Indocyanine green sentinel lymph node mapping|Indocyanine green dye is injected in the submucosa around the tumor to identify sentinel lymph nodes intra-operatively with near infrared fluorescence imaging.
11060962|NCT04350996||Continuous alcohol monitoring|Wearable BACtrack Skyn device
11060963|NCT04350970|Active Comparator|Control|The cardiopulmonary exercise test was performed with patient breathing room air.
11060964|NCT04350970|Active Comparator|NIV|The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
11060965|NCT04350970|Active Comparator|HFNT|The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
11060966|NCT04350957|Experimental|Low-dose Imaging|Enrolled patients will undergo two separate dynamic contrast-enhanced MRI's, one with 25% of the contrast dose and one with 100% of the contrast dose recommended by weight. During the first visit, the subject will receive 25% of the standard dose of contrast media 0.1 mM/kg will be administered at 2 mls/second followed by the acquisition of a series of DCE images. On the second visit, the subject will receive 100% of the contrast media followed by the same imaging protocol as the one subsequent to the first contrast administration.
11060967|NCT04350931|Active Comparator|BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds (In Egypt, the available BCG vaccine is the Copenhagen BCG vaccine - The Danish Strain 1331 of Mycobacterium Bovis). Each 0.10 mL vaccine contains 200000-800000 colony forming units.
11060968|NCT04350931|Placebo Comparator|intradermal normal saline|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds.
11060969|NCT04350918|Experimental|Muscle Energy Technique (MET)|MET Group received 12 treatment sessions of MET (Nagrale et al, 2010) two times a week in addition to conventional physiotherapy. The procedures employ voluntary muscle contractions by the patient in a precisely controlled direction and intensity against a counterforce applied by the Physiotherapist. The technique requires the therapist to provide stabilization to the segment on which the distal aspect of the muscle attaches. A command for anisometric contraction of the muscle is given that causes accessory movement of the joint. Several specific muscle energy techniques are described for the subcranial region of the cervical spine.
11060970|NCT04350918|Experimental|Static stretching (SS)|"Subjects in SS Group received 12 treatment sessions of static stretching (Dutton et al, 2008) two times a week in addition to conventional physiotherapy.
~Stretching involves the application of manual or mechanical force to elongate structures that have adaptively shortened and are hypo-mobile (Sullivan, 2007) Static stretching involves stretching a muscle to a point of discomfort and holding the stretch for a length of time, followed by a return to normal resting muscle length (Andrews et al, 2004). Muscles of the neck were stretched in especially in side flexion, extension, flexion and side rotation for 10 seconds and was repeated 10 times for a session."
11060971|NCT04350905|Experimental|Mosquito Feeding|Each participant will receive one mosquito feeding with 5 starved female Aedes aegypti mosquitoes.
11060972|NCT04350892|Active Comparator|Roux-en-Y Gastric Bypass Surgery|
11060973|NCT04350892|Active Comparator|Sleeve Gastrectomy Surgery|
11060974|NCT04350892|Active Comparator|Very Low Calorie Diet|
11060975|NCT04350879||Diabetic patients|Women between 18 and 40 years old with type 1 and type 2 diabetes
11060976|NCT04350866||Pre-Implementation (0-, 6-, 12-, or 18-months)|Following training in BBTI, all sites (except site 1) will enter the pre-implementation phase for 6-, 12-, or 18-months. During this phase, sites will not receive any access to or support for the implementation strategies. They will deliver and implement BBTI as they see fit. Qualitative interviews will be conducted at the end of this phase.
11061006|NCT04350671|Active Comparator|Control|Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine
11061007|NCT04350658||TAVR|all comers study including all transfemoral or transcarotid TAVR procédures. direct implantation is the default strategy usually used in our enter as in may centers
11060977|NCT04350866||Implementation (12-months)|After the pre-implementation phase, all sites will enter a 12-month implementation phase (except site 1, which will begin implementation following BBTI training). During this phase, sites will receive access to and support for the bundle of implementation strategies, both from the hub site and their local champion/internal facilitator. During this phase, PCMHI clinicians trained in BBTI will receive feedback as necessary regarding their BBTI skills from their local champion/internal facilitator. During this phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
11060978|NCT04350866||Post-Implementation (6-months)|Following the 12-month implementation phase, each site will have access to and support for the implementation strategies removed and similar to the pre-implementation phase, will deliver and implement BBTI as they see fit. During this 6-month phase, PCMHI clinicians will also complete quarterly surveys regarding implementation strategies they are using and which strategies are/are not helpful. Qualitative interviews will be conducted at the end of this phase.
11060979|NCT04350853|Experimental|Surgical extrusion group|Surgical extrusion is performed in each patient of this group
11060980|NCT04350840|Experimental|Feedback|Participating endoscopists with low levels will get the limitation of rate on high confidence according to their real-time optical diagnosis performance (starting from 50%)
11060981|NCT04350827|Active Comparator|Platelet Rich Plasma|Procedure will be carried out with excellent sterile technique. 54ml of whole blood will be drawn. 54ml will be processed by centrifugation using the GPS III system (Zimmer Biomet, Warsaw, IN) and 1 ml will undergo a complete blood count (for a baseline comparison to determine the fold increase in platelets). The resultant PRP (5ml) will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) into the patellar tendon using ultrasound guidance to accurately direct the injection to the site of the tendon abnormality. The patient will rest after the injection for 15 minutes and then be dismissed.
11060982|NCT04350827|Active Comparator|Platelet Rich Plasma plus IGF|The PRP preparation and blood draw will be identical to the above. 55ml of whole blood will be drawn (1ml will undergo a CBC and the remaining 54ml will be used to make PRP). In addition to preparing the PRP, the resultant PPP (instead of discarding it) will be placed into the Plasmax device (Zimmer Biomet, Warsaw, IN) and concentrated via a second centrifugation cycle. The plasmax concentrate (concentrated IGF) will be added to the PRP (3ml of PRP + 2ml of plasmax concentrate for a total of 5ml) and then will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) under ultrasound guidance followed by the same rest period.
11060983|NCT04350814|Experimental|Self-Compassion Intervention Arm|Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.
11060984|NCT04350814|Active Comparator|Self-Reflection|Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.
11060985|NCT04350801||high risk MCI|MCI patients with amyloid beta positive (based on peripheral blood level)
11060986|NCT04350801||low risk MCI|MCI patients with amyloid beta negative (based on peripheral blood level)
11060987|NCT04350788|Placebo Comparator|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
11060988|NCT04350788|Experimental|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
11060989|NCT04350775|Experimental|RE-IADL group|Reablement
11060990|NCT04350775|Placebo Comparator|Control group|General community rehabilitation
11060991|NCT04350762|Experimental|Supplement + Fish Oil|"Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.
~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA)."
11060992|NCT04350762|No Intervention|Control|No dietary supplements. Participants will continue current intake.
11060993|NCT04350749|Experimental|Test group (PRF group)|PRF membrane is added to the bone block to evaluate if any effect on bone healing, soft healing, post-operativ pain
11060994|NCT04350749|Active Comparator|Control group (Standard operation)|A standard bone augmentation procedure, which is weel-described is performed to compare the outcome of the test group
11060995|NCT04350736|Experimental|TD-0903 for SAD (Part A)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
11060996|NCT04350736|Experimental|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
11060997|NCT04350736|Experimental|TD-0903 for MAD (Part B)|8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
11060998|NCT04350736|Experimental|Placebo for MAD (Part B)|2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
11060999|NCT04350723|Experimental|Intervention - Awake Proning|"The oxygen mask or NIPPV or HFNC will be initiated at the treating team's discretion. The patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating oxygen mask or NIPPV or HFNC treatment.
~Once the patient achieves the above parameters within 15 minutes of initiating oxygen therapy through any modality, the healthcare team will start awake proning."
11061000|NCT04350723|No Intervention|Control - Standard of Care|"The patient will receive usual care without proning at the discretion of the treating team.
~The oxygen mask or NIPPV or HFNC will be initiated, the choice of starting oxygen mask versus NIPPV versus HFNC will be up to the treating team, the patient will be observed for 15 minutes to ensure that: SPO2 > 90% and the patient is tolerating NIPPV or HFNC treatment."
11061001|NCT04350697||Mini-Sternotomy|Patients underwent aortic surgery by Mini-Sternotomy
11061002|NCT04350697||Mini-Thoracotomy|Patients underwent aortic surgery by Mini-Thoracotomy
11061003|NCT04350684|Experimental|Umifenovir|Umifenovir + Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine + Standards of Care
11061009|NCT04350645|Placebo Comparator|Control group|The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)
11061010|NCT04350619||Genetic study in retrospective and prospective groups|Genetic screening using NGS technique in a retrospective and prospective groups. No therapeutic intervention
11061011|NCT04350606|Experimental|PF-006462700 group|All enrolled participants will be administrated PF-006462700.
11061012|NCT04350593|Active Comparator|Dapagliflozin 10mg|Dapagliflozin 10 mg daily
11061013|NCT04350593|Placebo Comparator|Placebo|Dapagliflozin matching placebo 10 mg daily
11061014|NCT04350580|Experimental|Intervention - IGIV|Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started between 24 and 36 hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.
11061015|NCT04350580|Placebo Comparator|Placebo|Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.
11061016|NCT04350567|Experimental|Intervention|
11061017|NCT04350554||Retrospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 and who became pregnant during this period.
11061018|NCT04350554||Prospective pregnancies|Women recruited in CoRIS from January 2004 to November 2019 who will become pregnant during the year 2020 and who agree to participate in a telephone survey.
11061019|NCT04350541|Experimental|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
11061020|NCT04350541|Active Comparator|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
11061021|NCT04350528||Chlorpromazine|
11061022|NCT04350528||Pentobarbital|
11061023|NCT04350515|Experimental|Cyberball: Other Exclusion|Cyberball Paradigm - the avatar will be excluded by the player
11061024|NCT04350515|Experimental|Cyberball: Player Exclusion|Cyberball Paradigm - the player will be excluded by the other players
11061025|NCT04350502|Experimental|complicated pleural infection patients|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g*3 by day) and clavulanic acid (200mg*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
11061026|NCT04350489||Control|Periodontally healthy group
11061027|NCT04350489||Periodontitis|Patients with periodontitis
11061028|NCT04350476|Other|Vital Connect Patch Arm|"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system:
~VitalConnect Vital Sign Patch (FDA approved for this indication)"
11061029|NCT04350463|Experimental|Arm A: SCLC in ICI naïve subjects|"CC-90011 will be given orally (PO) at a dose of 60 mg on a once weekly basis in a continuous 28-day cycle.
~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
11061030|NCT04350463|Experimental|Cohort B: SCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 60 mg on a once weekly basis in a continuous 28-day cycle.
~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
11061031|NCT04350463|Experimental|Cohort C: sqNSCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 60 mg on a once weekly basis in a continuous 28-day cycle.
~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice.:"
11061032|NCT04350450|Experimental|Treatment Group|Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study
11061033|NCT04350450|No Intervention|Control Group|Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms
11061034|NCT04350437|Other|induction of labor monitoring|meticulous data collection from patients and plotting that data in a machine learning model
11061035|NCT04350424||Propofol Arm|Outpatients receiving anesthesiologist-administered propofol for elective outpatient endoscopic procedures
11061036|NCT04350424||Opioid / Benzodiazepine Arm|Outpatients receiving endoscopist-administered opioid / benzodiazepine for elective outpatient endoscopic procedures
11061037|NCT04350411|Experimental|Conventional diathermy|DIEP/ MS-TRAM breast reconstruction free flap raise performed with conventional diathermy
11061038|NCT04350411|Experimental|PEAK PlasmaBlade™|DIEP/ MS-TRAM breast reconstruction free flap raise performed with PEAK PlasmaBlade™
11061039|NCT04350398|Experimental|Hippotherapy treated group|"During the initial week of intervention, sessions will be mainly carried on horseback. We will use the movement of the horse: (i) to allow patient re-appropriating her body and find harmony; (ii) to initiate rehabilitation of movements (shoulder, neck, upper extremity, whole body), gesture and femininity. The goal is to reconstruct a harmonic body image both in the private and public sphere, through different techniques. A few walking sessions may be needed to reinforce some landmarks.
~During the short stages the work will be mainly done by walking alongside the horse. These reinforcement periods act like a trampoline, necessary to have a new momentum providing the opportunity to take a step back from the everyday, to regenerate somehow. The reaction time is generally optimized considering the imprint done during the initial long stage. One of the main themes that come up during this period is fear (relapse, the future, not achieving the goals, pain, relationship issues, etc.)."
11061066|NCT04350190|Experimental|Apatinib combined with PD-1|Eligible patients begin to use apatinib mesylate tablets and PD-1, apatinib mesylate tablets at the recommended dose of 250mg,oral, QD, continuous administration, 4 weeks (28 days) as an observation cycle. Until the disease progressed or unbearable adverse reactions appeared. If missed medication occurs during the medication period, it is confirmed that the next medication time is less than 12 hours, then there will be no replenishment. The recommended dose of PD-1 is 200mg/time, Q2W, intravenous injection, 4 weeks (28 days) as an observation cycle, until disease progression or intolerable toxicity.
11075716|NCT04246463||Other indications|Isolated Iliac Artery Aneurysm (IIAA)
11061040|NCT04350398|Placebo Comparator|Conventional therapy treated group|Patients in the control group are followed by dedicated personnel of the Montpellier Institut du Sein. This personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
11061041|NCT04350385|Experimental|Group 1|Agility Training
11061042|NCT04350385|Active Comparator|Group 2|.Conventional intervention
11061043|NCT04350372|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NT System
11061044|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 5 x week|"TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
~All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci."
11061045|NCT04350359|Active Comparator|Fixed-dose TTNS protocol|"Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes.
~Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week."
11061046|NCT04350359|Active Comparator|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
11061047|NCT04350346|Active Comparator|The patient group who taken Motilitone|
11061048|NCT04350346|Active Comparator|The patient group who taken Gasmotin|
11061049|NCT04350333|Experimental|CBT-I group|Five sessions composed of: psychoeducation on sleep change during pregnancy and postpartum; sleep hygiene principles; stimulus control technique, sleep restriction technique (f this technique will be too difficult for the participants to be apply, a replacement and less disabling technique will be applied: sleep compression); psychoeducation on the child's sleep at birth and on the change in the sleep-wake cycle in the early stages of the child's life; cognitive control technique; cognitive reconstruction technique and de-catastrophization; relapses prevention.
11061050|NCT04350333|Active Comparator|Assertive communication training|Five sessions composed of: psychoeducation and explanation of the importance of emotional and cognitive factors for good sleep. Psychoeducation about the concept of assertiveness, explanation of the passive, aggressive and assertive style; explanation and exercises regarding self-esteem and positive self-image; explanation of the development of sleep of the child in the first years of life; explanation and exercises on the phase of the management of feedback and requests; conflict management; relapses prevention.
11061051|NCT04350320|Experimental|COLCHICINE|"The colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 28 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.
~+ standard therapy for COVID-19 according to the stablished hospital protocols."
11061052|NCT04350320|Placebo Comparator|control group|Standard therapy for COVID-19 according to the stablished hospital protocols.
11061053|NCT04350307|Active Comparator|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
11061054|NCT04350307|Active Comparator|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
11061055|NCT04350294||Serious Mental Illness|"Mothers with a serious mental illness* who have given birth since December 2019
~*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
11061056|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since December 2019
11061057|NCT04350281|Active Comparator|Treatment group|Subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3 and hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care
11061058|NCT04350281|Active Comparator|Control group|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days plus standard care alone.
11061059|NCT04350255|Active Comparator|Trident II Hemispherical cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup
11061060|NCT04350255|Active Comparator|Trident II Tritanium cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup
11061061|NCT04350229|Experimental|EXPERIMENTAL GROUP|"In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
~Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg."
11061062|NCT04350229|Active Comparator|CONTROL GROUP|Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg and dexamethasone 10mg.
11061063|NCT04350216|Experimental|Sarilumab therapy|Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
11061064|NCT04350203||Intracorporeal Anatomosis (IA)|Laparoscopic Right colectomy with intracorporeal (IA) side-to-side isoperistaltic anastomosis
11061065|NCT04350203||Extracorporeal Anastomosis (EA)|Patients submitted to a Laparoscopic Right Colectomy with extracorporeal anastomosis (EA)
11061108|NCT04349800|Experimental|Single Ascending Dose - 20 mg|
11061109|NCT04349800|Experimental|Single Ascending Dose - 40 mg|
11061067|NCT04350177|Active Comparator|single ascending Dose (SAD)|In Part A, cohorts will consist of eight (8) subjects; six (6) of whom will receive treatment with IkT-148009 and two (2) with matching placebo.
11061068|NCT04350177|Active Comparator|Multiple ascending Dose (MAD)|In Part B, cohorts will consist of twelve (12) subjects; nine (9) of whom will receive treatment with IkT-148009 and three (3) with matching placebo.
11061069|NCT04350164||treatment|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
11061070|NCT04350138|Experimental|Group 1|Bexsero vaccine will be administered as an intramuscular injection in 0.5-mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
11061071|NCT04350138|Placebo Comparator|Group 2|Placebo will be administered as an intramuscular injection in 0.5-mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
11061072|NCT04350125|Experimental|Platelet Rich Plasma Treatment|Male subjects diagnosed with Erectile Dysfunction (ED) will receive platelet rich plasma injections.
11061073|NCT04350086|Experimental|Experimental arm|
11061074|NCT04350073||COVID-19 ICU Patients|COVID-10 patients with respiratory failure admitted to the ICU
11061075|NCT04350073||ICU Patients (Control)|Non-COVID-19 respiratory failure patients requiring mechanical ventilation > 48 h receiving similar ICU standards of care at Duke
11061076|NCT04350060|Experimental|Intervention Group|Subjects with dementia will be living in a retro-fitted room with technological enhancements for a 12 month period.
11061077|NCT04350060|No Intervention|Standard of Care Group|
11061078|NCT04350047||Transabdominal inferior vena cava thrombectomy|Patients undergoing radical nephrectomy and inferior vena cava thrombectomy transabdominal without thoracotomy
11061079|NCT04350034|Experimental|Xbox training group|The study group received Xbox training plus routine physical therapy protocol treatment. The dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system (Xbox 360 Kinect console; Microsoft Inc., Redmond, Washington, USA).
11061080|NCT04350034|Placebo Comparator|Control group|patients participated in a routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
11061081|NCT04349995||Amplatzer PFO Occluder|Percutaneous PFO Closure using Amplatzer PFO occluder
11061082|NCT04349982||No cardiovascular risk|If no patients with no cardiovascular risk can be included in the study, we will divide the cohorts into different categories (e.g. low, medium and high cardiovascular risk).
11061083|NCT04349982||low cardiovascular risk|
11061084|NCT04349982||high cardiovascular risk|
11061085|NCT04349969|Experimental|Treatment|AK117 monotherapy
11061086|NCT04349956||Patients from a randomized placebo-controlled study of UBX0101|Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
11061087|NCT04349943|Experimental|inflammatory bowel disease|According to the patient's disease condition, tube feeding time, internal and surgical diagnosis and treatment plan, standard step-based nutrition treatment was carried out for the patients with adaptive signs of nutrition treatment, and dynamic nutrition evaluation and efficacy evaluation were carried out.
11061088|NCT04349930|Experimental|Cannabidiol|CBD vaginal suppository
11061089|NCT04349930|Placebo Comparator|Placebo|Placebo vaginal suppository
11061090|NCT04349917|Placebo Comparator|Placebo, then Methylphenidate|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
11061091|NCT04349917|Experimental|Methylphenidate, then Placebo|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
11061092|NCT04349891|Experimental|TEA at ST36 and PC6 first and then sham TEA|Patients in this group will be treated with TEA at ST36 and PC6 for 4 weeks, followed with a 2-week washout period and another 4-week period with sham TEA.
11061093|NCT04349891|Experimental|Sham-TEA and then TEA ST36 and PC6|Patients in this group will be treated with sham-TEA for 4 weeks, followed with a 2-week washout period and another 4-week period with TEA at ST36 and PC6.
11061094|NCT04349878|Placebo Comparator|Control|scaling and root planing alone
11061095|NCT04349878|Active Comparator|phytotherapeutic|scaling and root planing plus phytotherapeutic agent
11061096|NCT04349865||Idiopathic PD|PD patients without the LRRK2 G2385R mutation
11061097|NCT04349865||LRRK2 G2385R PD|PD patients with the LRRK2 G2385R mutation
11061098|NCT04349865||LRRK2 G2385R carriers|Subjects without PD who screen positive for the LRRK2 G2385R mutation
11061099|NCT04349865||Controls|Subjects without PD who screen negative for the LRRK2 G2385R mutation
11061100|NCT04349852|Experimental|BrainHQ Cognitive Training Arm|Participants will randomized into the BrainHQ Cognitive Training modules which are 45 minutes training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, noise cancelling head phones will also be provided to the participants. Participants will complete the training protocols in the lab under the study team's supervision to ensure the participants are engaged and are completing the tasks.
11061101|NCT04349852|Other|BrainHQ People Skills Arm|Participants will randomized into the BrainHQ People Skills Modules which are 45 minutes training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, noise cancelling head phones will also be provided to the participants. Participants will complete the training protocols in the lab under the study team's supervision to ensure the participants are engaged and are completing the tasks.
11061102|NCT04349839||ACRODAT study arm|No intervention
11061103|NCT04349839||Standard Practice Arm|No intervention
11061104|NCT04349826|Active Comparator|Azithromycin+Cefixime|Azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) AND Cefixime 20-30mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days.
11061105|NCT04349826|Placebo Comparator|Azithromycin+placebo|Azithromycin 20mg/kg/day oral dose once daily (Max 1gm/day) for 7 days AND Cefixime-matched placebo for 7 days.
11061106|NCT04349800|Experimental|Single Ascending Dose - 5 mg|
11061107|NCT04349800|Experimental|Single Ascending Dose - 10 mg|
11061116|NCT04349787||Colorectal polyp patients|Patients who have a colonoscopy in regular care as part of the Dutch colorectal screening program, in the context of complaints or in the context of the follow-up of previously diagnosed bowel diseases. And who have at least one colorectal polyp found and resected during the examination.
11061117|NCT04349774|Active Comparator|Control Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml 0.375% Bupivacaine
11061118|NCT04349774|Active Comparator|Treatment Group|Continuous Erector Spinae Plane block with 20ml 0.375% Bupivacaine and continuous infusion of 0.25% Lidocaine @ 12ml/hr, with single shot Serratus Anterior Plane block with 20ml Normal Saline.
11061119|NCT04349761|Experimental|Cohort 1 - 5mg MyMD1|8 subjects randomized to receive either 5mg MyMD1 (6 subjects) or Placebo (2 subjects)
11061120|NCT04349761|Experimental|Cohort 2 - 10mg MyMD1|8 subjects randomized to receive either 10mg MyMD1 (6 subjects) or Placebo (2 subjects)
11061121|NCT04349761|Experimental|Cohort 3 - 15mg MyMD1|8 subjects randomized to receive either 15mg MyMD1 (6 subjects) or Placebo (2 subjects)
11061122|NCT04349761|Experimental|Cohort 4 - 20mg MyMD1|8 subjects randomized to receive either 20mg MyMD1 (6 subjects) or Placebo (2 subjects)
11061123|NCT04349761|Experimental|Cohort 5 - 25mg MyMD1 or Placebo|8 subjects randomized to receive either 25mg MyMD1 (6 subjects) or Placebo (2 subjects)
11061124|NCT04349748|Experimental|Group 1|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the second observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
11061125|NCT04349748|Experimental|Group 2|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the third observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
11061126|NCT04349748|Experimental|Group 3|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fourth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
11061127|NCT04349748|Experimental|Group 4|The group is given health education, regular HIV and STDs testing prompting service in the whole study, and permission to query health status (partner notification) through app from the fifth observation period. HIV and STDs testing and questionnaire are given to the participants when they receive the testing service.
11061128|NCT04349735|Experimental|Adults with asthma or COPD|Assessment of inhalation technique by three methods in all patients
11061129|NCT04349722|Active Comparator|Hyoscine|Participants receive intravenous bolus of 1ml (20 mg) Hyoscine
11061130|NCT04349722|Placebo Comparator|Placebo|Participants receive intravenous bolus of 1ml normal saline
11061131|NCT04349709|Experimental|Brief school-based DBT-A|The students of classes randomized to experimental group receive the brief school-based DBT-A..
11061132|NCT04349709|No Intervention|control group|The students of classes randomized to control group continue their school activity as routine.
11061133|NCT04349696|Active Comparator|T2DM with Child-Pugh A|"All subjects with T2DM with normal hepatic function received a Mitiglinide Tablets 10 mg.
~Intervention: Drug: Mitiglinide Tablets 10 mg"
11061134|NCT04349696|Experimental|T2DM with Child-Pugh B|"All subjects with T2DM with moderate impaired hepatic function received a MitiglinideTablets 10 mg.
~Intervention:Drug: Mitiglinide Tablets 10 mg"
11061135|NCT04349683|Experimental|Experimental group|basic treatment combined with Jinshuibao
11061136|NCT04349683|Placebo Comparator|Control group|basic treatment and placebo
11061137|NCT04349657|Experimental|Supera Peripheral Stent System treatment group|These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).
11061138|NCT04349657|Active Comparator|Endarterectomy treatment group|These patients will be treated surgically with endarterectomy
11061139|NCT04349644|Experimental|SENSE Theatre|A peer-mediated, theatre-based intervention designed to improve social cognition and behavior.
11061140|NCT04349644|No Intervention|Waitlist Control Group|This group will not receive the intervention during the testing phase of the intervention but will eventually receive the theatre intervention.
11061141|NCT04349631|Experimental|HB-adMSCs|Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2,6,10, 14, 18, 22, 26.
11061142|NCT04349618|Active Comparator|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight
11061143|NCT04349618|Experimental|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20
11061144|NCT04349605|Experimental|Meditation|This is a daily 15 minute meditation with guided breathing. Accessible through an app.
11061145|NCT04349605|Experimental|Kundalini Yoga|This is a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
11061146|NCT04349605|No Intervention|Treatment as Usual|This group will serve as the comparison to assess the efficacy of the active treatments in that no study treatment will be provided. The participants will be asked to not start new treatments during the 8 weeks of the study.
11061147|NCT04349592|Experimental|Combination therapy group|hydroxychloroquine 200mg TID for 7 days plus Azithromycin 500mg OD 1st day and 250 from day 2 to 5
11061148|NCT04349592|Active Comparator|Monotherapy therapy group|hydroxychloroquine 200mg TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
11061149|NCT04349592|Placebo Comparator|Control group|Placebo Cap TID for 7 days plus Placebo 1 tab OD 1st day and 1 tab from day 2 to 5
11061150|NCT04349579|Experimental|Rifamycine|Rifamycine is a broad spectrum semi-synthetic antibiotic that acts on gram-positive and gram-negative microorganisms. As a local application, it has areas of use in dentistry such as washing fistula mouths, maxillary sinus and abscess wounds and treating osteomyelitis.
11076326|NCT04242004|Placebo Comparator|placebo group|
11061151|NCT04349579|Active Comparator|Saline|Saline, also known as saline solution, is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds. It is also used to dilute other drugs to be injected and to wash the operation site in dental surgery operations. It is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.
11061152|NCT04349553|Experimental|ZH9PA 1x10^9 CFU|1mL ZH9PA 1x10^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
11061153|NCT04349553|Experimental|ZH9PA 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
11061154|NCT04349553|Experimental|ZH9PA 1x10^10 CFU plus ZH9 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline and 1mL ZH9 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
11061155|NCT04349553|Placebo Comparator|Placebo|1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
11061156|NCT04349527||RB Group|In this Group Patients receive round-block oncoplastic breast coserving surgery
11061157|NCT04349527||RG Group|In this Group Patients receive retrogladular oncoplastic breast coserving surgery
11061158|NCT04349514||Friedreich ataxia|Individuals with a diagnosis of Friedreich ataxia.
11061159|NCT04349514||Control|Individuals without a diagnosis of Friedreich ataxia.
11061160|NCT04349501|Experimental|RSI-MRI|Participants will undergo RSI-MRI at three time points: before androgen deprivation therapy (ADT); after neoadjuvant ADT but before radiation therapy (RT); and after RT.
11061161|NCT04349488|Active Comparator|Treatment|Anode placed over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11061162|NCT04349488|Placebo Comparator|Placebo|Anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11061163|NCT04349475|Experimental|Omega 3 Supplementation|Supplementation of 4g of DHA/EPA daily
11061164|NCT04349475|Placebo Comparator|Safflower Oil Supplement|Supplementation of Safflower Oil daily
11061165|NCT04349462|Other|VFSS and Water Sip Test|Enrolled patients will undergo a water sip test and Videofluroscopy Swallow Test (VFSS)
11061166|NCT04349449||Vedolizumab Participants|Participants diagnosed with moderate to severe CD from approximately 20 investigational sites will be observed over a period of 12 months after initiation of treatment with vedolizumab, intravenous infusion under standard clinical care.
11061167|NCT04349436|Experimental|RP1, intra-tumoral injection, oncolytic virus|RP1 administered as an intra-tumoral injection every 2 weeks.
11061168|NCT04349423|Experimental|No Social Media Use|Participants will be asked to refrain from using all social media
11061169|NCT04349423|Experimental|Maximum 30 minutes of use|Participants will be asked to only use social media at most 30 minutes a day.
11061170|NCT04349423|Experimental|Maximum 1 hour of use|Participants will be asked to only use social media at most 60 minutes a day.
11061171|NCT04349423|Experimental|Maximum 2 hour of use|Participants will be asked to only use social media at most 120 minutes a day.
11061172|NCT04349423|Experimental|Maximum 3 hour of use|Participants will be asked to only use social media at most 180 minutes a day.
11061173|NCT04349410|Experimental|Treatment 1|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Azithromycin 500 mg IV on day 1, followed by 250 mg IV on days 2-5 (to prevent bacterial superinfection ).
11061174|NCT04349410|Experimental|Treatment 2|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Doxycycline 100mg IV q 12 hrs with each dose given over 1 to 4-hours (to prevent bacterial superinfection ).
11061175|NCT04349410|Experimental|Treatment 3|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
11061176|NCT04349410|Experimental|Treatment 4|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
11061177|NCT04349410|Experimental|Treatment 5|Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
11061178|NCT04349410|Experimental|Treatment 6|Remdesivir 200 mg IV on day 1, followed by 100 mg IV qD for a total of 10-days.
11061179|NCT04349410|Experimental|Treatment 7|"Tocilizumab 8mg/kg IV (not to exceed 800 mg) over 60-minutes. If clinical improvement is not noted, three additional doses may be administered at q 8-hour intervals from the initial infusion for a total of 4-doses maximum.
~ANY PATIENT DEMONSTRATING CYTOKINE RELEASE SYNDROME WILL HAVE THIS TREATMENT ARM AUTOMATICALLY ADDED."
11061180|NCT04349410|Experimental|Treatment 8|Methylprednisolone 125 mg IV every 6-hours for 3 days; then 125 mg IV every 12-hours for 2 days; then 125 mg IV daily for 2 days; then 60 mg IV daily for 2 days [with each infusion given over 30-minutes]; then Solumedrol dose pack to taper off steroids.
11061181|NCT04349410|Experimental|Treatment 9|Interferon alpha-2b 5 million units per nebulizer BID.
11061182|NCT04349410|Experimental|Treatment 10|Losartan 25 mg po qD. IRB held due to questions about benefit.
11061183|NCT04349410|Experimental|Treatment 11|Convalescent Plasma 2-units ABO-compatible with antibody titer of 1:320 dilution. Each unit intravenously infused over 4-hours.
11061184|NCT04349397||Pediatric tonsillectomy patients|All patients enrolled into study prior to undergoing tonsillectomy or adenotonsillectomy
11061185|NCT04349384||Colon adenocarcinoma|Patient who underwent surgical resection for colon adenocarcinoma
11061186|NCT04349384||Rectal adenocarcinoma|Patient who underwent surgical resection for rectal adenocarcinoma
11061187|NCT04349371|Experimental|CQ group|Participants will receive CQ supply for 3 months. Patients will receive a supply of 36 -- 250 mg tabs or placebo that will last 3 months (enough for taking two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
11061188|NCT04349371|Placebo Comparator|Placebo group|Participants will receive placebo supply for 3 months. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
11061189|NCT04349358|Other|FDG and FCH PET/CT|
11061190|NCT04349345||sperm count over time|observation
11061191|NCT04349332|Active Comparator|Helmet non invasive ventilation (NIV)|Patients randomized to the intervention group will be extubated to helmet NIV.
11061192|NCT04349332|No Intervention|Control invasive mechanical ventilation|Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
11061193|NCT04349319|Other|Digital preoperative planning|To use digital preoperative planning software
11061194|NCT04349306|Experimental|rasburicase|rasburicase 0.20 mg/kg/day by intravenous (IV) over 30 minutes for 1 to 5 days according to the level of plasma uric acid or Investigator's clinical judgement
11061195|NCT04349293|Experimental|Patients with cancer|
11061196|NCT04349280|Experimental|Participants receiving bintrafusp alfa|Participants will receive bintrafusp alfa 1200 milligram (mg), intravenous (IV) infusion, once every 2 weeks (Q2W) until progressive disease (PD), death, unacceptable toxicity, study withdrawal or up to 2 years.
11061197|NCT04349267|Experimental|BMS-986315|
11061198|NCT04349267|Experimental|BMS-986315 + nivolumab|
11061199|NCT04349267|Experimental|BMS-986315 + cetuximab|
11061200|NCT04349241|Experimental|favipiravir|favipiravir in a regimen of 3200 mg (1600 mg 12 hourly) loading dose on day-1 followed by 1200 mg maintenance dose (600 mg 12 hourly daily) on day-2 to day-10
11061201|NCT04349241|Active Comparator|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10.
11061202|NCT04349228|Experimental|Hydroxychloroquine (HCQ)|Exposed health care professionals working in the intensive care unit
11061203|NCT04349228|Placebo Comparator|Placebo|Exposed health care professionals working in the intensive care unit
11061204|NCT04349202||Beaumont employees|Beaumont employees (employees and affiliated non-employed physicians and advanced practice providers) undergoing serology testing for SARS-CoV-2 antibodies, their immediate family members, and members of other high-risk groups.
11061205|NCT04349189||Group 1|50 Men and Women with sickle cell disease and VTE
11061206|NCT04349189||Group 2|50 Men and Women with sickle cell disease but no VTE
11061207|NCT04349189||Group 3|50 Men and Women with sickle cell trait
11061208|NCT04349189||Group 4|50 ethnically matched Men and Women without sickle cell disease, sickle cell trait or VTE
11061209|NCT04349176|Experimental|Group A 100U|
11061210|NCT04349176|Experimental|Group A 155U|
11061211|NCT04349176|Experimental|Group B 100U|
11061212|NCT04349176|Experimental|Group B 155|
11061213|NCT04349163||Caregivers|Physicians and nurses working at the Emergency Department, Intensive care Unit, infectious disease Department, Anaesthesiology.
11061214|NCT04349150|Experimental|Virtual reality|Participants on this arm will have their colonoscopy initiated under virtual reality instead of standard sedatives and narcotics
11061215|NCT04349137|Experimental|In-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a synchronized (in-phase) manner at a frequency of 6Hz
11061216|NCT04349137|Active Comparator|Anti-phase 6Hz tACS|Transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC in a desynchronized (anti-phase, i.e. with a difference of 180deg) manner at a frequency of 6Hz
11061217|NCT04349137|Sham Comparator|Sham tACS|A sham transcranial alternating current stimulation (tACS) will be administered over the right PPC and the right DLPFC at a frequency of 6Hz using physical vibrations instead of electrical current
11061218|NCT04349124|Other|Treatment Group|The treatment group will provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
11061219|NCT04349124|Placebo Comparator|Control Group|The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the sever range (>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
11061220|NCT04349111|Other|Experimental: Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
11061221|NCT04349098|Experimental|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
11061317|NCT04348383|Experimental|Defibrotide + standard therapy|Defibrotide + standard therapy
11061318|NCT04348383|Placebo Comparator|Placebo|Placebo + standard therapy
11061222|NCT04349098|Placebo Comparator|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
11061223|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
11061224|NCT04349085|Experimental|Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
11061225|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
11061226|NCT04349085|Placebo Comparator|Placebo PBMT/sMF before WOD and Placebo PBMT/sMF after WOD.|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
11061227|NCT04349072|Experimental|Drug: Mavacamten|"Mavacamten Capsules
~Other names:
~MYK-461"
11061228|NCT04349072|Placebo Comparator|Drug: Placebo|Matching Placebo Capsules
11061229|NCT04349059|Active Comparator|Plant-based arm|Sequence one as outlined in the Study Description section consists of 7 visits to the doctors office, following a plant based diet and using the The Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
11061230|NCT04349059|Active Comparator|Animal-based arm|Sequence two as outlined in Study Description section consists of 7 visits to the doctors office, following a animal based diet and using the The Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
11061231|NCT04349046||Patient who received the Exception stem|Patient who received the Exception stem between January 2008 and September 2012 and consented to the original data collection.
11061232|NCT04349033|Experimental|Emotional Disclosure and Brain Education|Patients are interviewed about stress and other emotional issues and are educated about how emotions and the brain influence pain.
11061233|NCT04349033|Active Comparator|Emotional Disclosure only|Patients are interviewed about stress and other emotional issues only.
11061234|NCT04349033|Placebo Comparator|Pain Information Control|Patients are interviewed about their pain history and experience.
11061235|NCT04349007|Active Comparator|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in
11061236|NCT04349007|Experimental|School food ready-to-use|peanut-based school food ready-to-use
11061237|NCT04349007|Experimental|School food ready-to-use plus Milk|peanut-based school food ready-to-use with milk
11061238|NCT04348994|Experimental|Laser therapy|Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
11061239|NCT04348981|Experimental|Wearable|All patients eligible to enroll in the Enhanced Recovery after Cardiac Surgery pathway will be offered a wearable fitness tracking device.
11061240|NCT04348968||Patient who received a Maxera Cup of large diameter|Patient received a Maxera Cup with an outer diameter of 64 mm or 66 mm between Nov 2011 and Feb 2018.
11061241|NCT04348955||women with adjuvant breast cancer|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
11061242|NCT04348929|Experimental|Confinement group|Delivery during covid-19 confinement period
11061243|NCT04348929|Other|Control group|Start of pregnancy after confinement and delivery after the withdrawal of all sanitary measures (mask, social distancing, limited visits during post-partum immediate)
11061244|NCT04348929|Other|Epidemic group|Delivery after confinement period and before the withdrawal of sanitary measures implemented (mask, social distancing, limited visits during post-partum immediate)
11061245|NCT04348916|Experimental|Dose escalation of ONCR-177 by intratumoral injection|Dose escalation of ONCR-177 intratumoral injections alone in four cohorts in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
11061246|NCT04348916|Experimental|Dose expansion of ONCR-177 in subjects with solid tumors|Dose expansion of ONCR-177 intratumoral injections alone at the recommended phase 2 dose (RP2D) in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
11061247|NCT04348916|Experimental|ONCR-177 and pembrolizumab in subjects with solid tumors|Dose expansion of ONCR-177 intratumoral injections at the RP2D in combination with pembrolizumab in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
11061248|NCT04348903|Experimental|Virtual Reality Distraction|Virtual reality refers to a human-computer interface that completely immerse the child in a simulated environment. It integrates multiple perceptual senses including; the visual, auditory and kinaesthetic stimulation modalities. Virtual reality diverts children's attention away from the negative feelings associated with unpleasant experience.
11061249|NCT04348903|Experimental|Positive Pre-Visit Imagery Intervention|Positive pre-visit imagery is one of the superior cognitive- behavioral interventions. It is kind of psychological preparation that is designed to provide children with a step-by-step explanation of the dental local anaesthesia injection in an attractive approach
11061250|NCT04348890|Experimental|Treatment Arm|
11061251|NCT04348877|Other|Antibody-Rich Plasma|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
11061252|NCT04348864|Experimental|Positive-Antigen swab test for SARS-COV-2|Subjects who have tested positive for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular test from nasal pharyngeal self-swab or a swab administered in a clinical setting at the point of care by a trained clinician. Follow-up PCR-based testing occurs in an advanced laboratory.
11061253|NCT04348864|Sham Comparator|Negative-Antigen swab test for SARS-COV-2|Subjects who have tested negative for the presence of SARS-COV-2 viral antigen using a rapid test or LAMP/PCR-based molecular nasal pharyngeal self-swab or a swab administered in a clinical setting by a trained clinician. PCR-based testing occurs in an advanced laboratory.
11061288|NCT04348591|Experimental|Misophonia Group|Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
11076892|NCT04237831|Experimental|Arm D: Severe Renal Impairment|
11061254|NCT04348851|Experimental|4-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
11061255|NCT04348851|Experimental|8-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
11061256|NCT04348851|Active Comparator|8-Week Attention Control|The Registered Nurses (RNs) will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare provider.
11061257|NCT04348851|No Intervention|Standard Care|Caregivers receiving standard of care
11061258|NCT04348825||Patients, depression|Patients who receive ECT as part of clinical care
11061259|NCT04348825||Healthy|Healthy controls who do not receive ECT but otherwise the same assessments.
11061260|NCT04348825||Patients, atrial fibrilation|Patients who receive Electro Cardio Version (ECV) due to Atrial Fibrilation
11061261|NCT04348812|Experimental|tDCS Active|Transcranial direct current stimulation with ABMT
11061262|NCT04348812|Sham Comparator|tDCS sham|Transcranial direct current sham stimulation with ABMT
11061263|NCT04348799||BPD group|premature infants diagnosed with BPD after postnatal day 28
11061264|NCT04348799||control group|premature infants without BPD after postnatal day 28
11061265|NCT04348786|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate
11061266|NCT04348786|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole
11061267|NCT04348773|Experimental|Dehydration|
11061268|NCT04348773|Experimental|Rehydration|
11061269|NCT04348760|Experimental|Intervention|Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week
11061270|NCT04348747|Experimental|Treatment (anti-HER2/3 dendritic cell vaccine)|"TREATMENT PHASE: Patients receive anti-HER2/HER3 dendritic cell vaccine ID on days 1, 15, and 29. Patients also receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 15-17 and 29-31.
~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive a booster dose of anti-HER2/3 dendritic cell vaccine ID, celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV every 3 months in the opinion of principal investigator."
11061271|NCT04348708||Dose Level Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
11061272|NCT04348708||Dose Level Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
11061273|NCT04348708||Dose Level Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
11061274|NCT04348695|Experimental|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.
~Simvastatin 40 mg orally every 24 hours for 14 days."
11061275|NCT04348695|Other|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
11061276|NCT04348669|Experimental|Tele-yoga|This is a single group study with all subjects included in this single arm. All subjects will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
11061277|NCT04348656|Experimental|Convalescent plasma|~500 mL ABO compatible convalescent apheresis plasma
11061278|NCT04348656|No Intervention|Standard of care|Treated as per institutional standard of care.
11061279|NCT04348643|Experimental|CEA+ CAR-T|CAR-T cell reinfusion is carried out in 1~3 times
11061280|NCT04348630|Experimental|HOT condition|Participants are exposed to 36°C and 45% relative humidity for 8 hours. These conditions were chosen to represent an extreme heat condition (i.e., heatwave) and are similar to peak domicile conditions measured in low-income high-rise apartment complexes during heatwaves.
11061281|NCT04348630|Experimental|WARM Condition|Participants are exposed to 31°C and 45% relative humidity for 8 hours. These conditions are similar to mean domicile conditions measured in a variety of domicile types during heat waves complexes during heatwaves and are consistent with the World Heath Organization recommendation for maximal indoor temperatures.
11061282|NCT04348630|Experimental|TEMPERATE Condition|Participants are exposed to 26°C and 45% relative humidity for 8 hours. These conditions are consistent with Toronto Public Health recommendation for maximal indoor temperatures, which are based on the increase in mortality associated with increases in outdoor temperature above these limits.
11061283|NCT04348630|Experimental|COOL Condition|Participants are exposed to 22°C and 45% relative humidity for 8 hours. These conditions are consistent with actively cooled (air-conditioned) domicile.
11061284|NCT04348617|Experimental|Exercise-Rest|This group will perform the exercise condition at least 1 week after the preliminary visit and will perform the resting condition a minimum of 15 days and a maximum of 2 months after the exercise condition.
11061285|NCT04348617|Experimental|Rest-Exercise|This group will perform the resting condition at least 1 week after the preliminary visit and will perform the exercise condition a minimum of 15 days and a maximum of 2 months after the resting condition.
11061286|NCT04348604|Experimental|Customized Adherence Enhancement for AYA|This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
11061287|NCT04348604|Active Comparator|Enhanced Treatment as Usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
11061316|NCT04348396||Elderly patients affected by COVID-19|The group taken into consideration consists of elderly patients hospitalized with diagnosed COVID-19.
11076893|NCT04237818|Placebo Comparator|Placebo drink|
11061289|NCT04348591|Active Comparator|Emotional Dysregulation Clinical Group|Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
11061290|NCT04348578|No Intervention|control group|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL NaOCl and 5mL sterile saline in the control group.The root canals were dried with sterile paper points and were filled with gutta-percha and AH Plus sealer with the cold lateral condensation method and the entry cavity was restored with composite. All treatments were performed following a standardized procedure by one operator. After completion of the root canal treatment, periapical radiographs were taken using the paralleling technique. All the patients were called for follow-up examination at 12 months, and were examined radiographically.
11061291|NCT04348578|Experimental|QMix 2in1|The root canal was prepared using the WaveOne Gold file reciprocation system with VDW Silver motor. WaveOne Gold #25 (0.07) file was used for instrumentation. For larger canals, #35 (0.06) and #45 (0.05) files were used after the #25 file. During instrumentation procedure, irrigation was applied with 5mL 2.5% NaOCl using a side-vented needles. The final irrigation was applied with 5mL Mix 2in1 and 5mL sterile saline in the experimental group.
11061292|NCT04348565|Experimental|Diabetes Care Programme|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
11061293|NCT04348565|No Intervention|Standard Usual Care|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
11061294|NCT04348539|Experimental|Balance training|The balance training consists of 3 moments: warm up, main and stretch. Warm-up with mobility exercises for major joints and large muscle groups. The main part will have eight exercise stations divided into: a) five balance exercises (dynamic and static with or without object balance) on a varied floor, b) three agility exercises, and a stretching of the worked muscle groups and a final relaxation.
11061295|NCT04348539|Experimental|Strength training|Muscle strength training will consist of 3 moments: warm up, main and stretch. Warm up with mobility exercises for the main joints and large muscle groups. The main part will include strength exercises with lower and upper limbs with two sets of 6-12 repetitions according to periodization, and a stretching of the muscle groups worked
11061296|NCT04348539|Experimental|Cardiorespiratory endurance training|The older people walking training consists of 3 moments: warm up, main and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed, then walk according to the training cycle, and then a stretching of the main muscle groups. Will be held, twice a week for 45 minutes each session. The training intensity will follow 60-110% of the volume of the 6-minute Test (6MWT) and the Borg Scale at moderate to difficult intervals. the training
11061297|NCT04348539|No Intervention|Control group|control group: who will receive educational lectures on health, walking and aging.
11061298|NCT04348526|Experimental|Corticision|Patients will undergo a corticision procedure in order to accelerate tooth movement
11061299|NCT04348526|Active Comparator|Traditional treatment|Patients will undergo traditional orthodontic treatment without any surgical intervention.
11061300|NCT04348513|Experimental|T3 solution for injection|T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
11061301|NCT04348513|Placebo Comparator|Placebo|Composition identical apart from the active substance. Same dosage.
11061302|NCT04348500|Active Comparator|Clazakizumab|25 mg in 50 cc NS given by IV infusion x 1 dose
11061303|NCT04348500|Placebo Comparator|Placebo|50 cc NS given by IV infusion x 1 dose
11061304|NCT04348487|Other|Standard procedure|For the conventional TIVAPS with cephalic vein approach, incision was made either in the midline of infraclivular or supraclavicular. Cathether was introduced to the central and then connected to the laterally implanted port in the deltopectoral region. The experience in the local center experienced several pitfalls with this method such as pneumothorax, pinch-off syndrome, compression of the catheter by the clavicle, kinking of the catheter, and loss of patencty.
11061305|NCT04348474|Experimental|HCQ + AZT|All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (00 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care.
11061306|NCT04348461|No Intervention|Control|Patients receiving regular respiratory distress treatment
11061307|NCT04348461|Experimental|Treatment|Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
11061308|NCT04348435|Experimental|Allogeneic HB-adMSCs 200MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
11061309|NCT04348435|Experimental|Allogeneic HB-adMSCs 100MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
11061310|NCT04348435|Experimental|Allogeneic HB-adMSCs 50MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
11061311|NCT04348435|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14.
11061312|NCT04348422||Symptomatic|COVID-19 RT-PCR positive patients with reported symptoms
11061313|NCT04348422||Asymptomatic|COVID-19 RT-PCR positive patients without presenting any symptoms
11061314|NCT04348409|Experimental|nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
11061315|NCT04348409|Placebo Comparator|Placebo|Patients will receive placebo BID for 7 days
11061319|NCT04348370|Experimental|BCG Group|FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area.
11061320|NCT04348370|Placebo Comparator|Placebo Group|A single dose will consist of 0.1 mL saline
11061321|NCT04348357|Active Comparator|Traditional Visit|Patients come to the office for a traditional postoperative visit
11061322|NCT04348357|Experimental|Tele-medicine|Patients receive postoperative care via telemedicine
11061323|NCT04348344|Experimental|intervention group|"health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise，strength training and breath training.
~Patients in stable stages using the home-based rehabilitation exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training."
11061324|NCT04348344|No Intervention|control group|health education of pulmonary rehabilitation
11061325|NCT04348305|Experimental|Hydrocortisone|"Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care.
~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours)."
11061326|NCT04348305|Placebo Comparator|Isotonic Saline|"Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment).
~If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours)."
11061327|NCT04348292|Experimental|Treatment (sirolimus, durvalumab)|Patients receive sirolimus PO QD on days 1-21 in the absence of disease progression or unacceptable toxicity. Starting on day 22, patients receive durvalumab IV over 1 hour. Treatment with durvalumab repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within a 2-3 week period after the second dose of durvalumab, but not earlier than two weeks after the administration of durvalumab, patients undergo standard of care surgery.
11061328|NCT04348279|Active Comparator|custom made acrylic stent|the donor sites of the participants were covered with custom made acrylic stent
11061329|NCT04348279|Experimental|propylene mesh|in the test group, the donor sites received propylene mesh.
11061330|NCT04348266|Experimental|RFA|The assigned location will be treated with RFA at all lesion.
11061331|NCT04348266|No Intervention|Control|No treatment will not be performed at this location. However, if endoscopist detects any suspicious lesion during the scheduled endoscopy, the biopsy will be done and standard treatment will be performed accordingly.
11061332|NCT04348253|Active Comparator|Berger|Bergers capsulodesis
11061333|NCT04348253|Active Comparator|3LT|Three ligament tenodesis
11061334|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
11061335|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
11061336|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
11061337|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
11061338|NCT04348227||Before pandemic is declared|Positive endotracheal aspirates addressed from January 1st 2019 to January 1st 2020
11061339|NCT04348227||After pandemic is declared|Positive endotracheal aspirates addressed from February1st 2020 to February 1st 2021
11061340|NCT04348201|Active Comparator|foot reflexology|foot reflexology session which takes about 20 minutes.
11061341|NCT04348201|Active Comparator|dietary modification|diet must be rich in vitamins.
11061342|NCT04348188|Experimental|Supervised exercise group|Supervised intervention group: 3 weekly sessions of 1 hour during 6 weeks of therapeutic exercise in which aerobic physical activity will be combined with exercise strength of different muscle groups plus stretches on a supervised basis and strengthening of self-care.
11061343|NCT04348188|Active Comparator|Not supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
11061344|NCT04348175|Experimental|Mild impairment|
11061345|NCT04348175|Experimental|Moderate impairment|
11061346|NCT04348175|Experimental|Severe impairment|
11061347|NCT04348175|Experimental|Normal (control)|
11061348|NCT04348162|Active Comparator|Cocoa Flavanols|Cocoa is taken every day for 10-12 weeks.
11061349|NCT04348162|Active Comparator|Berries anthocyanins|Red-berries are taken every day for 10-12 weeks.
11061350|NCT04348162|Active Comparator|Cocoa flavanols plus berries anthocyanins|Cooa and red-berries are taken every day for 10-12 weeks.
11061351|NCT04348162|No Intervention|Control|Normal diet for 10-12 weeks
11061352|NCT04348149|Experimental|Intervention group|
11061353|NCT04348149|No Intervention|Wait-list|
11061354|NCT04348136|Experimental|JR-141|
11061355|NCT04348123|Experimental|Outreach educational program|"Participants will be given a survey to elucidate beliefs and barriers around breast health and mammography.
~A brief, culturally-appropriate educational session about breast health and mammography will follow and will be delivered by a female public health educator.
~After education, eligible women will be offered a free on-site mammogram"
11061356|NCT04348110|Placebo Comparator|Placebo tablets|
11061357|NCT04348110|Experimental|Blueberry Chewable Tablets|
11061358|NCT04348097|Experimental|activator trigger point therapy|"The Activator adjusting instrument used had force settings ranging from 1 to 6
~. For this study a force setting of 3 was used."
11061359|NCT04348097|Active Comparator|Trigger point dry needling|First, a tight band was held between the index finger and the thumb of the non-dominant hand and the needle (0.25-40 mm - Shen Long) was perpendicularly inserted into the muscle with the dominant hand.
11061360|NCT04348084||who developed POPF|Patients undergone curative distal pancreatectomy for PDAC who developed POPF
11061361|NCT04348084||who did not develop POPF|Patients undergone curative distal pancreatectomy for PDAC who did not develop POPF
11061362|NCT04348071|Experimental|Ruxolitinib|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
11061363|NCT04348058|No Intervention|Control group|Invitation letter and reminder letter to screening colonoscopy
11061364|NCT04348058|Experimental|Call Center|Telephone recruitment by motivational conversation and colonoscopy appointment
11061365|NCT04348058|Experimental|Combined|Non responders to invitation and reminder letter will be recruited by telephone conversation
11061366|NCT04348045|Experimental|ARM A - olaparib|Olaparib tablets at 300 mg orally twice daily until PD (RECIST 1.1) or unacceptable toxicity.
11061367|NCT04348045|Experimental|ARM B - durvalumab plus selumetinib|"Durvalumab plus selumetinib until PD (RECIST 1.1 and/or iRECIST), unacceptable toxicity, withdrawal of consent, or death.
~Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle,
~Selumetinib administered as 75 mg twice daily dose for 21 days on and 7 days off (a 28-day cycle)."
11061368|NCT04348045|Active Comparator|ARM C - FOLFIRI|FOLFIRI FOLFIRI (irinotecan 180 mg/m2 IV on day 1, folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2 every 2 weeks) until PD (RECIST 1.1) unacceptable toxicity, withdrawal of consent, or death.
11061369|NCT04348032|Active Comparator|PLD|PLD 40 mg/m2 D1 ivgtt q4w
11061370|NCT04348032|Experimental|PLD + Apatinib|PLD 40 mg/m2 D1 ivgtt q4w + Apatinib 250mg po qd
11061371|NCT04348019|Experimental|Time restricted feeding|Participants in the intervention arm of the study will consume food and beverages of their choice within one hour of waking and the feeding window will extend 6 hours. Beyond these hours, participants will observe a prolonged fast (i.e., an 18-h overnight fast).
11061372|NCT04348019|Placebo Comparator|Control|Participants in the control arm of the study will fast each night for 8 hours.
11061373|NCT04348006|Experimental|Induction Therapy|Bortezomib will be administered as part of VCD or VRD protocols
11061374|NCT04347980|Experimental|Dexamethasone and Hydroxychloroquine (HCQ/DXM)|"Patients included in the HCQ / DXM group will benefit from standardized ventilatory management and administration of HCQ in the same manner as the HCQ group. They will receive in addition to DXM at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of DXM before."
11061375|NCT04347980|Active Comparator|Hydroxychloroquine (HCQ)|"Patients included in the HCQ  group will benefit from standardized ventilatory management. Patients included in the HCQ group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before."
11061376|NCT04347967|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
11061377|NCT04347954|Experimental|Povidone-Iodine 2%|"Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.
~Participants will complete a daily symptom journal from Day 1 through Day 5."
11061378|NCT04347954|Experimental|Povidone-Iodine 0.5%|"Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.
~Participants will complete a daily symptom journal from Day 1 through Day 5"
11061379|NCT04347954|Placebo Comparator|Isotonic saline 0.9%|"Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.
~Participants will complete a daily symptom journal from Day 1 through Day 5."
11061380|NCT04347941|Experimental|Prone Positioning|Intervention patients will remain up to 16 hours per day in Prone Positioning with 45 minutes breaks for meals
11061381|NCT04347941|Active Comparator|Standard Care|Control patients will receive full standard care. Prone Positioning as a rescue intervention is permitted and is recorded.
11061382|NCT04347915|Experimental|Clevudine|Clevudine 120mg (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
11061383|NCT04347915|Placebo Comparator|Placebo|Matching Placebo (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
11061384|NCT04347902|Experimental|PN with SMOFLipid|Parenteral nutrition with MCT/LCT/olive oil/fish oil (SMOFLipid, Fresenius Kabi, Germany, SMOF group)
11061385|NCT04347902|Active Comparator|PN with Olive oil|Parenteral nutrition with Olive oil/LCT 80:20 (ClinOleic, Baxter Healthcare, USA, OO group)
11061386|NCT04347902|Active Comparator|PN with MCT/LCT|Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)
11061387|NCT04347889|Experimental|Hydroxychloroquine|Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months
11061388|NCT04347889|Active Comparator|Vitamin C|Oral Vitamin C 1,000 mg daily for three months
11061389|NCT04347876||Group A|COVID-19 positive with positive tuberculin test
11061390|NCT04347876||Group B|COVID-19 positive with negative tuberculin test
11061391|NCT04347863|Experimental|Experimental group|Group swallowing disorder diet preparation program
11061392|NCT04347863|No Intervention|Control group|No Intervention
11061393|NCT04347850||Patient with Covid-19 confirmed (middle form)|Covid-19 confirmed: middle form
11061394|NCT04347850||Patient with Covid-19 confirmed (severe form)|Covid-19 confirmed : severe form
11061395|NCT04347850||Patient with Covid-19 not confirmed|Covid-19 not confirmed
11061396|NCT04347837|Experimental|Investigational device|The investigational device will be used for all participants
11061480|NCT04347265|Experimental|NMP in level 1|Participants in this group received NMP of the sciatic nerve in the gluteus region
11061397|NCT04347824||low risk|"This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2* or more of the following findings:
~urine osmolarity below normal values
~leukozyturia
~hematuria
~albuminuria/ proteinuria * if urine is positive for nitrite or bacteria, abnormal urine status is defined as 3 or more of the findings."
11061398|NCT04347824||intermediate risk|This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.
11061399|NCT04347824||high risk|This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.
11061400|NCT04347811|Experimental|Death Cafe Arm|Participants undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
11061401|NCT04347811|No Intervention|Control Arm|Participants do not undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
11061402|NCT04347798||Inflammatory arthritis patients on biologic + anti-malarial|Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
11061403|NCT04347798||Inflammatory arthritis patients on biologic + NO anti-malarial|Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
11061404|NCT04347785||Neurologic deficit|All consecutive patients from a tertiary referral center who underwent CEA for carotid artery stenosis who presented alterations in the neurologic examination after ICA clamping during CEA area selected
11061405|NCT04347785||control|The control patients are submitted to the same procedure but with no neurologic alterations, are consecutively selected. a 1 to 1 ratio is used
11061406|NCT04347772|Experimental|Supplements Group - SS|"The SS will be received tailored and more intensive and ongoing nutrition support and lifestyle advice as compared with the NN and will be supplemented with ONS, available in 400g/can, providing 226 kcal/serving and 9.6 g protein/serving. Participants will be encouraged to consume the ONS in small, frequent, in between meals.
~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
11061407|NCT04347772|No Intervention|Control Group - NN|"While participants in NN which referred as control group will received the standard care of the clinic without supplemented with ONS. Nutritional advice will be based on a guideline specifically focused on treatment of symptoms such as nausea, vomiting, loss of appetite and diarrhoea, and how to deal with the symptoms through nutritional approaches. Basically, the advice will be given by the oncologist or nurses in the clinic.
~All participants will receive standard post-operative care from clinical and nurse staff with commencement of free fluids and reintroduction of normal diet without interference by the researcher or protocol. The postoperative course will be carefully monitored. While complications will be noted as major or minor by using validated criteria (Buzby et al., 1988)."
11061408|NCT04347759|Other|System with coaching messages|A telephone-computer interface IVR system to report symtopms and to receive coaching messages based on symptom severity.
11061409|NCT04347746|Active Comparator|Clinical group|Individuals with bilateral idiopathic CTS with clinical criteria and mild to moderate ENMG severity and symptom evolution time above six months.
11061410|NCT04347746|Active Comparator|Surgical group|Individuals with bilateral idiopathic CTS with clinical criteria and severe ENMG in at least one hand and symptom evolution time above six months. These will be submitted to surgery on the severe hand and if equal severity on both hands, the dominant hand will be operated, with the patient's consent.
11061411|NCT04347733|Experimental|Group A|Intra-articular injection, 20 mg (0.5 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.5 mL of normal saline
11061412|NCT04347733|Experimental|Group B|40 mg (1 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.0 mL of normal saline
11061413|NCT04347733|Active Comparator|Group C|20 mg (0.5 mL) of triamcinolone acetonide and 1 mL of hyaluronidase mixed with 2 mL of 2% lidocaine and 6.5 mL of normal saline
11061414|NCT04347720||Indomethacin Arm|Intravenous indomethacin at 0.1-0.3 mg/kg IV every 12-24h for a total of 3 doses as choice of initial pharmacotherapy.
11061415|NCT04347720||Standard dose ibuprofen Arm|Standard dose ibuprofen [Oral/intravenous] at 10 mg/kg followed by 2 doses of 5mg/kg at 24 h intervals irrespective of postnatal age as choice of initial pharmacotherapy.
11061416|NCT04347720||Adjustable dose ibuprofen Arm|Adjustable dose ibuprofen [Oral/intravenous] as choice of initial pharmacotherapy. The dose of ibuprofen will be 10 mg/kg followed by 2 doses of 5 mg/kg at 24 h intervals if treated within the first 7 days after birth. Higher doses of ibuprofen up to 20 mg/kg followed by 2 doses of 10 mg/kg at 24 h intervals if treated after the postnatal age cut-off for lower dose as per the local center policy
11061417|NCT04347720||Acetaminophen Arm|Acetaminophen [Oral/intravenous] at 15mg/kg every 6h for 3-7 days as choice of initial pharmacotherapy.
11061418|NCT04347720||Control group|Infants <29 weeks GA with echocardiography-confirmed PDA but never received any pharmacotherapy
11061419|NCT04347720||Reference group|Infants <29 weeks GA who were never diagnosed with PDA
11061420|NCT04347707|Experimental|BRIDGE Clinical Group|This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
11061421|NCT04347707|No Intervention|Baseline Comparison Group|This group of mother-child dyads will not meet diagnostic criteria for depression and will serve as a comparison group for baseline measures. Dyads will be matched to the BRIDGE clinical group based on household income and child age.
11061422|NCT04347681|Experimental|Treatment Group|We are aiming to include 40 patients (recipients) who have COVID 19 but have not recovered yet as per the inclusion criteria.
11061423|NCT04347681|No Intervention|control group|Patients who only consent for sharing their clinical and laboratory data will serve as a control group to compare the efficacy of the convulsant plasma. Age and sex matched historical control could be used if need.
11061683|NCT04345900|Active Comparator|6 mg Pegfilgrastim|Docetaxel + 6 mg Pegfilgrastim
11061424|NCT04347668|Active Comparator|Usual Care|All residents are seen by a RN, with care by Registered Practical Nurse (RPN) and Personal Support Worker (PSW) staff 24/7. Residents supported by behavior support Ontario staff; include Behavior responsive team. Residents prior to admission have been assessed by the Geriatric program. Residents may receive psychotropic or cognitive enhancement medications. The residents are seen routinely seen once a week by the physician. Their Dementia is monitored weekly but the physician as well as daily by the registered staff. Quarterly or more frequently cognitive assessments are completed and referrals made to appropriate specialists. A day would include meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
11061425|NCT04347668|Experimental|Virtual Reality|"Virtual Reality (VR) is a scenario that simulates experiences. The immersive environment is similar to the real world, creating an experience. A person using virtual reality equipment is able to look around the artificial world, move around in it, and interact with virtual features or items. VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds that simulate a user's physical presence in a virtual or imaginary environment. A library has been developed, set to music, as well, we will use library items already part of the BroomX. We will attempt to use BroomX in their own room or in a suitable room within the LTC home. The participants still get the immersive experience, and the projection device has automatic controls that conform the visuals to a 360 experience no matter what size the room is, or what chairs, window blinds, are in the room."
11061426|NCT04347655|Experimental|HFrEF|patients with heart failure with reduced ejection fraction
11061427|NCT04347655|Experimental|HFpEF|heart failure with preserved ejection fraction
11061428|NCT04347655|Active Comparator|Control|healthy (no heart failure) control participants
11061429|NCT04347642|Active Comparator|Umbilical port|A Hasson port will be inserted at the level of the umbilicus,in the midline, traversing only aponeurotic layers.
11061430|NCT04347642|Experimental|Paraumbilical port|A bladeless 12mm port will be inserted lateral to the midline, traversing aponeurotic layers and rectus abdominis muscle.
11061431|NCT04347629|No Intervention|Usual Care|Usual clinical care
11061432|NCT04347629|Experimental|Video Decision Aid|The video intervention consists of a video decision aid along with a video declaration (ViDec), which is recorded by the patient. The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
11061433|NCT04347616|Experimental|NK cells without IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. NK cells administration will not be followed by sc IL-2. N=3.
11061434|NCT04347616|Active Comparator|NK cells with low dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 3.0 x 10^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total. N=3
11061435|NCT04347616|Active Comparator|NK cells with higher dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 6.0 x 10^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total.
11061436|NCT04347603|Experimental|General Anesthesia|- General anesthesia : After pre-anesthetic preparation (25-50 mg Hydroxizine orally), the anesthesia induction will be performed by IV perfusion of Propofol 1 to 2 mg/kg, Sufentanyl for analgesia 0,2 to 0,4 µg/kg, curarisation with Atracurium 0,15 mg/kg. The anaethesia depth will be monitored by the bispectral index (BIS). Orotracheal intubation will be performed, the patient will be ventilated to controlled volume with 6-8 mL/kg of current volume based on expected body weight (PBW). The respiratory rate will be adjusted to have an ETCO2 between 35 and 45 mmHg. The anesthesia will be maintained through the Sevorane at 0.7-1 MAC, the average blood pressure will be controlled through a pressure cuff with a target between 60 and 80 mmHg. The Fio2 will be adapted to obtain saturation > 94% with 5 cmH2O PEEP.
11061437|NCT04347603|Active Comparator|Local Anesthesia|Local anesthesia at the device introduction site will be obtained by infiltration of Naropein.
11061438|NCT04347590|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
11061439|NCT04347590|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to at least 2 capillary glycemic tests per day.
11061440|NCT04347551|Experimental|Eye movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
11061441|NCT04347551|Active Comparator|Head movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
11061442|NCT04347538|No Intervention|Control Group, No intervention|control group, no nasal irrigation
11061443|NCT04347538|Experimental|Saline Nasal Irrigation|Nasal irrigation BID with normal saline
11061444|NCT04347538|Experimental|Saline with Baby Shampoo Nasal Irrigation|Nasal irrigation BID with normal saline and 1/2 teaspoon baby shampoo
11061445|NCT04347525|Experimental|Intervention|This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
11061446|NCT04347525|No Intervention|Control|This group will receive treatment as usual
11061447|NCT04347512|Experimental|Hydroxychloroquine|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).
~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc)"
11061448|NCT04347512|Active Comparator|Control|The patient is given antibiotics only. Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc).
11061684|NCT04345887|Active Comparator|Spironolactone|2 x 100 mg spironolactone
11061449|NCT04347512|Experimental|Hydroxychloroquine and Azithromycin|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).
~Azithromycin is given for 5 days, with a loading dose of 500 mg at D1, and 250 mg for the next 4 days.
~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc) In case of moderate renal failure (glomerular filtration rate between 30 and 60 mL/min/m²), hydroxychloroquine dosage are lowered by half."
11061450|NCT04347499|Experimental|Intervention|This group will receive CaCBT based guided selfhelp using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
11061451|NCT04347499|No Intervention|Control|This group will receive treatment as usual
11061452|NCT04347486|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
11061453|NCT04347486|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
11061454|NCT04347486|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex on reappearance of T2 by Train-of-Four stimulation
11061455|NCT04347486|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) on reappearance of T2 by Train-of-Four stimulation
11061456|NCT04347473|Experimental|Ilumya|Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
11061457|NCT04347460||COVID 19|Patients requiring ICU treatment due to severe COVID 19 interstitial pneumonia or otherwise COVID-19 related disease
11061458|NCT04347447|Experimental|normal protein diet|The normal protein diet (Control) will contain the RDA for protein of (0.8 g/kg/d), with the protein provided from a variety of animal and plant-based sources, including lean beef (one 3-oz portion per week), chicken, eggs, dairy, beans, grains, nuts, seeds.
11061459|NCT04347447|Experimental|a beef protein-rich diet|High protein diet predominantly provided from lean beef (one 3-oz portion per day; total beef intake 24 oz/week). The energy content of the additional protein foods will be isocalorically offset by substitution for low-protein foods.
11061460|NCT04347447|Experimental|a protein-rich diet non-red meat|High-protein group from a variety of animal and plant-based sources (excluding additional red meats).
11061461|NCT04347434|Experimental|Atorvastatin 80 mg|"Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.
~If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day."
11061462|NCT04347421|Experimental|Krill oil group|This group takes Krill oil for 12 weeks
11061463|NCT04347421|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
11061464|NCT04347408||Healthy Children|Healthy children of healthcare workers between 2 and 15 years of age
11061465|NCT04347395|No Intervention|Group 1: Control Group|Current best practice for prevention of HAP
11061466|NCT04347395|Experimental|Group 2: Intervention|Respiratory Bundle Intervention
11061467|NCT04347382|Experimental|Nigella Sativa & Honey Group|"Drug: Nigella Sativa seed Powder 80 mg/Kg/day grinded in capsule upto a max of 14 days) Drug: Natural Honey 1gm/kg/day orally upto a max of 14 days)
~along with standard medical care"
11061468|NCT04347382|Placebo Comparator|Standard Medical Care|Standard supportive medical care prescribed by treating physician, Lahore which includes standard symptomatic care along with use of antibacterial or antiviral (if advised by pulmonologist or infectious disease specialist)
11061469|NCT04347369||Observed group|The patients who were detected COVID-19 disease by RT-PCR and CT imaging.
11061470|NCT04347343|Experimental|COMBO|Neuromuscular Electrical Stimulation and Blood Flow Restriction (COMBO) in addition to standard postoperative rehabilitation.
11061471|NCT04347330|Experimental|Intensive BP Control|Participants randomized into the Intensive BP Control arm will have a goal of home SBP <120mmHg. For most participants in the Intensive Group, a two- or three-drug regimen should be initiated at randomization. Following the randomization visit, addition of another drug or medication dose titration is indicated if home SBP is ≥120 mmHg. Monthly visits will continue in the Intensive Group until home SBP <120 mmHg or no more titration planned. If the home SBP is not <120 mmHg at the every 6-month visit, then an antihypertensive drug from a class different from what is being taken should be added, rather than up-titration the dosage of previous drugs, unless there are compelling reasons against this practice.
11061472|NCT04347330|Active Comparator|Standard BP Control|Participants randomized into the Standard BP Control arm will have a goal of home SBP <135mmHg. The Standard BP protocol is designed to achieve a home SBP of 130-134 mmHg in as many participants as possible. Following the randomization visit, medication dose titration or addition of another drug is indicated if home SBP ≥135 mmHg. Monthly visits will continue in the Standard Group when home SBP ≥155 mmHg. Down titration (a reduction of the dose or number of antihypertensive drugs) should be carried out if the home SBP is <125 mmHg.
11061473|NCT04347317|Active Comparator|Low Intensity IMT|
11061474|NCT04347317|Experimental|High Intensity IMT|
11061475|NCT04347304|Experimental|cocoa polyphenols|21 grams of dark chocolate (289 mg polyphenols)
11061476|NCT04347304|Placebo Comparator|polyphenols free|21 grams of white chocolate (0 mg polyphenols)
11061477|NCT04347291|Experimental|FAMS 2.0|"Patient participants will receive FAMS 2.0 components (monthly phone coaching and text message support for goals and medication adherence) for nine months. Linked support persons will receive text message support tailored to the goal set by the patient participant.
~All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes."
11061478|NCT04347291|Placebo Comparator|Print Materials|All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes.
11061479|NCT04347278||Patients receiving treatment for COVID19|
11061685|NCT04345887|Placebo Comparator|Placebo|2 x 1 placebo
11061481|NCT04347265|Experimental|NMP in level 2|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
11061482|NCT04347265|Experimental|NMP in level 3|Participants in this group received NMP of the sciatic nerve before popliteus region
11061483|NCT04347252|Experimental|Glucagon at basal glycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 210 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 90 minutes.
11061484|NCT04347252|Experimental|Glucagon at hyperglycemia|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study. At time 210 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 90 minutes.
11061485|NCT04347252|Experimental|Glucagon at hyperglycemia with GLP-1R blockade|Subjects will present after an overnight fast and at time 0 an infusion of deuterated glucose will be started and continued for the remainder of the 5 hour study (4 mg/kg bolus followed by 0.04 mg/kg/min infusion). Blood will be sampled at 10 minute intervals throughout the study for measurement of substrates and hormones. At time 120 an infusion of 20% glucose, labeled to 2% with deuterated glucose, will be started and adjusted to raise the blood glucose to 8.3 mM for the remainder of the study; concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes. At time 210 an intravenous infusion of glucagon (10-100 ng.kg.min) will be started and continued for 90 minutes.
11061486|NCT04347239|Placebo Comparator|Placebo|
11061487|NCT04347239|Experimental|700mg Leronlimab|
11061488|NCT04347226|Experimental|BMS-986253|BMS-986253 2400mg IV
11061489|NCT04347226|No Intervention|Standard of Care treatment|Usual treatment of COVID-19 per study physician discretion
11061490|NCT04347213||omnivors|Participants who habitually consume all food groups in their diet.
11061491|NCT04347213||vegetarian|Participants who habitually avoid meat in their diet.
11061492|NCT04347213||vegan|Participants who habitually avoid all animal source food in their diet.
11061493|NCT04347213||low-carbohydrate high-fat diet|Participants who habitually avoid carbohydrate in their diet.
11061494|NCT04347174|Experimental|Suspension of Mw + Standard therapy of COVID-19|"0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days
~+ Standard therapy of COVID-19"
11061495|NCT04347174|Active Comparator|Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of water for injection intra-dermal for 3 consecutive days
11061496|NCT04347161|Experimental|Intervention Arm|Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
11061497|NCT04347161|Active Comparator|Control Arm|Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
11061498|NCT04347148|Experimental|SNAGs treatment|cervicogenic patients will undergo SNAGs treatment. Based on personal history, the offending active cervical movement (i.e. the movement predominantly causing dizziness) will be identified and treatment direction will be determined. As suggested, the active movement to most likely cause dizziness is cervical extension, though also rotation or flexion will be shown to provoke it. With the participant in an upright sitting position, a skilled physiotherapist (blinded to the allocation) will apply a sustained passive accessory movement (glide) while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing their symptoms. This procedure will be repeated six times.
11061499|NCT04347148|Placebo Comparator|Detuned Laser|cervicogenic patients will receive a sham treatment, carried out by the another skilled therapist (blinded to the allocation) and consisting in exposition to a detuned laser. A laser - deactivated by the manufacturer in order to produce no effective emission - will appear to operate normally, emitting a light signal and a beeping sound. Such procedure - which was shown to not activate somatosensory receptors and to have a very strong placebo effect - will be used for six applications, lasting 20 seconds, on various sites on the upper cervical spine, at a distance of 0.5-1cm from the skin.
11061500|NCT04347135|Experimental|F-18 FES PET/MRI|16α-(18)F-fluoro-17β-estradiol ([F-18] FES)
11061501|NCT04347122|Active Comparator|Bony tumor treated with Tranexamic acid (TXA)|This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
11061502|NCT04347122|No Intervention|Bony tumor treated without TXA|This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
11061503|NCT04347122|Active Comparator|Soft tissue sarcoma treated with Tranexamic Acid (TXA)|This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA
11061504|NCT04347122|No Intervention|Soft tissue sarcoma treated without TXA|This group of participants will undergo soft tissue sarcoma resection of the lower extremity.
11061505|NCT04347109||Biventricular Pacing|Patients implanted with a device enabling cardiac resynchronization therapy.
11061506|NCT04347109||Right Ventricular Pacing|Patients implanted with a right ventricular pacing device.
11061507|NCT04347096|Experimental|mHealth Intervention|The mHealth intervention group will have access to the Internet for using a newly developed Simple health web app and receive an activity tracker. The web app users are required to: (1) wear an activity tracker every day; (2) set goals of daily stand-up, physical activity, and healthy eating bi-weekly; (3) record stand-up, physical activity, and healthy eating behaviors daily; (4) set reminders to stand-up and record health behaviors; and (5) read educational and motivational tools. After completing the behavioral record, the personal advice will automatically provide to encourage, motivate and support the user. Moreover, the user will be able to look at his/her personal and team health ranking.
11061508|NCT04347096|Other|Control Intervention|The control intervention group will only receive educational tools (usual care).
11061509|NCT04347083|Experimental|Experiment|Reflex latency will be measured in this arm
11061510|NCT04347070||Patients accepted in ICU diagnosed with COVID-19|Patients accepted in ICU diagnosed with COVID-19
11061511|NCT04347057|Experimental|Arm 1|"Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period.
~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
11061512|NCT04347057|Experimental|Arm 2|"Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period.
~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
11061513|NCT04347044|Experimental|Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up plus Pulmonary rehabiltation
11061514|NCT04347044|Active Comparator|Non-Pulmonary Rehabilitation Group|Optimal medication and clinical follow-up
11061515|NCT04347031|Experimental|group 1 cohort 1|"80 patients who receive Mefloquine prescribed according to the following scheme:
~1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.
~Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.
~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
11061516|NCT04347031|Experimental|group 1 cohort 2|"80 patients who receive Hydroxychloroquine prescribed according to the following scheme:
~• 1st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day; 2nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
11061517|NCT04347031|Experimental|group 2 cohort 1|A concomitant therapy consisting of Mefloquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Mefloquine is same as for group 1 cohort 1.
11061518|NCT04347031|Experimental|group 2 cohort 2|A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients. Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
11061519|NCT04347018|Experimental|BRIUS|BRIUS orthodontic appliance (wire) will be used to treat the patients. BRIUS appliance will be engaged to regular orthodontic brackets intra-orally to initiate orthodontic treatment at the University at Buffalo Orthodontic Clinic.
11061520|NCT04347018|Active Comparator|Preadjusted edgewise full fixed appliance|regular full fixed orthodontic appliance (FFA) appliances will be used to treat patients. These are regular orthodontic brackets with standard orthodontic wires used to treat patients at the University at Buffalo Department of Orthodontics
11061521|NCT04347005|Experimental|AR882 (Dose A)|
11061522|NCT04347005|Experimental|AR882 (Dose B)|
11061523|NCT04347005|Experimental|AR882 (Dose C)|
11061524|NCT04347005|Experimental|AR882 (Dose D)|
11061525|NCT04347005|Experimental|AR882 (Dose E)|
11061526|NCT04347005|Experimental|AR882 (Dose B) Solid Oral Formulation|
11061527|NCT04347005|Placebo Comparator|Placebo|
11061528|NCT04347005|Active Comparator|Allopurinol|
11061529|NCT04347005|Active Comparator|Febuxostat|
11061530|NCT04346979|Experimental|Study Group|Telerehabilitation based yoga and mindfulness training will be given to the study group.
11061531|NCT04346979|Experimental|Control Group|Yoga and mindfulness training will be provided by sending a video recording to the control group.
11061532|NCT04346966|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
11061533|NCT04346966|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
11061534|NCT04346953|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
11061535|NCT04346953|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
11061536|NCT04346940|Experimental|Study Group|The group to which the exercise protocol consisting of chair-based exercises will be applied.
11061537|NCT04346940|Active Comparator|Control Group|Group to be given an exercise brochure
11061538|NCT04346927|Experimental|Study Group|The group to which the exercise protocol consisting of breathing exercises, posture exercises, peripheral muscle training and light aerobic exercises will be applied.
11061539|NCT04346927|Active Comparator|Control Group|group to be given an exercise brochure
11061540|NCT04346914|Experimental|Combined treatment group|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w
11061541|NCT04346901|Other|Single Intervention|Before-and-After type of research
11061542|NCT04346888|Experimental|HBM9161 (680mg and 340 mg)|Subcutaneous injection; Blinded: HBM9161 680mg; Open-label: HBM9161 340mg;
11061543|NCT04346888|Experimental|HBM9161 (340 mg)|Subcutaneous injection; Blinded: HBM9161 340mg; Open-label: HBM9161 340mg;
11061544|NCT04346888|Placebo Comparator|Placebo, HBM9161 (340 mg)|Subcutaneous injection; Blinded: Placebo; Open-label: HBM9161 340mg;
11061545|NCT04346875|Experimental|Regularly changing group|Participants will undergo dressing every 3 days by the senior wound care nurse
11061546|NCT04346875|Active Comparator|Non-changing group|Participants will not be subject to dressing change.
11061547|NCT04346862|Experimental|Acetyl-L-carnitine hydrochloride|
11061548|NCT04346862|Placebo Comparator|Placebo|
11061549|NCT04346849|Experimental|MTA pulpotomy|Teeth receiving pulpotomy using MTA
11061550|NCT04346849|Experimental|Biodentine pulpotomy|Teeth receiving pulpotomy using Biodentine
11061551|NCT04346849|Experimental|Bioceramic pulpotomy|Teeth receiving pulpotomy using Bioceramic
11061552|NCT04346836|Experimental|Metabolic Syndrome|"Elderly women with Metabolic Syndrome
~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
11061553|NCT04346836|Experimental|Non-Metabolic Syndrome|"Elderly women without Metabolic Syndrome.
~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
11061609|NCT04346459|Active Comparator|Group C- Protector|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using the Protector laryngeal mask airway as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
11077163|NCT04235959|Placebo Comparator|Placebo|Placebo administered SC.
11061554|NCT04346823|Experimental|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3 minutes. Then, parturients breath 1% of sevoflurane in mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min. Values of inspired (FI) and end-tidal (FET) concentrations of sevoflurane, oxygen and respiratory rate (RR) measured by end-tidal carbon dioxide (EtC02) were monitored continuously and recorded at 30 seconds intervals by a gas analyzer.
~30 seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure. HR, FI and FET concentration of sevoflurane, Sp02 and EtC02 will be recorded at 30-s interval during ECV. Non-invasive BP will be recorded every one minute. Duration of ECV in addition to level of difficulty estimated by obstetrician will be recorded.
~ECV considered successful when a cephalic presentation, confirmed by ultrasound scan, achieved."
11061555|NCT04346823|No Intervention|No sevoflurane|If the parturient is assigned to the control (nonintervention) group, the participants will not receive any medications neither tocolytics nor analgesics as the routine care in our hospital. However, the participants will be monitored throughout the procedure for vital signs and for pain scores as in the intervention group.
11061556|NCT04346810||Recovery room caregivers|Caregivers working at a recovery room shifted into an intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
11061557|NCT04346810||Intensive care unit caregivers|Caregivers working at a conventional intensive care unit for the management of patients suffering from coronavirus infection and needing a resuscitation
11061558|NCT04346797|Experimental|Eculizumab|Eculizumab
11061559|NCT04346797|No Intervention|Standard of Care|Best standard of care
11061560|NCT04346784|Experimental|maintaining positive working memory training|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
11061561|NCT04346784|Experimental|repressing negative working memory training|Repressing negative working memory training is a dual n-back task containing visual and auditory stimulus.Both two types of stimulus are negative.In this training, subjects are required to identify whether the location of picture presented on the screen or the word appeared in the headphone is the same as the picture or the word presented n before, then react with typing correspondingly.Each training session contains 16 blocks which are consisted with 20+n trails.
11061562|NCT04346784|Experimental|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
11061563|NCT04346784|Placebo Comparator|Positive placebo ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
11061564|NCT04346771|Experimental|Maintaining Positive Working memory|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
11061565|NCT04346771|Placebo Comparator|Positive Attention Bias Modification|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
11061566|NCT04346758|Other|Modified Shamrock approach|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
11061567|NCT04346745|Experimental|Treatment group|The treatment group will receive intervention of a peer mentoring program plus usual services they could receive from community agencies.
11061568|NCT04346745|No Intervention|Control group|The control group will receive usual services they could receive from community agencies.
11061569|NCT04346732|Experimental|Vapocoolant spray|Vapocoolant spray was applied to the donors in the vapocoolant spray group.
11061570|NCT04346732|No Intervention|Control|The donors in the control group were not given any intervention during the blood collection process.
11061571|NCT04346719|Experimental|10 kHz stimulation|"Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11061572|NCT04346719|Experimental|20 kHz stimulation|"Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11061573|NCT04346719|Sham Comparator|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
11061574|NCT04346706|Experimental|Immediate implantation|Tooth extraction, immediate insertion of an implant with immediate temporization
11061575|NCT04346706|Experimental|Delayed implantation|Implant inserted in a healed socket with immediate temporization
11061576|NCT04346693|Active Comparator|group 1|80 patients with moderate and critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). Standard therapy is prescribed recommended by the Ministry of Health of the Russian Federation.
11077297|NCT04234958|Sham Comparator|Sham|Participants received sham therapy
11061577|NCT04346693|Experimental|group 2|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome (ADRS). A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days).
11061578|NCT04346693|Experimental|group 3|80 patients with moderate to critical severity of the COVID19 with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional inhalation of the drug Dalargin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
11061579|NCT04346693|Experimental|group 4|80 patients with moderate to critical severity of the disease with respiratory symptoms without Acute Respiratory Distress Syndrome. A standard concomitant therapy will be given recommended by the Ministry of Health of the Russian Federation, with the additional intramuscular administration of the drug Dalargin (solution for intravenous and intramuscular doses of 1 mg once a day for 10 days) in conjunction with inhalation of the drug Dalargin, at a dose of 10 mg daily once a day until the symptoms of pulmonary complications will be ceased.
11061580|NCT04346680|Experimental|Experimental group|
11061581|NCT04346667|Active Comparator|Arm 1|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
11061582|NCT04346667|Experimental|Arm 2|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
11061583|NCT04346667|Active Comparator|Arm 3|Chloroquine 500 mg BID for 5 days plus standard of care
11061584|NCT04346667|Placebo Comparator|Arm 4|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
11061585|NCT04346654|Experimental|Eltrombopag + Dexamethasone|Patients will be treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg QD from day 1-4) to induce sustained response off treatment.
11061586|NCT04346654|Active Comparator|Dexamethasone|Patients will be treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 every 28 days) to induce sustained response off treatment
11061587|NCT04346628|Experimental|Favipiravir|In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.
11061588|NCT04346628|Active Comparator|Placebo|In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.
11061589|NCT04346615|Experimental|Zavegepant|Zavegepant (BHV-3500) 10 mg intranasal (IN) Q8h for 14 days
11061590|NCT04346615|Placebo Comparator|Placebo|Placebo Q8h for 14 days
11061591|NCT04346602||patients with COVID-2019|Patients with COVID-2019 would be observed.
11061592|NCT04346589|Experimental|Antibodies (immunoglobulins) infusion|Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
11061593|NCT04346576|Experimental|Probiotics (LcS per 65 mL) prevent health problems in children|Probiotic test product was fermented milk containing 6.5 billion of LcS per 65 mL (108 CFU/mL), manufactured by Yakult Vietnam, Co., Ltd. The nutritional composition of the test product is 0.8 g of protein, <0.1 g of fat, 12.4 g of carbohydrates, and the total energy is 52.7 kcal per bottle. Subjects were asked to drink one bottle of the test product per day after lunch for 12 weeks on consecutive days. The test products were stored in a refrigerator (< 10°C), protected from direct sunlight, and used before their expiration date. Adherence to the intervention protocol was confirmed as follows; teachers at kindergartens or parents at home provided the probiotic drinks (1 bottle/day x 7 days/week) after lunch.
11061594|NCT04346563|Experimental|Kinesio tape, functional correction applying|The experimental group, trained by Certified Kinesio tape researcher will attache the kinesio tape. Attaching the kinesio tape by using functional correction techniques, apply tape from the front of the acromion process to the spinous process T10 on both sides, providing 50% of the tape's tension (Kase, 2003, Han JT et al) to create a scapular retraction.
11061595|NCT04346563|Placebo Comparator|Placebo Kinesio taping apply|Apply kinesio tape without tension.
11061596|NCT04346550|Active Comparator|Drain Group|Suction drain was placed in sub hepatic region through 5 mm lateral trocar site.
11061597|NCT04346550|No Intervention|Without Drain Group|No drain was placed
11061598|NCT04346524||microbiome sampling|pregnant women with type 1 diabetes
11061599|NCT04346511|Experimental|Acupuncture|In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.
11061600|NCT04346511|Sham Comparator|Sham Acupuncture|Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site.
11061601|NCT04346498|Experimental|CB-SSC|The participant received CB-SSC for 2 hours per day for three consecutive days
11061602|NCT04346498|Placebo Comparator|CC-SSC|Following a 30 minute washout time, the same participant would continue to receive chest-to-chest (CC) SSC for 2 hours. This was also conducted for three consecutive days
11061603|NCT04346485|Experimental|SP TFL RIRS with 145 mcm fiber|Superpulse thulium fiber laser RIRS with 145 mcm laser fiber
11061604|NCT04346485|Experimental|SP TFL RIRS with 200 mcm fiber|Superpulse thulium fiber laser RIRS with 200 mcm laser fiber
11061605|NCT04346485|Active Comparator|Ho:YAG RIRS with 200 mcm fiber|Ho:YAG laser RIRS with 200 mcm laser fiber
11061606|NCT04346472||Gliomes de grade II initial|Gliomes de grade II initial
11061607|NCT04346459|Active Comparator|Group A- Fastrach (control group)|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using intubating laryngeal mask airway Fastrach following blind intubating method through Fastrach"
11061608|NCT04346459|Active Comparator|Group B- I-gel|"Group of 40 patients scheduled for elective surgery under general anesthesia are planned to be intubated using I-gel supraglottic airway device as a conduit for tracheal intubation guided by a fiberoptic bronchoscope."
11061681|NCT04345900|Experimental|10 mg/m^2 Plinabulin|Docetaxel + 10 mg/m^2 Plinabulin
11061610|NCT04346446|Experimental|Convalescent Plasma+Supportive Care|Convalescent Plasma+Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients
11061611|NCT04346446|Active Comparator|Random Donor Plasma+Supportive Care|Random Donor Plasma+Supportive Care
11061612|NCT04346433|Experimental|Adolescents with Normal Weight|This group will be comprised of 30 adolescents with normal weight (BMI equal to or greater than the 5th percentile but less than the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
11061613|NCT04346433|Experimental|Adolescents with Overweight or Obesity|This group will be comprised of 30 adolescents with overweight or obesity (BMI equal to or above the 85th percentile). Participants will be asked to engage in the sleep manipulation intervention.
11061614|NCT04346420|Experimental|O2 DTM+|The standard nasal cannula interface is accompanied with the DTM
11061615|NCT04346420|Active Comparator|O2 DTM-|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient, without the DTM
11061616|NCT04346407|Experimental|Dronabinol|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
11061617|NCT04346407|Placebo Comparator|Placebo|Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery
11061618|NCT04346394|Experimental|Yohimbine|The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.
11061619|NCT04346381|Experimental|camrelizumab combined with famitinib|Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.
11061620|NCT04346368|Experimental|Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)|Conventional treatment plus BM-MSCs
11061621|NCT04346368|Placebo Comparator|Placebo|Conventional treatment plus placebo
11061622|NCT04346355|Experimental|Experimental Arm|Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
11061623|NCT04346355|Other|Control Arm|Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
11061624|NCT04346342||Mechanical ventilation|COVID patients receiving invasive mechanical ventilation
11061625|NCT04346329|Placebo Comparator|Control|Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
11061626|NCT04346329|Experimental|treated|hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
11061627|NCT04346316|Active Comparator|SHR0302 Dose#1|
11061628|NCT04346316|Active Comparator|SHR0302 Dose#2|
11061629|NCT04346316|Active Comparator|SHR0302 Dose#3|
11061630|NCT04346316|Placebo Comparator|Placebo|
11061631|NCT04346303|Other|Short-term Interactive Video Games|Short-term video games will be applied to patients with mental illness who are staying in communities. Games will be applied in a group-activity format with 8 to 12 patients in each session. The interventions will be conducted at a two sessions per week for a 3-week long period. There are 3 time points for data collection, including 2-weeks before the intervention, the week before the intervention, and the week after the intervention. Each patient will be his/her own controlled comparison.
11061632|NCT04346290|No Intervention|Control|Standard anesthesia care for kidney donor
11061633|NCT04346290|Experimental|Dexmedetomidine|Standard anesthesia care and perioperative infusion of dexmedetomidine for kidney donor
11061634|NCT04346264||General Cohort|Population general cohort from the Austrian LEAD Study
11061635|NCT04346238||Patients with Friedriech Ataxia genetically confirmed|Patients with Friedriech Ataxia genetically confirmed
11061636|NCT04346225|Experimental|Cohort A: Hyperpolarized C13 MRI at a single time point|Participants will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at a single time point and will receive up to two 13C pyruvate (C-1 and C-2 labeled 13C pyruvate) investigational medicinal product (IMP) injections on the day of imaging (2nd injection is optional), as well as optional MR- or CT- guided tumor biopsies at baseline and at the time of disease progression following completion of HP C-13 MRI at the corresponding time point
11061637|NCT04346225|Experimental|Cohort B: Hyperpolarized C13 MRI at multiple time points|Participants will undergo hyperpolarized (HP) C13 MRI at baseline and 8 weeks (+/- 4 weeks) following initiation of a new line of systemic therapy for the treatment of advanced prostate cancer. Participants in Cohort B may undergo additional optional MR imaging at the time of disease progression. the same sequence of injections (C-1 labeled pyruvate first, C-2 labeled pyruvate second) will be used for subsequent scan time points as wel
11061638|NCT04346212||Patients infected by SARS-CoV-2|Patients infected by SARS-CoV-2 at the Hospital de Mataró, Hospital de St. Jaume i Sta. Magdalena and other medicalized facilities in Mataró.
11061639|NCT04346199|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
11061640|NCT04346199|No Intervention|Arm 2|Best Supportive Care
11061641|NCT04346186||Hospital Staff in the Capital Region of Denmark|
11061642|NCT04346186||Healthy volunteer blood donors|
11061643|NCT04346173|Experimental|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
11061644|NCT04346160||Patients with bilateral conjunctivitis|Hospitalized patient affected by COVID-19 disease with bilateral conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
11061645|NCT04346160||Patients without conjunctivitis|Hospitalized patient affected by COVID-19 disease without any signs of conjunctivitis defined as red eyes (macroscopic signs of conjunctival congestion)
11061646|NCT04346160||Healthy control group|group of healthy patients considered as controls
11061647|NCT04346147|Experimental|Imatinib 400 mg|Imatinib 400 mg 1 tablet 24 hours
11061648|NCT04346147|Experimental|Baricitinib 4 mg|Baricitinib 4 mg 1 tablet 24 hours
11061682|NCT04345900|Experimental|5 mg/m^2 Plinabulin|Docetaxel + 5 mg/m^2 Plinabulin
11061649|NCT04346147|Experimental|Supportive treatment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
11061650|NCT04346134|Experimental|mini-PNL group|In which percutaneous nephrolithotomy will be performed using miniature nephroscope.
11061651|NCT04346134|Experimental|SWL group|In which extracorporeal shock wave lithotripsy will be performed using Dornier lithotripter SII
11061652|NCT04346108|Experimental|Epoch 1: Immune Globulin Intravenous (IGIV)|Participants will receive 200 milligrams per kilogram (mg/kg) to 600 mg/kg of Immunoglobulin Globulin Intravenous (IGIV) infusion for every 3 or 4 weeks up to 13 weeks.
11061653|NCT04346108|Experimental|Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 50 and 200 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once a week for 24 weeks.
11061654|NCT04346108|Experimental|Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 100 and 400 mg/kg of IGSC infusion, 20% once every two weeks for 12 weeks.
11061655|NCT04346095|Experimental|Oral Sedative|"Participants will receive oral triazolam 30 minutes prior to surgery.
~Dose for BMI less than 35: 0.125 mg
~Dose for BMI greater than or equal to 35: 0.25 mg
~Followed by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.
~Vitals will monitored by the operating room nurses."
11061656|NCT04346095|Active Comparator|Intravenous Sedative|"This group will receive an intravenous sedative. The sedative is limited to midazolam, fentanyl, propofol.
~Follow by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.
~IV and monitoring will be performed by anesthesiologist or CRNA."
11061657|NCT04346082|Experimental|online mindfulness group|
11061658|NCT04346069|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group
11061659|NCT04346069|Other|Parent-child interaction therapy|Parent child interaction therapy will be provided to the experimental group
11061660|NCT04346030|Experimental|steroid and hydrodissection|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
11061661|NCT04346030|Active Comparator|steroid only|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)
11061662|NCT04346017|Experimental|Ventilation support|The experimental group will include Covid-19 infected patients with non-invasive or invasive ventilation support (BCRSS score ≥3).
11061663|NCT04346017|Other|Control group|The control group will include Covid-19 infected patients who don't have respiratory problems justifying a transfer to intensive care.
11061664|NCT04346004|Placebo Comparator|Control group|Participants in this group are administered N/S.
11061665|NCT04346004|Experimental|Iron isomaltoside group|Participants in this group are administered Iron isomaltoside & Vitamin B12.
11061666|NCT04345991|Experimental|COVID-19 convalescent plasma|A plasma unit provided by a COVID-19 convalescent pathogen-reduced plasma will be used for the treatment of the patients.
11061667|NCT04345991|No Intervention|Control patients|Control patients will receive the best standard of care
11061668|NCT04345978|Placebo Comparator|Normal Fasting|The patient starts fasting 8 hours before the operation,and does not take any solid or liquid foods and nutrients during the fasting process.The fasting period does not strictly limit the consumption of pure water,After surgery 8 hours,the patients was allowed to feeding.
11061669|NCT04345978|Experimental|Prolong Fasting|The patient starts fasting 24 hours before the operation, and does not take any solid or liquid foods and nutrients during the fasting process. The fasting period does not strictly limit the consumption of pure water.After surgery 24 hours,the patients was allowed to feeding.
11061670|NCT04345965||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
11061671|NCT04345952|Experimental|Calm Meditation|Participants in the Calm group will be asked to use the Calm app ad libitum during their time spent receiving chemotherapy at the Mays Cancer Center (~2 hours) and while at home between treatment cycles ad libitum. Participation will be measured during the entire intervention using internal tracking systems within the app (i.e., # of times logged in, type of meditation accessed, time spent meditating, date and time of meditation accessed). This data will be provided to us through data coordinator of the app.
11061672|NCT04345952|No Intervention|Usual Care|The usual care control group will not be offered anything to listen to during their chemotherapy treatment cycles or when they are between chemotherapy treatment cycles. They will receive their treatment as intended without any additional intervention.
11061673|NCT04345939||GenSeizer|Sputum and lavage fluids are tested for pathogens using GenSeizer
11061674|NCT04345939||PCR reverse hybridization|Sputum and lavage fluids are tested for pathogens using PCR reverse hybridization
11061675|NCT04345939||Target sequencing after incubation|Sputum and lavage fluids are tested for pathogens using Target sequencing after incubation
11061676|NCT04345926|Experimental|Dose-response|"- Concentration of propofol at the loss of consciousness (LOS) will be recorded in the presence of remifentanil (7.5 ng/mL) (LOS time).
~- Patients will be intubated and remifentanil will be decreased to 4 ng/mL.
~- Concentration of propofol that caused the LOS will be maintained for 20 minutes (Baseline time).
~- Propofol will be increased in steps of 0.3 mcg/mL for 7 minutes until an episode of burst suppression will be observed (Burst suppression time).
~EEG activity will be acquired using a SedLine® monitor during the complete protocol."
11061677|NCT04345913|Experimental|Phase I (eribulin, copanlisib)|Patients receive copanlisib IV over 60 minutes and eribulin IV over 2-5 minutes on days 1 and 15 or days 1 and 8. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
11061678|NCT04345913|Active Comparator|Phase II, Group I (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11061679|NCT04345913|Experimental|Phase II, Group II (eribulin, copanlisib)|Patients receive copanlisib IV over 60 minutes on days 1 and 8 and eribulin IV over 2-5 minutes on days 1 and 8 or days 1 and 15. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
11061680|NCT04345900|Experimental|20 mg/m^2 Plinabulin|Docetaxel + 20 mg/m^2 Plinabulin
11061686|NCT04345874|Experimental|Nutrition technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
11061687|NCT04345874|Experimental|Children's environmental health technical assistance|three encounters with Intervention team over three months: two virtual 60-90 minutes visits one-on-one with the FCCH each scheduled at the convenience of the provider and a 3- hour virtual group class with other providers.
11061688|NCT04345861|Active Comparator|monotherapy hydroxychloroquine|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) + placebo from Day 1 to Day 5
11061689|NCT04345861|Experimental|combination hydroxychloroquine + azithromycin|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) and azithromycin 500mg (Day 1 ), 250 mg (from day 2 to Day 5)
11061690|NCT04345848|Experimental|Therapeutic anticoagulation|Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.
11061691|NCT04345848|Active Comparator|Prophylactic anticoagulation|Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.
11061692|NCT04345835|Active Comparator|prone flexed|prone flexed PCNL position
11061693|NCT04345835|Active Comparator|prone|prone position PCNL
11061694|NCT04345822||normotension|patients without diagnosis or treatment for hypertension
11061695|NCT04345822||hypertension|patients with diagnosis or treatment for hypertension
11061696|NCT04345809||GROUP A. MESH WITH OMEGA-3|Group A - 6.4-cm diameter circular prosthesis C-QUR V-Patch with an omega-3 coating
11061697|NCT04345809||GROUP B. MESH WITHOUT OMEGA-3|Group B - 6.4-cm diameter circular prosthesis BARD Hernia Patch , without omega-3 in its composition
11061698|NCT04345796|Active Comparator|carvedilol+empagliflozin|Patients will receive carvedilol SR 16mg and empagliflozin 10mg qd.
11061699|NCT04345796|Active Comparator|carvedilol alone|Patients will receive carvedilol SR 16mg alone.
11061700|NCT04345796|Active Comparator|empagliflozin alone|Patients will receive empagliflozin 10mg and matching placebo of carvedilol.
11061701|NCT04345796|Placebo Comparator|placebo|Patients will receive matching placebo of carvedilol.
11061702|NCT04345783|Experimental|Camrelizumab+Apatinib Mesylate+Tegio|
11061703|NCT04345770|Sham Comparator|Without HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
11061704|NCT04345770|Experimental|With HIPEC|Patients will be treated with neoadjuvant chemotherapy (SOX) followed by a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX, 6 circles together with neoadjuvant chemotherapy)
11061705|NCT04345757|No Intervention|Standard instructions|Standard instructions: activity restrictions, including no strenuous exercise, sexual intercourse, or lifting objects greater than 25 pounds for 6 weeks or until evaluation at the 6 week postpartum visit
11061706|NCT04345757|Experimental|Study Group|Study group: Structured 10 week exercise protocol
11061707|NCT04345744|Experimental|Test group 1|administration of a hyaluronic and 0.2% chlorhexidine mouth rinse
11061708|NCT04345744|Experimental|Test group 2|administration of chlorhexidine 0.2% mouth rinse
11061709|NCT04345744|Active Comparator|Control Group|No administration of mouth rinses after surgery
11061710|NCT04345731|No Intervention|Condition 1 - Control|"We note that our within subjects experimental design, in which each subject receives all treatments, is not well suited to this system of reporting. Thus we are defining arms as the label treatments we are evaluating. This label is the control label treatment which represents the current, legally required over-the-counter labeling standard."
11061711|NCT04345731|Experimental|Condition 2 - Highlighted|This condition will involve a novel method of presenting critical active ingredient, drug/drug, and drug/diagnosis information with highlighting.
11061712|NCT04345731|Experimental|Condition 3 - FOP warning label|This condition will involve presenting critical drug/drug, and drug/diagnosis information in a novel Front-of-Pack (FOP) warning label.
11061713|NCT04345731|Experimental|Condition 4- FOP+Highlighting label|This condition will combine both the highlighting and FOP labeling interventions from conditions 2 and 3. Note: Across the four arms we are essentially doing a 2 (highlighting/no highlighting) by 2 (front of pack warning/ no front of pack warning) within subjects design.
11061714|NCT04345718|Experimental|Interventional|Single subcutaneous injection of a 28-day formulation of extended-release buprenorphine within 72 hours of anticipated hospital discharge.
11061715|NCT04345718|Active Comparator|Treatment as Usual|Community standard of care that includes initiation of either methadone, sublingual (SL) buprenorphine, or naltrexone prior to hospital discharge.
11061716|NCT04345692|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
11061717|NCT04345692|No Intervention|Usual Care|usual care for hospitalized patients diagnosed with COVID-19
11061718|NCT04345679|Experimental|Hospitalized patients with SARS CoV-2 infection|
11061719|NCT04345666|Experimental|Testosterone group|20 patients will receive a 200 mg testosterone cyprionate intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
11061720|NCT04345666|Placebo Comparator|Placebo group|20 patients will receive a sterile saline intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
11061721|NCT04345653|Experimental|Study arm|HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
11061722|NCT04345640||Covid-19 with liver disease|Covid-19 with liver disease
11061723|NCT04345640||Covid-19 without liver disease|Covid-19 without liver disease
11061724|NCT04345614|Experimental|Auxora|Patients will be randomized 1:1 to receive either Auxora or placebo
11061725|NCT04345614|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive either Auxora or placebo
11061726|NCT04345601|Experimental|Mesenchymal stromal cells|Patients will receive up to 2 infusions of mesenchymal stem cells.
11061727|NCT04345601|Other|Control Group|Patients will receive supportive care or treatment designated by their treating doctor.
11061728|NCT04345588|Active Comparator|group received dexamethasone perineural|injection dexamethasone 0.05 mg/kg perineural.
11061729|NCT04345588|Active Comparator|group received dexamethasone intravenous|injection dexamethasone 0.05 mg/kg intravenously.
11061730|NCT04345575|Experimental|VR Group|VR group participants were mailed an Oculus Go Virtual Reality headset preloaded with VR software developed by AppliedVR. Treatment content consisted of a variety of 21 sessions to support participants in learning cognitive and behavioral self-management skills based on evidence-based CBT principles and skills, biofeedback and mindfulness strategies used in pain management. The program was designed to improve self-regulation of cognitive, emotion, and physiological response to stress and pain.
11061731|NCT04345575|Active Comparator|Audio Group|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the Audio program included didactic and experiential content that was not identifical but was closely matched to the VR content (sans references to visual imagery that would be confusing in the absence of visual content). Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
11061732|NCT04345562|Active Comparator|Back and forth pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin prep over the suspected skin incision site for 30 sec - the first applicator will then be used in a back and forth pattern work up towards the upper edge of the surgical field. The first applicator will then be discarded. The second applicator will then again start at the expected site of the incision and again working inferiority until the lower edge of the surgical field is reached.
11061733|NCT04345562|Active Comparator|Circular pattern|Abdominal skin prep using ChloraPrep 2 x 26 mL single use applicators. The first applicator will be applied to the skin over the suspected skin incision site for 30 sec - the applicator will then be moved in a circular pattern moving outwards form the incision site until approximately half of thee surgical field is cleaned. The second applicator will then be used to complete the surgical prep until the entire surgical field is prepped in accordance with the package instructions.
11061734|NCT04345549|Experimental|Ayurveda|All the participants were advised to self-isolate for 7-days and maintain hygiene and self-care as per recommended guidelines. Along with that, participants were advised to constitution based Ayurveda treatment using herbs, life style and yoga.
11061735|NCT04345536||Patients hospitalized with confirmed Covid-19|All patients hospitalized with confirmed Covid-19
11061736|NCT04345523|Experimental|Treatment Arm|Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.
11061737|NCT04345523|Active Comparator|Control Arm|Standard of Care (SOC) for COVID-19
11061738|NCT04345497|Experimental|Diabetes-Specific Formula|Diabetes-specific formula 1-2 servings a day and Standard of Care
11061739|NCT04345497|Other|Standard of Care|Standard of Care
11061740|NCT04345484|Experimental|GMT Intervention + Health Lifestyle Program|The intervention group will participate in GMT, a standardized cognitive rehabilitation program which will be given as per the manual and which consists of 9 sessions each 2-hours in duration. They will also participate in the Healthy Lifestyle Program (HLP), which includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
11061741|NCT04345484|Active Comparator|Health Lifestyle Program|The control group enters directly into the HLP without any other study visits. The HLP includes physical activity monitoring (step count, calories burned and sleep) with the Garmin vívofit 4 Activity Tracker, and recording and monitoring of goals with the My Goals app. Moreover, participants will be offered an exercise program with weaning to community-based resources and home exercise recommendations for longer-term sustainability.
11061742|NCT04345471|Experimental|MD-120 100 mg|
11061743|NCT04345471|Experimental|MD-120 50 mg|
11061744|NCT04345471|Placebo Comparator|Placebo|
11061745|NCT04345458|Experimental|group I|twice weekly 25 mg prefilled liquid etanercept
11061746|NCT04345458|Experimental|group II|once weekly 50 mg prefilled liquid etanercept
11061747|NCT04345458|Active Comparator|group III|25 mg twice weekly lyophilized etanercept powder
11061748|NCT04345445|Experimental|Tocilizumab|Tocilizumab is given at 8 mg/kg (body weight) once and administered as an intravenous infusion within no less than 60 minutes.
11061749|NCT04345445|Active Comparator|Methylprednisolone|Reconstituted methylprednisolone is infused over 30 minutes and administered at a dose of 120mg/day for 3 days
11061750|NCT04345432|Experimental|Gabapentin|"The experiment will be divided into the following phases:
~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above
~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.
~7 day drug washout phase - no medication will be taken
~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.
~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
11061751|NCT04345432|Placebo Comparator|Placebo|"The experiment will be divided into the following phases:
~Baseline phase - Demographic and test data will be collected prior to dispensing trial medication using all measures listed above
~7 day trial phase with gradual increase of dose from 100 mg/day to 600 mg/day (300 b.i.d) on day 6 of gabapentin or placebo. A single morning dose (300 mg) will be given at the lab on day 7 followed by post-trial testing (using above measures) 1 hour after drug administration.
~7 day drug washout phase - no medication will be taken
~7 day crossover trial phase - baseline measurements will be repeated and groups will switch to gabapentin or placebo. Post-trial measurements will be taken 1 hour after a single morning dose (300 mg) on day 7.
~Follow-up phone call - Patients will be called 8-10 days after completion of study to ensure that there have been no unexpected events."
11061752|NCT04345419|Experimental|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine tablets
11061753|NCT04345419|Experimental|Remdesivir|Remdesivir as antiviral treatment
11061754|NCT04345406|Experimental|ACEIs|ACEIs with conventional treatment for COVID19
11061755|NCT04345406|Experimental|Conventional treatment of COVID19|Conventional treatment of COVID19
11061756|NCT04345393|Experimental|Digital Transformation Network (DTN) Program|IBD patients at the 3 sites will be sent a message to their Smartphone
11061757|NCT04345393|Active Comparator|Control Arm|Patients will enter the control group once they initially complete the ePRO and online assessment tools. They will remain in the control group, and then at set intervals each site will transition these patients into the DTN intervention arm.
11061758|NCT04345380|Active Comparator|Acrysof Rotation|Implantation of the Acrysof SN60WF Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
11061759|NCT04345380|Active Comparator|Tecnis Rotation|Implantation of the Tecnis ZCB00 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
11061760|NCT04345380|Active Comparator|Envista Rotation|Implantation of the Envista MX60 Intraocular lens to the 0 ±10, 45± 10, 90±10 or 135± axis.
11061761|NCT04345367|Experimental|Abrocitinib 200 mg plus placebo injection|Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24
11061762|NCT04345367|Active Comparator|Dupilumab 300 mg plus placebo tablets|Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26
11061763|NCT04345354||Patient with continuous positive airway pressure treatment|
11061764|NCT04345354||without continuous positive airway pressure treatment|
11061765|NCT04345341|Active Comparator|Laparoscopic assisted TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
11061766|NCT04345341|No Intervention|no TAP block|no TAP block would be done
11061767|NCT04345328||Roux-en-Y gastric bypass|Patients who were planned for surgery with Roux-en-Y gastric bypass and were operated
11061768|NCT04345328||Sleeve Gastrectomy|Patients who were planned for surgery with Sleeve Gastrectomy and were operated
11061769|NCT04345328||Control group|Obese patients involved in a weight loss program that focuses on diet and lifestyle changes
11061770|NCT04345315||asymptomatic population at high risk of infection|healthy individuals at high risk of infection, including individuals who have had contact with a patient tested positive for COVID-19, voluntary health workers and oncological patients candidate to immunosuppressive therapy
11061771|NCT04345315||COVID-19 patients|patients with confirmed diagnosis of COVID-19
11061772|NCT04345302|Experimental|Brief motivational treatment|"Participants in the intervention group will receive the Brief Motivational Treatment, which is a primary care-adaptation of the Motivational Enhancement Therapy as manualized in the Project MATCH [19]. This treatment consists of four 45-minute sessions, provided by a psychologist at weeks one, two, six, and twelve. The first three sessions, occurring during the first six weeks, are more active regarding the behavioural change, while the last session functions as closure and review of the process. If a participant asks for more support, they will be able to attend up to two extra sessions before the last one.
~The main adaptations are:
~The translation into Chilean Spanish.
~Update of Motivational Interview concepts.
~Companion training material that includes a demonstrative video and practical exercises.
~An adapted personalized feedback procedure.
~Information on additional resources available in the primary care centre and the community."
11061773|NCT04345302|Active Comparator|Enhanced usual care|"All participants will receive an educational brochure on alcohol use disorder, with self-help materials and guides on how to get additional support.
~The physicians within the PC centre will also receive information on how to diagnose alcohol use disorders, prescription guides for the medications that are available for treating these disorders in the PC centre (mainly Disulfiram and any other if available), and directions on when and where to refer clients for treatment."
11061774|NCT04345289|Active Comparator|Convalescent plasma|Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
11061775|NCT04345289|Placebo Comparator|Infusion placebo|Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.
11061776|NCT04345276|Experimental|Danoprevir+Ritonavir group|
11061777|NCT04345263|Active Comparator|MTA pulpotomy|Tooth will receive MTA & resin composite restoration
11061778|NCT04345263|Active Comparator|Biodentine pulpotomy|Tooth will receive Biodentine & resin composite restoration
11061779|NCT04345263|Active Comparator|Bioceramic pulpotomy|Tooth will receive Bioceramic & resin composite restoration
11061780|NCT04345250|Experimental|Participants|"For a period of 6 days between the exercise trials (i.e., following visit 3), each participant will be put on a restricted energy restricted diet consisting of a 25% reduction in their habitual total daily calorie intake. To keep the diet consistent and standardized, participants will record their typical food intake during a control week using the Eat This Much app, which will then provide an overall portion plan and the 25% caloric restriction measure for the intervention week. Thus, the intervention diet will mirror the control diet in terms of types of food consumed, with the difference being in the amount consumed. There will be no restriction regarding water, but drinks will be restricted according to the overall calorie intake plan."
11061781|NCT04345237|Experimental|Experimental group 1 (TS + placebo)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.
~Daily consumption for 3 months of placebo milk."
11061782|NCT04345237|Experimental|Experimental group 2 (TS + leucine)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.
~Daily consumption for 3 months of milk enriched with leucine."
11061783|NCT04345237|Experimental|Experimental group 3 (HRC + placebo)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.
~Daily consumption for 3 months of placebo milk."
11061784|NCT04345237|Experimental|Experimental group 4 (HRC + leucine)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.
~Daily consumption for 3 months of milk enriched with leucine."
11061785|NCT04345237|Experimental|Experimental group 5 (no physical exercise + leucine)|"The subjects will not carry out any type of physical activity.
~Daily consumption for 3 months of milk enriched with leucine."
11061786|NCT04345237|No Intervention|Control (no physical exercise + placebo)|"The subjects will not carry out any type of physical activity.
~Daily consumption for 3 months of placebo milk."
11061787|NCT04345224|Experimental|Dynamic tape|The gluteal muscle group will be covered with a dynamic tape.
11061788|NCT04345224|Experimental|Rigid tape|The gluteal muscle group will be covered with a rigid tape.
11061789|NCT04345224|Sham Comparator|Sham tape|The gluteal muscle group will be covered with a paper tape - a sham application.
11061790|NCT04345211|Active Comparator|Group1 (G1): walking group|"All walks will be done immediately after the MT and TB intervention, as this has been shown to improve the synergistic effect of combining the two interventions. The walking sessions will be organized twice a week. The walking sessions will begin with a 10-minute warm-up. After warming up, you will take a continuous walk for 10-20 min, at a target intensity of 13 (somewhat difficult) on the Borg scale. Using the Borg scale, which ranges from 6 to 20, participants will be asked to walk at an intensity of 13 (perception of somewhat difficult activity). Each session will be completed with a 10 minute cool down period. The objectives of Walinking will be individualized according to the level of physical condition of each participant. The walking group will include a weekly walking goal of 75 minutes."
11061791|NCT04345211|Active Comparator|Group 2 (G2): walking plus manual therapy|"Walking as previously described plus a self-administered manual chest therapy:
~- Neurolymphatic points pressure: Participants will be placed in a neutral position and their arms next to their bodies. They are asked to take a conscious breath. The physical therapist will apply firm, direct rotary pressure through the thumb or fingertip for 1 minute from the T1 transverse processes to the T12 transverse processes. Suboccipital decompression / mobilization, slippage of the cervical vertebral joints (anterior / posterior), myofascial release of sternocleidomastoid and trapezius, slippage of the sternoclavicular joint (anterior / posterior direction), myofascial release of intercostal muscles and paravertebral muscles (anterior rib mobilization, posterior, lateral), mobilization of the scapulothoracic joint, diaphragmatic release."
11061792|NCT04345211|Active Comparator|Group 3 (G3): walking plus thorax exercises with Theraband.|Walking as previously described plus a self-administered exercises with elastic-band. The exercises will include chest and arms exercises in sitting position.
11061793|NCT04345211|No Intervention|Group 4 (G4): control group|Control group will do usual life and assessments as the rest of the groups.
11061794|NCT04345198|Experimental|Intervension|Adrenal artery ablation is performed in PA patients with resistant hypertension.
11061795|NCT04345185||Project Viva|Project Viva (1999-present) enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age.
11061796|NCT04345185||Infant Feeding Practices Study II|The Infant Feeding Practices Study II (IFPS II, 2005-2007) enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years.
11061797|NCT04345172|Active Comparator|a lacrimal dilator group (Group LD)|The patients allocated to receive STB performed with a lacrimal dilator
11061798|NCT04345172|Active Comparator|a Wescott scissors (Group WS)|The patients allocated to receive STB performed with a Wescott scissors
11061799|NCT04345159||Patient with autoimmune disease|Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.
11061800|NCT04345146|Experimental|FSRT & Bevacizumab|Patients will receive Bevacizumab before and after FSRT: daily FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases with Bevacizumab(7.5mg/kg, q3w, IV)
11061801|NCT04345133|Active Comparator|Undersized Drilling Group|Exposed patients to the reduction of the final drill dimensions at the insertion implants protocol sequence
11061802|NCT04345133|Other|Conventional Drilling Group|Group with the conventional protocol recommended by the manufacturer
11061803|NCT04345120|Experimental|SY-008-6mg/d|2mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，12mg/d.
11061804|NCT04345120|Experimental|SY-008-12mg/d|4mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，18mg/d.
11061805|NCT04345120|Experimental|SY-008-18mg/d|6mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
11061806|NCT04345120|Placebo Comparator|SY-008 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
11061807|NCT04345107|Experimental|SY-009-1mg/d-1|0.5mg BID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-1mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
11061808|NCT04345107|Experimental|SY-009-1mg/d-2|1mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8.Start at the same time as the SY-009-1mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
11061809|NCT04345107|Experimental|SY-009-2mg/d-1|1mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
11061810|NCT04345107|Experimental|SY-009-2mg/d-2|2mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
11061811|NCT04345107|Experimental|SY-009-4mg/d|2mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. If the test and safety assessment of 4mg daily dose group (2mg bid) are completed and the dose termination standard is not met, the test will be terminated; if the safety assessment during or after the test reaches the dose termination standard, the study of 3mg daily dose group (1.5mg bid) will be carried out, and then the test will be terminated.
11061812|NCT04345107|Experimental|SY-009-3mg/d|1.5mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
11061813|NCT04345107|Placebo Comparator|SY-009 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
11061814|NCT04345094|Experimental|Comparator|Emulsion containing 1% Hexylresourcinol
11061815|NCT04345094|Active Comparator|Intervention|Emulsion containing 2% Hydroquinone
11061816|NCT04345081||SRNSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.
~This Group receive Skin Reducing Nipple Sparing Mastectomy"
11061817|NCT04345081||SSM Group|"Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction.
~This Group receive Skin Sparing Mastectomy"
11061818|NCT04345068|Experimental|Calm Meditation|"The intervention will be 8-weeks in duration and will consist of a series of pre-approved meditation classes. Patients will be asked to participate in at least 10 min/day of meditation (i.e., ~70 min/week). Week 1-4 will consist of the 7 Days of Calm followed by the 21 Days of Calm, which are introductory courses offered by Calm and provide basic, introductory meditation classes for beginners. Weeks 5-8 will consist of patients participating in the Daily Calm that Calm provides, consisting of 10-12 min meditation classes that have a unique focus each day. Patients will be instructed to participate in at least 10 min/day of meditation, but will be encouraged to do more if they can."
11061819|NCT04345068|Active Comparator|Health Education Podcast|The control group will serve as an active control group and will be matched for time and attention to the intervention group. Participants assigned to the control group will be asked to listen to/view 10-min/day (i.e., ~70 min/week) of health education podcasts via a smartphone app. Topics covered in the health education control vary and will be aimed at providing useful and informative health-related information pertinent to cancer patients. The podcast app was developed by an independent app developer, and it was designed to mirror the type of functionality that the Calm app offers its users.
11061820|NCT04345055|Experimental|Fascial treatment|Treatment the lumbar fasciae
11061821|NCT04345055|Placebo Comparator|Placebo group|Introduce in a machine off
11061822|NCT04345042|No Intervention|First Group|In the first group; the investigators applied the TP such as hot pack, ultrasound, exercise and TENS.
11061823|NCT04345042|Experimental|Second Group|In the second group; the investigators applied the classic massage (Swedish Technique) together with TP.
11061824|NCT04345029|Experimental|Experimental group (Lippia citriodora + sabdariffa)|"Consumption for 60 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.
~Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days."
11061825|NCT04345029|Placebo Comparator|control group Placebo (sucrose)|Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days.
11061826|NCT04345016|Experimental|All Participants|Eligible participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) during the intervention/treatment phase. Each was followed for one year or until study disenrollment, health plan disenrollment, death, or end of the study and follow-up period. Outcomes data from eligible participants from the two years prior to the intervention/treatment phase and the period of time after the intervention ended through the analysis date (2020-01-01) were evaluated. For this period, these participants received standard medical and diabetic foot care.
11061827|NCT04345003|Experimental|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.
~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
11061828|NCT04344990|Active Comparator|Group E- Epidural analgesia|Continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure. The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The epidural catheter is placed preoperatively.
11061829|NCT04344990|Active Comparator|Group F- Femoral blockade|Continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The femoral catheter is placed preoperatively.
11061830|NCT04344990|Active Comparator|Group I- Intraarticular infusion|Continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg for postoperative pain management right after the end of the procedure.The PCA pump is programmed with continuous infusion (Ropivacaine 0.2% + clonidine 150μg) 2ml/h and bolus dosage 0,5ml per 15min (max dosage 2ml/h). The intraarticular catheter is placed before the closure of the incision.
11061831|NCT04344977||Convalescent survivors of COVID-19|Convalescent survivors of COVID-19: history of COVID-19 like illness or positive test for SARS-CoV-2 and has the protocol-specified minimum anti-SARS-CoV-2 neutralizing antibody titer
11061832|NCT04344964||Phone consult group|Information collected prospectively on FTA patients and questionnaire (satisfaction)
11061833|NCT04344964||Face-to-face consult group|Information collected retrospectively on FTA patients
11062025|NCT04343612|Placebo Comparator|Placebo|anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation
11061834|NCT04344951|Experimental|UNIKINON (Chloroquine phosphate)|Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.
11061835|NCT04344938||medical personel|
11061836|NCT04344938||non medical personel|
11061837|NCT04344925||Aerosol-reducing Mask|The participant will be placed on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
11061838|NCT04344925||Standard Mask|The patient will be placed on BIPAP using the standard mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
11061839|NCT04344912||COVID19- Population|Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan
11061840|NCT04344912||COVID19+ Population|Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan
11061841|NCT04344899||Historical|Retrospective Review
11061842|NCT04344899||ERAS Patients|Prospective Review
11061843|NCT04344886|Experimental|Conventional (dual-phase) SPECT/CT|Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
11061844|NCT04344886|Experimental|Multi-phase SPECT/CT|Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
11061845|NCT04344873|Experimental|Older Adult participants|Older adult participants (ages 55-75) will be assessed for arterial function using FMD analysis, PWV calculations, T Cell phenotyping, and proportion of inflammatory biomarkers after injections of placebo and abatacept.
11061846|NCT04344860|Active Comparator|rVWF plus TA|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia) plus Tranexamic Acid 1 gm IV within 3 hours of delivery; and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
11061847|NCT04344860|Active Comparator|rVWF alone|Subjects randomized to this arm will receive recombinant von Willebrand factor 80 IU/kg IV within 5-10 minutes of delivery (or epidural anesthesia); and recombinant Von Willebrand factor 80 IU/kg on day 1 and day 2 postpartum.
11061848|NCT04344847|Other|coincidental GIST during LSG patients|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.
11061849|NCT04344834||Health care workers|Egyptian health care workers
11061850|NCT04344834||General population|Any Egyptian personnel
11061851|NCT04344821|Placebo Comparator|Control|No diet or exercise intervention
11061852|NCT04344821|Experimental|No Diet plus Exercise|No diet, exercise only intervention
11061853|NCT04344821|Experimental|High Protein Diet plus Exercise|High protein diet and exercise intervention
11061854|NCT04344821|Experimental|High Carbohydrate Diet plus Exercise|High carbohydrate diet and exercise intervention
11061855|NCT04344808|Experimental|Navigation group|Dental implants will be placed using a dynamic computer assisted surgery system
11061856|NCT04344808|Active Comparator|Freehand group|Dental implants will be place without any guidance. Only virtually planning the ideal position on a 3D image (Cone beam computed tomography)
11061857|NCT04344795|Experimental|TPST-1495 monotherapy dose escalation|Subjects will receive escalating doses of TPST-1495 administered orally twice daily until maximum tolerated dose is reached or until disease progression
11061858|NCT04344795|Experimental|TPST-1495 in combination with pembrolizumab dose escalation|Subjects will receive escalating doses of TPST-1495 administered orally twice daily in combination with pembrolizumab administered by IV infusion until maximum tolerated dose is reached or until disease progression
11061859|NCT04344795|Experimental|TPST-1495 monotherapy dose expansion|Subjects will receive selected dose of TPST-1495 administered orally twice daily until disease progression
11061860|NCT04344795|Experimental|TPST-1495 in combination with pembrolizumab dose expansion|Subjects will receive selected dose of TPST-1495 administered orally twice daily in combination with pembrolizumab administered by IV infusion until disease progression
11061861|NCT04344782|Experimental|Bevacizumab|
11061862|NCT04344782|No Intervention|Standard of Care|
11061863|NCT04344769||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
11061864|NCT04344769||Healthy individuals as controls|Age and gender-matched healthy controls
11061865|NCT04344756|Experimental|Active Coagulation|
11061866|NCT04344756|No Intervention|Standard of Care|Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance < 30mL/min.
11061867|NCT04344743|Experimental|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
11061868|NCT04344730|Placebo Comparator|Standard oxygen 1|Standard oxygen and placebo of Dexamethasone
11061869|NCT04344730|Experimental|Standard oxygen 2|Standard oxygen and Dexamethasone
11061870|NCT04344730|Experimental|CPAP 1|CPAP and placebo of Dexamethasone
11061871|NCT04344730|Experimental|CPAP 2|CPAP and Dexamethasone
11061872|NCT04344730|Experimental|HFNO 1|HFNO and placebo of Dexamethasone
11061873|NCT04344730|Experimental|HFNO 2|HFNO and Dexamethasone
11061874|NCT04344730|Placebo Comparator|mechanically ventilated 1|placebo
11061875|NCT04344730|Experimental|mechanically ventilated 2|Dexamethasone
11061876|NCT04344717|Experimental|Short bowel syndrome|Single dose administration of 2.5 mg and 5 mg (1 week wash out between 2 doses) apixaban to patients with short bowel syndrome requiring long term parenteral nutrition
11078263|NCT04228341|Experimental|9 % polished rice|9 % polished rice
11061877|NCT04344717|Other|Normal gastrointestinal tract|Single dose administration of 2.5 mg or 5 mg apixaban to patients with a normal gastrointestinal tract with an indication for anticoagulation with apixaban (atrial fibrillation).
11061878|NCT04344704||DX devices with SMART headset detection enabled|The SMART detection algorithm is designed to, with the aid of atrial rhythm assessment, discriminate between ventricular tachycardias and a variety of supraventricular tachyarrhythmias for which device intervention is not required or desired
11061879|NCT04344704||DX device programmed in single chamber mode|"with the activation of one of the available discrimination criteria:
~Onset: distinguishes slow onset or onset tachycardias from sudden onset
~Stability: distinguishes between irregularly transmitted supraventricular tachycardias and ventricular tachycardias requiring therapy by continuous interval monitoring.
~Morphmatch: helps to distinguish between supra and ventricular signals through analysis of episode QRS width"
11061880|NCT04344691|No Intervention|Control|5 minutes waiting time
11061881|NCT04344691|Experimental|Stretching|Rectus femoris static stretching during 90' (with three hold-relax progressions until final ROM)
11061882|NCT04344678|Placebo Comparator|Control group|Escitalopram 20 mg tablet plus one placebo tablet
11061883|NCT04344678|Experimental|Sildenafil group|Escitalopram 20 mg tablet plus one Sildenafil 50 mg tablet
11061884|NCT04344665|Experimental|Virtual Care and Remote Automated Monitoring|
11061885|NCT04344665|No Intervention|Standard Care|
11061886|NCT04344652|Experimental|Photoscreening|Photoscreening of patients 0 to 10 years of age
11061887|NCT04344626|Experimental|Brain tonometry|Participants undergoing intra-operative brain tissue stiffness measurements using a digital tonometer. Evaluated brain tissue is both presumed normal and abnormal based on results of pre-operative evaluations.
11061888|NCT04344613|Experimental|Blood samples|
11061889|NCT04344600|Experimental|Peginterferon lambda alfa-1a|peginterferon lambda-1a (Lambda) 180 micrograms by subcutaneous injection for participants who are not infected with SARS-CoV-2
11061890|NCT04344600|Placebo Comparator|Placebo|Placebo (saline) by subcutaneous injection for participants who are not infected with SARS-CoV-2
11061891|NCT04344587|Experimental|Intervention group|Participants in the intervention arm will receive a text message on their smartphones linking to the Qualtrics intervention website
11061892|NCT04344587|Active Comparator|Usual care group|Participants in the usual care arm will receive a text message on their smartphone linking to the Qualtrics usual care website
11061893|NCT04344561|Experimental|Postural Positioning|Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
11061894|NCT04344561|No Intervention|Standard Care|Participants in this group will have beds managed per standard nursing protocol.
11061895|NCT04344548|Experimental|Treatment group|Adult patients with COVID-19 infection with NEWS 2 score >4
11061896|NCT04344535|Active Comparator|Convalescent Donor Plasma|
11061897|NCT04344535|Placebo Comparator|Standard Donor Plasma|
11061898|NCT04344522|Experimental|sequential 2 stage procedure|In this arm , the procedure will be performed in two stages ; the first stage will include performing IOL exchange together with iridoplasty ( if required) and inferior peripheral iridectomy (PI) and the second stage is performing DMEK one month later
11061899|NCT04344522|Experimental|combined single stage procedure|In this arm, both IOL exchange and DMEK will be performed in the same setting
11061900|NCT04344509||COVID19-positive patients|
11061901|NCT04344509||COVID19-negative patients|
11061902|NCT04344483|Active Comparator|Group A ( Lidocaine + Adrenaline)|Group A patients will receive 2% Lidocaine and 1:100,000 adrenaline soaked gauze over skin graft donor site of thigh per operatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site.
11061903|NCT04344483|Placebo Comparator|Group B ( Normal Saline)|Group B patients will receive normal saline soaked gauze over skin graft donor site of thigh intraoperatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site
11061904|NCT04344470|Experimental|Healthy Volunteers|Healthy Volunteers
11061905|NCT04344444|No Intervention|Arm A|Supportive Care only
11061906|NCT04344444|Experimental|Arm B|Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5
11061907|NCT04344444|Experimental|Arm C|Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5
11061908|NCT04344431|Experimental|HBO group|
11061909|NCT04344431|No Intervention|Non-HBO group|
11061910|NCT04344418|Active Comparator|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at the Kenyatta National Hospital (KNH) and Aga Khan University Hospital Nairobi (AKUHN). A diagnosis will be selected based on the same pre-defined checklist and the time the diagnosis is made recorded.
11061911|NCT04344418|Experimental|Nurse-performed focused cardiac ultrasound (FoCUS)|The experimental arm will consist of nurse-performed FoCUS for patients with cardiorespiratory failure. A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
11061912|NCT04344405|Experimental|Vit D|
11061913|NCT04344405|Placebo Comparator|control|
11061914|NCT04344392|Other|Dysphagic hemiplegic patients|Dysphagic patients with hemiplegia as assessed by clinical examination
11061915|NCT04344392|Other|Control|Volunteers which do not have an active swallowing dysfunction.
11061916|NCT04344379|Active Comparator|Arm Title : hydroxychloroquine|
11061917|NCT04344379|Placebo Comparator|Placebo of hydroxychloroquine|
11061918|NCT04344379|Active Comparator|azythromycin|
11061919|NCT04344366||group A|children with low birth weight
11061920|NCT04344366||group B|children with normal birth weight
11061921|NCT04344327||Patients with COVID-19|Patients hospitalized in conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)
11061922|NCT04344314|Other|Small gauge arm|2 PIVCs of same gauge and different lengths
11061923|NCT04344314|Other|Large gauge arm|2 PIVCs of same gauge and different lengths
11061924|NCT04344301|Experimental|AUDIO|"Participant clinic visits will be audio recorded locally on a secure, HIPAA-compliant server. Patient access to recordings will be performed via a secure web-based platform.
~Additionally, participants will be offered the After Visit Summary (AVS) prior to clinic departure, per Usual Care (UC)"
11061925|NCT04344301|No Intervention|Usual Care|During the trial, patients will be offered to receive the AVS prior to clinic departure as is the current standard at each site.
11061926|NCT04344288|Experimental|Prednisone group|Prednisone during 10 days after randomization
11061927|NCT04344288|Other|Control group|
11061928|NCT04344275|Experimental|Kinesio-taping (KT)|The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
11061929|NCT04344275|Placebo Comparator|Placebo Kinesio-taping (KT)|Kinesio-tape was applied with no tension and technique on the middle trapezius.
11061930|NCT04344262|Active Comparator|control (C) group|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg
~Maintenance doses of muscle relaxant will be given throughout the intraoperative period
~to maintain the Train-of-four values continuously less than 2"
11061931|NCT04344262|Experimental|minimal dose (M) group|"Intubating dose of muscle relaxant will be 0.2 mg/kg will be injected
~boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal."
11061932|NCT04344236|No Intervention|Control|
11061933|NCT04344236|Experimental|Saline oral/nasal rinse|
11061934|NCT04344236|Experimental|0.5% Povidone/Iodine oral/nasal rinse|
11061935|NCT04344236|Experimental|0.12% Chlorhexidine oral/nasal rinse|
11061936|NCT04344223|Experimental|Experimental balance shoes|Tests and familiarization phases with experimental balance shoes (Axis Comfort Development®)
11061937|NCT04344223|Active Comparator|Personal shoes|"Same tasks than the condition Experimental balance shoes but realized with personal shoes (own personal shoes of subjects)"
11061938|NCT04344210|Experimental|Tele-Intervention|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
11061939|NCT04344210|No Intervention|Usual Care|Participants will receive the usual care
11061940|NCT04344184|Active Comparator|Infusion|L-Ascorbic Acid (Vitamin C), intravenous infusion
11061941|NCT04344184|Placebo Comparator|Standard of care|Dextrose 5% Water
11061942|NCT04344158|Experimental|AK105 combined with Anlotinib|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11061943|NCT04344158|Active Comparator|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
11061944|NCT04344145||Target Group|This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
11061945|NCT04344145||Control group|"This group includes healthcare workers who are actively involved in usual medical care units, referred in this study as non-Covid-19 units. They will fill same self-reported questionnaires and scales than those filled in the Target group, also upon their inclusion.This group will be the comparator of the Target Group to assess the frontline Covid-19 condition."
11061946|NCT04344106|Experimental|Prone positioning|"Participants are all turned to prone position for an optimal minimum duration of 3 hours .
~Tolerance, oxygen saturation, heart rate and position are monitoring during all procedure. Arterial blood gases are realized before, 1 to 2 hours after the beginning of the prone position, and 6 to 12 hours after resupination."
11061947|NCT04344093|Experimental|Connected patch validation|
11061948|NCT04344080|Active Comparator|CytoSorb-Therapy|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
11061949|NCT04344080|No Intervention|Standard of care|Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care
11061950|NCT04344067|No Intervention|Control Group|
11061951|NCT04344067|Experimental|Far Infrared Therapy Group|In this study, the top radiator of the far infrared emitter was set at a height of 25 cm above the umbilicus with a treatment time of 40 minutes during the initial 1 hour of both the first daily and the last night-time indwelling dialysate of each daily regular peritoneal dialysis regimen.
11061952|NCT04344054|Experimental|Arm 1|RV3-BB/TV P2-VP8 boost
11061953|NCT04344054|Experimental|Arm 2|RV3-BB/TV P2-VP8 co-administered
11061954|NCT04344054|Experimental|Arm 3|RV3-BB primed TV P2-VP8
11061955|NCT04344054|Experimental|Arm 4|Rotarix®/TV P2-VP8 Boost
11061956|NCT04344054|Experimental|Arm 5|Rotarix®/TV P2-VP8 co-administered
11061957|NCT04344054|Experimental|Arm 6|TV P2-VP8 alone
11061958|NCT04344041|Experimental|Intervention group|High dose of vitamin D3
11061959|NCT04344041|Active Comparator|Comparator group|Standard dose of vitamin D3
11061960|NCT04344028|Experimental|True Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program improves performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
11062358|NCT04341168||Adults with COVID-19|age range: from 18 years old, subgroups will be established
11061961|NCT04344028|Active Comparator|True Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
11061962|NCT04344028|Placebo Comparator|Control Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program increases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
11061963|NCT04344028|Sham Comparator|Control Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
11061964|NCT04344015|Other|Convalescent Plasma Donation|The goal of this study is to identify individuals who have previously been infected with COVID-19 and collect plasma from those who meet inclusion criteria for convalescent plasma donation. This protocol will allow for the collection, manufacturing, and storage of convalescent plasma that may be administered to patients with COVID-19 in the near future. In addition, it allows for testing of SARS-COV-2 antibody titers in the plasma that has been collected to inform studies assessing outcomes for patients currently infected with COVID-19 who have received convalescent plasma infusions.
11061965|NCT04344002||lung cancer+COVID-19|lung cancer patients diagnosed with COVID-19
11061966|NCT04343989|Experimental|Clazakizumab 25 mg|
11061967|NCT04343989|Experimental|Clazakizumab 12.5 mg|
11061968|NCT04343989|Placebo Comparator|Placebo|
11061969|NCT04343976|Experimental|Lambda Treatment|Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda
11061970|NCT04343976|Placebo Comparator|Saline Placebo|Subcutaneous injection of saline placebo
11061971|NCT04343963|Active Comparator|Pyridostigmine|Pyridostigmine bromide tablet (60mg P.O. once per day for 14 days)
11061972|NCT04343963|Placebo Comparator|Placebo|Placebo tablet (60mg P.O. once per day for 14 days)
11061973|NCT04343950|Experimental|Intervention 1: SMS reminders in colorectal cancer screening|SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
11061974|NCT04343950|Active Comparator|Usual Care 1: Reminder letter in colorectal cancer screening|Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
11061975|NCT04343950|Experimental|Intervention 2: SMS reminders to return the screening test|SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
11061976|NCT04343950|Active Comparator|Usual Care 2: No intervention|No reminders will be sent.
11061977|NCT04343950|Experimental|Intervention 3: SMS invitation among prior participants|Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
11061978|NCT04343950|Active Comparator|Usual Care 3: Invitation letter|Letter invitations will be sent.
11061979|NCT04343937||Retrolaminar block|Retrolaminar block for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
11061980|NCT04343937||İntravenous analgesia|İntravenous analgesia for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
11061981|NCT04343924|Experimental|Diving Group|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
11061982|NCT04343924|Active Comparator|Virtual reality Group|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates.
11061983|NCT04343924|No Intervention|Control Group|The subjects of this group will be monitored and treated for PTSD and will not attend the dive discovery course or virtual reality sessions.
11061984|NCT04343911|No Intervention|conventional positioning|positioning with shoulder braces
11061985|NCT04343911|Active Comparator|positioning on Pink Pad ®|
11061986|NCT04343885|Experimental|177Lu-PSMA+ Docetaxel|7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
11061987|NCT04343885|Other|Docetaxel (Control)|Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
11061988|NCT04343872|Active Comparator|Receive lifestyle modification alone (DPP)|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services
11061989|NCT04343872|Experimental|Receive lifestyle modification with metformin therapy|Participants in this arm will receive a lifestyle modification intervention program facilitated by Peer Coach (PC) services plus metformin recommendation
11061990|NCT04343859|Experimental|IMMH-010-60mg|Part A Dose escalation study: 60mg, QD, Cycle0Day1, Cycle1Day1-CycleN
11061991|NCT04343859|Experimental|IMMH-010-120mg|Part A Dose escalation study:120mg, QD, Cycle0Day1, Cycle1Day1- CycleN
11061992|NCT04343859|Experimental|IMMH-010-240mg|Part A Dose escalation study: 240mg, QD, Cycle0Day1, Cycle1Day1- CycleN
11061993|NCT04343859|Experimental|IMMH-010-360mg|Part A Dose escalation study:360mg, QD, Cycle0Day1, Cycle1Day1- CycleN
11061994|NCT04343846||group A|low birth weight children
11061995|NCT04343846||group B|normal birth weight children
11061996|NCT04343833|Active Comparator|Control with Standard dental implant|Patients were treated with implants Inhex Ticare Standard (Mozo Grau, Ticare, Valladolid, Spain). The implants presented a surface treated with Reabsorbable Blast Media (RBM), conical macro-design with non-aggressive threads, internal connection, and platform switching. On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
11061997|NCT04343833|Experimental|Test with the new implant design|Patients were treated with Implants Inhex Quattro Ticare (Mozo Grau, Ticare, Valladolid, Spain). The implants also presented a surface treated with RBM, conical macro-design with expanded micro threads, internal connection, and platform switching.On the implant shoulder, the beveled design of the platform was characterized by a rounded shape of 45º.
11061998|NCT04343820||Breast reconstruction|Women who have had a mastectomy and want a secondary breast reconstruction by implant.
11061999|NCT04343807|Active Comparator|PECS block|For patients in PECS group (PG), after induction of general anesthesia, the nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
11062000|NCT04343807|Active Comparator|Control Group|For patients in control group, after induction of general anesthesia, no nerve block will be performed and only intravenous nalbuphine will be given.
11062001|NCT04343794|Experimental|Biovitals|Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
11062002|NCT04343794|No Intervention|Control|Usual standard care
11062003|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a|
11062004|NCT04343768|Experimental|Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b|
11062005|NCT04343768|Active Comparator|Control group: hydroxychloroquine + Lopinavir / Ritonavir|
11062006|NCT04343755|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
11062007|NCT04343742||chlorine dioxide 3000 ppm. Bottle x 150 cc.|"Assignment of study medication Each patient will receive, in order of admission to the study, a consecutive patient number and the corresponding study medication. The assignment of this medication was made before the start of the study, using a computer generated list. Patients will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.
~7.1 Dosage and route of administration. Medication: chlorine dioxide 3000 ppm. Fco x 150 cc. 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots).
~Both the original dioxide bottle and the preparation for the day should be kept refrigerated."
11062008|NCT04343729|Active Comparator|Methylprednisolone|0.5mg/kg injectable methylprednisolone sodium succinate, twice daily, for 5 days.
11062009|NCT04343729|Placebo Comparator|Placebo|Saline solution, twice daily, for 5 days. Injectable.
11062010|NCT04343716|Experimental|White women|White women aged 65-75 with knee OA
11062011|NCT04343716|Experimental|Black women|Black women aged 65-75 with knee OA
11062012|NCT04343703|Experimental|Telephone-based management|Telephone-based management will consist of a three-phase intervention: 1) An initial 15-20 min call at 1 week of enrollment in which the cases manager introduces him/herself, and does a short assessment of the current suicide risk, 2) A 5-10 min telephone follow-up at 1, 3, 6, 9 and 12 months, 3) If suicide risk is detected, a 15-45 min crisis intervention call will be done, tailored to the participant's characteristics and context. If deemed necessary, an emergency face-to-face appointment will be scheduled. At each phone call information regarding the current treatment, adherence to mental health services, and current life stressors will be collected.
11062013|NCT04343703|Experimental|iFightDepression for Suicide|The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked. The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
11062014|NCT04343703|Active Comparator|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual. TaU will consist of any routine procedures applied at each participating site.
11062015|NCT04343703|Experimental|Self Awareness of Mental Health|The Self Awareness of Mental Health (SAM) is an adaptation of the Youth Awareness of Mental Health program, originally developed for the Saving and Empowering Young Lives in Europe (SEYLE) study. The SAM aims to raise mental health awareness about risk and protective factors associated with suicide, provide knowledge about depression and anxiety, and enhance the skills needed to cope with adverse life events and suicidal behavior. The intervention is delivered by trained clinical psychologists in five, 45-60 minutes, face-to-face sessions.
11062016|NCT04343690|Experimental|Health Care Workers|Faculty, staff, and trainees dealing with COVID-19 pandemic
11062017|NCT04343651|Placebo Comparator|Placebo|
11062018|NCT04343651|Experimental|700mg Leronlimab|
11062019|NCT04343638|Active Comparator|conventional nociception control arm|Intraoperative opioid will be administered by conventional clinical practice. ANI monitor readings will not be visible to the anesthesiologist.
11062020|NCT04343638|Experimental|ANI-monitor guided nociception control arm|Intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50.
11062021|NCT04343625|Experimental|Modified sitting, gentle yoga class|Participants attended a modified sitting gentle yoga class,10 weekly classes, each 60 minutes in duration.
11062022|NCT04343612|Experimental|Anodal|Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation
11062023|NCT04343612|Experimental|Bilateral|Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation
11062024|NCT04343612|Experimental|Cathodal|Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation
11062235|NCT04341896||Non-caregivers|Prior obese living kidney donors who were not the primary caregiver for their recipient
11062026|NCT04343599|Experimental|Hypopressive exercises|Patients completed 10 weeks of abdominal hypopressive exercises with two sessions of 30 minutes per week.
11062027|NCT04343599|No Intervention|Control group|Patients allocated to the control group did not receive any treatment.
11062028|NCT04343586|Experimental|Adult treatment arm|Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.
11062029|NCT04343573|Experimental|Proton CSI Followed by Standard of Care (NSCLC & Breast)|Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
11062030|NCT04343573|Experimental|Standard of Care|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
11062031|NCT04343573|Other|Proton CSI Followed by Standard of Care (Other Solid Tumors)|(Exploratory arm) Patients with solid tumor malignancies other than NSCLC or breast cancer will be enrolled to the exploratory proton CSI arm (Arm C) and will not undergo randomization. Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
11062032|NCT04343560||patients with MACS|Patients with adrenal adenoma and dexamethasone suppression test >1.8 mcg/dl
11062033|NCT04343560||healthy controls|no history of adrenal and pituitary disease, no exogenous steroids
11062034|NCT04343547|Experimental|1|
11062035|NCT04343547|Experimental|2|
11062036|NCT04343547|Experimental|Experimental 3|
11062037|NCT04343534||Original Shared Decision Making Process scale|Patients receive the original version of the Shared Decision Making Process scale.
11062038|NCT04343534||Revised Shared Decision Making Process scale|This group completes a new version of the scale with different wording for several items.
11062039|NCT04343521|Experimental|Targeted Indoor Residual Spraying (TIRS)|All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster
11062040|NCT04343521|No Intervention|Control|Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)
11062041|NCT04343508|Experimental|Fortified rice|fortified rice for daily lunch and dinner each day of the week (i.e. 14 meals/week) for six months
11062042|NCT04343469|Active Comparator|Bariatric surgery|The effect of bariatric surgery (RYGB or LSG) on central inflammation
11062043|NCT04343469|No Intervention|No intervention|Healthy lean volunteers
11062044|NCT04343443|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination centered on congestion
~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
11062045|NCT04343430|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination centered on congestion
~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
11062046|NCT04343417||Biorepository|Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
11062047|NCT04343391|Experimental|Brief Individual Psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
11062048|NCT04343391|Experimental|Brief Group Psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
11062049|NCT04343391|Active Comparator|Treatment as usual|Medication provided by a general practitioner.
11062050|NCT04343365||Participants Reviewed by ETB|Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
11062051|NCT04343352|Experimental|In application group; Mobile Epilepsy Training Program Impleme|"Mobile epilepsy training program will be introduced to the parents in the application group and pre-tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale).
~The participants will only use the mobile epilepsy training program application.
~Parents in the application group will be monitored for 3 months using the mobile epilepsy training program. The researcher will follow the participants' use of the mobile application with the interface of the mobile epilepsy training program.
~During the monitoring phase, the Epilepsy Information Questions screen will be given once every 15 days, and the training module will be reopened automatically on missing or incorrect answers and the parent's information on this subject will be renewed.
~- At the end of the 3rd month, posttests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale) will be applied face-to-face."
11062052|NCT04343352|No Intervention|In the control group|"- The purpose of the project will be shared with the parents in the control group, and the pre-tests Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied.
~There is no structured training program in the outpatient functioning. Routine practice of the hospital; is the education and information provided by the physician to the family during the outpatient clinic.
~At the end of the 3rd month, the final tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied face to face.
~After the work is completed, the mobile application will be installed on the phones of the control group, the application will be taught and applied."
11062053|NCT04343326|Active Comparator|accelerated corneal cross linking+ delivery of systemic oxygen|corneal cross linking is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
11062236|NCT04341883|Experimental|anti-PD-1|PD-1+albumin-bound paclitaxel
11062054|NCT04343326|Active Comparator|accelerated corneal collagen cross-linking|corneal cross linking with the same accelerated protocol without additional oxygen therapy.
11062055|NCT04343326|Active Comparator|conventional corneal collagen cross-linking|Conventional corneal cross linking using 30 mW/CM2 UV-A ablation for 30 minutes
11062056|NCT04343313|Experimental|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
11062057|NCT04343300|Other|Control group|Control group without Pilates exercise during 12 weeks Participants were advised to keep their routine Falls diary calendar
11062058|NCT04343300|Experimental|Pilates group|Pilates classes were held twice weekly for one hour. The classes were divided into a warm-up, mat Pilates with accessories and a cool-down. Participants used small items of equipment such as bands, circles or rings, blocks, spyke balls and foam rollers. The intervention lasted 12 weeks; the classes were supervised twice a week. The supervised exercises were evaluated every four weeks (frequency and intensity) focused on the lower limb (muscles related to gait), core and trunk (muscles related to posture). The participants were asked to perform supplementary at-home workouts three times a week using a booklet and video that was provided to the participants. The video and booklet to introduce the six principles of Pilates, warm-up exercises, exercises on the chair, mat Pilates exercises and cool-down exercises. Participants were advised to perform these exercises three times a week for 30 minutes at home.
11062059|NCT04343287|Active Comparator|BRM421 Ophthalmic Solution|A topical solution of BRIM421 ophthalmic drops
11062060|NCT04343287|Placebo Comparator|Placebo|A vehicle ophthalmic drops
11062061|NCT04343261|Experimental|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
11062062|NCT04343248|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks
11062063|NCT04343248|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks
11062064|NCT04343235|Experimental|labetalol + furosemide|labetalol + furosemide
11062065|NCT04343235|Active Comparator|labetalol only|labetalol only
11062066|NCT04343222|Experimental|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
11062067|NCT04343222|Experimental|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
11062068|NCT04343222|Placebo Comparator|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
11062069|NCT04343209||Individuals with confirmed or suspected cardiovascular disease|Individuals in this group will undergo myocardial perfusion imaging, utilizing Ammonia N-13 PET imaging agent. Each individual will receive two intravenous injections of Ammonia N-13 in accordance with site imaging protocol.
11062070|NCT04343196|Experimental|Group A: Low-dose DVA group|Image acquisition at a reduced X-ray dose, 0.36 µGy/frame (70% reduction) image processing by DVA
11062071|NCT04343196|Active Comparator|Group B: Normal-dose DSA group|Image acquisition at a normal dose (1.2 µGy/frame) image processing by DSA
11062072|NCT04343183|Active Comparator|HBOT treatment group|Patients will receive hyperbaric oxygen therapy
11062073|NCT04343183|No Intervention|Standard of Care group|Patients will not receive hyperbaric oxygen therapy and will receive the current standardized treatment protocol
11062074|NCT04343170|Placebo Comparator|control group|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo.
11062075|NCT04343170|Experimental|ultra-short-term treatment|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
11062076|NCT04343144|Experimental|Nivolumab|
11062077|NCT04343144|No Intervention|Standard of Card|
11062078|NCT04343131|Active Comparator|Mediterranean diet|Mediterranean diet for 7 days
11062079|NCT04343131|Active Comparator|Low-carb/high protein diet|Low-carb/high protein diet for 7 days
11062080|NCT04343131|Active Comparator|Reference diet|Reference diet for 7 days
11062081|NCT04343118||Group Removal|All patient receiving surgical removal of plate osteosynthesis
11062082|NCT04343105|Sham Comparator|sham group|will receive sham bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position
11062083|NCT04343105|Experimental|real group|will receive real bilateral ultrasounded guided single shot pecto-intercostal plane block between 3rd and 4th rib 2 cm lateral to sternal border for each side after induction of anaesthesia in supine position with 10 ml bupivacaine 0.5% + 10 ml lidocaine 2% in total volume 20 ml for each side.
11062084|NCT04343092|Experimental|Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)|Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily
11062085|NCT04343079|Experimental|braeast cancer|breast cancer patients
11062086|NCT04343066|Experimental|External hex implant|External hexagone implant connection
11062087|NCT04343066|Experimental|Internal hex implant|Internal implant connection
11062088|NCT04343053|Other|SARS-Cov-2 infection|Single study group of patients with respiratory failure due to SARS-Cov-2 infection. Three blood samples will be collected at different stages of disease: early, defined as first 96 hours, mid, defined as time from 96 hours and 14 days, late. defined as >14 days
11062089|NCT04343040|Experimental|perioperative glucose intake|glucose intolerant patients with perioperative glucose (carbohydrate supplement (Preload™) intake before Gastric By-Pass or Sleeve Gastrectomy.
11062090|NCT04343040|Sham Comparator|6 hours of preoperative fasting|glucose intolerant patients receiving 6 hours of preoperative fasting before Gastric By-Pass or Sleeve Gastrectomy.
11062091|NCT04343027|No Intervention|Standard of care group|Participants who did not have their physicians review their patient-reported outcome measurements with them during the office visit.
11081096|NCT04208412|Placebo Comparator|Placebo|
11062092|NCT04343027|Experimental|Consultation group|Participants who had their physicians review their patient-reported outcome measurements reviewed with them during the office visit.
11062093|NCT04343014|Experimental|Tongue Root Retractor|Patients in this arm will receive fibroscopic endotracheal intubation with tongue root retractors.
11062094|NCT04343014|Active Comparator|Conventional Fibroscope|Patients in this arm will receive fibroscopic endotracheal intubation without any other devices.
11062095|NCT04343001|No Intervention|Standard care|Usual standard of care at the study hospital
11062096|NCT04343001|Experimental|Aspirin|Aspirin 150mg once daily
11062097|NCT04343001|Experimental|Losartan|Losartan 100mg once daily. Dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
11062098|NCT04343001|Experimental|Simvastatin|Simvastatin 80mg once daily
11062099|NCT04343001|Experimental|Aspirin and Losartan|Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
11062100|NCT04343001|Experimental|Aspirin and Simvastatin|Aspirin 150mg once daily and Simvastatin 80mg once daily
11062101|NCT04343001|Experimental|Losartan and Simvastatin|Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
11062102|NCT04343001|Experimental|Aspirin, Losartan and Simvastatin|Aspirin 150mg once daily, Losartan 100mg once daily and Simvastatin 80mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
11062103|NCT04342988|Other|Cequa Treatment In Cataract Patients with Dry Eye Disease|Duration of Study Treatment - 4 weeks All patients will receive cyclosporine ophthalmic solution (0.09%) BID in both eyes for 28 days, 1 drop per dose. Dosing will be BID, both eyes, assuming both eyes will eventually undergo cataract surgery. Otherwise, single eye treatment in the operative eye will be permitted.
11062104|NCT04342975|Active Comparator|Basis|The investigational product, Basis™, contains a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels. Also contains Pterostilbene (Ptero) that is a stilbenoid compound, characterized by two aromatic rings connected by a methylene bridge backbone, and it has two methoxy groups and one hydroxyl group extending from the aromatic rings.
11062105|NCT04342975|Placebo Comparator|Placebo|Correspondent placebo, a capsule not containing the active component.
11062106|NCT04342962|Experimental|Experimental arm|"12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days.
~Patients will receive the study drug until disease progression or in case of toxicity."
11062107|NCT04342936|Experimental|Camrelizumab for Injection|Participants receive Camrelizumab 200mg intravenously (IV) on Day 1 of each 2-week cycle
11062108|NCT04342936|Active Comparator|Chemotherapy|Participants receive investigator's choice of chemotherapy (Gemox, IGEV or DHAP) for up to 6 cycles.
11062109|NCT04342923||Complete cohort|All patients undergoing PD during study period in all participating center/units in Spain.
11062110|NCT04342910|Experimental|camrelizumab (SHR-1210) combined with apatinib|Participants will receive camrelizumab on Day 1 and Day 15 of each 28-day cycle and apatinib mg/day up to 2 years.
11062111|NCT04342910|Active Comparator|Paclitaxel or Irinotecan|Participants receive paclitaxel on Days 1, 8, and 15 of each 28-day cycle, or irinotecan on Days 1 and 15 of each 28-day cycle.
11062112|NCT04342897|Experimental|LY3127804|LY3127804 administered intravenously (IV), with standard of care treatment
11062113|NCT04342897|Placebo Comparator|Placebo|Placebo administered IV, with standard of care treatment
11062114|NCT04342884||Clients of Wake Forest Baptist Health (WFBH)|
11062115|NCT04342884||Health care workers of Wake Forest Baptist Health (WFBH)|
11062116|NCT04342871|Experimental|Fam-CT|Patients will receive access to intervention materials.
11062117|NCT04342858|Other|Standard of care|Control will receive standard oral hygiene instructions (OHI every three months)
11062118|NCT04342858|Active Comparator|Standard of care + Fluoride varnish|Intervention 1 will receive standard OHI and application of topical fluoride varnish containing 5% NaF (Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK) every three months
11062119|NCT04342858|Experimental|Standard of care + Fluoride varnish with Tricalcium phosphate|Intervention 2 will receive standard OHI and application of topical fluoride varnish containing 5% NaF + TCP (Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA) every three months
11062120|NCT04342845|Experimental|Motivational interviewing|The intervention group received an education program in small groups that included no more than ten members. The content was designed based on MI theory and the theory of patient empowerment. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise. Each module started with a brief introduction to relevant background knowledge, which was followed by small-group discussions about personal barriers and techniques for overcoming challenges. During the small group discussions, educators acted as MI facilitators, using group MI techniques to strengthen participants' motivation.
11062121|NCT04342845|Placebo Comparator|Traditional lectures|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI.
11062122|NCT04342832|Active Comparator|Early invasive treatment (cryoballoon ablation)|
11062123|NCT04342832|No Intervention|Standard medical care|
11062124|NCT04342819|Experimental|SGLT2i|Empagliflozin 25 mg per oral once daily
11062164|NCT04342494|Experimental|Enhanced Feedback + Standard Feedback|Participants will receive enhanced feedback from the MyDataHelps study app in addition to standard feedback from the activity tracker.
11062237|NCT04341870|Experimental|Sarilumab + Azithromycin + Hydroxychloroquine|Sarilumab combined with Azithromycin and Hydroxychloroquine
11062125|NCT04342806||HCWs currently working in the US|"The HERO Registry will include HCWs currently working across the United States. For the purposes of this study, a healthcare worker is defined as an individual who currently works in a setting where individuals receive healthcare. (Note: individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as housekeeping, food service, etc.)"
11062126|NCT04342793|Placebo Comparator|Placebo|Placebo
11062127|NCT04342793|Experimental|ALS-L1023 1,200mg|ALS-L1023 600mg twice a day
11062128|NCT04342793|Experimental|ALS-L1023 1,800mg|ALS-L1023 900mg twice a day
11062129|NCT04342754|Experimental|Deep Brain Stimulation ON (DBS ON)|The device will be turned ON
11062130|NCT04342754|Sham Comparator|Deep Brain Stimulation OFF (DBS OFF)|The device will be turned OFF
11062131|NCT04342741|Active Comparator|Foley catheter inpatient|Participants had intracervical ripening with foley catheter after admission into the ward.
11062132|NCT04342741|Active Comparator|Foley catheter outpatient|Participants had intracervical ripening with foley catheter and allowed home.
11062133|NCT04342728|Active Comparator|Ascorbic Acid|8000 mg of ascorbic acid divided into 2-3 doses/day with food.
11062134|NCT04342728|Active Comparator|Zinc Gluconate|50 mg of zinc gluconate to be taken daily at bedtime
11062135|NCT04342728|Active Comparator|Ascorbic Acid and Zinc Gluconate|8000 mg of ascorbic acid divided into 2-3 doses/day with food and 50 mg of zinc gluconate to be taken daily at bedtime.
11062136|NCT04342728|Other|Standard of Care|Standard of care medications only as prescribed by patient's physician.
11062137|NCT04342715||Patients|Patients who have a diagnosis of visceral leishmaniasis and will be treated with SSG/PM
11062138|NCT04342715||Control|Healthy volunteers
11062139|NCT04342689|Experimental|Intervention|Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
11062140|NCT04342689|Placebo Comparator|Control|Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.
11062141|NCT04342676|Experimental|patients|LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
11062142|NCT04342663|Experimental|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
11062143|NCT04342663|Placebo Comparator|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
11062144|NCT04342650|Active Comparator|Intervention|CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration.
11062145|NCT04342650|Placebo Comparator|Placebo|Placebo tables of equal characteristics and duration of treatment.
11062146|NCT04342637||Practicing gastroenterologists|Practicing physicians performing gastrointestinal endoscpy
11062147|NCT04342624|Experimental|Cinnamon|Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.
11062148|NCT04342624|Placebo Comparator|Placebo|Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.
11062149|NCT04342611|Experimental|Patients under the care of TA Oncologist|These patients will be under the care of an oncologist who will be randomized to training in the TA intervention.
11062150|NCT04342611|No Intervention|Patients under the care of Usual Care Oncologist|These patients will be under the care an oncologist who will be randomized to usual care.
11062151|NCT04342598||Adult outpatient pulmonary MDR-TB patients|
11062152|NCT04342598||Household contact controls|
11062153|NCT04342598||Non-household contact controls|
11062154|NCT04342585|Active Comparator|Vaginal progestogen|200mg of vaginal progestogen will be inserted before bedtime every day from time of recruitment until 34 weeks gestation.
11062155|NCT04342585|Active Comparator|Vaginal pessary|Vaginal pessary with an internal diameter size of 32 or 35 mm will be inserted at the time of recruitment and kept until 34 weeks gestation.
11062156|NCT04342572|Experimental|Intra-arterial injections of melphalan|-Participants will receive intra-arterial injections of melphalan Q4W for 3 cycles.
11062157|NCT04342559|Experimental|Group I|"Belamy with sinodor Vaginal Moisturizer with Odor Neutralizer - code: 062603-07
~Participants will be instructed on how to use it as follows:
~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.
~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
11062158|NCT04342559|Experimental|Group II|"Belamy without sinodor Vaginal Moisturizer without Odor Neutralizer - code: 062603-08
~Participants will be instructed on how to use it as follows:
~Guidance The product has individual pre-filled applicators for single use and disposable after use. The applicator has an anatomical shape, in order to facilitate use, avoiding discomfort during application.
~A single application should be performed every 3 days (72 hours). I use it at night, before going to bed, before going to sleep."
11062159|NCT04342546|Experimental|Toxicity test|"For all patients, the NovaGray RILA Breast® test will be performed within 15 days of surgery , 12 months after the end of radiotherapy and in the case of neoadjuvant chemotherapy, within 15 days of starting chemotherapy.
~The test consists of a blood sample of 2x4 mL"
11062160|NCT04342533|Experimental|ThuFLEP|Patients who underwent thulium fiber enucleation of the prostate
11062161|NCT04342533|Active Comparator|HoLEP|Patients who underwent holmium laser enucleation of the prostate
11062162|NCT04342507|Other|Group A: conservative|conservative treatment with lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
11062163|NCT04342507|Experimental|Group B: probiotics|in addition to the conservative treatment they receive probiotics mixture (Streptococcus thermophilus, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus) once a day up to 3 months.
11062232|NCT04341909||Trainee Group|Patients who undergo ERCPs with trainee involvement
11062165|NCT04342494|Experimental|Headspace app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
11062166|NCT04342494|Experimental|Headspace app + Enhanced Feedback + Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback activity tracker.
11062167|NCT04342494|Experimental|SilverCloud app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
11062168|NCT04342494|Experimental|SilverCloud app +Enhanced Feedback +Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback from the activity tracker.
11062169|NCT04342455|No Intervention|traditional scanning protocol group|In coronary CTA examination,each subject will be injected 50 ml contrast agent (Iodixanol 320) with the flow rate of 5 ml/s in tube voltage of 120 kVp.
11062170|NCT04342455|Experimental|double-low scanning protocol group|In coronary CTA examination,the tube voltage(70，80,100kVp),contrast agent(Iodixanol 320) volume and flow rate of each subject are adapted to his or her cardiac ejection fraction(EF) and body mass index(BMI).
11062171|NCT04342442||Steroid-refractory a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-refractory a GvHD
11062172|NCT04342442||Steroid-responsive a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-responsive a GvHD
11062173|NCT04342429|Experimental|Prospective Study of Intensity-Modulated Proton Therapy (IMPT)|This is the first prospective study to investigate the safety and efficacy of IMPT for the treatment of SCLC. We will utilize adaptive planning throughout the radiation course. In addition, we will study the dosimetric parameters of IMPT and their correlation with treatment-related toxicities, particularly cardiac events.
11062174|NCT04342416|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):
~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
~Experimental: Intervention phase ('B'):
~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
~Intervention: Behavioral: Brief cognitive intervention"
11062175|NCT04342403||Sarcoidosis|Patients with sarcoidosis willing to participate
11062176|NCT04342390|Experimental|HIIT Intervention|Study participants will be asked to complete 8 high-intensity interval training (HIIT) sessions in 2-4 weeks.
11062177|NCT04342377|Experimental|Selective Targeted Sampling|"During patients' Endobronchial Ultrasound (EBUS) procedure, they will first undergo:
~Selective Targeted Sampling - endosonographic assessment of at least 3 mediastinal lymph node stations (4R, 4L, and 7) using the four criteria of the Canada Lymph Node Score (predictor of nodal disease during Endobronchial Ultrasound). Each lymph node will be assigned a CLNS ranging from 0 to 4. Triple Normal lymph nodes will be defined as those that appear normal on CT (diameter < 1 cm), AND normal on PET (SUV < 2.5), AND normal on EBUS (CLNS < 2). Lymph nodes that are found to be Triple Normal will be marked as Not for Biopsy, whereas all other lymph nodes will be biopsied."
11062178|NCT04342377|Active Comparator|Systematic Sampling|"Upon completion of Systematic Targeted Sampling, all patients will crossover and receive the standard of care:
~Systematic Sampling - all lymph nodes previously marked as Not for Biopsy will be biopsied.
~At the conclusion of the EBUS procedure, all nodal stations would have been sampled as is mandated by current guidelines."
11062179|NCT04342364|Active Comparator|Slush nitrogen|oocytes are randomized to undergo vitrification utilizing slush nitrogen
11062180|NCT04342364|Active Comparator|Liquid Nitrogen|oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care
11062181|NCT04342351|Experimental|Experimental: sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months
11062182|NCT04342351|Active Comparator|Active Comparator: perindopril|perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months
11062183|NCT04342325|Experimental|ADR-001|Intravenous infusion of ADR-001 (Mesenchymal stem cell)
11062184|NCT04342299||Responders|"Responders are participants who show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.
~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
11062185|NCT04342299||Non-responders|"Non-responders are participants who do not show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.
~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
11062186|NCT04342273|Experimental|KW-6356 therapeutic dose|Oral administration
11062187|NCT04342273|Experimental|KW-6356 supratherapeutic dose|Oral administration
11062188|NCT04342273|Placebo Comparator|Placebo|Oral administration
11062189|NCT04342273|Active Comparator|Moxifloxacin|Oral administration
11062190|NCT04342260|Experimental|Active Monitoring|
11062191|NCT04342260|Active Comparator|Passive Monitoring|
11062192|NCT04342247||androgen deficient|
11062193|NCT04342247||healthy|
11062194|NCT04342221|Experimental|Hydroxychloroquine Sulfate|First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
11062195|NCT04342221|Placebo Comparator|Placebo|Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)
11062196|NCT04342182|Experimental|Convalescent plasma|Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
11062197|NCT04342182|No Intervention|Standard of care|standard of care (supportive care, oxygen, antibiotics)
11062233|NCT04341909||control group|Patients who undergo ERCPs without any trainee involvement
11062234|NCT04341896||Caregivers|Prior obese living kidney donors who served as the primary caregiver for their recipient
11062198|NCT04342169|Experimental|HCQ|Participants randomized to the HCQ arm will receive HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days. The drug dose (2.4 gm over 5 days) falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
11062199|NCT04342169|Placebo Comparator|Placebo|Those randomized to placebo will receive a placebo to be taken on the same schedule.
11062200|NCT04342156|Experimental|Intervention|"Treatment arm will be given Hydroxychloroquine sulfate. Dose: 800 milligrams (mg) (4 pills of 200mg) in two divided doses on day 1 followed by 400mg (2 pills of 200mg) in two divided doses on day 2, 3,4, 5.
~Mode of administration: Oral pills of 200mg of HCQ; Supply: The total supply of all the pills (12 pills of 200mg per subject in the study group) will be given to the recruited subject from day 1."
11062201|NCT04342156|Other|Standard Preventive Measures|No intervention. Standard recommended preventive measures by the ministry of health.
11062202|NCT04342143||Stroke|Patients who have a diagnosis of stroke by a stroke consultant from UK National Health Service Trust within 3 months to 5 years of study start date.
11062203|NCT04342130|Experimental|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
11062204|NCT04342117||Duvelisib|Patients who take duvelisib.
11062205|NCT04342117||Other PI3K-inhibitors|Patients who take a PI3K-inhibitor other than duvelisib
11062206|NCT04342104||NIV|Patients on Bilevel NIV
11062207|NCT04342104||CPAP|Patients on CPAP
11062208|NCT04342091|Experimental|Microneedling|Participants with fibrosing alopecia will receive microneedling with a tattoo machine.
11062209|NCT04342078||Preterm Child group|Preterm children at the age of 5 years; Born before 34 gestation weeks in 2014-2017; Cared in Oulu University Hospital
11062210|NCT04342078||Preterm Adult group|Preterm born adults at the age of 24-25 years; Born before 34 gestation weeks in 1994-1997; Cared in Oulu University Hospital
11062211|NCT04342078||Adult Control group|Age and gender matched term born controls for comparison of the entry assessments in the Preterm Adult group
11062212|NCT04342065|Active Comparator|Group (G)|received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.
11062213|NCT04342065|Active Comparator|Group (C)|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
11062214|NCT04342039|Placebo Comparator|Placebo|Participants will use a placebo nasal spray before being exposed to a series of allergen and pollution challenges.
11062215|NCT04342039|Active Comparator|Budesonide nasal|Participants will use budesonide nasal spray before being exposed to a series of allergen and pollution challenges.
11062216|NCT04342026||Parent of patient with cryptorchidism|parent exposition of endocrine disruptors
11062217|NCT04342026||Parent of patient without cryptorchidism|Parent exposition of endocrine disruptors
11062218|NCT04342013|Experimental|Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations with use of the clinical decision support application in the perioperative setting.
11062219|NCT04342013|No Intervention|No Perioperative Clinical Decision Support Application|Participants will be observed performing clinical tasks and documenting medication administrations without use of the clinical decision support application in the perioperative setting.
11062220|NCT04342000|Experimental|Intervention Group|Movement Education Workshop
11062221|NCT04342000|Sham Comparator|Control Group|Sham Education Workshop
11062222|NCT04341987|Experimental|brief Imagery Rehearsal Therapy|"The brief two-session, behaviorally-based imagery rehearsal intervention is based on components from previous group and individual formats that have been published, but will be presented in an abbreviated manner. In the first session, Veterans will be presented with psychoeducation about dreaming, basics of sleep hygiene and stimulus control techniques, how to change negative dreams from a learned habit perspective, re-scripting, and how to rehearse new dream imagery. They will then be asked to complete in-session practice of imagery rehearsal with the new imagery developed. Veteran will be instructed in practice post-session."
11062223|NCT04341987|Other|Treatment As Usual|Patients in this condition are free to receive treatment as usual for nightmares, which may be a medication, supportive counseling or no treatment.
11062224|NCT04341974||surgical patients|Adult patients undergoing major elective general abdominal surgery for ontological disease
11062225|NCT04341961|Experimental|Pom Juice|The study participants will all be asked to drink pomegranate juice for 2 weeks, and 4 weeks of continued usual diet and avoid pomegranate juice (other than what is given to you), berries (strawberries, blackberries, raspberries (red, black, yellow), cranberries), walnuts, pecans, hazelnuts, pecans, chestnuts, red and white guava, pomegranates, flaxseeds, dark chocolate and cocoa, coffee, tea, rose hip, olives, artichoke, dried herbs and beefsteak tongue mushrooms).
11062226|NCT04341948|Active Comparator|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
11062227|NCT04341948|Sham Comparator|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
11062228|NCT04341935|Experimental|DPP4 group|Participants in the Dipeptidyl Peptidase 4 (DPP4) group will receive Linagliptin in addition to standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
11062229|NCT04341935|Active Comparator|Control group|Participants in the control group will receive only the standard of care insulin regimen as per hospital protocol during hospitalization for up to 14 days
11062230|NCT04341922|Experimental|Intervention: Online Cognitive-Behavioral intervention|The three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
11062231|NCT04341922|No Intervention|Wait-list|The wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).
11062239|NCT04341857|Experimental|Sintilimab combined with FLOT regimen|Oxaliplatin#80mg/m2d1#iv infusion for 2 hours# Calcium leucovate#200mg/m2d1#iv infusion# Fluorouracil#2600mg/m2,intravenous drip for 24h# Docetaxel#50mg/m2,intravenous drip for 1 h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
11062240|NCT04341844|Experimental|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
11062241|NCT04341844|Placebo Comparator|Control|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
11062242|NCT04341831|Experimental|Group 1|We will be added 200mg teicoplanin powder around instrument for each level.
11062243|NCT04341831|No Intervention|Group 2|We will not used any antibiotic powder in this group.
11062244|NCT04341818|Experimental|Strength Training and Vitamin D monthly|Four weeks of Vitamin D (50.000 IU once per month) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
11062245|NCT04341818|Experimental|Strength Training and Vitamin D daily|Four weeks of Vitamin D (800 IU once per day) followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
11062246|NCT04341818|Experimental|Strength Training and no Vitamin D|Four weeks of no vitamin D administration followed by a 10 week guided resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D intake remains. Over the whole study period participants get 400 mg calcium/day.
11062247|NCT04341805|Active Comparator|Group A. Physiological saline.|The surgical procedure in group A consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial was administered (Ecolav Physiological Washing Serum 0.9%, (SSF).
11062248|NCT04341805|Experimental|Group B. Solution hyperoxygenated fatty acids|The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
11062249|NCT04341779|Experimental|Intervention arm|Point-of-care adherence testing and Point-of-care viral load testing
11062250|NCT04341779|No Intervention|Standard-of-care arm|No adherence testing and lab-based viral load testing
11062251|NCT04341766||Patient hospitalised with COVID-19 infection|Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
11062252|NCT04341753|Experimental|Pulmonary rehabilitation|"In addition to the usual evaluation, other tests will be carried out in addition and specifically for this study:
~the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);
~2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
11062253|NCT04341740|Experimental|Marrow Infiltrating Lymphocyte Isolation and Expansion|Each patient in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate.
11062254|NCT04341727|Active Comparator|Hydroxychloroquine alone|Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
11062255|NCT04341727|Active Comparator|Hydroxychloroquine plus azithromycin|"Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.
~AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets."
11062256|NCT04341727|Active Comparator|Chloroquine alone|Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
11062257|NCT04341727|Active Comparator|Chloroquine plus azithromycin|"Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.
~AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets."
11062258|NCT04341714||patients enrolled|Patients with telephone consultation on neurourology department, age > 18
11062259|NCT04341701|Other|COPD|COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist
11062260|NCT04341701|Other|Asthma|asthma according to GINA 2019 but without any smoking restriction
11062261|NCT04341688|Experimental|Povidone-Iodine 0.2% (BETADINE®)|0.2% Povidone-Iodine (BETADINE®) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
11062262|NCT04341688|Experimental|Hydrogen peroxide 1% (ActiveOxy)|ActiveOxy (1% Hydrogen peroxide) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
11062263|NCT04341688|Active Comparator|Neem extract (Azadirachta indicia)|Neem extract (Azadirachta indicia) gargle will be prepared by chemistry laboratory. patients will do 10ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
11062264|NCT04341688|Active Comparator|Hypertonic saline (2%NaCl)|10 ml gargle and nasal lavage using Hypertonic saline for 20-30 seconds, thrice daily for 6 days.
11062265|NCT04341688|Placebo Comparator|Positive controls|10 ml gargle and nasal lavage using distilled water for 20-30 seconds, thrice daily for 6 days.
11062266|NCT04341675|Active Comparator|Sirolimus|Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
11062267|NCT04341675|Placebo Comparator|Placebo|Matching placebo
11062326|NCT04341324||Control arm: Subjects do not plan to receive hormonal therapy|"Control subject:
~Male patients 18 years or older
~Adenocarcinoma of the prostate either histologically or cytologically confirmed
~Able to consent for the participate in the study"
11062359|NCT04341168||Control group|all ages, any respiratory tract infection, subgroups will be established
11062268|NCT04341662|Experimental|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination & Escalation; and 3) an implementation strategy, focusing on simulation-based training, peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with action line, and MOTIVE emergency kits."
11062269|NCT04341662|Active Comparator|Usual care|Usual care with dissemination of the current guidelines
11062270|NCT04341649|Active Comparator|Head massage by therapist|Head massage therapist will practice massage covering the scalp, front head, occipital area and neck.
11062271|NCT04341649|Active Comparator|Helmet massage BREO|Breo helmet will be installed for massaging the head at different defined places.
11062272|NCT04341649|Active Comparator|Low Laser Therapy|Laser light can penetrate the skin and stimulate the nervous connections. The investigators will use a laser pen (Min Sheng).
11062273|NCT04341649|Active Comparator|Sham Low Laser Therapy|The investigators will use the same laser pen, but without laser beam.
11062274|NCT04341649|Active Comparator|TENS ear stimulation|The investigators will use the (Hwato) device that provides electrical pulse at various frequency and intensity. This TENS device is a prototype modified for ear stimulation.
11062275|NCT04341649|Active Comparator|Deep and Slow breathing|This intervention is guided by an app that leads to a full respiratory.
11062276|NCT04341649|Sham Comparator|Relaxed Reading time|Participants will read the newspaper in a quiet environment.
11062277|NCT04341636|Experimental|vertical bitewing|All of the bitewing radiographs will be evaluated by two experienced restorative dentists for caries. All observers will be instructed on the definition of the rating scale before the examination sessions. The observers will be using the following a 5-point confidence scale as follows: 1=caries definitely absent; 2=caries probably absent; 3=equal chance of caries being present or absent; 4=caries probably present; 5=caries definitely present. If caries was detected a second 5-point confidence scale as follows: 1=caries mostly absent (< 25%); 2=caries slightly presence( 25%-50%) ; 3=about half of the border are presence; 4=caries probably clear ( most boarders are presence); 5=caries definitely clear ( all borders are presence ).
11062278|NCT04341636|Active Comparator|horizontal bitewing|All of the bitewing radiographs will be evaluated by two experienced periodontist for bone loss measurements. The steel wire will be used to determine the magnification factor as explained by G Li et al. 8 The steel wire and cemento enamel junction (CEJ) - if not obscure by caries - will be used as reference points for bone loss measurements. Each tooth will be measured mesially and distally twice and all these measurements will be adjusted using the steel measurement.9 All the measurements will be conducted using IC measure INK software.
11062279|NCT04341623|Other|Control Group|All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis
11062280|NCT04341623|Other|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence.
11062281|NCT04341623|Other|GPSkin group|The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily.
11062282|NCT04341610|Active Comparator|ASC|100 million allogeneic adipose-derived mesenchymal stromal cell
11062283|NCT04341610|Placebo Comparator|Placebo|Saline
11062284|NCT04341597|Experimental|transperineal sonographic cervix assessment|
11062285|NCT04341597|Active Comparator|endovaginal sonographic cervix assessment|
11062286|NCT04341584|Experimental|ANAKINRA|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).
~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
11062287|NCT04341584|No Intervention|Standard of care|
11062288|NCT04341571|Experimental|Probiotics|15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
11062289|NCT04341571|Experimental|Metformin|15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
11062290|NCT04341558|No Intervention|Baseline|During this baseline period, postoperative monitoring will be continued as normal by nursing and medical staff without intervention. No training of family members will take place
11062291|NCT04341558|Active Comparator|Intervention|Family carers will be trained to perform and document basic vital signs whilst they provide personal care to their relatives after surgery in order to supplement patient monitoring conducted by nursing staff.
11062292|NCT04341545|Experimental|Letrozole|Participants will be given letrozole 10mg daily for one week after standard medical management for tubal ectopic pregnancy by methotrexate injection. Subsequently they will receive the standard management for medical management of tubal ectopic prengnacies.
11062293|NCT04341545|Placebo Comparator|Placebo|Participants will be given identical looking placebo for one week and receive the same standard management for medical management of tubal ectopic pregnancies.
11062294|NCT04341519||Family members|"Age>18y
~Non-opposition to participate to the telephone interviews
~One family member per patient: the family member the most implicated in the patient's care
~3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited."
11062325|NCT04341324||Active arm: Subjects received hormonal therapy|"Study subject inclusion criteria
~Male patients 18 years or older
~Adenocarcinoma of the prostate either histologically or cytologically confirmed
~Decided to be put on ADT -bilateral orchidectomy or luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist, with or without additional antiandrogen
~After ADT performed, serum testosterone level should reach castrated level, i.e. < 50 ng/dL after 6 weeks of treatment
~Able to consent for the participate in the study"
11062295|NCT04341519||Patients|"Patients:
~Age>18y
~Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic
~Having received invasive or noninvasive mechanical ventilation
~Non-opposition to participate to the telephone interviews.
~3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.
~COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)
~Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia
~Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs."
11062296|NCT04341519||healthcare providers|Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
11062297|NCT04341506||Participant ECG|The study has one arm, I.e., we will collect daily ECGs in 100 participants and track their ECG over three months. We will then compare ECGs pre and post COVID-19 diagnosis in any participant diagnosed with COVID-19 to assess for any early ECG changes that may aid with diagnosing.
11062298|NCT04341493|Experimental|Nitazoxanide + hydroxychloroquine|Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
11062299|NCT04341493|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200 mg PO every 12 hours for 7 days
11062300|NCT04341480||Chemotherapy group|Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
11062301|NCT04341480||Control group|No treatment, based on patient's choice. Total observation duration is 6 weeks.
11062302|NCT04341467|Experimental|Amisulpride group|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
11062303|NCT04341467|Active Comparator|Olanzapine group|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
11062304|NCT04341454|Experimental|DWP14012 X mg QD|"Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo
~Evening: 1 tablet of DWP14012 Y mg placebo"
11062305|NCT04341454|Experimental|DWP14012 Y mg BID|"Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg
~Evening: 1 tablet of DWP14012 Y mg"
11062306|NCT04341454|Placebo Comparator|placebo|"Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo
~Evening: 1 tablet of DWP14012 Y mg placebo"
11062307|NCT04341441|Active Comparator|Study Drug - Daily Dose|The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
11062308|NCT04341441|Active Comparator|Study Drug - Weekly Dose|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
11062309|NCT04341441|Active Comparator|Placebo|All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
11062310|NCT04341441|Active Comparator|Non-Randomized Active Comparator|A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.
11062311|NCT04341428|Experimental|DWP14012 20mg|Orally, once daily
11062312|NCT04341428|Active Comparator|Lansoprazole 15mg|Orally, once daily
11062313|NCT04341415|Experimental|Auricular neuromodulation|
11062314|NCT04341415|Sham Comparator|Control|
11062315|NCT04341402|Experimental|Experimental|miconazole 3% & diclofenac sodium 1% & urea 40% in topical gel daily for 6 months.
11062316|NCT04341389|Active Comparator|Arm 1|1×10^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
11062317|NCT04341389|Active Comparator|Arm 2|5×10^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
11062318|NCT04341389|Placebo Comparator|Arm 3|Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
11062319|NCT04341376|Experimental|Enhanced First Connections|Enhanced First Connections is a short-term risk assessment and response home visiting referral program. The goal of Enhanced First Connections is to identify family needs and link families to community resources, including evidence based home visiting models. Enhanced First Connections includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation. Women who enroll in Enhanced First Connections are expected to receive between four and eight home visits before being referred to other community resources.
11062320|NCT04341376|No Intervention|Treatment as Usual|Women who receive Treatment as Usual will follow the usual course of clinical care throughout their pregnancy and into the postpartum period, and will be eligible for the typical array of community services that may be offered to them.
11062321|NCT04341363|Experimental|Microneedling|Participants with androgenic alopecia will receive microneedling with a tattoo machine.
11062322|NCT04341350|Active Comparator|Usual sedation|Sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug of morphine type, on a maximum target sedation objective (sedation score)
11062323|NCT04341350|Experimental|Inhaled sedation|Sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a pain reliever of morphine type, up to the criteria of ventilatory withdrawal.
11062324|NCT04341337||expert|interviews of expert of pipac about ethical issues
11062327|NCT04341311|Experimental|Marizomib|"All patients will initially receive marizomib (MRZ) alone (Course A1) The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design
~-Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses."
11062328|NCT04341311|Experimental|Marizomib + Panobinostat|"If tolerated,combination of Marizomib: and panobinostat on subsequent cycles. The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design.
~Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses.
~Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course"
11062329|NCT04341298|Experimental|Avulux® device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
11062330|NCT04341298|Sham Comparator|Control/sham device|Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
11062331|NCT04341285|Active Comparator|Early ECMO|Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
11062332|NCT04341285|Active Comparator|Late ECMO|Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.
11062333|NCT04341272|Active Comparator|Upper Extremity Compression Device|Patients randomized to have pneumatic compression device placed on upper extremity following surgery
11062334|NCT04341272|Other|Control|Patients randomized to have pneumatic compression device placed on lower extremity following surgery
11062335|NCT04341259|Experimental|Ipatasertib as a Single Agent|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD). This study has three study periods: a screening period (up to 14 days in length), followed by a treatment period of up to approximately 2 years (Cycle 1 will be 35 days in length, all subsequent cycles will be 28 days in length) and a 28-day follow-up period after the treatment discontinuation or study completion.
11062336|NCT04341246||Cases|Cases are defined as those patients who have undergone liver biopsy and have confirmed NASH and fibrosis
11062337|NCT04341246||Controls|Controls are patients have undergone a liver biopsy with neither significant NASH nor significant fibrosis
11062338|NCT04341220|Experimental|Anodal tDCS + Exercise|Anodal tDCS applied over primary motor cortex (M1) - Dose: 1mA, 20 minutes + ( concomitantly) protocol of specific exercises for balance
11062339|NCT04341220|Sham Comparator|Sham tDCS + Exercise|Sham tDCS applied over primary motor cortex (M1) - Dose: 1mA, 30 seconds ON, + (concomitantly) protocol of specific exercises for balance
11062340|NCT04341207|Experimental|Cohort 1|Advanced Cancer Patients with SARS-CoV-2 positive test & Covid19 symptoms
11062341|NCT04341207|No Intervention|Cohort 2|Advanced Cancer Patients with SARS-CoV-2 negative test & Covid19 symptoms. Patients with a chest CT-scan compatible with Covid19 disease shall be treated in part B.
11062342|NCT04341207|No Intervention|Cohort 3|Advanced Cancer Patients with SARS-CoV-2 positive or negative test & no Covid19 symptoms
11062343|NCT04341207|Experimental|Cohort 4|Advanced Cancer Patients with SARS-CoV-2 positive test AND chest CT-scan compatible with Covid19 disease & no Covid19 symptoms & Pretreated or with frail conditions following the HCSP definition
11062344|NCT04341194|No Intervention|Standard care with glucose|Control Group with standard care comprises facilitated tucking done by a nurse or the parent, oral glucose (300 mg/ml) and the opportunity to suck on a pacifier or on a parent's or a nurse's plastic gloved finger. The infant is placed on an examination table for the venipuncture.
11062345|NCT04341194|Experimental|Skin-to-skin contact|Skin-to-skin contact is a method widely used in neonatal care globally. The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
11062346|NCT04341194|Experimental|Skin-to-skin contact/breastfeeding/parental singing|Parent-driven interventions are skin-to-skin care, breastfeeding and multi-sensory stimulation like vocalisation. They are all a combination of multiple sensory inputs comprising auditory, tactile and olfactory recognition. Research has started to investigate breastfeeding in combination with Kangaroo-mother- care for example, which has shown to be an effective mix. A multimodal approach that includes a combination of non-pharmacological approaches is considered more effective during venipuncture than single strategies and provides greater pain relief.
11062347|NCT04341181|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
11062348|NCT04341181|Experimental|Atezolizumab|Atezolizumab for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab.
11062349|NCT04341181|Experimental|Avelumab|Avelumab for patients with a molecular tumor profile that can potentially be targeted by Avelumab.
11062350|NCT04341181|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
11062351|NCT04341181|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by Erlotinib.
11062352|NCT04341181|Experimental|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib plus Cobimetinib.
11062353|NCT04341181|Experimental|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab plus Pertuzumab.
11062354|NCT04341181|Experimental|Trastuzumab emtansin|Trastuzumab emtansin for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab emtansin.
11062355|NCT04341181|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by Vismodegib.
11062356|NCT04341181|Experimental|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by Niraparib.
11062357|NCT04341168||Children and Adolescents with COVID-19|age range: newborn - 18 years old, subgroups will be established
11088617|NCT04155996||data collection|20 patients
11062360|NCT04341155|Active Comparator|Dexamethasone|"Eighty patients will be administered randomly dexamethasone 20 mg IV for 7 days.
~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) along with folic acid 1x1 tablet in accordance to national neurologist association guidelines."
11062361|NCT04341155|Placebo Comparator|Placebo|"Eighty patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days.
~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) along with folic acid 1x1 tablet in accordance to national neurologist association guidelines."
11062362|NCT04341142|Experimental|Serological tests will be applied on patients blood sampling|Serological tests will be applied on patients blood sampling
11062363|NCT04341129|Experimental|Abbreviated MRI using Dotarem|Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. The shorter imaging times achieved with the abbreviated DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol using Dotarem® (Gadoterate Meglumine) by comparing the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol.
11062364|NCT04341116|Experimental|TJ003234 6 mg/kg|
11062365|NCT04341116|Experimental|TJ003234 3 mg/kg|Part 1 only
11062366|NCT04341116|Placebo Comparator|Placebo|
11062367|NCT04341090|Experimental|Arm 1|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after low-fat meal, the third dose will be after high-fat meal
11062368|NCT04341090|Experimental|Arm 2|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after fasted, the third dose will be after low-fat meal
11062369|NCT04341090|Experimental|Arm 3|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after high-fat meal, the third dose will be after fasted
11062370|NCT04341090|Experimental|Arm 4|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after high-fat meal, the third dose will be after low-fat meal
11062371|NCT04341090|Experimental|Arm 5|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after fasted, the third dose will be after high-fat meal
11062372|NCT04341090|Experimental|Arm 6|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after low-fat meal, the third dose will be after fasted
11062373|NCT04341077|Experimental|SHR3162|A single dose of fluzoparib was administered orally
11062374|NCT04341064|Experimental|SHINE|Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
11062375|NCT04341064|No Intervention|Standard Education|Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.
11062376|NCT04341051||Case|we will observe the regional saturation of O2 through NIRS at the following time: T0(before peripheral anesthesia); T1 (5 minutes from the block); T2 (15 minutes from the block); T3 (30 minutes from the block); T4 (after revascularization); At each interval PA, SpO2 and NIRS were also recorded in the contralateral limb as control data.
11062377|NCT04341038|Experimental|Intervention|"Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml.
~In addition, these patients can receive all the treatments considered necessary for their clinical management."
11062378|NCT04341038|No Intervention|Usual care|These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.
11062379|NCT04341012||Normal|No known medical conditions
11062380|NCT04341012||Liver Cirrhosis|Clinically diagnosed with cirrhosis
11062381|NCT04341012||COVID-19 tested|Persons with known test results for COVID-19 RNA
11062382|NCT04341012||Other|Persons with other medical diagnosis, no known liver disease, negative for COVID-19
11062383|NCT04340999||Manifested Group|Manifested Group , enrolled patients who had any of the following manifestations(Fatigue,muscle cramps or numbness)
11062384|NCT04340999||Non-Manifested Group|Non-manifested group in which enrolled patients didn't report any of the following manifestations
11062385|NCT04340986||patients with Hepatocellular carcinoma|
11062386|NCT04340986||patients with Cholangiocarcinoma|
11062387|NCT04340973|Active Comparator|Anodal|Anodal tDCS: Anode placer over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11062388|NCT04340973|Active Comparator|Bilateral|Bilateral : Anode placer over the affected primary motor cortex, cathode over unaffected motor cortex. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11062389|NCT04340973|Active Comparator|Cathodal|Cathodal : Cathode placer over the unaffected primary motor cortex, anode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11062390|NCT04340973|Active Comparator|Extracephalic|Extracephalic : Anode placer over the affected primary motor cortex, cathode over right shoulder. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11062391|NCT04340973|Placebo Comparator|Placebo|Placebo : anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
11062445|NCT04340596|Experimental|Arm A: N-803 only|Participants will receive N-803 6 mcg/kg 1 week after Step 2 entry and then every 3 weeks for a total of eight doses.
11062392|NCT04340960|No Intervention|Control Group|"The control group will not be monitored with continuity of care. After this period 30 day emergency department visits will be measured and compared between the two groups, along with 30 day readmission rates, in-hospital length of stay, mortality, quality of recovery 40 item scale (QoR-40), European Quality of LIfe 5 Dimensions (EQ5D), patient satisfaction score, and societal and hospital cost.
~No intervention will be administered."
11062393|NCT04340960|Experimental|Home Monitoring Group|At the time of hospital discharge, the control group will be discharged without receipt of home monitoring and the intervention group will receive a home monitoring kit with (NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and ECG (electrocardiogram)) with instructions on how to use these devices. Patients in the intervention groups will receive digital communication for 4 weeks and have their ECG, NIBP, HR (heart rate), SPO2 and pain scores evaluated 4 times a day for 2 weeks.
11062394|NCT04340947|Other|Menthol very low nicotine cigarette|Participants will smoke menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one menthol flavored very low nicotine cigarette in the laboratory.
11062395|NCT04340947|Other|Non-menthol very low nicotine cigarette|Participants will smoke non-menthol flavored very low nicotine cigarettes in their home environment for 7 days. At the end of 7-days, they will also smoke one non-menthol flavored very low nicotine cigarette in the laboratory.
11062396|NCT04340934|Experimental|Use of REZUM system|Surgery of benign prostatic hyperplasia by REZUM system
11062397|NCT04340921||1. COVID-19+ (n=120)|"COVID-19 positive without evidence of myocardial injury (n=120). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection.
~Exclusion criteria: No biochemical evidence of acute myocardial injury (serum troponin>99th centile within previous 48-hour period)."
11062398|NCT04340921||2. COVID-19+ Myocardial injury+ (n=20)|"COVID-19 positive with myocarditis (n=20). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection and clinically suspected or confirmed myocarditis including evidence of acute myocardial injury (troponin >99th centile within the previous 48-hour period) at the time of recruitment.
~Exclusion criteria: significant chronic kidney disease (eGFR ≤30 or dialysis-dependent) or septic shock at the time of initial assessment. We will also exclude patients with a diagnosis of chronic heart muscle disease and those with known significant chronic or acute obstructive coronary disease."
11062399|NCT04340921||3. COVID-19+ Complication+ (estimated 10-25%)|Inclusion criteria: Participants form Groups 1 and 2 in whom a prespecified complication ocurs will be included in a derived Group3.
11062400|NCT04340908|Experimental|Treatment|Dapagliflozin 10 mg tablet
11062401|NCT04340908|Placebo Comparator|Control|matching placebo tablet
11062402|NCT04340895|Experimental|Intervention arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on participant self-monitoring of FC values and/or clinical symptoms (patient-reported outcome-2 [PRO-2] scoring).
~The FC Test and/or PRO-2 scoring will be done by the participant at home every month during active disease, every 3 months in remission, or when a participant feels the need/presents clinical symptoms."
11062403|NCT04340895|Active Comparator|Reference arm|"Treatment optimization (escalation/de-escalation) performed by the investigator based on clinical symptoms (PRO-2 scoring) only.
~The PRO-2 scoring will be assessed during clinic visits every 3-months during active disease, every 6 months during remission, or when a participant feels the need; as per recommended standard practice."
11062404|NCT04340882|Experimental|Treatment (docetaxel, ramucirumab, pembrolizumab)|Patients receive docetaxel IV over 60 minutes, ramucirumab IV over 60 minutes, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11062405|NCT04340869|Experimental|Theobromine|Natural extract from Cocoa
11062406|NCT04340869|Active Comparator|Remin Pro|Fluoride , Hydroxyapatite , and Xylitol
11062407|NCT04340869|Experimental|Combination|Remin Pro and Theobromine
11062408|NCT04340843|Experimental|Treatment (belinostat, guadecitabine)|Patients receive guadecitabine SC and belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11062409|NCT04340830|Experimental|smoker|Those consuming at least 10 cigarette a day for ten years were included in smoker group.
11062410|NCT04340830|Active Comparator|non-smoker|Patients who never smoke were included in non-smoker group. Patients who quit smoking were not included in this group.
11062411|NCT04340804|Experimental|Kcal labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal counter synchronised with the food amount changes (i.e., increasing/decreasing).
11062412|NCT04340804|Experimental|PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes (i.e., increasing/decreasing) with 4 min being equivalent to 20 kcal.
11062413|NCT04340804|Experimental|Kcal and PACE labelling|Participants allocated to this group will see on the screen the amount of food increasing or decreasing based on how many times they tap on the corresponding keys and a real-time kcal and PACE counters synchronised to the food amount changes (i.e., increasing/decreasing).
11062414|NCT04340804|No Intervention|No labelling|Participants allocated to this group will only see on the screen the amount of food increasing or decreasing based how many times they tap on the corresponding keys.
11062415|NCT04340791|No Intervention|Default proportion & no labelling|"No intervention:
~Default proportion condition (33% lower energy density items - 67% higher energy density items). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
~No labelling."
11062416|NCT04340791|Experimental|Default proportion & labelling|"When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
11062478|NCT04340310||Home respiratory poligraphy|Group A: Children between 4 and 14 years-old with initial OSA suspicion there will be allocated to Home Respiratory Polygraphy (HRP)
11062417|NCT04340791|Experimental|Increased proportion & no labelling|The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
11062418|NCT04340791|Experimental|Increased proportion & labelling|"The proportion of lower energy density items vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (33% lower - 67% higher). Lower energy density items will be defined as lower ED ≤ median of ED distribution within a food category.
~When energy density of a food item ≤ median of energy density distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions will introduce the badges to the participants as In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
11062419|NCT04340778|Experimental|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion.
11062420|NCT04340778|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
11062421|NCT04340778|Placebo Comparator|placebo|inert placebo Cream will be applied on the cervix at the time of copper IUD insertion plus vaginal placebo tablet 3 hours before IUD insertion
11062422|NCT04340765|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
11062423|NCT04340752|Experimental|Group 1:ICG 7.5 mg|Subjects in this group are randomized to receive 7.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
11062424|NCT04340752|Experimental|Group 2:ICG 12.5 mg|Subjects in this group are randomized to receive 12.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
11062425|NCT04340752|Experimental|Group 3: ICG 25 mg|Subjects in this group are randomized to receive 25 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
11062426|NCT04340739||Cohort 1 (8 Patients)|A wireframe mock-up of the GEMINI platform will be usability tested by 8 chronic pain patients from whom feedback will be collected by completing a virtual semi-structured interview. Outcomes: Quantitative Testing Data from Usability Testing Prompt. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
11062427|NCT04340739||Cohort 2 (16 Patients)|"A live version of GEMINI will be beta-tested by 16 chronic pain patients through completing a faux medical group visit (MGV). This will include things like exploring the education topics available, interacting with the other participating patients, and interacting with a medical provider posing as the faux group's health care provider, all in order to robustly test the system in a live environment. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide."
11062428|NCT04340739||Cohort A (8 Healthcare Providers)|Eight healthcare providers will be divided into pairs, and these pairs will each conduct a faux medical group visit (MGV) with faux patients (staff will pose as patients). They will be asked to complete the faux session as if it were actual patients of theirs, conduct pre- and post-session tasks, and provide usability feedback on the platform. Outcomes: Quantitative Testing/User Experience Data from Usability Testing Prompt, System Usability Scale, Perceived Feature Usefulness Scale, and the Technology Acceptance Model Based Survey. Qualitative data collected as feedback from semi-structured interview using the Usability Test Moderator Guide.
11062429|NCT04340713|Experimental|Information support group|The experimental group was given information support program intervention on the basis of routine information communication.
11062430|NCT04340713|No Intervention|Routine care group|The control group was given routine information communication.
11062431|NCT04340700|Experimental|THC|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
11062432|NCT04340700|Placebo Comparator|Placebo|Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
11062433|NCT04340687||IP group|All patients recevied pancreatic duct stent during ERCP and one single dose of 100mg rectal indomethacin after ERCP.
11062434|NCT04340687||IN group|All patients received one single dose of 100mg rectal indomethacin after ERCP.
11062435|NCT04340674|Experimental|Telerehabilitation based on aerobic exercise|Aerobic low-impact exercise guided by audiovisual material. The intensity of exercise is adapted to each participant and is established according to the perceived effort after each session, according to the modified Borg perceived effort scale.
11062436|NCT04340674|No Intervention|Control group|Group that maintain the same medical treatment and not receive additional intervention.
11062437|NCT04340661|Experimental|Bionocol arm|
11062438|NCT04340661|Placebo Comparator|Placebo arm|
11062439|NCT04340635||Multi-center data collection|Without intervention
11062440|NCT04340622|Active Comparator|Reduction in opioid cravings and use|These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.
11062441|NCT04340622|Placebo Comparator|Small reduction in opioid cravings and use|Sham condition.
11062442|NCT04340609|Experimental|Intravenous Group|Dosage of intravenous route is 2 million MSCs/kg for each subject.
11062443|NCT04340609|Experimental|Intracoronary Group|Dosage of intracoronary route is ±50 million MSCs for each subject.
11062444|NCT04340609|No Intervention|Control Group|Standard treatment of acute myocardia infarction
11062685|NCT04338698|Experimental|Comparator 6|Hydroxyquinine + Oseltamivir + Azithromycin
11062446|NCT04340596|Experimental|Arm B: N-803 in combination with 10-1074 and VRC07-523LS|"Participants will receive N-803 in combination with 10-1074 and VRC07-523LS as follows:
~At Step 2 entry:
~VRC07-523LS 20 mg/kg
~10-1074 30 mg/kg
~At Step 2, week 1: N-803 6 mcg/kg every 3 weeks for eight doses
~At Step 2, week 9: 10-1074 30 mg/kg"
11062447|NCT04340570|Experimental|Intervention|Receives pharmacist home televisit for medication management
11062448|NCT04340570|No Intervention|Usual Care|Usual care for outpatient medication management
11062449|NCT04340557|Experimental|Group A (Study drug+SOC)|Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
11062450|NCT04340557|No Intervention|Group B (SOC)|Standard of Care
11062451|NCT04340544|Experimental|Hydroxychloroquine|Hydroxychloroquine 600mg daily for 7 days
11062452|NCT04340544|Placebo Comparator|Placebo|Equivalent number of placebo capsules
11062453|NCT04340531|Experimental|Arm I (early arm)|Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 13-24. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
11062454|NCT04340531|Active Comparator|Arm II (delayed arm)|Female smokers receive usual care during months 13-24. Providers undergo training over 60 minutes to explain the Break Free program and basics of quitting smoking during months 25-36. Female smokers interested in quitting in the next 6 months will be referred to an in-person counseling session at the clinic. Participants then receive 4 phone counseling over 15-20 minutes with a trained tobacco treatment specialist.
11062455|NCT04340518|Experimental|Post-scleral lens wear|Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
11062456|NCT04340505||Active uveitis patients.|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist and requires an injectable fluocinolone acetonide implant to treat their inflammation.
11062457|NCT04340492|Experimental|Adapted Physical Activity group|
11062458|NCT04340492|Sham Comparator|control group|
11062459|NCT04340479||Absent lung ultrasound findings of active COVID infection|Absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
11062460|NCT04340479||Present lung ultrasound findings of active COVID infection|Presence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts
11062461|NCT04340466||Suspected or proven COVID-19 critically ill patients|
11062462|NCT04340466||Control|
11062463|NCT04340453|Active Comparator|Group 1 (Hip and Knee Exercise Program)|Standard exercise physiotherapy treatment of a Hip and Knee Exercise Program plus stretching.
11062464|NCT04340453|Experimental|Group 2 (BFR-training hip and knee exercise group)|BFR-training hip and knee exercise group plus stretching.
11062465|NCT04340440|Active Comparator|D1 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy
11062466|NCT04340440|Active Comparator|D2 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy
11062467|NCT04340427|Experimental|TQB3455 Tablets|TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
11062468|NCT04340414|Experimental|NCP patient with severe ARDS and/or high ventilator supported|The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment
11062469|NCT04340401|Experimental|TNT+SHR1210|"Patients with high-risk locally advanced rectal cancer will receive chemotherapy and SHR-1210 before chemoradiaton, after chemoradiaton, patient will receive consolidation chemotherapy. This arm is called Total Neoadjuvant Treatment (TNT) plus SHR-1210. The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX ( Capecitabine + Oxaliplatin ) plus SHR-1210 over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.
~Finally, patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs."
11062470|NCT04340388|Active Comparator|Switch from a non-integrase based regimen to dolutegravir|Participants with HIV-1 infection who have had viral suppression on a non-integrase based antiretroviral regimen for greater than or equal to 3 months will be switched to a dolutegravir based regimen dosed at 50 milligrams (MG) once daily. Background regimen will remain the same.
11062471|NCT04340388|Active Comparator|Continue on non-integrase inhibitor based regimen|Participants not currently on an integrase based regimen who remain on current suppressive therapy will remain on current antiretroviral regimen.
11062472|NCT04340375|Experimental|AP green tea extracts|8 weeks
11062473|NCT04340362|Experimental|VX-147|Subjects will receive VX-147 orally at Dose 1 for 2 weeks and at Dose 2 for 11 weeks.
11062474|NCT04340349|Experimental|Experimental: Hydroxychloroquine plus Bromhexine|200 mg of Hydroxychloroquine daily for 2 months 8 mg of Bromhexine every 8 hrs for 2 months
11062475|NCT04340349|Placebo Comparator|Bromhexine only|8 mg of Bromhexine every 8 hrs for 2 months
11062476|NCT04340323|Experimental|Group A-intensive exercise group|"Dosage of intensive exercise group - 12 weeks, five times a week for 30 minutes per day; five times with education by a physiotherapist, followed by continuation at home.
~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.
~Educating probands about anatomy, physiology and pelvic floor muscle function.
~Training of pelvic floor muscles in different positions.
~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
11062477|NCT04340323|Active Comparator|Group B-low-intensity exercise group|"Dosage of low-intensity exercise group - 12 weeks, twice a week for 15 minutes per day; five times with physiotherapist education, followed by continuation at home.
~PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist.
~Educating probands about anatomy, physiology and pelvic floor muscle function.
~Training of pelvic floor muscles in different positions.
~Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles."
11062479|NCT04340310||Polysomnography|Group B: Children between 4 and 14 years-old with initial OSA suspicion and concommitant diseases and false negative suspicion from HRP there will allocated to Hospital Nocturnal Polysomnography
11062480|NCT04340297|Experimental|Experimental group|Tongjiang granules are taken orally in liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally in spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally in cold-heat complicated syndrome, one bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
11062481|NCT04340297|Placebo Comparator|Control group|Tongjiang placebo granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua placebo granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei placebo granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal. At the same time, it was combined with acid inhibitors to reduce the steps of withdrawal treatment: in the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
11062482|NCT04340284|Experimental|Patients with nonunion of long bones|A total of 11patients ( november 2012 to august 2018) with atrophic non-union of long bones already treated with percutaneous SVF implantation
11062483|NCT04340271|Experimental|Extracorporeal shock wave therapy group|Patients in the ESWT group were explained to select the most hypertrophic and retracting area for the treatment on dominant hand. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
11062484|NCT04340271|Sham Comparator|sham stimulation group|The same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy
11062485|NCT04340258|Experimental|Pembrolizumab & Cesium-131|200 mg Pembrolizumab (Day -14 pre-surgery; Every 3 weeks after surgery) + Cesium-131 Seeds to deliver 60-70Gy of radiation (Single dose at the time of salvage surgery)
11062486|NCT04340232|Experimental|Baricitinib Arm|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of baricitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 2 mg baricitinib once daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving baricitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
11062487|NCT04340219||Cancer patients|Participants complete a survey consisting of sociodemographic information and self-administered questionnaires (CPDI, DASS-21, and WHOQOL-BREF).
11062488|NCT04340206|Experimental|face-to-face support and Chatbot online support group|Experimental, Intervention Group A: face-to-face support and Chatbot online support group: 5-week intervention according to ACT principles with the web- and mobile-based Youth Compass plus program, face-to-face support (2 meetings) and weekly online support and feedback from the Chabot eCoach built within the program (one third of the participants is randomly assigned to this group)
11062489|NCT04340206|Experimental|only chat-robot online support group|Experimental, Intervention Group B: only chat-robot online support group: 5-week intervention according to ACT principles with the web-and mobile-based Youth Compass plus program, no face-to-face support, and weekly online support and feedback from the chatbot eCoach built within the program (one third of the participants is randomly assigned to this group)
11062490|NCT04340206|Experimental|Experimental Control|"Experimental Control:
~Control group, no intervention (one third of the participants is randomly assigned to this group)"
11062491|NCT04340193|Experimental|Nivolumab + Ipilimumab + TACE|TACE (Trans-arterial Chemoembolization)
11062492|NCT04340193|Experimental|Nivolumab + Ipilimumab Placebo + TACE|TACE (Trans-arterial Chemoembolization)
11062493|NCT04340193|Placebo Comparator|Nivolumab Placebo + Ipilimumab Placebo + TACE|TACE (Trans-arterial Chemoembolization)
11062494|NCT04340180|Experimental|Subjects with enhancing breast lesions|
11062495|NCT04340167|Experimental|Autologous humanized anti-CD22 CAR-T treatment|
11062496|NCT04340154|Experimental|chimeric antigen receptor T cell treatment|
11062497|NCT04340141|Experimental|Arm I (perioperative chemotherapy, surgery)|Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Within 2-8 weeks of completing neoadjuvant chemotherapy, patients undergo surgical resection. Patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
11062498|NCT04340141|Active Comparator|Arm II (surgery, adjuvant chemotherapy)|Patients undergo surgical resection. Beginning 3-12 weeks after surgery, patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
11062499|NCT04340128|Active Comparator|1|Intra-lesional injection of Glucantime once a week
11062500|NCT04340128|Experimental|2|Intra-lesional injection twice a week, 0.1/cm2
11062501|NCT04340115||Participants treated with RINVOQ|Participants treated with upadacitinib in accordance with approved local label. Decision to treat with upadacitinib was made prior to offering participation in this study.
11062531|NCT04339842||Adults in quarantine due to the virus outbreak|Individuals over the age of 18 who spend most of their time at home in social isolation because of the Coronavirus to prevent the risk of contracting the virus
11062502|NCT04340102|Experimental|BecomeAnEx|Participants will have three individual meetings with a research staff person while they are in the hospital. At these meetings participants will answer questions about their smoking and interest in quitting, learn about BecomeAnEx, and register with the BecomeAnEx program so that they can use it when you leave the hospital. Participants will be given two weeks of nicotine replacement therapy when they leave the hospital. Participants will be asked to use BecomeAnEx as much as they want when they leave the hospital program.
11062503|NCT04340089||observation group|the patients can go to squatting on the toilet at any time as they want to after taking the capsule
11062504|NCT04340089||control group|The patients can move freely
11062505|NCT04340076|Experimental|Dose reduction|Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.
11062506|NCT04340076|Active Comparator|Normal dose|Patients will continue treatment with the normal/maintenance dose of the biologicals.
11062507|NCT04340063|Active Comparator|Treadmill group|Participants randomized to the Treadmill group will complete high intensity gait training on a treadmill.
11062508|NCT04340063|Experimental|Movement Amplification group|The locomotor training protocol described for the Treadmill group will be used for the Movement Amplification group with one exception. The Movement Amplification group will perform all gait training within the movement amplification environment.
11062509|NCT04340050|Experimental|Treatment with anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours
11062510|NCT04340037||proximal ureteral stone patient|Patients underwent percutaneous nephrolithotomy treating unilateral, solitary and proximal ureteral stones.
11062511|NCT04339998||Patients with Suspected or Confirmed COVID-19|Patients 18 years of age and older under investigation for COVID-19 and those patients that are positive for COVID-19 at University of Minnesota Medical Center and Bethesda Hospital. Informed consent will be obtained from the patient or decision maker prior to study inclusion
11062512|NCT04339985|Experimental|ATx201 OINTMENT 4%|ATx201 OINTMENT 4%
11062513|NCT04339985|Experimental|ATx201 OINTMENT 7%|ATx201 OINTMENT 7%
11062514|NCT04339985|Experimental|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
11062515|NCT04339972|Experimental|Active LIFUP|Real LIFUP is delivered to the participant during this condition.
11062516|NCT04339972|Sham Comparator|Sham LIFUP|Sham LIFUP (device turned on but no sonication delivered) during this condition
11062517|NCT04339959||Phase I|First, we will test proof-of-concept that participants will be able to follow the testing protocol and use the tablet computer to communicate with the investigator (10-12 participants). The test protocol will be refined based on what is learned after a minimum of 10 participants. We anticipate no more than 12 participants needed for this phase.
11062518|NCT04339959||Phase II|Next, 10-20 new participants will be enrolled to evaluate the validity of videoconference vs. face-to-face assessment (i.e., direct observation) of physical performance. Communication will occur between the remote assessor and the participant. The direct observer will not communicate directly to the participant, unless there is a safety issue. After completing 10 participants without a major change in the test protocol, we will proceed to the next phase.
11062519|NCT04339959||Phase III|This phase involves participants repeating the test protocol, but without the face-to-face assessment (i.e., direct observation). This will test the ability of the participant to receive the box of test instructions and materials in the mail, unpack the box, communicate with the remote assessor via videoconferencing, pack up the box, and return it (postage paid) to the study team. This step will involve 5-10 participants from Phases 1 and 2, who have provided approval for future contact (see approved Future Contact form). Once 5 participants have successfully and safely completed the test protocol, we will proceed to Phase 4.
11062520|NCT04339959||Phase IV|This phase is the same as Phase 3, except it includes newly enrolled participants, i.e., representing the first-time participants have enrolled/participated in this study. This will eliminate the practice effect that will occur in phase 3. This step will enroll 5-10 participants.
11062521|NCT04339946||Patients with suspicious of rectosigmoid endometriosis|
11062522|NCT04339933||BC|Patients who were diagnosed with bladder cancer
11062523|NCT04339920||Chinese patients with clinical suspicious of prostate cancer|Chinese patients with clinical suspicious of prostate cancer, due to elevated serum PSA or abnormal digital rectal examination, will be recruited for the study from the Prince of Wales Hospital and North District Hospital.
11062524|NCT04339907|Sham Comparator|Cataract surgery only|Participants needing cataract surgery, without glaucoma or any other corneal diseases.
11062525|NCT04339907|Sham Comparator|Glaucoma surgery only|Participants needing glaucoma filtration surgery, without any prior corneal transplantation.
11062526|NCT04339907|Experimental|Corneal transplantation|"Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.
~This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure."
11062527|NCT04339907|Experimental|Intraocular surgery following corneal transplantation|"Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).
~This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation."
11062528|NCT04339907|Experimental|Glaucoma surgery following corneal transplantation|"Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).
~This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation."
11062529|NCT04339868|Active Comparator|Terlipressin group|Terlipressin acetate 1 mg in 0.9% normal saline (NaCl) 50 mL (0.02 mg/mL) Initial dose 20 mcg/hr (1 mL/hr) titrate increase 1 mL/hr every 30 min to 100 mcg/hr (5 mg/hr) to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease terlipressin until stop
11062530|NCT04339868|Placebo Comparator|Placebo group|Placebo 0.9% NaCl 50 mL Initial dose 1 mL/hr titrate increase 1 mL/hr every 30 min to 5 mg/hr to keep mean arterial blood pressure (MAP) > 65 mmHg If MAP > 75 mmHg for > 30 min, decrease epinephrine and norepinephrine until < 0.15 mcg/kg/min, then decrease placebo until stop
11062532|NCT04339829|Other|Dacomitinib 45mg PO ,QD|Single arm
11062533|NCT04339816|Experimental|HC-A group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and 500 mg of Azithromycin once in 24 hours (with the first dose of hydrochloroquine)
~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval 250 mg of Azithromycin once in 24 hours (with the first daily dose of hydrochloroquine)"
11062534|NCT04339816|Active Comparator|HC group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)
~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)"
11062535|NCT04339816|Placebo Comparator|C group|• Day 1-5: Patients receive two doses of placebo in 12 hours interval and 1 extra dose of placebo once in 24 hours
11062536|NCT04339803|Experimental|mirror therapy|lower limb mirror therapy using ankle exercise
11062537|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
11062538|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
11062539|NCT04339777|Active Comparator|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
11062540|NCT04339777|Active Comparator|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
11062541|NCT04339764|Experimental|Experimental|Five participants will undergo RPE transplantation in one eye. Eligible eyes will have GA, best-corrected visual acuity (BCVA) between 20/100 and 20/500, and a fellow eye that has same or better BCVA. If the National Eye Institute (NEI) Data and Safety Monitoring Committee (DSMC) gives clearance to proceed based on review of data from the first cohort, a second cohort of up to seven additional participants with GA, BCVA between 20/80 and 20/500 in the eye being considered for RPE transplantation, and same or better visual acuity in the other eye may undergo the procedure to gather additional safety and potential efficacy data useful for planning future studies. Up to 20 participants may be enrolled to allow for screening failures or for participants withdrawing from the study prior to RPE transplantation.
11062542|NCT04339751|Experimental|single center, prospective pilot study|effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease
11062543|NCT04339738|Experimental|Arm I (nivolumab, paclitaxel)|Patients receive nivolumab IV over 30 minutes on day 1 and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11062544|NCT04339738|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11062545|NCT04339738|Experimental|Arm III (nivolumab, cabozantinib S-malate)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11062546|NCT04339725||Fecal DNA|Extraction fecal DNA and compare disease group to normal group
11062547|NCT04339712|Experimental|anakinra|In case of diagnosis of MAS, IV anakinra 200mg three times daily (every eight hours) for 7 days. Patients who will receive anakinra treatment and who suffer from kidney dysfunction will receive 50% of the dose i.e. 100mg anakinra three times daily for 15 days
11062548|NCT04339712|Experimental|tocilizumab|"In case of diagnosis of immune dysregulation IV tocilizumab 8mg/kg body weight once up to a maximum of 800mg. These patients will receive anakinra at the above dose in case they meet one of the following contra-indications for tocilizumab:
~absolute neutrophil count less than 2,500/mm3;
~absolute platelet count less than 100,000/mm3; and
~AST or ALT more than 1.5 x the upper normal limit"
11062549|NCT04339699|Active Comparator|NobleStitch EL|Participants treated with the NobleStitch EL device
11062550|NCT04339699|Active Comparator|Amplatzer PFO Occluder|Participants treated with the Amplatzer PFO Occluder device
11062551|NCT04339686||Suspicion of COVID 19|
11062552|NCT04339673|Active Comparator|MNB- masseteric nerve block|masseteric nerve block with local anesthesia lidocaine single app.
11062553|NCT04339673|Active Comparator|LA -trigger point injection with local anesthetic|local anesthetic injections on trigger points in masseter
11062554|NCT04339673|Placebo Comparator|DN-dry needling|dren needling to masseter
11062555|NCT04339660|Experimental|UC-MSCs treatment group|Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.
11062556|NCT04339660|Placebo Comparator|Control group|Participants will receive conventional treatment and Placebo intravenously.
11062557|NCT04339647|Experimental|The SIMS Programme|The SIMS programme is a community-based intervention which improvised the usual care (defined as the existing preschool oral health programme) offered by the Ministry of Health. The target group is 5-6-year-old preschool children and their parents. Apart from the usual care, the 5-6-year-old children receive interventions carried out by teacher in school and home tooth brushing supervision by parents. In addition, parents/guardians will receive OHE from the DT team, free toothbrush and toothpaste (1000ppm F) for child home tooth brushing and supervised child home tooth brushing for 6 months.
11062558|NCT04339647|No Intervention|Control|The control group receives the usual care from the preschool oral health programme. The usual care is described as a DT team visiting the school to do an oral examination, provides OHE to the children, and applies fluoride varnish (20,000 ppmF) twice/year.
11062559|NCT04339634||Program of All-Inclusive Care for the Elderly|The Program of All-Inclusive Care for the Elderly (PACE) provides comprehensive medical and supportive services for community-dwelling persons, mostly older adults (>55 years), as an alternative to institutionalization. Medical services are provided by an interdisciplinary team of healthcare professionals, Tabula Rasa HealthCare being the pharmacy care provider for several PACE organizations.
11062560|NCT04339621||Treatment Naive|20 patients with AIH will be recruited that will be treatment naive at the time of recruitment.
11062561|NCT04339621||Treatment cessation review|77 AIH patients will be recruited who will have been on treatment for the past 18-24 months and will be coming in to meet their physician to review treatment cessation options
11062562|NCT04339595|Experimental|Tildrakizumab|
11062563|NCT04339569||History of patellar tendinopathy|
11062564|NCT04339569||Healthy controls|
11062566|NCT04339504|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
11062567|NCT04339504|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
11062568|NCT04339504|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
11062569|NCT04339478||Autofluorescence|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:
~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
11062570|NCT04339478||Control|"The surgeon will perform the preplanned thyroidectomy with central lymph node compartment dissection without autofluorescence device. The following intraoperative variables will be recorded for all patients:
~Surgery date Duration of surgery Operation performed Procedure related comments Number and location of the visualized glands"
11062571|NCT04339465|Experimental|CARE-FAM|The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
11062572|NCT04339465|Experimental|WEP-CARE|The online intervention WEP-CARE addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 10 standardized writing tasks on a secured internet platform. The 10 writing tasks will be conducted with a weekly frequency and participants will receive personalized feedback. WEP-CARE aims at enhancing mental health problems and the coping strategies of the family.
11062573|NCT04339465|Experimental|CARE-FAM + WEP-CARE|The families will receive both the face-to-face intervention CARE-FAM and the online intervention WEP-CARE.
11062574|NCT04339465|No Intervention|Treatment as usual|The treatment as usual implies that families of the control group receive the treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system.
11062575|NCT04339439|No Intervention|Closure without vessel loop|These patients will receive standard of care closure of the carpal tunnel release incision.
11062576|NCT04339439|Experimental|Closure with vessel loop|These patients will receive closure of the carpal tunnel release incision with a vessel loop placed under the sutures.
11062577|NCT04339426|Experimental|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
11062578|NCT04339413|Experimental|Gantenerumab|Participants will continue receiving open-label gantenerumab by subcutaneous (SC) injection every four weeks (Q4W) at the same dose as administered in the parent studies.
11062579|NCT04339400|Experimental|TQ05105 Tablet|TQ05105 tablet 5mg administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
11062580|NCT04339387||Coronavirus Disease 2019 positive, suitable for discharge|Patients with Coronavirus Disease 2019 who do not require supplemental oxygen, do not require intensive care unit-level care, and do not die.
11062581|NCT04339387||Coronavirus Disease 2019 positive, not suitable for discharge|Patients with Coronavirus Disease 2019 who do require supplemental oxygen, do require intensive care unit-level care, or do die.
11062582|NCT04339374||Ex vivo imaging|"Patients with known adenomatous polyps or malignancies in the colon or rectum undergoing resection will be considered for enrollment
~Participation will include imaging of both normal and known pathologic portions of the specimen ex vivo immediately following resection. The specimen will then undergo fixation and standard pathologic evaluation, with subsequent correlation between imaging and pathologic findings.
~This data will also be used to develop a convolutional neural network (CNN) to assist in interpreting photoacoustic imaging data."
11062583|NCT04339374||In vivo imaging|"Patients with distal rectal lesions (benign or malignant tumors within 15cm of the anal verge) will be enrolled for the in vivo imaging portion of the study
~Participation will include an intraoperative, in vivo evaluation of the tumor with a novel endorectal photoacoustic ultrasound probe as well as ex vivo imaging post-resection as described above. Following the induction of anesthesia, patients will undergo a 20 minute endorectal imaging evaluation performed by their colorectal surgeon. After imaging, the patient will then undergo standard-of-care surgical resection of the rectum. The resection specimen will then be imaged ex vivo as performed in the ex vivo cohort of this study.
~For this portion of the pilot, enrollment will be limited to 10 participants"
11062584|NCT04339361|Experimental|lidocaine spray|four puffs (50ml, 10 mg/puff) of lidocaine spray will be applied to the cervical canal and cervix before tenaculum placement plus vaginal placebo will be given 3 hours before IUD insertion
11062585|NCT04339361|Active Comparator|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
11062586|NCT04339361|Placebo Comparator|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray will be applied to the cervical canal and cervix before tenaculum placement
11062587|NCT04339348|Experimental|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus vaginal inert placebo cream at the time of IUD insertion
11062588|NCT04339348|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine anesthetic cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo will be given 3 hours before LNG-IUD insertion
11088807|NCT04154696|Experimental|Normothermic perfusion of a graft|
11062589|NCT04339348|Placebo Comparator|placebo|inert vaginal placebo cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours before LNG-IUD insertion
11062590|NCT04339322||Patients with Covid-19|Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health
11062591|NCT04339309|Active Comparator|Kiel Center|Non-surgical periodontal treatment with interdental hygiene devices in periodontitis patients.
11062592|NCT04339309|Active Comparator|Cairo Center|Non-surgical periodontal treatment without interdental hygiene devices in periodontitis patients.
11062593|NCT04339296|Experimental|Intervention group|Intervention group included medication management with Spencer.
11062594|NCT04339296|No Intervention|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
11062595|NCT04339283|Experimental|Standardized Hibiscus sabdariffa tea Arm|300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days
11062596|NCT04339283|No Intervention|Water Arm|300 mL of distilled water is administered to the participants daily for 28 days.
11062597|NCT04339270|Active Comparator|Azithromycin according to symptoms|Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.
11062598|NCT04339270|Experimental|Azithromycin according to rheology|Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.
11062599|NCT04339244|Active Comparator|ONSD measurement under lower blood pressure|ONSD measurement under mean blood pressure of 60~70 mmHg
11062600|NCT04339244|Active Comparator|ONSD measurement under highly normal blood pressure|ONSD measurement under mean blood pressure of 90~100 mmHg
11062601|NCT04339231|Active Comparator|Ropivacaine group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
11062602|NCT04339231|Placebo Comparator|Saline 0,9% group|The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with saline solution, in a concentration of 0.9%, advancing it through the nasal cavities towards the posterior wall of the nasopharynx. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that the solution is absorbed by the mucosa up to the sphenopalatine ganglion, which, in general, is anatomically three millimeters deep from the surface. After the established time, the cotton buds are removed.
11062603|NCT04339218|Experimental|Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin|Cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
11062604|NCT04339218|Active Comparator|Arm pembrolizumab-pemetrexed-carboplatin|Combination of Pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
11062605|NCT04339192|Experimental|Surgery group|receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.
11062606|NCT04339192|No Intervention|Medical group|receiving medical treatment only
11062607|NCT04339166|Experimental|Group A|Single thawed blastocyst transfer with blastocyst selection according to the analysis of NICS and morphologic score.
11062608|NCT04339166|No Intervention|Group B|Single thawed blastocyst transfer with blastocyst selection according to morphologic score.
11062609|NCT04339153|Experimental|Parent Training (PT)|The goal of intervention plan is to teach the basic applied behaviour analysis techniques to find out the antecedent of the problem behaviour, enhance adaptive skills and reduce noncompliance. Sessions will be interactive, and action-oriented through the provision of workbooks, modelling, videos, rehearsal (with child when present), homework tasks, and feedback (Bearss et al., 2015). The parents will be trained on the protocol and delivered 60 to 90 minutes preferably individual sessions over 24 weeks.
11062610|NCT04339153|No Intervention|Parent Education (PE)|"The Parent education group will serve as an attention-placebo condition to control for general effects of the intervention.
~There will be 12 core sessions and 1 home visit regarding knowledge of autism, learning about the principles of managing behavior, teaching new skills; improving social interaction and communication. Each session will last for 60 to 90 minutes over 24 weeks."
11062611|NCT04339140|Experimental|Zafirlukast|Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
11062612|NCT04339127||Cohort NMDARE-HSE|Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.
11062613|NCT04339114|Sham Comparator|Control meal|Pancake
11062614|NCT04339114|Active Comparator|Control meal + Cinnamon|Pancake seasoned with cinnamon
11062615|NCT04339114|Active Comparator|Control meal + Italian herb mix|Pancake seasoned with Italian herb mix
11062616|NCT04339114|Active Comparator|Control meal + Active-Herbs/Spice mix|Pancake seasoned with pumpkin spice
11062617|NCT04339101|Experimental|Treatment (itacitinib adipate, tacrolimus, sirolimus)|"RIC: Patients receive fludarabine via infusion on days -9 to -5 and melphalan on day -4 in the absence of disease progression or unacceptable toxicity.
~ALLOGENEIC HSCT: Patients undergo HSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD beginning on day -3 and continuing until day 100 in the absence of disease progression or unacceptable toxicity. Patients also receive tacrolimus IV or PO and sirolimus PO beginning day -3 and continuing until day 100 with a taper in the absence of disease progression or unacceptable toxicity."
11062618|NCT04339088||HIFU|Patients that have undergone high focused ultrasound treatment for varicose veins
11062619|NCT04339075||Venablock|Patients that have undergone Venablock treatment
11062686|NCT04338698|No Intervention|Observational Cohort|Non-consenting to randomization
11062620|NCT04339062|Experimental|Cohort 1 Cemiplimab|"Participants who received allogeneic hematopoietic stem cell transplant
~-- Cemiplimab: via IV, flat predetermined dosage every 21 days"
11062621|NCT04339062|Experimental|Cohort 2 Cemiplimab + Everolimus/Sirolimus + Prednisone|"Participants who received a kidney transplant will receive
~Cemiplimab via IV, flat predetermined dosage every 21 days
~Everolimus or Sirolimus-least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
~Prednisone 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapering doses while receiving Cemiplimab"
11062622|NCT04339049|Experimental|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
11062623|NCT04339049|Active Comparator|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
11062624|NCT04339049|Placebo Comparator|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
11062625|NCT04339036|Experimental|Oral CapTem + Y90 Radioembolization|"Capecitabine 750 mg/m2 twice daily orally for 14 days and temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities.
~Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4."
11062626|NCT04339023|Experimental|OLP-Group|patients will receive in addition to TAU, 2 open-label Placebo (OLP) injections (containing each 5 ml of NaCl 9%) per day for two consecutive days following minimally invasive TLIF
11062627|NCT04339023|Other|TAU-group|The treatment as usual (TAU) group will serve as control group and will control for the natural course of postoperative pain under usual medication intake, following minimally invasive TLIF
11062628|NCT04339010|Experimental|Hypopressive|"st session: the meetings were provided by a physiotherapist, who also discussed the location and function of the pelvic organs, PFM, and the transversus abdominis (TrA) muscles. The participants learned how to activate TrA muscles. The training was performed during full expiration, the physiotherapist check and coordinate the group to maintain the Tra contraction. The women were also trained to inhale through the nose and exhale through the mouth maintaining an apical breathing pattern.
~nd session: The contractions were executed during six different positions the ones which they will keep following through the whole treatment.
~rd session: The patients were exposed to all the six positions (supplementary material) and their three variations (positions 1, 3, 5 and 6 ). Every meeting obeyed the same schedule through the five weeks of treatment and was accompanied by two physiotherapists."
11062629|NCT04339010|Active Comparator|Hypopressive + PFMC|This group receives the same protocol than the Hypopressive group, but with a verbal command to realize the PFM contraction during the activation of the deep abdominal muscle.
11062630|NCT04338997|Experimental|IZD174|Intra subject dose escalation of IZD174
11062631|NCT04338984|Active Comparator|General anesthesia alone (AG)|"Opioid based analgesia:
~Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).
~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
11062632|NCT04338984|Experimental|Erector Spinae Plane Block and General Anaesthesia (ESPAG)|"Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision.
~Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).
~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
11062633|NCT04338958|Experimental|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days
11062634|NCT04338945||Residents in surgical areas|
11062635|NCT04338919|Experimental|O-APT group|Ticagrelor 90 mg twice daily plus aspirin 100mg once daily in the first month, Ticagrelor 90mg bid between the second and the sixth months Ticagrelor 45mg bid between the seventh and the twelfth months
11062636|NCT04338919|Active Comparator|S-APT group|ticagrelor 90 mg twice daily plus aspirin 100mg once daily for 12 months
11062637|NCT04338906|Experimental|Camostat + Hydroxychloroquine|Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
11062638|NCT04338906|Active Comparator|Placebo + Hydroxychloroquine|Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)
11062639|NCT04338893|Active Comparator|ROSA Total Knee Robotic Instrumentation|Total knee arthroplasty performed with ROSA Total Knee Robotic instrumentation
11062640|NCT04338893|Active Comparator|Conventional TKA Instrumentation|Total knee arthroplasty performed with conventional instrumentation
11062641|NCT04338867|Active Comparator|Therapeutic arm|Patients who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN) with the release of 10 mg in 24 hours, for 24 hours with a 12-hour rest interval (to avoid saturation of receptors)
11062642|NCT04338867|Active Comparator|Control arm|Patients who received whole-brain radiotherapy (WBRT) (30 Gy in 10 fractions, in 10 days of treatment)
11062643|NCT04338854|Experimental|Root canal treatment|It's one of the restorative groups with LA (Local Anesthesia). An aerator and micromotor were used as cavity preparation in this group. Only conventional root canal treatment and extirpation were planned for the children included in the root canal treatment group in the measurement session.
11062644|NCT04338854|Experimental|Pulpotomy treatment|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. it was noted that at least one of the approximal surfaces of the teeth had decay and iron sulfate (ViscoStat®, UltraDent, South Jordan, USA) was used as pulpotomy material
11062645|NCT04338854|Experimental|two-surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
11062646|NCT04338854|Experimental|one surface restoration with Local Anesthesia|It's one of the restorative groups with LA (Local Anesthesia).An aerator and micromotor were used as cavity preparation in this group.
11088808|NCT04154683|Experimental|group using Cellvizio® optical biopsy|
11062647|NCT04338854|Experimental|two-surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group. A Tofflemire matrix retainer and 0.05 mm thick matrix band (Hahnenkratt, Königsbach-Stein, Germany) were used in groups with a two-surface cavity.
11062648|NCT04338854|Experimental|one surface restoration without Local Anesthesia|An aerator and micromotor were used as cavity preparation in this group.
11062649|NCT04338854|Experimental|fluoride application by disposable arch tray|It's one of the protective groups.Only the micromotor was used for polishing purposes in the protective treatment groups. 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
11062650|NCT04338854|Experimental|fluoride application by cotton roll|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups 2% NaF (Polimo® IMICRYL, Konya, Turkey) was preferred in groups who received fluoride application.
11062651|NCT04338854|Experimental|Fissure Sealant group|It's one of the protective groups. Only the micromotor was used for polishing purposes in the protective treatment groups.
11062652|NCT04338841|No Intervention|Phase1: Before HOME-CoV rule implementation|"Observational assessment of current practices: no recommendation is performed.
~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion.
~Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.
~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
11062653|NCT04338841|Experimental|Phase 2: After HOME-CoV rule implementation|"Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision.
~Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants.
~A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion."
11062654|NCT04338828|Experimental|Treatment Group|Inhaled nitric oxide
11062655|NCT04338828|Placebo Comparator|Control Group|Inhaled supplemental oxygen
11062656|NCT04338815|Experimental|Determine optimal assistance pattern|
11062657|NCT04338815|Experimental|Determine effects on endurance|
11062658|NCT04338802|Placebo Comparator|Placebo group|Empty capsules with the same appearance and ingredients as Nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
11062659|NCT04338802|Experimental|Nintedanib group|Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
11062660|NCT04338789|Experimental|Group 1|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed immediately before molar protraction on the left or right side of the patient.
11062661|NCT04338789|Experimental|Group 2|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed 3 months after molar protraction with no piezocision on the left or right side of the patient.
11062662|NCT04338789|No Intervention|Group 3|It consisted of 20 subjects (40 molars) where molar protraction was performed with no piezocesion.
11062663|NCT04338776|Experimental|UroLift|Patient randomized to the UroLift arm will receive the FDA-approved UroLift procedure.
11062664|NCT04338776|Experimental|Rezūm|Patient randomized to the Rezūm arm will receive the FDA-approved Rezūm procedure.
11062665|NCT04338763|Experimental|Arm A: RP72 monotherapy|
11062666|NCT04338763|Experimental|Arm B: RP72 in combination with Gemcitabine|
11062667|NCT04338750|Experimental|TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACTICs)
11062668|NCT04338750|Active Comparator|mEUC|minimally-Enhanced Usual Care (mEUC)
11062669|NCT04338737|Active Comparator|fluid and soft food|It consists of 100 patients that will be allocated for early post-operative oral feeding receiving water and clear fluid approximately 2 hours after surgery, followed by soft food and regular diet 4 hours later irrespective to intestinal sounds, flatus or stool.
11062670|NCT04338737|Active Comparator|fluid only|It consists of 100 patients that will be allocated for early Postoperative oral feeding receiving water and clear fluid approximately 2 hours after surgery till the return of intestinal sounds, then soft food and regular diet later on.
11062671|NCT04338737|Active Comparator|Npo|It consists of 100 patients that will receive no oral feeding till passage of flatus instead 2 to 3 Litres of intravenous fluid will be used for feeding. Water and fluid will be then offered, followed by soft foods and then a regular diet.
11062672|NCT04338724|Experimental|CS1002|
11062673|NCT04338711|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR E1 administered in the fasted state.
11062674|NCT04338711|Experimental|Treatment B|Single oral 10 mg dose of tofacitinib MR E2 administered in the fasted state.
11062675|NCT04338711|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR E3 administered in the fasted state.
11062676|NCT04338711|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR E1 administered in the fed state.
11062677|NCT04338711|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR E3 administered in the fed state.
11062678|NCT04338711|Active Comparator|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state.
11062679|NCT04338698|Active Comparator|Control Intervention|Hydroxychloroquine
11062680|NCT04338698|Experimental|Comparator 1|Azithromycin
11062681|NCT04338698|Experimental|Comparator 2|Oseltamivir
11062682|NCT04338698|Experimental|Comparator 3|Hydroxychloroquine + Azithromycin
11062683|NCT04338698|Experimental|Comparator 4|Hydroxychloroquine + Oseltamivir
11062684|NCT04338698|Experimental|Comparator 5|Oseltamivir + Azithromycin
11088841|NCT04154501|Experimental|Cohort 6 Drug|600 mg Oral Capsule
11062687|NCT04338685|Experimental|RO7119929|Participants will receive RO7119929 every week in 3-week cycles. In Part A (dose-escalation on a weekly schedule) maximum tolerated dose (MTD) and/or recommended dose for expansion cohorts (RDE) will be determined. Following determination of MTD and/or RDE, treatment will commence at up to three different doses in specific expansion cohorts of participants for extended PD analysis (Part B).
11062688|NCT04338672||Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in 2020.
11062689|NCT04338672||Pre Pandemic Period|Patients who presented to the emergency department at our medical institute Sheba Medical Center between January 1 - March 31 in the following years: 2017, 2018, 2019,
11062690|NCT04338659|Other|IBI322|
11062691|NCT04338646||Patients enrolled|Patient with multiple sclerosis and lower urinary tract symptoms, age >18 Expanded Disability Status Scale score between 1 and 6.5
11062692|NCT04338633|Active Comparator|Conventional calcium hydroxide paste|Application of Conventional calcium hydroxide paste
11062693|NCT04338633|Experimental|Calcium hydroxide nanoparticle|Application of Calcium hydroxide nanoparticle
11062694|NCT04338633|Experimental|Combined Calcium hydroxide with silver nanoparticle|Application of Combined Calcium hydroxide with silver nanoparticle
11062695|NCT04338620|Experimental|A: Experimental Group|Participants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and cisplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
11062696|NCT04338620|Experimental|B: Control group|Participants receive totally 3 cycles of albumin-bound paclitaxel combined with cisplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
11062697|NCT04338607||All study patients|All study patients will be in one group.
11062698|NCT04338581|Experimental|AMG 714|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
11062699|NCT04338581|Placebo Comparator|Placebo|Participants will be administered 300 mg AMG 714 subcutaneously on Day 0 and every 2 weeks thereafter through week 10 (for a total of 6 doses).
11062700|NCT04338568|Active Comparator|LUS observer 1|The subject will undergo a Lung Ultrasound by observer nr 1
11062701|NCT04338568|Active Comparator|LUS observer 2|The subject will undergo a Lung Ultrasound by observer nr 2
11062702|NCT04338555|Experimental|TEAS group|Patients in the TEAS group will receive electrical stimulation of acupoints at Baihui, Neiguan and Shenmen points for 30min every hour. The stimulation will repeat until the end of surgery.
11062703|NCT04338555|No Intervention|control group|In patients from the control group, the electrodes will only be attached to the corresponding sites, with no TEAS electrical stimulation given during the operation.
11062704|NCT04338542||neoadjuvant chemotherapy plus bevacizumab|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy plus bevacizumab and, finally, the surgical resection of liver metastasis.
11062705|NCT04338542||neoadjuvant chemotherapy|Patients treated with surgery of the primary tumor, neoadjuvant chemotherapy and, finally, the surgical resection of liver metastasis.
11062706|NCT04338542||control group|Patients presenting with synchronous primary tumour and metastasis resected without any preoperative systemic therapy.
11062707|NCT04338529||Group Alendronate 6m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 6 months and then followed for another 6 months without medication.
11062708|NCT04338529||Group Alendronate 12m|Postmenopausal Caucasian women who were treated with denosumab and became osteopenic (BMD T-score of > -2.5 at the LS and the non-dominant FN) and were assigned from their treating physician to receive treatment with alendronate in an effervescent tablet formulation for 12 months.
11062709|NCT04338516|Active Comparator|Bio-Oss® Collagen,|subjects treated with Bio-Oss® Collagen, (Geistlich, Inc.)
11062710|NCT04338516|Experimental|Ossix™ Bone|subjects treated with Ossix™ Bone (Datum Dental Ltd)
11062711|NCT04338503||HF patients|Decompensated heart failure patients undergoing right heart catheterization.
11062712|NCT04338490|Experimental|Intervention|
11062713|NCT04338490|No Intervention|Control|
11062714|NCT04338477|Experimental|Nephrosolid|Acute dosis day 1: 3X2 Nephrosolid tablets 0.5 h before intake of a meal Long-term dosis days 2-28: 2x1 Nephrosolid tablets 0.5 h before intake of a meal
11062715|NCT04338464|Experimental|Treatment Group|
11062716|NCT04338451|Active Comparator|Music during the first part of ESWL|Patients listen to music during the first part of ESWL treatment (first 1800 SW).
11062717|NCT04338451|Active Comparator|Music during the second part of ESWL|Patients listen to music during the second part of ESWL treatment.
11062718|NCT04338438|Experimental|Apatinib Mesylate tablets combined with S-1 capsules|single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
11062719|NCT04338425|No Intervention|No Communication group|Participants will not communicate with their surgeons until the post operative office visit.
11062720|NCT04338425|Active Comparator|Voice call group|Participants will receive voice call from the surgeon after being discharged and before their post operative office visit.
11062721|NCT04338425|Active Comparator|Video call group|Participants will receive video call from surgeon after being discharged and before their post operative office visit
11062722|NCT04338412|Active Comparator|Group U|Performers' umbilicus
11062723|NCT04338412|Active Comparator|Group R|Performers' lowest rib margin
11062724|NCT04338412|Active Comparator|Group X|Performers' xiphoid process
11062725|NCT04338399|Experimental|Buparlisib & Weekly Paclitaxel|"Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.
~Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason."
11062754|NCT04338126|Experimental|Tranexamic Acid Treatment|Oral dosing of tranexamic acid at dose of 1300 mg p.o. three times per day x 5 days; alternative dosing intravenously with loading dose of 10 mg/kg followed by 1 mg/kg/hr infusion x 5 days
11062726|NCT04338399|Active Comparator|Weekly Paclitaxel|Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
11062727|NCT04338373|Experimental|experimental|"0.01% Atropine Sulfate solution in Comfort Drops, nightly instillations to both eyes"
11062728|NCT04338334|Active Comparator|CONTROL GROUP|Control group includes physical therapy protocol composed of manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active arm therapeutic exercises.
11062729|NCT04338334|Experimental|COHESIVE BANDAGE GROUP|Cohesive bandage is a self-adherent lightweight bandage, made of a porous nonwoven polyester material. A single self-adherent inelastic bandage will be directly applied at full stretch on cleaned and dried skin (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States) in a spiral method around the limb, starting at the hand and a layer overlap of 50%, so that the greatest compression was located at the distal points, gradually decreasing toward the proximal shoulder part. Cohesive latex-free bandages will be available for those allergic women. Women will do progressive active arm therapeutic exercises with bandaging.
11062730|NCT04338321|Experimental|Esketamine Arm|Participants will receive treatment with esketamine nasal spray (28 milligram [mg] [initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments], 56 mg [initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study], or 84 mg [maximum dose esketamine nasal spray may be uptitrated to]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).
11062731|NCT04338321|Active Comparator|Comparator Arm|Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 [lowest effective dose]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.
11062732|NCT04338308||SVG PCI|
11062733|NCT04338295|Experimental|Microneedling|Participants with Alopecia Areata will receive microneedling with a tattoo machine.
11062734|NCT04338282|Experimental|treatment arm|anti-PD-1 antibody (toripalimab) 240mg/d, every 3 weeks, for up to one year or until disease progression.
11062735|NCT04338269|Experimental|Atezo+Cabo|Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
11062736|NCT04338269|Active Comparator|Cabozantinib|Participants will receive cabozantinib every day.
11062737|NCT04338256||Students enrolled in the Wellness Course|Students in this group are enrolled in the Wellness Course for the Spring 2020 or Fall 2020 semesters
11062738|NCT04338256||Controls|Students in this group are enrolled at study sites during the Spring 2020 or Fall 2020 semesters, but are not enrolled in the Wellness Course
11062739|NCT04338243|Experimental|Glumetinib+Osimertinib|The investigational product Glumetinib will be orally administrated when fasting at dose level of 300mg QD and Osimertinib will be orally administrated when fasting at dose level of 80mg QD
11062740|NCT04338230|Experimental|Experimental: Experimental group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points). Progressive muscle relaxation exercises are applied to the intervention group as 30-minute sessions three times a week for eight weeks.
11062741|NCT04338230|No Intervention|No Intervention: Control group|Women aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score of 23 and above points).
11062742|NCT04338217|Experimental|Bionator|The modified Bionator was used to correct the open bite malocclusion. Patients were asked to wear the appliance every day.
11062743|NCT04338217|Active Comparator|Removable Appliance with Posterior Bite Planes|A removable appliance with poster bite planes was used to correct the open bite malocclusion. Patients were asked to wear this appliance full time expect eating times.
11062744|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
11062745|NCT04338191|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy
11062746|NCT04338191|Active Comparator|mFOLFOX6 adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy
11062747|NCT04338178|Experimental|Experimental intervention|Standard outpatient program, with additional group sessions integrating the experimental intervention : Cognitive Remediation Therapy (CRT), Emotional Skills Training (EST), and Cognitive Behavioral Therapy focused on craving and food addiction (CBT), delivered once a week during 10 weeks.
11062748|NCT04338178|Active Comparator|Standard intervention|Standard outpatient program, with additional group sessions integrating control intervention : multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches, delivered once a week during 10 weeks.
11062749|NCT04338165|Experimental|Evolocumab, 420 milligrams|Single injection of 420 milligrams of evolocumab (REPATHA®) one month before coronary angiography and coronary microcirculation (IMR) measurement.
11062750|NCT04338165|No Intervention|Control arm|Measurement of coronary microcirculation (IMR) during coronary angiography, without prior evolocumab injection.
11062751|NCT04338152|Experimental|FFT-CHR|Family-Focused Therapy for Clinical High-Risk Individuals
11062752|NCT04338152|Active Comparator|Enhanced Care|Enhanced Care Psychoeducation for Clinical High-Risk Individuals
11062753|NCT04338139|Experimental|Bio-oss Collagen|90% xengeneic bovine bone partciles + 10% collagen type I
11062824|NCT04337606|Experimental|decitabine in combination with Camrelizumab|decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6
11062755|NCT04338126|Placebo Comparator|Placebo Treatment|2 tablets of placebo three times per day x 5 days; alternative dosing intravenous normal saline at volumes similar to those use for experimental arm
11062756|NCT04338100||Chest Ultrasound|Only one arm, all included patients having chest ultrasonography.
11062757|NCT04338087||Fertility treatments|Men participating in fertility treatments.
11062758|NCT04338087||Spontaneous pregnancy|Men whose wives conceived spontaneously.
11062759|NCT04338074|Experimental|Tranexamic Acid Treatment|
11062760|NCT04338074|Placebo Comparator|Placebo Treatment|
11062761|NCT04338061|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
11062762|NCT04338061|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
11062763|NCT04338061|Experimental|Evobrutinib: Open-Label Extension Period|
11062764|NCT04338035||Patients with rectosigmoid endometriosis|
11062765|NCT04338022|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
11062766|NCT04338022|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
11062767|NCT04338022|Experimental|Evobrutinib: Open-Label Extension Period|
11062768|NCT04338009|Experimental|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
11062769|NCT04338009|Experimental|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
11062770|NCT04337996|Experimental|experimental arm|These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
11062771|NCT04337970|Experimental|Phase Ib, Dose Level 1|3-6 participants
11062772|NCT04337970|Experimental|Phase Ib, Dose Level 2|3-6 participants
11062773|NCT04337970|Experimental|Phase Ib, Dose Level 3|3-6 participants
11062774|NCT04337970|Experimental|Phase II, Dose Expansion|Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)
11062775|NCT04337944|Experimental|Patients with KPro, PPV, and endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
11062776|NCT04337918|No Intervention|Prevention - Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols).
11062777|NCT04337918|Experimental|Prevention - NORS + Standard Precautions|Participants COVID-19 negative at baseline will be randomized to receive standard COVID-19 screening and protection (per their facility or organization's protocols) plus daily NORS treatment for 14 days.
11062778|NCT04337918|Other|Treatment Sub-Study|"Volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. Ten participants can be directly enrolled in the Treatment sub-study.
~Participants enrolled in the Prevention study who meet the criteria in this section will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
11062779|NCT04337905|Experimental|Children with ADHD|Children with ADHD that running the ADHD-VR diagnostic test and also did the psychiatric examination to determine the ADHD diagnosis and to rule out other mental disorders
11062780|NCT04337905|Active Comparator|Children without ADHD|Healthy children that also running the ADHD-VR diagnostic test and also psyhchiatric examination to rule out the ADHD diagnosis and other mental disorders
11062781|NCT04337879|Experimental|AL2846 + mFOLFOX6|AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.
11062782|NCT04337879|Experimental|AL2846 + FOLFIRI|AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
11062783|NCT04337853|Experimental|Intervention group|N=5
11062784|NCT04337853|Active Comparator|Control group|N=6
11062785|NCT04337827|Experimental|Rituximab and Acalabrutinib|Participants will receive treatment of Rituximab weekly for 4 weeks, and Acalabrutinib twice daily for 4 weeks. Response assessment via diagnostic CT scans will dictate further treatment decisions.
11062786|NCT04337814|Experimental|COTA Arm|Patients getting combined (C) oral (O) and topical (T) analgesics (A)
11062787|NCT04337814|Experimental|OA Arm|Patients getting oral (O) analgesics (A) and topical placebo
11062788|NCT04337814|Placebo Comparator|Placebo Arm|Patients getting oral placebo and topical placebo
11062789|NCT04337801|Experimental|Acupressure|The acupressure was carried out as two sessions, postpartum second (the first session of intervention) and fourth hours (the second session of intervention). The intervention was applied bilaterally and clockwise (left Pericardium 6, left Large Intestine 4, right Large Intestine 4 and right Pericardium 6) in this study. The acupressure was applied for three minutes in average, one minute for massage and two minutes for pressure per point; with an average of 12 minutes for the whole application. In addition, the pain score of the women was assessed by themselves through the VAS before the intervention (Time 1) and 15 minutes (Time 2) after the intervention at postpartum second hour. Also, it was assessed before the intervention (Time 3) and 15 minutes (Time 4) after the intervention at postpartum forth hour. Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
11062790|NCT04337801|Placebo Comparator|Placebo|The Pericardium 6 and Large Intestine 4 points were slightly touched without pressure to women in the placebo group. Touches were applied to each acupressure point for three minutes similar to the acupressure group, each session of placebo lasted approximately 15 minutes. Similar to the acupressure group, In parallel with the acupressure, the pain score of the women was recorded at the postpartum second hour (Time 1) before intervention and 15 minutes later after intervention (Time 2), and at the fourth hour (Time 3) before intervention and 15 minutes later after intervention (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the researcher.
11062823|NCT04337606|Experimental|chidamide in combination with decitabine|chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks
11063555|NCT04332302|No Intervention|Control group|Participants will be doing their normal life.
11062791|NCT04337801|No Intervention|Control Group|No intervention was applied to the control group except for the routine nursing care. The data collection process in the control group was conducted in parallel with the acupressure and placebo groups. Pain score of women was recorded prior to intervention in the acupressure and placebo groups. The duration of intervention in the acupressure and placebo groups was 12 minutes and the measurements were repeated 15 minutes after the intervention. The average duration between the first and the second measurements is 30 minutes in the acupressure and placebo groups. In parallel with the acupressure and placebo groups, the current pain score of the women was recorded at the postpartum second hour (Time 1) and 30 minutes later (Time 2), and at the fourth hour (Time 3) and 30 minutes later (Time 4). Additionally, the analgesic substance and its amount applied during the application were recorded by the first researcher.
11062792|NCT04337788|Experimental|gerontological telemonitoring action|"Nurses answer a daily resident-reported questionnaire (e.g. temperature, dyspnea, pain), edited by French health authorities. From D0 to D20, data are transmitted to the NHSP. Warning algorithms specially developed for older persons identify signs that are monitored by the NHSP geriatrician coordinator. A feedback is provided to the general physician for specific actions required and appropriate support.
~A last questionnaire is completed at D30 by the nurse in order to stop monitoring and know event occurred between D20 to D30."
11062793|NCT04337788|No Intervention|routine care without gerontological telemonitoring|routine care
11062794|NCT04337762||Healthy|Healthy adult individuals residing in the United States with no history of COVID-19
11062795|NCT04337762||COVID-19 Confirmed|United States adults that have tested positive for SARS-CoV-2 virus which causes the human disease COVID-19 (IE novel coronavirus) or those that have been exposed to a confirmed case and are awaiting testing
11062796|NCT04337749|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to participants for 2 weeks
11062797|NCT04337749|Active Comparator|ZnO-NPs socks|ZnO-NPs socks were given to participants for 2 weeks
11062798|NCT04337749|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks were given to participants for 2 weeks
11062799|NCT04337749|Placebo Comparator|Placebo|Placebo socks were given to participants for 2 weeks
11062800|NCT04337736|Active Comparator|Aerobic training|12-weeks, 3-days-a week, supervised aerobic (Nordic walking or Walking) physical exercise (PhE) protocol; duration of each PhE session: 70 minutes; rate of perceived exertion (RPE): 10-11 (1st-4th week); 12-13 (5th-8th week); 13-14 (9th-12th week).
11062801|NCT04337736|Active Comparator|Resistance training|12-weeks, 2.3-days-a week (total of 28 lessons), supervised resistance physical exercise (PhE) protocol; duration of each PhE session: 50 minutes.
11062802|NCT04337723|Experimental|Intervention|Clinic participants will be taught how to do ABI testing and WIfI scoring to identify patients with PAD/DM disease for early vascular referral.
11062803|NCT04337710|Experimental|Exclusive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
11062804|NCT04337710|Active Comparator|Progressive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
11062805|NCT04337684||Historical Control|
11062806|NCT04337684||Treated with Copper Histidinate|
11062807|NCT04337671|Experimental|Training group (A)|The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
11062808|NCT04337671|No Intervention|control group (B)|Control group not receiving any training . They are taking their prescribed medications only.
11062809|NCT04337658|Experimental|Trastuzumab± Pertuzumab+ Fulvestrant|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.
~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
~Fulvestrant(Faslodex): 500mg intramuscular injections at day 1, 15, 28 and every 4 weeks thereafter"
11062810|NCT04337658|Active Comparator|Trastuzumab± Pertuzumab+ Capecitabine|"Pertuzumab(Perjeta): Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. It depends on the patient's choice.
~Trastuzumab(Herceptin): Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
~Capecitabine: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination."
11062811|NCT04337645|Experimental|Test group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline) combined with implantoplasty
11062812|NCT04337645|Active Comparator|Control group|resective surgical treatment of peri-implantitis (decontamination performed with titanium brushes and sterile saline)
11062813|NCT04337632|Experimental|PP|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.
11062814|NCT04337632|Active Comparator|TP|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
11062815|NCT04337619|Experimental|Standard Behavioral Weight Loss Treatment|
11062816|NCT04337619|Experimental|Behavioral + Mindful Acceptance|
11062817|NCT04337619|Experimental|Behavioral + Values|
11062818|NCT04337619|Experimental|Behavioral + Mindful Awareness|
11062819|NCT04337619|Experimental|Behavioral + Acceptance + Values|
11062820|NCT04337619|Experimental|Behavioral + Acceptance + Awareness|
11062821|NCT04337619|Experimental|Behavioral + Values + Awareness|
11062822|NCT04337619|Experimental|Behavioral + Acceptance + Values + Awareness|
11063590|NCT04332081|No Intervention|Standard of Care|
11062825|NCT04337593|Experimental|treatment arm|2500 IU/m2 pegaspargase given on day 1, 20 mg basiliximab given on day 1 and 8, repeated every 3 weeks
11062826|NCT04337580|Experimental|Omeprazole Plus Standard of Care for Prostate Cancer Regimen|This intervention will be given on an outpatient basis. Omeprazole, 80 mg twice daily.
11062827|NCT04337567|Active Comparator|Patients over 75 years_RF ablation|Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
11062828|NCT04337567|Active Comparator|Patients over 75 years_ballon cryoablation|Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
11062829|NCT04337554||Older healthy|Individuals over 40 years of age
11062830|NCT04337554||Peripheral artery disease|Individuals over 40 years of age with peripheral artery disease.
11062831|NCT04337541|No Intervention|Normal recommendations, no mask|Normal behavior according to the authority's recommendations or
11062832|NCT04337541|Experimental|Normal recommendations AND mask|Normal behavior according to the authority's recommendations AND use of facial masks
11062833|NCT04337528|Experimental|Thrust Group|Participant will receive the thrust technique manipulation of the affected sacroiliac joint.
11062834|NCT04337528|Active Comparator|Muscle-energy group|Participant will receive the muscle-energy technique manipulation of the affected sacroiliac joint.
11062835|NCT04337528|Placebo Comparator|Placebo Group|Participant will receive a placebo manipulation of the affected sacroiliac joint.
11062836|NCT04337515|Experimental|Patients receiving allogeneic hematopoietic cell transplant|"The test product is a stem cell product which has been alpha-beta T- cell depleted using the CliniMACS system. Alpha-beta T-cell depleted cells are given intravenously over a period of time as dictated by the final volume of the infused product (5 ml/kg/hour).
~The target dose of CD34+ cells is ≥20x10^6/kg, but a minimum of
~≥2.5x10^6/kg is required. The target dose of T-cell receptor (TCR) alpha-beta CD3+ cells is ≤1x10^5/kg."
11062837|NCT04337502||severe group|The severe group was designated when the patients had one of the following criteria during hospitalization issued by the Chinese National Health Committee (Version 3-5). 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse Oximeter Oxygen Saturation ≤ 93% at rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen fraction, PaO2/FiO2) ≤ 300 mmHg; 4) One of the conditions as following: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.
11062838|NCT04337502||non-severe group|The non-severe group was designated when the patients did not occur in the mentioned severe criteria until discharged from the hospital.
11062839|NCT04337476|Experimental|mother's song|At the suggestion of the music therapist, the mothers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
11062840|NCT04337476|Experimental|father's song|At the suggestion of the music therapist, the fathers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
11062841|NCT04337476|Experimental|singing of the music therapist|Music therapist will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
11062842|NCT04337476|No Intervention|No singing|Control group (not subjected to musical stimulation- no singing). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
11062843|NCT04337463|Experimental|ATG-008 and Toripalimab|Toripalimab will be combined with ATG-008.
11062844|NCT04337450|Active Comparator|SOC|Standard-of-care (SOC)
11062845|NCT04337450|Experimental|DTG/3TC|Dolutegravir (DTG) and lamivudine (3TC) (known as DTG/3TC)
11062846|NCT04337437|Experimental|Genakumab injection：5 groups|150 mg/1ml/bottle, single subcutaneous injection. Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,
11062847|NCT04337437|Placebo Comparator|Placebo for this trial : 5 groups|"The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
~Group A : 0.3mg/kg, Group B : 1mg/kg, Group C : 2mg/kg, Group D：4mg/kg, Group E : 6mg/kg,"
11062848|NCT04337424||Participants with active infection test to SARS-COV2|Sampling of saliva (1 to 2 ml)
11062849|NCT04337424||Convalescent participants for SARS-COV2|Sampling of saliva (1 to 2 ml)
11062850|NCT04337424||Participants cured to SARS-COV2|Sampling of saliva (1 to 2 ml)
11062851|NCT04337424||Participants with negative test to SARS-COV2|Sampling of saliva (1 to 2 ml)
11062852|NCT04337411||Cohort 1|Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
11062853|NCT04337411||Cohort 2|Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
11062854|NCT04337398|Experimental|Wearables|Adults with several mental illness
11062855|NCT04337398|Experimental|Wearables and exergames|Adults with several mental illness
11062856|NCT04337385|Experimental|3 hours of Prolonged Sitting|Participants will sit continuously for three hours before receiving a mixed meal challenge.
11062857|NCT04337385|Experimental|3 hours of interrupted sitting with hourly HIIE|Participants will have their three hour sitting period interrupted with high intensity interval cycling exercise (HIIE) at 30, 90 and 150 minutes into the intervention. In each exercise bout, they will cycle at 90% peak power for 3 x 60 second periods with 75 seconds of recovery in-between.
11062858|NCT04337372|Experimental|Effects of shared book reading|There will be one arm since all participants will undergo the same intervention.
11062913|NCT04336774|Experimental|Echocardiogram patients|Patients scheduled to have an echocardiogram (echo) and who are also being evaluated for, or are positive for COVID-19.
11062859|NCT04337333|Other|Two-in-one stent|Endoscopic placement of a Two-in-one stent into the extrahepatic bile duct, considering the longitudinal location of the stricture segment and predicted safety margin
11062860|NCT04337307||standard decontamination|incubators decontaminated with antiseptic molecules, healthcare workers involved in this decontamination, patients housed in these incubators
11062861|NCT04337307||steam pulverization|incubators decontaminated with steam pulverization, healthcare workers involved in this decontamination, patients housed in these incubators
11062862|NCT04337268|Active Comparator|human glucagon-like peptide-1|"Intervention:
~Drug: human glucagon-like peptide-1 Other names: GLP-1"
11062863|NCT04337268|Placebo Comparator|Placebo|"Intervention:
~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1"
11062864|NCT04337255|Active Comparator|MIND DIET intervention|Allocation and blinding 3 year intervention of MIND Diet + counseling
11062865|NCT04337255|Placebo Comparator|Usual care diet intervention|3 year Intervention of usual care diet + counseling
11062866|NCT04337242|Experimental|Blended Dynamic Interpersonal Therapy (B-DIT)|B-DIT is based on the same treatment principles as face-to-face Dynamic Interpersonal Therapy (DIT) and has the same structure of treatment consisting of three phases: (a) an exploration and engagement phase, (b) a middle or working through phase, and (c) an ending phase. B-DIT consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
11062867|NCT04337242|Experimental|Blended Cognitive Behavioral Therapy (B-CBT)|B-CBT is based on the same treatment principles as face-to-face Cognitive Behavioral Therapy (CBT). These include (a) psycho-education about depression, (b) cognitive restructuring (i.e., identifying and challenging maladaptive thoughts and beliefs, fostering problem solving capacities), (c) mindfulness and acceptance based approaches, and (d) relapse prevention. B-CBT in this trial consists of 8 online modules that are alternated with up to 8 fortnightly face-to-face sessions.
11062868|NCT04337242|Active Comparator|Dynamic Interpersonal Therapy (DIT)|DIT is a short-term, integrative psychodynamic, 16 weekly sessions individual therapy for depression. DIT formulates the presenting symptoms of depression as responses to interpersonal difficulties or perceived threats to attachments (loss/separation) and hence also as threats to the self.
11062869|NCT04337242|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a brief talking therapy that consists of a maximum of 16 sessions, offered over 4 to 6 months. CBT is based on the assumption that depression is directly related to patterns of thinking. Specifically, dysfunctional and often automatic patterns of thinking are assumed to be related to the onset and maintenance of depression.
11062870|NCT04337229|Experimental|artificial intelligence techniques|Facial and body movements of newborns will be recorded by camera, and images will be processed in computer environment by using artificial intelligence techniques. As a result, it is planned to create a technology that determines the comfort level of the newborn quickly and simply and can be used by the mobile device.
11062871|NCT04337203|Experimental|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
11062872|NCT04337177|Experimental|90 mg/m2/day VAL-413|VAL-413 at 90 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as VAL-413 for during Cycle 1.
11062873|NCT04337177|Experimental|110 mg/m2/day VAL-413|VAL-413 at 110 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as VAL-413 for during Cycle 1.
11062874|NCT04337177|Experimental|75 mg/m2/day VAL-413|In the event the 90 mg/m2/day starting dose is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented. VAL-413 at 75 mg/m2/day administered with Temozolomide at 100 mg/m2/day orally for 5 consecutive days at the beginning of every 21-day cycle. A single dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO) will be substituted at the same dosage as VAL-413 for during Cycle 1.
11062875|NCT04337125|Other|ADHD group|ADHD children with their parents
11062876|NCT04337125|Other|Control group|Children with typical development and their parents
11062877|NCT04337086|Experimental|T4k|
11062878|NCT04337086|Active Comparator|Twin block|
11062879|NCT04337073|Placebo Comparator|normal saline (N) group|Before anesthesia induction, N group received corresponding intravenous normal saline of the same volume.
11062880|NCT04337073|Active Comparator|propofol (P) group|Before anesthesia induction, P group received intravenous injection of 0.3mg/kg propofol
11062881|NCT04337060|Active Comparator|Group LB|Ultrasound-guided bilateral erector spinae plane block (10 ml 1% lidocaine + 10 ml 0.5% bupivacaine) + intravenous morphine patient-controlled analgesia.
11062882|NCT04337060|Sham Comparator|Group S|Ultrasound-guided bilateral erector spinae plane block. block (20 ml Normal Saline) + intravenous morphine patient-controlled analgesia.
11062883|NCT04337047||Vik sein|Vik sein users
11062884|NCT04337047||Vik asthme|Vik asthme users
11062885|NCT04337047||Vik migraine|Vik migraine users
11062886|NCT04337047||Vik depression|Vik depression users
11062887|NCT04337034|Experimental|mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0)
11062888|NCT04337034|Active Comparator|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured
11062914|NCT04336761||Child suspected of infection with COVID-19.|Child included with positive included
11062915|NCT04336748|Active Comparator|Hydroxychloroquine|200mg once daily
11062916|NCT04336748|Placebo Comparator|Placebo|
11062917|NCT04336735|Experimental|Immunization Tool Users|Users will trial a novel transplant-specific immunization tool (app)
11062918|NCT04336722|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
11062919|NCT04336722|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 104 weeks.
11063013|NCT04336059|Experimental|group 2|will receive real PENG block with bupivacaine (0.25%) in total volume of 20 ml.
11063591|NCT04332068|Active Comparator|Arm 1|Permethrin cream plus placebo tablets
11062889|NCT04337021|Active Comparator|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving-related stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
11062890|NCT04337021|No Intervention|Usual Care|CGs in this arm will be contacted telephonically once by a CM. After a brief needs assessment, the CM will provide contact information for appropriate VA (e.g., local CSP clinicians) and non-VA community resources/services. CGs will be sent brochures for the national VA CSP. Information on both the program's website (which includes links to training, education, resources, and outreach programs for CGs) and the national CG hotline number will be included in the mailed packet. After this initial contact, CGs in this group will only be contacted again 4 and 9 months after baseline for administration of follow-up research assessments. CGs will be encouraged to seek medical, psychological, social support, and social services that are available to them through VAMCs or any other non-VA/community source. CGs in the SOS group will be offered similar information.
11062891|NCT04337008|Active Comparator|Positive COVID 19 patient with no respiratory distress|
11062892|NCT04337008|Experimental|Positive COVID 19 patient with respiratory distress|
11062893|NCT04336995|Other|Exercise|Everyone is in this arm
11062894|NCT04336982|Experimental|CC-90009 in combination with venetoclax and azacitidine|"CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Venetoclax will be administered orally QD.
~Azacitidine will be administered intravenously or subcutaneously on planned dosing days for each cycle."
11062895|NCT04336982|Experimental|CC-90009 in combination with gilteritinib|CC-90009 will be administered intravenously per dosing schedule in a 28-day cycle. Gilteritinib will be administered orally QD.
11062896|NCT04336969|Other|T1D Patients|Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
11062897|NCT04336956||hospitalized children with Covid19|- Children < 18 years old Patients under 18 years old, admitted in French pediatric wards with a confirmed COVID-19 infection on Nasal and pharyngeal swab specimens or blood samples tested positive for 2019-nCoV nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest CT signs
11062898|NCT04336943|Experimental|Treatment (durvalumab, olaparib)|All patients receive durvalumab IV over 1 hour on day 1 of each cycle. Patients with CDK12 mutation and MMRd/MSI-high also receive olaparib PO BID on days 1- 28 of cycles 3-6. Patients with homologous recombination mutation also receive olaparib PO BID on days 1-28 of cycles 1-6. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
11062899|NCT04336930||Cardiac Arrest group|Patients remaining comatose after a cardiac arrest
11062900|NCT04336917|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve Rhomboid Intercostal and Subserratus Plane Block under ultrasound guidence at the end of the surgery.
11062901|NCT04336917|No Intervention|Control Group|Routine standard perioperative and postoperative analgesic protocol will be given.
11062902|NCT04336904|Experimental|Favipiravir|"Experimental: Favipiravir Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction."
11062903|NCT04336904|Placebo Comparator|Placebo|"Comparator: Placebo Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
11062904|NCT04336891||Hypoactive Sexual Desire Disorder|Women with Hypoactive Sexual Desire Disorder (HSDD, n=23)
11062905|NCT04336891||Moderate to severe VVA|Women with dyspareunia due to moderate to severe vulvovaginal atrophy (VVA) (n=12)
11062906|NCT04336891||Mild to moderate VVA|Women with dyspareunia due to mild to moderate VVA (n=37)
11062907|NCT04336891||HSDD + VVA|Women with HSDD reporting also significant dyspareunia due to moderate to severe VVA (n=9).
11062908|NCT04336878|Experimental|Healthy Habits in Pregnancy and Beyond intervention|Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice & purchasing, portion size, eating behaviour & keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
11062909|NCT04336878|No Intervention|Control group|The control group will receive 'usual' antenatal care which does not involve routinely delivered specific or standardised dietary advice.
11062910|NCT04336826|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 52 weeks.
11062911|NCT04336813|Experimental|Group A|Receive ARS in lecture 1 and act as controller in lecture 2
11062912|NCT04336813|Active Comparator|Group b|Receive ARS in lecture 2 and act as controller in lecture 1
11062920|NCT04336709|Active Comparator|Calcipex II|Calcipex group Manufactures Nishika, Yamaguchi, Japan Color- White Formulation- Water based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Water-based calcium hydroxide paste without radio contrast agent (Barium Sulfate) Packaging- (1 syringe of Calcipex Plain II (1.8g), 2 needles of Nishika Spin with 2 needle caps) Storage requirement- Room temperature (1-30℃).
11062921|NCT04336709|Active Comparator|Metapex|Metapex group Manufactures- Meta Biomed, Korea Color- Yellow Formulation- Oil based Duration- 7 days Form: Paste Frequency: Used once on 1st day only till canal fills. Composition- Premixed oil-based paste composed of Calcium Hydroxide with Iodoform and silicon oil Packaging-2.2g paste in 1 syringe. 20 disposable tips. 1 ring rotator for direction control of the tip Storage requirement- Room temperature (1-30℃).
11062922|NCT04336696|Active Comparator|Comparison between the studied groups regarding management.|The postoperative RAI scan after 1 month, showed a positive residual tumour in lateral LN in 70 patients in the controlled group and 13 patients in Group II, 8 patients in group III. In group I, Patients with residuals were submitted to RAI ablation.
11062923|NCT04336696|Other|Recurrence free survival|patients with total thyroidectomy only had shorter recurrence free survival
11062924|NCT04336683|Other|Patient|Patients undergoing gynecological brachytherapy, will be imaged with a 3D ultrasound medical device for the purpose of efficacy testing.
11062925|NCT04336670|Experimental|Virtual Reality group|Immersive Virtual Reality exercise program.
11062926|NCT04336670|Active Comparator|Usual activities group|Usual center therapies
11062927|NCT04336644|Experimental|Continuous patch monitoring system|"Participants will receive standard of care treatment with either arsenic trioxide or capecitabine. They will have continuous patch monitor system (BodyGuardian Heart) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.
~Twelve-lead ECGs are routinely performed in patients receiving arsenic trioxide at baseline and twice weekly during the first 4 weeks of therapy. These ECGs (total of up to 9) will be accessed for the purposes of this study. Patients who receive capecitabine do not routinely have ECGs performed after baseline, but for the purposes of this study, two serial ECGs will be conducted on Day 14 and Day 28 of Cycle 1 of treatment (total of 5 including baseline)."
11062928|NCT04336631|Other|Routine Medical Follow Up, Counseling & Usual Care|Behavioral counseling was provided to the patients on each consecutive follow up after enrolling in this study. They were adequately followed on physical exercise, reduced salt intake, lifestyle modifications, and smoking cessation. All measurements of blood pressure and weight were maintained and recorded.
11062929|NCT04336631|No Intervention|Routine Medical Follow Up & Usual Care|Usual routine medical care was provided to the study participants only.
11062930|NCT04336605||Young-HUNT|The young-HUNT study is a renowned, representative, population-based study where all adolescents living in the Nord-Trøndelag county have been invited to participate in four subsequent waves, from 1995 to 2019. Information about the study can be found here: https://www.ntnu.edu/hunt/young-hunt. In this study data from the Young-HUNT1-4 studies (1995-2019) will be linked to longitudinal, individual data from the Norwegian prescription Database (NorPD) (2004-2020), providing a unique, longitudinal dataset in which research questions will be explored. To obtain good, reliable follow-up data and outcome measures for the young-HUNT3 participants (2006-2008) the investigators will additionally include longitudinal data from the HUNT4 study of young adults (2017-2019); applicable for those participating in both the YoungHUNT3 and the YoungHUNT4.
11062931|NCT04336592||Patients|Patients scheduled to receive a surgical spine procedure at Mayo Clinic
11062932|NCT04336592||Clinicians|Surgeons, Physician pain specialists and allied health caring for participating patients
11062933|NCT04336579||Control|Retrospective review of patients (participants) with standard analgesia post total knee arthroplasty
11062934|NCT04336579||Diaphragmatic Breathing|Intervention: Participants will perform diaphragmatic breathing exercises postoperatively as part of their multi-modal pain regimen.
11062935|NCT04336566|Active Comparator|Melatonin|5mg dose of melatonin manufactured by Good Neighbor Pharmacy
11062936|NCT04336566|Placebo Comparator|Placebo|Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient
11062937|NCT04336553|Experimental|Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS). SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
11062938|NCT04336540|Experimental|Energy labelling|Energy labelling provided on restaurant menus
11062939|NCT04336540|No Intervention|No energy labelling|No energy labelling provided on restaurant menus
11062940|NCT04336540|Experimental|Increased availability of lower energy meals|Higher proportion of meals are 600kcals or less
11062941|NCT04336540|No Intervention|Baseline availability of lower energy meals|Proportion of meals that are 600kcals or less at baseline level
11062942|NCT04336527|Experimental|Home Treatment with Peer Support|Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.
11062943|NCT04336527|Active Comparator|Home Treatment without Peer Support|Patients receive conventional home treatment by a homehome treatment/crisis resolution team without contacts to a peer support worker.
11062944|NCT04336514|Experimental|Experimental Arm|
11062945|NCT04336501|Experimental|IM19 CAR-T group|Subject will be treated with IM19 car-t cells
11062946|NCT04336488|Experimental|Orochem (Test)|fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
11062947|NCT04336488|Active Comparator|Conventional (Control)|fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.
11062948|NCT04336475|Experimental|Group 1|exercise regimen and oral hygiene care advices
11062949|NCT04336475|Active Comparator|Group 2|oral hygiene care advices
11062950|NCT04336462|Experimental|oxyhydrogen|conventional treatment + hydrogen/ oxygen inhaled
11062951|NCT04336462|Experimental|oxygen|conventional treatment + oxygen inhaled
11062955|NCT04336436|Experimental|Mindfulness Training and Nutrition Counseling|"Baseline and 3-6 month follow up visits will be arranged for all participants.
~Visits will be conducted at baseline prior to initiation of mindfulness training and nutrition counseling, and at the 3-6 month follow up. Clinical and laboratory assessments will be obtained at each visit."
11062956|NCT04336423||Healthy smoker|Healthy smokers with smoking history at least 10 pack-years and normal spirometry value
11062957|NCT04336423||COPD patient|Patients with smoking history at least 10 pack-years and persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
11062958|NCT04336410|Experimental|Group 1: INO-4800|Participants will receive one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
11062959|NCT04336410|Experimental|Group 2: INO-4800|Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
11062960|NCT04336410|Experimental|Group 3: INO-4800|Participants will receive one ID injection of 0.5 mg of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
11062961|NCT04336397|Active Comparator|High Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
11062962|NCT04336397|Active Comparator|Medium Intensity|navigated tribal health worker outreach, a mailed MT-sDNA kit, mailed culturally appropriate educational material describing CRC screening options available and follow-up reminders
11062963|NCT04336397|No Intervention|Usual Care|usual care (i.e., opportunistic screening recommendation at a clinic visit)
11062964|NCT04336371||Anxiety level|patient's psychological experience the anxiety level
11062965|NCT04336358|No Intervention|Standard Early medical abortion care|Counseling, history, instruction, family planning with clinic nurse. Ultrasound to assess gestational age.
11062966|NCT04336358|Experimental|Telemedicine|Online consultation questionnaire and counseling, family planning information. Instruction for the abortion received to the participants Facebook Messenger. Gestational age <9 weeks assessed by bimanual palpation, ultrasound only in case of uncertainty.
11062967|NCT04336332|Experimental|Arm 1: Hydroxychloroquine Sulfate + Azithromycin|"Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
~Azithromycin 500 mg taken by mouth on Day 1, followed by
~Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days."
11062968|NCT04336332|Experimental|Arm 2: Hydroxychloroquine Sulfate alone|• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
11062969|NCT04336332|No Intervention|Arm 3: Placebo|"Placebo pills Days 1-6.
~If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days"
11062970|NCT04336319|Experimental|Patients with a confirmed diagnosis of UC who underwent IPAA|Patients who meet inclusion criteria will be enrolled and will sign an informed consent form. The study includes six visits to the IBD clinic and phone calls between visits.
11062971|NCT04336306|Experimental|Evaluation of chronic hemodynamic and autonomic repercussions|Participants in a cardiovascular rehabilitation program will be randomly allocated to CR + VRBT interventions. This group will hold 3 weekly sessions (one for VRBT and two for CR) for 12 weeks. In the first, sixth and last week, chronic hemodynamic data and autonomic data will be evaluated.Furthermore,at the end of 12 weeks, a focus group with therapists and a focus group with patients will be held to identify qualitative aspects in relation to the insertion of VRBT. And in all eligible patients of CR wiil be applied the Questionnaire of barriers identification in frequenters of Cardiovascular Rehabilitation.
11062972|NCT04336293|Experimental|active|active sTMS
11062973|NCT04336293|Sham Comparator|sham|sham sTMS
11062974|NCT04336267|Experimental|Transcranial direct current stimulation (tDCS) group|7-day detoxification protocol + 5 consecutive days of anodal tDCS treatment over the primary motor cortex.
11062975|NCT04336267|Sham Comparator|Sham group|7-day detoxification protocol + 5 consecutive days of sham treatment over the primary motor cortex.
11062976|NCT04336254|Experimental|hDPSCs group|Routine treatment + Intravenous injection of human dental pulp stem cells
11062977|NCT04336254|Placebo Comparator|Control group|Routine treatment + Intravenous saline injection (Placebo)
11062978|NCT04336241|Experimental|Dose escalation of RP2 - superficial tumors|Dose escalation of RP2 alone in 3 cohorts with IT injections in superficial tumors.
11062979|NCT04336241|Experimental|Dose escalation of RP2 - deep/visceral tumors|Dose escalation of RP2 alone in 3 cohorts with imaging guided IT injections in deep/visceral tumors.
11062980|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - superficial tumors|Doses of RP2 (IT) in superficial tumors with nivolumab (IV).
11062981|NCT04336241|Experimental|Dose expansion of RP2 and nivolumab - deep/visceral tumors|Imaging guided doses of RP2 (IT) in deep/visceral tumors.
11062982|NCT04336241|Experimental|Seronegative cohort|Doses of RP2 (IT) in HSV seronegative participants.
11062983|NCT04336228|Placebo Comparator|Healthy Control Group|The healthy placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
11062984|NCT04336228|Placebo Comparator|Obsessive-Compulsive Disorder Control Group|The OCD placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
11062985|NCT04336228|Experimental|Healthy Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
11062986|NCT04336228|Experimental|Obsessive-Compulsive Disorder Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
11062987|NCT04336215||Healthcare Workers|500 HCW with high intensity direct patient care from two RBHS-affiliated academic hospitals: Robert Wood Johnson University Hospital (New Brunswick, NJ) and University Hospital (Newark, NJ) and Rutgers School of Dental Medicine (Newark, NJ) . Since rates of asymptomatic carriage, clinical infection, and morbidity likely vary by age and sex, the aim is to recruit 125 HCW in each of the following 4 groups: males ages 20-59; males ages ≥60; females ages 20-59; and females ages ≥60.
11063080|NCT04335552|Experimental|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
11088950|NCT04153773||Group 2|30 Control subject
11062988|NCT04336215||Non-Healthcare Workers|250 non-healthcare workers (NHCW) from Rutgers faculty, postdoctoral students, students, other trainees, administrators, and staff who do not have patient contact. The aim is to recruit even numbers of NHCW from each of these 4 groups: males ages 20-59; males ages ≥60; females ages 20-59; females ages ≥60.
11062989|NCT04336215||Household Members|Complementing the HCW cohort study, approximately 540 household members in a subset of the participants who test positive and negative for SARS-CoV-2 will be invited to be followed prospectively to assess patterns of viral transmission. The target population will be multigenerational households (e.g., with children and/or parents) from up to 6 infected HCW, 6 infected NHCW, 4 uninfected HCW, and 4 uninfected NHCW at each timepoint. The participant will ask household members to contact research staff if they wish to volunteer for the study. Research coordinators will individually consent adult members of the household for questionnaire and serial samples collection. When children are in the home, parental permission as well as assent for children ages 7 and older (written at ages 12 and older) will be the course of action. The estimated 540 participants assumes 20 houses per timepoint, 9 timepoints, and an average of 3 participants per house.
11062990|NCT04336202|Other|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
11062991|NCT04336189|Active Comparator|SP + DP placebo every 4 weeks|
11062992|NCT04336189|Active Comparator|DP + SP placebo every 4 weeks|
11062993|NCT04336189|Active Comparator|SP + DP given every 4 weeks|
11062994|NCT04336176|Active Comparator|PulseFlow DF boot|PulseFlow DF boot
11062995|NCT04336176|Active Comparator|Usual Care|Measurements will be taken from patients wearing usual standard of care
11062996|NCT04336176|Sham Comparator|Sham|Sham shoe (closest to barefoot or baseline pressures)
11062997|NCT04336163|Experimental|Prospective Study Group|For the experimental group, the laser surgeon will be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on the measurements.
11062998|NCT04336163|Other|Prospective Control Group|For the control group, the laser surgeon will not be exposed to the OCT measurements and will select laser settings and determine treatment parameters based on standard of care, intuition, and experience.
11062999|NCT04336150|Experimental|Hypopressive exercisesE|"Hypopressive exercises described according to Dr. Caufriez
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive exercises according to the original method described by Dr. Caufriez, which is based on performing the hypopressive maneuver in 33 postures that he described (1,2)."
11063000|NCT04336150|Experimental|Hypopressive exercises&PFM contraction|"Hypopressive exercises + active pelvic floor muscle contraction:
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive exercises according to the original method described by Dr.Caufriez, which is based on performing the hypopressive maneuver in 33 postures he described, plus the active contraction of the pelvic floor muscles (PFM) during the hypopressive maneuver."
11063001|NCT04336150|Experimental|Hypopressive maneuver|"Hypopressive maneuver:
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive maneuver with transabdominal ultrasound biofeedback."
11063002|NCT04336150|Experimental|Hypopressive maneuver&PFM contraction|"Hypopressive maneuver + pelvic floor muscles contraction:
~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).
~Hypopressive maneuver plus active contraction of the pelvic floor muscles with transabdominal ultrasound biofeedback."
11063003|NCT04336124|Experimental|CVM-1118 ER|Dose escalation (escalation from 400, 600, 800 to 1200 mg of CVM-1118 ER Capsule)
11063004|NCT04336111|No Intervention|control group|will receive sham bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position.
11063005|NCT04336111|Experimental|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
11063006|NCT04336098|Experimental|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
11063007|NCT04336098|Experimental|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
11063008|NCT04336085|Experimental|caudal group|Caudal block using ultrasound guidance. the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine and the depth and gain will be adjusted for optimal visual quality.the needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
11063009|NCT04336085|Experimental|PENG group|The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. the needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly.
11063010|NCT04336072|Experimental|Reminder Focused Positive Psychiatry (RFPP)|RFPP aims to enhance contextual discrimination and emotional regulation, and promote the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
11063011|NCT04336072|Active Comparator|Trauma Focused Cognitive Behavioral Therapy (TFCBT)|TFCBT is inclusive of the trauma narrative (TN) & processing components facilitated the child talking about memories individually and in groups, the last sessions focused on grief-specific elements.
11063012|NCT04336059|Other|group 1|will receive sham PENG block with normal saline in total volume of 20 ml.
11063014|NCT04336046|Sham Comparator|control group|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
11063015|NCT04336046|Experimental|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
11063016|NCT04336033|Experimental|Counseling + Renal Diet App|Subjects in the intervention group will receive an individualized dietetic counseling from the researcher aided with the newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients
11063017|NCT04336033|Placebo Comparator|Counseling + Printed Nutrition Pamphlet|Individualized dietetic counseling aided with printed nutrition pamphlet prepared by Ministry of Health, Malaysia
11063018|NCT04336007|Experimental|Radio-frequency group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode on.
11063019|NCT04336007|Placebo Comparator|Placebo group|The equipment used, INDIBA® Activ Ct9, (448kHz), with the switch-mode off.
11063020|NCT04336007|Sham Comparator|Control Group|NO INTERVENTION athlete's usual pre-competition warming-up
11063021|NCT04335994|Active Comparator|Standard of Care|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
11063022|NCT04335994|Experimental|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
11063023|NCT04335968|Experimental|Experimental group|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery
11063024|NCT04335968|Placebo Comparator|Control group|placebo of this drug with the same schedule, during the same period of time.
11063025|NCT04335942|Other|AFNOR 3.6 alerts|"Alert called AFNOR 3.6 in connection with the dispersion index described by Drummond et al 1985 and validated by Sprigle et al 2003. This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),"
11063026|NCT04335942|Other|AFNOR 3.6 alerts and Guidelines|"AFNOR 3.6 alerts and Guidelines alerts. By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009)."
11063027|NCT04335929|Experimental|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
11063028|NCT04335890|Experimental|DC IKKb|Vaccination with IKKb matured RNA loaded Dendritic Cells
11063029|NCT04335877|Experimental|Private sector component + modified BCC|Private sector component + modified BCC + current standard of care
11063030|NCT04335877|No Intervention|Control|Current standard of care + standard BCC
11063031|NCT04335864|Active Comparator|Group A|39 patients with hydrosalpinx will have laparoscopic salpingectomy
11063032|NCT04335864|Active Comparator|Group B|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
11063033|NCT04335851|Experimental|Physical Activity Group|"Individuals in this group will be given walk at home exercise video made by American Hearth Association. Videos for each week will be chosen by therapist. They will be asked to do exercise 3 days a week for 4 weeks by following the videos. The intensity and duration of the exercises will be gradually increased by therapists each week. Exercise follow-ups will be done over the phone and by asking individuals to keep an exercise diary."
11063034|NCT04335851|No Intervention|Control Group|Physically inactive individuals will be included to study as control. Individuals will be asked to continue their daily routines.
11063035|NCT04335838||Polytrauma Patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
11063036|NCT04335825|Active Comparator|phacotrabeculectomy|patients undergoing phacotrabeculectomy
11063037|NCT04335825|Active Comparator|ExPress device implantation|patients undergoing ExPress antiglaucoma surgery combined with phacoemulsification
11063038|NCT04335812|Experimental|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
11063039|NCT04335812|Active Comparator|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
11063040|NCT04335799|Experimental|Weight Loss Plus Stress Management|Diabetes Prevention Program Intensive Lifestyle Intervention augmented with stress management training
11063041|NCT04335799|Active Comparator|Weight Loss Only|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
11063042|NCT04335786|Experimental|Active treatment arm|Valsartan at a dosage and frequency titrated to blood pressure with 80mg or 160mg tablets up to a maximum dose of 160mg b.i.d.
11063043|NCT04335786|Placebo Comparator|Placebo arm|Matching 80mg or 160mg placebo tablets at a dosage and frequency titrated to systolic blood pressure
11063044|NCT04335773||Sars-CoV-2 positive|Children positive for SARS-CoV-2
11063045|NCT04335773||SARS-CoV-2 negative|Children negative SARS-CoV-2
11063081|NCT04335552|Experimental|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
11063082|NCT04335552|Experimental|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
11063340|NCT04333784||exercise with BFR|Patients with rotator cuff tendinopathy will perform the exercises with a pneumatic cuff and blood flow restricted.
11063046|NCT04335760||Patients with Coronary Artery Disease|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.
~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.
~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
11063047|NCT04335760||healthy subjects|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.
~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.
~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
11063048|NCT04335747||Group 1|Patients with inflammatory rheumatic diseases who are hospitalised due to a COVID-19 infection
11063049|NCT04335747||Group 2|Patients without inflammatory diseases who are hospitalised due to a COVID-19 infection
11063050|NCT04335747||Group 3|Patients with inflammatory rheumatic diseases who are having routine blood samples taken under the COVID-19 epidemic after inclusion and who have NOT been hospitalised due to a COVID-19 infection
11063051|NCT04335747||Group 4|Healthy subjects from the Danish Blood Donors have NOT been hospitalised due to a COVID-19 infection
11063052|NCT04335734|Active Comparator|Nissen fundoplication with fixation of the wrap|In this arm, which included 87 patients we performed the following manipulations: NF was supplemented with suturing wrap to the diaphragmatic crura (52 patients) on each side using two non-absorbable stitches. In case of weak conditions of crura or short esophagus (35 patients) fundoplication wrap was sutured to the body of stomach using two non-absorbable stitches on each side. .
11063053|NCT04335734|Active Comparator|Nissen fundoplication without fixation of the wrap|Arm included 51 patients, who underwent classic Nissen fundoplication without wrap fixation.
11063054|NCT04335721|Experimental|Voxelot|Voxelotor 1500mg once a day
11063055|NCT04335721|Other|Standard of Care (SOC)|Observational while receiving SOC
11063056|NCT04335708|Experimental|Intervention|Daily consumption of 5 mL of edible gel with intracellular content of Lactobacillus casei CRL-431 during 30-d
11063057|NCT04335708|Placebo Comparator|Placebo|Daily consumption of 5 mL of edible gel without intracellular content of Lactobacillus casei CRL-431 during 30-d
11063058|NCT04335695|Other|Vascular Rehabilitation and Follow Up|All subjects will be enrolled in a 6-12 Vascular Rehab Program (VRP) and then be followed for one year following discharge from the VRP.
11063059|NCT04335682|Active Comparator|Darolutamide (DARO)|Patients will take DARO at a dose of 600 mg (300 mg ×2 tablets) by mouth twice daily beginning on Day 1, of Week 1. Patients will take DARO throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
11063060|NCT04335682|Active Comparator|Enzalutamide (ENZ)|Patients will take ENZ at a dose of 160 mg PO once daily (QD), beginning on Day 1, of Week 1. Patients will take ENZ throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
11063061|NCT04335669|Active Comparator|Arm A (Platinum-based dose dense EC):|Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
11063062|NCT04335669|Experimental|Arm B (Platinum-based with capecitabine):|Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
11063063|NCT04335656|Experimental|Treatment Group|Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.
11063064|NCT04335656|Placebo Comparator|Placebo Group|Subjects will be randomized to the treatment or placebo group. The placebo is a capsule taken by mouth once a day for 6 months.
11063065|NCT04335643|Experimental|TEACH|Participants will undergo CBT and continue medical TAU.
11063066|NCT04335643|No Intervention|Control|Participants will only continue medical TAU.
11063067|NCT04335630||Cases|Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR.
11063068|NCT04335630||Controls|Age- and gender-matched subjects admitted to the hospital with similar symptoms but negative PCR testing for SARS-CoV-2 (one negative PCR test for patients of low clinical suspicion and two negative tests, 24 hours apart from each other, for patients of high clinical suspicion).
11063069|NCT04335617|Experimental|Investigational|Patients receive MMPF 500mg for one year
11063070|NCT04335617|Placebo Comparator|Placebo|Patients receive Placebo for one year
11063071|NCT04335604|Experimental|JPI-547|
11063072|NCT04335591|Experimental|Linzagolix 75 mg|
11063073|NCT04335591|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
11063074|NCT04335578|Experimental|Zampilimab Cohorts|Participants will be randomized to receive zampilimab (UCB7858) or Placebo in order to maintain the blinding. The dose for Stage 2 will be informed by DMC recommendation based on Stage 1 data.
11063075|NCT04335578|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo to maintain the blinding.
11063076|NCT04335565|No Intervention|Water|250 ml of water mixed with 1g of citric acid.
11063077|NCT04335565|Active Comparator|Sugar|65g of sugar dissolved in 250ml of water
11063078|NCT04335565|Experimental|Stevia|5g of stevia dissolved in 250ml of water
11063079|NCT04335552|Active Comparator|Standard of care|
11063592|NCT04332068|Experimental|Arm 2|Ivermectin (200 µg/kg) plus placebo cream
11063083|NCT04335539|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously on Day 1, in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
11063084|NCT04335539|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered intravenously every 8 hours for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
11063085|NCT04335526|No Intervention|Metformin alone|
11063086|NCT04335526|Other|Metformin with cholestyramine|
11063087|NCT04335513|Experimental|Intervention|Early diabetes management and education including focused education based on pathophysiology of type 1 diabetes, factors which impact blood glucose, and effects of insulin using data from continuous glucose monitoring device (CGM) worn unblinded at least 20 days per month with interpretation and education on results. Early initiation of insulin therapy, when warranted based on a pattern of prolonged or repeated high blood glucose values.
11063088|NCT04335513|Active Comparator|Control|Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK (ongoing studies at BDC). This includes: blood glucose checks 2-3 times per month, participant-led contact with study personnel when abnormalities are noted and transition to clinical care when criteria for clinical type 1 diabetes are met.
11063089|NCT04335487|Experimental|ICBT for PTSD Tailored for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy for PTSD tailored specifically for Canadian public safety personnel.
11063090|NCT04335487|Experimental|Transdiagnostic ICBT Tailored for PSP|Therapist-guided, transdiagnostic Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
11063091|NCT04335474||Surgical drainage|Cases that have surgical management
11063092|NCT04335474||Percutaneous drainage|Cases that have the nonoperative management by percutaneous drainage
11063093|NCT04335461|Placebo Comparator|Placebo|Placebo group, with no regional nerve blockade administered.
11063094|NCT04335461|Experimental|Fracture block|Patients will have an intrafragmentary fracture block using fluoroscopy guidance after surgical fixation with 30cc 0.25% marcaine
11063095|NCT04335461|Experimental|Fascia iliaca block|Fascia iliaca compartment blockade administered after surgical fixation using the loss of resistance technique with 30cc 0.25% marcaine
11063096|NCT04335448||Arterial Switch Operation - Transposition of Great Arteries|Patients with previous arterial switch operation for the treatment of a transposition of great arteries will constitute the sole group of the cohort.
11063097|NCT04335435|Experimental|Oat Bran Consumption|Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.
11063098|NCT04335422|Experimental|Robotic group|Robotic group will receive both routine physical and rehabilitation medicine program and additional upper extremity robot-assisted training by Armeo Spring. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and robotic therapy one hour/day. Routine PRM program and robotic therapy will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program plus robotic therapy).
11063099|NCT04335422|Active Comparator|Control group|Control group will receive only routine physical and rehabilitation medicine program. Routine physical and rehabilitation medicine program, including physical therapy and exercises, walking and balance training, and occupational therapy to improve activities of daily living will last nearly 2 hours/day and will be given through 6 weeks, 5 days a week (A total of 30 sessions of routine PRM program only).
11063100|NCT04335409|Experimental|Participants irradiated for lung cancer|Participants who receive radiotherapy for lung cancer and have risk factors for developing radiation pneumonitis. Risk factors include mean dose to the ipsilateral lung >13 Gy plus at least one other factor (significant cardiovascular disease, history of heavy smoking (≥40 pack years), previous/concurrent chemotherapy or previous/adjuvant immunotherapy) or mean dose to the ipsilateral lung >20 Gy without other factors.
11063101|NCT04335396||adult patients with diabetes mellitus|Subgroup 1 - consecutive patients with diabetes mellitus with scleredema skin disorder Subgroup 2 - consecutive patients with diabetes mellitus without scleredema Subgroup 3 - patients with diabetes and scleredema - already cared in the tertiary center of the Rheumatology Department of the University of Pécs, in Hungary.
11063102|NCT04335370||Patients with CF lung disease receiving Polymyxin B (PMB)|Participants receiving polymyxcin B as part of standard of care treatment for CF exacerbation will have blood drawn measure blood concentrations of PMB
11063103|NCT04335357|Placebo Comparator|placebo|The appearance and fill of placebo syringes will be identical to the active comparator.
11063104|NCT04335357|Active Comparator|TBR-760|TBR-760 is supplied as a ready-to-use solution in pre-filled syringes at a concentration of 5 mg/ml.
11063105|NCT04335344||Control|Healthy patients
11063106|NCT04335344||Periodontitis|Patients with periodontitis
11063107|NCT04335344||Cardiovascular disease|Patients with cardiovascular disease
11063108|NCT04335344||Periodontitis + cardiovascular disease|Patients with Periodontitis + cardiovascular disease
11063109|NCT04335331|Experimental|PreDM CDS|The PreDM CDS arm engages patients, clinicians, and health educators in the following 3 intervention components, followed by audit and feedback for clinicians: 1) Evidence-based information about T2D prevention 2) Tailored referral to local ILI programs through a novel platform integrated into the CDS; and 3) Prompt to consider metformin prescription using the routine EHR medication order function embedded in the CDS.
11063110|NCT04335331|Placebo Comparator|Standard Care|Standard care includes no additional intervention above the care routinely provided at the clinical partner site, Erie Family Health Center.
11063111|NCT04335318|Experimental|Colonoscopy with AI-assistance group|Colonoscopies were performed with AI-assistance.
11063112|NCT04335318|No Intervention|Standard Colonoscopy group|Standard clinical procedure
11063175|NCT04334928|Experimental|Emtricitabine/Tenofovir|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg
~Strength: 200 mg/245 mg tablets
~Dose: one tablet once a day (both at dinner)"
11063341|NCT04333784||Control|Patients with rotator cuff tendinopathy will perform the exercises without a pneumatic cuff.
11063113|NCT04335305|Experimental|Tocilizumab plus Pembrolizumab (MK-3475)|"Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.
~Patients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 ≤ 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."
11063114|NCT04335305|No Intervention|Continued Standard of Care|Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine.
11063115|NCT04335292|Experimental|Treatment Arm|"First-line treatment = osimertinib, 80 mg, oral, daily; Second-line treatment = platinum (carboplatin or cisplatin) + pemetrexed chemotherapy, prescribed as per institutional standards; Third-line treatment = osimertinib rechallenge, 80 mg, oral, daily.
~Patients may enter the study at first-line treatment, second-line treatment, or third-line treatment. This is dependent on meeting the eligibility criteria."
11063116|NCT04335279|Experimental|SPIN-CHAT: Videoconference Intervention|Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.
11063117|NCT04335279|No Intervention|Wait-list Control|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.
11063118|NCT04335266|Experimental|Treatment group A|Drug: SHR2554 fasted in P1, high-fat diet in P2 SHR2554 administration in fasted condition in period 1, SHR2554 administration after high-fat diet in period 2
11063119|NCT04335266|Experimental|Treatment group B|Drug: SHR2554 high-fat diet in P1, fasted in P2 SHR2554 administration after high-fat diet in period 1, SHR2554 administration in fasted condition in period 2
11063120|NCT04335253|Experimental|Multiple Ascending Dose|Dose escalation according to cohort allocation
11063121|NCT04335240|Experimental|Music Therapy Intervention|"This protocol is a Family Centered Care Music Therapy Intervention. The methodologies will provide early intervention from the first days of hospitalization in NICU and consist of music therapy sessions both active (parental chant, live music and lullaby) and receptive (listening to recorded tracks). The music therapy accompanies the newborn and the parents during the hospitalization and focuses its attention on the emotional-relational care, according to the different needs that they will develop over time.Therapy sessions will be performed starting from three times per week, on three different days of the week, during the entire hospitalization of the enrolled infants. After discharge music therapy treatment will be performed once a week until twelve months of corrected age.
~Stress level of infants and parents and neurobehavioral and neurological development of children will be assessed."
11063122|NCT04335240|No Intervention|No music therapy intervention|Music therapy is not administered in this group. Control group (no music therapy). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
11063123|NCT04335227|Experimental|Yoga therapy group|Structured yoga therapy program for 60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
11063124|NCT04335227|Experimental|Aerobic exercise group|Aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks and nutritional management uniquely prepared by dietitian
11063125|NCT04335227|Experimental|Combined yoga therapy and aerobic exercise group|Combined yoga therapy for three days and vigorous aerobic exercise program for three days with nutritional management uniquely prepared by dietitian
11063126|NCT04335227|Active Comparator|Control group|Nutritional management uniquely prepared by dietitian
11063127|NCT04335214|Other|Interview|One to one interview with older people from moroccon origin in Belgium
11063128|NCT04335201|Experimental|Arm Label|with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
11063129|NCT04335188||In-patients with SARS-CoV-2 infection|"In-patients fulfilling the following criteria:
~SARS-CoV-2 infection In-patient treatment Written informed consent for participation in observational study No explicit medical exclusion criteria are stated to avoid selection bias."
11063130|NCT04335175||Tourette Syndrome|Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
11063131|NCT04335175||Obsessive Compulsive Disorder|Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
11063132|NCT04335175||Healthy Controls|Individuals with no past or current neurologic or psychiatric illness. Participants must be 18 years of age or older.
11063133|NCT04335162||Patients with cardiovascular complications|Patients presenting with cardiomyopathies or venous thromboembolism
11063134|NCT04335162||Patients without cardiovascular complications|Patients without cardiomyopathies or venous thromboembolism
11063135|NCT04335162||Intensive Care Unit patients|Patients admitted in intensive care unit
11063136|NCT04335162||Hospital Ward patients|Patients admitted in hospital ward
11063137|NCT04335149||COREVALVE|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a COREVALVE
11063138|NCT04335149||EDWARDS|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a EDWARDS
11063139|NCT04335136|Active Comparator|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
11063140|NCT04335136|Placebo Comparator|Group B (placebo control)|
11063176|NCT04334928|Experimental|Hydroxychloroquine|"Hydroxychloroquine 200 mg + Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg
~Strength: 200 mg tablets
~Dose: one tablet once a day (both at dinner)"
11063342|NCT04333771|Placebo Comparator|Placebo|
11063343|NCT04333771|Experimental|SHR0302 dose1|
11063141|NCT04335123|Experimental|Open Label Losartan|50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Participants will continue losartan until they experience resolution of respiratory failure (normal oxygen levels on room air), are discharged from the hospital, meet stoppage criteria or complete 14 days of therapy.
11063142|NCT04335110|Other|Intervention|Care Partners and Persons with Dementia. Up to 40 Care Partners and their 40 care-recipients with ADRD will participate in this study. The primary focus of this study is on Care Partners, however, we will gather subjective and objective data on participants with Alzheimer's Disease and Related Dementias (ADRD) to assess the effect of the intervention on Care Partner affective responses to caregiving and quality of life for both. STELLA participants will be recruited from the existing cohort of patients, and their Care Partners, who are enrolled in the Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology) ORCASTRAIT Life Laboratory (OSLL).
11063143|NCT04335097|Active Comparator|Control|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service.
11063144|NCT04335097|Active Comparator|Intervention|Follow general recommendations fram doctor and health authorities what to do and pay attention to before new contact with health service. I addition active reporting of clinical status and continuous vital sign monitoring based on electronic sensors (Welfare technology).
11063145|NCT04335084|Experimental|Medical Workers|Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.
11063146|NCT04335084|Placebo Comparator|Placebo|Medical workers how are exposed to COVID-19 and as such are at a higher risk for infection
11063147|NCT04335071|Experimental|Actemra|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
11063148|NCT04335071|Placebo Comparator|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no improvement in the 8-point WHO scale is observed.
11063149|NCT04335058|Experimental|Group A: Lactoferrin plus oral iron|Treated for 2 months regularly with oral administration of 100 mg Lactoferrin tablet twice a day before meals with oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
11063150|NCT04335058|Active Comparator|Oral iron alone|Oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals
11063151|NCT04335045|Active Comparator|100mg Dose|1 x 100 mg PH100 capsule (n=6)
11063152|NCT04335045|Placebo Comparator|Control for 100mg Dose|1 placebo capsule (n=2)
11063153|NCT04335045|Active Comparator|200mg Dose|1 x 200 mg PH100 capsule (n=6)
11063154|NCT04335045|Placebo Comparator|Control for 200mg Dose|1 placebo capsule (n=2)
11063155|NCT04335045|Active Comparator|400mg Dose|2 x 200 mg PH100 capsules (n=6)
11063156|NCT04335045|Placebo Comparator|Control for 400mg Dose|2 placebo capsules (n=2)
11063157|NCT04335045|Active Comparator|800mg Dose|4 x 200 mg PH100 capsules (n=6)
11063158|NCT04335045|Placebo Comparator|Control for 800mg Dose|4 placebo capsules (n=2)
11063159|NCT04335045|Active Comparator|1200mg Dose|6 x 200 mg PH100 capsules (n=6)
11063160|NCT04335045|Placebo Comparator|Control for 1200mg Dose|6 placebo capsules (n=2)
11063161|NCT04335045|Active Comparator|1600mg Dose|8 x 200 mg PH100 capsules (n=6)
11063162|NCT04335045|Placebo Comparator|Control for 1600mg Dose|8 placebo capsules (n=2)
11063163|NCT04335032|Experimental|Eicosapentaenoic acid gastro-resistant capsules|"Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg gastro-resistant capsules 2g daily (two capsules twice daily).
~One capsule of EPA-FFA gastro-resistant capsules contains 500mg EPA-FFA in a capsule containing gelatin, glycerol, sorbitol, titanium dioxide, FD&C blue No. 1, hypromellose phthalate, dibutyl sebacate."
11063164|NCT04335032|Placebo Comparator|Placebo|Placebo capsules that cannot be visually differentiated from the active treatment
11063165|NCT04335006|Experimental|Experimental A|Subjects receive Carelizumab in combination with Nab-paclitaxel plus Apatinib,each 4-week cycle
11063166|NCT04335006|Experimental|Experimental B|Subjects receive Carelizumab in combination with Nab-paclitaxel,each 4-week cycle
11063167|NCT04335006|Active Comparator|Comparator C|Subjects receive nab-paclitaxel intravenously each 4-week cycle.
11063168|NCT04334993|Experimental|Blinatumomab pre-transplant to high risk Ph-negative ALL pts.|Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
11063169|NCT04334980|Experimental|bacTRL-Spike|"Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);
~Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;
~Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;
~Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older."
11063170|NCT04334967|Experimental|Treatment Arm|Patients in the treatment arm will receive 200 mg oral hydroxychloroquine. Day 1: 400 mg doses twice (800 mg total). Days 2-5: 200 mg dose twice (400 mg total daily).
11063171|NCT04334967|Active Comparator|Control Arm|Patients in the control arm will receive 500 mg oral Vitamin C. Day 1: 1000 mg dose twice (2000 mg total) Days 2-5: 500 mg dose twice (1000 mg total daily).
11063172|NCT04334954||1|Healthy Volunteers
11063173|NCT04334941|Active Comparator|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11063174|NCT04334941|Experimental|Arm II (atezolizumab, talazoparib)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and talazoparib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11063202|NCT04334733|Experimental|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography.
11063177|NCT04334928|Experimental|Emtricitabine/Tenofovir+Hydroxychloroquine|"Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Hydroxychloroquine 200 mg
~Strength FTC/TDF:200 mg/245 mg tablets
~Strength HC: 200 mg tablets
~Dose: one tablet FTC/TDF plus one tablet HC once a day (at dinner)"
11063178|NCT04334928|Placebo Comparator|Placebo|"Placebo of Tenofovir Disoproxil Fumarate 245 mg/Emtricitabine 200 mg + Placebo of Hydroxychloroquine 200 mg
~Placebo tablets with similar appearance to study drugs.
~Dose: one tablet once a day (both at dinner)"
11063179|NCT04334915|Experimental|Arm A: Cenicriviroc Mesylate (CVC)|"Cenicriviroc mesylate (CVC) 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing antiretroviral (ARV) regimens.
~For participants who are on an efavirenz (EFV)-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
11063180|NCT04334915|Placebo Comparator|Arm B: Placebo for CVC|"Placebo for CVC 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing ARV regimens.
~For participants who are on an EFV-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
11063181|NCT04334902||Abnormal|The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism
11063182|NCT04334902||Normal|The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism
11063183|NCT04334889||Chronic low back pain (CLBP)|All CLBP patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months.
11063184|NCT04334889||Asymptomatic controls|Asymptomatic participants should have had no history of LBP requiring medical attention during the last two years and no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics.
11063185|NCT04334876||High Risk Healthcare Workers|At home, finger prick, antibody test.
11063186|NCT04334863|Experimental|WP1066|There will be 5 groups based on the enrollment timing. The first group of participants will receive the lowest dose level of WP1066. Each subject within a group will receive an assigned dose of the investigational drug. The dose levels are 4, 6, 8, 12, and 16 mg/kg of the investigational drug given twice a day. The first group will receive the lowest dose level, 4mg/kg twice a day, and subsequent groups will escalate to the next higher dose level. All groups will be treated identically, except for the dose of drug administered, with the liquid formulation of the drug.
11063187|NCT04334850|Experimental|Targeted antibiotic treatment according to the results of mPCR|a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
11063188|NCT04334850|Other|Control arm|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
11063189|NCT04334824||Hydrochlorothiazide|Patients who received a new prescription for hydrochlorothiazide (alone or in combination with non-ACE inhibitor antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
11063190|NCT04334824||Angiotensin-converting enzyme (ACE) inhibitors|Patients who received a new prescription for an ACE inhibitor (alone or in combination with non-hydrochlorothiazide antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
11063191|NCT04334811|Other|Arm|No arm
11063192|NCT04334798|Experimental|PFM&electro&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).
11063193|NCT04334798|Experimental|PFM&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).
11063194|NCT04334798|Experimental|PFM&electro&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).
11063195|NCT04334798|Experimental|PFM&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).
11063196|NCT04334785|Experimental|cryo-ablation group|In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.
11063197|NCT04334772|Experimental|Muscle belly Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at hamstring muscular belly. The acupuncture needle will correspond to the negative electrode or cathode.
~The group will also receive a passive stretching exercise treatment by a physical therapist."
11063198|NCT04334772|Experimental|Tendon Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at the hamstring tendon. The acupuncture needle will correspond to the negative electrode or cathode.
~The group will also receive a passive stretching exercise treatment by a physical therapist."
11063199|NCT04334772|Active Comparator|Control|Group to receive treatment by assisted passive stretching performed by a physical therapist on tightness hamstrings.
11063200|NCT04334759|Experimental|Arm A: Durvalumab + Chemotherapy, then Durvalumab Maintenance|Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
11063201|NCT04334759|Active Comparator|Arm B: Chemotherapy, then Observation|Standard Chemotherapy for 4 to 6 cycles, followed by Observation
11063344|NCT04333771|Experimental|SHR0302 dose2|
11063203|NCT04334733|Experimental|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
11063204|NCT04334733|Experimental|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography and the children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
11063205|NCT04334733|Experimental|Control group|No intervention was made to children in the control group
11063206|NCT04334720||Observation group of positive F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
11063207|NCT04334720||Observation group of no abnormal changes in F&M|The baseline PET/MR scan was performed before comprehensive treatment, and the contrast scan was performed after treatment and the sequence and protocol was consistent. Get psychological assessment before and after treatment and the time interval shall not exceed half a year
11063208|NCT04334720||The control group|Corresponding to the observation group, the time, sequence and protocol were consistent
11063209|NCT04334707||Acute Kidney Injury Cohort|The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.
11063210|NCT04334707||Chronic Kidney Diseases Cohort|High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.
11063211|NCT04334694|Other|Atrial flow regulator|In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).
11063212|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
11063213|NCT04334681||LF Group|Patients who have been operated with the Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
11063214|NCT04334668|Active Comparator|Oral Sodium Chloride|Subject will be given 2 grams of oral sodium chloride three times daily with meals for approximately 4 days
11063215|NCT04334668|Placebo Comparator|Placebo|Subject will be given a placebo orally three times daily with meals for approximately 4 days
11063216|NCT04334655||Clinic 1|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
11063217|NCT04334655||Clinic 2|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
11063218|NCT04334655||Clinic 3|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
11063219|NCT04334655||Clinic 4|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
11063220|NCT04334642|Experimental|Athletes from the Paralympic Boccia Brazilian Team|The research will have as a convenience sample 11 Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis. This study includes the category called Other participants formed by staff, freshmen, technicians and other professionals who are present during the interventions.
11063221|NCT04334629|No Intervention|Standard of care|
11063222|NCT04334629|Experimental|Standard of care plus lipid ibuprofen|
11063223|NCT04334616|Active Comparator|Conventional Laryngocope|Patients in this arm will be intubated with conventional Macintosh laryngoscope
11063224|NCT04334616|Active Comparator|Video Laryngocope|Patient in this arm will be intubated with Karl Storz Video Laryngoscope
11063225|NCT04334603|Experimental|Home-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home
11063226|NCT04334603|Active Comparator|Clinical-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital
11063227|NCT04334590||Cleft Lip/Nose Repair without PSIO|Participants who will undergo cleft lip/nose repair prior to addition of PSIO as part of standard of care in Hopkins.
11063228|NCT04334590||Presurgical Infant Orthopedic Therapy|Participants who will undergo cleft lip/nose repair after addition of PSIO as part of standard of care in Hopkins.
11063229|NCT04334577|Experimental|Attenuated Zoster Vaccine, Live|One shot of the vaccine (with live viruses titer >=4.3 LgPFU per dose)
11063230|NCT04334577|Placebo Comparator|Placebo|one shot of placebo with no live virus
11063231|NCT04334564|Active Comparator|Test team|Patients were treated with ginkgo biloba capsule regularly. Take 2 capsules 3 times a day, orally
11063232|NCT04334564|Placebo Comparator|Control group|Patients were treated with placebo regularly.Take 2 capsules 3 times a day, orally
11063233|NCT04334551|Experimental|switch from etravirine to doravirine|switches to doravirine,
11063335|NCT04333823|Experimental|Intervention (Dapagliflozin)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
11063336|NCT04333823|Placebo Comparator|Control (Placebo)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
11063234|NCT04334538|Active Comparator|S-RUTF|Children will receive approximately 150 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
11063235|NCT04334538|Experimental|oat-RUTF|Children will receive approximately 150 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
11063236|NCT04334525|No Intervention|Generic placemats and frequent diner cards|Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
11063237|NCT04334525|Experimental|Placemats and frequent diner cards promoting healthier meals|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
11063238|NCT04334512|Experimental|Quintuple Therapy|Patients will be treated with quintuple therapy for 10 days.
11063239|NCT04334512|Placebo Comparator|Placebo|Patients will be treated with placebo.
11063240|NCT04334499||Age Related Macular Degeneration|Subjects with Age Related Macular Degeneration upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
11063241|NCT04334499||Glaucoma|Subjects with Glaucoma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
11063242|NCT04334499||Diabetic Retinopathy|Subjects with Diabetic Retinopathy upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
11063243|NCT04334499||Ocular Trauma|Subjects with Ocular Trauma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
11063244|NCT04334499||Control|Subjects with no ocular disease or trauma comorbidities upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
11063245|NCT04334486|Experimental|Video Game Trained|Subjects will participate in video gaming for 10 minutes prior to Eyesi simulator test of surgical skills.
11063246|NCT04334486|No Intervention|No Video Game Training|No video gaming will occur for warm up to Eyesi simulator test of surgical skills
11063247|NCT04334473|Other|cataract patients|Patients having cataract candidates for phacoemulsification with or without glaucoma are prepared to do cataract surgery with preoperative and postoperative assessment of intraocular pressure and ocular bio-metrics using UBM.
11063248|NCT04334460|Active Comparator|Active Group|
11063249|NCT04334460|Placebo Comparator|Placebo Group|
11063250|NCT04334447|Experimental|Intervention Group Patients|All HF patients that experience a HF education session
11063251|NCT04334434|Experimental|Study Group|The group to which the exercise protocol consisting of aerobic and strengthening exercises will be applied.
11063252|NCT04334434|No Intervention|Control Group|Control group where evaluations will be made.
11063253|NCT04334421||Mesh group|After resection, pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) and covered with subcutaneous flap.
11063254|NCT04334408|Active Comparator|Subjects with CADASIL treatment intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with Fremanezumab injections.
11063255|NCT04334408|Placebo Comparator|Subjects with CADASIL placebo intervention|Subjects that have been diagnosed with both CADASIL and moderately to severely disabling migraine headaches will be treated with placebo injections.
11063256|NCT04334382|Experimental|Hydroxychloroquine|
11063257|NCT04334382|Active Comparator|Azithromycin|
11063258|NCT04334369|Sham Comparator|Single Vision Contact Lenses|
11063259|NCT04334369|Experimental|Multifocal Contact Lenses|
11063260|NCT04334356|Experimental|App Intervention|All participants will receive the web app for prevention of posttraumatic stress.
11063261|NCT04334343|Active Comparator|Athletic group|
11063262|NCT04334343|Active Comparator|Sedentary exercise group|
11063263|NCT04334343|Active Comparator|Sedentary no-exercise group|
11063264|NCT04334330|Experimental|Treatment group|
11063265|NCT04334317|Experimental|Sentinel Cohort: TAK-071 7.5 mg + Placebo|TAK-071 7.5 milligrams (mg), tablets, orally, once daily for up to first 6 weeks in Period 1, followed by greater than or equal to (>=) 3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2.
11063266|NCT04334317|Experimental|Sentinel Cohort: Placebo + TAK-071 7.5 mg|TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by >=3 weeks washout period, followed by TAK-071 7.5 mg tablets, orally, once daily for up to next 6 weeks in Period 2.
11063267|NCT04334317|Experimental|TAK-071 + Placebo|TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by >=3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2. Dosage for the remaining participants will be determined depending on pharmacokinetic (PK) results, safety and physiologically based PK modelling data from the sentinel cohort.
11063268|NCT04334317|Experimental|Placebo + TAK-071|TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by >=3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2. Dosage for the remaining participants will be determined depending on PK results, safety and physiologically based PK modelling data from the sentinel cohort.
11063269|NCT04334304|Active Comparator|Posterior Stabilized TKA without robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA without robot-assistance
11063270|NCT04334304|Experimental|Posterior Stabilized with robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA with robot-assistance
11063271|NCT04334304|Experimental|Bicruciate retaining TKA without robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA without robot-assistance
11063272|NCT04334304|Experimental|Bicruciate retaining TKA with robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA with robot-assistance
11063273|NCT04334278|Experimental|3RP-OA|The Relaxation Response Resiliency Program (3RP) is an 8-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity (3RP-OA). The 3RP-OA will be delivered by secure telehealth.
11063274|NCT04334278|Active Comparator|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 8-week group mind body program that will be delivered via secure telehealth. To control for in between session practice, participants will receive an mp3 recording and informational handout to complete after each session.
11063275|NCT04334265|Experimental|Anluohuaxian combined with regular treatment group|Anluohuaxian: 6g each time, twice a day
11063276|NCT04334265|No Intervention|regular treatment group|
11063277|NCT04334239||Intervention|Cancer patients who have undergone substantial parts of inpatient treatment in a certified cancer centre.
11063278|NCT04334239||Control|Cancer patients who have not undergone inpatient treatment in a certified cancer centre.
11063279|NCT04334226||Patient and Caregiver Dyad|Individuals who participated in the Stoma Boot Camp study and their caregiver will form a dyad
11063280|NCT04334213|Experimental|Sequence 1|"Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.
~Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets)."
11063281|NCT04334213|Experimental|Sequence 2|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days
11063282|NCT04334213|Experimental|Sequence 3|Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
11063283|NCT04334213|Experimental|Sequence 4|Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).
11063284|NCT04334200|Experimental|Cultivate yourself: support for caregivers of dementia persons|There will be six sessions (1 or 2 session per week). The duration of each session will be 1.5-2 hours per session. The contents include: introduction on dementia, caregivers' role, how to communicate with dementia persons, tips on caregiving, stress and emotional management. The training content has been verified by one social worker, family caregivers of individuals living with dementia and a teacher who teach Chinese, Chinese history and culture in the secondary school in Hong Kong. No adverse comments are received from them.
11063285|NCT04334187|Experimental|Smoke Cessation Group|Mindfulness-based smoking cessation sessions will follow the mindfulness based addiction treatment (MBAT) intervention for smoking cessation. Sessions are in group format for two hours, weekly. Two groups of sessions with about 10 participants per group will be organized.
11063286|NCT04334174|Experimental|Single Arm|Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
11063287|NCT04334161||PHH patients|Patients with Roux-en-Y gastric bypass ≥1 year ago and confirmed postprandial hyperglycaemic hypoglycaemia (PHH). PHH is defined as postprandial plasma or sensor glucose<3.0mmol/l according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
11063288|NCT04334161||non-PHH gastric bypass patients|Patients with Roux-en-Y gastric bypass ≥1 year ago without evidence of PHH.
11063289|NCT04334161||non-PHH sleeve gastrectomy patients|Patients with sleeve gastrectomy ≥1 year ago without evidence PHH.
11063290|NCT04334161||non-PHH non-surgical controls|Absence of any conditions or previous surgery known to affect gastro-intestinal integrity and food absorption.
11063291|NCT04334148|Active Comparator|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
11063292|NCT04334148|Placebo Comparator|Placebo|Matching placebo tablets
11063293|NCT04334135|Experimental|MitoQ|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after acute MitoQ supplementation (80 - 160mg).
11063294|NCT04334135|Placebo Comparator|Placebo|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a placebo matched in appearance to the MitoQ.
11063295|NCT04334122|Experimental|Control group|"All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
~As a traditional treatment, patients received hot packs, conventional transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound and exercise.
~Hot packs used as superficial heat were wrapped in a towel and applied to the waist area for 20 minutes.
~Conventional TENS used as analgesic current were applied to the waist region for 20 minutes with 4 electrodes with 2 outputs, with a current time of 180 ms at a frequency of 80 Hz.
~It was applied with a dose of 1Mhz for 5 minutes with ultrasan (Chattanooga Intelect Mobile Combo model device) used to heat deep tissues.
~Waist exercises were asked to be done during the treatment, with 10 repetitions, each exercise twice a day (morning and evening)."
11063296|NCT04334122|Experimental|Experiment group|"In addition to the traditional physiotherapy program, tool-assisted soft tissue mobilization was performed 3 times a week (12 sessions with 1 day interval) in the experimental group.
~Instrument Assisted Soft Tissue Mobilization (IASTM) treatment was applied to ilicostalis lumborum, priformism, gluteus medius, erector spinas, quadratus lumborum muscles, superficial and deep fascia. Before applying the application, petroleum jelly was applied to the area and the tool was slipped.
~IASTM treatment was applied to the treated muscle fibers for 6 minutes, each technique (SWEEP-FAN-BRUSH-SWEEP techniques) with 8-10 repetitions.
~Sweep: Applied in all directions at 30 or 60 degree angle. Fan: It was applied by moving one side fixed arm at 30 degree angle. Brush: It was applied in straight steps at 30 degrees angle. Each stage of IASTM treatment was done by the physiotherapist."
11063337|NCT04333810||Active IBD patients|Patients with active IBD, based on colonoscopic evaluation and biopsy results.
11063338|NCT04333810||IBD patients in remission|IBD patients in remission, with no recently colonoscopic evidence of disease, and only on maintenance therapy.
11063297|NCT04334109|Experimental|Family-DSME|"Approach
~Family motivational interviewing techniques
~Family goal setting
~Understanding supportive and nonsupportive family behaviors
~Family behavioral changes Mode of Delivery
~Group sessions delivered by a certified diabetes educator (CDE) to patients and their family members Dosage
~10 hours delivered in one-hour sessions over 10 weeks Participants
~300 patients with T2D and 300 family members (family members will take part in educational sessions and data collection)"
11063298|NCT04334109|Active Comparator|Standard-DSME|"Approach
~Individual motivational interviewing techniques
~Individual goal setting
~Individual behavioral changes Mode of Delivery
~Group sessions delivered by a CDE to patients Dosage
~10 hours delivered in one-hour sessions over 10 weeks Participants
~300 patients with T2D (family members will take part in data collection but not educational sessions)"
11063299|NCT04334096|Experimental|QoL diagnosis and therapy|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
11063300|NCT04334083|Experimental|Emergency physicians|actors during the work
11063301|NCT04334083|Experimental|medical externship student|spectator during the emergency physician work
11063302|NCT04334083|Experimental|psychology student|spectator during the emergency physician work
11063303|NCT04334057||Patients with haemophilia A|New patients who have not previously been exposed to Esperoct® (Turoctocog alfa pegol or N8-GP in clinical trials) are eligible for this study.
11063304|NCT04334044|Experimental|Ruxolitinib|Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan
11063305|NCT04334031|Experimental|IMMINeNT cohort|
11063306|NCT04334018|Placebo Comparator|conventional CRT|
11063307|NCT04334018|Experimental|MPP CRT|
11063308|NCT04334005|Active Comparator|Usual care|Prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations.
11063309|NCT04334005|Experimental|Intervention group|25000 UI of vitamin D supplement in addition to the above-mentioned drug recommendations.
11063310|NCT04333992|Active Comparator|propofol-remifentanil group|"Anesthetic induction was achieved with an initial target concentration of propofol 4 ㎍/mL and remifentanil 3-4 ng/mL.
~Anesthesia was maintained with a fixed target concentration of propofol 2-4 ㎍/mL and remifentanil 2-3 ng/mL"
11063311|NCT04333992|Active Comparator|sevoflurane-remifentanil group|"Anesthetic induction was achieved with thiopental 5 mg/kg and initial target concentration of remifentanil 3-4 ng/mL.
~Anesthesia was maintained with 1.5-2.5% end-tidal concentration sevoflurane in 50% oxygen with air and remifentanil 2-3 ng/mL"
11063312|NCT04333979|Experimental|Drain replacement|Effects of drainage
11063313|NCT04333979|No Intervention|Drain not placed|Effects of not using drain
11063314|NCT04333966|Experimental|Interactive PBI|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
11063315|NCT04333966|Active Comparator|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call toAction: A Guide for Families.
11063316|NCT04333940|Experimental|1. 3D CBCT GROUP|Preoperative 3-dimensional CBCT will be taken.
11063317|NCT04333940|Active Comparator|2D PR GROUP|Preoperative 2-dimensional periapical radiographs will be taken using paralleling technique with customized Jig
11063318|NCT04333927|Experimental|Treatment|Patients in treatment group will receive camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. After 1 or 2 courses of camrelizumab, patients went on to receive capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week) concurrent with radiotherapy (45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed).
11063319|NCT04333927|Placebo Comparator|Observation|Patients in observation group will not receive any anti-cancer therapy.
11063320|NCT04333914|Experimental|Chloroquine analog (GNS651)|
11063321|NCT04333914|Experimental|Anti-PD-1 (nivolumab)|
11063322|NCT04333914|Experimental|Anti-IL-6 (tocilizumab)|
11063323|NCT04333914|Other|Standard of care|
11063324|NCT04333914|Experimental|anti-NKG2A (monalizumab)|
11063325|NCT04333914|Experimental|anti-C5aR (avdoralimab)|
11063326|NCT04333888|Experimental|Treatment|
11063327|NCT04333888|No Intervention|Control|
11063328|NCT04333875||TAVR/SAVR|Patients with critical aortic stenosis as defined by an AVA <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to transcatheter aortic valve replacement or surgical aortic valve replacement.
11063329|NCT04333875||Deferred Intervention|Patients with severe but not critical aortic Stenosis will undergo deferred intervention.
11063330|NCT04333862||Healthcare workers providing healthcare|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
11063331|NCT04333862||Healthcare workers staying at home|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
11063332|NCT04333862||Hospitalized patients|To compare the infection rate of hospitalized patients versus healthcare workers
11063333|NCT04333836|Experimental|Aligners group|Receiving full set of aligners ( Clear Removable Orthodontic appliance) until complete canine retraction
11063334|NCT04333836|Active Comparator|Conventional Brackets group|leveling and alignment of lower followed by complete canine retraction
11063339|NCT04333797|Other|Transitional age youth|Assessed group.
11063345|NCT04333758|Experimental|Jintronix Intervention|"2 consecutive phases of intervention for all participants using Jintronix virtual reality telerehabilitation software.
~Phase 1 consisted of 9 (3/week for 3 weeks) 45-min/session clinic-based sessions conducted by study team therapist, with concurrent caregiver training.
~Phase 2 consisted of 20 (5/week for 4 weeks) 45min/session home-based sessions supervised by trained caregiver, with telemonitoring by study team therapist."
11063346|NCT04333745|Experimental|Controlled Dietary Study|Participants will consume the controlled diet for four days. After two days on the diet, subjects will provide two 24-hour urine collections. After the diet has ended, subjects will provide a fasting blood sample.
11063347|NCT04333732|Experimental|M-M-R II ®|Education and surveillance plus M-M-R II ®
11063348|NCT04333732|Placebo Comparator|Placebo|Education and surveillance plus placebo
11063349|NCT04333719||terminally ill patients in specialized palliative|terminally ill patients in specialized palliative care facilities
11063350|NCT04333706|Experimental|Experimental Phase 1: Cohort A|To determine the status of Disseminated Tumor Cell (DTC) in bone marrow aspirate before and after adjuvant capecitabine only to establish the baseline response rate of bone marrow (BM) Disseminated Tumor Cell (DTC) to capecitabine alone.
11063351|NCT04333706|Experimental|Experimental: Phase I: Cohort B|A dose finding study of sarilumab plus capecitabine in patients with metastatic TNBC and metastatic HER2/neu-negative and hormone resistant breast cancer.
11063352|NCT04333706|Experimental|Phase 2 single arm study|Study of adjuvant sarilumab plus capecitabine in stage I to III TNBC with less than a pCR
11063353|NCT04333693||Cases|Adults (age>18years) undergoing any type of vascular surgery (open surgery, endovascular surgery or hybrid procedure) in an operating theatre and either before or after surgery: lab test confirmed COVID-19 or clinical diagnosis of COVI-19 infection (no test performed)
11063354|NCT04333680|Active Comparator|Phased Array|Operators who will be using a phased array-type transducer to perform the FAST exam on a healthy normal volunteer.
11063355|NCT04333680|Active Comparator|Curvilinear|Operators who will be using a curvilinear array-type transducer to perform the FAST exam on a healthy normal volunteer.
11063356|NCT04333667|Experimental|Intervention group|The intervention group will get an 8-week mindfulness-based internet intervention.
11063357|NCT04333667|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
11063358|NCT04333654|Experimental|Hydroxychloroquine|Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days
11063359|NCT04333654|Placebo Comparator|Placebo|Matching placebo
11063360|NCT04333641||small AAA patients|all patients with small AAA
11063361|NCT04333628|Experimental|low dose chloroquine|oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
11063362|NCT04333628|Experimental|Regular dose chloroquine|oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
11063363|NCT04333628|Other|Standard of care|The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
11063364|NCT04333615|Sham Comparator|Control Session|The control session will consist of resting on the treadmill for 30 min. It will be recommended that the patient do cycles in which he / she stands for 3 to 5 minutes and sits for 2 to 3 minutes in between, aiming to minimize the effect of body positioning on cardiovascular responses.
11063365|NCT04333615|Experimental|Self-selected Session|In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
11063366|NCT04333615|Active Comparator|Walking with pain|In the exercise until maximum pain session (current recommendation of walking exercise prescription for patients with PAD), individuals will perform series of 3 to 5 minutes with adjusted intensity so that they feel moderate to maximum pain. This means that the patient will start walking and the Physical Education professional, experienced and able to prescribe exercises for patients with PAD, will adjust the treadmill speed so that the patient walks with moderate pain or even maximum pain. There will be rest intervals of 2 to 3 minutes. The patient will be encouraged to complete a total of 30 minutes of exercise.
11063367|NCT04333602|Experimental|Screening and Treatment of Asymptomatic Bacteriruria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. If we detect asymptomatic bacteriuria specific treatment will be instituted.
11063368|NCT04333602|No Intervention|Screening and NO treatment of Asymptomatic Bacteriuria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. No treatment will be instituted.
11063369|NCT04333589|Experimental|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
11063370|NCT04333589|No Intervention|Regular treatment group|Treatments other than lopinavir and ritonavir, chloroquine phosphate, hydroxychloroquine sulfate, arbidol, and colomycin can be given.
11063371|NCT04333576|Experimental|Elagolix + Combined Oral Contraceptive (COC)|Participants will receive elagolix in combination with COC for 18 months.
11063372|NCT04333576|Experimental|Elagolix + Placebo for COC|Participants will receive elagolix in combination with placebo for COC for 3 months followed by elagolix in combination with COC for 15 months.
11063373|NCT04333576|Placebo Comparator|Placebo for Elagolix + Placebo for COC|Participants will receive placebo for elagolix in combination with placebo for COC for 3 months followed by elagolix in combination with COC for 15 months.
11063374|NCT04333563|Active Comparator|CPAP|respiratory stressed infants getting Continuous positive airway pressure (CPAP)
11063375|NCT04333563|Experimental|respiratory stressed infants getting NIV NAVA|respiratory stressed infants getting Non-invasive neurally adjusted ventilatory assist (NIV NAVA)
11063376|NCT04333550|Experimental|Experimental: Desferal addition to standard treatment|
11063377|NCT04333550|Experimental|Experimental: standard treatment|
11063378|NCT04333537|Experimental|Sentinel Lymph Node (SLN) Biopsy|Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy.
11063379|NCT04333537|Active Comparator|Elective Neck Dissection (END)|Patients undergo standard END.
11063380|NCT04333524||Group A|Staging
11063381|NCT04333524||Group B|Criteria for response assessment
11063382|NCT04333511|Experimental|Sequence 1|TPS first with crossover to Sham-TPS
11063383|NCT04333511|Experimental|Sequence 2|Sham-TPS first with crossover to TPS
11063384|NCT04333498|Experimental|Receiving Feedback From DBS|This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.
11063385|NCT04333485|Active Comparator|House Hold Active Case Finding (HHACF)|Existing health workers at the RNTCP TB Units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer standardized World Health Organization (WHO)-recommended TB symptom screen questionnaire (amended to include cough of any duration) to treated TB cases and their HH contacts. All those with any TB symptom will have a spot sputum taken at the home.
11063386|NCT04333485|Experimental|Telephonic Active case finding (TACF)|Standardised WHO-recommended TB symptom screen questionnaire will be administered to TB patients by existing health workers at the RNTCP via telephone calls at 6 and 12 months post-treatment completion. The TB patient (index case) will also be asked about any TB symptoms among household (HH) contacts. All HHs with suspected TB among the index TB case or a HH contact will be visited by RNTCP health workers to collect spot sputum specimens at their home.
11063387|NCT04333472|Experimental|Piclidenoson|Piclidenoson 2 mg every 12 hours orally added to standard of care
11063388|NCT04333472|Placebo Comparator|Placebo|Placebo every 12 hours orally added to standard of care
11063389|NCT04333459|Active Comparator|Group 1 - Full Dose Hataan|"Group 1 will be vaccinated with the Full Dose of HTNV DNA vaccine, 2 mg of pWRG/HTN-M(co) with 0.5 mg/each deltoid."
11063390|NCT04333459|Active Comparator|Group 2 - Half Dose Hataan|"Group 2 will be vaccinated with the Half Dose of HTNV DNA vaccine, 1 mg of pWRG/HTN-M(co) with 1.0 mg/each deltoid."
11063391|NCT04333459|Active Comparator|Group 3 - Full Dose Puumala|"Group 3 will be vaccinated with the Full Dose of PUUV DNA vaccine, 2 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
11063392|NCT04333459|Active Comparator|Group 4 - Half Dose Puumala|"Group 4 will be vaccinated with the Half Dose of PUUV DNA vaccine, 1 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
11063393|NCT04333433||MicroShunt treatment group|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device
11063394|NCT04333433||Trabeculectomy control arm|Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure
11063395|NCT04333420|Experimental|Arm A: SOC + IFX-1|
11063396|NCT04333420|Experimental|Arm B : SOC + Placebo|
11063397|NCT04333407|Experimental|Active Arm|
11063398|NCT04333407|No Intervention|Control Arm|
11063399|NCT04333394|Active Comparator|Probiotic|The probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei PXN 37, Lactobacillus rhamnosus PXN 54, Streptococcus thermophilus PXN 66, Bifidobacterium breve PXN 25, Lactobacillus acidophilus PXN 35, Bifidobacterium longum PXN 30, Lactobacillus bulgaricus PXN 39)
11063400|NCT04333394|Placebo Comparator|Placebo|Placebo capsules have an identical appearance to probiotic capsules and contain microcrystal cellulose.
11063401|NCT04333381|Active Comparator|Common Practice|Patients included in the phase I will receive common practice.
11063402|NCT04333381|Experimental|Educational and organizational measures|Patients included in the phase II will be attended by emergency nurses that received the educational and organizational intervention.
11063403|NCT04333368|Experimental|MSC|
11063404|NCT04333368|Placebo Comparator|NaCl|
11063405|NCT04333355|Experimental|COVID-19 patients receiving Convalescent Plasma|Convalescent Plasma from patients who recently recover from COVID-19
11063406|NCT04333342|Experimental|Wearable device group|Participants use wearable device and their heart rate and activity are monitored. If their resting heart rate (rHR) increase beyond the set range or they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If their rHR stay within set range and they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
11063407|NCT04333342|No Intervention|Control group 1|articipants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 6 months after discontinuing anti-thyroid drugs.
11063408|NCT04333342|No Intervention|Control group 2|Participants don't use wearable devices. If they have hyperthyroid symptoms and signs, they should come to the hospital and get tests for thyroid function. If they have no symptoms and signs, they come to hospital and get tests for thyroid function 3 and 6 months after discontinuing anti-thyroid drugs.
11063409|NCT04333329|Experimental|AD Patients|"All patients were treated with the TPS device (new name: NEUROLITH (Storz Medical AG))
~- 6 sessions within 2 weeks, each sessions consisting of 6000 TPS pulses of 0.2 mJ/mm²"
11063410|NCT04333316|Other|large head group|study the postoperative patient's satisfaction
11063411|NCT04333316|Other|dual mobility group|study the postoperative patient's satisfaction
11063412|NCT04333303|Experimental|Advance Care Planning Program|Implementation of a complex regional Advance Care Planning program.
11063413|NCT04333303|No Intervention|Care as usual|
11063414|NCT04333290|Experimental|Single Arm: Healthy subjects|The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
11063415|NCT04333277|Experimental|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
11063416|NCT04333277|Placebo Comparator|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
11063417|NCT04333264|Active Comparator|suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
11063418|NCT04333264|Active Comparator|no suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
11063419|NCT04333251|Experimental|convalescent plasma|This arm will receive convalescent plasma
11063420|NCT04333251|Placebo Comparator|best supportive care|Oxygen therapy
11063421|NCT04333238|Active Comparator|Standard template|Usual outpatient progress note with standard Subjective Objective Assessment Plan (SOAP) format
11063422|NCT04333238|Experimental|New template|The assessment and plan section is placed in the beginning, subjective data grouped into the assessment section, and elements not related to the current presentation were deemphasized
11063423|NCT04333225|Experimental|Treatment|Oral hydroxychloroquine 400 mg twice a day (two 200 mg tabs twice a day) on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks.
11063424|NCT04333225|No Intervention|Control|Subjects who opt not to receive the study drug will undergo all procedures to form the control group
11063425|NCT04333212|Other|study arm|We projected a total of 1,100 study cases, which encompassed 100 cases of women with no intraepithelial lesion or malignancy (NILM) cytology, 300 cases of ASCUS, 300 cases of low grade squamous intraepithelial lesion (LSIL) and 400 cases high grade squamous intraepithelial lesion (HSIL) in cervical cytology.
11063426|NCT04333199||Control|Patients do not receive an email
11063427|NCT04333199||Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
11063428|NCT04333199||Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
11063429|NCT04333173||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
11063430|NCT04333160|Experimental|JTA-004|single knee intra-articular injection of JTA-004 solution (2ml)
11063431|NCT04333160|Placebo Comparator|placebo|single knee intra-articular injection of saline solution (2ml)
11063432|NCT04333160|Active Comparator|Hylan G-F 20|single knee intra-articular injection of Hylan G-F 20 (6ml)
11063433|NCT04333147|Experimental|Participants receiving GSK3196165 in qualifying study|Participants receiving GSK3196165 in their qualifying study will continue to receive GSK3196165 at the same dose level (90 mg or 150 mg weekly) in this study.
11063434|NCT04333147|Experimental|Participants receiving comparator in qualifying study|Participants receiving a comparator (e.g. tofacitinib or sarilumab) in their qualifying study will be re-randomized to receive either GSK3196165 90 mg or 150 mg weekly in this study.
11063435|NCT04333134|Experimental|Dose level 1|Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.
11063436|NCT04333108|Experimental|Masitinib & BSC|"Experimental Arm:
~Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC).
~Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control."
11063437|NCT04333108|Placebo Comparator|Placebo & BSC|"Placebo Comparator:
~Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)"
11063438|NCT04333095|Active Comparator|Liposomal Bupivacaine Block|Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
11063439|NCT04333095|Placebo Comparator|Saline Block|Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
11063440|NCT04333069|Other|Uncorrected and best corrected visual acuity|Measuring of uncorrected and best corrected visual acuity after phaco emulsification and irrigation aspiration cataract surgery
11063441|NCT04333043||Hearing Aids|Hearing Aids use
11063442|NCT04333030||Psychiatry|patients who come for psychiatric consultation
11063443|NCT04333030||addictology (other than tabacco)|patients who come for addictology consultation
11063444|NCT04333030||endocrinology|patients who come for endocrinology consultation
11063445|NCT04333017|Experimental|treated patient|Percutaneous radiofrequency ablation of parietal endometriosis
11063446|NCT04333004|Experimental|Pembrolizumab Combined With Chemotherapy|
11063447|NCT04332991|Active Comparator|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
11063448|NCT04332991|Placebo Comparator|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
11063449|NCT04332978|Experimental|Group I|"Drug names: Fluticasone Propionate - PLURAIR® brand Pharmaceutical form: Nasal spray (50mcg / dose) Administration: Topical nasal route Posology 02 jets in each nostril 1 time a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.
~Manufacturer: Libbs Farmacêutica Ltda. Presentation: Deliver 1 bottle of 120 doses in original packaging"
11063450|NCT04332978|Active Comparator|Group II|"Fluticasone Propionate - FLIXONASE® brand Nasal spray (50mcg / dose) Topical nasal route 02 jets in each nostril once a day - Single daily topical nasal dose of 200 mcg / day (2 jets / nostril = 100 mcg / nostril), preferably in the morning, upon waking up and at the same time, for 4 weeks.
~GlaxoSmithKline. Deliver 1 bottle of 120 doses in original packaging"
11063451|NCT04332965|Experimental|Patients with chronic periodontitis|Patients with CP (n=30) had teeth with 30% periodontal bone loss and ≥ 2 non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and bleeding on probing.
11063452|NCT04332965|Experimental|Patients with gingivitis|Participants with G (n=30) had gingival index ≥ 2 and other inflammation signs.
11063453|NCT04332965|No Intervention|Participants with periodontal healthy|The H group (n=30) consisted of individuals with no attachment loss, no history of periodontal disease, PD ≤3 mm, and whole-mouth bleeding scores <10%.
11063454|NCT04332939|Experimental|Exercise + real tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.
~For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min)."
11063455|NCT04332939|Sham Comparator|Exercise + Sham tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.
~For the first week, participants will receive 5 daily sessions of sham tDCS."
11063456|NCT04332926|Active Comparator|Own Brand Cigarette|
11063457|NCT04332926|Experimental|ECIG 30 Watts, 0 mg/ml nicotine|
11063458|NCT04332926|Experimental|ECIG 30 Watts, 8 mg/ml nicotine|
11063459|NCT04332926|Experimental|ECIG 30 Watts, 15 mg/ml nicotine|
11063460|NCT04332926|Experimental|ECIG 30 Watts, 30 mg/ml nicotine|
11063461|NCT04332900|No Intervention|Control condition|In this condition there will not be any application of therapeutic approach
11063462|NCT04332900|Experimental|Intervention - First Stage|In this condition it will be randomized the therapeutic approach that will be applied - proximal or distal one.
11063463|NCT04332900|Experimental|Intervention - Second Stage|In this condition it will be applied the therapeutic approach that was not applied in the previous condition, Intervention - First Stage.
11063464|NCT04332887|Experimental|Multidimensional Exercise Program|Patients in this group will receive a 12 week exercise program including: (1) one 20-30 minute individual exercise consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) telephone follow-up once per week for 12 weeks.
11063465|NCT04332887|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
11063466|NCT04332874|Experimental|Participants with Sarcoma|Advanced/metastatic extremity sarcoma eligible for pembrolizumab and isolated limb infusion (ILI)
11063467|NCT04332861||Prospective observational cohort|"For data analysis, the cohort will be subdivided as follows:
~Identification and Validation cohorts
~Patients with and without complicating factors
~Patients with and without measured inflammatory marker levels"
11063468|NCT04332848|Experimental|(B) Empirical therapy|choose antibiotics according to drug history
11063469|NCT04332848|Active Comparator|(A) Susceptibility testing guided therapy|choose antibiotics according to susceptibility testing
11063470|NCT04332835|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol. Simultaneously, they will receive the standard therapy defined by institutional protocol.
11063471|NCT04332835|Active Comparator|Control Group|Participants included in the control group will receive standard therapy defined by institutional protocol.
11063472|NCT04332822|Active Comparator|Arm A - R-mini-CHOP|"Cycles 1-6, duration 21 days
~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
~Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6
~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
11063473|NCT04332822|Experimental|Arm B - R-pola-mini-CHP|"Cycles 1-6, duration 21 days
~Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6
~Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6
~Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6
~Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
~Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6"
11063474|NCT04332809|Active Comparator|Saline-gentamicin irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline-gentamicin solution
11063475|NCT04332809|Active Comparator|Saline irrigation|layer-by-layer irrigation of the appendectomy wound will be performed using Saline solution
11063476|NCT04332809|No Intervention|No irrigation|ayer-by-layer irrigation of the appendectomy wound will not be performed
11063477|NCT04332796|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
11063478|NCT04332796|Active Comparator|ZnO-NPs socks|ZnO-NPs socks to patients for 2 weeks
11063479|NCT04332796|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks to patients for 2 weeks
11063480|NCT04332783||Healthy Typical Adults|Observers including radiologists and non-radiologists will be asked to participate in computer based tasks in which they visually search for, detect, localize, and categorize tumors in x-ray images.
11063481|NCT04332770||Hypothyroid group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to withdraw their levothyroxine for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
11063482|NCT04332770||Control group|Patients with differentiated thyroid carcinoma underwent total thyroidectomy Patients who are planned to get rhTSH (not to withdraw their levothyroxine) for radioactive iodine therapy Biosignals will be monitored continuously using Fitbit devices
11063483|NCT04332757|Experimental|Training Intervention|18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation.
11063484|NCT04332757|No Intervention|Usual care control|Usual care acting as a control group.
11063485|NCT04332744|Active Comparator|Control Arm (Arm A)|Patients will receive enzalutamide capsules orally once daily continuously (160 mg) in addition to standard ADT (unless surgical castration).
11063486|NCT04332744|Experimental|Interventional Arm (Arm B)|Patients will receive enzalutamide capsules 160 mg in combination with talazoparib (PF-06944076) capsules 0.5 mg, both orally daily and continuously in 28-day cycle, in addition to standard ADT (unless surgical castration).
11063487|NCT04332731|Experimental|Renal angiography and Renal denervation|"Symplicity Spyral™ multi electrode renal denervation system
~After renal angiography, participants in the experimental group will be immediately treated with renal denervation procedure using standard techniques. The participants will remain blinded throughout the procedure."
11063547|NCT04332367|Experimental|Carboplatin, Taxane And Ramucirumab|Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
11063554|NCT04332302|Experimental|Power training group|Participants will be enrolled in a resistance training program.
11063488|NCT04332731|Sham Comparator|Renal angiography|In the control group, the sham procedure will consist of only a renal angiogram. Participants will undergo diagnostic renal angiogram but will not receive any therapeutic endovascular treatment. Participants will remain on the procedure table for at least 20 min after the angiogram to prevent possible unblinding of randomization allocation.
11063489|NCT04332718|No Intervention|24 Hour Holter|Patients who are randomised to the 24 Hour Holter monitoring will be contacted within one month from randomisation. The repeat 24 Hour Holter result will be explained to the patient at the end of 30-day follow-up.
11063490|NCT04332718|Active Comparator|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
11063491|NCT04332705||Patients with colon cancer|Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
11063492|NCT04332705||Patients without colon cancer|Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
11063493|NCT04332692|Experimental|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination focusing on congestion
~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds
~Blood sample retrieved for biological assessment and biobanking
~Telephone follow-up"
11063494|NCT04332679|Active Comparator|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
11063495|NCT04332679|Experimental|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
11063496|NCT04332666|Placebo Comparator|Placebo|Standard of care treatment
11063497|NCT04332666|Experimental|Study drug|Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h
11063498|NCT04332653|Experimental|Phase 1b: NT-I7 Dose Escalation|"NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.) Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
11063499|NCT04332653|Experimental|Phase 2a: CPI Treated Triple Negative Breast Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
11063500|NCT04332653|Experimental|Phase 2a: CPI Treated Non-small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
11063501|NCT04332653|Experimental|Phase 2a: CPI Treated Small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
11063502|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
11063503|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.
~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
11063504|NCT04332627|Active Comparator|sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
11063505|NCT04332627|Placebo Comparator|neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
11063506|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
11063507|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
11063508|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
11063509|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
11063510|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
11063511|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.
~Endowment: Give patients the impression they already have the account, so they value it more.
~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
11063512|NCT04332601|Experimental|ENERGY intervention|"ENERGY Intervention:
~14 sessions of 1h CBT intervention (standardized fatigue treatment comprising six modules over 14 individual therapy sessions)
~1 session per week
~With a psychologist (different to the psychologist who will perform the assessments)
~Individual sessions
~and Treatment as usual"
11063513|NCT04332601|Other|Treatment as usual (TAU)|"Comparison group
~TAU defined by antipsychotic medication coupled with day hospital care"
11063548|NCT04332354||T2D diabetes obese subjects|Patients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
11063549|NCT04332341|Experimental|Nicotinamide riboside (NR)|
11063550|NCT04332328||Ulcerative patients|
11063551|NCT04332328||Non ulcerative patients|
11091409|NCT04136873|Active Comparator|Part B 30 mg QD CVL-231|Oral Dose
11063514|NCT04332588|Experimental|Herceptin monotherapy cohort|Herceptin monotherapy cohort. Locally advanced HER2+ breast cancer patients receiving neoadjuvant Herceptin monotherapy prior to combination therapy will undergo three contrast-enhanced [18F]FMISO PET/MRI scans. Each imaging session will be identical. Imaging session one will be after diagnosis and before beginning monotherapy. Imaging session two will be within 10 days prior to beginning combination therapy with targeted HER2 agents. Imaging session three will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
11063515|NCT04332588|Experimental|Combination therapy cohort|Locally advanced HER2+ breast cancer patients that receiving neoadjuvant combination therapy including Herceptin will undergo two contrast-enhanced [18F]FMISO PET/MRI imaging. Imaging session one will be after diagnosis and before beginning combination therapy. Imaging session two will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
11063516|NCT04332562|No Intervention|normotensive control group|Normotensive volunteer
11063517|NCT04332562|No Intervention|hypertensive control group|Hypertensive patients with no restriction on their salt intake
11063518|NCT04332562|Experimental|hypertensive interventional group|intervention is going to be salt restriction
11063519|NCT04332549|Active Comparator|Reconstitution Method 1|
11063520|NCT04332549|Active Comparator|Reconstitution Method 2|
11063521|NCT04332536|Experimental|Chronic Heart Failure|
11063522|NCT04332536|Active Comparator|Age-matched healthy controls|
11063523|NCT04332523|Experimental|Group 1: Participants with Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
11063524|NCT04332523|Experimental|Group 2: Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
11063525|NCT04332523|Experimental|Group 3: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of JNJ-53718678 suspension on Day 1.
11063526|NCT04332523|Experimental|Group 4: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of JNJ-53718678 suspension on Day 1.
11063527|NCT04332510|Experimental|Infant milk 1|
11063528|NCT04332510|Experimental|Infant milk 2|
11063529|NCT04332510|Experimental|Infant milk 3|
11063530|NCT04332510|Experimental|Infant milk 4|
11063531|NCT04332497|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
11063532|NCT04332497|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11063533|NCT04332497|Active Comparator|Group ISCB = ISCB group|In group ISCB, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
11063534|NCT04332484||Acute on Chronic Liver Failure|All patients of Acute on chronic liver failure according to CANONIC definition, aged more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
11063535|NCT04332484||Cirrhosis of Liver|All patients with cirrhosis of liver with age more than 18 years were included. Sonoclot, TEG and conventional coagulation tests were done at baseline and at 72 hours. In case of clinically evident bleeding, Point of care tests were repeated to check for changes.
11063536|NCT04332471|Active Comparator|Control|Patients in the control group will be treated using the home therapy protocol only.
11063537|NCT04332471|Active Comparator|Radial shockwave therapy|Patients will receive 4 sessions of radial shockwave therapy.
11063538|NCT04332471|Active Comparator|Focused shockwave therapy|Patients will receive 4 sessions of focused shockwave therapy.
11063539|NCT04332458|Other|Patients with stroke without exercise experience|Patients who are discharged from the hospital within one month after a minor stroke or TIA and are not offered physical rehabilitation afterwards
11063540|NCT04332458|Other|Patients with stroke with exercise experience|Patients with a minor stroke who have participated in an exercise study (HITPALS)
11063541|NCT04332445|Experimental|Experimental|subjects, 18-70 y, healthy
11063542|NCT04332432|Experimental|belapectin|"Single dose of 4 mg/kg of lean body mass (LBM) belapectin solution for injection administered intravenously (infused over approximately 60 minutes).
~Group 1: 16 matched healthy subjects with normal hepatic function
~Group 2: 8 subjects with mild hepatic impairment (Child-Pugh Class A [4 x subjects with a score of 5 and 4 x subjects with a score of 6])
~Group 3: 8 subjects with moderate hepatic impairment (Child-Pugh Class B [score of 7 to 9])
~Group 4: 8 subjects with severe hepatic impairment (Child-Pugh Class C [score of 10 to 14])."
11063543|NCT04332419|Experimental|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
11063544|NCT04332393|Experimental|metformin group|
11063545|NCT04332393|No Intervention|No treatment group|
11063546|NCT04332380|Experimental|Intervention Group|Participants included in the experimental group will receive 500 milliliters of convalescent plasma, distributed in two 250 milliliters transfusions on the first and second day after starting the protocol.
11063552|NCT04332315|Active Comparator|VALS|Vaginally asissted laparoscopic sacrocolpopexy
11063553|NCT04332315|Active Comparator|AS|Abdominal Sacrocolpopexy
11063556|NCT04332289||PHH patients|Patients following Roux-en-Y gastric bypass surgery (≥1 year ago) with confirmed post-prandial hyperinsulinemic hypoglycemia
11063557|NCT04332289||Healthy controls|Non-PHH, non-surgical healthy individuals
11063558|NCT04332276|Experimental|Cerebroventricular administration of A- dopamine|Cerebroventricular administration of dopamine prepared and stored in anaerobia
11063559|NCT04332276|Active Comparator|Optimized oral dopaminergic treatment|Optimized oral dopaminergic treatment with L-dopa (at least 5 doses a day) with dopaminergic agonist, monoamine B inhibitor and catechol-o-methyl inhibitor (if tolerated) (A-dopamine replaced by saline un the pump during optimized oral dopaminergic treatment)
11063560|NCT04332263|Experimental|Neuromuscular Electrical Stimulation - NMES|NMES will be applied bilaterally on the quadriceps femoris muscle of ICU patients. An electrical stimulation system and an ICU-designed dynamometer will be used with the patients lying in bed, with the hips and the knees flexed at 60 and 90 degrees, respectively. Supramaximal single-pulse's peak force will be used to determine the NMES intervention level. NMES (alternating biphasic current, stimulation frequency = 80 Hz, 1 ms pulse duration) will be used to evoke tetanic forces (EF) at 50% of the supra-maximal single-pulse EF (i.e., 10-12% of a maximal voluntary isometric contraction). NMES protocol will be performed five times a week, lasting 20 min. Muscle fatigue will be evaluated every 5 min of the intervention, and will be determined as a 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol. If and when a 10% reduction of the single-pulse EF is achieved, the intervention protocol will be terminated before the 20 min.
11063561|NCT04332263|No Intervention|Control Group - CG|The control group (CG) will only perform conventional physiotherapy and will not receive any NMES training, but will be evaluated through the same evaluations and in the same moments of the two above mentioned intervention groups. Conventional physiotherapy will be given to all three groups.
11063562|NCT04332237||Hypothermia group|Hypothermic trauma patients or hypothermic patients with traumatic brain injury specifically.
11063563|NCT04332237||Normothermia group|Normothermic trauma patients or normothermic patients with traumatic brain injury specifically.
11063564|NCT04332224|Experimental|Non-shivering cooling group|Cooling devices
11063565|NCT04332211|Experimental|Pseudoephedrine Group|Patients randomized to pseudoephedrine prior to hyperbaric therapy
11063566|NCT04332211|Placebo Comparator|Placebo Group|Patients randomized to placebo prior to hyperbaric therapy
11063567|NCT04332198|Experimental|ALS patients|
11063568|NCT04332185|Experimental|Vestibulart socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
11063569|NCT04332172|Placebo Comparator|General information|Control
11063570|NCT04332172|Experimental|General information + SMS|SMS refers to tailored text messaging.
11063571|NCT04332172|Experimental|Baseline brief intervention|Brief technology-delivered intervention for alcohol use during pregnancy
11063572|NCT04332172|Experimental|Baseline brief intervention + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
11063573|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device.
11063574|NCT04332172|Experimental|Baseline brief intervention + 2 booster sessions + SMS|Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
11063575|NCT04332159|Experimental|Intervention group|Inhalation of Methoxyflurane through a Penthrox inhaler
11063576|NCT04332159|Placebo Comparator|Control group|Inhalation of placebo (0.9% salin solution) through a Penthrox inhaler
11063577|NCT04332146|Experimental|Mindfulness-based intervention|
11063578|NCT04332146|Active Comparator|Booklet-based psychoeducation group|
11063579|NCT04332133|Active Comparator|group 1|group 1 of DME which treated by SML
11063580|NCT04332133|Active Comparator|group 2|Group 2 of DME which treated by intravitreal injection of Ranibizumab
11063581|NCT04332133|No Intervention|group 3|control group of diabetic patients received no treatment
11063582|NCT04332120|Active Comparator|Mini Laparotomic|In patients undergoing spinal anesthesia, a suprapubic 3-5 centimeter incision was entered into the abdomen. After both tubes were isolated, bilateral tube ligation was performed by Pomeroy method. After bleeding control was achieved, it was repaired in accordance with the anatomy of the abdomen.
11063583|NCT04332120|Active Comparator|Laparoscopic|In patients undergoing general anesthesia, Verres was inserted into the abdomen through the umbilicus. Pneumo peritoneum was created with carbon dioxide (CO2). Optical imaging was placed into the abdomen from the umbilicus with 10-trochar. Auxiliary trochars from 3 centimeter supero-medial of both spina iliaca anterior superior were placed in the abdomen. bilateral tubas were isolated. Bilateral tubal ligation was performed with the help of bipolar cautery. bleeding control was achieved. trochars were taken out of the abdomen. the skin was closed.
11063584|NCT04332120|Active Comparator|posterior colpotomy|The patient underwent spinal anesthesia and was placed in a high lithotomy position. cervical uteri was observed with the help of speculum. A 3 centimeter vertical incision was opened 2 centimeter below the cervix uteri. Peritoneal cavity was entered from this area. bilateral tubas were isolated. Bilateral tubal ligation was performed using the pomeroy method. bleeding control was achieved. peritoneal and posterior cervical incision line was repaired.
11063585|NCT04332107|Experimental|Azithromycin|1.2g of oral azithromycin
11063586|NCT04332107|Placebo Comparator|Placebo|Matching placebo
11063587|NCT04332094|Experimental|Intervention|Early administration of tocilizumab associated with hydroxychloroquine and azithromycin.
11063588|NCT04332094|Active Comparator|Control|Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin.
11063589|NCT04332081|Experimental|Hyperbaric oxygen therapy (HBOT)|
11063593|NCT04332068|Experimental|Arm 3|Ivermectin (400 µg/kg) plus placebo cream
11063594|NCT04332068|Experimental|Arm 4|Ivermectin (800 µg/kg) plus placebo cream (except the Bangladesh site)
11063595|NCT04332055|Experimental|ERVIN PLUS|The doctor and the patient will have access to the ERVIN generated data
11063596|NCT04332055|No Intervention|ERVIN MINUS|The doctor and the patient will not have access to the ERVIN generated data
11063597|NCT04332042|Experimental|tofacitinib|Tofacitinib cp 5mg: 2pills twice a day for 14 days
11063598|NCT04332029|Experimental|CBT + WGP + CM|The experimental intervention includes three components: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation; 2) Weight Gain Prevention module (WGP) and; 3) Contingency Management (CM) procedure reinforcing tobacco abstinence.
11063599|NCT04332029|Active Comparator|CBT + WGP|The active comparator will include only the first two components of the experimental intervention: 1) Cognitive Behavioral Treatment (CBT) for gradual smoking cessation and 2) Weight Gain Prevention module (WGP).
11063600|NCT04332016||COVID-19 infected patients|
11063601|NCT04332003|Active Comparator|RIC Treatment|Participants will receive active RIC treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
11063602|NCT04332003|No Intervention|SHAM Comparator|Participants will receive sham treatment 3 times per week over the course of the study. Each session will last approximately 45 minutes
11063603|NCT04331990|Active Comparator|Standard Physical Therapy|Control group for the study. Intervention in the form of warm-up and strengthening, stretching and neuromuscular control exercises.
11063604|NCT04331990|Experimental|Intermittent Mechanical Traction|Standard care in addition to intermittent mechanical distraction of the knee joint.
11063605|NCT04331990|Experimental|Continuous Mechanical Traction|Standard care in addition to continuous mechanical distraction of the knee joint
11063606|NCT04331977|Experimental|Quadhelix Group|
11063607|NCT04331977|Active Comparator|Hyrax Group|
11063608|NCT04331964|Active Comparator|Mineral Trioxide Aggregate (MTA)|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The exposed pulp tissues will be directly capped with a 3mm of MTA (Pro Root MTA) layer.
11063609|NCT04331964|Experimental|MTA with platelet rich fibrin (PRF).|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The PRF membrane obtained after centrifugation of the patient's own blood is going to be placed over the exposed pulp. Then, a 3mm of MTA (Pro Root MTA) will be placed over the PRF membrane.
11063610|NCT04331951|Experimental|Targeted biopsy within Sydney Protocol|"The patients with history of gastric intestinal metaplasia will be included and using targeted biopsy within Sydney Protocol; both targeted biopsy at suspicious lesions and random biopsy at no suspicious area.
~All tissues will be sent to immunohistochemistry as a gold standard.
~Sensitivity, specificity,positive predictive value, negative predictive value, accuracy will be calculated."
11063611|NCT04331938|Experimental|Open Label Arm|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion. This will be performed on both sides. Patients will be asked to rate their pain pre- and 30 minutes post-procedure on a scale of 0-10. Patients will also be asked to rate their nausea and photophobia on a similar scale. Patients will be reevaluated at 24 hours and 48 hours post procedure.
11063612|NCT04331925|Other|Anxiety and depression screening|Hospital Anxiety and Depression Scale (HADS) questionnaire administered at the start of the study. After two weeks or at the time of discharge, participants will complete the HADS questionnaire again
11063613|NCT04331925|Experimental|Anxiety and depression screening with journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period. They will also complete the HADS questionnaire before and after the intervention period of two weeks. At the end of the intervention period, these parents will also complete a survey regarding their experience with journaling
11063614|NCT04331899|Experimental|Study drug Peginterferon Lambda-1a|Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
11063615|NCT04331899|Placebo Comparator|Placebo injection|Study participants will receive a placebo along with the standard of care treatment.
11063616|NCT04331873|Experimental|Ultrasound|An ultrasound will be obtained to evaluate placement of the gastrostomy tube prior to obtaining the standard contrast injection
11063617|NCT04331847||Quantitative observational descriptive study|among women presenting for abortion-related complications
11063618|NCT04331847||Qualitative study|among women with a near-miss or a potentially life-threatening complication
11063619|NCT04331847||Rapid health facility assessment with the health professional|in charge of Post-Abortion Care
11063620|NCT04331847||Knowledge Attitudes, Practice and Behavior quantitative survey|among health care providers involved in the management of abortion-related complications
11063621|NCT04331834|Experimental|Pre-exposure prophylaxis of SARS-CoV-2|Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
11063622|NCT04331834|Placebo Comparator|Control group with placebo|Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months
11063623|NCT04331808|Experimental|TOCILIZUMAB|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
11063624|NCT04331808|No Intervention|Standard of care|
11063625|NCT04331795|Experimental|Group A|Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
11063626|NCT04331795|Experimental|Group B|Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
11063627|NCT04331769|Experimental|Device group: AccuCinch Ventricular Restoration System|Subjects in this arm will receive the AccuCinch Ventricular Restoration System
11063628|NCT04331769|Active Comparator|Control group: Guideline-Directed Medical Therapy|Subjects in this arm will receive guideline-directed medical therapy (GDMT)
11063629|NCT04331756|Other|Guiding Emergence From Anaesthesia Without Tragus Pressure|Monitoring of patients and removal of laryngeal mask airway (LMA) as per routine practice in post anaesthesia care unit (PACU)
11063750|NCT04330859|Placebo Comparator|Routine care|Routine care per unit guidelines
11093458|NCT04122339|Experimental|MAX-10181|tablet
11063630|NCT04331756|Experimental|Guiding Emergence From Anaesthesia With Tragus Pressure|Tragus pressure documentation of planes of emergence from anaesthesia - regular 3-5 minutes follow up with Tragus pressure till removal of airway device or rejection of it by patient
11063631|NCT04331743|Experimental|PLM60|"Three dose levels will be tested according to the 3 + 3 dose-escalation design.The dose-limiting toxicity (DLT) will be assessed from the first administration of PLM60 to the end of the first cycle (28 days)."
11063632|NCT04331730|Experimental|AKST4290 (800 mg) + Aflibercept|Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
11063633|NCT04331730|Experimental|AKST4290 (1600 mg) + Aflibercept|Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
11063634|NCT04331730|Placebo Comparator|Placebo + Aflibercept|Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment
11063635|NCT04331717|Experimental|Diet and exercise with BAE|After enrollment in the clinical trial, all men will be enrolled in diet and exercise counseling through the weight management program for a total of 4 weeks. If participants lose >5 pounds of total body weight from weight management alone in the first 4 weeks, these participants will be excluded from study and will not undergo BAE but will be encouraged to continue with weight management. Those still enrolled will undergo BAE. Within 7 days of BAE, men will be given ADT (lupron subcutaneous injection).
11063636|NCT04331704|Experimental|Personalized Information|Participants randomized to this condition will complete a web-based questionnaire and then receive personalized information regarding their alcohol use and sexual health behavior. They will complete daily, phone-based IVR monitoring for assessment purposes and receive further personalized information based on their responses.
11063637|NCT04331704|Active Comparator|Educational Information|Participants randomized to this condition will complete a web-based questionnaire and then receive educational material regarding their alcohol use and sexual health behavior. They will complete daily phone-based IVR monitoring for assessment purposes.
11063638|NCT04331691|Active Comparator|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
11063639|NCT04331691|Experimental|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
11063640|NCT04331678|No Intervention|Usual Care|Participants will be complete survey at enrollment and then again in 3 months.
11063641|NCT04331678|Active Comparator|Active|"Participants in the App group will receive usual care and complete survey at enrollment and then again in 3 months.
~In addition, they will be asked to download the study app to their mobile device and use it at least once per week during the 3-month study period."
11063642|NCT04331665|Experimental|Ruxolitinib to prevent COVID-19 pneumonia|All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.
11063643|NCT04331652|Experimental|Polypectomy without anesthesia or analgo-sedation|Patient will undergo polypectomy without anesthesia.
11063644|NCT04331626|Experimental|Low-dose Gemcitabine Combined With nivolumab|Bristol-myers squibb (BMS) company's nivolumab injection liquid (trade name: odiwal). Recommended dosage: 3mg/kg, intravenously injected once every 2 weeks for 60 minutes. As long as clinical benefit is observed, continue treatment with this product for up to 6 courses. Gemcitabine hydrochloride injection from eli lilly. Use 50% of the recommended dose, i.e. 500mg/m2, intravenously for 30 minutes. Day 1 and day 8 administration. Depending on the patient's tolerance to gemcitabine, a reduced dose may be considered for each treatment cycle or one treatment cycle. Use for 1 year. If a Ⅲ magnitude of adverse reactions, it is necessary to permanently discontinued.
11063645|NCT04331613|Experimental|CAStem|A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there is no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose.
11063646|NCT04331600|Experimental|CHLOROQUINE|Standard of care + chloroquine phosphate + telemedical approach.
11063647|NCT04331600|Other|CONTROL GROUP|Standard of care + telemedical approach.
11063648|NCT04331587|Experimental|Bronchoscopy|"Following airway inspection, the radial endobronchial ultrasound probe will be inserted through the working channel of the 4mm bronchoscope and will be advanced into the targeted bronchial segment towards the targeted lesion. Bronchoscopy will be performed using monoplanar fluoroscopic guidance until the peripheral lesion is located and confirmed using radial probe EBUS.
~a. If a concentric view is obtained, biopsy will proceed using conventional instruments (TBNA) through the 4mm bronchoscope.
~b. If an eccentric view is obtained, the 4mm bronchoscope will be withdrawn and the 3mm bronchoscope with the radial ultrasound probe will be advanced to the target lesion. Attempts will be made using the 3mm bronchoscope to obtain concentric views and ability to do so will be recorded. Biopsies will be obtained using conventional instruments (TBNA)through the 3mm bronchoscope regardless of the final ultrasound image (concentric or eccentric)."
11063649|NCT04331574||covid-19 patients|Patients with certified diagnosis of COVID-19 recruited in Italian hospitals
11063650|NCT04331561|Experimental|Sensory Re-weighting|Adults with self-reported visually-induced dizziness will be recruited to help establish the feasibility and tolerability of the testing and training methods, as well as observe for any effects of the sensory re-weighting intervention. Tests involve assessing motion sickness, vision, somatosensation, balance, and perception of verticality. The treatment provided is designed to facilitate re-weighting of sensory feedback for orientation and balance. Participants will serve as their own controls.
11063651|NCT04331535|Experimental|Polygenic risk score (PRS) - high risk stratum|Patient-participants in the PRS-high arm and their providers will receive their high-PRS results at baseline, along with educational resources about the results.
11063652|NCT04331535|Active Comparator|Usual care (UC) - high risk stratum|Patient-participants in the UC-high arm and their providers will receive their high-PRS results after a 24-month observation period, along with educational resources about the results.
11063653|NCT04331535|Experimental|Polygenic risk score (PRS) - average risk stratum|Patient-participants in the PRS-average arm and their providers will receive their average-PRS results at baseline, along with educational resources about the results.
11063654|NCT04331535|Active Comparator|Usual care (UC) - average risk stratum|Patient-participants in the UC-average arm and their providers will receive their average-PRS results after a 24-month observation period, along with educational resources about the results..
11063655|NCT04331522||Antibiotics|Children aged 0-18 years investigated for allergy to antibiotics
11063656|NCT04331522||Milk|Children aged 0-18 years investigated for allergy to milk
11063657|NCT04331522||Egg|Children aged 0-18 years investigated for allergy to egg
11063658|NCT04331522||Peanut|Children aged 0-18 years investigated for allergy to peanut
11063659|NCT04331522||Hazelnut|Children aged 0-18 years investigated for allergy to hazelnut
11063660|NCT04331522||Sesame|Children aged 0-18 years investigated for allergy to sesame
11063661|NCT04331522||Wheat|Children aged 0-18 years investigated for allergy to wheat
11063662|NCT04331522||walnut|Children aged 0-18 years investigated for allergy to walnut
11063663|NCT04331522||cashew|Children aged 0-18 years investigated for allergy to cashew
11063664|NCT04331522||Pistachio|Children aged 0-18 years investigated for allergy to pistachio
11063665|NCT04331522||Almond|Children aged 0-18 years investigated for allergy to almond
11063666|NCT04331522||Soy|Children aged 0-18 years investigated for allergy to soy
11063667|NCT04331522||Fish|Children aged 0-18 years investigated for allergy to fish
11063668|NCT04331522||Shellfish|Children aged 0-18 years investigated for allergy to shellfish
11063669|NCT04331522||Poppy seed|Children aged 0-18 years investigated for allergy to poppy seed
11063670|NCT04331509||Symptom tracker users|No Intervention
11063671|NCT04331496|Experimental|Hypertonic solution|Hypertonic solution 4 ml 3% , for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
11063672|NCT04331496|Active Comparator|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow.
11063673|NCT04331483|Experimental|Physical activity intervention|"The intervention consists of an adapted physical activity (APA) program defined at baseline, incorporating supervised sessions with an APA teacher, as well as autonomous sessions. The program is individualized according to age, aerobic capacity, and PA preferences.
~The total duration of the intervention is a maximum of 3 months (during the period of hospitalization in a sterile room)."
11063674|NCT04331470|Experimental|Levamisole Pill + Budesonide+Formoterol inhaler+Standard care|This group will take Levamisole + Budesonide/Formoterol along side with standard treatment regime.
11063675|NCT04331470|Active Comparator|Standard care|This group will take standard treatment regime introduced by Ministry of health.
11063676|NCT04331444|Experimental|Group A, CGM|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin.
~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group A (intervention) will, in similarity to the HCPs, receive a CGM-education and training session led by the study investigator and will be interactive and hands-on, using case studies. The training session will include spoken and written instructions on how to insert and wear the CGM device and how to interpret the CGM information to better understand the relation between participants blood glucose and their diabetes self-management."
11063677|NCT04331444|Experimental|Group B, CGM + peer-support|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin plus 3 sessions of peer-support in groups of 6 participants.
~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group B (intervention incl. peer-support) will, in similarity to group A, receive a CGM-education and training session. The training and CGM-course for participants in group B are similar to the course for group A with the addition of three peer-support sessions. The approach will be participatory and adaptable to allow flexibility in the content of the peer-support sessions and involving customized use of participatory methods i.e. dialogue tools and exercises."
11063678|NCT04331444|Active Comparator|Group C, SMBG|"Standard self-monitoring of blood glucose according to standard guidelines, in 12 months.
~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly."
11063679|NCT04331431|Other|spinal cord tumors|
11063680|NCT04331418|No Intervention|control group|"On arrival to operating room, Noninvasive monitors, such as electrocardiography, noninvasive blood pressure (NIBP), oxygen saturation (SpO2), will be attached and baseline parameters such as heart rate, mean arterial pressure, and peripheral oxygen saturation will be recorded .
~General anesthesia will be induced with O2/sevo (FiO2 = 1 /sevoflurane 8% MAC), cis-atracurium 0.1 mg/kg iv, +/- fentanyl 1 mcg/kg iv. Trachea will be intubated with an appropriate sized, endotracheal tube and maintenance of anesthesia by O2/Air (FiO2 = 0.4), sevoflurane 2% MAC.
~Dexamethasone 0.15 mg/kg iv will be given as PONV prophylaxis. Increments of fentanyl 0.5 mcg/kg iv and cis-atracurium 0.03 mg/kg iv will be given according to hemodynamics and capnography."
11063681|NCT04331418|Experimental|caudal group|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
11063682|NCT04331418|Experimental|dexmetomidine group|Children in this group will be received (1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr) with a suggested maximum dose of 2 mcg/kg.of dexmedetomidine is available in a 100 mcg/mL concentration in a 2 mL preservative-free vial. It may be prepared as a 2 to 4 mcg/mL solution using normal saline
11063683|NCT04331405|Experimental|Pilot group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received hUCBMC infusions weekly (4 infusions overall) in addition to standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
11063746|NCT04330885|No Intervention|Care as usual|Control group will be treated with care as usual meaning information from a PT two weeks prior to the surgery with information on the surgery and to stay active. Both groups will be given information on to stay active and home exercises following the surgery.
11063684|NCT04331405|No Intervention|Control group|10 patients with acute severe contusion spinal cord injury (ASIA A/B) included into the group. Patients meeting inclusion/exclusion criteria underwent primary surgical treatment (decompression and stabilization) received standard therapy during in-hospital treatment. After the discharge patients were examined for 4 times. Observation period was 1 year.
11063685|NCT04331392|Experimental|Spatial navigation intervention|
11063686|NCT04331392|Active Comparator|Educational Videos|
11063687|NCT04331379|Experimental|Nasal Elevator|
11063688|NCT04331379|Active Comparator|Taping Alone|
11063689|NCT04331366|Experimental|Treatment with GO2 PEEP MOUTHPIECE|Participants receiving treatment with the GO2 PEEP MOUTHPIECE
11063690|NCT04331353|Active Comparator|Comparator 1 (tailored approach)|Multi-component intervention tailored to the participant's allergic profile.
11063691|NCT04331353|Active Comparator|Comparator 2 (insecticidal bait)|Insecticidal bait for cockroach reduction.
11063692|NCT04331340|Experimental|Pharmacist Intervention|Pharmacist assessment of LUTS, with recommendations and education regarding lifestyle, behaviour, and/or medications related to bladder health. Follow-up at 3 and 6 weeks.
11063693|NCT04331340|Active Comparator|Control|Pharmacist questions regarding presence of LUTS, with provision of healthy aging literature. Follow-up at 6 weeks.
11063694|NCT04331327|Active Comparator|Allogenic lyophilized growth factors|Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
11063695|NCT04331327|No Intervention|Standard of care|The patients were kept on their traditional medications without any intervention
11063696|NCT04331314|Experimental|SYMBIOS®|Sinus augmentation with SYMBIOS® Biphasic Bone Graft Material
11063697|NCT04331314|Active Comparator|Algipore®|Sinus augmentation with Algipore® Bone Substitution Material
11063698|NCT04331301|Active Comparator|vapoenucleation group|Group A
11063699|NCT04331301|Active Comparator|needlescopic enucleation|group B
11063700|NCT04331288|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.
11063701|NCT04331275|Experimental|Viral Specific T-cells (VSTs)|
11063702|NCT04331236|Experimental|Patient and Caregiver Intervention|Patient and Caregivers receive both cognitive behavioral intervention and yoga interventions each week, for 7 weeks.
11063703|NCT04331210|Active Comparator|Group 1|Using diclofenac sodium suppository 50 mg immediately after suturing and then every 8 hours
11063704|NCT04331210|Active Comparator|Group 2|Using diclofenac sodium tablets 50 mg every 8 hours after birth
11063705|NCT04331197|Active Comparator|Clomiphene Citrate-High BMI women|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
11063706|NCT04331197|Active Comparator|Letrozole-High BMI women|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
11063707|NCT04331184|Experimental|RFA using combined bipolar and monopolar energy delivery|Control group: The historic cohort is used to compare the results of the conventional alternating unipolar radiofrequency energy transfer mode with RFA.
11063708|NCT04331171||Web-application users|questionnaire of comorbidity and symptomes completed by the user on his smartphone
11063709|NCT04331158|Experimental|Dry cupping group|The dry cupping will be applied with a force of two suctions generating a negative pressure on the skin during the time of 15 minutes.
11063710|NCT04331158|Placebo Comparator|Dry cupping sham group|The dry cupping sham group will receive the same procedures as the dry cup group, with the difference that the negative pressure imposed after application will be released in a few seconds.
11063711|NCT04331145|No Intervention|Clopidogrel 75 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:
~Normal basal platelet reactivity (PRU < 208 assessed with VerifyNow P2Y12 assay): Patients will continue with clopidogrel 75 mg/day until TAVI and during the following three months. All patients will be assessed by clinical follow up and platelet reactivity according to the protocol. Prescription of aspirin 100mg/day will be encourage as per guidelines recommendations."
11063712|NCT04331145|Active Comparator|Ticagrelor 60 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hrs before the index-TAVI procedure, patients with:
~High on-treatment platelet reactivity (PRU ≥ 208 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24 hours before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
11063713|NCT04331132|Placebo Comparator|Conventional diuretic group|The conventional furosemide treatment will follow the modified 2019 Position Statement from the ESC Heart Failure Association
11063714|NCT04331132|Active Comparator|Vasopressin-2 antagonist group|Tolvaptan 15mg once daily for 2 days will be added-on the furosemide strategy based on the modified 2019 Position Statement from the ESC Heart Failure Association
11063747|NCT04330872|Active Comparator|Enteric coated Aspirin|"EC aspirin loading dose 300mg followed by 100 mg (2 days).
~The study's total duration is 3 days."
11063748|NCT04330872|Placebo Comparator|Plain Aspirin|"Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days)
~The study's total duration is 3 days."
11063749|NCT04330859|Experimental|Intervention|Parent-driven intervention bundle of 6 evidence-based elements: vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy
11094530|NCT04114643|Active Comparator|Frozen Plasma|
11063715|NCT04331119|Experimental|Duvelisib Maintenance|-Patients who received the standard BEAM regimen with autologous hematopoietic stem cells transplant will begin duvelisib maintenance at 25 mg PO BID after count recovery (approximately 30 days after transplant) for one year. If the patient is in a complete remission at day +100, with no evidence of disease on PET/CT, then the dosing schedule of duvelisib may be changed to 25 mg BID for 14 days, then 14 days off in 28 day cycles (at the treating physician's discretion). If the patient has residual disease, duvelisib will continue at 25 mg BID until they have a negative PET CT. PET CTs will be completed every 3 months for patients with residual disease. Duvelisib maintenance will be continued for one year post-transplant.
11063716|NCT04331106||Population in Germany|Reasonably large and representative sample of the general population in Germany
11063717|NCT04331093|Experimental|resectable stage III-IV Acral melanoma|
11063718|NCT04331080|Experimental|Granexin® gel 100 μM|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).
~Granexin® gel 100 μM will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list.
~Vehicle gel will be applied at the same schedule on the contralateral (opposite) breast."
11063719|NCT04331080|Experimental|Granexin® gel 200 μM|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).
~Granexin® gel 200 μM will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list.
~Vehicle gel will be applied at the same schedule on the contralateral (opposite) breast."
11063720|NCT04331067|Active Comparator|Arm A: Neoadjuvant chemo + nivolumab|-Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
11063721|NCT04331067|Experimental|Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab|"Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
~Cabiralizumab will be given IV at a dose of 4 mg/kg every 2 weeks for 12 weeks."
11063722|NCT04331054|Active Comparator|1: Usual practice|arm will be follow during 30 days
11063723|NCT04331054|Experimental|2: Usual practice + SYMBICORT RAPIHALER|Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)
11063724|NCT04331041|Experimental|MR-guided SBRT + Defactinib|-Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and two 21-day cycles of defactinib (beginning on Day 2 of radiation).
11063725|NCT04331028|Experimental|Shockwave therapy|After dental extraction, a shockwave therapy will be applied to the area.
11063726|NCT04331028|No Intervention|Control|After dental extraction, no treatment will be applied
11063727|NCT04331002|Experimental|Experimental|The experimental group will receive a single 32 mg Zilretta injection approximately 4 weeks after meniscus surgery.
11063728|NCT04331002|Placebo Comparator|Placebo|The placebo group will receive a single 5 mL injection of normal saline approximately 4 weeks after meniscus surgery.
11063729|NCT04330989|Experimental|Group 1a: iNSC and Adherence supporter training|HIV-positive women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for ART.
11063730|NCT04330989|No Intervention|Group 1b: Standard of Care|HIV-positive participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
11063731|NCT04330989|Experimental|Group 2a: iNSC and Adherence supporter training|HIV-negative women randomly assigned to the intervention arm will receive a multi-component support strategy comprising iNSC and adherence supporter training for PrEP.
11063732|NCT04330989|No Intervention|Group 2b: Standard of Care|HIV-negative participants randomly assigned to the control arm will receive educational material about HIV prevention and treatment (as appropriate to this arm).
11063733|NCT04330976|Experimental|Nutrition and physical activity intervention|
11063734|NCT04330976|Other|Control|
11063735|NCT04330963||Hypersomnolence group|All patients referred to the outpatient clinic/sleep center for investigation due to complaints for excessive daytime sleepiness (EDS) and/or Hypersomnia (H) and/or suspected central disorder of hypersomnolence (CDH)
11063736|NCT04330963||Healthy controls|
11063737|NCT04330963||SDB controls|Patients with EDS and diagnosis of severe sleep related breathing disorder (SBD) significantly improving with therapy.
11063738|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
11063739|NCT04330937|Experimental|experimental group|volunteers consume 1 capsule per day for 3 months. (500 mg citrolive).
11063740|NCT04330937|Placebo Comparator|control group Placebo (sucrose)|volunteers consume 1 capsule per day for 3 months. (saccharose).
11063741|NCT04330924|Experimental|Virtual Reality|3D avatar in a virtual simulation environment
11063742|NCT04330924|No Intervention|Live Simulation|Live-based simulation in a simulation ward
11063743|NCT04330911|Experimental|The HIIT Group (High Intensity Interval Training Group)|
11063744|NCT04330911|Experimental|The MICT Group (Moderate Intensity Continous Training Group)|
11063745|NCT04330885|Experimental|Prehab group|"The patients in the PREHAB group will meet with a PT for 6 weeks pre surgery. The PT will coach the patient in 1:1 visits with a graded activity program with the purpose to affect fear of movement and raising level of self-efficacy with physical activity. The intervention comprises; cycling on a stationary cycle. Instructions of exercises that strengthen the deep and the superficial abdominal muscles and the back muscles. Information to contract the abdominal muscles in posturally loaded position to support their back. Information on flexion exercises of their lumbar spine and to keep the back in a flexed position when standing and walking (as opposed to extension). Recommendation to use Nordic walk (stavar) for outdoor walking"
11063751|NCT04330846|Experimental|EBD group|"Post-procedural admission in the Short Stay Unit (SSU).
~Superficial sedation by endoscopist or anesthesiologist depending on the center.
~Pneumatic balloon type CRE Boston scientific®; diameter of the balloon at the endoscopist's discretion.
~A maximum of 2 dilations will be performed with a minimum interval of 15-30 days between each dilation.
~Dilation failure will be considered if > 2 dilations are required."
11063752|NCT04330846|Experimental|SEMS group|"Post-procedural admission in the Short Stay Unit (SSU).
~Superficial sedation by endoscopist or anesthesiologist depending on the center.
~Fully coated, self-expanding Tae Woong medical®-type metal prostheses; size of the prostheses at the discretion of the endoscopist
~Clips can be placed at the distal end of the prosthesis at the endoscopist's discretion.
~Removal time of the prosthesis 4 weeks."
11063753|NCT04330833|Active Comparator|Enhanced Usual Care Parent Education|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the enhanced usual care parent education group.
11063754|NCT04330833|Experimental|Novel Communication Intervention|Parent(s) and patients receiving care from clinicians whose practice has been randomized to the novel communication intervention group.
11063755|NCT04330820|Experimental|Venetoclax+Cytarabin+ Mitoxantron|The treatment plan combines a fixed dose of venetoclax and mitoxantrone with increasing doses of cytarabine (V-MAC).
11063756|NCT04330807|Other|Patient with chronic kidney disease|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
11063757|NCT04330807|Other|CONTROL GROUP|Patients will perform a Handgrip fatigability test with their dominant hand and will complete two questionnaires of assessment of subjective fatigue.
11063758|NCT04330794|Experimental|NMFACT|record the caries index using the NMFACT chart
11063759|NCT04330794|Active Comparator|DMF index|record the caries index using the DMF chart
11063760|NCT04330781|Experimental|Intervention group|N=123
11063761|NCT04330781|Active Comparator|Control group|N=31
11063762|NCT04330768|Experimental|PRF|
11063763|NCT04330768|Active Comparator|MTA|
11063764|NCT04330755|Placebo Comparator|Group C|Control group will received saline
11063765|NCT04330755|Active Comparator|Group L|Levosimendan group will received levosimendan infusion
11063766|NCT04330755|Active Comparator|Group M|Levosimendan and Magnesium sulphate group will received both drugs
11063767|NCT04330742||0 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 0, at which time 0 mL of fluids will have been administered.
11063768|NCT04330742||250 mL crystalloid.|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 1, after the spinal has been placed and approximately 250 mL fluids has been administered.
11063769|NCT04330742||500 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 2, at which time 500 mL of fluids will have been administered.
11063770|NCT04330742||1000 mL crystalloid|These are the measurements (aortic velocity time integral, inferior vena cava diameter, vital signs) that will be taken at time 3, at which time 1000 mL of fluids will have been administered.
11063771|NCT04330729|Experimental|Dialysis patients|Patients will tablet acetylsalicylic acid 75mg x 1 for 4 weeks.
11063772|NCT04330716|Active Comparator|Group A: In-person genetic counseling|Will receive in-person genetic counseling prior to genetic testing.
11063773|NCT04330716|Experimental|Group B: Educational video|Will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing.
11063774|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
11063775|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
11063776|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
11063777|NCT04330690|No Intervention|Control|This arm will receive standard supportive care guidelines for COVID-19. This is expected the vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
11063778|NCT04330690|Experimental|Remdesivir plus standard supportive care|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care
11063779|NCT04330690|Experimental|Interferon plus standard supportive care|Interferon-beta-1a, 22 or 44 micrograms subcutaneously on days 1, 3 and 6, plus optimized supportive care
11063780|NCT04330677|Experimental|1. Oxytocin spray, 2. Estrogen gel|
11063781|NCT04330677|Experimental|1. Oxytocin spray, 2. Placebo gel|
11063782|NCT04330677|Experimental|1. Placebo spray, 2. Estrogen gel|
11063783|NCT04330677|Placebo Comparator|1. Placebo spray, 2. Placebo gel|
11063784|NCT04330664|Experimental|Phase 1 Dose Exploration|Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849
11063785|NCT04330664|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens
11063786|NCT04330664|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination
11063787|NCT04330638|Placebo Comparator|Usual Care|
11063788|NCT04330638|Active Comparator|Anakinra|
11063789|NCT04330638|Active Comparator|Siltuximab|
11063790|NCT04330638|Active Comparator|Anakinra + Siltuximab|
11063791|NCT04330638|Active Comparator|Tocilizumab|
11063792|NCT04330638|Active Comparator|Anakinra + Tocilizumab|
11063793|NCT04330625|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for four weekly doses
11063794|NCT04330612|No Intervention|Control|In the control pathway, the surgeons communicated with the family only once near the completion of the procedure.
11063795|NCT04330612|Experimental|Intervention|In the intervention group, the families received additional standardized electronic updates via pagers.
11063796|NCT04330586|Experimental|Ciclesonide|Ciclesonide 320ug oral inhalation q12h for 14 days
11063797|NCT04330586|No Intervention|Control|Standard care without ciclesonide
11063798|NCT04330573||Chronic Non-Specific Neck Pain|Patients with chronic non-specific neck pain. No interventions
11063799|NCT04330573||Control/Healthy Group|Volunteers without pain. No interventions.
11063800|NCT04330560|Experimental|Electronic Activity Tracking system (EATs)|Receive the mHealth intervention by wearing activity tracker link with to the healthcare system with standard care
11063801|NCT04330560|Active Comparator|Fitness Tracker (FT)|Receive the mHealth intervention by wearing activity tracker without the link to the healthcare system
11063802|NCT04330560|Placebo Comparator|Control (C)|Standard care only
11063803|NCT04330547|Active Comparator|Analgesic administration|"The analgesic treatment will be tailored to the patient's medication and will be based on 3 levels (based on Ventafridda et al., 1985):
~Level 1 : Non-opioid analgesics
~Level 2 : Weak opioids analgesics
~Level 3 : Strong opioids analgesics
~If the patient is already on pain medications, we will add the lowest effective dose of the level above the level of the regular pain medications of the patient. (e.g. if the patient has no analgesic treatment, he will be given a non-opioid analgesic (level 1). If he already has a level 1 treatment, we will go for level 2 medication. If he has level 2 treatment, we will go for level 3. And if the patient is already at level 3, we will increase the dosage by steps (reference: 5mg oxycodone as first choice for level 3 drugs)). Preferably, the medication will be administered by oral intake or gastrostomy feeding tube. If it is not possible, other routes of administration are allowed."
11063804|NCT04330547|Placebo Comparator|Placebo administration|Folavit capsules will be used as a placebo
11063805|NCT04330534|Experimental|BCX9930|Parts 1, 2 and 3
11063806|NCT04330534|Placebo Comparator|Placebo|Parts 1 and 2 only
11063807|NCT04330508||Group A|Chronic hepatitis C without Cirrhosis
11063808|NCT04330508||Chronic hepatitis C with Cirrhosis|
11063809|NCT04330508||Healthy Volunteers|
11063810|NCT04330495|Experimental|Testing and prophylaxis of SARS-CoV-2|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
11063811|NCT04330495|Active Comparator|placebo|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
11063812|NCT04330482|Other|Internet Links|A tablet pre-loaded with a list of internet links relating to dementia caregiving that participants will be instructed to use at least 4 times weekly for 3 months.
11063813|NCT04330482|Experimental|CARE-Well App|A tablet pre-loaded with the CARE-Well app that participants will be instructed to use at least 4 times weekly for 3 months.
11063814|NCT04330469|Experimental|Periodontal therapy|Patients offered periodontal therapy in 2-4 sittings (n=40), Dental hygiene advised
11063815|NCT04330469|Sham Comparator|Control|Patients given standard medical treatment (n=40), Dental hygiene advised
11063816|NCT04330456|Experimental|SaE treatment|"This group will receive combined treatment of soft tissue sarcoma that include 3 steps:
~step - preoperative stereotactic radiation therapy in hypofractionation mode (5 fractions 5 Gy each)
~step - operation
~step - postoperative conformal radiation therapy in normofractionation mode (25 fractions 2 Gy each)"
11063817|NCT04330443|Experimental|Ultrasound group|The neonatologist-researcher (NR) performed the lung ultrasound at admission during the first hour of life. The neonatologist-assistant (NA) of the baby was not blinded to the result of the lung ultrasound. If the patient had a lung ultrasound score higher than >8 or when FiO2 exceeded 30% patient received surfactant therapy during in the first 72 hours of life
11063818|NCT04330443|No Intervention|Chest X Ray|The NR performed the LUS at admission/suspicion during the first hour of life. The NA was not blinded to the result of the LUS. Patient received surfactant therapy only when FiO2 exceeded 30% during the first 72 hours of life
11063819|NCT04330430|Experimental|T-VEC + Nivolumab|Patients will receive pre-surgically 4 courses T-VEC (up to 4ml; first dose 10^6 PFU per mL, subsequent doses at 10^8 PFU per mL). Patients will also receive a flatdose of 240mg Nivolumab every 2 weeks after the first T-VEC injections (starting at 2nd T-VEC course at week 3, followed by the next doses at week 5 and 7).
11063820|NCT04330417|Experimental|EMG Glove Group|A total of 12 sessions of robot-assisted hand training for 6 consecutive weeks.
11063821|NCT04330417|Active Comparator|Control Group|A total of 12 session of standard hand therapy sessions in 6 consecutive weeks.
11063822|NCT04330404|Experimental|Cognitive strategy training|The experimental group will receive the Cognitive strategy training (CST), which includes awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments.
11063823|NCT04330404|Active Comparator|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
11063824|NCT04330391|No Intervention|Usual Care|Individuals randomized to the usual care group will receive standard care. This may include a physical therapist and/or nutritionist referral. Brigham and Women's Hospital offers several programs for patients interested in losing weight, including the Nutrition Wellness Service (NWS) and Program for Weight Management (PWM). Insurance coverage for these programs varies by patient insurance.
11063825|NCT04330391|Experimental|Intervention|Intervention subjects will use the Nutrimedy mobile app and be connected at enrollment with a registered dietitian who will contact intervention participants weekly or bi-weekly via video calls and unlimited in-app text messaging for up to three months. The first week will include either one 55-minute video session or two 25-minute sessions. Weeks 2-4 will have weekly 25-minute video calls, and weeks 5-12 will have biweekly 25-minute sessions for a total of 8-9 sessions over 12 weeks. Together, participants and dietitians will come up with goals for the 12 weeks, and dietitians will check on progress toward these goals using in-app tools such as food logs and messaging between video calls. All patients will be encouraged to lose at least 20 pounds with a goal BMI<40 kg/m2 after 12 weeks. The intervention group will also receive all aspects of the usual care arm including the opportunity to have a physical therapist and/or nutritionist referral.
11063848|NCT04330235||Control Group|Children 2-10 years of age dining at fast-food restaurants in northern New Jersey, where a healthy default beverage policy will not be enacted.
11063849|NCT04330222||Patients with lacunar stroke due to SVD|
11063850|NCT04330222||Healthy stroke free volunteers|
11063930|NCT04329624|Active Comparator|Levosimendan|Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
11063826|NCT04330378|Experimental|Hospital-at-home|Once a patient has been randomised to the intervention group, the NUHS@Home team will be activated. Patients will be sent home via ambulance, where they will be reviewed by a NUHS@Home nurse. Intravenous therapies, pillboxes for medication, remote monitoring software, and telecommunication tools will be set up as indicated. NUHS@Home doctors will visit at least once daily, and nurses at least twice daily as required. Therapists will conduct home visits as necessary. The NUHS@Home team is available 24/7. When conventional discharge criteria are met, the patient will be discharged. The NUHS@Home clinical team will be under clinical governance of Division of Advanced Internal Medicine at NUH and patients will be considered 'inpatients' throughout the treatment period.
11063827|NCT04330378|Other|Usual in-hospital care|Patients who have been randomised to the control group will receive usual care in the wards that they are already in until they are discharged.
11063828|NCT04330365|Active Comparator|Whole Health Team (WHT) Intervention Arm|The WHT intervention arm includes four core elements: 1) An interdisciplinary WHT collaborating with primary care; 2) Personalized Health Planning with prioritization of multi-modal non-pharmacological and CIH pain management approaches; 3) Whole Health Coaching sessions to assist patients in developing and implementing a Personalized Health Plan for chronic pain care; and 4) the web/mobile Whole Health Resource Directory provided to patient participants (in addition to their providers) to support non-pharmacologic/CIH chronic pain care.
11063829|NCT04330365|Active Comparator|Primary Care Group Education (PC-GE) Intervention Arm|Primary Care Group Education (PC-GE) iss the comparator arm, which is an abbreviated form of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) adapted for group use in primary care.
11063830|NCT04330365|Placebo Comparator|Usual Primary Care (UPC) Arm|In VA, patient-aligned care teams (PACTs) or primary care is step 1 of VA's Stepped Care Model in the treatment of chronic pain. PCPs are expected to possess the requisite skill set for management of common chronic pain-causing conditions, which includes biopsychosocial assessment, multi-modal treatment, and coordination of specialty pain care after shared-decision making that incorporates patient preferences and values. Participants randomized to this arm will continue to have their PCP and PACT serve in this role.
11063831|NCT04330352|Experimental|"Mindfulness-based STOP touching your face intervention"|"Eligibility participants who are allocated to the intervention group will be required to find a time to monitor and record their behavior of hand-to-face contacts, including the frequency and length (in second) of face-touching in any of the mucosal area (eyes, nose, mouth) and nonmucosal area (ears, cheeks, chin, neck, forehead, hair) during a 60-minute period. Then, they will receive the online mindfulness-based STOP touching your face program. Each participant will be required to practice this technique until they feel confident and natural. The systematic review showed the efficacy of single session of brief MBIs, the average length was 15 minutes, ranged from less than 5 to 25 min. Thus, the requirement practice time will be at least 15 minutes (excluding the time of reading the text and the first time of listening to the audio). Later (at least 1-hour interval), they will be asked to self-monitor and report their one-hour face-touching behavior again."
11063832|NCT04330352|No Intervention|Contron information intervention|"Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive STOP touching your face program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval."
11063833|NCT04330339|Experimental|Fasting|"Eligible participants will undergo baseline assessments prior to starting the intervention.
~Baseline assessments include measurements of weight, height, quality of life, fatigue, mood, levels of physical activity, and blood markers.
~Participants will fast for 13 hours nightly for 12 weeks.
~Assessments will be repeated at the completion of the 12-week intervention."
11063834|NCT04330326|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
11063835|NCT04330326|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
11063836|NCT04330313|Experimental|Traction and stretching|This grup received stretching exercises after traction therapy for 18 sessions, 3 times per week.
11063837|NCT04330313|Experimental|Laser therapy and stretching|This grup received stretching exercises after laser therapy for 18 sessions, 3 times per week.
11063838|NCT04330313|Experimental|Hot pack and stretching|This grup received stretching exercises after hotpack therapy for 18 sessions, 3 times per week.
11063839|NCT04330313|Experimental|Stretching only|This grup received only stretching exercises for 18 sessions, 3 times per week.
11063840|NCT04330300|Experimental|Alternative anti-hypertensive medication|Switch to an alternative BP medication (specifically a Calcium channel blocker [CCB] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.
11063841|NCT04330300|Active Comparator|Continue ACEi/ARB antihypertensive|Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.
11063842|NCT04330274||Group 1|Unilateral transtibial amputee
11063843|NCT04330274||Group 2|Unilateral transfemoral amputee
11063844|NCT04330261||SARS-CoV-2 Positive Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-positive for SARS-CoV-2 will be considered the exposed group in this study. These children will have exactly the same prospective follow-up as the other group.
11063845|NCT04330261||SARS-CoV-2 Negative Children|All children screened for SARS-CoV-2 and presenting to participating sites will be enrolled in this study. Children who are eventually test-negative for SARS-CoV-2 will be considered the unexposed (control) group in this study. These children will have exactly the same prospective follow-up as the other group.
11063846|NCT04330248|Experimental|Erdafitinib and Rifampin|Participants will receive single oral dose of erdafitinib dose 1 on Day 1 after an overnight fast of at least 10 hours in Period 1 followed by repeated doses of rifampin orally (once daily Days 15 to 28) after an overnight fast of at least 10 hours in Period 2. After 6 Days of rifampin treatment, on Day 21, participants will receive a single oral dose of erdafitinib dose 1 with that day's rifampin dose.
11063847|NCT04330235||Intervention Group|Children 2-10 years of age dining at fast-food restaurants in New York City and Philadelphia, where a healthy default beverage policy will be enacted.
11063851|NCT04330209||LowGI/nutrigenetic|"114 overweight (n=1) and obese (n=113) subjects (M = 55, F = 59, age 24-56y, all of Romanian heritage and similar socio-economic status), who were patients at a weight management clinic (Bucharest, Romania), gave written informed consent for their weight loss data to be prospectively analysed for this study.
~Upon enrolment at the weight management clinic, the subjects self-selected either a ketogenic diet or a low-GI nutrigenetic diet. 61 subjects (34 female; age 42.0 ± 6.7y) selected the low-GI nutrigenetic diet plan."
11063852|NCT04330209||Ketogenic|As above + Fifty-three subjects (25 female; age 43.0 ± 7.2y) selected the ketogenic diet plan
11063853|NCT04330196|Experimental|Glucose condition|In the experimental condition patients ingest 200ml of water containing 75g of glucose
11063854|NCT04330196|Placebo Comparator|Control condition|In the control condition patients ingest 200ml of water sweetened with 255mg of aspartame
11063855|NCT04330183|Placebo Comparator|Normal Saline|Patients here will be administered 3cc of normal saline as placebo
11063856|NCT04330183|Experimental|Ketamine Interventions|Patients will be administered weight based 0.3mg/kg of ketamine
11063857|NCT04330144|Experimental|administration of hydroxychloroquine as PEP|
11063858|NCT04330144|Active Comparator|control with no PEP|
11063859|NCT04330131|Experimental|Treated families|The treated families will complete up to 3 interventions: 3Ts - Newborn, 3Ts - Well Baby, and 3Ts - Let's Talk! The ideal progression is that treated families will complete all three interventions. Before completing their first intervention, participants will complete set of baseline surveys measuring their knowledge and beliefs about child development. They will repeat these measures when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
11063860|NCT04330131|No Intervention|Comparison Families|Comparison families will not receive any of the 3Ts interventions but will complete the same surveys as the treatment group at study enrollment and again when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
11063861|NCT04330118||20 patients with DRESS syndrome|
11063862|NCT04330118||20 patients with drug induced MPE with eosinophilia|patients with drug induced maculopapular exanthema (MPE) with eosinophilia
11063863|NCT04330118||20 patients with drug induced MPE without eosinophilia|
11063864|NCT04330118||20 Healthy subjects|
11063865|NCT04330079|Experimental|Dapagliflozin|
11063866|NCT04330079|Other|Lifestyle modification|
11063867|NCT04330066||Exogenous hormone replacement thaw cycle|Participants in this group will follow Boston IVF's standard exogenous hormone replacement protocol. Participants will take Estrace 3mg twice daily by mouth for endometrial preparation. After 16-18 days of Estrace, endometrial thickness will be measured by transvaginal ultrasound but medication and ultrasounds will be continued until the endometrial lining is ≥ 7 mm. Once the final endometrial lining is ≥ 7 mm (T1), the doctor of record will start the participant the following day with intramuscular progesterone daily or intramuscular progesterone every 3 days with daily vaginal progesterone. Frozen embryo transfers would occur on the sixth day of progesterone.
11063868|NCT04330066||Natural thaw cycle|Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone < 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.
11063869|NCT04330053|Experimental|Experimental|Information - Education about falls and Exercise for Fall Prevention
11063870|NCT04330053|Active Comparator|Control|Information - Education about falls without Exercise for Fall Prevention
11063871|NCT04330040|Experimental|Single Arm|Intervention: Drug: Olaparib
11063872|NCT04330027|Experimental|Growth factors|Patients in this group will receive one lyophilized Growth Factors injection supplied as a powder in a tightly sealed container.
11063873|NCT04330027|Placebo Comparator|Saline|Patients in this group will receive an injection with equal volume of saline; i.e 2ml of 0.9% sodium chloride.
11063874|NCT04329988||Primary care patients aged 18 or more|All patients consulting in a general practitioner office, aged 18 or more, who completed the questionnaire
11063875|NCT04329975||Participants with Nocturia|Participants with nocturia due to nocturnal polyuria treated with MINIRINMELT OD Tablet 25μg or 50μg as per daily clinical practice.
11063876|NCT04329962|Experimental|Group I (blueberry extract, blueberry powder)|Participants undergo a washout on days -7 to -1 and then consume blueberry extract confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry powder confection on day 8.
11063877|NCT04329962|Experimental|Group II (blueberry powder, blueberry extract)|Participants undergo a washout on days -7 to -1 and then consume blueberry powder confection on day 0. Participants undergo a second washout on days 1-7 and then consume blueberry extract confection on day 8.
11063878|NCT04329949|Experimental|Relacorilant with nab-paclitaxel|Patients will be treated with relacorilant, administered orally, once daily in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
11063879|NCT04329923|Active Comparator|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
11063880|NCT04329923|Placebo Comparator|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
11063881|NCT04329923|Experimental|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
11063882|NCT04329923|Active Comparator|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
11063883|NCT04329923|Experimental|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
11063884|NCT04329923|Placebo Comparator|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
11063885|NCT04329910||Lean|BMI < 25
11063886|NCT04329910||overweight|BMI 25 - 29.9
11063890|NCT04329897|Experimental|Software Messaging|Acceptance and Commitment Therapy Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy
11063891|NCT04329897|No Intervention|Control|Subjects randomizing into this arm did not receive the text message study intervention.
11063892|NCT04329884|Active Comparator|Intra-articular corticosteroid injections|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. Radiology guidance will be used to guide needle placement within the affected hip to administer lidocaine and a corticosteroid intra-articularly.
11063893|NCT04329884|Active Comparator|Cooled radiofrequency ablation|The hip and groin areas will be prepped and draped in the usual sterile fashion with ChloraPrep. Preprocedural vital signs will be performed and will be in the nursing chart for review. The HALYARD* COOLIEF* SINERGY* Cooled Radiofrequency Probe (sterile, single use) is inserted through a COOLIEF* SINERGY* Introducer used with fluoroscopy guidance in the AP view to visualize the hip joint and sensory nerve areas over the acetabulum (femoral) and ischium (obturator) where the cooled radiofrequency ablation will be applied to create a focal thermal lesion to encompass and denervate the targeted nerves.
11063894|NCT04329858|Active Comparator|conventional glass ionomer|
11063895|NCT04329858|Experimental|zinc modified glass ionomer|
11063896|NCT04329858|Experimental|silver modified glass ionomer|
11063897|NCT04329845|Active Comparator|open splenectomy for splenic injury in trauma|open splenectomy as a technique for removal of the spleen in case of injury to spleen
11063898|NCT04329845|Active Comparator|laparoscopic splenectomy for splenic injury in trauma|laparoscopic splenectomy as a technique for removal of the spleen in case of injury to spleen
11063899|NCT04329832|Experimental|Hydroxychloroquine|
11063900|NCT04329832|Active Comparator|Azithromycin|
11063901|NCT04329806|Experimental|Moxonidine|Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
11063902|NCT04329806|Active Comparator|Valsartan|Valsartan to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
11063903|NCT04329806|Active Comparator|Amlodipine|Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
11063904|NCT04329793|Experimental|Intervention arm|Assisted gait training with Walkbot System and their usual Physical Therapy.
11063905|NCT04329793|Active Comparator|Control arm|Their usual Physical Therapy.
11063906|NCT04329767||IRIS Arm|Utilize the CT scan along with the IRIS 3D model preoperatively and intraoperatively
11063907|NCT04329767||CT Arm|Utilize only the standard 2D CT scan preoperatively and intraoperatively
11063908|NCT04329754|Other|iPure|"IPure IOL (PhysIOL, Belgium): a new single-piece hydrophobic acrylic IOL. The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration.
~Patient were allocated into two groups. The study group received the iPure lens (Physiol, Liege) while the control group received Tecnis ZCB00 (Johnson&Johnson). Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
11063909|NCT04329754|Other|ZCB00|"ZCB00 IOL (Johnson&Johnson, United States): a standard IOL.The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design.
~Patient were allocated into two groups. The study group received the iPure lens (Physiol, Liege) while the control group received Tecnis ZCB00 (Johnson&Johnson). Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
11063910|NCT04329741|Experimental|Intervention|6-week basic dog obedience training course
11063911|NCT04329741|No Intervention|Control|Waitlist control
11063912|NCT04329728|Experimental|• DLBCL and high-grade B-cell lymphoma|
11063913|NCT04329728|Experimental|• MCL|
11063914|NCT04329728|Experimental|• Primary mediastinal large B-cell lymphoma|
11063915|NCT04329728|Experimental|• Burkitt or Burkitt-like lymphoma/leukemia|
11063916|NCT04329728|Experimental|• CLL/SLL|
11063917|NCT04329728|Experimental|B or T ALL|• B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma
11063918|NCT04329715|Experimental|Expedited instructions|
11063919|NCT04329715|Active Comparator|Restricted instructions|
11063920|NCT04329702|Experimental|coping skills training plus therapist input|Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
11063921|NCT04329702|Experimental|coping skills training without therapist input|Participants will receive a call from a research coordinator to get them started with the trial. Participants will use the Blueprint mobile app for 1 month. No therapist calls will be provided. Chat room access in the app will be provided.
11063922|NCT04329702|No Intervention|usual care control|Control participants will receive the same safety oversight as intervention participants and will be provided with phone and email contacts for study staff.
11063923|NCT04329689|Experimental|septal myectomy alone versus septal myectomy|"The aims of the present study is to:
~Compare the results of adequate septal myectomy alone versus septal myectomy + mitral repair in patients with HOCM.
~Effect of mitral repair on outcome of patients with systolic anterior motion that accompanies HOCM."
11063924|NCT04329676|Experimental|Deep Brain Stimulation|Patients will undergo bilateral implant of directSTIM system in the STN.
11063925|NCT04329663|Experimental|training group|Ten children with ADHD who got the 20 sessions training of the Indonesian computer-based game prototype. They we were assessed by CATPRS, BRIEF and fMRI BOLD
11063926|NCT04329650|Experimental|Siltuximab 11mg/Kg|
11063927|NCT04329650|Active Comparator|Methylprednisolone 250mg/24h|
11063928|NCT04329637|Active Comparator|IHC (intergrative health care) arm|Meditation and care coordination in addition to usual care
11063931|NCT04329624|Placebo Comparator|Placebo|Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
11063932|NCT04329611|Active Comparator|hydroxychloroquine|hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days
11063933|NCT04329611|Placebo Comparator|Placebo|Matching Placebo
11063934|NCT04329598|Experimental|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
11063935|NCT04329598|Experimental|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
11063936|NCT04329585|Experimental|GABA antagonist|In the end of the experiment, 0.2mg of flumazenil(GABA antagonist) is given to the participant.
11063937|NCT04329585|Placebo Comparator|Placebo|In the end of the experiment, the same volume of normal saline is given to the participant.
11063938|NCT04329572|Experimental|HCQ + AZT|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) and AZT (500 mg/ 5 days) on top of standard care.
11063939|NCT04329546||Cases|Cases are patients with COVID-19.
11063940|NCT04329546||Contacts|Contacts are household contacts of an index (case) patient.
11063941|NCT04329533|Experimental|Intervention Group - access to meditation app|"Will receive a 30-day free trial of the mobile meditation app Calm on study day 0"
11063942|NCT04329533|No Intervention|Control Group - no access to meditation app|"Will not have the intervention until after the 30 day study period and then will receive a 30-day free trial of the mobile meditation app Calm on study day 30"
11063943|NCT04329494|Experimental|Arm I (PIPAC, cisplatin, doxorubicin)|Patients with ovarian, uterine, or gastric cancer, undergo PIPAC with cisplatin, followed by doxorubicin. Treatment repeats every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11063944|NCT04329494|Experimental|Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)|Patients with colorectal cancer undergo PIPAC with oxaliplatin. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11063945|NCT04329481|Active Comparator|mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder. These include Shiitake, Maitake, Trametes Coriolus Versicolor, Agaricus.
~Compliance to treatment will be considered as taking 80% of supplement/placebo treatment, and will be monitored by telephone calls and emails to patients during the study phase, and by counting the pills which were not taken at the end of the trial.
~Treatment with Mycodigest supplement will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
11063946|NCT04329481|Placebo Comparator|placebo|"will be be identical in size, shape and color to Mycodigest Treatment with Mycodigest placebo will initiate with 2 pills/day for 7 days, and gradually rise to 4 pills/day for 7 days, 6 pills/day for 42 days. Thus, the full dose of the treatment will be administered for 6 weeks."
11063947|NCT04329468|Experimental|DS-MCE examination|Subjects with or without digestive symptoms will be enrolled to take DS-MCE and conventional esophagogastroduodenoscopy (EGD) within 48h successively.
11063948|NCT04329455||Intervention group|
11063949|NCT04329442|Experimental|PrEP Received|Participants will be provided with a free 30-day supply of PrEP.
11063950|NCT04329429|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.5 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
11063951|NCT04329416|Other|Predicted depth of insertion|The predicted insertion depth of the DLT was calculated using the formula [0.249 x (BH) 0.916] before induction of anesthesia using an application on the smartphone
11063952|NCT04329403|Experimental|Test Group|Adapalene Gel, 0.1%, applied as thin film once daily for 12 weeks
11063953|NCT04329403|Active Comparator|Reference Group|Differin® (Adapalene) Gel, 0.1%, applied as thin film once daily for 12 weeks
11063954|NCT04329403|Placebo Comparator|Placebo Group|Placebo Gel, 0.1%, applied as thin film once daily for 12 weeks
11063955|NCT04329390||anticoagulant|Subjects of both sexes, aged 18 years or older, requiring the prescription of, or already on oral anticoagulant treatment, will be eligible for the study, irrespective of the index event, of the intended treatment duration, and the type of drug used.
11063956|NCT04329377||platelet count in iiron overload|
11063957|NCT04329364|Experimental|Laser Haemorrhoidoplasty (LAH)|treatment that we would like to study
11063958|NCT04329364|Active Comparator|Conventional Open Haemorrhoidectomy (COH)|gold standard treatment as comparator
11063959|NCT04329351|Experimental|Guided bone regeneration Group|After extraction, Guided bone regeneration was conducted using the PTFE-d membrane (CytoplastTM Ti-250 Titanium-Reinforced, Anterior Narrow 12 mm x 24 mm, Osteogenics, Lubbock, TX, USA) was customized with scissors and adjusted over the socket, exceeding three millimeters from its margins. Then, the membrane was inserted subperiostally under the buccal and palatal flaps with the help of the Molt detacher. Minimal flap reflection was performed to stabilize the membrane, which was maintained intentionally exposed to the oral environment. Before suturing, the passive stability of the membrane over the alveolus was confirmed, as well as the absence of folds or wrinkles in the membrane. The flaps were then be approached in the pre-extraction position and sutured with crossed sutures, aiming to increase the stability of the membrane, with PTFE 4-0 thread (Cytoplast PTFE, CS0618PREM, Osteogenics, Lubbock, TX, USA).
11063960|NCT04329351|Placebo Comparator|Non-Guided bone regeneration group|After extraction, no further treatment (No addition of Guided bone regeneration) was performed. The flaps were then repositioned and sutured with 5.0 nylon thread (Ethicon, Jonhson's Jonhson, São José dos Campos).
11063961|NCT04329338|No Intervention|Gut and vaginal sample collection|Gut and vaginal samples were collected for Nugent score, and 16S rRNA metagenomics communities.
11063962|NCT04329338|Experimental|Gut and Vaginal sample after Lactobacillus|Seven women diagnosed with BV by Nugent score (7-10) provided vaginal and gut sample after 14 days oral intake of 3 grams (2.5X108 cfu/g) of Lactobacillus pentosus KCA1
11063963|NCT04329325|Experimental|Blinatumomab & Concurrent Oral Tyrosine Kinase Inhibitor (TKI)|Patients may receive steroids and hydroxyurea pre-study entry and receive a 7-day steroid prephase before starting TKI therapy. Planned initial TKI is dasatinib 140 mg daily; dasatinib dose may be reduced or TKI may be changed to a different agent under certain conditions. Induction consists of continuous TKI + 24 days of dexamethasone, followed by taper of dexamethasone, with bone marrow aspirate/biopsy (BMA) and CNS prophylaxis at days 22 and 43. Patients achieving morphologic complete response post-induction proceed to consolidation with up to 3 cycles of blinatumomab (28-day cycles, 14 days between cycles) + TKI, with BMA and CNS prophylaxis between cycles. Patients achieving complete molecular response may proceed to maintenance with up to 4 more cycles of blinatumomab (28-day cycles with 28 days between cycles) + TKI, with CNS prophylaxis between cycles and BMA after cycles 5 and 7. Patients can come off study to undergo allogeneic hematopoietic cell transplantation at any time.
11063964|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063965|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063966|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063967|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063968|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063969|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063970|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
11063971|NCT04329299||Blood Biomarkers Analyses|15 ml of blood sample will be obtained from each study participant, for blood-based biomarkers analyses.
11063972|NCT04329273|Experimental|Training group|"For the balance exercise the participants will perform one-legged stance of certain duration, on a stable surface.
~For the sliding leg curl exercise the participants lay supine on a mat, wearing only socks in order to create a slippery surface between their heels and the gym floor. The player begins by extending the hip and having the working leg on knee flexion. The contralateral limb is on hip flexion and knee flexion. The base of support is the shoulder blades, the elbows and the heel of the working leg. After assuming this position, the player begins to extend the knee, as slowly as possible, resisting the low friction properties of the ground.
~The core stability program consists of front plank, side planks, supine bridge, leg lowering and superman exercise. These exercises will be performed at the end of the training session, in contrast to the balance and hamstring exercises which will be executed before the training session."
11063973|NCT04329273|No Intervention|Control group|The participants in this group will follow only the usual training program
11063974|NCT04329260||Pediatric population|"Children between 3 to 18 years old with severe (BMI> IOTF-30) and early (before the age of 6) obesity.
~A Saliva sample for screening of the deletion Δ6-8 of LEPR gene will be performed for each child."
11063975|NCT04329260||Adult member family|The screening of the same deletion according the same procedure will be proposed to the adult family member if the child presents the deletion Δ6-8 of LEPR gene.
11063976|NCT04329247|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 6 weeks.
11063977|NCT04329247|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 6 weeks. After this period of time, participants will begin the best treatment available.
11063978|NCT04329234||acute heart failure|Patients with acute heart failure
11063979|NCT04329221|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
11063980|NCT04329221|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
11063981|NCT04329208||Cerebral vasospasm|13 patients developed symptomatic cerebral vasospasm detected by CT angiography and TCD
11063982|NCT04329208||Non Vasospasm|27 patients without cerebral vasospasm
11063983|NCT04329195|Experimental|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
11063984|NCT04329195|Active Comparator|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
11063985|NCT04329169|Experimental|Virtual Implant Planning|
11063986|NCT04329156|Experimental|Digitally Flip Technique|
11063987|NCT04329156|Active Comparator|Stock Healing Abutment|
11063988|NCT04329143|Active Comparator|open completion cholecystectomy|open completion cholecystectomy for cystic duct stump stone
11063989|NCT04329143|Active Comparator|laparoscopic completion cholecystectomy|lap completion cholecystectomy for cystic duct stump stone
11063990|NCT04329130|Experimental|Chidamide combined Lenalidomide|"Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days.
~one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator."
11063991|NCT04329104|Experimental|Dose-escalation study: Arm 1: 5 mg/kg of CIS43LS|Participants will receive 5 mg/kg of CIS43LS on Day 0. Once all participants in Arm 1 reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin for Arm 2.
11063992|NCT04329104|Experimental|Dose-escalation study: Arm 2: 20 mg/kg of CIS43LS|Participants will receive 20 mg/kg of CIS43LS on Day 0. Once all participants in Arm 2 reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin for Arm 3.
11063993|NCT04329104|Experimental|Dose-escalation study: Arm 3: 40 mg/kg of CIS43LS|Participants will receive 40 mg/kg of CIS43LS on Day 0. After the last participant in Arm 3 reaches Day 7 safety follow-up, an interim safety evaluation will be performed before enrollment begins for the Efficacy study.
11063994|NCT04329104|Experimental|Efficacy study: Arm 1: 40 mg/kg of CIS43LS|Participants will receive 40 mg/kg of CIS43LS on Day 0.
11063995|NCT04329104|Placebo Comparator|Efficacy study: Arm 2: Placebo|Participants will receive placebo on Day 0.
11063996|NCT04329091|Experimental|Dexmedetomidine Arm|Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.
11063997|NCT04329065|Experimental|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11063998|NCT04329052|Experimental|Experimental group|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
11063999|NCT04329052|No Intervention|Control group|Participants would have their usual activity without any intervention.
11064000|NCT04329039|Active Comparator|Group 1|Active somatostatin analogue combined with perioperative antibiotics
11064001|NCT04329039|Placebo Comparator|Group 2|Placebo combined with perioperative antibiotics
11064002|NCT04329026|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
11064003|NCT04329026|Placebo Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
11064004|NCT04329013|Active Comparator|Left lateral position|The patient will be in left lateral position during EGD
11064005|NCT04329013|Experimental|Prone position|The patient will be in prone position during EGD
11064006|NCT04329000|Experimental|On-demand PPI therapy|The patients in this group were advised to take PPI for 8 weeks continuously, followed by on-demand PPI therapy for the following 40 weeks.
11064007|NCT04329000|Active Comparator|Continuous PPI therapy|The patients in this group were advised to take PPI QD continuously for 48 weeks.
11064008|NCT04328987||Clopidogrel user|"* Uninterrupted (continuous) use of clopidogrel: cessation of clopidogrel less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of clopidogrel is sum of before and after the CSP
~patient who stopped clopidogrel only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 1 day.
~patient who stopped clopidogrel from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of clopidogrel -> excluded from study.
~patient who stopped clopidogrel from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of clopidogrel was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of clopidogrel -> excluded from study."
11064009|NCT04328987||Aspirin user|"* Uninterrupted (continuous) use of aspirin: cessation of aspirin less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of aspirin is sum of before and after the CSP
~patient who stopped aspirin only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 1 day.
~patient who stopped aspirin from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of aspirin -> excluded from study.
~patient who stopped aspirin from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of aspirin was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of aspirin -> excluded from study."
11064010|NCT04328974||the lumbar CSF drainage group|We named the patients treated with the protocol and the lumbar CSF drainage as the lumbar CSF drainage group.
11064011|NCT04328961|Placebo Comparator|Ascorbic Acid|Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days
11064012|NCT04328961|Experimental|Hydroxychloroquine|Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days
11064013|NCT04328948|Experimental|Chemoradiation therapy with elective nodal irradiation|Chemoradiotherapy consists of 5-FU (1,000 mg / m2, day1-4, day29-32), CDDP (75 mg /m2, day1, 29) and radiotherapy (50.4 Gy/28Fr)
11064014|NCT04328948|Active Comparator|Chemoradiation therapy with involved field irradiation|Chemoradiotherapy consists of 5-FU (700 mg /m2, day1-4, day29-32), CDDP (70 mg /m2, day1,29) and radiotherapy (60 Gy/30Fr)
11064015|NCT04328935|Experimental|written exposure therapy|The treatment consists of written exposure therapy (WET), which is manualized trauma-focused CBT in five sessions over 5 weeks.
11064016|NCT04328922|Active Comparator|Fecal microbial transplantation|FMT capsules fecal capsules on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will be matched to donors according to their CMV status (past exposure - CMV positive donors will be used for CMV positive patients, and CMV negative donors will be used for CMV negative patients).
11064017|NCT04328922|Placebo Comparator|Placebo|Placebo capsules placebo capsules- on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will receive placebo capsules.
11064018|NCT04328909|Experimental|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
11064019|NCT04328909|Active Comparator|Control Group|Usual care - No E-Care app will be provided
11064020|NCT04328896|Experimental|Intervention|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
11064021|NCT04328883|Active Comparator|162 mg Non-Enteric-Coated Chewable aspirin|Non-enteric coated aspirin (162mg, single dose)
11064294|NCT04326881|Experimental|SHR-1314 C|single dosing SHR-1314 C
11064022|NCT04328883|Experimental|50 mg ASA inhalation powder|Dry powder inhaled aspirin (50mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
11064023|NCT04328883|Experimental|100 mg ASA inhalation powder|Dry powder inhaled aspirin (100mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
11064024|NCT04328870|Active Comparator|oxytocin and spinal anesthesia|spinal anesthesia combined with intravenous oxytocin infusion
11064025|NCT04328870|Active Comparator|general anesthsia|general anesthesia alone
11064026|NCT04328857|Experimental|Treatment|Upper limb rehabilitation with pseudoelastic orthosis
11064027|NCT04328857|No Intervention|Control|Upper limb rehabilitation without pseudoelastic orthosis
11064028|NCT04328844|Experimental|Single arm with IOA-244|
11064029|NCT04328831|Other|IBI322|Single arm
11064030|NCT04328805|Experimental|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
11064031|NCT04328805|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
11064032|NCT04328792||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
11064033|NCT04328779|Experimental|multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks.
11064034|NCT04328779|Active Comparator|multi-task treadmill walking|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill.
11064035|NCT04328779|Active Comparator|traditional rehabilitation|Traditional rehabilitation group will train strength, balance, and gait.
11064036|NCT04328766|Experimental|DWP14012 Cohort A|
11064037|NCT04328766|Experimental|DWP14012 Cohort B|
11064038|NCT04328766|Experimental|DWP14012 Cohort C|
11064039|NCT04328753|Experimental|super oxidized water group|
11064040|NCT04328753|Active Comparator|chlorhexidene group|
11064041|NCT04328753|Placebo Comparator|distilled water|
11064042|NCT04328740|Experimental|Monotherapy|TP-1454
11064043|NCT04328740|Experimental|Combination Therapy|TP-1454, ipilimumab and nivolumab
11064044|NCT04328727|Experimental|eltrombopag|Participants will receive eltrombopag in combination with r-ATG and CsA.
11064045|NCT04328714|Experimental|Adult Population|Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
11064046|NCT04328714|Experimental|Pediatric Population|Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
11064047|NCT04328701|Experimental|Mindfulness-based CBT|All participants will receive four individual mindfulness-based CBT sessions.
11064048|NCT04328701|No Intervention|Treatment as Usual|All participants will undergo surgery as usual, with no additional intervention.
11064049|NCT04328662||Cohort 1: Participants with RRMM|Participants diagnosed with relapsed or refractory multiple myeloma (RRMM) who have received at least one dose of ixazomib plus lenalidomide - low dose dexamethasone (IRd) treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
11064050|NCT04328662||Cohort 2: Participants with NDMM, RRMM, and Non-myeloma|Participants with NDMM, RRMM, and Non-myeloma Participants diagnosed with newly diagnosed multiple myeloma (NDMM) who have received at least one dose of ixazomib-based regimen treatment and diagnosed with RRMM who have received at least one dose non-IRd ixazomib-based regimens treatment, and diagnosed with non-myeloma who have received at least one dose of ixazomib-based regimens treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
11064051|NCT04328636|Experimental|NebMag|Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
11064052|NCT04328636|Active Comparator|IVMag|Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo
11064053|NCT04328623|Active Comparator|Infiltration|Ultrasound-guided hand infiltration
11064054|NCT04328623|Experimental|Hypnosis|Hypnosis before Ultrasound-guided hand infiltration
11064055|NCT04328610|Experimental|LYMPHA technique group|LVA at the time of Axillary Dissection
11064056|NCT04328610|No Intervention|Non-LYMPHA technique group|No preventive surgical approach
11064057|NCT04328597||Chronic postoperative pain|Patients scoring 3 or more on the EuraHS Quality of Life assessment after elective inguinal hernia repair
11064058|NCT04328597||Non chronic postoperative pain|Patients scoring less than 3 on the EuraHS Quality of Life assessment after elective inguinal hernia repair
11064059|NCT04328584|Experimental|SNS|Intraoperative imaging/surgical navigation system (SNS)
11064060|NCT04328571|Experimental|OLE enzymatically treated|Participants will receive 1 capsule of OLE enzymatically treated + 1 stick of maltodextrin each day in the morning for 21 days
11064061|NCT04328571|Experimental|OLE + probiotic|Participants will receive 1 capsule of OLE + 1 stick of probiotic each day in the morning for 21 days
11064062|NCT04328571|Active Comparator|OLE|Participants will receive 1 capsule of OLE + 1 stick of maltodextrin each day in the morning for 21 days
11064063|NCT04328558|Active Comparator|Group CPB = Clavipectoral fascia plane block group|In group CPB, CPB will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third of the clavicle. A 22-gauge block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 20 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
11064064|NCT04328558|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11064065|NCT04328545|Experimental|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 mins duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
11064066|NCT04328545|Active Comparator|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
11064067|NCT04328545|Sham Comparator|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
11064068|NCT04328532|Experimental|Pregnancy with suspicion of PAA|
11064069|NCT04328532|Other|Pregnancy without suspicion of PAA|
11064070|NCT04328519||patient(hospitalized)|patients who are admitted to the emergency department and hospitalized.
11064071|NCT04328519||control(not hospitalized)|patients who are admitted to the emergency department and not hospitalized.
11064072|NCT04328506|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (test product) under fasted state, after a wash period of 5 days, the subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state.
11064073|NCT04328506|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (test product) under fasted state.
11064074|NCT04328506|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of CM082 tablet (test product) after meal, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (reference product) after meal.
11064075|NCT04328506|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of CM082 tablet (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of CM082 tablet (test product) after meal
11064076|NCT04328493|No Intervention|Control arm|Patients randomized to the control arm will receive a standard of care therapy (a supportive care/treatment according to VN MoH's guideline).
11064077|NCT04328493|Experimental|Intervention arm|"In addition to standard of care therapy, patients randomized to the intervention arm receive chloroquine phosphate as below.
~For adult ≥ 53kg: 1000mg (4 tablets) at initial dose (T=0), followed by 500mg (2 tablets) at 6 hours later (T=6), and 500mg (2 tablets) once daily for 9 days.
~For adult from 45 - 52kg: 875mg (3.5 tablets) at T=0, followed by 500mg (2 tablets) at T=6 and 500mg (2 tablets) once daily thereafter.
~For adult weighted 38 -<45 kg: 750mg (3 tablets) at T=0, followed by 375mg (1.5 tablets) at T = 6 and 375mg (1.5 tablets) once daily thereafter.
~For adult weighted <38 kg: 625mg (2.5 tablets) at T=0, followed by 375mg (1.5 tablets) at T=6 and 375mg (1.5 tablets) once daily thereafter.
~The total duration of treatment with chloroquine will be 10 days."
11064078|NCT04328480|Active Comparator|Local standard of care plus colchicine|Local standard of care plus colchicine (specific dosage schedule)
11064079|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate / high-risk patients
11064080|NCT04328467|Experimental|Intervention Once Weekly|400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks
11064081|NCT04328467|Experimental|Intervention Twice Weekly|400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks
11064082|NCT04328467|Placebo Comparator|Control Group|Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks
11064083|NCT04328454||COVID-19 patients|Hospitalized patients with COVID-19
11064084|NCT04328441|Experimental|BCG vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
11064085|NCT04328441|Placebo Comparator|Placebo|Intracutaneously 0.1ml of 0.9% NaCl solution
11064086|NCT04328428|Experimental|(A)modified BL40 acupuncture|modified BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain.
11064087|NCT04328428|Active Comparator|(B)EM32 acupuncture|EM32 acupuncture Participants receive EM32 acupuncture once on the opposite site.
11064088|NCT04328428|Active Comparator|(C)BL40 acupuncture|BL40 acupuncture Participants receive BL40 acupuncture once on the same site of low back pain
11064089|NCT04328415|Experimental|healthy volunteers|
11064090|NCT04328415|Experimental|patients with Chronic Kidney Disease|
11064091|NCT04328402||Children and adolescents submitted to PSG in sleep laboratory|Children (1 to 11 years) and adolescents (12 to 18 years), who were referred to a sleep laboratory and submitted to full-night polysomnography due to suspicious of sleep disorders.
11064092|NCT04328389|Placebo Comparator|Placebo Comparator: electric toothbrush|Participats will be instructed to used electric toothbrush for home supragingival plaque removal
11064093|NCT04328389|Experimental|Professional oral hygiene|Full-Mouth professional oral hygiene consisting in scaling and root planing, four quadrants in one session.
11064094|NCT04328376|Experimental|Prospective FEMQT Group|Propositus patients with genetically proven LQTS and their relatives
11064095|NCT04328363|Experimental|Intervention|The intervention will be carried out by primary care nurses over eight visits: baseline visit and follow-up visits which take place 15 days, 1, 2, 4, 6, 9, and 12 months after baseline with a final visit evaluation at 18 months. The intervention will be based on the social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles in people with prediabetes. The content of the intervention proposed is based on the NHS and it will be carried out at three levels (individual, group and community) to facilitate the patient empowerment and promotion of healthy lifestyles with a positive orientation using the community resources.
11064096|NCT04328363|No Intervention|Control|The Control group will receive routine standard care.
11064295|NCT04326868|Active Comparator|Albendazole|ABZ (400mg)
11064097|NCT04328350||AYA who are on treatment 2-12 months post -diagnosis|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.
~Participants (30 on-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
11064098|NCT04328350||AYA who are off -therapy 1 to 4 years|"AYA will complete questionnaires assessing peer versus family connectedness, peer/romantic competence, coping, distress, social support, and quality of life.A study-specific needs assessment regarding interest in social functioning interventions will also be completed.
~Participants (20 off-therapy) will be interviewed to further explore aspects of peer/family connectedness and intervention interest."
11064099|NCT04328337|Experimental|Non-diabetic, normal weight individuals receiving Intralipid|Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)
11064100|NCT04328337|Placebo Comparator|Non-diabetic, normal weight individuals receiving saline|Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2
11064101|NCT04328311|Experimental|Active|Watermelon juice
11064102|NCT04328311|Other|Control|Low nitrate water.
11064103|NCT04328285|Experimental|Hydroxychloroquine (HCQ) vs Placebo|"Group 1.1: HCQ 200 mg : 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards
~Group 1.2: Placebo of HCQ, 2 tablets on the evening at Day 1 and 2 tablets on the morning at Day 2 and 1 tablet once daily afterwards."
11064104|NCT04328285|Experimental|Lopinavir/ritonavir (LPV/r) vs Placebo|"Group 2.1: LPV/r 200/50 mg, 2 tablets twice daily
~Group 2.2: Placebo of LPV/r, 2 tablets twice daily"
11064105|NCT04328272|Experimental|Hydroxychloroquine|tablet hydroxychloroquine (HCQ). Day-1 (initial) 1st dose, 3 tablets (200 mg per tablet), 2nd dose after 6 hours, 3 tablets (200 mg per tablet) per oral. From day 2 to 7 (maintenance dose), 2 tablets twice a day.
11064106|NCT04328272|Active Comparator|Azithromycin|Tablet azithromycin (AZC) 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 7.
11064107|NCT04328272|Placebo Comparator|Suger Tablets|Placebo (sugar tablet) twice daily for 7 days
11064108|NCT04328246|Experimental|IES Device + Standard of Care|Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.
11064109|NCT04328246|Active Comparator|Standard of Care|Standard of care treatment for pressure injuries is turning the patient every two hours.
11064110|NCT04328233|Experimental|Time-Restricted Eating|
11064111|NCT04328207|Other|No financial incentive|This group will receive standard of care eye health education alone and no financial incentive for completing a referral visit.
11064112|NCT04328207|Experimental|Financial incentive|This group will receive a financial incentive once the referral visit is completed (if one was required) as well as eye health education.
11064113|NCT04328194|Experimental|Study Group|80 patients with breast cancer
11064114|NCT04328194|Placebo Comparator|Control Group|20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
11064115|NCT04328181|Experimental|SPCCT and standard DECT|Comparative intra-patients (each patient will have both types of scanner imaging done), clinical superiority study, evaluating the imaging performances (e.g. image quality and radiation dose) of SPCCT and standard DECT for several body regions/anatomical structures.
11064116|NCT04328168|Active Comparator|Group1|Conventional Physiotherapy
11064117|NCT04328168|Active Comparator|Group2|robot-assisted gait training
11064118|NCT04328155|Experimental|Hotpack Group|Group I (15 subjects) received 18 sessions hotpack to hamstring muscles and self stretching exercise3 times per week.
11064119|NCT04328155|Experimental|Infrared Group|Group II (15 subjects) received 18 sessions infrared to hamstring muscles and self stretching exercise3 times per week.
11064120|NCT04328155|Experimental|Ultrasound Group|Group III (15 subjects) received 18 sessions ultrasound to hamstring muscles and self stretching exercise 3 times per week.
11064121|NCT04328155|Active Comparator|Control|Group IV (15 subjects) received 18 sessions self stretching exercise 3 times per week.
11064122|NCT04328142|Experimental|Qigong|The Qigong experimental group performed the 20 figures to improve health and longevity described by the master of Qigong 'Wang Ziping'. These are based on therapeutic exercises of Traditional Chinese Medicine. They work on breathing, flexibility and balance. Each figure was repeated 6 times. The sessions were administered twice a week during 45 minutes and were guided by a Doctor in Western Medicine who is also qualified as a Doctor of Traditional Chinese Medicine and Qigong teacher.
11064123|NCT04328142|Experimental|Physiotherapy|The physiotherapy experimental group completed an active exercises program guided by a qualified physiotherapist. The exercise programme was based on active shoulder, hips and spine kinesiotherapy. It included a warm up of 3-5 minutes walking, followed by 6 repetitions of shoulder and hip exercises in standing, cervical spine exercises in sitting or standing, according to the comfort of the patient, thoracic and lumbar spine exercises performed in supine on a mat and balance exercises in standing. Stretching exercises were also performed at the end of the session. The exercises were accompanied by gentle breathing coordinated with the movements. The sessions were administered twice a week during 45 minutes.
11064124|NCT04328142|No Intervention|Control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
11064125|NCT04328129|Experimental|Primary case|Subject with laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase chain reaction (PCR)
11064126|NCT04328129|Experimental|Family contact|Subject who lived in the household of the primary case while the primary case was symptomatic
11064127|NCT04328116||Study Group|Neodent GM Zygomatic Dental Implants will be placed. Multiple implants may be placed in a single subject.
11064128|NCT04328103|Active Comparator|Cognitive Behavior Therapy (CBT)|Following established procedures at the Depression Evaluation Service (DES) at New York State Psychiatri Institute (NYSPI), 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
11064129|NCT04328103|Placebo Comparator|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
11064130|NCT04328090|Experimental|CDSS-Antimicrobial stewardship|Computer-based, multicomponent intervention targeting on reduction of perioperative antimicrobial use will be delivered to teams in the intervention arm.
11064131|NCT04328090|No Intervention|Standard of care|Teams in the control arm will continue with usual standard clinical care.
11064132|NCT04328077|Experimental|TERN-101 dose level 1|Orally administered.
11064133|NCT04328077|Experimental|TERN-101 dose level 2|Orally administered.
11064134|NCT04328077|Experimental|TERN-101 dose level 3|Orally administered.
11064135|NCT04328077|Placebo Comparator|Placebo|Orally administered.
11064136|NCT04328064|Active Comparator|Rosuvastatin Drug|Active drug-rosuvastatin 40 mg
11064137|NCT04328064|Placebo Comparator|Placebo drug|Placebo oral tablet
11064138|NCT04328051|Active Comparator|Ocean E.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and external hexagon connection.
11064139|NCT04328051|Active Comparator|Ocean I.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and internal hexagon connection.
11064140|NCT04328051|Active Comparator|Ocean C.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and conical connection.
11064141|NCT04328038||USA|Cohort from the USA
11064142|NCT04328038||Germany|Cohort from Germany
11064143|NCT04328025|Active Comparator|Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP|"For TGW in the intervention arm, peers will deliver HIVST and PrEP medications monthly in between quarterly clinic visits. Quarterly clinic-based testing will confirm accuracy of self-tests and identify inaccurate test results. Additionally, peers will remind TGW to self-test before opening a new PrEP bottle. They will also distribute STI self-sampling kits to TGW for own use, and with regular partners as needed. They will present smart phone instructional videos showing trans women how to self-collect pharyngeal, rectal and urine specimens for Neisseria gonorrhoeae and Chlamydia trachomatis testing.
~Peers will: a) motivate ongoing adherence; b) promote repeat HIV testing; and c) support PrEP use as problems arise. Self-sampling for STIs will be performed monthly by participants (with questions answered by the peer or other study staff as needed)."
11064144|NCT04328025|No Intervention|Facility-Delivered Care|Participants will receive facility-based HIV counseling, PrEP prescriptions condoms, risk reduction counseling, and management of sexually transmitted infections as standard of care.
11064145|NCT04328012|Experimental|lopinavir/ritonavir|lopinavir/ritonavir 400mg/200mg mg po BID X 5-14 days depending on availablity
11064146|NCT04328012|Experimental|Losartan|losartan 25 mg po QD X 5-14 days depending on availability
11064147|NCT04328012|Placebo Comparator|Placebo|placebo BID X 14 days
11064148|NCT04327999|Experimental|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
11064149|NCT04327986|Experimental|1/Arm 1A|Escalating doses of M7824 / de-escalating doses of M9241
11064150|NCT04327986|Experimental|2/Arm 1B|De-escalating doses of M9241 in combination with M7824 and SBRT
11064151|NCT04327986|Experimental|3/Arm 2|RP2D of M7824 and M9241 in combination with SBRT
11064152|NCT04327947|Experimental|women, 18-39 y|Health volunteers, 18-39 y, with vaginal dryness
11064153|NCT04327947|Experimental|premenopause women|Health volunteers, 40 years to premenopause, with vaginal dryness
11064154|NCT04327947|Active Comparator|climacteric women|Health volunteers, climacteric, with vaginal dryness
11064155|NCT04327934|Active Comparator|Healthy Control|Healthy control participants.
11064156|NCT04327934|Experimental|AE-PCOS|Participants with AE-PCOS.
11064157|NCT04327921|Experimental|peer navigation social support for smoking cessation|36 HIV-positive smokers will have a 30-minute session with the study nurse to discuss smoking cessation. They will also discuss the importance of social support for quitting and the role of a Peer Navigator. Those participants who set a quit date will choose medication/s in collaboration with the nurse and/or physician. The Peer Navigator will be introduced and will reinforce adherence to medication. The Peer Navigator will ensure that the patient picks up the medication, and will help to manage side effects via physician/nurse consultation. The Peer Navigator will provide social support for quitting via weekly phone calls for 12 weeks.
11064158|NCT04327921|Active Comparator|Standard Condition|36 HIV-positive smokers will receive standard care. Participants will meet for a 30-minute session with a study nurse. They will receive counseling based on the 5A's. The nurse will ask about current smoking habits, advise the participant to quit, assess readiness to quit, and assist by providing resources (community programs, Quit line phone number). The nurse will calculate Lung Age which will serve as a motivation tool to encourage smokers to quit. Those willing to set a quit date will be instructed to call their physician for cessation medication and will provided with the National Cancer Institute self-help pamphlet. Those participants not willing to set a quit date will be instructed to contact their physician when they are ready.
11064159|NCT04327869||Abdominal symptoms group|The investigators selected 10 subjects (male: female = 1: 1) from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel
11064160|NCT04327869||Healthy control group|The investigators selected another 10 subjects (male: female = 1: 1) from healthy volunteers.
11064161|NCT04327856||Cataract surgery group|Patients which were administrated to the Ophthalmology Clinic Medical University of Bialystok due to scheduled cataract removal surgery
11064162|NCT04327843|Experimental|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
11064163|NCT04327830||Older adults and their caregivers|Older adults who have received or are receiving home care services and their caregivers
11064164|NCT04327830||Interdisciplinary health and social care providers|Interdisciplinary health and social care providers who provide home care services to older adults
11064165|NCT04327817|Other|Multifidus ReActiv8 stimulator|The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an implantable pulse generator, implantable leads, programmer, activator and magnet.
11064166|NCT04327804||Odd numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an odd numbered year will first have their left nostril swabbed by the foam swab followed by their right nostril being swabbed by the two polyester swabs.
11064167|NCT04327804||Even numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an even numbered year will first have their left nostril swabbed by the two polyester swabs followed by their right nostril being swabbed by a foam swab.
11064168|NCT04327791|Experimental|baloxavir|Baloxavir: 40 mg po once for wt < 80 kg OR 80 mg po once for wt >/= 80 kg
11064169|NCT04327791|Placebo Comparator|placebo|placebo po once
11064170|NCT04327778|Experimental|Music therapy|Patients will be exposed every two weeks
11064171|NCT04327765|Experimental|Cohort 1|Single orally-inhaled dose
11064172|NCT04327765|Experimental|Cohort 2|Single orally-inhaled dose
11064173|NCT04327765|Experimental|Cohort 3|Single orally-inhaled dose
11064174|NCT04327739|Experimental|Intervention 1 Exercise|Participants allocated to this group received a 10 weeks exercise programme for neck and upper limbs muscles
11064175|NCT04327739|Experimental|Intervention 2 Exercise and INIT|Participants allocated to this group received the same exercise programme as group 1 in combination with the integrated neuromuscular inhibition technique (INIT)
11064176|NCT04327739|Experimental|Intervention 3 Exercise and SMT|Participants allocated to this group received the same exercise programme as group 1 in combination with cervical manipulation
11064177|NCT04327739|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home based general exercise sheet
11064178|NCT04327726|Placebo Comparator|Control group|received ultrasonic nebulization of 4mL 0.9% saline twice daily for 3 days
11064179|NCT04327726|Active Comparator|Dexmedetomidine group|received ultrasonic nebulization of 1 µg/kg dexmedetomidine diluted in 4mL 0.9% saline twice daily for 3 days. The intervention will be continued until achieving a VAS score ≤3 and Lybecker et al. classification score <2 and or for a maximum of 72 hours. Patients in this group who achieved the target scores before 72 hours will be given 4ml of saline 0.9% nebulization to maintain blinding.
11064180|NCT04327713||fish oil supplementation|"fish oil supplementation, usually capsules with a defined content of EPA and DHA
~dosage and duration of intervention differ between the included studies of our meta-analysis"
11064181|NCT04327713||placebo supplementation|"placebo supplementation, usually capsules with a defined content of non-fish oil or other components
~content, dosage and duration of intervention differ between the included studies of our meta-analysis"
11064182|NCT04327700|Experimental|Regorafenib and TheraBionic|"TheraBionic is a device that consists of battery-driven radiofrequency electromagnetic field generator. The metal mouth spoon antenna is placed on the anterior part of the tongue during treatment.
~Regorafenib is a 40 mg tablet administered orally."
11064183|NCT04327687|Experimental|remote ischemic conditioning|remote ischemic conditioning is a physical strategy performed by an electric auto-control device with cuffs placed on bilateral arms: five cycles of 5-min inflation and 5-min deflation one or two times per day. The duration of the treatment is six months.
11064184|NCT04327687|Active Comparator|conventional therapy|conventional therapy
11064185|NCT04327661|Experimental|Tradipitant High Dose|
11064186|NCT04327661|Experimental|Tradipitant Low Dose|
11064187|NCT04327661|Placebo Comparator|Placebo|
11064188|NCT04327648|Active Comparator|Social interaction treatment|During the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. ASD children are followed up closely.
11064189|NCT04327648|Sham Comparator|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
11064190|NCT04327648|Other|Routine treatment|Children in routine treatment group will keep the same initial treatment. ASD children are followed up closely.
11064191|NCT04327635|Experimental|PEP in Acute Myocardial Infarction|Patients with an acute myocardial infarction who undergo cardiac catheterization at least four hours after onset of symptoms will receive a one-time intracoronary infusion of PEP within 20 minutes after stent placement or post-dilation.
11064192|NCT04327609|Experimental|SELUTION SLR™ DEB|Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
11064193|NCT04327609|Active Comparator|Control Treatment|POBA
11064194|NCT04327596|No Intervention|Conventional Treatment|Subjects will receive management of AF consisting of either rate or rhythm control.
11064195|NCT04327596|Active Comparator|AF Ablation|Subjects will undergo early RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
11064196|NCT04327583|Experimental|Coordinated pharmaceutical path|Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
11064197|NCT04327583|No Intervention|Standard of care|Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
11064198|NCT04327570||ICU-hospitalised COVID-19 patients|COVID-19 positive patients hospitalised in intensive care ('severe disease').
11064199|NCT04327570||ward-hospitalised COVID-19 patients|COVID-19 positive patients requiring hospitalisation,not on intensive care department ('non-severe').
11064200|NCT04327557|Experimental|MBCP Childbirth Education Course|This arm will undergo the 9-week MBCP course.
11064296|NCT04326868|Experimental|Albendazole and Mebendazole|ABZ 400mg + 1 tablet of MBZ (500mg)
11064201|NCT04327557|Active Comparator|Non-MBCP Childbirth Education Course|This arm will undergo the TAU (treatment as usual) childbirth education course (one that does not have a huge mindfulness component).
11064202|NCT04327544|Experimental|Frailty Intervention group|A multi-domain intervention program that includes nutrition education and low to moderate multi-component exercise intervention.
11064203|NCT04327544|No Intervention|Control group|Respondents in the control group will not receive any nutritional education or exercise intervention activities.
11064204|NCT04327518|Experimental|TECNIS® Toric II|Subjects will be implanted in one or both eyes with the study lens
11064205|NCT04327505|Experimental|Hyperbaric oxygen|Hyperbaric oxygen 1,6-2.4 Bar for 30-60 minutes (compression/decompression time, according to local routines) in addition to best practice
11064206|NCT04327505|No Intervention|Control|Best practice
11064207|NCT04327492||Carotid endarterectomy|"This study is a non-interventional prospective cohort study. The population corresponds to patients submitted to CEA under regional anesthesia. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) will be prospectively recruited. The expected patient follow-up will be of 5 years.
~The demographics will be recorded in a prospective, protected database. Blood samples will be collected in clot activator serum tubes at three timepoints: timepoint 1 - before surgery (until 15 days before surgery); timepoint 2 up to 48h postoperatively; timepoint"
11064208|NCT04327466|Experimental|Osciflow|Crossover sequence of experimental treatment and active comparator.
11064209|NCT04327466|Active Comparator|Highflow|Crossover sequence of experimental treatment and active comparator.
11064210|NCT04327453|Experimental|XP-endo Finisher file|removal of double antibiotic paste intracanal medication with XP-endo Finisher file
11064211|NCT04327453|Experimental|Irrisafe Ultrasonic tip|removal of double antibiotic paste intracanal medication with passive ultrasonic irrigation
11064212|NCT04327453|Active Comparator|side vented needle|removal of double antibiotic paste intracanal medication with conventional syringe irrigation
11064213|NCT04327440||Nyambi, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
11064214|NCT04327440||Nyambi, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
11064215|NCT04327440||Kalembo, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
11064216|NCT04327440||Kalembo, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)
~The duration of the cohort is six months."
11064217|NCT04327414|Experimental|Intervention group|Implementation of standing desks in classroom for 4 to 5 months. To ensure that adolescents will spend sufficient time at the standing desks, 1/3 to half of the classroom will be provided with standing desks. The school will be asked to actually replace some traditional desks with these standing desks, instead of just adding standing desks to the classroom set-up to ensure as much as possible that the desks are being continuously used throughout the intervention period.
11064218|NCT04327414|No Intervention|Control group|No implementation of standing desks in classroom.
11064219|NCT04327401|Experimental|Intervention group|Dexamethasone. After randomization, dexamethasone [20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
11064220|NCT04327401|No Intervention|Control|Standard treatment (according to the treatment protocol for 2019-nCoV infection).
11064221|NCT04327388|Experimental|Sarilumab Dose 1|Sarilumab Dose 1 given intravenously one time on Day 1. Patients may receive a second dose with Sarilumab Dose 1 24 to 48 hours after the first dose.
11064222|NCT04327388|Experimental|Sarilumab Dose 2|Sarilumab Dose 2 given intravenously one time on Day 1. Patients may receive a second dose with Sarilumab Dose 2 24 to 48 hours after the first dose.
11064223|NCT04327388|Placebo Comparator|Matching placebo|Matching placebo given intravenously one time on Day 1. Patients may receive a second dose with matching placebo 24 to 48 hours after the first dose.
11064224|NCT04327375||observational|observational
11064225|NCT04327362|Experimental|Cluster 1: Sham to active tDCS crossover at PE Session 4.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-3, and 20 min. of active tDCS prior to PE sessions 4-10.
11064226|NCT04327362|Active Comparator|Cluster 2: Sham to active tDCS crossover at PE Session 5.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-4, and 20 min. of active tDCS prior to PE sessions 5-10.
11064227|NCT04327362|Active Comparator|Cluster 3: Sham to active tDCS crossover at PE Session 6|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-5, and 20 min. of active tDCS prior to PE sessions 6-10.
11064228|NCT04327362|Active Comparator|Cluster 4: Sham to active tDCS crossover at PE Session 7.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-6, and 20 min. of active tDCS prior to PE sessions 7-10.
11064229|NCT04327362|Active Comparator|Cluster 5: Sham to active tDCS crossover at PE Session 8.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-7, and 20 min. of active tDCS prior to PE sessions 8-10.
11064230|NCT04327349|Other|COVID-19 Patients|
11064231|NCT04327336|Active Comparator|Manual|In this group non invasive mechanical ventilation will be manually titrated during a polysomnography. The Philips A40 ventilator will be used in Spontaneous-Timed (ST) mode.
11064232|NCT04327336|Active Comparator|Automatic|In this group the ventilator will run in an automatic mode (AVAPS) with the same Phillips A40 ventilator.
11064233|NCT04327310|Experimental|Meplazumab|The vial of meplazumab will be reconstituted with 1 mL of water for injection. The required amount of drug solution will be withdrawn and added to 100 mL sterile normal saline (0.9%) for IV infusion. A single dose of meplazumab will be infused over 60 minutes at a constant rate using an infusion pump.
11064234|NCT04327310|Placebo Comparator|Placebo|100ml placebo will be infused over 60 minutes at a constant rate using an infusion pump, single time.
11064235|NCT04327284|Experimental|test group|The test group will receive immediate molar implant placement in fresh extraction socket with nonocclusal loading immediate provisionalization (Straumann BLX 6.5mm).
11064297|NCT04326868|Experimental|Albendazole and Pyrantel|ABZ (400mg) + Pyr (125 mg)
11064236|NCT04327284|Active Comparator|Control group|The control group will receive delayed molar implant placement at least 12 weeks post molar extraction with nonocclusal loading immediate provisionalization (Straumann BLX 5.0mm).
11064237|NCT04327271|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
11064238|NCT04327271|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
11064239|NCT04327258||All patients|Patients undergoing elective surgery with anesthesia
11064240|NCT04327245|Experimental|Intervention ingest a 5000 mg of D-tagatose|Intervention: Women with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.e.
11064241|NCT04327245|No Intervention|No Intervention: Intervention ingest a water (control group)|Woman with resistance insulin who ingest a water (control group)
11064242|NCT04327245|Experimental|Intervention ingest a 15,3 mg of stevia|"Intervention: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
11064243|NCT04327232|Experimental|Active|"For patients randomized to active experimental arm: Spironolactone
~Patient will receive study drug for 18 months. Study drug dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day, with 1 tablet being 25mg spironolactone. Study drugs are titrated every 3 months based on patients' potassium and eGFR blood tests results."
11064244|NCT04327232|Placebo Comparator|Control|"For patients randomized to control arm: Placebo
~Patient will receive placebo for 18 months. Placebo dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day. Placebo are titrated every 3 months based on patients' potassium and eGFR blood tests results."
11064245|NCT04327219|Experimental|CDED diet|The CDED will be divided into 3 stages: 0-6 weeks- induction phase (phase 1), weeks 7-12 step-down phase (phase 2), week 13 -24 maintenance phase (phase 3). During these weeks the diet is structured and contains a list of allowed/disallowed foods, and mandatory foods with specific daily/weekly amounts. Patients will be asked to progress with the diet if they respond to the diet clinically. Patients who do not improve, but show a clinicaly significant trend in symptoms, may be asked to prolong a dietary phase until reaching clinical reaction.
11064246|NCT04327219|No Intervention|standard diet|The control standard diet will be personally tailored for nutritional needs according to patient's daily recommended intake (DRI) for calories and protein intake (25kcal/kg and 0.8-1gr/kg per day respectivlly), and will follow the clinical guidelines for dietary therapy of patients with IBD.
11064247|NCT04327206|Experimental|BCG vaccine|Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
11064248|NCT04327206|Placebo Comparator|0.9% Saline|Participants will receive a single 0.1 mL dose of 0.9%NaCl injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
11064249|NCT04327193|Experimental|Driving pressure|The selected PEEP which makes the driving pressure lowest is applied during the operation.
11064250|NCT04327193|Active Comparator|Conventional|Conventional PEEP (5cmH2O) is applied.
11064251|NCT04327180||patients suspected of infection with COVID-19.|Patients included with positive PCR and patients with negative PCR included
11064252|NCT04327167|Other|Digital intervention|
11064253|NCT04327154|Experimental|Digital nerve repair|There is no comparator for this study. All patients are in the treatment allocated group for digital nerve repair with the TISSIUM™ Nerve Coaptation Device.
11064254|NCT04327141|Experimental|Protein pacing and intermittent fasting|During the 8-week weight loss (WL) phase, participants assigned to the PP-IF will consist of PP days, whereby female participants will consume four and male participants will consume five meals/snacks total, two of which (breakfast and lunch) will include a protein powder meal replacement mixed with water (240-400 kcals per meal) along with an evening dinner meal (~500 kcals), an afternoon snack (men only), and an evening snack (250 kcals). Subjects will be calorie restricted to ~1500 and ~1800 calories per day, women and men, respectively during PP days. For each IF day, subjects will be provided a variety of supplements/snacks made by Isagenix International LLC. The PP-IF group will be further divided into two subgroups for weeks 1-4. One subgroup will consist of five days of PP and two days of IF, and the second subgroup will consist of six days of PP and one day of IF. For weeks 5-8 both subgroups will follow 6 days of a PP diet and 1 day IF.
11064255|NCT04327141|Experimental|Heart Healthy|The HH group will observe the dietary guidelines in compliance with the National Cholesterol Education Program Therapeutic Lifestyle Changes (TLC) diet. This diet consists of consuming <35% of kcal as fat; 50%-60% of kcal as carbohydrates; <200 mg/dL of dietary cholesterol; and 20-30 g/day of fiber. The total calorie intake will be 1200 and 1500 calories per day, women and men, respectively during the weight loss phase (weeks 0-8).
11064256|NCT04327128|Active Comparator|Intervention group|Standard heart failure care and a digital heart failure support system
11064257|NCT04327128|Other|Control group|Standard heart failure care
11064258|NCT04327115|Other|Arm 1|"(C-I-I-I) : the centers apply the Control strategy in Period 1 and then apply the Intervention strategy in Periods 2 to 4."
11064259|NCT04327115|Other|Arm 2|"(C-C-I-I) : the centers apply the Control strategy in periods 1 and 2 and then apply the Intervention strategy in periods 3 and 4."
11064260|NCT04327115|Other|Arm 3|"(C-C-C-I) : the centers apply the Control strategy in periods 1, 2 and 3 and then apply the Intervention strategy for period 4."
11064298|NCT04326855|Experimental|20 patients with advanced COPD|This will be a cross sectional observational study. COPD patients will be recruited from those referred to the Pulmonary Rehabilitation programme at RVI Hospital in Newcastle upon Tyne. Potentially eligible patients will be identified by the physiotherapy team within the Trust, who will provide initial information about the study. Delegated investigators will confirm eligibility and discuss full details of the trial. Patients will be given time to consider participation in the trial before written informed consent is obtained.
11064299|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
11064300|NCT04326842||Control|Patients without carotid artery stenosis
11064261|NCT04327102|Experimental|Experimental : intervention group|Combination of health education tools and health literacy intervention: on the basis of the control group, the hypertension health education tools are used as the education media to encourage patients to find out the elements of the tool chart, use the picture content to guide the topic development, encourage patients to discuss with each other, realize heuristic questions, rather than a single indoctrination, so as to deepen the understanding and memory of patients. At the end of the course, patients are encouraged to set short-term goals to encourage behaviors that continue to achieve larger goals. At the same time, health literacy lectures were organized during the hospitalization. Health literacy lecture is mainly to learn the information that hypertension needs to pay attention to in order to improve the health literacy of hypertension patients and other indicators.
11064262|NCT04327102|No Intervention|No intervention:The control group|No intervention except conventional care were performed for the control group
11064263|NCT04327089|Experimental|Part 1- Cohort 1|Single oral dose of 400 mg Setanaxib administered as 1x400 mg tablet in fasting conditions.
11064264|NCT04327089|Experimental|Part 1- Cohort 2|Single oral dose of 800 mg Setanaxib administered as 2x400 mg tablet in fasting conditions.
11064265|NCT04327089|Experimental|Part 1- Cohort 3|Single oral dose of 1200 mg Setanaxib administered as 3x400 mg tablet in fasting conditions.
11064266|NCT04327089|Experimental|Part 1- Cohort 4|Single oral dose of 1600 mg Setanaxib administered as 4x400 mg tablet in fasting conditions.
11064267|NCT04327089|Experimental|Part 2- Cohort 5|Repeated 10-Day dosing of 1200mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 1x400mg tablet in the evening in fedding conditions.
11064268|NCT04327089|Experimental|Part 2- Cohort 6|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions.
11064269|NCT04327089|Experimental|Cohort 7|Repeated 10-Day dosing of 1600mg/day of Setanaxib administered as 2x400mg tablet in the morning and as 2x400mg tablet in the evening in fedding conditions. Additionnaly, this cohort includes the evaluation of potential Drug-Drug interactions with CYPs and transporters.
11064270|NCT04327076|Experimental|Robot system intervention|"Evaluate the patient and sign the informed consent
~The patient was given general anesthesia
~Use magnetically guided tracheal intubation and airway cleaning robot system"
11064271|NCT04327063|Placebo Comparator|Placebo|Saline (30 mL maximum)
11064272|NCT04327063|Experimental|Ropivacaïne|Ropivacaïne 5 mg/mL (not to exceed 3 mg/kg and 30 ml of maximal volume)
11064273|NCT04327050|Experimental|Magnetic-ESD|Patients in MAG arm will be treated using magnetic anchored guided endoscopic submucosal dissection.
11064274|NCT04327037|Experimental|NK cells + IL-2|After cycle of chemotherapy patient receive one intravenous infusion of expanded haploidentical NK cells on day 0. On alternate days, 6 doses of subcutaneous IL-2 is administered with start on day -1.
11064275|NCT04327024|Experimental|Verinurad + allopurinol|Dose [mg] verinurad/allopurinol: Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 2 - target dose_12/300
11064276|NCT04327024|Experimental|Allopurinol alone|"Dose [mg] verinurad/allopurinol:
~Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300"
11064277|NCT04327024|Placebo Comparator|Placebo|Placebo [mg] in 3 steps 0/0
11064278|NCT04327011|Experimental|Experimental|Single arm Toca 511 vector/5-FC prodrug
11064279|NCT04326998|Active Comparator|non-solvent|mechanical or heat treatment
11064280|NCT04326998|Experimental|solvent|GuttaClear
11064281|NCT04326985|Experimental|Autologous Mesenchymal Stem Cells Treatment (MSCs)|"The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
~The treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.
~T0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
11064282|NCT04326985|Active Comparator|Hyaluronic acid (HA)|"The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.
~T0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
11064283|NCT04326959|Experimental|UC-MSCs + CM|A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
11064284|NCT04326959|Experimental|CM + CM|A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
11064285|NCT04326959|Experimental|Triamcinolon acetonide|A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.
11064286|NCT04326920|Active Comparator|Active sargramostim treatment group|Inhaled sargramostim 125mcg twice daily for 5 days on top of standard of care. Upon progression to ARDS and initiation of mechanical ventilator support within the 5 day period, inhaled sargramostim will be replaced by intravenous sargramostim 125mcg/m2 body surface area once daily until the 5 day period is reached. From day 6 onwards, progressive patients in the active group will have the option to receive an additional 5 days of IV sargramostim, based on the treating physician's assessment
11064287|NCT04326920|Placebo Comparator|Control group|standard of care. Subjects progressing to ARDS and requiring invasive mechanical ventilatory support, from day 6 onwards, will have the option (clinician's decision) to initiate IV sargramostim 125mcg/m2 body surface area once daily for 5 days
11064288|NCT04326907|Experimental|CAT injection group|After fistulectomy for complex anal fistula, CAT (harvested from abdominal subcutaneous adipose tissue by Coleman's procedure) was injected into the tissue surrounding the internal opening, and inside the perianal wound obtained after fistulectomy.
11064289|NCT04326907|No Intervention|No CAT injection group|Patients of this group were treated with anal fistulectomy without CAT injection.
11064290|NCT04326894|Experimental|Methotrexate|25mg oral MTX tablets
11064291|NCT04326894|Placebo Comparator|Placebo|25 mg/week placebo tablets
11064292|NCT04326881|Experimental|SHR-1314 A|single dosing SHR-1314 A
11064293|NCT04326881|Experimental|SHR-1314 B|single dosing SHR-1314 B
11064302|NCT04326816|Active Comparator|Direct restorative protocol|"All teeth were reconstructed using non-prep direct hybrid composite restorations (Clearfil AP-X, Kuraray, Japan). Restorations were placed following the DSO-technique ('Direct Shaping by Occlusion').
~Adhesion was acquired using a 3-step etch-and-rinse procedure, including 37% phosphoric acid (DMG, Germany), Clearfil SA Primer and Clearfil Photobond (Kuraray). If a pre-existing composite restoration was present, a repair procedure was performed; The adhesive surface was roughened by a bur, air-abraded ((CoJet (3M) and Danville MicroEtcher CD (Danville Materials, USA)) and a non-hydrolyzed silane coupling agent (Clearfil Porcelain Activator (Kuraray)) was mixed into the adhesive resin.
~Where needed for esthetical reasons, buccal veneers were made using a nanofilled composite (IPS Empress direct, Ivoclar Vivadent, Lichtenstein). If a buccal veneer was made in a separate session from the palatal direct restoration, then a repair procedure was used."
11064303|NCT04326816|Experimental|Indirect restorative protocol|"Teeth were restored using a combination of indirect and direct composite restorations. As a result this protocol actually is a hybrid protocol. 10 indirect restorations per patient were made; tabletop restorations on all first molars (n=4) and palatal veneers on maxillary anterior teeth (n=6) using Estenia C&B (Kuraray, Japan).
~Small retention grooves or pits were prepared and sharp edges on occlusal surfaces were polished using fine-grit burs. Silicone impressions were made for the fabrication of the indirect restorations. Indirect restorations were shaped and cured by a dental technician.
~Adhesive bonding was acquired using selective etching and ED-primer II (Kuraray, Japan). Before cementation, all indirect restorations were pretreated using phosphoric acid and a silane layer (Clearfil Ceramic Primer, Kuraray, Japan). Panavia F was used for cementation.
~Subsequently, all remaining teeth were restored with direct composite restorations according to the direct protocol."
11064304|NCT04326803|Experimental|Vaccine group|Administration of 3 doses hepatitis B vaccine (recombinant hepatitis B vaccine, injectable suspension for intramuscular use) at month 0, 1 and 2.
11064305|NCT04326790|Experimental|Intervention|Colchicine, on top of standard treatment
11064306|NCT04326790|Active Comparator|Control|Standard treatment, including all medications recommedned by the National Public Health Organization
11064307|NCT04326777|Other|Ballon pulmonary angioplasty|Ballon pulmonary angioplasty(BPA) is a stepwise procedure requiring several separate sessions. The interval of a series of BPA is one month. In a series of BPA, there are 2 sessions, which are repeated at a 2-week interval. BPA is performed primarily on one side of the lung in the first session, then after 2 weeks, performed on the other side of the lung. In each session, the fluoroscopy time or the amount contrast are less than 60min and 200ml, respectively.
11064308|NCT04326764|Experimental|Panobinostat|Panobinostat 20 mg oral three times weekly every second week
11064309|NCT04326764|No Intervention|Standard of Care|Treatment according to local standards
11064310|NCT04326738|Placebo Comparator|normal saline (N) group|N group received corresponding intravenous normal saline of 1ml·kg-1.
11064311|NCT04326738|Active Comparator|midazolam (M) group|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam.
11064312|NCT04326725||Hydroxychloroquine|Subjects with prophylaxis
11064313|NCT04326712||Group 1|Unilateral transtibial amputees using conventinional manufactured socket
11064314|NCT04326712||Group 2|Unilateral transtibial amputees using 3D manufactured socket
11064315|NCT04326699|Active Comparator|Sacroiliac joint injection group|The active group will receive bilateral sacroiliac joint injection of 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) under ultrasound guidance.
11064316|NCT04326699|No Intervention|control group|The other group will not receive the sacroiliac joint injection
11064317|NCT04326686|Other|N-of-1 study|For 24 weeks, each participant will measure their blood pressure and respond to questionnaires daily, and visit the institute to provide a blood sample every 4 weeks. The study is split into three 8-week phases, the first of which will start when each participant is enrolled. For the first 8-week observation phase (A1) the participant is instructed to continue with their usual diet and exercise habits. For the second 8-week intervention phase (B), the participant will be provided with wholegrains and nuts and recommended to substitute these in place of refined grains and other snacks, respectively. They will also receive dietary advice for following the Dietary Approaches to Stop Hypertension (DASH) diet. For the final 8 week follow-up period (A2), provision of wholegrains and nuts will cease but the participant will continue with measurements at the same frequency as previously.
11064318|NCT04326673||diurnal variation assessment|Assessment of diurnal variation in salivary testosterone adjusted for prandial state
11064319|NCT04326673||Glucose load measurements|Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load
11064320|NCT04326660|No Intervention|Control|Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.
11064321|NCT04326660|Experimental|SCOPE-Chinese Women Intervention|"SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention.
~Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant.
~Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total.
~Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences."
11064322|NCT04326647|Experimental|Kinesiotaping Group|We used kinesiotaping (gastrocnemius and lumbar back) plus exercise
11064323|NCT04326647|Active Comparator|Exercise Group|We used only exercise
11064324|NCT04326634|Experimental|Controlled exercises Group|
11064325|NCT04326634|Experimental|Non controlled exercises Group|
11064326|NCT04326621|Experimental|PRT group|pressure Release Technique and exercises
11064327|NCT04326621|Active Comparator|Exercises group|Only exercises
11064328|NCT04326595|Active Comparator|surgical termination|
11064330|NCT04326569|Experimental|adults with trans-sphenoidal endoscopic pituitary surgery|adult with trans-sphenoidal endoscopic pituitary surgery for tumour of the sellar region
11064331|NCT04326556|Experimental|Prospective cohort for etiological and prognostic purposes|
11064332|NCT04326543||ADHD and typically developing controls|120 subject: 53 with an ADHD clinical diagnosis and 57 typically developing controls aged between 3 and 16 years old.
11064333|NCT04326530||Persistent asthmatic children|"150 steroid-naive, persistent asthmatic children enrolled during their first consultation at the IRIB-CNR outpatient clinic.
~They will underwent three visits:
~screening visit (-2 days);
~baseline visit (day 0);
~last visit (+90 days).
~They will be treated with controller medications according to GINA recommendations (http://ginasthma.org)."
11064334|NCT04326517||Emphysematous pyelonephritis|This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.
11064335|NCT04326504||Patients starting DTG-based regimens|ART-naïve patients, starting cART regimens based on DTG
11064336|NCT04326504||Switch cohort|Patients on stable ART regimens switching to DTG (any reason)
11064337|NCT04326504||Therapy failure|ART-experienced patients switching to DTG-containing regimens due to virological failure
11064338|NCT04326504||Non-DTG group|Patients who started a non-DTG containing regimen
11064339|NCT04326491||HCC|Participants are diagnosed with HCC on top of cirrhosis
11064340|NCT04326491||Cirrhosis with no HCC|Participants are diagnosed with cirrhosis but have no HCC
11064341|NCT04326478|Experimental|Azithromycin Group|Enrolled children in a household randomized to the experimental group will receive a single weight-based dose of azithromycin administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera. They will then complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
11064342|NCT04326478|No Intervention|No Azithromycin Group|Enrolled children in a household randomized to the arm without intervention will not receive any azithromycin during their first study visit, which will occur within 12 hours of a member of their household testing positive for cholera. Like the participants in the intervention arm, they will complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
11064343|NCT04326465|Active Comparator|Fractional CO2 Laser Therapy at 5% Laser Density Coverage|Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 5% laser density. The patient will receive four laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
11064344|NCT04326465|Active Comparator|Fractional CO2 Laser Therapy at 10% Laser Density Coverage|Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10% laser density. The patient will receive four laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
11064345|NCT04326452|Experimental|Enrolled Subjects|The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support of any Person Under Investigation for infection by the COVID-19 virus.
11064346|NCT04326439|Experimental|Aflac-AML Regimen for Low Risk AML Patients|"Participants in this arm will receive the standard Aflac-AML Regimen with the following chemotherapy:
~Induction-1: patients on Induction-I will receive gemtuzumab + ADE therapy based on genotyping. Lasts a total of 28 days.
~Induction II - MA
~Intensification I - AE
~Intensification II - HD ARAC/LASP
~Patients with low risk status who had low risk markers and were MRD positive at the end of Induction I and continue to be MRD positive after Induction II will come off protocol."
11064347|NCT04326439|Experimental|Aflac-AML Regimen for High Risk AML Patients|"Participants in this arm will receive standard Aflac-AML Regimen with the following chemotherapy:
~Induction-1: patients will receive gemtuzumab in addition to ADE therapy based on genotyping. Induction I lasts a total of 28 days.
~Induction 1 for FLT3-ITD patients - ADE (10+3+5) with GO with Sorafenib
~Induction II - MA
~Induction II for FLT3-ITD patients - MA with Sorafenib
~Intensification I - AE
~Intensification I for FLT3-ITD patients - AE with sorafenib
~Intensification II - HD ARAC/LASP
~Intensification II for FLT3-ITD patients - HD ARAC/LASP with sorafenib
~Hematopoietic stem cell transplantation (HSCT)
~If a patient is classified as High risk after Induction I, they may proceed to best allogenic donor SCT following Induction II. These patients may receive a third course of chemotherapy prior to HSCT. In cases where HSCT is not an option, patients can receive 4 cycles of chemotherapy. Only patients with FLT3-ITD mutation will receive sorafenib."
11064348|NCT04326426|Experimental|Tradipitant|Tradipitant 85 mg PO BID
11064349|NCT04326426|Placebo Comparator|Placebo|2 capsules of matching placebo
11064350|NCT04326400||Hospital de la Princesa employees|
11064351|NCT04326387||Research Participants (Patients)|"Inpatients symptomatic of suspected COVID-19 Baseline swab of nose/throat, nasopharyx, or endotracheal tube aspirate. SAMBA II point of care test on this swab.
~Standard of care bloods taken for PHE and additional confirmatory diagnostic PCR assessment.
~Serum antibody tests on any excess blood tests during inpatient stay for immune response monitoring.
~Outcome assessment at 1 month"
11064352|NCT04326374|Experimental|TransCon hGH|"TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight.
~The treatment will continue 52 weeks."
11064353|NCT04326374|Active Comparator|Daily hGH|"Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight.
~The treatment will continue 52 weeks."
11064354|NCT04326348|Experimental|TQ05105 Tablet|TQ05105 tablet administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
11064355|NCT04326335|Active Comparator|Felt-tip marking|
11064356|NCT04326335|Experimental|Felt-tip marking + 3D printed ostomy button|
11064357|NCT04326322|Experimental|Methionine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
11064358|NCT04326309||Cohort 1|Individual Application Downloaders
11064359|NCT04326309||Cohort 2|Public Space and Vehicle Data Capture
11064360|NCT04326296|Experimental|Experimental Group|PD-L1 Monoclonal Antibody Combined With Lenalidomide
11064361|NCT04326283|Experimental|Trametinib (0.5 mg)|One tablet of trametinib 0.5 mg per day
11064362|NCT04326283|Experimental|Trametinib (1 mg)|Two tablets of trametinib 0.5 mg per day
11064363|NCT04326283|Experimental|Trametinib (2 mg)|One tablet of trametinib 2 mg per day
11064364|NCT04326283|Active Comparator|Riluzole (100 mg)|One tablet of riluzole 50 mg taken twice per day
11064365|NCT04326270|Active Comparator|nCPAP prongs|
11064366|NCT04326270|Active Comparator|Infant cannula|
11064367|NCT04326257|Experimental|Nivolumab+Relatlimab|"Nivolumab will be dosed 480mg IV q 4 weeks and Relatlimab 160mg IV q 4
~One cycle is defined as 4 weeks of treatment and both drugs are given on the same day.
~Patients will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
11064368|NCT04326257|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be dosed at 3mg/kg IV q 2 weeks and Ipilimumab 1mg/kg IV q 6 weeks.
~Patients will receive four doses of Ipilimumab and the last dosage of Nivolumab 3mg/kg IV q 2 weeks will be given at the time of the 4th dose of Ipilimumab, followed 2 weeks later by Nivolumab 480 mg IV q 4 weeks. A cycle of therapy will be defined as 4 weeks of treatment. The patient will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
11064369|NCT04326244||Snoring obesity patient|Constitution in Chinese Medicine Questionnaire, physical examination, blood test and genetic test are provided to subjects. The blood test includes High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin; the DNA test includes FTO、MC4R、BDNF、PPARG、ADRB3、UCP1. Epworth Sleepiness Scale, laryngoscope and polysomnography are also performed in the patients enrolled
11064370|NCT04326231|Experimental|Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
11064371|NCT04326218|Other|Cohort|All patients included will have to be taken blood samples
11064372|NCT04326205|Experimental|Dual-aided|active tDCS to the ipsilesional primary motor cortex (M1lesioned) followed by FES to the paretic hand during MT
11064373|NCT04326205|Active Comparator|FES-alone|sham tDCS to the M1lesioned followed by FES to the paretic hand during MT
11064374|NCT04326205|Active Comparator|tDCS-alone|active tDCS to the M1lesioned followed by sham FES to the paretic hand during MT
11064375|NCT04326205|Placebo Comparator|Dual-sham|sham tDCS to the M1lesioned followed by sham FES to the paretic hand during M
11064376|NCT04326192|Experimental|All subjects|All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.
11064377|NCT04326179||Age 0 to 4 at day of visit|This study is entirely based on surveys and chart reviews. Data collected as part of this study will not directly inform the care of participating patients and families.
11064378|NCT04326166||Group A|Patients who receive Double therapy or Insulin
11064379|NCT04326166||Group B|Patients who receive DPP-4 inhibitor
11064380|NCT04326166||Group C|Drug-naïve patients
11064381|NCT04326153|Experimental|experimental arm|Sintilimab+Albumin paclitaxel:+Carboplatin:
11064382|NCT04326140|Experimental|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
11064383|NCT04326140|Sham Comparator|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
11064384|NCT04326127||Control|Healthy volunteers
11064385|NCT04326127||Case|Volunteers with diagnosed sleep apnea
11064386|NCT04326114|Experimental|Inspiratory training|
11064387|NCT04326114|Experimental|Expiratory training|
11064388|NCT04326114|No Intervention|Control|
11064389|NCT04326088||head and neck cancer with free flap reconstruction|patients with head and neck cancer who underwent tumor wide excision and primary free flap reconstruction or secondary free flap reconstruction between March 2008 and February 2017
11064390|NCT04326075|Experimental|Early CPAP treatment|Early treatment with CPAP in addition to current clinical practice
11064391|NCT04326075|No Intervention|Control|Current clinical practice, which currently does not involve the use of CPAP.
11064392|NCT04326062|Experimental|Main Study|A pharmacist will join the practice team for six months.
11064393|NCT04326062|Experimental|PROM Study|A nested Patient Reported Outcome Measure (PROM) study will be undertaken during month four and five of the six-month intervention period to explore the impact of the intervention in older adults (aged ≥65 years).
11064394|NCT04326049|Experimental|LLETZ with videocolposcopy|The LLETZ procedure will be performed using a videocolposcopy
11064395|NCT04326049|Active Comparator|LLETZ with binocular colposcopy|The LLETZ procedure will be performed using a binocular colposcope
11064396|NCT04326036|Experimental|Lipoaspiration|Closed sterile, disposable microcannula of small volume adipose tissue, including the stromal vascular fraction (SVF) (cells and stromal tissue
11064397|NCT04326036|Experimental|Isolation & Concentration of cSVF|Isolation & Concentration of cellular stromal vascular fraction (cSVF) using Healeon Centricyte 1000 Centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
11064398|NCT04326036|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 250 cc of sterile Normal Saline IV solution and deployed though 150 micron in-line filtration and intravenous route over 30-60 minute timeframe
11064399|NCT04326036|Other|Liberase TM|Use of sterile Liberase TM enzyme to allow cSVF separation and isolation
11064400|NCT04326036|Other|Sterile Normal Saline|250 cc of sterile Normal Saline for Intravenous with sterile 150 micron in-line filtration for suspension of the concentrated cSVF and deployment IV
11064401|NCT04325997|Experimental|an ordinary laryngos with mouth opener|
11064404|NCT04325984||Dexamethasone group|Group of patients receiving dexamethasone 8 mg as part of the multimodal analgesia.
11064405|NCT04325984||Control group|Group of patients receiving multimodal analgesia, not comprising dexamethasone; moreover, ondansetron 4 mg is administered for the control of PONV.
11064406|NCT04325971|Experimental|Healthy Subjects|All healthy subject are gathered in one arm
11064407|NCT04325958|Placebo Comparator|Placebo cannabis|Participants will drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC)
11064408|NCT04325958|Experimental|Active cannabis|Participants will drive the simulator before and after smoking an active cannabis cigarette (12.5% THC)
11064409|NCT04325945|Experimental|Laser acupuncture|808nm low level laser therapy
11064410|NCT04325945|Sham Comparator|Sham laser acupuncture|no low level laser output but same device
11064411|NCT04325932|Experimental|Urinary Kallikrein group|Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
11064412|NCT04325932|No Intervention|control group|with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.
11064413|NCT04325906|Active Comparator|high flow nasal cannula only|Receive high flow nasal cannula only
11064414|NCT04325906|Experimental|HFNC plus prone positioning|Receive high flow nasal cannula plus prone positioning
11064415|NCT04325893|Active Comparator|Hydroxychloroquine|
11064416|NCT04325893|Placebo Comparator|Placebo|
11064417|NCT04325880|Placebo Comparator|Placebo arm|Patients in this arm will receive a placebo formula
11064418|NCT04325880|Active Comparator|Mirabegron arm|Patients in this arm will receive Mirabegrone 50 mg once daily
11064419|NCT04325880|Active Comparator|Tamsulosin arm|Patients in this arm will receive tamsulosin o.4 mg once daily
11064420|NCT04325880|Active Comparator|Solifenacin arm|Patients in this arm will receive solifenacin 10 mg once daily
11064421|NCT04325867|Experimental|All patients with known cardiovascular disease|"All these patients will be provided an electronic account on a dedicated platform were they can be supervised and can call for advice / help.
~This kind of tele-medical project aims to keep these patients in a so-called proximity, monitoring their vital parameters, checking their medication and providing dedicated advices according to their complaints.
~Moreover, all these patients will receive digital watches with ecg-recording capabilities, thus a dedicated physician could correlate their symptoms with few clear paraclinical variables.
~All of these patients' complaints will be stratified according to elaborated protocols based on the European Cardiovascular Guidelines.
~Moreover, a psychologist and a chaplain will deal with their (new) problems due to social isolation."
11064422|NCT04325854||Ectopic pregnancy population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all ART procedures (both I and II level) performed between 2009 and 2018.
11064423|NCT04325841|Experimental|Autologous Murine Anti-CD19 CAR-T treatment|
11064424|NCT04325828|Experimental|Apalutamide plus GnRH Agonist|Participants will receive apalutamide 240 milligram (mg) in combination with a gonadotropin-releasing hormone (GnRH) agonist until disease progression, unacceptable toxicity, death, or the end of the study and each treatment cycle will be of 28 days.
11064425|NCT04325815||CADDIE|The endoscopist will be assisted with CADDIE system to detect polyps. The endoscopist will perform optical diagnosis of polyps with the assistance of the CADDIE's polyp characterisation function.
11064426|NCT04325815||Standard Procedure|In addition to routine colonoscopy the endoscopist will perform optical diagnosis of detected polyps without the assistance of the CADDIE.
11064427|NCT04325802|Experimental|Cohort 1: Placebo, then Intervention|Patients will start with placebo in week 1 and cross over to Naltrexone in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
11064428|NCT04325802|Active Comparator|Cohort 2: Intevention, then Placebo|Patients will start with Naltrexone in week 1 and cross over to the palcebo treatment in week 3. There will be a wash-out phase during week 2 using only moisturizer regularly and if necessary as rescue medications topical corticosteroids and/or antihistamines. The same rescue medications can be used during the following weeks of the cross-over treatment. At visit 2 and 4 patients will be asked the area where they are experiencing most intense itch and we will take there suction blisters (preferably on the trunk). Suction blisters will be taken after week 1 (1 week on treatment arm 1) and after week 3 (1 week on treatment arm 2).
11064429|NCT04325802|No Intervention|Circadian Rhythm of Itch|Patients in this arm will receive no intervention, only data collection.
11064430|NCT04325789|No Intervention|group 1 control|Group 1 will serve as the control and undergo routine rotator cuff repair with suture anchors without the nanofiber scaffold.
11064431|NCT04325789|Active Comparator|Group 2|Group 2 will undergo rotator cuff repair with suture anchors and incorporation of the nanofiber scaffold.
11064432|NCT04325776|Experimental|AL2846+An analog of zoledronic acid injection|AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
11064433|NCT04325776|Active Comparator|An analog of AL2846+ zoledronic acid injection|An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.
11064434|NCT04325763|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11064435|NCT04325763|Experimental|TQB2450+Anlotinib(blank)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11064510|NCT04325204|Experimental|Caregivers|Caregivers of a person living with dementia will participate in the Faith-HAT intervention for 12 weeks.
11095678|NCT04106674|No Intervention|Non-surgical|No surgery
11064436|NCT04325763|Placebo Comparator|TQB2450(blank)+Anlotinib(blank)|TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11064437|NCT04325750|Placebo Comparator|Control|The simulated mode technique is applied (machine off)
11064438|NCT04325750|Experimental|TECAR THERAPY|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
11064439|NCT04325737|Experimental|SEP-363856|
11064440|NCT04325737|Placebo Comparator|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
11064441|NCT04325724|Other|Beginner psoriatic arthritis patients|Every patients consulting in dermatologic or rheumatologic department for a skin psoriasis with clinical symptoms which may lead to the suspicion of psoriatic arthritis
11064442|NCT04325724|Other|Confirmed psoriatic arthritis patients|Every patients with psoriatic arthritis followed in rheumatologic department
11064443|NCT04325724|Other|Rheumatoid arthritis or Digital osteoarthritis patients|Followed in rheumatologic department
11064444|NCT04325724|Other|Skin psoriasis patients without any articular symptoms|
11064445|NCT04325711|Experimental|CSPCH131 dose Escalation and expansion|"In the dose escalation part of Stage I, five dose levels will be tested according to the 3 + 3 dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131."
11064446|NCT04325698|Experimental|Arm A|PF-06439535 (CN) + paclitaxel + carboplatin
11064447|NCT04325698|Active Comparator|Arm B|Bevacizumab-EU + paclitaxel + carboplatin
11064448|NCT04325685|Placebo Comparator|Control group|
11064449|NCT04325685|Active Comparator|Antiseptic (Octenisept) group|
11064450|NCT04325685|Experimental|Bacteriophage (Sextaphag) group|
11064451|NCT04325672|Experimental|Convalescent Plasma Group|Subjects will receive 1-2 units (300-600 mL) of plasma with an anti-SARS-CoV-2 titer of >1:64.
11064452|NCT04325659|Active Comparator|Lofexidine/Sham Bridge Device|Lofexidine (Lucemyra) encapsulated
11064453|NCT04325659|Placebo Comparator|Sham Bridge Device /Placebo Study Drug|Inactive Bridge Device and placebo study drug
11064454|NCT04325659|Experimental|Active Bridge Device/ Placebo Study Drug|Active Bridge Device and placebo study drug
11064455|NCT04325646||CORSER-1a|Subjects who had been to China in the weeks before the outbreak began
11064456|NCT04325646||CORSER-1b|Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
11064457|NCT04325646||CORSER-2a|Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
11064458|NCT04325646||CORSER-2b|Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
11064459|NCT04325646||CORSER-2c|"Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.
~study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise
~study among pupils from 5 to 12 and their parents in elementary schools located in Oise
~study among choir members"
11064460|NCT04325646||CORSER-2d|Staff of health care institutions
11064461|NCT04325646||CORSER-2e|Subjects in care, hospitalized or residing in health care facilities
11064462|NCT04325646||CORSER-3|Subject returning from a humanitarian mission that started before 31/01/2020
11064463|NCT04325633|Experimental|1: Naproxen|Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
11064464|NCT04325633|Placebo Comparator|2: Standard of care|Standard of care
11064465|NCT04325620|Experimental|HIP1601 Amg|The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.
11064466|NCT04325620|Placebo Comparator|HGP1805|The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.
11064467|NCT04325607|Experimental|Negative Pressure Wound Therapy with instillation|Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
11064468|NCT04325607|Active Comparator|Negative Pressure Wound Therapy|Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
11064469|NCT04325594|Experimental|Main Group|Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1×10 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy
11064470|NCT04325594|Active Comparator|Control Group|Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy
11064471|NCT04325581|Experimental|Post LSG with Liraglutude|Liraglutide in incremental dose upto maximum of 1.8 mg per day subcutaneously once a day.
11064472|NCT04325581|Placebo Comparator|Post LSG without Liraglutide|Normal Saline in equivalent per day subcutaneously once a day
11064473|NCT04325568|Other|Clinician Manual|"Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability.
~Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'."
11064474|NCT04325568|Other|AutoTutor (PsyGist)|"AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing.
~PsyGist will guide participants through its three components."
11095679|NCT04106674|Active Comparator|Surgical|Surgeons preference
11064475|NCT04325555||Respondents on PrEP|"On PrEP status will be operationalized in multiple ways, and sensitivity analyses will be conducted using multiple definitions as a result of the self-reported nature of the study.
~Respondents on PrEP are respondents who reported that they are currently on PrEP
~Respondents on PrEP are respondents who reported to have ever been on PrEP
~When respondents are used as their own controls, years on PrEP will be those in which they reported to have been on PrEP for at lest 6 months, and PrEP initiation will be the first such year
~A comparison group will be constructed by matching on a variety of characteristics, when this method is applied. Most importantly, age, and STD testing frequency among others, which influence the likelihood of being on PrEP and via that avenue sexual practices, as well as the likelihood of detecting STDs (i.e., ascertainment bias). In other models adjustments will be made for these factors."
11064476|NCT04325542|Other|HBSAG positive with rapid test|Newborns from woman who are positive with HBSAG rapid test got WHO recommended HBV vaccination at birth to avoid HBV transmission
11064477|NCT04325529||remitted MDD|Unmedicated Remitted Participants with Past History of MDD
11064478|NCT04325529||Control subjects|healthy control subjects
11064479|NCT04325516|Experimental|People with a lower limb amputation|"Participants will perform four tasks in a randomized order:
~sit to stand
~dorsi flexion of the foot
~knee extension
~hip extension"
11064480|NCT04325516|Experimental|Able bodied individuals|"Participants will perform four tasks in a randomized order:
~sit to stand
~dorsi flexion of the foot
~knee extension
~hip extension"
11064481|NCT04325503|Experimental|Treatment|carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
11064482|NCT04325490|Experimental|Liquid powder|Liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin on the selected intertrigo area.
11064483|NCT04325490|Active Comparator|Hydrocortisone|1% hydrocortisone cream
11064484|NCT04325477|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
11064485|NCT04325464|Experimental|PEAR-003A|Digital Therapeutic
11064486|NCT04325438|Experimental|Pharmaceutical Care|Groups with usual care by health professionals and additional health interventions provided by pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
11064487|NCT04325438|No Intervention|Non-Pharmaceutical Care|Groups with usual care from health providers other than pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
11064488|NCT04325425|Experimental|mFOLFIRINOX|mFOLFIRINOX will be administered once every 14 days for up to 12 cycles. One cycle consists of 14 days (2 weeks) with injection on D1 of each cycle (D1=D15). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
11064489|NCT04325425|Active Comparator|platinum - etoposide|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
11064490|NCT04325399|Experimental|Planning|"The volitional help sheet (VHS) comprises of a list of challenges to being physically active (e.g. If I'm tempted not to go to the gym because it's cold outside) and a list of possible ways to overcome thes (e.g. then I will make myself go to the gym anyway because I know I will feel better afterward). In the experimental VHS link group, participants are asked to form if-then plans by drawing a line between challenges and solutions to link them together."
11064491|NCT04325399|No Intervention|No planning|Participants in the VHS tick group are presented with the exact same volitional help sheet as the experimental group, the only difference being that participants in this group are not asked to make if-then plans. Rather, participants in the control group are asked to tick challenges and solutions that they feel are relevant to them.
11064492|NCT04325386|Experimental|Education sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
11064493|NCT04325386|Placebo Comparator|No education sessions|
11064494|NCT04325360|Experimental|Cathodal Transcranial Direct Current Stimulation (c-tDCS)|Participants in this arm of the study will receive cathode transcranial direct current stimulation.
11064495|NCT04325360|Sham Comparator|Sham-tDCS|Participants in this arm of the study will receive sham transcranial direct current stimulation.
11064496|NCT04325347|Experimental|Virtual reality|Virtual Reality will be provided to all participants, just before sleeping.
11064497|NCT04325347|No Intervention|Control|No specific intervention will be provided.
11064498|NCT04325334|Experimental|Running volume increase|Participants will be be given a running program based on their running mileage on inclusion and supported by regular contacts with the study trainer.
11064499|NCT04325321|Other|Stress reactivity|Stress reactivity test
11064500|NCT04325308|Experimental|Protein-enriched human milk diet|Infants in this group will receive protein-enriched expressed human milk or donor human milk during the first 2 weeks after birth.
11064501|NCT04325308|Active Comparator|Usual human milk diet|Infants in this group will receive either expressed human milk or donor human milk during the first 2 weeks after birth.
11064502|NCT04325295|Active Comparator|Surgical treatment strategy:|
11064503|NCT04325295|Active Comparator|Gonadotrophins treatment strategy|
11064504|NCT04325282|Experimental|Children with BECTS|Children will receive sham and active rTMS on 2 separate study visits separated by at least 1 week.
11064505|NCT04325256||study group|All pregnant women who will attend the labor unit for induction of labour due to different indications during the study period will be invited to participate in the study.
11064506|NCT04325243|Experimental|study group|50 mg oral sildenafil citrate tablet
11064507|NCT04325243|Placebo Comparator|placebo group|placebo tablets of the same shape, color and size of sildenafil citrate tablets
11064508|NCT04325230|Experimental|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
11064509|NCT04325217||Patients newly initiating Ofev®/Nintedanib Capsules|
11064557|NCT04324892||Treat to target|The study has only 1 cohort with treat-to-target strategy
11064511|NCT04325204|Experimental|Persons living with dementia|Persons living with dementia will participate in the Faith-HAT intervention for 12 weeks.
11064512|NCT04325191|Experimental|High Salt and Melatonin|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.
11064513|NCT04325191|Placebo Comparator|High Salt and Placebo|Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.
11064514|NCT04325178|Experimental|Animal|Participants receive the majority of their protein from animal-derived protein sources (1.8g.kg.day).
11064515|NCT04325178|Experimental|Non-animal|Participants receive all their protein from non-animal-derived protein sources (1.8g.kg.day).
11064516|NCT04325165|Experimental|1: Chronic SCI subjects|"These subjects will undergo:
~Bilateral implantation of PPN DBS electrodes;
~Electrical stimulation of the DBS electrodes and
~Intensive locomotor training"
11064517|NCT04325152|Experimental|FCSEMS+Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. One to two centimeters of distal end of FCSEMS was left outside of the papilla and the stent was released. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
11064518|NCT04325152|Sham Comparator|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
11064519|NCT04325126||RBP4 in diabetes|RBP4 in diagnosed diabetes.
11064520|NCT04325126||RBP4 in pre-diabetes (pre-DM)|RBP4 in pre-diabetes (pre-DM).
11064521|NCT04325126||RBP4 in DM-CVD|RBP4 in diabetic cardiovascular disease.
11064522|NCT04325126||RBP4 in CVD|RBP4 in single coronary artery disease.
11064523|NCT04325126||RBP4 in NC|RBP4 in healthy controls.
11064524|NCT04325113|Placebo Comparator|NaCl 0,9%|patients receive 5ml of NaCl 0,9% at the level of the tonsils lodge
11064525|NCT04325113|Active Comparator|Xylocaine 2%|patients receive 5ml of Xylocaïne 2% at the level of the tonsils lodge
11064526|NCT04325113|Active Comparator|Levobupivacaine 0,5%|patients receive 5ml of Levobupivacaine 0,5% at the level of the tonsils lodge
11064527|NCT04325100|Experimental|Switch - i|Individual sessions
11064528|NCT04325100|Experimental|Switch - g|Group programme
11064529|NCT04325087|Experimental|Active iTBS|Active stimulation of the dlPFC directly after trauma exposure and on the following two days
11064530|NCT04325087|Placebo Comparator|Placebo iTBS|Same procedure as in the active stimulation group but with a placebo stimulation imitating the sensation of a real iTBS protocol.
11064531|NCT04325074|Experimental|Mental practice|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice group was n=12.
11064532|NCT04325074|Experimental|Mental practice + skill training|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of mental practice + skills training group was n=13.
11064533|NCT04325074|Active Comparator|Control group|The final sample therefore comprised of 35 participants (n=35), who were divided into three treatment groups. The sample of control group was n=10.
11064534|NCT04325061|No Intervention|Control group|Patients will be treated with standard intensive care
11064535|NCT04325061|Active Comparator|Dexamethasone|Standard intensive care plus dexamethasone
11064536|NCT04325035|Experimental|Istaroxime|Istaroxime IV infusion for 24 hours. Istaroxime administration can begin at 1.0 or 1.5 µg/kg/min; the target infusion rate is 1.5 µg/kg/min
11064537|NCT04325035|Placebo Comparator|Placebo|Placebo (lactose) IV infusion for 24 hours
11064538|NCT04325022||Primary Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in primary THA
11064539|NCT04325022||Revision Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in revision THA
11064540|NCT04325009|Experimental|RTRT|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
11064541|NCT04325009|Experimental|TRTR|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
11064542|NCT04324996|Experimental|NK cells|The NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
11064543|NCT04324996|Experimental|IL15-NK cells|The NK cells secreting super IL15 superagonist are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week) .
11064544|NCT04324996|Experimental|NKG2D CAR-NK cells|The NKG2D CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
11064545|NCT04324996|Experimental|ACE2 CAR-NK cells|The ACE2 CAR-NK cells are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
11064546|NCT04324996|Experimental|NKG2D-ACE2 CAR-NK cells|The NKG2D-ACE2 CAR-NK cells secreting IL15 superagonist and GM-CSF-neutralizing scFv are going to be give by intravenous infusion (10E8 cells per kilogram of body weight, once a week).
11064547|NCT04324983|Other|Biomarker|This single-arm study is a Phase I study to exploratively identify potential biomarkers in patients with early prostate cancer relapse and limited metastases in PSMA-PET, who need further assistance in treatment decisions (for or against local treatment options).
11064548|NCT04324970|Experimental|Tookie vest|Participant issued with Tookie vest
11064549|NCT04324944|Experimental|Collaborative Decision Skills Training|Collaborative Decision Skills Training (CDST) is the intervention group (experimental arm).
11064550|NCT04324944|Active Comparator|Money Management|Money Management is the active control arm.
11064551|NCT04324931|Experimental|Biomechanical corrections|In this group, biomechanical correction will be perform with the help of movement with mobilization to correct biomechanical misalignment and along with this conventional treatment will also be given for three days a week for three weeks.
11064552|NCT04324931|Active Comparator|Conventional treatment|In this group, the conventional treatment will be given, which includes Hydrocollatoral packs for 20 minutes, Interferential Therapy for 15 minutes with beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program for 3 sessions of 20 minutes on alternative days for 3 weeks. Which will be given for three days a week for three weeks.
11064553|NCT04324918|Experimental|HCP1102|
11064554|NCT04324918|Active Comparator|HGP1408|
11064555|NCT04324905|Experimental|Sequence 1|
11064556|NCT04324905|Experimental|Sequence 2|
11064558|NCT04324879|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
11064559|NCT04324866||Group 1|Patients with chronic plaque psoriasis on immunosuppressant therapy
11064560|NCT04324866||Group 2|Psoriatic patients' partners
11064561|NCT04324866||Group 3|Patients with atopic dermatitis treated with dupilumab
11064562|NCT04324853||S. haematobium positive|Preganant women infected with Schistosomia hematobium alone
11064563|NCT04324853||geohelminths positive|pregnant women infected with geohlminths alone
11064564|NCT04324853||Helminth negative|Pregnant women free of anyn helminths infection
11064565|NCT04324840|Experimental|Adjuvant Treatment|CC-90010-with standard dose TMZ
11064566|NCT04324840|Experimental|Concomitant treatment.|CC-90010 combined with standard dose TMZ and RT
11064567|NCT04324827|Experimental|Graston Technique® Group|The application was applied by a GT® certified therapist with 12 years of experience in orthopedic rehabilitation and soft tissue treatments. Hamstring, gastrosoleus and plantar fascia were scanned with GT® instruments and the treated soft tissue was treated. The instruments used differ according to the application protocol and regions are determined with reference to the GT® manual. The treatment lasted 8 minutes for each leg and was applied to both legs equally and by the same person for a total of 16 minutes.
11064568|NCT04324827|Experimental|Foam Roller Group|FR was applied to gastrosoleus and hamstring muscle groups and plantar fascia. TriggerPoint Grid X Foam Roller and Nano Foot X Roller were used in the application. Hamstring, gastrosoleus and plantar fascia for 3 minutes were performed for a single leg. The treatment lasted 8 minutes on one leg and was applied equally to both legs for a total of 16 minutes. Before the application, the participants were informed with verbal and visual warnings about how to do the applications. During the application, the participant was instructed about the time with a stopwatch. The patient himself regulated the pressure applied to the FR; however, the participant was instructed to apply FR as much body weight as possible. The frequency of application was about 0.5 Hz (ie, each rolling cycle lasted for about 2 seconds).
11064569|NCT04324827|Experimental|Dynamic Stretch|DS protocol was prepared with reference to the work of Faigenbaum et al 2005. The protocol consists of 10 dynamic exercises of 10 minutes of medium and high intensity. Each dynamic stretching exercise was performed at a distance of 13 meters. The participants were given a 10-second rest period between each exercise. The participants were given verbal feedback about their postures during the exercises and the video of the exercises was shown to the participant.
11064570|NCT04324814|Experimental|Dose level 1|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle
11064571|NCT04324814|Experimental|Dose level 2|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle
11064572|NCT04324814|Experimental|Dose level 3|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle
11064573|NCT04324814|Experimental|Dose level 4|Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 and Day 15 of each cycle
11064574|NCT04324801|Experimental|Single arm|This is a within-subject repeated-measures design.
11064575|NCT04324788||Group 1|"Transtibial amputation
~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
11064576|NCT04324788||Group 2|"Transfemoral amputation
~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
11064577|NCT04324775||Group 1|Exercise+Manual Lymphatic Drainage
11064578|NCT04324775||Group 2|Exercise+Swedish Massage
11064579|NCT04324749|Experimental|Group A (roasted peanuts)|Group A: Habitual diet + 25 g/day of whole skin roasted peanuts (RP)
11064580|NCT04324749|Experimental|Group B (peanut butter)|Group B: Habitual diet+ 2 tbsp/day (32 g/day) of peanut butter (PB)
11064581|NCT04324749|Experimental|Group C (control)|Group C: Habitual diet + 2 tbsp/day (32 g/day) of control supplement
11064582|NCT04324736||Patients with diabetes|
11064583|NCT04324736||Patients without diabetes|
11064584|NCT04324723|Experimental|Intervention|Participants in this group received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
11064585|NCT04324723|No Intervention|Control|Participants in this group did not received a WhatsApp message reminding them to seek further medical attention for their measurement indicated hypertensive condition.
11064586|NCT04324684||Covid19 pneumonia with comorbidities|"Patients with pneumonia from Covid 19 with at least one of the following comorbidities:
~Hypertension
~Obesity and/or type 2 diabetes
~Cardiovascular disease
~Chronic obstructive lung disease"
11064587|NCT04324684||Covid2 pneumonia without comorbidities|Without any of the following comorbidities
11064588|NCT04324645||Active Symptom Monitoring via Noona|Participants will undergo a single training session on how to use the Noona software no more than 4 weeks before starting standard of care therapy. They can start using the software immediately after the training session. Patients will be invited to complete either the Chest Radiotherapy (if radiotherapy alone) or Chemotherapy-18 (if chemoradiation therapy) at baseline, weekly throughout therapy, and every other week during follow up for 90-days. Patients will be encouraged by the treatment team to complete the baseline symptom report prior to starting any therapy and to complete the weekly reports during therapy and in follow up. Patients will also complete the EORTC QLQ-C30 and the NCCN Distress Thermometer at baseline (no more than 3 weeks before starting therapy), within 1 week of completing therapy, and at 90-days follow up. Patients will be encouraged to use Noona's other features beyond invited modules and PRO inventories, such as the diary during the study
11064589|NCT04324619|Experimental|Immediate|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning immediately.
11064590|NCT04324619|Experimental|3 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 3 months.
11064591|NCT04324619|Experimental|6 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 6 months.
11064592|NCT04324619|Experimental|12 month delay|After completing an online learning program about child abuse and its reporting, this group will receive follow-up micro-learning after a delay 12 months.
11064593|NCT04324606|Experimental|Group 1a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
11064594|NCT04324606|Active Comparator|Group 1b|Volunteers will receive a standard single dose of MenACWY vaccine delivered intramuscularly
11064595|NCT04324606|Experimental|Group 2a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
11064596|NCT04324606|Active Comparator|Group 2b|Volunteers will receive a standard single dose of MenACWY vaccine delivered intramuscularly
11064597|NCT04324606|Experimental|Group 2c|Volunteers will receive two doses of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly at week 0 and week 8
11064598|NCT04324606|Experimental|Group 2d|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of 2.5x10^10vp ChAdOx1 nCoV-19 at week 8 delivered intramuscularly
11064599|NCT04324606|Active Comparator|Group 2e|Volunteers will receive two standard single doses of MenACWY vaccine delivered intramuscularly at week 0 and week 8
11064600|NCT04324606|Experimental|Group 2f|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, delivered intramuscularly
11064601|NCT04324606|Active Comparator|Group 2g|Volunteers will receive two standard single doses of MenACWY vaccine delivered intramuscularly a minimum of 4 weeks apart
11064602|NCT04324606|Experimental|Group 3|Volunteers will receive one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and one dose of 5x10^10vp ChAdOx1 nCoV-19 at week 4 delivered intramuscularly
11064603|NCT04324606|Experimental|Group 4a|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
11064604|NCT04324606|Active Comparator|Group 4b|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 delivered intramuscularly
11064605|NCT04324606|Experimental|Group 4c|Volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 at week 0 and a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x1010vp) a minimum of 4 weeks later, delivered intramuscularly
11064606|NCT04324606|Active Comparator|Group 4d|Volunteers will receive two standard single doses of MenACWY vaccine delivered intramuscularly a minimum of 4 weeks apart
11064607|NCT04324580|Active Comparator|Delayed mobilization/Formal physical therapy group|Participants will be placed into a volar-based plaster splint post-operatively. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. After that, participants will be placed into a custom thermoplastic splint by a therapist. This will be worn for 5 weeks. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks. The splint will be removed only for formal and home physical therapy and hygiene.
11064608|NCT04324580|Active Comparator|Immediate mobilization/self guided physical therapy group|Participants will be placed into a soft dressing after surgery. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. This group will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
11064609|NCT04324567||APR-open|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparotomy.
11064610|NCT04324567||APR-robot|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparoscopic robot assisted technique.
11064611|NCT04324554||MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
11064612|NCT04324541||Mexican American Adults|No intervention
11064613|NCT04324528|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
11064614|NCT04324528|Other|control-arm: vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
11064615|NCT04324515|Other|Study Arm without cholecystectomy|Study Arm: Patients with gastric bypass without concomitant cholecystectomy
11064616|NCT04324515|Other|Control Arm with cholecystectomy|Control Arm: Patients with gastric bypass with concomitant cholecystectomy
11064617|NCT04324502||Neuroendocrine neoplasms (tumours)|Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization/ ablative therapies or surgery.
11064618|NCT04324489|Experimental|DAS181 Treatment|Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
11064619|NCT04324476|Experimental|Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI|"Induction chemotherapy:
~Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI:
~Bevacizumab: 5mg/kg, iv, 30min, d1, 2w; Oxaliplatin: 85mg/㎡, iv, 120min, d1, 4w; Irinotecan: 150mg/㎡, iv, 90min, d15, 4w; Capecitabine: 1000mg/㎡, bid, d2-8, 2w.
~Maintenance chemotherapy:
~Bevacizumab: 7.5mg/kg, iv, 30min, d1, q3w; Capecitabine: 1000mg/㎡, bid, d2-15, 2w."
11064620|NCT04324463|Experimental|Colchicine|"Outpatients:
~0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).
~Inpatients:
~1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.
~(*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days [total 28 days]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days)."
11064621|NCT04324463|Experimental|Interferon Beta|"Inpatients Only:
~0.25 mg by subcutaneous injection on days 1, 3, 5 & 7"
11064622|NCT04324463|Experimental|Aspirin (ASA)|"Outpatients:
~75 to 100 mg once daily for 28 days.
~Inpatients:
~75 to 100 mg once daily for 28 days"
11064623|NCT04324463|Experimental|Rivaroxaban|"Inpatients Only:
~2.5 mg twice daily for 28 days."
11064624|NCT04324463|No Intervention|Usual Care (Control)|Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.
11064625|NCT04324450|Experimental|Patients radiotherapy +|Patients cured of a brain tumour and who have received radiotherapy in childhood
11064708|NCT04323865||Study 2. Repeatability of FHRV|
11064626|NCT04324450|Experimental|Patients radiotherapy -|Patients cured of a brain tumour and who have received surgery and/or chemotherapy but were not irradiated
11064627|NCT04324450|Experimental|Healthy volunteers|"Healthy volunteers (control group) matched in age, manual laterality, gender and parental education to Patients radiotherapy +"
11064628|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|Two groups of patients with differing internet access: access from home or access in clinic only
11064629|NCT04324424|Experimental|Undialyzed ESRD subjects (P1)|"Part 1: Undialyzed end stage renal disease (ESRD) patients to receive a single dose of HMS5552 ( 25mg ) tablets orally
~."
11064630|NCT04324424|Experimental|Healthy volunteers (H)|"Part 1: Matched healthy volunteers to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~H group and P1 group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
11064631|NCT04324424|Experimental|Severe renal impaired subjects (P2)|"Part 2：Severe renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~P2 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
11064632|NCT04324424|Experimental|Moderate renal impaired subjects (P3)|"Part 2：Moderate renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~P3 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
11064633|NCT04324424|Experimental|Mild renal impaired subjects (P4)|"Part 2：Mild renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally
~Matching principle:
~P4 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
11064634|NCT04324411|Experimental|treatment group|combined sirolimus(serum concentration to be 4-10ng/ml) and ATRA (20mg bid) for at least 6 months
11064635|NCT04324398|No Intervention|group I (control )|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping, between each file and till the final rinse
11064636|NCT04324398|Experimental|Group II|irrigation with 5% cold sodium hypochlorite (2-5°C) from the beginning of cleaning and shaping and between each file. Final rinse was done by 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
11064637|NCT04324398|Experimental|Group III|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
11064638|NCT04324398|Experimental|Group IV|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of cold saline (2-5°C) for 5 minutes
11064639|NCT04324372|Experimental|HEC68498|HEC68498 will be administered daily
11064640|NCT04324359|Experimental|SURF-201|0.2% topical corticosteroid solution
11064641|NCT04324359|Placebo Comparator|Vehicle|Placebo
11064642|NCT04324346|Experimental|PICC-Line|Women allocated to PICC-line when receiving chemotherapy
11064643|NCT04324346|Experimental|Subcutaneous Venous Access Port (SVAP)|Women allocated to SVAP when receiving chemotherapy
11064644|NCT04324333|Experimental|Using Digital wearable system for fall detection|Digital wearable system (Owlytics Healthcare's app) enables a 24/7 health-tracking service, collecting personal health data from wearable wristbands and insoles. The data is analyzed by machine-learning algorithms that can detect abnormal physiological patterns. This allows the prediction and prevention of potentially harmful health events (such as falls).
11064645|NCT04324320||outpatients (oncological rehabilitation)|the population studied in this cross-sectional study includes patients with malignant tumour diseases and benign CNS tumours who present to the Outpatient Clinic for Oncological Rehabilitation at the Department of Physical Medicine and Rehabilitation of the Medical University of Vienna
11064646|NCT04324307|Experimental|PD-L1/CTLA4 BsAb|For 2nd line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W
11064647|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + GP|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Gemcitabine 1000 mg/m2 and Nab-paclitaxel 125 mg/m2 , 28days/cycle
11064648|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + FOLFIRINOX|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Oxaliplatin 68 or 85 mg/m2, Irinotecan 135 or 150 or 180 mg/m2, Calcium Folate 400 mg/m2, Fluorouracil 2400mg/m2, 14 days/cycle
11064649|NCT04324294|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
11064650|NCT04324268|Placebo Comparator|Placebo|Placebo
11064651|NCT04324268|Experimental|SC 0.3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.
11064652|NCT04324268|Experimental|SC 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.
11064653|NCT04324268|Experimental|SC 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.
11064654|NCT04324268|Experimental|SC 5 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.
11064655|NCT04324268|Experimental|IV 1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.
11064656|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.
11064657|NCT04324268|Experimental|IV 3 mg/kg of lirentelimab (AK002) (Priming)|Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.
11064658|NCT04324255||Low ratio|Liver recipient with low preoperative von Willbrand factor-to-protein C ratio
11064659|NCT04324255||High ratio|Liver recipient with high preoperative von Willbrand factor-to-protein C ratio
11064660|NCT04324242||Group1|visual feedback
11064661|NCT04324242||Group2|traditional feedback
11064662|NCT04324229|Active Comparator|liraglutide|
11064663|NCT04324229|Placebo Comparator|placebo|
11064664|NCT04324216|Experimental|Experimental group|3D virtual reality and hands-on aromatherapy
11064665|NCT04324216|No Intervention|Control group|No intervention
11065014|NCT04321824||the innovative programm (PASS de ville)|specific care for precarious people
11064666|NCT04324203|Experimental|Experimental group|Three-dimensional Virtual Reality and Horticultural Therapy
11064667|NCT04324203|No Intervention|Control group|No intervention
11064668|NCT04324190|Experimental|Online support program|Guided online support program, consisting of modules (structured in chapters) aiming at reduce stress related to the COVID-19 pandemic.
11064669|NCT04324190|Active Comparator|Waiting period (WHO recommendation)|"Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations Coping with stress during the 2019 nCoV outbreak. Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'."
11064670|NCT04324190|No Intervention|No intervention (natural course)|"This non-randomised arm (recruited separately; anticipated sample size of 500 subjects, not counted in the overall anticipated sample size) consists of subjects not intending to participate in the Selfapy online support program. Assessment points in this arm are comparable to those in the arm Online support program (in the 'No intervention (natural course)' arm, T1 refers to time of study inclusion)."
11064671|NCT04324138|Experimental|Experimental group|Jianpi Qinghua granules, 3 times a day and 1 hour after a meal
11064672|NCT04324138|Sham Comparator|Control group|Jianpi Qinghua placebo granules(inclued 5% of experimental drug),3 times a day and 1 hour after a meal
11064673|NCT04324112|Experimental|Arm 1/Experimental therapy|Treatment with encorafenib and binimetinib
11064674|NCT04324099||Conduct disorder|children and adolescents with CD
11064675|NCT04324099||Autism-Spectrum disorder|children and adolescents with ASD
11064676|NCT04324099||typically developing adolescents|typically developing adolescents
11064677|NCT04324086|Experimental|XP-endo Finisher file|removal of calcium hydroxide intracanal medication with XP-endo Finisher file
11064678|NCT04324086|Experimental|Irrisafe Ultrasonic tip|removal of calcium hydroxide intracanal medication with passive ultrasonic irrigation
11064679|NCT04324086|Active Comparator|side vented needle|removal of calcium hydroxide intracanal medication with conventional syringe irrigation
11064680|NCT04324073|Experimental|SARILUMAB|Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1).
11064681|NCT04324073|No Intervention|Standard of care|best standard of care
11064682|NCT04324060|Active Comparator|TPO treatment group|Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months
11064683|NCT04324060|Placebo Comparator|control|Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months
11064684|NCT04324034|Experimental|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
11064685|NCT04324034|Active Comparator|laparoscopy|conventional laparoscopy
11064686|NCT04324021|Active Comparator|Emapalumab|Emapalumab i.v infusion every 3rd day for a total 5 infusions. Day 1: 6mg/kg. Days 4, 7, 10 and 13: 3 mg/kg
11064687|NCT04324021|Active Comparator|Anakinra|Anakinra i.v infusion four times daily for 15 days. 400 mg/day in total, divided into 4 doses given every 6 hours
11064688|NCT04324021|No Intervention|Standard of care|Standard of care according to local practice
11064689|NCT04324008|Experimental|Constic|Constic (DMG, Hamburg, Germany)
11064690|NCT04324008|Experimental|G-ænial Universal Flo|G-ænial Universal Flo (GC Corporation, Tokyo, Japan) in combination with G-Premio Bond (self-etch mode)
11064691|NCT04324008|Experimental|Tetric N-Flow (self-etch)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (self-etch mode)
11064692|NCT04324008|Experimental|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (etch&rinse mode)
11064693|NCT04323982|Experimental|New Cataract Surgery|Traditional surgery combined triamcinolone staining of the anterior vitreous (TA)
11064694|NCT04323982|Active Comparator|Traditional Cataract Surgery|For patients younger than 2 years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + A-vit) For patients older than 2years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + primary intraocular lens implantation + anterior vitrectomy (ACCC+ I/A + PCCC + IOL + A-vit)
11064695|NCT04323969|Experimental|Specific Modification Target|A 15 degree relative increase to foot progression angle
11064696|NCT04323969|Experimental|Self-directed Modification|"A self-directed increase to foot progression angle that is as much as is comfortable."
11064697|NCT04323956|Experimental|Treatment (parsaclisib, R-CHOP)|Patients receive parsaclisib PO QD on days 1-10 or 1-14, rituximab IV, cyclophosphamide IV over 30 minutes, doxorubicin IV, and vincristine IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11064698|NCT04323943|Experimental|Carbon-AFO (C-AFO)|Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.
11064699|NCT04323943|Active Comparator|Custom-made thermo-plastic orthosis (CM-AFO)|Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.
11064700|NCT04323943|No Intervention|Without orthosis (NO)|No orthosis - patient will wear only their shoes
11064701|NCT04323930|Experimental|eyeWatch|
11064702|NCT04323930|Experimental|Trabeculectomy|
11064703|NCT04323917||Cases|Subjects affected by Pancreatic carcinoma (PC) confirmed by tissue biopsy
11064704|NCT04323917||Controls|Healthy Subject enrolled following colon cancer screening via colonoscopy
11064705|NCT04323904||Hantavirus Group|Patients with cultural, serological, molecular evidence of hantavirus infection
11064706|NCT04323904||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
11064707|NCT04323891||Higher Trainee/Service Doctor|
11064709|NCT04323852|Experimental|vitamin D|35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units
11064710|NCT04323852|Placebo Comparator|control group|35 patients that will receive placebo for 3 days and each day for 3 doses
11064711|NCT04323839||Pregnant Women|Women who are currently pregnant and are suspected or diagnosed COVID-19 positive.
11064712|NCT04323839||Post-partum women|Women who have been pregnant in the past 6 weeks and are suspected or diagnosed COVID-19 positive.
11064713|NCT04323826|Experimental|salads with olive oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water mixture will be provided to consume.
11064714|NCT04323826|Experimental|salads with olive oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
11064715|NCT04323826|Experimental|salads with coconut oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
11064716|NCT04323826|Experimental|salads with coconut oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water mixture will be provided to consume.
11064717|NCT04323813||Cases|CRC patients: primary, Stage I-IV (localized, node negative or node positive) colon carcinoma confirmed by tissue biopsy, and patients with advanced adenoma (including high-grade dysplasia, HGD).
11064718|NCT04323813||Controls|Controls subjects as well as healthy clean colonoscopy subjects or with hyperplastic polyps, and healthy subjects with diminutive adenoma-low grade dysplasia (LGD) and with inflammatory bowel disease (IBD).
11064719|NCT04323800|Experimental|High titer anti-SARS-CoV-2 plasma|Participants with High titer anti-SARS-CoV-2 plasma.
11064720|NCT04323800|Active Comparator|SARS-CoV-2 non-immune plasma|Participants with SARS-CoV-2 non-immune plasma.
11064721|NCT04323787||COVID19 test positive/pending or high clinical suspicion|COVID19 test positive/pending/high clinical suspicion- patient admitted to hospital
11064722|NCT04323774|No Intervention|Aim 1-Part 1 Stakeholder Interview|"This arm will focus on finding the best format for the study intervention (called AYA-RISE) whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.
~The research study procedures include:
~Using and reviewing AYA-RISE
~Participating in audio-recorded, 30-minute interviews"
11064723|NCT04323774|Experimental|Aim 1-Part 2|"This arm is a pilot study of the study intervention (called AYA-RISE).
~The activities involved in this part of the study are:
~Baseline Questionnaire
~Using and reviewing AYA-RISE
~Follow-up Questionnaire
~Brief interviews to get feedback on AYA-RISE"
11064724|NCT04323774|Active Comparator|Aim 2-Genetic Counseling|"The names of the study activities involved in this study are:
~Baseline Questionnaire
~Follow-up Questionnaire
~Medical record review
~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
11064725|NCT04323774|Experimental|Aim 2- Genetic Counseling with AYA-RISE|"The names of the study activities involved in this study are:
~Baseline Questionnaire
~Follow-up Questionnaire
~Medical record review
~Using the study intervention, AYA-RISE
~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
11064726|NCT04323774|No Intervention|Aim 3 Semi-structured interviews|Each site will conduct 30-minute interviews with patients, caregivers, and providers, and site principal investigators.
11064727|NCT04323748|Experimental|rituximab|All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
11064728|NCT04323735|Active Comparator|Low Dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 ]LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
11064729|NCT04323735|Active Comparator|High dosage|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
11064730|NCT04323722|Experimental|Empty bladder|Planning CT scan and CBCTs with empty bladder after standard Planning CT scan and CBCTs with filling bladder
11064731|NCT04323709||levosimendan group|All patients undergoing VA-ECMO from January 2012 to December 2018 and treated with levosimendan were eligible.
11064732|NCT04323709||group control|All patients undergoing VA-ECMO from January 2012 to December 2018 but not treated with levosimendan were eligible.
11064733|NCT04323696|Other|Over-sewing|Patients under over-sewing arm are subjected to staple line reinforcement using over-sewing method
11064734|NCT04323696|Other|Plication|Patients under over-sewing arm are subjected to staple line reinforcement using plication method
11064735|NCT04323683||Low progesterone|Women with progesterone level below 15 ng/ml
11064736|NCT04323683||Normal progesterone|Women with progesterone level above 15 ng/ml
11065015|NCT04321824||the standard of care|
11064737|NCT04323670|Other|Selectra 3D|Guiding catheter to position the brady lead into a untypical heart position
11064738|NCT04323657|Experimental|Phase 1|The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort.
11064739|NCT04323657|Experimental|Phase 2|The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen.
11064740|NCT04323644||Cohort 1|Patients with COVID-19 infection undergoing surgery
11064741|NCT04323631|Experimental|The intervention group|The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).
11064742|NCT04323631|Other|The control group|The control group will not receive hydroxychloroquine.
11064743|NCT04323618|Other|Free breathing or Breathe Well|Free breathing or Breathe Well
11064744|NCT04323605|Experimental|outpatient assistance program|
11064745|NCT04323592||Exposed to Methylprednisolone|Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
11064746|NCT04323592||Non-exposed to Methylprednisolone|Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.
11064747|NCT04323579||prospective cohort of stage I-II lung cancer patients|A prospective cohort of stage I-II lung cancer patients (N=80) candidates to surgery at Humanitas, and 40 controls with benign nodules.
11064748|NCT04323579||retrospective screening cohort of 50 patients|A retrospective screening cohort of 50 patients with screened lung cancer at MUG.
11064749|NCT04323579||prospective screening cohort of 30 patients|A prospective screening cohort of 30 patients with screened lung cancer and 100 matched negative controls enrolled at Humanitas cohort of 1000 participants (expected annual rate 1.5%).
11064750|NCT04323579||retrospective screening cohort from the NELSON study|A retrospective screening cohort from the NELSON study.
11064751|NCT04323579||Prospective cohort of stage IV lung cancer patients|A Prospective cohort of stage IV lung cancer patients (N=30) candidate to systemic therapy.
11064752|NCT04323566|Experimental|Treatment-first arm|Participants receive i.v. infusions with 500 mg Rituximab at 0 and 4 months, followed by placebo infusions (NaCl) at 8 and at 12 months, Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
11064753|NCT04323566|Experimental|Placebo-first arm|Participants receive placebo (NaCl) i.v. infusions at 0 and 4 months, followed by 500-mg-Rituximab infusions at 8 and 12 months. Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
11064754|NCT04323553||ESBL E.coli strains from 24 contact-index patients|48 ESBL-E. coli strains from 24 contact-index patients
11064755|NCT04323540|Active Comparator|Xenograft+collagen membrane|Reconstructive approach (Xenograft+collegen membrane)
11064756|NCT04323540|Experimental|Xenograft+collagen membrane+autologous soft tissue graft|Reconstructive approach (Xenograft+collegen membrane) plus soft tissue graft (autologous, harvested as FGG)
11064757|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days)|Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation.
11064758|NCT04323527|Active Comparator|High Dose Chloroquine Diphosphate (10 days)|High dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation.
11064759|NCT04323514|Experimental|Patients with COVID-19 pneumonia|Consecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
11064760|NCT04323501|Experimental|Experimental treatment group|"This group will undergo an intensive-rehabilitation treatment of post-stroke sensorimotor disability based on a guided self-rehabilitation contract. This approach is based on the fact that the patient must complete a diary of his self-rehabilitation activity in order to verify its correct and full execution. The treatment protocol will be defined on the basis of the clinical picture (patterns) manifested by the patient (the intensity and frequency of the exercises will be adapted according to the characteristics of each patient). The duration of treatment will be the same for all patients. The exercises will be performed every day throughout the study period (12 months).
~Before undertaking the intensive self-management treatment, each patient will undergo 10 sessions of neurorehabilitation treatment at the UOC Neurorehabilitation of the Integrated University Hospital according to normal clinical practice, during which the patient will be provided with infographic support material."
11064761|NCT04323501|Active Comparator|Control group|The patients allocated to the control group, during the study period they will undergo conventional outpatient rehabilitation treatment (usual care) at the Neurorehabilitation Unit of the AOUI according to the clinical practice through the procedures provided for by the Health System National.
11064762|NCT04323488|Experimental|Lindamood-Bell Seeing Stars|Subjects receive reading instruction focusing on the building blocks of reading
11064763|NCT04323475|Active Comparator|Standard of Care|Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
11064764|NCT04323475|Experimental|Cocktail-SPK and standard of care|The experimental drug consists of Cocktail-SPK used as an adjunct to the standard of care. Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
11064790|NCT04323319|Experimental|ESWT Group|Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
11065057|NCT04321499||lung cancer|stage IA-IIIA lung cancer
11064765|NCT04323462|Experimental|Intensive Glucose Control|"Intensive Glucose control Insulin ≥3 times per day; Goals: prePBG 80-130 & post PBG <180 (60% of all readings); HbA1c <8% at 3 months SMBG at least 14 readings/week (3-5 FBG, rest PPBG) and/or CGMS readings Reexamined weekly for 1 month; then fortnightly for 3 months and then monthly till 6 months
~Intensive subgroup will receive a standard glucometer with strips as one-week supply or CGMS for glycemic monitoring. They will receive a diabetic monitoring log/chart for home use. The chart and glucometer will have to be shown at each week of follow up. Number of hypoglycemic events in past week will be checked for each patient. This sub group will receive instructions to use 3 times bolus (regular/analogue) and single time basal insulin (glargine). Treatment goals will be conveyed at first contact and reinforced at each visit. Insulin dose modulation will be done telephonically. Patients will be reviewed weekly for 1 month and then fortnightly."
11064766|NCT04323462|Active Comparator|Conventional Glucose control|Fixed dosage of oral anti-diabetic drugs/insulin per week as patient is receiving prior; Insulin <3 times per day SMBG <3 times per day
11064767|NCT04323449|Experimental|Vision-guided control|New custom control method
11064768|NCT04323449|Experimental|Default control|Default control method (joystick or switch)
11064769|NCT04323436|Experimental|Run-in part|capmatinib in combination with spartalizumab
11064770|NCT04323436|Experimental|Randomized part - Arm 1 spartalizumab|capmatinib in combination with spartalizumab
11064771|NCT04323436|Experimental|Randomized part - Arm 2 placebo|capmatinib in combination with placebo
11064772|NCT04323423|No Intervention|Control (CON)|1) Condition A (CON): This will be the control condition. It will consist of uninterrupted sitting from 8 am until 7 pm, only rising from the chair to void.
11064773|NCT04323423|Experimental|one 10 minute bout - (LONG)|will consist of completing one 10-minute bout of light intensity walking (RPE 6-9) 30 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform this bout. The participant will repeat this after lunch and dinner, for an accumulated total of 30 minutes of light walking.
11064774|NCT04323423|Experimental|four 2.5 minute bouts SHORT|will consist of interrupting sitting with four 2.5-minute bouts of light walking at 30 minutes, 60 minutes, 90 minutes and 120 minutes post-prandial. Participants will rise from their seated position to walk ~10 metres to a treadmill to perform these bouts. The participant will repeat this after breakfast, lunch and dinner for an accumulated total of 30 minutes of light walking.
11064775|NCT04323410|Experimental|Cast immobilization|"In the casting group, padded synthetic dorsal above elbow and volar below elbow splints are applied in ED without local or general anesthesia. Dorsal displacement and shortening of the radius are not corrected, but the forearm is attempted to be manipulated straight during application of the splints. The casted forearm is then supported by a collar and cuff sling. Splints are removed in an outpatient clinic at 4 weeks.
~Cast immobilization is discontinued after 4 weeks and when the fracture site is nontender. If palpated tenderness is still present, the patient is given a dorsal forearm splint which can be removed (maximum of 2 weeks usage)."
11064776|NCT04323410|Active Comparator|Percutaneus pinning|In the surgery group, a padded dorsal above elbow splint is applied in ED. Reduction and percutaneous pinning are performed under anesthesia in operating room by an experienced attending pediatric orthopedic surgeon within 7 days from the injury. Pin fixation is performed with two 1.6 mm pins. Padded dorsal above elbow and volar below elbow splints are applied. Splints and pins are removed at the outpatient clinic at 4 weeks after surgery.
11064777|NCT04323397|Experimental|nasal high frequency oscillatory ventilation|"nHFO: flow 8-10 L/minute, frequency 10 Hz, MAP = MAP (before extubation) + 2 or 8 (preterm), 10 (term) cmH2O, dP = 2-3 times of MAP with visible chest oscillations or 25-35 cmH2O, I:E = 1:1, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%"
11064778|NCT04323397|Experimental|nasal synchronized intermittent positive pressure ventilation|"nSIPPV: flow 8-10 L/minute, rate 60/minute, PIP = PIP (before extubation) + 2-5 or 20 (preterm), 25 (term) cmH2O, PEEP = 5 cmH2O, IT = 0.5 s, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%. The highest trigger sensitivity avoiding auto triggering was selected."
11064779|NCT04323384|Experimental|Biotene® followed by Sham|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into either Protocol A or Protocol B. In their first session, participants in Protocol A will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the experimental condition. For the experimental condition, participants will be instructed to apply Biotene® Oralbalance Moisturizing Gel according to package directions. Testing will then be repeated. In the second session, after baseline testing, participants will receive the sham condition (instead of the experimental condition). For the sham condition, participants will be instructed to rinse their mouth with room temperature distilled water. Testing will then be repeated.
11064780|NCT04323384|Experimental|Sham followed by Biotene®|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into two protocols: 1) Protocol A and 2) Protocol B. In their first session, participants in Protocol B will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the sham condition. Testing will then be repeated. In the second session, after baseline testing, participants will receive the experimental condition (instead of the sham condition). Testing will then be repeated.
11064781|NCT04323371||Acute decompensated heart failure|patients admitted with Acute decompensated heart failure Complicated by cardiogenic shock
11064782|NCT04323358|Active Comparator|IOL Master® 700|Biometry will be performed three times consecutively.
11064783|NCT04323358|Active Comparator|Pentacam®|Keratometry will be performed three times consecutively.
11064784|NCT04323358|Active Comparator|Casia II®|Keratometry will be performed three times consecutively.
11064785|NCT04323358|Active Comparator|Spectralis Anterion®|Biometry will be performed three times consecutively.
11064786|NCT04323345|Experimental|Natural Honey Group|"Natural Honey
~1gm/kg/day divided into 2 to 3 doses for 14 days in addition to standard care"
11064787|NCT04323345|Active Comparator|Standard Care|Current standard care including supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
11064788|NCT04323332|Experimental|Traditional Chinese Medicine|TCM prescription and conventional treatments
11064789|NCT04323332|No Intervention|Control|conventional treatments
11064821|NCT04323150|Other|Open (conventional) suction|control group
11064791|NCT04323319|Experimental|Graston Technique® Group|The application was carried out by Graston Technique® (GT®) certified, a therapist with orthopedic rehabilitation and soft tissue treatments for over 12 years. GT® instruments were used to diagnose and treat the damaged soft tissue of gastrocnemius and plantar fascia. The application protocol and the instruments used according to the regions were determined with reference to the GT® manual. GT® treatment can be given to the same region twice a week. A minimum of 2 days break was given between the applications. Gastrocnemius and plantar fascia application completed in 5 minutes in one leg. GT2, GT4 and GT6 instruments used for application.The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
11064792|NCT04323319|Experimental|Control Group|Stretching group was accepted as the control group. the patient monitored once a week at the hospital and continue home stretching program at home. These patients will be given information about plantar fasciitis as well as other groups. Plantar fascia and gastrosoleus self-stretching exercises will be required to be performed twice a day for thirty seconds and three repetitions for 4 weeks. The patients will be followed with an exercise follow-up form.
11064793|NCT04323306|Active Comparator|Cohort 1 SAD|5 mg MMV533 with single ascending dose
11064794|NCT04323306|Active Comparator|Cohort 2 SAD|Single ascending dose to be determined after SRC review of previous cohort.
11064795|NCT04323306|Active Comparator|Cohort 3 SAD|Single ascending dose to be determined after SRC review of previous cohort.
11064796|NCT04323306|Active Comparator|Cohort 4 SAD|Single ascending dose to be determined after SRC review of previous cohort.
11064797|NCT04323306|Active Comparator|Cohort 5 SAD|Single ascending dose to be determined after SRC review of previous cohort.
11064798|NCT04323306|Active Comparator|Cohort 6 SAD|Single ascending dose to be determined after SRC review of previous cohort.
11064799|NCT04323306|Active Comparator|Cohort 7 SAD|Single ascending dose to be determined determine after SRT review of previous cohort. Dose will not exceed 400 mg.
11064800|NCT04323306|Active Comparator|Part 2: Food Effect|Open label, 2-period cross-over, randomized, pilot food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV533 determined to be safe in Part 1.
11064801|NCT04323293|Experimental|CPM - Cold Water Bath|
11064802|NCT04323293|Sham Comparator|CPM - SHAM|
11064803|NCT04323280|Active Comparator|Conventional Therapy|Ibuprofen 600mg every 8 hours for one week followed by tapering of dose by 200mg every week (3 weeks of therapy), in addition to Colchicine 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg) for 3 months
11064804|NCT04323280|Experimental|Dexamethasone therapy|Dexamethasone therapy 20 mg once daily per os for 4 day in addition to colchicine therapy for 3 months 0.5mg daily (<70kg) or 0.5mg twice daily (>70kg)
11064805|NCT04323267|Experimental|Digital Home Exercise Program|Limber Digital Application Device (3 x a week for 8 weeks)
11064806|NCT04323267|Active Comparator|Physical therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
11064807|NCT04323241|No Intervention|control group|In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.
11064808|NCT04323241|Experimental|Study Group|In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.
11064809|NCT04323228|Experimental|Intervention|the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.
11064810|NCT04323228|Placebo Comparator|Placebo|Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.
11064811|NCT04323215||Support system users|Usual care (behavioral treatment) plus the support system for self-monitoring of weight and communication with the clinic during one year of treatment.
11064812|NCT04323215||Control group|Children treated with usual care according to regular treatment routines registred in BORIS the Swedish childhood obesity treatment register
11064813|NCT04323202|Experimental|Permbrolizumab|Participants will undergo fine cut CT imaging (head and neck) followed by at least 4 doses of pembrolizumab q 3 weeks. After the 4th dose of pembrolizumab as appropriate, patients will undergo standard surgical resection, with all non-marginal tissue as well as the pre-op biopsy to be stored for collateral research. 2 weeks after initial flap or graft insert (which would be equivalent to stage 1 of a forehead flap) patients would continue for a total of approximately 1 year of pembrolizumab q 3 weeks (another 13 doses, thus 17 doses total).
11064814|NCT04323189|Other|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
11064815|NCT04323189|Other|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
11064816|NCT04323176|Experimental|Village Model|Participate as a member of the Village using a hyperlocal social app for 12 months.
11064817|NCT04323163|Experimental|Yoga Group|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet three times a week for 60 minutes over the 6 month study duration. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
11064818|NCT04323163|Experimental|Aerobic Group|Trained exercise instructors will lead participants through an aerobic group exercise class. Sessions will begin with a 15-20 minute aerobics class and increase in duration over the 6 months capping off at 40-minutes per session. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program.
11064819|NCT04323163|Active Comparator|Stretching Toning Group|Participants randomized to this group will meet three times a week for an hour-long structured group exercise session. This group will perform stretching and toning exercises using resistance bands, balance disks, and exercise mats.
11064820|NCT04323150|Experimental|Closed suction systems|
11064822|NCT04323137|No Intervention|Control|This group receives no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
11064823|NCT04323137|Experimental|High risk only|This group receives messages telling them they have been identified to be at high risk for flu complications without specifying how or why the health system believes this to be the case.
11064824|NCT04323137|Experimental|High risk based on medical records|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records.
11064825|NCT04323137|Experimental|High risk based on algorithm|This group receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by an AI/ML system.
11064826|NCT04323124|Experimental|Treatment|PF-07059013 assignment
11064827|NCT04323124|Placebo Comparator|Placebo|Placebo assignment
11064828|NCT04323098|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg with prophylactic corticosteroids
11064829|NCT04323085|Active Comparator|Speech-in-Noise Treatment Program|A behavioural speech therapy program involving 12, one-hour treatment sessions over a 4-week period
11064830|NCT04323085|Active Comparator|Speech-to-Noise Feedback Device Program|A speech treatment program involving the use of a speech-to-noise feedback device during 12, one-hour treatment sessions over a 4-week period
11064831|NCT04323085|No Intervention|Delayed Treatment|Assessments but no intervention for a period of 13 weeks.
11064832|NCT04323072|Experimental|Group A|Resection of antrum proximally 2 cm to the pylorus
11064833|NCT04323072|Active Comparator|Group B|Resection of antrum proximally 6 cm to the pylorus
11064834|NCT04323059|Experimental|Standardized milk-based formulation|Formulation of maize with milk that is rich in methionine
11064835|NCT04323059|Experimental|Standardized non-milk based formulation|Formulation of maize with soybeans that is rich in methionine and lysine
11064836|NCT04323059|Active Comparator|Hospital-based formulation|Formulation of maize, milk and soybeans
11064837|NCT04323046|Experimental|Group A (neoadjuvant nivolumab and placebo)|"NEOADJUVANT: Patients receive nivolumab IV over 30 minutes and placebo IV over 30 minutes 14 days before undergoing standard of care surgical resection.
~ADJUVANT COMBINATION INFUSION: After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11064838|NCT04323046|Experimental|Group B (neoadjuvant nivolumab and ipilimumab)|"NEOADJUVANT: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.
~ADJUVANT COMBINATION INFUSION: After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11064839|NCT04323046|Experimental|Group C (neoadjuvant placebo and ipilimumab)|"NEOADJUVANT: Patients receive placebo IV over 30 minutes and ipilimumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.
~ADJUVANT COMBINATION INFUSION: After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11064840|NCT04323033|Experimental|PERS stent|20 Patients will receive PERS stent
11064841|NCT04323033|Active Comparator|NEPTUN C stent|20 Patients will receive NEPTUN C stent
11064842|NCT04323020|Experimental|Comatose cardiac arrest patients|Comatose cardiac arrest patients will be undergoing CT perfusion test
11064843|NCT04323007|Other|Nephrotic syndrome patients|This study is to evaluate Thyroid Hormone profile in patients with Nephrotic syndrome to identify clinical predictor of Thyroid dysfunction in patients with Nephrotic syndrome
11064844|NCT04322994|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
11064845|NCT04322994|Experimental|Intervention|"Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
~Intervention: Device: High-flow nasal cannula"
11064846|NCT04322981|Experimental|Community Pharmacist-Led|Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.
11064847|NCT04322981|Active Comparator|Academic hepatology|Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.
11064848|NCT04322968|Experimental|Chronic pain with PTSD+IV ketamine infusion|
11064849|NCT04322968|Active Comparator|Chronic pain with PTSD+IV ketorolac infusion|
11064850|NCT04322968|Experimental|Chronic pain without PTSD+IV ketamine infusion|
11064851|NCT04322968|Active Comparator|Chronic pain without PTSD+IV ketorolac infusion|
11064901|NCT04322656|No Intervention|Control eye|The contralateral eye will serve as control eye
11065058|NCT04321499||benign nodules|ruled out lung cancer via Operation or CT-scan follow-up
11064852|NCT04322955|Experimental|Treatment with cabozantinib and nivolumab with nephrectomy|All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. The first three to six subjects (group 1) will have the cabozantinib held for three weeks prior to removal of the kidney. If there are no unexpected side effects from the surgery, then future subjects (group 2) will have the cabozantinib stopped for two weeks prior to the nephrectomy.
11064853|NCT04322942||Non-infection|
11064854|NCT04322942||Infection without sepsis|
11064855|NCT04322942||Sepsis-2|
11064856|NCT04322942||Sepsis-3|
11064857|NCT04322929|Experimental|Oral roflumilast|Oral roflumilast 250 microgram daily will be started at the baseline visit for 4 weeks. For those who can tolerate the initial 4-week treatment, roflumilast will be increased to 500 microgram daily, allowing subsequent dose reduction back to 250 microgram daily in case of CTCAE grade 3 or 4 toxicities.
11064858|NCT04322916||RM Pressfit vitamys|Participants treated with a RM Pressfit vitamys hip cup in combination with a Mathys hip stem
11064859|NCT04322903|Experimental|Trauma-informed mindfulness-based stress reduction program|The program includes three 2-hr sessions to promote physical and emotional wellbeing through mindfulness techniques and health promotion activities; two home visits to provide individualized sessions with a nurse and a community health navigator; and a follow-up session 4 weeks after intervention to discuss perception of the intervention.
11064860|NCT04322877|Experimental|Body surface mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and non-invasive body surface mapping.
11064861|NCT04322877|Experimental|Catheter-based mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and invasive catheter-based mapping.
11064862|NCT04322864|Active Comparator|In-person supervised intervention|
11064863|NCT04322864|Experimental|Web-based instrument intervention|
11064864|NCT04322851||B-line positive|
11064865|NCT04322851||B-line negative|
11064866|NCT04322838||Patients|30 patients with self-reported seasonal allergic airway symptoms in the period from 1st of August to 15.th of october
11064867|NCT04322838||Controls|15 non-allergic individuals
11064868|NCT04322825|Experimental|intervention|24 weeks of TENS
11064869|NCT04322812|Active Comparator|Active PBMT|Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
11064870|NCT04322812|Placebo Comparator|Placebo PBMT|Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
11064871|NCT04322799|Experimental|Acetabular cup HXLPE (Intervention)|Randomization to HXLPE acetabular component.
11064872|NCT04322799|Experimental|Acetabular cup Conventional PE (control)|Randomization to Coventional PE as control group
11064873|NCT04322786||ACEI user|Individuals with an ACEI prescription in the study population.
11064874|NCT04322786||Matched controls|Individuals without an ACEI prescription, and matched to the users by sex and 10-year age categories.
11064875|NCT04322773|Experimental|Roactemra iv|Single dose treatment with 400 mg tocilizumab intravensously
11064876|NCT04322773|Experimental|Roactemra sc|Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
11064877|NCT04322773|Experimental|Kevzara sc|Single dose treatment with 1 x 200 mg sarilumab subcutaneously
11064878|NCT04322773|Active Comparator|Standard care|Management as usual
11064879|NCT04322760|Active Comparator|Group A (control group)|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly without lidocaine patch
11064880|NCT04322760|Experimental|Group B|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly with a patch of lidocaine 5% was applied to the skin
11064881|NCT04322747||Participants scheduled to undergo skull-based surgery|Participants scheduled to undergo skull-based or mastoid surgery as part of their standard care will receive Audiometry for extended high frequencies, DPOAE, ECochG before and after the procedure in the non operated ear.
11064882|NCT04322734||ASD (General)|150 children with ASD and unknown MD status
11064883|NCT04322734||ASD (With MD)|50 children with ASD and confirmed MD
11064884|NCT04322734||ASD (No MD)|50 children with ASD and ruled out MD
11064885|NCT04322734||Epilepsy|50 children with epilepsy (primary) and no ASD
11064886|NCT04322734||Brain Tumor|50 children with brain tumor (primary) and no ASD
11064887|NCT04322734||Psychiatric Disorder|50 children with psychiatric disorder (primary) and no ASD, using lithium treatments
11064888|NCT04322734||MD (No ASD)|50 children with MD (primary) and no ASD
11064889|NCT04322734||TD (With ASD Sibling)|50 TD children with a sibling with ASD/neurodevelopmental delay
11064890|NCT04322734||TD (No ASD Sibling)|50 TD children with no siblings with ASD/neurodevelopmental delay
11064891|NCT04322708|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo.
11064892|NCT04322708|Experimental|1 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).
11064893|NCT04322708|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.
11064894|NCT04322695|Experimental|Rehabilitation Education Care Program (RECP)|Cancer rehabilitation program and patients education can improve disability and promote return to work.
11064895|NCT04322695|Other|Usual care|Usual care
11064896|NCT04322682|Active Comparator|Colchicine 0.5 mg|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
11064897|NCT04322682|Placebo Comparator|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
11064898|NCT04322669|Experimental|Pidotimod|
11064899|NCT04322669|Placebo Comparator|Placebo|
11064900|NCT04322656|Active Comparator|Effect of Lipiflow treatment on biometrical outcomes|One eye of each patient will be treated with Lipiflow
11064902|NCT04322643|Experimental|CPI therapy|Patients will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy.
11064903|NCT04322630||Pediatric Cardiac Bypass Patients|Blood samples obtained from patients ages from birth-19 years-old as well as cyanotic and acyanotic cardiac lesions who underwent cardiac bypass.
11064904|NCT04322604|Placebo Comparator|Placebo|Placebo
11064905|NCT04322604|Experimental|3 mg/kg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): a first dose of 1 mg/kg followed by 5 monthly doses of 3 mg/kg.
11064906|NCT04322565|Experimental|Colchicine|Administration of Colchicine 1mg (or 0.5 mg in CKD)/day + standard of care for COVID-19 pneumonia
11064907|NCT04322565|No Intervention|Standard of care|Standard of care for COVID-19 pneumonia
11064908|NCT04322552|Experimental|Treament|In phase A, subjects receiving a single 0.25 mg of digoxin orally and wash-out for 5 days, then apatinib once daily will be conducted on D5 through D16 ； In addition, a single dose of 0.25 mg digoxin (in combination with apatinib) will be orally administered in fasting conditions on D12；
11064909|NCT04322539|Experimental|fruquintinib plus best supportive care|In this arm, subjects will receive active study drug plus best supportive care
11064910|NCT04322539|Placebo Comparator|placebo plus best supportive care|In this arm, subjects will receive placebo plus best supportive care
11064911|NCT04322526|Experimental|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
11064912|NCT04322526|Placebo Comparator|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
11064913|NCT04322513||Covid-19 positive patients|all drugs used for standard treatment
11064914|NCT04322513||Covid-19 negative patients|
11064915|NCT04322500|Other|Group A: conservative|conservative treatment
11064916|NCT04322500|Experimental|Group B: probiotics|in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)
11064917|NCT04322461|Experimental|Parkinson disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
11064918|NCT04322461|Experimental|Alzheimer's disease|2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.
11064919|NCT04322448||Cubital Tunnel Syndrome Patients|Cubital Tunnel Syndrome patients. Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
11064920|NCT04322448||Peroneal Nerve Decompression Patients|Patients with compressive peroneal nerve neuropathy and will undergo a Peroneal Nerve Decompression (PND). Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
11064921|NCT04322435|Other|Adrenal insufficiency|Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.
11064922|NCT04322422|Experimental|ICS/LABA plus Montelukast|
11064923|NCT04322422|Active Comparator|ICS/LABA only|
11064924|NCT04322409|Experimental|NMES|The experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus.
11064925|NCT04322409|Placebo Comparator|TENS|The placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus
11064926|NCT04322396|Placebo Comparator|Control|This arm will receive standard care and placebo in 15 days.
11064927|NCT04322396|Active Comparator|Intervention|This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.
11064928|NCT04322383|Experimental|Arm 1/Experimental therapy|Treatment with binimetinib
11064929|NCT04322370|Active Comparator|Group A|VersaWrap Treatment Arm- Zone 2 flexor tendon repair with the use of VersaWrap
11064930|NCT04322370|Active Comparator|Group B|Standard of Care Treatment Arm- Zone 2 flexor tendon repair
11064931|NCT04322357|No Intervention|Daily Glucocorticoid (GC)|Existing data from age-matched, ambulatory, on daily GC therapy, and similar exclusion criteria will be selected from the ImagingDMD database to serve as a historical control.
11064932|NCT04322357|Active Comparator|WeekEnd Glucocorticoid with No Exercise|Participants with DMD will be given a low dose, weekend regimen of prednisone over the course of 1 year.
11064933|NCT04322357|Active Comparator|WeekEnd Glucocorticoid with Exercise|Participants with DMD will be given a low dose, weekend regimen of prednisone over the course of 1 year, in combination with a 6-month in-home exercise training program.
11064934|NCT04322344|Experimental|oral escin group|Standard therapy+Escin tablet 40mg*3, os for 12 days
11064935|NCT04322344|Sham Comparator|control group|standard therapy
11064936|NCT04322344|Experimental|parenteral escin group|standard treatment + sodium Escinate 20mg iv/day for 12 days
11064937|NCT04322331||T1N+|T1 tumor with positive lymph node,N1/N2/N3
11064938|NCT04322331||T2/T3N0|T2/T3 tumor with negative lymph node
11064939|NCT04322318|Experimental|Arm I (Regimen UH-3)|See outline in detailed description section.
11064940|NCT04322318|Experimental|Arm II (Regimen ICE/Cyclo/Topo)|"CYCLES 1, 2, 4, 5, 7, AND 9: Patients receive carboplatin IV over 15-60 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and ifosfamide IV over 2-4 hours on days 1-3. Treatment repeats every 21 days during cycles 1, 2, 4, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
~CYCLES 3, 6, 8, AND 10: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan IV over 30 minutes on days 1-5. Treatment repeats every 21 days during cycles 3, 6, 8, and 10 in the absence of disease progression or unacceptable toxicity."
11064941|NCT04322305|Experimental|Pregabalin|Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
11064942|NCT04322305|Placebo Comparator|Placebo|Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
11064943|NCT04322292|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.
11064944|NCT04322266|Experimental|Sequence 1 (Reference-Test)|Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
11064945|NCT04322266|Experimental|Sequence 2 (Test-Reference)|Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608
11064946|NCT04322253|Experimental|Neladenoson bialanate, mild hepatic impairment|Subjects with Child Pugh score 5 or 6 received a single immediate-release (IR) tablet dose of 10 mg neladenoson bialanate in the fasted state
11064947|NCT04322253|Experimental|Neladenoson bialanate, moderate hepatic impairment|Subjects with Child Pugh score 7-9 received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
11064948|NCT04322253|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
11064949|NCT04322240|Experimental|type 2 DM with peripheral neuropathy|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication, antidiabetic drugs, or medications used for managing arterial hypertension or dyslipidaemia during the study.
11064950|NCT04322227|Experimental|Healthy|
11064951|NCT04322227|Experimental|PD|
11064952|NCT04322214|Experimental|COBI period (5 days) + Placebo period (5 days)|volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB
11064953|NCT04322214|Experimental|Placebo period (5 days) + COBI period (5 days)|volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB.
11064954|NCT04322201|Experimental|Intervention group - Continuous passive paracentesis|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care.
11064955|NCT04322201|Active Comparator|Control group - Large volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter performed and repeated during ICU stay according to standard-of-care clinical practice.
11064956|NCT04322188||group 1|Patients in Cohort A were treated with siltuximab after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation
11064957|NCT04322188||Group 2|The control cohort will include all the patients with pneumonia/ARDS in need of non-invasive ventilation (CPAP or NIV) or intubation and not receiving experimental treatments in the ReCOVID-19-2020
11064958|NCT04322175|Experimental|Single dose pharmacokinetic test|The 72 healthy subjects enrolled were admitted to the trial ward the day before the trial. On the day of dosing, the subjects were given 0.1% meloxicam eye drops once, 1 drop / time.
11064959|NCT04322175|Experimental|Multiple dose tolerance test|Eight healthy subjects were enrolled in the trial ward the day before the trial. 0.1% meloxicam eye drops were administered 4 times, 1 drop / time, and were administered at 8:00, 12:00, 16:00 and 20:00 daily for 3 consecutive days.
11064960|NCT04322162|Experimental|Active implementation - Wave 1 (First and Second Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 1 corresponds to Wave 1."
11064961|NCT04322162|Experimental|Active implementation - Wave 2 (Third and Fourth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 2 corresponds to Wave 2."
11064962|NCT04322162|Experimental|Active implementation - Wave 3 (Fifth and Sixth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites, where active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves three phases at each of the six sites: two 7-month increments (total of 14 months) in the baseline phase, two 7 month increments in active implementation phase. The stepped-wedge design allows for 7 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 14 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on seven different cross-sectional samples. Thus, the investigators will have repeated information on each site. Here, arm 3 corresponds to Wave 3."
11064963|NCT04322149|Experimental|AT-1501|3 sequential dose cohorts
11064964|NCT04322136|Other|IPC (with talc pleurodesis if suitable)|"The patients will undertake daily drainage to day 14 post insertion. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter.
~Participants will be taught how to perform pleural drainage by the main study doctor at the hospital or a specialist nurse. They will drain their own IPCs at home with the either the help of a family member or friend or have access to community nursing support systems."
11065008|NCT04321863||Adults with Crohn's disease in remission|All patients recruited will submit two samples to facilitate faecal zinc and qFIT in addition to FC which is standard of care. All patients recruited will have an additional tube of blood taken to measure serum zinc at the same time as they have their routine (standard of care) monitoring bloods taken - no additional venepuncture will be required.
11064965|NCT04322136|Other|Pleurodesis via VATS|Participants will undergo VATS within two weeks of randomisation. VATS is usually performed in an operating theatre, using either general anaesthesia or local anaesthesia with sedation. The pleural fluid will be removed and adhesions can be divided (adhesiolysis). Assessment of lung re-expansion will be performed intra-operatively. If lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed to induce a pleurodesis, including, but not limited to, talc poudrage and mechanical abrasion. Decortication may be performed if deemed appropriate and feasible by the operating surgeon. A chest drain will be left in situ after the surgery. Post-operative care will be administered as per local practice.
11064966|NCT04322123|Experimental|Hydroxychloroquine|Hydroxychloroquine after randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 07 days.
11064967|NCT04322123|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 07 days.
11064968|NCT04322123|No Intervention|Control|standard treatment protocol for 2019-nCoV infection.
11064969|NCT04322110|Experimental|VLCK diet group|Subjects undergoing treatment with weight loss program PronoKal Method
11064970|NCT04322110|Active Comparator|Control group|Subjects undergoing treatment with low calorie diet
11064971|NCT04322097|Other|DISE patients|DISE
11064972|NCT04322084||Participants|Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.
11064973|NCT04322071||Lower risk of long term complications|Young people with diabetes who have HbA1c <58mmols/mol, and family members.
11064974|NCT04322071||Higher risk of long term complications|Young people with diabetes who have HbA1c ≥75mmols/mol and <100mmols/mol, and family members.
11064975|NCT04322058||Fathers or paternal caregivers to a child 0-18 years of age|Parenting and Healthy Relationship Education (10 Core 24/7 workshops covering- 15 hours of education), financial and economic mobility programming, comprehensive case management, and supplemental workshops utilizing the Within My Reach curriculum.
11064976|NCT04322045|Experimental|participants|All tested serum PSA. Some conducted mpMRI with/without prostate biopsy under instruction.
11064977|NCT04322032|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug"
11064978|NCT04322032|Experimental|Group 2|"Period 1: Test drug
~Period 2: Reference drug"
11064979|NCT04322019||"Amikacin treatment group"|Intensive care patients on renal replacement therapy with Amikacin treatment
11064980|NCT04322006|Experimental|TJ004309 Injection|2mg/kg~20mg/kg TJ004309 Injection is administered once a week for a treatment cycle every 28 days
11064981|NCT04321993|Experimental|Baricitinib|
11064982|NCT04321993|No Intervention|Clinical standard of care|
11064983|NCT04321980|Experimental|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a SC injection.
11064984|NCT04321980|Experimental|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
11064985|NCT04321967|Experimental|Nitroglycerine paste|The randomized breast will receive Nitroglycerine paste and Dermabond.
11064986|NCT04321967|Placebo Comparator|Dermabond|The control breast will receive Dermabond only
11064987|NCT04321954|Experimental|LENVATINIB|"Study procedures include screening for eligibility and study treatment, evaluations, and follow up visits
~Lenvatinib will be administered orally daily at a predetermined dose for 2 or 4 cycles, dependent on response. 1 cycle is 28 days.
~Surgery per standard of care will follow lenvatinib treatment."
11064988|NCT04321941|Experimental|CTE (Computerised Tomography Enterography)|CTE examination performed with experimental contrast agent, Lumentin.
11064989|NCT04321941|Active Comparator|MRE (Magnetic Resonance Enterography)|Comparative diagnostic method performed with the contrast agent Movprep®
11064990|NCT04321928|Other|Group A|General health education arm.
11064991|NCT04321928|Other|Group B|Personalized health education arm.
11064992|NCT04321915|Other|Children with Autism spectrum disorder|"Patients will realised quesstionnaires, a blood sample will be collected, the feces will be collected too.
~The analysis of intestinal microbiota and neuroinflammation markers will be processed."
11064993|NCT04321902|Experimental|The experimental group in acute cholecystitis|"inclusion criteria
~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
~Gallbladder with surrounding organs due to gallbladder inflammation
~Patients over 19 years of age
~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used as before and during surgery."
11064994|NCT04321902|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
~Gallbladder with surrounding organs due to gallbladder inflammation
~Patients over 19 years of age
~Sencond-generation cephalosporin (Shincef inj., 750mg, Cefuroxime sodium, Shin-poong pharm.co.) was used as before and during surgery."
11064995|NCT04321889|Experimental|BEO|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
11064996|NCT04321889|Placebo Comparator|Placebo|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
11064997|NCT04321876||NMG IM 211 E Chicago Ave|
11064998|NCT04321876||NMG IM ARKES|
11064999|NCT04321876||NMG IM 1460 N Halsted St|
11065000|NCT04321876||NMG IM 201 E Huron St|
11065001|NCT04321876||NMG Integrative Medicine 150 E Huron St|
11065002|NCT04321876||NMG IM 1776 N Milwaukee Ave|
11065003|NCT04321876||NMG IM 20 S Clark St|
11065004|NCT04321876||NMG IM FM 1704 Maple Ave|
11065005|NCT04321876||NMG IM 259 E Erie St|
11065006|NCT04321876||NMG IM 1135 S Delano Ct|
11065007|NCT04321876||NMG IM 1333 W Belmont Ave|
11065009|NCT04321850|Placebo Comparator|Group1|Control
11065010|NCT04321850|Experimental|Group 2|Intervention (Zinc)
11065011|NCT04321837|Active Comparator|Coral calcium complex and ibandronate|
11065016|NCT04321811||Participants|"Adult men and women currently in the United States and willing to provide written informed consent and:
~who are feeling sick but have not tested positive for COVID-19
~who are feeling sick and have tested positive for COVID-19
~People who are not feeling sick but want to participate"
11065017|NCT04321798|Experimental|Physical Activity|Promoting Engagement in Physical Activity
11065018|NCT04321785|Placebo Comparator|Placebo|
11065019|NCT04321785|Experimental|Caffeine|
11065020|NCT04321772|Experimental|High Intensity Interval Resistance Training (HIIRT)|"HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30 rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets."
11065021|NCT04321772|Active Comparator|Traditional Resistance Training (TRT)|"TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75 of rest between sets."
11065022|NCT04321759|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
11065023|NCT04321759|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health..
11065024|NCT04321746|Active Comparator|Ketamine|
11065025|NCT04321746|Placebo Comparator|Control|
11065026|NCT04321720|Experimental|3-g footbath|Footbath with 3g mustard flour per liter of water
11065027|NCT04321720|Experimental|6-g footbath|Footbath with 6g mustard flour per liter of water
11065028|NCT04321720|Experimental|12-g footbath|Footbath with 12g mustard flour per liter of water
11065029|NCT04321720|Placebo Comparator|Warm water footbath|Footbath with warm water only
11065030|NCT04321707|Experimental|15O-H2O PET/MR|All included patients will have two 15O-H2O PET/MR scan performed.
11065031|NCT04321668|Other|Injection of SYNVISC-ONE|Patients suffering from symptomatic knee osteoarthritis (OA), receiving intra-articular (IA) injection of SYNVISC-ONE® (Hylan G-F 20; 10 mL single-injection viscosupplement)
11065032|NCT04321655|Experimental|High Intensity LASER Therapy group (HILT)|Forty patients with chronic KOA in HILT group will received Class IV LASER therapy. A Class IV LASER emits power more than 500 milliwatt (mW) .
11065033|NCT04321655|Experimental|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in ibuprofen gel phonophoresis (IGP) group will administered with continuous ultrasound set at a frequency of 1 megahertz (MHz) and an intensity of 1 W/cm2 was applied on a circular basis.
11065034|NCT04321655|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with chronic KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
11065035|NCT04321655|Active Comparator|Conventional physiotherapy group (CPT)|Individual with chronic KOA will be educated on how to do the set of exercises correctly at their home during the first session. All the groups will receive the same, standardized exercise protocol for KOA which consisted of nine exercises including muscle strengthening and flexibility training.
11065036|NCT04321642|Experimental|Entonox|Inhalation Entonox in active phase of labor ( cervical dilatation more than 5 cm ) Inhaled Entonox before true uterine contraction in 30 sec , inhaled in 4-5 times for 1 contraction
11065037|NCT04321642|Active Comparator|Not receive Entonox|Not receive any gas when archive in active phase of labor( cervical dilatation more than 5 cm )
11065038|NCT04321629|Experimental|Autologous Fat Tissue Group|Group of patients treated with intra-articular injections of autologous adipose tissue.
11065039|NCT04321629|Active Comparator|PRP Group|Group of patients treated with intra-articular injections of platelet-rich-plasma.
11065040|NCT04321616|Active Comparator|Hydroxychloroquine|
11065041|NCT04321616|Active Comparator|Remdesivir|
11065042|NCT04321616|Active Comparator|Control group - SoC|
11065043|NCT04321603|Other|People living with HIV|Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
11065044|NCT04321590|Experimental|3 g 35% beta-glucan|Supplement containing 3 g of 35% oat beta-glucan
11065045|NCT04321590|Experimental|5 g 35% beta-glucan|Supplement containing 5 g of 35% oat beta-glucan
11065046|NCT04321590|Experimental|3 g 70% beta-glucan|Supplement containing 3 g of 70% oat beta-glucan
11065047|NCT04321590|Experimental|5 g 70% beta-glucan|Supplement containing 5 g of 70% oat beta-glucan
11065048|NCT04321577||Residual disease|Participants with incidental gallbladder cancer with presence of residual disease in the re-resection specimen or in intra-operative findings.
11065049|NCT04321577||No residual disease|Participants with incidental gallbladder cancer with absence of residual disease in the re-resection specimen or in intra-operative findings.
11065050|NCT04321564||Nullipar pregnant women|
11065051|NCT04321564||multipar pregnant women|
11065052|NCT04321551|Experimental|Provocative Hormonal Testing|"Recombinant follicle stimulating hormone (r-FSH) will be administered intravenously one time at a dose of 150 IU during the early follicular phase of the first menstrual cycle after enrollment (Menstrual Cycle I).
~Subjects will receive no intervention during Menstrual Cycle II (washout cycle).
~During the early follicular phase of Menstrual Cycle III, subjects will receive an intramuscular (i.m.) injection of estradiol valerate 5 mg on study day 1, followed by an i.m. injection of progesterone in oil 50 mg on study day 2."
11065053|NCT04321538||Failed Vision Screen Cohort|This cohort represents the entire group of study participants- children who were referred to Yale New Haven Hospital and Yale Medicine for a failed vision screen by either their primary care provider or their school.
11065054|NCT04321525|Active Comparator|Cognitive-behavioral therapy (CBT)|Individual Cognitive Behavioral Therapy
11065055|NCT04321525|Experimental|Personal construct therapy (PCT)|Individual Personal Construct Therapy
11065056|NCT04321525|Experimental|Personal construct therapy with virtual reality (PCT-VR)|Individual Personal Construct Therapy with an immersive virtual reality app
11065060|NCT04321460|Placebo Comparator|Placebo|Placebo once daily for 14 days
11065061|NCT04321447|Experimental|Clinical practice guideline (CPG) group|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme
11065062|NCT04321447|No Intervention|Usual care group|Usual care
11065063|NCT04321434|Experimental|Hyperoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests
~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
11065064|NCT04321434|Placebo Comparator|Normoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests
~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
11065065|NCT04321421|Experimental|treated|treated with hyperimmune plasma
11065066|NCT04321395|Experimental|Vigabatrin|
11065067|NCT04321395|Placebo Comparator|Placebo|
11065068|NCT04321356||Stryker Triathlon PCR TKA|Subjects implanted with a Stryker Triathlon PCR TKA
11065069|NCT04321356||Stryker Triathlon PS TKA|Subjects implanted with a Stryker Triathlon PS TKA
11065070|NCT04321356||Zimmer Persona PCR TKA|Subjects implanted with a Zimmer Persona PCR TKA
11065071|NCT04321356||Zimmer Persona PS TKA|Subjects implanted with a Zimmer Persona PS TKA
11065072|NCT04321343|Experimental|Group 1|PXL065 Dose 1
11065073|NCT04321343|Experimental|Group 2|PXL065 Dose 2
11065074|NCT04321343|Experimental|Group 3|PXL065 Dose 3
11065075|NCT04321343|Placebo Comparator|Group 4|Placebo oral tablet
11065076|NCT04321330|Experimental|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
11065077|NCT04321317|Other|Undernourished Patients|All patients included will be included in the unique arm of the study
11065078|NCT04321304|Sham Comparator|Sham|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial, but stays at 0 mA in the intervening time.
11065079|NCT04321304|Experimental|2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
11065080|NCT04321304|Experimental|4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
11065081|NCT04321291|Experimental|Nurse information|The patient will receive a generic information leaflet plus an Individual information by nurse on biosimilars
11065082|NCT04321291|Other|Information Leaflet|The patient will receive a generic information leaflet only
11065083|NCT04321278|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]
11065084|NCT04321278|Active Comparator|Hydroxychloroquine|Hydroxychloroquine [400mg 2x/day, 12/12h]
11065085|NCT04321252|Experimental|KAE609|Experimental study drug
11065086|NCT04321252|Placebo Comparator|Placebo|Matching Placebo
11065087|NCT04321239|Experimental|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
11065088|NCT04321239|No Intervention|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
11065089|NCT04321226|Experimental|Femtosecond Laser guided Arcuate Keratotomy|Arcuate keratotomy will be performed together with Laser cataract surgery
11065090|NCT04321213||Healthcare professionals in the Region of Västmanland|Healthcare professionals of all professions working in-hospital with patient contact at two hospitals in the Region of Västmanland, Sweden. Data is collected by questionnaires.
11065091|NCT04321213||Healthcare professionals in the Region of Dalarna|Healthcare professionals of all professions working in-hospital with patient contact at three hospitals in the Region of Dalarna, Sweden. Data is collected by questionnaires.
11065092|NCT04321200||Cross-sectional-150 infants (atypical vs typical)|Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
11065093|NCT04321200||Longitudinal cohort - 50 infants (atypical vs typical)|Arm (Study) 2: To discover the features related to long-term motor development. Here we will convert data collected longitudinally from 50 infants, using both instrumented gym and video recordings, into estimates standard clinical tests change over time and track features over developmental timescales.
11065094|NCT04321200||Cross-sectional-1500 infants (atypical vs typical)|Arm (Study) 3: To develop a computer vision-based algorithm to quantify infant motor performance from a single-camera video. Here using video data from 1200 infants, plus those gathered from Arm 1 and Arm 2, we will extract pose data from single-camera video recordings and convert these into kinematic features and relevant scores needed to classify infant movement.
11065095|NCT04321174|Experimental|Lopinavir/ritonavir|This arm will receive oral lopinavir/ritonavir 400/100 mg (or equivalent weight-based dosing) twice daily for 14 days.
11065096|NCT04321174|No Intervention|Control|This arm will receive no intervention.
11065097|NCT04321161|Experimental|AML relapse under DLI and Bicanorm treatment|Analysis of T cell metabolism, immune phenotype and serum pH before and after Bicanorm (Sodium bicarbonate) treatment.
11065098|NCT04321148|Other|standard of care PCI|
11065099|NCT04321148|Experimental|Impella-protected PCI|
11065141|NCT04320888|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
11065369|NCT04319250|Active Comparator|Group 1|Ischemic compression and rehabilitation program applied to the group 1
11065100|NCT04321135|Experimental|Guided Lifestyle Program|The Intervention will be conducted in a cohort of 20 (anticipated) and is designed to increase self-efficacy, social support and perceived access to healthy eating and exercise resources and promote weight loss. Participants assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies. The second hour will be supervised exercise including aerobics and resistance training. The second weekly session will be a one-hour supervised exercise session. Participants will also receive 2-3 text messages weekly.They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.The Guided Lifestyle program is four months long (16 weeks). Please note, the Guided Lifestyle program participants will be offered a booster session off-study.
11065101|NCT04321135|Active Comparator|Self-Guided Lifestyle Program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
11065102|NCT04321122|Experimental|Ultrasound cyclo plasty(UCP)|Ultrasound cyclo plasty treatment for primary open-angle glaucoma patients.
11065103|NCT04321109|Experimental|Collagen cone|Collagen matrix
11065104|NCT04321109|Active Comparator|Allograft|mineralized corticocancellous allograft
11065105|NCT04321096|Placebo Comparator|Placebo|2 pills 3 times daily for 5 days
11065106|NCT04321096|Experimental|Camostat Mesilate|2x100 mg pills 3 times daily for 5 days
11065107|NCT04321083|Experimental|O2 brain (central) measurement|INVOS will be applied simultaneously for monitoring along with the regular polysomnography (sleep lab) workup
11065108|NCT04321070|Experimental|Clindamycin Phosphate|Topical, once daily, for 84 days.
11065109|NCT04321070|Active Comparator|Clindamycin Phosphate RLD|Topical, once daily, for 84 days
11065110|NCT04321070|Placebo Comparator|Vehicle of the test product|Topical, once daily, for 84 days
11065111|NCT04321057||Group questionnaire|Patient's height and weight are asked by questionnaire in this group. It includes patients at the cardiological department of Saarland University.
11065112|NCT04321057||Group male doctor|Patient's height and weight are asked by a male doctor in this group. It includes patients at the cardiological department of Saarland University.
11065113|NCT04321057||Group female doctor|Patient's height and weight are asked by a female doctor in this group. It includes patients at the cardiological department of Saarland University.
11065114|NCT04321057||Group male nurse|Patient's height and weight are asked by a male nurse in this group. It includes patients at the cardiological department of Saarland University.
11065115|NCT04321057||Group female nurse|Patient's height and weight are asked by a female nurse in this group. It includes patients at the cardiological department of Saarland University.
11065116|NCT04321057||Group family doctor|Patient's height and weight are asked by questionnaire in this group. This is the control group,including patients at a family doctor.
11065117|NCT04321044|Other|Renal Denervation|We attempt to identify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch
11065118|NCT04321031|Placebo Comparator|Placebo|participants will receive medication for 48 weeks
11065119|NCT04321031|Experimental|PF-06865571 25 milligrams (mg) twice daily (BID)|participants will receive medication for 48 weeks
11065120|NCT04321031|Experimental|PF-06865571 75 mg BID|participants will receive medication for 48 weeks
11065121|NCT04321031|Experimental|PF-06865571 150 mg BID|participants will receive medication for 48 weeks
11065122|NCT04321031|Experimental|PF-06865571 300 mg BID|participants will receive medication for 48 weeks
11065123|NCT04321031|Experimental|PF-06865571 150 mg once daily (QD) + placebo QD|participants will receive medication for 48 weeks
11065124|NCT04321031|Experimental|PF-06865571 300 mg QD + placebo QD|participants will receive medication for 48 weeks
11065125|NCT04321031|Experimental|PF-06865571 (150 mg BID) + PF-05221304 (5 mg BID)|participants will receive medication for 48 weeks
11065126|NCT04321031|Experimental|PF-06865771 (300 mg BID) + PF-05221304 (10 mg BID)|participants will receive medication for 48 weeks
11065127|NCT04321018|Experimental|Meal with medium chain triglycerdies first|Arm 1: participants randomized to receive the mixed meal with medium chain triglycerides first.
11065128|NCT04321018|Active Comparator|Meal with medium chain triglycerdies second|Arm 2: participants randomized to receive the mixed meal without medium chain triglycerides first.te
11065129|NCT04320992||tested group|
11065130|NCT04320992||controlled group|
11065131|NCT04320979|Experimental|internal mammary nodal irradiation|chest wall and supraclavicular nodal+-axillary plus internal mammary nodal irradiation
11065132|NCT04320979|Active Comparator|no-internal mammary nodal irradiation|ipsilateral chest wall and supraclavicular +-axillary nodal irradiation
11065133|NCT04320966|Experimental|Interventional arm|"Drug: Ferric carboxymaltose
~The intervention includes two doses of 15 mg/kg given (max individual dose 750 mg) at least 7 days apart. The drug is administered as an infusion over 30 minutes."
11065134|NCT04320953|Experimental|Non-contact MCE examination|Study subject in this arm receives non-contact MCE examination.
11065135|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 20mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
11065136|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 40mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
11065137|NCT04320914|Experimental|High Intensity LASER Therapy group (HILT)|Fourty patients with chronic KOA in HILT group will receive Class IV LASER therapy. A Class IV LASER emits power more than 500 mW .
11065138|NCT04320914|Active Comparator|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in IGP group will administered with continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis
11065139|NCT04320901|No Intervention|Harmonic|Endoscopic procedure will be done by Harmonic ACE7+
11065140|NCT04320901|Experimental|Ligasure|Endoscopic procedure will be done by Ligasure
11065142|NCT04320875|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
11065143|NCT04320875|Active Comparator|Conventional Physiotherapy (CPT) group|Individual with KOA will be educated on how to do the set of exercises correctly at their home during the first session. Consisted of nine exercises including muscle strengthening and flexibility training.
11065144|NCT04320862||Duke Health region and beyond|Individuals in the Duke Health region as well as individuals beyond the Duke Health region who have flu-like symptoms, a viral test order for COVID-19, confirmed COVID-19, or concern for exposure to COVID-19.
11065145|NCT04320849||Patients with Biotronik Leads|"Patients with these models: LSiello S, Solia S
~Description: Active Fixation Leads"
11065146|NCT04320849||Patients with Boston Scientific Leads|"Patients with these models: 4452, 4453, 4456, 4457
~Description: FINELINE II/FINELINE II Sterox Passive Fixation (polyurethane)
~Boston Scientific 4463, 4464, 4465, 4469, 4470, 4471 FINELINE II/FINELINE II Sterox EZ Positive Fixation (polyurethane)"
11065147|NCT04320849||Patients with Abbott Leads|"Patients with these models: LDA 210Q
~Description: Optisure Single Coil Defibrillation Lead"
11065148|NCT04320849||Patients with Medtronic Leads|"Patients with these model: 6935M
~Description:Quattro Secure Single Coil Defibrillation Lead"
11065149|NCT04320836||Cervical epidural steroid injection|This group will receive an interlaminar cervical ESI at C6-7 or C7-T1 with 1 mL steroid (depo-methylprednisolone 40 mg at Johns Hopkins and the DC VA Hospital or dexamethasone 10 mg at Seoul National University) and 2 mL normal saline.
11065150|NCT04320810||mNGS diagnosis|Using mNGS to diagnosis infectious disease of this group
11065151|NCT04320797||Active lupus nephritis|Patients with proliferative lupus nephritis (Class III and IV)
11065152|NCT04320797||Control|Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI
11065153|NCT04320784|Experimental|Time restricted eating (TRE)|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
11065154|NCT04320784|Active Comparator|Control (CTRL)|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
11065155|NCT04320771|Experimental|Neladenoson bialanate, mild renal impairment|Subjects with eGFR ≥60 - <90 mL/min/1.73 received a single immediate-release (IR) tablet dose of 10 mg of neladenoson bialanate in the fasted state
11065156|NCT04320771|Experimental|Neladenoson bialanate, moderate renal impairment|Subjects with eGFR ≥30 - <60 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
11065157|NCT04320771|Experimental|Neladenoson bialanate, severe renal impairment|Subjects with eGFR <30 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
11065158|NCT04320771|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
11065159|NCT04320758|Experimental|single crown in dental aesthetic zone|teeth in dental aesthetic zone
11065160|NCT04320758|Experimental|teeth need single crown in dental aesthetic zone|teeth in dental aesthetic zone
11065161|NCT04320745|Experimental|Androderm®|All participants to receive standard dose of Androderm of 4 mg/day applied nightly on Visit 1. At Visit 2 testosterone concentration will be measured.
11065162|NCT04320732||Individuals with COVID-19 infection|"Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included.
~Only subjects >18 years old will be included in the study."
11065163|NCT04320732||Individuals tested for COVID-19 infection with negative test|Confirmed by routine laboratory diagnosis
11065164|NCT04320732||Healthy individuals|Recruitet from the general population
11065165|NCT04320732||Risk groups for COVID-19 exposure|Including, but not limited to healthcare workers.
11065166|NCT04320732||Patients admitted to hospital|Without COVID-19 infection.
11065167|NCT04320706|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
11065168|NCT04320706|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
11065169|NCT04320680|Other|lupus cohort follow up|it is a descrption lupus patients study
11065170|NCT04320667||Active ANCA glomerulonephritis|Patients with ANCA related disease (Microscopic Polyangiitis, Granulomatosis with Polyangiitis or Churg-Strauss Syndrome) and active renal involvement
11065171|NCT04320667||Control|Patients with ANCA related disease (MPA, GPA, CSS) without renal involvement or complete remission
11065172|NCT04320654|Experimental|advice of staying active|The patients will be advised to stay as physically active as possible and continue their everyday activities as normally as possible.
11065173|NCT04320654|Experimental|walking program|Patients will be encouraged to go about their normal daily activities. At week one, patients will be asked to familiarize themselves with wearing the pedometer and recording their daily steps in a walking diary for the subsequent 7 days. The patients will return to see the physiotherapist at the end of week one to discuss any issues with the program, pedometer or recording of desired information. A step target for week two will be agreed between the physiotherapist and the patient by referring to the mean daily step count recorded at baseline, and the average step count calculated from the walking diary
11065174|NCT04320654|Experimental|Backward walking|All patients will be instructed to walk at their desired pace 3 days per week with a steady rhythm. The duration of each training session will initially be 15 minutes and will gradually increase, and finally reach 25 minutes, for every session (Hao Chen, 2011). There will be no constraint or indication about head and trunk position during backward training
11065175|NCT04320654|Experimental|Targeted home-based hip exercise|Patients who will be assigned in this group will perform a hip exercise program for six weeks, three times / week to ensure an adequate recovery between exercise sessions (appendix V). The strengthening exercises will focus on strengthening the gluteus maximus (GMax), gluteus medius (GMed), gluteus minimus (GMin) and short hip external rotator muscles (Distefano et al., 2009).
11065176|NCT04320654|No Intervention|control group|The patients will not be given any intervention and will be asked to come after 6 weeks for re-assessment
11065177|NCT04320641|Experimental|acupressure|
11065178|NCT04320641|Experimental|music|
11065180|NCT04320628|Experimental|Experimental|Target ulcer cleansed with NaOCl. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NaOCl.
11065181|NCT04320628|Placebo Comparator|Control|Target ulcer cleansed with NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NSS.
11065182|NCT04320615|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
11065183|NCT04320615|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
11065184|NCT04320602|Experimental|Ravulizumab|Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
11065185|NCT04320589|Active Comparator|General Anesthesia|Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
11065186|NCT04320589|Active Comparator|Dexmedetomidine|Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
11065187|NCT04320576|Experimental|Bulk-fill resin composite|Bulk-fill resin composite will be places with bulk technique.
11065188|NCT04320576|Active Comparator|Nano-fill resin composite|Nano-fill resin composite will be placed with 2 mm thickness layering technique.
11065189|NCT04320563|Active Comparator|Full power treatment 4|These group of participants will receive the full power treatment 4
11065190|NCT04320563|Placebo Comparator|Comparative Power 1|These group of participants will receive the comparative power 1 treatment
11065191|NCT04320550||abdominal pain|one group of children complaining of recurrent abdominal pain
11065192|NCT04320537||MJ user|non-treatment-seeking chronic heavy marijuana (MJ) users of both sexes and all ethnicities between the ages of 21-40 years who are willing to follow the study protocol and abstinence from marijuana for three weeks
11065193|NCT04320537||Control|age- and sex-matched healthy control participants who are willing to follow the study protocol and remain in the study for three weeks
11065194|NCT04320524|Experimental|All subjects|
11065195|NCT04320511||Patients with SARS-COV 2|Patients with SARS-COV 2 undergoing CT-V
11065196|NCT04320498|Active Comparator|control group|The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)
11065197|NCT04320498|Experimental|PRP group|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
11065198|NCT04320472||Follow up|Follow up of all included patients up to 3 months after enrollement
11065199|NCT04320459||ankylosing spondylitis|55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic
11065200|NCT04320459||healthy control|age and sex matched healthy controls
11065201|NCT04320446|Experimental|Caffeine|A dose of 3 mg/kg of caffeine (i.e. a vegetable extraction from green coffee beans, Harrison Sport Nutrition®, Spain) was ingested before the beginning of each test.
11065202|NCT04320446|Placebo Comparator|Placebo|A dose of 3 mg/kg of placebo (i.e. 100% purity microcrystalline cellulose, Acofarma, Spain) was ingested before the beginning of each test.
11065203|NCT04320433|Experimental|Experimental|Participants will undergo two trials visit (with a week of separation). During the visits they will ingest an oral glucose load solution (oral glucose tolerance test) and gas exchange will be measured over the following 3-hours. The glucose levels will be monitored through a Glucose meter in different time frames.
11065204|NCT04320420|Experimental|Experimental arm|"The APA program is defined in 3 stages:
~STEP 1: during the initial chemotherapy over 3 months
~3 supervised APA sessions/week on site:
~two muscle strengthening sessions, stretching, flexibility in the gym
~a cardio session (Nordic Walking: outdoors)
~at home: exercise book if the patient wishes
~STEP 2: during hospitalization for the autograft, over 1 month:
~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work
~If the patient wishes, he can continue the exercises carried out with the APA engineer independently
~STEP 3: after the transplant
~the first 3 months:
~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),
~1-hour cardio session/week independently
~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
11065205|NCT04320407|Experimental|Osia 2 System|Osia 2 Active Osseointegrated Implant System for Bone Conduction
11065206|NCT04320394|Other|Septic shock patients|Patients with septic shock will be taken from an additional tube to analyze their immune response
11065207|NCT04320381||Group A|subjects in the hypertonic saline study randomized to discontinue or maintain therapy
11065208|NCT04320381||Group B|subjects in the dornase alfa study randomized to discontinue or maintain therapy
11065209|NCT04320381||Group C|subjects who were randomized but withdrew early from the SIMPLIFY Study.
11065210|NCT04320381||Group D|subjects in the hypertonic saline study randomized to discontinue or maintain therapy with FEV1% predicted between 40 and <60%
11065211|NCT04320381||Group E|caregiver participants (parents and legal guardians of eligible patient participants less than 18 years of age who were randomized in the SIMPLIFY study)
11065212|NCT04320368||Alzheimer's disease cohort|"40-100 years old (≥ 40 years old, ≤ 100 years old)
~cognitive impairment: Alzheimer's questionnaire >4 and MMSE<22
~informed consent is signed by the patient or his family members"
11065335|NCT04319484|Experimental|lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
11065213|NCT04320368||Vascular cognitive impairment cohort|"40-100 years old (≥ 40 years old, ≤ 100 years old)
~acute cerebral infarction is first diagnosed according to WHO criteria 1
~the time from onset to hospital ≤7 days
~informed consent is signed by the patient or his family members"
11065214|NCT04320368||A cohort of people with normal cognitive function|"40-100 years old (≥ 40 years old, ≤ 100 years old), without cognitive impairment, Alzheimer's questionnaire ≤4 and MMSE≥22
~informed consent is signed by the patient"
11065215|NCT04320355|Experimental|Soft tissue manual therapy|The researcher student will place the gloves with the force sensor on the thumb of her right and left hand. She will evaluate the Caesarean section scar and identify the most rigid scar areas when compression is applied. On these identified areas, the researcher student will apply the manual therapy procedure described in the independent variable (compression + shear) section. This procedure will be applied to all identified rigid areas of the Caesarean section scar.This procedure will last 10 minutes (approximately 2 minutes per rigid area). After this time, the researcher-student will remove the force sensor and leave the room.
11065216|NCT04320342|Experimental|BDP/FF/GB - CHF 5993|Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler
11065217|NCT04320342|Active Comparator|BDP/FF - CHF 1535|Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler
11065218|NCT04320316|Experimental|Crysvita (burosumab-twza) Treatment|"The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.
~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.
~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension."
11065219|NCT04320303|Experimental|adaptive NK cells infusion post transplantation|Adaptive donors expanded NK cells infusion at day 20±3d and 27±3d post transplantation
11065220|NCT04320290|Experimental|Treatment with Direct Acting Antiviral for HCV|8 weeks of treatment with HCV Direct Acting Antiviral tablet
11065221|NCT04320277|Experimental|Patients|All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.
11065222|NCT04320277|Active Comparator|Controls|All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.
11065223|NCT04320264|Active Comparator|Low oxidizers|
11065224|NCT04320264|Placebo Comparator|High oxidizers|
11065225|NCT04320251|Experimental|1|The single observational cohort
11065226|NCT04320238|Experimental|low-risk group|medical staff work in non-isolated general wards or laboratories, not directly contact with COVID-19 patients.
11065227|NCT04320238|Experimental|high-risk group|doctors and nurses work in isolated ward, directly contact with COVID-19 patients.
11065228|NCT04320225||Lower vitamin D level group|The vitamin D level is lower than 20 nmol/L.
11065229|NCT04320225||Higher vitamin D level group|The vitamin D level is higher than 20 nmol/L.
11065230|NCT04320212|Active Comparator|lumber epidural analgesia|: the patient will be placed in the lateral position, Lidocaine will be given using 5 ml syringe and a 18 G Tuohy needle will be introduced in the epidural space, using the ultrasound, under strict aseptic precautions. The ultrasound probe will be placed 90 degrees into transverse orientation and slided cephalad or caudad to obtain the transverse interspinous view (TI view) 2 levels above the operation level. patient will receive 20 ml of 0.25% plain bupivacaine after negative aspiration for blood or cerebrospinal fluid. Then, the patient will be placed in prone position to start the surgical procedure
11065231|NCT04320212|Active Comparator|erector spinae analgesia|the patient will be placed in the prone position. Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer. The Erector Spinae muscle and transverse process will be then identified, and a 18 G Tuohy needle will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side)
11065232|NCT04320199|Experimental|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
11065233|NCT04320199|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
11065234|NCT04320186|Active Comparator|Treatment|Participants viewed informational video content plus entertainment content
11065235|NCT04320186|Placebo Comparator|Control|Participants viewed entertainment content only
11065236|NCT04320173|Experimental|Lidocaine Patch (Sequence ABC)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied in Period 1, and 3 lidocaine 5% patches were applied in Period 2, and 3 lidocaine 5% medicated plasters were applied in Period 3.
11065237|NCT04320173|Experimental|Lidocaine Patch (Sequence CAB)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 2, 3 lidocaine 5% medicated plasters were applied in Period 1, and 3 lidocaine 1.8% patches were applied in Period 2, and 3 lidocaine 5% patches were applied in Period 3.
11065238|NCT04320173|Experimental|Lidocaine Patch (Sequences BCA)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 3, 3 lidocaine 5% patches were applied in Period 1, and 3 lidocaine 5% medicated plasters were applied in Period 2, and 3 lidocaine 1.8% patches were applied in Period 3.
11065239|NCT04320160|No Intervention|Positive control group|Include the thirty patients before any treatment
11065240|NCT04320160|Active Comparator|PRP group|Include fifteen patients that will recieve PRP sessions .Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
11065336|NCT04319484|Placebo Comparator|Placebo|The placebo pills are made identical to the investigating lenvatinib in appearance
11065241|NCT04320160|Active Comparator|Fractional CO2 group|Include fifteen patients that will recieve FR: CO2 laser sessions.Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
11065242|NCT04320147|Experimental|MRI tartget biopsy|"MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
~Next conventional ultrasound-guided 12-core systematic biopsy would be performed by urologist. This portion will be performed without information of the MRI report."
11065243|NCT04320121|Experimental|Nelutri™ group|This group takes Nelutri™ for 12 weeks
11065244|NCT04320121|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
11065245|NCT04320108|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
11065246|NCT04320108|Sham Comparator|Control group|Sham therapy
11065247|NCT04320095|Experimental|Bizact device for one tonsil|Bizact tonsillecotmy device which is an advanced bipolar device using radiofrequency and pressure to ligate the encountered vessels during tonsillectomy.
11065248|NCT04320095|Active Comparator|Electrocautery for second tonsil|Electrocautery is the standard technique used at our institution.
11065249|NCT04320095|Experimental|Bizact device for both tonsils|Consecutive cases of tonsillectomy will be done using Bizact device and compare the operative time collectively for those cases and compare it to same number of cases done using the standard procedure ( Electrocautery)
11065250|NCT04320095|Active Comparator|Electrocautery for both tonsils|As explained on the above arm description
11065251|NCT04320082||Elderly cohort|Patients >70 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
11065252|NCT04320082||Young cohort|Patients between 18 and 30 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
11065253|NCT04320069|Experimental|Single|All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days.
11065254|NCT04320056|Active Comparator|Control group|"Usual care will be provide to patients concerning their medical management.
~In the Control Group usual, oxygen will be delivered as per usual local practices"
11065255|NCT04320056|Experimental|Intervention group|"Usual care will be provide to patients concerning their medical management.
~In the Intervention group, automated oxygen administration will be delivered with FreeO2"
11065256|NCT04320043||Anterior cervical decompression surgery|Adult patients who underwent anterior cervical decompression surgery for radiculopathy and/or myelopathy due to cervical degenerative disc disease. Patients underwent one of the following interventions: ACD, ACDF, ACDF with plating or corpectomy.
11065257|NCT04320030|Experimental|[18F]-DPA-714|pretherapeutic [18F]-DPA-714 PET/CT scan
11065258|NCT04320017||COVID-19 patients|Patients diagnosed with COVID-19 by PCR done on nasal sample.
11065259|NCT04320004|No Intervention|Baseline|"Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a silent best practice alert (BPA) in these clinics. This Silent BPA is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list."
11065260|NCT04320004|Active Comparator|Education Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.
11065261|NCT04320004|Active Comparator|Education Intervention with Reminder|This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
11065262|NCT04320004|Active Comparator|Education + Disposal Bag Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.
11065263|NCT04320004|Active Comparator|Education + Disposal Bag Intervention with Reminder|This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
11065264|NCT04319991|Placebo Comparator|Placebo|
11065265|NCT04319991|Experimental|Probiotics product|
11065266|NCT04319978|Active Comparator|Group A|Group A will receive single dose of dexamethasone IM 8mg 1 hour pre-operatively.
11065267|NCT04319978|Active Comparator|Group B|Group B will receive a single dose of dexamethasone IM 8mg immediately after surgery.
11065268|NCT04319939||Participants receiving mechanical ventilation|
11065370|NCT04319250|Active Comparator|Group 2|IASTM and rehabilitation program applied to the group 2
11065269|NCT04319926|Experimental|Lidocaine Patch (Sequence T1T2)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
11065270|NCT04319926|Experimental|Lidocaine Patch (Sequence T2T1)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.
11065271|NCT04319913|Experimental|ANI-guided|ANI-guided narcotics use to maintain ANI value between 50 to 70
11065272|NCT04319913|No Intervention|Control|narcotics use guided by clinical experience, ANI is still recorded but would be covered up intraoperatively
11065273|NCT04319900|Experimental|favipiravir tablets+chloroquine phosphatetablets tablets group|favipiravir tablets+chloroquine phosphatetablets tablets
11065274|NCT04319900|Experimental|favipiravir tablets group|favipiravir tablets
11065275|NCT04319900|Placebo Comparator|placebo treatment group|placebo
11065276|NCT04319874|Sham Comparator|sham group|Treated with conventional chemotherapy drugs
11065277|NCT04319874|Placebo Comparator|NC group|Treated with conventional chemotherapy drugs and Placebo
11065278|NCT04319874|Experimental|experimental group|Treated with conventional chemotherapy drugs and Ganoderma lucidum
11065279|NCT04319861|Experimental|Anal fistula plug|The anal fistula plug procedure was performed as followings. A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
11065280|NCT04319848|Experimental|TE-EK treatment group|The TE-EK surgery will be performed by the Principle Investigator with a standard DSAEK technique. The PI has performed over 300, EK surgeries and we have previously shown that the corneal endothelial loss rates from the PI are 16% at 1 year with a primary graft failure rates of <1.5%. A patient's participation in the study or not will not change the treatment strategy in any manner.
11065281|NCT04319835|Experimental|Microdialysis catheter|Surface Microdialysis catheter will be placed onto the surgical reconstruction after esophagectomy and will be evaluated for clinical safety and performance. The metabolic profile as measured by Microdialysis will be correlated to the clinical outcome. No interventions based on the results will be performed.
11065282|NCT04319822|Experimental|blood samples, muscular biopsy, and quality of life|quality of life, blood samples, quadriceps biopsy in intensive care unit (before and after the ICU hospitalization and one at M6
11065283|NCT04319809|Experimental|Device feasibility|To investigate the utility of a device adaptation allowing Argus II users to detect the presence and location of desired objects. Performance of the unaided Argus II system will be compared with performance using the system augmented with object recognition.
11065284|NCT04319796||Ataxia & HSP|Patients suffering of Ataxia or HSP or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these Rare Neurological Disease (RND).
11065285|NCT04319796||Leukodystrophies|Patients suffering of Leukodystrophies or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
11065286|NCT04319796||Frontotemporal Dementia|Patients suffering of Frontotemporal Dementia or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
11065287|NCT04319796||Dystonia, Paroxysmal Disorders and Neurodegeneration with|Patients suffering of Dystonia, Paroxysmal Disorders and Neurodegeneration with Brain Iron Accumulation (NBIA) or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
11065288|NCT04319796||Atypical Parkinsonism|Patients suffering of Atypical Parkinsonism or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
11065289|NCT04319796||Huntington's Disease & Choreas|Patients suffering of Huntington's Disease or Choreas or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
11065290|NCT04319783|Experimental|Darolutamide|Darolutimide 600mg BD
11065291|NCT04319783|Experimental|Local consolidation Radiotherapy + Darolutamide|Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease
11065292|NCT04319770|Active Comparator|periodontal regenerative surgery + EMD (control)|periodontal regenerative surgery with enamel matrix derivative
11065293|NCT04319770|Experimental|periodontal regenerative surgery + HA (test)|periodontal regenerative surgery with hyaluronic acid
11065294|NCT04319757|Experimental|ACE1702 Dose Level 1|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.
~Dose Level: 1 Planned number of subjects: 1 to 6"
11065295|NCT04319757|Experimental|ACE1702 Dose Level 2|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 2 Planned number of subjects: 1 to 6"
11065296|NCT04319757|Experimental|ACE1702 Dose Level 3|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 3 Planned number of subjects: 3 to 6"
11065297|NCT04319757|Experimental|ACE1702 Dose Level 4|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: 4 Planned number of subjects: 3 to 6"
11065371|NCT04319237||All Participants|
11065298|NCT04319757|Experimental|Exploratory: HER2-positive Breast/ Gastric Cancer|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2 IHC 3+ (HER2-positive), breast or gastric cancer.
~Dose Level: established MTD/MAD Planned number of subjects: 3"
11065299|NCT04319757|Experimental|Exploratory: HER2-expressing Endometrial Cancer|"Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing, endometrial cancer. HER2 expressing is defined has having HER2 IHC 2+ or above.
~Dose Level: established MTD/MAD Planned number of subjects: 3"
11065300|NCT04319744||Assistants who have a habit of playing video|"Group I:Anesthesia assistants who have a habit of playing video games before Video game will be played for 5 days a day with 0.5 hours mobile phone (Pubg mobile) for those who have previous game experience.
~Intubation training will be provided with video style.Within the scope of this training, 1-All participants will watch videos about Video style application.
~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first
~4-Responsible investigators will practice and show on the real patient.
~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.
~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
11065301|NCT04319744||Assistants who do not have the habit of playing video|"Group II:Anesthesia assistants who do not have the habit of playing video games No video game will be played before intubation with video style for this group.
~Intubation training will be provided with video style. Within the scope of this training, 1-All participants will watch videos about Video style application.
~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first
~4-Responsible investigators will practice and show on the real patient.
~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.
~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
11065302|NCT04319731|Experimental|Treatment|"Treatment groups:
~1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)"
11065303|NCT04319718|Active Comparator|High Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)."
11065304|NCT04319718|Active Comparator|Low Eudragit MK-2048 vaginal film|"Single use of 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)."
11065305|NCT04319705|Experimental|Azithromycin|Azithromycin, 500mg capsule, 3 times per week, during a 12-week period, administered orally
11065306|NCT04319705|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP, capsule, 3 times per week, during a 12-week period, administered orally
11065307|NCT04319692|Experimental|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks.
11065308|NCT04319692|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
11065309|NCT04319679|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
11065310|NCT04319679|Sham Comparator|Control group|Sham therapy
11065311|NCT04319666|Experimental|PCI to left main with IVL|
11065312|NCT04319653|Experimental|Dynamic pelvic MRI|
11065313|NCT04319640|Experimental|CBTI|N= 80 participants are offered Cognitive behaviour therapy for insomnia (CBT-I)
11065314|NCT04319640|Active Comparator|psychoeducation|N= 80 participants are offered psychoeducation about information on ASD
11065315|NCT04319627|Experimental|Rosuvastatin|Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.
11065316|NCT04319627|Placebo Comparator|Placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
11065317|NCT04319614|Experimental|Tranexamic acid|
11065318|NCT04319614|Placebo Comparator|Saline|
11065319|NCT04319601|Experimental|rituximab combined with chidamde and lenalidomide|rituximab and chidamide, lenalidomide
11065320|NCT04319588|Experimental|Parasternal Group|"The parasternal group of patients will receive the pre-operative parasternal block (20 ml of 0.5% Ropivacaine per side) in association with infiltration with local anesthetic of access to thoracic drainage (drainage infiltration with 20 ml of 0.25% Ropivacaine) at the end of the intervention combined to General Anesthesia."
11065321|NCT04319588|Active Comparator|Case control group|"The case control group will only receive drainage infiltration with local anesthetic and standard intraoperative management with opioids."
11065322|NCT04319575|Experimental|Chitosan calcium hyroxide paste|after the access preparation and cleaning and shaping, chitosan calcium hydroxide paste will be placed in the canal and kept for 4 weeks.
11065323|NCT04319575|Active Comparator|triple antibiotic paste|after the access preparation and cleaning and shaping, ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.
11065324|NCT04319562|Experimental|needle-embedding therapy|The participants in this group will be treated with intradermal thumbtack needle.
11065325|NCT04319562|Sham Comparator|shame needle-embedding therapy|The participants in this group will be treated with shame intradermal thumbtack needle.
11065326|NCT04319549|Experimental|group 1 ketorolac tromethamine irrigant|group 1 patients with acute irreversible pulpitis with apical periodontitis
11065327|NCT04319549|Active Comparator|group 2 sodium hypochlorite irrigant|group 2 patients with acute irreversible pulpitis with apical periodontitis
11065328|NCT04319536||Healthy individuals|
11065329|NCT04319523||COPD patients|
11065330|NCT04319523||Healthy subjects|
11065331|NCT04319510|Experimental|Craniosacral therapy|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
11065332|NCT04319510|Experimental|Craniosacral self-help group training|24 CST units à 45 minutes over 12 weeks. Follow-up assessment 6 months after randomization.
11065333|NCT04319510|Other|Treatment as usual / wait list control|Waiting period of six months.
11065334|NCT04319497|Other|Refraction reproducibility and agreement|Subjective and objective refraction will be performed in all patients
11065462|NCT04318470||PPROM|Preterm premature rupture of membranes between 16 0/7 and 33 6/7 weeks gestation
11065337|NCT04319471|Experimental|Sufficient Chemotherapy Combine With Maintenance Chemotherapy|Patients with oligometastatic Nasopharyngeal Carcinoma was given S-1 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving sufficient chemotherapy and consolidative local therapy
11065338|NCT04319458|Experimental|Fotonovela|Fotonovela mental health literacy intervention: Secret Feelings/Sentimientos Secretos
11065339|NCT04319458|Active Comparator|Control|Control mental health literacy intervention: NIH publication - Depression: What You Need to Know
11065340|NCT04319445|Experimental|Migraine Patients/Providers/Faculty/Staff/Other|
11065341|NCT04319432|Experimental|3 days voice rest|
11065342|NCT04319432|Experimental|7 days voice rest|
11065343|NCT04319419|Experimental|Supplement with micronutrients|Nutrition education with a supplement
11065344|NCT04319419|Experimental|Nutrition education|Group received only nutrition education
11065345|NCT04319406|Experimental|PROLOTHERAPY|Prolotherapy will be performed with 12.5 % Dextrose into superior joint space of involved TMJ
11065346|NCT04319406|Active Comparator|DRY NEEDLING|Dry needling will be performed into superior joint space of involved TMJ
11065347|NCT04319393|Experimental|CBT Nurses|Interventional group
11065348|NCT04319393|No Intervention|Consultation Nurses|Control Group
11065349|NCT04319380|Active Comparator|SMC with SP+AQ|Administration of tetanus/diphtheria toxoids vaccine followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
11065350|NCT04319380|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1 and 2.
11065351|NCT04319380|Active Comparator|RTS,S/AS01 plus SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1 and 2.
11065352|NCT04319367|Active Comparator|Arm A|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion followed by intensively monitored Antiretroviral Treatment Interruption (ATI)
11065353|NCT04319367|Placebo Comparator|Arm B|ART plus placebo infusion followed by an ATI (control arm). On re-starting ART, participants will receive immediate dual LS bNAbs and then a second ATI 24 weeks after bNAb infusion.
11065354|NCT04319354|Experimental|pCR|
11065355|NCT04319354|Experimental|Partial responders|
11065356|NCT04319354|Active Comparator|Non-responders|
11065357|NCT04319328||Cefazolin|n = 20
11065358|NCT04319328||Ceftazidime|n = 20
11065359|NCT04319328||Ciprofloxacin|n = 20
11065360|NCT04319302||Paediatric biliary obstruction|This was a retrospective review of all paediatric patients who had undergone an IVGT graft procedure for biliary tract anatomical obstruction in the past five years. We looked at the indications for surgery, the demographic profile of the patients, outcomes following surgery and outlined the surgical technique used.
11065361|NCT04319289|Experimental|Group (A)|"Included 15 patients who are participating in an aerobic interval training exercise program with vitamin D supplementation (cholecalciferol 400 IU/day).
~The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks."
11065362|NCT04319289|Experimental|Group (B)|Included 15 patients who are receiving vitamin D supplementation only . One capsule containing (cholecalciferol 400 IU) was taken every day for 12 weeks
11065363|NCT04319289|Experimental|Group (c)|Included 15 patients who are participating in an aerobic interval training exercise program only. The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks.
11065364|NCT04319276|Experimental|Dose-escalation Phase (500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
11065365|NCT04319276|Experimental|Dose-escalation Phase (1,000 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
11065366|NCT04319276|Experimental|Dose-escalation Phase (1,500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
11065367|NCT04319276|Experimental|Dose-expansion Phase|A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
11065368|NCT04319263|Experimental|intermediate and high risk non muscle invasive bladder cancer|
11065372|NCT04319224|Experimental|Vopratelimab|Participants will continue to receive vopratelimab monotherapy per parent protocol.
11065373|NCT04319224|Experimental|Vopratelimab with ipilimumab|Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.
11065374|NCT04319224|Experimental|Vopratelimab with nivolumab|Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.
11065375|NCT04319211||People who isolate at home with the danger of coronavirus|Demographic data of the individuals participating in the study will be recorded. International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
11065376|NCT04319198|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan is a Trop-2-directed Antibody Drug Conjugate where the antibody, hRS7, is attached to SN-38. SN-38 is the active metabolite of irinotecan (CPT-11).
11065377|NCT04319185|Experimental|Intervention|All patients who qualify for the study will receive the intervention
11065378|NCT04319159|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).
~One single Photodynamic therapy (PDT)."
11065379|NCT04319146|Other|robot-assisted radical prostatectomy|patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis
11065380|NCT04319133|Experimental|intervention|Participants will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
11065381|NCT04319133|No Intervention|control|Participants will not doing fasting or intake restriction within 8 weeks
11065382|NCT04319120||questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed.
11065383|NCT04319107||Marfan Syndrome (MFS) patients|Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.
11065384|NCT04319107||Control patients|Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.
11065385|NCT04319094|Experimental|PEERS|Peer mentors who have experience of depression are trained and supervised to deliver depression care. Peers will meet with depressed older adults for 8 weekly meeting lasting approximately 45 minutes. Peer mentors will provide social support defined as emotional, informational and appraisal support that includes coping strategies. Peers will be supervised by a mental health professional.
11065386|NCT04319094|Active Comparator|Social interaction|A study staff member will provide eight weekly social interaction visits and phone calls to the depressed older adult.
11065387|NCT04319081||Uncontrolled patients with hypercholesterolemia|Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab
11065388|NCT04319068||Healthy|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years.
11065389|NCT04319068||Hypertensive|Eligible participants from the Biobank cohort at the National Heart Centre, Singapore, will be screened will be recruited for the study over a period of 3 years
11065390|NCT04319042|Active Comparator|Immediate Loading|Group A. The implant receives an artificial tooth the same day as it is placed.
11065391|NCT04319042|Active Comparator|Early Loading|Group B. The implant receives an artificial tooth 4 weeks after placement.
11065392|NCT04319029|No Intervention|Non-intervention|Patients received a conventional pharmaceutical care plan, the patients offered optimal pharmacological therapy wit statin.
11065393|NCT04319029|Active Comparator|Intervention|The Patients offered to predesign pharmaceutical care plans aimed to improved patient's knowledge, adherence, satisfaction, and quality of life. The patients offered optimal pharmacological therapy wit statin.
11065394|NCT04319003|No Intervention|Control School|This school did not receive intervention (until after the study was completed)
11065395|NCT04319003|Experimental|Intervention School|This school received a one-week sugar-reduction intervention
11065396|NCT04318990|Experimental|Distal radial artery access|Wrist rests on a comfortable underground which brings the wrist in passive ulnar flexion. Patient is asked to bring the thumb under the other four fingers. After disinfection, patient is covered with a sterile drape. Brachial drape is applied to the hand exposing the anatomical snuff box and the proximal radial. Under ultrasound guidance, local anesthesia applied by SC injection of 5cc of lidocaine filling the radial fossa. Puncture performed at the point of maximal pulsation proximal in the anatomical snuffbox. If fails, a puncture more distal, can be attempted. After successful anterior wall puncture a radial sheath wire is advanced. Proper position verified by fluoroscopy or by ultrasound to ensure the wire didn't traverse the palmar arch, followed by introduction of a hydrophilic sheath. After administration of a spasmolytic cocktail containing 200-400 mcg of nitroglycerin and 5 mg of verapamil, the operator can take up a position at the level of the patient's knees.
11065397|NCT04318990|Active Comparator|Proximal radial artery access|Half of the patients enrolled in the study undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized proximal radial access for cardiac catheterization.
11065398|NCT04318977|Experimental|high-frequency repetitive transcranial magnetic stimulation|repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex using 3000 pulses applied with 10Hz and 120% resting motor threshold
11065399|NCT04318977|Experimental|theta burst stimulation|intermittent theta burst stimulation over left dorsolateral prefrontal cortex using 600 pulses applied in trains of 10 triplets/bursts (50Hz) with 8s intertrain-interval and 120% resting motor threshold
11065400|NCT04318977|Placebo Comparator|sham rTMS|half of the patients with high-frequency repetitive transcranial magnetic stimulation and half of the patients with theta burst Stimulation with angled coil (45 degree) or sham coil
11065463|NCT04318470||Healthy controls|Gestational-age-matched controls without preterm premature rupture of membranes or other pregnancy complications
11065542|NCT04317989|Experimental|Practice Facilitation (top 50th percentile)|Practices with performance in the upper 50th percentile will receive practice facilitation for the duration of the intervention period.
11065401|NCT04318964|Experimental|TAEST16001 cells treat tumor antigen NY-ESO-1|"The dose escalation was carried out according to the principle of 3 + 3 increase. Four dose levels (calculated by the number of tcr-t positive cells) were set up: the dose level was 1: 5 × 108 ± 30%; the dose level was 2: 2 × 109 ± 30%; the dose level was 3: 5 × 109 ± 30%; the dose level was 4: 1.2 × 1010 ± 30%. Three patients in the first group, if there is no DLT, they will be enrolled in the next higher dose group; if one of the three patients in a certain dose group has DLT, three patients in the group will be supplemented with the same dose and method. If DLT occurred in 1 or more of the 3 cases, the dose increase was stopped. The former dose was defined as MTD; if DLT did not occur in 3 cases, the dose increased to the next group. Dose escalation is not allowed for the same patient."
11065402|NCT04318951|Experimental|Intensive communicative-pragmatic social interaction|Intensive Language-Action Therapy (ILAT).
11065403|NCT04318951|Other|Standard care|All participants will receive standard care.
11065404|NCT04318938|Active Comparator|Standard Arm with any available ALK TKI|"st line: Any approved 2nd-generation TKI according to investigator's choice
~nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)"
11065405|NCT04318938|Experimental|Experimental Arm with Brigatinib|"st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8
~nd line: Any available ALK TKI according to investigator's choice"
11065406|NCT04318925||1|Persons with diagnosed or suspected tick-borne disease age >=18 years
11065407|NCT04318912||COPD patients|Adults age 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) having been prescribed any COPD treatment (initial or subsequent) outside of a clinical trial.
11065408|NCT04318899|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.
11065409|NCT04318886|No Intervention|Usual Care|
11065410|NCT04318886|Experimental|Project ENABLE Cornerstone|
11065411|NCT04318873|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
11065412|NCT04318873|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
11065413|NCT04318847|Experimental|Ondransetron|Administration of ondansetron
11065414|NCT04318847|No Intervention|Habitual Clinical Practice|Habitual Clinical Practice
11065415|NCT04318834|Experimental|Individuals with advanced biliary tract cancer|Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
11065416|NCT04318821|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), PC6 (Neiguan, B3), ST25 (Tianshu, B3), ST36 (Zusanli, B2), CV4 (Guanyuan), CV12 (Zhongwan, B3).
11065417|NCT04318821|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
11065418|NCT04318808|Experimental|LA group|The subjects in the experimental group will receive 0.375 J of energy at each of the following acupoints: LI4 (Hegu, B3), LI11 (Quchi, B2), PC6 (Neiguan, B3), ST36 (Zusanli, B2), ST37 (Shangjuxu, B2), ST39 (Xiajuxu, B2), SP4 (Gongsun, B3) , SP9 (Yinlingquan, B2).
11065419|NCT04318808|Sham Comparator|Control group|The subjects in the control group will receive sham LA treatment, without any laser output (no stimulation) at the same acupoints used in experimental group.
11065420|NCT04318795|Experimental|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
11065421|NCT04318795|Experimental|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
11065422|NCT04318782|Experimental|Thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
11065423|NCT04318769|Experimental|AFFIRM|AFFIRM is an 8-session psychoeducational weekly group intervention
11065424|NCT04318769|No Intervention|Waitlisted control|Waitlisted control
11065425|NCT04318756||Italian patients suffering from mucinous neoplasms|Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
11065426|NCT04318756||Italian patients with familiarity/genetic predisposition|Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
11065427|NCT04318743|Experimental|autoinjector - vial/syringe - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
11065428|NCT04318743|Experimental|vial/syringe - autoinjector - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
11065429|NCT04318743|Experimental|vial/syringe - vial/syringe - autoinjector|Single dose of Glepaglutide 10 mg for each treatment sequence
11065430|NCT04318730|Experimental|Arm 1|
11065504|NCT04318236|Experimental|Online-Program + no factor|"In this arm no factor is set to active (i.e. yes):"
11065628|NCT04317417|Experimental|Condition 8|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11097210|NCT04095910|No Intervention|Control Group|Normal curricular classes
11065431|NCT04318717|Experimental|Pembrolizumab + Hypofractionated radiation therapy|"Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).
~Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy."
11065432|NCT04318704|Other|Single Arm Active|Ifenprodil
11065433|NCT04318691||acute respiratory failure group|60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure
11065434|NCT04318691||vascular surgery control group|10 control patients admitted to the ICU after a planned vascular surgery
11065435|NCT04318691||Healthy volunteers group|10 healthy subjects.
11065436|NCT04318678|Other|CD123+ CAR therapy|CD123-CAR T-cell dose and infusion Up to 4 Dose levels will be evaluated with a maximum dose of 2.5 x 10^8 CAR+ T cells. If dose limiting toxicities (DLTs) are observed on Dose level 1 then the cell dose is de- escalated.
11065437|NCT04318665|Experimental|CT Perfusion|Severe TBI patients will be undergoing CT perfusion test
11065438|NCT04318652|Other|Methylprednisolone eye drops|Preservative free steroids methylprednisolone 5% eye drops (prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company) was prepared and given for all enrolled cases by the following regimen 5 times/day for 5 days with gradual decrease every third day over the following 2 weeks
11065439|NCT04318652|Placebo Comparator|distilled water eyedrops|Distilled water eyedrops instilled 3 times per day for two weeks
11065440|NCT04318639|Experimental|Donepazil+CRT|Donepazil+CRT
11065441|NCT04318626|Other|PMPBB3|"Name: [18F] PMPBB3，[18F]1-Fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)ben
~Dosage form: intravenous injection
~Dose(s): 7mCi
~Dosing schedule: Visit 2
~Mechanism of action (if known): high affinity radiotracer for the tau protein
~Pharmacological category：Radio pharmaceutical"
11065442|NCT04318626|Other|THK|"Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline
~Dosage form: intravenous injection
~Dose(s): 10mCi
~Dosing schedule: Visit 2
~Mechanism of action (if known): high affinity radiotracer for the tau protein
~Pharmacological category：Radio pharmaceutical"
11065443|NCT04318600|Experimental|human amniotic mesenchymal stem cell treatment group|
11065444|NCT04318600|No Intervention|blank control group|
11065445|NCT04318587|Experimental|Allosure Arm|All subjects will be in arm one and will have AlloSure blood draws at multiple time points.
11065446|NCT04318574|Experimental|Interventional|Balance, Agility, Strengthening Exercise (BASE) class intervention - a 6-week exercise class to determine the change in balance performance, fear of falling and self-efficacy
11065447|NCT04318561|Experimental|Gallium-68 NODAGA-LM3 group|Patients will undergo a Gallium-68 NODAGA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
11065448|NCT04318561|Experimental|Gallium-68 DOTA-LM3 group|Patients will undergo a Gallium-68 DOTA-LM3 PET/CT as well as a Gallium-68 DOTATATE PET/CT.
11065449|NCT04318548|Experimental|MenB+MenACWY Group|Subjects will receive 1 dose rMenB+OMV NZ given concomitantly with MenACWY at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of placebo at Day 91.
11065450|NCT04318548|Experimental|MenB Group|Subjects will receive 1 dose of rMenB+OMV NZ and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ at Day 61 and 1 dose of MenACWY at Day 91.
11065451|NCT04318548|Experimental|MenACWY Group|Subjects will receive 1 dose of MenACWY and placebo concomitantly at Day 1, 1 dose of rMenB+OMV NZ each at Day 61 and at Day 91.
11065452|NCT04318535|Experimental|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
11065453|NCT04318535|Experimental|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
11065454|NCT04318535|Experimental|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
11065455|NCT04318522|Experimental|Stimulation Group|
11065456|NCT04318522|Sham Comparator|Control Group|
11065457|NCT04318509|Experimental|PKU GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
11065458|NCT04318496|Experimental|Acupuncture with press tack needle group (Acu)|the press tack needles (PYONEX Φ0.20×0.6 mm made by Seirin Corporation) has a diameter of 0.2 mm and length of 0.6 mm will be used on the following bilateral points; GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack needles retention time will be 4 days.
11065459|NCT04318496|Placebo Comparator|Placebo group (Con)|The pess tack placebo is PYONEX sticker and pack that is identical to the press needle, except that the needle part was removed. The acupuncturist will apply the stickers on the following bilateral acupoints: GB 36 (Waiqiu), GB 34 (YangLingQuan), ST 36 (Zusanli), LI 4 (HeGu), LU 7 (LieQue), TH 5 (Waiguan) press tack stickers retention time will be 4 days.
11065460|NCT04318483||Angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
11065461|NCT04318483||Without angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
11097788|NCT04091724||Delirium is determined by PAED score|
11065464|NCT04318457||Brochoscopy|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during bronchoscopy will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
11065465|NCT04318457||ERCP|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during ERCP will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
11065466|NCT04318444|Experimental|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
11065467|NCT04318444|Placebo Comparator|Placebo|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
11065468|NCT04318431|Other|Data collection and rhinopharyngeal swab|"After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.
~During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR."
11065469|NCT04318418||Cases|Patients who developed severe COVID-19 disease (including fatal events)
11065470|NCT04318418||Controls|Infected patients who did not develop severe COVID-19 respiratory disease (including individuals who recovered from the infection)
11065471|NCT04318392||Patients with suspected sarcoidosis|Patients presenting with suspected sarcoidosis.
11065472|NCT04318392||Healthy controls|Healthy controls matched for age and gender. Recruitment of spouses and partners will also take place where possible.
11065473|NCT04318379|Experimental|Low dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
11065474|NCT04318379|Experimental|High dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
11065475|NCT04318366||COVID-19 patients|
11065476|NCT04318353||early enteral feeding|start enteral feeding within 2 days postoperative
11065477|NCT04318353||control|start enteral feeding after 2 days postoperative according to clinician discretion based on clinical progress(ranging from 1-5 days after passage of flatus or stool.
11065478|NCT04318340|Active Comparator|Standard Applicators|All patients will be fitted with the 2.6 cm applicator and sized up to the 3.0 cm applicator if tolerable.
11065479|NCT04318340|Experimental|Tapered Applicator|All patients will be fitted with the novel tapered 3.0 cm applicator. Patients have the option of having magnetic resonance imaging with the tapered applicator in place.
11065480|NCT04318327|Experimental|PHE885|Patients will receive PHE885
11065481|NCT04318314||Healthy and asymptomatic healthcare workers|Healthy and asymptomatic healthcare workers
11065482|NCT04318301||ACEI/ARB|COVID-19 patients with hypertension who had previously taken ACEI/ARB for antihypertensive treatment
11065483|NCT04318301||non ACEI/ARB|COVID-19 patients with hypertension who had not previously taken ACEI/ARB for antihypertensive treatment
11065484|NCT04318262||Patient with Staphylococcus lugdunensis infection|All consecutive patients with S. lugdunensis infection (microbiological and clinical data)
11065485|NCT04318262||Patient with Staphylococcus aureus infection|Patients with S. aureus infection (microbiological and clinical data), matched to the hospital sector for S. lugdunensis infections
11065486|NCT04318262||Patient with other coagulase negative Staphylococcus infection|Patients with CoNS infection (microbiological and clinical data),matched to the hospital sector for S. lugdunensis infections
11065487|NCT04318249|Experimental|Assisted Relaxation Therapy|This group will be receiving an assisted relaxation therapy intervention
11065488|NCT04318249|Experimental|Modified Assisted Relaxation Therapy|This group will be receiving a modified version of an assisted relaxation therapy intervention
11065489|NCT04318236|Experimental|Online-Program + factors 1,2,3,4|"In this arm all four factors are set to active (i.e. yes):
~diagnostic interview
~motivational module
~guidance
~e-mail reminders"
11065490|NCT04318236|Experimental|Online-Program + factors 1,2,3|"In this arm three factors are set to active (i.e. yes):
~diagnostic interview
~motivational module
~guidance"
11065491|NCT04318236|Experimental|Online-Program + factors 1,2,4|"In this arm three factors are set to active (i.e. yes):
~diagnostic interview
~motivational module
~e-mail reminders"
11065492|NCT04318236|Experimental|Online-Program + factors 1,2|"In this arm two factors are set to active (i.e. yes):
~diagnostic interview
~motivational module"
11065493|NCT04318236|Experimental|Online-Program + factors 1,3,4|"In this arm three factors are set to active (i.e. yes):
~diagnostic interview
~guidance
~e-mail reminders"
11065494|NCT04318236|Experimental|Online-Program + factors 1,3|"In this arm two factors are set to active (i.e. yes):
~diagnostic interview
~guidance"
11065495|NCT04318236|Experimental|Online-Program + factors 1,4|"In this arm two factors are set to active (i.e. yes):
~diagnostic interview
~e-mail reminders"
11065496|NCT04318236|Experimental|Online-Program + factor 1|"In this arm one factor is set to active (i.e. yes):
~- diagnostic interview"
11065497|NCT04318236|Experimental|Online-Program + factors 2,3,4|"In this arm three factors are set to active (i.e. yes):
~motivational module
~guidance
~e-mail reminders"
11065498|NCT04318236|Experimental|Online-Program + factors 2,3|"In this arm two factors are set to active (i.e. yes):
~motivational module
~guidance"
11065499|NCT04318236|Experimental|Online-Program + factors 2,4|"In this arm two factors are set to active (i.e. yes):
~motivational module
~e-mail reminders"
11065500|NCT04318236|Experimental|Online-Program + factor 2|"In this arm one factor is set to active (i.e. yes):
~- motivational module"
11065501|NCT04318236|Experimental|Online-Program + factors 3,4|"In this arm two factors are set to active (i.e. yes):
~guidance
~e-mail reminders"
11065502|NCT04318236|Experimental|Online-Program + factor 3|"In this arm one factor is set to active (i.e. yes):
~- guidance"
11065503|NCT04318236|Experimental|Online-Program + factor 4|"In this arm one factor is set to active (i.e. yes):
~- e-mail reminders"
11065505|NCT04318223|Experimental|single-arm study following a Simon's two-stage optimal design|Single-arm study with the primary objective of assessing the efficacy and safety of palbociclib in combination with fulvestrant (Faslodex) in women with HR+, HER2-negative metastatic breast cancer, regardless of their menopausal status, whose disease has progressed after prior treatment with AI plus a CDK4/6 inhibitor.
11065506|NCT04318210|Experimental|TDF-FTC as PrEP|Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
11065507|NCT04318197|Active Comparator|Global rehabilitation|2 hours of daily rehabilitation, 3 days per week during 4 weeks
11065508|NCT04318197|Experimental|Personalized rehabilitation|2 hours of daily rehabilitation including at least 2 times 20 minutes of electrostimulation on atrophied muscles, 3 days per week during 4 weeks
11065509|NCT04318197|No Intervention|Classic rehabilitation|40 minutes of rehabilitation, once a week during 4 weeks.
11065510|NCT04318184|Experimental|Exercise|Submaximal aerobic exercise protocol
11065511|NCT04318171||Carotid arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
11065512|NCT04318171||Peripheral arteries.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
11065513|NCT04318171||AVF.|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
11065514|NCT04318171||Vein mapping|No intervention is required. Routine Doppler assessment + 3D scan immediately afterwards.
11065515|NCT04318158|Experimental|Group(B)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% on each side.
11065516|NCT04318158|Active Comparator|Group(BD)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
11065517|NCT04318158|Active Comparator|Group(BF)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
11065518|NCT04318145|Experimental|Part A: PL-3994 Dose Ascension|Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.
11065519|NCT04318145|Experimental|Part B: PL-3994 Single Dose|Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.
11065520|NCT04318106|Experimental|'Experimental' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be the optimum chromaticity to alleviate visual stress symptoms. To be worn for a minimum of 10 weeks for concentrated tasks.
11065521|NCT04318106|Placebo Comparator|'Control' coloured spectacle lenses|Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
11065522|NCT04318093|Experimental|BMS-986259|
11065523|NCT04318093|Placebo Comparator|Placebo|
11065524|NCT04318080|Experimental|Cohort 1: Tislelizumab Monotherapy Post HSCT|Participants with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after autologous hematopoietic stem cell transplantation (HSCT) and failed to achieve a response or progressed after brentuximab vedotin
11065525|NCT04318080|Experimental|Cohort 2: Tislelizumab Monotherapy Post Chemotherapy|Participants with relapsed or refractory cHL who have received at least 2 prior systemic chemotherapy regimens, and are not candidates for autologous or allogeneic HSCT due to disease refractory to salvage chemotherapy (did not achieve a Partial Response (PR) or Complete Response (CR)) and failed to achieve a response or progressed after brentuximab vedotin
11065526|NCT04318067|Experimental|Sleep problems i Attention Deficit Hyperactivity Disorder|Children age 6 to 12 years having ADHD and Sleeping problem will be treated with Melatonin 3 mg one a day (before bedtime)
11065527|NCT04318054|Experimental|Immediate intervention group|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, in the 2 months following the randomization, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
11065528|NCT04318054|Other|Deferred intervention group|Deferred intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, one year after the inclusion, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
11065529|NCT04318041|Experimental|diacerein (Artrodar)|
11065530|NCT04318041|Placebo Comparator|placebo|
11065531|NCT04318028|Experimental|Diagnostic (7 Tesla MRI)|Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and 6-9 months.
11065532|NCT04318015|Experimental|High-risk Treatment|Hydroxychloroquine 200mg per day for 60 days.
11065533|NCT04318015|Placebo Comparator|High-risk Placebo|Placebo tablet per day for 60 days.
11065534|NCT04318015|Experimental|Low-risk Treatment|Hydroxychloroquine 200mg per day for 60 days
11065535|NCT04318015|Placebo Comparator|Low-risk Placebo|Placebo tablet per day for 60 days.
11065536|NCT04318002|Experimental|Group 1A|Volunteers (aged 18-45 years) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and
11065537|NCT04318002|Experimental|Group 1B|Volunteers (aged 18-45 years) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.5.
11065538|NCT04318002|Experimental|Group 2A|Volunteers (aged 6-11 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /25µg Matrix-M intramuscularly at months 0, 1 and 2.
11065539|NCT04318002|Experimental|Group 2B|Volunteers (aged 6-11 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /25µg Matrix-M intramuscularly at months 0, 1 and 6.5.
11065540|NCT04318002|Experimental|Group 2C|Volunteers (aged 6-11 months) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /25µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /25µg Matrix-M at month 6.5.
11065541|NCT04318002|Experimental|Group 2D|Volunteers (aged 6-11 months) of high malaria exposure status will receive 2 doses of 50µg RH5.1 /25µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /25µg Matrix-M at month 6.5.
11066318|NCT04312425||Group C|General anesthesia was induced with classic rapid sequence induction protocol.
11065543|NCT04317989|Experimental|Practice Facilitation + Embedded Teleheath|The lower 50th percentile of practices (based on performance after 6 months of practice facilitation) will be randomized to 2 arms. Of those practices randomized, this arm will receive continued practice facilitation plus embedded telehealth services related to interventions for unhealthy alcohol use.
11065544|NCT04317989|Experimental|Practice Facilitation (bottom 50th percentile)|The lower 50th percentile of practices (based on uptake of services after 6 months of practice facilitation) will be randomized to 2 arms. Of those practices randomized, this arm will receive ongoing practice facilitation for the duration of the intervention period (but will not receive embedded telehealth services).
11065545|NCT04317976|Active Comparator|Centrally located oesophagus post GA|Oesophagus remained central after general anaesthesia, cricoid pressure applied by fingertips under ultrasound guidance
11065546|NCT04317976|Experimental|Eccentric located oesophagus post GA|Oesophagus eccentric located after general anaesthesia, paralaryngeal pressure and cricoid pressure applied by fingertips under ultrasound guidance
11065547|NCT04317963||Cases|Patients who have received bezlotoxumab 10 mg/kg intravenously in addition to standard CDI treatment.
11065548|NCT04317963||Controls|Patients who have received only standard CDI treatment.
11065549|NCT04317950|Other|Vojta group|All participants were properly instructed and signed an informed consent previous to the interventions. They were comfortably laid down on their back with eyes open, wearing the EEG cap during the intervention. They were asked to remain relaxed and still during the whole process. After a first minute of resting, the experimental group received a continuous reflex locomotion stimulus during the next 8 minutes.
11065550|NCT04317950|Sham Comparator|Control group|On the contrary, the control group received a continuous sham stimulus during the next 8 minutes.
11065551|NCT04317937|Experimental|Jaw Movement Group|"A: Jaw opening-closing movements
~Active jaw movements
~Active neck exercises
~Head-Neck extension on jaw opening (Mandible moves vertically downward);
~B: Isometric strengthening exercises (Same as control group) C: Postural Advice and Home Exercise Program with Dairy (Same as control group)"
11065552|NCT04317937|Active Comparator|Exercise therapy|"A: Active neck exercises Active neck exercises Active jaw movements (Active Jaw movement will not be perform in this group) B: Isometric strengthening exercises C: Postural Advice and Home Exercise Program with Dairy i: Postural Advise ii: Home Exercise Program (unsupervised) iii: Home Dairy
~Frequency and Duration of Treatment Non-specific Chronic Neck Pain (more than 3 months history of pain)
~Initial Assessment (week 1) 60 minutes First treatment session (week1) 40 minutes
~3 treatment sessions per week (week- 2) 40 minutes
~3 treatment sessions per week (week- 3) 40 minutes
~3 treatment sessions per week (week- 4) 40 minutes
~3 treatment sessions per week (week- 5) 40 minutes
~Last treatment session (week 6) 40 minutes
~Final Assessment (week 6) 60 minutes"
11065553|NCT04317924|Experimental|Reinforcement of air leak|Participants in this arm will receive reinforcement with the NEOVEIL (polyglycolic acid felt) which will be impregnated with human fibrinogen and thrombin.
11065554|NCT04317924|Active Comparator|No reinforcement of air leak|Participants in this arm will receive standard of care for air leak post lung resection.
11065555|NCT04317898|Active Comparator|serratus plane block|20 ml of Bupivacine 0.25% +80mg triamcinlone will be injected in serratus plane under ultrasound.
11065556|NCT04317898|Active Comparator|paravertebral block|10 ml of bubivacine 0.25% +80 mg triamcinlone will be injected at T2 level (paravertebral) under ultrasound.
11065557|NCT04317885|Experimental|EXP039|Autologous EXP039 administered by intravenous (IV) infusion
11065558|NCT04317872|Experimental|Current protocol|"Current protocol: patients will receive a single shot of 25mg of aacidexam iv (5cc) at induction. After 12 hours these patients will another shot of 10mg of aacidexam iv (2cc) on the ward."
11065559|NCT04317872|Active Comparator|Old protocol|"Old protocol: patients will receive a single shot of 5mg of aacidexam iv at induction (5cc). After arrival 12 hours these patients will receive a placebo, i.e. a shot of 2 cc of NaCl 0.9% iv (Mini-Plasco van B. Braun)."
11065560|NCT04317859|Experimental|Behavioural Activation (Intervention)|Originally a component of Cognitive Therapy, Behavioural Activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to modify one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations and mood symptoms.
11065561|NCT04317859|No Intervention|Waitlist (Control)|The Control group (waitlist) will receive treatment as usual while waiting to receive BA intervention (at the end of intervention group therapy time, which will consist of 18 sessions over an 14 week period). This group will be assessed by clinical staff that offer treatment as usual for mood symptoms and quality of life measures during the waiting time.
11065562|NCT04317846|Active Comparator|Intra-radial group|intra-radial administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
11065563|NCT04317846|Experimental|Intravenous-post group|intra-venous administration of the vasodilatory drugs after sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
11065564|NCT04317846|Experimental|Intravenous-pre group|intra-venous administration of the vasodilatory drugs 5 minutes before sheath insertion (verapamil 2.5 mg + isosorbide dinitrate 0.5 mg)
11065565|NCT04317833|Experimental|Dose Escalation SSS17|Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)
11065566|NCT04317833|Placebo Comparator|Escalation matching Placebo|Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)
11065567|NCT04317820|Experimental|DBR Condition|Involves 8 weekly sessions of DBR treatment.
11065568|NCT04317820|No Intervention|Wait-list Condition|No intervention for approximately 8 weeks.
11065569|NCT04317807|Active Comparator|Study Drug group|Participants in this group will receive 500 mg of levetiracetam twice daily for 12 weeks. After 12 weeks, levetiracetam will be gradually decreased and stopped over the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
11065629|NCT04317417|Experimental|Condition 9|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
11065630|NCT04317417|Experimental|Condition 10|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
11065570|NCT04317807|Placebo Comparator|Placebo Group|Participants in this group will receive a placebo that looks like the levetiracetam pill twice daily for 12 weeks. After 12 weeks, they will receive a tapering regiment of placebo pills for the next 9 days. Questionnaires will be administered at each visit to examine how participants are responding to the treatment. In addition, a brain scan and cognitive testing will be performed when feasible at the beginning and the end of the study.
11065571|NCT04317794||All Participants|Participants who were prescribed with nusinersen sodium injection in Korea according to local marketing authorization.
11065572|NCT04317781|Experimental|Treatment (tagraxofusp-erzs)|Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11065573|NCT04317768|Experimental|Study group|They will be educated and motivated by an intensive program consisting of verbal instructions, Power Point lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
11065574|NCT04317768|Other|Control group|They will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
11065575|NCT04317755|Experimental|Intervention|Comics-based body image programme
11065576|NCT04317755|No Intervention|Control|Schools lessons as usual
11065577|NCT04317742|Active Comparator|Sleep Healthy Using the Internet (SHUTi) Intervention Group|Participants will receive a direct link to access the SHUTi program (per randomization) from the study team.
11065578|NCT04317742|Active Comparator|Online Patient Education (PE) Control Group|Participants will receive a direct link to access online patient education (per randomization) from the study team.
11065579|NCT04317729|Experimental|Diagnostic|Collection of whole blood via fingerstick and venipuncture
11065580|NCT04317716|Experimental|Intervention|Fall prevention program
11065581|NCT04317716|Other|Control|Advice about fall risk factors
11065582|NCT04317703|Experimental|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
11065583|NCT04317703|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
11065584|NCT04317690||High Cholesterol|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
11065585|NCT04317690||High Blood Pressure|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
11065586|NCT04317690||Colorectal Cancer Screening|People between the ages of 50-75 with no previous diagnosis of colon cancer, who have been screened for colon cancer (or discussed screening for colon cancer) in the past 2 years, or who had first colon cancer screening in past 2 years. These people will see items only pertaining to colon cancer screening.
11065587|NCT04317690||Breast Cancer Screening|Females between the ages of 40-50 with no previous diagnosis of breast cancer who have had mammogram (or discussed having a mammogram) in the past 2 years, or had first mammogram in past 2 years. These people will see items only pertaining to breast cancer screening.
11065588|NCT04317690||Prostate Cancer Screening|Men between the ages of 45-69 with no previous diagnosis of prostate cancer who have been screened for prostate cancer (or discussed screening for prostate cancer) in the past 2 years or had first prostate cancer screening in the past 2 years. These people will see items only pertaining to prostate cancer screening.
11065589|NCT04317677|Other|Babies hospitalized in the pediatric sleep unit|
11065590|NCT04317664|No Intervention|Control Group|The Control Group will have the in-vehicle device installed in the teen's car, but all feedback features will be disabled.
11065591|NCT04317664|Experimental|Feedback Only Group|The Feedback Only Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens can review their driving data. Teens will also receive biweekly cumulative driving reports.
11065592|NCT04317664|Experimental|Feedback and Parent Communication Group|The Feedback and Parent Communication Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens and parents can review their driving data. The parent will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a motivational interviewing professional. A second booster session will also occur two months after the initial training. Both teens and parents will receive a biweekly cumulative driving report.
11065593|NCT04317638||breastfed group|Infants on exclusive breast feeding for the first 6 months of life and their mothers
11065594|NCT04317638||formula fed group|Infants on exclusive formula feeding for the first 6 months of life
11065595|NCT04317638||mixed fed group|Infants on mixed feeding (formula & breast feeding) and their mothers
11065596|NCT04317625|Experimental|participants|All of the participants tested serum PSA, some of them conducted mpMRI with/without prostate biopsy under instruction.
11065597|NCT04317612|Active Comparator|Active berry product|Once daily consumption over the period of the study
11065598|NCT04317612|Placebo Comparator|Reference product|Once daily consumption over the period of the study
11065599|NCT04317599||Non interventional|All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
11065600|NCT04317586|Other|Trident II Tritanium Acetabular Shell for Revision|
11065631|NCT04317417|Experimental|Condition 11|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
11066319|NCT04312425||Group M|General anesthesia was induced with modified rapid sequence induction protocol.
11065601|NCT04317573|Active Comparator|Personalised card|The personalised card was printed by the attending ophthalmologist for the patient via a web accessible software we have developed. The software allowed the reviewing physician to select the medications the patient was prescribed and auto-generate a personalised card that will be sent to the network printer. The card illustrated the patient's eye drop regime in a simple pictorial format using coloured pictures of the eye drop bottles and universally recognised symbols. It can be folded to a compact size of 11cm x 7.5cm to allow patients to carry around in their wallets. This card will be given to patients at the end of their consult and explanation will be provided by the attending physician who will manually tick in the corresponding boxes depending on the frequency of administration
11065602|NCT04317573|Active Comparator|Personalised card and telereminder|Patients who were recruited into the group receiving tele-monitoring were contacted via text messages daily by a programmed software at the scheduled time of eye drop administration. They were required to acknowledge the reminder by replying a 'Yes' if they had administered the eyedrop and 'No' if they had not. A nil reply was taken as a 'No'.
11065603|NCT04317573|No Intervention|No intervention|No intervention
11065604|NCT04317560|Active Comparator|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
11065605|NCT04317560|Experimental|Arthrocentesis plus i-PRF injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. Only the second needle was removed without removing the first needle inserted. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
11065606|NCT04317547|No Intervention|Control Group|The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
11065607|NCT04317547|Experimental|Intervention Group|Parents will receive STS, which will include 1) Individualized virtual communication training and a booster session delivered by a traffic safety communication specialist; and 2) An online parent-teen safe driving communication guide. In addition, the Azūga™ in-vehicle device and app will be installed as described above and all feedback features will be enabled. Three types of feedback will be provided to teens: 1) Direct audio feedback; 2) Detailed cumulative driving data; and 3) A customized weekly driving summary report. Parents in this group will receive access to the teen's cumulative driving data and a weekly driving summary report. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
11065608|NCT04317534|Experimental|Arm A- Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks x 17 cycles
11065609|NCT04317534|No Intervention|Arm B - Observation|Observation only
11065610|NCT04317508|Active Comparator|Intervention group|Topicale® topical anesthetic gel patch (Benzocaine 18%)
11065611|NCT04317508|Placebo Comparator|control group|Opahl® topical anesthetic gel (Benzocaine 20%)
11065612|NCT04317495|Experimental|Computerized Cognitive Training (CCT)|The patients will receive CCT during their standard rTMS treatments (after having 5 days of treatment until the pre-taper treatment).
11065613|NCT04317482|Other|Standard social stress task|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three standard scenarios presented in counterbalanced order. This will involve approximately 30 minutes of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
11065614|NCT04317482|Other|Stressful experience in the ED|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three experiences surrounding their most stressful ED visit. These experiences are presented in counterbalanced order. This will involve approximately 30 of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
11065615|NCT04317469||ARDS group ,|
11065616|NCT04317469||non ARDS group|
11065617|NCT04317443||Super-Mini Percutaneous Nephrolithotomy|Patients undergo SMP
11065618|NCT04317443||Extracorporeal Shock Wave Lithotripsy|Patients undergo ESWL
11065619|NCT04317430|Active Comparator|Treatment group|Niclosamide tablets 1 gram once daily
11065620|NCT04317430|Placebo Comparator|Control group|Lactose tablets
11065621|NCT04317417|Experimental|Condition 1|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
11065622|NCT04317417|Experimental|Condition 2|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
11065623|NCT04317417|Experimental|Condition 3|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
11065624|NCT04317417|Experimental|Condition 4|1) Cognitive Changes after Cancer, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065625|NCT04317417|Experimental|Condition 5|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
11065626|NCT04317417|Experimental|Condition 6|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
11065627|NCT04317417|Experimental|Condition 7|1) Cognitive Changes after Cancer, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
11097789|NCT04091724||No delirium is determined by PAED score|
11065632|NCT04317417|Experimental|Condition 12|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065633|NCT04317417|Experimental|Condition 13|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
11065634|NCT04317417|Experimental|Condition 14|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
11065635|NCT04317417|Experimental|Condition 15|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
11065636|NCT04317417|Experimental|Condition 16|1) Cognitive Changes after Cancer, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065637|NCT04317417|Experimental|Condition 17|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Sun Protection
11065638|NCT04317417|Experimental|Condition 18|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
11065639|NCT04317417|Experimental|Condition 19|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
11065640|NCT04317417|Experimental|Condition 20|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065641|NCT04317417|Experimental|Condition 21|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
11065642|NCT04317417|Experimental|Condition 22|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
11065643|NCT04317417|Experimental|Condition 23|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
11065644|NCT04317417|Experimental|Condition 24|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065645|NCT04317417|Experimental|Condition 25|1) Positive Events, Capitalizing and Gratitude, 2) Diet, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065646|NCT04317417|Experimental|Condition 26|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Financial Literacy and 5) Acts of Kindness
11065647|NCT04317417|Experimental|Condition 27|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/ Achievable Goals and 5) Sun Protection
11065648|NCT04317417|Experimental|Condition 28|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Weight Management, 4) Strengths/Achievable Goals and 5) Acts of Kindness
11065649|NCT04317417|Experimental|Condition 29|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Sun Protection
11065650|NCT04317417|Experimental|Condition 30|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Financial Literacy and 5) Acts of Kindness
11065651|NCT04317417|Experimental|Condition 31|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Sun Protection
11065652|NCT04317417|Experimental|Condition 32|1) Positive Events, Capitalizing and Gratitude, 2) Mindfulness, 3) Positive Reappraisal , 4) Strengths/ Achievable Goals and 5) Acts of Kindness
11065653|NCT04317404||Diabetic with Knee Osteoarthritis|HbA1c between 6.5% - 12.0% in the 3 months prior to Visit 1
11065654|NCT04317404||Pre-diabetic with Knee Osteoarthritis|HbA1c between 5.6% - 6.4% in the 3 months prior to Visit 1
11065655|NCT04317404||Non-diabetic with Knee Osteoarthritis|HbA1c < 5.6% in the 3 months prior to Visit 1
11065656|NCT04317391|Experimental|Pain management program|All enrolled patients participate in a 20 hour pain management program over a period of 8 weeks. The program is based on Mindfulness Based Stress Reduction with modifications to fulfill needs of the Taiwanese chronic pain population.
11065657|NCT04317365|Active Comparator|patients receiving remembering|
11065658|NCT04317365|No Intervention|patients not receiving extra remembering|
11065659|NCT04317352||Multivisceral resection (MRV)|MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
11065660|NCT04317339|Experimental|Zhigancao Tang granule group|Participants in experimental group will receive Zhigancao Tang granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters, diuretics as needed.
11065661|NCT04317339|Placebo Comparator|Zhigancao Tang placebo group|Participants in experimental group will receive Zhigancao Tang placebo granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
11065662|NCT04317326|Experimental|Life style modification|"Lifestyle modifications group (Control) will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 <55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88)"
11065663|NCT04317326|Active Comparator|Life style modificacion and automatic NIV(AVAPS-AE)|Automatic NIV: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 20 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight. These parameters may be modified according to patient tolerance or non-compensated leak.
11065702|NCT04317105|Experimental|Trial I (copanlisib, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11098029|NCT04090151||Swiss HIV Cohort Study (SHCS)|
11065664|NCT04317326|Experimental|Life style modification and titrated NIV(S/T mode)|In-laboratory polysomnographic NIV titration will be performed according to published guidelines (Berry R et al JCSM 2010). In addition to lifestyle modification and oxygen (if required), home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel PAP with backup respiratory rate (BIPAP S/T mode). The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG.
11065665|NCT04317326|Active Comparator|Life style modification and titrated CPAP|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines (SEPAR guideline or AASM guideline). In addition to lifestyle modification and oxygen (if required), home CPAP therapy at a fixed pressure will be initiated.
11065666|NCT04317300|Experimental|E-cigarette users|Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.
11065667|NCT04317287|Experimental|Cardio formulation|Tomato-based formulation with dietary supplement
11065668|NCT04317287|Placebo Comparator|Placebo|Placebo softgels
11065669|NCT04317274|Experimental|High Cholesterol Good Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
11065670|NCT04317274|Experimental|Colorectal Cancer Good Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
11065671|NCT04317274|Experimental|High Cholesterol Poor Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
11065672|NCT04317274|Experimental|Colorectal Cancer Poor Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.
11065673|NCT04317261|Experimental|Hematuria patients|
11065674|NCT04317248|Experimental|MSDCV immune therapy combined with radical surgery therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time before the first time of MSDCV immune therapy
11065675|NCT04317248|No Intervention|Radical surgery therapy|Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time
11065676|NCT04317248|Experimental|MSDCV immune therapy combined with TACE therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: the first time of TACE therapy must perform before the first time of MSDCV immune therapy， then perform when necessary according to subjects condition
11065677|NCT04317248|No Intervention|TACE therapy|Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: perform when necessary according to Subjects condition
11065678|NCT04317248|Experimental|MSDCV immune therapy combined with targeted agents therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
11065679|NCT04317248|No Intervention|Targeted agents therapy|Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
11065680|NCT04317235|Active Comparator|3 ml ropivacaine|interscalene block using 3 ml under ultrasound put medication on each nerve
11065681|NCT04317235|Active Comparator|5 ml ropivacaine|interscalene block using 5 ml under ultrasound put medication on each nerve
11065682|NCT04317222|Experimental|eCRRT group|Initiated CRRT within the first 24 post-transplant hours.
11065683|NCT04317222|No Intervention|Control group|Standard treatment.
11065684|NCT04317209|Experimental|SHR0410 low dosage|
11065685|NCT04317209|Experimental|SHR0410 medium dosage|
11065686|NCT04317209|Experimental|SHR0410 high dosage|
11065687|NCT04317209|Placebo Comparator|Placebo|
11065688|NCT04317183|Experimental|Chamomile topical gel|"Topical oral chamomile gel three times daily for three weeks.
~Topical oral chamomile gel is prepared with the aid of Pharmacognosy and pharmaceutics departments, faculty of pharmacy, Alexandria University and mucoadhesive hydrogels (Carbopol® 970)."
11065689|NCT04317183|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:
~Miconaz oral gel BBC oral spray Oracure gel
~Dose: Three times a day for three weeks"
11065690|NCT04317183|Experimental|combination therapy|"Topical oral chamomile gel three times daily for three weeks in combination with the symptomatic treatment
~Symptomatic treatment which included:
~Miconaz oral gel BBC oral spray Oracure gel
~Symptomatic treatment dose: Three times a day for three weeks"
11065691|NCT04317170|Experimental|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia.
11065692|NCT04317170|No Intervention|No Music|Patients will undergo their routine procedure without being played music.
11065693|NCT04317157|Experimental|Caffeine Clinical Trial|Participants will ingest 6 mg.kg-1 of caffeine ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
11065694|NCT04317157|Placebo Comparator|Placebo Clinical Trial|Participants will ingest placebo ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
11065695|NCT04317157|Experimental|Placebo-deceived Caffeine|Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
11065696|NCT04317157|Placebo Comparator|Placebo-deceived Placebo|Participants will be informed they are ingesting placebo ~45 minutes before the trial.
11065697|NCT04317157|Active Comparator|Control-Caffeine|Participants will be informed they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
11065698|NCT04317157|No Intervention|Control|Participants will perform a baseline trial with no intervention.
11065699|NCT04317144|Active Comparator|Web-based follow-up programme|Participant randomized to the Web-based follow-up programme receive access to web-portal called www.1177.se
11065700|NCT04317144|Active Comparator|No follow-up.|Participants does not receive the web-based follow-up programme. e-questionnaires are sent out.
11065701|NCT04317118||Neurodevelopmental|Individuals between 8 and 17 years old with neurodevelopmental disorders
11065703|NCT04317105|Experimental|Trial II (copanlisib, nivolumab, ipilimumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1 and ipilimumab IV over 90 minutes every 8 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11065704|NCT04317092|Experimental|tocilizumab treatment|All the patients enrolled are treated with tocilizumab.
11065705|NCT04317079|Active Comparator|15mg of hydroxytyrosol|15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
11065706|NCT04317079|Active Comparator|5mg of hydroxytyrosol|5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
11065707|NCT04317079|Placebo Comparator|placebo|2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
11065708|NCT04317066|Experimental|Pembrolizumab in Participants with rrPMBCL|Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months.
11065709|NCT04317053|No Intervention|Site-Directed Care (SDC)|Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.
11065710|NCT04317053|Experimental|Relay program (peer navigation)|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
11065711|NCT04317040|Experimental|CD24Fc Treatment|Single dose at Day 1, CD24Fc, 480mg, diluted to 100ml with normal saline, IV infusion in 60 minutes.
11065712|NCT04317040|Placebo Comparator|Placebo|Single dose at Day 1, normal saline solution 100ml, IV infusion in 60 minutes.
11065713|NCT04317027|Experimental|All subjects|All subjects in this trial will receive the new fighting clothing while performing the study protocol
11065714|NCT04317014||cases|early puberty girls of Han Chinese
11065715|NCT04317014||controls|normal development girls of Han Chinese
11065716|NCT04317001|Active Comparator|Active treatment with modafinil|active intervention
11065717|NCT04317001|Placebo Comparator|Placebo|placebo intervention
11065718|NCT04316988||Ultrasonography|Ultrasonography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by ultrasound machine over the trachea.
11065719|NCT04316988||Capnography|Capnography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by capnograph, evaluationg the graph character and end tidal CO2 value.
11065720|NCT04316975|Other|Biopsy: Barrett's Esophagus, Intramucosal adenocarcinoma|"Subjects will undergo standard of care (SOC) standard esophagogastroduodenoscopy (EGD) for the treatment of their condition (BE or IMC). Four (4) research biopsies will be taken from the midpoint of current disease. In cases where EMR (Endoscopic Mucosal Resection) is performed clinically, no research biopsies will be taken. Following CEIM, four (4) additional research biopsies will be collected, from the midpoint of previous BE site.
~Laboratory Biomarker Analysis: Correlative studies
~Esophagogastroduodenoscopy: Standard of care, research biopsies will be collected if clinical biopsies are taken"
11065721|NCT04316962|Experimental|Complex rehabilitation|See intervention described elsewhere.
11065722|NCT04316949||Derivation cohort|"Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020.
~."
11065723|NCT04316949||Validation cohort|Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
11065724|NCT04316936|Experimental|Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg|Omidria (= ketorolac + phenylephrine) and intracanalicular dexamethasone insert (punctal plug)
11065725|NCT04316936|Experimental|Omidria + Dexycu|Omidria (= ketorolac + phenylephrine) and intraocular dexamethasone suspension
11065726|NCT04316936|Active Comparator|Omidria + Prednisolone Acetate 1%|Omidria (= ketorolac + phenylephrine) and topical prednisolone acetate ophthalmic drops
11065727|NCT04316923||Children with cardiomyopathies|Children aged 0-18 years that have been diagnosed with DCM, HCM or LVNC on the basis of a two-dimensional echocardiography with color Doppler.
11065728|NCT04316923||Healthy children|The control group will be composed of healthy children, in whom heart disease will be excluded using echocardiography.
11065729|NCT04316910||Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
11065730|NCT04316910||Non-Postoperative delirium|The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.
11065731|NCT04316884||COVID-19|Patients with suspected or verified COVID-19 admitted to intensive care at Uppsala University Hospital
11065732|NCT04316871|Placebo Comparator|Group M0|
11065733|NCT04316871|Active Comparator|Group M1.5|
11065734|NCT04316871|Active Comparator|Group M3|
11065735|NCT04316871|Active Comparator|Group M4.5|
11065736|NCT04316858|Active Comparator|Water|Water will be used as solvent for sodium phosphate
11065737|NCT04316858|Active Comparator|Zero calorie carbonated drink|Zero calorie carbonated drink will be used as solvent for sodium phosphate
11065738|NCT04316845|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
11065739|NCT04316832|Experimental|Intervention/treatment|The mindfulness based cognitive training will be delivered in one session and will include short mindfulness exercises.
11065740|NCT04316832|Placebo Comparator|No intervention|Control exercise, participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
11065776|NCT04316585|Experimental|Participants receiving GSK2982772 960 mg|Participants will receive GSK2982772 960 mg oral tablets once daily for 12 weeks.
11065777|NCT04316585|Placebo Comparator|Participants receiving placebo|Participants will receive GSK2982772 matching placebo oral tablets once daily for 12 weeks.
11065741|NCT04316819|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
11065742|NCT04316819|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
11065743|NCT04316806|Experimental|Probiotic|Treatment with probiotic formula
11065744|NCT04316806|Other|Antibiotic|Treatment with antibiotic rifaximin
11065745|NCT04316793|Experimental|Dry needling (DN)|Intramuscular insertion
11065746|NCT04316793|Sham Comparator|Sham needling (SN)|Intradermal insertion
11065747|NCT04316780||Nintedanib until 0 day - 2 days before transplant|Nintedanib taken until 0 - 2 days before receiving transplant
11065748|NCT04316780||Nintedanib until 3 days - 28 days before transplant|Nintedanib taken until 3-28 days before receiving transplant
11065749|NCT04316780||Nintedanib until > 28 days before transplant|Nintedanib taken until more than 28 days before receiving transplant
11065750|NCT04316780||Pirfenidone until 0 day - 1 day before transplant|Pirfenidone taken until 0 - 1 day before receiving transplant
11065751|NCT04316780||Pirfenidone until 2 days - 28 days before transplant|Pirfenidone taken until 2-28 day before receiving transplant
11065752|NCT04316780||Pirfenidone until > 28 days before transplant|Pirfenidone taken more than 28 days before receiving transplant
11065753|NCT04316767|Experimental|App Intervention|Participants will download a mobile self-care app on their smartphones. The app guides users through exercises based on cognitive behavioral therapy principles. Participants will be able to use the app as frequently as desired throughout the course of the study.
11065754|NCT04316767|No Intervention|Control|Participants will receive usual supportive care provided to family members of ICU patients.
11065755|NCT04316754|No Intervention|Control group|No music will be played to the control group.
11065756|NCT04316754|Active Comparator|Intervention 1|During angiography, the Intervention-1 group will listen to the music that the child wants to listen.
11065757|NCT04316754|Active Comparator|Intervention-2|"The Intervention-2 group will listen to the music which determined by the researchers. The music which determined by the researchers is The art of fugue by Johann Sebastian Bach. The music to be played has been decided by examining the literature. (DOI: 10.4274/jpr.24892)"
11065758|NCT04316741|Experimental|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
11065759|NCT04316741|No Intervention|Control|Enhanced usual care brochure plus attention control with social media messaging
11065760|NCT04316728|Other|negative Patients|Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility
11065761|NCT04316715|Experimental|Life-Steps for PreP|Participants in this group will receive standard of care treatment plus daily text message reminders. A subset of participants who demonstrate continued adherence challenges will also receive 4-6 weekly sessions of the Lifesteps for PrEP intervention.
11065762|NCT04316715|No Intervention|Standard of Care|Participants in this group will not receive an intervention outside the standard of care.
11065763|NCT04316702|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
11065764|NCT04316702|Active Comparator|Pharmacotherapy|Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 2 weeks, patients will be evaluated and dose will be adjusted as necessary and tolerated, up to the maximum dosage recommended for FM. Patients may also be switched from one medication to the other according to clinical judgment of the physician.
11065765|NCT04316689|Experimental|S-588210 (S-488210 + S-488211)|Participants will receive subcutaneous injections once a week for 4 weeks and then a biweekly extension treatment for 8 weeks. Each treatment will consist of 1 subcutaneous injection of 1 mL of S- 488210 and 1 subcutaneous injection of 1 mL of S-488211 containing 1 mg each of the 5 peptides.
11065766|NCT04316676|Other|Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR|Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
11065767|NCT04316663|Experimental|Well-Being and Sleep Hygiene|Participants in the experimental group will receive an intervention focused on both principles of psychological well-being and sleep hygiene education.
11065768|NCT04316663|Active Comparator|Sleep Hygiene (Control)|Participants in the control group will receive sleep hygiene education alone.
11065769|NCT04316650|Other|SSRI Group|Treated by ISRS at inclusion
11065770|NCT04316650|Other|Anti-androgen Group|Treated by anti-androgen at inclusion
11065771|NCT04316650|Other|No SSRIs or antiandrogen treatment at inclusion|no treatment
11065772|NCT04316624|Experimental|C-CAR066|Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion
11065773|NCT04316611|Experimental|Potassium chloride|Potassium chloride
11065774|NCT04316598|Experimental|Cannabis (B)|"Subjects will be admitted in the center to receive 4 doses of inhaled cannabis in 3 days.
~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every cannabis administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
11065775|NCT04316598|Placebo Comparator|Cannabis placebo (B)|"Subjects will be admitted in the center to receive 4 doses of an inhaled treatment based on placebo-THC in 3 days.
~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
11065778|NCT04316572|Experimental|mental health specialist video consultation|"The intervention group will receive five video consultations with psychotherapists directly in the GP's practice.
~The consultations will be carried out via the web portal of a certified video service provider (arztkonsultation ak GmbH). The patient will be located in the GP's practice and the psychotherapist in his practice or another suitable room. Patients are scheduled for five sessions of 50 minutes."
11065779|NCT04316572|No Intervention|treatment as usual by the GP|Routine treatment by the GP, which may or may not include conversations about psychosocial problems and/or referral to specialised services (e.g., inpatient therapy, counseling, self-help).
11065780|NCT04316559|Placebo Comparator|Placebo|Placebo capsule
11065781|NCT04316559|Experimental|TRV734|TRV734 at different doses vs. oxycodone for withdrawal suppression
11065782|NCT04316546|Experimental|ARQ 092 (miransertib)|This is a single arm study. All study participants will be taking the experimental drug, ARQ 092 (miransertib).
11065783|NCT04316520|Experimental|Ketogenic diet|Ketogenic diet + standard of care
11065784|NCT04316507|Experimental|Oncologist led genetic counselling and testing|All subjects receive Oncologist Led Genetic Counselling and Testing
11065785|NCT04316494|Experimental|Hydroxychloroquine|"Patients will be receive 400mg of Hydroxychloroquine (2 x 200mg) to take daily for 52 weeks. Hydroxychloroquine will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.
~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
11065786|NCT04316494|Placebo Comparator|Placebo|"Patients will be receive 400mg of Placebo (2 x 200mg) to take daily for 52 weeks. Placebo will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.
~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
11065787|NCT04316481|Other|AngelMed Guardian System|All eligible subjects will have the AngelMed Guardian System implanted with alerting features turned ON; receive an external device which provides additional alerting; and receive training on system use.
11065788|NCT04316455|Experimental|Integrative Yoga Therapy|Participants engaging in a 6-week chronic pain self-management program. Intervention: Integrative Yoga Therapy
11065789|NCT04316442|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
11065790|NCT04316429|Active Comparator|Egg phase:|Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets.
11065791|NCT04316429|Placebo Comparator|Control phase:|The participants will consume a vegan diet for 6 weeks.
11065792|NCT04316416|Active Comparator|T7 Bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
11065793|NCT04316416|Active Comparator|T9 bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging transverse process T9 (9th thoracal vertebrae) by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
11065794|NCT04316416|Placebo Comparator|Control group|Postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard pain follow-up and monitorization will be performed. No block will be performed in this group.
11065795|NCT04316403|Experimental|Laser-assisted corticotomy|Er:YAG laser beam was used to perform several perforations to the alveolar bone around the canine in one side of the mouth hoping that would accelerate canine retraction
11065796|NCT04316403|No Intervention|Traditional treatment|Canines in this group were retracted by the conventional manner.
11065797|NCT04316390|Experimental|Hesperidin (A)|study drink without hesperidin and without vitamin C compared to study drink with hesperidin
11065798|NCT04316390|Experimental|Hesperidin + Vitamin C (B)|study drink with vitamin C compared to study drink with hesperidin and vitamin C
11065799|NCT04316377|Active Comparator|Treatment|Chloroquine therapy in addition to standard of care
11065800|NCT04316377|No Intervention|No Treatment|Standard of care
11065801|NCT04316364|Experimental|Treatment group A|"Neoadjuvant setting: SHR-316 and carboplatin and Paclitaxel (Albumin Bound) 3 cycles;
~Adjuvant setting: SHR-1316 up to 16 cycles"
11065802|NCT04316364|Placebo Comparator|Treatment group B|Neoadjuvant setting: Placebo and carboplatin and Paclitaxel (Albumin Bound) 3 cycles;
11065803|NCT04316351|Experimental|Toripalimab + Pemetrexed + Anlotinib|
11065804|NCT04316338|Experimental|Active intermittent theta-burst stimulation (iTBS)|6 weeks of iTBS delivered at 80% resting motor threshold will be delivered to personalized regions in the prefrontal cortex based on each individual's functional connectivity.
11065805|NCT04316325||Women and girls seeking abortion.|
11065806|NCT04316312|Experimental|Inspiratory muscle training group|
11065807|NCT04316299||AKI|COVID-19 patients with acute kidney injury
11065808|NCT04316299||non-AKI|COVID-19 patients without acute kidney injury
11065809|NCT04316286|Experimental|Tele-multidisciplinary participants|Patients undergoing televisit
11065810|NCT04316286|Other|In-office standard participants|Patients undergoing in-office visits
11065811|NCT04316260|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
11065812|NCT04316260|Active Comparator|Treatment As Usual|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
11065813|NCT04316234|No Intervention|A. Clean Air|Clean air - no vaping was done.
11065814|NCT04316234|Experimental|B. Passive vaping|E-cigarette users were present in an adjacent chamber during both exposures, but only in situation B they were vaping and the vape-polluted air was passed on to the exposure chamber.
11065815|NCT04316221|Active Comparator|Control|The standard of nutrition care in Guatemala includes the following clinical care, as determined to be necessary by the MHA medical and nutrition teams: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
11065816|NCT04316221|Experimental|Intervention|The intervention group will receive an intervention to promote daily egg consumption for a six month period, in addition to the local standard of nutrition care. Specifically, intervention group participants will be provided with enough eggs for the infant to consume one egg, daily, for six months, and also with education on preparation and consumption of eggs.
11065817|NCT04316208|Experimental|Supratentorial tumor surgery|Patients undergoing elective supratentorial tumor surgery under general anesthesia will be ventilated with positive end-expiratory pressures of 0, 5 and 10 cmH2O after craniotomy.
11065818|NCT04316195||Patient admitted for an acute traumatic spinal cord injury|
11065819|NCT04316182|Experimental|Cabozantinib|Cabozantinib at 60 mg/day in monotherapy until symptomatic tumor progression, unacceptable adverse events, patient decision or death
11065820|NCT04316169|Experimental|Abemaciclib and HCQ 200 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
11065821|NCT04316169|Experimental|Abemaciclib and HCQ 400 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
11065822|NCT04316169|Experimental|Abemaciclib and HCQ 600 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
11065823|NCT04316169|Experimental|Abemaciclib + HCQ (Optimal Dose) + endocrine therapy|"This group will be divided into two cohorts:
~eligible participants who are endocrine therapy naive.
~eligible participants who had one prior line of endocrine therapy."
11065824|NCT04316156|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
11065825|NCT04316156|Active Comparator|Exercise using brochure|brochure
11065826|NCT04316143|Experimental|50 mg zamicastat|50 mg zamicastat once daily (half a tablet of 100 mg)
11065827|NCT04316143|Experimental|100 mg zamicastat once daily|100 mg zamicastat once daily (one tablet of 100 mg)
11065828|NCT04316143|Experimental|150 mg zamicastat once daily|150 mg zamicastat once daily (one and a half tablet of 100 mg)
11065829|NCT04316143|Experimental|200 mg zamicastat once daily|200 mg zamicastat once daily (two tablets of 100 mg)
11065830|NCT04316130|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
11065831|NCT04316130|Active Comparator|Exercise using brochure|brochure
11065832|NCT04316117|Experimental|Diagnostic (FDG-PET/CT)|Patients receive FDG IV and undergo PET/CT scan over 15-30 minutes at baseline (within 21 days before start of standard systemic treatment) and at 12 weeks after start of standard systemic treatment in the absence of unacceptable toxicity.
11065833|NCT04316104|Experimental|CuidTXT|This intervention, CuidaTXT [Spanish for self-care and texting], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
11065834|NCT04316091|Experimental|Experimental group|neoadjuvant chemotherapy+SPIONs/SMF
11065835|NCT04316091|Sham Comparator|Control group|neoadjuvant chemotherapy
11065836|NCT04316078|Experimental|personalized engagement platform|Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.
11065837|NCT04316078|No Intervention|control group|The control group will not be registered to the PEP nor receive any PEVs.
11065838|NCT04316065|Other|Group 1|15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8
11065839|NCT04316065|Other|Group 2|15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8
11065840|NCT04316052|Experimental|aerobic training group|At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine.
11065841|NCT04316052|Experimental|strength training group|Strength training prescriptions will be in accordance with recommendations of the American College of Sports Medicine.
11065842|NCT04316039|Experimental|RT+TMZ|
11065843|NCT04316039|Active Comparator|RT|
11065844|NCT04316026|Experimental|interventional group|group receiving shock wave therapy
11065845|NCT04316026|Sham Comparator|control group|sham shock wave therapy
11065846|NCT04316013|Active Comparator|A|Sevoflurane + intravenous lidocaine
11065847|NCT04316013|Active Comparator|B|Sevoflurane + placebo
11065848|NCT04316013|Active Comparator|C|Propofol TIVA + intravenous lidocaine
11065849|NCT04316013|Active Comparator|D|Propofol TIVA + placebo
11065850|NCT04316000||A - Removal of the Subepithelial Tumour|The subephitelial tumour is successfully removed by endoscopic band ligation without resection.
11065851|NCT04316000||B - Non Removal of the Subepithelial Tumour|The subephitelial tumour is not successfully removed due to various reasons (size >15-mm, not technical success,...).
11065852|NCT04316000||C - Not Observed or Benign Subepithelial Tumour|The subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients.
11065853|NCT04315987|Experimental|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
11065854|NCT04315987|Placebo Comparator|Placebo|Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
11065855|NCT04315974||Nonvalvular atrial fibrillation patients (NVAF)|Eligible patients comprise men and women aged 18 years or older with nonvalvular atrial fibrillation diagnosis undergoing ablation procedure.
11065856|NCT04315961|Experimental|Within-Subjects Dose Conditions|All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
11066166|NCT04313647|Experimental|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)
11065857|NCT04315948|Experimental|Remdesivir|"Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.
~n=620"
11065858|NCT04315948|Experimental|Lopinavir/ritonavir (stopped on June 29, 2020)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.
~n=620"
11065859|NCT04315948|Experimental|Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)|"Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.
~Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).
~n=620"
11065860|NCT04315948|Experimental|Hydroxychloroquine (stopped on May 24, 2020)|Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620
11065861|NCT04315948|Active Comparator|Standard of care|Standard of care. n=620
11065862|NCT04315935|Experimental|butorphanol group|Butorphanol (10-20 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
11065863|NCT04315935|Active Comparator|fentanyl group|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
11065864|NCT04315922||Severe Ischemic Stroke|Severe Stroke as defined by inclusion criteria
11065865|NCT04315922||Mild Ischemic Stroke|Mild Stroke as defined by inclusion criteria
11065866|NCT04315922||Transient Ischemic Attack|Transient Ischemic Attack as defined by inclusion criteria
11065867|NCT04315909|Experimental|Intervention group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus vitamin supplements (E (200 IU/ 2day) and C (250 mg/ 2day) ) for 8 weeks.
11065868|NCT04315909|Experimental|Control group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus placebo for 8 weeks.
11065869|NCT04315896|Active Comparator|treatment|Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
11065870|NCT04315896|Placebo Comparator|placebo|identical placebo, one tablet every 12 hours for 10 days
11065871|NCT04315883||Standard Treatment|"Evaluation of change of HRQOL survey responses will be performed:
~at baseline (time of treatment) and
~1 month post treatment
~6 months post treatment
~12 months post treatment
~5 years post-treatment
~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
11065872|NCT04315857||diabetics|diabetics receiving chemotherapy for cancer
11065873|NCT04315844|Experimental|balloon|To evaluate the efficacy and security of Ewata combined with a stent device in the treatment of acute ischemic stroke within 8 hours To prove whether the clinical efficacy and safety of Ewata r is not inferior to other guidings.
11065874|NCT04315818||study group|expermintal
11065875|NCT04315818||control group|placebo
11065876|NCT04315805|Experimental|Integrative Yoga Therapy|Integrative Yoga Therapy will be provided by yoga therapist once a week and participants will be encouraged to practice at home once or twice a day.
11065877|NCT04315805|No Intervention|Wait-list Control|Participants in waiting list will serve as control group for the intervention period. After the ftherapy group has received treatment, the same program will be offered to participants in the wait-list control group.
11065878|NCT04315792|Experimental|Endoxifen Arm|Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks
11065879|NCT04315792|Placebo Comparator|Placebo Arm|Placebo tablets of endoxifen. Patients will continue administration with their initial randomized medication for 3 weeks
11065880|NCT04315779|Active Comparator|Conventional laparoscopy|In this arm, patients will be treated via conventional laparoscopy
11065881|NCT04315779|Active Comparator|Transvaginal natural orifice transluminal endoscopic surgery|In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery
11065882|NCT04315753||cancer patients (clinical stage I and II) +controls|70 lung cancer patients (clinical stage I and II) diagnosed outside screening and candidates to surgical resection at Humanitas Hospital, and 70 controls with benign nodules. Cancer patients will undergo blood collection before and at 4 months after surgical resection. Blood will be used for CTC analysis, exosome antigens and circulating free DNA (cfDNA) mutational analysis.
11065883|NCT04315753||prospective screening cohort of high risk individuals|a prospective screening cohort of high risk individuals enrolled at Humanitas Hospital (1000) will allow to recruit 50 patients with screening detected lung cancer and a large number of negative controls. Analysis of CTC, exosome antigens and cfDNA mutation profile will be performed.
11065884|NCT04315740|Sham Comparator|Clean Air|Just clean air - no exposure
11065885|NCT04315740|Experimental|Cooking|Four ovens were frying pork - one at a time. When the first oven finished, the next oven started and so forth for approx. 7 hours.
11065886|NCT04315740|Experimental|Candles|10 lit candles were placed at a table. Burning for approx. 7 hours with light ventilation.
11065887|NCT04315727|Other|Study population|"Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies.
~Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation)."
11065888|NCT04315714|Experimental|IBS Yoga Intervention|Ten participants with IBS will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
11065889|NCT04315714|Experimental|IBS Waitlist Control Condition|Ten participants with IBS will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
11065890|NCT04315714|Experimental|HC Yoga Intervention|Ten participants serving as HC will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
11065891|NCT04315714|Experimental|HC Waitlist Control Condition|Ten participants serving as HC will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
11065892|NCT04315701|Experimental|Treatment (cemiplimab, surgical resection)|Patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles (or up to 4 cycles for patients whose disease is unresectable after 3 cycles) in the absence of disease progression or unacceptable toxicity. Within 6 weeks of last dose of therapy, patients with potentially resectable tumors undergo surgical resection.
11065893|NCT04315688||Tresiba®|Patients with type 2 diabetes
11065894|NCT04315675|Experimental|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs The Guided Imagery Programs include: 1.) Relaxation and Wellness; 2.) Immune System Imagery; and 3.) Healing Trauma.
11065895|NCT04315675|Experimental|Cognitive Power Intervention|The participant who is randomly assigned to this group completes The Power as Knowing Participation in Change Version II (PKPCT) to determine 1.) Freedom to Act Intentionally, 2.) Involvement in Creating Change, 3.) Freedom to Act Intentionally and 4.) My Involvement in Creating Change.
11065896|NCT04315675|Experimental|Cognitive Power Intervention and Guided Imagery|The participant is randomly assigned to this group completes both the Guided Imagery Intervention and the Cognitive Power Intervention.
11065897|NCT04315675|No Intervention|Control Group|The participant is randomized to the control group and completes all study measures twenty-one days after the baseline data are competed. .
11065898|NCT04315662|Experimental|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
11065899|NCT04315662|Active Comparator|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
11065900|NCT04315649|Experimental|3D movie|3D movie viewing
11065901|NCT04315636|Experimental|Surfactant nebulisation|The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.
11065902|NCT04315636|No Intervention|Standard care|The control group will receive standard care (PEEP, +/- noninvasive positive pressure ventilation, without surfactant nebulisation).
11065903|NCT04315623|Experimental|Reginal citrate anticoagulation|Patients accepted regional citrate anticoagulation for CRRT. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L. Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+. Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.
11065904|NCT04315623|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
11065905|NCT04315610|Experimental|Access to mobile application|This application will help parents to recognize symptoms of reduced health status in their infant, provide decision-making support, increase their communication skills with health professionals, and provide easier access to quality assured information. At first login, the diagnosis, treatment, and contacts in the health service are registered to provide parents with personalized information that is adapted to their infant's needs. Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application.
11065906|NCT04315610|Active Comparator|Treatment as usual|This group receives traditional oral and written information about their child's heart defect and further follow-up.
11065907|NCT04315597|Experimental|Hypericum extract STW 3-VI (Laif® 900, BAY98-7108)|
11065908|NCT04315597|Placebo Comparator|Placebo|
11065909|NCT04315584|Experimental|Diagnostic|Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
11065910|NCT04315571|Active Comparator|Group A|Routine Large Volume Paracentesis (LVP) with albumin infusion
11065911|NCT04315571|Active Comparator|Group B|Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
11065912|NCT04315558|Experimental|Revefenacin|Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.
11065913|NCT04315558|Active Comparator|Ipratropium|Nebulized ipratropium will be delivered via nebulizer Q6 hours.
11065914|NCT04315545||Healthy women pregnant of singleton with a BMI ≥25 kg/m2|Healthy women pregnant of singleton with a BMI ≥25 kg/m2 will be followed from 12 weeks of gestation till 6 months postpartum. Neonates will be followed from birth up to 6 months of age.
11065915|NCT04315532|Active Comparator|Pregnancy Group|"GCF and saliva samples were taken from pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from pregnant periodontal healty individuals baseline and after 8 weeks.
~Intervention: Non-surgical periodontal treatment was performed for pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
11065916|NCT04315532|Active Comparator|Non-Pregnancy Group|"GCF and saliva samples were taken from non-pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from periodontal healty individuals baseline and after 8 weeks.
~Intervention: Non-surgical periodontal treatment was performed for non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
11065917|NCT04315519|Experimental|Blood Flow Restricted Aerobic (BFRA)|Low intensity Aerobic exercise with Blood Flow Restriction
11065918|NCT04315519|Experimental|Moderate Aerobic Exercise (MAE)|moderate intensity aerobic exercise
11065919|NCT04315506|Experimental|SGR|Scheduled gradual reduction. Participants are asked to gradually reduce smokeless tobacco usage.
11065920|NCT04315506|Active Comparator|Control group|Participants in this arm will be given the Enuff Snuff cessation manual.
11065921|NCT04315493|Experimental|A|
11065922|NCT04315493|Experimental|B|
11065923|NCT04315480|Experimental|tocilizumab|
11065924|NCT04315467|Experimental|SGM-101|SGM-101 (5-10 mg) will be administered intravenously over 30 minutes followed by a 50 mL flush of isotonic saline to account for the dead volume of the tubing. SGM-101 will be administered 3 to 5 days (+/-1 day) prior to surgery. As a prophylactic measure to ensure the possibility of allergic reaction is absolutely minimized, 25 mg of IV Benadryl may be given the subject prior to the infusion of SGM-101 at the discretion of the Principal Investigator.
11065925|NCT04315454|Placebo Comparator|Group A|patients will receive 20 ml of normal saline into interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
11065926|NCT04315454|Experimental|Group B|Patients will receive 20 mg 0.25% Levobupivacaine into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
11065927|NCT04315441||Soldiers|any soldier who attended the Military Medical Center of Sector N°5 for the annual re-engagement medical visit during the period from January 1, 2017 to November 13, 2018.
11065928|NCT04315441||Civilians|The civilian populations were recruited from two free cardiovascular risk factors screening campaigns carried out from January 04, 2017 to January 10, 2017 and from November 12, 2018 to November 18, 2018
11065929|NCT04315428||premature swaddled|the childs in this group will be wrap in a lange (swaddled)
11065930|NCT04315428||premature no swaddled|the childs in this group will be not swaddled
11065931|NCT04315415|Experimental|6 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
11065932|NCT04315415|Experimental|12 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
11065933|NCT04315402||Group 1 (provider-patient concordant)|
11065934|NCT04315402||Group 2 (provider-patient discordant)|
11065935|NCT04315389||EXPERIMENTAL|OPEN LABEL USING HEALTHCARE ROBOTS IN PARALLEL (non comparison) EXPOSURE: 90 MINUTES 3 TIMES PER DAY FOR 3 DAYS, NON CONSECUTIVE
11065936|NCT04315376|Experimental|Exercise-Diet Group|The participants receive a personal exercise program according to Astrand-rhyming test baseline results, and a hypo-caloric diet intervention
11065937|NCT04315376|Active Comparator|Diet Group|The participants no receive a personal exercise program, only the hypo-caloric diet
11065938|NCT04315363|Experimental|Intervention|Brain MRI and Motivational Behavioral Intervention
11065939|NCT04315363|Active Comparator|Active control|Brain MRI and Control Behavioral Intervention
11065940|NCT04315350|Experimental|Curcumin|Participant receives both curcumin and prednisolone. Curcumin for 11 days, prednisolone for 10 days. Curcumin: 2 tablets (each contains 100 mg curcumin) twice daily. Prednisolon: 50 mg (capsule) every morning
11065941|NCT04315350|Other|Prednisolon|Participant receives prednisolone and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon: 50 mg (capsule) every morning
11065942|NCT04315350|Placebo Comparator|Placebo|Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.
11065943|NCT04315337|Experimental|Virtual Training Arm|This is a within-participant study with one arm. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task and a control task.
11065944|NCT04315324|Experimental|Treatment (AKR1C3-activated prodrug OBI-3424)|Patients receive AKR1C3-activated prodrug OBI-3424 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
11065945|NCT04315311|Experimental|CREON|Participants will receive daily dose of CREON.
11065946|NCT04315298|Experimental|Sarilumab low dose (P2)|Phase 2
11065947|NCT04315298|Experimental|Sarilumab low dose (P3:C1)|Phase 3: Cohort 1
11065948|NCT04315298|Experimental|Sarilumab mid dose (P2)|Phase 2
11065949|NCT04315298|Experimental|Sarilumab mid dose (P3:C1)|Phase 3: Cohort 1
11065950|NCT04315298|Experimental|Sarilumab high dose (P3:C2)|Phase 3: Cohort 2
11065951|NCT04315285|Active Comparator|Control group|12 sessions of treadmill training with instruction of 'swing your arms'
11065952|NCT04315285|Experimental|Heel-strike group|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
11065953|NCT04315285|Experimental|Big step group|12 sessions of treadmill training with instruction of 'lift your foot up high'
11065954|NCT04315285|Experimental|Internal focus heel-strike|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
11065955|NCT04315285|Experimental|External focus shoe-strike|12 sessions of treadmill training with instruction of 'strike the ground with your shoe-heel'
11065956|NCT04315272|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
11065957|NCT04315272|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
11065986|NCT04315025|Active Comparator|UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar
11066218|NCT04313270||Patients with FH starting a treatment with Evolocumab®|
11098030|NCT04090151||Royal Free HIV Cohort Study|
11065958|NCT04315259|Experimental|Laser activated irrigation|conventional root canal treatment was done , 2.5% sodium hypochlorite was used and was activated by 980 nm with a repeated pulse mode using a pulse duration of 5 s and a pulse interval of 0.2 ms. The laser irradiation will be delivered for 1 minute into the canal up to 1 mm short of the working length, with circling movements from the apical part moving towards the coronal part (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100)
11065959|NCT04315259|Experimental|Soft tissue laser application|"Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices.
~Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product"
11065960|NCT04315259|No Intervention|conventional root canal|conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with no laser intervention
11065961|NCT04315246|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles (Part 1) and up to 104 weeks (Part 2).
11065962|NCT04315233|Experimental|Treatment: all patients|Ribociclib and belinostat will be given at escalating doses and on multiple administration schedules throughout the dose escalation component of the study. The MTD identified in the dose escalation component will be used to define the dose and administration schedule used in the dose expansion.
11065963|NCT04315220|Experimental|Experimental group (Core stability training (CST))|"Core stability training (CST) consists of two levels: level 1- Mat exercises (includes abdominal muscle contraction, bridging,cat stretch,single leg circle and superman) and level 2- Swiss ball exercises (includes abdominal muscle contraction, bridging and squatting by using therapy ball).
~There will be three sets of 15 repetitions of each exercises. The first set will consist of 10 seconds hold period, follow by 12 seconds hold in second set and 15 seconds hold in third set respectively. The entire session will last for approximately 30 minutes."
11065964|NCT04315220|Active Comparator|Control group|Will not receive any kind of training.
11065965|NCT04315207|Active Comparator|In-person visit|"In-person meeting with the patient in the out-patient department. The patient is free to bring up to four* relatives or other persons of their own choice to the in-person meeting.
~(* Restriction due to space limitation)."
11065966|NCT04315207|Experimental|Telephone call|Telephone call with the patient. The patient is free to turn on loudspeaker to include relatives or other persons in the telephone conversation, alternatively to ask the physician to call and inform one relative or other person after the patient-doctor telephone call
11065967|NCT04315194||clarithromycin-naproxen-oseltamivir|Efficacy of clarithromycin-naproxen-oseltamivir combination therapy vs. oseltamivir alone for hospitalised paediatric influenza patients
11065968|NCT04315181|Experimental|Oral opioid agonist|Participants will receive non-therapeutic experimental doses of active or placebo oral opioid agonist. Active opioid agonist/placebo will be administered once per session and will be administered orally.
11065969|NCT04315181|Experimental|Oral sedative|Participants will receive non-therapeutic experimental doses of active or placebo oral sedative. Active sedative/placebo will be administered once per session and will be administered orally.
11065970|NCT04315181|Experimental|Opioid agonist/sedative|Participants will receive non-therapeutic, experimental doses of active opioid agonist/placebo in combination with non-therapeutic, experimental doses of active sedative/placebo. Opioid/placebo and sedative/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid and sedative doses will be administered orally.
11065971|NCT04315155|Experimental|Double Regimen|belinostat in combination with nivolumab
11065972|NCT04315155|Experimental|Triplet Regimen|belinostat in combination with nivolumab and ipilimumab
11065973|NCT04315142|Experimental|Transcutaneous tibial nerve stimulation (TTNS)|
11065974|NCT04315142|Sham Comparator|TTNS sham stimulation|
11065975|NCT04315129|Other|Single arm|A single arm will have biosensor (experimental) diagnoses compared to clinical (control, current standard of care). All participants in this group willl have a biosensor, with the data masked to patients, providers and clinical researchers
11065976|NCT04315116|Experimental|Treament|Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
11065977|NCT04315103|Experimental|the combined-injection group|patients received a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
11065978|NCT04315103|Active Comparator|the one-injection group|patients received a single injection of 3 ml PRP
11065979|NCT04315077|Experimental|Experimental Group|Subjects will consume one serving per day (25mg) of the treatment condition (Oceanix ®) for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
11065980|NCT04315077|Placebo Comparator|Placebo Group|Subjects will consume one serving per day (25mg) of the microcrystalline cellulose-based placebo condition for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
11065981|NCT04315064|Experimental|Treatment with MTX110|
11065982|NCT04315051|Placebo Comparator|Placebo Gel|Placebo gel daily application for 4 weeks
11065983|NCT04315051|Active Comparator|Cohort 1|DBI-001 Gel daily application for 4 weeks
11065984|NCT04315038||All patients|Spinal anesthesia
11065985|NCT04315025|Active Comparator|Conditioned Medium (CM)|a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar
11066057|NCT04314531|Experimental|Arm A|
11066058|NCT04314531|Placebo Comparator|Arm B|
11065987|NCT04315025|Active Comparator|UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar
11065988|NCT04315012|Experimental|Receiving mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
11065989|NCT04315012|No Intervention|Standart|not to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
11065990|NCT04314999||Patients diagnosed with a chronic spontaneous urticaria|Patients with a chronic spontaneous urticaria who were being treated at the allergology of the university hospital Basel between the 1st of June and the 30th of September
11065991|NCT04314986|Experimental|AR882 (Dose A)|
11065992|NCT04314986|Experimental|AR882 (Dose B)|
11065993|NCT04314986|Experimental|AR882 (Dose C)|
11065994|NCT04314986|Experimental|AR882 (Dose D)|
11065995|NCT04314986|Placebo Comparator|Placebo|
11065996|NCT04314973|Active Comparator|Control phase|Patients will follow walking exercises sessions, without wearing the robotic device, for 30 sessions of 45 min.
11065997|NCT04314973|Experimental|Intervention phase|Patients will walk with the robotic device, for 30 sessions of 45 min.
11065998|NCT04314960|Experimental|CAI subjects|Subjects in this group will receive eight 20-minutes gait training sessions with functional electrical stimulation.
11065999|NCT04314934|Experimental|Active|ANAVEX2-73
11066000|NCT04314921|Experimental|10-week Yoga|Eighteen healthy elderly people, who were classified into two age groups, participated in this study. All participants had not practiced yoga before and were asked not to perform any sports activities while the research was ongoing. In the experimental group, participants (n = 18) had to participate in 10 weeks of yoga classes. In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life. All experimental group subjects participated in Himalayan yoga classes, which lasted 10 weeks: 2 times per week, 90 min per session. Yoga classes were conducted by 16-year-old qualified yoga instructor from Yoga Academy, Kaunas.
11066001|NCT04314921|No Intervention|Control|In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life.
11066002|NCT04314908|Experimental|Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0."
11066003|NCT04314908|Experimental|Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0 and sonic activation assisted irrigation will be applied."
11066004|NCT04314908|Experimental|Non Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point."
11066005|NCT04314908|Experimental|Non Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point and sonic activation assisted irrigation will be applied."
11066006|NCT04314895|Experimental|NanoPac|Intratumoral injection of NanoPac 15 mg/mL at a volume of up to 20% of the total calculated tumor and lymph node volume (not to exceed 40 mL) on up to three occasions 4 weeks apart.
11066007|NCT04314869|Experimental|Recipient|Patient with absolut uterine factor will undergo uterus transplantation.
11066008|NCT04314856|Experimental|Fragile X Syndrome|"Adult males aged 18-30 years diagnosed with FXS will undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.
~These participants will only be administered once with 18F-FTC-146."
11066009|NCT04314856|Experimental|Healthy Volunteers (Control)|"Adults aged 18-65 years undergo a PET/MRI scan using 18F-FTC-146 to determine sigma-1 receptor density.
~Test-retest studies will be performed where these individuals will each be injected twice with 18F-FTC-146."
11066010|NCT04314843|Experimental|Lenzilumab and Axicabtagene Ciloleucel|"Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab.
~Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0."
11066011|NCT04314830|Active Comparator|Gait training without perturbation|Walking on a treadmill with the same duration as a participants of the experimental arm matched for initial gait speed. Treadmill speed did not change along the training program
11066012|NCT04314830|Experimental|Gait training with perturbations|Walking on a treadmill with perturbations produced by changes in the speed of one of the belt of the split-belt treadmill during one gait cycle. Changes in treadmill speed were applied on the paretic or non-paretic side, with and increase or a decrease of the speed of the belt in various magnitude. Perturbations were either repeated with the same characteristics or with different characteristics. Outside of perturbations, treadmill speed did not change along the training program.
11066013|NCT04314817||Patients treated for Covid-19|
11066014|NCT04314804|Experimental|Smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
11066015|NCT04314804|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
11066016|NCT04314791||US scan with calculation of the PAI|
11066017|NCT04314778|Experimental|Intervention|Participants in the intervention arm will have a postoperative daily step goal that increases from baseline by 500 steps each day.
11066018|NCT04314778|No Intervention|Control|Participants in the control group will have data collected passively via Fitbit.
11066019|NCT04314765|Experimental|bayonet flap|Bayonet flap is performed to extract the the lower third molar
11066020|NCT04314765|Experimental|envelope flap|Envelope flap is performed to extract the the lower third molar
11066021|NCT04314739|Active Comparator|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
11066022|NCT04314739|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
11066059|NCT04314505|Experimental|Opioid Sparing Protocol|Preemptive(before incision): Parecoxib sodium 40 mg Postoperative: Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses.
11099395|NCT04080674||Dystonia|20 participants
11066023|NCT04314726|Active Comparator|amelogenins group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. Amelogenins effect was evaluated by applying them only in the test site and comparing healing results with those obtained on the contra-lateral site
11066024|NCT04314726|Placebo Comparator|placebo group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. In this group (control site) the conventional treatment was performed, and healing was ensured only by the simple blood clot
11066025|NCT04314713|Placebo Comparator|Scopolamine HBT 0.005 mg/kg|Dose of Scopolamine 0.005mg/kg verses Placebo
11066026|NCT04314713|Placebo Comparator|Scopolamine HBT 0.007 mg/kg|Dose of Scopolamine 0.007mg/kg verses Placebo
11066027|NCT04314713|Placebo Comparator|Scopolamine HBT 0.011 mg/kg|Dose of Scopolamine 0.011mg/kg verses Placebo
11066028|NCT04314713|Placebo Comparator|Scopolamine HBT 0.014 mg/kg|Dose of Scopolamine 0.014mg/kg verses Placebo
11066029|NCT04314713|Placebo Comparator|Scopolamine HBT 0.021 mg/kg|Dose of Scopolamine 0.021mg/kg verses Placebo
11066030|NCT04314713|No Intervention|Placebo|Placebo controlled
11066031|NCT04314687|Experimental|UCMSCs + CM|UCMSCs + CM is administered via intrathecal injection
11066032|NCT04314687|Experimental|UCMSCs|UCMSCs is administered via intrathecal injection
11066033|NCT04314687|Active Comparator|Standard Therapy|Physiotherapy
11066034|NCT04314674|Active Comparator|%3 HS bolus 3 mL.kg-1|After the head fixation 3 mL.kg-1 %3 hypertonic saline will be administered over the 20 min intravenously.
11066035|NCT04314674|Active Comparator|%3 HS infusion 20 ml/h|After the head fixation 3% hypertonic saline at 20 ml/h infusion rate will be administered during the operation
11066036|NCT04314674|Active Comparator|%20 mannitol 0,6 gr.kg-1|After the head fixation %20 mannitol 0,6 gr.kg-1 will be administered over the 20 min intravenously.
11066037|NCT04314661|Experimental|Arthoscopy + UC-MSCs + CM + CM|After arthroscopy patient will be given UC-MSCs 5 million cells, after 2 weeks patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
11066038|NCT04314661|Experimental|Non Arthoscopy + UC-MSCs + CM + CM|Patient will be given UC-MSCs 5 million cells, after 2 weeks patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
11066039|NCT04314661|Experimental|Non Arthoscopy + CM + CM|Patient will be given CM 2 cc and after 2 weeks later the patient will be given CM 2 cc
11066040|NCT04314648|Active Comparator|START|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.
~The components of the START intervention are as follows:
~Triage
~Engage, Assess, and Plan
~Treat
~Communicate and Coordinate
~Follow up
~Monitor"
11066041|NCT04314648|No Intervention|Usual Care|Usual care for people with alcohol or opioid use disorder.
11066042|NCT04314635|Active Comparator|TAU comparison group|TAU includes standard care modules (psychoeducation, coping, safety planning, problem solving, healthy lifestyle) administered to the teen while they are hospitalized on the inpatient unit. All teens, as part of TAU, also receive skills groups, individual treatment, and family planning meetings. All TAU families will receive a referral to an outpatient provider (standard care procedure) plus referral to specialized CHR case management services.
11066043|NCT04314635|Experimental|Brief intervention group|TAU + experimental intervention. The experimental group will receive all services provided to the TAU group (described above) and, additionally, the experimental intervention.The intervention includes 1 individual session for each teen and parent and 2 family sessions (focused on psychoeducation and motivational enhancement) with both the teen and parent, delivered during hospitalization (~45-60 minutes per session).
11066044|NCT04314622|Experimental|Supaglutide (Part A)|Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.
11066045|NCT04314622|Placebo Comparator|Placebo(Part A)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
11066046|NCT04314622|Experimental|Supaglutide (Part B)|Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.
11066047|NCT04314622|Placebo Comparator|Placebo (Part B)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
11066048|NCT04314609|Experimental|Ultrasound , fluroscope|After injection of corticosteroids with 1 ml contrast in sacroiliac joint using ultrasound and withdrawal of the needle, an antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular.
11066049|NCT04314596|Placebo Comparator|Placebo Group|Participants will engage in a one day, whole-body, cross-training course while consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
11066050|NCT04314596|Experimental|Experimental Group|Participants will engage in a one day, whole-body, cross-training course while consuming the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
11066051|NCT04314583|Active Comparator|Attention Control Group|Adult patients attending cardiovascular rehabilitation.
11066052|NCT04314583|Experimental|Gratitude Journaling Group|Adult patients attending cardiovascular rehabilitation.
11066053|NCT04314570|Experimental|Ropivacaine Treatment|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Ropivacaine through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
11066054|NCT04314570|Placebo Comparator|Saline Control|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
11066055|NCT04314544|Experimental|Arm A|
11066056|NCT04314544|Placebo Comparator|Arm B|
11066060|NCT04314505|Active Comparator|Opioid Based Patient Controlled Analgesia|Preemptive(before incision) and Postoperative: the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours; adjusted by the PCA staff
11066061|NCT04314492|Experimental|Intracapsular tonsillectomy with coblation|(Total) Intracapsular tonsillectomy (ICTE) with coblation
11066062|NCT04314479|Experimental|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes
11066063|NCT04314479|Other|Symptom Assessment Only|For participants randomized to the control condition weekly symptom assessment telephone calls will be completed by staff at the University of Arizona Cancer Center Behavioral Measurements Interventions Shared Resource (BMISR). At week 13 an exit interview will be completed by the study coordinator to record participants feedback regarding study intervention, length, coaches, etc… In addition, staff from BMISR will call to repeat all baseline measures with the exception of the demographic questionnaires. Symptom assessment calls will take approximately 15 minutes.
11066064|NCT04314453||T group|The degenerative lumbar spinal stenosis patients accepted the PELD with TESSYS procedure.
11066065|NCT04314453||U group|The degenerative lumbar spinal stenosis patients accepted the PELD with U route procedure.
11066066|NCT04314440|Experimental|Music therapy|After the initial warm up session music therapy will be delivered three times a week for 15-20 minutes. All babies in the experimental group will be exposed to three weeks of music therapy sessions that is a total of 9 music therapy session prior to discharge from the hospital. The baby will be placed at the bassinet 15 minutes before music therapy begins. The baby will be in the bassinet during music therapy and 15 minutes post music therapy to allow measurement of physiological indicators. If parents are present during music therapy they will not engage in kangaroo care during the music therapy session or when physiological measurements are being taken pre and post music therapy, but can do so at other times.
11066067|NCT04314440|No Intervention|Control|Infants in this group will not receive any music therapy but will receive all other standard care provided to infants at the Regina General Hospital (RGH). All measurements will be carried out for all the infants in this group at the time when observations are carried out for infants in the music therapy group.
11066068|NCT04314427||Gastric by-pass|Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
11066069|NCT04314427||Sleeve gastrectomy|Sleeve gastrectomy reduces the stomach size by vertical stapling
11066070|NCT04314414|Experimental|Intervention group|Participants in the intervention group will receive a semi-scripted brief motivational interview from the peer recovery coach (PRC) in addition to the standard of care at Boston Medical Center (BMC) for HIV, HCV, and opioid use disorder.
11066071|NCT04314414|Active Comparator|Standard of care group|Participants in this group will receive the standard of care at BMC for HIV, HCV and opioid use disorder.
11066072|NCT04314401||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 10 years.
11066073|NCT04314388|Experimental|Intervention: Outdoor walking Rehabilitation Programme|Participants in the intervention will be provided with an exercise diary. This will include walking routes for the instructor led 3-month outdoor-walking rehabilitation programme. The exercise diary will also include home exercises for the participants to complete twice-per-week that will be explained in detail, using coaching points and images to support. As these exercises will be completed at home. Each exercise has four progressions ranging from easy to hard.
11066074|NCT04314388|Other|Control: The light Stretches Programme|The control group intervention will be a non-exercise intervention to avoid training effects. The control group will be asked to keep to their normal activities of daily living and given ten targeted active stretches for the upper and lower body three times per week at home. Participants in the control group will each be provided a booklet for the given stretches.
11066075|NCT04314375|Experimental|Low Dose Budesonide|
11066076|NCT04314375|Experimental|High Dose Budesonide|
11066077|NCT04314375|Placebo Comparator|Placebo|
11066078|NCT04314362|Experimental|AZR-MD-001 Active|AZR-MD-001 ointment/semi-solid drug (1.0%)
11066079|NCT04314362|Experimental|AZR-MD-001 Active + Conventional Treatment|AZR-MD-001 ointment/semi-solid drug (1.0%) plus Hylo-Forte®
11066080|NCT04314362|Experimental|AZR-MD-001 vehicle|AZR-MD-001 vehicle control
11066081|NCT04314310|Active Comparator|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
11066082|NCT04314310|Placebo Comparator|placebo|equal volume of normal saline
11066083|NCT04314297|Experimental|Anlotinib In Combination With Durvalumab|
11066084|NCT04314284|Other|Historical Control Survey|-The investigators will conduct a historic control survey of 80-100 recently diagnosed gynecologic, colorectal, and lung cancer patients. They can complete the survey in-person, over the phone, or online. The survey will take approximately 15 minutes to complete. It will ask about their knowledge of health insurance and confidence communicating about care costs.
11066117|NCT04314037|Experimental|Sequence 2 (R1-T1-R2-T2)|Participants will receive first dose of Biltricide on Day 1 in treatment period 1 followed by first dose of Cesol on Day 8 in treatment period 2 followed by second dose of Biltricide on Day 15 in treatment period 3 followed by second dose of Cesol on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
11099469|NCT04080102|Experimental|High intensity interval training (HIIT)|
11066085|NCT04314284|Other|Oncology Providers|-The investigators will train 15 gynecologic, colorectal, and lung cancer care providers in using I Can PIC and discussing costs with patients in a brief 15 minute presentation that can be delivered in-person or virtually. Providers will complete a survey before and after their brief training at the start of the study. These surveys will take approximately 5-10 mins to complete in total. During the study, at 3- and 6- months, the investigators will give real-time feedback to providers on the percent of time that they screened for financial distress and referred patients to I Can PIC. At the end of the study, the investigators will examine adoption, implementation, and maintenance measures.
11066086|NCT04314284|Experimental|I Can PIC|-Approximately 80-100 participants will use I Can PIC. This will take approximately 10-15 minutes. After their next appointment with their provider, they will complete a brief survey about their knowledge of health insurance and confidence communicating about care costs. This will take about 10 mins. Patient participants who choose to complete the study in person may view I Can PIC on a tablet provided in the clinic or at the office. Then after their appointment, they can complete the survey on a tablet provided in the clinic or at the office. If they choose to complete it over the phone, the investigators will email them the link to I Can PIC and then call them when it is time to complete the survey. If they wish to complete it online, the investigators will email them the link to I Can PIC, and then the survey after their appointment. After 3-6 months, participants will receive a 5-10 minute follow-up survey which they can complete in-person, online, or over the phone.
11066087|NCT04314258|Experimental|Drinking Moringa oleifera tea|The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
11066088|NCT04314258|No Intervention|Drinking plain water|The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.
11066089|NCT04314245||Urothelial carcinoma group|Subjects who diagnosed with incident or recurrent urothelial carcinoma (including bladder/ureter/renal pelvis) by surgical pathology.
11066090|NCT04314245||interference group|Subjects who diagnosed with incident or recurrent bladder cancer other than urothelial carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer) by surgical pathology.
11066091|NCT04314245||Control group|Subjects who clinically diagnosed with benign disease of the urinary system, such as Urinary calculi, urinary tract infection (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.
11066092|NCT04314245||Healthy volunteers group|Volunteers who have a normal routine urine test / ultrasound examination of the urinary system and do not carry suspected tumors of other organs.
11066093|NCT04314219|Experimental|Arm 1: Intervention|
11066094|NCT04314219|Active Comparator|Arm 2: Standard of Care|
11066095|NCT04314206|Experimental|VNRX-5024|Capsule formulation
11066096|NCT04314206|Placebo Comparator|Placebo|Placebo for VNRX-5024
11066097|NCT04314193|Experimental|methotrexate|
11066098|NCT04314193|Active Comparator|prednisolone|
11066099|NCT04314180||Slit-lamp image quality assessment|Device: an artificial intelligence system for quality assessment of slit-lamp images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center
11066100|NCT04314167|Experimental|LDL lowering therapy|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
11066101|NCT04314154||Study group|Group of all patients hospitalized in the SMHC and due participate in rehabilitative procedures
11066102|NCT04314141||Transgender patients|Transgender patients who carry out sex reassignment surgery.
11066103|NCT04314141||Cismale patients|Cismale patients who carry out surgery to correct a congenital or acquired lack of penis.
11066104|NCT04314128|Other|Patients suspected of IIH at baseline|"Intervention: TOS and TCD measurements at baseline, and at routine follow-ups.
~Healthy controls will be recruited to match the patients."
11066105|NCT04314115|Active Comparator|Mindfulness|A brief intervention in mindfulness will be administered
11066106|NCT04314115|Active Comparator|Systemic therapy|A brief systemic therapy intervention will be administered
11066107|NCT04314115|Active Comparator|Cognitive behavioral therapy and positive psychology|A brief intervention of traditional cognitive behavioral therapy with positive psychology elements will be administered
11066108|NCT04314115|No Intervention|Waiting list|Waiting list, as a control group
11066109|NCT04314102||1|"Individuals will be evaluated before knee arthroplasty surgery. They will come for control in the 1st and 3rd months after surgery.
~No intervention will be made."
11066110|NCT04314089|Experimental|GT103|Participants will receive GT103 every 3 weeks. GT103 will be escalated from .3mg/kg up 10 to mg/kg or until MTD is found
11066111|NCT04314076|Active Comparator|Gait Training (GT) with Rythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS
11066112|NCT04314076|Other|Gait training (GT) without Rythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS
11066113|NCT04314050|Active Comparator|tramadol|1,5 mg /kg tramadol will perform intraoperatively in 100 ml saline within 15 minutes at 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
11066114|NCT04314050|Active Comparator|dexmedetomidine|1 mcg/kg dexmedetomidine bolus will perform after anesthesia induction and followed by infusion of 0.5 mcg/kg/h until 30 minutes before surgery completed. In addition, 1 gr paracetamol will be given intraoperatively.
11066115|NCT04314050|Placebo Comparator|control|1 gr paracetamol will perform intraoperatively
11066116|NCT04314037|Experimental|Sequence 1 (T1-R1-T2-R2)|Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
11066163|NCT04313673||randomized|Patients who were followed up in our clinic with a diagnosis of preterm labor that spontaneously took action and were born before 37 weeks of gestation will form a group.
11066118|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 1: A-B-C|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
11066119|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 2: A-C-B|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
11066120|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 3: B-A-C|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
11066121|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 4: B-C-A|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
11066122|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 5: C-A-B|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
11066123|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 6: C-B-A|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
11066124|NCT04314011|Experimental|HUC-MSCs Group|Human umbilical cord mesenchymal stem cells (80 Million cells/200ml): delivered via peripheral intravenous infusion.
11066125|NCT04314011|Placebo Comparator|Control Group|Placebo:normal saline(200ml) delivered via peripheral intravenous infusion.
11066126|NCT04313985|Active Comparator|Electrical Stimulation|"Treat the patient's wound area:
~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.
~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.
~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
11066127|NCT04313985|Sham Comparator|Sham Electrical Stimulation|"Treat the patient's wound area:
~Place self-adhesive, conductive electrode pads on either side of the wound on the skin where the pads are not placed in the open wound itself, but rather in the surrounding area with one pad on each side of the wound.
~Connect the pads to the lead wire to the Avazzia device. Turn on the Avazzia device and change modes to the RSI mode. Increase power to maximum comfortable power level for the patient. If the patient cannot feel the output, then increase power to 250.
~Instruct the patient to reduce the power level if it begins to feel too strong. (sometimes as the microstimulation is applied, the tissue will become more sensitive to the stimulation. In this case the power should be reduced for patient comfort.) Allow to run unattended for 15 minutes. Take a picture of the pad placement and display on the device to document location, power setting, and treatment mode while the treatment is running for the 15 minutes."
11066128|NCT04313972|Experimental|Low-dose naltrexone|
11066129|NCT04313972|Placebo Comparator|Placebo|
11066130|NCT04313959|Active Comparator|Local anesthetic|Patients assigned for local anesthetic group will receive a single-shot ultrasound-guided erector spine plane block with 25 mL of 0.2% of ropivacaine
11066131|NCT04313959|Active Comparator|Local anesthetic + steroid|Patients assigned for local anesthetic + steroid group will receive a single-shot ultrasound-guided erector spine block plane with 25 mL of 0.2% of ropivacaine with 4 mg dexamethasone
11066132|NCT04313946||Symptomatic Patients|Our goal is to identify an artificial intelligence algorithm that can be run on lung radiographs in patients with influenza / respiratory viral symptoms who come to the emergency department / triage. This algorithm aims to identify the radiographs of patients with COVID-19 and those with influenza pneumonitis, with accuracy verified by COVID-19 tests.
11066133|NCT04313920|Experimental|Nutritional Supplement|Ready to drink liquid
11066134|NCT04313907|Experimental|Acitve laser+topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus topical clonazepam 1 mg, 3 times at day, same 14 days both
11066135|NCT04313907|Sham Comparator|Sham laser+topical clonazepam|Using sham laser (six sesions) plus topical clonazepam 1 mg, 3 times at day, same 14 days both
11066136|NCT04313907|Placebo Comparator|Active laser+placebo of topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus placebo of topical clonazepam (lactose), 3 times at day, same 14 days both
11066137|NCT04313894|Experimental|Stem Cell Therapia Group|A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
11066164|NCT04313660|Experimental|Anlotinib In Combination With PD-1/L1 Inhibitor|
11066165|NCT04313647|Experimental|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)
11066138|NCT04313881|Experimental|Magrolimab + Azacitidine|"Participants will receive the following magrolimab and azacitidine dosing regimens:
~Magrolimab:
~Cycle 1: 1mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and 22
~Cycle 2: weekly doses of 30 mg/kg on Days 1, 8, 15, and 22
~Cycle 3 and onward: 30 mg/kg every 2 weeks on Days 1 and 15
~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle"
11066139|NCT04313881|Placebo Comparator|Control Arm (Placebo + Azacitidine)|"Participants will receive the following placebo and azacitidine dosing regimens:
~Placebo:
~Cycle 1: Days 1, 4, 8, 11, 15, and 22
~Cycle 2: Days 1, 8, 15, and 22
~Cycle 3 and onward: Days 1 and 15
~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle"
11066140|NCT04313868|Experimental|Phase 1A.1: Peripheral IV|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given intravenously on three consecutive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
11066141|NCT04313868|Experimental|Phase IA.2: Hepatic Artery Infusion|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given as a single hepatic artery infusion (HAI) on two successive days and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
11066142|NCT04313868|Experimental|Phase IA.3: Intratumoral Injection|GEN2 is administered in repeating three week cycles. On week one, GEN2 is given via injection directly into the tumor lesions on one day and the presence of the HSV-TK-m2 expression is monitored by [18F]FHBG PET scanning after 3 to 8 days. Valganciclovir dosing is initiated on day 7 to 9 for 5 days. An approximately one week drug holiday follows.
11066143|NCT04313855|Experimental|Chronic post-operative pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.
~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
11066144|NCT04313829|Active Comparator|Intervention group|The intervention group received Pharmacist counseling for 15 minutes include giving standard medicine information service and explaining the validated pharmacist counseling module which contained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed dose.
11066145|NCT04313829|No Intervention|Control group|The control group received standard medicine information services by Pharmacists.
11066146|NCT04313816||unique group|patients visiting their family physician
11066147|NCT04313803||American Fork|CGM usage months 1 and 3
11066148|NCT04313803||Central Orem|CGM usage for month 1
11066149|NCT04313803||North Canyon, Saratoga Springs, and Lehi|CGM usage for 1-3 months
11066150|NCT04313790|Experimental|Heparin Infusion|heparin infusion 500unit \hour
11066151|NCT04313790|Other|Subcutaneus Heparin|subcutaneous heparin 5000unit \ 8 hours
11066152|NCT04313777|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
11066153|NCT04313777|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
11066154|NCT04313764|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
11066155|NCT04313764|Active Comparator|Group Infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
11066156|NCT04313751|Experimental|Education, Physical Activity, and Stress Management Program|Classes for the intervention group will be run by a bilingual interventionist and will last 120 minutes weekly for 12 weeks and then monthly for 3 months.
11066157|NCT04313751|Active Comparator|Wait-list Control|Data in the wait-list control group will be collected at the same time intervals as the intervention group. After Time 3 data collection, they will be offered the Phase I intervention (12 weekly sessions).
11066158|NCT04313738|Experimental|Intervention group|Experimental: Intervention group Intervention group: Home visit, health education, telephone counseling At the intervention group; the researcher firstly made spirometry meausurement in hospital. After, the researcher made pretest (baseline measurement) before nursing interventions at the first home visit. At the first home visit, the researcher was offered education and guide smoking cessation. Second, Third and fourth home visit were made 15 days later, one and six months after visit first visit. During the second, third and fourth home visits, firstly the patient's stage of change was determined and then appropriate nursing intervention was performed in accordance with the guidelines.Between the third and fourth home visits, the participants were contacted through telephone calls once a month. At fourth home visit, the researcher made posttest. After the patient was invited to the hospital and spirometry measurements were repeated.
11066159|NCT04313738|No Intervention|Control Group|At the control group; No home visits were paid to the control group. The researcher made measurements twice at in the first and sixth months in the hospital. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
11066160|NCT04313712||Participants|All study participants will be observed before and after they receive exposure to tabernanthe iboga in other countries.
11066161|NCT04313686|Experimental|Mindfulness-based therapy|The mindfulness training program included mindfulness meditation practices, self-enquiries, mindful movement as well as understanding of stress physiology and cognitive awareness in the Breathworks/ Paradigm system of mindfulness-based approaches. Participants were enrolled in 5-10-person groups that met weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
11066162|NCT04313686|Active Comparator|No-Intervention|The control group would attend their routine follow-up visits at the neurology outpatient clinic.
11066167|NCT04313647|Experimental|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)
11066168|NCT04313647|Experimental|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)
11066169|NCT04313647|Experimental|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)
11066170|NCT04313647|Experimental|10X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (20.0*10E8 nano vesicles/3 ml)
11066171|NCT04313634|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
11066172|NCT04313634|Experimental|Fisetin Treatment Group|Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
11066173|NCT04313634|No Intervention|Untreated Control Group|Subjects will not receive any intervention
11066174|NCT04313608|Experimental|Arm A: Glofit-GemOx|Participants will receive up to 8 cycles of Glofit-GemOx (glofitamab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles, followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab.
11066175|NCT04313608|Experimental|Arm B: Mosun-GemOx|Participants will receive up to 8 cycles of Mosun-GemOx (mosunetuzumab in combination with gemcitabine and oxaliplatin) administered in 21-day cycles.
11066176|NCT04313595|Experimental|Breathing frequency monitoring|
11066177|NCT04313582|Experimental|SmartPrompt|
11066178|NCT04313569|No Intervention|Conservative treatment|Use of medications, like analgesic, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAID) and local painkillers, depending on the patient condition, and physiotherapy, lifestyle and daily activity modification, patient education about positioning of the knee
11066179|NCT04313569|Other|Arthroscopic menisctomy|
11066180|NCT04313556|Other|Lateral patellar release|Arthroscopic lateral patellar retinacular release
11066181|NCT04313543|Experimental|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. There is 3 days for wash out period. These tests will be repeated for 3 times for baseline glucose calculation. After that, volunteers take 50 g of longan syrup in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. Glycemic index of longan syrup is calculated from area under the curved of blood glucose after longan syrup taking divided to mean of area under the curved of blood glucose after glucose taking
11066182|NCT04313530|Experimental|fatigue in MSA Arm one|This arm will receive a total 10 sessions of TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
11066183|NCT04313530|Sham Comparator|fatigue in MSA Arm two|This arm will receive a total 10 sessions of sham-TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
11066184|NCT04313517|Experimental|Yoga@Work|Yoga session were developed to practice at work anytime feasible.
11066185|NCT04313517|No Intervention|Wait list Control group|Control group with no intervention. After Intervention period, group was offered same sessions.
11066186|NCT04313504|Experimental|Niraparib & Dostarlimab|"Niraparib starting on Day 0. Niraparib will be administered as continuous daily dose, orally 200 or 300 mg.
~Dostarlimab IV administered via a 30-minute infusion on Day 1 of every 21 day cycle. 500mg for first 4 doses followed by 1000 mg every 6 weeks."
11066187|NCT04313491|Experimental|Yoga@Work|
11066188|NCT04313478||Preterm Infants|They were as follows: being at 3 to 9 months' corrected age, gestational age of less than 36 weeks + 6 days, birth weight of 2000 g or less. Infants with any genetic, metabolic, orthopedic congenital abnormalities or chronic diseases and parents' rejection to participate in the study were excluded.
11066189|NCT04313478||Term Infants|They were as follows: being between 3 and 9 months of age, being full-term, had no complications during delivery. Infants that presented any type of sensory or motor disorder were excluded.
11066190|NCT04313465|No Intervention|Control (Routine Care)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a cardiac troponin blood test upon admission to the Emergency Department. Participants will then have a repeat cardiac troponin blood test in 3 hours.
11066191|NCT04313465|Experimental|Intervention (Immediate Discharge)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a troponin blood test upon admission to the Emergency Department. Participants will then be discharged.
11066192|NCT04313452|Placebo Comparator|regular diet|50% of energy from carbohydrates, 30% fat and 20% from protein
11066193|NCT04313452|Active Comparator|Mediterranean diet|60% of energy from carbohydrates, 25% fat and 15% from protein
11066194|NCT04313439|Experimental|Treatment|Online Cognitive Therapy (I-CT)
11066195|NCT04313426|Experimental|Integrative Yoga Therapy|Self managed Yoga based practices were included in one to one sessions for 6-sessions.
11066196|NCT04313413|Experimental|Yoga@Work|Yoga sessions specifically designed for office workers were provided in work settings. participants were given handouts and encouraged to practice in their own time and space during work days.
11066197|NCT04313400|Experimental|Part 1 Dose Escalation: 3% to 70% of the BSA|Open-label AMTX-100 CF 1.1% w/w, topically applied twice a day for 7 consecutive days to all treatable AD affected areas from 3% to 70% of the Body Surface Area (BSA) (3% BSA ≤ AD Affected Area ≤ 70% BSA)
11066198|NCT04313400|Experimental|Part 2 Group A: Low dose concentration (0.11% w/w)|AMTX-100 CF Low dose concentration (0.11% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
11066219|NCT04313257|Active Comparator|Passive Occlusion|This arm will include those participants who will follow a daily occlusive treatment of 2 hours.
11066199|NCT04313400|Experimental|Part 2 Group B: Medium dose concentration (0.33% w/w)|AMTX-100 CF Medium dose concentration (0.33% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
11066200|NCT04313400|Experimental|Part 2 Group C: High dose concentration (1.1% w/w)|AMTX-100 CF High dose concentration (1.1% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
11066201|NCT04313400|Placebo Comparator|Part 2 Group D: Placebo|Placebo (Vehicle) (0% w/w), topically applied twice a day for 28 consecutive days to all treatable AD affected areas
11066202|NCT04313387||Control group - Normal eyes (CG)|"• Control group - Normal eyes (CG): 351 eyes without KC of 351 patients who underwent LASIK or photorefractive keratectomy (PRK), stable after at least 18 months of follow-up, without any changes in the posterior elevation at the 18-month Pentacam in relation to the preoperative exam (surgeries performed in 2012-2018). Our objective topographic criteria were: both eyes with a KISA% index of less than 60%, Kmax of 47.2 D or less, and I-S difference of less than 1.45 D. Because no truly established tomographic parameter(s)/cut-off(s) for differentiating normal from keratoconus suspect eyes exist, we adapted our classification for normal eyes to the recent publication by Ambrósio et al. by adding the criterion of overall subjective normal topography and tomography examinations based on the evaluation of experienced refractive surgeon (GCAJ). Only one eye was randomly selected for further statistical analysis."
11066203|NCT04313387||Very assimetric ectasia with normal topography|• Very assimetric ectasia with normal topography group (VAE-NT G): 88 eyes of 88 patients with very asymmetric ectasia with normal topography (VAE-NT) in one eye and frank ectasia (VAE-E) in the fellow eye. The inclusion criteria followed previous studies (28, 32, 33) Eyes in this group with insufficient topographic findings to meet diagnostic criteria for keratoconus, and following features normal-appearing cornea on slit-lamp biomicroscopy, keratometry, retinoscopy. These cases were the less affected eye (fellow eye) of a keratoconic patient was included if the following criteria were met: KISA% index of less than 60%, I-S difference of less than 1.45 D, and Kmax of 47.2 D or less (ie, same topographic criteria as in normal eyes, except than in normal eyes, both eyes of the patient met the criteria). These patients can be considered with corneas highly susceptible to ectasia.
11066204|NCT04313387||Keratoconus group (KCG)|• Keratoconus group (KCG): 148 patients (one eye each) with bilateral clinical KC. The KCG included one eye randomly selected from 148 patients with keratoconus; one eye was randomly included per patient to avoid selection bias related to the use of both eyes from the same patient. The inclusion criteria were the same as for VAE-E, except that both eyes of the patient met the ectasia criteria.
11066205|NCT04313374|Active Comparator|Morphine PCA 1 mg|The patient controlled analgesia device give 1mg morphine for each demand of the patient.
11066206|NCT04313374|Active Comparator|Morphine PCA 0,5 mg|The patient controlled analgesia device give 0,5 mg morphine for each demand of the patient.
11066207|NCT04313374|Placebo Comparator|Placebo|The patient controlled analgesia device give 2 mL serum physiologic for each demand of the patient.The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.
11066208|NCT04313361||Smokers or Recent Smoking Quitters who Have lung Surgery|The enrolled eligible participants, that is smokers or recent smoking quitters, will be assessed for the current smoking status and smoking cessation attempts during the perioperative period, to describe postoperative complications (PCs) including postoperative pulmonary complications (PPCs) following a lung surgery, and to describe the smoking cessation methods and services participants received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example nodule, ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.
11066209|NCT04313348|Active Comparator|Control Arm|Study participants in this arm will receive no SMS reminders nor social supporter notifications.
11066210|NCT04313348|Experimental|Intervention Arm 1|"Participants will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery at their preferred time and day of the week will be sent to study participants. The content of the SMS reminders will be customized and determined by each individual at enrollment. If the participant has no preference, we will suggest This is your ANC visit reminder, encouraging you to attend. This technology is already integrated and running in Uganda via the Yo! Uganda Gateway."
11066211|NCT04313348|Experimental|Intervention Arm 2|"Participants will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information and SMS reminders same as those of scheduled SMS arm above + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for the study participant they are supporting for all the study follow-up period (also called the social support engagement arm). Social supporters will be able to personalize the SMS content at enrollment. They will be advised to assist study participants with any problems that may affect ANC attendance or facility delivery, but will not be given specific instructions on what to do."
11066212|NCT04313335|Experimental|Duloxetine|Apart from the standard treatment, participants in the Duloxetine Arm will be administered with oral duloxetine (up to 60 mg per day) in the acute herpes zoster period.
11066213|NCT04313335|No Intervention|Control|Participants will be given the standard treatment during the acute herpes zoster period.
11066214|NCT04313322|Experimental|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
11066215|NCT04313309|Experimental|Support Group|This is the only group in the study consisting of patients with chronic musculoskeletal pain who are receiving the Integrative Yoga Therapy Program
11066216|NCT04313296|Experimental|Patients identified at PBMC with a documented diagnosis of AF|Patients identified at PBMC with a documented diagnosis of AF (at any point in time) and who have undergone any cardioversion.
11066217|NCT04313283|Experimental|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders for 12 weeks.
11066220|NCT04313257|Experimental|Active Occlusion|This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.
11066221|NCT04313244|Experimental|Group 1|0.5 mL Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) intramuscular (IM) will be co-administered with 0.5 mL Dengue Tetravalent Vaccine (TDV) subcutaneous (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
11066222|NCT04313244|Experimental|Group 2|0.5 mL 9vHPV vaccine IM will be administered once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
11066223|NCT04313231||MDS|"Female and male patients aged 18 years and older
~MDS, MDS/MPN diagnosis based on current WHO classification. CCUS and CHIP defined by Valent (Valent, Oncotarget, 2018) and by Stauder (Stauder, Blood, 2018)"
11066224|NCT04313231||control|age-matched healthy persons
11066225|NCT04313218||A|recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
11066226|NCT04313218||B|women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
11066227|NCT04313205|Active Comparator|Capsule|JKB-122 capsule on period 1 followed by JKB-122 Tablet on period 2
11066228|NCT04313205|Active Comparator|Tablet|JKB-122 tablet on period 1 followed by JKB-122 capsule on period 2
11066229|NCT04313192|Experimental|Pulse rate 2Hz (hertz)|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
11066230|NCT04313192|Experimental|Pulse rate 10Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
11066231|NCT04313192|Experimental|Pulse rate 150Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
11066232|NCT04313179|Experimental|Music group|"Deep Sleep music track from Bedtime Mozart: Classical Lullabies for Babies, played through smart phone speakers, at maximum sound up to 60 A dB, starting 20 minutes before the heel prick procedure, continuing through the procedure and for 5 minutes after the procedure. Also given 0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure for baseline pain relief."
11066233|NCT04313179|Placebo Comparator|Placebo group|0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure. No music played.
11066234|NCT04313166|Experimental|Cu(II)ATSM|copper-containing synthetic small molecule
11066235|NCT04313153|Experimental|Vadadustat once daily|
11066236|NCT04313153|Experimental|Vadadustat three times weekly|
11066237|NCT04313153|Active Comparator|Darbepoetin alfa|
11066238|NCT04313127|Experimental|Low-dose Group|Subjects received one dose of 5E10 vp Ad5-nCoV at 18 to 60 years old
11066239|NCT04313127|Experimental|Middle-dose Group|Subjects received one dose of 1E11 vp Ad5-nCoV at 18 to 60 years old
11066240|NCT04313127|Experimental|High-dose Group|Subjects received one dose of 1.5E11vp Ad5-nCoV at 18 to 60 years old
11066241|NCT04313114|Active Comparator|PRIME CRC|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will also receive automated reminder calls and texts for both screening options to encourage screening.
11066242|NCT04313114|Active Comparator|Enhanced Usual Care|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will receive no reminder calls.
11066243|NCT04313101||Cases (ICUAW)|57 critically ill patients developing ICUAW during their stay in the intensive care unit will be included in the study as cases.
11066244|NCT04313101||Controls|A total of 57 Critically ill patients in the same period who did not develop ICU acquired weakness during their ICU stay will be included as controls.
11066245|NCT04313088|Other|Experimental Group A|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group A will take eluxadoline 100mg by mouth twice for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take matching placebo by mouth twice daily. Each participant in Group A will take 42 days of eluxadoline 100mg twice daily followed by 42 days of placebo over the course the study.
11066246|NCT04313088|Other|Experimental Group B|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group B will take placebo by mouth twice daily for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take eluxadoline 100mg by mouth twice daily. Each participant in Group B will take 42 days of placebo followed by 42 days of eluxadoline 100mg twice daily over the course the study.
11066247|NCT04313062|Experimental|Intervention|"The intervention group will receive the PM ACTIVAS' intervention model. This intervention will be done by a member of the technical staff (previously trained) at the patient's home (house call). In the house call, the trainee will perform a multidimensional assessment of the patient's falling risks factor (internal and external), deliver a  Falling Prevention Kit  and lastly establish together (with the patient and their family) a plan to change the hazards in their home. The patients will receive a telephone follow-up by the same technical staff member until the final house call, which will be 12 months after the recruiting. Finally, 12 months after recruitment, they will receive a last house call where the trainee will assess with the patient and the family the plan, ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period), and conduct the final survey."
11066317|NCT04312438|Experimental|13 mo to 15 yo children diagnosed with Cow's Milk Allergy|oral food challenge with cow's milk proteins
11099470|NCT04080102|Experimental|Essential Amino Acid Supplement|
11066248|NCT04313062|No Intervention|Standard care|"The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the  Falling Prevention Kit ."
11066249|NCT04313049|Active Comparator|Motor control|
11066250|NCT04313049|Experimental|Vocal control|
11066251|NCT04313036|Experimental|Defibrotide|5 day course of defibrotide at standard dosing 25 mg/kg/day in 4 divided doses of 6.25 mg/kg. If not in CR by day 5, will be given for >/= 21 days or per discretion of enrolling physician.
11066252|NCT04313023|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3, 6, and 10
11066253|NCT04313023|Placebo Comparator|Sterile saline for inhalation|Sterile saline for inhalation given by nebulization on Study Days 1, 3, 6, and 10
11066254|NCT04313010|Experimental|Regenerative endodontics therapy with PRF|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. Only the apex 1/3 of the root canal need to be filled with blood. PRF was injected into the root canal to a level below the CEJ, then wait for 10-15min to coagulate.
11066255|NCT04313010|Active Comparator|Regenerative endodontics therapy with BC|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. The adequate blood need to be full with canal space and below the CEJ, then wait for 10-15min to coagulate.
11066256|NCT04312997|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3 and 6
11066257|NCT04312997|Placebo Comparator|Sterile saline for inhalation|Sterile saline for Inhalation given by nebulization on Study Days 1, 3 and 6
11066258|NCT04312971|Placebo Comparator|Placebo|Infusion of normal Saline 0.9%will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
11066259|NCT04312971|Active Comparator|Norepinephrine|Infusion of norepinephrine (40 µg/ml) will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
11066260|NCT04312958||Trauma patients|Trauma patients experiencing traumatic injuries requiring a full trauma team response.
11066261|NCT04312958||Liver transplant patients|Patients undergoing liver transplant surgery.
11066262|NCT04312945|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11066263|NCT04312945|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11066264|NCT04312945|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11066265|NCT04312945|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11066266|NCT04312932|Experimental|Long chain polyunsaturated fatty acid (LCPUFA) Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days
11066267|NCT04312932|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
11066268|NCT04312919|Experimental|Intervention Group|3 in-person visit group
11066269|NCT04312919|Active Comparator|Control/Crossover Group|5 in-person visit group
11066270|NCT04312893|Experimental|Acupuncture group (ACU)|Patients in acupuncture group will receive traditional Chinese acupuncture combined with Tung's style acupuncture using Press Tack Needle (PYONEX Φ0.20×0.6 mm made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles. The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment will use bilateral acupuncture (if patient's condition does not allow it, unilateral acupuncture will be done). The patient will lie in a supine position during the treatment. Acupuncturist will disinfect the acupoint location with an alcohol pad (70% alcohol), then the acupuncturist will press the needles sticker to the mentioned above acupoints. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
11066271|NCT04312893|Placebo Comparator|Control group (CON)|Patients randomized to the control group will receive press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment methods and patients position will be identical to acupuncture group. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
11066272|NCT04312880|No Intervention|Control|Patient will receive no transexemic acid of any kind
11066273|NCT04312880|Experimental|IV-transexemic acid|weight adjusted standard dose of TXA will be administered to these subset of patients prior to incision in IV-form
11066274|NCT04312880|Experimental|Topical-transexemic acid|the wound site after the surgery is completed will be bathed in TXA for a standardized period of time prior to skin closure
11066275|NCT04312867|Experimental|Project STRONG|Project STRONG is an active skill-based intervention designed to prevent adolescent dating violence among middle school boys. Boys and a parent will complete the web-based program together focusing on improving communication and emotion regulation.
11066276|NCT04312867|Active Comparator|Health Promotion|Health Promotion is an information-based program designed to mimic content areas provided during middle-school health education. The content is provided via a web-based interface to mirror the content delivery in the active intervention (Project STRONG).
11099629|NCT04079062|Experimental|KLH+ONO-4685 (PartC)|
11066277|NCT04312841|Experimental|Treatment (letermovir)|Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
11066278|NCT04312815|Experimental|SM03 600 mg|"SM03: 600 mg intravenous (IV) Randomizd period:on week 0,2,4 and 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.
~Open-lable treatment on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
11066279|NCT04312815|Placebo Comparator|Placebo|"placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.
~SM03: 600 mg intravenous (IV) on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
11066280|NCT04312802||Observational|Single arm observational study
11066281|NCT04312789|Experimental|Treatment (avatrombopag)|Patients receive avatrombopag PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity. Avatrombopag will be titrated weekly until platelet count of greater than or equal to 60,000/uL is achieved and persists for 7 consecutive days, and the patient remains free from platelet transfusion.
11066282|NCT04312776||Patients infected with CA-MRSA|It is an observational study, no interventions to any of the two study arms.
11066283|NCT04312776||Healthy people without any infection|It is an observational study, no interventions to any of the two study arms.
11066284|NCT04312750|Experimental|Lidocaine Patch|All subjects received one lidocaine topical system, which was applied to a predetermined fixed area on subject's left side of the back or right side of the back (lower/mid back) according to randomization schedule and worn for 12 hours.
11066285|NCT04312724|Active Comparator|Clinical need|Participants enrolled that require a new socket.
11066286|NCT04312724|Experimental|No clincal need|Participants enrolled that do not require a new socket
11066287|NCT04312711|Experimental|intervention|All participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
11066288|NCT04312698|Experimental|Experimental Group 1|
11066289|NCT04312698|Placebo Comparator|Comparator Group 1|
11066290|NCT04312698|Placebo Comparator|Comparator Group 2|
11066291|NCT04312685|Active Comparator|Prometra Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refills 1-3) and will be compared to 3 months retrospectively collected pain scores (VAS, ODI and Global Pain Scale Assessments) and drug doses prior to peristaltic pump explant.
11066292|NCT04312685|No Intervention|Retrospective records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
11066293|NCT04312672||Follow up cohort|no intervention follow up study
11066294|NCT04312659||Infliximab|Participants with pediatric Crohn's disease (CD) who were treated with Infliximab (IFX) and signed the Informed Consent Form (ICF) for the study will be enrolled case by case. Each participants will be followed up for at least 30 weeks. After 30 weeks, participants continuing IFX treatment will be followed up, with a maximum follow-up period of 102 weeks. The primary data source will be participants medical records for all data entered into the CRF.
11066295|NCT04312646||patients with thyroid nodules|
11066296|NCT04312607||Philadelphia chromosome positive|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
11066297|NCT04312607||Philadelphia chromosome negative|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
11066298|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 50mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
11066299|NCT04312594|Experimental|Jaktinib Dihydrochloride Monohydrate 75mg and Basic treatment|Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
11066300|NCT04312594|Placebo Comparator|Placebo and Basic treatment|Mimic tablets of Jaktinib Dihydrochloride Monohydrate 50mg BID and 75mg BIDand basic treatment(Acetylcysteine Effervescent Tablets 600mg TID) for each 24 weeks cycle.
11066301|NCT04312581|Experimental|First group (shock wave)|Extracorporeal shock wave therapy
11066302|NCT04312581|Active Comparator|Second group (conventional rehabilitation)|conventional rehabilitation
11066303|NCT04312568|Experimental|Fadanafil|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
11066304|NCT04312568|Placebo Comparator|Placebo|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
11066305|NCT04312542||SRP with minocycline HCl microspheres|Participants in this cohort received the intervention of minocycline HCl microspheres, 1 mg in the interventional phase of the trial.
11066306|NCT04312542||SRP without minocycline HCl microspheres|Participants in this cohort did not have minocycline HCl microspheres, 1 mg administered during the interventional phase of the trial.
11066307|NCT04312529|Experimental|Overhead athletes|
11066308|NCT04312516||Controls|Healthy volunteers without neurocognitive impairment
11066309|NCT04312516||Patients|Patients undergoing surgical procedure with at least mild cognitive impairment preoperatively
11066310|NCT04312503||COHORT A: Lurasidone|Patients treated with Lurasidone
11066311|NCT04312503||COHORT B: aripiprazole, olanzapine, quetiapine or risperidone)|Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone)
11066312|NCT04312490|Experimental|patients|all patients with myocarditis
11066313|NCT04312477|Experimental|Experimental group|Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
11066314|NCT04312477|Active Comparator|Control group|Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
11066315|NCT04312464||Discharged group|The individual which is defined as patient discharged from hospital
11066316|NCT04312464||Dead group|The individual which is defined as patient with all-cause death
11066320|NCT04312399|Other|oral hormonal therapy|Postmenopausal women who start with oral hormonal therapy (Progesteron + uterogestan) according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066321|NCT04312399|Other|transdermal hormonal therapy|Postmenopausal women who start with transdermal hormonal (Oestrogel + uterogestan) therapy according to standard of care practice. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066322|NCT04312399|Other|oral hormonal therapy + hysterectomy|Postmenopausal women who start with oral hormonal therapy (progesteron) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066323|NCT04312399|Other|transdermal hormonal therapy + hysterectomy|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and had a hysterectomy in the past. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066324|NCT04312399|Other|oral hormonal therapy + IUD|Postmenopausal women who start with oral hormonal therapy (Progynova) according to standard of care practice and have already an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066325|NCT04312399|Other|transdermal hormonal therapy + IUD|Postmenopausal women who start with transdermal hormonal therapy (Oestrogel ) according to standard of care practice and have an intra-uterine device. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066326|NCT04312399|Other|selective oestrogenreceptor modulators|Postmenopausal women who start with hormonal therapy according to standard of care practice and take selective oestrogenreceptor modulators (Nolvadex) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066327|NCT04312399|Other|aromatase inhibitors|Postmenopausal women who start with hormonal therapy according to standard of care practice and who taken aromatase inhibitors (Femara) because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066328|NCT04312399|Other|Duavive|Postmenopausal women who start with hormonal therapy according to standard of care practice and who take duavive because of their cancer in their medical history. Before the start of the treatment blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066329|NCT04312399|Other|Control|Postmenopausal women who don't start with hormonal therapy according to standard of care practice. At the first study visit blood will be taken and 6 months after the start of the therapy blood will be taken for analysis. At the 2 study visits the patient will be asked to complete the questionaires (TANGO-SF, ICIQ, Cohen, Pittsburgh sleep quality). Only at the first study visit an MMSE test will be taken, to make sure the patient has no dementia.
11066330|NCT04312386|Experimental|A new 4-week lunch menu|Optimized lunch menu with 30% lower greenhouse gas emissions, nutritionally adequate
11066331|NCT04312360|Experimental|intervention track 1|"14 patient with right-sided colon cancer receive intervention before the hemicolectomi.
~both arms of this study use the same intervention."
11066332|NCT04312360|Experimental|intervention track 2a|"14 patient with right-sided colon adenoma receive intervention before the endoscopic mucosa resection.
~both arms of this study use the same intervention."
11066333|NCT04312347|Experimental|Personalized dosing of tamoxifen|Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.
11066334|NCT04312334|Experimental|Treatment 1|Treatment 1: Hand cleaning with the Supertowel for 15 seconds. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recorded by means of weighing the towel before and after soaking. The volunteers will use the soaked Supertowel for 15 seconds to clean their pre-contaminated hands.
11066335|NCT04312334|Experimental|Treatment 2|Treatment 2: Hand cleaning with a Supertowel that is damp for 60 seconds The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The water on the Supertowel will then be squeezed out so that it is not dripping. The Supertowel will be weighed before soaking and after squeezing. Volunteers will clean their pre-contaminated hands with the damp Supertowel for 60 seconds.
11066396|NCT04312035|Experimental|Non end-range mobilization|Non end-range mobilization performed in loose-packed position of the knee joint
11066397|NCT04312035|Placebo Comparator|Control|Sham technique performed in loose-packed position of the knee joint
11066336|NCT04312334|Experimental|Treatment 3|"Treatment 3: Hand cleaning for 60 seconds with a Supertowel that has been soaked in contaminated water.
~A Supertowel will be soaked in water which has artificially contaminated with non-pathogenic E.coli. The water will be designed to mimic highly contaminated grey water so it will be contaminated at 2,000 cfu/100 ml which is double the acceptable level of contamination for handwashing. Volunteers will clean their pre-contaminated hands with the contaminated Supertowel for 60 seconds."
11066337|NCT04312334|Experimental|Treatment 4|"Treatment 4: Hand cleaning for 60 seconds with a Supertowel that is visibly dirty and oily.
~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water .The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 60 seconds."
11066338|NCT04312334|Experimental|Treatment 5|"Treatment 5: Hand cleaning for 30 seconds with a Supertowel that is visibly dirty and oily and it is soaked in whater which has artificially contaminated with non-pathogenic E.coli.
~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water (which will be contaminated with E.coli).The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 30 seconds."
11066339|NCT04312334|Experimental|Treatment 6|Treatment 6: Hand cleaning with the Supertowel which is fully dry for 60 seconds.
11066340|NCT04312334|Other|Control 1|Control 1: Hand washing with bar soap and water for 15 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 15 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
11066341|NCT04312334|Other|Control 2|"Control 2: Handwashing with bar soap and water for 60 seconds The control group will wash their pre-contaminated hands with normal bar soap and water for 60 seconds by following the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps was given to them, appendix). After handwashing, hands will be allowed to dry for 3 minutes"
11066342|NCT04312334|Other|Control 3|"Control 3: Handwashing with bar soap and contaminated water for 60 seconds. Water which is contaminated with non-pathogenic E.coli. at 2,000 cfu/100ml will be stored in a bucket which has a tap at the base. The control group volunteers will wash their hands with the contaminated water and bar soap for 60 seconds. They will follow the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps will be given to them). After handwashing, hands will be allowed to dry for 3 minutes."
11066343|NCT04312334|Other|Control 4|Control 4: Hand cleaning for 60 seconds with a clean Supertowel. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recordedby means of weighing the Supertowel before and after soaking. The control group will clean their pre-contaminated hands of with thesoaked Supertowel for 60 seconds.
11066344|NCT04312334|Other|Control 5|Hand washing with bar soap and water for 30 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 30 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
11066345|NCT04312321|No Intervention|CONTROL|CONTROL group: low urgency cases with routine operation of paramedic crew with optional consultation with a doctor over the phone.
11066346|NCT04312321|Experimental|PHONE|In the PHONE group, there will be a mandatory consultation of a doctor over the phone in all low urgency cases.
11066347|NCT04312321|Experimental|VIDEO|In the VIDEO group, there will be a mandatory consultation of a doctor over the audiovisual consultation in low urgency cases
11066348|NCT04312308||Non-Small Cell Lung Cancer Treated with Atezolizumab|Patients with Non-Small Cell Lung Cancer Treated with Atezolizumab
11066349|NCT04312295|Experimental|ACP-SCT program|The ACP simulation-based communication training (ACP-SCT)program was designed 12 hours (4hours/week) workshop for nephrology nurses.
11066350|NCT04312295|No Intervention|Without ACP-SCT program|The control group only gives the ACP simulation-based communication training program handbook.
11066351|NCT04312282|Experimental|Cohort 1, Sequence 1A: Fed then fasted|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fed conditions
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions"
11066352|NCT04312282|Experimental|Cohort 1, Sequence 1B: Fasted then fed|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fed conditions"
11066353|NCT04312282|Experimental|Cohort 2: Tesetaxel plus itraconazole|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and itraconazole on Day -3 through Day 14 of a 21-day cycle"
11066354|NCT04312282|Experimental|Cohort 3: Tesetaxel plus rifampin|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle
~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and rifampin on Day -6 through Day 14 of a 21-day cycle"
11066355|NCT04312269|Experimental|All phase TMR|TMR during every stage of sleep
11066356|NCT04312269|Experimental|Slow-wave sleep (SWS) only TMR|TMR during slow-wave sleep only
11066357|NCT04312269|Experimental|Reduced frequency TMR|TMR during only subset of sessions
11066358|NCT04312269|Sham Comparator|Sham TMR|Patients receive no TMR
11066359|NCT04312256|Experimental|Group 1: Dominant Hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and great toe.
11066360|NCT04312256|Experimental|Group 2: Non-Dominant Hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and great toe.
11066361|NCT04312243|Experimental|Treatment Group|Inhaled NO (160 ppm) before and after the work shift. Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
11066362|NCT04312243|No Intervention|Control Group|Daily monitoring of body temperature and symptoms. SARS-CoV-2 RT-PCR test if fever or COVID-19 symptoms.
11066363|NCT04312217|Active Comparator|Medical clowning|Preoperative medical clown exposure
11066364|NCT04312217|No Intervention|Control|Normal preop care
11066365|NCT04312204|Experimental|Sintilimab+Gemcitabine+Carboplatin|
11066366|NCT04312191|No Intervention|Control Group|The Control Group participants (Group A) will be initiating radiation therapy and receiving only standard of care therapy per their Radiation Oncologist.
11066367|NCT04312191|Experimental|Test Group|The Test Group participants (Group B) will be initiating radiation therapy and receiving standard of care therapy per their Radiation Oncologist. This group will also be taught mantra-based meditation to use during each radiation treatment session and encouraged to practice MM ad libitum outside of the treatment setting.
11066368|NCT04312178|Other|return vaginal self-swab by mail|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail
11066369|NCT04312178|Other|financial incentive mail-back vaginal self-swab|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail to obtain a cash incentive
11066370|NCT04312178|Other|handing over the vaginal swab to a professional|Socially disadvantaged women who have received a vaginal self-swab and need to report it to a health professional
11066371|NCT04312178|Other|financial incentive the vaginal self-swab to a pro|Socially disadvantaged women who have received a vaginal self-swab and have to report it to a health professional to obtain a cash incentive
11066372|NCT04312165|Experimental|Duramesh Laparotomy Closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
11066373|NCT04312165|Active Comparator|Control group-Conventional suture closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
11066374|NCT04312152|Active Comparator|PMS Placebo|"If body weight is up to 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
11066375|NCT04312152|Active Comparator|ASD Placebo|"If body weight is up to 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
11066376|NCT04312152|Experimental|PMS Active compound|"If body weight is up to 20 kg:
~Q10 ubiquinol, 50 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Q10 ubiquinol, 100 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
11066377|NCT04312152|Experimental|ASD Active compound|"If body weight is up to 20 kg:
~Q10 ubiquinol, 50 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)
~If body weight is above 20 kg:
~Q10 ubiquinol, 100 mg b.i.d.
~Vitamin E 30 mg b.i.d.
~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
11066378|NCT04312139||Fast progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated fast progression from moderate to severe aortic valve stenosis: echocardiographic dVmax>0.25 m/sec/year (difference in transaortic Vmax).
11066379|NCT04312139||Slow progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated slow progression from moderate to severe aortic valve stenosis: echocardiographic dVmax<0.15 m/sec/year (difference in transaortic Vmax).
11066380|NCT04312139||Prospective Moderate Aortic Valve Stenosis|100 consecutive prospectively enrolled patients with moderate aortic valve stenosis. Plus 20 patients accounting for 20% drop-out rate, total prospective cohort = 120 patients.
11066381|NCT04312139||Negative calcium score group|50 patients at intermediate to high risk for Cardiovascular Disease (CVD) and negative aortic valve and coronary calcium score at CT scan, prospectively followed-up. Plus 10 patients accounting for 20% drop-out rate, total control cohort = 60 patients.
11066382|NCT04312126||Arm 1|46 healthy young (18-35) volunteers
11066383|NCT04312126||Arm 2|46 healthy older (50-80) volunteers
11066384|NCT04312126||Arm 3|46 chronic (>6 months post-stroke) stroke patients
11066385|NCT04312113|Experimental|Autologous mesenchymal stem cells|Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis.
11066386|NCT04312100||Mild cases with conventional oxygen therapy|COVID-19 patients who were considered mild cases will receive conventional oxygen therapy in addition to standard treatment
11066387|NCT04312100||Moderate/Severe cases with nasal high flow oxygen inhalation|COVID-19 patients who were considered Moderate/Severe cases will receive nasal high flow oxygen inhalation in addition to standard treatment
11066388|NCT04312100||Moderate/Severe cases with non-invasive ventilation|COVID-19 patients who were considered Moderate/Severe cases will receive non-invasive positive pressure ventilation in addition to standard treatment
11066389|NCT04312087|Experimental|MLND|Modified lateral neck dissection (compartment II-V) is performed in all patients.
11066390|NCT04312087|Experimental|SLNB|Sentinel lymph node biopsy in the lateral neck is performed. The decision of neck dissection is based on the result of sentinel lymph node biopsy.
11066391|NCT04312061|Experimental|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
11066392|NCT04312061|Placebo Comparator|placebo|oral placebo tablet given 1 hour before LNG-IUD insertion
11066393|NCT04312048|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
11066394|NCT04312048|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
11066395|NCT04312035|Experimental|End-range mobilization|End-range mobilization performed in end-position of the knee joint
11066553|NCT04310917|Other|Lipoprotein a level|blood lipoprotein (a) test
11066398|NCT04312022|Experimental|Berry extract intake|Intake of a berry extract supplement (hawthorn berry extract, tart cherry extract, and bromelain)
11066399|NCT04312022|Placebo Comparator|Placebo intake|Intake of a placebo (flour capsule)
11066400|NCT04312009|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
11066401|NCT04312009|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
11066402|NCT04311996|Experimental|Friend and Target Both|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
11066403|NCT04311996|Experimental|Friend Provides Support|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
11066404|NCT04311996|Experimental|Unfamiliar Peer and Target|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
11066405|NCT04311996|Experimental|Alone|There are four conditions: (1) Friend and Target both undergo the stressor, (2) Friend provides support but does not undergo the stressor, (3) Unfamiliar Peer and Target undergo the stressor, and (4) Alone (no partner).
11066406|NCT04311983|Active Comparator|Tobacco Quitline only|Smokers in this study group will be offered their state Tobacco Quitline programs
11066407|NCT04311983|Experimental|Tobacco Quitline plus Smoke Free Homes|Smokers in this study group will be offered their state Tobacco Quitline programs, but if they decline, they will be offered a Smoke Free Homes intervention
11066408|NCT04311970|Other|EoE patients|Patients will all be administered the EsoCheck device as a diagnostic test
11066409|NCT04311957|Active Comparator|Boosted PI Group|"Continuation of the same second-line regimen taken prior to entry:
~This includes either Lopinavir/ritonavir (LPVr) 400 mg/100 mg BID or Atazanavir/ritonavir (ATV/r) 300 mg/100 mg QD
~plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)."
11066410|NCT04311957|Experimental|B/F/TAF Group|Combination tablet of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
11066411|NCT04311944|Experimental|Early Fast-Track Care|Participants will be eligible for fast-track care after 8 to 12 weeks, if viral load is suppressed (<200 copies/mL)
11066412|NCT04311944|Active Comparator|Standard (Deferred Fast-track) Care|Participants will be eligible for fast-track care after 24 weeks, if viral load is suppressed (<200 weeks)
11066413|NCT04311931|Experimental|Experimental Creative Dance group|The experimental group intervention will attend the creative dance program. The program integrates 3 sessions / week of 60 minutes on alternated days.
11066414|NCT04311931|No Intervention|Control group|"The control group will maintain the usually daily activities, not attending any exercise program.
~After study end, the control group will have the opportunity to participate on an exercise program."
11066415|NCT04311905|Experimental|Laser activated irrigation LAI|Diode Laser activated irrigation
11066416|NCT04311905|Placebo Comparator|conventional root canal treatment|mock LAI , conventional root canal treatment 2.5% sodium hypochlorite
11066417|NCT04311879|Experimental|Soft tissue laser Diode laser application|Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices. Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product
11066418|NCT04311879|Placebo Comparator|conventional root canal treatment|Placebo : conventional root canal conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with mock laser intervention
11066419|NCT04311866|Active Comparator|Spica cast|Standard practice for the management of the femoral shaft fractures.
11066420|NCT04311866|Experimental|Synthetic fabric|Offer resistance, durability and low weight to treatment of femoral shaft fractures
11066421|NCT04311853||practitioner interviews|phone interviews conducted
11066422|NCT04311840||SAH patients with nimodipine|Patients with SAH receiving nimodipine as prevention of vasospasms and as a nootropic drug.
11066423|NCT04311840||SAH patients without nimodipine|Patients with SAH not receiving nimodipine as prevention of vasospasms and as a nootropic drug or in whom the drug has been temporarily discontinued.
11066424|NCT04311827||Serratus anterior plane block and traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
11066425|NCT04311827||Traditional analgesia|Serratus anterior plane block (Bupivacaine 75mg injected into facial plane once) Acetaminophen 1000mg IV every 6 hours as needed Toradol 15mg IV every 6 hours as needed Morphine 4mg every 2 hours as needed Hydromorphone 0.5mg IV every 2 hours as needed
11066426|NCT04311814|Other|v-MUCP value|All patients referred for urodynamics explorations will have a measure of the MUCP during a Valsalva manoeuver
11066427|NCT04311801|Experimental|OCT Arm|Each patient underwent OCT examinations.
11066428|NCT04311788|Experimental|Intervention group|Prophylactic self gripping mesh (Program, Medtronic) will be placed in rectorectus space to prevent incisional hernia.
11066429|NCT04311788|Active Comparator|Control group|Abdomen of the patients in the control group will be closed by using small stitch closure with suture to wound length of 4:1 and slowly absorbable monofilament suture.
11066430|NCT04311775||video laryngoscopy|video laryngoscope is a camera laryngoscope system used to see the larynx with camera
11066431|NCT04311775||laryngoscopy|laryngoscopy is a method used to see the larynx.
11066432|NCT04311749||Fetal growth restriction|
11066433|NCT04311749||Severe preeclampsia|
11066434|NCT04311749||Low PAPP-A|
11066435|NCT04311749||Healthy control|
11066436|NCT04311736|Active Comparator|Exergame|Moderate intensity cycling only 3 times per week for 12 weeks + concurrent virtual reality cognitive training, supervised by an exercise specialist
11066587|NCT04310579|No Intervention|Lead-In|Read Rebreathing Reproducibility Assessment
11066437|NCT04311736|Active Comparator|Cycling|Moderate intensity cycling only 3 times per week for 12 weeks, supervised by an exercise specialist
11066438|NCT04311736|Sham Comparator|Stretching|Stretching 3 times per week for 12 weeks, supervised by a therapist
11066439|NCT04311723|Active Comparator|Group I (conventional mechanical ventilation)|Patients receive anesthesia using a standard short breathing tube called LMA and then undergo standard of care bronchoscopy.
11066440|NCT04311723|Experimental|Group II (VESPA)|Patients receive anesthesia using a longer breathing tube called an endotracheal tube and then undergo standard of care bronchoscopy.
11066441|NCT04311710|Experimental|Part 1 Arm A: mM, mUC, HCC|metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)
11066442|NCT04311710|Experimental|Part 1: Arm B: mM|metastatic Melanoma (mM)
11066443|NCT04311710|Experimental|Part 2: Arm A: NSCLC|metastatic non small cell lung cancer (NSCLC)
11066444|NCT04311710|Experimental|Part 2: Arm B: RCC|advanced or metastatic renal cell carcinoma (RCC)
11066445|NCT04311697|Experimental|Aviptadil IV in escalating doses + standard of care|Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr
11066446|NCT04311697|Experimental|Placebo + standard of care|Patients will first be treated with placebo infusion + maximal intensive care
11066447|NCT04311684||Patients with proteinuria|Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements
11066448|NCT04311684||Healthy volunteers|Healthy men/women between age group 18-65 years will be included for urine protein measurements
11066449|NCT04311671|Experimental|Moxidectin|Moxidectin 8 mg per oral on Day 0
11066450|NCT04311671|Active Comparator|Ivermectin|Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
11066451|NCT04311658|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG-IUD insertion
11066452|NCT04311658|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to LNG- IUD insertion
11066453|NCT04311645|Other|1st group|Oral activated charcoal in a dose of 30 gm/day
11066454|NCT04311645|Other|2nd group|Dry seeds in a dose of 1 gm/ day
11066455|NCT04311645|No Intervention|3rd group|control group
11066456|NCT04311632|Experimental|Cohort A|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
11066457|NCT04311632|Experimental|Cohort B|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
11066458|NCT04311632|Experimental|Cohort C|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
11066459|NCT04311632|Experimental|Cohort D|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
11066460|NCT04311619|Experimental|Major Depression Disorder Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer before and after Repetitive Transcranial Magnetic Stimulation (rTMS) treatment
11066461|NCT04311606|Experimental|Saline and aflibercept|Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept
11066462|NCT04311606|Experimental|Hyaluronidase and aflibercept|Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept
11066463|NCT04311606|Placebo Comparator|Hyaluronidase alone|Group 3: Sub-tenon injection of HA injection alone
11066464|NCT04311593||group 1|control group with normal platelet count
11066465|NCT04311593||group 2|patients with acute ITP
11066466|NCT04311593||group 3|patients with chronic ITP
11066467|NCT04311580|Experimental|urothelial high risk non-muscle invasive bladder cancer|patients with urothelial high risk non-muscle invasive bladder cancer after failed intravesical bacillus Calmette-Guérin treatment.
11066468|NCT04311567|Experimental|Tofacitinib|Oral tablet tofacitinib 5 mg BID for 48 weeks
11066469|NCT04311567|Active Comparator|Methotrexate|Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks
11066470|NCT04311541||Dexlansoprazole|Participants diagnosed with GERD and initiated treatment with dexlansoprazole MR therapy will be observed prospectively at 150 sites in Russian federation for a period of 2 months.
11066471|NCT04311515|Active Comparator|30 mg PU AD|75 subjects will be treated with active PU-AD on a 1:1 ratio qd
11066472|NCT04311515|Placebo Comparator|30 mg Placebo|75 subjects will be treated with placebo SyrSpend on a 1:1 ratio qd
11066473|NCT04311502|Experimental|Arm 1: Experimental 3-month, with CFZ loading dose|Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
11066474|NCT04311502|Active Comparator|Arm 2: Standard of care for drug-susceptible (DS) TB|Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
11066475|NCT04311502|Experimental|Arm C: PK only subgroup|Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
11066476|NCT04311489|Experimental|Ularitide|Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
11066477|NCT04311489|Placebo Comparator|Placebo|Matching placebo. Continuous IV infusion for 48 hours.
11066478|NCT04311476|Placebo Comparator|Placebo|0.9% sodium chloride infusion within 24 hours after birth
11066479|NCT04311476|Experimental|ACBMNC|Autologous Umbilical Cord Blood Mononuclear Cells intravenously within 24 hours after birth,dose is 5×107cells/kg ,
11066480|NCT04311463|Experimental|Paroxetine hydrochloride 20 mg followed by PAXIL 20 mg tablet|In period 1, participants will receive orally single dose of test product (A) paroxetine hydrochloride 20 mg followed by reference product (B) PAXIL 20 mg tablet, along with 250 milliliter (mL) of water under fasting conditions. There will be a washout period of at least 7 days between successive dosing.
11066481|NCT04311463|Experimental|PAXIL 20mg followed by paroxetine hydrochloride 20mg tablet|In period 2, participants will receive orally single dose of reference product (B) PAXIL 20 mg tablet followed by test product (A) paroxetine hydrochloride 20 mg, along with 250 mL of water under fasting conditions. There will be a washout period of at least 7 days between successive dosing.
11066482|NCT04311450|Experimental|Behavioral Weight Loss|Behavioral: Participants randomized assigned to this arm will received 12 weeks of Behavioral Weight Loss (BWL) counseling.
11066483|NCT04311450|No Intervention|Waitlist Control|Waitlist Control: Participants assigned to this arm will attend follow-up visits to control for the effect of time. Following completion of post-treatment assessment participants in the waitlist control group will be offered an abbreviated BWL treatment.
11066484|NCT04311437|Experimental|Self-acupressure group|The subjects in experimental group will undergo additional self-acupressure therapy in addition to Valsalva and Toynbee maneuvers before the first HBOT. The acupoints used are TE17 (Yifeng, 翳風), TE21 (Ermen, 耳門), SI19 (Tinggong, 聽宮), GB2 (Tinghui, 聽會).
11066485|NCT04311437|Placebo Comparator|Control group|The subjects in control group will receive Valsalva and Toynbee maneuvers alone.
11066486|NCT04311424|Experimental|14C Tirzepatide|A single dose of [14C]-tirzepatide administered subcutaneously (SC).
11066487|NCT04311411|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
11066488|NCT04311411|Placebo Comparator|Placebo|Placebo administered SC.
11066489|NCT04311411|Active Comparator|Liraglutide|Liraglutide administered SC.
11066490|NCT04311398||Respiratory infection group|Patients went to fever clinic with respiratory infectious symptoms in Huashan Hospital affiliated to Fudan University
11066491|NCT04311385||Diverticulitis|"Patients admitted as an emergency with acute diverticulitis diagnosed by CT scan.
~Inclusion criteria
~Patients over 18 years old
~Informed consent form signed
~Diagnosed of acute diverticulitis
~CT scan reported as 1-2 pericolic bubbles with or without free fluid
~Exclusion criteria
~o CT scan showing free distant bubbles in the abdomen"
11066492|NCT04311372|Experimental|Educational session+Material+Videos (Group 1)|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
11066493|NCT04311372|Active Comparator|Educational session+Material ONLY (Group 2)|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
11066494|NCT04311359||Group/Cohort|Brain Oedema induced by drugs reported to the FAERS database from inception till first quarter of 2019
11066495|NCT04311346||Cardiac transplant|Patients exposed to cardiac transplantation
11066496|NCT04311333|Experimental|All patients|"All patients undergo endostomal three-dimensional ultrasonography, computerized tomography, clinical examination and laparotomy/laparoscopy.
~At all the respective examinations, the presence of a parastomal hernia as well as hernia location and size is evaluated."
11066497|NCT04311320|Experimental|Low-Resource Oxygen Blender|This is a single-arm study. All participants will receive respiratory support using the investigational device.
11066498|NCT04311307|Experimental|Patients|GSDIa patients
11066499|NCT04311307|Active Comparator|Controls|Healthy volunteers
11066500|NCT04311294|Active Comparator|ANS-6637 Low Dose|200mg ANS-6637 (2 tablets)
11066501|NCT04311294|Active Comparator|ANS-6637 High Dose|600mg ANS-6637 (2 tablets)
11066502|NCT04311294|Placebo Comparator|Placebo|0mg matched placebo (2 tablets)
11066503|NCT04311281||Suspected AD|"Participants with suspected AD enrolling in the trial must meet all of the following criteria:
~Cognitive deficits do not occur exclusively in the context of a delirium.
~Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).
~There is insidious onset and gradual progression of impairment in one or more cognitive domains.
~The participant has documented memory problems in one or more other cognitive domains, such as language, visual-spatial functioning, executive functioning, etc. (Busse et al., 2006)."
11066504|NCT04311281||Suspected CTE / TES|"Required Features:
~Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure; progressive course; and at least 1 supportive feature
~History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma
~Head trauma exposure is repetitive in nature
~Demonstrated progressive course
~Delayed symptom onset
~Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (executive, visuospatial, memory, and language).
~Supportive Features (only 1 required):
~Emotional dysregulation
~Behavioral change
~Motor disturbance"
11066505|NCT04311268|Experimental|Observational|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
11066506|NCT04311255|Active Comparator|intercostal group|group of patient receiving inrercostal nerve block as analgesia
11066507|NCT04311255|Active Comparator|pecs group|group of patient receiving pectoralis nerve block as analgesia
11066508|NCT04311229|Experimental|Negative-Pressure Wound Therapy group|NPWT was applied three times for Class III and pressure ulcers. An initial pre-treatment measurement was used as a baseline, followed by three post-treatment measurements after each round to evaluate wound healing. A total of four measurements were performed for each subject. Wound healing was measured using the PUSH Tool and the 3DWM device in both groups.
11066509|NCT04311229|Other|CONTROL GROUP|wet to dry dressing group
11066510|NCT04311216||Shoulder instability participants|Participants with previous a previous episode(s) of shoulder instability
11066511|NCT04311216||Age matched controls (no instability)|Participants with no previous a previous episode(s) of shoulder instability
11066512|NCT04311203|Experimental|Mental Health First Aid Intervention|Two-day MHFA training provided by MHFA England. Organisations will raise awareness of the presence of MHFA in the workplace, with delivery of MHFA by trained members to participants in the workplace.
11066513|NCT04311203|No Intervention|Control|A brief consultation from MHFAE on the promotion of mental health and well-being in the workplace.
11066514|NCT04311190|Experimental|ICU A|Family members' involvement in the care of their beloved one
11066515|NCT04311190|No Intervention|ICU B|Standard care
11066516|NCT04311177|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
11066517|NCT04311177|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
11066518|NCT04311164||Steno Tech Survey Respondents|This cohort is expected to consist of 1,400 people with Type 1 diabetes on insulin pump therapy treated at either Steno Diabetes Center Copenhagen or Nordsjællands Hospital Hilleroed.
11066519|NCT04311151|Experimental|self seizures visualization group|Visualization of the own epileptic seizures occured during hospital admission.
11066520|NCT04311151|No Intervention|usual management|Usual way management
11066521|NCT04311138|Experimental|Experimental group|Experimental group receive a 10-wk diversified community-based reablement service.
11066522|NCT04311138|Active Comparator|Control group|Control group receive a 10-wk multicomponent training.
11066523|NCT04311125|Active Comparator|total hip arthroplasty via the mini posterior approach|total hip arthroplasty via the mini posterior approach. This approach was first described by Kocher and Langenbeck and later modified by Gibson in 1950. There is a convex incision centered on the posterior rim of the major trochanter. The incision follows the curve of the buttock and at the height of the posterior lip of the major trochanter, it is peripherally oriented along the posterior outer surface of the femur. The major gluteus is divided along the muscle fibers. Guiding sutures are inserted into the tendon mass of the hip rotor muscles just prior to their origin on the major trochanter and dissected to expose and subsequently retract the posterior hip capsule.
11066524|NCT04311125|Active Comparator|THR via the anterior approach without traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
11066525|NCT04311125|Active Comparator|THR via the anterior approach with a traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
11066526|NCT04311112|Placebo Comparator|ZA placebo|
11066527|NCT04311112|Active Comparator|ZA low dose|
11066528|NCT04311112|Active Comparator|ZA high dose|
11066529|NCT04311099|Experimental|Group A|Ultrasound-guided TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and laparoscopic assisted injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
11066530|NCT04311099|Experimental|Group B|Laparoscopic assisted TAP with 20 ml ropivacaine 2 mg/ml solution bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
11066531|NCT04311099|Placebo Comparator|Group C|Laparoscopic assisted injection of 20 ml saline (placebo) bilaterally and ultrasound-guided injection of 20 ml saline (placebo) bilaterally at the beginning of surgery
11066532|NCT04311086|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
11066533|NCT04311073|Experimental|Tranexamic Acid|Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time
11066534|NCT04311073|Placebo Comparator|Placebo|Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision
11066535|NCT04311047|Experimental|USPIO-enhanced MRI|Ferumoxtran-10 contrast will be intravenously administered 24-36 before performing an MRI scan. The MRI scan will be discussed with the surgeon prior to resection. Findings on MRI will be compared to pathology.
11066536|NCT04311034|Experimental|RC48|
11066537|NCT04311021||Diabetes type 1|
11066538|NCT04310995|Experimental|Nicorandil|oral Nicorandil 5mg (Tablets) three times daily for 168 days
11066539|NCT04310995|Active Comparator|Diltiazem Hydrochloride|oral Diltiazem 180mg (Sustained-release Tablets) once daily for 168 days
11066540|NCT04310995|Active Comparator|Isosorbide Mononitrate|oral Isosorbide Mononitrate 50mg (Sustained-release Capsules) once daily for 168 days
11066541|NCT04310982||Health Adults|Forty-nine healthy participants (30 females, 19 males) completed the test-retest protocol with 7 days between tests. Participants were; 23,58±2,65 years of age, 62,9±10,08 kg of weight and 168,76±8,31 cm of height. Participants included in the study did not have any musculoskeletal, neurological or other pathology potentially affecting their gait and jump performance.
11066542|NCT04310969|Experimental|treatment group|Patients are treated every two weeks for a total of three times. Forceful expression of the meibomian glands is followed after each therapy.
11066543|NCT04310969|Sham Comparator|control group|Forceful expression of the meibomian glands only for patients.
11066544|NCT04310969|Active Comparator|active control group|LipiFlow® treatment is used as an active comparator.
11066545|NCT04310956|Experimental|Y-Knot group|Patients use Y-Knot all-suture anchor
11066546|NCT04310956|Active Comparator|Biocomposite suture anchor|Patients use Biocomposite suture anchor
11066547|NCT04310943|Experimental|Arm 1|Tislelizumab (200mg,Q3W )+Bevacizumab(15 mg/kg,Q3W)+Albumin paclitaxel(100mg/m2,d1,8,15) for 4 cycles, and if there is no disease progression, patients will receive Tislelizumab(200mg,Q3W) until progression or death.
11066548|NCT04310930|Active Comparator|Intensive Therapy A|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin AND clofazimine.
11066549|NCT04310930|Experimental|Intensive Therapy B|Following Randomisation 1, Participants will receive inhaled amikacin (IA), IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin AND clofazimine.
11066550|NCT04310930|Experimental|Intensive Therapy C|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin.
11066551|NCT04310930|Active Comparator|Consolidation A|Oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
11066552|NCT04310930|Experimental|Consolidation B|Inhaled amikacin (IA), oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
11066554|NCT04310904||ICU cardiac output (CO) assessment patients|all ICU patients intubated/ventilated with a central line and an arterial catheter who need trans esophageal echocardiography examination with a saline contrast test.
11066555|NCT04310891||Markerless|Markerless Tumour Tracking will be used to observe the radiation beam is accurately targeting the tumour.
11066556|NCT04310865|Experimental|Yinhu Qingwen Granula Group|Based on the standard medical treatment, the patients will be given Yinhu Qingwen Granula for 10 days.
11066557|NCT04310865|Placebo Comparator|Yinhu Qingwen Granula Low-dose Group|Based on the standard medical treatment, the patients will be given 10% dose of Yinhu Qingwen Granula for 10 days.
11066558|NCT04310839||outpatient left laparoscopic colectomy|Left laparoscopic laparoscopic colectomy patient managed on an outpatient basis
11066559|NCT04310826|Experimental|Prevention (dietary intervention)|Patients receive a dietary magnesium intervention consisting of a food reference list and phone calls or video interviews from a registered dietitian, integrative medicine physician, or a mid-level provider over 10-20 minutes once a week for up to the 6th cycle of chemotherapy (average 15 weeks).
11066560|NCT04310813||Endoscopic urologic patients|Patients with bladder cancer or benign prostate hyperplasia undergoing urologic endoscopic procedures.
11066561|NCT04310800|Experimental|LIFT-plug|The LIFT-plug procedure was performed as followings. A portion of the fistula tract was excised from ei¬ther end within the intersphincteric space. One porcine small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures.
11066562|NCT04310800|Experimental|LIFT|The LIFT procedure was performe as followings. The curvilinear incision and dissection of the intersphincteric tract were made as in the LIFT-plug technique. After the tract was isolated, the tract was doubly-ligated and suture-ligated with absorbable sutures as close as possible to the lateral margin of the internal anal sphincter and the medial margin of the external anal sphincter. The tract was then divided between the two sutures. A portion of the fistula tract was excised after ligation of ei¬ther end within the intersphincteric space. The medial ligature was very close to the internal opening, and nearly obliterated the internal opening. The external opening was then enlarged to allow adequate drainage. The internal and external sphincters were then re-approximated, and the skin was closed loosely with interrupted 3/0 absorbable suture.
11066563|NCT04310787||HBV-ACLF|To investigate the clinical events and prognosis of patients with hepatitis b associated acute on-chronic liver failure
11066564|NCT04310774|Experimental|Consolidation therapy|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
11066565|NCT04310761||pregnancy population after one single blastocyst transfer|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from a period between 2014 and 2018.
11066566|NCT04310748|Active Comparator|Total Intravenous Anesthesia(TIVA)|Anesthesia is maintaining with TIVA (Group 1)
11066567|NCT04310748|Active Comparator|Inhalation Anesthesia|Anesthesia is maintaining with inhalation anesthesia (Group 2)
11066568|NCT04310735|Experimental|Experimental: Expect-Yes|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will perceive an opportunity to smoke during the experimental session.
11066569|NCT04310735|Experimental|Experimental: Expect-No|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will not perceive an opportunity to smoke during the experimental session.
11066570|NCT04310722||Gram-negative bacilli and MRSA infections in ICU|Carbapenem-resistant Gram-negative bacilli [Carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Klebsiella pneumoniae (CRKP), and Carbapenem-resistant Pseudomonas aeruginosa (CRPsA) ] and methicillin-resistant Staphylococcus aureus (MRSA) is prevalent around the world, and the isolation rate and resistance rate has increasing in China, especially in ICU. So, investigators aim to study transmission mechanism, resistance mechanism and horizontal transfer mechanism of these pathogens.
11066571|NCT04310709|Experimental|REGONIVO|"Nivolumab - 480 mg IV on Day 1, every 4 weeks
~Regorafenib
~- 80 mg per oral once daily for 21 consecutive days starting on Day 1, every 4 weeks."
11066572|NCT04310696|Experimental|Buteyko group|Buteyko breathing exercises
11066573|NCT04310696|Active Comparator|Pursed lip breathing|Pursed lip breathing exercises
11066574|NCT04310683|Other|natural cycle for endometrium preparation|patients will have ovulation before embryo transfer
11066575|NCT04310683|Experimental|hormone replaced cycle for endometrium preparation|patients will do not have ovulation before embryo transfer
11066576|NCT04310670|Experimental|Patients with FND|Diagnosis of Functional Neurological Disorder of movement clinically established according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria
11066577|NCT04310657|Experimental|Precision therapy|
11066578|NCT04310657|No Intervention|control|
11066579|NCT04310644||Postural Orthostatic Tachycardia Syndrome|Patients with orthostatic intolerance because of Postural orthostatic tachycardia syndrome diagnosed in our outpatient clinic by tilt table examination.
11066580|NCT04310644||Ehlers Danlos Syndrome|Patients with hypermobile or classical EDS who are already diagnosed including genetical testing for classical or vascular EDS and Marfan Syndromes
11066581|NCT04310644||Autoimmune autonomic neuropathy/Pure autonomic failure|Patients who have an autoimmune autonomic neuropathy based on clinical diagnosis and antibody testing in our outpatient clinic. Cardial MIBG Scintigraphy should have been performed.
11066582|NCT04310644||Healthy controls|Healthy controls with no documented cardiovascular or neurological disorders and no symtoms of autonomic failure/dizziness/fainting
11066583|NCT04310618||Adults with bronchiectasis|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase
11066584|NCT04310605||Step 1 only|Participants in the study who only receive Step 1 of specialised CBT
11066585|NCT04310605||Step 1 and 2|Participants who receive both Step 1 and Step 2 of speciliased CBT for tinnitus.
11066586|NCT04310592|Experimental|Dose escalation/MTD or MPD determination|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
11066651|NCT04310098||CADASIL patients|
11066588|NCT04310579|Active Comparator|Part 1 Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) tablets and intravenous (IV) placebo 1x per day.
~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.
~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.
~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.
~Note: Initial doses of oxycodone will be 10 mg, but may be increased to 15 mg if necessary based on criteria specified in protocol. Initial doses of midazolam will be 0.0375 mg/kg but may be increased to 0.075 mg/kg based on criteria specified in protocol."
11066589|NCT04310579|Active Comparator|Part 2 Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.
~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.
~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
11066590|NCT04310553|Experimental|Arm 1|This project plans to enroll 40 patients receiving nanoknife treatment, our center enrolls 20 patients, and the other two centers will enroll 10 patients each. The number of patients expected to participate in the study is 240.
11066591|NCT04310540|Active Comparator|Surgical resection / Liver transplant|30 undergoing resection or transplant will under go a 68 Ga labeled PSMA 11 (or PSMA - HBED _ CC) PET/MRI or PET/CT scan
11066592|NCT04310540|Active Comparator|Locoregional therapy|30 undergoing locoregional therapy will under go a maximum of two 68 Ga labeled PSMA 11 (or PSMA - HBED _ CC) PET/MRI or PET/CT scan with possible biopsy after the first PET Scan
11066593|NCT04310527|Experimental|Treatment A: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib reference formulation will be given under fasted condition.
11066594|NCT04310527|Experimental|Treatment B: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib test formulation will be given under fasted condition.
11066595|NCT04310527|Experimental|Treatment C: Administration of ensidenib fed|A single oral 100 mg dose of enasidenib test formulation will be given under fed condition.
11066596|NCT04310514|Active Comparator|Experimental: glucose - fructose - xylitol - saccharose|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
11066597|NCT04310514|Active Comparator|Experimental: fructose - glucose - saccharose - xylitol|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
11066598|NCT04310514|Active Comparator|Experimental: xylitol - saccharose - glucose - fructose|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
11066599|NCT04310514|Active Comparator|Experimental: saccharose - xylitol - fructose - glucose|"glucose 35 g (500ml of 7% solution);
~fructose 35 g (500ml of 7% solution);
~xylitol 35 g (500ml of 7% solution);
~saccharose 35 g (500ml of 7% solution)"
11066600|NCT04310501||CKD Patients|"Patients (n=150) with CKD (Stages 1-5 pre-dialysis, undergoing dialysis, kidney transplantation) who fulfil the inclusion criteria from the Nephrology Dept and Renal Transplant Unit of the University Hospital of Ioannina.
~Sixty patients will be selected for the pilot study which will include blood and urine tests and specific polymorphism analysis (pharmacogenetic tests)"
11066601|NCT04310462|Experimental|New eRX Interface|Providers assigned to the intervention arm will be presented with a new eRX interface upon writing new prescriptions for hydroxychloroquine in the EHR.
11066602|NCT04310462|No Intervention|Standard Interface|Providers assigned to the no intervention arm will be presented with the usual ordering interface when prescribing new prescriptions for hydroxychloroquine in the EHR.
11066603|NCT04310449|Experimental|Connective tissue graft and customized healing abutment|Immediate implant placement with CTG and customized healing abutment.
11066604|NCT04310449|Experimental|Bone graft and customized healing abutment|Immediate implant placement with bone graft till the crest of the bone and customized healing abutment
11066605|NCT04310449|Experimental|Bone graft and ovate pontic|bone grafts in the socket and ovate Pontic
11066606|NCT04310449|Active Comparator|Bone graft in dual zone and customized healing abutment|immediate implant placement with bone grafts in the dual zone and customized healing abutment
11066607|NCT04310436|Experimental|Looking down to naval.|Modifying Saccade origin by looking down to naval.
11066608|NCT04310436|Placebo Comparator|Looking up in the air.|Modifying Saccade origin by looking up in the air.
11066609|NCT04310423|Placebo Comparator|Placebo|Matched to endotoxin
11066610|NCT04310423|Experimental|Endotoxin|Bolus dose of endotoxin (0.8 ng/kg)
11066611|NCT04310410|Experimental|Combined Focused Ultrasound and Radiotherapy|Combination of focused ultrasound and external beam radiotherapy
11066612|NCT04310397|Experimental|Treatment (dabrafenib, trametinib, surgery, spartalizumab)|"NEOADJUVANT TREATMENT: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo surgical resection of melanoma.
~ADJUVANT TREATMENT OF pCR PATIENTS: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity.
~ADJUVANT TREATMENT OF NON pCR PATIENTS: Patients receive spartalizumab IV over 30 minutes on day 1, dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeats every 28 days for 44 weeks in the absence of disease progression or unacceptable toxicity."
11066613|NCT04310384|Active Comparator|Endotracheal Intubation, gold standart|Standart of Care with Macintosh laryngoscope
11066614|NCT04310384|Active Comparator|Alternative|Endotracheal Intubation with novel device
11066615|NCT04310371|Experimental|Obese adolescents|BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention
11066616|NCT04310371|No Intervention|Control group|to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
11066617|NCT04310358|Experimental|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
11066618|NCT04310358|Experimental|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
11066619|NCT04310345|Experimental|Animal-Assisted Interaction|Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
11066620|NCT04310332||1L-PEG|Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.
11066621|NCT04310332||4L-PEG|Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.
11066622|NCT04310319|Other|Normal salt, low protein treatment period|6 grams of sodium chloride daily / Placebo
11066623|NCT04310319|Other|Normal salt, normal protein treatment period|6 grams of sodium chloride daily / 40 grams of protein daily
11066624|NCT04310319|Other|Low salt, low protein treatment period|Double placebo
11066625|NCT04310319|Other|Low salt, normal protein treatment period|Placebo / 40 grams of protein daily
11066626|NCT04310306||Rescue stenting group|
11066627|NCT04310293|Other|POOR RESPONDERS|poor responders low AMH LOW AFC
11066628|NCT04310280|Experimental|Topical insulin glargine|The wound surface is treated locally with glargine insulin injected sub-dermal in a daily matter for 7 days. Allocation is randomized.
11066629|NCT04310280|Placebo Comparator|0.9% saline solution|The wound surface is treated with conventional wound care in a daily matter for 7 days. Allocation is randomized.
11066630|NCT04310267|Active Comparator|classic occlusal level, low point of force application|the point of force application for maxillary protraction is at the level of the occlusal plane.
11066631|NCT04310267|Active Comparator|Nasal level, Medium point of force application|the point of force application for maxillary protraction is at 20 mm from the occlusal plane (Nasal floor).
11066632|NCT04310267|Active Comparator|Infrorbital level, High level|the point of force application for maxillary protraction is at the level of the infraorbital foramen
11066633|NCT04310254|Active Comparator|EDTA and CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA and CHX solution.
11066634|NCT04310254|Active Comparator|EDTA solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA solution.
11066635|NCT04310254|Active Comparator|CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for CHX solution.
11066636|NCT04310241||Control subjects|Subjects who state they have no eye or neurologic problems or disease other than perhaps wearing glasses or contact lenses and upon review of medical history.
11066637|NCT04310241||Amblyopia|Clinical diagnosis of amblyopia
11066638|NCT04310228|Experimental|Favipiravir Combined With Tocilizumab group|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
~Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
11066639|NCT04310228|Active Comparator|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
11066640|NCT04310228|Active Comparator|Tocilizumab group|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
11066641|NCT04310215|Experimental|Microfracture + CARTISTEM®|CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.
11066642|NCT04310215|Active Comparator|Microfracture|Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.
11066643|NCT04310202||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and additional follow-up visits after surgery.
11066644|NCT04310176|Active Comparator|Standard|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab for 12 cycles (24 weeks)
~Maintenance treatment (Standard): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab until disease progression or unacceptable toxicity"
11066645|NCT04310176|Experimental|Experimental|"Chemotherapy (mFOLFOX-6/mOXELL) + Bevacizumab + Valproic Acid administered oral daily from day -14 increasing doses and an intra-patient titration for a target serum level of 50-100µg/ml for 12 cycles (24 weeks)
~Maintenance treatment (Experimental): Fluoropyrimidines (5-Fluorouracil/Capecitabine) + Bevacizumab + Valproic Acid until disease progression or unacceptable toxicity"
11066646|NCT04310150|Experimental|Treatment arm label- Collastat®|
11066647|NCT04310150|Active Comparator|Control arm label- Floseal®|an marketed product is Floseal
11066648|NCT04310137|Experimental|Therapist-Directed Re-loading|Participants in this arm will be instructed to increase their activity by walking 10% more steps per day than the steps recorded in the most recent activity monitoring (i.e. StepWatch) measurement (e.g. 10% more than the initial monitoring values and 10% more than the second monitoring values once they are completed).
11066649|NCT04310137|No Intervention|Self-Directed Re-loading|Participants in this arm will be instructed to slowly increase their walking.
11066650|NCT04310111|Experimental|EUS-RFA|Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.
11066655|NCT04310085|Experimental|PfSPZ-DVI challenge and artemether lumefantrine|
11066656|NCT04310072|Experimental|neuromuscular electrical stimulation group|"For patients who underwent NMES therapy, four electrodes (two 50/100 mm and two 50/50 mm, Compex Performance) were placed on the skin above the quadriceps muscle approximately 5 cm below the inguinal fold and 3 cm above the upper patella border.
~The electrical stimulation protocol consisted of electrical current at frequency of 10 Hz, 20 seconds stimulation time (time on) and 20 seconds resting time (time off) with variable intensity (until visible muscular contraction) for one hour per day until discharge (Compex).The NMES therapy was on top of conventional rehabilitation described below."
11066657|NCT04310072|No Intervention|Control group|"The control group consisted of patients who performed daily active upper and lower limbs exercise in bed and in a stand position (3x10 repetitions, somewhat hard on the Borg scale)."
11066658|NCT04310059|Active Comparator|Folic acid 5mg|
11066659|NCT04310059|Active Comparator|Folic acid 0.5mg|
11066660|NCT04310059|Active Comparator|Materna|
11066661|NCT04310046|Other|PCI before TAVI|PCI is performed within 1-40 days before TAVI.
11066662|NCT04310046|Experimental|PCI after TAVI|PCI is performed within 1-40 days after TAVI.
11066663|NCT04310033||Cases|"> 18 years old
~Non-opposition of the patient or relatives
~Lung, head and neck or colorectal cancer
~Non scheduled ICU admission
~At least 24 hours of ICU stay
~Alive at ICU discharge
~Able to answer by phone to quality of life questionary"
11066664|NCT04310033||Controls|"Cancer patients not admitted in ICU, matched with the cases according to
~the type of primary cancer
~the presence or absence of oncogenic addiction
~the setting of anticancer treatment (curative/palliative)
~the line of anticancer treatment (none/L1/L2-L3/>L3)."
11066665|NCT04310020|Experimental|Treatment (hypofractionated radiation therapy, atezolizumab)|"RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity."
11066666|NCT04310007|Experimental|Arm A (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
11066667|NCT04310007|Experimental|Arm B (cabozantinib S-malate, nivolumab)|Patients receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
11066668|NCT04310007|Active Comparator|Arm C (standard chemotherapy,cabozantinib S-malate, nivolumab)|See Detailed Description
11066669|NCT04309994||Experimental|bypass surgery with blood cardioplegia by means of MPS
11066670|NCT04309994||Active Comparator|bypass surgery with blood cardioplegia by means of Cardioplexol ®
11066671|NCT04309981|Experimental|ARI0002h|Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized
11066672|NCT04309968|Experimental|solid tumors|Experimental: Solid tumors Part 1 - Dose-escalation of SYHA1801 in patients with advanced solid tumors.Daily dosing of SYHA1801 on Days 1 and 4-31 of 28-day cycle. Escalating dose cohorts.
11066673|NCT04309968|Experimental|advanced cancers|Part 2 - Dose-expansion of SYHA1801 in patients with advanced cancers potentially sensitive to BRD4 inhibitor.The dose level and schedule of SYHA1801 of 28-day cycle at the MTD determined in Part 1.
11066674|NCT04309955|Experimental|modified thoracic drainage group|After surgery, both a chest tube and a pigtail catheter are inserted into the middle and posterior axillary lines of the 7th intercostal space, respectively.
11066675|NCT04309955|No Intervention|traditional thoracic drainage group|After surgery, only a chest tube is inserted into the midaxillary line of the 7th intercostal space, traditionally.
11066676|NCT04309942|Experimental|Guided Clinical Pharmacy Consultation group|Patients following either Revlimid - Velcade - Dexamethasone or Revlimid - Dexamethasone protocols with the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
11066677|NCT04309942|No Intervention|Standard group|Patients following either Revlimid - Velcade - Dexamethazone or Revlimid - Dexamethazone protocols but without the benefit of a Guided Clinical Pharmacy Consultation before beginning oral anticancer treatment for multiple myeloma.
11066678|NCT04309929||Women with breast cancer|Female patients (age> 18yrs) in ASA class <4; candidate for a planned surgery for simple mastectomy, simple mastectomy with immediate reconstruction, mastectomy with sentinel node biopsy, modified radical mastectomy (unilateral or bilateral)
11066679|NCT04309916|Experimental|Tegoprazan 50mg|Tegoprazan 50mg tablet, once daily, oral administration
11066680|NCT04309916|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg tablet, once daily, oral administration
11066681|NCT04309903|Experimental|Manual Therapy|The experienced physiotherapist has applied manual therapy (MT) to the arthropathic joints. MT was started with myofascial release techniques (MRT), then continued with mobilization techniques using Kalternborn. Superficial MRT consisted of 3 strokes, via manual movement on the tissue, encourage release of the superficial fascia. In the Kalternborn mobilization technique, Grade I-II mobilization was applied with traction without using a strap. The same exercises given to the home exercise group were given to the patients in this group as well.
11066682|NCT04309903|Active Comparator|Home Exercise|The home exercises (HE) consisted of active ROM exercises, passive stretching exercises, progressive resistive exercises, weigh-bearing and stance exercises were performed by the patient for 30 minutes at home.
11066683|NCT04309890||Study group|
11066684|NCT04309877|Experimental|PO theophylline & IV LPS|Oral (PO) theophylline 400 mg/day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
11066685|NCT04309877|Experimental|PO placebo & IV LPS|PO methylcellulose (placebo) daily for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
11066686|NCT04309877|Experimental|PO theophylline & IV placebo|PO theophylline 400 mg/day for 2 weeks followed by a single IV bolus of 0.9% saline
11066687|NCT04309877|Placebo Comparator|PO placebo & IV placebo|PO methylcellulose (placebo) daily for 2 weeks followed by a single IV bolus of 0.9% saline
11066688|NCT04309864|No Intervention|Focus group-Veteran|Veterans will inform study staff regarding desired device design refinements
11066689|NCT04309864|No Intervention|Focus group-Clinicians|Clinicians will inform study staff regarding desired app design changes
11066690|NCT04309864|Other|Usability-inpatients|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
11066691|NCT04309864|Other|Usability-in-home|The Veteran will use the CMAP system at home for two weeks to use in their daily routines, along with wearing the acti-graph one week prior, two weeks during and one week after CMAP usage.
11066692|NCT04309825|Experimental|G-tube endoscopies patients|patients who will undergo an endoscopy through g-tube port
11066693|NCT04309812|Active Comparator|Short Stimulation|1 minute duration of stimulation per day for 30 days
11066694|NCT04309812|Experimental|Long Stimulation|30 minutes duration of stimulation per day for 30 days
11066695|NCT04309799|Other|Single 10 minute session|Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
11066696|NCT04309799|Other|Optional Extension|Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
11066697|NCT04309773|Experimental|Bezafibrate in addition to standard UDCA therapy|"Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (experimental arm)"
11066698|NCT04309773|Placebo Comparator|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy
11066699|NCT04309760|Active Comparator|gender dysphoria subjects|Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy
11066700|NCT04309760|Other|control subjects|Control group inclusions, of open-label patients without gender dysphoria.
11066701|NCT04309747|Experimental|nanosecond knife group|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
11066702|NCT04309734|Experimental|Part A - 60 mg AT-777 single dose|
11066703|NCT04309734|Experimental|Part A - 120 mg AT-777 single dose|
11066704|NCT04309734|Placebo Comparator|Part A - Placebo single dose|
11066705|NCT04309734|Experimental|Part B - 60 mg AT-777 + 550 mg AT-527 once daily for 8 weeks|
11066706|NCT04309721|Experimental|Perampanel|immediate enteral administration of Perampanel, 12 mg
11066707|NCT04309721|Placebo Comparator|Placebo|immediate enteral administration of placebo
11066708|NCT04309708|Experimental|Original Perfusor Line(Art.No.8723017)|
11066709|NCT04309708|Active Comparator|Original Perfusor Line(Art.No.8723010)|
11066710|NCT04309695|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
11066711|NCT04309682|Experimental|crestal sinus approach technique|Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
11066712|NCT04309682|Active Comparator|lateral sinus elevation technique|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take plac
11066713|NCT04309669|Experimental|Tot'hema|three ampoules per day during 12 weeks daily dose: 150mg of iron per day.
11066714|NCT04309656|Experimental|Panel 1: Pretomanid after meal|Each participant will receive four single-dose treatments. Panel 1 will receive a meal before dosing.
11066715|NCT04309656|Experimental|Panel 2: Pretomanid after fast|Each participant will receive four single-dose treatments. Panel 2 will fast before dosing.
11066716|NCT04309643|Experimental|CTP-543|In Period 1, participants will receive a single oral dose of the combination oral contraceptive (OC) on Day 1. There will be a washout period of 7 days between dosing in Period 1 and the first dose in Period 2. In Period 2, participants will receive twice daily oral doses of CTP-543 for 8 consecutive days with a single dose of the combination OC co-administered on Day 4.
11066717|NCT04309630|Active Comparator|intercostal block|patients received intercostal block will be evaluated by visual analog score for pain assesment
11066718|NCT04309630|Experimental|erector spina plane block|patients received erector spina plane block will be evaluated by visual analog score for pain assesment
11066719|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
11066720|NCT04309578|Experimental|treatment arm|Single arm
11066721|NCT04309565|Active Comparator|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
11066838|NCT04308746|Experimental|Collectivistic|Participants write 3 statements to 3 questions relating to his/her similarities with his/her immediate community
11066722|NCT04309565|Experimental|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
11066723|NCT04309552||High Grade Glioma (HGG)|Thirty newly diagnosed treatment-naïve subjects with suspected HGG based on clinical presentation and MRI findings and undergoing surgical planning will be accrued in this study.
11066724|NCT04309539|Active Comparator|Fascia iliaca block|Patients will receive Fascia iliaca block
11066725|NCT04309539|Active Comparator|combined LFCN block with PENG block|Patients will receive a combined lateral femoral cutaneous nerve block with pericapsular nerve group block
11066726|NCT04309526|Experimental|NCO-48 Fumarate|NCO-48 Fumarate
11066727|NCT04309526|Placebo Comparator|Placebo|Placebo Comparator
11066728|NCT04309513|Active Comparator|Step Counter to motivate physical activity|Participants will be encouraged to work up to achieving at least 10,000 steps a day, higher if possible and reasonable, as measured by a wearable device.
11066729|NCT04309513|Experimental|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device.
11066730|NCT04309500|Experimental|African-American Participant-Co-Participant Dyads|5 Non-Hispanic African-American participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT).
11066731|NCT04309500|Experimental|White Participant-Co-Participant Dyads|5 Non-Hispanic White participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT)
11066732|NCT04309487||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
11066733|NCT04309474|Experimental|Elezanumab|Participants will receive elezanumab dose A
11066734|NCT04309474|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
11066735|NCT04309461|Active Comparator|Stress Management Group|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
11066736|NCT04309461|Experimental|Adapted MBC2 Group|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
11066737|NCT04309448|Experimental|Perturbation-based balance training with FES|
11066738|NCT04309435|Experimental|Self-esteem intervention|"The self-esteem intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:
~Engagement and listening
~Positive regard and empathy
~Collaboration
~Development of a shared understanding of low self-esteem (a 'psychological formulation')
~Provision of written or audio-visual information relating to low self-esteem
~Between-session activity for participant
~Provision of structured self-help material relating to low self-esteem
~Testing of beliefs related to low self-esteem
~Practicing new strategies related to low self-esteem
~Development of a shared plan to maintain gains in self-esteem"
11066739|NCT04309435|Placebo Comparator|Self-esteem control group|'Assessment and support' for participants with low self-esteem will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
11066740|NCT04309435|Experimental|Self-stigma intervention|"The self-stigma intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:
~Engagement and listening
~Positive regard and empathy
~Collaboration
~Development of a shared understanding of high self-stigma (a 'psychological formulation')
~Provision of written or audio-visual information relating to self-stigma
~Between-session activity for participant
~Provision of structured self-help material relating to self-stigma
~Testing of beliefs related to self-stigma
~Practicing new strategies related to self-stigma
~Development of a shared plan to maintain reductions in self-stigma"
11066741|NCT04309435|Placebo Comparator|Self-stigma control group|'Assessment and support' for participants with high self-stigma will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
11067331|NCT04305314||Group 1: PRI > 70%|Compliance with the Enhanced Revovery protocol higher than 70%
11066742|NCT04309435|Experimental|Jumping to conclusions intervention group|"The 'jumping-to conclusions' (JTC) intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:
~Engagement and listening
~Positive regard and empathy
~Collaboration
~Development of a shared understanding of role of JTC (a 'psychological formulation')
~Provision of written or audio-visual information relating to JTC
~Between-session activity for participant
~Provision of structured self-help material relating to JTC
~Testing of beliefs related to JTC
~Practicing new strategies related to reducing JTC
~Development of a shared plan to maintain reductions in JTC"
11066743|NCT04309435|Placebo Comparator|Jumping to conclusions control group|'Assessment and support' for participants who demonstrate the JTC bias will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
11066744|NCT04309422||Overexpression of PDL1|Overexpression of PDL1
11066745|NCT04309422||Absence of overexpression of PDL1|Absence of overexpression of PDL1
11066746|NCT04309409|Experimental|Nivolumab (Arm A)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):
~Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines."
11066747|NCT04309409|No Intervention|Observation, High Risk (Arm B)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):
~Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines."
11066748|NCT04309409|No Intervention|Observation, Low Risk (Arm C)|"Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization:
~These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients."
11066749|NCT04309396|Experimental|Breath analyzer|Candidates who, after the screening period are eligible to receive the AIRE device.
11066750|NCT04309383||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
11066751|NCT04309370|Experimental|20 Hz rTMS targeting the LDLPFC|
11066752|NCT04309370|Experimental|20 Hz rTMS targeting the LSPC|
11066753|NCT04309344|Experimental|RF|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage
11066754|NCT04309344|Active Comparator|Control|The mechanical shaver is used to remove superficial fibrillations.
11066755|NCT04309331|Experimental|PKU Motion|amino acid based protein substitute
11066756|NCT04309318||Low pneumoperitoneum (10-12 mmHg) pressure range group|
11066757|NCT04309318||High pneumoperitoneum (13-15 mmHg) pressure range group|
11066758|NCT04309305|Experimental|Stroke RE|After discharge from the acute rehabilitation facility, participants in the stroke RE group will participate 3 days a week for 10 weeks in robotic exoskeleton gait training provided by a trained, licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
11066759|NCT04309305|Active Comparator|Stroke SOC|After discharge from the acute rehabilitation facility, participants in the stroke SOC group will participate 3 days a week for 10 weeks in standard of care gait training provided by a licensed physical therapist. Participants will be permitted to participate in additional prescribed standard physical therapy on their own.
11066760|NCT04309305|Other|Healthy Control|Participants in the healthy control group will not participate in any gait training. Healthy control participants will only be asked to complete 3 testing sessions.
11066761|NCT04309292|Experimental|Treatment Arm|protein supplementation plus prebiotic supplementation
11066762|NCT04309292|Placebo Comparator|Placebo Arm|Protein supplementation plus placebo
11066763|NCT04309279|Experimental|Zentangle group|
11066764|NCT04309279|No Intervention|Wait-list Control Group|
11066765|NCT04309266|Experimental|Robot Assisted Therapy with Metacognitive Skills Training|All participants will be enrolled in the single arm of this study, where they will receive robot assisted therapy combined with metacognitive skills training.
11066766|NCT04309253|Other|PMPBB3|"Primary endpoint(s):
~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.
~Secondary endpoints:
~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
11066767|NCT04309253|Other|AV45|"Primary endpoint(s):
~A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.
~Secondary endpoints:
~A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period."
11066768|NCT04309240|Experimental|rivaroxaban|oral Rivaroxaban 10mg per day for 90days
11066769|NCT04309240|No Intervention|blank control|mechanical prophylaxis
11066770|NCT04309227|Experimental|Traditional High-Intensity Training|Participants will perform their training at ~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
11066839|NCT04308733|Active Comparator|real tDCS|30 patients will be treated with real anodal tDCS over the contralateral pharyngeal motor cortex
11066771|NCT04309227|Experimental|Low Intensity plus Blood Flow Restriction Training|Participants will perform their training at ~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
11066772|NCT04309227|No Intervention|Control|Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.
11066773|NCT04309214|Experimental|MCT fats|MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption.
11066774|NCT04309188|Experimental|Stroboscopic Training Group|Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
11066775|NCT04309188|Active Comparator|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
11066776|NCT04309175|Experimental|Slow-Fast|
11066777|NCT04309175|Experimental|Fast-Slow|
11066778|NCT04309162|Experimental|soft tissue therapy|Soft tissue therapy includes various techniques which is usually done by manipulating the soft tissues. The techques like stroking, petrissage, percussing maniulations are proved helpful in managing various painful conditions. The main effect of the soft tissue therapy is enhanced blood circulation to the area. When the techniques of soft tissue therapy are applied they will results in stretching and rubbing the muscular tissue which results in increased venous flow to heart and removal of the lactic acid accumulation occurs as the fresh supply of blood to the area will increased. Endorphins the natural pain relievers are released as there is improved oxygenation and perfusion of oxygen in tissues.
11066779|NCT04309149|Experimental|MCT fats|Kanso MCT oils and margarine will be consumed daily for 7 days each to assess tolerability and compliance
11066780|NCT04309136|Experimental|Neoadjuvant Anlotinib|
11066781|NCT04309123|Experimental|Treatment|TransAeris stimulation therapy adjunctive to continued mechanical ventilation will begin 24 hours after leaving the operating room, if subject remains on mechanical ventilation. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.
11066782|NCT04309110|No Intervention|Standard care with geko™ T3 device|Current geko™ device incorporating hydrogel adhesive designated KM10T
11066783|NCT04309110|Active Comparator|geko™ X-T3|Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
11066784|NCT04309097|Experimental|Digital intervention|Participants will have access to a live-streaming App that offers Recess and Exercise Advocate Program (REAP).
11066785|NCT04309097|Active Comparator|Information-only intervention|Participants will have access to health information only.
11066786|NCT04309084|Experimental|Phase I|Up to two dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT.
11066787|NCT04309084|Placebo Comparator|Phase II|CYNK-001 or Placebo (using Phase I determined dose)
11066788|NCT04309071|Experimental|Salivary insulin responses to mixed meal tolerance test|Saliva samples and finger prick glucose will be collected after at least 4 hours of fasting and then at 60 and 90 minutes following ingestion of a standardized meal tolerance test.
11066789|NCT04309058|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
11066790|NCT04309058|No Intervention|Control|The other group do not interfere.
11066791|NCT04309045|Experimental|DBT|Standard DBT treatment
11066792|NCT04309045|Active Comparator|DDP|dynamic deconstructive psychotherapy (DDP) treatment, is part of a trend of dynamic therapies to treat borderline personality disorder. DDP is a treatment specifically developed for a population with more severe symptoms those dealing with borderline personality disorder.
11066793|NCT04309045|Placebo Comparator|control group|patients on the waiting list for treatment, or patients in the hospital under routine care. Which will form the control group.
11066794|NCT04309032|Experimental|Bladder fill|Retrograde bladder filling of 250cc of 0.9% normal saline for irrigation prior to removal of foley catheter
11066795|NCT04309032|No Intervention|No bladder Fill|no filling prior to removal of foley catheter
11066796|NCT04309006|Experimental|CTG and customized healing abutment|Customized healing abutment used with connective tissue graft
11066797|NCT04309006|Experimental|CTG and conventional healing abutment|Conventional healing abutment (same diameter of the implant) used with connective tissue graft
11066798|NCT04309006|Active Comparator|customized healing abutment|Customized healing abutment used without connective tissue graft
11066799|NCT04309006|Active Comparator|conventional healing abutment|Conventional healing abutment (same diameter of the implant) without connective tissue graft
11066800|NCT04308980|Experimental|Active treatment|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use specialized medical nutrition product together with diet based on the measured individual requirements in energy and protein intake.
11066801|NCT04308980|Placebo Comparator|Control group|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use masked placebo together with diet based on the measured individual requirements in energy and protein intake.
11066802|NCT04308967|Experimental|Balance exercises and information|Balance exercises six weeks and three days in a week and information about central sensitisation.
11066803|NCT04308967|No Intervention|Information|Information about central sensitisation.
11066804|NCT04308954|Experimental|Fragile X Syndrome|Adult males aged 18-30 years diagnosed with FXS will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
11066836|NCT04308759|Active Comparator|Group II (Texting)|Participants participate in texting program over 42 days where they receive messages to support quitting smoking. Therapy description withheld to protect the integrity of the study.
11066805|NCT04308954|Experimental|Idiopathic Intellectual Developmental Disorder|Adult males aged 18-30 years diagnosed with idiopathic intellectual developmental disorder will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
11066806|NCT04308941|Active Comparator|Scleral Tonopen|The first 10 subjects will be randomly chosen for the first cohort (scleral TonoPen)
11066807|NCT04308941|Active Comparator|Scleral Pneumatonometer|The second 10 subjects will be randomly chosen for the second cohort (scleral pneumatonometry)
11066808|NCT04308941|Active Comparator|Diaton|The third 10 subjects will be randomly chosen for the third cohort (Diaton).
11066809|NCT04308928||Children with suspected meningitis|Patients must have a clinical diagnosis of meningitis including one or more of the following symptoms: headache, irritability, vomiting, fever and neck stiffness (Table 1). The diagnosis of probable or possible TBM is based on 1) clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside the central nervous system and 5) additional laboratory criteria. A scoring system then determines whether a patient falls in the probable or possible TBM category. Points are allocated for a positive finding in each of the categories, with a maximum score for each category. A total score of at least 10 is compatible with probable TBM, while a total score of at least 6 equates with a possible TBM diagnosis.
11066810|NCT04308928||Children with definite tuberculous meningitis|Definite TBM requires demonstration of acid- fast bacilli in the CSF, Mycobacterium tuberculosis culture from CSF, a positive nucleic acid amplification test (PCR) of CSF or histopathological evidence of Mycobacterium tuberculosis from a central nervous system site.
11066811|NCT04308915|Experimental|Game-based training|Participants play games for cognitive training
11066812|NCT04308902||Children previously enrolled in the OptiMoM Fortifier Study|This is an observational study of children who were previously enrolled in a trial (Bovine vs. Human Milk-Based Fortifier Study) between 2014 and 2016 during which time they were randomized to have their feeds (mother's own milk or pasteurized donor breastmilk) nutrient enriched with a human milk-based fortifier or a bovine protein-based fortifier.
11066813|NCT04308902||Term-born Comparison|This is an observational study of children born at full term (>= 37 weeks gestation) and weighing more than 2500g. These children will be recruited from the communities in which the OptiMoM participants live.
11066814|NCT04308889|Active Comparator|Without Supplementation|No planned dietary supplementation
11066815|NCT04308889|Experimental|With Supplementation|The subject will take 4 capsules (1gram each) of Lovaza daily at 8pm, starting the evening before blister induction and continuing until the second blister fluid has been removed.
11066816|NCT04308876|Experimental|Manual therapy and strengthening exercises|Manual therapy and strengthening exercises were applied totally 15 sessions for 5 weeks 3 times a week in hospital by physiotherapist.
11066817|NCT04308876|Active Comparator|Strengthening exercises|Patients in this group performed the strengthening exercises given to the experimental group on their own at home with experimental group at the same time, frequency and dose.
11066818|NCT04308863|Experimental|Chitosan scaffold/ MTA pulp dressing material|
11066819|NCT04308863|Active Comparator|MTA pulp dressing material|
11066820|NCT04308850|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
11066821|NCT04308850|No Intervention|Control|The other group do not interfere.
11066822|NCT04308837|Experimental|Patients With Local Regional Advanced Gastric Cancer|Patients with local regional advanced gastric cancer after at least 4 weeks post diagnostic laparoscopy and HIPEC, will receive all of the treatments described in the study protocol.
11066823|NCT04308824|Active Comparator|Clipping|Prophylactic endoscopic clip will be placed after polypectomy
11066824|NCT04308824|Experimental|Cyanoacrilate|A solution of Cyanoacrilate will be nebulized after the placement of prophylactic clip
11066825|NCT04308811|Other|platelet rich plasma group|intrauterine platelet rich plasma injection and intrauterine balloon insertion after hysteroscopic lysis of intrauterine adhesions
11066826|NCT04308811|Other|amniotic membrane graft group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon covered by freeze-dried amniotic membranes.
11066827|NCT04308811|Other|intrauterine balloon group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon
11066828|NCT04308798|Experimental|Control group|No surgical glove changing during total knee arthroplasty procedure
11066829|NCT04308798|Experimental|Treatment 1 group|Changing surgical glove after draping and before cementation during total knee arthroplasty procedure
11066830|NCT04308798|Experimental|Treatment 2 group|Changing surgical glove before cementation during total knee arthroplasty procedure
11066831|NCT04308785|Experimental|Atezolizumab up to 12 months +/- 2 cycles of chemotherapy|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first). Participants will receive cisplatin or carboplatin by intravenous infusion after completion of atezolizumab dose. Etoposide should be administered following cisplatin or carboplatin administration on Day 1 of each cycle, and on Days 2 and 3 of each cycle.
11066832|NCT04308785|Active Comparator|Observation +/- 2 cycles of chemotherapy|Participants will receive cisplatin or carboplatin by intravenous infusion. Etoposide should be administered following cisplatin or carboplatin administration on Day 1 of each cycle, and on Days 2 and 3 of each cycle.
11066833|NCT04308772|No Intervention|Usual Care|Those randomised to the usual care arm will receive a leaflet which contains a standard programme of exercises Participants will be asked to complete their exercise programme as prescribed (at least once per day).
11066834|NCT04308772|Experimental|Web-based physiotherapy|Participants will receive a six week exercise programme, based on those in the usual care exercise sheet delivered via the web-based physio website (www.giraffehealth.com).
11066835|NCT04308759|Experimental|Group I (Quitbot)|Participants participate in the Quitbot program which involves prompted, focused conversations for 42 days. Therapy description withheld to protect the integrity of the study.
11066837|NCT04308746|Experimental|Individualistic|Participants write 3 statements to 3 questions relating to his/her differences from his/her immediate community
11066840|NCT04308733|Sham Comparator|sham tDCS|30 patients will be treated with sham tDCS over the contralateral pharyngeal motor cortex
11066841|NCT04308707||Surgical specialties|
11066842|NCT04308707||Anesthesiology|
11066843|NCT04308694|Experimental|Pharmacy-based methadone treatment|Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.
11066844|NCT04308681|Experimental|IPF Dose 1 + Post Treatment Follow-up or OTE|IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
11066845|NCT04308681|Experimental|IPF Dose 2 + Post Treatment Follow-up or OTE|
11066846|NCT04308681|Placebo Comparator|IPF Placebo + Post Treatment Follow-up or OTE|
11066847|NCT04308681|Experimental|PF-ILD Dose 1 + Post Treatment Follow-up or OTE|PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
11066848|NCT04308681|Experimental|PF-ILD Dose 2 + Post Treatment Follow-up or OTE|
11066849|NCT04308681|Placebo Comparator|PF-ILD Placebo + Post Treatment Follow-up or OTE|
11066850|NCT04308668|Experimental|Treatment|Participants in this arm will receive the study drug.
11066851|NCT04308668|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
11066852|NCT04308655||Patient participants|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until five days postpartum.
11066853|NCT04308655||Provider participants|This cohort will include clinicians who provide care for pregnant patients with OUD. Providers will be interviewed and will complete one survey cross-sectionally.
11066854|NCT04308629|Experimental|tDCS over PMAs|One session of transcranial direct current stimulation (tDCS) over premotor areas (PMAs)
11066855|NCT04308629|Active Comparator|tDCS over M1|One session of transcranial direct current stimulation (tDCS) over primary motor area (M1)
11066856|NCT04308616||Psoriasis|Patients with psoriasis
11066857|NCT04308603|Experimental|pregnant patient whose fetuses have an antenatal NIH|All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
11066858|NCT04308590|Experimental|Relacorilant|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
11066859|NCT04308590|Placebo Comparator|Placebo|Placebo matched to study drug
11066860|NCT04308577|Experimental|Ketogenic diet with MCT|Ketogenic Diet supplemented with MCT everyday for 8 weeks.
11066861|NCT04308551|Experimental|Indobufen|200 mg Indobufen, bid po, 90 days
11066862|NCT04308551|Active Comparator|Aspirin|100 mg Aspirin, qd po, 90 days
11066863|NCT04308538|Active Comparator|Standard Recession|Bilateral lateral rectus muscle recession using standard tables stated by Parks.
11066864|NCT04308538|Experimental|Reduced Recession|Bilateral lateral rectus muscle recession using reduced numbers by one millimeter than the standard tables.
11066865|NCT04308525||ERAS Group|Prospectively included patients after introduction of an ERAS programme
11066866|NCT04308525||Control group|We retrospectively evaluated our procedures for the period 2014-2016
11066867|NCT04308512|Experimental|Intervention Group (IG): Care coordination with Care4AD system|All participants will receive Care4AD device.All reminders will be activated in the intervention group (IG). Essential activity daily living (ADL) tasks will be pre-programmed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
11066868|NCT04308512|No Intervention|Control Group (CG): Standard of care|Participants in control group (CG) will also receive Care4AD device. However, all reminders and programming of activity daily living (ADL) tasks will be de-activated in the CG.
11066869|NCT04308499|Experimental|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions
11066870|NCT04308499|Active Comparator|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions
11066871|NCT04308473|Experimental|Arm 1: Ultra-processed Meal + Antibiotics to supress gut flora|Subjects in Arm 1 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of ultra-processed foods.
11066872|NCT04308473|Experimental|Arm 2: Ultra-processed Meal + No Antibiotics|Subjects in Arm 2 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of ultra-processed foods.
11066873|NCT04308473|Experimental|Arm 3: Whole Food Meal + Antibiotics to supress gut flora|Subjects in Arm 3 will take antibiotics for 3 days before the meal challenge to suppress the gut flora. The antibiotics to be used are: vancomycin, 125 mg three times daily; metronidazole, 500 mg twice daily; ciprofloxacin, 500 mg twice daily; and neomycin, 1 gram three times daily. These subjects will then consume a challenge meal of whole, unprocessed foods.
11066874|NCT04308473|Experimental|Arm 4: Whole Food Meal + No Antibiotics|Subjects in Arm 4 will not take any antibiotics prior to the meal challenge. They will consume a challenge meal of whole, unprocessed foods.
11066875|NCT04308460|Active Comparator|arthrocentesis group|the group of internal derangement patients which was treated with arthrocentesis procedure
11066876|NCT04308460|Active Comparator|operative arthroscopy group|the group of internal derangement patients which was treated with operative arthroscopy procedure
11066877|NCT04308447|Experimental|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
11066878|NCT04308434|Experimental|CSD190601-11|Subjects will self-assign to flavor variant CSD190601-11 of 1.5% ENDS products based on their preferred flavor.
11066879|NCT04308434|Experimental|CSD190601-12|Subjects will self-assign to flavor variant CSD190601-12 of 1.5% ENDS products based on their preferred flavor.
11066880|NCT04308434|Experimental|CSD190601-13|Subjects will self-assign to flavor variant CSD190601-13 of 1.5% ENDS products based on their preferred flavor.
11066881|NCT04308434|Experimental|CSD190601-14|Subjects will self-assign to flavor variant CSD190601-14 of 1.5% ENDS products based on their preferred flavor.
11099630|NCT04079062|Experimental|KLH+placebo (PartC)|
11066882|NCT04308434|Experimental|CSD190601-15|Subjects will self-assign to flavor variant CSD190601-15 of 1.5% ENDS products based on their preferred flavor.
11066883|NCT04308434|Experimental|CSD190601-16|Subjects will self-assign to flavor variant CSD190601-16 of 1.5% ENDS products based on their preferred flavor.
11066884|NCT04308434|Experimental|CSD190601-17|Subjects will self-assign to flavor variant CSD190601-17 of 1.5% ENDS products based on their preferred flavor.
11066885|NCT04308434|Experimental|CSD190601-21|Subjects will self-assign to flavor variant CSD190601-21 of 3.0% ENDS products based on their preferred flavor.
11066886|NCT04308434|Experimental|CSD190601-22|Subjects will self-assign to flavor variant CSD190601-22 of 3.0% ENDS products based on their preferred flavor.
11066887|NCT04308434|Experimental|CSD190601-23|Subjects will self-assign to flavor variant CSD190601-23 of 3.0% ENDS products based on their preferred flavor.
11066888|NCT04308434|Experimental|CSD190601-24|Subjects will self-assign to flavor variant CSD190601-24 of 3.0% ENDS products based on their preferred flavor.,
11066889|NCT04308434|Experimental|CSD190601-25|Subjects will self-assign to flavor variant CSD190601-25 of 3.0% ENDS products based on their preferred flavor.
11066890|NCT04308434|Experimental|CSD190601-26|Subjects will self-assign to flavor variant CSD190601-26 of 3.0% ENDS products based on their preferred flavor.
11066891|NCT04308434|Experimental|CSD190601-27|Subjects will self-assign to flavor variant CSD190601-27 of 3.0% ENDS products based on their preferred flavor.
11066892|NCT04308421|Experimental|Low level red light/laser|Patients will be treated twice a week for 12 weeks with low irradiation 650 nm +/- 5 nm red light on one randomly allocated side of the face or body
11066893|NCT04308421|No Intervention|Control side|An affected area on the contralateral side of the face or body or within a single patch will not be treated
11066894|NCT04308408|Active Comparator|Mexican Guideline Daily Allowance (GDA)|Guideline Daily Amounts (GDA) is a purely numerical and reductive labeling system, indicates the grams and percentages (according to the guideline-based daily intakes) per portion of kilocalories, saturated fats, other fats, sugars, and sodium, with no specific judgement, opinion or recommendation.
11066895|NCT04308408|Experimental|Ecuador's Multiple Traffic Light (MTL)|Multiple traffic light labels, an interpretive nutrient-specific FOP label, use the typical traffic light colors (green, yellow/amber, red) and text descriptors to indicate the high, medium, or low content of total fat, sugar and salt.
11066896|NCT04308408|Experimental|Chilean Warning Labels in Red|Warning Labels (WL), another nutrient-specific interpretive FOP labelling scheme, include 'high in' symbols for products that exceed limits of energy, sodium, sugar and saturated fat.
11066897|NCT04308395|Experimental|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
11066898|NCT04308369|Other|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6).
11066899|NCT04308343|Active Comparator|Methotrexate group|
11066900|NCT04308343|Active Comparator|Letrozole group|
11066901|NCT04308343|Active Comparator|Gonadotropins releasing hormone antagonist group|
11066902|NCT04308330|Experimental|Vorinostat|"The first cycle of chemotherapy will not include the experimental agent vorinostat. This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT.
~Cycle 1
~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.
~Temozolomide: 125 mg/m2/day PO Days 1-5.
~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.
~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.
~Cycles 2-12
~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.
~Temozolomide: 125 mg/m2/day PO Days 1-5.
~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.
~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.
~Vorinostat: Dose per escalation schema daily Days 1-5.
~Vorinostat will not be administered during Cycle 1."
11066903|NCT04308317|Experimental|Tetrandrine Cohort|"After the subjects were enrolled, they were given Tetrandrine 60mg QD for a course of 1 week(Take 6 days, stop using for 1 day)"
11066904|NCT04308317|No Intervention|Control Cohort|Treatment according to standard protocols without intervention
11066905|NCT04308304|Experimental|MK-1942|Dose Level 1: 8-mg MK-1942 twice daily (BID) x 7 days (7D), Day 1 to Day 7; Dose Level 2: 15-mg MK-1942 BID x 7D, Day 8 to Day 14; Dose Level 3: 30-mg MK-1942 BID x 7D, Day 15 to Day 21; Dose Level 4: ≤50-mg MK-1942 BID x 7D (Provisional Dose Level), Day 22 to Day 28 All participants to receive Donepezil once daily.
11066906|NCT04308304|Placebo Comparator|Placebo|Placebo to MK-1942 BID x 21 [28] D All participants to receive Donepezil once daily.
11066907|NCT04308291||MiniMed™ 780G System|Subject will use the MiniMed™ 780G System as per standard of care.
11066908|NCT04308278|Experimental|2LEBV® / 2LXFS®|6 months of treatment
11066909|NCT04308278|Placebo Comparator|Placebo|6 months of treatment
11066910|NCT04308252||Pharmaco-resistant epilepsy (PRE)|Pharmaco resistant patients are defined by seizures despite adequate dosing of ≥2 anticonvulsant drugs.
11066911|NCT04308252||Pharmaco-sensitive epilepsy (PSE)|Pharmaco-sensitive patients are defined by no seizures for 6 months.
11066912|NCT04308252||Sibling control|Sibling of the of the PRE study participants.
11066913|NCT04308239|Experimental|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.
~Reactive balance training involved both slip and trip training.
~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.
~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
11066940|NCT04308057||Mixed exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in both land-based and aquatic, primarily aerobic, exercise regimes on an equal basis, for more than 6 months.
11067332|NCT04305314||Group 2: PRI < 70%|Compliance with the Enhanced Revovery protocol lower than 70%
11066914|NCT04308239|Active Comparator|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.
~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
11066915|NCT04308226|No Intervention|Usual care without patient navigation|Participants assigned to this arm will be given basic educational materials on general lung health and referred back to their primary care provider (PCP) for management as per usual practice.
11066916|NCT04308226|Experimental|Usual care with patient navigation|Participants assigned to this arm will be informed about lung cancer screening (LCS), provided educational materials on LCS and patient navigation, and offered access to an LCS navigator who will partner with participants and primary care providers (PCPs) to facilitate low-dose computed tomography (LDCT) completion and follow-up.
11066917|NCT04308213|Experimental|Bone Marrow aspirate|All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit.
11066918|NCT04308200|Other|CO-OP+NDT group|The CO-OP+NDT group received twelve sessions of CO-OP approach, with the baseline and end of treatment assessments, each lasting approximately one hour. Parents and / or caregivers were advised to observe sessions as often as possible to encourage adaptation and transfer to life. Furthermore, CO-OP+NDT group received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist.
11066919|NCT04308200|Other|NDT group|NDT group received just NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity and postural reactions.
11066920|NCT04308174|Experimental|Durvalumab + Gem/Cis|"<Investigational arm: preoperative phase (up to 4 cycles)> Durvalumab 1,500 mg IV on Day 1, every 3 weeks (preop period) 1,500 mg IV Day 1, every 4 weeks (postop period) Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks
~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
11066921|NCT04308174|Active Comparator|Gem/Cis|"<Control arm: preoperative phase (up to 4 cycles)> Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks
~<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)"
11066922|NCT04308161|Experimental|vitamin D oral gel|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks.
~Topical oral Vitamin D gel is prepared with the aid of pharmaceutics department, faculty of pharmacy, Alexandria University. It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation."
11066923|NCT04308161|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Dose: Three times a day for six weeks"
11066924|NCT04308161|Experimental|combination therapy|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks in combination with the symptomatic treatment
~Symptomatic treatment which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Symptomatic treatment dose: Three times a day for six weeks"
11066925|NCT04308135||vascular parkinsonism|the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
11066926|NCT04308135||Parkinson's disease|50 patients diagnosed as Parkinson Disease
11066927|NCT04308135||Controls|30 healthy controls.
11066928|NCT04308122|Active Comparator|Cervical Orthosis (CO)|Cervical orthosis will be worn at all times for 6 weeks according the standard of care after posterior cervical fusion
11066929|NCT04308122|Experimental|No Orthosis (NO)|No cervical orthosis will be worn after posterior cervical fusion
11066930|NCT04308109|No Intervention|Control|No intervention, the same as the current state of education. Caregivers will still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
11066931|NCT04308109|Experimental|Active study|In addition to the current state of education, the active study group will undergo highly realistic simulation. This involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers will complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
11066932|NCT04308109|Active Comparator|Active control|In addition to the current state of education, the active control will undergo low-fidelity simulation that approximates the highly realistic clinical scenarios except with the use of a low-fidelity doll equipped with a tracheostomy and without the audiovisual inputs. If home invasive ventilation is anticipated, a home ventilator will be used. Caregivers still complete the teaching and post-discharge surveys (QDTS and PDCDS) and be followed for a year after discharge.
11066933|NCT04308096|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks (adult) 2 weeks (pediatric)
11066934|NCT04308083|Active Comparator|convergent neck|Group A Sweden & Martina Prama (P). Transgingival tapering machined collar, 2.8 mm in height.
11066935|NCT04308083|Sham Comparator|divergent neck|Group B Straumann Tissue Level (TL). Transgingival widening polished collar, 1.8 mm in height.
11066936|NCT04308070|Experimental|Catheter without Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter without hemostatic agent
11066937|NCT04308070|Experimental|Catheter with Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter with hemostatic agent
11066938|NCT04308057||Aquatic Exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in swimming or other aquatic, primarily aerobic-based, training regimes for more than 2 times a week, for more than 6 months, at the time of the assessments.
11066939|NCT04308057||Land-based exercise|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants engaging in land-based, primarily aerobic training regimes (e.g. aerobic exercise) for more than 2 times a week, for a period longer than 6 months, at the time of the assessments.
11066941|NCT04308057||Sedentary.|General inclusion criteria included being over 55 years of age and normotensive (e.g., <140/90 mm Hg). Specifically for this group, we include participants who are sedentary (e.g., defined as undertaking less than 60 min of structured/planned physical activity per week), for a period longer than 6 months.
11066942|NCT04308044||Chronic MSK Pain|Participants who have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), and psychological state via the completion of questionnaires by the patient.
11066943|NCT04308044||Healthy Control|Participants who do not have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), insole assessment (40 healthy control participants), and psychological state via the completion of questionnaires by the patient.
11066944|NCT04308031|Experimental|Ivabradine|Subject will be randomly assigned to either Ivabradine or Digoxin group. Ivabradine starting dose is 2.5 mg twice daily(BID). ECG will be performed at each visit during the treatment phase and dose will be adjusted based on the heart rate result from the ECG. Total treatment phase is 16 weeks ( 4 months).
11066945|NCT04308031|Active Comparator|Digoxin|Subject will be randomly assigned to either Ivabradine or Digoxin group. Digoxin starting dose is 0.125mg once daily(QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60. Dose adjustment will be based on heart rate result from ECG performed at each treatment visit and Digoxin level from blood sample collected from each visit during treatment phase. Total treatment phase is 16 weeks ( 4 months).
11066946|NCT04308018|Active Comparator|S1|Caudal end of the instrumentation at S1
11066947|NCT04308018|Active Comparator|S2alar-iliac|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
11066948|NCT04307992|Experimental|Intervention|Device: ANEUFIX
11066949|NCT04307979|Experimental|Bulletproof Coffee|A black coffee (bullet proof coffee keurig pod) with 29 grams of added fat (1 tablespoon bullet proof brain octane medium chain triglyceride oil, and 1 tablespoon bullet proof grass fed ghee) blended for 20 seconds with butter scent that is added to the lid.
11066950|NCT04307979|Placebo Comparator|Black Coffee|Black coffee that is blended for 20 seconds with butter scent added to the top of the lid.
11066951|NCT04307966||Intervention|537 pre-adolescent grade 6 learners and their parent (n=537) were invited to participate. Trained educators delivered lessons about HIV and obesity to all Grade 6 students at 5 government-run schools. The classroom curriculum for students required delivery of a five-hour face-to-face intervention delivered weekly through 10 30-minute lessons. Students were asked to communicate their learnings to their parents at home. Parents were requested to read through the lesson in a workbook and to sign acknowledgement that they had read the content. The workbook contained shared student-parent homework activities that took approximately 30 minutes per week. Data was only collected from Learners (n=425) and parents (n= 427)who had consented to the study. A pretest was conducted. The intervention was then implemented. A posttest was conducted afterwards. Both parents and learners answered self-reported questionnaires.
11066952|NCT04307953|Experimental|AZD0530|
11066953|NCT04307953|Experimental|Placebo/AZD0530|
11066954|NCT04307940|Experimental|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
11066955|NCT04307940|Active Comparator|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
11066956|NCT04307940|Placebo Comparator|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
11066957|NCT04307914|Active Comparator|External Beam Radiotherapy|In the control arm, patients will undergo standard radiotherapy for painful bone metastases.The radiation schedule is at the discretion of the treating radiation oncologist.
11066958|NCT04307914|Experimental|MR-HIFU|In the intervention arm, patients will be offered MR-HIFU treatment instead of standard radiotherapy. Treatment will be given following the international guidelines for MR-HIFU.
11066959|NCT04307914|Experimental|Combination EBRT + MR-HIFU|In the combination arm, patients will undergo standard radiotherapy followed by MR-HIFU in a short timeframe.
11066960|NCT04307901||Incomplete colonoscopy|Individuals referred to colon capsule endoscopy due to incomplete colonoscopy investigation.
11066961|NCT04307901||Colonoscopy general anesthesia|Individuals referred to colon capsule endoscopy as alternative to colonoscopy under general anesthesia.
11066962|NCT04307901||Colonoscopy declined|Individuals referred to colon capsule endoscopy after completion of bowel preparation for colonoscopy, but who have declined colonoscopy to be carried out.
11066963|NCT04307888||Study group|Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.
11066964|NCT04307875||Rohingya refugee camp population|A sample of 1500 randomly selected individuals aged 18 years and above living in the Rohingya refugee camp 1E.
11066965|NCT04307875||Shamlapur refugee hosting community population|A sample of 1500 randomly selected individuals aged 18 years and above living in the refugee hosting community Shamlapur neighbouring the Rohingya refugee camps.
11066966|NCT04307862|Experimental|ZEP-3Na 0.1%|The ZEP-3Na 0.1% cream will be applied topically twice daily
11066967|NCT04307862|Experimental|ZEP-3Na 1%|The ZEP-3Na 1% cream will be applied topically twice daily
11066968|NCT04307862|Placebo Comparator|Vehicle Control|The Vehicle Control cream will be applied topically twice daily
11066969|NCT04307849|Experimental|Adolescent Health Club|A systematic approach for the adaptation of sexual health/HIV-related evidence-based interventions
11066970|NCT04307849|Placebo Comparator|Wait-list Control|
11066971|NCT04307836|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
11066972|NCT04307836|No Intervention|Control group|Subjects are not treated with the renal denervation, not sham, after randomization and maintained baseline anti-hypertensive medications
11066973|NCT04307823|Active Comparator|Treadmill training group|Treadmill training according to American College of Sports Medicine's guidelines
11066974|NCT04307823|Experimental|Treadmill protocol and respiratory training group|Treadmill training, slow breathing training and incentive spirometry
11066975|NCT04307784|Experimental|Vitamin D3 alone Group|Treated with VD3 (50.000 IU/week)
11066976|NCT04307784|Experimental|Omaga-3 alone Group|Treated with (1000 mg) wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
11066977|NCT04307784|Experimental|Vitamin D3 and Omega-3 Combination, Group|Treated with 50.000 IU VD3 per week and 1000 mg wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
11066978|NCT04307784|Experimental|Control Group|No intervention was given.
11066979|NCT04307771|Experimental|m-health application|a mobile app designed to send reminders for brushing and give information on maintaining oral health
11066980|NCT04307771|Other|Leaflet|This is the control arm. An educational leaflet for maintaining oral hygiene will be given to participants in this arm
11066981|NCT04307758||Healthy Adults|Healthy subjects aged 18-35 years were enrolled in this study. The muscle strength assessment of the foot intrinsic muscles was assessed with the make test and the break test. The tests were performed with the hip and knee semiflexed in prone position with a hand-held dynamometer. The experimental protocols and methods were explained in detail to all subjects. All participants provided written informed consent in keeping with the ethical principles of the Declaration of Helsinki.
11066982|NCT04307745||Physiotherapist|
11066983|NCT04307745||Doctor|
11066984|NCT04307745||Physical trainer|
11066985|NCT04307745||Trainer|
11066986|NCT04307719||Mexican Jewish Community|Sample of Patients from the Mexican Jewish Community to be subjected to genetic testing
11066987|NCT04307706|Experimental|Intervention group|''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group
11066988|NCT04307706|No Intervention|Control group|Only data collection was carried out. No attempt was made by the researcher during the study.
11066989|NCT04307693|Experimental|Lopinavir/ritonavir|Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
11066990|NCT04307693|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
11066991|NCT04307693|No Intervention|Control|No lopinavir/ritonavir and hydroxychloroquine
11066992|NCT04307680|Active Comparator|Kegel exercise|Using high-intensity Kegel exercise regimen for 8 weeks (5 times a week; 3 times a day involved; 3 sets of 10-12 contractions)
11066993|NCT04307680|Active Comparator|Magnetic stimulation|Using 16 extracorporeal magnetic innervation treatments during 8 weeks (2 times a week).
11066994|NCT04307641|Experimental|Intervention|Pharmacists who received in the intervention.
11066995|NCT04307641|No Intervention|Control|Pharmacists who did not received in the intervention.
11066996|NCT04307628|Active Comparator|Walnut|Eat 2 ounces of walnuts provided by the study. Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
11066997|NCT04307628|Placebo Comparator|Nut-Free|Eating any other nuts is to be avoided. Background diet will be low in polyphenols.
11066998|NCT04307615|Experimental|Oxygen + CPAP-treatment|
11066999|NCT04307615|Active Comparator|Oxygen-treatment|
11067000|NCT04307602|Experimental|Children with cerebral palsy GMFCS IV-V|Exercise intervention in the waling aide Innowalk
11067001|NCT04307602|Active Comparator|Children with cerebral palsy GMFCS I-II|Exercise intervention on spinning bikes
11067002|NCT04307602|Active Comparator|Children without disabilities|Exercise intervention on spinning bikes
11067003|NCT04307589||Caregiving grandparents|
11067004|NCT04307589||Non-caregiving grandparents|
11067005|NCT04307589||Middle-aged and older adults not being a grandparent|
11067006|NCT04307576|No Intervention|R1 - SR standard arm|Standard risk arm receiving standard treatment (Delayed Intensification including Doxorubicin).
11067007|NCT04307576|Experimental|R1 - SR experimental arm|Standard risk arm, receiving Delayed Intensification without Doxorubicin IV 3 x 30 mg/m2/dose.
11067008|NCT04307576|No Intervention|R2 - IR-low standard arm|Standard treatment with Delayed Intensification including Doxorubicin and Maintenance including Vincristine+Dexamethasone pulses.
11067009|NCT04307576|Experimental|R2 - IR-low experimental arm A|Standard treatment with omission of Doxorubicin IV 3 x 30 mg/m2/dose in the Delayed Intensification phase.
11067010|NCT04307576|No Intervention|R3 - IR-high standard arm|Intermediate risk high arm receiving Standard Maintenance Therapy.
11067011|NCT04307576|Experimental|R3-InO - IR-high experimental arm|Inotuzumab IV 0,5 mg/m2, given on days 253, 260, 267 and on days 274, 281, 288 before start of Standard Maintenance Therapy.
11067012|NCT04307576|Experimental|ABL-class fusions intervention|Imatinib p.o. 340 mg/m2 given daily from day 15 or 30 (depending on age) to the end of therapy (week 106) in addition to Standard IR-high chemotherapy.
11067013|NCT04307576|Experimental|R3-TEAM - IR-high experimental arm|6-tioguanine p.o, 2,5-12,5 mg/m2, given daily in addition to Standard Maintenance Therapy.
11067014|NCT04307576|Experimental|ALLTogether1 DS Blinatumomab intervention|Blinatumomab IV, 5 mcg/m2/day up to 28 mcg/day (detailed dosing in protocol) continous infusion. Two 28 day courses with a two week treatment free interval in between. Blinatumomab courses replace Consolidation 1 and Consolidation 2 in the standard protocol adapted for Down syndrome patients.
11067015|NCT04307576|Experimental|R2 - IR-low experimental arm B|Standard treatment with omission of monthly pulses of Vincristine IV 1,5 mg/m2/dose and 5 days of Dexamethasone p.o. 6 mg/m2/day in the Maintenance Phase.
11067016|NCT04307563|Other|Mindfulness group|Participants will attend 6 weekly educational and mindfulness sessions.
11067017|NCT04307550|Experimental|Isopropyl Alcohol|10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
11067018|NCT04307550|Placebo Comparator|Sterile Saline|10 inhalations of a sterile saline pad held within 2cm from the nares
11067019|NCT04307537|Experimental|pcRUG|Peri-catheter retrograde urethrography
11067020|NCT04307537|Active Comparator|VCUG|Voiding cysto-urethrography
11067021|NCT04307524|Experimental|laparoscopic repair|suture repair of cesarean scar niche using laparoscopy
11067022|NCT04307524|Active Comparator|medical treatment|conservative management
11067333|NCT04305288|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FOLFIRINOX
11067023|NCT04307511|Experimental|low dose DAPT therapy|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT(ticagrelor 90mg plus aspirin 100 mg )treatment
11067024|NCT04307511|Active Comparator|standard dose DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
11067025|NCT04307498|Other|Intensive Outpatient Program - Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks plus seven augmentations designed to maximize treatment outcomes. If necessary, the treatment window may be extended for another week.
11067026|NCT04307485|Active Comparator|standard dose ticargrelor based DAPT therapy|treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group
11067027|NCT04307485|Experimental|low dose ticargrelor based DAPT|treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment
11067028|NCT04307472|No Intervention|Control|Control arm will receive no intervention.
11067029|NCT04307472|Experimental|Clinician nudge|"The clinician nudge using an active choice intervention in the electronic health record will be delivered to the clinician during the patient's visit. This will be through a Best Practice Advisory that describes the guideline criteria for which the patient is eligible for statin therapy, provides pre-selected options for a statin with alternative options.
~The clinician nudge using monthly peer comparison messages will be sent as an inbox message through the electronic health record. Clinicians will be told what percent of their eligible patients have been prescribed a statin and how that compares to peer clinicians at Penn Medicine."
11067030|NCT04307472|Experimental|Patient nudge|The patient nudge will be a text message. Patients with a visit scheduled with their primary care clinician will be identified and sent this text 72 hours before their scheduled visit. The text will remind them of the visit, inform them of their eligibility for a statin, describe the benefits and risks of statin therapy, and ask the patient to discuss statin therapy with their primary care clinician during the visit.
11067031|NCT04307472|Experimental|Clinician Nudge and Patient Nudge|The clinician nudge and patient nudge will be implemented.
11067032|NCT04307459||Coronavirus Infection|All patients admitted to the Respiratory Unit with SARS-CoV-2 infection and respiratory failure
11067033|NCT04307433|Experimental|Arm 1|ST Narrative + mHealth: Storytelling narrative video on tablets
11067034|NCT04307433|Active Comparator|Arm 2|mHealth: a video with a voice over presenting didactic materials on tablets
11067035|NCT04307433|Placebo Comparator|Arm 3|Control: non-narrative educational materials will be read
11067036|NCT04307420|Experimental|Sonic Fill Restoration|Using sonic activation system turns the highly filled sonic fill composite into a flowable which enables the material to rapidly fill the cavity effortlessly- greatly reducing procedure time.
11067037|NCT04307420|Active Comparator|Composite Resin Restoration|Direct composite restorations are the most requested and performed dental procedures. The incremental placement technique is the gold standard for posterior universal composite placement.
11067038|NCT04307407|Experimental|Aerobic Exercise|The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.
11067039|NCT04307407|No Intervention|Standard care|Participants in this arm will not receive any follow-up on exercise during the intervention period.
11067040|NCT04307407|Other|Reference Group|Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm
11067041|NCT04307394|Experimental|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
11067042|NCT04307381|Experimental|IONIS-PKK-LRx|Participants will be administered IONIS-PKK-LRx SC for up to 52 weeks
11067043|NCT04307368|Experimental|FODMAP diet|Patients with IBS. Interventions: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
11067044|NCT04307368|Experimental|Elimination-rotational diet|Patients with IBS. Interventions: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
11067045|NCT04307368|Experimental|Classic diet|Patients with IBS. Interventions: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
11067046|NCT04307355|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
11067047|NCT04307355|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
11067048|NCT04307342||Posterior MIPO|Patients treated with posterior MIPO for Humerus Diaphyseal Fractures With Extra-articular Distal Humeral Anatomical Plate
11067049|NCT04307329|Experimental|Monalizumab + trastuzumab - low TILs (<5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
11067050|NCT04307329|Experimental|Monalizumab + trastuzumab - high TILs (>=5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
11067051|NCT04307316|Experimental|ACBT group|Active cycle breathing technique
11067052|NCT04307316|Active Comparator|Conventional treatment group|Conventional treatment group
11067053|NCT04307303|Experimental|Abdominal functional electrical stimulation|
11067054|NCT04307303|Sham Comparator|Low dose abdominal functional electrical stimulation arm|
11067055|NCT04307290|Experimental|DEX group|received intravenous dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery
11067056|NCT04307290|Placebo Comparator|CON group|received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.
11067057|NCT04307277|Other|Control arm|
11067058|NCT04307277|Experimental|Experimental arm|
11067187|NCT04306263|Active Comparator|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
11067059|NCT04307264||Overall eligible participants|Eligible participants will receive standard esophagogasrtoduodendoscopy, liver stiffness measurement and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, Prothrombin time, albumin).
11067060|NCT04307251|Experimental|Navio™ Robotics-assisted Surgical System|
11067061|NCT04307251|Experimental|Conventional, non-robotics-assisted total knee surgical system|
11067062|NCT04307238|Other|Propofol group|General anesthesia will be maintained by continually intravenous administered propofol.
11067063|NCT04307238|Other|Sevoflurane Group|General anesthesia will be maintained by inhalative administered sevoflurane.
11067064|NCT04307225||CABG|Patients whom has undergone CABG surgery for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
11067065|NCT04307225||PCI|Patients whom has undergone PCI for NSTEMI, stable or unstable angina, with no previous history of Atrial Fibrillation
11067066|NCT04307212|Active Comparator|Trained|Participants who have been CrossFit training at least 3 times per week for the previous 3 months. These individuals will be invited in person to participate in the study.
11067067|NCT04307212|Active Comparator|Untrained|Nonactive/non--exercise trained participants who have participated in any type of exercise no more than 2 times per week for the past 3 months. These individuals will be recruited from the general public.
11067068|NCT04307199|Experimental|Group A|Membrane sweep @ 39 weeks' gestation only
11067069|NCT04307199|Experimental|Group B|Membrane sweep @ 40 weeks' gestation only
11067070|NCT04307199|Experimental|Group C|Membrane sweep @ 39, 40 and 41 weeks' gestation or until onset of labour
11067071|NCT04307199|Experimental|Group D|Membrane sweep @ 40 and 41 weeks' gestation or until onset of labour
11067072|NCT04307199|No Intervention|Control Group|Women in the control arm will not receive a membrane sweep and will receive usual care (as defined by local hospital protocols and vaginal examination to determine Bishop score only).
11067073|NCT04307186|Experimental|BAY1747846 + Gadobutrol|Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of BAY1747846.
11067074|NCT04307173|Experimental|Cohort 1|9 subjects for MAD 1 cohort. 6 subjects on KBL693, 3 subjects on placebo.
11067075|NCT04307173|Experimental|Cohort 2|9 subjects for MAD 2 cohort. 6 subjects on KBL693, 3 subjects on placebo.
11067076|NCT04307160||Group I|Patients ≤ 5 years of age
11067077|NCT04307160||Group II|Patients ≥ 7 years of age
11067078|NCT04307147|Experimental|NX (vinorelbine and capecitabine )|Standard therapy plus NX chemotherapy for 4 cycles, (vinorelbine 25 mg/m² d1,8 and capecitabine 1250 mg/m² d1-14, every 3 weeks)
11067079|NCT04307147|No Intervention|Control group|Standard therapy
11067080|NCT04307134||R/R ALL|Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia (ALL)
11067081|NCT04307082|Experimental|Ibrexafungerp|Oral [14C]-Ibrexafungerp Single Dose
11067082|NCT04307069|Experimental|Immediate oxytocin infusion|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, she will receive oxytocin for augmentation of labor.
11067083|NCT04307069|Experimental|Expectant management for 24 hours|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, we will wait for spontaneous delivery to occur. After 24 hours of rupture of membranes, the woman will receive oxytocin for augmentation of labor.
11067084|NCT04307056|Experimental|HIFU|Patients Treated with high intensity focused ultrasound (HIFU)
11067085|NCT04307056|Active Comparator|Prostatectomy|Patients Treated by Radical Prostatectomy
11067086|NCT04307043||postnatal age|
11067087|NCT04307043||General information and echocardiographic data|General information:(1)Record the gestational age, birth weight, length, delivery way, Apgar score, maternal pregnancy status, prenatal bleeding or not after admission.(2)PS use, ventilator mode, other illness and complications should be recorded during hospitalization. (3) Record the baby's heart rate, respiratory rate, blood pressure, body surface area on every check.
11067088|NCT04307030||0 ~ 18 years old children|Children During Outpatient or Hospitalization
11067089|NCT04307004|Other|Unattended vs Attended Blood Pressure|Participants blood pressure will be measured three times attended and three times unattended. Whether investigators measure blood pressure attended first and then unattended or unattended first and then attended will be assigned using a random number generator. At visit 2, clinic blood pressure will be measured three times attended and three times unattended, as at visit 1, but in the reverse order.
11067090|NCT04307004|Other|ABPM vs HBPM|Participants will be fitted with either the Microlife WatchBP O3 ambulatory blood pressure monitoring device or instructed on how to use the Microlife WatchBP Home N home blood pressure device, depending on which they are assigned to complete first. The order in which participants undergo ambulatory or home blood pressure monitoring will be assigned through a random number generator.
11067091|NCT04306991|Experimental|Fever|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
11067092|NCT04306991|Experimental|Apyrexia|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
11067093|NCT04306978|Active Comparator|CareLink Express RM system|Patients in the remote monitoring (RM) group will undergo the implantation of Ensura DR MRI SureScan pacing system. Patients in the RM group should visit the main follow-up clinic 12 weeks after discharge, and then the device data will be remotely transmitted to the CareLink Express Network at least once in 3 months. Research personnel will contact patients by telephone once in 6 months. If participants indicate they have experienced a study outcome event (corresponding to the study endpoints), the event will be recorded. If remote transmission or telephone call data require to make clinical decision an in-hospital visit will be induced.
11067094|NCT04306978|Active Comparator|Standard follow-up|Patients in the control group will receive Adapta DR pacing system without remote monitoring using. All patients from the control group should have the first in-hospital visit 12 weeks after pacemaker implantation. Then, the follow-up will be provided according to the standard guidelines
11067095|NCT04306965|Experimental|Apremilast|Apremilast will be administered to patients as 30 mg oral tablets taken twice daily for 24 weeks. An initial 5-day titration will be implemented to improve tolerability.
11067096|NCT04306952|Experimental|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
11067097|NCT04306952|Experimental|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
11067098|NCT04306952|Experimental|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional office hoursin between the bi-weekly group sessions and one all day meditation retreat."
11067099|NCT04306939||Case/Chronic complex disorders|Chronic complex disorders are composed of multiple population sub classifications - many of which have not been fully defined. Thus, all eligible patients should be included to maximize study power. Sufficient numbers of controls, those individuals in the general population, who may or may not have complex disorders are needed to match future comparison studies for a subset of questions, and so should also be included.
11067100|NCT04306939||Control|The number of controls that are anticipated for this study is less than patient numbers since they will not be needed for calculating the minor allele frequency of the majority of genetic polymorphism of interest in genetic association studies. This data is already available in public and research databases. Controls will be useful for evaluating case report form questions, providing assessment of the local genetic pool, and for possibly participating in future studies as provided by the consent.
11067101|NCT04306926|Experimental|TQB2450+SBRT|SBRT three days before TQB2450.
11067102|NCT04306913|Active Comparator|Control|
11067103|NCT04306913|Experimental|Esmolol|
11067104|NCT04306900|Experimental|Combo 1|TTX-030 plus budigalimab plus mFOLFOX6
11067105|NCT04306900|Experimental|Combo 2|TTX-030 plus budigalimab plus docetaxel
11067106|NCT04306900|Experimental|Combo 3|TTX-030 plus mFOLFOX6
11067107|NCT04306900|Experimental|Combo 4|TTX-030 plus budigalimab
11067108|NCT04306900|Experimental|Combo 5|TTX-030 plus budigalimab (selected tumors evaluated in expansion)
11067109|NCT04306887|Experimental|TQ-B3101|TQ-B3101 capsule administered orally.
11067110|NCT04306874|Experimental|High Protein Supplement|60 g total protein per day, administered via twice daily ensure max protein shakes
11067111|NCT04306874|No Intervention|Control|No intervention on diet; routine dietary practice
11067112|NCT04306861||Treatment Naïve PDAC Patients|Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
11067113|NCT04306848|Experimental|Pilot|Eligible subjects who have consented to the study, and have had the baseline data gathered as part of their participation in the Lifestyle Medicine Clinic, an intensive therapeutic lifestyle medicine program, will be given a CGMs device and supplies, and instructed in how to utilize these. They will set up the app on their smart phone to provide them with feedback on their glucose level to correlate with their lifestyle activities.
11067114|NCT04306835|Active Comparator|CPAP + CBT-i|Patients treated simultaneously with CPAP for their OSAS and cognitive behavioral therapy for their insomnia.
11067115|NCT04306835|No Intervention|CPAP only|Patients suffering from OSAS and insomnia, but only treated with CPAP.
11067116|NCT04306809|Experimental|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
11067117|NCT04306796|Experimental|intervention group|Patients receiving 3D-printed made to measure splints for postoperative or post-traumatic treatment in hand surgical patients
11067118|NCT04306796|Active Comparator|control group|Patients receiving thermoplastic splints individually adjusted by occupational therapists
11067119|NCT04306783|Experimental|Arm A: In-Home Sensor Monitoring|Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor. Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities. There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed. Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
11067120|NCT04306783|No Intervention|Arm B: Survey Only|Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
11067121|NCT04306770|Active Comparator|Intervention|OPTIMUM Programme
11067122|NCT04306770|No Intervention|Control|Treatment as usual
11067123|NCT04306757|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during cardiac surgery until admission to postoperative ICU. Individualisation will be established by compliance guided end-expiratory and peak pressure setting, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
11067124|NCT04306757|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during cardiac surgery until admission to postoperative ICU. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
11067125|NCT04306731|Experimental|Interventional (Group M)|The group of patients given nanotechnology structured water magnalife
11067126|NCT04306731|Active Comparator|Control (Group T)|The group of patients given Trimethoprim
11067127|NCT04306731|Placebo Comparator|Placebo (Group O)|The group of patients given ordinary bottled drinking water
11067128|NCT04306718|Experimental|studyarm|Hyalocytes from ERM and ILM are cultured in alphaMEM to examine their proliferation habits
11067129|NCT04306705||Tocilizumab|Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes. Tocilizumab was administered according to the local label.
11067130|NCT04306705||Continuous Renal Replacement Therapy|Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive 3 times or more.
11067131|NCT04306705||Standard care|Standard of care therapy per local written policies or guidelines.
11067132|NCT04306692|Experimental|Inositol group|Myo-inositol 4000 mg Dosing: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged) during 3 consecutive treatment cycles.
11067133|NCT04306692|Active Comparator|Clomiphene citrate group|Each tablet contains 50 mg of clomiphene citrate Dosing: 1 tablet per day, per os, from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days during 3 consecutive treatment cycles.
11067134|NCT04306679|Experimental|Interventional arm|The intervention, which was aimed to educate children on how to use pain scales and provide reliable pain assessments was based on a two short animation clips, lasting approximately 5 min each, and a short (5 min) guided interaction between the study nurse and the participants, in between the two clips.
11067135|NCT04306679|Other|Control|Children underwent the routine pre-operative preparations, which included a section on pain assessment.
11067136|NCT04306666||Walant group|Walant group
11067137|NCT04306666||Axillary Brachial Plexus Block|Axillary Brachial Plexus Block
11067138|NCT04306653|Experimental|ACTH|patients with acute gout treated with ACTH
11067139|NCT04306653|Active Comparator|Betamethasone|patients with acute gout treated with betamethasone
11067140|NCT04306640|Experimental|intervention group|the intervention group will receive the denneroll cervical traction orthotic in an attempt to improve the altered sagittal cervical spine alignment (AHT and ARA C2-C7).
11067141|NCT04306640|Active Comparator|Control group|Both the intervention group and the control group will complete a multimodal program of 10 weeks consisting of myofascial release, thoracic spine mobilization and manipulations, and physical pain relief methods.
11067142|NCT04306627|Active Comparator|Perindopril/Amlodipine arm|"Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.
~Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia."
11067143|NCT04306627|Active Comparator|Perindopril/Amlodipine/Atorvastatin arm|Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.
11067144|NCT04306614|Experimental|Capillary technique|
11067145|NCT04306614|Placebo Comparator|Suction technique|
11067146|NCT04306601|Experimental|Low-Intensity focused ultrasound brain stimulation|
11067147|NCT04306588|Experimental|Tele-rehabilitation exercise Group|Participants who are suffering from a chronic illness such as COPD or CHF and are referred for tele-rehabilitation intervention at the VA-Houston will be qualified for the purpose of this study.
11067148|NCT04306562|Experimental|Intervention group|Patients in an intervention group will be ask about a history of food consumption in the past seven days to analyze a nutritive value of food consumption with a program (INMUCAL-Nutrients V.4.0, Institute of Nutrition, Mahidol University) and estimate an enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day with nutritional counseling by researchers. Special enteral formula will be selected if patients have specific conditions including renal failure, hyperglycemia/diabetes and liver failure, acute and chronic pulmonary disease and immunocompromised states. Otherwise, standard formula will be provided. Duration of enteral protein supplementation is at least 14 days from a preanesthetic clinic visit to a day of surgery.
11067149|NCT04306562|No Intervention|Control group|Patients in a control group will be sent to assess and improve nutritional status by primary doctor as a conventional care pathway.
11067150|NCT04306549|Experimental|Bulk-fill resin composite-sonic activated|5 mm bulk-filling without capping lightcured 40s
11067151|NCT04306549|Experimental|Bulk-fill resin composite|4 mm bulk-filling without capping lightcured 10s
11067152|NCT04306549|Experimental|Microhybrid resin composite|2 mm layers, lightcured 20s
11067153|NCT04306536|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
11067154|NCT04306536|No Intervention|Control group|Best local diet
11067155|NCT04306523||Observational Cohort|One group of 100 sets of twin infants, observed from 4 months of age until 2years of age.
11067156|NCT04306510|Other|Group 1|TEGSEDI
11067157|NCT04306497||Cohort of western medicine|"Routine treatment：
~① support treatment:maintain water and electrolyte balance .
~②oxygen therapy: give nasal catheters to inhale oxygen.
~③ basic treatment of traditional Chinese and western medicine: antiviral drugs and proprietary Chinese medicines with similar composition or function to the observed scheme of differentiation and treatment of traditional Chinese medicine are not included in the scope of such drugs.
~Antiviral drugs ：Clinicians can judge according to the patient's condition according to the latest version of the diagnosis and treatment plan for COvID-19 issued by the General Office of the National Health Commission / the Office of the State Administration of traditional Chinese Medicine (currently the latest version is the sixth trial edition). Select any of the recommended antiviral drugs(for example:IFN-α、lopinavir-ritonavir、Ribavirin、Chloroquine Phosphate、Arbidol)or a combination of two antiviral drugs."
11067158|NCT04306497||Cohort of integrated TCM and western medicine|"routine treatment + Antiviral drugs + the following TCM regimens. 1.TCM regimens:① Early stage: Dampness trapped in exterior and interior. Recommended prescription: Huoxiang 15g, Suye15g, Cangzhu15g, Houpo10g, Qianhu15g, Chaihu15g, Huangqin10g, Qinghao20g, Xingren10g, JInyinhua15g, Lianqiao15g.
~Take decocted or granule, one dose a day.
~② Middle stage: Dampness-toxicity blocking lung Recommended prescription: Zhimahuang9g, Xingren10g, Sangbaipi30g, Tinglizi20g, Dongguazi20g, Fabanxia10g, Houpo10g, Suzi15g, Baijiezi10g, Gualoupi15g, Xuanfuhua9g, Xiangfu10g, Yujin10g, Taoren10g, Huangqi20g.
~Take decocted or granule, one dose a day."
11067159|NCT04306484||patients with tumoral brain lesion|The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.
11067188|NCT04306250|Experimental|anterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the anterior access, ie dissection through the anterior vaginal wall.
11067334|NCT04305275|Experimental|SAGE-324 60 mg|Participants will receive SAGE-324 60 mg dose (tablets) orally in the morning for 28 days.
11067160|NCT04306484||patients with non-tumoral brain lesion|The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).
11067161|NCT04306471|Experimental|Treatment arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition the study intervention involving a monthly subcutaneous injection of evolocumab 420 mg for 12 months
11067162|NCT04306471|Placebo Comparator|Control arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition a Placebo subcutaneous injection for 12 months.
11067163|NCT04306458|Experimental|Robot assisted minimally invasive esophagectomy|Robot assisted minimally invasive esophagectomy
11067164|NCT04306458|Active Comparator|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
11067165|NCT04306445|Active Comparator|GF-IGB: Obalon Balloon|Obalon balloons are gas-filled balloons used for weight loss by taking up more space in the stomach. There are three separate balloons that are placed. They are inflated once the capsules containing the balloons are swallowed. The second balloon is swallowed two weeks after the first balloon, and the third balloon is swallowed four to eight weeks after the second balloon. All three balloons are removed six months after the first balloon is placed.
11067166|NCT04306445|Active Comparator|Medically Supervised Meal Replacement Program: My New Weigh|Meal Replacements are used for weight loss in order to achieve a very low-calorie diet that is nutritionally balanced. Four to five meal replacements are consumed per day. If only four meal replacements are consumed per day, three servings of vegetables and two servings of fruit are consumed as well. This program lasts for about five months or twenty weeks.
11067167|NCT04306406|Other|Raspberry Smoothies|Single serving smoothies drink made with red raspberries to be consumed daily for two weeks
11067168|NCT04306393|Experimental|Treatment Group|Inhaled Nitric Oxide until PaO2/FiO2 >/= 300 mmHg
11067169|NCT04306393|No Intervention|Control Group|
11067170|NCT04306367|Experimental|Experimental|"Pembrolizumab Q3W, IV infusion (day 1 of each 3 week cycle)
~Olaparib bid, Oral tablet continuously"
11067171|NCT04306354|Experimental|Conventional oxytocin treatment (T + OC)|32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
11067172|NCT04306354|Placebo Comparator|Conventional treatment with placebo administration (T + PBO)|32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
11067173|NCT04306354|No Intervention|Conventional treatment (T)|32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.
11067174|NCT04306341|Experimental|Experimental|Neurofeedback in conjunction with Dialectical Behavior Therapy
11067175|NCT04306341|No Intervention|Control|Dialectical Behavior Therapy (treatment as usual)
11067176|NCT04306328|Experimental|Neurostimulation|
11067177|NCT04306315|Experimental|Brodalumab 210 mg + brodalumab 70 mg add-on*|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any visit with efficacy assessments after Week 16 will receive a dose adjustment to 280 mg brodalumab every 2 weeks.
11067178|NCT04306315|Placebo Comparator|Brodalumab 210 mg + placebo add-on*|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any time visit with efficacy assessments Week 16 will receive a dose adjustment to 210 mg brodalumab + placebo every 2 weeks.
11067179|NCT04306302|Experimental|Medium-dose ExPEC10V or Placebo: Group 1|Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
11067180|NCT04306302|Experimental|High-dose ExPEC10V or Placebo: Group 2|Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.
11067181|NCT04306289|Active Comparator|Real tDCS|The participant will receive anodal tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
11067182|NCT04306289|Sham Comparator|Sham tDCS|Identical to the real tDCS, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
11067183|NCT04306276||Patients undergoing direct IVF|Patients directly undergo IVF without receiving previous hormonal treatment
11067184|NCT04306276||Patients pretreated with DNG|Patients having received a three-month treatment with DNG before undergoing IVF
11067185|NCT04306263|Experimental|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics (Human milk oligosaccharide, Glucooligosaccharides) and probiotics.
11067186|NCT04306263|Active Comparator|Standard formula|Infants receiving a standard infant formula.
11067189|NCT04306250|Active Comparator|posterior approach for apical fixation to the SSL|In this group the apical fixation will be done using the posterior access, ie fixation through the vaginal posterior wall.
11067190|NCT04306237|Experimental|IMB-1018972|Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks
11067191|NCT04306237|Placebo Comparator|Placebo|Participants will receive matching placebo tablets twice daily for 16 weeks
11067192|NCT04306224|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
11067193|NCT04306211|Active Comparator|Facial mask|facial mask for oxygen delivery
11067194|NCT04306211|Experimental|SuperNO2VA|SuperNO2VA is CPAP device to deliver oxygen with nasal mask rather than with facial mask
11067195|NCT04306198|Active Comparator|Lag Screw|Device: Trochanteric Fixation Nail (TFN) whit lag screw Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
11067196|NCT04306198|Active Comparator|Helical Blade|Device: Trochanteric Fixation Nail (TFN) whit helical blade Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
11067197|NCT04306185|Experimental|OVARIAN FRAGMENTATION|Ovarian fragmentation through laparoscopy in patients who meet criteria ( Poor ovarian responders and poor ovarian reserve).
11067198|NCT04306172||Readmitted inpatients/Cases|"Outcome 1: Patients who were readmitted within 18 days of index hospitalization discharge date to the same hospital, with a diagnosis leading to the same Major Diagnostic Group as the index stay (definition according to Swiss Diagnosis Related Groups system, case merger)
~Outcome 2: Patients with an unplanned readmission within 30 days of index hospitalization discharge date to the same hospital. An unplanned readmission was defined as a readmission through the emergency department."
11067199|NCT04306172||Non-Readmitted inpatients/Controls|Outcome 1 & 2: Patients who were not readmitted within 30 days of index hospitalization discharge date.
11067200|NCT04306159|Sham Comparator|General anesthesia|Basal blood pressure and heart rate were recorded after midazolam administration of 0.02 mg/kg. Anesthesia was induced with sufentanil 0.4 μg/kg and propofol 2-2.5 mg/kg, IV route. An IV bolus of cisatracurium 0.1 mg/kg IV was given to facilitate tracheal intubation. Anesthesia was maintained with propofol 4-6 mg/kg/h combined dexmedetomidine 0.2 μg/kg/h(after 0.2 μg/kg/h loading dose within 15min)by bispectral index (BIS) 40-60 and additional bolus doses of remifentanil 0.2-0.5 μg/kg/min to keep arterial pressure values around 20% below baseline values. Sufentanil 0.1-0.2 μg/kg and flurbiprofen 100mg was administrated once the abdomen was closed, then a patient controlled analgesia pump was used. No RSB was performed.
11067201|NCT04306159|Experimental|Subcostal TAP combined with General anesthesia|After induction, TAP was performed. The transversus abdominis plane is imaged with the ultrasound probe obliquely on the upper abdominal wall, along the subcostal margin near the midline.The needle tip was advanced to the desired position where 20 mL 0.375%ropivacaine(Dexamethasone 5mg was added)were injected.The technique is repeated on the opposite side. Anesthesia method and management was same as general anesthesia group.
11067202|NCT04306159|Experimental|Modified RSB combined with General anesthesia|After induction, Modified RSB was performed based on midline incision-guided. The rectus muscle is imaged with the ultrasound probe in a transverse orientation below the xiphisternum and above the umbilicus.The needle tip was advanced to the two desired position where 10 mL ropivacaine 0.375% were injected causing hydrodissection of the rectus muscle away from the posterior rectus sheath.The technique is repeated on the opposite side.Anesthesia method and management was same as general anesthesia group.
11067203|NCT04306146|Experimental|CAD-9303|Capsules of CAD-9303 will be administered as a single dose. The initial dose will be 3 mg up to 1000 mg.
11067204|NCT04306146|Placebo Comparator|Placebo|Matching placebo will be provided in capsules and administered as a single dose.
11067205|NCT04306133|Experimental|PENG BLOCK AND WOUND INFILTRATION|Participants receiving PENG block combined to wound infiltration
11067206|NCT04306133|Active Comparator|WOUND INFILTRATION|Participants receiving wound infiltration alone
11067207|NCT04306120|Active Comparator|noxious cold group|The group received noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
11067208|NCT04306120|Active Comparator|noxious heat group|The group received noxious heat (46 - 47°C) stimuli on the affected leg for 30 minutes.
11067209|NCT04306120|Active Comparator|alternative thermal stimulation group|The group received alternative noxious heat (46 - 47°C) and noxious cold (3 - 4°C) stimuli on the affected leg for 30 minutes.
11067210|NCT04306107|Experimental|NIV with prone position|Use of prone position during NIV
11067211|NCT04306107|Placebo Comparator|NIV (conventional)|NIV on conventional position
11067212|NCT04306107|Experimental|HFNC on prone position|Prone position during HFNC
11067213|NCT04306107|Placebo Comparator|HFNC (conventional)|HFNC on conventional position
11067214|NCT04306081|Experimental|Treatment Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of evolocumab 420 mg via subcutaneous injections for 6 months.
11067215|NCT04306081|Placebo Comparator|Control Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of placebo via subcutaneous injections for 6 months.
11067216|NCT04306068|Experimental|Experimental group|Athletes included in the experimental group will perform a plyometric exercise protocol. Each session will consist of a 4-station circuit with 1 minute rest between each station and 30 seconds between sets
11067217|NCT04306068|No Intervention|Control group|Athletes included in the control group will follow their usual warm-up routine.
11067218|NCT04306055|Experimental|Questionnaire with precaution information|Questionnaire in this group includes information about precaution of blood donation during epidemic of COVID-19.
11067219|NCT04306055|Experimental|Questionnaire without precaution information|Questionnaire in this group dose not include information about precaution of blood donation during epidemic of COVID-19.
11067220|NCT04306055|No Intervention|No questionnaire group|Ever donors in this group would not receive the questionnaire.
11067221|NCT04306042||Treatment|Patients diagnosed with primary stage IIIB-IV squamous cell lung cancer and treated in 92 medical centers between 01 September 2019 and 30 June 2020 will be targeted for study inclusion.
11067222|NCT04306029|No Intervention|Pre-Intervention|
11067258|NCT04305847||Qual'AXI group|patients for whom distal arm surgery was performed under Axillary Brachial Plexus Block
11099661|NCT04078919|Placebo Comparator|Low calorie diet|Low calorie diet
11067223|NCT04306029|Experimental|Post-Intervention|"Postpartum staff has received the Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
11067224|NCT04306016|Experimental|Sensory stimulation|Participants allocated to the intervention group will receive a model-based sensory stimulation intervention, which is aimed at providing visual and auditory stimulation to ICU patients with additional support from family caregivers.
11067225|NCT04306016|No Intervention|Usual care|Participants in the control group will receive usual care routine that they are receiving or planning to receive. The registered ICU nurses will provide the same nursing care as previously, including but not limiting to the use of sedation, analgesia, spontaneous breathing trial, indwelling catheter, feeding, and bowel care.
11067226|NCT04306003|Experimental|Enhanced Recovery After Surgery (ERAS) pathway|"Preop
~Diet: Solids until midnight before surgery with a carbohydrate rich drink before midnight and 3-hours prior to surgery.
~Analgesia: Acetaminophen 975mg & Celecoxib 400mg administered PO 1-hour before surgery.
~Intraop
~Hypothermia prevention: Forced-air warming units and core temperature monitoring.
~Fluid management: Euvolemic fluid management with balanced crystalloid solution.
~Analgesia: 0.25% bupivacaine block of intercostal nerves and rectus sheath by the surgical team. Additional IV analgesia by anesthesiologist with the goal to minimize opioids.
~PONV prophylaxis: Ondansetron 4-8mg IV during emergence.
~Postop
~Diet: Clear fluids immediately post-op. Saline lock and advance to DAT on POD#1.
~Analgesia: Routine administration of Acetaminophen 975mg PO q6h & Celecoxib 200mg PO q12h. Opioids used as breakthrough analgesia only. No PCA.
~Early mobilization: Mobilization within the first 24 hours after surgery with assistance."
11067227|NCT04306003|Active Comparator|Standard Perioperative Care|Patients in the control arm received routine perioperative care as determined by respective surgeons participating in the study.
11067228|NCT04305990|Experimental|Demand-driven delivery followed by free-flow delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a demand-driven delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
11067229|NCT04305990|Experimental|Free-flow delivery followed by demand-driven delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
11067230|NCT04305977|Other|WAVE-TW Arm|All participants will receive the WAVE-TW intervention.
11067231|NCT04305964|Experimental|Nastent® users|Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) < 20/ hour sleep who receive Nastent® as treatment modality
11067232|NCT04305951|No Intervention|Routine care group|Subjects assigned to this group will continue their routine care without receiving any acupuncture and acupressure treatment during the study period. The routine care may include physiotherapy and intellectual activities. Post-trial treatment of either CAT, CAE, or CAT+CAE will be offered to serve as a compensation for their participation.
11067233|NCT04305951|Active Comparator|CAT group|Subjects assigned to comprehensive acupuncture therapy (CAT) group will receive CAT treatment in addition to routine care.
11067234|NCT04305951|Active Comparator|CAE group|Subjects assigned to 'Comfy Acupressure for the Elderly (CAE)' group will receive CAE in addition to routine care.
11067235|NCT04305951|Active Comparator|CAT + CAE group|Subjects assigned to CAT+CAE group will receive CAT+CAE in addition to routine care.
11067236|NCT04305925|Experimental|Focal Laser Ablation|The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
11067237|NCT04305912|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to verofilcon A daily disposable lenses for one week.
11067238|NCT04305912|Active Comparator|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
11067239|NCT04305899|Experimental|Treatment Group 1|
11067240|NCT04305899|Experimental|Treatment Group 2|
11067241|NCT04305899|Experimental|Treatment Group 3|
11067242|NCT04305899|Experimental|Treatment Group 4|
11067243|NCT04305899|Experimental|Treatment Group 5|
11067244|NCT04305899|Experimental|Treatment Group 6|
11067245|NCT04305899|Experimental|Treatment Group 7|
11067246|NCT04305899|Experimental|Treatment Group 8|
11067247|NCT04305899|Experimental|Treatment Group 9|
11067248|NCT04305899|Experimental|Treatment Group 10|
11067249|NCT04305886|Experimental|Intervention|Providers were placed in small groups and given the intervention of a discussion guide to facilitate discussion.
11067250|NCT04305886|No Intervention|Control|Providers were placed in small groups and not given a discussion guide to facilitate discussion.
11067251|NCT04305873||EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test <93%
11067252|NCT04305873||Non-EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test >95%
11067253|NCT04305873||Intermediate EIAH athletes|Athletes with arterial oxyhemoglobin saturation at maximal exercise during a graded exercise test of 93-95%
11067254|NCT04305860|Active Comparator|Modified starch without flavoring|Patients thicken water with modified starch during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
11067255|NCT04305860|Active Comparator|Modified starch with flavoring|"Patients thicken water with modified starch adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
11067256|NCT04305860|Active Comparator|Xanthan gum without flavoring|Patients thicken water with xanthan gum during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
11067257|NCT04305860|Active Comparator|Xanthan gum with flavoring|"Patients thicken water with xanthan gum adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization.They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
11067259|NCT04305834|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11067260|NCT04305808||Recurrent Urinary tract infection|Menopausal women, with two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year
11067261|NCT04305808||Healthy controls|Menopausal women, without prior history of UTIs or other urologic abnormalities.
11067262|NCT04305795|Other|Cohort 1 - 1L HNSCC|Recurrent locally advanced and/or metastatic head and neck squamous cell carcinoma
11067263|NCT04305795|Other|Cohort 2 - 1L cuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
11067264|NCT04305795|Other|Cohort 3 - 2L + cuSCC|Locally advanced or metastatic cutaneous squamous cell carcinoma
11067265|NCT04305782|Experimental|Release/Relock Socket - In Lab|The test socket will be operated by the participant in lab, following a structured protocol. This arm focuses on the order effects on the re-lock panel and pin mechanisms on limb volume.
11067266|NCT04305782|Experimental|Release/Relock Socket - Out of Lab|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the effects of the re-lock panel and pin mechanisms on participant comfort.
11067267|NCT04305782|Experimental|Release/Relock Socket & Control|The test socket will be operated by the participant out of lab, with no structured protocol. This arm focuses on the comparing participant experience using the novel mechanism versus traditional socket mechanisms.
11067268|NCT04305769|Placebo Comparator|Alanyl-glutamine 0g|
11067269|NCT04305769|Experimental|Alanyl-glutamine 4g|
11067270|NCT04305769|Experimental|Alanyl-glutamine 24g|
11067271|NCT04305769|Experimental|Alanyl-glutamine 44g|
11067272|NCT04305756|Experimental|Weight-based LMWH|"Participants will receive a weight-based dose of prophylactic enoxaparin.
~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours"
11067273|NCT04305756|Active Comparator|Fixed LMWH|"Participants will receive a fixed dose of prophylactic enoxaparin.
~For BMI <40: 40mg injected subcutaneously every 24 hours
~For BMI > or = to 40: 40mg injected subcutaneously every 12 hours"
11067274|NCT04305743|Experimental|5 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 5 injections of 2 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
11067275|NCT04305743|Active Comparator|20 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 20 injections of 0.5 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
11067276|NCT04305730|Experimental|Pedometer Group|This group will be given a pedometer following radical cystectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 1,000/day. POD 3-6: 2,000/day. POD 7-9: 3,000/day. POD 10-14: 4,000/day. POD 14-21: 5,000
11067277|NCT04305730|Active Comparator|Control group|This is the control group. Following radical cystectomy subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
11067278|NCT04305717|Experimental|ReDS-guided strategy|For patients in this arm, daily measurements from the device will be revealed to the treating physician. Discharge can be planned when the clinical stability is achieved and the ReDS value is ≤35%. In case of a ReDS value >35%, treating physicians will follow a predefined algorithm before discharge to improve the results of ReDS test.
11067279|NCT04305717|No Intervention|Standard of care strategy|The drugs dosage, especially diuretics, will be selected according to the presence of symptoms and signs of systemic congestion and according to current recommendations. All the daily ReDS measurements will be blinded to the treating physician.
11067280|NCT04305691|Experimental|Treatment (ixazomib)|Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
11067281|NCT04305678|Experimental|Single Arm|Patients with a biopsy proven diagnosis of eosinophilic fasciitis
11067282|NCT04305665||HIV-1 positive persons|
11067283|NCT04305652|No Intervention|Control group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 10 to 23 points)
11067284|NCT04305652|Experimental|Experimental group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 10 to 23 points) The caregivers of Alzheimer's patients will be trained for 3 months according to the Progressively Lowered Stress Threshold Model with a home visit.
11067285|NCT04305613||Cohort|Patients with locally advanced non-small cell lung cancer
11067286|NCT04305600||Aim 1|Aim 1 participants will be recruited from participants in the first BRAIN study at VUMC.
11067287|NCT04305600||Aim 2|Aim 2 participants will be recruited from the ICU populations at both VUMC and RUMC.
11067288|NCT04305587|Experimental|Active Obesity|Part B
11067289|NCT04305587|Placebo Comparator|Placebo Obesity|Part B
11067290|NCT04305587|Experimental|Active T2DM|Parts A and C
11067291|NCT04305587|Placebo Comparator|Placebo T2DM|Parts A and C
11067292|NCT04305574||Community sample|We plan to recruit a representative sample of the Singapore population.
11067293|NCT04305561|Other|Ultrasound + Contrast-enhanced ultrasound|"Patients are offered a contrast-enhanced ultrasound (CEUS) examination in addition to conventional imaging. All included patients undergo both CEUS and conventional imaging, enabling them to act as their own controls.
~Pilot study: 60 patients Main study: 112 patients"
11067294|NCT04305561|No Intervention|Conventional imaging|"Dual-tracer 99mTechnetium-pertechnetate/ 99mTechnetium-sestamibi subtraction scintigraphy with single-photon emission computerised tomographic/CT fusion imaging (SPECT/CT) combined with conventional ultrasound.
~Pilot study: 60 patients Main study: 112 patients"
11067295|NCT04305548|Experimental|Trabectedin|Trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
11067296|NCT04305535|Active Comparator|Peptidic+Probiotic|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and mix of probiotics during 6 months
11067297|NCT04305535|Active Comparator|Peptidic+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
11067298|NCT04305535|Placebo Comparator|Polymeric+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
11067299|NCT04305522|Experimental|Probiotic 1 group|A commercially-available multi-strain probiotic with added magnesium and vitamin B6
11067300|NCT04305522|Experimental|Probiotic 2 group|A multi-strain probiotic
11067301|NCT04305522|Placebo Comparator|Placebo group|Identical placebo
11067302|NCT04305509||LDH patients|Patients with lumbar disc herniation which was treated with manual therapy
11067303|NCT04305496|Experimental|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
11067304|NCT04305496|Placebo Comparator|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
11067305|NCT04305483|Active Comparator|Laser Bleaching|35% Hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative containing bleaching agent activated with diode laser
11067306|NCT04305483|Active Comparator|Chemical Bleaching|35% Hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water containing chemical bleaching agent used for control group without a laser activation
11067307|NCT04305470|Experimental|Single Arm|Open-label, single-arm
11067308|NCT04305457|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
11067309|NCT04305457|No Intervention|Control|Patients assigned to the control group will not receive any gas therapy.
11067310|NCT04305457|Experimental|Nitric Oxide Inhalation (Non-Randomized)|All subjects part of this arm will receive nitric oxide gas either as an inpatient or outpatient. Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system. Patients in this arm will not be randomized, so that all patients receive the study medication.
11067311|NCT04305444|Experimental|Disease-specific cohorts|Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days
11067312|NCT04305431|Experimental|1/All Subjects|Second phase participants
11067313|NCT04305418|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
11067314|NCT04305418|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
11067315|NCT04305405|Experimental|Dose 1|Below 35 kilos
11067316|NCT04305405|Experimental|Dose 2|Greater than/equal to 35 kilos
11067317|NCT04305392|Experimental|Normal liver function|Patients will receive single dose of SHR4640
11067318|NCT04305392|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR4640
11067319|NCT04305392|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR4640
11067320|NCT04305379|Experimental|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction (Sling + Intussusception)
11067321|NCT04305379|Active Comparator|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction (Intussusception Only)
11067322|NCT04305366||Head and Neck Cancers|This study will target patients with a diagnosis squamous cell carcinoma in the head and neck. In addition, this study will also target patients undergoing tonsillectomy or sleep surgery as the control group. This study will aim to enroll an equal number of patients into both the study group and control group. However, this will be dependent on patient encounters within the adult ENT clinic.
11067323|NCT04305353|Experimental|ICU Diary Group|Patients randomized to this group receive the ICU diary, along with PTSD education
11067324|NCT04305353|Other|PTSD Education-only Group|Control Group: patients randomized to this group only receive PTSD education
11067325|NCT04305340|Experimental|SKIIN Textile Device in children with healthy hearts|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down.
11067326|NCT04305340|Experimental|SKIIN Textile Device in children with heart failure|The Myant SKIIN Device will be worn by study participants while they lay down, sit, stand, exercise and cool-down
11067327|NCT04305327|Experimental|Brodalumab|Brodalumab for 52 weeks. The dose will be determined by the participant's body weight.
11067328|NCT04305327|Active Comparator|Ustekinumab|Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
11067329|NCT04305327|Placebo Comparator|Placebo/brodalumab|Placebo for the first 12 weeks and brodalumab for the following 40 weeks. The dose will be determined by the participant's body weight.
11067330|NCT04305327|Placebo Comparator|Placebo/ustekinumab|Placebo for the first 12 weeks and ustekinumab for the following 40 weeks. The dose will be determined by the participant's body weight.
11067335|NCT04305275|Placebo Comparator|SAGE-324 Matched Placebo|Participants will receive SAGE-324 matched placebo, oral tablets for 28 days.
11067336|NCT04305249|Experimental|ATG-017|ATG-017 will be administered orally on an empty stomach QD in the first cohort of solid tumors group and BID 12 hours apart (no food or drink other than water for 2 hours prior to, and for 1 hour after study treatment administration) in other cohorts. All doses of ATG-017 should be taken at approximately the same time each day. Patients will receive study treatment in 21-day cycles.
11067337|NCT04305236|Experimental|Abemaciclib and Fulvestrant|Abemaciclib will be administered orally at the dose of 150 mg twice daily. Fulvestrant will be administered intramuscularly at an initial loading dose of 500mg on days 1 and 15 of the first cycle and then 500 mg intramuscularly every first day of each subsequent cycle. One cycle is 28 days.
11067338|NCT04305223|Experimental|Dry needling and upper extremity stretching program Arm|"Participants will receive a combination of dry needling and upper extremity stretching.
~Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin America, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
~A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter."
11067339|NCT04305223|Active Comparator|Dry Needling Arm|Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin American, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
11067340|NCT04305210|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
11067341|NCT04305210|Experimental|18F-florbetapir|18F-florbetapir (AV45) imaging
11067342|NCT04305197|Experimental|Lower Dose|
11067343|NCT04305197|Experimental|Medium Dose|
11067344|NCT04305197|Experimental|Higher Dose|
11067345|NCT04305197|Placebo Comparator|Placebo|
11067346|NCT04305184|Experimental|ASP0598 SAD|A single topical application of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 4 dose levels.
11067347|NCT04305184|Experimental|ASP0598 MAD|Multiple topical applications of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 2 dose levels with additional treatment days.
11067348|NCT04305184|Experimental|ASP0598 Single Dose Expansion|A single topical application of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 2 dose levels.
11067349|NCT04305184|Experimental|ASP0598 Multiple Dose Expansion|Multiple topical application of ASP0598 onto the tympanic membrane through the external auditory canal via syringe at up to 2 dose levels with additional treatment days.
11067350|NCT04305184|Placebo Comparator|Pooled Placebo in SAD|For each dose level ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
11067351|NCT04305184|Placebo Comparator|Pooled Placebo in MAD|For each dose level ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
11067352|NCT04305184|Placebo Comparator|Placebo in Single Dose Expansion|ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
11067353|NCT04305184|Placebo Comparator|Placebo in Multiple Dose Expansion|ASP0598 matching placebo onto the tympanic membrane through the external auditory canal via syringe.
11067354|NCT04305171||coronary heart disease patients with periodontitis|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.
~Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth."
11067355|NCT04305171||coronary heart disease patients without periodontitisHD|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.
~Non-periodontitis classified as having PD ≤ 3 mm."
11067356|NCT04305171||non-coronary heart disease patients with periodontitis|Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth.
11067357|NCT04305171||non-coronary heart disease patients without periodontitis|Non-periodontitis classified as having PD ≤ 3 mm.
11067358|NCT04305158|Experimental|Nitrous Oxide|Patient receiving Nitrous Oxide are evaluated for success of the procedure
11067359|NCT04305158|Active Comparator|IV Sedation group|In this group a combination of Midazolam and Fentanyl is used per endoscopic discretion
11067360|NCT04305145|Experimental|Infliximab|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Infliximab: Predetermined intravenous single dose, up to 3 doses over 7 weeks.
~Cross over for inadequate response -- Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm at full initial dosing"
11067361|NCT04305145|Experimental|Inpatient|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~methylprednisone-Predetermined intravenous dose, 2x daily up to 7 weeks
~prednisone Oral daily predetermined dose
~Cross over for inadequate response -- Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm at full initial dosing"
11067362|NCT04305145|Experimental|Outpatient|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits
~Prednisone Predetermined oral dose, 2x daily up to 7 weeks
~Cross over for inadequate response -- Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm at full initial dosing"
11067363|NCT04305132||Depression|Subjects with depression treated with electroconvulsive therapy
11067364|NCT04305132||Healthy|Healthy subjects
11067365|NCT04305106|Experimental|Bevacizumab Group|
11067366|NCT04305106|No Intervention|Control Group|
11067367|NCT04305093||Precision Analytical patients|Individuals who had laboratory work completed at Precision Analytical and completed the associated questionnaire on symptoms and comorbidities.
11067368|NCT04305080|Experimental|Anodic Oxidation of implant abutment|
11067369|NCT04305080|Sham Comparator|Untreated implant abutment|
11067370|NCT04305067|Experimental|Supervised aerobic and resistance exercise|16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
11067371|NCT04305054|Experimental|Pembrolizumab + MK-7684|Participants will receive pembrolizumab intravenously (IV) plus MK-7684 IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
11067372|NCT04305054|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
11067373|NCT04305054|Experimental|Coformulation MK-1308A|Participants will receive MK-1308A (coformulation of pembrolizumab and MK-1308) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.
11067374|NCT04305054|Experimental|Coformulation MK-1308A + Lenvatinib|Participants will receive MK-1308A (coformulation of pembrolizumab and MK-1308) IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
11067375|NCT04305041|Experimental|Pembrolizumab + MK-1308 + MK-7684|Participants will receive pembrolizumab intravenously (IV) plus MK-1308 IV plus MK-7684 IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
11067376|NCT04305041|Experimental|Pembrolizumab + MK-1308 + Lenvatinib|Participants will receive pembrolizumab IV plus MK-1308 IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
11067377|NCT04305028||Experimental: Rivaroxaban [2.5 mg] + Aspirin|Drug: Rivaroxaban 2.5 mg twice daily, tablet Drug: Aspirin 75-100 mg once daily, tablet
11067378|NCT04305028||Active Comparator: Aspirin|Drug: Aspirin 75-100 mg once daily, tablet
11067379|NCT04305015|Active Comparator|Routine opioid management|Clinicians will be blinded to NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when
11067380|NCT04305015|Experimental|NOL-guided opioid administration|Clinicians will titrate fentanyl to keep NOL under 25 - always using good clinical judgement for individual patients
11067381|NCT04305002|Experimental|Exenatide|
11067382|NCT04305002|Placebo Comparator|Placebo|
11067383|NCT04304989|Experimental|Intervention|This group of participants will receive a video-based mHealth program which includes two main elements: 1) nurse case management supported by a social service team, 2) individual-specific video messages covering self-care topics delivered via smartphone
11067384|NCT04304989|Other|Control|The participants in this group will receive usual care
11067385|NCT04304976|Experimental|Training with ROBERT® Passive|Training performed with ROBERT® in passive mode, resulting in active assistive training.
11067386|NCT04304976|Experimental|Training with ROBERT® Active|Traning performed with ROBERT® in Active mode, resulting in active resistive training.
11067387|NCT04304963||T1DM and intact awareness of hypoglycaemia|200 participants with T1DM and intact awareness of hypoglycaemia
11067388|NCT04304963||T1Dm and impaired awareness of hypoglycaemia|50 participants with T1Dm and impaired awareness of hypoglycaemia
11067389|NCT04304963||insulin treated T2DM|350 participants with insulin treated T2DM ( > 1 injections / day)
11067390|NCT04304950|Experimental|Ulcerative Colitis: Azathioprine|Participants with Ulcerative Colitis taking Azathioprine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
11067391|NCT04304950|Experimental|Ulcerative Colitis: 6-Mercaptopurine|Participants with Ulcerative Colitis taking 6-Mercatopurine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
11067392|NCT04304950|Experimental|Crohn's Disease: Azathiopurine|Participants with Crohn's Disease taking Azathioprine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
11067393|NCT04304950|Experimental|Crohn's Disease: 6-Mercaptopurine|Participants with Crohn's Disease taking 6-Mercaptopurine orally once a day. Dosage amount is per clinical care and not defined by the study protocol.
11067394|NCT04304937||Cohort 1|test-retest at baseline and 7 days later
11067395|NCT04304937||Cohort 2|test at baseline and 8 weeks post treatment
11067396|NCT04304924|Experimental|Personalised telephone-based health education|"The personalized telephone based intervention:
~Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);
~Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
11067397|NCT04304924|No Intervention|Standard health educational program|
11067398|NCT04304911|Experimental|UP in blended format|Clinicians will follow the UP therapist manual, 2nd edition, recently translated by Osma and Crespo (13,14). The same contents through a digital material (video and audio) will be integrated in the UP-APP. The program can be developed in a range of 12 to 16 sessions. The UP includes 8 modules
11067399|NCT04304911|Active Comparator|Treatment as usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
11067400|NCT04304898||Single Group Assignment|Intervention group without a control group
11067401|NCT04304885||Sonication method|The treatment strategies of all patients in this group will be based on the culture results to be made by the sonication method.
11067402|NCT04304885||Conventional method|The treatment strategies of all patients in this group will be based on the culture results to be made by the conventional method.
11067403|NCT04304872|Experimental|Gamification Intervention|"Participants sign a pledge agreeing to try their best to meet their goals.
~Participants are entered into a game. Each week they receive 70 points. Each day, they are told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.
~Participants choose a support partner who receives a weekly email with the participant's progress. The study group will hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, the study group will have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
11067404|NCT04304872|Experimental|Loss-Framed Financial Incentive Intervention|Participants are informed that each week that $14 is placed in a virtual account for them. Each day, the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
11067405|NCT04304872|Experimental|Gamification and Loss-Framed Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
11067406|NCT04304859||Cases referred from GP|BASIC (Brief Assessment of Impaired Cognition) MMSE (Mini Mental State Examination) Extensive diagnostic work-up including clinical interview, neurological and physical examination, laboratory screening tests, structural neuroimaging
11067407|NCT04304859||Healthy controls|"Test performed:
~BASIC MMSE GDS-15 (Geriatric Depression Scale)"
11067408|NCT04304846||AMPLIFy group|Mother, premature child and teacher will complete questionnaires and interviews on attachment, maternal stress and child behavior
11067409|NCT04304833|Active Comparator|Provider-Based Care Model Arm|Non-connected home vital sign equipment will be given to patients in this group. The patients in the group will be instructed to record their daily readings on a paper log provided by the research team. These monitoring devices will not transmit readings to a centralized location and no one will be alerted to out-of-range readings or compliance with taking daily vital sign measures. At the front page of the log, normal ranges will be described with brief instructions about what participants/caregivers should do if their readings are out-of-range. Logs will be collected at baseline, 3-months and 6-months.
11067410|NCT04304833|Experimental|mHealth Model Arm|Connected home vital sign equipment (mHealth) will be given to patients in this group. The patients will be instructed to take their daily readings, which will automatically be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse (RN) Call Center will be automatically alerted and the event will be triaged. Daily measures and medical follow-up from the measures will be counted and collected at baseline, 3-months, and 6-months.
11067411|NCT04304820|Experimental|SAA|Subjects with SAA treated with early initiation of oral treatment
11067412|NCT04304807|Experimental|Group I|Forty five preterm infants with signs of feeding intolerance who received 20 mg of melatonin treatment in addition to traditional antibiotic treatment.
11067413|NCT04304807|Sham Comparator|Group II|Forty five preterm infants with signs of feeding intolerance who received traditional antibiotic treatment only.
11067414|NCT04304794||Group with prophylaxis|Group of 13 patients with euthyroid goiter who received prophylactic treatment before and after iodinated contrast medium (ICM) injection. 6 patients received thiamazole with sodium perchlorate, one day prior to ICM and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily). 7 patients received only thiamazole as prophylactic treatment due to lack of sodium perchlorate at the time.
11067415|NCT04304794||Group without prophylaxis|Group of 23 patients with euthyroid goiter who received no prophylactic treatment before iodinated contrast medium injection.
11067416|NCT04304781|Experimental|Dimer Application with SFE imaging|Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.
11067417|NCT04304768|Experimental|HIV positive opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
11067418|NCT04304768|Experimental|HIV positive non-opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
11067419|NCT04304768|Experimental|HIV negative opioid users|Participants will receive flu vaccination as part of the study
11067420|NCT04304768|Experimental|HIV negative non-opioid users|Participants will receive flu vaccination as part of the study
11067421|NCT04304755|Experimental|Zoledronic acid|Zoledronic acid 5 mg IV at baseline and after 24 weeks.
11067422|NCT04304755|Placebo Comparator|NaCl|100 ml 0.9% NaCl IV at baseline and after 24 weeks.
11067423|NCT04304742||Suspicion of hip fracture|Suspicion of hip fracture
11067424|NCT04304729||Diabetics|Girls and boys aged 14-18 years old, living with Type 1 Diabetes.
11067425|NCT04304729||Control|Age and sex matched adolescents without any type of diabetes
11067426|NCT04304716|Active Comparator|Fibular free flap-Block performed|For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
11067427|NCT04304716|Active Comparator|Anterolateral thigh free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
11067428|NCT04304716|Active Comparator|Radial forearm free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
11067429|NCT04304716|No Intervention|Fibular free flap -Control|No additional procedures beyond the normal standard of care will be performed
11067477|NCT04304391|Experimental|Group C|Er:YAG Laser Assisted Gingivectomy: Technique is performed with using Er:YAG laser.
11067430|NCT04304716|No Intervention|Anterolateral thigh free flap-Control|No additional procedures beyond the normal standard of care will be performed
11067431|NCT04304716|No Intervention|Radial forearm free flap-Control|No additional procedures beyond the normal standard of care will be performed
11067432|NCT04304703||Internal Medicine resident subjects|Subjects who are categorical Internal Medicine residents at Penn State Hershey Medical Center (PGY1-PGY3), and meet inclusion/exclusion criteria, will be enrolled in this study and wear the WHOOP strap 3.0 for real-time measurement of physiologic metrics.
11067433|NCT04304690|Other|caregiver|caregivers from emergency, ICU, virology and infectious disease services
11067434|NCT04304677||Pre PCI state|The current study will analyze the pre-PCI pullback recording and amount of FFR step-up. The association of the amount of FFR step-up with post-PCI percent FFR increase, post-PCI FFR, and clinical outcome at 2 years will be analyzed
11067435|NCT04304664|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
11067436|NCT04304664|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
11067437|NCT04304651|Active Comparator|Limited cancer screening|Limited screening alone.
11067438|NCT04304651|Experimental|Limited cancer screening + FDG PET/CT|Limited screening + FDG PET/CT
11067439|NCT04304638||Radiation(Chemo-radiation)|Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.
11067440|NCT04304638||radiation+EGFR-TKI|Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.
11067441|NCT04304638||EGFR-TKI|Patients in this group had been treated with EGFR-TKI without any other treatment until progression.
11067442|NCT04304625|Experimental|Tranexamic acid|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
11067443|NCT04304625|Placebo Comparator|Placebo|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
11067444|NCT04304599|Experimental|LoFric Elle|New hydrophilic female urinary catheter for single use. Ready-to-Use.
11067445|NCT04304573||Patients with hypocalcemia symptoms and low serum calcium|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
11067446|NCT04304573||Patients with hypocalcemia symptoms and normal serum calcium|Patients with hypocalcemia symptoms but without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
11067447|NCT04304560|Placebo Comparator|Control Group|Control group will receive the standard therapy for DM & HFrEF and placebo.
11067448|NCT04304560|Experimental|Dapagliflozin|Intervention group will receive 10mg of Dapagliflozin (Forxiga) ® tablet and standard therapy for HFrEF.
11067449|NCT04304547|Active Comparator|Sequence A|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
11067450|NCT04304547|Active Comparator|Sequence B|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
11067451|NCT04304547|Active Comparator|Sequence C|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
11067452|NCT04304534|Experimental|BAY 2433334 high dose|
11067453|NCT04304534|Experimental|BAY 2433334 medium dose|
11067454|NCT04304534|Experimental|BAY 2433334 low dose|
11067455|NCT04304534|Placebo Comparator|BAY2433334 matching placebo|
11067456|NCT04304521||Intensive care|Patients admitted in the intensive care unit of the University Hospital of Saint-Etienne, France between December 2018 and July 2019
11067457|NCT04304508|Experimental|BAY2433334 high dose|
11067458|NCT04304508|Experimental|BAY2433334 medium dose|
11067459|NCT04304508|Experimental|BAY2433334 low dose|
11067460|NCT04304508|Placebo Comparator|BAY2433334 matching placebo|
11067461|NCT04304495||Persons with Dementia|
11067462|NCT04304495||Caregivers of Persons with Dementia|
11067463|NCT04304495||65 to 69 years-old|
11067464|NCT04304495||70 to 74 years-old|
11067465|NCT04304495||75 to 79 years-old|
11067466|NCT04304495||80 years-old and older|
11067467|NCT04304482|Experimental|ANAVEX2-73 Active|ANAVEX2-73 liquid oral solution
11067468|NCT04304482|Placebo Comparator|ANAVEX2-73 Placebo|Placebo liquid oral solution
11067469|NCT04304469||women|women consulting for domestic violence
11067470|NCT04304456||HA-BSI|Patients with HA-BSI treated in an ICU
11067471|NCT04304430||Dapagliflozin|Patients who initiated a new therapy with dapagliflozin
11067472|NCT04304430||DPP-4i|Patients who initiated a new therapy with a DPP-4i
11067473|NCT04304404|Experimental|Intervention group|Individual interventions based on the Health Belief Model involving education, guidance, counseling, case management and surveillance for women with high breast cancer risk
11067474|NCT04304404|No Intervention|Control Group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks
11067475|NCT04304391|Experimental|Group A|Conventional Gingivectomy:Technique is performed with conventional surgical instruments.
11067476|NCT04304391|Experimental|Group B|Diode Laser Assisted Gingivectomy: Technique is performed with using diode laser.
11067479|NCT04304378|Active Comparator|Stabilization Techniques (ST)|"Participants randomized into ST will receive 6 weekly 1-hour sessions of Stabilization Techniques from a Khmer-speaking mental health professional. Sessions provide an opportunity to improve emotion regulation and provide coping skills for managing symptoms of PTSD.
~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
11067480|NCT04304378|Experimental|Stabilization Techniques with Behavioral Activation (ST+BA)|"Participants randomized into ST+BA will receive 3 weekly 1-hour sessions of ST and 3 weekly 1-hour sessions of BA from a Khmer-speaking mental health professional. Sessions include stabilization techniques and behavioral skills that aim to establish and maintain routines, reduce avoidance, and manage negative emotions.
~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
11067481|NCT04304365|Active Comparator|Clinic follow-up group|All participants in this group will receive the standard of care at BMC which includes receiving a follow-up visit date and time before leaving the initial visit, when they receive the medications for abortion. Patients then return to clinic 1-2 weeks later to be seen by a provider with an ultrasound for confirmation of abortion completion. Participants who do not come for a return visit receive one phone call to reschedule their appointment.
11067482|NCT04304365|Experimental|Home follow-up group|Participants enrolled in the home follow-up group will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. At enrollment, they will receive instruction for timing of contact, how to use the LSPT, as well as the test itself. The participant will take the pregnancy test at home in 14 days and answer completion questions by text message for follow-up. Patients that screen positive will be asked to return to clinic for a visit with a provider.
11067483|NCT04304352|Experimental|Metronomic VEX|Metronomic VEX (Oral Cyclophosphamide 50 mg daily continuous, Oral Capecitabine 500 mg, thrice daily continuous, Oral Vinorelbine 40 mg day 1,3 and 5 every week
11067484|NCT04304326|Experimental|Intervational|"FT: Functional training with elastic band Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.
~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group.
~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
11067485|NCT04304326|Experimental|Arms and Interventions|"Resistance exercise with weight training machines. Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.
~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).
~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
11067486|NCT04304313|Experimental|Sildenafil citrate tablets|
11067487|NCT04304300||Study group|Glioma, IDH mutated, grade 2 and 3
11067488|NCT04304287|Experimental|Experimental|Preoperative blood donations 14 day before total hip replacement procedure Donation of one dose of autologous blood 14 day before total hip replacement procedure
11067489|NCT04304287|Active Comparator|Active comparator|Preoperative blood donation 72 hours before total hip replacement procedure Donation of one dose of autologous blood 72 hours before total hip replacement procedure
11067490|NCT04304287|Other|Other|Without preoperative blood donation
11067491|NCT04304274|Experimental|PTPVB-ropivacaine|Programmed intermittent bolus infusion of a thoracic paravertebral block with ropivacaine and patient-controlled analgesia with morphine
11067492|NCT04304274|Placebo Comparator|PTPVB-saline|Programmed intermittent bolus infusion of a thoracic paravertebral block with saline and patient-controlled analgesia with morphine
11067493|NCT04304261|Experimental|Dapagliflozin|12 weeks of Dapagliflozin(10mg/day) treatment, randomly
11067494|NCT04304261|Experimental|Metformin|12 weeks of Metformin (1500-2000mg/day) treatment, randomly
11067495|NCT04304248|Experimental|Neoadjuvant chemo-immunotherapy|"Neoadjuvant treatment (Albumin-bound paclitaxel + carboplatin + toripalimab) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.
~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment."
11067496|NCT04304235|Active Comparator|Control|Hospital nurses will triage participants using the Emergency Triage and Treatment (ETAT) guidelines, the triage policy that is currently in place at the study hospital sites.
11067497|NCT04304235|Experimental|Intervention|Hospital nurses will triage participants using the digital triage tool (mhealth intervention).
11067498|NCT04304222|Other|Sequence A|To receive the conventionally made denture framework then the 3D printed denture framework.
11067499|NCT04304222|Other|Sequence B|To receive the 3D printed denture framework then the conventionally made denture framework.
11067500|NCT04304209|Experimental|Cohort A|Four cycles of neoadjuvant PD1 antibody Sintilimab, followed by curative surgery or watch and wait, then four cycles of adjuvant PD1 antibody Sintilimab ± Capeox according to pathologic response
11067732|NCT04302597|Active Comparator|Staples|Women who underwent repeated cesarean section with skin closure using staples.
11067501|NCT04304209|Experimental|Cohort B-arm 1|Four cycles of neoadjuvant PD1 antibody Sintilimab, Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy
11067502|NCT04304209|Active Comparator|Cohort B-arm 2|Four cycles of neoadjuvant Capeox chemotherapy and concurrent radiotherapy, followed by curative surgery or watch and wait, then four cycles of adjuvant Capeox chemotherapy
11067503|NCT04304196|Experimental|TEMPO|These patients and caregivers will be able to access the TEMPO modules and will receive technical support to use it effectively. Patients will receive usual care throughout the study.
11067504|NCT04304196|Active Comparator|Control|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).
11067505|NCT04304183||slow transit constipation|patients diagnosed with slow transit constipation had undergone surgery.
11067506|NCT04304170|Experimental|Verum group|The dietary supplement under study was composed of fructo-oligosaccharides - FOS: 4.95 gr / sachet and Bifidobacterium animalis lactis: VES002 (LMG P-28149): 5 billion / sachet. They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
11067507|NCT04304170|Placebo Comparator|Placebo group|The comparative product was a placebo that looked strictly identical to the verum and contained only excipients (60% maltodextrin / 40% sucrose).They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
11067508|NCT04304157|Experimental|satisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
11067509|NCT04304157|Experimental|unsatisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
11067510|NCT04304144|Experimental|CAEL-101|"Stage I, II and IIIa AL amyloidosis
~Treatment will continue until development of significant treatment-related toxicities"
11067511|NCT04304131|Experimental|Colorectal cancer|Confirmed colorectal cancer under colonoscopy
11067512|NCT04304131|Experimental|Colon polyp|Confirmed colorectal polyp under colonoscopy
11067513|NCT04304131|Active Comparator|Healthy|Confirmed no cancer nor polyp under colonoscopy
11067514|NCT04304092|Experimental|Low amount, low intensity|
11067515|NCT04304092|Experimental|Low amount, high intensity|
11067516|NCT04304092|Experimental|High Amount, low intensity|
11067517|NCT04304092|Experimental|High Amount, high intensity|
11067518|NCT04304092|No Intervention|Control|
11067519|NCT04304079|Experimental|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
11067520|NCT04304066|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 18F-WL12 or 68Ga-WL12 PET/CT scans
11067521|NCT04304053|Active Comparator|No Intervention- SARS-CoV-2 surveillance|"Study 1- Contacts will complete a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and day 14.
~Study 2- Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3 and 7.
~Isolation of patient and contact tracing as per national guidelines."
11067522|NCT04304053|Experimental|Testing, treatment and prophylaxis of SARS-CoV-2|"Study 1- Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14.
~Study 2- Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7.
~Isolation of patient and contact tracing as per national guidelines."
11067523|NCT04304040|Experimental|Single Arm|
11067524|NCT04304027|Experimental|Tailored exercise intervention|8 weeks of aerobic interval training at moderate intensity which is modified according to the levels of self-reported fatigue
11067525|NCT04304027|Active Comparator|Standard exercise intervention|8 weeks of aerobic interval training at a moderate intensity
11067526|NCT04304027|No Intervention|Usual care control|Participants in the usual care control group will continue to receive their standard care independent of this study
11067527|NCT04304014|Experimental|L. reuteri DSM17938|"Group that will receive L. reuteri DSM17938 one dose per day in an oral suspension
~Intervention: Dietary Supplement: L. reuteri DSM17938"
11067528|NCT04304014|Experimental|B. longum CECT7894 and P. Pentosaceus CECT8830|"Group that will receive B. longum CECT7894 and P. Pentosaceus CECT8830 one dose per day in an oral suspension.
~Intervention: Dietary Supplement: B. longum CECT7894 and P. Pentosaceus CECT8830"
11067529|NCT04304001|Experimental|Community Health Advisor|Intervention arm participants will be scheduled to receive the CHA intervention within 4 to 6 weeks after enrollment, a FIT kit, a mailed targeted CRC brochure, and a follow-up telephone survey at 3- and 12-months post-intervention
11067530|NCT04304001|Active Comparator|Usual care|Control group participants will receive a FIT kit, a mailed targeted CRC brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
11067531|NCT04303988|Experimental|Cohort HR+/HER2+|Hormone receptor negative, HER2 positive participants will receive Pyrotinib in combination with Temozolomide until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11067532|NCT04303988|Experimental|Cohort HR-/HER2-|Hormone receptor negative, HER2 negative participants will receive SHR1316 in combination with bevacizumab plus cisplatin or carboplatin until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11067533|NCT04303975||Group 1: Patients with neoadjuvant chemotherapy|"The patients of group1 will receive one of the following treatments:
~neoadjuvant chemotherapy & concurrent chemoradiotherapy
~neoadjuvant chemotherapy & radiotherapy
~neoadjuvant chemotherapy & radiotherapy & adjuvant chemotherapy"
11067534|NCT04303975||Group 2: Patients without neoadjuvant chemotherapy|"The patients of group2 will receive one of the following treatments:
~concurrent chemoradiotherapy
~concurrent chemoradiotherapy & adjuvant chemoradiotherapy
~radiotherapy & adjuvant chemotherapy"
11067535|NCT04303949|Experimental|Experimental|e-book for termination
11067536|NCT04303949|Other|Control|routine care Written form health education
11067537|NCT04303936|Other|Patients with severe HA under FVIII concentrates prophylaxis|
11067538|NCT04303923||Male group|Male patients who performed transthoracic echocardiography with arterial ultrasonography
11067539|NCT04303923||Female group|Female patients who performed transthoracic echocardiography with arterial ultrasonography
11067540|NCT04303897||XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
11067541|NCT04303884|Experimental|Experimental: Pembrolizumab|Chemo-resistant gestational trophoblastic neoplasias treated with pembrolizumab
11067542|NCT04303871|Active Comparator|patients|pregnant female with hypertension admitted in ICUfor control of BP invasive assessment of BP by radial cannulation was compared against non-invasive assessment of BP by an automated oscillometric BP device (Mobil-O-Graph )
11067543|NCT04303871|Placebo Comparator|control|matched control females of the same age but not pregnant invasive compared to non-invasive measurement of BP by same technique
11067544|NCT04303858|Experimental|RO7284755 as a Single Agent|Part 1: Dose-escalation of RO7284755 as a single agent. RO7284755 will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
11067545|NCT04303858|Experimental|RO7284755 in Combination with Atezolizumab|Part 2: Dose-escalation of RO7284755 in combination with atezolizumab.
11067546|NCT04303858|Experimental|RO7284755 as a Single Agent and/or with Atezolizumab|Part 3: Extension of RO7284755 as a single agent and/or in combination with atezolizumab.
11067547|NCT04303845|Experimental|Treatment with Erenumab|Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
11067548|NCT04303832|Experimental|eye exercise group|This group made different types of eye exercises beside the traditional treatment of strabismus which is eye glasses
11067549|NCT04303832|Sham Comparator|control group|This group had traditional treatment of strabismus which is eye glasses
11067550|NCT04303819||newly diagnosed T2DM participants|newly diagnosed T2DM participants without anti-diabetic drugs intake
11067551|NCT04303806|Experimental|Group 1|40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.
11067552|NCT04303806|Experimental|Group 2|40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily.
11067553|NCT04303780|Experimental|AMG 510|
11067554|NCT04303780|Active Comparator|Docetaxel|
11067555|NCT04303767|Experimental|Test (ART + CPP-ACP)|In this group, teeth selected will receive intervention with CPP-ACP and restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
11067556|NCT04303767|Active Comparator|Control (ART)|in this group, teeth selected will receive restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
11067557|NCT04303754|Experimental|Diabetes-Specific Formula|Diabetes-Specific Formula
11067558|NCT04303754|Experimental|Bread and Spread|White bread with spread
11067559|NCT04303754|Experimental|Rice Porridge|Rice Porridge
11067560|NCT04303741|Experimental|Camrelizumab +Apatinib+Eribulin|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv Q3W combination with Apatinib 250mg, po, daily (d1-d21)and Eribulin1.4mg/m2 iv d1, d8 Q3W
11067561|NCT04303728|Experimental|Muscle ultrasound|Muscle ultrasound will be performed for the patient on admission and at 1-2 months from inpatient rehabilitation.
11067562|NCT04303715|Experimental|No SLNB group|The study arm - BCS without SLNB
11067563|NCT04303715|Other|SLNB group|The Control Arm - BCS with SLNB(+/-ALND)
11067564|NCT04303702|Placebo Comparator|Control|
11067565|NCT04303702|Active Comparator|Oxytocin|
11067566|NCT04303689|Experimental|Colchicine|3 weeks of treatment with colchicine
11067567|NCT04303689|Placebo Comparator|Placebo|3 weeks of placebo-treatment
11067568|NCT04303676|Active Comparator|Virtual Practice Facilitation with e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions utilizing alcohol use e-learning modules to guide and focus the process and content
11067569|NCT04303676|Active Comparator|Virtual Practice Facilitation without e-Learning|A virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions without utilizing alcohol use e-learning modules
11067570|NCT04303663|Active Comparator|Fibular Plate|Open reduction and internal fixation of the fibular fracture Fixation of the fibular will be performed with a fibular plate +/- lag screws as judged intraoperatively
11067571|NCT04303663|Experimental|Fibular Nail|Percutaneous or mini-open reduction of the fibular fracture and fixation with a fibular nail.
11067572|NCT04303637||High school student|13-18 year old students enrolled in schools within Singapore.
11067573|NCT04303624||Community sample|Representative sample of the Singapore population
11067574|NCT04303598|Experimental|FNC Treatment Group|FNC 3mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;3TC placebo 1 tablet;daily oral before bedtime
11067575|NCT04303598|Active Comparator|3TC control group|3TC 300mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;FNC placebo 1 tablet;daily oral before bedtime
11067576|NCT04303585||SAP block|This group includes patients who receive preoperative Serratus Anterior Plane block
11067577|NCT04303585||ESP block|This group includes patients who receive preoperative Erector Spinae Plane block
11067578|NCT04303572|Experimental|Eloctate ITI plus Emicizumab|Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
11067579|NCT04303572|Active Comparator|Eloctate ITI|Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
11067846|NCT04301752||Non-neurobrucellosis|Brucellosis not associated with neuropsychiatric manifestations
11067580|NCT04303559|Active Comparator|Eloctate|Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
11067581|NCT04303559|Experimental|Emicizumab|Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.
11067582|NCT04303546||< 30 years|
11067583|NCT04303546||30-60 years|
11067584|NCT04303546||> 60 years|
11067585|NCT04303533|Experimental|EFP-NF|
11067586|NCT04303520|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients
11067587|NCT04303507|Experimental|Chloroquine or Hydroxychloroquine|"In Asia, the participant will receive chloroquine.
~In Europe, the participant will receive hydroxychloroquine
~Specific drug allocation will be determined by country prior to activation based upon factors such as inventory availability and importation requirements"
11067588|NCT04303507|Placebo Comparator|Placebo|
11067589|NCT04303494||Experimental1|preterm infants will be routinely immunised during primary hospitalisation
11067590|NCT04303494||Experimental2|preterm infants discharged and readmitted for immunisation during the 3-year period
11067591|NCT04303494||Control|healthy control infants
11067592|NCT04303481|Other|normal diet|
11067593|NCT04303481|Experimental|weight loss program kit|
11067594|NCT04303481|Experimental|weight loss program kit with A. muciniphila prebiotics|
11067595|NCT04303468|Experimental|GABA|GABA is a nutrient commonly present in our diet in for example tomatoes and potatoes. It is also commercially sold as dietary supplement. A dose of 500 mg, 3 times daily is used
11067596|NCT04303468|Placebo Comparator|Placebo|The placebo consists of capsules containing powdered cellulose.
11067597|NCT04303455||Study group|"The study will evaluate a cohort of participants meeting the following inclusion criteria:
~Admission to ICU after elective and emergency cardiac surgery following cardiopulmonary bypass
~Age 18 years and above
~Arterial, central venous and pulmonary arterial catheters have been inserted as part of routine care
~Data collection, serum renin among routine blood collection on admission, 6 and 24 hours after admission to ICU"
11067598|NCT04303442||Patients undergoing TEP|Patients diagnosed with unilateral or bilateral primary and/or recurrence inguinal hernia undergoing Total Extraperitoneal laparoscopic hernia repair.
11067599|NCT04303429|No Intervention|observation group|Patients enrolled in the observation group will not receive any chemotherapy drugs
11067600|NCT04303429|Experimental|adjuvant chemotherapy group|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
11067601|NCT04303416|Experimental|Patients|Patients before and after the treatment
11067602|NCT04303403|Experimental|Dose Escalation and Expansion|"Dose Escalation:
~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses.
~Dose Expansion:
~Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase.
~A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment."
11067603|NCT04303390|Active Comparator|24 hour Cefuroxime arm|25% of the entire study participants are assigned to 24 hours and second generation cephalosporin
11067604|NCT04303390|Active Comparator|24 hour Cefazolin arm|25% of the entire study participants are assigned to 24 hours and first generation cephalosporin
11067605|NCT04303390|Active Comparator|48 hour Cefuroxime arm|25% of the entire study participants are assigned to 48 hours and second generation cephalosporin
11067606|NCT04303390|Active Comparator|48 hour Cefazolin arm|25% of the entire study participants are assigned to 48 hours and first generation cephalosporin
11067607|NCT04303377|Experimental|Evolocumab|Evolocumab administration in the acute phase of ST elevation myocardial infarction
11067608|NCT04303377|No Intervention|Standard of care|
11067609|NCT04303364||Subjects without T2DM and without HF|
11067610|NCT04303364||Patients without T2DM and with HFpEF|
11067611|NCT04303364||Patients with T2DM and without HFpEF|
11067612|NCT04303364||Patients with T2DM and HFpEF|
11067613|NCT04303364||Patients without T2DM and with hypertrophic cardiomyopathy|
11067614|NCT04303364||Patients with T2DM and with hypertrophic cardiomyopathy|
11067615|NCT04303351||0-9 missing teeth|participants with 0-9 missing teeth
11067616|NCT04303351||10-19 missing teeth|participants with 10-19 missing teeth
11067617|NCT04303351||23-31 missing teeth|participants with 23-31 missing teeth
11067618|NCT04303351||Edentulous|participants with no teeth
11067619|NCT04303338|Experimental|Masotherapy with neural tension|The investigators are going to massage the patient´s upper limb applying a radial nerve neural tension. In order to the upper limb should be positioned lowering the scapula, elbow extended, internal rotation glenohumeral, forearm pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and finally glenohumeral abduction.
11067620|NCT04303338|Active Comparator|Masotherapy with non-neural tension|The investigators are going to practice a conventional upper limb massage
11067621|NCT04303325|Placebo Comparator|Control|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
11067622|NCT04303325|Active Comparator|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine.
11067623|NCT04303312|Active Comparator|Benzydamine Hydrochloride|"Control Group:Benzydamine Hydrochloride spray by mouth three times daily for 20 days.
~Follow up: The patients will be recalled at one week interval for 20 days."
11067624|NCT04303312|Experimental|90%solcoseryl and 10% pumpkin seed oil|Intervention group: 90% solcoseryl and 10% pumpkin seed oil spray by mouth three times daily for 20 days
11067625|NCT04303299|Experimental|Oseltamivir plus Chloroquine in Mild COVID19|Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19
11068257|NCT04298788|Experimental|blue dishware|specially designed blue dishware, plates and bowls
11067626|NCT04303299|Experimental|Darunavir and Ritonavir plus oseltamivir|Darunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19
11067627|NCT04303299|Experimental|Lopinavir and Ritonavir plus Oseltamivir in mild COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19
11067628|NCT04303299|Experimental|Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19
11067629|NCT04303299|Experimental|Favipiravir lopinavir /Ritonavir for mod. To severe|Lopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19
11067630|NCT04303299|Experimental|Darunavir /ritonavir oseltamivir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
11067631|NCT04303299|Experimental|Darunavir /ritonavir favipiravir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
11067632|NCT04303299|No Intervention|Conventional Qurantine|Patient who unwilling to treatment and willing to quarantine in mild COVID19
11067633|NCT04303286||Recovery Group|The liver function of HCC patients on the fifth day after the operation is recovered.
11067634|NCT04303286||Recovery Delay Group|The liver function of HCC patients on the fifth day after the operation is delayed recovered.
11067635|NCT04303286||Control Group|The patients on benign disease of the liver
11067636|NCT04303260|Active Comparator|Interventional arm|"Patients in the interventional arm will be asked to complete 3 different videos repeatedly, as many days a week as possible. This repetition is to be maintained even if a patient missed one day of training.
~The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation."
11067637|NCT04303260|Placebo Comparator|controled arm|"Patients in the controled arm will also be asked to practice generally recommended exercises in 3 different videos repeatedly, as many sets as possible..
~The control arm will practice generally recommended exercises, without particular attention to the abdomen."
11067638|NCT04303247|Experimental|CD19+CD22 targeted CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.
~dosage: the number of anti CD19+CD22 CAR T cells
~-1(if needed) 1×10^5/KG
~3×10^5 /KG
~6×10^5 /KG
~1×10^6/KG
~Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion."
11067639|NCT04303234|Active Comparator|Artinibsa|"Powerful local anesthetic with short time for patients who can not tolerate normal doses of vasoconstrictor latency.
~High lipid solubility gives a better diffusion through the soft tissue and bone being very effective in infiltrative techniques.
~Duration:
~Latency time: 2 minutes
~Each mL contains:
~4%Articaine 1:100000. Hydrochloride 40.00 mg, Epinephrine (D.C.I) 0.005 mg tartrate"
11067640|NCT04303234|Experimental|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
11067641|NCT04303221|Experimental|GAJL - Young adult with lymphedema|Women age 35 to 59 years (young adult) with lymphedema - exercise group
11067642|NCT04303221|Experimental|GAJ - Young adult without lymphedema|Women age 35 to 59 years (young adult) without lymphedema - exercise group
11067643|NCT04303221|Experimental|GIL - Elderly with lymphedema|Women aged 60 to 80 years (elderly) with lymphedema - exercise group
11067644|NCT04303221|Experimental|GI - Elderly without lymphedema|Women aged 60 to 80 years (elderly) without lymphedema - exercise group
11067645|NCT04303208|Other|study group|2 ml of whole blood sample will be collected on EDTA tube for detection of Plasmacytoid dendritic cells and Toll like receptor 8 by flow cytometry
11067646|NCT04303208|Other|control group|2 ml of whole blood sample will be collected on EDTA tube for detection of Plasmacytoid dendritic cells and Toll like receptor 8 by flow cytometry
11067647|NCT04303195|Experimental|NG101 - 5 mg|NG101 5 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
11067648|NCT04303195|Experimental|NG101 - 10 mg|NG101 10 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
11067649|NCT04303195|Experimental|NG101 - 20 mg|NG101 20 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
11067650|NCT04303195|Placebo Comparator|Placebo|Placebo-matching, capsules, orally, QID (4 times a day) for up to 12 weeks
11067651|NCT04303182|Active Comparator|Standard 3 port TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
11067652|NCT04303182|Active Comparator|LESS TEP|Group B will undergo laparoscopic TEP inguinal hernia repair with a single skin incision 2-3cm.
11067653|NCT04303169|Experimental|Pembrolizumab + MK-7684|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab intravenously (IV) plus MK-7684 IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.
~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
11067654|NCT04303169|Experimental|Pembrolizumab + V937|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus V937 intratumorally (IT) at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.
~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
11067728|NCT04302623|Experimental|Electronic yoga program|The electronic yoga intervention will be delivered through a video hosted on the University of Calgary study website over 8 weeks.
11068765|NCT04295161|Experimental|Prototype 4 fasted|administered in fasted state
11067655|NCT04303169|Experimental|Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.
~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
11067656|NCT04303156|Experimental|Islatravir|Single dose of 60 mg Islatravir (MK-8591)
11067657|NCT04303143||Primary|Primary
11067658|NCT04303130|Experimental|Camrelizumab (SHR-1210) Combined With Endostar|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.
~The combination regimen is a medication cycle every three weeks (21 days)."
11067659|NCT04303117|Experimental|Arm 1/Monotherapy|Treatment with NHSIL12 at deescalating doses if necessary
11067660|NCT04303117|Experimental|Arm 2/Combination therapy|Treatment with NHSIL12 at MTD and M7824 at a fixed dose
11067661|NCT04303104|Active Comparator|Mobile ACF|Xpert Edge performed at point-of-care employing a low-cost panel van that is staffed by three health care workers. Patients identified with active TB will be initiated on TB treatment on the same day at the nearest clinic. On site HIV testing will also be offered. Thus, the interventional package is one of ACF + POC TB testing (TB testing by Xpert will occur on site at the van).
11067662|NCT04303104|Placebo Comparator|Centralised ACF|Similar to active arm but Xpert Ultra will be performed at a centralized laboratory (samples will be transported to the laboratory with results being available in a few days). Thus, the standard of care package is ACF + distant TB testing (TB testing by Xpert will occur at a distant laboratory site).
11067663|NCT04303091|Experimental|Exercise group|Single-arm study. Participants enrolled engaged in a 12-week exercise program.
11067664|NCT04303078|Experimental|Participants|All 5 (anticipated) participants will be enrolled in the same arm and will undergo the same activities listed above.
11067665|NCT04303065|Experimental|Dexamethasone|"Dexamethasone will be a short and descending course: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
~Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain). The Son Espases Pharmacy Department will be in charge of developing and conditioning the 4mg, 2mg and 1mg dexamethasone / placebo capsules needed for 12 days of treatment, keeping the researchers blind"
11067666|NCT04303065|Placebo Comparator|Control|"The preparation and conditioning of the capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
~The Son Espases Pharmacy Department will be responsible for identifying the containers and sending them by courier to the participating hospitals. A record of the dispensing of test samples will be kept and will be sent in acknowledgment of receipt for control"
11067667|NCT04303052|Active Comparator|over-the-wire technique with 145 cm guidewire|Catheter tip placement using Seldinger over-the-wire technique with 145 cm guidewire
11067668|NCT04303052|Active Comparator|modified technique with 70 cm guidewire|Catheter tip placement using Seldinger modified technique with 70 cm guidewire
11067669|NCT04303039|Experimental|Treatment A|Single 1.0 mg dose of ABP-671 in the fasted state.
11067670|NCT04303039|Experimental|Treatment B|Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast.
11067671|NCT04303026|Active Comparator|Treatment Group|Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline
11067672|NCT04303026|Placebo Comparator|Placebo Group|Participants receiving Placebo with two infusions of 100 ml 0.9% saline with 3 months interval.
11067673|NCT04303013|Active Comparator|Standard of Care|
11067674|NCT04303013|Experimental|Meditation|
11067675|NCT04303000|Experimental|Opioid Overdose Education and Naloxone Distribution|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will be provided with a naloxone nasal spray kit (4mg).
11067676|NCT04303000|Active Comparator|Opioid Overdose Education|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will receive information about pharmacies in their area where they can purchase a naloxone kit.
11067677|NCT04302974||Sub-study 1: Trajectory study|All HA primary care patients aged 18 years or above with doctor-documented HT and/or DM receiving care in HA General Out-patient Clinics or Family Medicine Clinics (FMC) identified from the HA CMS database between 2006 and 2019, to explore the trajectory patterns for clinical, treatment and complication profiles and investigate the impact of multi-morbidity, continuity-of-care, different service delivery models and management strategies (including investigation frequency and specific drug regimens) on outcomes and health service utilization.
11067678|NCT04302974||Sub-study 2: RAMP-DM|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who attended the first RAMP-DM assessment between August 2009 to September 2010
11067679|NCT04302974||Sub-study 2: usual care only|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who have never attended any RAMP-DM assessment between August, 2009 to December, 2019
11067680|NCT04302974||Sub-study 3: RAMP-HT|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who attended the first RAMP-HT assessment between October 2011 to March 2013
11067731|NCT04302610|No Intervention|Control|No mask (CONT) wearing only the balaclava to which the HME and SHAM mask were attached. Mouth and face not covered.
11067681|NCT04302974||Sub-study 3: usual care only|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who have never attended any RAMP-HT assessment between October 2011 to December 2021
11067682|NCT04302974||Sub-study 4: PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have received the first PSCC call between September, 2012 to August, 2016 after the first RAMP-DM assessment
11067683|NCT04302974||Sub-study 4: without PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have never received any PSCC services between September 2012 to December 2021
11067684|NCT04302961|Experimental|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving auditory feedback.
11067685|NCT04302961|Active Comparator|No Feedback|Participants will complete 8 sessions over a 2-week period of walking on a treadmill without receiving feedback.
11067686|NCT04302948|No Intervention|Treatment as usual|TaU includes screening for anti-HCV using a rapid point-of-care (PoC) test to screen for exposure to HCV followed by counseling, brief education and referral to provider for further evaluation for HCV treatment.
11067687|NCT04302948|Experimental|Rapid PoC RNA testing|Intervention arm includes Tau ( screening for anti-HCV using a rapid point-of-care (PoC) test, and a rapid PoC screening test for HCV RNA, counseling plus, brief education and referral to a provider for further evaluation for HCV treatment. Rapid HCV RNA testing will be conducted using Cepheid Xpert (r) system.
11067688|NCT04302935||chronic pain patients|
11067689|NCT04302909|Active Comparator|Active Comparator|fESWT
11067690|NCT04302909|Sham Comparator|Sham Comparator|Sham fESWT
11067691|NCT04302896|Experimental|dolutegravir + emtricitabine/tenofovir alafenamide|Tivicay® (dolutegravir 50 mg tablet) + Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg combination tablet), one tablet of each taken by mouth once daily for 15 days
11067692|NCT04302896|Experimental|dolutegravir + tenofovir disoproxil fumarate + lamivudine|Tivicay® (dolutegravir 50 mg tablet) + Viread® (tenofovir disoproxil fumarate 300 mg tablet) + lamivudine 300 mg tablet, one tablet of each taken by mouth once daily for 15 days
11067693|NCT04302883|Experimental|Intervention group|TEE FEES
11067694|NCT04302883|Active Comparator|Control group|FEES
11067695|NCT04302870|Experimental|Memantine|
11067696|NCT04302870|Experimental|Trazodone|
11067697|NCT04302870|Placebo Comparator|Placebo|
11067698|NCT04302844|Active Comparator|Imago Relationship Therapy (IRT)|Couples will receive 12 to 16 Imago relationship therapy sessions (90 minutes each; one session per week) with an experienced and certified Imago Relationship therapist.
11067699|NCT04302844|Active Comparator|Workshop plus Imago Relationship Therapy (IRT)|"Couples in this group will be asked to attend a Getting the Love You Want Workshop that is designed to provide some of the education and principles underlying IRT in a weekend workshop that is usually about 18-20 hours. The workshops, led by certified Imago workshop presenters, include presentations, discussions, and practice of communication exercises. Couples assigned to this arm will then receive 12-16 sessions of IRT after attending the workshop."
11067700|NCT04302844|Active Comparator|Waitlist with Bibliotherapy followed by Workshop|Couples will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read during that time. After 12 weeks and the 12-week assessment has been completed, couples will receive a Getting the Love You Want workshop.
11067701|NCT04302831|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
11067702|NCT04302831|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
11067703|NCT04302818|Experimental|Social skills group training SKOLKONTAKT|Manualised social skills group training.
11067704|NCT04302818|Active Comparator|Active control comparison group|Social activities in a group setting.
11067705|NCT04302805|Placebo Comparator|PE/rATG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg).
11067706|NCT04302805|Active Comparator|PE/rATG/IVIG|Study participants will undergo therapeutic plasma exchange (PE, 1 plasma volume) before the transplant surgery and receive rATG (Thymoglobuline®) induction (1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg) and IVIG 0.5g/kg intravenous infusions, on 1st, 3rd and 5th postoperative day. This is a center standard of care regimen.
11067707|NCT04302792|No Intervention|Stage 1: Interviews and focus group sessions|"Group A: Cancer patients (requiring or have required texture-modified foods and/or experiencing or have experienced taste&smell alterations in the last 12 months) will be required to attend a one-hour online interview.
~Group B: Relatives of cancer patients (requiring texture-modified foods and/or experiencing taste&smell alterations) will be required to attend a 2-hour online focus group session.
~Group C: Healthcare professionals with a minimum of a year's experience with oncological patients that require texture-modified foods and/or have taste & smell alteration will be required to attend a 2-hour online focus group session.
~A food diary will be given to Group A and B to complete for 7-days prior to their session. Topics to be discussed during the interview and the focus group sessions will include the food requirements of cancer patients, the barriers of the current food products, possible solutions to these requirements if any and their expectations towards new food solutions."
11067729|NCT04302610|Experimental|HME MASK|During the Exercise, participants wore either an HME mask (MASK) (ColdAvenger® expedition balaclava, USA, www.coldavenger.com)
11068766|NCT04295161|Experimental|Prototype 4 fed|Administered in fed state
11067708|NCT04302792|Experimental|Stage 2: Texture-modified foods for cancer patients|The study will involve conducting a tasting trial over a 2-weeks period where participants will be required to consume a maximum of three 3D printed texture-modified food based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
11067709|NCT04302792|Experimental|Stage 3: Taste-optimised foods for cancer patients|The study will involve conducting a home test over a one-month period where participants will be required to consume taste-optimised products based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
11067710|NCT04302779|Experimental|Solid Model|Whey Permeate Lemon Cupcake and Protein Fortified Lemon Cupcake
11067711|NCT04302779|Experimental|Liquid Model|Whey Protein Beverage
11067712|NCT04302740|Active Comparator|LEAP|Housing First plus LEAP
11067713|NCT04302740|No Intervention|Service-As-Usual|Housing First
11067714|NCT04302727|Experimental|Med-South Weight Loss Intervention|The intervention will be delivered in 3 phases over 24 months: Phase I (4 months) provides a foundation for adopting and maintaining a healthful dietary pattern (Med-style, tailored for the southeastern United States); Phase II (8 months) focuses on weight loss; and Phase III (12 months) on maintenance of or continued weight loss, as appropriate.
11067715|NCT04302727|Active Comparator|Augmented Usual Care (WW)|The intervention that will be offered to control group participants is WW™ (formerly known as Weight Watchers). The study will provide access to the 'Workshop + Digital' option of WW™ during the 2 year intervention.
11067716|NCT04302714|Active Comparator|cervical injection|Fluorescent SLN Imaging With Indocyanine Green (ICG), using near-infrared fluorescence imaging, will be used as a dye for SLN mapping. Injections will be performed intraoperative. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room, and 4 mL is injected directly into the cervix. This solution was injected intracervically at 3 and 9 o'clock positions, both submucosally and deep into the cervical stroma. A spinal needle 18-gauce is used to inject the ICG. The 4 mL can be divided into 4 separate injections (1 mL each). The ICG should be injected slowly, at a rate of 5 to 10 seconds per quadrant.
11067717|NCT04302714|Experimental|hysteroscopic injection|hysteroscopy is performed using an operative hysteroscope. Uterine distension is obtained by means of saline solution. Usually, the fluid bag is placed 50 cm above the patient's plane so that the intracavitary pressure does not exceed 40 mm Hg. After visualization of uterine cavity a 22-gauce, 40-mm needle was introduced into the operative port and IGC is injected peritumorally. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room. The injection is performed subendometrially around the lesion, or, if the uterine cavity was totally involved by disease, at 3, 6, 9, and 12 o'clock . The depth of needle placement is modulated by visualizing endometrial elevation during injection.
11067718|NCT04302701|Experimental|Dichoptic arm|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
11067719|NCT04302701|Active Comparator|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near. Adherence to the treatment protocol will be assessed by having the parent call / send a message to an investigator at the start and end of the occlusion sessions completed each day, thus making the most as accurate as possible assessment of the patient's adherence to the prescribed treatment
11067720|NCT04302688||modeling cohort|The 445 patients were grouped in chronological order.
11067721|NCT04302688||validating colort|The remaining 224 patients.
11067722|NCT04302675|Experimental|Prevention, Maternal Immunization|
11067723|NCT04302649|Experimental|Intervention group|Patients received Peritoneal Equilibration Test (PET). In the intervention group, dialysate was warmed in a specific microwave oven calibrated to 37°C and infusion temperature was confirmed to be 37°C before infusion
11067724|NCT04302649|No Intervention|Control group|Patients received Peritoneal Equilibration Test (PET). In the control group, current practice was used (batch warming with a pad calibrated to 37°C) and dialysate temperature was measured just before infusion.
11067725|NCT04302636|Experimental|The hypoglycemic index diet group|"Patients in the experimental group ate two portions of food each day.This diet will last for 12 weeks.
~Food provided by the canteen: one egg for breakfast;Lunch and dinner are 50g of rice with all the dishes.
~Dietary nutrition and supplementary food: according to the weight and height of the patient, the daily energy required was calculated, which was divided into six levels: 1400kcal, 1600kcal, 1800kcal, 2000kcal, 2200kcal and 2400kcal.The six corresponding nutritional auxiliary food powders are: 20g-30g-40g-50g-60g-70 g.The suspension was prepared in the proportion of 160ml warm water poured into 55 grams and given to the patient."
11067726|NCT04302636|No Intervention|General diet group|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
11067727|NCT04302623|Experimental|Face-to-face yoga program|The face-to-face yoga intervention will be delivered in a class setting by a certified yoga instructor in private studio spaces of public libraries across all four quadrants of the city (Calgary, Alberta) over 8 weeks.
11067730|NCT04302610|Sham Comparator|SHAM mask|a sham mask (SHAM) which was the same HME mask with holes cut across the entire ventilator cup and the ventilator removed
11067733|NCT04302597|Experimental|Tissue adhesive|Women who underwent repeated cesarean section with skin closure using 2-octylcyanoacrylate tissue adhesive.
11067734|NCT04302584|Active Comparator|NE|patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
11067735|NCT04302584|Active Comparator|NE/VP|patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
11067736|NCT04302571|No Intervention|Healthy control|Voluntary subjects without peripheral arterial disease
11067737|NCT04302571|Sham Comparator|IC patients, no exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, given advices to perform regular aerobic activity
11067738|NCT04302571|Active Comparator|IC patients, exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, home-based combined physical exercise
11067739|NCT04302558|Experimental|Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while the blood flow to the leg is reduced by a blood flow restriction cuff.
11067740|NCT04302558|Sham Comparator|SHAM Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while a blood flow restriction cuff is applied but inflation pressure will be limited
11067741|NCT04302545|Experimental|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
11067742|NCT04302545|No Intervention|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
11067743|NCT04302532|Active Comparator|Clomiphene|clomiphene citrate 150 mg once a day for 5 days
11067744|NCT04302532|Experimental|clomiphene and coenzyme q10|clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day
11067745|NCT04302519|Experimental|Pulp mesenchymal stem cells|1. 3, 7 days to increase the injection of mesenchymal stem cells
11067746|NCT04302506||Patients with drug-induced liver injury|Patients who underwent liver biopsy and were diagnosed with drug-induced liver injury were diagnosed as DILI.
11067747|NCT04302493|Experimental|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course.
11067748|NCT04302493|Active Comparator|Stroke Support Group (SSG)|As a control group, participants will participate in 8 weeks of weekly Stroke Support Group.
11067749|NCT04302480|Experimental|Alternative smoking products (ASP)|
11067750|NCT04302480|Active Comparator|Sugar-sweetened beverages (SSB)|
11067751|NCT04302467|Experimental|GDFT group|Fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, when SVV>13%, 4 mL/kg bolus of hydroxyethyl starch will be infused within 5 min. If SVV falls below 13%, the bolus will be suspended. If SVV is still more than 13%, 100 μg of phenylephrine will be administered when CI is more than 2.5 L/min/m2, 1 mg of dopamine will be administered when CI is less than 2.5 L/min/m2. When SVV<13%, but mean arterial pressure (MAP)<65 mmHg, 8 μg of norepinephrine will be administered. The hemodynamic status will be repeatedly measured every 10 min.
11067752|NCT04302467|Experimental|restrictive fluid therapy group|fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, hydroxyethyl starch will be infused to supply blood loss, the ratio of hydroxyethyl starch to blood loss is 1:1. 0.01-0.1 μg/kg/min of norepinephrine will be administered to maintain MAP>65 mmHg.
11067753|NCT04302454|Active Comparator|Radiotherapy without hormonal therapy|Metastase-directed radiotherapy without the addition of hormonal therapy
11067754|NCT04302454|Experimental|Radiotherapy combined with hormonal therapy|Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
11067755|NCT04302441|Experimental|NXH group|Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
11067756|NCT04302441|No Intervention|H group|Patients should receive trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year.
11067757|NCT04302428||Pediatric CF Patients|Pediatric patients ages 3 months to 3 years with CF identified via newborn screening.
11067758|NCT04302415||only liver metastasis|There is no other intervention, only clinical treatment.
11067759|NCT04302415||only lung metastasis|There is no other intervention, only clinical treatment.
11067760|NCT04302415||only brain|There is no other intervention, only clinical treatment.
11067761|NCT04302415||No distant metastasis|There is no other intervention, only clinical treatment.
11067762|NCT04302415||More than two organs metastasis|There is no other intervention, only clinical treatment.
11067763|NCT04302402|Active Comparator|Rifaximin|Rifaximin 550mg thrice daily for 14 days Other Name: Normix
11067764|NCT04302402|Placebo Comparator|Placebo|Placebo thrice daily for 14 days
11067765|NCT04302389|Experimental|Virtual Group Coaching Program|This 6-month intervention includes the use of three components: WW's mobile app, Virtual Group Coaching (VGC), and Connect (an online community that has no coach posts). The WW weight loss curriculum involves: self-monitoring of weight, dietary intake, and physical activity; making dietary changes; increasing physical activity; and learning behavioral strategies to manage these goals. Each week, participants will set goals and weigh in with the coach via a private direct message function. The coach will post videos and start conversation threads in the VGC group based on the topic of the week. Participants will be encouraged to use the app and the virtual coaching group daily.
11067766|NCT04302376||Catheter-related thrombosis|The presence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
11067767|NCT04302376||No catheter-related thrombosis|The absence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
11067768|NCT04302363||Control Group|Healthy controls must be 18-75 years old with no tumors and no history of cancer.
11067769|NCT04302363||Test Group|Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.
11067770|NCT04302350|Active Comparator|group A 100% O2|After the targeted segment bronchus, artery, and intrasegmental vein were identified and dissected by ligation or stapler cutting, the sputum suction operation was performed on the healthy and surgical lungs,by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate of the ventilator (group A is 100% O2 ), adjust the APL valve to 20cmHg, so that the storage gas bag is filled with test gas, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg, after the lungs where the target segment is completely expanded, perform pure oxygen mechanical single lung ventilation, waiting for clear presentation of the plane between segments.
11067771|NCT04302350|Experimental|group B 75% N2O|After the surgeon has finely dissected the target artery, vein, and bronchi, accurately judged and processed it,and the patient with the end-of-breath carbon dioxide sampling tube on the monitor was terminated to a portable TD600-SH-N2O detection end of the nitrous oxide concentration detector to measure the test gas concentration (express in vol%), by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate to 1 and N2O flow rate of the ventilator to 3( group B 75% N2O), adjust the APL valve to 20cmHg, making the N2O concentration detector reach the predetermined gas concentration, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg.
11067772|NCT04302350|Experimental|Group C 50% N2O|After the surgeon has finely dissected the target artery, vein, and bronchi, accurately judged and processed it, and the patient with the end-of-breath carbon dioxide sampling tube on the monitor was terminated to a portable TD600-SH-N2O detection end of the nitrous oxide concentration detector to measure the test gas concentration (express in vol%), by adjusting the APL valve (adjustable pressure limit valve) of the anesthesia machine to 0 in advance to exhaust the residual gas in the airbag, change the anesthesia machine to manual control mode, adjust the oxygen flow rate to 1 and N2O flow rate of the ventilator to 1( group C 50% N2O), adjust the APL valve to 20cmHg, making the N2O concentration detector reach the predetermined gas concentration, and test the gas through the dual-lumen tracheal tube to positive pressure ventilation with high frequency and low tidal volume to expand the lungs, the pressure is limited to 20cmHg.
11067773|NCT04302337|Active Comparator|Conventional Curettage Adenoidectomy|Adenoidectomy with Beckmann Adenoid Curette
11067774|NCT04302337|Experimental|Curettage Adenoidectomy With Transoral Endoscopic Ablation|Transoral endoscopic adenoidectomy with Coblator 2 system
11067775|NCT04302324|Experimental|daratumumab/clarithromycin/pomalidomide/dexamethasone|"Induction Phase: 8 cycles (each cycle is 28 days)
~Daratumumab:
~1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8
~Clarithromycin
~500mg PO BID until VGPR or 8 cycles, whichever occurs first
~Pomalidomide 4mg PO on Days 1-21
~Dexamethasone 20mg IV as pre-medication on Day 1, 8, 15, 22 20mg PO on the day after daratumumab for Cycle 1-2 40mg PO pre-daratumumab on Day 1 and 15 for Cycle 3-6 40mg PO on non-daratumumab on Day 8 and 22 for Cycle 3-6 20mg PO pre-daratumumab on Day 1 for Cycle 7-8
~Maintenance Phase: up to 24 months (each cycle is 28 days)
~Daratumumab 1800 mg SC on Day 1
~Pomalidomide 4mg PO on Day 1-21
~Dexamethasone 20mg IV pre-daratumumab on Day 1"
11067776|NCT04302311|Active Comparator|Standard of Care|Holter monitoring
11067777|NCT04302311|Active Comparator|Enhanced Monitoring|Kardia/AliveCor monitoring with additional Holter monitoring as needed
11067778|NCT04302298|Experimental|Virtual Reality Group|This group will go through the virtual reality simulation of a procedure prior to doing it on a plastic SawBone.
11067779|NCT04302298|No Intervention|Technique Guide Group|This group will go be able to read through a technique guide on the procedure prior to doing it on a plastic SawBone. This is the current method of learning in surgical residencies.
11067780|NCT04302285|Experimental|Exercise trial|In this trial, participants were asked to exercise for one hour under controlled laboratory conditions. Participants were exercising on the treadmill at speed and grade corresponding to 60% of their V̇O2max. Participants were wearing a HR monitor and a face mask while exercising, connected to indirect calorimetry equipment. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
11067781|NCT04302285|Experimental|Control trial|In this trial, participants were asked to rest for one hour. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
11067782|NCT04302259|Experimental|SCI Patient|Complete or Incomplete Spinal Cord Injury (SCI) patients with Asia Impairment Score (AIS) of A or B between the levels of C7/T1 and T10
11067783|NCT04302233|Experimental|New pharmaceutical support (NPS)|"An NPS is an interview comprising the following elements:
~The delivery of the identification sheet of their implants with:
~a quiz to focus the patient's attention
~a description of the characteristics of their prosthesis using a specific photo of their implant
~a presentation of the medical device vigilance.
~an explanation of the value of the identification sheet for their implant, An in-depth presentation of an information booklet on living at home with their prosthesis and on medical and paramedical monitoring.
~For patients in orthopedic surgery: a booklet specific to their prosthesis and the surgical approach For plastic surgery patients, the information sheets published by the French Society of Plastic Reconstructive and Aesthetic Surgery (SOF.CPRE).
~A time to answer any questions the patient may have"
11067784|NCT04302233|No Intervention|Usual pharmaceutical support (UPS)|"An UPS is an interview comprising the following elements:
~The delivery of the same patient-implant sheet as in arm 1, but without additional oral information.
~The delivery and oral presentation of the same booklet as practiced in the arm 1 (NPS).
~And a time to answer any questions from the patient months"
11067785|NCT04302220||high myopia|Population who have high myopia.
11069506|NCT04289649|Active Comparator|Pitavastatin 2 mg|K-924 LD Placebo tablet once daily
11067786|NCT04302207|Experimental|High intervention hospital (Nationwide Childrens Hospital)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; provider surveys measuring the acceptability, appropriateness, feasibility, and perceived burden of piloted strategies; review of patient data extracted from electronic health record 1-year pilot, 10 months post-pilot data
11067787|NCT04302207|No Intervention|Low intervention hospital (Childrens Hospital Colorado)|patients 1-23 months with Bronchiolitis seen in emergency department, urgent care or admitted patients will be included; review of patient data extracted from electronic health record 1-year pilot, 10 months post-pilot data
11067788|NCT04302194||Patients with Phenylketonuria|
11067789|NCT04302194||normal healthy children|
11067790|NCT04302181|Experimental|Stellate Ganglion Block|One time administration of a stellate ganglion block
11067791|NCT04302168|Active Comparator|Choline Supplement Group|Choline Supplement 470 mg twice daily for total of 8 weeks.
11067792|NCT04302168|Placebo Comparator|Placebo Group|Placebo pill twice daily for total of 8 weeks.
11067793|NCT04302155|Experimental|Nintendo Wii|Balance-specific exer-games focusing on dynamic aspects of center of pressure (COP) on Wii fit system.
11067794|NCT04302155|Experimental|Traditional|Mini trampoline two balance exercises of 6 minutes on mini trampoline for a total duration of 3 min on each leg Inflatable discs 4 balance exercises of 12 minutes on BOSU ball 6 minutes on rounded side and 6 minutes on rigid side.
11067795|NCT04302142|Experimental|Intervention group|
11067796|NCT04302142|Placebo Comparator|Control Group|
11067797|NCT04302129|Experimental|ultrasound guided erector spinae block and general anaesthesia|Ultrasound guided erector spine plane block is done after general anaesthesia and prone positioning
11067798|NCT04302129|Active Comparator|Multimodal analgesia with general anaesthesia|Multimodal analgesia given with general anaesthesia in form of ketorolac and paracetamol
11067799|NCT04302116|Experimental|Combination therapy with vigabatrin and prednisolone|"Vigabatrin (tablet of 500 mg) dose based on weight divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment. Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks.
~Prednisolone (tablet of 5 mg), 40 mg of prednisolone (10 mg oral 4 times a day) for 14 days. Prednisolone will be increased to 60 mg/day (20 mg oral 3 times a day) if seizures still occur at Day 7 or recur within Day 8 - 14. Then, prednisolone will be reduced every 5 day until completely off within 1 month. Total prednisolone duration is 1 month."
11067800|NCT04302116|Active Comparator|Vigabatrin alone|"Vigabatrin (500 mg/tab) dose will be calculated on weight basis divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment.
~Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks."
11067801|NCT04302103|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
11067802|NCT04302103|Experimental|RC18 240 mg|Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
11067803|NCT04302090|Experimental|pain level changes according to the use of the Winner flow|"each included patient will experience :
~a period of consecutive spontaneous uterine contractions without using the regulated expiration mouthpiece
~a period of consecutive uterine contractions managed by the regulated expiration method using the Winner flow"
11067804|NCT04302077|Active Comparator|Telemedicine Post Op|Patients with an even-ending medical record number (0,2,4,6,8) will be randomized to virtual visit/telemedicine. This will be done by using Epic and MyChart-integrated telemedicine functionality for video visits with the Principal Investigator's patients. This is considered standard of care.
11067805|NCT04302077|Active Comparator|In-Office Post Op|Patients with an odd-ending medical record number (1,3,5,7,9) will be randomized to the office visit.
11067806|NCT04302064|Experimental|AKCEA-TTR-LRx|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of AKCEA-TTR-LRx administered SC.
11067807|NCT04302064|Placebo Comparator|Placebo|Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of AKCEA-TTR-LRx-matching placebo administered SC.
11067808|NCT04302051||Study Group|The hepatic fat estimation will be performed on the same subjects with the use of the thermo-acoustic device and by MRI-PDFF. The data obtained from the two estimations will be compared.
11067809|NCT04302038|Experimental|Potato protein|Participants will be provided with 25 g of potato protein twice per day in addition to a diet set at the recommended daily allowance. Total protein intake for this group will be 1.6 g/kg/day
11067810|NCT04302038|Placebo Comparator|Control group|This group will consume protein from food sources set at 0.8 /kg/day including 2 pudding placebo cups per day.
11067811|NCT04302025|Experimental|ALK Cohort|Patients will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All patients that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with alectinib. Choice of adjuvant treatment will be at the discretion of the treating physician, depending on the disease stage, as deemed clinically appropriate.
11067812|NCT04302025|Experimental|ROS 1 Cohort|Patients will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All patients that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Choice of adjuvant treatment will be at the discretion of the treating physician, depending on the disease stage, as deemed clinically appropriate.
11067813|NCT04302025|Experimental|NTRK Cohort|Patients will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All patients that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Choice of adjuvant treatment will be at the discretion of the treating physician, depending on the disease stage, as deemed clinically appropriate.
11067844|NCT04301765|Placebo Comparator|placebo gel|The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
11067845|NCT04301752||Neurobrucellosis|Brucellosis associated with neuropsychiatric manifestations
11067814|NCT04302025|Experimental|BRAF Cohort|Patients will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All patients that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with vemurafenib plus cobimetinib. Choice of adjuvant treatment will be at the discretion of the treating physician, depending on the disease stage, as deemed clinically appropriate.
11067815|NCT04301999|Active Comparator|PDT group|Patients in PDT group underwnt PDT
11067816|NCT04301999|Experimental|RFA group|Patients in RFA group underwent RFA
11067817|NCT04301986|Experimental|TNE Followed by EGD|Subjects will undergo administration of a transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
11067818|NCT04301986|Experimental|Cytosponge, then TNE, followed by EGD|Subjects will undergo administration of Cytosponge and transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
11067819|NCT04301973|Other|Healthy people|
11067820|NCT04301960|Experimental|Single task group|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
11067821|NCT04301960|Experimental|Dual-task|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
11067822|NCT04301947|Active Comparator|Standard warm-up protocol|The standard warm-up protocol consists of 5 (five) minutes of stationary cycling, followed by calf, hamstring and quadriceps stretching. For all stretching positions 30 (thirty) seconds will be set. For calf stretching, the participant places his hands on the waist and projects his dominant limb behind of the center of mass line, the contralateral limb will be placed forward until the stretch sensation on the dominant limb start. For hamstring stretching, the participant will be instructed to bend over the hip, reaching the foot of the dominant limb in dorsiflexion. Emphasis will be placed on maintaining the heel of the dominant limb on the floor and maintaining posture. Finally, for quadriceps stretching, the participant will perform a knee flexion and will hold the dominant lower limb foot close to the gluteus with the ipsilateral upper limb hand. Emphasis will be placed on maintaining trunk posture.
11067823|NCT04301947|Experimental|Gluteal activation warm-up|"The gluteal activation warm-up protocol consists of performing a standard warm-up protocol with additional shell exercise. The shell exercise will be performed with the participant side-lying with hip and knee flexed, an elastic band (PREFORM BETTER Inc. Rhode Island, USA) will be placed around the distal thigh to promote resistance and the participants will be instructed to perform hip abduction movements. The exercise will be performed in multiple sets (3 sets) of 12 repetitions, with 30 seconds interval between exercises in order to minimize the fatigue effect. Medium and heavy elastic bands tensions will be used and adjusted according to the effort perception parameter from the OMNI scale for effort perception for resistance training."
11067824|NCT04301934|Active Comparator|Vaginal Estrogen Therapy Group|Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
11067825|NCT04301934|Experimental|Laser Therapy Group|Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.
11067826|NCT04301921|Other|Group 1|Traditional puncture site + no anticoagulation
11067827|NCT04301921|Other|Group 2|Traditional puncture site + ACT-guided anticoagulation
11067828|NCT04301908||antiviral therapy group|Patients with chronic hepatitis B and cirrhosis were treated with antiviral drugs
11067829|NCT04301895|Other|Interactive|Subject will be asked to continually interactive with the investigators, answering a series of standard questions during the remifentanil infusion and recovery periods.
11067830|NCT04301895|Other|Non-interactive|All verbal interaction will be avoided and extraneous sounds will be eliminated from the environment during the remifentanil infusion and recovery periods.
11067831|NCT04301882||interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
11067832|NCT04301882||direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
11067833|NCT04301869|Active Comparator|Intravenous therapy|Intravenous antibiotics administered for pleural space infection
11067834|NCT04301869|Active Comparator|Oral therapy|Oral antibiotics administered for pleural space infection
11067835|NCT04301856||CF children treated with CFTR modul|Cystic fibrosis patients under 18 years treated with CFTR modulators according to french health recommendations observational cohort study
11067836|NCT04301843|Experimental|Eflornithine (DFMO)|"In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.
~Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.
~DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study."
11067837|NCT04301830||Spinal anesthesia|Patients undergoing cesarean section under spinal anesthesia
11067838|NCT04301817||Prone position|Patients undergoing surgery in prone position
11067839|NCT04301804|Experimental|Dose level 1|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 1
11067840|NCT04301804|Experimental|Dose level 2|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 2
11067841|NCT04301804|Experimental|Dose level 3|Subjects will be randomised to receive a single dose of SHR6390 at Dose level 3
11067842|NCT04301778|Experimental|Durvalumab and SNDX-6352|Participants will receive Durvalumab and SNDX-6352.
11067843|NCT04301765|Experimental|testosterone 1.62% gel|Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
11067847|NCT04301739|Experimental|HLX10 + chemotherapy→ HLX10|HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles)
11067848|NCT04301739|Placebo Comparator|Placebo + chemotherapy→ Placebo|Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → Placebo (9 cycles)
11067849|NCT04301726|Experimental|Deutetrabenazine|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
11067850|NCT04301726|Placebo Comparator|Placebo|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
11067851|NCT04301700|Experimental|relaxation|The progressive muscle relaxation intervention, designed by Jacobson (1987), will be consist of sessions involving straining and relaxing all muscle groups from head to foot with deep breathing and last for 20 min. The patients will be asked to tense a very muscle group for 5 s and relax after counting up to 10 s while breathing out. In this way, facial, head, neck, shoulders, arms, chest, abdomen, legs, hips, feet and fingers muscles are stretched and relaxed on purpose for relaxing in patients with COPD.
11067852|NCT04301700|Experimental|mindfulness meditation|The research team closely will be following the mindfulness meditation intervention, developed by Kabat-Zinn, Lipworth, and Burney (1985), which is a part of the mindfulness-based stress reduction program. Mindfulness meditation is including interventions such as yoga, body scan, walking meditation, and sitting meditations. In the present study, the researchers will prefer sitting meditation. In this context, the second co-author will want patients to sit up in the chair in an upright and comfortable position. The patients will focus on deep breathing and felled the breath flowing throughout their body during the interventions that will last for 20 min in each session.
11067853|NCT04301700|No Intervention|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
11067854|NCT04301687|Experimental|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
11067855|NCT04301687|Placebo Comparator|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
11067856|NCT04301674||Occupational Asthma|Patients refered for assesment of occupational asthma
11067857|NCT04301674||Respiratory Healthy Control|Employees at Oslo University Hospital
11067858|NCT04301661||ABC/3TC Cohort|"Persons on abacavir/lamivudine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.
~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
11067859|NCT04301661||TAF/FTC Cohort|"Persons on tenofovir alafenamide/emtricitabine-containing therapy as part of their standard HIV care will continue to take their prescribed HIV medications.
~Participants will be on study for 4 weeks, and will participate in directly observed therapy for the 4 weeks leading up to a single blood draw."
11067860|NCT04301661||Switch Cohort|"Persons switching from abacavir/lamivudine-containing therapy as part of their standard HIV care will change to their newly prescribed regimen.
~Participants will be on study for 3 weeks, and will have blood drawn at Days 0, 1, 3, 7, 10, 14, 18, and 21 following their switch."
11067861|NCT04301648|Active Comparator|Common Practice|Patients included in the phase before will receive common practice.
11067862|NCT04301648|Experimental|STAR Nurse|Patients included in the phase after will receive care by a STAR Nurse.
11067863|NCT04301635||Preoperative (Pre-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, preoperative
11067864|NCT04301635||Postoperative (Post-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, postoperative
11067865|NCT04301609|Active Comparator|ImmunoVita®|250 mg Yeast beta-glucan + 3.75 microg Vitamin D3 + 1.05 mg Vitamin B6 + 7.5 mg zinc)
11067866|NCT04301609|Placebo Comparator|Placebo|473,2 mg microcristalline cellulose + 0,06 mg Brown Oxide dye + 0,27 mg yellow A oxide dye
11067867|NCT04301596||SSc patients|
11067868|NCT04301583|Active Comparator|Procyanidin B2 enriched cocoa|Participants receiving cocoa capsules
11067869|NCT04301583|Placebo Comparator|Placebo group|Participants maltodextrin capsules
11067870|NCT04301570|Other|Ultrasound|The intervention measurement is the determination of bone age using the ultrasound device.
11067871|NCT04301570|Other|XR|The control measurement is the determination of the bone age by the imaging method using X-rays.
11067872|NCT04301557|Experimental|PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC|Induction regimen: Capeox+PD1 antibody for 1 cycle, Concurrent chemoradiotherapy regimen: Capeox+PD1 antibody for 2 cycles and concurrent , Interval regimen: Capeox+PD1 antibody for 1 cycle, TME surgery or watch and wait for cCR patients Adjuvant regimen: Capeox+PD1 antibody for 2 cycles, Capecitabine+PD1 antibody for 2 cycles
11067873|NCT04301544|Experimental|INDAK & Standardized Vascular Care Group|The experimental arm will receive training on the ballroom dance modules called INDAK (Improving Neurocognition through Dance and Kinesthetics), nutrition counseling and vascular risks management
11067874|NCT04301544|Active Comparator|Standardized Vascular Care Group|The control group will receive nutrition counseling and vascular risks management
11067875|NCT04301531|Experimental|Arm 1 (intervention arm)|Arm 1 or the intervention arm will involve seven communities: 4-monthly mass screening, and treatment of those who test positive by CHWs will be conducted. Febrile cases will be tested and treated by CHWs any time
11067876|NCT04301531|Other|Arm 2 (control arm)|Arm 2 or the Control arm will involve 2 communities: mass screening and treatment only done at baseline and at evaluation. Febrile cases will be tested and treated by CHWs any time.
11067877|NCT04301518|Experimental|PTB Prevention|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
11069507|NCT04289649|Active Comparator|Pitavastatin 4 mg|K-924 HD Placebo tablet once daily
11067878|NCT04301518|No Intervention|Control|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the Control arm will not receive the PreTRM® test results. Control arm subjects will continue on with standard of care.
11067879|NCT04301505|No Intervention|control|Usual care.
11067880|NCT04301505|Other|Intervention 1|COPD management checklist will be delivered at the beginning of the study.
11067881|NCT04301505|Other|Intervention 2|COPD management checklist will be delivered at the beginning of the study and repeated after 6 months.
11067882|NCT04301492|Experimental|Vortioxetine|first visit medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit (Week 1 - Visit 2) to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day (Visit 3- Phone contact). At Week 4-8-12 (Visits 4-5-6) patients will return to the site to perform all clinical evaluations required and to receive study drug. Visit 7 subjects will return to the site to perform all the assessment required by protocol.
11067883|NCT04301479|Active Comparator|Steroid|Patients assigned for steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
11067884|NCT04301479|Placebo Comparator|Control|Patients assigned for control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
11067885|NCT04301466|Experimental|Qi Zhi Tong Luo group|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. Each capsule was weighted 0.5g. Qi Zhi Tong Luo capsule (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
11067886|NCT04301466|Placebo Comparator|Placebo group|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
11067887|NCT04301453|Experimental|Maternal Scent Group|Infants in this group will be exposed to a breast pad worn by their mothers to extract maternal scent. This exposure will last 24 hours.
11067888|NCT04301453|No Intervention|Control Group|Infants in this group will receive standard of care.
11067889|NCT04301440|Other|patients with anxious and / or depressive characteristics|patients with anxious and / or depressive characteristics
11067890|NCT04301427|Other|Obese patient|
11067891|NCT04301414|Other|Safety lead-in|The first 4 subjects enrolled will be given degarelix plus BMS-986218.
11067892|NCT04301414|Active Comparator|Arm A|Degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy
11067893|NCT04301414|Experimental|Arm B|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy.
11067894|NCT04301401|Experimental|Patients being evaluated for changes in microbiota|Patients being evaluated for changes in vaginal microbiota following transvaginal surgery.
11067895|NCT04301388|Experimental|TVCL-based|Monitor progression of labor by shortening of cervix examined by transvaginal cervical length
11067896|NCT04301388|Active Comparator|Conventional-based|Monitor progression of labor by per vaginal exam to detect cervical change
11067897|NCT04301375|Experimental|Study treatment|
11067898|NCT04301349|Experimental|vaginal dinoprostone|vaginal dinoprostone 6 mg (two tablets) 3 hours prior to IUD insertion
11067899|NCT04301349|Active Comparator|vaginal misoprostol|vaginal misoprostol 400 mcg (two tablets) 3 hours prior to IUD insertion
11067900|NCT04301349|Placebo Comparator|placebo|two tablets of placebo similar in shape ,color, odor to the study drugs
11067901|NCT04301336|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
11067902|NCT04301336|Experimental|Vit-D experimental group|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
11067903|NCT04301336|Experimental|Zinc supplements experimental group|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
11067904|NCT04301336|Experimental|Statin experimental group|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
11067905|NCT04301336|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
~in addition, Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response in addition, Morphine medication as a pain killer is administered, if Patient weight <50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
~This group received regular blood transfusion session."
11067906|NCT04301323|Experimental|BHVI1|BHVI1 eye drops
11067907|NCT04301323|Experimental|BHVI2|BHVI2 eye drops
11067908|NCT04301323|Experimental|BHVI3|Combination of BHVI1 and BHVI2 eye drops
11067909|NCT04301323|No Intervention|Non-randomized control group|a separate control group including 105 children enrolled and followed with only single-vision spectacles.
11067910|NCT04301310|Experimental|Treatment Group|
11067911|NCT04301284|Experimental|CAD-1883|"Capsules of 150 mg of CAD-1883 will be administered orally, twice daily (BID). The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
~The initial dose regimen evaluated will be 150 mg BID. Additional dose regimens up to 600 mg BID will be determined based on forthcoming clinical data."
11067912|NCT04301284|Placebo Comparator|Placebo|Matching placebo will be provided in capsules, to be administered orally, twice daily. The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
11067913|NCT04301271|Experimental|Simvastatin|Simvastatin and Escitalopram
11067914|NCT04301271|Placebo Comparator|Placebo|Placebo and Escitalopram
11067915|NCT04301258||Articular Cartilage Defect of the Knee|Patients, who undergo an articular cartilage repair of the knee using ProChondrix CR.
11067916|NCT04301258||Articular Cartilage Defect of the Ankle|Patients, who undergo an articular cartilage repair of the ankle using ProChondrix CR.
11067917|NCT04301258||Articular Cartilage Defect of the Foot|Patients, who undergo an articular cartilage repair of the foot using ProChondrix CR.
11067918|NCT04301258||Articular Cartilage Defect of the Hip|Patients, who undergo an articular cartilage repair of the hip using ProChondrix CR.
11067919|NCT04301245||ETEP group|Exercise Training and Educational Program (ETEP) group. Patients who accepted the educational program in addition to the exercise training.
11067920|NCT04301245||ET group|Exercise Training (ET) group. Patients who refused the educational program and did only the exercise training.
11067921|NCT04301232||Fast-Track Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Patients who fulfilled criteria of all scoring systems were defined as eligible for PACU by-pass (fast-tracking) and transferred into phase II recovery area in the ward without observation in PACU (Group FT = Fast Track;)
11067922|NCT04301232||PACU Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Ineligible patients were taken into PACU where their treatments were continued until discharge criteria were achieved (Group PACU)
11067923|NCT04301206|Experimental|Intervention: Receiving video material|The parents who accepts to participate and receives videos and action cards by sms
11067924|NCT04301206|No Intervention|Control group|The parents who accepts to participate, but proceed to 1813 and do not receive videos and action cards
11067925|NCT04301193|Other|Pregnant Women|All subjects will have the same intervention. Samples will be taken and manipulated in the laboratory for use of the Hemosonic Qauntra Analyzer
11067926|NCT04301180|Experimental|Experimental|"The experimental group conducted 10 weekly sessions, with an approximate duration of 45 minutes per session, which consisted of the presentation of food education content while conducting an orchard with seasonal vegetables. Simple recipes were also described in which these vegetables were included to be made at home, along with information on children's books that dealt with the topic of food and were available in the public library.
~All children in the experimental groups were given written instructions so that they could perform at their home, together with their parents, the manipulative activities suggested each week. All these contents were common for all the participants in the study. Session material was renewed weekly."
11067927|NCT04301180|No Intervention|Control|"The control group received the usual training corresponding to the contents of the human body module that is currently taught in each center."
11067928|NCT04301167|Experimental|Single group|An AB single-case experimental design will be used. An RCT would be inappropriate since the befriending intervention is known to improve wellbeing. As such participants will have data collected in a pre- and post-intervention phase, for a maximum of 13 time points. This approach has been identified by What Works Clearinghouse as an acceptable empirical design to include in evidence based practice reviews (Kratchowill et al., 2010).
11067929|NCT04301154|Experimental|Group A|25 study participants aged ≥ 9 years will be enrolled and randomized into arms 1, 2 and 3. They will be from 3 different study sites (Stellenbosch University, Cape Town, South Africa; Chulalongkorn University, Bangkok, Thailand; Children's Hospital Bambino Gesù, Rome, Italy). The rationale for including aged 9 and above is because Cervarix is licensed for age ≥ 9 years.
11067930|NCT04301154|Experimental|Group B|20 participants will be enrolled to investigate the effects of vaccination with HIVIS DNA ± Cervarix and MVA-CMDR in youth previously enrolled in the PEDVAC study in which 10 had received HIVIS DNA and 10 did not receive vaccine in 2009-2012. They are perinatally HIV-infected and currently being followed at the Children's Hospital Bambino Gesù in Rome. Their median (range) ages are 21 (15 to 25) years old.
11067931|NCT04301141|Experimental|Virtual Reality Assisted Cognitive Behavioural Therapy|Between 8 to 20 individual in-person sessions of VR-assisted CBT will be delivered on a weekly basis by NHS therapists who are trained in delivering CBT to this patient group.
11067932|NCT04301128|Experimental|EXPERIMENTAL GROUP|Patients in the experimental group were able to install and set up mobile application on android phones via Bluetooth and were informed about the sick android application. Patients were reminded and guided by subcutaneous anti-TNF drug treatments from mobile application. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales.
11067933|NCT04301128|Active Comparator|CONTROL GROUP|An anti-TNF drug administration training booklet were given to patients in the control group and were required to take advantage of the booklet on subcutaneous anti-TNF drug production. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales. At the end of the study (twenty forth week) was applied to all patients.
11067934|NCT04301115|Active Comparator|conventional group|conventional partial denture
11067935|NCT04301115|Experimental|attachment group|unlateral attachment retained partial denture
11067936|NCT04301115|Experimental|tooth implant supporeted prosthesis|tooth implant supported bridge
11067968|NCT04300894|Experimental|Mamma Mia Plus group|"Usual prenatal/postpartum care plus use of the Mamma Mia program plus occasional contacts from study staff"
11067969|NCT04300881|Experimental|Treatment|Eplerenone
11067937|NCT04301102|Experimental|Experimental|"Hemodynamic management will be based on the functional hemodynamic parameters provided by Hemosphere platform with the Acumen IQ sensor, including cardiac output, stroke volume, SVV and Acumen IQ specific parameters: maximal arterial pressure rise (dP/dtmax), dynamic arterial elastance (Eadyn) and HPI
~As a pattern replacement of interstitial space, we will use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.
~The protocol of action on the intravascular space will be based on the maintenance of systolic volume with colloids (hydroxyethyl starch - Voluvén®)."
11067938|NCT04301102|Other|Control|"Hemodynamic management will be based on the functional hemodynamic parameters provided by the HemoSphere platform® with the FloTrac® sensor, including cardiac output (CO), stroke volume (SV), and stroke volume variation (SVV)
~As a pattern replacement of interstitial space, we use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.
~The protocol action for the intravascular space will be based on a recently published hemodynamic optimization algorithm (Heming N, Moine P, Coscas R, Annane D. Perioperative fluid management for major elective surgery. British Journal of Surgery. 2020;107:e56-62). The fluid used will be hydroxyethyl starch (Voluven®)."
11067939|NCT04301089|Experimental|Experimental intervention|Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
11067940|NCT04301076|Experimental|Treatment (lenalidomide, EPOCH)|"INDUCTION THERAPY: Patients receive lenalidomide PO QD on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients also receive doxorubicin hydrochloride IV continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients with CR, PR, or SD may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity."
11067941|NCT04301063||RV3278A arm|"study product RV3278A is applied twice a day on the face during the whole study.
~In case of reaction resulting from the use of the product, the subject will inform the investigator who will explain to him/her what to do : application reduction or stop applications for a while"
11067942|NCT04301050|Experimental|Yoga Intervention|Participants will complete 8-week course (75-minute, weekly yoga classes) delivered online via videoconferencing software. Participants will complete patient-reported outcomes at baseline (prior to class 1) and post-intervention (after class 8), as well as post-intervention measures of feasibility/acceptability.
11067943|NCT04301037|Active Comparator|Tension band wiring|This group was treated by k-wires fixation and tension band wiring
11067944|NCT04301037|Active Comparator|Cannulated screws|This group was treated by 2 cannulated screws
11067945|NCT04301024||nitrous oxide misusers|nitrous oxide misusers among the teenagers consulting in an addictology center dedicated to young drug users in Montpellier
11067946|NCT04301011|Experimental|Arm A: TBio-6517 alone|Dose escalation of TBio-6517 alone administered by direct injection into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months.
11067947|NCT04301011|Experimental|Arm B: TBio-6517 and Pembrolizumab|Dose escalation of TBio-6517 administered in combination with pembrolizumab. TBio-6517 will be directly injected into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 8 via intravenous (IV) infusion every 3 weeks for up to 24 months.
11067948|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in MSS-CRC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with microsatellite stable colorectal carcinoma (MSS-CRC). Booster injections of TBio-6517 are permitted for up to 24 months.
11067949|NCT04301011|Experimental|TBio-6517 and Pembrolizumab in TNBC|Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with triple negative breast cancer (TNBC). Booster injections of TBio-6517 are permitted for up to 24 months.
11067950|NCT04300998||B-cell lymphoma|Participants are undergoing CART therapy for relapsed refractory high-grade B-cell lymphoma
11067951|NCT04300985|Sham Comparator|Placebo group|Thirty patients in this group will receive infusion of 100 saline solution. After 15 min of beginning of this infusion they will start receiving general anesthesia administration.
11067952|NCT04300985|Active Comparator|Dexmedetomidine group|Thirty patients in this group will receive infusion of dexmedetomidine (0,5 mcg/kg/min). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
11067953|NCT04300985|Active Comparator|Magnesium sulfate group|Thirty patients in this group will receive infusion of magnesium sulfate (20 mg/kg/h). After 15 min of the beginning of this infusion they will start in the general anesthesia induction.
11067954|NCT04300972|Other|fixed dose|
11067955|NCT04300972|Experimental|weight and body type adapted dose|
11067956|NCT04300959|Experimental|Experimental group|Anlotinib in combination with Sintilimab with Gemcitabine plus(+)Cisplatin
11067957|NCT04300959|Active Comparator|Control group|Standard platinum-based chemotherapy
11067958|NCT04300946||TMS on the cerebellum followed by placebo TMS|TMS preceding the time prediction and language tests
11067959|NCT04300946||Placebo TMS followed by TMS on the cerebellum|TMS preceding the time prediction and language tests
11067960|NCT04300946||TMS on the cerebellum set in time on waiting periods|
11067961|NCT04300946||TMS on the cerebellum not set in time on waiting periods|
11067962|NCT04300933|Experimental|Neurofeedback therapy|Fifty participants conduct neurofeedback daily for 5 days.
11067963|NCT04300920|Experimental|N-acetylcysteine|600 mg oral N-acetylcysteine (NAC) three times daily for 24 months.
11067964|NCT04300920|Placebo Comparator|Placebo|Placebo tablet three times daily for 24 months.
11067965|NCT04300907|Experimental|Provant Infinity Therapy|Open-label treatment with Provant Infinity Therapy
11067966|NCT04300894|No Intervention|Usual care group|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
11067967|NCT04300894|Experimental|Mamma Mia group|"Usual prenatal/postpartum care plus use of the Mamma Mia program"
11067971|NCT04300855|Experimental|Sunphenon® 90D|Participants will be administered a standardized formulation of whole Green Tea Catechin for 24 months. The daily dose of Green Tea Catechin will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
11067972|NCT04300855|Placebo Comparator|Placebo|Participants will be administered a placebo for 24 months. The daily dose of placebo will be taken in divided doses, three capsules in the morning and 3 capsules in the evening, with food (within one hour of eating a substantial meal). On the day of monthly follow-up visit, capsules should be taken within 4 hours of visit and blood draw for required lab work. If the participant is scheduled to come in the afternoon, dose should be taken with lunch that day instead of with dinner for that day.
11067973|NCT04300842||Cancer patient|This project expects to enroll 60 cancer patients and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
11067974|NCT04300842||Healthy population|This project expects to enroll 60 healthy population and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
11067975|NCT04300829|Experimental|Simple hygiene rules of the site + Cicaderma ointment|Hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and Cicaderma ointment application)
11067976|NCT04300829|Active Comparator|Preventive standard cares|Preventive standard cares of the site including hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and a maximum of one topical treatment
11067977|NCT04300816|Experimental|CBT-UT|Seven telephone-based sessions of cognitive behavioral therapy for uncertainty tolerance (CBT-UT) delivered over seven weeks.
11067978|NCT04300816|Active Comparator|tCBT|Seven telephone-based sessions of traditional cognitive behavioral therapy (tCBT) delivered over seven weeks.
11067979|NCT04300816|No Intervention|TAU|Participant continues with their lives as they normally would.
11067980|NCT04300790|Experimental|CohortA: Normal fasting glycemia|"Alpelisib plus metformin and fulvestrant: During the first cycle, patients will receive fulvestrant and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (one tablet of 200mg and two tablets of 50mg once a day) on a continuous dosing schedule starting on Cycle 1• Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.
~Fulvestrant: 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles)."
11067981|NCT04300790|Experimental|CohortB: Fasting glycemia|"Alpelisib plus metformin and fulvestrant: During the first cycle, patients will receive fulvestrant and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (one tablet of 200mg and two tablets of 50mg once a day) on a continuous dosing schedule starting on Cycle 1• Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.
~Fulvestrant: 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles)."
11067982|NCT04300777||Treated with Non-Cervical Pedicle Screw Systems|
11067983|NCT04300764|No Intervention|Control|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Control participants' steps will be passively monitored. Data will continue to be collected for 30 days after discharge.
11067984|NCT04300764|Experimental|Gamification Intervention|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Intervention patients will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Data will continue to be collected for 30 days after discharge.
11067985|NCT04300751|Experimental|Alcohol|Participants will receive experimental doses of active or placebo alcohol, p.o. Alcohol/placebo will be administered once per session.
11067986|NCT04300751|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered orally
11067987|NCT04300751|Experimental|Opioid Agonist/Alcohol Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with experimental doses of active alcohol placebo. Opioid/placebo and alcohol/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Both opioid and alcohol doses will be administered orally.
11067988|NCT04300738|Other|Patients undergoing CT scann for CCS determination|
11067989|NCT04300725|No Intervention|Verbal Counseling|Patients in one study arm receive only verbal counseling prior to their induction of labor.
11067990|NCT04300725|Experimental|Video Counseling|Patients in other study arm will receive verbal + video counseling prior to their induction of labor.
11067991|NCT04300712|Other|Tracking of the children with difficulties|All parents and teachers will respond to the questionnaires and the beginning and end of school year which is not done in the routine for tracking the children in difficulty.
11067992|NCT04300699|Other|Ovarian cancer patients over 70 years receiving chemotherapy|Patients with ovarian cancer receiving chemotherapy as either first line treatment (i.e. newly diagnosed advanced stage III/IV cancer) or at first relapse. Patients to receive a Geriatric Assessment including interventions for functional or other identified deficits and appropriate specialist algorithm-determined interventions.
11067993|NCT04300686|Active Comparator|Tocilizumab|This group of 20 TAK cases are prescribed with tocilizumab (Dose: 8mg/kg. qm. ivgtt.) for 24 weeks.
11067994|NCT04300686|Experimental|Adalimumab|This group of 20 TAK cases are prescribed with adalimumab (Dose: 40mg.bim.IH.) for 24 weeks.
11067995|NCT04300673|Experimental|All patients|Intervention: radio guided surgery
11067996|NCT04300647|Experimental|Tiragolumab plus Atezolizumab|Participants will receive tiragolumab and atezolizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11067997|NCT04300647|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11067998|NCT04300634||Children whose parents are physiotherapists|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
11067999|NCT04300634||Children whose parents are athletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
11068000|NCT04300634||Parents of children who are atletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
11068001|NCT04300634||Parents of children who are physiotherapist|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
11068002|NCT04300621|Experimental|Treatment Sequence 1: OTF 1, 4, 2, 3|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 1 in period 1; followed by OTF 4 in period 2; followed by OTF 2 in period 3; followed by OTF 3 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
11068003|NCT04300621|Experimental|Treatment Sequence 2: OTF 2, 1, 3, 4|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
11068004|NCT04300621|Experimental|Treatment Sequence 3: OTF 3, 2, 4, 1|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 3 in period 1; followed by OTF 2 in period 2; followed by OTF 4 in period 3; followed by OTF 1 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
11068005|NCT04300621|Experimental|Treatment Sequence 4: OTF 4, 3, 1, 2|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 4 in period 1; followed by OTF 3 in period 2; followed by OTF 1 in period 3; followed by OTF 2 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
11068006|NCT04300595|Active Comparator|general anesthesia (Group G)|Patients receive general anesthesia with intravenous opioids and local infiltration of saline (Group G)
11068007|NCT04300595|Active Comparator|Local anesthesia (Group L)|Patients receive general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).
11068008|NCT04300582|Active Comparator|Standard pharmaco-invasive strategy|Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.
11068009|NCT04300582|Experimental|Fast pharmaco-invasive strategy|Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.
11068010|NCT04300569||Patients and Caregivers: Overall Population|"Overall population of this study will include both patients with ISWRD associated with AD-D, AD-D with CVD, and/or VaD, and care givers of patients. Patients and caregivers will undergo all study procedures. Caregivers may care either for a patients who undergo all study procedure (including interview) as well for patients who do not undergo any study procedures but give consent or assent for the use of their medical records in the study (non-interviewed patient)."
11068011|NCT04300556|Experimental|MORAb-202|"Dose Escalation: Participants will receive MORAb-202 at a starting dose of 0.9, 1.2, 1.6 milligram per kilogram (mg/kg) administered as an intravenous infusion once every 3 weeks in a 21 days cycle.
~Expansion: Participants will receive MORAb-202 at a recommended Phase 2 dose (RP2D) determined in dose escalation part, administered as an intravenous infusion once every 3 weeks in a 21 days cycle."
11068012|NCT04300543||Group 1 MS patients|patients with multiple sclerosis
11068013|NCT04300543||Group 2 patients with other neurological disorders|patients with inflammatory or non inflammatory neurological diseases other than multiple sclerosis
11068014|NCT04300543||Group 3 healthy control|No neurological or immunological disease
11068015|NCT04300517|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
11068016|NCT04300517|Placebo Comparator|maltodextrin|Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.
11100857|NCT04071119|Active Comparator|Oxytocin nasal spray|
11068017|NCT04300504||normal weight, not dynapenic|BMI 18.5 to 25kg/m2 healthy women aged 60-80 years,time to complete 5 chair stands <15 seconds
11068018|NCT04300504||normal weight, dynapenic|BMI 18.5 to 25kg/m2 healthy women aged 60-80 years, time to complete 5 chair stands >15 seconds
11068019|NCT04300504||obese, not dynapenic|BMI 30 to 40kg/m2 healthy women aged 60-80 years, time to complete 5 chair stands <15 seconds
11068020|NCT04300504||obese, dynapenic|BMI 30 to 40kg/m2 healthy women aged 60-80 years, time to complete 5 chair stands >15 seconds
11068021|NCT04300491||Beneficiaries of suspension walking|
11068022|NCT04300491||Non-Beneficiaries of suspension walking|
11068023|NCT04300478|Other|Sedentary Control/REx|Subjects will complete the Sedentary control testing sessions, have a 7-14 day washout period, and then complete the REx
11068024|NCT04300478|Other|REx/Sedentary Control|Subjects will complete the REx testing sessions, have a 7-14 day washout period, and then complete the Sedentary control
11068025|NCT04300465|Experimental|Rheumatoid arthritis - With Partner Group|In this group patients with stable rheumatoid arthritis and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
11068026|NCT04300465|Active Comparator|Rheumatoid arthritis - Without Partner Group|"In this group patients with stable rheumatoid arthritis undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.
~For the patients with rheumatoid arthritis, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
11068027|NCT04300465|Experimental|Chronic Kidney Disease - With Partner Group|In this group patients with stable stage 3 or 4 chronic kidney disease and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
11068028|NCT04300465|Active Comparator|Chronic Kidney Disease - Without Partner Group|"In this group patients with stable stage 3 or 4 chronic kidney disease undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.
~For the patients with chronic kidney disease, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
11068029|NCT04300452|Active Comparator|Carbetocin group|In the carbetocin group will be administered 100 mcg of carbetocin diluted in 100 cc of N/S 0.9% in a continuous rapid-flow intravenous infusion.
11068030|NCT04300452|Active Comparator|Ergometrin group|In the ergometrine maleate group will be administered intravenously 0.2 mg of the substance slowly in a bolus administration.
11068031|NCT04300439|Active Comparator|Arm A: metallic reusable ancillary.|This control group will be constituted of patients who will have the GMK® prosthesis with metallic reusable ancillary.
11068032|NCT04300439|Experimental|Arm B: Efficiency single use ancillary.|This group will be constituted of patients who will have the GMK® prosthesis with Efficiency single use ancillary.
11068033|NCT04300426|Experimental|ACHIM by gastroduodenoscopy|"Intestinal microbiota (acronym ACHIM - anaerobically cultured human intestinal microbiota) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml, containing approximately 10^9 bacteria / ml.
~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
11068034|NCT04300426|Placebo Comparator|Placebo by gastroduodenoscopy|"ACHIM culture media (no bacteria) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml.
~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
11068035|NCT04300413|Experimental|High-Intensity Rehabilitation plus Mobility (HeRo)|The HeRo group will receive a behavior-change intervention based in the principals of behavioral economics to improve mobility. Physical and occupational therapists have been trained to deliver a high-intensity, functional intervention as the standard of care in this skilled nursing facility.
11068036|NCT04300400||Delphi panel|Urologists of the Belgian Working group of Functional Urology willing to participate on the Delphi project.
11068037|NCT04300387|No Intervention|customary care|customary care for CKD
11068038|NCT04300387|Active Comparator|multidisciplinary care|multidisciplinary team care for CKD
11068039|NCT04300374||Sevoflurane only|inhalation of sevoflurane during general anesthesia
11068040|NCT04300374||Remifentanil and Sevoflurane|remifentanil infusion and inhalation of sevoflurane during general anesthesia
11068041|NCT04300361||Non-Western patients|Patients of non-Western descent with an indication for treatment with fluoropyrimidine-based chemotherapy. A patient is classified as non-Western if a one (1) of the parents or more than two (>2) of the grand parents are of non-Western descent.
11068042|NCT04300348|Active Comparator|Heel2Toe Group|The Heel2Toe group will have the 5 therapy sessions to learn to trigger the sensor with a strong heel strike and how to use device for home practice for 3 months. During the home practice, participants will be instructed to walk with the device for a minimum of 10 minutes per day in feedback mode.
11068043|NCT04300348|No Intervention|Control group|The Control group will do the same 5 sessions of training and 3 months of practice but without the Heel2Toe device in feedback mode, just in data acquisition mode.
11068044|NCT04300335|Experimental|High Risk - Individual Exercise|Patients who show an increased fracture risk and/or increased risk of fall in the screening assessments and are therefore allocated to an individualized personal training.
11068301|NCT04298515|Other|Obesity group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
11068045|NCT04300335|Experimental|Low Risk - Group Exercise|Patients who show neither increased fracture risk nor increased risk of fall in the screening assessments and are therefore allocated to the exercise group.
11068046|NCT04300322|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
11068047|NCT04300322|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
11068048|NCT04300309|Experimental|artemether:lumefantrine (2.5 mg:30 mg)|artemether:lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
11068049|NCT04300296|Experimental|Cutaneous lichen planus secukinumab 300mg Q4W|Secukinumab 300 mg every 4 weeks provided in 1ml PFS in cutaneous lichen planus patients
11068050|NCT04300296|Placebo Comparator|Cutaneous lichen planus placebo|Placebo in 1ml PFS in cutaneous lichen patients
11068051|NCT04300296|Experimental|Mucosal lichen planus secukinumab 300 mg Q4W|Secukinumab 300 mg every 4 weeks provided in 1 ml PFS in mucosal lichen planus patients
11068052|NCT04300296|Placebo Comparator|Mucosal lichen planus placebo|Placebo 1 ml PFS in mucosal lichen planus patients
11068053|NCT04300296|Experimental|Lichen planopilaris secukinumab 300 mg Q4W|Secukinumab 300 mg every 4weeks provided in 1ml PFS in lichen planopilaris patients
11068054|NCT04300296|Placebo Comparator|Lichen planopilaris placebo|Placebo in 1ml PFS in lichen planopilaris patients
11068055|NCT04300283|Experimental|Pre-operative hypnosis|
11068056|NCT04300270||Validation cohort|Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
11068057|NCT04300270||Clinical implementation cohort|Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
11068058|NCT04300244|Experimental|Arm A|Ipilimumab and nivolumab + UV1
11068059|NCT04300244|Active Comparator|Arm B|Ipilimumab and nivolumab
11068060|NCT04300231|Active Comparator|Thoracic epidural|1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
11068061|NCT04300231|Active Comparator|Rectus Sheath Block|2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
11068062|NCT04300231|Active Comparator|Surgeon Infiltration with Liposomal Bupivacaine (LB)|3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.
11068063|NCT04300231|Active Comparator|Surgeon Infiltration|4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
11068064|NCT04300218|Experimental|iCBT-I + CAU|Participants of this arm will get access to the course of the online cognitive-behavioral therapy for insomnia (iCBT-I) for 2 months along with the treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment
11068065|NCT04300218|Active Comparator|CAU|Participants of this arm will get a treatment prescribed by a consulting doctor (care as usual - CAU). After the 2-month course participants will pass the post-treatment assessment followed by the 3-month follow-up and post-follow-up assessment. Then provided completion of all the assessments and satisfying eligibility criteria participants of this arm will get tha access to the 2-month iCBT-I course followed by the post-treatment assessment
11068066|NCT04300205|Experimental|High intensity LED light treatment|Participants treated with high intensity LED phototherapy
11068067|NCT04300205|Experimental|Sham high intensity LED light treatment|Participants set up to be treated with light device but after being masked, the device is moved off the wound
11068068|NCT04300192|Experimental|Group 1: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of whole-cell pertussis (wP) vaccine during the first 2 years of life - Type: Experimental
11068069|NCT04300192|Experimental|Group 2: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 3 doses of wP followed by 1 dose of acellular pertussis (aP) vaccine during the first 2 years of life
11068070|NCT04300192|Experimental|Group 3: Adacel Quadra vaccine -|Adacel Quadra single injection at Day 0 in participants who received 2 doses of wP vaccine followed by 2 doses of aP vaccine during the first 2 years of life
11068071|NCT04300192|Experimental|Group 4: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 1 dose of wP vaccine followed by 3 doses of aP vaccine during the first 2 years of life
11068072|NCT04300192|Experimental|Group 5: Adacel Quadra vaccine|Adacel Quadra single injection at Day 0 in participants who received 4 doses of aP vaccine during the first 2 years of life
11068073|NCT04300192|Experimental|Group 6: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of wP vaccine during the first 2 years of life
11068074|NCT04300192|Experimental|Group 7: Adacel Quadra vaccine (HIV positive)|Adacel Quadra single injection at Day 0 in HIV + participants who received 4 doses of aP vaccine during the first 2 years of life
11068075|NCT04300166|Active Comparator|Telemedicine & Humidification Intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse/sleep technologist is checking the downloaded data three times per week. The contacts will be due to:
~CPAP usage <4h/ night for 3 consecutive night
~the median leakage was above 0.4 L/sec on 3 consecutive nights The nurse/sleep technologist informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits) will be discussed. The patient is encouraged to use CPAP every night. In the case of adherence >4h/night and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail."
11068076|NCT04300166|No Intervention|Control without Telemedicine & humidification|In the control arm, no wireless telemedicine and humidifier will be used with CPAP but data stored in the CPAP machine are collected at the follow-up visit after 1 month
11068077|NCT04300153|Experimental|ESP Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml 0.25% bupivacaine at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
11068078|NCT04300153|Sham Comparator|Control Group|At the end of the skin closure, patients will be positioned in lateral decubitis and unilateral ESP block will be performed with single injection of 30 ml normal saline at the level of T12 transverse process. All patients will receive intravenous (iv) paracetamol 1000 mg at the arrival to the recovery room. The dosage will be repeated at every 8-hours interval.
11068079|NCT04300140|Experimental|Phase 1b: AVB-S6-500+Cabo|
11068080|NCT04300140|Experimental|Phase 2: AVB-S6-500+Cabo|
11068081|NCT04300140|Experimental|Phase 2: Cabo alone|
11068082|NCT04300127|Experimental|Pioglitazone|Candidates who after the screening period are eligible to receive Pioglitazone
11068083|NCT04300114|Experimental|Maintenance Fluzoparib monotherapy|
11068084|NCT04300114|Placebo Comparator|Maintenance placebo monotherapy|
11068085|NCT04300101||DLBCL patients|All patients with diagnosis of DLBCL
11068086|NCT04300088||Patients with advanced solid cancer treated with anti-PD(L)1|Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
11068087|NCT04300075||CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
11068088|NCT04300062|Experimental|Rebiopsy|
11068089|NCT04300049|Experimental|Change in Glycerol Ra|The difference in rate of lipolysis (glycerol Ra) during the basal state (-120 -0 minute) between subjects receiving glucagon and saline represents the change in whole body lipolysis caused by glucagon.
11068090|NCT04300036|Experimental|longan syrup|Take 15 ml of longan syrup once a day for 3 months
11068091|NCT04300036|Placebo Comparator|Placebo syrup|Take 15 ml of placebo syrup once a day for 3 months
11068092|NCT04300023|No Intervention|Study 1: Normal Care Control Group|Study 1: Normal Care Control Group [will crossover and complete the cycling intervention following the initial 6-months]
11068093|NCT04300023|Experimental|Study 1: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
11068094|NCT04300023|Experimental|Study 2: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
11068095|NCT04300023|Experimental|Study 2: Solo Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to cycling without a partner for a target duration and intensity.
11068096|NCT04300010|Active Comparator|Blue Light Therapy|FDA cleared blue light product, Omniluxblue (Globalmed Technologies, Glen Elen, CA), which emits a 415 nm blue light irradiance of 40mW/cm2. Following the application of blue light protective eyewear, the blue light therapy device will be centered over the deltopectoral interval according to device standardized use instructions and a 23-minute treatment will be administered to dry skin. As was done in the topical BPO group, following treatment, a skin swab culture of the treatment shoulder will be taken, then both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder. Participants and research personnel conducting the blue light treatments will be wearing medical grade blue light protective glasses for safety.
11068097|NCT04300010|Active Comparator|5% Topical Benzoyl Peroxide Gel|A pea-sized amount, ~0.5 grams, will be applied to a 10cm strip over the deltopectoral interval beginning the morning 48 hours prior to schedule research visit to obtain cultures. The benzoyl peroxide will be applied on dry skin after a shower. The gel will be applied once in the morning and once in the evening for two consecutive days as well as the morning of the scheduled research visit. Following treatment, a skin swab culture of the treatment shoulder will be taken, both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder.
11068098|NCT04300010|Active Comparator|Light and Gel|Prior to treatment, a skin swab culture will be taken, 5% topical benzoyl peroxide treatment will be performed on dry skin immediately after a shower as described in the above paragraph. Again, five total treatments will be performed prior to research visit. On the day of the research visit, the blue light therapy protocol described above will be performed exactly the same followed by culture obtainment.
11068099|NCT04299997||163 mpMRIs corresponding to consecutive patients who underwent|The mpMRIs were performed on a 1.5T GE MR units or on 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
11068100|NCT04299984||Open Conversions|Patients undergoing total or partial endograft explantation for any EVAR complication.
11068101|NCT04299984||SemiConversions|Patients undergoing open or laparoscopic surgery for any EVAR complication (mostly endoleak correction) with complete endograft preservation.
11068102|NCT04299971|Active Comparator|methotrexate|This group of 38 TAK cases are prescribed with methotrexate tablets (Dose: 15.0 mg. qw. p.o.) for 24 weeks.
11068103|NCT04299971|Experimental|Tofacitinib|This group of 38 TAK cases are prescribed with tofacitinib tablets (Dose: 5.0 mg. bid. p.o.) for 24 weeks.
11068104|NCT04299945|Experimental|Dietary nitrate supplementation|The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)
11068105|NCT04299945|Placebo Comparator|Placebo|The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)
11068353|NCT04298099|Active Comparator|Ropivacaine 0.2% at 0.3ml/kg|Ropivacaine 0.2% at 0.3ml/kg
11068106|NCT04299932|Experimental|Electroacupuncture(EA) group|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 [Zhongliao], BL35 [Huiyang] and Spleen Meridian (SP) 6 [Sanyinjiao]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
11068107|NCT04299932|Sham Comparator|Sham Electroacupuncture (SA) group|Participants in SA group will receive treatment at bilateral sham BL33 [Zhongliao], sham BL35 [Huiyang] and sham SP6 [Sanyinjiao]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
11068108|NCT04299932|No Intervention|Waiting List (WL) group|Participants in WL group will be followed up for 20 weeks. Participants only receive healthcare education and advice on lifestyle modification, which will be received by all the participants in the three groups.
11068109|NCT04299919||Recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
11068110|NCT04299919||Non-recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
11068111|NCT04299906|Experimental|Solaris Vascular Stent Graft|Implant of Solaris Vascular Stent Graft in aorto-iliac lesions
11068112|NCT04299893|Experimental|Ozone Group|"Drug: Ozone Ozone Group: Usual treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
~Other Names: O3"
11068113|NCT04299893|Placebo Comparator|Control Group|"Drug: Oxygen Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
~Other Names: O2"
11068114|NCT04299880|Other|Napabucasin monotherapy|Patients in this arm will receive napabucasin administered orally, twice daily
11068115|NCT04299880|Other|Napabucasin in combination with Gemcitabine and Nab-paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously once weekly, on 3 of every 4 weeks.
11068116|NCT04299880|Other|Napabucasin in combination with Nivolumab|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly nivolumab 3mg/kg administered intravenously over 60 minutes.
11068117|NCT04299880|Other|Napabucasin in combination with paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly paclitaxel administered intravenously once weekly, on 3 of every 4 weeks.
11068118|NCT04299880|Other|Napabucasin in combination with FOLFIRI|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly FOLFIRI. Addition of bevacizumab, per Investigator choice, will be permissible.
11068119|NCT04299867||< 34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.
~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
11068120|NCT04299867||34 weeks gestational age|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.
~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
11068121|NCT04299854||Vaginal Dinoprostone|Induction of labor by 10mg of vaginal dinoprostone
11068122|NCT04299854||Single Balloon Foley Catheter|Induction of labor by single balloon Foley catheter
11068123|NCT04299815|Active Comparator|Oral lactate|Sodium D/L lactate solution, 25g/L in 300mL water
11068124|NCT04299815|Placebo Comparator|Iso-lactic intravenous lactate infusion|iv sodium D/L lactate to elevate [lactate] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
11068125|NCT04299802|Active Comparator|Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)|LR-PRP will be administered via usual protocol with venous blood draw and concentration via centrifugation. The LR-PRP will be injected under ultrasound guidance into the gluteus minimus and gluteus medius tendons, enthesis and surrounding bursae.
11068126|NCT04299802|Active Comparator|Percutaneous Ultrasonic Tenotomy|Percutaneous Ultrasonic Tenotomy will be administered via usual protocol within an outpatient surgical setting or in-office procedure. Patient will be anesthetized with local anesthetic and a <5mm incision will be made along the lateral hip with an #11 scalpel. A 14-G angiocath will be introduced through the defective area of the tendon down to the enthesis. Multiple passes will be made and then the percutaneous ultrasonic tenotomy device will be introduced to the defective area. No more than 5 minutes of energy cutting time will be used to address the defective area down to the enthesis, which will debride abnormal tissue but leave normal healthy tissue intact.
11068127|NCT04299789||Probable Civilian|This cohort represents those in which the Military Service Identification Tool has determined are a civilian and have not served in the Armed Forces.
11068128|NCT04299789||Probable Veteran|This cohort represents those in which the Military Service Identification Tool has determined are a military veteran and have served in the Armed Forces.
11068129|NCT04299776|Experimental|IPR therapy|Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position
11068130|NCT04299776|Active Comparator|Standard airway|Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position
11068131|NCT04299763|Experimental|Beta-Glucan (BETA)|experimental group, received a supplement of oats beta-glucan (5 g) for 12 weeks.
11068132|NCT04299763|Placebo Comparator|Control (CN)|placebo group, received a supplement of cellulose microcrystalline (5g) for 12 weeks.
11068133|NCT04299750|Experimental|Alveolar Ridge Preservation|Patients in this arm will undergo atraumatic extraction of an hopeless tooth and a socket preservation procedure. Alveolar ridge preservation will be performed using a slow-resorption bone substitute and a collagen membrane that covers the graft.
11068134|NCT04299750|Active Comparator|Natural healing|Patients in this arm will undergo atraumatic extraction of an hopeless tooth. The socket will follow natural healing.
11068135|NCT04299737||First patient in the case pair|This patient will receive the treatment bundle. S. aureus transmission surveillance will be conducted.
11068136|NCT04299737||Second patient in the case pair|This patient will receive usual care. S. aureus transmission surveillance will be conducted.
11068137|NCT04299724|Experimental|Injection of Covid-19/aAPC vaccine|
11068138|NCT04299711||Baseline|This study intends to recruit 3,428 Chinese adolescent students exposed to the novel coronavirus disease 2019 in the baseline survey
11068139|NCT04299711||6-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 6 follow-up study.
11068140|NCT04299711||12-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 12 follow-up study.
11068141|NCT04299711||18-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 18 follow-up study.
11068142|NCT04299698||Carbohydrate reduction group|Participants chose to control their body fat mass by reducing their carbohydrate intake through observation study periods.
11068143|NCT04299698||Fat reduction group|Participants chose to control their body fat mass by reducing their fat intake through observation study periods.
11068144|NCT04299698||Intense exercise group|Participants chose to control their body fat mass by vigorously increasing the time and intensity of exercise through observation study periods.
11068145|NCT04299698||Moderate exercise group|Participants chose to control their body fat mass by moderately increasing the time and intensity of exercise through observation study periods.
11068146|NCT04299672|Experimental|Postural reconstruction|"Maximum external rotation of the hip in lower limb elevation and the dorsal flexion of the ankle with flexion of the toes, performed in both lower limbs alternately and independent.
~Participant must control breathing. The detail phases of a general intervention are:
~PASSIVE displacement of the segment until reaching CRITICAL AMPLITUDE, which corresponds to the light myofascial stress or to the appearance of evoked responses.
~ACTIVE MAINTENANCE of the critical amplitude.
~WORK BREATHING.
~INDUCTIVE ACTIVE APPLICATIONS with movements of great relative amplitude.
~FINISHING CRITERIA: reduction or extinction of evoked responses, patient fatigue or execution of the technique for 15 minutes without any of the above premises having been reached."
11068147|NCT04299646|Experimental|Steretactic radiotherapy plus systemic treatment|
11068148|NCT04299646|Active Comparator|Systemic treatment|
11068149|NCT04299633|Experimental|Part 1: vadadustat plus sevelamer carbonate|Participants will receive vadadustat 300 milligrams (mg) once on Days 1, 3, 5, and 7. Participants will receive sevelamer carbonate 1600 mg once on Days 3, 5, and 7.
11068150|NCT04299633|Experimental|Part 2: vadadustat plus calcium acetate|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive calcium acetate 1334 mg once on Days 3, 5, and 7.
11068151|NCT04299633|Experimental|Part 3: vadadustat plus Auryxia®|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive Auryxia® 2 grams once on Days 3, 5, and 7.
11068152|NCT04299620|Experimental|Diagnostic (TRUS)|Patients may undergo TRUS prior to standard-of-care radical prostatectomy. Following radical prostatectomy, removed glands are scanned and micro-US, standard of care mpMRI, and whole mount images are analyzed and compared.
11068153|NCT04299607||AFI patients|"Blood will be collected from patients presenting with an undifferentiated fever.
~Samples will be tested with:
~the Malaria Ag Pf/Pan test SD Bioline
~the SD Bioline Dengue Duo IgM/IgG/NS1
~the DPP Zika Chikungunya Dengue test from Chembio
~the DPP Fever Panel II assay
~the Leptospira IgM ELISA test from Serion
~an in-house ELISA tests for scrub and murine typhus IgM
~blood culture for detection of Burkholderia pseudomallei"
11068154|NCT04299594||sickle cell disease patients|120 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study
11068155|NCT04299581|Experimental|Cryoablation in combination with Camrelizumab|Cryoablation treatment starts at day 1. Camrelizumab will be initiated on day 14 after Cryoablation. Camrelizumab will be administered every three weeks (3mg/Kg, IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11068156|NCT04299568|Experimental|Anti gravity treadmill training|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization followed by Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes.
11068157|NCT04299568|Active Comparator|Control|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization only
11068158|NCT04299542|Active Comparator|conventional Multi-detector CT (MDCT)|Percutaneous lung biopsy using MDCT
11068159|NCT04299542|Active Comparator|cone-beam CT (CBCT)|Percutaneous lung biopsy using CBCT
11068160|NCT04299529|Experimental|HTM plus UPP|Urinary proteomic profiling administered on top of home blood pressure telemonitoring and guideline-endorsed non-pharmacological and pharmacological management of risk factors
11068161|NCT04299529|Other|HTM alone|Home blood pressure telemonitoring administered on top of non-pharmacological and pharmacological management of risk factors
11068162|NCT04299516|Experimental|Two-team SBA|Two-team simultaneous bilateral total knee arthroplasty
11068163|NCT04299516|Active Comparator|Single-team SBA|Single-team simultaneous bilateral total knee arthroplasty
11068164|NCT04299503|Active Comparator|Crisaborole|ointment applied topically in the morning and in the evening
11068165|NCT04299503|Placebo Comparator|Placebo|ointment applied topically in the morning and in the evening
11068166|NCT04299490|Experimental|Sleep Continuity Disruption|The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.
11068354|NCT04298099|Active Comparator|Ropivacaine 0.5% at 0.3ml/kg|Ropivacaine 0.5% at 0.3ml/kg
11068167|NCT04299490|Experimental|Sleep Fragmentation|The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.
11068168|NCT04299490|Active Comparator|Undisturbed Sleep|An 8-hour period of undisturbed sleep is permitted on each night.
11068169|NCT04299477|Experimental|Patients with periodontitis and osteoporosis|Group 1 : Patients who have periodontitis and osteoporosis prescribed with bisphosphonates
11068170|NCT04299477|Experimental|Systemically healthy patients with periodontitis|Group 2: Patients who have no systemic diseases but diagnosed as periodontitis
11068171|NCT04299477|No Intervention|Systemically and periodontally healthy individuals|Group 3: Healthy controls
11068172|NCT04299464|Placebo Comparator|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
11068173|NCT04299464|Experimental|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
11068174|NCT04299464|Experimental|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
11068175|NCT04299451|Experimental|Open dialogue about CAM (ODC-COC)|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.
~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
11068176|NCT04299451|No Intervention|Standard care|Standard care including referral to a homepage about complementary alternative medicine
11068177|NCT04299438|Active Comparator|Propranolol|IV Propranolol - 2mg; one possible repeat dose ≥2 hours later
11068178|NCT04299438|Placebo Comparator|Placebo|Normal saline placebo- 2 mL; one possible repeat dose ≥2 hours later
11068179|NCT04299425|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).
11068180|NCT04299425|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).
11068181|NCT04299412||Melioidosis cases|serum samples collected from patients with B. pseudomallei positive cultures
11068182|NCT04299412||Non-melioidosis cases|serum samples collected from patients with B. pseudomallei negative cultures
11068183|NCT04299399||nomal|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of biomechanics with other groups will be performed.
11068184|NCT04299399||seasonal allergic conjunctivitis(SAC)|Eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of corneal biomechanics with other groups and correlation analysis of corneal biomechanical parameters and other measurement indicators will be performed.
11068185|NCT04299399||vernal keratoconjunctivitis (VKC)|At first visit, eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured. All patients will adopt a unified medication regimen:0.1% tacrolimus eye drops four times daily; 0.1% flumirone eye drops twice daily; azelastine hydrochloride eye drops four times daily; hyaluronic acid sodium eye drops four times daily. After 1M, 0.1% flumilone eye drops will be replaced with 0.02% flumirone eye drops twice daily, and rest of the medication will remain unchanged. The same ophthalmological examinations will be performed again after 3 month medication.
11068186|NCT04299399||keratoconus|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of these parameters with other groups will be performed.
11068187|NCT04299373|Experimental|Alcohol: Oral administration|Participants in this arm will consume a measured dose of alcohol orally, with the goal of achieving a target peak breath alcohol concentration of .065% within 20 minutes.
11068188|NCT04299373|Experimental|Alcohol: Intravenous administration|Participants in this arm will be infused intravenously with a dose of alcohol sufficient to raise their breath alcohol concentration to .065% within 20 minutes.
11068189|NCT04299360||standard BIV|the following group describes the effects of the left ventricular stimulation involving a dipole of two electrodes located inside a suitable vessel branch of the coronary sinus (CS). Standard BIV pacing modality can be achieved by either a quadripolar electrode implanted in the CS, of which only two poles will be used for cardiac resynchronization therapy, or by a bipolar electrode equipped with just two electrodes. The latter describes the old technology, requiring a change into typology of generator which has to display an IS-1 connection (due to different distal terminal of the electrode itself), instead of the new one IS-4 connection that has been developed for quadripolar electrodes.
11068190|NCT04299360||MPP BIV|Such modality of left ventricular stimulation requires a dynamic use of the four electrodes located in the proximal segment of the electrocatheter that allows the recruitment of a vast area of the left ventricle. It is limited by the presence of scars on left ventricle surface, or phrenic nerve inadvertent stimulation.
11068191|NCT04299308|Experimental|Moderate Intensity Aerobic Exercise|45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR
11068192|NCT04299308|Experimental|High Intensity Aerobic Exercise|65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR
11068193|NCT04299295|Experimental|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
11068194|NCT04299295|Active Comparator|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
11068195|NCT04299282|Active Comparator|CanGaroo|The treatment group will receive a CanGaroo envelope with implantation of a CIED
11068196|NCT04299282|No Intervention|No CanGaroo|The control group will not receive a CanGaroo envelope with implantation of a CIED
11068197|NCT04299256|Experimental|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
11068198|NCT04299256|No Intervention|Control|Like the intervention group, the control group session (attention-matched education) which composed of 10-12 participants were performed with a booklet containing hemodialysis and its use in a silent room located in the hemodialysis units. The patient information provided in-person training on hemodialysis and its use for 20 min in a group session at the hemodialysis unit, on the first day of the study. During the study period, the participants in the control group were not subjected to any additional intervention.
11068199|NCT04299243|Experimental|Spherical Lens|Randomized to Spherical Lens worn in a daily disposable mode
11068200|NCT04299243|Active Comparator|SiHy Daily|Randomized to SiHy Daily worn in a daily disposable mode
11068201|NCT04299217|Active Comparator|Mango Leaf Extract|300 mg Mangifera indica (mango) leaf extract standardized to ≥ 60% mangiferin (Zynamite®), plus carrier
11068202|NCT04299217|Placebo Comparator|Placebo|Carrier (placebo)
11068203|NCT04299204|Experimental|Years 1997-2007|Group-1, PCNL was performed in the first 10 years period (Years 1997-2007);
11068204|NCT04299204|Experimental|2008- to the present|The PCNL was performed in the second ten years period from 2008 to the present.
11068205|NCT04299191|Experimental|Dose Escalation|"The dose level corresponds to 80% of the maximum tolerated dose of 2-OHOA in adult patients when adjusted for body surface area. The escalation will be to the 100%, and 120% of the maximum tolerated dose of 2-OHOA in adult patients when adjusted for body surface area. Dose escalation decisions will be made by all active Investigators in collaboration with the Medical Monitor when at least three patients have completed the DLT observation period (Cycle 1) at each dose level. When the third patient at any given dose level has received 14 days of therapy, an escalation teleconference will be scheduled after that patient has completed the DLT observation period (Cycle 1). The decision to progress to the next dose level will be made on the basis of review of all significant 2-OHOA-related toxicities."
11068206|NCT04299165|Experimental|Device: KAIA COPD-App (Medical Mobile Application).|The study intervention is an exercise training program that requires only a chair or water bottles, consisting of training elements with progressive levels of intensity, individually adaptable to the participant's exercise level. This training program is delivered to the participants with the help of KAIA COPD-App. Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
11068207|NCT04299165|Active Comparator|Usual Care|"The Training of the control-group is performed by regular recommendations/ Standard of care. Standard of care in this context means to hand out the brochure  Besser Leben mit COPD  including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database."
11068208|NCT04299152|Experimental|Stem Cell Educator therapy treat patients with SARS-CoV-2|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
11068209|NCT04299152|No Intervention|Conventional treatment of patients with SARS-CoV-2|Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.
11068210|NCT04299126|Experimental|high absorption pad for blood and pus|High absorption pad for blood and pus with natural antimicrobial agent composes of sericin and chitosan. It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
11068211|NCT04299126|Active Comparator|commercial wound dressing|Commercial wound dressing is gauze dressing impregnated with paraffin, containing 0.5% chlorhexidine acetate (Bactigras). It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
11068212|NCT04299113|Experimental|Treatment (vinorelbine, mocetinostat)|Participants receive mocetinostat in combination with vinorelbine
11068213|NCT04299100|No Intervention|Control Group|Participants randomized to the Control Group will receive usual care from their pain physician.
11068214|NCT04299100|Experimental|Sleep Health Program - Suspected No/mild sleep apnea|Participants randomized to the Sleep Health Program with no/mild sleep apnea.
11068215|NCT04299100|Experimental|Sleep Health Program - Suspected Moderate/severe sleep apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea.
11068216|NCT04299087|Experimental|Dystonia and/or tremor|Adults with a diagnosis of dystonia and/or tremor
11068217|NCT04299087|Experimental|Control|Healthy adults without a history of any neurological disorder, with a similar age distribution and sex ratio as the dystonia and/or tremor group
11068218|NCT04299074|Other|Addiction|problematic addiction
11068219|NCT04299061|Experimental|Study Group|
11068220|NCT04299048|Experimental|subcutaneous injection|
11068221|NCT04299035|Experimental|Thoracic surgery + ESPblock|Thoracic surgery + ESPblock + standard pain management
11068222|NCT04299035|Experimental|Abdominal surgery + ESPblock|Abdominal surgery + ESPblock + standard pain management
11068223|NCT04299035|Experimental|Spinal surgery + ESPblock|Spinal surgery + ESPblock + standard pain management
11068224|NCT04299035|No Intervention|Thoracic surgery|Thoracic surgery + standard pain management
11068225|NCT04299035|No Intervention|Abdominal surgery|Abdominal surgery + standard pain management
11068226|NCT04299035|No Intervention|Spinal surgery|Spinal surgery + standard pain management
11068227|NCT04299022||Prospective Registry|Treatment for diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with Vivigen Cellular Bone Matrix
11068228|NCT04299022||Retrospective Data Collection|Treatment of diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with adjunct bone graft utilized in the acute, delayed, non-union and fusion settings.
11068229|NCT04298996||study group (passive smoking children)|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
11068230|NCT04298996||control group|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
11068231|NCT04298983|Experimental|Abemaciclib + ADT+ RT|Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
11068232|NCT04298970|Active Comparator|Intervention|Consuming a product containing 35-40 gram of freeze dried kale a day.
11068233|NCT04298970|Placebo Comparator|Placebo|Consuming a placebo product.
11068234|NCT04298957|Other|See and treat|Cone biopsi is offered to women age ≥ 45 years referred to Department of Obstetrics and Gynecology due to a positive cervical screening test and partly or invisible transformation zone.
11068235|NCT04298944||BeHealthY Cohort|Children from BeHealthY cohort who are obese/overweight but do not have mood disorders are eligible for this study. The children will be given additional questionnaires to assess emotional/behavioral well being.
11068236|NCT04298944||CHAMPION trial Cohort|"Children who are overweight/obese and have severe mental illness, and who have agreed to be contacted for future research.
~Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments."
11068237|NCT04298944||Pediatric Medical Psychiatric (PMP) Clinic Cohort|Children from the PMP Clinic who have severe mental illness but healthy weight. Tests will be done on all participants which includes cardiovascular assessments, actigraphy, laboratory assessments and emotional/behavioral assessments.
11068238|NCT04298931||Patients undergoing open abdominal surgery|
11068239|NCT04298918|Experimental|Dose Escalation Phase|Participants will receive venetoclax in combination with a fixed dose of trastuzumab emtansine.
11068240|NCT04298918|Experimental|Dose Expansion Phase|Participants will receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
11068241|NCT04298918|Experimental|Randomized Phase II Arm 1|Participants will receive trastuzumab emtansine + placebo.
11068242|NCT04298918|Experimental|Randomized Phase II Arm 2|Participants will receive trastuzumab emtansine + venetoclax.
11068243|NCT04298905|No Intervention|Standard of Care|Individuals randomized to standard of care will receive a standardized adherence education session and provided with a paper-based diary to track appointments and adherence. Instructions will be provided on the importance of daily adherence in the primary health care facility closest to patients' residence, as per standard of care. Directly observed therapy (DOT) is recommended for all patients at patients' nearest clinic. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
11068244|NCT04298905|Active Comparator|m-health intervention|Individuals randomized to the intervention arm will receive the same standardized adherence education, followed by an orientation session to the study intervention. This orientation will include education on basic smartphone operations and use. The CHW will set up appointment reminders for clinic visits as well as daily adherence reminders for submission of the video DOT sessions and symptom reports. A smartphone capable of downloading apps, receiving short message service (SMS) and access wifi and cellular connectivity will be provided to intervention patients. All patients are seen face-to-face monthly for adherence monitoring, monthly symptom reports and laboratory evaluations per standard of care treatment guidelines. All research participants will also receive a clinic visit quality checklist to ensure completeness of standard of care procedures.
11068245|NCT04298892||hematologic disorder or malignancy|
11068246|NCT04298879|Experimental|IBI376|IBI376 will be administered orally at a dose of 20 mg once daily for 8 weeks followed by 2.5 mg once daily.
11068247|NCT04298866|Other|Experimental arm|
11068248|NCT04298853|Active Comparator|Standard|Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.
11068249|NCT04298853|Experimental|Study|Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.
11068250|NCT04298840|Experimental|Creatine Monohydrate|
11068251|NCT04298840|Placebo Comparator|Placebo|
11068252|NCT04298827|Active Comparator|Unimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment.
11068253|NCT04298827|Active Comparator|Trimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation, nutritional counseling and group therapy, prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment. Patient nutritional assessments will be obtained with Patient Generated Subjective Global Assessment questionnaires as well as targeted questioning by the dietician.
11068254|NCT04298801|Experimental|Nurse-driven HIV screening for key populations+UD|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
11068255|NCT04298801|Active Comparator|Physician-directed diagnostic testing alone|
11068256|NCT04298788|Placebo Comparator|White dishware|standard white dishware used in the home
11100858|NCT04071119|Placebo Comparator|Placebo|
11068258|NCT04298775|Active Comparator|spinal anesthesia with morphine|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine + 200 mcg of Morphine
11068259|NCT04298775|Active Comparator|spinal anesthesia without morphine + peripheral nerve block|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine and peripheral nerve block with 0.2 to 0.375% Ropivacaine, in a volume of 20 to 30 mL.
11068260|NCT04298762|Placebo Comparator|Comparison Group|Physicians in the control group did not receive peer comparison emails.
11068261|NCT04298762|Experimental|Intervention Group|Physicians in the intervention group received peer comparison emails.
11068262|NCT04298749|Experimental|GX-P1 dose level 1|GX-P1 dose level 1
11068263|NCT04298749|Experimental|GX-P1 dose level 2|GX-P1 dose level 2
11068264|NCT04298749|Experimental|GX-P1 dose level 3|GX-P1 dose level 3
11068265|NCT04298749|Experimental|GX-P1 dose level 4|GX-P1 dose level 4
11068266|NCT04298736|Experimental|Bariatric Surgery|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy
11068267|NCT04298736|Active Comparator|Lifestyle Modification|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.
11068268|NCT04298723|Experimental|Left Atrial Appendage Occlusion|Percutaneous closure of the LAA by use of CE-mark approved LAA occlusion device Watchman / Watchman FLX
11068269|NCT04298723|No Intervention|Best medical therapy for anticoagulation|Standard of care (according to current guidelines)
11068270|NCT04298710|Experimental|Arm Cycling|Arm cycling on an arm crank ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
11068271|NCT04298710|Experimental|Leg Cycling|Leg cycling on a leg cycling ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
11068272|NCT04298710|Placebo Comparator|Sitting|Participants will remain seated after carbohydrates consumption.
11068273|NCT04298697|Experimental|TDF/FTC for one week|The first 10 participants (Arm A) will take TDF/FTC for three consecutive days of one week and will have biologic specimens collected at 8 study time points.
11068274|NCT04298697|Experimental|TDF/FTC for four weeks|The second 10 participants (Arm B) will take TDF/FTC for three consecutive days for four weeks and will have biologic specimens collected at 20 study time points.
11068275|NCT04298684|Experimental|Metformin|In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control.
11068276|NCT04298684|Placebo Comparator|Sitagliptin|In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months.
11068277|NCT04298671|Experimental|Yoga-Pilates Group|The 30-minute web-based video exercise program will combine the best yoga-Pilates exercises focused on the pelvic floor, based on prior research and expert opinion, in collaboration with yoga-Pilates instructors that participants will complete 4 times per week for 8 weeks.
11068278|NCT04298658||HIV and Insomnia|Participants will test positive for HIV and Insomnia.
11068279|NCT04298658||HIV Without Insomnia|Participants will test positive for HIV and test negative for Insomnia.
11068280|NCT04298658||Non HIV with Insomnia|Participants will test negative for HIV and test positive for Insomnia.
11068281|NCT04298658||Non HIV Without Insomnia|Participants will test negative for HIV and test negative for Insomnia.
11068282|NCT04298645|Experimental|High GI carbs breakfast / dinner|Participants will receive a meal rich in high GI carbohydrates for breakfast (day 5) first. After the wash-out day (day 6), the identical meal will be provided for dinner (day 7).
11068283|NCT04298645|Experimental|High GI carbs dinner / breakfast|Participants will receive a meal rich in high GI carbohydrates for dinner (day 5) first. After the wash-out day (day 6), the same meal will be provided for breakfast (day 7).
11068284|NCT04298632|Experimental|Youth-only|Only the youth receives the education program
11068285|NCT04298632|Experimental|Family enhanced|A parent and the youth both receive the education program
11068286|NCT04298632|No Intervention|Control|neither parent, nor youth receives the education program
11068287|NCT04298619||Standard cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
~symptom assessment
~blood tests
~physical examination"
11068288|NCT04298619||Imaging cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:
~symptom assessment
~blood tests
~physical examination
~Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes"
11068289|NCT04298606|Experimental|Prevention (recombinant human EGF-rP64K/montanide ISA 51)|"LOADING PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM at 0, 2, 4 and 6 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive recombinant human EGF-rP64K/montanide ISA 51 vaccine IM Q4W in the absence of disease progression or unacceptable toxicity."
11068290|NCT04298593|Other|ECG monitoring|All patient will be under telemetry
11068291|NCT04298580|Active Comparator|PVB before surgery|
11068292|NCT04298580|Active Comparator|PVB after surgery|
11068293|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg [BID] plus ASA 75mg [OD] has been made by the investigator.
11068294|NCT04298554|Experimental|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily
11068295|NCT04298554|Placebo Comparator|Placebo (hemp oil)|CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily
11068296|NCT04298541|Experimental|Patients with Meningioma|Subjects with suspected meningioma planned for surgery who meet the inclusion and exclusion criteria.
11068297|NCT04298528|Experimental|dronabinol|
11068298|NCT04298528|Placebo Comparator|placebo|
11068299|NCT04298515|Other|Type 2 Diabetes group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
11068300|NCT04298515|Other|Insulin resistance group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
11068302|NCT04298489|Experimental|stage III/IV gastrointestinal cancer patients|The study group (Personalized drug sensitivity test) was treated according to the physician's opinion. Tumor tissues are obtained during the surgery or via biopsy with informed consent, for the purpose of ex vivo assay.
11068303|NCT04298476|Placebo Comparator|A|Saline will be placed in syringe instead of ropivicaine 0.2% and the nerve block will be placed in the adductor canal at the desired location by the anesthesiologist
11068304|NCT04298476|Active Comparator|B|An adductor canal block will be placed with local anesthetic in the proximal 1/3 of the operative leg
11068305|NCT04298476|Active Comparator|C|An adductor canal block will be placed with local anesthetic in the middle 1/3 of the operative leg
11068306|NCT04298476|Active Comparator|D|An adductor canal block will be placed with local anesthetic in the distal 1/3 of the operative leg
11068307|NCT04298463||COHORT A: dalbavancin|Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.
11068308|NCT04298463||COHORT B: lipo and glyco-peptid drugs|Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.
11068309|NCT04298450|Experimental|Active SMS Intervention|Participants assigned to the experimental arm will receive the active SMS intervention. Participants in the active intervention group who consent to participate will be asked to complete a web-based survey. Based on survey findings, purposive sampling will be used to select a subsample of 12 to 20 participants for qualitative interviews.
11068310|NCT04298450|Sham Comparator|Sham SMS|Participants assigned to the sham comparator will receive the sham SMS intervention. They will not be re-contacted.
11068311|NCT04298437|Experimental|Parent Group Treatment|Families who meet inclusion criteria will participate in the Parent Group Treatment (ADAPT Program).
11068312|NCT04298437|No Intervention|No Treatment|Families who do not meet inclusion criteria will not be invited to participate in the ADAPT Program.
11068313|NCT04298424|Experimental|Peer-led|The experimental group will conduct a 4-week peer self-management program and receive the original outpatient routine care.
11068314|NCT04298424|No Intervention|No Peer-led|The control group will only issue a self-management manual and receive the original outpatient routine care.
11068315|NCT04298411|Experimental|Experimental Arm|Participants will take part in 12 one-hour rehabilitation sessions over 12 weeks in the clinic at Holland Bloorview Kids Rehabilitation Hospital and Institut de réadaptation en déficience physique de Québec, during which they will play games developed for the Novint Falcon.
11068316|NCT04298398|Experimental|Mindfulness (MBCT)|Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).
11068317|NCT04298398|Experimental|Emotion Focused Therapy (EFT-CR)|Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).
11068318|NCT04298398|Other|Control Group|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
11068319|NCT04298385||Individuals with oblique proximal phalanx fractures of finger|Traction orthosis and exercise
11068320|NCT04298346||Case|
11068321|NCT04298346||Control|
11068322|NCT04298333|Experimental|BP-C1|BP-C1 will be used as supportive care
11068323|NCT04298320|Experimental|SHR-1210 + AIN457|SHR-1210 was administered 200mg iv every 2 weeks in combination with AIN457 150mg or 300mg ih every 2 weeks
11068324|NCT04298307||Patients with calcified coronary artery disease|Patients with calcified coronary artery disease require an ICL using the Shockwave catheter.
11068325|NCT04298294|Experimental|injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with i-PRF& bone graft
11068326|NCT04298294|No Intervention|no injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with bone graft
11068327|NCT04298281||Parents of patients who have a family care conference criteria|These will be parents of patient who have one of our defined family care conference criteria
11068328|NCT04298281||Parents of patients who do not have a family care conference criteria|These will be parents of patients who do not have one our defined family care conference criteria
11068329|NCT04298255|Experimental|ROSI only|Option 1: injecting extracted round spermatids (less mature form of haploid germ cells than elongated spermatid or spermatozoon) from male partner into the harvested egg of a female partner
11068330|NCT04298255|Experimental|Half ROSI-half Sperm Donor Fertilization|Option 2: Harvested eggs from the female partner will be separated in two groups, with one group being fertilized with round spermatids and the other group fertilized with donor sperm
11068331|NCT04298242|Experimental|MRgFUS Treatment|The pancreatic tumor will be ablated with magnetic resonance guided focused ultrasound (MRgFUS).
11068332|NCT04298229|Active Comparator|Protocolized diuretic therapy|"The patient will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.
~The initial loop diuretic regimen after enrollment:
~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.
~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol."
11068333|NCT04298229|Experimental|Protocolized diuretic therapy plus SGLT2 inhibitor therapy|"The patient will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.
~The initial loop diuretic regimen after enrollment:
~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.
~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.
~The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge."
11068334|NCT04298216|Active Comparator|Assessment of Inferior Vena Cavae with Subcostal View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the subcostal region.
11068335|NCT04298216|Experimental|Assessment of Inferior Vena Cavae with Transhepatic View|Patients will have a novel operator attempt to visualize their Inferior Vena Cavae with the probe placed in the transhepatic region.
11068336|NCT04298203|Experimental|Meal Replacement Therapy|Participants who are enrolled in the study will be administered a short-term (six weeks) meal replacement induction period. Because the trial is deigned to evaluate weight loss maintenance, participants must achieve at least 5% BMI reduction at week six of the meal replacement period in order to be randomized. Subjects will be asked to strictly follow the eating regimen, which will include a total of approximately 1,000 kcals per day of commercially-available liquid shakes (breakfast and lunch), pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables. Shakes/meals will be provided free of charge - fruits/vegetables will be purchased by the participants. Guidance will be provided regarding the use of the meal replacement shakes at school, and participants will be encouraged to engage in family meal sessions despite eating different foods.
11068337|NCT04298203|Active Comparator|Phentermine/Topiramate|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to phentermine/topiramate will start treatment at 3.75 mg/23 mg orally once daily in the morning for 14 days, then increased to 7.5 mg/46 mg orally once daily in the morning for 14 days, then be increased to 11.25 mg/69 mg orally once daily in the morning for 14 days, then increased to 15 mg/92 mg orally once daily in the morning for the remainder of the trial. Following the final study visit, participants will be down-titrated gradually by taking medication every other day for seven days before stopping treatment altogether.
11068338|NCT04298203|Placebo Comparator|Placebo|Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo. Participants randomized to the placebo will receive inert tablets that look like the active comparator. In order to mimic the active comparator arm, subjects randomized to the placebo arm will up titrate their placebo at the beginning of the study treatment and will down titrate as in the active comparator arm. Participants will be instructed to take the medication under the supervision of a parent/guardian and pill counts of returned product will serve as a proxy of treatment compliance.
11068339|NCT04298190|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
11068340|NCT04298190|Active Comparator|Enhanced Usual Care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
11068341|NCT04298177|Experimental|QDOT-LAWT|"A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used.
~The primary ablation mode for PVI will depend on the calculated LAWT at each atrial point, as follows:
~<= 4-mm LAWT: vHPSD ablation will be performed using 90W and: a) If <= 1-mm LAWT for 2 seconds; b) If > 1-mm LAWT for 4 seconds.
~> 4-mm LAWT: QMODE ablation will be performed. VisiTag settings: Catheter position stability 3 mm for a minimum time of 3 s, maximum range 4 mm; force over time 25% with minimum force 3 g; lesion tag size 3 mm. Parameters: 50 W (power-controlled, without ramping); irrigation at 2 ml/min during mapping and 30 ml/min during ablation; minimum CF > 3 g; ablation index target = 500."
11068342|NCT04298177|Active Comparator|CLOSE|"In the CLOSE arm, the use of MDCT-derived LAWT information will not be available for the operator. A ThermoCool® SmartTouch® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) will be used. The ablation will be performed using a proprietary RF generator (SMARTABLATE®; Biosense Webster, Diamond Bar, CA, USA).
~Ablation will be performed according to the CLOSE study settings: Power-controlled mode (without ramping) with 25 to 35 W (irrigation flow 30 ml/min). RF will be delivered until an AI of ≥ 400 at the posterior wall/roof and ≥ 550 at the anterior wall are reached."
11068343|NCT04298164|Experimental|Intervention group|Group that receives the intervention
11068344|NCT04298164|Active Comparator|Control group|Group that receives treatment as usual
11068345|NCT04298151|Experimental|zirconomer improved|zirconia reinforced glass ionomer restoration
11068346|NCT04298151|Active Comparator|ketac molar aplicap|conventional viscous glass ionomer restoration
11068347|NCT04298138|Experimental|Low dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
11068348|NCT04298138|Experimental|Medium dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
11068349|NCT04298138|Experimental|High dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
11068350|NCT04298125|Experimental|Exercise in Pregnancy in Community|The Expecting intervention at the ACNC includes three 30-45 minute, in-person exercise sessions per week. The sessions are gradually increased in length over the first weeks of participation, and are comprised of 15-30 minutes of moderate aerobic activity (recumbent bike, walking on a treadmill or on an elliptical machine) as well as 5-10 minutes of resistance training using hydraulic exercise equipment. The sessions conclude with stretching exercises. Throughout the session, a personal trainer assesses the rating of perceived exertion using the 6 to 20 point Borg scale of exhaustion.41 Between sessions, participants are asked to monitor their daily step count with a target of 10,000 steps per day using a pedometer provided to the participant. This number is reported to or downloaded by the personal trainer at each in-person session. These elements will be adapted to provide a similar exercise experience that is accessible to women in their local community.
11068351|NCT04298125|No Intervention|Standard Care|Participants will receive guidance on exercise from their physician as usual.
11068352|NCT04298112||relapse after radical treatment for prostate cancer|prostate cancer patients with biochemical relapse following radical treatment, or patients with persistently elevated PSA levels after radical prostatectomy, that have been (or will be) referred to PSMA PET/CT and PSMA PET/MRI at one of the participating hospitals.
11068355|NCT04298086|Experimental|Exercise Treatment and Plant-Based Diet|Will consist of structured exercise treatment plus a calorie-restricted plant-based diet. Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed at MSK or on a treadmill under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service. Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
11068356|NCT04298086|Active Comparator|Physical activity and nutrition counseling|Will consist of a general physical activity recommendations and nutrition education by exercise physiologists and registered dietitians. Treadmills will be provided to patients in the counseling arm.
11068357|NCT04298060|Experimental|DAS181 SD group Cohort 1, Stage 1|DAS181 SD group 4.5mg/day for 7 or 10 days
11068358|NCT04298060|Experimental|DAS181 HD group Cohort 1, Stage 1|DAS181 HD group 9mg/day for 7 or 10 days.
11068359|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 1|Placebo 0mg/day for 7 or 10 days
11068360|NCT04298060|Experimental|DAS181 group, Cohort 1, Stage 2|DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.
11068361|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 2|Placebo 0mg/day for 7 or 10 days
11068362|NCT04298060|Experimental|DAS181 group, Cohort 2, Stage1 and 2|DAS181 4.5mg/day or 9mg/day for 7 or 10 days
11068363|NCT04298047|Experimental|Intervention group|The participants in the Intervention group will be participants of the MMFA participatory art-based activity.
11068364|NCT04298047|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the MMFA participatory art-based activity.
11068365|NCT04298034|Experimental|Treatment|The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.
11068366|NCT04298034|No Intervention|No-treatment|
11068367|NCT04298021|Experimental|AZD6738 + Durvalumab|"Durvalumab 1500 mg iv on D1
~AZD6738 240 mg bid on D15-D28 Every 4 weeks C1D1 dose of durvalumab will be delivered, and AZD6738 of 240 mg bid will be dosed at D15-D28. Every cycle consists of 4 weeks."
11068368|NCT04298021|Experimental|AZD6738 + Olaparib|"AZD6738 160 mg qd on D1-D7
~Olaparib 300 mg bid on D1-D28 Every 4 weeks Every cycle consists of 4 weeks. AZD6738 of 160 mg qd will be administered on D1-D7. Olaparib will be delivered as 300 mg bid dose on D1-D28."
11068369|NCT04298008|Experimental|AZD6738 + Durvalumab Cohort|This is a study enrolling advanced BTC patients who have been previously treated with immunotherapy, to explore the combination of AZD6738+durvalumab
11068370|NCT04297995|Experimental|HLX10 Plus HLX07 (stage 1L)|3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly
11068371|NCT04297995|Experimental|HLX10 Plus HLX07 (Stage 1H)|3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly
11068372|NCT04297982|Experimental|İntervention group (Mandala activity)|Scales were applied to the experimental group in the first encounter with the adolescent (pre-test). Then, a total of two sessions of individual mandala activities were performed at least 48 hours apart. Each adolescent freely drawn and painted the unstructured mandala on white paper, starting from the center and expanding. The same scales were reapplied last (post-test).
11068373|NCT04297982|Other|Control group|Scales were applied to the control group with an interval of 5 days and received routine nursing care (pre-test, post-test).
11068374|NCT04297969||GCK Glow fixation|Patients screened with GoCheck Kids flash concentrated iPhone 7+
11068375|NCT04297943|Active Comparator|3D Orthosis|See summary
11068376|NCT04297943|Active Comparator|Custom Thermoplastic Orthosis|See summary
11068377|NCT04297930||Paul Glaucoma Implant Surgery|Patients who had surgery with the Paul Glaucoma Implant
11068378|NCT04297917|Experimental|Healthy Volunteers with low dose vaccination|5 Healthy Volunteers receiving low dose vaccination
11068379|NCT04297917|Experimental|Healthy Volunteers with high dose vaccination|5 Healthy Volunteers receiving high dose vaccination
11068380|NCT04297917|Experimental|Chronic Hepatitis B participants with low dose vaccination|6 participants with Chronic Hepatitis B infection receiving low dose vaccination
11068381|NCT04297917|Experimental|Chronic Hepatitis B participants with high dose vaccination|6 participants with Chronic Hepatitis B infection receiving high dose vaccination
11068382|NCT04297891||ARSACS|Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.
11068383|NCT04297891||SPG7|Participants with genetically confirmed SPG7 (ORPHA:99013) will be recruited. Target sample size for the SPG7 cohort is 72.
11068384|NCT04297891||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as the ARSACS and SPG7 cohort. Target sample size for the control cohort is 50.
11068385|NCT04297878|Experimental|Group A|Taking two SsK12 lozenges at night on days 1, 7 and 14.
11068386|NCT04297878|Active Comparator|Group B|One SsK12 daily at night for 14 days.
11068387|NCT04297865|Experimental|A dose as CJ-15314 or placebo|Oral administration of A as CJ-15314 or placebo once a day
11068388|NCT04297865|Experimental|B dose as CJ-15314 or placebo|Oral administration of B as CJ-15314 or placebo once a day
11068389|NCT04297865|Experimental|C dose as CJ-15314 or placebo|Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days
11068390|NCT04297865|Experimental|D dose as CJ-15314 or placebo|Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days
11068391|NCT04297865|Experimental|E dose as CJ-15314 or placebo|Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days
11068392|NCT04297865|Experimental|F dose as CJ-15314 or placebo|Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days
11068393|NCT04297852|Active Comparator|Vegan drink|Treatment group
11068394|NCT04297852|Placebo Comparator|Control|Placebo group
11068452|NCT04297319|Experimental|1 - Laser intervention|Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks
11068453|NCT04297319|Placebo Comparator|2 - Laser placebo|Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks
11068395|NCT04297839|Active Comparator|Control Group|"Patients in this group will receive heparin during hemodialysis sessions, at a dose of 1.000 units at the beginning and 500 units per hour in a syringe infusion pump.
~If the patient has a contraindication for the heparin use, it will receive saline continuous administration.
~This is the actual standard of care performed in extended hemodialysis sessions."
11068396|NCT04297839|Experimental|Citrate Group|Patients in this group will receive regional citrate anticoagulation, with acid-citrate-dextrose 2.2% (ACD). Dose of 3 mmol per liter of filtered blood. The systemic calcium levels are measured every two hours and a solution of calcium chloride is infused in a peripheral venous access, accordingly to citrate infusion rate and the systemic calcium values.
11068397|NCT04297826|Experimental|Harvest for Health|The study is a gardening intervention among 150 older cancer survivors and individuals living with chronic disease (cardiovascular disease and diabetes) in the states of Alabama and Mississippi. This program focuses on 15 counties where a Community Health Advisor training program is in place (Bullock, Calhoun, Dallas Madison, Marengo, Monroe, Sumter, Talladega, Walker Counties in Alabama and Boliver, Granada, Humphrey, Panola, Sunflower, and Yazoo Counties in Mississippi). Participants are paired with Cooperative Extension certified Master Gardeners to plant a vegetable garden at their place of residence (the intervention). Baseline, midpoint, and 1 year follow up will occur. Previous pilot work provides an established relationship with the Cooperative Extension as well as training mechanisms for the Master Gardeners.
11068398|NCT04297813|Active Comparator|Control|The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
11068399|NCT04297813|Experimental|Test|Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
11068400|NCT04297787|Other|Treatment|The treatment protocol the study team will be following is as follows for all enrolled patients. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
11068401|NCT04297774|Experimental|virtual reality group|18 sessions of standard treatment plus virtual reality treatment.
11068402|NCT04297774|Active Comparator|standard treatment group|18 sessions of standard treatment plus balance training.
11068403|NCT04297761|Placebo Comparator|Filtered air|Subjects will be exposed once to filtered air for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
11068404|NCT04297761|Experimental|Wood Smoke|Subjects will be exposed to air containing wood smoke for 2 hours with alternating 15 min of exercise (cycle ergometer) and rest.
11068405|NCT04297748|Experimental|Cohort A|Patients (pts) will receive an initial trace (100 mg, IV) dose of zirconium-89 (1.8-2.5 mCi) labelled M7824 (89Zr-M7824) on day 1, sequential PET imaging over 1 week will be performed to determine the biodistribution 89Zr-M7824 into the tumour and normal tissues. All patients who remain on study after Day 14 will have a 1200 mg dose of M7824 q2w beginning on Cycle 1 Day 15. Pts will then receive a 2nd infusion of 100 mg of 89Zr-M7824 with cold M7824 making a total dose of 1200mg on Day 29. All patients will then receive a dose of cold 1200mg M7824 on Cycle 1 Day 43. Patients will continue to receive a therapeutic dose of 1200 mg q2w of M7824 until disease progression or unacceptable toxicity. Patients who do not achieve a CR after 3 doses of M7824 in Cycle 1, may then commence treatment with concurrent chemotherapy with carboplatin and pemetrexed at conventional doses.
11068406|NCT04297748|Experimental|Cohort B|Cohort A will determine whether or not high PD-L1 positive disease is required at study entry to Cohort B. All other assessments within cohort A will be undertaken.
11068407|NCT04297735|Active Comparator|Standard of care group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
11068408|NCT04297735|Experimental|Telemedicine group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
11068409|NCT04297696|Experimental|exercise group|therapeutic exercises
11068410|NCT04297696|No Intervention|control group|
11068411|NCT04297683|Experimental|Regimen A - Zilucoplan|Participants are randomized to receive either active zilucoplan or matching placebo.
11068412|NCT04297683|Experimental|Regimen B - Verdiperstat|Participants are randomized to receive either active verdiperstat or matching placebo.
11068413|NCT04297683|Experimental|Regimen C - CNM-Au8|Participants are randomized to receive either active CNM-Au8 or matching placebo.
11068414|NCT04297670||Unvaccinated against HPV boys|Sexually active unvaccinated against HPV 16-20 years old boys.
11068415|NCT04297657|Experimental|intervention group|
11068416|NCT04297657|No Intervention|control group|
11068417|NCT04297631|Experimental|Vancomycin|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
11068418|NCT04297631|Experimental|Tobramycin|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
11068419|NCT04297618|Experimental|Xiidra treatment|Each participant will use the same study drops, Xiidra, over the course of the 12-week study.
11068420|NCT04297605|Experimental|Experimental 1: pembrolizumab and Pemetrexed|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days
~Pembrolizumab 200 mg and Pemetrexed 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)"
11068421|NCT04297605|Experimental|Experimental 2: pembrolizumab and Nab-paclitaxel|"Treatment includes administration of pembrolizumab and chemotherapy, which are administered every 21 days
~Pembrolizumab 200 mg and Nab-paclitaxel 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles followed by pembrolizumab alone"
11068422|NCT04297592|Active Comparator|Group A - antibiotic group|Patients will be given 7-days of an oral antibiotic (either cephalexin or doxycycline) to be started after completion of standard perioperative intravenous antibiotics following primary hip or knee arthroplasty
11068423|NCT04297592|No Intervention|Group B - no additional antibiotic|No antibiotics will be prescribed following standard perioperative IV antibiotics following primary hip or knee arthroplasty.
11068424|NCT04297566||Crohn disease's patients|Crohn's disease patients seen in gastroenterology consultation or coming in day hospital for treatment
11068425|NCT04297553|Active Comparator|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
11068426|NCT04297553|Active Comparator|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
11068427|NCT04297540|Experimental|Active-tDCS group|8 sessions (in two weeks) of active tDCS combined with a virtual reality training
11068428|NCT04297540|Sham Comparator|Sham-tDCS group|8 sessions (in two weeks) of sham tDCS combined with a virtual reality training
11068429|NCT04297527|Experimental|Conventional Physiotherapy Group|Group I (18 subjects) received 15 sessions of Conventional Physiotherapy program (CPP) 5 times per week.
11068430|NCT04297527|Experimental|Mulligan Mobilization Group|Mulligan Mobilization was administered 9 sessions (3 days a week, for 3 weeks). .
11068431|NCT04297527|Experimental|Conventional Physiotherapy plus Mulligan Mobilization Group|Conventional Physiotherapy (15 session) plus Mulligan Mobilization Programme (9 session) were applied in this group. CP were applied 5 days a week and CP+MM 3 days a week for 3 weeks.
11068432|NCT04297501||All participants|All enrolled participants in this study
11068433|NCT04297488|Experimental|INR|Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.
11068434|NCT04297475||rheumatoid arthritis|The patients are diagnosed with RA according to the American College of Rheumatology (ACR) criteria, and the current clinical state was in-active or relapse. The patients receive final diagnosis and disease evaluation by two experienced rheumatologists
11068435|NCT04297462|Experimental|3-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during three consecutive days after the contact with influenza
11068436|NCT04297462|Active Comparator|7-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during seven consecutive days after the contact with influenza
11068437|NCT04297423|Experimental|Plenvu|Plenvu split dose
11068438|NCT04297423|Active Comparator|Citrafleet|citrafleet in split dose
11068439|NCT04297410|Experimental|Neoadjuvant LuPSMA|
11068440|NCT04297384|Active Comparator|Group I (standard educational materials, surveys)|Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
11068441|NCT04297384|Experimental|Group II (personalized information, surveys)|Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.
11068442|NCT04297371||CTD with RVH|The diagnosis of CTD was made based on the clinical classification criteria. The RVH patient was diagnosed by an echocardiography demonstration (later confirmed by CMR) of a hypertrophic RV (maximal end-diastole RV wall thickness >4 mm) due to CTD.
11068443|NCT04297371||CTD without RVH|The diagnosis of CTD was made based on the clinical classification criteria.The subjects were enrolled as having non-RVH if their RV wall thickness was ≤ 4 mm (later confirmed by CMR).
11068444|NCT04297371||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
11068445|NCT04297358|Experimental|Stroke patients|40 consecutive sessions of hyperbaric oxygen will be administered at a pressure of 2 absolute atmosphere (ATA) to 10 patients. If there are drop outs, recruitment will be continued until a total of 10 patients with at least 30 sessions.
11068446|NCT04297345|Experimental|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.
~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
11068447|NCT04297345|No Intervention|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
11068448|NCT04297332|Experimental|Arm I (active EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
11068449|NCT04297332|Experimental|Arm II (active EFT, control FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
11068450|NCT04297332|Experimental|Arm III (control EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
11068451|NCT04297332|Active Comparator|Arm IV (control EFT, control TFP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.
11068454|NCT04297306|Active Comparator|Exercise prescription|"This group will be provided with a prescript exercise program, taken from UK National Guidance.
~The advice will be directed to be undertaken for 6 weeks immediately prior to surgery."
11068455|NCT04297306|Experimental|Exercise prescription and Virtual Reality Exercise Gaming|"This group will be provided with a prescript exercise program as in Arm 1. However, this group of patients will also be presented with a Virtual Reality Headset, pre-programmed with Exercise promoted games which will be provided to support and encourage their exercise regimen.
~Again this advice and support will be directed to be undertaken for 6 weeks immediately prior to surgery."
11068456|NCT04297293|Experimental|Ramosetron-ODT|
11068457|NCT04297293|No Intervention|Control|
11068458|NCT04297280|Experimental|TACE in combination with sintilimab|TACE treatment starts at day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator decision. Sintilimab will be initiated on day 14 after the first TACE session. Sintilimab will be administered every three weeks (200mg fixed dose IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11068459|NCT04297267|Experimental|GP group|Patients should receive four cycles of GP regimen (cisplatin at 75 mg/m2 iv infusion on day 1 plus gemcitabine at 1250 mg/m2 iv infusion over 30 min on day 1 and 8 every 3 weeks).
11068460|NCT04297254|Experimental|Lenvatinib 12 mg or 8 mg|Participants with body weight (BW) greater than or equal to (>=) 60 kilogram (kg), will receive lenvatinib 12 milligram (mg) (03 capsules), and participants with BW less than (<) 60 kg, will receive lenvatinib 8 mg, (02 capsules), orally, once daily with or without food in 28-day cycles for a maximum 6 cycles of 4 weeks each for a total of 24 weeks or until disease progression, death, intolerable or unacceptable toxicity, or withdrawal of consent, whichever occurs earlier.
11068461|NCT04297241|Experimental|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
11068462|NCT04297228|Experimental|Step by Step Program|"Thirteen 1.5 hour weekday educational sessions, five 1-hour weekday fitness classes and seventeen 1 hour weekend walks/farmer's market trips were scheduled over 22 weeks. The planned total contact time was 41.5 hours, above the minimum effective amount and recommended by the USPSTF. Children participated in all activities. Weekly text messages with motivational messages and reminders were planned.
~Educational Topics included:
~Intro and Goal Setting How to Read Nutrition Labels How to Build a Healthy Meal Choose My Plate/Walking for Fitness Healthy Fast Food Add More Fruits/Vegetables to Meals Add More Physical Activity Each Day Healthy Snacks and Drinks Healthy Desserts Circuit Training at Home Favorite Recipe Makeover Step by Step Jeopardy Celebration of Completion"
11068463|NCT04297215|Placebo Comparator|Control group|This group will receive therapeutic clothing without antimicrobial agents
11068464|NCT04297215|Active Comparator|Chitosan group|This group will receive antimicrobial therapeutic clothing based on chitosan
11068465|NCT04297215|Active Comparator|Silver group|This group will receive antimicrobial clothing based on silver.
11068466|NCT04297202|Experimental|Apatinib Combined With SHR-1210 Injection|"SHR-1210 Injection: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle; Apatinib : D1-D21 : 250 mg, orally, qd; Before surgery, the patient's surgical pathology samples still need to be collected.
~D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation;
~After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. The cycle of a three-week plan will be performed with a total of 8 cycles with the treatment of Apatinib combination with SHR-1210 Injection."
11068467|NCT04297189|Experimental|Coaching Intervention|Single arm pilot study of coaching intervention
11068468|NCT04297176|Experimental|Traditional monitoring method|Patients are dosed using two timed vancomycin serum concentrations
11068469|NCT04297176|Active Comparator|One concentration method|Patients are dosed based on one timed vancomycin serum level
11068470|NCT04297163|Active Comparator|Hospital management|Patient's receive no intervention, the follow up is the usual for a patient following CPAP therapy.
11068471|NCT04297163|Experimental|Telemedicine management|CPAP remote monitoring of patients, including a mobile application and a voicemail.
11068472|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
11068473|NCT04297137|Experimental|Mycoprotein|Ingestion of 30 g mycoprotein drink
11068474|NCT04297137|Experimental|Spirulina|Ingestion of 30 g spirulina protein drink
11068475|NCT04297137|Experimental|Chlorella|Ingestion of 30 g chlorella protein drink
11068476|NCT04297137|Experimental|Pea|Ingestion of 30 g pea protein drink
11068477|NCT04297137|Experimental|Lupin|Ingestion of 30 g lupin protein drink
11068478|NCT04297137|Active Comparator|Milk|Ingestion of 30 g milk protein
11068479|NCT04297124|Experimental|[14C]-CC-90009|A single IV dose of 0.6 mg [14C]-CC-90009 containing approximately 2 µCi of radioactivity will be administered on Day 1 under fasted conditions.
11068480|NCT04297111|Placebo Comparator|Placebo|Maltodextrin containing capsule
11068481|NCT04297111|Experimental|Probiotic|Probiotic containing capsule
11068482|NCT04297098||Asthmatic patients|
11068483|NCT04297098||Allergic patients|
11068484|NCT04297098||Control group|
11068485|NCT04297085|Experimental|Cases|
11068486|NCT04297072||Rivaroxaban|Participants in this group administered oral anticoagulant Rivaroxaban
11068487|NCT04297072||Vitamin-K antagonists (VKAs)|Participants in this group administered oral anticoagulants VKAs
11068488|NCT04297059|Experimental|Intervention group|Implementation of Ajyal Salima intervention to promote healthy eating and encourage physical activity in Lebanese school-children.
11068489|NCT04297059|No Intervention|Control group|Group of students not receiving any intervention
11068490|NCT04297046|Active Comparator|QLB for total abdominal hysterectomy|Quadratus lumborum block (QLB) was performed bilaterally with 0,3 ml/kg 0.25% bupivacaine (maximum dose 3 ml/kg) solution injection on each side.Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
11068491|NCT04297046|Active Comparator|TAPB for total abdominal hysterect0my|The transversus abdominis plane block (TAPB)was performed bilaterally with 0.3 ml/kg of 0.25% bupivacaine (maximum dose 3 ml/kg) solution . Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
11101118|NCT04069143|Experimental|Part 1:18F-BMS-986327 (Safety Study)|
11068492|NCT04297033|Experimental|Lovastatin intervention|combination of 40mg/d 12m lovastatin and symptomatic treatment drugs as a treatment strategy for BAVM .
11068493|NCT04297033|Placebo Comparator|placebo|combination of placebo and symptomatic treatment drugs as a treatment strategy for BAVM
11068494|NCT04297020||Pre-menopausal BCS + ET|Pre-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
11068495|NCT04297020||Post-menopausal BCS + ET|Post-menopausal Breast Cancer Survivor (BCS) who have undergone Endocrine Therapy (ET)
11068496|NCT04297020||Pre-menopausal Healthy Control|Pre-menopausal healthy control group
11068497|NCT04297020||Post-menopausal Healthy Control|Post-menopausal healthy control group
11068498|NCT04297007|Active Comparator|Group P = PECS-II group|In group P, PECS will be performed with patients in the supine position at the end of the surgery before extubation by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions the high frequency linear probe (11-12 MHz) will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. US probe will be placed on the 4th rib. The muscles PMm, Pmm and Sam will be visualized. At the anterior axillary level or mid-axillary level, via the in-plane technique, Pecs II will be applied by injecting 20 mL of 0.25% bupivacaine in a cephalad to caudad direction to the fascia on Sam.
11068499|NCT04297007|Active Comparator|Group R = RIB group|In group R, RIB block will be performed with patients in the lateral decubitus position at the end of the surgery before extubation. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injectted into the fascial plane.
11068500|NCT04297007|No Intervention|Group C = Control group|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11068501|NCT04296994|Experimental|Open-label Dose Escalation and Expansion Study of QL1706|"Part 1 (Dose escalation): QL1706 will be administered in sequential cohorts each receiving 1 of 4 doses of QL1706 on day 1 of every 21-day cycle (3 weeks) via IV infusion. Dose escalation will continue until an MTD is reached.
~Part 2 (Dose Expansion): The PK parameters of QL1706 will be tested at 2-3 doses determined during the dose-escalation phase in subjects with advanced malignant tumor cohorts."
11068502|NCT04296981|Experimental|video-based patient information|Viewing an explanatory video (8 minutes) to improve communication and understanding of stroke issues and stages of the continuum of care
11068503|NCT04296968|Experimental|Expectation and experimental pain in humans|
11068504|NCT04296955|Experimental|Health communication intervention|Motivational interview as a new health communication intervention (one arm)
11068505|NCT04296955|No Intervention|Standard care|Standard care
11068506|NCT04296942|Experimental|1/M7824 + BN-Brachyury|Bifunctional fusion molecule involving PD-L1 with TGF-b sequestering agent added to a vaccine for the tumor associated antigen called brachyury.
11068507|NCT04296942|Experimental|2/M7824 + BN-Brachyury + T-DM1|Bifunctional fusion molecule involving PD-L1 with TGF-b sequestering agent added to a vaccine for the tumor associated antigen called brachyury. These investigational agents will be added to standard of care treatment called T-DM1.
11068508|NCT04296942|Experimental|3/M7824 + BN-Brachyury + T-DM1 + Entinostat|Bifunctional fusion molecule involving PD-L1 with TGF-b sequestering agent added to a vaccine for the tumor associated antigen called brachyury as well as to an oral HDAC inhibitor called entinostat. These investigational agents will be added to standard of care treatment called T-DM1.
11068509|NCT04296929|Experimental|Affected arm in lymphedema patients|Complex decongestive physiotherapy treatment will be applied to the arm (affected arm) that develops lymphedema after unilateral breast cancer treatment.
11068510|NCT04296929|No Intervention|Unaffected arm in lymphedema patients|After unilateral breast cancer treatments, the non-lymphedema side in the upper extremities, is the unaffected arm. No treatments will be applied to the unaffected side.
11068511|NCT04296916|Experimental|Intervention arm|medical reduction of IOP by eyedrops
11068512|NCT04296916|No Intervention|control arm|follow up without medication
11068513|NCT04296903|Experimental|MID-C treatment|
11068514|NCT04296890|Experimental|Treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
11068515|NCT04296877|Active Comparator|Habitual Contact Lens|All subjects are re-fit into habitual Acuvue® Oasys® contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days.
11068516|NCT04296877|Active Comparator|Daily Disposable Contact Lens|All subjects are fit into Precision1® contact lenses. Subjects are requested to wear the lenses for two weeks, for a minimum of at least 6 hours per day for 10 days.
11068517|NCT04296864|Placebo Comparator|Placebo|Placebo of Dupilumab
11068518|NCT04296864|Experimental|Dupilumab|one loading dose of Dupilumab 600 mg followed by Dupilumab 300 mg weekly for a total of 16 weeks
11068519|NCT04296851|Experimental|niclosamide|650mg daily
11068520|NCT04296851|Placebo Comparator|placebo|identical- appearing placebo
11068521|NCT04296838|Experimental|refractory UME patients treated with Conbercept|patients in this arm should meet the inclusion criteria and the definition of refractory UME
11068522|NCT04296825|Placebo Comparator|P|Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).
11068523|NCT04296825|Active Comparator|CA|Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
11068524|NCT04296825|Experimental|C|Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).
11068525|NCT04296825|Experimental|A|Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
11068552|NCT04296604|Experimental|Traumatic Brain Injury|This group consists of individuals diagnosed with traumatic brain injury. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068526|NCT04296812|Experimental|Injeti Self-Love Model|"Psychoeducational intervention focusing improving self-esteem and increasing self-awareness.
~The session will start with discussion on healthy relationships, self-esteem.
~A white board will be used in group format and regular 8.5 by 11 paper during individual session to illustrate the Self-Love model and the characteristics and traits that are effected by self-love and lack of self-love.
~At the end of illustration and discussion there will be handout of the self-love intervention.
~The session will end by answering questions and emphasizing the importance of having self-awareness of traits that promote low-self-esteem, and finally, strategies to promote and maintain self-esteem."
11068527|NCT04296799|Experimental|Single Ascending Dose|The study will consist of 6 cohorts (1 cohort per dose level) of 8 subjects (6 subjects receiving the study drug and 2 receiving matching placebo), for a total of 48 subjects.
11068528|NCT04296799|Experimental|Multiple Ascending Dose|The study will consist of 3 cohorts (1 cohort per dose level) of 8 subjects. Six subjects will receive study drug and 2 subjects will receive matching placebo, daily for 14 consecutive days, for a total of 24 subjects (18 study drug; 6 placebo).
11068529|NCT04296786|Experimental|Chidamide plus Sintilimab|Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.
11068530|NCT04296760||Women with suspicious of deep posterior pelvic endometriosis|
11068531|NCT04296747|Experimental|Induction therapy|patients would accept toripalimab combined with chemotherapy as induction therapy, then radical treatment(surgery or chemoradiotherapy) according to whether the tumor could be resectable or the evaluation result according to RECIST1.1. Ones with PD after induction therapy will enter survival follow-up directly
11068532|NCT04296721|Experimental|Intensive weight-loss program|The life style change program will consist of two stages. The first will consist of a 3-month period of intensive diet and progressive exercise with biweekly consultations with a nutritionist (in groups or individually). The second stage will last for 9 months, until completion, with a diet that is progressively higher in calories, with more intense exercise, under the supervision of a community nurse and an individual nutritional consultation at 9 months.
11068533|NCT04296721|Active Comparator|Standard dietary recommendations|Patients will be followed according to the usual recommendations: A written diet (designed by a hospital nutritionist) and an exercise plan, depending on the patient's age and activity level, without any other type of evaluation or visit Visits in the Sleep Disorders Unit will be scheduled at 3 and 12 months
11068534|NCT04296708|Experimental|ExerCube group|The ExerCube is an immersive fitness game setting that combines innovative soft- and hardware designs with state of-the-art training concepts. The ExerCube has three walls which serve as virtual reality projection screens and haptic interfaces. The ExerCube is a playful physical-cognitive exergame training. The user navigates a virtual environment/reality via whole body exercise. The video game navigates the user and triggers various cognitive functions. The used physical exercises are functionally and elicit the improvement of endurance and strength components. Via different monitoring systems (points and heart rate), the game adapts to the individual abilities and training level to tailor workout intensity. The ExerCube training consists of two sessions a week each session will last about 30 minutes of which 25 minutes will be pure playtime
11068535|NCT04296708|No Intervention|Control group|The control group does not have any additional ExerCube training.
11068536|NCT04296695|Experimental|B/F/TAF|50mg/600mg/300mg
11068537|NCT04296695|Active Comparator|TDF/3TC/EFV|300mg/300mg/400mg
11068538|NCT04296682|No Intervention|Atraumatic Extraction Without Gingival Graft|Alveolar closure with elevation of total flaps and simple suture (Silk thread 4.0, Ethicon, Johnson & Johnson, SJC).
11068539|NCT04296682|Experimental|Atraumatic Extraction With Gingival Graft|Closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual palate.
11068540|NCT04296669|Experimental|Full desk allocation|All children within this classroom received a sit-stand stand
11068541|NCT04296669|Experimental|Partial desk allocation|six sit-stand desks were provided in this classroom. Children were rotated between these desks and traditional desks
11068542|NCT04296669|No Intervention|Control|Traditional classroom furniture was used
11068543|NCT04296656|Active Comparator|Intervention group|"Mothers in the intervention group were taught the infant calming technique 5 S's, a part of The Happiest Baby (THB) method. THB is based on the theory that infants have an innate calming reflex that can soothe infant fussing, excessive crying and prolong sleep. This reflex is triggered by five activities that mimic the sensory milieu of the womb. The 5 S's include swaddling, side position, sound (white noise), swing and suck.
~The intervention consisted of a 20-minute face-to-face guidance session with the researcher, executed individually in the mother's hospital room. Each mother was given a leaflet to take home that explained the 5 steps in short. Safety issues, such as safest sleep position (supine), allowing hips to flex and how to avoid overheating when swaddled, were addressed. The same researcher executed each guidance session to maintain standardization."
11068544|NCT04296656|No Intervention|Control group|Standard care on postpartum ward (breastfeeding and infant care guidance and support in recovering from childbirth and transitioning into parenthood).
11068545|NCT04296643|Experimental|Medical Mask|Medical Mask worn when providing care to patient with febrile respiratory illness
11068546|NCT04296643|Active Comparator|N95 respirator|N95 respirator worn when providing care to patient with febrile respiratory illness
11068547|NCT04296630|Active Comparator|Message #1|This arm will receive one of three social media messages that is preferred by our target population through focus groups that are being conducted as part of a previous study.
11068548|NCT04296630|Active Comparator|Message #2|This arm will receive the second social media message that is preferred by our target population as identified from our previous focus group study.
11068549|NCT04296630|Active Comparator|Message #3|This arm will receive the third social media message that is preferred by our target population as identified from our previous focus group study.
11068550|NCT04296630|Active Comparator|Tailored Arm|This arm will receive social media messages that will be tailored by one of the following variables: gender (men/women), age (younger/older), location (urban/rural), or social economic status (level of education). Testing to be conducted in a previous study will identify the variable that messages are tailored by.
11068551|NCT04296617||Observational (medical chart review)|Patients' medical charts are reviewed.
11068553|NCT04296604|Experimental|Major Depressive Disorder|This group consists of individuals diagnosed with major depressive disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068554|NCT04296604|Experimental|Bipolar Disorder|This group consists of individuals diagnosed with bipolar disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068555|NCT04296604|Experimental|Schizophrenia|This group consists of individuals diagnosed with schizophrenia. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068556|NCT04296604|Experimental|Attention Deficit Hyperactivity Disorder|This group consists of individuals diagnosed with attention deficit hyperactivity disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068557|NCT04296604|Experimental|Borderline Personality Disorder|This group consists of individuals diagnosed with borderline personality disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068558|NCT04296604|Experimental|Substance Use Disorder|This group consists of individuals diagnosed with substance use disorder. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068559|NCT04296604|Active Comparator|Healthy Controls|This group consists of individuals diagnosed with healthy controls. This group will undergo three sessions of tDCS: two active sessions and one sham session. The order of the sessions is randomized.
11068560|NCT04296591||study group|The study group consisted of late preterm cases(34-37 weeks of gestation) and
11068561|NCT04296591||control group|the control group consisted of term cases (<37 weeks of gestation).
11068562|NCT04296578|Experimental|Cohort 1: 5.5 mg selenite|Given orally, 5.5 mg selenite with food (within 30 mins of eating), for 5 weeks and monthly there after
11068563|NCT04296578|Experimental|Cohort 2: 11 mg selenite|Given orally, 11 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
11068564|NCT04296578|Experimental|Cohort 3: 16.5 mg selenite|Given orally, 16.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
11068565|NCT04296578|Experimental|Cohort 4: 22 mg selenite|Given orally, 22 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
11068566|NCT04296578|Experimental|Cohort 5: 27.5 mg selenite|Given orally, 27.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
11068567|NCT04296578|Experimental|Cohort 6: 33 mg selenite|Given orally, 33 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
11068568|NCT04296565|Other|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
11068569|NCT04296565|Experimental|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
11068570|NCT04296552|Experimental|12 week lowFODMAP dietary intervention|Patients with IBS-D are enrolled in a 12 week strict lowFODMAP dietary intervention study.
11068571|NCT04296539||Sedentary|Involving little exercise or physical activity
11068572|NCT04296539||Exercise|Subjects who were performing regularly pilates exercises for at least six months
11068573|NCT04296526|Experimental|Precontemplation|
11068574|NCT04296526|Experimental|Contemplation|
11068575|NCT04296526|Experimental|Preparation|
11068576|NCT04296513||High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white-light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.
11068577|NCT04296513||High-definition magnification with digital chromoendoscopy.|The subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
11068578|NCT04296500||Decision tree algorithm training/testing|The investigators divided data of 67 patients into 5 groups to do 5 fold cross validation. Four groups were used to train decision tree algorithm and one group was used to test it.
11068579|NCT04296487|Experimental|Autologous Chondrocyte Injection|Autologous chondrocytes were isolated and expanded in laboratory, then injected at 2x10^6 of cells per cm^2 of the cartilage defect.
11068580|NCT04296474|Active Comparator|Active ILIT treated|Patients that have received ILIT with birch and grass allergen 5-6 years previously
11068581|NCT04296474|Placebo Comparator|Non- AIT treated|Patients that have received placebo ILIT 5-6 years previously and patients with birch and grass pollen induced allergic rhinitis that have not previously been treated with allergen immunotherapy (AIT).
11068582|NCT04296461|Experimental|Welgenaleucel (UWC19)|Part I The safety and efficacy of Welgenaleucel (UWC19) will be evaluated in a standard 3+3 dose escalation approach.The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10^6 CAR-T cells/kg administered intravenously once.
11068583|NCT04296448|No Intervention|Traditional Otoscope|Pediatric trainees use a traditional otoscope to evaluate pediatric patient ears. Trainees' supervisors will also evaluate patients with the traditional otoscope. The study evaluates concordance of the exams.
11068584|NCT04296448|Experimental|Cellscope|Pediatric trainees use a cellphone otoscope (Cellscope) to evaluate pediatric patient ears. Trainees' supervisors will evaluate patients remotely with the video on the cellphone otoscope. The study evaluates concordance of the exams.
11068694|NCT04295681|Placebo Comparator|Placebo|Oral administration. For 90 days according to MMH-MAP dosing regimen.
11068585|NCT04296422|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
11068586|NCT04296422|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
11068587|NCT04296422|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
11068588|NCT04296409||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Deglutition Handicap Index, and Turkish version of the Eating Assessment Tool.
11068589|NCT04296396|Experimental|Individualized Opioid Prescription|Individualized opioid prescription protocol and shared decision making
11068590|NCT04296396|Other|Fixed Opioid Prescription|fixed opioid prescription of 20 tablets of oxycodone 5mg
11068591|NCT04296383|Experimental|Azithromycin plus Xiyanping injection group|
11068592|NCT04296383|Active Comparator|Azithromycin group|
11068593|NCT04296370|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
11068594|NCT04296370|Experimental|Single Arm|Fluzoparib
11068595|NCT04296370|Active Comparator|Physician's choice chemotherapy|Capecitabine or Vinorelbine
11068596|NCT04296357||IVF children|Children born from in-vitro fertilization
11068597|NCT04296357||IVM children|Children born from in-vitro maturation
11068598|NCT04296344|Experimental|Treatment|Participants with chronic pain to receive acupuncture therapy treatments and yoga therapy sessions.
11068599|NCT04296331||POC only|Participants who enter the DC Department of Corrections within the first 2 months of the study will be offered opt-out Point-of-Care (POC) rapid testing
11068600|NCT04296331||POC + Ag/Ab|Participants who enter the DC Department of Corrections within the third and fourth months of the study will be offered opt-out POC and 4th generation laboratory-based antigen/antibody testing (Ag/Ab)
11068601|NCT04296331||Ag/Ab only|Participants who enter the DC Department of Corrections within the fifth and sixth months of the study will be offered Ag/Ab testing.
11068602|NCT04296305|Experimental|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.
~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
11068603|NCT04296305|Experimental|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.
~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
11068604|NCT04296292||AMBITION Trial Participants|Individuals who have been enrolled into the AMBITION trial
11068605|NCT04296292||The next-of-kin of AMBITION Trial Participants|Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline
11068606|NCT04296292||AMBITION Researchers|Individuals working on the AMBITION trial
11068607|NCT04296279|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP014 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
11068608|NCT04296279|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,2 month."
11068609|NCT04296279|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 4,5,6 month."
11068610|NCT04296279|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
11068611|NCT04296279|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
11068612|NCT04296279|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
11068613|NCT04296266|Experimental|Alda-341 treatment|Alda-341 treatment at 2 g/day for 14 days up until the day before regular medical care surgery.
11068614|NCT04296240|Experimental|Neoadjuvant chemotherapy|Oxaliplatin 130mg/m2 d1 and Capecitabine 1250mg/m2 bid1-14 or other fluorouracils, every 21 or 14 days for 2 to 4 cycles, and efficacy evaluation every 2 cycles;
11068615|NCT04296227|Experimental|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
11068616|NCT04296214||A|Azacitidine 50 mg/m2 for 10 days each 28 days
11068617|NCT04296214||B|Azacitidine 75 mg/m2 for 7 days each 28 days
11068618|NCT04296201|Experimental|Treatment in the face area|5 female subjects will receive treatment in the face area
11068619|NCT04296201|Experimental|Treatment in the buttocks area|5 female subjects will receive treatment in the buttocks area
11068620|NCT04296201|Experimental|Treatment in the abdominal region|5 male subjects will receive treatment in the abdominal region
11068621|NCT04296188|Active Comparator|serratus anterior plane block|The serratus anterior plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via patient controlled analgesia (PCA) device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
11068622|NCT04296188|Active Comparator|erector spina plane block|The erector spina plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via PCA device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
11068623|NCT04296175|Active Comparator|conventional group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 or 3 weeks followed by paclitaxel 80mg/m2 d1,d8,d15, every 3 weeks.
11068624|NCT04296175|Experimental|carboplatin group|epirubincin 90mg/m2 d1 and CTX 600mg/m2 d1, every 2 weeks followed by paclitaxel 80mg/m2 and carboplatin AUC=2 d1,d8,d15, every 4 weeks.
11068724|NCT04295512|Experimental|UOT Training|Therapists enrolled in UOT Training
11101119|NCT04069143|Experimental|Part 2: 18F-BMS-986327 (Test/Retest Study)|
11068625|NCT04296162|Experimental|Single arm|6 cycle of oral vinorelbine or capecitabine combined with trastuzumab (21 days per cycle), followed by sequential single trastuzumab to 1 year
11068626|NCT04296149|Experimental|Y-90-DOTATOC|Patients affected by Small Intestine neuroendocrine tumors
11068627|NCT04296136||High risk of mortality|Adult patients admitted to the hospital medicine service with a high risk of mortality
11068628|NCT04296136||Without a high risk of mortality|Adult patients admitted to the hospital medicine service without a high risk of mortality
11068629|NCT04296136||Not on the hospital medicine service|Adult patients admitted to the hospital (inpatient medicine ward) who are not on the hospital medicine service.
11068630|NCT04296123|Experimental|Intervention|
11068631|NCT04296123|No Intervention|Control|
11068632|NCT04296110|Active Comparator|Control|Participants will receive music relaxation therapy. They will be asked to listen to designated music daily for 12 weeks.
11068633|NCT04296110|Experimental|Biofeedback|Participants will receive a biofeedback intervention. They will be asked to practice breathing at their designated resonance frequency using provided biofeedback device daily for 12 weeks.
11068634|NCT04296097|Experimental|Deep Brain Stimulation (DBS) activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON
11068635|NCT04296097|Other|Deep Brain Stimulation (DBS) non-activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF
11068636|NCT04296084||healthy individuals|Volunteer healthy individuals who are between the ages of 20-40 and who do not have any medical condition to affect gait or arm swing.
11068637|NCT04296071||Group 1|patients who tend to have longer CPB
11068638|NCT04296071||Group 2|Patients who have shorter CPB
11068639|NCT04296058||SOX4 high|Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group
11068640|NCT04296058||SOX4 low|Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group
11068641|NCT04296045|Placebo Comparator|Glucose|
11068642|NCT04296045|Experimental|MCE|
11068643|NCT04296045|Experimental|MCE + Glucose|
11068644|NCT04296032|Experimental|virtual reality group|Standard treatment 30 minutes plus virtual reality game 30 minutes, twice a week for 9 weeks.
11068645|NCT04296032|Active Comparator|standard treatment group|Standard treatment 60 minutes, twice a week for 9 weeks.
11068646|NCT04296019|Experimental|Fruquintinib|Patients who achieved stable disease (SD) or partial response (PR) or complete response (CR) following palliative first-line treatment will receive maintenance therapy with fruquintinib.
11068647|NCT04296019|No Intervention|Observation|Patients who achieved SD or PR or CR following palliative first-line treatment will receive treatment-free observation.
11068648|NCT04296006|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
11068649|NCT04296006|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
11068650|NCT04295993|Experimental|methylene blue group|The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
11068651|NCT04295993|Active Comparator|Norepinephrine group|The patients in this group will receive norepinephrine infusion.
11068652|NCT04295980||Geschwind's area BAVMs|
11068653|NCT04295980||Healthy controls|
11068654|NCT04295967||1|presence of recurrence of urothelial carcinoma
11068655|NCT04295967||2|absence of recurrence of urothelial carcinoma
11068656|NCT04295954|Experimental|Yoga Intervention|"This group will receive the Yoga Intervention for dysmenorrhea that will consist of 3 yoga sessions a week of 30 minutes each, for 12 weeks. The first 4 weeks 1 of the sessions will be face to face and the other 2 home sessions guided by a vieo and a brochure, and tutored from the virtual platform by the yoga teacher and researchers. This space will also serve for participants to share experiences.
~After the first 4 weeks, participants will continue with the virtually tutored home yoga program, consisting of 3 weekly sessions of 30 minutes until completing the 12 weeks. They will be protected in all cases by the teacher and researchers.
~All intervention group participants will be invited to participate in online focus groups during week 12 to explore their experiences and satisfaction with the progress of the study and to implement adaptations, if necessary.
~They will be evaluated before the start of the yoga program per month, 3 months, 6 months and a year after the intervention."
11068657|NCT04295954|No Intervention|Control group without intervention|Participants in the comparison group without intervention will not receive yoga intervention, will follow their conventional treatment and their usual daily activities. They will be told not to do yoga. They will be evaluated in advance, per a month, 3 months, 6 months and a year after the intervention.
11068658|NCT04295941||Trazodone once-a-day treated patients|Major Depressive Disorder outpatients who, following an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible to enter the continuation therapy and will be observed up to 24 weeks.
11068659|NCT04295928|Experimental|Intervention|Implementation of a personalized pharmaceutical plan with a view to increasing the patient's therapeutic education in the hospital and in the community (entrance and discharge reconciliation, 3 pharmaceutical interviews in the hospital, strengthening of the community-hospital link , 3 outpatient pharmaceutical consultations)
11068660|NCT04295928|No Intervention|Usual care period|No changes to usual center practices
11068661|NCT04295915||Specimens that meet inclusion criteria|
11068662|NCT04295902|Experimental|VL-group|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Germany) with blades Miller nr 0 and Miller nr 1.
11068663|NCT04295902|Active Comparator|DL-group|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
11068664|NCT04295889|Active Comparator|Group A|"Group A will receive an invitation for home based albuminuria screening using a more conventional urine collection device (known as Peespot Test)."
11068665|NCT04295889|Active Comparator|Group B|"Group B will receive an invitation for home based albuminuria screening using an app (internet application) and an ACR dipstick test (known as ACR| EU Test)."
11068693|NCT04295681|Experimental|MMH-MAP|Oral administration. 2 tablets twice daily (approximately at the same time). The drug is taken outside a meal (between the meals or 15 min prior to meal or fluid intake). Tablets should be held in the mouth until completely dissolved. The overall duration of treatment is 90 months.
11068666|NCT04295876|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-PN supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment.
11068667|NCT04295876|Experimental|BRIDGES Arm|Women assigned to The BRIDGES Project intervention arm will be connected with and receive Ryan White HIV/AIDS Program services (see above as described under Control Arm), as well as receive Peer Navigation support via one-on-one sessions, phone/text-based check-ins, and 6 unique syndemic-responsive 120 -minute group sessions designed to build coping skills (3 sessions) and assertive communication and behavior (3 sessions).
11068668|NCT04295863|Experimental|standard interval dosing|
11068669|NCT04295863|Experimental|extended interval dosing|
11068670|NCT04295850||Low Dose Aspirin|Pregnant singletons with at least one high risk factor for preeclampsia (prior preeclampsia, chronic hypertension, pregestational diabetes, lupus, antiphospholipid antibody syndrome, or chronic kidney disease) who are planning to, but have not yet started, aspirin therapy <16 weeks' gestation. Patients will take 81mg aspirin as prescribed.
11068671|NCT04295837|Experimental|ABLE - A Better everday LifE|A home-based occupational therapy intervention addressing ADL task performance issues among persons living with chronic conditions. The ABLE intervention is occupation-focused and -based, and follows a structured process of assessment, goalsetting, intervention and evaluation.
11068672|NCT04295837|Active Comparator|Usual care|Community-based occupational therapy addressing ADL task performance issues among persons living with chronic conditions
11068673|NCT04295824||Mild AD|"20 subjects with mild local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally mild)."
11068674|NCT04295824||Moderate AD|"20 subjects with moderate local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally moderate)."
11068675|NCT04295824||Severe AD|"20 subjects with severe local AD on their volar forearm (At least 10 with lesions on the face | At least 10 which are globally severe)."
11068676|NCT04295824||Healthy|20 healthy volunteers
11068677|NCT04295811|Experimental|EsoCheck and EsoGuard vs. EGD with or without biopsies|All subjects will undergo both the EsoGuard lab assay run on distal esophageal cells collected with EsoCheck (non-invasive esophageal cell sample collection) device followed by Esophagogastroduodenoscopy (EGD) with or without biopsies
11068678|NCT04295798|Experimental|Traditional tDCS|At the beginning of stimulation, the current will be increased manually from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. Participants will be instructed to notify study personnel if and when they feel any uncomfortable sensation. The ramp-up will be stopped at this point and for the remainder of the session tDCS will be delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
11068679|NCT04295798|Sham Comparator|Traditional Sham|A traditional sham will be used to maximize blinding of traditional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration as described with the Traditional tDCS will be used; however, current will automatically be ramped down 60 seconds after ramp-up.
11068680|NCT04295798|Experimental|Personalized tDCS|Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average nE over the dlPFC of the same size as the one delivered by a traditional montage using sponges in an average subject at 1.5 mA of current. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
11068681|NCT04295798|Sham Comparator|Personalized Sham|An active sham will be used in which very low-level currents (0.5mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
11068682|NCT04295785||autoimmune necrotizing myopathy beginning before 18|
11068683|NCT04295772|Experimental|DOR/ISL|Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
11068684|NCT04295759|Experimental|Dose-finding|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
11068685|NCT04295746|Experimental|Serious Game ShopAut|Each participant played 10 game sessions, one per week, for no more than 30 minutes.
11068686|NCT04295733||Cohort 1|Hematopoietic Stem Celi Transplant (HSCT) patients
11068687|NCT04295733||Cohort 2|HIV infected subjects
11068688|NCT04295733||Cohort 3|Patients candidates for / in treatment with biological drugs such as monoclonal antibodies anti CD-20 (rituximab or ocrelizumab)
11068689|NCT04295720|Experimental|Transcranial magnetic stimulation (TMS)|We propose to test the efficacy of rTMS for the treatment of PCCI. Efficacy measures will include baseline and post-rTMS neuropsychological testing, functional MRI and biometry data using body worn sensors.
11068690|NCT04295707|Experimental|Monthly replacement orthokeratology without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
11068691|NCT04295707|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
11068692|NCT04295707|Active Comparator|Yearly replacement lenses with weekly protein removal|Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
11068695|NCT04295668||Usual care|A contemporaneous control group of patients was build using propensity score matching (PSM) methodologies taking into account the following matching variables: type of surgery, age, sex, American Society of Anesthesiologists Index (ASA) and adjusted morbidity groups (GMA) grading.
11068696|NCT04295668||Prehabilitation|"Prospective sample of risk patients who are candidates for major surgery attended in the outpatient offices of the Hospital Clínic de Barcelona.
~Inclusion criteria: i) American Society of Anesthesiologists Index (ASA) 3-4; and / or, ii) age ≥ 75 years; and / or iii) major aggressive surgery; and, iv) solid organ transplant candidate.
~Exclusion criteria: i) Non-elective surgery; ii) Known metastatic disease before surgery; iii) Unstable respiratory or heart disease; or, iv) Locomotive or cognitive limitations that prevent adherence to the program."
11068697|NCT04295655|Experimental|Global Exercise Group|all patients received the Control Group treatment added to global exercise treatment. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises. The number of repetitions was adapted to the subject's response taken into account the perceived dyspnea and fatigue during the exercise performance.
11068698|NCT04295655|Experimental|Functional Electrostimulation Group|"all patients received the Control Group treatment plus neuromuscular stimulation therapy (SEFAR Rehab X2, DJO France S.A.S., France) on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).
~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
11068699|NCT04295655|Active Comparator|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy.
11068700|NCT04295642|Placebo Comparator|Part 1|Will include 4 subjects (3 active + 1 placebo) that will receive a single 15mg dose with approximately 48 hours of confinement and a follow-up after 7 days.
11068701|NCT04295642|Experimental|Part 2|"2A: will include 14 subjects to complete 12 with 28 days of dosing with 7 days (+/-2) of follow-up, with at least 14 days of confinement.
~-or- 2B: will include 20 subjects to complete 12 with 2 dosing days and 5 days of washout with 7 days (+/-2) of follow-up, with 4 days of confinement (may be increased up to 12 days at the investigators discretion)."
11068702|NCT04295629|Active Comparator|VAS (Visüel Analog Score)|VAS : 0-10 points 0 means: no pain 10 means: incredible pain
11068703|NCT04295629|Active Comparator|LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)|LANSS 0-24 points >12 points : has chronic neuropathic pain <12 points: no chronic neuropathic pain
11068704|NCT04295616|Experimental|IPV & active breathing training|"Intrapulmonary Percussive Ventilation (IPV) and active breathing exercises, provided by trained speech and language therapists.
~This training will be performed in combination with a multidisciplinary rehabilitation programme."
11068705|NCT04295616|Active Comparator|Active breathing training only|Active breathing training provided by trained speech therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.
11068706|NCT04295603|Experimental|Toucher Massage intervention|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes on the foot area .
11068707|NCT04295603|Experimental|Homedics Machine intervention|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes."
11068708|NCT04295590|Experimental|Frequency then Intensity|Training period 1: Frequency comparison Training period 2: Intensity comparison
11068709|NCT04295590|Experimental|Intensity then Frequency|Training period 1: Intensity comparison Training period 2: Frequency comparison
11068710|NCT04295577||Cohort 1: Retrospective Cohort|"This cohort will include:
~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib but in whom quality of life data are not available.
~Patients who have previously commenced Niraparib prior to the MONITOR Study opening at the site but are now deceased but will be eligible for retrospective data collection without the need for informed consent.
~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site but have discontinued treatment.
~Data in respect of AEs, SAEs, ADRs and AESIs will be recorded in Case Report Forms and be identified via the patient's medical records. There is no requirement to complete trial specific SAE reporting forms in this cohort."
11068711|NCT04295577||Cohort 2: Prospective Cohort|"This cohort will include:
~Patients who have previously commenced maintenance Niraparib prior to the MONITOR study opening at the site and are still receiving Niraparib and in whom quality of life data is available.
~Patients who are due to commence maintenance Niraparib treatment."
11068712|NCT04295564|Experimental|eCPAP|Participants will remain on CPAP for 2 additional weeks once CPAP stability criteria is met.
11068713|NCT04295564|No Intervention|dCPAP|Participants will discontinue CPAP as per usual care once CPAP stability criteria is met.
11068714|NCT04295551|Experimental|Experimental group of ordinary COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
11068715|NCT04295551|Active Comparator|Control group of ordinary COVID-19|ritonavir/ritonavir treatment
11068716|NCT04295551|Experimental|Experimental group of severe COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
11068717|NCT04295538|Experimental|Elezanumab|Participants will receive elezanumab dose A
11068718|NCT04295538|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
11068719|NCT04295525|Placebo Comparator|Controls subjects placebo|Placebo mucoadhesive oral tablet
11068720|NCT04295525|Experimental|Controls subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
11068721|NCT04295525|Placebo Comparator|Diseased subjects placebo|Placebo mucoadhesive oral tablet
11068722|NCT04295525|Experimental|Diseased subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
11068723|NCT04295512|No Intervention|Usual Care|Community therapists delivering routine care to participant children with no training in UOT
11068725|NCT04295486|Experimental|Treatment Once Daily|Participant receives 81 mg aspirin taken once daily beginning the night before surgery and up to 28 days post surgery.
11068726|NCT04295486|Active Comparator|Treatment Twice Daily|Participant receives 81 mg aspirin taken twice daily (one in the morning and one at night) beginning at the night before surgery and up to 28 days post surgery.
11068727|NCT04295473|Experimental|Reduced port laparoscopic gastrectomy|The definition of reduced port laparoscopic gastrectomy was 1-3 ports used in laparoscopic gastrectomy for gastric cancer.
11068728|NCT04295473|No Intervention|Standard laparoscopic gastrectomy|5 ports were used in standard laparoscopic gastrectomy
11068729|NCT04295460|Experimental|Dual Therapy|Dolutegravir plus lamivudine
11068730|NCT04295460|Active Comparator|Triple Therapy|Dolutegravir plus TAF/FTC
11068731|NCT04295447|Other|Standard of care|"Observation only or
~An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
11068732|NCT04295447|Experimental|Apalutamide|30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care
11068733|NCT04295421|Active Comparator|Canal adductor block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
11068734|NCT04295421|Experimental|IPACK block|"IPACK was realized after spinal anesthesia. Patient was placed in a supine position and knee placed in position of 90° flexion. A low-frequency ultrasound probe was positioned in the popliteal crease, and the needle was inserted from medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle was placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.2% ropivacaine was injected for each side.
~A ACB was done postoperatively with 20 ml ropivacaine 0.2% and a catheter was kept for 48H with 4 ml/h saline"
11068735|NCT04295408|Placebo Comparator|PLACEBO|Pericapsular Nerve Group block with 40 ml saline
11068736|NCT04295408|Experimental|Pericapsular nerve group block|Pericapsular Nerve Group block with 2 mg.kg-1Ropivacaine in 40 ml of saline
11068737|NCT04295395||group1|preterm infant with closed ductus arteriosus, <32 weeks birth weight < 1500g, and > 72 hours of age
11068738|NCT04295395||group2|preterm infant with PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
11068739|NCT04295395||group3|preterm infant with hemodynamically significant PDA < 32 weeks, birth weight < 1500g, and > 72 hours of age
11068740|NCT04295382|Experimental|Software Application|
11068741|NCT04295369|Experimental|Lifestyle Medicine Group|
11068742|NCT04295369|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment.
11068743|NCT04295356|Active Comparator|Auto injector|a single dose (40 mg) of CT-P17 via AI
11068744|NCT04295356|Active Comparator|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
11068745|NCT04295343||Patients with suspicious of rectosigmoid endometriosis|
11068746|NCT04295330|Experimental|Lidocaine group|General anesthesia is induced in the lidocaine group by slow intravenous lidocaine 1.5mg/kg, followed by continuous injection of lidocaine 2mg/kg.h with micropump. At the end of the operation, the patient controlled intravenous analgesia with lidocaine is used, and the dose of lidocaine is 30mg/kg(no more than 2000mg at most) until 3 days postoperation.
11068747|NCT04295330|Placebo Comparator|Conventional analgesia group|During anesthesia induction, the loading dose of lidocaine, that is, the maintenance dose, is all replaced by the same amount of normal saline. After the operation, the patient controlled intravenous analgesia without lidocaine is used until 3 days postoperation.
11068748|NCT04295317|Experimental|Combined the therapy using Capecitabine and PD-1|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
11068749|NCT04295304|Experimental|NR600 device implantation|Retinal surgery and implantation of epi-retinal prosthesis
11068750|NCT04295278||Systemic inflammatory response syndrome|Systemic inflammatory response syndrome in patients in the pediatric intensive care unit.
11068751|NCT04295265|Experimental|Smartphone|Receive daily whatsapp/ SMS message remind the drug intake.
11068752|NCT04295265|No Intervention|Control|receive instruction to take the medication at recruitment
11068753|NCT04295252||cardiogenic shock patients|All-comers cardiogenic shock patients Admitted to the Intensive Coronary Care Units
11068754|NCT04295239|Experimental|MRI|Pre-operative AND post-operative MRI
11068755|NCT04295226||Participants in Structured post-stroke follow-up in Malmö|"Consecutive patients with acute ischemic stroke or intracerebral hemorrhage, treated in-hospital at Skåne University Hospital in Malmö and discharged straight to own home.
~The intervention consists of a structured follow-up visit, managed by a stroke nurse, 3 months after stroke followed by a multidisciplinary team rounds resulting in an individual treatment plan for stroke-related health problems, and a final follow-up at 12 months"
11068756|NCT04295213|Experimental|oligosaccharide group|intervention with oligosaccharides, total duration of study is 13 weeks
11068757|NCT04295213|Placebo Comparator|placebo group|Placebo comparator, total duration of study is 13 weeks
11068758|NCT04295200|Experimental|Dry needling with electrical stimulation|Use of dry needles (this is the generic name for sterile, solid filament needles) are inserted into the lumbar multifidi. Intramuscular electrical stimulation will then be applied by attaching a six-lead electrical stimulation unit to the needles. Electrical stimulation will be applied through the needles at the participant's desired frequency (between 4-6 Hz) and for up to 10 minutes total.
11068759|NCT04295187||Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
11068760|NCT04295187||Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
11068767|NCT04295148|Active Comparator|Semitendinosus graft|Participants receive the Semitendinosus Graft technique during ACL reconstruction.
11068768|NCT04295148|Active Comparator|Quadriceps tendon-bone graft|Participants receive the Quadriceps Tendon-Bone Graft technique during ACL reconstruction.
11068769|NCT04295135|Experimental|OneSheet access|Clinics or providers who receive access to, and training in the Chronic Pain OneSheet, and use it while caring for patients with chronic pain.
11068770|NCT04295135|No Intervention|Normal practice|Clinics or providers who do not receive access to, or training in the Chronic Pain OneSheet, and care for patients with chronic pain as they would normally.
11068771|NCT04295122|Active Comparator|Phacoemulsification + ECP laser|"Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. The viscoelastic will be washed-out of the capsular bag after IOL insertion. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment.
~Intracameral cefuroxime and dexamethasone will be injected into the anterior chamber and sutures used to close the incisions as required."
11068772|NCT04295122|Active Comparator|Phacoemulsification alone|Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. For this study, monofocal IOLs are required.
11068773|NCT04295109|Active Comparator|Fentanyl group(group F)|Fentanyl citrate injection, specification: 10mL: 0.5mg / piece (production unit: niching chang rendu Pharmaceutical Co., Ltd., valid period: 48 months) For group F patients,0.5mg fentanyl was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
11068774|NCT04295109|Experimental|Oxycodone group(group O)|Oxycodone hydrochloride injection, specification: 1mL: 10mg / branch (production unit: HAMOL LIMITED, valid period: 60 months) For group O patients,30mg oxycodone was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
11068775|NCT04295109|Experimental|Butorphanol group(group B)|Butorphanol tartrate injection, specification: 1 mL: 1 mg / branch (production unit: Jiangsu henryi Pharmaceutical Co., Ltd., valid period: 24 months); For group B patients,10mg butorphanol was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
11068776|NCT04295096|Other|Experimental|Healthy donor
11068777|NCT04295083|Experimental|Experimental group|The experimental group will be six 1,5 h weekly of clay based group study and interviewed face-to-face twice by the researchers.
11068778|NCT04295083|No Intervention|Control group|The control group will interviewed face-to-face twice
11068779|NCT04295070|Placebo Comparator|Placebo|Saline (0.9%) delivered intranasally via dropper
11068780|NCT04295070|Experimental|Low dose cohort|CodaVax-RSV delivered intranasally via dropper
11068781|NCT04295070|Experimental|High dose cohort|CodaVax-RSV delivered intranasally via dropper
11068782|NCT04295044|Experimental|High protein diet|received high protein diet, prescribed by dietitian
11068783|NCT04295044|Active Comparator|Normal protein diet|received normal protein diet, prescribed by dietitian
11068784|NCT04295031||DM2 without renal disease|patients with type 2 diabetes with normal renal function
11068785|NCT04295031||DM2 with renal impairment|patients with type 2 diabetes with impaired renal function
11068786|NCT04295018|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
11068787|NCT04295005||All patients who started an Empagliflozin therapy|
11068788|NCT04295005||All patients who started a DPP-4 inhibitor therapy|
11068789|NCT04295005||All patients who started a Sitagliptin therapy|
11068790|NCT04295005||All patients who started a GLP-1 receptor agonist therapy|
11068791|NCT04294992|Experimental|Granisteron group|
11068792|NCT04294992|Active Comparator|Ondansetron group|
11068793|NCT04294979|Experimental|Rehabilitation|Conventional Physical Therapy
11068794|NCT04294966|Placebo Comparator|Placebo|
11068795|NCT04294966|Active Comparator|7.5 mg THC|
11068796|NCT04294966|Active Comparator|15 mg THC|
11068797|NCT04294953|Active Comparator|Group (I) (D) : (Duloxetine group)|
11068798|NCT04294953|Placebo Comparator|Group (II) (P): (placebo group)|
11068799|NCT04294940|Other|Group A: standard of care|The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
11068800|NCT04294940|Other|Group B: standard of care + mobile application CardiCare™|The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
11068801|NCT04294927|Experimental|Risk-reducing salpingectomy with delayed oophorectomy|Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.
11068802|NCT04294927|Active Comparator|Risk-reducing salpingo-oophorectomy|Risk-reducing salpingo-oophorectomy.
11068803|NCT04294914|Active Comparator|Fibromyalgia|Individuals with fibromyalgia.
11068804|NCT04294914|Experimental|Healthy controls|Healthy, pain-free individuals
11068805|NCT04294901|Experimental|Gabapentin (Gaba)|Patients prescribed gabapentin with a total daily dose >1800mg without exclusion criteria who have a primary care appointment with a provider in the Gaba cohort
11068806|NCT04294901|Experimental|Diabetes (DM)|Patients prescribed either insulin or a sulfonylurea meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the DM cohort
11068807|NCT04294901|Experimental|Proton Pump Inhibitor (PPI)|Patients prescribed a PPI meeting inclusion/exclusion criteria who have a primary care appointment with a provider in the PPI cohort
11068837|NCT04294628|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11068808|NCT04294888|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80% of a patient's active motor threshold. rTMS will be administered in an excitatory iTBS pattern. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
11068809|NCT04294888|Sham Comparator|Sham stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80% of a patient's active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory performance, or whether practice effects or other non-specific effects are responsible for any changes in memory which may be observed.
11068810|NCT04294875|Other|MPT0B640|There is Single Arm in this Clinical Trials.
11068811|NCT04294862|Experimental|TNP-2092 300mg IV|TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
11068812|NCT04294849|Experimental|Venous Thromboembolism Arm|This will be a cohort of patients age 8- ≤ 21 years old with objectively diagnosed DVT and/or PE.
11068813|NCT04294836|Experimental|Curcumin|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)
11068814|NCT04294836|Placebo Comparator|Placebo|Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)
11068815|NCT04294823||FRANCE - CHU creteil|An internal physical examination including vital signs measurements and a 13C-UBT with the standard test meal (Helicobacter Test INFAI) will be performed. Patients with a positive UBT will undergo upper endoscopy. All biopsy samples will be analysed in the local laboratory of the centre. Patients with a negative UBT will undergo also upper endoscopy. Endoscopic procedures and subsequent investigations will be identical in patients with a positive and with a negative UBT. H. pylori positive and negative patients will perform the 13 C-UBT breath tests with new test meal on Day 30. The study will be conducted in outpatients. Starting on Day 1, H. pylori positive and negative patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast. Patients will return to the hospital/medical practice for UBT breath tests with new test meal on Day 30. Patients will be followed-up for 7 days after discontinuation of PPI treatment.
11068816|NCT04294810|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
11068817|NCT04294810|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
11068818|NCT04294784|Experimental|Nab-P/PD-1|Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.
11068819|NCT04294784|Active Comparator|Nab-P|Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.
11068820|NCT04294771||Myocarditis and other cardiovascular toxicities ICI-related|Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
11068821|NCT04294771||Non case|Non-case will be patients exposed to ICI without cardiovascular toxicities
11068822|NCT04294745|Experimental|Group A|Buccal infiltration of 4% Articaine
11068823|NCT04294745|Active Comparator|Group B|Inferior alveolar nerve block of 4% Articaine
11068824|NCT04294732|Placebo Comparator|Only spinal anesthesia|Only spinal anesthesia without peripheral nerve block
11068825|NCT04294732|Active Comparator|high concentration|8 ml saline with 8 ml bupivacaine
11068826|NCT04294732|Experimental|low concentration|8 ml bupivacaine with 16 ml of saline
11068827|NCT04294719||Inpatient Clients|Have a chart diagnosis of a schizophrenia spectrum illness, capacity to consent or availability of a substitute decision-maker to consent with the assent of the participant and is residing on a CAMH inpatient forensic unit (general security)
11068828|NCT04294706|Experimental|Hemp arm|Randomly assignment to Hemp arm (60 mg/day of hemp oil extract x 6 weeks)
11068829|NCT04294706|Placebo Comparator|Placebo arm|Randomly assigned to Placebo arm (60 mg/day of cellulose x 6 weeks)
11068830|NCT04294693||Pediatric Population|The investigator intends to collect information on all total joint arthroplasty patients identified within the surgical practice of Dr. Nathan Donaldson for non-tumor related diagnoses at Children's Hospital Colorado.
11068831|NCT04294680|Experimental|Opiate Sparing|Cryotherapy one hour daily four times per day for two weeks postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeproazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative Oxycodone 5 milligrams every six hours by mouth as needed for uncontrolled pain for fourteen days postoperative
11068832|NCT04294680|No Intervention|Opiate Based|Oxycodone 5 to 10 milligrams every four to six hours by mouth as needed for pain for fourteen days postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeprazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative
11068833|NCT04294667|Experimental|Dapirolizumab pegol|Subjects will receive dapriolizumab pegol througout the Treatment Period.
11068834|NCT04294667|Placebo Comparator|Placebo|Subjects will receive placebo througout the Treatment Period.
11068835|NCT04294654|Experimental|Vortioxetine|5 - 20 mg/day tablets
11068836|NCT04294641|Experimental|Intervention|Determine response rate via continuous daily dose by mouth to determine efficacy
11068838|NCT04294615|Experimental|FMT through a naso-jejunal tube|The purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
11068839|NCT04294615|Active Comparator|FMT through TET|The purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
11068840|NCT04294602|Experimental|Exercise Program|This group received therapeutic exercises and patient education. For patients to encounter fewer problems and to reduce their problems, some recommendations were made that should be taken into consideration in daily life. These suggestions were given in writing. The exercise program included muscle stretching, massage of painful muscles, guided opening and closing movements, gentle isometric tension exercises against resistance, correction of body posture and relaxation techniques. All exercises were done in 6 repetitions a set, 3 sets a day, 3 days a week, treatment program lasted 4 weeks.
11068841|NCT04294602|Experimental|Low Level Laser Therapy Program|This group received LLLT, therapeutic exercises and patient education in the therapy programs. LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points. The application was applied to MTrP or sensitive points in the mastication and cervical muscles.LLLT program was done in 3 days a week, the treatment program lasted 4 weeks.
11068842|NCT04294602|Experimental|Manual Pressure Release Program|ThisThis group received manual pressure release (MPR), therapeutic exercises and patient education in the therapy programs. MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, MTrPs in the mastication and neck muscle. Applied pressure gradually with finger over the MTrPs until the subject reported a 'moderate but easily tolerable' pain value of 7 out of 10. When the pain value decreased to at least 3 or 4 therapist increased pressure again until discomfort and/or pain appeared again. This process was repeated until there was no MTrP tension/tenderness or 60 s had elapsed. MPR program was done in 3 days a week, the treatment program lasted 4 weeks.
11068843|NCT04294576|Experimental|Arm 1; BJ-001|Phase 1a Part 1 and Part 2: dose escalation for BJ-001 as single agent
11068844|NCT04294576|Experimental|Arm 2; BJ-001 and PD-1 or PD-L1 inhibitor|Phase 1a Part 3: dose escalation for BJ-001 in combination with an PD-1 or PD-L1 inhibitor. Approximately Phase 1b: expansion cohorts for the combination of BJ-001 and an PD-1 or PD-L1 inhibitor.
11068845|NCT04294563|Experimental|Immediate Intervention Group|Participants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
11068846|NCT04294563|Active Comparator|Wait-llist Control Group|Participants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.
11068847|NCT04294537|Experimental|TAP block|Bilateral ultrasound-guided single-shot TAP block with 0,15% levobupivacaine 0,75 mg/kg per side.
11068848|NCT04294537|Active Comparator|LIA - local wound infiltration|Wound infiltration with 0,5% levobupivacaine 1.5 mg/kg
11068849|NCT04294511|Experimental|Experimental|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
11068850|NCT04294498|Experimental|Durvalumab|Durvalumab
11068851|NCT04294485|Experimental|Experimental group|Physical therapy intervention Efficacy of electrostimulation intervention combined with lower limbs exercise.
11068852|NCT04294485|No Intervention|Control group|Participants will no receive physical therapy intervention
11068853|NCT04294472|Experimental|Cohort 1|Cohort 1: MAU868 1350 mg IV approximately every 28 days for a total of 4 doses
11068854|NCT04294472|Experimental|Cohort 2|Cohort 2: MAU868 6750 mg IV on Study Day 1 and then 1350 mg IV approximately every 28 days for a total of 4 doses
11068855|NCT04294472|Experimental|Cohort 3|Cohort 3: MAU868 6750 mg IV approximately every 28 days for a total of 4 doses
11068856|NCT04294472|Placebo Comparator|Placebo Cohort 1, 2, 3|5% dextrose in water [D5W] IV delivered every 28 days for a total of 4 doses
11068857|NCT04294459|Experimental|Phase 1|Isatuximab dose level 1 or dose level minus 1 depending on predefined unacceptable toxicities observed.
11068858|NCT04294459|Experimental|Phase 2: Cohort A|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with living donor.
11068859|NCT04294459|Experimental|Phase 2: Cohort B|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with no living donor cleared for donation.
11068860|NCT04294433|Active Comparator|Infanrix-hexa+Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa
11068861|NCT04294433|Experimental|Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa
11068862|NCT04294433|Experimental|Infanrix-hexa+Twinrix|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively
11068863|NCT04294420|Experimental|Patient education program|Patient education program
11068864|NCT04294407||Stroke group|20 to 65 years old patients, with the clinical diagnosis of stroke (Mini-mental state examination (MMSE) score of ≥25)
11068865|NCT04294407||Healthy group|20 to 65 years old healthy subjects, without the clinical diagnosis of stroke
11068866|NCT04294394||rhomboid block|Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels
11068867|NCT04294394||erector spinae group|The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area (Thoracothomy,hysterectomy,Lomber surgery)
11068868|NCT04294381|Experimental|pilot of SMART-goal-setting health behavior decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
11068869|NCT04294368|Other|Control|Standard fortification of breast milk
11068870|NCT04294368|Experimental|Experimental|Targeted fortification of breast milk
11068871|NCT04294355|Experimental|Artificial intelligence-Assisted colonoscopy|Tandem colonoscopy of proximal colon assisted with artificial intelligence followed by conventional colonoscopy
11101527|NCT04066231|Experimental|VIPUN GMS|Single arm study.
11068872|NCT04294355|Active Comparator|Conventional colonoscopy|Tandem conventional colonoscopy of proximal colon followed by usual conventional colonoscopy
11068873|NCT04294342|Active Comparator|Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program which consists of three blocks. All sessions include: Balance, Strength, power and break fall exercises. The intervention group i tested before and after the 10 week exercise.
11068874|NCT04294342|No Intervention|Control Group|The subjects in the control group go about their normal life for 10 weeks without any intervention. The control group is tested before and after the 10 week period.
11068875|NCT04294329|Experimental|Group Quadratus lumborum block with bupivacaine|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine where a solution of 0.25% bupivacaine 0.2 ml /kg (lean body weight) is used on each side with care not to exceed the toxic dose.
11068876|NCT04294329|Placebo Comparator|Group Quadratus lumborum block with saline|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine.A volume of 0.2ml/kg normal saline will given for each side.
11068877|NCT04294316|Other|Sonovue group|ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest who are eligible for enhanced-contrast brain ultrasound, extracranial echo-color duplex, and ocular ultrasound.
11068878|NCT04294303|Experimental|Telemonitoring|Subjects were assigned to web based telemonitoring system.
11068879|NCT04294303|Other|Control|Subjects were assigned to conventional monitoring.
11068880|NCT04294290|Experimental|hCT-MSC infusion|
11068881|NCT04294277|Experimental|Treatment arm|Treatment with Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule until 12 months.
11068882|NCT04294264|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11068883|NCT04294251|Experimental|DWP450|
11068884|NCT04294251|Placebo Comparator|Placebo|
11068885|NCT04294238|Experimental|Post-exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage of peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
11068886|NCT04294225|Experimental|Treatment (anastrozole, letrozole)|Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 >= 1.3 pg/ml and E2 >= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11068887|NCT04294199|Active Comparator|Immobilization|Patients in this group will be given a knee immobilizer to wear for 2 weeks and then receive outpatient physical therapy evaluation and treatment
11068888|NCT04294199|Experimental|Early range of motion|Patients in this group will be allowed to move the knee and start outpatient physical therapy and treatment immediately.
11068889|NCT04294173|Experimental|video group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the experimental group in the classroom setting. Video presentation including powerpoint presentation and tracheostomy care skill application will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained by the researchers to the video group students in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be watched by the video-assisted teaching method, and the video of tracheostomy care The videos will be sent to students via e-mail. A two-day warning message will be sent to the students from the WhatsApp group to watch the video by the researchers. A week later, students will be invited to the basic skills laboratory for tracheostomy care.
11068890|NCT04294173|No Intervention|demonstration group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the control group in the classroom setting. Powerpoint presentation will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained to the control group students by the researchers in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be taken to the basic skills laboratory and tracheostomy care will be performed on the dummy by the researchers using the demonstration method. Then, students will be given the output of the powerpoint presentation and asked to study the lecture notes for a week. A two-day warning message will be sent by the researchers to students from the WhatsApp group to study. A week later, students will be invited to the basic skills laboratory to practice tracheostomy care.
11068891|NCT04294160|Experimental|Dabrafenib + LTT462 backbone arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
11068892|NCT04294160|Experimental|Dabrafenib + LTT462 + trametinib triplet arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
11068893|NCT04294160|Experimental|Dabrafenib + LTT462 + LXH254 triplet arm 2|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
11068894|NCT04294160|Experimental|Dabrafenib + LTT462 + TNO155 triplet arm 3|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
11068895|NCT04294160|Experimental|Dabrafenib + LTT462 + spartalizumab triplet arm 4|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
11068896|NCT04294147|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC)
11068897|NCT04294147|Active Comparator|Erenumab|Erenumab administered SC
11068919|NCT04294004|Experimental|KUR-113, Stage 2|During stage 2, subjects will receive TGplPTH1-34 in fibrin that will be applied within and around a PEEK intervertebral cage at a concentration of either 0.2mg/ml or 0.7mg/ml. The concentration received will be selected by the DSMB based on the results of stage 1. The maximum dose that will be applied is either 2 mg or 7 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
11068974|NCT04293575||In list group|patients on active heart transplantation (HTx) list with a low likelihood to receive a donation shortly (e.g. for body weight or blood group)
11068898|NCT04294134|Experimental|MIO-CPP|The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added. During the core phase of dyadic CPP the Child Parent Specialists will continue to build and strengthen parents' reflective functioning by embedding aspects from MIO. The 9 month MIO-CPP (intervention) model will begin with the standard 12 weeks of MIO for each mother, with the CPP assessment and engagement phase embedded during this time. This phase will be followed by the dyadic mother-child phase, the core intervention stage of CPP. If a parent needs additional stabilization, more individual time can be added.
11068899|NCT04294134|Active Comparator|CPP-only|"CPP (control) is typically offered through weekly sessions with the mother-child dyad that last 1 to 1.5 hours. The CPP control intervention will last 9 months. CPP is offered by mental health Child-Parent Specialist, who receive ongoing consultation and supervision in addition to initial training. This is the model that will be followed for the control group.
~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008)"
11068900|NCT04294121|Experimental|Children|"Children aged 5-13 years, all genders, will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Children will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Children will also be asked to rank the cereals in order of their preference (i.e., Most (1) to Least (6)). Children will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
11068901|NCT04294121|Experimental|Parents|"Parents or guardians of the children in the study will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Parents will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Parents will also be asked to rank the cereals in order of which they would be most likely to purchase for a child (i.e., Most (1) to Least (6)). Parents will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
11068902|NCT04294108||Patients underwent VATS lobectomy|All consecutive patients scheduled for video-assisted thoracoscopic surgery lobectomy.
11068903|NCT04294095|Experimental|Intervention|During the first four weeks of the MBMM+ program, participants will receive electronic informational handouts covering topics on weight management as well as the benefits and safety concerns related to prenatal physical activity. Starting week 5 of the 12-week intervention, participants will attend two in-person, group physical activity sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics. Sessions will be held on weekday evenings and weekend mornings as these times were preferred by pregnant women. Each session will include both didactic and experiential components to increase knowledge and skill building.
11068904|NCT04294095|Active Comparator|Control|Electronic materials related to various prenatal topics including preparation for birth, birthing options, and responsive parenting will be distributed twice a week for the first 4-weeks of the program. Starting week 5 of the 12-week intervention, participants will attend two in-person, group sessions per week with each session lasting approximately 60 minutes and will be held at a local community center located close to the recruitment clinics.
11068905|NCT04294082||Mindfulness based intervention|A shortened version of a mindfulness-based intervention originally developed by Jon Kabat-Zinn for management of chronic pain.
11068906|NCT04294069|Active Comparator|Azithromycin 500mg|500mg azithromycin PO daily for seven days
11068907|NCT04294069|Active Comparator|Azithromycin 1000mg|1000mg azithromycin PO once at admission
11068908|NCT04294056|Experimental|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
11068909|NCT04294056|Active Comparator|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
11068910|NCT04294043|Experimental|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
11068911|NCT04294030||Sexually active persons who self-select for HSV-2 testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
11068912|NCT04294030||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
11068913|NCT04294030||Low prevalence population|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
11068914|NCT04294030||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior; 1/2 low risk sexual behavior
11068915|NCT04294017||patients|participants undergoing a diagnostic laparoscopy and have a histologically confirmed Endometriosis
11068916|NCT04294017||controls|participants undergoing a diagnostic laparoscopy where no evidence of Endometriosis could be found
11068917|NCT04294004|Experimental|KUR-113, Stage 1|During stage 1, subjects randomized to this arm will receive TGplPTH1-34 in fibrin (0.4mg/ml) that will be applied within and around a polyetheretherketone (PEEK) intervertebral cage. The maximum dose that will be applied is 4 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.
11068918|NCT04294004|Active Comparator|Autologous Bone Graft|During stage 1 of the study, subjects randomized to this arm will receive local autologous bone graft. In the event of insufficient local autograft, Iliac crest bone graft may be used to supplement.
11068975|NCT04293575||"Bridge to decision BTD group"|patients suitable for HTx, but that were still waiting for clinical decision
11068920|NCT04293991|Active Comparator|High flow nasal cannula (HFNC) group|HFNC group will receive immediate connection to HFNC with a flow of 60L/min, and FIO2 adjusted to have SpO2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. In case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. Patients will be encouraged to have their mouth closed during HFNC to augment positive end expiratory pressure (PEEP) created by high flow.
11068921|NCT04293991|Active Comparator|Non invasive ventilation (NIV) group|NIV group, patients will be connected to ICU ventilatoron NIV mode for at least 4 hours, through a NIV continuous positive airway pressure (CPAP)mask with ventilator settings; pressure support (PS) level of 8 cmH2O and PEEP level of 5 cmH2O,which can be increased to 10 cmH2O to maintain tidal volume between 6-8 ml/Kg and FiO2 adjusted to keep SpO2 equal or more than 92%.At least patient will be on NIV for 12 hours during the day, alternating with Venturi mask 10-15 L/min to keep FiO2 equal or more than 92%.
11068922|NCT04293978|Experimental|Virtual Reality relaxation|Participants may request to use the application at any time during their stay at the ward, as many times as they wish. Participants sign in using an anonymous study ID and sessions (and outcomes) are automatically logged by the device to this ID.
11068923|NCT04293965|Experimental|Single Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in a single dose to assess the safety, tolerability, PK and PD profile of X842.
11068924|NCT04293965|Experimental|Multiple Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in multiple doses to assess the safety, tolerability, PK and PD profile of X842. The dose ascending at this stage will be based on the results of the single dose tolerability study.
11068925|NCT04293965|Experimental|Food Effect Study|A randomized, open label, single-dose, self-controlled, double-cycle, two-way crossover clinical trial.
11068926|NCT04293952|Experimental|BRACE group|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
11068927|NCT04293952|Active Comparator|BRE group|this group include Balance Resistance Exercises Stretching Range Of Motion exercises Ankle flexion Ankle extension Knee flexion Knee extension Hip flexion Hip extension Hip adduction Hip abduction
11068928|NCT04293939||Preterm children|Children born before the 37th week of gestation: clinical sample
11068929|NCT04293939||Full-term children|Children born after the 37th week of gestation: control sample
11068930|NCT04293926|No Intervention|Control|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises.
11068931|NCT04293926|Experimental|Exercise|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.
11068932|NCT04293913|Experimental|intervention group|In the intervention group, communication was established with the illustrated communication material. The pain, anxiety scores, and hemodynamic data of the patients were recorded by the intensive care nurse in three consecutive measurements starting with the first communication (0th minute) and at 30th and 60th minutes. On the first postoperative day, the satisfaction of the communication established with them, as well as their evaluations regarding the adequacy of this communication and their comfort levels were determined during the time they received mechanical ventilation therapy.
11068933|NCT04293913|No Intervention|control group|no intervention
11068934|NCT04293900||Study cohort|24-hour dietary recall, hand grip strength, accelerometer, International Physical Activity Questionnaire (IPAQ), Patient-reported outcomes survey (NCI-PRO-CTCAE), Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Treatment - Lymphoma (FACT-lym), urine sample (optional), fecal sample (optional)
11068935|NCT04293887|Experimental|Standard therapy + interferon therapy|Standard treatment + recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days.
11068936|NCT04293887|No Intervention|Standard therapy + blank therapy|Standard therapy
11068937|NCT04293874|Experimental|Low Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 6 oz. wild salmon (1 steak, 6oz /steak)or 14.3 oz. (5.5 packs, 2.6 oz/pack) of chunk light tuna (1020 mg Omega-3LC/week) for 6 weeks.
11068938|NCT04293874|Experimental|High Omega-3LC group|Participants will consume a personalized meal plan for 2 weeks and consume an increased quantity of fish to 12 oz. wild salmon (2 steak,12 oz /steak)or 28.6 oz. (11 packs, 2.6 oz/pack) of chunk light tuna (2040 mg Omega-3LC/week) for 6 weeks.
11068939|NCT04293861|Experimental|HYMOVIS Arm|A treatment cycle consists of two injections administered at one week interval. For the purpose of this study, two treatment cycles of two injections of HYMOVIS® at baseline and 6 months will be performed per patient at V1 (Day 0), V2 (Day 7), V5 (Day 180) and V6 (Day 187).
11068940|NCT04293848|Experimental|ambient sound with low-sinusoidal sound (vibrations)|Participants will listen to ambient sound and low-sinusoidal sound (vibroacoustic therapy).
11068941|NCT04293848|Placebo Comparator|Control Group|
11068942|NCT04293835||Cancer group|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.
11068943|NCT04293835||Normal group|200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
11068944|NCT04293822|Experimental|Study group|Group of 30 patients randomly selected will use topical Cetirizine 1% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
11068945|NCT04293822|Active Comparator|Control group|Group of 30 patients randomly selected will use topical Minoxil 5% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
11068946|NCT04293809|Experimental|Cohort 1 - EXPAREL|A total of 15 subjects will be enrolled in this cohort. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of saline
11068947|NCT04293809|Experimental|Cohort 2 - EXPAREL|A total of 15 subjects will be enrolled. Subjects in this cohort will receive 20mL EXPAREL (266mg) with 30mL of 0.5% bupivacaine HCl (150mg)
11069031|NCT04293172|Experimental|Ticagrelor|The double-blinded study drug dose will be weight dependent.
11068948|NCT04293796|Experimental|TNBC group|A group with TNBC in neoadjuvant therapy will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then 12 cycles of neoadjuvant polychemotherapy according to the paclitaxel 60-100 mg / m² scheme in 1 day + carboplatin AUC 2 1 p in 7 days. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
11068949|NCT04293796|Experimental|HER2-positive breast cancer group|ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
11068950|NCT04293783|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 two tablet by mouth 1 time per day
11068951|NCT04293783|Placebo Comparator|Placebo|Placebo two tablet by mouth 1 times per day
11068952|NCT04293770|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.
~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
11068953|NCT04293757|Experimental|Rotational angio|Patients that will undergo 3D rotational angiography before cryoballoon ablation
11068954|NCT04293757|No Intervention|No rotational angio|Patients that will receive no preprocedural imaging before cryoballoon ablation
11068955|NCT04293744|Experimental|Colloid priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL PrimECC.
11068956|NCT04293744|Active Comparator|Standard priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
11068957|NCT04293731|Active Comparator|Symbiter-Smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
11068958|NCT04293731|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
11068959|NCT04293718||Acute erosive gingivitis|Patients presenting acute erosive gingivitis, isolated or predominant compared to other oral lesions, which required at least one papillary gingival biopsy for diagnostic purposes. Patients were included in the study regardless of age and general health.
11068960|NCT04293705|Experimental|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions, in addition to 1-hour biweekly Skype sessions with a cognitive-behavioral psychotherapist. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
11068961|NCT04293705|Active Comparator|modified TOPS group|Patients are required to perform the modified TOPS program, composed of sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Skype sessions with a cognitive-behavioral psychotherapist are scheduled, but with the only aim of monitoring and sustaining training adherence.
11068962|NCT04293692|Experimental|UC-MSCs treatment group|Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).
11068963|NCT04293692|Placebo Comparator|Control group|Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7.
11068964|NCT04293679|Experimental|Cohort A: STP705 10 μg dose|Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks
11068965|NCT04293679|Experimental|Cohort B: STP705 20 μg dose|Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks
11068966|NCT04293679|Experimental|Cohort C: STP705 30 μg dose|Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks
11068967|NCT04293679|Experimental|Cohort D: STP705 60 μg dose|Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks
11068968|NCT04293679|Experimental|Cohort E: STP705 120 μg dose|Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks
11068969|NCT04293666|Experimental|Kefir drink|(2) The first phase of Kefir, the second phase of the placebo group (hereinafter referred to as group B
11068970|NCT04293666|Placebo Comparator|placebo|(1) first-stage placebo and second-stage Kefir group (hereinafter referred to as group A).
11068971|NCT04293653|Experimental|Care bundle|Patients above 75 years where emergency surgery is indicated and with a Clinical Frailty Scale Score of 1-6 will be included in a perioperative care-bundle. While waiting for surgery patients will be monitored and optimized if deteriorating. Antibiotics will be administered if indicated. Surgery is delivered within 2, 6 or 24 h depending on suspected abdominal pathology and clinical condition.
11068972|NCT04293601|Experimental|Experimental group|"All enrolled neonates will receive interventions that will be performed with different frequency and method according to newborns' risk factors, as well as the following standard interventions received by control group's newborns:
~appropriate use of hydrocolloid, headbands, masks and prongs
~frequently assess skin integrity
~humidity and heat gases"
11068973|NCT04293601|Other|Standard care|"Newborns have received the interventions according to local protocol (standard nursing care) in 2018, as detailed in the assigned intervention"
11069032|NCT04293172|Placebo Comparator|Placebo|The double-blinded study drug dose will be weight dependent
11068976|NCT04293575||"(Bridge to candidacy BTC group)"|patients who could not be yet in list for HTx because of concomitant, potentially reversible, contraindications such as severe pulmonary hypertension, elevated pulmonary-vascular-resistance, unsatisfactory response to vasodilator challenge or other causes resulting in a prohibitive peri-procedural risk (as pre-transplant body mass index [BMI] >35 kg/m2, severe renal dysfunction with creatinine clearance <30 mL/min) and other reasons (current alcohol, tobacco or drug abuse, poor social support, non-residents)
11068977|NCT04293562|Experimental|Arm A High Risk Group|Arm A High Risk Group: See Detailed Description.
11068978|NCT04293562|Experimental|Arm A Low Risk Group 1|Arm A Low Risk Group 1: See Detailed Description.
11068979|NCT04293562|Experimental|Arm A Low Risk Group 2|Arm A Low Risk Group 2: See Detailed Description.
11068980|NCT04293562|Experimental|Arm AC High Risk Group|Arm AC High Risk Group: See Detailed Description.
11068981|NCT04293562|Experimental|Arm AC Low Risk Group 2|Arm AC Low Risk Group 2: See Detailed Description.
11068982|NCT04293562|Experimental|Arm AD High Risk Group|Arm AD High Risk Group: See Detailed Description.
11068983|NCT04293562|Experimental|Arm AD Low Risk Group 2|Arm AD Low Risk Group 2: See Detailed Description.
11068984|NCT04293562|Experimental|Arm B High Risk Group|Arm B High Risk Group: See Detailed Description.
11068985|NCT04293562|Experimental|Arm B Low Risk Group 1|Arm B Low Risk Group 1: See Detailed Description.
11068986|NCT04293562|Experimental|Arm B Low Risk Group 2|Arm B Low Risk Group 2: See Detailed Description.
11068987|NCT04293562|Experimental|Arm BC High Risk Group|Arm BC High Risk Group: See Detailed Description.
11068988|NCT04293562|Experimental|Arm BC Low Risk Group 2|Arm BC Low Risk Group 2: See Detailed Description.
11068989|NCT04293562|Experimental|Arm BD High Risk Group|Arm BD High Risk Group: See Detailed Description.
11068990|NCT04293562|Experimental|Arm BD Low Risk Group 2|Arm BD Low Risk Group 2: See Detailed Description.
11068991|NCT04293549||rhNGF group|Therapeutic contact lens use was discontinued during the duration of the study. Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment. Changes in the corneal epithelium and stroma were evaluated by slit lamp biomicroscopy and photo documentation of the cornea after fluorescein staining.
11068992|NCT04293549||control comparator group|control comparator group was matched for age and gender and underwent assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline.
11068993|NCT04293523||Hemophilia A patients|All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.
11068994|NCT04293510||group study 1|children and adolescents who diagnosed as lupus patients
11068995|NCT04293510||group study 2|age and sex matched healthy children free from any infection with no family history of immunological diseases
11068996|NCT04293497|Experimental|Pancreatic Cancer|This arm includes patients with pancreatic cancer. Cytology specimens will be obtained with endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer. Cytology staining will be performed in the cytology specimens.
11068997|NCT04293484|Experimental|Real tDCS - Real tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
11068998|NCT04293484|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
11068999|NCT04293458|Experimental|EsoCheck vs. EGD with or without biopsies|All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
11069000|NCT04293432||Group/Cohort|Torsade de Pointes induced by drugs reported to the FAERS database from inception till first quarter of 2019 (1990-2019)
11069001|NCT04293406||Established Prostate Cancer Group|Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
11069002|NCT04293406||At Risk of Prostate Cancer Group|"At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.
~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study)."
11069003|NCT04293393|Active Comparator|Arm A: Doxorubicin plus cyclophosphamide and taxane|"Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
~Approximately duration of 24 weeks (6 months)."
11069004|NCT04293393|Experimental|Arm B: Letrozole plus abemaciclib +/- LHRH|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- luteinizing hormone-releasing hormone (LHRH) analogs in premenopausal women, up to 12 months, in 28-day cycles.
11069005|NCT04293380|Other|normal karyotype|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
11069006|NCT04293380|Other|down syndrome|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
11069007|NCT04293367|Experimental|Exercise|14 African American Women with obesity will be randomly assigned to the 14-week high intensity interval training program
11069008|NCT04293367|No Intervention|Control|14 African American Women with obesity will be randomly assigned to serve as a reference group, i.e. follow the same protocol as the experimental group, however, they will not undergo exercise training
11069009|NCT04293354|Active Comparator|Serratus Plane Block|The Serratus plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
11069010|NCT04293354|Sham Comparator|Control|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
11069011|NCT04293341|Experimental|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
11069012|NCT04293341|Active Comparator|Disorder Specific Therapies|To provide an evidence-based comparison for the TBT condition, DSTs will be used that are matched to the participant's most severe diagnosis, based upon the average of the ADIS interference and distress scores. If the scores are equivalent for two or more diagnoses, participants will be asked to list which diagnosis/symptoms that they find most impairing. DSTs will be included for each of the three targeted diagnoses, including PTSD (CPT for PTSD), PD/AG (CBT for PD/AG), and MDD (CBT for MDD). Each of these DSTs have published manuals for administration and have received extensive support in the literature (Barlow, 2014).
11069013|NCT04293328|Experimental|Monthly replacement lenses without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
11069014|NCT04293328|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
11069015|NCT04293315|No Intervention|Control|This is the usual care arm. Healthcare workers will provide people with the Fecal Occult Blood Test (FOBT) and information about risk to develop CRC and the importance of early detection.
11069016|NCT04293315|Experimental|Intervention|The same as the Control Arm plus the primary care team of the PCCs will be trained and participate in 8 improvement cycles.
11069017|NCT04293302||Brain abnormality|Newborn who had any gestational brain sonographic abnormality
11069018|NCT04293302||No brain abnormality|Newborn who did not have any gestational brain sonographic abnormality
11069019|NCT04293289|Other|Treatment|"BNCT(Boron Neutron Capture Therapy)
~SPM-011 iv administrates at 200 mg/kg/hr for 2 hours before neutron irradiation. During neutoron irradiation with CICS-1, SPM-011 iv continues at 100mg/kg/hr."
11069020|NCT04293276|Experimental|Treatment group|Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11069021|NCT04293263|Experimental|MCI patients hospitalised in the research departments|each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.
11069022|NCT04293263|Active Comparator|MCI patients hospitalized in the research departments|each of the elderly in the control group will Listen to random music twice a week for about 40 minutes each time, on personal headphones.
11069023|NCT04293250|Experimental|Physical activity group|"Investigators employ the recommendations of the American College of Sport Medicine and the World Health Organization for adults to divide our enrolled patients having moderate-intensity as 30-60 min∙d-1 (≥150 min∙wk-1 ) or vigorous-intensity as 20-60 min∙d-1 (≥75 min∙wk-1) for 6-8 weeks preoperatively.
~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.
~The operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
11069024|NCT04293250|Experimental|non-physical activity group|"No any moderate-intensity or vigorous-intensity physical activity for our enrolled patients preoperatively.
~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.
~Various types of operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
11069025|NCT04293224|Experimental|DGA Mediterranean diet pattern, energy balance|Diet plan focused on energy balance (meets calorie needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
11069026|NCT04293224|Experimental|DGA Mediterranean diet pattern, negative energy balance|Negative energy balance (~25% calorie reduction compared to needs), emphasizes fruits, vegetables and whole grains and limits calories from added sugars and saturated fats and reduces sodium intake per Dietary Guidelines for Americans (DGA) recommendations.
11069027|NCT04293224|Experimental|TAD diet pattern|Typical American Diet (TAD) with negative energy balance (~25% calorie reduction compared to needs) which mimics intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium based on data from What We Eat in America (WWEIA).
11069028|NCT04293211||Control|Upon completion of B-Con presentation, this group will be tested regarding tourniquet placement using the rubric. A tourniquet is regarded as appropriately placed if it is 2 inches above the wound, not located on a joint, appropriate tightness (meaning a finger cannot be placed under it and it is indenting the mannequin). This is as per prior studies. Feedback will be given at the end of this session.
11069029|NCT04293211||Simulation|This group will have to interact with a panicked actor/actress as well as the SIM MAN 3G who will have two wounds under his clothes. One that will be actively pumping a large amount of arterial blood that will require tourniquet placement and the other wound with trace venous bleeding that will require simple pressure with a clean cloth. Participants will be given feedback on items that they missed. The observer will fill out the rubric and give feedback to the group.
11069030|NCT04293185|Experimental|LentiGlobin BB305 Drug Product for SCD|"Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene.
~Plerixafor mobilization and apheresis will also be used for collection of rescue cells."
11069033|NCT04293159|Experimental|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
11069034|NCT04293146|Active Comparator|pre-pectoral IBBR|
11069035|NCT04293146|Active Comparator|sub-pectoral IBBR|
11069036|NCT04293120|Experimental|Training|Training 4 sessions over a one week time period of 180 catches/stops with a medicine ball.
11069037|NCT04293107||Phase 1: Content Validity Testing|Cohort of 6 parents/carers of children with cerebral palsy and GORD, who will be interviewed regarding the content validity of the PGSQ when used to assess symptoms of GORD in children with cerebral palsy.
11069038|NCT04293107||Phase 2: Reliability (test-retest) Testing|Cohort of 20 parents/carers of children with cerebral palsy and GORD, who will review and complete the adapted version of the PGSQ (post Phase 1) at two time points, two weeks apart.
11069039|NCT04293094|Experimental|Dose Exploration Phase|The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
11069040|NCT04293094|Experimental|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
11069041|NCT04293094|Experimental|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
11069042|NCT04293081|Active Comparator|chlorpheniramine maleate group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to chlorepheniramine maleate group (A)
11069043|NCT04293081|Placebo Comparator|placebo group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to placebo group (A)
11069044|NCT04293068||Control group|Related tests were normal, because the male factor alone required the first IVF/ICSI cycle; Follow-up of included patients was conducted to determine whether embryo transplantation was performed, and the score of transferred embryos was recorded, and the final control group would be confirmed after achieving clinical pregnancy
11069045|NCT04293068||Recurrent implantation failure|Previous ≥3 consecutive embryo transfer failures
11069046|NCT04293068||Recurrent spontaneous abortion(miscarriage)|≥2 consecutive spontaneous abortions or embryo damage
11069047|NCT04293055|Experimental|Maintenance program+possibility of phone coaching|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. Some participants randomized to this condition will also receive 4 consecutive weeks of phone coaching at some point over the 1-year intervention period (this is determined by a weight-based algorithm).
11069048|NCT04293055|Active Comparator|Maintenance program only|All participants are provided with a monthly newsletter which contains useful strategies for maintaining weight loss long-term. Participants are also encouraged to weigh themselves daily using a smart scale, which electronically transmits weight data to the research staff. No participants in this condition will receive phone coaching.
11069049|NCT04293042|Experimental|BK cystitis and/or nephropathy|All patients with symptoms that are consistent with BK cystitis and/or nephropathy (frequency, dysuria, hematuria, elevated creatinine) will have serum quantitative DNA PCR for BK virus level measured in log copies per mL (results also expressed in copies per milliliter), performed in the Children's Hospital of Philadelphia Infectious Disease Diagnostics Laboratory
11069050|NCT04293029|Experimental|Normal liver function|Patients will receive single dose of SHR0302
11069051|NCT04293029|Experimental|Mild Hepatic Impairment|Patients will receive single dose of SHR0302
11069052|NCT04293029|Experimental|Moderate Hepatic Impairment|Patients will receive single dose of SHR0302
11069053|NCT04293016|Active Comparator|Support as usual|
11069054|NCT04293016|Experimental|Problem Solving therapy|
11069055|NCT04293016|Experimental|ICU diary|
11069056|NCT04293003|Experimental|Fasting|6-hour morning fasting
11069057|NCT04293003|Experimental|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
11069058|NCT04293003|Experimental|Mediterranean|Consumption of a Mediterranean breakfast
11069059|NCT04292990|Experimental|Fentanyl|Intervention: Drug: Fentanyl Transdermal Patch
11069060|NCT04292990|Active Comparator|Morphine|Intervention: Drug: Morphine Controlled-Release Tablets
11069061|NCT04292951|Experimental|GDT group|Intraoperative fluid and inotropic/vasoactive drugs management based on information from FloTrac/EV1000
11069062|NCT04292951|Active Comparator|Control group|Intraoperative fluid and inotropic/vasoactive drugs management based on CVP, blood pressure, heart rate, and clinical signs at the discretion of attending anesthesiologists
11069063|NCT04292938|Active Comparator|Ketogenic diet|patients will follow a low carbohydrate high lipid personalized diet causing blood BOHB level to be between 1.5-4 mmol/l for six months
11069064|NCT04292938|No Intervention|control group|Patients will be asked to maintain their usual dietary regimen
11069065|NCT04292925|Experimental|Experimental Group|Intervention with the new treatment protocol will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
11069066|NCT04292925|Active Comparator|Control group|Intervention with conventional therapy will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
11069067|NCT04292912|Experimental|GSK2798745 3.2 mg once daily|Subjects will receive a single daily 3.2 milligram (mg) oral dose of GSK2798745 for 28 days.
11069068|NCT04292899|Experimental|Part A: Remdesivir (RDV), 5 Days (Not Mechanically Ventilated)|Participants who are not mechanically ventilated will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
11069069|NCT04292899|Experimental|Part A: Remdesivir, 10 Days (Not Mechanically Ventilated)|Participants who are not mechanically ventilated will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
11069070|NCT04292899|Experimental|Part B: Remdesivir, 5 or 10 Days (Extension)|Part B (Extension) will enroll participants after enrollment to Part A is complete. Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10.
11069071|NCT04292899|Experimental|Part B: Remdesivir 10 days (Mechanically Ventilated)|Participants on mechanical ventilation will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10
11069072|NCT04292886|Active Comparator|thin endometrium ,treatment,Tamoxifen|From the 2nd day of the menstrual cycle, the patient took tamoxifen and femoston
11069073|NCT04292886|Placebo Comparator|thin endometrium ,treatment,Vitamin C|From the 2nd day of the menstrual cycle, the patient took Vitamin C and femoston
11069074|NCT04292873|No Intervention|Control|
11069075|NCT04292873|Experimental|Vitamin D|Enteral supplement of 569,600 IU vitamin D
11069076|NCT04292860||Breast Cancer Pts|Post-operative (lumpectomy or mastectomy) female breast cancer patients who will receive radiation to the whole breast or chest wall and the regional nodes.
11069077|NCT04292847|Experimental|Geriatric Assessment|Participants fill out the geriatric assessment during a clinic visit and receive recommendations based on results
11069078|NCT04292821||Patients consulting for breast lesion Bi Rads 4 or 5|Patients consulting for breast lesion Bi Rads 4 or 5
11069079|NCT04292808|Other|Penthrox|Low Dose Methoxyflurane
11069080|NCT04292795|Experimental|Group A|Intervention: Shortwave Diathermy Frequency: 27.12 MHz Time Duration: 10min Duration of Treatment: 4 weeks. Sessions per Week: 2 sessions per week
11069081|NCT04292795|Experimental|Group B|Intervention: Therapeutic Ultrasound Frequency: 1-3MHz Intensity: 0.2-1W/cm2 Time Duration: 10mins Duration of Treatment: 4 weeks Sessions per Week: 2 sessions per week
11069082|NCT04292782|Active Comparator|CAUDAL BLOCK|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and needle of diameter and length respectively between 22G and 25G, 35mm and 40mm according to the child's size (Braun).The patient is positioned laterally with their hips flexed to 90°. The sacral hiatus is forming with the two posterior superior iliac spines an equilateral triangle. The puncture is performed between the two sacral cornuae. The sacrococcygeal ligament gives a perceptible 'pop' when crossed. After crossing the sacro-coccygeal ligament, the needle is redirected 30° to the skin surface, and then advanced a few millimeters into sacral canal. After verifying absence of spontaneous reflux of blood or cerebrospinal fluid, slowly injection of Ropivacaine 0.25% 1ml/ kg
11069083|NCT04292782|Experimental|anterior Quadratus lumborum block|Sonosite machine (M-Turbo) equipped with a large bandwidth, a multifrequency linear probe (6-19 MHz) and a 22G, 50-mm, insulated facet type needle (BBraun Stimuplex Ultra 360°). Patients were placed in the lateral position, a probe was placed transversely to the abdominal flank. The needle was inserted using an in-plane technique and was preceded further into the fascia between the QLM and PM. Following confirmation of the correct space with the administration of 0.5-1 ml local anesthetic, block was induced with 1 ml/kg, 0.25% Ropivacaine,
11069084|NCT04292769|Experimental|Decitabine combined with DC-CIK|Test group: decitabine combined with autologous DC-CIK cells infusion: decitabine 10mg / d, intravenous administration of d-5 to d-1, autologous DC-CIK cells infusion: first course: d1-d3 The second course: d14-d16; the total number of cells is about 5-10 × 109; IL-2: 200,000 IU / d subcutaneous injection, the first course: d0-d4, the second course: d13-d17, every 2 weeks 1 course of treatment, 2 courses in total.
11069085|NCT04292769|Active Comparator|DC-CIK|Control group: autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109; One course: d0-d4, the second course: d13-d17, 1 course every 2 weeks, a total of 2 courses.
11069086|NCT04292756|Active Comparator|Triamcinolone Acetonide 40 mg|Arm 1
11069087|NCT04292756|Active Comparator|Triamcinolone Acetonide 4 mg|Arm 2
11069088|NCT04292743|Experimental|Eryaspase plus FOLFIRINOX|"Eryaspase will be administered on day 1 and 15 of a 4 week cycle (intravenous infusion) in dose escalating/reduction depending on the cohort the patient is assigned to
~mFOLFIRINOX dosing will include 5-fluorouracil 2400 mg/m² over 46 hours, oxaliplatin 85 mg/m², Irinotecan 150 mg/m² (intravenous infusion) on Day 1 and 15 of the 4 weeks cycle for a maximum of 12 cycles."
11069089|NCT04292730|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
11069090|NCT04292730|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
11069091|NCT04292730|Active Comparator|Part A: Continued SOC Therapy|Participants will receive continued standard of care therapy.
11069092|NCT04292730|Experimental|Part B: Extension Treatment, Remdesivir 5 or 10 days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
11069093|NCT04292717|Active Comparator|Deficit-oriented training group|
11069094|NCT04292717|Active Comparator|Non-specific, standardised walking training group|
11069095|NCT04292704|Experimental|Laser group|Fractional CO2 laser therapy in consolidation treatment once a month for 3 months and treatment was prohibited during menstrual period.
11069096|NCT04292704|Other|Clotrimazole group|Clotrimazole tablets 500mg PV biw q3d in consolidation treatment once a month for 6 months and treatment was prohibited during the menstrual period.
11069097|NCT04292691|Experimental|Ropivacaine|A cumulative amount of approx. 40ml ropivacaine 0.5% (≙400mg (2x200mg) ropivacaine) is applied immediately before surgery. They are applied in a ring wall 10 cm cranially of the tip of the medial and lateral malleolus (N. peroneus superficialis (N. cutaneus dorsalis medius et intermedius, N. saphenus, N. suralis), as well as sonographically controlled (N. peroneus profundus and N. suralis)
11069098|NCT04292691|Placebo Comparator|Ringer's Lactate|Analog to the Experimental Arm, but the same amount of Ringer (40ml) will be plicated instead Ropivacaine
11069099|NCT04292678|Experimental|Relaxation|Caregivers of patients with advanced cancer will apply 20 minutes of progressive muscle relaxation exercise twice a week, for 8 weeks with a group session.
11069100|NCT04292678|Active Comparator|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
11069101|NCT04292665|Experimental|Classical Massage|Patients will receive a total of fourteen individual applied classical massage sessions, twice daily for seven days, each session lasting 30 minutes.
11069102|NCT04292665|Experimental|Relaxation|Patients will receive a total of fourteen individual counseling sessions, in a quiet room, twice daily for seven days, each session lasting 20 minutes.
11069103|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
11069104|NCT04292652||EVAR group|Individuals undergoing endovascular aortic repair. n=40
11069105|NCT04292652||OR group|Individuals undergoing open repair. n=40
11069106|NCT04292639|Experimental|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
11069107|NCT04292626|Experimental|Lymphoma|At least five (5) evaluable subjects with Hodgkin Lymphoma or Non Hodgkin Lymphoma. The tested injected dose of 500 MBq.
11069108|NCT04292600||UMMC|Cohort recruited at University of Mississippi Medical Center
11069109|NCT04292600||UAB|Cohort recruited at University of Alabama in Birmingham
11069110|NCT04292587||Women with hirsutism|Women between the ages of 18-45 with hirsutism
11069111|NCT04292587||Women without hirsutism|Women between the ages of 18-45 without hirsutism
11069112|NCT04292574||Participants with Spinal Muscular Atrophy|
11069113|NCT04292561|Experimental|light general anesthesia|During anesthesia maintenance, patients were received with low concentration sevoflurane to maintain a target of 0.8 MAC.
11069114|NCT04292561|Experimental|deep general anesthesia|During anesthesia maintenance, patients were received with high concentration sevoflurane to maintain a target of 1.0 MAC.
11069115|NCT04292548||study group (passive smoking children)|
11069116|NCT04292548||control group|
11069117|NCT04292535|Active Comparator|Passive Control|20 minute sedentary control period during which participants watched an emotionally neutral video.
11069118|NCT04292535|Experimental|Acute Exercise|20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.
11069119|NCT04292509|Experimental|SAP with predictive stop before low|Sensor-augmented pump therapy with the use of the predictive stop before low mode of action
11069120|NCT04292509|Active Comparator|SAP with stop on low|Sensor-augmented pump therapy with the use of the predictive stop on low mode of action
11069121|NCT04292496|Experimental|Intraperative leak testing group|i) the integrity of the anastomosis can be directly observed under gastroscopy. ii) the distal of Roux limb was temporarily blocked, then the bowel of anastomosis was inflated by air, following 60 milliliter methylene blue.
11069122|NCT04292496|No Intervention|Non-intraoperative leak testing group|Non intraoperative leak testing was performed intraoperatively.
11069123|NCT04292470|Experimental|Amitriptyline|Amitriptyline 10 mg daily
11069124|NCT04292457|Experimental|Propofol|Anesthesia is maintained with Propofol
11069125|NCT04292457|Experimental|Sevoflurane|Anesthesia is maintained with Sevoflurane
11069126|NCT04292444|Experimental|RAGE polymorphism (TT)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TT) will be selected and scanned twice.
11069127|NCT04292444|Experimental|RAGE polymorphism (TA/AA)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TA/AA) will be selected and scanned twice.
11069128|NCT04292418||study group 1|(rejector group )include Paediatric living donor kidney transplant recipients (aged 4-18 years) at least 35 child recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the study group 1 measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test
11069129|NCT04292418||study group 2|the second group (non rejector group ) include Paediatric living donor kidney transplant recipients (aged 4-18 years) recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the studied group at least 35 child measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test in the study group 2
11069130|NCT04292405||Heart Failure Patients|Simultaneous recordings of cardiac acoustic biomarkers (CABs) by the Wearable Cardioverter Defibrillator and the AUDICOR AM
11069131|NCT04292392|Experimental|A - ACB + Periarticular Block|Group A: patient will receive a preop ACB, followed by Intra-articular block during TKA surgery
11069132|NCT04292392|Experimental|B - ACB + IPACK Block|Group B: patient will receive a preop ACB+IPACK block before TKA surgery only
11069133|NCT04292392|Experimental|C - ACB + IPACK + Periarticular Block|Group C: patient will receive a preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
11069134|NCT04292366|Experimental|Intervention arm I|pre-notification approximately ten days prior to intervention, invitation and one reminder (three-staged intervention)
11069135|NCT04292366|Experimental|Intervention arm II|invitation, one reminder after 45 days and a second reminder three months after invitation (three-staged invitation procedure)
11069136|NCT04292366|Experimental|Intervention arm III|pre-notification, invitation, reminder after 45 days and reminder after three months (four-staged invitation procedure)
11069137|NCT04292366|Active Comparator|Control group|invitation and one reminder after 45 days (usual care)
11069138|NCT04292327||The ordinary COVID-19|Consistent with the diagnosis of ordinary COVID-19.
11069139|NCT04292327||The heavy COVID-19.|Consistent with the diagnosis of heavy COVID-19.
11069140|NCT04292327||The critical COVID-19|Consistent with the diagnosis of critical COVID-19
11069141|NCT04292314|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.
~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
11069177|NCT04292067||Healthy subjets|200 healthy subjets in control group
11069178|NCT04292067||patients with RA|100 RA patients
11069142|NCT04292314|Experimental|Nigella sativa experimental group|"50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.
~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
11069143|NCT04292314|Experimental|Hydroxyurea experimental group|"50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
11069144|NCT04292314|Experimental|Natural honey experimental group|"50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
11069145|NCT04292314|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
~in addition to iron chelator agent, this group receive regular blood transfusion session."
11069146|NCT04292301|Experimental|STrategically Acquired Gradient Echo (STAGE)|STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging. All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
11069147|NCT04292288||Foreign body granuloma|men injecting paraffin oil
11069148|NCT04292275|Experimental|Digital Health Tools + Standard of Care|
11069149|NCT04292275|Other|Standard of Care|
11069150|NCT04292262||AKI|
11069151|NCT04292262||Non AKI|
11069152|NCT04292249||Elective on-pump cardiac surgery patients|Adult patients (≥18 years) undergoing elective on-pump cardiac surgery (isolated coronary artery bypass graft (CABG), single and multiple valvular procedures, combined CABG and valvular surgery, and others).
11069153|NCT04292236|Placebo Comparator|Placebo|Administered at time 0 min and 300 min. Cellulose was used as the placebo.
11069154|NCT04292236|Active Comparator|Dietary Supplement|Administered at 0 min and 300 min. Combination of lauric acid, perilla oil and diindolylmethane was used as the dietary supplement.
11069155|NCT04292223|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg administered orally
11069156|NCT04292210|Experimental|CAPD handling|"A connecting device simplifying the steps during a cycle of Peritoneal dialysis. Instead of directly doing a manual connection and manually breaking a frangible, the device assist in connecting and breaking the frangible.
~This study was done demonstrating a continuous ambulatory peritoneal dialysis (CAPD)"
11069157|NCT04292197|Placebo Comparator|18-MC SAD Study|In Part 1, forty-two (42) healthy participants will be randomized in 6 cohorts to receive a bid dose of 18-MC HCl (n=30) or placebo (n=12) in a single day.
11069158|NCT04292197|Experimental|18-MC MAD Study (7-Day)|In Part 2, thirty-five (35) healthy participants will be randomized in 5 cohorts to receive a bid dose of 18-MC HCl (n=25) or placebo (n=10) for 7 consecutive days.
11069159|NCT04292184|Active Comparator|UW (perfusion solution) + sodium thiosulfate (STS)|We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
11069160|NCT04292184|No Intervention|UW (perfusion solution)|Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.
11069161|NCT04292171|Active Comparator|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
11069162|NCT04292171|Placebo Comparator|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
11069163|NCT04292158||Main Group|Hospitalized for at least 1 day clinic stay at the participating hospitals
11069164|NCT04292145|Experimental|Relaxation Application|Participants will follow the relaxation application.
11069165|NCT04292145|Active Comparator|Relaxation Only|Participants will use any relaxation technique they normally use to relax.
11069166|NCT04292132|Active Comparator|Conventional loading|Loading of 4 interforaminal implants three months after surgery.
11069167|NCT04292132|Experimental|Immediate Loading|Loading of 4 interforaminal implants immediately after surgery.
11069168|NCT04292119|Experimental|Lorlatinib and Crizotinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.
~Phase 1 (the dose-finding portion of the study) will follow a standard 3+3 design. Enrollment to the two different study arms will occur in parallel.
~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days
~Crizotinib will be administered orally twice daily at a predetermined dose for 28 days
~Phase II patients will be treated with Lorlatinib and Crizotinib at a dose recommended based on the phase I study."
11069169|NCT04292119|Experimental|Lorlatinib and Binimetinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.
~The phase I part of the study will follow a standard 3+3 design. Enrollment to the two different study arms will occur in parallel.
~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days
~Binimetinib will be administered orally twice daily at a predetermined dose for 28 days.
~Phase II patients will be treated with Lorlatinib + Binimetinib at a dose recommended based on the phase I study."
11069170|NCT04292106|Placebo Comparator|Placebo|
11069171|NCT04292106|Experimental|Red Spinach Extract (RSE)|
11069172|NCT04292093|Experimental|Home rehabilitation training|Home rehabilitation training
11069173|NCT04292093|Active Comparator|Home control activity|Home control activity
11069174|NCT04292080|Experimental|Group TECFIDERA™|30 patients will receive oral administration of Dimethyl Fumarate (Tecfidera™) 120 mg twice a day for the first week and then 240 mg of Tecfidera twice a day for 51 weeks following approved standard treatment scheme.
11069175|NCT04292080|Other|No comparator|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
11069176|NCT04292067||patients with SPA|100 SPA patients
11069277|NCT04291365|Other|Obesity Class 3|
11069179|NCT04292054|Active Comparator|active group|"The antibiotic prophylaxis will be cefazolin 2 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump, in case of absence of colonization to Pseudomonas aeruginosa prior to the surgical procedure.
~The dose administer is 2g.
~Antibiotic prophylaxis will be piperacilline-tazobactam 4 g powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe driver in patients with burn wound colonized to Pseudomonas aeruginosa.
~The dose administer is 4g."
11069180|NCT04292054|Placebo Comparator|Placebo group|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
11069181|NCT04292028|Experimental|pilates group|The Pilates group participated in an 8-week clinical Pilates training program
11069182|NCT04292028|Active Comparator|Control group|Control group were given a home-based exercise program
11069183|NCT04292015|Experimental|Standard then Intervention|Infant will undergo standard method of examination with binocular indirect opthalmoscope (BIO) followed by retinal imaging with Optos ultra-wide field retinal imaging device.
11069184|NCT04292015|Experimental|Intervention then Standard|Infant will undergo retinal imaging with Optos ultra-wide field retinal imaging device followed by standard method of examination with binocular indirect opthalmoscope (BIO).
11069185|NCT04292002|Experimental|Health Checks|Workplace health checks - in this intervention employees can select from a range of optional health checks/tests and receive tailored health advice and a health resource pack.
11069186|NCT04291989|Experimental|Earlobe and Finger Prick versus venous blood lactate sampling|Compare blood Lactate levels between ear lobe and finger against venous forearm blood sample using the electronic hand held lactate device in hip fracture patients with good cognitive function (AMT >/= 7)
11069187|NCT04291976|Experimental|back-to-back HDWLE|Similar to single-pass HDWLE, with a second introduction and inspection after the first examination in the same session. Equipment is similar to 1.
11069188|NCT04291976|Active Comparator|single-pass HDWLE|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
11069189|NCT04291976|Active Comparator|Chromoendoscopy|After introduction of the endoscope into the colon a dye (0.1% methylene blue or 0.3% indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two arms.
11069190|NCT04291963|Active Comparator|DGG + TUN|The multiple adjacent gingival recession sites were treated with DGG in conjunction with TUN technique.
11069191|NCT04291963|Active Comparator|SCTG + TUN|The multiple adjacent gingival recession sites were treated with SCTG in conjunction with TUN technique.
11069192|NCT04291950||Control group|Hispanic and NHW women undergoing either a benign breast surgery or prophylactic mastectomy.
11069193|NCT04291950||Newly diagnosed TNBC|Hispanic and NHW with newly diagnosed TNBC. Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy).
11069194|NCT04291924||Ablebodied individuals|
11069195|NCT04291924||Spinal Cord Injured Individuals|
11069196|NCT04291911||INTENSIVE CARE UNITS|
11069197|NCT04291898|Active Comparator|Device: ASO|Participants implanted with the AMPLATZER™ Septal Occluder (ASO)
11069198|NCT04291898|Active Comparator|Device: FSO|Participants implanted with the Occlutech Figulla Flex II® (FSO).
11069199|NCT04291898|Active Comparator|Device: GSO/GAO|Participants implanted with the GORE® CARDIOFORM ASD Occluder (GSO/GAO)
11069200|NCT04291885|Experimental|Avelumab|6 months of Avelumab at a dose of 800mg as a 60-minute IV infusion once every 2 weeks (13 doses)
11069201|NCT04291885|Placebo Comparator|Placebo|6 months of Placebo as a 60-minute IV infusion once every 2 weeks (13 doses)
11069202|NCT04291872|Experimental|Non-Heated Arm|Proximal cavities were restored with Equia Forte (GC Corporation, Europe) according to manufacturer's orders.
11069203|NCT04291872|Experimental|Heated Arm|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
11069204|NCT04291859|Experimental|Treatment Period 1|Titration of Lu AF28996 as add-on to levodopa - planned to be up to 26 days
11069205|NCT04291859|Experimental|Treatment Period 2|Stable dose of Lu AF28996 as add-on to levodopa - planned to be 2 days
11069206|NCT04291859|Experimental|Treatment Period 3|Flexible doses of Lu AF28996 as monotherapy (without levodopa) - up to 5 days
11069207|NCT04291846|Experimental|A|
11069208|NCT04291846|Experimental|B|
11069209|NCT04291833|Active Comparator|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
11069210|NCT04291833|Active Comparator|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
11069211|NCT04291833|Placebo Comparator|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
11069212|NCT04291820|Experimental|Intravenous induction with desflurane maintenance|The EMLA patch will be removed, and intravenous induction with propofol + opioid will be performed. The anaesthesia will be maintained with desflurane according to the levels of Bispectral index (BIS). Neuromuscular blockade is optional based on operator decision.
11069213|NCT04291820|Active Comparator|Inhalation induction with sevoflurane,sevoflurane maintenance|The EMLA patch will be removed, and inhalation induction with the sevoflurane will be performed. After peripheral vein cannulation, the opioid will be administered. The neuromuscular blockade is optional based on operator decision. Anaesthesia will be maintained with sevoflurane according to the set BIS levels.
11069214|NCT04291807|Experimental|Video education|A video of ERCP procedure has been viewed to the patients who will undergo ERCP and questions about the procedure had been answered by the primary investigator (experienced endoscopy nurse)
11069215|NCT04291807|No Intervention|Direct ERCP|Patients arranged ERCP for any reason underwent directly to the ERCP without any video education.
11069216|NCT04291794|Active Comparator|Conventional bolus induction|Hypnotic component of general anesthesia induction will be a single bolus of propofol 2mg/kg followed by turning on sevoflurane 2% at a fresh gas flow of 2L/min.
11069217|NCT04291794|Experimental|Target-controlled induction|Hypnotic component of general anesthesia induction will be target-controlled propofol infusion tritiated to loss of consciousness. Propofol target-controlled infusion will be maintained.
11069218|NCT04291781|Experimental|RC18 160mg|RC18 160mg SC once weekly ,and total of 24 doses
11069219|NCT04291781|Experimental|RC18 240mg|RC18 240mg SC once weekly ,and total of 24 doses
11069220|NCT04291781|Placebo Comparator|Placebo|Placebo SC once weekly ,and total of 24 doses
11069221|NCT04291768|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
11069222|NCT04291768|Active Comparator|Control group|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician
11069223|NCT04291755||Checkpoint inhibitor therapy|Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
11069224|NCT04291742|Experimental|0: cognitive|target prostate biopsies by cognitive fusion
11069225|NCT04291742|Experimental|1: software|target prostate biopsies by software
11069226|NCT04291729|Experimental|Ganovo+ritonavir with or without interferon nebulization|
11069227|NCT04291716|Other|Single Arm|This is a single-arm study. All subjects enrolled in the study will wear the device during stay in the EMU.
11069228|NCT04291703|Experimental|Antithymocyte globulin (ATG)|Antithymocyte globulin (ATG) will be intravenously administered over two days, with a total of 2 infusion periods. The first infusion is given at baseline visit (day 1), the second is given the next day at baseline visit (day 2). Body weight at baseline (Day 0- admission for the ATG/placebo infusion) will be used in calculating the doses for all infusions. The first dose (0.5mg/kg) will be infused over a minimum of 4 hours, and the second dose (2mg/kg) over a minimum of 4 hours with a maximum infusion time for each infusion of 10 hours. The second dose should be given no less than 12 and no more than 24 hours after completion of the previous dose. The final prepared product is to be labeled to protect the blind. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion.
11069229|NCT04291703|Placebo Comparator|Placebo|"0.9% Sodium Chloride Injection USP (Normal saline) is to be dispensed as the placebo for this study. The placebo is to be prepared dispensing an infusion bag of 0.9% Sodium Chloride Injection USP (Normal saline) with no additives (no ATG, no premedications) and label the product to protect the blind. The placebo will also be administered over a minimum of 4 hours for the first and second doses with a maximum infusion time of 10 hours. The second dose of the placebo arm should be given no less than 12 and no more than 24 hours after completion of the previous dose. Infusions may be administered either in a hospital or outpatient setting at the investigator's or institutions discretion."
11069230|NCT04291690|No Intervention|Control Group|Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.
11069231|NCT04291690|Experimental|Intervention Group|Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.
11069232|NCT04291677|Experimental|Intervention group in which musical intervention|Group A: Experimental group in which musical intervention will be applied between the first and the third day of mechanical ventilation.
11069233|NCT04291677|Other|Control group|Group B: Control group with standard treatment without musical intervention.
11069234|NCT04291664|Experimental|Prostate Cancer|
11069235|NCT04291651||Retrospective|The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts.
11069236|NCT04291651||Prospective|The prospectively enrolled patients in this study are the primary population of interest.
11069237|NCT04291638|Experimental|Remote Caregiver Training|The Remote Caregiver Training arm consists of participation in a 5-hour, videoconferencing-based caregiver training program.
11069238|NCT04291638|Experimental|Remote Caregiver Training + Intensive Treatment|The Remote Caregiver Training + Intensive Treatment arm consists of participation in a 5-hour, videoconferencing-based caregiving training program, followed by participation in the videoconferencing-based intensive group behavioral treatment program.
11069239|NCT04291625|Other|congenital ptosis|children who had congenital ptosis with levator function of 4mm or better, underwent levator muscle resection guided by intraoperative lagophthalmos formula.
11069240|NCT04291612||Part 1|Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.
11069241|NCT04291612||Part 2|Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)
11069242|NCT04291599|Experimental|Experimental Arm - Ketorolac (Opioid-Sparing)|Patients assigned to this arm of the study will follow the standardized step-up approach to pain management per the hospital Evidenced Based Guideline (EBG). If analgesia is not obtained with first-line medications such as acetaminophen, the patient will be given the NSAID ketorolac intravenously every 6 hours at the standard weight-based dose throughout hospitalization. If the patient experiences continued pain, they (or their guardian/ caregiver) may request a rescue medication in the form of low-dose morphine (or an alternative opioid if allergic to morphine) at 0.025 mg/kg/dose every 4 hours.
11069243|NCT04291599|Active Comparator|Control Arm - Conventional Treatment/Standard of Hospital Care|Patients assigned to this arm of the study will be treated per institutional policy and procedural care as dictated by established hospital order sets and at the discretion of the provider. This may involve the step-up approach per the hospital EBG utilizing acetaminophen or ibuprofen as first-line agents; however, it remains at the discretion of the treating provider. The current standard of care for children presenting to the ED is based on prescribing order sets within the electronic medical record (EMR). Physicians in the BCH emergency department choose in an intermittently-prescribed manner, standard doses of analgesia including acetaminophen (Tylenol) or ibuprofen per the hospital EBG, as well as opioids (morphine, hydromorphone).
11069278|NCT04291352|Experimental|Taurine|675mg taurine four times daily
11069279|NCT04291352|Placebo Comparator|Placebo|placebo four times daily
11069244|NCT04291586|Experimental|Virtual Reality|The Virtual Reality group will perform personalized activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
11069245|NCT04291586|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalized to their deficits and generated automatically through a Task Generator.
11069246|NCT04291573|Active Comparator|HD-tDCS and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with real stimulation (30min) over 13 consecutive training days (3 weeks)
11069247|NCT04291573|Sham Comparator|Sham stimulation and Virtual Reality Therapy|Patients will receive their usual rehabilitation program each day, which includes a conventional session (30min) and virtual reality therapy session (Armeo Spring) combined with Sham stimulation (30min) over 13 consecutive training days (3 weeks)
11069248|NCT04291560|Experimental|Prenatal Heart Smart Intervention|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, the group will complete a sequential static stretching exercise 5 days per week for 10 weeks. The stretching exercise consists of 20 seconds of stretching, for 3 repetitions per muscle group.
11069249|NCT04291560|No Intervention|Usual Care (Control)|This group will have usual care completed and supportive calls from a facilitator to discuss adherence to the home exercise. In addition, this group will complete moderate-intensity walking 5 days per week for 10 weeks in accordance to usual care.
11069250|NCT04291547|Experimental|Computerised Behavioural Activation Programme|All recruited young people will be given the BALM (Behavioural Activation for Low Mood) programme to work through
11069251|NCT04291521||Adult trauma patients requiring RSI|Patients who received an induction medication for intubation.
11069252|NCT04291508|Active Comparator|IV Acetaminophen-Active|Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).
11069253|NCT04291508|Active Comparator|IV Vitamin C-Active|Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses)
11069254|NCT04291508|Placebo Comparator|Acetaminophen-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
11069255|NCT04291508|Placebo Comparator|Vitamin C-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
11069256|NCT04291495|Experimental|ANDROSITOL®TEST|At least 45 patients (13 for each category: low, medium, and high responders, + 15% of hypothetical drop-outs)
11069257|NCT04291482|Experimental|Intervention arm|The intervention group participants will be assessed with EMA and they will provide daily data regarding their predictors of weight loss outcomes and their adherence to the personal weight loss plan (phase I, month 0-3). Then participants will receive tailored information regarding the most predictive factors relevant to their weight loss trajectories (phase II, month 3-6). The information will be tailored and delivered through emails and text messages.
11069258|NCT04291482|Other|Control arm|Control group participants will receive basic educational weight loss information in a form of educational factual emails and text messages.
11069259|NCT04291469|Placebo Comparator|Control group|Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks
11069260|NCT04291469|Experimental|Probiotics group|Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0*10^9 colony forming units, oral, daily for 14 weeks
11069261|NCT04291469|Experimental|Prebiotics group|Combined inulin+maltodextrin tables, oral, daily for 14 weeks
11069262|NCT04291456|Experimental|Minocycline|Minocycline 100 mg oral twice daily for up to 24 month
11069263|NCT04291443|Experimental|Upper First Premolar One Side|Heavy force (225 g)
11069264|NCT04291443|Experimental|Upper First Premolar Other Side|Light Force (25 g)
11069265|NCT04291417||CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis. Results will not be used to manage patients.
11069266|NCT04291404|No Intervention|Standard of Care (Control) Arm|Standard of care treatment, which may include a combination of the following, at the discretion of the treating team and family: parent/ caregiver support, child life services, healthcare provider support, etc.
11069267|NCT04291404|Experimental|Intervention Arm|Addition of distraction via an immersive, interactive VR experience to Standard of Care
11069268|NCT04291391|Experimental|Lean-normoglycemic (control)|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
11069269|NCT04291391|Experimental|Obese - normoglycemic|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
11069270|NCT04291391|Experimental|obese-glucose intolerant|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
11069271|NCT04291391|Experimental|obese with type 2 diabetes|All groups will consume a standardized North American/Canadian diet for 4 weeks designed to reflect (as closely as possible) current macronutrient intake averages in North America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein).
11069272|NCT04291378|Active Comparator|Photon radiation therapy|The patient is treated with standard radiation therapy based on photons
11069273|NCT04291378|Experimental|Proton radiation therapy|The patient is treated with experimental radiation therapy based on protons
11069274|NCT04291365|Other|Normal weight|
11069275|NCT04291365|Other|Obesity Class 1|
11069276|NCT04291365|Other|Obesity Class 2|
11069280|NCT04291339|Experimental|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
11069281|NCT04291339|Active Comparator|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
11069282|NCT04291313|Placebo Comparator|Current recommended dose of vitamin D|Women in this study arm receive 10 µg of vitamin D3 per day, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
11069283|NCT04291313|Experimental|Higher dose of vitamin D|Women in this arm receive 90µg of vitamin D3 per day: 10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3.
11069284|NCT04291300|Experimental|Lutetium treatment|Drug: Lutetium-177-PSMA-I&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
11069285|NCT04291287||Triple antithrombotic therapy|patients taking Triple antithrombotic therapy (aspirin and a P2Y12 inhibitor, in addition to either a DOACs or warfarin/acenocumarol)
11069286|NCT04291287||Dual antithrombotic therapy|patients taking Dual antithrombotic therapy (aspirin or P2Y12 inhibitor in addition to either a DOACs or warfarin/acenocumarol)
11069287|NCT04291274||inhalation anesthesia group|Unilateral and Bilateral cochlear implantation,which used inhalation anesthesia
11069288|NCT04291274||intravenous anesthesia group|Unilateral and Bilateral cochlear implantation, which used intravenous anesthesia
11069289|NCT04291261|Other|Extracorporeal photopheresis (ECP) with Uvadex|Patients in this single Arm study all receive the intervention consisting of ECP with Uvadex plus the standard of care treatment which consists of systemic corticosteroids 2mg/kg. Response to treatment will be evaluated on day 28. Patients will receive study treatment till day 56 and thereafter be followed until 1 year.
11069290|NCT04291248|Experimental|Anlotinib+AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11069291|NCT04291248|Experimental|AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
11069292|NCT04291235|Active Comparator|Airway Management Pathway|An airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients can breathe on their own and appear able to protect their airway
11069293|NCT04291235|Active Comparator|Usual Care|The usual clinical practice is often to keep the patient on artificial respiration for longer in the hope that the patient will wake up before removing the tube, or performing a tracheostomy if the patient doesn't wake up
11069294|NCT04291222|Experimental|IBS implantation|Implantation of IBS in PDA in duct-dependent cyanotic CHD
11069295|NCT04291209|Active Comparator|Experimental arm with Intratympanic NAC injection|One ear will be randomly chosen for the experimental treatment and receive intratympanic NAC injections 60 minutes prior to their scheduled chemotherapy sessions
11069296|NCT04291209|No Intervention|Control arm with No injection|The control ear will not receive any injections
11069297|NCT04291196|Experimental|Immersive Virtual Reality|Patients will be immersed in the ECT experience using VR-ECT 360o video (VR-ECT).
11069298|NCT04291196|Other|Standard Treatment|Patients will receive standard preparation for their ECT session.
11069299|NCT04291183|Experimental|elderly people to undergo hortic culture therapy|Horticultural Therapy will be applied to the elderly in the experimental group in the form of two days a week visit for eight weeks. Flower and vegetable seedlings suitable for the season will be planted in the garden with the elderly. The elderly will be asked to take care of the plants they planted every day (irrigation and collecting extra herbs) and the elderly people will be observed by doing these processes twice a week
11069300|NCT04291183|No Intervention|elderly people who will not receive horticultural therapy|pre-test data forms will be applied to the control group. Post-test data forms will be reapplied after 8 weeks
11069301|NCT04291170|Experimental|QDASH|Completing the tasks on the QuickDASH
11069302|NCT04291170|Active Comparator|KOOSJR|Completing the tasks on the KOOSJR
11069303|NCT04291157|Experimental|Proactive CVD prevention|Proactive invitation to total CVD risk estimation incorporating the PRS and provision of guideline based preventive interventions.
11069304|NCT04291157|Active Comparator|Usual care|Usual GP care (opportunistic CVD risk estimation and prevention upon usual GP contacts).
11069305|NCT04291144||Patients|Inclusion criteria are mild to moderate DLB, age above 50, ability to give informed consent.
11069306|NCT04291144||Healthy controls|Age above 50.
11069307|NCT04291131||Veterans with COPD|Veterans with COPD who will participate in a physical activity intervention or exercise program
11069308|NCT04291118|Other|Medical Management and Sinus Surgery in private system|These patients will first receive medical management for their symptoms and then will undergo sinus surgery much earlier than the other group as they will include patients being operated in the private system.
11069309|NCT04291118|Other|Medical Management and Sinus Surgery in public system|These patients will first receive medical management for their symptoms, and then will undergo sinus surgery after a waiting period of at least 1 year since they are on the public wait-list.
11069310|NCT04291118|Other|Medical Management Only|These patients will only receive medical management for their symptoms as they will not require sinus surgery.
11069311|NCT04291105|Experimental|Melanoma intratumoral|Melanoma, IV & IT VV1 + cemiplimab Patients will receive both intravenous (IV) VV1 and intratumoral (IT) VV1 on Day 1. Will also receveive an infusion of cemiplimab on Day 1.
11069312|NCT04291105|Experimental|Melanoma|Melanoma, IV + cemiplimab Patients will receive both IV VV1 and cemiplimab on Day 1.
11069313|NCT04291105|Experimental|Hepatocellular carcinoma|Hepatocellular carcinoma Patients will receive both IV VV1 and cemiplimab on Day 1.
11069314|NCT04291105|Experimental|Non-small cell lung cancer|Non-small cell lung cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
11069315|NCT04291105|Experimental|Endometrial cancer|Endometrial cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
11069316|NCT04291092|Experimental|single-arm|single-arm
11101633|NCT04065360|Experimental|Cognitive behavioural family intervention|
11069317|NCT04291079|Experimental|Part A1: Dose Escalation|Part A1 will determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of SRK-181 as a single agent and will determine the recommended Phase 2 dose (RP2D) of SRK-181 as a single-agent.
11069318|NCT04291079|Experimental|Part A2: Dose Escalation|Part A2 will determine the MTD or MAD of SRK-181 in combination with anti-PD-(L)1 antibody therapy and will determine the RP2D of SRK-181 in combination with anti-PD-(L)1 antibody therapy for use in Part B.
11069319|NCT04291079|Experimental|Part B: Dose Expansion|In Part B, parallel cohorts of patients with Non-small cell lung cancer (NSCLC), Urothelial Carcinoma (UC), Cutaneous melanoma (MEL), or other advanced or metastatic solid tumor type that is not NSCLC, UC, or MEL, will be enrolled to confirm the tolerability of the RP2D of SRK-181 (determined in Part A2) and to evaluate the anti-tumor activity of SRK-181 in combination with an anti-PD-(L)1 antibody therapy.
11069320|NCT04291079|Experimental|Long Term Extension Phase (LTEP)|"Patients may continue treatment in a LTEP:
~Part A1: Patients may continue treatment with SRK-181 as a single agent at the RP2D in the LTEP following 3 cycles of treatment with SRK-181 as a single agent in Part A1.
~Part A2: Patients may continue treatment with SRK-181 at the RP2D in combination with anti-PD-(L)1 antibody therapy in the LTEP following 3 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part A2.
~Part B: Patients may continue treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy following 9 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part B"
11069321|NCT04291066|Experimental|Treatment|oral N-acetyl cysteine and oral multivitamin tablets
11069322|NCT04291066|No Intervention|Non-Treatment|Routine Care
11069323|NCT04291053|Experimental|experimental group|Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)
11069324|NCT04291053|No Intervention|control group|standard therapy
11069325|NCT04291040|Experimental|Decision Aid|
11069326|NCT04291040|Active Comparator|Routine Care|
11069327|NCT04291027|Experimental|Aquatic Group Exercise|
11069328|NCT04291027|Active Comparator|Land Based Group Exercise|
11069329|NCT04291014|Experimental|BWLT once daily|Participants in this arm will receive bright white light therapy daily once a day (in the evening)
11069330|NCT04291014|Experimental|BWLT twice daily|Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
11069331|NCT04291014|Experimental|BWLT weekly|Participants in this arm will receive bright white light therapy once weekly (in the evening).
11069332|NCT04291014|Experimental|DRLT twice daily|Participants in this arm will receive dim red light twice daily (morning and evening).
11069333|NCT04291001|Active Comparator|ENG Implant alone|Women will receive a contraceptive implant in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
11069334|NCT04291001|Active Comparator|ENG Implant plus oral UPA|Women will receive a contraceptive implant and oral UPA the same day in the setting of a dominant follicle to assess ovulation incidence and timing following insertion.
11069335|NCT04290988|Experimental|Active EEG Neurofeedback|15 sessions of active EEG neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
11069336|NCT04290988|Sham Comparator|Sham Feedback|15 sessions of sham neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
11069337|NCT04290975|Experimental|Task-shifted arm|In the task-shifted arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a CHW, with a physician consult available to the CHW as needed.
11069338|NCT04290975|Active Comparator|Enhanced usual care arm|In the enhanced usual care arm, all children will be prescribed anti-epileptic medication and receive follow-up care from a physician, with a CHW collecting standardized data to mirror that of the intervention arm.
11069339|NCT04290962|Experimental|Supportive Care (web-based lifestyle intervention)|Participants complete the 12-month Precision Nutrition Coaching Program web-based lifestyle intervention consisting of physical activity at home or a local gym, nutritional/lifestyle habit with a new focus biweekly, and educational lessons about health, nutrition, fitness, or behavior change.
11069340|NCT04290936|Experimental|Arm 1|NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.
11069341|NCT04290936|Placebo Comparator|Arm 2|NUC-naïve patients will be randomization into placebo arm.
11069342|NCT04290936|Active Comparator|Arm 3|NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.
11069343|NCT04290910|Experimental|Weight Loss Program|Single arm, all participants receive the weight loss program
11069344|NCT04290897|Experimental|Supportive care (anhydrous enol-oxaloacetate)|Patients receive anhydrous enol-oxaloacetate PO BID for 8 weeks in the absence of worsening symptoms or unacceptable toxicity.
11069345|NCT04290884|Experimental|Local administration of tranexamic acid|"All patients hip fracture will be treated according to the hospital standard procedure
~Check complete blood count on admission and Day 3 post-operation.
~10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control
~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.
~Transfusion when clinically indicated or Hb < 8g/dL
~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)
~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.
~After discharge, patients will be seen in 6 weeks and 3 months"
11069346|NCT04290884|No Intervention|Control group|"All patients hip fracture will be treated according to the hospital standard procedure
~Check complete blood count on admission and Day 3 post-operation.
~10ml normal saline injected under the deep fascia around the fracture site under x-ray control
~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.
~Transfusion when clinically indicated or Hb < 8g/dL
~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)
~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.
~After discharge, patients will be seen in 6 weeks and 3 months"
11069347|NCT04290871|Experimental|Treatment Group|Nitric Oxide gas will be administered in the ventilatory circuit.
11069348|NCT04290871|Sham Comparator|Control Group|The delivery system will be set up anyway without study gas administration
11069349|NCT04290858|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
11069350|NCT04290858|No Intervention|Control|The control group will receive the standard of treatment without any active, placebo or sham Comparator.
11069351|NCT04290845|Experimental|Relief-Hybrid|Relief-Hybrid relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
11069352|NCT04290845|No Intervention|Referral to Mental Health/Usual Care|Continuation of medical attention and treatment provided by physicians and other medical professionals at the primary care practice. Referral for mental health based on clinical indication. Participants receive an educational booklet on pain.
11069353|NCT04290832|Experimental|CO intervention|"South Africa: All health facility staff working in facilities assigned to the intervention arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers) plus the CO intervention.
~Mexico: Doctors/anyone eligible to be an abortion provider working in facilities assigned to the intervention arm receive the CO intervention."
11069354|NCT04290832|No Intervention|Control|"South Africa: All health facility staff working in facilities assigned to the control arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers).
~Mexico: No intervention"
11069355|NCT04290819|Experimental|Resistance Training with Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
11069356|NCT04290819|Experimental|Resistance Training with Caffeine|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
11069357|NCT04290819|Experimental|Resistance Training with Caffeine and Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
11069358|NCT04290819|Placebo Comparator|Resistance Training with Placebo|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
11069359|NCT04290806||ESCC|250 patients with esophageal squamous cell carcinoma
11069360|NCT04290806||GAC|250 patients with gastric adenocarcinoma
11069361|NCT04290806||GEJAC|250 patients with gastroesophageal junction adenocarcinoma
11069362|NCT04290793|Experimental|Experimental group|Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
11069363|NCT04290793|Active Comparator|Control group|Patients will only receive Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
11069364|NCT04290767|Other|Sonovue|ICU patients with acute shock status (septic or non-septic) who are eligible for enhanced-contrast brain ultrasound with sulphur hexafluoride microbubbles contrast (Sonovue, BRACCO, Milan, Italy) examination.
11069365|NCT04290754|Experimental|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
11069366|NCT04290754|Active Comparator|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive-behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
11069367|NCT04290741|Experimental|Auricular (Battlefield) Acupuncture|Auricular acupuncture involves placement of needles based on battlefield acupuncture protocol which involves the placement of needles in up to 5 sites on each ear to treat pain.
11069368|NCT04290741|Experimental|Peripheral Acupuncture|Peripheral acupuncture involves placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
11069369|NCT04290741|No Intervention|Control|Standard of care without acupuncture
11069370|NCT04290728|Experimental|High flow|Apply high-flow nasal oxygenation during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
11069371|NCT04290728|Active Comparator|Control|Apply nothing during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
11069372|NCT04290715||group A|
11069373|NCT04290715||group I|
11069374|NCT04290702|Active Comparator|epidural|
11069375|NCT04290702|Active Comparator|combined|
11069376|NCT04290702|Active Comparator|dural puncture epidural|
11069377|NCT04290689||Botulinum Toxin-A injection treatment|Toe walking Cerebral Palsy subject who are subject to Botulinum toxin-A injection treatment. The dosage will be determined by the Orthopaedic Consultant
11069378|NCT04290689||Serial casting stretching treatment|Toe walking Cerebral Palsy subject who are subject to serial casting stretching treatment.
11069379|NCT04290676||DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
11069380|NCT04290663|Active Comparator|RAI group|
11069381|NCT04290663|Experimental|GUIDED FOLLOW-UP group|
11069498|NCT04289701||Hypertension Cohort|"Hypertension patients recruited in the Hypertension Prevention and Control Initiative in China project."
11069382|NCT04290650|Other|Modified CBT for insomnia|All patients admitted to one of the psychosis ward will be offered the same customized treatment focusing on sleep in addition to treatment as usual.
11069383|NCT04290650|Other|Treatment as usual|All patients admitted to the other two psychosis wards will only receive treatment as usual.
11069384|NCT04290637|Experimental|No sea swimming|Stop sea swimming for 4-6 weeks
11069385|NCT04290637|Active Comparator|Sea swimming|Continue sea swimming for 4-6 weeks
11069386|NCT04290624|Experimental|Intervention Group|Participants will be instructed to use a dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride, COREGA denture foaming cleanser and mouth rinse containing 90 parts per million (ppm) sodium fluoride. Participants will brush with a strip of the dentifrice (full brush head) applied to the full length of the toothbrush head for 2 minutes followed by 2 pumps of denture cleanser foam brushed onto removable partial denture (RPD) for 90 seconds and 10 milliliter (ml) of mouth rinse for swished around the mouth for 1 minute. Participants will apply all these products twice daily (morning and evening) for 12 weeks.
11069387|NCT04290624|No Intervention|Reference Group|Participants will not be supplied any products and will continue with their existing dental/denture hygiene practices and should not make changes to either their established habits nor to the products they use following screening.
11069388|NCT04290611||Enzalutamide drug-induced toxicity|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by enzalutamide, with a chronology compatible with the drug toxicity
11069389|NCT04290585|Experimental|Health Services Research (text message reminder)|Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.
11069390|NCT04290572|Experimental|Isotretinoin 10 mg/day|One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.
11069391|NCT04290572|Experimental|Isotretinoin 20 mg/day|One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.
11069392|NCT04290572|Active Comparator|Isotretinoin 30 mg/day|One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.
11069393|NCT04290546|Experimental|Cohort I without Ipilimumab Lead in|"Haploidentical donor derived CIML NK cell infusion with subcutaneous N-803 for eligible patients with platinum-refractory and immune checkpoint blockade-refractory, advanced head and neck squamous cell carcinoma (Cohort 1)
~CIML NK cell infusion (Dose 0 or -1) infused on Day 0.
~Interleukin-15 Superagonist dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles)."
11069394|NCT04290546|Experimental|Cohort 2 with Ipilimumab Lead In|"Cohort 2 treated with an ipilimumab lead-in prior to CIML NK cell infusion after safety is established with the NK cell and N-803 treatments alone.
~Participants in the ipilimumab subgroup (Cohort 2) will receive a single dose of lead-in ipilimumab via iv per protocol determined dose followed by lymphodepleting chemotherapy on Day -6 for a total of 5-days, prior to receiving CIML NK cell infusion.
~CIML NK cell infusion-Highest Dosed per cohort 1, infused on day 0
~Interleukin-15 Superagonist (N-803) Administration
~-- dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).
~Cohort 2 will receive the highest number of CIML NK cells that is still considered safe and ipilimumab."
11069395|NCT04290533|Experimental|Active HD-tDCS|
11069396|NCT04290533|Sham Comparator|Sham HD-tDCS|
11069397|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:
~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)
~Thereof: IVT eligible patients:
~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment
~Thereof: IV rtPA treated patients:
~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
11069398|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:
~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)
~Thereof: IVT eligible patients:
~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment
~Thereof: IV rtPA treated patients:
~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
11069399|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:
~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)
~Thereof: IVT eligible patients:
~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment
~Thereof: IV rtPA treated patients:
~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
11069400|NCT04290455|Experimental|treatment arm|using the microblepharoexfoliative procedure
11069401|NCT04290455|Active Comparator|control arm|using eyelid wipe (Optase)
11069402|NCT04290442|Active Comparator|Adductor canal block (ACB)|
11069403|NCT04290442|Experimental|Adductor canal block plus SPANK block|
11069404|NCT04290429|Experimental|SR-GI-GVHD|Analysis of patient's stool frequency, albumin serum levels and quantification of Paneth cell numbers in GI biopsies before and during teduglutide treatment.
11069405|NCT04290416|Experimental|Microwire electrodes|Activity of individual neurons will be recorded via microwire contacts. These microwire electrodes do not interfere with the macrowire clinical recordings.
11069406|NCT04290403|Experimental|Pull ups|Pull-up continence products
11069407|NCT04290403|Experimental|Styled briefs with tapes|Styled briefs with tapes
11069408|NCT04290390|Active Comparator|Annovera (alone)|Annovera taken alone (without itraconazole or rifampin)
11069409|NCT04290390|Active Comparator|Annovera with itraconazole use|Subjects will dose with 200 mg/day of itraconazole for five days before Annovera insertion and through Days 1 to 8 of Annovera use
11069410|NCT04290390|Active Comparator|Annovera with rifampin use|Subjects will dose with 600 mg/day rifampin for 8 days, between Days 4 to 11 of Annovera use during their respective treatment cycles
11069411|NCT04290377|Active Comparator|Conventional OT + Motor Imagery OT|Conventional OT (30 minutes/day) plus Motor Imagery OT (30 minutes/day) for 10 days.
11069412|NCT04290377|Experimental|Conventional OT + BMI-assisted Motor Imagery OT|Conventional OT (30 minutes/day) plus BMI-assisted motor imagery OT (30 minutes/day) for 10 days.
11069413|NCT04290364||Prospective cohort|Patients newly diagnosed with pancreatic cancer included in the prospective part of the study
11069414|NCT04290364||Retrospective cohort|Patients diagnosed with pancreatic cancer before early palliative care was introduced (historical control patients)
11069415|NCT04290351||Band ligation and phlebotonic group|"Patients with rubber band ligation and the prescribed anti hemorrhoidal drug will be examined in this group.
~(Note: The researcher has no contribution or intervention to the treatment method.)"
11069416|NCT04290351||Only phlebotonic group|"Patients who are prescribed the only 450mg of diosmin + 50mg of hesperidin as a treatment for bleeding internal hemorrhoids will be examined in this group.
~(Note: The researcher has no contribution or intervention to the treatment method.)"
11069417|NCT04290338|Experimental|PIOMI Group|Patients in this group will receive the intraoral and extraoral stimulations provided by the PIOMI protocol. These stimulations will last 5 minutes and will be performed once a day for 7 consecutive days for each patient.
11069418|NCT04290338|No Intervention|Control Group|Patients in this group will receive classic care.
11069419|NCT04290325|Experimental|HMPL-453|HMPL-453
11069420|NCT04290312|Other|Mastiha oil|As a control to the experimental design, timepoint 0 was considered.
11069421|NCT04290286|Experimental|intervention group|Trans persons (n = 105) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)
11069422|NCT04290286|No Intervention|waiting group|Trans persons (n = 105) wait 4 months until they are offered online intervention according to the i2TransHealth model of care (waiting group)
11069423|NCT04290273|Experimental|Morning exposure in week 1|Participants will have their first week of testing starting in the morning
11069424|NCT04290273|Experimental|Afternoon exposure in week 1|Participants will have their first week of testing starting in the afternoon
11069425|NCT04290260|Experimental|Use of breast bra|Patients allocated on this group wear a breast bra from admission to hospital discharge.
11069426|NCT04290260|Active Comparator|Usual care|Usual care: participants will not wear a breast bra until discharge from the hospital
11069427|NCT04290247|Experimental|Ultrasound + X-ray|Ultrasound first then x-ray examination
11069428|NCT04290234||Non-medicated healthy adults with childhood maltreatment|The 25-item retrospective Childhood Trauma Questionnaire (CTQ) will be administered to assess history of abuse and neglect. The CTQ measures five types of maltreatment: emotional, physical, and sexual abuse and emotional and physical neglect.
11069429|NCT04290221|Experimental|Percutaneous electrolysis in the lumbar nerv|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
11069430|NCT04290221|Active Comparator|Percutaneous electrolysis in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 3 weeks).
11069431|NCT04290208|Active Comparator|Intravenous Administration of Acetaminophen|A single peri-operative dose of acetaminophen 1000 mg IV over 15 minutes after skin is closed.
11069432|NCT04290208|Active Comparator|Per Oral Administration of Acetaminophen|A pre-operative liquid dose of acetaminophen 1000mg orally in the on-call to Operative Room.
11069433|NCT04290195|Experimental|ziv aflibercept patients|20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO
11069434|NCT04290182|Experimental|Single arm: MSC administration to vocal fold scar|1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)
11069435|NCT04290169|Other|Adults with hemiplegic spastic cerebral palsy|Adults (> 18 years old) with hemiplegic spastic cerebral palsy, with reduced hand function and spasticity as prevalent finding under clinical examination. Also these patients can walk but have problems with balance. Participants' cognitive function does not limit them to perform video game training.
11069436|NCT04290156|Experimental|Joint visits|Subjects in the intervention arm attend a total of four joint transition visits performed with the participation of both the adult and the pediatric gastroenterologist.
11069437|NCT04290156|No Intervention|Usual care|Adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists with respect the patient's treatment plan.
11069438|NCT04290143|Active Comparator|Colored healing water|Colored medical water in a bath tub. A single 20 minutes-long treatment will be performed.
11069439|NCT04290143|Placebo Comparator|Placebo - Colored tap water|Colored tap water. The temperature and the pH of the tap water will be adjusted to the temperature pH of the healing water. A single 20 minutes-long treatment will be performed.
11069440|NCT04290117|Experimental|ACT-Chrono|First Acceptance and Commitment (ACT) training, followed by chronobiological training
11069441|NCT04290117|Experimental|Chrono-ACT|First chronobiological training, followed by ACT training
11069442|NCT04290117|Other|Chrono|First no training, followed by chronobiological training
11069443|NCT04290117|Other|ACT|First no training, followed by ACT training
11069444|NCT04290104|Experimental|1gr oral ampicillin/sulbactam group|The group to be prescribed 1 g oral ampicillin/sulbactam twice a day while discharged after laparoscopic cholecystectomy due to ACC.
11069445|NCT04290104|No Intervention|Antibiotic not prescribed group|Antibiotics not prescribed when discharged after laparoscopic cholecystectomy due to ACC.
11069446|NCT04290091||Patients with CAD|
11069447|NCT04290091||Patients without CAD|
11069528|NCT04289532|Experimental|99mTc-RWY SPECT/CT|Volunteers and patients were injected intravenously with 11.1 MBq/kg of 99mTc-RWY in one dose and underwent SPECT/CT scan 30-60 min later.
11069448|NCT04290078|Experimental|Kaia Back Pain Study Intervention|"The study intervention consists of training sessions conducted daily by the participant via Kaia back pain program. This content combines several approaches that may be effective when used together such as physical exercises, relaxation practices and learning modules. Additionally, there is availability of an electronic motion coach on a set of exercises.
~Users also receive behavioural health coaching provided by Kaia's coaching staff based on a coaching curriculum."
11069449|NCT04290078|Active Comparator|Control Group|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth.
11069450|NCT04290065|Experimental|Experimental group|The intervention will take place over a period of 4 weeks, with 2 weekly sessions, with an estimated execution time of 1.50 to 3 minutes each. A manual therapy technique of inhibition of the suboccipital musculature and an axial traction of the upper hemiarchy will be performed
11069451|NCT04290065|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
11069452|NCT04290039|Active Comparator|Sequence A - Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.
~Each bottle will only be used to administer a single dose, to a single subject."
11069453|NCT04290039|Active Comparator|Sequence B - High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.
~Each bottle will only be used to administer a single dose, to a single subject."
11069454|NCT04290039|Active Comparator|Sequence C - IV|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.
~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.
~Each vial will only be used to administer a single dose, to a single subject."
11069455|NCT04290026|Active Comparator|metoclopramide versus granisetron|Ultrasound assessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section: A randomized, double-blind, placebo-controlled study
11069456|NCT04290013|Experimental|norethisterone -women with Dysfunctional uterine bleeding|
11069457|NCT04290013|Experimental|tranexemic acid-women with Dysfunctional uterine bleeding|
11069458|NCT04290000||hematological malignancies|hematological malignancies treated with CAR-T Cells
11069459|NCT04289987|Experimental|CVI-HBV-002|"CVI-HBV-002 1.0mL(20ug/dose)
~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
11069460|NCT04289987|Placebo Comparator|Normal Saline|"Normal Saline Choonwae Inj. 1.0 mL
~Intramuscular injection at Baseline, Week 2, 4, 8, 12, 16, 20 / total 7 doses"
11069461|NCT04289974||Palbociclib+fulvestrant|"100 cases of patients with ER+, HER2- breast cancer, experienced resistance after first line endocrinotherapy, will be assigned participants into treatment regimen, including palbociclib combined with fulvestrant.
~FFPE blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals on the points before administration and since resistance appearance. The tissue will be sequenced by a pan-cancer DNA panel (500+ genes) and whole transcriptome sequencing (WTS).
~5-10 ml peripheral blood will be collected from each patient on the points before administration, 1 month after treatment, every subsequent visit and resistance appearance. The liquid biopsy will be sequenced by a pan-cancer ctDNA panel (300+ genes).
~The genomic characteristics of patients received resistance will be analyzed. The relevant pathway mechanisms will be identified."
11069462|NCT04289961|Other|Single Arm|Observational study of CTC microemboli in portal vein blood samples.
11069463|NCT04289948|Experimental|Phage|
11069464|NCT04289948|Placebo Comparator|Placebo|
11069465|NCT04289935|Experimental|single arm|"Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy
~rCR / near-rCR in MRI
~Registration
~US-guided VAB
~Breast conserving surgery / mastectomy
~Pathology examination 1. Preoperative VAB, 2. Surgical specimen"
11069466|NCT04289909|Other|MS patients|RRMS Patients with optic neuritis, RRMS patients without optic neuritis or Progressive MS patients
11069467|NCT04289909|Other|Control group|Healthy volunteers
11069468|NCT04289896|Experimental|Experimental group|Each session will last 20 minutes, taking place 2 days a week, for a period of 4 weeks. Prior to the completion of the routine training of each team, the plyometric exercise program will be carried out in the experimental group. When the intervention ends, the members of the experimental group will perform the usual training
11069469|NCT04289896|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
11069499|NCT04289675||Interferon-Beta|Patients with first treatment : interferon beta (1a subcutaneous 22 or 44 µg thrice a week OR 1a intramuscular 30 µg once a week OR 1b subcutaneous 250 µg every other day OR 1a PEGylated subcutaneous 125 µg every two weeks)
11069500|NCT04289675||Dimethyl fumarate|Patients with first treatment : dimethyl fumarate (oral, 240 mg twice a day)
11069684|NCT04288362|Active Comparator|Control Group|
11069470|NCT04289883|Experimental|High molecular weight whey protein-alginate/Calcium alginate|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
11069471|NCT04289883|Experimental|Nano-particulated whey protein/Non-particulated whey protein|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
11069472|NCT04289870|Experimental|Innoventric Cavalve™ Stent Graft Single Arm|Single-arm, open label, multi-center study
11069473|NCT04289857|Experimental|Experimental group|Each session will last a maximum of 5 minutes, taking place for 3 days a week, over a period of 4 weeks. The intervention will be performed at the start of training (before warm-up).
11069474|NCT04289857|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
11069475|NCT04289844|Experimental|Experimental group|Each session of the intervention will have a duration of 15 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength and resistance strength
11069476|NCT04289844|Active Comparator|Control group|Each session of the intervention will have a duration of 10 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength
11069477|NCT04289831|Active Comparator|Direct Surgery (DS) group|patients subjected to direct surgery (DS) within 1 week after randomization
11069478|NCT04289831|Active Comparator|Preoperative Biliary Drainage (PBD) group|patients managed by Preoperative Biliary Drainage followed by surgery after 4-6 weeks.
11069479|NCT04289818|No Intervention|Control|Conventional Education Class
11069480|NCT04289818|Experimental|Coaching|Health Coaching
11069481|NCT04289805|Active Comparator|standard-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the French participating centres.
11069482|NCT04289805|Experimental|letrozole-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and wish to preserve their fertility by undergoing oocyte/embryo cryopreservation at the Belgian participating centres.
11069483|NCT04289805|No Intervention|non-stimulated cohort|this cohort includes all newly diagnosed breast cancer patients who are candidates to receive (neo)adjuvant chemotherapy and who have access to the Fertility Clinics in all the participating centres but are not willing to preserve their fertility by undergoing oocyte/embryo cryopreservation.
11069484|NCT04289792|Experimental|SBRT with concurrent chemotherapy|SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy
11069485|NCT04289779|Experimental|Treatment Arm|Cabozantinib 40 mg orally daily x 9 weeks plus Atezolizumab 1200 mg every 3 weeks x 3 doses
11069486|NCT04289766|Active Comparator|Conventional Treatment|Conventional Treatment includes exercises limbs
11069487|NCT04289766|Experimental|Focal Muscle Vibration (120Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.
~Conventional Treatment"
11069488|NCT04289766|Experimental|Focal Muscle Vibration (60Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.
~Conventional Treatment"
11069489|NCT04289753|Active Comparator|Brief clinician education|Clinicians attributed to clinics in the brief clinician education arm will receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
11069490|NCT04289753|Experimental|Clinical decision support nudges and brief clinician education|Clinicians attributed to clinics randomized to the clinical decision support nudges and brief clinician decision support arm will receive clinical decision support within the EHR when conditions meet alert triggering criteria. These clinicians will also receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
11069491|NCT04289740|Experimental|cognitive-bahavioral therapy|Trasdiagnotic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period.
11069492|NCT04289740|Active Comparator|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
11069493|NCT04289727||Group 1|Those with Type 1 Diabetes.
11069494|NCT04289727||Group 2|Those without Type 1 Diabetes.
11069495|NCT04289714|Experimental|R-DOT|Remote Directly Observed Therapy
11069496|NCT04289714|Experimental|Haillie|Smartinhaler Haillie
11069497|NCT04289714|Experimental|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
11069501|NCT04289675||Teriflunomide|Patients with first treatment : teriflunomide (oral, 14 mg once a day)
11069508|NCT04289636|Experimental|Weight loss and self-compassion|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week mindfulness-based self-compassion program which combines the skills of mindfulness and self-compassion as a means for improving emotional resilience, well-being, and weight control.
11069509|NCT04289636|Active Comparator|Weight loss and nutrition/cooking education|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week nutrition and cooking education program which will provide basic nutrition knowledge and cooking skills for healthy eating.
11069510|NCT04289623||Standard email|This email mentions the cost-saving benefits of enrollment by participants who met their 2018 goals. It also includes the message that registration can be completed quickly (in less than five minutes). Finally, it also includes reward incentive information, wherein registering by a March deadline provides qualified recipients with the potential to win prizes. This information is contained in all other emails.
11069511|NCT04289623||Loss frame email|"In addition to the content of the generic email, the subject line and content of the loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. This email further frames the reward as something recipients will miss out on if they do not sign up.
~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
11069512|NCT04289623||Testimonial (medical expert) email|"In addition to the content of the generic email, the testimonial (medical expert) email includes a testimonial from a doctor, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.
~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a presumed authority figure. Recipients may be more likely to enroll for this program if they see a physician - who would be seen as an authority on health and wellness - talking about the medical benefits of the program. It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
11069513|NCT04289623||Testimonial (rank-and-file) email|"In addition to the content of the generic email, the testimonial (rank-and-file) email includes a testimonial from a customer care specialist, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.
~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a peer (relative to most Geisinger employees). Recipients may be more likely to enroll for this program if they see a rank-and-file employee talking about the program as this person would be more relatable (relative to a doctor). It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
11069514|NCT04289623||Social norms (percentage) email|"In addition to the content of the generic email, the social norms (percentage) email will include communication about the percentage of benefit-eligible employees who had already registered for myHealth Rewards.
~This message sets up a descriptive norm, showing that a majority of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. The use of percentages makes it clear that this behavior is indeed being done by most people in the group. It is unclear in the current context and population if a message using percentages or numbers would be more effective."
11069515|NCT04289623||Social norms (number) email|"In addition to the content of the generic email, the social norms (number) email will include communication about the number of benefit-eligible employees who had already registered for myHealth Rewards.
~This message sets up a descriptive norm, showing that a large number of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. While the use of numbers does not indicate that this behavior is being done by a majority, using a large number can be more convincing just in showing sheer quantity."
11069516|NCT04289610|Sham Comparator|Control Group|In this group a pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). The device is not going to be activated in the control group. The device will be set at 0 V. TCPRF treatment is going to be applied for one session.
11069517|NCT04289610|Active Comparator|Study Group|A pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). It will be activated in the study group. In the study group device will be set at 80 V, every pulse will continue for 10 milliseconds and 5 pulses per second. TCPRF treatment is going to be applied for one session in both groups.
11069518|NCT04289597||Obese patients|Obese patients with BMI>30
11069519|NCT04289584|Experimental|Experimental group|Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session. Prior to training, strength and proprioception exercises will be performed.
11069520|NCT04289584|No Intervention|Control group|The players included in the control group will follow their usual routine prior to their Taekwondo training.
11069521|NCT04289571|Experimental|Participants|Participants with retinal disease, healthy volunteers
11069522|NCT04289558|Experimental|Sodium Nitrite|Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)
11069523|NCT04289545|Placebo Comparator|Control Bread|no added guar gum
11069524|NCT04289545|Active Comparator|Functional Bread 1|10% guar gum, low molecular weight
11069525|NCT04289545|Active Comparator|functional Bread 2|10% guar gum, high molecular weight
11069526|NCT04289545|Active Comparator|Functional Bread 3|15% guar gum, low molecular weight
11069527|NCT04289545|Active Comparator|Functional Bread 4|15% guar gum, high molecular weight
11070797|NCT04280718|Experimental|efgartigimod PH20 SC|Patients treated with efgartigimod PH20 SC
11069529|NCT04289506||Community-acquired pneumonia (Sepsis)|Community-acquired pneumonia with organ dysfunction
11069530|NCT04289506||Abdominal sepsis|Abdominal infection due to peritoneal soiling, biliary infection, urinary tract infection leading to organ dysfunction
11069531|NCT04289506||Infection of unknown origin (Sepsis)|Infection of unknown origin of less than 72 hours duration, including bacteraemia with organ dysfunction
11069532|NCT04289506||Organ dysfunction related to non-infectious cause (SIRS)|Patients admitted to the ICU following out-of hospital cardiac arrest OR Patients admitted to the ICU following major trauma (ISS>12) OR Patients admitted to the ICU following pancreatitis with organ dysfunction
11069533|NCT04289506||Healthy volunteers|Healthy volunteers
11069534|NCT04289493|Experimental|Group 1: first to receive therapy|27 patients that will receive study specific speech therapy in the first 3 months since study inclusion. From months 3-6 they will be group 2 controls.
11069535|NCT04289493|Experimental|Group 2: second to receive therapy|27 patients that will receive study specific speech therapy during months 3-6 since study inclusion. During the first 3 months of the study period, they will be group 1 controls.
11069536|NCT04289480||ENTERPRISE 2 group|"The study population enrolled for this clinical study is aneurysm patients who need stent-assisted coiling treatment, using ENTERPRISE 2 device."
11069537|NCT04289467|Experimental|Fenfluramine treatment|Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.
11069538|NCT04289454|Other|Effect of flavor modifiers|Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.
11069539|NCT04289441|Active Comparator|probiotic treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day
~Lactobacillus salivarius LS01 (DSM 22775): 10^9 CFU Bifidobacterium breve B632 (DSM 24706): 10^9 CFU Maltodextrin and silicon dioxide"
11069540|NCT04289441|Placebo Comparator|Placebo treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day
~Maltodextrin and silicon dioxide"
11069541|NCT04289428||A|Not currently on antiviral therapy for HBV and HBV DNA detectable
11069542|NCT04289428||B|Stable on HBV antiviral therapy for at least 3 months with HBV DNA < 20 IU/ml
11069543|NCT04289415|Experimental|Individual Placement and Support|"The intervention used in this study will be a time-limited version of IPS. The employment specialist offers up until nine months job-search support and four months in-work support, giving a total of 13 months job-related support. If a participant succeeds in obtaining work before nine months has passed the remaining job-search support months may be transferred to in-work support time.
~In the follow-up time while seeking employment, the employment specialists will work with the participants to identify skills and aspirations, establish contact with potential employers and ensure economic advice and help with benefits planning. The in-work support involves individual and regular contact with the participant and the employer.
~All participants who receive this intervention will do so in addition to their clinical treatment. The treatment provider and the employment specialist should cooperate and clarify roles together with the patient."
11069544|NCT04289415|Active Comparator|Selv help kit and work shop|The participants in the control intervention will be offered a self-help tool kit and a following introduction course to help participants see what their opportunities are, and specific tips on how to get further help. The course will last three hours a session over four days, with the offer of an individual one hour follow up session with the course leader when the course is over. The goal of the control group intervention is to enable the participants to make use of the services offered at the ordinary labor and welfare service.
11069545|NCT04289402|Experimental|Personalized tDCS|Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minutes session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
11069546|NCT04289402|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
11069547|NCT04289389||HUNT4 70+|All inhabitants in Nord-Trøndelag 70 years of age and older were invited.
11069548|NCT04289389||HUNT4 Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age and older were invited.
11069549|NCT04289376|Other|Gaze tracking|No intervention. Monitor gaze as subjects watch a video
11069550|NCT04289363||ED patients|Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.
11069551|NCT04289363||Stakeholders and community leaders|Stakeholders within and outside the hospital, including ED providers, hospital leadership, ED patients, ED staff, and community opinion leaders will be recruited to participate in the IF booster and qualitative focus groups and interviews.
11069552|NCT04289363||ED-initiated BUP patients|ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits and data matching.
11069553|NCT04289363||Data-matching ED patients|ED patients who are eligible to receive ED-initiated BUP but unable or unwilling to participate will provide authorization for health services review and data matching with available registry, claims or administrative data.
11069554|NCT04289337|Experimental|Combined probiotics (1)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
11069555|NCT04289337|Experimental|Combined probiotics (2)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.
11069556|NCT04289337|Experimental|Combined heat-killed probiotics (1)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
11101634|NCT04065360|Active Comparator|Usual group psychoeducation|
11069557|NCT04289337|Experimental|Combined heat-killed probiotics (2)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.
11069558|NCT04289337|Experimental|Probiotic metabolites|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.
11069559|NCT04289337|Placebo Comparator|Placebo|Does not contain probiotics, heat-killed probiotics and related metabolites.
11069560|NCT04289324|Experimental|Intervention|lung recruitment maneuvers performed every twelve hours during HFOV
11069561|NCT04289324|No Intervention|Control|no regular lung recruitment maneuvers during HFOV
11069562|NCT04289311|Experimental|Intervention arm|Single group study; all participants are in the intervention arm and receive the intervention
11069563|NCT04289298|Experimental|Engage-A|Participants receive 9 individual in-person or remote therapy sessions. Each session will last approximately 60 minutes. During the sessions, the therapist will encourage the participant to engage in physical and social activities that are pleasurable or rewarding.
11069564|NCT04289298|Experimental|Clinician|Clinicians will be trained in Engage-A and supervised while utilizing the therapy.
11069565|NCT04289285|Experimental|IBI306 450mg SC Q4W|
11069566|NCT04289285|Placebo Comparator|Placebo SC Q4W|
11069567|NCT04289285|Experimental|IBI306 600mg SC Q6W|
11069568|NCT04289285|Placebo Comparator|Placebo SC Q6W|
11069569|NCT04289285|Experimental|IBI306 600mg SC Q8W|
11069570|NCT04289285|Placebo Comparator|Placebo SC Q8W|
11069571|NCT04289272|Experimental|Dove Confident Me|Dove Confident Me body image intervention to be delivered to students 1 lesson per week for 5 weeks (5 x 45 minute lessons).
11069572|NCT04289272|No Intervention|Control|Students receive lessons-as-usual.
11069573|NCT04289259||Biopsy sample|Tumor mutational burden (TMB) will be assessed on a sample of the biopsy done during standard care of patients.
11069574|NCT04289259||Surgical sample|TMB will be assessed on a sample of the tumor surgical specimen resected during standard care of patients.
11069575|NCT04289259||Biopsy sample + surgical sample|TMB will be assessed both on a sample of the biopsy and a sample of the tumor surgical specimen resected during standard care of patients.
11069576|NCT04289246|Experimental|Treatment Group (TG)|On the first day of the intervention phase, research assistants visited TG's participants to introduce the MAD in the presence of caregivers. After the training session, which lasted 40 min approximately, the MAD was personalized according to the participant's prescriptions and through discussions with them on an appropriate schedule for presenting the reminders. Research assistants used the MAD administrator sub-system to enter the medication names, health problems to address, timetables, and the frequency at which medications should be taken. Then, they attached and configured NFC tags to each of the pill containers, which included selecting the images that best represented the pills and their containers to be used to form the visual reminders. Afterward, the MAD was placed in the homes' area where participants reported taking medications. MAD was used for 5 weeks during which data on medication adherence and system adoption was collected from the TG.
11069577|NCT04289246|No Intervention|Control Group (CG)|Participants in the CG followed their medication routine as usual. During 5 weeks data on medication adherence was collected.
11069578|NCT04289220|Experimental|Anti-CD19 CAR-T Cells Injection|Anti-CD19 CAR-T Cells Injection, Dosage form：injection Dosage:1-2.5x10^6/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
11069579|NCT04289207|Experimental|Romiplostim and danazol|Treatment group (romiplostim and danazol)
11069580|NCT04289194|Experimental|HCR040 (Phase 1)|Participants with moderate to severe acute respiratory distress syndrome (6 patients)
11069581|NCT04289194|Placebo Comparator|Control group (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
11069582|NCT04289194|Experimental|HCR040 (Phase 2)|Participants with moderate to severe acute respiratory distress syndrome (10 patients)
11069583|NCT04289181|Experimental|Medically Tailored Meals (MTM)|Participants randomized to the MTM arm will receive MTM for 4 weeks. Meals will be prepared and delivered by Meals on Wheels, a non-profit organization that has been delivering meals to seniors nationwide for decades. Meals on Wheels will deliver 21 complete meals to the patient's home each week. They can accommodate a wide range of patient needs and preferences (e.g., low sodium, gluten-free, no pork products, cultural preferences). Meals on Wheels will contact the patient directly to set up an initial assessment phone call to collect relevant data (e.g., specific patient goals for their HF) and to set up a delivery schedule. Nearing the 4-week mark when meal delivery ends, investigators will check-in with each participant to track progress, assess treatment fidelity and answer any questions. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
11069584|NCT04289181|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with HF. This includes regular visits with a HF provider (primary care or cardiology), standard nutrition teaching, medication optimization and post discharge support. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and HF self-management. These services follow guideline directed medical therapy. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
11069585|NCT04289168|Experimental|Music Class|Music Class attendance
11069586|NCT04289168|No Intervention|Play Class|Play date class attendance
11069587|NCT04289142|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1.2 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.2 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
11069588|NCT04289142|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
11069589|NCT04289129|Experimental|men|
11069590|NCT04289129|Experimental|women|
11069591|NCT04289116|Experimental|We Test|Each participant or couple will receive MI-CST + observation of ACT videos + CHTC. Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
11069686|NCT04288349|Placebo Comparator|epinephrine + saline|1% epinephrine solution + 50 ml of 0.9% saline in a ratio of 1: 200 000.
11069592|NCT04289116|Active Comparator|Individual HIV Testing and Counseling|Individual HIV Testing and Counseling (IHTC). Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
11069593|NCT04289103|Experimental|Inolimomab/Leukotac|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.
~Treatment phase - Leukotac will be given up to D28
~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion"
11069594|NCT04289090|Experimental|Group A|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only.
11069595|NCT04289090|Experimental|Group B|Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.
11069596|NCT04289077||Patients with histopathological proven DTF|
11069597|NCT04289064||Fundus image quality assessment|Device: an artificial intelligence system for quality assessment of fundus images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center.
11069598|NCT04289051|Experimental|HYDRAL Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
11069599|NCT04289051|Active Comparator|BIOTENE® Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
11069600|NCT04289051|Placebo Comparator|Placebo Oral Rinse|Subjects use the oral rinse four times daily adding to a regular oral hygiene routine with a fluoride toothpaste and a soft tooth brush.
11069601|NCT04289038|Experimental|training and relaxation|"Training: Following the patient assessment, on the second and third days of the weekly hemodialysis session, patients will be provided with training based on the need to manage the itching symptom.
~Autogenic Relaxation: It is an exercise program consisting of standard sentences that describe the body's absolute comfort and calm features."
11069602|NCT04289038|Experimental|training and virtual reality|"Training: Following the patient assessment, on the second and third days of the weekly hemodialysis session, patients will be provided with training based on the need to manage the itching symptom.
~Virtual reality: Playing games via smart phone with virtual reality glasses and headset"
11069603|NCT04289025|Active Comparator|Exercise|Personalised exercise programme is provided to the exercise group.
11069604|NCT04289025|No Intervention|No Intervention|This group of patients will receive no intervention.
11069605|NCT04289012|Experimental|Helicobacter Screening|All patients with confirmed MI (both STEMI and NSTEMI) will be tested for Hp infection with bedside UBT.
11069606|NCT04288999|Experimental|Arm A|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy
~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)
~Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)
~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
11069607|NCT04288999|Active Comparator|Arm B|"Surgery plus Adjuvant chemotherapy
~Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV
~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)
~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.
~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14
~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
11069608|NCT04288986|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 8-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 8-weeks. The activity sessions will include semi-structured free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
11069609|NCT04288973||Typical development children|Control sample
11069610|NCT04288973||Children with developmental disability|Clinical sample
11069611|NCT04288960||Chronic Stroke|Twenty chronic stroke patients (>3months post-stroke) will complete a one off session in a biomechanics lab. This session will include the Fugl Meyer Questionnaire and several walking trials along a flat, level 10m walkway. During this participants will wear a belt mounted accelerometer and small reflective markers on joints.
11069612|NCT04288947|Other|Usual Care|Training of midwives on 4 respectful maternal care modules.
11069613|NCT04288934|Active Comparator|patients with complete transection of the spinal cord|This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.
11069614|NCT04288934|Active Comparator|patients with SCI without total transaction.|This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla.
11069615|NCT04288921|Experimental|Nasal swab|Nasal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
11069616|NCT04288921|Experimental|Nasopharyngeal swab|Nasopharyngeal swab from subjects with signs and symptoms of influenza and/or RSV-like illness
11069617|NCT04288908|Experimental|Social exclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives fewer passes than the other two participants (i.e., 10 out of 60).
11069618|NCT04288908|Active Comparator|Social inclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives a comparable number of passes than the other two participants (i.e., 20 out of 60).
11069619|NCT04288895|Experimental|Vortioxetine|flexible-dose
11102160|NCT04061330|Experimental|Ketamine Group|
11069620|NCT04288869||Interventional radiology or surgery under general anesthesia|Monitoring of patients (mean arterial blood pressure, Transcranial Doppler , bispectral index, near infrared spectroscopy) who benefit from intraoperative hemodynamic optimization with norepinephrine (as noradrenaline tartrate) for maintaining blood pressure under general anaesthesia during the interventional neuroradiology or orthopedic surgery in adults .
11069621|NCT04288856|Experimental|Cohort A: BIIB078 First Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
11069622|NCT04288856|Experimental|Cohort B: BIIB078 Second Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
11069623|NCT04288856|Experimental|Cohort C: BIIB078 Third Dosage|BIIB078 will be administered as 3 doses during the loading period, approximately 2 weeks apart, and maintenance doses, approximately 4 weeks apart, via IT infusion.
11069624|NCT04288830|Experimental|TCMMMRT First|Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
11069625|NCT04288830|Active Comparator|Aerobic Exercise First|Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
11069626|NCT04288817|Active Comparator|Cryotherapy and intralesional tuberculin PPD|Efficacy of cryotherapy combined with intralesional tuberculin purified protein in treatment of multiple common warts
11069627|NCT04288817|Active Comparator|Intralesional tuberculin PPD|Efficacy of Intralesional tuberculin purified protein deravative monotherapy in the treatment of multiple common warts
11069628|NCT04288804||Control (healthy, non-PD participants)|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
11069629|NCT04288804||PD|An audio file made up of a voice recording of the sustained short a vowel sound, along with accelerometer data while maintaining various positions, will be collected.
11069630|NCT04288791|Experimental|Equia Forte Fil|
11069631|NCT04288791|Experimental|Zirconomer Improved|
11069632|NCT04288778|Experimental|Canagliflozin + Metformin Hydrochloride Immediate Release (IR)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.
11069633|NCT04288765|Experimental|Group A - Non transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone
11069634|NCT04288765|Active Comparator|Group B - transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone Autologous stem cell transplantation (ASCT)
11069635|NCT04288752|Experimental|Active Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
11069636|NCT04288752|Sham Comparator|Inactive Ring|Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
11069637|NCT04288739||Acute Myeloid Leukemia (AML) group|"patients who are diagnosed as Acute Myeloid Leukemia (AML) based on peripheral blood, bone marrow, immunophenotyping and who fulfill the WHO 2016 criteria.
~Complete blood count (CBC), bone marrow aspirate, flow cytometric immunophenotyping, cytogenetic analysis and fluorescence in situ hybridization (FISH) for XIST gene will be performed for all AML patients in the study."
11069638|NCT04288726|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.
~Dose Level 1: 4 × 107 CD30.CAR-EBVST cells
~Dose Level 2: 1 × 108 CD30.CAR-EBVST cells
~Dose Level 3: 4 × 108 CD30.CAR-EBVST cells"
11069639|NCT04288700|Active Comparator|Group A|
11069640|NCT04288700|Active Comparator|Group B|
11069641|NCT04288700|Active Comparator|Group C|
11069642|NCT04288700|Active Comparator|Group D|
11069643|NCT04288687|Other|Niraparib Arm (only arm)|Niraparib 200 mg by mouth daily (2 x 100 mg pills) on a 28 day cycle
11069644|NCT04288674||Leptospirosis group|Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.
11069645|NCT04288674||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
11069646|NCT04288661|No Intervention|Drain|The patients of this arm undergo perianastomotic drain placement, as per standard of care institutional practice
11069647|NCT04288661|Experimental|No drain|The patients of this arm do not undergo perianastomotic drain placement.
11069648|NCT04288648||SUI group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
11069649|NCT04288648||control group|Examination will include an abdominal ultrasound assessment of pelvic floor muscle in supine, sitting, standing and squatting. The Height of the bladder base will be measured during rest period and maximal contraction.
11069650|NCT04288635||Septic shock admitted in Angers' ICU|Patients aged more than 18, admitted in University Hospital of Angers, who meet the full criteria of septic shock
11069685|NCT04288349|Active Comparator|epinephrine + ropivacaine +saline|1% epinephrine solution + 30 ml of 1% ropivacaine solution diluted with 20 ml of 0.9% saline for achievement a 0.75% anesthetic solution in a ratio of 1: 200 000
11069651|NCT04288622|Experimental|ESM-derived personalised feedback (ESM-F) group|Participants will be required to participate in an ESM data collection procedure. Participants will be required to complete a beep-questionnaire 3 days a week, over a 6-week period. The mobile app will be programmed to emit a beep 10 times per day at random intervals between 7.30 and 22.30. At each beep, participants will use the app to digitally complete a brief beep-questionnaire, which covers current affect, current context and activities. Moreover, participants will receive weekly standardized feedback on personalized patterns of positive affect.
11069652|NCT04288622|No Intervention|ESM group|Participant will be required to participate in the same ESM data collection procedure as the ESM-F group. The personalised feedback report will be given to the participant after the whole study period (32 weeks) instead of weekly during data collection process.
11069653|NCT04288622|No Intervention|Control (CON) group|Participants will not be required to participate in the 6-week ESM data collection procedure. They will also receive the personalised feedback report based on the ESM data collected at baseline and week 7.
11069654|NCT04288609|Experimental|Intendu FBT inpatient|Motion Based Cognitive Video Games Software
11069655|NCT04288609|Active Comparator|paper and pencil tasks|paper and pencil tasks
11069656|NCT04288596||Eligible for Registry|All consecutive patients who undergo any of the five ACHDi interventions (complex catheterization, ASD closure, PFO closure, CoA stenting, and PPVI) at the time of Registry launch, who have also consented to participate.
11069657|NCT04288570|Active Comparator|Bone socket formation with a punch|suture anchor socket creation with punch
11069658|NCT04288570|Active Comparator|Bone socket formation with a drill|suture anchor socket creation with drill
11069659|NCT04288557||Sleep clinic patients|All adult patients, from 18 years and up to and including 65 years of age, on the waiting list for overnight polysomnography (PSG) recording at Leicester General Hospital.
11069660|NCT04288557||Healthy volunteers|All adults, from 18 and up to and including 65 years of age without a known sleep disorder.
11069661|NCT04288544|Active Comparator|Experimental: Intervention group|The patients get 1x 5,3g per day the microalgae Phaeodactylum tricornutumover for two weeks.
11069662|NCT04288544|Active Comparator|Omega-3 capsules|The patients get one capsule per day of the Omega-3-fatty acid capsules for 2 weeks.
11069663|NCT04288544|Experimental|sea fish (facultative)|as positive control, one portion of fish is eaten per week for 2 weeks after the Intervention of 8 weeks and 2 wash out (omega 3 must not be eaten).
11069664|NCT04288531||Pregnant and pregnant to be on iodine supplementation|Women in preconception, pregnant and lactating, receiving iodine supplementation
11069665|NCT04288531||Pregnant and pregnant to be not on iodine supplementation|Women in preconception, pregnant or lactating, not receiving iodine supplementation
11069666|NCT04288531||Women of childbearing age|Women of childbearing age not planning to become pregnant.
11069667|NCT04288518|Experimental|Primary Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.
~At least five (5) evaluable subjects with primary brain tumor. The tested injected dose 500 MBq."
11069668|NCT04288518|Experimental|Recurrence of Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.
~At least five (5) evaluable subjects with recurrence of brain tumor. The tested injected dose 500 MBq"
11069669|NCT04288505|Experimental|single arm|
11069670|NCT04288492|Experimental|biofeedback|Respiratory exercise using biofeedback device(ResCalm) 2-3 times / day for 3 minutes until discharge from hospital, once in recovery room before surgery
11069671|NCT04288492|No Intervention|general|General surgical schedule without control exercise
11069672|NCT04288479|Experimental|Doing a single HIT session in gestational week 22-36|
11069673|NCT04288466|Active Comparator|Adults|Adults < 60 years-old maltodextrin solution 450ml
11069674|NCT04288466|Active Comparator|Elders|Elders 65 or more years-old maltodextrin solution 450ml
11069675|NCT04288453|Experimental|Community-based activity program|Engagement in 8-week community-based activity program
11069676|NCT04288440|Active Comparator|Silicone filled eyes|Eyes filled with silicone oil
11069677|NCT04288440|Active Comparator|Idiopathic ERM|Eyes not filled with silicone oil
11069678|NCT04288427||Finasteride Treatment|Patients who are eligible will be given 5ARI therapy, Finasteride, for medical management of Benign Prostatic Hyperplasia (BPH) symptoms. Only patients with lower urinary tract symptoms (LUTS) as assessed by AUA urinary symptom score > than 8, (suggestive of moderate LUTS) prostate size > 40cc, no prostate nodule/tenderness/firmness and increased PSA between 4-10ng/ml requiring prostate biopsy will be enrolled. Then, they will have prostate MRIs/needle biopsies and blood/urine collection followed by treatment with Finasteride (standard of care). They will be followed in urology clinic for assessment of LUTS every 6 months and Finasteride responsiveness at the 12-month time point. Prostate biopsy samples will be evaluated for SRD5A2 gene expression/methylation, hormonal androgen/estrogen levels (which will be repeated in blood samples). Prostate MRIs will assess size/inflammatory changes at the start and 3-year time points.
11069679|NCT04288414||fNIRS applied|All of the participants' brain activity was evaluated with fNIRS.
11069680|NCT04288388|Experimental|massage group|Immediately before the episiotomy repair was started (after exit of placenta and applying local anesthetic agent), women assigned to the study (massage) group were asked to place plastic gloves filled with ice pieces in the LI4 point on hand. This application was made for 5 minutes to the right hand and for 5 minutes to the left hand. The episiotomy was opened by the same midwife as all the women to the right mediolateral and repaired by the same midwife with the same technique and material.The ice massage was repeated until the episiotomy repair was over; total massage time and episiotomy repair time were recorded. Women were asked to mark the perceived pain level before the application and at the end of the application using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair).
11069681|NCT04288388|No Intervention|Control group|I the control group women were not excluded from routine practice; women were asked to mark the perceived pain level before episiotomy repair begin and at the end the repair using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair) like the study (massage) group.
11069682|NCT04288375|Experimental|extremity soft tissue sarcoma (STS)|Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
11069683|NCT04288362|Experimental|Intervention Group|
11069687|NCT04288336|Experimental|Prevention (intermittent fasting)|Beginning when patients' PSA is detectable up to 24 months after surgery, patients follow a daily intermittent fasting routine consisting of restricting the daily eating period to 8 hours (e.g. between 1PM-9PM) followed by 16 hours of prolonged nightly fasting for up to 1 year or until secondary therapy commences.
11069688|NCT04288323|Experimental|Single arm|This is a single arm study in which all participants have one ultrasound and one abbreviated MR exam
11069689|NCT04288297||distal minimally invasive distal chevron|The investigators compare the results of a consecutive cohort of patients treated with the above mentioned technique in comparison to the results of patients treated with the minimally invasive Reverdin-Isham technique, presented in literature
11069690|NCT04288284||Emergency group|Patients presented to emergency by complicated colorectal cancer ( Obstruction, bleeding or perforation)
11069691|NCT04288284||Elective group|Patients presented with uncomplicated colorectal cancer for resection treatment
11069692|NCT04288271|Experimental|Intervention/ Coaching Sites|"The objective of the intervention is to improve medication adherence. Participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Participants will form an Adherence Support Team (AST) including the participant, a parent (or other) and the Coach. The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete if-then plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 14-week and 18-week check-ins.
~HCP at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. HCP will also be alerted by study staff to critical non-adherence events."
11069693|NCT04288271|Other|Control/ Healthy Living Education sites|"Control participants will receive 'healthy living education' intervention (attention-control) with the use of an e-pillbox (no dose reminders). Contacts with the research assistant (RA) will occur at the same intervals as at intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The RA will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the RA will either continue the conversation on the topic selected at the outset or provide education on another topic. The RA will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
~At 24 weeks, participants at control sites will be offered extended use of the e-pillbox, with dose reminders enabled, and access for themselves and their HCP to the adherence-tracking website for an additional 20 weeks. They will not receive coaching during this period."
11069694|NCT04288258|Experimental|Treatment|Health and Wellness Program
11069695|NCT04288245|Experimental|Immediate Start Vagus Nerve Stimulation group|The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
11069696|NCT04288245|Placebo Comparator|Delayed Start Vagus Nerve Stimulation group|The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
11069697|NCT04288232|Experimental|Intravitreal aflibercept|Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
11069698|NCT04288219|Active Comparator|Standard of Care Treatment|Continuous supplemental oxygen and nifedipine 30mg will be administered to patients.
11069699|NCT04288219|Experimental|Non-Invasive Positive Pressure Ventilation Management|CPAP at 10mmHg with supplemental oxygen, as well as nifedipine 30mg will be administered to patients.
11069700|NCT04288206|Placebo Comparator|Placebo control|Patient will receive 'study drug' which is comprised of 300 mL of normal saline without any medication/antibiotic, which will be delivered by intravenous means at the time of surgery.
11069701|NCT04288206|Active Comparator|Cefazolin prophylaxis|Patient will receive 'study drug' which is comprised of weight-based dose of cefazolin mixed in 300 mL of normal saline, which will be delivered by intravenous means at the time of surgery.
11069702|NCT04288193||Trinity Health LIFE New Jersey PACE|Participants enrolled in Trinity Health LIFE New Jersey PACE facility who received an antipsychotic medication for the treatment of BPSD or insomnia
11069703|NCT04288180||Social Anxiety Disorder|A group of adults with social anxiety disorder will be recruited for a psychological/behavioral research study.
11069704|NCT04288167|Experimental|Patients with suspected brain injury|This arm will consist of up to 30 pediatric patients who entered the Emergency Room and who are suspected of having mild traumatic brain injury. Two sample sets will be collected within the first 10 hours from the injury.
11069705|NCT04288167|Active Comparator|Healthy controls|This arm will consist of up to 30 healthy control subjects, the samples of whom will be compared to the samples of brain injury patients (Arm 1). One sample set will be collected from healthy children without any known brain injury.
11069706|NCT04288154|Experimental|EMS Group - Experimental|EMS device will be turned on during exercise for this group.
11069707|NCT04288154|Placebo Comparator|EMS Group - Control|EMS device will be turned off during exercise for this group.
11069708|NCT04288141||Group 1: Early HER2 positive breast cancer|Study participants in Group 1 will include patients prescribed neoadjuvant systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive early breast cancer.
11069709|NCT04288141||Group 2: Metastatic HER2 positive breast cancer|Study participants in Group 2 will include patients prescribed systemic therapy (including trastuzumab and pertuzumab) by their treating oncologist for a diagnosis of HER2 positive metastatic breast cancer.
11069773|NCT04287686|Experimental|rhACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
11069710|NCT04288128||SCA early-manifest and premanifest patients|This cohort is defined by individuals with a SARA score between 0 and 15 (both values included).
11069711|NCT04288128||Control participants|This cohort is defined by individuals with a SARA score less than 5 and no significant neurological symptoms.
11069712|NCT04288115|Active Comparator|"Levothyroxine group (sham discontinuation)"|Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
11069713|NCT04288115|Placebo Comparator|"Placebo group (real discontinuation)"|Stop the current dose of levothyroxine and take study placebo
11069714|NCT04288102|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|Participants will receive standard of care plus 3 does of UC-MSCs
11069715|NCT04288102|Placebo Comparator|Placebo|Participants will receive standard of care plus 3 does of placebo
11069716|NCT04288089|Experimental|Palbociclib + H3B-6545 (Escalation and Expansion)|
11069717|NCT04288076|Experimental|PEEP Titration Arm|
11069718|NCT04288063||Early onset T1D children|25 young, prepubertal and very early pubertal (Tanner stages 1 and 2) children (13 females and 12 males) with early onset T1D
11069719|NCT04288050||Diabetic subjects under dialysis|Diabetic subjects under dialysis
11069720|NCT04288024|Experimental|Postural|During training, participants in this group are instructed to focus on their posture during weight-shifting.
11069721|NCT04288024|Experimental|Suprapostural|During training, participants in this group are instructed to focus on their suprapostural task during weight-shifting.
11069722|NCT04288011||Clinical EDSS|The Kurtzke EDSS, is a clinical rating scale for multiple sclerosis having scores between 0 to 10 that are assigned by a trained clinician. Smaller impairments are assessed at lower scores and disability is assessed at higher scores. It is important to note, however, that despite being denoted on an ordinal scale, each level on the scale is not indicative of an equal change in disability.
11069723|NCT04288011||MLA EDSS|The Kurtzke EDSS, is a clinical rating scale or multiple sclerosis having scores between 0 to 10 that are assigned by a technique based upon several different Machine Learning Algorithms that are combined to produce a single score
11069724|NCT04287998||1|PE group
11069725|NCT04287998||2|Control group
11069726|NCT04287985|Placebo Comparator|Placebo|Placebo (0.9% NaCl) will be administered IV
11069727|NCT04287985|Experimental|Low Dose - VIS649|Low dose of VIS649 administered IV
11069728|NCT04287985|Experimental|Medium Dose - VIS649|Medium dose of VIS649 administered IV
11069729|NCT04287985|Experimental|High Dose - VIS649|High dose of VIS649 administered IV
11069730|NCT04287972|Experimental|LSG-DPC|Laparoscopic Sleeve Gastrectomy and Diaphragmatic Pillar Closure.
11069731|NCT04287972|Active Comparator|LSG|Laparoscopic Sleeve Gastrectomy
11069732|NCT04287959|Active Comparator|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
11069733|NCT04287959|Active Comparator|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
11069734|NCT04287946|Experimental|Ablation|
11069735|NCT04287933|Active Comparator|Drain|
11069736|NCT04287933|No Intervention|No drain|
11069737|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA less than 20|The first 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score less than 20.
11069738|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA more than 20|The second 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score more than 20.
11069739|NCT04287907|Experimental|Monitor|Qualitative End Tidal Co2 detector will be attached to the face mask used to provide mask ventilation to the preterm baby before connected to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
11069740|NCT04287907|No Intervention|Control|face mask used to provide mask ventilation to the preterm baby will be connected directly to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
11069741|NCT04287894|Experimental|Cohort 1A (firste cohort)|1 course Durvalumab (1500mg) + Tremelimumab (75mg) + 1 course of Durvalumab (1500mg) followed by CRT
11069742|NCT04287894|Experimental|Cohort 2A|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
11069743|NCT04287894|Active Comparator|Cohort 2B|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
11069744|NCT04287881|Other|Adult patients who have epileptic seizures|Patients with adult-onset epileptic seizures and diagnosed ischemic stroke.
11069745|NCT04287868|Experimental|Arm 1|Triple Therapy: PDS0101 + NHS IL12 + M7824; The dose level of NHS IL12 may decrease depending on DLT events. The dose level of HVP vaccine and M7824 will remain constant.
11069746|NCT04287868|Experimental|Arm 2|Triple Therapy: PDS0101 + NHS IL12 + M7824; Accrual will be expanded first to 8 patients and then to 20 evaluable patients at the dose level selected in Arm 1 if more than 3 of 8 patients have an objective response.
11069747|NCT04287855|Experimental|Intervention|Isatuximab, Carfilzomib, Pomalidomide
11069748|NCT04287842|No Intervention|control|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. This provides complete suppression of animal responses to pain, fixation, tracheal intubation. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed.
11069749|NCT04287842|Experimental|training ischemia|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. Comparison of a total GSK-3 and phosphorytated (Ser9) GSK-3beta (pGSK3b) in brain tissuesupracardiac bundle of vessels by means of a special hook after cardiac arrest and absence of ventilation lasts 10 min.
11069774|NCT04287686|No Intervention|Control group|Standard of care; no placebo
11069775|NCT04287673|Experimental|RIST-UR|"Group having performed the rehabilitation involving strongly the trunk for the first 3 months and then having performed its usual rehabilitation for the last 3 months.
~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
11069912|NCT04286594|Experimental|CBD|0.5ml of sublingual CBD solution (30mg/ml) administered twice daily for six weeks.
11069750|NCT04287842|Active Comparator|desflurane|Intervention. Drug: Desflurane. Desflurane 8 vol% anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Surgery: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
11069751|NCT04287842|Active Comparator|sevoflurane|Sevoflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
11069752|NCT04287829|Experimental|pembrolizumab and lenvatinib|"Patients will receive pembrolizumab 200mg/iv (fixed dose) every 3 weeks and lenvatinib 20mg QD in a three weekly cycle.
~Treatment continues until disease progression by modified (i)RECIST for MPM, severe toxicity, serious intercurrent illness, patient request for discontinuation, need or use for any other anti-cancer agent other than protocol treatment, except for palliative radiotherapy, for a maximum period of 35 cycles"
11069753|NCT04287816|Experimental|Zero hard-boiled egg|No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
11069754|NCT04287816|Experimental|One hard-boiled egg|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.
11069755|NCT04287816|Experimental|Two hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
11069756|NCT04287816|Experimental|Three hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
11069757|NCT04287803|Experimental|intervention Arm|Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)
11069758|NCT04287790||Health professionals after intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (July 2020)
11069759|NCT04287790||Hospitalized patient before intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 18 months before the start (January 1st 2020) of the implementation intervention
11069760|NCT04287790||Health professionals before intervention|Health professionals (physicians, advanced practice providers, pharmacists, social workers, and nurses) who work on the designated general medicine services at Yale New Haven Hospital after implementation intervention (December 2019)
11069761|NCT04287790||Hospitalized patient after intervention|Patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis 12 months after the start (January 1st 2020) of the implementation intervention
11069762|NCT04287777|Experimental|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
11069763|NCT04287777|Active Comparator|Mupirocin ointment|Topical administration of Mupirocin ointment 20mg/g TID for 7 days.
11069764|NCT04287777|Placebo Comparator|Placebo|Topical administration of Placebo (ointment) TID for 7 days
11069765|NCT04287751|Other|Overnight Oximetry|Participants record simultaneously overnight oximetry on night 1 and continue with prolonged recordings alone for a total of 4 nights
11069766|NCT04287738|Experimental|Navigated Care|Telephone-based collaborative dementia care navigation
11069767|NCT04287738|No Intervention|Survey of Care|Control group that will receive usual care and undergo the same regular assessments as patients enrolled in Navigated Care
11069768|NCT04287725|Experimental|exercise + active Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.
~Photobiomodulation therapy: will be performed using the active super pulsed laser (904nm)."
11069769|NCT04287725|Placebo Comparator|exercise + placebo Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.
~Photobiomodulation therapy: will be performed using the placebo super pulsed laser (904nm)."
11069770|NCT04287712||Participants received surgery|Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.
11069771|NCT04287699|Experimental|labor dance group|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment.The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
11069772|NCT04287699|No Intervention|Control group|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
11069908|NCT04286659||Control Group|90 Apparently healthy individuals
11069776|NCT04287673|Experimental|UR-RIST|"Group having performed its usual rehabilitation for the first 3 months and then having performed the rehabilitation involving strongly the trunk for the last 3 months.
~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
11069777|NCT04287673|No Intervention|Typically Developing children|Typically developing children who served as a control group in the first assessment (Trunk Control Measurement Scale, dynamic posturography on an unstable sitting device, clinical gait analysis)
11069778|NCT04287660|Experimental|BiRd combined with BCMA CAR T-cells infusion|
11069779|NCT04287647|Active Comparator|Transpyloric stent|In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
11069780|NCT04287647|Sham Comparator|Sham|In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
11069781|NCT04287634|Experimental|Segmental Mobilization|Hot Fermentation Soft tissue mobilization + Targeted Segmental Mobilization Home plan exercise= cervical muscles stretching, postural care
11069782|NCT04287634|Experimental|Entire Spine Mobilization|Hot fermentation Soft tissue mobilization + Entire spine mobilization Home plan exercises=cervical muscles stretches, postural care
11069783|NCT04287608||Patients with qualifying conjunctivitis events|
11069784|NCT04287608||Patients with no clinical signs of eye inflammation|
11069785|NCT04287595|Experimental|intervention group|inhalation aromatherapy with orange essential oil
11069786|NCT04287595|No Intervention|control group|routine care
11069787|NCT04287582||Level 1 DMD|According to Brooke Lower Extremity Functional Classification Level 1
11069788|NCT04287582||Level 2-3 DMD|According to Brooke Lower Extremity Functional Classification Level 2 or 3
11069789|NCT04287582||Healthy Group|healthy children with similar demographic characteristics with children with DMD
11069790|NCT04287569|Experimental|video recording of endoscopy|Record of sequences of video-endoscopy and the reflectance of light through fibroscopy
11069791|NCT04287556||Population in risk of MH|Patient with hypermetabolic response of skeletal musculature by causes related with Malignant Hyperthermia in the literature.
11069792|NCT04287543|Experimental|Melatonin group|Patients with PD who will receive 25 mg of melatonin gel at 12 hours a day and half an hour before sleeping for 12 months
11069793|NCT04287543|Placebo Comparator|Placebo group|Patients with PD who will receive 25 mg of placebo gel at 12 hours a day and half an hour before sleeping for 12 months
11069794|NCT04287530|Experimental|Tachidino + PUFA supplementation|Group 1 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform). The program will be delivered during four weeks, starting two months after the pre-testing session. Additionally, the children will receive daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
11069795|NCT04287530|Active Comparator|Tachidino + Placebo|Group 2 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session, exactly as Group 1. Additionally, the children will receive daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
11069796|NCT04287530|Experimental|PUFA supplementation|Groups 3 will receive only daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
11069797|NCT04287530|Placebo Comparator|Placebo|Groups 4 will receive only daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
11069798|NCT04287530|No Intervention|Control group|Typically Developing participants, as a comparison group for experimental tasks and for PUFA levels in the blood
11069799|NCT04287517|Active Comparator|Capacitive-Resistive Therapy Group|This group was treated with capacitive resistive diathermy and exercise
11069800|NCT04287517|Sham Comparator|Sham Group|This group was treated with sham capacitive-resistive diathermy and exercise
11069801|NCT04287504||Yeast, control|Women negative for vulvovaginal candidosis on Gram stain smear.
11069802|NCT04287504||Yeast, study group|Women positive for vulvovaginal candidosis on Gram stain smear.
11069803|NCT04287504||Bacterial vaginosis, control|Women negative for bacterial vaginosis on Gram stain smear.
11069804|NCT04287504||Bacterial vaginosis, study group|Women positive for bacterial vaginosis on Gram stain smear.
11069805|NCT04287491|Experimental|Virtual Reality Group|This group will receive the virtual reality intervention during out-patient bedside procedures.
11069806|NCT04287478|Experimental|Intravenous (IV)|Phage administered via the intravenous route.
11069807|NCT04287478|Experimental|Intravesical (IVS)|Phage administered via the intravesical route.
11069808|NCT04287478|Experimental|Subcohort A|Selected phage for E. coli administered via selected route based on previous Arms.
11069809|NCT04287478|Experimental|Subcohort B|Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
11069810|NCT04287478|Experimental|Subcohort C|Selected phage for E. coli administered via selected route based on previous Arms.
11069811|NCT04287478|Experimental|Subcohort D|Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
11069812|NCT04287452|Placebo Comparator|Control|Emergency department patients enrolled in the control arm will receive usual care. Emergency department providers enrolled in the control arm will work their shift as usual.
11069813|NCT04287452|Active Comparator|Intervention|Emergency department patients and providers in the intervention arm will be exposed to and/or interact with a certified therapy dog and handler
11069814|NCT04287439|Experimental|Relaxation|"Patients will receive a training session for progressive muscle relaxation exercise.
~They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence."
11069815|NCT04287439|Experimental|Meditation|Patients will receive a training session for minfullness meditation They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
11069816|NCT04287439|Active Comparator|Attention matched control group|Patients will receive a training session focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods.
11069817|NCT04287426|Active Comparator|Group receiving rocuronium at induction|Rocuronium 0,6 mg/kg at induction
11069818|NCT04287426|Active Comparator|Group receiving remifentanil at induction|Remifentanil 2 μg/kg at induction
11069819|NCT04287413|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
11069820|NCT04287413|Active Comparator|Usual care|The physician-led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, order diagnostic imaging, prescribe medications and/or refer based on their assessment findings and patient preferences.
11069821|NCT04287387|Experimental|Glucophage group|
11069822|NCT04287387|Experimental|Acarbose group|
11069823|NCT04287387|Experimental|Sitagliptin group|
11069824|NCT04287387|Experimental|Dapagliflozin group|
11069825|NCT04287387|Experimental|Pioglitazone group|
11069826|NCT04287387|Experimental|Glimepiride group|
11069827|NCT04287374|Experimental|Multi-component Well-being Intervention|Reading and writing activities based on cognitive restructuring (rephrasing automatic negative thoughts), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities)
11069828|NCT04287374|Sham Comparator|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
11069829|NCT04287361||Loading dose < 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam < 0.03 mg / kg
11069830|NCT04287361||Loading dose ≥ 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam ≥ 0.03 mg / kg
11069831|NCT04287348|Other|Beovu (Brolucizumab)|Prospective, one-treatment-arm, monocentre study
11069832|NCT04287335||High risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer
11069833|NCT04287335||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
11069834|NCT04287322|Experimental|Tactile-kinesthetic stimulation|Received tactile-kinesthetic stimulation three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
11069835|NCT04287322|Experimental|Recorded maternal voice|Listened to recorded maternal voice stimulation, three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
11069836|NCT04287322|No Intervention|Control|Received only standard nursery care
11069837|NCT04287296|Experimental|App users|The app users who are at least 18 years old.
11069838|NCT04287283||HBOT|Patients with chronic brain injury or cognitive complaints that have been treated with Hyperbaric oxygen therapy and underwent computerized cognitive tests before and after the treatment
11069839|NCT04287270|Other|Assesment of MSA patients|Demographic information (sex, age, occupation, height, bodyweight ...), clinical and medical status, diagnosis date and Mini-Mental Status Scale data of all participants will be recorded at the first visit. Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure and maximal inspiratory mouth pressure. Also, the pulmonary function test will be applied.
11069840|NCT04287257|Active Comparator|Standard treatment + Active FHP|The PEMF device - FHP (supplied by commercial support) will be placed under the cast in the ER after diagnosing the fracture and will be applied for 24 hours a day continuously for 30-40 days.
11069841|NCT04287257|Sham Comparator|Standard treatment + Sham FHP|Half of the PEMF devices will be not activated at random before the application to the patients. Two types of activators will be provided by the company: active and sham. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device. The company supplying the PEMF-devices will have no knowledge of patient outcome.
11069842|NCT04287244|Experimental|Active tSDCS|Anodal tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (designed by Sooma). The anode will be positioned over the spinal cord area at the level of the spinous processes of 10th-11th thoracic vertebra.
11069843|NCT04287244|Sham Comparator|Sham tSDCS|Sham stimulation will be delivered to the same spinal cord area using a sham tSDCS device that delivers a direct current for 10 seconds at the beginning and end of tSDCS to provide sensory experiences similar to active stimulation.
11069844|NCT04287231|Experimental|Dual-tDCS & PT|Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about 1 hours). Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program for lower limb performence.
11102161|NCT04061330|Active Comparator|Opioid group|
11069845|NCT04287231|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performence.
11069846|NCT04287218|Experimental|TG-iConquerFear|The participant is guided through the web-based sessions by minimum weekly contact with an experienced therapist (estimated ½ hour/week for 10 weeks). The therapist will motivate, answer questions and give feedback on written material and exercises.
11069847|NCT04287218|Active Comparator|Augmented treatment as usual|"The control group is described as augmented treatment as usual (aTAU), since the diagnostic telephone interview exceeds standard treatment. Further more, the participants will be referred to a website with a non-guided, publicly available E-learning program in cancer rehabilitation hosted by the Region of Central Jutland (livogkraeft.rm.dk). In addition to written material the website includes self-help instructions for meditation."
11069848|NCT04287205|Experimental|women with endometriosis|
11069849|NCT04287192|No Intervention|Control|Control: Control participants will complete surveys at 4 time points (baseline, 1-2 weeks, 1 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, and assess their quality of life. Aside from completion of these surveys, no changes to their usual care will occur.
11069850|NCT04287192|Experimental|(Digital Bridge intervention)|"Experimental (Digital Bridge intervention) participants will complete surveys at 4 time points (baseline, 1-2 weeks, 1 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, assess their quality of life, and goal attainment.
~One to two days before discharge, patients will work with their team to develop the PODS in Care Connector. Once the PODS is created, the patient and hospital provider will be prompted to set transition goals using the ePRO tool."
11069851|NCT04287179|Experimental|Semaglutide 0.50 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.
11069852|NCT04287179|Active Comparator|Semaglutide 0.25 mg|Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.
11069853|NCT04287153|Experimental|Croytherapy on abdomen and saddlebags|Six (6) to 10 applicators (application area of 17 cm X 6 cm) are applied on the dorsal side (back, waist, saddlebags) for 45 minutes and then on the ventral side (belly) for 45 minutes, with adjustments according to the size of the participant. The temperature applied with the device is variable (-10°c to -7°C).
11069854|NCT04287140|Experimental|Saline|1000 ml of 0.9% normal saline bolus over one hour.
11069855|NCT04287140|No Intervention|No Saline|10 ml of 0.9% normal saline over one hour.
11069856|NCT04287114|Experimental|Healthy young men and women|Single group consisting of 10 men and 10 women
11069857|NCT04287101|Experimental|home PAC|A home PAC team will care for patients in his/her home within 3 weeks after acute hospitalization. The patient will get a physical therapy (PT) or occupational therapy (OT) 1 to 6 session(s) per week.
11069858|NCT04287101|Active Comparator|hospital PAC|A rehabilitation PAC team will care for patients in the hospital within 3 weeks after acute hospitalization. The patient will have 1 to 2 session(s) of PT or OT on weekdays, and a daily physician visit and nurse care.
11069859|NCT04287101|No Intervention|conventional care group|usual care
11069860|NCT04287088|No Intervention|Control|After IMPROD bpMRI all men undergo prostate biopsies. In men with Likert scores of 1-2, TRUS guided systematic biopsies are performed. In men with Likert 3-5 score, in addition to systematic biopsies, two targeted biopsies are taken from each lesion (up to two lesions).
11069861|NCT04287088|Experimental|Intervention|After IMPROD bpMRI prostate biopsies are performed according to shared decision-making by the treating urologist and the patient. If biopsies are to be performed, in men with IMPROD bpMRI likert scores of 1-2, 12-core systematic TRUS guided biopsies are performed and in men with Likert 3-5 score lesions systematic biopsies are performed and two targeted biopsies are taken from each lesion (up to two lesions). If biopsies are not performed, men are referred for a PSA follow-up.
11069862|NCT04287075||Surgery|Participants who elect to undergo surgery for the treatment of their chronic, neuropathic pain
11069863|NCT04287075||Non-surgery|Participants who elect to not have surgery for the treatment of their chronic, neuropathic pain
11069864|NCT04287062|Placebo Comparator|Placebo|Placebo sleep medication (2 placebo oral capsules)
11069865|NCT04287062|Active Comparator|Suvorexant|Sleep medication (20mg suvorexant; 2 10mg capsules; patients can self-titrate to 1 10mg capsule)
11069866|NCT04287049|Experimental|14 Day Azithromycin Monotherapy|For the first 14 days of therapy, participants will receive Azithromycin 250mg PO daily as monotherapy. Beyond day 14, all participants will receive guideline-based standard multi-drug therapy for Mycobacterium avium lung disease, as dictated by the physicians treating the participants.
11069867|NCT04287023|Experimental|Group Physical therapy|1 physical therapists and groups of 10 patients during the sessions
11069868|NCT04287023|Active Comparator|Individual physical therapy|1 physical therapist and 1 patient during the sessions
11069869|NCT04286997|Experimental|GRAIL population|patients are treated with 20 sessions of GRAIL rehabilitation, associated to 20 traditional physiotherapy sessions (1+1 a day, during a period of 30 days)
11069870|NCT04286997|Active Comparator|traditional population|subjects are treated with 40 sessions of traditional physiotherapy (2 a day, during a period of 30 days)
11069871|NCT04286984||Pre-upPBM|Patients with a diagnosis of gastric cancer before the upPBM implementation in their attending center
11069872|NCT04286984||Post-upPBM|Patients with a diagnosis of gastric cancer after the upPBM implementation in their attending center
11069873|NCT04286958|Experimental|Camrelizumab|All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
11069874|NCT04286945|Other|SENSORY EXOTROPIA PATIENTS WITH LARGE ANGLES .|Patients with monocular low vision or loss of vision due to congenital or acquired cause with exodeviation of the poorly seeing eye ≥ 50PD, were included in the study.
11069875|NCT04286932||5-12y|
11069909|NCT04286659||IBD group|90 Previously or Newly Diagnosed Ulcerative Colitis and Crohn's disease
11069910|NCT04286646||Pupil diameter before/after cataract|The investigators measure the pupil diameter before and after (3 months) cataract. Mesopic and photopic conditions
11069911|NCT04286607|Experimental|ARQ-151 Cream 0.3%|
11069876|NCT04286919|Active Comparator|ExRx#1: Physical Activity Guidelines|ExRx#1 uses the Frequency, Intensity, Time, and Type or FITT principle of exercise prescription to prescribe the Physical Activity Guidelines for Americans which is a weekly goal of 150-minutes of moderate intensity aerobic physical activity plus 2 days of muscle strengthening physical activity. ExRx#1 communicates the ultimate goal of the physical activity guidelines for Americans using an image adopted from the physical activity guidelines website that depicts the weekly goal. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the physical activity guidelines ultimate weekly goal by providing a weekly prescription of Frequency, Intensity, Time, and Type of physical activity that accomplishes meeting the physical activity guidelines weekly goal.
11069877|NCT04286919|Experimental|ExRx#2: Heat Map|ExRx#2 uses the heat map image published in the 2018 Physical Activity Guidelines Advisory Committee Scientific Report that communicates the dose-response relationship between increased physical activity and improved health to prescribe the message that all physical activity across all Frequencies, Intensities, Time bouts and Types (FITT) counts towards health. ExRx#2 is founded in the Integrated Behavior Change Theory and emphasizes that all physical activity matters regardless of FITT as depicted by the heat map image. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the ExRx#2 heat map ultimate weekly goal of moving more throughout the day across all intensities in order to achieve optimal health as represented by the deep green color on the bottom right of the heat map image.
11069878|NCT04286906||One group (cohort)|Asthmatic patients
11069879|NCT04286893||TAVI group|Consecutive patients undergoing TAVI
11069880|NCT04286880|Experimental|TEST GROUP|Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle.
11069881|NCT04286880|Active Comparator|CONTROL GROUP|In control group, dry needling will be performed.
11069882|NCT04286867|Experimental|Alcohol Moderation Group 1|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
11069883|NCT04286867|Active Comparator|Alcohol Moderation Group 2|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
11069884|NCT04286841||Neoadjuvant immunotherapy|
11069885|NCT04286828||Females with Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
11069886|NCT04286828||Healthy Females|20 healthy volunteers with matching ages and genders.
11069887|NCT04286815|Experimental|Experimental Group|a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency）.
11069888|NCT04286802|Experimental|Salt-meter|Patients received salt-meter in conjunction with dietary education by trained dietician to help monitoring the salt content in food, as well as usual care by their primary physicians.
11069889|NCT04286802|Active Comparator|Control|Patients received dietary education by trained dietician and usual care by their primary physicians.
11069890|NCT04286789|Experimental|ORTD-1-Low Dose|5.6 mg/0.45 mL of active study drug
11069891|NCT04286789|Placebo Comparator|Vehicle Control -Low Dose|Vehicle (Identical formulation without the active DP)
11069892|NCT04286789|Experimental|ORTD 1-High Dose|22.5 mg/1.8 mL of active study drug
11069893|NCT04286789|Placebo Comparator|Vehicle Control -High Dose|Vehicle (Identical formulation without the active DP)
11069894|NCT04286776|Experimental|Direct Electrical Stimulation|Stimulation will be applied concurrently with the task, if applicable, and stimulation trials will be interleaved with sham trials, where no stimulation is delivered.
11069895|NCT04286763||Hilar stricture|Bile duct Stricture (corresponding to E3, E4 and E5 from of Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
11069896|NCT04286763||Low level Stricture|Bile duct Stricture (corresponding to E1 and E2 from Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
11069897|NCT04286750|Experimental|ACT-1004-1239 Dose level 1 (30 mg) to 5|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
11069898|NCT04286750|Placebo Comparator|Placebo|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
11069899|NCT04286737|Experimental|Intervention Group|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
11069900|NCT04286737|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
11069901|NCT04286724|Experimental|Intervention|
11069902|NCT04286711|Experimental|Albumin-paclitaxel Combined With Apatinib and Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day; Repeat the therapeutic schedule every 3 weeks
11069903|NCT04286698|Active Comparator|Complex decongestive physiotherapy program group|Manuel lymph drainage, compression mask, exercises and skin care
11069904|NCT04286698|Active Comparator|Home program group|Self-manuel lymph drainage and home exercises
11069905|NCT04286698|No Intervention|Control group|No intervention
11069906|NCT04286672||Group 1:|• 35 bladder cancer patients diagnosed by biopsy before treatment.
11069907|NCT04286672||Group 2:|35 apparently healthy individuals who were matched by age and sex .
11069913|NCT04286594|Placebo Comparator|Placebo|Matched placebo solution administered twice daily for six weeks.
11069914|NCT04286581|Experimental|Igel Larnygeal Mask Airway|Group 1 will receive the I-Gel Laryngeal Mask Airway for airway maintenance during general anesthesia
11069915|NCT04286581|Active Comparator|Ambu Auragain Laryngeal mask airway|Group 2 will receive the Ambu Auragain Laryngeal Mask Airway for airway maintenance during general anesthesia
11069916|NCT04286568|Experimental|WOW Intervention|"Participants will receive blood pressure monitor and health passport to record blood pressure readings for 3 months.
~Participants will receive daily text message reminders to take and record blood pressure readings.
~Participants will receive health education and health care navigation. Participants will be assessed for social determinants of health. Participants will take surveys 3 times over 3 months. Participants will receive home visits or phone calls to collect data and receive health coaching."
11069917|NCT04286555|Active Comparator|DASH4D diet with lower sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 1500 mg/day
11069918|NCT04286555|Active Comparator|DASH4D diet with higher sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 3700 mg/day
11069919|NCT04286555|Active Comparator|Comparison diet with lower sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 1500 mg/day
11069920|NCT04286555|Other|Comparison diet with higher sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 3700 mg/day
11069921|NCT04286542|Experimental|Provocation with cold air|Participants will be exposed to cold dry air for 15 minutes
11069922|NCT04286529|Active Comparator|Men-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
11069923|NCT04286529|Active Comparator|Premenopausal Women-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
11069924|NCT04286529|Placebo Comparator|Men-Placebo|0.25mcg capsule daily for eight weeks
11069925|NCT04286529|Placebo Comparator|Premenopausal Women-Placebo|0.25mcg capsule daily for eight weeks
11069926|NCT04286516|Experimental|Reaching with TMS|All participants enrolled in this group will receive TMS while performing reaching movements in a robotic system.
11069927|NCT04286503|Experimental|Carrimycin|basic treatment + Carrimycin
11069928|NCT04286503|Active Comparator|lopinavir/ritonavir or Arbidol or chloroquine phosphate|any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
11069929|NCT04286490|Experimental|Prone position|
11069930|NCT04286477||15 conventional hemodialysis patients|15 patients undergoing hemodialysis with high-flux dialyzer
11069931|NCT04286477||15 patients undergoing online-hemodiafiltration|15 patients undergoing conventional hemodialysis with high-flux dialyzer will be allocated to online-hemodiafiltration with the same dialyzer
11069932|NCT04286477||15 patients undergoing expanded hemodialysis with MCO dialyzer|15 hemodialysis patients undergoing hemodialysis with a high-flux dialyzer will be allocated to HDx with an MCO dialyzers (THERANOVA dialyzer, Baxter International Inc. (NYSE: BAX))
11069933|NCT04286477||15 patients undergoing peritoneal dialysis|15 patients undergoing peritoneal dialysis
11069934|NCT04286464||Term born group (H)|Healthy, white and term Born infants and Children Born 38-42 weeks postconceptional
11069935|NCT04286464||Preterm group (P)|Healthy, white preterm Born infants and Children Born <37 weeks postconceptional Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD)
11069936|NCT04286464||Risk pregnancy group (RP)|White preterm Born infants and Children, including Twins Born <37 weeks postconceptional With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE) With gestational Diabetes (GDM) With IVF or Amnion dysfunction
11069937|NCT04286451|Experimental|Sleep Restriction|Women will undergo 4 nights of sleep restriction treatment.
11069938|NCT04286451|Experimental|Habitual Sleep|Women will undergo 4 nights of habitual sleep treatment.
11069939|NCT04286438|Experimental|Bentracimab (PB2452) Infusion - Open Label Active Drug|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. Patients with uncontrolled major or life-threatening bleeding.
~Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients in need of urgent surgery or invasive procedure."
11069940|NCT04286425|Placebo Comparator|Placebo|"500 µl of saline solution applied in the vaginal volt twice :
~one month before the IVF procedure during the ovulation period
~Same month of the IVF procedure after ovum pick up"
11069941|NCT04286425|Active Comparator|seminal plasma|"500 µl of seminal plasma applied in the vaginal volt twice :
~one month before the IVF procedure during the ovulation period
~Same month of the IVF procedure after ovum pick up"
11069942|NCT04286412|Experimental|Treatment Arm|At least twenty five eligible male subjects will be enrolled in the treatment arm to receive Nonacog alfa until 16 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
11069943|NCT04286399|Other|Intensive Treatment Group|High dose of RAASi and beta-blockers (unless contraindicated) as well as preferential use of SGLT2i as per local drug label guidelines on top of standard therapy.
11069944|NCT04286399|No Intervention|Control Group|Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.
11069945|NCT04286386||Arm Ia (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy.
11069946|NCT04286386||Arm Ib (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy and at a second time 3-4 weeks after.
11069947|NCT04286386||Arm II (MRSI, surgery)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy, followed by standard of care surgery within 6 months after.
11069948|NCT04286373|Experimental|Active stimulation then placebo stimulation|"VNS active for 12 weeks, then VNS placebo for 12 weeks.
~The VNS placebo stimulation period being the control one."
11069949|NCT04286373|Experimental|Placebo stimulation then active stimulation|"VNS placebo for 12 weeks, then VNS active for 12 weeks.
~The VNS placebo stimulation period being the control one."
11069950|NCT04286347|Experimental|HCV, HBV, HIV testing|All patient ≥ 18 years-old with a next planned surgery in Lariboisiere Hospital, Paris, France, able to give written informed consent for testing will be proposed to be tested for HIV and HCV if no previous testing found in the medical record and will be proposed to be tested for HBV if the patient belong to a high-risk group: high prevalence area (Asia, sub-Saharan Africa, French Indies, East and South Europe, North-Africa, Middle-East, India, Pakistan, South-America), IVDU, prisoners, unprotected sexual intercourses.
11069951|NCT04286334|Active Comparator|Group A - control Group|Customized titanium mesh without collagen membrane 15 patients will undergo bone regeneration with custom-made mesh without a collagen membrane. (Meshes - 3D-mesh BTK, Biotec, Vicenza, Italy.) Digitally designed by an operator before the surgery (digital technique).
11069952|NCT04286334|Experimental|Group B - Test Group|Customized titanium mesh with collagen membrane 15 patients will undergo bone regeneration with a custom-made titanium mesh (BTK, Biotec- Vicenza, Italy). Digitally designed by an operator before the surgery (digital technique), covered by collagen membrane (Cytoplast RTM, Osteogenics, deore materials, Verona, Italy).
11069953|NCT04286321|Experimental|Zero hard-boiled egg|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
11069954|NCT04286321|Experimental|Two egg whites|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two egg whites (0 g fat) prior to the 72-h pharmacokinetics trial.
11069955|NCT04286321|Experimental|Two hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.
11069956|NCT04286321|Experimental|Vegetable oil|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with vegetable oil (9.6 g fat) prior to the 72-h pharmacokinetics trial.
11069957|NCT04286308|Experimental|Brain signal data collection|Brain signal data collection at the time of deep brain stimulation (DBS) surgery.
11069958|NCT04286295|Experimental|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
11069959|NCT04286295|Active Comparator|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
11069960|NCT04286282|Active Comparator|Standard of Care|The first 100 participants with HIV and depression will receive standard of care including SSRI therapy.
11069961|NCT04286282|Experimental|Standard of Care + Group Support Psychotherapy|The second 100 participants with HIV and depression will receive standard of care, including SSRI therapy, and group support psychotherapy.
11069962|NCT04286282|Active Comparator|Standard of Care (Non-Depressed)|100 participants with HIV and without depression will receive standard of care therapy for HIV and no depression treatment.
11069963|NCT04286269|Experimental|Intervention|Participants in this group will be randomized to receive the intervention.
11069964|NCT04286269|Sham Comparator|Placebo|Participants in this group will be randomized to receive a sham treatment.
11069965|NCT04286256|Experimental|Treatment Group|The treatment group received motivational interviewing.
11069966|NCT04286256|No Intervention|Control Group|The control group received standard information only.
11069967|NCT04286243|Active Comparator|Model 1 - Clinic Based Screening|Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA
11069968|NCT04286243|Experimental|Model 2 - Community Based Screening|Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive
11069969|NCT04286217||No prior hypertension (HTN); no HDP in pregnancy|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
11069970|NCT04286217||No prior HTN; de novo HDP, GH type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
11069971|NCT04286217||No prior HTN; de novo HDP, GH type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
11069972|NCT04286217||No prior HTN; de novo HDP, PE type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
11069973|NCT04286217||No prior HTN; de novo HDP, PE type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
11069974|NCT04286217||No prior HTN; no HDP in pregnancy; postpartum HDP|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
11069975|NCT04286217||Pre-existing HTN; no HDP in pregnancy|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
11069976|NCT04286217||Pre-existing HTN; de novo HDP, GH type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
11102221|NCT04060927|Experimental|Group 1|Freebreathing SBRT with SGRT
11069977|NCT04286217||Pre-existing HTN; de novo HDP, GH type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
11069978|NCT04286217||Pre-existing HTN; de novo HDP, PE type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
11069979|NCT04286217||Pre-existing HTN; de novo HDP, PE type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
11069980|NCT04286217||Pre-existing HTN; no HDP in pregnancy; postpartum HDP|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia,with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
11069981|NCT04286217||Other causes of macular injury leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury leading to HDP, either gestational hypertension or preeclampsia
11069982|NCT04286217||Other causes of macular injury not leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury not leading to HDP
11069983|NCT04286204|Experimental|Basic Life Support Training based on ICTs|It will be conformed with students from one highschool random selected. They will receive a basic life support training based on Information and communication technologies.
11069984|NCT04286204|Active Comparator|Classic Basic Life Support Training|It will be conformed with students from another highschool random selected. They will receive a full and conventional basic life support training based on American and Hear Association recommendations.
11069985|NCT04286191|Experimental|Up-conditioning (UC) Group|
11069986|NCT04286191|Sham Comparator|Control (NC) Group|
11069987|NCT04286178|Experimental|Treatment|patients in this arm will be treated with creatine and coenzyme Q10 supplements
11069988|NCT04286178|Placebo Comparator|Placebo|patients in this arm will be given placebo supplements that look and taste identical to the active supplements
11069989|NCT04286165|Active Comparator|BPS webSTAIR 6 Levels with Per Support|Participants in BPS webSTAIR will complete a baseline, posttreatment and 2-month follow-up assessment. In the BPS webSTAIR condition, participants will first complete a welcome module to orient them to the program. After randomization, participants will have 10 weeks to complete the 6 modules. Every time the Veteran logs on they will have the opportunity to engage with a Veteran peer for support through the web program. Contacts can last for up to an hour. Veterans will receive a series of automated reminders and engagement emails that the Vets Prevail program sends at various points in the program.
11069990|NCT04286165|No Intervention|Wait List|In Wait list, they will be asked to go about your life as usual. They will be asked not to participate in any other programs for PTSD or depression symptoms for 10 weeks. After the 10 weeks you can begin any other program for PTSD or depression. They will also be given the option of participating in BPS webSTAIR or be provided with information about other web-based programs that might be of interest or relevant to them.Participants in the WL condition will complete a baseline, a second assessment at the 10th week, conclude their involvement in the study and be offered the Vets Prevail coping program. During their time in the study wait list participants are asked to not seek any treatment from VetsPrevail or other entities for a period of 10 weeks. They are instructed to simply go about their lives as normal.
11069991|NCT04286152|Experimental|Mirabegron and narcotic analgesia|Drug: Mirabegron 50mg tablet, oral, daily from stent insertion until removal - 7days Drug: Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
11069992|NCT04286152|Placebo Comparator|Placebo|Drug: Placebo for Mirabegron, 1 tablet, oral, daily from stent insertion until removal - 7days Drug:Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
11069993|NCT04286139|Experimental|SHAPE Intervention|This group will receive the group based self-management course develop self-management skills in areas including decision making, symptom management and social interaction and to provide information on the disease process and the development of healthy behaviours in a supportive learning environment to prevent problems that are common in the later stages of the disease. Key themes of the intervention will include positive actions to improve and maintain health, how to talk about the impact of the disease on the life of the person with dementia, fear of losing independence and how to tackle and solve other sensitive issues. Running in parallel there will be an e-learning resource available to the carers which covers the similar material covered in the group sessions for the person with dementia, as well as some additional resources and signposting to help them in their role supporting the person with dementia.
11069994|NCT04286139|No Intervention|Treatment as usual|Participants in the TAU arm will receive normal services such as clinical reviews, psychiatric appointments and other services when needed. With TAU as the comparator condition ensures that participants receive any needed services and enable comparison between current best practice and the new intervention of SHAPE
11069995|NCT04286126|Active Comparator|bilateral DMPFC|This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.
11069996|NCT04286126|Active Comparator|right OFC|This arm will receive continuous theta-burst stimulation to the right OFC site.
11069997|NCT04286113|Active Comparator|Control group|Participants will receive non-personalized information (one-size-fits-all) diet, sleep and physical activity recommendations via messaging delivered by app.
11069998|NCT04286113|Experimental|Intervention Group|Participants will receive personalized messages about achieving healthy diet, physical activity and sleep as well as summary of their performance for the week and month. They will also receive personalized content about research volunteerism and altruistic activities.
11069999|NCT04286087|Experimental|Investigational Arm|
11070000|NCT04286087|Active Comparator|Control Group|
11070001|NCT04286074|Experimental|Experimental group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.
~Prior to training, the muscle training technique will be performed against a resistance of 50% of the maximum inspiratory pressure of each athlete"
11070054|NCT04285684|Other|Ketamine, lactation|Lactating women--4 subjects, 2 dosage format: ketamine 0;5mg/kg and 1.0mg/kg IM at least 5 days apart.
11071103|NCT04278508|Active Comparator|Group B|P < 10.0 ng/ml without change in drug regimen.
11070002|NCT04286074|Active Comparator|Control group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.
~Prior to training, the muscle training technique will be performed against a resistance of 10% of the maximum inspiratory pressure of each athlete"
11070003|NCT04286061|Experimental|Experimental group|Each session will last 1 or 2 minutes, with one intervention being carried out a week, over a period of 4 weeks. Prior to the start of training, the instrument-assisted soft tissue mobilization technique will be performed
11070004|NCT04286061|No Intervention|Control group|Players included in the control group will follow their usual training routine.
11070005|NCT04286048|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session.
~Prior to training, each pitcher will perform his normal warm-up routine, notifying the investigator when he feels ready to perform the training. The intervention through weight implements will consist in the application of the protocol described by Fleising et al. The objective of the application of the technique is to produce an increase in the speed of the throws."
11070006|NCT04286048|No Intervention|Control group|Athletes included in the control group will conduct their training and activities on a daily basis
11070007|NCT04286035|Active Comparator|Femoral group|
11070008|NCT04286035|Active Comparator|Adductor group|
11070009|NCT04286022|Experimental|Speed Loss 20% Group|The SL20% group will carry out a program based on the limitation of the speed loss, allowing to perform the exercise only until a speed loss of 20% is achieved, following a similar methodology previously published (Pareja-Blanco et al., 2017). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 6-series routine with an open number of repetitions will be carried out twice, allowing as many repetitions as possible to perform until a 20% loss of execution speed is reached. The intensity of work will be 70% 1RM, resting 4 minutes between sets. As an only exercise, an elbow flexion (bicep curl) with dumbbell will be performed.
11070010|NCT04286022|Experimental|Reduced Rest Time Group|The RRT group will carry out a program based on the reduction of rest time between series, following a previously published methodology (Stragier et al., 2019). The program will consist of a job for 4 weeks, with a frequency of 2 sessions a week. In each session, a 5 series routine with progressive repetition volume (3 to 7) at 70% 1RM will be performed twice, resting 15 seconds between sets and 150 seconds between each of the 2 blocks. The exercise to be performed will be an elbow flexion (bicep curl) with dumbbell.
11070011|NCT04285996|Other|All patients|Pilot study: All registered patients will undergo a PET scan using [18F]-FBA-A20FMDV2.
11070012|NCT04285983||Trelagliptin 25 mg|Trelagliptin 25 milligrams (mg) tablet, orally, once weekly for up to 12 months. Participants received interventions as part of routine medical care.
11070013|NCT04285970||Medullary injured|Injured Medullary users of manually driven wheelchairs for daily locomotion
11070014|NCT04285970||Healthy volunteers|Healthy volunteer with at least 2 hours' experience using a manual wheelchair
11070015|NCT04285957||pre-test Group|"Consecutive recruitment of 10 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.
~Inclusion criteria: age 18-90, stroke occurred within 3 months from enrollment; clinical stability (SIC = 0). The exclusion criteria are: stroke recurrence; visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the the patients' understanding of and the reliable answering to the two assessment tools"
11070016|NCT04285957||Validation Group|Recruitment of 60 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.Inclusion criteria: age 18-90, stroke occurred within 8 months from enrollment; clinical stability (SIC = 0). If the following criteria are present: visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the patients' understanding of and the reliable answering to the two assessment tools, the interview shall be carried out with a proxy
11070017|NCT04285944|Active Comparator|Study|
11070018|NCT04285944|No Intervention|Control|
11070019|NCT04285918||Cohort A|Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature)
11070020|NCT04285918||Cohort B|Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO
11070021|NCT04285905|Active Comparator|Enhanced standard of care|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner"
11070022|NCT04285905|Active Comparator|Group 2|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners"
11070023|NCT04285905|Active Comparator|Group 3|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners
~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
11070024|NCT04285905|Active Comparator|Group 4|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners
~Female partner delivered oral HIV self-testing kits for primary male partner"
11070025|NCT04285905|Active Comparator|Group 5|"Access to Fast Track TB Clinic
~Information leaflet for primary male partner
~Female participant sputum collection from male partners
~Female partner delivered oral HIV self-testing kits for primary male partner
~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
11070026|NCT04285892|Experimental|CAPA IVM|CAPA IVM is a 2-step In vitro Maturation system in which an additional culture step, in which the oocytes are kept in meiotic arrest by the presence of the C-type Natriuretic peptide (CNP) for 22-24 hours, is preceding the in vitro maturation step in which maturation medium is supplemented with amphiregulin (AREG). The 'IVM System' of Medicult-Origio is used as a base medium.
11070027|NCT04285892|No Intervention|Standard IVM|The IVM is performed as a single step protocol in which oocytes are immediately exposed to in vitro maturation medium for 30 hours. This is the current standard procedure in the clinical practice using the commercially available 'IVM System' of Medicult-Origio. Standard IVM medium: 10% HSA + 75mIU/ml FSH + 100mIU/ml hCG
11070091|NCT04285372|Experimental|Test group|No intervention on the side branch in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
11071104|NCT04278508|Active Comparator|Group C|P ≥ 10.0 ng/ml without change in drug regimen.
11070028|NCT04285879|Experimental|BFR Exercise Group|"In addition to the standard ACL protocol, patients in this study will utilize the Owen Recovery Science exercise protocol for BFR [18]. The following guidelines will be followed concerning exercise progression, occlusion pressure and difficulties with volume achievement.
~A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study."
11070029|NCT04285879|No Intervention|Non-BFR exercise group|As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine
11070030|NCT04285866||Durvalumab Group|Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
11070031|NCT04285853|Experimental|Oxycodone Arm|"Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 rescue medications, in the Oxycodone arm will be placebo rescue medications.
~All participants will also receive the following as part of standard of care:
~Oral non-opioid (1000 mg acetaminophen), every 8 hours.
~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.
~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.
~Intraoperative education on post-surgical pain management."
11070032|NCT04285853|Placebo Comparator|Placebo Arm|"Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 rescue medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone rescue tablets.
~All participants will also receive the following as part of standard of care:
~Oral non-opioid (1000 mg acetaminophen), every 8 hours.
~Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery.
~Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block.
~Intraoperative education on post-surgical pain management."
11070033|NCT04285840|Other|Single arm study|To establish a standardized procedure for venous ACT sampling during atrial fibrillation ablation. Analyses will examine the relationship and agreement between venous and arterial ACTs.
11070034|NCT04285827|Experimental|CSL889 Cohort 1 (Dose 1)|CSL889 administered as a single IV infusion
11070035|NCT04285827|Experimental|CSL889 Cohort 2 (Dose 2)|CSL889 administered as a single IV infusion
11070036|NCT04285827|Experimental|CSL889 Cohort 3 (Dose 3)|CSL889 administered as a single IV infusion
11070037|NCT04285827|Experimental|CSL889 Cohort 4 (Dose 4)|CSL889 administered as a single IV infusion
11070038|NCT04285827|Experimental|CSL889 Cohort 5 (Dose 5)|CSL889 administered as a single IV infusion
11070039|NCT04285827|Experimental|CSL889 Cohort 6 (Dose 6)|CSL889 administered as a single IV infusion
11070040|NCT04285814||Normal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with normal results.
11070041|NCT04285814||Abnormal CMA|150 women whose blood samples will be drawn for WFC testing who previously had a CMA performed with abnormal results.
11070042|NCT04285801||COVID-19 infection|critically ill patients with COVID-19 infection
11070043|NCT04285775||Insertion of Dialysis Catheter|Hospital inpatients planned for dialysis catheter insertion, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
11070044|NCT04285775||Removal of Dialysis Catheter|Hospital inpatients planned for dialysis catheter removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
11070045|NCT04285762||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA by a single surgeon from March 2016 to October 2018.
11070046|NCT04285749|Experimental|Fluvastatin|"Participants will receive Fluvastatin for 2 weeks.
~RNA-sequencing and gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision."
11070047|NCT04285736|Experimental|Group A Ivabradine Group|
11070048|NCT04285736|Active Comparator|Group B Control Group|
11070049|NCT04285723||alpelisib|Patients treated with alpelisib
11070050|NCT04285710|Other|Control|Subjects enrolled in the subject group will receive standard care treatment for infected diabetic wounds, including debridement surgery and wound dressings. However, in order to maintain consistency with the phototherapy arm, subjects within the control group will visit the clinic twice a week, with the first visit being for the debridement surgery, and the second visit being for clinical wound dressing redressing.
11070051|NCT04285710|Experimental|Phototherapy|For this intervention therapy, subjects enrolled in the experimental group will still receive standard care treatment for infected diabetic wounds. However, experiment group subjects will receive phototherapy treatments alongside standard care. A mobile pulsed laser device will be utilized to apply nanosecond pulsed 410 nm light onto both the cellulitis afflicted regions and open wound portions of a patient's infected diabetic ulcer wound twice a week over the course of the 3 month study. The device will be designed and produced by the Ji Xin Cheng Lab located at the Boston University Charles River Campus. Phototherapy sessions will occur twice a week, with the first session occurring after debridement surgery, and the second session occurring later in the week during clinical wound dressing redressing.
11070052|NCT04285697|Experimental|group 1|During the outpatient clinic visit, an information leaflet will be given about the subjects that should be considered for prevention of SSI before surgery. 2% mupirocin ointment will be applied to the nostrils with the swab twice-daily before surgery and once on the morning of surgery. Body cleaning will be done with 4% chlorhexidine gluconate shower the night before the surgery. Prophylactic antibiotics by weight will be administered within 60 minutes of anesthesia induction. The planned aseptic technique will be applied and a strict draping will be used in the incision site. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form. Before the skin closes, the surgical site will be washed with warm Isotonic NaCl solution. Wound care education will be provided to the patient and family before discharge.
11070053|NCT04285697|No Intervention|group 2 control|The pre-operative service sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 1 hour during the operation and data will be recorded on the data collection form.
11070055|NCT04285671|Experimental|Treatment (necitumumab, trastuzumab, osimertinib)|Patients receive necitumumab IV over 60 minutes and trastuzumab IV over 30-90 minutes on days 1 and 15. Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11070056|NCT04285658||Ureteroscopy|
11070057|NCT04285658||Percutaneous Nephrolithotomy|
11070058|NCT04285658||Shock Wave Lithotripsy|
11070059|NCT04285645|Experimental|Experimental group|Each session will last 15 minutes, taking place 2 days a week, over a period of 4 weeks. Prior to training, the exercise protocol will be carried out. Prior to the start of the intervention, the exercises to be performed will be explained to the participants and it will be verified that they are capable of performing them correctly.
11070060|NCT04285645|No Intervention|Control group|Athletes included in the control group will continue with their usual training routine.
11070061|NCT04285632|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of each training session.
~Prior to training, the Counter Movement Jump and Drop Jump exercises will be performed"
11070062|NCT04285632|No Intervention|Control group|Athletes included in the control group will continue with their usual warm-up routine.
11070063|NCT04285619|Experimental|Experimental group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
11070064|NCT04285619|Active Comparator|Control group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
11070065|NCT04285606|Experimental|Patient-led rehab group|Immobilization in arm sling for a short period time followed by patient-led shoulder exercises for rehab following reverse shoulder arthroplasty
11070066|NCT04285606|No Intervention|Supervised rehab group|Prolonged immobilization in arm sling followed by supervised physical therapy by therapists for rehab following reverse shoulder arthroplasty
11070067|NCT04285593|Experimental|Experimental group|"Each session will last 10 minutes, taking place two days a week, over a period of four weeks. The intervention will take place at the beginning of the training session.
~The players included in the experimental group will perform an exercise protocol with Bulgarian squats."
11070068|NCT04285593|No Intervention|Control group|The players included in the control group will continue with their usual warm-up routine.
11070069|NCT04285580|Experimental|Bimatoprost SR 10 μg|Participants will receive Bimatoprost SR 10 μg implant in the study eye on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
11070070|NCT04285580|Other|LUMIGAN 0.01%|Participants will receive topical LUMIGAN 0.01% in the study eye once daily starting evening Dose on Day 1 and standard of care treatment in the fellow eye for the duration of the study.
11070071|NCT04285567|Experimental|VEN + G|Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
11070072|NCT04285567|Active Comparator|FCR/BR|Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
11070073|NCT04285554|Experimental|Hepatic Denervation|
11070074|NCT04285528|Experimental|General Anesthesia|The first group which will undergo general anesthesia, will be anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway will be inserted afterwards.
11070075|NCT04285528|Experimental|PFK group|The second group will undergo intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine will be added, this aims to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water for injection will be added to the mixture.
11070076|NCT04285515|Experimental|Lumateperone 42mg|Lumateperone 42mg administered once daily in the evening
11070077|NCT04285515|Placebo Comparator|Placebo|Matching placebo administered once daily in the evening
11070078|NCT04285502|No Intervention|CONTROL GROUP|patients without a drain
11070079|NCT04285502|Experimental|CASE GROUP|Patients a drain inserted
11070080|NCT04285476|Experimental|Signature of 10 microRNA|Signature of 10 miRNA in patients with Thyroid Cytologies of undetermined type and with a Bethesda classification 3, 4 or 5
11070081|NCT04285450|Experimental|Vitamin K 1mg|
11070082|NCT04285450|Placebo Comparator|Control|
11070083|NCT04285437|Experimental|massage|neonates are massaged by their mother during the first 2 months after birth.
11070084|NCT04285437|No Intervention|control|neonates are not massaged.
11070085|NCT04285424|Experimental|HSCT patients with acute steroid-resistant GI-related GVHD|Patients will receive 500ml fecal microbiota which were sprayed evenly on the entire colon through colonscopy or duodenal nutrition tube injection which collected from one unrelated healthy donors. Patients receiving FMT treatment will be followed for at least 1,3,5,7 days.Stool, blood and colonic mucosa samples will be serially collected and tested (before pre-treatment, 1,3,5,7 days after FMT).
11070086|NCT04285411|Experimental|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
11070087|NCT04285398|Other|Study Group 1|One year follow up of patients with ophthalmic examination.
11070088|NCT04285398|Other|Study Group 2|One year follow-up of patients with ophthalmic examination and mobility testing.
11070089|NCT04285385|Experimental|Aromatherapy|0.10 ml of lavender essential oil 30 minutes prior surgery
11070090|NCT04285385|Sham Comparator|Sham Aromatherapy|0.10 ml mineral oil 30 minutes prior surgery
11070128|NCT04285060|Experimental|Training Group|All participants are assigned to the training group with the Samsung GEMS-H.
11070092|NCT04285372|Active Comparator|Control group|Side branch protection: Ballooning or Kissing Balloon Technique, in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
11070093|NCT04285346|Other|Open-label|ganaxolone suspension (50 mg/ml) TID for 12 weeks with 24 week extension
11070094|NCT04285333|Active Comparator|fascial iliaca|: A linear high frequency ultrasound probe (10-15MHz) was placed in a transverse direction over the anterior thigh below the inguinal ligament. We identified the femoral artery and the iliacus muscle lateral to it, covered by the fascia iliaca. The needle was inserted in plane and a 22 gauge, 50 mm needle was advanced until the tips placed underneath the fascia iliaca. Following negative aspiration, the local anesthetic solution was injected in 5mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine
11070095|NCT04285333|Experimental|Percapsular nerve group block|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL of 1.5% Lidocaine.
11070096|NCT04285320|Active Comparator|Intravesical antibiotic instillation|
11070097|NCT04285320|Active Comparator|Oral antibiotic suppressive therapy|
11070098|NCT04285307|Experimental|Study group|Study group
11070099|NCT04285294||RDEB patients with a cSCC|
11070100|NCT04285294||Non-RDEB patients with a SCC induced by ultraviolet radiation|
11070101|NCT04285294||Healthy donors without RDEB nor SCC|
11070102|NCT04285281|Experimental|Gabapentin|Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
11070103|NCT04285281|No Intervention|Control group|Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
11070104|NCT04285268|Experimental|Treatment (rituximab, venetoclax, bortezomib)|Patients receive rituximab IV on day -1 of cycle 1, then on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-14 and bortezomib IV or SC on day -1 of cycle 1, then on days 1, 8, and 15 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for rituximab and up to 26 cycles for venetoclax and bortezomib in the absence of disease progression or unacceptable toxicity.
11070105|NCT04285255|Active Comparator|Opioids anesthesia|received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
11070106|NCT04285255|Active Comparator|OFA|received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side
11070107|NCT04285242||Participants with Cancer|Assessments and observations for up to 40 days with one overnight hospital stay.
11070108|NCT04285242||Healthy Volunteers - Group A|Assessments and observations for up to 2 days with one overnight hospital stay.
11070109|NCT04285242||Healthy Volunteers - Group B|Assessments and observations for up to 2 days.
11070110|NCT04285229|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind and extended treatment periods.
11070111|NCT04285229|Placebo Comparator|Placebo|Placebo given SC during the double-blind period and then ixekizumab will be given SC during the extended treatment periods.
11070112|NCT04285216|Experimental|Dry needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
11070113|NCT04285216|Active Comparator|Strain counter strain|Hot pack 10 minutes, stretching,Neck isometrics, Strain counter strain (S C S)
11070114|NCT04285203|Experimental|Educational Video|Participants were exposed to 2 educational videos in addition to standard of care education.
11070115|NCT04285203|No Intervention|Standard of Care|Participants received standard of care education.
11070116|NCT04285190|Experimental|The T89 treatment group|Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID(every morning and evening), for 10 days (Depending on clinical need and practicability, the use can be extended for up to 14 days).
11070117|NCT04285190|No Intervention|The blank control group|All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
11070118|NCT04285177||Horizontal muscle surgery|Patients suffering from esotropia or exotropia, will have medial/lateral rectus recession/resection
11070119|NCT04285177||Patients with Inferior Oblique Overaction|Will undergo inferior Oblique Myectomy
11070120|NCT04285177||Patients with combined horizontal and oblique muscle surgery|Having combined surgery
11070121|NCT04285138|Experimental|Phantom limb exercises|Participants in this group will be treated with routine physical therapy, mirror therapy and Phantom limb exercises. Treatment time: 1 hour
11070122|NCT04285138|Active Comparator|conventional treatment|In this group, participants will be treated by routine physical therapy and mirror therapy protocol. Treatment time: 35 minutes
11070123|NCT04285099|Experimental|PD patients with FOG after STN-DBS[A]|Initially started by A setting
11070124|NCT04285099|Experimental|PD patients with FOG after STN-DBS[B]|Initially started by B setting
11070125|NCT04285086|Experimental|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
11070126|NCT04285086|Active Comparator|Anagrelide|Capsules, Daily, p.o.
11070127|NCT04285073|Experimental|Paclitaxel-eluting graft|Single-arm
11070129|NCT04285034||Ribavirin only|"Patients will receive ribavirin in accordance with Nigerian treatment guidelines. Patients will either receive the McCormick regimen or the Irrua regimen.
~PK blood tests will be done on Day 1,2,5,6,10,11,12,13, discharge; Paxgene RNA blood test on day 1, 3, 5, discharge Haematocrit finger prick test on day 1,2, 5, 6, 10, discharge"
11070130|NCT04285034||Cardiocascular study only|Cardiac tests (NICAS (daily), ECG (Day 1, 5, 10, discharge), Echocardiogram (Day 1, 5, discharge), Ultrasound (Day 1, 3, 5, 7, 10), Endopat (Day 1 and discharge)) will be done throughout; Haematocrit finger prick test daily PAXgene RNA blood test on day 1, 5, discharge
11070131|NCT04285008|No Intervention|standard Colonoscopy|"Control arm
~Colonoscopy procedure using standard flushing and suctioning - standard of care"
11070132|NCT04285008|Other|Pure-Vu System|Intervention - Colonoscopy procedure using Pure-Vu System
11070133|NCT04284995|Experimental|Cohort 1|Cohort 1: 0.075 mg/kg RUC-4. 8 STEMI Patients will be enrolled.
11070134|NCT04284995|Experimental|Cohort 2|Cohort 2: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
11070135|NCT04284995|Experimental|Cohort 3|Cohort 3: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
11070136|NCT04284982|Experimental|Heavy resistance training program|
11070137|NCT04284969|No Intervention|Control arm|Patients treated according current practice of the inclusion center. If interventions are implemented locally (geriatric assessment, nutrition, physical activity) they may be proposed to the patient.
11070138|NCT04284969|Experimental|Intervention arm : PROADAPT program|Patients benefiting from the PROADAPT (interventional arm) program.
11070139|NCT04284956|Experimental|Proximal group|Proximal segment of saphenous veins are harvested from the thigh by No-Touch technique and randomized to bypass the left or right territory of coronary system
11070140|NCT04284956|Active Comparator|Distal group|Distal segment of saphenous veins are harvested from the shank of the ipsilateral leg by No-Touch technique and used to bypass the right or left territory of coronary system (depending on the randomizing result of the proximal segments)
11070141|NCT04284943|Active Comparator|Long limb Roux-en-Y reconstruction|Long limb Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
11070142|NCT04284943|Active Comparator|Conventional Roux-en-Y reconstruction|Conventional Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
11070143|NCT04284943|Active Comparator|Billroth II reconstruction|Billroth II reconstruction method follows subtotal gastrectomy for gastric cancer
11070144|NCT04284930|Experimental|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
11070145|NCT04284930|Active Comparator|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
11070146|NCT04284930|Active Comparator|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
11070147|NCT04284917|Experimental|Receive Carglumic Acid|Experimental Case_ Carglumic Acid
11070148|NCT04284904||matched sibling hematopoietic stem cell transplantation|aGVHD biomarker in matched sibling donor hematopoietic stem cell transplantation
11070149|NCT04284904||unrelated allogeneic hematopoietic stem cell transplantation|aGVHD biomarker in unrelated donor hematopoietic stem cell transplantation
11070150|NCT04284904||haploidentical hematopoietic stem cell transplantation|aGVHD biomarker in haploidentical donor hematopoietic stem cell transplantation
11070151|NCT04284878||A|patients with inflammatory bowel disease
11070152|NCT04284878||B|healthy subjects
11070153|NCT04284865|Experimental|Intervention group|The web platform includes three respiratory exercises: diaphragmatic breathing, thoracic expansion exercise and thoracic expansion exercise assisted upper limbs. It is suggested to do each of the three exercises once a day (AM and PM), four repetitions each. An electronic logbook is also available on the platform to record the duration and the type of others cardiorespiratory exercise of their choice (cycling, walking, using stairs, etc.) as well as strengthening (upper and lower body).
11070154|NCT04284852|Experimental|Experimental arm|Niraparib 200 or 300mg daily orally for 18 cycles unless disease progression or intolerable side effects (whichever occurs first)
11070155|NCT04284839|Active Comparator|Direct Oral Anticoagulation (DOAC)|Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
11070156|NCT04284839|Placebo Comparator|Vitamin K Antagonist|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
11070157|NCT04284826|Experimental|mitomycin C injection group|A submucosal needle injection of 4mL of a MMC preparation (0.5mg/mL) into the tearing esophageal wall after esophageal bougie dilation on refractory benign esophageal stricture
11070158|NCT04284813|Experimental|Telemedicine|Community Reinforcement and Family Training for first episode psychosis delivered via telemedicine (CRAFT-FT) with 6-8 weekly sessions of 45-minute therapy.
11070159|NCT04284787|Active Comparator|Arm I (AZA, VEN)|"INDUCTION THERAPY PHASE: Patients receive azacitadine IV over 10-40 minutes or SCon days 1-7 and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY PHASE: Patients receive azacitadine IV over 10-40 minutes or SC on days 1-7 and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment per physician discretion."
11070189|NCT04284579|Experimental|time for cannulation|intravenous cannulation after sevoflurane induction
11070190|NCT04284566|Experimental|TAU + multicomponent treatment FIBROWALK|FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
11070233|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Lighter)|Subjects will perform exercise at ~200W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11071105|NCT04278495|Active Comparator|Losartan|"to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp & Dohme-UK),"
11070160|NCT04284787|Experimental|Arm II (AZA, VEN, pembrolizumab)|"INDUCTION THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitadine IV over 10-40 minutes or SC on days 1-7, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitadine IV over 10-40 minutes or SC on days 1-7, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment with azacitadine and venetoclax per physician discretion."
11070161|NCT04284774|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
11070162|NCT04284761|Experimental|Biolen|Biolen bicalutamide implant. Single implantation. In situ until prostatectomy
11070163|NCT04284748|Experimental|Plyometric training with blood flow restriction|Routine physiotherapy program + Plyometric training with blood flow restriction, 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
11070164|NCT04284748|Active Comparator|Plyometric training|Routine physiotherapy program + Plyometric training 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
11070165|NCT04284735|Other|Controls|Patients with RA and without ILD
11070166|NCT04284735|Other|Cases|Patients with RA and ILD
11070167|NCT04284722|Active Comparator|Metformin +|The study intervention involves the self-administration of metformin in the same dosage as the patient's regular dosage according to regular dosing schedule and randomization.
11070168|NCT04284722|No Intervention|Metformin -|The control group involves no intervention, which means cessation of oral metformin therapy 24 hours prior to surgery according to the local guidelines of the anesthesia department and the national anesthesiology guidelines.
11070169|NCT04284709|Experimental|exercise group|exergames with simultaneous cognitive-physical training
11070170|NCT04284709|Active Comparator|control group|multicomponent exercise intervention focused on physical and cognitive training
11070171|NCT04284696|Active Comparator|Verum|"patients with emesis gravidarum who take a chewing gum with vitamin C (verum) ad libitum several times daily for 2 weeks"
11070172|NCT04284696|Placebo Comparator|Placebo|"patients with emesis gravidarum who take chewing gum without vitamin C (placebo) ad libitum several times daily for 2 weeks"
11070173|NCT04284696|No Intervention|Nihil|patients with emesis gravidarum who do not use chewing gum during the study phase
11070174|NCT04284683|Experimental|Normal and overweight participants|"Healthy males and female, age 6 to 30. BMI range for participants age 6 to 18 is between 5th percentile to 85th percentile, overweight BMI between the 85 and 95th percentile, and obese, above the 95th percentile.
~BMI range for participants age 18 to 30 is between 18.5 to 24.9 for normal weight, 25-30 for overweight and above 30 for obese."
11070175|NCT04284670|Experimental|Eccentric treadmill training|The intervention group will perform an 8 week program, 2 sessions a week for a total of 16 sessions. training will be done on a designated negative gradient treadmill. first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
11070176|NCT04284670|Experimental|Control group|The control group will receive the same amount of training under neutral gradient surface(0%).The program will be 8 weeks while in each week there will be two exercise sessions and a total of 16 sessions. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. Training intensity will be 70%-80% out of maximal heart-rate.
11070177|NCT04284657|No Intervention|ARM I: Control group|Standard therapy alone
11070178|NCT04284657|Active Comparator|ARM II: PRAVASTATIN|Standard therapy and PRAVASTATIN 40 mg QD
11070179|NCT04284657|Active Comparator|ARM III: PRAV + Sodium Citrate|Standard therapy and PRAVASTATIN 40 mg QD and Sodium Citrate (up to 30 mL TID)
11070180|NCT04284644|Experimental|Group P|Patient received a dose of 1.5 mg/kg of Propofol slowly over 2 minutes for induction.
11070181|NCT04284644|Experimental|Group S|Patient received 8% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen.
11070182|NCT04284644|Experimental|Group C|Patient received 4% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
11070183|NCT04284618||assessment of radiographic angles on standardized films|On Standing standardized radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
11070184|NCT04284618||assessment of radiographic angles on off axis view films|On off axis view radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
11070185|NCT04284605|Experimental|Group1|
11070186|NCT04284605|Experimental|Group2|
11070187|NCT04284592|No Intervention|Control group|Patients do not receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
11070188|NCT04284592|Experimental|RIP group|Patients receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
11071106|NCT04278495|Placebo Comparator|Placebo|to receive either placebo
11070191|NCT04284566|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option. Patients were offered the opportunity to participate in the next wave of group intervention at the end of the study (3 months).
11070192|NCT04284553|Experimental|Base Order Entry Alert|
11070193|NCT04284553|Experimental|Base Open Encounter Alert|
11070194|NCT04284553|Experimental|Order Entry + Follow-up booster Alert|
11070195|NCT04284553|Experimental|Open Encounter + Follow-up booster Alert|
11070196|NCT04284553|Experimental|Order Entry + Cold State outreach|
11070197|NCT04284553|Experimental|Open Encounter + Cold State outreach|
11070198|NCT04284553|Experimental|Order Entry + Simplified|
11070199|NCT04284553|Experimental|Open Encounter + Simplified|
11070200|NCT04284553|Experimental|Order Entry + Sign-off alert|
11070201|NCT04284553|Experimental|Open Encounter + Sign-off alert|
11070202|NCT04284553|Experimental|Order Entry + Pre-commitment|
11070203|NCT04284553|Experimental|Open Encounter + Pre-commitment|
11070204|NCT04284553|Experimental|Order Entry + Different Risks|
11070205|NCT04284553|Experimental|Open Encounter + Different Risks|
11070206|NCT04284553|Experimental|Standard Epic Basic Alert|
11070207|NCT04284553|No Intervention|No Alert (Usual Care)|
11070208|NCT04284540|Experimental|Adjuvant Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have undergone surgery
11070209|NCT04284540|Experimental|Definitive Hypofractionated Radiation Treatment|Short course radiation therapy for patients who have not had surgery
11070210|NCT04284514|Experimental|AKB-9778 Ophthalmic Solution|Up to 4 daily dose levels of AKB-9778 Ophthalmic Solution will be evaluated. Doses will be administered in both eyes daily for 7 days.
11070211|NCT04284514|Placebo Comparator|Vehicle Control Ophthalmic Solution|Matched vehicle-control ophthalmic solution will be administered in both eyes daily for 7 days.
11070212|NCT04284501||Study|children with Migraine headache
11070213|NCT04284501||Control|Healthy children
11070214|NCT04284488|Experimental|APG-1387 in combination with Toripalimab|
11070215|NCT04284462|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
11070216|NCT04284462|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
11070217|NCT04284462|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
11070218|NCT04284462|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
11070219|NCT04284462|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
11070220|NCT04284462|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
11070221|NCT04284449||Enrolled Participants|This is a whole-practice precision medicine model in which a participant-specific Naturopathic treatment program is developed and implemented for older adults with cognitive complaints.
11070222|NCT04284436|Experimental|High Intensity Exercise|Treadmill exercise 4x per week at 80-85% HRmax.
11070223|NCT04284436|Active Comparator|Moderate Intensity Exercise|Treadmill exercise 4x per week at 60-65% HRmax.
11070224|NCT04284410|Experimental|CLASP-PE arm|
11070225|NCT04284397|Experimental|Critical Temperature 10 Torr (Lighter)|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070226|NCT04284397|Experimental|Critical Temperature 14 Torr (Lighter)|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070227|NCT04284397|Experimental|Critical Temperature 18 Torr (Lighter)|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070228|NCT04284397|Experimental|Critical Temperature 10 Torr (Light)|Subjects will perform exercise at ~300W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070229|NCT04284397|Experimental|Critical Temperature 14 Torr (Light)|Subjects will perform exercise at ~300W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070230|NCT04284397|Experimental|Critical Temperature 18 Torr (Light)|Subjects will perform exercise at ~300W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070231|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Lighter)|Subjects will perform exercise at ~200W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070232|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Lighter)|Subjects will perform exercise at ~200W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070260|NCT04284267|No Intervention|Healthy Control|This group consists of individuals with no psychiatric diagnosis.
11071107|NCT04278482|Active Comparator|DHA supplement|Supplement rich in DHA form algae source
11070234|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Light)|Subjects will perform exercise at ~300W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070235|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Light)|Subjects will perform exercise at ~300W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070236|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Light)|Subjects will perform exercise at ~300W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070237|NCT04284397|Experimental|Critical Temperature 10 Torr (Lighter) w/ Aspirin|Subjects will perform exercise at ~200W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070238|NCT04284397|Experimental|Critical Temperature 14 Torr (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070239|NCT04284397|Experimental|Critical Temperature 18 Torr (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070240|NCT04284397|Experimental|Critical Temperature 10 Torr (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient water vapor pressure set at 10 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070241|NCT04284397|Experimental|Critical Temperature 14 Torr (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient water vapor pressure set at 14 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070242|NCT04284397|Experimental|Critical Temperature 18 Torr (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient water vapor pressure set at 18 Torr. Ambient temperature will increase by 1 degree Celsius every 5 min until core temperature begins to rise.
11070243|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070244|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070245|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Lighter) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~200W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070246|NCT04284397|Experimental|Critical Vapor Pressure 26 Degrees (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient temperature set at 26 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070247|NCT04284397|Experimental|Critical Vapor Pressure 30 Degrees (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient temperature set at 30 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070248|NCT04284397|Experimental|Critical Vapor Pressure 34 Degrees (Light) w/ Aspirin|After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will perform exercise at ~300W with ambient temperature set at 34 degrees Celsius. Ambient water vapor pressure will increase by 1 Torr every 5 minutes until core temperature begins to rise.
11070249|NCT04284384||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years of age or older were invited to participate in HUNT4 70+.
11070250|NCT04284384||HUNT Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age or older were invited to participate in HUNT4 70+.
11070251|NCT04284358|No Intervention|Standard Instruction workshop|Standard instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and then attempt it themselves.
11070252|NCT04284358|Experimental|Technology Integrated Instruction workshop|Technology integrated instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application.
11070253|NCT04284345|Experimental|Saline Pd/Pa|Eligible subjects will undergo invasive coronary physiology measurements including whole cycle resting Pd/Pa, iFR, RFR, cFFR, Saline Pd/Pa and FFR
11070254|NCT04284319|Experimental|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
11070255|NCT04284293|Experimental|Group 1A|"Visual acuity of 20/200 or worse
~Single, unilateral, subretinal injection of 300,000 CNS10-NPC (n=3)"
11070256|NCT04284293|Experimental|Group 1B|"Visual acuity of 20/200 or worse
~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=3)"
11070257|NCT04284293|Experimental|Group 2|"Visual acuity between 20/80 and 20/200
~Single, unilateral, subretinal injection of 1,000,000 CNS10-NPC (n=10)"
11070258|NCT04284280|Experimental|Early Routine Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) when feeds of 150 ml/kg/day are reached (120Kcal/kg/day)
11070259|NCT04284280|Active Comparator|Selective Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) only for weight gain less than 15g/kg/day after full feeds of 180 ml/kg/day are achieved (120 Kcal/kg/day). If milk of any infant in the selective fortification group gets fortified the volume will be decreased to 150 ml/kg/day to keep the total caloric intake equal.
11070261|NCT04284267|Experimental|Bipolar Group: Low-Dose TMS|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive low-dose TMS (i.e., 600 pulses).
11070262|NCT04284267|Experimental|Bipolar Group: High-Dose TMS|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive high-dose TMS (i.e., 1800 pulses).
11070263|NCT04284267|Sham Comparator|Bipolar Group: Sham TMS|This group consists of individuals with a diagnosis of bipolar disorder who have been randomized to receive sham TMS (i.e., not actual stimulation is applied though the sensations of actual stimulation are mimicked).
11070264|NCT04284254|Experimental|Phase 1: Dose Escalation|
11070265|NCT04284254|Experimental|Phase 2 - Expansion at MTD|
11070266|NCT04284241|Experimental|Intervention group|"Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. Parents also undergo and active health education by the investigator with the  Parents' Health-Education Handbook, and Handbook will be given to them. Handbook includes the knowledge of symptoms, hazards, epidemiology, risk factors, therapy, and prevention of pediatric urolithiasis, and also baby's right feeding methods. Follow up is made every year in the first three years, and the program is done as the baseline."
11070267|NCT04284241|No Intervention|Control group|Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Newborns' parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. But parents do not undergo active health education. And Handbook will not be given to them. However, a poster which has the same content as the Handbook is normally displayed in the maternity ward. Parents have the opportunity to see the poster, but without any special remind. Follow up is made every year in the first three years, and the program is done as the baseline.
11070268|NCT04284228|Experimental|Safety Evaluation Phase|Treatment with NEXI-001 T cells, derived from PBMCs of original HLA- matched HCT donor.
11070269|NCT04284228|Experimental|Dose Expansion Phase|Dose Expansion Phase to further define the safety, tolerability and initial anti-tumor efficacy of the NEXI-001 T cell product at the dose established from the Safety Evaluation Phase.
11070270|NCT04284215|Experimental|Albumin paclitaxel|"Albumin paclitaxel 40mg/m2/week was injected into normal saline at the same time as radiotherapy, once a week. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)] Repeat every cycle (21-28 days/cycle, minimum 2 cycles).
~Three-dimensional radiotherapy:
~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
11070271|NCT04284215|Active Comparator|Paclitaxel|"Paclitaxel 175 mg/m2 was injected into saline solution on the first day. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and on the second day. (Because toxicity and heart problems can replace DDP)]Repeated every cycle (21-28 days/cycle, minimum 2 cycles).
~Three-dimensional radiotherapy:
~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
11070272|NCT04284202|Experimental|PD-1 plus Dasatinib|
11070273|NCT04284176|Experimental|Mirrow therapy and action-observation therapy|
11070274|NCT04284176|Experimental|Action-observation therapy|
11070275|NCT04284163|Experimental|Gamification group|Problem solving based methodology
11070276|NCT04284163|Active Comparator|Traditional teaching group|Master lesson methodology
11070277|NCT04284150|Experimental|dexmedetomidine or Midazola treat supraventricular tachycardia|Comparison of efficacy of dexmedetomidine and Midazolam in the treatment of SVT
11070278|NCT04284137|Experimental|Modified FE-SaLiR|FE-SaLiR is based on modified Ba Duan Jin and Wu Qin Xi exercises that include low to moderate intensity age-tailored activities targeting different parts of the body, integrating breathing and mindfulness. A trained Community Health Worker will serve as the class instructor.
11070279|NCT04284137|Experimental|Unmodified Chinese Medicine Exercise|The Ba Duan Jin and Wu Qin Xi low- to moderate- intensity exercises published by the General Administration of Sport of China. A trained Community Health Worker will serve as the class instructor.
11070280|NCT04284137|Active Comparator|Active Control|The active control program is a health education program for attention control. The participants will learn knowledge and skills about healthy aging and nutrition in a group with hands-on activities.
11070281|NCT04284124|Active Comparator|Erector Spinae block|Done unilaterally with the patient in the prone position about 20 min before induction of general anesthesia. Skin is prepared by 10% povidone iodine. An ultrasound machine with a large bandwidth, multifrequency convex probe (1-8 MHz) will be used for block performance. A 22G, 50-mm, at the T4 level of the spine using an in-plane approach. Probe is placed 2-3 cm laterally to the spine using a sagittal approach. Once the erector spinae muscle and the transverse processes is identified, the needle will be inserted deep into the muscle. The needle will be directed from a cranial to a caudal direction. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of local anesthetic, 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic will be observed in both cranial and caudal directions.
11070282|NCT04284124|Active Comparator|PECS type II block|Done unilaterally, patient is put in the supine position with ipsilateral arm abducted and externally rotated with elbow flexed 90 degrees. High frequency probe is put in the ipsilateral clavipectoral triangle between the clavicle medially and above and the shoulder joint laterally. The pectoralis major and minor and the plane between them are identified guided by pulsating thoracoacromial artery or its pectoral branch. Needle is advanced in plane targeting the space where the artery is located, 2ml of normal saline is injected to confirm the location. Then, 10 ml of bupivacaine 0.25% is injected. Probe is moved laterally and caudally towards the anterior axillary fold parallel to the deltopectoral groove till the serratus muscle slips appear underneath the pec minor attached to the underlying ribs. Targeting the plane between pec minor and serratus at the level of the third rib, 2 ml of normal saline is injected for confirmation of the needle tip then 20 ml of bupivacaine 0.25%.
11070382|NCT04283526|Experimental|MBG453|treatment with MBG453
11070283|NCT04284111||Children with myopia|"A total of 1,000 children from 8 hospitals in China is required to undergo ophthalmic examinations and complete questionnaires at baseline and
~1yr after wearing ortho-k lenses."
11070284|NCT04284098|Placebo Comparator|GA group|Group I (GA group): Standard general anesthesia (GA) .
11070285|NCT04284098|Active Comparator|Bupivacaine group|Group II (B group): ultrasound-guided PECS block using bupivacaine 0.25% + standard GA.
11070286|NCT04284098|Active Comparator|Dexmedetomidine&bupivacaine group|Group III (D group): ultrasound-guided PECS block using bupivacaine 0.25% and Dexmedetomidine 1µg/kg+standard GA.
11070287|NCT04284085|Experimental|Intervention group|There will be psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
11070288|NCT04284085|No Intervention|Control group|They will receive a fact sheet on suicide and also tips on how to increase suicidal ideation.
11070289|NCT04284072|Experimental|All subjects|Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.
11070290|NCT04284059|Active Comparator|vitamin AD group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin A 6000 IU/day and vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks.
11070291|NCT04284059|Experimental|vitamin D group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks. After the study, vitamin D group will be administrated with vitamin A on the basis of serum retinol concentration after the study.
11070292|NCT04284059|Placebo Comparator|placebo group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive placebo once a day in addition to methylphenidate for 8 weeks. After the study, the placebo group will be prescribed with vitamin A and vitamin D supplementation on the grounds of retinol and 25 (OH)D concentration.
11070293|NCT04284046||High CT score|
11070294|NCT04284046||Low CTscore|
11070295|NCT04284033|Experimental|Standard then Extended Infusion Set|Participants will start with wearing the standard infusion set for up to 7 days, then switch to the Extended Wear infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
11070296|NCT04284033|Experimental|Extended then Standard Infusion Set|Participants will start with wearing the Extended Wear infusion set for up to 7 days, then switch to the standard infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
11070297|NCT04284020|Experimental|Educational program & pelvic floor muscle training|"The educational strategy will consist of explaining a healthy lifestyle guide with videos, mobile apps and activities about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, high impact sports, constipation, smoking, or drinking too much caffeine and alcohol. They will also instruct in toilet habits.
~The pelvic floor muscle training (PFMT) protocol will be applied. Participants will perform exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.
~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
11070298|NCT04284020|Active Comparator|PFMT group|"They will receive a basic behavioral educational strategy in the first session including pelvic anatomy and physiology, recommendations to avoid risk factors and toilet habits.
~The PFMT protocol will be applied. Participants will perform PFMT exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.
~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
11070299|NCT04284007|Active Comparator|Perineural levobupivacaine with intravenous saline|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous saline.
11070300|NCT04284007|Experimental|Perineural dexamethasone in addition to levobupivacaine|Patients will receive levobupivacaine-dexamethasone in interscalene brachial plexus block plus intravenous saline.
11070301|NCT04284007|Experimental|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous dexamethasone.
11070302|NCT04283994|Experimental|Survey-based Patient/Clinician Jumpstart|The Jumpstart Guide will be developed with two types of data: 1) EHR data; and 2) Survey data. Using automated methods and NLP/ML algorithms, the presence/absence of POLST, advance directives and DPOA documentation will be identified from both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. The survey data will be completed patients or their surrogate/family at enrollment and will provide assessments of the following: a) preferences for discussions about goals of care; b) most important barrier and facilitator for having such discussions; and c) current goals of care. These elements are contained within the Jumpstart guides and the information is tailored to each recipient (i.e., patient, surrogate/family, or clinician).
11070303|NCT04283994|Active Comparator|EHR-based Clinician Jumpstart|The EHR-based Jumpstart Guide will be developed by using automated methods and NLP/ML algorithms to both inpatient and outpatient EHR notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation. It will not include survey-based information.
11070304|NCT04283981|Active Comparator|Control Group|
11070305|NCT04283981|Experimental|Treatment Group|
11070306|NCT04283968|Experimental|Treatment arm|All patients will receive 4 fecal microbial transplantations from healthy donors each 2 weeks apart
11071108|NCT04278482|Placebo Comparator|Placebo|Placebo supplement
11070307|NCT04283968|Placebo Comparator|Placebo followed by treatment arm|All patients will receive 4 placebo fecal transplantations followed by 4 fecal microbial transplantations from healthy donors each 2 weeks apart
11070308|NCT04283942|Experimental|Intermittent Calorie Restriction (ICR)|Eat only instant nutrition bar in two consecutive days each week, 4 sticks / day, 1 for breakfast, 2 for lunch, 1 for dinner. And the total caloric intake is 497.2kcal/day. In the rest 5 days each week, subjects are allowed ad libitum to their usual food.
11070309|NCT04283942|Other|Control|Followed by NAFLD guidelines' recommendation of 25 kcal / kg / day, we only ask them to adjust their daily diet. No experimental foods or drugs are supplied.
11070310|NCT04283929|Experimental|Intervention 1 (Int1)|Facilities assigned to the enhanced package for Int1 will receive alerts and reminders to promote linkage of HIV positives from diagnosis to care.
11070311|NCT04283929|No Intervention|Control 1 (Ctrl1)|Facilities assigned to the Ctrl1 will not receive any additional equipment, software tools, training or other forms of support.
11070312|NCT04283929|Experimental|Intervention 2 (Int2)|Randomise the Intervention 1 group into two additional arms: Intervention 2 (Int2) and Control (Ctrl2). Facilities assigned to Int2 will also receive alerts and reminders to improve lab reporting as part of their enhanced package.
11070313|NCT04283929|No Intervention|Control 2 (Ctrl2)|Facilities assigned to the Ctrl2 will not receive any additional equipment, software tools, training or other forms of support to improve lab reporting as part of their enhanced EMR.
11070314|NCT04283929|Experimental|Intervention 3 (Int3)|Randomise the Intervention 2 group into two additional arms: Intervention 3 (Int3) or Control (Ctrl3). Facilities assigned to Int3 will receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
11070315|NCT04283929|No Intervention|Control (Ctrl3)|Facilities assigned to Ctrl3 will not receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
11070316|NCT04283916||Botox injection|30 consecutive patients will have 300 IU of botulinum toxin injected to six spots in abdominal wall to gain abdominal wall musculature relaxation.
11070317|NCT04283890|Experimental|Phase Ib|
11070318|NCT04283890|Active Comparator|Phase II - Combination treatment|
11070319|NCT04283890|Active Comparator|Phase II - PHP|
11070320|NCT04283877|Experimental|Methylphenidate|30 mg methylphenidate, 60 minutes before testing
11070321|NCT04283877|Placebo Comparator|Control|30 mg of lactose pill, 60 minutes before testing
11070322|NCT04283864||Group A|
11070323|NCT04283864||Group B|
11070324|NCT04283864||Group C|
11070325|NCT04283838|Experimental|Humanistic care|Psychological and physical rehabilitation based humanistic care regimen was used to prevent depression and PTSD in healthcare workers who participated in the treatment of COVID-19.
11070326|NCT04283825|Experimental|Humanistic care|In addition to routine therapy, the combinations of different psychological and physical rehabilitation activities will be applied to the patients.
11070327|NCT04283825|No Intervention|Non-humanistic care|Patients only receive routine therapy.
11070328|NCT04283812|Experimental|D1 Stereotactic System Assessment|Participants in the clinical study will consist of subjects approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic. Subjects will have a Key secured to their skull for attachment of an MRI-compatible localizer box or D1 stereotactic frame. 3D Euclidian distance error(s), trajectory accuracy(s), operating room time, and comfort level of the system will be assessed.
11070329|NCT04283799|Experimental|The new HMF group|Very preterm infants tolerating 80mL/kg/day of enteral feeding for >24 hours are started to receive the new human milk fortifier. Study procedure is from the first day of full-strength fortification feeding to the 21th days of that.
11070330|NCT04283799|No Intervention|Other HMF group|This group is a historical control group using the other HMF. Infants with similar gestational age, birth weight, feeding start time and length of hospitalization are enrolled into the control group.
11070331|NCT04283786||General Practitioner|General Practitioners working within primary care in the UK
11070332|NCT04283786||Primary Care Patients|Patients cared for in primary care who started on oral bisphosphonates within the last 24 months for prevention of fragility fractures
11070333|NCT04283786||Secondary Care Clinicians|Clinicians working in secondary care as specialists (e.g. nurses, consultants) involved in the treatment of osteoporosis
11070334|NCT04283786||Secondary Care Patients|Patients cared for in secondary care receiving hospital based (intravenous) bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months
11070335|NCT04283786||Clinical Academics|Clinical academics involved in osteoporosis research
11070336|NCT04283786||Secondary Care Clinicians - Novel Care|Clinicians working in secondary care as specialists (e.g. nurses, consultants) from the osteoporosis service in Nottingham and Sheffield with insight into alternate bisphosphonate treatments
11070337|NCT04283786||Secondary Care Patients - Novel Care|Patients cared for in secondary care receiving alternative bisphosphonate treatments for prevention of fragility fractures who began treatment within the last 24 months at the osteoporosis service in Nottingham or Sheffield
11070338|NCT04283786||Commissioners|Commissioners involved in osteoporosis services
11070339|NCT04283760||Healthy Group|"Demographic Information
~Mental Chronometry Test
~Movement Imagination Questionnaire- Revised Second
~Beck Depression Inventory"
11070340|NCT04283760||Acute Stroke Patients|"Demographic Information
~Mental Chronometry Test
~Movement Imagination Questionnaire- Revised Second
~Beck Depression Inventory
~Trail Making Test
~Barthel Index
~Motor Assessment Scale
~Trunk Impairment Scale
~Mini Mental Test
~Glaskow Coma Scale"
11070341|NCT04283734|Experimental|Intervention group|Long/diffuse coronary lesion should be evaluated and guided by iFR pullback with Syncvision software to achieve a final iFR of 0.90
11070342|NCT04283734|No Intervention|Control group|Long/diffuse coronary lesion should be treated guided by angiography
11070343|NCT04283721|No Intervention|No Video|These patients will not see the educational video on epidural/spinal analgesia and will receive the usual Irish standard of care.
11070344|NCT04283721|Experimental|Antenatal Video|These patients will see the educational video on epidural/spinal analgesia only at the antenatal classes.
11070345|NCT04283721|Experimental|Labour Video|These patients will see the educational video on epidural/spinal analgesia only at the beginning of labour.
11070346|NCT04283721|Experimental|Video Twice|These patients will see the educational video on epidural/spinal analgesia twice (during antenatal classes and at the beginning of labour).
11070347|NCT04283708|Experimental|Skeletal chin deficiency|Advancement genioplasty with submental liposuction
11070348|NCT04283695|Experimental|Part 1|IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
11070349|NCT04283695|Experimental|Part 2|IV: [14C]-GX-I7 40 µg
11070350|NCT04283695|Experimental|Part 3|IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
11070351|NCT04283682|No Intervention|standard group|Feeding procedures follow clinical nursing practices
11070352|NCT04283682|Experimental|intervention group|At appropriate time to invite mothers of premature infants into the NICU for skin-to-skin and breastfeeding
11070353|NCT04283669|Other|Open Label Continuous Treatment|Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as >20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.
11070354|NCT04283656|Other|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
11070355|NCT04283656|Other|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
11070356|NCT04283656|Other|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
11070357|NCT04283643|Experimental|Healthy Human Subjects|Healthy human subjects will complete study procedures in the research lab at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation.
11070358|NCT04283643|Experimental|Acute Pain Patients|Acute Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
11070359|NCT04283643|Experimental|Chronic Pain Patients|Chronic Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
11070360|NCT04283630|Active Comparator|Randomization and Dietary supplement Interventions|The dietary nitrate supplement was provided in the form of commercial beetroot juice (Sport Beet IT shot, Heartbeet Ltd) for all participants, whereas vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the concentrated beetroot juice with breakfast meals, and then the vitamin C supplement (1000 mg)or placebo at the same time one-hour post beetroot juice supplementation
11070361|NCT04283630|Placebo Comparator|Placebo|Vitamin C placebo was matched with the active vitamin c capsules in shape, color, and size.
11070362|NCT04283617|Experimental|Diabetic with short duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes < 5 years
11070363|NCT04283617|Experimental|Diabetic with long duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes > 5 years
11070364|NCT04283604|Experimental|ADHD with MPH|ADHD participants, taking MPH before the second session
11070365|NCT04283604|No Intervention|ADHD no MPH|ADHD participants will perform motor tests in both session, without any intervention, for evaluation of learning effect among ADHD participants.
11070366|NCT04283604|No Intervention|Healthy participants|Non-ADHD participants will serve as a control group for learning effect on motor tests
11070367|NCT04283591|Experimental|Experimental Intervention|Intervention Group: will be treated with acupuncture on the hemiplegic side's DU 20, EX HN 3 points and bilateral LR 3, LI 4 points twice a week for 4 weeks. They also will continue to receive inpatient stroke rehabilitation.
11070368|NCT04283591|Other|No Intervention|Control Group: will continue to receive a rutin stroke rehabilitation programme but no interventional procedures will be made.
11070369|NCT04283578|Experimental|Oxytocin|intranasal administration of OT
11070370|NCT04283578|Placebo Comparator|Placebo|intranasal administration of placebo
11070371|NCT04283565|No Intervention|Strategy 1: Usual practice|No systematic screening of asymptomatic AOMI and routine management of FRCV.
11070372|NCT04283565|Experimental|Strategy 2: Motivationnal interviewing|No systematic screening of asymptomatic AOMI and management of CVRF by a motivationnal interviewing.
11070373|NCT04283565|Experimental|Strategy 3: Systematic screening of AOMI by BPI measurement|Systematic screening of AOMI by BPI measurement and routine management of FRCV.
11070374|NCT04283565|Experimental|Strategy 4: Both strategies|Systematic screening of AOMI by BPI measurement and management of CVRF by a motivationnal interviewing.
11070375|NCT04283552|Experimental|Dynamic FDG Imaging|-Dynamic PET/CT imaging will begin at approximately the same time as the FDG injection and will continue until approximately the start of the clinical scan
11070376|NCT04283539||CPI with ircAE|Participants on check point inhibitors with immune related cutaneous adverse event
11070377|NCT04283539||no ircAE|Participants who do not have a cutaneous adverse event
11070378|NCT04283526|Experimental|NIS793 + MBG453|treatment with NIS793 + MBG453
11070379|NCT04283526|Experimental|NIS793 + MBG453 + Spartalizumab|Treatment with NIS793 + MBG453 + Spartalizumab
11070380|NCT04283526|Experimental|NIS793 + MBG453 + Decitabine|treatment with NIS793 + MBG453 + Decitabine
11070381|NCT04283526|Experimental|NIS793|treatment with NIS793
11070383|NCT04283513|Experimental|Efficacy of IV Ribavirin|The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
11070384|NCT04283500|Experimental|BUP treatment arm|Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.
11070385|NCT04283487|Experimental|Fructans solution|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody.The fructans solution used in this study is 500 ml water containing 40g fructans
11070386|NCT04283487|Active Comparator|Glucose solution|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a positive control in this study. The glucose solution used in this study is 500 ml water containing 40g glucose.
11070387|NCT04283487|Placebo Comparator|Saline solution|The saline solution does't contain any sugar and used in this study is 500ml 0.9% normal saline.
11070388|NCT04283474|Experimental|XG005-03|XG005-03 in 3 dose levels
11070389|NCT04283474|Placebo Comparator|Placebo|Placebo in all cohort
11070390|NCT04283461|Experimental|Arm 1|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)
11070391|NCT04283461|Experimental|Arm 10|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
11070392|NCT04283461|Experimental|Arm 11|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
11070393|NCT04283461|Experimental|Arm 12|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
11070394|NCT04283461|Experimental|Arm 13|10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
11070395|NCT04283461|Experimental|Arm 2|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
11070396|NCT04283461|Experimental|Arm 3|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
11070397|NCT04283461|Experimental|Arm 4|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
11070398|NCT04283461|Experimental|Arm 5|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
11070399|NCT04283461|Experimental|Arm 6|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
11070400|NCT04283461|Experimental|Arm 7|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
11070401|NCT04283461|Experimental|Arm 8|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
11070402|NCT04283461|Experimental|Arm 9|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
11070403|NCT04283448|Experimental|Lentil|0.66 cups lentils
11070404|NCT04283448|Sham Comparator|Control|0.0 cups lentils
11070405|NCT04283435|Placebo Comparator|estradiol valerate + placebo|preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova) .from the first day of the cycle till 12th day and we add placebo from the first day of the cycle till the day of start progesterone (we stop 3 days before embryo transfer).
11070406|NCT04283435|Experimental|estradiol valerate + Sildenafil citrate|We add Sildenfil citrate 50 mg daily from the first day of the period till the day of starting the progesterone. and stop 3 days before the embryo transfer.
11070407|NCT04283422||patintes on mechanical ventilation|
11070408|NCT04283422||patintes not on mechanical ventilation|
11070409|NCT04283409|Experimental|Motor Control Exercise|The primary goal of motor control exercises is to retrain optimal control and coordination of the spine. It uses principles of motor learning such as segmentation, simplification and task-specific practice to retrain control of trunk muscles activation, alignment and movement. The first stage of the treatment involves assessment of the postures, movement patterns and muscle activation associated with symptoms and a retraining program designed to improve activity of muscles assessed to have poor control (usually the deep trunk muscles). Participants are taught how to contract these muscles independently. During this stage additional exercises for breathing control, posture of spine and movement are performed. The second stage of the treatment involves the progression of the exercises towards functional activities, firstly using static then dynamic tasks. Education is also included.
11070410|NCT04283409|Experimental|Graded Activity|The primary goal of graded activity is to address individual modifiable contextual factors associated with the pain experience such as self-efficacy, pain-related fear, kinesiophobia and unhelpful beliefs/behaviors about back pain while at the same time addressing physical impairments such as endurance, muscle strength and balance. A primary goal of the program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. Activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Cognitive-behavioral principles are used to help patients overcome the natural anxiety associated with pain and activities.
11070445|NCT04283188|Experimental|Adolescents with bipolar disorder|40 adolescents aged 14 to 21 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
11070446|NCT04283175|Other|Neuromuscular disease (MNM) subjects|
11070411|NCT04283383|Experimental|Intervention training|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out, and the improvement of knowledge and skills will be evaluated, as well as the improvement of quality of care based on clinical indicators.
11070412|NCT04283383|No Intervention|control|
11070413|NCT04283370|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
11070414|NCT04283370|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
11070415|NCT04283357|Active Comparator|Exercise Group|One group only treated with short foot exercises.
11070416|NCT04283357|Active Comparator|Virtual Reality Group|The second group treated with virtual reality
11070417|NCT04283344|Experimental|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula: (1) a fixed deduction, depending on county of residence, for transportation costs for six round trips to the grocery store per month; and (2) an earnings deduction equal to 10 percent of earned income for households with at least one employed household member.
11070418|NCT04283344|No Intervention|Control Group|Households in the control group continued to receive their regular monthly SNAP benefit amounts.
11070419|NCT04283331|Experimental|Bandage Contact Lens + Proparacaine|The eye that receives a bandage contact lens soaked in proparacaine.
11070420|NCT04283331|No Intervention|Bandage Contact Lens WITHOUT Proparacaine|The eye that receives a bandage contact lens (standard of care).
11070421|NCT04283318|Other|Healthy|Age >18 years; BMI 20-27 kg/m2; Fasting plasma Glucose <110 mg/dL
11070422|NCT04283318|Other|Obese people|Age >18 years; BMI >30 kg/m2; Fasting Plasma Glucose <110 mg/dL
11070423|NCT04283318|Other|Type 2 Diabetes|Age >18 years; Diagnosed Type 2 Diabetes mellitus (diet or a monotherapy or combination of metformin, DPP-4-inhibitors or sulfonylurea)
11070424|NCT04283318|Other|Type 1 Diabetes|Age >18 years; Diagnosed Type 1 Diabetes mellitus >12 months; Treated with multiple daily Insulin injections (MDII) or continuous subcutaneous Insulin Infusion (CSII); Stable Insulin therapy as clinically assessed by the study physician C-Peptide negative defined as 0.3 nmol/L; No diabetic ketoacidosis within the last 12 months; No severe hypoglycaemia requiring external assistance within the last 12 months; Running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring
11070425|NCT04283305|Experimental|Virtual reality approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training in the virtual reality. Alcoholic beverages are pushed away with a controller and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
11070426|NCT04283305|Active Comparator|Computer-based approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training on the computer. Alcoholic beverages are pushed away with a joystick and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
11070427|NCT04283305|No Intervention|Treatment as usual|Participants will receive treatment as usual on the wards. For ethical reasons, participants in this condition will get the offer to undertake the already scientifically validated computer-based approach avoidance training after their completion of the study.
11070428|NCT04283292|Experimental|Capsaicin|capsaicin 0.075% cream applied once topically
11070429|NCT04283292|Active Comparator|Placebo|placebo cream applied once topically
11070430|NCT04283279|Experimental|Virtual reality exercise|20 participants will be randomised to this arm
11070431|NCT04283279|Experimental|Vestibular rehabilitation exercise|20 participants will be randomised to this arm
11070432|NCT04283279|Other|Control|20 participants will be randomised to this arm
11070433|NCT04283266|Active Comparator|Synbiotic group|The synbiotic was composed of fructo-oligosaccharides (FOS): 4.95 g/ sachet and Bifidobacterium animalis lactis: 5 billion / sachet (n=13)
11070434|NCT04283266|Placebo Comparator|Placebo group|A placebo was composed of maltodextrin (60%) and sucrose (40%) : 5 g /sachet (n =14)
11070435|NCT04283253|Experimental|Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
11070436|NCT04283240|Active Comparator|Sildenafil|50 mg sildenafil oral. One dose
11070437|NCT04283240|Placebo Comparator|Placebo|Placebo pill. One dose
11070438|NCT04283227|Experimental|OTL-200 Gene Therapy|OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
11070439|NCT04283214|Active Comparator|Traditional manikin|CPR performed on a traditional manikin
11070440|NCT04283214|Experimental|Traditional manikin with athletic equipment|CPR performed on a traditional manikin wearing athletic equipment
11070441|NCT04283214|Experimental|Bariatric manikin|CPR performed on a bariatric manikin
11070442|NCT04283214|Experimental|Bariatric manikin with athletic equipment|CPR performed on a bariatric manikin wearing athletic equipment
11070443|NCT04283201|Experimental|Diet|
11070444|NCT04283201|Experimental|Physical activity|
11070449|NCT04283162|Experimental|conventional treatment plus calcium dobesilate|maintain lifestyle habits and the usual treatment, plus the use of calcium dobesilate (500 mg, orally, 3 times per day) for 12 months
11070450|NCT04283162|Active Comparator|conventional treatment group|maintain lifestyle habits and the usual treatment for 12 months
11070451|NCT04283149|Experimental|EVO ICL Surgery for Myopia|Enrolled subjects with myopia will undergo ICL surgery in one or both eyes with EVO MICL model.
11070452|NCT04283149|Experimental|EVO+ ICL Surgery for Myopia|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ MICL model.
11070453|NCT04283149|Experimental|EVO TICL Surgery for Myopia with Astigmatism|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO TICL.
11070454|NCT04283149|Experimental|EVO+ TICL Surgery for Myopia with Astigmatism|Enrolled subjects with myopia and astigmatism will undergo ICL surgery in one or both eyes with EVO+ TICL.
11070455|NCT04283136|Active Comparator|Type 1 tablet - part 1|Subjects will receive a single dose of padsevonil Type 1 tablet in the period defined by the pre-specified sequence they were randomized on to.
11070456|NCT04283136|Experimental|Type 2 tablet - part 1|Subjects will receive a single dose of padsevonil Type 2 tablet in the period defined by the pre-specified sequence they were randomized on to.
11070457|NCT04283136|Experimental|Type 3 tablet - part 1|Subjects will receive a single dose of padsevonil Type 3 tablet in the period defined by the pre-specified sequence they were randomized on to.
11070458|NCT04283136|Experimental|Type 4 tablet - part 1|Subjects will receive a single dose of padsevonil Type 4 tablet in the period defined by the pre-specified sequence they were randomized on to.
11070459|NCT04283136|Experimental|Type 5 tablet - part 1|Subjects will receive a single dose of padsevonil Type 5 tablet in the period defined by the pre-specified sequence they were randomized on to.
11070460|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fasted)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
11070461|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fed)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
11070462|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fasted)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
11070463|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fed)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
11070464|NCT04283123|Experimental|Treatment|Participants assigned to this group will receive an automated bidet (TOTO Washlet S300e with remote control) and an occupational therapy intervention over 3-4 in-home visits.
11070465|NCT04283123|Active Comparator|Waitlist Control|Caregivers will wait for 30 days and then will be offered the intervention.
11070466|NCT04283110|Active Comparator|Midazolam group|Midazolam group will receive 1 mg intrathecal midazolam once during induction for anethesia
11070467|NCT04283110|No Intervention|control group|control group will receive placebo ( 0.5cm of sterile saline
11070468|NCT04283097|Experimental|KPG-818|KPG-818 dose escalation
11070469|NCT04283084|Experimental|Study group|Number of participants in this group is anticipated to be 25. Participants in this group will be receiving 10 minutes of exercise with the virtual reality based balance and coordination training system (MARBES). In the MARBES system two exercises (1. Balance exercise, 2. Coordination exercise) will be played for 5 minutes each.
11070470|NCT04283045|Active Comparator|JASPER (6 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 6 weeks. If child is an early responder, he/she will do JASPER for 30 minutes with TA and 30 minutes of JasPEER (JASPER with two TAs and two students) daily, 5 times a week, for the remaining 18 weeks of the study.
~If child is a slow responder, he/she can get randomized to receive 30 minutes of Structured Teaching and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 18 weeks of the study.
~Or
~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 18 weeks of the study."
11070471|NCT04283045|Active Comparator|JASPER (12 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 12 weeks. If child is an early responder, he/she will do JASPER for 30 minutes with TA and 30 minutes of JasPEER (JASPER with two TAs and two students) daily, 5 times a week, for the remaining 12 weeks of the study.
~If child is a slow responder, he/she can get randomized to receive 30 minutes of Structured Teaching and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 12 weeks of the study.
~Or
~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 12 weeks of the study."
11070472|NCT04283032||Multiparametric magnetic resonance + transrectal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)
11070473|NCT04283032||Multiparametric magnetic resonance + transperineal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)
11070474|NCT04283032||Transrectal biopsy|The patient underwent a transrectal biopsy (BPTE)
11070475|NCT04283032||Transperineal biopsy|The patient underwent a transperineal biopsy (BPTP)
11070476|NCT04283019|Experimental|CBD without THC|oral formulation containing 100mg CBD and 0mg THC
11070477|NCT04283019|Experimental|CBD with 3.7 mg THC|oral formulation containing 100mg CBD and 3.7mg THC
11070478|NCT04283019|Experimental|CBD with 2.8 mg THC|oral formulation containing 100mg CBD and 2.8 mg THC
11070479|NCT04283006|Experimental|Administration of CD20/CD22 dual Targeted CAR T-cells|A dose levels of 3-5*10E6/kg are administrated for each subject.
11070480|NCT04282993|Experimental|Wearable Devices Monitoring|Patients will be provided with wearable devices for at-home monitoring heart rhythm and rate, blood pressure, pulse oximetry, quality and quantity of sleep, and pace counting.
11070481|NCT04282993|Active Comparator|Standard of Care Monitoring|Patients will be evaluated by periodical clinical visits.
11070482|NCT04282980|Experimental|DCC-2618|DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.
11070483|NCT04282967|Experimental|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
11070484|NCT04282954|Experimental|Group 1|JP-1366 A mg
11070485|NCT04282954|Experimental|Group 2|JP-1366 B mg
11070486|NCT04282954|Experimental|Group 3|JP-1366 C mg
11070487|NCT04282954|Active Comparator|Goup 4|Esomeprazole 40 mg
11070488|NCT04282941|Experimental|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
11070489|NCT04282941|Experimental|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
11070490|NCT04282928|Active Comparator|Routine treatment group|"Participants will receive the treatment according to the treatment principle of severe and critical cases in Influenza diagnosis and treatment plan (2019 version)"
11070491|NCT04282928|Experimental|HUC-MSCs adjuvant Group|Participants will receive intravenous infusion of definitive HUC-MSCs (1×10^6 cells/Kg × body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment.
11070492|NCT04282915|Active Comparator|Implementation as Usual|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme adapted by the Nepal Ministry of Health.
11070493|NCT04282915|Experimental|RESHAPE|Primary care providers will be trained in the 7-day curriculum of the mental health Gap Action Programme, plus they will have co-facilitation by mental health service users providing recovery testimonials as well as aspirational figures presenting testimonies and conducting myth-busting sessions.
11070494|NCT04282902|Experimental|Pirfenidone group|This study was designed to randomize approximately 147 adult subjects.The patients were stratified according to whether the onset time was less than 14 days, and randomly divided into groups at a ratio of 1:1. The group received pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer.
11070495|NCT04282902|No Intervention|Standard treatment group|This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤ 14 days and randomly divided into groups of 1: 1. This group only receives standard treatment
11070496|NCT04282889||Liver transplantation group|"The study population will include 20 adults (age range of 18 - 75 years) who are undergoing liver transplantation. Inclusion criteria are patients undergoing liver transplantation with English as their native language.
~Exclusion criteria include patient's refusal, or on medical anticoagulation therapy. Informed consents will be obtained from the patients who agree to participate in this clinical study."
11070497|NCT04282889||Healthy volunteer|The control population will include 20 adult volunteers (age 18-65 years) who meet the in the American Society of Anesthesiologists (ASA) Physical Status (PS) Classes 1 criteria. Exclusion criteria will be refusal, volunteers on any medication or significant history of bleeding.
11070498|NCT04282876||Degarelix|Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
11070499|NCT04282876||Control|Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
11070500|NCT04282863|Active Comparator|robotic-assisted laparoscopic myomectomy (RM)|After randomization, participants who are assigned to the robotic-assisted laparoscopic myomectomy (RM) agree to receive RM.
11070501|NCT04282863|Placebo Comparator|Conventional laparoscopic myomectomy (LM)|After randomization, participants who are assigned to the Conventional laparoscopic myomectomy (LM) agree to receive LM.
11070502|NCT04282850|Experimental|Pulmonary Vein Isolation (PVI) Group|Subjects randomized to this treatment arm will undergo atrial fibrillation ablation, and undergo routine post-procedural follow-up.
11070503|NCT04282850|No Intervention|Medical Management|Subjects randomized to this treatment arm will undergo medical management of the arrhythmia, but will not undergo invasive electrophysiologic procedures to address subject's AF.
11070504|NCT04282837||NW|normal weight control
11070505|NCT04282837||MHO|metabolic healthy obesity
11070506|NCT04282837||LMO|hypometabolic obesity
11070507|NCT04282837||HMO-U|hypermetabolic obesity with hyperuricemia
11070508|NCT04282837||HMO-I|hypermetabolic obesity with hyperinsulinemia
11070509|NCT04282824|Experimental|Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
11070510|NCT04282824|Experimental|Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
11070511|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
11070567|NCT04282343|Other|Arm II - DISCO app|Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans.
11070604|NCT04282057|Experimental|shockwave therapy group|This group performed aerobic exercise just after shock wave therapy in the abdominal region.
11070605|NCT04282057|Experimental|radiofrequency group|This group performed aerobic exercise just after radiofrequency in the abdominal region.
11070512|NCT04282798|Experimental|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
11070513|NCT04282785||Cohort of patients with severe infections|Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim
11070514|NCT04282772||Ectopic Eruption|The ectopic eruption of PFMs were classified in two ways: impacted and self-corrected.
11070515|NCT04282746|Experimental|JNJ-54135419|Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions.
11070516|NCT04282733|Experimental|Mindfulness Rounds|Participants will be exposed to thrice weekly Mindfulness Rounds education on the Unit; participation in the actual sessions is voluntary.
11070517|NCT04282733|No Intervention|Control|No intervention will take place on this Unit
11070518|NCT04282720|Other|SurgiMend Mesh|"SurgiMend Mesh - FDA approved noncross-linked bovine dermis biologic mesh. SurgiMend Mesh will be used according to FDA approved recommendations for the use of abdominal wall hernia reinforcement.
~SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend is specifically indicated for:
~Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias."
11070519|NCT04282707|Experimental|Endoscopic closure|Prospectively collected patients for gastric ESD and would undergo closure of defect
11070520|NCT04282707|Other|Historical control|Historical control of patients who underwent gastric ESD
11070521|NCT04282694||High risk (former) smokers|"Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
~Inclusion criteria
~Age between 50 and 75 years
~Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
~Status of current smoker or ex-smoker for <10 years.
~Exclusion criteria
~• Personal history of cancer within the prior 5 years"
11070522|NCT04282668|Experimental|TAS1440|TAS1440 as a single agent administered once daily (QD) on specific days during each 28-day cycle in Part 1.
11070523|NCT04282668|Experimental|TAS1440 + ATRA|TAS1440 administered QD on specific days during each 28-day cycle in combination with ATRA twice daily (BID) in Part 2.
11070524|NCT04282655|Active Comparator|Control|Standard method of warming breast milk in a hot water bath prior to feeding.
11070525|NCT04282655|Experimental|Treatment Guardian Milk Warmer (Medela TM)|External continuous milk warmer that heats milk within the tubing just posterior to the feeding tube to provide milk at body temperature for feeding infusion.
11070526|NCT04282642|Experimental|Cognitive Training|Computerized Cognitive Training
11070527|NCT04282642|Experimental|WLC|Waitlist Control
11070528|NCT04282629|Experimental|Milrinone|"milrinone group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on MRI. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely."
11070529|NCT04282629|Placebo Comparator|Standard Care|The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on MRI. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.
11070530|NCT04282616|Experimental|Home-based unstructured physical activity program|According to each patient's baseline physical activity level, the facilitator will advise patients to start or to increase their spontaneous activity by giving counselling on total exercise time, mode, intensity and frequency as suggested by the American College of Sport Medicine guidelines. Every patient will be provided with a log-book and a wearable physical activity monitor, which has to be returned in the subsequent controls, to favor adherence and objectively measure the exercise activities
11070531|NCT04282616|Experimental|Home-based structured low-intensity physical activity program|According to each patient's baseline physical activity level, a semi-personalized walking program, will be provided. This program, derived from previous experience on renal patients, includes a 10-min session/day of intermittent walking (1- or 2-min work and 1-min seated rest) to be performed at home at prescribed speed. The speed, converted into walking cadence and followed by a metronome, is weekly increased. Patients will be provided with a daily log containing the detailed exercise prescription and spaces to give a feedback on training execution and related symptoms.
11070599|NCT04282109|Active Comparator|Arm 2|ERBITAX (cetuximab + paclitaxel, follow by maintenance with cetuximab)
11070600|NCT04282096|Experimental|Caseine micellar|
11070601|NCT04282096|Other|Sodium Casein|
11070602|NCT04282096|Other|Calcium casein|
11070606|NCT04282057|Active Comparator|control group|This group only performed aerobic exercise.
11070532|NCT04282616|Experimental|In-hospital structured supervised physical activity program|"Patients will join the room properly equipped for the exercise program in groups of maximum four subjects for a 2-time/week thirty minutes training sessions, to be performed for dialysis patients immediately before or after the dialysis treatment, or in non-dialysis according to their preferences.
~Each sessions will include low-intensity walking exercises (similar to the structured home-based training), resistance and power exercises with elastic bands and light weights. Each sessions will begin and end with a warm-up and cool-down period of stretching. The total duration of the session will be about 30 minutes. Rate of perceived exertion will be collected and the training intensity will be set according to the patient's baseline capacity and weekly increased."
11070533|NCT04282616|No Intervention|No-training|Patients choosing this option will not start any physical activity program, but they will perform the outcome measures, acting as a control group.
11070534|NCT04282603|Experimental|Experimental Meal Replacement|Participants randomized to this arm will consume 5 servings/day of experimental meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of experimental meal replacement for 12 weeks during the weight maintenance portion of the trial.
11070535|NCT04282603|Active Comparator|Bariatrics Advantage Meal Replacement|Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.
11070536|NCT04282590|Experimental|Treatment Period 1: TRK-750, Treatment Period 2: placebo|
11070537|NCT04282590|Experimental|Treatment Period 1: placebo, Treatment Period 2: TRK-750|
11070538|NCT04282577||patients with chron's disease|
11070539|NCT04282577||patients with ulcerative cholitis|
11070540|NCT04282564|Experimental|CO-OP Arm (early phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 3 weeks.
11070541|NCT04282564|Experimental|CO-OP Arm (mid phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2.5 weeks.
11070542|NCT04282564|Experimental|CO-OP Arm (late phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2 weeks.
11070543|NCT04282551|Experimental|oligosaccharide group 1|
11070544|NCT04282551|Experimental|oligosaccharide group 2|
11070545|NCT04282551|Placebo Comparator|placebo group|
11070546|NCT04282538|Active Comparator|Group A - Active|Active rTMS for Gait Dysfunction of Hemiplegia
11070547|NCT04282538|Sham Comparator|Group A - Sham|Sham rTMS for Gait Dysfunction of Hemiplegia
11070548|NCT04282538|Active Comparator|Group B - Active|Active tDCS for Frontal Gait Dysfunction
11070549|NCT04282538|Sham Comparator|Group B - Sham|Sham tDCS for Frontal Gait Dysfunction
11070550|NCT04282512|Experimental|Group A : sodium bicarbonate-rich mineral water and tap water|"First 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
~15-days washout period Last 15-days period with daily intake of 1.5l of tap water."
11070551|NCT04282512|Experimental|Group B : tap water and sodium bicarbonate-rich mineral water|First 15-days period with daily intake of 1.5l of tap water. 15-days washout period Last 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
11070552|NCT04282499|Experimental|combined exercise|combined exercise (aerobic+resistance training)
11070553|NCT04282499|Active Comparator|aerobic exercise|aerobic exercise only
11070554|NCT04282473||with mesh|Placement of lightweight (<50g/m2) monofilament mesh during colostomy formation
11070555|NCT04282473||no mesh|colostomy without mesh placement
11070556|NCT04282460|Experimental|Baduanjin practice|Baduanjin practice group will be asked to use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
11070557|NCT04282460|Active Comparator|Regular physical exercise|The regular physical exercise group will be asked to take physical exercise for at least half an hour every day in addition to regular physical activities at school.
11070558|NCT04282408|Experimental|Treatment|Group treated with 3D printed brace
11070559|NCT04282395|Experimental|Resilience-Based Diabetes Self-Management Education|The RB-DSME structure involves 8 weekly classes, 8 bimonthly support group sessions, and 2 booster sessions. The RB-DSME builds on foundational resilience resources (e.g., self-efficacy, social support), infusing novel resilience resources (e.g., adaptation to stress, finding positive meaning, spiritual coping) into the RB-DSME curriculum.
11070560|NCT04282395|Active Comparator|Standard Diabetes Self-Management Education|The scope and sequence of the standard diabetes self-management education (DSME) curriculum are aligned with national standards of the American Diabetes Association. DSME groups receive a 10-month intervention: 8 weekly educational sessions, followed by 8 bimonthly support group sessions, followed by 2 booster sessions.
11070561|NCT04282369|Active Comparator|HHFNC|In this group patients will receive respiratory support by high flow nasal cannula.
11070562|NCT04282369|Active Comparator|nCPAP|In this group patients will receive respiratory support by nasal CPAP.
11070563|NCT04282369|Active Comparator|nIPPV|In this group patients will receive respiratory support by nasal IPPV.
11070564|NCT04282369|Active Comparator|nHFO|In this group patients will receive respiratory support by nasal high frequency oscillatory. ventilation.
11070565|NCT04282356|Experimental|Intraperitoneal chemotherapy|Cisplatin 100mg/m2 during surgery IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8 after surgery with at least 3 courses performed (up to 4-6 allowed)
11070566|NCT04282343|Other|Arm I- Usual care|Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plans.
11070603|NCT04282070|Experimental|SHR-1701|R/M NPC subjects failure after 2 lines of chemotherapy or after anti PD-1/PD-L1 antibody therapy.
11070568|NCT04282330|Other|CEST imaging performed|CEST imaging will be performed (15 min): Axial 3D volume acquisition at 3.5 mm isotropic voxel size, 20-30 offset frequencies, plus Axial 3D T1w and T2w map at same resolution for use in CEST quantification. A routine stroke MRI protocol will also be performed (10 min): Axial T2w; Axial DWI and ADC (apparent diffusion coefficient) using accelerated multi-band sequence; Axial T2w* or SWI (susceptibility weighted imaging); and dynamic susceptibility contrast-enhanced (DSC) perfusion imaging following contrast agent administration (5 min, provided Radiology Department protocols allow DSC (e.g. no renal impairment)).
11070569|NCT04282317|Other|Healthy Volunteer|This arm will enroll healthy volunteers as controls
11070570|NCT04282317|Other|Gastroparesis Subjects|This arm will enroll a) patients with gastroparesis from type 1 diabetes and b) patients with gastroparesis from vagus nerve trauma
11070571|NCT04282304|Other|Usual Care|The patients in this arm will have usual care during preoperative period, bariatric surgery and follow-up.
11070572|NCT04282304|Experimental|UGECAM|During the preoperative period, the patients in this arm will have usual care and a 4 weeks intensive, comprehensive behavioral lifestyle intervention. They will then have usual bariatric surgery and follow-up.
11070573|NCT04282291||SIPB (block)|patients who underwent a modified BRILMA (intercostal rami block, middle axilary line) ultrasound-guided block with portable device with lineal probe and needle 80 mm. With the patient lying supine, the probe was placed in the sagittal plane of the middle axillary line to identify the aim thoracic structures. Under aseptic conditions, the needle was inserted in plane, caudo-craneal, to reach the fascial plane between the serratus anterior muscle and the external intercostal muscle at the eighth rib. A bolus dose of levobupivacaine 0.25% was administered, 3 ml of local anesthetic for each segment we want to block
11070574|NCT04282291||control (morphine)|PCA (patient controlled analgesia) morphine was initiated immediately postoperatively using CADD Smith Medical pumps. All patients received PCA-morphine with the initial dose being 0.5-1 mg. The bolus dose was 0.01mg/kg mg morphine, with lockout time interval of 15 - 30 min, limiting of 8mg/hour, as the default program. The continuous (basal) dose was increased after 12-24 hours if using frequent demand doses or if pain not controlled and decreasing if no bolus was taken.
11070575|NCT04282278|Experimental|Group A|
11070576|NCT04282278|Experimental|Group B|
11070577|NCT04282278|Experimental|Group C|
11070578|NCT04282265|Placebo Comparator|Placebo|
11070579|NCT04282265|Experimental|Red Spinach Extract|
11070580|NCT04282252|Experimental|IV fluid restriction group|"No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:
~In case of severe hypoperfusion or severe circulatory impairment defined by:
~Lactate 4 mmol/L or above or mean arterial blood pressure below 50 mm Hg or mottling beyond the kneecap or urinary output less than 0.1 mL/kg bodyweight/h, but only in the first 2 hours after randomisation. A bolus of 250-500 mL of IV crystalloid solution may be given.
~In case of overt fluid losses (eg, vomiting, large aspirates, diarrhoea, drain losses, bleeding or ascites tap) IV fluid may be given to correct for the loss.
~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to correct dehydration or electrolyte imbalances and/or to ensure a total fluid input of 1 L per 24 hours."
11070581|NCT04282252|Active Comparator|Standard care group|There will be no upper limit for the use of IV or oral/enteral fluids. In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
11070582|NCT04282239|Experimental|Pectoral nerves block type 2 (PECS2)|The intervention is the PECS2 block, a previously developed modality for preventing pain in the anterior chest. The medication used in the block is Ropivicaine 0.5%, Lidocaine 1% + 1:100,000 epinephrine, and 40 μg dexmedetomidine. Patients will receive a standard post-operative pain regimen per institutional protocol.
11070583|NCT04282239|No Intervention|Control Group: standard post-operative pain regimen|Patients will receive a standard post-operative pain regimen per institutional protocol.
11070584|NCT04282226|Active Comparator|active tVNS|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical
11070585|NCT04282226|Placebo Comparator|sham tVNS|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
11070586|NCT04282213||Control samples|For each case, neuromuscular measurements gathered with GE CARESCAPE B450 monitor (E-NMT module).
11070587|NCT04282213||Case samples|For each case, neuromuscular measurements gathered with TOFCuff monitor.
11070588|NCT04282200|No Intervention|Standard of Care|Patients receiving standard of care pain management including opioids.
11070589|NCT04282200|Active Comparator|Ketorolac|Patients will receive standard of care pain management plus intravenous ketorolac.
11070590|NCT04282187|Experimental|Treatment (decitabine, ruxolitinib, fedratinib)|Patients receive decitabine IV QD over 1 hour on days 1-10, and either ruxolitinib PO BID or fedratinib PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11070591|NCT04282174|Experimental|Regimen A|Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: Hyperfractionated total body irradiation to dose of 1375cGy fractions at 4-6 hour intervals three times a day for a total of 11 or 12 doses depending on age and disease risk, followed by Thiotepa 5mg/kg/day x 2 (or 10mg/kg/day x 1) and cyclophosphamide 60mg/kg/day x 2 (or Fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
11070592|NCT04282174|Experimental|Regimen B|Regimen B: Busulfan/Melphalan/Fludarabine: Busulfan 0.8mg/kg/dose every six hours x 10-12 doses (depending on disease), Melphalan 70mg/m2/day x 2 and Fludarabine 25mg/m2/day x 5.
11070593|NCT04282161|Experimental|Axys EX device|
11070594|NCT04282148|Experimental|ABT NG DES 48 EECSS|Participants will receive ABT NG DES 48 EECSS device
11070595|NCT04282135||Infected|patients with detected Influenza RNA in nasopharyngeal swabs
11070596|NCT04282135||not infected|patients without detected Influenza RNA in nasopharyngeal swabs
11070597|NCT04282135||SARS CoV2|patients with SARS-Cov-2 infection
11070598|NCT04282109|Experimental|Arm 1|NIVOTAX (nivolumab + paclitaxel, follow by maintenance with nivolumab)
11070607|NCT04282044|Experimental|Dose Escalation|Dose escalation cohort for treatment of solid tumors that are relapsed, refractory or intolerant to standard care, or refusing standard therapies.
11070608|NCT04282031|Experimental|phase 1 (dose escalation)|Participants will first receive single dose BPI-1178 orally at dose levels of 25mg, 75mg, 150mg, 250mg and 400mg followed by a 7-day washout period , and then start receiving the 28 days/cycle continuous treatment until disease progression or unacceptable toxicity.
11070609|NCT04282031|Experimental|phase 2a cohort A|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with fulvestrant for 3 weeks followed by 1 week off as a treatment cycle, until disease progression or unacceptable toxicity.
11070610|NCT04282031|Experimental|phase 2a cohort B|Participants will receive BPI-1178 at dose levels of MTD, MTD-1 or MTD-2 in combination with letrozole for 3 weeks followed by 1 week off as a treatment cycle, until disease progression or unacceptable toxicity.
11070611|NCT04282018|Experimental|Part A: BGB-10188 Monotherapy Dose Escalation|BGB-10188 capsules administered orally once daily (QD) in 5 cohorts of escalating doses
11070612|NCT04282018|Experimental|Part B: BGB-10188 + Zanubrutinib Dose Escalation|BGB-10188 capsules administered orally QD at a dose level less than RP2D and RP2D in combination with zanubrutinib 160mg (2*80mg capsules) administered orally twice daily (BID)
11070613|NCT04282018|Experimental|Part C: BGB-10188 + Zanubrutinib Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part B in combination with zanbrutinib 160mg (2*80mg capsules) administered orally BID
11070614|NCT04282018|Experimental|Part D: BGB-10188 + Tislelizumab Infusion Dose Escalation|BGB-10188 capsules administered orally QD in upto 4 cohorts of escalating doses in combination with tislelizumab 200mg IV infusion administered every 3 weeks (Q3W)
11070615|NCT04282018|Experimental|Part E: BGB-10188 + Tislelizumab Infusion Dose Expansion|BGB-10188 capsules administered orally QD at RP2D of part D in combination with tislelizumab 200mg IV infusion administered Q3W
11070616|NCT04282005|Experimental|surgery group|Fourteen patients who meet study criteria will be assigned to the study group and will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
11070617|NCT04282005|Active Comparator|lifestyle and diet|Fourteen patients matched to the surgery group for age, gender, BMI, diabetes status, and NALFD score will undergo additional lifestyle interventions, dietary counselling and or meal replacement by a dietician aimed at inducing at least a 5-7% weight reduction, prior to their surgery (while on the waiting list for surgery).
11070618|NCT04281992|Experimental|AUP1602-C|AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.
11070619|NCT04281979|Experimental|Study Agent|
11070620|NCT04281979|Placebo Comparator|Placebo|
11070621|NCT04281966|Experimental|Experiment|For young people from schools randomly assigned to the experimental ASEP condition will participate in the ASEP intervention. The ASEP intervention is a Third-Party Policing partnership that involves a partnership between police and school, an ASEP conference and follow up which is organized and led by a conference facilitator with the young person, their parent (or guardian), a school representative (e.g., teacher), and a uniformed school-based police officer. The police and school representatives will be trained by the facilitator to utilize procedurally just dialogue during the entirety of the conference. The ASEP conference script will utilize a procedurally just dialogue to increase both the young person and their parents' perceptions and knowledge of the legitimacy of the truancy laws, police, and schools in order to gain willing compliance to follow the rules.
11070622|NCT04281966|No Intervention|Control|"Participants allocated to the control condition will be given the business-as-usual' approach to handling school non-attendance. The control participants will be sanctioned in the usual manner for engaging in truancy through the requirements denoted in the Queensland Education (General Provisions) Act (2006)."
11070623|NCT04281953||People with ototoxicity|People living with and beyond who experience ototoxicity as a result of chemotherapy
11070624|NCT04281927||Atrial fibrillation|Patients with presumed atrial fibrillation will undergo monitoring with the device and Holter ECG.
11070625|NCT04281927||Sinus rhythm|Patients with presumed sinus rhythm will undergo monitoring with the device and Holter ECG.
11070626|NCT04281927||Sinus rhythm and frequent extrasystoles|Patients with presumed sinus rhythm and frequent extrasystoles will undergo monitoring with the device and Holter ECG.
11070627|NCT04281901|Experimental|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
11070628|NCT04281901|Active Comparator|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
11070629|NCT04281875|Experimental|NIRAF Detection Technology +|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
11070630|NCT04281875|No Intervention|NIRAF Detection Technology -|Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
11070631|NCT04281862|Experimental|Group A|Dextenza
11070632|NCT04281862|Active Comparator|Group B|Topical Prednisolone
11070633|NCT04281849|No Intervention|Usual care|Patients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
11070634|NCT04281849|Experimental|BAMS-HF Program|
11070635|NCT04281836|Experimental|Breathing awareness through use of virtual reality breathing|Healthy participants were recruited in this group.
11070636|NCT04281836|Active Comparator|Traditional breathing awareness|Healthy participants were recruited in this group.
11070637|NCT04281823||Cardiovascular Magnetic Resonance|All patients who present to the Houston Methodist CMR Laboratory
11070638|NCT04281810|Experimental|TEDS|Subjects received transcutaneous electrical diaphragm stimulation (TEDS) for 30min/ day till the end of the weaning trial
11070639|NCT04281810|No Intervention|Control|Subjects received similar medical treatment except for the TEDS program.
11070678|NCT04281563|No Intervention|no massage groups|no intervention
11070640|NCT04281797||Kidney transplant recipients|Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
11070641|NCT04281797||HSCT-recipients|Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
11070642|NCT04281797||MSCT-recipients|Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
11070643|NCT04281797||Liver transplant recipients|Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.
11070644|NCT04281784|Experimental|EHR-based Clinician Jumpstart|The Jumpstart Guide will be developed by extracting data from the EHR using automated methods and NLP/ML algorithms with both inpatient and outpatient notes (e.g., progress notes, specialty consult notes, alerts and care plans) preceding the current hospitalization. It will summarize the presence/absence of POLST, advance directives and DPOA documentation.
11070645|NCT04281784|No Intervention|Usual Care|The clinicians (hospital teams) for patients in the control group will not receive Jumpstart guides. These subjects will receive usual care.
11070646|NCT04281771|Experimental|Patients who undergo cardiac MRI|Patients undergo cardiac within 30 days after TAVI to assess the amount of paravalvular leakage.
11070647|NCT04281758|Active Comparator|Caffeine beverage (control)|Flavored still beverage with caffeine 100 mg
11070648|NCT04281758|Experimental|Caffeine beverage plus bioactive 1|Flavored still beverage with caffeine 100 mg + quercetin 250 mg
11070649|NCT04281758|Experimental|Caffeine beverage plus bioactive 2|Flavored still beverage with caffeine 100 mg + curcumin 80 mg
11070650|NCT04281758|Experimental|Caffeine beverage plus bioactive 3|Flavored still beverage with caffeine 100 mg + methylliberine 75 mg
11070651|NCT04281745|Experimental|Coretox®|Botulinum toxin type A to be intramuscularly injected at 4 sites of corrugator muscle and at 1 site of procerus muscle with 0.1 mL (4U) at each site, for a total of 0.5 mL (20U). The administration of the investigational product was performed once at the start of each cycle
11070652|NCT04281719|Experimental|Mobile App|Youth will be assigned to interact with a novel mobile application during a course of outpatient psychotherapy for substance use disorder(s) and co-occurring mental health disorder(s).
11070653|NCT04281706||Etomidate-Time-Frame|Patients that underwent cardiac surgery between October 1st, 2012 and September 30th, 2013
11070654|NCT04281706||Propofol-Time-Frame|Patients that underwent cardiac surgery between February 1st, 2014 and January 31st, 2015
11070655|NCT04281693|Experimental|Screening participants|
11070656|NCT04281680||Pasireotide|Patients who received pasireotide perioperatively
11070657|NCT04281680||Octreotide|Patients who received perioperative octreotide
11070658|NCT04281680||Control|Patients who received no additional medication in the timely cohort
11070659|NCT04281667|Experimental|Mechanical Bowel Preparation and Oral Antibiotics|Mechanical Bowel Preparation and Oral Antibiotics
11070660|NCT04281667|Active Comparator|Mechanical Bowel Preparation Only|Mechanical Bowel Preparation Only
11070661|NCT04281654|Experimental|Ballroom Dance|The Dance group participants will take part in ballroom dance lessons twice/week for 45-minutes/session for 10 weeks
11070662|NCT04281654|Experimental|Ukulele|The Music group participants will take part in ukulele lessons twice/week for 45-minutes/session for 10 weeks
11070663|NCT04281654|Active Comparator|Control|The Control group participants will meet 2 times per week for 45-minutes/session for 10 weeks to participate in a social conversational group for 10 weeks
11070664|NCT04281641|Experimental|TCHP|"Neoadjuvant Therapy (Cycles 1-7):
~Cycle 1: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) Cycle 2-7: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) + followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).
~Adjuvant Therapy:patients would complete 1 year of PH-based regimen in the adjuvant setting.
~Patients are assessed by [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 68Ga-Affibody HER-2 Imaging PET. Besides, the changes of biomarkers would be examined by gene sequencing and organoid drug sensitivity test."
11070665|NCT04281628|Placebo Comparator|Control group|control group: where normal saline will be administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
11070666|NCT04281628|Active Comparator|ketamine group|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
11070667|NCT04281615|Experimental|Intervention (Generic Message)|Receives promotional materials that feature a generic messaging approach.
11070668|NCT04281615|No Intervention|Control (Threshold Message)|Receives promotional materials that use traditional, threshold messages.
11070669|NCT04281602||Rheumatoid arthritis patients|Adult patients suffering from rheumatoid arthritis, diagnosed according to American College of Rheumatology/European League Against Rheumatism 2010 criteria and requiring a anti-IL-6 treatment
11070670|NCT04281602||Healthy controls|Healthy controls not suffering from acute or chronic inflammatory disease at inclusion.
11070671|NCT04281589|Experimental|Group 1|tidal volüm is 4 ml/kg
11070672|NCT04281589|Experimental|Group 2|tidal volüm is 6 ml/kg
11070673|NCT04281589|Experimental|Group 3|tidal volüm is 8 ml/kg
11070674|NCT04281589|Experimental|Group 4|tidal volüm is 10 ml/kg
11070675|NCT04281576|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with XELOX. For HER-2 positive patients, Trastuzumab is given together with XELOX.
11070676|NCT04281563|Experimental|the MCT oil massage|The neonates received massage with MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
11070677|NCT04281563|Placebo Comparator|massage alone|The neonates received massage without MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
11070679|NCT04281550|Experimental|Think drink intervention|The Think Drink multicomponent hydration intervention was introduced into the intervention group care homes through a staff workshop.
11070680|NCT04281537||Patient with Fabry Disease on ERT (agalsidase alfa)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa)
11070681|NCT04281537||Patient with Fabry Disease on ERT (agalsidase beta)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase beta)
11070682|NCT04281537||Caregiver|Caregiver of patient with Fabry Disease on ERT
11070683|NCT04281524|Experimental|CSL312 Cohort 1 (Dose 1)|CSL312 administered as IV infusion
11070684|NCT04281524|Experimental|CSL312 Cohort 2 (Dose 2)|CSL312 administered as IV infusion
11070685|NCT04281524|Experimental|CSL312 Cohort 3 (Dose 3)|CSL312 administered as IV infusion
11070686|NCT04281524|Experimental|CSL312 Cohort 4 (Dose 4)|CSL312 administered as IV infusion
11070687|NCT04281524|Placebo Comparator|Placebo|Placebo administered as IV infusion
11070688|NCT04281498|Experimental|Patients with MPN|Ruxolitinib and Enasidenib combination therapy
11070689|NCT04281485|Other|Cohort 1|Approximately two thirds of participants will be randomized to Cohort 1.
11070690|NCT04281485|Other|Cohort 2|Approximately one third of participants will be randomized to Cohort 2.
11070691|NCT04281472|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC in both stage A as stage B
11070692|NCT04281472|Placebo Comparator|Placebo|patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B
11070693|NCT04281459|Experimental|SCT 4/7|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with short cycle scheme of 4 consecutive days on and 3 days off treatment
11070694|NCT04281459|Active Comparator|Control|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with standard scheme of 7 days per week of treatment
11070695|NCT04281446|Experimental|G-FBM-CEN|Photobiomodulation application in women of endogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
11070696|NCT04281446|Experimental|G -FBM- CEX|Photobiomodulation application in women of exogenous cycle. Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, acting 180 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius.
11070697|NCT04281446|Sham Comparator|G - Sham - CEN|"Sham Photobiomodulation (disabled) application in women of endogenous cycle.
~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:
~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
11070698|NCT04281446|Sham Comparator|G - Sham - CEX|"Sham Photobiomodulation (disabled) application in women of exogenous cycle.
~The procedure and equipment will be the same as for the experimental groups, however no dosage will be applied:
~Antares® equipment (IBRAMED, Amparo-SP, Brazil) will be used, by means of a cluster, with two wavelengths (13 LEDs of 630 nm, 300 mW + 13 LEDs of 850 nm, 500 mW), being its area of 80 cm² contact, with 0 J of energy being applied at 15 points on each thigh - 9 in the anterior region and 6 in the posterior region, in addition to 2 points in the gastrocnemius."
11070699|NCT04281433|Experimental|unilateral|
11070700|NCT04281433|Experimental|bilateral|
11070701|NCT04281420|Experimental|ATG-019 Alone|A starting does of 30 mg QoD×3 ATG-019
11070702|NCT04281420|Experimental|ATG-019 + Niacin ER|A starting dose of 60 mg ATG-019 and 500 mg niacin ER
11070703|NCT04281407|Experimental|Probiotics treatment on midazolam and acetaminophen metabolism|"Experimental:
~Day 1: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV) Days 1-28: Visbiome (2 capsules) administered BID Day 11: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV)"
11070704|NCT04281394|Experimental|Robot assisted gait training|Robot assisted gait training(RAGT) group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks. SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements.
11070705|NCT04281394|Active Comparator|conventional physical training group|The conventional group underwent conventional physical therapy( even level gait training and range of motion exercises) twice a day, 5 times a week in 12 weeks.
11070706|NCT04281381||Desmoid Fibromatosis|Participants will have a clinical diagnosis of desmoid fibromatosis, either new or newly recurrent
11070707|NCT04281355|Experimental|Randomisation A - Intervention|In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.
11070708|NCT04281355|Experimental|Randomisation B - Intervention|In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.
11070709|NCT04281342|Experimental|Aprocitentan 25 mg|Therapeutic dose level
11070710|NCT04281342|Experimental|Aprocitentan 100 mg|Supratherapeutic dose level
11070711|NCT04281342|Placebo Comparator|Matching placebo|
11070712|NCT04281342|Other|Moxifloxacin|
11070713|NCT04281316|Active Comparator|Non Invasive Ventilation device group|The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
11070714|NCT04281316|Experimental|Nasal High Flow (MyAirvo) device group|The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.
11070715|NCT04281303||Endoscopic vertical gastroplasty|Proof-of-concept study that will prospectively include a number of patients undergoing endoscopic vertical gastroplasty + lifestyle modifications to evaluate the effect of this technique in an adult population with obesity and NASH cirrhosis
11070716|NCT04281290|Experimental|Experimental group|
11070717|NCT04281277|Active Comparator|low target group|"target of mean arterial pressure(MAP) at 65-70 mmHg.
~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
11070718|NCT04281277|Experimental|high target group|"target of mean arterial pressure (MAP) at 80-85 mmHg.
~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
11070719|NCT04281264|No Intervention|NorCON|Normoxia Control Group
11070720|NCT04281264|Active Comparator|HypCON|Hypoxia Control Group
11070721|NCT04281264|Placebo Comparator|NorCIR|Normoxia Circuit Training with Elastic Bands Group
11070722|NCT04281264|Experimental|HypCIR|Hypoxia Circuit Training with Elastic Bands Group
11070723|NCT04281264|Placebo Comparator|NorVIB|Normoxia Whole-body Vibration Training Group
11070724|NCT04281264|Experimental|HypVIB|Hypoxia Whole-body Vibration Training Group
11070725|NCT04281251|Experimental|ERAT arm|This is the treatment arm where endoscopic therapy of acute appendicitis would be performed
11070726|NCT04281238|Experimental|yoga group|Participants in this group will be given yoga training 3 days a week for 8 weeks. In addition, patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
11070727|NCT04281238|Other|Control group|Patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
11070728|NCT04281225|Placebo Comparator|Placebo only condition|Participants in this condition will be told at the time of the initial assessments (T1) that the device they will be testing will improve their hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked if they perceive their hearing to be changed by the device in addition to qualitative descriptions of the audio. This group will allow researchers to investigate the main effect of the placebo hearing aid - without calling participant's attention to variability in their symptoms.
11070729|NCT04281225|Experimental|Placebo and ATV condition|Participants in this condition at the time of the initial assessments (T1) will be told that the device they will be testing will improve their hearing. They will then be told that in-order to receive the maximum benefit from the hearing device, they should focus on instances in which they can hear better and worse. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will asked 1) if they perceive their hearing to be changed by the device; 2) to note any changes in what they heard in the audio focusing on the story in the ballad; and 3) whether their hearing is possibly impacted by activities and behavior and what they were doing.This condition will enable researchers to test the effects of the interaction between attention to variability and the placebo effect.
11070730|NCT04281225|Experimental|ATV only condition|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
11070731|NCT04281225|No Intervention|Control condition- no ATV or Placebo effect.|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for ergonomic purposes. They will listen to the audio and record volume levels at the start and at the end of the audio and provide feedback on the design. They will be told that each day they will listen to a brief audio (ballad of under 3 minutes) and will be asked a few similar questions twice daily for 6 days. After the 2nd audio of the day, they will be asked for feedback on the hearing device design. They will also be asked about their general health and wellness, as compared to the last time they were contacted.This group will allow researchers to test for the effects of having any device at all.
11070732|NCT04281212||CTO|Period of 1 month in the participating centers, during which all the patients with CTO and responding to all selection criteria may be included in the study, in order to describe which therapeutic choices have been chosen for this type of patient.
11070733|NCT04281212||CTO with attempted angioplasty|Period of 2 months in the participating centers, during which all the patients for whom an angioplasty has been attempted after a CTO, and responding to all selection criteria, may be included in the study, in order to evaluate the success of the procedure
11070734|NCT04281199|Experimental|Treatment (TBI, IMRT)|Patients undergo TBI using IMRT with VMAT or tomotherapy BID on days -7 to -4 then undergo stem cell transplantation on day 0.
11070735|NCT04281186||Cross-sectional cohort|720 type 2 diabetic patients (>5 years duration), older than 65 years of age
11070736|NCT04281186||Prospective study-MCI|168 Patients from the cross-sectional cohort diagnosed with mild cognitive impairment during the cross-sectional evaluation
11070737|NCT04281186||Prospective study normocognitive|63 Patients from the cross-sectional cohort without mild cognitive impairment evaluated during the cross-sectional evaluation
11070738|NCT04281160||Clinical Metric|Patients and healthy controls were evaluated by expert raters with standard clinical metrics of neurologic function.
11070739|NCT04281160||Mobile Activity Metric|Patient performed mobile activity
11070740|NCT04281147||No Ra-223 received|Patients did not receive Ra-223
11070741|NCT04281147||Early Ra-223 (2nd line)|Patients received Ra-223 in 2nd line
11070742|NCT04281147||Late Ra-223 (3rd or later lines)|Patients received Ra-223 in 3rd or later lines
11070743|NCT04281134|Experimental|Summit RC+S DBS Implant for OCD|all subjects will receive surgical implantation of DBS system
11070770|NCT04280926||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
11070744|NCT04281134|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
11070745|NCT04281121|Active Comparator|supplemented|Life style modification, diet regimen and Omega-3 fatty acids supplementation
11070746|NCT04281121|Active Comparator|non supplemented|Life style modification and diet regimen
11070747|NCT04281108|Experimental|APT-1011|APT-1011 3 mg HS
11070748|NCT04281108|Placebo Comparator|Placebo|HS
11070749|NCT04281095|Experimental|Botulinum toxin type A(ATGC-110)|
11070750|NCT04281095|Active Comparator|Botulinum toxin type A|
11070751|NCT04281082||ICP|To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives
11070752|NCT04281069||"patients visiting the centre de santé"|Women visiting to the selected health centres in the Oujda province will be invited to participate
11070753|NCT04281056|No Intervention|Control|
11070754|NCT04281056|Experimental|Tooth removal|Tooth removal and their replacement by means of a denture Teeth have been removed and replaced by means of dentures for at least one year
11070755|NCT04281030|Active Comparator|Active Comparator: Progressive Muscle Relaxation (PMR) Therapy|After the PMR APP is loaded onto the subject's smartphone, the subject will perform PMR in the ED and discuss the optimal time and place to practice PMR at home. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
11070756|NCT04281030|Active Comparator|Active Comparator: Monitored Usual Care (MUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that the MUC subjects receive. All subjects will be asked to keep records of headache occurrence, side effects, compliance, and medication changes on the APP.
11070757|NCT04281017|Experimental|TIVA anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
11070758|NCT04281017|Active Comparator|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
11070759|NCT04281004|Active Comparator|Amniotic Fluid (AFED)|
11070760|NCT04281004|Placebo Comparator|Saline Solution|
11070761|NCT04280991|Experimental|Moderate intensity exercise under mild normobaric hypoxia|The participants will perform moderate intensity exercise at heart rate corresponding with 50%WMAX (determined during maximal workload test) under mild normobaric hypoxia (FiO2: 15%), two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge will be performed at day 5 to determine fasting/postprandial substrate oxidation.
11070762|NCT04280991|Placebo Comparator|Moderate intensity exercise under normoxia|The participants will perform moderate intensity exercise at 50% WMAX (determined during maximal workload test) under normoxia (FiO2: 21%) two times 30 minutes per day for 4 consecutive days on a cycle ergometer. 24h glucose concentration will be monitored continuously. Afterwards, a meal test challenge test will be performed at day 5 to determine fasting/postprandial substrate oxidation.
11070763|NCT04280978||Aquired Brain Injury|Suitable potential participants would be children with ABI, at least 6 months post onset, from 6 to 11 years old, without diagnosis of aphasia, dysarthria, apraxia, and/or sensorial difficulties (visual and hearing), with Italian as a first language.
11070764|NCT04280965|Experimental|Quetiapine|Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed
11070765|NCT04280965|Active Comparator|Treatment As Usual (TAU)|Standard of care medications
11070766|NCT04280952|Experimental|CONVIVO|tumor tissue identification with the CONVIVO system
11070767|NCT04280939|Active Comparator|spinal anesthetic without intrathecal narcotic|spinal anesthetic with standard painkillers without intrathecal narcotics
11070768|NCT04280939|Experimental|spinal anesthetic with morphine|spinal anesthetic with 100 micrograms of intrathecal morphine
11070769|NCT04280939|Experimental|spinal anesthetic with hydromorphone|spinal anesthetic with 20 micrograms of intrathecal hydromorphone
11070771|NCT04280913||COVID-19 patients|Hospitalized patients with COVID-19
11070772|NCT04280900|Experimental|cybertherapy|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
11070773|NCT04280900|Other|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
11070774|NCT04280887|Experimental|Intervention|Participants will wear the device for the specified test period (3 months)
11070775|NCT04280874|Active Comparator|GROUP A|106 randomly selected pregnant women
11070776|NCT04280874|Active Comparator|GROUP B|106 randomly selected pregnant women
11070777|NCT04280861|Experimental|Intervention Group|The intervention group will participate in multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
11070778|NCT04280861|No Intervention|Control Group|Usual clinical care,
11070779|NCT04280848|Experimental|UCPVax vaccine|UCPVax is a therapeutic vaccine derived from telomerase combined with Montanide ISA51 VG as adjuvant.
11070780|NCT04280835|Experimental|Group Psychoeducation that Focused on Social Skill Development|The Psychoeducation program that focused on social skill development, consists of 8 sessions, one day a week, each lasting an average of 60 Minutes. Psychoeducation was conducted in three groups and each of them consisted of eight patients.
11070781|NCT04280835|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
11070782|NCT04280822|Experimental|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles
~Surgery:
~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).
~After surgery/ maintain period:
~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)"
11070783|NCT04280822|Active Comparator|Neoadjuvant chemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
~Surgery:
~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
11070784|NCT04280809|Experimental|Laser|Subsequently to the suture, laser was applied in the right or left side randomly on each patient, according to a sheet of randomization. GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2.
11070785|NCT04280809|No Intervention|Non-laser|Every patient, on the control side, the same handpiece was applied intraorally, but laser was not activated
11070786|NCT04280796|Experimental|Substudy 1|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 1 an operant learning paradigm will be implemented to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement and vice versa.
~Primary objectives:
~To develop psychophysical methods that allow the independent assessment of sensory-discriminative and emotional-motivational pain responses and
~to show that emotional-motivational and sensory-discriminative pain components can be dissociated
~Secondary objective:
~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in how strongly sensory-discriminative and emotional-motivational pain responses can be dissociated"
11070787|NCT04280796|Experimental|Substudy 2|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.
~Primary objective:
~To demonstrate that in chronic pain patients, emotional-motivational pain responses are increased relative to sensory-discriminative pain responses
~Secondary objective:
~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in the present dissociation of sensory-discriminative and emotional-motivational pain responses in chronic pain patients"
11070788|NCT04280783|Experimental|PATH Treatment Group|The PATH group will be granted password protected access to one of the 3 PATH levels based on their baseline fitness status. The intervention is designed to help participants increase their baseline PA via health coaching, self-monitoring and pragmatic workout videos that provide convenient options for overcoming socio-environmental barriers to PA.
11070789|NCT04280783|Other|Wait-list control group|Participants in this group will not have access to the PATH intervention until after 12 weeks when they cross over. After randomization, the control group will be provided with a copy of the Be Active Your Way booklet, developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives.
11070790|NCT04280770|Sham Comparator|Non retinal detachment group|35 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
11070791|NCT04280770|Active Comparator|retinal detachment group|15 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
11070792|NCT04280757||Biopsied ICSI embryos|
11070793|NCT04280757||Non biopsied ICSI embryos|
11070794|NCT04280757||Natural pregnancy embryos|
11070795|NCT04280744|Experimental|Music therapy|Music listening intervention provided by a board certified music therapist.
11070796|NCT04280731|Experimental|Fermented drink|
11070798|NCT04280705|Placebo Comparator|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
11070799|NCT04280705|Experimental|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
11070800|NCT04280692|Experimental|Group 1: PfSPZ 6,400|"Group 1 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 6,400 sporozoites.
~Group 1 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).
~Group 1 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
11070801|NCT04280692|Experimental|Group 1: PfSPZ 12,800|"Group 2 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 12,800 sporozoites
~Group 2 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).
~Group 2 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
11070802|NCT04280692|Experimental|Group 3: PfSPZ 25,600|"Group 3 will receive a malaria infection by direct venous inoculation (DVI) with PfSPZ Challenge at a dose of 25,600 sporozoites
~Group 3 will be randomised (1:1) to receive either sub-curative Sulfadoxine-Pyrimethamine (SP) (500mg/25mg) or Piperaquine (PIP) (480mg).
~Group 3 will receive a final curative treatment of Artemether-Lumefantrine (AL) with single low dose Primaquine (SLDPQ)"
11070803|NCT04280679|Other|Arm of patient treated by HIFU|Compression bandages
11070804|NCT04280653|Experimental|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
11070805|NCT04280640||Metastatic Cancer Pts Receiving Molecularly Targeted Therapy|Metastatic cancer patients (with liver and/or lung metastasis) who will receive molecularly targeted therapy based on genomic testing data
11070806|NCT04280640||GI Cancer Pts|Gastrointestinal cancer patients (with liver and/or lung metastasis) who will receive 3rd line treatments or enrolled on a targeted therapy treatment trial
11070807|NCT04280640||Bladder Cancer Pts|Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment
11070808|NCT04280601|Other|Low vitamin level at baseline|At specific time points we will measure vitamin D status (baseline and 12-months) and re-enforcing vitamin D supplementation in those with insufficient or deficient vitamin D levels. More specifically, we will ask patients with insufficient or deficient vitamin D levels at enrollment to increase vitamin D intake by 1,000 IU units (to a maximum of 2,000 IU if the patient is already on vitamin D supplementation) for the 12 month period.
11070809|NCT04280588|Experimental|Treatment group|
11070810|NCT04280588|No Intervention|Control group|
11070811|NCT04280562|Experimental|"Real SPR"|"Participants will receive the device which will run the real Sana Pain Reliever (SPR) protocol and a tablet with a mobile application to record pain levels and other questionnaires"
11070812|NCT04280562|Sham Comparator|Sham SPR|Participants will receive the device which will run a sham SPR protocol and a tablet with a mobile application to record pain levels and other questionnaires
11070813|NCT04280549||Healthy Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
11070814|NCT04280549||Diabetic Subjects|Subjects will have a single visit where a short medical history/list of current medications and single blood draw will be performed.
11070815|NCT04280536|Experimental|Cohort A|Patients with prior exposure to fluoropyrimidines
11070816|NCT04280536|Experimental|Cohort B|Patients without prior exposure to fluoropyrimidines
11070817|NCT04280523|Experimental|ESR-specific PET Scan|"Specific Aim: To test the hypothesis that among PAH patients, higher lung ESR density associates with a more severe hemodynamic profile and worse 1 year outcomes.
~Study Design: Enroll 20 randomly selected subjects from each group (PAH vs. control)"
11070818|NCT04280510||Active coeliac patients|Patients with active coeliac disease
11070819|NCT04280510||Treated coeliac patients|Patients with coeliac disease on gluten free diet
11070820|NCT04280510||Sprue type I|Patients with refractory coeliac disease of type I
11070821|NCT04280510||Sprue type II|Patients with refractory coeliac disease of type II
11070822|NCT04280510||Intestinal Lymphoproliferations|Patients with intestinal lymphoproliferations
11070823|NCT04280510||Non coeliac enteropathies|Patients with non coeliac immune-mediated enteropathy
11070824|NCT04280510||Patients without neoplastic or inflammatory intestinal disease|Patients without neoplastic or inflammatory intestinal disease
11070825|NCT04280497|Experimental|Biomarker CIRCI neg: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
11070826|NCT04280497|Placebo Comparator|Biomarker CIRCI neg: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
11070827|NCT04280497|Experimental|Biomarker endocan: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
11070828|NCT04280497|Placebo Comparator|Biomarker endocan: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
11070829|NCT04280497|Experimental|Biomarker GILZ: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
11070830|NCT04280497|Placebo Comparator|Biomarker GILZ: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
11070831|NCT04280497|Experimental|Biomarker CPD: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
11070832|NCT04280497|Placebo Comparator|Biomarker CPD: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
11070833|NCT04280497|Experimental|Biomarker Transcriptomic SRS: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
11071109|NCT04278469|Active Comparator|Patients with chemotherapy|
11070834|NCT04280497|Placebo Comparator|Biomarker Transcriptomic SRS: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
11070835|NCT04280497|Experimental|Biomarker Endotype B: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
11070836|NCT04280497|Placebo Comparator|Biomarker Endotype B: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
11070837|NCT04280484|Experimental|Acute Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts
11070838|NCT04280484|Sham Comparator|Sham Acute Intermittent Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts.
11070839|NCT04280471|Experimental|Treatment (OpenBiome FMT capsule DE)|Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
11070840|NCT04280458|Experimental|Intervention group|patients will receive intensive care of rehabilitation of psychomotor
11070841|NCT04280458|Active Comparator|Control group|patients will receive standard care
11070842|NCT04280445|Experimental|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
11070843|NCT04280432||Cesarean|Women hospitalized for cesarean section
11070844|NCT04280419||Healty Subjects|Healthy Subjects Twenty-five healthy individuals will be included in the study. Physical properties of cases will be recorded. Respiratory functions and respiratory muscle strength will be evaluated. Physical activity will be assessed using the International Physical Activity Survey (IPAQ). Respiratory muscle endurance will be evaluated using an incremental workload test and fixed threshold load test. Tests will be repeated three times as motivational music, slow-paced music, and music. Heart rate, respiratory frequency, perceived exertion will be evaluated before and after the test.
11070845|NCT04280406|Active Comparator|Test|- 500mg of azithromycin one hour before implant placement
11070846|NCT04280406|Placebo Comparator|control|- identical placebo one hour before implant placement
11070847|NCT04280393|Experimental|Endocuff|Colonoscopy procedure with the use of endocuff
11070848|NCT04280393|Active Comparator|Control|Standard Colonoscopy procedure
11070849|NCT04280380||Mechanical ventilated patients without cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.
~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.
~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
11070850|NCT04280380||Mechanical ventilated patients with cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.
~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.
~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
11070851|NCT04280367||Comparator group|Specific learning disorders group
11070852|NCT04280367||neuro-developmental complexed group|Group of neuro-developmental complexe of learning
11070853|NCT04280367||Complexed with anxiety|Disorders in learning with anxiety
11070854|NCT04280354||patients with severe community acquired pneumonia (cases)|Cases: Patients with severe community acquired pneumonia with required ICU admission.
11070855|NCT04280354||patients without pneumonia or sepsis (controls)|Controls: Clinical phenotype of inflammation not due to suspected sepsis; patients with fever >38°C, C reactive Protein (CRP) >100mg/L, no infection focus expected in ≥ 24h.
11070856|NCT04280341|Experimental|RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody|RC48-ADC(Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate) JS001(Recombinant Humanized Anti-PD1 Monoclonal Antibody)
11070857|NCT04280328|Experimental|Ciforadenant in combination with daratumumab|Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.
11070858|NCT04280315||Cases|"Cases are patients with type 1 diabetes in three age strata:
~20 participants in the age of 2-10 years
~20 participants in the age of 11-20 years
~10 participants with more than 30 years of diabetes duration"
11070859|NCT04280315||Controls|Controls are age and sexmatched with the cases and are recruited from the neuropediatric clinic at Herlev Hospital as well as relatives and parents of patients in the whole Pediatric Department
11070860|NCT04280302|Experimental|Virtual reality based therapy|
11070861|NCT04280302|Active Comparator|Conventional Therapy|
11070862|NCT04280289|Experimental|Cannabidiol extract|"10 healthy subjects (5 female, 5 male), will be enrolled into the study. Each subject will receive a single CBDE dose delivering 2.5 mg/kg CBD, after consumption of a standardized meal.
~Nine (9mL) of blood for PK analysis, at each of the following timepoints: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the study drug administration.
~Urine will be collected at the following timepoints: Predose, 0-4 hrs, 4-8 hrs, 8-12 hrs, 12-24 hrs, 24-36 hrs, 36-48 hrs, and 48-72 hrs for PK analysis"
11070863|NCT04280276|Active Comparator|Group 1 - Patients with high IPV (designated as ≥ 30%).|Patients with high IPV (designated as ≥ 30%).
11070990|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
11070864|NCT04280276|Active Comparator|Group 2 - patients with normal IPV (< 30%).|Patients with normal IPV (< 30%). Will assess risk of subclinical acute rejection in patients with high IPV compared to normal IPV. All tacrolimus 12 h trough levels in patients with stable allograft function at least 3 months post-transplant.
11070865|NCT04280263|Active Comparator|Caffiene|This group will receive 150mg caffeine tablets to be taken twice per day
11070866|NCT04280263|Placebo Comparator|placebo|
11070867|NCT04280250|Active Comparator|Group 1|Active control arm: Volitional help-sheet with instruction: We want you to plan to increase your level of physical activity. Research shows that if people can identify situations in which they are likely to be tempted not to be physically active and ways to overcome temptation they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page are a series of common situations in which people feel tempted not to be physically active; please tick all those that apply to you personally. On the right hand side of the page are a series of possible solutions; please tick all those that apply to you personally. Tick as many or as few situations and solutions as you like.
11070868|NCT04280250|Experimental|Group 2|"Experimental arm: Volitional help-sheet with instruction:
~We want you to plan to increase your level of physical activity. Research shows that if people link being tempted not to be physically active with a way to overcome that temptation, they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page below is the temptation not to be physically active; on the right hand side of the page are a series of possible solutions. Please draw lines linking being tempted not to be physically active (left hand side) to solutions (right hand side) that you think might work for you personally. Please make as many situation-solution links as you like."
11070869|NCT04280237||Cefazolin in liver transplantation|Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin
11070870|NCT04280224|Experimental|NK Cells Treatment Group|Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2*10E7 NK cells/kg body weight).
11070871|NCT04280224|No Intervention|Conventional Control Group|Participants will only receive conventional treatment.
11070872|NCT04280211||COPD Group|Patients who are over 40 years old, diagnosed with COPD
11070873|NCT04280211||Control Group|Healthy adults over 40 years old
11070874|NCT04280198|No Intervention|No Intervention: Group 1 - Control|Participants will attend three laboratory visits: baseline 1, baseline 2, and post-test. At baseline 2 and post-test, the primary outcome of child RRV of food vs. parent child interaction is measured. Other measures include child height and weight, child self-regulation, and parenting in the context of a parent-child interaction task. Participants in the control group will not be assigned to complete any intervention activities during the 4-week intervention phase (which takes place between baseline 2 and post-test visits); however, they will receive contacts from a member of the lab each week in the form of electronic reminders (i.e. texts) to remind them of their upcoming post-test laboratory appointment and will receive some intervention materials after the post-test assessment.
11070875|NCT04280198|Experimental|Experimental: Group 2 - Intervention|Participants will attend the same three laboratory visits as the control group. The intervention group will also participate in a 4-week intervention, which consists of the parent watching brief weekly parenting videos from the online Triple P Parenting Program and completing interactive parent-child activities from activity boxes created by our laboratory (~60 min of interactive activities/week). Participants will use their activity boxes to practice specific parenting skills from the week's parenting video. Throughout the intervention phase, participants will receive regular text messages to remind them of the week's activities and ask several questions about engagement in study activities over the past 24 hours. The intervention group will also complete an exit interview about the intervention following the post-test assessment to provide insights on fidelity and acceptability.
11070876|NCT04280185|Experimental|Hyperthermic Intraperitoneal chemotherapy|Hyperthermic Intraperitoneal chemotherapy was started immediately after CRS, or the first HIPEC was completed within 48 hours after surgery: temperature 43℃, duration 60 minutes, Paclitaxel (60mg/m2) was selected. The second HIEPC was completed 7 days after the first HIPEC: temperature 43℃, duration 60min, carboplatin AUC (5-6) was selected. 30 minutes before using Paclitaxel, 10ML saline + 10mg dexamethasone intravenous infusion, 20mg diphenhyramine intramuscular injection, and 100ML saline + 0.3g cimetidine intravenous infusion. On the eighth day, intravenous chemotherapy with Paclitaxel (135mg/m2) was finally completed. 5 courses of TC intravenous chemotherapy were performed after 3 weeks
11070877|NCT04280185|No Intervention|intravenous chemotherapy|intravenous chemotherapy were performed 6 Cycles after CRS. Paclitaxel: 175mg/m2, iv infusion, no less than 3h per infusion, followed by carboplatin: AUC 5-6, iv infusion, no less than 1h per infusion, 1 dose on the first day of a week, 1 cycle every 3 weeks, a total of 6 cycles. Paclitaxel should be pretreated to prevent severe allergic reactions.
11070878|NCT04280172|Experimental|Cultural Competence Education|Participants in the intervention group will attend cultural competence education
11070879|NCT04280172|Active Comparator|Standard Mentoring Education|Participants in the control group will complete standard mentoring education that does not include a cultural competence component
11070880|NCT04280146|Active Comparator|Degree of food processing|unprocessed vs ultra-processed foods according to NOVA table.
11070881|NCT04280146|Active Comparator|eating rate|slow vs fast eating rate (kcal/min), manipulated by food form
11070882|NCT04280133|Experimental|Educational Video Tool|Patients randomized to the intervention arm will watch a 3-minute video educational tool about CAR-T cell therapy prior to admission for CAR-T cell therapy.
11070883|NCT04280133|No Intervention|Standard Care|Patients randomized to the control arm will receive usual care per the treating team. Any questions regarding CAR-T cell therapy will be directed to the patient's medical team
11070884|NCT04280120|Experimental|Neural Mobilisation Group|"Massage therapy.
~Faradic electrical stimulation.
~Exercises in front of the mirror.
~Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest."
11071110|NCT04278469|No Intervention|Patients without chemotherapy|
11070885|NCT04280120|Active Comparator|Conservative group|"Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
~Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
~Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes."
11070886|NCT04280107||Temporomandibular Dysfunction|For this study, 154 patient files who were admitted to the radiology department of the faculty of dentistry between 2013 and 2019 with complaints such as TMJ pain, mouth opening restriction, joint sound, joint function disorder were scanned retrospectively. Inclusion criteria: TMD patients with MR and CBCT images recorded in the digital archive. Exclusion criteria: Patients who have been operated or treated from TMJ, patients with head and neck trauma, patients with orthodontic treatment.
11070887|NCT04280081|Experimental|Selpercatinib|Selpercatinib given orally.
11070888|NCT04280068|Active Comparator|Clinician Guide|Clinician Guide is an evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
11070889|NCT04280068|Active Comparator|Clinician Guide plus HealthCall|Clinician Guide plus the use of HealthCall, a smartphone application to monitor daily alcohol use, ART adherence and other health behaviors.
11070890|NCT04280055|Experimental|Psilocybin|
11070891|NCT04280042||Thoracoscopic surgical ablation|Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
11070892|NCT04280042||Cather ablation|Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
11070893|NCT04280029|Experimental|SELUTION SLR™ DEB|
11070894|NCT04280029|Active Comparator|Control Treatment|"For subjects randomized to the control group (SOC) the treating physician may chose to implant a commercially available DES or alternatively may use POBA only to treat the patient. The decision should be based on the treating physicians' assessment of the best treatment option for the individual patient. However, it is expected that patients with one prior stent will receive DES and patients with two prior stents will receive POBA. Treating physicians may deviate from this if it is determined to be in the best interest of the patient, but the justification for the treatment decision must be recorded in eCRF.
~Choice of DES is at the treating physician's discretion, but is limited to ZES and EES devices."
11070895|NCT04280016|Experimental|Exercise Added to Off-loading|Participants in this arm will participate in exercise at the healthcare facility one time a week (away from where wound care is provided) and be instructed in a home exercise program that they will be encouraged to perform at least three days per week with no more than two days between sessions. Wound care will continue at the facility as is standard, utilizing off-loading.
11070896|NCT04280003|Experimental|Treatment group|15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.
11070897|NCT04280003|Placebo Comparator|Placebo group|15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group.
11070898|NCT04279990||Functional dyspepsia patients with JHS|Patients with functional dyspepsia as defined by the Rome III criteria and joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
11070899|NCT04279990||Functional dyspepsia patients without JHS|Patients with functional dyspepsia as defined by the Rome III criteria and WITHOUT joint hypermobility syndrome as defined by the Beighton Hypermobility criteria.
11070900|NCT04279990||Healthy subjects|Healthy subjects with no gastrointestinal diseases including no functional dyspepsia
11070901|NCT04279977||Inpatient Rehabilitation Facility|Individuals post-stroke who are discharged to an inpatient rehabilitation facility.
11070902|NCT04279977||Skilled Nursing Facility|Individuals post-stroke who are discharged to a skilled nursing facility.
11070903|NCT04279964|Experimental|Boot Camp Translation|Intervention practices will undergo the Boot Camp Translation process.
11070904|NCT04279964|Active Comparator|Control|Control practice will behave as usual.
11070905|NCT04279951|Experimental|Omega 3|"Intake of 1 gram omega-3 (capsules) per day for 20 weeks
~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
11070906|NCT04279951|Placebo Comparator|Placebo|"Intake of 1 gram sunflower oleic oil (capsules) per day for 20 weeks
~+ high-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)"
11070907|NCT04279951|No Intervention|Control|No intervention
11070908|NCT04279938|Other|Safety Run in & Main Efficacy Part|"Part 1 (safety run-in) aims to evaluate the maximum tolerated dose (MTD) of tinostamustinein combination with pembrolizumab (200mg Q3W) and rituximab (375mg/m2 Q3W). The dose of tinostamustineestablished to be safe and tolerable in this combination will be used in part 2 of the trial (main efficacy part).
~The aim of part 2 is to detect signals of anti-tumour activity and to further assess the safety of this combination treatment in r/r DLBCL. The study has a strong focus on correlative research in order to identify mechanisms of response and resistance to pembrolizumab and the pembrolizumab/R-tinostamustinecombination."
11070909|NCT04279925|Experimental|Locally-made Miniplate and screw|"The investigators define Biomet® miniplate 1.5 as miniplate produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate that is using in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog.
~The investigators define Biomet® screw 1.5 as screw produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws."
11070991|NCT04279223|Active Comparator|5 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
11071111|NCT04278456||general anesthesia|c-section with general anesthesia
11070910|NCT04279925|Active Comparator|Imported Miniplate and screw|"The investigators define locally-made miniplate as plate produced by the Faculty of Technique Universitas Indonesia, The particular plate that is using in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
~The investigators define locally-made screw as screw produced by the Faculty of Technique Universitas Indonesia, with dimensions of 4.57 mm long and 1.5mm diameter."
11070911|NCT04279912|Experimental|Patients with Multiple Sclerosis and Tremor|Participants will undergo MRgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
11070912|NCT04279886|Other|Three-dimensional scan arm|
11070913|NCT04279873||Adults with nosocomial pneumonia|Diagnostic procedures on pulmonary secretion collected by tracheal suctioning and bronchoalveolar lavage.
11070914|NCT04279847|Experimental|INCB057643 Monotherapy|INCB057643 dose confirmation (Part 1) and dose expansion (Part 2).
11070915|NCT04279834|Active Comparator|PAP Treatment|Participants will receive a PAP device and will attend four weekly sessions to receive education about this treatment.
11070916|NCT04279834|Active Comparator|Sleep Education I|Participants will attend four weekly sessions to receive education about strategies to improve sleep.
11070917|NCT04279834|Active Comparator|Sleep Education II|Participants will attend four weekly sessions to receive education about sleep health.
11070918|NCT04279821||Colonic diverticulosis and macroscopic signs of inflammation|No interventional study
11070919|NCT04279808|Experimental|measured distance|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will measure the distance between the skin puncture site and the outside of anterior wall of the jugular vein. Next, we will insert the dilator on the guidewire by the measured length."
11070920|NCT04279808|No Intervention|conventional method|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will insert the dilator on the guidewire as commonly used method of the practitioners."
11070921|NCT04279782||Exclusion group|Patients with two consecutive negative results of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swabs
11070922|NCT04279782||Confirmed group|Patients with positive result of detection for 2019 Novel Coronavirus nucleic acid from pharyngeal swab
11070923|NCT04279769|Experimental|Cohort 1|CB-280 twice daily at 50 mg for 14 days
11070924|NCT04279769|Experimental|Cohort 2|CB-280 twice daily at 100 mg for 14 days
11070925|NCT04279769|Experimental|Cohort 3|CB-280 twice daily at 200 mg for 14 days
11070926|NCT04279769|Experimental|Cohort 4|CB-280 twice daily at 400 mg for 14 days
11070927|NCT04279769|Placebo Comparator|Placebo|Placebo twice daily for 14 days
11070928|NCT04279756|Active Comparator|Mildly Impaired Group|This group is with participants with mildly impaired hip internal range of motion, from 25-30 degrees.
11070929|NCT04279756|Active Comparator|Moderately Impaired Group|This group is with participants with moderately impaired hip internal range of motion, from 20-24 degrees.
11070930|NCT04279756|Active Comparator|Severely Impaired Group|This group is with participants with severely impaired hip internal range of motion, less than 20 degrees.
11070931|NCT04279743|Experimental|ApoE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
11070932|NCT04279743|Experimental|ApoE4 non carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
11070933|NCT04279730||Inpatient pulmonary rehabilitation|Multidisciplinary inpatient pulmonary rehabilitation program lasting 4 weeks (40 sessions, 2 sessions per day, 5 days per week).
11070934|NCT04279717||Subjects with von Willbrand Disease Acquired|
11070935|NCT04279717||Subjects with von Willbrand Disease Congenital|
11070936|NCT04279691||periodontitis and rheumatoid arthritis|group 1: patiernts with periodontitis and rheumatoid arthritis. only
11070937|NCT04279691||periodontitis|group 2: patiernts with periodontitis
11070938|NCT04279678||patients undergone mitral repair|includes all patients undergone repair of mitral valve with CABG
11070939|NCT04279678||patients with no mitral repair|includes all patients where no repair done for mitral valve , only CABG
11070940|NCT04279665|Experimental|Subjects undergoing electrophysiology procedure|Subjects will wear a virtual reality (VR) headset for a total of 40 minutes separated over 2 sessions during an electrophysiology procedure they are already scheduled to undergo.
11070941|NCT04279652|Experimental|Supervised exercise group|The treatment program was determined as 3 sessions per week for 8 weeks and 60 minutes per session. The treatment program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
11070942|NCT04279652|Active Comparator|Home exercise group|The exercise program, which is prepared for the individual, will be applied to the home exercise group with 60 minutes of 3 times a week.
11070943|NCT04279652|No Intervention|Control group|Children will not be included in any treatment program. The assessments will be done again 8 weeks later.
11070944|NCT04279639||qigong practice|Patients in this arm participated in qigong as part of their treatment at the Pain Management Unit
11070945|NCT04279639||control|Patients attend the pain management unit but do not undertake qigong practice.
11070946|NCT04279626||LETS-M|Women who were older than 20 years old and had not reached menopause, with symptomatic uterine myomas, such as hypermenorrhea, infertility, a mass effect-related urinary frequency, and constipation, received LETS-M.
11070947|NCT04279613|Experimental|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s): 1mg/mL Dosing instructions: Once weekly on site
11070948|NCT04279613|Placebo Comparator|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
11070949|NCT04279600|Experimental|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
11070992|NCT04279223|Sham Comparator|10 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
11070993|NCT04279210|Experimental|PRP Treatment|Women with SUI received PRP injection into anterior vaginal wall (near external urethral sphincter) once per month for three times.
11070950|NCT04279600|Active Comparator|Taurine supplementation associated to exercise training|"Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
11070951|NCT04279600|Placebo Comparator|Placebo supplementation associated to exercise training|"Placebo supplementation composed of capsules of starch powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
11070952|NCT04279587|Experimental|Residential camp participant|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at a regional camp.
11070953|NCT04279574|Other|CAD/CAM Onlays|Lithium disilicate chairside CAD/CAM onlays (IPS emaxCAD/Ivoclar) will be adhesively bonded using a selective enamel etch technique with an adhesive (3M) and cement (3M).
11070954|NCT04279574|Other|CAD/CAM Crowns|Full contour zirconia crowns (3M Chairside Zirconia/3M) will be cemented using a self-adhesive cement (3M).
11070955|NCT04279561|Experimental|Diagnostic (68GA-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 and 2 weeks after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
11070956|NCT04279548|Active Comparator|On DBS|Patients in the on mode DBS
11070957|NCT04279548|Sham Comparator|Off DBS|Patients in the off mode DBS
11070958|NCT04279535|Experimental|Treatment group|Participants applied topical solution of ascorbic acid twice daily for 8 weeks
11070959|NCT04279509|Experimental|Cancer patient|Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
11070960|NCT04279483|Experimental|7-11 Group|Participants visit 7-11 every weekday during the 4-week (20 store visits total) intervention period
11070961|NCT04279483|Experimental|CVS Group|Participants visit CVS every weekday during the 4-week (20 store visits total) intervention period
11070962|NCT04279483|No Intervention|Control|Participants are not asked to alter their behavior during the 4-week (0 store visits) intervention period
11070963|NCT04279470||Adverse Events with cellular therapies|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Chimeric Antigen Receptor T-cell and Cellular Therapies, with a chronology compatible with the drug toxicity
11070964|NCT04279457|Active Comparator|Standardized Hydration protocol|These cases will follow Charleston Area Medical Centers standard Hydration protocol
11070965|NCT04279457|Active Comparator|Hydration + Device|These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
11070966|NCT04279444|Experimental|Active BKR-017|Open label study. All patients will receive 28 days of active treatment.
11070967|NCT04279431||SIC Negative|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC negative group are those patients who obtain a 'Negative' result on the BrainScope One Structural Injury Classifier (SIC) algorithm.
11070968|NCT04279431||SIC Positive/Equivocal|Subjects will include males and females ranging from ages 18 to 85 who are admitted to the ED with a traumatic, closed head injury within 3 days of injury. Subject will undergo site standard clinical ED evaluation and a BrainScope evaluation. The SIC positive group are those patients who obtain a 'Positive' or 'Equivocal' result on the BrainScope One SIC algorithm.
11070969|NCT04279418|Experimental|Mixed functional foods group with SCD|Thirty participants in this group will take mixed functional foods for three months.
11070970|NCT04279418|Placebo Comparator|Placebo group with SCD|Thirty participants in this group will take placebo for three months.
11070971|NCT04279405|Experimental|YY-20394|treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity.
11070972|NCT04279392|Active Comparator|Active Infusion|At 6 weeks post surgery, 5 mg of zoledronic acid in 100 ml of saline will be infused intravenously over a 15 minute time period.
11070973|NCT04279392|Placebo Comparator|Non-active Infusion|At 6 weeks post surgery, 100 ml of saline will be infused intravenously over a 15 minute time period.
11070974|NCT04279379|Experimental|treatment arm|Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.
11070975|NCT04279366||Winter course|The recruited particpants attending the winter course
11070976|NCT04279366||Fall course|The recruited particpants attending the winter course
11070977|NCT04279353|Experimental|Mindfulness Based Intervention|Participants was asked to answer PSS-10 questionnaire to measure their stress level, then they received Mindfulness Based Intervention program for 4 weeks and did the PSS-10 test again after 4 weeks.
11070978|NCT04279327||cases|cytology positive for malignancy
11070979|NCT04279327||controls|cytology negative for malignancy
11070980|NCT04279314|Experimental|Trofinetide|
11070981|NCT04279288|Experimental|participants enrolled with epistaxis and/or nasal fractures|
11070982|NCT04279275||Survey|Knowledge survey
11070983|NCT04279262||Anonymised records from 6 ambulance services|The total available sample for analysis for this cohort is estimated to be at least 50,000 incidents across 6 ambulance trusts. The investigators will describe the epidemiology of CFR provision to rural health areas using an anonymised dataset.
11070984|NCT04279262||Interviews with patients (and/or relatives)|The investigators will interview about 15-20 patients (and/or relatives) who have been attended by CFRs.
11070985|NCT04279262||Interviews with CFRs|The investigators will interview about 15-20 CFRs/ CFR scheme leaders.
11070986|NCT04279262||Interviews with Ambulance staff|The investigators will interview about 15-20 ambulance staff who have experience of working with CFRs.
11070987|NCT04279262||Interviews with GPs and commisioners|The investigators will interview about 10-15 GPs and ambulance service commissioners.
11070988|NCT04279249|Active Comparator|HEPA Filtration|
11070989|NCT04279249|Sham Comparator|Sham HEPA Filtration|
11071112|NCT04278456||spinal anesthesia|c-section with spinal anesthesia
11070994|NCT04279197|Experimental|Basic Treatment+Fuzheng Huayu Tablet|"basic treatment (respiratory function rehabilitation training + Vitamin C tablets)
~FZHY"
11070995|NCT04279197|Placebo Comparator|Basic Treatment+Placebo|"basic treatment (respiratory function rehabilitation training + Vitamin C tablets)
~placebo"
11070996|NCT04279158|Experimental|patients with optic ataxia (OA)|
11070997|NCT04279158|Experimental|patients with hemispatial neglect|
11070998|NCT04279158|Experimental|patients with attention-deficit hyperactivity disorder|
11070999|NCT04279158|Active Comparator|Healthy volunteers|
11071000|NCT04279145|Experimental|pulmonary hypertension group 1|each patient will be submitted to : swan-ganze catheterization detailed echocardiography blood sample for biomarkers (troponin, uric acid and micro RNA)
11071001|NCT04279132||TOTAL INTRAVENOUS ANESTHESIA|
11071002|NCT04279132||INHALATION ANESTHESIA|
11071003|NCT04279119|Experimental|ARQ-151 cream 0.3%|Open label study of ARQ-151 cream 0.3% applied once daily for 2 weeks
11071004|NCT04279106|Experimental|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11071005|NCT04279106|Active Comparator|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11071006|NCT04279106|Active Comparator|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11071007|NCT04279106|Placebo Comparator|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11071008|NCT04279093||Pregnant/postpartum women and their partners|"The investigators aim to recruit 20 women in late pregnancy from the Antenatal Assessment Unit and the Antenatal Clinic at St Mary's Hospital. Their partners will be invited to participate where applicable.
~Inclusion and exclusion criteria for pregnant women are as follows:
~Inclusion: after 36 weeks gestation, aged over 18 years and fluent in English, under the care of Manchester University NHS Foundation Trust
~Exclusion: current stillbirth (women experiencing a stillbirth during the study will be withdrawn from the study), fetal abnormality, or multiple pregnancy
~Inclusion criteria for partners: male or female partners of a mum participating in the study, aged over 18 and fluent in English."
11071009|NCT04279080||1|rectal cancer patients
11071010|NCT04279080||2|ovarian cancer patients
11071011|NCT04279067|Experimental|BCI-FES dorsiflexion therapy with physiotherapy|"Subjects will undergo placement of an EEG cap using standard technique connected to our custom BCI system. Subjects will provide 5 min of training EEG data as they engage in alternating epochs of idling and attempted foot dorsiflexion (of the paretic side). In the online phase, the subjects will perform 20-25 BCI-FES runs. A total of 12 sessions will be performed at a rate of 3x/week (over 4 weeks). Each BCI-FES therapy session will be followed by 1 hour of conventional physiotherapy.
~Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises."
11071012|NCT04279067|Experimental|Dose-and intensity-matched physiotherapy|"Conventional Physical Therapy: This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
~In the dose-matched control group (Group 2), it will be 2 hours/session."
11071013|NCT04279054|Active Comparator|Group A: 150 mcg morphine|Patients in this group will receive 150mcg of morphine in their neuraxial block
11071014|NCT04279054|Experimental|Group B: 50 mcg morphine|Patients in this group will receive 50mcg of morphine in their neuraxial block
11071015|NCT04279041|Experimental|Fanta and Zunba rotatory files|Fanta and Zunba rotatory files
11071016|NCT04279041|Active Comparator|manual K-files|manual K-files
11071017|NCT04279028|Active Comparator|Standard CBT|
11071018|NCT04279028|Experimental|Adapted CBT|
11071019|NCT04279015|Active Comparator|Conventional rehabilitation treatment|Conventional physiotherapy program, consisting of standardised active (exercise) and passive (hotpack, ultrasound, conventional TENS) physical therapy methods, was applied by the same physiotherapist.
11071020|NCT04279015|Active Comparator|Kinesio tape procedure|In addition to the conventional physiotherapy program Kinesio tape was performed every day of conventional treatment immediately after the session ended by the same physiotherapist.
11071021|NCT04279002||Respiratory rehabilitation course|Patients who has completed at least one respiratory rehabilitation course at the Espace du Souffle (Tours France) within the 5 years prior to inclusion
11071022|NCT04278989|Active Comparator|Anti-tumor B|1,200 mg three times a day.
11071023|NCT04278989|Placebo Comparator|Placebo|Placebo taken three times a day.
11071024|NCT04278976|Experimental|CoBaTriCE|Implementation of CoBaTrICE. The implementation of CoBaTrICE is based on: 1. Training the trainers; 2. Multiple Workplace-based assessment exercices; 3. The use of an electronic portfolio.
11071025|NCT04278976|No Intervention|Control|The participants of the control group will follow the current official model of training in ICM in Spain, which is based on exposure to experiences through time-based clinical rotations; a generic report, non-based on formal assessment, about knowledge, technical and nontechnical skills is performed after every clinical rotation, and yearly by the tutor.
11071026|NCT04278963|Experimental|Yin Hu Qing Wen Decoction Group|Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
11071027|NCT04278963|Placebo Comparator|Yinhu Qingwen Decoction low-dose group|Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
11071100|NCT04278534|Active Comparator|Observational Cohort (usual education materials)|Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
11071113|NCT04278456||epidural anesthesia|c-section with epidural anesthesia
11071028|NCT04278963|Active Comparator|Integrated Chinese and Western Medicine group|Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml). The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
11071029|NCT04278950|Active Comparator|Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with 0.10% PVP-I (0.01% available iodine). Patients will be instructed to dilute 2.5mL of the betadine (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
11071030|NCT04278950|Placebo Comparator|Placebo Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with a placebo PVP-I solution. Patients will be instructed to dilute 2.5mL of the placebo PVP-I (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
11071031|NCT04278937|Active Comparator|Azithromycin group|women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
11071032|NCT04278937|No Intervention|Control group|women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
11071033|NCT04278924|Placebo Comparator|Part A: Double Blind, Placebo|TAK-079 placebo-matching injection subcutaneously (SC) once weekly (QW) for 8 weeks.
11071034|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 1|TAK-079 Dose 1, SC injection QW for 8 weeks.
11071035|NCT04278924|Experimental|Part A: Double Blind, TAK-079 Dose 2|TAK-079 Dose 2, SC injection QW for 8 weeks.
11071036|NCT04278924|Experimental|Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1|Participants who received placebo in double-blind Part A and opted to receive further treatment will be randomized to receive TAK-079 Dose 1, SC injection QW for 8 weeks in OLE phase of Part A.
11071037|NCT04278924|Experimental|Part A: OLE Phase, TAK-079 Dose 2|Participants who received placebo in double-blind Part A and opted to receive further treatment will be randomized to receive TAK-079 Dose 2, SC injection QW for 8 weeks in OLE phase of Part A.
11071038|NCT04278924|Placebo Comparator|Part B: Double Blind, Placebo|TAK-079 placebo-matching injection SC, QW for 8 weeks.
11071039|NCT04278924|Experimental|Part B: Double Blind, TAK-079 Dose 3|TAK-079 Dose 3, SC injection QW for 8 weeks.
11071040|NCT04278924|Experimental|Part B: OLE Phase, TAK-079 Dose 3|Participants who received placebo in double-blind Part B and opted to receive further treatment will be randomized to receive TAK-079 Dose 3, SC injection QW for 8 weeks in OLE phase of Part B.
11071041|NCT04278911||Participates|This is an observational study
11071042|NCT04278898|Experimental|N-acetylcysteine then Placebo|
11071043|NCT04278898|Experimental|Placebo then N-acetylcysteine|
11071044|NCT04278885|Experimental|Lanadelumab|
11071045|NCT04278872|Experimental|SJX-653 Dose 1|Participants will receive Dose 1 of SJX-653
11071046|NCT04278872|Experimental|SJX-653 Dose 2|Participants will receive Dose 2 of SJX-653
11071047|NCT04278872|Placebo Comparator|Placebo|Participants will receive placebo
11071048|NCT04278859|Experimental|0.3mg/kg repeat dose every 21 days up to 2 years|
11071049|NCT04278859|Experimental|1 mg/kg repeat dose every 21 days up to 2 years;|
11071050|NCT04278859|Experimental|3 mg/kg repeat dose every 21 days up to 2 years;|
11071051|NCT04278859|Experimental|10 mg/kg repeat dose every 21 days up to 2 years;|
11071052|NCT04278846|Experimental|DepoFoam bupivacaine|local anesthetic
11071053|NCT04278846|Active Comparator|bupivacaine HCl|local anesthetic
11071054|NCT04278833|Other|Particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 10-80mg of triamcinolone or 3-9mg of betamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
11071055|NCT04278833|Other|Non-particulate Corticosteroid Injection|Intra-articular, peri-tendinous, or intra-bursal corticosteroid injection using 4-10mg of dexamethasone depending on anatomical structure. Injections may be repeated up to 3 times in the 6 month study period based on physician discretion.
11071056|NCT04278820|Experimental|Climbing group|
11071057|NCT04278820|Experimental|Titration group|
11071058|NCT04278820|Experimental|Extension group|
11071059|NCT04278807|Experimental|PENG-group|Ultrasound-guided PENG-block - 30 patients
11071060|NCT04278807|Experimental|FIB-group|Ultrasound-guided Fascia Iliaca block - 30 patients
11071061|NCT04278794|Experimental|Transitional Care Stroke Intervention (TCSI)|Participants randomly assigned to the intervention group will be offered the intervention in addition to usual care provided by in-patient and outpatient stroke rehabilitation services. The TCSI is a 6-month stroke transitional care intervention, provided in addition to usual stroke care, that includes four core components: comprehensive hospital discharge plan, structured home visits and telephone support, monthly intraprofessional case conferences, and linkages to primary care and other healthcare and community services. The TCSI will be delivered by an interprofessional team of care providers at the study site, including an occupational therapist, registered nurse, speech language pathologist, physical therapist, and social worker from a hospital-based outpatient stroke rehabilitation setting.
11071062|NCT04278794|No Intervention|Control|Usual care provided by in-patient and out-patient stroke rehabilitation services.
11071063|NCT04278781|Experimental|Chondrosarcoma|Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma
11071064|NCT04278768|Experimental|CA-4948 dose escalation|Patients receive CA-4948 PO BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11071065|NCT04278755|Experimental|Continuous OC|Continuous daily oral drospirenone + ethinyl estradiol for 84 days (i.e., 12-weeks).
11071066|NCT04278742|Experimental|Interventional - collaborative education|Collaborative style of communication whereby the clinician and patient co-creates the treatment plan
11071067|NCT04278742|No Intervention|Control group|Traditional directive and didactic style of patient information will be provided
11071068|NCT04278729|Experimental|Nephrotic Syndrome Arm|Patients diagnosed with Nephrotic syndrome will be in this arm.
11071069|NCT04278729|Experimental|Healthy Arm|Healthy volunteers will be in this arm.
11071101|NCT04278521|Other|Unipolar Depression|Patients diagnosed with unipolar depression.
11071070|NCT04278716||Utilization of a safe return to play checklist|Athletes who were treated for a capsulolabral tear who have undergone arthroscopic capsulolabral repair surgery will be evaluated using an objective checklist prior to being allowed to return to their sport. The utilization and outcome of using this checklist will be evaluated
11071071|NCT04278703|Active Comparator|15 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
11071072|NCT04278703|Active Comparator|25 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
11071073|NCT04278703|Active Comparator|35 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
11071074|NCT04278690|No Intervention|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
11071075|NCT04278690|Experimental|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
11071076|NCT04278690|Experimental|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
11071077|NCT04278677|Active Comparator|Melatonin supplementation|5mg melatonin tablets to be taken for 6 weeks
11071078|NCT04278677|No Intervention|No supplementation|
11071079|NCT04278651|Active Comparator|Oral Iron|325mg oral iron (ferrous sulfate) twice daily
11071080|NCT04278651|Experimental|Intravenous Iron|510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.
11071081|NCT04278638|Experimental|with IORT|
11071082|NCT04278638|Active Comparator|without IORT|
11071083|NCT04278625||Cyanotic CHD|Cyanotic congenital heart disease (CHD) patients presenting for Fontan palliation.
11071084|NCT04278625||Acyanotic CHD|Acyanotic congenital heart disease (CHD) patients presenting for repair via median sternotomy.
11071085|NCT04278612|Experimental|Intervention|"Provision of comprehensive care including the following:
~Baby:
~Measure weight and length Plot on appropriate growth charts in Road to Health Card (RTHC) Discuss with mother about the growth of the baby Identification of malnutrition and appropriate management Age-appropriate nutrition counselling Immunisation Developmental screening Vitamin A supplementation Deworming HIV Care: If mother is HIV positive -
~Polymerase chain reaction (PCR) test for the baby repeated at 10 weeks
~Nevirapine for the baby for six weeks
~Mother:
~Cervical cancer screening Provide family planning Screening tuberculosis (TB) and sexually transmitted infections (STIs)
~HIV Care:
~HIV positive mothers - provide ART for the mother and adherence support
~HIV negative mothers- HIV test every three months while breastfeeding"
11071086|NCT04278612|Active Comparator|Control|Routine maternal and child care service delivery
11071087|NCT04278599|Experimental|Test group|The patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
11071088|NCT04278599|Placebo Comparator|Control group|The patients will be administered Placebo tablets for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
11071089|NCT04278586|Experimental|Mindful Recovery OUD Care Continuum|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
11071090|NCT04278586|Active Comparator|Group-Based Opioid Treatment|Group-Based Opioid Treatment (GBOT) is the standard of care at CHA and the majority of our study sites and is increasingly popular across the country. GBOT is characterized by five core components (PACTT) (Participation, Adherence to billing regulations, Consistency, Toxicology, and Team-based approach to complexity, and fourteen malleable components.
11071091|NCT04278573|Experimental|Vitamin D3 Treatment Group|Subjects will receive a Vitamin D3 injection into their wart
11071092|NCT04278573|Placebo Comparator|Placebo Group|Subjects will receive a placebo injection into their wart
11071093|NCT04278560|Experimental|Behavioral intervention plus tDCS|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of transcranial direct current stimulation (tDCS) designed to increase the excitability of the left dorsolateral prefrontal cortex.
11071094|NCT04278560|Active Comparator|Behavioral intervention plus sham stimulation|This intervention will consist of a two-month, personalized, goal-based counseling approach to promote physical activity. Over the first two weeks of the behavioral intervention, participants will also received 10, once-daily, 20-minute sessions of sham stimulation.
11071095|NCT04278547|Experimental|Experimental group|Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis;
11071096|NCT04278547|No Intervention|Control group|Standard of care, universal prophylaxis with valgancyclovir for 3 months).
11071097|NCT04278534|Experimental|Arm I (VERT)|Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
11071098|NCT04278534|Active Comparator|Arm II Control Group I (usual education materials)|Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
11071099|NCT04278534|Active Comparator|Arm II Control Group II (face-to-face education module)|Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
11071102|NCT04278508|Active Comparator|Group A|P < 10.0 ng/ml with increasing P dosage from 800 mg to 1200 mg daily from the FET day.
11071114|NCT04278443||Low dose rate brachytherapy|20 patients receiving low dose rate brachytherapy
11071115|NCT04278443||High dose rate brachytherapy|20 patients receiving high dose rate brachytherapy.
11071116|NCT04278430|Experimental|Real tDCS group|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 1.5 mA intensity
11071117|NCT04278430|Sham Comparator|Sham tDCS|The tDCS applied over dorsolateral prefrontal cortex for 20 minutes with 0 mA intensity.
11071118|NCT04278430|Active Comparator|Control|The normal heathy children age matched undergo the same activity and brain stimulation as the real tDCS group.
11071119|NCT04278417|Experimental|Brolucizumab Arm|Intra-vitreal injection
11071120|NCT04278417|Active Comparator|Panretinal photocoagulation laser Arm|laser
11071121|NCT04278404||Children and young adults who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
11071122|NCT04278391|Experimental|A (RT)|Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
11071123|NCT04278391|Experimental|B (TR)|Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)
11071124|NCT04278378|Active Comparator|Riboflavin|1.6 mg riboflavin / day for 24 weeks
11071125|NCT04278378|Experimental|Folic Acid|0.4 mg folic acid/ day for 24 weeks
11071126|NCT04278378|Experimental|Riboflavin + Folic Acid|1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
11071127|NCT04278378|Placebo Comparator|Placebo|
11071128|NCT04278365|Experimental|AMP-A|Participants will complete 11, 90-minute sessions of positive affect training. The positive affect training will be conducted in an individual setting. Positive affect training directly targets reward and positive valence processing and has been shown by previous research to enhance positive affect (and decrease negative affect).
11071129|NCT04278352|Experimental|Mindfulness Based Relapse Prevention|MBRP is a group aftercare program that integrates mindfulness skills training with cognitive-behavioral relapse prevention strategies. The intervention consists of eight weekly two-hour group therapy sessions, delivered by two facilitators with 10-12 people. The experimental group will complete the intervention in weeks 1-8. They will continue treatment as usual for weeks 9-16.
11071130|NCT04278352|No Intervention|Control|The waitlist control group will not receive the MBRP program during weeks 1-8 and will continue treatment as usual. During weeks 9-16, the control group will receive MBRP.
11071131|NCT04278339|Experimental|CONTROLLED SUBJECTS|In this arm, only controlled subjects (pathological-free) will be investigated.
11071132|NCT04278339|Experimental|PATIENTS|In this arm, only patients with scyzophrenic syndrome will be investigated.
11071133|NCT04278326|Experimental|Experimental|"Patients infected by oncogenic HPV and presented a high grade cervical dysplasia or a cervical cancer
~Patients with cervical or vaginal cancer
~All patients"
11071134|NCT04278313|Experimental|PRP group|Platelet RICH Plasma prepared using RegenLab FDA approved device.
11071135|NCT04278313|Placebo Comparator|PPP group|Platelet POOR Plasma prepared using RegenLab FDA approved device.
11071136|NCT04278300||case|patient with age-related exudative macular degeneration
11071137|NCT04278300||control|Patient with no macular disorder and in need of cataract surgery
11071138|NCT04278287|Experimental|Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy|Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).
11071139|NCT04278274||artificial intelligence system arm|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment will be enrolled. In arm A, the post-neoadjuvant treatment MRI images features will be captured by the artificial intelligence system, which further generate a predicted pathologic response to neoadjuvant treatment for each enrolled patient (pCR or non-pCR).
11071140|NCT04278274||radiologist group|the patients with locally advanced rectal cancer (LARC) finished the neoadjuvant treatment will be enrolled. In arm B, the post-neoadjuvant treatment MRI images will be reviewed by the experienced radiologists, who further yield a predicted pathologic response to neoadjuvant treatment for each enrolled patient (pCR or non-pCR).
11071141|NCT04278261|Experimental|Focal therapy|Using focal therapy(Irreversible electroporation) to treat patients with localized Prostate cancer
11071142|NCT04278261|Active Comparator|Radical prostatectomy|Using radical prostatectomy to treat patients with localized Prostate cancer
11071143|NCT04278248|Experimental|experimental group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose
11071144|NCT04278248|Active Comparator|Positive control group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose
11071145|NCT04278222|Experimental|Anlotinib Plus Toripalimab|the combination of Anlotinib Plus Toripalimab as first-line treatment
11071146|NCT04278209|Experimental|Breakfast 1 - Breakfast 2|Participants will receive Breakfast 1 then Breakfast 2.
11071147|NCT04278209|Experimental|Breakfast 1 - water|Participants will receive Breakfast 1, then water.
11071148|NCT04278209|Experimental|Breakfast 2 - water|Participants will receive Breakfast 2, then water.
11071149|NCT04278209|Experimental|Breakfast 2 - Breakfast 1|Participants will receive 2 servings, then 1 serving of the study product.
11071150|NCT04278209|Experimental|Water - Breakfast 1|Participants will receive water, then Breakfast 1.
11071151|NCT04278209|Experimental|Water - Breakfast 2|Participants will receive water, then Breakfast 2.
11071152|NCT04278170||Case group|Rheumatoid arthritis patients who met the American College of Rheumatology (ACR) 2010 RA classification
11071153|NCT04278157|Experimental|SCBT-SB|A culturally centered CBT treatment protocol called Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
11071154|NCT04278157|Active Comparator|Treatment as Usual|Treatment as usual is base on the standard care for teens and their parents under a community mental health center.
11071155|NCT04278144|Experimental|Single agent BDC-1001|Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies
11071156|NCT04278144|Experimental|Combination BDC-1001 plus pembrolizumab|Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies
11071157|NCT04278131|Experimental|Cohort 1|BSO1 Cohort 1 dose
11071158|NCT04278131|Experimental|Cohort 2|BS01 Cohort 2 dose
11071160|NCT04278118|Experimental|Cohort I (hypofractionated radiation therapy)|Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
11071161|NCT04278118|Experimental|Cohort II (hypofractionated radiation therapy)|Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
11071162|NCT04278105|Experimental|HD-tCES & upper extremity rehabilitation|The experiment group will receive HD-tCES combined with upper extremity rehabilitation of affected side.
11071163|NCT04278105|Sham Comparator|Sham HD-tCES & upper extremity rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
11071164|NCT04278092|Experimental|Paclitaxel plus Cetuximab|Paclitaxel combination with weekly cetuximab will be administered for up to six cycles. Thereafter weekly cetuximab maintenance will be given.
11071165|NCT04278053|Experimental|Nitrosigine supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Nitrosigine (1.5 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
11071166|NCT04278053|Experimental|Citrulline-Malate supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Citrulline-Malate (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
11071167|NCT04278053|Placebo Comparator|Placebo|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, dextrose (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
11071168|NCT04278040|Experimental|Non-cystic fibrosis bronchiectasis (NCFB) patients|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 5 consequent days
11071169|NCT04278027|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy. CRT will be based on CIRCuiTS, a computerized program.
11071170|NCT04278027|No Intervention|Treatment as usual|Treatment as usual
11071171|NCT04278001|Other|Ambulatory blood pressure measurement|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
11071172|NCT04277988||Crossed leg position|Patients in this group will be randomly allocated to sit in crossed leg position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
11071173|NCT04277988||Standard Sitting position|Patients in this group will be randomly allocated to sit in standard position first.Ultrasonography will be performed in this position to measure the best visualized length of posterior longitudinal ligament, ligamentum flavum and interlaminar distance at L3-4 lumbar level as by Operator 1 . These measurements will be recorded by Operator 2 using intrinsic caliper software.Operator 1 will not be told the measurements.
11071174|NCT04277975|Active Comparator|A: liberal post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + liberal opioid prescription provided prior to surgery (standard prescription for opioid prescribed prior to surgery)
11071175|NCT04277975|Experimental|B: restricted post-discharge opioid prescribing|Standardized postoperative instructions on non-opioid pain control + opioid prescribed only 'as needed' after discharge
11071176|NCT04277962|Experimental|Patients having vaginal delivery|EBL will be estimated visually vs quantitatively at time of vaginal delivery.
11071177|NCT04277949|Experimental|Erbium laser|All participants will receive Erbium laser treatment on their right post-auricular region
11071178|NCT04277949|Experimental|DNA repair enzyme|All participants will apply topical DNA repair enzymes on their left post-auricular region
11071179|NCT04277936|Experimental|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
11071180|NCT04277923|Experimental|SMOF lipid emulsion|the SMOF lipid emulsion is SMOFlipid.
11071181|NCT04277923|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin.
11071182|NCT04277910|Active Comparator|MT2004|MT2004 oral capsules treated group
11071183|NCT04277910|Placebo Comparator|Placebo|Placebo oral capsules treated group
11071184|NCT04277897|Experimental|Drug SAD Cohorts|Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.
11102222|NCT04060927|Experimental|Group 2|Breath hold SBRT with SGRT
11071185|NCT04277897|Placebo Comparator|Placebo SAD Cohorts|Matching placebo, orally, once daily in one single administration.
11071186|NCT04277897|Experimental|Drug MAD Group|Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.
11071187|NCT04277897|Placebo Comparator|Placebo MAD Group|Matching placebo, orally, once daily for 7 days.
11071188|NCT04277897|Experimental|Food-influnced Group|Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.
11071189|NCT04277884|Experimental|Firibastat|Capsules
11071190|NCT04277884|Placebo Comparator|Placebo|Matching capsules
11071191|NCT04277871|Experimental|The intervention group|The intervention group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The intervention group attended on-site group practice sections and performed individual home-based practice.
11071192|NCT04277871|Active Comparator|The comparison group|The comparison group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The comparison group performed individual home-based practice only.
11071193|NCT04277858|Experimental|Neoadjuvant chemotherapy and surgery|"Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.
~Carboplatin may be used instead of Cisplatin."
11071194|NCT04277845|Experimental|Group 1|"Bortezomib 1.3mg/m2 SC D1, 8, 15
~- Dose adjustment for more than 85 : 1.0mg/m2 SC D1, 8, 15
~Lenalidomide 25mg/d D1-21
~Dexamethasone 40mg D1, 8, 15
~Dose adjustment for more than 75 years old: 20mg If it is difficult to maintain bortezomib due to unacceptable toxicity, it can early discontinue from Group 1.
~If a patient is frail, the starting dosage will be as follows.
~Bortezomib 1.0mg/m2 SC D1, 8, 15
~- Dose adjustment for more than 85 : 1.0mg/m2 SC D1,8,15
~Lenalidomide 15mg/d D1-21
~Dexamethasone 40mg D1, 8, 15
~Dose adjustment for more than 75: 20mg"
11071195|NCT04277845|Active Comparator|Group 2|"Lenalidomide 25mg/d D1-21
~Dexamethasone 40mg D1, 8, 15, 22
~Dose adjustment for more than 75: 20mg
~If a patient is frail in both study group, the starting dosage will be as follows.
~Lenalidomide 15mg/d D1-21
~Dexamethasone 40mg D1, 8, 15
~Dose adjustment for more than 75: 20mg ."
11071196|NCT04277832||single arm|Group of psoriasis patients will select randomly. All selected psoriasis patients will be consulted to a physician experienced in rheumatology and all of patients will fill TUPAST and TOPAS 2 forms.
11071197|NCT04277819||Patients with cystic fibrosis related liver disease|Patients with cystic fibrosis, who meet the criteria for diagnosis of liver disease according to the European Cystic Fibrosis Society best practice guidelines
11071198|NCT04277819||Patients without cystic fibrosis related liver disease|
11071199|NCT04277806|No Intervention|Standard group|No interventions would be conducted in this group and the preterm infants would be fed in the normal way.
11071200|NCT04277806|Experimental|Intervention group|The preterm infants in this group would be fed according to the new process.
11071201|NCT04277793|Experimental|Monitored self-guided problem solving intervention|Monitored self-guided problem solving intervention
11071202|NCT04277780|Experimental|CGM Sensor|Subjects will receive the Libre Pro Freestyle continuous glucose monitor (CGM) sensor that will be applied to their upper arm at the time of hospital discharge. They will be asked to peel off the sensor after 14 days and mail it to the endocrinology clinic in a stamped envelope that will be provided. They will also be provided the conventional diabetes management which will include instructions on fingerstick blood glucose monitoring and logging which they will start after the CGM sensor is removed. The sensor data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time the sensor is placed for further management of their diabetes.
11071203|NCT04277780|Active Comparator|Conventional Diabetes Care|Subjects will receive only the conventional diabetes management at the time of hospital discharge which includes instruction on fingerstick blood glucose monitoring and logging onto a blood glucose log sheet for 14 days. They will then be asked to fax/mail/call-in the blood glucose log. The log data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time of hospital discharge for further management of their diabetes.
11071204|NCT04277767||mild cognitive impairment (MCI)|observational
11071205|NCT04277767||Patients with mild to moderate AD|observational
11071206|NCT04277767||Normal controls|observational
11071207|NCT04277754||two-year-old children with typical development|
11071208|NCT04277741|Experimental|Resistant starch bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
11071209|NCT04277741|Active Comparator|Native wheat bar|The control group will consume one native wheat starch bar per day.
11071210|NCT04277715|Experimental|Parent training|Parents of participating children with chronic symptoms will receive the intervention in a group format. Groups will last 90-minutes and run for 8-weeks. Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
11071211|NCT04277702|Experimental|Montelukast + standard treatment|
11071212|NCT04277702|Placebo Comparator|Placebo+ standard treatment|
11071213|NCT04277689|Experimental|Brain signal data collection|Collection of brain data during deep brain stimulation
11071214|NCT04277663|Experimental|IBI310 + IBI308|Participants will be treated with IBI310 in combination with IBI308
11071215|NCT04277663|Experimental|IBI308|Participants will be treated with IBI308
11071216|NCT04277663|Active Comparator|high-dose recombinant interferon a-2B|Participants will be treated with recombinant interferon a-2B
11071217|NCT04277650|Active Comparator|Once weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided once weekly clinical evaluations
11071218|NCT04277650|Experimental|Twice weekly clinical evaluation|Outpatient participants evaluated as high risk by the machine learning algorithm and provided twice weekly clinical evaluations
11071277|NCT04277286||Control group|Patients transferred to adult service without a transition program, in the same center, before the implementation of Transend (between January 2015 and September 2016)
11071309|NCT04277104|Experimental|MCI (mild cognitive impairment) intervention|Acoustic stimulation
11071219|NCT04277637|Experimental|BGB-11417 Monotherapy Dose Finding: Part 1|Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined
11071220|NCT04277637|Experimental|BGB-11417 Monotherapy Expansion Cohorts: Part 2|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile
11071221|NCT04277624|Experimental|Fezolinetant: Test Formulation then Reference Formulation|Participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 2.
11071222|NCT04277624|Experimental|Fezolinetant: Reference Formulation then Test Formulation|Participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 2.
11071223|NCT04277611|Active Comparator|QLB|The patient is in the prone position. A low-frequency convex probe is placed in a transverse, oblique, and paramedian orientation approximately lateral to the posterior axillary line. The needle is then inserted in-plane from the medial side of the transducer and advanced laterally to enter the interfascial plane between the Quadratus Lumborum muscle and the kidney. We confirmed that the local anesthetic appeared to press down the kidney in the ultrasound image
11071224|NCT04277611|Active Comparator|ESPB|Using aseptic technique, a high frequency linear array transducer was placed at the T9 vertebral level. After identifying the ribs and sliding towards the midline in a longitudinal parasagittal orientation, the overlying Erector Spinae is identified by visualization of the transition between the rib and transverse apophysis a block needle is inserted in plane with ultrasound beam and is advanced in a cephalo-caudal direction until the tip contacted the transverse process.
11071225|NCT04277598|Experimental|Lead In Phase: APO-2: 25U/ml|Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;
11071226|NCT04277598|Placebo Comparator|Lead In Phase: Placebo|Topical administration of placebo; 0.5 ml per square cm wound;
11071227|NCT04277598|Experimental|Main Phase: APO-2: 12.5 U/ml|Topical administration of APO-2, 12.5 U/ml; 0.5 ml per square cm wound;
11071228|NCT04277598|Experimental|Main Phase: APO-2: 25 U/ml|Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;
11071229|NCT04277598|Experimental|Main Phase: APO-2: 50 U/ml|Topical administration of APO-2, 50 U/ml; 0.5 ml per square cm wound;
11071230|NCT04277598|Placebo Comparator|Main Phase: Placebo|Topical administration of placebo; 0.5 ml per square cm wound;
11071231|NCT04277585|Experimental|OASIS Clients|Clients of the OASIS Program who live at least 45 minutes away from an Early Psychosis Coordinated Specialty Care Program and are willing to engage in some of their services through telehealth.
11071232|NCT04277572||Aortic valve replacement|using different ways of aortic valve replacement either by prosthetic valves or by ozaki technique
11071233|NCT04277559|Active Comparator|Patient preferential music|The preference of the patients will be listened to preoperatively through the headphones.
11071234|NCT04277559|Active Comparator|Classical music|Classical music (Four Seasons from Vivaldi) will be listened to preoperatively through the headphones.
11071235|NCT04277559|Placebo Comparator|No music|the patients will not listen.
11071236|NCT04277546|Experimental|Brazikumab Maintenance Dose (Low)|Subcutaneous Brazikumab Day 1 and every 4 weeks through Day 365
11071237|NCT04277546|Experimental|Brazikumab Maintenance Dose (High)|Subcutaneous Brazikumab at Day 1 and every 4 weeks through Day 365
11071238|NCT04277546|Experimental|Brazikumab Induction Dose|Intravenous Brazikumab at Day 1, Day 15, and Day 43, followed by SC Brazikumab every 4 weeks beginning at Day 71 through Day 351
11071239|NCT04277533||Patient group|NEC preterm neonates with gestational ages are between 28-36 weeks regardless of birth weight. NEC diagnosis and staging will be according to Bell's staging criteria .
11071240|NCT04277533||Control group|Stable preterm neonate with matched gestational and postnatal ages without infectious diseases.
11071241|NCT04277520|Active Comparator|Continous rotation|Continuous Rotation motion
11071242|NCT04277520|Active Comparator|Reciprocation|Reciprocation motion
11071243|NCT04277520|Active Comparator|Adaptive motion|Adaptive motion
11071244|NCT04277507|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
11071245|NCT04277494|Experimental|Clorethyl cold spray® (Vapocoolant spray)|"23 volunteer athletes who are studying at the Faculty of Health Sciences of Acıbadem University, between the ages of 18-23, with a subcutaneous fold thickness of the quadriceps muscle between 5 mm and 15 mm (Shadgan et al., 2015).
~From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application."
11071246|NCT04277481||Group 1 (10 minute cold pack)|10 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
11071247|NCT04277481||Group 2 (12 minute cold pack)|12 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
11071248|NCT04277481||Group 3 (15 minute cold pack)|15 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
11071249|NCT04277481||Group 4 (20 minute cold pack)|20 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
11071278|NCT04277273|Other|Patients treated in the MaxilloFacial Prosthesis consultation|Patients treated in the MaxilloFacial Prosthesis consultation (Dental Department, Pitié-Salpêtrière Hospital Group)
11071250|NCT04277442|Experimental|Treatment (nivolumab, decitabine, venetoclax)|"INDUCTION: Patients receive nivolumab IV over 30 minutes on day 15 of cycle 1 and days 1 and 15 of subsequent cycles, decitabine IV over 60 minutes on days 1-10 of induction cycle 1 (and cycles 2 and 3 if needed), and venetoclax PO QD on days 1-21. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients who achieve a CR or CRi receive nivolumab IV over 30 minutes on days 1 and 15, decitabine IV over 60 minutes on days 1-5, and venetoclax PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11071251|NCT04277429||Normal cardiac function|Normal cardiac function
11071252|NCT04277429||Heart failure with reduced ejection fraction|Heart failure with reduced ejection fraction
11071253|NCT04277429||Heart failure with preserved ejection fraction|Heart failure with preserved ejection fraction
11071254|NCT04277416||Entrada Hip System|All orthopaedic patients that are scheduled to undergo primary total hip arthroplasty using the Entrada™ Hip System within 12 weeks will be screened for the following eligibility criteria.
11071255|NCT04277403|Experimental|HA-WBRT+SIB|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
11071256|NCT04277403|Active Comparator|SRS|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
11071257|NCT04277390||Controls|145 systemically and periodontally healthy pregnant women Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
11071258|NCT04277390||Group A|"Group A-100 Systemically healthy pregnant women with chronic periodontitis.
~Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155."
11071259|NCT04277390||Group B|Group B- 100 Preeclamptic pregnant women with chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
11071260|NCT04277390||Group C|Group C-100 Preeclamptic pregnant women without chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
11071261|NCT04277377||DSA in patients with kidney failure|Patients on kidney transplantation waiting list with DSA detected by Luminex (and mean fluorescence intensity (MFI) > 1000) in their blood.
11071262|NCT04277364|Active Comparator|High dose phosphatidic acid|750mg of phosphatidic acid per day for 8 weeks
11071263|NCT04277364|Active Comparator|Low dose phosphatidic acid|375mg of phosphatidic acid per day for 8 weeks
11071264|NCT04277364|Placebo Comparator|Placebo|750mg of corn starch per day for 8 weeks
11071265|NCT04277351|Experimental|tACS in individuals with and without dyslexia|Each participant in both the group of normo-readers and individuals with dyslexia receive all tACS stimulation conditions (fixed frequencies and sham) over different experimental days.
11071266|NCT04277338||The tested injected doses of 99mTc- HE3-G3 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.
~Subjects withdrawn from the study for any reason will be replaced."
11071267|NCT04277338||The tested injected doses of 99mTc- HE3-G3 2000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.
~Subjects withdrawn from the study for any reason will be replaced."
11071268|NCT04277325|Experimental|Intervention|Couples will receive 19-21 free sessions of Emotionally-Focused Therapy.
11071269|NCT04277325|No Intervention|Waitlist|Couples will receive no intervention during the trial. After the trial is ended, they will be invited to participate in a weekend intervention meeting.
11071270|NCT04277312|Experimental|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
11071271|NCT04277312|Experimental|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
11071272|NCT04277312|Experimental|Nourish and Engage|This arm of the intervention delivered both the Nourish and Engage interventions as detailed above.
11071273|NCT04277312|No Intervention|Delayed|The delayed arm of the intervention was the control arm. Schools randomised to this arm of the study were offered the Engage intervention resources after endpoint data collection.
11071274|NCT04277299|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Solution which is the surgical pathway currently practiced in the study hospital. The ICory-Solution has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
11071275|NCT04277299|No Intervention|Control group|Children in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care. Parents in this group will receive BuddyCare mobile app which is supposed to be as a normal routine in this hospital.
11071276|NCT04277286||Experimental group|Patients transferred to adult service according to the Transend transition program (between September 2016 and January 2018)
11071307|NCT04277104|Experimental|At risk intervention|Acoustic stimulation
11071279|NCT04277260||Full term delivery|In the cooperative obstetric hospital, 30 cases of full-term delivery healthy mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
11071280|NCT04277260||Preterm delivery(35-37 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(35-37 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
11071281|NCT04277260||Preterm delivery(32-35 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(32-35 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
11071282|NCT04277260||Preterm delivery(28-32 weeks)|In the cooperative obstetric hospital, 30 cases of preterm delivery(28-32 weeks) mothers and their infants are selected. Each pair of nursing mothers and infants will complete the observation for 6 months. The samples of human milk and newborn feces are the experimental objects.
11071283|NCT04277247|Experimental|Botulinum Toxin Type A Treatment|Injections
11071284|NCT04277247|Placebo Comparator|Placebo|Injections
11071285|NCT04277221|Experimental|Standard therapy with ADCTA vaccine (study group)|"- ADCTA vaccine as study treatment
~Dose(s): Ten doses, including 2~4×10^7 cells for the 1st dose (double doses), and 1~2×10^7cells for the 2nd to 10th doses.
~Administrative route: The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic.
~Frequency: The primary immunization inoculation is followed by 3 vaccines bi-weekly and then 6 vaccines monthly inoculation, for a total of 10 doses.
~- Bevacizumab as standard therapy"
11071286|NCT04277221|Active Comparator|Standard therapy (control group)|"No study treatment
~Bevacizumab as standard therapy"
11071287|NCT04277208||Arthroscopic Rotator Cuff Repair|
11071288|NCT04277195||NUH Adjuvant Breast Cancer Cohort: Historical|This is a series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (1986-1999; n=1650). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
11071289|NCT04277195||NUH Adjuvant Breast Cancer Cohort: New|A series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (2000-2006; n=2000). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
11071290|NCT04277195||NUH Neoadjuvant Breast Cancer Cohort|For many years clinical data on this cohort of breast cancer patients has been collected in a master clinical database by the clinical team supporting Dr Chan (1996-2021; n=900 patients). This has been used for internal audits and reviews of clinical practice. The study research team will work with a pseudo-anonymised copy of this dataset.
11071291|NCT04277195||NUH Oncotype DX tested Adjuvant Breast Cancer Cohort|A list of patients tested with Oncotype DX as part of their standard treatment pathway (2015-2021; n=200) will be collected and will form the basis of a master clinical database for this cohort. The database will be managed and populated by the clinical team supporting Dr Chan. The study research team will work with a pseudo-anonymised copy of this dataset.
11071292|NCT04277182|Placebo Comparator|Control group|It will be accepted as the control group and 4 experimental burn wounds will be created on the back of the rats in the group and no treatment will be given.
11071293|NCT04277182|Active Comparator|1% Silver Sulfadiazine|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 1% Silver Sulfadiazine will be done on the back of the rats every day for 21 days.
11071294|NCT04277182|Active Comparator|%0.2 Nitrafurozon|4 experimental burn wounds will be created on the back of the rats in the group and dressing with %0.2 Nitrafurozon will be done on the back of the rats every day for 21 days.
11071295|NCT04277182|Experimental|10% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 10% Propolis will be done on the back of the rats every day for 21 days.
11071296|NCT04277182|Experimental|15% Propolis|4 experimental burn wounds will be created on the back of the rats in the group and dressing with 15% Propolis will be done on the back of the rats every day for 21 days.
11071297|NCT04277182|Active Comparator|Propolis vehicle|4 experimental burn wounds will be created on the back of the rats in the group and dressing with Propolis vehicle will be done on the back of the rats every day for 21 days.
11071298|NCT04277156|Experimental|Flostrum Baby|"The test product will be Flostrum Baby, which is a food supplement consisting of two bacterial strains: Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063, 5x10^9 CFU and 1x10^8 CFU, respectively, per seven drops.
~Flostrum Baby - in children below 12 years of age, 7 drops, twice daily; in children older than 12 years, 14 drops, twice daily."
11071299|NCT04277156|Active Comparator|Dicoflor|"The control product will be Dicoflor, which is a food supplement containing L rhamnosus ATCC 53103, 5x10^9 CFU, per five drops.
~Dicoflor - the manufacturer recommends 5-10 drops daily, with no age specification. For the purposes of this study, 5 drops, twice daily, in children below 12 years of age; 10 drops, twice daily, in children older than 12 years."
11071300|NCT04277143||critical ill patient with bloodstream infections|Severe patients with bloodstream infections often have sepsis / septic shock, acute kidney injury (AKI), hypoproteinemia, and renal replacement treatment.
11071301|NCT04277130|Experimental|Intervention group|Intervention with active video games
11071302|NCT04277130|No Intervention|Control group|No intervention
11071303|NCT04277117|Experimental|Medically Tailored Meal Delivery|1 ready-to-eat and 1 frozen medically tailored meal delivered by Meals on Wheels volunteers/drivers Monday through Friday.
11071304|NCT04277117|Other|Remain on interest list|participants randomized to remain on the Meals on Wheels interest list will receive regular Meals on Wheels services when they reach the top of the list (typically 4-6 months from placement on the list).
11071305|NCT04277104|Experimental|Healthy intervention|Acoustic stimulation
11071306|NCT04277104|Sham Comparator|Healthy sham|No stimulation
11071310|NCT04277104|Sham Comparator|MCI (mild cognitive impairment) sham|No stimulation
11071311|NCT04277091|No Intervention|Control|No exercise
11071312|NCT04277091|Experimental|High-intensity interval exercise|10 x 60 s intervals at 80% peak power output (interspersed with 60 s recovery intervals at 10% peak power output)
11071313|NCT04277091|Experimental|Moderate-intensity continous exercise|50% peak power output (duration determined to elicit same energy expenditure as high-intensity interval exercise condition)
11071314|NCT04277078||Intubated asthma attack|Patients who had been hospitalised with asthma attack, then intubated during hospitalisation.
11071315|NCT04277078||Non-Intubated asthma attack|Patients who had been hospitalised with asthma attack without intubation during hospitalisation.
11071316|NCT04277065|Experimental|Bulldog tourniquet in laparoscopic Hepatectomy|The bulldog tourniquet , a reusable vessel occlusion instrument forblocking the liver inflow-blood in laparoscopic liver resection, was uniformly employed in all patients randomized to Bulldog laparoscopic hepatectom group in the present study.
11071317|NCT04277065|Active Comparator|cotton tourniquet in laparoscopic Hepatectomy|The cotton tourniquet ,a reusable vessel occlusion instrument for blocking the liver inflow-blood in laparoscopic liver resection
11071318|NCT04277052|Experimental|Group 1|Muscle disorders
11071319|NCT04277052|Experimental|Group 2|Disc displacements
11071320|NCT04277052|Experimental|Group 3|Other common joint disorders
11071321|NCT04277052|Experimental|Group 4|Mix type
11071322|NCT04277052|Experimental|Group 5|Healthy individuals
11071323|NCT04277039|Experimental|OMT+CT|It consists of 8 sessions of osteopathic treatment and two 20-min sessions of cognitive training per week per 2 months
11071324|NCT04277039|Active Comparator|osteopathic treatment|It consists of 8 sessions of osteopathic treatment throughout the 2-month study period
11071325|NCT04277039|Other|usual care|patients will continue the routine care as established by international guidelines
11071326|NCT04277026|Experimental|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals. The intervention will take place two times per week for four weeks (Weeks 1-4). During weeks 5-8 the experimental group will continue treatment as usual and will not be receiving the mindful walking intervention.
11071327|NCT04277026|No Intervention|Control|Participants will engage in treatment as usual during the first four weeks and will not be receiving the experimental intervention (mindful walking) during weeks 1-4. After the experimental group completes the mindful walking intervention, the control group will complete the mindful walking intervention (weeks 5-8).
11071328|NCT04276987|Experimental|MSCs-derived Exosomes Treatment Group|Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
11071329|NCT04276974|Experimental|Organic first then non-organic|Organic diet then non-organic diet, each for 4 consecutive days
11071330|NCT04276974|Experimental|Non-organic first then organic|Non-organic diet then organic diet, each for 4 consecutive days
11071331|NCT04276961|Experimental|Acupuncture plus usual care|Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
11071332|NCT04276961|Sham Comparator|Sham acupuncture plus usual care|Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
11071333|NCT04276948|Experimental|Active1|312 mg dose of active
11071334|NCT04276948|Experimental|Active2|812 mg dose of active
11071335|NCT04276948|Placebo Comparator|Placebo|placebo
11071336|NCT04276935||Health Services Research (cognitive interviews)|Participants take part in cognitive interviews in Spanish over 45-60 minutes.
11071337|NCT04276922|Experimental|Visual Arts Group|Visual Arts group - sketch journals
11071338|NCT04276922|Experimental|Music Group|Music group involves music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making.
11071339|NCT04276922|Experimental|Dance/Movement Group|Dance/Movement group - movement check-in, gentle physical warm-up, and then either a structured or improvisational movement process.
11071340|NCT04276922|Experimental|Writing/Poetry Group|Writing/Poetry group uses writing workshops using integral elements of good writing.
11071341|NCT04276922|Experimental|Control Group|Surveys at baseline and 12 weeks later.
11071342|NCT04276909|Experimental|Lum Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection at the beginning of the surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
11071343|NCT04276896|Experimental|pathogen-specific DC and CTLs|Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
11071344|NCT04276883|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
11071345|NCT04276883|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
11071346|NCT04276883|Placebo Comparator|Placebo|Sublingual placebo film
11071347|NCT04276870|Experimental|Subjects with hypodiploid B-ALL|
11071348|NCT04276870|Experimental|Subjects with t(17;19) B-ALL|
11071349|NCT04276870|Experimental|Infant subjects with very high risk KMT2A B-ALL|
11071350|NCT04276870|Experimental|Subjects with central nervous system (CNS) relapse who did not|
11071351|NCT04276857|Other|Single arm study|All eligible patients will receive combination chemotherapy and if there i s a positive response they will undergo IRE.
11071352|NCT04276844||Non diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test ≥ 16 mm for women and ≥ 18 mm for men
11071353|NCT04276844||Persistent diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test < 16 mm for women and < 18 mm for men
11071354|NCT04276831|Active Comparator|Laryngoscope McCoy|Patients will be intubated using laryngoscope McCoy
11071355|NCT04276831|Active Comparator|Laryngoscope Macintosh|Patients will be intubated using laryngoscope Macintosh
11071356|NCT04276818|Active Comparator|PRP group|Second-degree superficial burn group treated with PRP
11071357|NCT04276818|Active Comparator|conventional treatment group|second-degree superficial burn group treated with cream containing silver sulfadiazine
11071358|NCT04276805|Active Comparator|tVNS group|Participants will undergo cognitive training with tVNS
11071359|NCT04276805|Sham Comparator|Sham group|Participants will undergo cognitive training with earlobe sham
11071360|NCT04276792|Experimental|Horizontal implementation approach|The Horizontal implementation approach of the O-TLM intervention is accompanied by facilitated collaboration between Criminal Justice and Community Behavioral Health systems. Direct involvement of stakeholders with differing perspectives and buy-in from agency leadership and policymakers are key elements. The Horizontal approach involves first developing a prototype (including how to modify existing practices, overcome implementation barriers, and manage roles and responsibilities) that are tested and refined before being rolled out systematically to other units within an agency.
11071361|NCT04276792|Active Comparator|Vertical implementation approach|The Vertical implementation approach of the O-TLM intervention relies on the traditional criminal justice system's typical use of a hierarchical structure and the use of a top-down implementation approach (i.e., administrative orders) for directing change. Top-down regulatory and policy changes are viewed as vital levers for driving system change.
11071362|NCT04276779|Experimental|Alcohol and Negative Mood|
11071363|NCT04276779|Placebo Comparator|Placebo and Negative Mood|
11071364|NCT04276779|Active Comparator|Alcohol and Positive Mood|
11071365|NCT04276779|Placebo Comparator|Placebo and Positive Mood|
11071366|NCT04276766|Experimental|Beetroot|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the beetroot group were asked to consume 140ml beetroot juice (James White Drinks Company, Suffolk, UK). The 140 ml of beetroot juice equate to approximately 8.4 mmol of NO3- ."
11071367|NCT04276766|Placebo Comparator|Placebo|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the placebo group were asked to consume 140 ml nitrate-depleted beetroot juice (James White Drinks Company, Suffolk, UK)."
11071368|NCT04276753|Experimental|Terminalia Chebula fruit extract|"The test product is an emulsion. It contains Terminalia Chebula fruit extract.
~Test product will be applied topically on full face twice a day for 8 weeks."
11071369|NCT04276753|Placebo Comparator|Placebo|"The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.
~Placebo emulsion will be applied topically on full face twice a day for 8 weeks."
11071370|NCT04276740|Active Comparator|MitoQ|Participants will take oral MitoQ 40 mg daily
11071371|NCT04276740|Placebo Comparator|Placebo|Participants will take an oral matched placebo daily
11071372|NCT04276727|Active Comparator|Menthol|Menthol gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
11071373|NCT04276727|Placebo Comparator|Placebo|Placebo gel to be applied twice a day for 6 weeks - toes to knees, fingertips to elbows, top and base of spine.
11071374|NCT04276714|Experimental|Adjustable socket|First week of the study is with adjustable socket
11071375|NCT04276714|Experimental|Classical socket|First week of the study is with classical socket
11071376|NCT04276701|Experimental|Systemic lupus erythematosus (SLE)|
11071377|NCT04276688|Active Comparator|Study group|triple combination
11071378|NCT04276688|Active Comparator|Control group|single
11071379|NCT04276662|Experimental|Cohort 1: Mild hepatic impairment|Participants who have mild hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
11071380|NCT04276662|Experimental|Cohort 2: Moderate hepatic impairment|Participants who have moderate hepatic impairment as assessed by National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria.
11071381|NCT04276662|Experimental|Cohort 3: Healthy participants|Healthy participants who have normal hepatic function with sex, age (±10 years [y]), and weight (±20%) matching with the mild and moderate hepatic impairment cohorts.
11071382|NCT04276649|Experimental|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
11071383|NCT04276649|No Intervention|Control|The other group do not interfere.
11071384|NCT04276636|Experimental|Caltrate|This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
11071385|NCT04276636|No Intervention|Control|The other group do not interfere.
11071386|NCT04276610|No Intervention|Healthy Control Participants|Older adults (65+) without impairments in vision or hearing. This groups will simply be followed for the study period (1 year), measured at 6 months intervals, to provide control comparison data for all outcome measures
11071387|NCT04276610|Experimental|Low Vision Participants|Older adults (65+) with impairments in vision but without hearing impairment. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
11071388|NCT04276610|Experimental|Dual Sensory Impairment Participants|Older adults (65+) with impairments in both vision hearing hearing. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
11071389|NCT04276597|Experimental|Lu177 DOTATOC treatment|4 doses of 200mCi 177Lu- DOTATOC PRRT
11071390|NCT04276584|Active Comparator|Positive airway pressure (PEP)|Deep inspiration followed by expiration to a resistance of 10-15 cm H2O. Done three times, each time with 10 inspiration/expiration cycles
11071391|NCT04276584|Experimental|Speaking loudly|Speaking loudly during 3 minutes.
11071392|NCT04276584|Experimental|Singing|Singing a Swedish song. The study will end with this song.
11071393|NCT04276571|Experimental|GRAIL|
11071394|NCT04276571|No Intervention|No treatment|
11071395|NCT04276558|Experimental|Dose 1 - 0.5 µg/day|Dose of study drug per day: 0.5 µg/day Study drug concentration: 5 µg/mL MT8 given 1 drop QID
11071396|NCT04276558|Experimental|Dose 2 - 2.5 µg/day|Dose of study drug per day: 2.5 µg/day Study drug concentration: 25 µg/mL MT8 given 1 drop QID
11071397|NCT04276558|Experimental|Dose 3 - 5 µg/day|Dose of study drug per day: 5 µg/day Study drug concentration: 50 µg/mL MT8 given 1 drop QID
11071398|NCT04276558|Placebo Comparator|Vehicle|Dose of study drug per day: 0 µg/day Study drug concentration: Vehicle given 1 drop QID
11102356|NCT04059939|Experimental|Reading Plus Anxiety|
11071399|NCT04276545|Experimental|IV administration of dexmedetomidine|IV administration of a single loading dose DEX (0.5μg/kg)
11071400|NCT04276545|Active Comparator|IV administration of midazolam|IV administration of midazolam (0.05mg/kg)
11071401|NCT04276532|Experimental|Sentinel lymph node sampling|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN)
11071402|NCT04276532|Active Comparator|Pelvic lymphadenectomy|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
11071403|NCT04276519|Experimental|Experimental|Physiotherapeutic non-invasive position-induced opening of the intervertebral foramen and pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
11071404|NCT04276519|Active Comparator|Control group|Pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
11071405|NCT04276506|Experimental|information booklet group|information session before the coronary angiography
11071406|NCT04276506|Experimental|music group|music session before the coronary angiography
11071407|NCT04276506|No Intervention|control group|No information or music session before the coronary angiography
11071408|NCT04276493|Experimental|Cohort 1- ZW25 + Docetaxel|ZW25 intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer
11071409|NCT04276493|Experimental|Cohort 2- ZW25 + Tiselizumab + Chemotherapy|ZW25 intravenous (IV) infusion followed by tiselizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma
11071410|NCT04276480|Experimental|Intervention|The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
11071411|NCT04276454|Experimental|Single arm|
11071412|NCT04276441||Non- Atrial Fibrillation (AF) Cohort|Participants without a history of AF will be randomly assigned into the study to either an Apple Watch/iPhone group or an iPhone group only.
11071413|NCT04276441||Atrial Fibrillation (AF) Cohort|Participants with a diagnosis of AF taking a direct oral anti-coagulant (DOAC) for at least 30 days will be randomly assigned to Apple Watch/iPhone group or iPhone group only.
11071414|NCT04276428|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
11071415|NCT04276428|Active Comparator|Insulin Degludec|Insulin degludec administered SC.
11071416|NCT04276415|Experimental|Dose Escalation: DS-6157a|Participants with advanced gastrointestinal stromal tumor (GIST) who will receive an intravenous infusion of DS-6157a (escalating doses starting at 1.6 mg/kg).
11071417|NCT04276415|Experimental|Dose Expansion: Cohort 1 (3rd line or later) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
11071418|NCT04276415|Experimental|Dose Expansion: Cohort 2 (2nd line) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on imatinib (IM) and had not received a post-IM treatment (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
11071419|NCT04276402|Experimental|Right side of the maxilla|
11071420|NCT04276402|No Intervention|Left side of the maxilla|
11071421|NCT04276389|Active Comparator|OCT-guided arm|
11071422|NCT04276389|Placebo Comparator|Angiography-guided arm|
11071423|NCT04276376|Experimental|Cohort 1A-D|"Molecularly selected cohorts that harbor DNA repair deficiency, defined as bi-allelic loss-of-function alteration (mutation and/or deletion) in at least one of the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, PALB2, RAD51C, RAD51D, FANCA, NBN, RAD51, RAD54L.
~1.A - Non-Small Cell Lung Cancer
~1.B - Urothelial Bladder Cancer
~1.C - metastatic Castration Resistant Prostate Cancer
~1.D - others: any histology, excepted breast cancer or serous ovarian cancer"
11071424|NCT04276376|Experimental|Cohort 2A-C|Platinum-sensitive disease 2.A - Non-Small Cell Lung Cancer 2.B - Urothelial Bladder Cancer 2.C - Gastric or gastro-esophageal junction adenocarcinoma
11071425|NCT04276376|Experimental|Cohort 3|Metastatic Castration Resistant Prostate Cancer (mCRPC)
11071426|NCT04276376|Experimental|Cohort 4|Clear Cell Renal Cell Carcinoma
11071427|NCT04276363|Experimental|Thrive Professional Learning plus ParentCorps|1) Professional Development, Program Training and Coaching; 2) Program for Parents of Pre-K Students; and 3) Program for Pre-K Students. The three intervention components are expected to strengthen relationships and communication between parents and teachers and promote safe, nurturing and predictable environments, which contribute to child mental health and achievement.
11071428|NCT04276363|Experimental|Thrive Professional Learning only|Best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders.
11071429|NCT04276363|Experimental|Inspire Professional Learning|Led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
11071430|NCT04276350|Experimental|Acupuncture|"Acupuncture Regime:
~2-3 sessions per week, each lasting an hour, over a period of 10 weeks (with deviation of 2 weeks for scheduling), total of 30 sessions"
11071431|NCT04276350|Active Comparator|Best medical therapy|"Best Medical Therapy Regime:
~3 sessions to be completed over a period of 10 weeks (with deviation of 2 weeks for scheduling), with subjects learning and practicing biofeedback exercises daily"
11071432|NCT04276324|Active Comparator|Control Group|Only testing sessions
11071433|NCT04276324|Experimental|Resistance training group|Ten weeks of resistance training
11071434|NCT04276311|Experimental|symptomatic patients with complex de novo FP arterial lesions|in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo FP arterial lesions (TASC C).
11071435|NCT04276298|Active Comparator|Metronidazole|Group A receiving 10% metronidazole cream
11071436|NCT04276298|Active Comparator|Metronidazole + Diltiazem|Metronidazole 10% + Diltiazem 2%
11071437|NCT04276298|Active Comparator|Metronidazole + Lignocaine|Metronidazole 10% + Lignocaine 4%
11071438|NCT04276298|Active Comparator|Metronidazole + Diltiazem + Lignocaine|Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
11071439|NCT04276285|Active Comparator|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
11071440|NCT04276285|Active Comparator|US TAP|Subcostal TAP block will be performed after surgery under ultrasound guidance
11071441|NCT04276285|No Intervention|No TAP|No TAP block will be performed
11071442|NCT04276259|Experimental|Buprenorphine Injection + Oral Placebo Pill|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
11071443|NCT04276259|Experimental|Naltrexone Oral Tablet + Intramuscular Saline Injection|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
11071444|NCT04276259|Experimental|Oral Placebo Pill + Intramuscular Saline Injection|Inert pill and saline injection that have no inherent power to produce an effect. In the inert pill condition, participants will receive one IM arm injection of saline (1ML) and an oral placebo tablet.
11071445|NCT04276246|Experimental|Experimental|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to retentive components (Group A, Test) which are connected to the implants to retain the RPD
11071446|NCT04276246|Experimental|Control|All included participants receive each side 1 posterior implant in the edentulous areas bilaterally in Kennedy class I. Participants are provided with a conventional clasp retained removable partial denture (RPD) worn for 3 months. When implant osseointegration is ensured (3 months healing period), patients are assigned to supportive components (Group B, Control), which are connected to the implants to support the RPD
11071447|NCT04276233|Experimental|Subject severe eosinophilic asthma|Subjects with severe eosinophilic asthma will receive Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with oral corticosteroid (OCS) as part of their standard of care. Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
11071448|NCT04276220|Other|Tenosynovial Biopsy|
11071449|NCT04276207|Experimental|LY900014|LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
11071450|NCT04276207|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Humalog) administered by CSII in one of two study periods.
11071451|NCT04276194|Experimental|Treatment (intensity modulated proton therapy)|Patients undergo intensity modulated proton therapy once daily over 30 fractions and also undergo MRI over 20 minutes during fractions 7, 13, 20, and 30 of radiation in the absence of disease progression or unacceptable toxicity.
11071452|NCT04276181||CNaTT|The surgical procedures are described in the section Detailed description
11071453|NCT04276155|Experimental|Device|Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation
11071454|NCT04276155|No Intervention|Control|Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.
11071455|NCT04276142|Experimental|Tension type headache (1)|online program: ceprica
11071456|NCT04276142|Active Comparator|tension type headache (0)|Other: online evidence-based information regarding headache and care as usual
11071457|NCT04276142|Experimental|migraine (1)|online program: ceprica
11071458|NCT04276142|Active Comparator|migraine (0)|Other: online evidence-based information regarding headache and care as usual
11071459|NCT04276129|Other|Biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) at T0 and T24
11071460|NCT04276116|No Intervention|Usual Care|
11071461|NCT04276116|Experimental|Usual care + communication of pulmonary age|
11071462|NCT04276090|Experimental|Colorectal liver metastases|Patients with unresectable colorectal liver metastases will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (FOLFOX, FOLRIRI, or oxaliplatin/irinotecan)
11071463|NCT04276090|Experimental|Intrahepatic cholangiocarcinoma|Patients with unresectable intrahepatic cholangiocarcinoma will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. Patients will then receive hepatic artery infusion floxuridine as well as disease-appropriate systemic chemotherapy (gemcitabine/oxaliplatin or gemcitabine alone)
11071464|NCT04276077|Experimental|High-frequency electrical muscle stimulation|
11071465|NCT04276077|Experimental|Low-frequency electrical muscle stimulation|
11071466|NCT04276077|No Intervention|Control|
11071467|NCT04276064|Experimental|Patients with insomnia|Patients with insomnia disorder according to DSM-5 criteria
11071468|NCT04276064|Experimental|Healthy controls|Healthy controls
11071469|NCT04276051|Experimental|Visual-ICE Cryoablation|"The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40oC) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
~Participants will also receive standardized dietary and exercise counseling from a registered dietitian and exercise physiologist."
11071470|NCT04276051|Active Comparator|Lifestyle intervention only|Participants will receive standardized dietary and exercise counseling from a registered dietitian and exercise physiologist.
11071471|NCT04276038|Active Comparator|Active LLLT|"Patients will self-treat at home (active or sham), twice a day (excluding Weekends) for 1 month. The duration of each session will be 15-20 minutes and will include treatment over painful point on the knee and over regional lymph nodes (popliteal, inguinal). The treatment dose should be initiated gradually for the first week until reaching the maximum dose of 6-8 minutes per treatment point. This is the recommended dose for near infrared lasers for the indication of knee pain by the World Association for Laser Therapy (WALT). In the first days an increase in pain may be felt before the reduction in pain. If the increase in pain continues for more than a week under graded dosimetry, the treatment must be stopped.
~Laser therapy will be administered to the patients in addition to standard of care therapy as customary in our institution."
11071472|NCT04276038|Sham Comparator|Sham LLLT|Half of the LLT devices will be not activated at random before the application to the patients. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device.
11071473|NCT04276025||German cohort Bayreuth|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
11071474|NCT04276025||German cohort Hof|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
11071475|NCT04276025||Chinese cohort Beijing|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
11071476|NCT04276012|Experimental|Intervention group|The intervention group will participate in different intervention strategy depending on the individual needs (psychoeducational, recommendations of life style and diet, medication adherence and changes in pharmacological strategy)
11071477|NCT04276012|No Intervention|Control group|Usual clinical care
11071478|NCT04275999|Other|Control Group|In the control group, all subjects will receive ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea. Subjects will not receive any follow-up intervention from the study team.
11071479|NCT04275999|Experimental|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their use ivermectin generated by Causa Research; in addition to receiving ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
11071480|NCT04275999|Experimental|GPSkin group|The GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin once daily. Subjects also are receiving the ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
11071481|NCT04275986|Experimental|Experimental arm|Endoscopic resection+ concurrent chemoradiotherapy
11071482|NCT04275973|Other|Healthy controls|The Control subjects are for methods development and do not constitute a formal study group
11071483|NCT04275973|Experimental|Prosthesis user with transtibial amputation|Experiments will use standard commercially available prostheses for participants with lower-limb amputation. Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA).
11071484|NCT04275973|Experimental|Orthoses user with drop-foot|For participants with drop-foot, standard commercially-available orthoses or standard-of-care custom orthoses will be used, as well as standard commercially-available electrical stimulation neuro-orthoses.
11071485|NCT04275960|Experimental|Arm_25 + 75 mg (Fasted)|Healthy male participants receive a single dose of 25 mg selitrectinib (Period 1) and 75 mg selitrectinib (Period 2) in fasted state.
11071486|NCT04275960|Experimental|Arm_50 + 50 mg (Fasted/Fed)|Healthy male participants receive a single dose of 50 mg selitrectinib in fasted state (Period 1) and 50 mg selitrectinib in fed state (Period 2).
11071487|NCT04275960|Experimental|Arm_100 + 150 mg (Fasted)|Healthy male participants receive a single dose of 100 mg selitrectinib (Period 1) and 150 mg selitrectinib (Period 2) in fasted state.
11071488|NCT04275947||Training|
11071489|NCT04275947||Validation|
11071490|NCT04275934||Cohort|This project will evaluate the impact of self-insured employers implementing an innovative care model utilizing pharmacist-delivered MTM services for health plan beneficiaries with high blood pressure.
11071491|NCT04275921|Experimental|Study participants cohort I|3 stage III NSCLC patients receiving radiotherapy will be imaged, each for a single MRI session using TWIST and HASTE sequences.
11071492|NCT04275921|Experimental|Study participants cohort II|12 patients will be imaged, each for two MRI sessions taking place during the radiotherapy schedule and separated by at least a week.
11071493|NCT04275895|Experimental|Prematurely born Children|"Evaluation of different attention or/and postural activities :
~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).
~Child perception of the vertical compared to the real vertical
~Evaluation of the posture of the child during different visual conditions
~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
11071494|NCT04275895|Active Comparator|Term born Children|"Evaluation of different attention or/and postural activities
~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).
~Child perception of the vertical compared to the real vertical
~Evaluation of the posture of the child during different visual conditions
~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
11071495|NCT04275869|Experimental|Experimental Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
11071496|NCT04275869|No Intervention|Control Group|Control group will receive the standard treatment which consists of regular gynaecological visits; the Reproduction Service gynaecologists will recommend healthy lifestyle habits and give the patients a document detailing a specific diet they should follow for weight loss.
11071497|NCT04275843|Active Comparator|Traditional Diet|Unprocessed/minimally processed whole foods.
11071498|NCT04275843|Active Comparator|Modern Diet|Multi-ingredient, ultra-processed formulations of the traditional diet.
11071499|NCT04275830|Experimental|Baseline and HRVB+DS group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to HRVB+DS arm. This group will receive a standardized HeartMath© Inner balance device and HRV biofeedback training session at the start of the two-week intervention period. They will be asked to attend either a group or one-on-one 30-minute HRVB training session and asked to practice their HRV biofeedback skills at home for 10 minutes each day for a two-week period. Participants will also be asked to watch four digital stories of other HCT patients (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
11071500|NCT04275830|Other|Baseline and HRVB waitlist +DS control group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to HRVB waitlist +DS control arm. After the baseline data collection, during two weeks, they will be provided four digital stories of other HCT patients sharing their experiences (challenges, feelings, strategies, coping, each 2-3 minutes long). At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
11071501|NCT04275817||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking: unintentional weight loss of ≥ 5% between two assessments, 2) Weakness: a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy: answer of no to the question Do you feel full of energy? from the 15-item Geriatric Depression Scale; 4) Slowness: average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level: PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
11071502|NCT04275817||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).
~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.
~In this study, an individual will be considered a CHI if they meet the following criteria: no history of dementia, no use of anti-dementia drugs, normal cognitive performance on cognitive tests and normal scores of ADL and IADL scales. Different participant subgroups will be identified: 1) Individuals will be classified as MCI if they meet the following criteria: Objective cognitive impairment (i.e., performance between 1.5 and 1.9 SDs below the age-appropriate mean) in one or two cognitive domains (i.e., episodic memory and/or executive function) and normal scores of ADL and IADL scales; 2) Individuals will be considered older adults with mild-stage major neurocognitive disorders"
11071503|NCT04275817||Individuals with MCR|"The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
~Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?)."
11071504|NCT04275804|Active Comparator|Control group: conventional dressing|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Dressing by a specialized wound-nurse is the current gold-stand of treatment for diabetic ulcers.
11071505|NCT04275804|Experimental|Vibration group: conventional dressing and LMHFV|Alternate day dressing in a designated clinic by a trained nurse specialized in wound care Alternate dat 20-week course of whole-body vibration therapy Alternate day 20min sessions on a self-designed vibration platform with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement <0.1mm). Since the participants will return for dressing change on alternate days, the vibration group will also undergo the LMHFV on the same attendance.
11071506|NCT04275791|Experimental|hierarchized|Structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
11071507|NCT04275791|No Intervention|all-or-nothing|Structured regional health organization, composed of non-hierarchical trauma centers at different levels according to their capacity to receive severe trauma victims (all-or-nothing type).
11071508|NCT04275778|Active Comparator|Hydroxychloroquine|"Hydroxychloroquine will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.
~Treatment will be continueted during the pregnancy and will be stopped at delivery."
11071509|NCT04275778|Placebo Comparator|Placebo group|"Placebo will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.
~Treatment will be continueted during the pregnancy and will be stopped at delivery."
11071510|NCT04275765|No Intervention|Arm 1: Routine Care|Participants will undergo routine care but take part in assessments.
11071511|NCT04275765|Active Comparator|Arm 2:Behavioral Intervention with nudges & Facebook|Participants will receive nudges and be enrolled in social media platform.
11071512|NCT04275765|Active Comparator|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
11071513|NCT04275752|No Intervention|Usual Care Group|Subjects will receive no formal exercise recommendations
11071514|NCT04275752|Experimental|Exercise Intervention Group|Subjects will complete an exercise program
11071515|NCT04275739|Experimental|Experimental: Episodic Future Thinking|
11071516|NCT04275739|Active Comparator|Control: Vivid Memory Task|
11071517|NCT04275726|Experimental|Myval THV Series|"Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site.
~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
11071518|NCT04275726|Active Comparator|Contemporary Valves|"Stratification and equal allocation will be done for each valve within contemporary valves, i.e., 50% Sapien THV Series and 50% Evolut THV Series.
~Sapien THV Series will consist of Sapien 3/Sapien 3 Ultra THVs or any subsequent advanced version commercially available at the study site.
~Evolut THV Series will include Evolut R/Evolut PRO THVs or any subsequent advanced version commercially available at the study site.
~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
11071519|NCT04275713|Experimental|Standard Chemoradiotherapy +/- metformin|Metformin will be given orally at doses of 850 mg twice a day. Metformin will be started one week prior to the start of standard cisplatin-based chemoradiotherapy, and will be continued throughout the entire radiation treatment
11071520|NCT04275713|Active Comparator|Standard chemoradiotherapy|"Standard chemoradiotherapy is given as a combination of EBRT and IGT:
~45 Gy in 1.8 Gy/fraction to the pelvis/abdomen, 5 fractions/week
~55-57.5 Gy in 2.2-2.3 Gy/fraction to pathological lymph nodes as a simultaneously integrated boost (SIB)
~4 fractions of brachytherapy, 7.8 Gy/fraction, to the cervix
~Concomitant Cisplatin weekly during the external beam radiotherapy (EBRT)"
11071521|NCT04275700|Experimental|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma.
11071522|NCT04275687|Experimental|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.
~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin."
11071523|NCT04275661|Placebo Comparator|Group (C) (control group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7.
11071524|NCT04275661|Experimental|Group (K) (Ketamine group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg ketamine at each level with total dose 2mg/kg
11071525|NCT04275661|Experimental|Group (M) (magnesium sulphate group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg MgSo4 at each level with total dose 2mg/kg
11071526|NCT04275648|Experimental|Asthmatuner field tests vs laboratory tests|Each participant will perform two standardized field tests either before or after Eucapnic Voluntary Hyperpnea or Methacholine bronchial provocation test. In addition, unstandardized field tests will be performed in case of exercise induced respiratory symptoms.
11071527|NCT04275635||Children with myopia|A total of 3,000 children from Zhongshan Ophthalmic Center is required to undergo ophthalmic examinations and complete questionnaires at baseline and 1yr after wearing Ortho-K.
11071528|NCT04275622|Experimental|Intervention|Intervention group receives lifestyle intervention for hypertriglyceridemia.
11071529|NCT04275622|No Intervention|Control|Control group receives regular surveillance.
11071530|NCT04275609|Experimental|Artificial Intelligence generating endoscopic report|In this group, the endoscopic report was generated by artificial intelligence (AI) based on the structured diagnostic report generation system.
11071531|NCT04275609|Active Comparator|Physicians writing endoscopic report|In this group, the endoscopic report was writing by physicians.
11071532|NCT04275596|Active Comparator|2QR complex|Patients who undergo anal surgery will apply 2QR complex topical agent on the wound until healing
11071533|NCT04275596|Active Comparator|Placebo|Patients who undergo anal surgery will apply placebo cream on the wound until healing
11071534|NCT04275583|Experimental|TQB3602 capsule|TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.
11071535|NCT04275570|Active Comparator|Motivational Interview.|Repeated motivational interview during prenatal care visits
11071536|NCT04275570|No Intervention|Usual intervention|Usual intervention
11071537|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
11071538|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
11071539|NCT04275544||Patients with PCs|"HOCM Patients developing postoperative complications (PCs) following septal myectomy.
~PCs include all-cause mortality, heart failure, low cardiac output syndrome, stroke, spinal cord injury, acute respiratory distress syndrome, reintubation, reoperation, permanent implantable cardioverter defibrillator, kidney injury, renal failure, liver injury, and liver failure."
11071540|NCT04275544||Patients without PCs|HOCM Patients do not develope postoperative complications following septal myectomy.
11071541|NCT04275531||regional anesthesia|surgical procedures which will be performed under intrathecal anesthesia without sedation
11071542|NCT04275531||sevoflurane|surgical procedures which will be performed under general anesthesia and sevoflurane will be used for maintenance of anesthesia
11071543|NCT04275531||isoflurane|surgical procedures which will be performed under general anesthesia and isoflurane will be used for maintenance of anesthesia
11071544|NCT04275531||propofol|surgical procedures which will be performed under general anesthesia and propofol infusion will be used for maintenance of anesthesia
11071545|NCT04275518|Experimental|APG-115/APG-115+Cytarabine in Relapse/Refractory AML|
11071546|NCT04275518|Experimental|APG-115/APG-115+Aza in relapsed/progressed high risk MDS|
11071547|NCT04275505|Active Comparator|treatment group|the participants were given 10 sessions of shortwave diathermy treatment and elbow splint and told to avoid symptom provoking activities
11071548|NCT04275505|Placebo Comparator|control group|the participants were given 10 sessions of placebo shortwave diathermy treatment (the device was not turned on), elbow splint and told to avoid symtpom provoking activities
11071549|NCT04275492|Experimental|Fasting group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects were given 1 tablet of test preparation (T) orally and 240mL warm water on an empty stomach, and the other 15 subjects were given 1 tablet of reference preparation (R, Siforl®) orally and 240mL warm water on an empty stomach.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
11071586|NCT04275323|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
11071550|NCT04275492|Experimental|Feeding group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects took 1 tablet of the test preparation (T) orally and 240mL warm water about 30min after the high-fat meal, and another 15 subjects took 1 tablet of the reference preparation (R, Siforl®) orally and 240mL warm water about 30min after the high-fat meal.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
11071551|NCT04275479||SDS - without Diabetes diagnosis|SDS - without Diabetes diagnosis
11071552|NCT04275479||SDS with Diabetes Diagnosis|SDS with Diabetes Diagnosis
11071553|NCT04275479||Cystic Fibrosis (CF) patients data & lab results|De-identified data from age matched population norms, CF patients associated pancreatic insufficiency known or treated diabetes
11071554|NCT04275466|Experimental|necrotic cavity lavage|This arm was performed necrotic cavity lavage after debridement
11071555|NCT04275466|No Intervention|non-necrotic cavity lavage|This arm was not performed necrotic cavity lavage after debridement
11071556|NCT04275453|Experimental|Ketogenic diet - 24 hours|Subjects will undergo FDG PET/CT after 1 day of dietary modification (ketogenic diet for at least 3 meals) and 12 hours of fasting prior to FDG injection.
11071557|NCT04275453|Experimental|Ketogenic diet - 72 hours|Subjects will then undergo FDG PET/CT after 3 day of dietary modification (ketogenic diet for at least 9 meals) and 12 hours of fasting prior to FDG injection.
11071558|NCT04275453|Experimental|Exogenous ketone ester|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants. The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of ~3 mmol/L are reached within 60 minutes . By way of comparison, website marketing of the commercial drink recommends ingestion 30 minutes prior to athletic performance. We will also perform echocardiography immediately before and 30 minutes after the drink.
11071559|NCT04275440|Experimental|Exercise group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
11071560|NCT04275440|Experimental|Caloric restriction group|The caloric restriction plan will be designed based on individual basal metabolic rate.
11071561|NCT04275440|Experimental|Combined intervention group|Participants will receive both exercise and caloric restriction intervention at the same time.
11071562|NCT04275427|Experimental|study laser group|laser therapy on knee for 2 weeks
11071563|NCT04275427|No Intervention|control group|no intervention
11071564|NCT04275414|Experimental|bevacizumab plus standard care|Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.
11071565|NCT04275401||patients|patients with clinical presentions of change in muscle tone
11071566|NCT04275401||volunteers|healthy volunteers with normal muscle tone
11071567|NCT04275388||Xiyanping injection +other drugs|Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
11071568|NCT04275388||other drugs|Lopinavir tablet or Ritonavir tablet;Alpha-interferon nebulization;Abidor Hydrochloride
11071569|NCT04275375||hyperbaric bupivacaine|The dosage of hyperbaric bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
11071570|NCT04275375||plain bupivacaine|The dosage of plain bupivacaine decided by the clinical anesthesiologist. This study is an observational study.
11071571|NCT04275375||bupivacaine with intrathecal fentanyl|The dosage of bupivacaine with intrathecal fentanyl decided by the clinical anesthesiologist. This study is an observational study.
11071572|NCT04275362||DJO subjects for surgical technique|Subjects who meet the inclusion criteria and receive a DJO Empowr total knee replacement but will not participate in motion data collection
11071573|NCT04275362||DJO subjects for data collection|Subjects who meet the inclusion criteria and consent to be in the study will receive a DJO Empowr total knee replacement and participate in motion data collections at pre-op, and 6 and 12 months post-op. Subjects will also participate in pre-op, 6 month, 1 year, 2 year, 5 year, and 10 year post-op clinical data collections
11071574|NCT04275362||Prospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
11071575|NCT04275362||Stryker TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Stryker Triathlon total knee replacement and participated in motion analysis pre-surgery and 6 and 12 months post-surgery.
11071576|NCT04275362||Biomet TKA subjects|Subjects who met the inclusion criteria and consented to be in a study whereby they received a Biomet Vanguard total knee replacement and participated in motion analysis pre-surgery and 12 months post-surgery.
11071577|NCT04275362||Retrospective control subjects|Healthy age matched subjects who did not have any knee osteoarthritis and participated in motion data collections.
11071578|NCT04275349||Exposure group(continuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
11071579|NCT04275349||Exposure group(uncontinuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
11071580|NCT04275349||Completely unexposed group|xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
11071581|NCT04275349||Incompletely unexposed group|xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
11071582|NCT04275336|Experimental|Lidocaine group|Use compound lidocaine cream for the management of peripheral venipuncture pain.
11071583|NCT04275336|Experimental|Psychological interventions group|Use psychological interventions (books, toy whistle, cartoon animation, breathing exercises, electronic products）for the management of peripheral venipuncture pain.
11071584|NCT04275336|Experimental|Combined group|Use compound lidocaine cream combined with psychological interventions for the management of peripheral venipuncture pain.
11071585|NCT04275323|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
11071589|NCT04275297|Experimental|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
11071590|NCT04275297|Placebo Comparator|Attention Control|The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
11071591|NCT04275284||PCV10 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks and 9 months of age.
11071592|NCT04275284||PCV13 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks and 9 months of age.
11071593|NCT04275284||PCV10 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 14 weeks and 9 months of age.
11071594|NCT04275284||PCV13 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 14 weeks and 9 months of age.
11071595|NCT04275284||PCV10 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
11071596|NCT04275284||PCV13 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
11071597|NCT04275271|Experimental|Intervention group|Intervention group will be received sexuality teaching skills for promotion of professional competence based on information, motivation and behavioral skills model for adolescent sexuality after signing informed consent form and being informed about the goals and details of intervention for 6 sessions (one two hour session per week).
11071598|NCT04275271|No Intervention|Control group|The control group will not receive any intervention until the end of the research.
11071599|NCT04275258|Experimental|Intervention group|"Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge. In addition, subjects will receive:
~A face-to-face meeting prior to discharge where the PA will discuss with the subject their individualized pain management plan and individualized opioid taper plan.
~PA will contact subject on the phone within the first week after hospital discharge to ensure subject plans to follow up with PCP and to troubleshoot any subject concerns related to pain management."
11071600|NCT04275258|No Intervention|Control group|Subjects will receive standard trauma discharge plan and no more than a 2-week supply of opioids. Subjects will complete surveys at baseline, 12-week, and 24-week post hospital discharge.
11071601|NCT04275245|Experimental|Meplazumab|10mg Meplazumab by intravenous infusion, every day for 2 days
11071602|NCT04275232|Experimental|Allogenic Plasma Aliquots|Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
11071603|NCT04275219|Experimental|Tong-Fu-Xing-Shen herbal formula|Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
11071604|NCT04275219|Placebo Comparator|The Placebo of Tong-Fu-Xing-Shen herbal formula|The Placebo of Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.
11071605|NCT04275206|Experimental|Medicinal water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in tap water.)
11071606|NCT04275206|Placebo Comparator|Tap water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in medicinal water.)
11071607|NCT04275193|Experimental|Zishenqing|The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
11071608|NCT04275193|Placebo Comparator|Placebo|The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
11071609|NCT04275180|No Intervention|control|Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
11071610|NCT04275180|Experimental|Argatroban group|Argatraban is used on the basis of standard medical treatment.
11071611|NCT04275167|Experimental|Feasibility of TCE and TNE|Feasibility is measured by the number of participants that we have successfully deployed the Trans-nasal imaging device/Tethered capsule device in.
11071612|NCT04275154||CAR-T patients|Relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) or acute lymphoblastic leukemia (ALL) with intent to undergo commercially available CAR-T cell therapy
11071613|NCT04275141|Other|Mauriac syndrome|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 45-min cycling exercise at time 300 min.
11071614|NCT04275141|Other|Type 1 diabetes mellitus|An oral dose of glucose (labelled with 1% U-13C6-glucose) will be given at time 0 min followed by a 45-min cycling exercise at time 300 min.
11071615|NCT04275128||Conventional Genicular Ablation|This group is scheduled to receive conventional genicular ablation to treat their chronic knee pain.
11071616|NCT04275128||Cooled radiofrequency Ablation|This group is scheduled to receive cooled radiofrequency ablation to treat their chronic knee pain.
11071617|NCT04275115|Experimental|Foliglurax|Foliglurax, iv midazolam and cocktail of CYP450 probe substrates
11071618|NCT04275102|Experimental|Three times weekly symptom screening|Three times weekly symptom reporting by guardians and children using the SPARK platform for 12 weeks
11071619|NCT04275089|Experimental|Reia Vaginal Pessary|
11071620|NCT04275076|Experimental|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate
11071621|NCT04275076|Experimental|bipolar transurethral enucleation of the prostate|bipolar transurethral enucleation of the prostate
11071622|NCT04275050|Experimental|TQB3303 Tablet|TQB3303 Tablet administered orally once. Then TQB3303 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
11102357|NCT04059939|Active Comparator|BAU|
11071623|NCT04275037|Experimental|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
11071624|NCT04275037|Active Comparator|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
11071625|NCT04275037|No Intervention|Control Group|The control group will receive usual medical care
11071626|NCT04275024|Experimental|Experimental group|"AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.
~The basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
11071627|NCT04275011|Active Comparator|Static Posture and Balance Exercise|Participants in the control group will receive equal attention through a static posture and balance exercise class two times per week, in a small group setting.
11071628|NCT04275011|Experimental|Progressive Resistance and Impact Exercise|The exercise program will include two progressive resistance and impact exercise training sessions per week in a small group setting. Exercises will be individually tailored to the participants' abilities and designed to achieve a maximum 80-85% 1RM.
11071629|NCT04274998|Experimental|patient with Alzheimer disease|Patient is diagnosed with Mild Cognitive Impairment or Alzheimer's disease.
11071630|NCT04274998|Experimental|Healthy volunteer|Subject must be a Healthy.
11071631|NCT04274985||1|Patients with temporomandibular disorders
11071632|NCT04274972||Pancreaticoduodenectomy patients|All patients, affected by a resectable PDAC of the head of the pancreas, visited at the Department of Pancreatic Surgery of Verona, will be enrolled. All the patients must be scheduled for an elective PD. The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated.
11071633|NCT04274959|Active Comparator|ceramic onlay with shoulder preparation design.|posterior ceramic onlay restoration with shoulder design with 1 mm shoulder thickness
11071634|NCT04274959|Experimental|ceramic onlay with butt joint preparation design|posterior ceramic onlay with butt joint preparation design with flat occlusal reduction with inclined surface
11071635|NCT04274946|Active Comparator|RAI+PB+US|Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
11071636|NCT04274946|Experimental|RAI+ICG+US|Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
11071637|NCT04274946|Experimental|RAI+PB+ICG+US|Sentinel lymph node mapping with triple tracer (radioisotope,ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
11071638|NCT04274946|Experimental|PB+ICG+US|Sentinel lymph node mapping with triple tracer (ICG and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
11071639|NCT04274933|Experimental|Dose Escalation: Venetoclax and Capecitabine|Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
11071640|NCT04274933|Experimental|Dose Expansion: Venetoclax and Capecitabine|Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
11071641|NCT04274920|Experimental|Bioactive Glass|18 teeth were capped indirectly with dental adhesive containing bioactive glass applied according to the manufacturer's instructions and cured for 20 seconds and then resin composite restoration containing bioactive glass applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
11071642|NCT04274920|Active Comparator|Light cured calcium hydroxide|18 teeth were capped indirectly with light cured calcium hydroxide (control group) applied according to the manufacturer's instructions by calcium hydroxide applicator and light cured for 20 seconds then resin composite restoration was applied by golden plated composite applicator in increments 2 mm each and cured for 40 seconds for each increment.
11071643|NCT04274907|Experimental|Dose Escalation Phase: Venetoclax + Pembrolizumab|Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.
11071644|NCT04274907|Experimental|Randomization Phase: Venetoclax + Pembrolizumab|Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.
11071645|NCT04274907|Active Comparator|Randomization Phase: Pembrolizumab Monotherapy|Participants will receive pembrolizumab Dose A
11071646|NCT04274894|Experimental|AndroGel|Participants will receive AndroGel 1.62% once daily
11071647|NCT04274868||Children and adolescents with liver tumor|Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
11071648|NCT04274842|Other|D-OCT image observational|Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
11071649|NCT04274829||PTMC|Patients with papillary microcarcinoma of the thyroid
11071650|NCT04274816|Experimental|Tremelimumab|Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
11071651|NCT04274803|Experimental|Intralipid group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
11071652|NCT04274803|Active Comparator|Standard care group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
11071653|NCT04274790||Metastatic colon cancer|Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.
11071654|NCT04274764|Experimental|Personalized eHealth Education & Motivational Interviewing|Personalized eHealth Glaucoma Education & Motivational Interviewing
11071655|NCT04274764|No Intervention|Standard Education|Participant will receive standard glaucoma education.
11071656|NCT04274751||Transaxillary|TAVI, transaxillary approach
11071658|NCT04274738|Experimental|Mavorixafor and Ibrutinib|Each participant will receive mavorixafor at 200 mg (2 capsules of 100 mg each) QD in combination with ibrutinib 420 mg (3 capsules of 140 mg each) QD. If the dose is well tolerated with no dose limiting toxicities (DLTs) observed during 28-day DLT observation period (Cycle 1), the participant will receive 400 mg (4 capsules of 100 mg each) QD in combination with ibrutinib during Cycle 2. If participant does not experience a DLT at this dose level at the end of Cycle 2, participant will receive mavorixafor at 600 mg (6 capsules of 100 mg each) QD in combination with ibrutinib during Cycle 3. If participant tolerates 600 mg dose for 28 days and no DLTs are observed, the participant will continue to receive mavorixafor at 600-mg dose in combination with ibrutinib. Once the maximum tolerated dose (MTD) for participant has been identified, the participant may continue to receive treatment for up to 2 years or until disease progression, unacceptable toxicity, death, or study withdrawal.
11071659|NCT04274686|Experimental|Tegaderm application|Patients will receive bag-mask ventilation with Tegaderm placement.
11071660|NCT04274686|Active Comparator|No Tegaderm|Patients will receive bag-mask ventilation without Tegaderm placement.
11071661|NCT04274673|Other|low (less 10ng/dl)|Patients who have low cotinine levels (less 10ng/dl)
11071662|NCT04274673|Other|medium (10-500ng/dl)|Patients who have medium cotinine levels (less 10-500ng/dl)
11071663|NCT04274673|Other|high (more 500ng/dl)|Patients who have high cotinine levels (less 10-500ng/dl)
11071664|NCT04274660|Experimental|DWELL Intervention|People with type 2 diabetes participating in the 12-week DWELL (Diabetes and WELLbeing) Programme
11071665|NCT04274660|No Intervention|DWELL non-intervention/Control|People with type 2 diabetes who are receiving routine care from their GP and healthcare team. People with type 2 diabetes will continue to receive routine standard care. Routine care in this respect constitutes usual health and social care or any other nationally or locally commissioned education programmes
11071666|NCT04274647|Experimental|Device and Control|"NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose. 0.2ml"
11071667|NCT04274634||Conditions with predisposition to lens oscillations|Marfan Syndrome and Pseudoexfoliation
11071668|NCT04274634||Age-matched with normal axial lengths|
11071669|NCT04274634||Age-matched with extreme axial lengths|
11071670|NCT04274634||Intraocular lens|
11071671|NCT04274634||Pre- and post- cataract surgery|
11071672|NCT04274634||Normals|
11071673|NCT04274621||Patients, family members of patient, medical staff|
11071674|NCT04274608|Experimental|Intervention Arm|"Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above
~Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox."
11071675|NCT04274608|Active Comparator|Control Arm|Patients will undergo a 12-week weight management program.
11071676|NCT04274595|Experimental|Psoriasis patients|
11071677|NCT04274582|Experimental|Chokeberry extract consumption|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
11071678|NCT04274569|Active Comparator|Sodium fluoride (NaF)|Group 1: Quarterly application of a 5% NaF varnish (Duraphat® Varnish, Colgate-Palmolive Ltd, (UK) Ltd., Guildford, Surrey, UK)
11071679|NCT04274569|Experimental|NaF plus tricalcium phosphate (TCP )|Group 2: Quarterly application of 5% NaF-TCP (ClinproTM White Varnish; 3M ESPE, St Paul, MN, USA)
11071680|NCT04274569|Experimental|NaF plus CPP-ACP|Group 3: Quarterly application of a 5% NaF plus casein phosphopeptide-stabilized amorphous calcium phosphate complexes (CPP-ACP) (MI Varnish TM; GC corporation, Itabashi-Ku, Tokyo, Japan)
11071681|NCT04274543|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
11071682|NCT04274543|Active Comparator|Saline|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
11071683|NCT04274530|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy (CBT). Participants will complete a series of online modules via a mobile application in addition to standard of care for their fracture injury. Participants will be assigned a dedicated CBT therapist, and receive feedback and support from their therapist via in-app messaging. The CBT program will last approximately 6-8 weeks.
11071684|NCT04274530|No Intervention|Control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
11071685|NCT04274517|Experimental|Sterile Water|
11071686|NCT04274517|Experimental|3.5% betadine|
11071687|NCT04274517|Experimental|0.05% chlorhexidine gluconate|
11071688|NCT04274504||patients|metatstatic breast
11071689|NCT04274491||Pelvic Organ Prolapse Surgery Patients|Participants with greater than or equal to stage II pelvic organ prolapse who are scheduled for reconstructive surgery will be recruited. Participants will be asked to complete a preoperative online survey regarding their health, recovery expectancy, and different roles. Additional online surveys will be send on postoperative days 14 and 42 to measure postdischarge surgical recovery
11071690|NCT04274478|Other|Single group|
11071691|NCT04274465||Control|Negative high risk (HR)-HPV, cytology co-test
11071692|NCT04274465||CIN 1|Biopsy with low grade dysplasia
11071693|NCT04274465||CIN 2-3|Biopsy with high grade dysplasia
11071694|NCT04274452|Experimental|efgartigimod|Patients receiving an intravenous infusion of efgartigimod
11071695|NCT04274452|Placebo Comparator|placebo|Patients receiving an intravenous infusion of placebo
11071725|NCT04274231||TKI best effect group|TKI best effect was defined achieve complete cytogenetic response (CCyR)after 3 months of treatment and the level of BCR/ABL<10% after 3 months of treatment,the level of BCR/ABL<1% .
11071696|NCT04274439|Experimental|Internet-Based Pain Education and Exercise|"Patients allocated to the intervention group will receive a login and password for individual access to the website designed for the study. The content of this intervention will include videos and animations based on pain education, physical activity promotion and general exercises. The pain education component will be based on the E-pain intervention developed by Reis et al (2017), which includes nine main features: (1) acceptance, (2 and 3) education about pain, (4) sleep hygiene, (5) recognizing stress and negative emotions, (6) increasing positive coping in lifestyle, (7) exercises, (8) communication and (9) relapse prevention. The exercise component will include general exercises aiming to improve strength, flexibility, control and coordination.
~Patients in this group will also receive weekly text messages and a health coaching over the telephone. The text messages will include information on the benefits of exercises, motivation, and positive messages about dealing with pain."
11071697|NCT04274439|Active Comparator|Online Booklet|The patients allocated to the control group will have access to an online booklet containing general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. They will also receive one phone call at week 4 and text messages once a week during the study period.
11071698|NCT04274426|Active Comparator|Control arm with Platinum-based chemotherapy|"Carboplatin (AUC5, d1) as monotherapy q21d
~Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d
~Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 & d8) q21d
~Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d"
11071699|NCT04274426|Experimental|Carboplatin + Mirvetuximab soravtansine (IMGN853)|Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
11071700|NCT04274413|Experimental|Interventional Arm|All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
11071701|NCT04274400||Patients referred for polysomnography|Patients referred for polysomnography will be classified according to the presence of OSA, insomnia or both.
11071702|NCT04274387|Experimental|MBSR group|participants who receiving 8-week MBSR between the pretest and posttest
11071703|NCT04274387|No Intervention|passive control group|participants who not undergoing any interventions for 8 weeks between the pretest and posttest
11071704|NCT04274374|Experimental|experimental arm|In the experimental arm will receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day
11071705|NCT04274374|Active Comparator|control arm|the control arm will received 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
11071706|NCT04274361|Experimental|Ketamine arm|Early ketamine infusion therapy at a rate of 3 mcg/kg/min. All ketamine infusions will be calculated based on ideal body weight (IBW), unless actual body weight is less than ideal. Ketamine infusion therapy will be continued for 48 hours. At 2-4 hours post-infusion the patient's pain will be reassessed. If the NPS is more than 5 the infusion will be increased to 5mcg/kg/min. Following each change in the infusion rate the patient's pain will be reassessed at 2-4 hours and adjustments made accordingly. Maximum infusion rate will be set at 9mcg/kg/min. Conversely, The RAAPS team should be notified if neurologic symptoms (hallucinations, delusions, disturbing dreams, vertigo) are developing and, at the discretion of the RAAPS service, a single dose of lorazepam or midazolam may be utilized. The infusion can be decreased from in 2 mcg/kg/min increments if there are symptoms believed to be related to the infusion that do not respond to benzodiazepines.
11071707|NCT04274361|Placebo Comparator|Placebo arm|The 65 patients randomized to the control arm will receive placebo saline solution at a rate equivalent.
11071708|NCT04274348|Other|Skin biopsies and blood samples|
11071709|NCT04274335|Experimental|Intravenous tranexamic acid|
11071710|NCT04274335|Experimental|Intramuscular tranexamic acid|
11071711|NCT04274335|Experimental|Oral liquid tranexamic acid|
11071712|NCT04274335|No Intervention|No tranexamic acid|
11071713|NCT04274322||Cohort 1|High NUTRIC score
11071714|NCT04274322||Cohort 2|low NUTRIC score
11071715|NCT04274309||Patient's tissues exposed|Tonsil of each patient will be imaged using the medical device
11071716|NCT04274309||Patient's tissues not exposed|Tonsil of each patient will not be imaged using the medical device
11071717|NCT04274296||Control|Control-cohort in which no change in care is needed
11071718|NCT04274296||Advisory|Cohort in which advisory is activated
11071719|NCT04274270|Experimental|experimental group|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
11071720|NCT04274257|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
11071721|NCT04274257|Experimental|Double-Blind Rituximab|Participants will receive double-blind rituximab from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
11071722|NCT04274244|Experimental|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"The study participants will first undergo SCALE AND ROOT PLANING. This procedure is the same as that used in the active comparator group and the control group.
~Eight weeks following the initial therapy, reevaluation of the intrabony defects in the interproximal sites with a clinical probing depth >5 mm will be performed by radiographs as well as by using William's graduated periodontal probe to confirm the indication for periodontal surgery. Pairs of premolar and molar teeth in the maxilla or the mandible will be randomized to receive the test treatment (REGENERATIVE PERIODONTAL SURGERY with adjunctive hyaluronic acid gel application) or to serve as active comparators (regenerative periodontal surgery with adjunctive enamel matrix derivative application)."
11071723|NCT04274244|Active Comparator|Enamel Matrix Proteins|"SCALE AND ROOT PLANING
~REGENERATIVE PERIODONTAL SURGERY: Application of enamel matrix derivative."
11071724|NCT04274244|No Intervention|Scale and root planning|Control group: Just SCALE AND ROOT PLANING is performed
11071726|NCT04274231||TKI resistance group|TKI resistance was defined as the lack of a complete hematologic response (CHR) after 3 months of TKI treatment, the lack of any cytogenetic response after 6 months of treatment, the lack of major cytogenetic response (MCyR) (Ph-positive cells > 35%) after 12 months of treatment, an increase of white blood cell (WBC) count in at least two consecutive samplings (with a doubling of the count from the nadir to ≥ 20×109/L or an absolute increase of ≥ 50×109/L), or a relapse after a CHR or MCyR.
11071727|NCT04274231||TKI intolerance group|TKI intolerance was defined as at least grade 3 nonhematologic toxicity or grade 4 hematologic toxicity persisting for more than 7 days, related to TKIs at any dose.
11071728|NCT04274218|Experimental|Walking perturbation - Free|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with both arms free and individuals with amputation will walk with their prosthesis.
11071729|NCT04274218|Experimental|Walking perturbation - Limited|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with one arm bound to their side with straps and individuals with amputation will walk without their prosthesis.
11071730|NCT04274205|Active Comparator|Influence on brief supportive psychotherapy|Intervention group
11071731|NCT04274205|Active Comparator|Influence of brief supportive psychotherapy|Control group
11071732|NCT04274192|Experimental|Synchronized HFNC|This will be the experimental arm in which subjects will receive HFNC synchronized to his/her own efforts via NAVA
11071733|NCT04274192|Other|Continuous HFNC|This arm will be considered the control arm in which subjects will receive continuous HFNC.
11071734|NCT04274179|Experimental|Diet therapy|Modified Atkins Diet - high fat, low carbohydrate, outpatient initiated approach. Parents will check urine ketones twice weekly and follow by email, phone and clinic. Labs at baseline and 3 months. Dietitian support.
11071735|NCT04274179|Active Comparator|Drug therapy|Families will have the usual care for absence epilepsy at the discretion of the family's neurologist and the family choice. Typically ethosuximide bis in die (BID), however, if convulsions have occurred or other factors are involved, the child may be started on valproate or lamotrigine. The child will continue medications with dose adjustment and antiseizure drug levels checked as usual.
11071736|NCT04274166|Experimental|Experimental|2 s.c. secukinumab 150 mg injections
11071737|NCT04274153|Experimental|Gardasil9|Two doses of the 9-valent HPV vaccine to be administered to participants at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
11071738|NCT04274140||Obese Pregnant Women|obese, BMI 30-50
11071739|NCT04274140||Normal weight pregnant women|normal weight, BMI 18.5-25
11071740|NCT04274127|Other|children aged 16 to 24|estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
11071741|NCT04274114|Experimental|Experimental group|Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.
11071742|NCT04274114|Placebo Comparator|Placebo group|Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.
11071743|NCT04274101||Nifurtimox|Patients treated with Nifurtimox from 1984 to 2017
11071744|NCT04274101||Benznidazole|Patients treated with Benznidazole from 1984 to 2017
11071745|NCT04274088||Tecnis;|Patients who received the Tecnis multifocal IOL.
11071746|NCT04274088||Diffractiva|Patients who received the Diffractiva multifocal IOL.
11071747|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
11071748|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
11071749|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
11071750|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
11071751|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
11071752|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
11071753|NCT04274062||peri partum integrated nursing care of placenta previa|"Part (1) personal data:
~Part (2) baseline and characteristics of the patients participants:
~Tool II- An observation checklist: This tool is develop by researcher according to guideline of Royal College of Obstetricians and Gynaecologists, 2018), and divide into three main parts: preoperative, intraoperative and postoperative.
~Part (1) pre-operative: includes assessment of :
~patients general condition
~investigation
~reserved blood
~Hemoglobin level
~Impact of hysterectomy option. -9-
~Part (2) Intra-operative:
~Includes assessment of :-
~Investigation
~Vital signs
~Hypothermia
~Blood loss
~I.V fluid
~Blood gases
~Fetal condition and APGAR score.
~Part (3) Post-operative: Includes:
~maternal complication
~fetal complication
~psychological satisfaction"
11071754|NCT04274062||peri partum regular care of placenta previa|Routine nursing care of all cases of placenta previa (preoperative, intraoperative and postoperative)..
11071755|NCT04274049|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
11071756|NCT04274049|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
11071757|NCT04274036||Fibromyalgia Patients|Fibromyalgia patients diagnosed according to the 2016 American College of Rheumatology criteria.
11071758|NCT04274036||Healthy-Controls|Healthy controls without pain or chronic illness
11071759|NCT04274023|Experimental|TSR-042 arm|TSR-042 at a dose of 500 mg in IV infusion (given over t30-minutes) every 21 days for the first 4 doses, followed by 1.000 mg on day 1 of every 42 day.
11071760|NCT04273997|Active Comparator|Metronidazole Ointment|"Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
~One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound"
11071761|NCT04273997|Placebo Comparator|Placebo Ointment|"Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
~One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound."
11071762|NCT04273984|Active Comparator|1- Group 1 (misoprostol 200 mcg|"Group 1 :will take 1 tablet (200 mcg) of misoprostol and 1 placebo tablet,
~.,"
11071763|NCT04273984|Active Comparator|2- Group 2 (misoprostol 100 mcg)|Group 2: will take1 tablet (100 mcg) of misoprostol and 1 placebo tablet,
11071764|NCT04273984|Placebo Comparator|3- Group 3 (placebo group)|Group 3 ): will take2 placebo tablets
11071765|NCT04273971|Experimental|Plyometric exercise|
11071766|NCT04273958|Experimental|Virtual reality|The intervention will consist of the use of a virtual reality helmet during the painful medical procedure. The content has been developed by a private company with the goal of providing a relaxing and soothing exploration of a virtual world.
11071767|NCT04273958|Active Comparator|Computer screen|The comparator will consist in the screening of the same virtual world on the computer screen.
11071768|NCT04273945|Active Comparator|Macitentan 10 milligrams (mg) + Placebo|Participants will receive macitentan 10 mg once daily (qd) orally for 4 weeks in open-label Run-in phase prior to randomization (only for participants who are Endothelin Receptor Antagonist (ERA) treatment-naive. Other participants will bypass the Run-in period and go directly to randomization). Double-blind Treatment Period: participants will receive macitentan 10 mg qd and matching placebo of macitentan 37.5 for 4 weeks (Uptitration) and 75 mg thereafter orally up to End of Double-Blind Treatment period (EDBT). Treatment Extension Period: After EDBT, participants will receive macitentan 37.5 mg qd and macitentan 75 mg matching placebo orally for 4 weeks (Uptitration), followed by open-label macitentan 75 mg qd orally for 2 years.
11071769|NCT04273945|Experimental|Macitentan 75 mg + Placebo|Participants will receive macitentan 10 mg qd orally for 4 weeks in open-label Run-in phase prior to randomization (only for ERA treatment-naive. Other participants will bypass the Run-in period and go directly to randomization). Double-blind Treatment Period: participants will receive macitentan 37.5 for 4 weeks (Uptitration) and 75 mg qd along with matching placebo for macitentan 10 mg orally up to EDBT. Treatment Extension Period: After EDBT, participants will receive macitentan 75 mg qd and macitentan 37.5 mg matching placebo orally for 4 weeks (Uptitration), followed by open-label macitentan 75 mg qd orally for 2 years.
11071770|NCT04273932|Experimental|Lithium aspartate 15mg a day|15mg of elemental lithium administered every morning by mouth.
11071771|NCT04273932|Experimental|Lithium aspartate 45mg a day|20mg every morning and 25mg every evening of elemental lithium administered by mouth.
11071772|NCT04273932|Experimental|Lithium carbonate|The dose will be titrated based on weekly blood tests to achieve a target serum level of 0.40-0.50mmol/L, which represents an elemental lithium dose of about 85-170mg a day.
11071773|NCT04273932|No Intervention|No lithium treatment|Control arm
11071774|NCT04273919|Sham Comparator|Mindfulness Mediation|Subjects will undergo virtual reality in a non-embodied (no first person bodily experience) program called Lumen, which was developed by Stanford University's Virtual Human Interaction Lab.
11071775|NCT04273919|Experimental|Graded Motor Imagery|The subjects will engage in 2 therapeutic modules intended to help them practice increasing range of motion safely, and using small movements of the lower back.
11071776|NCT04273906|Experimental|End-range mobilization|End-range mobilization performed in end-position of the tibiofemoral joints' flexion and extension for 2*3 min
11071777|NCT04273906|Placebo Comparator|Placebo|Hands-on treatment technique performed in end-range of the tibiofemoral joints' flexion and extension for 2*3 min
11071778|NCT04273893|Experimental|Additional treatment planning dose optimization|Additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
11071779|NCT04273893|Active Comparator|No additional treatment planning dose optimization|Treatment planning that meets RTOG 0915/0813 SBRT trials with NO additional treatment planning.
11071780|NCT04273880|Experimental|10 mg Psychostimulant|Drug: Methylphenidate (MPH) Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 10mg of MPH an hour and a half before the testing session is set to begin, to account for the time taken for the effects of the drug to start.
11071781|NCT04273880|Placebo Comparator|90 mg Vitamin C|Placebo: Vitamin C Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 90mg of Vitamin an hour and a half before the testing session is set to begin, to follow the exact protocol that is used for MPH.
11071782|NCT04273867||Chronic Hypersensitivity Pneumonitis Patients|
11071783|NCT04273854|Experimental|Intervention|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice.
11071828|NCT04273516|Experimental|Intervention|Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily
11071784|NCT04273854|No Intervention|Control|The control arm will be managed as per usual NHS led care with assessment by their own health care professionals and adjustment of their medications as is needed. The BP of this group will be monitored and recorded at the same time-points and in the same manner as the intervention arm as will all other secondary outcome measures.
11071785|NCT04273841|Active Comparator|Caffeine Group|This group will receive caffeine gum.
11071786|NCT04273841|Placebo Comparator|Placebo|This group will receive gum without caffeine.
11071787|NCT04273815|Experimental|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.
11071788|NCT04273815|Experimental|TQ-A3334 tablets + anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11071789|NCT04273802|Experimental|Cohort A - First line treatment|Untreated patients
11071790|NCT04273802|Experimental|Cohort B - Hypomethylating failure|Patients in absence of response after hypomethylating agents treatment
11071791|NCT04273789|Experimental|far infrared reflecting sleepwear|Sleepwear (shorts + tshirt) with far infrared reflecting ceramic print produced by Dagsmejan AG (Zurich, Switzerland)
11071792|NCT04273789|Placebo Comparator|Placebo sleepwear|Sleepwear (shorts + tshirt)
11071793|NCT04273776|Active Comparator|Suvorexant Arm|10 mg of Suvorexant
11071794|NCT04273776|Active Comparator|Zolpidem Arm|5 mg of Zolpidem
11071795|NCT04273776|Placebo Comparator|Placebo|10mg of Avicel
11071796|NCT04273763|Experimental|Group A|Treatment group
11071797|NCT04273763|Active Comparator|Group B|Control group
11071798|NCT04273737|Experimental|Amantadine|Daily regimen of amantadine hydrochloride tablets for 6 weeks: dosing of 5mg/kg divided by two daily doses (max daily dose of 300 mg)
11071799|NCT04273724|Experimental|Geriatric assessment guided interventions|
11071800|NCT04273711||Obese patients|
11071801|NCT04273711||Non-obese patients|
11071802|NCT04273698|Experimental|Clinical intervention|The project involved recruiting families, with children under the age of five years old, who were experiencing one or more difficulties, and these families were offered five therapeutic sessions, based on a psychodynamic parent-infant psychotherapy approach.
11071803|NCT04273685|Experimental|Intervention Condition|Cognitive remediation training, cognitive behavioural therapy, social recovery therapy
11071804|NCT04273685|Active Comparator|Control Condition|Treatment as usual (TAU),non-directive counselling
11071805|NCT04273672||Parkinson's Disease|Subjects with Parkinson's Disease
11071806|NCT04273672||Control|Subjects without Parkinson's Disease
11071807|NCT04273659|Experimental|Pulses and Cereal 1|Pulses and cereal 1 containing study product is served. Dietary intervention.
11071808|NCT04273659|Experimental|Pulses and Cereal 2|Pulses and cereal 2 containing study product is served. Dietary intervention.
11071809|NCT04273646|Experimental|UC-MSCs Treatment Group|"Conventional treatment plus UC-MSCs:
~Participants will receive conventional treatment plus 4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1，Day 3，Day 5，Day7)."
11071810|NCT04273646|Placebo Comparator|Conventional Control Group|"Conventional treatment plus Placebo:
~Without UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1，Day 3，Day 5，Day7)."
11071811|NCT04273633|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant shoulder
11071812|NCT04273633|Placebo Comparator|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant shoulder
11071813|NCT04273620|Experimental|Intervention-Control (IC)|In the Intervention-Control (IC) arm, patients will first receive the intervention (OKS-READ) containing 15 individual therapy sessions within a maximum time period of 28 days. Afterwards they will receive the control therapy (again 15 sessions within max. 28 days).
11071814|NCT04273620|Active Comparator|Control-Intervention (CI)|In the Control-Intervention (CI) arm, patients will first receive the control therapy (15 sessions within max. 28 days), followed by the intervention phase (15 therapy sessions OKS-READ within a maximum time period of 28 days).
11071815|NCT04273607|Experimental|No anticoagulation|Participants in this arm will not receive unfractionated heparin during the course of ECMO. They will receive standard venous thromboembolism prophylaxis with subcutaneous enoxaparin or unfractionated heparin
11071816|NCT04273607|No Intervention|Anticoagulation, ECMO standard of care|Participants in this arm will receive the standard of care anticoagulation with unfractionated heparin during the course of ECMO.
11071817|NCT04273594|Experimental|FemBloc|Investigational device and procedure
11071818|NCT04273581|Placebo Comparator|Control group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. placebo：100mg/d，qn，for 14 days.
11071819|NCT04273581|Experimental|Thalidomide group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. thalidomide：100mg/d，qn，for 14 days.
11071820|NCT04273568|Experimental|Group1 (PNF group)|Scapular PNF and exercise program was applied to the PNF group.
11071821|NCT04273568|Active Comparator|Group 2 (Exercise group)|Exercise program was applied to the exercise group
11071822|NCT04273555|Experimental|[18F]-Fluorodeoxyglucose (FDG) PET/ MRI|
11071823|NCT04273542|Other|Control cohort|"In this cohort, women recruited participated to organised breast cancer screening. They must not have breast cancer.
~They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening)."
11071824|NCT04273542|Other|Patient cohort|"In this cohort, women for who a breast cancer has been diagnose will be included.
~Only one liquid biopsy will be collected before any treatment."
11071825|NCT04273542|Other|Exploratory cohort|"In this cohort, women with high risk of BRCA1/2 mutation but without breast cancer.
~6 liquid biopsies will be collected : each year after inclusion during 5 years."
11071826|NCT04273529|Placebo Comparator|Control group|placebo
11071827|NCT04273529|Experimental|Thalidomide group|thalidomide
11071829|NCT04273516|Placebo Comparator|Comparator|Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily
11071830|NCT04273503|Experimental|Intervention|All participants will receive education on maintaining a healthy diet and improving physical activity.
11071831|NCT04273490||Hereditary hypophosphatemia|Adult persons with genetically or biochemically verified hereditary hypophosphatemia.
11071832|NCT04273490||Control|Adult control persons without disturbances in calcium, vitamin D or phosphate homeostasis matched on age, gender and menopausal status.
11071833|NCT04273464|Experimental|Brava-group|External tissue expanders will be used 3 weeks prior to operation and 2 weeks postoperatively in order to enhance the volume and survival of fat cells. We expect that each patient in the fat transplantation group will need 4-6 transplantation sessions of about 1.5 to 2 hours each to achieve satisfactory volume and shape of the breast.30 participants.
11071834|NCT04273464|Active Comparator|DIEP-group|30 participants. We expect 1-2 operative sessions of respectively 5-7 and 2-3 hours duration in the DIEP group. The risk of reoperation (second operation during the first postoperative week) in the DIEP group is 5-10 %
11071835|NCT04273425||Study cohort (Confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.
~Those who receive a positive diagnosis will be followed up upon completion of first-line treatment, and questionnaire data and blood samples collected again."
11071836|NCT04273425||Control cohort (non-confirmed myeloma patients)|"Patients with suspected multiple myeloma will be recruited. They will be asked to fill in questionnaires (regarding pain, quality of life, catastrophizing), donate serum samples and allow the research team to access their clinical data and their diagnostic bone biopsy.
~Samples from patients who receive a negative myeloma diagnosis will be used as negative controls."
11071837|NCT04273412|Experimental|lifestyle intervention (LI)|moderate-intensity lifestyle intervention (Individualised counseling on diet, physical activity, and target weight gain) by license dietitian
11071838|NCT04273412|No Intervention|usual standard care group (UC)|standard antenatal care as per usual clinic protocol
11071839|NCT04273399|Experimental|Crohn's Disease|Twelve week jumping based exercise intervention
11071840|NCT04273399|Active Comparator|Controls|Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups
11071841|NCT04273386|Experimental|Evaluation|Cases will be evaluated for oral health and data will be recorded. In addition to evaluations by a single physiotherapist in the first evaluation, a second physiotherapist will independently implement the OMouth Handicap in Systemic Sclerosis Questionnaire (MHISS). The second assessment will be performed within 1-2 weeks to ensure that the patient's condition is stable and that he does not remember any previous answers to the questions, and that only the Mouth Handicap in Systemic Sclerosis Questionnaire (MHISS) will be applied.
11071842|NCT04273373|Active Comparator|Standard dose albumin+SOC|20% albumin1.5 g/kg at diagnosis and 1 g. SOC (Standard of Care)
11071843|NCT04273373|Experimental|Low dose albumin+SOC|20% albumin.5 g/kg at diagnosis and 0.5 g/kg. SOC (Standard of Care)
11071844|NCT04273360|Active Comparator|Systematic use group|
11071845|NCT04273360|Experimental|Restrictive use group|
11071846|NCT04273347||patient with brain trauma|all patient with brain trauma in intensive care unit
11071847|NCT04273347||patient with spinal cord injury|all patient with spinal cord injury in intensive care unit
11071848|NCT04273334|Experimental|68Ga-NEB injection and PET/CT scan|Patients for lymphatic disorders imaging: The patients were subcutaneously injected with 68Ga-NEB and underwent PET/CT scan 20~40min after the injection.
11071849|NCT04273321|Experimental|MP group|
11071850|NCT04273321|No Intervention|Con group|
11071851|NCT04273308|Experimental|whole-body vibration training|a 12-week whole-body vibration training that conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time.
11071852|NCT04273295|No Intervention|the control group|This group receives senna-based laxatives.
11071853|NCT04273295|Experimental|the study group|This group managed by abdominal massage with senna-based laxatives.
11071854|NCT04273282|Active Comparator|Dexycu Group|A total of 30 study subjects (30 eyes) will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa qd after surgery for 4 weeks.
11071855|NCT04273282|Active Comparator|Control Group|A total of 30 study subjects (30 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, Prolensa qd 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
11071856|NCT04273269|Experimental|3.2x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 3.2x10^12 vg/Kg LYS-GM101
11071857|NCT04273269|Experimental|8.0x10^12 vg/Kg LYS-GM101|Subjects will receive a single infusion: 8.0x10^12 vg/Kg LYS-GM101
11071858|NCT04273256|Experimental|Myo-inositol arm|Patients will be supplemented with 2 grams of Myo-inositol + at least 400 μg of folic acid (received from routinely prescribed multivitamins) every day for 3 months before the IVF cycle.
11071859|NCT04273256|No Intervention|Control arm|Patients will receive at least 400 μg of folic acid from routinely prescribed multivitamins every day for 3 months before the IVF cycle.
11071860|NCT04273243||Subjects who received AT-GTX-501 gene transfer|Subjects with CLN6 Batten disease who previously received AT-GTX-501 in the preceding study (Study AT-GTX-501-01).
11071861|NCT04273217|Experimental|AV-1|Single dose
11071862|NCT04273217|Placebo Comparator|Placebo|Single dose
11071863|NCT04273204|Experimental|UCP Group|
11071864|NCT04273204|Other|Control Group|
11071865|NCT04273191|Experimental|Brexanolone|Participants will receive a single dose of commercial brexanolone as part of standard of care.
11071896|NCT04272970|Active Comparator|New gene / protein variant functional study|Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional familial thrombocytopenia.
11072256|NCT04270526|Placebo Comparator|Placebo treatment|50 mL 1% lidocaine + 50ml of 0.9% normal saline
11071866|NCT04273178|Experimental|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
11071867|NCT04273165|Active Comparator|Etravirine Dose 1|Etravirine dose 200 mg per diem(100+100)
11071868|NCT04273165|Active Comparator|Etravirine Dose 2|Etravirine dose 400 mg per diem (200+200)
11071869|NCT04273152||children with allergy|children with allergies
11071870|NCT04273152||healthy control|healthy control (non allergic children)
11071871|NCT04273139|Experimental|Ibrutinib and Venetoclax (3 dose ramp up)|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~First 12 participants
~Ibrutinib will be administered at a predetermined dose, once daily for 28 days
~TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)
~Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2."
11071872|NCT04273139|Experimental|Ibrutinib and Venetoclax (2 dose ramp up)|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Ibrutinib will be administered at a predetermined dose, once daily for 28 days
~TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)
~Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up schedule during cycle 2."
11071873|NCT04273126|Experimental|Intervention|This arm consists of approximately 8 sessions lasting approximately one hour and consisting of psychoeducation and core components including communication, problem solving, goal setting, and dealing with stress, tailored to families with experiences of homelessness and parental substance use disorders.
11071874|NCT04273126|No Intervention|Treatment as usual|Families in the standard care condition will receive treatment as usual at their facility, which may include case management at the facility, and mental health services and supportive services from organizations affiliated with the sites.
11071875|NCT04273113|Experimental|Heart Rate Variance (HRV) biofeedback training|Patients to participate in 15 biofeedback sessions, 3 times a week (5 weeks in total).
11071876|NCT04273100|Experimental|Treatment group|The participants will receive the combined treatment of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE, lobaplatin and epirubicin and anti-angiogenic therapy (lenvatinib)
11071877|NCT04273074|Other|preoperative sonographic assessment group|preoperative sonographic assessment to airway
11071878|NCT04273061|Experimental|Breast Cohort|Cohort of participants whose primary tumour type is breast.
11071879|NCT04273061|Experimental|Lung Cohort|Cohort of participants whose primary tumour type is lung.
11071880|NCT04273061|Experimental|GI Cohort|Cohort of participants whose primary tumour type is gastrointestinal (including pancreas and hepatobiliary).
11071881|NCT04273061|Experimental|GU Cohort|Cohort of participants whose primary tumour type is genitourinary.
11071882|NCT04273061|Experimental|Gyne Cohort|Cohort of participants whose primary tumour type is gynecological.
11071883|NCT04273061|Experimental|Sarcoma Cohort|Cohort of participants whose primary tumour type is sarcoma.
11071884|NCT04273061|Experimental|Primary Unknown Cohort|Cohort of participants whose primary tumour type is unknown.
11071885|NCT04273061|Experimental|Other Cohort|Cohort of participants whose primary tumour type is not classified as one of the other study arms. This cohort includes participants with cancers from the head and neck, skin, or rare cancers.
11071886|NCT04273048|Active Comparator|Diet and Exercise|Group 1 = Diet Intervention group: They will be asked to follow a personalized diet during study period and record what they eat. The meal plan for this study is Mediterranean style and nutritionally complete for 8 to 12 weeks or until oocyte retrieval procedure. Exercise Intervention: Exercise 3 times/week at a gym of their choice or at home for 8 to 12 weeks or until oocyte retrieval procedure. Exercises will be light intensity and short duration at first and will gradually increase to moderate intensity and longer duration during the first 3 weeks. They will also be encouraged to walk an average 10,000 steps per day and wear a pedometer to monitor progress.
11071887|NCT04273048|No Intervention|Standard Care|Group 2 = Standard: They will receive standard care from the Little Rock Fertility Center.
11071888|NCT04273035|Active Comparator|Midazolam Group|"Midazolam(Buccolam 5mg/ml)
~0.5mg/kg oral, max 12mg
~one time
~given 30 min prior to going to holding"
11071889|NCT04273035|Active Comparator|IPAD group|"No premedication
~IPAD when arriving at the holding
~any games, movies, clips, puzzles"
11071890|NCT04273022|Experimental|SCT Group|Fifteen SCT subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
11071891|NCT04273022|Active Comparator|Control Group|Five healthy subjects will be recruited, consented, screened, and enrolled if they meet inclusion and exclusion criteria. Each subject will undergo a single bout of standardized exercise on a treadmill. Subjects will self-select treadmill speed at 0% grade and begin. After 3 minutes the grade will be increased by 1% every 2 minutes until the target heart rate (70% of heart rate reserve) is reached. Speed and grade will be held constant for 15 minutes, marking the end of the session.
11071892|NCT04273009|Active Comparator|Renew Anal Insert|The device is intended for self-insertion through the anal canal aided by a fingertip applicator.
11071893|NCT04273009|Active Comparator|Percutaneous tibial nerve stimulation|A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.
11071894|NCT04272996|Other|surgery alone|craniotomy for SDH evacuation
11071895|NCT04272996|Active Comparator|Surgery plus embolization|surgery for evacuation of SDH followed by embolization of middle meningeal vessel
11102358|NCT04059926||Patients with lumen metal apossing stent|
11071897|NCT04272970|Sham Comparator|Normal gene / protein variant functional study|"Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to provide control observations / analyses / measures for the Active Comparator arm"
11071898|NCT04272957|Experimental|HMPL-306|HMPL-306 administered continuously as a single agent orally every day in a 28-day cycle.
11071899|NCT04272944|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 3 mg/kg to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
11071900|NCT04272931|Experimental|Portal and Hepatic Vein Embolization|3 patients per center over one year approximately 90 patients in total. Patients will undergo portal vein and hepatic vein embolization instead of only portal vein embolization.
11071901|NCT04272918|Experimental|CSM condition|Social Worker 1 of CSM conditions will work with caregivers according to the guidelines and template of the Care Support Model, including the formulation of the intervention plan based on CNA scores of different need domains, the use of the caregiver intervention plan template, service matching drawing reference from caregiver resource database, service formulation based on CNA scores of different strength domains, the use of the case monitoring template and guideline.
11071902|NCT04272918|No Intervention|Non-CSM condition|Social Worker 2 of the Control Group will not be notified of the CNA scores of his/her caregivers. The intervention plan, services assignment and case management of participants of the control group will be based on Social Worker 2's own judgement using the information shared by the caregivers, and the social worker's own observation.
11071903|NCT04272918|Experimental|PP-E condition|Experimental Group will be led a consultant who is an expert, with the help of a degree-holder social worker to facilitate capacity building, empowerment and long-term well-being. Measurement of outcome variables will be conducted before the start of the program, at the end of the program, and 3 months after the program ended.
11071904|NCT04272918|No Intervention|Non PP-E condition|Measurement of outcome variables will be conducted at the same point of time as PP-E condition. There will be no treatment or intervention for the control group.
11071905|NCT04272905||Maternity patients|"> 18 years
~Post-natal following any form of delivery
~Between 4 and 48 hours after delivery
~Able to understand English adequately to give consent and complete the questionnaire"
11071906|NCT04272905||Maternity Unit Staff|"Doctors, midwives and other staff
~Work on labour ward"
11071907|NCT04272892|Experimental|Digital CBT-I|6 weeks digital (online) cognitive behavioural therapy for insomnia
11071908|NCT04272892|Active Comparator|Sleep hygiene information|Leaflet of sleep hygiene information
11071909|NCT04272866|Active Comparator|Group 1|Teeth in this group will be sealed with clinpro sealant
11071910|NCT04272866|Experimental|Group2|Teeth in this group will be sealed with embrace wetbond sealant
11071911|NCT04272866|Experimental|Group3|Teeth in this group will be sealed with triage sealant
11071912|NCT04272853||Athletes|440 subjects will be recruited (see calculation of the sample size for details): all subjects will be athletes, professional or non-professional, belonging to any sporting discipline, members of one of the sports federations of the Lombardy region, officially recognized by CONI (National Committee of Italian Olympic Team).
11071913|NCT04272840|No Intervention|Standard Care|Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record).
11071914|NCT04272840|Experimental|Low Glycemic Index|Standard care + Glycemic Index. Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record). Diabetes Canada and Dietitian's Canada resources on glycemic index will also be reviewed: the Glycemic Index Food Guide, Flip Cards, and Recipes.
11071915|NCT04272827|Active Comparator|Intervention Group|Patients receive the liposuction operation(s) in the following. The number varies according to need (maximum four operations) with 5-7 weeks interval between each respective operations.
11071916|NCT04272827|Other|Control group|The control group will be treated for 12 months with CDT alone.
11071917|NCT04272814|Experimental|Compression therapy|compression therapy
11071918|NCT04272814|Active Comparator|Standard treatment|standard treatment
11071919|NCT04272801|Experimental|Neoadjuvant endocrine therapy|All participants enrolled to the study will receive 3 months of neoadjuvant endocrine therapy (e.g. tamoxifen or aromatase inhibitors (AIs) such as letrozole, anastrozole, or exemestane). The choice and dose of endocrine therapy will be at the discretion of the treating medical oncologist.
11071920|NCT04272788||CD patients|CD patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.CD patients are followed for 14 weeks after the first administration of infliximab. At week 14 of Infliximab treatment, CD patients are classified as remission group (CDAI<150 and endoscopic mucosal healing, R group) and non-remission group (CDAI≥150 and/or mucosal non-healing group, N group).
11071921|NCT04272788||Healthy controls|Healthy controls without Crohn's Disease.
11071922|NCT04272775|Experimental|Cohort 1: Ixazomib 4.0 mg|Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
11071923|NCT04272775|Experimental|Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone|Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
11071924|NCT04272775|Experimental|Cohort 3: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
11071925|NCT04272775|Experimental|Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
11071926|NCT04272762|Active Comparator|Ablation|pulmonary vein isolation
11071927|NCT04272762|Placebo Comparator|Placebo|placebo procedure
11102394|NCT04059666|No Intervention|Mother's-own Breast Milk|
11071928|NCT04272749|Experimental|Dairy and non-dairy milks|Questionnaires and consumption behaviors of dairy and non-dairy milks
11071929|NCT04272736|Experimental|Low calorie protein substitute|Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.
11071930|NCT04272723||VMP members of the SFMV|VMP (vascular medicine physicians) members of the SFMV (French Society of Vascular Medicine )
11071931|NCT04272723||VMP registered as willing to do medical research|VMP (vascular medicine physicians) registered as willing to do medical research
11071932|NCT04272710||ACEI treatment|hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
11071933|NCT04272710||Control|hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
11071934|NCT04272697||Heterozygous Familial Hypercholesterolaemia|Adults and children with Heterozygous Familial Hypercholesterolaemia.
11071935|NCT04272697||Homozygous Familial Hypercholesterolaemia|Adults and children with Homozygous Familial Hypercholesterolaemia
11071936|NCT04272697||Unaffected (non-FH) relatives of FH individuals|Adults and children with unaffected (non-FH) relatives of FH individuals
11071937|NCT04272684|Experimental|Interventional|Driving Assessment
11071938|NCT04272671|Experimental|Educational Intervention Arm|The intervention arm will receive educational material that enhances the standard of care for deprescribing opioids and BZDs.
11071939|NCT04272671|No Intervention|Ususal Care (Control Arm)|Control group will receive standard of care
11071940|NCT04272658||value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma"
11071941|NCT04272645|Experimental|Arm A - Abemaciclib 200 mg|Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
11071942|NCT04272645|Experimental|Arm B - Abemaciclib 150 mg + atezolizumab|Atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily.
11071943|NCT04272645|Experimental|Experimental: Arm C - Patients with CDK12 loss|"Group 1 - Atezolizumab: Patients with CDK12 loss will receive atezolizumab monotherapy on the first day of each 21-day cycle
~Group 2 - Abemaciclib 150 mg + atezolizumab: Patients with CDK12 loss will receive atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily."
11071944|NCT04272632|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
11071945|NCT04272632|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
11071946|NCT04272632|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
11071947|NCT04272619|Experimental|Liver Cancer Education|
11071948|NCT04272606|Active Comparator|Treatment|1:1 randomization, given tranexamic acid during surgery, visual acuity exam
11071949|NCT04272606|Placebo Comparator|Placebo|1:1 randomization, given standard of care treatment during surgery, visual acuity exam
11071950|NCT04272593|Experimental|Simultaneous Control|Simultaneous pattern recognition style of control allows prosthetic users to actuate more than one hand/arm function on their device at the same time.
11071951|NCT04272593|Active Comparator|Conventional Control|Conventional, seamless sequential pattern recognition style of control allows prosthetic users to actuate a single hand or arm functions on their device at a time.
11071952|NCT04272580|Sham Comparator|Control group|No preload was given before spinal anesthesia
11071953|NCT04272580|Experimental|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia
11071954|NCT04272580|Experimental|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
11071955|NCT04272580|Experimental|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
11071956|NCT04272567|Sham Comparator|Control group|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
11071957|NCT04272567|Experimental|0.025 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).
11071958|NCT04272567|Experimental|0.05 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).
11071959|NCT04272567|Experimental|0.075 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).
11071960|NCT04272567|Experimental|0.1 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).
11071961|NCT04272541|Active Comparator|Psychopharmacology + psychoeducation|Intervention program consisted of psychopharmacology + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program will be implemented for three months, allocated in several sesions.
11071962|NCT04272541|Active Comparator|Habitual intervention|Intervention program consisted of psychopharmacology (standard intervention in mental health services). This program will be implemented for three months.
11071963|NCT04272528|Experimental|experimental group|Nurses provide uniform care to patients according to the quality standards.
11071964|NCT04272528|Placebo Comparator|control group|Nurses provide the routine care to patients.
11071965|NCT04272515|Experimental|BA patients and their parents|"Collection of blood samples from BA patients and their parents
~Collection of explanted liver tissue and skin biopsy of BA patients"
11071966|NCT04272502|Experimental|Sequence A|CKD-828, D326, D337, CKD-F1, CKD-F2
11071967|NCT04272502|Experimental|Sequence B|CKD-828, D326, D337, CKD-F1, CKD-F2
11071968|NCT04272502|Experimental|Sequence C|CKD-828, D326, D337, CKD-F1, CKD-F2
11071969|NCT04272489|Experimental|Adaptive Control|The adaptive control system updates the pattern recognition control algorithm by incorporating new EMG data each instance the prosthetic user recalibrates their device.
11071970|NCT04272489|Active Comparator|Non-Adaptive Control|The conventional, non-adaptive control systems resets the pattern recognition control algorithm by deleting old EMG data each instance the prosthetic user recalibrate their device.
11071971|NCT04272476|Experimental|Acupuncture and moxibustion|Acupuncture points: Baihui(GV 20), Mingmen(GV 4), Bilateral Neiguan(PC 6), Bilateral Shenmen(HT 7), Bilateral Hegu(LI 4), Bilateral Zusanli(ST 36), Bilateral Taichong(LR 3). Each treatment takes about thirty minutes,3 times a week(treatment on Monday, Wednesday and Friday) for 8 weeks.
11071972|NCT04272476|Active Comparator|Western medicine|Fluoxetine 20 mg capsule by mouth every day for 8 weeks.
11071973|NCT04272437|Experimental|TRA group|"Tokoro Combination and Rehmannia and Akebia Formula (TRA) in each one batch number were manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous manufacturer of concentrated herbal extract granules in agreement with the standards of good manufacturing practices (GMP) in Kaohsiung City, Taiwan.
~TRA contains Tokoro Combination and Rehmannia and Akebia Formula Tokoro Combination and Rehmannia and Akebia Formula consists of Dioscorea Hypoglaucae Rhizoma, Acori Graminei Rhizoma, Linderae Radix, Alpiniae Oxyphyllae Fructus, Poria, Rehmanniae Radix, Akebiae Caulis, Lophatheri Hebra, and Glycyrrhizae Radix at a 2:2:2:2:1:1.3:1.3:1.3:2.5 ratio."
11071974|NCT04272437|Placebo Comparator|placebo group|The placebo was also prepared as granules by Chung Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA.
11071975|NCT04272424|Active Comparator|group A|laparoscopic hernioplasty with no fixation
11071976|NCT04272424|Active Comparator|group B|laparoscopic hernioplasty with tacker fixation
11071977|NCT04272424|Active Comparator|group C|laparoscopic hernioplasty with histoacryl fixation
11071978|NCT04272411|Sham Comparator|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device
11071979|NCT04272411|Active Comparator|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device
11071980|NCT04272411|Active Comparator|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device
11071981|NCT04272398|Active Comparator|Treatment|Used dynamic elastomeric fabric orthoses with physiotherapy and rehabilitation program
11071982|NCT04272398|Experimental|Control|Only physiotherapy and rehabilitation program
11071983|NCT04272372||Group 1|Complete Decongestive Therapy
11071984|NCT04272372||Group 2|Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
11071985|NCT04272372||Group 3|Complete Decongestive Therapy + Local Ketoprofen gel
11071986|NCT04272359||Group 1|SGLT2 inibitori +/- Metformin
11071987|NCT04272359||Group 2|DPP4 inibitori +/- Metformin
11071988|NCT04272359||Group 3|GLP1-RA + Long-Acting Insulin +/- Metformin
11071989|NCT04272359||Group 4|SGLT2 inibitori + DPP4 inibitori +/- Metformin
11071990|NCT04272346|Experimental|Peer helping condition|Participants in the peer helping condition will be asked to write about their cancer experience with an emphasis on using the experience to benefit a newly-diagnosed AYA cancer patient.
11071991|NCT04272346|Experimental|Processing + peer helping condition|Participants in the processing + peer helping condition will be asked to first write about their deepest thoughts and feelings about their cancer experience (3 writings), then share advice to a newly-diagnosed AYA cancer patient (final writing).
11071992|NCT04272346|Placebo Comparator|Facts-only writing condition|Participants in the facts-only writing condition will be asked to write about their cancer experience. Unlike the previous conditions, they will not be instructed to write for the benefit of a newly-diagnosed AYA cancer patient.
11071993|NCT04272333|Experimental|CIVO Microdose Injection of Motolimod and Nivolumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of motolimod, nivolumab, or motolimod combined with nivolumab. Each microdose is simultaneously and percutaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
11071994|NCT04272320|No Intervention|Group C|
11071995|NCT04272320|Active Comparator|Group TFP|Transversalis fascia plane block, before the surgical procedure.
11071996|NCT04272307||Acute Severe Ulcerative Colitis group|
11071997|NCT04272307||Non-severe Ulcerative Colitis group|
11071998|NCT04272294|Experimental|Use of Optical Spectroscopy|Optical spectroscopy used to characterize treatment response
11071999|NCT04272281|Experimental|Share making tool decision|Patient recruited from general practitioner in this group will use a share making tool decision to adapt antibiotherapy
11072000|NCT04272281|Active Comparator|Standard recommandation|Patients recruited from general practitioner will receive the standard medical care
11072001|NCT04272268||Nasal High flow Oxygen|Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
11072002|NCT04272255|Active Comparator|DPI-386 nasal gel|"DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as 0.2 mg / 0.1 g"
11072003|NCT04272255|Placebo Comparator|placebo nasal gel|Placebo nasal gel product is the same but does not contain scopolamine HBr
11072004|NCT04272255|Experimental|Transderm Scop®|TDS patch delivers 1.5 mg of scopolamine over a 72-hour period. TDS arm will apply two TDS patches over the six treatment days.
11072005|NCT04272242|Experimental|Arm 1: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally twice daily (~12 hours apart). Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.
~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.
~Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses."
11072085|NCT04271683|Experimental|Pressure controlled ventilation with PEEP|In this group, ventilation after apnoea during induction of general anesthesia starts with pressure controlled ventilation with PEEP.
11072086|NCT04271683|Active Comparator|Manual ventilation without PEEP|In this group, ventilation after apnoea during induction of general anesthesia starts with manual ventilation without PEEP.
11072006|NCT04272242|Experimental|Arm 2: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally each morning. Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.
~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.
~Participants will remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. DTG will be from non-study ARV supply.
~NOTE: Arm 2 will only open based on assessment of DTG pharmacokinetics (PK) data from participants in Arm 1."
11072007|NCT04272229|Active Comparator|Control Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
11072008|NCT04272229|Experimental|Migrain Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
11072009|NCT04272216||Treatment with HydroPearl via radial access|all patients will be in the same group/cohort in this open-label, single-arm, observational registry.
11072010|NCT04272203|Experimental|Dose Escalation: Participants With AML|Participants with relapsed or refractory (R/R) AML will receive escalating doses of ABBV-184
11072011|NCT04272203|Experimental|Dose Escalation: Participants With NSCLC|Participants with relapsed or refractory (R/R) NSCLC will receive escalating doses of ABBV-184
11072012|NCT04272203|Experimental|Dose Expansion: Participants With AML|Participants with R/R AML will receive ABBV-184 at recommended Phase 2 dose (RP2D) determined in dose escalation phase for AML
11072013|NCT04272203|Experimental|Dose Expansion: Participants With NSCLC|Participants with R/R NSCLC will receive ABBV-184 at RP2D determined in dose escalation phase for NSCLC
11072014|NCT04272177|Experimental|SDM group|Shared decision making using PDAs. PDAs is used as a tool explain the advantages and disadvantages of the traditional reversal drugs and sugammadex. And by following SDM principles, the patients are guided to consider their individual values and preferences and helped to make a choice that best meet their needs.
11072015|NCT04272177|No Intervention|Control group|Current approach to explain details of anesthesia using a single introductory sheet made by the two hospitals or provided by the pharmaceutical companies is used.
11072016|NCT04272164|Active Comparator|technical taekwondo training|Light jogging,running, Stretching exercises,Pushups and sit ups, Punches,Kicks
11072017|NCT04272164|Experimental|weighted rope taekwondo training|weighted rope jump training along with tachnical taekwando training
11072018|NCT04272151|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
11072019|NCT04272138|Experimental|Calm Meditation|Participants in the intervention group will be exposed to 10 minutes per day of meditation via a smartphone application for 4 weeks. Participants will log their meditation participation in an online weekly log.
11072020|NCT04272138|Active Comparator|Educational Podcast Control|Participants in the control group will be exposed to 10 minutes per day of health education podcasts via a smartphone application for 4 weeks. Participants will log their podcast participation in an online weekly log.
11072021|NCT04272125|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
11072022|NCT04272112|Active Comparator|Glass-ceramic|30 dental crowns of lithium-disilicate glass-ceramic
11072023|NCT04272112|Active Comparator|Zirconia|30 dental crowns of high translucent zirconia
11072024|NCT04272112|Active Comparator|Zirconia with mini-veneer|30 dental crowns of high translucent zirconia with a mini-veneer of porcelain
11072025|NCT04272099||PG1 (patients with diabetes 0-25 years of age)|Patients 0 to 25 years of age, with a diagnosis of diabetes that are either followed at Kay Mackenson Pediatric Clinic, Haiti, or who are of Haitian ancestry, defined as both maternal and paternal grandparents being born in Haiti, and attend one of the three diabetes clinics in Montreal.
11072026|NCT04272099||PG2 (patient's principal caregiver)|The patient's principal caregiver (a parent of legal guardian).
11072027|NCT04272086|Placebo Comparator|Bupivacaine TAP|TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
11072028|NCT04272086|Experimental|Liposomal bupivacaine TAP|TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side
11072029|NCT04272073|Active Comparator|Standard Care|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.
~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
11072030|NCT04272073|Experimental|High-Protein Mediterranean Diet|"Participants will perform standard cardiac rehabilitation involving weekly (1-3 days) aerobic-focused exercise sessions in community gyms.
~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet
~eating more fruit and vegetables,
~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),
~replacing butter and margarine by olive oil as the main culinary fat,
~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 high-protein yoghurts to eat each day)."
11072031|NCT04272073|Experimental|Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.
~Participants will have received guidance on weight management and healthy eating from cardiac rehabilitation staff but will not receive any further dietary support."
11072087|NCT04271670|Experimental|Warm water footbath with ginger powder|Footbath with ginger powder with a maximum duration of 20 minutes.
11072088|NCT04271670|Experimental|Warm water footbath with mustard powder|Footbath with mustard powder with a maximum duration of 20 minutes.
11072089|NCT04271670|Active Comparator|Warm water only footbath|Warm water only footbath with a maximum duration of 20 minutes.
11072090|NCT04271644|Experimental|BCMA CAR-T cells treat|Patients will be be treated with BCMA CAR-T cells
11072091|NCT04271631|No Intervention|Control|Received conventional education group
11072032|NCT04272073|Experimental|High-Protein mediterranean Diet and Resistance Exercise|"Participants will be asked to perform resistance exercise. This involves weights or weight machines aimed at building muscle strength. Participants will be required to attend 3 sessions per week and each session is expected to last approximately 45 minutes.
~Personalised dietary advice: we will ask participants to make changes to their diet to adapt it to a high-protein, Mediterranean-style diet
~eating more fruit and vegetables,
~reducing commercial pastries, and replacing refined carbohydrate foods (white bread, white rice, white pasta) by wholegrains (wholegrain bread, rice and pasta),
~replacing butter and margarine by olive oil as the main culinary fat,
~reducing fatty meat and replacing by lean meat, fish, and legumes (peas, beans, lentils), and by high-protein, low fat foods, such as low-fat dairy (participants will be provided with 2 high-protein yoghurts to eat each day)."
11072033|NCT04272060|Experimental|CT Angiography|Research CT angiography.
11072034|NCT04272060|Active Comparator|Conventional Angiography|Standard medical care which includes cardiac catheterization and invasive coronary angiography.
11072035|NCT04272047|Experimental|Knee Control+|Knee Control+ consists of 6 different exercises, with 10 different variations/progressions, and takes 10-15 minutes to complete. In addition, teams are instructed to perform a 5-minute running warm-up before the Knee Control+ exercises. Teams are to carry out the running warm-up and Knee Control+ at all training sessions, and the running warm-up before all matches, during the whole season. Knee Control+ is based on the Knee Control program but with more variations for each exercise making it easier to tailor for the needs in the respective teams.
11072036|NCT04272047|Experimental|Adductor strengthening program|The Adductor strengthening program consists of a single exercise with three levels of difficulty. The exercise is based on the Copenhagen Adduction exercise. Teams are to carry out the Adductor strengthening program as part of their regular warm-up 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
11072037|NCT04272047|Active Comparator|Knee Control|Teams will carry on their normal training and warm-up routines using the Knee Control program with no intervention from the researchers. Knee Control consists of 6 different exercises, with 4 different variations/progressions and 1 pair-exercise.
11072038|NCT04272034|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
11072039|NCT04272034|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
11072040|NCT04272034|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
11072041|NCT04272021|Experimental|ADHD sample|Children with a diagnosis of ADHD
11072042|NCT04272008|Active Comparator|Annovera (alone)|Annovera without tampon use
11072043|NCT04272008|Active Comparator|Annovera with tampon use|Annovera with tampon use
11072044|NCT04271982||Cohort A|Cohort A includes patients (N=20 000) screened for nutritional risk at Haukeland University Hospital (HUS) during point prevalence surveys between 2008 and 2018. The point prevalence surveys included all adult patients in somatic departments, and were performed 2-4 times per year since 2008. We expect the sample in the study to include approx. 9000 patients ≥ 65 years.
11072045|NCT04271982||Cohort B|"Cohort B includes older service users (≥65 years) with information on nutrition variables from the KPR-registry in the period 2016 to 2018 (n=approx. 270 560). All Norwegian municipalities report data on nutritional risk screening and nutrition plan for individual service users in Kommunalt pasientregister (KPR). These nutritional data will be linked to registry data on health care services use and patient outcome variables from the The Norwegian Patient Registry (NPR)"
11072046|NCT04271956|Experimental|Tislelizumab + Zanubrutinib|"Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
~Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
~Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation"
11072047|NCT04271943|Active Comparator|COMPUTER BASED EXERCISES|
11072048|NCT04271943|Active Comparator|AEROBIC EXERCISES|
11072049|NCT04271930|Experimental|Mindfulness Awareness Practices for Insomnia|Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with 5 minutes and increasing to 20 minutes over the course of the 6-week intervention - as is standard with the Mindfulness Awareness Practices (MAPs) course - with practice prior to bedtime. An intervention training manual is the cornerstone of standardized delivery of MAP-I. Participants are also provided with a book on mindfulness (Fully Present: The Science, Art, and Practice of Mindfulness, authored by the Mindfulness Awareness Research Center (MARC) leader and MAP-I instructor Diana Winston) as well as access to the University of California Los Angeles (UCLA) Mindful App courtesy of the MARC at UCLA (via personal iPhone or study-administered tablets per patient preference), which contains pre-recorded guided meditations for use in daily practice.
11072050|NCT04271930|Active Comparator|Sleep Health Education|Six individual 1-hour videos will be shown to participants at the same time points as, and with equal duration to, the MAP-I intervention. These videos will be recorded presentations that have been modified for HCT recipients based upon similar SHE interventions delivered in prior studies. Similar to the intervention group, patients in the SHE group will also participate in group Zoom chat sessions with equal frequency and duration lead by a study research coordinator. These sessions will allow for general patient interaction to discuss sleep and any questions or comments they may have, as lead by the group facilitator.
11072051|NCT04271917|Active Comparator|Treatment As Usual (TAU)|"Participants will receive a 5-day supply of acetaminophen 500mg and ibuprofen 200mg.
~Instructions for use: Take one tablet of each medication at the same time every 4-6 hours as needed for pain."
11072052|NCT04271917|Placebo Comparator|Placebo|"Participants will receive a 5-day supply (15mL) of inactive placebo in a dropper vial.
~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
11072053|NCT04271917|Experimental|CBD 17mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 17mg/mL.
~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
11072054|NCT04271917|Experimental|CBD 37 mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 37mg/mL.
~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
11072474|NCT04268823|Placebo Comparator|Placebo|Oral use, one capsule twice daily.
11072055|NCT04271904|Experimental|Anti-inflammatory Diet|Those on the anti-inflammatory diet will be given a meal plan and recipes to be followed at home after consultation with the study dietitian. In brief, this meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, refined sugars and wheat, etc.). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, etc.). Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes.
11072056|NCT04271904|Placebo Comparator|Placebo Diet|Participants on the placebo diet will be given a meal plan and recipes by the study dietitian. The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). There are many counter-intuitive restrictions in the anti-inflammatory diet that we will be using (banned foods include white beans, soy, eggplant, oats, raspberries, strawberries, prunes, walnuts, cashews, soy milk. Allowed foods include maple syrup, honey, lean beef, lamb, brown rice, feta cheese, butter). Therefore, even fairly astute and educated participants may have trouble discerning which diet they are consuming (anti-inflammatory or placebo).
11072057|NCT04271904|No Intervention|Non-dieting Control|Those in the non-dieting control condition will not be asked to alter their diet in any way.
11072058|NCT04271891|Experimental|With WBPC|Intensive rehabilitation programs :The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks additional WBPC: The duration will be 30 minutes a time
11072059|NCT04271891|Placebo Comparator|Control|Intensive rehabilitation programs: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks without WBPC.
11072060|NCT04271878|Other|All participants|All participants will receive the same interventions
11072061|NCT04271865|Other|therapy induced anemia for HCV treated patients|"Four types of interventions:
~Educational to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
~Provision of Dates : Dates fruit intake for all the anaemic patients
~Recipe book
~Model kitchen for all patients having Hemoglobin lower than normal hemoglobin levels; less than 13.2 grams (g) of hemoglobin per deciliter (dL) of blood for men and less than 11.6 for women."
11072062|NCT04271852|Experimental|UUI patients|50 UUI patients will have biofeedback treatment once a week.
11072063|NCT04271852|No Intervention|Control|
11072064|NCT04271839|Experimental|Fluticasone/formoterol k-haler (medium strength)|In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength)
11072065|NCT04271839|Active Comparator|Standard of Care (SoC)|In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength)
11072066|NCT04271826|Experimental|cases with normal CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
11072067|NCT04271826|Experimental|cases with proven appendicitis on CT|evaluate level of bilirubin and phospholipase A2 and their relation to positive or negative appendicitis
11072068|NCT04271813|Experimental|Anlotinib and Sintilimab|the combination of Anlotinib with Sintilimab as first-line treatment
11072069|NCT04271800|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
11072070|NCT04271787||strongly dissatisfied|
11072071|NCT04271787||dissatisfied|
11072072|NCT04271787||neutral|
11072073|NCT04271787||satisfied|
11072074|NCT04271787||strongly satisfied|
11072075|NCT04271787||don't know|
11072076|NCT04271774||Infants with ASD-affected sibling|Infants, enrolled at 0-6 months of age, who have a sibling diagnosed with ASD.
11072077|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
11072078|NCT04271748|Experimental|Time Restricted Feeding|Subjects will be required to fast for 16 consecutive hours daily for 4 weeks. The registered dietitian will provide subjects counseling on the intermittent fasting regimen.
11072079|NCT04271735|Experimental|NR arm|Subjects will take two capsules of nicotinamide riboside by mouth (250mg NR) twice daily for a total of 4 weeks.
11072080|NCT04271735|Placebo Comparator|Placebo arm|Subjects will take two capsules of nicotinamide riboside by mouth (placebo) twice daily for a total of 4 weeks
11072081|NCT04271722|Experimental|Mifepristone|Mifepristone 200mg 24hours before the induction day
11072082|NCT04271722|Active Comparator|Balloon catheter|Balloon catheter with 40ml placed 24hours before the induction day
11072083|NCT04271709|Active Comparator|Enhanced Intervention|Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 2-year period.
11072084|NCT04271709|Placebo Comparator|Usual Care|Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
11072501|NCT04268615|Active Comparator|healthy subject group|
11072092|NCT04271631|Experimental|Intervention 1|Received conventional education group and Mobile Application-Based Diabetes Education
11072093|NCT04271631|Experimental|Intervention 2|Received Mobile Application-Based Diabetes Education and Health Coaching
11072094|NCT04271618|Active Comparator|Traditional Treatment Arm|Participants in this group will receive conventional rehabilitation program for postural correction 2 hours/3 sessions' weekly/3 successive months.
11072095|NCT04271618|Experimental|TheraTogs Undergarment Arm|Participants in this group will receive the same conventional rehabilitation program as in traditional group in addition to wearing of TheraTogs soft orthotic undergarment with strapping system.
11072096|NCT04271605|Experimental|behavior intervention and pharmacological therapy|"For participants with abnormal biochemical markers, pharmacological therapy and diet modification are applied.
~Dietary education on phosphorus additives is applied specifically for retention of phosphorus or high serum phosphorus level.
~Exercise for bone and cardiovascular health.
~Osteoporosis medications are initiated according to the reimbursed criteria of National Health Insurance, otherwise medications are used with non-insurance payment."
11072097|NCT04271592|Experimental|Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form|A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
11072098|NCT04271592|Placebo Comparator|Part 1: SAD Cohorts 1-7 Placebo Liquid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
11072099|NCT04271592|Experimental|Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form|Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
11072100|NCT04271592|Placebo Comparator|Part 1: MAD Cohorts 8-10 Placebo Liquid Form|Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts.
11072101|NCT04271592|Experimental|Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
11072102|NCT04271592|Placebo Comparator|Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form|A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
11072103|NCT04271592|Experimental|Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form|A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
11072104|NCT04271592|Placebo Comparator|Part 2: Single Dose Fed Cohort 12 Placebo Solid Form|A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1.
11072105|NCT04271579|Active Comparator|Unilateral lymphnode dissection|Salvage lymphnode dissection is performed on the PSMA PET positive side, according to template (obturator, iliac external, iliac internal, iliac commun) and possibly including other anatomical pelvic regions
11072106|NCT04271579|Active Comparator|bilateral Lymphnode dissection|In addition, a salvage lymphnode dissection is performed on the opposite side with resection of the corresponding fields, which were taken on the PSMA-PET positive side
11072107|NCT04271566|Experimental|Experimental|Patients receiving an education program along with usual medical care
11072108|NCT04271566|No Intervention|Non Experimental|Patients receiving usual medical care
11072109|NCT04271553|No Intervention|Control|Patient will undergo standard workflow for elective surgical admissions.
11072110|NCT04271553|Experimental|Video|In addition to standard workflow, will also receive the intervention bundle which consists of a cartoon video and sets of activity sheets
11072111|NCT04271540|Experimental|Subjects treated with Tildrakizumab|Informed consent will be obtained from study participants willing to participate in MiNIMA. Study participants will then undergo the baseline rest/stress cardiac PET scan along with echocardiography. The final PET scan and echocardiogram will occur at 6 months after the intervention.
11072112|NCT04271527|Experimental|cognitive targeted biopsy|a novel three-dimensional matrix positioning based cognitive fusion targeted biopsy combined with a standard 20-region template guided biopsy
11072113|NCT04271527|Active Comparator|software targeted biopsy|software-based fusion targeted biopsy combined with a standard 20-region template guided biopsy
11072114|NCT04271514|Experimental|COMPLETE -- Single Dose Escalation Part A - active|Increasing doses of RPT193 will be administered to healthy volunteers
11072115|NCT04271514|Placebo Comparator|COMPLETE -- Single Dose Escalation Part A - placebo|Matching placebo will be administered to healthy volunteers
11072116|NCT04271514|Experimental|COMPLETE -- Multiple Dose Escalation Part B - active|Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
11072117|NCT04271514|Placebo Comparator|COMPLETE -- Multiple Dose Escalation Part B - placebo|Matching placebo will be administered once/day for 7 days to healthy volunteers
11072118|NCT04271514|Experimental|RECRUITING -- Expansion Part C - active|RPT193 will be administered daily for 28 days to patients with atopic dermatitis
11072119|NCT04271514|Placebo Comparator|RECRUITING -- Expansion Part C - placebo|Matching placebo will be administered daily for 28 days to patients with atopic dermatitis
11072120|NCT04271501|No Intervention|Control|Area without surgical intervention
11072187|NCT04271007|Active Comparator|Group II|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Aché on the opposite side
11072121|NCT04271501|Active Comparator|Melanocyte-Keratinocyte Transplantation|Autologous skin cell suspension prepared by laboratory based melanocyte-keratinocyte transplantation procedure technique applied to a surgically prepared area of depigmentation
11072122|NCT04271501|Experimental|RECELL 1:5|Regenerative epidermal suspension diluted 1:5 applied to a surgically prepared area of depigmentation
11072123|NCT04271501|Experimental|RECELL 1:10|Regenerative epidermal suspension diluted 1:10 applied to a surgically prepared area of depigmentation
11072124|NCT04271501|Experimental|RECELL 1:20|Regenerative epidermal suspension diluted 1:20 applied to a surgically prepared area of depigmentation
11072125|NCT04271488|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 35 milligram (mg) tablet of E7090 in the morning with 150 milliliters (mL) of water following an overnight fast of at least 10 hours.
11072126|NCT04271488|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive 10 mg dose of E7090 as capsule (2 capsules each of 5 mg) in the morning with 150 mL of water following an overnight fast of at least 10 hours.
11072127|NCT04271488|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, race, gender and body weight) will receive a single 35 mg tablet of E7090 in the morning with 150 mL of water following an overnight fast of at least 10 hours.
11072128|NCT04271475|Experimental|Macitentan|Participant will receive macitentan at a dose of 10 mg once daily (OD) for 4 weeks, followed by a dose of macitentan 37.5 mg for another 4 weeks and continue with the target dose of macitentan 75 mg. Participants who have reached the target dose of macitentan 75 mg and completed the double blind (DB) period as per protocol (up to Week 52; either on treatment or in post treatment observation period [PTOP]) are eligible for transitioning into the open-label (OL) extension period and will receive macitentan 75 mg.
11072129|NCT04271475|Experimental|Placebo|Participants will receive placebo tablets matching the macitentan 10 mg, macitentan 37.5mg and macitentan 75 mg tablets, respectively. Participants who completed the DB period as per protocol (up to Week 52; either on treatment or in PTOP) are eligible for transitioning to the OL extension period and will receive macitentan 75 mg after an 8-week double-dummy uptitration (macitentan 10 mg for 4 weeks, followed by 37.5mg for another 4 weeks).
11072130|NCT04271462||Study group|Patients undergoing surgery (>120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).
11072131|NCT04271449|Experimental|Cerebellum tDCS|Cerebellum tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
11072132|NCT04271449|Experimental|Primary motor cortex|Primary motor cortex tDCS arm will be subdivided into two other arms according to the polarity of the stimulation (inhibitory vs excitatory stimulation). These two subgroups will be divided into two other subgroups according the the task exposed during prism exposure (pointing vs throwing).
11072133|NCT04271449|Sham Comparator|Sham tDCS|Sham tDCS arm will serve as a sham comparator for other experimental conditions. This arm will be subdivided into two groups depending on the localisation of the electrodes (cerebellum placement vs primary motor cortex placement).These two subgroups will be divided again in two subgroups depending on the task exposed (pointing vs throwing).
11072134|NCT04271436|Experimental|PET/CT + PET/MR|-Eligible patients will have imaging assessments (as part of the study) performed at three time-points: pre-treatment, following cycle 1 of treatment, and following cycle 2 of treatment. Baseline FDG PET/CT will be a standard-of-care procedure. If possible, PET/CT imaging will be performed, followed immediately by PET/MR imaging during each imaging session. At minimum, PET/MR should be obtained at least once during each time-point (i.e. either during the FDG or FLT procedure). FDG imaging and FLT imaging should be performed at least 24 hours apart and no more than 7 days apart.
11072135|NCT04271423|Active Comparator|Control|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
11072136|NCT04271423|Experimental|Test|The test will be a flapless technique, no flap will be reflected.
11072137|NCT04271410|Experimental|CD19 CAR-T cells treat|Patients will be be treated with CD19 CAR-T cells
11072138|NCT04271397|Other|Active tuberculosis|
11072139|NCT04271397|Other|Latent tuberculosis infection|
11072140|NCT04271384|Experimental|SABR + Nivolumab|"Pre-operative treatment with standard SABR (3 x 18 Gy or 5 x 10 Gy or 8 x 7.5 Gy) concomitant with nivolumab at 360 mg every 21 days x3 doses.
~Standard-of-care surgery to be performed after 12 weeks from D1 of treatment."
11072141|NCT04271371||Prototype intervention|To be developed through Phase 1 and 2
11072142|NCT04271358|Experimental|Peer Coaching|Participant receive a 6 month peer health coaching intervention.
11072143|NCT04271358|No Intervention|Education only|Participants receive education-only material (newsletter) biweekly for 6 months
11072144|NCT04271332|Experimental|Arbaclofen|Arbaclofen will be dosed flexibly, with maximum permissible dose depending on age.
11072145|NCT04271332|Placebo Comparator|Placebo|The placebo tablet is manufactured to match arbaclofen in shape, size, color, and taste, and will be administered in the same manner as arbaclofen.
11072146|NCT04271319|Experimental|BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.
11072147|NCT04271319|Sham Comparator|Electrical Stimulation - Sham Comparator|Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.
11072148|NCT04271306|Experimental|Groups 1A & 1B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
11072149|NCT04271306|Experimental|Groups 2A & 2B|Volunteers aged 18-45 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
11072150|NCT04271306|Experimental|Groups 3A & 3B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 2
11072151|NCT04271306|Experimental|Group 3C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
11072152|NCT04271306|Experimental|Groups 4A & 4B|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0, 1 and 6.5
11072153|NCT04271306|Experimental|Group 4C|Volunteers aged 5-12 years will receive doses of Pfs25-IMX313 (50µg)/Matrix-M (50µg) intramuscularly at months 0 and 1 and a dose of Pfs25-IMX313 (10µg)/Matrix-M (50µg) intramuscularly at month 6.5
11072154|NCT04271293||Patients with PEG and oral anticoagulan treatment|Patients with PEG and indication for treatment with long-term oral anticoagulant therapy due to non valvular atrial fibrillation (FNAV), according to the current guidelines.
11072155|NCT04271280||High Risk and Very High Risk Dyslipidemic Participants|Participants are stratified as High and Very High Risk (as assessed by the Framingham risk score for High Risk participants and the SMART score for Very High Risk participants and ) as well as if previously or newly diagnosed.
11072156|NCT04271267||Acute Rejection Cohort|The subset of samples corresponding to biopsy-proven acute rejection
11072157|NCT04271267||Rejection-free Cohort|The subset of samples corresponding to a transbronchial biopsy free of acute cellular rejection.
11072158|NCT04271254|Experimental|PET/MR|Each patient will undergo one combined PET/MR scan prior to surgery. The PET/MR scans are for research purposes and not part of the patient's standard of care.
11072159|NCT04271241|No Intervention|Control (Ctrl)|Ctrl group di not undergo any training
11072160|NCT04271241|Experimental|PS bilateral limbs (PSBil)|PSBil underwent 12 weeks of passive stretching on both the lower limbs
11072161|NCT04271241|Experimental|PS monolateral limb, stretched limb (PSMonoSL)|PSMonoSL underwent 12 weeks of passive stretching on just one lower limb (SL). Outcomes form this group were obtained from the stretched
11072162|NCT04271241|Experimental|PS monolateral limb, contralateral limb PSMonoCL|PSMonoCL involved the same participants as in PSMonoSL. Outcomes form this group were obtained from the contralateral not stretched limb (CL). Data from this limb helped in identify possible PS-induced crossover effects in the vasomotor response.
11072163|NCT04271228|Experimental|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
11072164|NCT04271215||Overweight/Obesity|BMI at diagnosis will be used. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
11072165|NCT04271202|Other|Treatment|Effects of galacenezumab (emgality) treatment (injectable 240 mg initial dose followed by 120 mg treatments 1 and 2 month later) on brain functioning.
11072166|NCT04271189|Experimental|POLYCHEM|Metformin (extended release), Pioglitazone, Sitagliptin and Empaglifozin.
11072167|NCT04271189|Active Comparator|STANDARD CARE|Standard of care according to the local health service.
11072168|NCT04271150|Experimental|Self-etch|Self-etch mode of the universal adhesive will be used
11072169|NCT04271150|Active Comparator|Total-etch|Total etch mode of the universal adhesive will be used
11072170|NCT04271137|Other|Orbital fractues|Orbital fractures
11072171|NCT04271124|Active Comparator|PR|
11072172|NCT04271124|Experimental|PR+ET|
11072173|NCT04271111|Experimental|Active treatment|Computerized intervention aimed at reducing perceived hostility.
11072174|NCT04271111|Active Comparator|Control condition|Computerized intervention aimed at increasing overall physical health.
11072175|NCT04271098||Open-heart surgery|Patients undergoing open-heart surgery with cardiopulmonary bypass
11072176|NCT04271085||Patients in the last phase of life|Patients in the last phase of life and their families
11072177|NCT04271072||Study|"Parturients that underwent cesarean delivery and is POSITIVE for the composite outcome of either:
~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), and/or
~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
11072178|NCT04271072||Control|"Parturients that underwent cesarean delivery and is NEGATIVE for the composite outcome of both:
~perinatal depression (Edinburgh postnatal depression scale >=10 during pregnancy or within 3 months after delivery), AND
~persistent pain (pain score >=3 at pelvic or lower abdominal areas at 3 months after delivery)"
11072179|NCT04271059||TBI without polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) within the last 12 hours, without additional polytrauma.
11072180|NCT04271059||TBI with polytrauma|Subjects who have experienced a severe traumatic brain injury (Glasgow Coma Scale (GCS) 3-13) and polytrauma, including major trauma to the chest, abdomen, pelvis or extremities. within the last 12 hours.
11072181|NCT04271059||Healthy Control|Subjects who have not experienced any TBIs within the last six months.
11072182|NCT04271046|Experimental|Experimental Group- STAR-C-VTF|"This study will use a parallel, two-arm randomized trial design. Participants will be 100 Person-with-Dementia-Caregiver dyads in which the person with dementia lives at home and recently filled a new prescription for antipsychotic medication. The experimental intervention will combine three elements:
~self-directed learning in which the caregiver will receive training materials delivered electronically through a web-based learning portal;
~one in-home visit with a coach;
~ongoing support from the coach via telephone and secure messaging in the web-portal.
~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
11072183|NCT04271046|Active Comparator|Control|"Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages.
~Participants will complete self-report assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment. Automated medication and primary care utilization data will be collected throughout the 6 month study period."
11072184|NCT04271033|Experimental|Carotid Artery Stenting|Consecutive male and female patients older than 18 year with symptomatic and increased-stroke-risk asymptomatic carotid lesions that require revascularization by Neurovascular Team decision.
11072185|NCT04271020|Experimental|UroLift|
11072186|NCT04271007|Active Comparator|Group I|Use of the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi, Medley on the opposite side
11072189|NCT04270981|Experimental|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250|single administration of 960 mg (4 × 240 mg capsules) acoziborole in oral and fasted condition
11072190|NCT04270968|Experimental|ESWT Group|received ESWT once a week for 4 weeks (0.25 ml/mm2, 1000 shocks) plus topical none steroidal anti-inflammatory drug (NSAID; 3 times /day for 4 weeks).
11072191|NCT04270968|Experimental|control group|received only topical NSAID.
11072192|NCT04270955|Active Comparator|Symptomatic, standard of care|Patients in this group will be offered all procedures and care deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
11072193|NCT04270955|Experimental|Symptomatic, MMA embolization + standard of care|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Symptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
11072194|NCT04270955|Active Comparator|Asymptomatic, standard of care|Patients in this group will be offered all procedures deemed appropriate by the Neurosurgeon in charge of their care. This could include surgical intervention, observation, medical management.
11072195|NCT04270955|Experimental|Asymptomatic, standard of care + MMA embolization|"Patients in this group will be treated with the standard of care treatment (the same care described in the arm Asymptomatic, standard of care) but will also undergo MMA embolization of the affected side(s)."
11072196|NCT04270942|Experimental|Teplizumab treated|Administration of teplizumab by intravenous infusion
11072197|NCT04270929|Experimental|Oxaliplatin PEDD-PRVI|Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
11072198|NCT04270903||Phototype I - II|EPR measurement at the surface of the skin (arm)
11072199|NCT04270903||Phototype III - IV|EPR measurement at the surface of the skin (arm)
11072200|NCT04270903||Phototype V - VI|EPR measurement at the surface of the skin (arm)
11072201|NCT04270890|Experimental|Study participants|Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
11072202|NCT04270877|Experimental|Naltrexone|"Low Dose Naltrexone (LDN) is administered for 12 weeks, including a titration phase of 4 weeks.
~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.
~The medicine is taken orally as tablets once daily in the evening."
11072203|NCT04270877|Placebo Comparator|Placebo|"LDN-placebo is administered for 12 weeks, including a titration phase of 4 weeks.
~Participants will be titrated up to 6 mg following a dose escalation scheme: Initial dosage of 1.5 mg daily, escalated every seventh day by 1.5 mg up to 6 mg at week 4. Dose escalation will be based on safety and tolerability, and if dose escalation is not feasible, delayed increments are allowed. After end of titration (week 4) the subjects will be maintained at the highest tolerated dose level for the last 8 weeks of the treatment period. Subjects are not allowed to change dose during the last 8 weeks of the treatment period.
~The medicine is taken orally as tablets (similar in size, shape and taste to the active medication), once daily in the evening."
11072204|NCT04270864|Experimental|Patients with Advanced Cancers|
11072205|NCT04270851||Borderline Resectability|Patients with colorectal liver metastases where the decision-making on technical resectability is difficult, i.e. 'borderline resectable,' where a group of liver surgeons might reasonably be expected to find the decision whether to operate to be challenging. A group of up to 20 such patients will undergo pre-operative LiMAx test and HepaT1ca pre-operative scanning. Recruited participants' data will be used to create anonymised online case scenarios to be used in a survey, assessing whether liver surgeons find these pre-operative assessments helpful in their decision-making on technical resectability.
11072206|NCT04270838|Experimental|Group 1|Volunteers aged 18-45 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
11072207|NCT04270838|Experimental|Group 2a|Volunteers aged 1-6 years. Volunteers will receive a standalone dose of 1×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
11072208|NCT04270838|Experimental|Group 2b|Volunteers aged 1-6 years. Volunteers will receive a standalone dose of 5×10^10 vp ChAdOx2 RabG on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
11072209|NCT04270838|Experimental|Group 2c|Volunteers aged 1-6 years. Volunteers will receive Rabies IRV on D0 followed by two doses of Rabies IRV (stimulated PEP), one on D365 and one on D372.
11072210|NCT04270825|Experimental|CBT with IPT|Group CBT with IPT will consist of 20 weekly two-hour sessions and has been developed for the proposed study based on the protocols for group CBT for HD and group IPT. Treatment includes strategies from CBT, including cognitive restructuring, behavioral exposures, and organizational strategies, as well as strategies from IPT, including role-play, interpersonal skills building, communication analysis, and decision analysis.
11072211|NCT04270812|Experimental|Sleep Treatment|This arm consists of the sleep treatment that will be administered to all participants in the single-arm open trial.
11072212|NCT04270799||Lung Nodules|"A cohort of 1000 patients with incidental lung nodules will be identified using clinical records at participating NHS sites.
~Link-anonymised CT scan images and data will be stored using a central database for radiomics and artificial intelligence research, to predict the risk of malignancy."
11072213|NCT04270786|Experimental|Early de-escalation|In the experiment arm, empirical antibiotics will be stopped and levofloxacin prophylaxis will be resumed in case of afebrile after 72 hours.
11072214|NCT04270786|Other|Standard|In the control group, empirical antibiotics will be continue until recovery of neutropenia or at least 7 days as standard clinical practice.
11072221|NCT04270747|Experimental|ABP 938-Treatment Group A|Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.
11072222|NCT04270747|Active Comparator|Aflibercept-Treatment Group B|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8).
11072223|NCT04270747|Active Comparator|Aflibercept-Treatment Group B1|Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48
11072224|NCT04270747|Experimental|ABP 938-Treatment group B2|Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
11072225|NCT04270734|Active Comparator|normal 25-36 gestational week preterm infant|
11072226|NCT04270734|Experimental|25-36 gestational week preterm infant with IVH|25-36 gestational week preterm infant with Intraventricular haemorrhages (IVH)
11072227|NCT04270721|Experimental|After intervention (sequence 1)|'After intervention' group receives the training immediately and data are only collected after the intervention.
11072228|NCT04270721|Experimental|Before and after intervention (sequence 2)|For the 'Before and after intervention' group, data are collected both before and after the training.
11072229|NCT04270721|No Intervention|Before intervention (sequence 3)|"The 'before intervention' group collects data only before the training.
~*This arm will receive the educational intervention after data collection is completed."
11072230|NCT04270708|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 3mcg/kg
11072231|NCT04270708|Active Comparator|Triclofos|Oral Triclofos Sodium 50mg/kg
11072232|NCT04270695||blood flow restriction|An inflatable cuff (14 cm in width * 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver both condition of BFR and BFR-free twice a week, for six weeks.
11072233|NCT04270682|Experimental|Adult Cohort|Patients in the adult cohort will participate in a randomized, double-blind, placebo-controlled, 2 period × 2-treatment crossover study with rescue medication and open-label run-in to assess the efficacy and safety of CDCA.
11072234|NCT04270682|Experimental|Pediatric Cohort|Pediatric cohort patients (≥1 month and <16 years) will participate in a 24-week, open-label cohort with an 8-week titration period and a 16-week treatment period at the tolerated dose.
11072235|NCT04270669|Experimental|RC28-E 0.5mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 0.5mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
11072236|NCT04270669|Experimental|RC28-E 1.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
11072237|NCT04270669|Experimental|RC28-E 2.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
11072238|NCT04270656|Experimental|Insulin pump therapy|
11072239|NCT04270656|Active Comparator|Multi-injection treatment ( MDI ).|
11072240|NCT04270643|Experimental|Vitamin D|Two oral doses of 5 mg (200,000 international units) vitamin D3 in 1 ml ethyl oleate, given at baseline and two weeks thereafter
11072241|NCT04270643|Placebo Comparator|Placebo|Two oral doses of 1 ml ethyl oleate
11072242|NCT04270630|No Intervention|Standard of care|Patients in the control arm of the study will undergo standard of care treatment, discussing catheterization with their treating physicians.
11072243|NCT04270630|Experimental|Shared decision aid|Patients in the interventional arm of the study will discuss catheterization with their treating physicians, in addition to having access to the shared decision aid tool and a shared decision conversation with a co-investigator clinician.
11072244|NCT04270617|No Intervention|Control arm|The control arm will involve usual care - 6 weeks of physical therapy, NSAIDs, and epidural steroid injections
11072245|NCT04270617|Experimental|Yoga Arm|The study arm will involve a yoga protocol devised by Eddie Stern - a renowned Ashtanga yoga practitioner, and can include NSAIDs.
11072246|NCT04270591|Other|SCC244 200mg|Phase Ib: SCC244 300mg, QD Phase II: SCC244 300mg, QD
11072247|NCT04270578||Women with GDM|
11072248|NCT04270578||Women without GDM|
11072249|NCT04270565|Experimental|Intervention Group|The intervention group will receive real-time gait-training interventions along with a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and wear a Garmin watch to get information from the sensors to the watch for feedback. They will also do home exercises during the study, and to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises and get instructions on feedback for the next week.
11072250|NCT04270565|Active Comparator|Control Group|The control group will receive only a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and do home exercises during the study. Participants will be asked to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises.
11072251|NCT04270552|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
11072252|NCT04270552|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
11072253|NCT04270539|Experimental|Experimental Group (nap)|The experimental group will be allowed to take a brief nap daily on school days during the study period.
11072254|NCT04270539|No Intervention|Control Group (no nap)|The control group will not be allowed to take daily nap on school days during the study period.
11072255|NCT04270526|Active Comparator|Active treatment|50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
11072257|NCT04270513||EVT by Flying Intervention Team in primary stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, for whom a Flying Intervention Team is flown to the primary stroke center in order to perform endovascular treatment.
11072258|NCT04270513||EVT after secondary transfer to comprehensive stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, who are transferred to a comprehensive stroke center for endovascular treatment.
11072259|NCT04270500|Active Comparator|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
11072260|NCT04270500|No Intervention|Standard of care (SOC)|Common to both groups as part of the enhanced recovery after surgery (ERAS) protocol as the standard of care in our institution.
11072261|NCT04270487|Experimental|IBS diet|The simple IBS diet is a diet based on the Low FODMAPs diet and the NICE (National Institute of Health and Care Excellence) IBS diet. Patients will be aid to follow the diet with a mobile app.
11072262|NCT04270487|Active Comparator|Otilonium bromide|Otilonium bromide is a a frequently used musculotropic spasmolytic. The dosis used will be 40 mg t.i.d.
11072263|NCT04270474|Experimental|Active Intervention (ACT)|Pharmacist-based Deprescribing
11072264|NCT04270474|Sham Comparator|Usual Care (UC)|Usual Care
11072265|NCT04270461|Experimental|Arms|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
11072266|NCT04270448|Active Comparator|Control|Practice of a joystick based motor sequence task. Participants receive feedback that they have completed the practice trials in that block of practice.
11072267|NCT04270448|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
11072268|NCT04270448|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
11072269|NCT04270422|Experimental|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial, twice a week, 12 sessions
11072270|NCT04270422|Active Comparator|Usual physiotherapy|Usual evidence based physiotherapy, twice a week, 12 sessions
11072271|NCT04270409|Experimental|Isatuximab, lenalidomide, and dexamethasone (ILd)|Isatuximab intravenous (IV) administration on Days 1, 8, 15, and 22 during Cycle 1 (28 days per cycle), and Days 1 and 15 during Cycles 2-12, and Day 1 during subsequent cycles; lenalidomide per os (PO) administration on Days 1 to 21; and dexamethasone IV administration only on Day 1 during Cycle 1 and PO on Days 8, 15 and 22 of Cycle 1 and Days 1, 8, 15, and 22 of subsequent cycles
11072272|NCT04270409|Active Comparator|Lenalidomide and dexamethasone (Ld)|Lenalidomide PO administration on Days 1 to 21 and dexamethasone PO administration on Days 1, 8, 15, and 22 of every 28-day cycle
11072273|NCT04270383||2019-nCoV infection group|Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019-nCoV infection group.
11072274|NCT04270383||Control group|Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019-nCoV infection group are classified as the control group.
11072275|NCT04270370|Experimental|LY3478045 (Part A)|LY3478045 administered orally.
11072276|NCT04270370|Placebo Comparator|Placebo (Part A)|Placebo administered orally
11072277|NCT04270370|Experimental|LY3478045 (Part B)|LY3478045 administered orally.
11072278|NCT04270370|Placebo Comparator|Placebo (Part B)|Placebo administered orally
11072279|NCT04270370|Experimental|LY3478045 + Atorvastatin (Part B)|LY3478045 co-administered with atorvastatin orally.
11072280|NCT04270370|Placebo Comparator|Placebo + Atorvastatin|Placebo co-administered with atorvastatin orally.
11072281|NCT04270331|No Intervention|A Before group|No protocol assigned
11072282|NCT04270331|Experimental|An After group|PADS (pain, agitation, delirium, sleep deprivation assessment and management) protocol assigned
11072283|NCT04270318|Active Comparator|CH pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the CH pulpotomy.Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
11072284|NCT04270318|Experimental|CH pulpotomy-NaOCl|After hemorrhage control,pulp chamber was cleansed with 5% NaOCl for 30 s prior the CH pulpotomy. Then, canal orifices were sealed with CH (Kalsin, Aktu, Izmir, Turkey) paste (CH powder mixed with physiologic saline). After the canal orifice dressing, the chamber was based with reinforced ZOE (IRM; Dentsply Caulk, Milford, DE) and the tooth immediately restored with a stainless steel crown (SSC; 3M ESPE, Seefeld, Germany).
11072285|NCT04270318|Active Comparator|MTA pulpotomy-control|After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
11072286|NCT04270318|Experimental|MTA pulpotomy-NaOCl|"After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. MTA NaOCl (n = 31 teeth): Pulp chamber was cleansed with 5% NaOCl for 30 s prior the MTA pulpotomy.
~Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs."
11072287|NCT04270305|Experimental|orientation|Orientation training with GRAIL
11072288|NCT04270305|Active Comparator|walking|Walking training with GRAIL
11072318|NCT04270032||benign group|women with benign lesions confirmed by pathology or stable in follow-up > 2 years
11072319|NCT04270032||normal group|women have normal images with follow up > 2 years
11072289|NCT04270279|Experimental|Xueshuanxinmaining Tablet|"Patients were given Xueshuanxinmaining tablet orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
11072290|NCT04270279|Placebo Comparator|Placebo|"Patients were given Xueshuanxinmaining tablet simulation orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
11072291|NCT04270266|Experimental|Group I (meditation)|Patients attend meditation group sessions over 75 minutes once weekly for up to 5 weeks.
11072292|NCT04270266|Active Comparator|Group II (educational)|Patients attend educational group sessions over 75 minutes once weekly for up to 5 weeks.
11072293|NCT04270253|Experimental|End-range mobilization|End-range mobilization applied 6 times for 2*2 min in end-range of flexion and extension end-range of the tibiofemoral and patellofemoral joint beside the same conservative therapy, as used for the Control
11072294|NCT04270253|Active Comparator|Control|Conservative therapy including aquatic exercises (5-times), land-based exercises (3-times), balneotherapy (5-times) and TENS therapy (3-times)
11072295|NCT04270214|Other|Dysport|Single arm study, all participants will receive Dysport injections
11072296|NCT04270201||Case group|OSCC patients (n = 60)
11072297|NCT04270201||Control group|Healthy volunteers (n = 240)
11072298|NCT04270188||anterior sacrospinofixation with autologous tissue|patients with middle and / or anterior prolapse ≥ II in the POP-Q classification and for whom an intervention by anterior sacrospinofixation by autologous tissues is planned.
11072299|NCT04270175|Experimental|daratumumab/pomalidomide/dexamethasone|"Pomalidomide:
~(4mg orally) on days 1-21 of a 28-day cycle
~Dexamethasone:
~20mg IV as premedication on days 1, 8, 15, and 22
~20mg orally the day after daratumumab dosing for cycles 1-2 of induction
~40mg IV as premedication on days 1 and 15 on daratumumab treatment days
~40mg orally on non-daratumumab days (8 and 15) for cycles 3-6
~20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)
~If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.
~Daratumumab:
~1800mg sub-cutaneously weekly x8 weeks
~1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)
~1800mg sub-cutaneously every 4 weeks cycles 7 and beyond"
11072300|NCT04270162|Experimental|New intervention protocol with inspirometer|Respiratory exercises without use of inspirometerwill be taken out 50% and 80% to have it as muscle strength training values for the respiratory muscles based on the contra-relax technique)
11072301|NCT04270162|Active Comparator|Protocol of use of inspirometer in a conventional way|This gonna be a experimental group 2 with conventional use of the conventional way.
11072302|NCT04270162|Active Comparator|Respiratory exercises without use of inspirometer|This group gonna be a control group with breathing exercises without the use of inspirometer.
11072303|NCT04270149|Experimental|ESR1 peptide vaccine|200 mcg ESR1 peptides plus 1ml Montanide and 100 mcg GM-CSF administered subcutaneously weeks 0, 1, 2, 4, 5, 6 for a total of 6 injections.
11072304|NCT04270136|Experimental|breast cancer mastectomy|
11072305|NCT04270123||Group 1|Group 1 consists of breast cancer patients with local or locally advanced disease. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. A subgroup of participants within this group (those who have changed disease or treatment status) will be asked to complete the above questionnaires again, three months later (+-1 week). They will also complete an anchor question. Completing twice is for the responsiveness to change analysis.
11072306|NCT04270123||Group 2|Group 2 consists of metastatic breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires at one time point only.
11072307|NCT04270123||Group 3 - follow up|Group 3 consists of follow up breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. One-to two weeks later, a subgroup of participants in this group (with no evidence of disease and /or change in health status) will complete the above questionnaires, as well as an anchor question. Completing twice is for the test-retest analysis.
11072308|NCT04270110||Case|Patients with subclinical hypothyroidism
11072309|NCT04270110||Control|Patients with Normal thyroid function
11072310|NCT04270097||Emirati Genetic T2D cohort|
11072311|NCT04270084|Other|Treatment|Participants will be asked use a mobile health (m-health) app for 2 months. The app is designed to provide weekly education and motivation about healthful diet and physical activity behaviors in adolescents and their parent/adult caretaker. Both adolescent and parent/adult caretaker participants will use the app to enter weekly self-report data, set healthy eating and exercise goals, and receive educational and motivational content. Participants will conduct a weekly self-assessment of waist circumference, diet, and physical activity during the 2 month trial.
11072312|NCT04270071|Experimental|Yangxin Shengmai Granules|"Patients were given Yangxin Shengmai granules orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
11072313|NCT04270071|Placebo Comparator|Placebo|"Patients were given Yangxin Shengmai granules simulation orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.
~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
11072314|NCT04270058||Cohort 1|Cohort 1 will be pregnant patients who have been exposed to at least 1 dose of TEGSEDI within 25 weeks prior to conception or during pregnancy.
11072315|NCT04270058||Cohort 2|Cohort 2 will be pregnant patients who have hATTR-PN, who were not exposed to TEGSEDI or have not received TEGSEDI within the previous 25 weeks prior to conception.
11072316|NCT04270045||Single|Non-invasive forced airway oscillometry
11072317|NCT04270032||malignant group|women with malignant lesions confirmed by pathology
11072540|NCT04268381||Gingivitis (n=20)|
11072320|NCT04270019|Experimental|Experimental|This group will receive polyethylene glycol (50% weight/volume) applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
11072321|NCT04270019|Placebo Comparator|Control|This group will receive normal saline applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
11072322|NCT04270006|Experimental|Exosomes|
11072323|NCT04269993|Placebo Comparator|Vaporized cannabis: placebo|Vaporized cannabis: placebo dose
11072324|NCT04269993|Experimental|Vaporized cannabis: medium THC/medium CBD|Vaporized cannabis: medium THC/medium CBD dose
11072325|NCT04269980|Active Comparator|Group (PHN)|Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure
11072326|NCT04269980|Active Comparator|Group MG|Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
11072327|NCT04269967||Tele-rehabilitation|Patients who choose tele-rehabilitation
11072328|NCT04269967||Usual care|Patients who choose usual (rehabilitation) care
11072329|NCT04269954|Experimental|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin.
11072330|NCT04269954|Other|Low-molecular-weight heparin therapy|Low-molecular-weight heparin combined with routine drug therapy.
11072331|NCT04269941||prognostic factors of gastrointestinal stromal tumors|for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.
11072332|NCT04269928|Experimental|Adrenal Artery Ablation|Patients in the intervention group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
11072333|NCT04269928|No Intervention|Adrenalectomy|Patients in this group will be treated with unilateral laparoscopic adrenalectomy
11072334|NCT04269915|Experimental|Intervention|Volunteers will be exposed to escalating doses of female Schistosoma mansoni cercariae
11072335|NCT04269902|Active Comparator|Arm I (delayed V-O)|Treatment begins once 2018 IWCLL indications are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
11072336|NCT04269902|Experimental|Arm II (early V-O)|Treatment begins as soon as eligibility criteria are met. Patients receive obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 22-28 of cycle 1 and on days 1-28 of cycles 2-12. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
11072337|NCT04269889|Experimental|Treatment arm|Diamond-Blackfan anemia patients
11072338|NCT04269876|Experimental|Marine Lipid Oil concentrate|Dietary Supplement: Marine Lipid oil concentrate softgel and dietary supplement capsules
11072339|NCT04269876|Placebo Comparator|Placebo|Placebo softgels with Placebo capsules
11072340|NCT04269863|Experimental|Control Group|This group of 75 patients is the control group that will be receiving the standard lowest dosage of 81mg aspirin.
11072341|NCT04269863|Experimental|Treatment Group|This group of 75 participants is the treatment group that will be receiving personalized aspirin dosage between 81mg-325mg (within standard clinical recommendations), which will be determined based on platelet analysis via PFA-200.
11072342|NCT04269850|Experimental|FMT+ruxolitinib+steroids|ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid
11072343|NCT04269837|Experimental|Supportive Care (sexual health counseling)|Patients receive sexual health counseling prior to starting and at the completion of radiation.
11072344|NCT04269824|Experimental|Intervention Group|Residents of the peri-urban ward randomized to this group will receive the norm and network-centric intervention package that includes individual, household, group and community-level interventions. No hardware will be provided. Behavior change components will focus on shifting empirical expectations of improved sanitation behaviors in their wards as well as building capacity to achieve toilet construction and behavioral goals.
11072345|NCT04269824|No Intervention|Control Group|Residents of these wards will not receive any intervention. They may be exposed to other WASH interventions promoted by the government and/or other parties independent of this study.
11072346|NCT04269811|Experimental|Flu-Bu-Mel|Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2
11072347|NCT04269798|Active Comparator|Traditional Treatment Arm|Will receive conventional rehabilitation program for the lower limbs, balance and gait training. Two hours of conventional physical therapy program /session - 3 sessions/week/ three successive months.
11072348|NCT04269798|Experimental|Functional Electrical Stimulation Group|Will receive 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
11072349|NCT04269785|Active Comparator|Radiofrequency ablation|These patients will receive ablation by radiofrequency catheter, guided by of 3-dimensional electro-anatomic mapping technology
11072350|NCT04269785|Active Comparator|Cryoballoon ablation|These patients will receive ablation by cryoballoon catheter, guided by X-ray fluoroscopy
11072351|NCT04269772|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.
~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
11072541|NCT04268381||Periodontitis (n=40)|
11102485|NCT04058977|No Intervention|Standard of Care|Standard of care
11072352|NCT04269772|Other|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided by prison and community providers, as part of routine care in the criminal justice re-entry context. Study staff will provide no additional treatment in this arm.
11072353|NCT04269759||Pregnancy women|
11072354|NCT04269746||Control group|The control population comprised normal healthy individuals.
11072355|NCT04269746||Precancerous group|patients with precancerous colorectal diseases
11072356|NCT04269746||CRC group|patients with colorectal cancer
11072357|NCT04269733||Subjects with a DDD-pacemaker due to high-degree AV block|
11072358|NCT04269720|No Intervention|Control|Participants will not receive biofeedback intervention.
11072359|NCT04269720|Experimental|Biofeedback|Participants will receive a biofeedback intervention daily for 8 weeks. Each biofeedback session lasts approximately 10 minutes.
11072360|NCT04269707|Other|IV Iron|The primary objective in this study is to allow participants who were randomized to receive oral iron in the 1VIT17044 trial and who had an unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in IBD treatment) to receive one course of FCM. This course of FCM will consist of two doses of FCM at 15 mg/kg (maximum single dose of 750 mg), separated by seven days.
11072361|NCT04269694|No Intervention|Control|No dressing applied in the donor site after harvesting the graft
11072362|NCT04269694|Experimental|Test|An antibacterial honey dressing material (Medihoney, http://www.medihoney.com) will be applied to donor site.
11072363|NCT04269681|Experimental|High Flow Nasal Cannula Arm|Participants will receive HFNC if they have no delirium and signs of ARF. The device is supposed to be used continuously in the nose with some changes in flow and/or temperature according to tolerance. There is no crossover to the standar of care arm.
11072364|NCT04269681|Active Comparator|Standard respiratory support|Participants will receive standard of care with low flow oxygen catheter or mask initially. If there is any sign of clinical deterioration NIV can be offered if tolerated by the patient. There will be no cross over with HFNC arm.
11072365|NCT04269668|Active Comparator|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
11072366|NCT04269668|Experimental|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
11072367|NCT04269655|Experimental|Intervention CB CGM|On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
11072368|NCT04269655|No Intervention|Usual Care|For UC, CGM data will be blinded to the care team and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours for patients who are not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring: UC (and intervention) participants' glucose levels will be managed using the glucose management protocol and the Diabetes APN will assess UC participants' POC data documented in the EMR from the previous 24-48 hours and make recommendations for changes to the basal/bolus regimen to improve glucose management.
11072369|NCT04269642|Placebo Comparator|PT320 2.0mg Placebo|will be injected subcutaneously once a week for 48 weeks
11072370|NCT04269642|Experimental|PT320 2.0mg treatment 1|will be injected subcutaneously once a week for 48 weeks
11072371|NCT04269642|Experimental|PT320 2.5mg treatment2|will be injected subcutaneously every two weeks for 48 weeks. (Actually, patients will be injected PT320 2.5 mg and placebo alternately once a week.)
11072372|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
11072373|NCT04269616|Experimental|Numerical survival, followed by disability information|Participants in this arm were presented with a pictograph displaying numerical survival information, followed by a pictograph displaying disability information.
11072374|NCT04269616|Experimental|Survival with description, followed by disability information|Participants in this arm were presented with a pictograph displaying survival information including the average course of stay in the NICU, followed by a pictograph displaying disability information.
11072375|NCT04269616|Experimental|Disability information, followed by numerical survival|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying numerical survival.
11072376|NCT04269616|Experimental|Disability information, followed by survival with description|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying survival information including the average course of stay in the NICU.
11072377|NCT04269603|Other|30 healthy adult volunteers|Healthy adult volunteers without hemorrhagic diathesis.
11072378|NCT04269590|Experimental|Dual Task (DT) training - PD|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of patients with Parkinson's disease (PD)
11072379|NCT04269590|Active Comparator|Single Task (ST) training - PD|Practice of the Swipe Slide Pattern task alone for a group of patients with Parkinson's disease (PD)
11072380|NCT04269590|Experimental|Dual Task (DT) training - HC|Combination of practicing the Swipe Slide Pattern task and a secondary task for a group of healthy age-matched controls.
11072381|NCT04269590|Active Comparator|Single Task (ST) training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls
11072382|NCT04269577|Experimental|SSP training - early PD|Practice of the Swipe Slide Pattern task alone for a group of patients with early Parkinson's disease (PD)
11072383|NCT04269577|Experimental|SSP training - mid PD|Practice of the Swipe Slide Pattern task alone for a group of patients with mid-stage Parkinson's disease (PD)
11072384|NCT04269577|Experimental|SSP training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls (HC)
11072385|NCT04269564|No Intervention|group A|Group A patients received the standard ventilation protocol as follows: volume-controlled ventilation mode, with VT 6 ml/kg of ideal body weight, inspiratory : expiratory ratio 1 : 2, a PEEP of 4 cmH2O, and respiratory rate 10-12 breaths/min that will be adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mmHg and inspired oxygen fraction of 0.5.
11072386|NCT04269564|Active Comparator|group B|Patients in group B received the standard ventilation protocol with stepwise peep until end of surgery and extubation.
11072387|NCT04269551|Experimental|BIVV020 IV|Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.
11072388|NCT04269538|Experimental|SAD Cohorts 1-2 Experimental Arm|Experimental Arm Active drug 150 mg and 450 mg SC dosing
11072389|NCT04269538|Placebo Comparator|SAD Cohorts 1-2 Placebo Arm|Placebo Arm
11072390|NCT04269525|Experimental|pneumonia|According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 * 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored.
11072391|NCT04269512|Active Comparator|extended lymph node dissection|Patients randomized to arm A undergo bilateral lymph node dissection in the pelvic area as part of prostatectomy. At least 10 lymph nodes must be removed.
11072392|NCT04269512|No Intervention|standard without lymph node dissection|Application of standardized surgical technique without extensive lymph node dissection. If, contrary to expectation, intraoperative suspicion of lymphogenic metastasis results, a lymph node dissection is performed and the patient is excluded from the study (freedom of the surgeon).
11072393|NCT04269499|Other|Study patients|All patients receive holmium radioembolization as per usual
11072394|NCT04269486||Inpatient participant|Inpatients who signed the informed consent form that she will be observed during the hospitalization period
11072395|NCT04269473|Experimental|Experimental Group|Participants in the experimental group will receive a telehealth gait retraining intervention in addition to standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
11072396|NCT04269473|Active Comparator|Control Group|Participants in the control group will receive standard physical therapy rehabilitation for running-related knee pain, which includes: an at-home exercise program, a return to running protocol, and standard physical therapy evaluations.
11072397|NCT04269460|Active Comparator|subcostal transversus abdominis plane block (sTAP)|patients will be in the supine position; after preparing the skin with with povidone iodine, a high frequency (5-10 MHz) ultrasound probe will be used tp identify the rectus abdominis muscle, then 1 mL/Kg of bupivacaine 0.25% will be injected in the plane between rectus abdominis and transversus abdominis muscles.The patient will then be positioned for the procedure if other than supine position is chosen.
11072398|NCT04269460|Active Comparator|quadratus lumborum block (QLB)|patients will be positioned in the lateral decubitus position so that the blocked side will be the uppermost one. After skin sterilization with povidone iodine the ultrasound probe will be positioned to identify the quadratus lumborum muscle. then 1 mL/Kg of bupivacaine 0.25% will be injected behind the QL muscle on the lateral border of the erector spinae muscle.The patient will then be positioned for the procedure if other than lateral decubitus position is chosen.
11072399|NCT04269434|No Intervention|Screening|In the screening arm, Ng/Ct results will be sent by the STI Laboratory to the study physicians and these participants will be treated and partner contact tracing will be done.
11072400|NCT04269434|Other|No screening|In the no screening arm, the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
11072401|NCT04269408|Experimental|NicaPlant®|"10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.
~In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines."
11072402|NCT04269408|Other|Control|Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
11072403|NCT04269395|Active Comparator|MAL Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit of the active cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
11072404|NCT04269395|Placebo Comparator|Vehicle Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit in the vehicle cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
11072405|NCT04269382|Other|Combined non-invasive and invasive BP measurements|Patients will all undergo measurement of BP through 3 different techniques over a 30-min period: continuous noninvasive BP measurement (with the finger cuff and Clearsight™ device), repeated intermittent oscillometric NIBP measurements with a cuff placed around a calf or an arm, and continuous invasive BP measurement (through an indwelling arterial catheter).
11072406|NCT04269369|Experimental|Group A|Dosage according to French guidelines
11072407|NCT04269369|Experimental|Group B|Dosage according to literature
11072408|NCT04269356|Experimental|BMS-986256|
11072409|NCT04269330|Sham Comparator|1-Normal size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
11072410|NCT04269330|Active Comparator|2- small size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
11072446|NCT04269031|Experimental|Cohort 2|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
11072596|NCT04268043|Experimental|proseal laryngeal mask airway|
11072411|NCT04269317|Experimental|Tixel C|Tixel Treatment, between 3-5 treatment session according to investigator's review of subject response follow by 3 Follow up sessions, 1,3 and 6 month after last treatment visit. Subject would be questioned about pain levvel, subjective dountime assessment and subjective response assessment. Images would be taken before treatment visit and in Follow-Up.
11072412|NCT04269304||Observational|Intermediate Age-Related Macular Degeneration Patients
11072413|NCT04269278||0 ng/ml|Blood specimen which was added 0 ul of dexmedetomidine
11072414|NCT04269278||0.5 ng/ml|Blood specimen which was added 0.25 ul of dexmedetomidine
11072415|NCT04269278||1.0 ng/ml|Blood specimen which was added 0.5 ul of dexmedetomidine
11072416|NCT04269278||1.5 ng/ml|Blood specimen which was added 0.75 ul of dexmedetomidine
11072417|NCT04269265|Experimental|All Participants|In this single-arm study, all participants will receive the intervention
11072418|NCT04269252|Placebo Comparator|CHI-804 at 6 mL|Standard 6 mL dose of placebo oil.
11072419|NCT04269252|Active Comparator|CHI-907 at 1.5 mL|Subjects are assigned to receive one dose of CHI-907.
11072420|NCT04269252|Active Comparator|CHI-907 at 3 mL|Subjects are assigned to receive one dose of CHI-907.
11072421|NCT04269252|Active Comparator|CHI-907 at 6 mL|Subjects are assigned to receive one dose of CHI-907.
11072422|NCT04269239|Other|Healthy Habits|This group will meet with a study therapist to discuss strategies to implement healthy habits that may enhance recovery from knee or hip surgery.
11072423|NCT04269239|Other|Sleep Habits|This group will meet with a study therapist to discuss strategies to implement healthy sleep habits that may enhance recovery from knee or hip surgery.
11072424|NCT04269226|Experimental|Recruitment maneuver|Recruitment maneuver
11072425|NCT04269226|Active Comparator|No recruitment maneuver|No recruitment maneuver
11072426|NCT04269213|Experimental|Treatment (CPX-351)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Patients who do not achieve remission receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Beginning 5-8 weeks after the start of the last induction, patients who achieve CR receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 45 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
11072427|NCT04269200|Active Comparator|Arm A (control)|Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
11072428|NCT04269200|Experimental|Arm B (durvalumab+placebo)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
11072429|NCT04269200|Experimental|Arm C (durvalumab+olaparib)|Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
11072430|NCT04269187|Experimental|With theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU and before administration of theophylline; 200 mg/d orally for 12 days then reassessment of diaphragm by ultrasound.
11072431|NCT04269187|No Intervention|No theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU then reassessment of diaphragm by ultrasound before discharge
11072432|NCT04269161|Experimental|Automatic Oxygen Control|In this arm, an automatic oxygen control device will be used to make adjustments to the blend of oxygen and air supplied to the subject.
11072433|NCT04269161|No Intervention|Manual Oxygen Control|In this arm, a nurse will manually make adjustments to the blend of oxygen and air supplied to the subject as in the standard of care.
11072434|NCT04269148||Head and Neck Cancer patients|Turkish patients diagnosed with head and neck cancer
11072435|NCT04269122||Part 1|30 eligible subjects will be asked to participate in 3 inpatient visits, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
11072436|NCT04269122||Part 2|90 eligible subjects will be asked to participate in 1 inpatient visit, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
11072437|NCT04269109||Control Cohort|A control cohort from September 1, 2018 - October 31, 2018
11072438|NCT04269109||Intervention Cohort|An intervention cohort from March 1, 2019 - April 30, 2019
11072439|NCT04269083|Experimental|experimental arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
11072440|NCT04269083|Active Comparator|control arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
11072441|NCT04269070|Active Comparator|Move, Stand|Usual behavior condition, followed by the standing condition, followed by the LPA condition.
11072442|NCT04269070|Active Comparator|Stand, Move|Usual behavior condition, followed by the LPA condition, followed by the standing condition.
11072443|NCT04269057||HFpEF|heart failure patients with preserved ejection fraction who using ARNI
11072444|NCT04269057||HFrEF|heart failure patients with reduced ejection fraction who using ARNI
11072445|NCT04269031|Experimental|Cohort 1|On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
11072473|NCT04268823|Experimental|QBW251|Oral use, one capsule twice daily.
11072447|NCT04269031|Experimental|Cohort 3|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
11072448|NCT04269031|Experimental|Cohort 4|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
11072449|NCT04269031|Experimental|Cohort 5|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
11072450|NCT04269031|Experimental|Cohort 6|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).
11072451|NCT04269018|Experimental|Cancer specific Mobile text message|This arm will receive daily mobile text message related with cancer risks and prevention
11072452|NCT04269018|Active Comparator|general health messages|This arm will receive general health message once a week
11072453|NCT04269005|No Intervention|Treatment as usual|"phase 0: Treatment as usual in combination with baseline and follow-up Survey but without any screening procedures (facilitating the study as a run-in phase to establish study procedures).
~phase 1: randomized and main control condition with TAU + collection of information on psychosocial distress in the baseline
~Intervention effects will be estimated, using the distressed focus sample, contrasting Phase 2 vs. Phase 1.
~We intend to conduct additional statistical analyses to compare data from phases 2 and 1 vs. phase 0 to estimate potential effects of introducing parts of the screening 1 without consequences."
11072454|NCT04269005|Experimental|Intervention condition|"phase 2: implementation of the SCCM
~The intervention (SSCM) will be implemented step-wise in predefined sections at all three sites using a stepped-wedge cluster randomized trial design. Clusters will be randomized to different sequences that dictate the timing at which each cluster will switch from the control to the intervention condition."
11072455|NCT04268992|Experimental|Long-term exercise|Supervised exercise training three times a week for three months.
11072456|NCT04268992|No Intervention|Usual care|Patients are not offered supervised exercise.
11072457|NCT04268979|Experimental|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
11072458|NCT04268979|No Intervention|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
11072459|NCT04268966|Experimental|CMX001|Initial dose of 200mg followed by 4 doses of 100mg
11072460|NCT04268953|Experimental|AC-SD-03|Study drug administered concurrently with a standard meal
11072461|NCT04268927|Experimental|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .
~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
11072462|NCT04268927|Active Comparator|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
11072463|NCT04268914|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for IV placement and induction of anesthesia. Current standard of care practices at CHLA for outpatient surgery induction will include the following steps. Children may receive midazolam, parental presence during induction and any other intervention or medication chosen by the HCP. The research team will have no input to the decision regarding the use of any therapy.
11072464|NCT04268914|Experimental|VR Randomization|When a child is assigned to the VR condition s/he will have the added component of VR distraction during pre-surgical preparation. Children in the VR condition will interact with an immersive 3D virtual environment presented via a HMD (head-mounted display), a helmet with computer screens for each eye. This study will use two HMDs at two possible time points: (1) Prior to and during IV placement, participants will play using the Oculus Go; (2) Prior to and during anesthesia induction, participants will play using the Mira Prism.
11072465|NCT04268901|No Intervention|Standard of Care (No VR) Randomization|In the standard of care treatment condition, participants will receive the standard CHLA treatment protocol for the medical procedure.
11072466|NCT04268901|Experimental|VR Randomization|Children in the VR condition will undergo the invasive procedure while distracted by interaction with an immersive virtual environment (VE) presented via a head mounted display (HMD). The intervention group will receive standard CHLA treatment with VR distraction.
11072467|NCT04268888|Active Comparator|TACE/TAE Alone|Transarterial Chemoembolisation (TACE) and/or Transarterial Embolisation (TAE) Alone.
11072468|NCT04268888|Experimental|TACE/TAE and Nivolumab|As above for TACE/TAE. Nivolumab adminstered as a flat dose of 480mg IV.
11072469|NCT04268875|Experimental|OCT|"Patient witch coronary artery disease who has been stented and is hospitalised for stable angina or acute coronary syndrome requiring a further coronary angiogram (regardless of time since implantation or type of the initial stent.
~- Identification of intrastent restenosis during coronary angiography and realisation of an immediate or deferred OCT."
11072470|NCT04268849|Active Comparator|Oral Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
11072471|NCT04268849|Active Comparator|IV Iron|The subject will receive one IV infusion of ferumoxytol administered as 1020 mg over 30 minutes or an equivalent volume of normal saline. At the time of the infusion, the patient will also be given an opaque bottle, containing either vitamin C tablets or ferrous sulfate 325 mg.
11072472|NCT04268836|Experimental|Treatment arm|Patients will be treated by the Optimal Acuity Clear-K Low Vision Aid System.
11072475|NCT04268810|Experimental|Chondroitin sulphate 2%|chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
11072476|NCT04268810|Active Comparator|DMSO 50%|DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks
11072477|NCT04268797|Experimental|HR rTMS H7-coil intervention group|
11072478|NCT04268797|Sham Comparator|sham control group|
11072479|NCT04268784|Experimental|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
11072480|NCT04268784|Placebo Comparator|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
11072481|NCT04268771|Experimental|Arm A: DRL_RI|Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with Rituximab, will be enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infusions on Day 1 and Day 15
11072482|NCT04268771|Active Comparator|Arm B: US-Rituximab or EU-Rituximab|"Subjects who have already received at least 1 full course comprising two 1000 mg infusions of either US-rituximab or EU-rituximab and are candidates for re-treatment with rituximab, will be enrolled.
~Patients enrolled in Arm -B will continue to receive US-rituximab or EU-rituximab. The rituximab reference product used (US-licensed rituximab [Rituxan] or EU-approved rituximab [MabThera]) should be the same in the prior and the randomized treatment course, respectively."
11072483|NCT04268745|Experimental|Virtual Reality|Progressive immersive training with the virtual reality app Scenes: start from most salient to the patient, eventually do all Duration: start at 60 seconds, increase over time up to 3 minutes per scene Complexity: start minimal, gradually increase up to most complex Tasks: standing with diverse base of support (BOS), head turns (progress with speed, planes); stepping, turning 8 weeks, 1 visit per week, 30 minutes long In home: Gait and balance exercises, No exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long
11072484|NCT04268745|Active Comparator|Traditional Vestibular Rehabilitation|"Progressive gait, gaze stability and balance exercises Gait: walking with head turns, progress with range, speed and planes of head movement; change of walking BOS: wide, normal, tandem Gaze: focus on a target while moving head side to side / up down. Progress with speed, duration, busier background, standing to walking.
~Balance: standing balance tasks, progress with BOS (wide to narrow to tandem), support surface, eyes closed, duration, head turns.
~8 weeks, 1 visit per week, 30 minutes long In home: Gait, gaze stability and balance exercises, including exercises with eyes closed, 8 weeks, 6 times per week, twice per day, 10 minutes long"
11072485|NCT04268719||Gastro-Esophageal Reflux Disease|Patients defined as having GERD as per Lyon Consensus
11072486|NCT04268719||Non-acid Reflux|Patient excluded for GERD as per Lyon Consensus
11072487|NCT04268706|Experimental|CD30 positive r/r classical Hodgkin Lymphoma|"Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.
~Patients will be treated with autologous CD30.CAR-T cells."
11072488|NCT04268693||Study cohort|urinary bisphenol and phthalate levels
11072489|NCT04268667|Experimental|Upper cervical spine manipulation group|Spinal thrust joint manipulation on the atlantoaxial joint
11072490|NCT04268667|Active Comparator|Cervicothoracic spine manipulations group|Different spinal thrust joint manipulations on the thoracic spine (T6), mid-cervical spine (C3-C4) and cervicothoracic junction (C7-T1).
11072491|NCT04268654|Experimental|Ischemic Conditioning|"Preoperative artery embolization prior to esophagectomy
~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
11072492|NCT04268654|No Intervention|Control|"Surgery without previous ischemic conditioning of the gastric conduit
~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
11072493|NCT04268641|Experimental|Use of positioning equipment order 1|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
11072494|NCT04268641|Experimental|Use of positioning equipment order 2|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
11072495|NCT04268641|Experimental|Use of positioning equipment order 3|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
11072496|NCT04268641|Experimental|Use of positioning equipment order 4|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
11072497|NCT04268641|Experimental|Use of positioning equipment order 5|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
11072498|NCT04268641|Experimental|Use of positioning equipment order 6|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
11072499|NCT04268628||Participants with mCRPC|Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen [PSA] response).
11072500|NCT04268615|Experimental|Patients|Patients suffering from chronic bilateral vestibular hypofunction
11072502|NCT04268602|Experimental|Intervention Group|intradermal 1% lidocain injection 4 cc+ exercise and transcutaneous electrical nerve stimulation
11072503|NCT04268602|No Intervention|Control Group|exercise and transcutaneous electrical nerve stimulation
11072504|NCT04268589|No Intervention|control group|routine study
11072505|NCT04268589|Experimental|virtual reality group|Three days a week, 2 times a day, 15 minutes in the morning and in the evening for 9 days in total
11072506|NCT04268563|Placebo Comparator|Placebo|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
11072507|NCT04268563|Experimental|Metformin|Intervention group 1: received Metformin (Glucophage, Merck, West Drayton, UK; 500 mg ,two times daily
11072508|NCT04268563|Experimental|Sitagliptin|Intervention group2: received Sitagliptin (Januvia, Merck,West Drayton, UK. 50 mg, two times daily
11072509|NCT04268563|Experimental|sitagliptin/metformin|Intervention group3: received Sitagliptin/metformin (Janumet, Merck,West Drayton, UK. 50/500 mg), two times daily
11072510|NCT04268550|Experimental|Treatment (selpercatinib)|Patients receive selpercatinib orally PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11072511|NCT04268537|Experimental|PD-1 group|Anti-PD-1 antibody, 200mg, IV, one time
11072512|NCT04268537|Experimental|thymosin group|Thymosin, 1.6 mg sc qd, last for 5 days
11072513|NCT04268537|Placebo Comparator|control group|stand treatment
11072514|NCT04268524|Experimental|monotherapy miltefosine|Miltefosine capsules (Impavido®) 2.5 mg/kg daily PO for 28 days <30 kg BW allometric miltefosine dose based on fat-free mass. (approx. 2.5 mg/kg); >30 - ≤44kg BW: 100 mg/day BID; ≥45kg BW 150mg TDS
11072515|NCT04268524|Experimental|Thermotherapy|Thermotherapy (ThermoMed 1.8 ®) 50°C for 30 seconds, 1 session
11072516|NCT04268524|Experimental|Combination miltefosine and thermotherapy|Miltefosine capsules 2.5 mg/kg daily PO for 21days, and thermotherapy 50°C for 30 seconds, one session on day 1 of the miltefosine.
11072517|NCT04268524|Active Comparator|° Meglumine antimoniate (Glucantime®) intralesional|Meglumine antimoniate (Glucantime®) intralesional injections 0.5-3ml, 8 sessions, bi-weekly
11072518|NCT04268511||Caudal epidural block group|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
11072519|NCT04268511||Pudendal nerve block group|The long axis of the ultrasound probe was positioned on a horizontal line connecting the ischial tuberosity that had been previously located by palpation to the anus. The ischial tuberosity could be easily identified as a hypoechoic area that is bounded superiorly by a hyperechoic line. The probe was then moved medially on the same axis until the rectum appeared as another hypoechoic area.
11072520|NCT04268498|Experimental|Arm A (VRD)|"Newly diagnosed patients with histologically confirmed multiple myeloma (MM).
~bortezomib, lenalidomide, dexamethasone (VRD)"
11072521|NCT04268498|Experimental|Arm B (KRD)|"Newly diagnosed patients with histologically confirmed multiple myeloma (MM).
~carfilzomib, lenalidomide, and dexamethasone (KRD)"
11072522|NCT04268498|Experimental|Arm C (KRD + DARA)|"Newly diagnosed patients with histologically confirmed multiple myeloma
~daratumumab, carfilzomib, lenalidomide, and dexamethasone (KRD+DARA)"
11072523|NCT04268485||IPF patients|Patients with an MDT diagnosis of idiopathic pulmonary fibrosis. Patients will be observed over a 12 month period and have serial serum samples taken for KL-6 level.
11072524|NCT04268472|Experimental|TR Sequence|In first Intervention period subjects was administered test medecine (GP30101) and in seconde Intervention period subjects was administered reference medecine (Prezista)
11072525|NCT04268472|Experimental|RT Sequence|In first Intervention period subjects was administered reference medecine (Prezista) and in seconde Intervention period subjects was administered test medecine (GP30101)
11072526|NCT04268459|Active Comparator|Regular exchange|Patients will be appointed each 3 months for regular exchange of voice prosthesis.
11072527|NCT04268459|Active Comparator|Leakage exchange|Patients will have voice prosthesis exchange when leakage occurs.
11072528|NCT04268420|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP013 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
11072529|NCT04268420|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,2 month."
11072530|NCT04268420|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 4,5,6 month."
11072531|NCT04268420|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
11072532|NCT04268420|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP013 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.
~Vaccination to be delivered on 0,1,6 month."
11072533|NCT04268420|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
11072534|NCT04268407|Experimental|2-day prophylactic antibiotics|use prophylactic antibiotic for 2 days after transoral thyroidectomy
11072535|NCT04268407|Other|7-day prophylactic antibiotic|use prophylactic antibiotic for 7 days after transoral thyroidectomy
11072536|NCT04268394|Experimental|Part 1: CC-99677 with Methotrexate and Sulfasalazine|Fixed-sequence involving CC-99677 + Methotrexate 7.5 mg and sulfasalazine 1000 mg
11072537|NCT04268394|Experimental|Part 2: CC-99677 with Itraconazole and Rifampin|Fixed-sequence involving CC-99677 + Rifampin 600 mg and Itraconazole 200 mg
11072538|NCT04268394|Experimental|Part 3: CC-99677, Midazolam, Digoxin, Metformin, Rosuvastatin|Fixed-sequence involving CC-99677 + Midazolam 2 mg, Digoxin 0.25 mg, Metformin 500 mg, and Rosuvastatin 10 mg.
11072539|NCT04268381||Healthy (n=23)|
11072542|NCT04268355|Experimental|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers
11072543|NCT04268342|No Intervention|Standard care|When clinical services are in the standard case phase of the study, all cases of gonorrhoea infection diagnosed at those services will be managed according to current standard of care management guidelines i.e. all cases of gonorrhoea infection will be treated with ceftriaxone by injection plus oral azithromycin tablets as first line therapy, regardless of whether the treatment is given at the initial clinic or the return clinic visit.
11072544|NCT04268342|Active Comparator|Implementation|When clinical services are assigned to the implementation phase, first line treatment for gonorrhoea infection for patients treated at their first clinic visit will remain the same as it is currently: ceftriaxone by injection plus oral azithromycin tablets. However, patients who are not treated presumptively will be treated at their return visit on the basis of the drug resistance test results. Patients with gonorrhoea infection that is shown to be susceptible to ciprofloxacin will be treated with oral ciprofloxacin therapy when they return for review at clinical services in the implementation phase. Patients with gonorrhoea infection that is not susceptible to ciprofloxacin or with an indeterminate ciprofloxacin result will be treated with ceftriaxone by injection.
11072545|NCT04268329|Other|Educational website: Patient|Patients with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. Patients will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. Patients will be asked to review the material on the website between their initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. Patients will be asked to record the number of times they visit the website and the time spent during each visit. Patients will be given a log sheet to document their use/time on the website. During the 2nd clinic visit patients will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, the patient's participation in the study will be completed.
11072546|NCT04268329|Other|Educational website: Family member|A family member of a patient with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. They will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. They will be asked to review the material on the website between their relatives initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. The family member will be asked to record the number of times they visit the website and the time spent during each visit. They will be given a log sheet to document their use/time on the website. During the 2nd clinic visit the family member will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, their participation in the study will be completed.
11072547|NCT04268316|Experimental|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for four weeks. In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
11072548|NCT04268316|Active Comparator|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for four weeks. In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
11072549|NCT04268316|No Intervention|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
11072550|NCT04268303|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms dexmedetomidine
11072551|NCT04268303|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms dexmedetomidine
11072552|NCT04268303|Placebo Comparator|Placebo|Sublingual placebo film
11072553|NCT04268290|Experimental|SILS plus one assistant ERAS|"Preoperative:
~preadmission information, education, counseling, optimization ( breathing training), shortening fasting time and carbohydrate load
~Intraoperative:
~The intravenous fluid therapy is restricted. All patients undergo single incision plus one port laparoscopic surgery(SILS plus one).
~A suitable warming device (such as forced-air heating blankets) and warmed intravenous fluids are been adopted routinely to keep body temperature
~Postoperative:
~multimodal analgesia (surgical site infiltration, a nonsteroidal anti-inflammatory drug, epidural analgesia) early oral intake and move. nasogastric tubes should not be used routinely. Nasogastric tubes inserted during surgery are been removed before reversal of an aesthesia."
11072554|NCT04268277|Experimental|Rituximab & Pembrolizumab|"Cycle 1 (21 days cycle):
~Rituximab: 375 mg/m2 day 1, 8, 15 Pembrolizumab: 200 mg IV fixed dose day 2
~Cycle 2-18 (21 days cycle) or until progression or non-tolerable toxicity:
~Rituximab: 375 mg/m2 day 1 every second cycle Pembrolizumab: 200 mg IV fixed dose day 1"
11072555|NCT04268264|Experimental|Treatment arm|Will receive trial intervention, Incremental haemodialysis (n=40)
11072556|NCT04268264|Other|Control arm|Historical controls. Matched controls from database of historical patients receiving conventional, three times weekly haemodialysis treatment (n=40)
11072557|NCT04268251|Experimental|Deep learning based denoising MR|1 mm slice thickness coronal contrast-enhanced T1 weighted imaging with deep learning based denoising vs. 3 mm slice thickness coronal contrast-enhanced T1 weighted imaging
11072558|NCT04268238|Experimental|Control group|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate). Afterwards, this group will receive no treatment. Instead of the sealant, water will be used and the laser will remain with power 0W, that is, there will be no light emission, giving the group the characteristic of the control group, no treatment.
11072597|NCT04268030||GBA mutation carriers with PD undergoing STN-DBS|
11072559|NCT04268238|Experimental|Sealant group|In this group, besides the instructions described in the control group, the teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal (sealant) for 5 seconds to the tooth surface and light curing for 20 seconds.
11072560|NCT04268238|Experimental|Low Level Laser Group|In this group, besides the instructions described in the control group, volunteers will receive irradiation with AsGaAl laser, wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, energy density of 35 J/cm2 (considering a spot size of 0.028 cm2 of this equipment), the dose will be 1 J per point. The irradiation will be performed at a cervical, an apical point and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
11072561|NCT04268238|Experimental|Low Level Laser + Sealant Group|In this group, patients will receive the treatments described in Control group, Sealant group and Low Level Laser Group.
11072562|NCT04268225|Experimental|Ultrasound Guided Dynamic Needle Tip Positioning Technique|In this arm the US transducer, protected with a sterile cover and sterile gel will be placed in the short axis above the distal end of the selected vein, moving the probe to place the vein in the center of the ultrasound screen under the middle mark of the image. The catheter needle will be inserted close to the transducer. The needle tip will be visualized as a white dot on the ultrasound screen. Then, the transducer will be shifted slightly proximally until the white dot disappears from the screen. The needle and the transducer will be moved alternately toward the patient several times to visualize the needle tip in real time. After penetrating the anterior wall of the vein, these steps will be repeated a few more times with a smaller insertion angle to visualize the white dot in the vein. Finally, the outer catheter will be fully advanced and the needle core will be extracted.
11072563|NCT04268225|Active Comparator|Traditional insertion group|For traditional insertion technique insertion attempt will be blind or tactile. Otherwise, the same protocol and measurements as elaborated for the US guided group will be applied.
11072564|NCT04268212|Experimental|Bitter Melon|The participants were asked to consume 100 ml of bitter melon juice 15 minutes prior to the 75-g oral glucose intake. Participants drank the juice within 5 minutes. Participants remained seated throughout the following 2 hours.
11072565|NCT04268212|Experimental|Exercise|Participants performed 30 minutes of treadmill walking at 65% of the age-predicted maximum heart rate. The exercise started 15 minutes after the 75-g oral glucose intake.
11072566|NCT04268199|Other|Self Injection of Bortezomib|Subcutaneous self administration of bortezomib
11072567|NCT04268186|Experimental|Direct tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target mid-cingulate cortex directly.
11072568|NCT04268186|Experimental|Indirect tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target the middle frontal gyrus, a brain area connected to mid-cingulate cortex.
11072569|NCT04268186|Experimental|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be individually optimized to simultaneously stimulate key nodes connected to mid-cingulate cortex, including anterior insula, MFG and supramarginal gyrus.
11072570|NCT04268186|Sham Comparator|Sham tDCS|Placebo transcranial direct current stimulation (tDCS) will be applied.
11072571|NCT04268173|Experimental|Immediate Intervention|Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention.
11072572|NCT04268173|Experimental|Delayed Intervention|Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention after being put on a wait-list for three months.
11072573|NCT04268173|No Intervention|Nonintervention|Participants enrolled in this arm will receive services as usual from Vivent Health and will not engage in the intervention.
11072574|NCT04268160||Patients with severe aortic stenosis undergoing TAVR|GPx activity levels will be measured on the day of TAVR procedure, the day of discharge, 1 month, and 6 months after the procedure
11072575|NCT04268160||Patients without aortic stenosis|GPx activity levels will be measured on day of recruitment
11072576|NCT04268147||Spinocerebellar Ataxia-1|individuals with a genetically confirmed diagnosis of SCA-1
11072577|NCT04268147||Spinocerebellar Ataxia-2|individuals with a genetically confirmed diagnosis of SCA-2
11072578|NCT04268147||Spinocerebellar Ataxia-3|individuals with a genetically confirmed diagnosis of SCA-3
11072579|NCT04268147||Spinocerebellar Ataxia-6|individuals with a genetically confirmed diagnosis of SCA-6
11072580|NCT04268147||Freidreich's Ataxia|individuals with a genetically confirmed diagnosis of FA
11072581|NCT04268147||FA Controls|Healthy, age-matched controls
11072582|NCT04268147||SCA Controls|Healthy, age-matched controls
11072583|NCT04268134|Experimental|Omega 3 fatty acid supplement|Omega-3 ethyl esters orally daily (containing 465 mg eicosapentaenoic acid [EPA] and 375 mg docosahexaenoic acid [DHA] per capsule,supplied as 4 x 1gm capsule)
11072584|NCT04268121|Experimental|Phase II|
11072585|NCT04268121|Active Comparator|Prospective cohort|
11072586|NCT04268108||group 1|"arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy.
~arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes"
11072587|NCT04268095|Experimental|No dressing change|Patients do not change dressing from procedure to first clinic followup after 14 days.
11072588|NCT04268095|Experimental|Ambulatory dressing change|Patients change dressing by an ambulatory nurse (not associated with the study) 2 times a week from surgery to first clinic followup after 14 days
11072589|NCT04268095|Experimental|No dressing|Patients take off dressing at post operative day 1 and clean it 3 times per day as instructed.
11072590|NCT04268082|Experimental|Experimental Group|The Experimental Group followed the training wearing sensorized insoles that provided plantar pressures and shift of foot center of pressure images reported on monitors.
11072591|NCT04268082|Active Comparator|Control Group|The Control Group followed verbal instructions of physiotherapist during training.
11072592|NCT04268069|Placebo Comparator|Placebo Ophthalmic Solution (vehicle)|vehicle
11072593|NCT04268069|Active Comparator|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution
11072594|NCT04268056||RT patients|100 patients with breast cancer undergoing radiation therapy
11072595|NCT04268043|Experimental|flexible laryngeal airway|
11072599|NCT04268004|No Intervention|Standard of Care (Control)|Participants will receive a standard of care fertility consult.
11072600|NCT04268004|Experimental|FP Decision Tool and Discussion (Treatment)|Participants will receive a standard of care fertility consult and will participate in a family-centered psychoeducational intervention consisting of completing a FP Decision Tool and participating in a guided discussion about responses and discrepancies identified in the FP Decision Tool.
11072601|NCT04267991||Tacrolimus|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
11072602|NCT04267991||Phototherapeutic Keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
11072603|NCT04267991||Control|patients received only artificial tears eyedrop
11072604|NCT04267978|Experimental|glioblastoma|
11072605|NCT04267978|Experimental|lower-grade glioma|
11072606|NCT04267965||Group A|Patients who have been successfully operated on with total parathyroidectomy for symptomatic secondary hyperparathyroidism and their PTH levels are below 72 pg/dL within one week after surgery.
11072607|NCT04267965||Group B|Patients who have had regular dialysis and their iPTH levels are around 500 pg/dL
11072608|NCT04267952|Experimental|first group|Hand hygiene intervention program prepared by using planned behavior theory will be applied to the students in this group.
11072609|NCT04267952|Active Comparator|second group|Students in this group will be given classic hand hygiene training
11072610|NCT04267939|Experimental|Dose escalation of BAY1895344 and fixed dose of Niraparib|"In participants with all solid tumor(excluding prostate cancer) and positive for DDR deficiency.
~DDR: DNA-Damage Repair"
11072611|NCT04267939|Experimental|Participants PARPi naïve|"Participants with ovarian cancer, PARPi naïve and with a platinum resistant/refractory disease and DDR deficiency.
~DDR: DNA-Damage Repair"
11072612|NCT04267939|Experimental|Participants with disease progression on PARPi|Participants with ovarian cancer and disease progression on PARPi
11072613|NCT04267926|Placebo Comparator|Placebo|Placebo
11072614|NCT04267926|Active Comparator|20mg of MitoQ|20mg of oral mitoquinol
11072615|NCT04267926|Active Comparator|40mg of MitoQ|40mg of Oral Mitoquinol
11072616|NCT04267913|Experimental|Arm A (docetaxel, dexamethasone, sapanisertib)|Patients receive docetaxel IV and dexamethasone IV over 30 minutes on days 1 and 8 and sapanisertib PO QD on days 2-4, 9-11, and 16-18. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel is discontinued, patients receive sapanisertib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11072617|NCT04267913|Active Comparator|Arm B (standard of care treatment)|Patients receive standard of care treatment comprising either docetaxel IV and dexamethasone IV over 30 minutes on day 1 or docetaxel IV, dexamethasone IV over 30 minutes, and ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11072618|NCT04267900|Experimental|99mTc-HPArk2 SPECT/CT|The patients were injected with 11.1 (MBq) per kilogram body weight of 99mTc-HPArk2 in one dose intravenously and underwent SPECT/CT scan 30-60 min later.
11072619|NCT04267887|Experimental|Treatment (apalutamide, abiraterone acetate, prednisone, ADT)|Patients receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of care.
11072620|NCT04267874|Experimental|Arm I (BRB nectar, placebo, biospecimen collection)|Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
11072621|NCT04267874|Experimental|Arm II (placebo, BRB nectar, biospecimen collection)|Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
11072622|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
11072623|NCT04267848|Active Comparator|Arm A (platinum doublet, observation)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONTINUANCE THERAPY: Patients then undergo observation."
11072624|NCT04267848|Experimental|Arm B (platinum doublet, sequential pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles or every 6 weeks for 16 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity."
11072625|NCT04267848|Experimental|Arm C (platinum doublet, combination pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity."
11072626|NCT04267835||MICS (Minimal invasive coronary surgery)|Patients undergoing MIDCAB surgery.
11072627|NCT04267835||OPCABG (thoracotomy off-pump CABG)|Patients undergoing thoracotomy OPCABG surgery
11072628|NCT04267822|Experimental|RV521 Capsules|RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
11072629|NCT04267822|Placebo Comparator|RV521 Placebo Capsules|RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.
11072630|NCT04267809|Experimental|Metformin 850mg once daily|Metformin 850mg tablet will be administered orally once daily for 10 consecutive days.
11072631|NCT04267809|Experimental|Metformin 850mg twice daily|Metformin 850mg tablet will be administered orally twice daily for 10 consecutive days.
11072632|NCT04267809|Experimental|Metformin 1000mg once daily|Metformin 1000mg tablets will be administered orally once daily for 10 consecutive days.
11103407|NCT04052776|Active Comparator|Levodopa-Carbidopa|400mg/100mg
11072633|NCT04267809|Experimental|Metformin 1000mg twice daily|Metformin 1000mg tablets will be administered orally twice daily for 10 consecutive days.
11072634|NCT04267796|Experimental|Group I (lifestyle intervention)|Participants complete lifestyle intervention consisting of 1-3 sets of high-resistance circuit training sessions per week, up to 150 minutes of aerobic training per week, and diet recommendations from a health coach or registered dietitian twice per week for 16 weeks.
11072635|NCT04267796|Active Comparator|Group II (wait-list, lifestyle intervention)|Participants are placed on a wait-list and then complete lifestyle intervention after 4 months.
11072636|NCT04267770|Experimental|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
11072637|NCT04267770|Active Comparator|flat rates|flat basal rate
11072638|NCT04267757|Experimental|group 1|RVF with Martius flap
11072639|NCT04267757|Experimental|group 2|RVF without Martius flap
11072640|NCT04267744|Other|Remote patient monitoring|"After consenting to the study, the Myia in-home suite of devices, and mobile phone application if the patient owns a smart phone, will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.
~Patients enrolled will transmit daily vital sign data to the Myia Health remote patient monitoring platforms for clinical review.
~Enrolled patients will complete medication change/compliance survey monthly to assess for medication changes.
~Enrolled patients will complete symptomatic assessments (KCCQ-12) at 0, 3, and 6 months.
~Enrolled patients will complete a Check-In survey to assess utility and usability of the intervention at the 2, 4, and 6 month timepoints"
11072641|NCT04267731|Placebo Comparator|Placebo|Cellulose 0.75g per day
11072642|NCT04267731|Experimental|Low dose|0.25g VMK223 per day
11072643|NCT04267731|Experimental|Middle dose|0.5g VMK223 per day
11072644|NCT04267731|Experimental|High dose|0.75g VMK223 per day
11072645|NCT04267718|Experimental|Patients with the Padua and IMPROVE Bleeding scores|A number of centres will be randomized to systematically evaluate all eligible patients with the Padua and IMPROVE Bleeding scores within 48 h after hospitalization.
11072646|NCT04267718|No Intervention|Patients will be evaluated according to clinical judgment only|A number of centres will be randomized to the Control arm of the study, in which patients will be evaluated for their thrombotic and hemorrhagic risk according to clinical judgment only.
11072647|NCT04267705|Active Comparator|Black bean|A cup of black bean 7 days/week over a 12-week period
11072648|NCT04267705|Active Comparator|Chickpea|A cup of chickpea 7 days/week over a 12-week period
11072649|NCT04267705|Placebo Comparator|Control|A cup of white rice 7 days/week over a 12-week period
11072650|NCT04267692|Experimental|Harm Reduction Treatment Circles (HaRTC)|Participants will attend 8, weekly Harm Reduction Treatment Circles. We will not limit participants' access to other treatment or services.
11072651|NCT04267692|No Intervention|No-Treatment control|We will not limit participants' access to other treatment or services.
11072652|NCT04267679|Experimental|Cannabidiol|Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.
11072653|NCT04267666|Experimental|Inspiratory Muscle Strength Training|in the form of: Inspiratory threshold muscle trainer in addition to traditional chest physical therapy intervention (Deep breath, cough training)
11072654|NCT04267666|Experimental|Incentive Spirometer|incentive spirometer, three sessions per week for six weeks
11072655|NCT04267653|Active Comparator|lactoferrin|Oral bovine lactoferrin (bfl) 100 mg once daily on empty stomach
11072656|NCT04267653|Active Comparator|ferrous sulfate|Oral ferrous sulfate 3-6 mg/kg of elemental iron/day in divided doses
11072657|NCT04267653|Active Comparator|combined|combined therapy (both lactoferrin and ferrous sulfate)
11072658|NCT04267640|Experimental|AMG0001 4mg|AMG0001 4mg + standard wound care
11072659|NCT04267640|Experimental|AMG0001 8mg|AMG0001 8mg + standard wound care
11072660|NCT04267640|Placebo Comparator|Placebo|Placebo + standard wound care
11072661|NCT04267627|No Intervention|Usual Care|No intervention.
11072662|NCT04267627|Experimental|CARING with telemedicine|Patients will receive the nurse-led supportive care intervention over telemedicine videoconferencing from home or from a satellite telemedicine site in Virginia.
11072663|NCT04267627|Experimental|CARING face-to-face|Patients will receive the nurse-led supportive care intervention in person.
11072664|NCT04267614||Patients with Rheumatoid Arthritis (RA)|Patients receiving etanercept from Baghdad teaching hospital registry(Rheumatology center) from 2012 till 2017. Patients were identified as receiving early versus delayed etanercept treatment.
11072665|NCT04267588||Navio App|The investigators propose to collect self-report and passively collected biological data and evaluate participants' relation to clinical and laboratory pain as well as patients' willingness to use and level of comfort with the mobile pain management digital platform and wearable biosensors. Eligible participants will be consented, given two biosensors (i.e., Apple Watch Series 1 with KardiaBand; Spire), a sleep monitoring device (actigraph watch), and a mobile app enabled smartphone, then trained on how to use the app (and device if appropriate) and biosensors. Participants will keep medications constant and not have any new pain treatment procedures over the course of the study period and 2 weeks prior to starting the study.
11072666|NCT04267575|Experimental|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
11072667|NCT04267562|Other|Single-Arm, Open-Label Treatment with the Minitouch System|Eligible participants will undergo a single treatment (endometrial ablation) with the Minitouch System
11072668|NCT04267549|Experimental|treatment|eligible patients will be given sintilimab (200mg, iv, q3w,)， apatinib (250mg/d， QD)，S1 （50mg PO，b.i.d d1-14 ）and nab-paclitaxel (260mg, iv, 3h, d1,q3w) for 3-6 cycles. If patients converted to surgery, then administer treatment post surgery upto 3cycles. Then give sintilimab and apatinib each 3 weeks for maintenance .
11072669|NCT04267536||Participants treated with upadacitinib monotherapy|Participants will receive upadacitinib for 12 months as prescribed by the physician
11072670|NCT04267536||Participants treated with upadacitinib in combination with MTX|Participants will receive upadacitinib in combination with MTX as prescribed by the physician for 12 months
11103686|NCT04050774|Experimental|Age group 4|65-80 years old
11072671|NCT04267523|Experimental|Web-based parenting intervention|Families randomized to this intervention group will receive a self-administered web-based parenting intervention. Parents have access to a weekly 6-modules parenting intervention.
11072672|NCT04267523|Active Comparator|Face-to-face parenting intervention|Families randomized to this intervention group will receive a face-to-face group parenting intervention. Groups will meet weekly for 120 minutes for 4 weeks.
11072673|NCT04267497|Experimental|Nebulized Amphotericin B|Amphotericin B.
11072674|NCT04267497|Placebo Comparator|Nebulized Placebo|Sterile water for injection.
11072675|NCT04267484||Older adults with mild cognitive impairment|"WP1, older adults with cognitive impairment will use a GPS tracker for 2 weeks, during which they are asked 1) to keep a daily diary about their activity (travel diary), 2) take the researcher on a walk that they often do (walking interview), and 3) participate in an in-depth interview after 2 weeks, in which their experience with the GPS ans the travel diary data are discussed.
~WP2, older adults with mild cognitive impairment, caregivers, health professionals and technology developers will collaborate during group discussion meeting to co-design the e-decision support platform to be adapted.
~WP3, older adults with mild cognitive impairment, caregivers and health professionals will then be asked to use the adapted e-decision support platform and fill a survey."
11072676|NCT04267471|Experimental|Tai Chi|3 sessions of Tai Chi per week for 12 weeks
11072677|NCT04267471|Active Comparator|Walking|3 sessions of walking per week for 12 weeks
11072678|NCT04267471|No Intervention|Waiting-list|
11072679|NCT04267458|Other|HCV infected patients with non-elevated sCr than basal levels|a group of egyption patients with HCV infection with non-elevated sCr than basal levels and treated with sofuspovir as an direct acting antiviral drug
11072680|NCT04267445||Embolization patients|"Single center, open label, pilot study. Eligible patients will undergo transarterial embolization of the prostatic vasculature. Each patient will undergo a single embolization procedure.
~After completion of treatment in the first 2 patients and a review of follow-up assessments after 7 days, subsequent patients will be enrolled if no safety concerns have arisen in the first 2 patients.
~Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
~Magnetic resonance imaging (MRI) and CEUS is used to assess changes in prostate volume and in central gland enhancement characteristics using 3D volume assessment software."
11072681|NCT04267432|Placebo Comparator|Placebo|Placebo
11072682|NCT04267432|Experimental|TCI633|Testing product
11072683|NCT04267432|Active Comparator|Type 2 collagen|Known drug for OA
11072684|NCT04267419||healthy Control|MDA and NO in saliva
11072685|NCT04267419||keratosis|MDA and NO in saliva
11072686|NCT04267419||leukoplakia|MDA and NO in saliva
11072687|NCT04267419||Oral lichen Planus|MDA and NO in saliva
11072688|NCT04267419||oral Squamous cell carcinoma|MDA and NO in saliva
11072689|NCT04267406||Cirrhosis|Patients who diagnosed as cirrhosis. 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
11072690|NCT04267406||Non-cirrhotic portal hypertension|Patients who diagnosed as extrahepatic portal hypertension (due to portal vein thrombosis). 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
11072691|NCT04267406||Control|Healthy volunteers, who admitted to our hospital for any complaints, but was not determined any organic disease. 2 ml EDTA blood sample was taken from healthy volunteers, during their hospital admition. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
11072692|NCT04267393|Experimental|Dose A BMS-986263|
11072693|NCT04267393|Experimental|Dose B BMS-986263|
11072694|NCT04267393|Placebo Comparator|Placebo|
11072695|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
11072696|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
11072697|NCT04267367|Experimental|Intervention|The intervention will include a dietitian-led nutrition education, counseling session and individual basis diet plan emphasis on glycemic control diet targeted to T2DM patients attending during the OPD visits in hospital.
11072698|NCT04267367|No Intervention|Usual care|The usual care arm will be only provided general education.
11072699|NCT04267354|Experimental|Arm cycling|Participants will perform arm cycling using a table-top arm cycler. Cadence and resistance of the exercise will be determined as per each individual's tolerance. All exercise will be supervised by the neuromuscular specialist physio, to ensure it is completed safely. Participants will be able to have plenty of breaks during the assessments.
11072700|NCT04267341||Mild Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 1-2
11072701|NCT04267341||Moderate Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 2.5-3
11072702|NCT04267341||Healthy Control|Healthy People
11072703|NCT04267328||Patients having surgery|Older adults undergoing elective orthopedic surgery.
11072704|NCT04267315|Active Comparator|Active|3 weekly sessions of TPI. Participants will undergo 1mL injections of 1% lidocaine in the muscles identified with either active or latent trigger points at the initial assessment. The same muscles will be injected at all procedures.
11072705|NCT04267315|Sham Comparator|Placebo|3 weekly sessions of subcutaneous saline injections. Participants will undergo 0.2mL subcutaneous saline injections superficial to the trigger points identified at initial assessment. The same superficial sites will be injected in all procedures.
11072706|NCT04267302|Other|Baby Bouncer Group|Participants in the group will be receiving a baby bouncer for use from infant's birth up to 8 months after birth.
11072707|NCT04267302|Other|Baby Bouncer Group with Infant T-Shirt with LENA|A subsample of the participants in the baby bouncer group will also receive infant t-shirts with wearable audio recorders.
11072708|NCT04267302|Other|Baby Carrier Group|Participants in the group will be receiving a baby carrier for use from infant's birth up to 8 months after birth.
11072809|NCT04266535||MCI|Patients receiving Manually Controlled Infusion (MCI) Anesthesia
11072709|NCT04267302|Other|Baby Carrier Group with Infant T-Shirt with LENA|A subsample of the participants in the baby carrier group will also receive infant t-shirts with wearable audio recorders.
11072710|NCT04267289|Experimental|iCBT treatment group|Subjects were given license to use Beating the Blues, a commercially available iCBT program. Subjects were given 3 months to use the program.
11072711|NCT04267276|Experimental|Part 1: BI 1265162 - intravenous|
11072712|NCT04267276|Experimental|Part 2: BI 1265162 - oral|
11072713|NCT04267263|No Intervention|Delayed Treatment Control group|Participants will receive the treatment after completion of the 3-month follow-up assessment
11072714|NCT04267263|Experimental|Lifestyle group|Participants will receive the treatment immediately
11072715|NCT04267250|Experimental|Sequence 1|In sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into period 2 where they will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10.
11072716|NCT04267250|Experimental|Sequence 2|In sequence 2, period 1, participants will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10. After a wash-out period of at least 10 days, participants will continue into period 2 where they will receive an additional single dose of OC.
11072717|NCT04267237|Experimental|Atezolizumab|Participants will receive atezolizumab on Day 1 of each 28-day cycle (Q4W) for 12 cycles.
11072718|NCT04267237|Experimental|Atezolizumab + RO7198457|Participants will receive atezolizumab Q4W along with RO7198457 for 12 cycles.
11072719|NCT04267224||Early group|Patients receiving the loading dose of Ticagrelol 90 mg more than 60 minutes before PCI.
11072720|NCT04267224||Late group|Patients receiving the loading dose of Ticagrelol 90 mg less than 60 minutes before PCI.
11072721|NCT04267211|Experimental|Illustrated Consult|
11072722|NCT04267211|Experimental|Standard Consult|
11072723|NCT04267198|Active Comparator|Massed Intention Treatment (massed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 3 weeks.
11072724|NCT04267198|Active Comparator|Distributed Intention Treatment (distributed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 12 weeks.
11072725|NCT04267185|Experimental|Immediate Intervention|PwMS-CG dyads will receive six group telerehabilitation sessions (~60 min each) every other week for a period of 12 weeks. This will be interspersed with brief one-on-one support telephone calls in the weeks that group sessions do not occur. All participants will be taught techniques for monitoring PA behaviour, setting personalized goals to increase PA and reduce sedentary time, and strategies for overcoming challenges to PA participation. Make-up sessions will be offered to those who miss group sessions. The one-on-one support telephone calls will serve to reinforce the information provided during the group sessions, monitor safety and troubleshoot any issues with intervention content.
11072726|NCT04267185|No Intervention|Delayed Control|The delayed control group will not receive the intervention during the study period. Participants assigned to the control group will be offered the intervention once the study is completed.
11072727|NCT04267172|Experimental|Surgical Residents with additional simulation training|Surgeon participant Group 1a: Interventional group ('StR's'): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving additional simulation training.
11072728|NCT04267172|Active Comparator|Surgical Residents with routine training|Surgeon participant Group 1b: control group (StR's): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving routine and normal training.
11072729|NCT04267172|Active Comparator|Orthopaedic Surgeon 'Experts & Fellows'|Consultant Orthopaedic Surgeons (n=5), and nationally appointed Arthroplasty Fellows (n=8). Surgeon participants within this group will not undergo any interventions.
11072730|NCT04267159|Active Comparator|Conventional treatment by acute cardioversion|Participants in the conventional treatment arm will be returned to sinus rhythm in the emergency department within 48 hours of symptom onset unless they convert to sinus rhythm spontaneously.
11072731|NCT04267159|Experimental|Elective treatment by delayed cardioversion|Participants in the elective treatment arm will be returned to sinus rhythm in an out-patient clinic approximately one week after randomizatio unless they convert to sinus rhythm spontaneously.
11072732|NCT04267146|Experimental|newly diagnosed high-grade glioma|"Phase I : Open label, non-randomized, safety run study in nine patients. In case of safety issue a -1 dose level will be tested.
~Phase II : Open label, non randomized, efficacy study of nivolumab in addition to radiotherapy and temozolomide. This phase will start when the RP2D has been defined after the last patients evaluable for DLT achieved the first 6 weeks of treatment (the radio-chemotherapy period) with a DLT rate below 30% during the the phase I study."
11072733|NCT04267133|Experimental|All Participants|
11072734|NCT04267120|Experimental|Lenvatinib + Pembrolizumab|-Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.
11072735|NCT04267107|Experimental|Managing Fatigue:The Individual Program|"Participants in the experimental group will receive the 6-week MFIP. Individuals in experimental group :
~will participate in six one-to-one sessions (each takes 60 to 90 minutes)
~will complete the Feasibility Questionnaire #1, after each session (10 questions) (Appendix 6)
~will complete Feasibility Questionnaire #2 after completing all six-sessions (12 questions) (Appendix 7)
~will complete the post-test measurement after completion of the program (approximately 60 minutes to complete)
~will complete the follow-up measurement, three months after the completion of the program (approximately 60 minutes to complete)
~will be advised to continue with their current healthcare services.
~may participate in one focus group (one-hour session)"
11072736|NCT04267107|No Intervention|Control Group|"Participants in the control group will not receive the IMFP and they will be advised to continue with their current healthcare services.
~Participants in the control group:
~will complete post-test measurements after 6 weeks (approximately 60 minutes),
~will complete the follow-up measurements three months later after completing the program (approximately 60 minutes).
~will be advised to continue with their current healthcare services.
~Following the study, participants in the control group will be offered the manual of the program and a three-hour training workshop after (three months after the baseline testing). In this workshop, they will learn about the about the program, including the pre-session activities, in-session activities, and homework. This workshop will be conducted by occupational therapists."
11073278|NCT04263285|Experimental|rTMS (Repetitive Transcranial Magnetic Stimulation)|
11072737|NCT04267081|Experimental|Arm 1 (de novo AML)|"This arm will recruit the patients with de novo AML unfit for conventional chemotherapy. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.
~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
11072738|NCT04267081|Experimental|Arm 2 (relapsed, refractory or secondary AML)|"This arm will recruit the patients with relapsed, refractory or secondary AML. In validation cohort all the participants will receive azacytidine-venetoclax. In study cohort the patients with ex vivo resistance to venetoclax will be excluded from the study therapy.
~All patients in validation and study cohorts (ARM1 and ARM2) will receive azacytidine and venetoclax. The purpose for the validation cohort is to validate the specificity and sensitivity of the ex vivo drug testing. Patients exhibiting ex vivo sensitivity and receiving azacytidine-venetoclax in validation cohort are analyzed also for study cohort."
11072739|NCT04267068|Experimental|Intervention|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
11072740|NCT04267068|Active Comparator|Control|Online daily activity scheduling interactive article (control)
11072741|NCT04267042|Active Comparator|Budesonide via Mucosal Atomization Device (MAD)|"Patients in this arm will administer budesonide using a mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) once a day at least 5 times a week for 6 months postoperatively. The MAD atomizes the medication into particles from 30-100 um in size thus increasing the surface area for drug absorption.
~Budesonide is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the MAD syringe."
11072742|NCT04267042|Active Comparator|Budesonide via nasal saline irrigation (INSI)|"Patients in this arm will administer impregnated budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed Pharmaceuticals, Santa Rosa, California) once a day at least 5 times a week for 6 months postoperatively.
~Budesonide is provided in nebules (1mg/2cc).Patients will place two nebules of budesonide into the 240mls of saline."
11072743|NCT04267029||Cases: CRTR (cardiorespiratory transfusion reaction)|Respiratory/cardiovascular disturbances after transfusion (>/=2 of respiratory distress, pulmonary edema, cardiovascular system changes, fluid shifts, cardiac strain indicators), with or without accompanying (or pre-existing) fever
11072744|NCT04267029||Controls: HRFTR (high risk febrile transfusion reactions)|Post-transfusion fevers requiring laboratory investigation (Tmax>/=39C, or lesser deflections if accompanied by chills/rigors), without respiratory features (hypoxia or dyspnea)
11072745|NCT04267016||All Subjects Enrolled|Renal transplant recipients who are undergoing routine management
11072746|NCT04267003|Experimental|DLPFC Stimulation + Task|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during cognitive task completion.
11072747|NCT04267003|Experimental|DLPFC Stimulation + Rest|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during rest.
11072748|NCT04267003|Sham Comparator|Sham Stimulation + Task|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during cognitive task completion.
11072749|NCT04267003|Sham Comparator|Sham Stimulation + Rest|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
11072750|NCT04266990|Experimental|Epilepsy patients|Epilepsy patients admitted for clinical purposes in the EEG monitoring units at the UZ
11072751|NCT04266990|Active Comparator|Healthy volunteers|Healthy volunteers recruited from among colleagues from the department and hospital staff
11072752|NCT04266977|Experimental|Treatment Dexamethasone|"The restrictive DEX regimen is applied from referral to the neurosurgical center until discharge. All administered steroids will be stopped immediately after study inclusion.
~If one or more of the previously defined failure criteria occurs, patients will be treated with DEX."
11072753|NCT04266938|Active Comparator|Prospective RAPID|The prospective RAPID arm will include all patients who meet inclusion criteria and who start BIC/F/TAF within 7 days of HIV diagnos
11072754|NCT04266938|Active Comparator|Prospective Non- RAPID|The prospective non-RAPID arm will include all patients identified as having new HIV diagnosis per health department records, but who failed to establish care at the 550 Clinic and begin BIC/F/TAF within one week of diagnosis
11072755|NCT04266938|Active Comparator|Retrospective Non- RAPID|The retrospective Non-RAPID arm will include historic controls who enrolled in the treatment program from 2012, when universal ART guidelines were implemented, until prior to the implementation of RAPID start of ART.
11072756|NCT04266925|Experimental|3 referees|Three referees were present on the field during these youth soccer matches.
11072757|NCT04266925|Active Comparator|1 referee|One referee was present on the field during these youth soccer matches.
11072758|NCT04266912|Experimental|Treatment (avelumab, M6620)|Patients receive avelumab IV over 60 minutes on days 1 and 15, and M6620 IV over 60 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11072759|NCT04266899|Experimental|FDS+Treadmill gait training|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Treadmill gait training during two weeks.
11072760|NCT04266886|Active Comparator|Arm I (usual care)|Patients receive usual care including receipt of multi-modal analgesia and the injection of a local analgesic at the time of surgery on the ERAS pathway.
11072761|NCT04266886|Experimental|Arm II (usual care, self-hypnosis guided relaxation)|Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.
11072762|NCT04266873|Experimental|AffloVest HFCWO intervention|Use of the AffloVest for 30 mins, twice a day for 6 weeks
11072763|NCT04266860|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
11072764|NCT04266860|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
11072765|NCT04266847|Experimental|unilateral mild cataract patients|The patients who underwent monocular IOL implantation before and then present mild cataract in the fellow eye.
11072766|NCT04266834|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
11072767|NCT04266834|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
11072768|NCT04266821|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
11072769|NCT04266821|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
11072770|NCT04266808|Experimental|An interactive telehealth monitoring and biofeedback system|Participants in this group will receive feedback of pressure relief maneuvers and wheelchair propulsion activity. Feedback for pressure relief will include information during the activity to identify adequate duration and magnitude of pressure relief activity, reminders of when the next pressure relief is due, and daily aggregate information regarding the number of successful pressure relief maneuvers performed.
11072771|NCT04266808|Sham Comparator|Education Control|Participants will receive education on the importance and recommended frequency of pressure relief maneuver for prevention of pressure ulcer/injury and on the importance and recommended amounts of physical activity for health.
11072772|NCT04266795|Experimental|Arm A: Pevonedistat + Venetoclax + Azacitidine|Pevonedistat 20 mg/m^2 as a 60-minute intravenous (IV) infusion on Days 1, 3, and 5 in each 28-day cycle plus venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. If remission is confirmed in Cycle 1 or thereafter, venetoclax 400 mg can be administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m^2 IV or subcutaneous (SC) dosing on Day 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle.
11072773|NCT04266795|Active Comparator|Arm B: Venetoclax + Azacitidine|Venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. If remission is confirmed in Cycle 1 or thereafter, venetoclax 400 mg can be administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m^2 IV or SC dosing on Days 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle.
11072774|NCT04266782|Experimental|Physical exercise program and Long-walking|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.
~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
11072775|NCT04266782|No Intervention|Usual care|The subjects will be followed according to current standard.
11072776|NCT04266782|Active Comparator|Control group-intervention|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.
~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
11072777|NCT04266769|Experimental|Patients with Malocclusion|
11072778|NCT04266756|Experimental|Cohort 1: Selexipag Matrix Tablets|Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
11072779|NCT04266756|Experimental|Cohort 2: Selexipag Encapsulated Pellets|Participants will receive oral doses of selexipag encapsulated) pellets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
11072780|NCT04266743|Experimental|Hemiparetic patient|patients who had a stroke at least 6 months before inclusion
11072781|NCT04266730|Experimental|PANDA-VAC|The final primary therapeutic neoantigen vaccine product will comprise 6 peptides at a dose of 300 μg per peptide and Poly-ICLC at a dose of 500 μg formulated in an aqueous solution containing <5% DMSO in isotonic dextrose for a total volume of 750 μL. The vaccine will be administered subcutaneously via 3 equal volume (250 μL) injections, one in an arm and one in each leg. The product will be administered on the following schedule: Days 1 and 4 of Week 1, Day 1 of Week 2, Day 1 of Week 3, Day 1 of Week 4, Day 1 of Week 11, and Day 1 of Week 21.
11072782|NCT04266717|Experimental|Baby Play Parent Education Group|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
11072783|NCT04266717|Active Comparator|Milestone Education Group|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
11072784|NCT04266704|Experimental|Intervention|Along with providing education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence, the intervention arm is designed to promote information sharing and stimulate broad cortical neural networks, the default mode (DMN), which focuses on emotion-management and self-awareness.
11072785|NCT04266704|Active Comparator|Control|education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence
11105738|NCT04036292|Active Comparator|OC-01 Low Dose|
11072786|NCT04266691||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
11072787|NCT04266691||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
11072788|NCT04266678|Experimental|Elastic band resistance training|Resistance training with elastic resistance bands two days per week for 6-weeks.
11072789|NCT04266678|Active Comparator|Dumbbell resistance training|Resistance training with dumbbell weights two days per week for 6-weeks.
11072790|NCT04266678|No Intervention|Non-exercise Control|Education and guidance for exercise recommendations in older adults but no active training sessions.
11072791|NCT04266665|Active Comparator|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
11072792|NCT04266665|Placebo Comparator|Normal saline|Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.
11072793|NCT04266652|Experimental|Autogenous bone block|the monocortical block grafts were harvested from the retromolar region (i.e. linea oblique) by using of rotating (i.e. carbide burs)
11072794|NCT04266652|Experimental|Tooth block|In the first group, a second mucoperiosteal flap was elevated to surgically remove the respective wisdom tooth. After its removal and during the same surgery, the crown was decapitated at the cemento -enamel junction using a rotating carbide bur under gentle sterile saline cooling and the exposed pulp was preserved. The separated tooth root was adapted to match the size and shape of the defect area. To improve ankylosis between the graft and the defect site, the layer of cementum at the respective downward aspects of the root was carefully removed using a diamond bur until the underlying dentin was entirely exposed
11072795|NCT04266639|Active Comparator|Remote Ischemic Conditioning|"Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.
~Initial Remote Ischemic Conditioning: < 2 hours from inclusion
~Remote Ischemic Postconditioning: twice daily for 7 days
~Usual care with or without acute reperfusion therapy"
11072796|NCT04266639|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.
~Initial Sham Remote Ischemic Conditioning: < 2 hours from inclusion
~Sham Remote ischemic Postconditioning: twice daily for 7 days
~Usual care with or without acute reperfusion therapy."
11072797|NCT04266639|No Intervention|Controls|The control group will not receive treatment with Remote Ischemic Conditioning.
11072798|NCT04266626|Experimental|Group A kinesiotaping therapy|"Protocols mentioned in kinesiological taping i.e. 45 minutes will be pursued as with longer sessions children may tire out easily. Taping Technique for lip muscles would be used by cutting 2 I tapes according to the structure of lip muscles.The tape will be fixed in the center of the mouth on the upper lip, will be placed on an open mouth and a 10% tension will be given to the paper. The tape will then end at the corner of the upper lip. Kinesiotape wouldn't be placed on the lips. The second tape piece will be fixed to the center of the lower lip.The edges of the tape should overlap slightly.
~The other piece of tape will be placed under chin (base of tongue) on sub mandibular triangle, inside the jaw line on the base of the tongue. A strip 1-1 ½ inch long will be cut, and then will further be cut in half such that the stretch is horizontal. It will be anchored in the middle on sub mandibular triangle. Paper off the tension to both sides."
11072799|NCT04266626|Active Comparator|Group B Oral Motor Manipulation therapy|"For the oral motor manipulation technique CP chair will be required to maintain the good sitting posture of children. Trunk will be in upright position with cut out lap board of the CP chair. Hips, knees and ankles would be flexed to 90 degrees. Shoulders and arms will be rested in symmetrical manner by keeping them rested in lap board and foot rest will be used to rest the feet tightly to control movement and maintain good posture. Each child would be taken for 12 weeks of therapy with three sessions per day of 15 minutes each. Oral motor manipulation like tapping protocols would be used for 45 minutes; slow, even rhythmic pressure will be applied around lip muscle and base of tongue muscle, keeping in view the comfort level of patient.
~Training to do manipulation exercises will be given to the parents of children with CP at ."
11072800|NCT04266613||All Subjects Enrolled|High immune risk transplant recipients who are undergoing routine management under current standard of care
11072801|NCT04266600|Experimental|Prospective arm (extended mesenteric resection)|"Surgery can be performed either laparoscopically or open depending on surgeon preference and the circumstances of the surgery. Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis. The entire mesentery related to the specimen will be removed.
~Outcomes in the prospective arm will be compared to historical controls."
11072802|NCT04266600|No Intervention|Retrospective arm|Retrospective patient data will be obtained by querying the Opera operating room database of both study institutions. Electronic records will be analyzed for all patients undergoing a first-time ileocolic resection for Crohn's Disease between January 1, 2009 - December 31, 2018.
11072803|NCT04266587|Experimental|Healthy volunteers|blood sampling is done on healthy volunteers
11072804|NCT04266574|Experimental|Near Infrared Spectroscopy (NIRS)|
11072805|NCT04266574|Active Comparator|Standard Care|
11072806|NCT04266561|Other|lap. recurent inguinal hernia repair|After induction of general anesthesia, the patient was placed supine in Trendelenburg's position. Insertion of the main umbilical port. Laparoscopic hernia repair was done by intracorporeal insertion of purse string technique with some modifications
11072807|NCT04266548|Experimental|super-selective hepatic artery ICG injection group|single arm for feasibility study of intra-hepatic artery base fluorescent segmental demarcation
11072808|NCT04266535||TCI|Patients receiving Target Controlled Infusion (TCI) Anesthesia
11072810|NCT04266522|Active Comparator|Arm I (printed materials)|Patients receive printed materials describing the technical aspects of their treatment.
11072811|NCT04266522|Experimental|Arm II (printed materials, physicist interaction)|Patients receive printed materials as in Arm I. Patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.
11072812|NCT04266509|Experimental|Rifampin and PF-06651600 DDI|In Period 1, participants will receive a single oral 50 mg dose of PF-06651600. In Period 2, participants will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, in the morning of Day 8 participants will be administered with rifampin 600 mg 2 hour prior to administration of a single 50 mg oral dose of PF-06651600.
11072813|NCT04266496|Other|<2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention
~Complete a 3 day Frequency Volume chart
~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
11072814|NCT04266496|Other|=> 2 nocturnal voids|"All interventions in this group are done twice: Once before surgical intervention, and once 2 months after surgical intervention
~Complete a 3 day Frequency Volume chart and collection of the urine of the last day and night to complete osmolality and sodium testing.
~Measuring the circumference off the lower limbs just after awakining and before falling asleep
~Questionnaires: ICIG FLUTS/MLUTS, PSQI and CIVIQ2"
11072815|NCT04266470|Experimental|Lara Device Scan|This imaging study will be obtained strictly for the research purposes of mid-treatment assessment of blood flow and uptake kinetics analysis
11072816|NCT04266444|Active Comparator|Level 4|10Cubes game in virtual reality using very small bouncing blocks
11072817|NCT04266444|Active Comparator|Level 3|10Cubes game in virtual reality using very small non-bouncing blocks
11072818|NCT04266444|Active Comparator|Level 2|10Cubes game in virtual reality using large bouncing blocks
11072819|NCT04266444|Active Comparator|Level 1|10Cubes game in virtual reality using large non-bouncing blocks
11072820|NCT04266431|Experimental|EMPOWER|EMPOWER is a multichannel, behavioral lifestyle intervention delivered remotely. The goals of EMPOWER are to induce a loss of 5% or more of initial weight within 6 months and to maintain these improvements at 12 and 24 months, by meeting dietary and physical activity goals. Coach-participant contacts will occur by phone and email, without in-person visits. Coaching contacts will be weekly for the first 12 weeks and then monthly thereafter. Men will have access to a web-based system that (1) provides support for behavioral methods of weight management and (2) allows coaches to review participant self-monitoring data and monitor participant progress towards goals. Men will record diet, exercise, and weight on the web or on a smart phone application.
11072821|NCT04266431|No Intervention|Standard of Care|Men randomized to the standard of care group will continue to receive treatment from the mens' medical oncologist. These men will also be provided with a one page informative brochure on lifestyle recommendations adapted from the American Cancer Society Prostate Cancer Survivorship Care Guidelines, at the time of randomization. At the end of the trial, men in this arm will be offered a one-time counseling session with an intervention coach on healthy lifestyle.
11072822|NCT04266418|Placebo Comparator|Placebo|consume 1 sachet per day for 2 months
11072823|NCT04266418|Experimental|Banana flower stamens extract|consume 1 sachet per day for 2 months
11072824|NCT04266405|Placebo Comparator|Placebo drink|
11072825|NCT04266405|Experimental|Collagen and Zhuyin Drinks|
11072826|NCT04266392|Experimental|1|
11072827|NCT04266379|Experimental|Closed-Loop Control (CLC)|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
11072828|NCT04266379|Active Comparator|Sensor Augmented Pump (SAP)|Closed-loop subcutaneous insulin infusion and continuous glucose monitoring manage by patient
11072829|NCT04266366|Active Comparator|Face-to Face rehabilitation program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience. This program will be developed in the rehabilitation service of the study health centers. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
11072830|NCT04266366|Experimental|Telemedicine Program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 8 weeks, with a total of 24 sessions
11072831|NCT04266353|Experimental|Single arm|Participants with receive resveratrol at 150 mg daily for 6 weeks
11072832|NCT04266340|Placebo Comparator|placebo|no premedication
11072833|NCT04266340|Experimental|oralmidazolam|0.5 mg/kg oral midazolam group
11072834|NCT04266340|Experimental|intravenous midazolam|0.05 mg/kg intravenous injection midazolam group
11072835|NCT04266340|Experimental|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
11072836|NCT04266327|Experimental|I-125 Seed Implantation|All the enrolled patients were treated with ct-guided radioactive i-125 seed implantation assisted by 3D printing template.Prescription dose 110-130gy.
11072837|NCT04266301|Experimental|MBG453 + Azacitidine|Participants will receive MBG453 plus Azacitidine
11072838|NCT04266301|Placebo Comparator|Placebo + Azacitidine|Participants will receive Placebo plus Azacitidine
11072839|NCT04266288|Experimental|Ketamine|Ketamine 0.5 mg/kg in 0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose.
11072840|NCT04266288|Placebo Comparator|Placebo|0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose
11072841|NCT04266275|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 20 weeks
11072842|NCT04266275|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of intravaginal placebo once a week for 20 weeks
11072843|NCT04266262|Experimental|High-Intensity interval training (HIIT)|
11072844|NCT04266262|Experimental|High-intensity resistance training (HIRT)|
11072845|NCT04266262|No Intervention|Usual care (UC)|Provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
11072846|NCT04266249|Experimental|Arm A (pCR after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.
~POST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate."
11072847|NCT04266249|Experimental|Arm B (residual invasive disease after surgery)|"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.
~POST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate."
11072848|NCT04266236|Active Comparator|L3 LPB technique (P group)|ultrasound-guided shamrock approach L3 lumbar plexus block with single-needle technique
11072849|NCT04266236|Active Comparator|T12 combined with L3 and L4 LPB technique (TP group)|ultrasound-guided posterior approach thoracic 12 combined with L3 and L4 lumbar plexus block with mulitple-needle technique
11072850|NCT04266236|Experimental|L3 LPB combined with QLB (LPQLB-SNT, PQ group)|ultrasound-guided shamrock approach L3 lumbar plexus block combined with quadratus lumborum block with single-needle technique
11072851|NCT04266223|Experimental|Mask-free surface monitoring|Lay in treatment position for 20 minutes with surface monitoring technology activated
11072852|NCT04266210|Experimental|Fuji Bulk|Glass ionomer (Fuji Bulk, GC, Tokyo Japan)
11072853|NCT04266210|Experimental|G-ænial Posterior|Posterior composite resin(G-ænial Posterior, GC, Tokyo Japan)
11072854|NCT04266197|Experimental|RT234-vardenafil inhalation powder|RT234 at capsule dose strength of 0.5 mg. RT234 will be administered using a variant of the RS01 Monodose Dry Powder Inhaler named Axially Oscillating Sphere dry powder inhaler (AOS DPI) device (RPC Plastiape, Osnago, Italy).
11072855|NCT04266184|Experimental|Kinesio tape (KT)|Abdominal and symphisis pubis supported lumbopelvic KT will be applied. This group will also receive the same educational program with the control group.
11072856|NCT04266184|Active Comparator|Pelvic belt (PB)|A narrow and flexible adjustable pelvic belt will be used in high position (just under the spina iliaca anterior superior). This group will also receive the same educational program with the control group.
11072857|NCT04266184|Other|Control group|This group will receive a 1-hour educational program composed of neuroscience education and ergonomic training.
11072858|NCT04266171|Experimental|CGMS Diet Education|
11072859|NCT04266171|Active Comparator|Conventional Diet Education|
11072860|NCT04266158|Active Comparator|MyoPro 2 Motion-G-orthosis-None|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
11072861|NCT04266158|Active Comparator|Comfy Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
11072862|NCT04266158|Active Comparator|No Splint|Following screening, all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, Comfy Splint orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects. After these training sessions, all subjects complete a battery of three tests while wearing one of the two devices, or no device. The order in which the tests are administered is randomized.
11072863|NCT04266145|Active Comparator|intravenous dexmedetomidine|20 mL 0.25% levobupivacaine plus 1 mL normal saline will be administrated for adductor-canal-blockade while for intravenous solution; 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline will be prepared
11072864|NCT04266145|Active Comparator|adductor-canal-blockade dexmedetomidine|20 mL 0.25% levobupivacaine containing 1 mL of 0.5 mcg.kg-1 dexmedetomidine will be used for adductor-canal-blockade whereas, 20 mL 0.9% saline will be prepared for intravenous infusion
11072865|NCT04266132|Active Comparator|Retrolamianar block (RLB)|General anaesthesia will be induced.Ultrasound-guided RLB will be performed under strict aseptic precautions with patient in the lateral position.The anesthetic solution will be injected.
11072866|NCT04266132|Active Comparator|Ilioinguinal nerve block (INB)|General anaesthesia will be induced. Ultrasound-guided INB will be performed under strict aseptic precautions with patient in the supine position.The anesthetic solution will be injected.
11072867|NCT04266119|Experimental|Intervention|"The HOPE intervention can be accessed through web. It consists of two sessions per week, with a total of four sessions. In this study, participants will be sent weekly weblinks for access to each session. Each session take about ten minutes to complete. Each session consist of pre-post multiple-choice and/or open-end question, video(s) and mental health information. The first session is about depression. The second session is about positive psychology and consists of relevant exercises such as gratitude, affect-based and strength-based exercises. The third session describes anxiety disorder. The last session describes relaxation techniques and self-management of unhelpful thoughts.
~Each session consists of quizzes, video(s), and graphical / written information"
11074535|NCT04254744||Acyanotic children|Acyanotic children undergoing cardiac surgery due to congenital heart disease
11072868|NCT04266119|Active Comparator|Control|The group will receive a control website intervention that consists of several graphical inspirational quotes. Examples of the quotes are, 'Today is full of possible' and 'You can do anything'.
11072869|NCT04266106|Placebo Comparator|Placebo Comparator|
11072870|NCT04266106|Experimental|probiotic|
11072871|NCT04266093||1|Subjects who have received treatment on an NCI ETIB Branch gene therapy protocol.
11072872|NCT04266080|Experimental|childhood cancer survivors & and one parent/legal guardian|The study plans to recruit 30 childhood cancer survivors and a parent/legal guardian for each survivor. Participants will be provided with a Fitbit Inspire HR wearable device to record their step counts for two weeks pre-intervention, and over the six-month follow-up period (3-month intervention and 3month follow-up).
11072873|NCT04266067|Active Comparator|PNF exercise|In the PNF exercise group; exercises were performed in company with a physiotherapist 5 days a week (30 minutes ) for 4 weeks. Five specific techniques were applied to the patients: dynamic stabilization, rhythmic stabilization, combined isotonic contractions, and hold-relax active motion
11072874|NCT04266067|Active Comparator|Frenkel exercise|In the Frenkel exercise group, Frenkel coordination exercises were given in home exercise program 5 days a week for 4 weeks.The physiotherapist demonstrated Frenkel exercises to them once.
11072875|NCT04266054|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care
11072876|NCT04266054|No Intervention|Control|The comparison group will receive usual clinical care.
11072877|NCT04266041|Experimental|High-density EEG localization in epilepsy|High-density EEG will be used for brain localization in epilepsy patients
11072878|NCT04266041|Active Comparator|High-density EEG localization in healthy controls|High-density EEG will be used for brain localization in healthy controls
11072879|NCT04266041|Experimental|High-density EEG localization in tumor patients|High-density EEG will be used for brain localization in tumor patients
11072880|NCT04266041|Experimental|High-density EEG localization in peripheral nerve patients|High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
11072881|NCT04266028|Experimental|Cohort 1|Cohort 1 randomized in 2:1 will receive a single s.c. dose of DM-101 or matching placebo
11072882|NCT04266028|Experimental|Cohort 2|Cohort 2 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
11072883|NCT04266028|Experimental|Cohort 3|Cohort 3 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
11072884|NCT04266028|Experimental|Cohort 4|Group 4 randomized in 3:1 will receive multiple ascending s.c. doses of DM-101 or matching placebo during 5 biweekly dosing occasions
11072885|NCT04266015|No Intervention|Control group|Patients assigned to control group will not receive feeding via the nasogastric tube during operation
11072886|NCT04266015|Experimental|Intraoperative feeding group|Patients assigned to intraoperative feeding group will receive enteral nutrition formula via the nasogastric tube during operation
11072887|NCT04266002|Other|HIV-1 infected adult associated neurocognitiv|HIV-1 infected adult subjects with HIV-associated neurocognitive disorders despite effective antiretroviral therapy in plasma for more than one year, analyzing the evolution of cognitive disorders with Global Deficit Score and HAND classification, and markers of macrophagic inflammation in blood and cerebrospinal fluid, after a change in HIV treatment with an increased of the new scale CHARTER score ≥ 3 (total treatment score to be ≥ 9)
11072888|NCT04265989|Experimental|coronary artery aneurysm with branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, accompany with branches origin from the aneurysm
11072889|NCT04265989|Experimental|coronary artery aneurysm without branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, without any branch origin from the aneurysm
11072890|NCT04265989|Experimental|Coronary artery aneurysm with localized stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. localized stenosis defined as lesion to more than 70% stenosis and length less than 20 mm
11072891|NCT04265989|Experimental|Coronary artery aneurysm with diffuse stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. Diffuse stenosis defined as lesion to more than 70% and length more than 20 mm
11072892|NCT04265963|Experimental|CD123 CAR-T cells treat|Patients will be be treated with CD123 CAR-T cells
11072893|NCT04265950|Experimental|Arm 1 (3 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment, and at 2 and 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
11072894|NCT04265950|Experimental|Arm 2 (2 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment and at 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
11072895|NCT04265950|Experimental|Arm 3 (1 dose of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
11072896|NCT04265950|Active Comparator|Arm 4 (1 dose of 9vHPV vaccine)|Participants without HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment . Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
11072897|NCT04265924|Active Comparator|>0.85 FIO2 group|This group receives FIO2 >0.85 during the surgery.
11072898|NCT04265924|Active Comparator|<0.7 FIO2 group|This group receives FIO2 <0.7 during the surgery.
11072899|NCT04265911|Experimental|ASP3772 (subcutaneous) in Adults|Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.
11072900|NCT04265911|Experimental|ASP3772 ((intramuscular) in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
11073022|NCT04265183|Experimental|patients treated with preformed metal crowns|All patients included received a preformed metal crown on their HSPM affected teeth.
11072901|NCT04265911|Experimental|ASP3772 (subcutaneous) in Elderly|Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.
11072902|NCT04265911|Experimental|ASP3772 (intramuscular) in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
11072903|NCT04265911|Active Comparator|PPSV23 (subcutaneous) in Elderly|Participants will receive a single subcutaneous injection of the standard dose of PPSV23 on Day 1.
11072904|NCT04265911|Active Comparator|PPSV23 (intramuscular) in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
11072905|NCT04265898||Test Group|Reported mild cognitive deficits
11072906|NCT04265898||Control Group|No cognitive deficits
11072907|NCT04265872|Experimental|Bortezomib followed by pembro/cis|There is only one arm.
11072908|NCT04265859|Experimental|Depressed|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
11072909|NCT04265859|Other|Healthy Control|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
11072910|NCT04265846|Experimental|bifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and bifocal IOLs implantation.
11072911|NCT04265846|Experimental|mix bifocal IOL group|The cataract patients who ask for phacoemulsification and mix different bifocal IOLs implantation bilaterally
11072912|NCT04265846|Experimental|trifocal IOL group|The cataract patients who ask for bilateral phacoemulsification and trifocal IOLs implantation.
11072913|NCT04265846|Experimental|EDOF IOL group|The cataract patients who ask for bilateral phacoemulsification and EDOF IOLs implantation.
11072914|NCT04265846|Experimental|blend vision group|The cataract patients who ask for phacoemulsification and different IOLs implantation bilaterally.
11072915|NCT04265846|Experimental|monovision designed group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
11072916|NCT04265846|Active Comparator|monofocal IOL group|The cataract patients who ask for bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
11072917|NCT04265833|Active Comparator|calcium hydroxide|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with calcium hydroxide. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed to prevent pulp exposure. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity.The residual demineralized dentin was covered with a thin layer of Ca(OH)2 (approximately 1 mm2) in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
11072918|NCT04265833|Experimental|Biodentine|Thirty seven primary molar teeth were selected to apply indirect pulp therapy with Biodentine. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide-bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. A thin layer of tricalcium silicate-containing pulp-capping material (Biodentine) (approximately 1 mm2) consisting of powder and liquid was applied to the demineralized dentin tissue and a 12-min setting time was allowed for hardening, in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
11072919|NCT04265833|Experimental|TheraCal LC|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with TheraCal LC. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. Flowable form of resin-reinforced tricalcium silicate-containing material (TheraCal LC) was applied directly onto the demineralized dentin at a maximum thickness of 1 mm and was polymerized for 20 sec (Valo LED), in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
11072920|NCT04265820|Experimental|Group 1|The unilateral cataract patients in the Group 1 will undergo phacoemulsification and unilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
11072921|NCT04265820|Active Comparator|Group 2|The bilateral cataract patients in the Group 2 will undergo phacoemulsification and bilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
11072922|NCT04265807|Active Comparator|Intervention Group|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on an upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
11072923|NCT04265807|Sham Comparator|Control Group|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
11072924|NCT04265794|Experimental|Intervention|6-week community-based behavioral program consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. The intervention targets knowledge, attitudes, and skills related to sugar-sweetened beverage consumption and water consumption, with reduction in sugar-sweetened beverage consumption and increase in water consumption being the primary behavioral targets.
11072925|NCT04265794|No Intervention|Comparison|Parent-child pairs in comparison sites will receive usual care (standard Boys and Girls Club programming) during the study and the intervention upon study completion.
11072926|NCT04265781|Experimental|Dose escalation BAY1817080|Participants receive dose 1 to 3 of BAY1817080 as a single dose on Day 1.
11072927|NCT04265781|Experimental|Dose expansion BAY1817080|Participants receive the highest dose 3 of BAY1817080 twice daily (BID) from Day 1 until Day 13 and a single dose on Day 14.
11072928|NCT04265781|Placebo Comparator|Dose escalation Placebo|Participants receive placebo tablets orally as a single dose on Day 1.
11072929|NCT04265781|Placebo Comparator|Dose expansion Placebo|Participants receive placebo tablets as BID multiple doses from Day 1 until Day 13 and as a single dose on Day 14.
11072930|NCT04265768|Placebo Comparator|No Soft tissue augmentation surgery|No soft tissue augmentation concomitant to implant placement. Negative control group.
11072931|NCT04265768|Experimental|Soft tissue augmentation surgery with Fibro-Gide|"Soft tissue augmentation concomitant to implant placement with a porcine, volume-stable cross-linked collagen matrix (Fibro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland).
~Test group."
11072932|NCT04265768|Active Comparator|Soft tissue augmentation surgery with patient's CTG|"Soft tissue augmentation concomitant to implant placement with a connective tissue graft (CTG) taken from the patient's palate or retromolar area.
~Positive control group."
11072933|NCT04265755|Experimental|Single arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
11072934|NCT04265742|Experimental|Group A. Normal BMD, no fracture|Post-menopausal women with normal bone density (BMD t-score >-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
11072935|NCT04265742|Experimental|Group B. Normal BMD, with fracture|Post-menopausal women with normal bone density (BMD T-score >-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
11072936|NCT04265742|Experimental|Group C. osteoporotic, no fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
11072937|NCT04265742|Experimental|Group D. osteoporotic, with fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
11072938|NCT04265729|Other|single test product arm|use of Neocate Infant and Junior marketed products (product type depending on subject's age and condition)
11072939|NCT04265716|Active Comparator|L. reuteri|Topical administration of ointment with L. reuteri DSM17938, rubbed into skin twice per day
11072940|NCT04265716|Placebo Comparator|Placebo|Rubbed into skin twice per day
11072941|NCT04265703|Active Comparator|Internal jugular vein site|Ultrasound-guided central venous catheterization at internal jugular vein site
11072942|NCT04265703|Active Comparator|Subclavian vein site|Ultrasound-guided central venous catheterization at subclavian vein site
11072943|NCT04265703|Active Comparator|Innominate vein site|Ultrasound-guided central venous catheterization at innominate vein site
11072944|NCT04265690|Experimental|Teen and Tot Centering subjects|The cooking classes and text messages will supplement the subject's standard of care by incorporating text messages and a cooking class.
11072945|NCT04265677|Experimental|Telemedicine FCR|These patients will be eligible to use telemedicine for Family Centered Rounds
11072946|NCT04265677|Placebo Comparator|Control|These patients will not be eligible to use telemedicine for Family Centered Rounds (standard of care)
11072947|NCT04265664|Experimental|Telerehabilitation|Receives the telerehabilitation protocol
11072948|NCT04265651|Experimental|Infigratinib 0.016 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
11072949|NCT04265651|Experimental|Infigratinib 0.032 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
11072950|NCT04265651|Experimental|Infigratinib 0.064 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
11072951|NCT04265651|Experimental|Infigratinib 0.128 mg/kg|"Dose Escalation:
~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
~Dose Expansion:
~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
11072952|NCT04265638|Experimental|Exercise|
11072953|NCT04265638|No Intervention|Usual Care|
11072954|NCT04265625|No Intervention|blind tracheotomy|no endoscopic guidance tracheotomy
11072955|NCT04265625|Experimental|endoscopic guidance tracheotomy|With endoscopic guidance tracheotomy
11072956|NCT04265612|Experimental|Negative Pressure dressing|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
11072957|NCT04265612|Active Comparator|Aquacel hydrogel dressing|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
11072958|NCT04265586|No Intervention|No insomnia|This group contains participants who report only mild symptoms of insomnia (Insomnia Severity Index, ISI<15).
11074536|NCT04254744||Cyanotic children|Cyanotic children undergoing cardiac surgery due to congenital heart disease
11072959|NCT04265586|Experimental|Digital Cognitive Behavioural Therapy (iCBT)|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Intervention is iCBT for participants with insomnia (7-16 weeks).
11072960|NCT04265586|Experimental|Sleep hygiene education|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Sleep hygiene education (approximately 1 hour)
11072961|NCT04265573||Children under-five|Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
11072962|NCT04265573||Individuals five years of age and above|Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
11072963|NCT04265573||Pregnant women|Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.
11072964|NCT04265560|Experimental|Progressive Resistance Training|"The intervention group will receive 8 weeks of Progressive Resistance Training (PRT), twice a week, in addition to usual care. An upper limb functional goal will be identified through discussion with the researcher and the participant. PRT will be individually tailored to target two muscle groups and will be chosen in order to develop strength to progress towards the participants functional goal.
~The chronic spinal cord injury exercise guideline parameters will be applied (3 sets of 8-10 repetitions, 1-2 mins rest between sets). Participants will be inducted to their PRT programme and will then independently complete the 8 week programme. During each of the following sessions, assistance for set up of equipment and/or limb position will be given by the researcher and/or the participants family, friend or carer, once they have been trained. PRT sessions will be recorded in a diary to monitor sets and repetitions completed, and intensity (visual analogue scale (VAS))."
11072965|NCT04265560|No Intervention|Usual care only|Participants will continue with their usual care, consistent with standard National Health Service (NHS) care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting up to 90 minutes. Physiotherapists provide a combination of group exercise and one to one function-orientated physiotherapy sessions to improve balance, general muscle strength, wheelchair and/or transfer skills.
11072966|NCT04265547|Experimental|Intervention Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Participants in the intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion.
11072967|NCT04265547|No Intervention|Control Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion. Control arm participants will be offered the chemical-free products, cleaning supplies, and air filter at this time.
11072968|NCT04265534|Experimental|Telaglenastat with Pembrolizumab and Chemotherapy|The glutaminase inhibitor telaglenastat will be administered orally, twice daily with food, every day in combination with standard-of-care pembrolizumab plus chemotherapy by intravenous (IV) infusion every 3 weeks.
11072969|NCT04265534|Placebo Comparator|Placebo with Pembrolizumab and Chemotherapy|Placebo will be administered orally twice daily with food every day in combination with standard-of-care pembrolizumab plus chemotherapy by IV infusion every 3 weeks.
11072970|NCT04265521|Experimental|Biocool Footcare|"Treatment regime:
~During week 1: Once daily for 7 days (7 doses) During week 2 and 3: Once every second day for 14 days (7 doses)"
11072971|NCT04265508||Low MELD score|MELD score of 6 - 11
11072972|NCT04265508||High MELD score|MELD score of ≥ 17
11072973|NCT04265495||DUAL TRIGGERING|PATIENTS WILL RECEIVE DUAL TRIGGERING
11072974|NCT04265495||URINARY HCG|PATIENTS WILL RECEIVE URINARY HCG
11072975|NCT04265495||RECOMBINANT HCG|PATIENTS WILL RECEIVE RECOMBINANT HCG
11072976|NCT04265469|Experimental|Patients with diabetics get mobile education|Patients with diabetics get mobile education
11072977|NCT04265469|No Intervention|Patients with diabetics|Patients with diabetics
11072978|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg IV Pregabalin|The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).
11072979|NCT04265456|No Intervention|Placebo|Saline solution
11072980|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg +/- 25 IV Pregabalin|Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.
11072981|NCT04265443||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI
11072982|NCT04265430|Experimental|MRI after radiation therapy (Cohort I)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy, and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.
11073048|NCT04264949|Active Comparator|Groupe conventional care (GCC)|benefit from conventional care in a rehabilitation center and therapeutic education program
11072983|NCT04265430|Experimental|MRI after surgery (Cohort II)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.
11072984|NCT04265417||RARC group|Participants in this group underwent robotic assisted rectal cancer resection
11072985|NCT04265417||NOSE group|Participants in this group underwent robotic rectal cancer resection assisted rectal with natural orifice extraction
11072986|NCT04265391|Experimental|Snakehead fish cookies|Subjects who were given intervention of snakehead fish cookies during the study period
11072987|NCT04265391|Placebo Comparator|Standard cookies|Subjects who were in control group and received standard cookies
11072988|NCT04265378|Experimental|Stimulation group|Anodal tDCS + intensive cognitive training
11072989|NCT04265378|Sham Comparator|Sham group|Sham tDCS + intensive cognitive training
11072990|NCT04265365|Experimental|rTMS+rPMS_iTBS_R|In this group, they received intermittent theta burst stimulation(iTBS) on affected hemisphere after following iTBS at radial nerve on affected hand.
11072991|NCT04265365|Experimental|rTMS+rPMS_cTBS_R|In this group, they received intermittent theta burst stimulation on affected hemisphere after following continuous theta burst stimulation(cTBS) at radial nerve on affected hand.
11072992|NCT04265365|Sham Comparator|rTMS +sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at radial nerve on affected hand.
11072993|NCT04265365|Experimental|rTMS+rPMS_iTBS_M/U|In this group, they received iTBS on affected hemisphere after following iTBS at median/ulnar nerve on affected hand.
11072994|NCT04265365|Experimental|rTMS+rPMS_cTBS_M/U|In this group, they received iTBS on affected hemisphere after following cTBS at median/ulnar nerve on affected hand.
11072995|NCT04265365|Sham Comparator|sham-rTMS+sham-rPMS|In this group, they received iTBS on affected hemisphere after following sham TBS stimulation at median/ulnar nerve on affected hand.
11072996|NCT04265365|Experimental|rTMS + optimal-rPMS|In this group, patient received iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation(rPMS) on affected hand.
11072997|NCT04265365|Experimental|rTMS+ sham-rPMS|In this group, patient received iTBS on affected hemisphere after following sham repetitive peripheral magnetic stimulation on affected hand.
11072998|NCT04265365|Sham Comparator|sham-rTMS+optimal-rPMS|In this group, patient received sham iTBS on affected hemisphere after following optimal repetitive peripheral magnetic stimulation on affected hand.
11072999|NCT04265352||Prenetal cardiac echogenic focus|Newborn infants who had prenatal cardiac echogenic focus
11073000|NCT04265339|No Intervention|None smokers|50 participants who are non-smokers
11073001|NCT04265339|Experimental|Smoking Cessation|50 smokers who quit smoking
11073002|NCT04265339|No Intervention|Active smokers|50 smokers who continue smoking
11073003|NCT04265326||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
11073004|NCT04265313||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
11073005|NCT04265300|No Intervention|Control|No intervention provided
11073006|NCT04265300|Experimental|Creative Roots|The intervention group will receive Creative Roots beverages and be instructed to have at least one drink (251mL) available at each meal (i.e. breakfast, lunch, and dinner) and drink as much as they would like throughout the day (i.e. ad libitum) of either Creative Roots or any other beverage they would normally consume. Subjects will be asked the keep their empty Creative Roots bottles to return them to the lab. Subjects will be instructed to refrigerate the beverages for better taste, and to refrigerate the beverages after opening.
11073007|NCT04265287||Pediatric patients with severe pneumonia|Pediatric patients admitted to PICU due to severe pneumonia
11073008|NCT04265274|Experimental|Disulfiram, vinorelbin, cisplatin, copper|Vinorelbine 25mg/m2 day 1 and 8, Cisplatin 75mg/m2 day 1, every 3 weeks, Disulifiram um 400mg daily and 2 mg of elementary Copper daily, continuously.
11073009|NCT04265261|Placebo Comparator|Group A|Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
11073010|NCT04265261|Experimental|Group B|Participants will receive a low oral dose of RG7774 QD
11073011|NCT04265261|Experimental|Group C|Participants will receive a high oral dose of RG7774 QD
11073012|NCT04265248|Experimental|Virtual Reality|"The subjects will use Fulldive VR as the first degree of difficulty where only tilt movements are necessary, for the second degree of difficulty the game VR Ocean Aquarium 3D will be used, where bending, extension and rotation movements will be integrated, also introducing a sensory element to integrate the sound of the sea.
~For these patients to perform the same work as group 2, the physiotherapist will have to count and control in each exercise the number of movements that the patient performs so as not to exceed the proposed dose in the active comparator group (3 sets of 10 repetitions of each exercise)."
11073013|NCT04265248|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
11073014|NCT04265235|Experimental|Home-based Exercise Program|12-weeks, remotely monitored home-based exercise program consisting or aerobic and resistance exercise
11073015|NCT04265222|Other|Conventional Fluoroscopy|Participants undergoing femoroplasty with conventional treatment
11073016|NCT04265222|Experimental|HipCheck|Participants undergoing femoroplasty with Stryker HipCheck System
11073017|NCT04265209|Other|SPECT and PET|[123I]-FP-CIT SPECT imaging procedure first, then [18F] LBT-999 PET Imaging procedure
11073018|NCT04265209|Other|PET and SPECT|[18F] LBT-999 PET imaging procedure first, then [123I]-FP-CIT SPECT imaging procedure
11073019|NCT04265196|Experimental|cognitive behavioral group therapy|A Cognitive Behavioral Therapy intervention is based on a unique protocol built in the light of previous research in the field and includes a 10-week treatment focused on coping with pain and stress.
11073020|NCT04265196|Experimental|Mindfulness-based group therapy|A mindfulness-based group therapy intervention was built inspired by a mindfulness protocol that is effective in treating pain, and includes adjustments to the physical distress of fibromyalgia patients as well as an emphasis on coping with stress and pain.
11073021|NCT04265196|No Intervention|control group|A control group will wait for 3 months, during which the subjects will complete the questionnaires and only after the end of the period will they participate in the treatment so that it will serve as a control group without intervention.
11073023|NCT04265170|Experimental|Single-arm|Eligible patients are treated with BlastX and VAC. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks and 8 weeks for larger wounds (2 subjects only). Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.
11073024|NCT04265157||Early occlusion of hepatoduodenal ligament|Early occlusion of hepatoduodenal ligament during mobilization of the liver of the recipient by using portal vein clamp or occlusive temporary bands.
11073025|NCT04265157||classical occlusion of hepatoduodenal ligament|classical occlusion of hepatoduodenal ligament after mobilization of the liver of the recipient immediately before explantation by suing of portal vein clamp
11073026|NCT04265144|Experimental|subjects SSc diagnosed|Patient with systemic scleroderma according to the American College of Rheumatology (ACR) / EULAR 2013 criteria
11073027|NCT04265131|Experimental|Experimental group|art therapy is delivered on top of treatment as usual (TAU). TAU means that individual verbal therapy takes place on a regular basis, whereby the frequency varies depending on the severity of the eating disorder and the patient's request for help. Cognitive-behavioral therapy is provided with elements of dialectical behavioral therapy, and there is also the possibility of family or couple counseling by a family-based therapist.
11073028|NCT04265118|Experimental|Sideward Tilt of Bed|During sleep, while lying in supine position, the participant will be tilted sidewards by the bed. In practice, the experimenter activates the bed at timepoints during the night where the participant is lying in supine position. Activating the bed results in one half of the bed lifting 10 to 40 Degrees sidewards.
11073029|NCT04265105|Active Comparator|standard of care|Short acting beta agonist or inhaled corticosteroids
11073030|NCT04265105|Experimental|fluticasone-vilanterol|LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
11073031|NCT04265079|Experimental|Added weight to hand|
11073032|NCT04265066||Measurement of sublingual microcirculation|
11073033|NCT04265053|Experimental|Male NOS|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
11073034|NCT04265053|Experimental|Male COX|Males visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
11073035|NCT04265053|Experimental|Female NOS|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit NOS). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
11073036|NCT04265053|Experimental|Female COX|Females visit MRI twice. Once for hypercapnia visit (no drugs), and once for hypoxia visit (IV and drug infusion to inhibit COX). CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
11073037|NCT04265027|Experimental|Group 1 (50 mg Dose)|"Test IMP: 50 mg BIA 9 1067 and Reference IMP: 50 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.
~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
11073038|NCT04265027|Experimental|Group 2 (25 mg Dose)|"Test IMP: 25 mg BIA9 1067 and Reference IMP: 25 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.
~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
11073039|NCT04265014|Active Comparator|Goal-directed fluid treatment|"Fluid management will be performed according to SVV and CI monitoring. When patients have SVV>10%, 250 cc crystalloid will be administered and when SVV fell below 10% during 30-minute monitoring standard (5 mL/kg/hr) crystalloid infusion continues. If SVV continues above 10%, a second fluid bolus of 250 cc colloid (minifluid challenge) will be administered.
~If the desired SVV level can not be reached, the Hct values will be examined. Blood replacement will be performed when Hct<30% in patients with coronary artery disease (CAD) and when Hct<25% for other patient groups. If the desired SVV level can not be reached in spite of blood replacement products, if CI will be below 2.5 L/min/m2 vasopressor will begun. If SVV will be at normal values with CI below 2.5 L/min/m2, inotrop will begun."
11073040|NCT04265014|Active Comparator|liberal fluid treatment|"Fluid management will be performed according to MAP, HR and urine output.
~If peroperative urine amounts will be <0.5 mL/kg/hr during two-hour monitoring, with MAP<65 mmHg, HR>100/min for at least 30 minutes and CVP falls 20% compared to basal values, the same anesthesiologist will begin additional fluid replacement of 5 mL/kg/hr based on clinical experience.
~Blood product replacement will be provided at Hct<30% for those with coronary artery disease and at Hct<25% for other patients."
11073041|NCT04265001|Active Comparator|Control group|Topical cholrhexidine hydrochloride 125 mg/100 ml available commercially (Hexitol; Arab Drug Company for Pharmaceutical and Chemical Industries, Cairo, Egypt) mouthwash. Topical cholrhexidine hydrochloride mouthwash treatment has been repeated three times per day for one week.
11073042|NCT04265001|Experimental|Hyaluronic acid group (HA group)|Topical hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash (Aftamed; Bioplaxpharma, UK).Topical hyaluronic acid mouthwash treatment has been repeated three times per day for one week.
11073043|NCT04264988||Patients who had pelvic hemorrhage|Patients who had pelvic hemorrhage during complex abdomino-pelvic surgery
11073044|NCT04264975|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation in patients who have advanced solid cancer with primary (group 1) or secondary resistance (group 2) to immuno-oncology
11073045|NCT04264962|Experimental|Yang Yin Fu Zheng Jie Du therapy|
11073046|NCT04264962|Placebo Comparator|Routine medical care|
11073047|NCT04264949|Experimental|group application (GA)|"benefit from conventional care in a rehabilitation center, therapeutic education program and education in the use of the smartphone application mon coach dos"
11073049|NCT04264936|Experimental|RC48-ADC and JS001|
11105739|NCT04036292|Active Comparator|OC-01 High Dose|
11073050|NCT04264923|Experimental|All patients enrolled|All patients enrolled with receive the HyGIeaCare Prep with a new lab sampling technique to be used on all patients enrolled in the study.
11073051|NCT04264910|Experimental|Calm Meditation|Participants (n=49) will be provided free access to and asked to register for the consumer-based mobile meditation app on their phone. Participants (n=49) will then receive an email containing 28 weeks of free access to Calm. Participants (n=49) will be asked to use Calm at least 10 minutes per day and encouraged to use it as much as they would like during the intervention. This prescription mimics how a new, paying member would use the app (full exposure with autonomy).
11073052|NCT04264910|No Intervention|Control|The control group will be asked to maintain normal activity and refrain from using Calm meditation app.
11073053|NCT04264897|Experimental|Metformin|"The investigators use a ramp up dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
11073054|NCT04264897|Placebo Comparator|Placebo|"Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate).
~The same dosing schedule will be followed as for metformin. The investigators use a ramp up dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
11073055|NCT04264858|Experimental|Treatment group|Immunoglobulin of cured patients
11073056|NCT04264858|Placebo Comparator|Control group|γ-Globulin
11073057|NCT04264845||Provider Focus Group|All heart failure providers at the participating centers will be screened as potential participants.
11073058|NCT04264845||Patient Interview Group|Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
11073059|NCT04264845||PROs/Clinical Data Integration Group|"Patients with heart failure who are seen in the heart failure outpatient clinics at the participating centers will be screened for this study. The Principal Investigator will confirm the presence of heart failure based on established and agreed criteria. A real world, diverse population ranging from patients with milder forms of HF to the most advanced disease will be included in this study and allow the researchers to validate the prognostic models in larger, regionally diverse populations to better define the comparative effectiveness of alternative treatments in patients with different risk profiles.
~This group includes a sub-study of patients providing blood samples."
11073060|NCT04264832||observation group|Participants were eligible if they met the Rotterdam diagnostic criteria of polycystic ovary syndrome (PCOS) and meet the inclusion and exclusion criteria , and all study participants received questionnaires and underwent the physical, transvaginal ultrasound and body composition examination. Blood samples were collected for analysis of metabolic markers, metabonomics and hormones.
11073061|NCT04264832||control group|The control group participants are normal women and had no history of any type of diabetes, cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization), stage 2 hypertension , malignant disease or severe renal or hepatic disease. They accepted the same examinations as the observation group.
11073062|NCT04264819|Experimental|RTH258/Brolucizumab|This is a single arm study in which all patients will be treated with brolucizumab 6mg; 3 loading injections (at Screening/Baseline, week 4 and week 8) followed by treat-to-control phase with adjustable treatment frequency based on disease activity from every 4 to up to 16 weeks; last treatment at week 44/46 based on the treatment regimen.
11073063|NCT04264806|Experimental|Azacitidine: Participants with MDS or CMML|Participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) will receive azacitidine 75 milligram per meter square (mg/m^2) body surface area (BSA) subcutaneously or Intravenously per local label on Days 1 through Day 7 of each 28-day cycle. Participants will be treated until disease progression; relapse from complete remission (CR), partial remission (PR), or marrow complete remission (mCR); transformation to acute myeloid leukemia (AML); death; or unacceptable toxicity.
11073064|NCT04264806|Experimental|Azacitidine and Cusatuzumab: Participants with MDS or CMML|Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.
11073065|NCT04264793|Experimental|Intervention|Behavioral Lifestyle Intervention (3 health centers): In addition to usual care in the health center, the intervention included individual counseling and group education on nutrition and physical activity.
11073066|NCT04264793|Active Comparator|Control|Control (4 health centers): Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
11073067|NCT04264780||Younger than 50 years of age|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently less than 50 years of age
11073068|NCT04264780||50 years of age or older|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently 50 years of age or more
11073069|NCT04264767||Cases Group|Peripheral blood collection via routine venipuncture
11073070|NCT04264767||Control Group|Peripheral blood collection via routine venipuncture
11074538|NCT04254718|Experimental|Digital Storytelling|Legacy intervention via digital story for NICU parents
11073071|NCT04264754||Cases Group|Subjects who have already been diagnosed with liver cancer, however did not yet undergo any surgery, ablation, embolization or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
11073072|NCT04264754||Control Group|"Cancer free subjects with high risk to development HCC. High risk subjects include the following:
~Subjects with HCV (hepatitis C virus) and cirrhosis
~Subjects with HBV (hepatitis B virus) and cirrhosis
~Non-cirrhotic chronic HBV subjects at intermediate or high risk of HCC, according to EASL (European Association for the Study of the Liver) Clinical Practice Guidelines for the management of hepatocellular carcinoma
~Subjects with NAFLD (Non-Alcoholic Fatty Liver Disease) with cirrhosis
~Cirrhotic patients due to any other reasons, including alcohol disease"
11073073|NCT04264741|Experimental|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 4 weeks.
11073074|NCT04264741|Sham Comparator|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday. Treatment will lasted for 4 weeks.
11073075|NCT04264715|Experimental|405nm light room|In this room, surgeries will be performed under ambient light including the wavelength 405nm
11073076|NCT04264715|No Intervention|Control room|In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies
11073077|NCT04264702||Prospective arm|Patients who have undergone surgery for stage II or III colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
11073078|NCT04264702||Control Arm|The control arm will consist of matched Stage II or Stage III CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
11073079|NCT04264689|Active Comparator|thoracic epidural|thoracic epidural will be done before induction of general anesthesia
11073080|NCT04264689|Experimental|serratus anterior block|ultrasound guided serratus anterior block will be done after induction of general anesthesia
11073081|NCT04264689|Experimental|erector spinae block|ultrasound guided erector spinae block will be done after induction of general anesthesia
11073082|NCT04264676|Active Comparator|Metronidazole|supplement of metronidazole 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6(6 treatments totally),and every 6 weeks for CapeOX (4 treatments totally).
11073083|NCT04264676|Placebo Comparator|Placebo|supplement of identical-appearing placebo 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6 (6 treatments totally),and every 6 weeks for CapeOX 4 treatments totally).
11073084|NCT04264663|Experimental|furazolidone-tetracycline-containing quadruple|patients in furazolidone-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and furazolidone 100mg po bid for 14d
11073085|NCT04264663|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive Esomeprazole 40mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
11073086|NCT04264650|No Intervention|Control group|Standard care
11073087|NCT04264650|Experimental|One active intervention group|provided with COOL Passport, a mobile healthcare application
11073088|NCT04264650|Experimental|The other active intervention group|provided with access to the Health Promotion Cloud system and use of game-based interactive platforms along with COOL Passport
11073089|NCT04264637|Experimental|Azelastine hydrochloride 0.15% + Placebo|Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively.
11073090|NCT04264637|Experimental|Placebo + Azelastine hydrochloride 0.15%|Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively.
11073091|NCT04264624|Experimental|Guided Biofilm Therapy with Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the adjunctive treatment, he/she will also receive subgingival biofilm removal with Perioflow combined with Erythritol powder at sites with PD≥ 5 mm, including the experimental sites, prior to subgingival biofilm removal with USD.
11073092|NCT04264624|Active Comparator|Guided Biofilm Therapy without Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the control treatment, all teeth present will receive the application of disclosing agent, full-mouth supragingival and intra-sulcular biofilm removal with Airflow at sites with PD up to 4 mm, full mouth supra gingival calculus removal with USD, and subgingival biofilm removal with USD at sites with PD> 4 mm, including the experimental sites, as required.
11073093|NCT04264611|Experimental|Short Foot Exercise Group|The group that received the short foot exercise
11073094|NCT04264611|Experimental|Towel Curl Exercise Group|The group that received the towel curl exercise
11073095|NCT04264611|No Intervention|Control Group|The group that received no exercise
11073096|NCT04264598|Experimental|Experimental Adult Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
11073097|NCT04264598|Experimental|Experimental Children Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
11073098|NCT04264598|Experimental|Experimental Infant Group - Medium dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV Intervention: Biological: Three-dose regimen of medium dosage investigational sIPV
11073099|NCT04264598|Active Comparator|Control Infant Group - commercialized sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV Intervention: Biological: Three-dose regimen of commercialized sIPV
11073100|NCT04264598|Active Comparator|Control Infant Group - commercialized IPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV Intervention: Biological: Three-dose regimen of commercialized IPV
11073101|NCT04264585|Experimental|Standard ICBT|Clients assigned to the Standard ICBT condition will receive the standard version of the ICBT course, which consists of four lessons spread across the span of five weeks. Clients will receive five weeks of therapist support.
11073102|NCT04264585|Experimental|ICBT with Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive the Planning for Change lesson before Lesson 1 of the UniWellbeing Course.
11073103|NCT04264585|Experimental|ICBT with Booster|Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course.
11073104|NCT04264585|Experimental|ICBT with Motivational Interviewing and Booster|Clients assigned to the ICBT with Motivational Interviewing and Booster condition will receive access to both the Motivational Interviewing content (before Lesson 1 of the UniWellbeing Course) and the booster session (one month after ICBT course).
11073105|NCT04264572|Experimental|Medically Tailored Meals (MTM)|Participants in this arm will receive MTM for 12 weeks. Meals will be prepared and delivered by MANNA, a non-profit organization that has provided MTM for patients with chronic illnesses in Philadelphia and Southern New Jersey since 1990. MANNA will deliver 21 complete meals to the patient's home each week, providing 45-60 grams of carbohydrates per meal for optimal glucose control based on ADA guidelines and 100% of overall nutritional requirements based on USDA guidelines. In addition, children and any senior dependents for whom the participant is the primary caregiver will receive meals for the entire 12 weeks for no additional cost, as this is standard of care of MANNA services. MANNA registered dieticians will cater the program to meet the specific needs (e.g., dietary restrictions, cultural preferences). Investigators will provide information on community resources in the area, including food resources, for all patients.
11073106|NCT04264572|Experimental|MTM + tele-Medical Nutrition Therapy (MNT)|Patients in this arm will receive MTM services as well as tele-MNT over 12 months. The tele-MNT intervention will be delivered by a registered dietician within the Jefferson endocrine clinic, with assistance by other endocrine dieticians and fellows. In the first months, video visits focus on supporting individuals who are not selecting, preparing or purchasing their own meals. As the end of MTM services approaches, the intervention shifts to focus on the transition from MTM to self-directed eating. Based on Academy of Nutrition and Dietetics recommendations, each participant's MNT will include the following core features: nutrition assessment, intervention, care coordination, monitoring and evaluation. The following will also be addressed: nutrition prescriptions, nutrient intake, energy intake, glycemic index and load, alcohol consumption and physical activity. The schedule includes individual visits in the first 6 months and monthly group session in months 7-12.
11073107|NCT04264572|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with DM, which includes regular visits with a diabetes provider (primary care or endocrine), standard ADA information pamphlets and referral to 1) diabetes education classes and 2) nutrition counseling by dieticians and nurse practitioners. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and diabetes self-management (e.g., diabetes.org). The standard of care at Jefferson for patients with DM is to begin with a single group MNT visit lasting from 60-90 minutes. Each participant's need for additional sessions and general time-frame for follow-up is individually determined following the group session, based on patient preference. Historically, only about 2% of the Jefferson population engages in these services, thus minimizing dilution of the effect of the tele-MNT.
11073108|NCT04264559|Other|Healthy control group|This group will include 40 healthy adults.
11073109|NCT04264559|Other|CSAP group|This study will include 40 patients with chronic stable angina pectoris (CSAP).
11073110|NCT04264559|Experimental|Healthy intervention group|This group will include 40 healthy adults. They will receive moxibustion intervention.
11073111|NCT04264546|Experimental|Experimental Adult Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
11073112|NCT04264546|Experimental|Experimental Children Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
11073113|NCT04264546|Experimental|Experimental Infant Group - High dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
11073114|NCT04264533|Experimental|VC|12g Vitamin C+sterile water for injection; total volume: 50ml. 12ml/h; infusion pump；q12h.
11073115|NCT04264533|Placebo Comparator|Sterile water for injection|50ml water for injection. 12ml/h; infusion pump; q12h.
11073116|NCT04264520|Experimental|PTSD Psychoeducation + Skills Intervention|
11073117|NCT04264494|Experimental|PRP group|Fifty RA patients were injected intra-articularly with 3 doses of PRP in their joints
11073118|NCT04264494|Placebo Comparator|placebo group|Fifty RA patients were injected intra-articularly with 3 doses of saline in their joints.
11073119|NCT04264481|Experimental|Adductor Canal Block|Adductor Canal Block (Saphaenous Nerve Block) done under Ultrasonographic guidance with 5cc of Bupivacaine, 5cc of lidocaine diluted with 10 cc of Normal Saline
11073120|NCT04264481|Active Comparator|Intra-articular Steroid and Lignocaine|Intra-articular knee joint injection of 40mg triamcinolone and 1-2cc of lidocaine
11073121|NCT04264468||response group and the non-response group|Received neoadjuvant chemotherapy according to the routine clinical diagnosis and treatment, and evaluated the clinical efficacy once every two cycles of chemotherapy. According to the clinical efficacy, the patients were divided into the neoadjuvant chemotherapy response group and the non-response group (evaluation standard RECIST1.1).
11073122|NCT04264455||Biomonitor only|Patients receive a Biomonitor only
11073123|NCT04264455||Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor|Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
11073124|NCT04264455||ICD Implantation|Patients receive an ICD only
11073125|NCT04264442|Experimental|Losmapimod|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until study drug approval or until the study is discontinued by the Sponsor.
11073126|NCT04264429|Experimental|Infrapatellar strap|This group will perform the functional tests with the infrapatellar strap positioned on the painful knee.
11073127|NCT04264429|Experimental|Elastic Band|This group will perform the functional tests with the elastic band positioned on the painful knee.
11073128|NCT04264429|No Intervention|Control|This group will perform the functional tests without elastic band or infrapatellar strap positioned on the painful knee.
11073129|NCT04264416|Experimental|Whole-Body Electromyostimulation|16 weeks of dynamic WB-EMS: one supervised session per week, 20 min session; impulse-frequency: 85 Hz; impulse breadth 350 µs; intermittent 4-6 s; of impulse - 4 s of impulse break; impulse intensity RPE 7 (hard+ to very hard) on Borg CR 10 Scale.
11073130|NCT04264416|No Intervention|Non exercising control|...maintained physical activity and exercise habits during the study period.
11073131|NCT04264403|Active Comparator|Renal Denervation|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. If randomized to the Renal Denervation Group RDN procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
11073132|NCT04264403|No Intervention|Sham Procedere|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. In these patients no RDN will be performed.
11073133|NCT04264390|Experimental|M2M|Participants will receive and be instructed to follow-along with 4 weeks of movement-to-music videos. Participants will also receive periodic behavioral coaching calls from a telecoach.
11073134|NCT04264390|No Intervention|Wait-list control|Participants will wait 4 weeks before starting the M2M program. Participants will be instructed to resume their normal daily activities during the wait-period.
11073135|NCT04264377||Healthy|26 healthy subjects
11073136|NCT04264377||Asthma|26 subjects with asthma
11073137|NCT04264364||laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy
11073138|NCT04264364||endoscopic sleeve gastroplasty|Patients who underwent endoscopic sleeve gastroplasty
11073139|NCT04264325||Malignant pleural effusions : diaphragmatic ultrasound measure|
11073140|NCT04264299|Active Comparator|T tube drainage|Closure of common bile duct after choledocholithotomy over T tube
11073141|NCT04264299|Experimental|Primary closure|Primary closure of the common bile duct after choledocholithotomy
11073142|NCT04264299|Experimental|Antegrade stenting|Closure of common bile duct over antegrade biliary plastic stent
11073143|NCT04264286|Active Comparator|Esmolol group|Patients will receive intravenous esmolol after the end of the surgical procedure.
11073144|NCT04264286|Placebo Comparator|Placebo group|Patients will receive intravenous saline after the end of the surgical procedure.
11073145|NCT04264273||Participants with Parkinson´s disease.|Participants who fulfilled the diagnostic criteria of Parkinson´s disease.
11073146|NCT04264273||Participants without a neurological disease|25 neurologically healthy patients of the local otolaryngological clinic, in whom submandibular gland needle biopsy was performed due to a clinical indication.
11073147|NCT04264260|Experimental|colchicine group|The participants will receive colchicine starting from 2 tablets after meal twice per day (total 2 mg). The dose will be adjusted ranging from total minimum 1.5 mg to maximum 3 mg per day based on the condition and tolerance of the participant. One cycle of treatment is defined as 4 days treatment and 3 days off. The participants will receive repeated cycles till the participants quit the trial.
11073148|NCT04264234|Experimental|Placenta Previa|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography and MRI.
11073149|NCT04264221|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.
~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
11073150|NCT04264221|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
11073151|NCT04264208|Experimental|68Ga-RM2 PET MRI/68Ga PMSA11 PET/MRI|Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
11073152|NCT04264208|Experimental|68Ga-PSMA-11 PET MRI/68Ga-RM2 PET MRI|Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
11073153|NCT04264195|Experimental|Constraint-induced movement therapy|Constraint-induced movement therapy (PEPS-MIT)
11073154|NCT04264195|Active Comparator|Bimanual manipulation|Bimanual manipulation (PEPS-Bimanual)
11073155|NCT04264182|Experimental|Ultra-conservative ICD programming|Single VF zone programming strategy with maximal detection extension to avoid ICD shock delivery with monitoring-only VT detection zones
11073156|NCT04264182|No Intervention|Standard programming (physician discretion)|Usual care ICD programming, which is historically unchanged from ICD programming pre-LVAD
11073157|NCT04264169||• Study group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will be complicated by placenta accreta spectrum
11073158|NCT04264169||• Control group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will not be complicated by placenta accreta spectrum
11073159|NCT04264156|Experimental|160 mg/kg|Lucinactant for inhalation, 160 mg total phospholipids (TPL)/kg Delivered as an aerosol once, with up to 3 repeats of 80 mg/kg allowed within 36 hours of birth
11073160|NCT04264156|Sham Comparator|nCPAP Only|nCPAP Only as sham comparator. Bubble nCPAP is standard of care. Treatment time behind barrier to match active treatment delivery time
11073161|NCT04264143|Experimental|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
11073162|NCT04264130|Active Comparator|artemisinin-based combination therapies|subjects given Artemisinin-based combined therapies according to the study instruction
11073163|NCT04264130|Sham Comparator|non-artemisinin drugs|subjects given non artemisinin based combined therapies like describe in the study protocol
11073164|NCT04264117|Active Comparator|FlexAbility (Mesh-like irrigated tip catheter) group|
11073165|NCT04264117|Experimental|TactiCath (Contract force monitoring catheter) group|
11073166|NCT04264104|Experimental|Low dose neural mobilization|Four series of 10 repetitions of neural mobilization targeting the tibial nerve.
11073167|NCT04264104|Active Comparator|High dose neural mobilization|Eight series of 10 repetitions of neural mobilization targeting the tibial nerve.
11073168|NCT04264078|Experimental|anti-CD7 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
11073169|NCT04264052||CBE & MRIE|Forty healthy volunteers split in different age ranges (20-30 years n=10, 30-40 years n=10, 40-50 years n=10 and 50-60 years n=10) will undergo two airway assessments at rest and during exercise. The exercise assessments will be a continuous bronchoscopy during exercise (CBE-1st visit) and magnetic resonance imaging during exercise (MRIE-2nd visit) separated by at least three days to ensure for a sufficient cardiorespiratory and musculoskeletal recovery.
11073170|NCT04264039|Experimental|anti-CD19 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD19 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
11073171|NCT04264026|Experimental|Open Label|Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 60 mg MDMA.
11073172|NCT04264013|Placebo Comparator|Exercise|Exercise
11073173|NCT04264013|Active Comparator|Exercise + Diet|Exercise + eggs
11073174|NCT04264000|Experimental|platelet-rich plasma|The perineural injection with PRP is a potential treatment for peripheral entrapment neuropathy
11073175|NCT04264000|Active Comparator|5% dextrose|The perineural injection of 5% dextrose is a novel management for peripheral entrapment neuropathy
11073176|NCT04263987|Active Comparator|Holmium Laser Enucleation of Prostate|Traditional holmium laser enucleation of the prostate as currently performed
11073177|NCT04263987|Experimental|Moses Holmium Laser Enucleation of Prostate|holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.
11073178|NCT04263974|Experimental|Smartphone Application|"A protocol of exercises and general recommendations based on the current scientific evidence will be provided through a smartphone application. A follow-up of the use of the application will be carried out. The treatment protocol will last 6 months, during which a minimum of 4 weekly sessions of exercises will be carried out at home.
~Each pathology will have an unique program of exercises and recommendations."
11073179|NCT04263974|Active Comparator|Conventional Treatment|Those in this group will received the conventional treatment protocol provided within the Andalusian Public Health System. This will consist on the delivery of an exercise program and recommendations using a sheet of paper. Participants will be told to perform the exercises during 6 months, with minimum of 4 weekly sessions of exercise that will be carried out at home.
11073180|NCT04263961||COPD GOLD I - II|"Inclusion for mild-moderate COPD patients (n = 100):
~Age between 45-65 years.
~GOLD classification I or II according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].
~Cessation of smoking for ≥6 months.
~≥5 packyears of smoking.
~Absence of asthma.
~Written informed consent."
11073181|NCT04263961||Controls|"Inclusion for healthy controls (n = 100):
~Age between 45-65 years.
~Absence of COPD according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].
~Cessation of smoking for ≥6 months.
~≥5 packyears of smoking.
~Absence of asthma.
~Written informed consent."
11073182|NCT04263948|Experimental|Picado Arm|Patient Under Picado Monitoring plateform
11073183|NCT04263922|Experimental|Huaiqihuang group|Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
11073184|NCT04263922|Active Comparator|Valsartan Group|Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
11073185|NCT04263909|Experimental|sufentanil SL arm|Each patient will receive 30mcg of sufentanil SL prior to extubation in the operating room, and then as needed in the recovery room, guided by pain scores.
11073186|NCT04263896|Experimental|Participants receiving pre-operative laxative|Participants will receive 10 doses, 17g each, of polyethylene glycol 3350. They will be instructed to take 1 dose/packet each day for 10 days leading up to their surgery.
11073187|NCT04263896|No Intervention|Participants not receiving pre-operative laxative|Participants will not be given any laxatives.
11073188|NCT04263883|Active Comparator|Conventional treatment|Usual Care Group: Conventional treatment: moist hot pack. manual therapy, Therapeutic Exercise.Home program routine.
11073222|NCT04263623|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
11073189|NCT04263883|Experimental|Study or Experimental Group|"moist hot pack.
~manual therapy.
~Therapeutic Exercise.
~Home program routine. 5.3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill. For 10 weeks(3Times/week for 20 minutes)."
11073190|NCT04263870|Experimental|Sintilimab plus capecitabine and oxaliplatin|Subjects enrolled are treated with oral capecitabine 1000mg per m2 bid for two weeks（every 3 weeks）and intravenous oxaliplatin 130mg per m2（every 3 weeks）in combination with sintilimab 200mg (every 3 weeks)
11073191|NCT04263844|Active Comparator|Dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine 1 mcg/kgBB thirty minutes before induction
11073192|NCT04263844|Active Comparator|Midazolam|subject will receive premedication with intranasal midazolam 0,1 mg/kgBB thirty minutes before induction
11073193|NCT04263831|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).
~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be two dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.
~The dose levels will be as follows:
~Cohort 1: 1.0x10^6 IU/m^2/day. Cohort 2: 1.25x10^6 IU/m^2/day."
11073194|NCT04263818|Experimental|Motions during colonoscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
11073195|NCT04263805|Experimental|Vignette with research climate|Participants in this arm will receive vignettes describing a dilemma situation in research (e.g adding honorary author) with additional sentence describing research climate (i.e. an environment where their peer had detrimental practice in a similar situation)
11073196|NCT04263805|Active Comparator|Vignette without research climate|Participants in this arm will receive vignettes describing a dilemma situation in research without the additional sentence describing research climate
11073197|NCT04263792|Other|Biodistribution cohort|The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [18F]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
11073198|NCT04263792|Other|The Dynamic cohort|The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of [18F]fluoropropyl-trimethoprim.
11073199|NCT04263779|No Intervention|Default List (case manager level)|In this condition, all SNF options will be presented to case managers in Repisodic in rank order according to Repisodic's algorithm that weights dimensions such as Centers for Medicare & Medicaid Services (CMS) quality metric ratings, distance, and the match between SNF features and specific patient need. The list only includes SNFs that accept the patient's insurance.
11073200|NCT04263779|Experimental|P-SNF Top-Sorted List (case manager level)|"This condition is the same as the Default List, except that relevant providers (i.e., those meeting patient needs and located within a threshold distance to be determined per hospital) who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
~Situations in which there are no relevant P-SNFs will be flagged yet still assigned to this condition, in an intent-to-treat analysis; the default algorithm-based rank-ordered approach will be applied to all non-preferred providers."
11073201|NCT04263779|No Intervention|Full List/Full Map (patient level)|All SNF options, both P-SNFs and NP-SNFs (up to a maximum of 10 by default) that case managers preselected for patients will be presented to patients in rank order (according to Repisodic's algorithm, as described above). Patients will also have the option of viewing the default Repisodic map, which will show the SNFs on the list.
11073202|NCT04263779|Experimental|P-SNF List/P-SNF Map (patient level)|This is the same as the Full List condition, except that both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. Moreover, the link to viewing the optional P-SNF advantage video will be highlighted.
11073203|NCT04263766|Experimental|Healthy Adult Volunteers|The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.
11073204|NCT04263753|Experimental|conservative surgery for bladder in placenta accretta|
11073205|NCT04263740|Experimental|Kinesio Taping plus Traditional Physical Therapy|Kinesio Taping plus Traditional physical therapy
11073206|NCT04263740|Other|Traditional Physical Therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises.
11073207|NCT04263727||Asthma|Non-Interventional. Patients with asthma will be screened and enrolled into the active Asthma disease-specific cohort.
11073208|NCT04263727||Chronic Obstructive Pulmonary Disease (COPD)|Non-Interventional. Patients with COPD will be screened into the inactive COPD disease-specific cohort.
11073209|NCT04263727||Idiopathic Pulmonary Fibrosis (IPF)|Non-Interventional. Patients with IPF will be screened into the inactive IPF disease-specific cohort.
11073210|NCT04263714|Experimental|Exercise|All subjects will perform both aerobic and resistance exercise
11073211|NCT04263701|Active Comparator|Conventional Physiotherapy Group|45 minutes, 2 days in a week for 8 weeks
11073212|NCT04263701|Experimental|Dual Task Training Group|45 minutes, 2 days in a week for 8 weeks
11073213|NCT04263688||Immunotherapy effective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
11073214|NCT04263688||Immunotherapy Ineffective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
11073215|NCT04263675||GDM+|Women with history of gestational diabetes
11073216|NCT04263675||GDM-|Women without history of gestational diabetes
11073217|NCT04263662||Pre-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours prior to implementation of an analgesia-sedation algorithm.
11073218|NCT04263662||Post-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours after implementation of an analgesia-sedation algorithm.
11073219|NCT04263649||All subjects|patients who require a PICC
11073220|NCT04263636||Study group|Patients that underwent uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs (PanOptix or PanOptix toric, Alcon Laboratories, Inc., Fort Worth, TX, USA)
11073221|NCT04263636||Control group|Patients of similar age without cataract that their crystalline lens has not been replaced.
11073223|NCT04263623|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
11073224|NCT04263623|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
11073225|NCT04263610|Experimental|Non-Germany: Dimethyl fumarate standard scheme|"Part 1: Participants will receive Dimethyl fumarate (DMF) standard scheme from baseline to Week 16.
~Part 2: Participants achieving a Psoriasis Area and Severity Index (PASI) 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
11073226|NCT04263610|Experimental|Germany: Dimethyl fumarate standard scheme|Part 1: Participants will receive DMF standard scheme from Baseline to Week 16. Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40.
11073227|NCT04263610|Experimental|Germany: Dimethyl fumarate simplified scheme|"Part 1: Participants will receive DMF simplified scheme from Baseline to Week 16.
~Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
11073228|NCT04263597|Experimental|2'-fucosyllactose|"Patients will be randomized 1:1 to either receive 2FL at dose level 0 (starting dose) or placebo (2g oral glucose).
~Starting Dose for ages 0-5 years: 2.5 g/day; Ages 5.1-10 years: 5 g/day; Ages >10 years: 10 g/day
~After 20 patients are enrolled at the first dose level for an arm, enrollment of that arm will be paused. Randomization for the 20 patients will be unblinded and the safety and tolerability of 2FL doses will be compared to placebo for that arm. If 6/10 patients can take 80% of their planned doses, that dose level will be determined as tolerable and a dose escalation will be performed. If 5/10 patients are unable to take at least 80% of planned doses the dose will be determined to not be well tolerated and a dose de-escalation will be done.
~Dose escalation for ages 0-5 years: 5 g/day; Ages 5.1-10 years: 7.5 g/day; Ages >10 years: 15 g/day
~Dose de-escalation for ages 0-5 years: 1.25 g/day; Ages 5.1-10 years: 2.5 g/day; Ages >10 years: 5 g/day"
11073229|NCT04263597|Placebo Comparator|Placebo (2g oral glucose)|Patients will be randomized 1:1 to either receive 2FL at dose level 0 (starting dose) or placebo (2 g oral glucose).
11073230|NCT04263597|Experimental|Initial enrollment to establish safety|The investigators will enroll 5 patients of ages ≥10 years undergoing allogeneic HSCT. 2'-FL will be administered to these patients from day-7 until day+30 after HSCT at the starting dose. Once safety is determined the investigators will then enroll an additional 5 patients of ages 5-10 years and administer 2'FL to these patients at the proposed dose for this age group from day-7 to day+30 after HSCT. Once safety is determined, the investigators will enroll 5 patients of ages 0-5 years and administer 2'FL at starting doses to children from day-7 to day+30 after HSCT. Once safety is established in these patients we will proceed with the randomized portion of the study.
11073231|NCT04263584|Experimental|Copanlisib and R-CHOP chemotherapy|All patients will receive 6 cycles of R-CHOP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/m² (dose capped at 2 mg or 1 mg for individuals above 60 years of age), prednisolone 500 mg. In addition, copanlisib at a dose of 60 mg will be administered on days 1 and 8 of each 21-day cycle of R-CHOP in the first 6 patients. If dose limiting toxicity (DLT) occurs in no more than one out of these 6 patients during cycle 1, additional 6 patients at 60 mg will be enrolled and treated for at least 1 cycle before opening the phase II portion of the study. If a DLT is observed in 2 or more of the first 6 patients during cycle 1 the dose of copanlisib will be reduced to 45 mg on days 1 and 8 for the next 6 patients. The data of the safety run-in analysis (first 12 patients) will be presented to the Data Safety Monitoring Board and the recommended phase 2 dose will be determined.
11073232|NCT04263558|Active Comparator|LHF|Long intervention (16 sessions) High parental involvement (5 sessions) Feedback
11073233|NCT04263558|Active Comparator|LHN|Long intervention (16 sessions) High parental involvement (5 sessions)
11073234|NCT04263558|Active Comparator|LLF|Long intervention (16 sessions) Low parental involvement (Brochure) Feedback
11073235|NCT04263558|Active Comparator|LLN|Long intervention (16 sessions) Low parental involvement (Brochure)
11073236|NCT04263558|Active Comparator|SHF|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions) Feedback
11073237|NCT04263558|Active Comparator|SHN|Short intervention (8 sessions, group) and 8 sessions web-based High parental involvement (5 sessions)
11073238|NCT04263558|Active Comparator|SLF|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure) Feedback
11073239|NCT04263558|Active Comparator|SLN|Short intervention (8 sessions, group) and 8 sessions web-based Low parental involvement (Brochure)
11073240|NCT04263545|Active Comparator|Intervention|
11073241|NCT04263545|Placebo Comparator|Standard Care|
11073242|NCT04263519|Active Comparator|Low Serum Level|Stable Blood Tacrolimus of 2-5 ng/ml.
11073243|NCT04263519|Active Comparator|High Serum Level|Stable Blood Tacrolimus of 5.1-10 ng/ml.
11073244|NCT04263506|Experimental|Vignette with supervisor's opinion|Participants in this arm will receive vignettes with an additional sentence describing supervisor's opinion (i.e. supervisor does not oppose to detrimental research practice)
11073245|NCT04263506|Active Comparator|Vignette without supervisor's opinion|Participants in this arm will receive vignettes without an additional sentence describing supervisor's opinion.
11073246|NCT04263493|Active Comparator|Early mobilization (loading)|"This constitutes the currently accepted regime and is therefore considered the control group.
~Cast/orthopedic boot for 6 weeks No weight bearing: week 0-2 Partiel weightbearing from week 3 Full weightbearing from week 7 ROM exercises 5 times a day from week 3"
11073276|NCT04263298|Experimental|Fulvestrant Group|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
11073277|NCT04263298|Active Comparator|Capecitabine Group|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
11073247|NCT04263493|Experimental|Delayed mobilization (loading)|Loading of the Achilles tendon is delayed for 6 weeks. Cast/orthopedic boot for 12 weeks No weight bearing: week 0-6 Partiel weightbearing from week 7 Full weightbearing from week 13 ROM exercises 5 times a day from week 3
11073248|NCT04263480|Experimental|Arm A: Carfilzomib + Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated. Patients will receive in addition Carfilzomib for two years.
11073249|NCT04263480|Active Comparator|Arm B: Ibrutinib|Patients will be treated with Ibrutinib until evidence of progressive disease or no longer tolerated.
11073250|NCT04263467|Experimental|Intervention group|Participants in the intervention group will receive a 6-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
11073251|NCT04263467|Experimental|Control group|Participants in the control group will receive standard oncological treatments; immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
11073252|NCT04263454|Other|Healthy Control|All healthy control participants will undergo the same screening and experimental procedures. Healthy controls must report no other medical conditions ( including fibromyalgia) to be considered for inclusion. All healthy controls will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
11073253|NCT04263454|Experimental|Fibromyalgia|All fibromyalgia participants will undergo the same screening and experimental procedures. However, fibromyalgia participants will need to meet 2010 American College of Rheumatology diagnostic criteria for fibromyalgia. All fibromyalgia participants will have an MRI scan performed both before and 3 hours post 0.4ng/kg endotoxin injection.
11073254|NCT04263441|Experimental|NICE Intervention|The proposed intervention will engage clients in the health care enrollment and navigation process in-person, at the time of the HIV testing event. Subjects will be asked to share thoughts on the satisfaction survey.
11073255|NCT04263441|No Intervention|Control Intervention|Subjects will be offered a handout on how to enroll in healthcare coverage This group will be provided with the site's standard healthcare enrollment and linkage to care, which is specific to the health care clinic they are visiting. Subjects will be asked to share thoughts on the satisfaction survey.
11073256|NCT04263428|Experimental|Irregular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights, including an adaptation night and a baseline night of 7.5 h time in bed (0:00-7:30). Afterwards, they are instructed to sleep in bed on a schedule alternated between 6 h, i.e. 1:30-7:30, and 9 h, i.e. 22:30-7:30).
11073257|NCT04263428|No Intervention|Regular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights of 7.5 h time in bed (0:00-7:30).
11073258|NCT04263415|Placebo Comparator|group P|once-weekly injection with placebo pen.
11073259|NCT04263415|Experimental|group S|Once-weekly application of semaglutide
11073260|NCT04263402|Experimental|Methylprednisolone(<40mg/d)|
11073261|NCT04263402|Experimental|Methylprednisolone(40~80mg/d)|
11073262|NCT04263389||control group|control group is a normal matched group.
11073263|NCT04263389||study group|study group is a group of chronic mechanical cervical pain
11073264|NCT04263363|Experimental|CDS pathway|When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP
11073265|NCT04263350|Experimental|Treatment A|Fixed-dose combination mini-tablet
11073266|NCT04263350|Experimental|Treatment B|Separate products taken at the same time
11073267|NCT04263337||Low Cognitive Functioning/Low Concussion History|Former NFL players with low cognitive function and low concussion history will be included in this group.
11073268|NCT04263337||High Cognitive Functioning/ High Concussion History|Former NFL players with high cognitive function and high concussion history will be included in this group.
11073269|NCT04263337||Low Cognitive Functioning/High Concussion History|Former NFL players with low cognitive function and high concussion history will be included in this group.
11073270|NCT04263337||High Cognitive Functioning/Low Concussion History|Former NFL players with high cognitive function and low concussion history will be included in this group.
11073271|NCT04263337||Healthy Male Controls|Healthy male demographically matched controls will be included in this group.
11073272|NCT04263324|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
11073273|NCT04263324|No Intervention|Control group|No intervention
11073274|NCT04263311|Experimental|Community Health Workers (CHW) treatment group|There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
11073275|NCT04263311|No Intervention|Control group|There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes
11073279|NCT04263272|Experimental|Upper Body Exercise|Seated upper body circuit training program for 16-weeks. Frequency - 1 to 3 one-hour sessions per week.
11073280|NCT04263259|Experimental|Attentional Bias Modification|Participants complete attentional bias modification using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
11073281|NCT04263259|No Intervention|Attentional Bias Control|Participants complete attentional bias assessment-only using a dot probe task on a mobile device up to 5 times per day for a 28-day period (80 trials per assessment).
11073282|NCT04263246|Experimental|PhytoDyNAmic|Six capsules per day b.i.d.
11073283|NCT04263246|Placebo Comparator|Inulin|Six capsules per day b.i.d.
11073284|NCT04263233||Other|This program, which is provided for all patients new to dialysis at the participating units, will be evaluated by assessing patient clinical outcomes and the results of surveys measuring patient-reported symptoms, quality of life, knowledge and activation. In addition, satisfaction with the program will be assessed.
11073285|NCT04263220|Experimental|Prototype exoskeleon 1|The experimental trial will be performed with the prototype exoskeleton
11073286|NCT04263220|Experimental|Prototype exoskeleon 2|The experimental trial will be performed with the prototype exoskeleton
11073287|NCT04263220|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
11073288|NCT04263207||anti-Tat Ab positive subjects|
11073289|NCT04263207||anti-Tat Ab negative subjects|
11073290|NCT04263194|Experimental|Default Mode Network (DMN)|The treatment will consist in the individually tailored stimulation of a DMN node (i.e. left inferior parietal lobe).
11073291|NCT04263194|Experimental|Central Executive Network (CEN)|The treatment will consist in the individually tailored stimulation of a CEN node (i.e. left dorsolateral prefrontal cortex).
11073292|NCT04263194|Placebo Comparator|Placebo|The treatment will consist in targeting the upper part of the scalp (i.e. CZ) while using a sham rTMS coil.
11073293|NCT04263181||Cohort 0|"A technical run-in consisting of five patients meeting enrollment criteria for any other cohort
~Any of the following:
~Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3).
~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle.
~Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 of each 28-day cycle.
~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter."
11073294|NCT04263181||Cohort 1|"Patients treated with cytarabine/idarubicin induction therapy
~Patients will receive a standard cytarabine/idarubicin induction, which includes cytarabine 200 mg/m2 CIVI in 0.9% normal saline over 24 hours for 7 consecutive days (Days 1-7) and idarubicin 12 mg/m2 per day in 0.9% normal saline over 15-30 minutes for 3 consecutive days (Days 1-3). Standard dose modifications are permitted at the treating physician's discretion."
11073295|NCT04263181||Cohort 2|"Patients treated with decitabine
~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Standard dose modifications are permitted at the treating physician's discretion, including de-escalation strategies in responding patients."
11073296|NCT04263181||Cohort 3|"Patients treated with azacitidine
~Patients will receive azacitidine 75 mg/m2/day as a subcutaneous injection on Days 1-7 of each 28-day cycle. Standard dose modifications are permitted at the treating physician's discretion and intravenous administration may be substituted."
11073297|NCT04263181||Cohort 4|"Patients treated with decitabine + venetoclax
~Patients will receive decitabine 20 mg/m2/day as a 1-hour infusion on consecutive Days 1-5 or 1-10 (per treating physician discretion) of each 28-day cycle. Patients will receive venetoclax PO 100 mg on Day 1, 200 mg on Day 2, and 400 mg daily thereafter. Standard dose modifications are permitted at the treating physician's discretion, including de-escalation strategies in responding patients."
11073298|NCT04263168|Experimental|Bariatric Surgery Candidates|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
11073299|NCT04263168|Sham Comparator|Laparoscopy Cholecystectomy|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
11073300|NCT04263155|Experimental|Experimental: The Body Project for high school young women|The 4-hour Body Project workshop delivered by trained peer leaders
11073301|NCT04263155|No Intervention|Control|The business-as-usual comparison group does not participate in the Body Project but may engage in any other programs or services they normally would
11073302|NCT04263142|Experimental|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11073303|NCT04263142|Experimental|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11073342|NCT04262882|Experimental|Multilevel Family Planning Intervention|A multi-level, community-based intervention delivered in groups of couples to increase contraceptive uptake, reduce discontinuation, and reduce the incidence of unintended pregnancy, and improve intermediate outcomes (knowledge, attitudes, norms, communication, equity).
11073304|NCT04263142|Experimental|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11073305|NCT04263142|Experimental|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11073306|NCT04263142|Experimental|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11073307|NCT04263116|Experimental|BAM group|Balloon assisted maturation
11073308|NCT04263116|Experimental|NO BAM|NO Balloon assisted maturation
11073309|NCT04263103|Experimental|Experimental group with SJ-RS-WL2015|Item code: SJ-RS-WL2015, a visual training software program, 15 minutes of one section, twice a day, and for 1 year
11073310|NCT04263103|No Intervention|control group|No special treatment, but observation
11073311|NCT04263090|Experimental|Rigosertib + Nivolumab|Rigosertib + Nivolumab in metastatic KRAS+ lung adenocarcinoma patients
11073312|NCT04263077|Placebo Comparator|PLACEBO|IN THE PLACEBO GROUP, THE ENDS OF THE TAPES WILL BE APPLIED NO TENSION WITHOUT OVERLAPPING EACH OTHER.
11073313|NCT04263077|Other|50% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 50% TENSION.
11073314|NCT04263077|Other|75% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 75% TENSION.
11073315|NCT04263077|Other|100% TENSION GROUP|KINESIOTAPE WILL BE APPLIED WITH 100% TENSION.
11073316|NCT04263064|Active Comparator|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine).
11073317|NCT04263064|Experimental|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
11073318|NCT04263051|Experimental|UCPVax + Nivolumab|"UCPVax vaccine (1 mg)
~Nivolumab (480 mg)"
11073319|NCT04263051|Other|Standard second line chemotherapy|"Standard second line chemotherapy at the choice of the investigator.
~This arm will permit to assess the good calibration of the hypothesis on the experimental arm."
11073320|NCT04263038|Active Comparator|Anticoagulation|Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.
11073321|NCT04263038|Placebo Comparator|No anticoagulation|Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.
11073322|NCT04263025|Experimental|CLARIX CORD 1K|They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).
11073323|NCT04263025|Active Comparator|Controls|They will undergo RARP without adjunctive CLARIX® CORD 1K.
11073324|NCT04263012||Patients with an implanted LVAD|Patients which received an implantation of a left ventricular assist device (LVAD) at the University Hospital Basel since 2014
11073325|NCT04262999||drug sodium valproate|individuals on antiepileptic drug sodium valproate for at least 1 year at the time of participation of the study.
11073326|NCT04262999||drug levetiracetam|individuals on antiepileptic drug levetiracetam monotherapy for at least 1 year at the time of participation of the study.
11073327|NCT04262999||drug sodium valproate + levetiracetam|individuals on antiepileptic drug sodium valproate + levetiracetam combination therapy for at least 1 year at the time of participation of the study.
11073328|NCT04262999||control group|systemically healthy individuals
11073329|NCT04262973|Experimental|experimental group|The experimental group will not only receive six-hour dementia care course, but also a half-day interprofessional education workshop, maintain a six-month interprofessional practice model, and join interprofessional practice experience-sharing conferences.
11073330|NCT04262973|Active Comparator|control group|The control group will only receive six-hour dementia care course.
11073331|NCT04262960|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
11073332|NCT04262960|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
11073333|NCT04262947|Active Comparator|Conventional Method|Placement of peripheral venous catheter using conventional methods
11073334|NCT04262947|Experimental|VeinViewer Visualization Only|Use of a VeinViewer to visualize the most suitable target. Once the target has been identified and marked, the device will be placed aside and the peripheral venous catheter will be placed using conventional methods
11073335|NCT04262947|Experimental|Constant Imaging with VeinViewer|Identification of the most suitable target and placement of a peripheral venous catheter under constant imaging with a VeinViewer
11073336|NCT04262934|Experimental|Cholecalciferol treatment|Arm A : Cholecalciferol 100.000 UI - oral - every month
11073337|NCT04262934|Active Comparator|No treatment|Arm B : No vitamin D administration
11073338|NCT04262908||Patients implanted with hip or knee prostheses|Patients who had hip or knee arthroplasty will be followed and asked at 3-months visit if they resumed their job or not. In both cases, further informations will be gathered
11073339|NCT04262895|Experimental|TTI-0102 2 mg/day|TTI-0102 2 mg/day
11073340|NCT04262895|Experimental|TTI-0102 4 mg/day|TTI-0102 4 mg/day
11073341|NCT04262895|Placebo Comparator|Placebo|Placebo
11073792|NCT04259606|Placebo Comparator|Calcined Magnesia|Placebo consists in calcined magnesia, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
11073343|NCT04262882|Active Comparator|Time and attention-matched control|A community sanitation intervention delivered in groups of couples to increase at-home and community hygiene practices.
11073344|NCT04262869|Experimental|Arm I (squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, paclitaxel IV over 3 hours and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV every 4 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11073345|NCT04262869|Experimental|Arm II (non-squamous NSCLC)|Patients receive carboplatin IV over 15-60 minutes, pemetrexed IV over 10 minutes and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV and pemetrexed IV every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11073346|NCT04262856|Experimental|Arm 1 (zimberelimab monotherapy)|Participants will receive zimberelimab monotherapy by IV infusion.
11073347|NCT04262856|Experimental|Arm 2 (domvanalimab and zimberelimab combination therapy)|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.
11073348|NCT04262856|Experimental|Arm 3 (domvanalimab, zimberelimab, and etrumadenant combination therapy)|Participants will receive oral etrumadenant in combination with zimberelimab and domvanalimab by IV infusion
11073349|NCT04262843|Experimental|Treatment (fludarabine, TMLI, HCT, cyclophosphamide)|"CONDITIONING: Patients receive fludarabine IV QD on days -7 to -5, and undergo TMLI BID on days -4 to 0 in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV QD on days 3-4 in the absence of disease progression or unacceptable toxicity. Beginning on day 5, patients also receive granulocyte colony stimulating factor and tacrolimus/mycophenolate mofetil per institutional standard."
11073350|NCT04262830||Cohort 1: Clinical Indication for Cardiac MRI|Individuals who are 13-25 years of age with a history of prior cancer treatment, which may include anthracyclines or chest radiation, with clinical indication for cardiac MRI.
11073351|NCT04262830||Cohort 2: Non-Clinically Indicated Cardiac MRI|Individuals who are 13-25 years of age with a history of prior cancer treatment, which may include anthracyclines or chest radiation, without clinical indication for cardiac MRI.
11073352|NCT04262817|Experimental|E-cigarette flavor|In this arm, participants will receive two experimental e-cigarette flavors
11073353|NCT04262817|Experimental|E-cigarette nicotine form|In this arm, participants will receive two forms of nicotine in an e-cigarette
11073354|NCT04262804|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
11073355|NCT04262804|Active Comparator|Trastuzumab & Chosen Chemotherapy|The dosage and administering of Trastuzumab is 8 mg/kg loading dose then 6 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
11073356|NCT04262791|Experimental|Healthy Volunteers|Healthy participants will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2.
11073357|NCT04262791|Experimental|Participants With Atopic Dermatitis (AD)|Participants with AD will be monitored overnight for two consecutive nights at an inpatient setting to collect wrist actigraphy and videography data. Sleep headband (at sites where polysomnography (PSG) is available and performed) data will be collected on Night 2. Participants will also be monitored at home via wrist actigraphy, sleep headband when available in the outpatient setting for 7 consecutive nights.
11073358|NCT04262765|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:
~Age: 18-49 years
~Weight: 55-105 kg
~Height: 163-188 cm
~BMI 18.5-29.9 kg/m²"
11073359|NCT04262752|Experimental|chronically constipated people|Adults with chronic constipation due to either neurogenic bowel dysfunction (NBD) as consequence of a neurogenic condition such as Multiple sclerosis or Parkinson Disease, or to unkwon origin (Idiopathic No-NBD)
11073360|NCT04262739|Experimental|NYH817G|
11073361|NCT04262739|Experimental|NYH100P|
11073362|NCT04262739|Experimental|NYH817G and NYH100P|
11073363|NCT04262726|Experimental|REMOTION + TAU|Participants in the REMOTION group receive REMOTION in addition to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
11073364|NCT04262726|Active Comparator|TAU|Participants in TAU receive psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
11073365|NCT04262713|Other|Patients implanted with Meije duo stem size 1 or 2|"Among this arm, patients that meet criteria ( weight>
~60kg and / or a long neck / varus and / or a DEVANE score ≥ 4 ) will perform hip X ray"
11073366|NCT04262700|Experimental|Intervention 01|Subjects use new LifeScan provided BGMS for 12 weeks.
11073367|NCT04262687|Experimental|Immunotherapy + chemotherapy|Xelox bevacizumab plus pembrolizumab every 3 weeks up until disease progression, unacceptable toxicity, refusal by the patient, withdrawal of consent, pregnancy or decision by the investigator.
11073368|NCT04262674|Experimental|Cognitive-motor training|Simultaneous cognitive-motor training (i.e. exergame) and strength training
11073369|NCT04262674|No Intervention|Control|Passive control group
11073370|NCT04262661|Experimental|NNC0472-0147 Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0472-0147.
11073371|NCT04262661|Placebo Comparator|Placebo Part 1|Part 1: Each cohort will consist of 8 healthy subjects - 2 subjects will receive a single s.c. dose of placebo.
11073372|NCT04262661|Experimental|NNC0472-0147 Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM. 9 subjects will receive once daily s.c. doses of NNC0472-0147 for 14 days
11073373|NCT04262661|Active Comparator|Insulin glargine Part 2|Part 2: Each cohort will consist of 12 subjects with T2DM - 3 subjects will receive once daily s.c. doses of insulin glargine for 14 days.
11073374|NCT04262648|Experimental|Treatment|
11073375|NCT04262648|Placebo Comparator|Control|
11073864|NCT04259099||QUALITY OF LIFE QUESTIONNAIRES|The group is anticipated to consist of 150 female and male with osteoporosis, osteopenia or normal bone mineral density.
11073376|NCT04262635|Experimental|ArmA Cetuximab plus Capecitabine|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
11073377|NCT04262635|Active Comparator|ArmB Cetuximab|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
11073378|NCT04262622|Active Comparator|Group TEA|
11073379|NCT04262622|Active Comparator|Group RSB|
11073380|NCT04262596|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
11073381|NCT04262596|Active Comparator|Traditional decision aid booklet|A traditional patient decision aid bookelet that includes provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
11073382|NCT04262570|Experimental|SMA patients (therapy arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~Magnetic Resonance Imaging (MRI) of lower leg
~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
11073383|NCT04262570|Active Comparator|SMA patients (control arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~Magnetic Resonance Imaging (MRI) of lower leg
~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
11073384|NCT04262557|Experimental|Sunrise+PSG|PSG and Sunrise® will be set at the patient's home by IC@dom. The first night, the patient will be equipped by both PSG and Sunrise® and only by the Sunrise® for the two following nights.
11073385|NCT04262544|Experimental|mHealth|Intervention group
11073386|NCT04262544|Active Comparator|Usual Care|Control group
11073387|NCT04262518|Other|Outcomes4Me App Users|This cohort will download and use the Outcomes4Me mobile app for breast cancer.
11073388|NCT04262505|Experimental|Mediterranean Diet Group (Group A)|The intervention is based on components of the traditional Mediterranean diet which is primarily a plant based diet and emphasises intakes of vegetables, whole grains and fruit with the main added fat being extra virgin olive oil.The diet will be modified and tailored to cultured preferences by the registered dietitian. Participants will be informed of their diet allocation group during the baseline visit and will commence the diet the following day or as soon as is feasible for 12 weeks. Participants will be provided with printed resources specifically designed to explain the components of the Mediterranean diet and how it will be followed. A food hamper will be provided to demonstrate the key staple foods (canned legumes, tinned salmon, extra virgin olive oil and nuts) of the Med diet and to encourage adherence to same.
11073389|NCT04262505|Experimental|Healthy Eating Group (Group B)|Participants assigned to the Healthy Eating group will be advised to adhere to the current healthy eating guidelines and will be provided with printed resources to inform them of these guidelines and sample meal plans that are readily available on the Healthy Ireland website. A food hamper will also be provided to demonstrate this type of eating pattern (low fat yogurt and cheeses and wholegrain cereals).
11073390|NCT04262479|Experimental|GAD-vaccination with vitamin D suppletion|"Each study participant will receive 3 injections of 4 µg GAD-alum (Diamyd). The first, second and third injection will be one month apart.
~Vitamin D (Divisun 2000 IE) will be given from one month before the first injection of GAD-alum until one month after the third injection (120 days in total)."
11073391|NCT04262466|Experimental|IMC-F106C - Arm A - Phase 1|Dose Escalation
11073392|NCT04262466|Experimental|IMC-F106C and an anti-PD(L)1 agent - Arm B - Phase 1|Dose Escalation
11073393|NCT04262466|Experimental|IMC-F106C - Phase 2|Monotherapy dose expansion
11073394|NCT04262427|Experimental|Single Group Assignment|Cyclophosphamide 50mg PO OD for 3 weeks as monotherapy followed by cyclophosphamide 50mg PO OD with pembrolizumab 200mg IV every 3 weeks
11073395|NCT04262401|Active Comparator|Standard health coaching|Standard health coaching to increase health behaviors
11073396|NCT04262401|Experimental|Habit-focused health coaching|Health coaching enhanced with a focus on habit formation using a mobile application called Habit Design
11073397|NCT04262388|Experimental|Window|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with locally advanced disease (window) and treated with durvalumab 1500 mg given by IV x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to definitive therapy (e.g. surgery)."
11073398|NCT04262388|Experimental|Metastatic|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with recurrent/metastatic (metastatic) disease and treated with durvalumab 1500 mg given by IV every 4 weeks and oleclumab 3000 mg given by IV every 2 weeks x 4 doses then IV every 4 weeks till disease progression, toxicity, withdrawal of subject consent, or another discontinuation reason."
11073399|NCT04262375|Experimental|Durvalumab and Oleclumab|A single dose level for oleclumab and durvalumab will be used, comprising of Oleclumab 3000 mg IV Q2W for 4 doses, then Q4W AND Durvalumab 1500 mg IV Q4W
11073400|NCT04262349|Experimental|intervention|"Every week because of differences in the number of pregnant women who attended the school participating women were divided into two groups using a random number table created in the program via the computer itself. The purpose of the study was explained to pregnant women, informed consent form and data collection tools of the study were collected by face to face interview technique. In the first interview to all pregnant women; Personal Information Form, Course Information Form, Pittshburg Sleep Quality Index (PUKI) and General Self-Efficacy Scale were applied. Pregnant women in the intervention group were given a two-session training program to improve sleep quality and Sleep Guide and Safe Baby Sleep Conditions Brochure."
11073431|NCT04262102|Experimental|Group 3 (HFV_SF)|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
11073899|NCT04258826|Placebo Comparator|Placebo|Placebo administered orally in one of two study periods.
11073401|NCT04262349|No Intervention|control|"Pregnant women in the control group were subjected to routine practice without any training given by the researcher. Four weeks after the completion of the sleep training, all pregnant women were contacted by telephone and the data collection tools were applied for the second time and the final test applications were completed. After completion of the data collection process made a new plan for training to improve the quality of sleep to pregnant women in the control group and the Sleep Guide and Safe Baby Sleep Conditions Brochure is given."
11073402|NCT04262336|Active Comparator|DB-020 for Injection, 12%/placebo|dosage
11073403|NCT04262336|Active Comparator|DB-020 for Injection, 25%/placebo|dosage
11073404|NCT04262310||Study Aims|To obtain normative data (median, 10th and 90th percentile) as well as inter-individual coefficient of variation (COV, assessed by [SD/mean]) with approximately 15 participants in each age group: 18-30, 31-45, 46-60, and 60-70 years old. To assess intra-individual COV [assessed by [SD/mean]. To assess effect of standard diets containing 16.25 or 32.5 g fiber/day during the two 24 hour periods before and during the measurement of permeability
11073405|NCT04262297||Prosthesis users|Prosthesis users with transtibial amputation
11073406|NCT04262297||Able-bodied Controls|Prosthesis users' age-, sex- and dominancy-matched healthy controls
11073407|NCT04262258|Experimental|Blueberry Enriched Diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
11073408|NCT04262245|Other|irrigation activation method|Irrigation activation is a crucial stage of root canal treatment. Therefore, the effect of activation methods on post treatment is an important fact for the comfort of patients.
11073409|NCT04262232|Experimental|Ca-HELP|This intervention arm will consist of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
11073410|NCT04262219|Experimental|iShare|Participants will be asked to listen to a podcast intervention.
11073411|NCT04262206|Experimental|atorvastatin 40mg|40mg atorvastatin po qd from consent to study end
11073412|NCT04262206|Placebo Comparator|Placebo|matching placebo po qd from consent to study end
11073413|NCT04262193|Placebo Comparator|Suvorexant placebo|Placebo (inert) tablet
11073414|NCT04262193|Experimental|Suvorexant 10mg|Suvorexant 10mg tablet
11073415|NCT04262193|Experimental|Suvorexant 20mg|Suvorexant 20mg tablet
11073416|NCT04262180|Experimental|Base intervention- Fitbit with EHR integration|All participants will receive a first-line intervention (i.e., Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal) and will be evaluated for response/non-response every 4 weeks until week 20.
11073417|NCT04262180|Experimental|Nonresponders -Stepped up to Online gym|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Online gym."
11073418|NCT04262180|Experimental|Nonresponders -Stepped up to Coaching calls|"Non-responders to 'fitbit with EHR integration' will be randomized to be stepped up to one of two augmentation strategies(either Online gym or coaching calls). This arm will be stepped up to Coaching calls."
11073419|NCT04262167|Experimental|Low Dose LSCs (cohort 1) n = 4 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 100 million Lung Spheroid Stem Cell (LSC) infusion.
11073420|NCT04262167|No Intervention|Usual Care (Cohort 1) n = 2 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
11073421|NCT04262167|Experimental|High Dose LSCs (Cohort 2) n = 12 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 200 million LSC infusion.
11073422|NCT04262167|No Intervention|Usual Care (Cohort 2) n = 6 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
11073423|NCT04262154|Experimental|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
11073424|NCT04262141|Experimental|IMG-7289 in ET and PV Patients|"Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered:
~The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity.
~The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity."
11073425|NCT04262128||Type 2 Diabetes Mellitus|women age 60-75 years with uncomplicated type 2 diabetes mellitus
11073426|NCT04262128||Healthy Controls|healthy women age 60-75 years
11073427|NCT04262115|Experimental|AM-EX|Participants in this group will be prescribed morning aerobic exercise.
11073428|NCT04262115|Experimental|PM-EX|Participants in this group will be prescribed evening aerobic exercise.
11073429|NCT04262102|Active Comparator|Group 1 (SD_SF)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
11073430|NCT04262102|Experimental|Group 2 (SD_BLW)|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
11073900|NCT04258813|Experimental|Control|40 PCP clinics; 400 patients
11073432|NCT04262102|Experimental|Group 4 (HFV_BLW)|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
11073433|NCT04262089|Experimental|primary dMMR uterine cancer patients|primary dMMR uterine cancer patients
11073434|NCT04262089|Experimental|primary POLE-EDM uterine cancer patients|primary POLE-EDM uterine cancer patients
11073435|NCT04262076|Experimental|Combination of pulpine with Polyamidoamine Dendrimer|Removal of Caries infected dentin from the walls and floor of the cavity and then apply polyamidoamine Denrimer for 30 secs ,then washed out of the cavity followed by placement of Pulpine over affected Dentin.
11073436|NCT04262076|Active Comparator|Pulpine|Removal of Caries infected dentin from the walls and the floor of the cavity followed by application of Pulpine over affected Dentin.
11073437|NCT04262063|Experimental|tell play do technique|Tell play do technique with a dental imitation toy and using euphemisms instead of demonstrating on a model or observing one. Tell play do technique provides a better explanatory concept of the dental procedure and can lead to more cooperation of the children patients which can influence the dental treatment in a good and positive way.
11073438|NCT04262063|Active Comparator|tell show do technique|Tell show do is the gold standard of the non-pharmacological behavior management techniques. It is based on the principle of learning theory and it is performed by the dentists themselves . It is the most important behavior modification technique practiced by dentists and it is commonly used for management of children anxiety in the first dental visit .
11073439|NCT04262050|Experimental|TMS + tDCS group|
11073440|NCT04262050|Experimental|sham TMS + tDCS group|
11073441|NCT04262050|Experimental|tDCS group|
11073442|NCT04262050|Experimental|TMS group|
11073443|NCT04262037|Experimental|HPPV|will receive high frequency positive pressure ventilation during cardiopulmonary bypass at tidal volume 2 ml/kg and respiratory rate 80. Lung ultrasound will be done at the beginning and end of surgery
11073444|NCT04262037|Experimental|CPPV|will receive continuous positive airway pressure of 10 cmH2o during the bypass. Lung ultrasound will be done at the beginning and end of surgery
11073445|NCT04262037|No Intervention|Control|will be disconnected from the ventilation (passive deflation). Lung ultrasound will be done at the beginning and end of surgery.Lung ultrasound will be done at the beginning and end of surgery
11073446|NCT04262024|Active Comparator|Cabergoline with health education by a nurse|Women with hyperprolactiemia scheduled for cabergoline therapy 0.5 mg twice weekly for one month plus health education by a nurse.
11073447|NCT04262024|Active Comparator|cabergoline without health education by a nurse|Women with hyperprolactiemia scheduled for cabergoline therapy 0.5 mg twice weekly for one month without health education by a nurse.
11073448|NCT04262011|Other|immediate treatment|After randomization, patients who are allocated to the immediate treatment group will receive treatment.
11073449|NCT04262011|Other|postponed treatment|After randomized patients will be allocated to this group, they will wait for the follow-up of the study to receive delayed treatment.
11073450|NCT04261998|Experimental|Service-learning group|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
11073451|NCT04261998|No Intervention|Control group|Control group will perform a physical therapy program for heart transplantation, but without meeting real patients. One meeting will be performed in order to establish groups and search information based on evidence in scientific databases.
11073452|NCT04261985|Active Comparator|Mobile Phone Obesity Intervention|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the intervention arm. Every week for 4 weeks, caregivers will receive 4 interactive multi-media phone prompts to support the intervention's targeted topics. Each mobile phone prompt starts with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share their goal/s, perceived barriers, questions, tips and strategies that may be helpful to other participants. Each week, caregivers will also receive strategies, and individual and group feedback on changing unhealthy behaviors. The content shared by caregivers are summarized by a team research assistant and sent back to participants at the end of every week.
11073453|NCT04261985|No Intervention|Control|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the control (no intervention) arm. Every week for 4 weeks, these caregivers will receive 4 interactive multi-media phone prompts around managing common illness in young children (i.e. fever, vomiting, constipation, etc.) Each mobile phone prompt will start with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share questions and strategies that may be helpful to other participants. Each week, caregivers will also receive tips and group feedback based on group questions. The content shared by caregivers will be summarized by a team research assistant and sent back to participants at the end of every week.
11073454|NCT04261972||CHARM|Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
11073455|NCT04261959||myoActivation only|Participants who receive one or more sessions of myoActivation. They may receive 1:1 counselling also, but will not receive physiotherapy or group counselling
11073456|NCT04261959||Physiotherapy only|Participants who receive one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive myoActivation or group counselling
11073457|NCT04261959||myoActivation and Physiotherapy|Participants who receive one or more sessions of myoActivation AND one or more sessions of physiotherapy. They may receive 1:1 counselling also, but will not receive group counselling
11073458|NCT04261933||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
11073459|NCT04261920|Experimental|Single decoction group: Huangqi Guizhi Wuwu decoction|The dosage of granules: Sheng huangqi granule 5.5g/bag, Guizhi granule 0.9g/bag, Baishao granule 1.6g/bag, Ganjiang granule 1.7g/bag, Dazao granule 7g/bag. Take twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
11073460|NCT04261920|Placebo Comparator|Simulator group: Huangqi Guizhi Wuwu decoction Placebo|The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
11073461|NCT04261907|Experimental|ASC09/ritonavir group|ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
11073462|NCT04261907|Active Comparator|lopinavir/ritonavir group|Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
11073463|NCT04261894|Experimental|OPTIMIZE|This arm includes implementation of the OPTIMIZE perinatal care checklist with patient navigation support.
11073464|NCT04261894|No Intervention|Standard Care|This arm includes provision of standard perinatal care.
11073465|NCT04261881|Active Comparator|Nutraceutical intervention, 5 capsules twice daily.|Participants will consume the nutraceutical blend ATP-Fuel at 5 capsules twice daily.
11073466|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules once daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules once daily.
11073467|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules twice daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules twice daily.
11073468|NCT04261868|Experimental|Virtual Reality|Dichoptic playing games with fine stimulation will present to the amblyopic eye.
11073469|NCT04261868|Active Comparator|Patching|Non- amblyopic eye will be recommended to patch.
11073470|NCT04261855|Experimental|Arm A|Avelumab plus External Beam Radiation Therapy (EBRT)
11073471|NCT04261855|Experimental|Arm B|Avelumab plus External Beam Radiation Therapy (EBRT)
11073472|NCT04261855|Experimental|Arm C|Avelumab plus Lutetium-177 (177Lu)-DOTATATE
11073473|NCT04261829||Autologous Fat Transfer|
11073474|NCT04261816||Early extubation（EE）|extubation (EE) in the operating room immediately following liver transplantation
11073475|NCT04261816||Delay extubation（DE）|extubation (DE) in the ICU following liver transplantation
11073476|NCT04261803||Familial Hypercholesterolemia children|
11073477|NCT04261803||Control children|
11073478|NCT04261790|Other|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
11073479|NCT04261777|Experimental|SPL-01-001|
11073480|NCT04261764|Experimental|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
11073481|NCT04261764|Active Comparator|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
11073482|NCT04261764|Placebo Comparator|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
11073483|NCT04261751||Clinicians|Physicians, Nurses, or Respiratory Therapists will be taking the Clinician Questionnaire electronically.
11073484|NCT04261738|No Intervention|Control|The first 2-hour session will be a control where participants will sit quietly (as they would in the hyperbaric chamber) and will not be allowed to consume carbohydrates unless directed to by the hyperbaric department hypoglycemia protocol.
11073485|NCT04261738|Experimental|Hyperbaric Oxygen|"The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute [ATA]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an air break. They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours."
11073486|NCT04261725||Squamous Cell Lung Cancer|Genetic analysis for searching EGFR mutation
11073487|NCT04261712|Experimental|Paltusotine|
11073488|NCT04261686|Other|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
11073489|NCT04261673|Experimental|Decompressive Craniectomy|After the evacuation of epidural hematoma, the bone flap should not be replaced at the end of the operation.
11073490|NCT04261673|Experimental|Craniotomy|After the evacuation of epidural hematoma, the bone flap must be replaced and fixed with an appropriate fixation system.
11073491|NCT04261660||fresh|NO INTERVENTION
11073492|NCT04261660||Frozen embro transfer natural|NO INTERVENTION
11073493|NCT04261660||Frozen embro transfer hormonal|NO INTERVENTION
11073494|NCT04261647|Experimental|Experimental group 1|kinesio- taping technique plus traditional physical therapy program.
11073495|NCT04261647|Experimental|Experimental group 2|Pelvic floor exercise plus traditional physical therapy program.
11073496|NCT04261647|Active Comparator|Control group|traditional physical therapy program in the form of stretching of piriformis, stretching of iliopsoas and clam shell exercise, seat cushioning and seat kitz.
11073497|NCT04261634|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
11073498|NCT04261634|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
11073499|NCT04261595|Active Comparator|Dates group 1|For the group of the date 1, Diagnosed autistic patients will be given three pieces of Dates will be given on daily basis for 12 weeks as follow: Three pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
11073500|NCT04261595|Active Comparator|Dates group 2|For the group of the date 2, Diagnosed autistic patients matched for age and sex will be given five pieces of Dates will be given on daily basis for 12 weeks as follow: five pieces (each about 10 -15 gm), of Dates, will be taken with breakfast or between breakfast and lunch as a test dose daily (without drinking any tea after it by at least one hour).
11073501|NCT04261595|Active Comparator|Group 3|Group 3 (no- Dates fruit group): Diagnosed autistic patients matched for age and sex will not receive any dates
11073502|NCT04261582||AERD participants|Participants with aspirin exacerbated respiratory disease. Adults with aspirin allergy, nasal polyps and adult-onset severe asthma.
11073503|NCT04261582||Healthy controls|Healthy participants that do not have asthma.
11073504|NCT04261582||Non-aspirin sensitive asthma participants|Participants with asthma, but that do not have a sensitivity to aspirin.
11073505|NCT04261569|Experimental|Illuminated arm|patients with intraventricular near-infrared light illumination
11073506|NCT04261569|No Intervention|control arm|patients without any medical device
11073507|NCT04261556|Experimental|Real HD-tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal high definition transcranial direct current stimulation (HD-tDCS).
~In the first 20 min of the 40 min-intervention, HD-tDCS and CCT will be provided simultaneously."
11073508|NCT04261556|Sham Comparator|Sham HD-tDCS + CCT|40 min/day of CCT + 20 min/day of apparent (sham) HD-tDCS. In the first 20 min of the 40 min-intervention, HD-tDCS and CCT will be provided simultaneously.
11073509|NCT04261543|Experimental|High Protein and Early Exercise|High protein is defined as a protein prescription of ≥2.2 gram/kg body weight; Early exercise is defined as exercise by using cycle ergometry for 45 minutes per day within 24 hours of randomization
11073510|NCT04261543|Active Comparator|Usual Care|Usual care has a protein prescription of ≤1.2 gram/kg body weight and exercise prescription as per the discretion of attending clinicians
11073511|NCT04261530|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
11073512|NCT04261530|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
11073513|NCT04261530|Experimental|Self-care|It is a 7-months 2 hours-session (1 session per month) of self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
11073514|NCT04261530|Experimental|Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
11073515|NCT04261530|Experimental|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
11073516|NCT04261517|Experimental|Hydroxychloroquine and conventional treatments|After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.
11073517|NCT04261517|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without hydroxychloroquine.
11073518|NCT04261504|Experimental|Integrative Body Mind Training (IBMT)|mindfulness
11073519|NCT04261504|Active Comparator|Relaxation Training (RT)|relaxation
11073520|NCT04261491|Experimental|postmenopausal women with low BMD and chronic periodontitis|postmenopausal women with low BMD and chronic periodontitis will be evaluated after SRP for serum bone resorption markers- CTX and inflammatory markers TNF-α, IL-6
11073521|NCT04261478|Active Comparator|Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be revascularized with a stent during the acute thrombectomy procedure.
11073522|NCT04261478|No Intervention|No Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be not revascularized with a stent during the acute thrombectomy procedure.
11073523|NCT04261465|Experimental|Paclitaxel Carboplatin Olaparib|"Subjects will receive weekly therapy with paclitaxel 60 mg/m2 IV and carboplatin AUC 2 IV for 3 weeks out of 4, and olaparib tablets at the dose of 150 mg bid administered orally for 3 consecutive days (D1-D3), every week for each cycle.
~After 3 cycles patients will be evaluated for interval debulking surgery. After surgery they will receive consolidation treatment with paclitaxel and carboplatin according to Investigator's choice"
11073524|NCT04261452|Other|COPD|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
11073901|NCT04258813|Experimental|iGuide Intervention|40 PCP clinics; 400 patients
11073525|NCT04261452|Other|Overlap|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
11073526|NCT04261439|Experimental|Arm 1|Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)
11073527|NCT04261439|Experimental|Arm 2|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1
11073528|NCT04261426|Experimental|IVIG therapy+ standard care|
11073529|NCT04261426|Placebo Comparator|Standard care|
11073530|NCT04261413|Experimental|RS-0139|There will be only RS-0139 arm in the study.
11073531|NCT04261400|Experimental|MAMAACT|Post graduate training of midwives in intercultural communication and health education materials for the pregnant women.
11073532|NCT04261400|No Intervention|Control|Care as usual
11073533|NCT04261387|Experimental|LUT014 Gel|LUT014 Gel topical application to the dermatitis area qd for 28 days
11073534|NCT04261374||Measurement of sublingual microcirculation|
11073535|NCT04261361|Experimental|CBT-AD intervention|"Adherence counseling
~Psycho-education package
~The intervention program consists of three components: 1) eight weekly sessions of face-to-face interventions, 2) four weekly consolidation individual telephone calls and 3) three monthly individual follow-up phone calls."
11073536|NCT04261361|Active Comparator|enhanced treatments usual (ETAU)|"Adherence counseling;
~Psycho-education package;
~To maintain some control over the contact time, we will give them 4 bi-weekly individual phone calls of about 10 minutes each while the CBT-AD intervention group is having their 8 weeks of face-to-face group sessions."
11073537|NCT04261335|Experimental|CL2020 cells|Intravenous injection of CL2020 cells
11073538|NCT04261322|Experimental|rabies patient 1|not received immunoglobulins and symptomatic
11073539|NCT04261322|Experimental|rabies patient 2|received immunoglobulins and symptomatic
11073540|NCT04261322|Experimental|rabies patient 3|not received immunoglobulins and not yet symptomatic
11073541|NCT04261322|Experimental|rabies patient 4|received immunoglobulins and not symptomatic
11073542|NCT04261309||Elderly with back pain in primary healthcare|Consecutive women and men 55 years of age or older who seek primary care (GP, physiotherapist or chiropractor) with a new episode of back pain (preceded by 6 months without visiting a primary care provider for similar complaints)
11073543|NCT04261296|Experimental|Dry needling|Arm 1: Dry needling group. Dry needling will be done with painful trigger point and it will be waited for about 20 minutes. This treatment will be repeated once a week for 3 weeks.No medication is used in this treatment.
11073544|NCT04261296|Experimental|balneotherapy|Arm 2: Balneotherapy A total of 15 sessions, 20 minutes a day, 5 days a week for 3 weeks, will be held in the spa, which operates within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.
11073545|NCT04261296|Experimental|Dry needling + balneotherapy|Arm3: dry needling + balneotherapy Both of these methods will be applied to patients in the third group.
11073546|NCT04261283|Experimental|Circuit Training|Specific exercise are designed in circuit training
11073547|NCT04261283|Active Comparator|Control Group|Conventional treatment
11073548|NCT04261270|Experimental|ASC09F+Oseltamivir|
11073549|NCT04261270|Experimental|Ritonavir+Oseltamivir|
11073550|NCT04261270|Experimental|Oseltamivir|
11073551|NCT04261257|Experimental|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a serum pregnancy test for women of childbearing age, a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of your care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks (CT scan of the cerebral arteries), a transcranial Doppler, a biological assessment, a 24-hour holter or long-term holter.
~Within 24 hours after admission: The cerebral artery scan, (usual care), is carried out and is supplemented by the additional examination of this research corresponding to a cardiac scanner (not requiring additional injection of contrast medium).
~The following examinations of usual care are carried out within 3 days of inclusion: a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care."
11073552|NCT04261244|Experimental|Experimental Arm|preoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
11073553|NCT04261244|Active Comparator|Standard treatment|standard treatment (postoperative radiotherapy) in breast cancer after neoadjuvant chemotherapy
11073554|NCT04261218|Experimental|Group 1 - Dose Finding|The first 3 patients enrolled in Group 1 will receive tomivosertib at a dose of 100 mg orally twice daily (BID), and will be assessed for dose limiting toxicities (DLTs) during this 'run-in' period. They will also receive the first cycle of tomivosertib IN COMBINATION with weekly paclitaxel in the 'post run-in' period. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2 (detailed in the arm below).
11073555|NCT04261218|Experimental|Group 2 - Dose Expansion|It is anticipated that Group 2 patients will receive tomivosertib at a dose of 200 mg orally twice daily (BID) during the 'run-in' period, which is taken in combination with weekly paclitaxel (according to market label) during the 'post run-in' period.
11073556|NCT04261179|Other|Lymphoseek + Nanocoll|Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
11073557|NCT04261166|Experimental|BOL-PK-ST-02F|Sublingual tablets
11073558|NCT04261166|Experimental|BOL-PK-ST-02E|Sublingual tablets
11073559|NCT04261166|Experimental|B3 is BOL-PK-ST-02D|Sublingual tablets
11073560|NCT04261166|Experimental|BOL-PK-ST-02A|Drops
11073561|NCT04261166|Experimental|BOL-PK-ST-02C|Drops
11073562|NCT04261166|Experimental|BOL-PK-ST-02B|Drops
11105740|NCT04036292|Placebo Comparator|Placebo|
11073563|NCT04261153|Other|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
11073564|NCT04261140|Experimental|High-viscosity glass ionomer|
11073565|NCT04261140|Experimental|flowable composite|
11073566|NCT04261140|Experimental|bulkfill composite|
11073567|NCT04261140|Experimental|nanohybrid composite|
11073568|NCT04261127|Experimental|experimental arm|"The analysis of phenotypic data in RADIAL and the analysis of DNA (analysis of the Friedreich gene ± PMDA panel) will be performed for all patients in order to meet the main objective and the secondary objectives.
~Specifically for the secondary objectives (N ° 3, 4 and 5), randomization via eCRF (electronic case report form) will be performed for the interpretation of genetic analyzes (PMDA panel) without inducing any change for the patients. This randomization, by block and by center, will allow the attribution of one of the following two groups:
~Control group: interpretation of genetic analyzes without the use of RADIAL;
~Experimental group: interpretation of genetic analyzes using RADIAL. Exome analysis (secondary objective n ° 6) will be carried out for all the patients who remained without diagnosis at the end of the first part, and for whom the DNA of relatives is available."
11073569|NCT04261101|Experimental|Block A|Test intervention with questions regarding diabetes and adrenal
11073570|NCT04261101|Active Comparator|Block B|Test intervention with questions regarding thyroid and hypophysis
11073571|NCT04261088||Experts in Swiss assisted suicide|Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.
11073572|NCT04261075|Experimental|IPH5201 monotherapy dose escalation|IPH5201 monotherapy
11073573|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab|IPH5201 plus durvalumab
11073574|NCT04261075|Experimental|IPH5201 dose escalation with durvalumab + oleclumab|IPH5201 plus durvalumab and oleclumab
11073575|NCT04261062||Subject|Patients in surgical intensive unit
11073576|NCT04261049|Experimental|ZILRETTA Injection|All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.
11073577|NCT04261036|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1g of vitamin C for 14 days.
11073578|NCT04261036|Placebo Comparator|Women on a placebo regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take placebo for 14 days
11073579|NCT04261023|Experimental|Abatacept|Treatment arm - 125mg sub-cutaneous injection at week 0 and once weekly thereafter for a maximum of 48 weeks
11073580|NCT04261023|No Intervention|Control arm - CCP Next Generation|Observational study cohort - usual care
11073581|NCT04261010|Experimental|Ustekinumab|Group 1 (n=12): ustekinumab 45 mg (or 90 mg for patients > 100 kg) subcutaneously at baseline (W0), 4 weeks later (W4), and every 12 weeks until week 24 (i.e. W0, W4, and W16).
11073582|NCT04261010|Experimental|Guselkumab|Group 2 (n=12): guselkumab 100 mg subcutaneously (regardless of the weight of the patient) at weeks 0 and 4, followed by a maintenance dose every 8 weeks through week 24 (i.e. W0, W4, W12 and W20).
11073583|NCT04261010|Active Comparator|ADALIMUMAB|Group 3 (n=12): adalimumab 40 mg (regardless of the weight of the patient), subcutaneously every other week, starting from the baseline until week 24 (i.e.W0, W2, W4, W6, W8, W10, W12, W14, W16, W18, W20 and W22).
11073584|NCT04260997|Experimental|Oral Probiotic Product|
11073585|NCT04260997|Placebo Comparator|Placebo product|
11073586|NCT04260984|Active Comparator|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
11073587|NCT04260984|Active Comparator|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
11073588|NCT04260971|Experimental|Cyclical Stimulation|This group will undergo cyclical stimulation mode of stimulation
11073589|NCT04260971|Active Comparator|Continuous Stimulation|This group will undergo the standard continuous mode of stimulation
11073590|NCT04260958|Experimental|Intervention center|Patients at intervention centers will be offered remote video exCR (first-hand option) or usual care centre-based exCR. The exercise program (remote/centre-based) will be standardized and performed for totally 60 minutes, 2 times a week for 3 months. Exercise will be individually prescribed and progressed by physiotherapists in accordance with guidelines. Patients will also be asked to perform one additional session of at least 30 min aerobic exercise per week, at intensity level 13-15 according to Borg RPE-scale.
11073591|NCT04260958|No Intervention|Control|At control centers, patients will be offered usual care centre-based exCR only.
11073592|NCT04260945|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
11073593|NCT04260932|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
11073594|NCT04260919|No Intervention|Control|The participants just received standard medical treatment
11073595|NCT04260919|Experimental|Intervention|The participants received medical treatment and chest physiotherapy sessions
11073673|NCT04260438|Experimental|Group 2|"Period 1: Treatment A
~Period 2: Treatment C
~Period 3: Treatment B"
11073674|NCT04260438|Experimental|Group 3|"Period 1: Treatment B
~Period 2: Treatment A
~Period 3: Treatment C"
11073675|NCT04260438|Experimental|Group 4|"Period 1: Treatment B
~Period 2: Treatment C
~Period 3: Treatment A"
11073676|NCT04260438|Experimental|Group 5|"Period 1: Treatment C
~Period 2: Treatment A
~Period 3: Treatment B"
11073596|NCT04260906|Active Comparator|Vagus nerve stimulation|Patients were admitted to the treatment as day visitors. Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears . The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
11073597|NCT04260906|Active Comparator|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
11073598|NCT04260893|Experimental|Tixel Treatment|3 Tixel treatment sessions, 2 weeks apart follow by 3 Follow up sessions
11073599|NCT04260880||Test group 1|individuals with mild depression
11073600|NCT04260880||Test group 2|individuals with moderate depression
11073601|NCT04260880||control group|systemically healthy individuals
11073602|NCT04260867|Experimental|Aromatherapy|
11073603|NCT04260867|Sham Comparator|Sham|
11073604|NCT04260854|Active Comparator|Bupivacaine HCl|Immediately prior to surgical wound closure, participants randomized to the bupivacaine arm will be injected with bupivacaine HCl along the closure site.
11073605|NCT04260854|Placebo Comparator|Saline|Immediately prior to surgical wound closure, participants randomized to saline, will receive saline injections along the closure site.
11073606|NCT04260828|Active Comparator|Aspirin|
11073607|NCT04260828|Placebo Comparator|Placebo (sugar pill)|
11073608|NCT04260815|Experimental|anodal tDCS on the left inferior frontal gyrus (IFG)|
11073609|NCT04260815|Experimental|anodal tDCS on the right IFG|
11073610|NCT04260815|Sham Comparator|sham tDCS|
11073611|NCT04260802|Experimental|Drug: Dose Escalation|Escalating doses of OC-001 administered intravenously (IV)
11073612|NCT04260802|Experimental|Drug: Combination: Tumor Type 1|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
11073613|NCT04260802|Experimental|Drug: Combination: Tumor Type 2|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
11073614|NCT04260789|Other|Treatment|Treatment with Seraph Filter
11073615|NCT04260789|No Intervention|Control|
11073616|NCT04260776|Experimental|Phase 1|Participants will be randomly assigned to one of the two text message programs that correspond with the web-based intervention (MyWebQuit): 1) standard, 1-way text messages, or 2) interactive, 2-way text messages
11073617|NCT04260776|Experimental|Phase 2|"For the first 5 weeks after randomization, engagement with the website will be monitored. Participants who continue to engage with the website will continue with the same Phase 1 treatment components until the 3-month follow-up.
~Participants who disengage with the website will be randomly assigned to receive one of three re-engagement strategies: 1) interactive, re-engagement text messages, 2) re-engagement email, or 3) no re-engagement strategy"
11073618|NCT04260763|Experimental|Social Cognition Group|Social Cognition Group
11073619|NCT04260750|Experimental|Expert-chosen content, regular guidance|Content chosen by the therapist, weekly guidance by a therapist.
11073620|NCT04260750|Experimental|Expert-chosen content, on-demand guidance|Content chosen by the therapist, guidance upon request from the health care team.
11073621|NCT04260750|Experimental|Participant-chosen content, regular guidance|Content chosen by participants themselves, weekly guidance by a therapist.
11073622|NCT04260750|Experimental|Participant-chosen content, on-demand guidance|Content chosen by participants themselves, guidance upon request from the health care team.
11073623|NCT04260737|No Intervention|Standard Care|The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.
11073624|NCT04260737|Experimental|Decision Aid + Standard Care|"The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:
~An overview about prostate cancer;
~An overview of different treatment options (e.g. surgery and active surveillance)
~The pros and cons of different treatment options (e.g., physical, emotional, social).
~A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option."
11073625|NCT04260724|Active Comparator|TMS group|Transcranial magnetic stimulation for four weeks
11073626|NCT04260724|Sham Comparator|Sham group|sham coil stimulation for four weeks (Although the sound of sham coil is the same to that of real TMS during intervension, no stimulation is applied. )
11073627|NCT04260711|Experimental|Discontinuation of DMT|Discontinuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
11073628|NCT04260711|No Intervention|Continuation of DMT|Continuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
11073629|NCT04260698|Experimental|omidubicel|"Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:
~Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))
~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.
~Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation."
11073630|NCT04260685|Active Comparator|lidocaine|the Patient will receive IV bolus of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h
11073631|NCT04260685|Active Comparator|esmolol|the Patient will receive IV bolus of esmolol 0.5 mg/kg over ten minutes followed by continuous infusion of 100-300 ug/kg/min
11073632|NCT04260672|Experimental|Child-Centred Health Dialogue (CCHD)|The intervention CCHD consists of two parts 1) a universal Child Centred Health Dialog by the CHS-nurse directed in the first place to all 4-year-olds and their families (10 minutes) and 2) a targeted Family Guidance by the CHS-nurse to families where a child is identified with overweight at the age of 4 (60 minutes). All children invites to their regular 5-yrs health visit.
11073677|NCT04260438|Experimental|Group 6|"Period 1: Treatment C
~Period 2: Treatment B
~Period 3: Treatment A"
11073902|NCT04258800|Experimental|With music|Colonoscopy performed with music
11073633|NCT04260672|No Intervention|usual care|Usual care for preschool children identified with overweight and obesity Usual care is performed according to national guidelines that invites all 4-year-olds to a '4-years health visit' including a health conversation. A survey on usual care in the case of identified overweight initial to this study among almost all nurses working at the participating CHCs showed that two thirds of questioned CHS-nurses used to invite families in which the child is identified with overweight for 1 or 2 extra visits outside the usual program. The majority o referred children to a dietician, or to another caregiver. All children invites to their regular 5-yrs health visit.
11073634|NCT04260659|Active Comparator|Opioid liberal group|
11073635|NCT04260659|Experimental|Opioid free group|
11073636|NCT04260646|Active Comparator|Standard Urotherapy without enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch.
11073637|NCT04260646|Experimental|Standard Urotherapy with enuresis alarm|Standard urotherapy inclunding normalized fluid intake and times voidings. The timed voiding regime of every 2 hours will be assisted by a timer Watch. In addition an enuresis alarm will be provided and worn by the participants during the night.
11073638|NCT04260633|No Intervention|Group 1|22-hour tray wear time, DM assisted aligner change frequency
11073639|NCT04260633|Active Comparator|Group 2|22-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
11073640|NCT04260633|Sham Comparator|Group 3|22-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
11073641|NCT04260633|Active Comparator|Group 4|12-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
11073642|NCT04260633|Sham Comparator|Group 5|12-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
11073643|NCT04260607|Experimental|Experimental-Ketamine|single dose IV Ketamine (Ketalar) 0.5mg/kg in 100ml Normal Saline infused over 40 minutes
11073644|NCT04260607|Placebo Comparator|Placebo-Saline|100ml Normal Saline infused over 40 minutes
11073645|NCT04260594|Experimental|Arbidol tablets + basic treatment|
11073646|NCT04260594|Sham Comparator|basic treatment|
11073647|NCT04260581|Experimental|PD patients who have taken amantadine|
11073648|NCT04260568||Persistent Postural Perceptual Dizziness|Semi-structured interviews
11073649|NCT04260555|Experimental|TEST|tid PO, DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml
11073650|NCT04260555|Active Comparator|Reference 1|tid PO, Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml
11073651|NCT04260555|Active Comparator|Reference 2|tid PO, Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml
11073652|NCT04260542|Active Comparator|FAST Lean|Short-term fasting (FAST), comparator group of lean subjects
11073653|NCT04260542|Experimental|FAST Obese|Short-term fasting (FAST), experimental group of obese subjects
11073654|NCT04260542|Experimental|KETO Obese|Medium-term ketogenic diet intervention (KETO), experimental group of obese subjects
11073655|NCT04260529|Experimental|CyPep-1|In cycle 1, patients receive CyPep-1 by intratumoral injection at days 1, 15 and 29. This cycle may be repeated in the absence of toxicity or progressive disease.
11073656|NCT04260516|Active Comparator|N-acetylcysteine group|Patients received oral n-acetylcysteine syrup on dose of 10 mg/kg/day as single dose for 3 months
11073657|NCT04260516|No Intervention|Non n-acetylcysteine group|Thalassemia major patients on regular chelation therapy who didn't receive n-acetylcysteine and served as controls
11073658|NCT04260503||Biliary Atresia|Disease group
11073659|NCT04260503||Choledochal cyst|Disease control
11073660|NCT04260503||Neonatal hepatitis|Disease control
11073661|NCT04260503||Healthy baby|Healthy control
11073662|NCT04260490||Cases|"Cases will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected.
~Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
11073663|NCT04260490||Controls|"Controls selected after stratification on department of residence, sex and age of the cases and who give a written informed consent to participate.
~Controls will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses in both cases and controls. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
11073664|NCT04260477|Experimental|6EH³R3Z|(Rifampicin (R)/ Isoniazid (H) / Pyrazinamide (Z)/Ethambutol (E)) 6-month high-dose treatment; New high-dose isoniazid / high-dose rifampicin retreatment regimen (6EH³R3Z) - that includes triple-dose rifampicin (R3; 30 mg/kg), and triple-dose isoniazid (H3; 15 mg/kg), complemented with pyrazinamide (Z) and ethambutol (E).
11073665|NCT04260477|Active Comparator|6EHRZ|Standard of care: 6-month 6RHZE regimen with dose combination tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E)
11073666|NCT04260464|Experimental|PF-06700841 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
11073667|NCT04260464|Experimental|PF-06700841 Normal Renal Function|This arm includes participants with normal renal function who will receive a single oral dose of 30 mg PF-06700841 on Day 1
11073668|NCT04260464|Experimental|PF-06700841 Moderate Renal Impairment|This arm includes participants with moderate renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
11073669|NCT04260464|Experimental|PF-06700841 Mild Renal Impairment|This arm includes participants with mild renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
11073670|NCT04260451|Experimental|Driving pressure group|Positive end expiratory pressure is adjusted to tidal volume of 5 mL/kg of ideal body weight, inspiratory:expiratory=1:2, and minimize driving pressure (plateau pressure minus end expiratory pressure) during one-lung ventilation. Other procedures are same with the control arm.
11073671|NCT04260451|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 5mL/kg of ideal body weight and positive end expiratory pressure of 5cmH2O during one-lung ventilation
11073672|NCT04260438|Experimental|Group 1|"Period 1: Treatment A
~Period 2: Treatment B
~Period 3: Treatment C"
11107245|NCT04025476||VKH patients|acute VKH patients
11073678|NCT04260425|Experimental|High then low avenanthramides content oats|This arm will receive the high avenanthramides content oatmeal at the first session and the low avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
11073679|NCT04260425|Experimental|Low then high avenanthramides content oats|This arm will receive the low avenanthramides content oatmeal at the first session and the high avenanthramides content oatmeal at the second session. Sessions will be at least 5 days apart.
11073680|NCT04260412|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO membrane, then dialysis for 4 weeks with MCO membrane and increased fiber intake
11073681|NCT04260412|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
11073682|NCT04260399|Experimental|Lavender Aromatherapy|Passive exposure via an ambient essential oil diffuser to lavender aromatherapy
11073683|NCT04260399|Placebo Comparator|Placebo Aromatherapy|Passive exposure via an ambient essential oil diffuser to saline water aromatherapy
11073684|NCT04260386||Staff receiving the MOMS training|Delegates taking part in the routine Multidisciplinary Obstetric and Midwifery Simulation (MOMS) training course at the Chelsea and Westminster Hospital.
11073685|NCT04260373|Experimental|[14C]SHR4640|Patients will receive single dose of [14C]SHR4640 (Suspension, 10mg/80μCi).
11073686|NCT04260360|Experimental|NanoDoce|Intratumoral injection of NanoDoce (2.0 to 6.0 mg/mL) at a volume not to exceed 5.0 mL. NanoDoce will be administered on up to two occasions with at least 4 weeks between doses.
11073687|NCT04260347||Patients >80 years after approval|
11073688|NCT04260347||Patients >80 years before approval|
11073689|NCT04260334|Experimental|Intervention Group|
11073690|NCT04260334|No Intervention|Control Group|
11073691|NCT04260321||AI|Artificial intelligence colonoscopy
11073692|NCT04260321||Control|White light colonoscopy
11073693|NCT04260308||residents|"Voluntary residents
~Can use mobile phone or computer"
11073694|NCT04260308||medical staff|"Voluntary residents
~Can use mobile phone or computer"
11073695|NCT04260282||Neutrophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils <300/mm3 in blood and <3% in induced sputum
11073696|NCT04260282||Eosinophilic asthma|Patients with asthma diagnosed according to guidelines, with eosinophils >300/mm3 in blood and/or >3% in induced sputum
11073697|NCT04260243|Sham Comparator|Sham Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + sham Myofascial Release
11073698|NCT04260243|Experimental|Experimental-Myofascial + Respiratory rehabilitation|Respiratory rehabilitation programme + Myofascial Release
11073699|NCT04260230|Experimental|Lifetemp/Lifetouch sensors|Participants will be asked to wear the sensors for six weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care in any way.
11073700|NCT04260217|Experimental|APG2575 400 mg|APG2575 400mg ramp up arm
11073701|NCT04260217|Experimental|APG2575 600 mg|APG2575 600 mg ramp up arm
11073702|NCT04260217|Experimental|APG2575 800 mg arm|APG2575 800 mg arm ramp up
11073703|NCT04260204|Active Comparator|Retrograde priming|retrograde autologous Blood Priming of Cardiopulmonary Bypass (RAP) in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
11073704|NCT04260204|Active Comparator|conventional priming|conventional cardiopulmonary priming in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
11073705|NCT04260191|Experimental|Dose-exploration|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 910 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
11073706|NCT04260191|Experimental|Dose-expansion|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
11073707|NCT04260178|Experimental|Experimental groups|For the experimental group, EBIP was implemented in three stages:(1) hospital training;(2) home visits + training, which includes motivational interventions that facilitate chronic disease self-care and symptom management with nurse-patient cooperation; and (3) telephone follow-ups and assistance. A handbook was developed in line with the relevant literature and input from two specialist physicians (1,17-20). The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior. The trainings sessions were conducted in a hospital seminar room using PowerPoint presentations. Afterward, patients were asked to demonstrate what they learned, and the parts that were not clear were explained again. The training was concluded after deciding for the first home visit appointment. For patients that could not effectively use the handbook, a close relative was included to all steps of the study.
11073708|NCT04260178|Other|Control groups|Control groups were evaluated with an introductory survey form, PFT, BDI, BMI and SCMP-G scales before and after the study. There were no additional interventions to the control group.
11073709|NCT04260165|Experimental|Proximal Row Carpectomy|
11073710|NCT04260165|Active Comparator|Four-corner fusion|
11073711|NCT04260152|Active Comparator|Control: CAF + CTG|Following root preparation and conditioning, the CTG is obtained from the palate according to the randomization scheme and shaped to the recipient site and may be sutured to the papilla region and the coronally advanced flap (CAF) is sutured into place.
11073712|NCT04260152|Experimental|Test: CAF + Geistlich Fibro-Gide® (test)|Following root preparation and conditioning, Geistlich Fibro-Gide® is cut to size and shaped to the recipient and may be sutured and the coronally advanced flap (CAF) is sutured into place.
11073713|NCT04260126|Experimental|Pembrolizumab and PDS0101|Pembrolizumab will be administered via IV Infusion followed by subcutaneous injections of PDS0101 five times throughout the course of the study. Pembrolizumab monotherapy will be administered every cycle there is not a combination treatment until disease progression or up to Cycle 35.
11073714|NCT04260113|Experimental|Apatinib Arm|
11073715|NCT04260100|Experimental|Intervention Group|
11073716|NCT04260100|No Intervention|Control Group|Routine care group
11073717|NCT04260087||New Daily Persistent Headache|"This cohort will consist of participants diagnosed with New Daily Persistent Headache (NDPH). New daily persistent headache (NDPH) is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. The headache is daily and unremitting from very soon after onset (within 3 days at most), usually in a person who does not have a history of a primary headache disorder.
~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
11073718|NCT04260087||Chronic Migraine|"This cohort will consist of participants diagnosed with chronic migraine. Chronic migraine is defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache. Chronic migraine occurs in approximately 1% of the population. Studies estimate that about 2.5% of people with episodic migraine will transition to chronic migraine each year.
~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
11073719|NCT04260087||Healthy Volunteers|"This cohort will consist of healthy volunteers who have not been diagnosed with either NDPH or chronic migraine.
~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
11073720|NCT04260074||Oral Cancer group|20 consecutive patients with oral squamous cell carcinoma referred to the Department of Otolaryngology - Head and Neck Surgery
11073721|NCT04260074||Healthy oral mucosa group|20 consecutive patients referred to a private clinic for oral and maxillofacial surgery with normal buccal mucosa upon examination.
11073722|NCT04260061|Experimental|exoskeleton group|The Hand of Hope therapy device will be used in this group. The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
11073723|NCT04260061|Experimental|end effector group|The Amadeo Hand-Therapy-System will be used in this group. The Amadeo is a mechatronic rehabilitation device that allows each individual finger to move independently and separately. The main target group are patients suffering from functional motor disabilities of the distal upper extremity. The Amadeo consists of the electrically driven moment mechanism, a supportive framework which is adjustable in height and includes a hand-arm support, and a control and operating unit (all-in-one PC). The finger slides can produce flexion/extension movement of the fingers and the thumb. The fingers and the thumb of the affected hand are attached to the slides and then passive, assistive, active or interactive therapy regime can be started. The integrated sensors for force and position measurement enable quantitative recording and evaluation of the finger range of movement and force.
11073724|NCT04260048||Normal weight|Group defined based on BMI percentile for age and sex.
11073725|NCT04260048||Overweight|Group defined based on BMI percentile for age and sex.
11073726|NCT04260048||With obesity|Group defined based on BMI percentile for age and sex.
11073727|NCT04260035|Active Comparator|Vasoactive Intestinal Polypeptide (VIP)|"Intravenous infusion of 8 pmol/Kg/min of Vasoactive Intestinal Polypeptide (VIP).
~The infusion is administered at constant speed by an automatic pump, lasting 120 minutes."
11073728|NCT04260035|Placebo Comparator|Sterile, isotonic, non-active saline (Placebo)|Intravenous infusion of sterile, isotonic, non-active saline 9 mg/ml (placebo). The infusion is administered at constant speed by an automatic pump, lasting 120 minutes.
11073729|NCT04260022|Experimental|HQP1351 30mg|
11073730|NCT04260022|Experimental|HQP1351 40mg|
11073731|NCT04260022|Experimental|HQP1351 50mg|
11073732|NCT04260009|Experimental|Phase 1: Brigatinib|Brigatinib tablet or age-appropriate formulation (AAF), orally once daily in 28-day Cycles with reference to adult dose of 90 mg in Week 1 and 180 mg starting in Week 2 based on participant's weight as dose level 1. Participants could receive dose level 2 based on safety and tolerability of dose level 1 in dose escalation phase (Ph).
11073733|NCT04260009|Experimental|Ph 2:Brigatinib (Unresectable/Recurrent ALK+ IMT) Participants|Brigatinib recommended phase 2 dose (RP2D) determined during phase 1, tablet or AAF orally QD in participants with Unresectable/ Recurrent ALK+ IMT for up to 2 years in dose expansion phase.
11073734|NCT04260009|Experimental|Ph 2 :Brigatinib (Relapsed/Refractory ALK+ ALCL) Participants|Brigatinib RP2D determined during phase 1, tablet or AAF orally QD in participants with Relapsed/ Refractory ALK+ ALCL for up to 2 years in dose expansion phase.
11073735|NCT04259996||MODIFIED NATURAL CYCLE|"The term 'modified natural cycle' refers to a natural cycle in which ovulation is triggered by exogenous hCG administration in order to provide optimal timing scheduling embryo transfer. In contrast to the natural cycle, the applied hCG may lead to a different luteal phase profile. Luteal phase support is common clinical practice in those cycles.
~On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.
~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
11073736|NCT04259996||STIMULATED CYCLE|"On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.
~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
11073737|NCT04259983||Patients with CF with normal obstruction severity|In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
11073738|NCT04259983||Patients with CF with mild obstruction severity|In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
11073739|NCT04259983||Patients with CF with moderate obstruction severity|In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
11073740|NCT04259970|Experimental|Phase 1|Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).
11073741|NCT04259970|Experimental|Initiation of CFTR Modulator|Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.
11073742|NCT04259957||Clinician using Virtual Reality in Pain Management Program|Clinicians who have used immersive virtual reality as part of Pain Management program group.
11073743|NCT04259944|Experimental|Liquid Biopsy-Guided Adjuvant Treatment|"A post-surgical LB executed 2-4 weeks after surgery will guide a Molecular Adjuvant treatment:
~ctDNA+ patients: CAPOX for 3 months
~ctDNA- patients: capecitabine (CAPE) for 6 months. LB after 1 cycle and if found ctDNA+ will be switched to CAPOX.
~A post-Molecular Adjuvant treatment LB will be performed and instruct subsequent treatment:
~ctDNA+/+ patients: up-scale to a Molecular Metastatic treatment with FOLFIRI for 6 months or until radiological progression or toxicity;
~ctDNA-/+ patients: up-scale to a Molecular Metastatic treatment with CAPOX for 6 months or until radiological progression or toxicity. LB after 3 months at the end of treatment and in case of positivity switch to FOLFIRI.
~ctDNA+/- patients: de-escalate treatment to CAPE for 3 months. 3 LB performed within 3 months and in case of positivity switch to FOLFIRI.
~ctDNA-/- patients: interventional follow-up comprising 2 further LB and in case of positivity switch to CAPOX treatment."
11073744|NCT04259931||No relapses|Patients with clostridium difficile infections without relapses
11073745|NCT04259931||Relapsing patiens|Patients with clostridium difficile infections with relapses
11073746|NCT04259918|Experimental|Control|no applying alveolar recuritment maneuver
11073747|NCT04259918|Active Comparator|Low ARM|Applying 30 cmH2O of alveolar recruitment maneuver 5 times every 5sec
11073748|NCT04259918|Active Comparator|High ARM|Applying 60 cmH2O of alveolar recruitment maneuver 5 times every 5sec
11073749|NCT04259905|Experimental|Active video game teleconference support group|Participants will attend enhanced support group meetings via zoom teleconferencing software. Support group meetings will include group play of active video games and discussion of survivorship topics. Participants will self-monitor physical activity using Fitbit wearable activity monitors and will receive a water bottle and tote bag.
11073750|NCT04259905|Active Comparator|Standard support group + pedometer|Participants will attend standard in-person support groups currently offered by the UTMB Breast Health Center. They will also receive a standard pedometer and a water bottle and tote bag.
11073751|NCT04259879|Experimental|Fasting|The participants will follow a short-term fasting period for 36 hours
11073752|NCT04259853|Experimental|QFR-guided PCI group|QFR-guided revascularization on non-culprit vessels in patients with STEMI
11073753|NCT04259853|Active Comparator|CAG-guided PCI group|CAG-guided revascularization on non-culprit vessels in patients with STEMI
11073754|NCT04259840||Peri-implantitis|Patients who underwent resective surgical treatment for peri-implantitis at the University of Michigan Graduate Periodontics clinic from January 1, 1990 through July 1, 2018
11073755|NCT04259827|Experimental|Online cognitive training|6-week online personalized cognitive training using Neuronation platform 4 training session three times a week. Each session is composed of 5 exercises from one out of 4 cognitive domains: Memory, Attention, Speed and Reasoning
11073756|NCT04259827|Active Comparator|Aspecific online games|online application not created with a cognitive training purpose, for the same amount of time and frequence as the experimental group
11073757|NCT04259827|No Intervention|No online cognitive training|normal clinical follow-up without cognitive training or gaming
11073758|NCT04259814|Experimental|Speech-Language Treatment plus mCIMT|"4 participants
~Baseline phase: Speech-language treatment (SLT), 1 hour a day, 3 days a week. The length of the baseline phase will be staggered across subjects.
~Treatment phase: SLT combined with modified constraint-induced movement therapy(mCIMT) 1 hour a day, 3 days a week.
~Total of baseline and treatment sessions will be 20 to 30 sessions."
11073759|NCT04259801|Experimental|NNC0480-0389 and semaglutide|"Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
~Part 2: 12 subjects will receive 4 doses of s.c. NNC0480-0389 co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c semaglutide."
11073760|NCT04259801|Experimental|NNC0480-0389 and placebo (semaglutide)|"Part 1: 4 subjects will receive a single dose of s.c. NNC0480-0389 co-administered with semaglutide placebo.
~Part 2: 4 subjects will receive 4 doses of s.c. NNC0480-0389, co-administered with semaglutide placebo after 8 weeks of dosing with semaglutide placebo."
11073761|NCT04259801|Active Comparator|Placebo (NNC0480-0389) with semaglutide|"Part 1: 2 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with s.c. semaglutide.
~Part 2: 4 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c. semaglutide"
11073762|NCT04259801|Placebo Comparator|Placebo (NNC0480-0389) with placebo (semaglutide)|"Part 1: 3 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with semaglutide placebo.
~Part 2: 2 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with semaglutide placebo, after 8 weeks of dosing with semaglutide placebo."
11073791|NCT04259606|Active Comparator|Cassia Cinnamon|Cassia cinnamon, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
11073903|NCT04258800|No Intervention|Without music|Colonoscopy performed without music
11073763|NCT04259788|Experimental|Intervention|The intervention group will receive in-person dietary counseling from a registered dietitian to help participants consume a diet that is consistent the AHEI dietary guidelines. Participants in this arm will be asked to consume this diet for a 12-week period and discontinue any vitamin or supplement intake during this time. During the first 4 weeks 2 meals and 1 snack/day will be shipped to the participant. During the last 8 weeks of the intervention, the study will provide the participants with a 14-day meal plan (3 meals and 2 snacks) that adheres to the AHEI maximum score criteria to help facilitate adherence to the diet.
11073764|NCT04259788|No Intervention|Control|Participants in this arm will not receive the dietary intervention.
11073765|NCT04259775|Active Comparator|Automated Insulin Dose Adjustment (AIDA)|Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
11073766|NCT04259775|Active Comparator|Control|Standard Care - change in therapy settings effected a regularly scheduled patients visits
11073767|NCT04259762|Experimental|Breast, Colorectal, and Cervical Cancer Screening|The investigators will train Community Health Representatives (CHRs) in interactive group discussions techniques. CHRs will administer 1 session/week, lasting approximately 2 hours, and conducted among 12 men or women ages 21-75 per cluster. The CHRs will distribute the cancer-specific (i.e., breast, colorectal, and cervical) small media during the first session and refer to it during the course of the 4 sessions. During the sessions, the CHRs will function as a facilitator linking information with practical skills. At the end of the 4-week INT, participants will receive a voucher to present to a designated point-person at the health center who would schedule the screening for the age- and gender-specific cancers.
11073768|NCT04259762|No Intervention|Control|Historical control
11073769|NCT04259749|Active Comparator|Status Quo|The StoreLab power wall will display all tobacco products.
11073770|NCT04259749|Experimental|Flavors Banned|The StoreLab will display tobacco products without characterizing flavors, but will allow mint and menthol products to be displayed.
11073771|NCT04259749|Experimental|Flavors and Menthol Banned|The StoreLab will display only tobacco products without characterizing flavors; mint and menthol will not be displayed.
11073772|NCT04259723|Experimental|Intervention|
11073773|NCT04259723|No Intervention|Control|
11073774|NCT04259710|Placebo Comparator|Pedometer only|participants will be given a pedometer and instructed how to use it, but will not participate in the goal setting intervention.
11073775|NCT04259710|Active Comparator|Pedometer and intervention|participants will be given a pedometer and participate in a weekly goal setting meeting with the investigator and will receive weekly tips.
11073776|NCT04259710|Experimental|Pedometer, intervention and implementation intentions|participants will be given a pedometer and participate in the weekly goal setting as above. In addition, 3 times during the intervention they will fill out a form that encourages performance of implementation intentions.
11073777|NCT04259697|Experimental|Clinical pilates|Exercises will be performed two times per week for twelve weeks.
11073778|NCT04259697|Experimental|Whole body vibration|Exercises will be performed two times per week for twelve weeks.
11073779|NCT04259684|Experimental|gNO Group|Participants in the treatment group will receive gNO added to the oxygenator gas flow at 20 ppm throughout the duration of cardiopulmonary bypass.
11073780|NCT04259684|No Intervention|Control Group|Participants in the control group will receive standard conduction of cardiopulmonary bypass.
11073781|NCT04259671|Experimental|Intervention- My Autism Passport App|"Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. The contact information for a member of the research team who will be able to provide technical support will be available on the consent form. Families will use the mobile application for a total of 18 months.
~Given that this is a pragmatic trial of a tool that tracks services, it also may be used to communicate service access to other providers."
11073782|NCT04259671|No Intervention|Control-Standard of care|Families in the control group will continue with standard of clinical care, and receive any of the usual supports their clinic and region provides, including access to physicians, service navigators, social workers, nurses, etc.
11073783|NCT04259658|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for cutaneous metastases.
11073784|NCT04259645|Experimental|Low Volume group|30 subjects randomized to Low Volume will receive unilateral Quadratus Lumborum block type II. Each block of 0.375% Bupivacaine x 20 ml
11073785|NCT04259645|Experimental|High Volume group|30 subjects randomized to High Volume will receive unilateral Quadratus lumborum block Type II. Each block of 0.375% Bupivacaine x 20 mL + Normal Saline Solution 20 mL
11073786|NCT04259632|Experimental|Time Restricted Eating (TRE)|For the TRE group, we will restrict the eating window to 8 hours, where they will eat ad libitum. This is the same interval established by Dr. Panda and by our preliminary data. This interval will be entered into the mCC app and participants will be asked to adhere to this eating window during the intervention. All eating occasions will be logged using the mCC app. Only water and medications will be allowed outside of the eating window.
11073787|NCT04259632|Active Comparator|Caloric Restriction (CR)|Participants randomized to CR will meet with the study dietitian prior to the intervention and be counseled on options to reduce their caloric intake by 15%, while maintaining their eating window. The 15% reduction was selected as our preliminary data and recent literature suggest that TRE with ad libitum intake reduces caloric intake by ~270 to 300 cal/day. The 15% CR is similar to the 11.9% CR achieved by the CALERIE-2 study, which is a 2 year study of CR.26 All eating occasions will be logged using the mCC app. The weekly dietitian review of the mCC information will include maintenance of the eating window and examination of dietary intake to determine compliance with the 15% CR.
11073788|NCT04259632|No Intervention|Unrestricted Eating (non-TRE)|For the unrestricted eating (non-TRE) group, participants will eat ad libitum per their usual habits. They will receive initial counseling about mCC logging. All eating occasions will be logged using the mCC app.
11073789|NCT04259619|Experimental|Low-Level Laser Therapy|During 2-3 days this group receives three low-level laser therapy (LLLT) treatments with the Soft Power Laser carried out by a specially trained breastfeeding consultant.
11073790|NCT04259619|Placebo Comparator|Placebo Therapy|During 2-3 days this group receives three placebo treatments with an identically looking laser, which in contrast submits only red colored light. The therapy is also carried out by a specially trained breastfeeding consultant.
11073793|NCT04259593|Experimental|Exercise Training Group|Exercise training group performed three weekly sessions for 16 weeks. This program consisted of moderate intensity aerobic, resistance, balance, and stretching exercises. The duration of every exercise session was 35 minutes during the first week and 65 minutes from the second week onward.
11073794|NCT04259593|No Intervention|Control Group|The control group received usual lymphoma care
11073795|NCT04259567|Active Comparator|Filter|Patients with CytoSorb absorber
11073796|NCT04259567|No Intervention|Control|Patients without CytoSorb absorber
11073797|NCT04259554|Experimental|OFC rTMS|repetitive transcranial magnetic stimulation
11073798|NCT04259528|Experimental|Patients with esophageal stricture following surgical repair|Patients with esophageal atresia following surgical repair who developed an esophageal stricture
11073799|NCT04259515|Active Comparator|Bukcberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
11073800|NCT04259515|Experimental|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
11073801|NCT04259502|Experimental|RIB Group|A single injection Rhomboid intercostal block will be performed under ultrasound guidance
11073802|NCT04259502|Active Comparator|ESP Group|A single injection Erector spinae plane block will be performed under ultrasound guidance
11073803|NCT04259489|No Intervention|Traditional therapy group|All patients in the control group will receive routine diabetes management, including lifestyle education, health guidance, blood glucose monitoring and medicine adjustment and other treatments which conducted by the endocrinology medical team. After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
11073804|NCT04259489|Active Comparator|Shared Care group|The Patients download the Shared Care mobile application and connect with the smart-glucometer BG1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
11073805|NCT04259476|Active Comparator|group A|WIll be given low dose perioperative ketamine infusion, as well as a ketamine bolus at start of surgery.
11073806|NCT04259476|Placebo Comparator|group B|will be given normal saline infusion and bolus at start of surgery.
11073807|NCT04259463||Concious sedation|Patients undergoing third molars extraction under concious sedation. The patient is fully familiarized with the sedation procedure. The anesthesiologist suppresses the patient's consciousness with the help of intravenous medication;
11073808|NCT04259463||Full anesthesia|Patients undergoing third molars extraction under full anesthesia. . The patient is fully acquainted with the procedure of general anesthesia. It is a controlled state of unconsciousness when protective reflexes disappear, the patient cannot breathe and does not respond to verbal commands. A special intubation tube is introduced into the airways.
11073809|NCT04259450|Experimental|AFM24|"Phase 1: Treatment of escalating doses of AFM24.
~Phase 2a: Treatment of AFM24 at maximum tolerated dose/recommended phase 2 dose, stratified into cohorts by tumor type."
11073810|NCT04259437|Experimental|High Protein, Energy Dense Nutritional Supplement|2 servings per day
11073811|NCT04259424|Experimental|Aerobic Exercise + Upper Extremity Rehabilitation|Subjects will receive a total of 18 intervention sessions. In each intervention session, subjects will perform 15 minutes of aerobic exercise on a stationary cycle followed by 200 repetitions of an upper extremity rehabilitation program.
11073812|NCT04259411|Experimental|MitraClip|Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
11073813|NCT04259398|Experimental|TIVA|propofol infusion targeting bispectral index 40-60
11073814|NCT04259398|Active Comparator|inhalation (Sevoflurane)|sevoflurane targeting bispectral index 40-60
11073815|NCT04259385|Active Comparator|Calorie/Control Label Condition|Beverages at the concession stand and in the parent survey in this arm will display solely a calorie label.
11073816|NCT04259385|Experimental|Text Warning Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display both a text warning and a calorie label.
11073817|NCT04259385|Experimental|Sugar Graphic Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display a sugar graphic warning label depicting the amount of sugar in the product, the same text warning, and a calorie label.
11073818|NCT04259372||Primary Diagnosis|Analysis of patient blood at primary diagnosis of AML
11073819|NCT04259372||Relapse|Analysis of patient blood at time point of relapse after allo-HCT
11073820|NCT04259372||Remission|Analysis of patient blood during remission after allo-HCT
11073821|NCT04259359||patients who will be treated with bee venom immunotherapy|
11073822|NCT04259346|Experimental|Ixekizumab (Reference)|Approved formulation of ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
11073823|NCT04259346|Experimental|Ixekizumab (Test)|Test formulation of ixekizumab administered as a SC injection via AI.
11073824|NCT04259333|Experimental|Test Arm|celecoxib 200 mg tablet by mouth every 12 hours for 7 days postoperatively prn pain
11073825|NCT04259333|Active Comparator|Control Arm|codeine 30mg-acetaminophen 300mg-caffeine 15 mg tabelt by mouth every 4 hours for 7 days postoperatively prn pain
11073826|NCT04259320|Experimental|Beeswax containing barrier|Beeswax containing barrier will be given to the breastfeeding mother within the first 24 hours. After breastfeeding, it can be placed on the breast after it is expected to dry a little.Outside of breastfeeding and bathing, it will be constantly attached to the breasts.
11073827|NCT04259320|Experimental|Breast milk|After breastfeeding, 2-3 drops of breast milk are applied to the nipple and areola. After the milk has dried, the breasts are closed. This application should be done at least 5 times a day.
11073828|NCT04259320|No Intervention|No treatment- control|It is a group that does not use any method to prevent nipple cracks. All follow-ups in the experimental groups are done.
11073829|NCT04259307|Experimental|Intensive nutrition group|Standard nutritional support with additional intravenous nutrition of 500 kcal per day for 3 weeks
11073830|NCT04259307|No Intervention|Control group|Standard nutritional support only per day for 3 weeks
11073831|NCT04259294|Experimental|Telerehabilitation group via mobile apps|The experimental group will receive home-based treatment program through mobile apps
11073832|NCT04259294|Active Comparator|Control group via paper and pencil instructions|The control group will receive treatment via written home program sheets
11073833|NCT04259281|Experimental|GTX-102 Cohort 1|Dose A
11073834|NCT04259281|Experimental|GTX-102 Cohort 2|Dose B
11073835|NCT04259281|Experimental|GTX-102 Cohort 3|Dose C
11073836|NCT04259281|Experimental|GTX-102 Cohort 4|Dose D
11073837|NCT04259281|Experimental|GTX-102 Cohort 5|Dose E
11073838|NCT04259268||Web based questionnaire|Information registered by patient in the web based questionnaire
11073839|NCT04259268||Outpatient assessment|"Information registered by the anesthesiologist and based on the web based questionnaire, the electronic records of patient and the face to face interview"
11073840|NCT04259268||Virtual assessment|Information registered by the anesthesiologist and based on the web based questionnaire and the electronic records of patient
11073841|NCT04259255||Edaravone|During an estimated 12-month period, eligible participants who are prescribed Edaravone within the approved indication will be invited to participate in the study.
11073842|NCT04259242|Experimental|premenopausal women with low BMD and periodontitis|Experimental: postmenopausal women with low BMD and chronic periodontitis postmenopausal women with low BMD and chronic periodontitis will be evaluated after SRP for serum bone resorption markers - CTX and inflammatory markers TNF-α, IL-6
11073843|NCT04259229|Experimental|Mushroom intervention|Subjects will be randomized and assigned to consume the Mediterranean Diet with mushrooms for eight weeks.
11073844|NCT04259229|Active Comparator|Control|Subjects will be randomized and assigned to consume the Mediterranean Diet without mushrooms for eight weeks.
11073845|NCT04259216|Experimental|IMPACT Intervention|"Remote brief video session, introducing basic principles of cognitive behavioral theory and the structure of the mobile application message portion of the intervention.
~Eight-weeks longitudinal tailored Cognitive Behavioral Therapy (CBT)-based messaging program"
11073846|NCT04259216|Active Comparator|Control Enhanced Online Resources (EOR)|1. We will provide a link to an online resource packet with information on bullying and mental health resources.
11073847|NCT04259203|Experimental|Erickson hypnosis|5 sessions of Erickson hypnosis (1 session per week), associated with autohypnosis at home in-between sessions.
11073848|NCT04259203|No Intervention|Usual care|Usual management of pain symptoms
11073849|NCT04259190|Experimental|Values rationale|Interoceptive exposure exercises will be introduced as a way to help participants engage in more that they value.
11073850|NCT04259190|Active Comparator|Standard rationale|Interoceptive exposure exercises will be introduced as a way to help participants experience less discomfort.
11073851|NCT04259164|Active Comparator|QMF149|Mometasone furoaat / Indacaterol
11073852|NCT04259164|Experimental|QVM149|Mometasone furoaat / Indacaterol / Glycopyrronium
11073853|NCT04259151|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
11073854|NCT04259151|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
11073855|NCT04259138|Other|Symptomatic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission.
11073856|NCT04259138|Other|Symptomatic and endoscopic remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.
11073857|NCT04259138|Other|Symptomatic, endoscopic and histological remission|Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.
11073858|NCT04259125||Acute symptomatic seizures|This is a cohort of 72 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after being diagnosed with seizures. They will be asked to contribute a blood specimen obtained within 24-72 hours after seizures are diagnosed, to participate in an optional blood draw at 2-4 months of age, and to complete surveys at 12 & 24 months of age.
11073859|NCT04259125||Control|This is a cohort of 15 participants who will be enrolled into this study from the neonatal intensive care unit (NICU) after having an EEG for possible seizures, but found to have a normal EEG. They will be asked to contribute a blood specimen obtained within 24-96 hours after birth.
11073860|NCT04259112|Experimental|high pressure + deep block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards post-tetanic count (PTC) 1-2.
11073861|NCT04259112|Experimental|high pressure + moderate block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards train-of-four (TOF) twitch 1-2.
11073862|NCT04259112|Experimental|low pressure + deep block|Intra-abdominal pressure will be set to 7-10 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
11073863|NCT04259112|Experimental|low pressure + moderate block|Intra-abdominal pressure will be set to 7-10 mmHg. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards TOF twitch 1-2.
11074036|NCT04257877||Diabetes type 1|Patients= diabetes type1
11073865|NCT04259086|Experimental|DAXI|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL) & Lateral Canthal Lines (LCL)
11073866|NCT04259073|Placebo Comparator|Group C|two capsules filled with sugar
11073867|NCT04259073|Active Comparator|Group P150|two capsules; one of them containing sugar (like the placebo one), the other is the active drug (pregabalin 150 mg)
11073868|NCT04259073|Active Comparator|Group P300|two capsules of pregabalin (150 mg)
11073869|NCT04259060|Active Comparator|Hydroxocobalamin with Butyrate|
11073870|NCT04259060|Placebo Comparator|Placebo with Butyrate|
11073871|NCT04259047|Experimental|Diabetes Regulation for Eyesight and Memory (DREAM)|DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
11073872|NCT04259047|Active Comparator|Enhanced Usual Care (EUC)|EUC consists of home visits by a CHW in which general DM education is provided.
11073873|NCT04259034||systemically healthy individuals with oral lichen planus|systemically healthy individuals diagnosed with oral lichen planus on clinical and histopathological basis.
11073874|NCT04259034||systemically healthy individuals without oral lichen planus|systemically healthy individuals without any clinical feature of oral lichen planus.
11073875|NCT04259008|Active Comparator|Standard neonatal trace elements|"Parenteral nutrition containing 5 mCg/kg/day manganese from Multitrace-4 Neonatal."
11073876|NCT04259008|Experimental|Manganese-free neonatal trace elements|"Parenteral nutrition containing the same trace element doses as Multitrace-4 Neonatal minus manganese."
11073877|NCT04258995|Experimental|GBS6 no aluminum phosphate (GBS6 no AlPO4)|
11073878|NCT04258995|Experimental|GBS6 with aluminum phosphate (GBS6 with AlPO4)|
11073879|NCT04258982||AECOPD group|The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.
11073880|NCT04258969|Experimental|Pedaling Group|During the first 2 hours of their chemotherapy infusions, participants will pedaling for 30 minutes using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. Additionally, subjects will complete both a physical activity questionnaire (International Physical Activity Questionnaire) and a quality of life questionnaire (European Organization for Research and Treatment of Cancer QLQ - CR 29) at baseline and following their last chemotherapy treatment. A questionnaire on chemotherapy side effects (Memorial Symptom Assessment Scale) will be gathered at baseline, during chemotherapy cycles 3, 6, and/or 12, and following completion of chemotherapy treatment. Lastly, muscular strength and physical performance will be measured via grip strength tests and TGUG tests within 2-4 weeks of the post-surgery and chemotherapy completion CT scans.
11073881|NCT04258943|Experimental|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
11073882|NCT04258930|Active Comparator|Group A: Aluminum sulphate and calcium acetate drying soaks|Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.
11073883|NCT04258930|Experimental|Group B: Topical sterile silicone gel for wounds|Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.
11073884|NCT04258930|Experimental|Group C: Hydrocolloid dressing|Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.
11073885|NCT04258917|Experimental|Total Knee Arthroplasty|
11073886|NCT04258917|Experimental|Anterior Cruciate Ligament Reconstruction|
11073887|NCT04258904|Experimental|Intervention|Skin Care Program
11073888|NCT04258904|No Intervention|Control|Usual Treatment
11073889|NCT04258865|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
11073890|NCT04258865|Experimental|Sequence 2|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
11073891|NCT04258865|Experimental|Sequence 3|"Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
11073892|NCT04258865|Experimental|Sequence 4|Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
11073893|NCT04258865|Experimental|Sequence 5|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
11073894|NCT04258865|Experimental|Sequence 6|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions
~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions
~Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions"
11073895|NCT04258852|Experimental|Low Strength, High Strength|
11073896|NCT04258852|Experimental|High Strength, Low Strength|
11073897|NCT04258839|Experimental|Arm 1|Brexpiprazole
11073898|NCT04258826|Experimental|LY3154207|LY3154207 administered orally in one of two study periods.
11073904|NCT04258787||Group A: No Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy but do not require surgery per standard-of-care guidelines.
11073905|NCT04258787||Group B: Surgery Group|This group consists of adults ages 18 or older who have been diagnosed with Fuchs' dystrophy or pseudophakic bullous keratopathy, who require Descemet's Stripping Endothelial Keratoplasty (DSAEK), Descemet's Membrane Endothelial Keratoplasty (DMEK), or Descemet's Stripping Only (DSO) surgery. All treatment decisions will be made by the attending physician based on standard-of-care guidelines. (The study does not designate a treatment modality or pay for the treatment.)
11073906|NCT04258774|Active Comparator|Healthy Adults|
11073907|NCT04258774|Active Comparator|Adults diagnosed with vascular pathology of the brain|
11073908|NCT04258761|Experimental|10XB-101 Solution for Injection 1.25% and 2.0%|Participants receive 10XB-101 Solution for Injection, 1.25% or 2.0% via subcutaneous injection up to 10 mL on Day 1 of subject participation.
11073909|NCT04258748|Experimental|Motivational Interviewing (MI)|
11073910|NCT04258748|Experimental|Gaming and MI|
11073911|NCT04258748|Active Comparator|Conventional dental health education|
11073912|NCT04258735|Other|Metastatic breast cancer cohort|Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
11073913|NCT04258722|Active Comparator|Experienced Provider|Experienced provider and nurse will perform resuscitation
11073914|NCT04258722|Experimental|Trainee + Teleneonatologist|Trainee, teleneonatologist, and nurse will perform resuscitation
11073915|NCT04258722|Active Comparator|Trainee|Trainee and nurse will perform resuscitation.
11073916|NCT04258709|Experimental|Antenatal Milk Expression (AME) Intervention Group|Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
11073917|NCT04258709|Active Comparator|Video-based Infant Care Education Control Group|Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).
11073918|NCT04258696|Active Comparator|Gingival retraction by ultrapak retraction cord|
11073919|NCT04258696|Experimental|Gingival retraction by diode laser|
11073920|NCT04258683|Experimental|Pembrolizumab with CyBorD|This will be a single arm study of pembrolizumab with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
11073921|NCT04258670||Cross-reactive loiasis|This cohort will prospectively enroll 50 adults (age 18+) with cross-reactive antigenemia based on a positive filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
11073922|NCT04258670||non-cross-reactive loiasis|This cohort will prospectively enroll 10 adults (age 18+) with a negative filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
11073923|NCT04258657|Experimental|Paclitaxel-albumin and S-1|
11073924|NCT04258644|Experimental|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&D8, 100～120 mg/m2 S-1：D1~14, 60mg bid
11073925|NCT04258631|Active Comparator|Arm I (laparotomy, liposomal bupivacaine)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine.
11073926|NCT04258631|Experimental|Arm II (laparotomy, liposomal bupivacaine, hydromorphone)|Patients undergo standard of care laparotomy and then receive liposomal bupivacaine and hydromorphone IT.
11073927|NCT04258618|Active Comparator|CBT-I (Cognitive Behavioral Therapy for Insomnia) with TMS|
11073928|NCT04258618|Other|rTMS (repetitive Transcranial Magnetic Stimulation)|Subjects will be getting Transcranial Magnetic Stimulation as part of their standard of care.
11073929|NCT04258605||ASHCOM Shoulder System subjects|Subjects implanted with the ASHCOM Shoulder System
11073930|NCT04258592|Experimental|Patients|A single dose of 18F-MFBG will be intravenously injected in 10 patients with neural crest tumors or neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and efficacy assessment.
11073931|NCT04258579|Experimental|Video PROTECT|Participants will receive PROTECT therapy once a week for 9 weeks.
11073932|NCT04258566|Experimental|Suspected hepatic malignancy|Malignancy determination of new onset hepatic lesion
11073933|NCT04258553||Cervix cancer|Cervix cancer n=62
11073934|NCT04258553||Healthy controls|Healthy volunteers n=61
11073935|NCT04258540|Experimental|Intervention group|The intervention group received a yoga course for 12 weeks, two times a week. Each yoga class was 1.25 hr in duration.
11073936|NCT04258540|Active Comparator|Control group waitlist|The control group were on a waitlist during the period of measurements, and received the same yoga course after all measurements had been completed.
11073937|NCT04258527|Experimental|Patients with advanced malignancies with FGF/FGFR alterations|
11073938|NCT04258514|Experimental|Virtual Reality Vasectomy|This group of men will undergo vasectomy while wearing VR goggles.
11073939|NCT04258514|Experimental|Standard Vasectomy|This group of men will undergo a standard vasectomy without using VR goggles.
11073940|NCT04258501|Experimental|Mulberry fruit extract|1.5 g of mulberry fruit powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
11073941|NCT04258501|Experimental|Mulberry leaf extract|1.0 g of mulberry leaf powdered extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
11073942|NCT04258501|Experimental|White bean extract|3 g of white bean powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
11073943|NCT04258501|Experimental|Apple extract|2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
11073944|NCT04258501|Experimental|Elderberry extract|2 g of elderberry powder extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
11073945|NCT04258501|Experimental|Turmeric extract|0.18 g of curcumin powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
11073946|NCT04258501|Experimental|Turmeric extract + Apple extract|0.18 g of curcumin powdered extract + 2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
11074037|NCT04257877||Healthy participants|Healthy participants = Control group
11073947|NCT04258501|Experimental|Turmeric extract + Elderberry extract|0.18 g of curcumin powdered extract + 2 g of elderberry powder extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
11073948|NCT04258501|Placebo Comparator|Rice porridge control|Bowl containing 60 g of extruded rice + 300 ml of boiling water
11073949|NCT04258488|Experimental|Oral Factor Xa inhibitor|
11073950|NCT04258488|Active Comparator|Vitamin K antagonist|
11073951|NCT04258475|Experimental|Raltegravir-Calcium PK measure|"Patients will have a total of 8 visits during the study after initial screening visit to gauge patient eligibility:
~Day 1 visit: Oral administration of Raltegravir. Day 7 visit: Oral administration of Raltegravir and Calcium 500 mg in the morning. Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 8).
~Day 8 visit: day 7's 24 hour phlebotomy visit. Day 14 visit: Oral administration of Raltegravir and Calcium 1000 mg in the morning. Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 15).
~Day 15 visit: Day 14's 24 hour phlebotomy visit. Day 21 visit: Timed serial Phlebotomy at .5, 1, 1.5, 2, 3, 4, 6, 24 hours after observed dosing (see visit day 22).
~Day 22 visit: Day 21's 24 hour phlebotomy visit. Day 51: Final safety visit. Follow-up for patient safety and data collection from diary."
11073952|NCT04258462|Experimental|Diagnostic (HP 13C pyruvate MRI)|Patients receive HP 13C pyruvate IV and then undergo 13C MRI scan 1-2 minutes post HP 13C pyruvate injection. Patients may receive an optional second HP 13C pyruvate injection and undergo 13C pyruvate MRI scan 15 to 60 minutes following completion of the first scan.
11073953|NCT04258449||Case|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
11073954|NCT04258436|Active Comparator|Group 1-Block Arm|Group1 will receive an ultra-sound guided serratus anterior block after induction of general anesthesia
11073955|NCT04258436|No Intervention|Group 2-No Block Arm|Group 2 will not receive a serratus block after induction of general anesthesia
11073956|NCT04258423|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
11073957|NCT04258423|Experimental|Study Arm|Everolimus as maintenance immunosuppression
11073958|NCT04258410|Placebo Comparator|Placebo|Blinded subjects in this arm will receive 2 placebo (blank) soft chews, twice daily, orally for 20 weeks.
11073959|NCT04258410|Experimental|Active Drug|Blinded subjects in this arm will receive 1 g/day of Quercetin delivered in 2 soft chews (250 mg/chew), twice daily, orally, for 20 weeks.
11073960|NCT04258397|Active Comparator|Experimental, pirfenidone|"Pirfenidone 267 mg capsules
~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
11073961|NCT04258397|Placebo Comparator|Placebo, pirfenidone|"Pirfenidone placebo capsules
~Randomized participants will take 5 capsules (1335 mg pirfenidone): 2 pills in the morning, 1 mid-day, and 2 in the evening, with meals."
11073962|NCT04258384||Patient|The study included individuals whose native language is Turkish, who are literate, over the age of 18, diagnosed with rheumatoid arthritis, without cognitive impairment and communication problems, and who want to participate in the study.
11073963|NCT04258371|Experimental|Dapagliflozin Treatment Arm|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
11073964|NCT04258371|Placebo Comparator|Placebo Arm|Placebo Matching Dapagliflozin Tablet for 12 weeks
11073965|NCT04258358|Experimental|People living with dementia intervention group|"Long term care and support are provided in a dementia care friendly environment with emphasis on 'the person's home'. Each resident's home carries a registered address to symbolise the person's home. Based on needs and strengths, people living with dementia and their families are supported to choose the technology to enable the person's independence plus developing new and maintaining existing skills. Examples of supportive and assistive technology include mobile devices, memory clocks, gas and flood detectors, sensor mats and global positioning system trackers or safe return ornaments. Routine care follows a holistic integrated health and social care plan tailored to the needs of the person living with dementia.
~Respite care provided in guesthouse facilities embody a similar approach only for a shorter period of time without assigning registered home addresses."
11073966|NCT04258358|No Intervention|People living with dementia control group|"People living with dementia in need of long-term rehabilitation or recovery for at least eight months; and people living with dementia in need of respite care for up to 14 days
~People living with dementia will continue to use standard care. Standard care in this respect constitutes usual health and social care or any other nationally acceptable form of therapy that people living with dementia would seek to use."
11073967|NCT04258345|Other|Active Feeding Arm|This is a feeding study.
11073968|NCT04258332|Other|High Salt Diet then Low Salt Diet|"The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.
~The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg)."
11073969|NCT04258332|Other|Low Salt Diet then High Salt Diet|"The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).
~The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure."
11073970|NCT04258319|Experimental|Affected (Lymphedema)|Subjects affected lymphedema extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
11073971|NCT04258319|Active Comparator|Unaffected (Control)|Subjects unaffected extremity will have elastic and viscoelastic parameters collected by ultrasound procedure
11073972|NCT04258306|Active Comparator|Resveratrol|180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
11073973|NCT04258306|Experimental|REVIFAST|180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold & Zucc. Root supported on Magnesium hydroxide).
11073974|NCT04258293||Patients|Patients on prolonged corticosteroid therapy (more than three months)
11073975|NCT04258280|Active Comparator|Usual Care|
11073976|NCT04258280|Experimental|Enhanced Care|
11073977|NCT04258267|Experimental|Early mobilization|Patients will be allowed to use their shoulder earlier. The immobilization period is shorter.
11073978|NCT04258267|Experimental|Delayed mobilization|The immobilization period is longer.
11073979|NCT04258254|Experimental|Multimodal|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer. Within each session, the child will engage in tasks requiring interpersonal synchrony, multilimb coordination (asymmetrical and ipsi/contralateral motions), and balance. Parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
11073980|NCT04258254|Active Comparator|General|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer. Within each session, the child will engage in structured physical activity focused on flexibility, strength, and endurance. Parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
11073981|NCT04258241|Active Comparator|Local infiltration analgesia with local anesthetic (LIA+)|Local infiltration analgesia will be performed at the end of the surgery by injection of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
11073982|NCT04258241|Placebo Comparator|Local infiltration analgesia without local anesthetic (LIA-)|Local infiltration analgesia will be performed at the end of the surgery by injection of 0.3 mg of epinephrine and 120 ml of normal saline.
11073983|NCT04258215|Experimental|Positive pressure achieved with PSA|Maximum airway inflation pressure achievable before a significant leak occurs.
11073984|NCT04258202|Experimental|positive end expiratory pressure group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. PEEP increased in a stepwise manner from 5 to 20 cmH2O, until plateau pressure 30 cmH2, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with positive end expiratory pressure (PEEP) 5cmH2O.
11073985|NCT04258202|Experimental|tidal volume group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. Tidal volume increased in steps of 4mL/kg of ideal body weight until plateau pressure 30 cmH2O, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with PEEP 5 cmH2O.
11073986|NCT04258189|Experimental|Panel 1: Treatment Sequence ABDC|Participants will receive Treatment A (a single dose of JNJ-64417184 [oral solution with preservatives] in fasted condition) in treatment Period 1; followed by Treatment B (a single dose of JNJ-64417184 [oral solution with preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment D (a single dose of JNJ-64417184 [oral solution without preservatives] in fed [high-fat meal] condition) in treatment Period 3, followed by Treatment C (a single dose of JNJ-64417184 [oral solution without preservatives] in fasted condition) in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073987|NCT04258189|Experimental|Panel 1: Treatment Sequence BCAD|Participants will receive Treatment B in treatment Period 1; followed by Treatment C in treatment Period 2; followed by Treatment A in treatment Period 3, followed by Treatment D in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073988|NCT04258189|Experimental|Panel 1: Treatment Sequence CDBA|Participants will receive Treatment C in treatment Period 1; followed by Treatment D in treatment Period 2; followed by Treatment B in treatment Period 3, followed by Treatment A in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073989|NCT04258189|Experimental|Panel 1: Treatment Sequence DACB|Participants will receive Treatment D in treatment Period 1; followed by Treatment A in treatment Period 2; followed by Treatment C in treatment Period 3, followed by Treatment B in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073990|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EFG|Participants will receive Treatment E (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fasted condition) in treatment Period 1; followed by Treatment F (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment G (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073991|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073992|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073993|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073994|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11074038|NCT04257864||Erlotinib followed by docetaxel|Erlotinib given for twelve consecutive days before docetaxel
11074039|NCT04257864||Docetaxel followed by erlotinib|Erlotinib given for twelve consecutive days after docetaxel
11073995|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
11073996|NCT04258176||Intervention group|Patients seen in the multidisciplinary pathway
11073997|NCT04258176||Comparison group|Multimorbid patients seen several outpatient clinics in other hospitals
11073998|NCT04258163||MCT Group|People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
11073999|NCT04258163||MET Group|People who received endocrine therapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
11074000|NCT04258163||Observation Group|People who didn't receive any maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks.
11074001|NCT04258150|Experimental|Experimental|SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 6 mg/kg (up to 480 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 (± 3 days) twice in total every 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Tocilizumab 8 mg/kg is given IV on day 1 (± 3 days) over 1-hour, repeated every 4 weeks. Tocilizumab infusion over 30 minutes is allowed after 5. infusion in the absence of infusion related events.
11074002|NCT04258137|Experimental|Experimental procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
11074003|NCT04258137|No Intervention|Standard procedure for colorectal cancer|Patients with Advanced colorectal cancer will be managedby initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
11074004|NCT04258137|Experimental|Experimental procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment)
11074005|NCT04258137|No Intervention|Standard procedure for non-small cell lung cancer|Patients with Advanced non-small cell lung cancer will be managed by initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging.
11074006|NCT04258124|Experimental|Experimental group|"Each session will last 10 minutes, taking place 3 days a week, over a period of 6 weeks. The intervention will take place at the beginning of the training session. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
~Exercise 1. In quadruped position, keeping the back flat, making an isometric contraction of the transverse muscle, and raising one arm and one leg contralaterally.
~Exercise 2. Training of the deep cervical flexor muscles, supine. Players will move their heads slowly towards craniocervical flexion.
~Exercise 3. In standing position, an ocular-cervical coordination exercise by means of a cranio-cervical flexion, adding a rotation, guided by an eye feedback provided by the physiotherapist by means of a laser projected on a wall."
11074007|NCT04258124|No Intervention|Control group|Athletes in the control group will be asked to follow their usual warm-up routine.
11074008|NCT04258111|Experimental|IBI310 + Sintilimab|
11074009|NCT04258098||OA+MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
11074010|NCT04258098||MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. No oral antibiotics was administered to the patients.
11074011|NCT04258085||Screening plus EMR|Individuals in this group are those residing in districts where health facilities have implemented a breast cancer screening program integrated with cervical cancer screening.
11074012|NCT04258085||Early diagnosis plus EMR|Individuals in this group are those residing in districts where health facilities will implement a breast cancer early diagnosis program focused on expediting evaluation for women with breast symptoms.
11074013|NCT04258072|Experimental|open label,single arm|Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
11074014|NCT04258059|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
11074015|NCT04258059|Sham Comparator|Inactive UV Device|A device that appears identical to the active comparator device except the lamp will not emit germicidal UV.
11074016|NCT04258046|Experimental|Oral Trametinib|Patients will receive oral trametinib once daily
11074017|NCT04258033|Experimental|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
11074018|NCT04258020|Experimental|Experimental: alternating BiPAP and HFNC|Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
11074019|NCT04258020|No Intervention|Historical Control: standard of care|A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
11074020|NCT04258007|Placebo Comparator|Reversal Neostigmine|Patients undergoing cardiac catheterization will receive a combination of 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
11074021|NCT04258007|Active Comparator|Reversal Sugammadex|Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
11074040|NCT04257864||Bevacizumab treated|Bevacizumab treated patients
11074041|NCT04257851|Active Comparator|Group T (n=30)|Theophylline group
11074022|NCT04257994||patients with arrhythmic disorders|Participants will include patients diagnosed with a heritable arrhythmic disorder (including arrhythmogenic, hypertrophic and dilated cardiomyopathy, cardiac sarcoidosis as well as cardiac channelopathies; Long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia) followed at the Inherited Cardiac Conditions (ICC) service of St. George's University Hospitals NHS Foundation Trust as well as family members of victims of SCD evaluated at the same clinic for risk assessment and diagnosis.
11074023|NCT04257981|Experimental|Experimental group|"Transcranial direct stimulation + virtual related group:
~Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp Virtual reality (KVR) is the use of a computer interface involving upper limb activity in pediatric rehabilitation. VR creates an artificial environment, presented to the user through appropriate sensory stimulations."
11074024|NCT04257981|Sham Comparator|Control group|Sham Transcranial direct stimulation Group + virtual related group; The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies.
11074025|NCT04257968|Experimental|Diagnostic intervention|Complete diagnostic intervention
11074026|NCT04257955||Pancreatic cancer|"Outpatients seen at the Gastroenterology, Pancreatic Surgery and Oncology Clinics of the Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele, Milan (Italy) will be considered includable if:
~Adult patients (≥18 years);
~Of Italian mother tongue;
~Have a histologic diagnosis of PDAC obtained during the 4 weeks before the visit
~The visit is the first visit after completion of diagnostic procedures and is set to communicate the diagnosis and treatment strategies
~Give full, written informed consent
~The following exclusion criteria will be applied:
~PDAC recurrence after previous diagnosis and treatment
~poor performance status (ECOG ≥ 3);"
11074027|NCT04257929|Active Comparator|Low dose pitolisant|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:
~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning.
~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:
~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning.
~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:
~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning."
11074028|NCT04257929|Active Comparator|High dose pitolisant|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:
~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.
~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:
~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning.
~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:
~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
11074029|NCT04257929|Placebo Comparator|Placebo|"Pediatric patients (6 to less than 12 years of age) Double-Blind Treatment Phase:
~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets
~Adolescent patients (12 to less than 18 years of age) Double-Blind Treatment Phase:
~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets
~Adult patients (18 to 65 years of age) Double-Blind Treatment Phase:
~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
11074030|NCT04257916|Experimental|Experimental group|"The intervention by kinesiotape will be done with the player in supine position with the foot in dorsal flexion, anchoring the strip below the sole of the foot without tension, adding 50-70% tension until internal and external malleolus, and ending without tension. Another strip will be placed under the external malleolus, anchoring the bandage and following the talus (50-70% tension), leaving the scaphoid bulge free, surrounding the plant without tension and leaving the 5th metatarsal free. The bandage continues on the peroneal-astragalin ligament and the external malleolus (50-70% tension), until the tendon without tension. In the end we will surround the internal malleolus to the Achilles tendon without tension, ending with the same tension in the external malleolus and the neck of the talus.
~The myofascial technique and strength training will be the same in both groups."
11074031|NCT04257916|Active Comparator|Control group|"The myofascial technique will be carried out by positioning the caudal hand of the physiotherapist in the astragalin and heel region, and the cranial hand in the middle foot. With a tibiotarsal traction, the foot will be everted, performing a shear in the astragalin zone, using a combined and slow technique.
~All players will warm up for 10 minutes on tape, at a speed of 7 km / h without inclination. The strength work was carried out with an isoinertial machine (Space Whell) with intervalic methodology: 20 -10, with 4 series and doing three exercises: Squat, Lunges and Deadlift. One minute breaks will be made between sets."
11074032|NCT04257903||Occlusal Splint Therapy|The data of patients who previously received occlusal splint therapy were evaluated. Participants in the study received occlusal splint therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received occlusal splint therapy as part of routine medical care, and a researcher studied the effect of occlusal splint therapy.
11074033|NCT04257903||Low-Level Laser Therapy|The data of patients who previously received Low-Level Laser Therapy were evaluated. Participants in the study received Low-Level Laser Therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received Low-Level Laser Therapy as part of routine medical care, and a researcher studied the effect of Low-Level Laser Therapy.
11074034|NCT04257890|Experimental|CBT intervention group|In addition to the information about IGD of the control group, the intervention group will receive eight weekly group-based 90-minute CBT sessions.
11074035|NCT04257890|Active Comparator|Wait-list control group|Members will receive printed education material about IGD but not CBT during the treatment period.
11074043|NCT04257838||Piperacillin-Tazobactam or Meropenem Cohort|Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.
11074044|NCT04257825|Other|Initial Off|Individuals were asked to not use their device on weeks 1 and 3 of the study. They were asked to use their device on weeks 2 and 4.
11074045|NCT04257825|Other|Initial On|Individuals were asked to not use their device on weeks 2 and 4 of the study. They were asked to use their device on weeks 1 and 3.
11074046|NCT04257812||Ceftolozane-Tazobactam cohort|Patients older than 18 years old that are hospitalised in the Virgen Macarena University Hospital that are being treated with Ceftolozane-Tazobactam in empiric or targeted treatment.
11074047|NCT04257799||Women with breast cancer diagnosis|Women with diagnosis of invasive breast cancer based on pre-surgical biopsy, and scheduled for breast-conserving surgery in the Dartmouth-Hitchcock (DH) Outpatient Surgical Center.
11074048|NCT04257786|Active Comparator|Group 1|1ry surgery
11074049|NCT04257786|Active Comparator|Group 2|Neoadjuvant Chemotherapy followed by surgery
11074050|NCT04257773|Experimental|Immediate Treatment|Participants in this group will receive treatment/intervention immediately.
11074051|NCT04257773|Experimental|Delayed Treatment|Participant in this group will receive treatment/intervention 2-week later.
11074052|NCT04257760|No Intervention|Standard care|These ALS patients and their caregivers will receive standard care.
11074053|NCT04257760|Experimental|Early palliative care|These patients will receive a palliative care consultation that would not be requested by their care team as standard of care.
11074054|NCT04257747|Sham Comparator|Healthy volunteers|
11074055|NCT04257747|Active Comparator|patients requiring radial forearm flap reconstruction|
11074056|NCT04257747|Experimental|patients having received hand allotransplantation|
11074057|NCT04257734||optic neuritis|Aquaporin 4 antibody seropositive optic neuritis patients, Myelin oligodendrocyte glycoprotein antibody seropositive optic neuritis patients, and double antibodies seronegative optic neuritis patients
11074058|NCT04257708||normal uterine cavity|
11074059|NCT04257708||abnormal uterine cavity|
11074060|NCT04257695|Experimental|TapPro|Biweekly telephone and in-person visits with a clinician over six months. At each visit, a protocol adapted from the Prescription Opioid Taper Study will be provided to participants, who will learn about pain coping, distraction techniques, diaphragmatic breathing, sleep techniques, and progressive muscle relaxation techniques. All are specifically designed for patients with chronic pain on chronic opioid therapy. During visits, taper parameters will be discussed and the provider will work through a dose reduction schedule, if participants are in agreement. Additionally, urine drug screens will be obtained.
11074061|NCT04257695|No Intervention|Usual Care|Participants randomized to the usual care arm will continue seeing their primary care providers as indicated.
11074062|NCT04257682|Active Comparator|Bupivacaine|The participant will receive Bupivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
11074063|NCT04257682|Active Comparator|Ropivacaine|The participant will receive Ropivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
11074064|NCT04257682|Active Comparator|Mepivacaine|The participant will receive Mepivacaine as anesthesia during his or her planned total hip or knee replacement surgery.
11074065|NCT04257669||Iron sufficient|Haemoglobin ≥120g/L Serum ferritin > 20μg/L
11074066|NCT04257669||Non-anaemic iron deficient|Haemoglobin ≥120g/L Serum ferritin ≤ 20μg/L
11074067|NCT04257669||Iron deficient anaemic|Haemoglobin <120g/L Serum ferritin ≤ 20μg/L
11074068|NCT04257669||Anaemic without iron deficiency|Haemoglobin <120g/L Serum ferritin > 20μg/L
11074069|NCT04257656|Experimental|Remdesivir group|active remdesivir
11074070|NCT04257656|Placebo Comparator|Control group|Placebos matched remdesivir
11074071|NCT04257643|Experimental|Experimental group|water-based exercise was conducted at a hydrotherapy pool for the Eden Heelth Care,Cairo The pool measures 8 × 15 m and ranges from 1 to 1.8 m in depth with access via steps. Interventions were conducted predominately in the deeper section of the pool so participants immerse their neck in water. Thermo neutral water temperature, 30-32 °C at room temperature. Females were instructed to adjust water depth completely covering clavicles from standing position. Diaphragmatic breathing during exercise routine to assist with lymph fluid clearance. Exercise continuously for 40 to 45 min Full-body warm-up exercise for 10 min and cooling down for 10 minutes. Plus land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.
11074072|NCT04257643|Active Comparator|Control group|Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles
11074073|NCT04257617|Experimental|Single arm, CD47 monotherapy|Single arm, CD47 monotherapy
11074074|NCT04257604||Perampanel|Participants with partial-onset seizures, with or without secondary generalization will receive perampanel tablets as add-on therapy according to the approved summary of product characteristics (SmPC) after the baseline visit as part of the clinical practice and will be observed after 3 months (visit 1), 6 months (visit 2), and 12 months (final visit).
11074075|NCT04257591|Experimental|hamstring strengthening|8-week protocol (3 days per week) based on isometric, concentric and excentric exercisesof hamstrings
11074076|NCT04257591|No Intervention|Control|No intervention added to regular training.
11074077|NCT04257578|Experimental|Treatment (acalabrutinib, axicabtagene ciloleucel)|Beginning up to 3 weeks and at least 24 hours prior to leukapheresis, patients receive acalabrutinib PO every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also receive axicabtagene ciloleucel IV at 36-96 hours after completion of lymphodepleting chemotherapy.
11074078|NCT04257565|Active Comparator|Control group|The Control Group will receive usual and customary care from their vascular specialist.
11074079|NCT04257565|Experimental|Intervention Group|The Intervention Group will receive usual and customary care from their vascular specialist and they will be provided and trained to use the wheeled knee walker.
11107246|NCT04025476||control|health people age/sex match to the VKH patients
11074080|NCT04257552|Active Comparator|Attention Control Group|If randomized to the attention control arm participants will receive discharge instruction from the postpartum nurses per usual care. Study investigators will ask them to provide us with an SMS number. This will enable collection of self-reported breast feeding duration as well as texts on general infant care. The infant care texts are educational in nature and no data will be collected. Participants will receive a total of two texts on general infant care in the first month postpartum. This increased attention to the control arm mirrors the attention received by the Healthy Beyond Pregnancy arms and seeks to isolate the effect of the intervention from a general increased level of contact with providers. Participants that answer 80% of the infant feeding questions will receive a financial compensation.
11074081|NCT04257552|Active Comparator|Pre-Scheduled Postpartum Visit:|If randomized the the usual care with pre-scheduled visit arm, participants will schedule their postpartum visit with the study coordinator and receive discharge information per usual care. Participants that answer 80% of the infant feeding questions (collected via text messaging) will receive a financial compensation.
11074082|NCT04257552|Experimental|Healthy Beyond Pregnancy|Healthy Beyond Pregnancy is a web platform with an electronic survey that assesses a participant's self-identified postpartum concerns. Participants are then presented with 3 educational videos that reflect their self-identified needs from the survey. The Healthy Beyond Pregnancy generates an individualized passport for postpartum care. This passport for care lists the women's self-identified postpartum needs as well as issues that should be prioritized based on her health history.The individualized passport for postpartum care will be printed out and given to participants. After the participant schedules her postpartum visit, she will receive a print out that includes the date and time of her appointment, a copy of the commitment statement as well as a reminder of the monetary incentive she will receive if she fulfills her commitment and attends her postpartum visit.
11074083|NCT04257539|Experimental|Intervention Group|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior. This will include an initial, in-person behavioral intervention with a health coach trained and a 4 week phone call. Participants will receive a wrist-worn activity prompter to aid in sedentary behavior reduction.
11074084|NCT04257539|No Intervention|Wait-list Control Group|Chronic low back pain participants in this group will not receive the intervention until completion of the study. Over the 8 week intervention period, participants will be asked to maintain currently levels of physical activity, sedentary behaviors, and treatment for low back pain.
11074085|NCT04257539|No Intervention|Pain-free Control Group|These subjects will be healthy, pain-free adults and receive no intervention. Over the 8 week intervention period, participants in this group will be asked to maintain currently levels of physical activity, sedentary behaviors, and medication regimen.
11074086|NCT04257526|Active Comparator|Intervention|Colorectal cancer free participants receive evidence-based diet and lifestyle advice in addition to the 'usual care' following a positive FIT test and diagnostic colonoscopy
11074087|NCT04257526|No Intervention|Control|Colorectal cancer free participants receive the 'usual care' following a positive FIT test and diagnostic colonoscopy
11074088|NCT04257513||Healthy controls subjects|Subjects without known family history of HD, or tested negative for the HD expansion mutation.
11074089|NCT04257513||Symptomatic HD subjects|Subjects HD gene expansion carriers who have clinical diagnostic motor symptoms of defined HD, and disease stage I to III.
11074090|NCT04257513||Presymptomatic HD subjects:|Subjects HD gene expansion carriers who not have clinical diagnostic motor features of HD.
11074091|NCT04257500|Experimental|Contraceptive Ring|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), which releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily.
11074092|NCT04257487|Active Comparator|Treatment A|Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
11074093|NCT04257487|Active Comparator|Treatment B|Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
11074094|NCT04257487|Placebo Comparator|Treatment C|2 indistinguishable placebo capsules BID, for 12 months
11074095|NCT04257474||Assessing Health Services Utilization Model (HSUM)|150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.
11074096|NCT04257474||Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI
11074097|NCT04257461|No Intervention|Group1 Arm A|Observation only
11074098|NCT04257461|Other|Group 1 Arm B|Mono- or bichemotherapy: fluoropyrimidine with or without Oxaliplatin (choice by physician/patient or by randomisation)
11074099|NCT04257461|Other|Group 2 Arm C|Monochemotherapy: fluoropyrimidine
11074100|NCT04257461|Other|Group 2 ARM D|Bichemotherapy: fluoropyrimidine with oxaliplatin
11074101|NCT04257448|Experimental|Romidepsin/nab-Paclitaxel/Gemcitabine (Arm A)|Part 1a: Romidepsin (2 mg/m² or 3.3 mg/m² or 7 mg/m²) will be administered in combination with nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
11074102|NCT04257448|Experimental|Azacitidine/nab-Paclitaxel/Gemcitabine (Arm B)|Part 1a: Azacitidine (20 mg/m² or 30 mg/m² or 40 mg/m²) will be administered on Days -7 to Day -3 of each treatment cycle. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
11074103|NCT04257448|Experimental|Romidepin/Azacitidine/nab-Paclitaxel/Gemcitabine (Arm C)|Part 1a: The intervention to be administered depends on the determined dose in Arm A and Arm B. Additionally nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be given on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle. Study treatment is given until intolerable toxicity or will escalate until the recommended dose for expansion for a maximum of 3 cycles.
11074104|NCT04257448|Active Comparator|nab-Paclitaxel/Gemcitabine (Standard Arm)|nab-Paclitaxel (125 mg/m²)/Gemcitabine (1000 mg/m²) will be administered on Day 1, Day 8 and Day 15 (every 28 days) of each treatment cycle.
11074199|NCT04256798|Active Comparator|No mouthwash and liberal oxygen during surgery|No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.
11074105|NCT04257448|Experimental|Arm C or B or A|In Part 1b (expansion part) of the study, one of the treatment arms (Arm C over Arm B over Arm A) will be continued. Treatment will only be performed with the study drug that were tolerable in Part 1a (dose escalation).
11074106|NCT04257448|Experimental|Durvalumab/Lenalidomide|Part 2: All patients from Part 1 who have not progressed after three cycles receive standard fixed dose Durvalumab (1500 mg) on Day 1 of each 28-day treatment cycle by IV infusion in combination with orally administered low-dose Lenalidomide (10 mg) on Days 1 to 21 until documented disease progression. Study treatment is given for a maximum of 13 cycles.
11074107|NCT04257435|Active Comparator|Traditional Behavioral Health Treatment|
11074108|NCT04257435|Experimental|Positive Psychological Group Treatment|
11074109|NCT04257422|Experimental|Intentional Rounding|In the centers randomized to Intentional Rounding the ward nurses will have to adopt a new proactive care method towards hospitalized patients
11074110|NCT04257422|No Intervention|Control|In randomized controlled centers, nurses guarantee the standard care provided by the ward
11074111|NCT04257409|Experimental|DF patient active|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
11074112|NCT04257409|Active Comparator|DF patient control|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
11074113|NCT04257409|Experimental|Diabetic patient with mild neuropathy|Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
11074114|NCT04257409|Experimental|Diabetic patient with severe neuropathy|Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
11074115|NCT04257396|Experimental|Arm 1 CARA Positioning|Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
11074116|NCT04257396|No Intervention|Arm 2 Standard of Care|Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.
11074117|NCT04257383|Experimental|Treatment|Families in the treatment cells will receive the Sugira Muryango treatment immediately after household identification and enrollment.
11074118|NCT04257383|Experimental|Waitlist Control|Families in the control cells will receive the Sugira Muryango treatment following the completion of the 12-month follow up on the original treatment group.
11074119|NCT04257370|Experimental|Kerecis™ Omega3 Wound|
11074120|NCT04257370|Active Comparator|Standard of care|
11074121|NCT04257357|Experimental|Exercise group|Eight-week supervised exercise program: Patients in the intervention group receive the same usual care as the patients in the control group. In addition, the patients participate in an eight-week supervised interval training program. Briefly put, the patients are required to participate in at least 16 out of 20 possible training passes over the period of eight weeks. The training consists of a brief warm up followed by 35-50 minutes of interval training on a bicycle. The intensity and duration will increase over time
11074122|NCT04257357|Active Comparator|Control group|"Patients in the control group receive usual care as a minimum. This includes three-five days of hospitalization where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
~It is considered an active comparator as all patients in the control group perform a watt-max cycle ergometer test with VO2 measurement 3 times, and this in it-self can influence patients' activity level."
11074123|NCT04257331|Experimental|SREIA group|Participants in this arm will be families who attend the first wave of the two rounds of delivery. They will be the intervention group.
11074124|NCT04257331|No Intervention|Waitlist Control|Participants in this arm will be families who attend the second wave of the two rounds of delivery. They will be the control group.
11074125|NCT04257318|Experimental|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregn
11074126|NCT04257279|Experimental|Robotic|Patients receiving spine surgery with posterior stabilization placed by ExcelsiusGPS
11074127|NCT04257266|Experimental|Cryo Cooling Pack|Cryo cooling pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
11074128|NCT04257266|Active Comparator|Commerical Ice Pack|The commercial ice pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
11074129|NCT04257253|Experimental|Targeted exercise program|Targeted motor control and isolated lumbar extensor strengthening exercises. Supervised 12-week program, 2 times a week.
11074130|NCT04257253|Active Comparator|General exercise program|General exercise program including upper body and lower body strengthening and flexibility exercises. Supervised 12-week program, 2 times a week.
11074131|NCT04257240||study group|patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver
11074132|NCT04257240||control group|patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
11074133|NCT04257227|Experimental|rTMS Intervention Group|
11074134|NCT04257214|No Intervention|Treatment as usual|Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.
11074135|NCT04257214|Active Comparator|Office based CBT|Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.
11074136|NCT04257214|Active Comparator|CRS/CPS|Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.
11074137|NCT04257214|Active Comparator|CBT+CRS/CPS|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
11108279|NCT04018131|Placebo Comparator|Placebo|
11074138|NCT04257201|Active Comparator|Control -- no mushrooms|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
11074139|NCT04257201|Experimental|Yellow Oyster -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
11074140|NCT04257201|Experimental|Yellow Oyster -- 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
11074141|NCT04257201|Experimental|White button -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
11074142|NCT04257201|Experimental|White button 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
11074143|NCT04257175|Experimental|Cyclophosphamide, Flodarabine,CAR-T cells|"The appropriate participants will undergo lymhopheresis to collect lymphocytes from PBMC peripheral blood. CAR T CD19 cells will be produced. The participants will receive cyclophosphamide 300 mg / m² and flodarabine 30 mg / m² lymphodeplition intravenously daily for 3 days.
~The CAR-T CD19 cells will be given on the 5 to 7 day post lymphodeplition ."
11074144|NCT04257162|Other|Experimental Arm|Samples from patients Ds8201-A-U301, Ds8201-A-U302 and Ds8201-A-U303 trials
11074145|NCT04257149|Experimental|Hemorrhagic stroke group (group A)|Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
11074146|NCT04257149|Experimental|Ischemic stroke group (group B)|Patient group B is defined as patients that are diagnosed with ischemic stroke.
11074147|NCT04257149|Experimental|Stroke mimic group (group C)|Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
11074148|NCT04257136|Experimental|Treatment|Treatment with VBI-S
11074149|NCT04257123|Experimental|Controlled-Feeding|For two weeks (separated by a wash-out week), participants will consume all meals in the Nutrition Science facility.
11074150|NCT04257123|Experimental|Free-Feeding|For two weeks (separated by a wash-out week), participants will receive no dietary guidance and will be allowed to consume whatever they desire.
11074151|NCT04257110|Experimental|Part 1: Dose-escalation|Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle.
11074152|NCT04257110|Experimental|Part 2: Cohort 1|Subjects will be administered BB-1701 at one or two dose levels (e.g. MTD and the dose below MTD)
11074153|NCT04257110|Experimental|Part 2: Cohort 2|Subjects will be administered BB-1701 at one or two dose levels (e.g. MTD and the dose below MTD)
11074154|NCT04257097|Active Comparator|Group A - control group|25 patients will undergo bone regeneration with a titanium reinforced PTFE Mesh (RPM - Osteogenics Lubbock Texas USA), manually shaped and modeled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption (Vitala - Osteogenics Lubbock Texas USA)
11074155|NCT04257097|Experimental|Group B - Test group|25 patients undergo bone regeneration with a custom-made titanium mesh (Yxoss CBR - Reoss Filderstadt Germany), digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption (Bio-Gide - Geistlich Baden Baden Germany)
11074156|NCT04257084|Active Comparator|CE-NBI|High definition chromoendoscopy with target biopsy, at 1st surveillance colonoscopy during the trial High definition NBI with target biopsy, at 2nd surveillance colonoscopy during the trial
11074157|NCT04257084|Active Comparator|NBI-CE|High definition NBI with target biopsy, at 1st surveillance colonoscopy during the trial High definition chromoendoscopy with target biopsy, at 2nd surveillance colonoscopy during the trial
11074158|NCT04257071|Active Comparator|Usual Care|Participants randomized to the usual care study arm will receive the usual care for their MS.
11074159|NCT04257071|Experimental|OOP Cost Communication and Optimization|Participants in this study arm in addition to usual care, will receive a personalized discussion of their OOP cost estimates for treatment obtained through an online price transparency tool, personalized analysis of expenses by financial counselor, and enrollment in any cost optimization opportunities for which they are eligible using a comprehensive financial navigation program.
11074160|NCT04257058|Experimental|Electronic educational material|Participants will complete an online pre-test survey via REDCap. One week after the pre-test survey is completed, AYAs will be sent electronic media via email to review on their own. Study staff will confirm receipt and review of material and schedule a post-test survey to be completed in REDCap two weeks after material is reviewed.
11074161|NCT04257045||Observational (interview, survey)|"STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.
~STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes."
11074162|NCT04257032|Experimental|Reference 1 (R1)|
11074163|NCT04257032|Experimental|Test 1 (T1)|
11074164|NCT04257032|Experimental|Reference 2 (R2)|
11074165|NCT04257032|Experimental|Test 2 (T2)|
11074166|NCT04257019|Experimental|Lavender|Lavender mask before and during procedure
11074167|NCT04257019|Active Comparator|Almond|Almond oil mask before and during procedure
11074168|NCT04257019|Sham Comparator|Water|Water mask before and during procedure
11074169|NCT04257006|Experimental|patients undergoing CRRT with oXiris membrane|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.
~Indications for CRRT (SCUF) with oXiris after ICU admission:
~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.
~Or high risk of pulmonary edema after cardiac surgery:
~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)
~CVP (central venous pressure) ˃ 12 mm H2O.
~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.
~In this arm the treatment of fluid overload will be provided via SCUF with oxiris membrane"
11074198|NCT04256798|Experimental|Mouthwash and liberal oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.
11108923|NCT04013815|Experimental|group E|patients receiving the ESP block
11074170|NCT04257006|No Intervention|standard protocol|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.
~Indications for CRRT (SCUF) with oXiris after ICU admission:
~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.
~Or high risk of pulmonary edema after cardiac surgery:
~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)
~CVP (central venous pressure) ˃ 12 mm H2O.
~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.
~In this arm the management of fluid overload will be provided via diuretics or IHD (in condition diuretics treatment resistance)"
11074171|NCT04256993||Ra-223 initiators|"Patients diagnosed with mCRPC (Metastatic Castration-Resistant Prostate Cancer) who start treatment with Ra-223. Patients will be identified from the Patient-overview Prostate Cancer (PPC), a sub-registry of the Prostate Cancer data Base Sweden (PCBaSe) data set."
11074172|NCT04256993||Initiators of other standard of care|The comparator cohort will be patients using standard of care other than Ra-223.
11074173|NCT04256980|Experimental|Pemigatinib in patients with advanced/metastatic or surgically|Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma
11074174|NCT04256967||Sport sciences|Bachelor and master students who study sport science or physical activity and health science
11074175|NCT04256967||Controls|Bachelor and master students who study other fields not related to sport or physical activity and health sciences.
11074176|NCT04256954|Experimental|Peer navigation|Those who are assigned to the intervention arm will receive peer navigation service by a trained peer navigator who will link them with mental health, medical and substance use services in the community.
11074177|NCT04256954|No Intervention|Standard of Care|SOC consists of TAU + monitoring and emergency referral, as is required to fulfil ethical obligations to trial participants. To determine the naturalistic effects and costs of adding peer navigation intervention, participants in both conditions can receive any other treatment available to them and we will not exclude participants receiving other treatment. We will carefully characterize TAU for each condition as part of our service utilization assessment.
11074178|NCT04256941|Experimental|Arm I (ribociclib, palbociclib, abemaciclib, fulvestrant)|Patients receive ribociclib PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive fulvestrant IM for 2 injections over 1-2 minutes each on days 1 and 15 of cycle 1 and day 2 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11074179|NCT04256941|Active Comparator|Arm II (ribociclib, palbociclib, abemaciclib, letrozole)|Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11074180|NCT04256928|Experimental|Intervention group|"This group of participants will have any body hair in the operative field clipped with an electrical clipper by hospital personnel, during preparation for planned surgery.
~4 microbiological samples will be taken from all participants in this group."
11074181|NCT04256928|No Intervention|Control group|"This group of participants serve as the control group. Any body hair in the operative field is left intact.
~4 microbiological samples will be taken from all participants in this group."
11074182|NCT04256915|Experimental|CBT-I + Bright Light|n = 50
11074183|NCT04256915|Active Comparator|CBT-I + Placebo Light|n = 50
11074184|NCT04256915|No Intervention|Wait-list Control|n = 50
11074185|NCT04256889|Experimental|nfant(R) feeding system|Addition of nfant(R) technology, along with visual assessments and cue-based feeding practices, to facilitate an infant's progression to full oral feeding and potentially improve developmentally supportive feeding practices.
11074186|NCT04256876|Active Comparator|Active TTNS|Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
11074187|NCT04256876|Sham Comparator|TTNS sham intervention|"Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.
~Home therapy: Daily stimulation during 60 minutes."
11074188|NCT04256863|Experimental|Breakfast / Lunch (BFL)|This group will complete a 16-week standard behavioral weight control intervention in which they will be asked to consume >50% of their daily energy goal before 3PM. To do so, they will complete weekly experiential learning sessions in conjunction with the SBT lessons.
11074189|NCT04256863|Active Comparator|Dinner (DIN)|This group will complete a 16-week standard behavioral weight control intervention. They will not be given any recommendations regarding the timing of their energy consumption, but instead encouraged to follow the same energy goals at the BFL group.
11074190|NCT04256850|Experimental|Acceptance and Commitment Therapy (ACT)|Focuses on addressing cognitive and emotional barriers to successful weight loss maintenance.
11074191|NCT04256850|Experimental|Self-Regulation (SR)|Focuses on using self-monitoring and self-reinforcement techniques to improve weight loss maintenance.
11074192|NCT04256837|Experimental|VNS - Live donor kidney recipients.|Live donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
11074193|NCT04256837|Sham Comparator|sham VNS - Live donor kidney recipients.|Live donor kidney recipients. As above, but without applying any VNS
11074194|NCT04256837|Experimental|VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal.
11074195|NCT04256837|Sham Comparator|sham VNS - Deceased donor kidney recipients.|Deceased donor kidney recipients. As above, but without applying any VNS
11074196|NCT04256824|Experimental|Coated Polyglactin 910 with Triclosan|Coated vicryl plus
11074197|NCT04256824|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated vicryl
11114118|NCT03976401|Placebo Comparator|Placebo|Main Study
11074200|NCT04256798|Experimental|Mouthwash and restrictive oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.
11074201|NCT04256798|Active Comparator|No mouthwash and restrictive oxygen during surgery|No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.
11074202|NCT04256785|Experimental|VSL#3|probiotic VSL#3, 2 sachets b.i.d for 3 months
11074203|NCT04256785|Placebo Comparator|placebo|matched placebo, 2 sachets b.i.d for 3 months
11074204|NCT04256759|Experimental|Dupilumab|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
11074205|NCT04256746|Placebo Comparator|Boiled Rice|63 g of raw rice was cooked.
11074206|NCT04256746|Experimental|Boiled Rice+0.37 gr extract|63 g of raw rice was cooked and 0.37 gr mulberry fruit powdered extract added and mixed
11074207|NCT04256746|Experimental|Boiled Rice+0.75 gr extract|63 g of raw rice was cooked and 0.75 gr mulberry fruit powdered extract added and mixed
11074208|NCT04256746|Experimental|Boiled Rice+1.12 gr extract|63 g of raw rice was cooked and 1.12 gr mulberry fruit powdered extract added and mixed
11074209|NCT04256746|Experimental|Boiled Rice+1.50 gr extract|63 g of raw rice was cooked and 1.50 gr mulberry fruit powdered extract added and mixed
11074210|NCT04256746|Placebo Comparator|Rice porridge|60 g of rice porridge was rehydrated with 300 ml boiling hot water
11074211|NCT04256746|Active Comparator|Rice porridge+1.50 gr extract|60 g of rice porridge was rehydrated with 300 ml boiling hot water and 1.50 gr mulberry fruit powdered extract added and mixed
11074212|NCT04256733|Experimental|Supra-threshold capsaicin|Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
11074213|NCT04256733|Placebo Comparator|Sub-threshold capsaicin|Participants will be exposed repeatedly to a single sub-threshold dose of aerosolized capsaicin through a nebulizer during treatment. This sub-threshold dose will elicit minimal or no urge-to-cough.
11074214|NCT04256707|Experimental|Monotherapy: Normal Hepatic Function (Selinexor)|"Cohort 1:
~Week 1: selinexor 5 x 20-mg tablet daily;
~Week 2: selinexor 1 x 100-mg tablet daily
~Cohort 2:
~Week 1: selinexor 1 x 100-mg tablet daily;
~Week 2: selinexor 5 x 20-mg tablet daily."
11074215|NCT04256707|Experimental|Monotherapy: Impaired Hepatic Function (Selinexor)|"Cohort 3:
~Patients with Moderate Hepatic Impairment with any Solid Tumors; - Selinexor 2 x 20-mg tablet once weekly (QW);
~Cohort 4:
~Patients with Severe Hepatic Impairment with any Solid Tumors;
~- Selinexor 2 x 20-mg tablet QW."
11074216|NCT04256707|Experimental|Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)|Selinexor 60 mg oral dose QW and docetaxel 75 mg/m^2 intravenously (IV) once every 3 weeks (Non-small cell lung cancer [NSCLC] patients).
11074217|NCT04256707|Experimental|Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)|Selinexor 80 mg oral does QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer [CRC] Patients).
11074218|NCT04256707|Experimental|Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)|"Cohort 1:
~Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5- fluorouracil (5-FU) 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).
~Cohort 2:
~Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5-FU 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients)."
11074219|NCT04256694||Healthy Adult Subjects|
11074220|NCT04256681|Experimental|patients affected by hereditary spastic paraplegia|40 subjects affected by genetically determined hereditary spastic paraparesis or subjects without defined genetics but who unequivocally show a dominant or recessive familiarity with exclusive involvement of the pyramidal system.
11074221|NCT04256681|Active Comparator|healthy subjects|40 healthy subjects will also be recruited to whom the questionnaire will be submitted to assess the variability of the score within a healthy population.
11074222|NCT04256668|Active Comparator|good embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with normal embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal fertilization rate >50% and normal blastocyst development rate >50%).
11074223|NCT04256668|Active Comparator|poor embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with poor embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal or slightly reduced fertilization rate <50% and low or absent blastocyst development (0 or only 1 blastocyst).
11074224|NCT04256668|Placebo Comparator|natural conception|20 previously infertile men, normal history, normal genital status, normal sperm count, DNA fragmentation rate <20% (as given by TUNEL) and achieving pregnancy naturally (without medical intervention).
11074225|NCT04256655|Experimental|Cohort 1 0.225 g|Randomized to treatment with either CDX-6114 0.225g or matching Placebo
11074226|NCT04256655|Experimental|Cohort 2 0.75g|Randomized to treatment with either CDX-6114 0.75g or matching Placebo
11074227|NCT04256655|Experimental|Cohort 3 2.25g|Randomized to treatment with either CDX-6114 2.25 g or matching Placebo
11074228|NCT04256642|Active Comparator|Intrathecal morphine|
11074229|NCT04256642|Experimental|Erector Spinae Plane Block|
11074230|NCT04256629|Experimental|Treatment ABC|Subjects will receive a single dose of all 3 treatments (A, B, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
11074231|NCT04256629|Experimental|Treatment BCA|Subjects will receive a single dose of all 3 treatments (B, C, and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
11074232|NCT04256629|Experimental|Treatment CAB|Subjects will receive a single dose of all 3 treatments (C, A, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
11074233|NCT04256629|Experimental|Treatment ACB|Subjects will receive a single dose of all 3 treatments (A, C, and B) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
11074234|NCT04256629|Experimental|Treatment BAC|Subjects will receive a single dose of all 3 treatments (B, A, and C) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
11074235|NCT04256629|Experimental|Treatment CBA|Subjects will receive a single dose of all 3 treatments (C, B and A) in a crossover design with wash-out periods of at least 7 days between each study dose administration.
11074236|NCT04256616||Bladder cancer patients|80 patients with carcinoma of the bladder; divided in 20 patients Ta (low grade), 20 patients Ta/T1 (high grade) and 20 patients T2. Only for liquid samples collection we will include 20 CIS (carcinoma in situ) patients
11074237|NCT04256616||Controls- Healthy subjects|30 age and sex-matched subjects not suffering from carcinoma of the bladder, already hospitalized in ICH; we expect to enroll 24 males and 6 females of which 10 of 40- 60 years old, 10 of 60-70 years old, 10 of >70 years old.
11074238|NCT04256603|Other|1|Gabapentin prior to admission
11074239|NCT04256603|Other|2|Gabapentin during admission
11074240|NCT04256603|Other|3|No gabapentin
11074241|NCT04256590||Study|Patients aged 16 years or younger who were to undergo adenoidectomy surgery were eligible for inclusion in this group. Tongue surface areas were measured twice by submental USG.The first measurements (TSA2) were done immediately after endotracheal intubation but before insertion and placement of the tongue depressor. The second measurements (TSA1) were done after adenoidectomy surgery and after removal of the tongue depressor but just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue swelling.
11074242|NCT04256590||Control|This group included patients aged 16 years or younger who did not need adenoidectomy surgery and any head and neck procedures. Tongue surface areas of the patients were measured twice by submental USG as in the study group. TSA1s were done immediately after endotracheal intubation, and TSA2s were done at the end of the surgical procedure just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue edema.
11074243|NCT04256577||patients proven having (SLE)|20 patients proven to have systemic lupus Erthematosus without renal impairment (eGFR) ≥ 80 ml/min/1.73 m2 and albumin / creatinine ≤ 30 mg/g)
11074244|NCT04256577||patients proven to have (LN) by renal biopsy|Group (2) 25 patients proven to have LN by renal biopsy before starting treatment and after 3 cycle of treatment (eGFR < 80 ml/min/1.73 m2 and albumin/creatinine ratio > 30 mg/g)
11074245|NCT04256577||healthy control|(20) patients healthy control matched in age and sex
11074246|NCT04256564|Experimental|Oblique visualization linear probe|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein
11074247|NCT04256564|Experimental|Y-shape visualization micro-convex probe|A micro-convex endocavity ultrasound probe will be utilized to place the central catheter into the brachiocephalic vein
11074248|NCT04256551|Experimental|Machine Learning App + Registered Dietitian facilitator|The ML-RD group will be provided access to the Heali mobile application as well as a personal RD to provide nutrition support and answer any questions through a real-time messaging system within the mobile app. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
11074249|NCT04256551|Active Comparator|Machine Learning App|The ML-APP group receives access to the Heali mobile dietary application. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
11074250|NCT04256551|Placebo Comparator|Standard Dietary Education|Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
11074251|NCT04256538||Crohn's Disease Group|Patients are diagnosed as Crohn's disease and have no history of colectomy.
11074252|NCT04256538||Ulcerative Colitis Group|Patients are diagnosed as ulcerative colitis and have no history of colectomy.
11074253|NCT04256538||Healthy Control Group|Individuals that have no past medical history.
11074254|NCT04256525|Experimental|Aspirin 100mg|
11074255|NCT04256525|Experimental|rivaroxaban 10mg|
11074256|NCT04256525|Experimental|low molecule heparin|
11074257|NCT04256525|No Intervention|Reference|mechanical prophylaxis
11074258|NCT04256512|Experimental|Cryotherapy|Subjects diagnosed with breast cancer undergoing 3 months of taxane based chemotherapy will be provided Elasto Gel® Therapy Mittens and Foot Wraps to be worn on both hands and feet at each chemotherapy infusion during their three months of treatment. Subjects will start wearing the mittens and foot wraps 15 minutes prior to each infusion, during the entire infusion, and for 15 minutes after the completion of each infusion. We will assess for peripheral neuropathy, physical functioning, and quality of life prior to initiation of taxane based therapy, immediately after completion of taxane based chemotherapy, and again at 3 months following completion of therapy.
11074259|NCT04256499||Water load test|Patients experiencing a syndrome of inappropriate antidiuresis who had an acute water load test
11074260|NCT04256499||Control group|Patients who had an acute water load test and who did not experience any water homeostasis anomalies
11074261|NCT04256486|Experimental|Family DSMES|
11074262|NCT04256486|Experimental|Wait List|
11074263|NCT04256473|Experimental|Intervention|"Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.
~Depending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes)."
11074264|NCT04256473|Active Comparator|Control|Usual care with alteplase 0.9 mg/kg in 60 minutes
11074265|NCT04256460|Experimental|Intervention arm|Behavior intervention including health education on diet, exercises and self management support through peer support, and also receive regular care and follow up in community health centers
11074266|NCT04256460|No Intervention|Control arm|Receiving regular care and follow up in Community health centers
11074267|NCT04256447||Sixty-eight children and adolescents with type 1 diabetes|Sixty-eight children and adolescents aged between 4 and 18 years with type 1 diabetes. Patients with celiac disease, thyroid disease, other autoimmune diseases, concurrent illness, patients with diabetic nephropathy, other renal disease and in therapy with natriuretic drugs were excluded.
11074268|NCT04256434|Experimental|Dinabuphine sebacate|Each subject in cohort 1 will receive 150 mg Dinalbuphine sebacate (75 mg/mL x 2 mL) intramuscularly.
11074269|NCT04256434|Active Comparator|Nalbuphine HCl|Each subject in cohort 2 will receive 20 mg Nalbuphine (20 mg x 1 mL) intramuscularly.
11074539|NCT04254705|Other|Subjects with CF and R334W mutation|Subjects with CF and R334W mutation
11074270|NCT04256421|Experimental|Tiragolumab + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
11074271|NCT04256421|Active Comparator|Placebo + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
11074272|NCT04256408|Experimental|Treatment group|Treatment group
11074273|NCT04256382|Experimental|experimental group|The experimental group took two-hour online course about dementia pain care in two weeks.
11074274|NCT04256382|Active Comparator|comparison group|The comparison group took two-hour online course about dementia care in two weeks.
11074275|NCT04256369||Primary Cohort|Starting premixed Olimel N9E and follow for electrolyte irregularities.
11074276|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at double dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 4,6 g per 100g of powder (group fed with double dosage of fermented matrix compare trial FERCT15)
11074277|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at triple dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 6,9 g per 100g of powder (group fed with triple double dosage of fermented matrix compare trial FERCT15)
11074278|NCT04256356|Placebo Comparator|Infants born by CS-fed standard formula|Infants born by CS-fed formula milk without fermented matrix
11074279|NCT04256356|Other|Infants born by CS-breastfed|Infants born by cesarean section fed with mother milk during were the reference group
11074280|NCT04256343|Experimental|D2O Dose 1|Lower dose of D2O for MPS
11074281|NCT04256343|Experimental|D2O Dose 2|Moderate dose of D2O MPS
11074282|NCT04256343|Experimental|D2O Dose 3|Higher dose of D2O for MPS
11074283|NCT04256330||Lean and metabolically healthy|
11074284|NCT04256330||Lean and metabolically unhealthy|
11074285|NCT04256330||Overweight and metabolically healthy|
11074286|NCT04256330||Overweight and metabolically unhealthy|
11074287|NCT04256330||Obese and metabolically healthy|
11074288|NCT04256330||Obese and metabolically unhealthy|
11074289|NCT04256317|Experimental|Phase 1, Stage A (Dose Escalation)|In Cycle 1 (28 days per cycle), single dose oral azacitidine will be administered, followed by subcutaneous (SC) azacitidine, ASTX030 and oral cedazuridine on a specific dosing schedule; in Cycle 2, oral ASTX030 (cedazuridine + azacitidine) will be administered
11074290|NCT04256317|Experimental|Phase 1, Stage B (Dose Expansion)|Oral cedazuridine + azacitidine will be administered at the recommended dose for expansion (RDE) as individual separate tablets
11074291|NCT04256317|Experimental|Phase 2, Sequence A|Oral ASTX030 (cedazuridine + azacitidine) will be administered in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
11074292|NCT04256317|Experimental|Phase 2, Sequence B|SC azacitidine will be administered in Cycle 1, followed by oral cedazuridine + azacitidine tablets in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
11074293|NCT04256317|Experimental|Phase 3, Sequence A|Participants will receive ASTX030 tablets in Cycle 1, followed by SC azacitidine in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
11074294|NCT04256317|Experimental|Phase 3, Sequence B|Participants will receive SC azacitidine in Cycle 1 followed by ASTX030 tablets in Cycle 2; all participants will receive ASTX030 in subsequent cycles (Cycles ≥3)
11074295|NCT04256304|Experimental|Intervention group|"Personalized Health Engagement Plan group
~First face-to-face session (Motivational interviewing) + Pre-tests
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus
~Phone call coaching
~A set of personalized home-based exercises
~Second face-to-face session (Motivational interviewing) + Post-tests
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
11074296|NCT04256304|No Intervention|Control group|"First meeting (Pre-tests)
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus
~Second meeting (Post-tests)
~Patient Health Engagement Scale
~Assessment Scale for Treatment Adherence in Type 2 Diabetes Mellitus
~The Diabetes Management Self-Efficacy Scale for Patients with Type 2 Diabetes Mellitus"
11074297|NCT04256278|Experimental|Intervention Group|
11074298|NCT04256278|Placebo Comparator|Control Group|
11074299|NCT04256252|Experimental|Rituximab|Intravenous rituximab was administered at a fixed dose of 100 mg once weekly for 3 weeks, followed by maintenance treatment with 100 mg rituximab every 6 months.
11074300|NCT04256239|Experimental|Dignity Therapy Group|"Dignity Therapy is a short-term psychotherapy aimed at improving patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress. Therapy sessions, lasting between 20 and 60 minutes, were offered at the patients' bedside and audiotaped, and were conducted by a trained psyco-oncologist. After each therapy session, the audiotaped interview data were transcribed verbatim by a different psycho-oncologist and edited and reshaped into a written narrative by an expert in DT over the course of the next two to three days. Once the editing process was completed, another session was held to allow the therapist to read the generativity document to the patient and to make any editorial changes the patient deemed necessary. The final version of the generativity document was given to the patient to bequeath it to individuals of their choosing"
11074301|NCT04256239|No Intervention|Control Group (Standard Palliative Care)|Standard Palliative Care was performed by a multidisciplinary care team composed of a palliative doctor, a psycho-oncologist, a nurse, a physiotherapist, a healthcare assistant, a social assistant, a volunteer and a spiritual assistant, tailoring care to the needs of patients and their families.
11074302|NCT04256213|Experimental|Nivolumab + Ipilimumab|
11074303|NCT04256200|Active Comparator|Dienogest|Deinogest (Visanne) 2mg/day orally for 24 weeks
11074304|NCT04256200|Active Comparator|Oral Contraceptive Pills|Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks
11074305|NCT04256187||Healthy group|Caregivers of children who treated with botulinum toxin.
11074306|NCT04256174|Experimental|Part 1:15mg cohort|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects.
11074307|NCT04256174|Experimental|Part 1: 50mg cohort|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects.
11074308|NCT04256174|Experimental|Part 1: 150mg cohort|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects.
11074309|NCT04256174|Experimental|Part 1: 300 mg cohort|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects.
11074310|NCT04256174|Experimental|Part 1: 600 mg cohort|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects.
11074311|NCT04256174|Experimental|Part 2: low dose cohort|Multiple low doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
11074312|NCT04256174|Experimental|Part 2: medium dose cohort|Multiple medium doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
11074313|NCT04256174|Experimental|Part 2: high dose cohort|Multiple high doses of AK120 or placebo are administered subcutaneously to subjects with moderate- to- severe atopic dermatitis.
11074314|NCT04256148|Experimental|ALXN1830 Dosing Regimen 1|
11074315|NCT04256148|Experimental|ALXN1830 Dosing Regimen 2|
11074316|NCT04256148|Experimental|ALXN1830 Dosing Regimen 3|
11074317|NCT04256148|Active Comparator|Placebo|
11074318|NCT04256135|Experimental|Experimental mobilization: Mulligan|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
11074319|NCT04256135|Active Comparator|Control mobilization: AP Maitland|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
11074320|NCT04256122||Responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.
~Patient treated with adjuvant MMC or BCG that did not experience recurrence for at least 42 months after TURBT
~Patients are tumor-free at the moment of the analysis"
11074321|NCT04256122||Non responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.
~o Patient treated with adjuvant MMC or BCG that experienced recurrence in the first 24 months after TURBT."
11074322|NCT04256096|Experimental|thrombectomy|mechanical thrombectomy with stent-retriever and/or thromboaspiration
11074323|NCT04256096|Active Comparator|Clinical treatment|Best Medical treatment
11074324|NCT04256083||AFE (amniotic fluid embolism)|Women for whom the diagnosis of amniotic fluid embolism was retained according to the UKOSS criteria.
11074325|NCT04256083||Control 1|Women admitted for prophylactic elective cesarean section.
11074326|NCT04256083||Control 2|Women with acute collapse in the peripartum period (with systolic blood pressure <80 mmHg twice and for> 5 minutes or acute peri-partum shock, for which the diagnosis of amniotic embolism has been ruled out).
11074327|NCT04256070|Experimental|Education, tele-consultation and training booklet|"Informed Consent Form will be taken in written from those who agree to participate in the research.
~In the first intervention, Information Form Based on Watson's Human Care Theory, Chronic Obstructive Pulmonary Disease Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected. Subsequently, education, counseling nursing care and education booklet based on Watson's Human Care Theory will be given.
~Teleconsultation based on Watson's Human Care Theory will be given during the intervention at weeks 2, 4, 6, 8 and 10.
~24-hour tele-consultancy will be given on subjects determined for the management of COPD in case of necessity at the request of the individual.
~In the last intervention in the 12th week, face to face with the individual, Consultancy based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form, Telephone Interview Evaluation Form will be applied."
11074328|NCT04256070|No Intervention|Standart care, no intervention|"Informed Consent Form will be taken in writing from those who agree to participate in the research.
~At the first meeting, Information Form Based on Watson Human Care Theory, Self-efficacy Scale, St. George Quality of Life Scale, Respiratory Function Test Form data will be collected.
~Interventions will not be applied to individuals in this group and routine treatment and follow-up will continue.
~- COPD Self-efficacy Scale, face-to-face meeting at the end of the 12th week. George Quality of Life Scale, Respiratory Function Test Form will be repeated.
~A training booklet for COPD management will be provided."
11074329|NCT04256057|Other|magnesium sulphate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
11074330|NCT04256044||Observational|Observational
11074331|NCT04256031||Excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are higher than 30
11074332|NCT04256031||Non-excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are 30 or less
11074333|NCT04256018|Experimental|LD TSEBT|"Mogamulizumab with low dose total skin electron beam therapy. •
~LD (12 Gy) TSEBT will be initiated on Cycle 1 Day 2 (± 2 days) of mogamulizumab over 2 to 3 week period per standard of care (SOC), as tolerated. Mogamulizumab (1 mg/kg) will be administered over 60 minutes as follows (per SOC and FDA approved use in MF and SS):
~Cycle 1 only: Days1; 8; 15; and 22 (± 2 days)
~Cycle 2 and beyond: Day 1 and Day 15 (± 3 days)"
11074334|NCT04256005|No Intervention|Control|Participants will attend the laboratory and complete no exercise. The participants will remain seated for the 29 minutes of the session.
11074335|NCT04256005|Experimental|105% VO2Peak|Participants will complete ten intervals at a work rate which equates to 105% VO2peak with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
11074537|NCT04254731|Other|Cross over study before and after drug switch|Stabilized on racemic methadone dose, switched to R-methadone of half racemic methadone dose. Cross over study, own control
11114119|NCT03976401|Experimental|EFX Dose (Cohort C)|
11074336|NCT04256005|Experimental|50% ∆ Gas Exchange Threshold|Participants will complete ten intervals at a work rate which equates to 50% ∆ GET with a 1:1 work rest ratio. The recovery period will involve free cycling against no resistance. The duration of the interval and recovery periods will vary between trials so that the total work done during each trial, excluding CON, will be the same, the duration of intervals will be determined by the 50% ∆ trial which will be set at 60 s for work and recovery intervals.
11074337|NCT04255992|Active Comparator|Calcium arm|1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
11074338|NCT04255992|Active Comparator|Vitamin D/Calcium|1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
11074339|NCT04255979|Experimental|Cohort 1|Single dose of HY209 0.1 mg/kg or placebo.
11074340|NCT04255979|Experimental|Cohort 2|Single dose of HY209 0.2 mg/kg or placebo.
11074341|NCT04255979|Experimental|Cohort 3|Single dose of HY209 0.4 mg/kg or placebo.
11074342|NCT04255979|Experimental|Cohort 4|Single dose of HY209 0.8 mg/kg or placebo.
11074343|NCT04255979|Experimental|Cohort 5|Single dose of HY209 1.6 mg/kg or placebo.
11074344|NCT04255979|Experimental|Cohort 6|Single dose of HY209 3.2 mg/kg or placebo.
11074345|NCT04255966||Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
11074346|NCT04255953|Active Comparator|Treatment as Usual|Following baseline assessment, patients randomized to the TAU arm will receive monthly dietary pamphlets and web-based obesity prevention educational materials from the U.S. Office of Disease Prevention and Health Promotion (https://healthfinder.gov/HealthTopics/). After the 6-month assessment, TAU patients will begin the weight loss intervention arm.
11074347|NCT04255953|Experimental|Group Telehealth Obesity|Participants will receive 24 weekly group phone counseling sessions and monthly individual sessions that encourage healthy eating and exercise. The planned intervention is guided by a social-cognitive framework and includes self-monitoring, goal setting, stimulus control, social support, cognitive reframing of unrealistic and negative thoughts, and developing positive expectancies for long-term weight control. The primary objective is to decrease caloric intake and increase physical activity to produce weight loss of approximately .4 to.9 kg per week, with the study goal of 10% reduction from baseline.
11074348|NCT04255940||After outbreak|
11074349|NCT04255940||Past 3 months|
11074350|NCT04255940||Last year|
11074351|NCT04255927|Experimental|Coated Polyglactin 910 with Triclosan|Coated Polyglactin 910 with Triclosan
11074352|NCT04255927|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated Polyglactin 910 without Triclosan
11074353|NCT04255914|Experimental|Root coverage procedure along with orthodontic treatment|subepithelial connective tissue graft and orthodontic levelling and alignment
11074354|NCT04255914|Active Comparator|Root coverage procedure only|sub epithelial connective tissue graft procedure for recession coverage
11074355|NCT04255888|Active Comparator|Thick periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
11074356|NCT04255888|Active Comparator|Thin periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
11074357|NCT04255875|Experimental|Treatment|Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326
11074358|NCT04255875|Placebo Comparator|Placebo|Participants will receive matching placebo
11074359|NCT04255862|Experimental|Test 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).
11074360|NCT04255862|Other|Reference 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).
11074361|NCT04255862|Experimental|Test 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).
11074362|NCT04255862|Other|Reference 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
11074363|NCT04255849|Experimental|9-valent HPV vaccine|Participants receive 9-valent HPV vaccine 0.5mL at entry, Month 2 and Month 6
11074364|NCT04255849|Placebo Comparator|Saline Placebo|Participants receive 0.9% NaCl 0.5 mL at entry, Month 2 and Month 6
11074365|NCT04255836|Experimental|Durvalumab therapy|Chemo+Durvalumab (PD-L1 monoclonal antibody)1500 mg every 3 weeks [q3w] intravenously [iv] for 4 cycles, then SBRT 50-60 Gy/≤10f + Durvalumab 1500 mg q4w, then Durvalumab 1500 mg q4w for up to 24 months or until progression or other discontinuation criteria are met.
11074366|NCT04255823|Experimental|Multi-faceted intervention|"A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (>300DDD/patient/year).
~Their general practitioner (GP) will receive a dear doctor letter with an algorithm related to PPI deprescribing."
11074367|NCT04255823|Experimental|"Dear doctor letter of the GP"|"Only the GP will receive the dear doctor letter with the algorithm.
~Their patients will not receive any patient education material."
11074368|NCT04255823|No Intervention|Control|Neither the patients nor their GP will receive information.
11074369|NCT04255810||Women with breast implants and self-reported symptoms of BII|Women undergoing elective breast implant removal without replacement who self-report systemic symptons associated with BII
11074370|NCT04255810||Women with breast implants and no self-reported BII|Women undergoing elective breast implant exchange or removal without self-reported symptoms of BII
11074371|NCT04255810||Women undergoing elective mastopexy (breast lift)|Women undergoing an elective mastopexy (breast lift) without breast implants or soft tissue support
11074372|NCT04255797|Experimental|experimental group|The experimental group will perform massage in an incubator. The researchers provide a natural plant-based massage oil for the parents.
11074373|NCT04255784|Experimental|Active iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days. Each session will deliver 1800 pulses of active iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
11074374|NCT04255784|Sham Comparator|Sham iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 1800 pulses of sham iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
11074375|NCT04255771|Experimental|Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI|This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.
11074376|NCT04255771|Placebo Comparator|Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion|As a control, this clinical trial also set up a placebo control group. The effect of adjuvant chemotherapy was obtained by random grouping and comparing the effects of patients in the experimental group and the control group.
11074377|NCT04255758|Experimental|Vigorous-intensity Aerobic Exercise|Vigorous-intensity aerobic exercise, single intervention
11074378|NCT04255745|No Intervention|Assessment-only control|30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
11074379|NCT04255745|Experimental|Intervention|60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
11074380|NCT04255732|Other|Extent of retinal periphery area viewing|For the 30 patients fundus photography will be performed using two ultra-wide-field imaging systems.
11074381|NCT04255719|Experimental|Unilateral DBS of the subthalamic nucleus (STN)|To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS. The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits. Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state. 45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
11074382|NCT04255719|Experimental|Unilateral DBS of the globus pallidus interna (GPi)|To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS. The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
11074383|NCT04255706|Other|Biometric measurement repeatability|Biometric measurements will be performed in all patients
11074384|NCT04255693|Experimental|Change in disease manifestations|The data of all the patients will be assessed from the viewpoint of changes in the disease flow (severity and frequency of symptoms, grade of oesophagitis). They will be compared to the changes of the major factors that could influence the disease flow: adherence to anti-secretory agents, presence of concomitant medications and their doses, adherence to diet, change in physical activity. These will be compared to the initial data. Thus, it would be possible to make a multivariate comparison and try to establish the influence (and, possibly, weight) of each of the con-founder on the disease flow.
11074385|NCT04255693|Active Comparator|No change in disease flow|"To this arm patients with no change in the disease manifestations will be assigned, based on the end-point evaluation. The same as in the experimental groups factors will be analysed to establish the difference."
11074386|NCT04255680||FRDA Subjects|Male and female subjects with FRDA confirmed by genetic testing (aim for a 50:50 distribution of males to females)
11074387|NCT04255680||Controlled Subjects|Male and female control subjects (matched by age [+/- 2 years] and sex)
11074388|NCT04255667||Study group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing with hemostat at start of surgery
11074389|NCT04255667||Control group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing without hemostat
11074390|NCT04255654|Experimental|Brief Intervention|There is only 1 intervention for this study. They will have the brief intervention completed on them. There is no control group.
11074391|NCT04255641||frozen embryos|
11074392|NCT04255628||with cancer pain|head and neck and esophageal cancer patients. with cancer pain
11074393|NCT04255628||without cancer pain|head and neck and esophageal cancer patients. without cancer pain=30
11074394|NCT04255615|Other|3D Ultrasound with AI|AI tool to assess antral follicle count using 3 D Ultrasound
11074395|NCT04255602|Experimental|low dose ticagrelor|After treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a week,subjects will be treated with ticagrelor 60mg twice daily and aspirin 100mg once daily for until one year after drug eluting stent implantation
11074396|NCT04255602|Active Comparator|standard dose ticagrelor|subjects will be treated with ticagrelor 90mg twice daily and aspirin 100mg once daily for a year since drug eluting stent implantation
11074397|NCT04255589|Experimental|Experimental Group|Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)
11074398|NCT04255589|Active Comparator|Active comparator Group|Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)
11074399|NCT04255576|Experimental|Experimental: JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg SC Q4W with a loading dose of 2 mg/kg SC on study days 8 and 15.
11074400|NCT04255563||DCB treatment|DCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
11074462|NCT04255238|Experimental|Gemigliptin 50 mg and Dapagliflozin 10 mg|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin 10 mg per day
~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
11074401|NCT04255537||Patients with STEACS intended for urgent angio/reperfusion.|This population mostly includes STEACS patients for whom primary PCI is intended. A minority of this population includes patients with STEACS intended for urgent angiography for persistent ST elevation and/or symptoms but with symptoms onset > 12 hours (secondary PCI), urgent angiography after failed fibrinolysis (rescue PCI), or patients receiving fibrinolysis.
11074402|NCT04255537||Patients with STEACS NOT intended for urgent angio/reperfusion|This population mostly includes STEACS patients not receiving reperfusion for late presentation (i.e. > 12 hours) or patient preference. Note that patient in this category may receive diagnostic angiography for better diagnostic assessment and/or risk stratification but NOT on an urgent basis.
11074403|NCT04255537||Patients with NSTEACS intended for invasive management|This population includes patients with NSTEACS managed invasively with coronary angiography within 72 hours. Most patients are a high-risk feature (i.e. positive troponin, GRACE risk score > 140, hemodynamic/electrical instability) for whom angiography is intended.
11074404|NCT04255537||Patients with NSTEACS NOT intended for invasive management|This population includes patients who are candidate for an initially conservative strategy. Note that this category may include patients who are subsequently managed with coronary angiography, including recurring symptoms of myocardial ischemia, or hemodynamic/ electrical instability.
11074405|NCT04255524|Experimental|Group 1/Control|Spherical equivalent: -2.00～+2.00 D
11074406|NCT04255524|Experimental|Group 1/Myopia|Spherical equivalent: -3.00～-6.00 D
11074407|NCT04255524|Experimental|Group 3/High|Spherical equivalent: -6.00～-10.00 D
11074408|NCT04255524|Experimental|Group 4/Super High|Spherical equivalent: <-10.00
11074409|NCT04255511|Experimental|Twin block|Removable Functional appliance
11074410|NCT04255511|Active Comparator|Fixed appliance|Preadjusted fixed appliance
11074411|NCT04255498|Experimental|Etanercept|50 MG/ML Prefilled Syringe (once a week for 4 weeks)
11074412|NCT04255498|Experimental|Mifepristone|(300 mg once a day for 7 days) will follow the etanercept.
11074413|NCT04255485||Short time anesthesia group|Unilateral cochlear implantation,which time of anesthesia is less than 3 hours
11074414|NCT04255485||Long time anesthesia group|Bilateral cochlear implantation, which time of anesthesia is more than 3 hours
11074415|NCT04255472|Experimental|WHO caregiver skills training program|Strategies to support children's communication skills by learning to engage in play activities and daily home routines activities with their caregivers.
11074416|NCT04255472|Experimental|Treatment as usual (TAU)|TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets.
11074417|NCT04255459|Other|Moist Snuff users|Subjects for whom moist snuff is their usual brand of tobacco product.
11074418|NCT04255459|Other|Camel Snus users|Subjects for whom Camel Snus is their usual brand of tobacco product.
11074419|NCT04255459|Other|Dual users of Camel Snus and cigarette|Subjects who use both Camel Snus and cigarettes as their usual brands of tobacco products.
11074420|NCT04255459|Other|Dual users of moist snuff and cigarettes|Subjects who use both moist snuff and cigarettes as their usual brands of tobacco products.
11074421|NCT04255459|Other|Cigarette smokers|Subjects for whom cigarettes is their usual brand of tobacco product.
11074422|NCT04255459|Other|Non-tobacco users|Subjects who do not use tobacco products.
11074423|NCT04255446||Dysfunctional Breathing|Patients with Dysfunctional breathing age between 16 to 75 will be included.
11074424|NCT04255446||Healthy Volunteers|Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.
11074425|NCT04255433|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
11074426|NCT04255433|Active Comparator|Dulaglutide|Dulaglutide administered SC once a week.
11074427|NCT04255420|Experimental|SPG Block|Sphenopalatine ganglion block using cotton-tipped applicators soaked in 1% lidocaine will be performed.
11074428|NCT04255420|Active Comparator|Standard Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg.
11074429|NCT04255407|Experimental|I-ONE® group|"I-ONE® therapy will be initiated in the 15 days preceding the ACL reconstruction surgery and in the first 60 days following the surgery.
~Paracetamol 1000 mg will be supplied to both groups, to be taken for pain control as per normal clinical practice."
11074430|NCT04255407|Placebo Comparator|Control group|Patients will not be treated with I-ONE®. Pain will be treated with common NSAID and Paracetamol.
11074431|NCT04255381|Experimental|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Use Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system
11074432|NCT04255368|Experimental|Water-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
11074433|NCT04255368|Experimental|Fat-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
11074434|NCT04255368|Active Comparator|No choline|A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.
11074435|NCT04255355|Active Comparator|Pelvic alignment and forceful expiration exercise|
11074436|NCT04255355|Experimental|Pelvic repositioning exercise|
11074437|NCT04255355|Experimental|Diaphragmatic breathing exercise|
11074438|NCT04255342|Active Comparator|Group 1|Group 1: 3 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
11074439|NCT04255342|Active Comparator|Group 2|Group 2: at 6 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed.
11074440|NCT04255342|Active Comparator|Group 3|Group 3: 9 months post-ARP-SG and dental implant placement using Azento® with an Astra Tech Implant® EV implant and immediate implant provisionalization using Azento®. At 3 months post-DIP&P, a definitive all-ceramic crown, fabricated using a digital workflow (CoreFile), will be placed
11074441|NCT04255329|Other|Usual reading group|The leader of the activity reads aloud a text to four participants seated around the table. The readen text is a normal, currently used in a everyday life support such as a journal article. Consequently it is not previously adaptated to people with cognitive impairements. After the reading phase, the leader asks the participants the questions about the content.
11074442|NCT04255329|Other|Montessori reading roundtable group|The group counts four participants and one activity leader. Each person have the same Montessori reading roundtable book.
11074443|NCT04255316|Experimental|Modified eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a modified eversion carotid endarterectomy
11074444|NCT04255316|Active Comparator|Standard eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a standard eversion carotid endarterectomy
11074445|NCT04255303|Experimental|Usability testing|"A near-live clinical laboratory for refining iCPR workflows with a high likelihood of adoption. Using think-aloud and thematic protocol analysis procedures, written simulations of sore throat and cough patient encounters with 6-8 RNs will be observed and analyzed. RNs will be instructed to follow think-aloud protocols throughout, which call for them to verbalize all thoughts as they interact with the system. Subsequent cohorts of 6-8 RNs will participate in rapid-cycle, low-cost, near-live usability sessions where they interact with a simulated patient rather than a written scenario. Simulations will be conducted in-situ at a representative practice location. All will be audio-taped and screen-capture software will be used to record all human-EHR interactions."
11074446|NCT04255303|Experimental|live-usability testing|"This pre-clinical testing serves as a near-live clinical laboratory for refining iCPR workflows with a high likelihood of adoption. Using think-aloud and thematic protocol analysis procedures, written simulations of sore throat and cough patient encounters with 6-8 RNs will be observed and analyzed. RNs will be instructed to follow think-aloud protocols throughout, which call for them to verbalize all thoughts as they interact with the system. Subsequent cohorts of 6-8 RNs will participate in rapid-cycle, low-cost, near-live usability sessions where they interact with a simulated patient rather than a written scenario. Simulations will be conducted in-situ at a representative practice location. Additional cycles of near-live usability testing will be conducted if required to model the impact of proposed changes to the iCPR tools or workflows. All sessions will be audio-taped and screen-capture software will be used to record all human-EHR interactions."
11074447|NCT04255303|No Intervention|Control No intervention group|standard care will continue as usual.
11074448|NCT04255290|Experimental|Experimental group|Leg Squat Lounge: The player will be placed in squat position and her partner will be placed behind, suspending the most posterior leg in the air. With the leg that is supported, you will perform a monopodal jump with controlled fall, supporting the foot from tip to heel. It will be done with both lower limbs performing 1 series of 5 repetitions with 30 seconds of rest between sets. 180 jump: The footballer will start in bipodal support, with the trunk erect and hands on the hips. Perform a bipodal jump with a 180º turn during this, keeping the fall for 2 seconds. Each repetition, the turn will be done in a different sense. It will carry out 2 series of 20 sec of execution with 20 sec of rest between series. Brad jump stick landing: The player will stand in hands-free standing. Perform a bipodal jump as far as possible. The knees will not exceed the tip of the foot and the fall will be with a trunk position as straight as possible. He will make 5 jumps the first two weeks.
11074449|NCT04255290|Active Comparator|Control group|"Nordic Funds: One player will stand on her knees, while the other, behind, fixes her legs. The kneeling footballer must drop forward in a controlled manner until she touches the ground and returns to the starting position. The Diver: Player in monopodal support on the lower limb to work, performing hip flexion with the arms forward and the opposite lower limb back, looking for a horizontality in the pelvis (with 10º-20º knee flexion) It will be done with both lower limbs.
~The Glider: With the footballer standing in front of her partner, holding both of them by the shoulders, she lets one leg slide back while the other stays fixed. To return to the starting position, it will be helped by the other player, while the knee will not exceed 10 degrees of flexion. The distribution of all the exercises will be: 2 sets of 5 repetitions with 20 sec rest between sets"
11074450|NCT04255277|Other|Period 1: First administration of combined oral contraceptives|Female participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.
11074451|NCT04255277|Other|Period 2: Second administration of Combined Oral Contraceptive|Female participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.
11074452|NCT04255277|Experimental|Period 2: Cenerimod 0.5 mg|Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.
11074453|NCT04255277|Experimental|Period 2: Cenerimod 4 mg|Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.
11074454|NCT04255277|Other|Period 2: Moxifloxacin|Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.
11074455|NCT04255277|Placebo Comparator|Period 2: Placebo|Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.
11074456|NCT04255277|Experimental|Period 3: Cenerimod 0.5 mg and charcoal|Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
11074457|NCT04255277|Experimental|Period 3: Cenerimod 4 mg and charcoal|Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
11074458|NCT04255277|No Intervention|Period 3: Cenerimod elimination period|Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.
11074459|NCT04255264||Study patients|Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status.
11074460|NCT04255251|Experimental|Intervention group|Subjects in this group will receive Silver Diamine Fluoride around their crown margins every six month for the next 3 years.
11074461|NCT04255251|Active Comparator|Fluoride varnish group|Subjects in this group will receive fluoride varnish around their crown margins every six month for the next 3 years.
11074531|NCT04254770|Active Comparator|ADA (American Dental Association) approved Manual Toothbrush|
11074463|NCT04255238|Active Comparator|Gemigliptin 50 mg and Dapagliflozin placebo|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin placebo per day
~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
11074464|NCT04255238|Active Comparator|Gemigliptin placebo and Dapagliflozin 10mg|"Subject shoud took 1 tablet of Gemigliptin placebo and 1 tablet of Dapagliflozin 10 mg per day
~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
11074465|NCT04255225|Experimental|10-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
11074466|NCT04255225|Experimental|20-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
11074467|NCT04255225|Experimental|30-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
11074468|NCT04255212|Experimental|Soft tissue treatment|Participants will be treated with 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms.
11074469|NCT04255212|Placebo Comparator|Mechaninsms explanation|Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
11074470|NCT04255212|Sham Comparator|Anatomy and human upper limb functions|Participants will be instructed with a 10 minute lesson on the anatomy of the upper limb and on upper limb functions in human evolution. It will be explained that human upper limb has the unique ability to throw objects stronger and faster than any other animal on the planet and also that compared to the monkeys is not properly developed for climbing. Human world records of single finger pull and double hands pull will be presented.
11074471|NCT04255199|Experimental|Intervention|Primary care and urgent care clinicians cluster randomized by clinic to the intervention arm will receive two to three visits with a standardized patient instructor who will physicians how to facilitate patient acceptance of a watchful waiting strategy with regard to spinal imaging in the context of acute low back pain.
11074472|NCT04255199|Placebo Comparator|Control|Primary care and urgent care clinicians cluster randomized by clinic to the control arm will receive a single visit with a standardized patient who simulates a visit with patient with acute low back pain but will deliver no instruction on patient communication or other content.
11074473|NCT04255186|Experimental|Thermal CRMRF|"9 sessions in 3 week of Thermal CRMRF: The power of the RFCR equipment in this intervention will be 225 VA in capacitive method (50% of the maximum power of the equipment) and 20 W in the resistive method (10% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
~In Thermal CRMRF it will be necessary to adapt to the patient's thermal sensitivity"
11074474|NCT04255186|Experimental|Subthermal CRMRF|9 sessions in 3 week of Subthermal CRMRF: The power of the RFCR equipment in this intervention will be 7 VA in capacitive method (2% of the maximum power of the equipment) and 4 W in the resistive method (2% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessions a week).
11074475|NCT04255186|Sham Comparator|Sham CRMRF|9 sessions in 3 week of sham stimulation: The application will be carried out in the same way as in the experimental groups, but in this case the manufacturer will introduce a simulated stimulation protocol so that the device does not emit current + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
11074476|NCT04255173|Experimental|Geriatric osteoporotic patients|We measured different anthropometric and body composition measurements as body weight, BMI, percentage body fat, skeletal muscle index (SMI), ABSI, waist (WC) and hip circumference (HC) in geriatric population to investigate the relation to osteoporosis.
11074477|NCT04255160|Experimental|Estradiol|Transdermal estradiol (0.1mg/day patch)
11074478|NCT04255160|Placebo Comparator|Placebo|Placebo
11074479|NCT04255147|Experimental|Mesenchymal Stromal Cell Therapy|Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee.
11074480|NCT04255134|Experimental|Abatacept|Drug administered to participants with active rheumatoid arthritis
11074481|NCT04255134|Active Comparator|Adalimumab|Comparator drug administered to participants with active rheumatoid arthritis
11074482|NCT04255121|Experimental|alkalinization of adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
11074483|NCT04255121|Active Comparator|adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using a adrenaline lidocaine solution
11074484|NCT04255108||Men/Women who meet the inclusion/exclusion criteria|
11074485|NCT04255095|Active Comparator|Nasobiliary drainage|
11074486|NCT04255095|Experimental|Naso-pancreatic drainage(negative pressure)|
11074487|NCT04255069|Placebo Comparator|Placebo|Placebo, oral, daily
11074488|NCT04255069|Experimental|Dose 1|JKB-122, Dose 1, oral, daily
11074489|NCT04255069|Experimental|Dose 2|JKB-122, Dose 2, oral, daily
11074532|NCT04254770|Experimental|Marketed Power Toothbrush|
11074533|NCT04254757|Other|Percutaneous endoscopic surgery group|
11074490|NCT04255056|Experimental|Pyrotinib|"Eligible patients will receive four cycles of epirubicin and cyclophosphamide combined with pyrotinib.
~Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.
~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
11074491|NCT04255043|Experimental|IVUS-guided DCB|In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.
11074492|NCT04255043|Active Comparator|Angiography-guided DCB|In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.
11074493|NCT04255030|Experimental|First stage: Self-directed Coping Together|
11074494|NCT04255030|Experimental|First stage: Minimally guided Cancer Chat Support|
11074495|NCT04255030|Experimental|Second stage: High intensity Motivational Interviewing (MI)|
11074496|NCT04255017|No Intervention|Symptomatic supportive treatment|Symptomatic supportive treatment
11074497|NCT04255017|Experimental|Abidol hydrochloride was added on the basis of group I.|Abidol hydrochloride 0.2g once,3 times a day,2 weeks
11074498|NCT04255017|Experimental|Oseltamivir was added on the basis of group I.|Oseltamivir 75mg once,twice a day,2 weeks
11074499|NCT04255017|Experimental|Lopinavir/ritonavir was added on the basis of group I.|Lopinavir/ritonavir 500mg once,twice a day,2 weeks
11074500|NCT04255004|Active Comparator|A-PBMNC therapy|Patients in A-PBMNC therapy are treated with wound bed multiple perilesional and intramuscular injections of PBMNC cells suspension (0.2-0.3cc in boluses). This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
11074501|NCT04255004|No Intervention|No A-PBMNC therapy|Patients in No A-PBMNC therapy receive only supportive treatment including wound care and pain killer drug.
11074502|NCT04254991||Infectious disease group|
11074503|NCT04254991||Non-infectious disease group|
11074504|NCT04254978|Experimental|IMG-7289|IMG-7289 administered daily for 169 consecutive days
11074505|NCT04254965|Experimental|Group 1|Participants of integrated music therapy (integration of active and passive music therapy) includes instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. The four stages of activities are warm-up, main activities, secondary activities, and the ending section.
11074506|NCT04254965|Active Comparator|Group 2|Participants of the music listening group will receive background music listening, music selection based on the musical preference and background of subjects, for relax or boost the spirit of the subjects.
11074507|NCT04254965|Sham Comparator|Group 3|Participants in the control group receive their regular occupational therapy during the experimental period.
11074508|NCT04254939|Experimental|CS3007(BLU-285)|
11074509|NCT04254926|Experimental|Revie ⊕ intervention early|participants randomized into (i) the intervention group (IG) receive the Revie ⊕ intervention early on.
11074510|NCT04254926|Experimental|Revie ⊕ intervention later|The control group (CG) receives the same intervention Revie ⊕ but later on (i.e., after eight weeks).
11074511|NCT04254913|Experimental|MT-1186|Patients receive the edaravone oral suspension.
11074512|NCT04254900||Male wheelchair athletes|Other
11074513|NCT04254900||Female wheelchair athletes|Other
11074514|NCT04254887|Experimental|EPBD|Small incision of the duodenal nipple + EPBD
11074515|NCT04254887|Active Comparator|EST|Large incision of the duodenal nipple
11074516|NCT04254874|Experimental|Abidol hydrochloride|Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day).
11074517|NCT04254874|Experimental|Abidol Hydrochloride combined with Interferon atomization|Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I.
11074518|NCT04254861|Experimental|Simplified Papilla Preservation Flap (SPPF) and PRGF|
11074519|NCT04254861|Active Comparator|Simplified Papilla Preservation Flap (SPPF) and GTR|
11074520|NCT04254848|Experimental|completely edentulous patients with maxillary tori|20 completely edentulous patients with maxillary tori will be recruited for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
11074521|NCT04254848|Active Comparator|completely edentulous patients without maxillary tori|20 completely edentulous patients without maxillary tori will serve as control group for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
11074522|NCT04254835|Experimental|intervention group|Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
11074523|NCT04254835|Active Comparator|control group|"Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study.
~Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks."
11074524|NCT04254822|Experimental|HVPG-guided therapy|HVPG will be determined before randomization. In this arm, patients with an adequate reduction in HVPG (responders) receive carvedilol whereas nonresponders receive TIPS.
11074525|NCT04254822|Active Comparator|Standard therapy|In this group, both responders and nonresponders will receive combination therapy of carvedilol and endoscopic variceal ligation as first-line therapy. If first-line therapy fails, TIPS will considered.
11074526|NCT04254809|Experimental|Re-Evaluating Suicidal Thoughts|Participants in this condition will complete the experimental intervention at the baseline appointment.
11074527|NCT04254809|Sham Comparator|Healthy Social Living|Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.
11074528|NCT04254796|Experimental|TARA Training|
11074529|NCT04254796|No Intervention|Control|
11074530|NCT04254783|Experimental|Cytochrome P450 (CYP) + Risankizumab|In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
11074540|NCT04254692|Active Comparator|Liposomal Bupivacaine|Participants in this study arm will receive intraoperative injection of Liposomal Bupivacaine mixed with Bupivacaine to the abdominal wall.
11074541|NCT04254692|Other|Bupivacaine|Participants in this study arm will receive intraoperative injection of bupivacaine without Liposomal bupivacaine to the abdominal wall.
11074542|NCT04254679|Experimental|Opioid analgesia|
11074543|NCT04254679|Active Comparator|Opioid-free analgesia|
11074544|NCT04254666|Other|Physical Literacy & Food Literacy Intervention|This is a pilot project to assess the feasibility of a physical literacy and food literacy intervention for adolescents with ID ages 12-16 years.
11074545|NCT04254653|Experimental|Immediate Intervention|Participants receive diabetes nutrition education classes immediately.
11074546|NCT04254653|Experimental|Wait list intervention|Participants wait listed (control) for 3 months and then receive the diabetes nutrition education classes.
11074547|NCT04254640|Experimental|C-CAG|cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.
11074548|NCT04254627|Experimental|Mifepristone 300 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 1 will receive one week of mifepristone at 300 mg daily.
11074549|NCT04254627|Experimental|Mifepristone 600 mg|All participants will receive etanercept 50 mg weekly for 12 weeks. After completion of the etanercept course, participants will be randomized between two Arms of mifepristone. Participants randomized to Arm 2 will receive one week of mifepristone at 600 mg (2x300 mg) daily.
11074550|NCT04254614|Experimental|Personalised mobile application for IBD patients|This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.
11074551|NCT04254601|Experimental|Experimental group 1|Patients in group (A) consisted of 15 participants, received a program of NBUB, DIXWELL EMLY 98 -ABRP 64 ,made in France (wavelength 311 to 313nm) , in addition to topical aknemycin medications (topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period after 8 weeks).
11074552|NCT04254601|Experimental|Experimental group 2|Participants in-group (B) consisted of 15 participants, received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks Plus topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
11074553|NCT04254601|Active Comparator|Control group|Patients in the group C, consisted of 15 participants, were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
11074554|NCT04254588||Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED.
11074555|NCT04254575||body dysmorphic disorder (BDD)|Adults with a current primary diagnosis of body dysmorphic disorder (BDD)
11074556|NCT04254562|Experimental|Experimental Group: HYPE Services|The experimental arm will be receiving the HYPE intervention for 12 months and followed for an additional 24 months.
11074557|NCT04254562|Active Comparator|Control Group: Enhanced Academic Services|"The control arm will receive a special personalized packet of resources available on campus as enhanced academic services as usual."
11074558|NCT04254549|Experimental|Intervention Treatment|Subjects diagnosed with gastroparesis will receive Rifaximin
11074559|NCT04254549|Placebo Comparator|Placebo Group|Subjects diagnosed with gastroparesis will receive a placebo
11074560|NCT04254523|Experimental|Programmed intermittent epidural bolus (PIEB)|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour.
11074561|NCT04254523|Experimental|Continuous epidural infusion (CEI)|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate in milliliters per hour.
11074562|NCT04254510|Experimental|Study Group|Myofascial relaxation technique
11074563|NCT04254510|No Intervention|Control group|
11074564|NCT04254484|Experimental|SIESTA Rehab|"Stroke floor on which nurses will be receiving training (SIESTA Rehab Education) on how to minimize nighttime disruptions and batching overnight tasks to preserve sleep for patients hospitalized on that floor. Stroke patients admitted to the SIESTA Rehab Unit will be screening for sleep disordered breathing using ApneaLink.
~Patients hospitalized on this unit will be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
11074565|NCT04254484|No Intervention|Control Unit|"Patients on this unit will receive usual care for stroke patients as outlined by SRALab. including routine nursing care without any intervention to promote sleep like SIESTA and routing sleep disorders screenings based on clinician judgement.
~Patients hospitalized on this unit will also be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
11074566|NCT04254471|Experimental|Dose escalation (AL3810 + carboplatin + etoposide)|Phase II:Participants will receive AL3810 orally in combination with carboplatin and etoposide during the Cycles 1-4 . AL3810 dose escalated form 5mg to 10mg step-up to determine the recommended dose of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
11074567|NCT04254471|Experimental|AL3810+ carboplatin + etoposide|Phase III:Participants will receive AL3810(recommended dose will be determined by safety monitoring committee (SMC) in Phase II) orally in combination with carboplatin and etoposide during the Cycles 1-4. Thereafter, participants will receive maintenance AL3810 until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
11074568|NCT04254471|Placebo Comparator|Placebo+ carboplatin + etoposide|Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
11074569|NCT04254458||PACG group|Cases who had first acute attack of primary angle closure glaucoma
11074570|NCT04254445|Experimental|Training video arm|Patients will watch a personalized custom training video, in addition to the standard explanation provided by the medical staff
11074571|NCT04254445|No Intervention|Verbal explanation arm|Patients will standard explanation about the procedure, provided by the medical staff
11074572|NCT04254432|Experimental|remote ischemic conditioning arm|Device: remote ischemic conditioningRIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 30+/-2days. Other Names:• RICDevice: ambulatory blood pressure monitoring diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment
11074573|NCT04254419|Experimental|NK cell infusion|"For source PBMCs from the patient, up to 3ml/kg (maximum 150ml) of heparinized peripheral blood will be drawn. NK cell product will be manufactured by a GMP facility. Once the NK cell goes through the appropriate procedures, it will undergo a lot release testing and cryopreservation by day 14 for infusion.
~If NK cells fail to meet release criteria or are insufficient in number for the dose level assigned, collection of PBMCs may be repeated up to 2 additional times.
~Duration of study therapy is up to 12 weeks and nine doses of NK cells."
11074574|NCT04254393|Experimental|Early Adolescent Skills for Emotions (EASE) Program|Early Adolescent Skills for Emotions (EASE) is a new, brief, targeted, group psychological intervention program (Dawson et al., 2019) based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (WHO, 2016).
11074575|NCT04254393|Placebo Comparator|Treatment as Usual (TAU)|Participants in control arm will be able to avail the routine services available in school settings.
11074576|NCT04254380|Experimental|Experimental: Gan & Lee Insulin Lispro Injection|Gan & Lee Insulin Lispro Injection for subcutaneous injection, 100 U/mL, in a disposable multidose pen injector with a pre-filled 3-mL type I glass cartridge. Subjects randomized to the Gan & Lee Insulin Lispro Injection group will participate in the study for 26 weeks.
11074577|NCT04254380|Active Comparator|Active Comparator: Humalog|EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled). Subjects randomized to the Humalog group will participate in the study for 26 weeks.
11074578|NCT04254367|Experimental|Intervention group - experimental TAU + intervention|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
11074579|NCT04254367|No Intervention|TAU - no intervention|Treatment as usual following local routines on each primary care center
11074580|NCT04254354||transgender men|no intervention
11074581|NCT04254341||patients with OSA|Subjects that underwent regular sleep studies (PSG) and found to have moderate/severe obstructive sleep apnea
11074582|NCT04254341||subjects without OSA|Subjects that underwent regular PSG and found not to have sleep apnea
11074583|NCT04254328|Experimental|Nintendo Wii Fit|Nintendo Wii Fit group work program; 13 exercises in 5 groups including 3 yoga exercises, 3 balance exercises, 2 aerobic, 2 training plus exercises and 3 muscle-workout will be done respectively. Patients in this group will exercise for 8 weeks, 3 days in a week and 40-50 minutes of exercise within resting interval.
11074584|NCT04254328|Experimental|Respiratory|Respiratory training group participants' will do deep breathing exercise against resistance of 30% of intraoral pressure. This exercise will be applied for 8 weeks, each day of the week, twice in a day for 15 minutes and 4-5 normal breaths after 4-5 deep breaths. Each week, intraoral pressure will be measured and new training intensity values will be determined.
11074585|NCT04254328|No Intervention|Control|Patients in the control group will not be included in any exercise program, but all groups will be advised of walking in order to increase physical activity level.
11074586|NCT04254315|Experimental|Cardiac rehabilitation+cognitive therapy|"The intervention group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively.
~In addition, the intervention group follows a standardized group based cognitive therapy program with participation of maximum four patients, consisting of 5 sessions (each 2 hours) performed by a trained cardiac rehabilitation nurse."
11074587|NCT04254315|No Intervention|Cardiac rehabilitation|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
11074588|NCT04254315|No Intervention|Control group without psychological distress|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
11074589|NCT04254302|No Intervention|Control|Participants randomized into the control arm will receive usual care as per the service delivery models and pathways planned in their region. As a pragmatic trial, no attempt will be made to standardize practices which may vary across professionals. Usual practices may be categorised as either reference to online websites deemed appropriate by their healthcare professional, general recommendations, referral for services, or none of the above.
11074626|NCT04254042|Active Comparator|Zofenopril Arm|30 mg Zofenopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
11074674|NCT04253691|Experimental|Virtual Reality Based Relaxation Therapy|This is a pilot trial with one treatment condition (VR mediation).
11074710|NCT04253444|Sham Comparator|sham breathing|Patients are instructed to count 10 breaths and tick a box every time they count ten breaths. The counting distracts the patient reducing the effect of focussing of breathing on their autonomic nervous system.
11074590|NCT04254302|Experimental|Experimental|WECARE intervention include: 1) 30-minute appointments with an occupational therapist or a physiotherapist, as part of a multidisciplinary team, to problem-solve the child's motor performance issues, provide recommendations to stimulate the child's motor development, and intervene online directly with the child, if needed; offered bimonthly during the first three months, then on a patient-identified needs-basis. 2) A chat function where participants can privately contact the therapist; flexible access as per participant needs. 3) A forum open to all intervention group participants where they can communicate with each other or with the therapist, who will also act as a forum moderator; flexible access as per participant needs. 4) Access to static online information via relevant websites and resources on child development; flexible access based on participant needs.
11074591|NCT04254289|Active Comparator|Usual Care|Usual care administered at the Pulmonary Arterial Hypertension (PAH) clinic at the University of Michigan.
11074592|NCT04254289|Experimental|Home-based exercise program|Home-based individualized exercise program based on heart rate reserve (HRR).
11074593|NCT04254276||Symptomatic group|Office workers with neck and shoulder area musculoskeletal pain
11074594|NCT04254276||Asymptomatic group|Office workers without neck and shoulder area musculoskeletal pain
11074595|NCT04254263|Experimental|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
11074596|NCT04254263|No Intervention|No Pyrotinib|Observation follow-up
11074597|NCT04254250||High risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
11074598|NCT04254250||Low risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
11074599|NCT04254237|Active Comparator|Intervention group|Infraumbilical Hasson trocar incision.
11074600|NCT04254237|Sham Comparator|Control group|Supraumbilical Hasson trocar incision.
11074601|NCT04254224||Diverticulitis Hinchey I-IV|Patients with complicated diverticulitis (Hinchey I-IV) treated conservatively (iv antibiotics with or without percutaneous, transrectal or transvaginal drainage) or surgically.
11074602|NCT04254211||EVAR|Patinets with AAA, treated electively by EVAR. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively. Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause
11074603|NCT04254198|Placebo Comparator|Control|Modified Attention Placebo Control
11074604|NCT04254198|Experimental|TERTULIAS structured dialogue peer support groups|Structured Dialogue peer support group
11074605|NCT04254185|Active Comparator|Simple decompression|In-situ decompression releases only the compressive ligamentous structures overlying the ulnar nerve.
11074606|NCT04254185|Active Comparator|Subcutaneous anterior transposition|Anterior transposition repositions the ulnar nerve, providing decompression and lengthening by moving the nerve anterior to the axis of elbow rotation
11074607|NCT04254172||Single cohort|There is no randomization or stratification in this study. All subjects will complete the same study assessments.
11074608|NCT04254159|Experimental|Neuromuscular Electrical Stimulation Group|Asthma Education Aerobic Exercise Quadriceps Strengthening by superimposed NMES
11074609|NCT04254159|Active Comparator|Control Group|Asthma Education Aerobic Exercise Quadriceps Strengthening
11074610|NCT04254146|Experimental|Study group|Aerobic exercise will be performed for a single session
11074611|NCT04254146|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
11074612|NCT04254133||Case Ascertainment|Men with metastatic prostate cancer
11074613|NCT04254133||Family Recruitment|Male relatives of men with metastatic prostate cancer found to have a germline DNA Repair Gene mutation
11074614|NCT04254120|Active Comparator|Cognitive-behavioral therapy (CBT)|
11074615|NCT04254120|Experimental|Integrated motivational interviewing and CBT|
11074616|NCT04254107|Experimental|Monotherapy (Parts A and B)|
11074617|NCT04254107|Experimental|Combination Therapy (Part C)|
11074618|NCT04254094||Early onset dementias (EOD)|Prospective multicenter cohort of EOD patients with a three-year follow-up in tertiary Reference Memory centers
11074619|NCT04254081|Experimental|Buprenorphine 0.15mg + 1% lidocaine paracervical block|Paracervical block with 18mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate plus 0.15mg of buprenorphine
11074620|NCT04254081|Placebo Comparator|1% lidocaine paracervical block|Paracervical block with 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate
11074621|NCT04254068|Experimental|Parent based prevention|Parent-Based Prevention (PBP; Sadeh-Sharvit & Lock, 2018) is a manualized preventive intervention, focused on increasing parental awareness and competence to facilitate healthy eating habits, body image, and self-regulation in children whose parent has an eating disorder history. PBP is comprised of three phases that focus on unique goals. The strategies in each session include psycho-education, behavioral experiment planning, and skill practicing to augment parents' insight into how the context of the parental cognitions and behaviors may impact child outcomes, with the goal of creating a longstanding effect.
11074622|NCT04254068|No Intervention|Usual care|Families randomized to usual care will be permitted to utilize any medical, psychological, or nutritional services they desire for the waitlist period of 16 weeks.
11074623|NCT04254055|Experimental|Experimental group|"Exercise 1 with medicine ball. Standing player with 90º shoulder abduction and elbow flexion. He will receive the ball with an external rotation returning it with internal rotation. Exercise 2 with elastic band. From standing, he will fix the elastic band with his foot and perform a shoulder flexion with his contralateral limb. Exercise 3 of iron with support of the hands on the floor and shoulder, elbow and wrist aligned. You should perform a scapula approach and separation without altering its initial position. Exercise 4 BodyBlade ©. From standing with 90º of 90 ° shoulder abduction and elbow flexion. It will perform an anteroposterior thrust, causing a wave effect to stabilize the shoulder joint for 30 seconds.
~Athletes will do 15 repetitions of each exercise."
11074624|NCT04254055|No Intervention|Control group|Players included in the control group will not receive any intervention.
11074625|NCT04254042|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
11074711|NCT04253431|Experimental|L01|Finger pricking using lancing device with personal lancets
11074627|NCT04254029|Experimental|Non-randomized single-arm of MOROLSTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.
~The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days."
11074628|NCT04254016|Experimental|Non-randomized single-arm of HIBISTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.
~The intervention consisted on the administration of Hibiscus-Stevia drink at a dose of 4 mg / kg / day / for Stevia and 4 g / day for Hibiscus for a period of 8 weeks and after meals."
11074629|NCT04254003|Other|Test, then Control|DT1 Toric contact lenses worn first, followed by AO1DfA contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
11074630|NCT04254003|Other|Control, then Test|AO1DfA contact lenses worn first, followed by DT1 Toric contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
11074631|NCT04253990|Experimental|Precut-EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.
~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
11074632|NCT04253990|Active Comparator|Conventional EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.
~Conventional EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current"
11074633|NCT04253977|Experimental|HEALTH-P2|Along with PAT National Center, parent educators affiliated with PAT sites in HEALTH-P2; with be trained to use the HEALTH-P2 training curriculum (implementation strategy).
11074634|NCT04253977|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual.
11074635|NCT04253964|Experimental|Performance Status 0-1 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.
~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.
~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:
~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
~PLUS
~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:
~Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS
~Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR
~Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
11074636|NCT04253964|Experimental|Performance Status 2 Participants|"ALL study participants will receive pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle.
~Participants with predictive biomarker PD-L1 greater than or equal to 50%: Participants will not receive any other drugs besides pembrolizumab.
~Participants with Non-squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will ALSO receive:
~- Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
~PLUS
~- Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
~Participants with Squamous subtype, predictive biomarker (PD-L1 less than 50%): Participants will also receive:
~Carboplatin AUC 5 IV on day 1 of each 3-week cycle for 4 cycles. PLUS
~Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles. OR
~Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles"
11074637|NCT04253951|Experimental|LUS-monitored management (LUS-m)|In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.
11074638|NCT04253951|Sham Comparator|Standard care management (SC-m)|Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.
11074639|NCT04253938|Other|Education|"Visit 1 - Parent/Caregiver will complete a questionnaire about breastfeeding/formula feeding practices and food insecurity. The questionnaire includes a nutrition history, asking how much formula is consumed, number of times they are breastfed per day, what types and amounts of solid foods are consumed, and if vitamins and/or iron drops are given (including frequency and amount). After the questionnaire, the participant will be asked to demonstrate how they typically prepare infant formula. Finally, the PI or designee will provide a brief education about appropriate feeding practices as recommended by the AAP. This will include appropriate formula preparation methods, use of juice, introduction of cow's milk and solids, as well as basic nutrition information.
~Visit 2 - If the family returns for a clinic visit again before the child turns 1 year of age, the same procedures as Visit 1 will be performed, including reinforcement of education."
11074640|NCT04253925|Experimental|global postural correction exercises|global postural correction exercises in addition to Kegel exercises
11074641|NCT04253925|Active Comparator|Kegel exercises|only Kegel exercises
11074642|NCT04253912|Experimental|VBP-245|Topical 2% Povidone-Iodine Gel
11074643|NCT04253912|Placebo Comparator|Control|Placebo Gel (no Povidone-Iodine)
11074644|NCT04253899|Active Comparator|Standard pediatric group:|patients ≤17 yo with acute perforated appendicitis and interval appendectomy (n=25)
11074645|NCT04253899|Experimental|Experimental pediatric group:|patients ≤17 yo with acute perforated appendicitis abscess and observation (n=25)
11074646|NCT04253899|Active Comparator|Standard adult group:|patients ≥18 yo with acute perforated appendicitis and interval appendectomy (n=25)
11074647|NCT04253899|Experimental|Experimental adult group:|Patients ≥18 yo with acute perforated appendicitis and observation (n=25)
11114120|NCT03976401|Placebo Comparator|Placebo (Cohort C)|
11074648|NCT04253886|Active Comparator|Group A|The Ovassapian Fibreoptic Intubating Airway has a flat lingual surface that widens distally. This provides better retraction of the tongue to prevent it and the soft tissues of the anterior pharyngeal wall from herniating around the side of the airway. The airway has a pair of vertical sidewalls and two pairs of curved guide walls at its proximal section. These walls are separated by a gap which allows removal of the airway after intubation has been completed
11074649|NCT04253886|Active Comparator|Group B|"Fekry airway:
~● It has two parts are: Airway body& Special connector
~Airway body consists of:
~Flange → it is the buccal end it is 7 cm wide to prevent it from
~moving deeper into mouth & may also serve to fix airway in place.
~Bite Portion → it is straight & fits between teeth &oral cavity.
~Oral straight part → open anterior lingual part; it varies in length according to size
~Pharyngeal curved part → extends backwards to correspond the shape oropharynx and ends below laryngeal inlet.
~The connector: it is a special type (two sizes: adult and pediatric) can attach to all ventilating machines& it has a teeth rest act as a bite block."
11074650|NCT04253873|Experimental|Apatinib mesylate + temozolomide|Apatinib mesylate tablets (0-14 days, 500 mg, qd), one week apart, then temozolomide (150mg/m2, 5 days);Every 28 days is a cycle, the drug until the disease progress, the toxicity of intolerable.
11074651|NCT04253860|Experimental|TENS|Transcutaneous electrical neurostimulation will be applied for 30 minutes three times a week during 90 days
11074652|NCT04253860|Sham Comparator|Sham|A sham comparator will be applied for 30 minutes three times a week during 90 days. The device does not emit electrical impulses
11074653|NCT04253847|Experimental|RAMPS group|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
11074654|NCT04253847|Active Comparator|SRPS group|"Standard retrograde pancreatosplenectomy(SRPS) includes several key points. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
11074655|NCT04253834|Active Comparator|Control Arm|Participants will be assigned to the Incentive spirometer after surgery
11074656|NCT04253834|Experimental|GO2 Mouthpiece|Participants will be assigned to the Bidirectional Oxygenation Valve (GO2 Mouthpiece) after surgery
11074657|NCT04253821|Active Comparator|Forward head posture|
11074658|NCT04253821|Active Comparator|Non-Forward head posture|
11074659|NCT04253808|Experimental|Experimental arm|The experimental arm (N=15) will be given a CRHF diet for 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for ~6.5 weeks. The CRHF diet will be composed of 45% unsaturated fats, 25% proteins, and 30% carbohydrates.
11074660|NCT04253808|Active Comparator|Control arm|The control arm (N=15) will receive standard of care including a well-balanced diet, prescribed with enough calories/proteins to maintain body weight for approximately 2 weeks (during radiotherapy preparation) followed by standard treatment for ~6.5 weeks.
11074661|NCT04253795|Active Comparator|Laryngeal mask group (Group 1)|Laryngeal mask will be placed in the airway by the anesthesiologist. Lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing
11074662|NCT04253795|Active Comparator|Double lumen tube Group (Group 2)|After the correct position of double lumen tube will be determined, one lung ventilation will be started. Lung isolation will be achieved by deflation of the nondependent lung.
11074663|NCT04253782|Experimental|Team Intervention Arm|Recovery coaches and trained health educators will team together and meet with participants (remotely/electronically and/or by phone) at least twice and for a maximum of 7 times. This includes access to mediation-assisted therapy, trained mental healthcare providers, and educational resources.
11074664|NCT04253756|No Intervention|18-gauge autogard catheter|Standard of care
11074665|NCT04253756|Experimental|20-gauge BD Nexiva Diffusics|Intervention
11074666|NCT04253743|Experimental|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households were randomly assigned to receive either: (1) $40 extra in SNAP benefits per eligible child (<5 years) per month (n=1,919); (2) $40 extra in SNAP benefits per eligible child per month plus case management and nutrition education (n=1,919); or (3) only regular monthly SNAP benefit (n=7,467). The first two groups were the treatment arms and the third was the control group.
11074667|NCT04253743|No Intervention|Control Group|The control group received regularly allotted SNAP benefits.
11074668|NCT04253730|No Intervention|Control Condition|Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
11074669|NCT04253730|Experimental|Cold Condition|Subjects will be cooled for 60-90 min at ~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at ~ 41°C using the liquid perfused suit.
11074670|NCT04253717|Experimental|Motor control exercise program|Participants will be physically trained during pregnancy and will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
11074671|NCT04253717|No Intervention|Control|Participants will receive the standard care including basic information on what to do when suffering from lumbopelvic pain.
11074672|NCT04253704|Experimental|2% IDL lotion|The left arm of each subject was used for the test material hydrating lotion (IDL).
11074673|NCT04253704|Placebo Comparator|Control lotion|The right arm of each subject was used for control lotion lacking the IDL component.
11074712|NCT04253431|Experimental|L02|Finger pricking using lancing device with personal lancets
11074675|NCT04253678||Study group|"Study participants will be started on a flexible-dose of vortioxetine (5-20 mg) followed by a baseline assessment of primary outcomes using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Perceived Deficit Questionnaire - 5 items (PDQ-5), and secondary outcomes using the EORTC Quality of life Questionnaire (QLQ-C30) and Clinical Global Impression (CGI). The assessment timelines will be at week 2, week 4, week 8, and week 12.
~Side effects, if any, will be recorded using the Antidepressant Side-effect Checklist (ASEC)."
11074676|NCT04253665|No Intervention|Usual care|Discharge teaching is usually not delivered in a systematic or consistenly way, nor by relying on a particular intervention model.
11074677|NCT04253665|Experimental|Discharge teaching|Receiving tailored discharge teaching by nurses during hospital stay.
11074678|NCT04253652||Oral iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed oral iron supplements as part of their treatment from their doctor. This will be in accordance with the NICE guidelines; 200mg capsules containing 65mg elemental iron, 2-3 times a day for a period of atleast 1 month.
11074679|NCT04253652||Intravenous iron|These patients will have diagnosed with iron deficiency anaemia and been prescribed intravenous iron as part of their treatment from their doctor. Participants will receive an infusion of either 1000mg or 1500mg
11074680|NCT04253639||Chronic pain patients|
11074681|NCT04253626|Experimental|Intravenous iron|Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
11074682|NCT04253626|Active Comparator|Oral iron|Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin < 9.
11074683|NCT04253613||periodontal therapy|Systemically healthy subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
11074684|NCT04253613||periodontal+laser therapy|Systemically healthy subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment(NSPT) split-mouth designed study
11074685|NCT04253613||diabetic periodontal therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the sides treated with non-surgical periodontal treatment (NSPT) split-mouth designed study
11074686|NCT04253613||diabetic periodontal+laser therapy|Type 2 diabetic(DM2) subjects with periodontitis that have the contra-lateral sides treated with laser biostimulation therapy(LBT) adjunct to non-surgical periodontal treatment (NSPT) split-mouth designed study
11074687|NCT04253600|Other|MRI Acquisition|This does not refer to any group intervention. At-risk and control children will take part in a natural-sleep MRI protocol.
11074688|NCT04253587|Experimental|LabyrinthVR Trackers|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via participant ambulation wearing leg-position trackers.
11074689|NCT04253587|Experimental|LabyrinthVR Scoot|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive spatial wayfinding challenge. Game movement via teleporting technique.
11074690|NCT04253587|Placebo Comparator|Placebo Controls|Multi-session cognitive intervention with handheld tablet or wireless virtual reality headset presentation of commercially available, narrative computer games.
11074691|NCT04253587|Active Comparator|Coherence|Multi-session cognitive intervention with head-mounted display virtual reality computer game that presents an adaptive rhythm training game.
11074692|NCT04253574||Patients with malignant melanoma|258 patients (w: 112, m: 146 age: 61±16 years) met the primary inclusion criteria. They were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)).
11074693|NCT04253561|Experimental|Ipatasertib + Trastuzumab + Pertuzumab|"Ipatasertib will be given from Day 1 to Day 21 in every 28-day cycles. The starting dose is 400 mg orally (PO) QD and may be decreased to 300 mg QD and further to 200 mg QD (dose levels 1, - 1 and -2, respectively).
~Pertuzumab will be given IV every 21 days at the dose of 420 mg.
~Trastuzumab will be given SC every 21 days at the dose of 600mg. Intravenous (IV) Trastuzumab"
11074694|NCT04253548|Experimental|iPeer2Peer Program|
11074695|NCT04253548|Other|Standard of Care|Waitlist Control Group
11074696|NCT04253522|Experimental|Arm 1 (early phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 3 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 5 weeks
11074697|NCT04253522|Experimental|Arm 2 (mid phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 4 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 4 weeks
11074698|NCT04253522|Experimental|Arm 3 (late phase B)|3 phases of cognitive training: Phase A1: rehabilitation program in standard ergotherapy during 5 weeks Phase B: cognitive training using Covirtua software and Transcranial random noise stimulation during 4 weeks Phase A2: return to the standard rehabilitation program in standard ergotherapy during 3 weeks
11074699|NCT04253509||Lung cancer|
11074700|NCT04253509||Benign pulmonary disease|
11074701|NCT04253496||Prospective|
11074702|NCT04253496||Retrospective|
11074703|NCT04253483|Experimental|Arm I (HDR)|Patients undergo HDR.
11074704|NCT04253483|Experimental|Arm II (SABR)|Patients undergo SABR every other day for 5 treatments.
11074705|NCT04253470||cleavage stage embryo|embryo which is on day 2 or 3
11074706|NCT04253470||blastocyst embryo|embryo which is on day 5
11074707|NCT04253457|Experimental|Corticosteroid injection|Single injection of 1ml of triamcinolone (40mg/1ml)
11074708|NCT04253457|Active Comparator|Corticosteroid and local anaesthetic injection|Single injection of 1ml of triamcinolone (40mg/1ml) + 1ml 1% Lidocaine
11074709|NCT04253444|Active Comparator|slow deep breathing|Patients are instructed to do deep breathing at full inspiratory capacity for 4 seconds followed by forced expiration in 6 seconds (forced vital capacity) for 10 minutes.
11074713|NCT04253431|Experimental|L03|Finger pricking using lancing device with personal lancets
11074714|NCT04253431|Experimental|L04|Finger pricking using lancing device with personal lancets
11074715|NCT04253431|Experimental|L05|Finger pricking using lancing device with personal lancets
11074716|NCT04253431|Experimental|L06|Finger pricking using lancing device with personal lancets
11074717|NCT04253431|Experimental|L07|Finger pricking using lancing device with personal lancets
11074718|NCT04253431|Experimental|L08|Finger pricking using lancing device with personal lancets
11074719|NCT04253431|Experimental|L09|Finger pricking using lancing device with personal lancets
11074720|NCT04253431|Experimental|L10|Finger pricking using lancing device with personal lancets
11074721|NCT04253418|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of target lesion.
11074722|NCT04253405|Active Comparator|High Flow Nasal Cannula (HFNC)|The HFNC (Airvo2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
11074723|NCT04253405|Active Comparator|Non-invasive positive pressure ventilation (NIPPV)|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.
11074724|NCT04253379|Experimental|pediatric epilepsy children|
11074725|NCT04253379|Active Comparator|healthy children|
11074726|NCT04253366|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
11074727|NCT04253353|Experimental|rosuvastatin and tafamidis fixed sequence|"Period 1: rosuvastatin 10 mg (single oral administration)
~Washout
~Period 2: tafamidis 61 mg capsule(multiple doses, twice a day) + rosuvastatin 10 mg (single oral administration)"
11074728|NCT04253340|Experimental|Bone mineral analyser|"Diagnostic Test: Bone mineral analyser
~high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12"
11074729|NCT04253327||BOT|Patients diagnosed and treated by surgery for borderline ovarian tumor
11074730|NCT04253327||controls|Patients after surgical treatment of benign ovarian tumor
11074731|NCT04253314||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label. Decision to treat with Venetoclax was made prior to offering participation in this study.
11074732|NCT04253301|Experimental|Treatment|Subjects will have the InnoVein Valve implanted
11074733|NCT04253288|Other|Patients with severe radiation toxicity|Patients who received radiotherapy and developed abnormal radiation-induced toxicity
11074734|NCT04253275|Other|Ischemic stroke patients|Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging
11074735|NCT04253275|Other|hemorragic stroke patients|Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging
11074736|NCT04253275|Other|healthy controls|Stroke-free
11074737|NCT04253262|Experimental|Dose Level -2|300 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
11074738|NCT04253262|Experimental|Dose Level -1|400 mg Rucaparib, 45 mg (day 1 & 15) Copanlisib
11074739|NCT04253262|Experimental|Dose Level 1|400 mg Rucaparib, 45 mg Copanlisib
11074740|NCT04253262|Experimental|Dose Level 2|500 mg Rucaparib, 45 mg Copanlisib
11074741|NCT04253262|Experimental|Dose Level 3|600 mg Rucaparib, 45 mg Copanlisib
11074742|NCT04253262|Experimental|Dose Level 4|600 mg Rucaparib, 60 mg Copanlisib
11074743|NCT04253236|Experimental|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
11074744|NCT04253236|Experimental|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
11074745|NCT04253223|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses
11074746|NCT04253210|Experimental|Sexualized images / High photo modification|
11074747|NCT04253210|Experimental|Sexualized images / Low photo modification|
11074748|NCT04253210|Experimental|Nonsexualized images / High photo modification|
11074749|NCT04253210|Experimental|Nonsexualized images / Low photo modification|
11074750|NCT04253210|Experimental|Control images|
11074751|NCT04253197|Other|Morbidly adherent placenta|This arm was given stage according to ultrasound features.
11074752|NCT04253171|Active Comparator|Lithoplasty lesion preparation|Balloon lithoplasty will be used as lesion preparation.
11074753|NCT04253171|Active Comparator|Conventional lesion preparation|Conventional and modified balloons will be used as lesion preparation.
11074754|NCT04253158|Experimental|Educational standard|The aim of this arm is to increase knowledge about alcohol and other drug use.
11074755|NCT04253158|Experimental|Educational standard and Harm prevention|The aim of this arm is to increase knowledge about alcohol and other drug use and increase intentions for the use of harm prevention strategies.
11074756|NCT04253158|Experimental|Educational standard and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use and shift alcohol-related expectancies.
11074757|NCT04253158|Experimental|Expectancies and Harm prevention|The aim of this arm is shift alcohol-related expectancies and increase intentions to use harm prevention strategies.
11074758|NCT04253158|Experimental|Educational standard and Normative perceptions|The aim of this arm is to increase knowledge about alcohol and other drug use and correct erroneous alcohol-related normative perceptions.
11074759|NCT04253158|Experimental|Normative perceptions and Harm prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions and increase intentions to use harm prevention strategies.
11074760|NCT04253158|Experimental|Educational standard, Normative Perceptions, and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use, correct erroneous alcohol-related normative perceptions, and shift alcohol-related expectancies.
11074761|NCT04253158|Experimental|Normative perceptions, Expectancies, and Harm Prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions, shift alcohol-related expectancies, and increase intentions to use harm prevention strategies.
11074799|NCT04252885|Active Comparator|Group B-Standard treatment+arbidol|In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).
11074800|NCT04252885|No Intervention|Group C-Standard treatment|In group C, 25 cases are only given ordinary treatment.
11074762|NCT04253145|Experimental|PM01183 w/ Atezolizumab|Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.) as a 60-minute infusion (the second and subsequent infusions may be administered over 30 minutes) followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every three weeks (q3wk). Following analysis of cohorts, dose levels can be escalated from 2.5mg to 3.2, to a maximum dose of 3.5 mg of PM01183
11074763|NCT04253132|Active Comparator|50 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
11074764|NCT04253132|Active Comparator|300 mg daily oral dose|300 mg daily, oral dose of tolfenamic acid
11074765|NCT04253132|Active Comparator|600 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
11074766|NCT04253132|Placebo Comparator|Placebo control - 50 mg daily oral dose|50 mg daily oral placebo control
11074767|NCT04253132|Placebo Comparator|Placebo control - 300 mg daily oral dose|300 mg daily oral placebo control
11074768|NCT04253132|Placebo Comparator|Placebo control - 600 mg daily oral dose|600 mg daily oral placebo control
11074769|NCT04253106|Experimental|Unaffected carriers of constitutional mutations|Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
11074770|NCT04253106|Active Comparator|All patients with FOGD|without observation of macroscopic lesions paired with cases (age and sex)
11074771|NCT04253080|No Intervention|patients with primary thin melanoma < 1mm|patients with primary thin melanoma (Breslow thickness less than 1 mm)
11074772|NCT04253080|No Intervention|patients with primary thick melanoma > 3 mm|patients with primary thick melanoma (Breslow greater than 3 mm)
11074773|NCT04253080|Other|patient with melanoma who received first line treatment|patient with melanoma (stages III or IV inoperable) and who received first line treatment with immunotherapy and / or targeted therapies
11074774|NCT04253067|Active Comparator|Active fCO2 laser treatment|Laser probe will be inserted into the vagina. The laser treatment is delivered at 6 points to the vaginal wall. Delivery begins at the most proximal and the wand is retracted by 1 cm and another row of laser treatment is delivered. The number of levels is determined by vaginal length.
11074775|NCT04253067|Sham Comparator|Sham fCO2 laser treatment|Laser probe will be inserted into the vagina. To prevent the delivery of laser energy, the laser will remain in standby mode during the visit. Keeping the laser in standby mode prevents laser exposure. The treatment will appear to be the same as the active treatment. The machine maintains a low humming noise while in standby mode.
11074776|NCT04253041|Experimental|Control|The control group will be exposed to 15 different appearance-neutral images of interior design, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was most prevalent in the previous image?) regarding characteristics of the last image they were exposed to.
11074777|NCT04253041|Experimental|Fitspiration|Participants assigned to the Fitspiration condition (n=30) will be exposed to 15 different fitspiration images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
11074778|NCT04253041|Experimental|Body Positive|Participants assigned to the Body Positive condition (n=30) will be exposed to 15 different body positive images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
11074779|NCT04253028|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after bariatric surgery (this includes: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Gastric Plication and Duodenal Switch).
11074780|NCT04253002|Experimental|Robinson's Culturally Adapted Coping with Stress Course|
11074781|NCT04253002|Active Comparator|Standard Care Control Condition|
11074782|NCT04252989||Children with active myopia treated with ATROPINE eye drops|
11074783|NCT04252976|Experimental|Mantra Meditation|8 weeks of mantra meditation with weekly group sessions.
11074784|NCT04252976|Experimental|Mantra Meditation plus Ethical Practice|8 weeks of mantra meditation plus ethical practice with weekly group sessions.
11074785|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises|8 weeks of mantra meditation plus Yoga Exercises with weekly group sessions.
11074786|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises plus Ethical Practice|8 weeks of mantra meditation plus Yoga Exercises plus ethical practice with weekly group sessions.
11074787|NCT04252963|Experimental|Mucolase|
11074788|NCT04252963|Placebo Comparator|Placebo|
11074789|NCT04252950|Experimental|CB-SET Treatment|Participants randomized to this group will receive a community-based structured exercise therapy (CB-SET) along with the standard of care (revascularization)
11074790|NCT04252950|Active Comparator|Control|Participants randomized to this group will receive standard of care (revascularization)
11074791|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 0.5 mg/kg|HAM8101 (Adrecizumab) : 0.5 mg/kg
11074792|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 2 mg/kg|HAM8101 (Adrecizumab) : 2 mg/kg
11074793|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 8 mg/kg|HAM8101 (Adrecizumab) : 8 mg/kg
11074794|NCT04252924||students|medical student, dental medicine student, pharmacy student, nursing student, physiotherapy student, dietetics student, kinesiology student, biomedical laboratory techniques student, biomolecular science student, psychology student, economy student, student of maritime sciences
11074795|NCT04252911||Anaesthetised patients|50 patients undergoing robotic surgeries under general anesthesia
11074796|NCT04252898|Experimental|Intervention arm|In this arm (site n°1), participants will purchase their products in the restaurant first in a control phase and then in an interventional phase with the Nutri-Score affixed on food products.
11074797|NCT04252898|No Intervention|Control arm|In this arm (site n°2), participants will purchase their products in the restaurant during the whole study without any label affixed on food products.
11074798|NCT04252885|Experimental|Group A-Standard treatment+lopinavir/ritonavir|In group A, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days).
11074801|NCT04252872|Experimental|Sequence A|"Period 1 : HCP0605+HGP1405
~Period 2 : HCP1401"
11074802|NCT04252872|Experimental|Sequence B|"Period 1 : HCP1401
~Period 2 : HCP0605+HGP1405"
11074803|NCT04252859|Experimental|All Participants|One session of [18F]FES PET/CT Imaging
11074804|NCT04252846||Perampanel|Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.
11074805|NCT04252833|Experimental|CT-044 600 mg|The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.
11074806|NCT04252820|No Intervention|Control|No prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer and zero-heat-flux temperature sensor will be used to measure the temperature throughout the perioperative period.
11074807|NCT04252820|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
11074808|NCT04252820|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
11074809|NCT04252820|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
11074810|NCT04252807|Experimental|Intervention arm|"Distressed mothers randomized to intervention arm will receive a common elements based integrated intervention that combines evidence based elements from packages of care addressing early stimulation, responsive feeding and perinatal depression. The integrated intervention is expected to a) improve mother psychological distress, b) improve family support, c) improve child development and d) promote mother-infant interaction.
~The participants will receive 15 monthly sessions at home by lay health workers. First three sessions will be delivered to the participants in the third trimester of pregnancy, followed by 12 monthly sessions afterwards."
11074811|NCT04252807|Active Comparator|Treatment as Usual (TAU)|The participants in the control arm will receive the routine monthly visits by the trained Lady Health Workers (LHWs) of their respective areas.
11074812|NCT04252794|Experimental|Patients who undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will undergo splenic artery ligation (graft inflow modulation)
11074813|NCT04252794|No Intervention|Patients who will not undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will not undergo splenic artery ligation (graft inflow modulation)
11074814|NCT04252781|Other|Exhaustive exploration|Exhaustive exploration of newly diagnosed COPD patients (pulmonary pathology and associated comorbidities)
11074815|NCT04252768|Experimental|Eftilagimod alpha + Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15 and 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
11074816|NCT04252755|Other|EEG Neurofeedback|Within-subjects sessions of EEG neurofeedback
11074817|NCT04252742|Experimental|Erenumab|"The 4-month DBTP has 2 phases:
~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.
~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptans as well as non-ictal burden."
11074818|NCT04252742|Experimental|Placebo|"The 4-month DBTP has 2 phases:
~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.
~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptans as well as non-ictal burden."
11074819|NCT04252729|Experimental|Psychotherapy|Psychotherapy sessions based on the theoretical line of Psychoanalytic Psychosomatics for 1 year, every 10 days.
11074820|NCT04252729|No Intervention|No psychotherapy|Follow-up according to institutional routine, without psychotherapy sessions.
11074821|NCT04252716||VISTHESIA 1.5|Ophtalmologic surgery supported by Visthesia OVD
11074822|NCT04252716||ProVisc|Ophtalmologic surgery supported by Provisc OVD
11074823|NCT04252703|Active Comparator|Minimalist|The 'Minimalist' strategy is PCI treatment of the culprit lesion only. Other coronary stenoses are to be managed medically. It is recognized that there may be multiple culprit lesions in such patients, though there are no data on how frequently this might be expected. Operators may elect to treat multiple putative culprit lesions in this case.
11074824|NCT04252703|Experimental|More complete|The 'More complete' strategy is PCI of the culprit lesion and fractional flow reserve (FFR)- or instantaneous wave-free ratio (iFR)-guided treatment of other angiographically significant (> 50% diameter) stenoses amenable to coronary stenting in vessels with reference diameters ≥2.5mm. Physiological assessment is strongly encouraged but not mandatory for lesions of ≥90% angiographic stenosis. PCI of chronic total occlusions will not be attempted as part of the study.
11074825|NCT04252690|Experimental|Mobiderm|MOBIDERM® autofit : auto-adjustable compression stocking
11074826|NCT04252677|Active Comparator|Obesity Prevention Only|"Three topics to improve adolescents' obesogenic behaviors will be addressed in the intervention:
~Health information:
~• Factual information about healthy eating and activity (PA) including diet and PA recommendations, physical and health effects of prevention behaviors, risk perception for obesity-related chronic illnesses, compensatory beliefs about obesogenic behaviors
~Motivation:
~Personal: Create positive attitudes toward engagement in healthy eating and PA
~Social: Enlisting social support to increase healthy eating and PA
~Social: Identification of community resources that promote and support healthy eating and PA
~Behavioral Skills
~Tips for engaging in prevention behaviors and avoiding risk behaviors in the context of existing barriers
~Skills for social situations around behaviors
~Skills for making behavior part of routine
~Build autonomy, self-efficacy and model good health decision-making for health behaviors"
11074854|NCT04252508|No Intervention|Standard route|"The information about the surgery will be given by the surgeon during the consultation.
~Those about anaesthesia will be delivered by anaesthesiologist during the anaesthetic consultation."
11074827|NCT04252677|Experimental|Health Literacy and Obesity Prevention|"Obesity prevention and health literacy (HL).
~Health Literacy
~Functional HL: skills for reading/understanding nutrition labels and medication instructions.
~Interactive HL: verbal skills for interacting with others on health issues.
~Critical HL: connections between advocacy and health
~Media HL: skills for accessing and identifying reliable source of media.
~Health information:
~• Factual information about healthy eating and activity (PA)
~Motivation:
~Create positive attitudes toward engagement in healthy eating and PA
~Enlisting social support to increase healthy eating and PA
~Identification of community resources that promote and support healthy eating and PA
~Behavioral Skills
~Tips for engaging in prevention behaviors and avoiding risk behaviors
~Skills for social situations around behaviors
~Skills for making behavior part of routine
~Build autonomy, self-efficacy and good health decision-making for health behaviors"
11074828|NCT04252664|Experimental|Remdesivir group|active remdesivir
11074829|NCT04252664|Placebo Comparator|Control group|Placebos matched remdesivir
11074830|NCT04252651||Blood Draw|This study will involve blood draws to test for specific cytokines
11074831|NCT04252638|Experimental|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment therapy is a well-established treatment for other disorders including depression, anxiety and chronic pain, but has not been thoroughly investigated for insomnia. The therapy consists of mindfulness, acceptance, identification of personal life values and committed action. In addition, patients in this group will receive sleep restriction, a behavioral therapy component of cognitive behavioral therapy for insomnia. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
11074832|NCT04252638|Active Comparator|Cognitive Behavioral Therapy including Sleep Restriction|The control intervention is Cognitive Behavioral Therapy for insomnia (CBT-I). This is the first line treatment for adults with chronic insomnia. The therapy consists of education, relaxation, and behavioral therapy, including sleep restriction. The treatment will consist of six weekly sessions of group psychotherapy and will be conducted in an outpatient setting.
11074833|NCT04252625|Active Comparator|Arm 1: Prosta-Q|"Patients will be randomized in a 1:1 ratio to receive Prosta-Q, one capsule, twice daily for 4-6 weeks after brachytherapy placement.
~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
11074834|NCT04252625|Placebo Comparator|Arm 2: Placebo|"Patients will be randomized in a 1:1 ratio to receive Placebo, one capsule, twice daily for 4-6 weeks after brachytherapy placement.
~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
11074835|NCT04252612|Experimental|Cohort 1: Pramlintide 60 mcg twice daily|Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
11074836|NCT04252612|Experimental|Cohort 2: Pramlintide 60 mcg three times daily|Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
11074837|NCT04252612|Experimental|Cohort 3: Pramlintide 120 mcg three times daily|Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
11074838|NCT04252599||Control group|
11074839|NCT04252599||Multiple sclerosis group|
11074840|NCT04252599||Multiple sclerosis trunk impairment|
11074841|NCT04252586|Experimental|GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
11074842|NCT04252573|Experimental|ChEVAS System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
11074843|NCT04252560||Colorectal|30 patients operated for colorectal cancer
11074844|NCT04252560||HIPEC|15 patients operated with CRS+HIPEC for peritoneal carcinomatosis
11074845|NCT04252547|Experimental|Grup 1|"-During the Procedure Group 1 The preprocedural measurements(weight, heart rate and oxygen saturation ) will be applied to the infants in Group 1 before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother.
~During the second feeding hour, his/her heart rate and oxygen saturation will begin to be recorded ten minutes before the feeding hour. The data will be recorded for ten minutes and then the infant will be taken out of the incubator and weight is measured only in his/her clean diaper. He/she will be handed over to the mother to breastfeed."
11074846|NCT04252547|Experimental|Grup 2|"- During the Procedure Group 2 The preprocedural measurements will be applied to the infants in Group 2 before the first feeding hour when they are included in the study and then they will be breastfed by their mothers.
~The preprocedural measurements (weight, heart rate and oxygen saturation) will be applied to the infant during the second feeding hour and then he/she will be held on his/her mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother."
11074847|NCT04252534|Active Comparator|Repetitive electromagnetic stimulation|Group 1 consists of 20 RP patients (40 eyes) who received combined rEMS with PRP. In this group, patients received rEMS for 30 minutes before subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
11074848|NCT04252534|Active Comparator|Platelet rich plasma|Group 2 consists of 20 RP patients (40 eyes). In this group, patients received only subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
11074849|NCT04252534|No Intervention|Natural course|Group 3 consists of 20 RP patients (40 eyes). Patients in this group did not accept any interventional application and were only followed up. The
11074850|NCT04252521|Active Comparator|metoclopramide+ dexketoprofen trometamol|10 mg metoclopramide+ 50 mg dexketoprofen trometamol
11074851|NCT04252521|Experimental|metoclopramide|10 mg metoclopramide
11074852|NCT04252521|Experimental|dexketoprofen trometamol|50 mg dexketoprofen trometamol
11074853|NCT04252508|Experimental|With animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
11074855|NCT04252495|Experimental|Subjects with moderate hepatic impairment (Group 1)|
11074856|NCT04252495|Experimental|Healthy subjects (Group 2)|
11074857|NCT04252482|Experimental|cpap|usage cpap 3month
11074858|NCT04252482|No Intervention|Usual care|Usual care 3month
11074859|NCT04252469|Experimental|intervention|receiving oral care with 20mL of 0.12% CHX by medicine cup, gargling 30 seconds.
11074860|NCT04252469|No Intervention|Control|Standardized care
11074861|NCT04252456|Other|standard chemotherapy for advanced colorectal cancer|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.
11074862|NCT04252443|Other|Nurse|The research population consisted of 190 nurses working in a university hospital. Because all of the nurses in the research population could not be reached, a sample was selected using a simple random sampling method. One hundred twenty-seven nurses were interviewed in the research population, with a 95% confidence interval and a 5% sampling error.
11074863|NCT04252430|Active Comparator|Patients with renal impaired function|6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe ranal impaired function
11074864|NCT04252430|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired renal function patients
11074865|NCT04252417|Active Comparator|Patients with hepatic impaired function|8 patients with hepatic impairment of moderate Child Pugh category
11074866|NCT04252417|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired hepatic function patients
11074867|NCT04252391|Active Comparator|Standard care|Standard care will consist of standard physical therapy care which may include the following: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, dry needling with or without electrical trigger point dry needling, soft tissue release and prescribed therapeutic exercises .
11074868|NCT04252391|Active Comparator|standard care with perineural electrical dry needling.|This arm will consist of standard care with perineural electrical dry needling, using a high frequency stimulation placed near the nerve, differing from addressing muscular trigger points. For example, a dry needle placed in the semispinalis capitus muscle along the greater occipital nerve pathway, stimulated at 80 Hz.
11074869|NCT04252378|Experimental|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and external intercostal muscle near 5th rib.
11074870|NCT04252378|Active Comparator|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
11074871|NCT04252365|Experimental|arm 1|"Patients with PD-L1 high expression (TPS≥50%) receive Sintilimab injection 200mg i.v. on day 1 every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
~Patients with PD-L1 low or negative expression (TPS<50%) receive Sintilimab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Sintilimab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
11074872|NCT04252365|Active Comparator|arm 2|"Patients with PD-L1 high expression (TPS≥50%) receive Pembrolizumab injection 200mg i.v. on day 1once every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
~Patients with PD-L1 low or negative expression (TPS<50%) receive Pembrolizumab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Pembrolizumab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
11074873|NCT04252352|Active Comparator|Ablative fractional CO2 laser resurfacing|One fractional CO2 laser treatment are performed of acne scars on one side of the face
11074874|NCT04252352|Active Comparator|Radio-frequency microneedling|One radio-frequency microneedling treatment are performed of acne scars on one side of the face
11074875|NCT04252339|Experimental|RLY-1971 - Dose Escalation/Expansion|"Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified
~Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified."
11074876|NCT04252326|Active Comparator|Doctor|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
11074877|NCT04252326|Active Comparator|Nurse|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
11074878|NCT04252326|Active Comparator|Dentist|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
11074879|NCT04252313|No Intervention|Group A|This arm represents the control group. They will be undergoing the circumcision without any music, with the established standard for analgesia [EMLA+Sucrose+Ring Block]
11074880|NCT04252313|Experimental|Group B: Music|"In addition to the standard analgesia as explained for group A, Music will be played from the Baby Go to Sleep playlist which includes nursery rhymes and lullabies metonymized to an actual human heartbeat (Houser, 1994). Music will start after the baby settles on the board and before the surgeon starts the procedure."
11074881|NCT04252300|Experimental|Healthy subjects_Period 1|Healthy adults from USA receive a single dose of rosuvastatin (interaction drug) in Period 1.
11074882|NCT04252300|Experimental|Healthy subjects_Period 2|The healthy adults from Period 1 receive both rosuvastatin + BAY1817080 in Period 2.
11074883|NCT04252287|Experimental|Canagliflozin 100 mg|Participants will be administered 100 milligram (mg) immediate-release, over-encapsulated tablets (as a capsule) orally once daily for 12 weeks.
11074884|NCT04252287|Placebo Comparator|Placebo|Participants will be administered matching placebo capsules orally once daily for 12 weeks.
11074885|NCT04252274|Experimental|Darunavir, Cobicistat and conventional treatments|After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments.
11074886|NCT04252274|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without darunavir and cobicistat.
11074887|NCT04252261|Experimental|sulforaphane|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
11074888|NCT04252261|Placebo Comparator|placebo|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
11074889|NCT04252248|Experimental|Stratum 1|Patients having received standard, definitive chemoradiotherapy according to current, national guidelines with curative intent and being at high risk for disease recurrence (patients are considered at high risk if they display a positive nodal status of their cancer (anogenital HPV-induced tumor) or if the tumor is locally advanced and/or if they display a positive nodal status with extracapsular extension (head and neck HPV-induced tumor). Study therapy (as additional therapy to standard chemoradiation) will start after a time interval of 6-8 weeks after finishing chemoradiotherapy
11074890|NCT04252248|Experimental|Stratum 2|"Patients with non-curative and progressive disease having received all standard, national approved systemic therapies (according to current, national guidelines with regard to the specific tumor entity), and/or presently not eligible for a respective therapy, and/or refused respective therapy. Study treatment thereby represents a potential palliative, last-line systemic therapy option (late salvage)."
11074891|NCT04252235|Sham Comparator|Sham air purifier|Participants will receive a sham air purifier that will be installed in the bedroom and living room. These purifiers will make a noise, but will not filter the air.
11074892|NCT04252235|Experimental|True air purifier|Participants will receive a HEPA air purifier in the bedroom and living room.
11074893|NCT04252222|Experimental|VL3|Tracheal intubation with VL3 videolaryngoscope
11074894|NCT04252209|Experimental|patients with sjogren's received natural mixture|"The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.
~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
11074895|NCT04252209|Active Comparator|patients with sjogren's recievrd CMC|"the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%.
~applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep"
11074896|NCT04252196|Experimental|Device Usability Study|Usability evaluators of medical device (Healthy volunteers).
11074897|NCT04252170|Experimental|Feasibility study, Stroke Survivors|BAC feasibility study at PowerBack, Piscataway NJ, with stroke patients.
11074898|NCT04252157|Experimental|kinesiotaping|Kinesotape will be apply with suitable tension and necessery region.
11074899|NCT04252157|Placebo Comparator|plesebo taping|Tape will be appy with randomly region without tension.
11074900|NCT04252157|Other|control|Nothing will be applied
11074901|NCT04252144|Experimental|GERD|Patients with verified gastroesophageal reflux disease
11074902|NCT04252144|Other|Contol|Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
11074903|NCT04252131|Experimental|Cassia seed|oral administration of Cassia seed (3.0g), once/day for 12 weeks
11074904|NCT04252131|Placebo Comparator|Cassia seed placebo|oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks
11074905|NCT04252118|Experimental|MSCs Treatment Group|Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
11074906|NCT04252118|No Intervention|Conventional Control Group|Without MSCs Therapy but conventional treatment should be received.
11074907|NCT04252105|Experimental|Antioxidant rich diet|
11074908|NCT04252105|No Intervention|Regular diet|
11074909|NCT04252092|Experimental|Sensory Group|15 patients who will be applied 15 sessions of sensory training
11074910|NCT04252092|Experimental|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
11074911|NCT04252079|Other|We compare different endovascular techniques as an alternative|We compare different endovascular techniques as an alternative to surgical reconstruction to repair JAAS regarding ; success rates, 30-day mortality, endoleak events secondary intervention rates
11074912|NCT04252066||Cohort 1|Cohort 1 will be pregnant and/or breastfeeding patients who have Fabry Disease, and have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
11074913|NCT04252066||Cohort 2|Cohort 2 will be pregnant and/or breastfeeding patients who have Fabry Disease, who were not exposed to migalastat during pregnancy and/or breastfeeding.
11074914|NCT04252053|Experimental|Supervised Pilates-Based Core Stability Training Group|In order to detect the effects of pilates-based core stabilization training (PBCST) on isokinetic knee strength and postural sways, individuals with MS will receive pilates-based core stabilization training for 8 weeks and 2 days a week. One educational session will perform to teach basic principles of pilates based training. Individuals in this group will receive treatment at the clinic by physiotherapist supervision. All sessions will be individualized (not group training).
11074915|NCT04252053|Active Comparator|Home exercise group|The home exercise group will perform the same PBCST exercises at home during the same period (8 weeks, 2 days a week) as the brochures prepared for them. Individuals in this group will receive one educational session which includes basic principles of pilates and one session which includes two-week exercise program. Participants will be invited to the clinic every two weeks to ensure the progression of the exercises and the exercise program will be updated.
11074916|NCT04252040|Experimental|Active tDCS with guided imagery|Subjects will receive 2 miliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
11074917|NCT04252014|No Intervention|Non-Tobacco Messages|Participants in the control group will receive messages about health topics unrelated to tobacco use (e.g., sun safety). Messages will be delivered online through 4 brief study communications.
11074918|NCT04252014|Experimental|Hookah Tobacco Messages|Participants in the hookah tobacco messaging group will receive hookah tobacco public education messages delivered online through 4 brief study communications. Messages will communicate about the risks of hookah tobacco use in the following theme areas: 1) Health Harms; 2) Addictiveness; 3) Social Use; 4) Flavorings. The order of message themes delivered in each study communication will be randomized.
11074919|NCT04252001|Experimental|Group YT|Group receives YESS! game and transition-toolkit
11074920|NCT04252001|Experimental|Group GT|Group receives control game and transition-toolkit
11074922|NCT04252001|No Intervention|Group O|Group receives usual transition care
11074923|NCT04251988|No Intervention|Standard of Care (No VR) Randomization|Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
11074924|NCT04251988|Experimental|VR Randomization|Patients will receive virtual reality in addition to standard of care.
11074925|NCT04251975|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
11074926|NCT04251975|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
11074927|NCT04251962|Experimental|Bupivacaine|Epidural solution containing 0.1% bupivaacaine in normal saline
11074928|NCT04251962|Experimental|Bupivacaine + Fentanyl|Epidural solution containing 0.1% bupivacaine and 3 mcg/ml of fentanyl in normal saline
11074929|NCT04251936|Experimental|Exercise training plus smoking cessation group program|
11074930|NCT04251936|Active Comparator|Smoking cessation group program|
11074931|NCT04251923|Experimental|vagianl prolapse surgery accompanied with TVT sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need. Patient who falls in Group will undergo mid urethral sling with tension free vaginal tape (TVT) using TVT mid urethral sling.
11074932|NCT04251923|No Intervention|vaginal prolapse surgery not accompanied with sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need.
11074933|NCT04251910|Active Comparator|Cohort 1- 30 Micrograms|Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
11074934|NCT04251910|Active Comparator|Cohort 2- 60 Micrograms|Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo
11074935|NCT04251910|Active Comparator|Cohort 3- 90 Micrograms|Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
11074936|NCT04251897|Active Comparator|Standard care mattress|Patient will have 2 days to familiarize with the novel support surface. Patient will be on standard care mattress. They will be turned over every 2 hours for 3 days.
11074937|NCT04251897|Experimental|Novel support surface|"After the standard care mattress, the same patient will be placed on novel support surface. They will be turned over every 2 hours for 3 days.
~Patient will then continue with the novel support surface and turned every 3 hours for 3 days.
~They will then continue with the novel support surface and turned every 4 hours for 3 days."
11074938|NCT04251884|Experimental|Receiving the pudendal nerve block|
11074939|NCT04251884|Active Comparator|Not receiving the pudendal nerve block|
11074940|NCT04251871|Experimental|Conventional medicines and TCMs granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
~Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days."
11074941|NCT04251871|Active Comparator|Conventional medicines|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
11074942|NCT04251858|Experimental|Athletes with oral problems|Athletes with periodontal diseases or gingivitis
11074943|NCT04251858|No Intervention|Athletes without oral problems|Athletes diagnosed without oral problems
11074944|NCT04251845|Active Comparator|Trial group|Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily
11074945|NCT04251845|Placebo Comparator|Control Group|Intervention : Placebo once daily
11074946|NCT04251832|Experimental|Ultrasound guided percutaneous lavage with STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using sodium thiosulfate 25 %: a volume of 1 mL of sodium thiosulfate will be prepared in a syringe and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. At the end of the procedure 1 mL (250 mg) of thiosulfate will be injected inside the calcific deposit. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.
~Only a single procedure will be performed and the outcomes measured after 1 week, 1 month and 3 months."
11074947|NCT04251832|Active Comparator|Ultrasound guided percutaneous lavage without STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using of saline solution and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.
~Only a single procedure will be performed and the outcomes measured after 1week, 1month and 3months"
11074948|NCT04251819|Placebo Comparator|Placebo|Participants randomized to this arm will receive Placebo.
11074949|NCT04251819|Experimental|Baclofen 5mg|Participants randomized to this arm will receive 5 mg of Baclofen.
11074950|NCT04251819|Experimental|Baclofen 10mg|Participants randomized to this arm will receive 10 mg of Baclofen.
11074951|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
11074952|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
11074953|NCT04251793||Er:YAG laser-assisted debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with the aid of the laser treatment two years ago at the Graduate Periodontics Clinic at University of Michigan.
11074954|NCT04251793||Standard mechanical debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with dental scalers two years ago at the Graduate Periodontics Clinic at University of Michigan.
11075038|NCT04251156|Placebo Comparator|Placebo (semaglutide)|Once-weekly injections of gradually increased doses of semaglutide placebo
11074955|NCT04251780|Experimental|Hyperaldosteronism treatment|Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinol Metab, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.
11074956|NCT04251767|Experimental|Observational group|5u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
11074957|NCT04251767|Placebo Comparator|Control group|5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
11074958|NCT04251741|Active Comparator|Usual care group|Based on a secondary randomization schedule patients are treated with etanercept or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
11074959|NCT04251741|Experimental|'Drug concentration guided' group|Patients with a concentration <1.0 mg/L switch to etanercept and patients with a concentration ≥ 1.0 start a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab)
11074960|NCT04251728|Experimental|Exercise plus AMPS group (AMPS-G)|Physical exercise and automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold, performed two times a week for 12 weeks.
11074961|NCT04251728|Sham Comparator|Exercise plus SHAM group (Exercise-G)|Physical exercise and simulated automated mechanical peripheral stimulation (AMPS) with intensity at the sensory threshold performed two times a week for 12 weeks.
11074962|NCT04251715|Experimental|mFOLFIRINOX, Floxuridine-DEX, mFOLFIRI|"Treatment Period 1 - mFOLFIRINOX for 4 cycles (cycle = 14 days) Cycle 1
~Oxaliplatin 85 mg/m2 intravenously (iv) over 2 hours
~Folinic acid 400 mg/m2 iv over 2 hours
~Irinotecan 165 mg/m2 iv over 90 minutes
~Fluorouracil 400 mg/m2 iv bolus after folinic acid
~Fluorouracil 2,400 mg/m2 continuous infusion over 46 hours
~Dosages on Cycle 2, 3, and 4 will be reduced by 25% Treatment Period 2 - HAI delivery of floxuridine + mFOLFIRI for 2 cycles (cycle = 28 days)
~Floxuridine-DEX (with heparin and saline) - 0.12 mg/kg/day; via HAI pump, adjusted for weight and flow rate
~mFOLFIRI on Day 15
~Irinotecan 180 mg/m2 iv over 30 minutes to 1 hour
~Folinic acid 400mg/m2 iv over 30 minutes to 1 hour
~5-FU 1000 mg/m2 continuous infusion over 46 hours"
11074963|NCT04251702||Healthy Low-Risk Nulliparous Women in Spontaneous Labor|Healthy Nulliparous women with a Singleton Term fetus in the Vertex position in spontaneous labor.
11074964|NCT04251689|Experimental|intervention|mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
11074965|NCT04251689|Placebo Comparator|placebo|0.9% normal saline 100 ml one hour after cisplatin
11074966|NCT04251663||HS subjects|Subjects with active HS disease, among which at least 5 will be treatment-naïve
11074967|NCT04251663||Healthy Controls|Healthy subjects
11074968|NCT04251650||low severity|patient with periodontitis stage I and II
11074969|NCT04251650||high severity|patient with periodontitis stage III and IV
11074970|NCT04251637||adult patients scheduled for thoracic pulmonary|"Adult patients scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.
~- Having stated their non opposition to be part of this protocol"
11074971|NCT04251624|Experimental|Goal Management Therapy|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length. Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.
11074972|NCT04251624|Active Comparator|Psychosocial Education|Psychosocial education will provide educational materials (e.g., brain function, neuroplasticity) and lifestyle interventions (e.g., sleep hygiene, stress, exercise). They will be matched for length and for amount of facilitator contact with the Goal Management Therapy sessions. Phase 1: Inpatients will attend group sessions twice per week for 3 weeks, each session being 2 hours in length. Phase 2: Outpatients from the community will attend 1 session per week for 9 weeks, each session being 2 hours in length.
11074973|NCT04251611|No Intervention|Control group|The usual care in patients with myocardial ischemia without other cardiovascular risk factors (CVFR) will be to attend one visit per year with doctor and nurse of the local health center. In this visit, it will be done a blood test and an electrocardiogram. Blood pressure, weight, body mass index, abdominal circumference will be measured and, in case of detecting enolic habit, smoking or sedentary lifestyle, generic advice will be done. If the patient, apart from myocardial ischemia, presents diabetes mellitus type 2, 3-4 follow-up visits per year will be recommended and will be increased according to specific needs. In case of presenting hypertension, will be recommended 2 visits with the nurse and one visit with the doctor per year and will be increased according to specific needs. In addition, in this case the blood pressure is checked every 6 months. During all visits, professionals will reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
11074974|NCT04251611|Experimental|Intervention group|"Patient will go to health center to visit the cardiac rehabilitation (CR) reference team, which is composed for a doctor and a nurse. This team will establish the guideline of action in the maintenance and/or increase in the physical exercise practice, in function of the resources of each zone and the preferences and motivations of the patient. They also reinforce the control of CVRF and the maintenance of a long-term cardio-healthy lifestyle.
~At the end of the visit, control visit will be given with the CR reference team at 3, 6 and 12 months after completing the supervised physical exercise program of phase II of the CRP. In case of detecting specific needs for the patient and/or relapses, the team will consult with the appropriate professional (cardiologist, cardiology nurse, physiotherapist, rehabilitator, nutritionist and/or psychologist). At the same time, the patient will be informed of the possibility of re-evaluating the CR reference team."
11074975|NCT04251598|Experimental|Education group|"Only I am Protecting my Child From the Sun program was given."
11074976|NCT04251598|Experimental|Education + SMS group|"The I am Protecting my Child From the Sun program was given. After the program, an SMS message was sent on Wednesday and Saturday for 12 weeks. A total of 25 SMS messages were sent to remind the subject and applications."
11074977|NCT04251598|No Intervention|Control group|"No attempt was made by the researcher during the study. Only data collection was carried out. At the end of the research, the I am Protecting my Child From the Sun program was given.."
11074978|NCT04251585|Experimental|Low Insulin|Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.
11074979|NCT04251585|Experimental|Medium Insulin|Regular insulin (Novolin-R) 40 international units (10 units) in each nostril twice daily for 21 days, 100 µl volume.
11074980|NCT04251585|Experimental|High Insulin|Regular insulin (Novolin-R) 80 international units (10 units) in each nostril twice daily for 21 days, 200 µl volume.
11074981|NCT04251585|Placebo Comparator|Placebo|0.9% sodium chloride in each nostril twice daily for 21 days, 100 µl volume.
11074982|NCT04251572|Experimental|HCV reinfection after DAA therapy in PWID|Hepatitis C virus reinfection after directly acting antiviral treatment in persons who inject drugs. DAA therapy is an inclusion criteria, not an intervention.
11074983|NCT04251559|Active Comparator|patients with gestational diabetes mellitus|study group
11074984|NCT04251559|Placebo Comparator|healthy participants|control group
11074985|NCT04251546||Observational group|Patients with suspected prostate cancer with a PSA test value of 4-10 ng / mL
11074986|NCT04251533|Experimental|alpelisib + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Single arm Open label in Study Part B1
11074987|NCT04251533|Placebo Comparator|placebo + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Not applicable in Study Part B1
11074988|NCT04251520|No Intervention|Control Group|Standard care by Palliative Medicine physician
11074989|NCT04251520|Experimental|Intervention Group A|Standard care by Palliative medicine physician plus pharmacist review of medications
11074990|NCT04251520|Experimental|Intervention Group B|Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
11074991|NCT04251507|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
11074992|NCT04251507|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
11074993|NCT04251494||Phenylketonuria (PKU) participants|"During their outpatient clinic appointment, participants will:
~Undergo routine height and weight measurements and blood tests. A full patient history will be taken, including a record of cardiovascular disease within the family. Blood samples will be collected, including phenylalanine, lipids, vitamin B12 and related biomarkers.
~Complete a 14-item diet history questionnaire, and fill in a 3 day diet diary before they arrive at their outpatient clinic appointment, which will be collected after the participant signs the informed written consent form.
~Undergo assessment of carotid Intima-media thickness (CIMT), pulse wave velocity (PWV), ankle brachial pressure index (ABPI) and systolic and diastolic blood pressure."
11074994|NCT04251494||Age and gender matched reference controls|Only Phenylketonuria (PKU) patients will be studied. Controls are generated from the literature. Reference CIMT values exist for a healthy population based on age and gender (Engelen et al., 2013), eliminating the need to assess age- and gender-matched controls. The study would otherwise require performing blood tests and vascular assessments on healthy individuals, generating a risk of harm and a possible incidental finding. It would be inconvenient for controls because they would need to travel to hospital and undergo invasive venepuncture.
11074995|NCT04251481|Experimental|Optimization of Techniques|To optimize the diffusion MRI methods for assessment of cell viability, metabolism and perfusion in head and neck cancer. There will be 24 subjects enrolled for 2 year duration. Treatment-naïve patients with cervical metastatic lymph nodes (diameter > 10 mm) of HNSCC will be recruited to have one research PET/MR scan (including dMRI) and one dMRI-only scan within three days prior to treatment. These data will be used to optimize the dMRI method and assess the repeatability.
11074996|NCT04251481|Experimental|: Longitudinal Monitoring|To assess the feasibility of using diffusion MRI metrics at early stages of treatment for prediction of treatment response in head and neck cancer patients undergoing standard-of-care chemoradiation therapy. There will be 36 subjects enrolled for 3 year duration. The study will do bi-weekly measurement to monitor tumor response longitudinally. This study will be restricted to treatment-naïve patients who present pathologically confirmed HNSCC with metastatic lymph nodes and who are scheduled to receive standard care of radiation therapy with concurrent chemotherapy. The patients enrolled in this arm of the study will have 4 dMRI scans. The imaging data for each patient will be the proposed dMRI measures at the baseline and their changes at each follow-up time period. DCE-MRI will be included in the baseline scan for tumor delination as in standard-of-care cancer imaging and to compare with the proposed dMRI method.
11074997|NCT04251468|Other|GEPII|All patients who completed the study.
11074998|NCT04251455||TMJ disease/disorder characterisation|Patients with the diagnosis disc displacement without reduction (DDwoR), or disc displacement with reduction (DDwR), or osteoarthritis (OA), or chronic inflammatory arthritis (CIA) were designated to TMJ surgery. According to the Swedish national guidelines on TMJ surgery DDwoR, OA, and CIA patients had arthroscopy and DDwR had discectomy.
11074999|NCT04251442|Experimental|Study Group|The study group will have soft tissue balance performed with the use of IOS.
11075000|NCT04251442|No Intervention|Control Group|Control group patients will have soft tissue balance performed manually, with final soft tissue balance values measured using IOS, while the surgeon will remain blinded to those values.
11075001|NCT04251429|Experimental|Immediate Intervention Group|SHIFT study team provides coaching to Health and Safety Committee to implement a participatory program for increasing committee effectiveness.
11075002|NCT04251429|Other|Delayed Intervention Group|Active Comparator for 2 years: status quo program remains in place with new ongoing data collection. Then experimental intervention as above.
11075003|NCT04251416|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
11075036|NCT04251169|Experimental|Pembrolizumab + Paclitaxel|Pembrolizumab 200 mg every 3 weeks (on D1 of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m2 administered at days 1, 8, 15 of each 21-day cycle beginning at cycle 2.
11075004|NCT04251403|Experimental|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
11075005|NCT04251390||trexo Home intervention|Participants family is renting a trexo Home from trexo. The decision to use the device was separate from this research, and the decision to do research on its use was secondary. The proposed procedures may be modified to adapt to the child and family's interest and needs. Participant will use the trexo Home in their home, school, and community.
11075006|NCT04251377|Experimental|Single-stage surgery + DAC® + topical antibiotics|Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
11075007|NCT04251377|No Intervention|control group : two-stage surgery|Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
11075008|NCT04251364|Experimental|Acetazolamide|Oral acetazolamide (250 mg/day) intake for 9 months
11075009|NCT04251364|Experimental|Atorvastatin|Oral atorvastatin (40 mg/day) intake for 9 months
11075010|NCT04251364|Placebo Comparator|Placebo|Oral placebo pill (daily) intake for 9 months
11075011|NCT04251351|Experimental|Arm 1|Paracetamol 15 mg/kg/dose 6 hourly for 72 hours
11075012|NCT04251351|Sham Comparator|Arm 2|Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.
11075013|NCT04251338||delayed visual maturation|children with delayed visual maturation
11075014|NCT04251325||Basic Life Support Course Participants|The study population includes all Danish citizens who attended a BLS training course certificate from 2016-2018 above the age of 15.
11075015|NCT04251325||Background population|The entire danish population above 15 years whom have not attended a BLS training course certificate from 2016-2018.
11075016|NCT04251312|Experimental|Preoperative dental hygiene education|Patients who are scheduled for elective esophageal or lung resections who consent to participate will undergo oral hygiene education and be given an oral hygiene packet. An oral hygiene assessment using the Plaque Assessment tool will be conducted in the clinic. A Dysphagia Screening Tool questionnaire will also be administered. Patients who screen positive for dysphagia will be referred to Speech Pathology for evaluation but for the study purposes, the only data collected from the evaluation will be whether or not the participant received this intervention. A repeat dental exam will occur on the day of surgery. Patients will be followed for 30 days post operatively.
11075017|NCT04251299|Experimental|Single Arm|All participants will receive the 10-month mentored, vegetable gardening intervention
11075018|NCT04251273|Experimental|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.
~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
11075019|NCT04251273|Other|Assessment only Control|After an initial enrollment message, participants will be contacted periodically to assess e-cigarette use. At the end of the intervention period, they will receive information on how to sign up for This is Quitting if they are interested in the program
11075020|NCT04251260|Experimental|Positioning in flexion|Intervention: Positioning of body in flexion and aligment towards midline with Snuggle up (Philips, USA)
11075021|NCT04251260|No Intervention|Control group|No intervention
11075022|NCT04251247||Acute aortic dissection|Patients with a diagnosis of acute aortic dissection.
11075023|NCT04251247||Acute pulmonary embolism|Patients with a diagnosis of acute pulmonary embolism
11075024|NCT04251247||Non-cardiac chest pain|Patients with non-cardiac chest pain
11075025|NCT04251234|Experimental|Healthy controls|"No co-morbid medical or psychiatry diagnoses
~No family history of mental illness
~No current medication use
~Non-smoking"
11075026|NCT04251234|Experimental|Bipolar I disorder|"Clinical diagnosis of Bipolar I disorder
~Can be (not required, not exclusionary) taking lithium and/or sodium valproate and/or antidepressants
~Can be (not required, not exclusionary) light smokers"
11075027|NCT04251221|Experimental|Social Drinkers|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08.
11075028|NCT04251208||Integrated Care|This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
11075029|NCT04251208||Referral-Based Care|This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
11075030|NCT04251195|Experimental|Cognitive Intervention|
11075031|NCT04251195|Active Comparator|Active Control Intervention|
11075032|NCT04251182|Placebo Comparator|Placebo|Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.
11075033|NCT04251182|Experimental|15mg T3D-959|T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.
11075034|NCT04251182|Experimental|30mg T3D-959|T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.
11075035|NCT04251182|Experimental|45mg T3D-959|T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.
11075037|NCT04251156|Experimental|Semaglutide|Once-weekly injections of gradually increased doses of semaglutide
11075040|NCT04251130||Cognitively Normal Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
11075041|NCT04251130||Mild Cognitively Impaired Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
11075042|NCT04251117|Experimental|GNOS-PV02 + INO-9012 + Pembrolizumab|"First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured.
~GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI."
11075043|NCT04251104|Experimental|Level of personal relevance of images|This is an exploratory randomized controlled study to compare the effectiveness of three types of autobiographical stimuli, classified according to their level of personal relevance (high, medium and low), in the induction of positive emotions resulting from the retrieval of specific positive autobiographical memories. To this end, the investigators will use three types of images, classified according to their personal relevance: a) personal autobiographical photographs (high personal relevance); b) images of locations related to the participants' lives (medium personal relevance); and c) images from the Internation Affective Picture System (IAPS; low personal relevance).
11075044|NCT04251104|Other|Age (young and older adults comparison)|To analyse any age-related differences in the effectiveness of the use of the three types of images to regulate emotion, the investigators will compare the efficacy of the three categories of pictures (high, medium and low relevance) in inducing positive mood states in a group of young adults (age range: 18-35 years) and a group of older adults (65 years or over).
11075045|NCT04251091|Experimental|ReWalk Soft Exosuit|During this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out an 18 session training protocol.
11075046|NCT04251078||Myelodysplastic Syndromes - Progression cohort|According to the literature (Greenberg et al, Blood. 2012), around 5-15% are expected to progress to high/very high-risk MDS subtype or to acute myeloid leukemia (AML). According to the total cohort of patients, it is expected that 20 of them would comprise this group and will be studied by targeted deep sequencing.
11075047|NCT04251078||Myelodysplastic Syndromes - Non Progression cohort|20 patients without progression will be analyzed by targeted deep sequencing in order to find out if there are any differences in the mutational spectrum compared with those disease progression cases.
11075048|NCT04251065|Experimental|Daratumumab-GDP|"This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell origin and a central evaluation of immunohistochemical positivity of CD38 on bioptic material used to perform local diagnosis of relapsed disease, or that used for the more recent biopsy in the case of refractory patients. A core needle biopsy is considered sufficient for review and CD38 evaluation. Evaluation at central laboratory can be performed in bone marrow sections in those patients with only bone marrow lymphoma infiltration.
~Only patients with confirmed eligible diagnosis and a percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for study treatment.
~The treatment consists of an induction phase and a maintenance phase."
11075049|NCT04251052|Experimental|Group I (bilateral salpingectomy)|Patients undergo bilateral salpingectomy. Patients may then undergo oophorectomy after initial surgery.
11075050|NCT04251052|Active Comparator|Group II (bilateral salpingo-oophorectomy)|Patients undergo bilateral salpingo-oophorectomy.
11075051|NCT04251039||PCI with pre-treatment with P2Y12 inhibitors|"SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo:
~Assessment of platelet reactivity (Time 0, T0) (VFN)
~PCI (start = T1; end= T2)"
11075052|NCT04251039||PCI with treatment with P2Y12 inhibitors only after procedure.|"SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo:
~Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0)
~Assessment of platelet reactivity (Time 0, T0) (VFN)
~PCI (start of PCI= T1; end of infusion of Cangrelor= T2)"
11075053|NCT04251026|Experimental|Cohort A|Dose escalation followed by continuous dosing in subjects with neuronopathic MPS II
11075054|NCT04251026|Experimental|Cohort B|Dose escalation followed by continuous dosing in subjects with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype
11075055|NCT04251013|Active Comparator|Group A: RX Cytology brush, Boston Scientific FIRST|A first biliary brushing will be carried out during ERCP using a standard brush RX Cytology Brush, Boston Scientific, then a second brushing will be carried out using a brush INFINITY®, US Endoscopy
11075056|NCT04251013|Active Comparator|Group B: Infinity®, US Endoscopy FIRST|A first biliary brushing will be carried out during ERCP using an INFINITY® brush, US Endoscopy then a second brushing will be carried out using standard RX Cytology Brush, Boston Scientific
11075057|NCT04251000|Experimental|Joovv Pilot Experimenta Arm|Individuals will receive 90 day access to the Joovv infrared mini light device.
11075058|NCT04250987|Experimental|IC connected to a sensor|Single use of a IC connected to a sensor
11075059|NCT04250974|Experimental|electroacupuncture|electroacupuncture at points after surgery
11075060|NCT04250974|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
11075061|NCT04250974|No Intervention|Control group|only oral or injection painkiller were used after surgery
11075062|NCT04250961|Experimental|Shower Group|Patients who had a shower in 48-72 hours after Median Sternotomy
11075063|NCT04250961|Active Comparator|Control Group|Patients whose sternal incision site was not connected water until remove sutures
11075064|NCT04250948|Active Comparator|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1
~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
~S-1:40~60mg Bid, d1~14, q3w;
~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;
~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
11115822|NCT03964571|Experimental|Diabetic foot patients|
11075065|NCT04250948|Experimental|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1
~JS001: 240mg, ivdrip, d1, q3w;
~S-1:40~60mg Bid, d1~14, q3w;
~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;
~Neoadjuvant chemotherapy for 3 cycles, adjuvant chemotherapy for 5 cycles."
11075066|NCT04250922|Placebo Comparator|Arm A: SoC + placebo for 2-OHOA|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm A will receive placebo every day from Day 1 of week 3 to the end of this Phase.
~The start of the first cycle during the Maintenance (Adjuvant) Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.
~Subjects in Arm A will receive placebo every day during the first 3 weeks of each 28-day cycle and until progression. Patients will continue with Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
11075067|NCT04250922|Experimental|Arm B: SoC + 12 g/day of 2-OHOA|"Chemoradiation Phase: all subjects undergo focal RT, with a treatment given 5 days per week over ~6 weeks (no more than 7 weeks). TMZ will be administered at 75 mg/m2 orally, once daily, continuously throughout the RT for a maximum of 49 days. Subjects in Arm B will receive 2-OHOA every day from Day 1 of week 3 to the end of this Phase.
~The start of the first cycle during the Maintenance Phase will be scheduled ~28 days (and never more than 42 days) after the last day of chemoradiation. During the Maintenance Phase, subjects will receive oral TMZ 150-200 mg/m2 once daily on Days 1-5 of each 28-day cycle for 6 cycles.
~Subjects in Arm B will receive 2-OHOA during the Maintenance Phase. Patients will continue to be administered with 2-OHOA after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression, unacceptable toxicity or refusal to continue study treatment."
11075068|NCT04250909||Passeo 18 PTA|Previous treatment with uncoated Passeo 18 PTA balloon catheter
11075069|NCT04250909||Passeo-18 Lux DCB|Previous teatment with Passeo-18 Lux DCB
11075070|NCT04250896|Other|Control|Control group will receive standard child care in health units plus exposure to EsIAN (Strategy of Integral Attention to Nutrition)
11075071|NCT04250896|Experimental|Intervention|Intervention group will receive SMS messages sent through a cell pone in addition to the control group receive (standard child care in health units plus exposure to EsIAN)
11075072|NCT04250883|Experimental|A. Experimental group 1|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement
11075073|NCT04250883|Experimental|B. Experimental group 2|low impact laparoscopy (low pressure (8 mmHg) and deep NMB (PTC 1-2)); 14 mmHg IAP after trocar introduction for perfusion measurement
11075074|NCT04250883|Active Comparator|C. Control group 1|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)); 8 mmHg IAP after trocar introduction for perfusion measurement
11075075|NCT04250883|No Intervention|D. Control group 2|standard laparoscopy (standard pressure (14 mmHg) and moderate NMB (TOF 1-2)); 14 mmHg IAP after trocar introduction for perfusion measurement
11075076|NCT04250870|Active Comparator|Nursing Home Residents|Nursing home residents (n=59) were evaluated in five different nursing homes.
11075077|NCT04250870|Active Comparator|Community-Dwelling Elderly|The community-dwelling elderly people (n=59) were selected from two different municipalities of the city.
11075078|NCT04250857||Suspected Sudden Cardiac Arrest|All subject with suspected of a circulatory arrest for any cause.
11075079|NCT04250844||Botulinum|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functional luminal imaging probe (EndoFLIP). The dosage will be determined by the patient's physician.
11075080|NCT04250844||Control|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections.
11075081|NCT04250831|Experimental|Glucomannan, oligofructose and chromium mixture|Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie
11075082|NCT04250818||Control Group|Patients with mTNBC who receive chemotherapy only
11075083|NCT04250818||Experimental Group|patients with mTNBC who receive a combination of chemotherapy and Immunotherapy
11075084|NCT04250805|Active Comparator|Lidocaine|Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
11075085|NCT04250805|Experimental|Lidocaine and Ropivacaine|Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance
11075086|NCT04250792|Experimental|single arm|Low dose naltrexone was prescribed to the patients affected with psoriasis.
11075087|NCT04250779|Placebo Comparator|Control Group|In this arm, patients are provided with standard-of-care instructions on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned off.
11075088|NCT04250779|Active Comparator|Treatment Group|In this arm, patients are provided with active guidance from CapMedic device on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned on.
11075089|NCT04250766|Other|Single arm echo-guided uterine biopsy|
11075090|NCT04250753||Patients with lumbar spinal stenosis|
11075091|NCT04250740|Experimental|Coffee A|
11075092|NCT04250740|Experimental|Coffee B|
11075093|NCT04250740|Experimental|Coffee C|
11075094|NCT04250727|Experimental|3% Nicotine Concentration|25 participants will be randomly assigned to receive a JUUL with 3% nicotine concentration JUULpods.
11075095|NCT04250727|Experimental|5% Nicotine Concentration|25 participants will be randomly assigned to receive a JUUL with 5% nicotine concentration JUULpods.
11075096|NCT04250714||Treatment patients|Subjects indicated for the treatment of AF with the cryoablation system according to current and future Guidelines and system indications for use
11075097|NCT04250701||Dyslexia (D)|
11075098|NCT04250701||Intellectual Disability (ID)|
11075099|NCT04250701||Control (C)|
11075100|NCT04250688|Experimental|Esko Bionics Suit + Functional Electrical Stimulation|
11075101|NCT04250688|No Intervention|Control|
11075102|NCT04250675|Sham Comparator|Sham|Participants will apply Intermittent Pneumatic Compression (IPC) using a customized version of the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The sham device applies a compression sequence of 30 mmHg to the foot, ankle and calf with inflatable cuffs.
11075103|NCT04250675|Active Comparator|Active Comparator - Intermittent Pneumatic Compression|Participants will apply Intermittent Pneumatic Compression (IPC) using the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The Arterial Assist Device® applies a compression sequence of 120 mmHg to the foot, ankle and calf with inflatable cuffs.
11075104|NCT04250662|Experimental|Active tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
11075105|NCT04250662|Experimental|Active tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes while remaining seated, no guided imagery will be provided.
11075106|NCT04250662|Sham Comparator|Sham tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
11075107|NCT04250662|Sham Comparator|Sham tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject will remain seated, no guided imagery will be provided.
11075108|NCT04250649|Active Comparator|Intervention|Betadine solution disinfection of the subcutaneous tissue during primary shoulder surgery
11075109|NCT04250649|No Intervention|Controle|Control group with surgery without disinfection of the subcutaneous tissue but dissection with an electric cautery during primary shoulder surgery
11075110|NCT04250636|Experimental|Study Participants|HIV-infected individuals, off ART, and with plasma HIV-1 RNA levels between 500 and 100,000 copies/ml by standard assays. Study participants will receive a single intravenous infusion of 3BNC117-LS and a single infusion of 10-1074-LS. The antibodies will be administered sequentially and dosed at 30 mg/kg.
11075111|NCT04250623|Experimental|subjects, 18-70 y, healthy|subjects, 18-70 y, healthy
11075112|NCT04250597|Experimental|1.0 mg/kg|
11075113|NCT04250597|Experimental|3.0 mg/kg|
11075114|NCT04250597|Experimental|10 mg/kg|
11075115|NCT04250597|Experimental|30 mg/kg|
11075116|NCT04250597|Experimental|60 mg/kg|
11075117|NCT04250584|Experimental|Test Device|Novel Mandibular Advancement Device
11075118|NCT04250584|Active Comparator|Predicate Device|Predicate Mandibular Advancement Device
11075119|NCT04250571|Experimental|No treatment group|Participants will receive no pills and will be told that they are in the no treatment group
11075120|NCT04250571|Experimental|Imaginary pill (IP) group|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence)
11075121|NCT04250571|Experimental|Open label placebo group|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo)"
11075122|NCT04250545|Experimental|Treatment (CB-839 HCl, sapanisertib)|Patients receive glutaminase inhibitor CB-839 hydrochloride PO BID and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11075123|NCT04250532||Lifeguard|Lifeguards who work on the Atlantic coast of Gironde France.
11075124|NCT04250519|Experimental|1% sodium hypochlorite & dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
11075125|NCT04250519|Active Comparator|1% sodium hypochlorite as irrigant &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
11075126|NCT04250519|Experimental|5.25% sodium hypochlorite and dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
11075127|NCT04250519|Active Comparator|5.25% sodium hypochlorite &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
11075128|NCT04250506|Experimental|Treatment A: Daridorexant 50 mg|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
11075129|NCT04250506|Experimental|Treatment B: Daridorexant 200 mg|Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.
11075130|NCT04250506|Placebo Comparator|Treatment C: Placebo|Placebo administered as tablets (4 x 50 mg) for oral use.
11075131|NCT04250506|Active Comparator|Treatment D: Moxifloxacin 400 mg|Moxifloxacin administered as film-coated tablets for oral use.
11075132|NCT04250493|Experimental|MSA patient|Patients will be recruited at the French Reference Center for MSA.
11075133|NCT04250493|Other|Control|Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
11075134|NCT04250480|Experimental|Beta-alanine|4 g by mouth, 3 times per day with regular meals for 14 days.
11075135|NCT04250480|Placebo Comparator|Placebo|4 g by mouth, 3 times per day with regular meals for 14 days.
11075136|NCT04250467|Experimental|L-Alanyl-L-Glutamine|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy.
11075137|NCT04250467|Placebo Comparator|Placebo-Physiological Saline|Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy.
11075138|NCT04250454|No Intervention|Control|Elsass Standard Care
11075139|NCT04250454|Active Comparator|Intervention|Enriched eviroment, Feed back training, Electrical stimulation, nutrition
11075140|NCT04250441|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
11075141|NCT04250428|No Intervention|Control|Women in the control arm will have (standard) access to antenatal care.
11075142|NCT04250428|Experimental|Demand intervention|Women in this arm will receive a home visit by a study nurse at the beginning of their pregnancy that will inform them regarding the importance of iron and folic acid supplementation as well as malaria prophylaxis.
11075143|NCT04250428|Experimental|Supply intervention|Women in this arm will get a monthly visit by study nurses. Women who did not obtain supplements or malaria prophyllaxis through routine antenatal care services will be directly provided with the supplements and malaria drugs by the study nurse.
11075144|NCT04250415||Operative Arm|
11075145|NCT04250415||Non-operative Arm|
11075146|NCT04250402||Arm 1|"Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
~Other Name: ESD"
11075147|NCT04250402||Arm 2|"Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally."
11075148|NCT04250402||Arm 3|Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
11075149|NCT04250402||Arm 4|Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
11075150|NCT04250389||Patients with VS receiving methylene blue infusion|The studied population will be all patients receiving methylene blue for refractory vasoplegic shock (VS) after Cardiopulmonary Bypass (CPB). Refractory VS is defined as follow: a dose of norepinephrine > 0.5µg/kg/min to obtain a mean arterial pressure of 65-75 mmHg with a normal or increase cardiac (> 2 L.min-1.m-2). Patients will be included in the investigator's 20-bed adult cardiothoracic intensive care unit (ICU) in a tertiary teaching hospital (Hopital Cardiologique Louis Pradel, Hospices Civils de Lyon).
11075151|NCT04250376|Experimental|Treatment|All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.
11075152|NCT04250363|Experimental|M5717|Participants will receive single ascending oral dose of M5717 powder in capsule after DVI of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
11075153|NCT04250363|Placebo Comparator|Placebo|Participants will receive placebo matched to M5717 after DIV of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
11075154|NCT04250350|Experimental|Lebrikizumab|Q2W
11075155|NCT04250337|Experimental|Lebrikizumab + Topical Corticosteroid|Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 followed by a single injection of lebrikizumab every 2 weeks (Q2W) from Week 4 until Week 14. TCS will be initiated at Baseline in all participants and may be tapered or stopped, as needed, based on treatment response.
11075156|NCT04250337|Placebo Comparator|Placebo + Topical Corticosteroid|Two subcutaneous (SC) injections of placebo as a loading dose at Baseline and Week 2 followed by a single injection of placebo every 2 weeks (Q2W) from Week 4 until Week 14. TCS will be initiated at Baseline in all participants and may be tapered or stopped, as needed, based on treatment response
11075157|NCT04250324|Experimental|BZ019|The subjects are enrolled into 2 dose-escalation cohorts, include 3x10^6/kg、6x10^6/kg, and dose-expansion cohorts, maybe 8x10^6/kg、10x10^6/kg.
11075158|NCT04250311|Experimental|MMH-407|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
11075159|NCT04250311|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
11075160|NCT04250298|Other|Iron deficient blood donors|Daily intake of 30 mg of sucrosomal iron during 90-120 days (male and female whole blood donors)
11075161|NCT04250272|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
11075162|NCT04250272|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
11075163|NCT04250259|Placebo Comparator|Placebo|Alcoholic Cirrhosis on placebo
11075164|NCT04250259|Experimental|1,200 mg SAMe|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
11075165|NCT04250259|No Intervention|Non-drinking Controls|Non-drinking healthy controls
11075166|NCT04250246|Experimental|Ipilimuamb plus nivoluamb plus guadecitabine|ipilimumab plus nivolumab combined with guadecitabine
11075167|NCT04250246|Active Comparator|Ipilimumab plus nivolumab|Ipilimumab plus nivolumab
11075168|NCT04250233||Standard neuraxial opioids|Standard neuraxial anesthesia for cesarean delivery (heavy bupivacaine 10 mg; fentanyl 20 mic; and low dose intrathecal morphine
11075169|NCT04250233||Non standard neuraxial opioids|"Non standard low-dose morphine group (with heavy bupivacaine 10 mg; fentanyl 20 mic)
~Women are offered - if they prefer not to receive low dose morphine, the option of either ultra-low dose morphine or no morphine - instead they can receive postoperative bilateral quadratus lumborum block (QLB) or erector spinus block."
11075170|NCT04250220|Experimental|intervention group|e-health-based strategy
11075171|NCT04250220|No Intervention|control group|symptom based AF-screening
11075172|NCT04250207|Experimental|K-321 QID|K-321 Ophthalmic Solution Dose A
11075173|NCT04250207|Experimental|K-321 BID|K-321 Ophthalmic Solution Dose B
11075174|NCT04250207|Placebo Comparator|Placebo|Vehicle Solution Dose
11075175|NCT04250194|Experimental|Navigation Bronchoscopy (NB) with F-Nav|
11075176|NCT04250194|Experimental|CT-guided Biopsy|
11075177|NCT04250181||Standard RF|ablation with RF power of 30 Watts (30W) and with 25 Watts (25W) on posterior wall
11075178|NCT04250181||High RF 40W (40 Watts)|ablation with RF power of 40 watts (40W)
11075179|NCT04250181||High RF 50W (50 Watts)|ablation with RF power of 50 watts (50W)
11075180|NCT04250155|Experimental|Phase 1a Dose Escalation|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
11075181|NCT04250155|Experimental|Phase 1a Dose Expansion|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
11075182|NCT04250155|Experimental|Phase 1b Dose Escalation|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
11075183|NCT04250155|Experimental|Phase 1b Dose Expansion|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
11075184|NCT04250142|Active Comparator|Conventional Glass Ionomer|Selective removal of carious tissue to soft dentin. Deep carious dentin will be lined by a conventional glass ionomer, followed by a composite resin restoration.
11075185|NCT04250142|Experimental|Self-etching Adhesive|Selective removal of carious tissue to soft dentin. Deep carious dentin will not be lined and a self-etching adhesive will cover the tissue, followed by a composite resin restoration.
11075186|NCT04250129||SLNB (-)&level 1-3 RT|SLNB (-)&level 1-3 RT
11075187|NCT04250129||SLNB (+)&level 1-3 RT|SLNB (+)&level 1-3 RT
11075188|NCT04250129||SLNB(+)&ALND&level 3 RT (+/-level 1-2)|SLNB(+)&ALND&level 3 RT (+/-level 1-2)
11075189|NCT04250116|Experimental|Anticoagulation mono therapy|Apixaban monotherapy
11075190|NCT04250116|Active Comparator|Dual antithrombotic therapy|
11075191|NCT04250103||patient|patients who receive home health care
11075192|NCT04250103||caregiver|caregivers who take care of patients with home health care
11075193|NCT04250090||Long-term type ureteral stent set|Patients with Long-term type ureteral stent set due to ureteral stricture.
11075194|NCT04250077|Experimental|CRAFT-A|"Participants assigned to the CRAFT-A will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1)Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.
~CRAFT-A participants also attend a weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations."
11075195|NCT04250077|Experimental|CRAFT-C|"Participants assigned to the CRAFT-C groups will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Withdrawing Reinforcement; 6) Allowing Natural Consequences; 7) Problem-solving; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills.
~CRAFT-C participants attend a weekly 60-minute individualized on-on-one coaching session with a CRAFT certified coach. During weekly individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations. One-on-one sessions involve roleplays that are tailored to the participants' specific circumstances"
11075196|NCT04250077|Active Comparator|PEER|"Participants assigned to the PEER group will participate in an online peer support forum with other CSOs.
~Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully. This individual also will report any adverse or severe adverse events that members mention online."
11075197|NCT04250064|Experimental|Concurrent low-dose Bevacizumab|Low-dose concurrent Bevacizumab with standard radiotherapy
11075198|NCT04250064|Experimental|Ultra-low-dose RT|Ultra-low-dose RT
11075199|NCT04250051|Experimental|Treatment (combination chemotherapy, ivosidenib)|"INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
11075200|NCT04250025|Experimental|EXPERIMENTAL GROUPE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
11075201|NCT04250025|No Intervention|CONTRO GROUPE|60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.
11075202|NCT04250012|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 10-week internet-based acceptance and commitment therapy intervention with three remote meetings with a psychologist"
11075203|NCT04250012|Active Comparator|Psychoeducation|"Group Psychoeducation will receive a self-help booklet and a link to mobile wellness training program"
11075204|NCT04249999|Experimental|Intervention|Access to online physical activity platform (www.activonline.com.au) in addition to usual care.
11075205|NCT04249999|No Intervention|Control|No access to online physical activity platform. Continue with usual care.
11075270|NCT04249570|No Intervention|No iodine|gastrostomy feeding tube is not coated with a layer of Betadine by aseptic gauze before PEG technique
11075206|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 17 and 19 lb BPW|Participants will be randomized to both 17 and 19 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
11075207|NCT04249986|Active Comparator|The Borg Rating of Perceived Exertion between 19 and 17 lb BPW|Participants will be randomized to both 19 or 17 pounds for the first hike and the alternate condition for the second hike. A random number generator will create 1 block that includes 10 participants in each block to ensure comparable numbers to subjects starting at different base backpack weight. Participants assignments will then be included in a sealed manila envelopes.
11075208|NCT04249973||IgE-mediated cow's milk allergy|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
11075209|NCT04249973||Suspected of cow's milk allergy, but with negative diagnosis|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
11075210|NCT04249973||IgE-mediated food allergy, other than cow's milk|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
11075211|NCT04249973||Healthy brothers and sisters|Feces and urine samples are collected by the parents at home. Feces is collected out of the diaper or using a fecotainer. Urine is collected directly or using a urine collection pad. Additionally, the parents fill in a short questionnaire regarding the symptoms of their child, their clinical history and relevant information regarding the development of food allergies.
11075212|NCT04249960|No Intervention|Transition as usual|Young people in this group will receive usual care and transition as usual, they will be our control group.
11075213|NCT04249960|Experimental|Managed transition|Young people in this group will do the managed transition, they will be our experimental group.
11075214|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1a)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
11075215|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)|Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
11075216|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1c)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
11075217|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)|Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
11075218|NCT04249934|Experimental|Caffeinated Coffee|
11075219|NCT04249934|Active Comparator|Decaffeinated Coffee|
11075220|NCT04249921||Experimental|"Use acupuncture to treat the patients who received the surgery of CPA tumor. Acupoints of reference: Yifeng(TE17),Tinggong(SI19),Xiaguan(ST07),Wind Pool(GB20),Outer Pass(SJ5),Union Valley(LI4),Yang Mound Spring(GB34),Leg Three Li(ST36).
~Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS)."
11075221|NCT04249921||Control|1.Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).
11075222|NCT04249908|Active Comparator|Healthy Subjects|
11075223|NCT04249908|Experimental|Mild Renal Impairment (RI)|
11075224|NCT04249908|Experimental|Moderate RI|
11075225|NCT04249908|Experimental|Severe RI|
11075226|NCT04249895||Main Cohort|All patients are undergoing radiotherapy in Tata Medical Center
11075227|NCT04249882|Placebo Comparator|Placebo|Matched to active medications
11075228|NCT04249882|Active Comparator|Varenicline|1 mg twice a day
11075229|NCT04249882|Active Comparator|Naltrexone|50 mg once a day
11075230|NCT04249869|Experimental|Group A|Group A will receive VGH-AD1 two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 8 weeks. Post-follow up will be 4 weeks later.
11075231|NCT04249869|Placebo Comparator|Group B|Group B will receive placebo two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the VGH-AD1 for another 8 weeks. Post-follow up will be 4 weeks later.
11075232|NCT04249856||Women examined by colposcopy|Women referred to colposcopy at our facilities who met inclusion criteria
11075233|NCT04249843|Experimental|Phase 1a: Dose Escalation|BGB-3245 administered orally (PO) as a continuous daily administration, in 28 day and 30 day cycles
11075234|NCT04249843|Experimental|Phase 1b, Group 1: Dose Expansion, non-V600 B-RAF mutations|BGB-3245 administered orally (PO) as a continuous daily administration, in 28 day and 30 day cycles in participants with non-V600 B-RAF mutations including RAF fusions
11075235|NCT04249843|Experimental|hase 1b, Group 2: Dose Expansion, B-RAF V600 mutations|BGB-3245 administered orally (PO) as a continuous daily administration, in 28 day and 30 day cycles in participants with B-RAF V600 mutated melanoma or NSCLC B-RAF and/or MEK inhibitor resistant tumors (i.e. have progressed on a B-RAF-inhibitor and/or MEK-inhibitor)
11075236|NCT04249830|Experimental|Stem Cell Transplant|The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. Participants will be followed for outcomes for two years.
11075340|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
11075237|NCT04249817|Experimental|Video conferencing with extended role practitioner|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
11075238|NCT04249817|No Intervention|Usual care|Participant goes to their rheumatologist's clinic for follow-up, including physical assessment by their rheumatologist, as they would normally.
11075239|NCT04249804|Experimental|Intrathecal Mg group|45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine
11075240|NCT04249804|Experimental|IV Mg infusion group|45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia
11075241|NCT04249804|No Intervention|control|0.5% heavy bupivacaine in the spinal with no additives
11075242|NCT04249791|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from live donor.
11075243|NCT04249778|Experimental|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
11075244|NCT04249778|Placebo Comparator|Placebo|Participants will receive placebo once daily
11075245|NCT04249765|Experimental|Hand strength|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer
~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned.
~The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer."
11075246|NCT04249752||Group 1 with GBS patients|GBS patients
11075247|NCT04249752||Group 2 with CIDP patients|with CIDP patients
11075248|NCT04249739|Experimental|CapeOx+Pembrolizumab|"Run in exploratory Biomarker group (N=10)
~Cycle 1 Only CapeOX monotherapy
~Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy
~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy CapeOx+Pembrolizumab therapy (N=68)
~Cycle 1 up to Cycle 8 CapeOX + pembrolizumab therapy
~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy : CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal."
11075249|NCT04249726|Experimental|Direct composite resin restoration|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations
11075250|NCT04249726|Active Comparator|Full coverage metal-ceramic crown|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations followed by full coverage metal-ceramic crown
11075251|NCT04249713|Experimental|Brodalumab|Brodalumab 210mg subcutaneously every week for 24 weeks
11075252|NCT04249700|Experimental|Whole-body Hyperthermia (WBH)|All participants receive WBH for 80-110 minutes in the Curve Sauna Dome infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
11075253|NCT04249687|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection
11075254|NCT04249687|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
11075255|NCT04249674||Patient under a CYP2D6 inhibitor and under Tramadol|
11075256|NCT04249674||Patient not under a CYP2D6 inhibitor but under Tramadol|
11075257|NCT04249648||Sub-study 1|Patients with new diagnosis of heart failure with reduced ejection fraction who will be started on renin-angiotensin-aldosterone system inhibitors or in whom there is a plan to increase renin-angiotensin-aldosterone system inhibitors (if already taking prior to diagnosis of heart failure).
11075258|NCT04249648||Sub-study 2|Healthcare professionals (doctors, pharmacists, non-medical prescribers) who manage patients with hyperkalaemia and/or heart failure and hyperkalaemia.
11075259|NCT04249635||Reference Group|Healthy term (> 37 weeks of gestation) newborns of women with pregestational body mass index (BMI) ≥18,5 and <24,9 in the first prenatal visit.
11075260|NCT04249635||Maternal obesity (MO) Group|Newborns of women with pregestational BMI ≥30 that received 200 mg/dayDHA supplementation.
11075261|NCT04249635||MO+DHA Group|Newborns from women with pregestational BMI ≥30 that received 800 mg/day DHA supplementation.
11075262|NCT04249622|Experimental|Arm I (rifaximin, pertuzumab-based chemotherapy)|Patients that experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy receive rifaximin PO BID on days 1-5 and standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
11075263|NCT04249622|Active Comparator|Arm II (pertuzumab-based chemotherapy)|Patients that do not experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy continue receiving standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
11075264|NCT04249609|Experimental|High Carbohydrate Meals Around Exercise|On day 1, high CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will consist of pasta, meat ball and orange juice. On the day 2, participants will exercise for 60 minutes and then in 60 minutes will consume morning meal, providing 30% of their total daily energy requirements. Morning meal will consist of oats, skimmed-milk, banana and seedless raisins.
11075265|NCT04249609|Experimental|Low Carbohydrate Meals Around Exercise|On day 1, low CHO dinner meal will provide 35% of participants total daily energy requirements. Meal will based on burger, cheese, mushroom, nuts, and butter.On the day 2, participants will exercise fro 60 minutes and then in 60 will consume morning meal, providing 30% of their total daily energy requirements. Meal will consist of white bread, egg, cheese, olive oil, nuts, and olives.
11075266|NCT04249596|Experimental|Open Treatment|All subjects will be treated for 8 weeks of treatment with Tianeptine (Tianeurax 12.5 mg) 3 times a day (9am, 1pm, 5pm).
11075267|NCT04249583|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
11075268|NCT04249583|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
11075269|NCT04249570|Experimental|Iodine|gastrostomy feeding tube is coated with a layer of Betadine by aseptic gauze before PEG technique
11076130|NCT04243304|Experimental|PD patients|At baseline and 2-year follow-up
11075271|NCT04249557|Experimental|EIM group|This contains: A 12-week Exercise is medicine teaching class containing 15-18 patients per group, homework are prescribed to participants to encourage regular exercise. The exercise level will be recorded by a tracker and provides feedback to the participants and physical trainer. The physical parameters such as fat percentage and blood pressure level will be feedback to the patients to encourage exercise.
11075272|NCT04249544|Experimental|Impulsive group, placebo then pramipexole|half of the impulsive group will first get the placebo on the first day and pramipexole on the second day
11075273|NCT04249544|Experimental|Impulsive group, pramipexole then placebo|half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day
11075274|NCT04249544|Experimental|Non-impulsive group, placebo then pramipexole|half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day
11075275|NCT04249544|Experimental|Non-impulsive, pramipexole then placebo|half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day
11075276|NCT04249531|Experimental|Amikacin|Patients will receive once amikacin i.v. 7,5 mg/kg in the first week
11075277|NCT04249518|No Intervention|nurse instruction of CPAP|Normal extradition. 45 minutes face to face with a nurse.
11075278|NCT04249518|Experimental|Video extradition|Access to 7 min video - explaining how to start CPAP and how to adjust the mask.
11075279|NCT04249492|Experimental|IOL implantation experimental|Experimental arm: Enhanced depth of focus (EDOF) intraocular lens.
11075280|NCT04249492|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens.
11075281|NCT04249479|Experimental|CM temperature 20° C|CM is administered to the patient at a temperature of 20° C.
11075282|NCT04249479|Active Comparator|CM temperature 37° C|CM is administered to the patient at a temperature of 37° C.
11075283|NCT04249466||Patient with cystic fibrosis|
11075284|NCT04249453||Chronic low back pain with high disability|Veterans with chronic, non-specific LBP and a Roland-Morris Disability Questionnaire (RMDQ) score of >12 (gender-balanced, n1=18)
11075285|NCT04249453||Chronic low back pain with low disability|Veterans with chronic, non-specific LBP and a RMDQ score of 12 (gender-balanced, n2=18)
11075286|NCT04249453||Controls|Asymptomatic veterans with no recent history of LBP (gender-balanced, n3=18)
11075287|NCT04249440||PST|patient accepts preoperative systemic treatment as upfront strategy
11075288|NCT04249440||upfront surgery|patient accepts upfront surgery and run postoperative systemic treatment
11075289|NCT04249427|Active Comparator|Erenumab|140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
11075290|NCT04249427|Placebo Comparator|Placebo|Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.
11075291|NCT04249401||Reduced dose NOAC|Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)
11075292|NCT04249401||Standard dose NOAC|Participants with NVAF initiating treatment with standard doses of individual NOACs
11075293|NCT04249401||Vitamin K antagonists (VKA)|Participants with NVAF initiating treatment with vitamin K antagonists (VKA)
11075294|NCT04249388||Decliners of Pulmonary Rehabilitation|No intervention, just observation
11075295|NCT04249362|Experimental|Cohort A|Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.
11075296|NCT04249362|Experimental|Cohort B|Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.
11075297|NCT04249349|Experimental|Robot-assisted Gait|Participants will receive assisted gait with a motorized ankle foot orthosis. Patient´s gait will be analyzed by a photogrammetry system during device assistance. Session will involve 1 hour of supervised training.
11075298|NCT04249336|Experimental|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
11075299|NCT04249336|Active Comparator|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
11075300|NCT04249336|Active Comparator|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
11075301|NCT04249336|Placebo Comparator|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
11075302|NCT04249323|Experimental|Part 1: SAD Cohorts A through H CORT113176|Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.
11075303|NCT04249323|Placebo Comparator|Part 1: SAD Cohorts A through H Placebo|Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.
11075304|NCT04249323|Experimental|Part 2: MAD Cohorts A through D CORT113176|Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.
11075305|NCT04249323|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.
11075341|NCT04249115|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of targeted lesion.
11075306|NCT04249323|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.
11075307|NCT04249310||Tiotropium/Olodaterol|Combination of Tiotropium and Olodaterol
11075308|NCT04249310||Tiotropium|
11075309|NCT04249297||IVF/Dydrogesteron|Females aged ≥ 18 years, underwent In-Vitro Fertilization with Elective single embryo transfer in fresh cycle, for whom were prescribed treatment with Duphaston® for luteal phase support as part of an Assisted Reproductive Technology
11075310|NCT04249284|Experimental|Treatment A : BMS-986165|
11075311|NCT04249284|Experimental|Treatment B: BMS-986165 prototype 1|
11075312|NCT04249284|Experimental|Treatment C: BMS-986165 prototype 2|
11075313|NCT04249284|Experimental|Treatment D: BMS-986165 prototype 2|
11075314|NCT04249271||euthyroid, no antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
11075315|NCT04249271||borderline euthyroid, no antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling
11075316|NCT04249271||hypothyroidism, no antibodies|TSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
11075317|NCT04249271||euthyroid, with antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
11075318|NCT04249271||borderline euthyroid, with antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling
11075319|NCT04249271||hypothyroidism, with antibodiesal|TSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
11075320|NCT04249258|Experimental|Dobutamine|Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
11075321|NCT04249245||Parkinson Patients|"These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).
~They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015."
11075322|NCT04249245||Control Subjects|"They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned.
~If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group."
11075323|NCT04249232|Active Comparator|abaloparatide prefilled syringe|Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.
11075324|NCT04249232|Placebo Comparator|Placebo prefilled syringe|For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.
11075325|NCT04249219|Experimental|E-Cigarette Ads|All individuals in the study will see the same e-cigarette advertisements presented in a random order.
11075326|NCT04249206|Experimental|Hydraulic Sealer Group|"The single-cone obturation technique is based on a master cone of gutta-percha in conjunction with a hydraulic sealer.
~Hydraulic endodontic cements exhibit excellent hydraulic properties, biocompatibility and bioactivity."
11075327|NCT04249206|Active Comparator|Zinc oxide-eugenol Sealer Group|The continuous wave of condensation of gutta-percha and a zinc oxide-eugenol (ZOE) sealer is a gold standard in endodontic obturation.
11075328|NCT04249193||Transfusion|
11075329|NCT04249167|Experimental|Treatment (cryoablation, atezolizumab, nab-paclitaxel)|Patients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab IV on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11075330|NCT04249154|Other|Post-op IMRT & hormonal therapy|The protocol is designed to recruit patients who have undergone prostatectomy and high risk features of the disease were found post-operatively or for patients that, after prostatectomy, a PSA rise has been documented will be enrolled in the Phase II trial. Patients will receive Eligard injection 8-12 weeks before starting radiation. The second injection is given 12 weeks after the first one concomitant with radiation therapy.
11075331|NCT04249141||ICU providers|Surveys and a concept mapping exercise will be administered to ICU providers who participated in the ICU Liberation Collaborative
11075332|NCT04249141||Secondary Data Analysis|Secondary data analysis will used information on patients and providers who participated in the ICU Liberation Collaborative
11075333|NCT04249128|Experimental|Veg Collagen & Keratin Free (Hair Skin Nails)|Participants will receive a free 3 month supply of Collagen & Keratin for Hair, Skin & Nail Health
11075334|NCT04249128|Experimental|Veg Collagen Extended with Powder Free (Hair Skin Nails)|Participants will receive a free 3- month supply of Collagen & Keratin for Hair, Skin & Nail Health extended with a pro-berry powder
11075335|NCT04249128|Experimental|Veg Collagen & Keratin $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin for Hair, Skin & Nail Health
11075336|NCT04249128|Experimental|Veg Collagen Extended with Powder $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin extended with pro-berry powder for Hair, Skin & Nail Health
11075337|NCT04249128|Experimental|Ceramides and Astaxanthin Free (Skin)|Participants will receive a free 3-month supply of ceramides and Astaxanthin for Hair, Skin & Nail Health
11075338|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder Free (Skin)|Participants will receive a free 3-month supply of Ceramides and Astaxanthin for Hair, Skin & Nail Health
11075339|NCT04249128|Experimental|Ceramides and Astaxanthin $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
11075342|NCT04249102|Experimental|CGM Group|The study group will be provided with a Continuous Glucose Monitoring system (Guardian Connect from Medtronic).
11075343|NCT04249102|Active Comparator|FGM Group|The control group will be provided with a Flash Glucose Monitoring system (Abbott Diabetes Care).
11075344|NCT04249089|Active Comparator|Relaxation Group|
11075345|NCT04249089|No Intervention|Control group|
11075346|NCT04249076|Experimental|Clobetasol propionate|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage ofe one drop four (4) times a day during 14 days
11075347|NCT04249076|Placebo Comparator|Vehicle|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage ofe one drop four (4) times a day during 14 days
11075348|NCT04249063|Experimental|Treatment Group|NovaSure EA with an injection of local anaesthetic into the fundus. Paracervical block and procedural sedation as per usual.
11075349|NCT04249063|Placebo Comparator|Control Group|NovaSure EA with an injection of normal saline into the fundus. Paracervical block and procedural sedation as per usual.
11075350|NCT04249050|Experimental|Intervention group|The intervention group is receiving a nutritional drink containing potential immune stimulating ingredients (fish oil, arginine, nucleotides)
11075351|NCT04249050|No Intervention|Control group|The Control group is receiving the hospital´s Standard Of Care.
11075352|NCT04249037|Active Comparator|Arm A: Rapid Start Group|Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
11075353|NCT04249037|Placebo Comparator|Arm B: Standard Group|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
11075354|NCT04249024|Experimental|Laser treatment|
11075355|NCT04249024|Active Comparator|Mucosal flap surgery|
11075356|NCT04248998|Experimental|Chemotherapy plus Fasting-Mimicking Diet (FMD)|"Experimental Arm A will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD.
~Chemotherapy will consist of:
~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by
~twelve consecutive cycles of weekly paclitaxel 80 mg/mq
~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles."
11075357|NCT04248998|Experimental|Fasting-mimicking diet plus metformin plus chemotherapy|"Experimental Arm B will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD and daily metformin
~Chemotherapy will consist of:
~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by
~twelve consecutive cycles of weekly paclitaxel 80 mg/mq
~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles.
~Metformin will be administered at an initial dosage of 850 mg/dya, and then escalated to the maximum dosage of 1700/day (two 850 mg tablets) if well tolerated. Metformin will be interrupted 7 days before surgery."
11075358|NCT04248985||Pre-Intervention|Baseline measurement of timing and behavior in OOH cardiac arrest patients presenting with ongoing CPR.
11075359|NCT04248985||Post-Intervention|Timing and behavior in OOH cardiac arrest patents presenting with ongoing CPR
11075360|NCT04248972|Experimental|Intervention|A treatment with whole body red light therapy (NovoTHOR®) will be carried out
11075361|NCT04248972|Placebo Comparator|PLACEBO INTERVENTION|A placebo whole body red light will be carried out
11075362|NCT04248959|Experimental|PREHAB|Facility and home-based multimodal prehabilitation (aerobic exercise training, resistance exercise training, mindfulness)
11075363|NCT04248959|No Intervention|USUAL CARE|Self-directed physical activity and provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
11075364|NCT04248946|Experimental|MRI stream|"In this stream all patients receive 2 experimental interventions (anodal tDCS and cathodal tDCS) and a sham intervention (sham tDCS). These are delivered in randomised order, ensuring a balanced distribution of participants across possible orders. They will receive 5 sessions per condition (on consecutive days), for a total of 15 sessions.
~I. Anodal, cathodal, sham II. Anodal, sham, cathodal III. Cathodal, anodal, sham IV. Cathodal, sham, anodal V. Sham, anodal, cathodal VI. Sham, cathodal, anodal"
11075365|NCT04248946|Experimental|Bedside stream|"In this stream all patients receive 1 experimental interventions (either anodal tDCS or cathodal tDCS) and 1 sham intervention (sham tDCS). These include only 1 session per condition and are delivered in randomised order, resulting in the following possible combinations:
~I. Anodal, sham II. Cathodal, sham III. Sham, anodal IV. Sham, cathodal
~Participants will be randomly assigned to the above groups ensuring a balanced distribution of participants across them."
11075366|NCT04248933|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRC-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
11075367|NCT04248920|Experimental|Intervention Group|Intervention Group. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO). As part of the C2C program, participants will be contacted 6 months later for a supplementary consultation over the telephone and to answer any questions. Epilepsy is unique among chronic, episodic disorders in that PWE lose their ability to make choices during a seizure and depend to a greater degree on the decisions of others including family, friends and colleagues. For this reason, we encourage the PWE to invite their support network to attend the patient education sessions.
11075368|NCT04248920|Other|Waitlist Control Group|Waitlist Control Group. The control group continues TAU and will be followed up 12 months after randomization. The control group will receive C2C after the 12-month follow-up.
11075457|NCT04248335|Experimental|Not in Weight Management Program|Evaluate the effect of liver fat on drug metabolism of PPI's, and if applicable midazolam
11076131|NCT04243304|Active Comparator|Healthy controls|At baseline and 2-year follow-up
11075369|NCT04248907|Experimental|Socket A|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
11075370|NCT04248907|Active Comparator|Socket B|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
11075371|NCT04248907|Active Comparator|Socket C|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
11075372|NCT04248894|Experimental|High-intensity interval training (HIIT)|High-intensity interval training (HIIT) = the exercise of high intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the HIIT session was established based on the HR and workload levels corresponding to 5% above the respiratory compensation point.
11075373|NCT04248894|Experimental|Moderate-intensity continuous training (MICT)|Moderate-intensity continuous training (MICT) = the exercise of moderate intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the MICT session was established based on the HR and workload levels corresponding to anaerobic threshold and respiratory compensation point
11075374|NCT04248894|Sham Comparator|No training|The patients are instructed to avoid any regular exercise program or any non-supervised exercise protocol during the study.
11075375|NCT04248881|Active Comparator|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
11075376|NCT04248881|No Intervention|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2020 (first timers) and have not yet received health education information."
11075377|NCT04248868|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
11075378|NCT04248855|Experimental|SAD Cohort 1|All enrolled patients will receive one dose of KAN-101 Dose A
11075379|NCT04248855|Experimental|SAD Cohort 2|All enrolled patients will receive one dose of KAN-101 Dose B
11075380|NCT04248855|Experimental|SAD Cohort 3|All enrolled patients will receive one dose of KAN-101 Dose C
11075381|NCT04248855|Experimental|SAD Cohort 4|All enrolled patients will receive one dose of KAN-101 Dose D
11075382|NCT04248855|Experimental|MAD Cohort 5|All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
11075383|NCT04248855|Experimental|MAD Cohort 6|All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
11075384|NCT04248855|Experimental|MAD Cohort 7|All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo
11075385|NCT04248829|Experimental|Lazertinib + Gefitinib-matching placebo|Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule
11075386|NCT04248829|Active Comparator|Gefitinib + Lazertinib-matching placebo|Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule
11075387|NCT04248816|Experimental|Usual Care|Standard of care
11075388|NCT04248816|Experimental|Opt-out|Facilitated outreach and opt-out framing
11075389|NCT04248816|Experimental|Opt-out + Incentive|Facilitated outreach and opt-out framing plus a financial incentive
11075390|NCT04248803|No Intervention|Total etch control group|No gluma desensitizer application
11075391|NCT04248803|Experimental|TE - GLUMA application prior to acid etching|TE- Total Etch GLUMA - Desensitizing agent
11075392|NCT04248803|Experimental|TE - GLUMA application after acid etching|TE- Total Etch GLUMA - Desensitizing agent
11075393|NCT04248803|No Intervention|Self etch control group|No gluma desensitizer application
11075394|NCT04248803|Experimental|SE - GLUMA application prior to acid etching|SE - Self Etch GLUMA - Desensitizing agent
11075395|NCT04248803|Experimental|SE - GLUMA application after acid etching|SE - Self Etch GLUMA - Desensitizing agent
11075396|NCT04248790|Experimental|Experimental: the mobile App|Participants in the intervention arm will receive access to all the app capabilities. The app features include information on HIV testing locations, sex and PrEP diary and reminder of taking PrEP.
11075397|NCT04248777|Other|left main PCI guided by OCT|The LM PCI strategy is guided by 3 OCT runs, according to a pre-defined standardized protocol.
11075398|NCT04248764|Experimental|Foam roller group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, foam roler will be applied to the participants' quadriceps femoris muscles in a prone position for five minutes.
11075455|NCT04248361|Active Comparator|SOC/Empiric Diagnosis|The Standard of Care for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
11075399|NCT04248764|Experimental|Massage group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
11075400|NCT04248764|No Intervention|Control group|Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, the participants will rest in the long sitting position for 5 minutes.
11075401|NCT04248751|Experimental|Graft-Augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin. Then, the graft will be delivered to the subacromial space and positioned over the bursal surface of the suprasinatus tendon, ensuring that the lateral edge of the implant will overlap with the head of the humerus. The graft will be fixed with tendon and bone staples.
11075402|NCT04248751|Active Comparator|Non-augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin.
11075403|NCT04248738|Experimental|SocNSuppR|Inpatient teams systematically provided with information about patients' social needs and supportive resources.
11075404|NCT04248725|Experimental|E-TIPS|The E-TIPS intervention is based upon a cognitive-behavioral intervention for pain that was developed for and shown to be effective in people with chronic pain and a physical disability such as the conditions of interest in this study. Eight, 45-minute telephone sessions will be delivered by a clinician. A patient workbook will be used to facilitate skill acquisition and rehearsal in and outside of sessions. The intervention includes education about the role of unhelpful thoughts, particularly pain catastrophizing, and unhelpful pain coping behaviors; instruction in how to identify and change unhelpful or negative thinking about pain; utilization of helpful coping strategies; relaxation techniques; behavioral activation including setting goals for physical activation, activity pacing and scheduling; and coping with pain flare-ups. Each session includes a brief relaxation exercise. Participants receive digital audio recordings of relaxation exercises to practice at home.
11075405|NCT04248725|No Intervention|Usual care|Participants assigned to the control intervention will continue to pursue standard care (a waitlist). Waitlist control subjects will be offered the opportunity to receive the intervention following completion of the final 6-month follow up outcome assessment.
11075406|NCT04248712|Experimental|Treatment Group|Participants receive Famotidine 40 mg tab twice daily by mouth and Loratadine 10 mg tab once daily by mouth for 12 weeks.
11075407|NCT04248712|Placebo Comparator|Placebo Group|Participants receive Famotidine placebo tablet matching Famotidine orally twice daily for 12 weeks, and Loratadine placebo tablet matching Loratadine orally daily for 12 weeks.
11075408|NCT04248699|Experimental|Lumenato Supplement|tomato oleoresin
11075409|NCT04248686|No Intervention|Control|Referral to standard care - student health center on campus.
11075410|NCT04248686|Active Comparator|Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity.
11075411|NCT04248673|Placebo Comparator|carbohydrate rich bread|
11075412|NCT04248673|Experimental|carbohydrate reduced bread|
11075413|NCT04248660||Uterine artery doppler measurements|"Uterine artery doppler measurements will be made in the same patients at 11-14 weeks and 20-22 weeks of pregnancy.
~Doppler results will be classified according to pregnancy results and primary results will be doppler findings."
11075414|NCT04248647|Experimental|Intervention Group|4-week multimodal preoperative intervention (i.e., Prehabilitation) consisting of an aerobic and strength training program, nutritional counselling and psychological support to help improve physical and psychological health prior to surgical resection of colorectal cancer.
11075415|NCT04248621|Experimental|Intermittent Androgen Deprivation|ADT including luteinizing hormone-releasing hormone (LHRH) agonist and antagonist, antiandrogen, or maximum androgen blockade (MAB) should be withdrawn after 6 months of ADT, if the prostate-specific antigen (PSA) reaches its nadir (< 4 ng/dL) and serum testosterone reaches castration level (< 50 ng/dL).
11075416|NCT04248621|Active Comparator|Continuous Androgen Deprivation|ADT including LHRH agonist and antagonist, antiandrogen, or MAB without any discontinuation during study period.
11075417|NCT04248608|Experimental|erector spinae block|Ultrasound guided erector spinae block with will be done after induction of intravenous anesthesia. After identification of trapezius, rhomboid major, and erector spinae muscles. The needle will be inserted in a cephalad-to-caudal direction until the tip contact transverse process and the needle tip is visualized in the plane deep to the erector spinae muscle. The needle tip position is confirmed by visualizing linear spread of test dose between the muscles after injection. A total dose of 25 mL of 0.25% bupivacaine will be injected.
11075418|NCT04248608|Experimental|serratus anterior block|Ultrasound guided serratus anterior block will be done after induction of intravenous anesthesia. The serratus anterior, latissimus dorsi, and the intercostal muscles will be identified in the fourth and fifth intercostal level, an 18 G Tuohy needle will be advanced in the plane between the serratus anterior muscle and the intercostal muscles. A total dose of bupivacaine 25ml in a concentration of 0.25% will be administered under the serratus muscle after a test dose using an in-plane technique.
11075419|NCT04248608|Active Comparator|intravenous morphine|intravenous morphine will be administrated in a dose of 0.1 mg per kg after induction of general anesthesia
11075420|NCT04248595|Experimental|Azacitidine plus HAG|"Patients of denovo or relapsed AML(age≥60y) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), maintenance therapy with AZA+lenalidomide/AZA will be used every 4-6 weeks until progression or total of 12cycles.
~AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF"
11075421|NCT04248595|Experimental|Azacitidine plus HIA|"Patients of denovo or relapsed AML(age<60y) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.
~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin"
11075422|NCT04248595|Experimental|Azacitidine plus HDA|"Patients of denovo or relapsed AML(age<60y) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines.
~AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Daunorubicin"
11075423|NCT04248582|Experimental|Cryotherapy|Patients will receive neoadjuvant cryotherapy at specified dose frequency interval
11075424|NCT04248569|Experimental|DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab|
11075425|NCT04248556|Experimental|subjects, 18-70 y, healthy|
11075426|NCT04248543|Experimental|quantitative MRI at 4 weeks|
11075427|NCT04248530|Experimental|Renal denervation therapy group|The subject treated by renal denervation by using DENEX system.
11075428|NCT04248517|Experimental|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
11075429|NCT04248517|No Intervention|Treatment as Usual group|participants will undergo their routine treatment.
11075430|NCT04248491|Active Comparator|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
11075431|NCT04248491|Sham Comparator|Emsella Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (<10% power).
11075432|NCT04248478||Fibromiyalgia Patients|Patients diagnosed with fibromyalgia according to 2013 American College of Rheumatology criteria are planned to be included in this arm.
11075433|NCT04248478||Healthy Volunteers|Healthy volunteers are planned to be included in this arm.
11075434|NCT04248465|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
11075435|NCT04248465|Placebo Comparator|Placebo|Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
11075436|NCT04248452|Experimental|Arm A (FOLXFOX)|Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11075437|NCT04248452|Experimental|Arm B (CAPOX)|Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11075438|NCT04248452|Experimental|Arm C (radiation therapy, FOLFOX)|One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
11075439|NCT04248452|Active Comparator|Arm D (FOLFOX)|Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
11075440|NCT04248452|Experimental|Arm E (radiation therapy, CAPOX)|One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
11075441|NCT04248452|Active Comparator|Arm F (CAPOX)|Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
11075442|NCT04248439|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
11075443|NCT04248426|Experimental|ATI-2173|
11075444|NCT04248426|Placebo Comparator|ATI-2173 Placebo|
11075445|NCT04248413|Other|Standard rehabilitation protocol|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution.
11075446|NCT04248413|Experimental|Standard rehabilitation plus Blood Flow Restriction Therapy|Patients with non-operative rotator cuff and biceps tendinopathy assigned to this study arm will undergo the standardized physical rehabilitation protocol at our institution in addition to the BFR therapy. Per recommendations of Owens Recovery Science, the organization responsible for certifying physical therapists in BFR therapy, the therapy will take place concurrently throughout the duration of the rehabilitation.
11075447|NCT04248400|No Intervention|Control|No intervention
11075448|NCT04248400|Active Comparator|Meditation|A 24 weeks meditation training with three 1-hour section per week
11075449|NCT04248400|Active Comparator|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
11075450|NCT04248400|Experimental|Tai Chi|A 24 weeks Tai Chi training with three 1-hour section per week
11075451|NCT04248387|Experimental|Toripalimab group|The subjects in this group receive intravenous drip infusion of Toripalimab at a dose of 3 mg / kg once every 2 weeks for a total of two cycles
11075452|NCT04248374|No Intervention|Fatty Acid Taste|Fatty acid taste without sour adaptation
11075453|NCT04248374|Experimental|Fatty Acid Taste after sour adaptation|Fatty Acid Taste after sour adaptation
11075454|NCT04248361|Experimental|TEM-PCR Diagnosis|The TEM-PCR diagnostic technology will be used to assess for a source pathogen involved in the subject's acute respiratory illness. Results of the TEM-PCR URI Panel will be used by the physician to guide treatment decisions. If indicated, the investigator may also utilize rapid strep testing and rapid influenza testing for diagnosis. In the event a lower respiratory infection is suspected a chest x-ray or complete blood count (CBC) with differential may also be performed.
11075456|NCT04248335|Experimental|In Weight Management Program|Evaluate the effect of liver fat on pharmacology of PPI's, and if applicable midazolam
11076181|NCT04242953|Placebo Comparator|Arm B|
11075458|NCT04248322||Subjects who used a Connected Catheter|Subjects will have Neurogenic Lower Urinary Tract Dysfunction and will have participated in a study with a Connected Catheter. These characteristics will create a 2 (bladder management) x ~5 (etiology) = 10 cell matrix for recruiting for participant interviews.
11075459|NCT04248322||Caregiver of Subject who used a Connected Catheter|Caregiver (n=20) interviews will be done for those who care for individuals with similar bladder managements and etiologies.
11075460|NCT04248309|Experimental|A1|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
11075461|NCT04248309|No Intervention|A2|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A2：without additional treatment
11075462|NCT04248309|No Intervention|B|Group B：serum progesterone ≥7.24ug/L， without additional treatment
11075463|NCT04248283|Experimental|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
11075464|NCT04248270|Other|The relationship between image and AD disease|To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.
11075465|NCT04248257|Experimental|PeACE peer coaching arm|Behavioral, PeACE, PeACE consists of 3 streamlined 30-minute psychosocial telephone counseling sessions delivered by a well-trained peer coach. Coaches are lay YARs from HBOC families demonstrating good knowledge, communication skills, and protocol mastery.
11075466|NCT04248257|Active Comparator|Community peer coaching arm|Behavioral, usual care, Participants in the usual care arm will receive navigation to peer support with a range of community groups who provide these services.
11075467|NCT04248244|Experimental|Early Palliative Care Integration|12 months of PC with concurrent standard treatment for MM, QOL assessments
11075468|NCT04248218|No Intervention|Normal/Control|Control Group/Standard Care
11075469|NCT04248218|Active Comparator|Active Rehabilitation Group/Case|Active Rehabilitation Cohort/Intervention
11075470|NCT04248205|Active Comparator|Intraoperative ketamine infusion|Subjects in this group will receive standard anesthesia during surgery and a dose of ketamine at 0.3 mg/kg IV bolus prior to surgical incision. If the procedure lasts more than 1 hour, an additional bolus dose will be given.
11075471|NCT04248205|No Intervention|Control group|This group will only receive the standard anesthesia during surgery with no ketamine.
11075472|NCT04248192|Experimental|Donor Derived HIV-Specific T-cells (DD HST-NEETs)|Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
11075473|NCT04248179|Active Comparator|Active|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Ropivacaine 5mg/ml corresponding to 3 * 10ml * 5mg/ml Ropivacaine = 150mg Ropivacaine.
11075474|NCT04248179|Placebo Comparator|Placebo|Preoperative Multiple-injection Costotransverse Block (MICB) with three injections of each 10ml of Sodium chloride 9mg/ml corresponding to 3 * 10ml * 9mg/ml Sodium chloride = 189mg Sodium chloride.
11075475|NCT04248153|Experimental|Group A|BR55 will be performed in the early follicular phase first and in the late follicular phase thereafter.
11075476|NCT04248153|Experimental|Group B|BR55 will be performed in the late follicular phase first and in the early follicular phase thereafter.
11075477|NCT04248140|Experimental|WiFi - Sham|first Intervention WiFi, second intervention sham
11075478|NCT04248140|Experimental|Sham - WiFi|first intervention sham, second intervention WiFi
11075479|NCT04248127|Experimental|Honey sweetened yogurt|1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.
11075480|NCT04248127|Placebo Comparator|Sugar sweetened yogurt|Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.
11075481|NCT04248101|Active Comparator|Group 1|88 cases of umbilical granulomas who were treated with double ligation
11075482|NCT04248101|Active Comparator|Group 2|88 cases of umbilical granulomas who were treated with topical silver nitrate
11075483|NCT04248088|No Intervention|Educational Control Group|Education provided for optional use
11075484|NCT04248088|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly for 6 months
11075485|NCT04248075||Control|Patients who do not want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
11075486|NCT04248075||Dexmedetomidine|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
~After the induction of spinal anestheisa, dexmedetomidine is administered for sedation during surgery."
11075487|NCT04248075||Propofol|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
~After the induction of spinal anestheisa, propofol is administered for sedation during surgery."
11075488|NCT04248075||Midazolam|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
~After the induction of spinal anestheisa, midazolam is administered for sedation during surgery."
11075489|NCT04248062||IEM experts|Heterogeneous group of health professionals (physicians, psychologists, nutritionists) working in the field of Inborn Errors of Metabolism (IEM)
11075490|NCT04248062||Paediatric IEM patients|IEM patients between 10 and 18 years
11075491|NCT04248062||Parents of paediatric IEM patients and patient representatives|"Parents of IEM patients (between 0 and 18 years)
~Patient representatives"
11075492|NCT04248049|Experimental|Experimental side|Roots covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
11075493|NCT04248049|Active Comparator|Control side|Roots covered with coronally advanced flap (CAR)
11075494|NCT04248036|Other|Circle Of Security Parenting, COS-P|Pilot study, assessing eligibility, outcome measures and compliance to Group intervention
11116731|NCT03957915|Experimental|INA03|INA03 administration
11075495|NCT04248023|Experimental|Intervention Practices|Intervention practices will work with a practice facilitator to make practice specific changes to address unhealthy alcohol use.
11075496|NCT04248023|No Intervention|Control Practices|Control practices will continue to screening and address unhealthy alcohol use based on their existing practice patterns.
11075497|NCT04248010|Active Comparator|standard tDCS|20 min of standard 2-electrode transcranial direct current stimulation (2 mA) at a previously reported scalp location.
11075498|NCT04248010|Active Comparator|HD-tDCS - anterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to anterior language areas of the brain.
11075499|NCT04248010|Active Comparator|HD-tDCS - posterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to posterior language areas of the brain.
11075500|NCT04248010|Sham Comparator|sham tDCS|sham transcranial direct current stimulation using a brief pulse at the beginning and end of the 20 min intervention.
11075501|NCT04247997|Experimental|Group D|disconnect pulmonary vague nerve branches
11075502|NCT04247997|No Intervention|Group P|preserve the pulmonary vague nerve branches
11075503|NCT04247984|Experimental|mXELIRI+ Bevacizumab|
11075504|NCT04247984|Active Comparator|FOLFIRI + Bevacizumab|
11075505|NCT04247971||Obese, early-onset asthmatics|Obese adults (BMI>or= 30) between the ages of 21-60 with an initial asthma diagnosis at <12 years of age
11075506|NCT04247971||Obese, late-onset asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with an initial asthma diagnosis at >12 years of age
11075507|NCT04247971||Obese non-asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with no asthma diagnosis
11075508|NCT04247958||Robotic-assisted colorectal resection|Subjects with either a suspected or confirmed benign or malignant disease of the colon and rectum who are scheduled to undergo a robotic-assisted resection of the colon or rectum.
11075509|NCT04247945|No Intervention|HSC|
11075510|NCT04247945|Experimental|MSC+HSC|
11075511|NCT04247932||Municipal|Individual participants receiving active labor market intervention from municipal providers
11075512|NCT04247932||Non-profit|Individual participants receiving active labor market intervention from non-profit providers
11075513|NCT04247932||Register|Matched sample from register data, no intervention provided
11075514|NCT04247893|Active Comparator|Exercises with blood flow restriction|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Device: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.
11075515|NCT04247893|Experimental|Exercises with blood flow restriction + photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.Photobiomodulation a mesh composed of multiple diodes containing 50 Infrared LEDs.
11075516|NCT04247893|Placebo Comparator|Blood flow restriction exercises + placebo photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted. Photobiomodulation turned off with a mesh composed of multiple diodes containing 50 Infrared LEDs.
11075517|NCT04247880|Experimental|Mentees|This arm consists of apprentice-level, female-identifying construction workers who will receive active mentorship (the intervention) for two years from trained journey-level mentors.
11075518|NCT04247880|No Intervention|Control Apprentices|This arm consists of apprentice-level, female-identifying construction workers who will not receive mentorship.
11075519|NCT04247867|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO (Theranova) membrane then dialysis for 4 weeks with MCO membrane and increased fiber intake
11075520|NCT04247867|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
11075521|NCT04247854|Active Comparator|Probiotic|
11075522|NCT04247854|Placebo Comparator|No intervention|
11075523|NCT04247841|No Intervention|Phase I: Current Practice|This represents the first phase of the study in which a prospective cohort of patients will complete the survey to define baseline rates of recall of perioperative risk and level of patient satisfaction with risk discussion
11075524|NCT04247841|Experimental|Phase II Visual Aid & Scripted Risk Discussion|This will involve a group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
11116732|NCT03957902|Experimental|Arm 1 (100 mg/24h)|
11075525|NCT04247841|Active Comparator|Phase II Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
11075526|NCT04247828|Experimental|Adaptive and individualized AAC|Adaptive and individualized AAC for subjects with SPI
11075527|NCT04247815|Experimental|ATI-450 plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
11075528|NCT04247815|Placebo Comparator|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
11075529|NCT04247802|Experimental|Backwards Walking (BW) programme|This group will undertake a routine course of one to one out-patient physiotherapy which will include a BW programme. The BW programme will be prescribed by a physiotherapist and the participant will carry it out, along with other prescribed exercises, in their own home. Each participant will initially be prescribed a 5 minute BW programme to be completed once a day. The length of the BW programme and intensity will be progressed or regressed as deemed appropriate by the treating clinician with the aim for patients to achieve at least 10 minutes of BW every day of the week.
11075530|NCT04247802|Active Comparator|Usual Care|This group will undertake a routine course of one to one out-patient physiotherapy over 12 weeks. To allow comparison between the two groups the control group will also have up to four review appointments where their home exercise programme can be progressed or regressed. The physiotherapy treatments will be not be restricted (apart from no BW programme) to allow for a pragmatic approach based on the treating clinician's clinical judgement, however their content will be recorded on treatment logs.
11075531|NCT04247789||Total sample|This group consists of older adults living in a rest home, who are proper for inclusion criteria
11075532|NCT04247776|Experimental|Prehab|General nutrition, relaxation, and exercise instructions. Home-based functional exercises, Fitbit goals, and nutrition supplements.
11075533|NCT04247776|Active Comparator|ERAS|Enhanced Recovery After Surgery standard of care plus Fitbit.
11075534|NCT04247763|Experimental|Arm 1 (Saturated Fat Meal, Oleic Sunflower Oil Meal)|
11075535|NCT04247763|Active Comparator|Arm 2 (Oleic Sunflower Oil Meal, Saturated Fat Meal)|
11075536|NCT04247750|Experimental|Open label trial|Sirolimus 0.5 mg tablets
11075537|NCT04247737|Experimental|gluten free diet|six week gluten free diet
11075538|NCT04247724|Experimental|Active group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of men playing recreational handball"
11075539|NCT04247724|Experimental|Active group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of women playing recreational handball"
11075540|NCT04247724|Experimental|Inactive group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of men continuing their normal lifestyle patterns"
11075541|NCT04247724|Experimental|Inactive group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:
~*1 group of women continuing their normal lifestyle patterns"
11075542|NCT04247711|Experimental|OTCH|OTCH is based on OTNY, a Coordinated Specialty Care program for people with first-episode psychosis. The program is implemented by a multidisciplinary team, who provide coordinated, evidence-based services based on the interests, needs, and preferences of each participant.
11075543|NCT04247711|Placebo Comparator|Usual FEP services|This is generally provided in mental health outpatient clinics which serve a population enrolled in the public health care system.
11075544|NCT04247685|Experimental|12-Lead ECG|The study group patients will have MRI with 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical
11075545|NCT04247685|Active Comparator|3-lead ECG gating system|the control group will have MRI with 3-lead ECG gating which is standard of care.
11075546|NCT04247659|Experimental|Experimental group|In the experimental group, sodium aescinate is added on the basis of conventional treatment(such as anti-platelet and improve circulation).The treatment course of sodium aescinate is 10 days,20mg/day.
11075547|NCT04247659|No Intervention|Control group|The control group will receive conventional treatment(anti-platelet and improve circulation) without sodium aescinate.
11075548|NCT04247646|Active Comparator|Melatonin|Melatonin 5 mg sublingual nightly x 29 nights, starting on post-operative day 0.
11075549|NCT04247646|Placebo Comparator|Placebo|Placebo troche, sublingual nightly x 29 nights, starting on post-operative day 0.
11075550|NCT04247633|Experimental|palbociclib plus endocrine therapy treatement|"Patients with Clinical high risk/Genomic High risk (in BCT score)-high and ER positive/HER2 negative EBC after Curative Surgery
~Palbociclib at a dose of 125mg, orally once daily on Day 1 to Day 21 followed by 7 days off in a 28-day cycle for a total duration of 2 years
~Standard adjuvant endocrine therapy for a duration of at least 5 years from the start of the treatment."
11075551|NCT04247620|Experimental|DiaBetter Together Intervention|Young Adult participants with type 1 diabetes (ages 17-25) who are approaching transfer from pediatric to adult care will be randomized to either the DiaBetter Together Intervention group or the Usual Care group. After randomization to the intervention group, young adults will be assigned a Peer Mentor. Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
11075552|NCT04247620|Other|Peer Mentors|Peer Mentors will deliver the DiaBetter Together intervention and will also be enrolled as study participants to permit assessment of their own outcomes from delivering this peer support intervention to younger people with diabetes. Peer Mentors will be experienced young adults with T1D who have transferred to adult diabetes care.
11075553|NCT04247620|No Intervention|Usual Care|Participants randomized to the comparison condition will receive usual diabetes care only, without additional intervention through the study. They will participate in all study activities related to data collection, but will not receive the Peer Mentor intervention. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
11075554|NCT04247594|Experimental|Cohort A open label|Participants will receive progressively higher doses of voxelotor administration starting from 1500 mg
11076413|NCT04241341|Active Comparator|axillary lymph node dissection (ALND) without ILR|
11075555|NCT04247594|Experimental|Cohort B open label|Participants will receive doses higher than 1500 mg administered without up-titration
11075556|NCT04247568|Experimental|Hypnosis|
11075557|NCT04247568|Placebo Comparator|Control|
11075558|NCT04247542|Experimental|ACX-362E [ibezapolstat]|Active investigational antibacterial agent: ibezapolstat 450 mg po Q12H x 10 days
11075559|NCT04247529|Placebo Comparator|No exposure to conflict|
11075560|NCT04247529|Experimental|Exposure to conflict|
11075561|NCT04247516|No Intervention|Standard Control Group|The standard control group (CG) will not have access to the self-regulatory (SR) intervention program.
11075562|NCT04247516|Experimental|Online-intervention group I (IGI)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:
~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration."
11075563|NCT04247516|Experimental|Online-intervention group II (IGII)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:
~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration; iii) the program includes gamification strategies with the purpose of promoting engagement in participants."
11075564|NCT04247490||Pediatric AIH|Patients diagnosed with hepatitis type 1 and type 2 formulated between the ages of 0 and 18.
11075565|NCT04247477|Experimental|A-B-A-C|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B) - Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C)
11075566|NCT04247477|Experimental|A-C-A-B|Four consecutive steps (45 min per step) are tested in the following order: Peep titration strategy according to Express method (A) - Peep titration strategy according to estimation of lung inhomogeneity (C) - Peep titration strategy according to Express method (A) - Peep titration strategy according to overdistension and collapse estimation (B)
11075567|NCT04247464|No Intervention|Standard diet|The participants will follow an standard diet during the chemotherapy treatment
11075568|NCT04247464|Experimental|Fasting|The participants will follow a short-term fasting period for 44-48 hours, starting 24 hours before chemotherapy treatment
11075569|NCT04247451|Experimental|Interventional group|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.
~Metabolic data: body composition using BIA (Nutrilab Akern) and REE using indirect calorimetry (Cosmed Q NRG) will be analyzed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
11075570|NCT04247438|Other|Biofilm formation|Biofilm formation after 12 and 36 h on PMMA (polymethyl methacrylate) dentures and the number of brushing cycles needed to remove it.
11075571|NCT04247425|Experimental|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
11075572|NCT04247399|Experimental|Simulation-based learning + clinical training|
11075573|NCT04247399|No Intervention|Clinical training|
11075574|NCT04247386|Experimental|PEG-Mizone prep|"The evening before the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 60g Polyethylene Glycol (PEG-4000) with 0.6L Mizone+0.4L water at a rate of 250 ml every 15 min.
~On the day of the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 120g Polyethylene Glycol (PEG-4000) with 1.2L Mizone+0.8L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
11075575|NCT04247386|Active Comparator|PEG-ELS prep|"The evening before the colonoscopy: In the PEG-ELS prep group, all the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min.
~On the day of the colonoscopy: all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
11075576|NCT04247373|Experimental|laparoscopic gastrectomy with pneumoperitoneum|
11075577|NCT04247360|Other|cuff pressure with 20cmH2O|continuous monitoring and maintaining cuff pressure with 20 cmH2O during surgery
11075578|NCT04247360|Other|cuff pressure with 30cmH2O|continuous monitoring and maintaining cuff pressure with 30 cmH2O during surgery
11075579|NCT04247347|Experimental|Self-Management|
11075580|NCT04247347|Active Comparator|Usual Care|
11075581|NCT04247334|No Intervention|Cautious Participants|Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
11075582|NCT04247334|Experimental|Impulsive Participants- Active Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
11075583|NCT04247334|Sham Comparator|Impulsive Participants- Sham Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
11075584|NCT04247321|Experimental|Subjects with acute brain injury|Subjects requiring placement of a Licox Brain Tissue Oxygen device for their clinical care will also have Near-infrared spectroscopy (NIRS) monitoring system placed
11075585|NCT04247308|Experimental|experimental group|"Sensory stimulations (ATVV) will be consisting of Soft lullaby between of 30-40 dB for Auditory, Gentle stroking massage in supine position(upper and lower limb)for Tactile, Visual Stimulations with Black and white card (distance of 8-10 in), gentle rocking (vertical and horizontal direction) for the stimulation of vestibular system and oral stimulation including stocking cheeks, lips, jaw and tongue, rubbing gum.Each stimulation will be given for 3 minutes.
~Movement therapy will include: Guided range of motion: flexion-extension movements of lower limb (bicycle riding pattern). Hand should be placed around knee joint. Care must be taken as PI consist the cartilaginous joints at wrist and ankle. Anti gravity movements in prone (neck and spinal extension), Anti gravity movements in sitting (supported) and Upright positioning for 3min each"
11076894|NCT04237818|Experimental|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|
11075586|NCT04247308|Active Comparator|control group|receives routine care from the nursing team as well as daily maternal care, such as being held in the mother's arms
11075587|NCT04247295|Experimental|Wood cast|Participants will be trialling the woodcast plaster method
11075588|NCT04247295|Placebo Comparator|Traditional Cast|Traditional cast used to be compared to.
11075589|NCT04247282|Experimental|A/arm A|M7824 (Days 1, 15)
11075590|NCT04247282|Experimental|B/arm B|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (Day 1)
11075591|NCT04247282|Experimental|C/arm C|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
11075592|NCT04247269||Enteral formula standard|Children fed an intact protein formula
11075593|NCT04247269||Enteral formula semi-elemental|Children fed a semi-elemental protein formula
11075594|NCT04247256|Experimental|Treatment arm|SCO-101 in combination with FOLFIRI
11075595|NCT04247243|Experimental|Rapid testing|Abbott ID NOW Strep A testing.
11075596|NCT04247243|Active Comparator|Reference testing|Culture-based testing.
11075597|NCT04247230|Experimental|PET500 (0.1%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:
~PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg"
11075598|NCT04247230|Experimental|PET500 (0.25%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:
~PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg"
11075599|NCT04247230|Experimental|PET500 (0.5%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:
~PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg"
11075600|NCT04247230|Experimental|PET500 placebo comparator|Each actuation of the pump spray dispenses 130µl PET500 [vehicle only]. Two pumps will dispense 260µl
11075601|NCT04247230|Active Comparator|STUD100 (9.6%)|Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R
11075602|NCT04247204|Experimental|Platelet-rich plasma (PRP) intrauterine infusion|
11075603|NCT04247191|Experimental|P-Chat|The P-Chat is a brief individually delivered intervention
11075604|NCT04247191|Experimental|PBI|The PBI is a handbook developed by the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
11075605|NCT04247191|Experimental|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above.
11075606|NCT04247191|No Intervention|Control|This group will only complete assessments and will not receive any intervention.
11075607|NCT04247178||Patients undergoing elective orthopaedic surgery|
11075608|NCT04247178||Healthy Volunteers|
11075609|NCT04247165|Experimental|Experimental|"Nivolumab 3 mg/kg will be given on day 1 (± 2 days) of each 28-day treatment cycle until the progression of disease, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given once only on day 1 cycle 1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Pre-medication for chemotherapy (based on standard-of-care and local institutional standards) and chemotherapy will then be administered after a further 30 minutes rest period.
~The recommended dose of nab-paclitaxel is 100 mg/m2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle. Gemcitabine 800 mg/m2 will be administered over 30 to 40 minutes immediately after nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle."
11075610|NCT04247152|Other|Intraoperative Aberrometry vs Preoperative Biometry|Retrospective view of existing chart data.
11075611|NCT04247139|Experimental|Commercial Kefir|Commercially produced kefir
11075612|NCT04247139|Experimental|Traditional Kefir|Traditionally grown kefir
11075613|NCT04247126|Experimental|Single Agent Dose Escalation|Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.
11075614|NCT04247126|Experimental|SY-5609 + Fulvestrant|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.
11075615|NCT04247113|Experimental|PBP-B|Parent-based Prevention following a Bariatric Surgery (PBP-B) is a 6-session parent-based program designed to guide parents who have undergone a weight loss surgery and their partners in developing healthy eating habits in their children
11075616|NCT04247100|Experimental|Active Stimulation (8)|"Participants will receive active auricular microstimulation via TENS unit for 8 weeks.
~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks."
11075617|NCT04247100|Sham Comparator|Sham Stimulation (4), Active (4)|"Participants will receive sham therapy via inactive TENS unit for 4 weeks, followed by active auricular microstimulation via TENS for 4 weeks.
~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks (4 weeks of therapy with inactive TENS, 4 weeks with active TENS)."
11075618|NCT04247087|Experimental|Intervention group|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
11075619|NCT04247087|Placebo Comparator|Control group|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
11075620|NCT04247074|Experimental|QM1114-DP in the LCL + Placebo in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
11075621|NCT04247074|Placebo Comparator|Placebo in the LCL and GL|"A buffered solution; Mode of administration:
~intramuscular injection"
11075622|NCT04247074|Experimental|Placebo in the LCL + QM1114-DP in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
11075623|NCT04247074|Experimental|QM1114-DP in the LCL + GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
11075624|NCT04247061|Experimental|Smoking Cessation intervention|At a dental cleaning visit, participants will watch a brief educational video that provides guidance and advice on smoking cessation. Participants will then interact with a text program for a month to motivate them to use smoking cessation resources. Participants will also be required to make contact with the resources in order to demonstrate feasibility of study flow.
11075625|NCT04247048|Experimental|Control group|Patients with no major LDL cholesterol abnormalities (patients eligible for LDL-apheresis, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / LDL-C) dl in primary prevention)) and a level of Lp (a) <50 mg / dl
11075626|NCT04247048|Experimental|High-dose group|Patients with no major LDL-cholesterol abnormalities (LDL-apheresis eligible patients, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / dl in primary prevention)) and a level of Lp (a)> 80 mg / dl
11075627|NCT04247022|Experimental|female subjects, 18-70 y, healthy|75 female subjects, 18 to 70 years of age, healthy with complaints of vaginal dryness that will receive the heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days.
11075628|NCT04247009|Active Comparator|Meat|Patients with RA served a meal of meat
11075629|NCT04247009|Active Comparator|Fish|Patients with RA served a meal of fish
11075630|NCT04247009|Active Comparator|Vegan|Patients with RA served a vegan meal
11075631|NCT04247009|Active Comparator|Meat controls|Matched controls served a meal of meat
11075632|NCT04246996|Active Comparator|Gentamicin Arm|At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
11075633|NCT04246996|Sham Comparator|Control Arm|If the patient is randomized to no instillation, at the end of the surgery but prior to awakening from anesthesia, the surgeon will clamp the catheter and label the catheter with the clamping time. The purpose of clamping the catheter for subjects receiving usual care will be to ensure patients are masked to study arm assignment if they wake up and notice their catheter. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
11075634|NCT04246983|Experimental|Patients with HIV undergoing point of care ultrasound|
11075635|NCT04246970|No Intervention|Control group|Conventional medical care
11075636|NCT04246970|Experimental|Prehabilitation group|Conventional medical care and 8 weeks of a Prehabilitation supervised program
11075637|NCT04246970|Experimental|Prehabilitation and posttransplant training group|Conventional medical care, 8 weeks of a Prehabilitation supervised program and a posttransplant training program.
11075638|NCT04246931||Pulmonologists|Interviews with pulmonologists
11075639|NCT04246931||General practitioners|Interviews with general practitioners
11075640|NCT04246931||Patients|Survey with COPD patients
11075641|NCT04246918|Placebo Comparator|Standard Treatment Group|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
11075642|NCT04246918|Active Comparator|Intervention Arm|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
11075643|NCT04246905|Active Comparator|sulforaphane|sulforaphane treatment arm
11075644|NCT04246905|Placebo Comparator|placebo|placebo arm
11075645|NCT04246892||group before alarm withdrawal|
11075646|NCT04246892||groupe after alarm withdrawal|
11075647|NCT04246879|Experimental|MRI|
11075648|NCT04246866|Experimental|Dose 1|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the lowest dose of GEM103
11075649|NCT04246866|Experimental|Dose 2|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the medium dose of GEM103
11075650|NCT04246866|Experimental|Dose 3|A single dose of GEM103 will be administered via intravitreal injection. This arm will be a higher dose of GEM103
11075651|NCT04246866|Experimental|Dose 4|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the highest (extension) dose of GEM103
11075652|NCT04246853|Active Comparator|Active tDCS of the resting state motor network|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
11075653|NCT04246853|Sham Comparator|Sham tDCS of the resting state motor network|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
11075654|NCT04246840||Study group|15 adult patients who underwent allogenic hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficieny 15 to 45 years ago
11075655|NCT04246840||Control group|15 age-matched healthy individuals
11075656|NCT04246827|Experimental|Enhanced Lifestyle Weight Management Condition|The Enhanced Lifestyle Weight Management condition participants participated in a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors was integrated into a lifestyle behavioral weight loss intervention.
11075657|NCT04246827|No Intervention|Standard Care Control|Participants received standard care of rheumatoid arthritis.
11075658|NCT04246814|Placebo Comparator|CC + dressing|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
11075707|NCT04246515|Active Comparator|Classic rehabilitation|This group will undergo the classic rehabilitation program.
11075659|NCT04246814|Active Comparator|LG1 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.
11075660|NCT04246814|Active Comparator|LG2 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.
11075661|NCT04246814|Active Comparator|LG3 + dressing|The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.
11075662|NCT04246801|Experimental|Clobetasol propionate|"Clobetasol propionate (Clobetasol propionate ophthalmic nanoemulsion 0.05%)
~First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage of one drop four (4) times a day during 14 days."
11075663|NCT04246801|Placebo Comparator|Vehicle|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage of one drop four (4) times a day during 14 days.
11075664|NCT04246788|Experimental|Cohort 1 : experimental group|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
11075665|NCT04246788|Active Comparator|Cohort 2 : controle group|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
11075666|NCT04246775|Other|Treatment|Peristeen given
11075667|NCT04246762|Experimental|Olokizumab 128 mg +Cocktail drugs|"All subjects will receive the following treatment:
~Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) administered on Day 1, single subcutaneous injection of OKZ 128 mg administered on Day 8 and second dose of Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) administered on Day 22"
11075668|NCT04246749|Experimental|Part A: [14C]-CRN00808 Oral Solution|Single oral dose of CRN00808 containing [14C]-CRN00808
11075669|NCT04246749|Experimental|Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer|Single oral dose of CRN00808 followed by [14C]-CRN00808 IV microtracer injection
11075670|NCT04246736|Experimental|Intervention group|"The intervention group received a Recovery programme including three group sessions."
11075671|NCT04246736|No Intervention|Control group|The control group was on a waiting list to receive the intervention after the last follow-up measure (six months after the intervention group's last group session).
11075672|NCT04246723|Experimental|Cohort A (Narlaprevir + Ritonavir + Sofosbuvir for 12 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg Once a day (QD)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 12 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.
~Sofosbuvir can be taken with or without meals."
11075673|NCT04246723|Experimental|Cohort B (Narlaprevir + Ritonavir + Sofosbuvir for 8 weeks)|"All of enrolled patients receive equal study therapy with Narlaprevir 200 mg QD (once daily)/Ritonavir 100 mg QD/Sofosbuvir 400 mg QD orally for 8 weeks. Narlaprevir should be taken with ritonavir and food and should be taken at approximately the same morning time each day.
~Sofosbuvir can be taken with or without meals."
11075674|NCT04246697|Active Comparator|Standard of Care A|"Randomized controlled prospective trial to compare two standards of care for head and neck surgery pain management. Arm A, will include:
~Scheduled Tylenol 1000 mg IV one time dose intra-operatively, then 650 mg via PEG tube or PO Q4H to a max dose of 4gm/24 hrs
~Opioids prn based on Numeric Pain Scale (0-10, with 0 indicating no pain and 10 indicating worst pain ever):
~0-3: no prn meds, reassurance, listen to music, watch TV.
~4-7: Oxycodone 5 mg q4h prn via PEG tube or PO with a maximum of 30 mg/24 hours.
~8-10 Morphine 2 mg IV q2h prn breakthrough pain."
11075675|NCT04246697|Experimental|Standard of Care B|"Arm B, will include:
~Arm A description with addition..
~Scheduled Ketorolac starting post-op day #1, 15 mg q6h (max 120 mg/day), for a total of 5 days
~Scheduled Gabapentin starting 7 days preoperatively to continue postoperatively
~Regional block per anesthesia protocol - Initial block: 0.5% bupivacaine, 20 ml Continuous infusion: 0.125% bupivacaine at 6 ml/hr with a 5 ml bolus available every 30 mins"
11075676|NCT04246684|Active Comparator|Control arm|In the control arm patients receive 5x5 Gy followed by 9 cycles of consolidation chemotherapy mFOLFOX6 or alternatively 6 cycles of CAPOX, followed by re-staging at week 22-24 as established as new preferred neoadjuvant regimen by the RAPIDO trial.
11075677|NCT04246684|Experimental|Experimental arm|The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
11075678|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^7 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^7 Inf.U.
11075679|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^8 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^8 Inf.U.
11075680|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^9 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^9 Inf.U.
11075681|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 1 (TVH 1x10^10 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10^10 Inf.U.
11075682|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (Trastuzumab + TVH)|TAEK-VAC-HerBy will be administered to patients who are on stable dose of Trastuzumab. TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total.
11075683|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (T-DM1 + TVH)|TAEK-VAC-HerBy will be administered to patients who are on stable dose of T-DM1. TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total.
11075684|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (Trastuzumab + Pertuzumab + TVH)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of Trastuzumab and Pertuzumab. TAEK-VAC-HerBy will be administered every three weeks with three administrations in total.
11075708|NCT04246502|Experimental|A|
11075709|NCT04246502|Active Comparator|B|
11075685|NCT04246671|Experimental|TAEK-VAC-HerBy Stage 2 - (Her2 + TVH + PD1/PD-L1)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total in combination with a HER2 antibody and a PD-1/PD-L1 Antibody.
11075686|NCT04246658|Experimental|Treatment group|gait training on platform swing walkway for 30 minute.
11075687|NCT04246658|Experimental|control group|conventional physical therapy program
11075688|NCT04246645|No Intervention|CONTROL GROUP|received the selective physiotherapy exercises
11075689|NCT04246645|Experimental|STUDY GROUP|received the same selective physiotherapy exercises program in addition to core stability exercises three times/week for 60 min for 12 weeks
11075690|NCT04246619|Experimental|Pregabalin Krka Arm|"ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN.
~Investigator can choose on V2:
~Total Pregabalin Krka daily dose: 25 mg/day
~Total Pregabalin Krka daily dose: 50 mg/day
~Total Pregabalin Krka daily dose: 75 mg/day
~Total Pregabalin Krka daily dose: 150 mg/day
~Total Pregabalin Krka daily dose: 300 mg/day (from Phone call 1 further on)
~V3: daily dose should be achieved: MINIMUM dose 150 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day
~V4: Investigator can choose: total Pregabalin Krka daily dose 150 mg/day or 300 mg/day or 600 mg/day"
11075691|NCT04246619|Experimental|Dulsevia® Arm|"• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:
~Investigator can choose on V2:
~Total Dulsevia® daily dose: 30 mg/day
~Total Dulsevia® daily dose: 60 mg/day
~V3: daily dose should be achieved: MINIMUM dose 60 mg/day Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day.
~V4: Investigator can choose total Dulsevia® daily dose 60 mg/day or 90 mg/day or 120 mg/day."
11075692|NCT04246606||ER+/HER2- infiltrating early breast cancer|Patients with ER+/HER2- infiltrating early breast cancer for which EndoPredict molecular signature was performed.
11075693|NCT04246593|Experimental|Intervention - Market|"Partner sites that are randomized to the Intervention - Market will plan and start (or expand) a Mobile Market and run the Market weekly for at least 10 months (non necessarily nonconsecutive). The Mobile Market will follow the Veggie Van Model which includes a share model, price reductions (incentives), and an educational component."
11075694|NCT04246593|No Intervention|Control - Planning|At Control - Planning (comparison) sites, engagement will focus on involving community members in food access program planning and research. It is anticipated that each organization will create one or more community advisory committees to oversee their food access work. At comparison sites, engagement efforts will be more generally centered on food access and understanding what types of programs would be most acceptable. Examples of community engagement activities include community forums and listening sessions, informational tables at community events, and establishment of text, e-mail or social media sites for ongoing communication and feedback around food access issues. As part of this community engagement work, partners will collect contact information from community members that will assist in the data collection process.
11075695|NCT04246580||Indocyanine green|Women with endometrial and cervical cancer undergoing indocyanine green-guided systematic pelvic lymphadenectomy by laparoscopy or robotic surgery
11075696|NCT04246580||Control|Women with endometrial and cervical cancer undergoing systematic pelvic lymphadenectomy by laparoscopy or robotic surgery without the use of indocyanine green tracer injection.
11075697|NCT04246567|Active Comparator|Total intravenous anesthesia technique for group 1 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 6-10 mg / kg / h propofol and 0.0,4mcg / kg remifentanyl infusion / min. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.
~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.
~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
11075698|NCT04246567|Active Comparator|Inhalation anesthesia technique for group 2 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 40% Oxygen 60% N2O2 and Sevoflurane at a concentration of 1.5-3.5% with 2 L / minTGA to provide a value of BIS between 40-60. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.
~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.
~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
11075699|NCT04246554|Experimental|Control|Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
11075700|NCT04246554|Experimental|Ketorolac|Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control
11075701|NCT04246541|Experimental|Control|Patients will receive standard of care Percocet for post-operative pain control following meniscus debridement surgery
11075702|NCT04246541|Experimental|Ketorolac|Patients will receive IV ketorolac during surgery. They will then receive 3 days of oral ketorolac every 6 hours for pain control following surgery.
11075703|NCT04246528|Experimental|Intervention group|Access to the online SPIN-SELF program
11075704|NCT04246528|No Intervention|Control group|Usual care, no access to the online SPIN-SELF program
11075705|NCT04246515|Experimental|Blood Flow Restriction Training|As from week 2 in the rehabilitation proces, this experimental group will receive exercises in combination with blood flow restriction. While occluding the vascular flow of the limb (startpoint = above the injury site), participants will perform 3 exercises: wall squat, leg press and bridge (3 sets of 30 repetitions). These blood flow restricted exercises are always on top of the classic rehabilitation.
11075706|NCT04246515|Sham Comparator|Sham Blood Flow Restriction Training|The same description as the experimental arm is applicable here. However, The Blood Flow restriction material will be attached to the injured limb without occluding the vascular blood flow.
11075717|NCT04246450|No Intervention|LVEF between 35%-50%, no noninvasive risk factors (NIRFs)|Follow up, no further intervention
11075718|NCT04246450|No Intervention|LVEF between 35%-50%, NIRFs present, noninducible|Follow up, no further intervention
11075719|NCT04246450|Active Comparator|LVEF between 35%-50%, NIRFs present, inducible|All patients in this group will receive an ICD
11075720|NCT04246450|Sham Comparator|LVEF <35%, no NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
11075721|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
11075722|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, inducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
11075723|NCT04246437|Experimental|[18F]F-DOPA|All patients will receive [18F]F-DOPA for PET imaging to measure pre-synaptic dopamine in the brain.
11075724|NCT04246424|Active Comparator|Fitbit + Coaching|Fitbit + coaching will receive both the fitbit and coaching interventions.
11075725|NCT04246424|Active Comparator|Coaching|Coaching group will receive weekly remote coaching lessons by phone email or text for 1-6 weeks. They will also receive a weekly email lesson for 1-6 weeks on things such as basics of sleep, enhancing sleep environment and managing stress.
11075726|NCT04246424|Active Comparator|Fitbit|Fitbit group will receive a Fitbit and are asked to monitor their sleep over the smartphone application for 1-6 weeks.
11075727|NCT04246424|No Intervention|Self-management|Self-management participants will be given some information of improving sleep but asked to keep their same schedule. Once their participation concludes, they will be given the opportunity to receive a fitbit and coaching if they so choose.
11075728|NCT04246411|Active Comparator|Ultrasound|Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field
11075729|NCT04246411|Placebo Comparator|Auscultation|Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field
11075730|NCT04246398|Experimental|Fecal microbiota transplant (FMT)|"10 capsules per dose for 6 consecutive weeks, twice a week, for a total of 120 capsules.
~Each inoculum will be prepared from the feces of 1 donor and a dose of 10 capsules contains sieved, concentrated material derived from a mean of 10 grams of fecal matter. Donors are healthy, nonpregnant adults aged 18 to 50 years, taking no medications, and with a normal body mass index (18.5-25 [calculated as weight in kilograms divided by height in meters squared])."
11075731|NCT04246398|Placebo Comparator|placebo|Placebo capsules will consist of a combination of saline/glycerol (same vehicle as FMT capsules). The inner capsules is dark (green colored), so the general appearance of the capsules is the same to the people who do not prepare them.
11075732|NCT04246385|Experimental|Allocated to intervention|Participants will participate in a one on one session to complete their COPM and set their goal for the group. Participants will participate in 6 group sessions focusing on the CO-OP approach.
11075733|NCT04246385|No Intervention|Allocated to control|"The control group will receive usual care occupational therapy including a mix of individual sessions and occupational therapy groups that do not include the CO-OP group."
11075734|NCT04246372|Experimental|On Treatment|Tofacitinib 5mg oral tablets twice daily for 16 weeks
11075735|NCT04246359|Experimental|RP induction and maintenance|"1. Induction phase:
~Rituximab: 375mg / m2, ivd, d1;
~Pegylated interferon α-2b: 135 μg (500,000 U), H, d1, 8 Repeated every 21 days, Maximum 6 cycles 2. Maintenance phase:
~1) Rituximab: 375mg / m2, ivd, d1; 2) Pegylated interferon α-2b: 135 μg (500,000 U), H, d1,30 Repeated every 2 months, Maximum 12 cycles"
11075736|NCT04246346|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
11075737|NCT04246333|No Intervention|Gastric Feeds|Patients in this arm will receive feeds via the standard route which is gastric feeds.
11075738|NCT04246333|Experimental|Duodenal Feeds|Patients in this arm will receive feeds via the experimental route which is duodenal feeds.
11075739|NCT04246320|Experimental|Intervention|Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
11075740|NCT04246294||Sleep apnea patients|"This group of patients will have been monitored over night with cardiorespiratory monitoring (CRM). CRM enables the physician to establish an Apnea-Hypopnea Index (AHI) which will be used for diagnosis. An AHI > 15 is considered moderate-to-severe sleep apnea, and this is the focus group of patients in the current project.
~These patients will be followed for 12 months during continuous positive airway pressure (CPAP) treatment. Adherence to the CPAP treatment will be closely monitored."
11075741|NCT04246281|Active Comparator|Group 1: Peripheral Nerve Stimulation (PNS)|Subjects in Group 1 will have leads placed in their lower back. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
11075742|NCT04246281|Active Comparator|Group 2: Standard Interventional Management (Standard of Care)|Subjects in Group 2 will receive the standard of care. Group 2 subjects may be able to crossover to receive PNS after 12 months from start of treatment (Visit 16).
11075743|NCT04246268|Experimental|Treatment Group|"Device: INVOcell Intravaginal Culture System
~Intervention: During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5-days vaginal incubation."
11075744|NCT04246255|Placebo Comparator|Group C|Serum Physiologic %0,9 ampules ; 0,3ml {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
11075858|NCT04245319|Other|NbUVB|Group A: patients will receive three NB-UVB sessions per week for 48 sessions.
11076895|NCT04237805|Experimental|SAF-189s|
11075745|NCT04246255|Experimental|Group L|xylocaine %10 pump spray ; 30mg lidocaine {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
11075746|NCT04246229|Experimental|transcutaneous bilirubinometry|in this arm the bilirubin level to monitor the effect of phototherapy will be measured through transcutaneous mbiirubinometry
11075747|NCT04246229|Active Comparator|serum bilirubin|In this arm the bilirubin level to monitor the effect of phototherapy wil be measured through measurements of serum bilirubin obtained through blood draws
11075748|NCT04246216|Experimental|Percutaneous Electrical Nerve Stimulation|The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
11075749|NCT04246216|Active Comparator|Surgery|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
11075750|NCT04246203||Group A|Patients are allocated to group A according to preoperative presence of detectable ctDNA.
11075751|NCT04246203||Group B|Patients are allocated to group B according to preoperative absence of detectable ctDNA.
11075752|NCT04246190|Experimental|Group 1|"Period 1: CKD-501 and D759
~Period 2: CKD-396"
11075753|NCT04246190|Experimental|Group 2|"Period 1: CKD-396
~Period 2: CKD-501 and D759"
11075754|NCT04246177|Experimental|Lenvatinib plus Pembrolizumab plus TACE|Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
11075755|NCT04246177|Active Comparator|Oral Placebo plus IV Placebo plus TACE|Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
11075756|NCT04246164|Active Comparator|HD-tDCS combined with CT|HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
11075757|NCT04246164|Sham Comparator|sham HD-tDCS combined with CT|sham HD-tDCS combined with CT, administered to participants with amnestic MCI (aMCI) in blocks of 5 daily treatments for a total of 15 sessions. There will be one treatment block/month for a total of 3 months
11075758|NCT04246151|Experimental|Vancomycin & probiotic placebo|Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
11075759|NCT04246151|Experimental|Probiotic & vancomycin placebo|Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
11075760|NCT04246151|Placebo Comparator|Probiotic placebo & vancomycin placebo|Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
11075761|NCT04246138|Active Comparator|kinematically alignment|
11075762|NCT04246138|Active Comparator|mechanical alignment|
11075763|NCT04246125||Therapeutic interventional radiology|Patients undergoing an interventional radiology procedure, at risk for developing radiation-induced skin lesions, including acts of therapeutic interventional neuroradiology (angioplasties, embolization of aneurysms, embolization of arteriovenous malformations , etc…), embolizations and ablations of thoracic tumors, therapeutic cardiac acts (transluminal angioplasties and chronic coronary occlusions) and abdominal embolizations.
11075764|NCT04246112|Experimental|Treatment group|Participants are diagnosed with tic disorder and/or Tourette syndrome. They will undergo treatment to improve overall handwriting skills.
11075765|NCT04246099||Group opioid free anesthesia|Patient benefit of the opioid free anesthesia protocol
11075766|NCT04246099||Group opioid based anesthesia|Patient don't benefit of the opioid free anesthesia protocol
11075767|NCT04246086|Experimental|Mosunetuzumab + Lenalidomide|Participants will receive treatment with mosunetuzumab for 8-12 cycles, plus lenalidomide for up to 12 total cycles (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
11075768|NCT04246086|Experimental|Glofitamab + Lenalidomide|Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab for 8-12 cycles, plus lanalidomide for up to 12 total cycles (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
11075769|NCT04246086|Experimental|Glofitamab + Obinutuzumab + Lenalidomide|Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab and obinutuzumab for 8-12 cycles, plus lenalidomide for up to 12 cycles (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
11075770|NCT04246060||Cohort 1|Patients on extended release cysteamine treatment at study enrollment
11075771|NCT04246060||Cohort 2|Patients switching from immediate release cysteamine to extended release cysteamine during the study
11075772|NCT04246060||Cohort 3|Patients remaining on immediate release cysteamine treatment
11075773|NCT04246047|Experimental|Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)|
11075774|NCT04246047|Active Comparator|Daratumumab and Bortezomib plus Dexamethasone (Arm B)|
11075775|NCT04246034|Experimental|Cases|As described by Saaristo et al. in 2012, the surgical technique starts with wide axillary scar removal, followed by elevation of contralateral dual flap which includes DIEP/MS-TRAM with attached groin lymph nodes and fat, then the anastomosis is preferably done to internal mammary vessels.
11075860|NCT04245306|Experimental|Children with Autism Spectrum Disorders|A group of 25 children with autism spectrum disorders (ASD)
11075776|NCT04246021|Experimental|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.
~Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion
~If the needed Ferric carboxymaltose dose is > 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
11075777|NCT04246008|Experimental|Neuromuscular training group|This group will receive a 60-min neuromuscular training sessions twice a week, for 10 weeks until the completion of twenty sessions
11075778|NCT04246008|Active Comparator|Conventional training group|This group will receive a 60-min convencional cardiac rehabiliation session twice a week, for 10 weeks until the completion of twenty sessions
11075779|NCT04245982||group (C)|healthy controls group
11075780|NCT04245982||group (P)|periodontitis group
11075781|NCT04245982||group (DP)|diabetes and periodontitis group
11075782|NCT04245969|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the shoulder
11075783|NCT04245969|Experimental|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the affected shoulder
11075784|NCT04245969|Experimental|No intervention group|To evaluate at the same time than the others groups but without being treated with 448 kilohertz Capacitive Resistive Monopolar Radiofrequency.
11075785|NCT04245956|Experimental|Transcatheter Mitral Valve Repair arm|Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
11075786|NCT04245943|Experimental|Exercise|18 weeks supervised strength and aerobic exercise training
11075787|NCT04245930|Active Comparator|Bovine Pericardial Patch|Immediate implant breast reconstruction using bovine pericardial patch. n=88
11075788|NCT04245930|Experimental|TiLOOP® Bra Mesh|Immediate implant breast reconstruction using TiLOOP® Bra Mesh. n=88
11075789|NCT04245917||MNGIE Patients|Patients with mitochondrial neurogastrointestinal encephalomyopathy
11075790|NCT04245904||proffesional basketball player|
11075791|NCT04245904||sedentary control|
11075792|NCT04245891||Control group|boli of ephedrine phenylephrine (45μg/mL-3mg/mL) if the variation of MAP < 20% of baseline (MAP before spinal anaesthesia).
11075793|NCT04245891||Protocol group|continuous infusion of norepinepineprhine at 20 μg/mL, started at 0.05 μg/kg/min. The dosage of norepinephrine was then adjusted to maintain a variation in MAP < 20% of baseline. In case of failure, the use of a control group boli injection was possible.
11075794|NCT04245878||intensive care unit inpatient|Inpatient intubated resuscitation patient with a scheduled extubation
11075795|NCT04245865|Experimental|Arm A, standard treatment + tocotrienol|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + tocotrienol OR capecitabine + bevacizumab + tocotrienol
11075796|NCT04245865|Placebo Comparator|Arm B, standard treatment + placebo|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + placebo OR capecitabine + bevacizumab + placebo
11075797|NCT04245852|Experimental|Experimental group|Experimental group will receive standard physical therapy care in addition to being provided a strength education video.
11075798|NCT04245852|Active Comparator|Control Group|The control group will receive standard physical therapy care at the University of Illinois at Chicago Faculty Practice.
11075799|NCT04245839|Experimental|Administration of JCAR017|"Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents.
~JCAR017 will be infused on Day 1 at a dose of 100 × 10^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells."
11075800|NCT04245826||Low-calorie Sweetened Beverages (LCSBs)|Beverages exclusively using zero-energy (e.g., acesulfame-potassium, aspartame, cyclamate, saccharin, sucralose, advantame, neotame), and /or reduced-energy food additives (e.g., stevia, monk fruit).
11075801|NCT04245813|Experimental|Intervention|"Consists of 3 interdisciplinary educational sessions and Face-to-face with a fortnightly telephone follow-up and text messages. Each session will be directed by medical staff (cardiologist and / or physiatrist) and supported by other health professionals (physical therapist, occupational therapist, nutritionist and psychologist). The educational sessions, include the topics knowledge of the disease, recognition of alarm signs, pharmacological treatment, healthy lifestyle habits, mental health and regular aerobic exercise; The entire educational component will be based on the Colombian clinical practice guide for the prevention, diagnosis, treatment and rehabilitation of heart failure."
11075802|NCT04245813|No Intervention|Control|Once the patient ends phase II of the cardiac rehabilitation program, he/she will receive the usual care, which consists of a 5-minute educational intervention by a physiatrist at the end of the functional test, where recommendations are given on healthy lifestyle habits, adherence to pharmacological treatment and regular aerobic exercise. This educational intervention will be performed after each of the functional tests (at the end of phase II of the program and during the follow-up of patients at months 1, 3, 6 and 12 during Phase III of the program) performing 5 educational interventions in total .
11075803|NCT04245800||Observational|All participants will be part of the prospective observational cohort. If participants develop flu-like symptoms, they will be prompted to complete the flu@home self-test kit. Analysis will be conducted for various subgroups (e.g. age, vaccination status)
11075804|NCT04245787|Experimental|Self assembling peptide with fluoride|
11075805|NCT04245787|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|
11075806|NCT04245774|Experimental|Group L (Hyperbaric Levobupivacaine)|"7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
~In order to obtain hyperbaric levobupivacaine, 1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water."
11075807|NCT04245774|Active Comparator|Group B (Hyperbaric Bupivacaine)|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (Marcaine® Spinal Heavy, 0.5%, 4 mL ampoule, AstraZeneca/England, Eczacıbaşı/Turkey, dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
11075808|NCT04245761|Experimental|Sonidor®|Application: following the summary of product characteristics (l tablet per day) At the 7-day phone call the Investigator can increase the dosage to 2 tablets per day only in non-responding subjects.
11075809|NCT04245748|Active Comparator|Escitalopram|Adaptively randomized, double-blind treatment with escitalopram for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with escitalopram or citalopram for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
11075810|NCT04245748|Active Comparator|Duloxetine|Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
11075811|NCT04245722|Experimental|FT596 Monotherapy, Lymphoma|FT596 monotherapy in adult subjects with r/r B-cell Lymphoma
11075812|NCT04245722|Experimental|FT596 in Combination with Rituximab, Lymphoma|FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma
11075813|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, Lymphoma|FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma
11075814|NCT04245722|Experimental|FT596 Monotherapy, CLL|FT596 monotherapy in adult subjects with r/r CLL
11075815|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, CLL|FT596 in combination with Obinutuzumab in adult subjects with r/r CLL
11075816|NCT04245709|Experimental|Open label Arm|This is an open label pilot trial in which 25 people with ALS will take clenbuterol orally at 40-80 micrograms twice daily for 24 weeks.
11075817|NCT04245696|Experimental|Single Group|Single Arm: All subjects will undergo treatment for skin laxity in the submentum with a Dermal and SubQ handpiece
11075818|NCT04245683||Operative Group|Patients who select operative treatment and follow up after successful neoadjuvant treatment.
11075819|NCT04245683||Non-operative Group|Patients who select non-operative follow up after successful neoadjuvant treatment
11075820|NCT04245670|Experimental|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
11075821|NCT04245657||Breast Cancer Survivors|Female breast cancer survivors who underwent unilateral breast cancer surgery ( total or conservative) and completed their adjuvant therapies such as chemotherapy and radiotherapy prior to participation in this study.
11075822|NCT04245631||RAA assay for 2019-nCoV|a simple, fast and portable recombinase aided amplification (RAA) assay for 2019-nCoV
11075823|NCT04245605||Early angiography|Patients admitted to hospital with acute heart failure undergoing coronary angiography within 14 days of hospital admission
11075824|NCT04245605||Control|Patients admitted to hospital with acute heart failure not undergoing coronary angiography within 14 days
11075825|NCT04245592|Experimental|Extra Virgin Olive Oil|Women with fibromyalgia will consume Extra Virgin Olive Oil.
11075826|NCT04245592|Experimental|Refined Olive Oil|Women with fibromyalgia will consume Refined Olive Oil.
11075827|NCT04245579|Experimental|Experimental Group|"The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures.
~In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.)."
11075828|NCT04245579|No Intervention|Control Group|The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
11075829|NCT04245566|Experimental|Prostatic Artery Embolization (PAE)|PAE will be performed as an inpatient or outpatient procedure by interventional radiologists who are familiar with the procedure and according to established techniques. A unilateral femoral sheath is placed in the right common femoral artery under local anaesthesia. The prostatic arterial supply is identified by selective internal iliac arteriography. Prostatic arteries are selectively catheterised and embolised by use of 250-600 μm microspheres . PAE is performed bilaterally if possible and considered successful in the absence of the normal blush of the prostate and stasis of flow in the prostate arteries on angiography after embolisation.
11075830|NCT04245566|Placebo Comparator|Pharmocotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations. Thus, patients with a prostate size smaller than 40mL will be treated with 0.4 mg tamsulosin once daily, while patients with larger prostates will be treated with 0.4 mg tamsulosin plus 0.5 mg dutasteride once daily during the complete study follow-up.
11075831|NCT04245553|Experimental|All Participants|
11075832|NCT04245540|Experimental|Active|1,050 mg per day of encapsulated Pau d' Arco taken orally for 2 months.
11075833|NCT04245527|Experimental|Study Arm|20 minutes Joovv Solo every day for 8 weeks.
11075834|NCT04245514|Experimental|Durvalumab with 3 RT cohorts|Patients will be allocated in a 1:1:1 ratio to the three radiotherapy regimens (Arm A: 20 x 2 Gy weekdaily, Arm B: 5 x 5 Gy weekdaily, and Arm C: 3 x 8 Gy q2d) using the minimization method with a random component (80% allocation probability) to reduce predictability of allocation according to the following stratification factor: T classification (T1-2 vs T3-4).
11075835|NCT04245501|Experimental|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized 16-session intervention aimed at reducing interpretation bias. In this study, CBM-I is personalized to youth anxiety symptoms. During CBM-I sessions, youth indicate whether word-sentence pairs are related, and are provided with feedback aimed to reduce bias.
11075859|NCT04245319|Experimental|Combined nbUVB and Acitretin|Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3-0.5 mg/kg/day daily.
11075836|NCT04245501|Placebo Comparator|Interpretation Control Condition (ICC)|"Computerized 16-session intervention that is not believed to significantly modify bias. In this study, youth see stimuli personalized to their anxiety symptoms. During ICC sessions, youth see word-sentence pairs and are required to indicate whether word and sentence are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
11075837|NCT04245488|Other|taste testing|Participants will first taste 5 sour solution containing acetic acid for sour compounds, sucrose esters, and xanthan gum to help them stay dissolved). Then rate them for their taste intensities. Next, participants will taste 5 butyric acid solutions, 5 hexenoic acid solutions, 5 caprylic acid solutions, 5 lauric acid solutions, 5 palmitic acid solutions, 5 oleic acid solutions, and 5 linoleic acid solutions (all will also contain the sucrose esters and xanthan gums.) and rate them for their taste intensities. This should take no longer than 1 hour. Participants will spit all samples into a cup after tasting them. They will not swallow any samples.
11075838|NCT04245475|No Intervention|Control Group|No treatment
11075839|NCT04245475|Active Comparator|Passive Virtual Reality Group|Passive, less immersive virtual reality
11075840|NCT04245475|Experimental|Interactive Virtual Reality Group|Interactive, more immersive virtual reality
11075841|NCT04245462||Participants|Older aged (>60 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco, Mexico).
11075842|NCT04245449|Experimental|e learning+therapy (TEAACH)|TEAACH-Training to Empower Activity-dependent plasticity-based Arm-use habits in the Community and at Home
11075843|NCT04245436|Active Comparator|Duloxetine|Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.
11075844|NCT04245436|Active Comparator|Escitalopram|Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
11075845|NCT04245423|Active Comparator|Augmented Usual Care (AUC)|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. Almost all practices have hired mental health clinicians, equivalent to the care managers in the investigators' collaborative care model, to treat mild and moderate depression and anxiety. These clinicians typically are licensed clinical social workers; a few are nurses or psychologists. No care managers have received systematic training in treating patients with OUD. The clinicians will retain their role and continue to treat and monitor patients with mental health conditions in these practices. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD. Patients are informed that the primary care practice provides both OUD and mental health treatment and are referred back to their provider for referral or to schedule care. A list of available community resources are available to the patient.
11075846|NCT04245423|Experimental|Collaborative Care (CC)|"CC condition includes the following elements:
~Personnel trained to assist with scheduling, reminders and referrals;
~PCP trained and waivered to provide evidence-based pharmacotherapy for OUD;
~Addictions psychiatrist with collaborative care expertise to provide treatment consultation and supervision in both OUD and mental health issues;
~A care manager trained in evidence-based interventions for individuals with OUD and psychiatric disorders, who provides care in the primary care practice as part of the collaborative care team;
~Measurement-guided care and treat-to-target practices, using validated measures of substance use, depression, anxiety as well as measures of adherence and side effects;
~Electronic and in-person systematic communication regarding patient care among team members, facilitated by the electronic health record; and
~Shared patient-provider decision making."
11075847|NCT04245423|Experimental|Collaborative Care + Certified Recovery Specialist (CC+)|In addition to the collaborative care model described above, patients in the CC+ condition will have access to a Certified Recovery Specialist (CRS) to assist with treatment engagement and retention. A CRS is a person in the community who is in recovery and may share similar experiences and barriers that participants have faced. They will work with participants as a peer to help them coordinate information and needs with their providers. The CRS will take participants to their PCP appointments and any other appointments that they may have to help them engage and stay in care to remain healthy. They will also provide education and help participants work on their recovery goals. They will identify and support linkages to community resources and help participants identify barriers to full participation in their recovery and develop strategies to overcome those barriers.
11075848|NCT04245410||Patients surgically treated of pancreatic metastases from RCC|Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.
11075849|NCT04245397|Experimental|Oral Dose of S-682|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
11075850|NCT04245384|Experimental|Internet-based treatment|Internet-based dietetic treatment with video calls, no physical meetings
11075851|NCT04245384|Active Comparator|Standard treatment|Dietetic treatment with physical meetings
11075852|NCT04245371|Active Comparator|Active|Lidocaine Patch 1.8% applied to affected hand at night for 2 weeks following FDA approved dosing recommendations, i.e. 12 hours during each 24-hour daily cycle.
11075853|NCT04245371|Placebo Comparator|Placebo|Placebo Patch applied to affected hand at night for 2 weeks for 12 hours during each 24-hour daily cycle.
11075854|NCT04245358|Other|Ainara|Ainara is a class II medical device, already marketed in several EU countries. Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
11075855|NCT04245345|Other|Single-arm|
11075856|NCT04245332|Experimental|Fish Oil|This group will receive fish oil (4g/d).
11075857|NCT04245332|Placebo Comparator|Placebo|This group will receive coconut oil (4g/d) as an iso-energetic, iso-lipidic placebo comparator to the fish oil arm.
11075861|NCT04245306|Active Comparator|Typically Developing children|A larger group of 150 typically developing children (TD)
11075862|NCT04245306|Experimental|Children with Developmental Language Disorders|A group of 25 children with developmental language disorders (DLD)
11075863|NCT04245293|Experimental|Ainara|Experimental: Ainara Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
11075864|NCT04245293|Active Comparator|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.
~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
11075865|NCT04245280|Active Comparator|PENG and LFCN blocks with ropivacaine|For the PENG block, and after negative aspiration, 20 ml of a solution of ropivacaine 0.5% with epinephrine 2.5 mcg/ml will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same solution will be injected with the same needle.
11075866|NCT04245280|Placebo Comparator|PENG and LFCN blocks with saline solution|For the PENG block, and after negative aspiration, 20 ml of a saline solution will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same saline solution will be injected with the same needle.
11075867|NCT04245267|No Intervention|Control|Patients in the wait-list being attended with the standard model of care for diabetes in primary care units.
11075868|NCT04245267|Experimental|DIABEMPIC program|Intervention comprised by an interdisciplinary team care, patient-centered care approach, structured diabetes education program, promotion of self-management, audit, and guaranteed supply of anti-diabetic medication.
11075869|NCT04245254|Experimental|Intervention Arm|Single arm study. Receives collagen protein powder.
11075870|NCT04245228|No Intervention|Usual Care Group|Routine caregiver transplant education
11075871|NCT04245228|Experimental|Wellness Coaching Intervention|Caregivers will be assigned a wellness coach
11075872|NCT04245215|Placebo Comparator|1. Subcutaneous ustekinumab every 8 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
11075873|NCT04245215|Active Comparator|2. Subcutaneous ustekinumab every 4 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
11075874|NCT04245202|Active Comparator|Active Comparator: HFNC group|Set between 2 to 25 l/min, adjusted to obtain oxygen saturation >92%.
11075875|NCT04245202|Active Comparator|Active Comparator: Simple Face Mask|To obtain oxygen saturation >92%
11075876|NCT04245176|Experimental|Quantitative Genetic Counseling|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:
~-- Quantitative genetic counseling: Discussion is guided by tables and graphs."
11075877|NCT04245176|Active Comparator|STANDARD GENETIC COUNSELING|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:
~-- Standard genetic counseling: Standard of care discussion"
11075878|NCT04245163|Experimental|Intervention Group|Participants in the intervention group will be invited for the training program.
11075879|NCT04245163|No Intervention|Control Group|Participants who will be randomized in control group will receive normal care (the care that each clinic provides to the patients) and will be given an educational material (without telling them that they are in the control group). They will receive, however, the education class later (at the end of the study).
11075880|NCT04245150||Ductal Carcinoma In Situ (DCIS) or invasive breast cancer|Participants with DCIS or invasive breast cancer
11075881|NCT04245124|Experimental|SMART INTERVENTION|N= 81 20 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
11075882|NCT04245124|Experimental|TCR|N= 81 60 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
11075883|NCT04245111||Open Fracture Cohort|Patients 18 years of age or older. Open extremity fracture. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent.
11075884|NCT04245111||Complication Cohort|Patients 18 years of age or older. Extremity fracture. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. Will have all fracture care surgeries performed by a participating surgeon or delegate. Provision of informed consent
11075885|NCT04245111||Closed Fracture Cohort|"Patients 18 years of age or older Closed extremity fracture Planned definitive fracture management with external fixation, internal fixation, or joint fusion.
~Provision of informed consent"
11075886|NCT04245098|Experimental|Amyloid|Biopsy
11075887|NCT04245085|Active Comparator|Arm A|"Atezolizumab (1200 mg) Q3W, until PD
~Bevacizumab (15 mg/kg), Q3W, until PD
~Carboplatin (AUC5) Q3W, 4-6 cycles
~Paclitaxel (200 mg/m2), Q3W, 4-6 cycles"
11075888|NCT04245085|Active Comparator|Arm B|"Atezolizumab (1200 mg), Q3W, until PD
~Bevacizumab (15 mg/kg), Q3W, until PD
~Pemetrexed (500 mg/m2), Q3W, until PD"
11075889|NCT04245072|Active Comparator|Ranibizumab|Arm 1
11075890|NCT04245072|Active Comparator|Aflibercept|Arm 2
11075933|NCT04244734|Active Comparator|Group 1|The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load (initially at 40% load from results in MIP).
11075966|NCT04244487|No Intervention|Non-intraoperative endoscopic variceal ligation group|Every patient of conventional group will receive single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation procedure
11075891|NCT04245059|Experimental|Transcranial Direct Current Stimulation|Each subject will receive transcranial electrical stimulation at primary motor cortex in both hemispheres. The pilot program will include 12 sessions with a frequency of 3 times per week during 4 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 milliamp using 6x4 cm electrodes. The participants will also complete a set of manual dexterity, grip and pinch tests bilaterally at baseline and post-intervention to determine if the subject responds to tDCS. Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin disorders and other possible side effects of tDCS.
11075892|NCT04245046|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:
~Age: 18-49 years
~Weight: 55-105 kg
~Height: 163-188 cm
~BMI 18.5-29.9 kg/m²"
11075893|NCT04245033|Experimental|IPTsc arm|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) will be given in all wards in the IPTsc arm at an interval of four months, three times a year.
11075894|NCT04245033|No Intervention|Control|No intervention will be given to wards randomised in this arm
11075895|NCT04245020|Active Comparator|Text Message|Patients will be followed up with a series of text messages at 6-8 weeks
11075896|NCT04245020|Active Comparator|Telephone|Patients will be followed with a telephone conversation at 6-8 weeks
11075897|NCT04245020|Active Comparator|In person|Patients will be followed in person in the Outpatient department at 6-8 weeks
11075898|NCT04245007|Experimental|Intervention|Subject will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
11075899|NCT04245007|No Intervention|Control|Subject will prohibited from doing fasting or intake restriction within 8 weeks
11075900|NCT04244994|Other|Intervention and Control|Self-taken penile meatal swabs versus first-catch urine for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
11075901|NCT04244981|Experimental|PCC group|When APTT is prolonged (>1.5 times normal), patients will be given a 4-factor PCC based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR>6, PCC 50 IU/kg).
11075902|NCT04244981|Active Comparator|FFP group|When APTT is prolonged (>1.5 times normal), patients will be given a dose of 10-15 ml/kg FFP.
11075903|NCT04244929|Experimental|PCL removal|Patients will undergo surgery by sacrificing the PCL
11075904|NCT04244929|Active Comparator|PCL preservation|Patients will undergo surgery with retaining the PCL
11075905|NCT04244890||Uninterrupted CPAP|Newborn infants in need of respiratory support directly after birth
11075906|NCT04244877|Experimental|Rifaximin|Rifaximin 550 mg by mouth three time daily for two weeks followed immediately with Rifaximin 550 mg by mouth two times daily for six weeks.
11075907|NCT04244864|Active Comparator|Treatment as usual (TAU)|8-12 months of treatment
11075908|NCT04244864|Experimental|Cross-sectoral social intervention|8-12 months of treatment
11075909|NCT04244851||Malnourished patients|Malnourished patients
11075910|NCT04244838|Experimental|MP-TKA group|20 patients candidates for cemented TKA with MP design for tri-compartment gonarthrosis will be recruited on indications of the surgeon and according to normal clinical practice at the Orthopedic and Traumatological Clinic 2nd of the Rizzoli Orthopedic Institute.
11075911|NCT04244825|Experimental|Cohort 1a BLD-2660|900 mg (6 x 150 mg capsules) BID
11075912|NCT04244825|Experimental|Cohort 1b BLD-2660|900 mg (6 x 150 mg capsules) BID (Optional)
11075913|NCT04244825|Experimental|Cohort 2 BLD-2660|600 mg (4 x 150 mg capsules) BID
11075914|NCT04244825|Experimental|Cohort 3 BLD-2660|300 mg (2 x 150 mg capsules) BID
11075915|NCT04244825|Placebo Comparator|Cohort 1a Placebo|900 mg (6 x 150 mg capsules) BID
11075916|NCT04244825|Placebo Comparator|Cohort 1b Placebo|900 mg (6 x 150 mg capsules) BID (Optional)
11075917|NCT04244825|Placebo Comparator|Cohort 2 Placebo|600 mg (4 x 150 mg capsules) BID
11075918|NCT04244825|Placebo Comparator|Cohort 3 Placebo|300 mg (2 x 150 mg capsules) BID
11075919|NCT04244812|Other|CSAP group|"Participants in the CSAP group will receive examination of laser doppler flowmetry(LDF).
~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian"
11075920|NCT04244812|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
11075921|NCT04244812|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
11075922|NCT04244799|Experimental|Behavioral nudges|Schools randomized to this arm will receive the behavioral nudges intervention and the Philippines Department of Education national WASH in Schools (WinS) policy.
11075923|NCT04244799|Active Comparator|Control group|Schools in the control group will not receive handwashing nudges but will receive DepEd's national WASH in Schools (WinS) policy.
11075924|NCT04244786|Active Comparator|active anodal tDCS to ventrolateral prefrontal cortex (VLPFC)|1.5 milliamp (mA) anodal tDCS over right ventrolateral prefrontal cortex; 20-minutes, 6-sessions
11075925|NCT04244786|Sham Comparator|sham anodal tDCS to VLPFC|Identical electrode montage, sham tDCS over 6 sessions.
11075926|NCT04244773|Experimental|Intervention group: ENDS and smoking cessation|
11075927|NCT04244773|Active Comparator|Control group: Smoking cessation counseling|
11075928|NCT04244760|Active Comparator|Verbal Patients|
11075929|NCT04244760|Active Comparator|Non-verbal Patients|
11075930|NCT04244747|Active Comparator|induction of labour by breast stimulation|women at term with previous cesarean section and an indication to induce labor. In order to induce labour by breast stimulation, an electrical pump was used. The cup was alternated between the nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes, with a total induction time of 6 hours.
11075931|NCT04244747|Active Comparator|induction of labour by catheter balloon|women at term with previous cesarean section and an indication to induce labor. In the catheter balloon group, a 16-F Foley catheter was inserted into the cervical canal and inflated with 60 cc sterile saline solution and was kept in place for 12 hours.
11075932|NCT04244747|No Intervention|spontaneous labour|women in latent phase of spontaneous labour .
11075934|NCT04244734|Experimental|Group 2|The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load (initially at 60% load from results in MIP).
11075935|NCT04244721|Sham Comparator|a group of children receiving the usual therapy (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
11075936|NCT04244721|Experimental|a group of children receiving TAU plus the PACT intervention.|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
11075937|NCT04244708|Experimental|Radiotherapy plus temozolomide|Undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day), followed by six cycles of adjuvant temozolomide.
11075938|NCT04244708|Placebo Comparator|Radiotherapy plus placebo|Radiotherapy treatment alone undergoing fractionated radiotherapy, total 54 Gy, 2GyX27, received placebo.
11075939|NCT04244695|Experimental|Dexamethasone 16 mg|Dexamethasone (4mg) 4 tab oral once daily in the morning
11075940|NCT04244695|Active Comparator|Dexamethasone 8 mg|Dexamethasone (4mg) 2 tab and placebo 2 tab oral once daily in the morning
11075941|NCT04244695|Placebo Comparator|Placebo|Placebo 4 tab oral once daily in the morning
11075942|NCT04244682|Other|Healthy participants receiving rTMS|Participation will require up to three visits. One visit will take up to an hour, and the other visits will each take up to three hours each. During the first visit, participants will be consented, and their brains will be scanned using magnetic resonance imaging. Participants will receive rTMS during two study visits.
11075943|NCT04244669|Experimental|SCS with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% of pain in that area.
11075944|NCT04244669|Experimental|SCS with SCS DTM Stimulation|IIn this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms.
11075945|NCT04244656|Experimental|CTX120|Administered by IV infusion following lymphodepleting chemotherapy.
11075946|NCT04244643||Patients with soft contact lenses|
11075947|NCT04244630|Other|Antioxidants|Eligible patients will receive over-the-counter anti-oxidants, namley CoQ10, vitamin E, NAc cysteine, and L-cystine at defined doses.
11075948|NCT04244617|Experimental|iCBT with addition of peer-support (iCBT-PS)|Participants in the iCBT-PS, are guided by both a psychologist and a peer-support in the iCBT-program used in the study.
11075949|NCT04244604|Experimental|High Sodium Meal (2500 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a high sodium meal (2500 mg sodium).
11075950|NCT04244604|Placebo Comparator|Low Sodium Meal (140 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a low sodium meal (140 mg sodium) which will serve as the control condition to demonstrate whether or not observed changes are due to high sodium or occur irrespective of sodium in the postprandial state.
11075951|NCT04244591|Placebo Comparator|standard care|standard care
11075952|NCT04244591|Experimental|standard care + methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
11075953|NCT04244578|Experimental|Active-Sham tDCS|Each tDCS sessions will be delivered for 5 days for a total of non consecutive two weeks. The first session will be active tDCS and two months after, a sham tDCS will follow.
11075954|NCT04244578|Active Comparator|Sham-Active tDCS|"Each tDCS sessions (sham tDCS and active tDCS) will be delivered for 5 days for a total of non consecutive two weeks.
~The first session will be sham tDCS and two months after, an active tDCS will follow."
11075955|NCT04244565||Self-directed clinical learning|examining the effect of Self-directed clinical learning model as compared to the traditional models to improve nurses' Airway management competencies and minimize airway related incidents.
11075956|NCT04244552|Experimental|ATRC-101 Dose Escalation|
11075957|NCT04244539|Experimental|Experimental group|a received routine physical therapy program, in addition to HILT. Patients in the study group received pulsed Nd: YAG laser treatment, produced by a HIRO 3 device (ASA Laser, Arcugnano, Italy). The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2),
11075958|NCT04244539|Active Comparator|Control group|The control group received traditional physical therapy program in the form of strengthening exercise, stretching , and range of motion exercise.for the affected digits and wrists. for one hour, three sessions per week for 8 weeks.
11075959|NCT04244526||Group1|Group 1:pregnant women with cystitis
11075960|NCT04244526||Group2|Group 2: pregnant women with Pyelonephritis
11075961|NCT04244526||Group3|Group 3: pregnant women with asymptomatic bacteriuria
11075962|NCT04244513|Experimental|HD-DBS|This group will be routinely activated after surgery and then stimulated for 6 months.
11075963|NCT04244513|Sham Comparator|HD-sham-DBS|This group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months
11075964|NCT04244500||Influenza|Influenza testing
11075965|NCT04244487|Experimental|intraoperative endoscopic variceal ligation group|intraoperative endoscopic variceal ligation group Every patient of vagus nerve-preserving group will receive the synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation procedure
11076182|NCT04242940|Experimental|Ponto 4 sound processor|All patients will be fitted with a bone-anchored sound processor (Ponto 4), unilaterally or bilaterally.
11075967|NCT04244474|Experimental|vitamin D3 supplementation|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) . Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
11075968|NCT04244474|Placebo Comparator|Placebo|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
11075969|NCT04244461|Experimental|Personalized normative feedback|Personalized feedback about drinking behavior compared to peers
11075970|NCT04244461|No Intervention|Control|Control participants will receive content similar in length but different in content from the PNF (i.e., non-drinking focused). These participants will receive information based on their actual and perceived behavior of playing video games, a strategy used in prior PNF work to balance attention to non-targeted behaviors.
11075971|NCT04244448|Other|BIKTARVY® ADMINISTRATION DISSOLVED IN WATER|BIKTARVY® route in healthy volunteers: dissolved in water in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of dissolved in water versus crushed and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
11075972|NCT04244448|Other|BIKTARVY® ADMINISTRATION CRUSHED|BIKTARVY® route in healthy volunteers: crushed in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of crushed versus dissolved in water and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
11075973|NCT04244448|Other|BIKTARVY® ADMINISTRATION SOLID|BIKTARVY® route in healthy volunteers: solid tablet in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of solid form of BIKTARVY® versus dissolved in water and crushed in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
11075974|NCT04244435|Experimental|Thoracic epidural analgesia|CABG and thoracic epidural analgesia will be used for perioperative analgesia postoperative period
11075975|NCT04244435|Active Comparator|Opioids|CABG and opioids will be used for perioperative analgesia
11075976|NCT04244435|Active Comparator|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
11075977|NCT04244422|Active Comparator|cyst enucleation using piezosurgery|SATLEC ACTEON peizotome 2 was used for bone cutting and separating the cystic lining from the surrounding bone.After complete removal of the cyst, the bony window was replaced back in place and the flap was sutured.
11075978|NCT04244422|Active Comparator|cyst enucleation using conventional surgery|A carbide bur was used to remove the bone to uncover the cyst. A periosteal elevator and a curette were used to aid in the removal of the cystic lesion.
11075979|NCT04244396||Drug refractory, symptomatic persistent atrial fibrillation|Asian population
11075980|NCT04244383|Experimental|chronic hepatitis C virus patients|50 chronic hepatitis C virus patients taking will be trated with direct acting antiviral treatment with three months regimen (Sofosbuvir + Daclatasvir).
11075981|NCT04244383|Experimental|treated chronic hepatitis C virus patients|the selected 50 chronic hepatitis C virus patients received direct acting antivirals: Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virological response at 12 weeks following the end of treatment (SVR12).
11075982|NCT04244370|Experimental|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
11075983|NCT04244344|Experimental|interventional|"all High fall risk subjects who meet the criteria by STRATIFY Tool"
11075984|NCT04244318|Experimental|Video Feedback ODISEA 2.0.|Once a week, the 5 session intervention of Video-feedback ODISEA 2.0 will be done with the family. In the first session, a play interaction between the child and the caregiver will be recorded for 10 minutes. The second session will be done between the therapist and caregivers, where they will watch different selected parts of the video, and will provide feedback through a mentalization constructed framework. Then, in the third session another play interaction video will be recorded, that will be discussed on the fourth session with the caregiver. Finally, in the fifth session a final interaction video will be recorded.
11075985|NCT04244318|No Intervention|Control Group.|Patients in control group will be placed as a non intervention group. After collecting the post-test data, they will be offered the same intervention than the experimental group.
11075986|NCT04244305|Experimental|Treadmill Training|"Participants in the treadmill training group will perform endurance training during the post-operative period using a treadmill (Salter Housewares, UK) for a minimum of 20 sessions. Intensity of training will be set according to 80% of the mean speed achieved during the 6MWT for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week.
~After the endurance training, participants will perform resistance training for 20 - 30 minutes for conditioning of the main muscles in the upper and lower limbs using elastic bands, dumbbells and body-weight exercises. Intensity will progressively increase up to 70% of the maximum isometric strength measured with a hand-held dynamometer. Volume of training will also increase from 1 to 3 sets of 12 repetitions each. When needed patients will also be taught breathing exercises and airway clearance techniques."
11075987|NCT04244305|Active Comparator|Cyclo-ergometry Training|Participants in this group will perfom endurance training during the post-operative period using a cycle ergometer (Monark 828e, Monark AB, Sweeden) for a minimum of 20 sessions. Intensity of training will be set according to the results of a symptom-limited incremental cycle-ergometry test performed on the first day to achieve 80% of the maximal workload obtained for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week. Participants in this group will also perfom resistance training and breathing exercises as in the treadmill training group.
11075988|NCT04244292|Other|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
11075989|NCT04244279|Experimental|Intervention group|The intervention group will participate in a workshop regarding ergonomic principles in baby care. Finally, a brochure will be distributed summarizing the main contents of the workshop. One month and two months after the intervention, the intervention group will receive a videotaped reminder of the principles presented at the workshop via an email or WhatsApp message.
11075990|NCT04244279|No Intervention|Control group|The control group will not receive any intervention during the data collection period. The intervention will be given three months after the beginning of the research, in the format of the brochure and videos sent via email or WhatsApp.
11075991|NCT04244266||Ideal Body Weight|groups of patients divided according to neostigmine dose weight, ideal body weight (IBW)
11075992|NCT04244266||Total Body Weight|groups of patients divided according to neostigmine dose weight, total body weight (TBW),
11075993|NCT04244266||Adjusted Body Weight|groups of patients divided according to neostigmine dose weight, , adjusted body weight (ABW)
11075994|NCT04244253|Experimental|OPC-64005 20 mg|
11075995|NCT04244253|Experimental|OPC-64005 10 mg|
11075996|NCT04244253|Placebo Comparator|Placebo|
11075997|NCT04244240||Sickle cell disease patient|Adults with sickle cell disease (homozygous SS or heterozygous SC, Sβ0 or Sβ+) with cognitive complaint.
11075998|NCT04244227|Experimental|Active treatment|Participants will self-administer treatment with the Empower device at the active treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower active treatment.
11075999|NCT04244227|Sham Comparator|Sham treatment|Participants will self-administer treatment with the Empower device at the sham treatment anatomic location once daily for three weeks. Participants will complete daily and weekly surveys to evaluate the effects of the Empower sham treatment.
11076000|NCT04244214||More Stamina users|This group of patients will use the app for 60 days and all information about utilization will be recorded
11076001|NCT04244201|Experimental|VHT treatment|Patients will be treated with VHT for 1 hour four times per week
11076002|NCT04244188||Patients treated for aortic arch aneurysms|Patients treated for aortic arch aneurysms by double branched endovascular repair (Bolton Medical) will be included.
11076003|NCT04244175|Experimental|High Dose: CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Day 92 during the treatment period.
11076004|NCT04244175|Experimental|Low Dose: CVL-865 7.5 mg|Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg until Day 92 during the treatment period.
11076005|NCT04244175|Placebo Comparator|Placebo|Participants will receive a placebo matched to CVL-865 tablets orally BID until Day 92 during the treatment period.
11076006|NCT04244162||Study Group|brain scans, cognitive tests, blood biomarkers
11076007|NCT04244149|Experimental|Intervention group|Participants will exert an exercise prolonged session
11076008|NCT04244123||growth hormone deficiency|growth hormone deficiency, requiring growth hormone treatment
11076009|NCT04244123||small for gestational age|small for gestational age and failure of post natal catch up height gain, requiring growth hormone treatment
11076010|NCT04244123||Turner syndrome|short stature due to Turner syndrome, on growth hormone treatment
11076011|NCT04244123||chronic renal failure|short stature due to chronic renal failure, treated with growth hormone treatment
11076012|NCT04244123||Prader Willi syndrome|short stature due to Prader Willi syndrome, treated with growth hormone treatment
11076013|NCT04244097|Experimental|B group|-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.
11076014|NCT04244097|Active Comparator|BN group|Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.
11076015|NCT04244084|Experimental|MMH-407|"Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.
~Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed."
11076016|NCT04244084|Placebo Comparator|Placebo|According to the scheme of receiving MMN-407 until the end of the study.
11076017|NCT04244071|Active Comparator|Group C|"Usual care (Group C): The patients in this group received routine hospital care.
~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
11076018|NCT04244071|Experimental|Group A|"The patients in Group A were warmed up using a gown blowing warm air starting at least 30 min prior to the surgery until they were anesthetized.
~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
11076019|NCT04244071|Experimental|Group B|"Routine care was provided for the patients in Group B in the preoperative and intraoperative periods. In the postoperative period, patients were warmed up using a gown blowing warm air after they were transferred to the post-anesthesia care unit, and continued to be warmed up on the basis of the temperature set by themselves until they wore their own clothes in the ward.
~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
11076020|NCT04244058|Active Comparator|NMDA blocker|Comprehensive functional analyses of dynamic [18F]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second [18F]FPEB-PET will be acquired.
11076021|NCT04244058|Experimental|NMDA blocker + L-DOPA|All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of [18F]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each [18F]FPEB-PET acquisitions.
11076022|NCT04244045|Experimental|Experimental group 1|suboccipital muscle inhibition plus passive stretch of hamstring muscle.
11076023|NCT04244045|Experimental|Experimental group 2|Neural slump strtch position plus passive stretch of hamstring muscle.
11076024|NCT04244045|Active Comparator|Control group|passive stretch of hamstring muscle
11076025|NCT04244032|Experimental|Working Memory Training (WM)|Participants complete training in a working memory task designed to utilize individually-adapted difficulty levels.
11076026|NCT04244032|Experimental|Inhibitory Control Training (IC)|Participants complete training in an inhibitory control task designed to utilize individually-adapted difficulty levels.
11076027|NCT04244032|Active Comparator|Bias Modification Training (BM)|Participants complete training in an active comparator task designed to weaken approach responses to alcohol-associated cues.
11076028|NCT04244032|No Intervention|Non-Trained control (NTC)|No active intervention is delivered beyond typical care.
11076029|NCT04244006|Experimental|Dupilumab|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).
11076030|NCT04244006|Placebo Comparator|Placebo|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of placebo (syringe of 2 mL for subcutaneous administration)..
11076031|NCT04243993|Other|Bio-MA|Calcium silicate cement containing calcium chloride accelerator
11076032|NCT04243993|Other|ProRoot MTA|Calcium silicate cement without calcium chloride accelerator
11076033|NCT04243980||Group 1|Patients after total hip arthroplasty with short femoral stem
11076034|NCT04243967|Experimental|MUSIC THERAPY|
11076035|NCT04243967|Experimental|CONTROL|
11076036|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose = 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.
~The PCA setting:
~1) Continuous dose = 0; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
11076037|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose ≠ 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.
~The PCA setting:
~1) Continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
11076038|NCT04243954|Active Comparator|Oral Morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.
~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
11076039|NCT04243941|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
11076040|NCT04243928|Active Comparator|control group|15 diplegic children received regular exercise program including balance exercise
11076041|NCT04243928|Experimental|study group|15 diplegic children recieved regular exercise program plus putting kinesiotape
11076042|NCT04243915|Experimental|PNMES plus exercise|6-week intervention program with 3 treatment sessions of PNMES and motor control exercise program.
11076043|NCT04243915|Sham Comparator|Sham PNMES (introducing the needle) plus exercise|Sham PNMES (introducing the needle) plus motor control exercise program
11076044|NCT04243915|Active Comparator|TENS plus exercise|6-week intervention program with 3 treatment sessions of TENS plus motor control exercise program.
11076045|NCT04243915|Placebo Comparator|Placebo PNMES (without inserting the needle) plus exercise|6-week intervention program with 3 treatment sessions of placebo PNMES (without inserting the needle) and exercise
11076046|NCT04243902|Experimental|1 - standard manual valve (without leg-bag)|"The valve will initially be tested in 8 participants who currently use a standard manual valve (without leg-bag).
~This first group will include a safety cohort of participants (n=4). All safety data will be reviewed from the initial 4 participants before further participants can undergo the study investigation."
11076047|NCT04243902|Experimental|2 - drainage bag with free drainage|The valve will then be tested with participants (n=8) who currently use a drainage bag with free drainage.
11076048|NCT04243889|Experimental|NEOX Cord 1K applied fetoscopically|
11076049|NCT04243876||paraoxanase|Enzyme level
11076050|NCT04243876||Myocardial infarction|RESULTS OF ANGIOGRAPHY
11076051|NCT04243863|Experimental|VNRX-7145|Oral dosing
11076052|NCT04243863|Placebo Comparator|Placebo|Oral dosing
11076053|NCT04243850|Experimental|Empagliflozin|Empagliflozine 7 days
11076054|NCT04243850|Placebo Comparator|Placebo|Placebo 7 days
11076055|NCT04243837|Experimental|LYT-100 in healthy volunteers with Food|LYT-100, multiple ascending
11076056|NCT04243837|Placebo Comparator|Placebo in healthy volunteers with Food|Placebo, multiple administrations
11076057|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fasted|LYT-100, Dose below MTD for 1 dose
11076058|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fasted|Placebo, for 1 administration
11076059|NCT04243837|Experimental|LYT-100 in healthy volunteers, Fed|LYT-100, Dose below MTD for 1 dose
11076060|NCT04243837|Placebo Comparator|Placebo in healthy volunteers, Fed|Placebo, for 1 administration
11076061|NCT04243837|Experimental|LYT-100 in patients with BCRL|LYT-100 BID for 6 months
11076062|NCT04243837|Placebo Comparator|Placebo in patients with BCRL|Placebo BID for 6 months
11076063|NCT04243824|Experimental|All participants|All enrolled study participants will receive Ga-68MAA and PET/MRI scan.
11076064|NCT04243811|Experimental|laser group|local anesthesia applyed with 940 nm diode laser
11076065|NCT04243811|Active Comparator|conventional group|local anesthesia applyed with topical anesthesia
11076066|NCT04243798|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
11076067|NCT04243798|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
11076091|NCT04243603|Active Comparator|Treatment as Usual (TAU)|Child and Adolescent Mental Health Services (CAMHS) offer specialized treatment for children and adolescents. TAU encounters a variety of clinical treatment and assessment offers, representing a highly inhomogeneous group of treatments, for instance: Pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy, supportive counselling and psychoeducation. Throughout the trial course the treatment responsibility is handled by clinicians providing TAU.
11116733|NCT03957902|Experimental|Arm 2 (300 mg/24h)|
11076068|NCT04243785|Experimental|Phase 1a (Dose Escalation Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 20 mg (60 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
11076069|NCT04243785|Experimental|Phase 1b (Cohort Expansion Phase)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). Phase 1b will continue at the MTD or the highest dose achieved in Phase 1a.
11076070|NCT04243785|Experimental|Continued Treatment Phase|Participants who complete one cycle of BTX-A51 treatment in either Phase 1a or Phase 1b will be offered continued access to treatment for up to eight 28-day cycles if the Investigator determines that the benefit outweighs the risk. Dosing will continue at the assigned dose or may be increased (not to exceed a level already tolerated by at least one participant if Phase 1a is ongoing or the MTD/recommended Phase 2 dose if already established).
11076071|NCT04243772||Lithiasic patients|Lithiasic patients of the CHU Brugmann Hospital
11076072|NCT04243759|Experimental|Control App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
11076073|NCT04243759|Experimental|Standard App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
11076074|NCT04243759|Experimental|Experimental, Feedback App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
11076075|NCT04243746|Experimental|Time Restricted Feeding +Standard Malaysian Healthy Plate(QQH)|Subjects practise time restricted feeding (TRF) in addition to the Standard Malaysian Healthy Plate (QQH).
11076076|NCT04243746|Active Comparator|Standard Malaysian Healthy Plate (QQH)|Subjects practise the QQH dietary plan.
11076077|NCT04243733|Other|calcium enriched mixture material (CEM)|Using CEM as a pulpotomy agent against MTA pulpotomy agent.
11076078|NCT04243733|Experimental|Mineral trioxide aggregate material (MTA)|Using MTA as a pulpotomy agent against CEM pulpotomy agent.
11076079|NCT04243720||IRIS|Patients with a histological or cytological diagnosis of solid malignancies. Patients must have progressed on immunotherapy as their most recent line of therapy.
11076080|NCT04243694|Experimental|Intervention group|mindfulness intervention administered
11076081|NCT04243694|No Intervention|Control group|no intervention administered
11076082|NCT04243681|Experimental|Combination MSC and HSC|Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance
11076083|NCT04243681|Active Comparator|Standard of care for Cirrhosis management|Diuretics, Hepatoprotective agents and Lactulose
11076084|NCT04243668|Experimental|ANTI REFLUX MUCOSAL ABLATION THERAPHY|In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.
11076085|NCT04243655|Experimental|Hemoperfusion treatment with HA 330-II|Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with SMT as per patients requirement.
11076086|NCT04243655|Active Comparator|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
11076087|NCT04243629|Experimental|Rapid Insulin-Plus-Pramlintide|Rapid insulin and pramlintide infusion in two insulin pumps
11076088|NCT04243629|Placebo Comparator|Rapid Insulin-Plus-Placebo|Rapid insulin and placebo (saline) infusion in two insulin pumps
11076089|NCT04243616|Experimental|Drug Treatment|Cemiplimab, Paclitaxel, Carboplatin (not mandatory), Doxorubicin, Cyclophosphamide
11076090|NCT04243603|Experimental|Internet-based ERITA-DK|ERITA is a youth-adapted version of Emotion Regulation Group Therapy (ERGT), based on cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and Acceptance and Commitment Therapy (ACT), which encounters emotional recognition and regulation, crisis strategies and skills training. The ERITA intervention is provided as add-on to TAU and consists of 12 weeks, manualized, therapist guided internet-based therapy. The intervention also provides six modules for the parents focusing on NSSI and other risk-taking behaviors, emotional awareness, and validation skills. The participants must complete one module every week while the parents must complete a module every second week. A mobile app is available to complement the online treatment. The app includes reminders of homework and skills and allows to report on both self-destructive behaviors and impulses daily.
11076092|NCT04243590||Neonatal brachial plexus palsy|"25 patients will be included. The level of the brachial plexus lesion will be recorded. Parents of all patients were asked to fill in the Turkish version of the Hand-at-Home Questionnaire and in addition, the upper extremity section of the Pediatric Outcomes Data Collection Instrument (PODCI) in patients with OBP."
11076093|NCT04243590||Unilateral cerebral palsy|"25 patients will be included. The level of Manual Ability Classification System (MACS) will be recorded. Parents of all patients were asked to fill out the Turkish version of the Hand-at-Home Questionnaire at Home, as well as the Children's Hand-Use Experience Questionnaire (CHEQ) in patients with CP."
11076094|NCT04243577|Experimental|Experimental Sensors|This arm will include the use of the experimental wearable sensors we are developing.
11076095|NCT04243577|Active Comparator|Conventional Sensors|This arm will include the use of the conventional sensors: regular snap on sEMG electrodes and IOPI device bulb.
11076096|NCT04243564|Active Comparator|PLMA|The PLMA, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
11076097|NCT04243564|Active Comparator|I-gel|The I-gel, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
11076098|NCT04243551|Active Comparator|Latiglutenase|IMGX003
11076099|NCT04243551|Placebo Comparator|Placebo|Placebo
11076100|NCT04243538|No Intervention|Control arm|Standard of care.
11076101|NCT04243538|Experimental|I-HoME intervention|
11076102|NCT04243512|Experimental|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
11076103|NCT04243499|Experimental|IV ICT01 Monotherapy|Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
11076104|NCT04243499|Experimental|IV ICT01 + Checkpoint Inhibitor|A range of IV ICT01 doses administered every 3 weeks will be tested in combination with an approved dosing regimen of CPI in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
11076105|NCT04243486|Experimental|UHE-105 Shampoo|UHE-105 Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
11076106|NCT04243486|Placebo Comparator|Vehicle Shampoo|Vehicle Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
11076107|NCT04243473||Prostate Biopsy, Urine sample and Blood sample|For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
11076108|NCT04243460|Experimental|CTG connective tissue graft augmentation|CTG connective tissue graft (CTG) was used for soft tissue augmentation. I
11076109|NCT04243460|Active Comparator|XCM Xenogeneic collagen matrix (XCM)graft augmentation|Xenogeneic collagen matrix (XCM) was used for soft tissue augmentation.
11076110|NCT04243434|Experimental|Cohort A|Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
11076111|NCT04243434|Experimental|Cohort B|VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
11076112|NCT04243421|Experimental|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).
~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.
~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
11076113|NCT04243408|Experimental|group 1|
11076114|NCT04243408|Placebo Comparator|group 2|
11076115|NCT04243395|Experimental|Pork|1 ounce lean pork
11076116|NCT04243395|Experimental|Egg|1 large whole egg
11076117|NCT04243395|Experimental|Black beans|0.5 cups of cooked black beans
11076118|NCT04243395|Experimental|Almonds|0.5 ounce of whole almonds
11076119|NCT04243382|Experimental|group 1|Autologous umbilical cord blood transfusion Single dose of an Autologous umbilical cord blood transfusion
11076120|NCT04243382|Experimental|group 2|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml,
11076121|NCT04243356|Experimental|Nurse Encounter Group|Nurses that are assigned to this group will be asked to take surveys before and immediately following the post-ICU clinic encounter with a patient that they had cared for in the ICU during a follow-up care visit with the former ICU - patient.
11076122|NCT04243356|Other|Nurse Control Group|Nurses assigned to this group will only complete surveys and will not see a former patient in a post-ICU visit.
11076123|NCT04243343|Experimental|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program.
11076124|NCT04243343|Active Comparator|Standard of care|Standard of care prescribed home exercise program.
11076125|NCT04243330|No Intervention|Implementation as Usual|Implementation support consisting of clinical decision support tools, trainings, technical assistance and quality assurance to support implementation of VA Suicide Risk Identification Strategy. Available to all facilities.
11076126|NCT04243330|Experimental|Audit and Feedback|Audit and Feedback will serve as the first stage implementation intervention for sites that do not meet the benchmark for adequate implementation following 9 months of implementation as usual.
11076127|NCT04243330|Experimental|External Facilitation|Audit and Feedback plus External Facilitation will serve as the second stage implementation intervention for sites that still do not meet the benchmark for adequate implementation following 9 months of implementation as usual plus audit and feedback.
11076128|NCT04243317|Active Comparator|Control|The control group will adhere to a 1200 kcal restriction daily for 12 weeks.
11076129|NCT04243317|Experimental|Experimental|The experimental group will adhere to a 1200 kcal restriction daily for 12 weeks and will maintain sleep improvement
11076132|NCT04243278|Experimental|PO LD-ASA|Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
11076133|NCT04243278|Placebo Comparator|PO Placebo|A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.
11076134|NCT04243265|Experimental|Patients treated with MPFL reconstruction|"Patients underwent MPFL reconstruction using a minimally invasive technique using a fascia lata allograft performed at the Rizzoli Orthopedic Institute between 2011 and 2015 by the team of Prof. Marcacci.
~Clinical and radiographic evaluation will be performed during outpatients visits."
11076135|NCT04243252|Experimental|Intervention Food Pantries|Food pantries will complete online training to help them rank foods by nutritional value and promote those foods to pantry clients; the effect on pantries and their clients will be measured.
11076136|NCT04243252|Active Comparator|Control Food Pantries|Food pantries will continue to operate as usual during the study period; the effect on pantries and their clients will be measured.
11076137|NCT04243226|Experimental|this study is to develop exercise prescription of TBI patients|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve cognitive performance, depression relief and quality of life with improvement of CBF. This will be a three-year study, with the first two year using a mixed method to explore the feasibility of such a safety exercise prescription. In the second to third year, a randomized clinical control trial will be applied in TBI patients to evaluate the effectiveness of programmed aerobic exercise to promote cognitive status, 6 minutes walk test, depression relief and quality of life.
11076138|NCT04243226|No Intervention|No exercise prescription in TBI patients|Routine Care of TBI Patients
11076139|NCT04243213|Experimental|Vibration Group|Intervention group I receives a unit of 10 minutes daily on the vibrating plate with an upright posture of 15 ° postoperatively from the 2nd to the 7th day
11076140|NCT04243213|Experimental|15° Tilt Group|Intervention group II is positioned postoperatively from day 2 to day 7 for 15 minutes at 15 degrees, but without vibration
11076141|NCT04243213|Placebo Comparator|Control Group|The control group only receives standard physiotherapy and no further treatments
11076142|NCT04243200||Analyses of repeat ambulance calls and costs|For our analyses of repeat ambulance calls and costs we will use routine anonymised data from routine call-and-dispatch and clinical records data from EMAS for 12 months before the intervention was first introduced (September 2017) to at least 6 months after the final step of the introduction in April 2019, i.e. October 2019. This is likely to involve the analysis of an estimated 11916 cases so that we can implement a stepped wedge (non-randomised control)design .
11076143|NCT04243200||Survey of patients receiving intervention|We will survey about 447 patients who received the intervention in order to obtain data from a sample of n=96
11076144|NCT04243200||Survey of ambulance staff|We will send out surveys/questionnaires to all front-line ambulance staff (n=approximately 600)
11076145|NCT04243200||Qualitative interviews of staff|We will sample 10-15 staff for qualitative interviews.
11076146|NCT04243200||Qualitative interviews of patients|We will sample 10-15 patients for qualitative interviews
11076147|NCT04243187|Experimental|Clinical Study|"9 visits, once a week, for bean intake (80 grams of dried beans, soaked for 12 hours, cooked in new water for 1.5 - 2 hours. This is approximately 160 grams of cooked beans).
~Four varieties of beans (3 native and 1 commercial) will be analyzed, which will be consumed in duplicate by participants (8 visits).
~A ninth visit will be made to perform a exhaled hydrogen test with raffinose (5 grams), as a positive control."
11076148|NCT04243174|Other|SMS Messages|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
11076149|NCT04243161|Experimental|Group 1|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.
11076150|NCT04243161|Active Comparator|Group 2|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.
11076151|NCT04243148|Experimental|Multifactorial intervention|Frail and pre-frail patients will receive multifactorial intervention consisting of home exercise, BCAA supplements and a multispecies probiotic for 12 months.
11076152|NCT04243148|Experimental|Control group|Frail and pre-frail patients will be followed but will not receive any specific intervention.
11076153|NCT04243135|Active Comparator|ESWT group|All patients in both groups were applied with a hot pack for 40-minutes, transcutaneous electrical nerve stimulation for 30-minutes (100 Hz frequency and 60 milliseconds pulse duration), and a home-based exercise program around the knee for 30-minutes per day for three weeks. Also, each patient in group 1 received shockwaves of continuous frequency and intensity (2000 shocks, 10 Hz, 2.0 to 3.0 bar), while the second group of patients received sham-ESWT. In group 1, for a total of 3 weeks, r-ESWT was undertaken with 2000 pulse each time at a week interval totaling 6000 pulse by using a radial shock wave therapy system (vibrolith ortho tip ESWT (ELMED Turkey)).
11076154|NCT04243135|Sham Comparator|Sham-ESWT group|The other group received sham-ESWT at 0.1 bar in the same area. The patients were placed supine with the affected knee at 90 degrees flexion at each treatment session. The shock wave probe was held stationary on painful points around the knee or at the patellofemoral and tibiofemoral borders of the target knee.
11076155|NCT04243122|Active Comparator|Aspirin and cytoreductive therapy (if applicable)|Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.
11076156|NCT04243122|Experimental|Apixaban and cytoreductive therapy (if applicable)|Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.
11076157|NCT04243109|Experimental|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:
~Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started.
~Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.
~Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles.
~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
11076158|NCT04243096|Experimental|Physical Therapy|12 week in-person exercise-based physical therapy
11076159|NCT04243083|Experimental|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
11076160|NCT04243083|Experimental|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
11076161|NCT04243083|Experimental|Food Effect Panel|Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.
11076162|NCT04243070|Other|3-channel Holter ECG recording for EPS patient|Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
11076163|NCT04243070|Other|12-channel Holter ECG recording for non-EPS patients|Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period
11076164|NCT04243044|Experimental|Intensity 1 (0.8x resting threshold, 30 minute duration)|Transcutaneous spinal cord stimulation will be applied continually at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
11076165|NCT04243044|Experimental|Intensity 2 (1.2x resting threshold, 30 minute duration)|Transcutaneous spinal cord stimulation will be applied continually at 1.2x resting threshold as determined from baseline testing of posterior root muscle reflexes.
11076166|NCT04243044|Experimental|Intensity 3 (burst 0.8x rest threshold, 30 minute duration)|Transcutaneous spinal cord stimulation will be applied in bursts at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
11076167|NCT04243044|Experimental|Frequency 1 (30 Hz, 30 minute duration)|Transcutaneous spinal cord stimulation will be applied at a frequency of 30 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
11076168|NCT04243044|Experimental|Frequency 2 (50 Hz, 30 minute duration)|Transcutaneous spinal cord stimulation will be applied at a frequency of 50 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
11076169|NCT04243044|Experimental|Frequency 3 (80 Hz, 30 minute duration)|Transcutaneous spinal cord stimulation will be applied at a frequency of 80 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
11076170|NCT04243031||All subjects|Those with TB and those without TB.
11076171|NCT04243018|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Intervention to improve well-being and reduce the negative effects of shame and self-stigma in a population of adults experiencing homelessness.This will involve participating in two sessions, lasting two and a half hours each, over a period of two weeks. Well-being will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition participants will be provided with an acceptance and commitment training workbook. The workbook will foster core processes of the ACT model through psycho-education, daily exercises, tips and tools.
11076172|NCT04243018|Active Comparator|Peer Support Group|This peer support group will involve discussing themes around experiencing homelessness, shame and stigma and will be facilitated by an experienced peer support group leader.This will involve participating in two sessions, lasting two hours each, over a period of two weeks.
11076173|NCT04243005|Active Comparator|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
11076174|NCT04243005|Experimental|Supramarginal surgery|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
11076175|NCT04242992|Experimental|CETA (Common Elements Treatment Approach)|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based cognitive behavioral therapy (CBT) elements so the provider can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include Short Message Service (SMS) text reminders of their HIV care appointments, similar to the active control group.
11076176|NCT04242992|Active Comparator|Active control|Our comparison arm will be an active control receiving usual care for intimate partner violence. Short Message Service (SMS) text messages will be sent monthly to our control group participants to remind them of HIV care appointments.
11076177|NCT04242979|Other|Human albumin use in liver cirrhosis|"Each participant involved in the study will be assessed for his or her knowledge using (tool I).
~5-Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.
~6-Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).
~7-Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians."
11076178|NCT04242966|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
11076179|NCT04242966|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
11076180|NCT04242953|Experimental|Arm A|
11076183|NCT04242927|Experimental|Nicotinic acid + Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
11076184|NCT04242927|Active Comparator|Routine care|Routinely apply urea ointment and provide best supportive care.
11076185|NCT04242914|Experimental|Research: Ketamine + Midazolam|Research group will receive ketamine and midazolam.
11076186|NCT04242914|Experimental|Control: Midazolam|Control group will receive midazolam.
11076187|NCT04242901||Colorectal cancer|Patients recently diagnosed colorectal cancer
11076188|NCT04242888|Experimental|Rotator Cuff Facilitation|The function of Rotator cuff muscles is passively augmented in one of the 5 trials
11076189|NCT04242888|Experimental|Serratus Anterior Stretch|Seratus anterior muscles is stretched through a novel technique
11076190|NCT04242888|Experimental|Posterior Capsular Stertch|Posterior capsule is stretched through a novel maneuver
11076191|NCT04242888|Experimental|Acromioclavicular Joint Mobilization|Acromio clavicular joint is mobilized posterio-anterior
11076192|NCT04242888|Experimental|Pragmatic Interventions|"The pragmatic interventions is a set of interventions which include
~Rotator cuff facilitation
~Posterior capsular stretch
~Serratus anterior muscle stretch
~Acromioclaicualr joint mobilization
~Thoracic spine manipulation and
~Stretch to the subclavious muscles"
11076193|NCT04242875||PanOptix|Participants will receive the PanOptix intraocular lens.
11076194|NCT04242849||IDH1/2 mutated patients|Patients harboring mutations in IDH1 or IDH2 genes
11076195|NCT04242849||Patients without IDH1/2 mutations|Patients that don´t present any mutation in IDH1/2 genes
11076196|NCT04242836||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language
~30 patients with low vision (LVG) with adequate literacy of written Greek language
~These patients are tested on the printed Greek MNREAD"
11076197|NCT04242836||Study group|The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
11076198|NCT04242810|Active Comparator|Active rTMS|rTMS applied over memory task-based brain target
11076199|NCT04242810|Placebo Comparator|Sham rTMS|Sham rTMS applied over memory task-based brain target
11076200|NCT04242797|Active Comparator|Calmare|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
11076201|NCT04242797|Active Comparator|Traditional TENS|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
11076202|NCT04242784||Spoke Hospital|Patients that undergo the Code Stroke process at Spoke Hospitals
11076203|NCT04242784||Hub Hospital|Patients that undergo the Code Stroke process at Hub Hospitals
11076204|NCT04242784||Transfer|Patients that undergo the Code Stroke process at a Spoke Hospital and transfer to the Hub Hospital
11076205|NCT04242771|Experimental|Experimental group|Participants will utilize a daily sleep program available within a widely used smartphone app, which includes seven soundtracks (10-15min each) for guided mindfulness practice at bedtime. Techniques include breathing exercises, mental imagery, awareness of body and mind, and muscle and body relaxation.
11076206|NCT04242771|No Intervention|Control group|Participants randomized to the waitlist control group will be asked to maintain their usual care during the one month after baseline assessment. They will be asked not to start any new treatments for their insomnia. At the end of the one-month study, they will be given access to the mobile app.
11076207|NCT04242758|Experimental|Dapaglifozin|People undergoing SGLT2i (Dapaglifozin) therapy
11076208|NCT04242758|Experimental|Hydrochlorothiazide|People undergoing thiazide (Hydrochlorothiazide) therapy
11076209|NCT04242745|Experimental|Intervention group|Procedure/Surgery:The intervention group was given education and a wristwatch which gave an audible alarm to remind them to drink liquid.
11076210|NCT04242745|No Intervention|Control group|The control group was given only education.
11076211|NCT04242732|Experimental|MPFL reconstructed|20 patients with previous recurrent patella dislocation who underwent MPFL reconstruction surgery with fascia lata allograft between 2012 and 2013
11076212|NCT04242719|Active Comparator|Only electromagnetic stimulation|Only rEMS was preferred as the initial step
11076213|NCT04242719|Active Comparator|Combined with electromagnetic stimulation and PRP|Order to augment the effect of the rEMS, sub-tenon aPRP injection was added.
11076214|NCT04242719|No Intervention|Natural course|Served as control group, and existing systemic disorder(s) were consulted and treated accordingly.
11076215|NCT04242706|Active Comparator|Control group|Endotracheal tube with evacuation lumen without Bactiguard coating.
11076216|NCT04242706|Experimental|Experimental group|Endotracheal tube with evacuation lumen with Bactiguard coating.
11076217|NCT04242693|Experimental|Experimental Group|The experimental group were asked to count the number of times they ate any red/orange vegetables and set a goal to eat one more time the next day over three days.
11076218|NCT04242693|No Intervention|Control Group|The control group uploaded photos and/or descriptions of their meals only. They did not self-monitor their vegetable intake nor set a goal to eat more.
11076219|NCT04242680|Experimental|Brainstim DLPFC|tRNS over bilateral DLPFC + cognitive training
11076220|NCT04242680|Experimental|Brainstim PPC|tRNS over bilateral PPC + cognitive training
11076221|NCT04242680|Sham Comparator|Brainstim Sham|Sham tRNS (bilateral DLPFC/bilateral PPC) + cognitive training
11076222|NCT04242667|Experimental|Actionable gene result for cancer risk|
11076223|NCT04242667|Experimental|Actionable gene result for cardiovascular disease risk|
11076224|NCT04242654|Experimental|Doppler ultrasound|Placement of Doppler US on chest to obtain newborn's heart rate.
11076225|NCT04242654|No Intervention|Stethoscope|Placement of stethoscope on chest to obtain newborn's heart rate.
11076226|NCT04242641|Experimental|WW (formally Weight Watchers)|The intervention will consist of engaging with the WW programme for 12 weeks, including weekly attendance at a local WW workshop and access to digital tools. Only the parent will take part in the WW intervention. No modifications will be made to the current WW programme to support child weight loss.
11076227|NCT04242641|No Intervention|Control|Participants randomised to the control group will receive no intervention during the 3 month period. Following final data collection control participants will receive 3 month complimentary access to WW.
11076286|NCT04242316|Active Comparator|Bilateral arm training|Patients performed customized bimanual upper limb exercises without a mirror.
11076228|NCT04242628|Experimental|Facebook course|T1 study members attended a three week course (two classes per week) on smartphones and SNS use. Specifically, the course covers the following topics: smartphone use; Facebook use; WhatsApp use, privacy rules and fraud risk prevention using Facebook. Throughout the duration of the intervention, a tutor was available every Tuesday and Thursday to assist T1 participants in using SNSs.
11076229|NCT04242628|Experimental|Lifestyle course|T2 study members attended 5 interactive 90-min meetings on lifestyle education and brain functioning in older people. These meetings covered the following topics regarding good habits for wellbeing at older age: nutrition, brain ageing, physical activity, leisure activities, resources of the city for older people. A goodbye tea was offered after the meetings.
11076230|NCT04242628|No Intervention|Waiting list|Throughout the duration of the intervention, we put C study members on a waiting list; at the end of the intervention, in June 2019, interested group C study members attended the SNSs course (held on June 2019).
11076231|NCT04242615||Prognostic score cohort|323 patients included between January 1, 2001 to December 31, 2004
11076232|NCT04242615||Prognostic score validation cohort|534 patients included between January 1, 2010 to December 31, 2013
11076233|NCT04242602|Other|Study Subjects|
11076234|NCT04242589|Active Comparator|Radiotherapy|Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)
11076235|NCT04242589|Experimental|Vertebroplasty + Radiotherapy|"Vertebroplasty followed by radiotherapy within 2-3 weeks
~Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)"
11076236|NCT04242576|Experimental|Action Observation|Subjects will watch 30-second videos, with a one-minute break between videos. The videos show the actions that subjects should imagine while watching the video.
11076237|NCT04242576|Experimental|Right/Left Judgment Task|"The laterality will be trained with the Recognize® application. Once the subjects have been trained, they are instructed to solve the different sections of the application, starting with the simplest tasks until reaching the most difficult ones.
~These tasks would consist of indicating left or right, among the different images that appear on the iPad screen, indicating if the image's neck is rotated to the left or right. Being every level more complicated, so that people of different skin tones, with clothes or in a work environment are added."
11076238|NCT04242576|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
11076239|NCT04242563|No Intervention|CONTROL GROUP|No virtual reality
11076240|NCT04242563|Experimental|INTERVENTION GROUP|Patient equipped with Virtual reality in transfer room.
11076241|NCT04242550|Experimental|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT with executive function training, enhancing CBT with a focus on teaching compensatory strategies, habit learning, and plan for generalization to real-world behaviors.
11076242|NCT04242550|Active Comparator|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
11076243|NCT04242537|Experimental|High flow oxygen delivery|Oxygen delivery with high flow nasal cannula with head side elevation to 30 degrees
11076244|NCT04242537|Experimental|Low Flow oxygen delivery|Low flow oxygen delivery through nasal cannula with head side elevation to 30 degrees
11076245|NCT04242537|No Intervention|Standard practice of care|No oxygen delivery either high flow or low flow through nasal cannula
11076246|NCT04242524|Experimental|Circadian Clock Alignment - High BMI|Subjects will come to the Sleep Lab three nights before their bariatric surgery procedure for an intervention that will align their central circadian clock. The intervention includes eating meals and snacks at fixed times and having lights off at a specific time at night and lights on at a specific time in the morning.
11076247|NCT04242524|Active Comparator|Circadian Clock Control - High BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
11076248|NCT04242524|Active Comparator|Circadian Clock Control - Low BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
11076249|NCT04242511||Cases|"Tuberculosis patients with diabetes mellitus:
~Subject aged 18 years of age or over
~Written, informed consent obtained.
~New diagnosis of tuberculosis and started on anti-tuberculosis treatment
~Known diagnosis of diabetes or two consecutive raised IFCC HbA1c levels (>= 48 mmol/mol) at the time of TB diagnosis"
11076250|NCT04242511||Controls|"Tuberculosis patients without diabetes mellitus:
~1), 2), 3) as above 4) IFCC HbA1c level < 48mmol/mol 5) Weight matched to cases (+/- 2kg)"
11076251|NCT04242498|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
11076252|NCT04242498|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
11076253|NCT04242498|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
11076254|NCT04242498|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
11076255|NCT04242485|Other|AFTER MATCH + OMT|Players undertook a recording session the day after a rugby match and received osteopathic manipulative treatment
11076256|NCT04242485|Other|AFTER MATCH + sham treatment|Players undertook a recording session the day after a rugby match and received sham treatment
11076257|NCT04242485|Other|NO MATCH + OMT|Players undertook a recording session the day after a resting day and received osteopathic manipulative treatment
11076258|NCT04242485|Other|NO MATCH + sham treatment|Players undertook a recording session the day after a resting day and received sham treatment
11076259|NCT04242472|Experimental|SMS group|Nutrition-related SMS messages in addition to standard of care TB treatment with directly observed therapy
11076260|NCT04242472|No Intervention|Control group|Standard care of TB treatment with directly observed therapy alone
11076285|NCT04242316|Experimental|Mirror Therapy|Patients performed customized bimanual upper limb exercises with a mirror. They can observe the mirror visual feedback of their non-paretic hand during the movements.
11076261|NCT04242459|No Intervention|Feasibility Study|This is a radiotherapy planning study to evaluate the feasibility to acquire longitudinal MRI scans during radiotherapy (prior to the main study) thus, participants will receive standard-of-care chemoradiation therapy (CRT) as per departmental protocol without any treatment adaptation.
11076262|NCT04242459|Experimental|HPV associated OPC Participants|"Participants will be treated initially with the standard radiotherapy dose of:
~65 grays (Gy) in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease
~In the 2nd week and 4th week of treatment, the participants will undergo Adaptive Radiotherapy to account for anatomical changes."
11076263|NCT04242459|Experimental|HPV negative OPC Participants - Radiotherapy dose escalation|"Participants will be treated initially with the standard radiotherapy dose of:
~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease
~After 10 fractions the participants will be stratified into either responders or non-responders categories based on Apparent Diffusion Coefficients (ADC) response at week 2 of CRT.
~Participants classified as responders will complete treatment without any radiotherapy dose changes. Their radiotherapy treatment target volumes will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.
~The non-responders will undergo an increase in dose per fraction to Clinical Target Volume-1 (CTV-1) primary for fractions 11 to 30."
11076264|NCT04242459|Experimental|Base of Skull HNC Participants|"Participants will be treated initially with the standard radiotherapy dose of:
~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.
~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease
~Participants will undergo standard treatment with 3 cycles of induction chemotherapy followed by chemo-radiotherapy dose. Their radiotherapy treatment will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour."
11076265|NCT04242446|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
11076266|NCT04242446|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
11076267|NCT04242446|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
11076268|NCT04242446|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
11076269|NCT04242433||Viremic Person living with HCV|All persons enrolled in the MMPHCRF treatment programme are provided free of charge direct acting antiviral agents and followed up for outcomes.
11076270|NCT04242420|Other|Connexin genotype|
11076271|NCT04242407|Active Comparator|DMTS|DMTS applied to the upper arm
11076272|NCT04242407|Placebo Comparator|Placebo|Placebo system (with no drug) to match DMTS applied to the upper arm
11076273|NCT04242394||Chronic gallbladder diseases|Routine ERCP participants with chronic gallbladder diseases
11076274|NCT04242394||Without Chronic gallbladder disease|Routine ERCP participants without chronic gallbladder diseases
11076275|NCT04242381|Experimental|Group 1: Cold application, Kinesiotaping treatment|"Cold application: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
~Kinesiotaping application: KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)."
11076276|NCT04242381|Experimental|Group 2: Cold application, EX treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
11076277|NCT04242381|Sham Comparator|Group 3: Cold application, sham-KT treatment|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
11076278|NCT04242368|Active Comparator|Isotonic rinse, then hypertonic rinse|Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses isotonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete hypertonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
11076279|NCT04242368|Experimental|Hypertonic rinse, then isotonic rinse|"Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses of hypertonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete isotonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
~Fluticasone propionate nasal spray - two sprays to each nare twice a day used for the entire study duration"
11076280|NCT04242355|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
11076281|NCT04242355|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
11076282|NCT04242342|Experimental|Experimental arm|Patient with a localized primary tumor (hepatocellular carcinoma or cholangiocarcinoma) or a secondary hepatic localization of a solid carcinoma, with one to three hepatic lesions accessible to a treatment by stereotactic radiotherapy.
11076283|NCT04242329|Experimental|PD1-inhibitor + surgery|Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
11076284|NCT04242329|Active Comparator|PD1-inhibitor|Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
11076287|NCT04242303|Experimental|EM Technique|use of extramedullary technique by means of inertial sensors for the execution of femoral cuts
11076288|NCT04242303|Active Comparator|IM Technique|Use of conventional intramedullary technique for the execution of femoral cuts
11076289|NCT04242290||Cervicogenic headache|The group with cervicogenic headaches
11076290|NCT04242290||Neck pain|The group with isolated neck pain
11076291|NCT04242277||WF-OCT imaging of excised breast lumpectomy tissue|Excised lumpectomy tissue from all consented patients will be imaged on an investigational OCT-based device. No clinical decisions will be made based on the images acquired.
11076292|NCT04242264|Experimental|Group 1|Vaccine: 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
11076293|NCT04242264|Experimental|Group 2|Placebo+Vaccine: 30 ml of Placebo administered orally on Day 1 and 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
11076294|NCT04242264|Placebo Comparator|Group 3|Placebo: 30 ml of Placebo administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
11076295|NCT04242251|No Intervention|Usual Care|Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.
11076296|NCT04242251|Experimental|SPARKLE intervention group|Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.
11076297|NCT04242238|Experimental|Advanced High-grade Sarcoma|Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma
11076298|NCT04242212||Clinic-based|Women who get misoprostol from a clinic-based provider
11076299|NCT04242212||PMV-based|Women who get misoprostol from a patent medicine vendor
11076300|NCT04242199|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
11076301|NCT04242199|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
11076302|NCT04242199|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
11076303|NCT04242186|Experimental|Nursing home residents and staff|Nursing home residents at high risk for injurious falls, as well as nursing home staff at participating facilities
11076304|NCT04242173|Experimental|Cemiplimab-rwlc treatment|Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
11076305|NCT04242160|Experimental|Modified Clamshell Thoracotomy First|Participants randomized to perform the MCT first, then cross over to the perform the alternate LAT.
11076306|NCT04242160|Active Comparator|Left Anterolateral Thoracotomy First|Participants randomized to perform the LAT first, then cross over to the perform the alternate MCT.
11076307|NCT04242147|Experimental|Monotherapy|KD033 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W)
11076308|NCT04242134|Experimental|PS-DCB|"For PS-DCB group
~NC balloon dilating ostial side branch (SB) (1:1 ratio).
~DCB dilating SB. Specifically, the DCB, which had to be 2-3 mm longer on each side than the predilatation balloon, was inflated at nominal pressure for 30~ 60 s. The ratio of the DCB diameter to the nominal diameter of the SB was recommended to be between 0.8 and 1.0. DCB should be delivered to the lesion within 2 min after entering human body.
~Kissing inflation using 2 noncomplian balloons.
~Stenting side branch with T and protrusion (TAP) technique if any of the following issues was observed after kissing balloon inflation: >type C dissection or thrombolysis in myocardial infarction (TIMI) flow <3.
~Final kissing inflation and proximal optimal technique (POT)."
11076309|NCT04242134|Active Comparator|PS-NCB|"For PS-NCB group
~NC balloon dilating ostial SB (1:1 ratio).
~Kissing inflation using 2 NC balloons.
~Stenting side branch with TAP technique if any of the following issues was observed after kissing balloon inflation: >type C dissection or thrombolysis in myocardial infarction (TIMI) flow <3.
~Final kissing inflation and proximal optimal technique (POT)."
11076310|NCT04242108||Angle Closure|
11076311|NCT04242108||Open angle|
11076312|NCT04242095||Observational (biospecimen collection, medical record review)|Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
11076313|NCT04242082||patients with psoriasis vulgaris only|
11076314|NCT04242082||patients with psoriasis vulgaris and type 2 diabetes mellitus|
11076315|NCT04242082||healthy control|
11076316|NCT04242069|Experimental|Intervention|Healthy for my Baby Intervention
11076317|NCT04242069|Other|Control|Usual care
11076318|NCT04242056|Other|Using image to diagnosis Multiple sclerosis (MS)|In current study, we will enroll 38 patients with MS and evaluate their clinical severity; measure the WM lesion and disease activity by magnetic resonance imaging (MRI); myelination state and amyloid deposition by amyloid PET scan; tau deposition by state of-art tau PET scan
11076319|NCT04242043||AI|
11076320|NCT04242030|Other|COPD group|"Participants in the COPD group will receive examination of laser doppler flowmetry(LDF).
~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian."
11076321|NCT04242030|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
11076322|NCT04242030|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
11076323|NCT04242017|Active Comparator|salvage RT + 6 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 6 months ADT
11076324|NCT04242017|Experimental|salvage RT + 24 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 24 months ADT
11076325|NCT04242004|Experimental|DHA group|
11076327|NCT04241991|Experimental|Active laser|Each participant will receive the application of the active laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
11076328|NCT04241991|Placebo Comparator|Placebo laser|Each participant will receive the application of the placebo laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
11076329|NCT04241978|Experimental|Intervention group|The participants will complete the baseline assessment and will be asked to read the project information sheet. Then, patients allocated to the intervention group will review the PtDA accompanied by the researcher and will complete the questionnaires assessing the outcome measures, in the same web interface.
11076330|NCT04241978|Active Comparator|Control group|Patients in the control group will follow the same procedure, but they will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
11076331|NCT04241965|Experimental|Intervention 1|Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
11076332|NCT04241965|Placebo Comparator|Placebo|Single dose; potential for a matching OPC-214870 dose to be administered.
11076333|NCT04241952|Experimental|Exercise group|Usual care and bedcycling.
11076334|NCT04241952|No Intervention|Control group|Usual care
11076335|NCT04241939|Experimental|Numberless BDS and Modified-MI|Use of numberless BDS (color coded), app, and motivational interviewing. Participants will weigh daily and receive weekly motivational interviewing at clinic visits and via a weekly phone call.
11076336|NCT04241939|Active Comparator|Digital Scale|Use standard digital scale (number readout). Participants will weigh daily.
11076337|NCT04241913|Experimental|Treatment|The treatment group receives the 10-week, group-based Mom Power intervention; intervention is provided to both mothers and children by trained providers. Treatment delivery will be consistent with the Mom Power manual.
11076338|NCT04241913|No Intervention|Waitlist control|Participants randomized to waitlist control will not receive treatment during the experimental period; they will be offered treatment following completion of post- assessments.
11076339|NCT04241900|Experimental|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
11076340|NCT04241887|Experimental|group PVB|standard analgosedation + paravertebral thoracic blockade with 20 ml 0.25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa warszawa S.A.)
11076341|NCT04241887|Active Comparator|group BB|standard analgosedation + local anesthesia of the skin and subcutaneous tissue with 5ml 0,5% lignocaine (Lignocainum hydrochlorici, WZF 1%).
11076342|NCT04241874|Experimental|Low PEEP and full inspiratory synchronization|PEEP = 5 cmH2O + clinically selected pressure support (PSVclin)
11076343|NCT04241874|Experimental|High PEEP and full inspiratory synchronization|PEEP = 15 cmH2O + clinically selected pressure support (PSVclin)
11076344|NCT04241874|Experimental|Low PEEP and inspiratory desynchronization|PEEP = 5 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
11076345|NCT04241874|Experimental|High PEEP and inspiratory desynchronization|PEEP = 15 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
11076346|NCT04241861|Experimental|High-flow oxygen therapy|Nasal high flow oxygen therapy will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort33. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
11076347|NCT04241861|Experimental|Helmet PSV|"Dedicated helmets for noninvasive ventilation will be used and size will be chosen according to neck circumference or according to manufacturer recommendations.
~Each patient will be connected to a compressed-gas based ventilator through a bitube circuit with no humidification.
~The ventilator will be set in PSV, with the following suggested settings 34-38:
~initial pressure support≥8-10 cmH2O and adequate to permit of a peak in the inspiratory flow of 100 l/min;
~positive end-expiratory pressure=10-12 cmH2O and increased to achieve the oxygenation target according to the choice of the attending physician.
~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
~Inspiratory flow trigger = 1 l/min or according to the practice of each institution;
~fastest pressurization time;
~expiratory trigger: 10-50% of the maximum inspiratory flow;
~maximum inspiratory time 1.2 second."
11076348|NCT04241861|Experimental|Helmet CPAP|"Dedicated helmets for noninvasive ventilation will be uses and size will be chosen according to neck circumference or according to manufacturer recommendations.
~Treatment will be delivered through a high-flow generator. The following settings will be applied:
~Continuous air flow=50-60 L/min.
~Expiratory positive end-expiratory pressure valve set to achieve a PEEP==10-12 cmH2O and eventually increased to achieve the oxygenation target according to the choice of the attending physician.
~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%. Pressure inside the helmet will be monitored with a manometer in order to maintain the set PEEP."
11076349|NCT04241848|Experimental|Powered Orthotic Exoskeleton Training Group|Participant in 36 session ambulation training using a powered orthotic exoskeleton.
11076350|NCT04241848|Active Comparator|Control Group|Participant in 36 session ambulation training without using a powered orthotic exoskeleton.
11076351|NCT04241835|Experimental|Open label Tazemetostat|Single and BID doses of oral tazemetostat 800 mg
11076352|NCT04241822|Experimental|Vestibular exercises combined with cognitive therapy|The intervention is in groups of 8-10 patients. The interventions consists of cognitive therapy, vestibular exercises and body awareness therapy, 8 group sessions
11076353|NCT04241822|Experimental|Exergaming|The intervention is individual and consist of non-immersive virtual reality exercises to improve balance
11076354|NCT04241809||A: Notified TB with sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.
~Repeat bioaerosol sampling will be conducted at 14 days."
11076414|NCT04241315|Experimental|Near-Infrared Imaging group|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
11076355|NCT04241809||B: Notified TB without sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.
~Repeat bioaerosol sampling will be conducted at 14 days."
11076356|NCT04241809||C: Not Notified for TB|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.
~Repeat bioaerosol sampling will be conducted at 14 days."
11076357|NCT04241796|Experimental|Elevated Risk and Non-Elevated Risk Groups|"Two cohorts:
~Elevated risk group (approximately 70% of the total enrollment) on the basis of history of smoking, documented genetic cancer predisposition, or personal history of invasive or hematologic malignancy.
~Non-elevated risk group (approximately 30% of the total enrollment) with none of the conditions listed in the Elevated Risk Group."
11076358|NCT04241757||Patient with indication of ElectroCardioGram (ECG)|Patient with indication of ElectroCardioGram (ECG) will be included. They will have a collection of results ElectroCardioGram (ECG).
11076359|NCT04241744|Active Comparator|vancomycin oral solution|vancomycin oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
11076360|NCT04241744|Placebo Comparator|placebo oral solution|placebo oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
11076361|NCT04241731|Experimental|Raltitrexed Plus Cetuximab|Raltitrexed Plus Cetuximab
11076362|NCT04241718|Other|Single-arm|No comparator, placebo, or randomization
11076363|NCT04241705|Active Comparator|Control arm|The control arm will provide optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services.
11076364|NCT04241705|Active Comparator|Reactive Case Detection (RCD) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive, passively-detected index cases at the health post or health center; individuals who reside within a 100-meter radius of the index case will receive diagnosis for malaria using a conventional RDT. Positive individuals will receive treatment and follow-up as per the national treatment guidelines. 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing. Additional procedures will include the collection of a dried blood spot.
11076365|NCT04241705|Experimental|Targeted Mass Drug Administration (tMDA) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive index cases at the health post or health center, all eligible individuals who reside within a 100-meter radius of the index case will receive presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) (0.25mg/kg daily). 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing.
11076366|NCT04241692|Experimental|Application of Carnation Ambulatory Patch Monitoring System|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
11076367|NCT04241692|Experimental|Application Conventional 24-Hour Holter Monitor Recorder|The patient will wear a Standard Holter Monitor and the CAM Patch system simultaneously for 24 hours.
11076368|NCT04241679|Experimental|Intervention Group|Patients undergoing a translabyrinthine approach for vestibular schwannoma resection will have the health of their auditory nerve monitored during tumor dissection. If the auditory nerve is visually confirmed to be intact, then concurrent cochlear implantation will be performed.
11076369|NCT04241666||normal renal function|individuals with renal clearance >89 ml/min/1.73m²
11076370|NCT04241666||mild renal insufficiency|individuals with renal clearance 60-89 ml/min/1.73m²
11076371|NCT04241666||moderate renal insufficiency|individuals with renal clearance 30-59 ml/min/1.73m²
11076372|NCT04241653|Active Comparator|Spontaneous Ventilation|Patients will spontaneously ventilated. Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
11076373|NCT04241653|Active Comparator|Unparalyzed Controlled Ventilation|Patients will be mechanically ventilated without muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
11076374|NCT04241653|Active Comparator|Paralyzed Controlled Ventilation|Patients will be mechanically ventilated with muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
11076375|NCT04241640|Experimental|Nefopam group[|
11076376|NCT04241640|Placebo Comparator|placebo group|
11076377|NCT04241627|Experimental|Cell Phone Support|An adherence facilitator will deliver Cell Phone Support by daily phone calls Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
11076378|NCT04241627|Experimental|Live Text Support|An adherence facilitator will deliver Live Text Support, Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
11076379|NCT04241627|Active Comparator|Automated Text Reminders|"The comparison condition will include automated text message reminders, using this template: Take [name of medication] at [set time]. To confirm intake, press REPLY, type CARE 1, and press SEND."
11076380|NCT04241614||The First Hospital of Ji Lin University|CT data and corresponding CT raw data of patients with lung nodule will be collected.
11076381|NCT04241601|Active Comparator|low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Active and Placebo doses appearing identical at point of issue and administration.
11076382|NCT04241601|Placebo Comparator|Placebo|Commercially available dextrose 5% injection with a UK marketing authorisation at equivalent dose volume will be used for the placebo formulation. Placebo and Active doses appearing identical at point of issue and administration.
11076383|NCT04241588||3D prostheses users|Children with unilateral congenital upper-limb reductions
11076384|NCT04241588||Typically Developing Children|Age- and sex-matched control group of typically developing children.
11076411|NCT04241354|Experimental|Intra- and extra- articular LP-PRP Injection|A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.
11076412|NCT04241341|Experimental|axillary lymph node dissection with ILR|
11076385|NCT04241575|Experimental|Intervention group|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:
~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.
~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
11076386|NCT04241575|No Intervention|Control group|Patients in the control group will undergo the same assessments as patients in the intervention group. Although physicians will have access to the raw liver biochemistry results and platelet count, the fibrosis score results will not be specifically shown, and there will be no electronic reminder messages regardless of the fibrosis scores. This is to mimic usual care when there is no dedicated care model for case identification.
11076387|NCT04241549|Experimental|Part 1 (Dose Finding): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
11076388|NCT04241549|Experimental|Part 2 (Dose Expansion): Cusatuzumab + Azacitidine|Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.
11076389|NCT04241536|Other|No arm|This is an epidemiologic study. No arms are considered.
11076390|NCT04241523|Experimental|Treatment|The patients will receive lenvatinib treatment and will be evaluated for the feasibility of liver resection every 8 weeks. For those who underwent liver resection, they will receive lenvatinib treatment for another 48 weeks. In case of tumor recurrence, intolerance, death, or need for other antitumor treatment, the treatment shall be stopped.
11076391|NCT04241510|Active Comparator|Facilitation Tape|Diaphragm and Intercostal muscles will be taped with facilitation technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
11076392|NCT04241510|Active Comparator|Mechanical Correction Tape|Thorax will be taped with mechanical correction technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
11076393|NCT04241510|No Intervention|No Tape|Patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea with no tape.
11076394|NCT04241497|Experimental|Patients with Pulmonary Arterial Hypertension|12 weeks home-based rehabilitation
11076395|NCT04241484|Experimental|Piezowave|"Initiation of Piezowave MyACT treatment to include parameters from the user manual
~Set for frequency of five pulses per second
~Delivery of 500 to 1000 pulses over multiple injured area sites, not to exceed 4000 pulses per session
~Intensity ranging from 0.1 to 18 millijoule per square millimeter. This intensity if energy flux as the rate of transfer of the energy through the surface of the tissue is applied.
~Focal transducer
~Head size will be variable based on depth of tissue treated. The user manual will be consulted for depth of penetration recommendations"
11076396|NCT04241471|Active Comparator|traditional incision and drainage (I&D)|
11076397|NCT04241471|Experimental|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
11076398|NCT04241458|Experimental|BI 706321|
11076399|NCT04241458|Placebo Comparator|Placebo|
11076400|NCT04241445||novice observers|who have practiced GMA sporadically (def.: < = 2 GMA/week for < = 2 years), have limited experience, and do not use GMA in clinical settings
11076401|NCT04241445||GMA experts|GMA tutors and individuals who have applied GMA regularly (def.: > 2 GMA/week for > 2 years)
11076402|NCT04241432|Active Comparator|Platform type 1|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
11076403|NCT04241432|Active Comparator|Platform type 2|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
11076404|NCT04241419|Experimental|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
11076405|NCT04241406|Experimental|transcutaneous spinal cord stimulation|"Transcutaneous application of electrical (biphasic current, 1ms, 30Hz) stimulation over the back for a 10 minutes session.The intensity of the current will increase until motor reflex threshold. If it will not possible, intensity will be increase until participants report a strong but comfortable sensation.
~Transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
11076406|NCT04241406|Experimental|sham stimulation|"Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequently.
~Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
11076407|NCT04241393|Experimental|Tavapadon|
11076408|NCT04241380|Active Comparator|Conventional treatment group|Patients in this group will received conventional treatments. Drug: None. Drug: For the high-risk patients, doctors will assess their risk factors and choose continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) if needed. Aspirin 5 mg/kg may be given every eight hours subsequently for 3 months.
11076409|NCT04241380|Experimental|Anti-coagulant treatment|Continuous infusion heparin. Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5mg/kg will be given every eight hours subsequently for three months. Study will follow the intention-to-treat principle.
11076410|NCT04241354|Active Comparator|Intra-articular LP-PRP Injection|A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.
11076415|NCT04241315|Other|No Imaging Group|All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
11076416|NCT04241302|Active Comparator|Free Field Voice test|The examiner will inform the patient to repeat a sequence of Spondee words or a combination of numbers and letters whispered by the examiner initially. The examiner will be standing at the same distances as in the FFCT examination (starting with 2 feet). If the patient fails to hear the whispered voice at 2 feet, the examiner increases the loudness of voice to conversational tone at the same distance. The test is repeated thrice each time with a different set of Spondee words to avoid the patients recognizing the same sequence. If the patient is unable to respond, the examiner moves closer to 6 inches and whispers to the patient, and if no further response, then, conversational voice is used. The patient's free-field threshold is the voice and distance level at which more than 50% correct is obtained.
11076417|NCT04241302|Experimental|Free Field Click Test|The app is designed by our team by a broadband (500-3000 Hz) click sound of 30-40 dB for soft sound/whisper and 60-70dB for loud sound/conversation voice. This app is designed by the Flutter-Dart programming tool and the speaker is produced via hand-held devices of Apple and Android brands. The tone is produced 3 times, with 2 out of 3 answers are considered as the patient's hearing threshold. The examiner stands at the distance of 2 feet away behind the seated patient and a soft sound from the FFCT is tested. The patient is then asked to respond yes or to nod if able to hear the sound. When the patient is unable to answer or no response is received upon thrice testing, the examiner then moves closer to 6 inches to the patient and again the soft sound is tested thrice. Loud sound is then tested if the patient is unable to respond, starting from 2 feet distance for three times. And then, the loud sound is tested at 6 inches of distance if no further response is obtained.
11076418|NCT04241276|Active Comparator|Gemcitabine + nab-paclitaxel|Patients will receive Gemcitabine and nab-Paclitaxel in 28 day cycles until disease progression.
11076419|NCT04241276|Experimental|Gemcitabine + nab-paclitaxel + ATRA|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
11076420|NCT04241263|Other|Comparative assessment of data quality|Quantitative comparison between the current wired system and the new wireless system
11076421|NCT04241263|Other|Usability|Qualitative assessment of the new wireless system
11076422|NCT04241250|Experimental|EAW+SCES|Three months of exoskeleton training followed by 6 months of epidural stimulation.
11076423|NCT04241250|Experimental|EAW+TS|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
11076424|NCT04241237||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
11076425|NCT04241224|Experimental|Excimer Laser Photoablation|"Device: DABRA Laser System
~Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System."
11076426|NCT04241211|Active Comparator|Control group|
11076427|NCT04241211|Experimental|TP group|
11076428|NCT04241185|Experimental|Pembrolizumab + Chemotherapy + Radiotherapy|Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
11076429|NCT04241185|Placebo Comparator|Placebo + Chemotherapy + Radiotherapy|Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
11076430|NCT04241172|Experimental|Immersive Virtual Reality (HIVR)|"The HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:
~Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;
~Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving visual and auditory biofeedback."
11076431|NCT04241172|Active Comparator|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:
~exercises with patients sitting on the swimming pool edge with lower limb immersed in the water;
~flexion-extension of the knee;
~leg and hip circling;
~flexion-extension of the ankle;
~triple flexion;
~water walking exercises."
11076432|NCT04241172|Active Comparator|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:
~exercises with a patient sitting on a chair (3 minutes per exercise):
~flexion-extension of the knee;
~leg and hip circling;
~flexion-extension of the ankle;
~triple flexion;
~walking (with and without aids)."
11076433|NCT04241159|Experimental|Geriatric participants with frailty|"Geriatric participants aged 65-80 who have a diagnosis of frailty (Fried Frailty score of 3 or greater).
~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
11076434|NCT04241159|Experimental|Geriatric participants with HFpEF|"Geriatric participants aged 65-80 who have a diagnosis of HFpEF.
~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
11076435|NCT04241146|Active Comparator|Standard Blind Technique of Tube placement|FDA approved technique of enteral nutrition tube placement
11076436|NCT04241146|Active Comparator|CORTRAK enteral access system (CEAS) placement|An electromagnetic device used to enable enteral nutrition tube placement
11076504|NCT04240626|Experimental|Multi-Modal|Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.
11076437|NCT04241133|Experimental|Experimental Group|A 12 week pilot trial will be conducted at two rural food pantries in Montana with 40 low-income adults to measure within-participant changes over time. The study will provide the initial investigation of the extent to which UP3 will improve overall dietary quality as measured by the Healthy Eating Index-2015 (HEI) compared to baseline. Psychosocial factors will be measured to understand changes in knowledge, attitudes, and perceptions about processed foods. Data on biomarkers of health (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to assess the feasibility of measuring potential short-term health effects of UP3.
11076438|NCT04241133|No Intervention|Control Group|20 separate participants from a different food pantry will be enrolled into a control group. The control group will be assessed at baseline and 12 weeks for dietary intake, height, weight, waist circumference, food security, demographics, and psychosocial factors.
11076439|NCT04241120|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
11076440|NCT04241120|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
11076441|NCT04241107|Active Comparator|Laparoscopic approach group(A)|Uterine niche will be repaired through Laparoscopic approach.
11076442|NCT04241107|Active Comparator|Transvaginal approach group(B)|Uterine niche will be repaired through Transvaginal approach.
11076443|NCT04241094|Experimental|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
11076444|NCT04241081|No Intervention|Control group-no exercise|A no-exercise control. Must maintain <4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
11076445|NCT04241081|Experimental|Exercise intervention 1|Two consecutive days of <4,500 steps per day followed by an intervention day on day 3. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 2 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
11076446|NCT04241081|Experimental|Exercise intervention 2|Two consecutive days of <4,500 steps per day followed by an intervention day. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 6 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
11076447|NCT04241068|Experimental|Aducanumab|Participants will be administered 10mg/kg aducanumab by intravenous (IV) infusions every four weeks for a total duration of 100 weeks.
11076448|NCT04241055|Active Comparator|Control|"The control condition of a standard values affirmation intervention"
11076449|NCT04241055|Experimental|Values affirmation|"The treatment condition of a standard values affirmation intervention"
11076450|NCT04241042||Down syndrome volunteers|Males and females from 16 to 35 years
11076451|NCT04241042||Healthy volunteers|Males and females from 18 to 35 years
11076452|NCT04241029|Experimental|Intervention with probiotics|Intervention with the probiotic compound IDOFORM®Travel. The patient will receive four capsules orally every 24 hour (12*10^9 cfu/day) for eight weeks as adjuvant therapy to his/her anti-TNF treatment. The intervention arm will at the end of intervention serve as their own controls compared to baseline data (before intervention).
11076453|NCT04241016|Active Comparator|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery. Postoperative treatment consists of daily nasal douching, daily nasal steroid sprays, pain medication when necessary and at least one postoperative control visit including endoscopy two weeks after the operation. Additionally medical treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
11076454|NCT04241016|No Intervention|Control|Conservative treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
11076455|NCT04241003|Experimental|SmartDrive - baseline and intervention|One arm for all users. Baseline - two weeks data collection documenting usage of wheelchair prior to intervention. Introduction of SmartDrive, a time period to get used to the SmartDrive and then two weeks data collection documenting usage of wheelchair with the intervention.
11076456|NCT04240990|Experimental|Prospective cohort|Children included in the cohort will all be in the same arm. The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.
11076457|NCT04240977|Experimental|Treatment Group|
11076458|NCT04240964||Dd group|Patients with diabetic foot osteomyelitis
11076459|NCT04240964||ND group|Foot osteomyelitis without diabetes
11076460|NCT04240951|Other|Study Session 1|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the laboratory
11076461|NCT04240951|Other|Study Session 2 (repeat of Study Session 1)|Arm Type: Validation: Regional sweat collection with prototype vs. reference patch in the laboratory
11076462|NCT04240951|Other|Study Session 3|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
11076463|NCT04240951|Other|Study Session 4 (repeat of Study Session 3)|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
11076464|NCT04240951|Other|Study Session 5|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
11076465|NCT04240951|Other|Study Session 6 (repeat of Study Session 5)|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
11076466|NCT04240938|Other|Lacrimal sac mucocele|Adult patients with lacrimal sac mucocele
11076467|NCT04240925|Experimental|Standard NIMV protocol with sigh breaths|
11076468|NCT04240925|Active Comparator|Standard NIMV protocol without sigh breaths|
11076469|NCT04240899|Experimental|Tele-yoga|This is a single group study, therefore all subjects will be included in this single arm and will undergo the same telerehabilitation yoga intervention delivered through videoconferencing.
11076470|NCT04240886|Experimental|fosmanogepix (APX001)|
11076471|NCT04240873|Experimental|MASTER cell|Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis
11076472|NCT04240873|Placebo Comparator|Saline|Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis
11076473|NCT04240860|Experimental|platelet rich plasma preparation|"About 15 ml of autologous blood from the patient was collected slowly in 20 ml syringe containing 1.5 ml anticoagulant citrate dextrose solution A (ACDA) under complete aseptic precautions.
~2- Blood was mixed by swinging the syringe slowly. 3- By using 18G needle, the gathered blood was transfused into tube maintaining a slope of 45°.
~4- The centrifugation step was then done by using non digital angle type centrifuge :the tube was put with water tube on the opposite side to achieve centrifuge balance.
~5- The centrifugation occurred in one step by power 3600 RPM for 6 minutes. 6- The buffy coat was elevated up to the buffy coat line (Figure 1). 7- the buffy coat (2-3 ml PRP) was extracted from slim neck by tornado technique so that sunk platelets can be floated and drawn easily.
~8- the remaining platelet poor plasma(PPP) was drawn using 5 cc syringe. then inserted by ovum pick up needle into subendometrium"
11076474|NCT04240860|Active Comparator|endometrial scratch|using scissor of hysteroscopr 3 snips was done in the fundus
11076475|NCT04240847|Active Comparator|Midline incision|Skin incision at the midline, 1 cm medial to tibial tubercle
11076476|NCT04240847|Experimental|Lateral incision|Skin incision at 1 cm lateral to tibial tubercle
11076477|NCT04240834|Experimental|LD group|Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months
11076478|NCT04240834|Active Comparator|Control group|Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months
11076479|NCT04240821|Experimental|Open-label theophylline|Oral theophylline - either once daily capsule or q6h elixir.
11076480|NCT04240808|Experimental|UCD19 CAR T Cells|Participants will receive lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector [LV] Transduced Autologous Peripheral Blood Lymphocytes
11076481|NCT04240795|Experimental|Low lubricity (LL) hydrogels containing fibre-based beads|"Participants are given a preload of 30 g of low lubricity hydrogels (alginate beads in kappa-carrageenan hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
11076482|NCT04240795|Active Comparator|High lubricity (HL) hydrogels containing no fibre-based beads|"Participants are given a preload of 30 g of high lubricity hydrogels (no beads in kappa-carrageenan and alginate mixed hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
11076483|NCT04240795|Placebo Comparator|Water|"The water containing the same watermelon flavor, color and sweetness was given as control to match the gels. Participants receive the same amount of water like hydrogels - 30 g after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
11076484|NCT04240782|Experimental|Education with Produce Allocations|Participants will attend nutrition education and hands-on cooking classes with weekly produce allocations from a local farm.
11076485|NCT04240782|Experimental|Education only|Participants will attend nutrition education and hands-on cooking classes (with produce coupons provided after intervention).
11076486|NCT04240782|No Intervention|Control group|Participants will receive a delayed intervention once the study period is over.
11076487|NCT04240769||Knee Arthroplasty Patient|Patients undergoing primary total or unicompartmental knee arthroplasty for treatment of end-stage osteoarthritis.
11076488|NCT04240756|Experimental|Parent Stimulant Medication + Child Treatment Strategy|Parent stimulant medication first followed by a child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired.
11076489|NCT04240756|Active Comparator|Child Treatment Strategy|Child treatment strategy consisting of behavioral parent training followed by a recommendation for child stimulant medication to the primary care provider if the child remains impaired. In this arm, parents do not receive stimulant medication before behavioral parent training.
11076490|NCT04240743|Active Comparator|cephalomedullary nail|Cephalomedullary nails was inserted and fixed to the femoral head. In this study, all patients were treated with short nails (Profin®, TST).
11076491|NCT04240743|Active Comparator|sliding hip screw|Sliding hip screws was inserted and fixed to the femoral head. In this study, all patients were treated with a side plate with three holes (DHS plate, TST).
11076492|NCT04240730||extremely obese patients with early-stage endometrial cancer|
11076493|NCT04240717|Experimental|Patient Decision Aid|Patients review an interactive, web-based Patient Decision Aid regarding their treatment options. Afterwards they receive medical consultation.
11076494|NCT04240717|No Intervention|Treatment As Usual|Patients receive medical consultation.
11076495|NCT04240704|Experimental|JBH492 single agent|
11076496|NCT04240691||60-Minutes-For-Health|60-Minutes-for Health: this is a psychological intervention which seeks to correct factors underlying decisions to delay or avoid HIV care and strengthen abilities to overcome HIV care utilization barriers. This is achieved through assistance identifying and reducing misinformation guiding HIV care attendance decisions; enhancing motivation to maintain HIV care via personal health goals; building skills for coping with negative feelings related to living with HIV; and increasing self-efficacy for navigating structural barriers and maintaining HIV care amidst competing priorities.
11076497|NCT04240691||Time-and-Attention Control Session|60 Minute diet & nutrition control session
11076498|NCT04240678|Experimental|HBV Alert Group|
11076499|NCT04240678|No Intervention|Control Group|
11076500|NCT04240665|Experimental|DMN Intervention|Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
11076501|NCT04240652||Subjects with fundus photography|Subjects diagnosed with diabetes or not who have fundus images from MMCs and other medical institutes.
11076502|NCT04240639|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to MRI/US guided laser irradiation using an FDA cleared laser and an interstitial optical fiber diffuser.
11076503|NCT04240626|Active Comparator|Standard of Care|The group will receive the standard of care pain control protocol after index Bariatric Surgery which includes the use of a PCA (patient controlled analgesia) with Dilaudid or Morphine Sulphate, transitioning to oral narcotic based pain control medications.
11076505|NCT04240613|Other|women treated by TVT-O|All women treated by TVT-O during the years this study was made were included.
11076506|NCT04240600|Experimental|Hyperproteic, hypercaloric formula|Each patient will receive 2 bottles per day of Supportan DKN during the hospital stay (nutritional contribution: 600 kcal and 40 g of protein).
11076507|NCT04240600|Active Comparator|Standard formula|Each patient will receive 2 cans or bottles per day of Fresubin® Original DRINK (nutritional contribution: 474.2 kcal and 17.6 g of protein).
11076508|NCT04240587|Active Comparator|TrueTear™ intranasal neurostimulator (ITN) Active Arm|TrueTear™ intranasal neurostimulator (ITN) with active tips - The tips carry the current from the base to the nasociliary nerve.
11076509|NCT04240587|Placebo Comparator|TrueTear™ intranasal neurostimulator (ITN) Placebo/Sham Arm|"TrueTear™ intranasal neurostimulator (ITN) with sham tips - The sham tips and do not properly carry the current."
11076510|NCT04240574|Other|Micro Water Jet Technology (Debritom)|"Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
~All subject will get the Debritom."
11076511|NCT04240561|Experimental|Hearing Aid Fitting Order A|Participants wear hearing aids with a high level of signal manipulation, followed by a low level of signal manipulation
11076512|NCT04240561|Experimental|Hearing Aid Fitting Order B|Participants wear hearing aids with a low level of signal manipulation, followed by a high level of signal manipulation
11076513|NCT04240548|Experimental|Arm: A|regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation
11076514|NCT04240548|No Intervention|Arm: B|chest wall or whole breast only irradiation
11076515|NCT04240535|Experimental|Active- onabotulinumtoxinA|BOTOX Cosmetic (onabotulinumtoxinA) for injection, is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A intended for intramuscular use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The complex is dissolved in sterile sodium chloride solution containing Albumin Human and is sterile filtered (0.2 microns) prior to filling and vacuum-drying.
11076516|NCT04240535|Placebo Comparator|Placebo-Bacteriostatic 0.9% Sodium Chloride|Placebo subjects will have injections in the same manner, but will be injected with Bacteriostatic 0.9% Sodium Chloride.
11076517|NCT04240496|Other|Schizophrenic patients|"Determination of trough plasma concentration of clozapine (C0)
~Genotyping of CYP1A2 & CYP2C19 Drug: Leponex (Clozapine) : was started at a dose of 25 mg/j, the dose was gradually increased and was administered in one, two or three divided doses."
11076518|NCT04240483|Experimental|Intracutaneous sterile water injections (ISWI) group|
11076519|NCT04240483|Sham Comparator|Intracutaneous dry injections (IDI) group|
11076520|NCT04240470|Experimental|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
11076521|NCT04240457|Experimental|Pulsed, accelerated|18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
11076522|NCT04240457|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination.
11076523|NCT04240444|Experimental|SeQuent® SCB|patients will receive sirolimus (rapamycin)-coated balloon (SeQuent® SCB)
11076524|NCT04240444|Active Comparator|SeQuent® Please Neo|patients will receive SeQuent® Please Neo balloon
11076525|NCT04240431||Epiphora|Adult patients suffering from watering of the eye included in the study to detect level of obstruction
11076526|NCT04240418||Lyon University Hospital employees|
11076527|NCT04240405||Elderly people without cognitive impairment|
11076528|NCT04240405||Amnestic type mild cognitive impairment patients (aMCI)|
11076529|NCT04240405||Dysexecutive type mild cognitive impairment patients (dMCI)|
11076530|NCT04240392|Experimental|Collaborative Care (CC)|The CC team includes an obstetrical provider and a nursing case manager. The obstetrician will see all participants, initially to discuss preferences for addiction treatment, buprenorphine, methadone (MAT) or no MAT. The obstetrician will see participants every 1-2 weeks, as needed and will provide prenatal care. The care team will meet at least monthly and review the participants' status. For research purposes, the CM will obtain informed consent, collect and enter results of the urine drug screen (UDS) into a database. At enrollment and at 26 and 34 weeks' gestation the care manager will ask participants to complete an assessment battery of self-reported measures.
11076531|NCT04240392|Active Comparator|Extension for Community Healthcare Outcomes (ECHO)|ECHO is a remote education model that provides mentorship and guided practice and participation in a learning community, via video conferencing. The practice members who participate in ECHO will include obstetricians and nurses as well as other members of the care team who wish to join. Providers are given access to a password-protected website containing the recorded sessions, a discussion board, and resource library. CME credits are available for each session and can motivate providers to attend.
11076532|NCT04240366|Other|Group 1|Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone
11076533|NCT04240366|Experimental|Group 2|Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation
11076534|NCT04240353||COPD group|Patients with high-risk COPD receiving guideline-based COPD care, support for COPD self-management and support of the use of home NIV treatment via regular engagement with a digital health service model
11076535|NCT04240327||GG2+ Prostate Cancer Risk|Participants at risk for Grade Group 2 (GG2+) prostate cancer. Participants will be followed for up to two years to rule out the presence of GG2+ prostate cancer
11076536|NCT04240314|Experimental|Cohort 1 (Minimal Efficacious Dose)|The Minimal Effective Dose (MED) will be delivered.
11076537|NCT04240288|Other|Control Arm|Participants randomized to the control arm will be managed with the current standard of care including daily white blood cell count and vital sign documentation. The control group will also have daily procalcitonin levels drawn but the results will not be used to make decisions regarding antibiotic duration. Antibiotics will be given orally or intravenously at the discretion of the treating physician and will be given for a 10-day course, the current standard of care.
11076615|NCT04239677|Experimental|RAP|Retrograde autologous priming
11076616|NCT04239664|Experimental|Acceptance Based Telephone Support (ABS+UC)|One face-to-face session to be informed of the group they have been randomised into and Acceptance Based Support, followed by five 30-minute telephone sessions of Acceptance Based Support. Usual care continues as normal.
11116734|NCT03957902|Experimental|Arm 3 (100 mg/12h)|
11116735|NCT03957889||Student|
11076538|NCT04240288|Experimental|Treatment Arm|These participants will be managed with procalcitonin-guided antibiotic therapy. An index procalcitonin will be drawn within 24 hours of admission followed by daily procalcitonin levels. Per standard of care, patients will have daily white blood cell counts drawn and regular vital sign documentation. Antibiotics will be given orally or intravenously at the discretion of the treating physician. Antibiotics in this arm will be stopped once the procalcitonin value drops to ≤80% of its index value or to <0.5 ng/ml. Extension of antibiotics for more than 24 hours past this time will be documented.
11076539|NCT04240275||Children with Cerebral Palsy|Children diagnosed with Spastic Cerebral Palsy (Unilateral or Bilateral) among the age range of 5-15 who can walk independently
11076540|NCT04240249|Experimental|Constructive self-assertiveness with guidance|10 weeks of internet-based treatment with weekly assignments. The homework is commented on by the guide using electronic communication.
11076541|NCT04240249|Experimental|Constructive self-assertiveness without guidance|10 weeks of internet-based treatment with weekly assignments. The homework is NOT commented on by any guide. Hence, same treatment as group 1 but without guidance.
11076542|NCT04240249|No Intervention|Waitlist control|No treatment, no guidance, just waiting for 10 weeks. After the ten weeks the participants will receive the treatment.
11076543|NCT04240236|Experimental|Group S|Group S received scalp block with 20 ml of 0.5% bupivacaine
11076544|NCT04240236|Placebo Comparator|Group C|Group C will not have any intervention
11076545|NCT04240223|Experimental|50 mg Brilacidin tablet|
11076546|NCT04240223|Experimental|100 mg Brilacidin tablet|
11076547|NCT04240223|Experimental|200 mg Brilacidin (2 x 100 mg Brilacidin tablets)|
11076548|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 50 mg tablet)|
11076549|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 100 mg tablet)|
11076550|NCT04240223|Placebo Comparator|Placebo (2 x replica of shape/size of 100 mg tablets)|
11076551|NCT04240210|No Intervention|To assess degree of adherence to ART in a real world seeting.|Part I of the study is a Cohort Survey of HIV+ outpatient clinic patients currently receiving ART to assess medication adherence and tolerability by determining a change in adherence and tolerability from baseline to 4 months, measured by standardized patient reported outcome and adherence surveys
11076552|NCT04240210|Experimental|Potential changes in ART adherence when switced to Symtuza.|Part 2 of the study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
11076553|NCT04240197|Sham Comparator|Standard Pressure Transducer|Epidural pressure waveforms will be measured by using a standard invasive monitor pressure transducer
11076554|NCT04240197|Active Comparator|CompuFlo|Epidural pressure waveforms will be measured by using the CompuFlo Instrument
11076555|NCT04240171||dapagliflozin|Group 1(n=30): are the patients who are prescribed dapagliflozin to control their blood sugar level.
11076556|NCT04240171||glimepiride|Group 2 (n=30): are the patients who are prescribed glimepiride
11076557|NCT04240158|Experimental|IW-6463|IW-6463 tablets administered orally
11076558|NCT04240158|Placebo Comparator|Placebo|Matching placebo tablets administered orally
11076559|NCT04240132|Experimental|Adherence to hand hygene|The face-to-face interview will be held in an appropriate empty room in the intensive care unit (ICU) in a time schedule suitable for the healthcare workers. The researchers will provide training to healthcare workers working in the ICU in accordance with the World Helath Organization (WHO) Hand Hygiene Guidelines. One day training on nursing interventions related to enteral feeding treatment will be provided to nurses and their questions will be answered. At the end of the each training, trainees will be given a data collection form to assess the effectiveness of the training.
11076560|NCT04240106|Experimental|Niraparib 100mg in combination with Aromatase Inhibitors|Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
11076561|NCT04240093|Experimental|Experimental|Experimental: Behavioral Activation (8 sessions) + Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
11076562|NCT04240093|Active Comparator|Standard of Care|Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
11076563|NCT04240080|No Intervention|Control Goup|Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping
11076564|NCT04240080|Experimental|Intervention Group|Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder
11076565|NCT04240067||Acute Heart Failure|
11076566|NCT04240067||No Acute Heart Failure|
11076567|NCT04240054|Experimental|Safety Lead-in Cohort A|"Six transplant-eligible multiple myeloma patients with renal impairment will be enrolled.
~Bortezomib (1.5 mg/m^2) subcutaneous on days 1,8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
11076568|NCT04240054|Experimental|Expansion Cohort A|"15 transplant-eligible multiple myeloma patients with renal impairment will be enrolled.
~Bortezomib (1.5 mg/m^2)subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
11076569|NCT04240054|Experimental|Expansion Cohort B|"20 transplant-eligible non-renal impairment multiple myeloma patients will be enrolled.
~Bortezomib (1.5 mg/m^2) subcutaneous on days 1, 8 and 15 Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22 Cyclophosphamide (250 mg/m^2) IV on days 1, 8 and 15 Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9,15,16, 22 and 23"
11076570|NCT04240041||Pregnant women at 32-36 weeks gestational age|Pregnant women at 32-36 weeks gestational age with sure dates and crown-rump length dating ultrasound
11076617|NCT04239664|No Intervention|Usual Care (Control Group) (UC)|One face to face session to be informed of the group they have been randomised into and encouraged to ask any questions, and will be informed they will be contacted again in 8 weeks. Usual care continues as normal.
11076685|NCT04239209|Active Comparator|Redirection|Redirection to a conversation about the values of the patient and possible future decisions.
11116736|NCT03957889||Trainers|
11076571|NCT04240028||Individuals with prefrailty|"This is defined as a co-existing prefrailty using the Fried criteria. Frailty defined by the CHS index as proposed by Fried et al. will be identified by the presence of ≥ 3 of the following 5 components: 1) Shrinking as identified by an unintentional weight loss of ≥ 5% between two assessments, 2) Weakness as identified by a maximal grip strength in the lowest quintile stratified by body mass index quartile; 3) Poor energy as identified by an answer of no to the question Do you feel full of energy? from the 30-item Geriatric Depression Scale; 4) Slowness as identified by an average walk speed in the lowest quintile stratified by median standing height, and 5) Low physical activity level as identified by a PASE score in the lowest quintile. Participants with none of the above components will be considered to be vigorous and those with 1 or 2 components will be considered to be in a prefrail stage."
11076572|NCT04240028||Individuals with cognitive-prefrailty|"A combination of prefrailty stage using Fried criteria and subjective cognitive impairment (SCI).
~The IANA/IAGG consensus defines cognitive frailty as CDR = 0.5 and frailty by the Fried criteria.SCI will be defined using a proxy for subjective cognitive complaint (i.e. memory complaint) and following the procedure used in previous multicenter prevalence studies on MCR syndrome. Memory complaint used to define MCR syndrome was based on standardized memory loss question on the 15-item or 30-item Geriatric Depression Scale (GDS; Do you feel you have more problems with memory than most?). Memory complaint in our study will be elicited from this item of 30-item GDS."
11076573|NCT04240028||Individuals with MCR|The diagnosis of MCR syndrome will be made following the criteria of Verghese et al. 5: a combination of subjective cognitive complaint, in particular of memory complaint, with the presence of an objective slow gait and the absence of dementia or mobility disability. MCR syndrome will be defined at baseline assessment and each year of follow-up period. Slow gait speed will be defined as gait speed that is one standard deviation (SD) or more below age-and sex-appropriate mean values established in the present cohort like in previous studies. The mean value and SD of female and male will be determined separately. Gait speed was determined from the 3-meter walking test using the best time of the two trials recorded and expressed as meters per second.
11076574|NCT04240015||Periodontitis|Periodontitis group consisted of patients diagnosed with periodontitis
11076575|NCT04240015||Patients without periodontitis|Patients without periodontitis group constituted patients without periodontitis
11076576|NCT04240002|Experimental|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
11076577|NCT04240002|Experimental|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
11076578|NCT04240002|Experimental|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
11076579|NCT04240002|Experimental|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
11076580|NCT04239989|Experimental|Treatment (itacitinib)|Patents receive itacitinib PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity.
11076581|NCT04239976|Experimental|Supportive Care (scrambler therapy, sensory test, gait test)|Patients undergo scrambler therapy over 30-45 minutes QD Monday-Friday for 2 weeks. Patients also undergo a quantitative sensory test and a gait assessment test using a FitBit before receiving scrambler therapy, at the end of the first and second weeks of scrambler therapy, and 1 month after the last day of scrambler therapy.
11076582|NCT04239963||Healthy Controls|Subjects who have no history of clinical depression or other psychological disorder
11076583|NCT04239963||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
11076584|NCT04239950|Placebo Comparator|Placebo|Placebo, orally, twice daily after breakfast and dinner for 12 weeks.
11076585|NCT04239950|Experimental|Ethyl Icosapentate 1.8g|Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.
11076586|NCT04239950|Experimental|Ethyl Icosapentate 3.6g|Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.
11076587|NCT04239924|Experimental|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program
11076588|NCT04239911|Active Comparator|Enhanced usual care|Home health aides in the enhanced usual care arm will receive a heart failure training course .
11076589|NCT04239911|Experimental|Intervention arm|Home health aides in the intervention arm will receive a heart failure training course and an electronic tablet.
11076590|NCT04239898|Experimental|Red cabbage microgreens|2 cups of fresh red cabbage microgreens per day
11076591|NCT04239898|Experimental|Red beet microgreens|2 cups of fresh red beet microgreens per day
11076592|NCT04239872|Experimental|Participants with normal to dry mouth|"Participants with normal to dry mouth will be treated, in a crossover design, with two interventions: a fluoride mouthwash alone, or a fluoride mouthwash preceded by a calcium mouthwash.
~Participants will be randomized to determine which intervention they will use in the first experimental phase; the other intervention will the tested in the second phase."
11076648|NCT04239404||PMI|
11076649|NCT04239404||non-PMI|
11076593|NCT04239859|Experimental|Secukinumab|"Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.
~secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care."
11076594|NCT04239859|Active Comparator|Standard Care|"The management of PsO in the control arm will be the same as that in the standard care.
~The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A."
11076595|NCT04239846|Experimental|AC-701|AC-701 Topical Gel 0.3%
11076596|NCT04239846|Placebo Comparator|Placebo|Placebo Gel
11076597|NCT04239833|Experimental|SH-1028 tablets+Placebo Gefitinib|"SH-1028 tablets (200 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
~Interventions:
~Drug: SH-1028 tablets 200 mg Drug: Placebo Gefitinib 250 mg"
11076598|NCT04239833|Active Comparator|Gefitinib+Placebo SH-1028 tablets|"Gefitinib (250 mg orally, once daily) plus placebo SH-1028 tablets (200mg orally, once daily), in accordance with the randomisation schedule.
~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).
~Interventions:
~Drug: Gefitinib 250 mg Drug: Placebo SH-1028 tablets 200mg"
11076599|NCT04239820||RRMS patients initiating cladribine|Patients will be imaged using PET and MRI at baseline prior the cladribine treatment initiation and 18 months after baseline
11076600|NCT04239807|Experimental|Group 1 WBV - training with wbv|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera
~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).
~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training
~Month 1:
~Day 1: From this day subjects are supposed to start their training accoridng to protocol
~Day 2: Telephone Visit
~Day 5: Telephone Visit
~Day 7: Telephone Visit
~Day 10: Telephone Visit
~Day 13: Telephone Visit
~Day 20: Telephone Visit
~Day 27: Telephone Visit
~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training
~Month 2:
~Week 5, Day 34:
~Week 6, Day 41:
~Week 7, Day 48:
~Week 8, Day 55:
~Month 3:
~Week 9, Day 62:
~Week 10, Day 69:
~Week 11, Day 76:
~Week 12, Day 83: Final Visit"
11076601|NCT04239807|Other|Group 2 Control - training without WBV|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera
~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).
~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training
~Month 1:
~Day 1: From this day subjects are supposed to start their training accoridng to protocol
~Day 2: Telephone Visit
~Day 5: Telephone Visit
~Day 7: Telephone Visit
~Day 10: Telephone Visit
~Day 13: Telephone Visit
~Day 20: Telephone Visit
~Day 27: Telephone Visit
~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training
~Month 2:
~Week 5, Day 34:
~Week 6, Day 41:
~Week 7, Day 48:
~Week 8, Day 55:
~Month 3:
~Week 9, Day 62:
~Week 10, Day 69:
~Week 11, Day 76:
~Week 12, Day 83: Final Visit"
11076602|NCT04239794|Active Comparator|Inhalation anesthesia|Patients are anesthetized with sevoflurane and remifentanil infusion for maintenance of anesthesia during the surgery
11076603|NCT04239794|Experimental|Total intravenous anesthesia|Patients are anesthetized with target-controlled intravenous infusion of propofol and remifentanil infusion for maintenance of anesthesia during the surgery
11076604|NCT04239768|Experimental|MonoDermà HA gel combined to a low level laser|"Monodermà HA Bio-revitalizing gel is a sterile, biodegradable, isotonic intradermal filler produced by Innate S.r.l. (Italy) and distributed by Giuliani S.p.A. (Italy) in non-pyrogenic pre-filled syringe of 2 ml containing 2% (20mg/ml) of medium chain (1.0-1.5 x 106 Dalton) hyaluronic acid (HA), obtained from bacterial fermentation, in a physiologic buffer (see Appendix 1) and used as a filler for the correction of deep skin sagging and roughness."
11076605|NCT04239755|Active Comparator|Doxycycline|Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.
11076606|NCT04239755|Placebo Comparator|Placebo|group (2) will be 25 patients will receive placebo in addition to the standard treatment.
11076607|NCT04239742|Experimental|18F-PSMA PET/CT and 18F-Fluciclovin PET/CT|patients undergo an 18F-PSMA PET/CT scan and an 18F-Fluciclovin PET/CT scan, within a time frame of two weeks.
11076608|NCT04239729|Experimental|ACT Website and Coaching Condition|Participants will be asked to complete 16 brief self-help website sessions, each taking around 15-20 minutes to finish, twice a week for eight weeks. Website exercises and examples primarily focus on hoarding, although some examples also discuss related mental health concerns such as anxiety, low mood, health behaviors, etc. The sessions use multimedia and are interactive. Participants assigned to the website condition will also receive coaching. The purpose of coaching will be to help participants engage with the website and adhere to the intervention. Coaching will consist of an initial phone call of 10-15 minutes followed by weekly email contact during the 8-week treatment period. Coaches will be graduate students trained in clinical psychology.
11076609|NCT04239729|No Intervention|Waitlist Condition|Participants assigned to the waitlist will be asked to wait 12 weeks without intervention (access to the website or coaching). They will receive access to the website after 12 weeks, but supportive coaching will not be provided to waitlist participants.
11076610|NCT04239716|Experimental|regional anesthesia|combination of erector spinae plane block (ESPB) and interscalene block(IB).the ESPB will be performed using linear ultrasound transducer (Philips® cx 50 extreme edition, USA) and we will inject 20 ml solution(10 ml 0.5% bupivacaine, 5 ml 2% lidocaine, and 5 ml normal saline). the IB will be performed using the same ultrasound machine and injecting the same solution
11076611|NCT04239703||Kidney transplant biopsies for cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.
11076612|NCT04239690|Experimental|Micromethods for blood sample analysis|Blood gases are analysed using 0.045 ml whole blood Levels of CRP are analysed using 0.010 ml whole blood
11076613|NCT04239690|No Intervention|Standard clinical methods for blood sample analysis|Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
11076614|NCT04239677|Active Comparator|control|Conventional crystalloid solution-based priming
11076618|NCT04239651|Active Comparator|Enrolment in rTMS sessions alone|All patients will be scheduled to receive 30 sessions of rTMS treatments over a six-week period as pre-determined by Alberta Health Services' Strategic Clinical Network for Addiction and Mental Health.
11076619|NCT04239651|Active Comparator|Enrolment in iCBT Plus rTMS|Patients in the rTMS plus iCBT arm of the study, would be assisted to register on the iCBT program (Moodgym) to receive unique login information. They would be assisted to participate in 12 one-hour sessions of iCBT at the clinic prior to receiving rTMS treatments. These in-clinic iCBT sessions would be scheduled in about three days intervals (ideally Tuesdays and Thursdays) so that patients receive two iCBT sessions each week. Patients would also be encouraged to continue with iCBT treatments on their own at home outside the sessions delivered in the clinic.
11076620|NCT04239625|Experimental|ALK-001|
11076621|NCT04239612|Other|Physical exercise|Specified circular training, 60 minutes, 1-3 times/week
11076622|NCT04239599|Experimental|Hypofractionation|Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost) + 18-36 months of Eligard Hormone injection.
11076623|NCT04239599|Active Comparator|Standard Fractination|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy + 18-36 months of Eligard Hormone injection.
11076624|NCT04239586|Experimental|Sulfonylurea treatment group|Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.
11076625|NCT04239573|Experimental|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
11076626|NCT04239573|Experimental|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
11076627|NCT04239560|Experimental|Boron-based Gel|During each radiation therapy session, 15 minutes before radiotherapy, 3% sodium pentahydrate panteurate will be used.
11076628|NCT04239560|Placebo Comparator|Radiation Traumatic Dermatitis Treated with Placebo|During each radiotherapy session, 15 minutes before radiotherapy, the gel will be free of any chemical treatments
11076629|NCT04239547|Experimental|Recruitment|Patients classified to receive recruitment maneuver + 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
11076630|NCT04239547|Experimental|Non-recruitment|Patients classified to receive only 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
11076631|NCT04239534|Other|Single Arm|In this Single Arm Study, Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access. Followed by the sue of an endocardial ablation catheter that will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.
11076632|NCT04239521||Cases|Patients with a confirmed diagnosis of Alopecia areata within the study period will be included as cases for analysis.
11076633|NCT04239521||Controls|The control cohorts will be defined by matching cases with patients who have never been diagnosed with Alopecia areata either prior to or during the study period, by age and sex, at General Practice practice level.
11076634|NCT04239508||Minimal Neonatal Dataset MNDS|All Swiss live-born infants below 32 weeks gestational age or 1501g birth weight
11076635|NCT04239508||Below 34, B34|All Swiss live-born infants between 32 0/1 and 33 6/7 weeks gestational age that are above 1500g birth weight
11076636|NCT04239508||Swiss Asphyxia and Cooling Registry, ASP|Infants between 35 0/7 and 42 6/7 weeks' gestational age with moderate or severe encephalopathy due to perinatal asphyxia
11076637|NCT04239482|Experimental|L-arginine + Nitrate/Nitrite|Subjects will receive 1 L-arginine tablet per day and drink 35 mL of beetroot juice for 8 weeks.
11076638|NCT04239482|Placebo Comparator|Placebo|Subjects will receive 1 cellulose tablet per day and drink 35 mL of nitrate/nitrite depleted beetroot juice for 8 weeks.
11076639|NCT04239469|Active Comparator|KL16-012|Patients will use a liquid standardized extract of cannabis sativa. Each drop will contain 1 mg of THC and 0.45 mg of CBD. Administration will be sublingual, while dosing will begin at 3 drops per day and be escalated to 15 drops per day by week 5 according to an escalation chart.
11076640|NCT04239469|Placebo Comparator|Placebo|Patients will use a liquid placebo identical to the active principle in both appearance and taste.
11076641|NCT04239456|Experimental|Group A|Receive intervention 2 weeks after group assignment.
11076642|NCT04239456|Other|Group B|Wait List - Receive intervention 3 months after initial testing.
11076643|NCT04239443|Experimental|SHR1210 and Apatinib|"NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).
~The duration of treatment will till the disease progression, death, or unacceptable toxicity show up."
11076644|NCT04239417|Experimental|The Study group A|they received graduated abdominal strengthening exercises for 30 min., 3 times per week for 6 weeks preoperatively.
11076645|NCT04239417|Experimental|The Study group B|they received Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
11076646|NCT04239417|Experimental|The Study group C|they received combination between graduated abdominal strengthening exercises and Russian stimulation on abdominal muscles for 30 min., 3 times per week for 6 weeks preoperatively.
11076647|NCT04239417|No Intervention|The Control group D|they were instructed to presume in normal activities of daily living preoperatively, without abdominal exercises or Russian stimulation.
11076650|NCT04239391|Experimental|Triferic via IV and Hemodialysate|Upon completion of the Baseline observational periods, all enrolled patients will transition to the interventional period where they will then receive Triferic. The Triferic will be administered via the liquid bicarbonate concentrate at a dialysate concentration of 2 uM or via IV at a dose of 0.1 mg Fe/kg, if the patient does not receive dialysis using liquid bicarbonate, for up to an additional 36 weeks (depending on duration of observational Baseline period). Hgb and CHr will continue to be measured bi-weekly and iron profiles will be obtained at 4 week intervals. In the Triferic phase of the study,changes in ESA dose will be allowed according to the study site existing protocol. IV iron will only be administered if ferritin meets the criteria for iron deficiency. Patients will remain in the interventional period for either 36 or 28 weeks (depending on randomization assignment), at which time a final study visit will take place
11076651|NCT04239391|No Intervention|Historic Control Observational Arm|Up to 75 patients will be enrolled in the Observational Arm. Patients who participate in the historical control observational arm will not receive any study medication, but will have Hgb, CHr and serum iron profiles collected at 4 week intervals for up to a total of 44 weeks.
11076652|NCT04239378|Experimental|Test group -Autogenous dentin matrix and collagen membrane|Test group - After atraumatic tooth extraction , socket will be augmented with autogenous dentin matrix and covered with collagen membrane and sutures are placed.
11076653|NCT04239378|Active Comparator|Control group-bovine derived xenograft and collagen membrane|control group- After atraumatic tooth extraction, socket will be augmented with bovine derived xenograft and covered with collagen membrane and sutures are placed.
11076654|NCT04239365|Experimental|Group A: WLE followed by NBI|EMR scar is interrogated using WLE followed by NBI
11076655|NCT04239365|Active Comparator|Group B: NBI followed by WLE|EMR scar is interrogated using NBI followed by WLE
11076656|NCT04239352||healthy pregnant women|"Blood samples taken from 40 healthy pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.
~this group will be the control group."
11076657|NCT04239352||preeclamptic pregnant women|"Blood samples taken from 40 preeclamptic pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.
~this group will be the study group."
11076658|NCT04239339|Placebo Comparator|Control Group|The placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo pill.
11076659|NCT04239339|Experimental|Intervention Group|The intervention group will be administered 20mg of Escitalopram daily for approximately 3 weeks.
11076660|NCT04239313|Experimental|Population I|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose vaccine.
11076661|NCT04239313|Active Comparator|Population II|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of low dose adjuvant.
11076662|NCT04239313|Placebo Comparator|Population III|Population I has 10 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo.
11076663|NCT04239300|Experimental|Main group|The participant in main group have water labour
11076664|NCT04239300|No Intervention|Control group|The participant in control group will not have water labour
11076665|NCT04239287||Preterm|Children age 8-16 years born at <32 weeks gestation.
11076666|NCT04239287||Control|Children age 8-16 years born at >37 weeks gestation
11076667|NCT04239274|Experimental|Transcranial Direct Current Stimulation (tDCS)|
11076668|NCT04239274|Experimental|Transcranial Pulsed Stimulation tPCS|
11076669|NCT04239274|Sham Comparator|No Stimulation|
11076670|NCT04239261|Active Comparator|Nutritional therapy|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
11076671|NCT04239261|Placebo Comparator|Placebo|Hydrolyzed gelatin 10.0 grams once daily
11076672|NCT04239248|Experimental|ACTIVE-RCT-I Tasty&Healthy intervention group|Patients with mild-moderately symptomatic disease, will follow the Tasty&Healthy dietary approach.
11076673|NCT04239248|Active Comparator|ACTIVE-RCT-I Control group|Patients with mild-moderately symptomatic disease, will receive EEN with Modulen formula only.
11076674|NCT04239248|Experimental|MH-RCT-II Tasty&Healthy intervention group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will follow the Tasty&Healthy dietary approach.
11076675|NCT04239248|No Intervention|MH-RCT-II Control group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will continue their habitual diet.
11076676|NCT04239235|Experimental|Intervention|Community Reinforcement Approach and Family Training is a 10-session rolling group for the support person.
11076677|NCT04239235|No Intervention|Control|This condition is for support persons who do not receive CRAFT. They will receive no intervention or usual care services available at the clinic.
11076678|NCT04239222|Experimental|Revo-M to Proflex XC|Transtibial amputees randomized to start with Revo-M and cross over to Proflex XC
11076679|NCT04239222|Experimental|Proflex XC to Revo-M|Transtibial amputees randomized to start with Proflex XC and cross over to Revo-M
11076680|NCT04239222|Experimental|Revo-M to Taleo|Transfemoral amputees randomized to start with Revo-M and cross over to Taleo
11076681|NCT04239222|Experimental|Taleo to Revo-M|Transfemoral amputees randomized to start with Taleo and cross over to Revo-M
11076682|NCT04239209|Placebo Comparator|Direct Communication (control)|A direct response where the intensivist acknowledges that he is not certain but believes the patient will not survive hospitalization.
11076683|NCT04239209|Active Comparator|Indirect - other patients|An indirect response describing the prognosis of other people similar to the patient in question.
11076684|NCT04239209|Active Comparator|Indirect - physiology|An indirect response describing the severe physiologic abnormalities present in the patient and potential future problems.
11076686|NCT04239196|Experimental|tocilizumab and IV steroids combination|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (with intravenous pulses of 1000 mg/day of methylprednisolone for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months. Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week).
11076687|NCT04239196|Other|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (with intravenous pulses of 1000 mg/day of methylprednisolone for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
11076688|NCT04239170|Experimental|Camrelizumab(SHR-1210) Combined With GEMOX|
11076689|NCT04239157|Experimental|Treatment (canakinumab)|Patients receive canakinumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11076690|NCT04239144|No Intervention|Medical therapy group|Arm 1 Medical Treatment Control - 10 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.
11076691|NCT04239144|Active Comparator|Catheter ablation|Intervention Arm 2 -10 patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
11076692|NCT04239144|Experimental|Left trunk sympathectomy|Interventional arm 3 - In 10 patients, left truck sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches.
11076693|NCT04239131|Other|All Patients|It is a single arm study. Skin prick testing and laboratory Tests are carried out on all patients in the same way
11076694|NCT04239118|Experimental|Applications of autoplasma, enriched with platelets and|Endoscopic applications of autoplasma, enriched with platelets and granular sorbent aseptisorb-A in bleeding gastroduodenal ulcers
11076695|NCT04239118|Other|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents.
11076696|NCT04239105||Breast cancer Group|The biopsy result is breast cancer.
11076697|NCT04239092|Experimental|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
11076698|NCT04239092|Experimental|9-ING-41 plus Irinotecan|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days (cycle duration is 21 days).
11076699|NCT04239079||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
11076700|NCT04239079||AD/aMCI and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Alzheimer's disease or Amnestic Mild Cognitive Impairment (aMCI)
11076701|NCT04239066|Experimental|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
11076702|NCT04239066|Experimental|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
11076703|NCT04239053||ESPB block group|Patients receiving ESPB will be enrolled to this group.
11076704|NCT04239040|Experimental|Relapsed or Refractory High Risk Neuroblastoma|"Tissue Collection of Cancerous cells during primary or clinically indicated surgical resection.
~Manufacture and cryopreservation of vaccine. Treatment with vaccine, nivolumab and ipilimumab.
~Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
~Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
~Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
11076705|NCT04239027|Experimental|RTH258/Brolucizumab|This is a single-arm study in which all patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment from Week 16/Week 20 up to Week 40/Week 44.
11076706|NCT04239014|Experimental|Arm 1 (ceralasertib+olaparib)|Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).
11076707|NCT04239014|Experimental|Arm 2 (olaparib monotherapy)|Olaparib 300 mg BD PO daily continuous.
11076708|NCT04239014|Experimental|Arm 3 (placebo)|Placebo to match olaparib BD PO daily continuous.
11076709|NCT04239001|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
11076710|NCT04238988|Experimental|Carboplatin-Paclitaxel-Pembrolizumab|"Patients will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).
~After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.
~After surgery, patients presenting with high risk factors will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles."
11076711|NCT04238975|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
11076712|NCT04238975|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
11076713|NCT04238962|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
11076714|NCT04238962|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
11076715|NCT04238949|No Intervention|Standard Diabetes Care Group|Patients receive standard diabetes care.
11076716|NCT04238949|Experimental|Community Health Worker Group|Patients are assigned a community health worker for the first year in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
11076717|NCT04238936||study group ; Patients with gestational diabetes|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
11076718|NCT04238936||control group ; healthy pregnant women|Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
11076719|NCT04238923|Experimental|Topical Gentamicin and Vancomycin|Immediately prior to closure of the incision, 1g of vancomycin will be mixed in 4mL of normal saline and applied as a paste directly to the muscle, fascia and subcutaneous tissue. Gentamicin-eluting collagen sponges will be cut to the appropriate size to cover the defect and applied after application of vancomycin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
11076720|NCT04238923|No Intervention|Control|The surgical wound is closed in the standard fashion with 3 layer closure with staples for skin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
11076721|NCT04238910|Experimental|Maximizing Energy|"The Maximizing Energy (MAX) intervention consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventions are delivered by occupational therapists.
~The MAX intervention was developed by combining two active ingredients - Problem Solving Therapy and energy conservation strategy education. Participants engage in two introductory sessions during the first week of the intervention. During the first session in a week, participants practice the steps of MAX Intervention with a fatigue-related problem. At the end of the session, the participants identify a clearly defined action plan for solution implementation. Participants are asked to implement the solution over the next few days. The second session takes place later in the week. The interventionist reviews the problem, the identified solution, and its implementation. Participants use a workbook to support their application of the MAX Intervention."
11076722|NCT04238910|Active Comparator|Health Education|consists of two weekly 30-minute sessions delivered live via the Internet using web-camera technology for 8 weeks. The interventionist delivered health education using a variety of health related topics relevant to individuals with TBI (e.g., characteristics and prevalence of fatigue after TBI, diet and nutrition, importance of exercise, energy conservation strategies).Participants use a workbook to follow along with the interventionist during the weekly sessions.
11076723|NCT04238897|Experimental|Ticon Aspherical Daily Disposable Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
11076724|NCT04238897|Placebo Comparator|Ticon Daily Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
11076725|NCT04238884|Experimental|Experimental group|Based on the genetic study carried out and the patient's characteristics (age, weight, indication), the Pharmacogenetics Unit of the University Hospital La Paz will indicate the dose to be administered based on the therapeutic individualization protocol guided by pharmacogenetics.
11076726|NCT04238884|Active Comparator|Control group|No information will be provided and procedure will be carried out according to normal clinical practice, with clinical monitoring by the doctor in charge.
11076727|NCT04238871||children or adults with Idiopathic Lung Disease|
11076728|NCT04238858|Active Comparator|Before application|Forty-nine eyes belonging to 37 patients before injection aPRP.
11076729|NCT04238858|No Intervention|After application|Forty-nine eyes belonging to 37 patients after injection aPRP.
11076730|NCT04238858|Sham Comparator|Sham application|11 patients before - after aPPP injection
11076731|NCT04238845|Active Comparator|SMC alone|Children under SMC Coverage, receiving AQSP alone with no supplementation
11076732|NCT04238845|Experimental|SMC+ Plumpy'Nut®|Children under SMC Coverage, receiving AQSP plus Plumpy'Nut® supplementation
11076733|NCT04238845|Experimental|SMC+ Vitamin A-Zinc|Children under SMC Coverage, receiving AQSP plus Vitamin A-Zinc supplementation
11076734|NCT04238832|Active Comparator|Free Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and free base nicotine e-liquid to sample for one week.
11076735|NCT04238832|Active Comparator|Salt Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and salt base nicotine e-liquid to sample for one week.
11076736|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
11076737|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
11076738|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
11076739|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
11076740|NCT04238806|Active Comparator|Desflurane Continuous|In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
11076741|NCT04238806|Active Comparator|Desflurane Intermittent|In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
11076742|NCT04238793|Experimental|Cohort 1|KLS-2031 low dose(1x10^11 VG/DRG) or Placebo
11076743|NCT04238793|Experimental|Cohort 2|KLS-2031 medium dose(1x10^12 VG/DRG) or Placebo
11076744|NCT04238793|Experimental|Cohort 3|KLS-2031 high dose(1x10^13 VG/DRG) or Placebo
11076745|NCT04238780|Active Comparator|ESP( Erector Spinae Plane Block)|After induction parturient in the ESPB underwent bilateral ESPB at the level of T7 using a linear ultrasound (US) transducer.
11076746|NCT04238780|Sham Comparator|control group|Control group
11076747|NCT04238767||HIV-1-positive individuals|HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.
11076748|NCT04238754|Experimental|All Participants|Each participant will receive Epidiolex oral solution and Cherry syrup oral solution (placebo) in a randomized fashion.
11076749|NCT04238728|Experimental|Silverlon arm|
11076750|NCT04238715|Experimental|E7090 140 mg|Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.
11076751|NCT04238702|Experimental|Empagliflozin + Losartan|Empagliflozin + Losartan
11076752|NCT04238702|Experimental|Losartan + Placebo|Losartan + Placebo
11076753|NCT04238702|Experimental|Empagliflozin + Placebo|Losartan + Placebo
11076754|NCT04238702|Placebo Comparator|Placebo + Placebo|Placebo + Placebo
11076755|NCT04238689|Experimental|Group 1 - 0,1mg/kg TB31F|0.1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. Subjects will be observed for the occurrence of any adverse events. There will be a minimum of 48 hours between TB31F administration to each subsequent volunteer. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
11076756|NCT04238689|Experimental|Group 2 - 1mg/kg TB31F|1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
11076757|NCT04238689|Experimental|Group 3 - 3mg/kg TB31F|3 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
11076758|NCT04238689|Experimental|Group 4 - 10mg/kg TB31F|10 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
11076759|NCT04238676|Experimental|PP353|
11076760|NCT04238676|Placebo Comparator|PP353-B|
11076761|NCT04238663|Experimental|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11076762|NCT04238663|Active Comparator|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11076763|NCT04238663|Active Comparator|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11076764|NCT04238650|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11076765|NCT04238650|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11076766|NCT04238637|Experimental|Arm 1|Durvalumab
11076767|NCT04238637|Experimental|Arm 2|Durvalumab in combination with Tremelimumab
11076768|NCT04238624|Experimental|BRAF-mutant ATC|Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
11076769|NCT04238611|Experimental|Lactate microneedle|Measurement of lactate through microneedle
11076770|NCT04238598|Active Comparator|Active|intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency
11076771|NCT04238598|Placebo Comparator|Control|intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency
11076772|NCT04238598|Experimental|Experimental|intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency
11076773|NCT04238585|Active Comparator|Negative message frames|Participants will receive messages framed in a negative manner to avoid sugar-sweetened beverages
11076774|NCT04238585|Active Comparator|Sugar content information messages|Participants will receive messages framed in a positive manner to promote healthy beverage consumption
11076896|NCT04237792|Experimental|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
11076775|NCT04238585|Placebo Comparator|Attention Control-Infant Safety|Participants will receive messages with infant safety education materials-attention control group
11076776|NCT04238572|Experimental|Audiovisual distraction device|Audiovisual distraction device, analgesia nociception index monitoring, remifentanil added to local anesthesia technique
11076777|NCT04238572|Active Comparator|Active comparator group|Analgesia nociception index monitoring, remifentanil added to local anesthesia technique
11076778|NCT04238546|Experimental|Sirolimus-coated group|
11076779|NCT04238546|Active Comparator|Uncoated group|
11076780|NCT04238533|Active Comparator|eADAPT|This arm includes transradial amputees who will be assessed while using the eADAPT trainer.
11076781|NCT04238533|Active Comparator|Conventional program|This arm includes transradial amputees who will be assessed while using the conventional training program.
11076782|NCT04238520|Other|Control|20 PWD/CG dyads
11076783|NCT04238520|Experimental|Interventional|20 PWD/CG dyads
11076784|NCT04238507|Active Comparator|Guedel airway (OPA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
11076785|NCT04238507|Active Comparator|McKay Airway (MA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
11076786|NCT04238494|Experimental|Frail/prefrail|Fried's criteria >3 = frail, 1 or 2 = prefrail The 5 Fried criteria mainly target the muscle function: low muscle strength, decreased physical activity and low gait speed. One refers to depressive symptoms with the use of 2 CES-D (Centre for Epidemiologic Studies - Depression Scale) questions and one to nutrition with the weight loss criteria. The second most famous definition of frailty was developed by ROCKWOOD and MITNISIKI (2). It describes frailty as the accumulation of deficits including cognitive, functional and social alterations
11076787|NCT04238494|Other|non frail|No Fried's criteria
11076788|NCT04238481|Experimental|ASP5354 dose-A group|Participants will receive a single dose-A of ASP5354 once the surgical area of interest is in view.
11076789|NCT04238481|Experimental|ASP5354 dose-B group|Participants will receive a single dose-B of ASP5354 once the surgical area of interest is in view.
11076790|NCT04238481|Experimental|ASP5354 dose-C group|Participants will receive a single dose-C of ASP5354 once the surgical area of interest is in view.
11076791|NCT04238481|Experimental|ASP5354 dose-D group|Participants will receive a single dose-D of ASP5354 once the surgical area of interest is in view. This arm will be added only if the visualization in lower doses are not succeeded.
11076792|NCT04238481|Experimental|ASP5354 dose-E group|Participants will receive a single dose-E of ASP5354 once the surgical area of interest is in view. This arm will be added only if the visualization in lower doses are not succeeded.
11076793|NCT04238481|Experimental|ASP5354 dose-F group|Participants will receive a single dose-F of ASP5354 once the surgical area of interest is in view. This arm will be added only if the visualization in lower doses are not succeeded.
11076794|NCT04238468|Experimental|Intradermal injection of stromal vascular fraction|Most lateral 5 cm of abdominal donor site will be injected with stromal vascular fraction just after the wound is closed.
11076795|NCT04238468|No Intervention|control|Most contralateral 5 cm of abdominal donor site will serve as control.
11076796|NCT04238455|Sham Comparator|Control Group|Sham serratus anterior plane block plus usual car
11076797|NCT04238455|Active Comparator|Treatment Group|Serratus anterior plane block plus usual care
11076798|NCT04238442|Experimental|BP oscillometric measurement|Oscillometric BP measurement
11076799|NCT04238429|Experimental|Toothpaste containing effective ingredients|Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
11076800|NCT04238429|Placebo Comparator|Negative control toothpaste|Use the negative control dentifrice to brush teeth twice daily for 8 weeks
11076801|NCT04238416|Experimental|IV BCAA + Lactulose|IV Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
11076802|NCT04238416|Active Comparator|Lactulose alone|Oral Lactulose alone
11076803|NCT04238403|Experimental|Behavioral Parent Training|Parent training intervention based on social learning and operant conditioning theory, generally referred to as Behavioral Parent Training.
11076804|NCT04238390|Experimental|Ceftolozane-tazobactam|Participants will receive ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins
11076805|NCT04238390|Active Comparator|Meropenem|Participants will receive meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins.
11076806|NCT04238377|Active Comparator|Stellate Group|will receive pre-operative ultrasound guided stellate ganglion block one hour before surgery and multimodal analgesia and will be followed for 6 months for neuropathic pain as the Stellate Group
11076807|NCT04238377|Placebo Comparator|Control Group|will receive multimodal analgesia only and will be followed for 6 months for neuropathic pain as the control Group
11076808|NCT04238364|Experimental|EI1071 Tablets|EI1071 tablet(s) administered orally as single ascending dose, multiple ascending daily doses
11076809|NCT04238364|Placebo Comparator|Placebo|Matching placebo tablet(s) administered orally
11076810|NCT04238351|Experimental|Control|usual mask ventilation during anethesia induction
11076811|NCT04238351|Active Comparator|THRIVE|Applying Transnasal humidified rapid insufflation ventilator exchange during anesthesia induction
11076837|NCT04238182|Active Comparator|wet cupping|smokers in this group will receive single wet cupping session
11076838|NCT04238182|Active Comparator|dry cupping|smokers in this group will receive single dry cupping session
11076839|NCT04238169|Experimental|SBRT+Toripalimab|Immunotherapy：Toripalimab: 240 mg once every three weeks for 9 cycles. SBRT：30-50Gy/5F（2-4 locations).
11076897|NCT04237792|Experimental|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
11076898|NCT04237792|Experimental|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
11076812|NCT04238338||high MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).
~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
11076813|NCT04238338||low MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).
~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
11076814|NCT04238312|Experimental|RESPeRATE™|RESPeRATE™: 2breathe Tech. Ltd., Eshtaol, Israel. The device includes a belt-type respiration sensor worn outside of the clothing that is placed around the torso. It is connected to a computerized box that generates musical patterns listened through an earbud. The device guides the user interactively to slow breathing with a relatively prolonged expiration.
11076815|NCT04238312|Active Comparator|Tell, Show and Do technique|
11076816|NCT04238299||Main study cohort|Patients with CKD recruited from specialist nephrology clinics
11076817|NCT04238286|Experimental|Dry needling group|Patients treated with dry needling
11076818|NCT04238286|Sham Comparator|Sham group|Patients treated with a simulated dry needling
11076819|NCT04238286|No Intervention|Control|Patients never treated
11076820|NCT04238273||HHHFNC|it included 63 preterm neonates on Heated, Humidified High Flow Nasal Cannula, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
11076821|NCT04238273||NCPAP|it included 60 preterm neonates on Nasal Continuous Positive Airway Pressure, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
11076822|NCT04238260|Active Comparator|Usual Physical Therapy Care|Physical Therapists continue usual care
11076823|NCT04238260|Experimental|Enhanced Physical Therapy Usual Care|Best practice implemented
11076824|NCT04238247|No Intervention|Group 1: Control Group|"Participants will be randomized to this arm after completion of the baseline survey. They will receive no intervention throughout the study.
~Group 1 will not have access to the study's website throughout the study. They will gain access to the site after their 12-month follow-up appointment.
~All participants will complete the baseline visit and a 6- and 12- month follow-up appointment. Also, all participants will get text messages related to monthly photo requests and receive the same study handouts."
11076825|NCT04238247|Experimental|Group 2: Basic Intervention Group|"Participants will be randomized to this arm after completion of the baseline survey. They will receive the motivational interviewing intervention in the ED or after an ED visit.
~Group 2 will gain access to the study's website after completion of the baseline survey. The site will provide custom feedback based on their answers within the surveys regarding how their child normally rides in a car and general child passenger safety practices.
~All participants will complete the baseline visit and a 6- and 12- month follow-up appointment. Also, all participants will receive text messages related to monthly photo requests and receive the same study handouts. Group 2 will receive additional tailored text messages each month based on their answers within the surveys."
11076826|NCT04238247|Experimental|Group 3: Enhanced Intervention Group|"Participants could be randomized to this arm after completion of their 6 month follow-up visit if they are continuing suboptimal child passenger safety behaviors. Only participants in group 2 could be re-randomized to group 3.
~In addition to the Group 2 intervention elements described above, Group 3 will receive a second motivational interviewing session (by phone) after the 6-month follow-up assessment.
~Group 3 will receive more frequent tailored text messages between months 7-12 based on their answers within the surveys."
11076827|NCT04238234||study group|Participants will be adult patients (above 18 years), ASA I-II-III, scheduled for elective surgeries under general anesthesia.
11076828|NCT04238221|Experimental|Doxofylline+inhalation therapy|4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy, followed by 4-week treatment of maximal inhalation therapy only
11076829|NCT04238221|Experimental|Inhalation therapy|4-week treatment with maximal inhalation therapy only, followed by 4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy
11076830|NCT04238208|Active Comparator|Group LL|Group LL patients received the 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm containing 700 mg of Lidocaine for 60 minutes
11076831|NCT04238208|Placebo Comparator|Group LP|Group LP received an identical placebo patch
11076832|NCT04238208|Experimental|Group LC|Group LC received the 8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK).
11076833|NCT04238195|Experimental|Treatment A|600 mg TBPM-PI-HBr (2 x 300 mg tablets) and TBPM-PI-HBr-matching placebo (2 x matching placebo tablets) administered at Hour 0 on Day 1.
11076834|NCT04238195|Experimental|Treatment B|1200 mg TBPM-PI-HBr (4 x 300 mg tablets) administered at Hour 0 on Day 1.
11076835|NCT04238195|Placebo Comparator|Treatment C|TBPM-PI-HBr-matching placebo (4 x matching placebo tablets) administered at Hour 0 on Day 1.
11076836|NCT04238195|Other|Treatment D|Positive Control - unblinded: 400 mg moxifloxacin (1 x 400 mg tablet) administered at Hour 0 on Day 1.
11076840|NCT04238169|Experimental|SBRT+Bevacizumab+Toripalimab|Immunotherapy：Toripalimab: 240 mg once every three weeks for 9 cycles. SBRT：30-50 Grays(Gy) in 5 fractions（2-4 locations）. Bevacizumab：7.5mg/kg once every three weeks for 9 cycles.
11076841|NCT04238156|Experimental|Hypopressive abdominal exercises|"Hypopressive abdominal exercises will be performed in basic postures (standing, sitting and supine position). In each posture, three slow cost-diaphragmatic respiration will be performed followed by an expiratory apnea and a rib cage opening, during 2 to 10 seconds, and an exhalation of 10 to 30 seconds. Each exercise will be repeated three times.
~There will be 3 stages of application throughout the 12 intervention sessions, supervised by a physical therapist:
~First stage: To explain the concept of hypopressive respiration and how to perform it.
~Second stage: To explain and apply the hypopressive abdominal exercises: 1. Axial auto-elongation (reducing curvatures in the sagittal plane); 2. Cervical auto-elongation (chin toward the neck); 3. Moving forward of gravity axis; 4. Activation of the shoulder girdle (shoulder joint decoaptation); 5. Slight knee flexion; 6. Dorsal ankle flexion.
~Third stage: To review and update all the exercises, increasing their intensity."
11076842|NCT04238143|Experimental|tSVF + PRP Arm1|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate
11076843|NCT04238143|Experimental|tSVF + PRP + cSVF Arm 2|Tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) Concentrate + Cellular Stromal Vascular Fraction (cSVF)
11076844|NCT04238143|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Sterile Normal Saline Intravenous (IV) Introduction
11076845|NCT04238130||Perioperative ctDNA Dynamic Monitoring Group|Samples were obtained at multiple pre-specified time points including before surgery (plasma samples)，during surgery after tumor resection (tumor samples) and after surgery(plasma samples were obtained every 6 months from ctDNA positive patients at baseline in the following 2 years)
11076846|NCT04238117|Experimental|LA group|The participants in LAT group underwent 10 sessions of LAT over 2 weeks, using a gallium aluminum arsenide Laser Pen. The participants in the LAT group received 0.375 J of energy at each of the following acupoints bilaterally: BL23 (Shenshu, B2), BL25 (Dachangshu, B2), BL26 (Guanyuanshu, B2), BL40 (Weizhong, B2) and SP6 (Sanyinjiao, B2).
11076847|NCT04238117|No Intervention|Control group|The participants of the control group received standard obstetric care.
11076848|NCT04238104||sea level|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center of sea level were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
11076849|NCT04238104||altitude <1000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude less than 1000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
11076850|NCT04238104||altitude 1000-2000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 1000-2000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
11076851|NCT04238104||altitude 2000-3000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 2000-3000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
11076852|NCT04238104||altitude 3000-4000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 3000-4000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
11076853|NCT04238104||altitude 4000-5000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 4000-5000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
11076854|NCT04238091|Active Comparator|Antibiotics prior to FMT|Participants will take a standardized regimen of antibiotics for three days prior to fecal transplant.
11076855|NCT04238091|Active Comparator|No Antibiotics prior to FMT|Participants will not take antibiotics before the transplant.
11076856|NCT04238078||Polycystic ovary syndrome|Women with PCOS diagnosed according to Rotterdam criteria
11076857|NCT04238078||Healthy control|Healthy women without any feature of ovulatory dysfunction or androgen excess
11076858|NCT04238065|Experimental|VR treatment|"The arm will use the virtual reality headset reproduces dynamic video content with perceptual learning and binocular perception (including stereopsis) that is visually perceived a little bit faster, brighter, and higher contrast to the amblyopia eyes .
~The each VR therapy length is 30 minutes with 5 minute break after 15 minutes' therapy sequence, 3 times per week, total 13 weeks.
~All amblyopia eyes are best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity."
11076859|NCT04238065|Placebo Comparator|control|"This arm of amblyopia eyes are all best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.
~No VR therapy."
11076860|NCT04238026|Experimental|Distal radial artery approach|Puncture in the snuff box area of the arm with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
11076861|NCT04238026|Active Comparator|Proximal radial artery approach|Puncture in the ventral side of the arm (2 cm proximal to the styloid apophysis) with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
11076862|NCT04238013|Active Comparator|Corticospinal Tract Excitability|During the Corticospinal Tract Excitability arm, corticospinal excitability will be assessed by measuring motor evoked potentials after transcranial magnetic stimulation pre-post each intervention in conjunction with other outcome measures.
11076863|NCT04238013|Active Comparator|Spinal Reflex Circuit Excitability|During the Spinal Reflex Circuit Excitability arm, spinal reflex circuit excitability will be assessed by measuring low frequency depression after Hoffmann-Reflex testing pre-post each intervention in conjunction with other outcome measures.
11076864|NCT04238000|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
11076865|NCT04238000|Placebo Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
11076866|NCT04237987|Experimental|Interleukin-2 and ciclosporin and corticosteroid|One million units of Recombinant Human Interleukin-2 (IL-2) will be administered subcutaneously every other day for 3 months. Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 3 months after withdraw of IL-2.
11076867|NCT04237987|Active Comparator|ciclosporin and corticosteroid|Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 6 months.
11076868|NCT04237961|Experimental|Upper third interference|Botox & brow lift
11076869|NCT04237961|Experimental|Middle third|Botox and fat injection
11076870|NCT04237961|Experimental|Lower third|Suspension suture
11076871|NCT04237948|Active Comparator|physical therapy plus REAL tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.
~Real Cerebellar tDCS will be applied for 10 days of time."
11076872|NCT04237948|Placebo Comparator|physical therapy plus SHAM tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.
~Sham Cerebellar tDCS will be applied for 10 days of time."
11076873|NCT04237935||Clopidogrel 75 mg|Reference group
11076874|NCT04237935||Ticagrelor 90 mg|Exposure group
11076875|NCT04237922||Clopidogrel 75 mg|Reference group
11076876|NCT04237922||Prasugrel 10 mg|Exposure group
11076877|NCT04237909|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
11076878|NCT04237883|Placebo Comparator|Arm 1: Standard Communication Arm|Monthly email communication: Monthly standard communication via email informing physicians of their health maintenance completion rate over the prior three-month period. The email will also include a link to the performance dashboard, a link to a FAQ page that outlines their incentive plan, a link to helpful resources such as care guidelines, key tips from top performers, the quality measure on which they are performing the best, and the two quality measures that they could improve on the most.
11076879|NCT04237883|Experimental|Arm 2: Arm 1 Message + Social Comparison Intervention|"Monthly email communication as in Arm 1
~Social comparison: In addition to the information given in Arm 1 email messaging, physicians in this arm will receive a list of the names of the top 25 performers from the prior month, and a high performer benchmark. Each physician in this group will receive a personalized message and subject line based on where in the performance distribution they fall (categories: top 25 performers, high performers, nearly high performers, and low performers). Message content will incorporate language utilizing principles of social comparison theory."
11076880|NCT04237883|Experimental|Arm 3: Arm 2 Interventions + Leadership training|"Monthly email communication as in Arm 1 and Arm 2.
~Social comparison as in Arm 2.
~Quality improvement leadership training: Physician leads and clinic managers within clinics randomized to Group 3 will receive an in-person quality improvement and primary care clinic performance training, using the principles of quality improvement, self-determination theory and social comparison. Clinic leaders will be trained on how to guide these conversations, formulate their own performance/quality improvement goals, design effective strategies to reach these goals, and track their clinic's progress. Check-in emails and calls will be provided on a monthly basis to follow up on clinic-based quality improvement efforts and share key take-aways from the new Primary Care Clinical Excellence Recognition Program. This program aims to support a positive and collaborative culture of clinical excellence by recognizing and sharing best practices from high performing physicians and clinical teams."
11076881|NCT04237870|Active Comparator|Active treatment|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS repeat twice with 15 min interval. Treatment will be applied in central suleus.
11076882|NCT04237870|Sham Comparator|Sham treatment|Sham rTMS will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
11076883|NCT04237857||LSG|Chinese patients who received laparoscopic sleeve gastrectomy at Prince of Wales Hospital, The Chinese University of Hong Kong for more than 36 months
11076884|NCT04237844||no BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，infants without BPD
11076885|NCT04237844||classic BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts >25%
11076886|NCT04237844||BPD after RDS|In preterm infants(GA<32 weeks and hospital day>14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2<23% within 7 days, and the condition is aggravated to FiO2>25%.
11076887|NCT04237844||Delayed BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，There is no RDS performance after birth, FiO2 lasts <25%
11076888|NCT04237844||Early, lethal BPD|In preterm infants(GA<32 weeks and hospital day>14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities
11076889|NCT04237831|Experimental|Arm A: Normal Renal Function|
11076890|NCT04237831|Experimental|Arm B: Mild Renal Impairment|
11076891|NCT04237831|Experimental|Arm C: Moderate Renal Impairment|
11076899|NCT04237779|Experimental|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in microTESE material.
11076900|NCT04237766|Experimental|Experimental group|All patients included in the experimental group should be on prophylactic treatment with factor 8 (FVIII) or factor 9 (FIX) concentrates. Likewise, the factor should be administered on the same day that they receive each movement display therapy treatment sessions. Each session will last approximately 40 minutes, with 7 physiotherapy sessions a week taking place over a period of 4 weeks.
11076901|NCT04237766|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through mirror therapy and motion display. They will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with factor 8 (FVIII) or factor 9 (FIX) concentrates. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
11076902|NCT04237753|Active Comparator|MyHealthebladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
11076903|NCT04237753|Active Comparator|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
11076904|NCT04237740|Experimental|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
11076905|NCT04237714|Experimental|IBI-based automated support|Internet-based intervention with automated support by the system. It consistes in phone text messages twice a week for users. The content of the messages focuses on motivating and reminding users to complete the activities proposed in the program and reviewing the treatment contents. Additionally an automatic email is send if participants have not access the program for a week. The program also provides continuous feedback to users through transversal tools.
11076906|NCT04237714|Experimental|IBI-plus human support|In this condition, the participants receive automated support explained above and additionally human support for a maximum of 5 minutes that consist in a weekly phone call provided by a psychologist. The content of phone calls is related with resolve questions or doubts about the use and clinical content of the IBI and also motivating and reminding the importance to complete activities in the program.
11076907|NCT04237714|No Intervention|Control group|Waiting list control group.
11076908|NCT04237675||regional anesthesia|
11076909|NCT04237675||general anesthesia|
11076910|NCT04237662|Experimental|Test Group|"Root Instrumentation + Enamel Matrix Derivative Application
~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
11076911|NCT04237662|Active Comparator|Control Group|"Root Instrumentation
~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour."
11076912|NCT04237649|Experimental|Arm A|KAZ954
11076913|NCT04237649|Experimental|Arm B|KAZ954 + PDR001
11076914|NCT04237649|Experimental|Arm C|KAZ954 + NIR178
11076915|NCT04237649|Experimental|Arm D|KAZ954 + NZV930
11076916|NCT04237636||Patients with post-operative AKI|"Patients developing acute kidney injury (AKI) following heart valve replacement surgery.
~AKI was classified according to the KDIGO definition[10]. Stage-1 AKI: increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.5μmol/l) or increase to more than or equal to 150% to 200% (1.5≤x<2) from baseline within 7 days. Stage-2 AKI: Increase in serum creatinine to more than 200% to 300% (2≤x<3) from baseline. Stage-3 AKI: Increase in serum creatinine to more than 300% (3≤) from baseline (or serum creatinine of more than or equal to 4.0 mg/dl (≥ 353.6μmol/l) or when the patient commenced RRT."
11076917|NCT04237636||Patients without post-operative AKI|Patients with normal kidney function (without acute kidney injury (AKI)) following heart valve replacement surgery
11076918|NCT04237623|Experimental|GM-CSF post-transplant|Sargramostim (GM-CSF) will start on Day +5 and continue until ANC >1000 x3 days or >1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.
11076919|NCT04237610||Bipolar disorder type I|
11076920|NCT04237610||Bipolar disorder type II|
11076921|NCT04237610||healthy controls|
11076922|NCT04237597|Experimental|K-877 & CSG452|K-877 Single dose on Day 1 and Day 15 CSG452 Repeat dose on Day 2 Through Day 15
11076923|NCT04237584|Active Comparator|Lead-in ARB followed by Radium-223/ARB|Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Radium-223 + ARB.
11076924|NCT04237584|Placebo Comparator|Lead-in ARB followed by Placebo/ARB|Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Placebo + ARB.
11076925|NCT04237571|Experimental|CANE Adult Participants|This sample population consists of an active intervention group of prior Tanglewood to Table walking program adult participants.
11076926|NCT04237558|Active Comparator|Vaginal hysterectomy|Removal of uterus through vagina in absence of prolapse
11076927|NCT04237558|Active Comparator|Laparoscopic hysterectomy|Key hole surgery through small incisions of the abdomen
11076928|NCT04237545|Experimental|T3 short implant|The short implants are available in lengths of 5mm and 6mm and in diameters of 5mm and 6mm. For study both configurations, T3 short without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 short with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
11076962|NCT04237272|Active Comparator|Customizable Tank|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week sampling period.
11076963|NCT04237272|Active Comparator|Control|Participants assigned to this arm will not receive any e-cigarette
11076929|NCT04237545|Active Comparator|T3 standard length|The T3 external hex implants available for this study will consist of lengths of 10mm, 11.5mm, 13mm, 15mm, 18mm and diameters of 4mm, 5mm, and 6mm. They have integrated platform switching (medialized implant/abutment junction). For study both configurations, T3 without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
11076930|NCT04237532|Experimental|Intranasal Dexmedetomidine|
11076931|NCT04237532|Experimental|Sublingual Dexmedetomidine|
11076932|NCT04237519|Experimental|SFL training|"Practice recommendation 3 times per week:
~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).
~Cognitive exercises: minimum of 15 min."
11076933|NCT04237519|Active Comparator|Active control training|"Practice recommendation 3 times per week:
~Physical exercises: between 30 to 45 minutes that can be split during the day (e.g. 2x15 or 20 minutes, or 3x10 or 15 minutes during the same day).
~Cognitive exercises: minimum of 15 min."
11076934|NCT04237506|Experimental|Intervention group|All participants in this group will take the one-hour ballet dance class twice per week for six weeks
11076935|NCT04237493|Experimental|Low-dosage therapy|
11076936|NCT04237493|Active Comparator|Regular-dosage therapy|
11076937|NCT04237467||Older transgender men|This cohort will consist of transgender men aged 50-75 years old who have taken testosterone for at least one year.
11076938|NCT04237467||Younger transgender men|This cohort will consist of transgender men aged 18-40 years old who have taken testosterone for at least one year.
11076939|NCT04237454|Experimental|Infrared Imaging undertaken|
11076940|NCT04237428|Experimental|hCD19 CAR-T cells Infusion|
11076941|NCT04237415|Experimental|EMG biofeedback group|
11076942|NCT04237415|No Intervention|control group|
11076943|NCT04237402|Other|Intra individual|Before and after pregnancy, hair follicles will be analysed
11076944|NCT04237389|Active Comparator|Ablation Index guided catheter radiofrequency ablation|30 patients, who undergo Ablation Index (AI) guided catheter RF ablation
11076945|NCT04237389|Active Comparator|Thoracoscopic surgical epicardial ablation|"30 patients, who undergo thoracoscopic ablation using Box-lesion set"
11076946|NCT04237376||Treatment Arm A: CHB Mothers treated with TAF during Pregnancy|120 pregnant women with double positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL were recruited from all four treatment centers. Mothers were enrolled and observed from gestational week 24-28 until postpartum week 28, and treated with TAF (25mg oral daily) from gestational week 28 until delivery (if the liver function is significantly abnormal after delivery, that is, ALT ≥ 5 × Upper Limit of Normal (ULN), the oral antiviral drug can be continued according to the wishes of the pregnant woman and the test results). All babies were given 3 HBV vaccines (0, 1, 6) and 1 routine Hepatitis B immunoglobin (HBIG) after birth. All babies were followed up to 2 years. According to the mother's wishes, if the mother agrees to collect breast milk and determine TAF concentration, breast milk was collected every day, and continuously collected 5-7 days for TAF concentration measurement. The time of last TAF dose taken as well as the time between milk collection and delivery was recorded.
11076947|NCT04237376||Comparative Arm C: CHB Pregnant Mothers|This arm C consists of 360 cases of pregnant women with HBsAg and HBeAg double-positive, and HBV DNA level ≥ 2 × 10^6 IU/mL. The mothers in this historical cohort did not receive any antiviral treatment during their pregnancy. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
11076948|NCT04237376||Comparative Arm B: CHB Pregnant Mothers treated with TDF|This retrospective cohort arm B consists of 120 cases of pregnant women with double-positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. Pregnant mothers were treated with TDF (300mg oral daily) starting from gestational week 28 and discontinued the drug at delivery. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
11076949|NCT04237363|Experimental|Exercise|Walk training
11076950|NCT04237350||visual impairment group|"The visual impairment group is defined as a VA out of the 95% reference range in at least 1 eye or worse with structural abnormalities."
11076951|NCT04237350||likely healthy group|"For the likely healthy group, the visual acuity of both eyes is in the 95% referenced range with no structural abnormalities.
~The referenced range could be found in the following publication:
~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
11076952|NCT04237337||serious cancer ICSRs (cases)|
11076953|NCT04237337||other serious reactions ICSRs (non-cases)|
11076954|NCT04237324|Experimental|NAFL group|One side of the patient face has been therapied by 1565nm fiber nonablative fractional laser(Lumenis Co., Yokneam, Israel).
11076955|NCT04237324|Active Comparator|FMR group|Another side of the patient face has been therapied by FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
11076956|NCT04237298|Active Comparator|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
11076957|NCT04237298|Experimental|Modified vacuum-formed retainer covering the palate|The modified vacuum-formed retainer is designed to cover the palate. It is cheaper, easier to fabricate and more esthetic. Patients will be instructed to wear the retainer 24 hours during the study period.
11076958|NCT04237285|Experimental|Lavender 15|Participant who inhalates lavender oil for 15 minutes.
11076959|NCT04237285|Experimental|Lavender 60|Participant who inhalates lavender oil for 60 minutes.
11076960|NCT04237285|Placebo Comparator|Jojoba|Participant who inhalates jojoba oil for 15 minutes.
11076961|NCT04237272|Active Comparator|Pod System|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
11076996|NCT04236960|Experimental|18~55 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
11076964|NCT04237259|Experimental|Parent-administered TCM massage group|Parents of subjects in the parent-administered TCM massage group (n=30) will attend 2 training sessions (5 hours in total) to learn and practice the parent-administered TCM massage for ADHD before treatment starts. The parents will be told to practice the TCM massage on their child every 2 days for 2 months.
11076965|NCT04237259|Active Comparator|Parent-child interaction group|Parents in the parent-child interaction group (comparison group, n=30) will attend a 3-hour training course on line and spend extra time on interacting with their child at home.
11076966|NCT04237246|Experimental|Once daily Tacrolimus (Advegraf)|
11076967|NCT04237181|Other|Acute diarrhoea or colitis presumed to be of infectious origin|
11076968|NCT04237168||DLBCL patients|newly diagnosed DLBCL (de novo, all ages) patients treated with RCHOP (first-line treatment regimen)
11076969|NCT04237155|Other|Healthy controls involved in step 1|30 healthy individuals will complete a verbal material scoring questionnaire
11076970|NCT04237155|Other|Patients with schizophrenia involved in step 1|30 patients with schizophrenia will complete a verbal material scoring questionnaire
11076971|NCT04237155|Other|Healthy controls involved in step 2|30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference
11076972|NCT04237155|Other|Patients with schizophrenia involved in step 2|30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference
11076973|NCT04237142|Experimental|Eligible patients who had consented to participate|Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation < 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.
11076974|NCT04237129|Experimental|Gan & Lee Insulin Aspart|100 units/mL, 3 ml prefilled pen
11076975|NCT04237129|Active Comparator|NovoRapid® Insulin Aspart|"Product approved and marketed in the EU
~FlexPen100 units/mL prefilled pen"
11076976|NCT04237129|Active Comparator|NovoLog® Insulin Aspart|"Product approved and marketed in the US
~FlexPen100 units/mL prefilled pen"
11076977|NCT04237116|Experimental|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
11076978|NCT04237116|Placebo Comparator|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
11076979|NCT04237103|Experimental|methotrexate|Methotrexate once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months after Methotrexate therapy for 6 months.
11076980|NCT04237103|Placebo Comparator|placebo|Placebo once a week orally for 8 months in conjunction with narrow band UVB phototherapy starting 2 months afterplacebo therapy, for 6 months.
11076981|NCT04237090|Active Comparator|Diphenhydramine + placebo|"Diphenhydramine 50 mg intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.
~Lactose tablet 100 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water."
11076982|NCT04237090|Experimental|Cetirizine + placebo|"Cetirizine tablet 10 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.
~1 milliliter of sodium chloride 0,9 percent intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion."
11076983|NCT04237077|Experimental|"Group with telephone coaching program ."|subjects aged 75 years or more living at home, with telephone coaching program
11076984|NCT04237077|Active Comparator|"Group without telephone coaching program."|subjects aged 75 years or more living at home, without telephone coaching program
11076985|NCT04237064||Patients with carotid artery stenosis|In this study, patients in the age of > 18 year will be included that are scheduled for an endarterectomy procedure at CZE.
11076986|NCT04237038|Experimental|laparoscopic Nissen fundoplication short gastric vessel divi|Randomized clinical trial conducted in forty patients submitted to short gastric vessel division (SGVD) forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life.
11076987|NCT04237025|Experimental|Nordic walking exercise group|Supervised Nordic walking exercise training 3 times per week for the first two weeks and 2 times per week for next four weeks (total 6 weeks). In addition to independent Nordic walking exercise twice weekly during intervention phase and three times weekly during the 3-month followup phase.
11076988|NCT04237012|Experimental|Dextenza|Treatment Arm-Dextenza insertion lower lid punctum at time of screening and use of OTC artificial tears as needed
11076989|NCT04237012|Active Comparator|Over the counter Artificial tears|Controlled arm: continuation of OTC artificial tears no placement of Dextenza intracanular insert
11076990|NCT04236999|Experimental|YSLQQ group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Unplugged in its original name, but the adaptation made by the research team for Chile is called Yo Sé Lo Que Quiero (YSLQQ). 12 one-hour sessions taught once a week by class teachers, previously trained in a 3-day course. Each session will be delivered during the time of Orientation lessons."
11076991|NCT04236999|No Intervention|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
11076992|NCT04236986|No Intervention|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
11076993|NCT04236986|Experimental|Post-LPS [11C]PBR28 PET Scan|Subjects will complete a second120-minute [11C]PBR28 PET scan 3-hours after LPS administration (1.0ng/kg; IV)
11076994|NCT04236973|Experimental|clinical performance of the Truenat™ HCV assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the Common Technical Specifications 2009/886/EC (CTS) of the CE-IVDD and WHO TSS-10 (draft) for IVDs medical devices used for the qualitative and quantitative detection of Hepatitis C RNA.
11076995|NCT04236973|Active Comparator|comparison CE-IVD marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
11076997|NCT04236960|Experimental|2~17 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
11076998|NCT04236960|Experimental|7~23 mos|2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.
11076999|NCT04236960|Experimental|3 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.
11077000|NCT04236960|Experimental|2 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.
11077001|NCT04236947|Experimental|SCPP-YA group|SCPP-YA adapted to Chile consist of ten sessions promoting self-regulation strategies, prosocial, and problem-solving skills. It also includes a module (6 sessions) specially designed for substance use prevention, developing social competence, and assertiveness to deal with peer pressure. These 16 sessions will be implemented during an academic year (2020), and complemented with three booster sessions the following year (2021).
11077002|NCT04236947|No Intervention|Control Group|The control schools will continue providing their traditional preventive actions.
11077003|NCT04236934||All included patients|Patients with recurrent unilateral pleural effusion
11077004|NCT04236921|Experimental|Treatment A|1 x DopaSnap® tablet, administered under fasting conditions.
11077005|NCT04236921|Active Comparator|Treatment B|1 x RLD of CD-LD tablet administered under fasting conditions.
11077006|NCT04236921|Experimental|Treatment C|Test - fed 1 x DopaSnap® tablet , administered under fed conditions.
11077007|NCT04236921|Experimental|Treatment D|DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.
11077008|NCT04236921|Experimental|Treatment E|½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose
11077009|NCT04236908|Experimental|Group 1 (NSAIDS only)|NSAIDs only (naproxen 500mg by mouth twice a day as needed)
11077010|NCT04236908|Experimental|Group 2 (Acupuncture+GV26)|Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
11077011|NCT04236908|Experimental|Group 3 (Battlefield Acupuncture+NSAIDS)|Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
11077012|NCT04236908|Experimental|Group 4 (Battlefield Acupuncture+GV26+NSAIDS)|GV26 with manual tonification + Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed).
11077013|NCT04236895|Active Comparator|Lantus ® US|Insulin glargine (Lantus®, product approved and marketed in the USA (US RLD)), 100 U/mL in 3 mL pre-filled pens
11077014|NCT04236895|Active Comparator|Lantus ® EU|Insulin glargine (Lantus®, product marketed in Germany (EU RP)), 100 U/mL in 3 ml pre-filled pens
11077015|NCT04236895|Experimental|Gan & Lee Insulin Glargine|Insulin glargine 100 U/mL in 3 mL pre-filled pens
11077016|NCT04236882|Experimental|Group I (sleep intervention, health coaching session)|Participants receive a web-based sleep intervention during weeks 1-4. Participants then receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out at weeks 5 and 7. Participants may optionally complete an interview over 1 hour at week 9.
11077017|NCT04236882|Experimental|Group II (health coaching session, sleep intervention)|Participants receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out at weeks 1 and 3. Participants then receive a web-based sleep intervention during weeks 5-8. Participants may optionally complete an interview over 1 hour at week 9.
11077018|NCT04236882|Active Comparator|Group III (health education material, health coaching session)|Participants receive educational material on healthy homes. Participants also receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out at weeks 1 and 3. Participants may optionally complete an interview over 1 hour at week 9.
11077019|NCT04236856|Other|Robotic Endovascular Procedure|Subjects with a clinical indication for endovascular coil and/or stent assisted coiling embolization of cerebral aneurysms will be treated using the CorPath GRX System.
11077020|NCT04236843|Active Comparator|Smal intestine once|90-g fecal transplant given into the small intestine once.
11077021|NCT04236843|Active Comparator|Small intestine twice|90-g fecal transplant given into the small intestine twice with 1 week interval.
11077022|NCT04236843|Active Comparator|Large intestine once|90-g fecal transplant given into the large intestine once.
11077023|NCT04236830|Experimental|Silver diamine fluoride/ potassium iodide group|Riva Star Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia
11077024|NCT04236830|Experimental|Silver diamine fluoride group|Advantage arrest TM, Elevate Oral Care, USA
11077025|NCT04236830|Active Comparator|Resin modified glass ionomer cement group|Riva light cure, SDI, Bayswater, Australia
11077026|NCT04236817|Experimental|Pre-packed blisters for distribution of medications|Patients in the intervention group received prescriptions pre-packaged in individual packets that were delivered by the pharmacy.
11077027|NCT04236817|Placebo Comparator|Routine distribution of medications|Patients in the control group continued to receive medications from pharmacies as they did prior to enrollment.
11077028|NCT04236804|Experimental|TMC-CP01 Intervention|Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines.
11077029|NCT04236804|No Intervention|Standard of Care|Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
11077030|NCT04236791|Experimental|Intervention group|
11077031|NCT04236791|Active Comparator|Control group|
11077032|NCT04236778|Experimental|Cohort 1|Cohort 1 received oral vancomycin followed by a single dose of VE303.
11077033|NCT04236778|Experimental|Cohort 2|Cohort 2 received oral vancomycin followed by a single day of 5 doses of VE303.
11077034|NCT04236778|Experimental|Cohort 3|Cohort 3 received oral vancomycin followed by a single day of 10 doses of VE303.
11077035|NCT04236778|Experimental|Cohort 4|Cohort 4 received oral vancomycin followed by 5 days of 10 doses daily of VE303.
11077036|NCT04236778|Experimental|Cohort 5|Cohort 5 received oral vancomycin followed by 14 days of 10 capsules daily of VE303
11077037|NCT04236778|Experimental|Cohort 6|Cohort 6 received 21 days of 10 doses daily of VE303
11077038|NCT04236778|Experimental|Cohort 7|Cohort 7 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
11077039|NCT04236778|Experimental|Cohort 8|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
11077040|NCT04236778|Experimental|Cohort 9|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
11077041|NCT04236778|Placebo Comparator|Vancomycin only|This cohort only received oral vancomycin.
11077042|NCT04236765|Experimental|TB infection-screening benefiting group|children VFRs under 15 years of age (which are children of immigrants and born or not in Spain) who travel to countries with an elevated incidence of TB will be screened for LTBI after their return.
11077043|NCT04236752|Experimental|Single arm radiotherapy|HDR Brachytherapy Boost of 15Gy to the prostate followed by Stereotactic Ablative Body Radiation (SBRT) 25 Gy in 5 fractions, once weekly to prostate, SVs and pelvic lymph nodes + 6-18 months of ADT
11077044|NCT04236739|Experimental|IMPACT|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) during one surgical procedure.
11077045|NCT04236739|No Intervention|Control|Optional physical therapy or pain medication, according to participants' desire for 9 months.
11077046|NCT04236726||Non-invasive ventilation|Users of non-invasive ventilation
11077047|NCT04236726||Long term tracheostomy ventilation|Long term tracheostomy ventilated patients
11077048|NCT04236713|Experimental|Dietary intervention 1|
11077049|NCT04236713|Experimental|Dietary intervention 2|
11077050|NCT04236700||beach workers|"Workers must undergo clinical examinations of the upper and lower lips, performed by previously calibrated researchers, through semi-technical inspection and palpation maneuvers, in order to identify injuries. Photo cameras can be used to improve the visibility of the lips using the image enhancement feature, to confirm the diagnosis. The clinical examination will include: dryness, atrophy, scaly lesions, lip swelling, erythema, ulcerations, cloudy demarcations between the vermilion of the lip and skin, demarcated folds along the lip, white spots or plaques, crusts, stained or pale areas.
~They should be evaluated with the application of a previously validated questionnaire containing information related to personal data, information on occupation and health was completed according to the responses of the volunteers. The OHIP-14 quality of life questionnaire will be applied together"
11077051|NCT04236687|Experimental|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
11077052|NCT04236687|Active Comparator|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate.
11077053|NCT04236674|No Intervention|No intervention|
11077054|NCT04236674|Experimental|Buzzy|Thermomechanical device for periprocedural analgesia
11077055|NCT04236674|Experimental|Music Selection|Patient specified music selection for procedural room
11077056|NCT04236674|Experimental|Buzzy and Music Selection|A combination of use of the Buzzy device and patient specified music selection
11077057|NCT04236661|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
11077058|NCT04236648|Other|Minimally-invasive non-surgical therapy (MINST)|Study treatment
11077059|NCT04236635|Experimental|Single CCH Subcutaneous Injection Technique|Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.
11077060|NCT04236635|Experimental|Multiple CCH Subcutaneous Injection Technique|Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.
11077061|NCT04236622||Health|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
11077062|NCT04236622||Peri-implantitis|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
11077063|NCT04236609|Active Comparator|Abluminus DES+ sirolimus- eluting stents (SES)|Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
11077064|NCT04236609|Active Comparator|XIENCE Everolimus-Eluting Stents (EES)|Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
11077065|NCT04236596|Experimental|Medtronic Interstim II Model 3058 Neurostimulator|
11077066|NCT04236583|Experimental|Telehealth|Eligible patients will be given the option to consent to having one virtual visit with their primary care physician within four weeks after discharge from the hospital. Usual follow-up care will occur during this visit.
11077067|NCT04236570|Other|Pain tests with the standardized protocol|This arm will consisted of pain tests using the standardized protocol (thermode(hot plate) and cold water bath)). The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the standardized protocol, the TS will consisted of a noxius heat stimulus generated by a thermode (hot plate), applied for two minutes on the non-dominant anterior forearm. The CS will consisted of a cold pressor test (CT), wherein participants immersed their dominant forearm in a cold water bath for two minutes.
11077126|NCT04236193||Controls|Subjects from a prospective influenza vaccine study
11077127|NCT04236180|Active Comparator|Intervention Group|Patients enrolled in the Specialised Paediatric Palliative Care (SPPC) programme at the University Children's Hospital Zurich.
11077298|NCT04234958|No Intervention|Control|Participants received no intervention
11077068|NCT04236570|Other|Pain tests with the TENS protocol|This arm will consisted of pain tests using the TENS protocol. The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the TENS protocol, the TS will consisted of a noxius electrical stimulus generated by TENS, applied for 5 seconds on the non-dominant knee at a frequency of 1 Hz and 5 Hz. The CS will consisted of a noxius electrical stimulus generated by TENS' applied for 120 seconds on the non dominant knee and ankle at a frequency of 2 Hz
11077069|NCT04236557|Experimental|Intervention|
11077070|NCT04236557|Placebo Comparator|Wait-list Control|
11077071|NCT04236544|Experimental|PExMS and DECIMS-Wiki|After allocation, the intervention group will receive access to PExMS and DECIMS-Wiki for a four-week period. The former is a multimedia website providing experiential information. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
11077072|NCT04236544|Active Comparator|DECIMS-Wiki|After allocation, the control group will receive access to the DECIMS-Wiki for a four-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
11077073|NCT04236531|Experimental|individuals at ultra-high risk for psychosis (UHR)|"30 individuals meeting the UHR criteria according to the Comprehensive Assessment of at-risk mental state (CAARMS) will be recruited and will complete cognitive task and MRI scan"
11077074|NCT04236531|Experimental|patients with first episode psychosis (FEP)|30 patients with first episode psychosis (FEP) will be recruited and will complete cognitive task and MRI scan
11077075|NCT04236531|Sham Comparator|healthy controls|30 healthy individuals will be recruited and will complete cognitive task and MRI scan
11077076|NCT04236518|Experimental|: hypertriglyceridimic waist phenotype / animal protein source|20 men between 25 and 55 years old with a high waist circumference and high triglyceridemia receiving diets with predominantly animal protein sources
11077077|NCT04236518|Experimental|hypertriglyceridimic waist phenotype / plant protein source|20 men between 25 and 55 years old with a high waist circumference and high triglyceridemia receiving diets with predominantly plant protein sources
11077078|NCT04236505|Experimental|ACT group intervention|4 weekly 2hour group therapy interventions drawing from an Acceptance and Commitment Therapy (ACT) based protocol.
11077079|NCT04236505|Experimental|Mindfulness skills group intervention|4 weekly 2 hour group therapy interventions drawing from an Mindfulness based stress reduction (MBSR) based protocol
11077080|NCT04236505|Placebo Comparator|Wait list control group|Wait list control group who at the time of the experimental group interventions are not attending a group and receiving treatment as usual. This group are offered a Mindfulness skills group intervention after the follow up data has been collected.
11077081|NCT04236492||Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
11077082|NCT04236479|Experimental|Bone marrow-derived mesenchymal stromal cell (BM-MSC)|The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD.
11077083|NCT04236466|Experimental|hyrax group|cleft lip and palate patients with hyrax appliance
11077084|NCT04236466|Experimental|haas group|cleft lip and palate patients with haas appliance
11077085|NCT04236453|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
11077086|NCT04236453|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COB] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
11077087|NCT04236440|Experimental|Part A: A1A2 + Part B|"Part A: Participants will receive a single dose administration of BAY2586116 (A1) in treatment period 1, and a single dose administration of placebo (A2) in treatment period 2.
~Part B: After successfully completing Part A, participants will proceed to Part B of the study.
~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.
~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3)."
11077088|NCT04236440|Experimental|Part A: A2A1 + Part B|"Part A: Participants will receive a single dose administration of placebo (A2) in treatment period 1, and a single dose administration of BAY2586116 (A1) in treatment period 2.
~Part B: After successfully completing Part A, participants will proceed to Part B of the study.
~Participants will receive a single dose administration of BAY2586116 (B1) in treatment period 3.
~Based on the result of the interim analysis there are two possible scenarios regarding mode of application and doses of BAY2586116 to be administered in treatment period 4: 1) a single dose administration of BAY2586116 (B2) Or 2) a single dose administration of BAY2586116 (B3)."
11077089|NCT04236427|Experimental|Treatment Group|Chinese Medicine of Angong Niuhuang Wan
11077090|NCT04236427|Placebo Comparator|Placebo Group|Placebo of Angong Niuhuang Wan
11077091|NCT04236414|Experimental|Cohort A: ≥12 to <18 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
11077128|NCT04236180|No Intervention|Comparison Group|Patients treated at the Children's Hospital Aarau, University Children's Hospital Basel, and the University Hospital Inselspital Bern.
11077092|NCT04236414|Experimental|Cohort B: ≥3 to <12 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
11077093|NCT04236414|Experimental|Cohort C: ≥6 months to <6 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards, using the AAF when available (if required). Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets/AAF can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
11077094|NCT04236414|Experimental|Signal identification|A secondary analysis of response in patients recruited into the signal identification phase will be conducted. Patients included in this analysis must have documented evidence of a deleterious or suspected deleterious germline or tumour HRR gene mutation. A minimum of 10 patients across age and dose cohorts with deleterious or suspected deleterious HRR mutations will be enrolled.
11077095|NCT04236401|Other|electrosurgery will be used inanterior abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall electrosurgically.
11077096|NCT04236401|Other|scalpel will be used in abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall sharply.
11077097|NCT04236388|Active Comparator|Dietary Ketone|Participants will consume three daily ketone drinks (one before each meal) for 2 weeks.
11077098|NCT04236388|Placebo Comparator|Placebo|Participants will consume three daily placebo drinks (one before each meal) for 2 weeks. .
11077099|NCT04236375||Normal|Subjects over 45 years old without cognitive dysfunction
11077100|NCT04236375||Mild cognitive decline|Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists.
11077101|NCT04236375||Alzheimer's disease|Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists.
11077102|NCT04236375||Vascular dementia|Subjects who are diagnosed as vascular dementia(VD) according to neurologists.
11077103|NCT04236375||Lewy body dementia|Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists.
11077104|NCT04236375||Frontotemporal dementia|Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists.
11077105|NCT04236375||Other dementia|Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD.
11077106|NCT04236362|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11077107|NCT04236349||CO1TB: observational|patients with pulmonary and extrapulmonary tuberculosis
11077108|NCT04236349||CO2TB: immunogenetics|"patient with pulmonary and extrapulmonary tuberculosis and meet the following criteria:
~informed consent form signed by the patient or by the representative of parental authority
~affiliation to social security (beneficiary or assignee)
~HIV negative"
11077109|NCT04236323|Experimental|not used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair not used intraoperative remifentanil infusion
11077110|NCT04236323|No Intervention|used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair used intraoperative remifentanil infusion maintaining target concentration of 2-6ng/ml
11077111|NCT04236310|Experimental|SHR6390+Anastrozole+Pyrotinib+Trastuzumab±Ovarian Suppression|
11077112|NCT04236297|Active Comparator|Standard Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a standard bite block is used
11077113|NCT04236297|Other|Modified Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a modified bite block is used
11077114|NCT04236284|Experimental|Home-based tDCS + Prolonged Exposure Therapy|Participants will come in person to the clinic office to complete the baseline visit and the in-person training for the use of both home-based self-administered tDCS and the home-based telehealth device (iPad) for the PE sessions. They understand that they will start the sessions of tDCS once they start the in vivo and imaginal exposures assignments at home. They will self-administer (under televideo supervision) the tDCS session before doing in vivo and/or imaginal exposures assignments. The participants will be remotely supervised by trained research staff at each stimulation to ensure the technique is correct and to monitor any adverse events. We will provide secure videoconferencing software (e.g., WebEx) and ensure the participants are comfortable using the telehealth software.
11077115|NCT04236271|Experimental|patient|interventional group
11077116|NCT04236258|Active Comparator|Nifedipine|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start nifedipine extended release 30 mg daily as their starting antihypertensive.
11077117|NCT04236258|Active Comparator|Enalapril|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start enalapril 10 mg daily as their starting antihypertensive.
11077118|NCT04236245|Other|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
11077119|NCT04236232||Patients who will be diagnosed as Subclinical Hypothyroidism|50 pt who will be diagnosed as Subclinical Hypothyroidism by elevated level of TSH (TSH: >4.5 mu/l) and normal T4
11077120|NCT04236232||Patients with normal thyroid function|50 pt with normal thyroid function (TSH &T4)
11077121|NCT04236219|Experimental|ALLN-346|ALLN-346
11077122|NCT04236219|Placebo Comparator|Placebo|Placebo
11077123|NCT04236206|Experimental|SMS Recipients|• Mobile phone SMSs will be sent to the intervention group with the aim of improving medication adherence and knowledge about diabetes, its complications, diet and physical activity.
11077124|NCT04236206|No Intervention|Non-SMS Recipients|Control group with no intervention.
11077125|NCT04236193||SIRVA|Subjects with shoulder pain >7 days after vaccination
11077129|NCT04236167|No Intervention|Control half of scar|one half of the scar will receive standard scar treatment with topical products and pressure garments, but no ablative fractional CO2 laser
11077130|NCT04236167|Experimental|Laser treatment half of scar|The other half of the scar will receive standard scar treatment with topical products and pressure garments and, in addition, will receive ablative fractional CO2 laser treatment
11077131|NCT04236154|Experimental|10%|Increase exercise daily step count by 10% above individual baseline.
11077132|NCT04236154|Experimental|20%|Increase exercise daily step count by 20% above individual baseline.
11077133|NCT04236154|Experimental|30%|Increase exercise daily step count by 30% above individual baseline.
11077134|NCT04236154|Experimental|50%|Increase exercise daily step count by 50% above individual baseline.
11077135|NCT04236154|Experimental|80%|Increase exercise daily step count by 80% above individual baseline.
11077136|NCT04236141|Experimental|Polatuzumab Vedotin plus BR|
11077137|NCT04236141|Active Comparator|Placebo plus BR|
11077138|NCT04236128|Experimental|Intervention Group|The intervention group will receive the same usual care as the control group plus be enrolled in the integrated discharge monitoring system.
11077139|NCT04236128|Active Comparator|Control Group|The control group will receive usual follow up care that is currently provided at the 3 participating centres.
11077140|NCT04236115|Active Comparator|Articaine 4% with 1:00.000 Adrenaline|if the patient was in articaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
11077141|NCT04236115|Active Comparator|Prilocaine with 3% Felypressin (0.03 I.U. per ml)|if the patient was in prelocaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
11077142|NCT04236102|Experimental|EGFR, KRAS, BRAF Lung adenocarcinoma LBC|Will use residual material from existing LBC cytology samples sent to the laboratory. Routine testing will take priority. Cases identified as non small cell lung carcinoma will have the residual LBC sample tested on the Idylla platform for EGFR, KRAS and BRAF. The EGFR, KRAS and BRAF mutation results obtained using the routine diagnostic procedure (FFPE samples) will be compared to those produced using the LBC samples.
11077143|NCT04236102|Experimental|KRAS Pancreatic adenocarcinoma|Will involve testing archived FFPE clot samples from confirmed pancreatic adenocarcinoma patients since 2014 (Approximately 20 cases per year). KRAS testing will be performed using the Idylla platform to establish if there is a KRAS codon 12 mutation present in 94% percent of the cases reported at RCHT. Patients will have consented to the use of their tissue at the time of procedure. Prospectively new patients diagnosed with pancreatic adenocarcinoma will have KRAS testing on the FFPE clot made as part of the routine diagnostic work up and KRAS testing on the LBC sample.
11077144|NCT04236102|Experimental|EGFR, KRAS, BRAF Blood plasma|Will involve a blood sample being taken at the time of the procedure from patients that have a clinical suspicion of having lung or pancreatic cancer. The single blood sample will be taken from the cannula inserted for the procedure. The blood sample will be processed using the Biocartis Idylla ™ circulating tumour cell cartridges (EFGR, KRAS and BRAF for lung and KRAS for pancreas).
11077145|NCT04236089|No Intervention|mirror therapy of healthy adults|Traditional mirror therapy in electroencephalography of healthy adults.
11077146|NCT04236089|Experimental|robotic mirror therapy of healthy adults|Robotic mirror therapy in electroencephalography of healthy adults.
11077147|NCT04236089|No Intervention|mirror therapy of stroke patients|Traditional mirror therapy in electroencephalography of stroke patients.
11077148|NCT04236089|Experimental|robotic mirror therapy of stroke patients|Robotic mirror therapy in electroencephalography of stroke patients.
11077149|NCT04236076|Experimental|PulseHaler™|Patients will receive PulseHaler for home treatment
11077150|NCT04236076|Sham Comparator|Sham PulseHaler - CONTROL group|Patients will receive Sham device for home treatment
11077151|NCT04236063||Haematological malignancy|Patients with haematological malignancy
11077152|NCT04236050|Experimental|rocuronium is administered via continuous infusion|"40 patients. General anesthesia is maintained with propofol and remifentanil, with standard anesthetic monitoring, bispectral index (BIS) and train-of-four(TOF). In experimental group, rocuronium was administered via continuous infusion so that theTOF ratio was 5%. Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.
~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
11077153|NCT04236050|Active Comparator|rocuronium is administered in bolus doses|"40 patients. General anesthesia was maintained with propofol and remifentanil, with standard anesthetic monitoring, BIS and TOF. In this group, rocuronium was administered in separate bolus doses with the TOF ratio of 5%.
~Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.
~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
11077154|NCT04236037|Active Comparator|Ultrasound-guided thoracentesis|Ultrasound guided thoracentesis
11077155|NCT04236037|Experimental|Ultrasound-guided pleural biopsy and thoracentesis|Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
11077156|NCT04236024|Experimental|Experimental group|The students in this group will learn medication knowledge by using board game.
11077157|NCT04236024|Active Comparator|Comparison group|The students in this group will learn medication knowledge through tradition lecture.
11077158|NCT04236011|Experimental|GC012F treatment|BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
11077159|NCT04235998||Systematic lung ultrasound|Patients with unilateral pleural effusion of unknown course
11077160|NCT04235985|Other|All time points|
11077161|NCT04235972|Other|Arthrodesis surgery patients|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
11077162|NCT04235959|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
11077164|NCT04235946|Experimental|accompanied and adapted water polo program|"16 and 20 aqua polo sessions (adapted water polo) over a period of 20 weeks, at the rate of one session per week at the Cercle des Nageurs de Marseille (CNM). They will be divided into 3 cycles imitating the preparation of the season of a high-level athlete: a first cycle intended for physical preparation, a second cycle intended for practical learning (technique and tactics) and the third cycle for preparation of a mini tournament.
~Each session will be organized as follows: 1 hour of training in the water followed by 30 min of debriefing as a team or individually with the coach. The announced duration of the session will be 2 hours, transport and changing rooms included."
11077165|NCT04235933|Experimental|Tai Ai(RC18) 80mg|·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
11077166|NCT04235933|Experimental|Tai Ai(RC18) 160mg|·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
11077167|NCT04235933|Experimental|RC18 240mg|·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18
11077168|NCT04235920||Impaired Cognition|First group was cognitively impaired test with MoCA score of 25 or less.
11077169|NCT04235920||Preserved cognition|The second group was cognitively preserved with MoCA score of higher than 25.
11077170|NCT04235907|Active Comparator|Traditional Physical Therapy|Patients will be given a prescription to see a physical therapist and a paper-based rehabilitation protocol. Patients will be allowed to receive physical therapy at a location of patients' choosing. This arm represents the current standard of care.
11077171|NCT04235907|Active Comparator|Telerehabilitation|Patients will be given access to a website containing instructions with pictures and videos for the exercises patients are to complete as part of patients' rehabilitation. Patients will not be given a prescription to physical therapy. Patients in this group will receive weekly calls from a physical therapist during weeks 6-12 post-operatively.
11077172|NCT04235894||Patients undergoing GI endoscopy at Osijek University Hospital|Observational study. A total of 130 consecutive patients undergoing gastrointestinal endoscopy were included. The anesthesia was provided with propofol, starting with 0,5 mg/kg, and titrated until a patient was unresponsive to painful stimuli and maintaining spontaneous breathing. The blood pressure, pulse and Bispectral index values were measured in 6 defined points. On the emergence from anesthesia, the patient's facial expression was rated numerically by the investigator.
11077173|NCT04235881|Experimental|MBSR group|Enforcement of the standardized program Mindfulness-Based Stress Reduction
11077174|NCT04235881|Experimental|App group.|Enforcement of the emotional regulation program based on mindfulness (ERM) through the mobile phone application REM volver a casa
11077175|NCT04235881|No Intervention|Control group|Usual care
11077176|NCT04235868|Active Comparator|control group|
11077177|NCT04235868|Experimental|experimental group|
11077178|NCT04235855|Experimental|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
11077179|NCT04235855|Active Comparator|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
11077180|NCT04235842|No Intervention|Control Group (CG)|The CG will receive the standard indications routinely provided by the hospital which consists in information about practice of regular physical activity according to World Health Organization. A leaflet with illustrations and indications will be provided and will be explained by the principal investigator.
11077181|NCT04235842|Experimental|Moderate-intensity continuous exercise training group (GMICT)|The GMICT will be submitted to a physical exercise program in which the aerobic component will be a moderate-intensity continuous exercise training, performed at 60% of the heart rate reserve, two days a week, for 30 minutes.
11077182|NCT04235842|Experimental|High-intensity interval training exercise group (GHIIT)|The GHIIT will be will be submitted to a physical exercise program in which the aerobic component will be a high-intensity interval exercise training, performed in a protocol consisted of four one-min sprint at 90% of the heart rate reserve, alternated with one-min rest (at week 1) and progressing until reach 10 bouts of one-min sprint alternated with one-min rest.
11077183|NCT04235816|Active Comparator|Group 1|AZi at DTP-1 visit at 6 weeks of age, AZi (plus IPTi) at measles visit at 9 months of age and AZi (plus IPTi) at measles booster visit at 15 months of age.
11077184|NCT04235816|Placebo Comparator|Group 2|Placebo at DTP-1 visit at 6 weeks of age, placebo (plus IPTi) at measles visit at 9 months of age and placebo (plus IPTi) at measles booster visit at 15 months of age.
11077185|NCT04235803|Experimental|Telemedicine|Patients in the telemedicine arm will have their post-operative week one visit via a telemedicine portal.
11077186|NCT04235803|No Intervention|Routine|Patient in the routine arm will have their post-operative week one visit in clinic.
11077187|NCT04235790|No Intervention|Medical Student or Resident|Subjects will perform simulated central venous catheters (CVC) insertions.
11077188|NCT04235790|Other|Novice and Expert IBP Teachers|Expert teachers will be identified based on years as faculty, number of supervised procedures, prior teacher awards, and participation in IBP teaching at international conferences. Novice teachers will include those that have performed less than 50 CVCs. Teachers will supervise 3 simulated central venous catheters (CVC) insertions with increased complexity while wearing an eye tracking device.
11077189|NCT04235777|Experimental|Arm 1|Treatment with M7824 and deescalating doses of M9241 if appropriate
11077190|NCT04235777|Experimental|Arm 2|Treatment with M7824 and deescalating doses of M9241 (if appropriate) with sequential SBRT
11077191|NCT04235777|Experimental|Arm 3|Treatment with M7824 and deescalating doses of M9241 (if appropriate) with concurrent SBRT
11077192|NCT04235764||1/ Cohort 1|Bladder Cancer Patients
11077193|NCT04235751|Experimental|Immediate Coaching Intervention|Subjects will receive 6 professional coaching sessions
11077194|NCT04235751|Experimental|Delayed Coaching Intervention|Subjects will receive no coaching for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
11077195|NCT04235699|Experimental|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood [3-OHB] ≥0.5 mM.
11077299|NCT04234945|Experimental|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
11077196|NCT04235699|Experimental|Low-fat mixed Diet|This arm will be provided food consisting of ~25% fat, and the remaining calories from carbohydrate (~55% after accounting for protein at ~20%).
11077197|NCT04235686|Active Comparator|Mydayis - Active|"MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase.
~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
11077198|NCT04235686|Placebo Comparator|Placebo|"Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase.
~12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days"
11077199|NCT04235673|Experimental|melatonin|melatonin oral drops; 3 mg/kg/day for 15 days
11077200|NCT04235673|Placebo Comparator|placebo|oral drops manufactured to mimic melatonin
11077201|NCT04235660|Active Comparator|Yttrium-90 Radiation Segmentectomy|
11077202|NCT04235660|Active Comparator|Stereotactic Body Radiation Therapy|
11077203|NCT04235647|Experimental|Study group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
11077204|NCT04235647|Active Comparator|Control group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
11077205|NCT04235634||Intra-arterial Prostglandin therapy|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
11077206|NCT04235621||FSGS/TR-MCD|Patients with FSGS/TR-MCD
11077207|NCT04235621||Diabetic Nephropathy (DN)|Patients with DN
11077208|NCT04235608|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane, as vaporized via the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
11077209|NCT04235608|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs
11077210|NCT04235595|Experimental|Connective Tissue Manipulation|The participants were administered CTM by a physiotherapist with 11 years of experience in the application from the point at which their menstrual cycles had ended to the beginning of the next cycle. Another assessment was made immediately after the treatment and this was repeated at the second, third and fourth menstrual cycles. The CTM took an average of 20-30 minutes to complete.
11077211|NCT04235595|Experimental|Transcutaneous Electrical Nerve Stimulation|Following the assessment made in the participants' first menstrual cycle, on the most painful day of their second cycle (1st or 2nd day of the cycle), high-frequency TENS was applied at a frequency of 120 Hertz, at intervals of 100 µsn for 20 minutes. The intensity of the current was increased until the participant felt it.
11077212|NCT04235582|Experimental|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
11077213|NCT04235582|Experimental|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:
~Drug adherence to prescribed SUD pharmacotherapy
~Attendance at individual and group psychotherapy sessions"
11077214|NCT04235582|Experimental|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:
~Drug adherence to prescribed SUD pharmacotherapy
~Attendance at individual and group psychotherapy sessions
~Random saliva tests"
11077215|NCT04235569|Experimental|Group I|"a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.
~Bleeding events due to overanticoagulation were monitored through the follow up period."
11077216|NCT04235569|Experimental|Group II|"a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.
~Bleeding events due to overanticoagulation were monitored through the follow up period."
11077217|NCT04235556||Historic cohort|Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
11077218|NCT04235556||Prospective cohort|All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
11077219|NCT04235543||autistic children aged 6:12 years|show the occurrance of traumatic dental injury compared to normal children
11077220|NCT04235543||normal children aged 6:12 years|show the occurrance of traumatic dental injury
11077221|NCT04235530||VAS and DVAS|To measure the pain score of patients after surgery
11077222|NCT04235517||Axial deviations in children|Children with axial deviations in the lower extremity treated with guided growth
11077223|NCT04235517||Limb length discrepancy in children|Children with limb length discrepancy treated with temporary epiphysiodesis
11077224|NCT04235504|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy (MDI+FGM or MDI+CGM) for 6 months during the Study Phase. During the Continuation Phase of 6 months Control Arm will start using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0
11077225|NCT04235504|Experimental|Treatment Arm|The Treatment Arm will use the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0 for 6 months during the Study Phase and other 6 months during the Continuation Phase.
11077226|NCT04235491||Micra AV leadless pacemaker therapy|All Medicare patients implanted with a Micra AV leadless pacemaker system
11077663|NCT04232592|Experimental|Injected stem cell group|The stem cells will injected.
11077227|NCT04235491||Dual Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) dual-chamber transvenous pacemakers
11077228|NCT04235478|Experimental|Cervical interlaminar epidural steroid injecion|Floroscopy-guided cervical interlaminar epidural steroid injecion will be applied to the patients with cervical radiculopathy related neck and arm pain
11077229|NCT04235465||Dyslexia Group|30 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7-day interval by two evaluators
11077230|NCT04235465||Healthy Control Group|30 healthy children will be included. Dynamic Gait Index will be performed.
11077231|NCT04235452||Epileptic myoclonus|Juvenile Myoclonic Epilepsy and Progressive Myoclonic Epilepsy
11077232|NCT04235452||Non-epileptic myoclonus (secondary)|Post hypoxic myoclonus, Post ischemic stroke myoclonus, Hepatic, Chronic kidney disease, and Drug induced myoclonus
11077233|NCT04235439|Experimental|Gan & Lee Insulin Lispro Injection|Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)
11077234|NCT04235439|Active Comparator|EU - approved Humalog ®|Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
11077235|NCT04235439|Active Comparator|US - licensed Humalog ®|Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
11077236|NCT04235426|Experimental|surgical group.|30 patients went to the surgical release of carpal tunnel.
11077237|NCT04235426|Experimental|medical group.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
11077238|NCT04235426|Experimental|injection group.|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
11077239|NCT04235413|Experimental|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 9 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
11077240|NCT04235413|No Intervention|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
11077241|NCT04235400||patient with dry eye disease|
11077242|NCT04235387||Robotic prostatectomy|All patients undergoing robotic assisted prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
11077243|NCT04235387||Laparoscopic prostatectomy|All patients undergoing standard laparoscopic prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
11077244|NCT04235374|Experimental|FFC-AC-EIT|The stakeholder team will meet with the research nurse facilitator to review the details of the 12 month intervention and identify unit goals. The research nurse facilitator will then work with the identified champion for 10 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to implement Steps 1 to 4 of FFC-AC-EIT [(1) Environment and Policy Assessments; (2) Education; (3) Establishing Patient Goals; and (4) Mentoring and Motivating of Staff, Patients and Families]. The stakeholder team will meet with the Research Nurse Facilitator monthly to review progress. In addition to monthly visits, weekly emails containing motivational Tidbits will be sent to all stakeholder team members within the cohort. The Tidbits include such things as updates about benefits of engaging patients with ADRD in physical activity while hospitalized.
11077245|NCT04235374|Placebo Comparator|Education Only|Education Only (EO) Control Intervention: Hospitals randomized to EO will be provided with an in-service for nursing staff on function focused care in patients with ADRD by an EO Research Nurse Facilitator using our developed PowerPoint presentations in 30-minute sessions as is currently done in usual practice.
11077246|NCT04235361||EVD patients|"The samples of all subjects (male, female, adults and children) meeting the WHO case definition of suspected and probable EVD case eligible for real time RT-PCR assay, according to the currently used case definition in DRC, will be tested by differential RPA."
11077247|NCT04235348||BELIEVE|Consists of subjects referred to a colonoscopy between June 1, 2017, and December 1, 2019, in the hospital of Southern Denmark
11077248|NCT04235335|Other|Wait List Control|Participants receive intervention after 12 week delay
11077249|NCT04235322|Experimental|2LHERP® arm|2LHERP® treatment (6 months of treatment)
11077250|NCT04235322|Placebo Comparator|Placebo arm|Placebo treatment (6 months of treatment)
11077251|NCT04235309||Total Knee Replacement Cohort|Any patients who are scheduled to undergo a total knee replacement.
11077252|NCT04235296|Active Comparator|control group|epidermal growth factor
11077253|NCT04235296|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
11077254|NCT04235283|Experimental|Group I|Primary total knee replacement by pinless navigation and minimally invasive technique
11077255|NCT04235283|Active Comparator|Group II|Primary total knee replacement by traditional jig and minimally invasive technique
11077256|NCT04235270|Experimental|Group 1 (Bioequivalence Part)|Participants will receive Treatment A (single oral dose of an fixed dose combination [FDC] of macitentan/tadalafil [10 milligram [mg]/40 mg] in fasted conditions [test]) or Treatment B (single oral dose of a free combination of 10 mg macitentan and 40 mg tadalafil in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment B or Treatment A on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
11077257|NCT04235270|Experimental|Group 2 (Food-effect Part)|Participants will receive Treatment C (single oral dose of an FDC of macitentan/tadalafil [10 mg/40 mg] in fed conditions [test]) or Treatment D (single oral dose of an FDC of macitentan/tadalafil (10 mg/40 mg) in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment D or Treatment C on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
11077258|NCT04235257|Experimental|Bivalent HPV vaccine|One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously
11077259|NCT04235257|Experimental|Nonavalent HPV vaccine|One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously
11077260|NCT04235244|Experimental|upper right abdomen|5 minutes before and after application to the right upper abdominal region. local cold application
11116784|NCT03957538|Experimental|Virtual reality|Addition of VR headset
11077261|NCT04235244|Experimental|upper left abdomen|Thermomechanical-analgesia device will be operated 30 seconds before the injection in the right lower abdominal region and the device will be injected by sliding the device to the side of the selected region during the injection,
11077262|NCT04235244|Experimental|lower left abdomen|Coolant spray will be applied to the upper left abdominal region for 15 sec.
11077263|NCT04235244|No Intervention|lower right abdomen|SC injection will be applied to the left lower abdominal region without any cold application.
11077264|NCT04235231|Experimental|Lateral tilt bed|Bed tilting (15° lateral tilt, original product brand name LINET Eleganza 5)
11077265|NCT04235231|Experimental|Body positioning|Manual positioning of body by nurse.
11077266|NCT04235205|Experimental|Elobixibat and cholestyramine|The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
11077267|NCT04235205|Experimental|Elobixibat|The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
11077268|NCT04235205|Experimental|cholestyramine|The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
11077269|NCT04235205|Placebo Comparator|Placebo|The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
11077270|NCT04235179|Experimental|SABR|Pelvic SABR for post-op endometrial cancer
11077271|NCT04235166||Patient cohort|Different risk score was used to assess the prognosis of acute upper gastrointestinal bleeding in cirrhosis.
11077272|NCT04235153||Patients with solid or hematological cancer|All the patients complete the CANUT-QVA questionnaire
11077273|NCT04235140|Experimental|LUM/IVA|Subjects will receive LUM/IVA for 96 weeks.
11077274|NCT04235127||Catalan population|The target population consists of the dynamic cohort of all Catalan residents during the 6-year period 2014-2019. Annual total population of Catalonia is between 7.5-7.6 million, with annual rates for immigration, emigration, birth and death being ~2.5%, ~1.9%, ~0.9%, and ~0.8%, respectively. Based on these figures, we expect a maximum of ~9.1 million individuals with Catalan residency status on at least one point in time over the 2014-2019 period. However, we expect SA in Catalonia to be extremely rare before the age of 10, in line with findings that self-injurious behaviour generally occurs as from the adolescent period. We will therefore exclude cases and controls that have not reached age 10 by the end of the 2014-2019 period (i.e., ~10.9%), lowering the total expected target population to ~8.1 million.
11077275|NCT04235114|Experimental|Establish Imaging Time|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging at four different time points till day 7 after infusion. Vitals, blood sample and urine sample will be collected every time before imaging. Participants will be followed up for any adverse event until day 30 post administration
11077276|NCT04235114|Experimental|Diagnostic Quality|Participants will receive an i.v. injection of 50 mg 2 mCi 89Zr-DFO-nimotuzumab. Participants will undergo imaging once at the best time calculated from arm 1 participants. Vitals, blood sample and urine sample will be collected before imaging. Participants will be followed up for any adverse event until day 30 post administration
11077277|NCT04235101|Experimental|SYD985 + Niraparib|SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
11077278|NCT04235088|Experimental|Somatosensory intensive intervention|
11077279|NCT04235088|Active Comparator|Conventional therapy and dose|
11077280|NCT04235075|Experimental|Pregnancy volunteer subjects|Subjects who will agree to participate in the study will be pregnant women referred to the Grenoble Alpes University Hospital for expert fetal cardiac ultrasound examination who have not revealed any abnormalities.
11077281|NCT04235062|Experimental|Fluid Expansion and Diuretic Challenge|Subject receive intravenous infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution, followed by diuretic challenge with 40mg Furosemide intravenous bolus.
11077282|NCT04235049|No Intervention|In prison treatment arm|Of patients who achieved SVR, 100 inmates will be enrolled for long-term monitoring for re-infection after they have completed treatment. Patients will be seen every 6 months to test for reinfection, however they will not be subject to any medical or behavioral interventions through the study team. Limited opioid agonist therapy may be available as per the standard practice of the DOC, however syringe exchange and other harm reduction services will not be accessible to inmates, per DOC policy.
11077283|NCT04235049|Active Comparator|Community Linkage - Rapid Initiation Arm|The rapid initiation group will receive HCV medication immediately upon release from prison/jail.
11077284|NCT04235049|Active Comparator|Community Linkage - Clinic-Based Initiation Arm|The group will receive medication after attending first ANCHOR clinic visit.
11077285|NCT04235049|No Intervention|In prison - Retrospective Review|a retrospective review of de-identified available data provided by the DOC for all patients previously treated with DAAs through standard of care in the DOC will be reviewed for rates of SVR.
11077286|NCT04235036|Experimental|Rituximab + Ibrutinib|Eligible patients will be those with a first episode of symptomatic cGVHD, requiring systemic immunosuppression for control of symptoms. Following study entry, patients will be started on rituximab plus ibrutinib.
11077287|NCT04235023|Other|OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index ≥ 15 per hour
11077288|NCT04235023|Other|non OSA patients|30 patients investigated for suspected OSA with an apnea hypopnea index < 15 per hour
11077289|NCT04235010|Experimental|Manual toothbrush|Patients used manual orthodontic toothbrush (Oral B Ortho, Procter & Gamble, USA) for four months
11077290|NCT04235010|Experimental|Genius toothbrush|Patients used genius orthodontic toothbrush (Oral B Genius 8900, Procter & Gamble, USA) for four months
11077291|NCT04234997|Experimental|Suvorexant 20 mg|
11077292|NCT04234997|Placebo Comparator|Suvorexant 0mg|
11077293|NCT04234984||Conventional radiofrequency treatment|All patients with chronic knee pain who qualify for a conventional RF treatment of the genicular nerves
11077294|NCT04234971|Experimental|Intervention group (DBM/BMP)|Patient undergoes Alveolar bone graft with DBM/BMP
11077295|NCT04234971|Active Comparator|Control group(autologous ICBG)|Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
11077296|NCT04234958|Experimental|Experimental|Participants received osteopathic treatment
11077300|NCT04234945|Placebo Comparator|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
11077301|NCT04234932|Experimental|Netarsudil alone|Topical application of netarsudil 0.02%
11077302|NCT04234932|Active Comparator|Netarsudil plus latanoprost|Topical application of netarsudil 0.02% with latanoprost 0.005%
11077303|NCT04234919||Consented adult lung transplant recipients|
11077304|NCT04234906|Active Comparator|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
11077305|NCT04234906|Active Comparator|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
11077306|NCT04234906|Active Comparator|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
11077307|NCT04234906|Active Comparator|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
11077308|NCT04234893||Drug-coated balloon|The Patients who treated with Bingo drug-coated balloon
11077309|NCT04234867|Experimental|Dapagliflozin - Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of 250µg ACTH (Synacthen)
11077310|NCT04234867|Experimental|Dapagliflozin and Placebo Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of Placebo matching Synacthen
11077311|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of 250µg ACTH (Synacthen)
11077312|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Placebo Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of Placebo matching Synacthen
11077313|NCT04234854||Carotid Artery Stenting|Consecutive patients older than 18 yrs with symptomatic carotid artery stenosis qualified for endovascular revascularization.
11077314|NCT04234841||Surgical Aortic Valve Replacement (SAVR)|This cohort includes patients who will be undergoing surgical aortic valve replacement
11077315|NCT04234841||Transcatheter Aortic Valve Implantation (TAVI)|This cohort includes patients who will be undergoing Transcatheter Aortic Valve Implantation
11077316|NCT04234828||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings Sleep Device and overnight PSG
11077317|NCT04234815|Experimental|CETA Short Session (CSS)|A single-session, 1.5-2 hour group workshop that includes psychoeducation, self-assessment, safety screening, and training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance. On this phone call they will also be asked about their use of the cognitive coping skill over the last week, and provided feedback if using it incorrectly.
11077318|NCT04234815|Active Comparator|Enhanced Treatment as Usual (eTAU)|A single-session, approximately 1-hour group workshop that includes the same psychoeducation, self-assessment, and safety screening as the experimental condition, but no training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance.
11077319|NCT04234802|Active Comparator|HEAT intervention group|Workers in the intervention group will receive the HEAT training, and supervisors in the intervention group will receive the HEAT awareness application and training on how to use it.
11077320|NCT04234802|No Intervention|Comparison group|The comparison group will not be offered HEAT trainings or the HEAT awareness application. They will be offered an alternative training on another topic.
11077321|NCT04234789|Other|Cardiopulmonary exercising test|All patients underwent to diagnostic tests protocol
11077322|NCT04234776|Experimental|Rapid-acting antidepressant|Subjects eligible to participate in the study will receive IM ketamine and will use 2 placebo tablets as randomized.
11077323|NCT04234776|Active Comparator|Comparator|Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized
11077324|NCT04234763|Experimental|T2D patients|T2D patients (n=24) will be randomized to high GI and low GI MCT randomly.
11077325|NCT04234763|Active Comparator|Healthy individuals|Healthy individuals (n=24) will be randomized to high GI MCT only.
11077326|NCT04234750|No Intervention|control group|no intervention
11077327|NCT04234750|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
11077328|NCT04234737|Experimental|Hypnotherapy|
11077329|NCT04234737|No Intervention|Control|
11077330|NCT04234724|Experimental|Variant|Volunteers with known ANGPTL3 variants
11077331|NCT04234724|Other|Non-variant|Healthy volunteers with no ANGPTL3 variants
11077332|NCT04234711||Conventional surgical group|Patients with total pulmonary venous connection undergo conventional surgical repair
11077333|NCT04234711||Sutureless surgical group|Patients with total pulmonary venous connection undergo sutureless surgical repair
11077334|NCT04234685|Experimental|HIPL Therapy™ group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).
~The HIPL Therapy™ group will receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks. Participants will lay in a relaxed position on a therapy plinth with the light applied using the Invitalizer 2.0. The phototherapy will illuminate the affected knee for 20 minutes. In the case of bilateral knee OA, the treatment time will be doubled and applied to both knees. The knee will be positioned at a determined distance from the lamp with an intensity setting of 150 mW/cm2."
11077391|NCT04234308|Experimental|Polyglycolic Acid Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
11077392|NCT04234308|Experimental|Chromic Gut Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
11077393|NCT04234308|Experimental|ePTFE Non absorbable suture|Periodontal and periimplant flaps closed with at least one suture with ePTFE Non absorbable suture, synthetic, 4-0. (TAGUM®)
11077335|NCT04234685|Placebo Comparator|Placebo Control group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).
~The placebo control group will also receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks, in the same setting as the HIPL Therapy™ group and for the same duration. However, the intensity setting will be set at 5 mW/cm2, a dosage, at which there is no therapeutic benefit expected, but the light will still be visible to the participant."
11077336|NCT04234672|Experimental|TAK-831 500 mg + [14C]TAK-831 50 mcg + [14C]TAK-831 500 mg|TAK-831 500 mg, tablet, orally, once on Day 1, followed by [14C]TAK-831 50 mcg (approximately 1 mcCi), infusion, intravenously, once on Day 1 of Period 1, followed by a washout period of at least 7 days, further followed by [14C]TAK-831 500 mg (approximately 100 mcCi), suspension, orally, once under fasted state on Day 1 of Period 2.
11077337|NCT04234659||Individuals Receiving Mechanical Circulatory Device Support|Individuals receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
11077338|NCT04234659||Individuals Without Mechanical Circulatory Device Support|Individuals not receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
11077339|NCT04234646|Active Comparator|Group 1: One-on-One Patient Navigation|One-on-one Patient Navigation will be based on a Case Management Model where patients navigators perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources.
11077340|NCT04234646|Experimental|Group 2: Patient Navigation 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
11077341|NCT04234633||SLE patients|Any SLE patients between 18 and 40 years old.
11077342|NCT04234620||Toripalimab injection|Use of Toripalimab injection in the real world
11077343|NCT04234607|Experimental|TQB2450+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11077344|NCT04234607|Experimental|TQB2450（blank）+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+ Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11077345|NCT04234607|Active Comparator|TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11077346|NCT04234594|Experimental|QL1203|Participants only receive QL1203, 6mg/kg on Day 1.
11077347|NCT04234594|Active Comparator|Vectibix®|Participants only received Vectibix®，6 mg/kg on Day 1.
11077348|NCT04234581|Experimental|Lysulin|Participants will be randomly allocated in blocks for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) per os with breakfast, lunch and dinner.
11077349|NCT04234581|Placebo Comparator|Placebo|Subjects will be instructed to take two tablets of placebo per os with breakfast, lunch and dinner.
11077350|NCT04234568|Experimental|Treatment (lutetium Lu 177 dotatate, triapine)|Patients receive lutetium Lu 177 dotatate IV over 30-40 minutes on day 1 and triapine PO QD on days 1-14. Treatment repeats every 8 weeks (56 days) for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11077351|NCT04234555||Provoked vestibulodynia (PVD)|Provoked vestibulodynia (PVD) is characterized by severe sharp and/or burning pain felt at the entrance to the vagina (i.e. the vulvar vestibule) when pressure is applied to this area or during attempts at vaginal insertional activities (i.e. provoked).
11077352|NCT04234555||Provoked vestibulodynia (PVD) + Vaginismus (VAG)|PVD is sometimes accompanied by intense, involuntary contraction of the PFMs3, termed vaginismus (VAG).
11077353|NCT04234555||Control|Participants matched by age (within 2 years), parity (parous vs nulliparous) and use of oral contraceptive medications (yes vs no) to women in the PVD group, with no signs and symptoms of PVD.
11077394|NCT04234308|Experimental|Nylon Non absorbable sutures|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
11077395|NCT04234295|Active Comparator|Lean, Healthy Controls|Subjects with a body mass index (BMI) of 25 or less will have a fat tissue biopsy collected
11077396|NCT04234295|Experimental|Obese, Non-Diabetic|Subject with a BMI between 30 and 50 kg/m2 will have fat tissue biopsy collected
11077397|NCT04234282|No Intervention|Control Group|The control group will receive a 30-minute class on knee osteoarthritis diagnosis, prognosis, various treatment options, and will conclude with a question and answer session. This will account for the 30 minute face to face time provided in the treatment group
11078199|NCT04228770|Experimental|Warfarin patients|Patients on high risk medication - warfarin
11077354|NCT04234542|Experimental|Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using a protocol developed in collaboration with BioFlexTM Laser. Each treatment will last approximately 45 minutes and will include the laser array first being applied to the skin overlying the sacral spine in a horizontal placement then in oblique placement bilaterally (red and infrared light) while a laser probe is applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light) and the focal probe will be applied to painful sites on the perineum. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. All the stages will involve use of the same array and probe placement, but at each stage the dosage will be increased according to the BioFlex protocol. During teach treatment session, women will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones.
11077355|NCT04234542|Sham Comparator|Sham Low Level Laser Therapy Group|15 treatments will be provided over a 12 week period using the same protocol developed in collaboration with BioFlexTM Laser, but at an intensity of 1% output for all sites and at all stages. Each treatment will last approximately 45 minutes. At each visit, the laser array will first be applied to the skin overlying the sacral spine in a horizontal then oblique placement bilaterally (red and infrared light) concurrently with a laser probe applied over the base of the spine (red and infrared light). Next, the array will be applied to the surface of the perineum (red and infrared light), followed by treatment at specific painful sites using the red light probe. Finally, the infrared light probe will be applied to the skin overlying branches of the pudendal nerve. Participants randomized to this group will listen to an audio recording of a mindfulness-based meditation on CD through noise cancelling headphones while receiving the sham laser treatment.
11077356|NCT04234529|Active Comparator|AMATEA|3x 450mg capsules of AMATEA which contains 270mg of caffeine total
11077357|NCT04234529|Active Comparator|Caffeine|3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
11077358|NCT04234529|Placebo Comparator|Placebo|3x 450mg capsules of microcellulose
11077359|NCT04234516|Active Comparator|Buprenorphine|Sublingual buprenorphine-naloxone films
11077360|NCT04234516|Active Comparator|Morphine|Oral morphine sulphate tablets
11077361|NCT04234503|Experimental|Ethics Quarter|Nurse managers perform 12 educational packages in web-page www.etiikanvartti.fi.
11077362|NCT04234503|No Intervention|Standard organisational ethics structures|Nurse managers continue in their standard organisational ethics structures
11077363|NCT04234477|Experimental|Beta-blocker strategy|MICU patients assigned to Team Blue will receive an intravenous (IV) beta-blocker strategy to manage AF with RVR
11077364|NCT04234477|Experimental|Calcium channel blocker strategy|MICU patients assigned to Team Red will receive an intravenous (IV) calcium channel blocker strategy to manage AF with RVR
11077365|NCT04234477|Active Comparator|Physician preference strategy|MICU patients assigned to Team Green will receive a physician preference strategy with usual/standard of care interventions to manage AF with RVR
11077366|NCT04234464|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027)
11077367|NCT04234464|Placebo Comparator|Placebo MDI|
11077368|NCT04234451|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
11077369|NCT04234451|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
11077370|NCT04234438|Active Comparator|Before application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa Before subliminal micropulse laser application
11077371|NCT04234438|Active Comparator|After application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa After 12 months subliminal micropulse laser application
11077372|NCT04234425|Experimental|Experimental Group|20 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
11077373|NCT04234412|Experimental|Osteoarthritic knee patients|Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.
11077374|NCT04234399||Group|All patients receiving SOC imaging and Axumin PET scans.
11077375|NCT04234386|Active Comparator|Dose Level 1: 21 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
11077376|NCT04234386|Active Comparator|Dose Level 2: 24 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
11077377|NCT04234386|Active Comparator|Dose Level 3: 27 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
11077378|NCT04234386|Active Comparator|Dose Level 4: 30 Gy|Participants will receive radiation therapy to the partial breast using the GammaPod technology before a lumpectomy.
11077379|NCT04234373|Experimental|Low Carb dietary Intervention|
11077380|NCT04234360|Experimental|Eosinophil count > 2%; corticotherapy|Eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
11077381|NCT04234360|Experimental|Eosinophil count <= 2%; corticotherapy|Non-eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
11077382|NCT04234360|Placebo Comparator|Eosinophil count > 2%; placebo|Eosinophilic patients randomized to this arm will receive 5 days of placebo.
11077383|NCT04234360|Placebo Comparator|Eosinophil count <= 2%; placebo|Non-eosinophilic patients randomized to this arm will receive 5 days of placebo.
11077384|NCT04234347|Active Comparator|Long Axis approach|Utilize the longitudinal orientation when placing an USGPIV.
11077385|NCT04234347|Active Comparator|Short axis approach|Utilize the transverse orientation when placing an USGPIV.
11077386|NCT04234334|Experimental|Egg intake|Consumption of 2 eggs with spinach daily for breakfast for 4 weeks
11077387|NCT04234334|Experimental|Egg Subsitute|Consumption of 2 egg substitutes daily for breakfast for 4 weeks
11077388|NCT04234321|Experimental|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
11077389|NCT04234321|Experimental|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
11077390|NCT04234321|Placebo Comparator|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
11078048|NCT04229836|Experimental|Tildrakizumab|Participants will receive subcutaneous (SC) injection of tildrakizumab 100 milligrams (mg).
11077398|NCT04234282|Experimental|Manual Physical Therapy|The treatment group will receive one 30-minute session of orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment. The manual therapy and exercises are tailored to the individual based on their limitations and restrictions.
11077399|NCT04234269||Assessment Group|Individuals with spinal cord injury. There is one group.
11077400|NCT04234256|Experimental|Static exercise|The experimental group doing static exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
11077401|NCT04234256|Experimental|Dynamic exercise|This group doing dynamic exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
11077402|NCT04234256|No Intervention|Control group|Control group doing not the stretching exercise
11077403|NCT04234243||HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC
11077404|NCT04234243||No HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only
11077405|NCT04234230||VAD Patients|Patients with implanted ventricular assist device in the outpatient setting
11077406|NCT04234217|No Intervention|Untreated|Untreated condition (obstructive sleep apnea)
11077407|NCT04234217|Active Comparator|Continuous positive airway pressure (CPAP) treatment|Continuous positive airway pressure (CPAP) treatment
11077408|NCT04234217|Active Comparator|Niacin|Untreated, pharmacological suppression of lipolysis by Niacin
11077409|NCT04234204|Experimental|Fezolinetant group|Participants will receive fezolinetant once daily for 24 weeks.
11077410|NCT04234204|Placebo Comparator|Placebo group|Participants will receive matching placebo for 12 weeks, and then receive fezolinetant for 12 weeks once daily.
11077411|NCT04234191|Experimental|Rapid Micro-Induction|On Day 1, participants will receive 0.5mg bup/nx sublingually (SL) every 3 hours (Q3H) - total daily dose of 4mg. On Day 2, they will receive 1mg bup/nx SL Q3H - total daily dose of 8mg. On Day 3, they will receive 12mg bup/nx SL once and 1-4mg bup/nx SL Q3H as needed (PRN) - maximum daily dose of 24mg. On Day 4, their day 3 total dose will be consolidated to once daily dosing - maximum daily dose of 24mg. On Days 1 and 2, participants will concurrently receive 1-16mg hydromorphone orally, intravenously, subcutaneously, or intramuscularly (PO/IV/SC/IM) every 1-3 hours (Q1-3H) PRN to meet their opioid requirements, titrated to effect - maximum daily dose of 96mg. For the 1st dose of hydromorphone on Day 1, a maximum 8mg PO or 4mg SC/IV/IM dose will be given. Hydromorphone will be discontinued on Days 3 and 4.
11077412|NCT04234191|Active Comparator|Standard Induction|Day 1 is initiated when participants score 11 or above on the Clinical Opiate Withdrawal Scale (COWS), and when they have been abstinent from short-acting opioids for at least 6-12 hours or from long-acting opioids for 24-72 hours. On Day 1, participants will start with 2-4mg bup/nx SL. If they do not experience withdrawal symptoms 60-90 minutes after this dose, additional dosing can be done in increments of 2-4mg bup/nx SL. The suggested total dose target for Day 1 is 8-12mg. On Day 2, participants will start with a dose equal to the total amount of bup/nx SL administered on Day 1. The dose will be then titrated in increments or decrements of 2-8mg bup/nx SL to a level that holds the patient in treatment and suppresses opioid withdrawal. On Day 3, their day 2 total dose will be consolidated to once daily dosing. For both Days 2 and 3, the suggested total daily dose is at least 8mg, recommended 12-16mg, maximum daily dose of 24mg.
11077413|NCT04234178|Active Comparator|Dural puncture epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
11077414|NCT04234178|Active Comparator|Combined spinal-epidural with epidural volume extension|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
11077415|NCT04234165|Active Comparator|Monopolar arm|monopolar cautery was used for TURBT
11077416|NCT04234165|Experimental|Bipolar Arm|bipolar cautery was used for TURBT
11077417|NCT04234152|Experimental|MV Photo-protection|Includes infants in whom the new procedure of MV separation and photo-protection will be applied. This arm will be stratified to male and female 1:1
11077418|NCT04234152|Placebo Comparator|Standard of care|Includes infants in whom the standard method of preparation and infusion of PN will be applied. This arm will be stratified to male and female 1:1
11077419|NCT04234139||Retrospective Cohort|Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)
11077420|NCT04234139||Prospective Cohort 1|Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)
11077421|NCT04234139||Prospective Cohort 2|Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)
11077422|NCT04234113|Experimental|Experimental: Part A (SO-C101 Monotherapy)|Drug: SO-C101
11077423|NCT04234113|Experimental|Experimental: Part B (SO-C101 combined with pembrolizumab)|Drug: SO-C101 Drug: pembrolizumab
11077424|NCT04234100|Experimental|Orange juice rich in hesperidin and narirutin|The consumption of the orange juice will be made in a single dose of 500 ml. The juice is presented in a concentrated and frozen format, packed in opaque cans of 500 mL, for which it must be thawed and diluted with mineral water up to 1.5 L before its ingestion.
11077425|NCT04234087|No Intervention|Control group|The supervised exercise program included: continues endurance training on cycle ergometers (6 sessions a week). Every session included warm up (<50% target intensity 2 min, gradually increasing load 1-10 w/min up to target intensity within 5 - 10 min); exercise phase (100% of the target intensity (30-50% watts or 30-50% HRmax), starting with >5 minutes and gradually prolonged up to 30 min); cool down with gradual reduction of the load within 3 minutes); additional aerobic exercises performed sitting and/or standing (30 minutes, 5 days/week); respiratory muscle training (7 days/week, for 15 minutes) using ball trainer.
11077459|NCT04233853|Experimental|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
11077460|NCT04233853|Active Comparator|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
11078200|NCT04228770|Experimental|Parkinson's patients|Patients with high risk disease - parkinson's
11077426|NCT04234087|Other|Intervention group|Exercise program as for a control group together with additional resistance and balance training 3 sessions/week. The resistance training was started with low intensity (<30% 1-RM, RPE ≤ 11, 5-10 repetitions), increased gradually to moderate intensity (30-50% and up to 60% 1-RM, RPE 12-13, after 8-15 repetitions) with 3 sets and 3 minute rest between sets, if tolerated. The balance training included exercises to improve static as well as dynamic balance ability. It was performed on 2-3 days/week for 10-15 minutes. The complexity of the balance exercises was selected and incremented individually by changing the stand-position, the base on which the stands were performed and/or using unstable surfaces. If tolerated, the visual information was varied and/or additional tasks performed while balancing. After completion participants were encouraged to continue exercise training at home according to recommendations.
11077427|NCT04234074|Other|Breathing test or sleep study|infants undertaking cardiorespiratory polysomnography
11077428|NCT04234061|Experimental|Single|ibrutinib and Tisagenlecleucel
11077429|NCT04234048|Experimental|Phase 1|"Accelerated Phase 1a + Standard Phase 1a + Phase 1b
~Accelerated Phase 1a
~Up to 8 patients for accelerated phase 1a (single patient cohort); dose levels of ST-001 nanoFenretinide (mg/m^2/day X 5 days every 21 days):
~Dose Level 1 1.25 (1 patient) Dose Level 2 2.5 (1 patient) Dose Level 3 5.0 (1 patient) Dose Level 4 10 (1 patient) Dose Level 5 20 (1 patient) Dose Level 6 40 (1 patient) Dose Level 7 80 (1 patient) Dose Level 8 160 (1 patient)
~Standard Phase 1a
~Up to 18 patients for standard phase 1a (3+3 design); dose level (mg/m2/day X 5 days every 21 days):
~Dose Level 9 320 (3-6 patients) Dose Level 10 448 (3-6 patients) Dose Level 11 627 (3-6 patients)
~Phase 1b
~20 patients for phase 1b at the maximum tolerated dose (MTD)"
11077430|NCT04234035|Experimental|Shared Decision-Making (via Decision Aid)|The intervention is a decision aid, which both encourages and facilitates a shared decision-making conversation between the clinician and the patient. The decision aid educates patients regarding evidence-based approaches to the management of suspected kidney stones in the ED. Clinicians will receive training specific to this decision aid, though the decision aid is designed to be used with no additional training.
11077431|NCT04234035|Active Comparator|standardized educational intervention (pamphlet +usual care)|The control arm will receive Usual Care and a standardized educational intervention (pamphlet). This intervention (pamphlet) contains information about kidney stones. Usual care for this clinical scenario generally involves the clinician choosing the management plan. Clinicians of subjects assigned to the usual care group will be asked to practice usual, evidence-based medical care, without shared decision-making.
11077432|NCT04234022||Zn-DDC|samples to be exposed with Zn-DDC (Imuthiol) alone
11077433|NCT04234022||Lenalidomide with Zn-DDC|samples to be exposed with Lenalidomide in combination with Zn-DDC
11077434|NCT04234022||Pomalidomide with Zn-DDC|samples to be exposed with Pomalidomide in combination with Zn-DDC
11077435|NCT04234009|Experimental|Healthy lifestyle|Healthy lifestyle intervention, which includes physical activity and dietary advice according to the dutch guidelines.
11077436|NCT04234009|No Intervention|Control|Maintenance of habitual physical activity and diet
11077437|NCT04233996|Experimental|Extended infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in half time of the dosing interval
11077438|NCT04233996|Active Comparator|Intermittent infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in 30 minutes
11077439|NCT04233983|Active Comparator|Study Group|The study group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed.
11077440|NCT04233983|No Intervention|Control Group|The control group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will be performed IVF&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then.
11077441|NCT04233970|Experimental|Intervention group|Participants randomized to the intervention group will receive access to the multi-component, web-based intervention programme. The intervention programme will be developed in line with principles of patient empowerment and based on the Theory of Planned Behaviour.
11077442|NCT04233970|Active Comparator|Control group|Participants randomized to the control group will receive access to the web-based control programme with optimized standard care.
11077443|NCT04233957|Experimental|High Sodium|Consumption of an extra 3900 mg of dietary sodium per day.
11077444|NCT04233957|Placebo Comparator|Placebo|Control Condition
11077445|NCT04233944||Pregnant women and their infants|Mothers and their infants were followed throughout the first two years of the infant's life. Data were collected at enrollment, birth, 3, 6, 9,12, 18 and 24 months from the date of delivery.
11077446|NCT04233931|Experimental|participant|all participants in the study receive the mobile app.
11077447|NCT04233918|Experimental|Evinacumab|Part A: Single intravenous (IV) dose Part B: IV dose every 4 weeks (Q4W) until week 20 Part C: IV dose Q4W
11077448|NCT04233905||mute children|mute children and their mothers
11077449|NCT04233905||healthy children|healthy children control group
11077450|NCT04233905||mute adults|formerly mute adults
11077451|NCT04233905||healthy adults|healthy adults control group
11077452|NCT04233892|Experimental|CBD-bFGF|
11077453|NCT04233892|Experimental|Collagen/BMMNCs|
11077454|NCT04233892|Experimental|Estrogen|
11077455|NCT04233879|Experimental|Group 1: DOR/ISL|Treatment-naïve participants with HIV-1 receive DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) for 96 weeks.
11077456|NCT04233879|Active Comparator|Group 2: BIC/FTC/TAF|Treatment-naïve participants with HIV-1 receive BIC/FTC/TAF and placebo to DOR/ISL QD for 96 weeks.
11077457|NCT04233866|Experimental|Arm A (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11077458|NCT04233866|Experimental|Arm B (fluorouracil, leucovorin, liposomal irinotecan)|Patients receive fluorouracil IV over 46 hours starting on day 1. Patients also receive leucovorin IV over 90-120 minutes and liposomal irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11077567|NCT04233164|Experimental|250 mg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
11077461|NCT04233840|Experimental|Sequential administration of P1101 and anti-PD1|"Phase I of Study : To determine the safety, tolerability, DLT, and potential phase 2 dose of sequential administration of P1101 and anti-PD1
~:Sequential administration 6 doses (450mcg) of P1101 and 3 doses of anti-PD1 (Escalating from 0.3, 0.75, 1.5, 3 mg/kg) for Phase I Study"
11077462|NCT04233840|Active Comparator|anti-PD1|Phase II Study Group I: anti-PD1 arm 3mg/kg 3 doses
11077463|NCT04233840|Active Comparator|P1101 monotherapy|Phase II Study Group II: P1101 arm 450mcg 12 doses
11077464|NCT04233840|Experimental|sequential administration of P1101 and anti-PD1|Phase II Study GroupIII:Sequential administration of 6 doses of 450mcg P1101 and followed by 3 doses of anti-PD1 dosage (base on Phase I study result)
11077465|NCT04233814|Sham Comparator|Placebo|Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)
11077466|NCT04233814|Experimental|SAD Cohort 1|LTI-03 20 mg delivered qd x 1 day via DPI
11077467|NCT04233814|Experimental|SAD Cohort 2|LTI-03 40 mg delivered qd x 1 day via DPI
11077468|NCT04233814|Experimental|SAD Cohort 3|LTI-03 80 mg delivered qd x 1 day via DPI
11077469|NCT04233814|Experimental|MAD cohort 1|LTI-03 dose TBD based on SAD, delivered qd x 14 days via DPI
11077470|NCT04233814|Experimental|MAD cohort 2|LTI-03 dose TBD based on SAD, delivered qd x 14 days via DPI
11077471|NCT04233814|Experimental|MAD cohort 3|LTI-03 dose TBD based on SAD, delivered qd x 14 days via DPI
11077472|NCT04233801|Experimental|Empagliflozin low dose|
11077473|NCT04233801|Experimental|Empagliflozin high dose|
11077474|NCT04233801|Placebo Comparator|Placebo|
11077475|NCT04233788||Patient Group 1 (15 Patients)|First two pulse sequence will be applied to this group at a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 2.
11077476|NCT04233788||Patient Group 2 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 1) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 3.
11077477|NCT04233788||Patient Group 3 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 2) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 4.
11077478|NCT04233788||Patient Group 4 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 3) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Best sequence propagates to Patient Group 5.
11077479|NCT04233788||Patient Group 5 (15 Patients)|Two pulse sequence (one will be the best performing pulse sequence of Patient Group 4) will be applied to this group using a 3T Prisma and a 7T Terra scanner. At the end the best performing sequence will result.
11077480|NCT04233788||Healthy Control Group 1 (10 Persons)|First two pulse sequences will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used as normative data.
11077481|NCT04233788||Healthy Control Group 2 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 1) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
11077482|NCT04233788||Healthy Control Group 3 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 2) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used as normative data.
11077483|NCT04233788||Healthy Control Group 4 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 3) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
11077484|NCT04233788||Healthy Control Group 5 (10 Persons)|First two pulse sequences (one will be the best performing pulse sequence of Healthy Control Group 4) will be applied to this group using a 3T Prisma and a 7T Terra scanner. Data will be used normative data.
11077485|NCT04233762||Female Natural Cycle Group|Females with regular natural menstrual cycle.
11077486|NCT04233762||Female Oral Contraceptive Pill Group|Females taking the combined oral contraceptive pill.
11077487|NCT04233762||Male Group|Males with no history of anabolic steroid use.
11077488|NCT04233749|Experimental|Treatment|All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
11077489|NCT04233736|Active Comparator|Treatment group|
11077490|NCT04233736|Sham Comparator|Control group|
11077491|NCT04233710|Experimental|Robot + tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period, with 20 minutes of 1mA cathodal tDCS applied to the contralesional M1 area during first 20 minutes of robotic therapy. Robotic therapy will be conducted using the Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
11077492|NCT04233710|Sham Comparator|Robot + sham tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period with 20 minutes of SHAM tDCS applied during the first 20 minutes of the robotic therapy. As with experimental arm, electrode will be placed on contralesional M1. Current will ramp up and then immediately ramp down to simulate the cutaneous sensations felt with actual tDCS. Robotic therapy will be delivered with Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
11077493|NCT04233697|Experimental|Copanlisib and Romidepsin|"Copanlisib and romidepsin will be both administered via IV (through a vein in arm) on days 1, 8, and 15 every 28 days, also called a cycle."
11077494|NCT04233684|Experimental|Study|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.
~Pathologic test for H. pylori by H&E stain and Giemsa stain
~All tissues will be sent to immunohistochemistry as a gold standard"
11077495|NCT04233671|Experimental|Mindfulness based relapse prevention and peer mentoring|MiMP is a twelve week program, meeting once per week for 12 weeks for approximately two hours. Eight weeks are facilitated by a licensed counselor, and four weeks are facilitated by a peer mentor.
11077496|NCT04233671|No Intervention|12 Step Treatment Program Control|The control group will meet for 12 weeks for standard 12 Step Facilitation meetings.
11077497|NCT04233658|Placebo Comparator|Placebo|
11077498|NCT04233658|Experimental|Cynara Scolymus|
11077568|NCT04233151|Experimental|mFOLFOX6 + QL1203|Participants receive QL1203, 6mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity
11078201|NCT04228757|Experimental|Investigational Herbal Blend|A phytoestrogen herbal blend
11077499|NCT04233645|Experimental|Study Group|The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
11077500|NCT04233645|Active Comparator|Usual Care Group|The group will be given a standard scripted verbal and identical written instructions as per usual care.
11077501|NCT04233632|Active Comparator|FC2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit.
11077502|NCT04233632|Active Comparator|Cupid Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
11077503|NCT04233632|Active Comparator|Cupid 2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
11077504|NCT04233606|Placebo Comparator|Control|Participants will be infused with normal (0.9% NaCL) saline for a 120 minute period.
11077505|NCT04233606|Experimental|Hypertonic Saline|Participants will be infused with hypertonic (3% NaCL) saline for a 120 minute period.
11077506|NCT04233593|Experimental|LPS Challenge|Subjects will undergo one 120-minute [11C]PBR28 PET scan before and one scan 3-hours after LPS administration (1.0ng/kg; IV)
11077507|NCT04233580|Active Comparator|Weekly AmnioEXCEL+ group|AmnioEXCEL+ will be applied weekly at study visits
11077508|NCT04233580|Active Comparator|PRN AmnioEXCEL+ group|AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
11077509|NCT04233567|Experimental|Treatment (infigratinib)|Patients receive infigratinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11077510|NCT04233554|Experimental|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
11077511|NCT04233554|No Intervention|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
11077512|NCT04233541||Fallers|Participants who reported one or more falls within the 12 months preceding the study consist the group of ''fallers''.
11077513|NCT04233541||Non-fallers|Participants with no fall history consist the group of ''non-fallers''
11077514|NCT04233528|Experimental|healthy volunteers|metabolically healthy eutrophic individuals (BMI ≥18.5 and <25 kg / m2) without any IDF criteria for metabolic syndrome
11077515|NCT04233528|Experimental|metabolically healthy obesity|obese individuals (BMI ≥ 30.0 kg / m2) meeting the criteria for metabolically healthy obesity
11077516|NCT04233528|Experimental|metabolically unhealthy obesity|volunteers diagnosed with metabolically unhealthy obesity
11077517|NCT04233502|Experimental|Melatonin|Slenyto® 1 mg / 5 mg prolonged release Melatonin tablets (pink and yellow) film coated 3 mm in diameter,
11077518|NCT04233502|Placebo Comparator|Placebo melatonin|Placebo melatonin will be identical in appearance (pink and yellow) and formulation to active Slenyto® tablets, but will contain no active melatonin.
11077519|NCT04233489|Experimental|Family Nurture Intervention (FNI)|This arm contains the combined GDM+FNI and control+FNI cohort.
11077520|NCT04233489|No Intervention|Non-FNI|This arm contains the combined GDM+no FNI and control+no FNI cohort.
11077521|NCT04233476|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection dosage form:Injection dosage:0.3mCi/kg frequency:single dose
11077522|NCT04233463|Active Comparator|Modulen Diet|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
11077523|NCT04233463|Active Comparator|Budesonide Treatment|Crohn patients will be given Budesonide treatment
11077524|NCT04233450||Patient group|
11077525|NCT04233437|Experimental|CYP Cohort|MLC1501 & CYP cocktail drugs
11077526|NCT04233437|Experimental|Transporter Cohort|MLC1501 & Transporter cocktail drugs
11077527|NCT04233424|Experimental|D-PLEX+SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
11077528|NCT04233424|Other|Standard of care|The SoC for prophylactic antibiotic treatment is based on international guidelines
11077529|NCT04233411|Active Comparator|Milk|Acute ingestion of 20 g milk protein
11077530|NCT04233411|Experimental|20g|Acute ingestion of 20 g mycoprotein
11077531|NCT04233411|Experimental|40g|Acute ingestion of 40 g mycoprotein
11077532|NCT04233411|Experimental|60g|Acute ingestion of 60 g mycoprotein
11077533|NCT04233411|Experimental|80g|Acute ingestion of 60 g mycoprotein
11077534|NCT04233398|Experimental|Test group HIFU treatment|Patients in the test group (120) will be treated with high intensity focused ultrasound (HIFU). The primary objective of this clinical trial is to evaluate the efficacy of the test device in the treatment of benign thyroid nodules, and the secondary objective is to evaluate the safety of the test device in the treatment of benign thyroid nodules and the improvement of symptoms (VAS score).
11077535|NCT04233398|No Intervention|Control group|Patients in the control group (120) will be actively observed and followed up. The primary objective of this clinical trial is to evaluate the efficacy of the test device in the treatment of benign thyroid nodules, and the secondary objective is to evaluate the safety of the test device in the treatment of benign thyroid nodules and the improvement of symptoms (VAS score).
11077536|NCT04233385|Experimental|Myofascial Massage|Participants randomized to this group will receive 30 minutes of myofascial massage to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed 8 week protocol developed with a massage therapy consultant and the study team.
11077537|NCT04233385|Active Comparator|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months.
11077630|NCT04232839|Experimental|T6 (Test 6)|
11077631|NCT04232839|Experimental|R1 (Reference 1)|
11118152|NCT03947957|Other|collection of expectoration, stools and blood|
11077538|NCT04233359|Active Comparator|US-guided pleural biopsy and thoracentesis|"Pleural biopsy:
~Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis."
11077539|NCT04233359|Experimental|LAT and thoracentesis|Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
11077540|NCT04233346|Experimental|Ponatinib|CP-CML:Chronic Phase Chronic Myeloid Leukemia; AP-CML:Accelerated Phase Chronic Myeloid Leukemia; BP-CML:Blast Phase Chronic Myeloid Leukemia; Ph+ ALL:Ph+ Acute Lymphoblastic Leukemia;
11077541|NCT04233333|Active Comparator|mustache fixation|
11077542|NCT04233333|Experimental|W.K fixation|
11077543|NCT04233320|Experimental|silicone cream containing Allium Cepa extract|Silicone cream containing Allium Cepa extract will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
11077544|NCT04233320|Active Comparator|commercial scar gel|Commercial scar gel will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
11077545|NCT04233307|Other|Wound photographs|Telethermographic photographs of fracture wound and contralateral limb before and after propofol infusion.
11077546|NCT04233294|Experimental|chidamide in combination with camrelizumab plus decitabine|chidamide 10mg/day, days 1-4, 20mg/day, day 8, 11, 15, 18; camrelizumab 200mg d6; decitabine 10 mg/day, days 1-5, every 3 weeks
11077547|NCT04233281|Experimental|Kori-tofu added to a carbohydrate rich meal|Kori tofu as part of a carbohydrate rich meal
11077548|NCT04233281|Active Comparator|Whey protein added to a carbohydrate rich meal|Whey protein as part of a carbohydrate rich meal
11077549|NCT04233268||Critically ill children|Children with severe infection requiring mechanical ventilation
11077550|NCT04233268||Non critically ill cohort|Children with suspected COVID19 admitted to hospital but not requiring mechanical ventilation
11077551|NCT04233268||Maternal and neonatal cohort|Babies born where mother has a recent diagnosis of COVID19
11077552|NCT04233255||Patients with muscle disease(myositis, hereditary myopathy)|Includes 32 symptomatic patients with muscle disease subdivided into two subgroups (a) 16 patients with acute inflammatory myositis; And (b)16 patients with hereditary myopathy. The patients will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline,after 6 months and after 12 months. The number and location of studied muscles will be determined according to pattern of clinical presentation.
11077553|NCT04233255||Healthy volunteers as control group|Includes 32 healthy volunteers as control group. They will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline. Their age, sex, number and location of studied muscles will be matched with patients' group.
11077554|NCT04233242|Experimental|Intervention|The viral load ≥400 c/mL before enrolment triggers genotypic resistance testing (GRT), followed by GRT-informed patient management and counselling. If drug resistance mutations are present, the participant is switched to a different drug regimen line (or the drug regimen backbone is optimised) and drug selection is informed by the GRT result; if no drug resistance mutations are present, the current drug regimen is maintained and the patient receives targeted enhanced adherence support.
11077555|NCT04233242|No Intervention|Control|Standard of care according to national guidelines and recommendations of the World Health Organization: The viral load ≥400 c/mL before enrolment is followed by 3 sessions of enhanced adherence counselling and a follow-up viral load test. If the viral load remains ≥400 c/mL, the participant is switched to a different regimen line with drug selection based on empiric guidelines; if the viral load drops to <400 c/mL, the current drug regimen is maintained. The follow-up viral load test may be postponed in favour of additional counselling if there is clear evidence of poor adherence to therapy, defined as i) a pill count of <90%, and/or ii) a self-reported period of no drug intake of ≥2 days in the last 4 weeks.
11077556|NCT04233229|Experimental|closed-loop and home care services|
11077557|NCT04233229|Active Comparator|usual care|
11077558|NCT04233216|Experimental|Part 1, Group 1: ISL + ART|HTE participants with HIV-1 infection take ISL 0.75 mg once daily (QD) in combination with failing ART from Day 1 to Day 7 in Part 1.
11077559|NCT04233216|Experimental|Part 1, Group 2: DOR + ART|HTE participants with HIV-1 infection take DOR 100 mg QD in combination with failing ART from Day 1 to Day 7 in Part 1.
11077560|NCT04233216|Experimental|Part 1, Group 3: DOR/ISL + ART|HTE participants with HIV-1 infection take 100 mg DOR/0.75 mg ISL FDC QD in combination with failing ART from Day 1 to Day 7 in Part 1.
11077561|NCT04233216|Placebo Comparator|Part 1, Group 4: Placebo + ART|HTE participants with HIV-1 infection take placebo QD in combination with failing ART from Day 1 to Day 7 in Part 1.
11077562|NCT04233216|Experimental|Part 2, Group 5: Open-Label DOR/ISL + OBT|HTE participants from Groups 1 to 4 with HIV-1 infection take open-label 100 mg DOR/0.75 mg ISL + OBT in Part 2 (Day 8 to Week 97).
11077563|NCT04233203||Faster Aspart|All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII and insulin Faster Aspart.
11077564|NCT04233190|Experimental|Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)|Formoterol 12mcg + budesonide 400mcg / Formoterol 6mcg + budesonide 200mcg
11077565|NCT04233190|Active Comparator|Alenia® (12/400mcg e 6/200mcg)|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
11077566|NCT04233164|Experimental|1 mg/kg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
11077569|NCT04233151|Active Comparator|mFOLFOX6 + Placebo|Participants received Placebo，6 mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
11077570|NCT04233138|Experimental|Intervention|The intervention group will have immediate access to the SUPPORT platform.
11077571|NCT04233138|Experimental|Control|The control group will have a 6-month delayed access to the SUPPORT platform.
11077572|NCT04233125|Active Comparator|Core Decompression (CD) Only|Participants in this group receive standard care
11077573|NCT04233125|Experimental|Added Polymethylmethacrylate (PMMA)|Participants in this group receive standard care with an additional treatment
11077574|NCT04233112|Placebo Comparator|Placebo/Mock|Placebo capsules; mock osteogenic loading
11077575|NCT04233112|Experimental|Melatonin/Mock|Melatonin capsules; mock osteogenic loading
11077576|NCT04233112|Experimental|Placebo/Osteogenic loading|Placebo capsules/osteogenic loading
11077577|NCT04233112|Experimental|Melatonin/Osteogenic loading|Melatonin capsules/osteogenic loading
11077578|NCT04233099||Healthy Subjects|20 Healthy subjects in a good state of health comparable by age and sex with the other selected groups
11077579|NCT04233099||Amyotrophic Lateral Sclerosis with Bulbar onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Bulbar onset, comparable by age and sex with the other selected groups
11077580|NCT04233099||Amyotrophic Lateral Sclerosis with Spinal onset|20 subjects affected by Amyotrophic Lateral Sclerosis with Spinal onset, comparable by age and sex with the other selected groups
11077581|NCT04233099||Parkinson's Disease|20 subjects affected by Parkinson's Disease comparable by age and sex with the other selected groups
11077582|NCT04233099||Alzheimer's Disease|20 subjects affected by Alzheimer's Disease comparable by age and sex with the other selected groups
11077583|NCT04233086||Patients referred through the BNP pathway|Patients throughout 2016 referred through the BNP pathway at Queen Alexandra Hospital will retrospectively be assessed for Reddy et al (2018) H2FPEF score.
11077584|NCT04233060|Experimental|CS3005|
11077585|NCT04233034|Active Comparator|HCL and placebo|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or the Medtronic 670G 4.0 AHCL. This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.
~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.
~Whether drug is active or placebo is blinded to both participant and site.
~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
11077586|NCT04233034|Active Comparator|HCL and verapamil|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or the Medtronic 670G 4.0 AHCL. This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.
~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.
~Whether drug is active or placebo is blinded to both participant and site.
~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
11077587|NCT04233034|Active Comparator|non-HCL and verapamil|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.
~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.
~Whether drug is active or placebo is blinded to both participant and site.
~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
11077588|NCT04233034|Placebo Comparator|non-HCL and placebo|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.
~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.
~Whether drug is active or placebo is blinded to both participant and site.
~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
11077589|NCT04233021|Experimental|Osimertinib|Osimertinib 80 mg/d
11077590|NCT04233008|Experimental|6 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
11077591|NCT04233008|No Intervention|12 hour foley|The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 12 hours, determined by randomization. At that point health care providers will manage active labor.
11077592|NCT04232995|Experimental|Experimental Group|"Balance training by 9 positions with 1 min hold, repeated twice
~Stand with feet together, eyes remain open
~Stand with together, eyes closed
~& 4) Tandem Standing with Right and Left in front alternately
~5) Forward Reaching 6) & 7) Single Leg Standing, with Right and Left foot alternately 8) & 9) Step up, with Right and Left foot alternately
~General Exercises for 25 min
~Active Range of Motion Exercises and Foot Care Education-5 min
~Treadmill- 15 min
~Cycling -5 min
~No. Of Sessions 24, thrice a week for 8 weeks"
11077593|NCT04232995|Active Comparator|Control Group|"General Exercises for 25 min
~Active Range of Motion Exercises and Foot Care Education-5 min
~Treadmill- 15 min
~Cycling -5 min
~No. Of Sessions 24, thrice a week for 8 weeks"
11077594|NCT04232982|Experimental|MicroPulse Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered by micropulse waves will be given 4-8 weeks before the Boston keratoprosthesis surgery.
11077595|NCT04232982|Experimental|G-Probe Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered with a diode laser using the G-Probe device, will be given 4-8 weeks before the Boston keratoprosthesis surgery.
11077632|NCT04232826|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
11121403|NCT03924908|Active Comparator|VR|Virtual reality
11077596|NCT04232982|No Intervention|Historical Cohort|"An historical cohort composed of patients who received a Boston keratoprosthesis between january 2017 and january 2019 will be included. Only patients who did not receive any glaucoma treatment 3 months before their surgery will be included. A total of 10 patients will be selected with the goal of matching the preoperative characteristics of the interventional patients.
~This group will serve as the control group in our study. Retrospective chart review will be performed for this branch."
11077597|NCT04232969|Active Comparator|Exenatide|Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks n=100
11077598|NCT04232969|Placebo Comparator|Placebo|Exenatide extended release placebo once weekly for 96 weeks n=100
11077599|NCT04232943|Active Comparator|IMOVAX Only|IMOVAX® Polio (Inactivated Poliomyelitis Vaccine) is to be administered by the IM route. Group 1, will receive one dose, 0.5mL of IPV.
11077600|NCT04232943|Experimental|IMOVAX + dmLT|Group 2 will receive IPV along with dmLT as an adjuvant, as a single dose. The vaccine product will be prepared in the clinical research pharmacy from the components described above on each day of vaccination as described in step by step formulation procedures summarized below and detailed in the Pharmacy Preparation Manual. The vaccine product preparation will be carried out by an unblinded qualified research pharmacist and witnessed by another study staff member. The research pharmacist will dispense the vaccine product in a blinded manner to the clinical staff.
11077601|NCT04232943|Active Comparator|bOPV|Group 3 and all the study participants later in the challenge phase of the study will receive one dose of bOPV vaccine in two drops, which are delivered from the polyethylene dropper supplied with the multi-dose container.
11077602|NCT04232930|Active Comparator|Music group|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
11077603|NCT04232930|No Intervention|Non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
11077604|NCT04232917|Experimental|2LPAPI® arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
11077605|NCT04232917|Placebo Comparator|Placebo arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
11077606|NCT04232904|Active Comparator|TAP Block Group|this is study group.
11077607|NCT04232904|No Intervention|Control Group|This patients are control group. TAP block will be not perform
11077608|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 1: 0.5mg CVL-936|Oral suspension/solution
11077609|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077610|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 2:TBD mg CVL-936|Oral suspension/solution
11077611|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077612|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 3:TBD mg CVL-936|Oral suspension/solution
11077613|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077614|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 1:TBD mg CVL-936|Oral suspension/solution
11077615|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077616|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 2:TBD mg CVL-936|Oral suspension/solution
11077617|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077618|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 3:TBD mg CVL-936|Oral suspension/solution
11077619|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077620|NCT04232878|Active Comparator|Active Comparator: Group 3: TBD mg CVL-936|Oral suspension/solution
11077621|NCT04232878|Placebo Comparator|Placebo Comparator: Group 3: TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
11077622|NCT04232865|Experimental|Bןםפ Sטדאקצ|Biop Colposcopy procedure
11077623|NCT04232852|Active Comparator|Probiotics|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.
~This group will receive a probiotic mix, which will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule. During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
11077624|NCT04232852|Placebo Comparator|Placebo supplement|"Demographics, anthropometric measurements (weight, height, waist circumference, BMI) will be recorded, clinical data related to the patient's cardiovascular risk (MI with or without angioplasty, acute coronary syndrome with or without angioplasty). Systolic and diastolic pressure will be measured before and after the 12-week intervention.
~Patients of this group will receive an identical capsule of maltodextrin (placebo). During the intervention, participants will follow their eating habits as well as the physical activity of their personal routine, with the advice not to consume fermented dairy products."
11077625|NCT04232839|Experimental|T1 (Test 1)|
11077626|NCT04232839|Experimental|T2 (Test 2)|
11077627|NCT04232839|Experimental|T3 (Test 3)|
11077628|NCT04232839|Experimental|T4 (Test 4)|
11077629|NCT04232839|Experimental|T5 (Test 5)|
11077633|NCT04232813|Active Comparator|Estradiol 10 micrograms vaginal tablets|One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
11077634|NCT04232813|Active Comparator|Promestriene 10mg./g vaginal cream|One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
11077635|NCT04232800|Experimental|Riboflavin|Participants in this group will receive 100mg riboflavin TID during study participation.
11077636|NCT04232800|Placebo Comparator|Placebo|Participants in this group will receive inert placebo capsules TID during study participation.
11077637|NCT04232787||Case|Thai patients with diagnosed Brugada syndrome by confirmed Brugada type 1 ECG.
11077638|NCT04232787||Control|Healthy volunteers without Brugada marker from ECG.
11077639|NCT04232774|Experimental|Treated by the study device|
11077640|NCT04232761||CRPC patients|Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan
11077641|NCT04232748||stage IV colorectal cancer|stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes
11077642|NCT04232735|Experimental|Intervention|"The Source tool is used by care givers for informing patients about the outcomes of treatment. Prediction models are developed and built in the website in order to generate a personalized prediction of the outcomes: survival, toxicity and/or complications and HRQL. These predictions are visualized in clear and comprehensible graphs with a broad variation of options available for tailoring of the visualizations.
~In order for care givers to be able to use this tool effectively, we designed the Source training. This communication skills training is comprised of an e-learning, two face-to-face group sessions and an individual booster session. Aside from an instruction video on the navigation within the Source tool, the e-learning consists of theory and tips and tricks on how to inform patients and communicate risks. The face-to-face components of the training are focused on getting the skilled use of the source tool into practice, by receiving personal feedback on the performance."
11077643|NCT04232722|Experimental|Sorafenib + arsenical|After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w
11077644|NCT04232709|No Intervention|After-hours care|Patients in the after-hours care (AH) group will receive the usual (telemedicine) care. That is, they will have the option to call the after-hours centre and receive help from the oncology nurses using the COSTaRS practice guides to manage their after-hours symptoms.
11077645|NCT04232709|Experimental|After-hours care w/personal health info|Patients in the after-hours care with personal health information (AH-PHI) group will also receive the usual (telemedicine) care. However, if they call the telemedicine service, the oncology nurses will have access to some of their personal health information from the cancer centre (i.e., a shared electronic patient record) via the MedChart platform.
11077646|NCT04232696|Experimental|Neuspera Implantable Sacral Nerve Stimulation System|Implantation of the simulator.
11077647|NCT04232683|Experimental|Preoperative Tamsulosin|The study group will receive one oral dose .4mg of Tamsulosin prior to surgery.
11077648|NCT04232683|Placebo Comparator|Preoperative Placebo|The control group will receive one oral dose of placebo pill prior to surgery.
11077649|NCT04232670|Sham Comparator|EUS + SHAM|All subjects will undergo anesthesia administered sedation and endoscopic ultrasound (EUS). The endoscopist will assess the pancreas for parenchymal and ductal features of chronic pancreatitis and confirm the absence of exclusion criteria (such as the presence of an occult pancreatobiliary malignancy).
11077650|NCT04232670|Experimental|EUS + Pancreatic Endotherapy|If randomized to ERCP with pancreatic endotherapy, the endoscopist will proceed with this intervention immediately following the completion of EUS and treatment allocation (during the same anesthesia). Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement. Overall technical success will be defined by the ability to insert at least one pancreatic stent across the dominant main pancreatic duct obstruction. Technical success for pancreatic stone treatment will be defined by the ability to remove all fluoroscopically visible main pancreatic duct stones.
11077651|NCT04232657|Experimental|Romosozumab Treatment (baseline to month 11)|Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
11077652|NCT04232657|Placebo Comparator|Placebo (baseline to month 12)|Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
11077653|NCT04232657|Active Comparator|Denosumab (month 12 to month 24)|Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
11077654|NCT04232644|Active Comparator|Treatment A|crushed d-amphetamine IR tablets
11077655|NCT04232644|Experimental|Treatment B|manipulated ADAIR IR capsules
11077656|NCT04232631||patients with diabetic foot ulcers|"Patient of the investigators
~Diagnosis of diabetes mellitus
~One or more moderate to severe diabetic foot ulcers/infections
~18-89 years of age"
11077657|NCT04232618||FIND cohort|Evaluation of biomarkers in serum samples from 500 people with suspected TB from non-African countries provided by FIND diagnostic biorepository.
11077658|NCT04232618||Phase 1|Evaluate the basic 3-marker multi-biomarker test (MBT) signature in 300 participants across three African sites. This will be used to lock down the final MBT signature to be used in the next phase of testing.
11077659|NCT04232618||Phase 2|Enrolment of 600 participants across three African sites using the locked down MBT signature from phase 1.
11077660|NCT04232605|Active Comparator|GLP-1|Receive intravenous infusion of GLP-1.
11077661|NCT04232605|Placebo Comparator|Placebo|Receive intravenous infusion of saline.
11077662|NCT04232592|Experimental|Stem cell preparation solution injection group|The solution of stem cells preparation will be injected.
11077664|NCT04232579||Chronic obstructive respiratory disease|The out-patient population with chronic obstructive respiratory disease consulted at Nguyen Tri Phuong Hospital, Ho Chi Minh city, Vietnam.
11077665|NCT04232566|Experimental|Weight loss post surgery|Gastric bypass surgery will be followed by weight loss. Liver fibrosis by elastography will be determined before and after surgery in parallel w weight loss
11077666|NCT04232553|Experimental|Mirikizumab SC|Mirikizumab given subcutaneously (SC).
11077667|NCT04232553|Experimental|Mirikizumab IV and SC|Mirikizumab given intravenously (IV) and SC.
11077668|NCT04232540|Experimental|Patients with undetectable viral load for at least 2 years|Patient and provider will view and discuss results of the MedViewer test.
11077669|NCT04232540|Experimental|Patients with detectable viral load once in past 2 years|Patient and provider will view and discuss results of the MedViewer test.
11077670|NCT04232527||Professional Footballers|About 110 players (out of about 400 competing in the Premier League of Bosnia and Herzegovina) would be included in the research.
11077671|NCT04232514|Experimental|Part A|Subjects will receive HEC74647 on Day 1~7 and Day13~19, co-administration with HEC110114 on Day13~19.
11077672|NCT04232514|Experimental|Part B|Subjects will receive HEC110114 on Day 1~7 and Day13~19, co-administration with HEC74647 on Day13~19.
11077673|NCT04232501|Experimental|Cirvo Compression device post surgery|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
11077674|NCT04232501|No Intervention|Standard of Care Post Surgery|Patients receive standard-issue SCDs (pneumatic compression) and wear in surgery and after surgery until they are discharged home.
11077675|NCT04232488|Experimental|Angiography performed using distal radial artery|Patients undergoing coronary angiography with or without intervention using distal radial artery ('snuff box') as a vascular access
11077676|NCT04232488|Active Comparator|Angiography performed using proximal radial artery|Patients undergoing coronary angiography with or without intervention using proximal radial artery as a vascular access
11077677|NCT04232475|No Intervention|Control|Seated control
11077678|NCT04232475|Experimental|1 minute SCD|1 minute of stair climbing and descending
11077679|NCT04232475|Experimental|3 minute SCD|3 minute of stair climbing and descending
11077680|NCT04232475|Experimental|10 minute SCD|10 minute of stair climbing and descending
11077681|NCT04232449|Active Comparator|Intervention group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of 40 mg (2 tablets of 20 mg) of prednisone (intervention group) are provided by General Physicians (GPs) to participants. PREDNISON Galepharm Tabl. 20 mg are manufactured according to Good Manufacturing Practice (GMP)-guidelines.
~The prednisone medication is manufactured by Galepharm AG, 8700 Küsnacht (ZH) and packaged and labelled by the Hospital Pharmacy of the University Hospital Basel. The PREDNISON tablets' active substance is Prednisonum; the tablets also contain Excipiens pro compresso. Swissmedic authorization 50821"
11077682|NCT04232449|Placebo Comparator|Control group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of placebo (control group) are provided by General Physicians (GPs) to participants.
~The content of the placebo tablets is as follows: Lactose monohydrate 140 mg, microcrystalline cellulose 68 mg, Croscarmellose sodium 5 mg, Magnesium stearate 2mg. The placebo tablets were manufactured by Apotheke Hotz, Zürichstrasse 176, CH- 8700 Küsnacht."
11077683|NCT04232436||Planned vaginal delivery|Planned vaginal delivery
11077684|NCT04232436||Planned cesarean delivery|Planned cesarean delivery
11077685|NCT04232423|Experimental|OLN 0-5-10|Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3
11077686|NCT04232423|Experimental|OLN 5-10-0|Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3
11077687|NCT04232423|Experimental|OLN 10-0-5|Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3
11077688|NCT04232410||OSA Pcrit-DISE|Patients diagnosed with OSA and eligible for non-CPAP treatments
11077689|NCT04232397|Experimental|therapy|therapy with 1 arm. Anlotinib 8mg qd po。
11077690|NCT04232384|Active Comparator|Standard paracentesis group (SPG)|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
11077691|NCT04232384|Experimental|Rollover paracentesis group (ROG)|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
11077692|NCT04232371|Active Comparator|New Ablation Technique|Will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
11077693|NCT04232371|Active Comparator|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
11077694|NCT04232358|Experimental|Corticosteroid injections + resistance training|Corticosteroid injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
11077695|NCT04232358|Placebo Comparator|Local anesthesia injections + resistance training|Local anesthesia injections every 4 weeks until symptoms resolve with a maximum of 3 injections + resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
11077696|NCT04232345|Experimental|AZD4831 Dose 1|Randomized subjects will receive oral suspension of AZD4831 Dose 1 once daily in the morning for a period of 10 days
11077697|NCT04232345|Experimental|Placebo Dose 1|Randomized subjects will receive oral suspension of placebo Dose 1 once daily in the morning for a period of 10 days
11077698|NCT04232345|Experimental|AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
11077699|NCT04232345|Experimental|Placebo Dose 2|Randomized subjects will receive oral suspension of placebo Dose 2 once daily in the morning for a period of 10 days.
11077700|NCT04232345|Experimental|AZD4831 Dose 3|Randomized subjects will receive oral suspension of AZD4831 Dose 3 once daily in the morning for a period of 10 days.
11077701|NCT04232345|Experimental|Placebo Dose 3|Randomized subjects will receive oral suspension of placebo Dose 3 once daily in the morning for a period of 10 days.
11077702|NCT04232345|Experimental|AZD4831 Dose 4|Randomized subjects will receive oral suspension of AZD4831 Dose 4 once daily in the morning for a period of 10 days.
11077703|NCT04232345|Experimental|Placebo Dose 4|Randomized subjects will receive oral suspension of placebo Dose 4 once daily in the morning for a period of 10 days.
11077704|NCT04232332|Experimental|3.75μg (pre test)|Single dose
11077705|NCT04232332|Experimental|7.5μg|Single dose
11077706|NCT04232332|Placebo Comparator|15μg single dose|Intramuscular injection once
11077707|NCT04232332|Placebo Comparator|30μg single dose|Intramuscular injection once
11077708|NCT04232332|Placebo Comparator|45μg single dose|Intramuscular injection once
11077709|NCT04232332|Placebo Comparator|60μg single dose|Intramuscular injection
11077710|NCT04232332|Placebo Comparator|75μg single dose|Intramuscular injection
11077711|NCT04232332|Placebo Comparator|90μg single dose|Intramuscular injection once
11077712|NCT04232332|Placebo Comparator|30μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
11077713|NCT04232332|Placebo Comparator|60μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
11077714|NCT04232319|Experimental|Sleep Hygiene Training|The intervention will be delivered online by an occupational therapist. The intervention consists of 3 weekly sessions; each session will be 30-45 minutes long. The focus of the intervention is to teach breast cancer survivors sleep hygiene strategies to improve their sleep.
11077715|NCT04232306|Experimental|Liposomal Bupivacaine + Bupivacaine HCL|Liposomal bupivacaine + bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
11077716|NCT04232306|Active Comparator|Bupivacaine HCl surgical-site incision infiltration|Bupivacaine HCl surgical-site incision infiltration following spinal anesthesia
11077717|NCT04232293|Experimental|Blood tests|Two diagnostic tests (eLift and FibroMeter) will be performed to evaluate liver fibrosis
11077718|NCT04232280|Experimental|CMV-seronegative|Escalating dose levels
11077719|NCT04232280|Experimental|CMV-seropositive|Escalating dose levels
11077720|NCT04232267||Patients prescribed Polysomnology (PSG - sleep study)|Patients that are at least 18 years old but not older than 75 years old, who have been referred to a sleep clinic for sleep disturbance.
11077721|NCT04232254|Active Comparator|Animal Protein - Skewed Distribution|Animal-based protein foods with 3 meals per day consisting of 10-, 30-, and 60 g of dietary protein for breakfast, lunch, and dinner, respectively.
11077722|NCT04232254|Experimental|Plant Protein - Skewed Distribution|Plant-based protein foods with 3 meals per day consisting of 10-, 30-, and 60 g of dietary protein for breakfast, lunch, and dinner, respectively.
11077723|NCT04232254|Experimental|Animal Protein - Balanced Distribution|Animal-based protein foods with 5 meals per day consisting of 20 g of dietary protein per meal.
11077724|NCT04232254|Experimental|Plant Protein - Balanced Distribution|Plant-based protein foods with 5 meals per day consisting of 20 g of dietary protein per meal.
11077725|NCT04232241|Active Comparator|Treatment A|Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor
11077726|NCT04232241|Experimental|Treatment B|Allogeneic stem cell transplantation from haploidentical donor
11077727|NCT04232228||Participants with Crohn's Disease (CD)|Adult participants with moderate to severe CD who agree to be part of the study and who fit the inclusion/exclusion criteria and use Care4Today inflammatory bowel disease (C4T IBD) alongside standard of care (SOC) at participating centers will be observed. Data available per clinical practice and via the C4T IBD application will be collected within this study. Participants will also be asked to complete questionnaires that are sent directly to the patients, which are not completed as part of clinical practice or via the application. Relevant data will be collected by prospectively following participants from the index date for 12 months, and also by retrospectively collecting data for the 6-month period prior to the index date from participant's medical records. Index is the activation date of C4T IBD application in participant's smartphone.
11077728|NCT04232215|Experimental|HeraBEAT™ Intervention Group|Subjects will monitor their fetal heart beat once weekly using the HeraBEAT™ device. After approximately 8 weeks of monitoring subjects will crossover to using the doppler fetal heart rate monitor
11077729|NCT04232215|Active Comparator|Standard Fetal Doppler Group|Subjects will monitor their fetal heart beat once weekly using the doppler fetal heart rate monitor. After approximately 8 weeks of monitoring subjects will crossover to using the HeraBEAT™ device
11077730|NCT04232202|Experimental|Laser|After extraction, Er:YAG and Nd:YAG lasers used for degranulation, disinfection, deepithelialization, clot stabilization and photobiomodulation.
11077731|NCT04232202|Active Comparator|Control|Standard extraction procedure.
11077732|NCT04232163|Experimental|Immediate Treatment Group|Participants will receive the intervention right away
11077733|NCT04232163|No Intervention|Delayed Treatment Group|Participants will receive usual care (no intervention), however, they will receive the intervention after a 3 week delay
11077734|NCT04232150|Experimental|Group C (control group)|control group will receive no sedation under spinal anesthesia.
11077735|NCT04232150|Experimental|Group O (single dose group)|patients will receive 0.025mg/kg midazolam sedation under spinal anesthesia.
11077736|NCT04232150|Experimental|Group M (double dose group)|patients will receive 0.025mg/kg midazolam sedation twice under spinal anesthesia.
11077737|NCT04232137|Experimental|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
11077738|NCT04232137|No Intervention|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
11121489|NCT03924271|Experimental|ONCOLOGY|Patient with a cancer
11077739|NCT04232124|Experimental|Hypertension Management Model|Aim 1. Execute a smaller version of the LA Barbershop BP Study through the new Nashville network as the test case for: A) recruiting regular patrons with uncontrolled HTN, B) conducting a research protocol and evaluating a HTN intervention; and C) creating a local registry of potential subjects as platform for enrolling black men in future research studies.
11077740|NCT04232111|Sham Comparator|Thermoneutral|Neither heat nor vacuum applied to hand
11077741|NCT04232111|Experimental|Heat and Vacuum|Heat and vacuum applied to hand
11077742|NCT04232111|Experimental|Heat only|Only heat applied to hand
11077743|NCT04232098|No Intervention|Thermoneutral|thermoneutral condition
11077744|NCT04232098|Experimental|Feet heated|Hot water up to ankles
11077745|NCT04232098|Experimental|Calf heated|Hot water up to top of calves
11077746|NCT04232085|Experimental|PID/IDS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).
~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Total body irradiation: 200 cGy will be administered in a single fraction on day -1.
~Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.
~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.
~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
11077747|NCT04232085|Experimental|IBMFS|"Alemtuzumab IV infusion over 2 hours on days -14, -13, and -12. Day -14 3 mg followed by 10 mg. Day -13 15 mg (or 10 mg if <10 kg). Day -12 20 mg (or 10 mg if <10 kg).
~Fludarabine 30 mg/m2/day IV infusion over 2 hours on days -6 to -2. Melphalan 70 mg/m2/day IV infusion over 30-60 minutes on days -3 and -2. (Or may be given as a single infusion of 140 mg/m2/day on day -2.) Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant.
~Tacrolimus begins on day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 4 hours every 12 hours.
~Mycophenolic acid mofetil (MMF) begins on day 5 at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID)."
11077748|NCT04232072|Active Comparator|Group ESPB = Erector spinae plane block group|ESPB will be performed 30 min before induction of general anesthesia, with patients in the sitting position by using US. Under aseptic conditions, the high frequency linear probe will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. Local anesthetic infiltration with 2% of lidocaine will be applied under the skin. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block. The same procedure will be performed for the opposite site.
11077749|NCT04232072|Active Comparator|Group Ibuprofen = Ibuprofen|In Group Ibuprofen, a dose of 800 mg ibuprofen IV will be administrated 30 min before induction of general anesthesia.
11077750|NCT04232072|No Intervention|Group C = Control group|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
11077751|NCT04232059|Active Comparator|Group 1: hyperventilation|• Group 1: hyperventilation (ETco2 25-30 mm Hg) for 20 minutes that will start immediately after skin incision followed by normoventilation (ETco2 31-35 mm Hg) for another 20 minutes.
11077752|NCT04232059|Active Comparator|Group 2: normoventilation|• Group 2: normoventilation (ETco2 31-35 mm Hg) for 20 minutes immediately after skin incision followed by hyperventilation (ETco2 25-30 mm Hg) for another 20 minutes.
11077753|NCT04232046|Experimental|Intervention|Trigger point massage
11077754|NCT04232046|Active Comparator|Control|Treatment with standard drug Nortriptyline
11077755|NCT04232033|Active Comparator|Fibroblast growth factor 21 infusion|Fibroblast growth factor 21 infusion
11077756|NCT04232033|Placebo Comparator|Placebo infusion (saline)|Saline infusion
11077757|NCT04232007|Experimental|Closed-loop|Closed-loop system to titrate vasopressor during surgery
11077758|NCT04231994|Experimental|TPE|additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid
11077759|NCT04231994|No Intervention|SMT|Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines
11077760|NCT04231981|Experimental|Interventional arm|Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.
11077761|NCT04231968|Experimental|AK0529|Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
11077762|NCT04231968|Placebo Comparator|Placebo|Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
11077763|NCT04231955|Experimental|pain rating scales|"patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10, on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end and on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
11077794|NCT04231708|Experimental|active stressor, sham rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + sham (inactive) rTMS over the left dlPFC
11077795|NCT04231708|Experimental|active stressor, active rTMS|Stressor (yohimbine 54mg + hydrocortisone 20mg) + active 10Hz rTMS over the left dlPFC
11077796|NCT04231682|Experimental|Denosumab receiving group.|Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months. (A total of 4 injections)
11077764|NCT04231942|Experimental|Group 1 (experimental): continuous using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).
~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;"
11077765|NCT04231942|Experimental|Group 2 (experimental): intermittent using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).
~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;"
11077766|NCT04231942|No Intervention|Group 3 (control): no use of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).
~The use of GCS will be possible on-demand when symptoms or risk factors appear after appropriate coordination with the Investigator"
11077767|NCT04231929|Experimental|BioPearl™ loaded with doxorubicin|Chemoembolization with doxorubicin-loaded BioPearl™ microspheres
11077768|NCT04231916|Experimental|Patients aged 5-18 years|"Patients with Osteogenesis Imperfecta (with known vertebral fractures)for phase one of the study.
~Patients with Osteogenesis Imperfecta for phase 2 of the study In both groups patients will be aged 5 years and over"
11077769|NCT04231903||EAC|Patients undergoing surgery endo-aortic clamp.
11077770|NCT04231903||TTC|Patients undergoing surgery through trans-thoracic aortic clamp.
11077771|NCT04231890|Experimental|IPI group|IPI monitoring
11077772|NCT04231890|No Intervention|Control group|Standard monitoring
11077773|NCT04231877|Experimental|Treatment (polatuzumab vedotin, combination chemotherapy)|Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim SC 24-72 hours after the last dose of each treatment cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11077774|NCT04231864|Experimental|Treatment (durvalumab, epacadostat)|Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice a day (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.
11077775|NCT04231851|Experimental|CPX-351 and Glasdegib|"In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.
~If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.
~In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.
~If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year"
11077776|NCT04231838|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
11077777|NCT04231838|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS
11077778|NCT04231825|Experimental|Verum Stimulation|This group will receive 6-Hz tACS
11077779|NCT04231825|Active Comparator|Frequency Control|This group will receive 1-Hz tACS
11077780|NCT04231812|Other|open lable|Prospective, open-label
11077781|NCT04231799|Experimental|Bathing within 24-48|Participants who will have their first bath in 24-48th hours after birth.
11077782|NCT04231799|Experimental|Bathing within 48-72|Participants who will have their first bath in 48-72th hours after birth.
11077783|NCT04231773|Experimental|12.1% Oxygen and Inhaled Nitric Oxide|Moderate level of hypoxia (12.1% Oxygen) and Inhaled Nitric Oxide (40 ppm)
11077784|NCT04231773|Placebo Comparator|12.1 % Oxygen Placebo|Moderate level of hypoxia (12.1 % Oxygen) and Placebo (0 ppm Nitric Oxide)
11077785|NCT04231773|Experimental|13.6 % Oxygen and Inhaled Nitric Oxide|Severe level of hypoxia (13.6% Oxygen) and Inhaled Nitric Oxide (40 ppm)
11077786|NCT04231773|Placebo Comparator|13.6 % Oxygen and Placebo|Severe level of hypoxia (13.6% Oxygen) and Placebo (0 ppm Nitric Oxide)
11077787|NCT04231760|Experimental|Chronic Obstructive Pulmonary Disease|Mild & Moderate COPD to receive either placebo or inhaled nitric oxide (40ppm)
11077788|NCT04231760|Active Comparator|Healthy Controls|Control group to receive either placebo or inhaled nitric oxide (40ppm)
11077789|NCT04231747|Experimental|CC-97540 monotherapy|Subjects will be assigned to receive CC-97540 followed by 3 consecutive doses of lymphodepleting chemotherapy (fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day).
11077790|NCT04231734|Experimental|All Subjects|Low tumor burden, treatment-naïve MCL
11077791|NCT04231721||Healthy controls|
11077792|NCT04231708|Placebo Comparator|placebo stressor, sham rTMS|Placebo stressor (lactose) + sham (inactive) rTMS over the left dlPFC
11077793|NCT04231708|Experimental|placebo stressor, active rTMS|Placebo stressor (lactose) + active 10Hz rTMS over the left dlPFC
11078011|NCT04230122|Experimental|LY3478006 - Intravenous (IV)|LY3478006 administered IV
11077797|NCT04231682|Placebo Comparator|Placebo receiving group.|Patients in this arm will receive Placebo injection subcutaneously every 6 months. (A total of 4 injections)
11077798|NCT04231669|No Intervention|Control: bolstered care|Female adolescents in the bolstered care will receive services/education as usual in their respective schools. The usual care will be bolstered by providing school notebooks and lunch in the control arm (bolstered care will also be provided to treatment arm). Primary school education is universal and free in Ghana. Yet notebooks and lunch are costly expenses for families that create a barrier to school attendance. Hence, these will be provided to participants in all study schools.
11077799|NCT04231669|Experimental|Anzansi Family Program|In addition to bolstered care, participants in this arm will receive the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG).
11077800|NCT04231656|Experimental|Sequence A before sequence B|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence A of positioning (before the procedure), and sequence B after the procedure.
11077801|NCT04231656|Experimental|Sequence B before sequence A|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence B of positioning before the procedure, and sequence A after the procedure.
11077802|NCT04231643|Experimental|Bipolar Disorder|adults with bipolar disorder
11077803|NCT04231643|Active Comparator|Healthy Volunteers|adults with no psychiatric disease
11077804|NCT04231630|Other|Observational Case|1 infant will be enrolled as an observational case. Will receive an exclusive human milk diet at home.
11077805|NCT04231617|Active Comparator|CGRP and glibenclamide|Participants will recieve CGRP infusion after glibenclamide/placebo administration
11077806|NCT04231617|Active Comparator|CGRP and placebo|Participants will recieve CGRP infusion after glibenclamide/placebo administration
11077807|NCT04231604|Experimental|A Lust for Life programme group|A Lust for Life programme will be delivered to adolescents by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
11077808|NCT04231604|Other|Waiting list control group|Participants will be placed on a twelve-week waiting list for the programme.
11077809|NCT04231591||ACDH Pregnancy - Study group|Pregnant women with known adult congenital heart disease.
11077810|NCT04231591||Uncomplicated pregnancy - Control group|Healthy women with an uncomplicated pregnancy
11077811|NCT04231578|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
11077812|NCT04231578|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
11077813|NCT04231565|Active Comparator|TAF group|50 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long.
11077814|NCT04231565|No Intervention|Observation group|50 patients would not receive treatment from baseline to life-long.
11077815|NCT04231552|Experimental|Chemotherapy and PD1 inhibitor|CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
11077816|NCT04231539|Experimental|Low Nicotine (nicotine vapor) 24 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
11077817|NCT04231539|Experimental|High Nicotine (nicotine vapor) 42 mg.ml|After 8-10 hours after nicotine abstinence, participants attend 4 vaping sessions over 2-2.5 hours, 5-7 days apart. During each session, participants take 20 puffs over 10 minutes (one puff every 30 seconds) of vaporizer filled with freebased nicotine e-liquid solution of unflavored, free-based nicotine e-liquid solution of tobacco flavor, salt-based nicotine e-liquid solution of unflavored, or salt-based nicotine e-liquid solution of tobacco flavor assigned in a random order.
11077818|NCT04231526|Experimental|ARM A - Pembrolizumab + Surgery|
11077819|NCT04231526|Active Comparator|ARM B - Surgery|
11077820|NCT04231513|Experimental|Cohort 1: E2814 or E2814-matched Placebo|Participants will receive either E2814 or E2814-matched placebo at starting dose level, as an intravenous infusion, once, on Day 1.
11077821|NCT04231513|Experimental|Cohort 2: E2814 or E2814-matched Placebo|Participants will receive either E2814 (anticipated dose will be based on emerging safety, tolerability, Pharmacokinetic [PK] data from Cohort 1) or E2814-matched placebo as an intravenous infusion, once, on Day 1.
11077822|NCT04231513|Experimental|Cohort 3: E2814 or E2814-matched Placebo|Participants will receive either E2814 (anticipated dose will be based on emerging safety, tolerability, PK data from Cohort 2) or E2814-matched placebo as an intravenous infusion, once, on Day 1.
11077823|NCT04231513|Experimental|Cohort 4: E2814 or E2814-matched Placebo|Participants will receive either E2814 (anticipated dose will be based on emerging safety, tolerability, PK data from Cohort 3) or E2814-matched placebo as an intravenous infusion, once, on Day 1.
11077824|NCT04231500||patients with GVHD after allo-HSCT|Exploration of the skin-microbiota in patients with GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure and additional skin biopsies from affected and healthy skin sites in case of GVHD
11077825|NCT04231500||patients without GVHD after allo-HSCT|Exploration of the skin-microbiota in patients without GVHD after allo-HSCT by sampling of skin swabs and a skin punch biopsy before conditioning procedure
11077826|NCT04231487||Essential tremor|"This is not an intervention study.
~Specific to group: a) Diagnosis of ET, b) stable dose of medication for 30 days"
11077827|NCT04231487||Parkinson's Disease|"This is not an intervention study.
~Specific to group: a) Diagnosis of PD, b) stable dose of medication for 30 days"
11077828|NCT04231487||Huntington's Disease|"This is not an intervention study.
~Specific to group: a) Diagnosis of HD, b) stable dose of medication for 30 days"
11077829|NCT04231487||Primary Focal Dystonia|"This is not an intervention study.
~Specific to group: a) Diagnosis of PFD, b) stable dose of medication for 30 days"
11077830|NCT04231487||Spinocerebellar Ataxia|This is not an intervention study. Specific to group: a) Diagnosis of SCA, b) stable dose of medication for 30 days
11077831|NCT04231487||Functional Movement Disorder|This is not an intervention study. Specific to group: a) Diagnosis of FMD, b) stable dose of medication for 30 days
11077832|NCT04231487||Healthy Controls|"This is not an intervention study.
~People with Healthy Controls"
11077833|NCT04231474||Demographic and clinical features of the patients|Number of patients Time from injury to hospitalization Time from injury to urodynamic evaluation Duration of hospitalization
11077834|NCT04231474||Comparison of urodynamic outcomes|Treatment options in patients with level SCI : cervical, thoracical and lumbar spinal cord injury
11077835|NCT04231448|Experimental|CR-CHOP|
11077836|NCT04231448|Placebo Comparator|R-CHOP|
11077837|NCT04231435|Experimental|Treatment Administration|"All subjects will receive the following oral doses of IP following an overnight fast in the fixed-sequence below:
~Day 1 (Period 1): 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet.
~Day 7 (Period 2): 6 × 100-mg fedratinib capsules PLUS (after approximately 1 hour from the time of fedratinib administration) 1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet."
11077838|NCT04231422||Treatment Group|Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.
11077839|NCT04231409|Active Comparator|WaveWriter Settings|WaveWriter Programming
11077840|NCT04231409|Active Comparator|Conventional Settings|Conventional Programming
11077841|NCT04231396|Other|Audiobooks for Hearing Loss|"study participants will use the Audiobooks for HL App for 12 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:
~BKB-SIN will be administered
~Conduct a comprehension test.
~Address any usability issues the participant brings up.
~Based on discussion with participant (and parent/guardian if available), the usage log, and the comprehension test results: (a) suggest adjusting the speech mode (clear vs. habitual speech, noise level); (b) suggest switching off a visual support (face, synchronized text); discuss next milestone (e.g. completion of a story or book).
~Discuss real-world rewards with parent/guardian if milestones are met."
11077842|NCT04231370|Experimental|treatment arm|Sintilimab, 200mg, iv day1 Lenalidomide, 25mg/d, oral, day 1-14 repeated every 3 weeks
11077843|NCT04231357|Experimental|Platelet rich plasma (PRP)|6-7 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
11077844|NCT04231357|Active Comparator|control|needle tenotomy with lidocaine
11077845|NCT04231331|Placebo Comparator|Placebo|All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
11077846|NCT04231331|Active Comparator|Ertugliflozin|All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
11077847|NCT04231318|Experimental|Cingal|
11077848|NCT04231318|Active Comparator|Triamcinolone Hexacetonide (TH) - Lederlon|
11077849|NCT04231318|Placebo Comparator|Placebo|
11077850|NCT04231292|Experimental|Experimental Group A +Group a|Group A: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week;Group a: refers to the weekly dose at the end of the first stage , once every two weeks, 19th~46th week
11077851|NCT04231292|Experimental|Experimental Group B +Group b|Group B: 1.2μg/kg RD01, once every two weeks, Day 1~ 18th week; Group b: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
11077852|NCT04231292|Experimental|Experimental Group C +Group c|Group C: 1.6μg/kg RD01, once every two weeks, Day 1~ 18th week; Group c: refers to the weekly dose at the end of the first stage , once every six weeks, 19th~46th week
11077853|NCT04231292|Experimental|Experimental Group D +Group d|Group D: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week; Group d: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
11077854|NCT04231292|Active Comparator|Experimental Group E +Group e|Group E: 150IU/kg rHuEPO, once a weeks, subcutaneous administration, Day 1~ 18th week; Group e: refers to the weekly dose at the end of the first stage , once a weeks, intravenous administration, 19th~46th week
11077855|NCT04231292|Placebo Comparator|Experimental Group F +Group f|Group F: 8μl placebo, once every two weeks, for 6 weeks; 150 IU/kg rHuEPO, once week, subcutaneous injection, 7th ~ 18th week; Group f: refers to the weekly dose at the end of the first stage , once a weeks, subcutaneous administration, 19th~46th week
11077856|NCT04231292|Experimental|Experimental Group G|Group G: 1.6μg/kg RD01, once every four weeks, Day 1~ 28th week;
11077857|NCT04231279|Active Comparator|ChiRhoStim Group 1|Patients undergoing EGD with ePFT for symptoms of suspected or known pancreatic insufficiency.
11077858|NCT04231279|Experimental|ChiRhoStim Group 2|Patients undergoing diagnostic EGD that consent to undergo ePFT.
11077859|NCT04231266|Active Comparator|ManNAc|Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
11077860|NCT04231266|Placebo Comparator|Placebo|Oral Placebo will be administered three times daily.
11077861|NCT04231240||Adult cardiac surgery with normothermia|
11077862|NCT04231240||Adult cardiac surgery with hypothermia|
11077863|NCT04231240||Pediatric cardiac surgery with normothermia|
11077864|NCT04231240||Pediatric cardiac surgery with hypothermia|
11077865|NCT04231240||Adult cardiac surgery without cardiopulmonary bypass|
11077866|NCT04231214|Experimental|Treatment sequence 1|Spiolto® Respimat® on Day 1 0.9% nebulized saline on Day 9 Spiolto® Respimat® from Day 10 to Day 24
11077867|NCT04231214|Experimental|Treatment sequence 2|0.9% nebulized saline on Day 1 Spiolto® Respimat® on Day 9 Spiolto® Respimat® from Day 10 to Day 24
11077868|NCT04231188||Primary Caregiver and infant pair|Primary Caregiver and infant who is less than or equal to 12 months old
11077869|NCT04231175|Experimental|experimental arm A|patients will undergo dedicated MRI imaging of the pelvis, abdomen, and thorax. Based on the findings of the MRI scan patients will be allocated to one of the diagnostic/treatment options
11077870|NCT04231175|No Intervention|arm B|patients will undergo the current standard diagnostic work-up of DLS at indication (MDT decision) and otherwise continue to CRS-HIPEC.
11077871|NCT04231162|Experimental|probiotic powder, Bifidobacterium lactis|
11077872|NCT04231162|Placebo Comparator|Placebo|
11077873|NCT04231149|Experimental|Test product 2|Test catheter 2
11077874|NCT04231149|Experimental|Test product 3|Test catheter 3
11077875|NCT04231149|Active Comparator|Comparator|SpeediCath Flex
11077876|NCT04231136|Experimental|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg tablet once a day
11077877|NCT04231136|Active Comparator|EAPA115|Oral administration of EAPA115 once a day
11077878|NCT04231136|Active Comparator|RAPA115|Oral administration of RAPA115 once a day
11077879|NCT04231123|Experimental|PENG group|PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine
11077880|NCT04231123|Placebo Comparator|Placebo group|PENG block with 20 ml of 0,9% saline
11077881|NCT04231110|Experimental|FMT and vedolizumab|People who are initiating vedolizumab per standard of care for ulcerative colitis will also be offered FMT weekly for 6 weeks.
11077882|NCT04231097|Experimental|Virtual MBCT|Two cohorts of MBCT participants with approximately 10 participants per cohort.
11077883|NCT04231084|Active Comparator|Inhaled Nitric Oxide|Vasodilator testing will be performed with inhaled nitric oxide
11077884|NCT04231084|Experimental|Inhaled Epoprostenol|Vasodilator testing will be performed with inhaled epoprostenol
11077885|NCT04231071|Active Comparator|Sutured group|Controlled group: Primary suture repair of the small umbilical hernia defect
11077886|NCT04231071|Experimental|Onlay Mesh group|Intervention group: Primary suture repair of the small umbilical hernia defects + a small Onlay mesh on the closed defect.
11077887|NCT04231058|Experimental|acupuncture|15 experimental subjects treated with Acupuncture and Pulmonary Rehabilitation
11077888|NCT04231058|Experimental|Transcutaneous Electrical Nerve Stimulation (TENS)|15 experimental subjects treated withTENS and Pulmonary Rehabilitation
11077889|NCT04231058|No Intervention|Rehabilitation|15 experimental subjects treated with Pulmonary Rehabilitation only
11077890|NCT04231045||Patients on PiCCO monitoring system|ALL intensive care patients on PiCCO monitoring system and over 18 years old and on PiCCO for more than 24 hours. Those medical or surgical patients admitted in a UK NHS unit, elective, semi-elective or emergency admission.
11077891|NCT04231032|Active Comparator|Active ventricular pacing|Asynchronous dual chamber pacing (DOO mode) at 10-15 bpm higher than intrinsic heart rate
11077892|NCT04231032|Placebo Comparator|Back-up ventricular pacing|Asynchronous atrial pacing with intrinsic ventricular activation (AOO mode) at 10-15 bpm higher than intrinsic heart rate
11077893|NCT04231019||Dental practitioners (general, specialists or students)|Two self-administered questionnaires will be used in the study one to general practitioners and specialists and another one with a plain language describing the study will be distributed to the fifth year dental students in Egypt with total 1000 dentist to assess their knowledge, awareness and perception regarding MIH.
11077894|NCT04231006|Experimental|Single arm|Single arm
11077895|NCT04230993|Experimental|Ocean Bio Actif-Fluid+|Moderate hypertonic seawater solution (15 g / L NaCl) with polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
11077896|NCT04230993|Experimental|Ocean Bio Active-Stuffy nose|Moderate hypertonic seawater solution (15 g / L NaCl) without polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
11077897|NCT04230993|Active Comparator|Ocean Bio Active-Hygiene of the nose|Isotonic seawater solution (9 g / L NaCl). The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
11077898|NCT04230980|Experimental|Gabapentin|Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
11077899|NCT04230980|Placebo Comparator|Placebo|Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days
11077900|NCT04230967|Experimental|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit InspireTM devices will be set to this goal and notifications will be given on the device for the participants meeting their goals. Upon enrollment, they will be given a pamphlet with instructions to ambulate out of the room at least once per day with a goal of 2,000 steps daily and their Fitbits will be pre-programmed with this goal. Study staff will also remind participants to ambulate via email, text or in-person if they are not meeting their goal of 2,000 steps per day.
11077901|NCT04230967|Active Comparator|Routine Care|Participants in the routine care arm will be allowed ad lib activity but no encouragement to walk will be given. They will not have any goals set on their Fitbits. Upon enrollment, they will be given pamphlets with no instruction on whether or not to ambulate and their Fitbits will be pre-programmed to have no goal.
11077902|NCT04230954|Experimental|Cabozantinib (XL 184) Plus Pembrolizumab|A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
11077903|NCT04230941|Experimental|MAAT-G Intervention|MAAT-G Workshops & participant workbook use (8 workshops)
11077904|NCT04230928|Placebo Comparator|Standard GLB Control|Individuals will receive the standard Diabetes Prevention Program-Group Lifestyle Balance (GLB) program as outlined by the American Diabetes Association. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
11077905|NCT04230928|Experimental|VLC-GLB Intervention|Individuals will receive a version of the DPP-GLB program in which 4 of the 12 modules will teach a very low carbohydrate diet instead of the standard. All other components of the DPP-GLB will follow the standard. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
11077906|NCT04230915|Active Comparator|Low Dose Rocuronium|This group patients will determine as those who were administered 0.3 mg/kg rocuronium
11078012|NCT04230122|Placebo Comparator|Placebo - IV|Placebo administered IV
11077907|NCT04230915|No Intervention|Strandart Dose Rocuronium|This group patients will determine as those who were administered 0.6 mg/kg rocuronium
11077908|NCT04230902|Experimental|Lipogems|The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.
11077909|NCT04230902|Active Comparator|Steroid|The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study.
11077910|NCT04230889|Other|Usual Diet Group|Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.
11077911|NCT04230889|Experimental|Group 1 Nutritional Shake|Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.
11077912|NCT04230889|Experimental|Group 2 Nutritional Shake|Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.
11077913|NCT04230863|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation.
11077914|NCT04230850|Active Comparator|Mildly Impaired Group|This group will consist of participants with 35-50 degrees of lumbar flexion.
11077915|NCT04230850|Active Comparator|Moderately Impaired Group|This group will consist of participants with 20-34 degrees of lumbar flexion.
11077916|NCT04230850|Active Comparator|Highly Impaired Group|This group will consist of participants with less than 20 degrees of lumbar flexion.
11077917|NCT04230837|Experimental|A: Abutments of 1 mm|Definitive abutments of 1 mm height were located.
11077918|NCT04230837|Experimental|B: Abutments of 3 mm|Definitive abutments of 3 mm height were located.
11077919|NCT04230824|Active Comparator|Pre-workout plus and Protein recovery plus|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise
~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
11077920|NCT04230824|Placebo Comparator|Placebo|Non-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise
11077921|NCT04230824|No Intervention|Control|This arm will receive no intervention
11077922|NCT04230798|No Intervention|Control|This group did not perform any specific exercise program nor injury prevention program. They continued their normal training routine
11077923|NCT04230798|Experimental|Prevention program|This group performed two sessions per week of the injury prevention program. The program included strength training, plyometrics and core stability training.
11077924|NCT04230785||AIS before EVT group|This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)
11077925|NCT04230785||AIS after EVT group|This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)
11077926|NCT04230772|Experimental|Natural Orifice Specimen Extraction Surgery|Natural orifice specimen extraction surgery will performed in patients assigned to this group.
11077927|NCT04230772|Active Comparator|Traditional Robotic-assisted Surgery|Traditional robotic-assisted surgery will performed in patients assigned to this group.
11077928|NCT04230759|Active Comparator|5FU+Mitomycin C|Radiochemotherapy for anal cancer
11077929|NCT04230759|Experimental|5FU+Mitomycin C+Durvalumab|Radiochemotherapy with Durvalumab for anal cancer
11077930|NCT04230746|Placebo Comparator|Placebo|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with placebo to be taken twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
11077931|NCT04230746|Experimental|Bactrim|Participants will be recruited and enrolled. Participants will be surveyed regarding environmental, health, and behavioral practices. (Instrument 1) . Then a clean catch urine specimen will be collected. Participants will be provided with Bactrim 800/120 to take twice daily. This will be considered day 0. Participants will then be instructed to take the study drug twice daily and return on Day 2, Day 5, Day 10, Day 30, and Day 180 for additional clean-catch urine specimen.
11077932|NCT04230720|Experimental|Artificial Tears|One eye of each participant is randomized to receive Systane Complete artificial tears 4 times a day for 14 days
11077933|NCT04230720|No Intervention|No Artificial Tears|One eye of each participant is randomized to receive no artificial tears for 14 days
11077934|NCT04230694|Active Comparator|Control Group|Control Group subjects will wear the CGM device during their hospitalization, up to 14 days, but glucose readings will NOT be continuously monitored. Control Group subjects will have their glucose management guided by routine standard of care finger sticks. The readings from the CGM device are recorded and reviewed retrospectively, but not used for glucose management during the hospital stay.
11077935|NCT04230694|Experimental|Treatment Group|Treatment Group subjects will wear the CGM device during their hospitalization, up to 14 days, and glucose readings WILL be continuously monitored. Treatment Group subjects will have their glucose management guided by readings from the CGM device and standard of care finger sticks.
11077936|NCT04230681|Active Comparator|Fentanyl|
11077937|NCT04230681|Active Comparator|Hydromorphone|
11077938|NCT04230655|Active Comparator|Control group|"All participants in the control group are treated with LED and CBT-based group treatment as described below.
~All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants. Two groups of about the same size start simultaneously.
~The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended."
11078013|NCT04230122|Experimental|LY3478006 - Subcutaneous (SC)|LY3478006 administered SC
11077939|NCT04230655|Experimental|IGB group|"All participants in the IGB group are treated with LED and CBT-based group treatment as described for the control group.
~Participants in the intervention group are treated with an IGB for 6 months from 6 months from start."
11077940|NCT04230642|Experimental|Robotic device|Needle placement to the tumor, one time, the day of the ablation procedure
11077941|NCT04230629|Active Comparator|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
11077942|NCT04230629|Active Comparator|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
11077943|NCT04230616|Active Comparator|Conventional total knee arthroplasty|conventional total knee arthroplasty with standard intramedullary alignment guide
11077944|NCT04230616|Active Comparator|NAVIO total knee arthroplasty|NAVIO assisted total knee arthroplasty
11077945|NCT04230603|Experimental|Hyperspectral imaging|diagnostic hyperspectral imaging of the human tissue an correlation with local blood parameters and local pathological examination
11077946|NCT04230590||Participants with schizophrenia spectrum disorders|Within 8 weeks post discharge from hospitalization at the Institute of Mental Health
11077947|NCT04230577|Active Comparator|Real LED Intervention|Participants receive 15 Real (active) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal). Parameters: NIR, 810nm, pulsed at 10 Hz, 50% duty cycle, synchronized for a 20-minute treatment time. Total Energy Dose per head set plus intranasal: 225 J/cm2+ 15 J/cm2 = 240 J/cm2 per 20 min LED treatment. Total Energy Dose delivered (3x/Week, 5 Weeks) = 3600 J/cm2. The light from these LEDs is not visible to the eye. There is no potential for eye damage because the LEDs are not laser light. The head frame device falls within the FDA category General Wellness, low-risk devices, and no medical claims are made. It is approved for use by the VA Boston Healthcare System Safety Committee and Institutional Review Board.
11077948|NCT04230577|Sham Comparator|Sham LED Intervention|Participants receive a series of 15 Sham (control) LED treatments with the Vielight Neuro Alpha head frame device (with intranasal) containing Sham LEDs, synchronized for a 20-minute treatment time (3x/Week, 5 Weeks). Sham and Real devices are identical in look and feel, except no photons are emitted from the Sham devices.
11077949|NCT04230564||AML|Patients diagnosed with AML
11077950|NCT04230551|Active Comparator|Reference Group|Five symptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
11077951|NCT04230551|Experimental|Study Group|Five asymptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
11077952|NCT04230551|No Intervention|Observation Group|Five asymptomatic HOCM patients with severe LVOT obstruction will not undergo PTSMA
11077953|NCT04230538|Experimental|DJO Walker|Application of DJO Walker
11077954|NCT04230538|Active Comparator|Traditional plaster cast|Application of traditional plaster cast
11077955|NCT04230525||Bioimpedence|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia.
11077956|NCT04230512|Experimental|Locked|The prototype mechanical system is locked from compressing
11077957|NCT04230512|Experimental|Unlocked|The prototype mechanical system is free to compress normally
11077958|NCT04230499|Experimental|Cohort 1|Cohort 1 will receive 0.5mg of eRapa every other day.
11077959|NCT04230499|Experimental|Cohort 2|Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.
11077960|NCT04230499|Experimental|Cohort 3|Cohort 3 will receive 0.5 mg of eRapa daily.
11077961|NCT04230473|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
11077962|NCT04230460|Placebo Comparator|0% THC/ 0% CBD|
11077963|NCT04230460|Experimental|THC (5-10% [37.5 mg]) / Low CBD (<1% [2.5 mg])|
11077964|NCT04230460|Experimental|THC (>10% [62.5 mg]) / Low CBD (<1% [2.5 mg])|
11077965|NCT04230460|Experimental|0.065% BAC|
11077966|NCT04230447||a cohort of patients with sepsis encephalopathy|This study is an observational study without drug and other interventions
11077967|NCT04230447||a cohort of patients with sepsis|This study is an observational study without drug and other interventions
11077968|NCT04230447||a cohort of patients with SIRS|This study is an observational study without drug and other interventions
11077969|NCT04230434|Experimental|Safety Plan Intervention|The Safety Plan Intervention (SPI) performed in ED or in ambulatory appointment
11077970|NCT04230421|Experimental|Monsenso with feedback|Daily smartphone-based monitoring and treatment using the Monsenso system with a clinical feedback loop feedback.
11077971|NCT04230421|Active Comparator|Monsenso without feedback|Daily smartphone-based monitoring and treatment using the Monsenso system WITHOUT a clinical feedback loop feedback.
11077972|NCT04230421|Active Comparator|Control|CAG Bipolar treatment alone and daily mood monitoring using only the mood monitoring part of the Monsenso system.
11077973|NCT04230408|Experimental|DURVALUMAB (MEDI4736) + carboplatin-paclitaxel|"Induction chemo-immunotherapy phase:
~Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.
~Concurrent chemo-immuno-radiotherapy phase:
~Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.
~Concurrent chemo-immuno-radiotherapy:
~Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses"
11077974|NCT04230395|Experimental|CAP (Counseling on Alcohol Problems)|The CAP intervention is an up to 4-session alcohol reduction intervention that uses a combination of Motivational Enhancement Therapy and Cognitive Behavioral Therapy. The intervention will also include 3 booster sessions.
11077975|NCT04230395|Other|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
11077976|NCT04230382||Adults|Adults (above 18 years) with completed National Health and Health System Survey 2019 (without diagnosis of diabetes)
11077977|NCT04230369|Experimental|Internet-CBT|The internet-CBT will comprise 8 weekly modules with therapist-support, encouraging exposure for fear of asthma symptoms while ensuring a stable asthma medication through a written medical plan on medical adherence Participants work independently from home with the treatment and receive weekly support from their psychologist through written messages online.
11078014|NCT04230122|Placebo Comparator|Placebo - SC|Placebo administered SC
11077978|NCT04230369|Other|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment, but psychological, from pre-assessments to 2 months after treatment completion. Participants in this arm will be crossed over to Internet-CBT after the primary endpoint at to 2 months follow up.
11077979|NCT04230356|Experimental|VSTs to Prevent|VSTs are given through an IV infusion 21 days after transplant to see if the VSTs will help prevent a viral infection.
11077980|NCT04230356|Experimental|VSTs to Treat|VSTs will be given only if a viral infection develops.
11077981|NCT04230343|Experimental|Self-benefit arm|
11077982|NCT04230343|Active Comparator|Social-benefit arm|
11077983|NCT04230330|Experimental|Nivolumab|After 4 doses of nivolumab, if the patient has complete responses (CR) or good partial response (PR), the patient will continue on nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment. During PET4-directed treatment with single agent nivolumab, if patient has PD, they will proceed to the Nivo+GDP/L-aspa arm.
11077984|NCT04230330|Experimental|Nivolumab + GDP/ L-asparaginase|After 4 doses of nivolumab, if the patient has PR, stable disease (SD), or progressive disease (PD), the patient will switch to nivolumab-GDP/L-aspa treatment. After 6 cycles of treatment, if CR is achieved, the patient will continue on single agent nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment.
11077985|NCT04230317|Experimental|Low dose chest CT simulation|VBN result driven using raw data acquired with low dose CTs taken with three different protocols
11077986|NCT04230317|Active Comparator|Standard protocol chest CT simulation|VBN result driven using raw data acquired with standard protocol CT
11077987|NCT04230304|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11077988|NCT04230291|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP
~Survey A
~Routine clinic visit
~Verbal consultation only
~Survey B
~Verbal consultation AND Written Action Plan
~Survey C"
11077989|NCT04230291|Experimental|Written Action Plan|"INTERVENTION GROUP
~Survey A
~Routine clinic visit
~Verbal consultation AND Written Action Plan
~Survey C"
11077990|NCT04230278|Experimental|START-Play Intervention|
11077991|NCT04230278|Active Comparator|Usual Care Physical Therapy|
11077992|NCT04230265|Experimental|UniCAR02-T-CD123|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the recombinant antibody derivative TM123.
11077993|NCT04230252|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
11077994|NCT04230252|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8 hour ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
11077995|NCT04230239|Experimental|CPX-351|
11077996|NCT04230226|Active Comparator|Pre-workout and Post-workout Product|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise
~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
11077997|NCT04230226|Placebo Comparator|Study Placebo|non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
11077998|NCT04230213|Experimental|Treatment Arm 1|Subcutaneous (SC) injection given every other week
11077999|NCT04230213|Active Comparator|Treatment Arm 2|SC injection given every other week
11078000|NCT04230200||Healthy cohort|People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.
11078001|NCT04230200||Malignancy Cohort|People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer
11078002|NCT04230187|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
11078003|NCT04230187|Active Comparator|mFOLFOX6 Plus Bevacizumab|Patients will receive mFOLFOX6 plus bevacizumab once every two weeks for 8 cycles as the first-line treatment.
11078004|NCT04230174|Experimental|Multiple sclerosis patients|Multiple sclerosis patients will be evaluated with 11C-PBR28 MR-PET at baseline before and at 12 month follow up after Ocrelizumab therapy.
11078005|NCT04230161||Standard LLIN|This group receives Yahe LN ITNs during the mass distribution campaign.
11078006|NCT04230161||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
11078007|NCT04230161||Standard LLIN and IRS|This group receives Yahe LN ITNs during the mass distribution campaign and IRS.
11078008|NCT04230148|Experimental|Egaten|All subjects will receive Egaten as two 10 mg/kg doses given 12 hours apart.
11078009|NCT04230135|Active Comparator|Generic (surface adaptation)|The generic version of Hap-pas-Hapi includes only surface adaptations (i.e., adaptation of text and illustrations that are inacceptable or non-meaningful for the target group)
11078010|NCT04230135|Experimental|Adapted (deep structure adaptation)|For the experimental intervention, Hap-pas-Hapi was adapted to Albanian immigrants' cultural concepts of distress (CCD). An ethnopsychological study was conducted for this purpose, since evidence on CCD in South Eastern Europe is scarce. Based on this study, three deep-structure adaptations were done: i) the symptom narrative provided by the narrator in the app was re-written to reflect Albanian immigrants' CCD; ii) a new explanatory model builder was implemented to address the target group's fatalistic beliefs; and iii) a goal-setting task was programmed to address the target group's socio-centric notion of the self.
11078015|NCT04230109|Experimental|Sacituzumab Govitecan|"- The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Sacituzumab govitecan via iv, predetermined dosage per protocol, IV, 2 days per each 21-day cycle, for 4 cycles.
~This can be followed by standard chemotherapy at the discretion of treating physician."
11078016|NCT04230096|Experimental|applied group|low level laser therapy applied in one group
11078017|NCT04230096|No Intervention|controlled group|other group will be controlled in which low level laser will not be applied
11078018|NCT04230083|Experimental|Dienogest Test Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
11078019|NCT04230083|Active Comparator|Dienogest Reference Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
11078020|NCT04230070|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
11078021|NCT04230070|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
11078022|NCT04230057||Healthy volunteer|"In good general health and feeling well (no diagnosed disorders/illnesses)
~At least 18 years old
~BMI in the range of 18-29.9 kg/m²
~No known history of substance abuse
~No known allergies to food/drug"
11078023|NCT04230044||Fycompa® (perampanel)|Fycompa® (perampanel) (oral tablets) treatment will be initiated at 2 milligram (mg) once daily according to the approved package insert, as an add-on drug in addition to other anti-epileptic drugs (AEDs) as prescribed by physician. The dose will be increased based on clinical response and tolerability (by increments of 2 mg/day to a maintenance dose of 4 to 12 mg/day) and participants will be enrolled and observed prospectively for up to 54 Weeks.
11078024|NCT04230031|Experimental|1: Daratumumab|Pre-ASCT and Post-ASCT: Daratumumab
11078025|NCT04230018||primary and metastasis lesion|tissue of colorectal cancer primary lesion and tissue of colorectal cancer metastasis were obtained
11078026|NCT04229992|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
11078027|NCT04229992|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
11078028|NCT04229992|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
11078029|NCT04229992|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
11078030|NCT04229979|Experimental|Galinpepimut-S|"A maximum of 15 total injections will be administered as follows:
~First 6 galinpepimut-S injections: every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment. The first series of 6 injections of galinpepimut-S define the initial immunization induction phase.
~Injections 7-12: every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment. The second series of injections of galinpepimut-S define the early immune booster phase.
~Injections 13 to 15: every 6 weeks (between Weeks 40 and 52). The third series of injections of galinpepimut-S define the late immune booster phase."
11078031|NCT04229979|Active Comparator|Best Available Therapy|"Four options (per treating investigator's choice):
~Observation (whereby palliative management with hydroxyurea is allowed), or
~HMA (decitabine or azacitidine) monotherapy, or
~Venetoclax monotherapy, or
~Low-Dose Ara-C"
11078032|NCT04229953||US scan with 3D/4D VRU software|
11078033|NCT04229940|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
11078034|NCT04229940|Active Comparator|No bridging|The hernia defect is left without closure prior to application of the mesh.
11078035|NCT04229927|Experimental|Arm 1|
11078036|NCT04229927|Placebo Comparator|Arm 2|
11078037|NCT04229914|Other|stroke patients|Assessment
11078038|NCT04229901|Experimental|HepaStem|Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 millions of cells/kg (7 day interval)
11078039|NCT04229901|Placebo Comparator|Placebo|Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)
11078040|NCT04229888|Experimental|Subjects Treatment Light Based|All subjects will receive light based treatment.
11078041|NCT04229888|Experimental|Subjects Treatment LipiFlow|All subjects will receive LipiFlow treatment.
11078042|NCT04229875|Experimental|CAG Bipolar|"Patients will be treated in a localized CAG Bipolar clinic within each psychiatric centre increasing the number of bipolar patients for each clinician
~All clinicians will get certified in diagnosing and treating bipolar disorder by joining an educational course and ongoing courses continuously
~Treatment will include a group-based psychoeducation program
~Coordinated targets to improve quality of life of patients by increasing concordance between clinicians, patients and relatives on well-defined treatment goals
~Continued ongoing supervision of patient cases in CAG Bipolar staff by the Copenhagen Affective Disorder Clinic
~Three-month bidirectional exchange of two clinical staff members between the Copenhagen Affective Disorder Clinic and each CAG Bipolar clinic
~Recovery mentors"
11078043|NCT04229875|No Intervention|Control group|Standard treatment
11078044|NCT04229862|Experimental|Evaluation with 14 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 14 cm high pillow.
11078045|NCT04229862|Active Comparator|Evaluation with 7 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 7 cm high pillow.
11078046|NCT04229849|Experimental|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
11078047|NCT04229849|Active Comparator|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
11078202|NCT04228757|Placebo Comparator|Placebo|Tablet without active ingredients
11078049|NCT04229823||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
11078050|NCT04229823||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
11078051|NCT04229823||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
11078052|NCT04229810|Active Comparator|STD-02|Conventional standardized lung protective ventilation.
11078053|NCT04229810|Experimental|iOLA-iHFNC|Individualized ventilatory strategy that mantains an open lung condition.
11078054|NCT04229797|Active Comparator|Comparator|Extraction of the unerupted third molars before distalization of mandibular first molar using Mandibular buccal shelf mini-screws.
11078055|NCT04229797|Experimental|Intervention|Leaving the unerupted third molars and distalizing using Mandibular buccal shelf mini-screws.
11078056|NCT04229784|Experimental|RF ARM|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
11078057|NCT04229771|Experimental|Participants with obstruction of the lacrimal system|Participants who have a blockage in their tear drainage system on probing and irrigation. Participants will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
11078058|NCT04229771|Experimental|Participants with no obstruction of the lacrimal system|Participants who do not have a blockage in their tear drainage system on probing and irrigation. Patients will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
11078059|NCT04229758|Experimental|1 week|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
11078060|NCT04229758|Experimental|2 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
11078061|NCT04229758|Experimental|4 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
11078062|NCT04229732|Experimental|ClearMate Intervention|Participants undergo passive isocapnic hyperventilation via the ClearMateTM device and have regular venous blood samples obtained to measure ethanol clearance kinetics.
11078063|NCT04229732|No Intervention|Supportive Management|Participants receive standard of care, supportive management, for alcohol intoxication, having regular venous blood samples obtained to measure ethanol clearance kinetics.
11078064|NCT04229719|Experimental|Melatonin group|Melatonin powder (N-Acetyl-5-methoxytryptamine) 1.2mg topical application in osteotomy site.
11078065|NCT04229719|No Intervention|Control group|No drug intervention
11078066|NCT04229706|Experimental|High dose group|xiangjurupining capsule ,8 capsules，tid
11078067|NCT04229706|Experimental|Lower dose group|xiangjurupining capsule, 4 capsules,tid, xiangjurupining capsule placebo ,4 capsules，tid，po
11078068|NCT04229706|Placebo Comparator|Placebo group|xiangjurupining capsule placebo ,8 capsules，tid，po
11078069|NCT04229680|Experimental|High Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 6,900 mg/d sodium.
11078070|NCT04229680|Placebo Comparator|Recommended Salt|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with placebo pills.
11078071|NCT04229615|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
11078072|NCT04229615|Experimental|Single Arm|Fluzoparib
11078073|NCT04229615|Placebo Comparator|Placebo|Placebo
11078074|NCT04229602|Experimental|Venlafaxine Hydrochloride Sustained-Release Capsules|During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.
11078075|NCT04229602|Active Comparator|Active Comparator: EFEXOR® XR|During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.
11078076|NCT04229589||Study population|Consecutive patients undergoing pacemaker implantation for bradyarrhythmic syncope
11078077|NCT04229576|Active Comparator|Using TENS to relief pain during hystroscopy|device intensity (amplitude) will be individually adjusted to each participant's maximum sensory level (strongest reported tingling feeling without pain and with no muscle contractions, the TENS output intensity will be increased during the treatment every time the patient accommodated to the TENS stimulus.
11078078|NCT04229576|Placebo Comparator|Using placebo TENS (not active) during hystroscopy|participants will be connected to the TENS unit in exactly the same way as participants in the active TENS group with the unit emitting the active indicator light and sound but delivering no electrical stimulation.
11078079|NCT04229563||Study patients|Eligible PAD patients who are routinely treated with atherectomy by AURYON™ Atherectomy System.
11078080|NCT04229550|No Intervention|Control subjects|1 week of normal daily life and only by the National Health Board recommendated alcohol consumption.
11078081|NCT04229550|Experimental|Festival subjects|1 week's participation in Roskilde Festival 2016
11078082|NCT04229537|Experimental|SCT-I10A combined SCT200 in ESCC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
11078083|NCT04229537|Experimental|SCT-I10A combined SCT200 in CRC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
11078084|NCT04229537|Experimental|SCT-I10A combined SCT200 plus Chemotherapy in CRC|"SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W.
~Chemotherapy: Capecitabine and Oxaliplatin."
11078085|NCT04229524|Experimental|angiographic intervention group|Enrolled patients will undergo thoracoscopy combined with a three-incision esophageal carcinoma radical mastectomy and two-field (chest-abdomen) lymph node dissection.Quantitative assessment of blood supply in the gastic conduit was performed using fluoroscopy before esophagogastric anastomosis.
11078260|NCT04228341|Experimental|Brown Rice|Cooked brown rice
11078086|NCT04229524|No Intervention|control group|The same surgical method as the experimental group.The only difference is that the position of the gastic conduit anastomosis is determined based on the experience of the doctor.
11078087|NCT04229511||Infection caused by CRKp|Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
11078088|NCT04229511||Infection caused by any other bacteria|Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
11078089|NCT04229511||No infection|Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria
11078090|NCT04229498||Carbapenem resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
11078091|NCT04229498||Carbapenem hetero-resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-heteroresistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
11078092|NCT04229472|Experimental|Normal subject control group|High density mapping of left atrial voltages in patients with supraventricular tachycardia
11078093|NCT04229472|Experimental|Atrial fibrillation group|High density mapping of left atrial voltages
11078094|NCT04229472|Experimental|AcQMap atrial fibrillation group|High density mapping of left atrial voltages and AcQMap propagation patterns alongside cardiac MRI
11078095|NCT04229459|Experimental|Neoadjuvant Treatment|All subjects will receive induction chemotherapy and chemoradiation combined with cetuximab followed by nivolumab and cetuximab as neoadjuvant treatment
11078096|NCT04229446|Experimental|Receive the music based intervention|After the healthcare workers have accomplished the MBC program the eight week intervention program will be applied by the trained staff at the intervention wards. The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement. The movement will be adapted to their physical capacity.
11078097|NCT04229446|No Intervention|Standard care group|Standard care
11078098|NCT04229433|Experimental|SHR2285|Participants received one of 2 dose levels of SHR2285 administered as multiple oral doses.
11078099|NCT04229433|Experimental|Placebo|Participants received one of 2 dose levels of placebo administered as multiple oral doses.
11078100|NCT04229420|Active Comparator|Rectus sheath block group (RSB)|After preparing the skin, a high frequency (5-10 MHz) ultrasound probe will be placed in a longitudinal orientation above the level of the umbilicus with the Patient in the supine position. After identifying the rectus abdominis muscle, A 22 G echogenic needle using the in plane technique will be inserted just below the costal margin then, a total of 20 ml of 0.25% bupivacaine will be injected into the plane between the rectus muscle and posterior rectus sheath. Negative aspiration will be confirmed every 5 ml. The block will then be repeated on the other side.
11078101|NCT04229420|Active Comparator|Erector spinae plane block group (ESPB)|After induction of anesthesia; the patient will be positioned on the lateral position. The skin will be prepared with povidone iodine, and a high frequency (5-10 MHz) ultrasound probewill be placed in a transverse orientation on the T9 spinous process which will be located by palpating and counting down from the C7 spinous process. The tip of the T9 transverse process will be identified and centred on the ultrasound screen, the probe will then be rotated into a longitudinal orientation to produce a parasagittal view. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is conﬁrmed by injecting 0.5-1 ml saline and seeing the ﬂuid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20 ml of 0.25% bupivacaine will then be injected into the ESP of both sides.
11078102|NCT04229407|Experimental|Dietary supplement|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).
~After 32 subjects in MRI strata is reached. subjects will be randomized to intake Dietary supplement twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks"
11078103|NCT04229407|Placebo Comparator|vitamin B|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).
~After 32 subjects in MRI strata is reached. subjects will be randomized to intake placebo vitamin B twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks."
11078104|NCT04229394|Experimental|2ccPA|"Only day 1 Intra-articular injection can be given under direct ultrasound guidance; the only one strength for 2ccPA injection vial is 2,400 μg (1.2 mL per vial).
~IP name: 2-carba-cyclic phosphatidic acid (2ccPA)"
11078105|NCT04229394|Placebo Comparator|Placebo|Only day 1 Intra-articular injection can be given under direct ultrasound guidance; placebo
11078106|NCT04229381|Experimental|Supportive Care (physical therapy, muscle relaxation)|Patients participate physical therapy sessions consisting of cardiovascular and resistance training exercises in person or online and also undergo progressive muscle relaxation sessions once weekly for up to 12 weeks.
11078107|NCT04229368|Active Comparator|Low Vitamin D3 Supplementation|Subjects enrolled into Group 1 (low-dose Vitamin D3 supplementation) will receive 800 IU of oral Vitamin D3 (Cholecalciferol) daily for 4 weeks prior to surgery, followed by 800 IU of oral Vitamin D3 daily for 3 months after surgery. Vitamin D3 supplementation will be given for a total of 4 months. Supplementing Vitamin D-deficient patients with a minimum of 800 IU of Vitamin D3 daily is supported by the IOM.
11078133|NCT04229199|No Intervention|control group (CG)|Dyads assigned to the CG were provided only the standard practice on their day admission to the hospital.
11078261|NCT04228341|Experimental|3 % polished rice|Cooked 3 % polished rice
11078108|NCT04229368|Active Comparator|High Vitamin D3 Supplementation|Subjects enrolled into Group 2 (high-dose Vitamin D3 supplementation) will receive 50,000 IU of oral Vitamin D3 (Cholecalciferol) twice per week for 1 weeks followed by 50,000 IU once per week for 3 weeks prior to surgery. After surgery they will receive 50,000 IU of oral Vitamin D3 once per week for 4 weeks followed by 800 IU daily for 8 weeks. Vitamin D3 supplementation will be given for a total of 4 months.
11078109|NCT04229368|No Intervention|No supplementation|Subjects with serum 25(OH)D level ≥30ng/mL will not receive any Vitamin D supplementation both pre- and postoperatively, as these are considered sufficient. These control patients will be asked to take any supplements containing Vitamin D for the duration of their participation in the trial. All patients in group 3 will have their serum 25(OH)D checked at 3 months after the surgery.
11078110|NCT04229355|Experimental|DEB-TACE plus Sorafenib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive sorafenib (400 mg/d, po, bid) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
11078111|NCT04229355|Experimental|DEB-TACE plus Lenvatinib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive lenvatinib (8 mg/d, po, qd) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
11078112|NCT04229355|Active Comparator|DEB-TACE plus PD-1 inhibitor|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive PD-1 inhibitor (200 mg, iv, 3 weeks) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. PD-1 inhibitor will be taken for six months, untill tumor progression, or intolerable adverse reactions.
11078113|NCT04229342|Active Comparator|Conventional|"In the conventional group, standard posterior myotomy will be performed and the sling or the oblique fibers will not be spared beyond the gastroesophageal junction."
11078114|NCT04229342|Experimental|Oblique or sling fiber sparing group|In the oblique or sling fiber group, only the circular muscle fibers will be severed selectively and the sling fibers will be spared
11078115|NCT04229329|Experimental|Intervention|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded visually and auditory when a higher degree of finger individuation will be measured. Specifically, when the applied force of the instructed fingers hit the predefined force target and at the same, the force in the non-instructed fingers stay as low as possible
11078116|NCT04229329|Sham Comparator|Control|The patient hand will be restrained to a robotic arm AMADEO(TM) which enables the measurement and manipulation of forces at each finger individually. After appropriate calibration, the force measurements obtained from the robot will be used to move a cursor on the screen. The patient will be rewarded in a way that is unrelated to the degree of individuation. In other words, a successful trial considered when the applied force of the instructed fingers hits the predefined force target regardless of the force exerted in the non-instructed fingers.
11078117|NCT04229316|Experimental|zLock Facet Locking Implant System|
11078118|NCT04229303|Experimental|Active Voriconazole inhaled (ZP-059)|Part 1 - 4 separate cohorts planned to receive single doses of ZP-059 Part 2 - 3 separate cohorts planned to receive daily doses of ZP-059 on Day 1 to 10.
11078119|NCT04229303|Active Comparator|Cross-over with VFEND|Part 3 - 1 cohort randomised to receive VFEND (Cross-over with ZP-059).
11078120|NCT04229290|Experimental|Dolutegravir|Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
11078121|NCT04229290|Active Comparator|Protease Inhibitor|Participants in this arm will be maintained on their protease inhibitor based second line regimen
11078122|NCT04229277|Other|in tumours|consecutive enrollment of newly referred skin tumour patients
11078123|NCT04229264|Active Comparator|Control group|Aspirin 100 mg (oral, once-daily) for 1 year plus Clopidogrel 75 mg (oral, once-daily) for 3 months.
11078124|NCT04229264|Experimental|Apixaban group|Apixaban 2.5 mg (oral, twice daily) for 1 year plus Aspirin 100 mg (oral, once-daily) for 1 year.
11078125|NCT04229251|Experimental|Online Mindfulness-based Intervention|iMBI will be delivered to participants in 8 online sessions, approximately 2 hours per session.
11078126|NCT04229251|Sham Comparator|Online Introductory Psychology Program|An online introductory psychology courses will be delivered to participants in 8 online sessions, approximately 2 hours per session.
11078127|NCT04229238||Home-dwelling older adults|Older adults (70 +) receiving regular health care from the home nursing service. Setting is two rural municipalities in southern Norway.
11078128|NCT04229225|Experimental|UBX0101 single dose (SD)|"Cohort 1 (n=18): UBX0101 8.0 mg or placebo IA at Week 0
~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
11078129|NCT04229225|Experimental|UBX0101 repeat dose (RD)|"Cohort 2 (n=18): UBX0101 4.0 mg or placebo IA at Weeks 0 and 4
~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
11078130|NCT04229212|No Intervention|No drainage|No drainage
11078131|NCT04229212|Experimental|Drainage|a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed
11078132|NCT04229199|Experimental|intervention group (IG)|Dyads of children and parents allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
11078262|NCT04228341|Experimental|6 % polished rice|Cooked 6 % polished rice
11078134|NCT04229186|Experimental|Patients with assumption of EVOO-C|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg EVOO-C
11078135|NCT04229186|Experimental|Patients with assumption of ROO|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg ROO
11078136|NCT04229173|Other|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:
~a clinical examination;
~blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;
~MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
11078137|NCT04229173|Other|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
11078138|NCT04229160|Experimental|patient with persistent atrial fibrillation|persistent atrial fibrillation is defined as lasting longer than 6 months documented by a 24h holter monitoring
11078139|NCT04229134|Other|Pilot Arm: Project CONNECT|8-week home based reciprocal peer support pain self-management program for chronic musculoskeletal pain
11078140|NCT04229121||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation positive.
11078141|NCT04229121||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation negative.
11078142|NCT04229108|Other|Healthy volunteer|Will record traditional timed up and go followed by two digitised versions
11078143|NCT04229095|Active Comparator|Belsomra,(suvorexant)|20 mg single-dose administration given on an inpatient clinical research unit
11078144|NCT04229095|Placebo Comparator|Placebo|Placebo single-dose administration given on an inpatient clinical research unit
11078145|NCT04229082||lean|BMI between 18-25
11078146|NCT04229082||obese|BMI between 27.5-35
11078147|NCT04229069|Active Comparator|Basica|4-week dietary supplementation with an alkaline salt (Basica)
11078148|NCT04229069|Placebo Comparator|Placebo|4-week dietary supplementation with a placebo
11078149|NCT04229056|Experimental|Specific computer-based cognitive rehabilitation|300 patients (200 with stroke, 50 with Parkinson's disease and 50 with heart attack) will be allocated to specifif computer-based cognitive rehbailitation. This group will train with 11 exercises from the cognitive rehabilitation software 'Scientific Braintraining PRO'. These 11 exercises are designed to train various executive functions.
11078150|NCT04229056|Sham Comparator|General computer-based cognitive stimulation|300 patients (200 with stroke, 50 with Parkinson's disease and 50 with heart attack)will be allocated to general computer-based cognitive stimulation. This group will train with 11 generally mentally stimulating games on a sham-webside specifically dedigned for this trial. These 11 games are chosen because they are believed to have a low load on executive functions.
11078151|NCT04229043|Active Comparator|Early labor, no analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
11078152|NCT04229043|Placebo Comparator|Early Labor, no analgesia: Water|Subject will ingest 100 ml of water
11078153|NCT04229043|Active Comparator|Early labor, analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
11078154|NCT04229043|Placebo Comparator|Early labor, analgesia: Water|Subject will ingest 100 ml of water
11078155|NCT04229030|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL RZL-012 (5mg).
~Lipomas in the size of:
~2-3.9 cm will be dozed with 0.4mL RZL-012 (20mg). 4-5.9 cm will be dozed with 0.8mL RZL-012 (80mg). 6-7.9 cm will be dozed with 1 mL RZL-012 (100mg). 8-10 cm will be dozed with 1.2 mL RZL-012 (120mg)."
11078156|NCT04229030|Placebo Comparator|Vehicle of RZL-012|"A single-treatment injection, multiple subcutaneous injections of vehicle administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL vehicle.
~Lipomas in the size of:
~2-3.9 cm will be dozed with 0.4mL vehicle. 4-5.9 cm will be dozed with 0.8mL vehicle. 6-7.9 cm will be dozed with 1 mL vehicle. 8-10 cm will be dozed with 1.2 mL vehicle."
11078157|NCT04229017|Active Comparator|Anterior Cervical Discectomy and Fusion (ACDF)|ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.
11078158|NCT04229017|Experimental|Circumferential Cervical Fusion (CCF)|Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).
11078159|NCT04229004|Active Comparator|Gemcitabine combined with nab-paclitaxel|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed.
11078160|NCT04229004|Experimental|SM-88|"460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.
~All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal."
11078161|NCT04229004|Active Comparator|mFOLFIRINOX|Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion
11078162|NCT04228991|Active Comparator|Control|Conventional fractionation for locoregional radiotherapy
11078163|NCT04228991|Experimental|Experimental|Hypofractionation for locoregional radiotherapy
11078164|NCT04228978|Experimental|Weight loss + exercise (WL+EX)|Weight loss + home based walking exercise (WL+EX)
11078165|NCT04228978|Active Comparator|Exercise alone (EX)|Home based walking exercise (EX)
11078166|NCT04228965|Other|Co-Use Group|Cannabis and tobacco co-use group.
11078167|NCT04228965|Active Comparator|Tobacco Only Group|Tobacco only group.
11078168|NCT04228952||Smokers with very low or no CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with little or no CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of <0.6).
11078169|NCT04228952||Smokers with high CYP2A6 activity|Japanese American smokers (daily > 5 cigarettes) with high CYP2A6 activity (CYP2A6 activity defined as a ratio of trans-3-hydroxycotinine:cotinine ratio of > 3.0)
11078170|NCT04228939|Experimental|Intervention group (IG)|
11078171|NCT04228939|Active Comparator|Control group (CG)|
11078172|NCT04228926|Experimental|0.002% ZKY001 eye drops|Experimental group A: 35 subjects .0.002% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
11078173|NCT04228926|Experimental|0.004% ZKY001 eye drops|Experimental group B: 35 subjects .0.004% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
11078174|NCT04228926|Placebo Comparator|The placebo|Placebo group C: ZKY001 simulated eye drops .4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 simulated eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
11078175|NCT04228913|Other|Ah plus|The root canals obturated with Ah plus root canal sealer (Dentsply, Sirona) and gutta-percha cones with cold lateral condensation technique.
11078176|NCT04228913|Other|ROEKO GuttaFlow® 2|The root canals obturated with GuttaFlow 2 root canal sealer (Coltene,Whaledent) and single tapered gutta-percha cone with cold free flow compaction technique.
11078177|NCT04228913|Other|GuttaCore Obturators|The root canals obturated with GuttaCore obturators (Dentsply,Sirona) and Ah plus root canal sealer with thermoplasticized solid-core carrier technique
11078178|NCT04228900|Experimental|Intervention group|Drug review and tailored nutritional supply.
11078179|NCT04228900|No Intervention|Control group|"Follow-up by home nurse service and family physician as usual."
11078180|NCT04228887|Active Comparator|Control Group|The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
11078181|NCT04228887|Active Comparator|Training Group|The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
11078182|NCT04228848|Active Comparator|Healthy adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
11078183|NCT04228848|Experimental|ACL adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
11078184|NCT04228848|Active Comparator|Healthy adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
11078185|NCT04228848|Experimental|ACL adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video.Legs muscle strength will be assessed using hand held dynamometer
11078186|NCT04228835|Experimental|ICGFC-LC|ICG fluorescence cholangiography assisted laparoscopic cholecystectomy (ICGFC-LC) arm patients received intravenous bolus of 2.5mg of ICG before the induction of anaesthesia. Near infrared laparoscopic light camera was utilized intermittently during dissection of Calot's triangle until critical view of safety was achieved.
11078187|NCT04228835|No Intervention|Conventional LC|Conventional laparoscopic cholecystectomy (LC) arm patients underwent standard white light laparoscopic cholecystectomy without fluorescence cholangiography.
11078188|NCT04228822|Experimental|Low carb diet intervention group|Low carbohydrate diet defined as 25-35% of total energy intake
11078189|NCT04228822|No Intervention|Control|Standard diet defined as 45-65% total energy intake
11078190|NCT04228809|Experimental|anodal tDCS|anodal tDCS stimulation
11078191|NCT04228809|Active Comparator|cathodal tDCS|cathodal tDCS stimulation
11078192|NCT04228809|Placebo Comparator|sham tDCS|sham tDCS stimulation (stopped after 30 seconds)
11078193|NCT04228783|Experimental|Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1)|Participants will receive Intramuscular injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp], Lot A) on Day 1, followed by Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U], Lot 1) on Day 57.
11078194|NCT04228783|Experimental|Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot B) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 2) on Day 57.
11078195|NCT04228783|Experimental|Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot C) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 3) on Day 57.
11078196|NCT04228783|Placebo Comparator|Control Vaccine: Group 4 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9 percent [%] saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57.
11078197|NCT04228783|Experimental|Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, a single Lot) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, a single Lot) on Day 57 and a booster dose of Ad26.ZEBOV (at a dose of 5*10^10 vp, a single Lot) 4 months after Dose 2 (on Day 177).
11078198|NCT04228783|Placebo Comparator|Booster Cohort: Group 6 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9% saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57 and a booster dose of matching placebo on Day 177.
11078203|NCT04228744|Experimental|Bilateral surgical implantation of DBS system|All the participants will receive bilateral surgical implantation of DBS system to VIC and NAc. The experimenter will active the DBS system and adjust the parameters for all the participants after surgery.
11078204|NCT04228731|Experimental|Outpatient|Patients in the outpatient group (same day discharge following TKA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
11078205|NCT04228731|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following TKA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
11078206|NCT04228705||The elders|Patients aged over 59 years old
11078207|NCT04228705||The young adults|Patients aged from 18 to 59 years old
11078208|NCT04228692|Active Comparator|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary
11078209|NCT04228692|Experimental|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.
~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
11078210|NCT04228679|Experimental|Erbium laser treatment|Women with vaginal laxity treated with real laser.
11078211|NCT04228679|Sham Comparator|Sham laser treatment|Women with vaginal laxity treated with sham laser.
11078212|NCT04228666|Experimental|HB-adMSCs|HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells.
11078213|NCT04228653|Experimental|No Arm|As this is the follow up study, there are no arms
11078214|NCT04228640|Experimental|Investigational Product|Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
11078215|NCT04228640|Placebo Comparator|Placebo|Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
11078216|NCT04228627|Active Comparator|Treatment|Intravenous Iron to correct Iron deficiency without anaemia
11078217|NCT04228627|No Intervention|Prophylaxis|Usual antenatal care
11078218|NCT04228614||Retrospective cohort|Whole exome sequencing of 2500 retrospective tissue sample.
11078219|NCT04228614||Prospective cohort|Whole exome sequencing of 500 prospectively collected tissue samples. Panel sequencing of 451 genes of prospectively collected blood samples.
11078220|NCT04228601|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
11078221|NCT04228601|Placebo Comparator|Placebo+mFOLFIRINOX|Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy
11078222|NCT04228588|Experimental|Mepolizumab|Mepolizumab 100mg, SC, every 4 weeks
11078223|NCT04228575|Experimental|Extended Contact|Clients in the Extended Contact condition will be asked at the 6 week mark if they like they can extend their treatment and receive up to 12 weeks of support. They will be informed that this may be helpful if they feel they have fallen behind in reviewing of the materials, if they would like to receive support while they work on supplementary resources or if they would like extended support while they work on core lessons. If they would like additional support, participants will answer questions presented on the website about their desire for this additional support what they would like to focus on during this time. Those clients who indicate that they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks. Those that do not request the additional support will end treatment as planned at the end of 8 weeks.
11078224|NCT04228575|Experimental|8 Week ICBT no Booster|In the standard condition, clients will receive 8 weeks of therapist support. They will not be given the option to extend their treatment and support to 12 weeks. The booster course will not be offered in this condition.
11078225|NCT04228575|Experimental|Extended Contact with Booster|"Clients in the Extended Contact condition will receive an email at the 6 week mark letting them know that they if they like they can extend their treatment and receive up to 12 weeks of support. At week 6, clients will answer questions on the website about whether they would like this additional support or not and what they would like to focus on during this time. Clients who indicate they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks.
~They will also be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks."
11078226|NCT04228575|Experimental|8 week ICBT with Booster|Clients in the booster condition will be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks.
11078227|NCT04228562|No Intervention|Non-modifiable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
11078228|NCT04228562|Experimental|Non-modifiable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
11078229|NCT04228562|Experimental|Non-modifiable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
11078230|NCT04228562|Experimental|Non-modifiable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
11078231|NCT04228549|No Intervention|Control|Usual care
11078232|NCT04228549|Experimental|MyPADMGT|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed.
11078233|NCT04228549|Experimental|MyPADMGT + Nudging|Online access to system, with ability to record and study progress with social interaction, diet, physical activity, smoking cessation, blood glucose, blood pressure and weight. Also access to educational content, journal recording, communication to others, setting target levels, contact support as needed. In addition, nudging support available to help patients make better choices and decisions.
11078234|NCT04228523|Experimental|Therapeutic education workshop|Two group receive therapeutic education workshop already existing in Toulouse University Hospital
11078235|NCT04228523|Other|Speaking Therapy|One group receive speaking therapy already existing in Toulouse University Hospital
11078236|NCT04228510||Study group|ST elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention who will be followed up in Assiut University hospital.
11078237|NCT04228497|Active Comparator|clear fluids fasting for one hour|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml one hour before surgery
11078238|NCT04228497|Placebo Comparator|clear fluids fasting for two hours|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml two hours before surgery
11078239|NCT04228484|Other|Intervention|During the intervention period insulin, empagliflozin and metformin will be used as tools to near-normalise plasma glucose.
11078240|NCT04228471|Experimental|Spontaneous Breathing Group|"Spontaneous breathing activity will be allowed during APRV within one hour after randomization throughout the first 48 hours.
~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
11078241|NCT04228471|Experimental|Controlled Mechanical Ventilation Group|"Pressure controlled mechanical ventilation will be applied throughout the first 48 hours.
~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
11078242|NCT04228458|Experimental|Thermal Imaging|Thermal Imaging acquisition
11078243|NCT04228445|Experimental|HIGH DOSE|48 subjects randomly treated with 5 mL of drug
11078244|NCT04228445|Experimental|LOW DOSE|48 subjects randomly treated with 2.5 mL of drug
11078245|NCT04228445|Placebo Comparator|Saline|96 subjects treated with 5 ml of saline than crossover to treatment arm
11078246|NCT04228432|Experimental|Patients with breast cancer treated by adjuvant hormonotherapy|
11078247|NCT04228419|Active Comparator|<-10 Degrees of Retroversion|
11078248|NCT04228419|Active Comparator|>-10 Degrees of Retroversion|
11078249|NCT04228406|Experimental|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
11078250|NCT04228393|Active Comparator|Standard treatment regimen|6-mercaptopurine was administered according to the Chinese Children Cancer Group (CCCG) protocol-ALL 2015.
11078251|NCT04228393|Experimental|Individualized treatment regimen|6-mercaptopurine was administered on the basis of Chinese Children Cancer Group (CCCG) protocol-ALL 2015 combined with Clinical Pharmacogenetics Implementation Consortium (CPIC), genotypes and the concentrations of 6-TGN in red blood cells.
11078252|NCT04228380||Inclusion|Inclusion criteria: The cohort is made up of adult patients over 18 years of age, admitted to intensive care units in Sweden, for other reason than postoperative care or simple monitoring.
11078253|NCT04228380||Exclusion|Exclusion criteria: Children under the age of 18 will be excluded as well as patients admitted for simple monitoring or postoperative care.
11078254|NCT04228367|Experimental|Meniscal repair|Patients in need of meniscal repair
11078255|NCT04228354|Experimental|Semaglutide 0.68 mg/mL|Semaglutide administered with the PDS290 pen-injector
11078256|NCT04228354|Experimental|Semaglutide 1.0 mg/mL|Semaglutide administered with the PDS290 pen-injector
11078257|NCT04228341|Other|Glucose Reference 1|Glucose solution 1
11078258|NCT04228341|Other|Glucose Reference 2|Glucose solution 2
11078259|NCT04228341|Other|Glucose Reference 3|Glucose solution 3
11078264|NCT04228341|Experimental|20 % Polished rice|Cooked 20 % Polished rice (White Rice)
11078265|NCT04228315|Experimental|Early primaquine group|Thirty (30) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and 15 mg/day of oral primaquine for 14 days
11078266|NCT04228315|Active Comparator|Delayed Primaquine group|Sixty (60) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and the primaquine regimen (15 mg/day for 14 days) not given until 42 days after enrollment
11078267|NCT04228315|No Intervention|Healthy control group|Ten (10) age- and gender-matched controls will be enrolled for one day to obtain biological samples to be compared to the 2 intervention arms
11078268|NCT04228302|Experimental|EC5026|Single Ascending Doses of oral EC5026
11078269|NCT04228302|Placebo Comparator|Placebo|Single doses of matching oral placebo
11078270|NCT04228289|Experimental|Oxytocin|40 IU intranasal oxytocin
11078271|NCT04228289|Placebo Comparator|Placebo|intranasal saline spray
11078272|NCT04228276|Experimental|Active rTMS|Receive active rTMS
11078273|NCT04228276|Sham Comparator|Sham rTMS|Receive sham rTMS
11078274|NCT04228263|Other|hydroxychloroquine group|hydroxychloroquine 400 mg preconceptional
11078275|NCT04228263|Other|Placebo group|will receive placebo
11078276|NCT04228250|Experimental|Overlapping buprenorphine initiation|Overlapping buprenorphine initiation and full agonist opioid discontinuation among patients on high-dose long-term full agonist opioid therapy who have opioid physical dependence
11078277|NCT04228224|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 2 sessions per week for 12 weeks, each lasting about 1 hour.
11078278|NCT04228224|Active Comparator|Conventional Gait Rehabilitation|Participants in this group will perform conventional gait rehabilitation on a rehabilitation institution with assistance of a physical therapist. Training involve 24 sessions, 2 sessions per week, each session lasting about 1 hour.
11078279|NCT04228198||Radical cystectomy|Patients with histologically confirmed diagnosis of bladder cancer undergoing radical cystectomy surgery at 28 Urology departments in Italy
11078280|NCT04228185|Experimental|Laparoscopic banded sleeve gastrectomy|Group undergoing banded sleeve
11078281|NCT04228185|Active Comparator|Laparoscopic sleeve gastrectomy|Group undergoing standard sleeve
11078282|NCT04228172||Parkinson's disease (PD) glucocerebrosidase (GBA) carriers|Parkinson's disease subjects with GBA mutation
11078283|NCT04228172||Parkinson's disease (PD) non glucocerebrosidase (GBA) carriers|Parkinson's disease subjects without GBA mutation
11078284|NCT04228159|Experimental|Perturbation training|"Session1 - baseline assessment (detailed above) Session2 - 13 - each session will begin with reassessment and documentation of balance tutor parameters for each participant as were calibrated at the end of previous session.
~After reassessment the training program will include:
~Warm up - walking without perturbation.
~Perturbation during standing position.
~Perturbation during walking.
~Perturbation during tandem position.
~Perturbation with vestibular stimulation.
~Rest according to patient needs The relative duration of each component, as well as intensity and frequency of perturbations, will be adjusted to each individual according to his ability, reassessment parameters and progression.
~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
11078285|NCT04228159|Active Comparator|Balance and strengthening exercise|"Session1 - baseline assessment (detailed above).
~Session2 - 13 - each session will include:
~Warm up (free walking or cycling).
~Static balance exercise - standing position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.
~Dynamic balance exercise - walking position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.
~Strengthening exercise - general strengthening, particularly for lower limb.
~Cool down. Level of difficulty and duration of each component will be adjusted to each individual according to his ability and progression.
~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
11078286|NCT04228146|Experimental|CBT-I condition|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment six weeks after the post-intervention assessment.
11078287|NCT04228146|Other|Waitlist control condition|Participants in the waitlist control group complete the post-intervention assessment six weeks after the baseline assessment, start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment, and complete the follow-up assessment right after they finish the 6-week CBT-I.
11078288|NCT04228133|Experimental|Home-delivered attention control training (ACT)|A home-delivered ACT comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV).
11078289|NCT04228133|Placebo Comparator|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat.
11078290|NCT04228120|Experimental|intervention group|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
11078291|NCT04228120|No Intervention|control group|routine care
11078292|NCT04228107||Cohort|Participants will be enrolled in medication use monitoring. Their medication use patterns will be available to themselves and their guardians via a smartphone application, and to their asthma care providers via a portal. There will be no interventions to change medication use patterns. A portion of them will be asked to participate in a semistructured interview during which they will be asked questions about their perception of their asthma, health beliefs regarding medication use, and what they feel would be the most helpful to get them to take their asthma medicines.
11078332|NCT04227847|Experimental|Part B|SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS
11078293|NCT04228094||TDApp1|This cohort will use TDApp1: an eHealth tool to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
11078294|NCT04228081||UTI Positive|"In phase I of the study testing residual urine samples the aim is to include at least 50 positive samples from each bacterial species known to be commonly associated with urinary tract infections. We selected 2000 positive urines to enable capturing enough of these organisms in the development process.
~For phase II of the study, the same number of positive samples in order to include all common species causing urinary tract infection. The number of negative samples included is reduced to 1000.
~Phase 3 - approximately one third of all urine sample submitted will be positive for a uropathogen. Sample size of 3000 we expect 1000 these to be culture positive. We expect most uropathogens occurring at a frequency of 5% or more will be included with sufficient numbers in the validation process."
11078295|NCT04228081||UTI Negative Control|2000 negative urine samples are being run as controlled to ensure the false positivity rate is low.
11078296|NCT04228068|Experimental|Intervention|The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
11078297|NCT04228068|Active Comparator|Conventional care|Usual care
11078298|NCT04228055|Experimental|CLIPP2|24 Week Lifestyle Modification Intervention
11078299|NCT04228042|Experimental|Treatment (infigratinib, surgery)|Patients receive infigratinib PO QD on days 1-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. During weeks 8-9 (at least 48 hours after last dose of infigratinib), patients undergo surgery.
11078300|NCT04228029|Active Comparator|Carboxytherapy|
11078301|NCT04228029|Active Comparator|Intralesional steroids|
11078302|NCT04228029|Active Comparator|Combination of carboxytherapy and intralesional steroids|
11078303|NCT04228016|Experimental|Experimental: Device : nasal airway stent|All patients consulting for predominantly nocturnal nasal obstruction who have benefited from Nasal Respiratory Functional Exploration with detection of pathological resistance in the decubitus.
11078304|NCT04228003|Experimental|Pendulum|Pendulum Glucose Control formulation for T2D will be taken twice daily - 1 capsule with the morning meal and 1 capsule with the evening meal for 8 weeks with an option of continuing up to 6 months.
11078305|NCT04227990|Active Comparator|TAC + Pegfilgrastim (6 mg)|
11078306|NCT04227990|Experimental|TAC + Plinabulin 10 mg/m^2|
11078307|NCT04227990|Experimental|TAC + Plinabulin 20 mg/m^2|
11078308|NCT04227990|Experimental|TAC + Plinabulin 30 mg/m^2|
11078309|NCT04227990|Experimental|TAC + Pegfilgrastim (1.5 mg) + Plinabulin (20 mg/m^2)|
11078310|NCT04227990|Experimental|TAC + Pegfilgrastim (3 mg) + Plinabulin (20 mg/m^2)|
11078311|NCT04227990|Experimental|TAC + Pegfilgrastim (6 mg) + Plinabulin (20 mg/m^2)|
11078312|NCT04227977|Experimental|Treatment|JuxtaFlow
11078313|NCT04227964|Experimental|Periodontal regeneration|Periodontal regeneration consisting of papilla preservation flaps, application of FDA approved CE marked periodontal regenerative devices, tooth splinting and root canal treatment as required.
11078314|NCT04227964|Active Comparator|Extraction and tooth replacement|Tooth extraction and replacement with a dental implant or a fixed partial denture following healing and reconstruction of the extraction area. Choice based on standard of practice.
11078315|NCT04227951|Sham Comparator|Drain|Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
11078316|NCT04227951|Experimental|No Drain|Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
11078317|NCT04227938|Experimental|ALPN-101|All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101-as identified in Part A-will be evaluated.
11078318|NCT04227912|Active Comparator|Group TAP|Ultrasound-guided TAP Block
11078319|NCT04227912|Active Comparator|Group Local|Ultrasound-guided Local Infiltration
11078320|NCT04227912|Active Comparator|Group Dexketoprofen|Intravenous Dexketoprofen
11078321|NCT04227899|Experimental|ESPRIT™ BTK|Participants who receives ESPRIT™ BTK device will be included in this arm
11078322|NCT04227899|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
11078323|NCT04227886||Good response|TRG of 0-1 is defined as good response.
11078324|NCT04227886||Poor response|TRG of 2-3 is defined as poor response.
11078325|NCT04227886||Light toxicity|No grade 3-4 toxicities occur during neoadjuvant therapy.
11078326|NCT04227886||Heavy toxicity|Grade 3-4 toxicities occur during neoadjuvant therapy.
11078327|NCT04227860|Active Comparator|Group 1: G I primary KOA|Exercise and balance training
11078328|NCT04227860|Active Comparator|Group 2: G II primary KOA|Exercise and balance training
11078329|NCT04227860|Active Comparator|Group 3: G III primary KOA|Exercise and balance training
11078330|NCT04227860|Active Comparator|Group 4: G IV primary KOA|Exercise and balance training
11078331|NCT04227847|Experimental|Part A|SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS
11122552|NCT03916939|Experimental|Osteopathy|osteopathic treatment
11078333|NCT04227847|Experimental|Part C|SEA-CD70 expansion cohort in relapsed/refractory AML
11078334|NCT04227834|Active Comparator|Single education|Single health hygiene education
11078335|NCT04227834|Experimental|Repeated education|Four-monthly health hygiene education
11078336|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
11078337|NCT04227808|Experimental|Lenvatinib Arm|Experimental: Participants will be given lenvatinib (12 mg/d for body weight≥60kg, 8 mg/d for body weight < 60kg) for 12 months until disease recurrence or intolerance AEs or death.
11078338|NCT04227795|Experimental|Artificial intelligence-Assisted real time colonoscopy|AI assisted real-time detection of colonic lesions
11078339|NCT04227782||NAFLD|
11078340|NCT04227782||NASH|
11078341|NCT04227782||Cirrhosis|
11078342|NCT04227782||Healthy Volunteers|
11078343|NCT04227769|Experimental|healthy individuals|Two crossover visits with a washout period of at least 4 days in-between visits and at most two weeks: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal. Treatments will be placebo controlled, crossover, double blinded. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
11078344|NCT04227769|Experimental|obese patients with type 2 diabetes|Three crossover visits with a washout period of at least 4 days in-between: A) subcutaneous saline injection 3h before an oral standardized meal, B) subcutaneous injection of 100 mg of the IL-1 receptor antagonist anakinra 3h before an oral standardized meal, C) Additionally, after the second study day, participant in group 2 will be trained to self-inject the medication for 6 days. On the 7th day, an oral standardized meal test will be performed. Standard dose of Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB), i. e. 100 mg/ 0.67 ml s. c. or 0.67 ml of saline s. c. (placebo)
11078345|NCT04227756|Experimental|LSD-100|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
11078346|NCT04227756|Active Comparator|Psilocybin-20|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
11078347|NCT04227756|Active Comparator|Mescaline-300|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
11078348|NCT04227756|Placebo Comparator|Placebo|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
11078349|NCT04227743|Experimental|patients with endobronchial lesions|flexible bronchoscoy will be performed to patients with endobronchial lesions and biopsy from the lesions by forceps and cryoprope will be obtained
11078350|NCT04227730||group A|group A (+ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
11078351|NCT04227730||group B|group B (-ve GBS) 300 pregnant of gestational age 35-37 weeks were screened by a group B streptococcal (GBS) conventional PCR assay. Patients who were followed till delivery without prolonged rupture of membrane were eligible to enter the study and details with regard to labor and delivery were recorded. Infant data were also recorded.
11078352|NCT04227717||Thoracic, lumbar and sacral spine lesions|Participants will have thoracic, lumbar and sacral spine lesions
11078353|NCT04227704|Placebo Comparator|Control|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection and 40-minute intravenous infusion of 0.9% sodium chloride.
11078354|NCT04227704|Experimental|Ketamine SC|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.5 mg/kg of ketamine and a 40-minute intravenous infusion of 0.9% sodium chloride.
11078355|NCT04227704|Experimental|Ketamine IVI|Shortly after cesarean delivery of their baby, participants will receive a subcutaneous injection of 0.9% sodium chloride and a 40-minute intravenous infusion of 0.5 mg/kg ketamine.
11078356|NCT04227691|Active Comparator|Long-pulsed Nd YAG laser treatment|Ten patients will be randomized to receive Long-pulsed Nd:YAG in either left or right axilla. (The other axilla will serve as within-person control)
11078357|NCT04227691|Active Comparator|IPL treatment|Ten patients will be randomized to receive IPL treatment in either left or right axilla. (The other axilla will serve as within-person control)
11078358|NCT04227678|Other|Control group- A0|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);
~A0: without heparin administered"
11078359|NCT04227678|Other|LPLD group-A0|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
~A0: without heparin administered"
11078360|NCT04227678|Other|Control group-A1|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g OGTT glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);
~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
11078361|NCT04227678|Other|LPLD group-A1|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;
~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
11078362|NCT04227665|Experimental|Sea level|Sea level training camp
11078363|NCT04227665|Experimental|Altitude|Altitude training camp
11078364|NCT04227652|Experimental|Aggressive treatment strategy|The antipyretic strategy was initiated immediately upon increase of the temperature above 38.3°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
11078448|NCT04226898|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the synbiotic supplement. In this arm, the participant will take 1 powder stick of the placebo daily for 12 weeks after a 2 week placebo run-in.
11078449|NCT04226885|Active Comparator|fentanyl|patients will be given nebulized fentanyl 2μg/kg body weight 30 min before surgery
11078365|NCT04227652|Experimental|Conservative treatment strategy|The antipyretic strategy was initiated only after the body temperature exceeded 39.5°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
11078366|NCT04227639|Active Comparator|T-piece trial|In patients assigned to control group all spontaneous breathing trials will be performed using T-piece trial.
11078367|NCT04227639|Experimental|Pressure-Support trial|In patients assigned to experimental group all spontaneous breathing trials will be performed with a pressure-support level of 8 cm H2O without positive end-expiratory pressure.
11078368|NCT04227626|Experimental|GlucoSTAT|Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is > 0.75 u/kg or ≥ 2 u/kg.
11078369|NCT04227600|Experimental|Part1 JR-171|Drug: JR-171 IV infusion, dose escalation weekly
11078370|NCT04227600|Experimental|Part2 JR-171|Drug: JR-171 IV infusion, dose escalation, low dose, high dose, week
11078371|NCT04227587|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx.
11078372|NCT04227587|Active Comparator|Sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse. Each subject will receive a handout and a sleep hygiene log.Subjects will be told to record their daily compliance with sleep hygiene instructions using yes/no questions in the sleep hygiene log.
11078373|NCT04227574|Experimental|Zero Time Exercise training + WhatsApp anti-inertia reminders|Subjects in this group will receive daily WhatsApp anti-inertia reminders from the research assistant to remind and encourage them to practice Zero Time Exercise.
11078374|NCT04227574|Active Comparator|Zero Time Exercise training alone|Subjects in this group will not receive any WhatsApp reminders from week 8 to 24.
11078375|NCT04227561|Active Comparator|Pudendal nerve block|Neurostimulation-guided pudendal nerve block
11078376|NCT04227561|Active Comparator|Penile nerve block|Ultrasound-guided penile nerve block
11078377|NCT04227548|Experimental|Healthy individuals|
11078378|NCT04227535||Rheumatoid arthritis - Interstitial lung disease patients|"Assessment are as follows :
~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic: chest HRCT scan
~Genetic: DNA, mRNA
~Biologic: serum"
11078379|NCT04227535||Rheumatoid arthritis - no Interstitial lung disease patients|"Assessment are as follows :
~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic: chest HRCT scan
~Genetic: DNA, mRNA
~Biologic: serum"
11078380|NCT04227522|Experimental|Arm A (Rucaparib)|Rucaparib treatment (starting dose 600 mg) after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
11078381|NCT04227522|Placebo Comparator|Arm B (Placebo)|Placebo treatment after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
11078382|NCT04227509|Experimental|Experimental|
11078383|NCT04227509|Placebo Comparator|Placebo|
11078384|NCT04227496|Active Comparator|Noise1|A sound will be played while moving a body part through range of motion
11078385|NCT04227496|Active Comparator|Noise2|A sound (different from Noise 1) will be played while moving a body part through range of motion
11078386|NCT04227496|No Intervention|No noise|No sound will be played while moving a body part through range of motion
11078387|NCT04227483|Active Comparator|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
11078388|NCT04227483|Experimental|Deflazacort|Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks. Then taper by 6 mg every 2 weeks and discontinue. All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
11078389|NCT04227470|Experimental|Experimental: HBM9161, 340mg|HBM 9161 injection, 340mg, weekly administered by subcutaneous for a period of 4 weeks.
11078390|NCT04227470|Experimental|Experimental: HBM9161, 680mg|HBM 9161 injection, 680mg, weekly administered by subcutaneous for a period of 4 weeks.
11078391|NCT04227431||Tresiba®|A broad real world type 2 diabetes (T2D) patient population in China, treated with oral anti-diabetic drugs (OAD(s)) or basal insulin prior to treatment initiation with Tresiba®
11078392|NCT04227418||Mental Health|
11078393|NCT04227418||Psychiatric|
11078394|NCT04227405|No Intervention|Control group|Control group of couples will receive no intervention
11078395|NCT04227405|Experimental|Intervention|Intervention group of couples received the intervention: case management (connection to community services), 20 hour pscycho-educational workshop on communication, conflict resolution, problem-solving, stress management, and financial management, booster session, and employment support services if needed
11078396|NCT04227392|Experimental|Experimental|women who undergo radiofrequency therapy
11078397|NCT04227379|Experimental|DD-TXT|Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g. nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
11078398|NCT04227379|Active Comparator|DSE|"The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care. Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from the content of the workbook but shortened to fit the 160-character limit of a text message. There will be no customizable or interactive content for the DSE arm."
11078399|NCT04227366|Experimental|Group 1|BCD-089
11078400|NCT04227366|Placebo Comparator|Group 2|Placebo
11078401|NCT04227353|Experimental|HEAL ABC|Participants allocated to the intervention will be encouraged to follow the HEAL ABC resources in order to make a healthy eating and active lifestyle change. This will be achieved by setting specific goal(s) and by making concrete plan(s) to implement changes in their everyday life. Interventions will be delivered in the form of written resources that will guide participants. Supportive phone calls using motivational interviewing techniques will be provided to participants every two weeks to encourage lifestyle changes.
11078402|NCT04227353|No Intervention|HEALTH|Participants allocated to the control group will be referred to publicly available resources on healthy lifestyle recommendations but will not receive any additional support.
11078403|NCT04227340|Experimental|Photobiomodulation Therapy (PBM)|The PBM will be administered extra-oral and intra-oral.
11078404|NCT04227327|Experimental|Abemaciclib + aromatase inhibitors|Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily
11078405|NCT04227314|Experimental|Apremilast|apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
11078406|NCT04227314|Placebo Comparator|Placebo|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period
11078407|NCT04227301||Hyponatremic patients|Patients hospitalized at the University Hospital of Basel and presenting with hyponatremia will be screened for the study
11078408|NCT04227288|Experimental|Enstilar Foam|Eligible subjects will be provided twice daily daily Enstilar Foam (calcipotriene and betamethasone dipropionate).
11078409|NCT04227275|Experimental|Dose Escalation|Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
11078410|NCT04227262|No Intervention|the control group|Group (a) control group received traditional physical therapy program.
11078411|NCT04227262|Experimental|the study group|group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months.
11078412|NCT04227249||Experimental|women who do not undergo lymph node dissection
11078413|NCT04227236|Experimental|E-based virtual training|Participants in the e-based virtual training (up to 8 participants per session) will be placed at one of eight computers (with headphones), which we estimate will take less time (about 40 minutes), due to the individualized learning and 1:1 nature of the training instead of 1:15. Participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
11078414|NCT04227236|Active Comparator|In-person training|Participants in-person training will participate in a class with 15-20 participants like the usual MPC training environment. The training will last 1 hour. Like the e-based virtual training, participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
11078415|NCT04227223|Experimental|Study Group|Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy
11078416|NCT04227223|Active Comparator|Control Group|Control Group - 14 patients, healthy volunteers.
11078417|NCT04227210|Experimental|RSV Vaccine: Dosage Group #1|Participants in this group will receive a single dose of the RSV vaccine at dosage #1
11078418|NCT04227210|Experimental|RSV Vaccine: Dosage Group #2|Participants in this group will receive a single dose of the RSV vaccine at dosage #2
11078419|NCT04227197|Experimental|Intervention Group|The participants randomized to the intervention group completed the DSC2U questionnaire, and received online access to a personalized Caregiver Checklist and PCP plan. Caregivers were encouraged to share and discuss the PCP plan at their next wellness visit with the PCPs.
11078420|NCT04227197|No Intervention|Control Group|The participants randomized to the control group, received usual care for 7 months, after their scheduled PCP appointment. They did not receive DSC2U during these 7 months, but did receive the online, personalized health assessment tool (DSC2U) at the end of the 7 months, after the primary and secondary outcomes were measured.
11078421|NCT04227184|Experimental|Placebo/Trospium|Placebo first for 12 weeks followed by Trospium for 12 weeks.
11078422|NCT04227184|Experimental|Trospium/Placebo|Trospium first for 12 weeks followed by Placebo for 12 weeks
11078423|NCT04227171||FSH only|GnRH agonist protocol & GnRH antagonist protocol
11078424|NCT04227145|No Intervention|Usual Care|We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey and study staff will provide a referral for participants to seek more information on contraception and services. Study staff will record whether the participant accepted the referral. Follow-up will occur via phone call at 2-weeks, 1-month and 3-months post-enrollment to determine if they accessed contraceptive referral services if they initiated any contraceptive method, and if so: if they continued, changed, or discontinued this contraception method. We will recruit, complete baseline and usual care referral at recovery sites on a timely rotation that mirrors the intervention period (e.g., every fourth Friday morning at Site 1), in order to increase the chance of recruiting a comparable population.
11078450|NCT04226885|Active Comparator|midazolam|The patients will be given nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
11078451|NCT04226885|Active Comparator|dexmedetomidine|The patients will be given nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
11078452|NCT04226872|Experimental|Intervention|"The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet."
11078516|NCT04226404|Experimental|CSD1905-13|Subjects will be assigned to flavor variant CSD1905-13 of 4.8% ENDS products based on their preferred flavor.
11122717|NCT03915899|Experimental|WIN Intervention|WIN Intervention
11078425|NCT04227145|Experimental|SexHealth Mobile|We will train Swope providers in contraceptive counseling before intervention. We will recruit up to 85 women with substance abuse disorder (or opioid abuse disorder) from recovery centers. Eligible women will complete a baseline survey. Study staff will provide a referral for participants to seek more information on contraception and services. Women will have direct access to contraceptive counseling and services on-site via the mobile medical unit if they choose to use it. Counseling will focus on presenting the most effective contraceptive methods first (i.e., LARC). If women participate in contraceptive counseling, study staff will record the uptake of contraceptive medication and clinic referral at the time of enrollment and conduct follow-up surveys at 2-weeks, 1-month, and 3-months post-enrollment. If the participant refuses contraceptive counseling on MMU, a referral will be given.
11078426|NCT04227132|Experimental|Labyrinth training, then Standard training|Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
11078427|NCT04227132|Experimental|Standard training, then Labyrinth training|Patients will receive at first the Standard training for 10 sessions of 45 minutes, delivered 4 days per week. Then they will undergo the Labyrinth training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.
11078428|NCT04227119|Experimental|Irrigated ablation catheter and 6F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a F6 balloon tipped pulmonary artery (PA) catheter (for study purposes only).
11078429|NCT04227106|Experimental|EB-101|One-time surgical application of EB-101 on up to 6 chronic, RDEB wounds
11078430|NCT04227093|Active Comparator|Acetazolamide|Acetazolamide will be prescribed in unembellished white capsules of 250 mg. The drug will be administered twice daily in the morning and evening (approximately one hour before bedtime). The total treatment length will amount to 16 weeks. In case of side effects hampering treatment adherence, the daily dosage will be reduced to a single evening dose of 250 mg.
11078431|NCT04227093|Placebo Comparator|Placebo|The placebo regimen will be identical.
11078432|NCT04227067|Active Comparator|TENS|A TENS device consists of an electric pulse generator and pads that are attached to the skin on around the area of maximal pain. We will use the conventional mode, which provides nerve stimulation with a pulse width of 60 microseconds and a pulse rate of 60 pulses per second. The channel intensity will be gradually increased until the intensity is noticeable but not painful.
11078433|NCT04227067|Sham Comparator|SHAM TENS|In the SHAM TENS group the TENS pads will be attached to the pulse generator and the patients skin around the painful area. The investigator will turn the knobs on but the batteries will be removed from the device.
11078434|NCT04227054|Experimental|Intervention|
11078435|NCT04227041|Experimental|HER2 positive metastatic colorectal cancer|
11078436|NCT04227028|Experimental|Treatment (brigatinib, bevacizumab)|Patients receive brigatinib PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive bevacizumab IV on day 8 of cycle 1 and day 1 of subsequent cycles. Starting cycle 2, cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11078437|NCT04227015|Experimental|Administration of CTA101|Dose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.
11078438|NCT04226989|Experimental|Administration of CT-RD06|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
11078439|NCT04226976|Experimental|Otoband efficacy on AUV|Participants will wear the Otoband during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. Half the participants will be given the Otoband at power level 96db and half will be given the Otoband at power level 98db (all bone conduction levels re:1dyne). This will be randomized and neither the participant nor the investigator will know what power level the Otoband is set at. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
11078440|NCT04226976|Placebo Comparator|Placebo device efficacy on AUV|Participants will wear the placebo device during the single site visit against the skin, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. The placebo device will be set at a power level of 90db (bone conduction level re:1dyne). Neither the participant nor the investigator will know that this device is the placebo device. The participants will be fitted with the placebo device and will undergo the vestibular battery test. The investigator will record the outcome measurements.
11078441|NCT04226950|Active Comparator|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers.
11078442|NCT04226950|Experimental|Pegylated Interferon Alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area < 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
11078443|NCT04226924|Experimental|Trehalose|Trehalose 9% solution: The dose is 0.75 g/kg administered IV over 60 ± 5 minutes once weekly.
11078444|NCT04226924|Placebo Comparator|0.9% Normal Saline|Normal saline: weight-based volume administered IV over 60 ± 5 minutes once weekly.
11078445|NCT04226911|Experimental|Sweeteners and sweetness enhancers (S&SEs)|Healthy diet < 10 energy % (E%) sugar, foods and drinks with S&SEs allowed.
11078446|NCT04226911|Active Comparator|Sugar group|Healthy diet, < 10 E% sugar, foods and drinks with S&SEs not allowed.
11078447|NCT04226898|Experimental|Synbiotic Supplement|The active synbiotic supplement consists of a stick/packet containing 4 strains of probiotic microorganisms: Lactobacillus acidophilus, LA-5® (material number 501082 FD LAK KGPharma); Lactobacillis paracasei subsp. paracasei, L. CASEI 431® (material number 684301 FD L. casei 431 HA Granulate); Lactobacillus rhamnosus, LGG® (material number 699817 FD LGG HA-W-IF); and Bifidobacterium animalis subsp. lactis, BB-12® (material number 699813 FD BB-12 HA-W-IF). In addition, the stick/sachet contains 5 g inulin. The product is a powder which participants will be asked to take with liquid or food. In this arm, the participant will take 1 powder stick of the synbiotic supplement once a day for 12 weeks after a 2-week placebo run-in.
11078453|NCT04226872|No Intervention|Control|"The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet. Data collection for outcome variables will be the same as participants in the intervention group."
11078454|NCT04226833|Experimental|Mild|Participants with mild hepatic impairment will receive 1x100 milligram (mg) F06 (entrectinib) capsule administered orally with approximately 240 milliliter (mL) water within 30 minutes after consumption of a standardized meal.
11078455|NCT04226833|Experimental|Moderate|Participants with moderate hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
11078456|NCT04226833|Experimental|Severe|Participants with severe hepatic impairment will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
11078457|NCT04226833|Experimental|Normal|Participants with normal hepatic function will receive 1x100 mg F06 (entrectinib) capsule administered orally with approximately 240 mL water within 30 minutes after consumption of a standardized meal.
11078458|NCT04226820|Experimental|participant|Participants are divided into 3 groups based on their diagnosis: diabetes mellitus type 1, diabetes mellitus type 2, and healthy persons. Each participant (independent of group) will have the same examinations. There is no retesting of the same participant in other conditions.
11078459|NCT04226807|Experimental|Early Postpartum Contact|Patient receive a phone call from research staff 2-3 weeks after giving birth in addition to routine postpartum visit
11078460|NCT04226807|No Intervention|Routine Postpartum Care|Patient receives routine postpartum visit only
11078461|NCT04226794|Experimental|a-tDCS and nutritional counseling|a-tDCS and nutritional counseling
11078462|NCT04226794|Active Comparator|s-tDCS and nutritional counseling|s-tDCS and nutritional counseling
11078463|NCT04226794|Active Comparator|a-tDCS|a-tDCS
11078464|NCT04226794|Active Comparator|Nutritional counseling|Nutritional counseling
11078465|NCT04226781|Active Comparator|ICG|Fluorescence imaging for blood Perfusion of the gastrointestinal tissue
11078466|NCT04226781|Experimental|HSI|Hyperspectralimaging for blood Perfusion of the gastrointestinal tissue
11078467|NCT04226768|Experimental|"Enhanced Haematology Palliative Care (Fast-track) Group"|"Patients who are assigned to enhanced haematology palliative care (fast-track group) will be seen, within 2 days of enrollment, at the out-patient clinic or in-patient setting by the haematology palliative care team that comprises a palliative medicine specialist or a haematologist with palliative care experience, a full-time palliative care nurse, and a medical social worker concentrating on haematology palliative patients."
11078468|NCT04226768|Active Comparator|Conventional Supportive Care Group|"Patients who are assigned to the conventional supportive care group will be under care of haematologists and nurse specialists in haematology After 12 weeks of conventional supportive care, patients randomized to this group will receive services from the palliative care team and assessed every two weeks same the fast-track group"
11078469|NCT04226755|Experimental|Heart failure|After a run-in phase of 2 weeks, patients will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks. A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
11078470|NCT04226755|Active Comparator|Healthy volunteer|After a run-in phase of 2 weeks, volunteers will add 3 g of sodium chloride to every meal, using a NaCl tablet of 1 g. They will continue the sodium tablet for 4 weeks with a study visit every 2 weeks.A skin biopsy will be performed before the start of the augmented salt intake and after 4 weeks.
11078471|NCT04226742|Experimental|Treatment|Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.
11078472|NCT04226742|Active Comparator|Control|Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.
11078473|NCT04226716|Other|Multiparous, pregnant women|
11078474|NCT04226703||Study group|Patients over the age of 18 who underwent surgery in the ear, nose and throat department.
11078475|NCT04226690|Experimental|Cannabidiol/Tetrahydrocannabinol (CBD/THC)|Participants will receive the most tolerable CBD/THC dose with repeated dosing for 7 days. On day 1, 3 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
11078476|NCT04226690|Placebo Comparator|Matching Placebo|Participants will receive a placebo with repeated dosing for 7 days. On day 1, 3 and 7 of the 7-day dosing, subjects will complete laboratory sessions.
11078477|NCT04226690|Experimental|Cannabidiol (CBD)|Participants will receive the most tolerable CBD dose with repeated dosing for 7 days. On day 1, 3 and 7 of the 7-day dosing, subjects will complete laboratory sessions
11078478|NCT04226677|Experimental|aerobic exercise group|Aerobic exercise group is received treadmill training.
11078479|NCT04226677|Experimental|Video based exercise group|Video based exercise group is received exergame training.
11078480|NCT04226677|Experimental|Combined group|Control group
11078481|NCT04226664|Active Comparator|Intervention|Bariatric surgery will consist of laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy performed at the discretion of the surgeon and according to local standards.
11078482|NCT04226664|No Intervention|Control|Medical Weight Management (MWM) corresponds to the standard medical practice for weight loss that is available at the local participating centre, and thus reflects the local standard of care.
11078483|NCT04226651|Active Comparator|First dental visit|Virtual Reality Exposure Therapy
11078484|NCT04226651|Placebo Comparator|Second Dental Visit|Protective Glasses
11078485|NCT04226625|Active Comparator|Propofol|Patients will receive Propofol as an intravenous (IV) agent, which is administered into a vein through an IV line as a continuous infusion.
11078486|NCT04226625|Active Comparator|Desflurane|Patients will receive Desflurane as a gas that is administered through an anesthesia machine.
11078487|NCT04226599|Experimental|Dissolve AVF Group|This group treated with Peripheral scoring drug balloon.Dissolve AVF
11078488|NCT04226599|Active Comparator|PTA Group|This group treated with plain balloon catheter.Armada 35
11078515|NCT04226404|Experimental|CSD1905-12|Subjects will be assigned to flavor variant CSD1905-12 of 4.8% ENDS products based on their preferred flavor.
11078489|NCT04226586|Active Comparator|Treatment Group|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.
~Children in the treatment (intervention) arm will receive essential amino acids (EAA) twice a day.
~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.
~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.
~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
11078490|NCT04226586|Placebo Comparator|Placebo|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.
~Children in the placebo arm will receive placebo twice a day. EAA and placebo supplements will look and taste alike. The same flavoring ingredients (stevia blend, citric acid, malic acid, natural flavors, tartaric acid, fruit and vegetable juice for color) will be used in both products at the same amount.
~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.
~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.
~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
11078491|NCT04226573||Low anxiety, Middle and High anxiety|State Trait Anxiety İndex Scale: Values of less than 60, Low anxiety State Trait Anxiety İndex Scale: Values above 60, Middle and High anxiety
11078492|NCT04226560|Experimental|41% Silicone hydrogel Soft contact lenses (SHSCL)|Healthy adult males or females age ≥20-45 years of age
11078493|NCT04226560|Active Comparator|ACUVUE® VITA™|Healthy adult males or females age ≥20-45 years of age
11078494|NCT04226547|Experimental|Device Group|Randomized to Amplatzer Amulet LAA occluder
11078495|NCT04226547|Active Comparator|Control Group|Randomized to NOAC
11078496|NCT04226534|Other|Maximal effort test|Physiological database
11078497|NCT04226521|Experimental|Photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
11078498|NCT04226521|No Intervention|No prophylactic photopheresis|Standard post-transplant protocol without prophylactic extracorporeal photopheresis
11078499|NCT04226508|No Intervention|Control|
11078500|NCT04226508|Experimental|Physical exercise|
11078501|NCT04226495|Active Comparator|Sufentanil Bolus|
11078502|NCT04226495|Experimental|Sufentanil Infusion|
11078503|NCT04226482|Active Comparator|New Device|Laparoscopic appendectomy will be done using new ultrasonic shears.
11078504|NCT04226482|Experimental|Used Device|Laparoscopic appendectomy will be done using reprocessed ultrasonic shears.
11078505|NCT04226469||Subjects require canine retraction|Subjects require canine retraction during orthodontic tooth movement and their gingival crevicular fluid is collected during the tooth movement. The control is the initial timepoint.
11078506|NCT04226456|No Intervention|Control|"Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)
~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
11078507|NCT04226456|Experimental|N-acetylcysteine|"Experimental arm (Arm B):
~0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.
~Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)
~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
11078508|NCT04226443|Active Comparator|Group 1|In Group 1(n=50); continuous infusion of intravenous midazolam (Dormicum, Deva Pharmaceutical, Turkey) at a dose of 0.02 to 0.04 mg/kg/h was started at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
11078509|NCT04226443|Active Comparator|Group 2|in Group 2 (n=49), intravenous bolus doses of midazolam at a dose of 0.015 mg/kg every 10 minutes were administered at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
11078510|NCT04226430||Before cytosorb|Arterial blood samples were taken from patients before the Cytosorb therapy course.
11078511|NCT04226430||after cytosorb|Arterial blood samples were taken from patients immediately after the Cytosorb therapy course.
11078512|NCT04226417|Active Comparator|Dual-tDCS & home program exercise|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered for 20 minutes before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
11078513|NCT04226417|Sham Comparator|Sham-tDCS & home program exercise|Sham transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered only 30 seconds before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
11078514|NCT04226404|Experimental|CSD1905-11|Subjects will be assigned to flavor variant CSD1905-11 of 4.8% ENDS products based on their preferred flavor.
11078517|NCT04226404|Experimental|CSD1905-14|Subjects will be assigned to flavor variant CSD1905-14 of 4.8% ENDS products based on their preferred flavor.
11078518|NCT04226404|Experimental|CSD1905-15|Subjects will be assigned to flavor variant CSD1905-15 of 4.8% ENDS products based on their preferred flavor.
11078519|NCT04226404|Experimental|CSD1905-16|Subjects will be assigned to flavor variant CSD1905-16 of 4.8% ENDS products based on their preferred flavor.
11078520|NCT04226404|Experimental|CSD1905-17|Subjects will be assigned to flavor variant CSD1905-17 of 4.8% ENDS products based on their preferred flavor.
11078521|NCT04226391||RAS Partial Nephrectomy|
11078522|NCT04226391||RAS Radical Prostatectomy|
11078523|NCT04226391||Ankle Luxation Facture Treatment|
11078524|NCT04226391||Radius Fracture Treatment|
11078525|NCT04226378||Omnipod cohort|Adults with T1D who switch from MDI therapy to insulin pump therapy with Omnipod.
11078526|NCT04226378||MDI cohort|Adults with T1D who continue MDI therapy.
11078527|NCT04226365|Experimental|Experimental|10mg capsule once daily for 4 weeks of nortriptyline
11078528|NCT04226365|Placebo Comparator|Control|10mg capsule once daily for 4 weeks of Thick-It filler
11078529|NCT04226352|Experimental|Dose 1|60 mg DXM a day for 28 days
11078530|NCT04226352|Experimental|Dose 2|300 mg DXM every 2 weeks for 28 days.
11078531|NCT04226352|Experimental|Dose 3|300mg DXM once, with 60mg DXM daily afterwards
11078532|NCT04226339|Experimental|total knee arthroplasty with a kinetic alignment|
11078533|NCT04226339|Active Comparator|total knee arthroplasty with a mechanical alignment|
11078534|NCT04226326|Other|Subjects with Chronic Total Occlusion (CTO)|All subjects in this study have been scheduled for a clinically-indicated cardiac catheterization.
11078535|NCT04226313|Active Comparator|Self-sampling device sent at home|Women randomly selected from a commercial vendor database (both attenders and non-attenders) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked (Conformité Européenne, In Vitro Diagnostics) HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
11078536|NCT04226313|Experimental|Self-sampling device sent by gynecologist(s)|Women selected from databases of cooperating gynecologists (non-attenders for at least 3 years) receive a mail inviting them to perform a cervicovaginal self-sampling at their home (with the device provided). Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
11078537|NCT04226313|Experimental|Self-sampling device obtained from general practitioner(s)|Women selected from databases of cooperating general practitioners (non-attenders for at least 3 years) receive a self-sampling device. Returned self-sampled swabs will be tested by CE-IVD-marked HPV diagnostic test validated for use in primary cervical cancer screening. The arm will include approx. 5000 participants.
11078538|NCT04226300|Experimental|Laparoscopic-Assisted|Surgeons will place TAP block laparoscopically using a camera prior to beginning a surgical procedure.
11078539|NCT04226300|Active Comparator|Ultrasound-Guided|Anesthesiologists will use ultrasound to place TAP block prior to beginning a surgical procedure.
11078540|NCT04226287|Experimental|Monterey Pneumatic Compression Device|All participants will receive treatment with the Monterey investigational pneumatic compression device
11078541|NCT04226274|Experimental|REN001|Oral
11078542|NCT04226248|Active Comparator|Active (Rivastigmine)|Rivastigmine Transdermal Patches
11078543|NCT04226248|Placebo Comparator|Placebo|Placebo Matched Transdermal Patches
11078544|NCT04226235|Experimental|1-hour vinyasa yoga session|One hour of vinyasa yoga was completed by all participants while following a DVD.
11078545|NCT04226222||Triple negative Breast Cancer|Triple Negative Breast Cancer operatable from the outset
11078546|NCT04226209|Experimental|PSSE|Physiotherapeutic Scoliosis-Specific Exercises PSSE group will receive corrective exercise for scoliosis
11078547|NCT04226209|No Intervention|Control|Control group will be taken to the queue list.
11078548|NCT04226196|Experimental|Axis 0|IOL Implantation at the 0 +/- 10 degrees axis
11078549|NCT04226196|Experimental|Axis 45|IOL Implantation at the 45 +/- 10 degrees axis
11078550|NCT04226196|Experimental|Axis 90|IOL Implantation at the 90 +/- 10 degrees axis
11078551|NCT04226196|Experimental|Axis 135|IOL Implantation at the 135 +/- 10 degrees axis
11078552|NCT04226183|No Intervention|control group|pregnant women without pregnancy workout and consume guava juice
11078553|NCT04226183|Experimental|positive control group|prenatal pregnant women with pregnancy workout but not consume guava juice
11078554|NCT04226183|Experimental|treatment group|prenatal pregnant women with pregnancy workout and consume guava juice
11078555|NCT04226170|Active Comparator|treatment|ondansetron + pyridostigmine
11078556|NCT04226170|Placebo Comparator|Placebo|placebo+ pyridostigmine
11078557|NCT04226157|Experimental|Home Blood Pressure Self Management|The HBPS group will check their blood pressure at home daily using a smart BP cuff with telemonitoring capability (Home Qardio) and guided to use a self-titration plan between office visits for persistently elevate blood pressures.
11078558|NCT04226157|Active Comparator|Usual Care|The Usual Care group will have their blood pressure monitored and medications adjusted by their primary care provider.
11078559|NCT04226144|Active Comparator|Breath Stacking Group|The lungs are inflated as fully as possible by stacking successive breaths without expiration until the patients' maximal inspiratory capacity (MIC). The participant will be instructed to sustain the air in the lung, closing the glottis. Once the lungs are maximally inflated, the compressed air volume is released under expiratory muscle force, thus generating a cough with lung and chest wall recoil. They will perform 5-8 cycles of breath stacking per session, stacking 3-5 breaths per cycle.
11078560|NCT04226144|Experimental|Breath stacking and EMT|This group will perform the breath stacking technique in addiction with EMT. It will change the one-way valve in this group to VUP (Lumiar, Sao Paulo, Brazil) one-way valve, which allows the patients blow out the air with a counter resistance during all expiratory phase. The initial expiratory pressure will be 8 cmH2O, and could be changed at each visit according to participants' tolerance (either report easy or difficult to exhale assessed by research coordinators. The participants are encouraged to blow out the most slowly that they can do it.
11078561|NCT04226131|Other|Early Rheumatoid Arthritis (RA)|"Early RA defined as duration of disease/symptoms of less than 6 months (where duration denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD) therapy"
11078562|NCT04226131|Other|Age-, Sex-, BMI-matched Healthy Controls|Healthy Controls.
11078563|NCT04226118|No Intervention|Control Group|Patients who have a peripheral venous access by a classic procedure, without using a Vein Illumination System.
11078564|NCT04226118|Experimental|Experimental Group|Patients who have a peripheral venous access by a procedure using a Vein Illumination System.
11078565|NCT04226105|Experimental|GP40081|Subcutaneous (SC), up to Week 26
11078566|NCT04226105|Active Comparator|NovoMix® 30 FlexPen®|Subcutaneous (SC), up to Week 26
11078567|NCT04226092|Experimental|Subjects with atopic dermatitis|
11078568|NCT04226092|Experimental|Control subjects|
11078569|NCT04226079||Normal control|Normal population with low prevalence of gastrointestinal bleeding who underwent EGD and CFS which revealed no abnormal finding.
11078570|NCT04226079||Patients with GI bleeding|Patients who visited emergency room and were highly suspected to have recent or active upper GI bleeding and scheduled for upper GI endoscopy.
11078571|NCT04226066|Experimental|T601/T601+5-FC|Part 1: Dose-escalation study of T601 single-dose; Part 2: Dose-escalation study of T601 single-dose combined with 5-FC; Part 3: Dose-escalation study of T601 multiple-dose combined with 5-FC; Part 4: Extended study of T601 multiple-dose combined with 5-FC.
11078572|NCT04226053|Experimental|Intervention Group|The treatment group will consist of 160 mothers who were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby through a combination of one-on-one sessions with an expert clinical social worker in-person every three months and provision of essential baby items and equipment.
11078573|NCT04226053|No Intervention|Control Group|The control group will consist of 160 mothers who will not receive Room to Grow services.
11078574|NCT04226040||DOW and illness perception|Exploration of the association between DOW and illness perception
11078575|NCT04226027|Experimental|T2.coach|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center) and are asked to use T2.coach for 6 months.
11078576|NCT04226027|No Intervention|Control|Participants receive standard care (diabetes self-management education provided by their Federally Qualified Community Health Center).
11078577|NCT04226014||Patients with echo-endoscopic ultrasound of the pancreas|Patients requiring endoscopic ultrasound of the pancreas were included in the cohort.
11078578|NCT04226001||Patients|Patients screened for carriers infected or colonized by emerging highly resistant bacteria.
11078579|NCT04225988|Experimental|Extended-release tacrolimus|Kidney transplant recipients will receive extended-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
11078580|NCT04225988|Active Comparator|Immediate-release tacrolimus|Kidney transplant recipients will receive immediate-release tacrolimus in addition to standard-dose mycophenolate and prednisone for maintenance immunosuppression.
11078581|NCT04225962||Women with cystic fibrosis|Women with cystic fibrosis
11078582|NCT04225949|Experimental|line graph|
11078583|NCT04225949|Active Comparator|bar graph|
11078584|NCT04225936|Experimental|Group A: Mild Hepatic Impairment|Part 1
11078585|NCT04225936|Experimental|Group B: Moderate Hepatic Impairment|Part 1
11078586|NCT04225936|Experimental|Group C: Severe Hepatic Impairment|Part 2
11078587|NCT04225936|Experimental|Group D: Normal Hepatic function (control group)|Part 1
11078588|NCT04225936|Experimental|Group E: Normal Hepatic Function (optional, control group)|Part 2
11078589|NCT04225923|Experimental|NPC-21 Low dose|NPC-21 (Low dose) will be administered
11078590|NCT04225923|Experimental|NPC-21 High dose|NPC-21 (High dose) will be administered
11078591|NCT04225923|Placebo Comparator|NPC-21 Placebo|Placebo (normal saline) will be administered
11078592|NCT04225910|Experimental|mCRPC for PSMA RLT|225Ac-PSMA 100KBq/kg, iv. Totally 2 doses, every 8 weeks.
11078593|NCT04225897|Experimental|RV521|"sisunatovir is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. The RV521 dry powder blend will be supplied in capsules containing 10, 20, or 50 mg RV521. The Investigational Medicinal Product (IMP) will be dispersed in a defined volume of water prior to oral administration on a mg/kg basis. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of water prior to administration will be provided in the Pharmacy Manual.
~The proposed dosing regimen for Part A is a single open label dose of RV521. Part B and C is RV521 or placebo administered BID, 12 hours apart, for a period of 5 consecutive days with a total of 10 doses. However, this is subject to the recommendation of the DSMC."
11078594|NCT04225897|Placebo Comparator|Placebo|The placebo capsules administered in Part B and C will contain mannitol and microcrystalline cellulose (vehicle). The placebo dry powder will be dispersed in water and given orally BID. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of water prior to administration will be provided in the Pharmacy Manual.
11078595|NCT04225884|Active Comparator|DTx for pain|Treatment A software
11078596|NCT04225884|Sham Comparator|Control|Treatment B software
11078597|NCT04225884|Other|Standard care|Pain medication
11078598|NCT04225871|Experimental|0.3 mg/kg zilucoplan (RA101495)|
11078599|NCT04225858|Experimental|Omission of sentinel lymph node biopsy|No surgical axillary staging (i.e. sentinel lymph node biopsy) will be performed.
11078600|NCT04225845|Experimental|Home visits treatment|Weekly home visits by lay trained personnel to deliver problem solving therapy.
11078601|NCT04225845|Experimental|Home visits plus group activity treatment|Weekly home visits by lay trained personnel to deliver problem solving therapy. Combined with weekly facilitated group activities with other elderly individuals.
11078602|NCT04225845|No Intervention|Control|Control group.
11078637|NCT04225572|No Intervention|Control Group|Patient will not receive physical therapy treatment or further instruction from the research team. The patient will receive standard care recommended by their medical provider which may or may not include physical therapy treatment.
11078638|NCT04225572|Experimental|Physical Therapy Group|
11122718|NCT03915899|No Intervention|Standard of Care|No WIN intervention.
11078603|NCT04225832|Experimental|CBT Coping Intervention|The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).
11078604|NCT04225832|No Intervention|Control|Participants who are randomized to the control condition will be referred to the standard of care program at Bienestar, which includes an ongoing weekly open wellness-oriented support group available to all clients.
11078605|NCT04225819|Experimental|Vitamin D3 supplement|Two- 5,000 IU capsules, taken daily with a meal
11078606|NCT04225819|Placebo Comparator|Placebo|Two placebo capsules, taken daily with a meal
11078607|NCT04225806|Experimental|Investigational|Subjects will be treated with the investigational device and followed per protocol.
11078608|NCT04225793|Active Comparator|Eziklen®|potassium, magnesium and sodium sulphates-based laxative
11078609|NCT04225793|Active Comparator|Macrogol|Macrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep
11078610|NCT04225780|Experimental|Treatment of low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group and low-dose IL-2 is defined as 1 million IU per day subcutaneously.
11078611|NCT04225780|Placebo Comparator|Treatment of ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in ganciclovir treatment group.
11078612|NCT04225767|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for malignant cutaneous and subcutaneous tumours
11078613|NCT04225741|Experimental|training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs.22,23 Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.22-24
11078614|NCT04225741|No Intervention|Control Group|None of the interventions described above were applied to the control group.
11078615|NCT04225728|Active Comparator|Iron sucrose IV arm|Perfusion of diluted iron sucrose i.v. in two weeks. Half of the total dose at Day 0 and the other half at Day 14
11078616|NCT04225728|Active Comparator|Ferric polymaltose hydroxide complex IM arm|Injection in two series, begin at Day 0 and the second at Day 14. In each series, we administered 300 mg of iron IM until reach half of the dose
11078617|NCT04225728|Placebo Comparator|Placebo arm|100 ml i.v. of normal saline administered at Day 0 and at day 14.
11078618|NCT04225715|Active Comparator|Nucleos(t)ide (NUC) Control Arm|Participants will continue their background NUC therapy for the 48-week treatment period. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless Hepatitis B surface antigen (HBsAg) loss is observed.
11078619|NCT04225715|Experimental|CpAM (RO7049389) + TLR7 (RO7020531) + NUC|Participants will receive RO7049389 (600 mg QD) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg QOD) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will discontinue all study treatments (i.e., CpAM + TLR7 + NUC).
11078620|NCT04225702||Group Aspirin|The elderly patients who using Aspirin at least three months before operation were in the Group Aspirin
11078621|NCT04225702||Group Control|The elderly patients who not using Aspirin before operation were in the Group Control
11078622|NCT04225689|Experimental|CD-TREAT diet|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).
~Daily for a maximum of 21 days. Individualised diet based on energy requirements and physical activity levels."
11078623|NCT04225689|No Intervention|Unrestricted diet|Free, unrestricted diet. Daily for a maximum of 21 days.
11078624|NCT04225676|Experimental|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.
~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients > 50 kg body weight."
11078625|NCT04225663|Active Comparator|Intervention group|The Intervention group will receive 30-minute sessions of guided meditation. During meditation, they will lie down with their backs and torsos elevated by a mat/soft blocks. They will undergo guided breath work.
11078626|NCT04225663|No Intervention|Control group|The Control group will not have intervention. They will have quiet, independent study for 30-minute sessions.
11078627|NCT04225637|Experimental|Slow maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw once every other day.
11078628|NCT04225637|Experimental|Rapid maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw twice daily.
11078629|NCT04225624|Experimental|Emotion Regulation Therapy - Attention Regulation (ERT-AR)|Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation.
11078630|NCT04225624|Active Comparator|Supportive Psychotherapy (SPT)|Individuals with repetitive negative thinking receiving Supportive Psychotherapy.
11078631|NCT04225611|Experimental|Dexamethasone|Therapeutic Contact Lens Drug Delivery System (TCL-DDS) of Dexamethasone, up to 300 μg per day with a total release of 1,100 μg over 7 days
11078632|NCT04225598|Experimental|XR-BUP|Injectable buprenorphine
11078633|NCT04225598|Active Comparator|Standard SL-BUP|Sublingual buprenorphine
11078634|NCT04225585|Experimental|Targeted Pain Coping Skills Training (Targeted-PCST)|novel pain coping skills training intervention designed specifically for women with persistent pain (PP) following breast cancer surgery (active intervention group)
11078635|NCT04225585|Placebo Comparator|General health education|general health education Intervention (control group)
11078636|NCT04225585|No Intervention|Usual care alone|usual health care and usual medical treatment for pain
11078639|NCT04225546||Patient group|Patients with hemiplegic and diplegic cerebral palsy between 4 - 10 years of age
11078640|NCT04225546||Control group|Healthy volunteer typically developing peers
11078641|NCT04225533|Experimental|SP16|Patients will receive a single dose of SP16 0.2 mg/kg by subcutaneous injection
11078642|NCT04225520|Other|Treatment recommendation based on guidelines|Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.
11078643|NCT04225520|Experimental|Treatment recommendation based on mechanical dyssynchrony|Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.
11078644|NCT04225507|Other|Lifestyle Intervention|Diet and exercise.
11078645|NCT04225507|Experimental|Lifestyle Plus CPAP Intervention|CPAP treatment, diet and exercise.
11078646|NCT04225481||SVF from healthy subjects from aesthetic plastic surgery|Subjects undergoing plastic surgery as scheduled by clinic routine to obtain waste adipose tissue
11078647|NCT04225481||OA patients|Subjects undergoing prosthetic surgery as scheduled by clinic routine to obtain waste synovium and cartilage
11078648|NCT04225468|No Intervention|Treatment As Usual (TAU)|No intervention will be administered.
11078649|NCT04225468|Experimental|Opioid Exposure Reduction Program 1 (OERP1)|Participants will engage in a brief, educational intervention at their pre-surgery appointment approximately 2-3 weeks before ACL reconstruction surgery.
11078650|NCT04225468|Experimental|Opioid Exposure Reduction Program 2 (OERP2)|"Participants will engage in the same intervention as OERP1, but those in OERP2 will also receive a 5-minute booster intervention session 3 days after surgery."
11078651|NCT04225442|Other|Fatty meal|To study how a fatty meal modifies the physiological chronobiome in young and old, an isocaloric controlled liquid high fat meal (ICLHFM) will be consumed within 5 min. The ICLHFM contains an equivalent to 35% of the estimated total daily energy requirements (TDE), 60% of kcal delivered from fat while 13% come from protein and 27 % from carbohydrate.
11078652|NCT04225403|Experimental|Telephone-based motivational interviewing|Experimental intervention consisted of a motivational intervention for smoking cessation through telephone every 3 months for one year, performed by IBD nurse
11078653|NCT04225403|No Intervention|usual care|No intervention consisted of a single telephone contact one year after the star of the study
11078654|NCT04225390|Experimental|Dacarbazine|Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy
11078655|NCT04225364|Experimental|camrelizumab plus concurrent chemotherapy|Neoadjuvant immunotherapy, PD-1, plus concurrent chemotherapy（albumin-bound paclitaxel + Cisplatin） will be applied to patients with operable esophageal squamous cell carcinoma before surgery.
11078656|NCT04225351|Experimental|MCAF+CM|Modified coronally advanced flap + collagen matrix
11078657|NCT04225351|Active Comparator|MCAT+CM|Modified coronally advanced tunnel technique + collagen matrix
11078658|NCT04225325|Active Comparator|A: SYMTUZA|TAF/FTC 245 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single tablet QD
11078659|NCT04225325|Active Comparator|B: DESCOVY+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DTG 50 mg QD
11078660|NCT04225325|Experimental|C: SYMTUZA+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DRV/cobicistat single tablet QD + +DTG 50 mg QD
11078661|NCT04225312|Experimental|Personalized extended interval dosing|Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 10mcg/ml.
11078662|NCT04225312|Experimental|Personalized longer extended interval dosing|Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 5mcg/ml.
11078663|NCT04225312|Other|Standard interval dosing|Patients who prefer to stay on standard interval dosing.
11078664|NCT04225312|Other|Historic cohort|Historic cohort of natalizumab treated patients on standard interval dosing.
11078665|NCT04225299|Experimental|TOOKAD®|TOOKAD® , lyophilized formulation, given at a dose of 4mg/Kg.
11078666|NCT04225299|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have intermediate risk localised prostate cancer
11078667|NCT04225286|Experimental|Intranasal human breast milk|"Human breast milk delivered intranasally to preterm infants (<33 weeks gestation at birth, stratified < and ≥28 weeks) with grade III IVH and/or grade IV IVH/intraparenchymal hemorrhage/infarction identified on head ultrasound in the first 10 days of life.
~Dosing: Escalating dose starting at 0.2mL into one nostril with repeat dose 10-15 minutes later 1-2x daily, depending on availability of fresh HM"
11078668|NCT04225273|Experimental|Investigational Arm in pivotal study- 43USSA1705|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection
11078669|NCT04225260|Experimental|QM1114-DP in the LCL and the GL areas|"The investigational product (QM1114-DP) is a BoNT Type A.
~At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines."
11078670|NCT04225247|Active Comparator|Group-I Single Bond Universal|"it is a seventh generation bonding agent used as desensitizer, manufactured by 3M ESPE.
~applied on the affected surface of the group-I participants."
11078671|NCT04225247|Active Comparator|Group-II Xeno V+|"it is a seventh generation bonding agent used as desensitizer, manufactured by Dentsply.
~applied on the affected surface of the group-II participants."
11078672|NCT04225247|Placebo Comparator|Group-III Bifluorid 12|it is a fluoride varnish used as desensitizer, manufactured by VOCO. applied on the affected surface of the group-III participants.
11078673|NCT04225234|Active Comparator|Weight loss incentive|Participants will receive incentive rewards based on WEIGHT LOSS outcomes.
11078674|NCT04225234|Experimental|Weigh-in incentive|Participants will receive incentive rewards based on WEIGH-INs frequency
11078675|NCT04225234|Experimental|Combination incentive|Participants will receive half of the incentive from WEIGHT LOSS and WEIGH-INs
11078676|NCT04225234|Experimental|Choice option incentive|Participants will choose one out of the three incentive programs (Weight-loss, Weigh-ins, and Combination).
11078704|NCT04225065|Active Comparator|Chlorhexidine prep|Chlorhexidine prep prior to their operation
11078705|NCT04225065|Active Comparator|Betadine prep|Betadine prep prior to their operation
11078677|NCT04225221|Experimental|Sequence A: estradiol followed by progesterone|"Participants are randomly assigned to treatment Sequence A: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence A will receive estradiol addback first, followed by progesterone.
~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
11078678|NCT04225221|Experimental|Sequence B: progesterone followed by estradiol|"Participants are randomly assigned to treatment Sequence B: after achieving hormone suppression using Lupron, participants begin the addback period and take study medications for 8 weeks. During the 8 week period, participants will take placebo or estradiol or progesterone. Participants will not know when or for how long they are on active medication (i.e., estradiol or progesterone) or inactive (i.e., placebo) medication. When active medication is administered, participants randomized to treatment sequence B will receive progesterone first followed by estradiol.
~Estradiol and progesterone are never given simultaneously. Participants are on active medication for a total of 4 weeks."
11078679|NCT04225208|Experimental|[14C]-AZD4205|A single dose of [14C]-AZD4205
11078680|NCT04225195|Experimental|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"Patients with invasive candidiasis (IC) will only receive intravenous treatment with ABCD. ABCD will be administered once a day at a dose of 3-4 mg/kg.
~Patients with invasive aspergillosis (IA) will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. ABCD dosing regimen will be the same as that for IC patients."
11078681|NCT04225182|Experimental|with instrumented Orthosis|patient will follow 8 weeks of muscular strengthening with the orthosis connected to the phone app associated
11078682|NCT04225182|Active Comparator|without instrumented Orthosis|patient will follow 8 weeks of traditional muscular strengthening without orthosis
11078683|NCT04225169|Experimental|Exercises|diaphragmatic breathing exercises
11078684|NCT04225169|No Intervention|Control|Patients in the control group received routine patient care consisting of cold therapy
11078685|NCT04225156|Experimental|efgartigimod|patients receiving efgartigimod
11078686|NCT04225143|Experimental|bilateral|25 patients with an overactive bladder
11078687|NCT04225143|Active Comparator|unilateral|25 patients with an overactive bladder
11078688|NCT04225130|Experimental|Written Exposure Therapy -for Suicide|Written Exposure Therapy-for Suicide (WET-S) consists of 5 treatment sessions. Each session includes a written exposure exercise. It also includes CRP. Participants assigned to WET-S will complete the CRP prior to beginning their writing in session 1. Patient use of the CRP since the previous session will be briefly reviewed at the start of each WET-S session to manage safety and problem solve fluctuations in risk during treatment.
11078689|NCT04225130|Active Comparator|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team. TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
11078690|NCT04225117|Experimental|Cohort 1: HR+/HER2- breast cancer|"Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
~HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative"
11078691|NCT04225117|Experimental|Cohort 2: Triple negative breast cancer (TNBC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
11078692|NCT04225117|Experimental|Cohort 3: Squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
11078693|NCT04225117|Experimental|Cohort 4: Non-squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
11078694|NCT04225117|Experimental|Cohort 5: Head and neck cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
11078695|NCT04225117|Experimental|Cohort 6: Gastric; GEJ or esophageal cancer|"Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
~GEJ= gastroesophageal junction"
11078696|NCT04225104|Experimental|Yogic breathing intervention|Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.
11078697|NCT04225104|No Intervention|Control|Participants in the control group will be asked to maintain their current daily activities and will be given access to the yogic breathing video once all follow-up testing has been completed at the end of week 4.
11078698|NCT04225091|Placebo Comparator|Placebo drink|
11078699|NCT04225091|Experimental|Triple up® Collagen Drink|
11078700|NCT04225078|Experimental|Treatment Sequence 1: Treatment ADBC|Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period.
11078701|NCT04225078|Experimental|Treatment Sequence 2: Treatment BACD|Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period.
11078702|NCT04225078|Experimental|Treatment Sequence 3: Treatment CBDA|Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period.
11078703|NCT04225078|Experimental|Treatment Sequence 1: Treatment DCAB|Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period.
11078706|NCT04225052|Other|Group1|16 subjects, Cross-over, Single dose of comparator on day1, Single dose of YHP1903 on day8
11078707|NCT04225052|Other|Group2|16 subjects, Cross-over, Single dose of YHP1903 on day1, Single dose of comparator on day8
11078708|NCT04225039|Experimental|Cohort A|Subjects in this arm (N=16) receive a single priming dose of both INCMGA00012 (500mg) and INCAGN01876 (300mg) prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions). Following SRS, INCMGA00012 (500mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
11078709|NCT04225039|Experimental|Cohort B sub-arm #1|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 (500mg) + INCAGN01876 (300mg) + SRS. Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (500 mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
11078710|NCT04225039|Experimental|Cohort B sub-arm #2|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 + INCAGN01876 (without SRS). Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
11078711|NCT04225026|Experimental|GC4419|
11078712|NCT04225013||Control (no CIN)|Patients who receive contrast media but do not develop contrast-induced nephropathy
11078713|NCT04225013||Case (yes CIN)|Patients who receive contrast media and develop contrast-induced nephropathy
11078714|NCT04225000|Active Comparator|Exercise Group|Hip & Knee Exercises
11078715|NCT04225000|Experimental|Mobilization Group|Tibiofemoral joint anterior-posterior mobilization combined Hip & Knee Exercises
11078716|NCT04224987|Active Comparator|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo to children 12-59 months old
11078717|NCT04224987|Active Comparator|Azithro 1-59|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
11078718|NCT04224987|Placebo Comparator|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
11078719|NCT04224974|Experimental|Other: Usual Care|
11078720|NCT04224974|Experimental|Behavioral: Usual Care + EASE Intervention-psy|EASE Intervention = EASE-psy + EASE-phys
11078721|NCT04224961|Experimental|Minimal to No Respiratory Weakness|MIP ≥ 70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
11078722|NCT04224961|Experimental|Mild to Moderate Inspiratory Weakness|MIP 40-70% predicted Complete home-based RMT program and participate in weekly web-based RMT therapy sessions.
11078723|NCT04224948|Experimental|PET-MR arm|Every eligible patient will be scanned by PET-MR at baseline and following 1 cycle of chemotherapy. PET-CT at baseline will also be obtained as it is the current standard of care and will be used to determine trial eligibility (no evidence metastasis at baseline).
11078724|NCT04224935|Active Comparator|Leukocyte Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin will be used
11078725|NCT04224935|Active Comparator|connective tissue|connective tissue will be used
11078726|NCT04224922|Experimental|single-arm|weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
11078727|NCT04224909||Patients with Sudden Sensorineural Hearing Loss|
11078728|NCT04224896||NBI PATIENT|
11078729|NCT04224896||LUGOL PATIENT|
11078730|NCT04224883|Active Comparator|24-hours group|"The critical patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
11078731|NCT04224883|Experimental|16-hours group|"The critical patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days."
11078732|NCT04224883|Experimental|intermittent group|The critical patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.Feeding will be started within 24 hours in admission of ICU. The time of therapy is 5 days
11078733|NCT04224870||Surgical Incision|A single cohort study, of 12 participants with a scheduled surgical procedure, of at least 4 hours, for up to six (6) timed tissue sampling at surgical incision. No investigational therapy is planned.
11078734|NCT04224857|Experimental|AMT-101|AMT-101
11078735|NCT04224857|Placebo Comparator|Placebo|Placebo
11078736|NCT04224844|Active Comparator|Erector spinae plane block group (Group 1)|Patients will receive erector spinae plane block in addition to intravenous patient-controlled analgesia device containing tramadol.
11078737|NCT04224844|Active Comparator|Control group (Group 2)|Control group will receive only intravenous patient-controlled analgesia device containing tramadol.
11078738|NCT04224831|Active Comparator|Before application|"The chronic CSCR cases included here meet one or more of the following criteria:
~Complaints of recurrent symptoms lasting longer than 3 months;
~Recalcitrant or unresponsive to all known current treatment modalities including PDT and MPL;
~Typical B-scan SD-OCT findings of chronicity such as elongation of photoreceptor outer segments indicating chronic nature of sub-macular fluid and/or the presence of serous flat-irregular RPED and focal areas of thickened RPE that lie below the collection of SRF;
~Widespread RPE/photoreceptor damage, RPE mottling and atrophy along with chronic submacular fluid;
~Widespread multifocal areas of chronic serous retinal detachment and/or flat-irregular RPEDs in those eyes that effective and reliable laser application is impossible."
11078739|NCT04224831|Active Comparator|After application|The changes in SMT, CMT, DRCD, and BCVA before and after the interventions were compared.
11078740|NCT04224818|Experimental|Dual trigger|Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
11122878|NCT03914807|Active Comparator|Whole (3.25%) milk|
11078741|NCT04224818|Active Comparator|hCG (standard)|HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
11078742|NCT04224805|Active Comparator|Control|Interocclusal conventional splint is used to reposition the maxilla.
11078743|NCT04224805|Experimental|Study|Bone-borne splint is used to reposition the maxilla.
11078744|NCT04224792|Experimental|Center-based exercise group|Subjects will be enrolled into a center-based exercise program.
11078745|NCT04224792|Experimental|Home-based exercise group|Subjects will be enrolled into a home-based exercise program.
11078746|NCT04224779|Experimental|Tumors and blood collection|"For all the patients included in the study :
~Blood samples will be collected at different times T1 (Baseline), T2 (1 or 2 weeks after the beginning of the treatment), T3 (3 or 4 weeks before the surgery) and T4 (1 month after the surgery).
~Tumors biopsy will be collected for some patients who will benefit from an initial biopsy in the course of his management care in our Institute (before the surgery).
~In parallel to this biological collection, imaging and clinical data will be entered into a database treatment."
11078747|NCT04224766|Experimental|suprascapular nerve block with costoclavicular infraclavicular|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL bupivacaine 0.5%, then single shot US-guided costoclavicular block (CCB) with 10 ml bupivacaine 0.5%.
11078748|NCT04224766|Active Comparator|Interscalene brachial plexus block|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL bupivacaine 0.5%.
11078749|NCT04224753|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
11078750|NCT04224740|Experimental|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy
~Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
11078751|NCT04224727|No Intervention|Control|
11078752|NCT04224727|Experimental|Group Commitment Contract + Information|
11078753|NCT04224727|Experimental|Individual Monetary Rewards + Information|
11078754|NCT04224727|Experimental|Individual Commitment Contract + Information|
11078755|NCT04224727|Experimental|Group Commitment Contract|
11078756|NCT04224727|Experimental|Individual Monetary Rewards|
11078757|NCT04224727|Experimental|Individual Commitment Contract|
11078758|NCT04224714|Experimental|Coronary heart disease patient|Quantitative coronary angiography (QCA) showed that there was a critical lesion in the proximal or middle segment of the coronary artery (diameter stenosis rate was 50% - 70%), and the diameter of the artery was more than 2.5mm
11078759|NCT04224701|Experimental|Investigational Product, 30 µg/ Placebo|30 µg IM, months 0, 2 and 6
11078760|NCT04224701|Experimental|Investigational Product, 300 µg/ Placebo|300 µg IM, months 0, 2 and 6
11078761|NCT04224688|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
11078762|NCT04224688|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
11078763|NCT04224675|Other|Ate|
11078764|NCT04224675|Other|Cap|
11078765|NCT04224662||Patients with Gout|Patients who have been diagnosed with Gout
11078766|NCT04224649|Experimental|Test Device Group(HARA filler)|
11078767|NCT04224649|Active Comparator|Comparator Group(Restylane® Lidocaine)|
11078768|NCT04224636|Experimental|Up-front Atezo/Bev, then TACE|Patients will receive atezolizumab and bevacizumab iv every three weeks for up to 24 months. Upon detection of at least one unequivocal progressive hepatic lesion, selective TACE directed against progressive lesion(s) (sdTACE) will be performed. RFA or MWA are permitted as alternative to TACE to treat one or more lesion that cannot be reasonably selectively targeted by TACE
11078769|NCT04224636|Experimental|Atezo/Bev combined with TACE|First TACE will be performed as selectively as possible against all viable tumor lesions. Atezo/Bev will be initiated within three days from TACE. Upon detection of at least one unequivocal progressive hepatic lesion, treatment with Atezo/Bev will be continued if RFA or MWA can be used to treat this/these progressive lesion.
11078770|NCT04224597||Patients with acne vulgaris|patients with acne vulgaris aged between 18-25 year
11078771|NCT04224597||Healthy controls|healthy controls aged between 18-25 year
11078772|NCT04224584|Active Comparator|Duloxetine|Duloxetine is a serotonin-norepinephrine reuptake inhibitor. Duloxetine will be administrated as follows: 20 mg/daily duloxetinefor 1 week, 40 mg/daily duloxetine for 1 week, 60 mg/daily duloxetine for 10 weeks, 40 mg/daily duloxetine for 1 week, 20 mg/daily duloxetine for 1 week.
11078773|NCT04224584|Placebo Comparator|Placebo|Placebo will be administrated for 14 weeks.
11078774|NCT04224571|Experimental|rituximab and bortezomib|"to test whether adding rituximab in CD20 positive patients will have improvement in remission rate.
~to add bortezomib in high risk patients at Consolidation 1 to improve remission rate."
11078775|NCT04224558|Experimental|HSCT after mobilization and conditioning|"Mobilization and leukopheresis allow for stem cell harvest. Then conditioning is provided prior to stem cell transplantation, followed by post-transplant conditioning.
~Interventions include:
~Stem cell mobilization
~Leukopheresis
~Preparative regimen
~Peripheral blood stem cell infusion
~Post-PBSC infusion conditioning"
11078776|NCT04224545|Experimental|Colchicine|Colchicine 1 mg day
11078777|NCT04224545|Placebo Comparator|Placebo|Sugar pill
11078778|NCT04224532|Experimental|Group P|Pneumoperitoneum is induced before reverse Trendelenburg position.
11078779|NCT04224532|Experimental|Group RT|Pneumoperitoneum is induced after reverse Trendelenburg position.
11078780|NCT04224519|Experimental|Batch 1 of sIPV|The first commercial batch of sIPV
11078781|NCT04224519|Experimental|Batch 2 of sIPV|The second commercial batch of sIPV
11078782|NCT04224519|Experimental|Batch 3 of sIPV|The third commercial batch of sIPV
11078783|NCT04224506||Myasthenia Gravis|Patients who have been diagnosed with Myasthenia Gravis.
11078820|NCT04224194|Other|Interventional, Single arm to evaluate autoinjector handling|To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who selfinject AVT02 (adalimumab) subcutaneously (SC).
11078784|NCT04224493|Active Comparator|Tazemetostat + R2 Arm|"tazemetostat RP3D administered PO twice daily in continuous 28-day cycles.
~rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
~lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles."
11078785|NCT04224493|Placebo Comparator|Placebo + R2 Arm|"placebo administered PO twice daily in continuous 28-day cycles.
~rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
~lenalidomide 20 mg (if creatinine clearance ≥60 mL/minute) or 10 mg (if creatinine clearance <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles."
11078786|NCT04224480|Experimental|Treatment|Neoadjuvant treatment will consist of one dose of IV pembrolizumab. Tumor resection will be performed approximately 4 weeks after neoadjuvant pembrolizumab. Adjuvant treatment with pembrolizumab will be administered 4 weeks after the surgery.
11078787|NCT04224467|Experimental|Indocyanine Green Fluorescent Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then, a NIR imaging systems included the NIR (800-900 nm) and white-light (400-650nm) dual-channel will be used to detect In situ lesions, metastatic lesions, lymph nodes, obturator nerve, pelvic autonomic nerve, etc during surgery according to disease and clinical needs.
11078788|NCT04224454||Primary Sjögren's syndrome|111 consecutive patients with primary Sjögren's syndrome (European-American 2002 criteria)
11078789|NCT04224441|Experimental|Standard protocol plus chlorpromazine (CPZ)|Combination of chlorpromazine to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol.Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide (TMZ)
11078790|NCT04224428|Placebo Comparator|Control group|
11078791|NCT04224428|Active Comparator|Fexofenadine group|
11078792|NCT04224415|Other|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:
~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
11078793|NCT04224402|Other|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion
11078794|NCT04224389||Radiotherapy|IMRT on the primitive site and the lymph nodes. +/- Concomitant chemotherapy at the discretion of the meeting multidisciplinary
11078795|NCT04224389||Surgery|transoral resection of the primary tumor, with cervical lymph node dissection. Radiotherapy complementary according to the histological criteria of severity
11078796|NCT04224376|No Intervention|Conventional rehabilitation|Normal postoperative treatment protocol with physiotherapy after ACL surgery
11078797|NCT04224376|Experimental|Serious Gaming|In the training group each patient was additionally provided with a GenuSport knee trainer device (prototype plus tablet with software application) with the active knee extension training program for 6 weeks. Other postoperative treatment was identical.
11078798|NCT04224363|Experimental|Downward Staining|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
11078799|NCT04224363|Experimental|Upward Staining|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
11078800|NCT04224350|Experimental|Once-Daily Tacrolimus|Experimental arm: TacroBell SR Cap.
11078801|NCT04224350|Active Comparator|Twice a Day Tacrolimus|Active Comparator arm: TacroBell Cap.
11078802|NCT04224337|Experimental|Experimental|Durvalumab + doxorubicin + ifosfamide
11078803|NCT04224324||T & A patients|pediatric patients undergoing tonsillectomy and adenoidectomy
11078804|NCT04224311|Active Comparator|Low number plateletpheresis donations|Participants that have had 1-2 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
11078805|NCT04224311|Active Comparator|Medium number plateletpheresis donations|Participants that have had 3-19 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
11078806|NCT04224311|Active Comparator|High number plateletpheresis donations|Participants that have had 20-24 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
11078807|NCT04224285|Experimental|Early Dayzz|Participants receive a Sleep Health and Wellness education session and download the Dayzz app. Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries.
11078808|NCT04224285|No Intervention|Late Dayzz|Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries. At the end of nine months, participants have the opportunity to receive a Sleep Health and Wellness education session.
11078809|NCT04224272|Experimental|ZW25 (zanidatamab) + palbociclib + fulvestrant|ZW25 (zanidatamab) plus palbociclib, fulvestrant
11078810|NCT04224259|Experimental|ultrasound pre-scan group|Perform ultrasound pre-scan before central venous cannulation
11078811|NCT04224259|Sham Comparator|landmark guidance group|Use the traditional landmark method to perform central venous cannulation
11078812|NCT04224246|Experimental|One arm with Gamma-OH® treatment|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours between 10 p.m. to 4 a.m.
11078813|NCT04224233|Experimental|Home-based physical activity group|The experimental group will receive the iLiFE.
11078814|NCT04224233|Active Comparator|Control group|The control group will receive a leaflet with exercises and PA recommendations.
11078815|NCT04224220|Active Comparator|Adult Medical Care Coordination|This group will receive adult medical care coordination following discharge from a recent hospitalization.
11078816|NCT04224220|Active Comparator|Remote Patient Monitoring|This group will receive remote patient monitoring following discharge from a recent hospitalization.
11078817|NCT04224220|No Intervention|Usual Care|The usual care group will not receive additional supportive care following discharge from a recent hospitalization beyond what is typically offered through their primary care team.
11078818|NCT04224207|Active Comparator|Before application|RP patients with progressive visual acuity and visual field loss: before stem cell application.
11078819|NCT04224207|Active Comparator|After application|RP patients, after stem cell applications.
11078821|NCT04224181||Women with HIV|Individuals with female nascent sex who have been diagnosed with HIV.
11078822|NCT04224181||Women without HIV|Individuals with female nascent sex who do not have HIV.
11078823|NCT04224168|Experimental|Green Beans|Green beans will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from green beans will be given. This equates to 3x 4 ounce jars of green beans per day.
11078824|NCT04224168|Experimental|Liquid Pectin|Liquid pectin will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from liquid pectin will be given. This equates to 6 teaspoons or 30mL of liquid pectin per day.
11078825|NCT04224155|Experimental|enVista MX60EFH trifocal intraocular lens (IOL)|
11078826|NCT04224155|Active Comparator|enVista MX60E monofocal intraocular lens (IOL)|
11078827|NCT04224142||PKU sphere|PKU sphere (an FSMP) as per individual requirements determined by a dietitian.
11078828|NCT04224116|Experimental|Group TA|receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
11078829|NCT04224116|Placebo Comparator|Group SSI|Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
11078830|NCT04224103||Inhaled nitric oxide|
11078831|NCT04224090||Congenita coronary abnormalities (CAA)|"All the coronary arteries were differing from the definition of normal: when do not arise from the appropriate sinus of Valsalva (right or left) and not present a proper course and termination."
11078832|NCT04224077|Experimental|Intervention|Healthy volunteers
11078833|NCT04224064|Experimental|Healthy subjects cohort|A single blood sample will be made in healthy subjects.
11078834|NCT04224064|Experimental|Liposarcoma patients cohort|Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
11078835|NCT04224051|Experimental|Metformin target dose of 2g daily|Metformin tablets taken orally with target dose of 2g daily plus standard care
11078836|NCT04224051|Active Comparator|Standard care|Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.
11078837|NCT04224025|Experimental|exercise and respiratory therapy|Rehabilitation program for three weeks in-Hospital and continuation at home
11078838|NCT04224012|No Intervention|Conventional therapy group (control group)|patients of the control Group receive usual care
11078839|NCT04224012|Experimental|Interventional group (training group)|Specialized exercise and respiratory therapy for patients with pulmonary hypertension
11078840|NCT04223999|Experimental|Intervention|In this arm, trial participants receive the intervention that is being tested, skullremodeling surgery. This is in combination with tumor treating fields and best practice medical treatment.
11078841|NCT04223999|Active Comparator|Control|"In this arm, the trial participant receives tumor treating fields and best practice medical treatment.
~This serves as an active comparative control arm to the intervention."
11078842|NCT04223986|Other|Ultrasound and Troponin T|5 images transferred to cardiologist
11078843|NCT04223973|Experimental|Active Group|Using the Medtrum Pump A7+ during 3 months
11078844|NCT04223973|Active Comparator|Control Group|using the usual Insulet Patch pump
11078845|NCT04223960|Experimental|EA1080: Part 1A|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1. In Part 1A, there will be up to seven planned cohorts. Sentinel dosing will be used in all cohorts in Part 1A.
11078846|NCT04223960|Experimental|EA1080: Part 1B|Healthy Japanese participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1. In Part 1B, there will be up to four planned cohorts. Anticipated dose in all cohorts of Part 1B will be based on emerging safety, tolerability, and PK (pharmacokinetics) data from cohorts in Part 1A.
11078847|NCT04223960|Experimental|EA1080 Formulation (A,Fast + B,Fast + A,Fed + B,Fed): Part 2A|Healthy Caucasian participants will receive EA1080 Formulation A orally, once on Day 1 in fasted state in Treatment Period 1, followed by EA1080 Formulation B orally, once on Day 1 in fasted state in Treatment Period 2, followed by EA1080 Formulation A orally, once on Day 1 in fed state in Treatment Period 3, followed by EA1080 Formulation B orally, once on Day 1 in fed state in Treatment Period 4. Each treatment period was separated by a washout period of 7 days. In Part 2A, there will be one planned cohort. Anticipated dose in Part 2A cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1.
11078848|NCT04223960|Experimental|EA1080 Formulation (B,Fast + A,Fast + A,Fed + B,Fed): Part 2A|Healthy Caucasian participants will receive EA1080 Formulation B orally, once on Day 1 in fasted state in Treatment Period 1, followed by EA1080 Formulation A orally, once on Day 1 in fasted state in Treatment Period 2, followed by EA1080 Formulation A orally, once on Day 1 in fed state in Treatment Period 3, followed by EA1080 Formulation B orally, once on Day 1 in fed state in Treatment Period 4. Each treatment period was separated by a washout period of 7 days. In Part 2A, there will be one planned cohort. Anticipated dose in Part 2A cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1.
11078849|NCT04223960|Experimental|EA1080 Formulation (A,Fed + B,Fast + B,Fed + A,Fast): Part 2A|Healthy Caucasian participants will receive EA1080 Formulation A orally, once on Day 1 in fed state in Treatment Period 1, followed by EA1080 Formulation B orally, once on Day 1 in fasted state in Treatment Period 2, followed by EA1080 Formulation B orally, once on Day 1 in fed state in Treatment Period 3, followed by EA1080 Formulation A orally, once on Day 1 in fast state in Treatment Period 4. Each treatment period was separated by a washout period of 7 days. In Part 2A, there will be one planned cohort. Anticipated dose in Part 2A cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1.
11078850|NCT04223960|Experimental|EA1080 Formulation (B,Fed + A,Fed + A,Fast + B,Fast): Part 2A|Healthy Caucasian participants will receive EA1080 Formulation B orally, once on Day 1 in fed state in Treatment Period 1, followed by EA1080 Formulation A orally, once on Day 1 in fed state in Treatment Period 2, followed by EA1080 Formulation A orally, once on Day 1 in fast state in Treatment Period 3, followed by EA1080 Formulation B orally, once on Day 1 in fast state in Treatment Period 4. Each treatment period was separated by a washout period of 7 days. In Part 2A, there will be one planned cohort. Anticipated dose in Part 2A cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1.
11078883|NCT04223804|Experimental|Stage 1: Arm C|Participants will receive ABBV-181 dose B.
11122879|NCT03914807|Active Comparator|Reduced fat (1%) milk|
11078851|NCT04223960|Experimental|EA1080: Part 2B Fed + Fasted|Healthy Japanese participants will receive EA1080 orally, once on Day 1 in fed state in Treatment Period 1, followed by EA1080 orally, once on Day 1 in fasted state in Treatment Period 2. Each treatment period was separated by a washout period of 7 days. In Part 2B, there will be one planned cohort. Anticipated dose in Part 2B cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1. Formulation in Part 2B will be decided based on data from Part 2A.
11078852|NCT04223960|Experimental|EA1080: Part 2B Fasted + Fed|Healthy Japanese participants will receive EA1080 orally, once on Day 1 in fasted state in Treatment Period 1, followed by EA1080 orally, once on Day 1 in fed state in Treatment Period 2. Each treatment period was separated by a washout period of 7 days. Anticipated dose in Part 2B cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1. In Part 2B, there will be one planned cohort. Formulation in Part 2B will be decided based on data from Part 2A.
11078853|NCT04223960|Experimental|EA1080: Part 3A|Healthy Caucasian participants will receive EA1080 orally, once on Day 1. Anticipated dose in Part 3A cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1 and 2. In Part 3A, there will be three planned cohort. Formulation in Part 3A will be decided based on data from Part 2A.
11078854|NCT04223960|Experimental|EA1080: Part 3B|Healthy Japanese participants will receive EA1080 orally, once on Day 1. Anticipated dose in Part 3B cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1 and 2. In Part 3B, there will be three planned cohort. Formulation in Part 3B will be decided based on data from Part 2A.
11078855|NCT04223960|Experimental|EA1080: Part 3C|Healthy Caucasian participants will receive EA1080 Formulation C orally, once on Day 1. Anticipated dose in Part 3C cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1. In Part 3C, there will be one planned cohort.
11078856|NCT04223960|Experimental|EA1080: Part 4A|Healthy Caucasian participants will receive EA1080 or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 4, with the last dose received on Day 10. Anticipated dose, dosing frequencies, and timing with respect to meal in Part 4A cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1, 2 and 3. In Part 4A, there will be three planned cohort. Formulation in Part 4A will be decided based on data from Part 2A.
11078857|NCT04223960|Experimental|EA1080: Part 4B|Healthy Japanese participants will receive EA1080 or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 4, with the last dose received on Day 10. Anticipated dose, dosing frequencies, and timing with respect to meal in Part 4B cohorts will be based on emerging safety, tolerability, and PK data from cohorts in Part 1, 2 and 3. In Part 4B, there will be three planned cohort. Formulation in Part 4B will be decided based on data from Part 2A.
11078858|NCT04223934|Experimental|optima4BP|"Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment.
~The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration."
11078859|NCT04223934|No Intervention|Standard of Care (SOC)|The treating physician follows usual care practices.
11078860|NCT04223921||Patients who will be discharged from hospital (acute geriatric|Patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020
11078861|NCT04223908||FCS|patient with genetically documented familial chylomicronemia syndrome
11078862|NCT04223908||MCS|patient with genetically or phenotypically documented multifactorial chylomicronemia syndrome
11078863|NCT04223895|Experimental|Group 1|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F1(1 tab, once)/ Period 3: CKD-386 F2(1 tab, once)
11078864|NCT04223895|Experimental|Group 2|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F2(1 tab, once)/ Period 3: CKD-386 F1(1 tab, once)
11078865|NCT04223895|Experimental|Group 3|Period 1: CKD-386 F1(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once) Period 3: CKD-386 F2(1 tab, once)
11078866|NCT04223895|Experimental|Group 4|Period 1: CKD-386 F1(1 tab, once) / Period 2: CKD-386 F2(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
11078867|NCT04223895|Experimental|Group 5|Period 1: CKD-386 F2(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once)/ Period 3: CKD-386 F1(1 tab, once)
11078868|NCT04223895|Experimental|Group 6|Period 1: CKD-386 F2(1 tab, once) / Period 2: CKD-386 F1(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
11078869|NCT04223882|Experimental|Group Intervention- Management of stress|Patients in the intervention group will receive usual medical care and more stress management intervention. Stress management with cognitive behavioral techniques will be implemented one month after hospital discharge in the intervention group. Group sessions will be held between 6-9 people. There will be 4 1-hour meetings for 8 weeks. The intervention will be performed by psychologist.
11078870|NCT04223882|No Intervention|Group Control|Patients in the control group will receive usual medical care.
11078871|NCT04223869|No Intervention|periodontally healthy group|Control
11078872|NCT04223869|Active Comparator|Chronic Periodontitis|non-surgical periodontal treatment was performed
11078873|NCT04223869|Active Comparator|Aggressive Periodontitis|non-surgical periodontal treatment was performed
11078874|NCT04223856|Experimental|Arm A|Enfortumab vedotin + pembrolizumab
11078875|NCT04223856|Active Comparator|Arm B|Gemcitabine + cisplatin or carboplatin
11078876|NCT04223856|Experimental|Arm C (Not Recruiting)|Enfortumab vedotin + pembrolizumab + Cisplatin or carboplatin
11078877|NCT04223843|Experimental|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
11078878|NCT04223843|Placebo Comparator|Placebo Arm|Matching placebo via Respimat
11078879|NCT04223830|Experimental|Exalt DScope 01B|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
11078880|NCT04223817|Experimental|7.0 Tesla MRI of both hands|Single 7.0 Tesla MRI of both hands for all the SSc and control subjects
11078881|NCT04223804|Placebo Comparator|Stage 1: Arm A|Participants will receive placebo.
11078882|NCT04223804|Experimental|Stage 1: Arm B|Participants will receive ABBV-181 dose A.
11122982|NCT03914105|Experimental|With music|
11078884|NCT04223804|Placebo Comparator|Stage 2: Arm D|Participants will receive Placebo.
11078885|NCT04223804|Experimental|Stage 2: Arm E|Participants will receive ABBV-181 dose C.
11078886|NCT04223804|Experimental|Stage 2: Arm F|Participants will receive ABBV-181 dose D.
11078887|NCT04223791|Experimental|DOR/ISL|A fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 96 weeks; and placebo to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) for 96 weeks
11078888|NCT04223791|Active Comparator|BIC/FTC/TAF|50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 96 weeks, and placebo to FDC DOR/ISL for 96 weeks
11078889|NCT04223778|Experimental|Immediate Switch to DOR/ISL|Participants receiving continuous antiretroviral therapy (ART) will switch to MK-8591A, a fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 96 weeks
11078890|NCT04223778|Active Comparator|Baseline Regimen with Delayed Switch to DOR/ISL|Participants receiving continuous ART for 48 weeks will switch to MK-8591A, a FDC of 100 mg DOR/0.75 mg ISL for 48 weeks
11078891|NCT04223765|Experimental|CAR.k.28/CAR.k.4-1BB|Up to 12 patients will receive a single infusion of CAR.k.28. The starting dose will be 2.5x10^5 cells/kg of each product. Up to 3 dose levels of CAR.k.28 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 8 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and bendamustine. Patients with a known history of intolerance to bendamustine may be considered for lymphodepletion with fludarabine and cyclophosphamide.
11078892|NCT04223752|Experimental|Group 1: Ceftolozane/Tazobactam 12 to <18 Years of Age|Participants 12 to <18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.
11078893|NCT04223752|Experimental|Group 2: Ceftolozane/Tazobactam 7 to <12 Years of Age|Participants 7 to <12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
11078894|NCT04223752|Experimental|Group 3: Ceftolozane/Tazobactam 2 to <7 Years of Age|Participants 2 to <7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
11078895|NCT04223752|Experimental|Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of Age|Participants 3 months to <2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
11078896|NCT04223752|Experimental|Group 5: Ceftolozane/Tazobactam Birth to <3 Months of Age|Participants from birth to <3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
11078897|NCT04223739|Active Comparator|Landiolol|Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.
11078898|NCT04223739|Active Comparator|Amiodarone|Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.
11078899|NCT04223713|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
11078900|NCT04223713|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
11078901|NCT04223700|Experimental|Group 1|Ultrasound scanning of the rhomboid muscle
11078902|NCT04223687|Experimental|Sugar-Sweetened Beverage Warning Label|
11078903|NCT04223687|Other|Neutral label|
11078904|NCT04223674|Experimental|Serological screen and treat|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided for those with Pv seropositive and/or microscopic Pv/Po positive regardless of their symptoms.
11078905|NCT04223674|No Intervention|Routine care|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided only for symptomatic children with microscopic Pv/Po positive.
11078906|NCT04223661|Experimental|Frailty score 1|"Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg
~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
11078907|NCT04223661|Experimental|Frailty Score 2 or above|"Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.
~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
11078908|NCT04223648|Experimental|Treatment|"Subjects will receive 1 cycle of tremelimumab/durvalumab
~Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s
~TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.
~Subjects will receive 3 cycles of ipilimumab/nivolumab
~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.
~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
11078909|NCT04223635|Experimental|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
11078910|NCT04223635|Experimental|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
11078911|NCT04223596|Experimental|Experimental: Brigatinib Arm|Brigatinib 90 mg for the first 7 days and then 180 mg daily thereafter for QW4 cycles of duration (28 days +- 3 days)
11078912|NCT04223583|Experimental|Anrotenil hydrochloride capsule|Anrotenil hydrochloride capsule was used to treat soft tissue sarcomas with first-line chemotherapy failure (doxorubicin + ifosfamide). Oral administration was conducted on an empty stomach before breakfast (12mg), and the drug was discontinued for 2 weeks for one week (3 weeks for one cycle) until the disease progressed or became intolerable.
11078913|NCT04223570|Active Comparator|Ameluz (amino-levulinic acid topical gel) Only|Ameluz is a topical gel approved for use in photodynamic therapy for treatment of actinic keratoses, among other skin conditions. It is being applied to all participants in this study to measure the levels of PpIX in different areas of skin as detailed in study description. This arm includes those participants who have not been prescribed photodynamic therapy and thus they will not receive any light treatment during this study.
11123778|NCT03908307|Experimental|Study Eye|OZURDEX implant 700 μg
11078914|NCT04223570|Active Comparator|Ameluz and Light Therapy|Ameluz is a topical gel approved for use in photodynamic therapy for treatment of actinic keratoses, among other skin conditions. It is being applied to all participants in this study to measure the levels of PpIX in different areas of skin as detailed in study description. For patients who have been prescribed photodynamic therapy, the investigators will perform one additional round of measurements of Protoporphyrin IX using our camera device, in addition to the other secondary outcomes including skin temperature.
11078915|NCT04223557|Experimental|Treatment|In treatment group,participants will receive the whole peri-renal fat modification therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating)
11078916|NCT04223557|Sham Comparator|Sham control|In sham control group,participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
11078917|NCT04223544||GPs Healthcare Workers|
11078918|NCT04223544||Hospital Healthcare Workers|
11078919|NCT04223531|Other|Saline|Each participant will receive a saline infusion of normal saline 0.9%NaCl
11078920|NCT04223518|Active Comparator|Serum Bovine Immunoglobulin|Study product: Serum bovine immunoglobulin, also known by the trade name of Enteragam Dosage form: powdered packet Dosage: Each packet (10 g net weight) consists of 5 g of serum-derived bovine immunoglobulin/protein isolate (SBI) which is the active ingredient Frequency: one packet a day Duration: 60 days
11078921|NCT04223518|Placebo Comparator|Hydrolyzed Collagen|Placebo: hydrolyzed collagen Dosage form: powdered packet Dosage: 10 g of hydrolyzed collagen per packet Frequency: one packet a day Duration: 60 days
11078922|NCT04223505|Active Comparator|TEE arm|TEE will be performed as per clinical routine using multiple standard tomographic planes to rule-out LA/LAA thrombus. Echocardiographic analysis will include: LAA-emptying velocity, and grading the severity of LAA spontaneous ECHO. The severity of the SEC will be graded on a 4 point scale with 1 = minor homogeneous contrast enhancement, 2 = significant homogeneous contrast enhancement, 3 = significant, dense, and inhomogeneous, slow-moving contrast, and 4 = dense slow-moving contrast.
11078923|NCT04223505|Experimental|CCT arm|As per local protocol, a non-contrast enhanced prospective ECG-triggered image acquisition will be acquired. This will be followed by a contrast-enhanced prospective ECG-triggered will be acquired using a tri-phasic contrast protocols. Delayed CT images will be acquired 60 seconds after the initial contrast-enhanced CT scan.Cardiac CT image interpretation will be performed as per clinical routine. The LA and LAA will be assess for filling defects and characterized based upon attenuation values. If LA/LAA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. It will be recommended that patients with thrombus will undergo TEE.
11078924|NCT04223492|Other|Neoadjuvant systemic treatment|All patients undergo standard neoadjuvant treatment and additional multi-parametric MRI and liquid biopsies during neoadjuvant treatment.
11078925|NCT04223479|Experimental|Probiotic Formula Capsule|In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
11078926|NCT04223479|Placebo Comparator|Placebos|In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.
11078927|NCT04223466|Experimental|Subxiphoid group|Subxiphoid procedure for thymectomy.
11078928|NCT04223466|Active Comparator|VATS group|Video-assisted thoracoscopic thymectomy through chest wall.
11078929|NCT04223440|Experimental|Postero-superior Rotator Cuff Tear|MRI, ultrasonographic explorations
11078930|NCT04223440|Other|Healthy Postero-superior Rotator Cuff|MRI, ultrasonographic explorations
11078931|NCT04223427|Active Comparator|Single ring STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
11078932|NCT04223427|Experimental|Directional STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
11078933|NCT04223401|Experimental|Prehabilitation group|Patients in the experimental group will undergo prehabilitation before the elective surgery for gastric cancer.
11078934|NCT04223401|No Intervention|Control group|Patients in the control group will not undergo prehabilitation.
11078935|NCT04223388|Experimental|Probiotic|
11078936|NCT04223388|Placebo Comparator|Placebo|
11078937|NCT04223375|Experimental|Nutrition Group|"After the health status of the mothers in the experimental group was stabilized, approximately 20-30 minutes of nutritional education was given at the first interview before the hospital discharge. After nutrition education, motivational messages were sent to women's phones once a week. In addition, mothers were given nutritional counseling during their home visits during the 1st and 3rd months, and their questions and problems regarding nutrition were evaluated. The mother was supported where she needed it.
~In nutritional education, information was given such as adequate and balanced nutrition in the postpartum period, adequate fluid intake, consumption and importance of prebiotic and probiotic foods, the importance of healthy microbiota for infant health and the amount of nutrients equivalent to one serving. In addition, the handbook which contains the educational content is given to the mothers to facilitate the recall."
11078938|NCT04223375|No Intervention|Control Group|No intervention was made to the control group.
11079253|NCT04221217|Experimental|MND-2119 2g|MND-2119 2 g, orally, once daily after breakfast for 52 weeks.
11078939|NCT04223362|Experimental|PR+ Community-based physical activity programme|After pulmonary rehabilitation, the experimental group will integrate a community-based physical activity programme.
11078940|NCT04223362|Active Comparator|Pulmonary Rehabilitation|The control group will only receive pulmonary rehabilitation, which integrates PA recommendations.
11078941|NCT04223349|Experimental|Part 1: Treatment A|Participants will receive JNJ-70033093 dose twice daily (BID) for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
11078942|NCT04223349|Experimental|Part 1: Treatment B|Participants will receive JNJ-70033093 dose BID for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
11078943|NCT04223349|Experimental|Part 1: Treatment C|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
11078944|NCT04223349|Experimental|Part 1: Treatment D|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
11078945|NCT04223349|Experimental|Part 2: Treatment Sequence EFG|Participants will receive Treatment E (JNJ-7003309 single dose in the morning in fasted condition) in treatment Period 1; followed by Treatment F (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 2; followed by Treatment G (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
11078946|NCT04223349|Experimental|Part 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
11078947|NCT04223349|Experimental|Part 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
11078948|NCT04223349|Experimental|Part 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
11078949|NCT04223349|Experimental|Part 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
11078950|NCT04223349|Experimental|Part 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
11078951|NCT04223336|No Intervention|Control Group|When a participant in the control group is identified via a mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will not receive any computer alerts for physical activity and fruits/vegetable consumption. However, practitioners will still have access to the physical activity and diet data as part of the baseline assessment (Screening). Practitioners will also continue to have access to all the same resources as they currently do (treatment as usual).
11078952|NCT04223336|Experimental|Intervention Group|When a participant in the intervention group is identified via mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will receive computer alerts (screening), prompting to provide participant with a brief intervention (risk communication) and a self-monitoring resource for physical activity and/or fruits/vegetable consumption.
11078953|NCT04223323|Experimental|Intervention|The intervention arm consists of daily consumption of the investigator's intervention snack over the course of 12 weeks.
11078954|NCT04223323|Placebo Comparator|Isocaloric Control|The control arm consists of daily consumption of an isocaloric snack over the course of 12 weeks.
11078955|NCT04223310|Experimental|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure
~Preselect drug with optimal antiarrhythmic effects in the patient.
~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection
~Drug selection should be decided according to the guidelines.
~A follow-up of rhythm follow-up has to be conducted according to the above study design."
11078956|NCT04223310|Active Comparator|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure
~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection
~Drug selection should be decided according to the guidelines.
~A follow-up of rhythm follow-up has to be conducted according to the above study design."
11078957|NCT04223284|Active Comparator|Experimental1|"During the Cross-Over study, patients will be randomly assigned to one of the arms:
~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with D-Limonene at visit 2 and olfactory Stimulation with lavender oil (SLVO) at visit 3"
11078958|NCT04223284|Active Comparator|Experimental2|"During the Cross-Over study, patients will be randomly assigned to one of the arms:
~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with SLVO at visit 2 and olfactory Stimulation with D-Limonene at visit 3"
11078959|NCT04223271||Acutely Decompensated Heart Failure Patients|Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing. Testing with the Indicor device will occur every day during hospitalization, and twice a day for up to 30 days after discharge.
11078960|NCT04223258|Experimental|Automatic Oxygen Control|Infants randomized to this arm will be monitored using automatic oxygen control system on the ventilator. When infants oxygen saturation are out of the target range the ventilator will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation int he target range.
11078995|NCT04223037|Experimental|Day 0，28 immunization shedule|Japanese Encephalitis Vaccine produced by IMBCAMS Dosage form: 0.5mL/vial Two Dose injection with 28 days interval
11123967|NCT03906981||Caries free|6-9 year old caries free children
11078961|NCT04223258|Active Comparator|Manual oxygen control|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
11078962|NCT04223245|Experimental|exercise+MMSF|Group of PWPD who performed a base exercise program of speed and large amplitude stepping and standing balance exercises with Multimodal real-time sensory feedback
11078963|NCT04223245|Active Comparator|exercise only|Group PWPD who did the same exercise program without MMSF
11078964|NCT04223232|Experimental|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
11078965|NCT04223219|Active Comparator|High Opioid Group|-The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate >20% of baseline or hypertension: increase of mean blood pressure >20% of baseline).
11078966|NCT04223219|Placebo Comparator|Low Opioid Group|The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).
11078967|NCT04223219|Experimental|Non-Opioid Group|The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.
11078968|NCT04223206|Experimental|Hemodialysis with sarcopenia|10 HD patients, affected by sarcopenia will a undergo 3-months supplementation with NATURLENS
11078969|NCT04223206|No Intervention|Controls|10 HD patients, affected by sarcopenia will be followed for 3 months without any supplementation
11078970|NCT04223193|Experimental|Tavapadon|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.
11078971|NCT04223193|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
11078972|NCT04223180||Stroke patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with an upper limb impairment due to neurologic or orthopedic disorders.
11078973|NCT04223167|Experimental|Energy Drink 1|The participants in this group are caffeine naive and consumed 473 ml Red Bull Energy Drink
11078974|NCT04223167|Experimental|Energy Drink 2|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and consumed 473 ml Red Bull Energy Drink
11078975|NCT04223167|Experimental|Energy Drink 3|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and consumed 473 ml Red Bull Energy Drink
11078976|NCT04223167|Placebo Comparator|Control|The participants in this group are caffeine naive and consumed 473 ml water
11078977|NCT04223154|Experimental|Real iTBS to the dlPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
11078978|NCT04223154|Sham Comparator|Sham iTBS to the dlPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
11078979|NCT04223141|Experimental|Study group|Robot-assisted laparoscopic resection of sigmoid colon with colorectal anastomosis constructed by the double purse-string technique
11078980|NCT04223128|Active Comparator|Magnesium sulfate group(M)|Participants in group (M) will receive 50 mg/kg MgSO4 in 100 ml isotonic saline intravenous (I.V) over 20 minutes prior to induction of general anesthesia by 30 minutes then ultrasound guided TAPblock after closure of the abdomen
11078981|NCT04223128|Active Comparator|Dexamethasone group(D)|participants in group (D) will receive 2 mg Dexamethasone in 100 ml isotonic saline IV then ultrasound guided TAPblock after closure of the abdomen
11078982|NCT04223128|Placebo Comparator|Placebo group(C)|participants in group (C) will receive 100 ml isotonic saline IV (placebo) by the same route and over the same duration as control then ultrasound guided TAPblock after closure of the abdomen
11078983|NCT04223115|Experimental|Digitalized CBT intervention with phone coaching|Participants receive weekly sessions of internet-based CBT, including telephone coaching
11078984|NCT04223115|Active Comparator|Psychoeducation about depression|Participants receive psychoeducative material about depression in digitalized form.
11078985|NCT04223102|Other|Tissue collection|Tissue collection
11078986|NCT04223089||Revascularization|This group will include patients whose cutaneous oxygen partial pressure (PO2) around the wound of interest measures less than 40 mmHg and therefore require revascularization.
11078987|NCT04223089||Medical Management|This group will include patients whose cutaneous PO2 around the wound of interest measures greater than 40 mmHg and will be managed conservatively in wound clinic
11078988|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash control|Chlorhexidine 0.2%, Corsodyl Intervention rinsing 60 sec twice daily
11078989|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System|Chlorhexidine 0.2%, Curasept Intervention rinsing 60 sec twice daily
11078990|NCT04223063|Experimental|Exercise Intervention|Participants allocated to the exercise intervention will engage in a multimodal, home-based program including strength and endurance exercises. Participants will initially be seen in person and instructed to begin a moderate-intensity (i.e., 3-4 on 10-point Borg Scale) walking (or preferred aerobic exercise) program for a minimum of 30 minutes/day, 3-5 days/week and perform strength exercises at least 2 days/week.
11078991|NCT04223063|No Intervention|Control|Participants allocated to the control group will not receive any formal exercise prescription or guidance, however they will be offered the opportunity to participate in a home-based intervention pending the completion of data collection.
11078992|NCT04223050|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94%
11078993|NCT04223050|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92%
11078994|NCT04223037|Active Comparator|Day 0，7 immunization shedule|Japanese Encephalitis Vaccine produced by Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and Japanese Encephalitis Vaccine produced by Liaoning Chenda CO.,LTD Dosage form: 0.5mL/vial Two Dose injection with 7 days interval
11125064|NCT03899558|No Intervention|Control|Usual care alone
11078996|NCT04223024|Experimental|CCRT + Nimotuzumab|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
11078997|NCT04223024|Active Comparator|CCRT alone|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
11078998|NCT04223011|Experimental|In-Hospital Recovery Coach Intervention|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically in-hospital manualized sessions with the recovery coach.
11078999|NCT04222998|Experimental|Intervention group|90 villages with 1,080 caregiver-child dyads; child aged 9 - 14 months who receive the home-based growth charts
11079000|NCT04222998|Active Comparator|Control group|90 villages with 1,080 caregiver-child dyads; child aged 9 - 14 months who do not receive the home-based growth charts
11079001|NCT04222985|Experimental|Part A - Group 1|HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079002|NCT04222985|Experimental|Part A - Group 2|HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079003|NCT04222985|Experimental|Part A - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079004|NCT04222985|Experimental|Part A - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
11079005|NCT04222985|Experimental|Part A - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.
11079006|NCT04222985|Placebo Comparator|Part A - Group 6|Sodium chloride 0.9% (in both arms) at Month 0 and Month 2
11079007|NCT04222985|Experimental|Part B (Stage 1) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079008|NCT04222985|Experimental|Part B (Stage 1) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079009|NCT04222985|Experimental|Part B (Stage 1) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079010|NCT04222985|Experimental|Part B (Stage 1) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
11079011|NCT04222985|Experimental|Part B (Stage 1) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
11079012|NCT04222985|Placebo Comparator|Part B (Stage 1) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
11079013|NCT04222985|Experimental|Part B (Stage 1) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079014|NCT04222985|Experimental|Part B (Stage 2) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079015|NCT04222985|Experimental|Part B (Stage 2) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079016|NCT04222985|Experimental|Part B (Stage 2) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079017|NCT04222985|Experimental|Part B (Stage 2) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
11079018|NCT04222985|Experimental|Part B (Stage 2) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
11079019|NCT04222985|Placebo Comparator|Part B (Stage 2) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
11079020|NCT04222985|Experimental|Part B (Stage 2) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
11079021|NCT04222972|Experimental|Pralsetinib|Patients randomized to the Experimental Arm will receive pralsetinib
11079022|NCT04222972|Active Comparator|Platinum doublet with or without pembrolizumab|"Patients randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology)
~Nonsquamous histology
~Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance.
~Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance.
~Squamous histology
~• Carboplatin or cisplatin / gemcitabine"
11079023|NCT04222959|Experimental|Girls Invest Intervention|Girls Invest intervention participants will have been randomized to receive the intervention immediately upon completion of the baseline survey. Intervention participants will also complete the 6 month follow-up survey. (n=50 dyads; 100 total participants)
11079024|NCT04222959|No Intervention|Wait-List Control Condition Participants|Control condition participants will be randomized upon completion of the baseline survey and put on a wait-list to receive Girls Invest behavioral intervention after the 6 month follow-up survey. (n=50 dyads; 100 total participants)
11079025|NCT04222946|Experimental|Experimental:|bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
11079026|NCT04222933|Experimental|Motorized cryotherapy|Application of motorized cryotherapy after ACL reconstruction for 6 postoperative days
11079027|NCT04222933|Active Comparator|Classical cryotherapy|Application of ice bags for 6 postoperative days
11079028|NCT04222920|Experimental|Low serum drug concentration|Adalimumab dose reduction aiming a drug level of 2 mg/L
11079029|NCT04222920|Active Comparator|High serum drug concentration|Adalimumab dose reduction aiming a drug level of 5 mg/L
11079030|NCT04222907||Women screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were screened for GBS during pregnancy
11079031|NCT04222907||Women not screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were not screened for GBS during pregnancy
11079032|NCT04222894|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 12 weeks
11079033|NCT04222894|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 12-week study period.
11079034|NCT04222881||End To Side|End to Side Anastomosis
11079035|NCT04222881||Side To Side|Side To Side Anastomosis
11079036|NCT04222855|Experimental|Diltiazem|Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
11079037|NCT04222855|Active Comparator|Nifedipine|Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).
11079038|NCT04222842|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25mg BID/50mg QD/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
11079039|NCT04222829||Megadose Shinbaro Pharmacopuncture Group|"The Megadose Shinbaro Pharmacopuncture group who are treated with korean medical treatment including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
11079040|NCT04222829||Control Group|"The control group who are treated with Korean medical treatment not including Megadose Shinbaro Pharmacopuncture will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna and Korean herbal medicine."
11079041|NCT04222816|Active Comparator|Lithium carbonate|Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
11079042|NCT04222816|Experimental|Add-on Sodium chloride|Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.
11079043|NCT04222790|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
11079044|NCT04222790|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
11079045|NCT04222777|Other|Heatlhy volunteers.|Healthy volunteers will undergo two cinematographic recordings of the cervical spine
11079046|NCT04222764|Experimental|Real-time three-dimensional echocardiography|
11079047|NCT04222751|Experimental|Stretch Group|Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
11079048|NCT04222751|Placebo Comparator|No Stretch Group|Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
11079049|NCT04222738|Experimental|Non-randomized single-arm of GINOFF1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.
~The intervention consisted on the administration of Zingiber officinale Roscoe extracts, at a daily dose of 2g/day (equivalent overall daily dose of extract in simple powdered form) for a period of 6weeks. The extracts were given as capsules, either one capsule three times per day (1 capsule x 3 / day) and after meals. Each capsule contains 399mg of pure Zingiber officinale Roscoe extracts."
11079050|NCT04222725|Experimental|TRS01 low dose|
11079051|NCT04222725|Experimental|TRS01 medium dose|
11079052|NCT04222725|Experimental|TRS01 high dose|
11079053|NCT04222725|Placebo Comparator|Placebo|
11079054|NCT04222712|Experimental|TRS01 low dose|
11079055|NCT04222712|Experimental|TRS01 high dose|
11079056|NCT04222699|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
11079057|NCT04222686|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
11079058|NCT04222686|Active Comparator|Losartan Arm|100 mg Losartan tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
11079059|NCT04222673|Experimental|Peer Specialist|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
11079060|NCT04222660|Experimental|Type 2 diabetes without neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
11079061|NCT04222660|Experimental|Type 2 diabetes with neuropathy|Subjects with type 2 diabetes will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
11079062|NCT04222660|Experimental|Normal subjects, aged match with no symptoms of diabetes|Healthy, aged matched control subjects will be enrolled and determination if they have neuropathy will be determined from their clinical record and evaluation.
11079063|NCT04222647|Experimental|WO533|Formulation containing WO533 for intravaginal application
11125220|NCT03898531||hip prosthesis ceramic/polyethylene in double mobility|
11079064|NCT04222634|Other|MDT for oligoprogressive lesions in CRPC|"metastasis-directed therapy:
~radiotherapy (SBRT or conventional radiotherapy in case of local recurrence or untreated primary tumor)
~metastasectomy
~salvage lymphadenectomy
~salvage prostatectomy in case of local recurrence or untreated primary tumor"
11079065|NCT04222621||Pregnant women|
11079066|NCT04222595|No Intervention|1- naive|Group 1: up to 10 children aged 4-6 years that never received LAIV before.
11079067|NCT04222595|Active Comparator|2- Fluenz Tetra nasal spray suspension|Group 2: up to 10 children aged 4-6 years that received LAIV once before. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
11079068|NCT04222595|Active Comparator|3- Fluenz Tetra nasal spray suspension|Group 3: up to 10 children aged 4-6 years that were vaccinated twice before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
11079069|NCT04222595|Active Comparator|4- Fluenz Tetra nasal spray suspension|Group 4: up to 10 children aged 4-6 years that were vaccinated 3 or 4 times before.Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
11079070|NCT04222582|Active Comparator|Active tDCS|"Administration of a 2 milliamp (mA) current delivered via two scalp electrodes for 20 minutes (ramp-in + ramp-out periods, 30s total) 2 times per day for 5 consecutive days, >3 hour interval between sessions, for a total of 10 tDCS sessions.
~tDCS will be administered with a constant current regulator (NeuroConn DC-Stimulator Plus®, Germany) using 2 saline-soaked sponge electrodes applied over the scalp. Using the 10-20 international EEG system for tDCS electrode placement, the anode will be positioned midway between F3 and Fp1 (left DLPFC) and the cathode midway between T3 and P3 (left TPJ)."
11079071|NCT04222582|Sham Comparator|Sham tDCS|Administration of 2mA tDCS for 30 seconds followed by 19.5 minutes of no current via two scalp electrodes for 20 min (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
11079072|NCT04222582|Other|Open-label Active tDCS|Subjects who have received sham tDCS will be given the option to subsequently receive 10 sessions of open-label active tDCS (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
11079073|NCT04222582|No Intervention|Healthy Control|Healthy volunteers will complete the same questionnaires, EEG recording procedures, and neuroimaging scans as the schizophrenia patient group, but will not undergo tDCS.
11079074|NCT04222569|Experimental|T-piece and PSV 7 PEEP 0 and PSV 0 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
11079075|NCT04222569|Experimental|T-piece and PSV 0 PEEP 0 and PSV 7 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
11079076|NCT04222569|Experimental|PSV 0 PEEP 0 and PSV 7 PEEP 0 and T-piece|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
11079077|NCT04222569|Experimental|PSV 0 PEEP 0 and T-piece and PSV 7 PEEP 0|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
11079078|NCT04222569|Experimental|PSV 7 PEEP 0 and T-piece and PSV 0 PEEP 0|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
11079079|NCT04222569|Experimental|PSV 7 PEEP 0 and PSV 0 PEEP 0 and T-piece|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
11079080|NCT04222556|Experimental|Thiwáhe Gluwáš'akapi|"Weeks 1-7: Weekly in-person 2.5 hour family sessions 30 minute family meal 1 hour separate youth and adult sessions
~1 hour family session"
11079081|NCT04222556|Active Comparator|Woyute Waśte|"Respect for community and cultural values regarding research protocols precluded use of a randomized controlled design with a control group receiving no intervention, so we identified a cost-effective comparison condition program to offer value to study participants. A focus on healthy eating and exercise was of interest to community partners and not expected to directly confound the primary outcomes of the TG program (substance use and suicide risk).
~Week 1 in-person 2.5 hour family session 30 minute family meal 2 hour interactive family session (3 stations) Weeks 2-7: text messages with program content and questions"
11079082|NCT04222543|Active Comparator|HPV Negative tumours|Patients will receive four scans.
11079083|NCT04222543|Active Comparator|HPV positive tumours|Patients will receive four scans.
11079084|NCT04222530|Experimental|Linear EUS|patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy
11079085|NCT04222530|Experimental|ME-NBI|patients underwent magnifying narrowband endoscopy followed by linear endoscopic ultrasonography
11079086|NCT04222517|Experimental|Standart sublay retromuscular technique|Apply standard intervention (sublay retromuscular)
11079087|NCT04222517|Experimental|Standart sublay retromuscular technique with Hemoblock|Local hemostatic Hemoblock is used in retro-muscular and subcutaneous spaces
11079088|NCT04222504|Experimental|Intervention Salons|
11079089|NCT04222504|No Intervention|Control Salons|
11079090|NCT04222491|Experimental|active peanut OIT|active peanut oral immunotherapy
11079091|NCT04222478|Experimental|Real Auriculotherapy|"Patients benefit from 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
11079092|NCT04222478|Sham Comparator|Sham Auriculotherapy|Patients are treated according to the same scheme as the experimental group but with semi-permanent needles positioned on non-specific points.
11079093|NCT04222452||Hypophosphatasia patients (HPP)|Patients with known hypophosphatasia (HPP) as diagnosed using genetic testing.
11079094|NCT04222452||Controls|Healthy individuals (controls) matched to the cases by gender and age.
11079095|NCT04222439|Experimental|AI monitoring gastrointestinal endoscopy|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
11079096|NCT04222426|Experimental|89Zr-atezolizumab PET scan|All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. The 89Zr-atezolizumab PET scan will be performed 4 days after tracer injection. Procedures within the ImaGelato study will be completed after the two 89Zr-atezolizumab PET scans, but patients will continue treatment with carboplatin combined with atezolizumab in the GELATO trial.
11079097|NCT04222413|Experimental|1/Arm 1|Escalating/de-escalation doses of metarrestin
11079098|NCT04222413|Experimental|2/Arm 2|MTD of metarrestin
11079099|NCT04222400|Active Comparator|Transplantation|Frailty assessment before, after and 6 month after surgery
11079100|NCT04222400|Active Comparator|VAD Implantation|Frailty assessment before, after and 6 month after surgery
11079101|NCT04222387|Experimental|Participants with hair dye|Hair dye product with pPD Type Aromatic Amines used up to 1 month before
11079102|NCT04222361|Experimental|KDIGO guide recommendations|Preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI
11079103|NCT04222361|No Intervention|Standard care|The patients assigned to the control group will receive the current standard care of the septic patients of the Unit according to our protocols
11079104|NCT04222348|Experimental|Metformin|850-2550 mg every 24h.
11079105|NCT04222348|Active Comparator|Insulin Detemir|Individual doses according to glycemic controls.
11079106|NCT04222335|Other|Blood sampling|Blood sampling
11079107|NCT04222322|Experimental|Epitomee Capsule|Epitomee Capsule combined with moderate intensity lifestyle counseling
11079108|NCT04222322|Placebo Comparator|Control-Placebo|Visually matching (to Epitomee capsule) placebo capsule combined with moderate intensity lifestyle counseling
11079109|NCT04222309|Experimental|Laparoscopically harvested omental free flap|"Standard neurosurgical removal of recurrent GBM,
~Removal of fat from the abdomen called omentum using a camera (laparoscopically),
~Lining the brain tumor cavity with the piece of omentum,
~Joining the blood vessels of the omentum to blood vessels in the scalp or neck to ensure that it maintains good blood flow."
11079110|NCT04222296|Other|Cochlear Implant and Hearing Aid|Comparing performance of conventional hearing aid fitting to Phonak's Bimodal Fitting formula using the Phonak Naida Link hearing aid. All patients are tested in a bimodal (hearing aid plus cochlear implant) setup. Initial tests are completed with the Advanced Bionics Naida Q70 or Q90 sound processor and the patient's own hearing aid. In this arm, a patient's own hearing aid is replaced with the Phonak Naida Link hearing aid to test if there is a benefit.
11079111|NCT04222296|Other|Cochlear Implant alone|To determine if the addition of a contralateral routing of signal (CROS) microphone on the un-implanted ear improves performance. Baseline tests are completed with Advanced Bionics Naida Q70 or Q90 sound processors. Patients are then given the Phonak Naida Link CROS aid to test if there is a benefit.
11079112|NCT04222296|Other|Hearing Aid and Hearing Aid|Comparing performance of conventional hearing aid fitting to a modified signal processing strategy more aligned with how a cochlear implant manages sound. All patients are tested initially with their own hearing aids to obtain a baseline measurement. Patients are then fitted with a modified Phonak hearing aid to determine if performance improves.
11079113|NCT04222283|Experimental|open label, multicentric, non randomized|one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.
11079114|NCT04222270|Experimental|Intervention|Caregiver peer support from Champion caregivers (Peer mentors) to caregivers of unsuppressed children living with HIV (CLHIV) on child care and medication adherence strategies to enhance achievement of viral suppression: Champion Caregivers (Peer Mentors) will be assigned to the intervention arm and will be trained to support 10-15 caregivers for 18 months post enrollment. Champion Caregivers (CCs) be trained using an adapted Mentor-Mother Peer Support curriculum and topics will include pediatric treatment gaps, ARV formulations/dosing, adherence counseling, and virological failure/suppression. Champion caregivers will conduct monthly-to-quarterly 30 min to 1 hr clinic-aligned caregiver group training sessions and home visits at least once quarterly, targeting Child living with HIV (CLHIV) adherence, age-appropriate disclosure, and keeping clinic appointments. The intervention arm will in addition to peer support intervention, receive routine standard of care at the health facility.
11079115|NCT04222270|No Intervention|Control|Unsuppressed Children living with HIV and their caregivers recruited in the control arm will receive no champion caregiver peer support intervention but will continue to receive the standard of care at their health facilities which include routine care, including age-appropriate antiretroviral therapy and clinic appointments (typically every 2-3 months). Routine, albeit brief (5-10 min) adherence counselling is provided to CLHIV/caregivers by trained healthcare workers (HCWs) at every visit. In Nigeria, routine VL is done at 6 months post-ART initiation and repeated 12 months post- initiation 20. VL is done yearly thereafter for suppressed clients. Those unsuppressed receive 3-months' enhanced adherence counselling (EAC) (15-30 min) by Healthcare workers, with intensified appointment schedules and repeat VL upon EAC completion. This rigorous intervention continues until viral suppression is achieved or ART is switched; drug resistance testing (DRT) is not routine.
11079116|NCT04222257|Experimental|Short course|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
11079117|NCT04222257|Active Comparator|Standard course|Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
11079118|NCT04222244||Headache Attributed to Rhinosinusitis Group (HAR)|No interventions will be provided.
11079119|NCT04222244||Headache-Free Control Group (Control)|No interventions will be provided.
11079120|NCT04222231|Experimental|Blood-flow restriction resistance training|Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
11079121|NCT04222231|Experimental|Classical resistance training|Resistance training with high loads (60-80% RM).
11079122|NCT04222218|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
11125221|NCT03898531||Primary implanted hip prosthesis|
11079123|NCT04222218|Sham Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
11079124|NCT04222205|Active Comparator|Crossover sequence 1|"Cluster-randomization crossover sequence 1:
~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
11079125|NCT04222205|Experimental|Crossover sequence 2|"Cluster-randomization crossover sequence 2:
~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
11079126|NCT04222192|Sham Comparator|Conventional Epidural application|Epidural catheter insertions with conventional (anatomical landmarks use) method
11079127|NCT04222192|Active Comparator|Paramedian sagittal application|Epidural catheter insertions with real time ultrasound guided Paramedian sagittal approach
11079128|NCT04222192|Active Comparator|Transverse Interlaminar application|Epidural catheter insertions with real time ultrasound guided Transverse Interlaminar approach
11079129|NCT04222179|Other|Naso-enteric tube placement|The participants needed nutrition from naso-enteric tube feeding are enrolled into this study. Double-blind was not needed here.
11079130|NCT04222140|Experimental|ERIPTO Protocol|Protocol arm actively being studied
11079131|NCT04222140|Active Comparator|BMAC only|bone marrow aspirate concentrate only arm
11079132|NCT04222127|Experimental|EUS-guided injection of CYA of GVs|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate & lipidol using 19G EUS-FNA needle
11079133|NCT04222127|Experimental|Direct endoscopic injection of CYA of GVs|Direct endoscopic injection of CYA of the gastric varix using standard endoscopy
11079134|NCT04222114|Experimental|Catumaxomab group|
11079135|NCT04222114|Active Comparator|IC group|IC group is defined as the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
11079136|NCT04222101|Other|cardiomyopathy|only one arm, all participants undergo oral glucose tolerance testing and results are used to evaluate association with degree of cardiac dysfunction
11079137|NCT04222088|Other|Patient|Participants recruited that pass the inclusion and exclusion criteria
11079138|NCT04222075||Acute Pancreatitis|Patients after acute pancreatitis
11079139|NCT04222062|No Intervention|Standard of Care Arm|The tumor will be removed surgically. Within 6 weeks after surgery, the resection will be treated with stereotactic radiosurgery (SRS).
11079140|NCT04222062|Experimental|GLIADEL Arm|Once the tumor has been removed, GLIADEL wafers will be applied to the resection cavity. The number of wafers used will be determined by the size of the cavity. Enough wafers should be used so that as much of the cavity is covered as possible.
11079141|NCT04222049|Experimental|spastic Tongue Dysarthria|The purpose of gadget is to transmit the mechanical vibration waves to the brain of the subjects.
11079142|NCT04222023|Experimental|IVIG group|Administration of a single dose of IVIG at day 10+/- 4 days, day 41 +/- 7 days and day 62 +/- 7 days. The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
11079143|NCT04222023|No Intervention|Control group|
11079144|NCT04222010|Experimental|serratus loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
11079145|NCT04222010|Experimental|paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
11079146|NCT04222010|Experimental|serratus and paravertebral bloc Loco-regional anesthesia|patient who underwent thoracoscopic surgery will be assigned to serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
11079147|NCT04221997|Experimental|sertraline|90 patients will be randomized to sertraline
11079148|NCT04221997|Placebo Comparator|Placebo|30 patient will be randomized to placebo
11079149|NCT04221997|No Intervention|Healthy Control|30 healthy comparison subjects will be followed over the course of 12 weeks
11079150|NCT04221971|Experimental|AML patients with NK cells infusion|The relapsed/refractory AML patient received Flu+CTX (Flu 25mg/m2 (-6d to -2d)，CTX 1.0g/m2 (-6d to -5d) and haploidentical NK cells infusion postchemotherapy for at least 48 hours. NK cell dose was over 1+E07/ kg with 3 consecutive infusions. NK cells infusion interval was 1 day.
11079151|NCT04221958||Electrocardiogram (ECG) Mapping|Participants will have 10 superficial electrode-patches placed on their chest in two vertical columns of 5 electrode-patches. The channels V1-V5 will be connected to one of the columns. The channel V6 will be connected to each of the electrode-patches in the second column ad recordings will be taken for approximately 2 minutes on each electrode-patch. ECG readings will be recorded.
11079152|NCT04221945|Experimental|chemoradiotherapy + pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 weeks plus 45-50 Gray units (Gy) of external beam radiotherapy (EBRT) given over 40 days followed by 25-30 Gy of brachytherapy given with the total duration of radiation treatment not to exceed 56 days.
11079153|NCT04221945|Experimental|chemoradiotherapy + placebo for pembrolizumab|Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. During the Q3W dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 weeks plus 45-50 Gray units (Gy) of external beam radiotherapy (EBRT) given over 40 days followed by 25-30 Gy of brachytherapy given with the total duration of radiation treatment not to exceed 56 days.
11079154|NCT04221932||Pre Intervention|Retrospective evaluation of data from 2 years prior to the implementation of our CRRT KPI reports. This will include approximately 1500 participants.
11079254|NCT04221217|Experimental|MND-2119 4g|MND-2119 4 g, orally, once daily after breakfast for 52 weeks.
11079155|NCT04221932||Post Intervention|This will be a prospective evaluation of all new ICU patients receiving CRRT in Alberta over a 2 year periods. This will include approximately 1500 participants
11079156|NCT04221919|Experimental|Carvedilol|
11079157|NCT04221919|Experimental|Bisoprolol|
11079158|NCT04221919|Experimental|Metoprolol tartrate|
11079159|NCT04221919|Experimental|Metoprolol succinate|
11079160|NCT04221906|Experimental|BOS-475 0.5%|Daily application of BOS-475 0.5%
11079161|NCT04221906|Experimental|BOS-475 1%|Daily application of BOS-475 1%
11079162|NCT04221906|Experimental|BOS-475 2%|Daily application of BOS-475 2%
11079163|NCT04221906|Placebo Comparator|Active ingredient-free vehicle cream|Daily application of vehicle cream
11079164|NCT04221906|Active Comparator|Daivonex cream|Daily application of Daivonex cream (calcipotriol 0.005%)
11079165|NCT04221906|Active Comparator|Betnesol-V cream (betamethasone 0.1%)|Daily application of Betnesol-V cream (betamethasone 0.1%)
11079166|NCT04221893|Experimental|Radiation therapy (RT)|Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols
11079167|NCT04221880|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine and Saline iv. bolus and infusion (same volume as Group Lidocaine)
11079168|NCT04221880|Active Comparator|Group Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion and, Ultrasound-guided erector spinae plane block with 20 ml saline
11079169|NCT04221880|Sham Comparator|Group Control|Ultrasound-guided erector spinae plane block with 20 ml saline and, Saline iv. bolus and infusion (same volume as Group Lidocaine)
11079170|NCT04221867|Experimental|Esophageal stricture patients|Patients suffering from benign esophageal stricture are treated with through-the scope CRE dilation balloon. Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
11079171|NCT04221854|Experimental|Stool-based SDC2 DNA methylation test group|Subjects will received the stool-based SDC2 DNA methylation test for the screening of colorectal advanced adenomatous polyps and cancer.
11079172|NCT04221854|Active Comparator|Fecal immunochemical test group|Subjects will received the fecal immunochemical test for the screening of colorectal advanced adenomatous polyps and cancer.
11079173|NCT04221828|Experimental|NanoPac|Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.
11079174|NCT04221815|Active Comparator|IVUS guided PCI|Patients will recieve a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS
11079175|NCT04221815|Placebo Comparator|Angiographic-guided PCI|Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator
11079176|NCT04221789|Experimental|intervention: TB treatment assistant|Patients receiving instructions to use phone application
11079177|NCT04221789|No Intervention|Control|Patients receiving instructions for usual care self administered treatment
11079178|NCT04221776|Experimental|Intensive toilet training group|Intervention group was subjected to an intensive TT group session lasting 2-hours during 2 consecutive days in daycare centers.
11079179|NCT04221776|Active Comparator|Standard care toilet training group|Children participating in control group did not receive the intensive training, but parents got a leaflet and were encouraged to start TT their child at home, in their own manner.
11079180|NCT04221763|Experimental|Heart failure and abnormal cardiac conduction|Subjects will have an attempt at His-bundle pacing, left bundle pacing and biventricular pacing. Pacing at the His bundle and the left bundle will be attempted using a Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Biventricular pacing will utilise a left ventricular lead placed in the coronary sinus using any of the 5 manufactures of CS leads Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical or in participants receiving permanent conduction system pacing left ventricular pacing will be achieved using a Cordis ATW™ wire placed in the coronary sinus.
11079181|NCT04221750|Experimental|Lifestyle Therapy plus Metformin|Diet-induced weight loss and Exercise Training plus Metformin 1 gm bid
11079182|NCT04221750|Placebo Comparator|Lifestyle Therapy plus Placebo|Diet-induced weight loss and Exercise Training plus Placebo
11079183|NCT04221750|Active Comparator|Healthy lifestyle plus Metformin|Healthy lifestyle and Metformin 1 gm bid
11079184|NCT04221737|Active Comparator|Conventional ventilation|Protective lung conventional strategy with volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, with low tidal volume and adequate positive end expiratory pressure (PEEP) level.
11079185|NCT04221737|Experimental|Time-controlled adaptive APRV|Airway Pressure Release Ventilation with Time-controlled adaptive ventilation method. Allowing for spontaneous breathing.
11079186|NCT04221724|Experimental|Intervention Group|Multicomponent physical exercise intervention
11079187|NCT04221711|Experimental|Repetitive pulsed magnetic stimulation|Patients randomized in this group will receive rPMS (80 milliTesla ; 2 Hertz; OMNITRON® promed; Healthfactories Holding GmbH) three times a week for a total of 12 weeks. Thereby they will be lying in a prone position or sitting for 20 minutes with the magnet coil positioned over the mid-portion of the affected Achilles tendon (manufactures instruction).
11079188|NCT04221711|Active Comparator|Eccentric Calf Muscle Training for Achilles Tendinopathy|Two types of eccentric exercises will be used. The calf muscle will be eccentrically loaded both with the knee straight and with the knee bent. Each of the two exercises will include an increasing number of repetitions (1. Week, 2-3 weeks, 4-12 weeks) done in 3 sets (e.g. 3x15, 3x20, 3x30 repetitions). The patients will be informed that muscle soreness during the first 1 to 2 weeks of training was to be expected. Patients will receive a visual exercise protocol.
11079189|NCT04221698|Experimental|Gait Retraining Group|Athletes from the Triathlon Plan in High Performance of the Valencian Community in Spain performing individual gait retraining sessions
11079247|NCT04221256|Experimental|Administration of SSRI|Participants will be administered either 5, 10 or 20mg of SSRI escitalopram prior to paired associative stimulation.
11079190|NCT04221685|Active Comparator|Artinibsa|Powerful local anaesthetic with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.4%Articaine 1:100000.
11079191|NCT04221685|Experimental|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride,Epinephrine (D.C.I) (tartrate) 0.01 mg
11079192|NCT04221672|Experimental|Terlipressin plus standard care|Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.
11079193|NCT04221672|Other|Standard care|Participants were not administrated with terlipressin during surgery and were routinely managed after surgery.
11079194|NCT04221659|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
11079195|NCT04221659|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
11079196|NCT04221659|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
11079197|NCT04221646|Experimental|Thighs circumference reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously.
11079198|NCT04221646|Experimental|Saddlebags fat thickness reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too.
11079199|NCT04221633|Experimental|Webinar only|Participants in this arm will attend a webinar training program (3 webinars over the course of 4 to 8 weeks) to receive training in evidence-based engagement strategies, trauma, evidence-based practices, and mental health screening.
11079200|NCT04221633|Experimental|Webinar plus consultation|Participants in this arm will receive the same webinar training as subjects in arm 1, but they will also receive 10 consultation calls over the course of four months to further develop their skills in engaging families and screening for mental health services.
11079201|NCT04221633|No Intervention|Delayed training group|This group will not receive any training for the duration of the study year, in order to serve as a waitlist control group. They will be eligible to receive the training after the randomized control trial has been completed.
11079202|NCT04221620|Experimental|EEG neurofeedback|All participants will receive 20 sessions of traditional occupational therapy services while receiving EEG neurofeedback.
11079203|NCT04221607|Experimental|Sensate Focus Exercise + Usual care|Sensate Focus Exercises aim to help couples be more present with one another through talking and through touch.
11079204|NCT04221607|No Intervention|Usual care|
11079205|NCT04221594||CAD detection/risk assessment|Patients with angina referred for the assessment of CAD will undergo imaging studies to develop tools to fuse coronary anatomic data obtained from CCTA with dPET data to non-invasively measure absolute MBF, MFR and RFR along vessels centerlines and across coronary lesions.
11079206|NCT04221581||Patients receiving FHK ASYMETRIQUE prosthesis|
11079207|NCT04221555|Experimental|the main treatment group|pMMR tumor
11079208|NCT04221555|Active Comparator|the exploratory group|dMMR tumor
11079209|NCT04221542|Experimental|Dose exploration phase|"The dose exploration phase of the study will estimate the MTD of AMG 509 using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
~Recommended phase 2 dose (RP2D) may be identified based on emerging safety, efficacy, PK, and PD data prior to reaching an MTD. Alternative dosing schedule(s) (including a second step dose) may be explored based on emerging safety and PK data."
11079210|NCT04221542|Experimental|Dose expansion phase|A dose expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and correlative biomarker analysis.
11079211|NCT04221529|Experimental|Atezolizumab|Four 21-day cycles of induction therapy with atezolizumab+carboplatin+etoposide followed by 21-day cycles of maintenance therapy with atezolizumab.
11079212|NCT04221516|Experimental|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks), from 4 to 12 weeks after the completion of radiotherapy.
11079213|NCT04221503|Experimental|Cohort A|Cohort A is for subjects with recurrent glioblastoma who do not have clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort A will initiate and continue TTFields therapy for 5-7 days prior to starting niraparib.
11079214|NCT04221503|Active Comparator|Cohort B|Cohort B is for subjects with recurrent glioblastoma who have a clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort B will receive TTFields for 5-7 days prior to planned surgical resection, undergo surgical resection, resume TTFields postoperatively, and initiate niraparib 5- 7 days after starting TTFields postoperatively.
11079215|NCT04221490|Experimental|Treatment|Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
11079216|NCT04221477|Experimental|Obinutuzumab|"Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit.
~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.
~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
11079217|NCT04221477|Placebo Comparator|Placebo|"Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone.
~Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.
~Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80."
11079248|NCT04221256|Placebo Comparator|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
11079249|NCT04221243|Experimental|Group 1: Children with 3D printed space maintainer|
11079250|NCT04221243|Active Comparator|Group 2: Children with conventional band and loop|
11079251|NCT04221230|Experimental|BTRX-335140|
11079218|NCT04221464|Experimental|Tumors and blood collection|"For all the patients include in the study :
~Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression.
~Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery
~In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery"
11079219|NCT04221451|Experimental|GZ402671|"Primary population: participant will receive venglustat dose 1 once daily during 104 weeks.
~Secondary population: participant will receive venglustat at various doses once daily during 104 weeks (open label period)."
11079220|NCT04221451|Placebo Comparator|Placebo|Primary population: participants will receive placebo once daily during 104 weeks.
11079221|NCT04221438|Experimental|Treatment (18F-FLT, PET/CT, encorafenib, binimetinib, surgery)|"NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.
~SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.
~ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity."
11079222|NCT04221425|Experimental|VRRS GROUP|Home rehabilitation program is provided through a virtual reality based telerehabilitation system
11079223|NCT04221425|Active Comparator|CONTROL GROUP|Home rehabilitation program is provided through illustrative booklet containing characteristics of exercises and indications for recovery
11079224|NCT04221399|Experimental|DWP16001 Single dose|Single dose
11079225|NCT04221399|Experimental|DWP16001 Multiple dose|Up to 7 days
11079226|NCT04221386|Experimental|MIT group|Subjects will receive the developed Melodic Intonation Therapy.
11079227|NCT04221386|No Intervention|Control group|Subjects will not receive any intervention.
11079228|NCT04221373|Experimental|Exoskeletal-assisted walking training group|Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
11079229|NCT04221373|Active Comparator|Standard of care group|Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.
11079230|NCT04221360|Experimental|Group 1|"Period 1: D390
~Period 2: CKD-375"
11079231|NCT04221360|Experimental|Group 2|"Period 1: CKD-375
~Period 2: D390"
11079232|NCT04221347||Group A - Hepatocellular carcinoma|"Patients with with proved hepatocellular carcinoma in cirrhosis.
~N=100"
11079233|NCT04221347||Group B - Cirrhosis|"Cirrhotics of multiple aethiology will be sampled for spectroscopy in order to detect possible differences among cirrhotics with and without subsequent hepatocellular carcinoma.
~N=100"
11079234|NCT04221347||Group C - Healthy controls|Healthy controls - healthy military personnel. N=50
11079235|NCT04221334|Active Comparator|Experimental Toothbrush 1|1. A connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
11079236|NCT04221334|Active Comparator|Experimental Toothbrush 2|2. A non-connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
11079237|NCT04221321|Placebo Comparator|Atorvastatin 40 mg|Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
11079238|NCT04221321|Experimental|Atorvastatin 40 mg + Tegoprazan 50 mg|Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
11079239|NCT04221321|Active Comparator|Atorvastatin 40 mg + RAPA114|Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days
11079240|NCT04221308||single port laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
11079241|NCT04221308||Vaginal hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
11079242|NCT04221295|Experimental|Exercise Group|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
11079243|NCT04221295|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
11079244|NCT04221282||Epileptic elderly patients|Elderly patients with partial-onset seizures
11079245|NCT04221269|Active Comparator|Enhanced Treatment as Usual|Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
11079246|NCT04221269|Experimental|Coping Long-term with Active Suicide Program for Schizophrenia|Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
11079252|NCT04221230|Placebo Comparator|Placebo|
11125222|NCT03898531||metal / metal prosthesis removed|
11079255|NCT04221204|Experimental|Open-Label, Dose-Escalation|"To explore the maximum tolerated dose (MTD) and the recommended dose for subsequent studies (RPTD) of 3D185 monotherapy in subject with advanced solid tumors.
~The starting dose in this dose-escalation study is 25 mg, and the preset 7 dose-escalation cohorts are 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively. This study adopts a combination of accelerated titration and i3+3[1] for dose escalation. All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily [QD], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first."
11079256|NCT04221191||Standard of Care (SoC) Group|SoC neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice (non-coached participants).
11079257|NCT04221191||OroSEP PSP (OPSP) Group|OPSP neurologists will include and follow-up all study participants who receive DMF according to their standard of care practice and the OroSEP PSP (coached participants).
11079258|NCT04221178||MRD-Negative Participants|
11079259|NCT04221165|Active Comparator|Opioid Analgesia|Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.
11079260|NCT04221165|Experimental|Multimodal Analgesia|Pregabalin (50 mg to 300 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)
11079261|NCT04221152|Experimental|Treatment of empagliflozin|"The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study.
~The administration is oral administration with water once daily before or after breakfast."
11079262|NCT04221139||Healthy young adults|Healthy young adults will play four virtual reality games: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
11079263|NCT04221126|Experimental|TMFI +cream|TMFI + ALA cream
11079264|NCT04221126|Experimental|TMFI + gel|TMFI + ALA gel
11079265|NCT04221126|Active Comparator|ALA creAM|ALA cream
11079266|NCT04221126|Active Comparator|ALA GEL|ALA gel
11079267|NCT04221126|No Intervention|Control|Untreated control with no intervention
11079268|NCT04221113|Active Comparator|Group A ( Immobilization protocol)|Group A patients will receive static splints.By the end of 4 weeks the splint will be modified and patients will start doing physiotherapy. Movement at MCPJ will be from 0 to 45 degrees.
11079269|NCT04221113|Active Comparator|Group B( early active mobilization protocol).|Group B patients will receive splints in such a way that from 3rd post operative day patients will be instructed to do physiotherapy. Initially MCPJ movement will be from 0 to 30 degrees.
11079270|NCT04221100|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
11079271|NCT04221100|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
11079272|NCT04221087|Placebo Comparator|Placebo Arm|Participants will be given a placebo of sugar water (0.6ml/kg/dose) in a single oral dose and standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
11079273|NCT04221087|Experimental|Dexamethasone Arm|Participants will be given dexamethasone (0.6mg/kg/dose) in a single oral dose in addition to the standard of care for bronchiolitis (supplemental oxygen, antipyretics, suctioning etc.)
11079274|NCT04221074|Active Comparator|Modified Pectoral Plane (PECSII ) block (P)|done after induction of general anaesthesia in supine position of the patient with his arm of the side of the operation abducted 90 degree with the probe with frequency L4-12t (Logiq e machine) at the midclavicular level and angled infero-laterally,the axillary artery and vein and the second rib identified the probe moved laterally until the pectoralis minor and serratus anterior are identified,the local anesthetic was injected at two points using (echoplext guge20 length 50 mm ) needle:the first injection of 10 ml of 0.25% Bupivacaine and 4 mg dexamethasone injected between the pectoralis major and minor muscles,and the second injection of 20 ml of 0.25% Bupivacaine and 4 mg dexamethasone between the pectoralis minor and serratus anterior muscles .
11079275|NCT04221074|Active Comparator|Erector Spinae Plane ( ESP )block (E)|after induction of general anaesthesia in lateral position of the patient where the surgical side up and at T4 level the probe with frequency L4-12t (Logiq e machine) placed lateral to the spine by 3 cm in parasagittal plane the needle (echoplext guge20 length 50 mm ) advanced between the transverse process and the erector spinae muscle at that level 20 ml of 0.25% Bupivacaine and 8 mg dexamethasone injected.
11079276|NCT04221061|Other|Non-surgical candidates|In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
11079277|NCT04221061|Other|Surgical candidates|In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.
11079278|NCT04221048||PREG-GUCH|Pregnant women with congenital heart diseases
11079279|NCT04221035|Experimental|R-I|R-I: induction regimens RAPID COJEC vs GPOH Assuming a baseline 3-year EFS of 40%, with a sample size of 686 patients (343 in each arm) and a two-sided alpha=5% this trial will have 90% power to demonstrate an improvement of 12% in 3-year EFS, within a recruitment period of 3 years and a minimum follow up of 1.5 years.
11079280|NCT04221035|Experimental|R-HDC|R-HDC: consolidation regimen Bu-Mel vs Thiotepa + Bu-Mel The 3-year EFS in the Bu-Mel arm (with immunotherapy) is estimated to be 55%. This study aims to show an improvement of 12% for the Thiotepa + Bu-Mel arm (3-year EFS of 67%). With a recruitment of 448 patients (224 in each arm) over a period of 3 years and a minimum follow-up of 2 years, the power to show a 12% difference is 80% (two-sided logrank test and α=5%).
11079281|NCT04221035|Experimental|R-RTx|R-RTx: 21.6 Gy radiotherapy vs 21.6 Gy + 14.4 Gy boost in patients with macroscopic residual disease
11079320|NCT04220788|Active Comparator|Usual care|Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
11079415|NCT04219995|Experimental|Interventional start|Patients who randomize to the interventional start arm will receive the study drug, methylprednisolone sodium succinate, in the first month of the study, followed by placebo in the cross-over phase of the study.
11079282|NCT04221022|Active Comparator|Light physical activity (Group 1)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into Light Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
11079283|NCT04221022|Active Comparator|Moderate physical activity (Group 2)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into moderate Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
11079284|NCT04221022|Active Comparator|Vigorous physical activity (Group 3)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into vigorous Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
11079285|NCT04215094||infected group|Intracranial infection were diagnosed according to the Centers for Disease Control (CDC) definitions
11079286|NCT04215094||non-infected group|the postoperative recovery was uneventful with no infection
11079287|NCT04221009|Experimental|Intervention (single arm)|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
11079288|NCT04220996|Experimental|Vortioxetine|10-20 mg vortioxetine tablets
11079289|NCT04220983|Other|MR-Guided Prostate SBRT|
11079290|NCT04220970||BIA-ALCL|
11079291|NCT04220957|Experimental|Digital Impression Technique|Impression with an intraoral scanner (TRIOS 3, 3Shape, Denmark)
11079292|NCT04220957|Active Comparator|Conventional Impression Technique|Conventional impression with alginate (Orthoprint, Zhermack)
11079293|NCT04220944|Experimental|Locoregional therapies combined with Anti-PD-1 antibody|Percutaneous microwave ablation combined with simultaneous TACE was performed. Sintilimab will be initiated on day 3-7 after the first locoregional therapies. Sintilimab will be administered every three weeks (200mg fixed dose IV) until disease progression for up to one year.The second locoregional procedure will be repeated according to the enhanced CT images.
11079294|NCT04220931|Experimental|botulinum toxin injection|"Injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
~The endoscopic procedure will be performed under unconscious sedation with intravenous injection of propofol by an anesthesiologist."
11079295|NCT04220931|No Intervention|standard care|standard care (no endoscopy)
11079296|NCT04220892|Experimental|Pembrolizumab plus Pemetrexed|Pembrolizumab plus Pemetrexed
11079297|NCT04220892|Experimental|Pembrolizumab plus Abemaciclib|Pembrolizumab plus Abemaciclib
11079298|NCT04220879||Malignant Glaucoma|To determine the biometric measurements.
11079299|NCT04220879||Fellow Eyes|To determine the biometric measurements.
11079300|NCT04220879||Matched Eyes|To determine the biometric measurements.
11079301|NCT04220866|Experimental|MK-1454+Pembrolizumab|Participants receive MK-1454 540 ug via intratumoral (IT) injection on Day 1 of every week for two 3-week cycles (Cycles 1-2), then on Day 1 of each 3-week cycle for up 33 cycles (Cycles 3-35), for a total of 35 cycles PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
11079302|NCT04220866|Active Comparator|Pembrolizumab|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
11079303|NCT04220853|Experimental|Septoplasty|The patients indicated for septoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
11079304|NCT04220853|Experimental|Turbinoplasty|The patients indicated for turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
11079305|NCT04220853|Experimental|Septoplasty and turbinoplasty|The patients indicated for septoplasty and turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
11079306|NCT04220840||Study Group|All consecutive patients who underwent damage control surgery (DCS) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers
11079307|NCT04220840||Control group|All consecutive patients who underwent other than DCS surgery (resection with primary anastomosis, Hartmann´s procedure, laparoscopic lavage) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers which do not apply DCS routinely.
11079308|NCT04220827|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IP over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.
11079309|NCT04220814|Experimental|Patients|
11079310|NCT04220814|Other|Healthy Volunteer|
11079311|NCT04220801|Experimental|Cohort 1 of Part 1 (SAD)|300 mg ZM-H1505R or placebo
11079312|NCT04220801|Experimental|Cohort 2 of Part 1(SAD)|450 mg ZM-H1505R or placebo
11079313|NCT04220801|Experimental|Cohort 3 of Part 1(SAD)|150 mg ZM-H1505R or placebo (2 periods)
11079314|NCT04220801|Experimental|Cohort 4 of Part 1(SAD)|75 mg ZM-H1505R or placebo
11079315|NCT04220801|Experimental|Cohort 5 of Part 1(SAD)|25 mg ZM-H1505R or placebo
11079316|NCT04220801|Experimental|Cohort 1 of Part 2 (MAD)|75 mg ZM-H1505R or placebo
11079317|NCT04220801|Experimental|Cohort 2 of Part 2 (MAD)|150 mg ZM-H1505R or placebo
11079318|NCT04220801|Experimental|Cohort 3 of Part 2 (MAD)|300 mg ZM-H1505R or placebo
11079319|NCT04220788|Experimental|Enhanced pharmacist service|The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
11079350|NCT04220567|Experimental|Exercise and Patient-centred education|
11079351|NCT04220567|Active Comparator|Exercise|
11079321|NCT04220775|Experimental|Treatment (bintrafusp alfa, SBRT)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 15 of cycle 1, patients also undergo SBRT over 5 fractions once QOD for 2 weeks in the absence of disease progression or unacceptable toxicity.
11079322|NCT04220762|Experimental|Test Group 1|The randomized patients are administered 3 tablets of the investigational product (400mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
11079323|NCT04220762|Experimental|Test Group 2|The randomized patients are administered 3 tablets of the investigational product (800mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
11079324|NCT04220762|Experimental|Test Group 3|The randomized patients are administered 3 tablets of the investigational product (1200mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
11079325|NCT04220762|Placebo Comparator|Placebo group|The randomized patients are administered 3 tablets of the placebo drug twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
11079326|NCT04220749|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
11079327|NCT04220749|Experimental|Arm 2, TOS + Neck Dissection|Trans-oral Surgery (TOS) + Neck Dissection (plus radiation is required)
11079328|NCT04220736||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
11079329|NCT04220736||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
11079330|NCT04220723||End-Stage Liver Disease|End-stage liver disease patients who are being followed up at the Department of Gastroentereology of Hacettepe University Faculty of Medicine will be included in the study. When the participants come to the gastroenterology department for control, they will be directed to us and the assessment will begin after written and verbal approval is obtained. The Liver Frailty Index will be used to assess the frailty of the participants. Accordingly, hand grip test, 5 repeat sit-up test and side, semi-tandem and tandem balance measurements will be made and a total frailty score will be obtained. Submaximal aerobic capacities and functional capacities will be evaluated by 6 Minute Walk Test. Then, maximal inspiratory muscle pressure and maximal expiratory muscle pressure of the participants will be measured and respiratory muscle strength will be evaluated. Finally, maximal aerobic capacity will be measured by Shuttle Walk Test.
11079331|NCT04220710||Marker selection group|Methalation detection of circulating free DNA and FFPF samples from pathologically confirmed patients with ovarian endometriosis(30 cases), ovarian cancer (30 cases)and other benign ovarian tumors (30 cases)will be performed to select markers for ovarian endometriosis diagnosis.
11079332|NCT04220710||Marker validation group|The selected markers will be validated in patients with ovarian cysts (300 cases )found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.
11079333|NCT04220697|Experimental|patients undergo lateral thoracotomy for primary lung cancer|"Electroencephalography (EEG) will be acquired before surgery
~Questionnaires assessing psychological status of the patients before and after surgery
~High frequency electrical stimulation of the skin (HFS) will be delivered before surgery
~Quantification of mechanical sensitivity after HFS and after surgery"
11079334|NCT04220684|Experimental|Cohort I (fludarabine, cytarabine, NK cell therapy)|Patients who are < 60 years old, are able to tolerate intensive chemotherapy, and not insensitive to cytarabine receive fludarabine IV and cytarabine IV on days -6 to -2 in the absence of disease progression or unacceptable toxicity. All patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells via infusion on days 0, 2, 4, 7, 9, and 11.
11079335|NCT04220684|Experimental|Cohort II (fludarabine, decitabine, NK cell therapy)|Patients who are >= 60 years old, unable/unwilling to tolerate intensive chemotherapy, or disease insensitive to cytarabine (tp53, TET2 mutations) receive fludarabine IV on days -5 to -2 and decitabine IV on days -6 to -2 in the absence of disease progression or unacceptable toxicity. All patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells via infusion on days 0, 2, 4, 7, 9, and 11.
11079336|NCT04220671|Experimental|Intervention|Standard dose measles vaccine, 0.5 ml
11079337|NCT04220671|Placebo Comparator|Control|Saline injection, 0.5 ml
11079338|NCT04220645|Active Comparator|Standard of care|Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
11079339|NCT04220645|Experimental|Opportunistic treatment|Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
11079340|NCT04220632|Experimental|Itacitinib+corticosteroids|Itacitinib administered in combination with corticosteroids
11079341|NCT04220619|No Intervention|Conventional ACLS|Patients who have conventional ACLS during in-hospital Cardiac arrest, they will not have RescueTEE
11079342|NCT04220619|Experimental|RescueTEE guided ACLS|Patients who have RescueTEE guided ACLS
11079343|NCT04220606|Other|Migraine without aura subjects|Drug: Glyceryl trinitrate (GTN)
11079344|NCT04220606|Other|Healthy subjects|Drug: Glyceryl trinitrate (GTN)
11079345|NCT04220593|Experimental|aETCC before TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
11079346|NCT04220593|Experimental|aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
11079347|NCT04220593|Experimental|aETCC after TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
11079348|NCT04220593|Sham Comparator|Simulated aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
11079349|NCT04220580|Other|Cold Pressor Test|The participants are instructed to keep the non-dominant hand submerged in ice-water for as long as possible with a maximum of 10 minutes.
11079352|NCT04220554|Experimental|Intervention group|"Intervention group:
~All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream.
~During the study period, a nurse or pharmaconomist will deliver;
~Improved support and instructions to the patients
~Patients will receive a diary and access to more consultations."
11079353|NCT04220554|No Intervention|Non-intervention group|"All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream."
11079354|NCT04220541|Experimental|Motor learning based exercise group|
11079355|NCT04220541|Experimental|Symptomatic exercise group|
11079356|NCT04220528|Experimental|Radical chemoradiotherapy plus oral capecitabine/teggiol|Patients with newly diagnosed, non-metastatic stage N3 NPC was given Teggio 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving radical chemoradiotherapy.
11079357|NCT04220515|Experimental|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Primary 3-dose of sIPV and booster 1 dose of sIPV
11079358|NCT04220502|Experimental|Magic Shave Powder Gold|This group will receive magic shaving powder gold and instructions on how to apply it. They will keep a log for their facial hair removal
11079359|NCT04220502|Other|Traditional Methods|This group will continue using traditional razors with the standard of care directions to shave. They will keep a log of their facial hair removal
11079360|NCT04220489|Experimental|Ketamine Group|Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
11079361|NCT04220489|Placebo Comparator|Placebo Group|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
11079362|NCT04220476|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
11079363|NCT04220476|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
11079364|NCT04220463|Experimental|Hypnosis group|For the hypnosis group, hypnotic support is set up by an IDE previously trained and dedicated during the implementation of the NIV. The dedicated IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated IDE.
11079365|NCT04220463|Placebo Comparator|Control group|In the control group, in order to preserve the knowledge of the evaluator, the IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
11079366|NCT04220437||CAG and OCT group|Images of CAG and OCT patients obtained from ISR patients were retrospectively collected and analyzed.
11079367|NCT04220411|Experimental|AR100DP1 (1.25%)|topical application twice per day with at least 4 hour interval
11079368|NCT04220411|Experimental|AR100DP1 (2.5%)|topical application twice per day with at least 4 hour interval
11079369|NCT04220411|Experimental|AR100DP1 (5%)|topical application twice per day with at least 4 hour interval
11079370|NCT04220398|Experimental|NCHT Group|Neoadjuvant chemotherapy combined with hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
11079371|NCT04220398|Active Comparator|NHT Group|Neoadjuvant hormonal therapy, radical Prostatectomy (RP)+ extended lymph node dissection.
11079372|NCT04220398|Other|RP Group|Radical Prostatectomy (RP)+ extended lymph node dissection alone.
11079373|NCT04220385|Active Comparator|Wii fit Plus|"This study group will perform the following Wii fit plus exercises
~Single-Leg Extension
~Arm and Leg Lift
~Balance Bridge
~Single-Leg Twist
~Single-Leg Reach
~Sideways Leg Lift
~Single Arm Stand
~Torso Twists
~Plank"
11079374|NCT04220385|Active Comparator|Core Stability|"This study group will perform the following exercises.
~Curl-up
~Side Bridge
~Bird Dog"
11079375|NCT04220372|Experimental|Tongxinluo Capsule|
11079376|NCT04220372|Placebo Comparator|Placebo Capsule|
11079377|NCT04220346|Experimental|Tablet group|The Tablet group played the game with Tablet during the whole circumcision.
11079378|NCT04220346|No Intervention|Control group|The control group did not play game with Tablet during the procedure.
11079379|NCT04220333|Placebo Comparator|Control|Participants received the instruction: 'please, lie down, relax and pay attention to your breath'. This procedure was carried during 15 minutes. Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings.
11079461|NCT04219670||Healthy Control Group|Individuals without any known significant health problems
11079380|NCT04220333|Experimental|Intervention|"The intervention protocol was divided in two steps: first, patients spent 5 minutes in the phase of harmonization with five colored stones of a size of a walnut (green, red, yellow, white and black) placed around their bodies.
~Second, in accordance to the emotion chosen by the participant, a matching mandala was placed next to the feet, on the abdomen, or next to the head depending on the self-perceived personality type, intuitive, emotive and rational for the remaining 10 minutes (Figure 3B). The researcher also checked the control subjects once during the 15 fifteen minutes of experiment.
~Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings."
11079381|NCT04220320||Classic BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation, effacement, texture, station and position.
11079382|NCT04220320||Modified BISHOP score|Gynecological evaluation based on vaginal examination including cervical dilatation and effacement alone.
11079383|NCT04220320||Cervical Length|Gynecological evaluation based on cervical length measured by transvaginal sonography.
11079384|NCT04220307|Experimental|AK104|AK104 IV every 2 weeks (q2w)
11079385|NCT04220294|Active Comparator|Interrupted sutures|Subcutaneous tissue closure by interrupted sutures.
11079386|NCT04220294|Active Comparator|Continuous sutures|Subcutaneous tissue closure by continuous sutures.
11079387|NCT04220281|Active Comparator|propofol group|propofol group will receive propofol infusion
11079388|NCT04220281|Active Comparator|nitroglycerin group|will receive nitroglycerin infusion
11079389|NCT04220268||Participants|All the patients with proved malignant ground glass nodule will be enrolled.
11079390|NCT04220229|Experimental|Treatment (cabozantinib S-malate, radiation therapy)|Patients receive cabozantinib S-malate PO QD on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients also undergo standard of care radiation therapy for 5-6 weeks.
11079391|NCT04220216|Experimental|H4H fitness program|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Patients will attend the 16-week program of boxing conditioning.
~This 16-week program will include supervised exercises designed to improve strength, flexibility, balance,and cardiopulmonary fitness.
~There will be 4, 1-hour sessions each week per participant"
11079392|NCT04220190|Experimental|Single agent RAPA-501 T cells (dose level 1)|Dose level 1 is 40 x 10^6 cells/infusion
11079393|NCT04220190|Experimental|Single agent RAPA-501 T cells (dose level 2)|Dose level 2 is 160 x 10^6 cells/infusion
11079394|NCT04220190|Experimental|RAPA-501 + PC Regimen|RAPA-501 T cell therapy preceded by the pentostatin-cyclophosphamide (PC) regimen
11079395|NCT04220177|Experimental|treatment arm|SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.
11079396|NCT04220164||Dyslipidemic patients|Patients who meet the criteria of high-risk category according to 2017 Taiwan Lipid Guideline for High-Risk Patients have a abnormal serum LDL-C level
11079397|NCT04220151||Hepatocellular carcinoma|Sixty patients with HCC
11079398|NCT04220151||Hepatic cirrhosis|Thirty patients with hepatic cirrhosis
11079399|NCT04220151||Healthy controls|Ten healthy controls.
11079400|NCT04220138|Other|cataract patients with poor red reflex|included cataract patients with poor red reflex
11079401|NCT04220125|Experimental|Ketamine Group|Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
11079402|NCT04220125|Active Comparator|MIdazolam Group|Midazolam 0.045 mg/kg administered via intravenous catheter.
11079403|NCT04220112|Experimental|Real Time Functional MRI (rt-fMRI)|Real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) intervention
11079404|NCT04220112|Sham Comparator|Sham|Sham-controlled group
11079405|NCT04220099||schizophrenia patients needed ECT treatment|Whether patients need ECT treatment are assessed by clinicians according to American Psychiatric Association(APA) guidelines.
11079406|NCT04220086|Experimental|Pediatric massage|Children with ASD will receive pediatric massage for 12 weeks.
11079407|NCT04220086|Sham Comparator|Waitlist control|Waitlist control
11079408|NCT04220073|Experimental|JS005|
11079409|NCT04220073|Placebo Comparator|placebo|
11079410|NCT04220047|Experimental|Left Atrial Appendage Resection|
11079411|NCT04220047|No Intervention|off-pump coronary artery bypass|
11079412|NCT04220034||Patients receiving inhibitor checkpoint treatment|adult patients that will receive for the first time checkpoint inhibitor for a neoplasic disease in a center participating to the study
11079413|NCT04220021|Experimental|C9orf72 positive ALS|"Subjects with C9orf72 positive ALS will be instructed in the use of Metformin and receive the first dose of Metformin under supervision of the investigator during Visit 1, Day 2.
~Subjects will then continue on Metformin per the dose escalation schedule twice daily for 24 weeks."
11079414|NCT04220008|Experimental|Treatment (busulfan, vorinostat, gemcitabine, clofarabine)|"Patients receive a low-level test dose of busulfan IV over up to 1 hour on days -15 to -9, vorinostat PO QD on days -8 to -4, gemcitabine IV over about 90 minutes on days -7 and -5, clofarabine IV over about 1 hour and high-dose busulfan IV over 3 hours on days -7 to -4. Patients with CD20 positive (+) lymphoma also receive rituximab IV over 3 to 6 hours on days -15, -8, 1, and 8. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 2 hours on days 3 and 4. Beginning day 5, patients receive standard of care tacrolimus IV over 24 hours and mycophenolate mofetil IV over 2 hours TID until they can be tolerated PO. Once tolerated PO, patients receive tacrolimus PO BID for 6 months and mycophenolate mofetil PO TID for up to 30 days in the absence of disease progression or unacceptable toxicity. After 30 days, patients who develop GVHD continue treatment with mycophenolate mofetil at physician's discretion"
11079460|NCT04219670||Inpatient Group|Inpatient stroke survivors who are currently undergoing rehabilitation at the Shirley Ryan AbilityLab setting
11079416|NCT04219995|Placebo Comparator|Placebo start|Patients who randomize to the placebo start arm will receive placebo in the first month of the study, followed by the study drug, methylprednisolone sodium succinate, in the cross-over phase of the study.
11079417|NCT04219982|Experimental|DPI-386 Nasal Gel|Active DPI-386 Nasal Gel
11079418|NCT04219982|Placebo Comparator|DPI-386 Placebo Nasal Gel|Placebo Nasal Gel
11079419|NCT04219982|Active Comparator|Transderm Scop® (TDS)|FDA approved Transderm Scop® (TDS).
11079420|NCT04219969|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
11079421|NCT04219956|Experimental|Polyamine deficient diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
11079422|NCT04219956|No Intervention|Control|Usual Diet plus two snacks
11079423|NCT04219943|Experimental|Conservative Treatment for Impacted Femoral Neck Fracture|Conservative Treatment for Impacted Femoral Neck Fracture
11079424|NCT04219930||epileptic children|fifty patient with epilepsy
11079425|NCT04219930||Healthy controls|thirty healthy control
11079426|NCT04219917|Experimental|Hip|Gluteus medius facilitation tape
11079427|NCT04219917|Experimental|Knee|Patellar sling tape
11079428|NCT04219917|Experimental|Hip and Knee|Gluteus medius facilitation and patellar sling tape
11079429|NCT04219904|Experimental|Diagnostic (PET/MRI)|Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.
11079430|NCT04219878|Active Comparator|Know@Home App and Test Kit|Participants in this study arm will have access to Know@Home, a mobile HIV prevention app and will receive mail-out HIV self-testing kits.
11079431|NCT04219878|Active Comparator|Mail-Out Testing Kit Only|Participants in this study arm will receive mail-out HIV self-testing kits.
11079432|NCT04219865|Active Comparator|Compound Edaravone|10 mL per vial (containing edaravone 10 mg and 2-aminoethanesulfonic acid 200 mg)
11079433|NCT04219865|Placebo Comparator|Placebo|10 mL per vial
11079434|NCT04219852||"bariatric surgery group"|Women between 18 and 50 years, who undergone bariatric surgery at the University Hospital of Reims.
11079435|NCT04219839|No Intervention|SOC only patient education post- kidney transplant|Participants in this group will receive only SOC patient education following kidney transplant
11079436|NCT04219839|Experimental|SOC + Videos for patient education post-kidney transplant|Participants in this group receive SOC patient education following kidney transplant and access to educational videos designed specifically for post-kidney transplant patients.
11079437|NCT04219826|Experimental|CK-3773274 - Cohort 1|Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
11079438|NCT04219826|Placebo Comparator|Placebo - Cohort 1|Subjects will receive placebo for up to 10 weeks
11079439|NCT04219826|Experimental|CK-3773274 - Cohort 2|Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
11079440|NCT04219826|Placebo Comparator|Placebo - Cohort 2|Subjects will receive placebo for up to 10 weeks
11079441|NCT04219813|Other|Patients affected with Non-celiac Gluten/Wheat Sensitivity|The researchers will deliver to each patient 10 kits for the analysis of the GIP and they will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks. Both gastrointestinal and extra-intestinal symptoms which the patients will attribute to the accidental intake of gluten, will be considered.
11079442|NCT04219800|Experimental|mHealth|"Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.
~SMS text messages; reminds of activity breaks.
~Mobile video instruction for standing pause gymnastics."
11079443|NCT04219800|Other|Control|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
11079444|NCT04219787|Experimental|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
11079445|NCT04219787|Active Comparator|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
11079446|NCT04219774|Experimental|Endovascular arm|
11079447|NCT04219774|Active Comparator|Medical arm|
11079448|NCT04219748|Experimental|Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.
~Receiving the CM intervention doesn't exclude treatment as usual."
11079449|NCT04219748|No Intervention|Control|Only treatment as usual in the Emergency Department (and in the Health and Social Services Network).
11079450|NCT04219735|Experimental|Minocycline|Minocycline 100 mg BID
11079451|NCT04219735|Placebo Comparator|Placebo|Placebo capsules identical to experimental arm
11079452|NCT04219722|Active Comparator|Desirial only group|Administration of DESIRIAL® at Day 0 (Visit 1)
11079453|NCT04219722|Placebo Comparator|Placebo and Desirial group|Administration of placebo at Day 0 (Visit 1). If still eligible 12 weeks (Visit 3) after placebo injection, patient will be treated with DESIRIAL®
11079454|NCT04219709|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
11079455|NCT04219709|Active Comparator|Standard diet|Dietary Intervention, food delivery
11079456|NCT04219696|Active Comparator|1 session|Participants will complete one 45-minute session of reactive balance training. Participants will experience 40-60 perturbations during this session.
11079457|NCT04219696|Experimental|3 sessions|Participants will complete three 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
11079458|NCT04219696|Experimental|6 sessions|Participants will complete six 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
11079459|NCT04219683|Experimental|Patient with resected Mandible|Patient with resected mandible who is candidate for free fibula flap
11125223|NCT03898531||ceramic / ceramic prosthesis removed|
11079462|NCT04219657|Experimental|skin grafting only|All the cases in this group are managed with skin grafting only. Every odd case are kept in skin grafting only group.
11079463|NCT04219657|Experimental|skin grafting and stem cell group|All the cases in this group are managed with skin grafting and application of stem cells. every even cases are kept in skin grafting and stem cells group.
11079464|NCT04219644|Other|Breathing test or sleep study|To evaluate the usability of the device in non-clinical and clinical settings
11079465|NCT04219631|Experimental|WINNER- FLOW-URO-MG GROUP|After admission to the delivery room, all women assigned to WF + group will have an interview with one of the midwifes responsible for the study. The latter will explain the use of the WINNER FLOW®-URO MG® device which is the expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate. Then, WF+ patients will use the expiratory mouthpiece device during all their childbirth process.
11079466|NCT04219631|No Intervention|NO WINNER-FLOW-URO-MG GROUP|Women enrolled in WF- group will be managed classically during their child birth process regardless to the study participation.
11079467|NCT04219618|Experimental|Off-Pump|
11079468|NCT04219618|Active Comparator|On-Pump|
11079469|NCT04219605||Symptomatic vaginitis patients|Symptomatic patients evaluated in the clinic for vulvovaginal symptoms.
11079470|NCT04219592||SSc|74 SSc patients aged 18 - 85
11079471|NCT04219592||Healthy controls|80 Healthy blood-donors aged 18 - 85
11079472|NCT04219579|Experimental|Continuous infusion|Immediately after operation, 2000 international unit (IU) of Antithrombin-III (AT-III) concentrate is loaded for 1 hour. AT-III concentrate 3000 IU is continuously infused through following 71 hours.
11079473|NCT04219579|Active Comparator|Intermittent infusion|Every 6 hours, 500 IU of AT-III concentrate is infused through 1 hour during the first 72 hours after liver transplantation.
11079474|NCT04219566|Active Comparator|Active VeNS|The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
11079475|NCT04219566|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
11079476|NCT04219553|Other|Retrospective group|Comparator group (pre-intervention)
11079477|NCT04219553|Experimental|Prospective group|Study group (post-intervention)
11079478|NCT04219540|Experimental|extended-release buprenorphine (XR-B)|Subjects who agree to XR-B treatment will receive an XR-B injection to the abdomen. The injection is a liquid medication in the amount of either 100 or 300 mg buprenorphine in 1.5 cc volume and will last in the body for about 30 days. The medication is stored in a small nodule under the skin of the belly where it was injected. The buprenorphine is gradually released into the body over time for a 30-day period.
11079479|NCT04219540|Experimental|extended release naltrexone XR-NTX|Subjects who agree to XR-NTX treatment will receive an injection of XR-NTX to the outer upper part of your buttock. The injection is a liquid medication in the amount of 380 mg naltrexone in 4 cc volume (about 1 teaspoon) and will last in your body for about 30 days. Following release, visits with study physicians at Bellevue Hospital will offer further counseling or medication treatment referrals, the option to receive additional XR-NTX injections once a month following the first injection and continued encouragement to avoid relapses and stay on treatment.
11079480|NCT04219540|No Intervention|Treatment as Usual (TAU)|In this group you will not receive any study medication. You will be able to receive any treatments available to individuals in the jail or prison who are not in the study. Trained study staff at the first two visits will provide counseling focusing on relapse and overdose prevention, treatment engagement, and navigating re-entry challenges.
11079481|NCT04219527|Experimental|Dual-Target injection|Corticosteroid injection into the subacromial bursa and biceps tendon
11079482|NCT04219501|No Intervention|Control Group|Subjects presenting for PVC/VT ablation will undergo ablation procedures using standard of care invasive electroanatomical mapping systems.
11079483|NCT04219501|Experimental|VIVO Arm|Subjects presenting for PVC/VT ablation, that have a previously acquired cardiac CT/MRI scan or are having a cardiac CT/MRI scan as per routine care, will undergo ablation procedures using VIVO, a novel, non-invasive mapping system.
11079484|NCT04219488|Experimental|Neuromobilization group|The neuromobilization group received a supervised home program plus radial nerve mobilization. Radial nerve mobilization exercises were performed by the physiotherapist for 3 days a week for 3 weeks. The patients in the neuromobilization group also performed self-neuromobilization exercises at home for 6 weeks. Supervised home program including patient education and eccentric exercises was administered three times daily for 6 weeks.
11079485|NCT04219488|Active Comparator|Control group|The control group received a supervised home program. Supervised home program including patient education and eccentric exercises was administered 3 times a day for 6 weeks.
11079486|NCT04219475||GBM patients|Newly diagnosed patients above 18 years of age with GBM receiving standard of care, i.e., maximal surgical resection possible followed by radiation therapy (RT) plus temozolomide (TMZ) therapy and maintenance TMZ.
11079487|NCT04219462|Active Comparator|study group|twenty men receive extracorporeal shock wave (ESWT) twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura +sildenafil 5mg once daily for 3 months.
11079488|NCT04219462|Sham Comparator|control group|twenty men will receive sham treatment underwent identical therapy with Extracorporal shock wave therapy (ESWT) application with a similar appearance and sound as the active low intensity extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
11079489|NCT04219449||study group|Diagnosed beta-thalassemia patients at Assiut University Hospital.
11079490|NCT04219436|Active Comparator|periosteal suturing technique|periosteal suture is done to close the flap
11079491|NCT04219436|Active Comparator|figure of eight suturing technique|figure of eight suture is done to close the flap
11079492|NCT04219423|Experimental|multimodal physical therapy|The multimodal intervention is 75 minutes in duration and meets two days per week for two weeks, then once per week for six weeks, followed by weekly phone calls to determine adherence to home-exercise program (HEP) for four weeks. The total duration of the intervention is twelve weeks. The intervention will be led in a group format with a ratio of one physical therapist to two participants and groups never exceeding 4 participants. All verbal and written communications in the intervention will be conducted in Spanish. The multimodal intervention consists of progressive lower extremity strengthening training targeting the quadriceps and gluteal groups in both legs, progressive stationary bicycle exercise, self-management training and education, manual therapy and home exercise program (HEP) instruction. Participants are asked to do their strengthening exercises at least three days per week for the 12-week study duration including sessions in the clinic
11079493|NCT04219410||Cases|Patients who underwent minimally invasive esophagectomy with this novel procedure at Kaiser Permanente, Northern California, Oakland Medical Center
11079494|NCT04219397|No Intervention|Control|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol. There will be no interventions provided. They will receive a follow up phone call survey and be asked to return a completed medication education calendar that is provided as a part of usual APS care.
11079495|NCT04219397|Experimental|Medication take back education intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive a standardized education intervention. This intervention will educate patients and their families about medication take back programs, and will provide tailored directions to the closest medication take back center from their home, and also an option for medication take back that is located in close proximity to Riley Hospital clinics.
11079496|NCT04219397|Experimental|Home disposal kit intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive standardized education about how to use the medication home disposal kit : Dispose Rx(r), and they will be instructed to use this kit to dispose of any left over opioid medications that they may have after they have competed therapy for pain management at home.
11079497|NCT04219384||Critical-illness related cardiac arrest (CIRCA)|Those experiencing a critical illness-related cardiac arrest in a participating adult, general ICU
11079498|NCT04219371||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
11079499|NCT04219358|Active Comparator|Placebo & Standard Treatment|
11079500|NCT04219358|Experimental|Imiquimod 5% & Standard Treatment|
11079501|NCT04219358|Experimental|Imiquimod 0.05% & Standard Treatment|
11079502|NCT04219358|Experimental|Imiquimod nanoencapsulated 0.05% & Standard Treatment|
11079503|NCT04219345|Active Comparator|Active group|In the group A will be administered anodic tDCS and instructed in mindfulness practices.
11079504|NCT04219345|Sham Comparator|Sham group|In the group B will be administered sham tDCS and instructed in mindfulness practices.
11079505|NCT04219332|Experimental|Subserosal injection of indocyanine green tracer group|Subserosal injection, with a concentration of 0.5 mg / ml, 3 points for each size, 2 ml for each point.
11079506|NCT04219332|Active Comparator|Submucosal injection of indocyanine green tracer group|Submucosal injection, concentration of 1.25mg / ml, four points around the lesion, each point 1ml.
11079507|NCT04219319|Experimental|LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T-cell lym|An open label, single center, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T-cell lymphoma.
11079508|NCT04219306|Experimental|Machine alert|These cardiac suspected cardiac arrest will have had an alert generated by the machine learning model in addition to standard Emergency Medical Services response.
11079509|NCT04219306|No Intervention|Usual care|These suspected cardiac arrests will receive standard Emergency Medical Services response.
11079510|NCT04219293|Other|Microneedling with NO PRP|Patient will receive Standard of Care micro needling on randomized side of the face.
11079511|NCT04219293|Active Comparator|Microneedling WITH PRP|Patient will receive Standard of care microneedling with PRP on randomized side of the face.
11079512|NCT04219280|Active Comparator|Quillivant XR|Once-daily, long-lasting MPH solution with the following dosing schedules: 10mg/20mg/30mg/40mg for children 20-25kg, 20mg/30mg/40mg/50mg for children 26-30kg, and 20mg/33mg/46mg/60mg for children > 30 mg.
11079513|NCT04219280|Placebo Comparator|Placebo|Liquid-based suspension to match the color and banana-flavor of Quillivant XR.
11079514|NCT04219267|Experimental|The intervention group|Character strengths-based intervention, 3 hours every week for four weeks
11079515|NCT04219267|Placebo Comparator|The control group|Early memories for placebo control, 3 hours every week for four weeks.
11079516|NCT04219254|Experimental|BI-1206|BI-1206 administrated IV with a starting dose of 1 mg/kg every third week using mTPI2 Design in escalation Phase I. RP2D to be used i Phase IIa.
11079517|NCT04219241|Experimental|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
11079518|NCT04219228||Students in urban counties|All first-grade students in urban counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
11079519|NCT04219228||Students in rural counties|All first-grade students in rural counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
11079520|NCT04219215|Experimental|HBO|Patients with T2D receive an 2 hour treatment with 100 % oxygen in a hyperbaric chamber
11079521|NCT04219215|Experimental|Ambient Air|Patients with T2D receive an 2 hour treatment with 21% oxygen in a hyperbaric chamber
11079522|NCT04219202|Active Comparator|Proton Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment
11079523|NCT04219202|Experimental|Carbon Ion Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment
11079524|NCT04219189|Experimental|Vaping to Non-vaping Group|Participants in this arm will undergo the vaping condition during the first visit and the non-vaping condition during the second visit.
11079525|NCT04219189|Experimental|Non-vaping to Vaping Group|Participants in this arm will undergo the non-vaping condition during the first visit and the vaping condition during the second visit.
11079526|NCT04219163|Experimental|CLL-1.CAR|Group A
11079527|NCT04219150|Experimental|Electrical cardiometry (EC)|
11079528|NCT04219150|Experimental|"Fluid and Catheter Treatment Trial FACTT Lite"|
11079529|NCT04219137||Localized Esophagogastric Adenocarcinoma|Patients diagnosed with gastroesophageal adenocarcinoma who will undergo surgical resection for curative intent, with or without neo-adjuvant chemotherapy or chemoradiotherapy.
11079530|NCT04219137||Metastatic Esophagogastric Adenocarcinoma|Patients diagnosed with de novo metastatic gastroesophageal adenocarcinoma who will undergo platinum based first line chemotherapy.
11079531|NCT04219124|Active Comparator|Dapagliflozin|Investigational product: Dapagliflozin 10 mg Dosage form and strength: Green, plain, diamond shaped, film coated 10 mg tablet with frequency of 1 tablet per day for 4 weeks
11079532|NCT04219124|Placebo Comparator|Placebo|Investigational product: Matching placebo for Dapagliflozin 10 mg. Dosage form and strength: Green, plain, diamond shaped, and film coated tablet with frequency of 1 tablet per day for 4 weeks
11079533|NCT04219098|Experimental|Treatment|Butterfly IQ utilized to inject 10cc prior to surgery the remainder after incision
11079534|NCT04219098|Active Comparator|Control|Entire injection will be given after initial incision is made.
11079535|NCT04219085|Active Comparator|Routine Care|Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
11079536|NCT04219085|Experimental|Continuous Glucose Monitor|Monitoring of control of gestational diabetes with use of a continuous glucose monitor
11079537|NCT04219046|Experimental|Experimental Treatment|ERAS program with administration of experimental treatment: Naloxegol 25mg administrated once daily from surgery for up to 7 days
11079538|NCT04219046|Placebo Comparator|Placebo|ERAS program with administration of placebo: Placebo administrated once daily from surgery for up to 7 days
11079539|NCT04219033||with postoperative cognitive dysfunction|
11079540|NCT04219033||without postoperative dysfunction|
11079541|NCT04219020||Children with a CP diagnosis|"Children younger than 18 years with a CP diagnosis. Intervention will be determined later based on baseline results. Self- and/or proxy-reported survey and/or participation in interviews.
~Parents of all participants will provide proxy report. Children with CP > 8 years of age and cognitively able (approx. 50%) will provide self-report."
11079542|NCT04219020||Controls|Siblings (12-17 years) of children with cerebral palsy. No intervention, self-reported survey.
11079543|NCT04219020||Health Care Professionals|Health Care Professionals identified as providers of pain care. No intervention, interview participants
11079544|NCT04219007|Experimental|Genetic Short Stature|"Vosoritide, also known as BMN 111 or modified recombinant human C-type natriuretic peptide (CNP), is a 39-amino-acid peptide analog that includes the 37 C-terminal amino acids of the human CNP53 sequence plus the addition of 2 amino acids (Pro-Gly) on the N-terminus. This structural modification conveys resistance to neutral endopeptidase (NEP) degradation, resulting in prolonged half-life (t1/2) in comparison to endogenous CNP. This increase in t1/2 allows once daily subcutaneous (SC) administration.
~Vosoritide will be administered as a single 15 μg/kg subcutaneous injection given daily for 12 months."
11079545|NCT04218994|Experimental|Group A|Subjects instructed on flossing technique.
11079546|NCT04218994|No Intervention|Group B|No instructions for flossing provided. Subjects asked to continue their normal oral hygiene care.
11079547|NCT04218981|Experimental|Schizophrenia group|"Schizophrenia was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks
~Choose one of the antipsychotics drugs treatment( olanzapine, risperidone, aminosulpiride) according to the patient's condition"
11079548|NCT04218981|Experimental|Bipolar disorder group|"Bipolar disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks
~Choose one of the mood stabilizer drugs treatment( lithium, valproate) according to the patient's condition"
11079549|NCT04218981|Experimental|Major depressive disorder group|"Major depressive disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks
~Choose paroxetine treatment"
11079550|NCT04218981|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
11079551|NCT04218968|Experimental|carvedilol therapy|
11079552|NCT04218955||1|Asking parents if they can accept staining from treat their children by silver Diamine Flouride or Not
11079553|NCT04218942|Experimental|Prospective non randomised feasibility study|
11079554|NCT04218929|Experimental|Study Formula (SF)|New infant formula for term infants
11079555|NCT04218929|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
11079556|NCT04218929|No Intervention|Human Milk Reference Group|Human milk
11079557|NCT04218916|Experimental|Rhodiola Rosea Capsule|
11079558|NCT04218916|Placebo Comparator|Placebo Capsule|
11079559|NCT04218903|Experimental|Combined Training 4 times per week (CT4)|The CT4 group will perform four sessions per week of combined exercise program. This intervention will last 12 weeks.
11079560|NCT04218903|Active Comparator|Combined Training 2 times per week (CT2)|The CT2 group will perform two sessions per week of combined exercise program. This intervention will last 12 weeks.
11079561|NCT04218890||SLE patients without lupus nephritis|"40 SLE patients
~40SLE patients( All SLE pt. satisfied the ACR criteria for SLE diagnosis) these patients will be without any evidences of nephritis"
11079562|NCT04218890||SLE patients with lupus nephritis|40SLE patients with evidences of nephritis
11079563|NCT04218890||healthy control group|20 healthy subjects matched age and sex with be enrolled as healthy control group
11079564|NCT04218877||Children with atopic dermatitis|Children 1-3 years old with atopic dermatitis
11079565|NCT04218877||Children without atopic dermatitis|
11079566|NCT04218877||Children with genetic predisposition|Children with genetic predisposition to atopic dermatitis, but without manifestations
11079567|NCT04218864|Experimental|Strength for U in Relationship Empowerment (SURE)|Theory-driven and derived from empirical support
11079568|NCT04218864|Active Comparator|Attention, time, and information matched control|Well-validated
11079569|NCT04218851|Experimental|Posaconazole|On Day 1 participants will receive two treatments of Posaconazole (POS)) 6 mg/kg body weight by intravenous (IV) infusion; on Days 2 through 7 participants will receive POS 6 mg/kg body weight once daily by IV infusion; beginning at Day 8 up to Day 84, participants may transition to receiving an oral formulation, or they may remain on an IV formulation
11079570|NCT04218838|Active Comparator|CornerLoc SI Joint Stabilization Group|Patient will receive the CornerLoc minimally invasive SI Joint Stabilization procedure. This procedure will be performed in an outpatient surgery center under local sedation or general anesthesia, and normally takes around 45 minutes. During the procedure, the physician will make two small incisions in the patient's lower back to access the SI joint, and place four small cadaveric bone grafts into the SI joint to help stabilize the SI joint.
11079571|NCT04218838|Active Comparator|SI Joint Steroid Injections Group|Patient will receive an injection of steroid medication directly into their SI joint. The area around the SI joint will be numbed with an injection of local anesthetic and then ultrasound guidance will be used to guide the needle of steroid medication directly into the SI joint. This procedure will be performed in the physician's office or an outpatient surgery center, and normally takes around 30 minutes.
11079572|NCT04218825|Experimental|Adult patients with early stage MF-CTCL (stage IA-IB)|Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.
11079573|NCT04218812|Active Comparator|No electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data without ESI
11079574|NCT04218812|Experimental|Automated Electrical source imaging (ESI)|The multidisciplinary teams take decisions based on considering all data with ESI
11079575|NCT04218799|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|
11079576|NCT04218786|Active Comparator|Colchicine Group|This group will receive low dose colchicine, 0.5 mg.
11079577|NCT04218786|Placebo Comparator|Placebo group|This group will receive a placebo drug with a similar shape and mass as that to experimental drug
11079578|NCT04218773|Experimental|Induced hypertension|The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
11079579|NCT04218760|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.
11079580|NCT04218747|Experimental|VA 365 Demonstration Benefits|Children in treatment schools received: (1) three meals during the school day and food packages for weekends and school breaks; (2) $60 monthly Electronic Benefit Transfer (EBT) benefits during summer months if they were eligible for FRP meals; and (3) nutrition education for their parents.
11079581|NCT04218747|No Intervention|Control Group|"Schools in the control group operated under business as usual."
11079582|NCT04218734|Experimental|metformin hydrochloride+DBPR108|metformin hydrochloride 500 mg+DBPR108 100 mg
11079583|NCT04218734|Placebo Comparator|metformin hydrochloride+placepo|metformin hydrochloride 500 mg+placebo 100 mg
11079584|NCT04218721|Experimental|eHealth application|Participants get access to the eHealth application InvolveMe
11079585|NCT04218708|Active Comparator|counseling + nicotine replacement therapies NRT|A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (NRT). Participants will also receive their NRT to last them to the following visit based on their baseline smoking.
11079586|NCT04218708|Active Comparator|Counseling + Standardized Research E-cigarettes (SREC)|Participants in the SREC arm to practice using the SREC and give them instructions to return with their SREC and used refill tanks on every visit. A research assistant (RA) trained in motivational interviewing and qualitative methods will support the PI to deliver counseling sessions and conduct interviews. Briefly, during each visit, with help of the RA, participants will provide exhaled CO and saliva cotinine test, and complete surveys in REDCAP using a tablet, allowing programmed logic checks and skip patterns to minimize burden. The RA will also deliver brief motivational counseling tailored to the participant's readiness to quit and arm in the study (SREC). Participants will also receive their SREC to last them to the following visit based on their baseline smoking.
11079587|NCT04218695|Experimental|Treatment|1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
11079588|NCT04218695|Placebo Comparator|Placebo|Normal saline (50cc) once daily for up to one week or until end of hospitalization
11079589|NCT04218682|Experimental|Immediate Game Use|AYACS randomly assigned to this arm will immediately play the Shadow's Edge Game following enrollment for a duration of 7 weeks. Following the designated 7-week game-play period, they will continue to have access to the game. They will continue to receive all usual care health care throughout and following the study.
11079590|NCT04218682|No Intervention|Wait-List Comparison Group|AYACS randomly assigned to this arm will begin to play the Shadow's Edge game 7 weeks following enrollment. They will continue to receive all usual health care throughout and following the study.
11079591|NCT04218669|Active Comparator|T-tube drainage|The T-tube was placed for biliary drainage
11079592|NCT04218669|Experimental|Roux-en-Y Hepaticojejunostomy|biliary-enteric anastomosis was performed
11079593|NCT04218656|Experimental|Group A|165 patients with intermittent claudication
11079594|NCT04218656|Experimental|Group B|165 patients with critical limb ischemia with pain at rest and/or foot ulcers
11079595|NCT04218643|Active Comparator|Standard technique|Intravenous catheter inserted via standard technique
11079596|NCT04218643|Experimental|Ultrasound-guided technique|Intravenous catheter inserted via ultrasound guidance
11079597|NCT04218630|Experimental|Reformer pilates group|All participants were informed about the reformer machine and the treatment program by the physiotherapist in reformer pilates group. Reformer pilates exercises were applied in the form of general muscle strengthening and flexibility exercises under the supervision of physiotherapist. Exercises were performed in 2 times a week for 6 weeks. The duration of one session was 60 minutes.
11079598|NCT04218630|Active Comparator|Home mat pilates group|In home mat pilates group, clinical pilates exercises were applied as a home program. Brochures and exercise follow-up forms, which illustrated and written all the exercises in this program, which consisted of clinical pilates-based general muscle strength and flexibility exercises, were given to all participants in this group. Exercises were performed in 2 times a week for 6 weeks at home. Participants marked the follow-up form when they performed exercises. Attendance of participants to exercise was checked by phone calls.
11079599|NCT04218617|Experimental|Arm 1 - Single fraction|sSRS 18 Gy in 1 fraction
11079600|NCT04218617|Active Comparator|Arm 2 - Two fraction|sSRS 24 Gy in 2 fractions
11079601|NCT04218604|Experimental|Personalized AF ablation using MDCT-derived LAWT|Pre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness < 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; > 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is > 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.
11079602|NCT04218591|Active Comparator|PRP|Intra-articular injection PRP
11079603|NCT04218591|Placebo Comparator|Saline|Intra-articular injection Saline
11079604|NCT04218578||Device group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with MitraClip
11079605|NCT04218578||Control group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with optimal medical treatment
11079606|NCT04218565|Experimental|Golimumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
11079607|NCT04218552|Experimental|Experimental 1|AD-209 High
11079608|NCT04218552|Experimental|Experimental 2|AD-209 Middle
11079609|NCT04218552|Experimental|Experimental 3|AD-209 Low
11079610|NCT04218552|Active Comparator|Active Comparator 1|Amlodipine Low
11079611|NCT04218552|Active Comparator|Active Comparator 2|Amlodipine High
11079612|NCT04218552|Active Comparator|Active Comparator 3|Telmisartan
11079613|NCT04218552|Placebo Comparator|Placebo comparator|Placebo
11079614|NCT04218539|Experimental|Placebo/Placebo|Subjects will receive a dose of placebo, followed by a dose of placebo approximately 7 days later.
11079615|NCT04218539|Experimental|Placebo/Psilocybin|Subjects will receive a dose of placebo, followed by a dose of psilocybin approximately 7 days later.
11079616|NCT04218539|Experimental|Psilocybin/Placebo|Subjects will receive a dose of psilocybin, followed by a dose of placebo approximately 7 days later.
11079617|NCT04218539|Experimental|Psilocybin/Psilocybin|Subjects will receive a dose of psilocybin, followed by a dose of psilocybin approximately 7 days later.
11079618|NCT04218526|Experimental|Vercise DBS Group|All participants will have the Vercise DBS system implanted.
11079619|NCT04218513|Experimental|Compound Edaravone|30 mL (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg)
11079620|NCT04218513|Experimental|Edaravone|30 mL (containing edaravone 30 mg)
11079621|NCT04218513|Experimental|2-Aminoethanesulfonic Acid|30 mL (containing 2-aminoethanesulfonic acid 600 mg)
11079622|NCT04218500|Active Comparator|Niacinamide 4%|Niacinamide 4%, applied twice daily for 28 days
11079623|NCT04218500|Active Comparator|Virgin coconut oil 30%|Virgin coconut oil 30%, applied twice daily for 28 days
11079624|NCT04218487|Experimental|XFZY group|2.4g (6 capsules) three times daily for 12 weeks
11079625|NCT04218487|Placebo Comparator|Control group|2.4g (6 capsules) three times daily for 12 weeks
11079626|NCT04218474|Other|patient lost sensation ant half of lower lip|patient with injured inferior alveolar nerve at one side
11079627|NCT04218448|No Intervention|Somatosensory evoked potentials without hypnorelaxation|"As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination.
~Somatosensory evoked potentials are carried out according to the usual management."
11079628|NCT04218448|Experimental|Somatosensory evoked potentials with hypnorelaxation|As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination. Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes. The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of suggestions and metaphors. The protocol is adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. The investigator, thanks to hypnosis, allows the development of a creative imagination which allows a modification of the relation to space and time.
11079661|NCT04218240|Experimental|PGB/LFX;|0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
11079662|NCT04218240|Active Comparator|Lofexidine and PLACEBO|0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
11079776|NCT04217551|Experimental|6 hours - non shockable|Participants with non-shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
11079869|NCT04216927|Placebo Comparator|Oxygen|Standard CPB without NO administered at any point intraoperatively
11079629|NCT04218435||Observational|"Sacubitril/valsartan is a combination of a neprilysin inhibitor, sacubitril and an angiotensin II receptor blocker, valsartan.
~The recommended starting dose is one 49/51 mg (sacubitril/valsartan) tablet twice-daily. Double the dose of Sacubitril/valsartan after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.
~Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for:
~Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
~Patients with severe renal impairment (CrCl less than 30 ml/min)
~Patients with moderate hepatic impairment. (Child Pugh B) Double the dose of Sacubitril/valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient"
11079630|NCT04218422|Experimental|Treatment|2 treatments of battlefield acupuncture to the bilateral ears spaced one week apart
11079631|NCT04218422|Sham Comparator|Control|2 treatments with sham acupuncture to the bilateral ears at acupuncture points not associated with pain relief (2 liver and 1 stomach)
11079632|NCT04218409|Active Comparator|oxycodone+oxytocin|Combined effects of oxycodone and oxytocin
11079633|NCT04218409|Active Comparator|oxycodone+placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
11079634|NCT04218409|Active Comparator|oxytocin+placebo|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo
11079635|NCT04218409|Sham Comparator|placebo+placebo|Serves as the control
11079636|NCT04218396|Experimental|Standard Treatment, Then Virtual Reality + Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment only. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment AND virtual reality
11079637|NCT04218396|Experimental|Virtual Reality + Standard Treatment, Then Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment AND virtual reality. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment only.
11079638|NCT04218383|Active Comparator|Experimental: Active Left OFC Group|2mA will be applied for 20 minutes with the tDCS anode applied to the left OFC and Cathode applied to the right primary motor cortex.
11079639|NCT04218383|Sham Comparator|Sham Comparator: Sham left OFC Group|Current will be ramped up for 30s followed by a 30s ramp down to mimic the physical sensation of stimulation and habituation. The anode placed over the left OFC and cathode placed over the right primary motor cortex.
11079640|NCT04218370|Active Comparator|Conventional|Thrice-weekly intermittent dialysis until pre-specified criteria for recovery are met
11079641|NCT04218370|Experimental|Conservative|Conservative dialysis strategy--dialysis prescribed only when specific metabolic or clinical indications are met. These indications are: blood urea nitrogen >112 mg/dL (40 mmol/L; blood potassium concentration >6 mmol/L; blood potassium concentration >5.5 mmol/L despite medical treatment; arterial blood gas pH <7.15, or in the absence of an available blood gas, serum bicarbonate <12 mmol/L, acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min or equivalent via face mask/tracheostomy mask to maintain SpO2 >95% or requiring FiO2 >50% in patients with tracheostomy already on invasive or non-invasive mechanical ventilation and despite diuretic therapy; clinician judgement
11079642|NCT04218357|Experimental|Probenecid|2g probenecid, one pill by mouth once, for one day
11079643|NCT04218357|Placebo Comparator|matching placebo|Placebo, one pill by mouth once, for one day
11079644|NCT04218344||Acute Coronary Syndrome - Iscaemia|Patients who present with chest pain, undergo emergency angiogram and receive a cardiac stent.
11079645|NCT04218344||Acute Coronary Syndrome - Non-Ischaemic|Patients who present with chest pain but angiography reveals normal coronary arteries.
11079646|NCT04218331|Experimental|JASPER only|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
11079647|NCT04218331|Active Comparator|JASPER + PROMPT|This group will consist of the child and therapist having one-on-one, JASPER sessions plus Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT), twice a week.
11079648|NCT04218318|Active Comparator|Low-threshold group|Neonates in the low-threshold group phototherapy will be stopped if TSB reached ˃100 µmol/L below the AAP phototherapy threshold.
11079649|NCT04218318|Active Comparator|High-threshold group|Neonates in high-threshold group phototherapy will be ceased if TSB level is 50-100 µmol/L below the appropriate AAP phototherapy threshold.
11079650|NCT04218305||The first group|Include One hundred patients with type 2 diabetes mellitus with average body mass index.
11079651|NCT04218305||The second group|Include One hundred patients whose body mass index is 30 or over without diabetes.
11079652|NCT04218305||The third group|Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.
11079653|NCT04218305||The fourth group|Include One hundred apparently healthy adult person as a control.
11079654|NCT04218279|Experimental|Sleep Health Education|At baseline, the experimental group will have immediate access to 10 brief education modules focused on diverse elements of sleep health and fatigue.
11079655|NCT04218279|Active Comparator|Wait List Control|At 3 months after baseline, the wait-list control group will be provided access to the 10 education modules focused on diverse elements of sleep health and fatigue..
11079656|NCT04218266|Experimental|BAY2433334 50mg+Apixaban matching placebo|
11079657|NCT04218266|Experimental|BAY2433334 20mg+Apixaban matching placebo|
11079658|NCT04218266|Active Comparator|BAY2433334 matching placebo+Apixaban|Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
11079659|NCT04218253|Experimental|nutritional intervention|300 or 500 calories nutritional support before operation according to the level of malnutrition
11079660|NCT04218253|Other|control group|Dietary education was conducted according to preoperative nutritional requirements
11079963|NCT04216147|Experimental|Surgery group|Patients received surgery for median nerve release.
11079663|NCT04218227||Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
11079664|NCT04218227||Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
11079665|NCT04218227||Self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
11079666|NCT04218227||Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
11079667|NCT04218227||Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
11079668|NCT04218214||LIFE-DM Group|The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.
11079669|NCT04218201|Experimental|Subthreshold Opioid Use Disorder Prevention(STOP) Intervention|"Participants will receive the intervention components of brief advice from their PCP and a video doctor at the baseline primary care visit, printed educational materials, interaction with the NCM, and telephone health coaching. Patient participants in the STOP arm will receive brief advice at the baseline primary care visit, consisting of PCP-delivered counseling and viewing a video doctor and receive an educational pamphlet about opioid overdose prevention and an introduction to the role of the NCM and telephone health coaches. Brief advice will be delivered by the patient participant's PCP as part of the medical visit. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the RA or clinical staff. Following the PCP encounter, and before completing the post-visit assessments or leaving the clinic, patient participants will meet with the RA to view a video on tablet or desktop computer that reinforces the PCP's counseling."
11079670|NCT04218201|No Intervention|Enhanced Usual Care (EUC)|PCPs will conduct primary care as usual, without the support of the NCM. At the baseline visit, patient participants receive an educational pamphlet and view a short video on overdose and cancer screening. The pamphlet includes information about preventing opioid-related overdose, including how to obtain a naloxone kit. The video content will feature the health benefits of exercise. It will be viewed on a tablet or desktop computer and will be approximately 2 minutes long. All EUC patient participants receive the same video, which is not tailored to the responses given on their questionnaires. There is no study intervention after the baseline visit.
11079671|NCT04218175|Experimental|neuromobilization stretching group|In the neuromobilization stretching group; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed.
11079672|NCT04218175|Experimental|neuromobilization shifting group|In the neuromobilization shifting group, the subjects were brought to shoulder depression and 90 degrees of abduction while the dominant forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side. Thus, the participants performed median nerve shift.
11079673|NCT04218175|No Intervention|Control Group|The dominant sides of the individuals are experimental sides and the other nondominant sides of the participants are control sides. And no intervention was made. All measurements were done bilaterally before and after.
11079674|NCT04218162|Experimental|Lasmiditan 50mg|
11079675|NCT04218162|Experimental|Lasmiditan 100mg|
11079676|NCT04218162|Placebo Comparator|Placebo|
11079677|NCT04218149|Active Comparator|Group S|Serratus plane block with 25 ml %0.25 bupivacaine
11079678|NCT04218149|Active Comparator|Grup E|Erector spinae plane block with 25 ml %0.25 bupivacaine
11079679|NCT04218136||patient with head and neck cancer|Patients treated by standard treatment and have a minimum of 4 blood samples.
11079680|NCT04218123|Experimental|Venlafaxine Arm|
11079681|NCT04218123|Placebo Comparator|Placebo|
11079682|NCT04218110|Experimental|Project X 26ml|3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 26ml volume. Single use.
11079683|NCT04218110|Experimental|Project X 10.5ml|3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 10.5ml volume. Single use.
11079684|NCT04218110|Experimental|Project X 5.1ml|3.15% w/v CHG/70% v/v IPA contained within a saturated at use applicator. 10.5ml volume. Single use.
11079685|NCT04218110|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG/70% v/v IPA contained within pre-saturated applicator. 5.1ml volume. Single use.
11079774|NCT04217551|Experimental|60 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079686|NCT04218097||Addict patients|"Obese type 2 and 3 with food addict according to the Yale Food Addiction Scale (YFAS) questionnaire.
~Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
11079687|NCT04218097||Control patients|"Obese type 2 and 3, non food addict Cohort design: identification of patients treated in hospital for obesity assessment over the period 1 January 2017 to 1 January 2018 whose addictive or non-addictive status was characterised by the YFAS questionnaire. To talk about food addiction, the person must have at least 3 out of 7 positive criteria AND also meet the marked suffering criterion."
11079688|NCT04218084|Experimental|Voxelotor|Voxelotor 1500mg or equivalent daily as a tablet or as powder for oral suspension.
11079689|NCT04218084|Placebo Comparator|Placebo|Matching placebo.
11079690|NCT04218071|Experimental|9-ING-41|9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
11079691|NCT04218071|Experimental|9-ING-41 plus Ruxolitinib|9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
11079692|NCT04218058|Active Comparator|study (ultrasound guided closed reduction of zygomatic arch))|reduction of zygomatic arch guided by ultrasound
11079693|NCT04218058|Active Comparator|control (open reduction of zygomatic arch)|open reduction of zygomatic arch through coronal incision
11079694|NCT04218045|Active Comparator|Laparoscopic sleeve gastrectomy group|The group of morbidly obese patients undergoing laparoscopic sleeve gastrectomy
11079695|NCT04218045|Experimental|SASI bypass group|The group of morbidly obese patients undergoing laparoscopic single- anastomosis sleeve ileal bypass (the new procedure being evaluated)
11079696|NCT04218032|Experimental|blood pressure|blood pressure is measured from the participants, by using two methods. A new developed device and a reference device. The new device measures, using oscillometry, the blood pressure from the finger tip. The reference device is a standard sphygmomanometer.
11079697|NCT04218019|Experimental|Early Tumor Treating Fields (TTFields, Optune®) treatment|TTF will be started together with hypofractionated radiotherapy (+/- 5 days) with or without Temozolomide (according to the standard and local physician's decision). Chemoradiotherapy with temozolomide and hypofractionated radiotherapy is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator.
11079698|NCT04218019|Active Comparator|Late TTF treatment|Patients will be treated with hypofractionated radiotherapy with or without temozolomide (according to the local standard and physician's decision). Radiotherapy and treatment with temozolomide is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator. Late TTFields treatment will start 4 weeks after the end of radiotherapy.
11079699|NCT04217993|Experimental|Jaktinib hydrochloride tablet 100mg twice a day.|This is the dose group was given Jaktinib hydrochloride 100mg （2 tablets）dose group for twice a day.
11079700|NCT04217993|Experimental|Jaktinib hydrochloride tablet 150mg once a day|This is the dose group was given Jaktinib hydrochloride 150mg （3 tablets）dose group for once a day.
11079701|NCT04217993|Experimental|Jaktinib hydrochloride tablet 100mg once a day|This is the dose group was given Jaktinib hydrochloride 100mg （2 tablets） dose group for once a day
11079702|NCT04217980|Experimental|Lung ultrasonography (LUS) group|Group 1: Lung ultrasonography is performed as the main (first) pulmonary image test
11079703|NCT04217980|Active Comparator|Chest X ray (CXR) group|Group 2: Chest X ray is performed as main (first) pulmonary image test
11079704|NCT04217967|Active Comparator|Lenalidomide group|lenalidomide 25mg qod d1~21 days, rest 7 days
11079705|NCT04217967|Active Comparator|Ixazomib group|ixazomib 4mg orally, once a week, 3 times a month
11079706|NCT04217967|Experimental|Combination group|ixazomib 4mg orally, once a week, 3 times a month lenalidomide 25mg qod d1~21 days, rest 7 days use in combination
11079707|NCT04217954|Experimental|OXA, 5-FU and Bev plus Toripalimab|the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab
11079708|NCT04217941|Active Comparator|Health Education with practical demonstration|Participants assigned to the intervention arm received health education with practical demonstration of nasal spray and intranasal ointment .
11079709|NCT04217941|Placebo Comparator|Health education without practical demonstration|Participants assigned to the control arm received only health education regarding nasal spray and intranasal ointment .
11079710|NCT04217928|Active Comparator|Arthroscopic Debridement|Patients who are randomized into this arm will receive arthroscopic debridement
11079711|NCT04217928|Active Comparator|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Patients who are randomized into this arm will receive arthroscopic hemi-trapeziectomy with mini tightrope
11079712|NCT04217902||People living with diabetes in Grenoble and Lyon areas|Eligible patients with type 1 or type 2 diabetes 1) during or after hospitalization for decompensation, ketoacidosis, or other emergency or elective interventions such as insulin pump installation, 2) followed in routine care in specialized diabetes services, 3) participating in patient associations.
11079713|NCT04217902||Health care professionals working in diabetes care in Grenoble|Health care professionals working with diabetes care in specialized services or ambulatory care.
11079714|NCT04217889||Adherent patient|This group is composed of adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
11079715|NCT04217889||Not-adherent patient|This group is composed of not-adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
11079775|NCT04217551|Experimental|72 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079839|NCT04217187|Experimental|Electrical Stimulation Group|This arm will receive neuromuscular electrical stimulation to the antagonist muscles of the upper extremity.
11079716|NCT04217876||Clinically suspected infarct-like acute myocarditis|Diagnosis of infarct-like AM was based on five criteria: (a) history of flu-like symptoms within 8 weeks prior admission; (b) new onset of symptoms such as fatigue/breathlessness, chest pain, mild dyspnea, and/or palpitation; (c) ischemic ECG pattern (ST-segment elevation and/or T-wave anomalies); (d) increase of inflammatory markers (non-high- sensitivity CRP > 8 mg/L and/or white blood cell count > 11.000/mm3) and cardiac enzymes; and (e) preserved global systolic function (EF > 50%). We excluded patients with New York Heart Association (NYHA) functional heart classifications II-IV, LVEF < 50% and those patients with electrocardiographic evidence of bradyarrhythmias (≥second-degree atrioventricular block) or tachyarrhythmias (ventricular or supraventricular arrhythmias).
11079717|NCT04217863|Experimental|The experimental intervention (GDP): It includes three writing|"Participants will be required to describe memories associated with traumatic event in a sequential order, with an objective and detached attitude
~They will be asked to describe
~Their opinion regarding the traumatic event and emotions perceived during the experience
~Its impact on their daily lives, and how it has altered their attitudes toward life.
~The actual situation will be focused, while reviving the whole traumatic event experience which aids in exploring the following aspects:
~Present thoughts and feelings regarding the traumatic experience, and also clarify the differences between the ones felt at the time of traumatic event in comparison to the current feelings.
~How much they understand and appreciate themselves for successfully dealing with the traumatic event
~To what extent the traumatic event has modified their vision, attitude, knowledge, and skills, and how it can help in their future;
~What will be their future reactions to other similar events."
11079718|NCT04217863|No Intervention|The control intervention:|A day prior to each writing session, the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet. Details regarding the inability to contact the subject will also be recorded in the patient form.
11079719|NCT04217850|Experimental|500 kcal Energy Deficit|The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
11079720|NCT04217837||Major Depressive Disorder|Participants who meet the DSM-5 clinical diagnostic criteria, in the opinion of the treating clinician, for primary diagnosis of unipolar, non-psychotic MDD.
11079721|NCT04217824|Active Comparator|karydakis flap|An asymmetric elliptical excision is performed, defective tissues between the lower and upper ends are removed until they reach healthy borders. The wound edge is then mobilized and the flap is slid over the corresponding wound edge by suturing to the fascia and the skin to the appropriate wound layers. Thus, the gluteal groove is lateralized. Subcutaneous tissue and skin are closed.
11079722|NCT04217824|Active Comparator|limberg flap|Rhomboid excision and pilonidal sinuses together with damaged tissue. On the right side of the patient, the intact skin is shifted to the medial area where the tissues are removed without tension. Thus, the defective part and gluteal groove are corrected.
11079723|NCT04217811||Late neutropenia|Neutrophil count < 1500
11079724|NCT04217811||No late neutropenia|Neutrophil count > 1500
11079725|NCT04217798|Experimental|Niparib combined with oral etoposide|Subjects will receive niraparib 200mg/day in combination with oral etoposide (50 mg/ day, on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be discontinued. Subjects will receive niraparib alone until disease progression, intolerable toxicity or withdrawal of informed consent.
11079726|NCT04217785|Active Comparator|A-AT eye drops|Optive Fusion UD eye drops + Genteal lubricant gel
11079727|NCT04217785|Active Comparator|B-UCS eye drops|UCS eye drops + GentTeal lubricant gel
11079728|NCT04217772|Experimental|Eyes post-lensectomy|Eyes of children after cataract surgery
11079729|NCT04217772|No Intervention|Healthy Eyes|Eyes of healthy volunteers
11079730|NCT04217759|Experimental|Intervention group|Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks via face-to-face sessions and social media tools (Facebook and WhatsApp)
11079731|NCT04217759|No Intervention|Control group|Control group only received leaflets on healthy lifestyle with no further guidance.
11079732|NCT04217746|Experimental|High flow nasal cannula (HFNC) group|The HFNC group will receive heated (approximately 37 ⁰C) and humidified (100% relative humidity) oxygenated gas delivered at high flow at 50L/min. Flow could be decreased to as low as 30L/min and temperature to 31 ⁰C as per patient's tolerance.
11079733|NCT04217746|No Intervention|Conventional flow nasal oxygen (CFNO) group|The conventional flow nasal oxygen (CFNO) group is the control group which will receive ambient temperature and non-humidified oxygen delivered at flow rates of up to 8L/min (standard care).
11079734|NCT04217733|Active Comparator|Mebeverine|Mebeverine 3 times daily for 3 months
11079735|NCT04217733|Experimental|Ethosuximide|Ethosuxemide 3 times daily for 3 months
11079736|NCT04217733|Experimental|Pentoxyifylline|pentoxyifylline 2 times daily for 3 months
11079737|NCT04217720|Experimental|SNS-301|SNS-301
11079738|NCT04217707|Other|Pre- and Post-Surgical Transgender Therapeutic Support Groups|
11079739|NCT04217694|Experimental|Prevention (memantine, CogState)|Patients receive memantine PO BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT.
11079740|NCT04217681|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
11079741|NCT04217681|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
11079742|NCT04217681|Experimental|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
11079743|NCT04217681|Experimental|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
11079744|NCT04217668|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day.
11079745|NCT04217655|Experimental|Low-dose computed tomography group|Patients undergo low-dose computed tomography-guided lung biopsy for lung nodule on day 1.
11079746|NCT04217655|Active Comparator|Standard-dose computed tomography group|Patients undergo standard-dose computed tomography-guided lung biopsy for lung nodule on day 1.
11079747|NCT04217642||Delay surgery|Patients who have passed more than 48 hours from admission to surgery
11079748|NCT04217629|Experimental|SY-005 single-dose 0.75mg|4 subjects will be envolved in this group and be injected with 0.75mg of SY-005.
11079749|NCT04217629|Placebo Comparator|SY-005 single-dose 2.5mg|This group will be intiated in healthy subjects at a 2.5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
11079750|NCT04217629|Placebo Comparator|SY-005 single-dose 5mg|This group will be intiated in healthy subjects at a 5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
11079751|NCT04217629|Placebo Comparator|SY-005 single-dose 10mg|This group will be intiated in healthy subjects at a 10mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
11079752|NCT04217629|Placebo Comparator|SY-005 single-dose 15mg|This group will be intiated in healthy subjects at a 15mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
11079753|NCT04217629|Placebo Comparator|SY-005 single-dose 20mg|This group will be intiated in healthy subjects at a 20mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
11079754|NCT04217629|Placebo Comparator|SY-005 multiple-doses 5mg|This group will be intiated in healthy subjects at a 5mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
11079755|NCT04217629|Placebo Comparator|SY-005 multiple-doses 10mg|This group will be intiated in healthy subjects at a 10mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
11079756|NCT04217629|Placebo Comparator|SY-005 multiple-doses 20mg|This group will be intiated in healthy subjects at a 20mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
11079757|NCT04217616||Headache Resistant Participants|Male participants who have never had a headache.
11079758|NCT04217616||Non-Resistant Participants|Male participants who have experienced headache. Age matched.
11079759|NCT04217603|Experimental|Group 1|This group will perform a 6MWT with CPAP
11079760|NCT04217603|Sham Comparator|Group 2|This group will perform a 6MWT with a sham-CPAP
11079761|NCT04217590|Experimental|Sodium Zirconium Cyclosilicate (SZC)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
11079762|NCT04217590|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
11079763|NCT04217577|Experimental|Dried Plums|Consume dried plums daily.
11079764|NCT04217564|Experimental|Intervention group|The intervention group will receive a counselling session then instructed on the subsequent follow up dates and final assessment by the end of the study.
11079765|NCT04217564|No Intervention|Control group|The control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study.
11079766|NCT04217551|Experimental|6 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
11079767|NCT04217551|Experimental|12 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
11079768|NCT04217551|Experimental|18 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
11079769|NCT04217551|Experimental|24 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079770|NCT04217551|Experimental|30 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079771|NCT04217551|Experimental|36 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079772|NCT04217551|Experimental|42 Hours - shockable|Participants with shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079773|NCT04217551|Experimental|48 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079777|NCT04217551|Experimental|12 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
11079778|NCT04217551|Experimental|18 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
11079779|NCT04217551|Experimental|24 hour - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079780|NCT04217551|Experimental|30 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079781|NCT04217551|Experimental|36 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079782|NCT04217551|Experimental|42 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079783|NCT04217551|Experimental|48 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079784|NCT04217551|Experimental|60 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079785|NCT04217551|Experimental|72 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
11079786|NCT04217538||EBH|
11079787|NCT04217525||Spinal Disorders|This group includes patients with any spinal deformity or disorder coming in for treatment.
11079788|NCT04217525||Spinal Tumors|This group includes patients with spinal tumors or metastasis of the spine, coming in for treatment.
11079789|NCT04217512|Active Comparator|Standard hydration alone|Cisplatin with standard hydration
11079790|NCT04217512|Active Comparator|Pantoprazole high dose|Cisplatin with standard hydration with pantoprazole 1.6 mg/kg
11079791|NCT04217512|Active Comparator|Pantoprazole Low dose|Cisplatin with standard hydration with pantoprazole 0.6 mg/kg
11079792|NCT04217499||Patients with pelvic ring fractures|This retrospective study will be carried out on the data of patients who have received treatment or followed for a pelvic ring fracture, in the Orthopedic Surgery department of the Paris Saint-Joseph Hospital Group between January 2015 and September 2019.
11079793|NCT04217486|Experimental|A - will be shown their photograph at 2 weeks post-operative.|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
11079794|NCT04217486|Active Comparator|B - will not be shown their photograph|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will not be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
11079795|NCT04217473|Experimental|TILT-123|"Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.
~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
11079796|NCT04217460|Active Comparator|Intervention for fluency difficulty (controls)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for controls.
11079797|NCT04217460|Experimental|Intervention for fluency difficulty (experimental)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for experimental group
11079798|NCT04217447|Active Comparator|Experimental group|Patients intaking full-dose OAC + ASA 100mg od
11079799|NCT04217447|Placebo Comparator|Control group|Patients intaking full-dose OAC + Placebo of ASA 100mg od
11079800|NCT04217434|Experimental|Group 300µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 300 µm fibre length will be used in continuous contact mode at a power setting of 1.5 to 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
11079801|NCT04217434|Experimental|Group 300µm in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes, 300 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 - 3 W. Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
11079802|NCT04217434|Experimental|Group 400µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
11079868|NCT04216927|Experimental|Nitric Oxide|Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care
11079803|NCT04217434|Experimental|Group 400µm in pulsed contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.
~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 t 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
11079804|NCT04217421|Active Comparator|Allopurinol|
11079805|NCT04217421|Placebo Comparator|Placebo|
11079806|NCT04217408|Experimental|ON stimulation followed by OFF stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of ON (active) stimulation, followed by 2 weeks of OFF (sham) stimulation
11079807|NCT04217408|Experimental|OFF stimulation followed by ON stimulation|All patients complete the same 52 week open-label phase with active stimulation. After this, they enter a blinded randomized crossover phase of 2 weeks of OFF (sham) stimulation, followed by 2 weeks of ON (active) stimulation
11079808|NCT04217395||Reinforced support: X-ailes program users|
11079809|NCT04217369|No Intervention|Control|A control arm. The participant will be given a version of the Diabits app without predictions of blood glucose enabled. They will then use the Diabits app as if they were using their usual companion app to manage their diabetes for the duration of the study.
11079810|NCT04217369|Experimental|Intervention|The intervention arm. The participants in this arm will be provided with a version of the Diabits app which provides predictions of where their blood glucose will be one hour into the future, based on historic data and user inputs. The participant will then manage their blood glucose using these predictions for the duration of the study.
11079811|NCT04217356||Hematopoietic stem cell transplant (HCT)|Standard of care hematopoietic stem cell transplant with a matched donor.
11079812|NCT04217356||Best available non-transplant therapies (BAT)|Standard of care treatment with a janus kinase (JAK) inhibitor drug called ruxolitinib or treatment with an antimetabolite drug called hydroxyurea.
11079813|NCT04217343||non-complement mediated pAMR(H+)|
11079814|NCT04217343||complement mediated pAMR(I+)|
11079815|NCT04217330|Experimental|Intervention|Pulmonary rehabilitation programs assigned to the intervention group will offer eligible participants the choice of participating in an 8-week program of either home-based pulmonary rehabilitation or traditional centre-based pulmonary rehabilitation.
11079816|NCT04217330|Active Comparator|Control|Pulmonary rehabilitation programs assigned to the control group will offer eligible participants the opportunity to participate in an 8-week centre-based pulmonary rehabilitation program, as per current practice.
11079817|NCT04217317|Experimental|CPI-613 in Combination with Bendamustine|CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.
11079818|NCT04217304|Experimental|Sonothrombolysis|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity® plus Sonothrombolysis
11079819|NCT04217304|No Intervention|Standard of Care|Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity®
11079820|NCT04217291|Experimental|SY-004-1|a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week
11079821|NCT04217291|Experimental|SY-004-2|a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.
11079822|NCT04217291|Experimental|SY-004-3|a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.
11079823|NCT04217291|Placebo Comparator|placebo|a dose of SY-004 matching placebo taken orally
11079824|NCT04217278|Active Comparator|R1: Intermediate dose Cytarabine|First Randomisation - control arm: Intermediate dose Cytarabine (1g/m^2 administered by intravenous infusion over 2 hours on days 1-5 inclusive)
11079825|NCT04217278|Experimental|R1: Vyxeos|First Randomisation - experimental arm: Vyxeos (29mg/65mg/m^2 administered by intravenous infusion over 90 minutes on days 1 and 3)
11079826|NCT04217278|Active Comparator|R2: FB4|Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
11079827|NCT04217278|Experimental|R2: TBF|Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
11079828|NCT04217278|Active Comparator|R3: FB2|Third Randomisation - 55 years and over - control arm: Fludarabine (30mg/m^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
11079829|NCT04217278|Experimental|Mini-TBF|Third Randomisation - 55 years and over - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
11079830|NCT04217265|Experimental|study group|2 tablets of Letrozole 2.5 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
11079831|NCT04217265|Placebo Comparator|control group|2 tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum three doses
11079832|NCT04217252|Experimental|the experimental group|high throughput sequencing of infectious pathogens
11079833|NCT04217252|No Intervention|the control group|no intervention
11079834|NCT04217239|Experimental|Ivor-Lewis group|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
11079835|NCT04217239|Active Comparator|McKeown group|minimally invasive esophagectomy (MIE) with cervical anastomosis
11079836|NCT04217226||study group|adult patients (18-59 years), ASA I-II-III, scheduled for elective surgeries under general anaesthesia.
11079837|NCT04217213|Experimental|ropivacaine combined with mecobalamine|Intercostal nerve block with 0.5% ropivacaine combined with mecobalamine (0.5mg).
11079838|NCT04217213|Active Comparator|ropivacaine|Intercostal nerve block with 0.5% ropivacaine alone.
11079840|NCT04217187|Sham Comparator|Sham Stimulation Group|This arm will receive sensory stimulation without muscle contraction to the antagonist muscles of the upper extremity.
11079841|NCT04217174|Experimental|Avatar intervention app|The intervention is a mobile phone app that features a realistic talking human avatar who promotes adherence to ART and retention in care, motivates, and provides information and opportunities for HIV care-related behavioral skills.
11079842|NCT04217174|Other|Control app|The control app is a mobile phone app that features a realistic talking human avatar who primarily promotes food safety and also offers knowledge of sugar content in food. This app is expected to have no effect on ART adherence and retention in care, however, it has never been tested to determine if it may have any effect so it has been categorized as Other (arm type) rather than as placebo.
11079843|NCT04217161|Experimental|Dexcom G6 Continuous Glucose Monitor|
11079844|NCT04217148|Experimental|ATRA and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and ATRA 10mg bid po, 12 consecutive weeks
11079845|NCT04217148|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
11079846|NCT04217135|Active Comparator|conventional treatment|This group will receive conventional evidence-based medications with up-titration to maximal tolerable dose. The evidence-based medications include angiotensin converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist, ivabradine and entresto. Which evidence-based medications will be started first depends on the decision of in-charge doctors without strict regulation. However, all evidence-based medications should be up-titrated to maximal tolerable dose. (Excuse me! Up-titration of evidence-based medications in heart failure isn't multiple intervention. Those medications should be prescribed in each heart failure case if no contraindication was noted.)
11079847|NCT04217135|Active Comparator|high-dose hydralazine group|another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred. Since the half-life of hydralazine is around 4-6 hours and 3-5 half-life achieves the steady blood concentration, up-titration of hydralazine will be done per 1-2 days. For example, initial dose of hydralazine would be 25 mg tid and the dose would be 50 mg bid next day if no adverse effect occurred. Following this rule, one week is enough to reach high-dose hydralazine with daily dose of 300-400 mg.
11079848|NCT04217122|Experimental|Strawberry intervention group|Participants consume two packages of 13 g of standard strawberry powder in the morning and afternoon/evening per day for 4 weeks
11079849|NCT04217122|Placebo Comparator|Placebo group|Participants consume two packages of 13 grams placebo powder in the morning and afternoon/evening for 4 weeks.
11079850|NCT04217109|Experimental|Odour sampling|Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).
11079851|NCT04217096|Experimental|paclitaxel liposome + S-1|paclitaxel liposome at 175 mg/m^2 on day 1; S-1 at a dose according to the body surface area（<1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；>1.50m^2,60mg Bid，d1-14，q3w）
11079852|NCT04217083||Colorectal cancer patients|Patients with histologically proven Colorectal cancer detected during the colonoscopy
11079853|NCT04217083||healthy controls|Patients with no sign of any colorectal disease who are submitted to colonoscopy
11079854|NCT04217057|Experimental|64Cu-DOTA-ECL1i-PET/CT|-64CU-DOTA-ECL1i-PET/CT imaging consisting of a dynamic scan centered at the level of the known tumor followed by a limited body scan of the head/neck and upper chest will be performed
11079855|NCT04217031||Decision variability assessment group|Patients with angiographically confirmed 3-vessel or left main disease will be enrolled. Patients data and heart team decision will be collected to analyze the variability between different heart team decisions.
11079856|NCT04217005|Experimental|experimental group|amputees or diabetics receiving intervention
11079857|NCT04216992||Three dimensional-rotational epidurography (3D-RE)|3D-RE is obtained on a commercial digital bi-plane angiography system. Reconstruction time was 30 seconds. Detailed information regarding technical performance and reconstruction procedure has been reported. Postprocessing techniques provided by the software included real-time 3D volume rendering and multiplanar reformatting. Real-time 3D volume rendering creates a 3D model of the examined object. The software allows emphasizing bony structures or soft tissue by changing intensity, brightness, and opacity of different X-ray structures. Additionally, rotation of the 3D object in all directions is possible, as is a virtual stereoscopic view provided by the software in combination with special glasses. The multiplanar reformatting modus generates virtual sections according to the three main axes and free defined axes. The section planes can be freely chosen, and curved sectioning is also possible.
11079858|NCT04216979|Experimental|randomization|Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
11079859|NCT04216979|Experimental|group A|these are the patient with palmars point as primary entry site
11079860|NCT04216979|Experimental|group B|these are the patient with umbilicus as primary entry site
11079861|NCT04216966|Placebo Comparator|Control group|This group did not undergo any instrumentation.
11079862|NCT04216966|Experimental|Gracey Curette group|Teeth under this group were subjected to debridement with Gracey curette .
11079863|NCT04216966|Experimental|After Five group|Teeth under this group were subjected to debridement with After 5 curette .
11079864|NCT04216966|Experimental|Mini Five group|Teeth under this group were subjected to debridement with Mini Five curette .
11079865|NCT04216953|Experimental|Atezolizumab + Cobimetinib|"Atezolimumab :
~Adult Patient and patients ≥12 years-old with a BW ≥60kg: 840mg, Q2W
~Pediatric Patient including patients ≥12 years-old with a BW <60kg: 15mg/kg, Q2W with a maximum of 840mg.
~Cobimetinib :
~Pediatric patients<12 years old: 1mg/kd, D1 to D21 over a 28-day cycle. A lower DL of 0.8mg/kg could be investigated. Maximal dose of 60mg/d. Pediatric patients ≥ 12 and a BW < 60kg:1mg/kg. Pediatric patients ≥ 12 and with a BW ≥ 60kg: 60mg/d.
~Adult Patients: 60mg/d D1 to D21 over a 28-day cycle."
11079866|NCT04216940|Experimental|M-pro|
11079867|NCT04216940|Experimental|Hyflex|
11079870|NCT04216914|Experimental|Use of hand outline for bone age xray|Where children and young people are having left hand X-rays for clinical purposes the radiographer will place a template under their hand. The plate is designed not to show up on the X-ray and to not interfere with the X-ray itself. They will be asked to match their hand to the hand outline on the template.
11079871|NCT04216888|Experimental|Open label|Open label intranasal ketamine
11079872|NCT04216875||single primary care practices intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility following the best practice procedure of the diabetes score.
11079873|NCT04216875||primary care group practice intervention|Independent primary care practices with more than one medical doctor working in their responsibility following the best practice procedure of the diabetes score.
11079874|NCT04216875||single primary care practices no intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility without the intervention (not using Diabetes score)
11079875|NCT04216875||primary care group practice no intervention|Independent primary care practices with more than one medical doctor working in their responsibility without the intervention (not using Diabetes score).
11079876|NCT04216862|Experimental|Strengthening exercise treatment|This exercise targets the deep flexor muscles of the upper cervical region the longus capitis and longus colli muscles.
11079877|NCT04216862|Active Comparator|Stretching exercise treatment|The subject's forearm is stabilized by a vertical plane before the trunk is rotated in the opposite direction. Therefore the arm on the involved side is externally rotated and abducted to 90.
11079878|NCT04216849|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.
11079879|NCT04216849|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
11079880|NCT04216836|Experimental|High magnesium diet (SUP condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
11079881|NCT04216836|Experimental|Low magnesium diet (CON condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
11079882|NCT04216823||Sevoflurane Group|sevoflurane is used for anesthetic induction
11079883|NCT04216823||Propofol Group|intravenous anesthetic propofol is used for anesthetic induction
11079884|NCT04216810|Active Comparator|Exercise group|
11079885|NCT04216810|Experimental|Exercise group and dry cupping|
11079886|NCT04216797|Active Comparator|Oral Administration|10 mg diazepam tablets to be taken orally once daily for 4 weeks.
11079887|NCT04216797|Active Comparator|Rectal Administration|10 mg diazepam tablets to be taken rectally once daily for 4 weeks.
11079888|NCT04216784|Active Comparator|Furosemide (Lasix) alone|Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours
11079889|NCT04216784|Active Comparator|Combination of furosemide (Lasix) and albumin|Cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams IV BID for at least 48 hours
11079890|NCT04216771|Experimental|IDA with ID Cytarabine|
11079891|NCT04216771|Active Comparator|ID Cytarabine|
11079892|NCT04216758|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
11079893|NCT04216758|Experimental|tegafur + gemcitabine|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; tegafur: Body surface area < 1.25 m^2, 60 mg/d; Body surface area ≥ 1.25 m^2 to < 1.5 m^2, 80 mg/d; Body surface area ≥ 1.5 m^2, 100 mg/d; Oral (po), Bid, D1-21
11079894|NCT04216732||Observational (questionnaire, blood pressure)|"AIM I & II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease.
~AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks."
11079895|NCT04216719|Experimental|OCM-RISE|Opioid court team provided external facilitation to generate action plans to develop and roll out or improve practice of the county opioid court.
11079896|NCT04216706||Tailored treatment advise in suboptimal adaptation|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment are invited to participate in a follow-up program at four time-points during a subsequent pregnancy (i.e. at 12, 16, 20 and 30 weeks of gestational age). This program is additive to regular pregnancy check-ups, and all women are otherwise managed by their referring physicians. The aim of this program is to evaluate adaptation of maternal hemodynamic parameters in response to pregnancy, and to adjust deviant adaptation with tailored antihypertensive medication. Participation in this program is on voluntary basis, and not restricted to severity of complications in the first pregnancy.
11079897|NCT04216706||Care as usual during pregnancy|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment who do not participate in the additional follow-up program.
11079898|NCT04216693|Experimental|Digoxin tablet|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
11079899|NCT04216693|Placebo Comparator|Placebo|Digoxin-like oral placebo
11079900|NCT04216667|Active Comparator|PVI|Pulmonary vein isolation alone will be performed using radiofrequency energy
11079901|NCT04216667|Experimental|PVI + PWI|Pulmonary vein isolation plus posterior wall isolation will be performed using radiofrequency energy
11079902|NCT04216667|Experimental|PVI + PWI + LAAEI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation will be performed using radiofrequency energy
11079903|NCT04216667|Experimental|PVI + PWI + LAAEI + CSI|Pulmonary vein isolation plus posterior wall isolation plus left atrial appendage electrical isolation plus coronary sinus isolation will be performed using radiofrequency energy
11079904|NCT04216654||Group(A)|52 cases of type 2 diabetic patients.They have +ve Serum antibody and Stool antigen specific for Helicobacter pylori.
11079905|NCT04216654||Group(B)|36 cases of type 2 diabetic patients. They have +ve Serum antibody and -ve Stool antigen-specific for Helicobacter pylori.
11079906|NCT04216654||Group(C)|112 cases of type 2 diabetic patients. They have -ve Serum antibody and Stool antigen-specific for Helicobacter pylori.
11079907|NCT04216641|Experimental|Intervention arm|"At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert).
~For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food):
~The standard food.
~The food refers to a more elaborate texture.
~The food refers to a food with a stronger smell.
~The food refers to a more important flavor.
~The patient will indicate the version of the food that will be preferred."
11079908|NCT04216628|Other|Early amniotomy group|Amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.
11079909|NCT04216628|Other|Late amniotomy group|Oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion
11079910|NCT04216615||patients with preoperative anxiety|
11079911|NCT04216615||patients without preoperative anxiety|
11079912|NCT04216589|Experimental|Semaglutide|All participants will receive a dose of 0.25 mg of semaglutide weekly starting at study entry, followed by 0.5 mg weekly starting at Week 2, and then 1.0 mg weekly from Weeks 4 through 24.
11079913|NCT04216576|Active Comparator|Standard of Care|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
11079914|NCT04216576|Experimental|Standard of Care + Intervention|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
11079915|NCT04216563|Experimental|Treatment (asciminib)|Patients receive asciminib PO BID for up to 36 months while receiving standard of care dasatinib or nilotinib in the absence of disease progression or unacceptable toxicity. Patients may continue to receive asciminib after 36 months at the discretion of investigator.
11079916|NCT04216550||Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
11079917|NCT04216524|Experimental|Treatment (SL-401, venetoclax, chemotherapy)|See detailed description.
11079918|NCT04216511||Case-Lung Cancer|Patients with definite lung cancer diagnosis
11079919|NCT04216511||Control|Either patients with benign pulmonary nodule, or healthy individuals without pulmonary nodule but with risk factors to develop lung cancer matched to lung cancer group
11079920|NCT04216498||Pre-Transfer Patients aged 10-16 years|
11079921|NCT04216498||Post-Transfer Patients aged 16-25 years|
11079922|NCT04216498||Parents/Guardians of Pre-Transfer Patients|
11079923|NCT04216485|Experimental|Lifestyle intervention|Intervention group: Intensive lifestyle intervention will be initiated from the first trimester (8-12wks) to delivery, with follow up every 2-4 weeks. Participants in the intervention group will be provided with an individualized dietary protocol with not less than 1500 calories per day in the first trimester and not less than 1800 calories per day after 13 weeks of gestation. Guidance on regular exercise is reinforced at the first and each follow up visit.
11079924|NCT04216485|Active Comparator|Standard Care|Standard care group: Participants will receive a 1.5-hour group session in which standard prenatal intervention on diet, nutrition and physical activity and recommendation for gestational weight gain are reviewed by a registered dietitian. Thereafter, participants will receive their regularly scheduled follow up visits without additional lifestyle guidance.
11079925|NCT04216472|Experimental|Treatment (alpelisib, nab-paclitaxel)|Patients receive alpelisib PO QD on days 1-21, and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may then undergo surgery to remove the tumor.
11079926|NCT04216459|No Intervention|Low risk group|no specific treatment will be given
11079927|NCT04216459|No Intervention|High risk control|no specific treatment will be given
11079928|NCT04216459|Active Comparator|High risk DP|patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
11079929|NCT04216459|Active Comparator|High risk CB|Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
11079930|NCT04216446|Experimental|Mobile Health Coaching Program during pregnancy|Eligible pregnant women would be randomized to intervention or the control arm after consenting to participate. Participant in the intervention arm will receive free subscription of web-based m-Health program for a six months. The program will provide individualized coaching on diet, supplement use and lifestyle. Participants would undergo dietary screening at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow-up to monitor the improvement (if any) in diet. Women will receive advice in the form of recommendations after completion of the screening questionnaire. Also, individual coaching in the form of push messages containing tips and recommendations for diet and lifestyle would be delivered a maximum of three times a week. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line.
11079931|NCT04216446|No Intervention|Standard Counseling|"For the control group, dietary counseling will be provided face to face by the trained research assistant at the baseline and scheduled follow-ups using the AKUH pamphlet Diet during Pregnancy. Alike intervention group, control group will complete an interviewer based paperless screening questionnaire at five points i.e. at baseline and at 6, 12, 18 and 24 weeks follow up. Furthermore, a subset of participants would undergo objective dietary assessment through biochemical testing of serum folate, serum ferritin, and serum calcium and serum vitamin D at baseline and at end line."
11079932|NCT04216420|Experimental|Electronic pillbox-enabled self-administered therapy (SAT)|TB patients in the experimental arm will be dispensed with TB medication supply (HRZE fixed-dose combination therapy) for every 15 days in medication event reminder monitor (MERM) pillbox device (evriMed500 digital medication monitoring and reminder device manufactured by Wisepill Technologies, South Africa) to self-administer throughout the intensive phase
11081482|NCT04205682|Placebo Comparator|Placebo|Drug: Placebo (days 1-5: placebo matched BD)
11079933|NCT04216420|No Intervention|Standard directly observed therapy (DOT)|TB patients in the standard DOT arm will visit the healthcare facility each business day in the intensive (2 months) phase to swallow their daily dose of HRZE with direct observation of the healthcare provider per the standard currently practicing DOT procedure.
11079934|NCT04216407|Experimental|Remote Ischemic Preconditioning|Short-term tourniquet on to the lower extremity before surgery
11079935|NCT04216407|No Intervention|Control|No intervention
11079936|NCT04216368|Experimental|experimental group|
11079937|NCT04216368|Other|controlled group|
11079938|NCT04216355|Experimental|AZA with CAG derived regimen|Azacitidine 50mg/m²/day, D1-D5 (IV) Aclarubicin 5mg/m²/day, D1-D4 (IV) Cytarabine 10mg/m²/12h, D1-D6 (IV) G-CSF 5-10ug/kg/day, D1-D7 (SC)
11079939|NCT04216342|Experimental|1|subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).
11079940|NCT04216329|Experimental|1/Experimental therapy|Selinexor with temozolomide and radiation
11079941|NCT04216316|Experimental|Arm A (avelumab, gemcitabine, carboplatin, M6620)|Patients receive avelumab IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Patients also receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive avelumab IV over 60 minutes on days 1 and 8 and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients then receive avelumab alone IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days for up to 1 more year in the absence of disease progression or unacceptable toxicity.
11079942|NCT04216316|Active Comparator|Arm B (avelumab, gemcitabine, carboplatin)|Patients receive avelumab, gemcitabine, and carboplatin as in Arm A.
11079943|NCT04216290|No Intervention|Step I, Arm A (no intervention)|ARM A: Patients registered after completion of >= 3 cycles of induction chemotherapy proceed to Step 2 - Randomization.
11079944|NCT04216290|Experimental|Step I, Arm B (chemotherapy)|Chemotherapy naive patients receive 1 of 4 chemotherapy regimens: gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 every 21 days for 3 cycles; carboplatin IV over 30-60 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 every 21 days for 3 cycles; gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and cisplatin IV 30-60 minutes on day 1 every 21 days for 3 cycles; or methotrexate IV over 3 minutes, vinblastine sulfate IV over 3 minutes, doxorubicin hydrochloride IV over 5 minutes, and cisplatin IV over 30-60 minutes on day 1 every 14 days for 3 cycles. Cycles repeat in the absence of disease progression or unacceptable toxicity.
11079945|NCT04216290|Experimental|Step II, Arm C (durvalumab, radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice weekly for 6 weeks; cisplatin IV over 30-60 minutes for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
11079946|NCT04216290|Active Comparator|Step II, Arm D (radiation therapy, chemotherapy)|Patients undergo radiation therapy for 6-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes twice weekly for 6 weeks; cisplatin IV over 30-60 minutes for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity.
11079947|NCT04216290|Experimental|Step III, Arm E (durvalumab)|Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
11079948|NCT04216290|Active Comparator|Step III, Arm F (observation)|Patients previously randomized to Arm D who achieve clinical CR or clinical benefit, or patients previously randomized to Arm C with no clinical CR or clinical benefit undergo observation.
11079949|NCT04216277|Experimental|Procalcitonin in addition to usual care|Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care
11079950|NCT04216277|No Intervention|Usual care|Usual best standard care. No procalcitonin values disclosed to attending physician .
11079951|NCT04216264|Other|Response|
11079952|NCT04216264|Other|Non-response|
11079953|NCT04216251|Experimental|AMR101|"Study procedures include screening for eligibility and study treatment including ARM101 Lifestyle questionnaire, Nutritional survey. Flexible sigmoidoscopy (24 biopsies of normal colorectal mucosa, one stool sample),blood, evaluations, and follow up visits.
~- AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks"
11079954|NCT04216238||Cardiovascular surgical patients|Patients who received cardiovascular surgery and was released from the hospital due to meeting and exceeding a certain walking distance.
11079955|NCT04216199|Experimental|Point of care Ultrasound|Point of care Ultrasound for placement of endotracheal tube
11079956|NCT04216199|No Intervention|Traditional|Traditional method of insertion of endotracheal tube
11079957|NCT04216186|Active Comparator|Atomoxetine and Coenzyme Q|Atomoxetine and Coenzyme Q
11079958|NCT04216186|Placebo Comparator|Placebo and Atomoxetine|Placebo and Coenzyme Q
11079959|NCT04216173|Experimental|Acupuncture|
11079960|NCT04216160|Experimental|Verum|Patients with mild to moderate acne using ACN Cream
11079961|NCT04216160|Experimental|Placebo|Patients with mild to moderate acne using the placebo cream
11079962|NCT04216147|Experimental|PNE group|Patients received 4 sessions, separated one week between them. The treatment consisted the application of a galvanic current through an acupuncture needle (0,30x30mm). The approach were performed with a transverse axis with a needle in plane, being superficial and deep interface of medium nerve the target tissue. The parameters will be 2 mA (milliamps), 10 seconds, 3 impacts (3: 3: 3).
11081483|NCT04205669|Active Comparator|Individual Treatment|
11079964|NCT04216134|Experimental|Diagnostic (68GA-PSMA-11 PET)|Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.
11079965|NCT04216108|Experimental|23G gauge needle vitrectomy surgery|
11079966|NCT04216108|Experimental|27G gauge needle vitrectomy surgery|
11079967|NCT04216095|Active Comparator|Electroconvulsive Therapy (ECT)|Right unilateral (RUL, N=15), or Bitemporal (BT, N=15) ECT
11079968|NCT04216095|Active Comparator|Magnetic Seizure Therapy (MST)|High-dose magnetic seizure therapy (HD-MST)
11079969|NCT04216082|Experimental|Anlotinib|Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11079970|NCT04216069|Experimental|Total 12 regimen group|This group will use the following procedure: Colgate Ultrasoft toothbrush, Colgate Total 12 toothpaste and Plax Mouthwash.
11079971|NCT04216069|Experimental|Tooth brushing alone group|This group will use Colgate Ultrasoft toothbrush and Colgate Cavity Protection toothpaste.
11079972|NCT04216056|Experimental|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
11079973|NCT04216056|No Intervention|Control group|Subjects in the control group will be asked to maintain their usual diet and physical activity patterns over the 12 weeks.
11079974|NCT04216043|Experimental|RUSF skimmed milk powder|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
11079975|NCT04216043|Experimental|RUSF milk protein concentrate and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
11079976|NCT04216043|Experimental|RUSF soy protein and whey permeate|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
11079977|NCT04216043|Experimental|RUSF soy and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
11079978|NCT04216030|Experimental|High iron Irish potato|Meal sequence B, IP High Fe
11079979|NCT04216030|Active Comparator|Regular Irish potato|Meal sequence A, OFSP control
11079980|NCT04216017|Placebo Comparator|Controls|Patients receiving lidocaine
11079981|NCT04216017|Active Comparator|Cases|Patients receiving Kenalog
11079982|NCT04216004|Experimental|Full-fat dairy|3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
11079983|NCT04216004|Active Comparator|Non-fat diary|3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.
11079984|NCT04216004|Placebo Comparator|Non-dairy control|3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.
11079985|NCT04215991|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously on Day 1, in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
11079986|NCT04215991|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered intravenously every 8 hours for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
11079987|NCT04215991|Active Comparator|Multiple Dose Phase: Standard of Care Alone|Participants will receive standard of care treatment according to local standards.
11079988|NCT04215978|Experimental|Phase 1a: BGB-A445 Monotherapy|Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 5 increasing dose levels on day 1 of each 21-day cycle
11079989|NCT04215978|Experimental|Phase 1a: BGB-A445 + Tislelizumab Combination Therapy|Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 3 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle
11079990|NCT04215978|Experimental|Phase 1b:BGB-A445 Monotherapy or Combination with Tislelizumab|Dose Expansion: Participants will receive recommended Phase 2 doses (RP2D(s)) of IV BGB-A445 alone or in combination with tislelizumab as determined from Phase 1a Dose Escalation
11079991|NCT04215965|Experimental|Experimental Standard citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
11079992|NCT04215965|Active Comparator|Conventionnal citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Prismocal B22 (calcium and phosphate free) in the dialysate mode, and Phoxilium in the postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
11079993|NCT04215952|Experimental|SFA Experimental Intervention|A modified version of Semantic Feature Analysis will be administered.
11079994|NCT04215952|Active Comparator|SFA Active Comparator Intervention|A standard version of Semantic Feature Analysis will be administered.
11080017|NCT04215848|Experimental|As-needed Budesonide/Formoterol|As-needed Budesonide/Formoterol (160/4.5 ug)
11080018|NCT04215848|Active Comparator|Budesonide|Budesonide (200 ug) twice daily
11080050|NCT04215653|Active Comparator|Rabeprazole +Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
11081484|NCT04205669|Active Comparator|Household Treatment|
11079995|NCT04215939|Experimental|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11079996|NCT04215939|Experimental|Thermoneutral environment participants with spinal cord injury|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11079997|NCT04215939|Experimental|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11079998|NCT04215939|Active Comparator|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11079999|NCT04215939|Active Comparator|Thermoneutral environment healthy male participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11080000|NCT04215939|Active Comparator|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11080001|NCT04215939|Active Comparator|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11080002|NCT04215939|Active Comparator|Thermoneutral environment healthy female participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11080003|NCT04215939|Active Comparator|Warm enviroment healthy fmale participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
11080004|NCT04215926||HIV-monoinfected outpatients|No intervention; cross-sectional study
11080005|NCT04215913||Normal lung tissue|Normal lung tissue from PSC patients
11080006|NCT04215913||PSC tissues|PSC tissues from PSC patients
11080007|NCT04215913||Metastasis tissues|Metastasis tissues from PSC patients
11080008|NCT04215900|Experimental|High-Speed Multi-Directional Yoga|The duration of the intervention is 18 weeks, with 16 weeks of training.
11080009|NCT04215900|No Intervention|Waitlist control|During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.
11080010|NCT04215887||Sleep unit|Children admitted to sleep unit for sleep study
11080011|NCT04215887||School|Healthy children in school
11080012|NCT04215887||Emergency department|Children seen in triage in emergency department at SCH
11080013|NCT04215887||General practice|Adults or children attending general practice
11080014|NCT04215887||Ambulance|Adults or children in rapid response vehicle
11080015|NCT04215874||Dorsal penile nerve block group|"Ultrasound (US) guided dorsal penile nerve block with in plane technique was done.
~Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis."
11080016|NCT04215874||Caudal epidural block group|A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed 0.25% bupivacaine at a dose of 0.2 ml/kg was administered.
11125415|NCT03897309|Placebo Comparator|Placebo|Placebo tablets
11080019|NCT04215835|Experimental|study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
11080020|NCT04215835|Placebo Comparator|control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
11080021|NCT04215822||acute myeloid leukemia patients - control group|acute myeloid leukemia
11080022|NCT04215809|Experimental|APG2575 200mg|APG2575 200mg ramp up
11080023|NCT04215809|Experimental|APG2575 400mg|APG2575 400mg ramp up
11080024|NCT04215809|Experimental|APG 2575 600mg|APG2575 600mg ramp up
11080025|NCT04215809|Experimental|APG2575 800mg|APG2575 800mg ramp up
11080026|NCT04215809|Experimental|APG2575 1000 mg|APG2575 1000 mg ramp up
11080027|NCT04215809|Experimental|APG2575 1200mg|APG2575 1200mg ramp up
11080028|NCT04215796|Experimental|ReX-C intervention|Subjects use ReX-C to receive CFTR modulators medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
11080029|NCT04215770|Active Comparator|Inj Co-amoxiclav|Group A children were advised Inj Co-amoxiclav 50 units/kg/day in 3 divided doses daily
11080030|NCT04215770|Active Comparator|Inj Benzyl Penicillin|Group B patients were advised inj Benzyl Penicillin 25000 units/kg/day in 3 divided doses
11080031|NCT04215757|Experimental|Intervention group|"Patient received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.
~For L4 radiculopathy Saphenous nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For S1 radiculopathy Sural nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%)"
11080032|NCT04215757|Placebo Comparator|Control group|"Patients received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.
~For L4 radiculopathy Saphenous nerve block with 10ml distilled water For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 10ml distilled water For S1 radiculopathy Sural nerve block with10ml distilled water"
11080033|NCT04215744|Experimental|Ice water immersion group|Ice water immersion of the left hands(30 minutes before the infusion, during the infusion, and 30 minutes after the end of infusion).
11080034|NCT04215744|No Intervention|Control group|No intervention of the right hands as control.
11080035|NCT04215731|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive neoadjuvant mFOLFOXIRI plus bevacizumab once every two weeks for 4 cycles and the same mFOLFOXIRI for 2 cycles. After completing all 6 cycles chemotherapy, the patient will have an MRI scan to examine the tumor. If MRI restaging is ycT4a/b, or MRF involved, the patient will receive concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks). If MRI restaging is ycT0-3 and MRF negative, then the patient will proceed directly to surgery.
11080036|NCT04215731|Active Comparator|Induction FOLFOX Followed by Concomitant Chemoradiotherapy|Patients will receive induction FOLFOX chemotherapy for 4 cycles and followed by concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks), then the patient will proceed to surgery.
11080037|NCT04215718|Active Comparator|fistulotomy group|46 patients with simple anal fistula underwent fistulotomy and marsupialization of wound edges
11080038|NCT04215718|Active Comparator|fistulectomy group|46 patients with simple anal fistula underwent fistulectomy and closure of the wound
11080039|NCT04215705|Active Comparator|Group Q|Patients in this group receive Quadratus Lumborum Block with 20 ml bupivacaine 0.5%
11080040|NCT04215705|Active Comparator|Group L|Patients in this group receive peritubal local infiltration at 6 and 12 o'clock position with 20ml bupivacaine 0.5%
11080041|NCT04215692|Experimental|Ultrasound Guided Fluid Therapy|
11080042|NCT04215692|No Intervention|Conventional Fluid Therapy|
11080043|NCT04215679|Experimental|Three-dimensional immersive virtual reality application|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose mini Mental State Examination (MMSE) scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
11080044|NCT04215679|Active Comparator|Motor imagery|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
11080045|NCT04215679|Active Comparator|Conventional physiotherapy|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
11080046|NCT04215666||Mild ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
11080047|NCT04215666||Moderate ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
11080048|NCT04215666||Severe ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
11080049|NCT04215653|Experimental|Anaprazole Sodium + Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
11080051|NCT04215640|Experimental|MIFI group|Patients in the MIFI group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using microfidelity (MIFI) catheter.
11080052|NCT04215640|Active Comparator|Control|Patients in the control group receive standard radiofrequency ablation procedure for the supraventricular tachycardia using conventional ablation catheter (Blazer II).
11080053|NCT04215614|Active Comparator|Group Lateral Sagittal|Ultrasound-Guided lateral sagittal brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
11080054|NCT04215614|Active Comparator|Group Costoclavicular|Ultrasound-Guided costoclavicular brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
11080055|NCT04215588|Active Comparator|Individualized heparin and protamine titration|The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).
11080056|NCT04215588|Active Comparator|Activated Clotting Time guided heparin and protamine dose|Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)
11080057|NCT04215575|Active Comparator|BGI model 101-350 placement (BGI group)|A 350 mm2 Baerveldt glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.
11080058|NCT04215575|Experimental|AGV model FP7 or S2 placement (AGV group)|A 184 mm2 Ahmed glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits. The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures
11080059|NCT04215562|Other|patients with peripheral facial palsy|collection of data from records on the outcome of rehabilitation therapy on patients with peripheral facial palsy and types of complications associated with this therapy type
11080060|NCT04215549||Participants|OCD patients come from 13 hospitals located in the north, south, east and west of China
11080061|NCT04215536||DPP4i|Reference group
11080062|NCT04215536||Empagliflozin|Exposure group
11080063|NCT04215523||Dapagliflozin|Exposure group
11080064|NCT04215523||DPP-4 inhibitor|Reference group
11080065|NCT04215510|Experimental|endonasal endoscopic surgery group|39 participants in group 1 will undergo endoscopic surgery
11080066|NCT04215510|Active Comparator|radiation therapy group|39 participants in group 2 will undergo radiation therapy(IMRT)
11080067|NCT04215497|Experimental|Physiotherapeutic Scoliosis-Specific Exercises|PSSE group will receive corrective exercise for scoliosis
11080068|NCT04215497|No Intervention|Control|Control group will be taken to the queue list.
11080069|NCT04215484||P|P (previa) : pregnant women with placenta previa on ultrasound and no suggestive signs of placenta accreta
11080070|NCT04215484||I|I (abnormal placental Invasion) : pregnant women with placenta previa on ultrasound,and suggestive signs of placenta accreta on ultrasound with or without MRI
11080071|NCT04215484||N|N (placenta normally located) : pregnant women without suggestive signs of placenta previa or accreta on ultrasound
11080072|NCT04215471|Experimental|NeoAdjuvant Therapy With PD-L1 Antibody SHR-1316 group|Patients will receive the neoadjuvant therapy with SHR-1316 followed by the operation.
11080073|NCT04215458|Other|sample collection|Collection of samples investigating for yeast colonization in either patients with inflammatory skin disease or healthy controls.
11080074|NCT04215445|Active Comparator|Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
11080075|NCT04215445|Active Comparator|Non-Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
11080076|NCT04215432|Experimental|Test group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water, Propolis Extract (2%), Ascorbic Acid (0.2%) and Tocopherol Acetate (0.2%).
11080077|NCT04215432|Placebo Comparator|Placebo group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water and E155/151 coloring.
11080078|NCT04215406||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
11080079|NCT04215393|Experimental|Conbercept eye drop (0.1mg/ mL)|Subjects in this arm will receive 0.1mg/mL Conbercept eye drop 4 times a day, one drop at a time.
11080080|NCT04215393|Experimental|Conbercept eye drop (0.5mg/ mL)|Subjects in this arm will receive 0.5mg/mL Conbercept eye drop 4 times a day, one drop at a time.
11080081|NCT04215393|Experimental|Conbercept eye drop (1.0mg/ mL)|Subjects in this arm will receive 1.0mg/mL Conbercept eye drop 4 times a day, one drop at a time.
11080082|NCT04215380|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form as 30-grams-dose for 12 weeks
11080083|NCT04215380|Placebo Comparator|Control group|This group will be provided with pectin powder provided as two-gram-dose fo
11080084|NCT04215367|Experimental|High phenolic EVOO intake|Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,
11081639|NCT04204538||Urban|Young adults living in urban communities of Rwanda
11080085|NCT04215367|Experimental|No High phenolic EVOO intake|Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.
11080086|NCT04215354|Experimental|MAGNET GROUP|Patients were exposed to very low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional using magnet mattress.
11080087|NCT04215354|Experimental|VIRTUAL REALITY|"Balance training was done using the Wii Fit plus machine which required balance board .Using video game console designed by Nintendo.
~The program consisted of three games: soccer heading, ski slalom and table tilt."
11080088|NCT04215354|Active Comparator|PLACEBO|Patients in the placebo group had identical program to magnet group. They were asked to lie down in the magnet mattress; however, the magnet was not switched on and the patient doesn't know (blind).
11080089|NCT04215354|No Intervention|HEALTHY SUBJECT|healthy subjects with age, gender and BMI matched with the patients with MS were recruited to participate in the study. This group was recruited to establish the normal balance and fatigue parameters. Subjects in this group sign the consent form of healthy subjects and all measurement was taken as balance, fatigue, depression, quality of life and urinary incontinence screening questionnaire.
11080090|NCT04215341|Experimental|1|The study contains a single arm. All children participating in the study will receive the primary intervention which is physiotherapy.
11080091|NCT04215328|Experimental|Mixed-Meal|Ensure Nutrition Shake
11080092|NCT04215328|Placebo Comparator|Electrolyte Solution|Pedialyte Solution
11080093|NCT04215302||laryngeal mask size|laryngeal mask size determines according to weight measurement
11080094|NCT04215276|Active Comparator|Valsalva Maneuver|Patient will do valsalva maneuver for 20 seconds
11080095|NCT04215276|Placebo Comparator|control|Patient will do nothing
11080096|NCT04215263||Geriatric patient underwent general anesthesia procedure|geriatric patients (≥60 years) ware assessed for cognitive impairment after general anesthesia for non-neurologic noncardiac surgery.
11080097|NCT04215250|Active Comparator|Andropulous method|"Andropulous method uses equations to determine the depth of CVC insertion.
~For subject with <100 cm in height:
~Depth of CVC insertion (cm) = (height (cm)/ 10)-1
~For subject with >100 cm in height:
~Depth of CVC insertion (cm) = (height (cm)/ 10)-2"
11080098|NCT04215250|Active Comparator|ECG method|change in p wave from ECG
11080099|NCT04215237|Other|Atorvastatin regulates intestinal flora|
11080100|NCT04215198|Experimental|Move3™ (NEM + fish oil)|NEM, 500 mg, #0 capsule, + fish oil, 1,500 mg, softgels, once daily orally for 2 weeks
11080101|NCT04215198|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, + placebo oil, 1,500 mg, softgels, once daily orally for 2 weeks
11080102|NCT04215185|Experimental|Blood pressure monitor|Non-anesthetized subjects in the ICU (Intensive Care Unit) or in the CICU (Cardiac Intensive Care Unit) with arterial line placement in the radial artery will be fitted with the CardiacSense 1BP device. The first measurement will be of up to 24h. Subsequent measurements will be of up to 5h.
11080103|NCT04215172||macrolides group|"Every patient of this group will be educated and instructed about usage, dosing and side effects of the drug.
~Dose: azithromycin 500 mg three times weekly for 6 months. added to the conventional treatment."
11080104|NCT04215172||conventional group|Every patient of this group will receive the conventional treatment.
11080105|NCT04215159|Experimental|Samfenet and Treatment of physician's choice|"Samfenet : 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
~Treatment of physician's choice (Gemcitabine or Irinotecan)
~Gemcitabine : 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
~Irinotecan : 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks."
11080106|NCT04215146|Active Comparator|Cohort 1|Patients receive paclitaxel alone.
11080107|NCT04215146|Experimental|Cohort 2|Patients receive pelareorep + paclitaxel.
11080108|NCT04215146|Experimental|Cohort 3|Patients receive pelareorep + paclitaxel + avelumab.
11080109|NCT04215133|Experimental|İnspiratory muscle training group|
11080110|NCT04215133|Experimental|Calf muscle training group|
11080111|NCT04215133|No Intervention|Control|
11080112|NCT04215120|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
11080113|NCT04215120|Experimental|Epoetin Injection|Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
11080114|NCT04215107|Other|Control group|Crossover study Group. Each patient will be examined 2 seperate days. Randomized to standard breakfast meal or prolonged fasting. The examinator will be blinded to patient meal status.
11080115|NCT04215107|Other|IUGR group|Will only be examined one day. First ultrasound during fasting, and the second ultrasound 2 hours after a standard breakfast meal.
11080116|NCT04215081|Experimental|ExoAtlet II Safety and Efficacy|20 participants with paraplegia from SCI will participate in gait training using ExoAtlet II powered exoskeleton.
11080117|NCT04215055|Active Comparator|study group|Group I (study group); children receiving intraoral injection of local anasethia using the vibration assisted syringe.
11080118|NCT04215055|Active Comparator|control group|Group II (control group): children receiving intraoral injection of local anasethia using the standard syringe.
11080119|NCT04215042|Active Comparator|Standard hydration|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and 6 hours after procedure
11080120|NCT04215042|Experimental|Short hydration|All patients received shot intravenous saline hydration (3 ml/kg for 1 hour before the procedure and after 1ml/kg/h for 6 hours)
11080121|NCT04215029|Experimental|Group I (exercise plan, coaching calls, nutrition counseling)|Patients and their partners receive an exercise plan and printed materials that includes instructions for walking or other moderate-intensity activities. Patients and their partners also receive coaching calls discussing physical activity and diet related questions, each lasting 45-60 minutes and occurring every 2 weeks for 6 months. In addition, patients and their partners complete 2 nutrition counseling sessions over 1 hour each at baseline and before month 3 with an MD Anderson registered dietitian.
11080122|NCT04215029|Active Comparator|Group II (physical activity/healthy eating information)|Patients and their partners receive information/materials regarding physical activity and healthy eating.
11080174|NCT04214756||AP Diagnosis before guidelines|All patients diagnosed with acute pancreatitis that were treated between August 2011 and December 2014 before guidelines were implemented.
11080123|NCT04215029|Experimental|Provider Interviews (interviews)|Healthcare providers participate in an interview regarding their opinions on family-focused care and its ability to improve health behaviors.
11080124|NCT04215016|Experimental|Humanized anti-CD19 and anti-CD20 dual specific CAR-T cells|
11080125|NCT04215003|Active Comparator|A|6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.
11080126|NCT04215003|Experimental|B|2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery
11080127|NCT04215003|Experimental|CL1|If patients were HR+ and HER2- without PI3K-AKT pathway mutation
11080128|NCT04215003|Experimental|CL2|If patients were HR+ and HER2- with PI3K-AKT pathway mutation
11080129|NCT04215003|Experimental|CLH1|If patients were HR+ and HER2+ without PI3K-AKT pathway mutation
11080130|NCT04215003|Experimental|CLH2|If patients were HR+ and HER2+ with PI3K-AKT pathway mutation
11080131|NCT04215003|Experimental|CH1|If patients were HR- and HER2+ without PI3K-AKT pathway mutation
11080132|NCT04215003|Experimental|CH2|If patients were HR- and HER2+ with PI3K-AKT pathway mutation
11080133|NCT04215003|Experimental|CT1|If patients were HR- and HER2- with LAR subtype
11080134|NCT04214990|Active Comparator|Aspirin|Enteric coated aspirin
11080135|NCT04214990|Placebo Comparator|Placebo|Enteric coated aspirin placebo
11080136|NCT04214977|Experimental|group S|Patients in group S had spinal anesthesia in the sitting position under complete aseptic technique through a standard mid-line approach. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
11080137|NCT04214977|Experimental|group L|Patients in group L received standard general anesthesia. Proper (weight-based) classic laryngeal mask airway was then blindly inserted.
11080138|NCT04214964||Gynecological cancer|patients who has been pathological diagnosed with Gynecological cancers between 2002 and 2022 in China
11080139|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
11080140|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.
11080141|NCT04214938|Active Comparator|Hypertonic sea water|The patient was applied intranasal hypertonic sea water (3.5% sodium chloride) before the nasoendoscopy procedure.
11080142|NCT04214938|Active Comparator|Lidocaine|The patient was applied intranasal Vemcaine as TLA (10% lidocaine; AstraZeneca, Södertälje, Sweden) before the nasoendoscopy procedure.
11080143|NCT04214938|Active Comparator|Xylometazoline|The patient was applied intranasal Otrivine (0.1% xylometazoline hydrochloride, GlaxoSmithKline, Brentford, UK ) before the nasoendoscopy procedure.
11080144|NCT04214938|Placebo Comparator|0.9% Sodium chloride|The patient was applied intranasal placebo (0.9% sodium chloride) before the nasoendoscopy procedure.
11080145|NCT04214925|Experimental|Group of Tai Chi intervention|Tai Chi exercise program will create by selecting the first-basic 10 forms from 24 short forms of Yang style. The forms' name: Beginning, Parting the Horse's Mane, Stork Spreading Its Wings, Brushing Your Knees and Stepping, Playing The Pipes, Fending Off the Monkey, Grasping the Sparrow's Tail Left, Grasping the Sparrow's Tail Right, Simple Whip, Moving Hands Like Clouds-Conclusion. All forms will be completed at 10 weeks. Each session will take 1 hour (15 min for warming up exercises, 30 min of Tai Chi forms, and 15 min for cooling down exercises). The 14 patients of SS in this group will be divided into two groups of 7.
11080146|NCT04214925|Other|Group of home exercises|The home exercise group will receive a one-hour home program, 2 days a week. The first and last 15 minutes of the exercise program will consist of warm-up and cooling- down exercises. After warm-up exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles will be performed 10 times each for 30 minutes.
11080147|NCT04214912|No Intervention|General module|"General module will serve as a roadmap plan which will cover the most common problems and major issues related to current and future treatments, side effects, psychological distress, daily function and physical condition. The contents will be developed based on empirical review, our current research findings in Taiwan, OC health care experts' suggestions."
11080148|NCT04214912|Experimental|Personalized module|Personalized Survivor Care Plan (PSCP) will deliver based on what we assess or interview about patients' distress, concerns and care needs in each interview or/and assessment. We will assess OC patients of the above items by valid assessment tools. For the factors or concerns about RTW assessment, we will develop and test a modified instrument for the study purpose. For each assessment, the computer -assisted assessment will help the OC educator to immediately catch the patients care distress and care needs. It will provide the direction for caring of their personalized distress, concerns and needs.
11080149|NCT04214886|Experimental|CAR 5 x 105 transduced T cells/kg (Dose Level -1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 5 x 105 transduced T cells/kg.
11080150|NCT04214886|Experimental|CAR 1 x 106 transduced T cells/kg (Dose Level 1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1 x 106 transduced T cells/kg.
11080175|NCT04214756||AP Diagnosis after guidelines|All patients diagnosed with acute pancreatitis that were treated between January 2015 and October 2018.
11080176|NCT04214730|Experimental|Combination of NK with chemotherapy group|Patients will receive NK treatments combined with Chemotherapy.
11080151|NCT04214886|Experimental|CAR 1.5 x 106 transduced T cells/kg (Dose Level 2)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
11080152|NCT04214886|Experimental|CAR 2 x 106 transduced T cells/kg (Dose Level 3)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 2 x 106 transduced T cells/kg.
11080153|NCT04214873|Experimental|POH|Treatment of POH Using PiQo4 Laser System
11080154|NCT04214860|Experimental|APR-246|APR-246 4.5 g/day
11080155|NCT04214847|Experimental|polypropylene plate of Ahmed Glaucoma Valve|polypropylene plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The polypropylene plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
11080156|NCT04214847|Active Comparator|silicone plate of Ahmed Glaucoma Valve|silicone plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The silicone plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
11080157|NCT04214834|Active Comparator|Rapid-wean|15% decrements from the stabilization dose of morphine/methadone
11080158|NCT04214834|Active Comparator|Slow-wean|10% decrements from the stabilization dose of morphine/methadone
11080159|NCT04214821|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080160|NCT04214821|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080161|NCT04214821|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080162|NCT04214821|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection
11080163|NCT04214821|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080164|NCT04214821|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080165|NCT04214821|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080166|NCT04214821|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080167|NCT04214808|Experimental|Avodart Soft Capsule 0.5mg to AD-208|Period 1: Avodart Soft Capsule 0.5mg, 1 Capsule Period 2: AD-208, 1 tab
11080168|NCT04214808|Experimental|AD-208 to Avodart Soft Capsule 0.5mg|Period 1: AD-208, 1 tab Period 2: Avodart Soft Capsule 0.5mg, 1 Capsule
11080169|NCT04214795||Infants born after a complete course of antenatal steroids.|Preterm Infants born with less than 32 w GA whose mothers had received a complete course (two doses of celestone in the period between 24 hours and 7 days before delivery.
11080170|NCT04214795||Infants born without a complete course of antenatal steroids|Preterm Infants born with less than 32 w GA whose mothers did not received any dose of celestone or an uncompleted course (less than 24 hours or more than 7 days from delivery).
11080171|NCT04214782|No Intervention|Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images without the help of Artificial Intelligence (AI) algorithm
11080172|NCT04214782|Experimental|AI enabled Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images with the help of Artificial Intelligence algorithm
11080173|NCT04214769||Head and Neck Cancer patients|
11080177|NCT04214730|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
11080178|NCT04214717|Experimental|Combination of DC-CIK with chemotherapy group|Patients will receive DC-CIK treatments combined with Chemotherapy .
11080179|NCT04214717|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
11080180|NCT04214704|Experimental|Genteel arm|In the Genteel arm, the subjects exclusively use the Genteel device for the first 12 weeks, and then switch to the conventional method of SMBG for an additional 12 weeks. This arm will use Butterfly Touch Lancets (BTL) throughout the study.
11080181|NCT04214704|Active Comparator|Conventional arm|In the Conventional arm, the subjects use the conventional method of SMBG for the first 12 weeks and then switch to the Genteel device for an additional 12 weeks. This arm will use the lancet and lancing device which they were using prior to randomization to the study.
11080182|NCT04214691|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
11080183|NCT04214691|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
11080184|NCT04214678|Experimental|Underwater clip closure|The post-resection defect is closed using endoscopic clips with underwater technique
11080185|NCT04214678|Active Comparator|Conventional clip closure|The post-resection defect is closed using endoscopic clips with conventional gas insufflation (CO2)
11080186|NCT04214665|Experimental|Test/Reference|Single dose of test tablet in period I. Followed by single dose of reference tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
11080187|NCT04214665|Experimental|Reference/Test|Single dose of reference tablet in period I. Followed by single dose of test tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
11080188|NCT04214652|Experimental|IDP-126 Gel|
11080189|NCT04214652|Placebo Comparator|IDP-126 Vehicle Gel|
11080190|NCT04214639|Experimental|IDP-126 Gel|
11080191|NCT04214639|Placebo Comparator|IDP-126 Vehicle Gel|
11080192|NCT04214626|Experimental|R-CHOP regimen Combined With Lenalidomide|"Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.
~PS: Methotrexate, 3mg/m2, Intravenous administration on day 3 of each 3-week cycle, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
~Maintenance Treatment: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 4 weeks, up to 2 cycles; Lenalidomide, 10mg oral administration on day 1 to 21 repeated every 4 weeks, up to 12 cycles."
11080193|NCT04214600|Experimental|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
11080194|NCT04214600|No Intervention|Control|This group will be scheduled the same number of visits as a follow up for diabetes
11080195|NCT04214587||baseline assessment group|n=150 patiënts for baseline assessment
11080196|NCT04214587||clinical need for reintervention group|n=20-30 patiënts for re-bronchoscopy
11080197|NCT04214587||clinical stable controls|n=20 stable treated control patiënts
11080198|NCT04214574|Experimental|Real time ultrasound-guided Parasagittal oblique technique|
11080199|NCT04214574|Experimental|Real time ultrasound-guided paramedian tranverse technique|
11080200|NCT04214561||SB group|Patients diagnosed with SB.
11080201|NCT04214561||Healthy controls|Patients without diagnosed SB.
11080202|NCT04214548||Eczema|Patients diagnosed with eczema
11080203|NCT04214535|Experimental|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Cervical Cage at one or two-levels
11080204|NCT04214522||Acute stroke patients|Acute stroke patients
11080205|NCT04214509||PD + LRRK2|Patients with LRRK2-associated Parkinson's syndrome
11080206|NCT04214509||no PD + LRRK2|Participants with LRRK2-mutations but without Parkinson's symptoms
11080207|NCT04214509||no PD + no LRRK2|Participants without mutations and without Parkinson's symptoms
11080208|NCT04214509||PD+ other than LRRK2|Parkinson patients with mutations in other genes than LRRK2
11080209|NCT04214509||PD+ no LRRK2|Patients with idiopathic Parkinson's disease
11080210|NCT04214496||Postoperative Delirium Risk Patients|Preoperative cognitive function testing- EEG monitorization during surgery - Postoperative function testing
11080211|NCT04214483||Diagnosis of Acne|Patients who have been diagnosed with acne, subdivided into the various types.
11080212|NCT04214470||Irritable Bowel Syndrome Patients|Patients with IBS.
11080213|NCT04214457||Myometrial tumor with suspected leiomyosarcoma|Women between 18 and 75 years of age diagnosed with a myometrial tumor (probably leiomyoma) with suspected leiomyosarcoma
11080214|NCT04214444|Active Comparator|Single-dose before treatment|12 patients will receive a single-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection
11080215|NCT04214444|Active Comparator|Single-dose after treatment|12 patients will receive a singe-dose of prevenar three weeks after the beginning of the immunochemotherapy (R-CHOP) following two months later by pneumovax injection
11080216|NCT04214444|Experimental|Double-dose before treatment|12 patients will receive a double-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection.
11080217|NCT04214431|Experimental|Mindfulness-Based Childbirth Education|Women in the experimental group received eight week mindfulness-based childbirth education program delivered one class each week.
11080218|NCT04214431|No Intervention|Control group|Women in the control group received standardized care.
11080219|NCT04214418|Experimental|Phase 1: MTD|"Subjects will be treated with combination therapy at the designated dose levels:
~Dose 1 - Hydroxychloroquine 600mg twice per day, Cobimetinib 40mg, no Atezolizumab Dose 2 - Hydroxychloroquine 600mg twice per day, Cobimetinib 40mg, Atezolizumab 840mg Dose 3 - Hydroxychloroquine 600mg twice per day, Cobimetinib 60mg, Atezolizumab 840mg"
11080220|NCT04214418|Experimental|Phase 2: Cohort 1|Advanced Pancreatic Adenocarcinoma (N = 23-67) subjects will receive study treatment based on the MTD determined from Phase 1
11080221|NCT04214418|Experimental|Phase 2: Cohort 2|Advanced Colorectal Adenocarcinoma (N = 20-34) subjects will receive study treatment based on the MTD determined from Phase 1
11080222|NCT04214418|Experimental|Phase 2: Cohort 3|Histology Agnostic Adenocarcinoma (N = 23-56) subjects will receive study treatment based on the MTD determined from Phase 1
11080223|NCT04214392|Experimental|Treatment (CAR T cell therapy)|Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one or two CAR T cell infusions (one at each catheter site) and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
11080224|NCT04214379|Other|severe congenital ptosis|Patients with severe congenital ptosis with poor levator muscle function
11080225|NCT04214366|Experimental|Carbon Ion irradiation|22 x 3 Gy(RBE) Carbon Ions
11080226|NCT04214366|Active Comparator|Bimodal Arm|25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
11080227|NCT04214353|Experimental|Experimental arm|Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
11080228|NCT04214327|Active Comparator|Strengthening Families Program Online eLearning Game|This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
11080229|NCT04214327|Active Comparator|SFP Home-use DVD/video series|"This arm of the study receives an 11-session home-use DVD or coupon code for viewing the SFP videos online at home that contains the same SFP skills and lesson content as the online condition. However, the lesson material is not animated and involves simply viewing the videos at home. This arm represents an attention-control condition as the requirements of participation and exposure to the intervention will match the online condition, as participants use the Internet or a DVD player to view lesson material in a self-paced format. There are no differences in recruitment for this condition; all assignment to experimental conditions is based on their recruiter's location using a randomized control trial design. Participants in this condition will be provided a hyperlink URL to answer pre- and posttest assessments and at the 3-month follow-up. Process evaluation materials will be delivered via a hyperlink to a commercial survey vendor during the trial and at the conclusion."
11080230|NCT04214327|Active Comparator|Wait-Listed Control|"This arm of the study receives no active intervention for the initial intervention period of 22 weeks; however, following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention. During the initial trial of 22 weeks, participants in this condition receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. The intent of these weekly emails is to stimulate continued participation and reduce attrition.
~Individual families will be randomly assigned to one of the three interventions with a computerized random number generator."
11080231|NCT04214327|No Intervention|SFP Group Norms|This arm of the study provides a means to conduct a non-inferiority trial contrasting the active intervention conditions (SFP Online and Home-use DVD/videos) to the traditional 14-session in-person group-delivery format, which serves as a benchmark of effectiveness for SFP. There is no data collection as the Group Norms are part of an existing database of families that already took SFP classes. All effect size comparisons are conducted using secondary data analysis. The expected margin of equivalence is set at 10% so that any condition that exceeds another in the magnitude of effect size is considered as 'good as' the comparison condition. All effect sizes will be adjusted for demographic and site-specific factors to control for clustering and within-site contextual factors that can influence program outcomes.
11080232|NCT04214314||Control|The control group will continue to receive the integral rehabilitation provided by the center.
11080233|NCT04214314||Experimental|The participants of the experimental group, in addition to the integral rehabilitation of the center will receive the training of the attention through NeuronUp APT. There will be 3 rehabilitation sessions of one hour a week for about a month and a half or two.
11080234|NCT04214301|Experimental|BLI800|BLI800
11080235|NCT04214288|Experimental|AZD9833 Dose A|The patients will receive AZD9833 (Dose A).
11080236|NCT04214288|Experimental|AZD9833 Dose B|The patients will receive AZD9833 (Dose B).
11080237|NCT04214288|Experimental|AZD9833 Dose C|The patients will receive AZD9833 (Dose C).
11080238|NCT04214288|Active Comparator|Fulvestrant 500 mg|The patients will receive Fulvestrant (500 mg).
11080239|NCT04214275|Experimental|intervention group|standard care and participated in a pulmonary rehabilitation program
11080240|NCT04214275|No Intervention|control group|received standard care after coronary artery bypass graft
11080241|NCT04214262|Experimental|Arm A (atezolizumab, SBRT)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 8 cycles. Starting on day 1 cycle 3, patients also undergo SBRT for 3-5 treatments over 1-3 weeks.
11080242|NCT04214262|Active Comparator|Arm B (SBRT)|Beginning 21 days after randomization, patients undergo SBRT for 3-5 treatments over 1-3 weeks.
11080243|NCT04214249|Experimental|Arm I (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
11080244|NCT04214249|Active Comparator|Arm II (cytarabine, idarubicin, daunorubicin, HSCT)|See Design details.
11080245|NCT04214236|Experimental|ciNPT group|Subjects will receive post-operative incisional wound care by ciNPT (125 mmHg, continuous suction) for the first 7 days after surgery.
11080246|NCT04214236|Sham Comparator|Control group|Subjects will receive post-operative incisional wound care by standard non-adherent surgical dressing (vaseline petrolatum gauze),
11080247|NCT04214223||PANE -> PAC|First, the patient carry out her Pre-Anesthesic Numerical Evaluation and then she benefits from her Pre-Anesthesic Consultation.
11080248|NCT04214223||PAC -> PANE|First, the patient benefits from her Pre-Anesthesic Consultation and then, she carry out her Pre-Anesthesic Numerical Evaluation
11080249|NCT04214210|Experimental|Tailored Family Gene Toolkit|"The tailored FGT will include 5 modules designed to increase knowledge of cancer genetics (1); provide decisional support for genetic testing (2); increase active coping to challenges faced by HBOC families (3); provide a 5-steps, skills-building communication training (4); and provide information about management of hereditary cancer risk (5).
~Messages will involve shallow tailoring (e.g. sex of mutation carrier), and deep tailoring with complex elements of relevance (e.g. coping style). Tailoring will be based on personalization, tailored feedback, and content matching, based on Swiss and Korean languages and legislation, health insurance policy, and cultural values.
~Participants will be asked to complete the 5 modules within 4 weeks after they first engage with the intervention. The 4-week interval will enable learning new information while having time to reflect and act. They will receive email alerts to complete the 5 modules with the URL link directing them to the FGT."
11080250|NCT04214210|Active Comparator|Targeted intervention|The comparator will provide targeted information about HBOC and enable sharing genetic test results. The Korean team will define the contents of the comparator that will mimic the structure and function of an existing website, already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and the three Swiss national languages. Both trial arms the tailored and the targeted platform will be technically implemented in the same system, in order to track access and usage of the platform and provide a user-friendly experience to participants. The Swiss team will also provide the implementation of the comparison website.
11080251|NCT04214197|Other|Crisaborole|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
11080252|NCT04214184|Experimental|Increased Sleep Duration Intervention|Following baseline assessments, participants will complete a 4-week increased sleep duration intervention followed by one night of sleep in the lab on this increased sleep duration schedule. In the morning, participants will have blood collected for metabolomics analyses and complete oral glucose tolerance testing
11080253|NCT04214171||group 2 years|The group underwent total hip arthroplasty at 2 years
11080254|NCT04214171||group 5 years|The group underwent total hip arthroplasty at 5 years
11080255|NCT04214171||group 10 years|The group underwent total hip arthroplasty at 10 years
11080256|NCT04214171||group control|healthy patients
11080257|NCT04214158||Professional Folk Dancers|Individuals who have been actively dancing for at least two years will be included in the study.
11080258|NCT04214158||sedentary|According to the international physical activity questionnaire, individuals with low levels of physical activity will be included in the study.
11080259|NCT04214145|Experimental|Phenylephrine|
11080260|NCT04214145|Experimental|Norepinephrine|
11080261|NCT04214145|Experimental|Vasopressin|
11080262|NCT04214132|Experimental|virtual patients group|Only nursing undergraduates from AY2017/2018 cohort, who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module will receive additional training using Virtual Patients in each semester (2 semesters per year) of year 2 and year 3 before they go for the clinical posting. Students will have unlimited access to the Virtual Patients (available scenarios depend on which semester the student is in) by logging in through the school portal.
11080263|NCT04214132|No Intervention|Blended learning group|Nursing undergraduates from AY2016/2017 cohort who who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module that comprised of weekly online e-lectures and face-to-face tutorials.
11080264|NCT04214119||Control|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and does not have a diagnosis of Barrett's esophagus or esophageal/gastric malignancy.
11080265|NCT04214119||Barrett's esophagus|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and diagnosed with Barrett's esophagus via pathology.
11080266|NCT04214119||Esophageal carcinoma|Patients age 18 or greater who have diagnosis of primary esophageal carcinoma.
11080267|NCT04214119||Gastric cancer|Patients age 18 or greater who have diagnosis of primary esophageal cancer.
11080268|NCT04214106||Thiamine group|group 1: ICU patients who did not receive IV thiamine
11080269|NCT04214106||Non-thiamine group|group 2: ICU patients who received IV thiamine,100-500 mg/day for at least one day
11080270|NCT04214093|Experimental|Arm A|Dose escalation for patients with solid tumors, lymphoma and multiple myeloma with low risk of TLS. Each cohort within Arm A will test a single dose level.
11080271|NCT04214093|Experimental|Arm B|Dose escalation for patients with hematologic malignancies with an intermediate to high risk of TLS. Intrapatient dose ramp-ups within each cohort will be used.
11080272|NCT04214080|Experimental|Study Group (SG)|"In addition to feeding and oral motor intervention strategies, intensive neck and trunk stabilization exercises based on Neurodevelopmental treatment-Bobath (NDT-B) concept principles were applied to this group.
~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
11080273|NCT04214080|Placebo Comparator|Control Group (CG).|"(NDT-B) concept approaches and feeding and oral motor intervention strategies were applied to this group in routine treatment.
~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
11080274|NCT04214067|Active Comparator|Arm I (EBRT, brachytherapy)|Patients undergo pelvic EBRT daily for 5-6 weeks and vaginal brachytherapy completed within 7 days after completion of EBRT in the absence of disease progression or unacceptable toxicity.
11080275|NCT04214067|Experimental|Arm II (EBRT, brachytherapy, pembrolizumab)|Patients undergo EBRT and brachytherapy as in Arm I. Within 7 days prior to the start of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 6 weeks for up to 1 year (9 cycles) in the absence of disease progression or unacceptable toxicity.
11080276|NCT04214054|Experimental|Moldable self-hardening biphasic calcium phosphate graft|Easy graft, a moldable osteocondutive allograft formed of 60% hydroxylapatite and 40% β-tricalcium phosphate (Easy-graft, Sunstar, Gruidor, Degradable solutions AG, Swizerlard).
11080277|NCT04214054|Placebo Comparator|No graft material|
11080278|NCT04214041|Experimental|Autologous fat grafting|
11080279|NCT04214041|Active Comparator|Sub-epithelial connective tissue graft|
11080280|NCT04214028||Maviret Participants|Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
11080281|NCT04214015||Patients with metastatic mesothelioma|Patients who have been diagnosed with metastatic mesothelioma
11080282|NCT04213989|Active Comparator|Conservative Care|Conservative care (may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT)
11080283|NCT04213989|Experimental|Flexitouch Plus and Conservative Care|Flexitouch Plus with conservative care
11080284|NCT04213976||Ileostomy in continuity|Paediatric patients having had an ileostomy in continuity as part of the treatment for a complex intestinal obstruction, as described by Santulli or by Bishop-Koop.
11080285|NCT04213976||Conventional ileostomy|Paediatric patients having had a loop ileostomy as part of the treatment for a complex intestinal obstruction.
11080286|NCT04213950|Experimental|Post-implementation group|The post-implementation group will receive care that is enhanced by the rabies PEP quality improvement bundle.
11080287|NCT04213950|No Intervention|Historical control group|The historical control group received care prior to implementation of the quality improvement bundle.
11080288|NCT04213937|Experimental|nab-paclitaxel|nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles
11080289|NCT04213937|Active Comparator|Topotecan|Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
11080290|NCT04213924|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
11080291|NCT04213924|Active Comparator|Group NSAII|lidocaine 5% gel and 800 mg ibuprofen intravenously
11080292|NCT04213911||Morbid obese|BMI>40 kg/m2
11080293|NCT04213911||Non-obese|BMI<30 kg/m2
11080294|NCT04213898|Experimental|SHR-1210+Albumin-bound paclitaxel+Epirubicin|Neoadjuvant therapy：SHR-1210+Albumin-bound paclitaxel+Epirubicin
11080295|NCT04213885|Experimental|Pulsed Accelerated|30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
11080296|NCT04213885|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
11080297|NCT04213872|Experimental|Meditative Movement (MM)|The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.
11080298|NCT04213859|Experimental|Virtual Reality Exposure Therapy (VRET)|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.
~nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm).
~rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session.
~th stage: After treatment, participants will complete measures of fear of flying and emotional variables."
11080299|NCT04213859|No Intervention|control|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.
~nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm)
~rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period.
~th stage: Participants will complete measures of fear of flying and emotional variables."
11080300|NCT04213846|Experimental|Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive twice daily intervention messages for three weeks and have access to other psycho-educational alcohol information.
11080301|NCT04213846|No Intervention|Assessment-only Control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
11080302|NCT04213833|Placebo Comparator|group I (control group)|patients will receive propofol 50 mg
11080303|NCT04213833|Active Comparator|group II|patients will receive propofol 50 mg + dexmedetomidine 0.5 mcg/ kg
11080304|NCT04213833|Active Comparator|group III|patients will receive propofol 50 mg +15 g palatable lidocaine gel
11080305|NCT04213820|Active Comparator|Treatment as usual|Participants will receive treatment as usual at the eating disorder unit at the Child and adolescent psychiatric clinic and at the Psychiatric clinic during 4 weeks.
11080306|NCT04213820|Experimental|TMS and body image intervention|Participants will receive TMS and a body image intervention daily 5 times/week during 4 weeks
11080307|NCT04213820|Sham Comparator|sham TMS and body image intervention|Participants will receive sham TMS and a body image intervention Daily 5 times/week during 4 weeks
11080308|NCT04213807|Experimental|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
11080309|NCT04213807|Placebo Comparator|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
11080310|NCT04213794|Experimental|Treatment (cytoreduction, HIPEC)|Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours.
11080311|NCT04213781|Other|Usual care|Sedation according to Dixon's up-and-down method.
11080312|NCT04213781|Experimental|Audiovisual distraction|Audiovisual distraction using HappyMed Video Glasses during procedure. Sedation according to Dixon's up-and-down method.
11080313|NCT04213768|Experimental|Plication|
11080314|NCT04213768|Active Comparator|Resection|
11080315|NCT04213755||patients with risks of intraoperative massive bleeding|patients with risks of intraoperative massive bleeding
11080316|NCT04213742|Active Comparator|Gratitude diary|
11080317|NCT04213742|No Intervention|No intervention|
11080318|NCT04213742|Active Comparator|Gratitude visit|
11080319|NCT04213729|Active Comparator|Crohn's Disease (CD) Control Group|Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
11080320|NCT04213729|Experimental|Experimental CD Low Fat Diet (LFD) Group|Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
11080321|NCT04213729|Experimental|Experimental CD LFD + DPS Group|Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
11080322|NCT04213716|Experimental|intracanal medication|After instrumentation of the canals and drying , using Lentulo Spiral Filler medicaments will be placed under aseptic conditions into the canals experimental Intracanal medication of 1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
11080323|NCT04213716|Active Comparator|intracanal medicament|After instrumentation of the canals and drying , using Lentulo Spiral Filler comparator intracanal medicaments will be placed under aseptic conditions into the canals which is 100 mg Ca (OH) 2 mixed with 1ml sterile water
11080324|NCT04213703||Patients with Epidermolysis Bullosa|Patients who have been diagnosed with Epidermolysis Bullosa
11080325|NCT04213690||Patients with Lupus|Patients who have been diagnosed with Lupus
11080326|NCT04213677|Experimental|Dapagliflozin|Dapagliflozin (Participants will receive dapagliflozin 10mg po qd).
11080327|NCT04213677|Placebo Comparator|Placebo|Placebo (Participants will receive placebo po qd)
11080328|NCT04213664||non-metastatic renal cell carcinoma|Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell
11080329|NCT04213651||Diabetes Mellitus|Patients with diabetes mellitus
11080330|NCT04213638|Experimental|Group：1|Intervention: Other：Single Microneedle Radiofrequency therapy
11080331|NCT04213638|Active Comparator|Group：2|Intervention: Other：Photodynamic therapy
11080332|NCT04213625|No Intervention|Control Group|Information sheet with only their surgeon's educational background.
11080333|NCT04213625|Experimental|Intervention|Experimental group will receive an information sheet with their surgeon's educational and personal background.
11080334|NCT04213612|Experimental|PLD+CTX+VCR|CTX 1g/m2/d，D1-2 VCR 1.5mg/m2，D1
11080335|NCT04213599||Anterior infarction|Patients with anterior ST-elevation myocardial infarction
11080336|NCT04213599||Inferior infarction|Patients with inferior ST-elevation myocardial infarction
11080337|NCT04213599||Lateral infarction|Patients with lateral ST-elevation myocardial infarction
11080338|NCT04213586|Experimental|Whey Protein|Each participant will be supplemented with whey protein (7 d/wk) during 10 weeks.
11080339|NCT04213586|Experimental|Leucine-matched collagen|Each participant will be supplemented with collagen (7 d/wk) during 10 weeks.
11080340|NCT04213573|Experimental|Group 1: topical application of silver diamine fluoride|38% silver diamine fluoride liquid
11080341|NCT04213573|Active Comparator|Group 2: topical application of MI varnish.|MI Varnish:5% sodium fluoride varnish which also contains RECALDENT™* (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate
11080342|NCT04213560|Experimental|Weighted waist-hooping|Participants weighted waist-hooping on their own for ten minutes a day, four days a week, for six weeks resulting in a total of 40 minutes of weighted waist-hooping each week. Participants weighted waist-hooped with a three-pound weighted hula hoop at the waist for ten minutes. Half time hooping to the left and the other half hooping to the right. If discomfort while hooping occurred participants were instructed to take breaks, change directions more frequently, or where thicker clothing to lessen the impact of the hoop around their waists. The investigators would check in on the participants weekly to provide feedback on technique and answer all questions throughout the six-week intervention.
11080343|NCT04213560|No Intervention|Control|No Intervention
11080344|NCT04213547|Experimental|Intervention|This will be a single-arm study utilizing a loss-framed incentive intervention to induce increased sleep duration.
11080345|NCT04213521|Experimental|Multisensory balance training group|The participants in the multisensory balance training group were provided with multiple-sensory balance exercises using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system-postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
11080346|NCT04213521|Active Comparator|Conventional balance training group|The participants in the Conventional balance training group performed conventional balance exercises, such as static and dynamic standing balance without altered sensory inputs.
11080347|NCT04213508|Active Comparator|Isotonic saline with frequency of 2 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
11080348|NCT04213508|Active Comparator|Hypertonic saline with frequency of 2 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
11080349|NCT04213508|Active Comparator|Isotonic saline with frequency of 5 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
11080350|NCT04213508|Active Comparator|Hypertonic saline with frequency of 5 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
11080351|NCT04213495||Patients undergoing anesthesia in Czech Republic|Patients undergoing anesthesia in Czech Republic in the selected period from the confirmed Anesthesia Center
11080352|NCT04213482||oncology patients|For this study, panoramic images were taken from pediatric patients who received radiotherapy and/or chemotherapy because of any oncologic disease.
11080353|NCT04213482||healthy|panoramic images of patients(pediatric) who have no systemic disease were collected from the archive of dental radiology clinic of the university hospital.
11080354|NCT04213469|Experimental|Quikin CD19-CART|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine 4-6 days before CART infusion. A dose of Quikin CD19-CART will be infused on day 0.
11080355|NCT04213456|Experimental|Nutritional supplementation|Powder added to water,high protein and multi vitamin and minerals
11080356|NCT04213456|Placebo Comparator|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
11080357|NCT04213443||Women of short stature|Women that are under 1.6 meters.
11080358|NCT04213430||Training dataset|Retinal images collected from hospitals and multiple screening sites all over China
11080359|NCT04213430||Validation dataset|Retinal images separated from training dataset
11080360|NCT04213430||Testing dataset|Retinal images prospectively collected from the hospitals and ocular disease screening sites totally different from training dataset
11080361|NCT04213417|Experimental|Bobath therapy plus Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the Bobath therapy was applied to the affected side of the body and lower extremity for 60 minutes in each session.
11080362|NCT04213417|Active Comparator|Bobath therapy|Both groups were treated with the Bobath therapy as a neurodevelopmental therapy.
11080363|NCT04213404|Experimental|Ribociclib-spartalizumab|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
11080364|NCT04213391|Experimental|sulforaphane group|The patients will take sulforaphane for 24 weeks, 2550mg once a day.
11080365|NCT04213391|Placebo Comparator|Placebo group|The patients will take placebo for 24 weeks, 2550mg once a day.
11080366|NCT04213378|Experimental|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent restenosis with paclitaxel eluting PTCA balloon
11080367|NCT04213378|Active Comparator|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent restenosis with SeQuent® Please paclitaxel eluting balloon
11080368|NCT04213365|Other|cognitive stimulation and adapted physical activity|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
11080369|NCT04213352|No Intervention|Control Group|The subjects will be asked to type on a computer for 5 minutes without splint or taping. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
11080370|NCT04213352|Experimental|Splint Group|The subjects will be asked to type on a computer for 5 minutes with a splint. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
11080371|NCT04213352|Experimental|Rigid Taping Group|The subjects will be asked to type on a computer for 5 minutes with rigid taping which limits the wrist flexion at the dominant side. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
11080372|NCT04213339|Experimental|Kegal Exercises|
11080373|NCT04213339|No Intervention|Control|
11080374|NCT04213326||Cancer Cohort|Subjects interested in the cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
11080375|NCT04213326||Non-Cancer Cohort|Subjects interested in the non-cancer cohort, will sign an informed consent, complete an optional survey, and have 60mLs of blood draw by a licensed phlebotomist.
11080376|NCT04213313||Control Group|health volunteers
11080377|NCT04213313||Infectious Keratitis Group|Infectious corneal patients
11080378|NCT04213300||Low carbohydrate dietary group|"Participants n = 23
~Participants:
~Male, female or unspecified gender;
~18 years of age or over;
~Type 1 diabetes for ≥1 year from diagnosis date and
~Individuals who administer insulin using multiple daily injections."
11080379|NCT04213287|Experimental|Peri-Articular Injections and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine
~At the end of surgery;
~PAI: 30 ml 0,025% bupivacaine and
~IPACK: 20 ml 0,025% bupivacaine"
11080380|NCT04213287|Active Comparator|Adductor Canal Block, and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine
~At the end of surgery;
~ADD: 20 ml 0,025% bupivacaine and
~IPACK: 20 ml 0,025% bupivacaine"
11080381|NCT04213274|Placebo Comparator|Placebo - placebo|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo
11080382|NCT04213274|Other|Placebo - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104
11080383|NCT04213274|Experimental|80 mg RPH-104 - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo
11080384|NCT04213274|Experimental|80 mg RPH-104 - 160 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104
11080385|NCT04213261|Experimental|FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts|Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.
11080462|NCT04212754||Procedure: Emergency surgery for traumatic brain injury|
11080386|NCT04213248|Experimental|UMSC-exo treatment|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks.
11080387|NCT04213235|Experimental|Physical exercise|
11080388|NCT04213209||Brentuximab Vedotin 1.8 mg/kg (body weight)|The usual dosage for intravenous administration is 1.8 milligrams per kilograms (mg/kg) (body weight) as Brentuximab Vedotin (genetic recombination) once every three weeks (up to 12 months). The dose may be reduced appropriately according to the participant's condition. Participants receive interventions as part of routine medical care.
11080389|NCT04213196|Active Comparator|HSK21542 0.2 μg/kg|Healthy volunteers 0.2 μg/kg HSK21542
11080390|NCT04213196|Placebo Comparator|HSK21542 0.5 μg/kg|Healthy volunteers 0.5 μg/kg HSK21542 or Placebo
11080391|NCT04213196|Placebo Comparator|HSK21542 1 μg/kg （15min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
11080392|NCT04213196|Placebo Comparator|HSK21542 1 μg/kg （2min)|Healthy volunteers 1 μg/kg HSK21542 or Placebo
11080393|NCT04213196|Placebo Comparator|HSK21542 2 μg/kg|Healthy volunteers 2 μg/kg HSK21542 or Placebo
11080394|NCT04213196|Placebo Comparator|HSK21542 5 μg/kg|Healthy volunteers 5 μg/kg HSK21542 or Placebo
11080395|NCT04213196|Placebo Comparator|HSK21542 10 μg/kg|Healthy volunteers 10 μg/kg HSK21542 or Placebo
11080396|NCT04213196|Placebo Comparator|HSK21542 20 μg/kg|Healthy volunteers 20 μg/kg HSK21542 or Placebo
11080397|NCT04213183||development dataset 01|Slit-lamp and retinal fundus images collected from Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University.
11080398|NCT04213183||development dataset 02|Slit-lamp and retinal fundus images collected from Affiliated Huadu Hospital of Southern Medical University.
11080399|NCT04213183||development dataset 03|Slit-lamp and retinal fundus images collected from Nantian Medical Centre of Aikang Health Care.
11080400|NCT04213183||test dataset 01|Slit-lamp and retinal fundus images collected from Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University.
11080401|NCT04213183||test dataset 02|Slit-lamp and retinal fundus images collected from Huanshidong Medical Centre of Aikang Health Care.
11080402|NCT04213170|Experimental|Sintilimab and Bevacizumab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 every 21 days
11080403|NCT04213144|Experimental|Magdent Cap MED|Soft and hard tissue healing with electomagnetic healing abutment.
11080404|NCT04213144|Sham Comparator|Sham MED|Soft and hard tissue healing with a regular healing abutment.
11080405|NCT04213131|Other|Rehabilitation control group|Routine rehabilitation treatment for chronic spinal cord injury and Intravenous injection of 100 mL 0.9% saline solution.
11080406|NCT04213131|Experimental|hUC-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUC-MSCs
11080407|NCT04213131|Experimental|hUC-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUC-MSCs and 5 mL of cerebrospinal fluid
11080408|NCT04213131|Experimental|hUC-MSCs local administration group|hUC-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUC-MSCs/point.
11080409|NCT04213131|Experimental|hUCB-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUCB-MSCs
11080410|NCT04213131|Experimental|hUCB-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUCB-MSCs and 5 mL of cerebrospinal fluid
11080411|NCT04213131|Experimental|hUCB-MSCs local administration group|hUCB-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUCB-MSCs/point.
11080412|NCT04213118|Experimental|Group A|Administration anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
11080413|NCT04213105|Experimental|QL1206|QL1206 injection (60mg) by subcutaneous injection once on the first day
11080414|NCT04213105|Active Comparator|Prolia®|Prolia® injection (120mg) by subcutaneous injection once on the first day
11080415|NCT04213092||ERCP+LC|Patients in this group underwent 2-stage ERCP+LC in a single setting. And, it was compared with our control group
11080416|NCT04213092||OC+CBD|This group with 2-stage OC+CBD exploration in a single setting approach was taken as a control group.
11080417|NCT04213079|Experimental|Vestibulo-ocular reflex (VOR)|Treatment by re-adaptation of the vestibulo-ocular reflex (VOR) for participants with motion triggered MdDS
11080418|NCT04213079|Experimental|Habituation of velocity storage|Participants with motion triggered MdDS
11080419|NCT04213066|Active Comparator|Control group|This group received eye-hand practice for drawing pictures.
11080420|NCT04213066|Experimental|Grating group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies.
11080421|NCT04213066|Experimental|Random dot group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies constructed by random dots of stochastic resonance.
11080422|NCT04213053|Other|Concomitant strabismus patients|Horizontal strabismus surgery
11080423|NCT04213040||Open-Heart Surgery for a six months duration|In a single group of patients including 146 patients undergoing openheart surgery during a period of six months, the collected parameters include; serum levels of procalcitonin, C-reactive protein, and lactate as well as postoperative complications and after this, depending on the development of postoperative complications or not in the intensive care unit patients were divided into two groups. The Group Without Complications, n=112, includes patients without a postoperative complication after open-heart surgery with cardiopulmonary bypass. The Group With Complications, n=34, includes patients with a postoperative complication after open-heart surgery with cardiopulmonary bypass.
11080424|NCT04213027|Active Comparator|SSLF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Sacrospinous ligament fixation (SSLF) .
11080425|NCT04213027|Active Comparator|ISFF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Ischial spinous fascia fixation (ISFF)
11080463|NCT04212741|Experimental|A+ HA(tm)|20 ml oral solution of hyaluronic acid mixture in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
11080426|NCT04213014|Experimental|Guys/Girls Opt for Activities for Life Intervention (GOAL)|Receives the 4 month (16-wk) GOAL intervention, which has 3 components: (1) After-school GOAL Club: 26 events (2 d/wk; 120 min/event/day; 13 wks due to no club during 3 school break wks) for boys and girls to engage in physical activity and healthy eating and cooking activities;5 (2) Three parent-adolescent meetings (group meetings at each school): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality during a prior wk.
11080427|NCT04213014|No Intervention|Control|Received usual school activities.
11080428|NCT04213001|Other|measure|circumference measure, ultrasonographic measure
11080429|NCT04212988|Experimental|the trial group|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
11080430|NCT04212988|Placebo Comparator|the control group|In control group patients, only place the probe for NIRS monitor.
11080431|NCT04212975|Experimental|group 1|lavage by dextrose
11080432|NCT04212962|Experimental|Treatment group|The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
11080433|NCT04212962|Experimental|Control group|The control group receives usual discharge planning and post-discharge care.
11080434|NCT04212949|Experimental|Repetitive transcranial magnetic stimulation following TESI|Active repetitive transcranial magnetic stimulation will be performed to the patients with lumbar radiculopathy who receive transforaminal epidural steroid injection.
11080435|NCT04212949|Active Comparator|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection will be applied to the patients with lumbar radiculopathy.
11080436|NCT04212936|No Intervention|Control group|8 mmHg pressure group
11080437|NCT04212936|Experimental|Study group|10 mmHg group
11080438|NCT04212923|Experimental|Medical Dashboard based self-management intervention|Chronic kidney disease patients in the intervention group will receive the usual care plus the tailored 'Medical Dashboard' based self-management intervention.
11080439|NCT04212923|No Intervention|Usual care services|Chronic kidney disease patients in the comparison group will receive usual care consisting of personalised in- and outpatient treatment based on symptoms experienced and disease severity, as outlined in the Kidney Disease Improving Global Outcomes (KDIGO).
11080440|NCT04212897|Experimental|Music Therapy|This group will be asked to practice a rhythmic auditory SFT intervention task at home.
11080441|NCT04212897|No Intervention|No Music Therapy|This group will not engage in an intervention task at home and will be asked to continue their normal daily routine.
11080442|NCT04212884||PLWH|PLWH followed up at the five participating HIV centers
11080443|NCT04212884||HIV-uninfected individuals|Age and sex-matched HIV-uninfected individuals
11080444|NCT04212871|Experimental|watch mukbang|"In the online study, participants were assigned to watch a ramen mukbang, by Yuka Kinoshita (https://youtu.be/ArPaid2Iuck, accessed: 2018-10-12).
~In the in-person study, participants were assigned to watch a hotpot mukbang by Alun (https://youtu.be/QCTOo9UGZD8, accessed: 2018-11-29)."
11080445|NCT04212871|Experimental|watch another food content video|"In the online study, participants were assigned to watch a donut mukbang, by Yuka Kinoshita (https://youtu.be/ntMT2y0MgHk, accessed: 2018-10-12).
~In the in-person study, participants were assigned to watch a hotpot cooking show by the Cat's kitchen (https://youtu.be/EH5Ei-sMP60, accessed: 2018-11-29)."
11080446|NCT04212871|Placebo Comparator|watch a non-food content video|"In the online study, participants were assigned to watch a silent documentary introducing the Palace Museum by China Central Television (CCTV) (https://youtu.be/hWnm1BQOTZY, accessed: 2018-10-12).
~In the in-person study, participants were assigned to watch a video introducing Cornell University is used for the non-food content video (https://youtu.be/GuM8vTq0jd4, accessed: 2018-11-29)."
11080447|NCT04212858|Experimental|case|myeloma patients
11080448|NCT04212858|Experimental|control|healthy control
11080449|NCT04212845|Active Comparator|Group ESP|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine and 8 mg dexamethasone
11080450|NCT04212845|Active Comparator|Group TF|Fluoroscopy-guided transforaminal injection with 4 ml of 0.25% bupivacaine and 8 mg dexamethasone
11080451|NCT04212832|Active Comparator|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block with 0.5 ml/kg % 0.25 bupivacaine
11080452|NCT04212832|Other|No intervention|Standard Pain Followup and Monitorization
11080453|NCT04212819|Experimental|Before erythrocyte suspension (ES) transfusion group|50 (Female/Male: 25/25) patients were included in this study. Total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients after diagnoses of anemia.
11080454|NCT04212819|Experimental|After erythrocyte suspension transfusion group|24 hours after ES transfusion, total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients.
11080455|NCT04212793|Experimental|NIR endoscopic TSS with 4.5 mg bevacizumab-800CW|IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
11080456|NCT04212793|Experimental|NIR endoscopic TSS with 10 mg bevacizumab-800CW|IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
11080457|NCT04212793|Experimental|NIR endoscopic TSS with 25 mg bevacizumab-800CW|IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
11080458|NCT04212780|Active Comparator|Treatment Naive|Participants receiving Long-term stimulation of the thalamus via dual leads for Essential Tremor
11080459|NCT04212780|Active Comparator|Refractory Participants|Patients with recurrent, debilitating intention tremor despite ongoing, optimized VIM DBS therapy
11080460|NCT04212767|Experimental|Test group|Post-extraction sockets covered with Platelet-Rich Fibrin membrane (n=16)
11080461|NCT04212767|No Intervention|Control Goroup|Post-extraction sockets left to spontaneous healing/clot and primary closure (n=16).
11080464|NCT04212741|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
11080465|NCT04212728|Experimental|AMSCs plus PRP group|Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
11080466|NCT04212728|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
11080467|NCT04212715|Experimental|Experimental arm|SABR 35Gy/5 to prostate, up to 50Gy/5 to MR nodule, and 25Gy/5 to pelvic nodes and SVs
11080468|NCT04212689|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. Physiotherapy approaches include stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
11080469|NCT04212689|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
11080470|NCT04212676|Experimental|PR+BAT Group|In addition to the PR program, the BAT will be administered to the experimental group by a physiotherapist with 5 years of experience in BAT for 8 weeks.
11080471|NCT04212676|Active Comparator|PR Group|Patients in the control groups will receive a 30-minute Pulmonary Rehabilitation (PR) program every day of the week for 8 weeks.
11080472|NCT04212663|Placebo Comparator|control|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release
11080473|NCT04212663|Experimental|experiment|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release+ The tendon release of musculi tibialis posterior
11080474|NCT04212650|Experimental|Losartan|12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
11080475|NCT04212650|Placebo Comparator|Placebo|Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.
11080476|NCT04212637|Experimental|Healthy Volunteers|MRI exam
11080477|NCT04212637|Experimental|Parkinson patient|MRI exam
11080478|NCT04212624|Experimental|test arm|The 25G or 23G conjunctival seamless vitrectomy was performed on the anterior eye to remove the anterior-posterior direction and tangential direction of the rupture hole. The area outside the macular foveal lesion was selected, but 100 μl of HuRPE cell injection was injected within about 2 PD. In combination with the Medone syringe and the combined 35G or 37G needle, the silicone oil injection module is used for injection, and the injection is performed in an amount of 100 μl (depending on the cell concentration). The doses of the three dose groups from low to high were 300,000 cells, 500,000 cells, and 1 million cells, respectively, in a single injection.
11080479|NCT04212611|Experimental|Group L|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L)
11080480|NCT04212611|Experimental|Group R|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% ropivacaine (group R).
11080481|NCT04212598|Experimental|Definitive concurrent chemoradiotherapy or radiotherapy arm|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
11080482|NCT04212585||children with upper gastrointestinal symptoms|
11080483|NCT04212585||children without upper gastrointestinal symptoms|
11080484|NCT04212559||NPV group|Patients who had treated in pulmonary rehabilitation unit with NPV
11080485|NCT04212546|Placebo Comparator|Control drink|200 mL milk + 16 g maltodextrin
11080486|NCT04212546|Active Comparator|Test drink|200 mL milk + 16 g inulin + Lactobacillus casei [>106 cfu/mL]
11080487|NCT04212533|Active Comparator|supplementation arm|43 patients undergoing total thyroidectomy received 40000 IU vit D and once before operation and 500mg calcium tab 4 times in the day before surgery
11080488|NCT04212533|Active Comparator|non-supplementation arm|43 patients undergoing total thyroidectomy received rice starch tablets /6 hrs in the day before surgery
11080489|NCT04212507||1|50 psoriatic patients
11080490|NCT04212507||2|30 age and sex-matched healthy volunteers as a control group
11080491|NCT04212494|Experimental|Thrombus aspiration|Upfront manual thrombus aspiration followed by PCI
11080492|NCT04212494|Active Comparator|PCI Alone|PCI without upfront manual thrombus aspiration
11080493|NCT04212481|Experimental|single port group|Uniport video-assisted thoracoscopic surgery for NSCLC
11080494|NCT04212481|Active Comparator|two ports group|video-assisted thoracoscopic surgery for NSCLC using two ports
11080495|NCT04212481|Active Comparator|three ports group|video-assisted thoracoscopic surgery for NSCLC using three ports
11080496|NCT04212442|Experimental|Immediate Intervention|Upon enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
11080497|NCT04212442|Experimental|Wait-list Control|Two months after study enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
11080498|NCT04212429|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080499|NCT04212429|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080563|NCT04212039|Sham Comparator|ultrasound guided sham block|Ultrasound guided 0.5 ml/kg saline injection injection between to iliopubic eminentia and psoas tendon
11080500|NCT04212429|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080501|NCT04212429|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080502|NCT04212429|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080503|NCT04212429|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080504|NCT04212429|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080505|NCT04212429|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 8-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
11080506|NCT04212416|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
11080507|NCT04212403|Active Comparator|Control|The control groups receives antimicrobial prophylaxis (AMP) as recommended by the guidelines.
11080508|NCT04212403|No Intervention|Treatment group|The treatment group receives no AMP.
11080509|NCT04212390||FISiM MDS patients|Patients receiving a diagnosis of MDS and prospectively enrolled in the FISiM registry.
11080510|NCT04212377|Experimental|exploratory|single arm exploratory, single-centre study
11080511|NCT04212364|Experimental|Peer Education|"During Session 1, participants will be trained in Peer Education and how to use Nasal Narcan. They will be given two Nasal Narcan kit that includes 2 doses. One kit if for their use and one kit is to give someone in their social network after they have trained them in how to use it.
~A week after Session 1, participants will be scheduled for Session 2.
~During session 1 and 2 participants, Index participants will be taught information and skills pertaining to overdose prevention and response and how to train network members in overdose prevention and response.
~At the 2nd session, index participants will be given 1 coupon to give to 1 member from their social network to attend Session 3.
~Session 3 will be a dyad session where Index participants will use their peer mentors' skills to train their network member in overdose prevention and response.
~Index participants will also be invited to up to 3 Booster Session (monthly) after they complete Sessions 1-3."
11080512|NCT04212364|Active Comparator|Standard of care|"Participants randomized to this condition will participate in one 1-hour session. This session will be an individual session where the participant will meet with a trained staff member in a private room at the Lighthouse.
~This session will be standard overdose prevention and response information. Participants will also be trained in Narcan administration. Participants will be given 1 nasal Narcan kit.
~At the end of this session, participants will be asked to refer a network member to the study for survey visits"
11080513|NCT04212351||Patients with NF1 and active LGGs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of low grade glioma but no clinical or radiographic evidence of plexiform neurofibroma.
11080514|NCT04212351||Patients with NF1 and active PNs|Patients with Neurofibromatosis Type 1 with clinical or radiographic evidence of plexiform neurofibroma but no clinical or radiographic evidence of low grade glioma.
11080515|NCT04212351||Patients with NF1 with no active LGGs or PNs|Patients with Neurofibromatosis Type 1 with no clinical or radiographic evidence of both active plexiform neurofibroma and active low grade glioma.
11080516|NCT04212338|Experimental|study group 1|Before intravitreal injection music intervention: These patients received the standard treatment and listened to music for a period of 15 minutes 30 minutes before the injection.
11080517|NCT04212338|Experimental|study group 2|During-intravitreal injection music intervention:These patients received the standard treatment and listened to music during the injection (approximately 5 minutes).
11080518|NCT04212338|No Intervention|control group|The music intervention was not conducted with the patients in the control group. These patients received the standard treatment.
11080519|NCT04212325|Active Comparator|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
11080520|NCT04212325|Active Comparator|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the single injection at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
11080521|NCT04212312||Single course of Betamethasone|Women with twin pregnancy who received 1 course of betamethasone between 24 - 34 weeks' gestation.
11080522|NCT04212312||Repeat course of Betamethasone|Women with twin pregnancy who received 2 courses (Repeat course) of betamethasone between 24 - 34 weeks' gestation.
11080523|NCT04212286|Experimental|Diagnostic CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions with Diameters ≤ 2cm will receive CEUS and EOB-MRI examinations.
11080524|NCT04212273|Experimental|Diagnostic Sonazoid-CEUS and EOB-MRI|Patients with high risk of HCC having suspicious lesions on US will receive Sonazoid-CEUS and EOB-MRI examinations.
11080525|NCT04212260|Experimental|Oro-pharyngeal exercises|Use of oro-pharyngeal exercises
11080526|NCT04212260|Sham Comparator|Sham control|Use of sham exercises.
11081640|NCT04204538||Rural|Young adults living in rural communities of Rwanda
11080527|NCT04212247|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
11080528|NCT04212247|Placebo Comparator|Control condition|The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
11080529|NCT04212234|Experimental|free ultrasound propagation velocity|ultrasound exams will be performed using several ultrasound propagation velocities
11080530|NCT04212234|No Intervention|conventional ultrasound propagation velocity|ultrasound exams will be performed using the 1540m/s conventional celerity
11080531|NCT04212221|Experimental|MGD013|MGD013 monotherapy dose escalation and expansion
11080532|NCT04212221|Experimental|MGD013+Brivanib Alaninate|MGD013+Brivanib Alaninate dose escalation and expansion
11080533|NCT04212208|Experimental|Intervention group|EMLA cream + High-frequency USG probe kept for 15minutes.After 15 minutes IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
11080534|NCT04212208|Active Comparator|Control group|EMLA cream+Low frequency USG probe kept over the cream for 15 minutes. IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
11080535|NCT04212195||Part 1|Genetic determinants (n=500)
11080536|NCT04212195||Part 2|Biomarker discovery (n=40)
11080537|NCT04212182|Experimental|HFNC group|AECOPD patients receive ventilation support via HFNC.
11080538|NCT04212182|Active Comparator|NPPV group|AECOPD patients receive ventilation support via NPPV.
11080539|NCT04212169|Experimental|MEDI3506 at dose level 1|Participant will receive multiple doses of MEDI3506 at dose level 1.
11080540|NCT04212169|Experimental|MEDI3506 at dose level 2|Participant will receive multiple doses of MEDI3506 at dose level 2.
11080541|NCT04212169|Experimental|MEDI3506 at dose level 3|Participant will receive multiple doses of MEDI3506 at dose level 3.
11080542|NCT04212169|Placebo Comparator|Placebo|Participant will receive multiple doses of Placebo
11080543|NCT04212156||TMH test|Patient will be asked to lay supine while the head and neck maintained in a neutral position using a pillow under the head. By using digital depth gauge, the TMH will be measured from the anterior border of the thyroid cartilage directly on the thyroid notch till the anterior border of the mentum
11080544|NCT04212143||children with kidney disease|Kidney transplant recipients age 3 to 21 years
11080545|NCT04212143||healthy control|Healthy children age 3 to 21 years
11080546|NCT04212130|Experimental|Evaluation of environmental cleanliness|"In this study,
~fluorescent marking,
~microbiological sampling and
~BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
11080547|NCT04212117|Other|Arm 1 - Educational Platform, PALS|The Patient Activated Learning System is a free, health education platform written bu trusted MDs.
11080548|NCT04212117|Other|Arm 2 - WebMD|WebMD is a widely used educational platform for health information.
11080549|NCT04212104|Experimental|watch mukbang|participants are assigned to watch a dim sum mukbang by a famous host, Peggie Neo (https://youtu.be/2dRf535eAPK, accessed: 2018-9-12)
11080550|NCT04212104|Placebo Comparator|watch non-food content video|participants are assigned to watch the Big Bang Theory, The Euclid Alternative ( https://youtu.be/V8kUL9owk6Q, accessed: 2018-9-12).
11080551|NCT04212091|Experimental|Part A (Group 1): PGT121.414.LS (3 mg/kg)|Participants will receive 3 mg/kg of PGT121.414.LS by intravenous (IV) infusion at Month 0.
11080552|NCT04212091|Experimental|Part A (Group 2): PGT121.414.LS (10 mg/kg)|Participants will receive 10 mg/kg of PGT121.414.LS by IV infusion at Month 0.
11080553|NCT04212091|Experimental|Part A (Group 3): PGT121.414.LS (30 mg/kg)|Participants will receive 30 mg/kg of PGT121.414.LS by IV infusion at Month 0.
11080554|NCT04212091|Experimental|Part A (Group 4): PGT121.414.LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS by subcutaneous (SC) infusion at Month 0.
11080555|NCT04212091|Experimental|Part B (Group 5): PGT121.414.LS + VRC07-523LS (20 mg/kg)|Participants will receive 20 mg/kg of PGT121.414.LS and 20 mg/kg of VRC07-523LS by IV infusion sequentially in this order at Months 0, 4, and 8.
11080556|NCT04212091|Experimental|Part B (Group 6): PGT121.414.LS + VRC07-523LS (5 mg/kg)|Participants will receive 5 mg/kg of PGT121.414.LS and 5 mg/kg of VRC07-523LS by SC infusion sequentially in this order at Months 0, 4, and 8.
11080557|NCT04212078|Active Comparator|A-Levofloxacin|0.1 ml/0.5mg of levofloxacin 0.5% ophthalmic solution
11080558|NCT04212078|Active Comparator|B-Intracameral Cefuroxime|0.1 ml/1mg of Cefuroxime
11080559|NCT04212065|Active Comparator|Sublingual Suboxone|Women randomized to sublingual dosing will be provided prescription to fill.
11080560|NCT04212065|Active Comparator|Subcutaneous Sublocade|Women randomized to subcutaneous administration will have drug administered by nurse during routine prenatal care visits.
11080561|NCT04212052|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 30Gy/6f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 40Gy/8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly nab-paclitaxel(50mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, or nab-paclitaxel(30mg/㎡) and nedaplatin(10mg/㎡) twice every week.
11080562|NCT04212039|Active Comparator|ultrasound guided pericapsular nerve group block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection between to iliopubic eminentia and psoas tendon
11080564|NCT04212026|Experimental|Nivolumab|"Nivolumab treatment will be given every 2 weeks at a standard flat dose of 240 mg for a total of 5 doses, and the IRE procedure will be performed using the standard setting to ablate tumors at the level of the liver that is well tolerated by the patients. Two weeks after the last dose of nivolumab (Week 8), radiological restaging will be performed (=Week 10)."
11080565|NCT04212013|Experimental|Ibrutinib/Rituximab|All subjects meeting eligibility criteria will receive rituximab: 375 mg/m^2 on days 1, 8, 15 and 22 on cycle 1.
11080566|NCT04212013|Placebo Comparator|Ibrutinib/Placebo|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis. Placebo capsules will be similarly dosed at 4 capsules daily.
11080567|NCT04212000|Experimental|Levoketoconazole|Levoketoconazole 150 mg
11080568|NCT04212000|Active Comparator|Ketoconazole|Ketoconazole 200 mg
11080569|NCT04211987|Active Comparator|Fast track care protocol|patients treated using fast track care protocol
11080570|NCT04211987|Active Comparator|Standard care protocol|patients treated using standard care protocol
11080571|NCT04211961|Placebo Comparator|Control|Participants randomised to the placebo group will receive one 15-minute IV infusion of Saline at 4 visits.
11080572|NCT04211961|Active Comparator|Treatment|Participants randomised to the treatment group will receive one 15-minute IV infusion of Scopolamine at 4 visits.
11080573|NCT04211948|Experimental|robotic pancreatectomy|robotic pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
11080574|NCT04211948|Active Comparator|open surgery|open pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
11080575|NCT04211935|Experimental|Patient Controlled Analgesia|This technique involves connecting a patient controlled analgesia pump to the intravenous line. The patient has the ability to push a button to obtain a predetermined dose of an intravenous opioid with a set lockout time period to minimize the potential for over sedation. PCA pumps will be connected to the intravenous line of the patient at the end of the MIRPE operation. anesthesiologists with experience in regional anesthesia.
11080576|NCT04211935|Experimental|Erector Spinae Block|This method consists of the anesthesiologist placing two catheters on each side of the vertebrae which then delivers pain medicine continuously via pumps for 2-3 days post-surgery.
11080577|NCT04211935|Experimental|Intercostal Nerve Cryoablation|The INC technique relies on multilevel freezing of the intercostal neurovascular bundle intraoperatively to block sensation and pain for approximately 2 months postoperatively. Trained pediatric surgeons will perform the INC at the time of a MIRPE procedure.
11080578|NCT04211922|Experimental|Alkotinib 400mg QD|400mg orally once daily. Take Alkotinib at least 1 hour before or at least 2 hours after a meal.
11080579|NCT04211909|Experimental|SOF/VEL|Participants with chronic HCV infection, genotype 1 or 2, who are treatment-naive or treatment-experienced with Interferon (IFN)-based treatments will receive SOF/VEL.
11080580|NCT04211909|Experimental|SOF/VEL/VOX|Participants with chronic HCV infection, genotype 1, who are treatment-experienced with non-structural protein (NS)5A direct acting antiviral (DAA)-based treatments will receive SOF/VEL/VOX.
11080581|NCT04211896|Experimental|anlotinib plus nivolumab|
11080582|NCT04211883|Experimental|Active intervention|Participants will come to the Project Active clinic and be asked questions about their health history, assist in their health goals, medications will be adjusted, lab work and screening tests will be ordered. At end of each visit, current health recommendations and goals as well as previous health changes will be given after each visit.
11080583|NCT04211883|No Intervention|Standard Clinical Treatment|Participants will continue with their usual clinic care.
11080584|NCT04211870|Active Comparator|Group 1|Treatment with low-level laser therapy.
11080585|NCT04211870|Sham Comparator|Group 2|Sham treatment (simulated laser therapy).
11080586|NCT04211844||sofosbuvir plus daclatasvir|50 patients receiving 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
11080587|NCT04211844||sofosbuvir plus ledipasvir|50 patients receiving 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
11080588|NCT04211831|Experimental|Cohort 1: URO-902 24 mg; Placebo|Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo.
11080589|NCT04211831|Experimental|Cohort 2: URO-902 48 mg; Placebo|Participants will receive either a single treatment of URO-902 48 mg or matching placebo.
11080590|NCT04211818|Experimental|Patients|
11080591|NCT04211805||Arm (A) TAF Group Comprised of Patients from 6 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Alafenamide (TAF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eight centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
11080592|NCT04211805||Arm (B) TDF Group Comprised of Patients from 6 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Disoproxil Fumarate (TDF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eight centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
11080593|NCT04211792||Glaucoma suspect or patients|Patients who has or suspected Glaucoma will be approached for the recruitment into this study. IOP will be measured in the sitting position with Icare tonometers in a random order in both the eyes. IOP measurements by GAT will be taken after Icare measurements followed by CCT recording with ultrasound pachymeter.
11080594|NCT04211779|Experimental|Real tDCS and Exercise|tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and active tDCS intervention at the same time.
11080654|NCT04211415|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
11080595|NCT04211779|Sham Comparator|Sham tDCS and Exercise|Sham tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and sham tDCS intervention at the same time.
11080596|NCT04211779|Other|Exercise|Exercise group in which will receive the active intervention of aerobic exercise training no tDCS intervention.
11080597|NCT04211766|Active Comparator|Group I (supplemental fiber and fat followed by placebo)|Participants receive a fiber supplement daily and a fish oil supplement PO daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group II.
11080598|NCT04211766|Active Comparator|Group II (placebo followed by supplemental fiber and fat)|Participants receive a fiber supplement placebo daily and a fish oil supplement placebo daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group I.
11080599|NCT04211753|Experimental|Treatment as usual plus mobile app|Those who will receive naturalistic treatment in outpatient setting and also the mobile app
11080600|NCT04211753|Active Comparator|Treatment as usual|Those who will receive naturalistic treatment in outpatient setting but not the mobile app
11080601|NCT04211740|Active Comparator|OCH-NCNP1 3 mg|
11080602|NCT04211740|Placebo Comparator|Placebo|
11080603|NCT04211727||Cohort 1|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
11080604|NCT04211727||Cohort 2|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
11080605|NCT04211714|Experimental|EXG34217|single autologous CD34+ cells contacted ex vivo with EXG-001
11080606|NCT04211701|Experimental|Connective Tissue Massage|Connective tissue massage will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions, respectively. The treatment will be administered for four weeks, five days a week.
11080607|NCT04211701|Experimental|Classical Massage|Classic massage will be applied to the lower back and upper back, respectively, while the patient is lying in the prone position. The treatment will be administered for four weeks, five days a week.
11080608|NCT04211688|Experimental|Combined individual + group Schema therapy|Those who will receive both individual plus group schema therapy
11080609|NCT04211688|Active Comparator|Only group Schema therapy|Those who will receive group schema therapy
11080610|NCT04211675|Other|Treatment|"The planned therapy will involve 6 cycles of 21 days each consisting of irinotecan, temozolomide, dinutuximab, and sargramostim (Cycle 1), or irinotecan, temozolomide, dinutuximab, sargramostim, and natural killer (NK) cells (Cycles 2-6).
~Treatment cycles will be repeated every 21 days based upon disease response and toxicity criteria. Tumor response will be assessed after Cycles 2, 4 and 6. Patients who do not experience dose-limiting toxicities and achieve complete response, partial response or stable disease may continue to receive the assigned therapy for as many cycles as are possible with the number of NK cells manufactured.
~Patients will be assigned an initial NK cell dose level at time of registration. If the NK cell dose is tolerated, intra-patient dose escalation will occur at cycle 4 and cycle 6."
11080611|NCT04211662|Experimental|Intervention Group|Tailored Multidimensional Intervention
11080612|NCT04211662|No Intervention|Control Group|Regarding the control group, the participants will receive a simple educational booklet through one home visit.
11080613|NCT04211649|Experimental|3 days of antibiotherapy|The patient viewed for the first time at the hospital and suspected of leptospirosis received a probabilistic antibiotherapy
11080614|NCT04211649|No Intervention|7 days of antibiotherapy (Amoxycilline or Doxycycline)|When the leptospirosis is confirmed ( PCR Leptospirosis positive) the pobabilistic antibiotherapy is switched to a prophylactic antibiotherapy with Amoxicillin or Doxycycline.
11080615|NCT04211636||Complete SCI, AIS A|Patients with complete spinal cord injury (AIS A)
11080616|NCT04211636||Incomplete SCI, AIS B, C, D|Patients with incomplete spinal cord injury (AIS B, C, D)
11080617|NCT04211636||Vertebral injuries without SCI|Patients with vertebral injuries without spinal cord injury (control)
11080618|NCT04211623|Active Comparator|Constraint induced movement therapy group|Constrained on more affected side for three hours.
11080619|NCT04211623|Active Comparator|Bimanual activities group; BIM training|Set of bimanual activities performed.
11080620|NCT04211610||Group 1 - Healthy subjects without any evidence of cardiac o|"Inclusion criteria:
~Normal serum troponin (below the 99th percentile)
~GFR 60ml/min
~Proteinuria <1gr/gr creatinine
~Blood and urine samples will be collected for troponin and other measures."
11080621|NCT04211610||Group 2 - Subjects with acute myocardial infarction and norm|"Inclusion criteria:
~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.
~GFR 60ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
11080622|NCT04211610||Group 3 - Subjects with acute myocardial infarction and decr|"Inclusion criteria - Group 3a:
~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.
~30 GFR <60ml/min/1.73m2
~Inclusion criteria - Group 3b:
~At least one measurements of serum troponin above the 99th percentile, with either a rise or fall in cardiac troponin levels.
~GFR <30ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
11080623|NCT04211610||Group 4 - Subjects with decreased GFR but without any eviden|"Inclusion criteria - Group 4a:
~Normal serum troponin (below the 99th percentile)
~No known past medical history of any cardiac disease and/or procedure.
~30 GFR <60ml/min/1.73m2
~Inclusion criteria - Group 4b:
~Normal serum troponin (below the 99th percentile)
~No known past medical history of any cardiac disease and/or procedure.
~GFR <30ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
11080624|NCT04211610||Group 5 - Subjects with chronic myocardial injury and normal|"Inclusion criteria:
~At least one measurements of serum troponin above the 99th percentile, with neither a rise nor fall in cardiac troponin levels.
~GFR 60ml/min/1.73m2
~Blood and urine samples will be collected for troponin and other measures."
11080625|NCT04211610||Group 6 - patients on RRT|"Inclusion criteria:
~a. Patients who are dependent on renal replacement therapy, including hemodialysis, peritoneal or hemodiafiltration.
~Blood and urine samples will be collected for troponin and other measures."
11080626|NCT04211597|Sham Comparator|Group 1: Control|Participants receive no scar prevention and treatment for Cesarean wounds.
11080758|NCT04210687|Active Comparator|Trapeziectomy|Standard simple trapeziectomy, no pins.
11080627|NCT04211597|Active Comparator|Group 2: Silicone gel|Each participant in Group 2 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months.
11080628|NCT04211597|Experimental|Group 3: Silicone gel plus Me-EGF|"The day of Cesarean delivery was recorded as Day 0. For participants in Group 3, on day 0 prior to final dermal closure, 4ml of Me-EGF (containing 40mcg microencapsulated polysaccharide and rhEGF) was sprayed evenly along the incision site, subsequently covered with antibiotic ointment and sterile gauze. Another 0.5 ml (5 mcg of Me-EGF) was sprayed during dressing change on day 1 and day 5 respectively. At each dressing change, the sutured wound was cleaned by sterile normal saline, followed by Me-EGF sprays, and waited for two minutes to allow for absorption, then covered with dry sterile gauze.
~Each participant in Group 3 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months."
11080629|NCT04211584|Active Comparator|forearm radial artery access|traditional access (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
11080630|NCT04211584|Active Comparator|anatomic snuffbox access|access in the snuffbox area of the wrist (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
11080631|NCT04211571|Experimental|MCO group|Hemodialysis using Theranova 400 dialyzer
11080632|NCT04211571|Active Comparator|High-flux group|Hemodialysis using high-flux dialyzer (Fx CorDiax 60 and 80; Fresenius Medical Care)
11080633|NCT04211558|Experimental|Ozanimod 0.46mg|Ozanimod single doses of 0.46 mg (1 x 0.46 mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
11080634|NCT04211558|Experimental|Ozanimod 0.92mg|Ozanimod single doses of 0.92 mg (1 x 0.92-mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
11080635|NCT04211545|Experimental|Administration of CC-92480 and Rabeprazole|Test Formulation CC-92480 and Reference Formulation will be administered orally at 1.6 mg. Rabeprazole will be administered orally at 40 mg.
11080636|NCT04211519|Experimental|Permanent teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
11080637|NCT04211519|Experimental|Primary teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
11080638|NCT04211506|Experimental|Sleep Arm 1|This will be the first of four arms of controlled sleep manipulation.
11080639|NCT04211506|Experimental|Sleep Arm 2|This will be the second of four arms of controlled sleep manipulation.
11080640|NCT04211506|Experimental|Sleep Arm 3|This will be the third of four arms of controlled sleep manipulation.
11080641|NCT04211506|Experimental|Sleep Arm 4|This will be the fourth of four arms of controlled sleep manipulation.
11080642|NCT04211493|Experimental|Experimental-Condition|"20 minutes whole-body-workout with simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
11080643|NCT04211493|Placebo Comparator|Placebo-Condition|"20 minutes whole-body-workout without simultaneous muscle stimulation (EMS).
~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout they are stimulated with the lowest possible stimulation intensity (1). This is perceptible as a slight tingling sensation but the impulse intensity lies below the muscular threshold and therefore generates no muscular activity."
11080644|NCT04211480|Experimental|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
11080645|NCT04211467||Depression|Patients who have been diagnosed with depression
11080646|NCT04211454||Migraine|Patients with migraine headaches
11080647|NCT04211428||Bipolar Disorder|Patients with bipolar disorder
11080648|NCT04211415|Experimental|Part 1: DS-2741a Cohort 1, 5 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 5 mg.
11080649|NCT04211415|Experimental|Part 1: DS-2741a Cohort 2, 15 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 15 mg.
11080650|NCT04211415|Experimental|Part 1: DS-2741a Cohort 3, 50 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 50 mg.
11080651|NCT04211415|Experimental|Part 1: DS-2741a Cohort 4, 150 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 150 mg.
11080652|NCT04211415|Experimental|Part 1: DS-2741a Cohort 5, 500 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 500 mg.
11080653|NCT04211415|Experimental|Part 1: DS-2741a Cohort 6, 1000 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 1000 mg.
11126115|NCT03892603|Experimental|Motor control exercises program|
11080655|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a X mg, where X mg will be based on the maximum tolerated dose identified in Part 1.
11080656|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a Y mg, where Y mg will be based on the maximum tolerated dose identified in Part 1.
11080657|NCT04211415|Experimental|Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)|Participants will be randomized to receive a receive a single, subcutaneous injection of DS-2741a Z mg, where Z mg will be based on the maximum tolerated dose identified in Part 1.
11080658|NCT04211415|Placebo Comparator|Part 3: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
11080659|NCT04211402||Obsessive-Compulsive Disorder|Patients with obsessive-compulsive disorder
11080660|NCT04211389|Active Comparator|ARQ-151 cream 0.3%|Active comparator
11080661|NCT04211389|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
11080662|NCT04211376||Anxiety|Patients with anxiety
11080663|NCT04211363|Active Comparator|ARQ-151 cream 0.3%|Active comparator
11080664|NCT04211363|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
11080665|NCT04211350|Experimental|NightBalance Sleep Position Therapy|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
11080666|NCT04211350|Experimental|Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
11080667|NCT04211337|Experimental|Selpercatinib|Selpercatinib given orally.
11080668|NCT04211337|Active Comparator|Cabozantinib or Vandetanib|Cabozantinib or vandetanib given orally.
11080669|NCT04211324||TENS group|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
11080670|NCT04211324||electro-acupuncture group|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
11080671|NCT04211311|Experimental|FES-legcycling with voluntary arm-work|FES-legcycling combined with arm ski-ergometer or arm-cycling
11080672|NCT04211298|Active Comparator|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
11080673|NCT04211298|Placebo Comparator|Propofol|Propofol will be used for sedation during bronchoscopy
11080674|NCT04211285||community dwelling elderly|community dwelling elderly patients (60 years or older), can read and write, able to use the android software applications
11080675|NCT04211272|Experimental|Part A: Macitentan + Substrate Drug (Sildenafil/Riociguat)|Participants will receive a single dose of film-coated tablet of sildenafil under fasted condition (Treatment A1), then riociguat under fasted condition (Treatment A2) followed by macitentan under fed condition (Treatment B1), then riociguat along with macitentan under fasted conditions followed by macitentan under fed conditions (Treatment B2) and then sildenafil along with macitentan under fasted condition (Treatment B3). Macitentan will be administered in an up-titration regimen.
11080676|NCT04211272|Experimental|Part B: Macitentan + Substrate Drug (Rosuvastatin/Tadalafil)|Participants will receive a single dose of film-coated tablet of rosuvastatin along with tadalafil under fasted condition (Treatment A1), then macitentan under fed condition (Treatment B1) followed by rosuvastatin along with tadalafil and macitentan under fasted condition followed by macitentan under fed condition (Treatment B2). Macitentan will be administered in an up-titration regimen. Part B of the study will be conducted depending on the results of Part A and feedback from Health Authorities.
11080677|NCT04211259|Experimental|Cohort I (loratadine)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
11080678|NCT04211259|Placebo Comparator|Cohort II (placebo)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
11080679|NCT04211246|Active Comparator|Standard group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2.
11080680|NCT04211246|Experimental|ORI group|Fraction of inspired oxygen (FiO2) is titrated guided by SpO2 and ORI
11080681|NCT04211233|Active Comparator|Invasive subdural arm|Implantation of invasive subdural electrode in patients after surgical treatment of acute subdural hematoma
11080682|NCT04211233|Sham Comparator|Standard treatment arm|Patients with acute subdural hematoma who underwent surgical Treatment and receive Standard medical treatment
11080683|NCT04211220|Experimental|Type 1 diabetes|
11080684|NCT04211194||Patients with upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding undergoing endoscopic procedures at AdventHealth Hospitals in Central Florida
11080685|NCT04211181|Experimental|The multifaceted QI interventions|Hospitals randomized into experimental group will implement follow interventions including：the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.
11080686|NCT04211181|Active Comparator|Routine VTE prophylaxis in local clinical practice|Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.
11080687|NCT04211168|Experimental|Toripalimab Plus Lenvatinib|"Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
11080688|NCT04211155|Experimental|Primary Parent|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11080689|NCT04211155|Experimental|Close Friend|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11126116|NCT03892603|Active Comparator|Education and advice|
11080690|NCT04211155|Experimental|Experimenter|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11080691|NCT04211155|Experimental|No Social Partner|Participants will be randomly assigned to one of 4 conditions that differ by who is with them in the MRI scanner room: Primary Parent, Close Friend, Experimenter, No Social Partner.
11080692|NCT04211142|Active Comparator|Laparoscopic repair|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)
11080693|NCT04211142|Active Comparator|Open repair|Open Inguinal Hernia Repair (Lichtenstein repair)
11080694|NCT04211129|Experimental|acupuncture group|Receiving acupuncture and moxibustion
11080695|NCT04211129|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion
11080696|NCT04211116||Pediatric patients indicated to CVC insertion|Paediatric patients indicated to central venous line insertion
11080697|NCT04211103|Experimental|Pembrolizumab single agent|"Pembrolizumab single agent as neoadjuvant treatment before surgical conization and/or partial or radical vulvectomy.
~Pembrolizumab 200 mg flat dose will be administered every 3 weeks for 5 cycles. Within 3 weeks from the last Pembrolizumab administration patients will be submitted to surgical conization or partial or radical vulvectomy."
11080698|NCT04211090|Experimental|Camrelizumab with pemetrexed / carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer
11080699|NCT04211077||Group 1|Occurrence of a SA according to PMSI
11080700|NCT04211077||Group 2|Occurrence of accidental opioid analgesics overdose according to PMSI code
11080701|NCT04211077||Group 3|Controls : Absence of SA and accidental opioid analgesics overdose
11080702|NCT04211064|Other|Deep neuromuscular block|Patients undergoing deep neuromuscular blockade with rocuronium (TOF 0 PTC 1-2)
11080703|NCT04211064|Active Comparator|Moderate neuromuscular block|Patients undergoing moderate neuromuscular blockade with rocuronium (TOF 1-2)
11080704|NCT04211051|Experimental|Arm A|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
11080705|NCT04211038|Experimental|healthy subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
11080706|NCT04211038|Experimental|COPD subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
11080707|NCT04211025|Experimental|Modest|This approach is feasible to integrate into workflows of a wide-range of clinics, and should have a minimal impact on human resources. Materials and strategies to support staff in this work will be provided. .
11080708|NCT04211025|Experimental|Intensive|This approach is more robust, and requires a greater commitment of human resources.
11080709|NCT04211012|Experimental|Treatment Arm|
11080710|NCT04210999|Experimental|Homebased resistance training|Resistance training at home instructed via a smart phone training app and avoidance of pain aggravating activities for 3 months
11080711|NCT04210999|Active Comparator|Supervised resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist and avoidance of pain aggravating activities for 3 months
11080712|NCT04210986|Experimental|Fisetin|Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
11080713|NCT04210986|Placebo Comparator|Placebo|Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
11080714|NCT04210973|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
11080715|NCT04210973|Placebo Comparator|Placebo|Placebo,oral, twice per day
11080716|NCT04210960||Patients group|50 multiple sclerosis patients
11080717|NCT04210960||Control group|30 normal healthy control
11080718|NCT04210947|Experimental|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
11080719|NCT04210947|Experimental|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
11080720|NCT04210947|Experimental|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
11080721|NCT04210947|Experimental|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
11080722|NCT04210947|Experimental|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
11080723|NCT04210947|Experimental|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
11080724|NCT04210921|Experimental|Treatment group|"In the treatment group, the Park needle with a real acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi (feeling of needle sensation refers to tenseness around the needle felt by the practitioner and numbness, distension, soreness, and heaviness around the point felt by the patient), and needles will be stimulated manually at least 10 s, then the needles will be retained for 30 minutes."
11080725|NCT04210921|Placebo Comparator|Control group|In the control group, the Park sham needle will instead of the real needle. It is retractile and adopts the sleeve type blunt needle design. When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin. The sham needle may be manipulated by lifting, thrusting or twirling as the real one, but it will not insert into the skin authentically.
11080726|NCT04210908|Experimental|Biofeedback|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the study group, patients will observe the descent of the head during contraction on the ultrasound display screen.
11080759|NCT04210687|Active Comparator|trapeziometacarpal limited excision|Trapeziometacarpal limited excision; Narrow pseudarthrosis of the trapeziometacarpal joint.
11080727|NCT04210908|No Intervention|Control|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the control group, patients will not observe the ultrasound display screen.
11080728|NCT04210895|Experimental|Warm footbath with ginger powder|Participants receive a daily warm water footbath with added ginger powder over a two-week period
11080729|NCT04210895|Active Comparator|Warm water only footbath|Participants receive a daily warm water footbath over a two-week period
11080730|NCT04210882|Experimental|12-week Moderate-Intensity Exercise Program|"Exercise intervention: Participants will complete 57 total sessions of moderate-intensity exercise (walking while tracking heart rate) over 12 weeks. Exercise intensity, frequency, and session duration will increase during the first 4 weeks of the intervention until participants are completing five (5) sessions weekly and walking for 30 min each session at 60-75% of Heart Rate Reserve (HRR) (moderate-intensity exercise), as follows:
~Week 1: Three sessions, lasting ≥ 15 minutes, at 50-75% of HRR; Week 2: Four sessions, lasting ≥ 20 minutes, at 50-75% of HRR; Week 3: Five sessions, lasting ≥ 30 minutes, at 50-75% of HRR; Weeks 4-12: Five sessions, lasting ≥ 30 minutes, at 60-75% of HRR"
11080731|NCT04210869|Experimental|Experimental|Mixed nuts
11080732|NCT04210869|No Intervention|Control|No mixed nuts
11080733|NCT04210856|Experimental|Sequence of Landscape exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
11080734|NCT04210843|Experimental|Ligelizumab Dose 1 and 3|Liquid in vial 72 mg/mL followed by 120 mg/mL PFS
11080735|NCT04210843|Experimental|Ligelizumab Dose 2 and 3|Liquid in vial 120 mg/mL followed by 120 mg/mL PFS
11080736|NCT04210817||Patients|Patients who have been diagnosed with Rheumatoid Arthritis
11080737|NCT04210804|Experimental|Omega-3|1gEPA and 1gDHA in 200mls smoothie
11080738|NCT04210804|Placebo Comparator|Placebo|200mls smoothie without EPA or DHA. Looks and tastes identical to omega-3 arm
11080739|NCT04210778|Experimental|CRAFT (Cognitive Training and Functional Treatment)|Over 12 weeks this group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training, in addition to a weekly 1 hour remote CO- OP (Meta cognitive strategy training) session. Each participant will set three occupational goals that will be the focus of the CO -OP treatment
11080740|NCT04210778|Active Comparator|Computerized Cognitive Training|This group will be instructed to complete 3 weekly sessions of Computerized Cognitive Training
11080741|NCT04210778|No Intervention|Treatment As Usual|This group will receive no intervention
11080742|NCT04210765|Active Comparator|Clomiphene citrate group 1|Clomiphene citrate dose 50mg/day for 5 days starting on cycle day (2-4).
11080743|NCT04210765|Active Comparator|Clomiphene citrate group 2|Non-responsive to ovulation induction with Clomiphene Citrate with dose:50mg/day; and treated with dose:100mg/day in the succeeding cycle for 5 days, starting on cycle day (2-4).
11080744|NCT04210752|Experimental|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Component Description (per dose):
~Antigen (recombinant VZVgE protein): 50μg Excipients: CIA09A1 dLOS: 10 μg; QS21: 50 μg; DOTAP: 500 μg; DMPC: 500 μg
~Route of administration: Intramuscular injection"
11080745|NCT04210752|Experimental|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Component Description (per dose):
~Antigen (recombinant VZVgE protein): 50μg Excipients: CIA09A2 dLOS: 20 μg; QS21: 50 μg; DOTAP: 500 μg; DMPC: 500 μg
~Route of administration: Intramuscular injection"
11080746|NCT04210752|Experimental|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Component Description (per dose):
~Antigen (recombinant VZVgE protein): 50μg Excipients: CIA09A3 dLOS: 30 μg; QS21: 20 μg; DOTAP: 500 μg; DMPC: 500 μg Route of administration: Intramuscular injection"
11080747|NCT04210752|Experimental|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)
~Component Description (per dose):
~Antigen (recombinant VZVgE protein): 50μg Excipients: CIA09A0 dLOS: 30 μg; QS21: 0 μg;
~DOTAP: 500 μg; DMPC:
~500 μg
~Route of administration: Intramuscular injection"
11080748|NCT04210752|Experimental|Treatment 5 (Shingrix)|"Shingrix
~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.
~Route of Administration: Intramuscular injection"
11080749|NCT04210739|Experimental|trus guided betamethason injection arm|
11080750|NCT04210726|Active Comparator|Active Group - 25% Saline Bath|The Active group's patients will separately have an immersion bath in 25% Sea Salt in Water solution (made by adding pure Sodium Chloride in the form of Sea Salt to Tap Water Bath) at a temperature comfortable to every participant (please note that Solubility of Sodium Chloride in Water does not change significantly with change in temperature, therefore the concentration will remain the same regardless of water temperature), whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers.
11080751|NCT04210726|Placebo Comparator|Control Group - 0.9% Saline Bath|The Control group's patients will separately have a bath in 0.9% Sea Salt in Water (Isotonic solution, made by adding Sodium Chloride in form of Sea Salt to Tap Water) at a comfortable temperature whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers
11080752|NCT04210713|Active Comparator|AUD-Minocycline|
11080753|NCT04210713|Placebo Comparator|AUD-Placebo|
11080754|NCT04210713|Active Comparator|Healthy Control-Minocycline|
11080755|NCT04210713|Placebo Comparator|Healthy Control-Placebo|
11080756|NCT04210700|Active Comparator|Fascia iliaca compartment block|Participants will receive fascia iliaca compartment block before spinal anesthesia and operation
11080757|NCT04210700|Experimental|Pericapsular nerve group block group|Participants will receive pericapsular nerve group block before spinal anesthesia and operation
11080760|NCT04210674|Experimental|The traditional medicinal product of Argan spinosa oil|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the traditional medicinal product of Argan spinosa oil on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
11080761|NCT04210674|Active Comparator|The conventional topical steroid ointment|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the conventional topical steroid ointment on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
11080762|NCT04210661|Active Comparator|classic prediction software|test with classic precition software
11080763|NCT04210661|Experimental|prediction software with spell checker|test with prediction software with spell checker
11080764|NCT04210648|Experimental|Intervention group|Those who will use the mobile app
11080765|NCT04210648|No Intervention|Non-intervention group|Those who will not use the mobile app
11080766|NCT04210609|Experimental|VHT treatment|Patients will be treated with VHT for 55 minutes at a minimum frequency of 2 times per week
11080767|NCT04210596|Active Comparator|Control group|Connective tissue graft harvested from the palate
11080768|NCT04210596|Experimental|Collagen matrix|Pig-derived collagen matrix (Fibro-Gide, Geistlich Biomaterials, Wolhusen, Switserland)
11080769|NCT04210583|Experimental|Vulvovaginal Treatment|"At visit 1 -(6 months post treatment in the CS0716 study):
~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional),
~At Visit 2 (6 months post treatment in the CS0716 study):
~AE assessment, VLQ, FSFI, GRAS and GAIS (optional), Vaginal pH and vaginal smear (optional), Administer study treatment (optional: internal, mons pubis and/or labia treatment).
~Discomfort/pain 10 cm VAS, immediate response assessment (applicable only if treatment provided)
~Final AE follow-up 30 days post Visit 2 Treatment (if applicable): AE assessment (applicable only if treatment provided at Visit 2 in the FE1019 study)."
11080770|NCT04210570|Experimental|Memsorb GA|Memsorb Filter will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
11080771|NCT04210570|Active Comparator|CGA GA|Chemical CO2 absorber (CGA) will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
11080772|NCT04210570|Experimental|Memsorb low-flow|Memsorb Filter will be used during low flow general anesthesia (GA)
11080773|NCT04210570|Experimental|CGA low flow|Chemical CO2 absorber (CGA) will be used during low flow general anesthesia (GA)
11080774|NCT04210570|Experimental|Memsorb laparoscopic surgery|Memsorb Filter will be used during general anesthesia for laparoscopic surgery
11080775|NCT04210570|Experimental|CGA laparoscopic surgery|Chemical CO2 absorber (CGA) will be used during laparoscopic surgery
11080776|NCT04210557|Experimental|TMS to insula|"This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.
~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham."
11080777|NCT04210557|Experimental|TMS to cerebellum|This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
11080778|NCT04210544|Experimental|Dietary protein|Postprandial effects after consuming 20 g of a experimental dietary protein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
11080779|NCT04210544|Active Comparator|Casein|Postprandial effects after consuming 20 g of casein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
11080780|NCT04210544|Placebo Comparator|Water|Postprandial effects after consuming 20 g of water mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
11080781|NCT04210531|Experimental|BJ supplementation|Acute beetroot juice (BJ) supplementation
11080782|NCT04210531|Placebo Comparator|PLA supplementation|Acute placebo (PLA) supplementation
11080783|NCT04210518|Experimental|Neuromuscular training|"Neuromuscular training consisting of:
~Single limb balance task.
~Balance training on an unstable surface.
~Hop drills."
11080784|NCT04210518|Experimental|Stroboscopic glasses group|"This group performed the same neuromuscular training with the addition of stroboscopic glasses during the training performance.
~Single limb balance task.
~Balance training on unstable surfaces.
~Hop drills."
11080785|NCT04210518|No Intervention|Control group|This group received no intervention
11080786|NCT04210505|Experimental|Nasal Povidone-Iodine Decolonization Intervention|Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.
11080787|NCT04210505|No Intervention|Concurrent Control|Standard of Care. This will be usual care at each hemodialysis center.
11080788|NCT04210492|Experimental|45 Gy|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
11080789|NCT04210479|Experimental|Filled-bladder|Bladder filling with 300ml diluted methylene blue.
11080790|NCT04210479|Active Comparator|non filled-bladder|
11080791|NCT04210466|Experimental|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|an ACT intervention + 2 sessions of explicit self-compassion meditation exercises.
11080792|NCT04210466|Active Comparator|Acceptance & Commitment Therapy (ACT)|an ACT intervention + 2 Q&A sessions.
11080793|NCT04210453|Placebo Comparator|Control group|Participants in this group are administered IV normal saline.
11080794|NCT04210453|Experimental|Vitamin C group|Participants in this group are administered IV vitamin C diluted in normal saline.
11080795|NCT04210440|Experimental|Hip avascular necrosis|patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria
11080796|NCT04210427|Experimental|Intervention with polyethylene glycol & SmartPill|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
11080797|NCT04210414|Experimental|Day 3 transfer|Transfer on day 3 when only one embryo is available
11080798|NCT04210414|Experimental|Day 5 transfer|Transfer on day 5 when only one embryo is available
11080799|NCT04210388|Experimental|AZD5718 tablet, Treatment A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions.
11080800|NCT04210388|Experimental|AZD5718 tablet, Treatment B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions.
11080801|NCT04210388|Experimental|AZD5718 tablet, Treatment C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
11080802|NCT04210388|Experimental|AZD5718 tablet, Treatment D|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
11080803|NCT04210388|Active Comparator|AZD5718 film-coated tablet|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions.
11080804|NCT04210375|Active Comparator|JK07|Single dose of JK07 administered by intravenous infusion over 60 minutes
11080805|NCT04210375|Placebo Comparator|Matching Placebo|Single dose of placebo administered by intravenous infusion over 60 minutes
11080806|NCT04210362|Experimental|Educational intervention for 30 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 30 months.
11080807|NCT04210362|Experimental|Educational intervention for 24 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 24 months.
11080808|NCT04210362|Experimental|Educational intervention for 12 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 12 months.
11080809|NCT04210362|No Intervention|Comparison group|Group comprised of children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca, Mexico. Children and their caregivers will not be exposed to the intervention at the moment of their measurements.
11080810|NCT04210349|Experimental|Group A: 6 to 35 months, previously unvaccinated, step 1|Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
11080811|NCT04210349|Experimental|Group 1: 6 to 35 months, step 2|Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11080812|NCT04210349|Experimental|Group 2: 3 to 8 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11080813|NCT04210349|Experimental|Group 3: 9 to 17 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
11080814|NCT04210349|Experimental|Group 4: 18 to 60 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
11080815|NCT04210349|Experimental|Group 5: >=61 years|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
11080816|NCT04210336|Experimental|PAPILOCARE|"Randomized patients will receive two different guidelines depending on the time of randomization:
~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).
~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
11080817|NCT04210336|Placebo Comparator|PLACEBO|"Randomized patients will receive two different guidelines depending on the time of randomization:
~Guideline A (from patient 1 to 100 in order of randomization): guideline of 1 cannula per day x 21 days + 7 days rest during the 1st month + 1 cannula / alternate days until completing 6 months (except for menstruation days ).
~Guideline B (from patient 101 to 200 in order of randomization): pattern of 1 cannula per day x 21 days + 7 days rest for 3 months + 1 cannula / alternate days until completing 6 months (except for menstruation days) ."
11080818|NCT04210323|Experimental|Shotblocker group|ShotBlocker® was used by an experienced registered nurse under the researcher supervision. The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
11080819|NCT04210323|Placebo Comparator|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
11080820|NCT04210323|No Intervention|Control group|Subcutaneous injection was performed with normal subcutaneous drug administration steps by an experienced registered nurse and no additional method was applied. The application process of each patient was managed by the researcher.
11080821|NCT04210310|Experimental|high-dose intranasal oxytocin|Subjects will be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). Subjects will take 4 sprays daily of oxytocin for the entire study.
11082229|NCT04200248|Experimental|RBM-007 + Aflibercept|RBM-007 + Aflibercept intravitreal injection
11080822|NCT04210310|Placebo Comparator|Nasal spray|Subjects swill be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). The spray can be taken with or without food. Subjects will take 4 sprays daily of the placebo for the entire study.
11080823|NCT04210297||Training cohort|Training cohort consists of the cirrhotic patients who collected from January 2018 to October 2019 of Qilu Hospital retrospectively.
11080824|NCT04210297||Internal validation cohort|Internal validation cohort consists of the cirrhotic patients who collected from November 2019 of Qilu Hospital prospectively.
11080825|NCT04210297||External validation cohort|External validation cohort consists of the cirrhotic patients who collected from Jinan Central Hospital retrospectively.
11080826|NCT04210284|Experimental|Nutritional supplementation|Given Ensure Max Protein Nutrition shake 2 weeks before surgery and continued 2 weeks after surgery.
11080827|NCT04210284|No Intervention|No Nutritional supplementation|Treatment as usual
11080828|NCT04210271|Experimental|HIV Self-testing|brief intervention to teach and support consistent self-testing with a friend
11080829|NCT04210271|Active Comparator|Generic Self-screening|time and attention control providing basic self-screening education on a range of health outcomes
11080830|NCT04210245|Experimental|Daily 0.3 mg dose|Administered by subcutaneous injection
11080831|NCT04210245|Experimental|Daily 1 mg dose|Administered by subcutaneous injection
11080832|NCT04210245|Experimental|Daily 3 mg dose|Administered by subcutaneous injection
11080833|NCT04210245|Placebo Comparator|Placebo|Administered by subcutaneous injection
11080834|NCT04210232|Experimental|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
11080835|NCT04210219|Experimental|JNJ-64264681: Dose Escalation and Expansion|Participants will receive oral administration of JNJ-64264681 capsule at a dose assigned by the sponsor Study Evaluation Team (SET), based on the available safety, pharmacokinetics, and pharmacodynamics data in dose escalation treatment group (Part 1); and recommended Phase 2 dose (RP2D) determined in Part 1 in cohort expansion treatment group (Part 2).
11080836|NCT04210206|Experimental|Diet|
11080837|NCT04210206|No Intervention|Control|
11080838|NCT04210193|Active Comparator|Active booster|After three basic open label grass allergen ILIT injections the patient is randomized to an active ILIT booster 1 year after the first treatment.
11080839|NCT04210193|Placebo Comparator|Placebo booster|After three basic open label grass allergen ILIT injections the patient is randomized to a placebo ILIT booster 1 year after the first treatment.
11080840|NCT04210180|Experimental|Varenicline plus e-cigarette|Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. The FDA approved starter kit of varenicline will be provided to participants at V3 (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) along with additional G6 cartomizers. After the first week of varenicline, participants will receive the FDA-approved standard dose of varenicline (1 mg twice daily) and will continue to receive enough G6 cartomizers for the next 11 weeks.
11080841|NCT04210167|Experimental|web-based training and telephone monitoring|The heart failure patients in the intervention group were given web-based training for three months after discharge and followed up by telephone at the first, fourth, eighth and 12th weeks. At the same time, a text message was sent once a week. Scale data were collected before the patient was discharged from the hospital and at the third month of discharge.
11080842|NCT04210141|Active Comparator|Standard of care|Patients will receive an initial antivenom dose of 80mL lyophilized BPI viper antivenom, as per current national guidelines
11080843|NCT04210141|Experimental|Adaptive arm|Patients will receive an initial dose of lyophilized BPI viper antivenom determined by the adaptive model.
11080844|NCT04210128||Breast cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of neoadjuvant chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
11080845|NCT04210115|Experimental|Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy|"Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:
~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)] 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray [Gy] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR
~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.
~All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year."
11080846|NCT04210115|Placebo Comparator|Placebo+FP or FOLFOX Therapy+Radiotherapy|"Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:
~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR
~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.
~All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year."
11080847|NCT04210102|Other|CR + LUS|Patient will be performed first the Chest radiography then the Lung ultrasound.
11080848|NCT04210102|Other|LUS + CR|Patient will be performed first the Lung ultrasound then the Chest radiography
11080849|NCT04210089|Experimental|Soft Cast with a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast with removable cam boot.
11080919|NCT04209647|Experimental|REHIT Exercise|At %100 of heart rate 15 seconds, after this period 15 sec recovery period for all step
11080850|NCT04210089|Experimental|Soft Cast without a Removable Cam Boot|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will be provided with a total contact soft cast.
11080851|NCT04210089|No Intervention|Conventional|Patients with a foot, ankle, or lower leg ulcer (which we expect to be mostly diabetic foot ulcers) will use conventional offloading including total contact casting, removable cast boots (cam boots), CROW boots, bracing, AFO's, offloading shoes, insoles, padding, shoe modifications, crutches, wheelchairs, rollabout, and surgical correction.
11080852|NCT04210076|Experimental|Mindfulness-Based Attention Training for Teams (MBAT-T)|Teams randomized to this group will receive 2-2.5-hour session deliver over up to 5 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises.
11080853|NCT04210076|Active Comparator|Mindfulness-Based Attention Training for Individuals (MBAT-I)|Individuals randomized to this group will receive 2-2.5-hour session deliver over up to 5 weeks of mindfulness training and 15 minutes of daily, out-of-class mindfulness exercises.
11080854|NCT04210076|No Intervention|No-training|Teams will not engage in any mindfulness training
11080855|NCT04210063|Experimental|IMT Intervention|During the first month, participants will be in a month-long control wash in period where no intervention will be provided. During the second month, participants will be in a 4-week daily IMT intervention period. During the third month, participants will be in a month-long efficacy period with no intervention provided.
11080856|NCT04210050|Other|Usual care|Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
11080857|NCT04210050|Active Comparator|Usual care plus NIPPV group only|Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
11080858|NCT04210037|Experimental|APG-1252 160 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
11080859|NCT04210037|Experimental|APG-1252 240 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
11080860|NCT04210037|Experimental|APG-1252 80 mg|intravenous infusion over 30 minutes on days 1, 8 and 15
11080861|NCT04210024|Other|Rural-Dwelling Community Members/Residents|Rural-dwelling adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. A subset of participants (~4) will be identified as Community Health Workers and will receive training with the Diabetes Empowerment Education Program (DEEP).
11080862|NCT04209985|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach will call patients up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
11080863|NCT04209985|No Intervention|Usual care|Patients assigned to usual care have access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
11080864|NCT04209972|Active Comparator|Patients on CT1|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a standard CT scanner. (Aquilion One Genesis, Canon Medical Systems)
11080865|NCT04209972|Active Comparator|Patients on CT2|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a UHRCT scanner. (Aquilion One Precision, Canon Medical Systems)
11080866|NCT04209959|Experimental|low dose group|
11080867|NCT04209959|Experimental|middle dose group|
11080868|NCT04209959|Experimental|high dose group|
11080869|NCT04209946|Active Comparator|Less Invasive Surfactant Administration (LISA)|Infants that are spontaneously breathing with a normal heart rate will be randomized to receive prophylactic surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) by the LISA procedure in the first 2 hours of life, using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. Any repeat dosing for surfactant will be based on clinical indication at the physician discretion by the conventional endotracheal approach.
11080870|NCT04209946|Active Comparator|Continuous Positive Airway Pressure (CPAP)|Infants that are spontaneously breathing with a normal heart rate will be randomized to early Continuous Positive Airway Pressure (CPAP).
11080871|NCT04209933|Active Comparator|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
11080872|NCT04209933|Active Comparator|Colloidal pectin bismuth capsules containing quadruple therapy|Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
11080873|NCT04209933|Active Comparator|Colloidal pectin bismuth particles A quadruple therapy|Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
11080874|NCT04209933|Active Comparator|Colloidal pectin bismuth particles B quadruple therapy|Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
11080875|NCT04209920|Active Comparator|PMMA crown Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
11080876|NCT04209920|Active Comparator|Cast metal coping Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
11080877|NCT04209907|Active Comparator|the group which retrolaminar block will be approved|the retrolaminar block will be made for postoperative analgesia
11080878|NCT04209907|No Intervention|the group which retrolaminar block will not be approved|the retrolaminar block will not be made for postoperative analgesia
11080879|NCT04209894||Psoriasis|They will undergo dermatological assessment and a blinded ultrasound (US) evaluation.
11080880|NCT04209894||Control|They will also undergo dermatological assessment and a blinded ultrasound (US) evaluation.
11080920|NCT04209634|Experimental|Active PLE|Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease
11080921|NCT04209621|Other|Single Arm|single-arm, open-label phase 2 study with a safety lead-in cohort
11080922|NCT04209595|Experimental|1/Arm 1|Escalating doses of PLX038 and rucaparib
11080923|NCT04209595|Experimental|2/Arm 2|MTD of PLX038 and rucaparib
11080881|NCT04209881||Patients with Ankylosing spondylitis|"Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.
~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
11080882|NCT04209881||Healthy women as controls|"Regular menstruation with intervals of 21-35 days; cycle length variations <4 days; and both ovaries still present healthy women will create the control group.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.
~Amh will be looked for. (pmol / l). Antral folukul census in the overin folukular stage will be valued as number. Fsh (iu / l) and Estradiol (pmol / l) values will also be recorded."
11080883|NCT04209868|Placebo Comparator|Pre-PVB with saline|Placebo (20ml Saline) pre-PVB performed post-induction and pre-incision.
11080884|NCT04209868|Experimental|Pre-PVB with 0.25% Levo-bupivacaine|20ml 0.25% Levo-bupivacaine pre-PVB performed post-induction and pre-incision.
11080885|NCT04209855|Experimental|mirvetuximab soravtansine (MIRV; IMGN853)|MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)
11080886|NCT04209855|Active Comparator|Investigator's choice of chemotherapy|"Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle
~Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)
~Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)"
11080887|NCT04209842|Experimental|gastric ballon placement|will receive gastric balloon placed via endoscopy
11080888|NCT04209829||Patients with haematological malignancy|Patients, aged 15 years or over, with haematological malignancy (Lymphoma, ALL, MM) integrated into a CAR-T Cells program treatment
11080889|NCT04209816||ApoC-III LOF|Carriers of apo-CIII loss-of-function mutation
11080890|NCT04209816||ApoC-III GOF|Carriers of apo-CIII gain-of-function mutation
11080891|NCT04209816||TM6SF2-KK|Carriers of TM6SF2 E167K mutation
11080892|NCT04209816||PNLPLA3-MM|Carriers of PNLPLA3 I148M mutation
11080893|NCT04209816||Control|No ApoC-III, TM6SF2 E167K or PNLPLA3 I148M mutation
11080894|NCT04209816||ApoE variants|Carriers of E2/2, E3/3 or E4/4 mutation
11080895|NCT04209816||LIPG|LIPG gene LOF or GOF variant carriers
11080896|NCT04209816||ANGPTL3 or ANGPTL8|ANGPTL3 and ANGPTL8 gene LOF or GOF variant carriers
11080897|NCT04209803|Active Comparator|Minoxidil group|The first group will receive Minoxidil 5% topically twice daily for 4 months.
11080898|NCT04209803|Active Comparator|NAC group|The second group will receive NAC orally 600 mg 3 times a day for 4 months.
11080899|NCT04209803|Active Comparator|Minoxidil + NAC group|The third group will receive combined treatment of Minoxidil 5% twice daily and oral NAC 600 mg 3 times a day for 4 months.
11080900|NCT04209803|No Intervention|Control group|The fourth group will be the patients who are refusing the treatment and will be followed-up over 4 months.
11080901|NCT04209790|Other|Neoadjuvant chemoradiation and surgical resection|The experimental part of the study would be this selection of resectable patients and sequencing neoadjuvant chemoradiation prior to surgery.
11080902|NCT04209777|Active Comparator|Antibiotics|The antibiotic group is provided with amoxicillin capsules 500mg and metronidazole tablets 400mg three times a day for 7 days along with the placebo of probiotics twice daily for 30 days.
11080903|NCT04209777|Experimental|Probiotics|The probiotic group is provided with Lactobacillus-reuteri probiotics (2x10(8)CFU) twice daily after brushing for 30 days.
11080904|NCT04209751||Children with summer diarrhea|Children aged 0 to 16 years with diarrhea
11080905|NCT04209738||Eurythmy Therapy (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified therapist: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by an eurythmy manual and an exercise video. This complements the regular care.
11080906|NCT04209738||Tai Chi (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified teacher: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by a Tai Chi manual and a practice video. This complements the regular care.
11080907|NCT04209738||Standard Care|"Brochure with detailed description of different evidence-based measures for fall prevention, created for the specific age group (Gleichgewicht & Kraft - Trittsicher durchs Leben https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf) and recommendation to visit the family doctor and discuss fall prophylaxis with him."
11080908|NCT04209725|Experimental|CPX-351 and Quizartinib treatment|Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
11080909|NCT04209712|Experimental|haploid allogeneic NK cell therapy|haploid allogeneic NK cell therapy with chemotherapy
11080910|NCT04209699|Experimental|Treatment A: BMS-986165 alone, fasted|
11080911|NCT04209699|Experimental|Treatment B: BMS-986165 alone, fed|
11080912|NCT04209699|Experimental|Treatment C: BMS-986165 with famotidine pretreatment, fasted|
11080913|NCT04209686|Experimental|All Participants|All Participants will receive Paclitaxel, Olaparib and Pembrolizumab.
11080914|NCT04209673||Transcutaneous nerve stimulation (TENS) patients|Patients who received a TENS unit after surgery
11080915|NCT04209673||No TENS|Historic controls- Patients who did not receive a TENS unit after surgery
11080916|NCT04209660|Experimental|recurrent/metastatic adenoid cystic carcinoma (R/M ACC)|"All eligible patients will undergo informed consent and screening for trial enrollment.
~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
11080917|NCT04209660|Experimental|recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).|"All eligible patients will undergo informed consent and screening for trial enrollment.
~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
11080918|NCT04209647|Active Comparator|Continuous Exercise|At %60 of maximal heart rate, 30-60 minutes exercise
11080924|NCT04209569|Active Comparator|NIPP|The NIPP group is a standard social behavior change (SBCC) intervention that tackles a set of underlying causes of malnutrition, with the potential to have both a curative and preventative impact on child malnutrition. The approach in this group/arm involves training and pragmatic behavior change education reinforced by practical activities over a 12-week period to both men and women in selected communities. It aims to utilize easy, viable and accessible solutions within the community that can be used to improve and protect household health and nutrition. The 12-week lesson plans for the circles are divided into 3 components, i) hands-on behavior change sessions that focus on the key pre-identified causes of malnutrition to improve awareness and practice ii) micro-gardening for improved household nutrition security and iii) participatory cooking demonstrations to stimulate improvements in nutritional status and care practices.
11080925|NCT04209569|Experimental|NIPP+|In addition to establishing the circles and implementing the three NIPP components also implemented in the NIPP arm, those randomized to the NIPP+ arm will be provided access to innovations to allow and encourage the households and communities to translate the knowledge into positive practices. The innovations and access to vendors who sell innovations will be made available during the training to the NIPP+ volunteers who will provide trainings and access to vendors during the circle meetings. Most of the additions will be made accessible at a subsidized/low cost. The NIPP+ officers from the program will support NIPP+ volunteers in collaboration with agricultural extension officers.
11080926|NCT04209569|No Intervention|Control|No Intervention
11080927|NCT04209556|Placebo Comparator|Placebo|Placebo
11080928|NCT04209556|Experimental|PF-06826647 100 mg once a day (QD)|PF-06826647 100 mg once a day (QD)
11080929|NCT04209556|Experimental|PF-06826647 300 mg QD|PF-06826647 300 mg QD
11080930|NCT04209556|Experimental|PF-06826647 600 mg QD|PF-06826647 600 mg QD
11080931|NCT04209556|Experimental|Open Label Extension, PF-06826647 400 mg QD|PF-06826647 400 mg QD
11080932|NCT04209543|Experimental|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for up to 13 consecutive weeks
11080933|NCT04209543|Experimental|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 13 consecutive weeks
11080934|NCT04209543|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for up to 13 consecutive weeks
11080935|NCT04209543|Experimental|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
11080936|NCT04209530|Experimental|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
11080937|NCT04209504|Active Comparator|Continuous Perineural Catheter|Placement of preoperative continuous perineural catheter using 25 millimeters (mL) 0.2% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.
11080938|NCT04209504|Active Comparator|Liposomal Bupivacaine Single Shot|Placement of preoperative single shot using 20mL liposomal bupivacaine admixed with 5mL 0.5% bupivacaine.
11080939|NCT04209478|Experimental|TAP Block|Cases were assessed transversus abdominis plane block for postoperative analgesia
11080940|NCT04209478|Experimental|QL Block|Cases were assessed quadratus lumborum block for postoperative analgesia
11080941|NCT04209465|Experimental|Phase 1 - Dose escalation|In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
11080942|NCT04209465|Experimental|Phase 2 - Dose expansion|In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
11080943|NCT04209452|No Intervention|Control|No intervention will be provided for participants enrolled in the control group.
11080944|NCT04209452|Experimental|Rehearsal|Participants will receive instruction on rehearsal strategy.
11080945|NCT04209452|Experimental|Reinforcement|Participants will receive reinforcement for correct recall.
11080946|NCT04209452|Experimental|Rehearsal + Reinforcement|The participants in this group will receive instruction on rehearsal strategy and reinforcement for correct recall.
11080947|NCT04209439|Active Comparator|ultrasound guided erector spinae plane block|30 ml %0.25 ultrasound-guided erector spinae plane block at the level of T8
11080948|NCT04209439|Active Comparator|Dexketoprofen-trometamol|intravenous 50 mg dexketoprofen-trometamol
11080949|NCT04209426||HMB-DMR-HA|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a hydroxyapatite-coated outer surface as well as two pegs and one screw.
11080950|NCT04209426||HMB-DM-CEM|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a bare metal outer surface to be covered with bone-compatible cement.
11080951|NCT04209400|Experimental|Sci-B-Vac®|The third-generation HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
11080952|NCT04209400|Active Comparator|Engerix-B®|The second-generation HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.
11080953|NCT04209387||Control|No PTSD, TBI, and Depression
11080954|NCT04209387||PTSD|Veterans ith PTSD
11080955|NCT04209374||HMB-DMR-HA|Primary total hip arthroplasty with hemispherical dual-mobility acetabular cup
11080956|NCT04209348|Experimental|Physical Activity Intervention|The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather). The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place. The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
11080957|NCT04209348|Active Comparator|Wellness Education|The Wellness Education intervention will deliver information on mom and baby wellness that is unrelated to physical activity, diet, metabolism, or weight (e.g., immunizations during pregnancy and encouragement to immunize the baby on schedule, postpartum contraceptive options and developing a contraceptive plan, infant car seats & safety checks).
11080958|NCT04209335|Other|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
11080959|NCT04209322|Experimental|Pulsed Radiofrequency|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. PRF treatment was administered at 5 Hz and a 2 ms pulsed width for 10 minutes at 45V under the constraint that the electrode tip temperature not exceed 42°C. Finally, patients received 1 mL lidocaine 20 mg/ml mixed with 40 mg triamcinolone acetonide.
11080960|NCT04209322|Active Comparator|Transforaminal Epidural Steroid Injection|Aseptic technique was adopted. Imaging guided (CT) catheter needle (active tip electrode) was inserted and a sensory stimulation test was carried out using an RF generator. The catheter needle was then advanced toward the DRG until the patient reported a tingling sensation and/or dysesthesia at less than 0.3V. After 10 minutes await (as per pRF), patients received 1 mL lidocaine 20 mg/ml mixed with 40 mg triamcinolone acetonide.
11080961|NCT04209309|Experimental|leDLPFC|single session rTMS of the left dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F3)
11080962|NCT04209309|Experimental|riDLPFC|single session rTMS of the right dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F4)
11080963|NCT04209309|Sham Comparator|shamDLPFC|single session sham rTMS over the medial prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the midline with tilted coil)
11080964|NCT04209296||Major Depressive Disorder (MDD)|DSM-5 Diagnosis of MDD
11080965|NCT04209296||Bipolar Disorder|DSM-5 Diagnosis of Bipolar Disorder
11080966|NCT04209296||Obsessive Compulsive Disorder (OCD)|DSM-5 Diagnosis of OCD
11080967|NCT04209296||Post-traumatic Stress Disorder (PTSD)|DSM-5 Diagnosis of PTSD
11080968|NCT04209283|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):
~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
~Experimental: Intervention phase ('B'):
~A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game-play with mental rotation) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a daily diary four times a day following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
~Intervention: Behavioral: Brief cognitive intervention"
11080969|NCT04209257|Experimental|Functional Electrical Stimulation protocol|Participants will be evaluated with and without the use of functional electrical stimulation while walking to determine the neuroprosthetic and neurotherapeutic effects.
11080970|NCT04209244|Experimental|Fish oil|Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)
11080971|NCT04209244|Placebo Comparator|Placebo|Rapeseed Oil, 10 ml per day
11080972|NCT04209231||chronic periodontitis|
11080973|NCT04209231||chronic gingivitis|
11080974|NCT04209231||periodontally healthy|
11080975|NCT04209218|Placebo Comparator|Routine blood pressure management + placebo|Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
11080976|NCT04209218|Experimental|Routine blood pressure management + dexamethasone|Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
11080977|NCT04209218|Experimental|Targeted blood pressure management + placebo|Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
11080978|NCT04209218|Experimental|Targeted blood pressure management + dexamethasone|Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
11080979|NCT04209205|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
11080980|NCT04209205|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
11080981|NCT04209192|Active Comparator|Control group (Amikacin)|"Patients in the control group will receive amikacin as prophylactic antibiotic. It will be administered intravenously 30 minutes before procedure. Patients with an estimated glomerular filtration rate (EGFR) greater or equal than 70 ml/min will receive 1 gram of Amikacin. Patients with an EGFR less than 70 ml/min will received a calculated dose following the next parameters.
~Patients with EGFR between 69-40 ml/min should receive: the calculated GFR x 0.18 = mg/kg.
~Patients with EGFR less than 40 ml/min should receive: the calculated GFR x 0.36 = mg/kg."
11080982|NCT04209192|Experimental|Intervention group (Fosfomycin)|Patients in the intervention group will receive Fosfomycin trometamol as prophylactic antibiotic. It will be administered orally in the night before procedure. Patients must be on fasting and will receive 3 grams.
11080983|NCT04209179|Experimental|PCO371 Low Dose and Low administration frequency|PCO371 low dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
11080984|NCT04209179|Experimental|PCO371 High Dose and Low administration frequency|PCO371 high dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
11080985|NCT04209179|Experimental|PCO371 High Dose and High administration frequency|PCO371 high dose and high administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
11080986|NCT04209179|Placebo Comparator|Placebo|Placebo by oral administration.
11080987|NCT04209166|Experimental|FAD|the first-episode major depressive disorder with atypical feature
11080988|NCT04209166|Experimental|RAD|the recurrent major depressive disorder with atypical feature who have been medication-free for no less than 2 weeks
11080989|NCT04209166|No Intervention|BD|the depressive episode of bipolar disorder
11080990|NCT04209166|No Intervention|HC|healthy control
11080991|NCT04209140||bipolar I disorders who initiate lithium treatment|
11127492|NCT03882918|Experimental|OV101|once daily at bedtime (gaboxadol)
11080992|NCT04209127|Experimental|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis
11080993|NCT04209127|Active Comparator|Control|Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof
11080994|NCT04209114|Experimental|Combination|Neoadjuvant (pre-surgical treatment) nivolumab + bempeg, followed by radical cystectomy (RC), followed by adjuvant (post-surgical treatment) nivolumab + bempeg
11080995|NCT04209114|Experimental|Monotherapy|Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab
11080996|NCT04209114|Other|Standard-of-care|RC alone, without neoadjuvant or adjuvant therapy
11080997|NCT04209088|Experimental|Pulmonary ultrasounds|All patients will be included in the experimental arm
11080998|NCT04209075|Placebo Comparator|Placebo + Metformin|Will take metformin 850mg twice daily (after titrating up over 1-3 days) for 1 week, plus twice daily placebo (powder compounded by NIH pharmacy mixed with a shake provided by study team)
11080999|NCT04209075|Active Comparator|Prebiotic + Metformin|Will take metformin 850mg twice daily (after titrating up over 1-3 days) for 1 week, plus twice daily prebiotic (powder mixed with a shake provided by study team)
11081000|NCT04209062|Experimental|Study device|
11081001|NCT04209062|Active Comparator|Control device|
11081002|NCT04209049|Experimental|Normal renal function|All subjects will receive one dose of NNC0174-0833.
11081003|NCT04209049|Experimental|Mild renal impairment|All subjects will receive one dose of NNC0174-0833.
11081004|NCT04209049|Experimental|Moderate renal impairment|All subjects will receive one dose of NNC0174-0833.
11081005|NCT04209049|Experimental|Severe renal impairment|All subjects will receive one dose of NNC0174-0833.
11081006|NCT04209036||3D laparoscopy arm|patients submitted to total hysterectomy using a 3D laparoscopic camera
11081007|NCT04209036||2D laparoscopy arm|patients submitted to total hysterectomy using a 2D laparoscopic camera (standard laparoscopic camera)
11081008|NCT04209023|Experimental|navigated TMS|All patients are required to have an advanced MRI of the brain including a structural T1, volume measurements of various brain regions, ASL, and BOLD sequences. Patients will also undergo an in-scanner task designed to activate key neurofunctional regions of interest; these areas will provide the cerebral coordinates to be validated by TMS.
11081009|NCT04209010||One-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in one stage using silicone implant and acellular dermal matrix.
11081010|NCT04209010||Two-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in two stages using expander to silicone implant technique.
11081011|NCT04208997|Experimental|Continuation of antiarrhythmic drugs|Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
11081012|NCT04208997|No Intervention|Discontinuation of antiarrhythmic drugs|Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.
11081013|NCT04208984||Control|Patients randomized to this group will receive standard of care induction of anesthesia
11081014|NCT04208984||Study|Patients randomized to this group will receive induction of anesthesia using the Lullabreath game
11081015|NCT04208984||Music Video|Patients randomized to this group will receive induction of anesthesia using the music video game
11081016|NCT04208971||BEAGLE Participants|Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
11081017|NCT04208958|Experimental|VE800 combination treatment with Nivolumab|Subjects will receive 5 days of oral vancomycin, followed by daily VE800 in combination with Nivolumab every 4 weeks.
11081018|NCT04208945|Experimental|Inhaled colistin|Inhaled colistin three times daily for 10 days
11081019|NCT04208945|No Intervention|Standard management|
11081020|NCT04208932||MDD|major depressive disorder
11081021|NCT04208932||HC|healthy control
11081022|NCT04208919|Experimental|DCreg Prior to Weaning|Regulatory dendritic cells that were derived from the recipient's liver donor will be infused into the recipient one week prior to the initiation of immunosuppression weaning.
11081023|NCT04208906|Experimental|Children with congenital cardiac disease|Pediatric patients aged < 7 years undergoing cardiac surgery
11081024|NCT04208893|Experimental|Aerobic training only|The aerobic training intervention will include 60 minutes/session, 3 times/week for 12 weeks at an intensity of 65% - 85% of participants' heart rate reserve (HRR), as determined by the CPET. Patients will be asked to wear a fitness-tracking device to monitor their heart rate response and in order to comply with the prescribed training intensity. All training sessions will start with a 10-minute warm up, 40-minute aerobic interventions, and ends with 10-minute of cool down. One study doctor will be on call during in-hospital training. Onsite supervised aerobic interventions will include play-based activities, whereas home-based aerobic activities will include stationary bikes and exercise activities that would target desired heart rate ranges. Home exercise equipment will be provided.
11081025|NCT04208893|Experimental|Combined aerobic and strength training|Participants in this group will perform a combination of aerobic and strength training activities for 60 minutes/session, 3 times/week for 12 weeks. Aerobic activities for this group will be similar to Arm 1. Strength training will be based on participant's individual assessment findings and developmental status. Resistance level will be set at approximately 50% of the patient maximal load and increased by 3 pounds (or the next level of resistance band) once the patient is able to perform 30 repetitions. Closed kinetic chain exercises such as pushups, squats, and lunges will be made more challenging by the addition of weight or change in body position. Training sessions will include a 10-minute warm up, 40-minute aerobic and strength exercises, and a 10-minute cooldown.
11081026|NCT04208880|Experimental|TBH Brain Workout 1.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be easy to master.
11081062|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 2|Placebo tablets by mouth twice daily for 14 days
11081063|NCT04208672|Experimental|Patient attending for PSG in Sleep Assessment Unit|Subjects referred to the SAU will be invited to participate into this study
11129430|NCT03869684|Experimental|MT-0814 Low dose|MT-0814 plus placebo
11081027|NCT04208880|Experimental|TBH Brain Workout 2.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be moderately difficult to master.
11081028|NCT04208880|Experimental|TBH Memory 1.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be easy to master.
11081029|NCT04208880|Experimental|TBH Memory 2.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be moderately difficult to master.
11081030|NCT04208880|Active Comparator|Book Club|The Book Club will be given a book to read on how to improve brain health and will discuss separate chapters across 8 sessions. These sessions will be led by the participants and no formal structure will be provided. No personal challenges will be asked of participants and no log will be required. All groups will have a sign-in sheet to record individual participation.
11081031|NCT04208880|No Intervention|No Contact Wait List|The Wait List group will simply take the the surveys at each time point as the other groups.
11081032|NCT04208867|Experimental|Intervention - Women|Women who receive MH services from a facility participating in the QI collaborative to improve PCC
11081033|NCT04208867|No Intervention|Control - Women|Women who receive MH services from a facility not participating in the QI collaborative to improve PCC
11081034|NCT04208867|Experimental|Intervention - Provider|Provider working at a facility participating in the QI collaborative to improve PCC
11081035|NCT04208867|No Intervention|Control - Provider|Provider working at a facility not participating in the QI collaborative to improve PCC
11081036|NCT04208854||VINORELBINA|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.
~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.
~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
11081037|NCT04208841|No Intervention|Control - Patient|Participants who receive maternal health services at a facility not participating in the Quality Improvement Intervention or implementing the change package
11081038|NCT04208841|Experimental|Sustaining - Patients|Participants who received maternal health services at a facility where a quality improvement collaborative had been implemented
11081039|NCT04208841|Experimental|Spread - Patients|Participants who received maternal health services at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
11081040|NCT04208841|No Intervention|Control - Providers|Providers who work at a facility not participating in the Quality Improvement Intervention or implementing the change package
11081041|NCT04208841|Experimental|Sustaining - Providers|Providers who work at a facility where a quality improvement collaborative had been implemented
11081042|NCT04208841|Experimental|Spread - Providers|Participants who work at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
11081043|NCT04208815|Experimental|MPL-rich dairy beverage|Daily consumption of 100 g of dairy powder containing 5.3 g MPL for 4 weeks
11081044|NCT04208815|Placebo Comparator|Control dairy beverage|Daily consumption of 100 g of dairy powder containing 0.3 g MPL for 4 weeks
11081045|NCT04208802||Smokers|Volunteers smoking at least 10 cigarettes per day
11081046|NCT04208802||Non-smokers|Non-smoking volunteers
11081047|NCT04208789||Positive Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Positive Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
11081048|NCT04208789||Negative Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Negative Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
11081049|NCT04208776|Experimental|Midodrine+Propranolol|
11081050|NCT04208776|Active Comparator|Propranolol|
11081051|NCT04208763|Experimental|Imipenem+Tigecycline+GM-CSF|
11081052|NCT04208763|Active Comparator|Imipenem+Tigecycline|
11081053|NCT04208750|Experimental|R-Refraction|
11081054|NCT04208750|Active Comparator|S-Refraction|
11081055|NCT04208737|No Intervention|control group|"3 FRC measurements will be perforemed, whereby : First measurement; after aneshesia induction and intubation. Second measurement; after pneumoperitoneum Third measurement; end of the operation
~After the operation,Postoperative Room Air Test (RAT) will be applied."
11081056|NCT04208737|Experimental|study group|"5 FRC measurements will be performed We will apply recruitment maneuver two times to patients with 30cmH2O pressure for 15 seconds .
~First Recruitment maneuver will be applied after the fşrst measurement of FRC following intubation Second Recuitment maneuver will be applied at the end of operation
~First FRC measurement after anesthesia induction and intubation. Second FRC measurement after first recruitment maneuver Third FRC measurement; after pneumoperitoneum Fourth FRC measurement before second recruitment maneuver Fifth FRC measurement after second recruitment maneuver and at the end of operation"
11081057|NCT04208724|Experimental|Training program|Community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members.
11081058|NCT04208711|Other|positive HIV patient not treated by ARV yet|"Before starting HIV treatment, 15 patients will be included in the study and 50mL of whole blood will be taken. After treatment initiation 8 of the 15 patients will entered in the follow-up phase for 1 year (5 followup visit, M1, M3, M6, M9, M12) and 30mL of whole blood will be taken at each visit.
~The duration of the study for the 7 other patients will be 1 day."
11081059|NCT04208698|Experimental|CIN-102 Tablets Dose 1|CIN-102 tablets by mouth twice daily for 14 days
11081060|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 1|Placebo tablets by mouth twice daily for 14 days
11081061|NCT04208698|Experimental|CIN-102 Dose 2|CIN-102 tablets by mouth twice daily for 14 days
11081095|NCT04208412|Experimental|KVD900|
11081064|NCT04208659|Experimental|Self-administration of Auricular Acupuncture Group|There is only one arm in this pilot project, whose purpose is to determine safety of self-administration of Battlefield Acupuncture over a six month period and how well a prosthesis facilitates needle insertion. Five ASP (Aiguille D'acupuncture semi-permanente) needles will be self-inserted into each participant's ear every two weeks according to the standardized acupuncture points in Battlefield Acupuncture.
11081065|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
11081066|NCT04208646|Experimental|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells high-dose group
11081067|NCT04208646|Placebo Comparator|No mesenchymal progenitor cells|No mesenchymal progenitor cells
11081068|NCT04208633|Other|Horizontal placement of the intraocular lens|The eyes randomised to have horizontal placement of intraocular lenses
11081069|NCT04208633|Other|Vertical placement of the intraocular lens|Fellow eye receiving vertical placement of intraocular lens.
11081070|NCT04208620|Placebo Comparator|Placebo|Placebo administered subcutaneously
11081071|NCT04208620|Experimental|Cotadutide|Cotadutide administered subcutaneously
11081072|NCT04208607|Experimental|Study group|Patients with bronchiectasis
11081073|NCT04208594|Active Comparator|GROUP (P):|will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.
11081074|NCT04208594|Experimental|GROUP (I):|will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.
11081075|NCT04208581|Experimental|Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive Yiqi Huoxue Huatan granule in addition to Western medicine.
11081076|NCT04208581|Placebo Comparator|Placebo Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive placebo Yiqi Huoxue Huatan granule in addition to Western medicine.
11081077|NCT04208568|Active Comparator|Gallbladder retrieval from umbilical port|Gallbladder retrieved from 10 mm umbilical port.
11081078|NCT04208568|Active Comparator|Gallbladder retrieval from epigastric port|Gallbladder retrieved from 10 mm epigastric port.
11081079|NCT04208555|Experimental|Boric acid vaginal suppository|
11081080|NCT04208555|Active Comparator|Terconazole vaginal suppository|
11081081|NCT04208542|Active Comparator|Interventional|Under general anaesthesia, ultrasound guided ESP block will perform at the T5 level with 0.375% ropivacaine 20ml. Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
11081082|NCT04208542|No Intervention|Control|Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
11081083|NCT04208529||CTX001|All subjects who complete or discontinue the parent study (CTX001-111 or CTX001-121) after CTX001 infusion will be asked to participate in this long-term follow-up study.
11081084|NCT04208516|Active Comparator|Continuous nerve blocks|A total of 30 subjects equally distributed to either continuous Erector Spinae Plane block for unilateral thoracic surgery , or continuous Quadratus Lumborum block for major abdominal surgery. Patients in this group will receive 20ml 0.5% ropivacaine per block performed after positioning of the needle followed by continuous perineural infusion of 0.25% lidocaine (10ml/hr) beginning in the post-anesthesia care unit (PACU) and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
11081085|NCT04208516|Experimental|Single nerve blocks plus IV lidocaine infusion|A total of 30 subjects equally distributed to either Erector Spinae Plane block for unilateral thoracic surgery, or Quadratus Lumborum block for major abdominal surgery, will be included . Patients in this group will receive 20ml 0.5% ropivacaine, 4mg dexamethasone, and 20mcg dexmedetomidine (30mcg if only one block is performed) per block after proper positioning of the Tuohy needle. Upon patient arrival in the recovery room a continuous infusion of IV lidocaine 50 mg /hr will be started and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
11081086|NCT04208490|Other|HN-STAR|
11081087|NCT04208490|No Intervention|Usual Care|
11081088|NCT04208477|Experimental|BSG patients|
11081089|NCT04208464|Experimental|Arm A|Participants will receive 4mg baracitinib daily for 24 weeks from the baseline visit in week 0. After treatment participants will be followed up for 12 weeks.
11081090|NCT04208464|Experimental|Arm B|After the baseline visit in week 0, participants will wait for a 12 week treatment delay and will then receive 4mg baracitinib daily from week 12-week 36 (i.e. for 24 weeks). After treatment participants will be followed up for 4 weeks for safety.
11081091|NCT04208451|Experimental|Experimental group|Patients on hemodialysis who consumed one month Standardized Aronia Melanocrpa extract
11081092|NCT04208438||BVI Cohort|Cohort to have ultrasound and Mespere BVI device applied.
11081093|NCT04208425|Experimental|Project Personality|The web-based growth mindset intervention, called Project Personality, is delivered entirely via Qualtrics and takes approximately 30 minutes to complete. All intervention activities are self-administered by youth and delivered in a web-based format, including illustrations and audio-recordings of text. Intervention content is designed to maximize relevance for youths experiencing symptoms of depression, including excessive sadness and hopelessness.
11081094|NCT04208425|Active Comparator|Sharing Feelings Intervention|The Sharing Feelings Intervention is delivered entirely via Qualtrics, is self-administered by youth, and takes approximately 30 minutes to complete. It is structurally similar to the growth mindset intervention, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention is to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions.
11081097|NCT04208399|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
11081098|NCT04208399|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive a single oral dose of JNJ-56136379 in fed condition.
11081099|NCT04208399|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
11081100|NCT04208399|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
11081101|NCT04208386|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive single subcutaneous (SC) injection of JNJ-73763989 on Day 1 under fasted condition.
11081102|NCT04208386|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
11081103|NCT04208386|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
11081104|NCT04208386|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive SC injection of JNJ-73763989 on Day 1 under fasted condition.
11081105|NCT04208373|Experimental|Panel 1: JNJ 64417184 plus Itraconazole|Participants will receive single oral dose of JNJ 64417184 on Day 1 followed by itraconazole once daily on Days 6 to 13 along with a single dose of JNJ 64417184 on Day 9 orally.
11081106|NCT04208373|Experimental|Panel 2: JNJ 64417184 plus Etravirine|Participants will receive single oral dose of JNJ-64417184 on Day 1 followed by etravirine twice daily on Days 6 to 19 along with single dose of JNJ 64417184 on Day 15.
11081107|NCT04208347|Experimental|Apatinib and Camrelizumab and S-1 and Oxaliplatin|
11081108|NCT04208347|Experimental|Apatinib and S-1 and Oxaliplatin|
11081109|NCT04208347|Active Comparator|S-1 and Oxaliplatin|
11081110|NCT04208334|Experimental|Curcumin|Curcumin 4000mg/day x 60 days
11081111|NCT04208334|Placebo Comparator|Placebo|Placebo x 60 days
11081112|NCT04208321|Experimental|Cohort 1|40 mg (1 tablet of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
11081113|NCT04208321|Experimental|Cohort 2|80 mg (2 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
11081114|NCT04208321|Experimental|Cohort 3|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
11081115|NCT04208321|Experimental|Cohort 4|320 mg (4 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
11081116|NCT04208321|Experimental|Cohort 5|640 mg (8 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
11081117|NCT04208321|Experimental|Cohort 6|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6, or matching placebo, n=2, after high-calorie, high-fat meal on Day 1 in a double-blind manner.
11081118|NCT04208308|No Intervention|Control negative group|Without supplementation
11081119|NCT04208308|Experimental|Experimental negative group I|"Chia seeds supplementation (25 g)
~On dose (25g) of chia seeds contains:
~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
11081120|NCT04208308|Experimental|Experimental negative group II|"Chia seeds supplementation (15 g)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
11081121|NCT04208308|Experimental|Experimental negative group III|"Combine supplementation: chia seeds and fish oil
~Daily dose:
~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
11081122|NCT04208308|Experimental|Experimental negative group IV|"Fish oil supplementation
~Daily dose:
~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
11081123|NCT04208308|No Intervention|Control positive group|Without supplementation
11081124|NCT04208308|Experimental|Experimental positive group I|"Chia seeds supplementation (25 g)
~On dose (25g) of chia seeds contains:
~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
11081125|NCT04208308|Experimental|Experimental positive group II|"Chia seeds supplementation (15 g)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
11081190|NCT04207853|Sham Comparator|"the vibration group  sham in non-diabetics (G5)"|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
11081191|NCT04207853|No Intervention|non-diabetic control group (G6)|no treatment
11081192|NCT04207840|Experimental|Primatene Mist, E004|Participants who dosed with Primatene Mist.
11082230|NCT04200248|Active Comparator|Sham + Aflibercept|Sham + Aflibercept intravitreal injection
11081126|NCT04208308|Experimental|Experimental positive group III|"Combine supplementation: chia seeds and fish oil
~Daily dose:
~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
~On dose (15g) of chia seeds contains:
~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
11081127|NCT04208308|Experimental|Experimental positive group IV|"Fish oil supplementation
~Daily dose:
~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
11081128|NCT04208295||Patients|Type 2 diabetics
11081129|NCT04208295||Healthy controls|Matched healthy controls
11081130|NCT04208282|Experimental|Trial Arm A|Quickset infusion system for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the 7 day set infusion set, entering Phase 2.
11081131|NCT04208282|Active Comparator|Trial Arm B|7 day set infusion set for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the Quickset infusion systems , entering Phase 2.
11081132|NCT04208269|Active Comparator|Postcard campaign|
11081133|NCT04208269|Active Comparator|Provider-only intervention|
11081134|NCT04208269|Active Comparator|Patient and provider intervention|
11081135|NCT04208269|No Intervention|Standard care|
11081136|NCT04208256|Sham Comparator|Energy Neutral|Bottled water (300 ml) with added fruit punch-flavored non-nutritive sweetener (aspartame) will be used as the energy neutral stimulus.
11081137|NCT04208256|Active Comparator|Energy Surplus|300ml fruit punch-flavored Glucola (75-gram[g], Azer Scientific) will be used as the energy surplus stimulus.
11081138|NCT04208243|Experimental|Oncology Patient|Any Oncology patient in the CCBD who has not previously received more than two sessions of CAT in the outpatient unit and who will be receiving approximately weekly infusions of at least one hour in the infusion center will be identified by a research assistant.
11081139|NCT04208230||Subjects diagnosed with type 2 diabetes mellitus|Subjects with type 2 diabetes defined as those with (1) history and diagnosis of T2D and pharmacologic treatment for a minimum of 3 years OR (2) history and diagnosis of T2D with documented HgbA1C of 6.5 or higher for a minimum of 3 years if they are not under pharmacologic treatment (i.e., diet-controlled)
11081140|NCT04208230||Control|Non-diabetic control group. These subjects must not have pre-diabetes.
11081141|NCT04208217|Experimental|Modeling to Learn (MTL)|12 clinics randomly assigned to MTL
11081142|NCT04208217|Experimental|Usual quality improvement (QI)|12 clinics randomly assigned to usual QI
11081143|NCT04208204|Experimental|Somatocognitive physiotherapy|Every participant will maximally receive 15 individual sessions of somatocognitive physiotherapy
11081144|NCT04208191|No Intervention|Control - Women|Participants who delivered or received family planning services at a facility that was not implementing a QI project on PCC
11081145|NCT04208191|Experimental|Intervention - Women|Participants who delivered or received family planning services at a facility that was implementing a QI project on PCC
11081146|NCT04208191|No Intervention|Control - Provider|Provider working in a facility that is not implementing a QI project on PCC
11081147|NCT04208191|Experimental|Intervention - Provider|Provider working in a facility that is implementing a QI project on PCC
11081148|NCT04208178|Experimental|Part 1: Alpelisib + Trastuzumab + Pertuzumab|"In the Part 1, up to 3 alpelisib dose levels may be sequentially tested in 3 cohorts of subjects (Cohort A, Cohort B, and Cohort C)
~Cohort A: Alpelisib 300mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)
~Cohort B: Alpelisib 250+ trastuzumab (6mg/kg) + pertuzumab (420 mg)
~Cohort C: Alpelisib 200mg + trastuzumab (6mg/kg) + pertuzumab (420 mg)"
11081149|NCT04208178|Experimental|Part 2: Alpelisib + Trastuzumab + Pertuzumab|trastuzumab (6mg/kg i.v.) + pertuzumab (420 mg i.v.) in combination with alpelisib at dose identified in Part 1
11081150|NCT04208178|Placebo Comparator|Part 2: Alpelisib matching Placebo + Trastuzumab + Pertuzumab|trastuzumab (6mg/kg i.v.) + pertuzumab (420 mg i.v.) in combination with alpelisib matching placebo
11081151|NCT04208165|Active Comparator|Group P (ultrasound-guided PVB)|In group P, the patient is in sitting position, a linear transducer (6-15 MHz) placed just lateral to the spinous process. Once the transverse processes and ribs are identified, the transducer is moved slightly cauded into the intercostal space between adjacent ribs to identify the thoracic paravertebral space (PVS) and the adjoining intercostal space. The hyper echoic line of the pleura and underlying hyper echoic air artifacts move with respiration. The needle stimuplex needle will be inserted and 0.5- 1 ml local anesthetic injection administered to show the displacement of pleura downward followed by 15 cc bupivacaine 0.25% into each side the PVS. A pop often is felt as the needle penetrates the internal intercostal membrane. Intravascular injection will be eliminated by negative aspiration before injection. Local anesthetic (15- 20 ml) is slowly injected in small increments, avoiding forceful high-pressure injection to reduce the risk of bilateral epidural spread.
11081152|NCT04208165|Active Comparator|Group T (ultrasound-guided TAB)|In group T, Subcostal blockage will be done in plane technique with 22 G needle (BRAUN Stimuplex D Plus 0,71 50- 80 mm 22 G). The puncture area and the ultrasound probe will be prepared in an aseptic manner. The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. On each side, The rectus abdominis and underlying transverses abdominis muscles near the costal margin and xiphoid process will be identified. In-plane image will be obtained and the needle will be inserted through the rectus muscle 2-3 cm medial to the probe. Once the tip of the needle is visualized to be in the plane, 0.25% bupivacaine will be administered incrementally. The drug will be injected along the oblique subcostal line, extending inferolaterally from the xiphoid towards the anterior part of the iliac crest by multiple punctures; a total of 15 ml will be given on each side.
11081153|NCT04208152|Active Comparator|anle138b|Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
11081154|NCT04208152|Placebo Comparator|placebo|Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
11081155|NCT04208126|Active Comparator|Early ECMO|ECMO is placed immediately after admission to the intensive care unit
11081156|NCT04208126|No Intervention|Control|Conservative therapy unless failure of therapy.
11081157|NCT04208113|Experimental|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.
~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the eight week MBSR programme (2,5 hour group meeting once a week) and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b (48 hours) The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
11081158|NCT04208113|No Intervention|Usual practice|Usual practice
11081159|NCT04208087|Experimental|SI-722|
11081160|NCT04208087|Placebo Comparator|Placebo|
11081161|NCT04208074|Experimental|Exercise|Four months of muscle resistance training (exercise) designed to increase muscle mass and strength. The exercise protocol includes four different lifts with weights including, squats, bench press, dead lift and overhead press. The weights for each lift will be optimized for each participant and increased as the participant adapts to the exercise routine.
11081162|NCT04208061|Experimental|Panel 1: Dabigatran etexilate +DRV/COBI|Participants will receive Treatment A (single dose of Dabigatran etexilate orally) on Day 1 followed by Treatment B (single dose of Darunavir/ cobicistat [DRV/COBI] as fixed dose combination tablet orally and single dose of dabigatran etexilate) on Day 4 followed by Treatment C ([DRV/COBI] as fixed dose combination tablet orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
11081163|NCT04208061|Experimental|Panel 2: Dabigatran etexilate +DRV+rtv|Participants will receive Treatment D (single dose of dabigatran etexilate orally) on Day 1 followed by Treatment E (single doses of Darunavir, and ritonavir [rtv], and single dose of dabigatran etexilate on Day 4), followed by Treatment F (DRV and rtv orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
11081164|NCT04208048||FLXfit 15|The FLXfit 15 device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
11081165|NCT04208022||Healthy Musician|At least 15 hypermobile musicians and at least 15 non-hypermobile musicians will be included in the study.
11081166|NCT04208022||Healthy Individuals|The study will include at least 15 healthy non-hypermobile individuals who do not deal with music and at least 15 healthy hypermobile individuals who do not deal with music.
11081167|NCT04208009|Experimental|Advance care planning animated videos|This arm consists of viewing four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
11081168|NCT04207983|Experimental|Treatment Arm A (Re-administration)|Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
11081169|NCT04207983|Experimental|Treatment Arm B (Single administration)|One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
11081170|NCT04207970||Clients under PDS Community Team|27 adult clients under PDS Community Team
11081171|NCT04207957|Other|IV|2 h IV infusion (Groups A/B)
11081172|NCT04207957|Other|oral (fasted)|30 mg tablets given after an overnight fast (Groups A/B)
11081173|NCT04207957|Other|oral (fed)|30 mg tablets given after a high fat breakfast (Groups A/B)
11081174|NCT04207957|Other|oral (intact tablet)|30 mg tablets (Group C)
11081175|NCT04207957|Other|oral (NG tube)|30 mg tablets in water via NG tube (Group C)
11081176|NCT04207944|Experimental|Sulindac|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Patients will continue drug for 3 years during follow-up.
11081177|NCT04207944|Placebo Comparator|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus placebo. Patients will continue placebo for 3 years during follow-up.
11081178|NCT04207931|Active Comparator|Topical steroid plus oral antibiotic group|Participants in this group receive topical steroid (class I-II applied once daily) plus oral antibiotic group (doxycyline 100 mg twice daily for 6 months), and then topical minoxidil (5% solution or foam) after 8 months of treatment.
11081179|NCT04207931|Active Comparator|Topical steroid plus intralesional steroid injection group|Participants in this group receive topical steroid (class I-II applied once daily) plus intralesional steroid group (7.5mg/cc of kenaolog, max dose of 3 cc), and then topical minoxidil (5% solution or foam) after 8 months of treatment
11081180|NCT04207918|Experimental|Neoadjuvant Chemoradiotherapy（NCRT）|NCRT arm receives intensity-modulated radiotherapy concurrently with S-1（40-60/m2/d，orally twice a day） and nimotuzumab（400mg/d，by intravenous infusion once a week）.
11081181|NCT04207905||Exempt for Evaluation Purposes|Individuals who would have been subject to the Healthy Michigan Plan (HMP) work requirements but have been randomly assigned to a control group that is exempt from reporting for evaluation purposes
11081182|NCT04207905||Work Requirement|Individuals who are subject to the Healthy Michigan Plan (HMP) work requirements
11081183|NCT04207879||weight loss group|Dynamic changes in body composition, biochemical metabolomics and gut microbiome will be reported among overweight and obese patients.
11081184|NCT04207866|Experimental|Remote AT services|Experimental group will consist of participants who access auditory therapy services from a remote location. Services will be conducted with this group via teleconferencing over the Ontario Health Network.
11081185|NCT04207866|Active Comparator|In House AT|This group will receive auditory therapy services face-to-face at the treatment site.
11081186|NCT04207853|Experimental|whole body vibration in diabetics (G1)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
11081187|NCT04207853|Sham Comparator|the sham vibration group in diabetics (G2)|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
11081188|NCT04207853|No Intervention|diabetic control group (G3)|no treatment
11081189|NCT04207853|Active Comparator|whole body vibration group in non-diabetics (G4)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
11082231|NCT04200235|Experimental|High weight group|High weight group
11081193|NCT04207840|Active Comparator|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
11081194|NCT04207840|Active Comparator|Albuterol HFA|Participants who dosed with Albuterol HFA.
11081195|NCT04207827|Experimental|xSmoker app|"The xSmoker app was developed with European Commission funding. xSmoker is a digital health coaching mobile app that helps individuals stop smoking and remain smoke free. The initial version of the xSmoker application was received from the developers and translated into Romanian by the research team. The content has been divided into three main sections: Daily Tips (approximately 630 items), which includes information on the beneficial effects of quitting smoking, Panic Tips (approximately 100 items), which can be accessed at that time when risk of smoking relapse is high, as well as a section called Library (about 120 items), where detailed information on the topics included in the first two sections is provided."
11081196|NCT04207827|Experimental|xSmoker app + SMSs|The xSmoker app + phone text messages with content based on the Motivation and Problem Solving approach and informed by our prior work. The investigators developed six categories of messages sent to participants: (1)Importance and trust, (2)Fear of relapse, (3)Partner support, (4)Breastfeeding, (5)The need to smoke, and (6)Relapse. Four major objectives were established based on the content of the SMS text messages, with the help of the literature: (1)supporting motivation, (2)supporting self-efficacy, (3)supporting dyadic effectiveness, and (4)developing problem-solving skills. The messages were delivered using Textit, a platform for visually building interactive SMS applications (htpps://textit.in). All the messages were uploaded in the platform and different flows and sub-flows were created for every day of the intervention to automatize the process of SMS delivery. A combination of trigger words and skip patterns was used in order to tailor the messages.
11081197|NCT04207827|Other|Control|Usual postnatal care
11081198|NCT04207814|Experimental|Cases|
11081199|NCT04207801|Experimental|Arm-1|400 mg AUR101 twice daily
11081200|NCT04207801|Experimental|Arm-2|600 mg AUR101 twice daily
11081201|NCT04207801|Placebo Comparator|Arm-3|Matching Placebo twice daily
11081202|NCT04207788|Experimental|Intervention|HIP-REP programme offers elderly with hip fracture add on activity-focused interventions.
11081203|NCT04207788|Active Comparator|Usual care|The elderly with hip fracture in the control group will receive usual care.
11081204|NCT04207775||NSCLC|Patients with confirmed EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed from first line EGFR-TKI therapy who will receive different treatment
11081205|NCT04207762||PET/CT Diagnostic Imaging|Each subject will have a PET/CT scan, using 18F-AmBF3-TATE. 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada.
11081206|NCT04207736|Active Comparator|Reproxalap Ophthalmic Solution (0.25%)|
11081207|NCT04207736|Placebo Comparator|Vehicle Ophthalmic Solution|
11081208|NCT04207723|Experimental|TENS Therapy|Tens therapy + placebo drug therapy
11081209|NCT04207723|Sham Comparator|Control|Standard treatment (paroxetine 20 mg) + sham therapy
11081210|NCT04207723|Experimental|Combination therapy|Tens therapy + standard treatment (paroxetine 20 mg)
11081211|NCT04207710|Experimental|Microbial growth after application of Pain Ease|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Pain Ease numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
11081212|NCT04207710|Experimental|Microbial growth after application of Ethyl Chloride|An area of skin on the wrist and lower back of an individual's skin will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Ethyl Chloride numbing spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
11081213|NCT04207684|Experimental|Testosterone|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration (6 fractions: 0-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h post-administration).
11081214|NCT04207671|Other|Omission of chest tube|After wedge resection and the air-leak test, patients will receive complete omission of chest tube and directly close the incision.
11081215|NCT04207671|Experimental|Improved drainage strategy|After wedge resection and the air-leak test, patients willreceive a two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-removal.
11081216|NCT04207658|Experimental|Valsalva's Pushing|The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. At the expulsion phase (baby's head is visible in vulva), they are encouraged to perform the Valsalva's manoeuvre that they have practised in routines of delivery; When contractions start, breathe twice normally. Take a deep breath and hold. Compress the air with the help of diaphragm and abdominal muscles. Push strongly and long (for 10-15 sec). Breathe out and take another deep breath, hold it and push as strongly as possible for another 10-15 seconds. Stop pushing when contractions are mild. Breathe 2-3 times in normal style. Relax and have a rest until the next contraction.
11081217|NCT04207658|No Intervention|control|Practices on Spontaneous Pushing Group The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. Just after feeling the push, the gravitas are requested perform pushing as follows; Breathe normally until participants feel the push when contractions start, pull back muscles surrounding the uterus while breathing. Start pushing gradually and breathe out smoothly by minimizing lips. Push between breaths for 5-6 seconds while pushing downwards by breathing out. Breathe normally when contractions weaken.
11081218|NCT04207645||African|patients originating from Nigeria and Sudan (11 centres)
11081219|NCT04207645||Latin American|patients originating from Mexico (5 centres)
11081220|NCT04207645||South Asian|patients originating from India and Pakistan (10 centres)
11081221|NCT04207645||European|patients originating from Spain (11 centres).
11081222|NCT04207632||Intervention|The Group of patients will receive routine treatment of muscle hypertonia with botulinum toxin type A in their elbow flexors.
11081378|NCT04206514|No Intervention|control|Participants receive the standard of care for post-abortion patients in Kenya.
11081223|NCT04207619|Experimental|Arm 1|Participants will have their glial acetate metabolism measured by carbon-13 magnetic resonance spectroscopy as well as their neuroendocrine response to hypoglycemia 3 days later.
11081224|NCT04207606||Epidural Steroid Injection Patients|Patients who are to receive an epidural steroid injection as an outpatient.
11081225|NCT04207593|Active Comparator|Oxygen Therapy provided|Patients will be divided in a supplemental-oxygen group (primary intervention group) throughout the study
11081226|NCT04207593|Sham Comparator|no-supplemental-oxygen group (control group)|Patients of the control group will beginn the study without Oxygen Therapie and will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group).
11081227|NCT04207580||Inclusion and follow up of pediatric patients|"Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome, from the beginning of the disease to 18 years old or transfer of the follow-up to a nephrology unit for adults.
~130 new patients are expected to be included on an annual basis."
11081228|NCT04207567|Experimental|Intervention Arm|Participants in this arm will be instructed to perform one set each of push-ups, angled-rows and bodyweight squats every weekday without supervision for a total of 24 weeks. They will receive the equipment necessary to perform the exercises as well as guidance on proper performance. They will also receive training in the Tiny Habits® Method at baseline and digital coaching for the duration of the study.
11081229|NCT04207567|No Intervention|Waitlist Control Arm|"Participants in the control arm will be instructed to refrain from resistance training for the initial 12 weeks of the study.
~Note that, after the 12-week follow-up assessment (at which the primary outcome of composite reps will be assessed), this group will begin the RT program. They will receive the same equipment, training, and coaching as the intervention group, and they will continue the RT program for 12 weeks, followed by a 24-week assessment."
11081230|NCT04207554||Pregnancy Positive|Pregnant subjects within 11 weeks since the first day of last period.
11081231|NCT04207554||Pregnancy Negative|Non-pregnant subjects.
11081232|NCT04207541|Experimental|Control group and Intervention group|For control group, participants will be treated with usual care. For intervention group, participants will be provided a session of education regarding insulin initiation with brief motivation interviewing.
11081233|NCT04207528|Experimental|Peer Helping Condition|Participants in the peer helping condition will be asked to write about their experiences in their first-year at UCLA (freshman or first-year after post-transfer), with an emphasis on using the experience to benefit someone who is about to be a first-year student.
11081234|NCT04207528|Active Comparator|Facts-only Control|Participants in the facts-only writing condition will be asked to write facts about their experiences in their first-year at UCLA (freshman or first-year post-transfer). Unlike the previous conditions, they will not be instructed to write for the benefit of another individual.
11081235|NCT04207515|Experimental|Removal of wisdom tooth under conscious sedation|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure, oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia , intraoperative time-after extraction , postoperative time . In this group removal of wisdom teeth was done under conscious sedation. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
11081236|NCT04207515|Active Comparator|Removal of wisdom tooth under local anesthesia|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure , oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia, intraoperative time-after extraction, postoperative time. In this group, removal of wisdom teeth was done under local anesthesia. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
11081237|NCT04207489||endoscopic submucosal injection of indocyanine green|
11081238|NCT04207476|Experimental|Treatment arm|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
11081239|NCT04207476|Placebo Comparator|Placebo|Placebo magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
11081240|NCT04207463|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11081241|NCT04207450|Placebo Comparator|Placebo Group|Placebo Gel + Placebo Solution (Distilled Water)
11081242|NCT04207450|Experimental|Placebo Gel + Glutaraldehyde (GPG)|Placebo Gel + 5% Glutaraldehyde Aqueous Solution
11081243|NCT04207450|Experimental|Phosphoric Acid + Glutaraldehyde (GAG)|37% Phosphoric Acid + Glutaraldehyde Aqueous Solution (GAG)
11081244|NCT04207437|Experimental|Vibration Therapy|Patients will hold a hand held vibrating device for 3 minutes on each hand daily for 4 weeks.
11081245|NCT04207424|Experimental|Embolization|Patients undergoing embolization of the gastro-epiploic arcade
11081246|NCT04207411|Experimental|Bupivacaine|The dose received at each injection will be 5 mg. One injection per week will be carried out over 4 consecutive weeks
11081247|NCT04207411|Sham Comparator|Lidocaine|The dose received at each injection will be 1.25mg. An injection unique per week will be carried out over 4 consecutive weeks.
11081248|NCT04207398|Experimental|TIPS|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver.
11081418|NCT04206202|Experimental|PSI group|3D-printed patient-specific instrumentation (PSI) will be used in the total knee arthroplasty (TKA) of this group.
11081249|NCT04207398|Active Comparator|NSBB+EBL|Participants randomized to this group will receive the combination therapy of non-selective beta-blocker (NSBB) and endoscopic band ligation (EBL) . NSBB, including propranolol and carvidilol, will be started at day 5 after the index bleeding and elective EBL sessions started 2 weeks after the index bleeding.
11081250|NCT04207385|Active Comparator|A group: Routine treatment group|Routine dosage of venlafaxine during the first 4 weeks.
11081251|NCT04207385|Experimental|B group: PGx-guided group|The PGx test results guide the dosage of venlafaxine during the first 4 weeks.
11081252|NCT04207385|Active Comparator|C group: Routine PGx-guided group|The PGx test results guide the dosage of venlafaxine between 4th and 8th weeks.
11081253|NCT04207385|Active Comparator|D group: The combination of PGx and TDM group|The PGx and TDM test results guide the dosage of venlafaxine between 4th and 8th weeks.
11081254|NCT04207372|Experimental|Whey protein isolate|
11081255|NCT04207372|Experimental|Zein|
11081256|NCT04207372|Placebo Comparator|Protein-free|
11081257|NCT04207359|Experimental|Creatine Supplement Group|Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Participants will be given a fitbit (electronic watch that measures steps or heart rate) as well to track heart rate and monitor activity throughout the study.
11081258|NCT04207359|No Intervention|Exercise Only Control Group|Participants will not participate in the creatine intervention (creatine supplementation). Participants will engage in three center-based exercise sessions each week for 12 weeks; each session lasting roughly 1-hour. Exercise sessions will be held by trained study staff held at the Medical Arts and Research Center Physical Therapy clinic (address listed above).
11081259|NCT04207346|Experimental|TMS|transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
11081260|NCT04207346|Sham Comparator|Sham|sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
11081261|NCT04207333|Experimental|Prolonged sitting, followed by mental stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
11081262|NCT04207333|Experimental|Brief sitting, followed by mental stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
11081263|NCT04207320|Experimental|Stage I|Stage I will include eligible subjects between the ages of 10-25 years.
11081264|NCT04207320|Experimental|Stage II|Stage II will include eligible subjects between the ages of 2-25 years.
11081265|NCT04207307|Experimental|Multimodal exercise intervention|Behavioral: Multimodal exercise intervention with machine-based resistance, coordination and endurance training, 1-2 times per week for 30-45 min (increasing amount of training).
11081266|NCT04207307|Sham Comparator|Usual Care|General recommendations for healthy ageing, usual physical activity. No machine-based strength training intervention.
11081267|NCT04207294|Experimental|Vitamin D-enriched pork|One portion of Vitamin D-enriched pork
11081268|NCT04207294|Placebo Comparator|Control pork|One portion of control pork
11081269|NCT04207294|Active Comparator|Vitamin D supplement|Equivocal dose of Vitamin D supplement
11081270|NCT04207294|Experimental|Vitamin D-enriched chicken|One portion of Vitamin D-enriched chicken
11081271|NCT04207294|Placebo Comparator|Control chicken|One portion of control chicken
11081272|NCT04207281|Active Comparator|Honey|Raw honey (1.5 tablespoons)
11081273|NCT04207281|Placebo Comparator|Placebo|Honey placebo (1.5 tablespoons)
11081274|NCT04207268|Experimental|Gardening and Nutrition Advice|Participate in gardening activities, food demonstrations and nutrition advice
11081275|NCT04207268|Placebo Comparator|Nutrition Advice alone|Participate in only nutrition advice
11081276|NCT04207255|Experimental|Cohort 2: Opaganib with abiraterone|
11081277|NCT04207255|Experimental|Cohort 3: Opaganib with enzalutamide|
11081278|NCT04207255|Experimental|Cohort 1a: Opaganib with abiraterone|
11081279|NCT04207255|Experimental|Cohort 1b: Opaganib with enzalutamide|
11081280|NCT04207229||CODMAN CERTAS Programmable Valves|CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve.
11081281|NCT04207203|Other|Single arm study|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
11081282|NCT04207190|Experimental|Treatment (talazoparib, gemtuzumab ozogamicin)|Patients receive talazoparib PO daily on days 1-28 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11081283|NCT04207177|Active Comparator|Mycophenolate mofetil|In the subgroup of living donor recipients included before transplantation this group will be treated with mycophenolate mofetil (750 mg BID) for one week
11081284|NCT04207177|Active Comparator|Tacrolimus|In the subgroup of living donor recipients included before transplantation this group will be treated with tacrolimus (BID, dose by weight) for one week
11081285|NCT04207151|No Intervention|Standard of Care|Participants will receive HIV and STI testing, clinical monitoring, client centered counseling and PrEP prescriptions as standard of care, this includes scheduled visits every three months.
11081286|NCT04207151|Experimental|Pre- and Post- SNAPS intervention|In addition to the standard of care treatment, approximately twenty subjects will be selected for interview pre- and post-SNAPS intervention to assess PrEP facilitators and barriers for uptake. Participants of interest include cis- and trans-women, for which there is limited data regarding PrEP and HIV prevention.
11081287|NCT04207125|No Intervention|Without multilevel intervention|patients after liver or kidney transplantation / standard care
11081288|NCT04207125|Active Comparator|With multilevel intervention|patients after liver or kidney transplantation / multilevel intervention program
11081289|NCT04207112|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
11081290|NCT04207112|Experimental|Regimen 2: Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
11081291|NCT04207112|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
11081292|NCT04207112|Active Comparator|Control regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB
11081293|NCT04207099||ARM 1|Patients receive standard of care treatment for their diabetic foot ulcer
11081294|NCT04207099||ARM 2|Patients receive MolecuLight i:X guided treatment for their diabetic foot ulcer
11081295|NCT04207086|Experimental|6 wk pembrolizumab & lenvatinib, surgery, 46 wk pembrolizumab|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks.
11081296|NCT04207073|No Intervention|Control group|No intervention.
11081297|NCT04207073|Experimental|Exercise group|Participants in the exercise group will perform 2 sets of 5 repetitive Median nerve mobilization exercises (total of 20 sessions) per day for 10 days.
11081298|NCT04207060|Experimental|Oral indomethacin 50 mg po BID|The study intervention is oral indomethacin. Indomethacin is an FDA approved, commonly prescribed NSAID. Commercially available indomethacin will be utilized in this study. One capsule orally BID for 28 days. Those in the indomethacin arm will receive indomethacin 50 mg BID. Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication.
11081299|NCT04207060|Placebo Comparator|Placebo po BID|"Participants in both study arms will receive study medication, one capsule orally BID for 28 days. Those in the placebo arm will receive placebo capsules BID.
~Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication."
11081300|NCT04207047|Experimental|Group A|Group A (up to n=5): Genius exposure 1-3 hours before tissue resection
11081301|NCT04207047|Experimental|Group B|Group B (up to n=5): Genius exposure 30+7 days, 14+3 days, and 7+3 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
11081302|NCT04207047|Experimental|Group C|Group C (up to n=5): Genius exposure 90+14 days, 60+10 days, and 30+7 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
11081303|NCT04207047|Experimental|Group D|Group D (up to n=10): Genius, LaseMD, LaseMD FLEX, eCO2 and/or PicoPlus exposure 14+3 days, 7+3 days, and 1-3 hours before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
11081304|NCT04207034|Experimental|flap surgery and diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.
~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
11081305|NCT04207034|Active Comparator|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
11081419|NCT04206189|Active Comparator|Carbohydrate group|
11081420|NCT04206189|No Intervention|Control group|
11081306|NCT04207021|Experimental|intervention|"the study involves the intake of two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks of a nutritional supplement
~INTERVENTION CAPSULE COMPOSITION active substances for 2 capsules Bio Curcumin 400 mg Polydatin 00 mg Beta-Caryophyllene 48 mg"
11081307|NCT04207021|Placebo Comparator|placebo|particpants included in the placebo group will take two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
11081308|NCT04207008|Experimental|iBDecide App Decision-support Arm|Participants will download the iBDecide app on their smartphone approximately two weeks prior to the scheduled clinic visit. Approximately one week after the clinic visit, survey data, along with demographic data will be collected from all participants via a brief telephone call. We will collect data on app use between installation and the clinic visit as well as in the 3 months following the clinic visit.
11081309|NCT04207008|No Intervention|Control Arm|Control participants will not use the iBDecide app prior to their clinic visit. They will complete a brief telephone survey approximately one week from clinic visit.
11081310|NCT04206982|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
11081311|NCT04206982|Active Comparator|Pulmonary vein isolation arm|
11081312|NCT04206969|Experimental|Transcultural psychotherapy|In addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
11081313|NCT04206969|No Intervention|standard care|usual care provided by the referent medical team
11081314|NCT04206943|Experimental|A Low Dose|4 x 10^6 Car-T cell/ kg
11081315|NCT04206943|Experimental|B High Dose|6 x 10^6 Car-T cell/ kg
11081316|NCT04206930|No Intervention|Control|Standard support: information on alcoholic pathology, medico-psycho-social assessment, relapse prevention program
11081317|NCT04206930|Experimental|Art-Therapy|in addition to standard treatment, art therapy treatment program: 1 session of 2 hours per week in a closed group for 10 weeks
11081318|NCT04206917|Experimental|Multi Pulse Therapy|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
11081319|NCT04206891||Group 1|Bilateral lobular invasive breast cancer
11081320|NCT04206891||Group 2|Invasive lobular breast cancer with age at onset <= 45 years
11081321|NCT04206891||Group 3|Invasive lobular breast cancer with family history for breast cancer
11081322|NCT04206891||Group 4|In situ lobular breast cancer with age at onset <= 45 years
11081323|NCT04206891||Group 5|In situ lobular breast cancer with family history for breast cancer
11081324|NCT04206878||HIV-exposed infants (HEI) eligible for birth testing|All HEI live births born at, or presenting to, one of the 3 study sites, within 3 days of birth.
11081325|NCT04206865|Experimental|ARNI therapy|Patient's randomized to this arm will receive sacubitril-valsartan per study protocol and titrated per titration guidelines.
11081326|NCT04206865|Active Comparator|Standard Oral Vasodilator|Patient's randomized to this arm will receive the oral vasodilator that the clinician chooses including angiotensin receptor blocker (ARB), isosorbide dinitrate, hydralazine, and angiotensin-converting enzyme inhibitor (ACEi).
11081327|NCT04206826|Experimental|PREDELFI Film|
11081328|NCT04206826|Placebo Comparator|CONTROL Film|
11081329|NCT04206813|Experimental|Intervention group|240 eligible women will receive a 2-dose regimen of Gardasil 9 at (0 and 6 months, followed by a rescue 3rd dose at month 12)
11081330|NCT04206813|Active Comparator|Control group|120 eligible women will receive the standard 3-dose regimen of Gardasil 9 at (0, 2, 6 months)
11081331|NCT04206800|No Intervention|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
11081332|NCT04206800|Experimental|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
11081333|NCT04206787||Patients with non-small cell lung cancer (NSCLC)|
11081334|NCT04206761|Experimental|Treatment - QVM149|Participants will complete a two week treatment with QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160 μg delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication via inhalation.
11081335|NCT04206761|Active Comparator|Control|Participants will continue their clinically prescribed treatment with a high dose dual therapy of Inhaled Corticosteroid (ICS)/Long-Acting Beta2-Agonist (LABA) in any approved drug formulation and delivery device for the treatment period of two weeks. (Participants will continue receiving high dose ICS/LABA therapy at the same dose and in the same formulation as at baseline).
11081336|NCT04206748|Experimental|iGlucose Smart Meter|
11081337|NCT04206748|Placebo Comparator|Rx glucose meter|
11081338|NCT04206735|Experimental|Interprofessional Education (IPE)|Each hospital needs to assign a 'COPD-NIV' team of champions to lead the implementation strategy at the local level. We will provide a virtual or in-person (if safety permits) training for the COPD-NIV teams (one RT, one RN, and one MD). The training will consist of 2 modules: 1) NIV knowledge and skills 2) principles of IPE and delivery practice. We will use the train the trainer method; after we train the COPD-NIV team champions, the champions will hold training sessions for their peers either virtually or in-person ( if safety permits). The sessions will be offered 2-4 times/month for 3 months. All sessions will include mixed groups of RTs, RNs and MDs. Full sessions will be offered once/ month every six months for the new staff. For the entirety of the study, there will be conference calls every other month with the investigators and the champions.
11081417|NCT04206215|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
11081526|NCT04205370|Experimental|Active device|Wear active device for remainder of pregnancy (including 3 day run-in period)
11081339|NCT04206735|Active Comparator|On-line Education (OLE)|The COPD-NIV team will be the first at their hospital to complete the on-line educational training and will then encourage the rest of their peers to complete the training. Sites will be given access to free 30 minute continuing education modules customized for each discipline (RN, RT, MD). The training will include 1) knowledge evidence-based indications, contraindication, monitoring and weaning for about NIV in COPD; and 2) skills to manage and monitor patients while on NIV. The training will be offered for the entire period of the study for all staff. The COPD-NIV team will distribute algorithms and printed materials. Conference calls between the investigators and the COPD-NIV team will continue every quarter for the duration of the study with a follow-up call at the end of the study. The calls will discuss distribution of the guidelines and NIV algorithm, problem-cases regarding NIV management, and strategies to recruit clinicians for the educational sessions.
11081340|NCT04206722|Experimental|Treatment group|Shock Wave therapy on the affected hip, for 10 days, 1 application every 2 days
11081341|NCT04206722|Active Comparator|Control group|Ultrasound therapy on the affected hip, for 10 days, 1 application daily
11081342|NCT04206709|Experimental|aerobic effort|Active upper limbs pedaling
11081343|NCT04206709|Sham Comparator|passive pedaling|passive pedaling
11081344|NCT04206670|Experimental|In-Home Technology System|Participants (N=300) will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over a six month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter).
11081345|NCT04206670|Other|Waiting Control|Participants (N=100) will be assigned a date for receiving and installing the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) six months after they enter the study. During that six-month period, questionnaires (e.g., health and well-being) will be administered 3 times (at the start of the study and every 3 months thereafter). At the end of the six-month period, participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over an additional six-month period with questionnaires (e.g., health and well-being) administered 2 times (every 3 months following installation).
11081346|NCT04206657|Experimental|Single dose administration of 1mg KHK7580|
11081347|NCT04206657|Experimental|Single dose administration of 3mg KHK7580|
11081348|NCT04206657|Experimental|Single dose administration of 6mg KHK7580|
11081349|NCT04206657|Experimental|Single dose administration of 12mg KHK7580|
11081350|NCT04206657|Experimental|Multiple dose administration of 6mg KHK7580 for 8days|
11081351|NCT04206644||Systemic sclerosis patients|
11081352|NCT04206644||Healthy donors|
11081353|NCT04206631|Placebo Comparator|Doxycycline Group|Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
11081354|NCT04206631|Active Comparator|Comedone Extraction Group|Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
11081355|NCT04206618||premenopausal normal|premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
11081356|NCT04206618||postmenopausal normal|postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
11081357|NCT04206618||postmenopausal osteopenia|postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage
11081358|NCT04206618||postmenopausal osteoporosis|postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage
11081359|NCT04206618||hip fracture|postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis
11081360|NCT04206618||controls (knee osteoarthitis)|postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls
11081361|NCT04206618||teriparatide group|postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months
11081362|NCT04206618||denosumab group|postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months
11081363|NCT04206605|Experimental|Lanadelumab|Participants will receive 300 milligrams (mg) of lanadelumab solution in a prefilled syringe (PFS) as subcutaneous (SC) injection once every 2 weeks (q2w) for 26 weeks.
11081364|NCT04206605|Placebo Comparator|Placebo|Participants will receive 300 mg of placebo matched to lanadelumab SC injection once q2w for 26 weeks.
11081365|NCT04206592|Active Comparator|i Gel LMA|The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
11081366|NCT04206592|Active Comparator|Ambu Aura Gain|It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
11081367|NCT04206579|Experimental|10% Dextrose|Oral 10% Dextrose
11081368|NCT04206579|Experimental|Natrium Dextrose|Oral Natrium Dextrose
11081369|NCT04206553|Experimental|dupilumab|
11081370|NCT04206553|Experimental|Matching placebo|
11081371|NCT04206540|Experimental|ABVN and Vagal Maeuvers|There is only one arm and subjects can choose the intervention.
11081372|NCT04206527|Experimental|Intervention - Women|Women who receive enhanced FP counseling from an ASHA
11081373|NCT04206527|No Intervention|Control - Women|Women who receive standard FP counseling from an ASHA
11081374|NCT04206527|Experimental|Intervention - ASHA|ASHA who receive enhanced FP counseling training
11081375|NCT04206527|No Intervention|Control ASHA|ASHA who receive standard FP training
11081376|NCT04206514|Experimental|Peer Counselor|Participants receive personalized text messages and phone calls from a peer counselor- a women who had an abortion and was trained in post abortion care and PCC
11081377|NCT04206514|Experimental|Nurse|Participants receive personalized text messages and phone calls from a nurse trained in post abortion care and PCC
11081379|NCT04206501|Experimental|ICM guided Medical Management Group|A pre-specified management regimen based on standard clinical practice will be provided to the study team in which medical management including medication dosing (focusing on beta-blockers and diuretics) will be monitored and modified using Cardiac Implantable Electronic Devices (CIED) and OptiVol Monitor data. Based on CIED and patient engagement data, the study team will adjust medications and dosages, and optimize activity/exercise steps.
11081380|NCT04206501|No Intervention|Conventional Management Control Group|Non-study physicians will receive CIED/OptiVol data (as in usual care) and its use and the management strategy will be left to his/her discretion. To control for patient contact, patients in the conventional management group will have the same study visits as the interventional group and will include in-person device interrogation, and documentation of any medications changes.
11081381|NCT04206488|Experimental|JNJ-70033093 + Digoxin|Participants will receive JNJ-70033093 as oral capsules (Treatment A) in Period 1, followed by digoxin tablets as loading dose and maintenance doses (Treatment B) in Period 2, and then digoxin tablets along with JNJ-70033093 (Treatment C) in Period 3. There will be a washout period of minimum 5 days (and maximum 7 days) between the last dosing day of Period 1 and the first dosing day of Period 2. There is no washout between Periods 2 and 3 (that is, the last day of Treatment B is to be followed by the first day of Treatment C).
11081382|NCT04206475|Experimental|IM-FTP|rehabilitated over 1-month through IM-FTP, including physio-kinesis/occupational, speech, and neuropsychology treatments
11081383|NCT04206475|Active Comparator|standard rehabilitation|physio-kinesis, occupational, speech, and neuropsychology treatments
11081384|NCT04206462||Osteoarthritis|Questionnaire of eating habits, markers of oxidative stress
11081385|NCT04206449|Experimental|Infrared thermography system|Therapeutic decision taken with infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and Apnea-Hypopnea Index (AHI).
11081386|NCT04206449|Active Comparator|Standard Polysomnography (PSG)|Therapeutic decision taken with Standard Polysomnography (PSG), to determine the sleep stages and Apnea-Hypopnea Index (AHI)
11081387|NCT04206436||on CFTR|For patients on or near time of initiation CFTR modulator therapy
11081388|NCT04206436||Controls|controls will be patients not eligible for available treatment
11081389|NCT04206423||Healthy Controls|Age and sex matched healthy controls
11081390|NCT04206423||Lateral epicondylitis|"Newly diagnosed lateral epicondylitis patients.
~Pain in lateral epicondylitis region
~Pain increase with palpation
~Positivity in two diagnostic test out of three (Maudley's test, Mill's test or Cozen's test)"
11081391|NCT04206410|Experimental|Probiotic and prebiotic|Multistrain probiotic with prebiotics (fructooligosaccharides)
11081392|NCT04206410|Placebo Comparator|Placebo|maltodextrin
11081393|NCT04206371|Other|Defibrillation testing during ICD replacment|
11081394|NCT04206358|Experimental|treatment group|The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001), Once every 2 weeks
11081395|NCT04206345|Experimental|Blood Flow Restriction Group|Elbow bending exercises with resistance exercise band (%20 of 1 maximum repetition) for one session. Blood flow restriction band will be placed during exercise session. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
11081396|NCT04206345|Experimental|Exercise Group|Elbow bending exercises with resistance exercise band (%70 of 1 maximum repetition) will be performed for one session.
11081397|NCT04206345|No Intervention|Control Group|10 minutes resting period will be given between evaluation.
11081398|NCT04206332|Experimental|Group 1|5mg/kg IV
11081399|NCT04206332|Experimental|Group 2|5mg/kg SC
11081400|NCT04206332|Experimental|Group 3|20 mg/kg IV
11081401|NCT04206332|Experimental|Group 4a|40mg/kg IV
11081402|NCT04206332|Experimental|Group 4b|40 mg/kg IV
11081403|NCT04206332|Experimental|Group 5|Control
11081404|NCT04206319|Experimental|1|Patients will receive radium-223 treatment every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
11081405|NCT04206293|Experimental|Intradermal Injection - Volar left forearm|Treatment zone
11081406|NCT04206280|Experimental|Pedometer group|This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
11081407|NCT04206280|Active Comparator|Control group|This is the control group. Following radical prostatectomy, subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
11081408|NCT04206267|Experimental|Acceledent group|Patients up to 18 years old who were planned first premolar extractions assigned to study group. AcceleDent Aura appliance was applied for 20 minutes per day. during canine retraction.
11081409|NCT04206267|No Intervention|Control group|Patients up to 18 years old who were planned first premolar extractions assigned to control group. The canine retractions were performed without any additional vibrational device.
11081410|NCT04206254|Experimental|gp96 group|"Patients only receive autologous gp96 vaccination after surgery (do not accept other anti-tumor treatments)
~6 times of gp96 vaccination are administered via subcutaneous injection in 25μg doses within 8 weeks after surgery. gp96 is administered once a week."
11081411|NCT04206254|No Intervention|Control group|Patients do not accept any anti-tumor treatmentsafter surgery
11081412|NCT04206241||High-risk infants|"Mother answered yes to any of the following questions on a risk-screening tool:
~Mother diagnosed with HIV in labor and delivery?
~Mother start ART after 32 weeks' gestation?
~Maternal viral load above 1000 copies/ml in the 3rd trimester?
~Mother seroconvert during pregnancy?
~Was the mother not adhering to ART during pregnancy?"
11081413|NCT04206241||Low-risk infants|Mothers did not answer affirmatively to any of the four screening questions
11081414|NCT04206228|Active Comparator|Active treatment|Active drug: Intravenous iron isomaltoside dissolved in 100 ml NaCl 0.9 %
11081415|NCT04206228|Placebo Comparator|Placebo|Placebo: Intravenous NaCl 0.9 % dissolved in 100 ml
11081416|NCT04206215|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
11081421|NCT04206176|Experimental|Single group crossover|The patients who are on a maintenance dose of clopidogrel 75mg once daily will be transitioned to ticagrelor 45mg twice daily after which they will be tested.
11081422|NCT04206163|Experimental|Acute myocarditis|Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
11081423|NCT04206163|Experimental|Cardiac sarcoidosis|Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
11081424|NCT04206150|Active Comparator|Group 1(femoral triangle apex)|the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal)
11081425|NCT04206150|Active Comparator|Group 2(femur length/15*2 cm above)|the adductor canal catheter is inserted femur length/15*2 cm above the location where the nerve block performed in group 1
11081426|NCT04206150|Active Comparator|Group 3(femur length/15*2 cm below)|the adductor canal catheter is inserted femur length/15*2 cm below the location where the nerve block performed in group 1.
11081427|NCT04206137|Experimental|Group A (PNF rhythmic initiation group )|PNF rhythmic initiation with bilateral asymmetrical upper and lower limb pattern will administered on both sides, there will be 10 repetition and 3 sets for each side, 20 second rest between two sets.
11081428|NCT04206137|Active Comparator|Group B (Swiss ball exercise group)|Swiss ball exercises will be administered. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
11081429|NCT04206124|Experimental|Single Arm Study Group|Includes all consented patients, male and female, undergoing anterior cervical spine surgery, parathyroidectomy or thyroidectomy (18-60 years old), without history of diabetes mellitus and not pregnant or incarcerated.
11081430|NCT04206111||Preoxygenation|
11081431|NCT04206098||Sex|Male/Female
11081432|NCT04206085|Experimental|Active treatment|Radiofrequency and Cryogen
11081433|NCT04206085|Active Comparator|Cryogen-Only|Crygen-Only
11081434|NCT04206085|Sham Comparator|Sham|Sham comparator
11081435|NCT04206072|Experimental|D-0316|D-0316 (75 mg or 100 mg orally, once daily), in accordance with the randomization schedule.
11081436|NCT04206072|Active Comparator|Icotinib|Icotinib (125 mg orally, three times daily), in accordance with the randomization schedule.
11081437|NCT04206059|Experimental|CLASS-D Cohort|Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.
11081438|NCT04206046|Active Comparator|General Anaesthesia|Patients will receive a general anaesthetic, together with a femoral nerve block.
11081439|NCT04206046|Active Comparator|Spinal Anaesthesia|Patients will receive a spinal anaesthetic
11081440|NCT04206020|Placebo Comparator|Placebo Comparator: SkQ1 Vehicle|Vehicle for SkQ1 Ophthalmic Solution
11081441|NCT04206020|Active Comparator|SkQ1|SkQ1 Ophthalmic Solution
11081442|NCT04206007|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
11081443|NCT04205994|Experimental|Tolcapone|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in a single 200mg dosage once in randomized, double-blind, counterbalanced fashion with a placebo.
11081444|NCT04205994|Placebo Comparator|Placebo|Placebo will be administered in a single pill once in randomized, double-blind, counterbalanced fashion with a placebo.
11081445|NCT04205981|Experimental|Aerobic exercise|Exercise intervention. The experimental group increased their energy expenditure according to American College of Sports Medicine and WHO-based physical activity recommendations for all adults to promote clinically significant weight loss and for additional health benefits: 300 min of moderate-intensity aerobic training throughout the week (WHO, 2010; Swift et al. 2014). Participants underwent five 60 min moderate-intensity cycling sessions per week for a period of 8 weeks, 40 sessions in total. Each session involved 5 min of warm up at 40 Watts, cycling for 50 min at a speed that increased their HR to a target HR obtained at 50-60% of peak VO2, and a 5 min of cool down at 40 Watts.
11081446|NCT04205981|No Intervention|Control|. In the control group, participants did not undergo any intervention and were instructed to maintain their regular physical activity and diet regime for 8 weeks.
11081447|NCT04205968|Experimental|Arm I (ramucirumab, paclitaxel)|Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15, and paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11081448|NCT04205968|Experimental|Arm II (irinotecan, leucovorin, fluorouracil)|Patients receive irinotecan IV over 90 minutes on days 1 and 15, leucovorin IV over 2 hours on days 1 and 15, and fluorouracil IV bolus on days 1 and 15. Patients also receive fluorouracil IV over 46-48 hours on days 1-3 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11081449|NCT04205955|Experimental|Arm I (diet modification coaching, motivational messages)|Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
11081450|NCT04205955|Active Comparator|Arm II (standard of care, motivational messages)|Patients receive general healthy living education via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
11081451|NCT04205942|Experimental|Plasma|regular treatment with Argon Plasma Jet according to manufacturer's instructions, 8 times within 14 days
11081452|NCT04205942|Sham Comparator|Placebo|Sham-treatment with Argon Plasma Jet, Plasma producing electric field switched off - no Plasma is produced, just argon gas as effluent, 8 times within 14 days
11081453|NCT04205929|Placebo Comparator|Placebo group|Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
11081454|NCT04205929|Experimental|Curcumin group|Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
11081480|NCT04205695|Active Comparator|OESP (open-ended single port catheter) group|Infraclavicular open-ended single port nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
11081455|NCT04205916|Experimental|Experimental Group|A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.
11081456|NCT04205916|Active Comparator|Control Group|A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
11081457|NCT04205903|Experimental|Group I (paclitaxel, nilotinib hydrochloride monohydrate)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nilotinib hydrochloride monohydrate PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11081458|NCT04205903|Placebo Comparator|Group II (paclitaxel, placebo)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive placebo PO on days 7, 8, 14, and 15 of cycle 1 and days -1, 1, 7, 8, 14, and 15 of cycle 2. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11081459|NCT04205890|Experimental|Ketamine|The present study is designed as a prospective data analysis of patient response to the use of ketamine to treat treatment-resistant depression. For Phase I trail, 10 patients of any gender with an age range of 18 to 70 who have undergone the outlined procedure will be recruited for inclusion. A week before the scheduled ketamine treatment, the patients will have fMRI scans, including structural T1, Arterial Spin Labeling, and Resting BOLD. The scans take around 30 minutes at no charge to the patients. The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage will vary (see below) depending on every individual's unique treatment plan. The same scans will be taken two days after treatment.
11081460|NCT04205877||Registry Group|All participants will have the same data collected at the same time points.
11081461|NCT04205864|Active Comparator|Conventional pelvic lymphadenectomy|Conventional pelvic lymphadenectomy
11081462|NCT04205864|Experimental|Thrombin gel matrix pelvic lymphadenectomy|Thrombin gel matrix applicated after conventional pelvic lymphadenectomy
11081463|NCT04205851|Experimental|KIN-1901|Single or repeat (once weekly for 4 weeks) KIN-1901 subcutaneous injection
11081464|NCT04205851|Placebo Comparator|Placebo|Single or repeat (once weekly for 4 weeks) placebo subcutaneous injection
11081465|NCT04205838|Experimental|Prevention (anakinra, CAR T-cell therapy)|Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.
11081466|NCT04205825|Experimental|New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
11081467|NCT04205825|No Intervention|Habitual Practice|Patients randomized in this arm they will receive the habitual practice.
11081468|NCT04205812|Experimental|INCMGA00012 + chemotherapy (nonsquamous NSCLC)|INCMGA00012 with pemetrexed + cisplatin OR carboplatin followed by INCMGA00012 plus pemetrexed until progression.
11081469|NCT04205812|Active Comparator|Placebo + chemotherapy (nonsquamous NSCLC)|Placebo with pemetrexed + cisplatin OR carboplatin followed by placebo plus pemetrexed until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
11081470|NCT04205812|Experimental|INCMGA00012 + chemotherapy (squamous NSCLC)|INCMGA00012 with carboplatin + paclitaxel OR nab-paclitaxel followed by INCMGA00012 until progression.
11081471|NCT04205812|Active Comparator|Placebo + chemotherapy (squamous NSCLC)|Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
11081472|NCT04205799|Experimental|CABOZANTINIB|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
11081473|NCT04205786|Active Comparator|Control - Standard of Care|"Day 0:
~Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form
~Blood collection
~Continue Usual Care
~Day 45:
~Repeat of baseline questionnaires with addition of vitamin B12 supplements form and investigational agent accountability record
~Blood collection
~Continue Usual Care
~Day 90:
~-Repeat of day 45"
11081474|NCT04205786|Experimental|Study Medication Group (B12)|"Day 0:
~Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form
~Blood collection
~Oral intake of Vitamin B12 Daily in the morning
~Day 45
~Repeat of baseline questionnaires with addition of investigational agent accountability record
~Blood collection
~Oral intake of Vitamin B12 Daily in the morning
~Day 90:
~-Repeat of day 45 without additional study drug intake."
11081475|NCT04205760|No Intervention|Control group|Standard Care as per local guidelines
11081476|NCT04205760|Experimental|Intervention|Oral nutrition support (ONS) and bed-cycling before surgery
11081477|NCT04205721|Experimental|Scripted lesson plan life orientation curriculum|Participants in this arm were in schools where the life orientation teachers in grades 7-9 (in 2016 and 2017) and grade 10 in 2018 were trained to use the new life orientation curriculum that included scripted lesson plans for the sexual and reproductive health content of the program. There are eight lessons for grade 7, eight for grade 8, 11 for grade 9, and 10 for grade 10.
11081478|NCT04205721|No Intervention|Standard life orientation curriculum|Participants in this arm were in schools where the standard life orientation curriculum was used with no additional training and no use of the new materials.
11081479|NCT04205695|Active Comparator|CEMP (closed-ended multiport catheter) group|Infraclavicular closed-ended multiport nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
11081481|NCT04205682|Experimental|Cannabidiol (CBD)|Drug: Cannabidiol (day 1: 1200 mg (800 mg BD); day 2-4: 800 mg (400 mg BD); day 5: placebo BD).
11081485|NCT04205656|Experimental|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
11081486|NCT04205656|Experimental|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
11081487|NCT04205656|Placebo Comparator|Control|Patients randomized in the placebo arm will undergo their standard of care treatment and will not receive LP-PRP or BMC.
11081488|NCT04205643|Experimental|CT-P13 SC|
11081489|NCT04205643|Placebo Comparator|Placebo SC|
11081490|NCT04205630|Experimental|SYD985|SYD985, Intravenous, every 3 weeks (Q3W)
11081491|NCT04205617|Experimental|Healthy Food Prescription|Participants receive services through the Living Hungry program for food insecure diabetic patients.
11081492|NCT04205604|Experimental|Single Arm,|Patients with clinically diagnosed congenital hyperinsulinism
11081493|NCT04205591|Active Comparator|Autologous cortical plate|Thin autologous cortical plates that allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
11081494|NCT04205591|Experimental|Porcine cortical plate|Thin porcine cortical platesthat allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
11081495|NCT04205578|Active Comparator|Butylphthalide (NBP)|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
11081496|NCT04205578|Placebo Comparator|Normal saline|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
11081497|NCT04205565|Active Comparator|L-oxiracetam|
11081498|NCT04205565|Active Comparator|Oxiracetam|
11081499|NCT04205565|Placebo Comparator|Plaecbo|
11081500|NCT04205552|Experimental|Nivolumab|"Nivolumab 2 cycles, every two weeks (q2w)
~o Nivolumab 240 mg i.v. over 30 min"
11081501|NCT04205552|Experimental|Nivolumab/Relatlimab|"Nivolumab/Relatlimab 2 cycles, every two weeks (q2w)
~Nivolumab 240 mg i.v. over 30 min
~Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)"
11081502|NCT04205539|Experimental|Dexmedetomidine|All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
11081503|NCT04205526|Experimental|Active rTMS|Sub-acute stroke patients will be randomized to receive actual rTMS treatment. 1Hz rTMS will be applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
11081504|NCT04205526|Sham Comparator|Sham control|Sub-acute stroke patients randomized to receive sham rTMS. For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
11081505|NCT04205513|No Intervention|Control Group|Standard titration management strategy, consisting of regular in-office visits.
11081506|NCT04205513|Experimental|Study Group|Remote titration management strategy, consisting of telephone contacts, which will utilize data from the Medly system.
11081507|NCT04205500|Experimental|Children with juvenile idiopathic arthritis|The specific carbohydrate diet has been shown to have beneficial effects on IBD and has been implemented in Seattle Children's IBD centre, with some patients using SCD either as primary or complementary therapy. The SCD is a nutritionally balanced diet focused on removing many complex carbohydrates such as grains, dairy products except for yoghurt fermented over 24 hours, vegetables rich in starch and sugars except for monosaccharides like in honey. Participants can eat meat but since it has to be unprocessed food the investigator's experience is that the amounts of meat are not very big. Fish, eggs, sea-food is allowed. Bread is baked from nut and almond flour.
11081508|NCT04205487|Experimental|Contingency Management (CM)|CM will include financial incentives for stimulant abstinence during thrice-weekly urine screening as well as financial incentives for PrEP clinical evaluation and uptake.
11081509|NCT04205487|Experimental|Motivational Interviewing|Four motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered.
11081510|NCT04205474|Active Comparator|VSRR with tricuspid aortic valve|Patients with a tricuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
11081511|NCT04205474|Active Comparator|VSRR with bicuspid aortic valve|Patients with a bicuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
11081512|NCT04205461||Programmed ventricular stimulation before PVR|
11081513|NCT04205448|Experimental|Exercize group|
11081514|NCT04205448|No Intervention|Control group|
11081515|NCT04205435|Experimental|β-globin restored autologous HSC|each subject will accept one dose of β-globin restored autologous hematopoietic stem cells
11081516|NCT04205422|Active Comparator|BIPAP group|Biphasic Intermittent Positive Airway Pressure group
11081517|NCT04205422|Active Comparator|APRV group|Airway Pressure Release Ventilation group:
11081518|NCT04205409|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11081519|NCT04205396|Experimental|Written emotional disclosure|
11081520|NCT04205396|Experimental|Resilience training|
11081521|NCT04205396|Other|Control arm|
11081522|NCT04205383||pregnancy|pregnant women with normal pregnancy
11081523|NCT04205383||pregnancy with complications|pregnant women with placental-mediated complications of pregnancy type complications
11081524|NCT04205383||healthy volunteer|healthy, non-pregnant women volunteers
11081525|NCT04205370|Active Comparator|Deactivated device|Wear deactivated pregnancy coach device for the remainder of pregnancy.
11082232|NCT04200235|Experimental|Low weight group|Low weight group
11081527|NCT04205357|Other|Sulfasalazine in addition to stereotactic radiosurgery|"3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.
~The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery."
11081528|NCT04205344|Experimental|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
11081529|NCT04205344|Experimental|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
11081530|NCT04205331||obese patients|compare between ultrasonography and conventional clinical methods of airway assessment prior to induction of anesthesia correlating it to the Cormack-Lehane scoring system after induction of anesthesia in obese patients
11081531|NCT04205318||study|obese (BMI ≥25.00 kg/m2, n=200)
11081532|NCT04205318||control|non-obese (BMI= 18.50-24.99 kg/m2, n=200)
11081533|NCT04205305|Active Comparator|Conventional blood pressure control group|systolic blood pressure <180 mmHg
11081534|NCT04205305|Experimental|Intensive blood pressure control group|systolic blood pressure <140 mmHg
11081535|NCT04205292|Active Comparator|Dilatation and Evacuation (D&E)|Women in this group will receive an in-patient treatment with Dilatation and Evacuation (D&E) after two doses of Methotrexate .
11081536|NCT04205292|Experimental|hysteroscopic surgery|Women in this group will receive hysteroscopic surgery after two doses of Methotrexate .
11081537|NCT04205279|Experimental|Treadmill training|Subjects randomly assigned to the treadmill training, would undergo either a stance or walking perturbation training protocol. The stroke subjects and older adults would be assigned to either the stance or walking perturbation training protocol. All the participants would be asked to perform voluntary stepping, backward and forward with both limbs pre and post perturbation training. Also, all the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd.
11081538|NCT04205279|Experimental|Overground training|Subjects randomly assigned to overground slip will be made to walk at their comfortable natural walking speeds either for 5-8 trials on the instrumented walkway (7 m 1.5 m) at their self-selected preferred speed. All the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd. After establishing baseline walking ability, a slip will be introduced without warning which will comprise the baseline slip test followed by a trip in the form of the trip plate. This is followed by a block of 8 trials for slip training, block of 8 trials for trip training and then the mixed block consisting of slip and trip trials interspersed with walking trials. Slips and trips could be induced under either of the limbs.
11081539|NCT04205279|Experimental|Surefooted training|"Subjects randomly assigned to Surefooted (Surefooted LLC) would be donned a safety harness and instructed that when you experience slip-like or trip-like movements, try to keep walking on the platform. Subjects would undergo 4-minute training block on each of the 6 different conditions. The first 3 training blocks would be unidirectional perturbation (either slip or trip) followed by 3 training blocks of mixed directional perturbations while the subjects are walking on the platform. 3 surface conditions- slippery (vinyl surface plate), normal friction with obstacles (surface plate with 6 tall structures embedded), and a foam surface with obstacles embedded would be used."
11081540|NCT04205266|Experimental|IV Iron|Will receive 2 infusions of 510mg of ferumoxytol, administered over 15 minutes, 3-8 days apart
11081541|NCT04205266|Active Comparator|Oral Iron|Will receive 325mg ferrous sulfate tablets daily for 60 days
11081542|NCT04205253||Study|The first group is the study group. Patients aged 20 years or older and were to undergo suspension laryngoscopy procedure were eligible for inclusion in this group. Tongue areas were measured twice by submental USG. The first measurements (TA1) were done immediately after endotracheal intubation before introducing the rigid direct laryngoscope, whereas the second measurements (TA2) were done after the SL procedure and after removing the rigid direct laryngoscope just before extubation.The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
11081543|NCT04205253||Control|The second group was the control group, which included patients who did not need SL and any head and neck procedures.The tongue areas of these patients were measured twice by submental USG as in the study group. The TA1 measurements were done immediately after endotracheal intubation, whereas the TA2 measurements were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
11081544|NCT04205240|Experimental|Treatment (conditioning regimen, stem cell transplant)|Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
11081545|NCT04205227|Experimental|ENB003 150 ug + Pembrolizumab|150 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
11081546|NCT04205227|Experimental|ENB003 300 ug + Pembrolizumab|300 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
11081547|NCT04205227|Experimental|ENB003 500 ug + Pembrolizumab|500 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
11081548|NCT04205227|Experimental|ENB003 750 ug + Pembrolizumab|750 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
11081549|NCT04205227|Experimental|ENB003 1000 ug + Pembrolizumab|1000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
11081550|NCT04205227|Experimental|ENB003 RP2D from dose eascalation + Pembrolizumab|The recommended phase 2 dose (RP2D) of ENB003 will be selected from the dose escalation portion of the study and administered in combination with a fixed dose of pembrolizumab (200mg)
11081579|NCT04204967|Experimental|transdermal fentanyl|transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
11081551|NCT04205214|Experimental|Integrative Cognitive Behavioural Therapy Intervention Group|The group receive 12 weekly individual Integrative Cognitive Behavioural Therapy sessions from the principal investigator and Trainee counselling Psychologist. The sessions last up to 60 minutes on a weekly basis. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week intervention.
11081552|NCT04205214|No Intervention|Wait List Control Group|The group do not receive the intervention and are told that they can start the intervention after 12 weeks. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week waiting period. After this 12-week waiting period, they are offered the individual therapy and their data is added to the experimental group data.
11081553|NCT04205201|Experimental|Group A|Latanoprost
11081554|NCT04205201|Other|Group B|Brimonidine
11081555|NCT04205188|Experimental|exercises and verbal information|therapeutic exercises 3 days in a week and total 8 weeks and 60 minutes verbal information
11081556|NCT04205188|No Intervention|verbal information|60 minutes information about effects of exercises on joint functions
11081557|NCT04205162|Experimental|Verofilcon A / Etafilcon A|The participant will wear Verofilcon A in their right eye and Etafilcon A in their left eye.
11081558|NCT04205162|Experimental|Etafilcon A / Verofilcon A|The participant will wear Etafilcon A in their right eye and Verafilcon A in their left eye.
11081559|NCT04205149||Pre-ERAS implementation arm|
11081560|NCT04205149||Post-ERAS implementation arm|
11081561|NCT04205136|Experimental|Spironolactone|Dose of 25 mg daily that may be titrated up to 50 mg daily, if tolerated and will receive treatment as usual for obstructive sleep apnea.
11081562|NCT04205136|Placebo Comparator|Placebo|Placebo and will receive treatment as usual for obstructive sleep apnea.
11081563|NCT04205123||sickle cell syndrome|Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.
11081564|NCT04205097|Placebo Comparator|Moderate NMB group|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
11081565|NCT04205097|Experimental|Deep NMB group|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2~4 mg/kg
11081566|NCT04205084|Experimental|Standard Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. The subjects will be allowed to eat meals and use their own insulin as usual, under observation, in the clinical center. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose will be collected at the same time as the CGM timestamp every 15 min and analyzed.
11081567|NCT04205084|Experimental|Hypoglycemic Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. Hypoglycemia will be induced using a hyperinsulinemic infusion and samples will be obtained at 5 - 10 min intervals. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose collected at the same time as the CGM timestamp and analyzed.
11081568|NCT04205084|Experimental|Hyperglycemic Protocol|Subjects with type 1 diabetes, receiving treatment with insulin will be admitted at the clinical research Study Site. Two CGM devices will be inserted on each subject. Hyperglycemia will be induced using a dextrose infusion and samples will be obtained at 5 -10 min intervals. Interstitial glucose values measured by CGM will be paired with the YSI 2300 blood glucose collected at the same time as the CGM timestamp and analyzed.
11081569|NCT04205071|Experimental|Treatment (lorcaserin)|Patients receive lorcaserin PO on day 1. The starting dose of lorcaserin will be 10 mg.
11081570|NCT04205058|Experimental|standard coffee|Hot standard coffee with caffeine (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
11081571|NCT04205058|Placebo Comparator|caffeine-free coffee|Hot caffeine-free coffee (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
11081572|NCT04205058|Sham Comparator|water|Hot water (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
11081573|NCT04205045||Non-Habitual Milk Consumers (NHMC)|"Healthy subjects who are non-habitual milk consumers because of gastrointestinal discomforts upon milk consumption.
~Lactose breath test; Gut permeability test; Milk test."
11081574|NCT04205045||Habitual Milk Consumers (HMC)|"Healthy subjects with regular milk consumption.
~Intervention to be performed:
~Lactose breath test; Gut permeability test; Milk test."
11081575|NCT04205019|Experimental|Neuro-Cell group|Patient receives treatment once at start of study and followed up for safety.
11081576|NCT04205006||STROKE CARD Cohort|Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).
11081577|NCT04204993|Experimental|Experimental: Influenza A|Participants will be inoculated with Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0,5mL via intranasal drops or spray. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood, respiratory tract sampling, and sensor monitoring. Following discharge, they will be followed up for up to 6 months post-inoculation.
11081578|NCT04204980|Experimental|Dose escalation and full dose|"Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
~Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab"
11081580|NCT04204967|Active Comparator|IV Remifentanil alone|remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit
11129431|NCT03869684|Placebo Comparator|Placebo|
11081581|NCT04204954|Other|Group 1: Topical 0.3% Ciprofloxacin [Cipro]|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.
11081582|NCT04204954|Active Comparator|Group 2: Cipro + 50% diluted baby shampoo|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.
11081583|NCT04204954|Active Comparator|Group 3: Cipro + Blephaclean|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.
11081584|NCT04204954|Experimental|Group 4: Cipro + Tea tree oil.|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.
11081585|NCT04204941|Experimental|Tazemetostat + Doxorubicin Arm|"Tazemetostat 800 mg (or RP3D from the phase 1b) administered orally twice daily in continuous 21-day cycles.
~Doxorubicin 75 mg/m2 intravenously (IV) on day 1 cycle 1 then on day 1 of cycles 2-6."
11081586|NCT04204941|Experimental|Placebo + Doxorubicin Arm|"Placebo administered orally twice daily in continuous 21-day cycles.
~Doxorubicin 75 mg/m2 IV on day 1 of cycle 1 then day 1 of cycles 2-6."
11081587|NCT04204915|Active Comparator|Group A: Aortic valve replacement|Participants randomised to AVR will be investigated and managed according to local protocols and standard practice. Participants will be placed on the waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists.
11081588|NCT04204915|No Intervention|Group B: Expectant management|Participants randomised to expectant management will continue to have regular monitoring of their condition in line with the procedures and standard practices of their hospital.
11081589|NCT04204902|Experimental|Test Treatment then Reference Treatment|Participants will receive a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 1 followed by a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 2. The treatment periods will be separated by 21 day washout period.
11081590|NCT04204902|Experimental|Reference Treatment then Test Treatment|Participants will receive a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 1 followed by a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 2. The treatment periods will be separated by 21 day washout period.
11081591|NCT04204889|Experimental|Oxaloacetate|3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.
11081592|NCT04204876||patients with GCA|All patients presenting with a new diagnosis of LV-GCA and all patients already treated for LV-GCA and planned for treatment termination
11081593|NCT04204863||SE patients|
11081594|NCT04204850|Experimental|Cabozantinib|Cabozantinib, at a dose of 60 mg orally (by mouth), once a day (at bedtime), continuously.
11081595|NCT04204837|Experimental|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
11081596|NCT04204824|Experimental|Ultrasound and exercise|This group will receive ultrasound treatment, strengthening exercises and stretching exercises.
11081597|NCT04204824|Active Comparator|Sham Ultrasound and exercise|This group will receive sham ultrasound treatment, strengthening exercises and stretching exercises.
11081598|NCT04204811||Participants with Ovarian Cancer|Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)
11081599|NCT04204798|Experimental|Dexmedetomidine group|Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
11081600|NCT04204798|Placebo Comparator|Placebo group|Normal saline is infused for the same duration as in the dexmedetomidine group.
11081601|NCT04204785|No Intervention|Pre-Education|Patient and Anesthesiologist participants completing surveys prior to OR staff education sessions.
11081602|NCT04204785|Experimental|Post-Education|Patient and Anesthesiologist participants completing surveys after OR staff education sessions.
11081603|NCT04204772|Experimental|Daily AC|A total of 4 combinations (2 activated Charcoal doses and 2 solutions) is given to the participants. The dose levels are 12 and 25 of medical grade oral AC. The AC will be mixed with 4 oz of either tap water or apple juice for a total of 4 combinations.
11081604|NCT04204759|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the ventromedial prefrontal cortex and one cathodal electrode (35cm2) will be placed over the occipital cortex. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 30 seconds at the beginning and end of the stimulation period.
11081605|NCT04204759|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
11081606|NCT04204746||3 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
11081607|NCT04204746||6 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
11081608|NCT04204720|Active Comparator|Group Whitacre|Group whitacre receives the whitacre needle during caudal block
11081609|NCT04204720|Experimental|Group Chiba|Group chiba receives the chiba needle during caudal block
11081610|NCT04204707||Conservative surgery|
11081611|NCT04204707||Radical surgery (segmental resection)|
11081612|NCT04204694||Patient in septic shock|
11081613|NCT04204694||blood donor tests|
11081638|NCT04204551|No Intervention|Healthy Controls|healthy controls without any kind of therapy
11134737|NCT03832816|Experimental|Vaporized low CBD alone|50mg pure CBD
11081614|NCT04204681||Study|Patients aged 16 years or younger who were to undergo tonsillectomy surgery were eligible for inclusion in this group. Tongue areas were measured twice by submental USG.The first measurements (TA2) were done immediately after endotracheal intubation but before insertion and placement of the tonsillar retractor. The second measurements (TA1) were done after tonsillectomy surgery and after removal of the tonsillar retractor but just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
11081615|NCT04204681||Control|This group included patients aged 16 years or younger who did not need tonsillectomy surgery and any head and neck procedures. Tongue areas of the patients were measured twice by submental USG as in the study group. TA1s were done immediately after endotracheal intubation, and TA2s were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
11081616|NCT04204668|Active Comparator|Targeted Muscle Reinnervation (TMR)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then cleaned up to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
11081617|NCT04204668|Active Comparator|Regenerative peripheral nerve interface (RPNI)|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a muscle graft. The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
11081618|NCT04204668|Active Comparator|Vascularized, denervated muscle target (VDMT )|"In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then cleaned up to enhance the possibility of healthy healing. The surgeon will then identify a local muscle along with a small artery and vein that supply blood to part of the muscle. A small sample of muscle, still attached to the artery and vein, is then created. The nearby nerves are then nestled into this segment of muscle that is still connected to the artery and vein. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain."
11081619|NCT04204655||Cohort|rehabilitants of the phase B, C and D during neurological rehabilitation
11081620|NCT04204642||Cerebral amyloid angiopathy (CAA)|Cerebral amyloid angiopathy (CAA) patients
11081621|NCT04204629|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
11081622|NCT04204629|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
11081623|NCT04204616|Experimental|Nemolizumab|Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
11081624|NCT04204603|Placebo Comparator|Placebo|
11081625|NCT04204603|Experimental|CKD-506 Dose A|
11081626|NCT04204603|Experimental|CKD-506 Dose B|
11081627|NCT04204603|Experimental|CKD-506 Dose C|
11081628|NCT04204590|Other|Participants|The aim of this study is to test the feasibility of this algorithm as an intervention to carry out deprescribing a targeted medication group, proton pump inhibitors (PPI's) and statins, among nursing home residents.
11081629|NCT04204577|No Intervention|Thermal ablation|Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
11081630|NCT04204577|Experimental|Thermal ablation combined with apatinib|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take about half an hour after a meal (the daily dose should be as much as possible), and take it with warm water. Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib."
11081631|NCT04204577|Experimental|Ablation combined with apatinib and PD-1 antibody SHR-1210|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take it with warm water about half an hour after a meal (the daily dose should be as much as possible). Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib.
~SHR-1210, 200mg, intravenous infusion for 30 minutes (including the time of the tube,the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks; the first dose with the apatite Simultaneous administration of PD, PD-1 injection is not affected by thermal ablation."
11081632|NCT04204564||paclitaxel coated balloon angioplasty|Procedures with paclitaxel coated balloon angioplasty of the superficial femoral-popliteal artery
11081633|NCT04204564||plain balloon angioplasty|Procedures with plain balloon angioplasty of the superficial femoral-popliteal artery
11081634|NCT04204564||paclitaxel eluting stent|Procedures with paclitaxel eluting stenting of the superficial femoral-popliteal artery
11081635|NCT04204564||bare metal stenting|Procedures with bare metal self expanding stenting of the superficial femoral-popliteal artery
11081636|NCT04204551|Experimental|PD-TR|"Intervention
~exercise, dose: two cycles of 12-week HIIT program (three times a week) separated with 3 months break
~& conventional physical therapy"
11081637|NCT04204551|Active Comparator|PD-NTR|conventional physical therapy
11081641|NCT04204525||Patients with chronic whiplash associated disorders|Male or female, aged between 18 and 65 years. Inclusion: 1) whiplash trauma (at least three months old) and pain since at least 3 months, self-reported mild to severe pain-related disability (score of 5/50 or more on the neck disability index), classified as wad II or wad III on the modified Quebec task force scale; 2) not undertaking exercise 1 day before the experiment; 3) not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation (to obtain a steady state); 4) native dutch speaker and 5) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments
11081642|NCT04204525||Healthy controls|Male or female, aged between 18 and 65 years. Inclusion: 1) no history of whiplash trauma, no pain with a mean pain intensity of more than 2/10 on the visual analogue scale for > 8 consecutive days in the preceding year in the neck-shoulder-arm region 2) painfree at the day of testing 3) native dutch speaker and 4) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments.
11081643|NCT04204486|Experimental|Face to face exercise intervention|Participants will participate in face to face exercise programme delivered by a strength and conditioning coach. Sessions will last 1 hour, 3 times a week, and will be offered at the work place. The coach will register attendance in order to monitor compliance.
11081644|NCT04204486|Active Comparator|Online exercise intervention|"Participants will be given the same training programme as the face to face group, but via an online app. Sessions should last 1 hour and should be completed 3 times a week. Participants will be asked to post a work-out picture on the social platform of the app as proof that they completed their session."
11081645|NCT04204486|No Intervention|Control|This group will undergo all pre and post tests, but will not receive an intervention.
11081646|NCT04204473|Experimental|TY-9591|Find maximum tolerated dose of TY-9591 given orally. Escalating doses of TY-9591 starting at 20mg daily.
11081647|NCT04204447|Experimental|Brochure intervention|Subjects will be asked to read an educational brochure about Hepatitis C
11081648|NCT04204447|Experimental|Video intervention|Subjects will be asked to watch an educational video about Hepatitis C
11081649|NCT04204421|Experimental|Experience Sampling Method (ESM)|Both patients with functional dyspepsia and healthy controls will be asked to fill out ESM questionnaires during 1 week. Moreover, at the end of this week, usual questionnaires for complaints assessment will be filled out.
11081650|NCT04204408|Experimental|Single dose (part 1) Mim8|Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 5 cohorts, 6 participants will receive Mim8.
11081651|NCT04204408|Placebo Comparator|Single dose (part 1) placebo|Blinded. Single doses in healthy volunteers. In each of the 5 cohorts, 2 participants will receive placebo.
11081652|NCT04204408|Experimental|Multiple dose (part 2)|Open-label. There will be 3 cohorts receiving once-weekly doses (part 2 cohorts 1, 2 and 3) and one cohort receiving once-monthly doses (part 2 cohort 4).
11081653|NCT04204395|Experimental|Experimental group|"When complete the admission process, the caregiver will give a peanut ball to perform, besides the routine health brochure.
~The participants will be at independent compartment."
11081654|NCT04204395|No Intervention|Control group|Take the routine health brochure. The participants will be at independent compartment.
11081655|NCT04204382|Experimental|test group|
11081656|NCT04204382|Experimental|control group|
11081657|NCT04204369|Experimental|Teaching arm|This group received the teaching intervention and was evaluated before and after the intervention. Improvement was compared to their performance prior to the intervention.
11081658|NCT04204356|Experimental|tDCS group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment with active tDCS.
11081659|NCT04204356|Sham Comparator|Sham group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment without active tDCS (sham)
11081660|NCT04204343|Active Comparator|Caudal Block|US-guided caudal block with 0.7 ml/kg 0.25% Bupivacaine
11081661|NCT04204343|Active Comparator|Erector Spinae Plane Block|US-guided erector spinae plane block with 0.5 ml/kg 0.25% Bupivacaine
11081662|NCT04204330|Experimental|CardioQVARK group|"Inclusion criteria:
~Males and females aged 20 to 96 years having one or more of the following risk factors:
~hypertensive heart disease;
~history of ischemic stroke or transient ischemic attacks;
~type 1 and 2 diabetes;
~class 1-3 obesity;
~heart failure or decreased tolerance to physical activity due to dyspnea;
~coronary artery disease (CAD) or chest pain without established CAD diagnosis;
~peripheral artery atherosclerosis;
~abnormal heart rhythms (episodes of palpitations, pauses in heartbeat).
~A patient's consent to participate in the study and the ability to sign an informed consent form.
~Exclusion criteria:
~acute coronary syndrome;
~acute ischemic or hemorrhagic stroke;
~mental illness;
~severe concomitant disease with life expectancy less than 2 years.
~Withdrawal criteria:
~1. Refusal to participate in the study."
11081663|NCT04204317||Autofluorescence|"The surgeon will perform the preplanned operation with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:
~Surgery date
~Duration of surgery
~Operation performed
~Procedure related comments
~Number and location of the visualized glands
~Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
11081664|NCT04204317||Control|"The surgeon will perform the preplanned operation without FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:
~Surgery date
~Duration of surgery
~Operation performed
~Procedure related comments"
11081665|NCT04204304|Experimental|Isotretinoin-induced adverse effect group|Patients receiving isotretinoin with dose of 0.5-1 mg/kg/day and had musculoskeletal adverse effects
11081666|NCT04204304|Active Comparator|Control group|Pateients receiving isotretinoin with dose of 0.5-1 mg/kg/day had no musculoskeletal adverse effects
11081667|NCT04204291|Experimental|All|
11081668|NCT04204278|Other|Monovisc|
11081669|NCT04204265|Other|Monovisc|
11081670|NCT04204252|Active Comparator|Inhaled AAT|"Daily inhalation of 80 mg/day Kamada-AAT for Inhalation for 104 weeks"
11081671|NCT04204252|Placebo Comparator|Placebo|Daily inhalation of a solution of NaCl in phosphate buffer solution with 0.01% TWEEN-80
11081887|NCT04202549|Experimental|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy
11081672|NCT04204226|Experimental|Social Worker vs Autism Behavioral Health Navigation (ABHN)|"Phase 1: Families providing informed consent will then be randomized to social work consultation or to the Autism Behavioral Health Navigation (ABHN) intervention.
~Non-responders to ABHN will move to ABHN + Complex Autism Program (CAP)."
11081673|NCT04204226|Experimental|Social work + ABHN vs Social work + ABHN + CAP|"At 3 months, children who are considered to be responders to their current treatment will continue; children who are nonresponders in the social work arm of the study will be randomized to either ABHN or ABHN+CAP. Children in the ABHN arm who are non-responders will receive ABHN + CAP"
11081674|NCT04204213||8 Section Brocade Tai Chi Therapy|Subject participants with end stage osteoarthritis knee were enrolled into a customised multidisciplinary education program that consisted of one hour healthcare education seminars followed by another hour of 8 Section Brocade (Baduanjin) sitting Tai Chi classes for 4 consecutive weeks.
11081675|NCT04204200|Active Comparator|Allocated to conventional vitamin C (n= 22)|"Received allocated conventional vitamin C (n= 22)
~Did not receive allocated conventional vitamin C (n= 0)"
11081676|NCT04204200|Active Comparator|Allocated to liposomal vitamin C (n= 22)|"Received allocated liposomal vitamin C (n= 22)
~Did not receive allocated liposomal vitamin C (n= 0)"
11081677|NCT04204200|Placebo Comparator|Allocated to placebo (n= 22)|"Received allocated intervention (n= 22)
~Did not receive allocated intervention (n= 0)"
11081678|NCT04204174|Experimental|Tyrosine loading|
11081679|NCT04204161|Experimental|CAR-T19/CAR-T22|CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.
11081680|NCT04204148||Clinical characteristics of the patients|including sex,age,smoking history,tumor location and tumor diameter
11081681|NCT04204148||Logistic regression analysis of influencing factors of c|The Leicester Cough Questionnaire in Mandarin Chinese (LCQ-MC) was used to evaluate the degree of cough in patients. The LCQ-MC is divided into three dimensions: physical, psychological and social. There are a total of 19 questions, and each question has seven options (positive scoring, grades 1-7; the higher the score is, the lighter the cough).
11081682|NCT04204122|Experimental|Arm 1: Eye treated with Vigamox|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
11081683|NCT04204122|Placebo Comparator|Arm 2: Eye treated with placebo|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
11081684|NCT04204109|Experimental|Interprofessional case-based learning|The experimental intervention will be the interprofessional group receiving case-based learning about gastro-intestinal toxicities and side effects of children and adolescents with cancer.
11081685|NCT04204109|Active Comparator|Monoprofessional case-based learning|The control group is the monoprofessional group that will receive the same case-based learning as the intervention group.
11081686|NCT04204096|Experimental|Vi-DT Multi-dose|"750 participants (6 mo - 45 yrs)
~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)
~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (multi-dose formulation Vi-DT contains preservative 2 PE)
~Mode of Administration: Intramuscular injection
~Frequency of administration: Once"
11081687|NCT04204096|Experimental|Vi-DT Single-dose|"750 participants (6 mo - 45 yrs)
~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)
~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (single dose formulation Vi-DT without any preservative)
~Mode of Administration: Intramuscular injection
~Frequency of administration: Once"
11081688|NCT04204096|Active Comparator|Control|"300 participants (6 mo - 45 yrs)
~Dose: 0.5mL, Locally available Meningococcal conjugate vaccine
~Dosage form: Lyophilized white powder
~Mode of Administration: Intramuscular injection
~Frequency of administration: Once (For participants 6 months to 1 year, one more dose will be provided after the study unblinding)"
11081689|NCT04204083|Other|Monovisc|
11081690|NCT04204070|Experimental|Group I Accuro|epidural catheter insertion using the Accuro ultrasound imaging assisted technique
11081691|NCT04204070|Experimental|Group II APAD|epidural catheter insertion using the real time ultrasound guided technique combined with the use of the acoustic puncture assist device (APAD) technique.
11081692|NCT04204057|Experimental|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
11081693|NCT04204044|Experimental|GROUP A ( metformin 500 mg TDS)|Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day
11081694|NCT04204044|Experimental|GROUP B( myoinositol 2000mg x BD )|Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day
11081695|NCT04204044|Experimental|GROUP C.(both metformin,& myoinositol)|Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,& myoinositol three and two times a day respectively
11081696|NCT04204031|Other|Presentation of the adherence record|"Following a first observation period of 15 days, participants whose actual time of use will be less than prescribed will be offered an intervention which will consist of a presentation of the adherence record. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
~Only participants with an actual time of use less than prescribed will be offered this intervention and will continue the monitoring over a period of 15 additional days."
11081697|NCT04204018|Experimental|Experimental|Experimental-arm providers will complete four simulated patient cases (CPVs) with two additions described in the next column:
11081698|NCT04204018|No Intervention|Control|These providers will complete four simulated patient cases (CPVs) only.
11081699|NCT04204005|Active Comparator|Probiotics|Composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams)
11081700|NCT04204005|Placebo Comparator|Placebo|Composition: maltodextrin (2 grams)
11081701|NCT04203992|Experimental|Videogame|Educational videogame, five 60-minute sessions over one month
11081702|NCT04203992|Active Comparator|Booklet|Educational booklet, one session
11081888|NCT04202536|Experimental|TDF switch to Besifovir Dipivoxil Maleate|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate 183mg daily
11081703|NCT04203966||Common mental disorders/ versus no common mental disorders|No intervention This is a prevalence study- presence of CMDs will be assessed using the 12-item general Health Questionnaire, with responses above validated cutpoints taken to indicate presence of CMDs
11081704|NCT04203966||Alcohol use disorders/ versus no alcohol use disorders|No intervention This is a prevalence study- presence of alcohol use disorders will be assessed using the WHO-AUDIT, with responses above validated cutpoints taken to indicate presence of alcohol use disorders
11081705|NCT04203940|Active Comparator|Cyanoacrylate|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue (Histoacryl®).
11081706|NCT04203940|Active Comparator|Suture|mesh fixation was done with polypropylene 2/0 sutures
11081707|NCT04203927|Placebo Comparator|Placebo|Placebo
11081708|NCT04203927|Active Comparator|Empagliflozin|SGLT-2 inhibitor
11081709|NCT04203914|Experimental|Intervention|Empagliflozin 25mg daily add-on therapy
11081710|NCT04203901|Experimental|Combination Arm|CMN-001 dosing (1x10^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
11081711|NCT04203901|Active Comparator|Standard Treatment|1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.
11081712|NCT04203888|Other|Massage|A licensed massage therapist will deliver 60-minute Swedish Massage in the participant's home, 2 times per week with at least 48-hours between massage sessions. Each massage arm will be 2 weeks in length, and consist of 4 total Swedish massages.
11081713|NCT04203888|Other|Yoga|"A certified yoga instructor will deliver 60-minute yoga instruction in the participant's home, 2 times per week with at least 48-hours between yoga session. Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005). Each yoga arm will be 2 weeks in length, and consist of 4 total yoga sessions."
11081714|NCT04203888|No Intervention|Usual Care|Participants will be instructed to abstain from any massage or yoga activity, and instructed to treat their chronic lower back pain as they normally would. Each usual care arm will be 2 weeks in length.
11081715|NCT04203875|Experimental|Orencia® (Abatacept)|Abatacept 125 mg, subcutaneous once a week for 6 months or up to one year if subject has a favorable response
11081716|NCT04203862|Experimental|1|Single administration of low dose NPC-22
11081717|NCT04203862|Experimental|2|Single administration of low/middle dose NPC-22
11081718|NCT04203862|Experimental|3|Single administration of middle dose NPC-22
11081719|NCT04203862|Experimental|4|Single administration of middle/high dose NPC-22
11081720|NCT04203862|Experimental|5|Single administration of high dose NPC-22
11081721|NCT04203862|Experimental|6|Single administration of placebo dose NPC-22
11081722|NCT04203836|Experimental|Fed|Single oral dose given after a full breakfast
11081723|NCT04203836|Experimental|Fasting|Single oral dose given in fasting state
11081724|NCT04203823|Experimental|Algorithm Testing|"The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm
~The study population will be enrolled as 2 separate cohorts to test each algorithms individually"
11081725|NCT04203810|Experimental|Ectoin® Mouth and Throat Spray Althaea Honey|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
11081726|NCT04203810|Active Comparator|EMSER® Hals- und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
11081727|NCT04203797|Experimental|dupilumab|A loading dose at the start of the treatment followed by once every two weeks (Q2W).
11081728|NCT04203797|Experimental|Matching placebo|Matching dupilumab
11081729|NCT04203784||Meropenem treated patients|
11081730|NCT04203784||Piperacillin treated patients|
11081731|NCT04203771|Experimental|Probiotic|Orodispersible tablets containing AB-DENTALAC probiotic formula.
11081732|NCT04203771|Placebo Comparator|Control|Orodispersible tablets without probiotic strains (excipients only).
11081733|NCT04203758|Experimental|Wholegrain rye products with a high content of dietary fiber|Cereal products based on wholegrain rye
11081734|NCT04203758|Active Comparator|Refined wheat products with a low content of dietary fiber|Cereal products based on refined wheat
11081735|NCT04203732||Total Joint Arthroplasty|The cohort includes patients undergoing outpatient primary total joint replacement surgeries from 2017 to 2019. Primary total joint surgery is defined as patients who undergo unilateral total knee replacement or total hip replacement for the first time during the study years
11081736|NCT04203719|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11081737|NCT04203706|Experimental|Normal-weight subjects|
11081738|NCT04203693||Cohort 1: Tildrakizumab Treated Participants|Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
11081739|NCT04203693||Cohort 2: Newly Tildrakizumab Prescribed Participants|Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
11081740|NCT04203680|Sham Comparator|HTK group|Patients received 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
11081741|NCT04203680|Active Comparator|blood cardioplegia group|patients received one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
11081889|NCT04202536|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
11081742|NCT04203667|Other|EndoRotor Resection Arm|The mucosal resections are performed during standard flexible colonoscopy procedures. All medications given, pre- and post-procedure precautions and follow-up assessments are part of routine standard of care. This protocol concerns itself with the actual removal of the scarred mucosal lesion once the abnormal area is identified using the colonoscope.
11081743|NCT04203654|Other|Cognitive-behavior group therapy group|
11081744|NCT04203641|Experimental|L-DOS47 + doxorubicin|Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin [20 mg/m2/week] will be administered in combination with L-DOS47 across all cohorts.
11081745|NCT04203628|Experimental|Prospective cohort|"Any child with presumptive TB will be proposed to participate in the study.
~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies.
~For children identified from the routine practice, the nurse will collect 2 respiratory samples (sputum or GA) in consecutive children with presumptive TB to be tested using Ultra as done in routine care, record symptoms and refer the child for clinical exam and for chest X-ray. For the purpose of the study, 2 stool samples will be collected to be tested with Ultra. In addition, for study purpose the two respiratory samples will be tested with Mycobacterial culture as this test is not routinely prescribed for TB diagnosis in the study sites"
11081746|NCT04203628|Experimental|Enrichment cohort|"Any child with presumptive TB and a positive Xpert result from one respiratory sample (NPA, IS or GA) will be proposed to participate in the study.
~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies
~For children identified from the routine care, once enrolled, samples collected as routine practice will be tested with mycobacterial culture in addition to Xpert. If needed an additional respiratory sample will be collected (sputum or GA) and tested with Mycobacterial culture. The nurse will also record symptoms, refer the child for clinical exam and for chest Xray, and collect stool samples. HIV-testing will be offered for children with unknown HIV-status"
11081747|NCT04203615|Active Comparator|PD patients with real rTMS|Patients will receive real rTMS in a two weeks long sessions (10 sessions).
11081748|NCT04203615|Sham Comparator|PD patients with sham rTMS|Patients will receive sham rTMS in a two weeks long sessions (10 sessions).
11081749|NCT04203602|Experimental|Telepresence round|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
11081750|NCT04203602|Active Comparator|conventional round|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
11081751|NCT04203589|Experimental|The Explorer Early Intervention Program|The Explorer Early Intervention Program is used in this group.
11081752|NCT04203589|Active Comparator|Neurodevelopmental Therapy|Neurodevelopmental therapy is used in these group by two experienced and certificated physiotherapist
11081753|NCT04203576|Experimental|FIRE1 System|FIRE1 System
11081754|NCT04203563|Experimental|Group 1|Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks. Intervention Group.
11081755|NCT04203563|Other|Group 2|Group 2 participants receive twice weekly progressive strength training classes in January 2020 for 12 weeks. Delayed Intervention Group.
11081756|NCT04203550|Active Comparator|Irrigation group (IR)|A burr-hole craniostomy is performed and the dura is opened sharply and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. Subdural space is irrigated by repeated rinsing with body temperature saline solution with a syringe and blunt needle until surgeon considers exudate to be clear. Minimum volume of irrigation will be 200 ml per operated side. The subdural drain is inserted 3-5 cm underneath the skull and parallel to it. The total volume of irrigation as well as the duration of operation is recorded.
11081757|NCT04203550|Experimental|No-Irrigation group (N-IR)|A burr-hole craniostomy is performed and a small incision to the dura is made and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. The subdural drain is inserted approximately 3-5 cm underneath the skull and parallel to it. The duration of operation is recorded.
11081758|NCT04203537|Active Comparator|CA-008|Single administration
11081759|NCT04203537|Placebo Comparator|Placebo|Single administration
11081760|NCT04203524|Experimental|Procalcitonin Arm|The medical team will be provided with a daily PCT for the patient, along with the PCT-guided algorithm that outlines the suggested management based on the PCT levels.
11081761|NCT04203524|Other|Control Arm|Procalcitonin levels will be measured for those patients, but the medical team will be blinded from their results
11081762|NCT04203511|Experimental|Chemoradiation therapy + INCMGA00012|
11081763|NCT04203511|Active Comparator|Chemoradiation therapy + Placebo|
11081764|NCT04203498|Experimental|Nabiximols|
11081765|NCT04203498|Placebo Comparator|Placebo|
11081766|NCT04203485|Experimental|Camrelizumab 200mg + Apatinib Mesylate 250mg|Camrelizumab 200mg q2w ivgtt+ Apatinib Mesylate 250mg once daily po qd
11081767|NCT04203485|Experimental|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
11081768|NCT04203485|Active Comparator|Pemetrexed/Paclitaxel injection+ Carboplatin|For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin; For squamous NSCLC: Paclitaxel injection + Carboplatin
11081769|NCT04203472|Experimental|Budesonide or budeosonide/formoterol administered by DPI|In every patient cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI for 14 days
11081770|NCT04203472|Active Comparator|Budesonide or budeosonide/formoterol administered by MDI|In every patient inhaler will be changed and cough severity and tolerance of therapy will be analyzed during therapy with the same drugs administered by MDI . Order of using different types of inhalers will be accidental
11081890|NCT04202523|Experimental|RT&RFA|
11081891|NCT04202523|Active Comparator|RFA|
11081771|NCT04203459||Pancreatic cancer patient|(1) patients with pancreatic cancer confirmed by imaging, pathology and body fluid biopsy, or patients who recovered well one month after operation but still had residual lesions, recurrence or metastasis. ② age ≥ 30 and ≤ 75. ③ no chemotherapy, radiotherapy or targeted drugs were used before admission. ④ patients who had used immunosuppressive drugs, hormones, antibiotics and probiotics one month before admission were excluded. ⑤ patients with HIV positive and active hepatitis B or C infection were excluded. ⑥ exclude the previous history of other malignant tumors or the current combination of other malignant tumors. The patients with serious cardiopulmonary disease and liver and kidney dysfunction were excluded. ⑧ patients with obstructive jaundice were excluded.
11081772|NCT04203459||Healthy person|(1) no history of digestive tract diseases, infectious diseases or immune diseases.(2) no history of smoking or drinking.(3) did not take antibiotics and other drugs and probiotics for 1 month before enrollment.
11081773|NCT04203446||Adults with asthma or COPD|Adults (18-85 years old) with asthma or COPD diagnosed at least 3 months earlier, who are regularly treated with at least one inhlaer daily
11081774|NCT04203433|Experimental|DLX105-DMP Single-Dose|Single-Dose of 1mg DLX105-DMP applied to a target lesion.
11081775|NCT04203433|Experimental|DLX105-DMP Multi-Dose|4 Weeks of 1mg DLX105-DMP applied to a target lesion.
11081776|NCT04203420||patients with PA|patients who finally been diagnosed with primary aldosteronism
11081777|NCT04203420||patients without PA|patients who finally been diagnosed without primary aldosteronism
11081778|NCT04203407|Experimental|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
11081779|NCT04203407|Active Comparator|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
11081780|NCT04203394|Experimental|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
11081781|NCT04203394|Experimental|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
11081782|NCT04203381||Transgender Participant|Transgender children at Tanner stage II or early Tanner stage III between the ages of 9 and 14. Must be a current patient at a gender patient and within 6 weeks of initiating pubertal blockade treatment
11081783|NCT04203381||Cisgender Control Participant|Cisgender children Tanner II or early Tanner III between 9 and 14 matched by race, age, and BMI.
11081784|NCT04203368|Active Comparator|adenosine group|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil
11081785|NCT04203368|Sham Comparator|verapamil group|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
11081786|NCT04203342|Experimental|Ketoconazole 2% cream (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Test product is Ketoconazole 2% cream manufactured by Douglas Pharmaceuticals America Ltd.
11081787|NCT04203342|Active Comparator|Ketoconazole 2% cream (Teva Pharmaceuticals USA)|Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.
11081788|NCT04203342|Placebo Comparator|Placebo (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Placebo comparator is manufactured by Douglas Pharmaceuticals America Ltd.
11081789|NCT04203316|Experimental|Treatment (enasidenib)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11081790|NCT04203303||Observational|Observational
11081791|NCT04203290|Active Comparator|General anesthesia|Patients will be applyed 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium for anesthesia induction, after intubation sevoflurane will be used for anesthesia maintenance with low flow anesthesia (0.5 l/min).
11081792|NCT04203290|Active Comparator|General anesthesia combined with thoracic epidural anesthesia|Before anesthesia induction epidural catheter will be inserted giving 7 ml bupivacaine %0.25 in saline + 50 mcg fentanyl after confirming the location of catheter, following 15 minutes the standard anesthesia induction will be applied ( 0.03 mg/kg midazolam, 2 mcg/kg fentanyl, propofol until reaching the appropriate anesthetic depth by observing entropy value (40-60) and 0.5 mg/kg rocuronium ). For anesthesia maintenance epidural infusion will be applied ( 7ml/h %0.25 bupivacaine solution) together with low flow (0.5 l/min) sevoflurane anesthesia.
11081793|NCT04203277|Experimental|Step Wedge Randomized Group 1|Includes two pediatric practices randomized to the first step of the step-wedge randomized trial
11081794|NCT04203277|Experimental|Step Wedge Randomized Group 2|Includes two pediatric practices randomized to the second step of the step-wedge randomized trial
11081795|NCT04203277|Experimental|Step Wedge Randomized Group 3|Includes two pediatric practices randomized to the third step of the step-wedge randomized trial
11081796|NCT04203277|Experimental|Step Wedge Randomized Group 4|Includes two pediatric practices randomized to the fourth step of the step-wedge randomized trial
11081797|NCT04203238|Experimental|Potatoes Lean Meat (PLM)|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
11081798|NCT04203238|Experimental|Lean Meat Pulses (LMP)|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses. The diet is designed to provide six or less ounces of meat/day which is consistent with the DASH diet.
11081799|NCT04203225|Active Comparator|Single LET|One (single) application of LET topical gel [Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)] applied for 30 minutes
11081800|NCT04203225|Experimental|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
11082010|NCT04201652|Active Comparator|Deep|Intervention: Superficial and deep local anesthetic infiltration.
11081801|NCT04203212||Endometriosis Group|20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.
11081802|NCT04203212||Control Group|20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.
11081803|NCT04203199|Experimental|Real rTMS to the mPFC using H7 Coil|One session of low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
11081804|NCT04203199|Sham Comparator|Sham rTMS to the mPFC using H7 Coil|One session of sham low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (sham rTMS - 20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
11081805|NCT04203199|Experimental|Real rTMS to the dlPFC using H1 Coil|One session of high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
11081806|NCT04203199|Sham Comparator|Sham rTMS to the dlPFC using H1 Coil|One session of sham high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (sham rTMS- 20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
11081807|NCT04203186|Active Comparator|Group 1 - PfSPZ, (NF54) strain|Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
11081808|NCT04203186|Active Comparator|Group 2 - PfSPZ, (7G8) strain|Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
11081809|NCT04203173|Experimental|FINANCE-DM Intervention|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives.
11081810|NCT04203173|Active Comparator|TIDES Intervention|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change.
11081811|NCT04203160|Experimental|Phase 1 and Phase 2, Arm A (investigational)|On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.
11081812|NCT04203160|Active Comparator|Phase 2, Arm B (standard of care)|On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.
11081813|NCT04203147|Experimental|Home DM-BAT Intervention|A trained nurse educator will deliver the manualized Home DM-BAT intervention in a group setting. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12.
11081814|NCT04203147|Active Comparator|Control Group (GHE+ST)|Patients randomized to the control group will receive group-based in-home 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12.
11081815|NCT04203134|Experimental|Treatment Group|Patients in the randomly assigned treatment group will receive a mouthguard at first visit along with standard treatment of BMS.
11081816|NCT04203134|No Intervention|Control Group|Control group will proceed through treatment for BMS in an otherwise standard treatment protocol and will not receive a mouthguard.
11081817|NCT04203121|Experimental|arm1|"An initial 5 patients will be enrolled in the first treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.
~subjects 1-5 : 9 Gy in 5 fractions of 1.8 Gy on 5 consecutive days"
11081818|NCT04203121|Experimental|arm2|"Subjects in this arm will be enrolled in the second treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.
~subjects 6-10 : 5.4 Gy in 3 fractions of 1.8 Gy on 3 consecutive days"
11081819|NCT04203108|Experimental|ATG group|ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.
11081820|NCT04203108|Active Comparator|non-ATG group|Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.
11081821|NCT04203095||patient with PD1 antibody treatment|"Investigators will detect cfDNA CIN of lung cancer patients 1day (Day 0) before treatment with PD1 antibody, then Day 22 and Day 64 after treatment with PD1 antibody, as well as at the time of disease progression confirmed.
~The correlation of CIN and drug resistance to PD1 antibody was analyzed."
11081822|NCT04203082|Experimental|Exposure Intervention|Participants randomized to receive the Exposure Intervention will be scheduled to come to clinic for a 1-hour session for the intervention. During this time, they will receive psychoeducation and behavioral exposure to the Cesarean section procedure.
11081823|NCT04203082|Other|Usual Care|Participants randomized to the Care as Usual condition will receive the typical standard of care that is offered in the center. This involves the anesthesiologist meeting with the patient during a delivery planning meeting to provide patients with the opportunity to review anesthetic technique and ask questions.
11081824|NCT04203069|Placebo Comparator|Control group : Day-time compression sleeve|Control group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) during 90 days.
11081825|NCT04203069|Experimental|Day-time compression sleeve and Night-time MOBIDERM Autofit|Intervention group : Patients will wear the Day-time compression sleeve : THUASNE lymphatrex (± mitten) + night-time Auto-Adjustable MOBIDERM® Autofit Armsleeve device with the possibility to wear an additional MOBIDERM® glove if a patient has a finger edema during 90 days.
11081892|NCT04202510|Active Comparator|iStent|iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
11081826|NCT04203056|Experimental|AL-LAI: Long-Acting Injectable Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: For patients assigned to the AL-LAI (aripiprazole lauroxil- long-acting injections), initiation of AL-LAI will begin with a one-day initiation regimen (using AL-NCD IM (aripiprazole lauroxil NanoCrystal Dispersion)). Subsequent dosing of AL-LAI will be flexible based on clinician judgment. Treatment with AL-LAI can be initiated at a dose of 441mg or 661mg (administered monthly), 882mg (administered monthly or every 6 weeks), or 1064mg (administered every 2 months).
11081827|NCT04203056|Active Comparator|ARI-ORAL: Aripiprazole Oral Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: Patients assigned to the oral medication condition will continue with ARI-ORAL. ARI-ORAL dosage will be flexible and dosage will be at the discretion of the treating psychiatrist. Patients discontinuing ARI-ORAL study drug after Randomization to oral antipsychotic medication, can remain in active treatment and follow-up within the study, and may be prescribed any of a number of first-line oral antipsychotics.
11081828|NCT04203043|Active Comparator|Pycnogenol oral product to prevent Hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
11081829|NCT04203043|Placebo Comparator|Placebo to prevent hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
11081830|NCT04203030|Experimental|Physical Activity|16 week physical activity intervention
11081831|NCT04203017|Experimental|AutoHSCT + FMT|AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
11081832|NCT04203004|Experimental|HOPE-CytoSorb|Patients transplanted with livers preserved by HOPE with cytokine filtration by CytoSorb, a CE approved medical device for extracorporeal cytokine removal
11081833|NCT04203004|No Intervention|HOPE-standard|Patients transplanted with livers preserved by HOPE without cytokine filtration
11081834|NCT04202991||COPD with pain|People with COPD who also report pain more often than not over the previous 3 months
11081835|NCT04202991||COPD with no pain|People with COPD who do not report pain more often than not over the previous 3 months
11081836|NCT04202978|Experimental|Camrelizumab+ Apatinib +XELOX +RFA|Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer
11081837|NCT04202965|Experimental|PTG-300|PTG-300 Subcutaneous
11081838|NCT04202952|Experimental|600 mg multiple doses|Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
11081839|NCT04202952|Experimental|800 mg multiple doses|Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
11081840|NCT04202952|Experimental|1200 mg multiple doses|Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
11081841|NCT04202939||nursing homes residents|all residents present in a nursing home unit on nutritionDay
11081842|NCT04202926|Experimental|10hz group|a high frequency stimulation
11081843|NCT04202926|Sham Comparator|sham group|a sham coil which frequency is 10hz but do not induce stimulation
11081844|NCT04202913|Experimental|Health Coaching|1:1 Health coaching with student
11081845|NCT04202900|Other|Phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.
~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
11081846|NCT04202887|Active Comparator|Low Fentanyl (LF)|fentanyl cumulative dose below 100mcg
11081847|NCT04202887|Active Comparator|High Fentanyl (HF)|fentanyl cumulative dose above 100mcg
11081848|NCT04202874|Experimental|Bupivacaine|Administration of 20ml of bupivacaine 0.25% on each side, for a total of 40ml.
11081849|NCT04202874|Placebo Comparator|Saline|Administration on 20ml of normal saline on each side, for a total of 40ml.
11081850|NCT04202861|Experimental|in vitro antibiotic combination testing (iACT)|For the intervention arm, CRGNB isolates from the index culture should be transported to the Pharmacy Research Lab in Singapore General Hospital as soon as possible to begin iACT. For external sites, a licensed medical courier will be engaged. Once testing is complete, the iACT results will be sent to the physicians and the ID specialist managing the patient. Several antibiotic combinations can usually be used to treat the infection; a subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and/or the consulting infectious disease doctor may exercise their discretion in continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement, according to the clinical conditions and reactions of the patient to the treatment
11081851|NCT04202861|No Intervention|Control|The standard arm will receive standard therapy of either antibiotic monotherapy or unguided combination therapy, a choice based on treating physicians' best clinical judgment. iACT will only be performed on CRGNB isolates from the standard arm at least 30 days after enrolment for collection of microbiological, proteomic and molecular data. Antibiotic combinations found from delayed iACT will be made known to the Infectious Diseases physician caring for the participant.
11081852|NCT04202835|Experimental|ATG/PTCy|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4.
11081853|NCT04202835|Active Comparator|ATG|Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1).
11081854|NCT04202822|Other|Biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) at T0 and T24
11081855|NCT04202809|Experimental|Chemo- and Radiochemotherapy + Durvalumab|
11081856|NCT04202809|No Intervention|Chemo- and Radiochemotherapy|
11081893|NCT04202510|Active Comparator|iStent Inject|iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
11081894|NCT04202510|Active Comparator|Hydrus|Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
11081857|NCT04202783|Experimental|Treatment of Craniofacial Neuralgia|All patients will receive the same amount (5mL concentrated) of exosomes delivered via ultrasound-guided, regional epineural injection and the same amount (5mL unconcentrated) delivered via IV. Patients will be given 3 mL of the exosome product intravenously, which contains about 45mg of the exosome product containing 15-21 million neonatal stem cell products, and 3 mL of the exosome hyperconcentrate product delivered epineurally using ultrasound guidance, which contains about 15mg of the exosome product carrying 5-7 million neonatal stem cell products.
11081858|NCT04202770|Experimental|Treatment|Patients deemed potentially appropriate candidates for exosome and focused ultrasound therapy for either treatment refractory depression (trMDD), anxiety, or neurodegenerative dementia will be treated with exosomes derived from healthy, full-term Cesarean section amniotic fluid. Up to one hour of transcranial focused ultrasound will be administered immediately prior to exosome treatment in an attempt to facilitate enhanced deployment to the subgenual cingulate for trMDD, the amygdala for anxiety, or the hippocampus for dementia. Target location will be determined by the physician upon enrollment depending on the patient's specific syndrome. Patients will be given 15cc of unconcentrated solution allogenic exosomes (equivalent to 21 million stem cells, Kimera Corporation) intravenously in 200 ccs of normal saline dripped over thirty minutes to one hour.
11081859|NCT04202757|Active Comparator|Young Fresh Frozen Plasma (yFFP)|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
11081860|NCT04202757|Placebo Comparator|Saline|0.1% riboflavin in normal saline
11081861|NCT04202744||Water Polo Group|"Participants were active water polo players who train regularly with ages in between 10-30 years.
~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
11081862|NCT04202744||Non-Water Polo Group|"Participants who do not engage in overhead sports with ages in between 10-30 years.
~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
11081863|NCT04202731|Experimental|Sleep Extension|Participants will be asked to extend their time in bed with the goal of improving the total time they sleep each night.
11081864|NCT04202718|Other|Single group|Where a wearable biosensor is being considered for use in the health management of individuals at high-risk for poor health outcomes, and in the detection or prevention of adverse events within settings where traditional monitoring devices are not currently in use, the ECG interpretation will provide Arrhythmia detection which will help ensure that irregular rhythms will be reported quickly.
11081865|NCT04202705|Experimental|SYD1875|5T4-targeting Antibody-Drug Conjugate
11081866|NCT04202692|Experimental|GERDOff Plus|Hyaluronic acid + chondroitin sulphate + magnesium trisilicate melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
11081867|NCT04202692|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period, patients will take either placebo or GERDOff Plus q.i.d. (three after meals, one before resting) for another three weeks.
11081868|NCT04202679|Experimental|Dupilumab|Dose regimen 1 on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
11081869|NCT04202679|Placebo Comparator|Matched placebo|Placebo on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
11081870|NCT04202666|No Intervention|not convex skin barrier|no intervention
11081871|NCT04202666|Experimental|convex skin barrier|intervention
11081872|NCT04202653|Active Comparator|Naive:ETV|Entecavir 0.5 mg po daily for 24 weeks in naive patients
11081873|NCT04202653|Experimental|Naive:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in naive patients
11081874|NCT04202653|Experimental|Naive:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus inhibitor of TQ-B2450 for 24 weeks in naive patients
11081875|NCT04202653|Active Comparator|Experienced:ETV|Entecavir 0.5 mg po daily for 24 weeks in treatment experienced patients
11081876|NCT04202653|Experimental|Experienced:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in treatment experienced patients
11081877|NCT04202653|Experimental|Experienced:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus TQ-B2450 for 24 weeks in treatment experienced patients
11081878|NCT04202640|Experimental|Arm A - Mechanical Stimulation|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, mechanical stimulation
11081879|NCT04202640|Sham Comparator|Arm B - Massages|Patients in this arm will receive, in addition to standard rehabilitation physiotherapy, massages.
11081880|NCT04202601|Experimental|Neoadjuvant therapy group|
11081881|NCT04202601|Experimental|first-line therapy group|
11081882|NCT04202601|Experimental|≥second-line therapy group|
11081883|NCT04202575|No Intervention|conventional setup|Blood and gas from the coronary and cardiotomy suction devices is continuously evacuated via the additional reservoir to the standard reservoir.
11081884|NCT04202575|Experimental|Intervention setup|The connecting tube between the additional and standard venous reservoir is clamped. Thus, blood and gas from the coronary and cardiotomy suction devices are collected in the additional venous reservoir. During the intervention setup, the blood in the additional venous reservoir is only evacuated to the standard reservoir if the volume exceeded 800ml, and always with a remaining volume of 100 mL blood to keep the CO2-gas trapped in the additional venous reservoir.
11081885|NCT04202562|Experimental|Combined surgery|Participants intervened of combined ab interno trabeculectomy and cataract surgery at the same time
11081886|NCT04202562|Active Comparator|Cataract surgery|Participants intervened of cataract surgery alone
11081934|NCT04202172|Experimental|COMBO|Implantation of Bioactive coronary stent in patients with myocardial infarction.
11081895|NCT04202497|Experimental|TAK-418 1.5 mg|TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of [18F]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.
11081896|NCT04202484|Experimental|Toripalimab combine CT|
11081897|NCT04202471|Experimental|Chlorhexidine Cloth|The intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive preoperative abdominal application of 2% chlorhexidine cloths.
11081898|NCT04202471|No Intervention|Standard Preoperative Care|The no intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive standard preoperative care.
11081899|NCT04202458|Experimental|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA
11081900|NCT04202432||Coronary Artery Bypass Surgery patients|Patients undergoing coronary artery bypass surgery (on-pump / off-pump) measured perioperatively and postoperatively.
11081901|NCT04202406|Experimental|Acetaminophen, codeine,and caffeine|Oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine.
11081902|NCT04202406|Experimental|Acetaminophen|Oral single dose of 1000mg acetaminophen.
11081903|NCT04202406|Placebo Comparator|Placebo|Maize starch.
11081904|NCT04202393|Experimental|Integrated Treatment Adherence Program (ITAP)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
11081905|NCT04202393|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
11081906|NCT04202380|Other|Azithromycin 1 day group|Patients will receive Azithromycin 1000mg once orally
11081907|NCT04202380|Other|Azithromycin 5 days group|Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days
11081908|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.25%|Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
11081909|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.125%|Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block
11081910|NCT04202354|Experimental|ARO-HSD|
11081911|NCT04202354|Placebo Comparator|Placebo|
11081912|NCT04202315|No Intervention|Control|Standard of care, no Virtual Reality
11081913|NCT04202315|Experimental|Virtual Reality|Standard of care plus Virtual Reality
11081914|NCT04202289|Active Comparator|Silver Sulfadiazine Cream 1%|In the control group, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of Silver Sulfadiazine Cream 1% was applied and covered with gauze and bandage. The dressing changes occurred every 48 hours. The patients were evaluated every 48 hours for the study parameters.
11081915|NCT04202289|Experimental|Nile Tilapia Fish Skin|In the test group, the treatment was Nile Tilapia Fish Skin, which have a patent registered at the National Institute of Industrial Property (INPI) under number BR 10 2015 021435 9. Nile Tilapia Fish Skin was subjected to a rigorous process of chemical sterilization, glycerolization and irradiation, followed by microbiological tests for bacteria and fungi, before storage in sterile refrigerated packaging. Prior to its use in the patient, the skin was washed thrice in sterile 0.9% saline for 5 minutes, in order to remove glycerol. Regarding application in the study patients, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, Nile Tilapia Fish Skin was applied and covered with gauze and bandage. Throughout the treatment, dressings with Nile Tilapia Fish Skin were only changed if the biomaterial was not properly adhered to the wound bed. The patients were evaluated every 48 hours for the study parameters.
11081916|NCT04202276|Other|Patients with GERD|The data of Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire to be performed in children and adolescents with GERD.
11081917|NCT04202276|Other|Control group|The same examinations as in experimental group are to be performed in patients of the control group (no GERD according to the results of the examination): Food frequency questionnaire (FFQ), 24-hours oesophageal pH-impedance examination, GERD-Q questionnaire.
11081918|NCT04202263|Placebo Comparator|Placebo|Placebo cream without minocycline
11081919|NCT04202263|Active Comparator|Minocycline Arm|Minocycline cream (1%,2%,3%)
11081920|NCT04202250|Active Comparator|CEMP (closed-ended multiport catheter) group|closed-ended multiport femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
11081921|NCT04202250|Active Comparator|OESP (open-ended single port catheter) group|open-ended single port femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
11081922|NCT04202224|Experimental|Study|Receives pre-emptive analgesia 30min. prior to third molar extraction. NSAID: Ibuprofen 400mg and Acetaminophen 500mg/
11081923|NCT04202224|Placebo Comparator|Placebo|Receives glucose tablets as pre-emptive analgesia 30min. prior to third molar extraction.
11081924|NCT04202224|Active Comparator|Control|Receives no medication prior to third molar extraction.
11081925|NCT04202211|Placebo Comparator|Placebo oral & enema|twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema
11081926|NCT04202211|Active Comparator|LYO-FMT oral + placebo enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema
11081927|NCT04202211|Active Comparator|LYO-FMT oral + LYO-FMT enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema
11081928|NCT04202198|Experimental|pinhole surgical technique with Platelet Rich Fibrin|minimally invasive tunneling procedure followed by coronal advancement with placement of Platelet Rich Fibrin membrane
11081929|NCT04202198|Active Comparator|pinhole surgical technique only|coronal advancement following minimally invasive tunneling procedure
11081930|NCT04202185||G1a|infants under 3 years deaf severe to deep
11081931|NCT04202185||G1b|children under 16 years of age with audiologically proven auditory neuropathy
11081932|NCT04202185||G2|patients <25 years old with one or two Otoferlin mutations
11081933|NCT04202172|Active Comparator|BIOFREEDOM|Implantation of Drug-eluting coronary stent without polymer in patients with myocardial infarction.
11081935|NCT04202159||Perampanel|Participants with PGTC or SGTC seizures may receive perampanel tablets or oral suspension as only add-on therapy based on physicians decision in accordance with summary of product characteristics (SmPC) and will be observed at baseline, 6 months (intermediate visit), and 12 months (final visit).
11081936|NCT04202146|Experimental|Contingency Management + Motivational Interviewing|Participants will complete a seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling.
11081937|NCT04202133|Experimental|WW (formerly Weight Watchers)|16-weeks of the group-based WW program
11081938|NCT04202133|Other|Waitlist Control|16-weeks on waitlist then participants will be provided with 16-weeks of the group-based WW program
11081939|NCT04202120|Experimental|Age-related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with age-related primes.
11081940|NCT04202120|Active Comparator|Non-age related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with NON age-related primes.
11081941|NCT04202107||Urban|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.
~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
11081942|NCT04202107||Rural|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.
~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
11081943|NCT04202094|Experimental|Biopsy group|Young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood and who have chosen to undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy.
11081944|NCT04202094|Experimental|No biopsy group|Young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood and who have refused to undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy.
11081945|NCT04202094|No Intervention|Control group|Spontaneously conceived young adults whose data on reproductive health have already been published (Belva F et al., 2016/2017/2019).
11081946|NCT04202068|Experimental|Ceftriaxone sodium and Sulbactam Sodium for injection|combinations of β-Lactamase inhibitors
11081947|NCT04202055||Neuromyelitis optica with anti-MOG|
11081948|NCT04202055||Patients with Neuromyelitis optica with anti-AQP4|
11081949|NCT04202055||Seronegative patients with Neuromyelitis optica|
11081950|NCT04202055||Patients with recurrent-remitting multiple sclerosis|Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement
11081951|NCT04202055||Progressive multiple sclerosis patients|
11081952|NCT04202055||Symptomatic controls|
11081953|NCT04202042|Experimental|Psychological first aid|PFA responders are trained to deliver 8 core actions in the aftermath of traumatic event (: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services (within the first 24 hours)
11081954|NCT04202042|Active Comparator|Usual organisational intervention|One phone call by workplace psychologist (within the first 48 hours) and reference to employee aid program
11081955|NCT04202029|Other|pulseoxymetry arm|pulseoxymetry arm: standard monitoring: pulseoxymetry and non-invasive blood preassure monitoring
11081956|NCT04202029|Experimental|thoracic impedance monitoring arm|thoracic impedance monitoring arm: standard monitoring and additionally thoracic impedance measurement)
11081957|NCT04202016|Experimental|Piezocision on high facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
11081958|NCT04202016|No Intervention|High facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
11081959|NCT04202016|Experimental|Piezocision on average facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
11081960|NCT04202016|No Intervention|Average facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
11081961|NCT04202003|Experimental|TJ011133|TJ011133 is tentatively administered once a week for a treatment cycle every 28 days
11081962|NCT04201990|Experimental|treatment group|Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years
11081963|NCT04201977|Active Comparator|Exercise session followed passive recovery|Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). The interval between each exercise session will be one week. Volunteers will not perform any form of recovery for 20 min after resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
11081987|NCT04201808|Experimental|Single Arm Intervention Group|All approximately 100 patients experienced previous suboptimal response to other direct acting antivirals. Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence. All patients in this study are in the same arm.
11081964|NCT04201977|Active Comparator|Exercise session followed active recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Active recovery for 20 minutes (MIKA et al., 2016; CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010);
11081965|NCT04201977|Active Comparator|Exercise session followed immersion in cold water recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will be immersed in cold water immediately after exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009).
11081966|NCT04201977|Active Comparator|Exercise session followed foam roller recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will undergo an FR session immediately after resistance exercise session (PEARCEY et al., 2015).
11081967|NCT04201964|Experimental|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
11081968|NCT04201951|Active Comparator|Tranexamic group|Group A will receive 1gm Tranexamic acide diluted in 20 ML 5% glucose water
11081969|NCT04201951|Placebo Comparator|Placebo group|Group B will receive 30ML 5% glucose water
11081970|NCT04201938|Active Comparator|Symbiter-Omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
11081971|NCT04201938|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
11081972|NCT04201925||blepharoplasty|Patients will undergo blepharoplasty surgery
11081973|NCT04201912|Placebo Comparator|control patients|Evaluation of Toll like receptor activity from whole saliva obtained from control patients
11081974|NCT04201912|Active Comparator|Periodontal patients without diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients without diabetes
11081975|NCT04201912|Active Comparator|Periodontal patients with diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients with diabetes
11081976|NCT04201886|Other|RA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
11081977|NCT04201886|Other|OA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
11081978|NCT04201873|Experimental|Group A (pembrolizumab, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
11081979|NCT04201873|Active Comparator|Group B (placebo, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
11081980|NCT04201860||Blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue handled explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
11081981|NCT04201860||Not blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue did not handle explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
11081982|NCT04201847|Active Comparator|Infertile women with normal ovarian reserve|Infertile women with normal ovarian reserve will be included.
11081983|NCT04201847|Active Comparator|Infertile women with high ovarian reserve|Infertile women with high ovarian reserve will be included.
11081984|NCT04201847|Active Comparator|Infertile women with poor ovarian reserve|Infertile women with poor ovarian reserve will be included.
11081985|NCT04201834|Experimental|Risperidone|Participants will initiate risperidone 0.5 mg nightly the day after the baseline visit. Dose assessment will occur at pre-specified intervals during the titration phase (week 2, 3, 4, 6, 7). The investigator will increase the dose by 0.5 mg at the week 2, week 3, week 4, and week 6 visits until either optimal chorea benefit has been obtained, an intolerable adverse event occurs, or the maximum allowable dose (3.0 mg) is reached.
11081986|NCT04201821|Experimental|FMT Administration|This is a single arm study in which all eligible participants will receive FMT.
11081988|NCT04201795|Experimental|pressure and traction|pressure and traction durin 5 minutes will be applied in plantar fascia
11081989|NCT04201795|Sham Comparator|Laser|Applied during 5 minutes each plantar fascia of sham laser
11081990|NCT04201782|Experimental|Cohort 1|Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.
11081991|NCT04201769|Experimental|Arm A|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.
~No further anti-emetic prophylaxis on days 2 thorough 4."
11081992|NCT04201769|Experimental|Arm B|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.
~Oral dexamethasone 4 mg once per day in the morning of days 2 and 3."
11081993|NCT04201769|Active Comparator|Arm C|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.
~Oral dexamethasone 4 mg twice per day on days 2 thorough 4."
11081994|NCT04201756|Experimental|Afatinib|
11081995|NCT04201743|Active Comparator|1 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 1 mL NyDYN injection.
11081996|NCT04201743|Active Comparator|2 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 2 mL NyDYN injection.
11081997|NCT04201730|Experimental|ERAS|Perioperative intervention with individual Enhanced Recovery After Surgery （ERAS）
11081998|NCT04201717|Active Comparator|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed.After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
11081999|NCT04201717|Experimental|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion.In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
11082000|NCT04201704|Active Comparator|Liberal IV Fluid|"Maintenance fluid rate calculated by 4-2-1 formula for patients <110kg: 4 mL/kg for first 0-10kg + 2 mL/kg for 11-20kg + 1 mL/kg for each kg >20kg
~Patients >110kg maintenance 150 mL/hr
~Bolus Criteria: change in 1 of: >20% decrease in systolic blood pressure 50th percentile for age and sex, >20% increase in heart rate over 50th percentile for age, base excess > -5mmol/L, blood lactate >2mmol/L, AND urine output (UO) <1 mL/kg/hr if <50kg or <50 mL/hr if >50kg
~If criteria met: bolus 20 mL/kg if <50kg or 1 L if ≥50 kg
~For transfusion: give 10 mL/kg packed red blood cells, platelets, or fresh frozen plasma up to 250 mL. If >25kg give 250 mL.
~Diuresis- after minimum 24hrs: if UO <2 mL/kg/hr (or <100 mL/hr if >50 kg) continue maintenance rate and bolus per initial phase. If UO >2 mL/kg/hr (or >100 mL/hr if >50kg), and lactate, systolic blood pressure, heart rate, creatinine are normal then lower IV fluid rate to ½ maintenance rate and then to keep vein open once on regular feeds"
11082001|NCT04201704|Experimental|Restricted IV Fluid|"Maintenance fluid rate calculated by 70% of 4-2-1 formula if <110 kg: 4 mL/kg for first 0-10 kg, + 2 mL/kg for 11-20 kg, + 1 mL/kg for every kg >20 kg
~Patients >110 kg: maintenance is 105 mL/hr
~If same bolus criteria met: 10 mL/kg for patients <50kg, or 500 mL if ≥50 kg
~If meet transfusion criteria: transfuse 10 mL/kg with packed red blood cells, platelets, or fresh frozen plasma by weight up to 250 mL. Patients >25 kg get 250 mL per transfusion
~Diuresis (after minimum 24 hrs): if UO <1 mL/kg/hr (or <50 mL/hr if >50 kg) then continue IV fluids at maintenance rate and bolus as needed. If UO 1-2 mL/kg/hr (or 50-100 mL/hr if >50 kg) then decrease IV rate to ½ maintenance rate. If UO >2 mL/kg/hr (or >100 mL/hr if >50 kg), and Lactate, systolic blood pressure, heart rate, creatinine normal then reduce to keep vein open and consider Furosemide for goal UO >2-4 mL/kg/hr (100-200 mL/hr if >50 kg) until euvolemic"
11082002|NCT04201691|Experimental|conventional group|Conventional group is received conventional rehabilitation program.
11082003|NCT04201691|Experimental|mobilization group|Mobilization group is received cervical mobilization in addition to conventional rehabilitation program.
11082004|NCT04201678|Active Comparator|CLIA (conventional local anesthesia infiltration) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.
~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
11082005|NCT04201678|Active Comparator|EPIAA (Extrapedicular infiltration anesthesia) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.
~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
11082006|NCT04201678|Active Comparator|ESP (Erector Spina Plane Block) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.
~In the ESP group, a high-frequency-50 15-6 Megahertz (MHz) linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
11082007|NCT04201665|Experimental|carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
11082008|NCT04201665|Active Comparator|oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
11082009|NCT04201652|Active Comparator|Superficial|Intervention: Superficial local anesthetic infiltration.
11082011|NCT04201639|Experimental|Refit|Refit and dispense patient with Verofilcon A contact lenses and evaluate lens performance.
11082012|NCT04201626|Experimental|ERAS|
11082013|NCT04201626|No Intervention|Control|
11082014|NCT04201613|Active Comparator|Early Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive one hour of treatment per day for 20 days.
11082015|NCT04201613|Active Comparator|Early Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
11082016|NCT04201613|Active Comparator|Late Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive one hour of treatment per day for 20 days.
11082017|NCT04201613|Active Comparator|Late Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
11082018|NCT04201613|Active Comparator|Control Group|This group will receive usual care with robotic assessment.
11082019|NCT04201600||Middle-aged and Older adults with Prediabetes|Middle-aged and Older adults with Prediabetes
11082020|NCT04201587|Experimental|Henna application group|
11082021|NCT04201587|No Intervention|Control group|
11082022|NCT04201574|Placebo Comparator|Vehicle Ophthalmic Solution|
11082023|NCT04201574|Experimental|ALY688 Ophthalmic Solution Concentration 1|
11082024|NCT04201574|Experimental|ALY688 Ophthalmic Solution Concentration 2|
11082025|NCT04201561|Experimental|Experimental group|The patient will receive an intravenous selenium 2000 μg/40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
11082026|NCT04201561|Placebo Comparator|Placebo group|The patient will receive an intravenous normal saline 40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
11082027|NCT04201548|Active Comparator|Active Comparator|This is the constant-load Endurance Training (ET) group which will constitute the control group.
11082028|NCT04201548|Experimental|Long High Intensity Interval Training|This is the Long High Intensity Interval Training (Long-HIIT) group.
11082029|NCT04201548|Experimental|Short High Intensity Interval Training|This is the Short High Intensity Interval Training (Short-HIIT) group.
11082030|NCT04201535||Group 1A:|at least 10 patients, maximum 70,with RA in remission, but presenting p• Group 1B: at least10 patients maximum 70, with RA in remission, without bone erosion A group of 80 controls,
11082031|NCT04201535||Group 2:|10 patients with osteoarthritis (OA) who must undergo a surgical procedure.
11082032|NCT04201535||Group 3|"70 without RA and OA but hospitalized for any other orthopedics pathology who must undergo a surgical procedure.
~rogressive bone erosion who must undergo a surgical procedure."
11082033|NCT04201522|Active Comparator|Training intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance
11082034|NCT04201522|Sham Comparator|Sham intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance in the training group compared to the sham group.
11082035|NCT04201509||ADHD group|Participants in the clinical group were recruited to the project when they were assessed for and diagnosed with ADHD at the Neuropsychiatric Unit of the CAP Clinic in Lund in 2011-2012. The ADHD group was treated as usual in the clinic and re-assessed during 2014-2015.
11082036|NCT04201509||Non-clinical group|Participants in the non-clinical group were recruited recruited 2012 from schools in the same district and among children of the same average age as the ADHD-group 2012. The non-clinical group did not have any intervention during the follow-up time. Th non-clinical group was re-assessed during 2015.
11082037|NCT04201496|Experimental|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)
11082038|NCT04201496|Experimental|Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks|Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)
11082039|NCT04201496|Active Comparator|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)
11082040|NCT04201496|Active Comparator|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)
11082041|NCT04201483|Active Comparator|DCE group|DCE exercise without RUSI feedback
11082042|NCT04201483|Experimental|DCE + RUSI group|DCE exercise with RUSI feedback
11082043|NCT04201470|Experimental|MS patients|Patients with atypical MS identified in our cohort
11082044|NCT04201470|Active Comparator|Controls|
11082045|NCT04201457|Experimental|Phase 1 Stratum 1 BRAF V600E LGG or HGG|LGG or HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
11082046|NCT04201457|Experimental|Phase 1 Stratum 2 BRAF aberration or LGG with NF1|LGG with BRAF duplication or fusion with any partner or LGG with NF1 will received Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the assigned dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
11082047|NCT04201457|Experimental|Phase 2 Stratum 3 LGG with BRAF V600 mutation|LGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
11082048|NCT04201457|Experimental|Phase 2 Stratum 4 HGG with BRAF V600 mutation|HGG with BRAF V600E/D/K mutation will receive Dabrafenib, Trametinib and Hydroxychloroquine. All medications are administered orally with Dabrafenib and HCQ given twice a day and Trametinib given once per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria
11134738|NCT03832816|Experimental|Vaporized medium CBD alone|100mg pure CBD
11082049|NCT04201457|Experimental|Phase 2 Stratum 5 LGG with BRAF aberration|LGG with BRAF duplication or fusion with any partner will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
11082050|NCT04201457|Experimental|Phase 2 Stratum 6 LGG with NF Type 1|LGG with Neurofibromatosis Type 1 will receive Trametinib and Hydroxychloroquine. All medications are administered orally with Trametinib given once per day and HCQ give twice per day at the recommended Phase 2 dose for a 28 day course. Courses may repeat until the patient meets an off treatment criteria.
11082051|NCT04201444|Experimental|Patient group|
11082052|NCT04201444|Active Comparator|Remission control group|
11082053|NCT04201444|Active Comparator|Bilateral surrenalectomy control group|
11082054|NCT04201431|Experimental|Group 1|15 volunteers receiving 3 doses of 50ug PvDBPII in 50ug Matrix M1 on days 0, 28 and 56. Volunteers will undergo CHMI between days 70 and 84. 2 volunteers acting as backups will also be recruited.
11082055|NCT04201418||Patisiran Prospective Cohort|Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.
11082056|NCT04201418||Patisiran Mixed Cohort|Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.
11082057|NCT04201418||Patisiran Retrospective Cohort|Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.
11082058|NCT04201405|Experimental|Haematopoietic stem cell gene therapy for MPS IIIA|Open label
11082059|NCT04201379||neck pain patients|servical disk hernisi servical spondilosis servical problems
11082060|NCT04201379||control|healthy people
11082061|NCT04201366||Sample 1|All participants fulfilling the inclusion criteria.
11082062|NCT04201366||Sample 2|Participants fulfilling the inclusion criteria and reports no neck/shoulder pain at baseline.
11082063|NCT04201353|Experimental|Conditional Cash Transfer|Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
11082064|NCT04201353|No Intervention|Control|Participants attending control clinics will receive the standard of care.
11082065|NCT04201327|Active Comparator|PrEP information only arm|Information to for accessing HIV prevention tools will be provided to participants.
11082066|NCT04201327|Experimental|PrEP counseling arm|Stigma focused counseling (one-session) aimed at addressing barriers to health care access will be provided.
11082067|NCT04201327|Experimental|PrEP counseling plus text messaging arm|Stigma focused counseling (one-session) and interactive text messaging aimed at addressing barriers to health care access will be provided.
11082068|NCT04201327|Experimental|PrEP counseling plus text messaging and on demand counseling|Ongoing stigma focused counseling and interactive text messaging aimed at addressing barriers to health care access will be provided.
11082069|NCT04201314|Placebo Comparator|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
11082070|NCT04201314|Experimental|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
11082071|NCT04201288|Experimental|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered in person at session 1 and by telephone at session 2.
11082072|NCT04201288|Placebo Comparator|Enhanced-Treatment-as-Usual (ETAU)|In addition to receiving treatment-as-usual at the clinic, ETAU participants will receive a 2-session program of HIV education.
11082073|NCT04201275|Experimental|Cohort 1|up to HEC74647PA capsule 50 mg once daily for 3 days
11082074|NCT04201275|Experimental|Cohort 2|up to HEC74647PA capsule 100 mg once daily for 3 days
11082075|NCT04201275|Experimental|Cohort 3|up to HEC74647PA capsule 200 mg once daily for 3 days
11082076|NCT04201275|Placebo Comparator|Cohort 4|up to placebo once daily for 3 days
11082077|NCT04201262|Experimental|Ravulizumab|"During the Primary Treatment Period, all participants will receive open-label ravulizumab via intravenous (IV) infusion starting on Day 1. The end of the Primary Treatment Period will be triggered when the last enrolled participant completes between 26 and 50 weeks in the study (depending on the number of adjudicated On-Trial Relapse observed).
~After completion of the Primary Treatment Period, all participants will have the opportunity to continue receiving ravulizumab in the Long-Term Extension Period of the study. For each participant, the Long-Term Extension Period continues for up to 2 years, or until ravulizumab is approved and/or available (in accordance with country-specific regulations), whichever occurs first."
11082078|NCT04201249|Active Comparator|Mesotherapy with piroxicam and lidocaine|
11082079|NCT04201249|Sham Comparator|Mesotherapy without piroxicam and lidocaine|
11082080|NCT04201236|Experimental|Oropharyngeal exercises|Oropharyngeal exercises include soft palate, tongue and facial muscle exercises as well as stomatognathic function exercises. Training sessions were held once a day, 5 days a week for 12 weeks under the supervision of a mirror.
11082081|NCT04201236|Experimental|Inspiratory muscle training|The inspiratory muscle training group was administered for 12 weeks starting from 30% of maximal oral pressure, 7 days a week, 15 minutes twice a day. Patients came to the control once a week, mouth pressures were measured and training pressure was adjusted in 30% of the new value.
11082082|NCT04201236|No Intervention|Control|This group was only monitorized without any rehabilitation intervention.
11082083|NCT04201223|Experimental|FLARE Intervention|Participants will be randomized to receive an intervention that works with melanoma survivors and their children as a family unit to improve melanoma preventive behaviors.
11082084|NCT04201223|No Intervention|Standard Education|Participants will be randomized to receive information on child sun protection that is publicly available.
11082085|NCT04201210|Experimental|Experimental Arm|Patients with no matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the experimental arm
11082086|NCT04201210|Active Comparator|Control Arm|Patients with a matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the control arm
11082087|NCT04201197|Active Comparator|Inje Cocktail|Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)
11082088|NCT04201197|Experimental|Inje Cocktail + THC extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC
11082089|NCT04201197|Experimental|Inje Cocktail + THC/CBD extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 40mg THC and 1350mg CBD
11082090|NCT04201184|Experimental|Little Holy One intervention|The participants will receive 12 1-hour lessons on parenting, stress, and culture over a period of 12 weeks.
11082091|NCT04201184|Active Comparator|Nutrition control|The participants will receive 6 1-hour lessons on nutrition over a period of 12 weeks.
11082092|NCT04201158||Obese Group (Girl)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria.Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
11082093|NCT04201158||Obese Group (Boy)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
11082094|NCT04201158||Control Group (Girl)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
11082095|NCT04201158||Control Group (Boy)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
11082096|NCT04201145|Experimental|Run in cohort: pembrolizumab only|"Treatment with pembrolizumab as a single agent for 56 days
~- 2 doses during treatment cycle, intravenous, at predetermined protocol dose"
11082097|NCT04201145|Experimental|Cohort 1: pembrolizumab + defactinib 12 days|"Treatment with Defactinib in combination with Pembrolizumab for 12 days
~Defactinib oral, twice daily, per predetermined dose for 12 days of treatment in combination
~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
11082098|NCT04201145|Experimental|Cohort 2: pembrolizumab + defactinib 35 days|"Treatment with defactinib in combination with pembrolizumab to 35 days
~Defactinib oral, twice daily, per predetermined dose for 35 days of treatment in combination
~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
11082099|NCT04201145|Experimental|Expansion cohort|Tolerated phase IA regimen will be administered in a phase IB expansion cohort
11082100|NCT04201132|Experimental|Carotid artery stenting|Carotid artery stenting procedure with Neuroguard IEP System
11082101|NCT04201119|Experimental|With Oxiris|
11082102|NCT04201119|No Intervention|Without Oxiris|
11082103|NCT04201106|No Intervention|Control|In the control group, the participants will not be taking any placebos or undergoing any other study-related treatments.
11082104|NCT04201106|Experimental|Open Label Placebo Group with Rationale|
11082105|NCT04201106|Active Comparator|Open Label Placebo Group without Rationale|
11082106|NCT04201093|Experimental|Tavapadon 5 mg|Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.
11082107|NCT04201093|Experimental|Tavapadon 15 mg|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.
11082108|NCT04201093|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
11082109|NCT04201080|Experimental|Part A: TRV250 for SC injection|2 SC injections of (10 mg/ml per injection)
11082110|NCT04201080|Placebo Comparator|Part A: Placebo for SC injection|2 SC injections (identical to the TRV250)
11082111|NCT04201080|Experimental|Part B: TRV250 dose 1 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
11082112|NCT04201080|Experimental|Part B: TRV250 dose 2 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
11082113|NCT04201080|Experimental|Part B: TRV250 dose 3 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
11082114|NCT04201080|Placebo Comparator|Part B: Placebo for SC injection|Placebo (using syringes identical to the TRV250 arms)
11082115|NCT04201054|Experimental|Fluconazole|Subjects receive a single-dose treatment.Urine samples will be collected after administration (4 fractions: 0-12, 12-24, 24-48, 48-72 hours post-administration).
11082116|NCT04201041|Active Comparator|trans-gluteal approach|received pudendal nerve pulsed radiofrequency through trans-gluteal approach
11082117|NCT04201041|Active Comparator|trans-vaginal approach|received pudendal nerve pulsed radiofrequency through trans-vaginal approach
11082118|NCT04201028|Experimental|Video Conferencing Health Coaching with devices|The DEV group participants will meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) to discuss exercise and diet goals. Participants in this group were provided with a blood pressure and body weight scale which connected to the CoachCare App®.
11082119|NCT04201028|Experimental|Video Conferencing Health Coaching with no devices|The NODEV group participants meet via the DiscoverHealth® app using their smartphone, and met 18 times with the registered dietitian (RD) for health coaching to discuss exercise and diet goals. Participants in this group did not receive devices.
11082120|NCT04201015|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
11082121|NCT04201015|Active Comparator|Rate-response settings off|Patients allocated to deactivated rate-response settings.
11082122|NCT04201015|Experimental|Optimized rate-response settings|Patients allocated to optimised rate-response settings.
11082123|NCT04200989|Experimental|Treatment|Peanut ILIT
11082124|NCT04200976|Experimental|Tele-CABA|Participants who engage in the Tele-CABA intervention.
11082125|NCT04200976|Placebo Comparator|Usual Care|Participants who do not engage in the Tele-CABA intervention during their time in the study. They will be eligible to receive Tele-CABA following completion of the 6-month questionnaires and cognitive assessment (as a courtesy).
11082126|NCT04200963|Experimental|IK-175 Dose Escalation|Approximately 5 dose escalation steps are planned during the dose escalation phase of the study.
11082127|NCT04200963|Experimental|IK-175 Dose Expansion|A dose expansion phase will be performed in patients with IK-175 after completion of the dose escalation to confirm the RP2D.
11082128|NCT04200963|Experimental|Single-Dose Run-In|A single dose of IK-175 will be administered to all patients prior to entering the dose escalation phase.
11082129|NCT04200950|Experimental|Intervention|Previse alert arm
11082130|NCT04200950|No Intervention|Control|No alert
11082131|NCT04200937||Tactra Malleable Recipients|All subjects who meet the inclusion and exclusion criteria and receive the Tactra Malleable implant.
11082132|NCT04200924||Children with idiopathic toe walking|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
11082133|NCT04200924||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
11082134|NCT04200911|Experimental|RAPA intervention|Sirolimus 1mg orally once a day for 8 weeks
11082135|NCT04200885|Active Comparator|Postoperative NSAID Prescription|Patients in this arm received common postoperative prescriptions following removal of their impacted third molars for seven days; twice a day 500 mg amoxicillin+125 mg clavulanic acid, twice a day 25 mg dexketoprofen trometamol and three times a day 1.5 mg/ml clorhexidine gluconate+1.2 mg/ml benzydamine hydrochloride containing 200 ml mouthwash.
11082136|NCT04200885|Active Comparator|Preoperative Submucosal Corticosteroid Injection|Patients in this arm were administered 8mg/2ml dexamethasone 21-phosphate preoperatively after local anesthesia were obtained. Injection site was the depth of buccal sulcus near operation site. For the patients in this arm 25 mg dexketoprofen trometamol was excluded from postoperative prescription in order not to affect the anti-inflammatory effects of corticosteroid. Instead of NSAID, three times a day 500 mg paracetamol was prescribed. The patients were advised not to exceed maximal dosage of 3000 mg (6 tablets) in a day.
11082137|NCT04200885|Active Comparator|Postoperative Therapeutic Elastic Bandage Application|In this arm the therapeutic elastic bandage applications were immediately performed after removal of mandibular third molars. The distance between tragus-lateral commissura line and supraclavicular lymph nodes was measured and the tapes were then cut into 5 tails. The base of the tape was placed on supraclavicular lymph nodes and tails were placed on the site to cover parotid, submandibular, submental and superficial cervical lymph nodes. The tapes were removed on postoperative second day.
11082138|NCT04200872||biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
11082139|NCT04200872||without biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
11082140|NCT04200859|Experimental|Cold application with ice pack|Before the chest tube was removed, two ice packs with a size of 15.5x9cm were inserted around the chest tube so as to make as much contact as possible
11082141|NCT04200859|Experimental|Cold application with gel pad group|Before the chest tube was removed, a gel pad with a radius of 15 cm was completely inserted around the chest tube
11082142|NCT04200859|No Intervention|Control group|Routine analgesic drugs are not administered to patients before removal of the chest tube in thoracic surgery clinic. However, analgesic is performed according to the severity of pain after the procedure.
11082143|NCT04200846|Experimental|Exercise intervention|Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64*age in years).
11082144|NCT04200846|No Intervention|Control|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.
11082145|NCT04200833||group 1|All JIA patients that were switched from adalimumab to golimumab because of Treatment failure of their JIA associated uveitis at the Medical University of Graz Austria from 2010 to 2019
11082146|NCT04200820|Experimental|Trampoline|The participants will jump on a mini-trampoline for 30 seconds and then will have a 30 seconds break. This will be repeated 16 times. This resulted in a cumulative total intervention time of 8 minutes.
11082147|NCT04200807||Healthy preterm neonate|Neonate 26 weeks to 36 weeks + 6 days of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
11082190|NCT04200573|Experimental|Normal Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
11134739|NCT03832816|Experimental|Vaporized high CBD alone|200mg pure CBD
11082148|NCT04200807||Healthy term neonate|Neonate from 37 weeks of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
11082149|NCT04200807||Sick neonate|Neonate of any gestation, without congenital heart defects, with clinically and laboratory-identified infection.
11082150|NCT04200794|Experimental|musical instrumental training|Bi-weekly musical string instrument training in a group setting, over 24 months, provided by professional string instrument teachers
11082151|NCT04200794|Active Comparator|sensitization to music|Bi-weekly sensitization to music in a group setting, over 24 months, involving listening, playing small percussive instruments and choir singing, provided by professional school music teachers
11082152|NCT04200781|Experimental|Shengdi Dahuang Decoction|To clarify the clinical effects of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke and to explore the possible mechanism. Participants will take the granules of Shengdi Dahuang Decoction that contains 15 grams of rehmannia and 5 grams of rhubarb, one pack per time, twice a day for 7 days.
11082153|NCT04200781|Placebo Comparator|Placebo|To explore the effective clinical therapy in acute hemorrhagic stroke. Participants will take placebo contains 2% rehmannia and rhubarb, one pack per time, twice a day for 7 days.
11082154|NCT04200768|Other|Standard|Standard of care
11082155|NCT04200755|Experimental|Dupilumab|30 patients; Dupilumab s.c. injection; 2 ready-to-use syringes (600 mg) initial (V1), 1 ready-to-use syringe (300 mg) every 14 days (V2- V13) Dupilumab s.c. injection in healthy skin, 24 weeks
11082156|NCT04200755|Placebo Comparator|Placebo|15 patients; placebo s.c. injection; 2 ready-to-use syringes initial (V1), 1 ready-to-use syringe every 14 days (V2-V13) placebo s.c. injection in healthy skin, 24 weeks
11082157|NCT04200729|Experimental|Irrigation with PVI|
11082158|NCT04200729|Active Comparator|Usual care|
11082159|NCT04200716|Active Comparator|Moderate intensity continuous training - session|The volunteers perform a 30-minute moderate-intensity exercise session on the exercise bike.
11082160|NCT04200716|Active Comparator|High intensity interval training - session|The volunteers perform a session of high intensity interval exercise on the exercise bike.
11082161|NCT04200703|Experimental|Intervention|Implementation of the Adult and Survivor Centered Approach.
11082162|NCT04200703|No Intervention|Comparison|No implementation of intervention.
11082163|NCT04200690|Experimental|Interdisciplinary management|Interdisciplinary combined clinical care
11082164|NCT04200690|Active Comparator|Usual-care management|Usual-care
11082165|NCT04200677|Experimental|MCN1|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
11082166|NCT04200677|Experimental|BCN05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
11082167|NCT04200677|Experimental|BCN1|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
11082168|NCT04200677|Experimental|BCN2|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
11082169|NCT04200677|Experimental|MCM1|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
11082170|NCT04200677|Experimental|BCM05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
11082171|NCT04200677|Experimental|BCM1|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
11082172|NCT04200677|Experimental|BCM2|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
11082173|NCT04200677|Experimental|BC25|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
11082174|NCT04200664||Siderosis (iSS) group|participants with a known diagnosis of infratentorial superficial siderosis (defined using standardised radiological criteria) confirmed by a consultant neurologist with expertise in this condition at University College London Hospitals National Health Service (NHS) Foundation Trust
11082175|NCT04200664||Age-related hearing loss (ARHL) group|participants with age-related hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
11082176|NCT04200664||Control group|participants with no known or previously reported hearing loss (as identified from participant's clinical history and examination, with hearing thresholds confirmed on a pure-tone audiogram)
11082177|NCT04200651|Experimental|DEXTENZA® arm|This arm will receive the DEXTENZA® insert after cataract surgery and MIGS.
11082178|NCT04200651|Active Comparator|Prednisolone acetate 1% arm|This arm will receive the prescription for daily prednisolone acetate 1% eye drops after cataract surgery and MIGS.
11082179|NCT04200638|Experimental|ProTaper Next group|Clean and shape the necrotic canals with ProTaper instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
11082180|NCT04200638|Experimental|WaveOne Gold group|Clean and shape the necrotic canals with Wave One Gold instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
11082181|NCT04200625||Semaglutide|Patients using standard of care weekly GLP-1A analog Semaglutide
11082182|NCT04200625||Dulaglutide|Patients using standard of care weekly GLP-1A analog Dulaglutide
11082183|NCT04200625||Metformin|Patients using standard of care daily Metformin.
11082184|NCT04200612|Experimental|Intervention Group|Participants in the intervention group will go through the 5-week EAP program consisting of the clinical processing following some activities found in EAP manuals.
11082185|NCT04200612|Active Comparator|Active-control group|Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities).
11082186|NCT04200612|Placebo Comparator|Placebo-control group|Participants in the placebo-control group will undergo a 5-week movie screening of 1 hour each session that is related to horses.
11082187|NCT04200599|Experimental|Early oxytocin Infusion|labour augmentation with oxytocin was started early following amniotomy.
11082188|NCT04200599|Active Comparator|Late oxytocin infusion|oxytocin augmentation was delayed at two hours after amniotomny and this practice is currently being used as standard protocol in this hospital to manage women in labour.
11082189|NCT04200586|Experimental|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground
11082228|NCT04200248|Experimental|Sham + RBM-007|Sham + RBM-007 intravitreal injection
11082191|NCT04200573|Experimental|Mild Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
11082192|NCT04200573|Experimental|Moderate Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
11082193|NCT04200573|Experimental|Severe Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment
11082194|NCT04200560|Experimental|Healthy Adult Subjects|Healthy adult subjects (18 - 30 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise
11082195|NCT04200560|Experimental|Healthy Older Adult Subjects|Healthy older adult subjects (> 60 years) will be assessed for markers of EC autophagy, eNOS activation, and NO generation before and after Rhythmic Handgrip Exercise and after Chronic Exercise Training.
11082196|NCT04200547|Experimental|Immunomonitoring-based follow-up|Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum.
11082197|NCT04200547|Active Comparator|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. This strategy is the standard strategy for post-operative follow-up of Crohn's disease patients.
11082198|NCT04200534|Experimental|Group I (centralized care strategy)|Participants receive counseling over the phone to help them quit smoking and learn about lung cancer screening over 15-20 minutes for 6-8 sessions over 8 weeks. Participants may also receive nicotine patches.
11082199|NCT04200534|Active Comparator|Group II (usual care)|Participants receive counseling on lung cancer screening and smoking cessation from primary care providers at health care visit.
11082200|NCT04200521||Healthy weight individuals|Cross-sectional observation on healthy participants who will be recruited from the general population from both genders (Lebanese and Emirati Subjects).
11082201|NCT04200521||Obese individuals|Prospective study of 3 months duration (pre and post design) on obese Emirati and Lebanese participants undergoing bariatric procedure irrelevant of the study, from Qassimi Hospital In sharja and Middle East Institute of Health University Hospital, Lebanon
11082202|NCT04200508|Experimental|Intervention|Targeted gown and glove use for high risk care activities in high risk residents
11082203|NCT04200508|No Intervention|Baseline|Standard of Care
11082204|NCT04200495||Healthy Controls|No sleep-wake disorder present
11082205|NCT04200495||Active Sleep-Wake Disorder|Presence of Sleep-Wake Disorder
11082206|NCT04200482|Active Comparator|Arm A (low dose nutrition and PA class, eHealth intervention)|Participants attend one diet and physical activity class delivered remotely via Zoom and receive an eHealth communication intervention for 6 months.
11082207|NCT04200482|Experimental|Arm B (high dose nutrition and PA class, eHealth intervention)|Participants attend 12 twice monthly diet and physical activity online sessions delivered remotely via Zoom and receive an eHealth communication intervention for 6 months.
11082208|NCT04200469|Experimental|QFR Intervention|Patients submitted to a coronary angiogram with at least one non-left main stable coronary stenosis between 50 and 90% and PCI indication with paired assessment of QFR, dFR, RFR and FFR, before and after PCI once informed consent is provided.
11082209|NCT04200456|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
11082210|NCT04200456|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
11082211|NCT04200443|Experimental|Treatment (cabozantinib, temozolomide)|Patients receive cabozantinib PO QD on days 1-28 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11082212|NCT04200417|Experimental|Lung, Endobronchial, Mediastinal or Pleural Metastases|Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy
11082213|NCT04200404|Experimental|Phase Ib arm|arms 1. Phase Ib: advanced or refractory solid tumors;
11082214|NCT04200404|Experimental|Phase II arm|arms 2.Phase II: subjects with tumor of specific types
11082215|NCT04200391|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
11082216|NCT04200378||Subjects undergoing TMVr|Subjects with severe, symptomatic primary mitral regurgitation (MR) scheduled to undergo a transcatheter mitral valve repair (TMVr) as standard of care will have intra-op baseline and post repair blood draws. Pre-procedure and post-procedure transthoracic echocardiograms (TTE) will assess the hemodynamic implications of the repair.
11082217|NCT04200365|Experimental|Itacitinib|
11082218|NCT04200352|Experimental|TEV-50717|The dose of the TEV-50717 should be increased on a weekly basis to reach a clinically meaningful reduction in dyskinesia, as indicated by a reduction in the Clinical Global Impression of Improvement;(CGI-I).
11082219|NCT04200339||Adolescents|Adolescents between the ages of 12 and 17 years old (inclusive).
11082220|NCT04200313|Experimental|Bionic Pancreas (BP)|Adults and peds will use the Bionic Pancreas (BP) with lispro or aspart for 13 weeks
11082221|NCT04200313|Experimental|Bionic Pancreas with Fiasp (BPFiasp)|Adults will use the Bionic Pancreas (BP) with Fiasp for 13 weeks
11082222|NCT04200313|No Intervention|Usual Care (UC)|Adults and peds will use their own diabetes regimen
11082223|NCT04200300||Nurses working with patients with mental disorders|Nurses in Germany currently working with patients with mental disorders
11082224|NCT04200287|Experimental|Young adult female (YA-F) cancer survivors|YA-F cancer survivors will complete a baseline survey (T1) of sociodemographic and patient reported outcomes (PRO) and then will be sent a link to access the decision aid tool (website) with instructions to review the website before their upcoming visit. A follow-up survey (T2) will be emailed 4-weeks post-baseline, prior to their clinic visit, to evaluate website access and PROs. A post-visit survey (T3) will be emailed 6- weeks post-baseline (after their survivorship care visit) to assess PROs.
11082225|NCT04200274||Mental Health Nurses in Germany|Nurses in Germany currently working with patients with mental disorders
11082226|NCT04200261|Experimental|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
11082227|NCT04200261|Placebo Comparator|placebo|sodium chloride injection Once daily for 7 days
11082233|NCT04200222||Preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
11082234|NCT04200222||Control|Pregnant women with uncomplicated pregnancies were randomly selected to serve as controls. Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications were accepted into the control group.
11082235|NCT04200209|Experimental|Hospital|Twelve wards of the hospital will be evaluated at the same time.
11082236|NCT04200196|Experimental|"Fabrique à histoire"|"Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the fabrique à histoire (Lunii(R)) arm in addition to the routine anaesthetic cream patch."
11082237|NCT04200196|Active Comparator|Usual care|Children 3 to 6 years in pediatric emergency needing to venous puncture and randomized in the habitual care arm in addition to the routine anaesthetic cream patch.
11082238|NCT04200183|Experimental|iACTwithPain|
11082239|NCT04200183|Experimental|ACT-only intervention|
11082240|NCT04200183|No Intervention|Wait list (inactive control)|
11082241|NCT04200170|Experimental|Intervention Arm|Eligible participants had been scheduled for either weekly or biweekly sessions with their therapists. Participants in the intervention arm were asked to download the Rose application on to their personal mobile phones and were given their therapist's unique ID for verification in the app. During the first week of the study, participants were prompted to complete key surveys and assessments at predetermined time intervals. Participants seen weekly will use the app for a total of 5 weeks and receive weekly in-person therapy for a total of 4 weeks (one-week application only lead-in, four weeks application plus in-person psychotherapy). Participants seen biweekly will use the app for a total of 10 weeks and receive biweekly in-person therapy for a total of 8w weeks (two-week application only lead-in, eight weeks application plus in-person psychotherapy).
11082242|NCT04200170|No Intervention|Waitlist Control Arm|The participants in the waitlist control arm served as controls for the study. They completed the pre-pilot and post-pilot assessments only. The waitlist participants continued their standard care and were offered entrance to the intervention arm at the end of the study period or earlier if patients in the intervention arm dropped out mid-study. During their time on the waitlist, participants could reach out to study personnel if they needed assistance with their psychiatric care.
11082243|NCT04200157||1|"Group assigned to the following answer combination:
~2 sessions
~4 sessions"
11082244|NCT04200157||2|"Group assigned to the following answer combination:
~2 sessions
~4 sessions
~7 sessions"
11082245|NCT04200157||3|"Group assigned to the following answer combination:
~2 sessions
~7 sessions"
11082246|NCT04200157||4|"Group assigned to the following answer combination:
~2 sessions
~7 sessions
~10 sessions"
11082247|NCT04200157||5|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~4 sessions (60 minutes)"
11082248|NCT04200157||6|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~4 sessions (60 minutes)
~7 sessions (105 minutes)"
11082249|NCT04200157||7|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~7 sessions (105 minutes)"
11082250|NCT04200157||8|"Group assigned to the following answer combination:
~2 sessions (30 minutes)
~7 sessions (105 minutes)
~10 sessions (150 minutes)"
11082251|NCT04200157||9|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~4 sessions (60 minutes) - 30% chance of quitting"
11082252|NCT04200157||10|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~4 sessions (60 minutes) - 30% chance of quitting
~7 sessions (105 minutes) - 30% chance of quitting"
11082253|NCT04200157||11|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~7 sessions (105 minutes) - 30% chance of quitting"
11082254|NCT04200157||12|"Group assigned to the following answer combination:
~2 sessions (30 minutes) - 10% chance of quitting
~7 sessions (105 minutes) - 30% chance of quitting
~10 sessions (150 minutes) - 30% chance of quitting"
11082255|NCT04200144|Active Comparator|active endoscopic treatment|Patients that will undergo Endoscopic Sleeve Gastroplasty
11082256|NCT04200144|Active Comparator|standard medical therapy control diet group|Patients that will undergo diet
11082257|NCT04200131|Experimental|Moray micro-forceps|
11082258|NCT04200105|Active Comparator|EBUS TBNA|Patients will undergo a standard EBUS examination, with sampling using a standard 22G EBUS needle.
11082259|NCT04200105|Experimental|Acquire TBNB|Patients will undergo a standard EBUS examination, with sampling using an Acquire TBNB needle.
11082260|NCT04200092|Experimental|Cohort 1|Single orally-inhaled dose
11082261|NCT04200092|Experimental|Cohort 2|Single orally-inhaled dose
11082262|NCT04200092|Experimental|Cohort 3|Single orally-inhaled dose
11082263|NCT04200092|Experimental|Sequence 1|Single orally-inhaled dose
11082264|NCT04200092|Active Comparator|Sequence 2|Single IV administered dose
11082265|NCT04200079||COPD|Observational
11082266|NCT04200066|Experimental|Experimental Arm|This arm will combine maprotiline with temozolomide and tamoxifen to determine the maximum tolerated dose.
11082267|NCT04200053|Experimental|Reflexology massage|Reflexology massage
11082268|NCT04200053|Experimental|Reflexology massage and passive music|Reflexology massage and passive music
11082269|NCT04200053|No Intervention|Control|Control
11082270|NCT04200040|Experimental|treatment group|"OrienX010 will be administered once every two weeks by intratumoral injection. The treatment dose , depends on the patient's tumour size, The maximum dose of OrienX010 in at each treatment , the expected accumulated dose in 10 mL. The investigator should be confirmed the injectable tumor size and adequate dose within 24 hours prior to treatment.
~OrienX010 treatment will be continuous and extend from first dose of study medication until to complete response, clinical related progression disease (PDr), untolerated toxicities, lost to follow up, death or meet end of treatment criteria."
11082271|NCT04200040|Active Comparator|Control group|Dacarbazine will be administered once every three weeks by intravenous 1000mg/square meter. Dacarbazine treatment will be continuous and extend from first dose of study medication until to progression disease (PD), untolerated toxicities, lost to follow up, death or meet end of treatment criteria.
11082272|NCT04200027||Robotic total mesorectal Excision|robotic assissted total mesorectal excision
11082273|NCT04200027||Transanal total mesorectal excision|Transanally assissted total mesorectal excision
11082274|NCT04200014||Syncope and Implantable loop recorder|Patients implanted with a subcutaneous Loop Recorder after syncope in Nancy University Hospital
11082275|NCT04200001||adjuvant hormonal therapy for breast cancer|women less than 51 years old, during adjuvant hormonal therapy for breast cancer
11082276|NCT04199988||Athletes with shoulder pain|Overhead athletes with shoulder pain
11082277|NCT04199988||Athletes without shoulder pain|Overhead athletes without shoulder pain
11082278|NCT04199975|Other|Orthoses|Only one single arm in this study
11082279|NCT04199962||pneumonia without sepsis|adult patients with community acquired pneumonia change in SOFA score <2 (other than respiratory component)
11082280|NCT04199962||pneumonia with sepsis|adult patients with community acquired pneumonia change in SOFA score greater or equal to 2 (other than respiratory component)
11082281|NCT04199949|No Intervention|Control|5 consecutive days of normal daily levels of physical activity and matched food intake
11082282|NCT04199949|Experimental|Inactivity|5 consecutive days of reduced step count by 80% compared to the Control trial, whilst placing the non-dominant arm in a sling, and reduced food intake (~ 20%) to match the reduction in energy expenditure induced by inactivity
11082283|NCT04199936|Experimental|EMG leg|Quadriceps muscle group of postoperative patients randomly selected leg which will undergo electrical muscle stimulation for upto 2 hours on each postoperative day
11082284|NCT04199936|No Intervention|Control leg|Quadriceps muscle group of postoperative patients leg not selected to undergo electrical muscle stimulation
11082285|NCT04199923|Experimental|15 Day immobilisation|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 15 continuous days
11082286|NCT04199923|Experimental|5 Day immobilisation young|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
11082287|NCT04199923|Experimental|5 Day immobilisation old|The dominant leg of aged patients (65-80 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
11082288|NCT04199910||Liver cirrhosis with spironolactone|
11082289|NCT04199910||Liver cirrhosis with rifaximin|
11082290|NCT04199910||Liver cirrhosis without spironolactone or rifaximin|
11082291|NCT04199910||Pneumonia|
11082292|NCT04199910||Crohn's disease|
11082293|NCT04199910||Ulcerative colitis|
11082294|NCT04199897|Experimental|Intervention group (sucrose + probiotics)|Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
11082295|NCT04199897|Active Comparator|Intervention group (sucrose + placebo|Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
11082296|NCT04199897|Placebo Comparator|Control group (xylitol + probiotics)|Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
11082297|NCT04199897|Placebo Comparator|Control group (xylitol + placebo|Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
11082298|NCT04199884|Experimental|Active IU-focused Psychoeducation Intervention|
11082299|NCT04199884|Active Comparator|Health-focused Psychoeducation Intervention|
11082300|NCT04199871|Experimental|Group1|dichoptic 3D movies
11082301|NCT04199871|Sham Comparator|Group 2|dichoptic standard movies
11082302|NCT04199858|Experimental|Nocebo induction|Conditioning and evocation of a nocebo response to a sham (inert) medication contained in a blue or a brown jar, controlled within subjects.
11082303|NCT04199845|Experimental|PS128|PS128 will be given twice daily for 8 weeks Active capsule containing 300 mg of probiotics, equivalent to 3 x10^10 CFU of Lactobacillus plantarum PS128.
11082304|NCT04199845|Placebo Comparator|placebo|Placebo containing starch will be given twice daily for 8 weeks.
11082305|NCT04199832||Nasogastric tube|The patient had difficulty swallowing before chemoradiotherapy and placed a nasogastric tube.
11082306|NCT04199832||gastrostomy feeding|Patients with dysphagia before chemoradiotherapy began to voluntarily choose gastrostomy feeding.
11082307|NCT04199832||Oral intake|Patients with normal swallowing or not receiving tube feeding.
11082308|NCT04199819|Other|HBsAg-negative recipients|Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.
11082309|NCT04199806|Other|Questionnaire Review|
11082310|NCT04199793|Active Comparator|Lavare Cycle On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
11082311|NCT04199793|Active Comparator|Lavare Cycle Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
11082312|NCT04199780|Experimental|Group 1- real tDCS and real CBI|4 active treatments of tDCS and active cognitive behavioral intervention (CBI)
11082313|NCT04199780|Experimental|Group 2- real tDCS and sham CBI|4 active treatments of tDCS and education-only-control cognitive intervention
11082314|NCT04199780|Experimental|Group 3- sham tDCS and real CBI|4 sham treatments of tDCS and active cognitive behavioral intervention (CBI)
11082315|NCT04199780|Sham Comparator|Group 4- sham tDCS and sham CBI|4 sham treatments of tDCS and education-only-control cognitive intervention
11082393|NCT04199221|Active Comparator|Hands-on training|an initial brief lecture with addition hands-on training for the task
11082316|NCT04199767|Experimental|20 IU Insulin first, then 40 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 40 IU) at visit 3 during second intervention period.
11082317|NCT04199767|Experimental|40 IU Insulin first, then 20 IU Insulin|Participants will be randomly assigned to receive regular insulin (U100, 40 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 20 IU) at visit 3 during second intervention period.
11082318|NCT04199754|Experimental|Contrast Enhanced Cone Beam CT|60 seconds after the start of the administration of IV contrast, cone beam CT will be initiated.
11082319|NCT04199741||Phase I|Up to 12 participants with tumors that are found to be >/= 50% positive for DLL3 by IHC
11082320|NCT04199741||Phase II|Up to 18 participants with tumors that are found to be >/= 50% positive for DLL3 by IHC
11082321|NCT04199728|Experimental|Investigational group|Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased over 30 days. After six days, the dose will increase by 0.6 mg every six days until participants reach the recommended dose of 3.0 mg once per day. Liraglutide will be administered by injection pen.
11082322|NCT04199728|Placebo Comparator|Control group|Participants in the control group will have placebo administered by injection pen following the same low dose titration to 3.0 mg once per day.
11082323|NCT04199715|Experimental|Heplisav-B Vaccine Recipient|There will be a single group of 18 immune compromised patients who will receive the Heplisav-B vaccine.
11082324|NCT04199702|Other|Same day discharge|
11082325|NCT04199689|Experimental|9vHPV vaccine|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
11082326|NCT04199689|Placebo Comparator|Placebo|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
11082327|NCT04199676||Intervention|75g glucose tolerance test to be administered during postpartum hospitalization
11082328|NCT04199663||categories of Socioeconomic Status (SES)|"by proxy gender- and calendar year-specific quintiles of disposable income per household consumption unit.
~In logistic regression models of associations with secondary prevention activities and established treatment goals: highest vs. lowest income quintile.
~In multivariable Cox regression analyses with stepwise built models: quintiles of disposable income and models including covariates level of education and marital status."
11082329|NCT04199650||Mild ARDS|153mmHg<PaO2/FiO2≤230mmHg
11082330|NCT04199650||Moderate ARDS|76mmHg<PaO2/FiO2≤153mmHg
11082331|NCT04199650||Severe ARDS|PaO2/FiO2≤76mmHg
11082332|NCT04199637|Experimental|Experimental group|Experimental group is provided therapeutic video games
11082333|NCT04199637|No Intervention|Control group|Control group is provided regular care
11082334|NCT04199624|Experimental|Experimental: omeprazole and ascorbic acid|
11082335|NCT04199611|Experimental|Integrated Therapy Group|Both liposuction and psychological therapy are delivered to the participants in this group.
11082336|NCT04199611|Active Comparator|Liposuction Group|This group experiences only liposuction and do self-help care after the liposuction.
11082337|NCT04199611|Active Comparator|Psychological Therapy Group|This group experiences only cognitive behavioral therapy (CBT; psychological therapy) during the intervention period.
11082338|NCT04199611|No Intervention|Self-help Group|This group do not receive any interventions and do self-help care.
11082339|NCT04199598|Experimental|Treatment A (test product): Abediterol (2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
11082340|NCT04199598|Experimental|Treatment B (Test Product): Abediterol (4.8 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via PARI LC SPRINT nebulizer following an overnight fast of at least 8 hours
11082341|NCT04199598|Experimental|Treatment C(Test Product):Abediterol(2.4 μg)|Randomized subjects will receive single dose treatment of Abediterol nebuliser solution for inhalation via OMRON NE-C900-E nebulizer following an overnight fast of at least 8 hours
11082342|NCT04199598|Experimental|Treatment D (Reference Product): Abediterol (2.5 μg)|Randomized subjects will receive single dose treatment of Abediterol (as napadisylate) inhalation powder via dry powder inhaler (DPI) following an overnight fast of at least 8 hours
11082343|NCT04199585|Experimental|Cohort A: single-ascending oral dose|Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
11082344|NCT04199585|Experimental|Cohort B: (fasting/fed conditions)|"Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.
~B1: fed-fasting-fasting condition (spiked dosage)
~B2: fasting-fed-fasting condition (spiked dosage)
~B3: fasting-fasting-fed condition"
11082345|NCT04199572|Experimental|Diclofenac and Oral Paracetamol|Diclofenac (75mg intramuscular), Placebo (100ml intravenous Normal Saline), Paracetamol (per oral 1gm)
11082346|NCT04199572|Experimental|Diclofenac and IV Paracetamol|Diclofenac (75mg intramuscular), Paracetamol (intravenous1gm in 100ml solution), Placebo (sugar tablets)
11082347|NCT04199572|Experimental|Diclofenac and Placebo|Diclofenac (75mg intramuscular),Placebo (100ml intravenous Normal Saline),Placebo (sugar tablets)
11082348|NCT04199559|Experimental|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal.
11082349|NCT04199546|Other|A child with Coffin-Lowry Syndrome|A boy with a known CLS diagnosis with a history of coughing during eating, long-lasting wheezing, sputum and inability to intake solid food will be included.
11082350|NCT04199533||Classroom Observation|The investigators will use day-long observational and interview procedures with eight staff from four schools. The classroom observation will focus on documenting episodes of classroom disruptive behavior, including antecedents and consequences to the behaviors. The interview will involve discussing with staff decision-making processes and current needs around classroom behavioral management.
11082351|NCT04199533||RUBI Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing adaptation or pruning needs related to RUBI content and structure to ensure the redesigned curriculum (RUBIES) is contextually appropriate for schools.
11082394|NCT04199221|Experimental|Stress management and hands-on training|an initial brief lecture with both stress management lecture and additional hands-on training
11082352|NCT04199533||RUBIES Collaborative Design|Eight staff from 4 schools will attend one of four 2-hour in-person feedback sessions to support collaborative feedback around RUBI redesign, including feasibility and appropriateness and methods supporting implementation.
11082353|NCT04199533||RUBIES Redesign|Two separate demonstration studies comprising 6 staff members each will focus on informing final RUBIES adaptation or pruning needs.
11082354|NCT04199520|Experimental|surgery combined with systemic therapy|surgery combined with systemic therapy
11082355|NCT04199520|Active Comparator|systemic therapy|systemic therapy
11082356|NCT04199507||Autism|Assessment of physical activity level and physical fitness
11082357|NCT04199507||Healthy|Assessment of physical activity level and physical fitness
11082358|NCT04199468|Experimental|Active Delta-9-THC and Placebo Ketamine|Active IV Delta-9-THC and Placebo Ketamine
11082359|NCT04199468|Experimental|Active Delta-9-THC and Active Ketamine|Active IV Delta-9-THC and Active Ketamine
11082360|NCT04199468|Experimental|Placebo Delta-9-THC and Placebo Ketamine|IV Placebo Delta-9-THC and Placebo Ketamine
11082361|NCT04199468|Experimental|Placebo Delta-9-THC and Active Ketamine|IV Placebo Delta-9-THC and Active Ketamine
11082362|NCT04199455|Experimental|Integrative Treatment Group|Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
11082363|NCT04199455|Placebo Comparator|Control Group|Patients randomly assigned to the control group will receive recipe simulators as placebo, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
11082364|NCT04199429|Experimental|Experimental|"Each nurse applied the RBC model through the treatment Take 5 minutes (T5M), to parents allocated to the experimental group. This consisted in devoting some time (from 5 to 10 minutes) to improving the relationship with the parent. This treatment can be considered as the practical development of the core principles of the RBC model by the study team.
~During the T5M the nurse applied the strategies of empathic communication and active listening, learned during the education and training phase. The treatment lasted from 5 to 10 minutes and was delivered once per day during the admission of the patient.
~The T5M time was considered as additional or supplementary, but not substitutive, of the standard nursing time dedicated daily to patients and parents."
11082365|NCT04199429|Active Comparator|Control|Standard nursing time dedicated daily to patients and parents.
11082366|NCT04199416|Experimental|mRehab app|Participants randomized to the intervention group will be given the mRehab app free of charge to perform self-management of their knees in their homes.
11082367|NCT04199416|Sham Comparator|Sham app|Participants randomized to the control group will receive a sham app free of charge to perform self-management of their knees in their homes.
11082368|NCT04199403||Single Group|
11082369|NCT04199390|Active Comparator|Clinic-based Physical Therapy|
11082370|NCT04199390|Active Comparator|Home-based Physical Therapy|
11082371|NCT04199377|Experimental|hip or knee replacement|total hip or knee replacement
11082372|NCT04199364|Experimental|Low FiO2 threshold|A fraction of inspired oxygen (FiO2) of 25% to have an oxygen saturation (SpO2) of 90-92%.
11082373|NCT04199364|Experimental|Medium FiO2 threshold|A fraction of inspired oxygen (FiO2) of 35% to have an oxygen saturation (SpO2) of 90-92%.
11082374|NCT04199351|Experimental|Part A|AMG 171 or placebo, 7 SAD cohorts
11082375|NCT04199351|Experimental|Part B|AMG 171 or placebo, 4 MAD cohorts
11082376|NCT04199351|Experimental|Part C|AMG 171 or placebo, 1 cohort
11082377|NCT04199338|Experimental|Randomized|Randomized
11082378|NCT04199325|Experimental|Intervention group|
11082379|NCT04199325|Placebo Comparator|Control group|
11082380|NCT04199312|Experimental|Muscle Toning, Firming and Strengthening|The EMS device will be evaluated for muscle toning, firming and strengthening in the abdomen.
11082381|NCT04199299||Persons who cannot communicate unequivocally|Persons with intellectual disability, childhood autism, and/or cerebral palsy who cannot communicate unequivocally and therefore cannot communicate their needs and wishes, e.g. whether they are uncomfortable, in pain, scared, angry, happy, pleased.
11082382|NCT04199286|Active Comparator|Asymmetrical surgery|This asymmetrical horizontal muscle surgery done as recess-resect in one eye or 3 muscle surgery
11082383|NCT04199286|Active Comparator|Symmetrical|This symmetrical horizontal muscle surgery includes bilateral medial rectus recession in esotropia cases or bilateral lateral rectus recession in exotropia
11082384|NCT04199273|Experimental|Magnetic stimulation and electric stimulation|The patient receive first the magnetic stimulation with MagStim 200 tool. Then 15 min after he will receive the electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
11082385|NCT04199273|Experimental|Electric stimulation and magnetic stimulation|The patient receive first electric stimulation with the SonoStim tool : ultrasonography phrenic nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager). Then 15 min after he will receive the magnetic stimulation with MagStim 200 tool
11082386|NCT04199260||Papilocare|all patients gonna received papilocare treatment as per usual practice.
11082387|NCT04199247|Experimental|Exercise|Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.
11082388|NCT04199247|No Intervention|Usual Care|Participants will continue with their return to play progression based upon the advice given to them at their initial post-injury evaluation.
11082389|NCT04199234|Experimental|experimental group|60 mg Iron
11082390|NCT04199234|Active Comparator|control group|60 mg Iron sulphate
11082391|NCT04199221|No Intervention|Lecture|an initial brief lecture with no further training
11082392|NCT04199221|Experimental|Stress management|an initial brief lecture with stress management lecture
11082395|NCT04199208|Active Comparator|Standard Care Arm|Standard perioperative care is given.
11082396|NCT04199208|Experimental|Interventional Arm|Intervention of prehabilitation and immunonutrition is given prior to surgery
11082397|NCT04199195||Males and females aged at least 60 years.|"A longitudinal study of one cohort of 360 participants aged at least 60 years. Participants will be required to provide a stool sample, provide a blood sample and complete a health questionnaire every 6 months for 4 years. At alternate visits, participants will be required to under go cognitive assessments and physical measurements.
~Participants will be required to under go an Optical Coherence Tomography Scan 3 times over 4 years.
~Sub group 1 - During a routine care colonoscopy, at least 90 participants will have 6-8 colon tissue biopsies taken for research purposes.
~Sub group 2 - Participants from cohort 3 only will be offered an optional brain MRI until the required number of 30 participants is achieved."
11082398|NCT04199182|Experimental|Exercise|Progressive, multi-component supervised exercise training group.
11082399|NCT04199182|Active Comparator|Healthy Aging Attention Control|A health education program that addresses topics relevant to older adults.
11082400|NCT04199169|Experimental|Cohort 1, Group 1|"Ten subjects in the first cohort will receive a 10 mcg dose of HeV-sG-V on Visits 1 and 6.5 (Days 1 and 169*).
~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
11082401|NCT04199169|Placebo Comparator|Cohort 1, Group 2|"Two subjects in the first cohort will receive a dose of the placebo on Visits 1 and 6.5 (Days 1 and 169*).
~*Second dose was administered at 6 months due to study pause from local COVID-19 shutdown."
11082402|NCT04199169|Experimental|Cohort 2, Group 3|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) with placebo on Visit 3 (Day 29).
11082403|NCT04199169|Experimental|Cohort 2, Group 4|Thirty subjects in the second cohort will receive a 30 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) with placebo on Visit 2 (Day 8)
11082404|NCT04199169|Placebo Comparator|Cohort 2, Group 5|Twelve subjects in the second cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
11082405|NCT04199169|Experimental|Cohort 3, Group 6|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visit 1 (Day 1) and placebo on Visits 2 and 3 (Days 8 and 29).
11082406|NCT04199169|Experimental|Cohort 3, Group 7|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 2 (Days 1 and 8) and placebo on Visit 3 (Day 29).
11082407|NCT04199169|Experimental|Cohort 3, Group 8|Thirty subjects in the third cohort will receive a 100 mcg dosage of HeV-sG-V on Visits 1 and 3 (Days 1 and 29) and placebo on Visit 2 (Day 8).
11082408|NCT04199169|Placebo Comparator|Cohort 3, Group 9|Eighteen subjects in the third cohort will receive a dose of the placebo on Visits 1, 2, and 3 (Days 1, 8 and 29).
11082409|NCT04199143|Experimental|healthy voluntary controls|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
11082410|NCT04199143|Experimental|Depressive Patients|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
11082411|NCT04199130|Experimental|Intervention Group 1|This arm will receive BrainHQ for the first four weeks of the study, and Goal Management Training for the second four weeks.
11082412|NCT04199130|Experimental|Intervention Group 2|This arm will receive Goal Management Training for the first four weeks of the study, and BrainHQ for the second four weeks.
11082413|NCT04199130|No Intervention|Treatment-as-usual|
11082414|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082415|NCT04199117|Experimental|Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082416|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082417|NCT04199117|Experimental|Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082418|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082419|NCT04199117|Experimental|Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082460|NCT04198870|Experimental|Device Arm|MitraClip™ device implantation
11082420|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082421|NCT04199117|Experimental|Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will have access to $40 incentives for completing a first smoking cessation counseling call up to 4 times over 2 years, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082422|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will have not access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082423|NCT04199117|Experimental|No Incentive,Tailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082424|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082425|NCT04199117|Experimental|No Incentive,Tailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 tailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082426|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Intensive Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082427|NCT04199117|Experimental|No Incentive,Untailored,Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will receive 5 Tobacco Care Management support and motivational encouragement calls over 2 years, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082428|NCT04199117|Experimental|No Incentive,Untailored,No Care Manage,IntensiveTreatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not Tobacco Care Management support and motivational encouragement calls, and will have access to 3 smoking cessation quit counseling calls and 12-weeks of either combination nicotine replacement or varenicline up to 4 times over 2 years.
11082429|NCT04199117|Active Comparator|No Incentive,Untailored,No Care Manage,Standard Treatment|Participants randomly assigned to this condition will not have access to incentives for completing smoking cessation counseling, will receive 5 untailored letters promoting use of smoking cessation treatment over 2 years, will not receive Tobacco Care Management support and motivational encouragement calls, and will have access to standard smoking cessation treatment (referral to the state tobacco quitline and/or their primary care provider) over 2 years.
11082430|NCT04199104|Experimental|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
11082431|NCT04199104|Active Comparator|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months).
11082432|NCT04199091|Experimental|Craniosacral self-help techniques (CST)|The experimental group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. The course starts with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients will also receive a script with theoretical CST basics and descriptions of the techniques, which should facilitate the correct practice at home.
11082433|NCT04199091|Active Comparator|Progressive muscle relaxation (PMR)|The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
11082434|NCT04199078|Experimental|A - papilocare alternative days treatment|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
11082435|NCT04199078|Experimental|B - papilocare semiintensive treatment|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
11082436|NCT04199078|Experimental|C - papilocare intensive treatment|Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
11082437|NCT04199078|No Intervention|D - standard of care|Arm D: usual clinical practice - no treatment
11082438|NCT04199065|Experimental|Good Practice Guidelines group|Implementation of Good Practice Guidelines
11082439|NCT04199065|No Intervention|usual practices group|Not Implementation of Good Practice Guidelines, so working as the usual way
11082440|NCT04199052|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-Virtual Peer Navigator (PN) supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment. It is important to note that the case management approach is self-guided versus intensive virtual PN assistance.
11082441|NCT04199052|Experimental|LinkPositively Intervention|Women assigned to the LinkPositively intervention arm will have access to all four components of the LinkPositively app. Women will be scheduled for a session with staff to inform them of their assigned virtual Peer Navigator (PN). Staff will train participants on how to download the app, explain the five components, using each component, and contacting their PN. Within the first week after, virtual PNs will complete a one-on-one, in-person or phone intake session with the participant, based on the participant's preference. During this intake session, the PN will conduct a participant needs assessment to connect her to HIV medical care via local health clinics and identify other areas of need, services of need, and assisted referrals (domestic violence services, mental health care, substance abuse treatment, housing and legal support, etc.). PNs will provide trauma-informed emotional and informational support, including guidance on accessing information about referred services.
11082442|NCT04199039|Experimental|ET fixation with ET holder|ET fixation of the patients in the study group was performed with an ET holder when they arrived at the CVS ICU
11082443|NCT04199039|No Intervention|ET fixation with plaster|ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted.
11082444|NCT04199026|Experimental|Device Feasibility (microdevice, surgery)|Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.
11082445|NCT04199013|Active Comparator|Ropivacaine With Fentanyl|2.5ml of 0.75% Isobaric ropivacaine with 0.5ml (25mcg) Fentanyl
11082446|NCT04199013|Active Comparator|Ropivacaine Without Fentanyl|2.5ml of 0.75% Isobaric Ropivacaine with 0.5ml of Normal Saline
11082447|NCT04198974|Experimental|PreVenture Training (PTtT)|Schools randomized to this arm will identify 4 staff members to participate in a 2-day training workshop + 3 hours of supervised practice and will be provided with access to screening and PreVenture intervention materials through the local trainer. Local trainers will deliver 2-day workshops and then supervise school staff in the delivery of two 90-minute group sessions (for at least one personality profile).
11082448|NCT04198974|Experimental|PreVenture Training + Implementation Facilitation (PTtT+IF)|Schools randomized this arm will receive the standard PreVenture TtT protocol plus an additional Implementation Facilitation package that will contain 3 new components designed to increase the likelihood that schools will continue to implement the program with high quality and satisfaction: 1) Youth Engagement, 2) ongoing coaching and supervision for Facilitators, and 3) access to easy-to-use performance metrics.
11082449|NCT04198974|No Intervention|Control (TAU)|For schools randomized to this arm, students will have usual access to drug and alcohol prevention through the standard curriculum and mental health care provided through student counseling at the participating schools. The schools will be incentivized to participate in the study with the promise of free PreVenture training and materials in subsequent years of the trial. Information on other drug prevention efforts implemented at the school will be collected, but the randomized design should control for any potential differences between intervention conditions on this random factor.
11082450|NCT04198961|Experimental|Electronic Intervention|Individualized opioid taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
11082451|NCT04198948|Active Comparator|Omeprazole treatment arm|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.
11082452|NCT04198948|Placebo Comparator|Placebo treatment arm|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.
11082453|NCT04198935|Experimental|Intervention|Participants will be enrolled on to a 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
11082454|NCT04198922|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib 100 mg PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11082455|NCT04198909|Experimental|Cohort 1|
11082456|NCT04198896||CAD-only|patients with diagnosed coronary artery diseases (CAD) without any other atherosclerotic cardiovascuar diseases at the entry of SHIP
11082457|NCT04198896||CAD with poly-arterial diseases|patients with diagnosed coronary artery diseases (CAD) with other atherosclerotic cardiovascuar diseases such as any of aortic and/or peripheral artery diseases at the entry of SHIP
11082458|NCT04198883|Experimental|Protheracytes|Single arm study : Stem cells injection called Protheracytes
11082459|NCT04198870|Other|Control Arm|Mitral Valve Repair Surgery
11082461|NCT04198857|No Intervention|Standard Care + Telemonitoring: Control|Standard care for GDM will be modifying diet and increasing exercise. Participants will have consultations with a dietitian and a physical therapist to develop a diet and physical activity plan based on pre-pregnancy weight and disease severity. In addition to verbal information about managing GDM with diet and physical activity, patients will be provided with leaflets and brochures. As per the standard care protocol, GDM patients will be asked to visit the OPD for glucose testing every two weeks, and after each testing, blood glucose levels will be recorded in paper booklets assigned to each patient. In addition, the women will be provided with a glucometer and a blood pressure monitor machine. Alongside the devices, they will be taught to use them for self-monitoring and will be provided guidelines to follow at home. The OB/GYN physicians will monitor the blood glucose levels across testing, and will prescribe oral hypoglycemic medications or insulin to the patient if needed.
11082462|NCT04198857|Experimental|Standard Care + mGDM app + Telemonitoring|In addition to standard care and telemonitoring, this group will use the mGDM app. This group will be provided with the same devices as the control group and in addition, the GDM app will be set up in their cellular device. The app will be on their smart phone and will support self-management by: i) providing health education, ii) helping patients identify and set target health goals (for diet, physical activity, and glucose levels), iii) enhancing their self-efficacy to meet target goals, and iv) facilitating desired support from family members. The core component of the mGDM app will be to allow GDM patients to record and self-monitor their carbohydrate intake, physical activity and blood glucose levels. Patients will be able to manually enter their weekly blood glucose levels and blood pressure readings.
11082463|NCT04198844||Warfarin user|
11082464|NCT04198844||Apixaban user|
11082465|NCT04198831|Experimental|acupuncture group|Receiving acupuncture and moxibustion treatment
11082466|NCT04198831|Sham Comparator|sham acupuncture group|Receiving sham acupuncture and sham moxibustion treatment
11082467|NCT04198818|Experimental|Dose escalaltion study of HH2710|to determin the MTD of HH2710 and/or Recommended Phase II dose (RP2D).
11082468|NCT04198805|Active Comparator|Vitamin E (1000 mg)|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months.
11082469|NCT04198805|Active Comparator|DHA EE (1.89 g)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months).
11082470|NCT04198805|Active Comparator|DHA EE (1.89 g) and Vitamin E (1000 mg)|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months.
11082471|NCT04198805|Placebo Comparator|Placebo|Matching soybean oil placebo (3 capsules) of all arms daily for 6 months.
11082472|NCT04198792||ECPR patients|Patients that is put om ECMO during cardiac arrest
11082473|NCT04198792||ECMO patients, non-ECPR|Patients that is put on ECMO due to circulatory failure but not cardiac arrest
11082474|NCT04198779|Experimental|APPLI|Care support with implementation of the application
11082475|NCT04198779|No Intervention|CONTROL|Conventional care support
11082476|NCT04198766|Experimental|Part 1 INBRX-106 Escalation|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
11082477|NCT04198766|Experimental|Part 2 INBRX-106 Expansion|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D.
11082478|NCT04198766|Experimental|Part 3 INBRX-106 Escalation in Combination with Pembrolizumab|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
11082479|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D in combination with pembrolizumab.
11082480|NCT04198753||Parent of Peanut Allergic Child|"The researchers will identify patients or study subjects aged 1-18 who have been diagnosed with peanut allergy based on skin prick testing, serologic testing, and/or history of reaction. They will then contact mothers or fathers of these patients/subjects who are 18 and older and enroll those who do not themselves have a history of food allergy, with a goal of 40 subjects per group.
~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
11082481|NCT04198753||Parent of Non-atopic Child|"To establish normal controls, the researchers will enroll parents age 18 or older with no history of food allergy or eczema in themselves or their offspring.
~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
11082482|NCT04198740||Control group|Healthy, normal ocular surface
11082483|NCT04198740||Dry eye syndrome|"Patients suffering from either:
~Lacrimal insufficiency
~Anterior blepharitis
~Posterior blepharitis
~Sjögren syndrome"
11082484|NCT04198740||Allergic conjunctivitis|Patients suffering from allergic conjunctivitis
11082485|NCT04198740||Mucous membrane pemphigoid|Patients suffering from mucous membrane pemphigoid
11082486|NCT04198740||Infectious keratoconjunctivitis|"Patients suffering from keratitis and/or conjunctivitis of various etiology:
~Viral
~Bacterial
~Fungal
~Acanthamoeba"
11082487|NCT04198727|Experimental|DPD activity|
11082488|NCT04198714|Experimental|Pudendal block|9cc of 0.25% Marcaine + 1cc of 40mg/mL triamcinolone. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
11082489|NCT04198714|Sham Comparator|Sham injection|10cc normal saline. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
11082490|NCT04198701|Experimental|Pilot|
11082491|NCT04198688||With cancer|Patients diagnosed with cancer (with at least one of the following ICD-10 diagnoses: C00-43; C46.1-99; D09)
11082492|NCT04198688||Without cancer|Patients without cancer (without any of the following ICD-10 diagnoses: C00-99; D09; D30.1-9; D32-33; D35.2-4; D41.1-9; D44.3-5)
11082493|NCT04198675|Active Comparator|Supervised EMG Biofeedback Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
11082494|NCT04198675|Active Comparator|Home-Based Exercise Training Group|Frequency: 3/week Duration:6 weeks Dosage: Tolerable intensity-dependent increase in exercises program.
11082495|NCT04198675|Sham Comparator|Posture Training/Ergonomic Regulations Group|1 session, no further intervention until second evaluation for 6 weeks.
11082496|NCT04198662|Active Comparator|Cryoneurolysis|Active cryoneurolysis: 3 mL of normal SALINE will be injected into the muscle superficial to the nerve followed by an ACTIVE cryoneurolysis procedure using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
11082497|NCT04198662|Sham Comparator|Sham|Sham cryoneurolysis: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block followed by a SHAM cryoneurolysis procedure with a probe that vents the nitrous oxide prior to reaching the probe tip using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods.
11082498|NCT04198649|Experimental|Azithromycin|62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days
11082499|NCT04198649|Placebo Comparator|Placebo|62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days
11082500|NCT04198636|Experimental|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
11082501|NCT04198636|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
11082502|NCT04198623|Other|Montelukast (Singulair)|Montelukast(Singulair) 10mg to be taken in addition to standard institutional premedication
11082503|NCT04198610|No Intervention|healthy|Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
11082504|NCT04198610|No Intervention|chronic gingivitis|Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm, relative attachment loss (RAL) ) less than or equal to 3mm and more than to 25% sites with gingival bleeding present (BOP)
11082505|NCT04198610|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.
~Non surgical periodontal therapy (SRP) was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy"
11082506|NCT04198597|Experimental|Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
11082507|NCT04198597|Experimental|Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
11082508|NCT04198597|Experimental|Process-based treatment, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
11082509|NCT04198597|Experimental|Process-based treatment, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
11082510|NCT04198584|Experimental|VC-CBCS Intervention|The VC-CBCS intervention will be delivered via WebEx videoconferencing technology and will include 14, 2-hour long sessions that include group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials include a hard copy Patient Workbook and audio-recorded relaxation techniques.
11082511|NCT04198584|No Intervention|Standard of Care (SC)|Patients randomized to SC will receive no intervention and will be followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.
11082512|NCT04198571||Zinforo Treated|Only those Adults treated with this treatment for CAP or cSSTi
11082513|NCT04198558|Experimental|Dose Level 1|MEDI0618 or placebo
11082514|NCT04198558|Experimental|Dose Level 2|MEDI0618 or placebo
11082515|NCT04198558|Experimental|Dose Level 3|MEDI0618 or placebo
11082516|NCT04198558|Experimental|Dose Level 4|MEDI0618 or placebo
11082517|NCT04198558|Experimental|Dose Level 5|MEDI0618 or placebo
11082518|NCT04198558|Experimental|Dose Level 6|MEDI0618 or placebo
11082519|NCT04198558|Experimental|Dose Level 7|MEDI0618 or placebo
11082520|NCT04198558|Experimental|Dose Level 8|MEDI0618 or placebo
11082521|NCT04198558|Experimental|Dose Level 9|MEDI0618 or placebo
11082522|NCT04198532|Experimental|Complex Regional Pain Syndrome(CRPS) group|Stroke patients with complex regional pain syndrome
11082523|NCT04198532|Other|Control Group|Stroke patients without complex regional pain syndrome
11082524|NCT04198519|Active Comparator|Poor Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Poor cardiovascular health is considered for two or less metrics.
11082525|NCT04198519|Active Comparator|Ideal-intermediate Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Ideal cardiovascular health is considered for those with five or more metrics within this qualification, and intermediate for the presence of three or four metrics.
11083726|NCT04189484|Placebo Comparator|Arm I: Placebo|Single dose of placebo SC
11082526|NCT04198506|Experimental|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.
11082527|NCT04198506|Active Comparator|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
11082528|NCT04198493|Experimental|Continuous Positive Airway Pressure(CPAP)|"Patients with CPAP treatment. Titration will be performed by polysomnography CPAP to determine the optimal treatment pressure.
~This group will also be instructed in sleep hygiene and dietary counseling
~Intervention:
~Device: CPAP Other: Conservative treatment for OSA"
11082529|NCT04198493|Active Comparator|CONSERVATIVE TREATMENT for OSA|Sleep hygiene and dietary counseling. Sleep hygiene (regular sleep schedule, physical exercise) and dietary counseling Intervention: Other: Conservative treatment for OSA
11082530|NCT04198480|Experimental|JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.
11082531|NCT04198467|Experimental|PRP (100billion platelets)|platelet rich plasma having 100 billion platelets in 10 ml plasma prepared from 60 ml blood
11082532|NCT04198467|Placebo Comparator|hyaluronic acid|Four ml of high-molecular-weight hyaluronic acid (HMWHA) with a concentration of 22mg/ml
11082533|NCT04198454|Active Comparator|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking. This is considered a standard measure in the recovery of lower extremity wounds and often recommended.
11082534|NCT04198454|Other|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound.
11082535|NCT04198454|Experimental|Compression bandages with FACL|Class I compression (20-30 mmHg) bandage or stocking with FACL.
11082536|NCT04198441|Active Comparator|Omeza Value-based Bundle Test|The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.
11082537|NCT04198441|Active Comparator|Standard Wound Care Control|Standard wound care control is saline wound wash and wet to dry dressing.
11082538|NCT04198428|Experimental|Receives OUD-CDS|Clinics will have access to the OUD-CDS (Opioid Wizard)
11082539|NCT04198428|No Intervention|Does not Receive the OUD-CDS|"Clinics will not have access to the OUD-CDS (Opioid Wizard). These will be usual care clinics."
11082540|NCT04198415||Venetoclax Participants|Participants prescribed and treated with venetoclax.
11082541|NCT04198402||Patient with digestive neuroendocrine tumor|naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
11082542|NCT04198402||Patient without tumor|Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
11082543|NCT04198389|Experimental|partial knee replacement|medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI
11082544|NCT04198376|Experimental|The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes. Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures
11082545|NCT04198376|Experimental|Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator .A second surgical site will be prepared to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site. After sutures are slid through each tunnelled interdental area the needle will be pushed through the CTG before it is guided back through the undermined tissues.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.
11082546|NCT04198363|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
11082547|NCT04198363|Active Comparator|Esomeprazole 20 mg|Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
11082548|NCT04198350|Experimental|Islet implantation|
11082549|NCT04198337|Experimental|Endoscopic Full Thickness Resection|Resection of the gastric GIST by ESD techniques followed by endoscopic closure of defect with suturing or clips and loop
11082550|NCT04198324|Active Comparator|Entire fold uterine closure|The uterus will be sewn with full fold locked sutures that pass through myometrium and endometrium.
11082551|NCT04198324|Experimental|Non-endometrial uterine closure|The uterus will be sewn with locked sutures that pass through myometrium without endometrium.
11082552|NCT04198311|Experimental|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks
11082553|NCT04198311|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
11082554|NCT04198298|Active Comparator|Group 1 EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
11082555|NCT04198298|Active Comparator|Group 2 ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
11082556|NCT04198298|Active Comparator|Group 3 Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
11082557|NCT04198285|Experimental|Retrograde filled|This arm will contain patients who had retrograde bladder filling upon completion of surgery with 200 milliliters (mL) of sterile saline.
11082558|NCT04198285|No Intervention|Control|This arm will contain patients who simply had the urinary catheter removed upon completion of surgery, and were left with an empty bladder.
11082559|NCT04198272|Experimental|Facilitated|"Schools that are randomized to this arm will be exposed to all of the components in the self-service version in addition to the following:
~-Peer facilitation of the CyberRwanda platform at the school-based cyber clubs that will house an online tablet with the educational components of CyberRwanda with a facilitator."
11082560|NCT04198272|Active Comparator|Self-service|"Schools that are randomized to this arm will be exposed to the following components of the intervention:
~Availability of the fully functional online CyberRwanda web portal through school-based cyber clubs;
~SMS-based ordering of contraceptives and SMS-based FAQs Online (through web portal on computer or smartphone) ordering of contraceptives;
~Facility finder: A list of the closest health centers and pharmacies where youth can get contraceptives and other FPRH services;
~Promotion of the CyberRwanda program through school launch events; and
~Access to Youth Centers (1 per district) that will house tablets with the fully functional online CyberRwanda web portal"
11082561|NCT04198272|No Intervention|Control|Schools in this arm will not receive any intervention
11082562|NCT04198259|Active Comparator|interventional devascularization|Interventional devascularization includes BRTO and similar procedure. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils.
11082563|NCT04198259|Experimental|Transjugular intrahepatic portosystemic shunt|TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
11082564|NCT04198233|Experimental|Diazepam group|Rectal Diazepam suppository
11082565|NCT04198233|Placebo Comparator|Placebo group|Placebo suppository
11082566|NCT04198194||Participants with events|Individuals who have experienced any of the listed outcomes
11082567|NCT04198194||Participants without events|Individuals who have not experienced any of the listed outcomes
11082568|NCT04198168||ICU patients|ICU patients who are assessed by their attending physician as having need for fluid therapy and are planned to receive IV crystalloid fluid due to oliguria and/or to improve GFR.
11082569|NCT04198155|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to bilateral renal arteries determined by CT-guidance.
11082570|NCT04198142|Experimental|Imagery Rehearsal Therapy Intervention|This group receives one to two sessions of Imagery Rehearsal Therapy.
11082571|NCT04198142|Active Comparator|Treatment as Usual with dream diaries|This group receives the usual inpatient care without additional Imagery Rehearsal Therapy sessions, but also keeps dream diaries.
11082572|NCT04198129|Experimental|Treatment|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
11082573|NCT04198129|Active Comparator|Control|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
11082574|NCT04198116|Experimental|Varenicline + Guanfacine ER|Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.
11082575|NCT04198116|Active Comparator|Varenicline|Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
11082576|NCT04198103|Experimental|SoracteLite|Transperineal Focal Laser Ablation (TPLA)
11082577|NCT04198090|Other|Sexual & Gender Minority (SGM) Competence Training|Personnel will be trained using a validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for Oncology.
11082578|NCT04198077|Experimental|CONSERVATIVE|Participants in the conservative group will receive the lowest FiO2 to maintain SpO2 between 94 and 98 percentage, or when available a PaO2 between 70 mmHg and 100 mmHg. A SpO2 alarm limit of 99 percent will apply whenever supplemental oxygen is being administered. The FiO2 will be reduced or oxygen supplementation discontinued whenever the SpO2 or PaO2 exceeded 98 percent or 100 mm Hg. An oxygen supplementation will be given only if SpO2 falls below 94 percent. Pre-oxygenation with FiO2 1.0 will not be performed during in-hospital transports or in anticipation of diagnostic and therapeutic manoeuvres.
11082579|NCT04198077|Active Comparator|CONVENTIONAL|In the conventional group, participants will receive a FiO2 aiming to maintain a SpO2 equal or major than 98 percentage, accepting an upper limit of PaO2 of 150 mmHg and a lower limit of 70 mmHg. The use of a FiO2 of less than 0.3 whilst ventilated is discouraged. According to standard Intensive Care Unit practice, control patients will receive a FiO2 of 1.0 during endotracheal intubation manoeuvre, airway suction or in-hospital transfers.
11082580|NCT04198064|Experimental|Group A- Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/~2 cups of %0.9 saline solution) during the insertion of the cystocopy tube during their cystoscopy."
11082581|NCT04198064|Other|Group B- No Bag Squeeze|Participants will receive a standard cystoscopy procedure.
11082582|NCT04198051|Experimental|treatment group|
11082583|NCT04198038|Experimental|cognitively impaired children|This is a single-group study; all participants will be offered the songwriting intervention.
11083755|NCT04189276|Active Comparator|Group2|T101+ETV/TDF
11082584|NCT04198025||Patients who underwent colorectal resection|"Patients in this observational study will have undergone CT scan as routine work up prior to resection of elective colorectal cancer.
~Psoas muscle density will be measured (in Hounsfield units from CT images) at lumbar vertebral level L3."
11082585|NCT04198012|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
11082586|NCT04197999|Experimental|Single Ascending Dose followed by Multiple Doses|Up to 3 single ascending doses of GMI-1359 followed by the highest tolerated dose given for 3 consecutive days.
11082587|NCT04197986|Experimental|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
11082588|NCT04197986|Placebo Comparator|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
11082589|NCT04197960|Experimental|microwave ablation|ablate all tumors including at least 5mm safe margin except for tumors adjacent to thyroid capsule.
11082590|NCT04197960|Active Comparator|surgical resection|lobectomy + central lymph node dissection
11082591|NCT04197947|Experimental|PD patient who have FoG|
11082592|NCT04197934|Experimental|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11082593|NCT04197934|Experimental|Dose expansion Cohort I (WSD0922-FU)|Patients with GBM/AA receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11082594|NCT04197934|Experimental|Dose expansion Cohort II (WSD0922-FU, surgery)|Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11082595|NCT04197934|Experimental|Dose expansion Cohort III (WSD0922-FU)|Patients with NSCLC LM receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11082596|NCT04197921|Other|Sham/Active ExAblate Treatment Stage 1 and 2|Subject will undergo both Treatment 1 (sham) and Treatment 2 (with enhanced intensity). Subjects are blinded to the order of the sham vs active treatment.
11082597|NCT04197908|Experimental|EUS-guided gallbladder drainage (EGBD)|The procedure would be performed with a linear echoendoscope using a 10mm x 10mm or a 15 x 10mm stent. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder would be completely emptied by suction and irrigation until the effluent through the stent is clean.
11082598|NCT04197895|Experimental|test group|Socket preservation with APRF
11082599|NCT04197895|Active Comparator|control group|natural healing
11082600|NCT04197882|Experimental|treatment|"This study consisted of 3 cycles of neoadjuvant treatment, surgical, and adjuvant treatment. Neoadjuvant treatment period: OrienX010 in combination with Treprizumab injection. Treprizumab injection: 3 mg/kg, IV infusion: Once every 2 weeks (1 treatment cycle every 2 weeks) for 4 doses (4 cycles); OrienX010: Maximum injection volume 8 × 108 pfu, intratumoral injection: Once every 2 weeks (1 treatment cycle every 2 weeks) for 4 doses (4 cycles); Surgical treatment period: 2 weeks after the last dose of neoadjuvant treatment (± 7 days), the investigator designed the surgical protocol of the melanoma radical surgery according to the patient's individual disease, and performed postoperative care according to the patient's condition.
~Adjuvant treatment period: 3 weeks after operation (± 7 days), the patient was given Treprizumab injection. Treprizumab injection: 3 mg/kg intravenously given every 3 weeks (1 treatment cycle every 3 weeks) for up to 1 year."
11082601|NCT04197869|Experimental|Experimental|The experimental group will take a pre-operative course of polyethylene glycol daily for seven days prior to procedure date.
11082602|NCT04197869|No Intervention|Control|The control group will not be given any intervention preoperatively.
11082603|NCT04197856|Active Comparator|Control / Family-mediated disclosure (standard care)|Genetic counseling according to current clinical practice
11082604|NCT04197856|Experimental|Intervention / Health-care assisted disclosure|Genetic counseling according to current clinical practice with the addition of an offer from health care provider to mail letters directly to eligible at-risk relatives.
11082605|NCT04197843|Experimental|NaviCam (ANKON)|NaviCam (ANKON)
11082606|NCT04197817|Active Comparator|JS002|JS002, Subcutaneous or intravenous injection
11082607|NCT04197817|Placebo Comparator|Placebo,|Placebo,Subcutaneous or intravenous injection
11082608|NCT04197804||Tourette group|20 subjects with Tourette Syndrome undergoing an evaluation to identify the IQ. Subsequently, 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
11082609|NCT04197804||Control group|20 subjects without Tourette Syndrome subjected to an evaluation to identify the IQ. Subsequently 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) concerning the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration of about 3 minutes) concerning the linguistic field.
11082610|NCT04197791|Experimental|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
11082611|NCT04197791|Experimental|Core Stabilization Exercises|Core stabilization exercises will be applied to 18 patients with idiopathic pulmonary fibrosis. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
11082612|NCT04197778|Experimental|group A|
11082613|NCT04197778|Experimental|group B|
11082614|NCT04197765|Sham Comparator|Sham|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
11082615|NCT04197765|Active Comparator|Active acTBS|"For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.
~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays."
11082616|NCT04197752||Obese patients|Body mass index > 30 kg/m2
11082617|NCT04197752||Non-obese patients|Body mass index < 30 kg/m2
11082618|NCT04197739|Experimental|Fixed dose|patients will receive a fixed, single daily dose of amikacin, 500 mg, a day.
11082619|NCT04197739|Active Comparator|Adjusted body weight dose|patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram.
11082620|NCT04197726|Experimental|sbeIIa/b white bread|sbeIIa/b white bread with high resistant starch content
11082621|NCT04197726|Active Comparator|Control white bread|Reference white bread (wild-type)
11082622|NCT04197713|Experimental|Treatment (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-5 and 15-19 of each cycle and adavosertib PO QD on days 8-12 and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11082623|NCT04197700|Other|Personalized Arm|"Personalized Arm: The target MAP will be defined as +/- 5% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements:
~Pre-operative anesthesia or surgical consultation;
~Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery;
~Inpatient measurement the night before surgery;
~Pre-anesthetic MAP
~The order of the measurements prioritizes outpatient MAPs given that temporary pre-operative discontinuation of anti-hypertensive agents could potentially raise, while fasting and/or fluid restriction pre-operatively could potentially lower resting blood pressure.39 The lower and upper safety limits of personalized MAP targets will be 50mmHg and <90mmHg, respectively."
11082624|NCT04197700|Other|Protocolized Arm|"Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician.
~In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician."
11082625|NCT04197687|Experimental|Arm I - No pCR (trastuzumab emtansine, TPIV100, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive TPIV100 ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of TPIV100 ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
11082626|NCT04197687|Placebo Comparator|Arm II - No pCR (trastuzumab emtansine, placebo, sargramostim)|Patients receive standard of care maintenance therapy with trastuzumab emtansine and receive placebo ID and sargramostim ID on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive two additional booster injections of placebo ID and sargramostim ID at 3 and 12 months after completion of trastuzumab emtansine maintenance therapy.
11082627|NCT04197687|Experimental|Treatment (pCR)|Patients receive standard of care maintenance therapy with trastuzumab and pertuzumab for 1 year in the absence of disease progression or unacceptable toxicity.
11082628|NCT04197674||Peritoneal dialysis group|Patients who randomized to peritoneal dialysis
11082629|NCT04197674||Hemodialysis group|Patients who randomized to conventional in-center hemodialysis
11082630|NCT04197661|Active Comparator|Elderly groupⅠ|Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486
11082631|NCT04197661|Active Comparator|Elderly group Ⅱ|Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486
11082632|NCT04197661|Active Comparator|Elderly group Ⅲ|Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486
11082633|NCT04197661|Active Comparator|Non-elderly group IV|Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486
11082634|NCT04197648|Experimental|Exercise group|24 week, supervised exercise program at the PPMC (pavillon de prevention des maladies cardiaques). 3x/week. Blood pressure response evaluated during every session.
11082635|NCT04197648|No Intervention|Control goup|No exercise program. Continuation of the daily life activities. Consultation with a kinesiologist at baseline, 3 months and 6 months for advice on physical activities and lifestyle habits.
11082636|NCT04197635|Active Comparator|Dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive dapagliflozin 10 mg per day.
11082637|NCT04197635|Placebo Comparator|Placebo identical to dapagliflozin 10 mg|After providing informed consent, patients will be randomly assigned to receive placebo (one tablet a day orally).
11082638|NCT04197622|Experimental|Hydrochlorothiazide|Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).
11082639|NCT04197596|Experimental|BK CTL|Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.
11082696|NCT04197154|Experimental|3. High-threat nocebo|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and threat suggestions (i.e., fear-inducing suggestions).
11082697|NCT04197141|Active Comparator|Conventionally-fractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
11082640|NCT04197570|Active Comparator|Opioid-based anesthetic|"Premedication
~-midazolam 2mg IV x 1 as need for anxiety, at the discretion of the anesthesiologist
~Induction
~Fentanyl 2-4 mcg/kg IV bolus
~Propofol 1-3 mg/kg IV
~Paralytic and vasoactive medications at the discretion of the anesthesiologist
~Maintenance
~Fentanyl 1-2 mcg/kg IV bolus immediately prior to sternotomy & aortic cannulation
~Fentanyl 1-2mcg/kg IV bolus immediately following removal of bypass cannula
~Dexmedetomidine 0.4 mcg/kg/hr IV infusion
~Isoflurane titrated at the discretion of the anesthesiologist
~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management
~During chest closure:
~start Propofol 25-75mcg/kg/min IV infusion
~continue dexmedetomidine 0.4mcg/kg/hr IV infusion
~titrate off isoflurane
~Acetaminophen 1000mg IV"
11082641|NCT04197570|Experimental|Opioid-free anesthetic|"Premedication
~-midazolam 2mg IVx1 as needed for anxiety, at the discretion of the anesthesiologist
~Induction
~Dexmedetomidine 1mcg/kg IV
~Propofol 1-3mg/kg IV
~Paralytic and vasoactive medications at the discretion of the anesthesiologist
~Maintenance
~Dexmedetomidine 0.8-1.0 mcg/kg/hr IV infusion
~Isoflurane titrated at the discretion of the anesthesiologist
~May add propofol infusion if clinically indicated
~Vasoactive medications at the discretion of the anesthesiologist for hemodynamic management
~During chest closure:
~start Propofol 25-75mcg/kg/min IV infusion
~continue dexmedetomidine 0.4 - 1.0 mcg/kg/hr IV infusion
~titrate off isoflurane
~Acetaminophen 1000mg IV"
11082642|NCT04197544|Experimental|Intervention group|
11082643|NCT04197544|No Intervention|Control group|
11082644|NCT04197531|Experimental|EndoActivator|
11082645|NCT04197531|Experimental|Conventional Endodontic Syringe|
11082646|NCT04197518|Experimental|Children With Enlargement Adenoid and Tonsils|Children With Enlargement Adenoid and Tonsils
11082647|NCT04197505|Experimental|Acute fracture specific|The FLIR E95 camera will be used for the study. The injured extremity will be scanned with the thermal camera and a second scan will be performed on the non-injured extremity to provide an internal control for any differences in room temperature and humidity. Prior to scanning, both the injured and non-injured extremity will remain uncovered for 10 minutes, about the length of an average office visit, and the areas to be scanned will remain free from contact by the patient or interviewer during this time period. The camera will be held 2 feet away from the extremity at a 90º angle to limit reading contamination from objects other than the patient.
11082648|NCT04197492|Experimental|HSRT With Anlotinib|"Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.
~Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance."
11082649|NCT04197479|Experimental|Open label: resmetirom|100 mg daily
11082650|NCT04197479|Placebo Comparator|Double blinded: matching placebo|Placebo daily
11082651|NCT04197479|Experimental|Double blinded: resmetirom 80 mg|80 mg daily
11082652|NCT04197479|Experimental|Double blinded: resmetirom 100 mg|100 mg daily
11082653|NCT04197466|Experimental|Pelvic Floor Exercise Group|Pelvic floor muscle exercises will be recommended as a home program for 6 weeks every day of the week.
11082654|NCT04197466|Experimental|Kinesiotape Group|In addition to pelvic floor exercise,kinesio tape application will be performed by ligament technique to the sacral region.
11082655|NCT04197466|Experimental|Electrical Stimulation Group|In addition to pelvic floor exercise,electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
11082656|NCT04197453||Consented Arm|Subjects with a recent (within 18 months) hospitalization for myocardial infarction, unstable angina, ischemic stroke, or critical limb ischemia, and subjects undergoing coronary, peripheral, or carotid revascularization, including surgical and percutaneous revascularization, with an LDL-C greater than or equal to 70 mg/dL who may be eligible for PCSK9 inhibitor therapy.
11082657|NCT04197453||Electronic Health Record (EHR) arm|Subjects with an inpatient or outpatient diagnosis of clinical ASCVD within the prior 12 months including coronary heart disease, ischemic cerebrovascular disease, atherosclerotic peripheral arterial disease, or prior coronary or peripheral or carotid revascularization.
11082658|NCT04197440|Experimental|Bam8-22|
11082659|NCT04197440|Experimental|SPT pricks|
11082660|NCT04197427|Experimental|Experimental Oral Rinse|"In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days.
~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
11082661|NCT04197427|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
11082662|NCT04197414||Prostate cancer|Patients diagnosed as prostate cancer and have undergone prostatectomy
11082663|NCT04197414||Renal cell cancer|Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
11082664|NCT04197414||Bladder cancer|Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
11082665|NCT04197414||Ureter cancer|Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy
11082666|NCT04197375|Experimental|Pre-cooling scenario|One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
11082667|NCT04197375|Sham Comparator|Sham evaluation|Participants were monitored during a usual game without any kind of pre-cooling strategy
11082668|NCT04197362|Experimental|ASICS Women's Gel-Venture 6 Running-Shoe|ASICS Women's Gel-Venture 6 Running-Shoe
11082669|NCT04197362|Experimental|Nike Air Max 270|Nike Air Max 270
11082670|NCT04197362|Experimental|La Vida+|La Vida+
11082671|NCT04197349|Experimental|Part A Cohort 1-8|ALD1910/Placebo; Single Dose IV infusion on Day 1
11082672|NCT04197349|Experimental|Part B Cohort 9|ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
11082673|NCT04197349|Experimental|Part B Cohort 10|ALD1910/Placebo; Single dose subcutaneous injection on Day 1
11082698|NCT04197141|Experimental|Hypofractionated WPRT|15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.
11082699|NCT04197128|Active Comparator|Resorbable collagen membrane and bone graft|Subjects will receive bovine derived bone graft and resorbable collagen membrane for augmentation.
11082700|NCT04197128|Experimental|Ribose cross-linked collagen matrix|Subjects will receive ribose cross linked collagen matrix for augmentation
11082674|NCT04197336|Sham Comparator|Control Arm|27 participants enrolled in the procedure arm. Participants randomized to the control arm will follow the same screening. Pre-procedure assessment will take the same pre-procedure meds. Procedure day, interventional radiologist will determine radial or groin access. After the participant and procedure area are prepped, participants will be under standard moderate sedation medications; all participants will receive lidocaine & a skin nick to their groin or their wrist as determined by the operating physician. Participant will have a blind fold placed & their hearing damped either with ear plugs or noise cancelling headphones. Participants randomized to the control arm will not receive other procedural intervention. Procedural team will follow a prescribed simulated protocol. Participants randomized to the control arm will be given under skin lidocaine and receive a skin nick on the wrist or groin.
11082675|NCT04197336|Active Comparator|Bariatric Embolization Procedure|27 subjects will be enrolled in the bariatric embolization(BM) procedure arm. BM procedure will be performed under moderate sedation. Procedure will take 1.5 hr to 3 hr subject will be placed on the X-ray fluoroscopy table. Radial or femoral vascular access will be achieved using a small gauge needle, dilated over a guidewire to accommodate a 5 French vascular sheath. Standard catheters, 3 dimensional imaging will be acquired of the stomach, the arteries supplying the fundus arising off the celiac vessel. Microcatheter into the left gastric and/or gastroepiploic arteries supplying the fundus and small calibrated spheres will be infused until stasis of anterograde arterial flow is achieved, with particular care to avoid infusion of non-target arteries. The left gastric and/or gastroepiploic arteries will be embolized. Repeat 3 dimensional imaging: assess bead distribution and fundal coverage. Subject will be monitored in the recovery room and will be observed overnight.
11082676|NCT04197323|Experimental|Alprostadil liposomes for injection|
11082677|NCT04197323|Active Comparator|KAISHI for injection|
11082678|NCT04197310|Experimental|Nivolumab and Cabozantinib|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Cabozantinib will be administered at a dose of 40mg orally, once daily
~Nivolumab will be given at a dose of 240mg every 14 days, intravenously
~Retreat Phase (Optional)
~Participants may elect to stop nivolumab and cabozantinib with confirmed CR after at least 24 weeks of treatment.
~Participants who elect to stop and then the condition progresses after stopping study treatment may be eligible to resume nivolumab and cabozantinib therapy.
~This resumption will be termed as a retreatment second course phase and is available only while the study remains open and the subject meets specified criteria."
11082679|NCT04197297|Other|CT and MRI Scans|Each patient will undergo a 3T MRI scan as well as a dynamic contrast-enhanced CT scan within one week prior to the start of treatment. Patients will also undergo a research 3T MRI scan and research dynamic contrast-enhanced CT scan at the one week post radiotherapy mark. An MRI scan during their 3 month post-treatment follow up visits will take place as per routine standard of care.
11082680|NCT04197284|Active Comparator|Control group|In control group subjects will undergo individual kinesitherapy- isometric exercise for strengthening of the quadriceps muscle.
11082681|NCT04197284|Active Comparator|Biofeedback group|Biofeedback group will perform physical therapy using biofeedback device for better activation control of the quadriceps muscle with audio and visual signal. They will also perform isometric exercise.
11082682|NCT04197284|Active Comparator|Electrical stimulation|Electrical stimulation group will receive electrical stimulation of the quadriceps muscle and they will also perform isometric exercise.
11082683|NCT04197271||Patients with acutely symptomatic abdominal wall hernia|Patients presenting to emergency surgical services with acutely symptomatic abdominal wall hernia (excluding parastomal).
11082684|NCT04197258|Experimental|intervention group|"For 6 months after discharge, patients in the intervention group will benefit from peer support by a trained patient (number and frequency of contacts defined according to the patient's needs).
~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon discharge at home, including identifying and seeking for the necessary health or social resources"
11082685|NCT04197258|No Intervention|control group|Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
11082686|NCT04197245|Experimental|group on treatment|saline injection has been given intradermal in atrophic scars of acne on face.
11082687|NCT04197232||exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
11082688|NCT04197232||not exposed|The modality of study is a cohort study that evaluates the performance of children exposed to biologic agents during pregnancy compared to the performance of children born at the same gestational age not exposed to biologic agents.
11082689|NCT04197219|Experimental|Pembrolizumab & axitinib|All participants enrolled will receive pembrolizumab as standard of care (SOC) combined with axitinib. Axitinib will be self-administered orally twice daily at 5 mg. On days when both drugs are administered, axitinib will be administered first, followed by pembrolizumab. Treatment will continue until disease progression or unacceptable grade 3/4 toxicities. For patients with a complete response to therapy, maintenance therapy with both drugs will be continued for 12 months.
11082690|NCT04197206|Experimental|Costotransverse block|The Costotransverse block will be administrated to this group before induction of anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively.
11082691|NCT04197206|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine. No block will be performed.
11082692|NCT04197180|Experimental|Hybrid Argon Plasma Coagulation|The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
11082693|NCT04197167|Experimental|Women undergoing hysteroscopy|Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or abnormal cervical or uterine findings.
11082694|NCT04197154|Experimental|1. Control nocebo group|Conditioning and extinction of a nocebo response using moderate pain stimuli, nocebo negative suggestions, and no threat suggestions.
11082695|NCT04197154|Experimental|2. High-pain nocebo group|Conditioning and extinction of a nocebo response using higher pain stimuli, nocebo negative suggestions, and no threat suggestions.
11082701|NCT04197115|No Intervention|Phase 1|Septic patients admited to ICU whick will be treated as specified in current guidelines.
11082702|NCT04197115|Active Comparator|Phase 2|"Septic patients admitted to ICU which will be treated as specified in current guidelines adding:
~Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)"
11082703|NCT04197102|Active Comparator|CBD oil|300 mg/day of CBD isolate
11082704|NCT04197102|Placebo Comparator|Placebo oil|300 mg/day of placebo oil
11082705|NCT04197089|Experimental|Vitamin D treatment|Treatment with 10.000 IU or 50.000 IU Vitamin D weekly during 4 weeks
11082706|NCT04197076||Neoadjuvant immunotherapy|pd-1 or pd-l1 inhabitors
11082707|NCT04197076||Neoadjuvant targeted therapy|TKIs
11082708|NCT04197076||Neoadjuvant chemotherapy|chemotherapy
11082709|NCT04197063|Experimental|Current SSB restaurant portions purchase refill|Offered a menu with current SSB restaurant portion sizes with the option to purchase refills
11082710|NCT04197063|Experimental|Current SSB restaurant portions free refill|Offered a menu with current SSB restaurant portion sizes plus free beverage refills
11082711|NCT04197063|Experimental|</= 16 oz. SSB portions with the option to purchase refills|Offered a menu with </= 16 oz. SSB portion sizes with the option to purchase refills
11082712|NCT04197063|Experimental|</= 16 oz. SSB portions plus free refills|Offered a menu with </= 16 oz. SSB portion sizes plus free refills
11082713|NCT04197050|Experimental|sacubitril/valsartan group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. sacubitril/valsartan will be given.
11082714|NCT04197050|No Intervention|control group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. Valsartan will be given.
11082715|NCT04197037||People with schizophrenia treated with clozapine|People more than 18 with diagnosis of schizophrenia and treated with clozapine in a stable dose and stable status of the disease (at least 2-3 weeks).
11082716|NCT04197024|Experimental|Traditional exercise capacity test|Patients of the Ministry of the Interior and Administration hospital in Głuchołazy with a diagnosed disease unit of Chronic Obstructive Pulmonary Disease (COPD).
11082717|NCT04197024|Experimental|Immersive virtual reality exercise capacity test|Healthy volunteers, Students of Department of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
11082718|NCT04197011||Prosthesis users|Individuals with unilateral transfemoral amputation.
11082719|NCT04197011||Control|Individuals without unilateral transfemoral amputation.
11082720|NCT04196998|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
11082721|NCT04196998|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
11082722|NCT04196998|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
11082723|NCT04196985|Experimental|Patients with HNSCC|Patients who have histologically confirmed HNSCC and have received CRT for it
11082724|NCT04196972|Experimental|Arm A (ECHO telementoring)|Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
11082725|NCT04196972|Experimental|Arm B (wait-list, ECHO telementoring)|Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
11082726|NCT04196959|Experimental|Single Arm|All patients will receive TYR sphere, a Food for Special Medical Purposes, as part of thier restricted diet for 28 consecutive days.
11082727|NCT04196946|Experimental|Group I|25 mcg fentanyl intrathecally
11082728|NCT04196946|Experimental|Group II|250 mcg alfentanil intrathecally
11082729|NCT04196933|Experimental|Normal Controls|"normal control subjects - no history of neurologic or inner ear disease
~The investigators will characterize vestibular spatial and temporal precision by calculating perceptual thresholds and reaction times for vestibular (yaw rotation, ytranslation) stimuli in normal subjects over a wide age range. Vestibular-visual temporal binding is then performed on each subject and the relationship between the principal parameters (vestibular perceptual thresholds [inversely related to spatial precision], vestibular reaction time variability [inverse of temporal precision], and the PSS and TBW from the temporal binding paradigm) will be examined. The investigators will collect qualitative assessments of dizziness/disbalance (DHI: dizziness handicap index) and quantitative measurements of balance and vestibular function (FGA: functional gait analysis, postural sway, and standard rotational testing - VOR gain, time constant, asymmetry)."
11082730|NCT04196933|Experimental|Central Vestibular Dysfunction|"Migraine and Vestibular Migraine patients
~The investigators intend to evaluate vestibular (yaw rotation or y-translation) - visual temporal binding in people with a wide range of motion sickness sensitivities (as quantified with standard questionnaires), including normal subjects, people with migraine and with vestibular migraine. The investigators will use our standard adaption method to narrow the TBW in these subjects, and will also employ PSS adaptation if a consistent pattern emerges that relates MS sensitivity to the PSS. The investigators will induce motion sickness using a pseudo-Coriolis task (so susceptibility can be quantified pre and post training)."
11082731|NCT04196933|Experimental|Peripheral Vestibular Dysfunction|"Vestibular Schwannoma patients
~The basic approach is to characterize the precision of their vestibular information (perceptual thresholds for spatial precision, reaction times for temporal precision), and their temporal binding characteristics for vestibular (yaw rotation or y-translation)-visual inputs, in three states: pre-op, sub-acute post-op (6 weeks), and chronic post-op (6 months). At each state the investigators will also assess the quality of their vestibular-mediated behaviors through questionnaires (e.g. DHI), postural sway, functional gait analysis, and standard rotational testing (VOR gain, time constant, and asymmetry)."
11082764|NCT04196686|Experimental|Ice bath with with Active VR/AR|250 participants will place hand in ice bath while using active VR/AR where they will engage by playing a game and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
11082732|NCT04196933|Experimental|Implant Subjects|"Cochlear Implant (CI)/Vestibular Implant (VI) patients
~A causative role for vestibular precision in temporal binding will be investigated in the VI patients, since the noise characteristics of the vestibular channel will be varied and to determine how this affects thresholds and temporal binding. As part of a second aim, the investigators will use VI and CI prosthetic signals in patients who have never received them together to see how the brain process sensory cues to which it is essentially naïve. Finally, after the acute experiments the investigators will provide 8 hours of 'physiologic' VI and CI stimulation by turning both implants on, sound modulates activity in the CI as usual, and angular head motion modulates activity in the VI while the subject actively explores the hospital environment."
11082733|NCT04196920||Cohort with TNF combination therapy|Cohort with TNF combination therapy (infiximab/adalimumab) with azathiorpine
11082734|NCT04196920||Cohort with anti-TNF combination therapy|Cohort with anti-TNF combination therapy (infiximab/adalimumab) with methotrexate
11082735|NCT04196881|Experimental|Training|group will receive training about ADHD
11082736|NCT04196881|No Intervention|Control|group will not receive training about ADHD
11082737|NCT04196868|Experimental|Experimental arm|
11082738|NCT04196868|Placebo Comparator|Control arm|
11082739|NCT04196855|Experimental|Intervention - Teriparatide Treatment|Teriparatide 20ug/day from confirmation of stress fracture for 16 weeks, with the potential to extend to 24 weeks if required.
11082740|NCT04196855|No Intervention|Control - Standard Care|Standard rehabilitation care with additional monitoring to assess healing.
11082741|NCT04196842|Experimental|Telemonitoring|Blood pressure and heart rate monitoring, scale, activity tracker.
11082742|NCT04196842|No Intervention|No intervention|No intervention.
11082743|NCT04196829|Experimental|silver diamine fluoride ⁄ potassium Iodide|38% silver diamine fluoride and a saturated solution of potassium iodide
11082744|NCT04196829|Active Comparator|silver diamine fluoride|38% silver diamine fluoride
11082745|NCT04196803|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
11082746|NCT04196803|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
11082747|NCT04196803|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
11082748|NCT04196803|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
11082749|NCT04196777|Experimental|Intervention|We will randomly select 3 intervention sites from the top quartile of all VHA sites, as ranked by the frequency of excessive post-procedural antimicrobial use after the 3 urologic procedures of interest. We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be shared at baseline with the intervention sites. Updated data will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail. These data will include an anonymous comparison to all other VHA hospitals.
11082750|NCT04196777|No Intervention|Control|"After the 3 intervention sites are identified, 3 control sites will be chosen. To qualify as a control site, a hospital's baseline rate of excessive post-procedural antimicrobial use must be comparable to that of its matching intervention site. Matching on the outcome of interest will minimize selection bias and will make the study less subject to regression to the mean, which is the key threat when selecting poor performers.To further ensure that intervention and control sites are as similar as possible, attempts will also be made to match each intervention site to a comparable control site based on academic affiliation (yes/no), VHA-defined hospital complexity, urologic procedural volume, antimicrobial stewardship resources, and location (rural versus urban).
~Feedback will not be provided to the control sites."
11082751|NCT04196751|Experimental|Clinical Supervision Intervention|All the enrolled participants will be undergoing Clinical Supervision sessions with their selected supervisors for pre-identified objectives for their skill and knowledge development.
11082752|NCT04196738|Experimental|Dual Mode first|Four consecutive steps (45 min per step) in the following order: APRV (A), Dual Mode (B) , APRV (A) and VAC (C). (ABAC)
11082753|NCT04196738|Experimental|VAC fist|Four consecutive steps (45 min per step) in the following order: APRV (A), VAC (C) , APRV (A) and Dual Mode (B). (ACAB)
11082754|NCT04196725|Experimental|Physical therapy treatment|
11082755|NCT04196725|Experimental|Lifestyle treatment|
11082756|NCT04196725|No Intervention|Control|Parallel control group, not undertaking any treatment and not part of the cross-over design
11082757|NCT04196712||Coronary angiography arm|Patient undergoing invasive coronary angiography
11082758|NCT04196686|No Intervention|Control|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors without the use of VR/AR
11082759|NCT04196686|Experimental|Sensory perception with VR/AR|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors the use of VR/AR
11082760|NCT04196686|Active Comparator|Sensory perception with Active VR/AR|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors using active VR/AR where they engage by playing a game
11082761|NCT04196686|Active Comparator|Sensory perception with Passive VR/AR|250 participants will do Sensory perception threshold (time, amplitude) captured via biosensors using VR/AR where they will passively watch a movie
11082762|NCT04196686|Experimental|Ice bath Control|250 participants will place hand in ice bath captured without the use of VR/AR and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
11082763|NCT04196686|Experimental|Ice bath with VR/AR|250 participants will place hand in ice bath captured with the use of VR/AR and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
11082861|NCT04195880|Experimental|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
11083756|NCT04189276|Active Comparator|Group3|ETV or TDF
11082765|NCT04196686|Experimental|Ice bath with with Passive VR/AR|250 participants will place hand in ice bath while using VR/AR where they will passively watch a movie keep and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
11082766|NCT04196673|Experimental|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
11082767|NCT04196673|Experimental|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
11082768|NCT04196660|Experimental|The Dance Practitioner Spouse/Partner Group|The Dance Practitioner Spouse/Partner Group (DPSG)
11082769|NCT04196660|Experimental|The Dance Practitioner Midwife Group|The Dance Practitioner Midwife Group (DPMG) included 40 pregnant women and midwives who had received labor dance training
11082770|NCT04196660|No Intervention|The Control Group|The Control Group included 80 pregnant women who were subjected to routine treatment without dance
11082771|NCT04196634||People on sick leave|People on sick leave due to musculoskeletal conditions for at least 4 weeks.
11082772|NCT04196621|Active Comparator|High viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, high viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
11082773|NCT04196621|Active Comparator|Low viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, low viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
11082774|NCT04196608||P. aeruginosa isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
11082775|NCT04196608||Enterobacterales isolates|All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
11082776|NCT04196582|Active Comparator|Gastro-laryngeal tube Group (Group G)|Patients wear Gastro-laryngeal tube after receiving general anesthesia for biliopancreatic procedures
11082777|NCT04196582|Active Comparator|LMA Gastro Airway Group (Group L)|Patients wear LMA Gastro Airway® after receiving general anesthesia for biliopancreatic procedures
11082778|NCT04196569||trifocal intraocular lens|
11082779|NCT04196556|Experimental|Active Families|Usual care plus intervention active families. This intervention, based on the methodology of meaningful learning, will have two components: group education directed to parents (caregivers) and education directed to children in the reviews in consultation. The group intervention will consist of 6 sessions, with a biweekly / monthly frequency, will be taught as determined in the program monitoring annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
11082780|NCT04196556|Active Comparator|Control group|"Usual care:
~The activities included in the Service for Attention to Patients with Childhood Obesity will be carried out in the Cartera de Servicios Estandarizados de Atención Primaria de Madrid, which establishes a monthly follow-up in the first 6 months and bimonthly of month 6 to 12. To this At least the child and the primary caregiver, the child's educational agent, will be consulted and will receive support documentation to exercise and reinforce their role."
11082781|NCT04196543|Experimental|écho-doppler with ultrasonar Sonovue® injection|
11082782|NCT04196530|Experimental|Dose Escalation of BDB001 with atezolizumab|"This part of the study will follow a traditional 3+3 dose escalation design.
~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of BDB001 with atezolizumab is reached."
11082783|NCT04196530|Experimental|Dose Expansion of BDB001 with atezolizumab|"At the end of the dose escalation part of the study, the BDB001 dose to be used in combination with atezolizumab in the expansion part of the study will be established after thorough review of all available safety, preliminary efficacy, PK and PD data.
~A biologically active dose will be selected that is either the MTD, if one was established in the escalation part, or an RP2D if no MTD was established. Approximately 20 additional subjects will initially be enrolled in the dose expansion part."
11082784|NCT04196517|Experimental|Arm 1 - PALS|The Patient Activated Learning System (Palsforhealth.com)
11082785|NCT04196517|Experimental|Arm 2 - WebMD|WebMD.com
11082786|NCT04196491|Experimental|Dose Escalation|"bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10^6 CAR+ T cells.
~Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later"
11082787|NCT04196465|Experimental|Neoadjuvant IMC-001|Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma
11082788|NCT04196452||Arm A: participants 12 to under 18|
11082789|NCT04196452||Arm B: participants under 12|
11082790|NCT04196439|Active Comparator|continuous epidural analgesia|continuous lumbar epidural catheter inserted preoperatively before induction of general anaesthesia
11082791|NCT04196439|Active Comparator|continuous supra-inguinal fascia iliaca compartment block|ultrasound guided supra-inguinal FICB with insertion of catheter for continuous infusion before induction of general anaesthesia.
11082792|NCT04196426|Experimental|nutrition education group|The nutrition education group receive the intervention first, which include 2 nutrition lessons about osteoporosis and calcium and calcium rich foods. The 2 lessons are delivered in one week for 2 hours each lesson. After this week, participants in the intervention group receive handouts about osteoporosis and calcium once a week for a period of 4 weeks.
11082793|NCT04196426|Active Comparator|delayed nutrition education group|After the intervention group finish their intervention (5 weeks period), post data collection will be administered in both nutrition education and delayed nutrition education group. After this post data collection, the delayed nutrition education group receive the same intervention.
11082794|NCT04196413|Experimental|GD2-CAR T|"Dose escalation in subjects with DIPG:
~A standard 3+3 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG, starting with Dose
~Level 1:
~Dose Level 1: 1x10^6 CAR+ T cells/kg body weight (+/- 20%)
~Dose Level 2: 3x10^6 CAR+ T cells/kg body weight (+/- 20%)
~Dose Level 3: 10x10^6 CAR+ T cells/kg body weight (+/- 20%)
~Dose Level -1 will be explored if the first subject treated experiences dose limiting toxicity (DLT) or if >2 of 6 subjects treated at Dose Level 1 experiences DLT.
~Dose expansion in subjects with DIPG and spinal DMG: Once the MTD or RP2D is determined, up to 20 evaluable subjects with H3K27M-mutant DIPG and 10 evaluable subjects with H3K27M-mutant spinal DMG will be treated at the RP2D (including subjects treated during dose escalation)."
11082795|NCT04196400|Active Comparator|Steroid injection|Steroid (betamethasone) 2 ml is injected subcutaneously after finishing the operation at the repair site.
11082796|NCT04196400|No Intervention|Control Group|
11082797|NCT04196361||Ventilated72h|Patient that were ventilated for at least 72 hours
11082798|NCT04196348|Active Comparator|Short BPL RYGB in glucose-tolerant participants|Procedure: short biliopancreatic limb (BPL) Roux en Y Gastric Bypass (RYGB) Obese patients without type 2 diabetes mellitus (T2DM) to be submitted to short BPL (n=10)
11082799|NCT04196348|Active Comparator|Long BPL RYGB in glucose-tolerant participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome without T2DM to be submitted to long BPL (n=10)
11082800|NCT04196348|Active Comparator|Long BPL RYGB in diabetic participants|Procedure: long BPL RYGB Obese patients with metabolic syndrome and T2DM to be submitted to long BPL (n=10)
11082801|NCT04196335|Experimental|single-arm|
11082802|NCT04196322||Controlled|
11082803|NCT04196322||Uncontrolled|
11082804|NCT04196309|Experimental|Tinzaparin group|LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)
11082805|NCT04196309|No Intervention|Control group|No intervention
11082806|NCT04196296|Active Comparator|Psychoeducation|
11082807|NCT04196296|Experimental|Psychoeducation plus Motivation Enhancement|
11082808|NCT04196283|Experimental|Arm 1: ABBV-368 + Tilsotolimod|Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.
11082809|NCT04196283|Experimental|Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel|Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.
11082810|NCT04196283|Experimental|Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181|Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.
11082811|NCT04196270|Experimental|Ropivacaine|This double-blind dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anesthetic administered to each patient depends on the response from the previous one. The TQL block is performed preoperatively, and the first patient recruited receives 20 mL of ropivacaine 0.75%. In case of block failure, the next patient will receive a higher volume (defined as the previous volume with an increment of 2 mL). Given a successful block for the first patient, the next patient will be randomized to either a lower volume (defined as the previous volume with a reduction of 2 mL) or the same volume as the previous patient. The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume. Block success is defined as patient reported numeric rated scale (NRS) pain (NRS value ≤ 3 (0-10/10)), 30 minutes after arrival in the post anesthesia care unit (PACU).
11082812|NCT04196257|Experimental|BP1001-A monotherapy|Dose escalation of BP1001-A monotherapy
11082813|NCT04196257|Experimental|BP1001-A and Paclitaxel|Dose expansion of selected dose of BP1001-A with paclitaxel
11082814|NCT04196244|Experimental|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
11082815|NCT04196244|Active Comparator|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
11082816|NCT04196231|Active Comparator|FR insulin/GLP-1RA|Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
11082817|NCT04196231|Active Comparator|Insulin/SGLT-2i|Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
11082818|NCT04196231|Active Comparator|Basal Bolus|Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
11082819|NCT04196218|Other|Driving assessment|All subjects will undergo a driving assessment(s) following shoulder surgery.
11082820|NCT04196205|Experimental|Anti-CD19 CAR-T|Anti-CD19 CAR-T
11082821|NCT04196192||Group 1|All infants aged 0-90 days (inclusive) undergoing routine assessments for fever without source.
11082822|NCT04196179|Experimental|SAD|"A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral
~A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral
~A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral
~Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral
~A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral
~A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral
~D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg *with and without food* (n=6)/ Placebo (n=2) Oral"
11082823|NCT04196179|Experimental|MAD|"B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)
~B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)
~B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)
~B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)
~C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)
~C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)"
11082824|NCT04196166||Cases|nested from on going retrospective cohort study. Participants who had change in their surgical plan after hospitalization.
11082825|NCT04196166||Controls|nested from on going retrospective cohort study. Participants who didn't have change in their surgical plan after hospitalization.
11082826|NCT04196153|Active Comparator|Neuronavigation / O-arm group|Under neural navigation with the use of intraoperative three dimensional imaging quality O-arm , pedicle screws inserted at the thoraolumbar/lumbar spine after insertion of the reference frame at the spinous process above or below the level of instrumentation followed by O-Arm imaging and uploading the images to the stelth navigation system and pedicle tract identification using instrumented tools guided by the Navigation polyaxial screws is inserted.
11083041|NCT04194372||Metabolic Patient|"Patients with a metabolic desease, defined as
~Metabolic Syndrom
~Diabetic
~Obese"
11082827|NCT04196153|Active Comparator|Cervical distractor screws group|pedicle screws inserted using marker screws after posterior exposure of thoracolumbar /lumbar spine by either open midline posterior exposure or minimal invasive posterior wiltse style exposure with expandable tubular retractor, anatomical landmark for insertion of pedical screws identified and followed by inserting of a cervical distraction screw size 3 / 12 mm as a stable marker using high speed drill. C-arm floro is used to take antroposterior and lateral view to confirm the position of the marker screws at this stage.free hand technique supported by the images provided to cannulate the pedicle with the use of information on the images taken for all the marker screws simultaneously.
11082828|NCT04196140|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
11082829|NCT04196127||TTH|Patients with tension-type headache. They may not experience migraine, but can experience neck pain and/or temporomandibular dysfunction.
11082830|NCT04196127||Healthy controls|Participants without frequent headaches. They may experience neck pain and/or temporomandibular dysfunction.
11082831|NCT04196114|Experimental|All patients|All patients implanted.
11082832|NCT04196101|Experimental|EDP-938|Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days
11082833|NCT04196101|Placebo Comparator|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days
11082834|NCT04196088|Active Comparator|Ultivision AI Software enhanced screening colonoscopy|Ultivision Artificial Intelligence enhanced screening colonoscopies will be performed.
11082835|NCT04196088|Placebo Comparator|No AI enhancement screening colonoscopy|Screening colonoscopies without Artificial Intelligence enhancement will be performed.
11082836|NCT04196075|Experimental|Andrographis Paniculata treatment|Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard
11082837|NCT04196062|Experimental|Robotic ESD|Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system
11082838|NCT04196036|Active Comparator|Day 3 vitrification|Day of vitrification of supernumerary embryos is day 3
11082839|NCT04196036|Active Comparator|Day 5 vitrification|Day of vitrification of supernumerary embryos is day5
11082840|NCT04196023|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
11082841|NCT04196023|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
11082842|NCT04196023|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
11082843|NCT04196023|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
11082844|NCT04196010|Experimental|Treatment (CI-CLAM, G-CSF)|Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
11082845|NCT04195997|Experimental|bivalurudin|Bivalirudin will be given as a bolus of 0.75 mg/kg once transseptal puncture is successully performed with no pericardial effusion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
11082846|NCT04195997|Active Comparator|heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
11082847|NCT04195984|Experimental|Treatment|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
11082848|NCT04195971|Experimental|Liver CT with dual arterial phase|
11082849|NCT04195958|Experimental|Omalizumab|
11082850|NCT04195958|Placebo Comparator|Placebo|
11082851|NCT04195945|Experimental|Arm I (CPX-351)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of CPX-351 intravenously IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
~POST-REMISSION: Patients who achieve a CR/CRi receive a reduced dose of CPX-351 IV over 90 minutes on days 1, 3, and 5 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
11082852|NCT04195945|Experimental|Arm II (CLAG-M)|"INDUCTION: Patients receive cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity.
~POST-REMISSION: Patients who achieve a CR/CRi receive an intermediate dose of cytarabine IV over 2 hours on days 1-6 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
11082853|NCT04195932|Experimental|Exercise|6 moths of supervised moderate intensity aerobic and resistive exercise training
11082854|NCT04195919|Experimental|Group1|Hemodialysis patients(MDRD-eGFR ≤ 15 mL/min/1.73m2)
11082855|NCT04195919|Experimental|Group2|Healthy control(MDRD-eGFR ≥ 90 mL/min/1.73m2)
11082856|NCT04195906|Experimental|SNF472 (Double-Blind Period)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
11082857|NCT04195906|Placebo Comparator|Placebo (Double-Blind Period)|Matching placebo (saline) diluted in 100 mL physiological saline.
11082858|NCT04195906|Experimental|SNF472 (Open-Label)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
11082859|NCT04195893|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to etafilcon A daily disposable lenses for one week.
11082860|NCT04195893|Active Comparator|etafilcon A|Subjects will be randomized to wear etafilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
11082862|NCT04195880|No Intervention|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
11082863|NCT04195867|Experimental|Salmeterol|Subjects receive a 3-day treatment and collect urine from 2 days before first administration to 24 hours post-administration.
11082864|NCT04195841|Experimental|Test group|Two horizontal incisions placed 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles.
11082865|NCT04195841|Experimental|Control group|Sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth
11082866|NCT04195828|Experimental|Camrelizumab + Apatinib + nab-paclitaxel +S-1|Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
11082867|NCT04195828|Active Comparator|nab-paclitaxel +S-1|nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
11082868|NCT04195789||Sample population|Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
11082869|NCT04195776|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
11082870|NCT04195763||Participants with Pediatric-onset HPP|Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.
11082871|NCT04195750|Experimental|Belzutifan|Participants receive 120 mg of belzutifan orally once daily (QD)
11082872|NCT04195750|Active Comparator|Everolimus|Participants receive 10 mg of Everolimus orally once daily (QD)
11082873|NCT04195737|Experimental|Root coverage with ossix volumax collagen matrix|Evaluation of root coverage achieved by collagen matrix in conjunction with coronally advanced flap in patients with multiple gingival recession.
11082874|NCT04195737|Active Comparator|Root coverage with connective tissue graft|Evaluation of root coverage achieved by connective tissue graft in conjunction with coronally advanced flap in patients with multiple gingival recession
11082875|NCT04195724|Experimental|Patients with decompensated ascites and receiving TIPS|Patients with decompensated ascites and receiving TIPS will be enrolled. In this study, diagnostic paracentesis will be performed to get the ascites sample before the patients receiving TIPS. Next, the blood sample from superior mesenteric vein and hepatic vein will be collected under the procedure of TIPS.
11082876|NCT04195711||blinq screened|Patients screened by new birefringent screener
11082877|NCT04195698|Experimental|Upadacitinib|Participants will be administered with upadacitinib once daily (QD)
11082878|NCT04195685|Experimental|NFB Intervention and Delayed Intervention|The NFB system will read and interpret a participant's brain wave pattern which will be instantaneously fed back to the participant providing information, to which a participant can respond accordingly. The NFB specialist assumes a coaching role with people training on the NFB special use system to assist in the achievement of a focused relaxed state, which enhances the overall brain functioning. The significance and unique aspect of NFB is the direct impact on physiological dysregulation, which is the basis of this treatment approach. Twenty, one-hour, NFB training sessions will be provided to each participant in the intervention group and Delayed intervention group (those participants who completed the Control Group activities) by a trained NFB specialist over an 8-10-week period. Participants in the intervention group will receive up to 5-sessions but usually 3 sessions a week
11082879|NCT04195685|No Intervention|Control Group|Participants in the control group will continue with their usual treatment and will receive a 15-minute call once a week for eight weeks from the PI on a health topic. This will help to keep members of the control group engaged in the project and receive the same information that is offered to the intervention group members. The health topics that are generally discussed during NFB sessions include sleep hygiene, basic nutritional concepts, beverage choices, positive thinking, thought reframing, fitness, daily calming activity, and enhancement of focus strategies.
11082880|NCT04195672||Children under 3 years-old intubated/sedated in intensive care|NIPE and CBS ware measured for each included patient
11082881|NCT04195659||Top Surgery|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, and who are undergoing mastectomy and chest masculinization in one of three plastic surgery practices in Chicago.
11082882|NCT04195659||Control|Individuals assigned the female sex at birth, who identify as a gender other than female, are between the ages of 13 and 25 years, were seen in a gender development clinic in Chicago, and who are not planning to undergo top surgery. Controls will be matched with top surgery patients on age and number of months of testosterone.
11082883|NCT04195646|Experimental|EndoVigilant CAD Software assisted Colonoscopy Procedure|The gastroenterologist performing the colonoscopy procedure will be able to observe a standard colonoscopy video on the primary monitor and video augmented by EndoVigilant CAD software on the second monitor. The gastroenterologist will primarily rely on the second monitor but the standard procedure monitor will be always operational and available for maneuvers such as fast insertion, polypectomy etc.
11082914|NCT04195360||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
11082915|NCT04195360||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilization
11083042|NCT04194359|Experimental|Sintilimab + XELOX + Bevacizumab|
11083043|NCT04194359|Active Comparator|XELOX + Bevacizumab|
11082884|NCT04195633|Experimental|Arm A (high dose treosulfan)|Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is > 1,000/uL for 3 consecutive days.
11082885|NCT04195633|Experimental|Arm B (low dose treosulfan)|Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.
11082886|NCT04195620|Experimental|Low loneliness, low self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
11082887|NCT04195620|Experimental|Low loneliness, high self-disclosure|Individuals in this arm report lower levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
11082888|NCT04195620|Experimental|high loneliness, low self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the low self-disclosure group which involves questions that are unlikely to involve meaningful personal disclosure. All members of this group will also complete the high self-disclosure condition later in the study.
11082889|NCT04195620|Experimental|high loneliness, high self-disclosure|Individuals in this arm report higher levels of loneliness than the mean level reported by similar individuals. They will start the study in the high self-disclosure group which involves questions that are likely to involve meaningful personal disclosure. All members of this group will also complete the low self-disclosure condition later in the study.
11082890|NCT04195594|Experimental|Nic's Keto Diet|
11082891|NCT04195568|Experimental|Surpass Evolve Flow Diverter System|This is a prospective single arm study in which all subjects who present for flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment (Surpass Evolve Flow Diverter).
11082892|NCT04195555|Experimental|Treatment (ivosidenib)|Patients receive ivosidenib PO QD. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11082893|NCT04195542||women in obstetric ward in Rennes CHU|women in obstetric ward in Rennes CHU
11082894|NCT04195542||CHU professionals|All CHU professionals contacted via their email address
11082895|NCT04195516|Experimental|Health Promotion Group|Experimental group will be applied Health Promotion Model Basic Health Promotion Program. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.
11082896|NCT04195516|No Intervention|Control Group|The control group will be given educational brochures to develop healthy eating and physical activity behaviors.
11082897|NCT04195503|Other|liver transplantation|Surgical Intervention - Liver transplantation
11082898|NCT04195490|Other|children with disorders of sex development|children with disorders of sex development needing feminizing genitoplasty
11082899|NCT04195477|Experimental|vDPP|Participants will take part in a 4 week study to develop the program.
11082900|NCT04195464|Experimental|DN|
11082901|NCT04195464|Sham Comparator|Sham-DN|
11082902|NCT04195464|No Intervention|Control|
11082903|NCT04195451|Experimental|Live Video-Supervised Exercise Intervention Arm|Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
11082904|NCT04195451|Experimental|Live-Video-Supervised Exercise Control Arm|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
11082905|NCT04195438|Other|Intervention Arm|CO and ABG Testing Arm
11082906|NCT04195412|Experimental|tDCS|Bihemispheric tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After stimulation, individual and intensive upper limb rehabilitation will be performed.
11082907|NCT04195412|Sham Comparator|Control|Bihemispheric sham tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After sham stimulation, individual and intensive upper limb rehabilitation will be performed.
11082908|NCT04195399|Experimental|Treatment (nirogacestat)|Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11082909|NCT04195386|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
11082910|NCT04195386|Active Comparator|Resin-Modified Glass ionomer Cement|Single placement of Resin-Modified Glass ionomer Cement on atypical cavities.
11082911|NCT04195373|Experimental|TMV-018 + 5-FC|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
11082912|NCT04195373|Experimental|TMV-018 + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
11082913|NCT04195373|Experimental|TMV-018 + 5-FC + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
11082916|NCT04195347|Experimental|CM4620 Treatment|"Phase I:
~Cohort 1 patients receive CM4620 IV at dose level 1 on days 1-4. Cohort 2 patients receive CM4620 IV at dose level 2 on days 1-4. Cohort 3 patients receive CM4620 IV at either dose level 1 or 2 on days 1-4
~Phase II:
~Patients will receive CM4620 IV on days 1-4 at the recommended Phase II dose (RP2D) as determined in Phase I."
11082917|NCT04195334|Experimental|IMN and union|putting an intramedullary nail in femoral shaft fractures and finding a relation between the nail diameter to femoral canal diameter and how this will affect healing or predict union
11082918|NCT04195321|Active Comparator|norepinephrine group|patients will receive NE infusion at a starting of rate of 1 ml/min of 8 mcg/ml solution (prepared by diluting 4 mg NE in 500 ml normal)
11082919|NCT04195321|Active Comparator|phenylephrine|patients will receive PE infusion at a starting rate of 1 ml/min of 100 mcg/ml solution (prepared by diluting 10 mg of PE in 100 ml normal saline)
11082920|NCT04195308|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
11082921|NCT04195308|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.
11082922|NCT04195295|Experimental|periosteal membrane and egg shell graft|Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material and periosteal pedicle as barrier membrane.
11082923|NCT04195295|Experimental|only egg shell graft|Only Egg shell derived nano hydroxyapatite (EnHA) as graft material.
11082924|NCT04195295|Active Comparator|open flap debridement|open flap debridement procedure only.
11082925|NCT04195282|Active Comparator|Plasma exchange group|10 patients will receive conventional treatment plus plasma exchange
11082926|NCT04195282|Experimental|RL-1 Novel Human-derived Bio-artificial Liver treatment group|10 patients will receive conventional treatment plus RL-1 Novel Human-derived Bio-artificial Liver treatment
11082927|NCT04195269|Experimental|Pure Green Sublingual Tablet - Daily|Subjects will take 2 tablets daily, one in the morning and one in the evening, and are able to take up to 2 additional tablets per day as needed for pain.
11082928|NCT04195256|Experimental|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
11082929|NCT04195256|Experimental|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
11082930|NCT04195256|Experimental|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
11082931|NCT04195256|Active Comparator|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
11082932|NCT04195243|Experimental|Dapagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
~Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal"
11082933|NCT04195243|Experimental|Empagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
~Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal"
11082934|NCT04195243|Placebo Comparator|Placebo|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.
~Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal"
11082935|NCT04195230|Active Comparator|Computerized Cognitive Training 1|Participants will undergo a training protocol where they will have to set tables under different instructions, rules and difficulty level. Later, participants will perform a multi-tasking training combining table setting and cooking protocols.
11082936|NCT04195230|Active Comparator|Computerized Cognitive Training 2|Participants will undergo a training protocol where they will have to cook different meals under different instructions, rules and difficulty level. Later, participants will perform a multi-tasking training combining cooking and table setting protocols.
11082937|NCT04195217|Active Comparator|With art therapy|Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care
11082938|NCT04195217|No Intervention|Without art therapy|6 consecutive sessions of cancer treatments without art therapy with other supportive care added.
11082939|NCT04195204|Experimental|Tropisetron|Patients allocated to this arm will receive intravenous Tropisetron (5mg) before anesthesia induction and once daily for 7 days after surgery.
11082940|NCT04195204|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of normal saline before anesthesia and once daily for 7 days after surgery.
11082941|NCT04195191|Placebo Comparator|Placebo|The usual practice by community pharmacies
11082942|NCT04195191|Experimental|ANM|This is an intervention based on pharmaceutical-patient communication through an open and fluid conversation, aimed at evaluating the patient's relationship with their new prescription, detecting possible problems, concerns and false beliefs or visual expectations.
11082943|NCT04195178||Anesthesia Providers|Clinically active anesthesia providers
11082944|NCT04195165|Experimental|SIT|Subject will be asked to take <3,000 steps for two intervention days prior to an oral glucose tolerance test on the third day.
11082945|NCT04195165|Experimental|SIT+EX|Subject will be asked to take <3,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
11082946|NCT04195165|Experimental|ACTIVE+EX|Subject will be asked to take >10,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
11082947|NCT04195152||Difficult intubation group|An intubation is called difficult if a normally trained anesthesiologist needs more than 3 attempts or more than 10 min for a successful endotracheal intubation.
11082948|NCT04195152||Non difficult intubation group|An intubation is called non difficult if a normally trained anesthesiologist needs only one attempt for a successful endotracheal intubation.
11082949|NCT04195139|Experimental|Nivolumab and Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment
11082950|NCT04195139|Active Comparator|Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment
11082951|NCT04195126|No Intervention|Control group|Patients are treated according to most recent guidelines in burn trauma and corresponding emergency and intensive therapy. All patients included are treated with early continous veno-venal renal replacement therapy.
11082952|NCT04195126|Active Comparator|Treatment group|Besides treatment strategies of the control group, the investigators start early haemadsorption treatment right after patient admission (and inclusion).
11082953|NCT04195113||Direct Oral Anticoagulants (DOACs)|In this study, DOACs include apixaban, dabigatran, edoxaban and/or rivaroxaban.
11082954|NCT04195113||Vitamin K Antagonist (VKA)|In this study, the VKA is warfarin.
11082955|NCT04195100|Active Comparator|Low dose pilocarpine|low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
11082956|NCT04195100|Active Comparator|High dose pilocarpine|high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
11082957|NCT04195087||Non-hypotension|Patients with a mean arterial pressure reduction of less than 20% and/or systolic arterial pressure above 80 mmHg after spinal anesthesia.
11082958|NCT04195087||Hypotension|Patients with a 20% reduction in mean arterial pressure and/or systolic arterial pressure below 80 mmHg after spinal anesthesia.
11082959|NCT04195074|Experimental|ETV group|100 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
11082960|NCT04195074|Experimental|TDF group|100 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
11082961|NCT04195074|Experimental|TAF group|100 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
11082962|NCT04195061|Other|Cardiopulmonary exercise testing|
11082963|NCT04195048||Cancer patients with acute ischemic stroke|Eighty patients previously or currently suffering from manifest cancer on or not on cancer treatment who developed stroke
11082964|NCT04195048||Control patients with acute ischemic stroke without cancer|Eighty patients with acute ischemic stroke without cancer
11082965|NCT04195035|Experimental|Air-Q intubating laryngeal airway mask|"Where Air-Q intubating laryngeal airway will be used for ventilation & intubation through fiberoptic bronchoscope.
~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Air-Q will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2were recorded 5 minutes after device insertion.
~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
11082966|NCT04195035|Experimental|Ambu-Aura intubating laryngeal mask|"Ambu-Aura intubating laryngeal mask will be used for ventilation & intubation through fiberoptic bronchscope.
~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Ambu-Aura laryngeal mask will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2 will be recorded 5 minutes after device insertion.
~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
11082967|NCT04195022|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
11082968|NCT04195022|Active Comparator|Bulk fill resin composite|Single placement of Bulk fill resin composite on atypical cavities.
11082969|NCT04194996||Operative|"Inclusion criteria:
~≥18 years old at time of treatment
~Diagnosis of cervical deformity- must meet one or more of the following criteria:
~C2-C7 sagittal kyphosis (Cobb > 15o)
~T1S-CL > 35o
~Segmental cervical kyphosis > 10o between any 2 vertebra between C2-T1 or > 15o across any 3 vertebra between C2-T1
~Cervical scoliosis > 10o (Cobb angle must include end vertebra within the cervical spine)
~C2-C7 SVA > 4cm
~McGregor's slope > 20 degrees or CBVA > 25 degrees
~Plan for surgical correction of cervical deformity in the next 6 months"
11082970|NCT04194983|Experimental|Fish oils and dairy fats|
11082971|NCT04194983|Placebo Comparator|Fish oils and plant fats|
11082972|NCT04194970|Experimental|Group I (monitoring with live-feedback system)|MarWAS is a product that can monitor the pressure under the foot and provide live feedback (if this option activated) to the user in case of exceeding the specified limits. Its components are insole with pressure sensors and mobile applications (IOS, Android). Post-operative patients (osteochondral lesion of the talus) will be monitored with the MarWAS product in case live feedback is turned on. We aimed to ensure the compliance of patients to specified weight bearing limits. We will follow up this grup for 6 weeks periods with MarWAS. Pre-op. and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. Also we will monitor the compliance success of patients with MarWAS during 6 week. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate.
11083104|NCT04193878|Placebo Comparator|Placebo|4 ml aerosolized 0.9% saline every 12 hours x 10 doses
11082973|NCT04194970|Active Comparator|Group II (monitoring without live feedback)|"The post-operative patients (osteochondral lesion of talus), follow-up with product in live-feedback closed condition.
~After surgery, we will educate the patients about weight bearing protocol on post-op first day and post op 3 week. The protocol is  first 3 weeks, %0 body weight bearing (BWB), second 3 weeks between %10-%20 BWB. Patients' compliance to BWB protocol will be monitored daily with the MarWAS product in case live-feedback is turned off. Pre-op and post-op 6 week, we evaluate the patients in case of ankle function, pain with The American Orthopaedic Foot & Ankle Society (AOFAS) Scoring. The relationship with compliance to weight bearing success and AOFAS scores will be evaluate."
11082974|NCT04194957|Experimental|Wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
11082975|NCT04194957|Experimental|heterozygous carrier of c.1236G>A or c.2846A>T DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for c.1236G>A or c.2846A>T of these SNPs
11082976|NCT04194957|Experimental|Homozygous or compound heterozygous carrier of DPYD variants|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be homozygous or compound heterozygous for these SNPs
11082977|NCT04194944|Experimental|Selpercatinib|Selpercatinib administered orally.
11082978|NCT04194944|Active Comparator|Pemetrexed with or without Pembrolizumab|Pemetrexed administered intravenously (IV) plus the investigator's discretion of carboplatin IV or cisplatin IV with or without pembrolizumab IV.
11082979|NCT04194944|Active Comparator|Pemetrexed with Pembrolizumab|Pemetrexed administered IV plus the investigator's discretion of carboplatin IV or cisplatin IV with pembrolizumab IV.
11082980|NCT04194931|Experimental|Mixed BCMA/CD19 CAR-T Transfer|Subjects with BCMA/CD19+ multiple myeloma will be infused with CD19-targeting CAR T Cells and BCMA-targeting CAR T Cells in one time or in parts
11082981|NCT04194918|Experimental|Prevention (Flexiquit+, text message, handout)|Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
11082982|NCT04194905|Experimental|Levonorgestrel Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
11082983|NCT04194905|Active Comparator|Levonorgestrel Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
11082984|NCT04194892|Experimental|Pegilodecakin Vial|Pegilodecakin administered subcutaneously (SQ) in one of two study periods.
11082985|NCT04194892|Experimental|Pegilodecakin Pre-filled syringe (PFS)|Pegilodecakin administered SQ in one of two study periods.
11082986|NCT04194879||Cancer|Case subjects (at least 50) will be men and women age 40-74 who are recently diagnosed, through colonoscopy, with different stages of colorectal cancer and have not yet had surgical intervention.
11082987|NCT04194879||Negative|Approximately 250 prospectively enrolled subjects will be men and women age 40-74 who are at average risk of developing colorectal cancer and eligible for colonoscopy. About 150 Control subjects will be enrolled prospectively, who have no colorectal neoplasia detected on colonoscopy, including cancer, advanced adenoma, sessile serrated lesions and small, non-advanced adenoma.
11082988|NCT04194866|Other|Day group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group ( 8:00-12:00)
11082989|NCT04194866|Other|Night group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
11082990|NCT04194853|Experimental|EMG Biofeedback assisted Quadriceps exercises.|Hot Pack will be applied before session for general relaxation for 10 minutes. Knee isometric exercises will be performed via an EMG Biofeedback device; patients in the EMG BF group will receive visual and auditory feedback.Knee isometrics will be performed with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets) Session will be performed thrice a week for six weeks.
11082991|NCT04194853|Active Comparator|Quadriceps exercises without EMG Biofeedback|Hot Pack will be applied before session for general relaxation 10 minutes. In the control group, the active electrode will not be connected, so subjects will not receive any feedback from the device. Knee isometrics perform with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets)Session will be performed thrice a week for six weeks.
11082992|NCT04194840|Experimental|Transplant Wellness Clinic|"Physical therapy consult
~Intake vitals
~CARG online survey, mental status exam
~Medication review
~Nutrition survey
~Social work: available on prn basis (as-needed)
~Exit survey
~Recommendations made and given to the participant and sent to the referring MD. Participant receives post clinic phone call before transplant. Referring MD receives questionnaires. Data collected depending on if participant moved forward with transplant"
11082993|NCT04194827|Experimental|Concentration guided dose reducion|Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
11082994|NCT04194827|Active Comparator|Disease activity quided dose reduction|Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
11082995|NCT04194814|Other|crisaborole and topical Corticosteroid|"crisaborole (2%) ointment on the other forearm, twice daily application for 4 weeks (randomised site allocation)
~betamethasone valerate (0.1%) cream on one forearm, twice daily application for 4 weeks (randomised site allocation)"
11082996|NCT04194801|Experimental|Fisogatinib in combination with CS1001|
11082997|NCT04194775|Experimental|CS1003|
11082998|NCT04194775|Placebo Comparator|CS1003 placebo|
11082999|NCT04194762|Experimental|treadmill training|Three training sessions per week for two months of treadmill. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
11083757|NCT04189276|Active Comparator|Group4|Peg-IFNα-2b+ETV/TDF
11083000|NCT04194762|Active Comparator|Cycling|Three training sessions per week for two months of cycling. The intensity of exercise is monitored through the heart rate (HR). Patients ought to maintain a HR between 40 and 50% of the reserve HR
11083001|NCT04194749|Experimental|Digital Media Therapy|The digital media based group will receive a modified post immobilization protocol. This will include giving the patients a Universal Serial Bus (USB) drive loaded with a 12 week physical therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health & Science University website.
11083002|NCT04194749|Active Comparator|Traditional Therapy|The traditional group will have clinic-based physical therapy protocol.
11083003|NCT04194736||Children|Minor patients hospitalized in pediatric intensive care unit having a percutaneous central venous catheter.
11083004|NCT04194723|Experimental|Antireflux Mucosectomy|Antireflux mucosectomy targeted at resection of gastric cardia muocsa to induce fibrosis and improve on the flap value over the gastroesophageal junction
11083005|NCT04194710|Active Comparator|Arthroscopic Resection|43 patients will be assigned to this arm. This is the standard technique to treat lateral epicondylitis. After randomization, patients will be informed and the surgery will be scheduled.
11083006|NCT04194710|Experimental|Cytokine rich serum injection|43 patients will be assigned to this arm. After randomization, patients will be informed and the first injection of serum rich cytokines will be scheduled. After 15 days, they will be injected again with serum rich cytokines.
11083007|NCT04194697|Experimental|Exercise group|Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.
11083008|NCT04194697|Other|Non-exercise group|Participants will not change the amount of activity or exercise in daily life from before the study.
11083009|NCT04194684|Experimental|Assigned Interventions|Nab-paclitaxel
11083010|NCT04194671|Experimental|Mesenchymal stem cells cohort|
11083011|NCT04194671|Placebo Comparator|Saline cohort|
11083012|NCT04194658|Active Comparator|Case group|Case group will receive pretreatment letrozole 12.5 mg for 2 days before administration of misoprostol in a dosage according to ACOG guidelines based on gestational age.
11083013|NCT04194658|No Intervention|Control group|Control group will receive only misoprostol in a dosage according to ACOG guidelines based on gestational age.
11083014|NCT04194645|Experimental|BI 474121|
11083015|NCT04194645|Placebo Comparator|Placebo|
11083016|NCT04194632|Experimental|Single Arm|All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.
11083017|NCT04194606|Active Comparator|Forearm radial access|Patients who undergo coronary angiography or intervention by forearm radial artery access
11083018|NCT04194606|Experimental|Distal radial access|Patients who undergo coronary angiography or intervention by accessing the distal radial artery in the area of the anatomical snuff-box
11083019|NCT04194593||Glioma|FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)
11083020|NCT04194580|Experimental|Physical activity|In the program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors
11083021|NCT04194580|No Intervention|Physical activity control|This group will not participate in the intervention
11083022|NCT04194567|Experimental|Black Ragi|During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
11083023|NCT04194567|Experimental|White Ragi|During the second week of the study, participants are to consume pancakes made from the white variety of ragi
11083024|NCT04194554|Experimental|Niraparid Dose Escalation|"Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT
~Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT
~Dose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles."
11083025|NCT04194541|Experimental|Treatment Group|Participants will be provided a kit containing 3 dressings: Cutimed Sorbact Hydroactive B, Cutimed Siltec, and Sorbion Sana multi-star. Participant can use their dressing of choice and can change their dressings as needed for 6 consecutive weeks.
11083026|NCT04194528|Experimental|Oxycodone/acetaminophen (5/325 mg) DMP|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
11083027|NCT04194515||YH1 group|
11083028|NCT04194515||Metformin group|
11083029|NCT04194502|Other|Pre-operative and intra-operative TEE|All patients enrolled in the study will undergo a pre-op research TEE and a intra-op clinical transesophageal echo.
11083030|NCT04194489|Experimental|FMF Connect Intervention|
11083031|NCT04194463|Experimental|ChemoFit exercise prehabilitation intervention|Exercise intervention consisting of walking and increasing daily step count. This is monitored by wearing a pedometer device. Other part of intervention are 5 simple strengthening exercises.
11083032|NCT04194450|Experimental|Ketone monoester|Acute dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.3 ml/kg body weight)
11083033|NCT04194450|Placebo Comparator|Placebo|Acute dose of flavour-matched placebo.
11083034|NCT04194437|Experimental|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
11083035|NCT04194424|Experimental|Multidisciplinary program|Multidisciplinary weight loss program
11083036|NCT04194424|Other|Control|Standard care
11083037|NCT04194411||Valve surgery|Patients older than 65 years and undergoing elective valvular heart surgery
11083038|NCT04194398||OCS Expand Trial Cohort|All patients previously enrolled in the EXPAND Lung trial.
11083039|NCT04194385|Active Comparator|Upper trunk block|In the supraclavicular region, UTB will be applied with 20 ml 0.25% bupivacaine.
11083040|NCT04194385|Active Comparator|Costoclavicular brachial plexus block|In the infraclavicular region, CCBPB will be applied with 20 ml 0.25% bupivacaine.
11136330|NCT03821688|Active Comparator|MGB|laparoscopic mini gastric bypass
11083044|NCT04194346|Experimental|Determination of local pleural strain|The average Von Mises coefficient will be calculated for each recorded ultrasound loop using a non-invasive vascular elastography platform.
11083045|NCT04194333||Standard Fluoroscopy Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and standard fluoroscopy using the C-arm under general anesthesia.
11083046|NCT04194333||Cone Beam CT Guided EMN|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
11083047|NCT04194320|Placebo Comparator|"Group I Placebo"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 ml 0.9% normal saline.
11083048|NCT04194320|Active Comparator|"Group II Nalbuphine "|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 10 mg nalbuphine hydrochloride (completed to 2 ml with 0.9% normal saline).
11083049|NCT04194320|Active Comparator|"Group III Dexamethasone"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 mL dexamethasone 0.4% (8 mg).
11083050|NCT04194294|Active Comparator|Liocaine|Group Lid
11083051|NCT04194294|Active Comparator|Na CL 0.9%|group C
11083052|NCT04194281|Experimental|Action Observation Therapy [AOT]|
11083053|NCT04194268|Experimental|Interventional arm|Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks
11083054|NCT04194255|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
11083055|NCT04194255|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
11083056|NCT04194255|Experimental|ferrous fumarate + 15 g FOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g FOS
11083057|NCT04194255|Experimental|ferrous fumarate + 15 g acacia gum|labelled iron as ferrous fumarate + prebiotics in the form of 15 g acacia gum
11083058|NCT04194242|Experimental|HEC96719 tablets|Including 7 dose groups(0.1-、0.2、0.5-、1-、2-、3-、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240 mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
11083059|NCT04194242|Placebo Comparator|placebo tablets|Including 7 dose groups(0.1-、0.2、0.5-、1-、2-、3-、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
11083060|NCT04194229||Group 1|Patients that receive Cytoflavin® medication i/v drop infusion at a dose of 10 ml of solution for injection per 200 ml of 0.9 % sodium chloride solution for 10 days in addition to a set of neurorehabilitation activities
11083061|NCT04194229||Group 2|Patients that subjected to the standard set of neurorehabilitation activities for 10 days without being prescribed Cytoflavin® medication
11083062|NCT04194216|Active Comparator|Treatment arm A|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."
11083063|NCT04194216|Active Comparator|Treatment arm B|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg every 4 hours or clindamycin 150mg every 6 hours, for a duration of three days."
11083064|NCT04194203|Experimental|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
11083065|NCT04194203|Placebo Comparator|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
11083066|NCT04194177|Experimental|protective|
11083067|NCT04194177|Active Comparator|conventional|
11083068|NCT04194164|Experimental|Fluid intake app|Participants in this arm will use the fluid intake app to help them decrease interdialytic fluid intake. Participants will take a survey to assess the efficacy of the fluid app..
11083069|NCT04194151|Active Comparator|2 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol
11083070|NCT04194151|Active Comparator|2 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol
11083071|NCT04194151|Active Comparator|2 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol
11083072|NCT04194151|Active Comparator|1 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol
11083073|NCT04194151|Active Comparator|1 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol
11083074|NCT04194151|Active Comparator|1 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol
11083105|NCT04193878|Active Comparator|Intervention|aerosolized formoterol (20 mcg/2 ml) and budesonide (1.0 mg/2 ml) every 12 hours x 10 doses
11083149|NCT04193592|Experimental|Oral Pirfenidone 2403 mg per day|Enrolled subjects will receive oral pirfenidone 801 mg taken three times a day. Pirfenidone will be supplied in 267 mg capsules.
11083948|NCT04188002|Other|Control - Fruit and Vegetable|Participants in this arm will receive usual care.
11083075|NCT04194138||Operative|"A. Multicenter, prospective, nonrandomized analysis of operatively treated complex ASD patients B. Inclusion Criteria
~18 years of age or greater at the time of treatment
~Diagnosis of adult congenital, degenerative, idiopathic or iatrogenic spinal deformity
~Full body EOS radiographic assessment (sagittal and coronal visualization from skull to foot)
~Complex patients are defined as and meeting any one of the subsequent criteria:
~a. Radiographic criteria: i. PI-LL ≥ 25 degrees ii. TPA ≥ 30 degrees iii. SVA>15cm iv. Thoracic scoliosis ≥ 70 degrees v. Thoracolumbar/lumbar scoliosis ≥ 50 degrees vi. Global coronal malalignment >7cm b. Procedural criteria: i. Posterior spinal fusion > 12 levels ii. 3 column osteotomy or ACR c. Geriatric criteria: i. Age >65 years and minimum 7 levels of spinal instrumentation during surgery"
11083076|NCT04194125|Experimental|177Lu-DOTATOC combined with CAPTEM|"The therapy will include 4 courses (14 days per one) with 8-week intervals;
~177Lu-DOTATOC in doses from 5,55GBq up to 7,4 GBq will be administered i.v. up to four times at 10th day;
~Concomitant amino acids will be given with each administration;
~Capecitabine will be administrated for 14 days (twice a day) followed by Temozolomide at 10-14th days in each therapy sessions."
11083077|NCT04194112|Other|NMIBC patients|Patients with primary or recurrent NMIBC for whom complete TURBT was done.
11083078|NCT04194099|Experimental|20 Hz rTMS (Brain) + Anode tsDCS (Spinal)|"Brain:
~Train pulse: 2 sec
~Inter-train: 28 sec
~Total time: 1200 sec
~Spinal:
~Continuous direct current (DC): 1200 sec"
11083079|NCT04194099|Experimental|20 Hz rTMS (Brain) + 20 Hz current square-wave pulses (Spinal)|"Brain and spinal:
~Train pulse: 2 sec
~Inter-train: 28 sec
~Total time: 1200 sec"
11083080|NCT04194099|Experimental|iTBS rTMS (Brain) + Anode tsDCS (Spinal)|"Brain:
~Train pulse: 2 sec
~Inter-train: 8 sec
~Total time: 190 sec
~Spinal:
~Continuous direct current (DC): 190 sec"
11083081|NCT04194099|Experimental|iTBS rTMS (Brain) + iTBS (Spinal)|"Brain and spinal:
~Train pulse: 2 sec
~Inter-train: 8 sec
~Total time: 190 sec"
11083082|NCT04194099|Sham Comparator|sham (no stimulation on brain nor spinal)|Sham stimulation.
11083083|NCT04194086|Experimental|posaconazole as antifungal prophylaxis|
11083084|NCT04194073|Experimental|Pulse oximeter calibration population|All subjects within this single arm of the study will undergo the calibration experiment as described in the Detailed Description
11083085|NCT04194060|Experimental|Enhanced recovery after surgery group|"ERAS GROUP
~Tracheal intubation.
~Short acting anesthetic agents,avoid opioid agents
~Omental patch repair with placement of sub hepatic drain
~Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.
~Post operative nausea and vomiting prophylaxis.
~Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
~Initiation of feeding-Oral sips on day 1, step up day 2 onward
~Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.
~Removal of urinary catheter-after weaning from the effect of general anesthesia.
~Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
~Avoid opiod analgesics."
11083086|NCT04194060|Active Comparator|Conventional group|"CONVENTIONAL GROUP
~Tracheal intubation
~Short acting anesthetic agents, avoid opiod anesthesia agents.
~Omental patch repair along with sub hepatic drain placement.
~Post operative nausea and vomiting prophylaxis.
~Ambulation-as per patients' own request.
~Initiation of oral feed- after passage of 1st flatus.
~Nasogastric tube removal-output <300ml/day with resolution of ileus.
~Removal of urinary catheter- when patient sits on bed side/ambulate.
~Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.
~Patient will receive opiod analgesics.
~I"
11083087|NCT04194047||RBC group|Patients who received RBC transfusion
11083088|NCT04194047||crystalloids group|Patients who received fluid resuscitation with crystalloids
11083089|NCT04194034|Experimental|TG6002 and flucytosine (5-FC) combination|
11083090|NCT04194008|Experimental|Nerivio device treatment|Treatment with active Nerivio device
11083091|NCT04193995|Experimental|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
11083092|NCT04193982|Experimental|Saraglitazar|Patients will receive Saraglitazar 4 mg once daily for 6 months
11083093|NCT04193982|Experimental|Vitamin E|Patients will receive Vitamin E 400mg twice daily for 6 months
11083094|NCT04193982|Experimental|Combination|Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months
11083095|NCT04193982|Active Comparator|Lifestyle|Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months
11083096|NCT04193969|Experimental|Radiculopathy due to nerve root compression|"Participants with radicular leg pain due to lumbar disc herniation or to foraminal- or recess stenosis.
~Baseline assessments of pain intensities are performed through questionnaires prior to protocol. Data regarding initial pain, function, age, gender, pain-duration, weight and height is retrieved from the clinical registry SpineData.
~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit in the treatment program. The protocol is repeated at the last visit in the treatment program."
11083097|NCT04193969|Experimental|Healthy controls|"Healthy controls Healthy age and gender-matched controls. Gender, weight and height are registered on questionnaires prior to protocol.
~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit. The tests are repeated at the next visit. The interval between the two sessions will be determined by the averaged interval between tests in the patient group."
11083098|NCT04193956||POINTING|
11083099|NCT04193930|Other|Soft ovarian stimulation protocol|
11083100|NCT04193930|Other|conventional ovarian stimulation protocol|
11083101|NCT04193904|Experimental|MRx0518 with hypofractionated preoperative radiation|Subjects will take one capsule of MRx0518 twice daily from one week prior to radiation therapy until surgical resection (6 to 9 weeks approx.) Radiation therapy will be delivered as 30Gy/10 fractions over 2 weeks.
11083102|NCT04193891||Diet Group|Participants choosing to newly initiate the modified Atkins diet, a high fat low carb diet, for improved epilepsy control.
11083103|NCT04193891||Control Group|Participants not choosing to initiate dietary therapy for epilepsy. The participants in the control group will continue with the treatment regimen they have chosen together with their physician.
11083106|NCT04193865||Extracorporeal Life Support with Renal Replacement Therapy|"This cohort will include all subjects receiving extracorporeal life support with concurrent continuous renal replacement therapy.
~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each participants's CRRT course."
11083107|NCT04193865||Renal Replacement Therapy|"This cohort will include all subjects receiving continuous renal replacement therapy (no extracorporeal life support).
~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each patient's CRRT course."
11083108|NCT04193852|Experimental|Dienogest and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
11083109|NCT04193852|Active Comparator|Dienogest and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
11083110|NCT04193839||Paper Order Entry cohort|Patients admitted to the NICU during the pre-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the pre-intervention period will be handled with the paper order entry
11083111|NCT04193839||CPOE + BCMA cohort|Patients admitted to the NICU during the post-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the post-intervention period will be handled with the Computerized Provider Order Entry + Bar Code Medication Administration (BCMA)
11083112|NCT04193826|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the Conformal LAAC device will be performed according to the device Instructions for Use, based on ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
11083113|NCT04193813||POAF|
11083114|NCT04193813||Non POAF|
11083115|NCT04193800||Rotational paramedic pilot group|
11083116|NCT04193800||Paramedic control group|
11083117|NCT04193787|Experimental|EPIC-P|Participants will enroll in a bio-behavioral intervention aimed at preventing HIV transmission in people who inject drugs.
11083118|NCT04193774|Placebo Comparator|Drop of artificial tears|
11083119|NCT04193774|Active Comparator|Drop op anesthetic|
11083120|NCT04193761|Active Comparator|Control|
11083121|NCT04193761|Active Comparator|Chronic hepatitis|
11083122|NCT04193761|Active Comparator|Cirrhosis|
11083123|NCT04193761|Active Comparator|Hepatocellular carcinoma|
11083124|NCT04193748|Active Comparator|Control group|Topical triamcinolone acetonide 0.1% available commercially (Kenacort- in orabase) has been used. Topical corticosteroid treatment has be repeated four times per day for four weeks.
11083125|NCT04193748|Experimental|Group S|Topical pomegranate seeds extract treatment has been repeated four times per day for four weeks.
11083126|NCT04193748|Experimental|Group P|Topical pomegranate peel extract treatment has been repeated four times per day for four weeks.
11083127|NCT04193735||CIPO (case)|MRI scan of gastrointestinal content and activity
11083128|NCT04193735||Chronic constipation (control)|MRI scan of gastrointestinal content and activity
11083129|NCT04193722|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
11083130|NCT04193722|No Intervention|Usual care|Usual care may consist of physiotherapy, analgetics, edema therapy
11083131|NCT04193709|No Intervention|Measure symptomatic indices of autonomic dysreflexia|The purpose of this arm is to systematically measure symptomatic indices of autonomic nervous system activation and corresponding cardiovascular changes in persons with spinal cord injuries during bladder filling and bowel stimulation.
11083132|NCT04193709|Experimental|Cardiovascular spinal cord epidural stimulation|The purpose of this arm is to use spinal cord epidural stimulation for maintenance of blood pressure and heart rate in the lab during cystometry (bladder filling) and anorectal filling (bowel distension) and in the at-home setting for maintenance of normative blood pressure and heart rate that can be triggered from bladder filling and during bowel evacuation.
11083133|NCT04193696|Experimental|radiotherapy plus PD-1|
11083134|NCT04193683|Sham Comparator|Sham-Ultrasound|Intervention will include one session sham-ultrasound application to both lower extremities of participant. The total time will be 15 minutes.
11083135|NCT04193683|Experimental|Myofascial Release Technique+Sham-Ultrasound|In addition to one session sham-ultrasound, the intervention will include one session myofascial release technique to both lower extremities of participant. The total time will be 30 minutes.
11083136|NCT04193670|Experimental|Atopic dermatitis classical form|15 patients
11083137|NCT04193670|Experimental|Atopic dermatitis with atopic prurigo type|10 patients
11083138|NCT04193657||Chemotherapy|30 participants starting chemotherapy
11083139|NCT04193657||Abiraterone|20 participants starting Abiraterone
11083140|NCT04193657||Enzalutamide|20 participants starting Enzalutamide
11083141|NCT04193657||Radium-223|20 participants starting Radium-223
11083142|NCT04193644|Active Comparator|Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax).
11083143|NCT04193644|Experimental|Mindfulness and Self-Compassion focussed Walking-Group|Participants in this group walk 45 minutes 3 times a week (plus 15 minutes of warm up and cool-down) in a moderate intensity range (64-76% HRmax) and additionally practice mindfulness exercises and self-compassion exercises during the 60 minutes.
11083144|NCT04193644|No Intervention|TAU-Group|Participants in this group receive no intervention.
11083145|NCT04193631|Experimental|Pure Green Tablet|A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
11083146|NCT04193618|Experimental|Conservative surgery for placenta accretta|
11083147|NCT04193605|Active Comparator|Mindfulness Based Stress Reduction|MBSR sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
11083148|NCT04193605|No Intervention|Standard of Care|The control condition will continue receiving usual care or standard of care.
11083150|NCT04193579|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
11083151|NCT04193579|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
11083152|NCT04193566|Active Comparator|Dapagliflozin|"Patients in the active arm will be treated with dapagliflozin 50 mg once on site for visit 2 and once at home on the evening before visit 3.
~Forxiga®, dapagliflozin 10 mg film-coated tablet.
~For further information please refer to:
~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf."
11083153|NCT04193566|Placebo Comparator|Placebo|"Patients in the placebo arm will be treated with placebo once on site for visit 2 and once at home on the evening before visit 3.
~Placebo drug:
~The composition equals the composition of Forxiga® - just with the active ingredient omitted. Active drug and placebo are similar in appearance and smell."
11083154|NCT04193553|Experimental|Lenvatinib + Best Supportive Care|
11083155|NCT04193553|Placebo Comparator|Placebo + Best Supportive Care|
11083156|NCT04193540||ACE questionnaire|Every patient under mechanical ventilation (intubated or tracheotomized), with or without sedatives, able to communicate and alert (RASS -1 to +1), and not delirious (CAM-ICU negative) will be assessed by Johns Hopkins ACE questionnaire by a person not in charge of the patient.
11083157|NCT04193527|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ (123I) ioflupane. Single photon emission computed tomography (SPECT) imaging will be performed between 3 to 6 hours post-injection and will last approximately 20 minutes to 1 hour.
11083158|NCT04193514|Experimental|Acceptance and Commitment Therapy|
11083159|NCT04193514|No Intervention|Treatment as Usual|
11083160|NCT04193501|Experimental|Experimental arms|Melatonin dose: 3mg/OD
11083161|NCT04193501|Placebo Comparator|Control arms|Placebo
11083162|NCT04193488|Active Comparator|MTP block (Group MTP)|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasaggital scan, the block needle (50 mm 22 Gauge will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
11083163|NCT04193488|Active Comparator|ESP block (Group ESP)|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
11083164|NCT04193488|Active Comparator|no block (Group C)|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
11083165|NCT04193475||Chest pain|Individuals presenting with chest pain requiring a stress echocardiogram.
11083166|NCT04193462|Experimental|Post-partum depression- Dyadic psychotherapy|Mothers and infants will be treated with 8 weeks dyadic psychotherapy at their home using video-feedback of mother-infant interaction to discuss main issues in the mother-infant relationship.
11083167|NCT04193462|Active Comparator|Post-partum depression- Psycho-educational therapy|8 weeks of supportive therapy for the mother at her house, involving the baby. Each session will include different aspects of psycho-education regarding development of the baby.
11083168|NCT04193462|No Intervention|Control- Healthy mothers and their babies|No intervention for 8 weeks.
11083169|NCT04193449||Adult patients undergoing colonoscopy|All patients' ≥18 years of age who underwent endoscopy at Portsmouth Hospitals NHS Trust, including repeat colonoscopies performed for surveillance purposes aged ≥18 in either males or females.
11083170|NCT04193436|Experimental|PF-06835919 with severe hepatic impairement|This arm includes participants with severe hepatic impairment who will receive a 25mg oral dose of PF-06835919
11083171|NCT04193436|Experimental|PF-06835919 with moderate hepatic impairement|This arm includes participants with moderate hepatic impairment who will receive a 25mg oral dose of PF-06835919
11083172|NCT04193436|Experimental|PF-06835919 with mild hepatic impairement|This arm includes participants with mild hepatic impairment who will receive a 25mg oral dose of PF-06835919
11083173|NCT04193436|Experimental|PF-06835919 without hepatic impairment|This arm includes participants without hepatic impairment who will receive a 25mg oral dose of PF-06835919
11083174|NCT04193423|Experimental|A-Group: craniocervical and cervicothoracic extension training|
11083175|NCT04193423|Experimental|B-Group: craniocervical flexion training|
11083176|NCT04193423|Active Comparator|C-Group: control group|No intervention will be performed due to the fact that they will be still on the waiting list.
11083177|NCT04193397|Other|Physical exercise|To study the effects of a concurrent training program on physical-functional fitness, physical activity level, endothelial function, blood pressure, biochemical markers of cardiovascular risk and bone metabolism, bone density and microstructure and quality of life indicators of post-bariatric patients (Study 1). To compare bone and muscle changes in post-bariatric patients with non-bariatric controls, as well as to correlate these health indicators with the time of surgical procedure and weight loss (Study 2)
11083178|NCT04193384||Group 1≤ (G1≤)|Group 1≤ (G1≤) - patients that performed bariatric surgery for ≤ 1 year
11083179|NCT04193384||Group 1> (G1>)|Group 1> (G1>) - patients that performed bariatric surgery for > 1 year
11083180|NCT04193371|Experimental|active acupuncture + lifestyle management|Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
11083983|NCT04187768||Healthy Group|Healthy volunteers will donate a sample of blood to be used as controls
11083181|NCT04193371|Sham Comparator|control acupuncture + lifestyle management|Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
11083182|NCT04193358|Experimental|FERTILIS HOMME® group (group A)|Group A will receive 2 FERTILIS HOMME capsules twice daily to be taken with meals for 3 months.
11083183|NCT04193358|Placebo Comparator|Placebo group (group B)|Group B will receive 2 placebo capsules twice daily to be taken with meals for 3 months
11083184|NCT04193345||Early cord clamping|The umbilical cord will be clamped within 15 seconds from delivery of the baby
11083185|NCT04193345||Delayed cord clamping|The umbilical cord will be clamped after 60 seconds from delivery of the baby
11083186|NCT04193332|Experimental|Plus NIR optical imaging|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery
11083187|NCT04193332|No Intervention|Minus NIR optical imaging|Conventional identification of parathyroid glands during thyroid surgery
11083188|NCT04193319|Other|Single arm|
11083189|NCT04193306|Experimental|Alirocumab|alirocumab 150 mg s.c. every 2 weeks, for 48 weeks
11083190|NCT04193306|Placebo Comparator|Placebo|placebo s.c. every 2 weeks, for 48 weeks
11083191|NCT04193293|Experimental|Duvelisib BID + Pembrolizumab q3w|"Stage 1: Duvelisib BID for 1 week followed by combination therapy with duvelisib BID + pembrolizumab q3w. (Cycle 1 will be 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib. Subsequent cycles will be 3 weeks .)
~Stage 2: Duvelisib BID + pembrolizumab q3w in 3 week cycles."
11083192|NCT04193267|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
11083193|NCT04193241|Active Comparator|Conventional purse-string suture closure|A common-place conventional method of closure of chest tube or thoracostomy wound using a Prolene 1 purse-string suture (also known as U-suturing), at the time of chest tube removal.
11083194|NCT04193241|Experimental|Suture-less occlusive-absorbent dressing closure|Unconventional method of closing chest tube or thoracostomy wounds using Occlusive adhesive-absorbent dressing material (Primapore*) application i.e. Un-reapproximated wound edges, at time of chest tube removal
11083195|NCT04193228||People with distal hereditary motor neuropathy|This is a single arm, feasibility study
11083196|NCT04193215|Experimental|V114|Participants will receive an intramuscular (IM) injection.
11083197|NCT04193215|Other|Control|
11083198|NCT04193202|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
11083199|NCT04193202|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
11083200|NCT04193189|Experimental|Group A, Arm 1: HEPLISAV-B (two injections)|Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
11083201|NCT04193189|Experimental|Group A, Arm 2: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
11083202|NCT04193189|Experimental|Group A, Arm 3: ENGERIX-B (three injections)|Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
11083203|NCT04193189|Experimental|Group B: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
11083204|NCT04193176|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
11083205|NCT04193176|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
11083206|NCT04193163||Patients receiving ESOP 2 stem|
11083207|NCT04193150||Reassessment Cohort|"150 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.
~Intervention includes:
~Extensive pulmonary and allergy assessments. Questionnaires, FeNO-measurement, Skin prick-test, Spirometry, Blood sampling, Body Plethysmography and Diffusion capacity measurement, Bronchial challenge test, Induced sputum.
~Treatment optimization As per GINA and Nordic Severe Asthma Network guidelines. Treatment can either be stepped up (e.g. added biological treatment), stepped down or held constant.
~Treatment is then monitored with regard to symptoms and socioeconomical parameteres such as sick leave over a 12 month period using questionnaires and official databases."
11083208|NCT04193150||Control Cohort|"400 invited participants in active treatment with high-dose inhaled corticosteroids plus second controller as per NICE guidelines, without active treatment from a pulmonologist.
~The control cohort is followed for 12 months using questionnaires and official databases with regard to disease control and socioeconomic parameteres such as sick leave."
11083209|NCT04193137||Primary Aldosteronism(PA)|plasma aldosterone /renin ratio (ARR)>10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC>200 pg/ml，plasma renin concentration(PRC)<2.5μIU/ml，with hypokalemia
11083210|NCT04193137||non Primary Aldosteronism|ARR<10 pg/μIU or ARR>10 pg/μIU and PAC post FST<60pg/ml
11083211|NCT04193124||Prolonged vasospasm|Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Prolonged vasospasm was defined for patients who persisted with vasospasm after day 21 of cerebral bleeding.
11083212|NCT04193111||Positive TMD pain screener|Patients who have ≥3 points on the TMD pain screener (0-7 range) are anticipated to have a painful TMD based on the DC/TMD and are therefore considered having a positive outcome on the TMD pain screener.
11083213|NCT04193111||Negative TMD pain screener|Patients who have <3 points on the TMD pain screener (0-7 range) are anticipated NOT to have a painful TMD based on the DC/TMD and are therefore considered having a negative outcome on the TMD pain screener.
11083214|NCT04193098|Experimental|Arm: CTL plus PD-1 inhibitor|CTL , Toripalimab Toripalimab intravenous infusion 240mg d1; CTL, 1x10^9, intravenous infusion,d14; Q3W.
11083215|NCT04193085||Spinal Muscular Atrophy (SMA)|ambulatory children and adults at least 5 years old by the time of enrollment with genetically confirmed SMA
11084198|NCT04186286|Active Comparator|2nd drug Ivabradine|Patients will take either Propranolol or placebo first and then Ivabradine
11083216|NCT04193085||Duchenne / Becker Muscular Dystrophy (DMD/BMD)|ambulatory children and adults ages at least 5 years old by the time of enrollment with genetically confirmed Duchenne or Becker muscular dystrophy or evidence on muscle biopsy with a clinical presentation consistent with DMD /BMD.
11083217|NCT04193085||Healthy Control|The healthy control group will be age and gender-matched to the SMA and DMD groups as best as possible
11083218|NCT04193072||Obstetric brachial plexus palsy|
11083219|NCT04193072||Healthy|
11083220|NCT04193059|Active Comparator|PANSY-1: EC-T|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+ cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of T (docetaxel 100 mg/m^2 ivgtt d1, 21 days per cycle)
11083221|NCT04193059|Experimental|PANSY-1: PCb|6 cycles of weekly PCb (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15+ carboplatin Area Under Curve (AUC)=2 ivgtt d1, d8, d15, 28 days per cycle)
11083222|NCT04193059|Active Comparator|PANSY-2: EC-TH(P)|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of TH(P) (docetaxel 100 mg/m^2 ivgtt d1 + trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). After 8 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
11083223|NCT04193059|Experimental|PANSY-2: PCbH(P)|6 cycles of weekly PCbH(P) (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15 + carboplatin AUC=2 ivgtt d1, d8, d15 + trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). Participants may also choose to receive trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy. After 6 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
11083224|NCT04193046|Other|Participants with PH and non-PH|Blood samples will be collected for biomarker analysis from new (incident) and existing (prevalent) participants who undergo right heart catheterization (RHC). Participants will be categorized into non-PH or PH based on the results of the RHC and those who are found to have PH will be further classified into the different groups of PH. A transthoracic echocardiography (TTE) will be performed if not done previously.
11083225|NCT04193033|Experimental|FLOW intervention|Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
11083226|NCT04193033|No Intervention|Waitlist until Time 2|Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
11083227|NCT04193033|No Intervention|Waitlist until Time 3|Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.
11083228|NCT04193020||steroid only group (SG)|
11083229|NCT04193020||combined (steroid and adjuvant drug) group (CG)|
11083230|NCT04193020||bilogic therapy group (BTG)|
11083231|NCT04193007|Experimental|molecular targeted therapy group|Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
11083232|NCT04193007|Experimental|Brain Radiotherapy and molecular targeted therapy group|Brain Radiotherapy (stereotactic radiotherapy was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain )was used for more than 3 intracranial lesions);Molecular targeted therapy(according to the results of gene detection, targeted drugs were selected, such as EGFR mutation using the first generation of EGFR-TKI,ALK or ROS1 mutation using the first generation of ALK inhibitors)
11083233|NCT04192994|Active Comparator|Group 1: Antibiotic injection|A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.
11083234|NCT04192994|Active Comparator|Group 2: Pars Plana Vitrectomy|Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.
11083235|NCT04192981|Experimental|Concurrent GDC-0084 with Radiation|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily, with a potential de-escalation cohort to 30mg, to determine MTD in combination with whole brain radiation therapy radiation therapy to 30Gy in 10 fractions. Once MTD is determined, 12 additional patients will be treated with GDC-0084 at MTD in combination with whole brain radiation therapy.
11083236|NCT04192968||Patients|Children implanted cochlear since 3 years in uni or bilateral and followed in the pediatric otolaryngology department of Necker-Enfants Malades Hospital.
11083237|NCT04192955|Active Comparator|Active|Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
11083238|NCT04192955|Placebo Comparator|Control|Lactose100-mg tablets to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.
11083239|NCT04192942|Experimental|intensive care management|Administration of childern with major burn in intensive care to improve out comes
11083240|NCT04192929|Placebo Comparator|High definition white light endoscopy|colonoscopy performed using high definition equipment
11083241|NCT04192929|Active Comparator|Chromoendoscopy|indigo carmine is sprayed on the colon mucosa during withdrawal phase
11083242|NCT04192929|Experimental|Narrow band imaging|Narrow band imaging is used during withdrawal phase
11083243|NCT04192916||MPN patients treated with DOACs|
11083305|NCT04192474|Other|Flexible cystoscopy|50% of the patients undergo flexible diagnostic cystoscopy; 50% of the patients undergo flexible cystoscopy intervention with endoscopic accessories.
11083244|NCT04192903|Experimental|Chidamide combined with Cisplatin|"Chidamide: 30mg,PO,biw one week before cycle 1 treatment
~Combined treatment period:
~Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off Patients whose efficacy was evaluated as Complete Response (CR) / Partial Response (PR) / Stable Disease (SD) after the end of the combined treatment period received maintenance treatment with chidamide combined with cisplatin reduction.
~Maintenance treatment period:
~Cisplatin 25mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off"
11083245|NCT04192890|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
11083246|NCT04192877||Experimental|30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits. If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead. The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest. The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI). Assessors will be blinded to their results. Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
11083247|NCT04192864|Experimental|Lingually based triangular flap|
11083248|NCT04192864|Active Comparator|Buccally based triangular flap|
11083249|NCT04192851|Experimental|Tent Pole Grafting Technique|"Bone graft [NanoBone® granulate 0,6 mm (24% Silica / 76% Hydroxylapatite)] is mixed with the patient blood and placed to cover the screws completely, the defect is overcorrected with particulate material in anticipation of future graft resorption.
~PRF membrane is prepared by:
~Ten milliliters of whole venous blood will be collected in sterile glass test tubes without anticoagulant. Then the test tubes will be placed in a table centrifuge machine at 3000 revolutions per minute (rpm) for 10 minutes.After separation of PRF, the membrane is prepared compression device."
11083250|NCT04192838|Experimental|LVHR|Laparoscopic incisional ventral hernia repair
11083251|NCT04192838|Active Comparator|OVHR|Open incisional ventral hernia repair
11083252|NCT04192812|Experimental|GnRHa|3,75 MG LEUPROLIDE ACETATE FOR EVERY 4 WEEKS THROUGHOUT 3 MONTHS BEFORE SURGERY
11083253|NCT04192812|Placebo Comparator|no GnRHa|NO TREATMENT
11083254|NCT04192799|Experimental|Direct Admission|Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
11083255|NCT04192799|Active Comparator|ED Admission|Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.
11083256|NCT04192786|Experimental|Treatment Group 50 Hz|
11083257|NCT04192786|Experimental|Treatment Group 100 Hz|
11083258|NCT04192786|Active Comparator|Control Group|
11083259|NCT04192773|Experimental|IV lidocaine|"1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects.
~The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia <50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study.
~Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion."
11083260|NCT04192760|Active Comparator|Culotte Technique|"Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first.
~The first stent is placed from main branch into the side branch side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed (to prevent metal-to-metal jail) and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure (e.g. 20 atm) individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Finally, a lower pressure kissing inflation is made."
11083261|NCT04192760|Active Comparator|DK-Crush Technique|Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed). After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by a second kissing balloon-dilatation and final proximal optimisation (POT) procedure (single balloon inflation in proximal segment).
11083262|NCT04192747|Experimental|Elixir Bioadaptor (ELX1805J)|The Elixir Bioadaptor (ELX1805J) 2.5-3.5 mm diameter and 14, 18, 23 and 28 mm in length
11083263|NCT04192747|Active Comparator|Medtronic Resolute Onyx Stent|The Medtronic Resolute Onyx Stent 2.5-3.5 mm diameter and 14, 15, 18, 22 and 30 mm in length
11083264|NCT04192721|Experimental|Cognitive Behavioral Therapy-Based Group Counseling|The CBT-based group counseling provided to the intervention group was carried out as a group intervention with structured sessions in which various techniques and methods of CBT, having mainly educational content, were applied, including an experiential interaction process. The counseling was performed in a total of six 60- to 90-minute sessions, comprising one session per week for four groups consisting of six to 10 members each.
11083265|NCT04192721|No Intervention|Control group|No counseling was given to the control group during the study.
11083266|NCT04192708|Experimental|DV-ICNB group|intercostal nerve block under direct vision
11083267|NCT04192708|Experimental|UG-ICNB group|intercostal nerve block under ultrasound guidance
11083268|NCT04192708|Experimental|PV group|thoracic paravertebral block under ultrasound guidance
11083306|NCT04192461|Experimental|tooth guided immediate implant placement group|
11083269|NCT04192695|Experimental|Cytosponge|"This part of the study will have an active prospective recruitment of patients. Recruitment will involve two patient populations:
~Patients with ESCC
~Patients at high risk for ESCC
~Following inclusion in the study, subjects will be asked to complete a behavior questionnaire, have blood collected, and undergo a Cytosponge™ procedure followed by diagnostic gastroscopy using advanced imaging with biopsies. During gastroscopy, additional tissue samples will be collected for research purposes. These samples, along with cytological specimens from the Cytosponge™, will be analyzed to assess the diagnostic accuracy of biomarkers in the diagnosis of LG-IEN, HG-IEN, and ESCC."
11083270|NCT04192682|Experimental|Anlotinib Combined With Sintilimab|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
11083271|NCT04192669||Anxio-depressive patients|Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
11083272|NCT04192656|Experimental|PAP plus medication|patients treated by both PAP and medication
11083273|NCT04192656|Active Comparator|medication|patients treated by medication only
11083274|NCT04192643|Experimental|TRANEXAMİC ACİD|. 1 gr tranexamic acid in 100 ml salin given in 15 minutes
11083275|NCT04192643|Placebo Comparator|NO TRANEXAMİC ACİD|100 ml salin solution
11083276|NCT04192617|Experimental|SM03 600 mg*2|SM03: 600 mg intravenous (IV) on week 0,2, and week 12,14; placebo: 600 mg intravenous (IV) on week 4 and16; Methotrexate: 7.5-20 mg/wk oral.
11083277|NCT04192617|Experimental|SM03 600 mg*3|SM03: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
11083278|NCT04192617|Placebo Comparator|placebo*3|placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16; Methotrexate: 7.5-20 mg/wk oral.
11083279|NCT04192591|Experimental|Superion® IDS device|Superion® Indirect Decompression System (IDS)
11083280|NCT04192578|Experimental|Unilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083281|NCT04192578|Experimental|Bilateral upper limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083282|NCT04192578|Experimental|Unilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083283|NCT04192578|Experimental|Bilateral upper limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral upper limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083284|NCT04192578|Experimental|Unilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083285|NCT04192578|Experimental|Bilateral lower limb 60mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083286|NCT04192578|Experimental|Unilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083287|NCT04192578|Experimental|Bilateral lower limb 200mmHg RIC|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral lower limb and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
11083288|NCT04192565|Experimental|Robotic Endoluminal Resection|Robotic resection of mucosal lesions of the colon and rectum
11083289|NCT04192552|Active Comparator|Apixaban|Patients currently taking apixaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
11083290|NCT04192552|Active Comparator|Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
11083291|NCT04192552|Active Comparator|Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require an elective high-bleed-risk surgery/neuraxial anesthesia.
11083292|NCT04192539|Active Comparator|Control|
11083293|NCT04192539|Active Comparator|Inflammation|
11083294|NCT04192539|Active Comparator|Benign group|
11083295|NCT04192539|Active Comparator|Malignant group|
11083296|NCT04192513|Active Comparator|Cohort 1 DBI-001 Gel and placebo|Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
11083297|NCT04192513|Active Comparator|Cohort 2 mid dose DBI-001 Gel and placebo|Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
11083298|NCT04192513|Active Comparator|Cohort 3 high dose DBI-001 Gel and placebo|Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum. Drug: J. lividum and placebo
11083299|NCT04192500|Experimental|OVX836 - 90µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 90µg dose on Day 1.
11083300|NCT04192500|Experimental|OVX836 - 180µg dose|Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 180µg dose on Day 1.
11083301|NCT04192500|Active Comparator|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020. One full dose to be administered at Day 1
11083302|NCT04192487|Experimental|Healthy Volunteers (HIV-negative)|Drug: crofelemer delayed-release tablets, 125 mg BID x 30 days
11083303|NCT04192487|Experimental|HIV+ Patients (Fully Suppressed, Viral Load < 50c/mL)|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
11083304|NCT04192487|Experimental|HIV+ Patients (Not fully suppressed viral load > 1000c/mL|Drug: crofelemer delayed-release tablets, 125mg BID x 30 Days
11083758|NCT04189263|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
11083307|NCT04192448|Experimental|AlcoholxAnger|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
11083308|NCT04192448|Experimental|AlcoholxControl|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
11083309|NCT04192448|Experimental|SoberxAnger|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
11083310|NCT04192448|Sham Comparator|SoberxControl|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
11083311|NCT04192435|Active Comparator|Tranexamic acid|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
11083312|NCT04192435|Placebo Comparator|Placebo|At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.
11083313|NCT04192409|Experimental|Intervention-Smartphone Application|Patients will install a smartphone application that custom-developed for the study and learn to use it with the help of researchers. The application will have the following functions: 1) providing health education information about glycemic control, postoperative management and important of drug compliance; 2) providing alert & record service on patients' DM and CAD medication treatment; 3) aiding patients to conduct self-evaluate by providing questionnaire about patients' recent basic health parameters on times. The information will be interpreted automatically by application and brief feedback will be provided to patients; 4) recording patients' fasting plasma glucose value that input by patients and generate a recent glycemic control report.
11083314|NCT04192409|No Intervention|Control|Patients will receive no additional intervention from researchers except the usual care provided by hospital.
11083315|NCT04192396||RIF patients|Repeated implantation failure patients
11083316|NCT04192396||Oocyte/embryo donation program|Patients awaiting for oocyte/embryo-donation recipient patients
11083317|NCT04192383||Cyberknife|
11083318|NCT04192370|Experimental|Cannabidiol|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.
11083319|NCT04192357|Experimental|M3F program|Participants will receive the M3F program. The M3F program is divided into three phases method, being the first two of weight loss and the third phase of weight maintenance.
11083320|NCT04192357|Active Comparator|Low-carb diet|Participants will receive the low-carb diet program. The low-carb diet program is divided into two phases method, being the first of weight loss which follows a low carb diet, and a second phase of weight maintenance.
11083321|NCT04192344|Experimental|ABSK021|"Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by3+3 escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles."
11083322|NCT04192331||2/3dose strategy|HER2 negative advanced breast cancer patient
11083323|NCT04192331||3/4dose strategy|HER2 negative advanced breast cancer patient
11083324|NCT04192318|Experimental|Hospital-based violence prevention with community initiative|Youth who are living in communities that receive Communities that Care Prevention System (CTC) will also receive Bridging the Gap (BTG), a hospital-based violence prevention program with 6-months of community case management.
11083325|NCT04192318|Experimental|Hybrid hospital based violence prevention|Youth who do not live in a community that has CTC but will receive BTG.
11083326|NCT04192318|Active Comparator|Treatment as usual|Youth living in a community without the CTC program and will receive treatment as usual (TAU) in the hospital.
11083327|NCT04192318|Experimental|Treatment as usual with community initiative|Youth living in a community with the CTC program and will receive treatment as usual (TAU) in the hospital.
11083328|NCT04192305||lung protective ventilation (LPV)|lung protective ventilation low tidal volume, minimum PEEP and higher PEEP and lung recruitment based on total lung compliance, low inspiratory oxygen concentration and CPAP during extubation without prior suctioning inside the endotracheal tube.
11083329|NCT04192305||routine lung ventilation (LV)|ventilation and adapting PEEP, LRM and oxygen only when saturation drops.
11083330|NCT04192292|No Intervention|No Treatment|No change to participants standard care
11083331|NCT04192292|Experimental|Low dose sulphonylurea alone|Participants will be given a single dose of low dose sulphonylurea once daily for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily.
11083332|NCT04192292|Experimental|DPP4 inhibitor alone|Participants will be given a single dose of DPP4 inhibitor once daily for 14 days as a physiological stimulus. The DPP inhibitor given in this study will be sitagliption 100mg orally once daily.
11083333|NCT04192292|Experimental|Low dose sulphonylurea + DPP4 inhibitor|Participants will be given a single dose of low dose sulphonylurea once daily and a single dose of DPP4 inhibitor for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily and the DPP4 inhibitor will be sitagliptin orally100mg once daily.
11083334|NCT04192279||lactate group|Lactate early guide resuscitation
11083335|NCT04192279||control group|early guide resuscitation without lactate
11083336|NCT04192266|Experimental|Prolonged Exposure (PE) therapy with estradiol|A 2.0 mg pill of estradiol (a form of estrogen) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD. A single dose of estradiol 2mg or placebo will be taken at home by the study participant 5-6 hours before each of 5 PE treatment sessions (sessions 2 to 6)
11083362|NCT04192084|Experimental|Traumatic amputations of the digits|we will perform microvascular partial toe transfer for patients with traumatic amputations of one or more digits
11083337|NCT04192266|Placebo Comparator|Prolonged Exposure (PE) therapy with placebo|A 2.0 mg placebo pill will be given with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). Prolonged Exposure (PE) therapy is a validated treatment for PTSD.
11083338|NCT04192253|Experimental|neo-adjuvant Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
11083339|NCT04192240|Experimental|Training with external feedback|Sit to Stand training with external feedback for 10 minute and then, stepping training with external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
11083340|NCT04192240|Active Comparator|Training without external feedback|Sit to Stand training without external feedback for 10 minute and then, stepping training without external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
11083341|NCT04192227|Experimental|Wellness Group 1|Administered by wellness facilitator and co-facilitator.
11083342|NCT04192227|Active Comparator|Wellness Group 2|Administered by wellness facilitator and co-facilitator.
11083343|NCT04192214|Active Comparator|BC 007|The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.
11083344|NCT04192214|No Intervention|Control|The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.
11083345|NCT04192188||Test Group|Patients undergoing supportive periodontal therapy and independently antiresorptive therapy.
11083346|NCT04192188||Control Group|Patients undergoing supportive periodontal therapy without the need for antiresorptive therapy.
11083347|NCT04192162|Experimental|Group of sulfur balneotherapy and mud pack therapy|Experimental group patients underwent sulfur balneotherapy and mud pack therapy. The duration of spa therapy program was 12 days.From the blood of patients, serotonin values, parameters of complete blood count, lipid status and inflammatory markers were analyzed before and after the therapy.
11083348|NCT04192162|Active Comparator|Group of sulfur balneotherapy, mud pack therapy and exercise|Control group of patients had mud pack therapy, sulfur balneotherapy and exercise in hygienic water. This group is a hydro group. From the blood of patients we analyzed parameters od complete blood count, serotonin values, lipid status and inflammatory markers before and after the therapy.
11083349|NCT04192149|Experimental|Patients receiving Craniotomy|Patients receiving an awake or asleep craniotomy for brain tumors and/or epilepsy will undergo a brain mapping procedure using electrical stimulation as a part of their normal care. The research procedures will duplicate this mapping with an invasive Focused Ultrasound mapping.
11083350|NCT04192149|Experimental|Epilepsy Patients|Patients undergoing long term monitoring for epilepsy will receive a non-invasive form of Focused Ultrasound stimulation which will be measured by their EEG cap and intracranial electrodes which are a part of their normal care.
11083351|NCT04192149|Experimental|Tremor Patients receiving FUS|Patients undergoing high intensity FUS treatment for tremor will be asked to wear a research provided EEG cap while undergoing a non-invasive low intensity Focused Ultrasound research procedure and changes in their tremor will be monitored.
11083352|NCT04192149|Experimental|Tremor Patients receiving DBS|Patients undergoing Deep Brain Stimulation (DBS) treatment for tremor will receive a non-invasive Focused Ultrasound stimulation observed through their newly implanted electrode.
11083353|NCT04192149|Experimental|Patients receiving Spinal Surgery|Patients receiving a spinal surgery will undergo a spinal stimulation using electrical stimulation as a part of their normal care. The research procedures will duplicate this with an invasive Focused Ultrasound stimulation.
11083354|NCT04192136|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).
~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.
~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.
~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
11083355|NCT04192136|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).
~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.
~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.
~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
11083356|NCT04192136|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.
~Participants in this arm will receive both the Exercise Intervention and the NR."
11083357|NCT04192136|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.
~Participants in this arm will receive both the Exercise Intervention and the Placebo."
11083358|NCT04192123|Experimental|Experimental|"All patients will receive an occlusive patch per test treatment as follows:
~Treatment 1: HM242-Solution
~Treatment 2: HM242-Gel
~Treatment 3: HM242-Solution and HM242-Gel
~Treatment 4: Irritant control (sodium lauryl sulfate (SLS))
~Treatment 5: Negative control"
11083359|NCT04192110|Experimental|Diuretic initiation or augmentation|Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
11083360|NCT04192097|No Intervention|Traditional teaching|No specific curriculum about professionalism
11083361|NCT04192097|Experimental|Professionalism curriculum|Traditionnal teaching + professionalism curriculum
11083524|NCT04190953|No Intervention|Control|Patients will wait 1,5 years before the start of treatment
11083363|NCT04192071|Active Comparator|high interactive virtual human administered nutrition module|The virtual health assistant will interactively collect nutrition information (alcohol, red meat, and processed meat intake) and report risk information back to users in visual and audio format
11083364|NCT04192071|Active Comparator|low interactive virtual human module|Complete the current intervention module that includes items assessing alcohol and meat intake.
11083365|NCT04192071|Sham Comparator|attention control module|The attention control group, will complete a related module not related to colorectal cancer or nutrition
11083366|NCT04192058|Sham Comparator|sham tDCS|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
11083367|NCT04192058|Experimental|active tDCS|The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively.
11083368|NCT04192032|Experimental|Preferred flavor (5% nicotine)|Preferred flavor Juul pod (5% nicotine)
11083369|NCT04192032|Active Comparator|Classic Tobacco Flavor|Control flavor (5% Classic Tobacco flavor Juul pod)
11083370|NCT04192032|Experimental|Preferred flavor with HWL|Preferred flavored Juul pod (5% nicotine) with HWL
11083371|NCT04192032|Experimental|Preferred flavor (3% nicotine)|Preferred flavored Juul pod (3% nicotine)
11083372|NCT04192032|Experimental|Preferred flavor (0% nicotine)|Preferred flavored Juul pod (0% nicotine)
11083373|NCT04192019|Experimental|Micro-dose glucagon|80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
11083374|NCT04192019|Experimental|Mini-dose glucagon|150 µg mini-dose of subcutaneous Dasiglucagon 5 min before exercise the start of exercise
11083375|NCT04192019|No Intervention|No treatment|No treatment before the start of exercise
11083376|NCT04192006|Active Comparator|Conventional|Jig-based procedure
11083377|NCT04192006|Experimental|Robotic arm-assist|Mako robotic-arm assist based procedure
11083378|NCT04191993|Experimental|Direct Superior Approach (DSA)|Direct superior incision during surgery
11083379|NCT04191993|Active Comparator|Posterior Approach (PA)|Posterior approach incision during surgery
11083380|NCT04191980||Patients with a MRI on a 3 Tesla (T) unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 3T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
11083381|NCT04191980||Patients with a MRI on a 1.5 Tesla unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 1.5T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
11083382|NCT04191967|Experimental|Thermocoagulation|Thermal ablation of cervix for treatment of CIN2/3 among HIV-positive women
11083383|NCT04191954|Active Comparator|Fasudil eye drops (concentration 0.5 percent)|twice daily
11083384|NCT04191954|Placebo Comparator|receive artificial tears drop with the same frequency|
11083385|NCT04191941|Experimental|Novel CAR-T|Novel CAR-T cells will be administered intravenously
11083386|NCT04191915||Frail|Participants with 3 or more components of Fried frailty scale
11083387|NCT04191915||Moderately Frail|Participants with 1-2 components of Fried frailty scale
11083388|NCT04191915||Not Frail|Participants without any components of Fried frailty scale
11083389|NCT04191902||1|control
11083390|NCT04191902||2|treated
11083391|NCT04191889|Experimental|TRIPLET|
11083392|NCT04191876|Experimental|Active|This study has only one arm. All patients enrolled will take part in the experimental arm.
11083393|NCT04191863||Children with enuresis|28 epileptic children with induced secondary nocturnal enuresis in valproate monotherapy.
11083394|NCT04191863||Children without enuresis|232 epileptic children without induced secondary nocturnal enuresis in valproate monotherapy.
11083395|NCT04191850|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
11083396|NCT04191850|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
11083397|NCT04191837|Experimental|Self-administered acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
11083398|NCT04191837|Active Comparator|Knee health education|A course regarding knee health will be offered to the subjects in this group.
11083399|NCT04191824|Active Comparator|Immediate Return of Results|Immediate return of results to inform participant of APOL1 status (either positive or negative).
11083400|NCT04191824|Active Comparator|Delayed Return of Results|Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.
11083401|NCT04191811||Depression Internet-delivered CBT|12 weeks of guided internet-delivered CBT for depression.
11083402|NCT04191811||Insomnia Internet-delivered CBT|12 weeks of guided internet-delivered CBT for insomnia.
11083403|NCT04191811||Health Anxiety Internet-delivered CBT|12 weeks of guided internet-delivered CBT for health anxiety.
11083404|NCT04191798|Experimental|KinexConnect|Rehab at Home Patients
11083405|NCT04191798|Active Comparator|Outpatient PT|In-person PT patients
11083406|NCT04191785|Experimental|plasmatic NGAL and MRI|
11083407|NCT04191772|Experimental|MS - training goal 1|Persons with Multiple Sclerosis (PwMS) with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
11083759|NCT04189263|Active Comparator|No dietary intervention|Standard of care aromatase inhibitors
11083408|NCT04191772|Experimental|HC - training goal 1|Healthy control (HC) persons with a 'poor VO2max', a 'fair VO2max' with no running experience and a 'good VO2max' with no running experience (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the first training group will be trained to run continuously for 45 minutes.
11083409|NCT04191772|Experimental|MS - training goal 2|PwMS with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
11083410|NCT04191772|Experimental|HC - training goal 2|HC with a 'fair VO2max' and running experience, a 'good VO2max and running experience', an 'excellent VO2max' and a 'superior VO2max' (VO2max values according to V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics) will receive an exercise intervention existing of home-based running sessions. Participants of the second training group will be trained to run continuously for 75 minutes.
11083411|NCT04191772|No Intervention|MS - sedentary control group|Twenty PwMS will receive no intervention, only usual care.
11083412|NCT04191772|No Intervention|HC - sedentary control group|Twenty HC will receive no intervention, only usual care.
11083413|NCT04191759|Experimental|Test-Retest reproducibility group|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
11083414|NCT04191746||Participants with critical limb disease|This registry will collect data from participants with critical limb disease from Duke University and approximately 40 sites in North America.
11083415|NCT04191733|Experimental|Anterior Approach with KINCISE|Anterior Approach THA using KINCISE(TM) Surgical Automated System
11083416|NCT04191733|Active Comparator|Anterior Approach without KINCISE|Anterior Approach THA with a mallet (without KINCISE)
11083417|NCT04191720|No Intervention|Control group|The control group, or usual care group, will receive occupational therapy standard of care. Occupational therapy standard of care provide training, education, and therapeutic activities including relaxation strategies. These coping mechanisms are aimed at reducing the impact of anxiety on a patient's performance and participation in necessary and meaningful activities of daily living, refeeding and medical stabilization. Specifically, these interventions will include diaphragmatic and yogic breathing exercises, mindfulness-based cognitive therapy (MBCT) education and exercises, therapeutic restorative yoga activities, occupational therapy group participation, aromatherapy, identifying and promoting engagement in meaningful leisure activities, client-centered sensory diets to provide patients with consistent preferred sensory experiences, and individualized checklists and schedules to grade the self-initiation of effective coping strategies.
11083418|NCT04191720|Experimental|Weighted blanket group|In the weighted blanket intervention group, patients will receive usual occupational therapy care in addition to a weighted blanket. The patient will be given an appropriately weighted blanket, within 1 lb +/- of 10% of body weight as measured on day of admission. Further, the occupational therapy will provide education to the patient on the use of the weighted blanket. Patients will be free to use the weighted blanket at their discretion, however, during meals, over the shoulders or head, and during ambulation, weighted blanket use will not be permitted.
11083419|NCT04191707||Outpatients with Inflammatory Bowel Disease|This study was performed with plasma samples from IBD patients recruited in a previous study after informed consent. (1) IBD outpatients attending the Hospital de Sabadell Gastroenterology Day-care unit were consecutively included for analytical monitoring of immunosuppressant treatment or infliximab infusion
11083420|NCT04191694|Other|Control|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively)
11083421|NCT04191694|Active Comparator|Chewing Gum|Patients will receive the standard dose of anti-emetic according to hospital practice (Ondansetron 4mg IV, intra-operatively) they will also receive chewing in the recovery room and on the post-natal ward.
11083422|NCT04191681|Experimental|Sacubitril-valsartan study arm|"Start medication-naïve patients on low-dose sacubitril-valsartan (24/26 mg PO BID) without a washout period per guideline and label recommendations.
~Switch patients to equivalent dose sacubitril-valsartan if on prior ACE inhibitor (after a 36 hour washout period) or ARB therapy (after discontinuing one day prior).
~If therapeutic range MAP (65 to 85 mm Hg), discontinue other oral vasodilator (e.g., hydralazine, isordil) or non-rate limiting dihydropyridine calcium channel blocker (non-DHP CCB, e.g., amlodipine) therapy on the day prior to sacubitril-valsartan initiation. If MAP > 85 mm Hg, low-dose sacubitril-valsartan will be added with or without discontinuation of other oral vasodilator or non-DHP CCB per physician's discretion based on drug tolerability and maintenance of therapeutic range MAP.
~Sacubitril-valsartan can be up-titrated every 2-4 weeks per standard practice guidelines per physician's discretion as above."
11083423|NCT04191681|Active Comparator|Usual care (standard-of-care) arm|"1. Continue current regimen of patients on oral vasodilator therapy (e.g., ACE inhibitor, ARB, hydralazine, isordil), allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above.
~2. Start medication-naïve patients de novo on one of the oral vasodilators as below per guideline and label recommendations, allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above: i. ACE inhibitor: Enalapril 2.5 mg PO BID or Lisinopril 5 mg PO daily; ii. ARB: Valsartan 20 mg PO BID or Losartan 25 mg PO daily; iii. Other: Hydralazine 10 mg PO TID or Isordil 5 mg PO TID."
11083760|NCT04189250|Placebo Comparator|Optimized carbonmonoxid rebreathing protocol (oCO)|2 min rebreathing period seated position capillary blood sampling
11083424|NCT04191668|Other|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
11083425|NCT04191655|Experimental|High Definition White Light Colonoscopy|
11083426|NCT04191655|Active Comparator|Dye Spraying Chromo-colonoscopy|
11083427|NCT04191629|Experimental|50K to 200K cells|
11083428|NCT04191629|Experimental|50K to 200K cells with endothelial brushing|
11083429|NCT04191629|Experimental|500K cells|
11083430|NCT04191629|Experimental|500K cells with endothelial brushing|
11083431|NCT04191616|Experimental|Carfilzomib combined with pomalidomide and dexamethasone|Carfilzomib, pomalidomide, and dexamethasone (KPd)
11083432|NCT04191603|Active Comparator|MONOPOLAR HOOC|COLPOTOMY WITH USAGE MONOPOLAR HOOC
11083433|NCT04191603|Active Comparator|PLASMAKINETIK BIPOLAR SPATULA|COLPOTOMY WITH USAGE MONOPOLAR HOOC
11083434|NCT04191590|Other|Patient with Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of Chronic Rhinosinusitis (CRS)
11083435|NCT04191590|Other|Patient without Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of endonasal surgery for nasal obstruction or patients requiring an endonasal surgical approach such as pituitary adenomas for example.
11083436|NCT04191577|Placebo Comparator|Placebo|Placebo to be administered once daily.
11083437|NCT04191577|Active Comparator|CVN424 (Low Dose)|Low dose of CVN424 to be administered once daily.
11083438|NCT04191577|Active Comparator|CVN424 (High Dose)|Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.
11083439|NCT04191564|Experimental|low perfusion|fluid restriction based on the goal directed fluid therapy is maintained during the whole case and a state of low perfusion is created by reducing the systolic blood pressure below 100 mmHg by vasoactive medications like cleviprex or nicardipine, by increasing positive end expiratory pressure (PEEP) and by a very short period of a high IAP of 20 mmHg only during firing.
11083440|NCT04191564|Experimental|normal perfusion|Perfusion pressure is maintained above 100 mmHg with free fluid loading iv and the lowest IAP possible during the whole procedure.
11083441|NCT04191551||Gastric intestinal metaplasia|Subjects with histologically-confirmed intestinal metaplasia found during endoscopy with protocoled biopsies.
11083442|NCT04191551||Controls|Subjects without intestinal metaplasia found during endoscopy with protocoled biopsies (age and sex matched to cases)
11083443|NCT04191538|Experimental|Conditioning electrical stimulation|Patients will receive percutaneous electrical stimulation one week prior to carpal tunnel release. They will receive sham stimulation immediately after surgery to ensure blinding.
11083444|NCT04191538|Active Comparator|Postoperative electrical stimulation|Patients will receive electrical stimulation immediately following carpal tunnel release, per out previous studies. They will receive sham stimulation 1 week prior to surgery to ensure blinding.
11083445|NCT04191538|Sham Comparator|No electrical stimulation|Patients will not receive electrical stimulation. They will receive electrical stimulation before and after surgery to ensure blinding.
11083446|NCT04191525|Experimental|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
11083447|NCT04191525|Placebo Comparator|Placebo|1 capsule/day
11083448|NCT04191512||Upper airway stimulation|
11083449|NCT04191512||Continuous positive airway pressure|
11083450|NCT04191499|Experimental|GDC-0077 + Palbociclib + Fulvestrant|Participants will receive GDC-0077, palbociclib, and fulvestrant.
11083451|NCT04191499|Placebo Comparator|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
11083452|NCT04191486|Experimental|T-817MA (448 mg)|
11083453|NCT04191486|Placebo Comparator|Placebo|
11083454|NCT04191473|Experimental|group P|
11083455|NCT04191473|Other|group C|
11083456|NCT04191460|Experimental|WP-I dose A|n=7. Injection of 0.05 mg/kg cRGD-ZW800-1, within 16-20 hours before imaging/surgery
11083457|NCT04191460|Experimental|WP-I dose B|n=7. Injection of (to be determined) mg/kg RGD-ZW800-1, within (to be determined) hours before imaging/surgery.
11083458|NCT04191460|Experimental|WP-II selected dose|n=15: expansion cohort (n=15) will be added to the group of patients that had received the selected dose in WP-I. Injection of 0.05 ór (to be determined) mg/kg cRGD-ZW800-1, within 48 hours before imaging/surgery.
11083459|NCT04191447|Experimental|FLAMBOYANT 200/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Flamboyant 200/12 capsule
~1 Budesonide/formoterol Placebo capsule."
11083460|NCT04191447|Active Comparator|Budesonide/formoterol 400/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Budesonide/formoterol 400/12 capsule
~1 Flamboyant 200/12 Placebo capsule."
11083461|NCT04191434|Experimental|FLAMBOYANT 125/12|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Flamboyant 125/12 capsule
~1 Budesonide/formoterol 200/6 Placebo capsule."
11083462|NCT04191434|Active Comparator|Budesonide/formoterol 200/6|"The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
~1 Budesonide/formoterol 200/6 capsule
~1 Flamboyant 125/12 Placebo capsule."
11083463|NCT04191421|Experimental|Treatment spartalizumab and siltuximab Phase I dose level 1|Arm 1 (Phase I dose level 1) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 6 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11083464|NCT04191421|Experimental|Treatment spartalizumab and siltuximab Phase I level 2|Arm 2 (Phase I dose level 2) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 11 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11083465|NCT04191421|Experimental|Treatment spartalizumab and siltuximab phase I level 2a|Arm 3 (Phase I dose level 2a) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 9 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11136331|NCT03821688|Active Comparator|LSG|laparoscopic sleeve gastrectomy
11083466|NCT04191421|Experimental|Treatment spartalizumab and siltuximab phase II|Arm 4 (Phase II ) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab at dose determined in Arm 1 to 3 IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11083467|NCT04191408|Experimental|Mechanically ventilated patients after surgery|After ICU admission the patient's hemodynamics (MAP, HR, CO, PPV) will be measured in supine position. It will be remeasured after PEEP has been increased from +5 to +15 cmH20. Then the baseline measurement will be repeated. Then passive leg raise will be performed and all the parameters will be remeasured.
11083468|NCT04191395||Inflammatory bowel disease|
11083469|NCT04191395||Chronic inflammatory rheumatic disease|
11083470|NCT04191382|Experimental|SAR439859 dose regimen 1|SAR439859 dose regimen 1 administered for 14 days
11083471|NCT04191382|Experimental|SAR439859 dose regimen 2|SAR439859 dose regimen 2 administered for 14 days
11083472|NCT04191382|Active Comparator|letrozole|letrozole 2.5 mg administered once daily for 14 days
11083473|NCT04191369|Placebo Comparator|EGD evaluation|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
11083474|NCT04191369|Experimental|EUS evaluation|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.
~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
11083475|NCT04191343|Experimental|The control group|
11083476|NCT04191330|No Intervention|Control|Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.
11083477|NCT04191330|Experimental|Intervention|Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.
11083478|NCT04191317|Experimental|Pain Neuroscience Education and gradual exposure|"Education explaining the neurophysiological processes that lead to chronic pain, in order to change maladaptive belief towards disease, reconceptualising them and desensitizing the Central Nervous system.
~On first session of gradual exposure the patients are challenged to create a hierarchically list with the functional activities they experience fear, and exposure begins with the one they have less. Both the therapist and participant will determine a specific group of exercises after the patient understands the benign nature of pain, and will be evaluated the maximal performance of the individual to perform each exercise separately."
11083479|NCT04191317|Active Comparator|Pilates and postural education|In the first session, basic Pilates principles will be taught and reinforced at the beginning of the follow up sessions, including: postural alignment (neutral spine position, shoulder blade and neck position) and core recruitment along with a controlled breathing. Each session will have a warm up, mobility, stability and strengthening exercises and a cool down period.
11083480|NCT04191304|Experimental|Benralizumab arm|1x Benralizumab SC injection
11083481|NCT04191304|Placebo Comparator|Placebo arm|1x Benralizumab matching placebo SC injection
11083482|NCT04191291|Experimental|Shortened lunch period|The lunch period will last only 20 minutes.
11083483|NCT04191291|Experimental|Longer lunch period|The lunch period will last 30 minutes.
11083484|NCT04191278|Active Comparator|Varenicline|An α4β2 nicotinic acetylcholine receptor partial agonist
11083485|NCT04191278|Experimental|Varenicline + mobile app|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications
11083486|NCT04191278|Experimental|Varenicline + mobile app + contingency management|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications + monetary reinforcers for being adherent to medication
11083487|NCT04191239||PRVC|Preterm infants with need of mechanical ventilation will receive PRVC mode until extubation
11083488|NCT04191239||Bilevel VG|Preterm infants with need of mechanical ventilation will receive Bilevel VG mode until extubation
11083489|NCT04191213|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks
11083490|NCT04191213|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age & two-gram-dose for children above 5 years of age
11083491|NCT04191187|Experimental|Conditioning Regimen + Transplant|All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)
11083492|NCT04191174||Adults undergoing lung resection for lung cancer|
11083493|NCT04191161|Experimental|Brace group|patients will receive their brace 2 weeks after the first consultation (usual delay to conceive and deliver the brace), they will be asked to wear the brace all day and will be allowed to redraw it at night. Brace must be worn for 3 months. A specific eduction on how to wear the brace will also be delivered. A thermal sensor chip will be placed in the brace to assess the observance. No physiotherapy will be prescribed during this period. Patient will attend to 3 consultations, day 0, 3 months and finally at 6 months later. These three consultations are part of usual care.
11083494|NCT04191161|Placebo Comparator|Control group|patients will continue physiotherapy sessions if already prescribed but no extra sessions will be prescribed. Pain killers will be adjusted. Patients will also attend to three consultations such as described above. Main outcome will be assessed at M3. After M3, patients who did not receive the brace will have the choice to receive it for the next 3 months and secondary outcome will be assessed at 6 months.
11083495|NCT04191148|Experimental|LBP-EC01|crPhage cocktail
11083496|NCT04191148|Placebo Comparator|Placebo|Lactated Ringer's solution, injection, USP
11083525|NCT04190940|Experimental|High Intensity Focused Ultrasound|Patients receiving high intensity focused ultrasound as a treatment will be asked to complete the behavioral task pre and post their treatment.
11083526|NCT04190940|Experimental|Deep Brain Stimulation|"Patients receiving deep brain stimulation as a treatment will be asked to complete the behavioral task while their DBS electrode is on and off."
11084416|NCT04184856||non-BED controls|Individuals that do not experience binges
11083497|NCT04191135|Experimental|pembrolizumab + carboplatin and gemcitabine|Participants receive both carboplatin Area Under The Curve (AUC) 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will continue to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
11083498|NCT04191135|Experimental|pembrolizumab + olaparib|Participants receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
11083499|NCT04191122|Active Comparator|COPESS and Treatment as usual|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible, and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.
~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."
11083500|NCT04191122|No Intervention|Treatment as usual only|The control group will receive Treatment-as usual (TAU), defined as the standard care provided to individuals struggling with self-harm (SH) as detailed within the 'Managing SH in primary care' NICE guidelines. These include: an initial comprehensive psychosocial assessment of skills and risks; co-production of a care and risk management care plan, which should include harm reduction plans, the need for between 3 and 12 sessions of psychological intervention as well as treatment for associated mental health conditions. Primary care practices in the control arm will be asked to provide information on what constitutes TAU within their organisation. This trial may enhance TAU as researchers will provide details of NICE guidance to GP practices that may not currently be following these guidelines. We will collect data regarding the acceptability of TAU for SH offered by GPs within both treatment arms.
11083501|NCT04191109||1|Subacute stroke patients admitted to an inpatient rehabilitation facility.
11083502|NCT04191096|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
11083503|NCT04191096|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
11083504|NCT04191083|Experimental|Motor Imagery|
11083505|NCT04191083|Experimental|Double Time Motor Imagery|
11083506|NCT04191083|Experimental|Action observation|
11083507|NCT04191083|Placebo Comparator|Placebo group|
11083508|NCT04191070|Experimental|Class II correction using infrazygomatic crest miniscrews|class II correction by distalization using infrazygomatic crest miniscrews (G1)
11083509|NCT04191070|Experimental|Class II correction using zygomatic miniplates|class II correction by distalization using zygomatic miniplates (G2)
11083510|NCT04191057|Experimental|Healthy twin|Free light chains of twins compared to non-twin siblings
11083511|NCT04191044||NAFLD with mild steatosis and grade <3 fibrosis in patients|NAFLD with mild steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
11083512|NCT04191044||NAFLD with severe steatosis and grade <3 fibrosis in patients|NAFLD with severe steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
11083513|NCT04191044||NAFLD with advanced fibrosis|NAFLD with advanced fibrosis (i.e. grade 3 or 4 fibrosis) without previous portal hypertension-related complications
11083514|NCT04191044||Decompensated NAFLD cirrhosis|Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points)
11083515|NCT04191031|Experimental|Superficial Genicular Nerves|Subjects will receive iovera° cryoneurolysis treatment of superficial genicular nerves (anterior femoral cutaneous nerve [AFCN] and infrapatellar branches of the saphenous nerve [ISN]) of the target knee
11083516|NCT04191031|Sham Comparator|Sham Comparator|Subjects will receive sham iovera° treatment of superficial genicular nerves (AFCN and ISN) of the target knee
11083517|NCT04190992|Experimental|Application (APP) group|After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based & personalized breast reconstruction surgery decision aid at clinic.
11083518|NCT04190992|Other|Usual care group|After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
11083519|NCT04190979|Experimental|Single arm|TrackCath
11083520|NCT04190966|Active Comparator|Integrated smoking cessation|Integrated smoking cessation delivered by trained health-care practitioners in the thoracic surgical pathway: a three part package of behaviour interventions and pharmacotherapy as per NICE/NCSCT guidance which is supported by an adjunct web-based application.
11083521|NCT04190966|No Intervention|Usual care smoking cessation|Usual care of standard community/hospital based NHS smoking cessation.
11083522|NCT04190953|Experimental|Twin Block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion using Twin block prior to Hyrax
11083523|NCT04190953|Experimental|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement using Hyrax prior to Twin block
11083527|NCT04190927|Experimental|Treatment|All patients will be symptomatic peri or post menopausal and will all be started on the same protocol. The Dosing schedule of topical estradiol and topical progesterone will be modified for each subject in the first three months to address individual symptoms. The dosing will be relatively unique to each patient. Patients will remain on their dosing schedule for the remainder of the three year study and will be assessed during at the end of the study for changes in mood, symptoms of menopause, breast health, BMD and thickness of uterine lining .
11083528|NCT04190914|Active Comparator|necrotic primary molar treated with pulpectomy followed by SSC|control group treated by pulpectomy under rubber dam isolation access cavity will be prepared by a round bur then filling and irrigation will be performed and the tooth will be restored with a temporary filling. After one week all signs and symptoms will be assessed in case of absence of signs and symptoms the tooth will be restored with zin oxide and eugenol and SSC
11083529|NCT04190914|Experimental|necrotic primary molar treated with regeneration using triple|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then triple antibiotic paste will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
11083530|NCT04190914|Experimental|necrotic primary molar treated with regeneration using metape|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then calcium hydroxide with iodoform (metapex) will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After 2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
11083531|NCT04190901|Experimental|Simulated Black Male Physician|Participants are randomized to view the clinical vignette with a simulated Black Male physician.
11083532|NCT04190901|Experimental|Simulated Black Female Physician|Participants are randomized to view the clinical vignette with a simulated Black Female physician.
11083533|NCT04190901|Experimental|Simulated White Male Physician|Participants are randomized to view the clinical vignette with a simulated White Male physician.
11083534|NCT04190901|Experimental|Simulated White Female Physician|Participants are randomized to view the clinical vignette with a simulated White Female physician.
11083535|NCT04190888||Sickle Cell Disease|Patients with sickle cell disease will be followed prospectively
11083536|NCT04190862|Experimental|Cell Therapy Treatment|Patients who present with simple anal fistula and elect to undergo fistulotomy for treatment will be eligible to have E-CEL UVEC injected into the fistula at the time of fistulotomy to aid in healing.
11083537|NCT04190849||Non-alcoholic fatty liver disease patients|Children (<18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.
11083538|NCT04190836|Experimental|Self-Managed Exercise Strategy|
11083539|NCT04190823|Experimental|RC98|
11083540|NCT04190810|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures that are not related to smoking by swiping/pulling them towards themselves, whereas pictures with tobacco-related content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
11083541|NCT04190810|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon non-smoking related images by swiping/pulling towards themselves the picture. Pictures containing tobacco-related content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
11083542|NCT04190810|Sham Comparator|Control group|This type of active control group receives the instructions to swipe tobacco-related pictures to the left and non-tobacco related pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
11083543|NCT04190797|Experimental|Experimental|Photobiomodulation + patiente controled anaethesia (PCA) group (G1): patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
11083544|NCT04190797|Active Comparator|Control|Placebo + PCA group (G2): patients undergoing knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve blockade (femoral nerve and obturator nerve). With conventional analgesia and with the PCA apparatus.
11083545|NCT04190784|Experimental|60 seconds stretching group|"Stretching exercises for upper Trapezius and Levator scapula .
~From supine position , the examiner will passively place the participant's head into flexion, side-bending away and rotation towards the side to be stretched (for upper trapezius muscle) and flexion, side-bending away and rotation away from the side to be stretched (for levator scapula ). The patient introduces a light resisted effort to take the stabilized shoulder towards the ear and the ear towards the shoulder. The contraction is sustained for 10 seconds and, upon complete relaxation of effort, the therapist gently eases the head/ neck into an increased degree of side-bending and rotation, where it is stabilized, as the shoulder is stretched caudally. The examiner will depress the participant's shoulder with 100 Newton's of force measured with pressure dynamometer. Once the examiner achieved this level of force, he maintains the stretch for 60 seconds . The procedure is repeated three times."
11083546|NCT04190784|Experimental|30 seconds stretching group|The same procedures while the therapist will maintain the stretch for 30 seconds.
11083547|NCT04190784|Experimental|15 seconds stretching group|The same procedures while the therapist will maintain the stretch for 15 seconds.
11083548|NCT04190784|Placebo Comparator|60 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 60 seconds
11083549|NCT04190784|Placebo Comparator|30 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 30 seconds
11083550|NCT04190784|Placebo Comparator|15 seconds placebo stretching group|The therapist will maintain the same manual contact without stretching force for 15 seconds
11083789|NCT04189055|Experimental|Cohort #2|Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
11083551|NCT04190771|Experimental|TAU + multicomponent treatment NAT-FM|NAT-FM is a multicomponent non-pharmacological program based on mindfulness ingredients, pain neuroscience education, and nature exposure. NAT-FM is conceived as an add-on therapy.
11083552|NCT04190771|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for fibromyalgia, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
11083553|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
11083554|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
11083555|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
11083556|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
11083557|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
11083558|NCT04190745|Experimental|The control group|
11083559|NCT04190745|Experimental|The experimental group|
11083560|NCT04190732|Experimental|Physician phone call|Participants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
11083561|NCT04190732|No Intervention|Routine care|Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test.
11083562|NCT04190719|Experimental|Paprika group|Patients coming for elective major surgery will participate to Paprika program
11083563|NCT04190719|No Intervention|Historical group|Patients previously operated with same characteristics
11083564|NCT04190706|Experimental|bioactive components fortified food products|
11083565|NCT04190706|Placebo Comparator|control food products|
11083566|NCT04190693|Placebo Comparator|Follow-up|No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
11083567|NCT04190693|Experimental|IMCY_0098|No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
11083568|NCT04190680|Experimental|Kokkerelli Learning Street|The classes included in this group will participate in the Kokkerelli Learning Street; a school-based nutrition education programme included classroom-based lessons, a visit to a grower's farm and a cooking workshop.
11083569|NCT04190680|No Intervention|Control group|The classes included in this group will not participate in the Kokkerelli Learning Street and will continue with their regular curriculum.
11083570|NCT04190654|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh class A score of 5 or 6)
11083571|NCT04190654|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh class B score of 7 to 9)
11083572|NCT04190654|Experimental|Healthy Subjects|Healthy adults matched with the subjects in Group A and Group B at 1:1 for age (± 10 years), sex, and BMI (± 20%)
11083573|NCT04190641|Other|Flexible cystoscopy|Visualization of the urethra and bladder with the Ambu® aScope™ 4 Cysto and aView™ Urologia
11083574|NCT04190628|Experimental|Dose Escalation|"A classic 3+3 design will be used to determine MTD and RP2D. Three to six patients per treatment cohort will be assigned to receive sequentially higher oral doses of ABM-1310 on a twice daily schedule (bid) for 28-day cycles, starting at a dose of 25 mg bid. Patients will receive twice daily oral doses of ABM-1310 until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
11083575|NCT04190628|Experimental|MTD/RP2D Confirmation|Patients will receive twice daily oral doses of ABM-1310 in 28-day treatment cycles until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
11083576|NCT04190615||0 to 3 months|0 (term newborns) to 3 month of age
11083577|NCT04190615||4 to12 months|infants from 4month to 12month of age
11083578|NCT04190615||13 to 24 months|children from 13month to 2years of age
11083579|NCT04190615||2 to 5 years|children from 2 to 5 years of age
11083580|NCT04190615||6 to 10 years|children from 2 to 10 years of age
11083581|NCT04190615||11 to16 years|children from 11 to 16 years of age
11083582|NCT04190589|Experimental|Robotic CME|Robot-assisted extended right colectomy
11083583|NCT04190576|Experimental|Minimally invasive ridge augmentation with LLLT|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) and low-level laser therapy
11083584|NCT04190576|Active Comparator|Minimally invasive ridge augmentation|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) alone
11083585|NCT04190563|Experimental|Pain De-Catastrophizing|Brief behavioral education on how to modify the interpretation of pain.
11083586|NCT04190563|Placebo Comparator|Pain Education|Brief behavioral education on pain.
11083587|NCT04190550|Experimental|Treatment (AMG 232, cytarabine, idarubicin)|Patients receive AMG 232 PO QD on days 1-7, cytarabine IV on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment but with signs of AML may receive cytarabine for 5 days and idarubicin for 2 days in the middle of cycle 1. Patients who have no signs of AML may then receive cytarabine IV on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
11083588|NCT04190524|Other|Intervention/Control|Each subject will serve as their own control. The esophagus diameter will be measured on each subject, then cricoid pressure will be applied and the esophagus diameter will again be measured.
11083589|NCT04190511|Experimental|Prebiotic-containing dairy intervention group|
11083590|NCT04190511|Active Comparator|Dietary intervention group|
11083591|NCT04190511|No Intervention|Conventional care group|
11083592|NCT04190498||NASH-related HCC|The study is focused on patients suffering from NASH-induced HCC. Each patient with NASH-related HCC will be paired with 2 patients with non NASH-related HCC (HCV-induced CHC).
11083593|NCT04190498||HCV-related HCC|HCV-related HCC has been chosen as control population for several reasons: HCV represent a common etiology of HCC; with a distinct pathophysiology distinct from that of post-NASH HCC; populations with post-NASH and post-HCV CHC share similar epidemiological characteristics.
11083594|NCT04190485|Experimental|Placebo and GMNL-143 Probiotic Toothpastes|Subjects will receive placebo and GMNL-143 probiotic toothpastes.
11083595|NCT04190485|Experimental|Placebo and GMNL-464 Probiotic Toothpastes|Subjects will receive placebo and GMNL-464 probiotic toothpastes.
11083596|NCT04190472||IOP VPH test|Immediately after the LEEP, a cervical sample is token for the IOP-HPV test
11083597|NCT04190459||LSG|laparoscopic sleeve gastrectomy
11083598|NCT04190459||LRYGB|laparoscopic Roux-en-Y gastric bypass
11083599|NCT04190446|Experimental|Arm I (proton beam radiation therapy)|Patients undergo proton beam radiation therapy 5 days a week over 3 weeks.
11083600|NCT04190446|Experimental|Arm II (IMRT)|Patients undergo IMRT 5 days a week over 5 weeks.
11083601|NCT04190433|Active Comparator|Standard Therapy Group|Carvedilol and Lisinopril titrated to maximally tolerated doses as per standard practice
11083602|NCT04190433|Experimental|Expanded Therapy Group|Pravastatin 40 mg per day and Spironolactone 25 mg per day in addition to maximally titrated Carvedilol and Lisinopril doses
11083603|NCT04190420||Patients|250 patients with primary hypertension
11083604|NCT04190420||Healthy Controls|60 healthy control subjects, matched in age and gender
11083605|NCT04190407|Other|Pediatric patients scheduled for day case surgery|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
11083606|NCT04190394||Patients following the CONT program|"In the  CONT continuous training group, the control group, the patient benefits from a retraining program according to the continuous mode (see details in section 3.4) for 8 weeks, with three 40-minute sessions per week."
11083607|NCT04190394||Patients following the IT program|"In the IT intermittent training group, group, (the experimental group), the patient benefits from a retraining program according to the intermittent mode (see details in section 3.4) for 8 weeks, with three 45-minute sessions per week."
11083608|NCT04190381|Experimental|FR-Mask application|
11083609|NCT04190368|Experimental|Team Clinic|Participants attend quarterly visits (1 visit every 3 months) and participate in thematic group visits aimed at improving glycemic control and treatment adherence, increasing social supports and diabetes care satisfaction, and aid in the transition from caregiver led treatment to self care.
11083610|NCT04190368|No Intervention|Usual Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
11083611|NCT04190355|Active Comparator|5.25% NaOCl solution|5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation
11083612|NCT04190355|Active Comparator|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation
11083613|NCT04190342|Other|wait list control|Routine methods of treatment and care (intervention provided after the completion of the trial)
11083614|NCT04190342|Experimental|tai chi group|Tai chi intervention + routine methods of treatment and care
11083615|NCT04190329||10 non-frail (robust) study patients|Patients fulfill 0 criteria according to modified Fried frailty score.
11083616|NCT04190329||10 pre-frail study patients|Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
11083617|NCT04190329||10 frail study patients|Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.
11083618|NCT04190316|Other|Evaluation of patient and patient-care environment ESBL|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
11083619|NCT04190303||Baseline (pre-intervention)|Current routine care
11083620|NCT04190303||Post-intervention|Care following development and delivery of the system-level intervention
11083621|NCT04190290|Experimental|Intervention|Mobilizations and exercises training Respiratory exercises Body image exercises
11083622|NCT04190290|Active Comparator|Control|Muscle strength evaluation and Eating behavior evaluation and Quality of life
11083623|NCT04190277|Experimental|36-week Closed-Loop|2-week baseline period in open-loop condition, then 12-week period in closed-loop condition followed by a 24-week extension period in closed-loop condition
11083624|NCT04190277|Active Comparator|12-week open-loop and 24-week closed-loop|2-week baseline period in open-loop condition, then 12-week period in open-loop condition followed by a 24-week extension period in closed-loop condition
11083625|NCT04190264|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
11083626|NCT04190264|Active Comparator|Cold Water Immersion|Participants, following exercise-induced hyperthermia, will be cooled using cold water immersion. Participants will be immersed up to their chest in cold water (~50-55 Degrees Fahrenheit).
11083627|NCT04190264|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
11083690|NCT04189731||supra-scapular block|Patient will have a short ISB (between 2h and 4h) relayed by a supra-scapular block (SSB) long (72h) through the placement of a perineural catheter thus allowing a continuous diffusion of Naropein® by an elastomeric pump
11083790|NCT04189042||Parkinson Group|Patients with Parkinson's Disease (Hoehn and Yahr stage 1-4)
11083628|NCT04190251|Other|Intervention group A|Intervention group A will benefit of the medication adherence support program during 12 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
11083629|NCT04190251|Other|Intervention group B|Intervention group A will benefit of the medication adherence support program during 6 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
11083630|NCT04190238|Experimental|Spasticity after stroke 1|Physical therapy with super inductive system on the agonist and antagonist muscles
11083631|NCT04190238|Active Comparator|Spasticity after stroke 2|Physical therapy with super inductive system on the agonist muscles
11083632|NCT04190225|Experimental|Multi-technology physical activity intervention|Digital/social media
11083633|NCT04190225|No Intervention|Control|Control group receives a Fitbit but none of the intervention components.
11083634|NCT04190212|Experimental|High-intensity interval training|Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
11083635|NCT04190212|No Intervention|Standard care|Participants will not participate in on-site supervised exercise sessions.
11083636|NCT04190199||Type 2 diabetes mellitus (T2DM)|Subjects in this group are diagnosed with type 2 diabetes mellitus. They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
11083637|NCT04190199||Pre-diabetes (IFG or IGT)|Subjects in this group are diagnosed with pre-diabetes (impaired fasting glucose [IFG] or impaired glucose tolerance [IGT]). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
11083638|NCT04190199||Non-type 2 diabetes mellitus (healthy)|Subjects in this group are not diagnosed with type 2 diabetes mellitus or pre-diabetes (healthy). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
11083639|NCT04190186|Active Comparator|BioMonitor3®-guided AF management|ICM obtained data will be actively used to guide and monitor treatment .
11083640|NCT04190186|No Intervention|Conventional AF Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
11083641|NCT04190173|Experimental|Prucalopride|Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C
11083642|NCT04190173|Placebo Comparator|Placebo|Placebo tablet to mimic Prucalopride made by starch
11083643|NCT04190160|Experimental|12 months treatment|replacement of whatever pre-existing hypoglicaemic therapeutic scheme, with or without insulin, with a single daily and flexible administration of IDegLira in a pilot little group of very old diabetic patients
11083644|NCT04190147||Moderate-to-late preterm group|
11083645|NCT04190147||Full-term group|
11083646|NCT04190134|Experimental|Immediate Robot|One month after study entry, participants will receive the robot at home for two months, followed by a three month observation period without the robot.
11083647|NCT04190134|Active Comparator|Delayed/Waitlist Robot|Three months after study entry, participants will receive the robot at home for three months.
11083648|NCT04190121|Experimental|GROUP A|
11083649|NCT04190121|No Intervention|GROUP B|
11083650|NCT04190108||Case patients|All consecutive, new patients older than 18 years with PsA (CASPAR criteria) at onset observed over 3-year period, who had any abdominal symptoms.
11083651|NCT04190108||Controls|All consecutive new patients meeting the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) at onset.
11083652|NCT04190095|Experimental|User Interaction with Device|A user will wear motion sensors and VR device to interact with object or another user in VR environment
11083653|NCT04190082||Group Control|Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
11083654|NCT04190082||Group BIS|Group who maintain deep sedation using Bispectral Index (BIS) score.
11083655|NCT04190069|No Intervention|OPTIFAST only|Control group will consist of participants that have not undergone behavioral modifications with the Prescription for Wellness Program. These are participants that only go through the OPTIFAST Program.
11083656|NCT04190069|Experimental|UPMC PFW followed by OPTIFAST|The intervention group will consist of participants that have undergone behavioral modifications with the Prescription for Wellness Program. These are participants who undergo the Prescription for Wellness Program prior to the OPTIFAST Program.
11083657|NCT04190056|Experimental|Arm A (pembrolizumab, vorinostat, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1, vorinostat PO QD for 4 days weekly, and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
11083658|NCT04190056|Experimental|Arm B (pembrolizumab, tamoxifen)|Patients receive pembrolizumab IV over 30 minutes on day 1 and tamoxifen PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity.
11083659|NCT04190030|Experimental|Mindfulness|
11083660|NCT04190030|Active Comparator|Cognitive reappraisal|
11083661|NCT04190004|Experimental|vasopressin|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
11083662|NCT04190004|Placebo Comparator|Placebo|All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
11083663|NCT04189991|Active Comparator|Manual then automated oxygen titration|First will be performed the manual oxygen titration and then the automatic oxygen titration.
11083664|NCT04189991|Active Comparator|Automatic then manual oxygen titration|First will be performed the automatic oxygen titration and then the manual oxygen titration.
11083665|NCT04189978||2001-2002 study participants|Children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period.
11083791|NCT04189042||Healthy Control|Healthy People
11083666|NCT04189965|Other|Pilot group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.
~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses to validate it.
~The subject will also have headphones and different shouts or noises will be broadcast and he will have to rate the level of dislike of each sound stimulation."
11083667|NCT04189965|Other|Experimental group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.
~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.
~3 sessions of stimulation will be done (D0, D2 and D30)"
11083668|NCT04189952|Experimental|Acalabrutinib + R-ICE|Acalabrutinib in combination with rituximab, ifosfamide, carboplatin and etoposide (R-ICE). All participants will receive combination treatment for 3 cycles. Each cycle lasts 21 consecutive days. Combination treatment includes twice daily dose of Acalabrutinib, Rituximab on Day 1 of each cycle, Ifosfamide and Carboplatin on Day 2 of each cycle, and Etoposide on Days 1-3 of each cycle.
11083669|NCT04189939||subjects with treatment-resistant depression|approximately 48 subjects with treatment-resistant depression will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
11083670|NCT04189939||healthy subjects|approximately 48 healthy subjects will undergo (1) clinical assessments, (2) perform a computer-based decision-making task while (3) their brain activity is monitored using a 3T MRI scanner.
11083671|NCT04189900|Experimental|Triptorelin|The subjects in this group receive a single dose treatment. Biologic sample collection (urine) from 48 hours pre-administration to 48 hours post administration.
11083672|NCT04189887||PD+AEX|The group of people with PD which will perform aerobic exercise after motor skill acquisition
11083673|NCT04189887||PD-AEX|The group of people with PD which will not perform aerobic exercise after motor skill acquisition
11083674|NCT04189887||CON+AEX|The group of control participants which will perform aerobic exercise after motor skill acquisition
11083675|NCT04189887||CON-AEX|The group of control participants which will not perform aerobic exercise after motor skill acquisition
11083676|NCT04189874|Active Comparator|Conventional stool testing|"All patients randomly allocated to this arm will have their stools tested for the following:
~a) Bacterial culture for Salmonella, Shigella, E.coli O157 and Campylobacter - specimen in Enteric Pathogen Transport medium (EPT) planted to: i) MacConkey agar, Sorbitol-MacConkey agar, Hektoen agar and Selenite broth all incubated overnight at 350C ii) Campylobacter agar incubated for 48 hours at 420C in a microaerophilic atmosphere b) Bacterial culture for Yersinia (≤ 18 years old): EPT specimen sent to Dynacare Laboratories for processing, results back in 10-14 days c) Ova & Parasites investigation: Sodium acetate-Acetic Acid-Formalin specimen sent to the Public Health Laboratories (PHL) for testing, results back in 7-10 days d) Viral culture: rarely requested, requires a specimen in a sterile container, sent to the PHL for testing, results back in 5-7 days e) Clostridioides difficile: specimen in sterile container, results in 1h (GeneXpert)"
11083677|NCT04189874|Experimental|BioFire FilmArray Gastrointestinal Panel|All patients randomly allocated to this arm will have their stools tested using a PCR-based molecular assay that can simultaneously test for 22 different infectious pathogens with a turnaround time of approximately 1 hour. As results become available, they will be available for review by the patient's healthcare providers in the electronic medical record.
11083678|NCT04189848|Experimental|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
11083679|NCT04189848|Experimental|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
11083680|NCT04189835||Kidney transplant recipients|Adults and children undergoing kidney transplantation in Norway and the western part of Denmark.
11083681|NCT04189796|Active Comparator|Jarlsberg|Daily intake of Jarlsberg Cheese in at least 6 weeks
11083682|NCT04189796|Sham Comparator|Camembert|Daily intake of Camembert Cheese in 6 weeks
11083683|NCT04189783|Active Comparator|Arm I (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.
11083684|NCT04189783|Experimental|Arm II (liposomal bupivacaine)|Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.
11083685|NCT04189770||Observational (questionnaire, accelerometer, EMA, survey)|Patients and partners complete questionnaires over 60 minutes about demographic information, stress, coping, and lifestyle behaviors at baseline and end of study. Patients and partners also receive an accelerometer and complete EMA questionnaire on stress, coping, physical activity, and eating behaviors over 5-10 minutes QID (7:30 am, 11:30 am, 3:30 pm, and 7:30 pm) via an smartphone app for 14 days. Patients and partners also complete a survey on nutrition BIW for a total of 4 surveys.
11083686|NCT04189757|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
11083687|NCT04189744|Placebo Comparator|IPTp-SP plus MTZ placebo (control)|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
11083688|NCT04189744|Active Comparator|IPTp-SP plus MTZ|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
11083689|NCT04189744|Active Comparator|IPTp-DP plus MTZ|3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
11137639|NCT03812744|Placebo Comparator|Placebo|
11083691|NCT04189718|Experimental|osseodensification protocol|Experimental: In the test group, osteotomy site preparation was performed using Osseodensification technique at 1100 rpm and implant was placed
11083692|NCT04189718|Active Comparator|conventional implant site preparation protocol|Control: in the control group, osteotomy site was prepared using conventional drilling protocol at 1100 rpm and implant was placed.
11083693|NCT04189705|Experimental|MCT-SR|Drug: MCT-SR 2 times/day for 2 weeks
11083694|NCT04189705|Active Comparator|Mucosta Tab.|Drug: Mucosta Tab. 3 times/day for 2 weeks
11083695|NCT04189692||Patients with Inflammatory Bowel Disease and fatigue|Patients with Inflammatory Bowel Disease and fatigue that participated in the two studies (1,2).
11083696|NCT04189679||First line|20 patients in first line of treatment
11083697|NCT04189679||Second or third line|40 patients in second and third line of treatment
11083698|NCT04189666|Active Comparator|Group R: patients receive Rivastigmine patch|receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
11083699|NCT04189666|Active Comparator|Group M: patients receive Melatonin patch|receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
11083700|NCT04189653||General Ward Inpatients 2017-2018|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
11083701|NCT04189653||General Ward Inpatients 2018-2019|ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
11083702|NCT04189640|Active Comparator|Group 20 = 20 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20ml will be injected here.
11083703|NCT04189640|Active Comparator|Group 30 = 30 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30ml will be injected here.
11083704|NCT04189640|Active Comparator|Group 40 = 40 ml volume adductor canal block|ACB will be performed at the end of the surgery, before extubation. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 40ml will be injected here.
11083705|NCT04189627||Participants Treated with GLE/PIB|Participants treated with all oral glecaprevir/pibrentasvir (GLE/PIB) and the decision to treat with GLE/PIB is made before the decision to offer an opportunity to join this study. Prescription of the treatment regimen is at the discretion of the physician and in accordance with local clinical practice and label.
11083706|NCT04189614|Experimental|Cofetuzumab Pelidotin|Participants will receive 2.8mg/kg of cofetuzumab pelidotin by IV every 3 weeks
11083707|NCT04189601||Study subjects|Patients with Fabry disease, Gaucher disease, or Niemann-Pick disease, type D
11083708|NCT04189601||Controls|Age- and sex-matched to Study subjects
11083709|NCT04189588|Active Comparator|Cohort A|Cetirizine HCl 10 mg/mL: a single 1 mL injection.
11083710|NCT04189588|Active Comparator|Cohort B|Diphenhydramine 50 mg/mL: a single 1 mL injection.
11083711|NCT04189575|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
11083712|NCT04189562|Experimental|SMS Intervention|All parents of participants will receive customized text messages once a day, Sunday through Friday, for a duration of 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
11083713|NCT04189536|Experimental|SMS Intervention|All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
11083714|NCT04189523|Active Comparator|Standard of Care Pain Management|
11083715|NCT04189523|Experimental|Early Administration of US Guided Nerve Blocks|
11083716|NCT04189510|Experimental|Artificial Pancreas (AP) Insulin Group|
11083717|NCT04189510|Active Comparator|Multiple Daily Injections (MDI) Insulin Group|
11083718|NCT04189484|Experimental|Arm A: Evolocumab low dose|Single dose of evolocumab 21 mg subcutaneous (SC)
11083719|NCT04189484|Experimental|Arm B: Evolocumab intermediate low dose|Single dose of evolocumab 35 mg SC
11083720|NCT04189484|Experimental|Arm C: Evolocumab intermediate high dose|Single dose of evolocumab 70 mg SC
11083721|NCT04189484|Experimental|Arm D: Evolocumab high dose|Single dose of evolocumab 140 mg SC
11083722|NCT04189484|Experimental|Arm E: Alirocumab low dose|Single dose of alirocumab 15 mg SC
11083723|NCT04189484|Experimental|Arm F: Alirocumab intermediate low dose|Single dose of alirocumab 25 mg SC
11083724|NCT04189484|Experimental|Arm G: Alirocumab intermediate high dose|Single dose of alirocumab 50 mg SC
11083725|NCT04189484|Experimental|Arm H: Alirocumab high dose|Single dose of alirocumab 100 mg SC
11083727|NCT04189458|Experimental|Multimodal exercise program|The experimental group intervention will attend the multimodal exercise program. The program integrates 3 sessions / week of 60 minutes on alternated days. The multimodal exercise program includes exercises promoting simultaneous motor and cognitive stimulation.
11083728|NCT04189458|No Intervention|Control Group|Usual care. After the study, it will be offered the opportunity to integrate a similar exercise program for the control group (CG) participants.
11083729|NCT04189445|Experimental|Futibatinib (Cohort A)|Advanced or metastatic solid tumors harboring FGFR1-4 rearrangements
11083730|NCT04189445|Experimental|Futibatinib (Cohort B)|Advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification
11083731|NCT04189445|Experimental|Futibatinib (Cohort C)|Myeloid or lymphoid neoplasm harboring FGFR1 rearrangement
11083732|NCT04189432|Experimental|SCM-CGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells
~Dose: 1x10^6 cells/Kg"
11083733|NCT04189432|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
11083734|NCT04189419|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow derived mesenchymal stem cells
~Dose: 1x10^6 cells/Kg"
11083735|NCT04189419|Placebo Comparator|Placebo|IV infusion.
11083736|NCT04189406||Girls with Turner syndrome|"Girls with a pre- or perinatal diagnosis TS who are born in a medical centre in the Netherlands during the duration of the study.
~The subjects will have an extra venapuncture of 3.5 mL blood at 3 and 9 months."
11083737|NCT04189406||Controle group|"No diagnosis of TS or any other diagnosis that might affect the HPG axis;
~Girls that will have a blood collection within their usual care at 3 months and at 9 months of age.
~During a regular outpatient visit, an extra blood tube will be taken of 3,5ml at 3 and 9 months."
11083738|NCT04189380|Experimental|Cohort 1|liver transplanted patient
11083739|NCT04189367|Experimental|Western medicine + TCM|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.
~Blood test and physiological assessment, and do the TCM model.
~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks
~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.
~TCM therapy: one bag of Qingre Liangkou Ningxin Fang, three times a day for 12 weeks."
11083740|NCT04189367|Active Comparator|Western medicine|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.
~Blood test and physiological assessment, and do the TCM model.
~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks
~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks."
11083741|NCT04189354|Experimental|Active t-DCS|Use of the t-DCS machine with the following stimulation parameters: current intensity of 2mA, electrode size of 25 cm2, duration of stimulation 20 minutes (excluding the fade-in and fade-out periods of 15 seconds).
11083742|NCT04189354|Sham Comparator|Sham t-DCS|"The condition of use in sham mode follows the same procedure as the active t-DCS except that the active stimulation lasts only 30 seconds at 3mA (60 seconds of active stimulation taking into account the periods of fade in and fade out).
~The stimulator remains switched on during the procedure but does not deliver current. The devices are fully automatic and deliver an active or sham current according to a randomized stimulation code whose meaning is unknown by the operator, in order to respect the triple blind."
11083743|NCT04189341|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
11083744|NCT04189341|Active Comparator|Group T = mTLIP group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
11083745|NCT04189341|No Intervention|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11083746|NCT04189328|Active Comparator|control group|conventional macrosurgical implant placement
11083747|NCT04189328|Experimental|test group|microsurgical implant placement
11083748|NCT04189315|Experimental|Group 1 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 36 weeks.
11083749|NCT04189315|Experimental|Group 2 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 12 weeks and then asfotase alfa at a lower dose for 24 weeks.
11083750|NCT04189302|Experimental|palatal connective tissue graft harvest with KPM blade|palatal connective tissue graft is harvested using single incision technique using KPM blade
11083751|NCT04189302|Active Comparator|palatal connective tissue graft harvest with 15C blade|palatal connective tissue graft is harvested using single incision technique using 15 C blade
11083752|NCT04189289|Active Comparator|ESP block group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. patient controlled analgesia (PCA) protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
11083753|NCT04189289|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. PCA analgesia protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
11083754|NCT04189276|Active Comparator|Group1|T101+ETV(Entecavir) /TDF(Tenofovir)
11083761|NCT04189250|Active Comparator|Automatized carbonmonoxide rebreathing protocol (aCO)|10 minutes rebreathing period supine position venous blood sampling
11083762|NCT04189237|Experimental|electroacupuncture|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of two times per week for six weeks, for a total of twelve times.
~Acupoint selection: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints."
11083763|NCT04189237|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of two times per week for six weeks, for a total of twelve times.
11083764|NCT04189224|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
11083765|NCT04189224|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
11083766|NCT04189211|Experimental|1.2mg/kg of BAT8001|BAT8001 100mg/box, 1.2mg/kg IV infusions
11083767|NCT04189211|Experimental|2.4mg/kg of BAT8001|BAT8001 100mg/box, 2.4mg/kg IV infusions
11083768|NCT04189211|Experimental|3.6mg/kg of BAT8001|BAT8001 100mg/box, 3.6mg/kg IV infusions
11083769|NCT04189211|Experimental|4.8mg/kg of BAT8001|BAT8001 100mg/box, 4.8mg/kg IV infusions
11083770|NCT04189211|Experimental|6.0mg/kg of BAT8001|BAT8001 100mg/box, 6.0mg/kg IV infusions
11083771|NCT04189198|Experimental|Articaine group|Patients in this group are assigned to recieve 30 ml of Articaine 2%
11083772|NCT04189198|Experimental|Bupivacaine|Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%
11083773|NCT04189185|Active Comparator|K-wire tension band wiring|The patient is treated with 1.6 mm k-wires and 1 mm cerclage
11083774|NCT04189185|Active Comparator|Suture fixation|The fracture is reduced and fixed with 2.0 Orthocord suture.
11083775|NCT04189172||Neuro-Patch|Patients receiving Neuro-Patch® for duraplasty
11083776|NCT04189159|Experimental|PROMPT Treated|PROMPT treatment, twice a day, for 5 days a week, for 3 consecutive weeks
11083777|NCT04189159|No Intervention|Control|Usual treatment
11083778|NCT04189146|Experimental|Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules or 10 hours long course and 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
11083779|NCT04189133|Experimental|Study group|The study group will receive the daily administration sc of Luveris with increasing dosages two weeks (Treatment phase) as follows: Rec-LH 75 IU daily for 2 weeks; Rec-LH 150 IU daily for 2 weeks; Rec-LH 300 IU daily for 2 weeks; Rec-LH 600 IU daily for 2 weeks.
11083780|NCT04189133|Active Comparator|Control group|"The control group will receive the administration im of Gonasi HP as follows:
~hCG 500 IU two times weekly, for 2 weeks; hCG 1000 IU two times weekly, for 2 weeks; hCG 1500 IU two times weekly, for 2 weeks; hCG 2000 IU two times weekly, for 2 weeks."
11083781|NCT04189120|Active Comparator|Thoracic epidural analgesia (TEA)|Under full aseptic conditions and wearing sterile gloves while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine, then an 18-G Epidural needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal or IV injection. After negative response, 15 ml of 0.25% epidural bupivacaine will be injected and the patient will be turned to the supine position.
11083782|NCT04189120|Active Comparator|Ultrasound-guided superficial serratus plane block (SSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. The muscles will be identified easily overlying the fifth rib, the latissimus dorsi , teres major and serratus muscles . A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle beneath the latissimus dorsi. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected
11083783|NCT04189120|Active Comparator|Ultrasound-guided deep serratus plane block (DSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane between the posterior border of the serratus anterior muscle and the corresponding surface of the rib. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected deep to the serratus muscle separating the serratus anterior muscle from the external intercostal muscle.
11083784|NCT04189107|Experimental|Experimental|High dose Dexamethasone
11083785|NCT04189107|Placebo Comparator|Control|Standard dexamethasone dosage and placebo
11083786|NCT04189094|Experimental|Sintilimab + CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions). After PCI, Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
11083787|NCT04189094|Active Comparator|CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
11083788|NCT04189055|Experimental|Cohort #1|Cetuximab monotherapy (500mg/m² IV, day 1)
11083792|NCT04189029||HFpEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≥ 50%, 1000 patients anticipated among which 300 with extensive phenotyping
11083793|NCT04189029||HFrEF patients|Heart failure patients (NYHA II-IV) with left ventricular ejection fraction ≤ 40%, 1000 patients anticipated among which 100 with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
11083794|NCT04189029||Subjects apparently without heart failure|Subjects without history or signs of heart failure, 100 subjects anticipated with extensive phenotyping (age- and gender-matched on participating HFpEF patients)
11083795|NCT04189016|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
11083796|NCT04189016|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
11083797|NCT04188990|Active Comparator|Intervention arm|"The Intervention arm includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients"
11083798|NCT04188990|Placebo Comparator|By demand arm|"The By demand arm will include patients in whom the nutritional intervention, if given, is performed by demand by the medical staff responsible for each patient."
11083799|NCT04188990|Placebo Comparator|Usual care arm|"In the Usual care arm usual hospital practice is followed without any explicit nutritional intervention"
11083800|NCT04188977|Other|Usual Practice|OTPs are able to request from state and federal health department officials to utilize interim methadone treatment to address admission delays in their OTP.
11083801|NCT04188977|Experimental|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
11083802|NCT04188964|Experimental|Treatment|Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 64 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 64 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
11083803|NCT04188951|Other|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|
11083804|NCT04188938||Occult pneumothorax in trauma patients|Age>16, multi-trauma, consulted thoracic surgeon, underwent CXR- CT.
11083805|NCT04188925|Experimental|Group A|True LA with EA
11083806|NCT04188925|Sham Comparator|Group B|Sham LA with EA
11083807|NCT04188912||Observational (sample collection, survey, imaging, spirometry)|Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomography before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed.
11083808|NCT04188873|Active Comparator|Standard 12-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083809|NCT04188873|Active Comparator|Preparation 12-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week priors to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083810|NCT04188873|Active Comparator|Standard 24-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083811|NCT04188873|Active Comparator|Preparation 24-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11085811|NCT04175379|Experimental|group 40|In group 40, target PaCO2 is 40 during surgery
11083812|NCT04188873|Active Comparator|Standard 12-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083813|NCT04188873|Active Comparator|Preparation 12-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week priors to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083814|NCT04188873|Active Comparator|Standard 24-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083815|NCT04188873|Active Comparator|Preparation 24-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083816|NCT04188873|Active Comparator|Standard 12-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083817|NCT04188873|Active Comparator|Preparation 12-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants will receive a 10-20 minute phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083818|NCT04188873|Active Comparator|Standard 24-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083819|NCT04188873|Active Comparator|Preparation 24-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants will receive a brief (10-20 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
11083861|NCT04188613|Active Comparator|ETT|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed through the vocal cords.
11083862|NCT04188613|Active Comparator|LMA|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed and laryngeal mask airway device inserted.
11083820|NCT04188873|Active Comparator|Standard 12-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083821|NCT04188873|Active Comparator|Preparation 12-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083822|NCT04188873|Active Comparator|Standard 24-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083823|NCT04188873|Active Comparator|Preparation 24-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants who smoke within 30 minutes of waking will be given 4 mg nicotine mini-lozenges, all others will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
11083824|NCT04188860|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
11083825|NCT04188847|Experimental|Study group|The patients would accept the regimen of apatinib combined with cisplatin and paclitaxel
11083826|NCT04188834|Experimental|Sensory Flicker Stimulation|"Patients will be exposed to Sensory Flicker Stimulation.
~In one experiment, patients will be exposed, for about 10 minutes at a time, to a sequence of sensory flicker trials each lasting a few seconds. Each trial may include the following modalities and frequencies of flicker:
~Modalities: auditory only, visual only, or audiovisual combined.
~Frequencies: random, or anywhere from 5Hz to 100Hz.
~In another experiment, patients will undergo a behavioral task in which they will be exposed to one of 2 flicker conditions on separate days."
11083827|NCT04188834|Active Comparator|Electrical Flicker Stimulation|"Patients will be exposed to direct electrical brain stimulation with low-amplitude current, at given flicker frequencies. Patients will be exposed to frequencies ranging from 5-100Hz, for up to 10 seconds at a time. Initially, frequencies of 5.5Hz and 40Hz will be tested.
~During brain stimulation sessions, bipolar electrical stimulation will be applied to one or more areas of the brain at a time either with or without associated behavioral task. Stimulation in the absence of any behavioral task will be applied in order to assess the subject's neurophysiological response to stimulation and to identify the optimal stimulation parameters for use during behavioral task. Stimulation during behavioral task will be applied in an attempt to affect the subject's behavior."
11083828|NCT04188821|Active Comparator|output based group|Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days with no further signs of infection, fluid collection or impaired wound healing
11083829|NCT04188821|Experimental|early-removal group|Investigators remove the drains at hospital discharge, 3-4 days after surgery, regardless of the output at that time
11083830|NCT04188808|Experimental|Popliteal artery aneurysm|Asymptomatic popliteal artery aneurysm patients will undergo surgery with a femoropopliteal/femorodistal bypass
11083831|NCT04188808|Active Comparator|Peripheral artery disease|Patients with peripheral artery disease defined as (ankle - brachial index, ABI <0.5 or typical symptoms); intermittent claudication (IC), or resting pain and/or minor tissue loss. Will undergo surgery with a femoropopliteal/femorodistal bypass
11083863|NCT04188600|Experimental|treatment group|"The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations:
~Responding patients: this population, defined by FSFI score > 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks).
~Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks)."
11085812|NCT04175379|Experimental|group 50|In group 50, target PaCO2 is 50 during surgery
11083832|NCT04188795|Experimental|Intervention|"Participants who met the criteria for inclusion in the study and volunteered to participate in the study were divided into experimental and control groups by block randomization method.
~After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.
~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
11083833|NCT04188795|No Intervention|Control Group|After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Routine nursing care was applied to hip fracture patients in the control group. Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
11083834|NCT04188782||Pediatric patients undergoing radiotherapy|"Pediatric patients undergoing general anesthesia for radiotherapy treatment. General anesthesia will be accomplished exclusively by the administration of sevoflurane.
~The inhalatory induction will be performed with sevofluorane at 8% with O2 4Lt/min. The maintenance will be with sevofluorane at an end tidal of 2.5% with 1Lt/min of O2.
~The EEG will be obtain with SedLine monitor"
11083835|NCT04188769|Sham Comparator|uninflated - rest|splint around the arm is not inflated both arms are in rest during the entire trial
11083836|NCT04188769|Sham Comparator|uninflated - triggered|splint around the arm is not inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
11083837|NCT04188769|Active Comparator|constantly inflated - rest|splint around the arm is constantly inflated both arms are in rest during the entire trial
11083838|NCT04188769|Active Comparator|constantly inflated - triggered|splint around the arm is constantly inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
11083839|NCT04188769|Experimental|intermittently inflated - rest|splint around the arm is intermittently inflated both arms are in rest during the entire trial
11083840|NCT04188769|Experimental|intermittently inflated - triggered|splint around the arm is intermittently inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
11083841|NCT04188756|Other|Exercise|Group under exercise training for 15 weeks with High intenstiy interval training under medical control
11083842|NCT04188756|No Intervention|Control|Group with standard care according to current guidelines
11083843|NCT04188743|Experimental|Allogenic FMT|Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It's frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
11083844|NCT04188743|Placebo Comparator|Autologous FMT|Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It's processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
11083845|NCT04188743|No Intervention|No intervention|"Participants in the No intervention-group will not receive any treatment but will be monitored similarly as the Allogenic FMT and Autologous FMT groups."
11083846|NCT04188730|Active Comparator|Granules for reconstitution then tablets|Participants will first be administered one 0.36 mg dose of lofexidine granules for reconstitution. After a washout period of 7 days, participants will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
11083847|NCT04188730|Active Comparator|Tablets then granules for reconstitution|Participants will first be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets. After a washout period of 7 days, participants will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
11083848|NCT04188704|Placebo Comparator|Anterior cruciate ligament normal|normal Anterior cruciate ligament reconstruction
11083849|NCT04188704|Experimental|Anterior cruciate ligament reconstruction|Anterior cruciate ligament reconstruction and Position screw fixation
11083850|NCT04188691|Experimental|vaccine group 1|vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
11083851|NCT04188691|Experimental|vaccine group 2|vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
11083852|NCT04188691|Experimental|vaccine group 3|vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
11083853|NCT04188691|Placebo Comparator|Normal saline|（0.5ml / dose）produced by NVSI
11083854|NCT04188691|Placebo Comparator|Aluminum adjuvant|（0.5ml / dose）produced by NVSI
11083855|NCT04188678|Other|Interventional Arm- Bone Marrow Transplant|"Study visits will include the performance of assessments prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. Assessments include:
~Physical function assessments
~questionnaires about general health and current health compared to health one year ago
~assessments that measure cognition, attention and memory
~assessments regarding personality and psychological and social stressors
~Physiological measures including
~blood tests- 160 mL of blood during evaluations, and 90mL of blood at the day 180 visit.
~bone marrow aspirate collected during standard of care bone marrow biopsies pre-transplant and at day 180
~Saliva collections pre-transplant
~ACTH Stimulation Test
~Oral Glucose Tolerance Test
~Holter Monitor- to record hear rate variability
~MRI pre-transplant and at Day 180 in a subset of 10 subjects"
11083856|NCT04188665|Experimental|MASL treated|Patients treated with lozenge containing MASL
11083857|NCT04188665|Placebo Comparator|Placebo treated|Patients treated with lozenge without MASL
11083858|NCT04188639|Experimental|Treatment with emicizumab|
11083859|NCT04188626|Experimental|Driving session|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving.
11083860|NCT04188613|Experimental|HFJV|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. The patient was extubated, and the jet ventilator catheter was inserted to trachea and ventilation will be start.
11083946|NCT04188015|Experimental|5.0mg ANX007|1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.
11083864|NCT04188600|Active Comparator|active control group|The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
11083865|NCT04188587|Experimental|177Lu-PSMA-I&T|177Lu-PSMA-I＆Tradioligand therapy with 2.0-8.0GBq in every circle were performed. And then 177Lu-PSMA post-therapy scans were performed at 24 h and 48 h respectively, and the fusion phenomenon was performed at the second day to pre evaluate the efficacy of the patients.
11083866|NCT04188574|Experimental|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
11083867|NCT04188574|Experimental|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
11083868|NCT04188574|Experimental|BB2603-1|Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine
11083869|NCT04188561|Active Comparator|Intraarticular injection Group|Patients included in the study had been received 2 ml hyaluronic acid with concentration of 22mg/ml . Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval
11083870|NCT04188561|Active Comparator|Radiofrequency Group|Radiofrequency Generator is a four electrode pain management for interventional pain management procedures. Patients had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
11083871|NCT04188548|Experimental|Dose Escalation LY3484356|LY3484356 given orally.
11083872|NCT04188548|Experimental|Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI|LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
11083873|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E3: LY3484356|LY3484356 given orally.
11083874|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus|LY3484356 and everolimus given orally.
11083875|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib|LY3484356 and alpelisib given orally.
11083876|NCT04188548|Experimental|Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib|LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
11083877|NCT04188548|Experimental|Part D: Dose Expansion: LY3484356 +/- Abemaciclib|LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
11083878|NCT04188535|Experimental|Esophageal Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
11083879|NCT04188535|Experimental|Glioblastoma Cohort|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
11083880|NCT04188535|Experimental|Glioblastoma Expansion Cohort Serial MR Imaging Registry|"The research study procedures include:
~Screening for eligibility
~Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards."
11083881|NCT04188522||Minor Stroke|"We will enroll a cohort of 15 adult patients previously admitted to Johns Hopkins Bayview Medical Center with small/minor acute ischemic stroke visible on neuroimaging. Patients will follow-up in clinic 4-6 weeks following hospital discharge. To be eligible for the study, patients must have a minor stroke, defined as NIH Stroke Scale score at follow-up of less than or equal to 8, modified Rankin score of 0-2, be competent speakers of English, and have no prior history of stroke, dementia, or untreated psychiatric disease. Those with proximal large vessel (M1) or branch (M2) occlusions will be excluded."
11083882|NCT04188522||Controls|For comparison, we will recruit a group of age-similar controls without neurologic disease or prior clinical history of stroke.
11083883|NCT04188509|Experimental|Voxelotor|"All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years will receive a voxelotor dose of 1500 mg QD, regardless of their body weight. Participants aged < 12 years will receive a voxelotor dose based on their body weight, to provide exposure corresponding to the adult dose of 1500 mg QD. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. The dose should be adjusted if the participant's weight increases or decreases over 2 consecutive clinic visits.
~Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source."
11083884|NCT04188496|Experimental|PULMONARY FUNCTION TEST (PFT) GROUP|"Thoracic joint Mobilization was applied on Experimental group.
~Thoracic Flexion:
~Patient sits on the treatment table with arms across the chest and hands on opposite shoulders. Stand facing the patient's left side.
~Thoracic Extension:
~Performed by asking sits on a treatment chair with arms folded across the chest and hands on opposite shoulders.
~Thoracic Segment Rotation:
~Performed by asking the patient to lie on left side. Place a pillow under patient's waist to assist left side bending. Position the patient's arms are folded across the chest with hands on opposite shoulders to stabilize the shoulder girdle and minimize movement there."
11083885|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
11083886|NCT04188483|Experimental|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. Thirty days after the start of the supplementation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
11083887|NCT04188483|Other|Non-Selenium Supplementation|The control group will not receive selenium supplementation. Thirty days after allocation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
11083888|NCT04188470|Experimental|person-centered care model|healthcare multidisciplinary team will review the appropriateness of medication by a person-centered care model and then the healtcare team will propose changes in the therapeutic plan to the patient or caregiver
11083889|NCT04188470|No Intervention|usual care|the healthcare team will practice usual care
11083890|NCT04188457||Stroke - usual follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with regular follow-up
11083891|NCT04188457||Stroke - intensive follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with intensive follow-up
11083892|NCT04188457||myocardial infarction - usual follow-up|Patient who has had a first or recurrent myocardial infarction with usual follow-up
11083893|NCT04188457||myocardial infarction -intensive follow-up|Patient who has had a first or recurrent myocardial infarction with intensive follow-up
11083894|NCT04188444||Agonist|Ovarian stimulation with agonist of GnRH
11083895|NCT04188444||Antagonist|Ovarian stimulation with antagonist of GnRH
11083896|NCT04188431|Experimental|Dexamethasone|Single intraoperative administration of 0.15 mg/kg of Dexamethasone intravenously with a maximum dose of 5 mg
11083897|NCT04188431|Placebo Comparator|Sodium chloride|Single intraoperative administration of Sodium Chloride (NaCl) 0.9% intravenously
11083898|NCT04188418|Experimental|Group I (shuttle walk test, FBT)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive FBT sublingually daily on days 6-19.
11083899|NCT04188418|Experimental|Group II (shuttle walk test, morphine)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive morphine PO daily on days 6-19.
11083900|NCT04188418|Active Comparator|Group III (shuttle walk test, placebo)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive placebo (sublingually or PO) daily on days 6-19.
11083901|NCT04188405|Experimental|Treatment (ponatinib, venetoclax, decitabine)|See Detailed Description.
11083902|NCT04188392|Experimental|open-label treatment|pimavanserin 34mg at bedtime for 6 weeks
11083903|NCT04188379|Experimental|efgartigimod|Patient receiving efgartigimod
11083904|NCT04188379|Placebo Comparator|Placebo|Patients receiving placebo
11083905|NCT04188366|Experimental|FAMES Modification|3-month trial of FAMES. Results from modifications will be used to by stakeholders (i.e., family members, client, providers, organizational leadership,) to inform finalization and implementation of FAMES
11083906|NCT04188366|Experimental|FAMES Pilot Trial|Pilot testing of FAMES and implementation toolkit
11083907|NCT04188340|Placebo Comparator|control group|using bergamot massage oil apply to GV20, GV24 SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
11083908|NCT04188340|Experimental|test group|using Su-Man formula massage oil ap-ply to GV20, GV24, SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
11083909|NCT04188327|Sham Comparator|Control group(Group I)|Patients will receive sham stellate ganglion block weekly for three times
11083910|NCT04188327|Experimental|Stellate Ganglion block group (Group II)|Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
11083911|NCT04188314|Experimental|Desflurane Interventional Group|"The intervention group will receive desflurane for maintenance of anaesthesia. Standard protocols for induction and maintenance of anaesthesia will be followed, as discussed with Prof. F. Puehringer, an international expert in the field of desflurane use. A detailed leaflet describing the protocol has been developed, which will be handed to the treating anaesthetist on the day of surgery.
~After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the desflurane vaporiser is opened to 12%. This is maintained until 1MAC is reached. The fresh gas flow will then be turned down to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand."
11083912|NCT04188314|Active Comparator|Isoflurane Control Group|The control group will receive Isoflurane for maintenance of anesthesia. After induction of anaesthesia and after the airway is secured, fresh gas flow is reduced to 2 l/min and the Isoflurane vaporiser is opened and adjusted to attain 1MAC. Once 1MAC is attained, the fresh gas flow will be reduced to 0.2-0.5 l/min (taking into consideration the machine leak) and the vaporiser will be adjusted to maintain 1MAC. The use of basal to minimal fresh gas flow is intentional, to minimise the amount of anaesthetic vapour used. When basal flow is used, 100% oxygen is required to meet oxygen demand.
11083913|NCT04188301|Active Comparator|IVM + ALB|Single dose of oral IVM (150 µg/kg) plus ALB (400 mg)
11083914|NCT04188301|Experimental|IDA x 1 dose|Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
11083915|NCT04188301|Experimental|IDA x 3 doses|Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
11083916|NCT04188288|Experimental|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
11083917|NCT04188288|Other|Control feedback|Three imaging (fMRI) sessions of control feedback.
11083918|NCT04188275||Metastatic Castration Resistant Prostate Cancer|Metastatic Castration Resistant Prostate Cancer patients who are eligible for endocrine therapy with ARTA plus LHRH agonist.
11083919|NCT04188262|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
11083920|NCT04188249||RA patients|"Patients (or a representative) must provide informed consent before any procedures occur.
~Main Inclusion Criteria:
~18 years and older
~Fulfil the ACR/EULAR classification criteria for RA in 2010
~Patients able to understand and complete self-evaluation questionnaires.
~General Exclusion Criteria:
~Contraindications for golimumab
~Prior exposure to TNFi/JAKi"
11083921|NCT04188223|Experimental|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
11083947|NCT04188015|Sham Comparator|Sham Procedure|1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.
11083922|NCT04188223|Active Comparator|Control Product: Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg and purified and inactivated by several physicochemical steps such as ultracentrifugation, column chromatography and formaldehyde treatment.
11083923|NCT04188197|Experimental|e-Cigarette Matched to Usual Brand Cigarette|"JUUL and cigarette flavor matched (Mint for menthol smokers and Virginia Tobacco for non-menthol smokers);"
11083924|NCT04188197|Experimental|e-Cigarette Unmatched to Usual Brand Cigarette|"JUUL and cigarette flavor unmatched (Virginia Tobacco for menthol smokers and Mint for non-menthol smokers)."
11083925|NCT04188184|Active Comparator|tranexmic acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
11083926|NCT04188184|Active Comparator|Epinephrine roup|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
11083927|NCT04188171|Experimental|Polidocanol foam sclerotherapy|"During the intervention period the participants are observed at 3-week intervals (maximum of 3 sessions).
~The required number of polidocanol foam sclerotherapy sessions (maximum of 3) is determined by clinical and anoscopic evaluation (if the participant is non-symptomatic and/or there is no significant hemorrhoidal disease on anoscopy, the patient will not be a candidate for additional instrumental therapy moving directly to the follow-up period). After each session all patients were instructed to adopt dietary measures and adequate hydration maintaining therapy with systemic venotropic, topical and laxative if necessary.
~After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
11083928|NCT04188158|Experimental|Intervention Group|3 cycles XELOX + Surgery+ 5 cycles XELOX
11083929|NCT04188158|Other|Control group|Surgery + 8 cycles XELOX
11083930|NCT04188145|Active Comparator|Fluoropyrimidine|
11083931|NCT04188145|Active Comparator|Fluoropyrimidine + Bevacizumab|
11083932|NCT04188132|Experimental|EEG BCI closed loop feedback for rehabilitation of upper limb|"This study is a pilot study to examine the feasibility of a SMR based EEG BCI using motor task and motor imagery and involve a gaming feedback for same.
~The first two days will be used for calibrating the BMI using commands in computer screen followed by further two days for testing the BMI and feedback control during gaming in computer to move the ball in the computer screen."
11083933|NCT04188119|Experimental|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
11083934|NCT04188119|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
11083935|NCT04188106|Experimental|Hydroxyzine and Varenicline|Participants enrolled in the study will take the FDA approved starter kit of varenicline for the first week of medication administration (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7). During the first week, participants will also receive hydroxyzine dosed in a similar manner, 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night. After the first week, participants will receive the FDA-approved dose of varenicline (1 mg twice daily) combined with hydroxyzine, 25 mg in the morning and 50 mg at nighttime. All medications will be dosed orally.
11083936|NCT04188080|Experimental|Jarlsberg cheese starting dose|The participants obtaining an Osteocalcin increase > 10% during the previous 6 weeks intake of Jarlsberg cheese, will get a percent reduction in the daily cheese-dose equal to the increase in the Osteocalcin level
11083937|NCT04188067|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic, the non-fluent variant or the semantic variant. All participants will receive the same study interventions in a within-subject crossover design.
11083938|NCT04188054|Experimental|Intervention|Will be asked to change the position they lie on their bed when sleeping; that is, to re-position themselves when lying on their back so that their feet (and ankles) hang over the end of the mattress.
11083939|NCT04188054|Placebo Comparator|Control|Will be asked to make no change in the way they normally lie on their mattress when sleeping
11083940|NCT04188041|No Intervention|Qualitative|"Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.
~In Aim 1, 30 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO)."
11083941|NCT04188041|Other|Quantitative|Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 20 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
11083942|NCT04188041|Other|Retrospective chart review|Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.
11083943|NCT04188028|Experimental|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
11083944|NCT04188028|Experimental|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
11083945|NCT04188015|Experimental|2.5mg ANX007|1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.
11083949|NCT04188002|Other|Physical Activity Intervention|Participants in this arm will be encouraged via tailored newsletters and email/or text reminders to improve diet and physical activities.
11083950|NCT04187989|Experimental|Social Media Intervention|Facebook page that will deliver health information focused on increasing well-being and reducing risky behaviors.
11083951|NCT04187989|No Intervention|Control|An Attention-Control E-News (control) condition
11083952|NCT04187976||Patients with moderate to severe uncontrolled asthma|Patients with moderate to severe uncontrolled asthma defined on clinical assessment and spirometric criteria. Non controlled asthma is considered when ACQ score ≥ 1.5 or in case of acute exacerbation
11083953|NCT04187976||Patients with recalcitrant CRSwNP requiring sinus surgery|The medical failure in CRSwNP is defined as persistent disease in spite of 3 courses of oral corticosteroid and double dose of local corticoid over 12 months
11083954|NCT04187976||Patients with concomitant CRSwNP and uncontrolled asthma|Patients with concomitant CRSwNP and moderate to severe uncontrolled asthma
11083955|NCT04187976||Healthy subjects|Patients without any airway inflammatory disease or atopy
11083956|NCT04187963|Experimental|Group physical therapy|Groups of 6 patients and 1 physical therapist for the 1.5 hour physical therapy session
11083957|NCT04187963|Active Comparator|Individual physical therapy|1.5 hour physical therapy session 1 on 1 (1 patient and 1 physical therapist)
11083958|NCT04187950|Placebo Comparator|Yogurt with inactivated B. lactis and added cane sugar|Participants will consume yogurt with heat inactivated B. lactis and added cane sugar twice daily for 14 days.
11083959|NCT04187950|Experimental|Yogurt with B. lactis and added honey|Participants will consume yogurt with B. lactis and added honey twice daily for 14 days.
11083960|NCT04187937|Experimental|Experimental|Stereotactic image-guided non-anatomical resection
11083961|NCT04187924|Active Comparator|Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage. Sputum will be collected during the session.
11083962|NCT04187924|Active Comparator|SIMEOX + Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during the session.
11083963|NCT04187911|Experimental|Intervention - Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. DDP aims to treat trauma-related problems and Attachment Disorders over about 20 1-hour sessions using the core communication techniques of Playfulness, Acceptance, Curiosity and Empathy (PACE)
11083964|NCT04187911|Active Comparator|Control - Services as Usual (SAU)|SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise.
11083965|NCT04187898|Experimental|Eflapegrastim @ 30mins post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).
~Supplied in prefilled single-use syringes for subcutaneous injection.
~Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.
~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
11083966|NCT04187898|Experimental|Eflapegrastim @ 3 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).
~Supplied in prefilled single-use syringes for subcutaneous injection.
~Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.
~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
11083967|NCT04187898|Experimental|Eflapegrastim @ 5 hours post TC|"Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).
~Supplied in prefilled single-use syringes for subcutaneous injection.
~Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.
~Cycles 2-4: Administered 24 hours after TC chemotherapy administration."
11083968|NCT04187885|Active Comparator|Group/Cohort 1 : CTL|"Label : control
~Type : comparator
~Description: Outside academic stress period (represented by exams), without the physical activity program (no Intervention)."
11083969|NCT04187885|Experimental|Group/Cohort 2: PAP|"Label : physical activity program without stress Type : experimental
~Description: outside academic stress period (exams), with the physical activity program:60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday."
11083970|NCT04187885|Experimental|Group/Cohort 3: AS|"Label : academic stress Type : experimental
~Description: during academic stress period (exams), without the physical activity program (no Intervention)"
11083971|NCT04187885|Experimental|Group/Cohort 4: ASPAP|Label : academic stress and physical activity program Type : experimental Description: during academic stress period (exams), with the physical activity program: 60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday.
11083972|NCT04187872|Experimental|Patients with Recurrent Brain Metastes|Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed SRS treatment will receive LITT per standard of care in combination with Pembrolizumab 200mg IV every 3 weeks (+/-3 days) up to 2 years.
11083973|NCT04187859|Other|Education Session|The participant will receive an education session in their home, lasting between 15-30 minutes from a District Nurse. The District Nurses will advise the participant on how to drink more fluids, the importance of hydration and the effects of dehydration.
11083974|NCT04187859|Other|Prompting Cup|Participants will receive a Droplet Cup with an electronic prompting device and a brief tutorial session from the District Nurse. The Droplet Cup will encourage the participant to stay hydrated during the day, by emitting a voice or light to encourage them to drink more.
11083975|NCT04187859|No Intervention|Control Group|There will be no change to the care the participant receives from the District Nurse.
11083976|NCT04187859|Other|Prompting Cup and Education|Participants will receive a Droplet Cup with an electronic prompting device and an education session on the importance of hydration and the effects of dehydration.
11083977|NCT04187833|Experimental|Nivolumab + Talazoparib|Nivolumab 480mg intravenously every 4 weeks (28 days) + Talazoparib 1mg orally daily
11083978|NCT04187820|Experimental|Acupuncture group|Participants receiving acupuncture and mild moxibustion.
11083979|NCT04187807|Experimental|Melatonin 5mg|Melatonin 5mg, every 24 hours for 14 days
11083980|NCT04187807|Placebo Comparator|Placebo|Starch based placebo, every 24 hours for 14 days
11083981|NCT04187781|Other|external microphone old|
11083982|NCT04187781|Other|external microphone new|
11083984|NCT04187768||NSCLC Group|Patients with advanced NSCLC will have blood collected prior to treatment and after completing 3 cycles of immune checkpoint therapy. . If a patient is noted to have progressive disease after 2 cycles of treatment, a sample will be collected after the 2nd cycle. If a patient is noted to have pseudoprogression (determined at the discretion of the treating physician), an additional sample may be collected after 3 cycles of therapy.
11083985|NCT04187755|Active Comparator|Group I|Participants were given ceftazidime as the antibiotic therapy with standard regimens and dose of antibiotic
11083986|NCT04187755|Experimental|Group II|Participants were given cefepime as the antibiotic therapy with standard regimens and dose of antibiotic
11083987|NCT04187742|Active Comparator|LTC Physicians Receive Social Comparison Email|All LTC physicians who receive a social comparison email
11083988|NCT04187742|No Intervention|LTC Physicians Do Not Receive Social Comparison Email|All LTC physicians who do not receive a social comparison email
11083989|NCT04187742|Active Comparator|LTC Physicians Receive Maintenance Certification Email|All LTC physicians who receive a maintenance certification email
11083990|NCT04187742|No Intervention|LTC Physicians Do Not Receive Maintenance Certification Email|All LTC physicians who do not receive a maintenance certification email
11083991|NCT04187742|Active Comparator|LTC Physician Has (or has not) Opened Prior Report|LTC physicians who opened (or has not opened) at least one report receive an email informing them of their report opening status
11083992|NCT04187742|No Intervention|LTC Physician Has (or has not) Opened Prior Report (Control)|LTC physicians who opened (or has not opened) at least one report receive a standard email without report opening status
11083993|NCT04187729||Diseased|Subjects with a known disease.
11083994|NCT04187729||Non-diseased|Subjects without a known disease and reportedly healthy.
11083995|NCT04187716|Experimental|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.
~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
11083996|NCT04187716|Other|remedies|Treatment for anemia will include remedies such as iron (oral or intravenous), hematopoietic accelerators, and blood transfusions, and will be determined by researchers at each institution to provide optimal treatment for patients.
11083997|NCT04187703|Experimental|5AZA-alt-DEC|"Participants will be treated for a minimum of 24 weeks in the absence of clear evidence of progressive disease. Patients who have any response will be permitted to continue treatment until relapse or progression of disease that is not sensitive to protocol defined dose escalation.
~Treatments will include:
~5-azacytidine (50mg/m^2) Day 1 every week
~Decitabine (5mg/m^2) Day 4 every week
~Weeks 1-8 will be an induction phase, and weeks 9+ will be a long-term treatment phase"
11083998|NCT04187690|Experimental|Jin-shui Huan-xian granule|Participants in this arm will be given Jin-shui Huan-xian granule.
11083999|NCT04187690|Placebo Comparator|Jin-shui Huan-xian granule placebo|Participants in this arm will be given Jin-shui Huan-xian granule placebo.
11084000|NCT04187677|Active Comparator|Hand Therapy Group|
11084001|NCT04187677|Experimental|Sensory Training Group|
11084002|NCT04187664|Experimental|EXCARE Pathway Group|The proposed pathway comprises a range of actions that include individual patient-centered risk assessment by the SAMPE Risk Model (30-day probability of death), specialized care in Post-Anesthetic and Intensive Care Units, and also in the surgical wards performed by the nursing, anesthesia, clinic and surgery teams.
11084003|NCT04187651|Experimental|PRP gel application|PRP application for perianal fistula
11084004|NCT04187638|Experimental|Olive oil|Participants will receive 30ml/day of olive oil for two weeks
11084005|NCT04187638|Placebo Comparator|Butter|Participants will receive 30g/day of butter also for two weeks.
11084006|NCT04187625|Experimental|Intervention|Patients will be given autologous endothelial progenitor cells
11084007|NCT04187612||Total body water measurement|Total body water will be measured using Bioelectrical Impedance Analysis (BIA).
11084008|NCT04187599|Experimental|Paragon CRT®100 Contact Lens|participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.
11084009|NCT04187586||Extracorporeal shock wave therapy group|The ESWT group received shock waves with low-energy flux density (0.05-0.30 mJ/mm2). The interval between treatments is a 1-week. To evaluate the effect of ESWT, we reviewed the skin test results (thickness, melanin, erythema, TEWL, sebum, and skin elasticity levels) immediately before ESWT and immediately after the sixth session. And also the ESWT group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
11084010|NCT04187586||conventional therapy without extracorporeal shock wave therapy|Conventional therapy group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
11084011|NCT04187560|Active Comparator|Part A Cohort 1|LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day
11084012|NCT04187560|Active Comparator|Part A Cohort 2|LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day
11084013|NCT04187560|Active Comparator|Part A Cohort 3|LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day
11084014|NCT04187560|Active Comparator|Part A Cohort 4|LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day
11084015|NCT04187560|Active Comparator|Part A Cohort 5|LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day
11084016|NCT04187560|Active Comparator|Part B Cohort 6|LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
11084017|NCT04187560|Active Comparator|Part B Cohort 7|LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
11084018|NCT04187560|Active Comparator|Part B Cohort 8|LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
11084019|NCT04187547|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
11084020|NCT04187547|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
11084021|NCT04187534|Experimental|Albumin Fluid Resuscitation Optimization Intervention|Our quality improvement intervention seeking to improve appropriate use and reduce inappropriate use of albumin for fluid resuscitation will consist of establishing a clinical champion, educating clinicians, changing the process for albumin ordering through development of an albumin order sheet, and providing quarterly unit-level audit/feedback data to clinicians on albumin utilization.
11085813|NCT04175379|Experimental|group 60|In group 60, target PaCO2 is 60 during surgery
11084022|NCT04187534|Active Comparator|Usual Practice|Stepped-wedge roll out of 'Albumin Fluid Resuscitation Optimization Intervention' will permit those ICUs wherein intervention has not yet been implemented to serve as controls. These ICUs will prescribe albumin according to usual practice and not be exposed to any components of the intervention.
11084023|NCT04187521|Other|Sensitivity defect|Participants defined as having abnormal insulin sensitivity without an absolute defect in insulin secretion.
11084024|NCT04187521|Other|Secretory defect|Participants defined as having abnormal insulin secretion without a defect in insulin sensitivity.
11084025|NCT04187521|Other|Unclassified|Participants who cannot be classified as having abnormal insulin secretion or abnormal insulin sensitivity or who have both abnormal insulin sensitivity and abnormal insulin secretion.
11084026|NCT04187508|Experimental|AZD8154|Subjects will receive AZD8154 QD dosing for 10 days
11084027|NCT04187508|Placebo Comparator|Placebo|Subjects will receive AZD8154 matching placebo QD dosing for 10 days
11084028|NCT04187495|Experimental|MAX-40279-01|
11084029|NCT04187482|Experimental|Exercise training group|All participants will be receiving same exercise training intervention
11084030|NCT04187469|Experimental|Regimen 1: 2HRM/4HR|Two month of chemotherapy with Moxifloxacin, Isoniazid and Rifampicin, followed by four month of Isoniazid and Rifampicin only.
11084031|NCT04187469|Active Comparator|Regimen 2: 2HRZE/4HR (control regimen)|Two month of chemotherapy with Isoniazid, Rifampicin, Pyrazinamide and Ethambutol, followed by four month of Isoniazid and Rifampicin only.
11084032|NCT04187456|Experimental|Midazolam + Savolitinib|"Treatment Period 1: Single administration of midazolam (1 mg) will occur on Study Day 1, after a high fat, high calorie breakfast, followed by PK sampling for 24 hours.
~Treatment Period 2: Single administration of midazolam 1 mg in combination with a single administration of savolitinib (600 mg), after a high fat, high calorie breakfast will occur on Study Day 5 and PK sampling will occur for 24 hours."
11084033|NCT04187443|Experimental|MS-553 low dose|low dose of MS-553 taken orally
11084034|NCT04187443|Experimental|MS-553 mid dose|mid dose of MS-553 taken orally
11084035|NCT04187443|Experimental|MS-553 high dose|high dose of MS-553 taken orally
11084036|NCT04187430||Retrospective group|
11084037|NCT04187430||Prospective group|
11084038|NCT04187417|Experimental|Topical tetracaine|Topical tetracaine hydrochoride 1%
11084039|NCT04187417|Placebo Comparator|Balanced artificial tear solution|Balanced artificial tear solution (Systane)
11084040|NCT04187404|Experimental|5-cohort study design|"Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.
~Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 2A and 2B) with adrenal carcinoma.
~Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 3A and 3B) with progressive malignant pheochromocytoma/paraganglioma."
11084041|NCT04187391|Experimental|Active tDCS plus individual language training|Active tDCS plus individual language training
11084042|NCT04187391|Active Comparator|placebo tDCS plus individual language training|placebo tDCS plus individual language training
11084043|NCT04187391|Active Comparator|Active tDCS plus unstructured cognitive stimulation|Active tDCS plus unstructured cognitive stimulation
11084044|NCT04187378|No Intervention|Control Group|Body temperature of the patients will be measured in the pre-operative service and in the waiting room. Sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
11084045|NCT04187378|Experimental|Underbody Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
11084046|NCT04187378|Experimental|Surgical Access Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown surgical access blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
11084047|NCT04187365|No Intervention|GROUP 1 (NonSevere PUR and women without PUR)|Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.
11084048|NCT04187365|Experimental|GROUP 2 (Severe PUR)|Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.
11084049|NCT04187352|Experimental|CS1001+ Fluorouracil+Cisplatin|
11084050|NCT04187352|Active Comparator|Placebo+ Fluorouracil+Cisplatin|
11084051|NCT04187339|Experimental|NGM395 Dose 1|NGM395 Subcutaneous Injection
11084052|NCT04187339|Experimental|NGM395 Dose 2|NGM395 Subcutaneous Injection
11084053|NCT04187339|Experimental|NGM395 Dose 3|NGM395 Subcutaneous Injection
11084054|NCT04187339|Experimental|NGM395 Dose 4|NGM395 Subcutaneous Injection
11084055|NCT04187339|Experimental|NGM395 Dose 5|NGM395 Subcutaneous Injection
11084056|NCT04187339|Experimental|NGM395 Dose 6|NGM395 Subcutaneous Injection
11084057|NCT04187339|Placebo Comparator|Placebo|Placebo
11084093|NCT04187027|Experimental|the medical care and standard care + P.E.M.F group|Group (B) which received the same medical care and standard urotherapy in addition to pulsed electromagnetic field therapy that applied for 20 min, ,three times / weak for three successful months.
11084058|NCT04187326|Experimental|6 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test.
11084059|NCT04187326|Experimental|12 Month Micro Expression Training Task|The Micro Expression Training Task (METT) presents videos of subtle emotional face expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. Participants in this group will complete this task twelve month after their first visit.
11084060|NCT04187313|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention package (i.e. private practitioners in the selected areas who agree to participate).
11084061|NCT04187313|No Intervention|Control|Private practitioners in the control areas will receive no intervention.
11084062|NCT04187300|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (Formulation D)
11084063|NCT04187300|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (Formulation B)
11084064|NCT04187287|Active Comparator|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will be given for 3 weeks, 1 days in a week. Moreover 10-12 minutes cold pack will apply for every session.
11084065|NCT04187287|Active Comparator|Deep Friction Massage|Deep Friction Massage treatment will be given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
11084066|NCT04187235||Keyhole rapair|74 patients who undervent parastomal hernia repair with keyhole technique 1997-2009
11084067|NCT04187235||Sugarbaker repair|61 patients who undervent parastomal henia repair a.m. Sugarbaker 2009-2015
11084068|NCT04187222|Experimental|Test Group|Mechanical treatment + Bifidobacterium animalis subsp. lactis
11084069|NCT04187222|Placebo Comparator|Control Group|Mechanical treatment + Placebo
11084070|NCT04187209|Other|Non-traumatic hemiplegia in post stroke acute subacute phase|
11084071|NCT04187196|Experimental|Sedation with propofol group|Participants in this group will be randomized to sedation with bolus dosing of propofol for cardioversion.
11084072|NCT04187196|Experimental|Sedation with methohexital group|Participants in this group will be randomized to sedation with bolus dosing of methohexital for cardioversion.
11084073|NCT04187183|Experimental|Fresh PRP with concentrate Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma with concentrated Leukocytes
~1 infiltration weekly, for 3 weeks."
11084074|NCT04187183|Active Comparator|Fresh PRP without concentrated Leukocyte|"Three infiltrations of fresh Platelet Rich Plasma without concentrated Leukocyte.
~1 infiltration weekly, for 3 weeks."
11084075|NCT04187170|Experimental|Healthy sedentary subjects exposed to the training program|
11084076|NCT04187157||Blue-light filtering intraocular lens (IOL)|Bilateral implantation of blue-filtering intraocular lens. Blue-IOL, in addition to ultraviolet, also impede the transmission of the lower visible blue spectrum between 400 and 500nm.
11084077|NCT04187157||Conventional intraocular lens (IOL)|Bilateral implantation of conventional ultraviolet light-blocking intraocular lens
11084078|NCT04187144|Experimental|Gepotidacin|Participants will be administered oral doses of 1500 mg gepotidacin plus nitrofurantoin matching placebo BID; approximately every 12 hours for 5 days
11084079|NCT04187144|Active Comparator|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
11084080|NCT04187131|Experimental|augmented reality|
11084081|NCT04187118||Lymphoma patients|Patients being in complete response after a first therapy for malignant lymphoma.
11084082|NCT04187092|Experimental|KneeBright group|Participants in this group will perform exercises aimed to improve the muscle strength, balance and precision. Participants will perform exercises three times a week for 12 weeks. Each session will last for an hour. Some of the exercises will be performed with the KneeBright Device while playing a video game.
11084083|NCT04187092|Active Comparator|Standard Rehabilitation group|Participants in this group will perform exercises with the same focus and frequency. No exercises will be performed with the KneeBright device.
11084084|NCT04187079||IPF|Patients diagnosed with idiopathic pulmonary fibrosis after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
11084085|NCT04187079||Other ILDs|Patients diagnosed with other interstitial diseases other than IPF after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
11084086|NCT04187066||Obese|severe obesity
11084087|NCT04187066||Control|Control group with normal weight
11084088|NCT04187053|Experimental|Conventional mechanical therapy with aPDT adjunct|Traditional non-surgical mechanical debridement along with antimicrobial photodynamic therapy will be done at implant sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. The dye will be applied topically confined to the epithelialized space surrounding the implant fixture and will not be internalized. After 5 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the implant using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
11084089|NCT04187053|Sham Comparator|Conventional mechanical therapy with sham aPDT treatment|"Control group will have conventional mechanical instrumentation of implant site with Sham aPDT treatment with saline and non-light emitting laser"
11084090|NCT04187040|Active Comparator|3-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 3-step hand hygiene technique.
11084091|NCT04187040|Active Comparator|6-step hand hygiene technique|Wards assigned to this study arm will receive instructions, educational materials and tutorials about the 6-step hand hygiene technique.
11084092|NCT04187027|No Intervention|the medical care and standard care only group|Group (A) received medical care and standard urotherapy only.
11084159|NCT04186533|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read brief nutrition education handouts before online grocery shopping.
11084094|NCT04187014|Active Comparator|Tranexamic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid are 650 mg each. The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
11084095|NCT04187014|Experimental|Aminocaproic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic tablets are 1000 mg each.The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For the aminocaproic acid, a total dose of 6 grams (6 tablets) divided between the 3 administrations (2 gram each, ie 2 tablets of 1000 mg) will be administered."
11084096|NCT04187001||Judges|Professionals that assess the content validity of the exercise protocol
11084097|NCT04187001||Target population|People that assess the exercise protocol for cultural adaptation
11084098|NCT04186988|Experimental|Diagnostic ([18F]-AraG)|Patients receive [18F]-AraG IV and then undergo PET/CT over 2 hours at baseline and within 2 weeks after starting immunotherapy. Patients may also undergo blood sample collection.
11084099|NCT04186975||Low-risk pregnant women|Normal cohort: this cohort consists of pregnancies which are not at risk. Data are recorded during the normal checkup happening as part of the usual care pathway
11084100|NCT04186975||High-risk pregnant women|Risk cohort: this cohort consists of pregnancies at risk and which are regularly recorded for the purpose of fetal surveillance. Specifically, the investigators recruit pregnancies with intra uterine growth restricted fetuses for this study.
11084101|NCT04186962|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
11084102|NCT04186962|No Intervention|Usual care|Usual care
11084103|NCT04186936|Experimental|Treatment Sequence AB|Participants will receive Test Product A (single dose of 2 caplets [Combination caplet with loperamide hydrocloride [HCl] 2 milligram [mg] + simethicone 125 mg]) orally on Day 1 followed by Reference Product B (single dose of 2 Imodium Express tablets-lyophilizate [2*2 mg loperamide HCl] + 6 Espumisan capsules [6*40 mg simethicone]) orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
11084104|NCT04186936|Experimental|Treatment Sequence BA|Participants will receive Reference product B orally on Days 1 followed by Test product A orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
11084105|NCT04186923|Experimental|Intervention group (IG)|Families receive permanent contact persons to support in the organisation of everyday life, financial applications, during emotional coping with illness and open communication within the family.
11084106|NCT04186923|No Intervention|Control Group|In the control group the families are treated according to the standard of care.
11084107|NCT04186910|Placebo Comparator|Control group|The control group will not receive any feedback on levels of physical activities but will receive any planned usual care rehabilitation activities
11084108|NCT04186910|Experimental|Feedback group|The feedback group will have an active feedback intervention of physical activities, consisted of daily feedback, received through a Fitbit application, and weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. The experimental group will receive any planned usual care rehabilitation activities.
11084109|NCT04186897|Experimental|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
11084110|NCT04186897|Sham Comparator|No occlusal reduction|Occlusal surfaces kept intact. No actual occlusal reduction..
11084111|NCT04186884||Observational (questionnaires)|Patients and caregivers visiting SCC for a consult or admitted to PCU complete questionnaires over 35 minutes.
11084112|NCT04186871|Experimental|SLE: branebrutinib|
11084113|NCT04186871|Placebo Comparator|SLE: placebo|
11084114|NCT04186871|Experimental|pSS: branebrutinib|
11084115|NCT04186871|Placebo Comparator|pSS: placebo|
11084116|NCT04186871|Experimental|RA: branebrutinib followed by abatacept|
11084117|NCT04186871|Placebo Comparator|RA: placebo followed by abatacept|
11084118|NCT04186858||Symptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.
11084119|NCT04186858||Asymptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.
11084120|NCT04186845|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
11084121|NCT04186832|Active Comparator|Group I (pedometer)|Patients wear a pedometer for step count monitoring over 6 weeks.
11084122|NCT04186832|Experimental|Group II (FitBit)|Patients wear a FitBit for step count monitoring over 6 weeks.
11084123|NCT04186819|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
11084124|NCT04186806|Experimental|3M Dry Mouth Moisturizing Spray|Dry mouth agent
11084125|NCT04186806|Active Comparator|Biotene Moisturizing Mouth Spray|Dry mouth agent
11084126|NCT04186793|Experimental|Guided Grocery Shopping|Participants in this study arm will receive a guided grocery shopping intervention for four weeks.
11084127|NCT04186793|Experimental|Diet Provision Group|"Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low free sugars diet (goal of <3% of total calories)."
11084128|NCT04186780|Experimental|Intervention group|Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
11084129|NCT04186780|Placebo Comparator|Placebo group|Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.
11084130|NCT04186767|Experimental|Weight loss|
11084195|NCT04186299|Experimental|Clonidine + articaine/epinephrine|1.7mL of 4% articaine/epinephrine(1:100,000) + clonidine (15ug/ml)
11084196|NCT04186299|Active Comparator|articaine/epinephrine|1.7mL of 4% articaine with 1:100,000 epinephrine
11084197|NCT04186286|Active Comparator|1st drug Ivabradine|Patients will take Ivabradine first followed by Propranolol and Placebo
11084131|NCT04186754|Experimental|Comprehensive functional care plan|"The intervention will be carried out thanks to the reeducation to the effort carried out in the individuals, which will have the following interventions:
~The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy."
11084132|NCT04186754|Active Comparator|Traditional intervention without rehabilitation|"Nursing care.
~Medical care.
~Spiritual attention."
11084133|NCT04186741||HBO Group|Patients already recieving hyperbaric oxygen therapy for treatment of other medical conditions requiring it as in diabetic foot , cerebral infarctions
11084134|NCT04186728|Placebo Comparator|Placebo to magnesium|Participants will be asked to consume a daily placebo (cellulose) capsule for 12 weeks. They will then cross-over and consume 200mg of elemental magnesium in the form of magnesium glycinate daily for 12 weeks.
11084135|NCT04186728|Experimental|Magnesium to placebo|Participants will be asked to consume 200mg of elemental magnesium in the form of magnesium glycinate daily. They will then cross-over and consume a daily placebo (cellulose) capsule for 12 weeks.
11084136|NCT04186715||TOETVA|The demographic data of the patients undergoing TOETVA surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
11084137|NCT04186715||Open thyroidectomy|The demographic data of the patients undergoing open thyroidectomy surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
11084138|NCT04186702|Active Comparator|visual acuity letter score|visual acuity letter score is used to compare between the two groups after interventional procedures
11084139|NCT04186702|Active Comparator|macular thickness(CST)|macular thickness(CST)is used to compare between the two groups after interventional procedures
11084140|NCT04186689||children in fully food secure households (G1)|preschool children live in a fully food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
11084141|NCT04186689||children in marginally food secure households (G2)|preschool children live in a marginally food secure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
11084142|NCT04186689||children in food insecure households (G3)|preschool children live in a food-insecure household have at least a carious tooth that needs treatment under local anesthesia other than extraction without any previous dental treatment experience.
11084143|NCT04186676||MINOCA patients|Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites
11084144|NCT04186663|Experimental|Advantage Arrest|38% silver diamine fluoride, topical, 1 drop, single application
11084145|NCT04186650|Experimental|Autologous genetically modified tissue-engineered skin graft|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
11084146|NCT04186637|Experimental|Dose escalation and expansion|ALPN-202 0.001 - 20 mg/kg IV
11084147|NCT04186624|Experimental|Supervised Exercise Program|The exercise program that applied at the hospital includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
11084148|NCT04186624|Active Comparator|Home-based Exercise Program|The home-based exercise program given with a brochure that includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
11084149|NCT04186611|Experimental|Early daily occupational therapy intervention|A daily occupational therapy intervention is performed with the patients included. The intervention will consist of assessment as well as early positioning and/or rehabilitation in activities of daily living.
11084150|NCT04186598|Experimental|Experimental: CPAP|Participants will be treated with CPAP. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
11084151|NCT04186598|Placebo Comparator|Control: High flow oxygen|Participants will be treated with an altered CPAP mask that will deliver high flow oxygen. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
11084152|NCT04186585|Experimental|First design level|All the 8 patients receives a daily oral dose of BP-C2 in ml equals the body weight divided by 5 for 4 weeks. This represents 15 ml for a patient of 75 kg
11084153|NCT04186585|Experimental|Second design level|Based on the results from the first design level, the daily BP-C2 dose will individually be increased by a factor of 1.4 or 1.2 in case of none or mild toxicity increase. If moderate or severe increase in toxicity is observed, the individual dose will be reduced by 0.8 or 0.6, respectively. Duration of the treatment is 4 weeks
11084154|NCT04186585|Experimental|Third design level|Based on the results from the second design level, the daily BP-C2 dose will individually be increased in case of none or mild toxicity increase and reduced if moderate or severe increase in toxicity is observed. Duration of the treatment is 4 weeks
11084155|NCT04186559|Experimental|Topical pentoxifylline (PTX) gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical PTX gel in their initial course of treatment will receive topical placebo gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
11084156|NCT04186559|Placebo Comparator|Topical placebo gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical placebo gel in their initial course of treatment will receive topical PTX gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
11084157|NCT04186546||Cases|Zephyr Valve Procedure
11084158|NCT04186533|Experimental|Default Intervention|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
11137873|NCT03811236|No Intervention|Room temperature|
11084160|NCT04186520|Experimental|8-Day Production of Car-T Cells|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.
~Phase 1b: Six to nine patient expansion cohorts at eight- and 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
11084161|NCT04186520|Experimental|12-Day Production of Car-T Cells|"Phase 1: Determine safety of 2.5x10^6 cells/kg IL-7/IL-15 expanded CAR-20/19-T cells in patients with relapsed, refractory B-cell NHL. Patients will be enrolled in 3+3 fashion.
~Phase 1b: Six to nine patient expansion cohorts at eight- and 12-day manufacturing. If six patients are enrolled in Phase 1 then only six additional patients will be added. If three patients are enrolled in Phase 1 then nine additional patients will be treated for a total of 12 in each group."
11084162|NCT04186520|Experimental|Phase 2 - Efficacy of CAR-20/19-T cells in MCL|"Single-stage Phase II design with 3-month CR as the target endpoint.
~Optimal production times will be determined following phase 1 of the study."
11084163|NCT04186507||Prelaminary group|To confirm that Li+ is detectable in sweat .
11084164|NCT04186507||Spectrophon LTD biosensors for Li+ detection in sweat|In this group will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat
11084165|NCT04186494|Active Comparator|Continuous positive airway pressure (CPAP)|Standard CPAP Therapy
11084166|NCT04186494|Experimental|Liraglutide-based weight loss regimen|Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
11084167|NCT04186494|Experimental|Combination CPAP/Liraglutide|Combination of both interventions
11084168|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
11084169|NCT04186468|Experimental|ICU follow-up clinic|Participants will be invited to visit the ICU follow-up clinic.
11084170|NCT04186468|No Intervention|Usual care|Participants will solely receive usual care.
11084171|NCT04186455|Active Comparator|insertion time|lma pro seal and basks-mask in patients undergoing ups
11084172|NCT04186455|Active Comparator|oropharyngeal leak pressure|lma baska-mask undergoing urs
11084173|NCT04186442|Experimental|Botulinum toxin type A (Botulax®)|
11084174|NCT04186442|Active Comparator|Botulinum toxin type A (Botox®)|
11084175|NCT04186429||traumatic brain injury|Children with traumatic brain injury
11084176|NCT04186429||orthopedic injury|Children with orthopedic injury
11084177|NCT04186416||Patients less than 6 months old|Patients less than 6 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
11084178|NCT04186416||Patients between 6 and 12 months old|Patients between 6 and 12 months old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
11084179|NCT04186416||Patients between 1 and 6 years old|Patients between 1 and 6 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
11084180|NCT04186416||Patients between 6 and 10 years old|Patients between 6 and 10 years old admitted to the pediatric surgical ICU of the Necker-Enfants Malades university hospital and for whom volume expansion is indicated.
11084181|NCT04186403|Experimental|Study Drug|2 to 3 mg per day
11084182|NCT04186390||Medical doctors|Medical doctors with no prior experience in the evaluation of small bowel capsule endoscopy.
11084183|NCT04186377|Active Comparator|Standard-of-care managed group|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
11084184|NCT04186377|Experimental|S26E|This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application
11084185|NCT04186364|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the ED visit will serve as our intervention group. The participants will be assigned an Ambassador throughout the child's ED visit and will complete a patient satisfaction survey afterwards. The investigators hold to enroll 120 controls.
11084186|NCT04186364|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the ED visit will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the ED visit, however no ambassador will be assigned during the ED visit. The investigators hope to enroll 120 controls.
11084187|NCT04186351|Experimental|Encounter notification service|For participants randomized to the intervention group, their encounter information stored in the eHRSS will be provided to the SCHSA via the automated notification service. Healthcare professionals of the SCHSA would access the electronic health record and provide caring support and services via telephone calls during the 12-month study period.
11084188|NCT04186351|No Intervention|Usual care service|For participants randomized in the control group, no notification will be sent to the SCHSA. Usual care service will be provided during the 12-month study period. In addition, each control participant will receive placebo phone calls at least once every three months (e.g., the calls could be about greeting and general checking).
11084189|NCT04186338||Patients with myelomeningocele|Patients diagnosed myelomeningocele with the neurological level between L5 and S3
11084190|NCT04186338||Healthy controls|age-, sex-, and body mass index-matched healthy controls
11084191|NCT04186325|No Intervention|Group C|Group C: the regular mechanical ventilation protocol will be followed.
11084192|NCT04186325|Experimental|Group T|Group T: inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
11084193|NCT04186312|Experimental|Immediate Treatment|Cognitive-Behavioral Treatment program known as ACCESS
11084194|NCT04186312|Other|Delayed Treatment|Allowed to receive treatment as usual during study, then received ACCESS after delay of two-semesters
11084199|NCT04186286|Active Comparator|3rd drug Ivabradine|Patients will take Propranolol and placebo first and then Ivabradine
11084200|NCT04186273|Sham Comparator|Donor Site Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
11084201|NCT04186273|Experimental|Donor Site Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
11084202|NCT04186273|Experimental|Donor Site Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
11084203|NCT04186273|Sham Comparator|Skin Graft Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.
11084204|NCT04186273|Experimental|Skin Graft Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
11084205|NCT04186273|Experimental|Skin Graft Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
11084206|NCT04186260|Experimental|NAFLD-specific weight loss intervention|Participants will attend 12 weekly 30-45-minute individual counseling sessions and receive tailored lesson materials focused on behavioral strategies for adopting and maintaining healthy eating and physical activity (PA) behaviors. Participants will self-monitor their body weight, eating, and PA behaviors in a weekly journal. Dietary recommendations will follow nutritional guidelines for the treatment of NAFLD. To facilitate the adoption of the dietary recommendation, participants will be provided culturally-tailored meal plans and grocery lists that allow them to make small, practical dietary changes of ~100 calories. Participants will be prescribed weekly exercise goals with the duration increasing from 15-45 minutes, 5 days/week, over the 12-month program. After the completion of 12 weekly individual counseling sessions, participants will complete a 12-week follow-up including bi-weekly phone calls, followed by a 6-month follow-up period in which no intervention contact is made.
11084207|NCT04186260|Other|Wait-list control|The wait-list control group will receive the same intervention strategies described for the NAFLD-specific weight loss intervention after study comparisons have been made.
11084208|NCT04186247|Other|Standard of Care|SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
11084209|NCT04186247|Experimental|Standard of Care + Antibiotics|"SOC induction (nutritional therapy) for up to 12 weeks, as assigned by the treating gastroenterologist prior to study entry.
~Azithromycin (weeks 4-12)
~Metronidazole (weeks 4-12)"
11084210|NCT04186234|Experimental|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 35 to 50 Grays in 5 fractions over 5 to 14 days.
11084211|NCT04186221|Experimental|Treatment arm|
11084212|NCT04186195||Diabetic children aged 1-16 years and their families|Diabetic children aged 1-16 years and their families. A child's disease duration must be over 1 year so that possible remission period is over.
11084213|NCT04186182|Other|CICI - Feasibility trial study group|The feasibility of the entire CICI-protocol will be evaluated. See details above.
11084214|NCT04186169|Placebo Comparator|Arm 1: Paroxysmal AF - PVI arm|The subjects with paroxysmal AF undergo pulmonary vein isolation (PVI).
11084215|NCT04186169|Placebo Comparator|Arm 2: Persistent AF - PVI arm|The subjects with persistent AF undergo pulmonary vein isolation (PVI).
11084216|NCT04186169|Experimental|Arm 3: Persistent AF - PVI + Fat-targeted ablation|The subjects with persistent AF undergo pulmonary vein isolation (PVI) and additional ablation to target the inflammatory fat tissue
11084217|NCT04186156|Experimental|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
11084218|NCT04186143|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, closed cinetic chain exercises were applied for 12 weeks.
11084219|NCT04186143|Active Comparator|Active Comparator|In addition to the conservative treatment of the control group, opened cinetic chain exercises were applied for 12 weeks.
11084220|NCT04186143|Other|Control Group|Conservative treatment was applied for 12 weeks.
11084221|NCT04186130||SB|Children over 3 years old and under 12 years old who have been diagnosed with spinal bifida with spinal MRI. They should not have known inflammatory bowel disease or cloacal anomaly
11084222|NCT04186130||Control|Children over 3 years old and under 12 years without known inflammatory bowel disease or cloacal anomaly
11084223|NCT04186117|Experimental|Biological collection|"For all the patients include in the study :
~- Blood samples collected at before any treatment
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11084224|NCT04186104|Experimental|Patients with routine outpatient service process|After registration, the patient waits in line at the door of the doctor's office. His doctor uses traditional methods to enter medical records by hand and make diagnosis independently. Then the patient waits in line to pay the bill and queues up for examination. Finally, the patient would take the examination report back to the doctor.
11084225|NCT04186104|Experimental|Patients with AI assisted outpatient service process|After registration, the patient binds his information to the mobile phone application through outpatient' number. First, AI system would ask the patient a series of questions. Then it would make a judgment based on the patient's response. The system transmits the examination items to the doctor's computer and, with the doctor's approval, sends items back to the patient. So, patient could go straight to do the examination. While waiting for his turn, the patient enters the phone program again, and the AI system collects his medical history. The information is sent back to the doctor. When the patient goes to the doctor's office with the examination report, the doctor's computer already has his medical records. The doctor only needs to adjust the history according to the actual situation. After writing the medical history, the AI system could automatically make the diagnosis. Doctor uses the AI' results and his own judgment to make a comprehensive diagnosis.
11084226|NCT04186078||obstructive sleep apnea (OSA)|5 or more predominantly obstructive respiratory events [obstructive and mixed apneas, hypopneas or respiratory effort-related arousals (RERAs)] per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
11084227|NCT04186078||central sleep apnea (CSA)|"PSG shows all of the following:
~5 or more central apneas and/or central hypopneas per hour of sleep.
~The number of central and/or central hypopneas is > 50% of the total number of apneas and hypopneas."
11137935|NCT03810846|Experimental|Exercise|Walking football exercise program
11084228|NCT04186078||control|apnea-hypopnea index < 5 per hour of sleep during a PSG or per hour of monitoring (respiratory polygraphy)
11084229|NCT04186052|Experimental|BCMA CAR-T cells Infusion|
11084230|NCT04186039|Experimental|Congenital diaphragmatic and parietal malformations|Patients with fetal magnetic resonance imaging as part of their usual medical care, for fetal / placental indications of diaphragmatic hernia, omphalocele or gastroschisis.
11084231|NCT04186026|Other|Saline+Saline|
11084232|NCT04186026|Other|Neurotensin+Saline|
11084233|NCT04186026|Other|GLP-1+Saline|
11084234|NCT04186026|Other|Neurotensin + GLP-1|
11084235|NCT04186013|Experimental|Experimental arm|Atezolizumab 1200 mg intravenous infusion every 3 weeks for a total of 6 doses combined with External Beam Radiation Therapy (EBRT) (dosage: 60 Gy in 30 fractions overs 6 weeks at 2Gy/day)
11084236|NCT04186000|Experimental|group 1|Booster vaccine with AD26.ZEBOV after 1 year
11084237|NCT04186000|Experimental|group 2|Booster vaccine with AD26.ZEBOV after 2 years
11084238|NCT04185987|Experimental|Microbial colonisation|microbial sample collection was done at the end of the time periods T1 (6 weeks after bonding ), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
11084239|NCT04185987|Experimental|Plaque index|Plaque index was measured prior to bonding (T0), 6 weeks after bonding (T1),10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
11084240|NCT04185987|Experimental|Gingival index|Gingival index was measured prior to bonding (T0), 6 weeks after bonding (T1), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
11084241|NCT04185987|Experimental|surface roughness|surface roughness was measured before usage and after 4-weeks usage
11084242|NCT04185974|Experimental|C12 irradiation|Evaluation of Safety and Toxicity of C12 ion reirradiation
11084243|NCT04185974|Active Comparator|Photon irradiation|Evaluation of Safety and Toxicity of photon re-irradiation
11084244|NCT04185961|Experimental|EVERA-RAPHA with 60mmHG|EVERA-RAPHA apply 15 minutes with 60mmHG every day for 4 weeks
11084245|NCT04185961|Experimental|EVERA-RAPHA with 100mmHG|EVERA-RAPHA apply 15 minutes with 100mmHG every day for 4 weeks
11084246|NCT04185948|Experimental|Mediterranean diet plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
11084247|NCT04185948|Active Comparator|Eatwell guide plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
11084248|NCT04185935||Ancillary-correlative (biospecimen collection)|Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.
11084249|NCT04185922|Experimental|Hemopatch|The RARP and BPLND are performed in the usual manner. Towards the end of the operation, Hemopatch is laid over the ends of raw truncated lymphatic tissue.
11084250|NCT04185922|No Intervention|Control|The RARP and BPLND are performed in the usual manner. Hemopatch will not be applied to control group.
11084251|NCT04185909|Experimental|All Subjects|Subjects will be treated with the Renuvion Dermal System.
11084252|NCT04185883|Experimental|Sotorasib + MEK inhibitor|"Experimental: Sotorasib + MEK inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
11084253|NCT04185883|Experimental|Sotorasib + PD1 inhibitor|"Experimental: Sotoasib + PD1 inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
11084254|NCT04185883|Experimental|Sotorasib + SHP2 allosteric inhibitor|"Experimental: Sotorasib + SHP2 allosteric inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors."
11084255|NCT04185883|Experimental|Sotorasib + Pan-ErbB tyrosine kinase inhibitor|"Experimental:Sotorasib + pan-ErbB tyrosine kinase inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
11084256|NCT04185883|Experimental|Sotorasib + PD-L1 inhibitor|"Experimental: Sotorasib + PD-L1 inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
11084257|NCT04185883|Experimental|Sotorasib + EGFR inhibitor +/- Chemotherapeutic regimen|"Experimental: Sotorasib + EGFR inhibitor +/- Chemotherapeutic regimen Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors."
11084258|NCT04185883|Experimental|Sotorasib + PD-1 inhibitor|"Sotorasib + PD-1 inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
11084314|NCT04185545|Placebo Comparator|Immunogenicity Group - Placebo|3 oral doses of Placebo; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
11084259|NCT04185883|Experimental|Sotorasib + Chemotherapeutic regimen|"Experimental: Sotorasib + Chemotherapeutic regimen Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer."
11084260|NCT04185883|Experimental|Sotorasib Monotherapy|"Experimental: Sotorasib only Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases."
11084261|NCT04185883|Experimental|Sotorasib + CDK inhibitor|"Experimental: Sotorasib + CDK inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor."
11084262|NCT04185883|Experimental|Sotorasib + mTOR inhibitor|"Experimental: Sotorasib + mTOR inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor."
11084263|NCT04185883|Experimental|Sotorasib + MEK inhibitor + EGFR inhibitor|"Experimental: Sotorasib + MEK inhibitor + EGFR inhibitor Dose Exploration and Dose Expansion
~Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
~Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant advanced colorectal cancer."
11084264|NCT04185870|Experimental|3D scan and standard photography arm|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum. In addition, all participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
11084265|NCT04185857||Patients with primary aldosteronism (PA)|"After two biochemical and clinical evaluations under baseline conditions PA patients will be treated with canrenone 50-100 mg orally once a day.
~After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1). After, they will continue with a combination therapy with canrenone, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension.
~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2)."
11084266|NCT04185831|Experimental|NF1/MAP2K1|Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
11084267|NCT04185831|Experimental|MTOR/TSC1/TSC2|Everolimus, 10mg po daily.
11084268|NCT04185831|Experimental|Mutation burden|Atezolizumab. 1200mg iv every 3 weeks.
11084269|NCT04185818|Experimental|Reading group|"Participants will:
~Read a book for 15 to 30 mins
~Read immediately before trying to go to sleep."
11084270|NCT04185818|No Intervention|Control Group|"Participants will:
~1. Not read a book"
11084271|NCT04185805|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
11084272|NCT04185805|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
11084273|NCT04185792||Patients with spinal cord injury|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
11084274|NCT04185792||Patients with multiple sclerosis|NBSS, Qualiveen and SF-Qualiveen questionnaires will be administered to participants.
11084275|NCT04185779||Group A (Cross-sectional arm)|This group will comprise of 10,000 patients who have been referred for a colonoscopy. We will be collecting information on their past medical history, smoking history, alcohol history, medication history and family history in addition to their colonoscopy findings. In 6000 of these patients, they will have blood tests, Faecal Immunochemical Test (FIT) level, blood or saliva for DNA extraction and stool microbiome taken. In 4000 of these patients, we will record recent blood tests of interest and they will have no new samples taken. All 10000 patients will also either complete a food frequency questionnaire or endoscopy patient experience questionnaire.
11084276|NCT04185779||COLO-SPEED (Group B, consent for contact arm)|This will be 10,000 patients who will consent for future contact for future research studies.
11084277|NCT04185766|Placebo Comparator|Placebo (0,5 ml/Kg)|
11084278|NCT04185766|Placebo Comparator|Placebo (1 ml/Kg)|
11084279|NCT04185766|Experimental|Destrogel (0,5 ml/Kg)|
11084280|NCT04185766|Experimental|Destrogel (1 ml/Kg)|
11084281|NCT04185753||Obese adolescents with CI|Obese adolescents with chronotropic incompetence
11084282|NCT04185753||Control group|Obese adolescents without chronotropic incompetence
11084283|NCT04185740|Experimental|Home-based validation|The home-based validation of the TTT will give insight in the task performance of patients OFF-medication compared to ON-medication and on different time points in the medication cycle during 7 days
11084284|NCT04185727|No Intervention|Standard of Care (SOC)|Therapy control group
11084285|NCT04185727|Experimental|Standard of Care (SOC) + strength training|Strength training intervention as add on to therapy
11084286|NCT04185714|Experimental|Experimental group|Experimental group will be applied Kinesotaping , twice a week and home exercise programme will be given for each day.
11084287|NCT04185714|Placebo Comparator|Placebo group|Placebo group will be applied sham taping , twice a week and home exercise programme will be given for each day.
11084288|NCT04185714|No Intervention|Control group|Home exercise programmewill be given .
11084289|NCT04185701|Experimental|Eye examination by expert and SiVIEW software|Eye examination by an expert and by a technician with the SiVIEW system.
11084315|NCT04185545|Experimental|Other Efficacy Group - RV3 Vaccine (Bio Farma)|3 oral doses of RV3 vaccine (Bio Farma) administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
11084316|NCT04185545|Placebo Comparator|Other Efficacy Group - Placebo|3 oral doses of Placebo administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
11084317|NCT04185532|Experimental|Rebound ACL brace and physiotherapy|The intervention will be the use of rebound ACL brace for 9 weeks, which initially is locked followed by a gradually increased range of motion. A standardized rehab protocol is applied.
11084290|NCT04185688||Multiple Sclerosis|"Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
~Biodex Balance System: Biodex Balance System is used to evaluate limits of stability. The limits of stability test consists of standing on the platform and leaning in eight directions to make a cursor displayed on the system's screen hit a target.
~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).
~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
11084291|NCT04185688||Healthy People|Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
11084292|NCT04185675|Active Comparator|Macintosh laryngoscope|
11084293|NCT04185675|Experimental|nonadjustable videolaryngoscope|
11084294|NCT04185675|Experimental|adjustable videolaryngoscope|
11084295|NCT04185662|Placebo Comparator|placebo|intake 200 ml water daily for 3 months
11084296|NCT04185662|Experimental|low dose sucrolose group|intake 12.3mg sucralose in 200 ml water daily for 3 months
11084297|NCT04185662|Experimental|moderate dose sucrolose group|intake 73.8mg sucralose in 200ml water daily for 3 months
11084298|NCT04185649|Experimental|BAT8001 for injection|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
11084299|NCT04185649|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
11084300|NCT04185636||Skin Graft Patients|There will only be 1 group, patients receiving a skin graft and MolecuLight i:X imaging
11084301|NCT04185623||Group A (immediate denudation)|Oocytes were denudated immediately after oocyte retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
11084302|NCT04185623||Group B ( 2hs denudation after ovum pickup)|Oocytes were denudated 2 hours after retrieval and were microinjected at 4 hours from ovum pickup. Microinjection was performed on all matured oocytes only and they were cultured to blastocyst stage.The rates of maturation, fertilization, good quality blastulation, chemical pregnancy and clinical pregnancy were analysed and compared between the two groups.
11084303|NCT04185610|Experimental|Qi Gong|Weekly QiGong for Chemotherapy-Induced Neuropathy classes for 10 weeks
11084304|NCT04185597|Experimental|HFP Intervention: Delivery by Community Farmers|"HFP- Delivered by community farmers, supported by the study and linked to eligible households to educate on growing nutritious food and poultry rearing or fish culture
~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female community nutrition promoters (CNPs) will refer PLW to service delivery points; gradually this will be completed by peer leaders
~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices
~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will later be replaced by peer leaders"
11084305|NCT04185597|Experimental|HFP Intervention: Delivery by agricultural Retailers|"HFP- Delivered by agricultural Retailers, supported by the study and linked to eligible households to educate on growing nutritious food and either poultry raring or fish culture
~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female CNPs will refer PLW to service delivery points; gradually this will be completed by peer leaders
~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices
~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will be replaced by peer leaders"
11084306|NCT04185597|Active Comparator|Standard of Practice|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
11084307|NCT04185571|Experimental|PEPA membrane|PEPA membrane is an adsorbant synthetic copolymer (Poly Ester Poly Arylate)
11084308|NCT04185571|No Intervention|non adsorbent membrane|Comparison with non adsorbent membrane used in routine
11084309|NCT04185558|Experimental|ActiGraft|Whole blood clot (WBC) gel
11084310|NCT04185558|Active Comparator|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
11084311|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 1|3 oral doses of RV3 vaccine (Bio Farma) batch 1; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
11084312|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 2|3 oral doses of RV3 vaccine (Bio Farma) batch 2; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
11084313|NCT04185545|Experimental|Immunogenicity Group - RV3 Vaccine (Bio Farma) Batch 3|3 oral doses of RV3 vaccine (Bio Farma) batch 3; administered at 0-5 days, 8-10 weeks, and 12-14 weeks of age.
11138228|NCT03808844|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
11084318|NCT04185532|Active Comparator|Physiotherapy|A standardized rehab protocol comparable to the experimental group but with no brace
11084319|NCT04185519|Experimental|AI (model)|This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
11084320|NCT04185519|No Intervention|DR1|Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
11084321|NCT04185506|Experimental|DBT and behavioral weight loss|The intervention is a 16-week group-based behavioral program consisting of a combination of Dialectical Behavioral Therapy (DBT) skills and behavioral weight loss techniques.
11084322|NCT04185493||CCTA Cohort|Consecutive patients with suspected coronary artery disease and low/intermediate pre-test probability
11084323|NCT04185480|No Intervention|Conventional|Historical cohort of patients that underwent axillary clearance without hemopatch.
11084324|NCT04185480|Experimental|Intervention|Prospective cohort of patient undergoing axillary clearance with hemopatch
11084325|NCT04185467|No Intervention|Usual care(both arms)|Usual care (both arms): Patients in both arms will receive usual medical, physiotherapy and nursing care according to usual protocols. This does not involve exercise rehabilitation or advice.
11084326|NCT04185467|Experimental|Intervention (exercise rehabilitation)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
11084327|NCT04185454|Experimental|First design level|Three Healthy Voluntary (HV) women were give the same starting daily dose of 100 g Jarlsberg
11084328|NCT04185454|Experimental|Second design level|Based on the results from the starting dose 5 + 5 HV get a new daily doses of Jarlsberg cheese
11084329|NCT04185454|Experimental|Third design level|Based on the results from the second design level, the daily dose of Jarlsberg cheese for the next 7 HVs was given
11084330|NCT04185441|Experimental|TANZÂNIA|"The study is double-dummy. The patient must take 2 pills, as follow:
~1 capsule Tanzânia association, oral, once a day, and
~1 tablet tamsulosin placebo, oral, once a day."
11084331|NCT04185441|Active Comparator|Omnic Ocas|"The study is double-dummy. The patient must take 2 pills, as follow:
~1 tablet Omnic Ocas, oral, once a day, and
~1 capsule Tanzânia association placebo, oral, once a day."
11084332|NCT04185428|Experimental|Standard of care with integrative therapy|For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
11084333|NCT04185428|No Intervention|Standard of care only|For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
11084334|NCT04185415|Experimental|bepranemab|Subjects will be randomized to receive bepranemab.
11084335|NCT04185415|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo.
11084336|NCT04185402|Active Comparator|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
11084337|NCT04185402|No Intervention|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
11084338|NCT04185389||Control|Women in the original HPV FOCAL control arm who completed the 48 month exit screen (HPV/LBC co-test) and who had no CIN2+ detected during the trial or at trial exit will be invited to submit another LBC sample for HPV and cytology co-testing.
11084339|NCT04185376||group A 200 patients|patients with one or more PFDs significant psychological strain in at least one pelvic floor domain
11084340|NCT04185376||group B 200 patients|patients without any pelvic floor complaints
11084341|NCT04185363|Experimental|Maralixibat|All subjects will receive Maralixibat oral solution
11084342|NCT04185350|Experimental|68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 60 min later.
11084343|NCT04185337|Experimental|Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)|Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.
11084344|NCT04185324|Experimental|Standard zippering vest|Children receive three supervised sessions for them to practice engaging and pull up a zipper, using a standard teaching zippering vest.
11084345|NCT04185324|Experimental|Modified zippering vest|Children receive three sessions of specially designed zippering instruction using a modified zippering vest, where they can practice engaging and pulling up a zipper after being read a related story.
11084346|NCT04185311|Experimental|Treatment (talimogene laherparepvec, nivolumab, ipilimumab)|Participants receive talimogene laherparepvec intratumorally on days 1, 22, and 36, nivolumab IV over 60 minutes on days 1, 15, 29, and 43, and ipilimumab IV over 90 minutes on days 1 and 43 in the absence of disease progression or unacceptable toxicity.
11084347|NCT04185298|Active Comparator|Group 1 (No treatment)|Group 1: Participants will have continuous activity monitoring (via Fitbit)
11084348|NCT04185298|Experimental|Group 2 (Experimental)|Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)
11084349|NCT04185272|Experimental|non-metastatic colon cancer|
11084350|NCT04185272|Experimental|metastatic colon cancer|
11084351|NCT04185259|Experimental|Acupuncture group|
11084352|NCT04185259|Sham Comparator|Sham acupuncture|
11084353|NCT04185259|No Intervention|Waitlist control group|Participants will receive no treatment for their heel pain for a period of 16 weeks after randomization, and subsequently have the option of 4 weeks (12 sessions) of acupuncture with free of charge at the end of follow-up.
11084354|NCT04185246|Experimental|Single arm|"Subjects will be enrolled with sequential allocation to 1 of 3 cohorts with the following intravenous (IV) doses of NH002: 2.5 µl/kg, 5.0 µl/kg, or 10.0 µl/kg.
~Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day"
11084355|NCT04185233|Experimental|iPad distraction|"Children of this group will receive the iPad when the nurse will prepare the material for the venous track. They will choose a game adapted to their age and will be able to play it during all the procedure time.
~Intervention : game on iPad"
11084356|NCT04185233|Active Comparator|Nitrous Oxide|"Children of this group will receive the Nitrous Oxide 3 minutes before the intervention (venous track). They will keep the mask during all the procedure time.
~Intervention : Nitrous Oxide"
11084357|NCT04185220|Experimental|1- Experimental Treatment: Dose Escalation|IL-15 by CIV infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with mogamulizumab by IV infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle to determine MTD.
11084358|NCT04185220|Experimental|2- Experimental Treatment: Dose Expansion|IL-15 by CIV infusion at the MTD on days 1- 5 of each 28-day cycle (max 6 cycles) with mogamulizumab by IV infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle.
11084359|NCT04185194|Active Comparator|group A|received especially designed physical therapy program
11084360|NCT04185194|Experimental|group b|received pulsed ultrasound in addition to physical therapy program
11084361|NCT04185194|Experimental|group c|received lidocaine phonophoresis in addition to physical therapy program
11084362|NCT04185181|Active Comparator|virtual reality|
11084363|NCT04185181|Active Comparator|propreoceptive neuromuscular facilitation|
11084364|NCT04185168|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 tablets)
11084365|NCT04185168|Placebo Comparator|control|2 tablets of placebo
11084366|NCT04185155|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
11084367|NCT04185155|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
11084368|NCT04185142||combined procedure group|patients underwent cryoballoon ablation and left atrial appendage closure
11084369|NCT04185129|Experimental|Foster|uncontrolled asthma patients were randomized into Foster treatment group
11084370|NCT04185129|Active Comparator|Relvar|uncontrolled asthma patients were randomized into Relvar treatment group
11084371|NCT04185116|Experimental|3D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
11084372|NCT04185116|No Intervention|2D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
11084373|NCT04185116|Experimental|3D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
11084374|NCT04185116|No Intervention|2D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
11084375|NCT04185103||Sacubitril-Valsartan cohort|Patients with left systolic disfunction (left ventricle ejection fraction<40%) heart failure and diagnosed with grade II heart failure that have been treated with an ACE or ARA II+betablocker at stable doses during the last 4 weeks and after being evaluated by the cardiologist start Sacubitril-Valsartan treatment.
11084376|NCT04185090|Active Comparator|ID1801|qd daily for 6days Intervention: Drug: administration of ID1801 for 6days.
11084377|NCT04185090|Active Comparator|ID1803|qd daily for 10days Intervention: Drug: administration of ID1803 for 10days.
11084378|NCT04185090|Experimental|ID1801 and ID1803|qd daily for 7days Intervention: Drug: administration of ID1801 and ID1803.
11084379|NCT04185077|Experimental|Experimental|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
11084380|NCT04185077|Active Comparator|Control|a bolus dose of 100 U/kg Heparin was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
11084381|NCT04185064|Experimental|Cryopnematic Device (Randomized Component)|Game Ready shoulder wrap is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises.
11084382|NCT04185064|Active Comparator|Standard Care|Ice is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the ice will be applied by the patient or a health care provider; as cold as comfortable; 30 min on:60 min off; use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off; use minimum of twice/day. The patients in the control group will receive pain management strategies as would be normally dictated by the physician/therapist. This may include the use of ice, ice packs and compression bandages, as well as pain medications, range of motion, and positioning exercises
11084383|NCT04185064|Other|Cryopneumatic Device (Observational Cohort)|Game Ready® shoulder wrap is applied in the operating room and used in the recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises
11084384|NCT04185051|Experimental|Cohort 1: JNJ-67953964 or Placebo|Participants will receive JNJ-67953964 or matching placebo oral capsules once daily (QD) over 4 weeks (28 days).
11084385|NCT04185051|Experimental|Cohort 2: JNJ-67953964 or Placebo|Participants in this cohort will receive JNJ-67953964 only or will be randomly assigned to receive JNJ-67953964 or matching placebo.
11084386|NCT04185038|Experimental|ARM A (Tumor Cavity Infusion)|Patients with non-DIPG supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
11084387|NCT04185038|Experimental|ARM B (Ventricular System Infusion)|Patients with non-DIPG either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the ventricular system
11084388|NCT04185038|Experimental|ARM C (DIPG)|Patients with DIPG for whom CAR T cells will be delivered into the ventricular system
11084389|NCT04185025|Experimental|CeraVe Moisturising Lotion|
11084390|NCT04185025|Active Comparator|Half Mu ceramide body milk|
11084391|NCT04185012|Experimental|Benralizumab|Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
11084392|NCT04185012|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
11084393|NCT04184999|Experimental|Test|dexamethasone intraocular suspension, 9% + topical ophthalmic prednisolone acetate
11084394|NCT04184999|Active Comparator|Control|topical ophthalmic prednisolone acetate
11084395|NCT04184986||inflammatory bowel disease|100-150 pts with dg. inflammatory bowel disease
11084396|NCT04184986||unspecific GI symptoms|100-150 pts unspecific GI symptoms
11084397|NCT04184960||Gastric cancer cohort|Cohort of patients with gastric cancer
11084398|NCT04184960||Non-gastric cancer cohort|Cohort of patients without gastric cancer
11084399|NCT04184947||SGLT2i|Patients who received new prescription of a SGLT-2 inhibitor
11084400|NCT04184947||GLP-1RA|Patients who received new prescription of a GLP-1 receptor agonist
11084401|NCT04184921||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
11084402|NCT04184921||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
11084403|NCT04184908|Experimental|GROUP EXPERIMENTAL|Gel xerostomia Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
11084404|NCT04184908|Placebo Comparator|CONTROL GROUP|Gel placebo Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
11084405|NCT04184895|Experimental|ASP2390 Low Dose (Cohort 1)|Participants will receive a low dose of ASP2390 once weekly for a total of 12 doses. After all participants in cohort 1 complete 4 doses of treatment, the overall safety and tolerability of the dose will be evaluated by the Dose Escalation Committee (DEC).
11084406|NCT04184895|Placebo Comparator|Placebo Low Dose (Cohort 1)|Participants will receive a low dose of matching Placebo once weekly for a total of 12 doses.
11084407|NCT04184895|Experimental|ASP2390 High Dose (Cohort 2)|Participants will receive a high dose of ASP2390 once weekly for a total of 12 doses. The dose for cohort 2 may be adapted after the DEC evaluates emergent safety and tolerability data.
11084408|NCT04184895|Placebo Comparator|Placebo High Dose (Cohort 2)|Participants will receive a high dose of matching Placebo once weekly for a total of 12 doses.
11084409|NCT04184882|Experimental|ASP0367 group|Participants will be dosed investigational product (IP) at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks in the DB part and OLE part, respectively.
11084410|NCT04184882|Placebo Comparator|Placebo to ASP0367 group|Participants will be dosed matching placebo in the DB part. In OLE part, participants will dosed IP at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks.
11084411|NCT04184869|Other|Wild Type UGT1A1|"Cohort A: Wild Type, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
11084412|NCT04184869|Other|Heterozygous UGT1A1*28|"Cohort B: Heterozygous, UGT1A1, Belinostat IV Dose: 1000 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
11084413|NCT04184869|Other|Homozygous UGT1A1*28|"Cohort C: Homozygous, UGT1A1, Belinostat IV Dose: 750 mg/m2 Frequency: 30-minute infusion once daily from Day 1 to Day 5 of a 21-day cycle.
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
11084414|NCT04184869|Other|Belinostat & Atazanavir|"Arm: Homozygous UGT1A1*28 genotype subjects with Belinostat IV & Atazanavir
~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir)
~Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5
~Duration: Up to five 21-day cycles (15 weeks) Treatment Period: Up to a total of six 21-day cycles (18 weeks) of treatment total from both the original study protocol and this extension protocol."
11084415|NCT04184856||Binge eating disorder (BED) patients|Individuals with BED diagnosis.
11084417|NCT04184856||subsyndromal BED controls|individuals that experience binges but do not fulfill the requirements for BED diagnosis.
11084418|NCT04184843|Experimental|iWalk Toolkit|"Intervention period: 5 months
~Intervention:
~A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.
~Access to a clinical expert by email or phone"
11084419|NCT04184830|Experimental|tDCS arm|"Active stimulation:
~Direct current will be transferred using a pair of saline-soaked surface sponge electrodes (5x7). For anodal stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 minutes, which will result in current density of 0.08 mA/cm².In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
11084420|NCT04184830|Sham Comparator|tDCS sham|"Sham stimulation:
~During the sham stimulation a pair of saline-soaked surface sponge electrodes (5x7) will be places on the scalp For sham stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 seconds.In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
11084421|NCT04184817||Medical data collection|The medical data of patients diagnosed by Achondroplasia will be collected. The radiological data will analyse to evaluate the severity of stenosis as well as its clinical tolerance and evolution.
11084422|NCT04184804|Experimental|Behavioral Intervention|School-based intervention
11084423|NCT04184804|No Intervention|Control|Control. No intervention (usual education). The school does not receive any material and gets the information that they are part of a study on eating habits of primary school children.
11084424|NCT04184791|Experimental|Deep Brain Stimulation(DBS) OFF Medication|Subthalamic-DBS in the Levodopa OFF state.
11084425|NCT04184791|Experimental|Deep Brain Stimulation(DBS) ON Medication|Subthalamic-DBS in the Levodopa ON state.
11084426|NCT04184778|Experimental|Woman tube size 6.0|Smaller tube than normal
11084427|NCT04184778|No Intervention|Woman tube size 7.0|Usual tube size
11084428|NCT04184778|Experimental|Man tube size 7.0|Smaller tube than normal
11084429|NCT04184778|No Intervention|Man tube size 8.0|Usual tube size
11084430|NCT04184765||Total laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
11084431|NCT04184765||Abdominal hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
11084432|NCT04184752||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
11084433|NCT04184752||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
11084434|NCT04184752||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
11084435|NCT04184739|Active Comparator|Group A|Standard treatment information (verbal and written) and access to a basic version of the App with a toothbrushing timer. The timer is necessary as the health behaviour outcome is toothbrushing duration.
11084436|NCT04184739|Experimental|Group B|As for group A, however, additionally the App will provide generic treatment information (a combination of videos and text)
11084437|NCT04184739|Experimental|Group C|As for group B, however, the patients will have access to the full functionality of the App and the App will allow patients to input their own personalised treatment information (including progress photographs), set goals, develop plans for achieving these and provide the patient and clinicians with appropriate dashboards to monitor progress.
11084438|NCT04184726|Experimental|MBCT-vision|8 x once weekly group sessions, and home practice between sessions
11084439|NCT04184713|Experimental|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
11084440|NCT04184713|Active Comparator|Control group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
11084441|NCT04184700|Experimental|EHCF + LGG|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
11084442|NCT04184700|Active Comparator|RHF|Extensively hydrolyzed rice formula
11084443|NCT04184700|Active Comparator|EHWF|Extensively hydrolyzed protein formula
11084444|NCT04184700|Active Comparator|AAF|Amino acid based formula
11084445|NCT04184687|Experimental|Nanofractures treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction with concomitant treatment of the cartilaginous lesions with nanofractures technique.
11084446|NCT04184687|Active Comparator|no treatment of the cartilaginous lesions|Patients undergoing to anterior cruciate ligament reconstruction. Cartilaginous lesions won't be treated
11084447|NCT04184674|Other|Acute Respiratory Distress Syndrome|Children of more than one month of age and adults hospitalized in Intensive Care Unit for Acute Respiratory Distress Syndrome.
11084448|NCT04184661||hypophosphatemic rickets patients|15 hypophosphatemic rickets patients older than 2 years will be included in this study
11084449|NCT04184648||There was no adverse systems outcome after PMA36 weeks|Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
11084720|NCT04182763|Placebo Comparator|Placebo|6 months of placebo, followed by 18 months of CoA-Z at dose 2
11084450|NCT04184648||Death or adverse respiratory outcome after 36 weeks of pma|Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death
11084451|NCT04184635|Experimental|Experimental ECMO + IABP Arm|"VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.
~An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible)."
11084452|NCT04184635|No Intervention|Control Conventional Treatment Arm|Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
11084453|NCT04184622|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11084454|NCT04184622|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11084455|NCT04184622|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11084456|NCT04184622|Placebo Comparator|Placebo|Placebo administered SC once a week.
11084457|NCT04184609|Experimental|Exercise test|"All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design:
~Control
~Albuterol
~Ipratropium Bromide"
11084458|NCT04184596||Stated-Preferences Observational Group|A discrete choice experiment will be conducted with participants with peripheral neuropathic pain in the stated-preferences observational group. The instrument will measure patient preferences for topical versus systemic pain treatment.
11084459|NCT04184557|Experimental|"App Staying Calm in the OR"|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) or Mindfulness Self Compassion (MSC)."
11084460|NCT04184557|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) arm will not download the app until the study is completed.
11084461|NCT04184544|Experimental|Maternal and Newborn health districts|Group one included maternal and newborn health districts. These districts are further divided into three sub groups. Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (, Lasbila and Badin).
11084462|NCT04184544|Experimental|Child Health|Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD [4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad).
11084463|NCT04184531||Children with Sensenbrenner Syndrome|Children with Sensenbrenner followed from 2005. Variable phenotype related to the mutation gene will be analysed to determine some possible prognostic factors of the risk of developing end-stage kidney disease.
11084464|NCT04184518|Experimental|Cediranib plus durvalumab|
11084465|NCT04184505|Active Comparator|Standard clinical treatment|"If BM-blasts >= 10%: Conventional chemotherapy: induction one cycle (3+7 protocol) and one optional consolidation cycle, followed by HSCT if a suitable sibling or unrelated donor is available versus
~If BM blasts are <10%: HSCT upfront"
11084466|NCT04184505|Experimental|Experimental treatment|"If BM-blasts >= 10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available
~If BM blasts are <10%: Azacitidine (AZA) 75mg/sqm/day subcutaneously for 7 days every 28 days (1 cycle of 28 days) for at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor is available"
11084467|NCT04184492|Experimental|GP-40081|Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg
11084468|NCT04184492|Active Comparator|NovoMix® 30 Penfill®|Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg
11084469|NCT04184479|Active Comparator|A-LEVAmetoden by Bertz et al|Individual dietary advices for weight loss, based on the participants' food record of 4 consecutive days aimed to achieve an energy intake reduction of 500 kcal/d with a nutrient composition according to the Nordic Nutrition Recommendations. Follow up visits after 3 months, 1 year and 2 years after baseline. Follow up by electronic platform every other week until 3 months after baseline and each month after 3 months until 1 year after baseline.
11084470|NCT04184479|Placebo Comparator|B-Ordinary treatment|Dietary advices for weight loss aimed to achieve calorie restriction. Follow up visits after 3 months, 1 year and 2 years after baseline. Additional visits, up to 4 times in the first year after baseline.
11084471|NCT04184466|Experimental|Insulin Aspart|Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg
11084472|NCT04184466|Active Comparator|NovoRapid® Penfill®|Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg
11084473|NCT04184453|Experimental|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patient.
11084474|NCT04184440|Placebo Comparator|placebo|corn starch；capsule，2 g/day，2 times/day；3 months
11084475|NCT04184440|Experimental|Cyclocarya paliurus extract|aqueous extract of Cyclocarya paliurus；capsule，2 g/day，2 times/day；3 months
11084476|NCT04184440|Experimental|Cyclocarya paliurus compounds|mixed aqueous extract of Cyclocarya paliurus and other traditional Chinese herbal medicines including Astragalus propinquus Schischkin，Dioscorea oppositifolia L.，Dendrobium nobile Lindl.，Salvia miltiorrhiza Bge. and Inulin；capsule，2 g/day，2 times/day；3 months
11084477|NCT04184427|Active Comparator|Group I|6 mm height of power arm
11084478|NCT04184427|Experimental|Group II|3 mm height of power arm
11084479|NCT04184427|Experimental|Group III|9 mm height of power arm
11084480|NCT04184414|Experimental|CART cells|dosage：Once dose，1.0*10^6cells/kg CART cells Administration mode:Intravenous infusion
11084481|NCT04184401|Experimental|Replacement with albumin|"Check drain amount every 4 hour after SICU admission
~Replacement of 70% of drainage from previous 4 hours over next 4 hours
~30% of the drainage with 5% albumin
~40% of drainage with Hartmann's solution
~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution
~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
11084482|NCT04184401|Active Comparator|Replacement with Hartmann's solution|"Check drain amount every 4 hour after SICU admission
~Replacement of 70% of drainage from previous 4 hours with Hartmann's solution over next 4 hours
~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution
~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
11084483|NCT04184388|Experimental|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng extract for 1g/day
11084484|NCT04184388|Placebo Comparator|Placebo|Hydrolysed Red Ginseng extract for 0g/day
11084485|NCT04184375|Experimental|TONIC|"The cognitive stimulation sessions are carried out using Liliane Israël's TRAIN YOUR MEMORY software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient.
~This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules."
11084486|NCT04184375|No Intervention|Control|The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.
11084487|NCT04184362|Experimental|Experimental group tested at the active treatment site|The theranova empower device will be tested at the active treatment site.
11084488|NCT04184362|Sham Comparator|Control sham group tested at the sham control treatment site|The theranova empower device will be tested the sham control treatment site.
11084489|NCT04184349|Active Comparator|Local Anesthetic (LA Group)|
11084490|NCT04184349|Active Comparator|B group|
11084491|NCT04184336||Persons of all ages|Persons of all ages admitted between January 1, 2016 and December 31, 2020 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
11084492|NCT04184323|Active Comparator|EX-527|The drug will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
11084493|NCT04184323|Placebo Comparator|Placebo|The placebo will be administered daily for 5 days beginning with the start of progesterone therapy and ended 24 hours before embryo transfer
11084494|NCT04184310|Experimental|old patient with rectal prolapse|old co-morbid patient with complete rectal prolapse unfit for abdominal operation
11084495|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
11084496|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
11084497|NCT04184284||Primary Study Cohort - Anti-IL5/IL5R naïve patients|Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
11084498|NCT04184284||Secondary Study Cohort - Biologic experienced patients|Patients that previously received a biologic treatment for severe asthma (at least one dose).
11084499|NCT04184271|Experimental|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
11084500|NCT04184258|Experimental|SLE patients MSC treatment|Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols
11084501|NCT04184258|Active Comparator|SLE patients standard treatment|Patients with SLE, who receive standard treatment according to the Clinical protocols
11084502|NCT04184232|Experimental|Dendritic cells|Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
11084503|NCT04184232|Active Comparator|Control|Patients with the recurrent bladder cancer receiving standard treatment
11084504|NCT04184219||Group|People potentially interested in health issues
11084505|NCT04184206|Active Comparator|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness influence
11084506|NCT04184206|Active Comparator|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness influence
11084507|NCT04184206|Active Comparator|attention training intervention 3|14-day smartphone-based audio-guided intervention without mindfulness emphasis
11084508|NCT04184193||Pulmonary Rehabilitation|
11084509|NCT04184167|Active Comparator|intermittent fasting|intermittent fasting before ICSI
11084510|NCT04184167|Placebo Comparator|No intermittent fasting|Usual diet
11084511|NCT04184141|Experimental|alprazolam|
11084512|NCT04184141|Experimental|hydroxyzine|
11084513|NCT04184141|Placebo Comparator|control|
11084514|NCT04184128||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
11084515|NCT04184128||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
11084516|NCT04184128||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
11084517|NCT04184115|Experimental|DPI-386 Nasal Gel + placebo patch|DPI-386 Nasal Gel: Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
11084518|NCT04184115|Placebo Comparator|Placebo nasal gel + Placebo patch|Placebo
11084519|NCT04184115|Active Comparator|placebo nasal gel + TDS patch|Transderm Scop® is a commercial transdermal scopolamine (TDS) patch worn behind the ear containing a 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period.
11084520|NCT04184102|Experimental|Intervention exercise|The experimental group received education and exercise training before a mastectomy.
11084521|NCT04184102|No Intervention|Control|Received routine hospital care which did not include any exercise education
11084522|NCT04184089|No Intervention|Control group|High flow rate of 5 L/min and FiO2 of 40%
11084523|NCT04184089|Experimental|Group 1|Nasal cannula at flow rate of 15 L/min and FiO2 of 40%
11084524|NCT04184089|Experimental|Group 2|Nasal cannula at flow rate of 30 L/min and FiO2 of 40%
11084525|NCT04184089|Experimental|Group 3|Nasal cannula at flow rate of 60 L/min and FiO2 of 40%
11084721|NCT04182750|Experimental|Intervention group|Pharmacist consultation in early pregnancy (gestation week <12)
11084526|NCT04184076|No Intervention|Dietary counseling alone|"Controls will be instructed to maintain their weight throughout the trial, and not to change their eating or physical activity habits. Controls will visit the research center on a weekly basis for weigh-ins. Body composition and metabolic disease risk variables will be assessed in control subjects every 12 weeks.
~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.
~The blood draws will be taken at approximately 11:00 am. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
11084527|NCT04184076|Experimental|Time-restricted feeding (TRF) with dietary counseling|"Subjects will be instructed to eat ad libitum from 10:00 to 18:00 h daily, and fast from 18:00 to 10:00 h daily. During the 8-h feeding window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, subjects will be encouraged to drink plenty of water and will be permitted to consume energy-free beverages.
~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.
~The blood draws will be taken at approximately 11:00 am, especially prior to the first consumption of food by subjects in the TRF group. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
11084528|NCT04184063|Experimental|active treatment with NBMI|
11084529|NCT04184063|Placebo Comparator|Placebo|
11084530|NCT04184050|Experimental|Part 1 (Dose Escalation)|HPN217 is IV administered 1x weekly for about 1 hour. Doses will vary between cohorts as MTD is being determine.
11084531|NCT04184050|Experimental|Part 2 (Dose Expansion)|HPN217 is IV administered 1x weekly for about 1 hour. Doses will be determined from Part 1 (dose escalation)
11084532|NCT04184037|Experimental|Auditory neurofeedback (NFB)|Participants in this arm will meditate with the help of a custom version of the Muse app, which guides users in meditation while providing auditory neurofeedback on their state of mindfulness. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app. The neurofeedback consists of changing weather sounds that are heard against a background soundscape (e.g., a beach or rainforest sound). When a user is in a focused state, the weather in the soundscape is good (e.g., it is quiet or a light breeze can be heard). When a user starts mind-wandering, the weather sounds change for the worse: it begins to rain, the wind gets louder, and there may be thunder. When the user returns to a calm state, the weather sounds quiet down again and only the background soundscape is heard. Participants are asked to pay attention to the weather sounds and to use this feedback to train their mind to remain focused on the present moment.
11084533|NCT04184037|Active Comparator|No neurofeedback (no-NFB)|Participants in this arm will meditate using a custom version of the Muse app that is identical in all respects to the mobile app used by the NFB group, expect that the auditory neurofeedback is not active. Participants will wear the EEG headband and headphones when completing the meditation sessions using the app, but the soundscape during the sessions will only contain the background sounds (e.g., the breach or rainforest scene), without any changes to the weather.
11084534|NCT04184024|Active Comparator|Massage group|Patients in this group were applied to massage plus neck stabilization exercise.
11084535|NCT04184024|Active Comparator|Kinesio taping group|Patients in this group were applied to Kinesio taping plus neck stabilization exercise.
11084536|NCT04184011||SRT for keloid scars|Individuals who are voluntarily scheduled to be treated at one of the participating study sites with SRT (SRT-100™, SRT-Vision™ or SRT-100+™) for the treatment of one or more recurrent keloids.
11084537|NCT04183998|Experimental|tsES|trans-spinal Electrical Stimulation (tsES)
11084538|NCT04183985|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
11084539|NCT04183985|Active Comparator|Conventaional total knee arthroplasty|Use conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
11084540|NCT04183972|Experimental|Image collecting Group|An computer algorithm will be developed and evaluated by these image data.
11084541|NCT04183959|Active Comparator|Group- video stylet intubation (VS)|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
11084542|NCT04183959|Active Comparator|Group- fiberoptic intubation (FO)|: intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
11084543|NCT04183946|Other|Online Cognitive Behavioural Therapy|Screened participants diagnosed with minor to moderate anxiety and/or depression will receive online CBT therapy (8 interactive sessions) aiming to treat their symptomatology. Each session can be completed at one's own pace.
11084544|NCT04183933|Active Comparator|Pilates Exercise Group|Pilates exercises will given for 6 weeks, 3 days in a week.
11084545|NCT04183933|Active Comparator|Combined Exercise group|Combined exercises will given for 6 weeks, 3 days in a week.
11084546|NCT04183920|Active Comparator|Group A|Participants in this arm will be provided cranberry juice to consume for 42 days in total. After a 10-21-day washout period participants will receive placebo juice for 42 days.
11084547|NCT04183920|Active Comparator|Group B|Participants in this arm will be provided placebo juice to consume for 42 days in total. After a 10-21-day washout period participants will receive cranberry juice to consume for 42 days
11084548|NCT04183907|No Intervention|Control group|The control group completes three questionnaires in months 1, 3 and 6, including questions on health behaviours, workaholism and work outcomes.
11084549|NCT04183907|Experimental|Transform|Intervention (see next page)
11084550|NCT04183894|Experimental|Personalized Intervention Based on Network|Participants will receive personalized interventions based on their personalized network.
11084551|NCT04183881|Experimental|Brodalumab 210mg SC|Brodalumab 210mg subcutaneous injection
11084588|NCT04183608|Active Comparator|Group Standard of care|In standard of care, patient only visits every 3 months the doctor so the optimization of treatment can be done only at this frequency.
11084722|NCT04182750|No Intervention|Control group|Standard care.
11084552|NCT04183868|Experimental|Empagliflozin|"Eligible patients (meeting all inclusion criteria) will be randomized to receive empagliflozin in addition to existing metformin background therapy (daily dose of ≥1.500 mg, which has to remain unchanged throughout the study) for 26 weeks.
~At the end of 26 weeks of treatment, subjects belonging to empagliflozin arm will be shifted to glimepiride treatment."
11084553|NCT04183868|Active Comparator|Glimepiride|"Eligible patients will be randomized to receive glimepiride (starting dose: 2 mg daily) treatment arm, can undergo to up-titration of glimepiride to a maximum of 6 mg/day, if they experience fasting plasma glucose (FPG) levels > 112 mg/dl (6,2 mmol/l) at scheduled visit at 6th week or at any later scheduled visit.
~Whereas, glimepiride-treated patients experiencing recurrent hypoglycemic episodes should down-titrate glimepiride to a dose, considered as appropriate by Investigator.
~Hypoglycemic events are defined as symptoms suggestive of low blood glucose confirmed by self monitored blood glucose (SMBG) < 56 mg/dl (3,1 mmol/l).
~Severe hypoglycemia is defined as any hypoglycemic episode requiring the assistance of another party for recovery.
~At the end of 26 weeks of treatment, subjects belonging to glimepiride arm will be shifted to treatment with empagliflozin for 26 weeks."
11084554|NCT04183855|Experimental|control|no supplement will be provided on the day of the experiment
11084555|NCT04183855|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
11084556|NCT04183855|Experimental|Mirexus PhytoSpherix|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
11084557|NCT04183842|Experimental|LACIME Anti-hangover|Combination of plant extracts under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
11084558|NCT04183842|Placebo Comparator|Placebo|Carrot juice under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
11084559|NCT04183816|Experimental|Total cold-water immersion group|"Participants allocated to the TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C. Each Participant was totally immersed in a pool while his/her head and neck remained above water level. The water's temperature was continuously measured by a mercury-in-glass thermometer and maintained at the aforementioned temperature by continuously adding ice blocks.
~With respect to depth of immersion, TCWI is more efficient than partial CWI since exposing a larger area of the body is needed for cardiovascular changes to occur (Murray and Cardinale, 2015; Stephens et al., 2016)."
11084560|NCT04183816|Active Comparator|Ice massage group|Participants in the IM group were seated. The investigator in charge of this intervention group applied Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
11084561|NCT04183803|Experimental|rosa robot assistance|Patients with ACL rupture requiring surgical treatment will be included. The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
11084562|NCT04183790|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
11084563|NCT04183764|Experimental|MAX-40279-01|capsule, 5mg and 25mg
11084564|NCT04183738|Active Comparator|SOC|darunavir/ritonavir 800/100mg + 2 NRTIs po od
11084565|NCT04183738|Experimental|DOL|darunavir/ritonavir 800/100mg + dolutegravir 50mg po od
11084566|NCT04183738|Experimental|D2N|dolutegravir 50mg + tenofovir + emtricitabine or lamivudine po od
11084567|NCT04183725|Experimental|Experimental group|Reduning injection +Oseltamivir phosphate granule simulants
11084568|NCT04183725|Active Comparator|Control group|Oseltamivir phosphate granules+ Reduning injection simulants
11084569|NCT04183712|Experimental|target therapy with GEMOX|Target therapy
11084570|NCT04183712|Active Comparator|conventional chemotherapy|The patients wil receive conventional chemotherapy(GEMOX).
11084571|NCT04183699|Experimental|MRI targeted + systematic random biopsy|
11084572|NCT04183686|Experimental|Part A (SAD): Dose A1|Single dose A1 of ACT-1014-6470; soft capsule for oral use.
11084573|NCT04183686|Experimental|Part A (SAD): Dose A2|Single dose A2 of ACT-1014-6470; soft capsule for oral use.
11084574|NCT04183686|Experimental|Part A (SAD): Dose A3|Single dose A3 of ACT-1014-6470 under fasted and fed conditions, separated by at least 18 days; soft capsule for oral use.
11084575|NCT04183686|Experimental|Part A (SAD): Dose A4|Single dose A4 of ACT-1014-6470; soft capsule for oral use.
11084576|NCT04183686|Experimental|Part A (SAD): Dose A5|Single dose A5 of ACT-1014-6470; soft capsule for oral use.
11084577|NCT04183686|Experimental|Part A (SAD): Dose A6|Single dose A6 of ACT-1014-6470; soft capsule for oral use.
11084578|NCT04183686|Experimental|Part B (MAD): Dose B1|Multiple doses B1 of ACT-1014-6470; soft capsules for oral use.
11084579|NCT04183686|Experimental|Part B (MAD): Dose B2|Multiple doses B2 of ACT-1014-6470; soft capsules for oral use.
11084580|NCT04183686|Experimental|Part B (MAD): Dose B3|Multiple doses B3 of ACT-1014-6470; soft capsules for oral use.
11084581|NCT04183686|Experimental|Part B (MAD): Dose B4|Multiple doses B4 of ACT-1014-6470; soft capsules for oral use.
11084582|NCT04183673|Experimental|Laser-cryo-usual care|Sessions 5 days a week for 3 weeks. Each session includes laser therapy+ cryo-thermal followed by standard rehabilitation program
11084583|NCT04183673|Active Comparator|usual care|Sessions 5 days a week for 3 weeks. Each session includes only standard rehabilitation program
11084584|NCT04183647|Active Comparator|Local Vibration / Whole body vibration|"Local vibration will be sequentially applied to the bilateral gastrosoleus complex with the Vibrasens © device. Application, the largest part of the muscle, each limb 5'er for a total of 10 minutes, static semi-squat position will be done.
~The vibration frequency is 80 Hz and the amplitude is 1 mm."
11084585|NCT04183647|Active Comparator|Whole body vibration/local vibration|Whole body vibration application will be done with Compex® Winplate device. During this application, patients will be asked to continue static semi-squat position with 5 minutes of vibration and then 5 minutes of vibration.Vibration frequency, 30 Hz amplitude will be selected 2 mm.
11084586|NCT04183634|Experimental|Period 1: Rotigotine TTS (Test) - Period 2: Neupro (Reference)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
11084587|NCT04183634|Active Comparator|Period 1: Neupro (Reference) - Period 2: Rotigotine TTS (Test)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
11084717|NCT04182763|Experimental|CoA-Z dose 1|6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
11084589|NCT04183608|Active Comparator|Groupe T2T with telemonitoring and patient education|Treatment with e-Monitoring, home fecal calprotectin testing and therapy education.
11084590|NCT04183595|Experimental|Arm A: NBMI (Study Medication)|400mg / day N1, N3-BIS- (2-MERCAPTOETHYL) ISOPHTHALAMIDE (NBMI) treatment for 14 days, administered as two capsules of 100 mg of NBMI every 12 hours.
11084591|NCT04183595|Placebo Comparator|Arm B: Placebo|((Excipients microcrystalline cellulose, silica and magnesium stearate)) capsules will be administered every 12 hours for 14 days.
11084592|NCT04183582|Experimental|Intervention Group|Single arm group receiving Behavioural Activation, a facilitated self-help programme delivered by trained Health Visitors as six one hour sessions over four weeks.
11084593|NCT04183569||Primary diffuse cutaneous B-cell lymphoma, leg type|Cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international standards through RCP monthly cutaneous lymphomas managed by Professor Beylot-Barry and inclusion of cases in the national database of rare cancer network French Study Group of Cutaneous Lymphomas in Bordeaux managed by Prof. Beatrice Vergier.
11084594|NCT04183556|Active Comparator|1/NSAI(nonsteroidal anti-inflammatory agent) group|Patients with naproxen drug therapy for early onset dysmenorrhea.
11084595|NCT04183556|Placebo Comparator|2/NSAI+ Turmeric (1 gram oral powder formula per day )|NSAI(nonsteroidal anti-inflammatory agent) + Turmeric for early onset dysmenorrhea (1 gram oral powder formula in mens time)
11084596|NCT04183543|Experimental|Pulsed Electromagnetic Field Therapy|Study participants will receive 20 minutes of PEMFs (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
11084597|NCT04183543|Sham Comparator|Sham Therapy|Study participants will receive 20 minutes of placebo treatment (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
11084598|NCT04183530||SCOPD|Participants with stable COPD diagnosed according to GOLD criteria and hasn't encountered acute exacerbations in the past six months, generally include outpatient clinical patient and community patients.
11084599|NCT04183530||AECOPD|Participants with COPD diagnosed according to GOLD criteria and suffered from acute exacerbations, characterized by worsening clinical symptoms(such as acute worsening of dyspnea, and/or cough and sputum production, and/or increased sputum purulence) and positive laboratory biomarkers suggesting AECOPD (such as serum CRP and serum neutrophilia or eosinophilia) at the time of registering into the group, particularly include inpatient.
11084600|NCT04183530||Smoking healthy controls|Participants with a smoking history of more than ten years and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
11084601|NCT04183530||Non smoking healthy controls|Participants without a smoking history and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
11084602|NCT04183517|Experimental|Fasted|PXS-5382A administered as a single dose in the fasted state
11084603|NCT04183517|Experimental|Fed|PXS-5382A administered as a single dose in the fed state
11084604|NCT04183517|Experimental|Twice daily|PXS-5382A administered twice daily for 5 days in the fed state
11084605|NCT04183504|Experimental|Early Steps Coaching|Coaching session on positive parenting practices and promoting child development.
11084606|NCT04183491|Experimental|Arm A: Interferon beta-1a low dose|Single dose of interferon beta-1a 7.5 µg intramuscular (IM)
11084607|NCT04183491|Experimental|Arm B: Interferon beta-1a intermediate dose|Single dose of interferon beta-1a 15 µg IM
11084608|NCT04183491|Experimental|Arm C: Interferon beta-1a high dose|Single dose of interferon beta-1a 30 µg IM
11084609|NCT04183491|Experimental|Arm D: Peginterferon beta-1a low dose|Single dose of peginterferon beta-1a 31.25 µg subcutaneous (SC)
11084610|NCT04183491|Experimental|Arm E: Peginterferon beta-1a intermediate dose|Single dose of peginterferon beta-1a 62.5 µg SC
11084611|NCT04183491|Experimental|Arm F: Peginterferon beta-1a high dose|Single dose of peginterferon beta-1a 125 µg SC
11084612|NCT04183491|Placebo Comparator|Arm G: Placebo|Single dose of placebo
11084613|NCT04183478|Experimental|Best Support Care Plus K-001|Best support care including analgesic treatment, anti-infection therapy, biliary obstruction treatment, nutritional support, psychological support, reasonable advice from physicians, good communication with patients and etc. K-001 9,720mg per day which means that take K-001 capsule 18 tablets (270mg per tablet) orally twice a day (morning and evening), 56 days as a cycle.
11084614|NCT04183478|Placebo Comparator|Best Support Care Plus placebo|Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.
11084615|NCT04183465|Active Comparator|Health Education|All patients randomized to health education during the inclusion visit are managed according to current guidelines and as follows. Quality of life, functional capacity and home physical activity are assessed by proper tools.
11084616|NCT04183465|Experimental|Exercise Intervention|All patients randomized to physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge [T0]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed.
11084617|NCT04183452||17-Hydroxyprogesterone Caproate 250 mg IM Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 250 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
11084718|NCT04182763|Experimental|CoA-Z dose 2|6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
11138229|NCT03808844|Active Comparator|Propofol|2.0mg/kg/1.0mg/kg
11084618|NCT04183452||17-Hydroxyprogesterone Caproate 275 mg SC Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 275 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
11084619|NCT04183439||Surgeons Interviewed|We recruited surgeons from two University academic health centers, one specializing in adults and the other in children. The surgeons were selected through a snowball technique and emailed to participate. DK and GS interviewed eleven surgical attendings representing 10 surgical specialties. (Table 2) Each subject had at least 10 years of experience in their respective fields and regularly taught residents.
11084620|NCT04183413|No Intervention|Standard of Care|Health services for diabetes and hypertension are provided as was the standard of care prior to the healthcare reform. Healthcare for diabetes and hypertension is provided only through physician-led teams at hospitals and health centers.
11084621|NCT04183413|Experimental|PEN|Screening for diabetes and hypertension, as well as all care for uncomplicated cases of diabetes and hypertension, will be provided through nurse-lead teams at primary healthcare facilities.
11084622|NCT04183413|Experimental|enhanced PEN (ePEN)|"This arm consists of all activities of arm 2 (the PEN arm) plus additional responsibilities for community health workers."
11084623|NCT04183400|Experimental|Safety Awareness For Empowerment (SAFE)|Brief mindfulness-based cognitive-behavioral skill-building intervention
11084624|NCT04183400|No Intervention|Usual case management only|Control condition receives only services as usual
11084625|NCT04183387|Experimental|Simvastatin and standard treatment|40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
11084626|NCT04183387|No Intervention|standard treatment|conventional treatment of uveitis
11084627|NCT04183374|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
11084628|NCT04183361||Patients with noise exposure and salivary cortisone|"male and female
~ages 19-35
~exposure to noise level ≥ 85 dB (A) per week at the workplace
~work in noise from 1 to 16 years
~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)
~unilaterally or bilaterally normal otoscopic findings
~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
11084629|NCT04183361||Patients without noise exposure and salivary cortisone|"male and female
~ages 19-35
~no exposure to noise level ≥ 85 dB (A) per week at the workplace
~work in noise from 1 to 16 years
~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)
~unilaterally or bilaterally normal otoscopic findings
~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
11084630|NCT04183348|Experimental|Group A|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
11084631|NCT04183348|Experimental|Group B|10 normal hearing adults (NH) 10 unilateral deafness adults (SU) 10 mono-implanted adults (uIC) 10 bi-implanted adults (bIC)
11084632|NCT04183335|Experimental|Dupilumab|Dose regimen 1 on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
11084633|NCT04183335|Placebo Comparator|Matched placebo|Placebo on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
11084634|NCT04183322||Women of childbearing age|Healthy non-pregnant women between 18 and 45 years old living in Goroka, Papua New Guinea, will receive one dose of 13-valent pneumococcal conjugate vaccine (PCV).
11084635|NCT04183309||Pediatric anesthetized patients|Pediatric anesthetized patients undergoing abdominal laparoscopy surgery (simple-arm study).
11084636|NCT04183296|Experimental|TIVA(Total Intravenous Anesthesia and Volatile Anesthesia )|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
11084637|NCT04183296|Active Comparator|Inhalation|Arm Description: In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
11084638|NCT04183283|Experimental|LY3526318|LY3526318 administered orally in three of four study periods.
11084639|NCT04183283|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
11084640|NCT04183270||Patients|Non-valvular atrial fibrillation (NVAF) patients who will start treatment with a non-VKA oral anticoagulants (NOAC).
11084641|NCT04183270||Physicians|Treating physicians for NVAF patients.
11084642|NCT04183257|Experimental|vitamin D|vitamin D arm will receive oral vitamin D in escalating dosage.
11084643|NCT04183257|No Intervention|Conventional|This arm will receive conventional treatment only.
11084644|NCT04183244|Active Comparator|Erector spinae block|"Ultrasound guidance will be used to visualize the transverse processes of T2 and the overlying muscles.
~Under sterile conditions, a 5-cm, 21-gauge needle will be inserted using the out-of-plane technique parallel to the sagittal plane directly over the transverse process,then 30mL of the local anesthetic solution will be injected and observed for the linear spread of LA the under direct ultrasound visualization"
11084645|NCT04183244|Active Comparator|infraclavicular subomohyoid block|Performing posterior approach infraclavicular BP block followed by subomohioid block via the same puncture site under ultrasound guidance.
11084646|NCT04183231|Experimental|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
11084647|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
11084648|NCT04183205|Placebo Comparator|Placebo only arm|For individuals who are placebo responders during the 2 week placebo lead in phase, they will remain on placebo for the duration of the study (i.e., the 12 weeks where the placebo non-responders are taking sertraline).
11084649|NCT04183205|Active Comparator|Sertraline arm|After the 2-week placebo lead-in phase, placebo-non responders will receive sertraline 25 mg daily for 2 weeks. Thereafter, sertraline will be increased flexibly by 25 to 50 mg per day (at a rate no higher than 50 mg per week) to achieve a total daily dose of 50 to 200 mg, based on clinical response and tolerability, with a maximum dose of 200 mg/d. Subjects unable to tolerate higher doses may be dropped back to the previous dose and remain at that dose for the remainder of the study.
11084650|NCT04183192|Experimental|Arm A: Mepolizumab low dose|Single dose of mepolizumab 3 mg SC
11084651|NCT04183192|Experimental|Arm B: Mepolizumab low intermediate dose|Single dose of mepolizumab 6 mg SC
11084652|NCT04183192|Experimental|Arm C: Mepolizumab high intermediate dose|Single dose of mepolizumab 12 mg SC
11084653|NCT04183192|Experimental|Arm D: Mepolizumab high dose|Single dose of mepolizumab 24 mg SC
11084654|NCT04183192|Experimental|Arm E: Reslizumab low dose|Single dose of reslizumab 0.1 mg/kg IV
11084655|NCT04183192|Experimental|Arm F: Reslizumab intermediate low dose|Single dose of reslizumab 0.2 mg/kg IV
11084656|NCT04183192|Experimental|Arm G: Reslizumab high intermediate dose|Single dose of reslizumab 0.4 mg/kg IV
11084657|NCT04183192|Experimental|Arm H: Reslizumab high dose|Single dose of reslizumab 0.8 mg/kg IV
11084658|NCT04183192|Placebo Comparator|Arm I: Placebo|Single dose of placebo
11084659|NCT04183179|Experimental|Program|"The 14-week healthy eating program activities including four components:
~A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home
~Three parent face-to-face meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges
~14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children
~Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
11084660|NCT04183166|Experimental|Arm A : Early study treatment initiation|TG4050 treatment initiation at completion of primary treatment
11084661|NCT04183166|Experimental|Arm B: Study treatment initiation at recurrence|TG4050 treatment initiation at the time of recurrence
11084662|NCT04183153|Experimental|Healthy Arm|
11084663|NCT04183140|Active Comparator|Transradial|
11084664|NCT04183140|Active Comparator|Transulnar|
11084665|NCT04183127||ACP|ACPs, either qualified or in training, working in the South Yorkshire and Bassetlaw area.
11084666|NCT04183114|Experimental|IP batch MRUK-0317|135 Subjects received Bio Farma's vaccine batch MRUK 0317
11084667|NCT04183114|Experimental|IP Batch MRUK-0417|135 Subjects received Bio Farma's vaccine batch MRUK 0417
11084668|NCT04183114|Experimental|IP Batch 550118|135 Subjects received Bio Farma's vaccine batch MRUK 0417
11084669|NCT04183114|Active Comparator|Control|135 Subjects received SII's MR vaccine batch 012W72230Z
11084670|NCT04183101|Experimental|Aliskiren treatment|Patients will be randomized to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for 6 months. After 6 months the patients will be switched to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for the coming 2,5 years.
11084671|NCT04183101|Active Comparator|Enalapril treatment|Patients will be randomized to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for 6 months. After 6 months the patients will be switched to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for the coming 2,5 years.
11084672|NCT04183088|Experimental|Part 1: Tislelizumab intravenously + regorafenib orally|Part 1 is a single-arm study. All eligible patients will receive tislelizumab 200 mg intravenously on day 1 every 3 weeks plus regorafenib orally 80 mg per day.
11084673|NCT04183088|Experimental|Groups (1) of part 2: Tislelizumab intravenously + regorafenib|Tislelizumab 200 mg intravenously on Day 1+Regorafenib its dosage in the randomized cohort will be determined according to results in the safety cohort.
11084674|NCT04183088|Active Comparator|Groups (2) of part 2: regorafenib|"Daily dose of regorafenib 80mg/day is for week 1; Daily dose of regorafenib 120mg/day is for week 2; Daily dose of regorafenib 160mg/day is for week 3; Dosing-free interval is for week 4.
~The dose of regorafenib will not be escalated if treatment-related AE > grade 1 occurs at the previous dose level.
~For subjects in the group 2, when imaging evaluation of tumor response indicates stable disease or progressive disease, according to RECIST v1.1, study treatment will be shifted to regorafenib + tislelizumab combination regimen."
11084675|NCT04183075|Experimental|FontActiv Superprotein/Hypercaloric Fiber|Full Nutritional Supplement
11084676|NCT04183075|Active Comparator|Carbohydrates and C Vitamin|Nutritional Supplement
11084677|NCT04183062|Experimental|Chemotherapy plus BIO-11006|Patients will receive BIO-11006 in addition to GemTax chemotherapy. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles of GemTax and then will be stopped. Subjects will continue with GemTax treatment for three additional cycles. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
11084678|NCT04183036|No Intervention|Small EST combined with EPLBD|
11084679|NCT04183036|Experimental|Large EST combined with ECPP|
11084680|NCT04183023|Experimental|Single arm|"There is a unique arm in which all the participants will be included. The intervention consists in the collection of a salivary sample Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.
~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and a subset of 4,000 DNA will be sequenced.
~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.
~Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.
~Finally, a bioinformatics analysis will be performed on sequencing data."
11084719|NCT04182763|Experimental|CoA-Z dose 3|6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
11084681|NCT04183010|No Intervention|Control|At the end of this initial week of monitoring, participants will be randomized to a control group or an intervention group. Both groups will be followed for three months, with outcome measurements collected monthly. Both arms will continue to receive their seven day physical activity assessment using the phone's core motion sensors and HealthKit/ Google Health step count. Both groups will also be prompted to complete monthly fitness tests: the 6-minute walk test, a 12 minute run test, and the Tecumseh step test.
11084682|NCT04183010|Experimental|Physical activity coaching|"In addition to the tasks performed and feedback received by the Control arm (see above), the intervention arm will also undergo daily coaching with the goal of increasing their daily step count. Members of this arm will receive daily app notifications indicating that they have activities to complete. They will be provided with 5 exercise options:
~Low intensity activity options (i.e. walking in the part, bicycling to the store, etc.).
~Moderate to vigorous endurance activity, performed on their own (running, bicycling, rowing, swimming, etc)
~An on demand group session video
~No exercise today
~Alternate physical activity -- the participants will have the option to record alternate physical activity that they performed
~Participants will be asked to indicate if they completed the exercise with three options:
~Yes
~No
~Request for a different exercise to be shown"
11084683|NCT04182997|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
11084684|NCT04182997|Active Comparator|Dexamethasone Group|Patients in this group will be given the study drug (dexamethasone).
11084685|NCT04182984||Patients with autoimmune ocular MG|Newly-onset OMG patients who agreed to join the follow-up cohort
11084686|NCT04182971|Active Comparator|Whole fruit|Phase 1 of study is an orange, Phase 2 of study is an apple
11084687|NCT04182971|Active Comparator|Juice|Phase 1 of study is orange juice, Phase 2 of study is apple juice
11084688|NCT04182971|Experimental|Juice plus pomace fiber|Phase 1 is orange juice with added fiber, Phase 2 is apple juice with added fiber
11084689|NCT04182958|Experimental|(14C)-OPC-61815|
11084690|NCT04182945|Other|Unobtrusive data collection|Unobtrusive data collection using noninvasive sensor systems.
11084691|NCT04182932|Experimental|CJ-40010 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11084692|NCT04182932|Experimental|CJ-40010 EV71 B dose|Inactivated EV71 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11084693|NCT04182932|Experimental|CJ-40010 CVA16 C dose|Inactivated CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11084694|NCT04182932|Experimental|CJ-40010 CVA16 D dose|Inactivated CVA16 vaccine(D dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11084695|NCT04182932|Experimental|CJ-40010 Bivalent E dose|Inactivated EV71/CVA16 vaccine(E dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11084696|NCT04182932|Experimental|CJ-40010 Bivalent F dose|Inactivated EV71/CVA16 vaccine(F dose) or placebo in 10 healthy adults (three doses, 28 days interval)
11084697|NCT04182919|Experimental|Arm 1|Phlai 2 capsules (compound D 8 mg) od evening after meal x 4 weeks
11084698|NCT04182919|Experimental|Arm 2|Phlai 1 capsules (compound D 4 mg) and placebo 1 capsule od evening after meal x 4 weeks
11084699|NCT04182919|Placebo Comparator|Arm 3|Placebo 2 capsules od evening after meal x 4 weeks
11084700|NCT04182906|Active Comparator|No ACEs screen|Participants complete all measures except an ACEs screening tool
11084701|NCT04182906|Experimental|Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences.In this version, specific ACEs items are reported, Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
11084702|NCT04182906|Experimental|De-Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences. In this version,total number of ACEs items are reported, only. Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
11084703|NCT04182893||Pulmonary nodules population|We will enroll 300 pulmonary nodules penplein this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
11084704|NCT04182893||Healthy population|We will enroll 100 healthy penple in this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
11084705|NCT04182880|Placebo Comparator|Placebo|Placebo
11084706|NCT04182880|Experimental|CPL-01|CPL-01
11084707|NCT04182867|Experimental|UK dietary guideline diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.
11084708|NCT04182867|Other|Shift worker diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). Typical 'shift diet' based on previous research investigating what UK night workers eat. The 'shift diet' will contain ~15% energy from added sugar, 15g fiber, 2.5 portions fruit/vegetable, no whole grains. Required energy intake (calories) for each day to maintain their current body weight. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.
11084709|NCT04182854|Experimental|diuretics|
11084710|NCT04182841|Other|RheOx Treatment|RheOx is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
11084711|NCT04182828|Placebo Comparator|Placebo Group(PG)|It will be normal saline 0.9%
11084712|NCT04182828|Active Comparator|Lidocaine Group(LG)|It will be lidocaine 2%
11084713|NCT04182815||Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
11084714|NCT04182802||eosinophilic asthma|
11084715|NCT04182789|Experimental|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
11084716|NCT04182776||Pelvis fracture type II to IV|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
11138300|NCT03808324|Experimental|Heart transplant recipients|
11084723|NCT04182737|Experimental|IgM titer-based treatment|The treatment with IgM preparation will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The calculation of the dose is based on IgM single compartment distribution. The first dose of IgM preparation will be calculated on IgM serum concentration obtained within 24 hours after shock appearance to achieve serum titers above 100mg/dl. In the next days, the daily IgM preparation dose will be assessed individually on the basis of IgM serum titers assessment performed in the morning with the purpose of maintaining IgM serum titers above 100 mg/dl, up to discontinuation of vasoactive drugs or day 7 after enrolment. Daily, the calculated dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg per hour (20mg/kg per hour). IgM preparation will be administered up to the withdrawal of vasoactive drugs with a maximum allowed of 7 days of therapy and a maximum dose of 350mg/Kg/day.
11084724|NCT04182737|Active Comparator|IgM Flat treatment|The IgM treatment will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The dose of IgM preparation will be 250mg/kg for 3 days, the dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg (20mg/kg per hour) until reaching 250mg/kg.
11084725|NCT04182724|Experimental|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib 250 mg p.o. qd Nab-paclitaxel 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
11084726|NCT04182711|Experimental|Device Arm|The aim in the 1st phase is to benchmark the device against manual counting of respiration (number of breaths per minute). The aim in the 2nd phase is to benchmark the device against existing technologies, namely lead-based-ECG sensing, acoustic sensing and capnography. This phase can have a mix of patients having either COPD, asthma, pneumonia or any other respiratory diseases
11084727|NCT04182698|Experimental|Experimental|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.
~. Group II: 10 mg po qd, Group III: 12 mg po qd;
~Combined chemotherapy:
~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).
~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
11084728|NCT04182685||ZIKV-exposed children|Children age 5-15 with a positive Zika virus PCR test result.
11084729|NCT04182685||ZIKV-unexposed children|Children age 5-15 who have not had a Zika virus infection as determined by serological assays.
11084730|NCT04182672|Experimental|Zilretta|
11084731|NCT04182659|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
11084732|NCT04182659|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
11084733|NCT04182646|Experimental|Single arm|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.
11084734|NCT04182633|Experimental|Group A - Treatment Group|This group will receive vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota for 2 days at high dose, then intestinal microbiota for 12 weeks at a maintenance dose
11084735|NCT04182633|Placebo Comparator|Group B - Control Group (Miralax only for 1 day)|This group will receive placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota for 2 days at high dose, then placebo intestinal microbiota for 12 weeks at a maintenance dose
11084736|NCT04182620|Experimental|Catheter ablation + renal denervation|Catheter ablation + renal denervation
11084737|NCT04182620|Active Comparator|Catheter ablation only|Catheter ablation
11084738|NCT04182607||hand-assisted kidney transplant|Kidney donors and recipients who underwent a hand-assisted kidney transplant
11084739|NCT04182607||robotic kidney transplant|Kidney donors and recipients who underwent a robotic kidney transplant
11084740|NCT04182594|Experimental|Degarelix|GnRH Antagonist
11084741|NCT04182594|Active Comparator|GnRH-agonist|GnRH Agonist
11084742|NCT04182581|Experimental|CAR-T treatment group|The patients will receive one dose of BCMA/CD19 dual-target CAR-T. BCMA/CD19 dual-target CAR-T dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.
11084743|NCT04182568|Experimental|nab-paclitaxel|
11084744|NCT04182568|Active Comparator|Docetaxel|
11084745|NCT04182555|Experimental|Newborns in St.Olavs Hospital and Haugesund Hospital|All newborns will be examined through 4 different methods of determining jaundice.
11084746|NCT04182542|Experimental|RF|The right side will be treated with radiofrequency
11084747|NCT04182542|No Intervention|NI|The left side will not receive treatment.
11084748|NCT04182529|Experimental|Photoneuromodulation Therapy|In this study low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800 will be used. The United States Food and Drug Administration (FDA) has approved this type of device as imposing insignificant risk (FDA-cleared for home treatment, 2005). At each visit, LED clusters will be applied simultaneously for 20 minutes on the Fp1, Fp2 and Pz regions according to the International 10-20 system (Homan, Herman and Purdy, 1987) (energy density, 13 Joules/cm2 [J/cm2] per each LED cluster head placement). The total LED treatment time per visit was 20 minutes.
11084749|NCT04182529|Sham Comparator|Control Group|Subject will not be given any active stimulation
11084750|NCT04182516|Experimental|Dose Escalation Part|Patients with histologically confirmed diagnosis of locally advanced/metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer.
11084751|NCT04182516|Experimental|Dose Expansion Part - Epithelial Ovarian Cancer|Patients with gBRCA mutation and epithelial ovarian cancer previously treated with a PARP inhibitor.
11084752|NCT04182516|Experimental|Dose Expansion Part - Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer previously treated with a PARP inhibitor.
11084753|NCT04182516|Experimental|Dose Expansion Part - No Pretreated HER 2 Neg. Breast Cancer|Patients with gBRCA mutation and HER2 negative breast cancer who have not received prior therapy with a PARP inhibitor.
11084754|NCT04182516|Experimental|Dose Expansion Part - CRPC|Patients with gBRCA mutation and castration-resistant prostate cancer (CRPC) who have not received prior therapy with a PARP inhibitor.
11084755|NCT04182516|Experimental|Dose Expansion Part - Pancreatic Cancer|Patients with gBRCA mutation and pancreatic cancer who have not received prior therapy with a PARP inhibitor.
11084756|NCT04182503||Beijing|
11084757|NCT04182503||Guangzhou|
11084758|NCT04182503||Jinan|
11084759|NCT04182503||Nanjing|
11084760|NCT04182503||Hangzhou|
11084761|NCT04182503||Wuhan|
11084762|NCT04182503||Zunyi|
11084763|NCT04182503||Xiangyang|
11084764|NCT04182503||Nantong|
11084765|NCT04182503||Suizhou|
11084766|NCT04182503||Huangshi|
11084767|NCT04182503||Changzhou|
11084768|NCT04182503||Suqian|
11084769|NCT04182503||Shiyan|
11084770|NCT04182503||Xiaogan|
11084771|NCT04182503||Huanggang|
11084772|NCT04182490|Active Comparator|3000-mg cohort|LMN-101, six 500-mg capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7)
11084773|NCT04182490|Active Comparator|1000-mg cohort|LMN-101, two 500-mg capsules and four 500-mg placebo capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7)
11084774|NCT04182490|Active Comparator|300-mg cohort|LMN-101, one 300-mg capsule and five 500-mg placebo capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7)
11084775|NCT04182477||Patients with at least one general anesthesia in anamnesis|Patients who underwent during their life at least one anesthesia in anamnesis
11084776|NCT04182477||Patient without general anesthesia in anamnesis|Patients who never underwent general anesthesia during their life
11084777|NCT04182464|Experimental|Sucralose|The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
11084778|NCT04182464|Placebo Comparator|Placebo|The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group.
11084779|NCT04182451|Experimental|Meso Wound Matrix and Standard of Care|This is a single arm study
11084780|NCT04182438|Experimental|Low potassium then normal potassium|After giving the vegetables with low potassium content vegetables for 2 weeks, the serum potassium level was recorded; after 2 weeks of washing time, the normal potassium content vegetables was given for 2 weeks, and the serum potassium concentration was recorded and the test was terminated.
11084781|NCT04182438|Experimental|Normal potassium then low potassium|After giving the normal potassium content vegetables for 2 weeks, the serum potassium concentration was recorded; after 2 weeks of washing time, the low potassium content vegetables use for 2 weeks, then the serum potassium level was recorded at the time. The test was terminated.
11084782|NCT04182412|Active Comparator|Suture|laparoscopic narrowing of linea alba with continuous suture
11084783|NCT04182412|Active Comparator|suture and mesh|narrowing of linea alba with continuous suture and mesh
11084784|NCT04182399|Active Comparator|Patients 25 ZNS|30 patients receive oral 25 mg ZNS daily
11084785|NCT04182399|Active Comparator|Patients 50 ZNS|30 patients receive oral 50 mg ZNS daily
11084786|NCT04182399|Placebo Comparator|Patients Placebo|30 patients receive placebo
11084787|NCT04182386||rPVE|Right portal vein embolization. All patients subjected to selective right portal vein embolization prior to planned hepatobiliary surgery.
11084788|NCT04182386||rPVE+S4|Right portal vein embolization including segment 4 portal vein branches. All patients subjected to selective right portal vein embolization including segment 4 portal vein branches prior to planned hepatobiliary surgery.
11084789|NCT04182373|Experimental|KW-3357|72 IU/kg
11084790|NCT04182373|Placebo Comparator|placebo|
11084791|NCT04182360|Active Comparator|Carbetocin 10mcg|Patient is given 10mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11084792|NCT04182360|Active Comparator|Carbetocin 20mcg|Patient is given 20mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11084793|NCT04182360|Active Comparator|Carbetocin 40mcg|Patient is given 40mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11084794|NCT04182360|Active Comparator|Carbetocin 60mcg|Patient is given 60mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11084795|NCT04182360|Active Comparator|Carbetocin 80mcg|Patient is given 80mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11084796|NCT04182360|Active Comparator|Carbetocin 100mcg|Patient is given 100mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11084797|NCT04182347|Other|People with IDD and caregivers|
11084798|NCT04182334|Experimental|Slow Tempo Music|Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
11084799|NCT04182334|Sham Comparator|Attention Control|One-hour sessions consisting of a silence track twice daily delivered through noise-cancelling headphones for up to 7 days.
11084800|NCT04182321|Experimental|Combination Therapy|Adding Metformin to the standard treatment for patients with HBeAg-negative chronic hepatitis B
11084801|NCT04182321|Placebo Comparator|Standard Therapy|The standard treatment for patients with HBeAg-negative chronic hepatitis B
11084861|NCT04181918|Experimental|MI|This group will imagine motorically the same action as the first group and afterwards they will execute the imagined actions
11141621|NCT03785093||Chinese Family|Chinese parents and their offsprings
11084802|NCT04182295|Experimental|real acupuncture-full disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
11084803|NCT04182295|Experimental|real acupuncture-partial disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
11084804|NCT04182295|Sham Comparator|sham acupuncture-full disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
11084805|NCT04182295|Sham Comparator|sham acupuncture-partial disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
11084806|NCT04182282|Experimental|Immediate|Immediate participants receive the intervention (online training and certification exam) during the study.
11084807|NCT04182282|Experimental|Control|Control participants do not receive the intervention (online training and certification exam) during the study. However, they do receive access to the intervention program (at no cost) at the conclusion of the study.
11084808|NCT04182269||Multiple Sclerosis Patients|
11084809|NCT04182269||Healthy Subjects|
11084810|NCT04182256|Experimental|MS group|In the MS group, the MS grips the HVC through the magnet adsorbed onto the wall of the basin containing the liver. By changing the position of the MS on the wall of the basin, the surgeon is able to expose the surgical field.
11084811|NCT04182256|No Intervention|MA group|In MA group, assistants use vessel forceps to pull the HVC according to the attending's requirements.
11084812|NCT04182243|Other|Emergency Health Care Provider|Working in emergency health services in Northern Cyprus
11084813|NCT04182204|Experimental|Pola-R-GemOx (Stage 1)|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg per cycle (mg/cycle) administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
11084814|NCT04182204|Experimental|Pola-R-GemOx (Stage 2)|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) for a maximum dose of 240 mg/cycle administered intravenously (IV) and rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
11084815|NCT04182204|Active Comparator|R-GemOx (Stage 2)|Participants will receive rituximab 375 milligrams per square meter (mg/m^2) administered IV on Day 1. Participants will receive gemcitabine 1000 mg/m^2 administered IV and oxaliplatin 100 mg/m^2 administered IV on Day 2. Each cycle will consist of 21 days with up to 8 cycles of treatment administration.
11084816|NCT04182191|Experimental|Interventional group|89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
11084817|NCT04182178||Gastroesophageal reflux|Laparoscopic total (Nissen) or posterior 270 degree (Toupét) partial fundoplication for the treatment of gastroesophageal reflux disease.
11084818|NCT04182165|Experimental|Subjects measured by the study staff|Subjects measured by the study staff via the investigational device at the hospital (up to 50 subjects).
11084819|NCT04182165|Experimental|Subjects measuring themselves autonomously|Subjects measuring themselves autonomously with the investigational device at their homes (up to 10 subjects from the first arm).
11084820|NCT04182152|Experimental|Bronchoscopic ICG localization|The nodule will be located preoperatively by ENB-Guided bronchoscopic ICG injection; During the VATS operation, a near-infrared fluorescence thoracoscopy will be used to identify ICG distribution in the visceral pleura to guide an accurate surgical resection.
11084821|NCT04182152|Active Comparator|percutaneous hook-wire localization|The nodule will be located preoperatively by percutaneous placement of hook wire; During the VATS operation, the resection scope is determined by the location relationship between hook wire and the nodule under CT scan.
11084822|NCT04182139|Experimental|30 seconds and %50 intensity stretching|The participants in this group performed an 30 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
11084823|NCT04182139|Experimental|30 seconds and %75 intensity stretching|The participants in this group performed an 30 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
11084824|NCT04182139|Experimental|30 seconds and %100 intensity stretching|The participants in this group performed an 30 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
11084825|NCT04182139|Experimental|60 seconds and %50 intensity stretching|The participants in this group performed an 60 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
11084826|NCT04182139|Experimental|60 seconds and %75 intensity stretching|The participants in this group performed an 60 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
11084827|NCT04182139|Experimental|60 seconds and %100 intensity stretching|The participants in this group performed an 60 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
11084828|NCT04182126|Placebo Comparator|Regular long-lasting insecticidal nets|All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
11084829|NCT04182126|Experimental|Piperonyl butoxide-treated LLIN|"All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction.
~PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO."
11084830|NCT04182126|Experimental|PBO-LLIN plus larval source management|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including both physical and chemical methods by physical filling or removal of temporary larval habitats and larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. We will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
11084831|NCT04182126|Experimental|PBO-LLIN plus enhanced methods|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2. The enhanced intervention is determined by machine learning method.
11084832|NCT04182126|Experimental|LLIN plus indoor residual spraying|All participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the recommended frequency of once a year.
11084833|NCT04182126|Experimental|LLIN+IRS+LSM|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. LSM will be added on these clusters at Stage 2 interventions. LSM at Stage 2 will be the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
11084834|NCT04182126|Experimental|LLIN+IRS plus enhanced method|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is determined by machine learning method.
11084835|NCT04182113|Experimental|1 Hz rTMS Stimulation|
11084836|NCT04182113|Experimental|20 Hz rTMS Stimulation|
11084837|NCT04182113|Sham Comparator|Sham rTMS Stimulation|
11084838|NCT04182100|Experimental|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
11084839|NCT04182087||Focal Brain Injury|Patients with focal brain injury (post-stroke or post-cortical resection)
11084840|NCT04182061|Experimental|The AMTE Protocol|"Will receive the AMTE (Aprende a Manejar tus Emociones) Protocol; this is a modified UP-A adapted as an internet-based program of T-CBT, consisting in 10 modules delivered over 12 weeks."
11084841|NCT04182061|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
11084842|NCT04182048||All patients|
11084843|NCT04182035|Experimental|Patient-tailored treatment group|Objectives & approach: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
11084844|NCT04182035|Active Comparator|Non patient-tailored treatment group|Objectives & approach: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
11084845|NCT04182035|No Intervention|Control group|The subjects randomized to the control group will not receive any intervention, if necessary medication use is permitted and will be monitored using the iMTAQ. Patients will be asked not to seek other treatment options (if possible). If this is not possible, patients will be considered lost to follow-up.
11084846|NCT04182022|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
11084847|NCT04182022|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
11084848|NCT04182009|Other|Omron|Omron group will undergo sputum induction with the Omron nebuliser at Visit 1, followed by the Akita Jet nebuliser at Visit 2.
11084849|NCT04182009|Active Comparator|Akita|Akita group will undergo sputum induction with the Akita Jet nebuliser at Visit 1, followed by the Omron nebuliser at Visit 2.
11084850|NCT04181996|Placebo Comparator|Placebo|Placebo: Sugar pill manufactured to mimic colchicine 0.6 mg capsule. Placebo to be taken once a day.
11084851|NCT04181996|Experimental|Colchicine|Colchicine: 0.6 mg colchicine capsule to be taken once a day.
11084852|NCT04181983|Experimental|Personalized exercise program|A home-based personalized exercise program using a smartphone app
11084853|NCT04181983|Active Comparator|Active Control WHO guidelines|A standard exercise program based upon WHO guidelines
11084854|NCT04181983|No Intervention|Control|No exercise program
11084855|NCT04181957|Placebo Comparator|Placebo|Participants receive placebo tablet composed of lactose.
11084856|NCT04181957|Active Comparator|Active|Participants receive a 50mg tablet of lisdexamfetamine dimesylate (LDX) once.
11084857|NCT04181944|Experimental|Exercise Treatment Group|
11084858|NCT04181931|Experimental|neo-TACE-HAIC with surgery|neoadjuvant TACE-HAIC with surgery for HCC patients with PVTT
11084859|NCT04181931|Active Comparator|surgery alone|surgery alone for HCC patients with PVTT
11084860|NCT04181918|Experimental|AOT|This group will observe videos depicting daily actions and afterwards they will execute the seen actions
11084862|NCT04181918|No Intervention|Control|This group will neither observe nor imagine actions, but simply observe videos with no motor content. Afterwards they will execute the same actions as in AOT and MI.
11084863|NCT04181892|Experimental|CAF+ CTG positioned apical to the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG apical of the CEJ level
11084864|NCT04181892|Other|CAF+CTG positioned on the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG on the CEJ level
11084865|NCT04181879|Experimental|Intervention|GPs will receive the intervention package and conduct medication reviews with recruited patients
11084866|NCT04181879|No Intervention|Usual care|GPs will continue to treat recruited patients as usual
11084867|NCT04181853|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
11084868|NCT04181853|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
11084869|NCT04181853|No Intervention|No Intervention: Control group|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
11084870|NCT04181840|Experimental|Impedance spectroscopy|"Maximum 56 women up to 16 weeks from a natural delivery, with at least one perinatal anal sphincter injury risk factor, such as: the extended second delivery phase, instrumental delivery (vacuum or forceps), shoulder dystocia, birth weight of the child > 4kg, episiotomy, uncontrolled perineal laceration (in patients with crotch protection).
~The planned interventions are:
~Blood and faeces tests
~Impedance spectroscopy test
~Full gynecological and proctological examination
~Transanal ultrasonography
~Anorectal manometry"
11084871|NCT04181827|Experimental|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
11084872|NCT04181827|Experimental|Arm B: JNJ-68284528|Participants will receive one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
11084873|NCT04181814||Diabetic patients|Diagnosed as diabetes
11084874|NCT04181788|Experimental|Arm A1 (Phase 1b)|
11084875|NCT04181788|Experimental|Arm B1 (Phase 1b)|
11084876|NCT04181788|Experimental|Arm A2 (Phase 2)|
11084877|NCT04181788|Experimental|Arm B2 (Phase 2)|
11084878|NCT04181762|Experimental|secukinumab|secukinumab 300 mg s.c.
11084879|NCT04181762|Placebo Comparator|placebo|secukinumab placebo s.c.
11084880|NCT04181749|No Intervention|No treatment|Patients will not be prescribed aspirin and statin
11084881|NCT04181749|Active Comparator|Aspirin and Atorvastatin|Patients prescribed aspirin and atorvastatin
11084882|NCT04181736|Experimental|Guanfacine Treatment Group|Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg.
11084883|NCT04181736|Placebo Comparator|Placebo Group|Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
11084884|NCT04181723|Experimental|Drug - Trofinetide|Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
11084885|NCT04181723|Placebo Comparator|Placebo|Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
11084886|NCT04181710|Experimental|HEMO2life|HEMO2life® will be used for ex vivo graft preservation at the dose of 1g per liter of preservation solution.
11084887|NCT04181710|Other|Control|Organ preserved in preservation solution routinely used according to the local practice
11084888|NCT04181697||PwH A|People with Haemophilia (PwH) A, moderate or severe.
11084889|NCT04181697||Controls|Demographically and seasonally matched non-haemophilia controls.
11084890|NCT04181684|Experimental|Experimental: LITT with Hypofractionated radiation therapy|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.
11084891|NCT04181671|Experimental|Low Resistance Training Group|The experimental group will receive low resistance blood flow restriction training with 30% of 1 RM.
11084892|NCT04181671|Active Comparator|High Resistance Training Group|Participants of this group will receive High resistance training (80% of 1 RM) without blood flow restriction.
11084893|NCT04181658|Experimental|Real tDCS and Physical Therapy|This arm combines tDCS and Physical Therapy intervention. The real tDCS will be delivered before each physical therapy visit for up to 10 combined sessions. The tDCS montage was designed to target the left dorsal lateral prefrontal cortex (DLPFC) for around 20 minutes. The direct current delivered by any electrode will not exceed 2.0 milliamp(mA) and the total amount of current from all electrodes will not exceed 4 mA.
11085012|NCT04180878|Experimental|Intervention Arm 2|Received an interactive physical activity monitoring system (the Gruve®) and group based phone counseling (GBPC).
11142833|NCT03776721|Experimental|Active treatment|
11084894|NCT04181658|Sham Comparator|Sham stimulation and Physical Therapy|This arm combines sham stimulation and Physical Therapy intervention. The sham stimulation will be delivered before each physical therapy visit for up to 10 combined sessions. We will use an active sham stimulation in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This montage was designed to deliver currents not significantly influence their cortical tissue, but still, mimic the cutaneous sensations induced by tDCS over the same brain site (i.e. left DLPFC).
11084895|NCT04181645|Experimental|SHR-120, Paclitaxel-albumin and Gemcitabine|"Subjects receive SHR-1210 200mg (Day 1) and Paclitaxel-albumin 125mg/m2 (Day1 and Day8) and gemcitabine 1000mg/m2 (Day 1 and Day 8) of each 21-day cycle for at most 6 cycles until documented PD or intolerable adverse event or new anti-cancer treatment or loss to follow-up or death.
~Subjects receive SHR-1210 200mg (Day1) to maintain after 6 cycles treatment without PD or listed situation to terminate."
11084896|NCT04181632|Active Comparator|Shot Blocker|The three interventional groups are currently marketed distraction devices. Arm 1 will be Shot Blocker® Number 1-25 (RED).
11084897|NCT04181632|No Intervention|Control Group|The control group is the current clinical standard of care option for pre-allergy injection application. Ethyl Chloride/Pain Ease Spray Number 76-100 (YELLOW).
11084898|NCT04181632|Active Comparator|Buzzy I|The three interventional groups are currently marketed distraction devices. Arm 2 will be Buzzy® I (vibrating only) Number 26-50 (GREEN).
11084899|NCT04181632|Active Comparator|Buzzy II|The three interventional groups are currently marketed distraction devices. Arm 3 will be Buzzy® II (vibrating and ice wings) Number 51-75 (BLUE).
11084900|NCT04181619|Experimental|Coffeeberry beverage|300 mg Coffeeberry extract in 300 ml beverage
11084901|NCT04181619|Placebo Comparator|Color and flavor matched beverage|0 mg Coffeeberry extract in 300 ml flavor and color-matched beverage
11084902|NCT04181606|Active Comparator|Esmolol Infusion Study Visit|The hemodynamic responses at rest, during isometric handgrip exercise, and post-exercise arm occlusion will be measured during Esmolol infusion.
11084903|NCT04181606|Placebo Comparator|Saline Infusion Study Visit|The hemodynamic responses at rest, during isometric handgrip exercise, and post-exercise arm occlusion will be measured during Saline infusion.
11084904|NCT04181593|Experimental|OmegaD|OmegaD Softgels
11084905|NCT04181593|Placebo Comparator|Placebo|Placebo Softgels
11084906|NCT04181580|Other|Fit test of made-to-measure garments|Healthy subjects will test maximum 2 compression garments out of 6 garments under investigation
11084907|NCT04181567|Experimental|electroconvulsive therapy + agomelatine|electroconvulsive therapy 2 times weekly + agomelatine 50 mg daily
11084908|NCT04181567|Active Comparator|electroconvulsive therapy + placebo|electroconvulsive therapy 2 times weekly + placebo
11084909|NCT04181554||DRAM group|The post-partum women with DRAM
11084910|NCT04181554||The control group|The post-partum women without DRAM
11084911|NCT04181541|Active Comparator|Women receiving abortion care by physicians|Patients who receive second trimester medical abortion care from a physician.
11084912|NCT04181541|Experimental|Women receiving abortion care from midlevel providers|Patients who receive second trimester medical abortion care from a midlevel provider.
11084913|NCT04181528|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned TKA implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
11084914|NCT04181528|Active Comparator|Conventaional total knee arthroplasty|Use conventional TKA implant (Legion total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
11084915|NCT04181515|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor (lactose), sham rTMS (inactive coil)
11084916|NCT04181515|Active Comparator|placebo stressor, active rTMS|placebo stressor (lactose), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
11084917|NCT04181515|Active Comparator|stressor, sham rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), sham rTMS (inactive coil)
11084918|NCT04181515|Active Comparator|stressor, active rTMS|stressor (yohimbine 54mg + hydrocortisone 20mg), active rTMS (10 Hz dlPFC in group 1; 1 Hz mPFC in group 2)
11084919|NCT04181502|Experimental|Inflation of a pneumatic tourniquet|
11084920|NCT04181502|Sham Comparator|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
11084921|NCT04181489|Experimental|Sintilimab + R-CHOP|
11084922|NCT04181476|Other|Topical products and Untreated areas|The subject will serve as their own control. Four different products will be tested.
11084923|NCT04181463|Experimental|Arm I (isopropyl alcohol)|Patients receive isopropyl alcohol via nasal inhalation.
11084924|NCT04181463|Placebo Comparator|Arm II (placebo)|Patients receive placebo via nasal inhalation.
11084925|NCT04181437|Experimental|NVP-1203-R1|"Drug: NVP-1203-R1
~1 tablet, oral dosing"
11084926|NCT04181437|Experimental|NVP-1203-R2|"Drug: NVP-1203-R2
~1 tablet, oral dosing"
11084927|NCT04181437|Experimental|NVP-1203-R1 and NVP-1203-R2|Drug: NVP-1203-R1 1 tablet and NVP-1203-R2 1 tablet co-administration(oral dosing)
11084928|NCT04181424|Active Comparator|Group 1- Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
11084929|NCT04181424|Experimental|Group 2 - Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
11084930|NCT04181424|Experimental|Group 3 - Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
11084931|NCT04181424|Experimental|Group 4 -- Diabetes Education Plus Combination of Monthly Food|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
11084932|NCT04181398|Experimental|Baseline high hs-CRP|"Anthropometry:
~Actual Height and weight
~Calculated BMI from measured weight and height.
~Pubertal development (Tanner stage)
~Waist circumference
~Skin fold measurement (Triceps and Subscapular)
~Waist-to-height ratio.
~Blood pressure (mean of 3 measurements)
~Peripheral arterial tonometry
~Questionnaire
~Blood sample (hsCRP)"
11084933|NCT04181398|Experimental|Baseline low hs-CRP|"Anthropometry:
~Actual Height and weight
~Calculated BMI from measured weight and height.
~Pubertal development (Tanner stage)
~Waist circumference
~Skin fold measurement (Triceps and Subscapular)
~Waist-to-height ratio.
~Blood pressure (mean of 3 measurements)
~Peripheral arterial tonometry
~Questionnaire
~Blood sample (hsCRP)"
11084934|NCT04181385|Experimental|Olanzapine|Olanzapine, 10mg, oral, single dose
11084935|NCT04181385|Experimental|Olanzapine plus bromocriptine|Olanzapine, 10mg, oral, single dose Bromocriptine, 5mg, oral, single dose
11084936|NCT04181385|Placebo Comparator|Placebo|Placebo, oral, single dose
11084937|NCT04181372|Experimental|Anlotinib plus Platinum-based chemotherapy|"Take anlotinib hydrochloride 12mg once daily for two weeks, stop for one week, the program repeats every 21 days for 2 cycles.
~Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles."
11084938|NCT04181372|Active Comparator|platinum-based chemotherapy|Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
11084939|NCT04181359|Experimental|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
11084940|NCT04181359|Placebo Comparator|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
11084941|NCT04181346|Experimental|Pregabalin|Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5
11084942|NCT04181346|Experimental|Placebo|Placebo, twice a day, from the night before chemotherapy to day 5
11084943|NCT04181320|No Intervention|Venous Leg Ulcer Standard of Care|Subjects will recieve standard of care treatment.
11084944|NCT04181320|Experimental|Venous Leg Ulcer Standard of Care with Granulox|Subjects will recieve standard of care treatment with Granulox added as an adjunct therapy.
11084945|NCT04181307|No Intervention|standard EPIC instantiation|As per standard procedure at NewYorkUniversity Langone Health
11084946|NCT04181307|Experimental|standard EPIC instantiation plus the BE-EHR module.|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
11084947|NCT04181294|Experimental|Pre-intervention|Baseline data on patient characteristics and outcomes will be collected for 4 months prior to intervention.
11084948|NCT04181294|Experimental|Post-intervention|The quality improvement intervention will be conducted sequentially at all 3 medical centers (LAC-USC, Olive View, and Harbor-UCLA Medical Centers). Data on patient characteristics and outcomes will be collected for 4 months after the intervention
11084949|NCT04181281||young adult|18 - 40 years old (n=10) Healthy male or female and able to give informed, written consent.
11084950|NCT04181281||older adult|70 years or older (n=10) Healthy male or female and able to give informed, written consent.
11084951|NCT04181268|Active Comparator|Rotational Atherectomy|"The procedure is performed by using a Rotablator system, which consists of a spring coil shaft with a burr at the tip. The front edge of the burr is the ablating portion, oval shaped, and covered with fine diamond crystals.
~The rotational atherectomy catheter is introduced into the coronary artery over a dedicated long rotational atherectomy wire, which consists of a monofilament stainless steel 0.09-inch wire.
~The device is connected to a console that houses the turbine that rotates the burr with pressurized nitrogen gas. Typically the rpm is set at 150,000 to 180,000 rpm.
~After the lesion is crossed with the wire, the lesion is crossed with multiple pecking movements of the burr, with each run lasting not more than 20 seconds. After successful rotational atherectomy with one or more burrs, the procedure is completed with balloon angioplasty and stent placement. This can be achieved by exchanging the rota wire with a workhorse wire and using standard equipment."
11084952|NCT04181268|Active Comparator|Intravascular Lithotripsy|"The procedure is perforemed with a Coronary intravascular lithotripsy (IVL) System that consists of a generator, a connector cable with a push button to allow manually controlled delivery of electric pulses, and semi-compliant balloon catheter.
~The balloon integrates two radiopaque lithotripsy emitters 6 mm that receive electrical pulses from the generator vaporising the fluid within the balloon and creating a rapidly expanding and collapsing bubble. This bubble can transmit unfocused circumferential pulsatile mechanical energy into the vessel wall, in the form of sonic pressure waves equivalent to approximately 50 atmospheres (atm). The IVL therapy consists on a maximun of 8 runs of 10 pulses (80 pulses). The number of therapies needed per lesion will depend on lesion resistance; however, a mínimum of 20 pulses is recommended.
~Alter IVL, an optional additional post-dilatation with non-compliant balloons, a stent is implanted"
11084953|NCT04181268|Active Comparator|Excimer Laser|"Excimer laser is pulsed gas laser that use Xenon chloride (XeCl) as the active medium to generate pulses of short wavelength, high-energy ultraviolet (UV) light.
~Excimer laser tissue ablation is mediated through three distinct mechanisms: photochemical, photo-thermal and photomechanical. UV laser light is absorbed by intra-vascular material and breaks carbon-carbon bonds (photochemical). It elevates the temperature of intra-cellular water, causing cellular rupture and generates a vapor bubble at the catheter tip (photo-thermal). Expansion and implosion of these bubbles disrupts the obstructive intra-vascular material (photomechanical). The laser catheter is advanced slowly over a conventional wire while the therapy is aplied and saline is inffused. After laser, balloon dilatation is usually performed finishing the procedure with stent implantation"
11084954|NCT04181255|Experimental|Curosurf|
11084955|NCT04181255|Placebo Comparator|Sham (air)|
11085013|NCT04180865||Parkinson's disease patients|150 de novo treatment naive Parkinson's disease patients.
11084956|NCT04181229|Experimental|DBS Treatment|Patients in the treatment arm will receive DBS of bilateral centromedian nucleus (2 electrodes per patient). DBS is a standard of care treatment option for drug-resistant epilepsy patients who have previously failed VNS at 12 months or more after instigation and optimization of therapy.
11084957|NCT04181229|No Intervention|Continued VNS (control)|For the control arm, the patients will be monitored for one year with the same standard assessments used for the measurement of seizure frequency and severity. No changes will be made to these patients' treatment plan. These patients will be placed on a wait list for CM-DBS treatment of seizures if that is the desire of the patient and/or their family. After the 12 months of observation, these patients can choose to undergo DBS surgery.
11084958|NCT04181216|Experimental|anatomically aligned total knee arthroplasty prosthesis|Total knee arthroplasty with anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew)
11084959|NCT04181216|Active Comparator|Conventaional total knee arthroplasty group|Total knee arthroplasty with conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew)
11084960|NCT04181203|Active Comparator|SRT + 6 months of LHRHa|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.
~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
11084961|NCT04181203|Experimental|SRT + 6 months of LHRHa + 6 months of Apalutamide|"Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.
~Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.
~SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks."
11084962|NCT04181190||Mepolizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL-5 monoclonal antibody (Mepolizumab)
11084963|NCT04181190||Benralizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL5 receptor monoclonal antibody (Benralizumab)
11084964|NCT04181177||Informed group|This group will receive the Cosmetic product RV4429A balm and targeted educational action between V1 and V2 or between V2 and V3 according to the randomization
11084965|NCT04181177||Control group|"The control group, in the first period between V1 and V2, is a group not informed about his skin condition, not receiving any emollient product and not receiving targeted educational action. It's representative of the real life called best supportive care/Supportive care: the doctor prescribes what it seems to be the best for his patient according to his opinion in view of his condition, at a given moment.
~A high variability exists within this group. In order to answer the investigator's hypothesis and demonstrate the effectiveness of the RV4429A balm, the parallel group design is chosen for the first follow-up period and then a second follow-up period is chosen for the initial control group to replace the inter-individual variability by intra-individual variability."
11084966|NCT04181164||HPP-Group|Adults with hypophosphatasia.
11084967|NCT04181164||Control-Group|Healthy control subjects.
11084968|NCT04181151||Stroke patients|
11084969|NCT04181151||Healthy Subjects|
11084970|NCT04181125||Children with increased femoral anteversion|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
11084971|NCT04181125||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
11084972|NCT04181112|Experimental|Fecal microbiota transplantation|
11084973|NCT04181112|Experimental|Fecal microbiota transplantation with antibiotic pre-treatment|
11084974|NCT04181112|No Intervention|No intervention follow-up|
11084975|NCT04181099|Other|Zirconia structure|The participants will carry an orthodontic device containing 4 discs of differently structured zirconia and titanium to test the biofilm formation in order to determine the ideal structure for the neck area of zirconia dental implants.
11084976|NCT04181073|Active Comparator|Jet Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Jet Nebuliser
11084977|NCT04181073|Experimental|Vibrating Mesh Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Vibrating Mesh Nebuliser
11084978|NCT04181060|Active Comparator|Arm A (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11084979|NCT04181060|Experimental|Arm B (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11084980|NCT04181047|Experimental|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
11084981|NCT04181047|Active Comparator|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
11085014|NCT04180865||Healthy control subjects|150 Healthy sex- and age-matched controls, also matched according to presence and severity of constipation, serving as a control group for microbiome composition analyses.
11142834|NCT03776721|Placebo Comparator|Placebo treatment|
11084982|NCT04181034|Experimental|PYD|Case managers meet with participating pregnant and parenting females at least two times a month over 12 months. In the short term, the program seeks to improve social competence, problem-solving skills, autonomy, increased sense of purpose, improved knowledge and use of contraceptives, increased linkages and support networks, improved quality of relationships, increased access to and strengthen relationship with a trusted adult, increased knowledge of and access to healthcare and improved health and well-being of expectant or parenting mother. In the long term, the program aims to delay subsequent pregnancy and reduction in health risk behaviors, improved health and well-being of parent and child, improved educational and employment outcomes and increased self-sufficiency.
11084983|NCT04181034|Active Comparator|AFLP|Case managers meet with participating pregnant and parenting females once a month over 24 months to deliver older, business-as-usual version of the program that does not have positive youth development component.
11084984|NCT04181021|Experimental|Intervention|Providers and community-based promoters will participate in the VCAT workshop. Providers and community-based promoters will take part in two different workshops at different times.
11084985|NCT04181021|No Intervention|Control|Providers and promoters in the control arm will not be invited to participate in the VCAT workshop.
11084986|NCT04181008|Experimental|0.2 mg|
11084987|NCT04181008|Experimental|0.4 mg|
11084988|NCT04181008|Experimental|0.6 mg|
11084989|NCT04180995|Experimental|Toripalimab, Axitinib|The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.
11084990|NCT04180982|Experimental|Treatment group A|SHR4640 dose1 Oral Tablet plus Febuxostat dose1 Oral Tablet Day1~Day28 qd.
11084991|NCT04180982|Experimental|Treatment group B|SHR4640 dose1 Oral Tablet plus Febuxostat dose2 Oral Tablet Day1~Day28 qd.
11084992|NCT04180982|Experimental|Treatment group C|SHR4640 dose2 Oral Tablet plus Febuxostat dose3 Oral Tablet Day1~Day28 qd.
11084993|NCT04180969|Placebo Comparator|placebo stressor, sham rTMS|placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil
11084994|NCT04180969|Experimental|placebo stressor, active rTMS|placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
11084995|NCT04180969|Experimental|active stress, sham rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil
11084996|NCT04180969|Experimental|active stress, active rTMS|active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex
11084997|NCT04180956|Experimental|Intervention|The bias-reduction intervention opened with a didactic on health disparities, stereotypes, microaggressions, interracial provider-patient interactions and racism. Then, a guided, interracial eye-contact mindfulness exercise was performed to increase providers' awareness and acceptance of subtle bias that occurs in interracial interactions. Then, in small, mixed-race groups, participants practiced the above mindfulness skills while reciprocally sharing and responding with empathy to each other's personal life histories and personal narratives of loss and/or betrayal. The intervention ended with explicit practice component, involving practice and feedback.
11084998|NCT04180956|No Intervention|Control|The control condition was a waitlist condition. Doctors were given workshop materials after the study ended.
11084999|NCT04180943|Active Comparator|liposomal bupivicaine|interscalene nerve block using liposomal bupivacaine (Exaprel) 10 ml mixed with 0.5% bupivacaine in same syringe - volume of bupivacaine per MD based on pt weight, etc but CANNOT EXCEED 13mL
11085000|NCT04180943|Active Comparator|bupivicaine|interscalene block using standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%) (volume per MD based on pt weight) + decadron
11085001|NCT04180930||Cohort 1|Individuals randomized to Cohort 1 will be assigned to the CAPS-5 and will complete between two and seven research visits. Participants will be administered the CAPS-5 during visit 2, and then will be randomized a second time into groups 1-A and 1-B. Group 1-A will end participation after visit 2. Group 1-B will complete visits 3-7 and will be administered the CAPS-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
11085002|NCT04180930||Cohort 2|Individuals randomized to Cohort 2 will be assigned to the PSSI-5 and will complete between two and seven research visits. Participants will be administered the PSSI-5 during visit 2, and then will be randomized a second time into groups 2-A and 2-B. Group 2-A will end participation after visit 2. Group 2-B will complete visits 3-7 and will be administered the PSSI-5 at each of these visits along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
11085003|NCT04180930||Cohort 3|Individuals randomized to Cohort 3 will have three office visits and will complete the CAPS-5 and the PSSI-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
11085004|NCT04180930||Cohort 4|Individuals randomized to Cohort 4 will have three office visits and will complete the CAPS-IV and the CAPS-5 in a counter-balanced order during visits 2 and 3, along with other measures of cognitive and behavioral functioning, and will provide biofluid samples.
11085005|NCT04180904|Active Comparator|Diet 1|Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
11085006|NCT04180904|Active Comparator|Diet 2|Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
11085007|NCT04180904|No Intervention|Diet 3|Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.
11085008|NCT04180891||successful test|Students that have successfully passed the test procedure (directly with written exam or after written and oral interviews) and that can enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery).
11085009|NCT04180891||failed test|Students that have failed to enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery) after the selection procedure.
11085010|NCT04180878|No Intervention|Control Arm|Participants in this group were informed to continue to receive usual care.
11085011|NCT04180878|Experimental|Intervention Arm|Received an interactive physical activity monitoring system (the Gruve®).
11085015|NCT04180852||Neurosurgical patients|"Non-elective admission to the neurosurgical ICU with one of the following acute intracranial pathologies which also serve as predefined subgroups:
~Intracranial hemorrhage (subarachnoid, subdural hemorrhage or intracerebral hemorrhage)
~Acute and severe head trauma with an initial Glasgow Coma Scale ≤10"
11085016|NCT04180852||Elderly patients|Age ≥ 70 years, predefined subgroups: ≥ 70 years and ≥80 years
11085017|NCT04180852||Obese patients|BMI ≥ 35 kg/m2, furthermore predefined subgroups of patients with BMI ≥ 40 kg/m2 and BMI ≥ 45 kg/m2
11085018|NCT04180852||Cardiac surgery patients|"Admission to the cardiosurgical ICU after one of the following procedures using cardiopulmonary bypass, which also serve as predefined subgroups:
~Coronary revascularization (coronary artery bypass graft)
~Heart valve surgery
~Combined or complex heart surgery"
11085019|NCT04180852||Abdominal surgical patients|Admission to the abdominal surgery ICU after abdominal surgery
11085020|NCT04180839|Experimental|gaming-related retrieval-extinction|about 30 individuals with IGD will be randomly assigned to the R-E training group
11085021|NCT04180839|Other|nongaming-related retrieval-extinction|about another 30 individuals with IGD will be randomly assigned to the NR-E training group
11085022|NCT04180826||Stenosis|Patients with stenosis
11085023|NCT04180826||No stenosis|Patients without stenosis
11085024|NCT04180813||Subjects with Diabetes Mellitus, Type 2|
11085025|NCT04180800||Folic acid deficiency|Those with a folic acid defiency
11085026|NCT04180800||No deficiency|Those with no folic acid deficiency
11085027|NCT04180787|Experimental|Keto Coffee|VPX Bang® Keto Coffee beverage
11085028|NCT04180787|Placebo Comparator|Placebo|Flavor-matched placebo beverage
11085029|NCT04180774|Experimental|Melanoma Adjuvant|Patients with completely resected stage III or IV melanoma receiving GMV in the adjuvant setting
11085030|NCT04180774|Experimental|Melanoma Therapeutic|Patients with incompletely resected stage III or IV melanoma receiving GMV in the therapeutic setting
11085031|NCT04180774|Experimental|Renal Cell Adjuvant|Patients with completely resected stage III or IV kidney cancer receiving GMV in the adjuvant setting
11085032|NCT04180774|Experimental|Renal Cell Therapeutic|Patients with incompletely resected stage III or IV kidney cancer receiving GMV in the therapeutic setting
11085033|NCT04180761|Experimental|HIPEC-Treatment|"Doxorubicin (15 mg/m²/body surface) Cisplatin (75 mg/m²/body surface) applied as hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy.
~All drugs used are approved."
11085034|NCT04180748||Normal skin|
11085035|NCT04180748||Oily skin|
11085036|NCT04180748||Dry skin|
11085037|NCT04180748||Combination skin|
11085038|NCT04180748||Sensitive skin|
11085039|NCT04180735||Perforation|Perforation
11085040|NCT04180735||No perforation|No perforation
11085041|NCT04180722|Experimental|Intervention|Participants will receive multi-component Virtual Transition Intervention facilitated through the aTouchAway™ platform including the usual care provided by specialist HMV programs.
11085042|NCT04180722|No Intervention|Control|Usual care will be delivered in accordance with the Canadian Thoracic Society (CTS) clinical practice guidelines and includes scheduled face-to-face clinic visits with the ventilator team with the ventilator team within the first month of starting HMV and then every 3, 6, or 12 months depending on medical stability with additional telephone calls/email contact for equipment trouble shooting and management of intercurrent illnesses as needed.
11085043|NCT04180709|Experimental|Sleepio Intervention + Treatment As Usual (TAU)|Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis care team.
11085044|NCT04180709|No Intervention|Treatment As Usual (TAU) alone|Participants will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis care team. They will however be offered access to the Sleepio intervention during the follow-up period of the study.
11085045|NCT04180696|Experimental|AdaptivCRT ON (aCRT ON, treatment group)|"AdaptivCRT programmed to Adaptive Bi-V and LV The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise."
11085046|NCT04180696|Active Comparator|AdaptivCRT OFF (aCRT OFF, control group)|"AdaptivCRT programmed to Nonadaptive CRT (standard CRT). Control group subjects will be optimized per physician's discretion. The method of AV and VV optimization in the control group will be collected."
11085047|NCT04180683||Semi-structured interview group|Participants assigned to this group will be administered the GDS-30, GDS-15, GDS-10 nad GDS-5, and also the BDI-II and a semi-structured interview based on the DSM-5 criteria. The psychologists performing the assessment will answer a questionnaire about which GDS version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
11085048|NCT04180683||No semi-structured interview group|Participants assigned to this group will be administered the GDS-30 and the GDS-15, and also the BDI-II.
11085049|NCT04180657||Patients with protein C deficiency|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
11085050|NCT04180657||Healthy controls|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
11085051|NCT04180644||Atopic Dermatitis|Participants with atopic dermatitis active lesions
11085052|NCT04180644||Healthy Control|Participants without a history of atopic dermatitis
11085053|NCT04180631|Experimental|Quantitative ultrasound imaging parameter|Quantitative ultrasound imaging parameter (QUS)
11085054|NCT04180618|Experimental|Patients(Care givers)|"1,000 patients(caregivers) are enrolled and use the personal health wallet service.
~They fill out questionnaire to evaluate the service
~Some of them are invited for an in-depth interview."
11085055|NCT04180618|Experimental|Medical staffs|"12 medical staffs are enrolled and use the personal health wallet service.
~After that, they are invited for an in-depth interview."
11085126|NCT04180163|Experimental|Lanadelumab|Participants will receive 300 milligram (mg) lanadelumab solution once every 2 weeks (q2w) for 26 weeks (treatment period A), followed by treatment period B during which participants may remain on treatment period A regimen or will receive 300 mg lanadelumab solution once every 4 weeks (q4w) for 26 weeks if well tolerated with overall treatment period of 52 weeks.
11085056|NCT04180605|Active Comparator|Standard of care treatment arm|"When patients are randomized to the standard treatment arm, patients will be treated according to the participating site's routine practice. As pre-procedural imaging, a cardiac CT-scan has to be performed; this can also be complemented with TEE at the discretion of the operator. The LAA closure procedure should be performed according to routine practice of the participating site - either in general or local anesthesia.
~For those cases randomized to the standard treatment arm, the pre-procedural CT-scans will still be collected at completion of the study and FEops HEARTguideTM simulations will be generated, blinded for the procedural images and outcome. These simulations will be compared with the final device size and implant position and will be used for an additional comparative PREDICT-LAA sub-study."
11085057|NCT04180605|Experimental|Computational simulation arm|When patients are randomized to the computational simulation arm, the procedure will still be performed according to the participating site's routine practice - however, the procedure will only be performed after careful review of the FEops HEARTguideTM simulation results. The only prerequisite is that all patients randomized to this arm will have to undergo a pre-procedural cardiac CT-scan that will be uploaded into the FEops HEARTguideTM platform. Following this upload, a pre-procedural simulation plan will be provided to the operator, containing a set of optimal and suboptimal closure device sizes and implant positions. Software and technology upgrades of the FEops HEARTguideTM platform will be allowed during the course of the study.
11085058|NCT04180592|Experimental|CT Fusion Biopsy + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
11085059|NCT04180592|Other|Transrectal U/S Guided Prostate Biopsy + CT Fusion Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
11085060|NCT04180579|Experimental|Participants with Breast Cancer|Any adult woman with a new diagnosis of breast cancer, Stage I-III
11085061|NCT04180566|Other|Weekly antenatal testing|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
11085062|NCT04180566|Other|Growth ultrasound examination every 4 weeks|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.
11085063|NCT04180553|Experimental|Point-Of-Care Ultrasound Guided Resuscitation|Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment.
11085064|NCT04180553|Active Comparator|Usual Care|The comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria
11085065|NCT04180540|Experimental|Percutaneous Closure|Participants randomized to undergo percutaneous closure with PerClose after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
11085066|NCT04180540|Active Comparator|Manual Compression|Participants randomized to undergo manual compression after radiofrequency ablation or cryoablation for treatment of atrial fibrillation.
11085067|NCT04180527||Pre-Quality Improvement Initiative|This group of patients have not received previous patients' stories about their hip or knee surgery before undergoing their own hip or knee surgery.
11085068|NCT04180527||Post-Quality Improvement Initiative|This group of patients have received previous patients' stories regarding about their hip or knee surgery before undergoing their own hip or knee surgery.
11085069|NCT04180514||Intradialytic hypotension|subjects with intradialytic hypotension episode
11085070|NCT04180514||Non-intradialytic hypotension|subjects without intradialytic hypotension episode
11085071|NCT04180501|Experimental|SRS sequential sintilimab|
11085072|NCT04180488|Experimental|Study A Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
11085073|NCT04180488|Placebo Comparator|Study A Matched Placebo|placebo, on top of non-sedating H1-antihistamine
11085074|NCT04180488|Experimental|Study B Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
11085075|NCT04180488|Placebo Comparator|Study B Matched Placebo|placebo, on top of non-sedating H1-antihistamine
11085076|NCT04180475|Experimental|MedRem application|MedRem smartwatch application
11085077|NCT04180462|Experimental|Intervention Group|Practice's randomly assigned to this arm will receive the multi-component intervention.
11085078|NCT04180462|No Intervention|Wait list control group|Practices randomly assigned to this arm will be placed on a waiting list to receive the intervention in the last two years of the study.
11085079|NCT04180449||Dysphagia screening positive|
11085080|NCT04180449||Dysphagia screening negative|
11085081|NCT04180436|Experimental|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
11085082|NCT04180436|Experimental|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
11085083|NCT04180436|Experimental|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
11085084|NCT04180436|Experimental|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
11085085|NCT04180423||Off-the-Shelf Total Knee Arthroplasty Patients|
11085086|NCT04180423||Conformis iTotal Total Knee Arthroplasty Patients|
11085087|NCT04180410|Other|EIT|Electrical Impedance Tomography is performed before extubation, during follow up visits of extubation and 48H after extubation
11085127|NCT04180150|Experimental|TQ-A3334 combined with entecavir|Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks
11085088|NCT04180397|Active Comparator|Furosemide|40 mg (4 ml) of furosemide iv. followed by infusion of furosemide. Infusion rate: 0-40 mg/hour. Starting rate: 20 mg/hour. The infusion is adjusted according effect. Target is a negative fluid balance of 1 ml/kg/hour. The fluid balance is calculated 3 times a dag at 6:00 am, 2:00 pm and 10:00 pm. Goal directed fluid removal is stopped when the fluid balance is +/- 750 ml.
11085089|NCT04180397|Placebo Comparator|Placebo|Isotonic saline dosed the same way and by the same algorithm as for furosemide. Start bolus of 4 ml. Infusion is started at 2 ml/hour and adjusted according to effect and fluid balance. Infusion rate: 0 - 4 ml/hour. Stopped when the fluid balance is +/- 750 ml.
11085090|NCT04180384|Experimental|Oraxol (paclitaxel capsules+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules
~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
11085091|NCT04180384|Active Comparator|Oraxol (paclitaxel tablets+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg tablets
~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
11085092|NCT04180371|Experimental|Phase I - Dose escalation (BT5528)|Cohorts of participants will receive increasing doses of BT5528. It is expected that up to 48 participants will participate in this dose escalation arm.
11085093|NCT04180371|Experimental|Phase I - Dose escalation combination (BT5528 & nivolumab)|Cohorts of participants will receive increasing doses of BT5528 and a standard dose of nivolumab. It is expected that up to 24 participants will participate in this dose escalation combination arm.
11085094|NCT04180371|Experimental|Phase II - Dose expansion (BT5528)|A cohort of non-small cell lung cancer participants will receive the selected dose of BT5528. It is expected that up to 40 participants will participate in this dose expansion arm.
11085095|NCT04180371|Experimental|Phase II - Dose expansion combination (BT5528 & nivolumab)|A cohort of non-small cell lung cancer participants will receive the selected dose of BT5528 in combination with a standard dose of nivolumab. It is expected that up to 40 participants will participate in this dose expansion arm.
11085096|NCT04180358|Experimental|Impact group|The impact group will receive the interventions in the classrooms
11085097|NCT04180358|Placebo Comparator|Comparison group|Comparison group will not receive the intervention
11085098|NCT04180345||Validation of the questionnaire|Items reduction, ajustment and psychometric validation of the questionnaire
11085099|NCT04180332|Experimental|Healthy|The patients were healthy subjects without Periodontal disease or any systemic manifestation
11085100|NCT04180332|Experimental|Periodontal disease without diabetes|Patients with periodontal diseases without diabetes
11085101|NCT04180332|Experimental|Periodontal disease with diabetes|Patients with periodontal disease and diabetes
11085102|NCT04180306|Other|Inpatient pediatric oncology patients|All patients admitted to the pediatric oncology ward will be in the cohort
11085103|NCT04180293|Other|Military Veterans and their families|This group will participate in both the pilot psychoeducation program and its evaluation.
11085104|NCT04180280|Active Comparator|Phone Delivered|Participants receive 5 sessions of phone-delivered behavioral counseling to improve HIV care.
11085105|NCT04180280|Active Comparator|Office Delivered|Participants receive 5 sessions of office-delivered behavioral counseling to improve HIV care.
11085106|NCT04180267|No Intervention|Control Group|Subject assigned to Control Group will not receive LMHFV
11085107|NCT04180267|Active Comparator|LMHFV group|Subject assigned to LMHFV group will receive LMHFV (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year.
11085108|NCT04180254|Experimental|Experimental: normal-hearing and hearing-impaired participants|normal and hearing-impaired participants
11085109|NCT04180241|Active Comparator|total division of the muscle layer|POEM- total division of the circular muscle layer into the gastroesophageal junction
11085110|NCT04180241|Active Comparator|partial division of the muscle layer|POEM - partial division of the circular muscle layer into the gastroesophageal junction
11085111|NCT04180228||Systemic lupus erythematosus|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire with systemic lupus erythematosus.
11085112|NCT04180228||Idiopathic juvenile arthritis|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire, with idiopathic juvenile arthritis.
11085113|NCT04180215|Experimental|Ph I, Group 1|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
11085114|NCT04180215|Experimental|Ph I, Group 2|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
11085115|NCT04180215|Experimental|Ph I, Group 3|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
11085116|NCT04180215|Experimental|Ph I, Group 4|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
11085117|NCT04180215|Experimental|Ph II, Group A|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
11085118|NCT04180215|Experimental|Ph II, Group B|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care and are eligible to receive immune checkpoint inhibitor as part of standard of care.
11085119|NCT04180215|Experimental|Ph II, Group C|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
11085120|NCT04180215|Experimental|Ph II, Group D|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care therapy.
11085121|NCT04180215|Experimental|Ph II, Group E|Patients with HPV 16+ HNSCC who had tumor progression or recurrence on standard of care and are eligible to receive immune checkpoint inhibitor as part of standard of care.
11085122|NCT04180215|Experimental|Ph II, Group F|Patients with HPV 16+ cancers with a safe and accessible tumor site amenable for IT administration who had tumor progression or recurrence on standard of care therapy.
11085123|NCT04180189|Active Comparator|Weighted fiber blanket|Using a weighted blanket
11085124|NCT04180189|Placebo Comparator|Regular fiber blanket|Using a specially designed fiber blanket without extra weight.
11085125|NCT04180176|Experimental|Arm A|Participants with mNSCLC or ES-SCLC will give blood samples at three separate timepoints for ctDNA profiling.
11085857|NCT04175054|Experimental|Vigorous Intensity Group|More than 60% Heart Rate Reserve
11085128|NCT04180150|Placebo Comparator|Placebo combined with entecavir|Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks
11085129|NCT04180137|Experimental|Surgical treatment with subsequent pharmacotherapy|
11085130|NCT04180137|Other|Isolated surgical treatment|
11085131|NCT04180124|Experimental|GaitRite|"Patients will walk on the GaitRite.
~forward walking at comfortable gait speed (6 x 10 meter)
~backward walking at comfortable gait speed (4 x 10 meter)"
11085132|NCT04180124|Experimental|Treadmill walking self-paced|"Patients will walk on the treadmill in self-paced mode. They can control walking speed by themselves.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
11085133|NCT04180124|Experimental|Treadmill walking fixed speed - comfortable speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at comfortable gait speed, which is determined in the familiarization period.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
11085134|NCT04180124|Experimental|Treadmill walking fixed speed - fast speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at a gait speed, which is 1 minimal clinical difference faster than their comfortable gait speed.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
11085135|NCT04180124|Experimental|Treadmill walking fixed speed - backward walking|"Patients will walk on the treadmill in fixed speed mode. Patient will walk backwards on the treadmill if they are able to.
~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
11085136|NCT04180098|Experimental|Context specific C-mill training|Five week C-mill training on gait adaptability.
11085137|NCT04180098|Other|Usual care|Usual care for participants with HSP. May vary per individual.
11085138|NCT04180085|Experimental|BELATACEPT|
11085139|NCT04180072|Experimental|Atezolizumab plus bevacizumab|Atezolizumab 1200 mg IV on Day 1 +Bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle.
11085140|NCT04180059|Experimental|CTL 19 : T cell therapy|Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg.
11085141|NCT04180033|Other|Colonoscopy surveillance in TC survivors|TC survivors treated with platinum-based chemotherapy will be invited to undergo a colonoscopy surveillance.
11085142|NCT04180020|Active Comparator|TAU|Treatment as Usual (TAU).
11085143|NCT04180020|Experimental|ID/LAB|Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).
11085144|NCT04180007|Experimental|Neoadjuvant arm|Patients receive Apatinib orally qd up to 12 wk.
11085145|NCT04179994|Experimental|Miswak extract-containing toothpaste group|Test group.
11085146|NCT04179994|Active Comparator|Toothpaste containing Potassium Nitrates|Positive control.
11085147|NCT04179994|Placebo Comparator|Placebo group|Toothpaste contains same ingredients of test group except for the active ingredient as negative control.
11085148|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
11085149|NCT04179981|Active Comparator|PAP therapy arm|PAP Therapy will be provided to eligible patients with OVS. This is the active therapy arm.
11085150|NCT04179968|Experimental|Patients with suspected prostate cancer|Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy
11085151|NCT04179942|Active Comparator|Patients|full night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured
11085152|NCT04179942|Placebo Comparator|control|CRP level was measured
11085153|NCT04179929|Other|CHEMOTHERAPY|Pediatric-type of chemotherapy
11085154|NCT04179929|Other|allogeneic HSCT|allogeneic HSCT
11085155|NCT04179916|Experimental|Healthy volunteers|Participants between 21 and 25 years, the Faculty of Physical Education and Physiotherapy of the Opole University of Technology Students
11085156|NCT04179903|Active Comparator|Gym Trainer|Physical Activity program is performed in a group in a gym (Gym Group Training-GGT), with activity sessions conducted by a trainer graduated in Science and Techniques of Preventive and Adapted Physical Activity
11085157|NCT04179903|Active Comparator|Individual Home|Physical Activity program is performed at home individually (Individual Home Training-IHT), without the supervision of a trainer during the exercise session.
11085158|NCT04179890||Uncommon mutation cohort|Patients with non-small-cell lung cancer (NSCLC)
11085159|NCT04179890||Sequencing cohort|Patients with non-small-cell lung cancer (NSCLC)
11085160|NCT04179877|Experimental|Individual placement and support|Group of patients receiving IPS to increase workforce participation.
11085161|NCT04179877|No Intervention|Control|Group of patients receiving treatment as usual.
11085162|NCT04179864|Experimental|Tazemetostat in Combination with Abiraterone/Prednisone|Abiraterone/prednisone will be administered on cycle 1 day 1 and Tazemetostat on day 2
11085163|NCT04179864|Experimental|Tazemetostat in Combination with Enzalutamide|Enzalutamide will be administered on cycle 1 day 1 and Tazemetostat on day 2
11085164|NCT04179838|Experimental|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
11085165|NCT04179838|Experimental|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
11085166|NCT04179799||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
11085167|NCT04179786|Other|Sci-B-Vac™|Single arm study in healthy volunteers who had never been vaccinated with any hepatitis B vaccine and who were seronegative for antibodies to HBsAg, HBc and HBs at baseline.
11085168|NCT04179773||Cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
11085169|NCT04179773||Non-cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
11085170|NCT04179760|Experimental|SCM-AGH|"Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells
~Dose: 1x10^6 cells/Kg"
11085171|NCT04179760|Placebo Comparator|Placebo|3 times with 2-week intervals by IV infusion.
11085172|NCT04179747|Experimental|Group A|The cognitive behavior psychotherapy was administered to participants in this treatment arm.
11085173|NCT04179747|Active Comparator|Control Group|This group received the administration of pharmacotherapy (PDE5i) for treatment of Erectile Dysfunction.
11085174|NCT04179734|Experimental|Intervention|Bremelanotide 1.75 mg - prefilled subcutaneous autoinjector containing 1.75 mg Bremelanotide in a 0.3 mL solution volume.
11085175|NCT04179734|Placebo Comparator|Placebo|1.75 mg equivalent - prefilled subcutaneous autoinjector containing Bremelanotide formulation without the active ingredient in a 0.3 mL solution volume.
11085176|NCT04179721|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and NAs who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of hospital caregivers towards patients. IV. Staff Training
11085177|NCT04179721|Active Comparator|The attention control condition|The control group consists of NAs that work on a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 NA (1:8 ratio), that primarily cohorts older patients with geriatric syndromes. All components of the intervention arm are the same with the exception of the PES staff. The control arm (NAs) will receive the same training as the intervention arm.
11085178|NCT04179708|Experimental|pain neuroscience education|
11085179|NCT04179708|Active Comparator|Conventional education|"patient receiving a classical education on spinal physiology and ergonomics"
11085180|NCT04179695|Experimental|consultation with Parkinsun|
11085181|NCT04179695|Active Comparator|consultation as usual without Parkinsun|
11085182|NCT04179682|Active Comparator|4-week 2-hours/day CIMT program|a 4-week 2-hours/day constraint program, total 40 hours CIMT, in preschool education.
11085183|NCT04179682|Active Comparator|2-week 4-hours/day CIMT program|one was a 2-week 4-hours/day constraint program, total 40 hours CIMT, in preschool education.
11085184|NCT04179669|Experimental|IBI306|Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
11085185|NCT04179669|Experimental|placebo|Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
11085186|NCT04179656|Experimental|Pyrotinib Treatment|This arm for HER2-postive solid tumor
11085187|NCT04179643|Experimental|3 x 10e13vg NAN-101|Intracoronary Infusion of NAN-101 at 3 x 10e13vg up to 4 subjects
11085188|NCT04179643|Experimental|1 x 10e14vg NAN-101|Intracoronary Infusion of NAN-101 1 x 10e14vg up to 4 subjects
11085189|NCT04179643|Experimental|3 x 10e14 vg NAN-101|Intracoronary Infusion of NAN-101 3 x 10e14 vg up to 4 subjects
11085190|NCT04179630|Experimental|Aldafermin (NGM282)|Administered by subcutaneous injection
11085191|NCT04179617|Experimental|Preferred nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 5% nicotine content pod (their preferred pod)
11085192|NCT04179617|Experimental|Low nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 3% nicotine content pod (non-preferred pod)
11085193|NCT04179604|Experimental|Levosimemdam|Levosimendan 2.5 mg / ml concentrate for solution for infusion. A 5 ml vial contains 12.5 mg of levosimendan. The concentrate is a clear solution, yellow or orange, for dilution before administration. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
11085194|NCT04179604|Placebo Comparator|Placebo|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
11085195|NCT04179591|Experimental|Exercise|Exercises will be performed three times per week for six weeks.
11085196|NCT04179591|Experimental|Insole|Customized arch support insoles will be worn for six weeks.
11085197|NCT04179591|Experimental|Exercise plus Insole|Exercises will be performed three times per week, and customized arch support will be worn for six weeks.
11085198|NCT04179578|Active Comparator|Crura|Closure of the diaphragmatic hiatus by a running suture alone
11085199|NCT04179578|Active Comparator|Crura and lateral release|Closure of the diaphragmatic hiatus by a running suture and an incision of 4 cm of the left diaphragm (lateral release)
11085200|NCT04179565|Active Comparator|Immediate intervention|The immediate education (IE) group will receive the intervention, Healthy Children, Healthy Families: Parents Making a Difference! in period 1. In period 2, IE will receive no education and will be followed longitudinally for periods 2 and 3.
11085201|NCT04179565|Active Comparator|Delayed intervention|The delayed education (DE) group will serve as controls in period 1, receiving no intervention. In period 2, the treatments will cross over, so DE will receive the Healthy Children, Healthy Families: Parents Making a Difference! intervention.
11085202|NCT04179552|Experimental|PAAG-OA|All subjects receive treatment with PAAG-OA
11085203|NCT04179539|Experimental|Intervention|"Patients with suspected acute PE undergo CTPA and V/Q PET/CT imaging within 24 hours. V/Q PET/CT images are not used for patients management.
~After completion of inclusion, central readings will be independently conducted:
~CTPA will be interpreted by two radiologists, blinded to the results of any clinical information or imaging test results. The results of this interpretation will be used as a reference standard.
~V/Q PET/CT will be interpreted by two independant nuclear medicine physicians, blinded to the results of any clinical information or imaging test results (including the reference standard)."
11085858|NCT04175041|Other|ADHD|Patients with ADHD.
11085204|NCT04179526|Experimental|Transdiagnostic Internet-delivered REBT|Protocol is based on Rational Emotive Therapy (Ellis, 1962, 1994), structured in 8 modules delivered over 6 weeks (Module 1- Introduction and psychoeducation about emotions, Module 2 - Psychoeducation anxiety and depression, Module 3 - Relaxation, Module 4 - Negative patterns of thinking and cognitive restructuring, Module 5 - Problem solving, Module 6 - Exposure and Behavioral activation, Module 7 - Positive emotions and Module 8 - Gaining maintenance)
11085205|NCT04179526|No Intervention|Waitlist|Participants in the control group will complete pre-treatment and post-treatment assessments. After participants in the experimental group complete post-treatment assessment, they will receive the intervention.
11085206|NCT04179513|Experimental|GB224 10mg|GB224 10mg
11085207|NCT04179513|Experimental|GB224 20mg|GB224 20mg
11085208|NCT04179500|Experimental|Study Participants|Healthy volunteers will receive 200 mg of Pretomanid (Pa) daily for 26 weeks.
11085209|NCT04179487||Pregnant Patients with Suspected PE|Pregnant Patients with Suspected pulmonary embolism undergoing low dose CT pulmonary angiogram
11085210|NCT04179474|Experimental|Part 1, Study Intervention A|Single dose ubrogepant
11085211|NCT04179474|Experimental|Part 1, Study Interventions B|Single dose subcutaneous (SC) injection of erenumab
11085212|NCT04179474|Experimental|Part 2, Study Intervention A|Single dose ubrogepant
11085213|NCT04179474|Experimental|Part 2, Study Interventions C|2 SC injections of galcanezumab
11085214|NCT04179474|Experimental|Part 1, Study Interventions D|Multiple dose ubrogepant
11085215|NCT04179474|Experimental|Part 2, Study Interventions D|Multiple dose ubrogepant
11085216|NCT04179461|Experimental|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.
~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
11085217|NCT04179448|Experimental|Side Access Mucosal Releasing Incision (SAMRI)|SAMRI incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
11085218|NCT04179448|Active Comparator|Sulcular Tunnell access|Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
11085219|NCT04179435|Other|Tourette syndrome|Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures
11085220|NCT04179435|Other|Controls|Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures
11085221|NCT04179409|Experimental|Casimersen|This arm will involve the treatment of boys with DMD who have a duplication of exon 45, for which casimersen will target skipping of this exon.
11085222|NCT04179409|Experimental|Eteplirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 51, for which eteplirsen will target skipping of this exon.
11085223|NCT04179409|Experimental|Golodirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 53, for which golodirsen will target skipping of this exon.
11085224|NCT04179396|Experimental|Arm A: Oral rucaparib and enzalutamide|
11085225|NCT04179396|Experimental|Arm B: Oral rucaparib and abiraterone|
11085226|NCT04179383|Other|Patient|Patient presenting a Reversible Cerebral Vasoconstriction Syndrome (RCVS) for which a biobank will be constitute
11085227|NCT04179383|Other|Volunteers|Volunteers admitted for a non neurological or non vascular pathology or healthy volunteers accompanying a patient for which a biobank will be constitute
11085228|NCT04179344||Integrated e-healthcare services (IeHS) web-based app|This usability study is conducted under 3 steps: IeHS simulation, user experience survey using SUS questionnaire, and qualitative study through the in-depth interview.
11085229|NCT04179331|Experimental|Neurotensin|
11085230|NCT04179331|Experimental|Saline|
11085231|NCT04179318||low risk|BCT Score <4
11085232|NCT04179318||high risk|BCT Score ≥4
11085233|NCT04179305|Experimental|Oncolo_GIST Arm|Physicians assigned to this arm will receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with an Oncolo-GIST trained physician.
11085234|NCT04179305|Placebo Comparator|Usual Care Arm|Physicians assigned to this arm will not receive the Oncolo-GIST training intervention. Patients assigned to this arm will will discuss scan results revealing progressive disease with a physician that was not trained with the Oncolo-GIST intervention.
11085235|NCT04179292|Experimental|Physiotherapy Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist for 3 sessions per week. On the other days, it will be implemented as an 8-week home program with 5 sessions per week.
11085236|NCT04179292|Experimental|Home Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients as home program. Motivation will be provided by contacting by phone / call once a week for follow-up.
11085237|NCT04179279||Pilot|
11085238|NCT04179279||Pivotal|
11085239|NCT04179253|Other|Unexplained infertility|"The patient was placed in the dorsal lithotomy position. Normal saline was used for uterine distension connected to the inflow channel on the sheath with intravenous tubing. The tip of the hysteroscope was positioned in the vaginal introitus, the labia being slightly separated with fingers. The vagina was distended with saline.
~The uterine cavity was systematically explored by rotating the fore-oblique scope in order to identify any anomaly in the uterine walls and/or the right and left tubal ostia. At this stage it was crucially important to avoid lateral movements as much as possible to reduce patient discomfort to a minimum. After that, the scope was removed Finally the evaluation and the data that had been found were written in details by the surgeon. Operative intervention was done if needed. Any complication in the form of pain, bleeding, vasovagal attack and perforation, were registered in the patient sheet."
11085273|NCT04179006|Active Comparator|LF chocolate + antidepressant(s)|Participants with LF chocolate add-on to their antidepressants regimen.
11085240|NCT04179240|Experimental|audio and animated cartoon questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with audio and animated cartoon questionnaire. The animation was an 8-minute cartoon video divided into different parts according to different questions. The first part of the animation was the introduction of biospecific nonspecimen specimen and our survey, while the other parts showed the content of the questionnaire about donating biospecific nonspecimen specimen in a vivid way. The background music built a relaxed and pleasant atmosphere, and some cartoon pictures were made into question options to simplify the understanding and data analysis.
11085241|NCT04179240|No Intervention|text questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
11085242|NCT04179240|Other|Parent group|After a brief introduction to our survey, participants(parent) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
11085243|NCT04179227||Observational (focus group)|Participants attend a focus group session and review printed copies of planned posts for the to-be-developed Facebook intervention over 90 minutes to 2 hours.
11085244|NCT04179214|Experimental|Group I Experimental: thoracic manipulation|The experimental group will receive thoracic manipulation along with conventional pt protocol.
11085245|NCT04179214|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol
11085246|NCT04179201||IBD with CDI|Inflammatory bowel disease with clostridium difficile infection
11085247|NCT04179201||IBD without CDI|Inflammatory bowel disease without clostridium difficile infection
11085248|NCT04179188||Bariatric OSA Group|Bariatric surgery plannified intervention patient with obstructive sleep Apnéa
11085249|NCT04179188||Bariatric without OSA Group|Bariatric surgery plannified intervention patient without obstructive sleep Apnéa
11085250|NCT04179175|Active Comparator|secukinumab 1 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 2 weeks
11085251|NCT04179175|Active Comparator|secukinumab 2 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 4 weeks
11085252|NCT04179175|Placebo Comparator|placebo 1 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300mg every 2 weeks
11085253|NCT04179175|Placebo Comparator|placebo 2 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300 mg every 4 weeks
11085254|NCT04179175|Active Comparator|HiSCR non-responders|non-responder to core trial treatment; secukinumab 300mg every 2 weeks
11085255|NCT04179162|Experimental|Bacillus Calmette-Guérin (BCG) and Gemcitabine|Eligible patients will receive combination intravesical chemoimmunotherapy. Treatment is sequential, with twice-weekly intravesical gemcitabine given at weeks 1, 4, 7, and 10, for a total of 8 doses, administered in a standard fashion. In phase I, the dose of gemcitabine will depend on the dose level being assessed for the determination of the MTD. phase II, 1 dose level will be given (the MTD from phase I). Fixed doses of once-weekly intravesical BCG therapy (TICE strain, 50 mg) will be given at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6 (+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days), for a total of 6 doses, also administered in a standard fashion. All intravesical therapy will be administered in the chemotherapy suite on an outpatient basis, in accordance with standard clinical practice. Intravesical therapies will be retained in the bladder for up to 2 h (BCG) or 1 h (gemcitabine), or as tolerated.
11085256|NCT04179149|Experimental|Environmental enrichment|Subjects randomized to the intervention condition will receive the EE intervention (social support, open spaces, novel stress relief activities) as an adjuvant to standard gynecological care consisting of hormonal, analgesic or surgical treatment as necessary according to their symptoms during the study period.
11085257|NCT04179149|No Intervention|Controls|Participants randomized to the control condition will receive only standard care as necessary according to their symptoms during the study period PLUS an online patient training module.
11085258|NCT04179136|Active Comparator|High enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
11085259|NCT04179136|Placebo Comparator|High enterolactone producer's (Control)|Placebo treatment matching intervention
11085260|NCT04179136|Active Comparator|Low enterolactone producer's (intervention)|lignan capsules contain 300 mg flaxseed (SDG) extract
11085261|NCT04179136|Placebo Comparator|Low enterolactone producer's (Control)|Placebo treatment matching intervention
11085262|NCT04179123|Experimental|Healthy|Conventional and customised PAP interfaces
11085263|NCT04179123|Experimental|Patients|Conventional and customised PAP interfaces
11085264|NCT04179110|Experimental|Pembrolizumab and Ramucirumab|Patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor will receive Pembrolizumab and Ramucirumab.
11085265|NCT04179084|Experimental|fruquintinib + Sintilimab|
11085266|NCT04179071|Experimental|Savolitinib|Subjects will receive single dose of 600mg savolitinib after a high-fat, high-calorie meal.
11085267|NCT04179071|Experimental|Savolitinib + Famotidine|Subjects will receive savolitinib 600mg single dose after high-fat, high-calorie meal and after 1.5 hours (Part A) or 5.5 hours (Part B) of famotidine 40mg dose. Famotidine will be administered after an overnight fast of at least 8 hours with approximately 240 mL of water.
11085268|NCT04179058||IPAF patients|IPAF definition according to 2015 ERS/ATS criteria
11085269|NCT04179058||non-IPAF patients|
11085270|NCT04179045|Experimental|Bioheart|Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.
11085271|NCT04179032|Experimental|Participants receiving belimumab 200 mg|In Part A, participants will receive 200mg/ml belimumab via auto-injector for 12 weeks. Frequency of administration will be based on body weight. Participants who weigh >=50 kilogram (kg) at Baseline will be assigned to Cohort 1 and receive 200 mg/mL belimumab QW SC. Participants who weigh >=30 kg and <50 kg at Baseline will be assigned to Cohort 2 and receive 200 mg/mL belimumab Q10d SC. Participants who weigh <30 kg at Baseline will be assigned to Cohort 3 and receive 200 mg/mL belimumab Q2W SC. In Part B (optional), dosing of SC belimumab will continue at the same frequency or may require a change in frequency according to changes in participant's body weight for 40 weeks.
11085272|NCT04179019|Experimental|Amlodipine|Amlodipine (dose 10 mg, once daily)
11085274|NCT04179006|Active Comparator|Erinacine A-enriched Hericium chocolate + antidepressant(s)|Participants with Erinacine A-enriched Hericium chocolate add-on to their antidepressants regimen.
11085275|NCT04179006|Placebo Comparator|Plain chocolate + antidepressant(s)|Participants with plain chocolate add-on to their antidepressants regimen.
11085276|NCT04178993|Placebo Comparator|Placebo Comparator: Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11085277|NCT04178993|Active Comparator|Active Comparator: Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Methamphetamine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
11085278|NCT04178980|Active Comparator|case|
11085279|NCT04178980|Placebo Comparator|control|
11085280|NCT04178967|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W."
11085281|NCT04178967|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W."
11085282|NCT04178967|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebikizumab injection."
11085283|NCT04178967|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):
~Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
11085284|NCT04178941|Experimental|Intervention (Single Arm)|The intervention is a combined educational outreach and audit and feedback strategy that includes providing the hospital's own continuous pulse oximetry use data back to them on a weekly basis. The data will be accompanied by staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
11085285|NCT04178928|Active Comparator|group A|patiWill receive L-T4 treatment at a dose 1 µg/kg/day for 12 weeks. And the dose will be titrated every 4 weeksents with SCH will be subjected to clinical, laboratory and imaging assessment and
11085286|NCT04178928|No Intervention|Group B|.pWill not receive treatment.atients with SCH will be subjected to clinical, laboratory and imaging assessment and
11085287|NCT04178915||Patients with severe bacterial infections|
11085288|NCT04178902|Experimental|Part A: ABBV-467 Dose Escalation|ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended phase 2 dose is determined.
11085289|NCT04178902|Experimental|Part B: ABBV-467 Dose Expansion|ABBV-467 administered by intravenous (IV) infusion at recommended phase 2 dose as identified in Part A.
11085290|NCT04178876|Experimental|Aspiration and Sclerotherapy of endometriomas|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
11085291|NCT04178876|Active Comparator|laparoscopic stripping technique|cystectomy of endometriomas during laparoscopy
11085292|NCT04178863|Active Comparator|lataprost|latanoprost use
11085293|NCT04178863|Active Comparator|timolol|timolol group
11085294|NCT04178850|Experimental|GB242|3mg/kg
11085295|NCT04178850|Active Comparator|Infliximab|3mg/kg
11085296|NCT04178824|Experimental|Experimental 15% discount intervention|15% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
11085297|NCT04178824|Experimental|Experimental 30% discount intervention|30% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
11085298|NCT04178824|No Intervention|No intervention control group|0% discount on fruits, vegetables and non-caloric beverages at the designated supermarkets
11085299|NCT04178811|Active Comparator|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia
11085300|NCT04178811|Active Comparator|Prostatic Uretheral Lift|Use of Holmium Prostatic Uretheral Lift in Management of Benign Prostatic Hyperplasia
11085301|NCT04178798|Experimental|Arm A_Acalabrutinib|Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.
11085302|NCT04178798|No Intervention|Arm B_Standard of care|"Patients assigned to arm B, will receive standard of care for the management of early Binet stage A patients clinical observation (watch & wait) until disease progression or early withdrawal."
11085303|NCT04178785|Active Comparator|REMIFENATIL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
11085304|NCT04178785|No Intervention|FENTANYL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
11085635|NCT04176588|Placebo Comparator|Placebo Comparator: Placebo|matching tablet, administratered orally, once daily
11085305|NCT04178772|Experimental|JJVC Marketed Contact Lens|Eligible subjects that have no experience with soft multifocal lenses for more than 2 years will be assigned to a single study lens type worn in both eyes daily for at least 6 hours per day, everyday for approximately 12 weeks.
11085306|NCT04178759|Active Comparator|Control|Patients with benign liver disease, who undergo liver resection
11085307|NCT04178759|Experimental|Experimental|Patients with liver metastases and received chemotherapy, who undergo liver resection
11085308|NCT04178746||IVH subjects in the Hyper-Acute Phase|The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in approximately 20 subjects with intracerebral hemorrhages utilizing the Artemis Neuro Evacuation Device in the hyper-acute phase. For the purposes of this registry, the hyper-acute phase as defined by initiation of the MIS procedure no longer than 12 hours from initial NCCT scans and no longer than 18 hours since time patients last known well.
11085309|NCT04178733|Experimental|LY3493269 - Subcutaneous (SC)|LY3493269 administered SC.
11085310|NCT04178733|Placebo Comparator|Placebo - SC|Placebo administered SC.
11085311|NCT04178733|Experimental|LY3493269 - Intravenous (IV)|LY3493269 administered IV.
11085312|NCT04178707|Other|Intervention|Using microdialysis the patients inner enviorment of the anal fistula will be measured - levels of lactate, glucose and pyruvate.
11085313|NCT04178694|Experimental|non-invasive ventilation|All subjects will be submitted to non-invasive ventilation with different settings. During the whole period indirect calorimetry will be performed and haemodynamic parameters will be monitored using a non-invasive device. Reversed combined RPE scale will be asked on a regular base.
11085314|NCT04178681|Experimental|V-A-C|"Order of administration:
~100% vegetable fat blend
~100% Anhydrous Milk Fat (AMF)
~100% Cream (AMF + milk fat globular membranes)"
11085315|NCT04178681|Experimental|V-C-A|"Order of administration:
~100% vegetable fat blend
~100% Cream (AMF + milk fat globular membranes)
~100% Anhydrous Milk Fat (AMF)"
11085316|NCT04178681|Experimental|A-V-C|"Order of administration:
~100% Anhydrous Milk Fat (AMF)
~100% vegetable fat blend
~100% Cream (AMF + milk fat globular membranes)"
11085317|NCT04178681|Experimental|A-C-V|"Order of administration:
~100% Anhydrous Milk Fat (AMF)
~100% Cream (AMF + milk fat globular membranes)
~100% vegetable fat blend"
11085318|NCT04178681|Experimental|C-A-V|"Order of administration:
~100% Cream (AMF + milk fat globular membranes)
~100% Anhydrous Milk Fat (AMF)
~100% vegetable fat blend"
11085319|NCT04178681|Experimental|C-V-A|"Order of administration:
~100% Cream (AMF + milk fat globular membranes)
~100% vegetable fat blend
~100% Anhydrous Milk Fat (AMF)"
11085320|NCT04178668|Experimental|20-40 years old|33 patients between 20 and 40 years old
11085321|NCT04178668|Experimental|70-90 years old|33 patients between 70 and 90 years old
11085322|NCT04178655|Experimental|Tranexamic Acid Treatment|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
11085323|NCT04178655|Placebo Comparator|Placebo|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
11085324|NCT04178642|Experimental|(experimental group)|Evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group)
11085325|NCT04178642|Active Comparator|(standard group)|The absence of adjuvant treatment (standard group).
11085326|NCT04178616|Other|systemic sclerosis patients population|All the patients with systemic sclerosis disease followed in day-care in a tertiary hospital are eligible to be enrolled in the study.
11085327|NCT04178603|Experimental|Acute Exercise Trial|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise. Glucose metabolism is investigated before exercise (basal), during exercise and for 120 min of recovery.
11085328|NCT04178603|Experimental|Insulin Sensitivity post Exercise|Lean control subjects and insulin resistant subjects perform an acute bout of one-legged knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action is investigated by a 120 min euglycemic-hyperinsulinemic euglycemic clamp.
11085329|NCT04178590|Experimental|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
11085330|NCT04178590|Placebo Comparator|SRP + placebo|Scaling and root planing in conjunction with saline
11085331|NCT04178577|Experimental|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
11085332|NCT04178564|Experimental|Intervention Group|Intervention group will receive 47 sessions of group CS and participate in 3 evaluation sessions. The CS program will last 1 year and each group CS session will last approximately 60 minutes.
11085333|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
11085334|NCT04178551|No Intervention|Comparison Cohort|All other sites in VA not receiving CONDUIT implementation support or participating in other dedicated MOUD implementation activities during the same time period
11085335|NCT04178538|Experimental|25 years and older- ACL recon with DBM, Internal brace|Patients in this arm will be 25 years of age and over and receive ACL reconstruction augmented with demineralized bone matrix, bone marrow, and internal brace
11085336|NCT04178538|Active Comparator|25 years and older- Standard ACL reconstruction|Patients in this arm will be 25 years of age and over will receive an allograft All-Inside ACL reconstruction
11085337|NCT04178538|Experimental|24 years and younger- ACL recon with DBM, Internal brace|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft augmented with demineralized bone matrix, bone marrow, and internal brace
11085338|NCT04178538|Active Comparator|24 years and younger- Standard ACL reconstruction|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft standard all inside technique
11085339|NCT04178525|Experimental|Arm A (Experimental group|ChitoCare gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
11085636|NCT04176588|Experimental|Etrasimod 2mg (optional open-label extension period)|2mg/tablet, administratered orally, once daily
11085340|NCT04178525|Placebo Comparator|Arm B (Control group)|Placebo gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
11085341|NCT04178512|Active Comparator|group Dexamethasone|Patients will receive 8 mg of dexamethasone(2ml) in addition to 2ml of hyperbaric bupivacaine 0.5% (total volume 4 ml) intrathecal injection.
11085342|NCT04178512|Active Comparator|group Fentanyl|patients will receive 20 microgram fentanyl(diluted in sterile normal saline0.9% to 2ml)in addition to 2ml of hyperbaric bupivacaine 0.5%(total volume 4 ml) intrathecal injection.
11085343|NCT04178512|Active Comparator|group Control|patients will receive 2ml of sterile normal saline0.9% in addition to 2ml of hyperbaric bupivacaine o.5% (total volume 4 ml) intrathecal injection.
11085344|NCT04178499||smokers|active smokers
11085345|NCT04178499||non-smokers|never smokers
11085346|NCT04178486|Experimental|Amnesia|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions to experience amnesia for the food pictures they had just seen.
11085347|NCT04178486|Experimental|Cognitive Rehearsal|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a future where they will control their eating behaviors.
11085348|NCT04178486|Experimental|Memory Substitution|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a past where they have always controlled their eating behaviors.
11085349|NCT04178486|Placebo Comparator|Control|Hypnosis formed from only hypnotic induction (an adapted version from Barber Suggestibility Scale).
11085350|NCT04178473|Active Comparator|total abdominal hysterectomy|Total abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
11085351|NCT04178473|Active Comparator|subtotal abdominal hysterectomy|subtotal abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
11085352|NCT04178460|Experimental|Assigned Interventions|Niraparib combined with MGD013
11085353|NCT04178447|Experimental|Group 1: ESRD subjects not on dialysis or severe RI|subjects with eGFR <15 mL/min/1.73 m2) or (eGFR 15 to <30 mL/min/1.73 m2)
11085354|NCT04178447|Experimental|Group 2: normal renal function|subjects with eGFR ≥90 mL/min/1.73 m2
11085355|NCT04178447|Experimental|Group 3: moderate RI|subjects with eGFR 30 to <60 mL/min/1.73 m2
11085356|NCT04178447|Experimental|Group 4: mild RI|subjects with eGFR 60 to <90 mL/min/1.73 m2
11085357|NCT04178434|Active Comparator|Internet-based CBT intervention|A nine step internet-based intervention with focus on stress and cardiac anxiety
11085358|NCT04178434|No Intervention|Treatment as usual|Regular follow-up with two doctor and one nurse appointment
11085359|NCT04178421|Experimental|Experimental Group|A computerized eye -tracking program training the eye gaze fixation with the target to improve impulse control and sustained attention of children with special needs
11085360|NCT04178421|Placebo Comparator|Control Group|Computerized program
11085361|NCT04178408||Cases|Cases of inflammatory bowel disease
11085362|NCT04178408||Controls|Two controls per case. 1. Sibling or other second degree relative of similar age. 2. neighbourhood control matched for age
11085363|NCT04178395|Experimental|real tDCS group|Patients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric transcranial direct stimulation and repetitive peripheral stimulation for 5 consecutive days.
11085364|NCT04178395|Sham Comparator|sham group|Patients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days.
11085365|NCT04178382|Experimental|experiment group|Combined detection of PCR and CRISPR/Cas12a in alveolar lavage fluid to guide early target adjustment of antibiotics
11085366|NCT04178382|No Intervention|control group|Guide the target adjustment of antibiotics according to traditional microbiological detection methods
11085367|NCT04178369|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proximal and distal tibiofibular joint manipulations will be applied for 6 weeks.
11085368|NCT04178369|Active Comparator|Control Group|All participants were given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept (conservative treatment) for 5 days a week, 45 minutes each.
11085369|NCT04178356|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proprioceptive neuromuscular facilitation techniques will be applied for 4 weeks.
11085370|NCT04178356|Active Comparator|Control Group|Conservative treatment of low back pain will be applied for 4 weeks.
11085371|NCT04178343|Experimental|Group A|Meningeal Metastases, with or without brain metastases
11085372|NCT04178330|Experimental|Group A|patients with multiple brain metastases (no less than 3 lesions) ,who have not recived whole brain radiotheray (WBRT).
11085373|NCT04178317||Venetoclax Participants|Participants receiving venetoclax for chronic lymphocytic leukemia according to the approved local label, and the decision to prescribe Venetoclax is independent from the enrollment into the study.
11085374|NCT04178304|Experimental|G1 patients receive prolotherapy|Intra and extra articular dextrose 25%
11085375|NCT04178291|Experimental|Conventional debridement and air polishing|All participants will receive full mouth EPAP as an adjunct to RSD using ultrasonic scalers and Gracey currettes. The EPAP procedure will be performed using the Air-Flow Master R (EMS) equipment. For supragingival biofilm removal, the Air-Flow handpiece will be used, while the Perio-Flow handpiece with a disposable nozzle will be used for subgingival debridement at sites with PPD ≥ 5mm. No time limit is applicable for supragingival air polishing. However, for subgingival debridement, the nozzle will be inserted for 5 seconds into each pocket, and moved vertically up and down. Gracey currettes will be used at sites with PPD ≥ 5mm.
11085376|NCT04178291|Active Comparator|Conventional debridement|All participants will receive full mouth RSD using ultrasonic scalers and Gracey currettes. Gracey currettes will be used at sites with PPD ≥ 5mm.
11085377|NCT04178278|Experimental|Shuttle walking test group|Patients will performed shultte walking test.
11085378|NCT04178278|Active Comparator|Exercise stress test group|Patients will performed exercise stress test.
11085379|NCT04178278|Active Comparator|6 minutes walking test group|Patients will performed 6 minutes walking test.
11085571|NCT04177108|Experimental|Cohort 1 Arm A|PD-L1 Non-Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1:1 ratio.
11085380|NCT04178265|Experimental|Electroacupuncture group|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of three times per week for four weeks, for a total of twelve times.
~Acupoint selection: needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints."
11085381|NCT04178265|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of three times per week for four weeks, for a total of twelve times.
11085382|NCT04178252|Active Comparator|standard drug|Standard treatment of primary headache with 10 mg metoclopramide IV in 150 ml saline given over 10 minutes
11085383|NCT04178252|Active Comparator|drug mask|Standard treatment plus eye mask
11085384|NCT04178252|Active Comparator|drug headset|Standard treatment plus headset
11085385|NCT04178252|Active Comparator|drug mask headset|Standard treatment plus headset plus eye mask
11085386|NCT04178239||Chronic Fatigue|MFI score >53 points
11085387|NCT04178239||No Chronic Fatigue|MFI score < 54 points
11085388|NCT04178226|No Intervention|Control|conventional therapy (NSAIDs and OCP)
11085389|NCT04178226|Experimental|Manual Acupuncture|manual acupuncture therpy
11085390|NCT04178226|Experimental|Laser Acupuncture|laser acupuncture therapy
11085391|NCT04178213|Experimental|ADAPT 3D ALR|Patients treated with ADAPT 3D ALR
11085392|NCT04178200||1.5 ml Dose|For retrobulbar anesthesia, 1.5 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
11085393|NCT04178200||3 ml Dose|For retrobulbar anesthesia, 3 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
11085394|NCT04178187|Active Comparator|Lactolevure|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Probiotics
11085395|NCT04178187|Placebo Comparator|Placebo|Patients will receive quadruple eradication therapy for Helicobacter Pylori infection with Amoxicillin, Clarithromycin, Metronidazole, Omeprazole and Placebo
11085396|NCT04178174|Experimental|SABR boost and de-escalated chemoradiation|SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.
11085397|NCT04178174|Active Comparator|Standard chemoradiation|The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.
11085398|NCT04178161|Experimental|Treated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.
~Treatment side receives laser treatment of the sweat glands."
11085399|NCT04178161|No Intervention|Untreated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.
~Control side is untreated."
11085400|NCT04178148|Experimental|BestDose|Therapeutic drug optimization of amikacin using the BestDose software algorithm
11085401|NCT04178148|No Intervention|Control|
11085402|NCT04178135|Experimental|rLH supplementation from day 1 of stimulation|rLH supplementation from day 1 of stimulation
11085403|NCT04178135|Active Comparator|rLH supplementation from day 6 of stimulation|rLH supplementation from day 6 of stimulation
11085404|NCT04178122|Experimental|Immediate Results|Participants in the Immediate Results arm will receive their genetic testing results from a genetic counselor at baseline following randomization.
11085405|NCT04178122|Experimental|Delayed Results|Participants in the Delayed Results arm will receive their genetic testing results from a genetic counselor 6 months after randomization.
11085406|NCT04178109|Active Comparator|Group A|"Group A was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.
~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.
~Group A was given the oral combination dexketoprofen/tramadole (25mg/75mg) 2h after surgery every 8h for 72h."
11085407|NCT04178109|Placebo Comparator|Group B|"Group B was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.
~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.
~Group B received postoperative analgesia with intravenous tramadole 75mg and paracetamol 1g every 8h with the first dose beginning 2h after the end of the surgery. For 72h"
11085408|NCT04178096|Other|Quality Improvement Intervention|Twelve low-performing sites will receive a package of strategies which have been empirically determined to be associated with successful implementation of evidence based practices that lead to improved health outcomes for Veterans with cirrhosis.
11085409|NCT04178096|No Intervention|Control Arm|All sites besides the pre-selected twelve, a total of one hundred eighteen sites, will not receive the intervention and will provide care as usual.
11085410|NCT04178083||Laparoscopic Sacrohysteropexy,|"Under general anesthesia,laparoscopic approach is used to enter the abdomen.Following this, visceral peritoneum is held with forceps from the point where the sacro-uterine ligaments adhere to the uterus.
~cut with unipolar scissors to the sacrouterin ligaments approximately 2-4 cm in the midline a transverse incision is made and the posterior wall of the cervix is reached. Approx. 10-15 x2 cm polypropylene mesh 5 mm trocar is inserted into the abdomen with the help of grasper and one end three points with 2/0 non-absorbable prolene sutures in the midline cervix Intracorporeal suture technique.
~After the sacral promontorium on peritona about 2 The transverse incision is made to the normal anatomical position and the appropriate mesh length is determined and the other end is fixed to the area prepared on the sacral promontorium at 3 points with 2-0 prolene. Bleeding reperitonization according to intracorporeal suture technique with 2/0 vicry"
11085445|NCT04177940|Active Comparator|Denosumab (DMAB) to Alendronate (ALN)|Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)
11085446|NCT04177940|Active Comparator|"DMAB to Early Zoledronic Acid (ZA)"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one early zoledronic acid infusion (5 mg; 6 months after last denosumab dose)"
11085447|NCT04177940|Active Comparator|"DMAB to Late ZA"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one late zoledronic acid infusion (5 mg; 9 months after last denosumab dose)"
11085411|NCT04178083||Modified Laparoscopic Lateral Suspension|A 10 cm diameter trocar is passed through a 1 cm infraumbical incision. In addition, two 5 mm diameter trocar are placed on 4 cm on both sides of the spinal iliac crest, and a 5 mm diameter trocar is placed laterally in the rectus muscle at the left lateral level of the umbilicus. A Prolene network of 25 cm in length is prepared. Dissection of the uterine cavity is performed to expose a mustache. The bottom of the web is secured by suturing the web in the midline and sides of the web with 2-0 prolene. The left and right modified lateral ports are then removed by moving under the bottom of the planet with the help of the planet until the isthmus reaches the bottom of the round ligament. The lateral ports are again slid onto the mesh, placed and sutured with peritoneal 2-0 vicryil, the mesh ends are cut at the skin level and the procedure is terminated.
11085412|NCT04178083||Laparoscopic Pectopexy|"First, the peritoneal layer on the top and side of the bladder opens parallel to the round ligament toward the right pelvic sidewall.
~The iliopectineal ligament is then located under the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medially of the outer iliac vein.
~iliopectineal (Cooper) ligament exposing a segment of approximately 3-4 cm is formed.
~After completion of the dissections, the ends of the mesh are sutured to both iliopectineal ligaments by intracorporeal suture using nonabsorbable sutures. The middle of the net is fixed with three sutures to the lower anterior segment of the uterus. The peritoneum on the mesh is sutured with an absorbable suture material."
11085413|NCT04178070|Experimental|GB224 2mg|single dose
11085414|NCT04178070|Experimental|GB224 5mg|single dose
11085415|NCT04178070|Experimental|GB224 10mg|single dose
11085416|NCT04178070|Experimental|GB224 15mg|single dose
11085417|NCT04178070|Experimental|GB224 20mg|single dose
11085418|NCT04178070|Experimental|GB224 30mg|single dose
11085419|NCT04178070|Placebo Comparator|Placebo 2mg|single dose
11085420|NCT04178070|Placebo Comparator|Placebo 5mg|single dose
11085421|NCT04178070|Placebo Comparator|Placebo 10mg|single dose
11085422|NCT04178070|Placebo Comparator|Placebo 15mg|single dose
11085423|NCT04178070|Placebo Comparator|Placebo 20mg|single dose
11085424|NCT04178070|Placebo Comparator|Placebo 30mg|single dose
11085425|NCT04178057|Experimental|GB222 3mg/kg|GB222 3mg/kg
11085426|NCT04178057|Experimental|GB222 5mg/kg|GB222 5mg/kg
11085427|NCT04178057|Experimental|GB222 7.5mg/kg|GB222 7.5mg/kg
11085428|NCT04178057|Experimental|GB222 10mg/kg|GB222 10mg/kg
11085429|NCT04178044|Experimental|GB223-group 1|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg,single dose administration; 2 subjects receive placebo.
11085430|NCT04178044|Experimental|GB223-group 2|21mg/kg
11085431|NCT04178044|Experimental|GB223-group 3|63mg/kg
11085432|NCT04178044|Experimental|GB223-group 4|119mg/kg
11085433|NCT04178044|Experimental|GB223-group 5|140mg/kg
11085434|NCT04178031|Experimental|IUD insertion group|All participants will have IUD inserted and follow up for occurance of complications
11085435|NCT04178018|Experimental|Transvaginal photoacoustic imaging/ultrasound|"Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled
~Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound
~For the exploratory outcome measure for high risk participants (approximately 50 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally at 6 months, 12 months, 18 months, 24 months, and at the time of surgery
~For the exploratory outcome measure for high risk participants (approximately 10 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally every 2 weeks at follicular phase and at the luteal phase for 3 months"
11085436|NCT04178005|Other|Cladribine|"All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI.
~Each treatment course is divided into 2 treatment cycles:
~Administration of first treatment course (year 1 treatment):
~First cycle: Starts on Day 1 of the study
~Second cycle: Administered 23 to 27 days after the last dose of first cycle.
~Administration of second treatment course (year 2 treatment):
~First cycle: Administered at least 43 weeks after the last dose of year 1 treatment
~Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment.
~The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days."
11085437|NCT04177992|Experimental|Servo control|"Automated control of oxygen. The oxygen saturation target range will be set to 93%.
~Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
11085438|NCT04177992|No Intervention|Manual control|Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
11085439|NCT04177979|Experimental|Near assisted learning group|Participants in this arm were supervised by the trained peer-instructors.
11085440|NCT04177979|No Intervention|Self directed learning group|Participants in this arm were practicing independently. They were not supervised by any instructors.
11085441|NCT04177966|Experimental|women watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term The day before surgery the women will watch a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation
11085442|NCT04177966|Placebo Comparator|women not watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term Women will receive general information about the surgery as part of informed consent, without watching a pre- prepared film.
11085443|NCT04177953|Active Comparator|Carboplatin or Cisplatin and Pemetrexed|"Four cycles (q4w) platinum-based adjuvant chemotherapy i.v.:
~carboplatin AUC5 or cisplatin 75 mg/m2
~pemetrexed 500 mg/m2"
11085444|NCT04177953|Experimental|Carboplatin or Cisplatin and Pemetrexed + Nivolumab|"Four cycles (q4w) of a combination of platinum-based adjuvant chemotherapy and immunotherapy i.v.:
~carboplatin AUC5 or cisplatin 75 mg/m2
~pemetrexed 500 mg/m2
~nivolumab 480 mg flat-dose.
~Followed by up to 12 cycles (q4w) maintenance immunotherapy:
~- nivolumab 480 mg flat-dose i.v."
11085604|NCT04176848|Experimental|CFI-400945 + Durvalumab|
11085448|NCT04177927|Experimental|endtidalcarbondioxide monitoring group|The patients performed gastrointestinal endoscopy will be monitored with Capnostream 20p / Coviden for etCO2 (End tidal CO2), RR (Respitarory rate), SpO2 and PR (heart rate).
11085449|NCT04177927|Active Comparator|Control Group|Rutine monitorization will be performed to control group of patients.
11085450|NCT04177914|Active Comparator|ETV+CPC|Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus
11085451|NCT04177914|Active Comparator|Ventriculoperitoneal Shunt|Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus
11085452|NCT04177901|Active Comparator|Brachial plexus blockage group|
11085453|NCT04177901|Active Comparator|local anesthesia group|
11085454|NCT04177888|Experimental|Experimental group|Experimental group with 45 participants, received hot pack, which was a single-use pack filled with magnesium sulfate and water, squeezed between the hands to activate the warming effect, applied to the lower back area for 30 minutes followed by 10 minutes rest then again applied for 30 minutes. This procedure was repeated till delivery.
11085455|NCT04177888|No Intervention|Control group|Control group with 46 participants received the hospital routine care that included Entonox inhalation as optional labor pain management.
11085456|NCT04177875|Experimental|Chemoradiation and pd-1|Subjects in Arm A receive 2 cycles of Docetaxel /Albumin-bound Paclitaxel + Cisplatin, for neoadjuvant therapy Neoadjuvant radiotherapy for 40Gy/20F
11085457|NCT04177862|Experimental|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
11085458|NCT04177862|Active Comparator|IV Fentanyl|single dose of IV fentanyl for acute pain.
11085459|NCT04177849|Active Comparator|Anterior Cervical Decompression and Fusion (ACDF)|Patients entered into this arm are treated via an anterior approach with disk excision, root canal decompression and fusion of the affected segment with a cage and plate.
11085460|NCT04177849|Experimental|Posterior Foraminotomy (PF)|Patients entered into this arm are treated via a posterior approach through intermuscular planes. The root canal is decompressed by burring the medial third of the facet joint. No fusion is performed.
11085461|NCT04177836|Experimental|MIndfulness|This arm was developed to increase attention towards and acceptance of current experiences.
11085462|NCT04177836|Active Comparator|Active Control|This arm is a relaxation-based active treatment comparison intervention, developed to parallel the structure of the mindfulness intervention without the attention towards or acceptance of present experiences.
11085463|NCT04177823|Experimental|Chinese participants with relapsed/refractory multiple myeloma|Participants will be administered belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
11085464|NCT04177810|Experimental|Cemiplimab and Plerixafor|All participants will receive Cemiplimab and Plerixafor.
11085465|NCT04177797|Experimental|Toripalimb|Single arm, non randomized, open label study.The patients will receive Toripalimb concurrently caboplatin and paclitaxel treatment.
11085466|NCT04177784|Experimental|Intervention (I)|This arm was randomized to a 20 min video that emphasized information about factors other than individual behaviors that influence weight, weight loss and ability to maintain weight. It also indirectly addressed weight bias by explaining how to have conversation about weight and health with a patient with obesity that is free of biases.
11085467|NCT04177784|Active Comparator|Weight Control (C1)|This arm was randomized to a 20 min video that emphasized the controllable aspects of weight and gave dietitians an overview of a tool to help plan and monitor weight loss.
11085468|NCT04177784|Placebo Comparator|Weight Neutral Control (C2)|The arm was randomized to a 20 min video about the role dietitians play in society, that made no mention of weight or obesity.
11085469|NCT04177758|Placebo Comparator|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
11085470|NCT04177758|Experimental|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
11085471|NCT04177745|Experimental|Hot Application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
11085472|NCT04177745|Experimental|Cold Application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
11085473|NCT04177745|No Intervention|Standard Practice|The standard practice of the clinic was made. Accordingly, the researcher performed the vein assessment after the participants filled out the questionnaire, and then inserted the 20-G catheter into the inner surface of their forearm without any application. Afterwards, she assessed the pain and anxiety levels of the patients twice before and after the catheter insertion procedure.
11085474|NCT04177732|Other|Healthy peri-implant status|Patient with healthy peri-implant status
11085475|NCT04177732|Other|Presence of peri-implant diseases|Patients with presence of peri-implant diseases
11085476|NCT04177719|Experimental|Oxytocin|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
11085477|NCT04177719|Placebo Comparator|Placebo|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
11085478|NCT04177706|Experimental|Group A (Ketamine)|
11085479|NCT04177706|Placebo Comparator|Group B (Placebo)|
11085480|NCT04177693|Experimental|EGCG daily alone.|EGCG daily alone. 800mg
11085481|NCT04177693|Experimental|EGCG with clomiphene citrate|EGCG 800 mg daily with clomiphene citrate 100mg for 5 days.
11085482|NCT04177693|Experimental|EGCG with letrozole|EGCG 800mg daily with letrozole 5mg for 5 days.
11085483|NCT04177680|Experimental|Omega-3 pentaenoic acid (MAT9001)|2g MAT9001 capsules twice daily with meals
11085484|NCT04177680|Active Comparator|Icosapent ethyl (Vascepa)|2g Vascepa capsules twice daily with meals
11085605|NCT04176835|Experimental|oxytocin|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
11085485|NCT04177667|Active Comparator|Proxeed arm|Subjects received 2 packets per day for 6 months of supplement (1000 mg of L-carnitine, 725 mg of fumarate, 500 mg of acetyl-L-carnitine, 1000 mg of fructose, 50 mg of citric acid, 50 µg of selenium, 20 mg of coenzyme Q10, 90 mg of vitamin C, 10 mg of zinc, 200 µg of folic acid and 1.5 µg of vitamin B12)
11085486|NCT04177667|Placebo Comparator|Placebo arm|Subjects received 2 packets per day for 6 months of placebo
11085487|NCT04177654||Cambodia|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085488|NCT04177654||Bangladesh|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085489|NCT04177654||Vietnam|The group of school-aged children from Vietnam who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085490|NCT04177654||Lao PDR|The group of school-aged children from Lao PDR who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085491|NCT04177654||Ghana|The group of school-aged children from Ghana who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085492|NCT04177654||Senegal|The group of school-aged children from Senegal who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085493|NCT04177654||Rwanda|The group of school-aged children from Rwanda who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085494|NCT04177654||Haiti|The group of school-aged children from Haiti who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
11085495|NCT04177641||low grade squamous intraepithelial lesion(LGSIL)|low grade squamous intraepithelial lesion(LGSIL) n=100
11085496|NCT04177641||high grade squamous intraepithelial lesion(HGSIL)|high grade squamous intraepithelial lesion(HGSIL) n=100
11085497|NCT04177641||Healthy controls|Healthy volunteers n=100
11085498|NCT04177628|Experimental|Arm A: Shared decision making|Patients will be informed by a doctor randomized to practice shared decision making and use the in-consultation PtDA during the consultation on adjuvant radiotherapy.
11085499|NCT04177628|No Intervention|Arm B: Usual practice|Patients will be informed by a doctor randomized to inform about adjuvant radiotherapy according to usual practice.
11085500|NCT04177615|Experimental|Thromboectomy and rTPA|use thromboectomy and rtpa for patient with basilar artery occlusion stroke in 24 hour
11085501|NCT04177615|No Intervention|rTPA( recombinant tissue plasminogen activator )|use rtpa for patient with basilar artery occlusion stroke in 24 hour
11085502|NCT04177602|Experimental|Trifluridine/tipiracil based radiotherapy|Trifluridine/tipiracil based chemoradiotherapy (CRT)
11085503|NCT04177602|Active Comparator|standard calibration arm (internal control)|capecitabine based chemoradiotherapy
11085504|NCT04177576||Patients with myeloproliferative neoplasms (MPN)|Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
11085505|NCT04177563|Experimental|a group of ten students with high physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.
~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
11085506|NCT04177563|Experimental|a group of eight students with moderate physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.
~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
11085507|NCT04177537||Pre-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work with traditional therapies selected from one rehabilitation facility
11085508|NCT04177537||Post-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies selected from one rehabilitation facility
11085509|NCT04177524|Experimental|Arm 1|Participants alternate between using the Manual Mode of the app for 2 weeks and Auto-Detect Mode of the app for 2 weeks, for a total of 4 periods (8 weeks).
11085510|NCT04177524|Experimental|Arm 2|Participants use the Auto-Detect Mode of the app for 4 weeks, followed by the Manual Mode for 4 weeks.
11085511|NCT04177524|Experimental|Arm 3|Participants use the Background Mode of the app for 4 weeks, followed by the Auto-Detect Mode of the app for 4 weeks.
11085540|NCT04177355|Placebo Comparator|Part B, Group 3 (P3): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
11085512|NCT04177511|Experimental|Transcutaneous auricular vagus nerve stimulation|"A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus.
~Standard treatment will be continued by the patients of this arm."
11085513|NCT04177511|No Intervention|Standard treatment|Patients of this arm will continue their standard treatment.
11085514|NCT04177498|Experimental|Treatment (rigosertib sodium)|Patients receive rigosertib sodium either oral or IV over a 52 week period. Patients will take oral rigosertib continuously for a total of three weeks, every four-week cycle (three weeks on, one week off drug). For IV, rigosertib is administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter.
11085515|NCT04177485|Experimental|Standard of Care + SMS text reminders|Standard of Care + SMS text reminders to be sent to caregivers for each of their subsequent vaccination visits, as per the EPI schedule (Penta2/OPV2/PCV2, Penta3/OPV3/PCV3, and MCV)
11085516|NCT04177485|No Intervention|Standard of Care|*Standard of care was defined as the health worker providing vaccination cards (home based records) to caregivers, as available, and providing verbal instruction of when to return for the next visit.
11085517|NCT04177472|Experimental|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
11085518|NCT04177472|No Intervention|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
11085519|NCT04177459|Experimental|Health promoting dialogue in addition to treatment as usual|Health promoting dialogues in addition to follow-up from primary and secondary health care, and from schools, which is individually customized due to fatigue and other symptoms present.
11085520|NCT04177459|Active Comparator|Treatment as usual|Follow-up from primary and secondary health care, and from Schools, which is individually customized due to fatigue and other symptoms present..
11085521|NCT04177446|Placebo Comparator|control group|Patients will be given basic energy intake according to their weight, and will be extra maltodextrin as the placebo
11085522|NCT04177446|Experimental|intervention group|Patients will be given basic energy intake according to their weight, and will be extra protein intake
11085523|NCT04177433|Experimental|Corticosteroid Injection|Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
11085524|NCT04177433|Placebo Comparator|Saline|Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.
11085525|NCT04177420|Experimental|Experiment Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night.
11085526|NCT04177420|Placebo Comparator|Control Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night. the FIR-C mattress and the FIR-C abdominal pad is malfunction and it can not produce the FIR-C.
11085527|NCT04177407|Experimental|BPF group|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
11085528|NCT04177407|No Intervention|control group|Regarding to the pelvic peritoneum reconstruction, in control group, the pelvic peritoneum will be closed with running suturing. If not possible, the peritoneum covering the surface of the bladder will be secured on the anterior surface of the sacrum with nonabsorbable sutures at the level where the anatomic structure obliterates the pelvic entrance. If neither method was feasible, the pelvic peritoneum defect will be left unclosed.
11085529|NCT04177394||MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system
11085530|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue with dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue with drain
11085531|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue without dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue without drain
11085532|NCT04177381|Active Comparator|non closure of subcutaneous tissue with drain|In the drain group,a closed non vacuum drain will be inserted in the tissue and exit from the skin through a separate opening and stitch to the skin
11085533|NCT04177381|Active Comparator|non closure of subcutaneous tissue and no drain|75 women without subcutanous sutures and without drain
11085534|NCT04177368||assess nutrition with regular dialysis|This study aims to assess the growth and the nutritional status in children with end-stage kidney disease on regular hemodialysis to define the degree of malnutrition , predict and quantify the risk for complications deriving from impaired nutritional status .Giving them theragran 60ml ,twice daily for 3 month.
11085535|NCT04177355|Experimental|Part A, Group 1 (T1): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 1 mcg of 3M-052-AF and 500 mcg of Aluminum Hydroxide Suspension (Alum), as one intramuscular (IM) injection at Months 0 and 2.
11085536|NCT04177355|Placebo Comparator|Part A, Group 1 (P1): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
11085537|NCT04177355|Experimental|Part A, Group 2 (T2): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 5 mcg of 3M-052-AF and 500 mcg of Alum, as one IM injection at Months 0 and 2.
11085538|NCT04177355|Placebo Comparator|Part A, Group 2 (P2): Placebo|Participants will receive placebo as one IM injection at Months 0 and 2.
11085539|NCT04177355|Experimental|Part B, Group 3 (T3): BG505 SOSIP.664 gp140 + CpG 1018 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 300 mcg of CpG 1018 and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
11085541|NCT04177355|Experimental|Part B, Group 4 (T4): BG505 SOSIP.664 gp140 + 3M-052-AF + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with either 1 mcg or 5 mcg of 3M-052-AF (the highest tolerated dose from Part A), and 500 mcg of Alum, as one IM injection at Months 0, 2, and 6.
11085542|NCT04177355|Placebo Comparator|Group 4 (P4): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
11085543|NCT04177355|Experimental|Part B, Group 5 (T5): BG505 SOSIP.664 gp140 + GLA-LSQ|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with GLA-LSQ (GLA 5 mcg, and QS-21 2 mcg), as one IM injection at Months 0, 2, and 6.
11085544|NCT04177355|Placebo Comparator|Part B, Group 5 (P5): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
11085545|NCT04177355|Experimental|Part B, Group 6 (T6): BG505 SOSIP.664 gp140 + Alum|Participants will receive 100 mcg of BG505 SOSIP.664 gp140, admixed with 500 mcg of Alum, administered as one IM injection at Months 0, 2, and 6.
11085546|NCT04177355|Placebo Comparator|Part B, Group 6 (P6): Placebo|Participants will receive placebo as one IM injection at Months 0, 2, and 6.
11085547|NCT04177342|Active Comparator|fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
11085548|NCT04177342|Experimental|oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
11085549|NCT04177316||hypermethylation|The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.
11085550|NCT04177316||hypomethylation/no change|The hypomethylation were defined as differential methylation status of tumor- normal <5%
11085551|NCT04177303|Active Comparator|Metformin|Patients will continue with their standard insulin therapy and will additionally receive orally metformin 2gr/day.
11085552|NCT04177303|Placebo Comparator|Placebo|Patients will continue with their standard insulin therapy and will additionally receive placebo
11085553|NCT04177290|Experimental|sintilimab (M1b) 200mg|
11085554|NCT04177290|Active Comparator|sintilimab (approved) 200mg|
11085555|NCT04177264|Experimental|Osteopathic Manipulative Treatment (OMT)|In 4 randomized study sessions, combinations of two different osteopathic manipulative treatment (OMT) techniques (occipito-atlantal decompression [OA DC] and splenic lymphatic pump technique [SpLPT]) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of OMT techniques or sham interventions will be performed.
11085556|NCT04177264|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
11085557|NCT04177264|No Intervention|Time Control|In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
11085558|NCT04177238|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no anthocyanin content
11085559|NCT04177238|Experimental|Cherry juice|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
11085560|NCT04177238|Experimental|Blueberry|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
11085561|NCT04177225||Patients with normal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their normal left ventricular diastolic function.
11085562|NCT04177225||Patients with abnormal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their abnormal left ventricular diastolic function.
11085563|NCT04177186|Experimental|strength training group|ST group only strength training will be provided.
11085564|NCT04177186|Experimental|strength training with botulinum toxin|BT-ST group, strength training will be provided after the administering Botulinum toxin into the muscle belly guided under Ultra sound imaging.
11085565|NCT04177173|Experimental|Simvastatin & Methotrexate|Methotrexate 10 mg once a week per oral for 6 months and Statins (Simvastatin) 20 mg once a day per oral
11085566|NCT04177173|Active Comparator|Methotrexate|Methotrexate 10 mg once a week for 6 months
11085567|NCT04177160|Experimental|SCD subjects|Patients were diagnosed with subjective cognition decline and referred by neurologists.
11085568|NCT04177160|Experimental|Healthy controls|Voluntary healthy elderly recruited from the community.
11085569|NCT04177147|Experimental|Clinical decision support via alert tool|Clinicians received access to the electronic alert tool, which automatically displayed patients' risk of hypoglycemia.
11085570|NCT04177147|No Intervention|Usual care|Clinicians did not receive access to the electronic alert tool.
11085606|NCT04176835|Placebo Comparator|Placebo|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
11085572|NCT04177108|Experimental|Cohort 1 Arm B|PD-L1 Non-Positive Participants receiving Paclitaxel, Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
11085573|NCT04177108|Active Comparator|Cohort 1 Arm C|PD-L1 Non-Positive Participants receiving Paclitaxel, Placebo for Ipatasertib and Placebo for Atezolizumab. Participants will be randomised in a 1:1:1 ratio.
11085574|NCT04177108|Experimental|Cohort 2 Arm A|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Ipatasertib. Participants will be randomised in a 1:1 ratio.
11085575|NCT04177108|Active Comparator|Cohort 2 Arm B|PD-L1 Positive Participants receiving Paclitaxel, Atezolizumab and Placebo for Ipatasertib. Participants will be randomised in a 1:1 ratio.
11085576|NCT04177095|Experimental|Belatacept treated patients|Renal transplant recipients treated with a combination of belatacept and any of the following: mycophenolate, sirolimus, everolimus and prednisone
11085577|NCT04177082|Experimental|Pulsed 6mW/cm2|6mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 30 minute total treatment time
11085578|NCT04177082|Experimental|Pulsed 4mW/cm2|4mW/cm2, with pulsed mode, 10 seconds on, 10 second off, for 45 minute total treatment time
11085579|NCT04177069||Visucomplex Plus monotherapy|Patients with early dry AMD will be treated with Visucomplex Plus monotherapy.
11085580|NCT04177069||anti-VEGF drug plus Visucomplex Plus|Dry or wet AMD patients under treatment with a stable dose of an anti-VEGF drug, Visucomplex Plus will be added-on, upon physician decision.
11085581|NCT04177056|Experimental|SBRT|
11085582|NCT04177043|Other|Screening|
11085583|NCT04177030|Experimental|Group A-Morning First|Within the first week of the study, Group A will consume fruits and vegetables within time-restriction morning window (9am-12pm). Following washout week, Group A will consume fruits and vegetables within time-restriction night window (7pm-10pm) for one week.
11085584|NCT04177030|Experimental|Group B-Night First|Within the first week of the study, Group B will consume fruits and vegetables within time-restriction night window (7pm-10pm). Following washout week, Group B will consume fruits and vegetables within time-restriction morning window (9am-12pm) for one week.
11085585|NCT04177017|Experimental|Experimental group|The experimental group is the one that participates in the intervention
11085586|NCT04177017|No Intervention|Control group|The control group belonged to the same school but did not participate in the intervention. Instead, they continued with regular curricular classes
11085587|NCT04177004|Experimental|Group A (conditioning, goat milk, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
11085588|NCT04177004|Active Comparator|Group B (conditioning, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
11085589|NCT04176991|Experimental|CTI-1601|
11085590|NCT04176991|Placebo Comparator|Placebo|
11085591|NCT04176978|Experimental|T2T + statin|Patient in this arm will receive treat-to-target strategy with rousavastin 20mg
11085592|NCT04176978|Active Comparator|T2T only|Patient in this arm will receive treat-to-target strategy only.
11085593|NCT04176952|Experimental|FOLFOX-A|"FOLFOX A arm (14-day cycle)
~nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.
~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.
~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
~Patients will also receive daily G-CSF as primary prophylaxis against neutropenic events for all cycles. This should be given as per local policy for chemotherapy regimens given every 14 days e.g. it may be started on day 4 for 7 days (preparation and dose should be given as per local policy)."
11085594|NCT04176952|Active Comparator|Abraxane and Gemcitabine|"Nab-Paclitaxel + Gemcitabine (AG) arm (28-day cycle)
~nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).
~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
11085595|NCT04176939|Experimental|HZ/su Group|Eligible participants who had a complete 2-dose HZ/su vaccination course in the primary study (NCT02058589) will be enrolled in this extension study, to receive 2 doses of HZ/su vaccine- first dose at Month 24 and second dose at Month 25 and will be followed up until the study end.
11085596|NCT04176926||Group 1: SR|Group 1: Subjects in the sinus rhythm (SR) cohort should not have any history of atrial fibrillation and should not be in atrial fibrillation or other atrial arrhythmia at the time of enrollment based on the screening ECG.
11085597|NCT04176926||Group 2: AF|Group 2: Subjects in the atrial fibrillation (AF) cohort must have a known history of AF and must be in AF at the time of enrollment based on the screening ECG.
11085598|NCT04176913|Experimental|Anti-CD20 Allogeneic CAR-T Cell Therapy|An open label, single center, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
11085599|NCT04176900|Experimental|Alternating 3D boluses|Both rigid and flexible 3D printed boluses made for each patient. Each is used on alternate days during radiation therapy.
11085600|NCT04176887|Experimental|Levetiracetam|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
11085601|NCT04176887|Active Comparator|Phenytoin|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
11085602|NCT04176874||Diastasis of the rectus abdominis muscles|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
11085603|NCT04176861|Experimental|Home based intervention|Participants using hBET technology at home (all participants).
11085607|NCT04176822|Experimental|Educational Animated Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched an educational animated movie through VR Goggles. The educational animated movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
11085608|NCT04176822|Experimental|Documentary Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched a documentary movie through VR Goggles. The documentary movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
11085609|NCT04176822|No Intervention|Control Group|No intervention was made, pain and fear levels were measured using scales only.
11085610|NCT04176809|Experimental|Interventional arm|The intervention will consist in an electronic measurement of HRQoL before each consultation with delivery scores to clinicians, who can discuss it with patients and coupled with therapeutic information. Patients will complete the EORTC-Quality of Life Questionnaire (QLQ)-C30 and the EORTC-QLQ-Breast (BR) 23 questionnaires using the CHES software before their consultation, via a touch pad or from their home via a secure web portal. Therapeutic information will consist on workshops on various themes. Only attendance Workshop 1 will be required, other workshops will be optional. The aim of workshop 1 is to inform patients about their ET and treatment benefits. Two additional optional workshops on nutrition (Workshop 2) and fatigue (Workshop 3) will be offered. This workshops will be collective. Every month, a letter encouraging patients to regularly take their medication will be sent. This letter will also include some tips on how to deal with some particular side effects of ET.
11085611|NCT04176809|No Intervention|Control arm|Participants in the control arm will receive standard care. They will not undergo digital HRQoL collection, and therapeutic information workshops will not be proposed.
11085612|NCT04176796|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
11085613|NCT04176796|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
11085614|NCT04176783|Active Comparator|Opioid|The opioid-based arm utilizes traditional, standard-of-care treatment for each applicable surgery. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.
11085615|NCT04176783|Active Comparator|Opioid-Free|The opioid-free arm utilizes medications that do not belong to the opioid family of medications. All medications used are FDA-approved and no experimental medications are being used. The medications (including dosage and frequency) used in this arm vary depending on the surgery being performed; however, tend to include medications such as Gabapentin, Tylenol, Meloxicam, Bupivacaine, or Ketorolac.
11085616|NCT04176770|Experimental|ESP group|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
11085617|NCT04176770|Experimental|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
11085618|NCT04176757|Experimental|ZN-c5|
11085619|NCT04176744|Experimental|Magnetic Phrenic Nerve Stimulation|Each participant will be tested with 4 different stimulation setups (coils and stimulator) on 3 different days.
11085620|NCT04176731|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm
11085621|NCT04176718|Experimental|Daratumumab,Carfilzomib, Pomalidomide and Dexamethasone|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.
~Participants will receive daratumumab, carfilzomib, pomalidomide, and dexamethasone on a 28 day schedule.
~Daratumumab will be given according to cycle and dosage determined by protocol.
~Carfilzomib will be given 3 times per cycle
~Pomalidomide will be given daily during cycle.
~Dexamethasone will be given 8 times per cycle."
11085622|NCT04176705|Experimental|Laser|
11085623|NCT04176705|Placebo Comparator|No laser|
11085624|NCT04176666|Experimental|Intervention group receiving NettOpp|The effectiveness study will be conducted as a randomized controlled trial with an intervention group and a waiting-list control group. Data will be collected at baseline (T1, pre intervention) and after about 2 weeks of intervention (T2, post intervention). A follow-up evaluation (T3) will be conducted after about 3 months to examine if the effects were stable over time.
11085625|NCT04176666|No Intervention|Control group|The control group will receive the intervention after study completion.
11085626|NCT04176653|Placebo Comparator|Placebo|
11085627|NCT04176653|Experimental|0.3 mg/kg|
11085628|NCT04176653|Experimental|1.0 mg/kg|
11085629|NCT04176653|Experimental|3.0 mg/kg|
11085630|NCT04176653|Experimental|10.0 mg/kg|
11085631|NCT04176614|Experimental|cereal-legume snack|Certain amount of cereal-legume snack daily for 12 weeks
11085632|NCT04176614|Active Comparator|cereal snack|Certain amount of cereal snack daily for 12 weeks
11085633|NCT04176601|Experimental|Engage Coaching|
11085634|NCT04176588|Experimental|Experimental: Etrasimod 2mg|2mg/tablet, administratered orally, once daily
11085859|NCT04175041|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
11085637|NCT04176575|Experimental|Acupuncture|This study will provide acupuncture treatment to patients with moderate to severe pain from their advanced cancer. Participants will attend acupuncture sessions at CIM ideally twice a week their first 4-6 weeks of study involvement and then once per week for up to 12 total study visits for no longer than 12 weeks after their study enrollment. Participants will also be asked to complete a follow-up 4 to 6 weeks after their last study visit. Their total study involvement will range from 12 to 18 weeks.
11085638|NCT04176549||Ectopic Pregnancy|Patients diagnosed with ectopic pregnancy Samples collected: Plasma, Serum, Urine, Oral swab, Vaginal Swab If surgery required for tubal ectopic: Fallopian tube, peritoneal washing, trophoblast
11085639|NCT04176549||Surgical termination of pregnancy|Patients undergoing elective surgical termination of pregnancy Samples collected: Plasma, Serum, Urine, Oral swab Vaginal swab, Trophoblast
11085640|NCT04176549||Elective hysterectomy and salpingo-oophorectomy|Patients undergoing elective hysterectomy and salpingo-oophorectomy Samples collected: Fallopian tube, peritoneal washing
11085641|NCT04176536|Experimental|All participants|
11085642|NCT04176523||Methylmalonic_acidemia|Patients with confirmed diagnosis of methylmalonic acidemia, and treated with carglumic acid, at any dose form, any dosage,
11085643|NCT04176523||Propionic_Acidemia|Patients with confirmed diagnosis of propionic acidemia, and treated with carglumic acid, at any dose
11085644|NCT04176510|Experimental|Patient Centered Medical Home (PCMH) plus Health Coach|A health coaching intervention that employs a positive affect/self-affirmation intervention to help motivate patients to succeed at implementing self-management by setting life goals, in addition to the usual care provided for patients with multiple chronic diseases by the The Patient-Centered Medical Home (PCMH).
11085645|NCT04176510|No Intervention|Patient Centered Medical Home (PCMH)|Usual care provided for patients with multiple chronic diseases by the Patient-Centered Medical Home (PCMH).
11085646|NCT04176497|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
11085647|NCT04176484||Survey|Women, 18 years of age or older, who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be given a handout (attached) by clinic staff during routine pre-op counseling informing them that they may be called and asked to participate in a research survey. Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview. Participation will be voluntary and all data collected will be recorded without any identifiers.
11085648|NCT04176484||Operating Room Feasibility|A list of women 25 or older who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be generated to include MRN, procedure date, and pocedure type. A medical record review will be undertaken of these women and we will collect information about conditions that would facilitate or hinder the ability to perform a salpingectomy. No patient interaction will occur by the study team and all data will be de-identified at the time of collection.
11085649|NCT04176471|Experimental|Therapeutic Hypothermia|Therapeutic hypothermia will be achieved using a servo-controlled temperature regulating blanket that is approved for use in neonates and is currently used for the treatment of neonates with moderate-severe HIE. The goal target temperature is 33.5°C ± 0.5°C for 72 hours and the subject will then be rewarmed at a rate of 0.5°C per hour to a goal of 36.5°C.
11085650|NCT04176471|Active Comparator|Normothermia|Normothermia will be achieved using a servo-controlled temperature regulating blanket with the temperature goal of 36.5-37.3°C for 72 hours.
11085651|NCT04176458|Other|MBT in liver disease|Methacetin Breath test (MBT) intervention
11085652|NCT04176445|Other|Bedside Sitting followed by Orthostatic Board|Bedside sitting posture protocol followed by orthostatic board posture protocol.
11085653|NCT04176445|Other|Orthostatic Board followed by Bedside Sitting|Orthostatic board posture protocol followed by bedside sitting posture protocol.
11085654|NCT04176419|Experimental|Treatment Group|"Perioperative intervention (preoperative acetaminophen, gabapentin, and celecoxib and intraoperative ketamine and lidocaine).
~The Investigational Drug Service will mix and prepare the study medications necessary for each participant. An Investigational Drug Service staff member will deliver the oral medications to the nursing team in the preoperative holding unit and the IV medications to the anesthesia team in the OR unit."
11085655|NCT04176419|Placebo Comparator|Control Group|"Perioperative placebo
~Placebo oral drugs will be encapsulated versions provided by the Investigational Drug Service and will appear identical to the interventional oral drugs. Placebo IV infusions will be prepared by Investigational Drug Service as per institutional guidelines and will appear identical to the interventional IV drugs."
11085656|NCT04176406|Active Comparator|rTMS over a node within the fronto-parietal network|excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
11085657|NCT04176406|Sham Comparator|Sham rTMS over a node within the fronto-parietal network|electrical sham coil applied over a node within the fronto-parietal network.
11085658|NCT04176406|Active Comparator|rTMS over the DLPFC|excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
11085659|NCT04176406|Sham Comparator|Sham rTMS over the DLPFC|electrical sham coil applied over the DLPFC.
11085660|NCT04176393|Experimental|Ivosidenib (CS3010) tablet|Ivosidenib (CS3010) tablet
11085661|NCT04176380|Experimental|Administration of RAPA-201 cells|
11085662|NCT04176367|Experimental|Test: Nicergoline manufactured in China|
11085663|NCT04176367|Active Comparator|Reference: Nicergoline manufactured in Italy|
11085664|NCT04176354||Palbociclib + an aromatase inhibitor|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
11085665|NCT04176354||Palbociclib + Letrozole|Adult metastatic breast cancer patients who initiated Palbociclib +Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
11085666|NCT04176354||Letrozole|Adult metastatic breast cancer patients who initiated Letrozole as first line therapy between Feb 3, 2015 to 3 months prior to date of data cutoff in the Flatiron Health Analytic Database.
11085860|NCT04175028|Other|ADHD|Patients with ADHD.
11142868|NCT03776539|Experimental|ELX-02|Drug: ELX-02
11085667|NCT04176341|Other|Intervention group|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
11085668|NCT04176341|No Intervention|Control group|chronic pain patient consulting in Lyon University Hospital who will receive usual care.
11085669|NCT04176328|Experimental|Cystic Fibrosis patients treated with Teicoplanin|Hospitalized male and female patients aged ≥ 18 years, suffering of Cystic Fibrosis.
11085670|NCT04176315|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty autonomously
11085671|NCT04176315|Experimental|ReHub Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty but use the telerehabilitation platform ReHub to do the exercises at home and to have their progress monitored.
11085672|NCT04176302|Active Comparator|Parkinson Holter|The neurologists in the study will receive information from the Parkinson Holter (device being studied)
11085673|NCT04176302|Active Comparator|Parkinson's diary|The neurologists in the study will receive information from a motor fluctuations diary
11085674|NCT04176302|Placebo Comparator|Traditional clinical practice|The neurologists in the study will receive no additional information other than what is obtained during the visit
11085675|NCT04176289|Active Comparator|PPI-guided pain therapy|At the end of anesthesia a PPI targeted opioid pain therapy will be performed by gradual administration of piritramid in 3 mg steps up to a PPI score ≤ 3.
11085676|NCT04176289|No Intervention|Non-PPI-guided pain therapy|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
11085677|NCT04176276||Patients with Type2 Diabetes|200 patients with type 2 diabetes consecutively enrolled among those referring to our Diabetes outpatient clinic.
11085678|NCT04176276||Patients without Type2 Diabetes|100 patients without diabetes among those referring to our outpatient clinic most of them affected by hypercholesterolemia, obesity or CV disease.
11085679|NCT04176263|Experimental|SBT|The SBT group will receive a 4-week split-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
11085680|NCT04176263|Active Comparator|TBT|The TBT group will receive a 4-week tied-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
11085681|NCT04176250|Experimental|TBA-7371 100 mg QD|
11085682|NCT04176250|Experimental|TBA-7371 100 mg BID|
11085683|NCT04176250|Experimental|TBA-7371 200 mg QD|
11085684|NCT04176250|Experimental|TBA-7371 100 mg TID|
11085685|NCT04176250|Experimental|TBA-7371 400 mg QD|
11085686|NCT04176250|Active Comparator|HRZE|
11085687|NCT04176237|Experimental|Intervention|Schools receive 3 one hour lessons on sun safety, followed by a 1 hour UV dosimtery laboratory session.
11085688|NCT04176237|No Intervention|Control|Schools receive 3 one hour lessons on sun safety.
11085689|NCT04176237|No Intervention|Observation|Schools do not receive any lessons.
11085690|NCT04176224|Experimental|MT-1186|Patients receive the edaravone oral suspension.
11085691|NCT04176198|Experimental|TP-3654|
11085692|NCT04176185|Experimental|Active|HDM SLIT-tablet once daily for approximately 24 weeks
11085693|NCT04176185|Placebo Comparator|Placebo|Placebo tablet once daily for approximately 24 weeks
11085694|NCT04176172|Active Comparator|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
11085695|NCT04176172|Active Comparator|NMR-Tailored Medication & Standard Cessation Counseling|varenicline or nicotine patch plus standard behavioral smoking cessation treatment
11085696|NCT04176172|Experimental|Varenicline & Standard Cessation Counseling + MAPS|varenicline plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
11085697|NCT04176172|Experimental|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
11085698|NCT04176159|Experimental|Motor imagery and task-oriented training group|Two modules. A first module of motor imagery. A second module of task-oriented training and the incorporation of collective activities.
11085699|NCT04176159|No Intervention|Usual school routines group|Children continue with the usual school routine. Once the study is completed and the corresponding measurements have been made, the subjects included in this group will be subjected to the same program detailed in the intervention, to not deprive them of their benefits.
11085700|NCT04176146|Experimental|Nudge Letter|Participants receive a letter that highlights their performance vs. peer organizations on up to seven care delivery practices featured in the National Survey of Healthcare Organizations and Systems (NSHOS). The letter includes a link to access technical assistance resources and is sent alongside the participant's NSHOS respondent report.
11085701|NCT04176146|No Intervention|Control Letter|Participants receive a letter with a link to technical assistance resources; the letter is sent alongside the participant's NSHOS survey respondent report.
11085702|NCT04176133|Experimental|Dose Level 1|Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)
11085703|NCT04176133|Experimental|Dose Level 2|Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)
11085704|NCT04176133|Experimental|Dose Level 3|Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)
11085705|NCT04176133|Placebo Comparator|Placebo|Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.
11085706|NCT04176120|Experimental|TTAX01|TTAX01 plus standard care
11085707|NCT04176120|Other|Control|Standard Care alone
11085861|NCT04175028|Other|Healthy Control|Volunteers without Neuropsychiatric Disorders.
11085708|NCT04176107|Other|Study group- video+questionnaire|"The study group will be exposed to a video at admission to an elective cesarean delivery. The video will have information regarding the admission, pre-operation preparation and post- operation recovery.
~All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate the impact of exposure to informative video before caesarean delivery on anxiety and stress measured by State-Trait Anxiety Inventory (STAI)."
11085709|NCT04176107|No Intervention|Control group- questionnaire only|All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate anxiety and stress measured by State-Trait Anxiety Inventory (STAI) without intervention.
11085710|NCT04176094|Experimental|16 hour schedule|All residents assigned to an ICU randomized to a 16h overnight schedule will complete 16h overnight calls not preceded by an 8h daytime shift.
11085711|NCT04176094|Active Comparator|24 hour schedule|All residents assigned to an ICU randomized to a 24h overnight schedule will complete 24h shifts when scheduled for overnight calls (8h daytime shift followed by a 16h overnight call).
11085712|NCT04176081|Active Comparator|Group 1: Radiation Therapy Only|Participants randomized to Group 1 will receive radiation therapy only.
11085713|NCT04176081|Experimental|Group 2: Radiation Therapy + darolutamide + degarelix|Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.
11085714|NCT04176068|Experimental|Combined microfocused ultrasound and calcium hydroxylapatite|One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks. Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.
11085715|NCT04176055|Experimental|HALO|
11085716|NCT04176042|Experimental|Track 1|"Subjects will be randomized to one of two 4-week tracks.
~Track 1 (intervention + follow-up) will consist of the following:
~Subjects will be randomized to one of two 4-week tracks. Track 1 (intervention + follow-up) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention participants will complete a baseline questionnaire battery consisting of measures including demographics, medical history and sleep. After completion, a 2-hour educational presentation will take place with a question-and-answer session. Participants will then complete post-intervention questionnaires to assess immediate impact of the session on knowledge, beliefs and practices. After 4 weeks, Track 1 participants will be contacted and will be asked to re-complete all baseline questionnaires (see above), in order to evaluate changes over 4 weeks."
11085717|NCT04176042|Active Comparator|Track 2|"Subjects will be randomized to one of two 4-week tracks. Track 2 (wait list + intervention) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention for Track 1 participants will complete the same baseline questionnaire battery.
~An identical intervention session, scheduled 4 weeks into the future. At that time, an identical procedure to the other track will be followed, including the pretest questionnaires, 2-hour session, and post-session assessment. No additional 4-week follow-up will be performed."
11085718|NCT04176029||Children admitted with confirmed severe malaria|
11085719|NCT04176016|Experimental|Single Study Arm, no competitor|
11085720|NCT04176003||Patients with CPPD|
11085721|NCT04176003||Healthcare professionals working with CPPD patients|
11085722|NCT04176003||Stakeholders working on behalf of CPPD patients|
11085723|NCT04175990|Experimental|Progestogen|Oral Dydrogesterone 10mg tds was given from day 1 of menses till day of trigger
11085724|NCT04175990|No Intervention|standard combine minimal stimulation protocol|Oral clomiphene citrate 100mg daily given from day 1 till day 10 of menses with additional gonadotrophin (Menopur 225mg daily) from day 3 of menses till trigger day
11085725|NCT04175977|Experimental|Aliviado Dementia Care-Hospice Edition|A multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
11085726|NCT04175977|Active Comparator|Control phase|PWD subjects will receive usual care as provided by their hospice agency during the control phase
11085727|NCT04175964|Experimental|Group 1|PCO patients that will receive ketogenic diet only
11085728|NCT04175964|Experimental|Group 2|PCO patients that will receive caloric diet with Metformin
11085729|NCT04175964|Experimental|Group 3|PCO patients that will receive caloric diet only
11085730|NCT04175951|Active Comparator|Tecnis Eyhance|Tecnis Eyhance hydrophobic IOL is a monofocal IOL with added advantage of slightly better unaided intermediate vision at 60 cms.
11085731|NCT04175951|Active Comparator|Rayner RayOne|Rayner Rayone is a monofocal hydrophilic IOL which is not intended to give better unaided or near vision.
11085732|NCT04175938|Active Comparator|Subjects with Fuch's Endothelial Dystrophy|Persons with a diagnosis of Fuch's Endothelial Dystrophy will wear a contact lens in an affected eye for three hours.
11085733|NCT04175938|Other|Subjects with healthy eyes|Persons with healthy eyes will wear a contact lens in one eye for three hours.
11085734|NCT04175925|Experimental|Part A: BMS-986322|
11085735|NCT04175925|Experimental|Part B: BMS-986322 Placebo|
11085736|NCT04175925|Experimental|Part C: BMS-986322 with famotidine|
11085737|NCT04175912|Experimental|Arm A (pevonedistat)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11085738|NCT04175912|Experimental|Arm B (pevonedistat, paclitaxel, carboplatin)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 15-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Starting cycle 5, patients may receive pevonedistat monotherapy at the discretion of treating physician.
11085739|NCT04175899|Experimental|POCCP (Pharmacist-led Oral Chemo Care Program)|"Intervention Group :
~Subjects undergo structured intensified pharmaceutical care program (POCCP) led by oncology experienced pharmacist (run alongside oncologist patient review at the clinic or daycare) in addition to Current Standard Best Care (SBC)"
11085862|NCT04175015|Experimental|Experimental|Participants will be randomised to eat an orange coloured smartie©
11085740|NCT04175899|No Intervention|SBC (Current Standard Best Care)|"Control Group :
~Subjects undergo usual procedure which is Current Standard Best Care (SBC) for oral chemotherapy treatment which includes pre-chemotherapy review by doctor and prescribing of chemotherapy and supportive medications according to patient's chemotherapy protocol at each visit. Subsequently the patients will collect their prescribed oral medications at the ambulatory pharmacy counter according to the standard procedure of medication dispensing which includes prescription screening, medication filling, double checking, dispensing and counselling at the pharmacy counter as per usual practice of pharmaceutical care of patients."
11085741|NCT04175886||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day
11085742|NCT04175886||Healthy subjects|Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)
11085743|NCT04175873|No Intervention|Group C|Control group.
11085744|NCT04175873|Experimental|Group M|Music group.Preoperative 1 hour and during the operation of Classical Turkish Music (Acemaşiran makam) listening group
11085745|NCT04175860|Experimental|Intervention group|"Consists of a series of non-pharmacological preventive interventions that will focus on the - transition-discharge-hospital program including individualized non-pharmacological interventions such as dyad characterization, competency assessment, risk assessment, inherent program strategies, and monitoring.
~The intervention or program  Hospital Discharge Plan to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes an educational session and weekly telephone follow-up according to the patient's risk characterization."
11085746|NCT04175860|No Intervention|Control group|This group of patients-family caregivers will be carried out the discharge activities that are regularly developed in the second level institution and recorded in a check-sheet and field diary.
11085747|NCT04175847|Experimental|RC88|
11085748|NCT04175834|Other|diphenhydramine|25 mg diphenhydramine capsule, generic, sourced from Major Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
11085749|NCT04175834|Active Comparator|cetirizine|10 mg cetirizine tablet, generic, sourced from Mylan Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
11085750|NCT04175808|Experimental|Part A|Treatment 1 omecamtiv mecarbil
11085751|NCT04175808|Experimental|Part B|3 treatments in 1 of 6 sequences
11085752|NCT04175795|Experimental|Dashboard group|The intervention group will receive their personal profile via this e-mail along with instructions on goal-setting and tips to improve brain health.
11085753|NCT04175795|No Intervention|No Dashboard group|The control group will receive only the goal-setting instructions and tips.
11085754|NCT04175782|Experimental|ERAS group|A standardized ERAS protocol is applied to the ERAS group based on the latest guidelines. Smoking and alcohol consumption is stopped 4 weeks before the surgery. Preoperative anemia is corrected with intravenous iron supplementation. Prolonged fasting, bowel preparation, and premedication are avoided in this group. Clear fluids are allowed up to 2 h and solids rich in carbohydrate up to 6 h hours prior to induction of anesthesia. Warmed up intravenous fluids are administered to maintain normothermia intraoperatively. This group of subjects receives general anesthesia. Volume and salt overload and drain usage are avoided to the utmost. Intravenous paracetamol is administered for postoperative analgesia before the completion of the surgical procedure. Nasogastric tube placement is avoided and catheters are removed as soon as possible. Nonopioid oral analgesics and NSAIDs are utilized for postoperative pain medication.
11085755|NCT04175782|No Intervention|Control|This group will receive conventional pre-and postoperative care.
11085756|NCT04175769|Experimental|Experimental intervention|Standard intervention of chemotherapy, immunotherapy or combination of immunotherapy and chemotherapy, plus the experimental intervention nutritional product.
11085757|NCT04175769|Placebo Comparator|Non-experimental intervention|Standard intervention of chemotherapy, immunotherapy or combination of immunotherapy and chemotherapy, plus the non-experimental intervention placebo product.
11085758|NCT04175743|Experimental|200 mg CT-044 HCl or Placebo|200 mg of CT-044 HCl administered every 8 hours vs placebo
11085759|NCT04175743|Experimental|400 mg CT-044 HCl or Placebo|400 mg of CT-044 HCl administered every 8 hours vs placebo
11085760|NCT04175743|Experimental|600 mg CT-044 HCl or Placebo|600 mg of CT-044 HCl administered every 8 hours vs placebo
11085761|NCT04175730|Other|MRI and Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI positive for suspected prostate cancer followed by MRI/ultrasound fusion directed prostate needle biopsies
11085762|NCT04175730|Other|Ultrasound|men with elevated PSA or abnormal DRE for which prostate biopsy is indicated and mpMRI negative for suspected prostate cancer followed by standard ultrasound guided prostate needle biospies
11085763|NCT04175717|Experimental|physiotherapy-led follow-up programme|
11085764|NCT04175704|Other|Cohort 1|0.2 mg/kg UB-221 or placebo
11085765|NCT04175704|Other|Cohort2|0.6 mg/kg UB-221 or placebo
11085766|NCT04175704|Other|Cohort 3|2 mg/kg UB-221 or placebo
11085767|NCT04175704|Other|Cohort 4|6 mg/kg UB-221 or placebo
11085768|NCT04175691||AIS group|This group includes patients with acute ischemic stroke (AIS).
11085769|NCT04175691||HC group|This group includes healthy controls (HC).
11085770|NCT04175678|No Intervention|Normal/Active|No intervention
11085771|NCT04175678|No Intervention|Obese/Inactive|Observational clinic visits
11085772|NCT04175678|Experimental|Diet|low fat/low caloric diet
11085773|NCT04175678|Experimental|Exercise Training|≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
11085774|NCT04175678|Experimental|Diet and exercise training|low fat/low caloric diet and ≥3 sessions with fitness trainer per week, for ≥30 min, at moderate to high intensity
11085775|NCT04175652|Experimental|Laughter yoga group, group doing laughter yoga|The duration of the laughter yoga was 30 minutes and a total of 16 sessions were performed on a twice-weekly basis.
11085776|NCT04175652|No Intervention|No laughter yoga group, group not doing laughter yoga|
11085807|NCT04175405|Experimental|Right side of the maxilla|The 635-nm laser parameters; dose: 10J per point (20J/cm2), time: 100 sec per point, 2 points (irradiation on a buccal, and a palatal side of the alveolus/implant), the total energy per session 20J.
11085808|NCT04175405|No Intervention|Left side of the maxilla|
11085777|NCT04175639|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
11085778|NCT04175639|No Intervention|mHealth-Education (mHealth-Ed)|mHealth-Education (mHealth- Ed): Participating in mHealth will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic with a nurse about cancer care.
11085779|NCT04175626||Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
11085780|NCT04175613|Experimental|Patients treated with Apremilast|Subjects with a weight between 20 kg to < 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
11085781|NCT04175600|Experimental|Selexipag|Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose.
11085782|NCT04175600|Placebo Comparator|Placebo|Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing.
11085783|NCT04175587|Experimental|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Induction: a) RIF: 60 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR; Consolidation: a) RIF: 60 mg/kg daily, in a 4-week on 4-week off regimen for four cycles in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles
11085784|NCT04175587|Other|Arsenic trioxide Plus Retinoic Acid|Induction: a) Arsenic trioxide: 0·15 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR Consolidation: a) Arsenic trioxide: 0.15mg/kg daily, in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles Expected Efficacy: Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for achieving 2-year EFS.
11085785|NCT04175574|Experimental|Intervention group|The intervention consist of the patients in the experimental group listening to pre-recorded music played through a set of noise cancelling Sony headphones which are padded for extra comfort from a Sony Digital Walkman. The duration of the intervention is 30 minutes without interruption, such as eating, talking and being on their mobile phones.
11085786|NCT04175574|No Intervention|Control group|Whereas, patients in the control group will be given similar headphones but without any music. They will also be briefed not to eat, talk and being on their mobile phones.
11085787|NCT04175561|Experimental|Intervention|Participants in the intervention arm will be given a green prescription (gardening activities).
11085788|NCT04175561|No Intervention|Control|Participants in the control arm will not be given the intervention.
11085789|NCT04175548||surgery for a pertrochanteric fracture|Patients having had surgery for a pertrochanteric fracture at the CHU Brugmann Hospital between January 2013 and May 2019.
11085790|NCT04175535|Other|The experimental group|PPECD was performed in the experimental group
11085791|NCT04175535|Other|control group|ACDF was performed in the control group
11085792|NCT04175522|Experimental|Experimental|Investigational product(IP)
11085793|NCT04175509|Active Comparator|Rectal acetaminophen|Patients will receive two 650mg suppositories rectally of acetaminophen for a total dose of 1300mg at the end of surgery.
11085794|NCT04175509|Active Comparator|Intravenous acetaminophen|Patients will receive one dose of 1000mg of acetaminophen, administered intravenously, at the end of surgery.
11085795|NCT04175496|Experimental|Test Foods|Blueberry Cake, Snack with Cheese and spicy Crackers will be used as test foods.
11085796|NCT04175496|Experimental|Reference Food|Glucose solution will use as reference food.
11085797|NCT04175470|Experimental|Arm A: Discontinue treatment after first treatment cycle|
11085798|NCT04175470|Experimental|Arm B: Continue treatment until progression|
11085799|NCT04175457|Experimental|e-cigarette inhalation with nicotine|inhalation of e-cigarette vapor with nicotine for 30 minutes.
11085800|NCT04175457|Active Comparator|e-cigarette inhalation without nicotine|inhalation of e-cigarette vapor without nicotine for 30 minutes.
11085801|NCT04175444||Normal Subjects|This is a study of normal subjects to establish a normative database.
11085802|NCT04175431|Active Comparator|Group I (observation with fluciclovine PET/CT)|Patients who do not have any abnormalities outside the prostatic fossa by fluciclovine PET/CT imaging undergo PSA rechecks every 3 months once PSA is > 2 ng/ml. If still no abnormalities are found, patients continue to undergo PSA rechecks every 3 months once PSA is > 5 ng/ml. Patients are off study once PSA reaches 10 ng/ml.
11085803|NCT04175431|Experimental|Group II (ADT/abiraterone/prednisone +/- surgery +/- RT)|Patients who have =< 3 regions of metastatic disease outside the prostatic fossa may undergo lymphadenectomy and/or radiation therapy, depending on the location of metastases. Patients with surgically treatable disease receive ADT comprising any LHRH agent, abiraterone acetate 1000 mg PO QD, and prednisone PO QD 6 weeks after surgery. Patients with radiation treatable disease receive 2 cycles of ADT, abiraterone acetate, and prednisone followed by radiation therapy. Treatment repeats every 4 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
11085804|NCT04175431|Experimental|Group III (ADT/abiraterone/prednisone)|Patients who have > 3 regions of metastatic disease receive ADT, abiraterone acetate, and prednisone as in Group II.
11085805|NCT04175418|Experimental|Supervised Exercise Program Group|Participants in the supervised exercise group were included to a program that consisted of 16 individual physiotherapist supervised sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
11085806|NCT04175418|Experimental|Online Education Program Group|Participants in the online education group were included to a program that consisted of 16 online sessions (two 60-minutes sessions/week), which were prepared to improve physical activity.
11085809|NCT04175392|Active Comparator|Treatment Group: Probiotic|Probiotic 1 billion units Supplement Once Daily
11085810|NCT04175392|Placebo Comparator|Control Group: Placebo|Placebo Capsule Once Daily
11085814|NCT04175366|Experimental|Shared Decision Making|Intervention with Shared Decision Making procedure regarding decision on planning of care and treatment before discharge.
11085815|NCT04175366|No Intervention|Care as usual|Discharge planning as usual.
11085816|NCT04175353|Experimental|Dairy snack|Drink high in milk protein, 250 ml
11085817|NCT04175353|Active Comparator|Orange juice|Regular orange juice, 250 ml
11085818|NCT04175353|Experimental|Berry snack 1|Bilberry-blackcurrant purée, 139 g
11085819|NCT04175353|Experimental|Berry snack 2|Lingonberry purée, 122 g
11085820|NCT04175353|Active Comparator|Berry soup|Bilberry soup, 250 ml
11085821|NCT04175327||CardioCel group|Patients who require repair of cardiac and vascular defects including intracardiac defects; septal defects, valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing
11085822|NCT04175314||Case -|Patient presenting one or more periodontal recession more than 1mm of height
11085823|NCT04175314||Control-|Patient presenting no periodontal recession or recession of less than 1 mm of height
11085824|NCT04175301|Experimental|Hydrogen|Five times per day for 6 weeks subjects will dissolve a hydrogen generating tablet into water and drink the effervescent water. Dissolving one tablet in 250 mL of water will achieve a saturating hydrogen concentration of approximately 1.6 ppm.
11085825|NCT04175301|Placebo Comparator|Placebo|Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
11085826|NCT04175288|Experimental|Ultrasound, manual therapy and exercise|This group will receive Ultrasound, manual therapy and exercise
11085827|NCT04175288|Active Comparator|manual therapy and exercise|This group will receive manual therapy and exercise
11085828|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
11085829|NCT04175249|Experimental|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
11085830|NCT04175223|Experimental|probiotics|probiotic administration
11085831|NCT04175223|No Intervention|without probiotic|no change from the usual care
11085832|NCT04175210|Experimental|ARM 1-4050cGY and boost to tumor bed of 4800cGY in 15fractions|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
11085833|NCT04175210|Experimental|ARM 2 - 3200cGY and boost to tumor bed of 4200cGY -10fractions|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
11085834|NCT04175197||Study Cohort|Subjects with symptoms of intermittent claudication and/or critical limb ischemia (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee arterial occlusion or stenosis
11085835|NCT04175184|Experimental|Experimental group|"Exercise programme: 2-3 sets of 10-15 repetitions of shoulder girdle and glenohumeral strengthening exercises performed in different positions in addition to three stretching exercises.
~Mobilisation with movement (MWM): the participant and physiotherapist will decide one movement more functionally relevant to the patient. Afterwards, attempts of MWM will be applied to different joints in order to identify one particular MWM that improves significantly the movement previously selected. Then, one set of six to ten repetitions will be applied. This process of pragmatically using MWM will be conducted in every session, but from the second session onwards, two to three sets of ten repetitions will be applied, with an interval of sixty seconds between sets. In case of failure to identify an MWM that improves the movement significantly, the patient decides which one seemed to be best and one set of six repetitions will be applied to the onset of discomfort."
11085836|NCT04175184|Sham Comparator|Placebo group|"The exercise programme is exactly the same as the experimental group.
~Sham MWM: the participant and physiotherapist will decide together one movement that is more functionally relevant to the patient. Afterwards, a sham MWM (Delgado-Gil et al 2015) will be applied and the movement previously selected will be repeated six times in the first consultation. The participant will be informed that he/she should move to the onset of symptoms, if they occur.This process will be conducted in every session, but from the second session onwards, two to three sets of 10 repetitions will be applied, with an interval of sixty seconds between sets. In case the sham MWM failed to improve the movement significantly, one set of six repetitions will be applied only."
11085837|NCT04175171|Experimental|GB221|Coprelotamab Injection, 8mg/kg, single dose
11085838|NCT04175171|Active Comparator|Herceptin|Trastuzumab Injection, 8mg/kg, single dose
11085839|NCT04175158|Experimental|GB222|1mg/kg
11085840|NCT04175158|Active Comparator|Bevacizumab|1mg/kg
11085841|NCT04175132|Experimental|Healthy subjects|
11085842|NCT04175132|Experimental|PD patients|
11085843|NCT04175119|Experimental|Main study group|All participants signed up for experiment 1, 2, or 3 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses.
11085844|NCT04175106|Experimental|a phytochemical-rich blueberry variety|Single-time consumption of 150 g phytochemical-rich blueberry per participant.
11085845|NCT04175106|Experimental|a phytochemical-poor blueberry variety|Single-time consumption of 150 g phytochemical-poor blueberry per participant.
11085846|NCT04175106|Experimental|"a minimally processed blueberry-rich protein bar"|Single-time consumption of blueberry-rich protein bar matched for 150 g blueberry phytochemicals.
11085847|NCT04175106|Placebo Comparator|a blueberry control beverage of matched-nutritive content|Single-time consumption of control beverage matched for the macronutrient content of the blueberry-rich protein bar.
11085848|NCT04175093||Mild persistent asthma|• Group I, patients with mild persistent asthma.
11085849|NCT04175093||Moderate persistent asthma|• Group II, patients with moderate persistent asthma.
11085850|NCT04175093||Severe persistent asthma|• Group III ,patients with severe persistent asthma.
11085851|NCT04175080||Control|
11085852|NCT04175080||HFpEF group|
11085853|NCT04175080||Hypertensive group|Patients in which the results of BNP/NT-proBNP did not confirm the diagnosis of HFpEF were classified as hypertensive group.
11085854|NCT04175067||Endometrium cancer|stage I endometrium cancer n=57
11085855|NCT04175067||Healthy controls|Healthy volunteers n=60
11085856|NCT04175054|Active Comparator|Low Intensity Group|Less than 40% Heart Rate Reserve
11085863|NCT04175015|Active Comparator|Control Group|Participants will be randomised to eat a pink coloured smartie ©
11085864|NCT04175002||Anovulatory PCOS women with a BMI greater than 27|
11085865|NCT04175002||Anovulatory PCOS women with a BMI lower than 25|
11085866|NCT04175002||Healthy fertile women with a BMI greater than 27|
11085867|NCT04175002||Healthy fertile women with a BMI lower than 25|
11085868|NCT04174989|Experimental|Plasminogen-Depleted Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
11085869|NCT04174989|Other|Fresh-Frozen Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of FFP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
11085870|NCT04174976||Wall hernia repair|"All patients admitted for wall hernia repair with mesh between 28/12/2017 and 28/12/2020.
~."
11085871|NCT04174963|Experimental|eToke + TPsy|All participants will receive the intervention (eToke+TPsy). The intervention consists of eToke (a brief computerized intervention that uses motivational enhancement therapy to improve readiness to decrease cannabis use and increase motivation to engage in substance use treatment) AND 6-8 interactive text messages regarding cannabis use reduction over 4 weeks . Text messages will contain written content, and queries, as well as links to publicly available websites and YouTube videos.
11085872|NCT04174950|Active Comparator|control group|Routine perioperative nursing intervention
11085873|NCT04174950|Experimental|experimental group|Perioperative ERAS Based Nursing Model
11085874|NCT04174937|Experimental|Potentiator of antibiotics (PA)|Potenciator of antibiotics (PA) , albumin complex of tetraiodid was given per os, single and multiple doses for the different periods (but not exceeding 14 days)
11085875|NCT04174937|Placebo Comparator|Patients taking placebo PA|Placebo without any active pharmaceutical ingredients was given per os dosed for the patients in same periods of time as per experimental group, single and multiple doses for the different periods (but not exceeding 14 days)
11085876|NCT04174924||Phakic intraocular lens (pIOL) explantation|Patients with pIOLs where a combined pIOL explantation and cataract surgery is needed.
11085877|NCT04174924||Cataract extraction|Healthy control group of patients scheduled for regular cataract surgery without comorbidities affecting an immune response.
11085878|NCT04174911|Experimental|BOL-DP-o-08|BOL-DP-o-08
11085879|NCT04174911|Placebo Comparator|Placebo|Placebo
11085880|NCT04174898|Experimental|Treatment Population|100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours
11085881|NCT04174885|Other|AF epicardial ablation|Patient with persistent AF will receive an epicardial ablation.
11085882|NCT04174872|Other|Dexmedetomidine|It has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
11085883|NCT04174872|Other|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
11085884|NCT04174859||NVAF patients|Start treatment with rivaroxaban at the discretion of physician.
11085885|NCT04174846|Active Comparator|Treatment of SAM children with RUTF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with standard ready-to-use therapeutic food (RUTF)
11085886|NCT04174846|Experimental|Treatment of SAM children with RUSF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with ready-to-use-supplementary food (RUSF)
11085887|NCT04174820||Retrospective Low-Grade Glioma|Inclusion of patients with Low-Grade Glioma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
11085888|NCT04174820||Retrospective Medulloblastoma|Inclusion of patients with Medulloblastoma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
11085889|NCT04174820||Prospective patients|Inclusion of prospective patients with an indication to surgery of a Posterior Fossa Tumor, with evaluation of post-operative mutism and then one year after the end of mutism, an evaluation with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
11085890|NCT04174820||Control patients|Inclusion of patients without Posterior Fossa Tumor, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
11085891|NCT04174807||Cohort|
11085892|NCT04174781|Experimental|TACE-DEB in combination with Sintilimab Injection|Treatment will be divided into 4-week cycles from the starting date of TACE-DEB. The first TACE-DEB session and Sintilimab Injection will be initiated simultaneously. The repetition of TACE-DEB procedures will be initiated on demand according to tumour response assessment. Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression for up to one years.
11085893|NCT04174768|Experimental|Bariatric surgery patients|Bariatric patients undergoing sleeve gastrectomy or Roux-en-Y gastric bypass
11085894|NCT04174755|Experimental|Semaglutide 0.25/0.5/1 mg plus standard of care|
11085895|NCT04174755|Other|Standard of care alone|
11085896|NCT04174742||A|Subjects 45 years of age or younger
11085897|NCT04174742||B|Subjects over 45 years of age
11085961|NCT04174209|Experimental|Cohort 1|70 patients are involved and will perform the three conditions.
11085898|NCT04174729|Experimental|Hand strength|"The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength. The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength.
~In the first session, the volunteers performed the movements 3 times in each device of daily living activities with the right limb, with a 1-minute rest interval between the 3 measurements. The entire procedure performed in the session was repeated again after 30 minutes to verify the reliability and reproducibility of the Intra-evaluator test. The Inter-rater test was repeated after 7 days by the second rater to analyze reliability between the rater."
11085899|NCT04174716|Experimental|IDX-1197|Patient will be receive IDX-1197HCl oral capsules (80mg) once daily for 28 continuous days
11085900|NCT04174703|Experimental|Self-compassionate letter-writing intervention|An online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks
11085901|NCT04174703|No Intervention|Control condition|
11085902|NCT04174690|Experimental|Balance|Volunteers aged from 18 years to over 60 years were selected without compromise. The tests were performed in a single session lasting 1 hour where the volunteers will do the tests on the force platform.
11085903|NCT04174677|Experimental|Inebilzumab Treatment|Infusion of Inebilizumab
11085904|NCT04174677|Experimental|VIB4920 Treatment|Infusion of VIB4920
11085905|NCT04174677|Experimental|Inebilzumab+VIB4920 Treatment|Infusion of Inebilizumab and VIB4920
11085906|NCT04174651|Experimental|Participants with AD with MRI|Participants that are diagnosed with AD will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
11085907|NCT04174651|Experimental|Healthy Participants with MRI|Healthy participants will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart. These subjects will be evaluated with MRI.
11085908|NCT04174651|Experimental|Participants with AD with behavioral only|Participants that are diagnosed with AD will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart.
11085909|NCT04174651|Experimental|Healthy Participants with behavioral only|Healthy participants will receive both the acute stress condition (TSST) and the control condition (watching a landscape video). The order when the 2 conditions will be provided is randomized per participant and completed 2 weeks apart.
11085910|NCT04174638|Experimental|Randomized|Motivational Interview and Education Based on Watson Human Care Model
11085911|NCT04174625|Experimental|Omega3-FA group|Omega3-FA group 1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
11085912|NCT04174625|Experimental|Control group|VD3 group 50,000 IU/week
11085913|NCT04174612|Active Comparator|Standard clinical treatment|"Patients will complete 3+7 + Midostaurin induction course."
11085914|NCT04174612|Experimental|Experimental treatment|"The experimental arm will provide 2 main modifications compared to standard:
~i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status"
11085915|NCT04174599|Experimental|F-627|Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
11085916|NCT04174599|Active Comparator|GRAN®|Subjects will receive GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
11085917|NCT04174586|Experimental|cord blood group|standard induction and consolidation chemotherapy with cord blood microtransplantation
11085918|NCT04174573|Experimental|Group therapy only (GTO)|Patients in GTO group will receive structured group therapy programme
11085919|NCT04174573|Experimental|Group therapy with tDCS (GT-tDCS)|Patients in this group will receive group therapy along-with tDCS intervention
11085920|NCT04174560|Experimental|Cohort 1|Single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^3 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
11085921|NCT04174560|Experimental|Cohort 2|Single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^4 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
11085922|NCT04174560|Experimental|Cohort 3|Single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given orally to subjects with functional FUT-2 gene (secretor positive), n=15, and single dose (3.5x10^5 copies) of norovirus GII.4 CIN-3 Batch No.: 01-16C3 inoculum (with 60 mL of a 2% sodium bicarbonate before and after inoculum administration) will be given to subjects with a lack a non-functional FUT-2 gene (non-secretor), n=1, on Day 1
11085923|NCT04174547||Clonal hematopoiesis (AIM 1)|"The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: Health and Anemia study [Haematologica 2010;95:1849], and Monzino 80-plus study [BMC Neurol.2011;11:54, validation cohort]. Overall in 5000 subjects aged >65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations."
11085962|NCT04174196|Experimental|Participants with Plasmacytoma|Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas
11085963|NCT04174183|Experimental|Prevena (right side) - Dry dressing (left side)|
11085964|NCT04174183|Experimental|Prevena (left side) - Dry dressing (right side)|
11085924|NCT04174547||Innovative predictive models in MDS (AIM2)|"The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.
~The investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value."
11085925|NCT04174547||Predictive biomarkers in MDS (AIM3)|The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal.
11085926|NCT04174521||Mother-Child|Mothers who have delivered at VUMC and their children who are seen by Vanderbilt-affiliated physicians.
11085927|NCT04174495||Obese patients followed at Nancy University Hospital|
11085928|NCT04174482|Experimental|flat foot patients|20 patients recruited consecutively and candidates for surgery to correct the adult flat foot according to the Grice technique.
11085929|NCT04174456|Experimental|Olmesartan group|olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
11085930|NCT04174456|Active Comparator|Valsartan group|valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
11085931|NCT04174443|Experimental|Pulsed radiofrequency + Continuous radiofrequency|
11085932|NCT04174443|Active Comparator|Pulsed radiofrequency|
11085933|NCT04174430||mild to moderate bronchiolitis|Bronchiolistis patients without Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks, Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency and Neurologic disease
11085934|NCT04174417|Active Comparator|systolic blood pressure (SBP)|Systolic blood pressure (SBP) for group 1 patients 80-90 mmHg
11085935|NCT04174417|Active Comparator|mean blood pressure (MBP)|Mean blood pressure (MBP) for group 2 patients 50-65 mmHg
11085936|NCT04174404|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Circumcision which is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
11085937|NCT04174404|Active Comparator|Control group|The participants in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care.
11085938|NCT04174391|Experimental|Mediterranean diet supplemented with extra-virgin olive oil|
11085939|NCT04174391|Active Comparator|Low-fat diet|
11085940|NCT04174378||GnRH agonist with progestogen support|
11085941|NCT04174378||progestogen support only|
11085942|NCT04174365|Experimental|Brexpiprazole|
11085943|NCT04174365|Placebo Comparator|Placebo|No Intervention
11085944|NCT04174352|Experimental|Tamoxifen Dose Levels|"Three participants will be enrolled to each dose level of oral tamoxifen (n = 12)
~Dose Level 1 = 20 mg daily Dose Level 2 = 80 mg daily Dose Level 3 = 160 mg daily Dose Level 4 = 200 mg daily
~Tamoxifen should be started within 14 days of the FES-PET/CT scan, at least 24 hours after FES injection. Participants will continue tamoxifen therapy until there is radiologic or clinical evidence of progressive disease or drug intolerance."
11085945|NCT04174339|Experimental|camrelizumab plus apatinib and POF|Participants will receive camrelizumab in combination with apatinib plus POF until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11085946|NCT04174326|Experimental|Intervention group|A weekly 2 hour CBT for chronic pain group intervention for a duration of 6 weeks
11085947|NCT04174326|No Intervention|Delayed intervention group|A waiting list for CBT for chronic pain group intervention.
11085948|NCT04174313||VILI Risk and specific power|Measurement of pulmonary pressures and volumes in the same patient
11085949|NCT04174300|Experimental|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
11085950|NCT04174287|Experimental|F-18-AV45|F-18-AV45 imaging
11085951|NCT04174274||positive|ventilator-associated pneumonia-developed group followed by mechanical ventilation
11085952|NCT04174274||negative|not ventilator-associated pneumonia-developed group followed by mechanical ventilation
11085953|NCT04174261|Experimental|Ticagrelor - Remote Ischemic Preconditioning|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
11085954|NCT04174261|Other|Ticagrelor - Control|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. BP-cuff uninflated around the non-dominant arm
11085955|NCT04174261|Active Comparator|Clopidogrel - Remote Ischemic Preconditioning|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
11085956|NCT04174261|Other|Clopidogrel - Control|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. BP-cuff uninflated around the non-dominant arm
11085957|NCT04174248|Experimental|Experimental group|Experimental group with BCSMS App using
11085958|NCT04174248|No Intervention|Control group|Control group without BCSMS App using
11085959|NCT04174222|Active Comparator|Moderate block|5-10mg rocuronium is administered to maintain train-of-four count 1-2. At the end of surgery, sugammadex 2mg/kg is administered IV for reversal of neuromuscular block.
11085960|NCT04174222|Experimental|Deep block|5-10mg rocuronium is administered to maintain train-of-four count 0, and post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
11085965|NCT04174170|Experimental|Brexpiprazole + Sertraline|3 pills: Fixed dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
11085966|NCT04174170|Experimental|Sertraline|3 pills: Fixed dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
11085967|NCT04174170|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
11085968|NCT04174157||Prospective observational registry|This is a prospective, multi center, multinational, non-interventional observational registry.
11085969|NCT04174144||TLIF group|Participants with degenerative spondylolysthesis who underwent a single-level TLIF procedure.
11085970|NCT04174131|Experimental|Treatment A (right) B (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
11085971|NCT04174131|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
11085972|NCT04174118|Experimental|DCR-A1AT|"SAD Group A: Healthy volunteers will be administered a single dose of DCR-A1AT.
~MAD Group B: Participants will be administered multiple doses of DCR-A1AT."
11085973|NCT04174118|Placebo Comparator|Placebo|"Group A: Healthy volunteers will be administered a single dose of matching placebo.
~Group B: Participants will be administered multiple doses of matching placebo."
11085974|NCT04174105|Experimental|Initial Dose Cohort|Dose 1 of AT845 administered via intravenous infusion
11085975|NCT04174105|Experimental|Second Dose Cohort|Dose 2 of AT845 administered via intravenous infusion
11085976|NCT04174092|Experimental|rheumatoid arthritis|Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months
11085977|NCT04174092|Experimental|spondyloarthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).
~Patients will be seen at 3, 6 and 12 months"
11085978|NCT04174092|Experimental|Psoriatic arthritis|"Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).
~Patients will be seen at 3, 6 and 12 months"
11085979|NCT04174079|Experimental|Experimental group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
11085980|NCT04174079|No Intervention|control group|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma were reviewed regularly after surgery.
11085981|NCT04174066||SNLGM|70 patients with an SNLGM
11085982|NCT04174066||primary FSH|74 with a primary FSH
11085983|NCT04174053|Experimental|Temperature measurement|"enteric capsule will be ingested every 24 hours during aplasia. Temperature measurement will be made continuously during aplasia.
~In parallel, auricular temperature will be measure every 4 hours during aplasia."
11085984|NCT04174040|No Intervention|Control 1|Applied any intervention.
11085985|NCT04174040|Active Comparator|Control 2|Gross's Process of Emotion Regulation Model interventions applied.
11085986|NCT04174040|Active Comparator|Control 3|Musical rhythm interventions applied.
11085987|NCT04174040|Experimental|Experimental|Musical rhythm integrated Gross's Process of Emotion Regulation Model interventions applied.
11085988|NCT04174014|Experimental|Recruitment manoeuvre|"Volume control (VC) ventilation mode with a tidal volume of 6 mL/kg of ideal body weight
~P/V tool assessment
~Baseline measurements
~CT scan of chest without EIT belt
~Re-establishment of EIT belt, continuous EIT and transpulmonary pressure measurement during the recruitment and de-recruitment manoeuvre.
~increment phase:
~constant volume settings
~increasing PEEP with 4 cmH2O following each 10 consecutive controlled breath until reaching a peak pressure of 40 cmH2O
~decrement phase:
~constant volume settings
~decreasing PEEP with 4 cmH2O following each 10 consecutive controlled breath not lower than 2 cmH20 from target PEEP
~target PEEP level is defined where the end-expiratory transpulmonary pressure is 0-1 cmH2O
~P/V recruitment with target end-PEEP level
~Removal of EIT belt, CT scan of chest
~Continuous EIT and transpulmonary pressure measurement with the initial FiO2 and the new PEEP settings"
11085989|NCT04174001||Neuro group|"Patients who meet the following criteria:
~18 years of age or younger
~diagnosed with one or more of the following neurological disorders: moyamoya disease, congenital anomalies of the brain, hypoxic-ischemic encephalopathy, brain tumor, Chiari malformation, epilepsy and stroke
~planned for any surgical procedures that require general anesthesia
~planned to receive intraoperative and/or postoperative invasive arterial blood pressure monitoring
~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or are scheduled for a cardiac procedure will be excluded."
11085990|NCT04174001||Control group|"Patients who meet the following criteria:
~18 years of age or younger-planned for any surgical procedures that require general anesthesia
~planned postoperative invasive blood pressure monitoring
~Patients who have a surgical procedure that contraindicates the placement of a NIRS probe on the forehead or have symptoms of neurological disorders will be excluded."
11085991|NCT04173988|Experimental|alloCART-19|"For the very first patient, the initial dose could be administered via one or three intravenous infusions within 1 to 5 days. Starting from the second patient, the investigator will decide whether to use single or multiple alloCART-19 infusions, based on the treatment experience at previous dose level(s) and the patient's baseline disease burdens.
~A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before alloCART-19 infusion."
11085992|NCT04173975|Experimental|With knee exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).
~Each session will be 45 minutes long. Three time per week, for three weeks.
~The patients allocated in this arm will perform the training wearing the BELK device."
11085993|NCT04173975|No Intervention|Without exoskeleton|"The rehabilitation training will be focused on lower limb with specific activities for knee instability, and will concern both physical training (e.g., locomotion task, balance exercise, muscle reinforcement, proprioceptive task) and occupational treatment tasks (e.g., transferring/mobility, meal preparation, house-working).
~Each session will be 45 minutes long. Three time per week, for three weeks.
~The patients allocated in this arm will perform the training without any exoskeleton."
11085994|NCT04173962|Experimental|Ketamine group|One 0.5mg/kg intravenous dose of ketamine
11085995|NCT04173962|Active Comparator|Midazolam group|One 0.045mg/kg intravenous dose of midazolam
11085996|NCT04173949|Experimental|Ramipril 2.5 MG|Ramipril 2.5 MG orall, daily.
11085997|NCT04173936||Tai Chi|All participants enrolled in a 12 week community-based tai chi program.
11085998|NCT04173910||LPEC/Sellick ultrasound|
11085999|NCT04173897|Experimental|Intervention arm|12 weeks access to LIBERATE online supportive intervention (dose not specified) including symptom monitoring questionnaire component, with questionnaire results integrated within electronic medical records for clinician review.
11086000|NCT04173897|No Intervention|Waiting list control arm|Care and support as usual; no access to intervention. Placed on waiting list to receive intervention following study completion.
11086001|NCT04173884|Active Comparator|Live Surgical Peer Coaching|Coaches will facilitate an initial, individual, introductory phone call with participants prior to the first formal coaching session. The objective of this call is to develop rapport, explore each other's background, experience, and motivation for participation in the program, set overall goals for the program, set specific goals for the first coaching session, develop an action plan including identification of the key characteristics of the first case for review, and develop a timeline and plan for meetings. Peer coaching sessions will be scheduled at three national meetings that are commonly attended by ACHQC surgeons. In advance of each meeting, participants will record and upload a self-selected video to a secure server maintained by the study team, and coaches will have the opportunity to review the video if they wish to prepare. A live coaching session will be organized at the meeting where the coaches and participants will have parallel one-hour coaching sessions.
11086002|NCT04173884|Active Comparator|Asynchronous Video-based Constructive Feedback|There will be no real-time interpersonal contact between coaches and participants in this arm. Participants will upload their self-selected procedural video to the video review platform, together with a short description of the case and any specific questions. The coach will review the video within one week of its posting and provide time-stamped feedback on the video platform. Participants will then review the coach's feedback within one week with the ability to respond to the comments. The coach and participant will continue communication via the internet-based review platform until no further comments are made by either party. Coach-participant dyads are expected to review three videos during the 6 month intervention period.
11086003|NCT04173884|Active Comparator|Wait-List Control|One-third of participants will be randomized to an intervention, but wait-listed to provide a control group. These surgeons will submit two videos for technical skill evaluation during each of the baseline and follow-up periods, and ACHQC data will be tracked for short-term outcomes prior to their crossover to the intervention for long-term follow-up. Selecting the control group using the identical sampling frame of ACHQC surgeons participating in the interventions affords the opportunity for a comparable group with outcome metrics recorded systematically.
11086004|NCT04173871|Experimental|Intervention|Intervention group
11086005|NCT04173871|No Intervention|Control|Control group
11086006|NCT04173858||Experimental|Patients with confirmed opioid-induced constipation diagnosis and inadequate response to laxatives.
11086007|NCT04173845|Experimental|Tianqi Pingchan Granule group|Tianqi Pingchan Granule were manufactured according to Good Manufacturing Practice (GMP) by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. , granule, twice a day, for six months.
11086008|NCT04173845|Placebo Comparator|Tianqi Pingchan Granule Placebo group|placebo, granule, twice a day, for six months.
11086009|NCT04173832|Experimental|Tianqi Pingchan Granule Combined With Amantadine|
11086010|NCT04173832|Placebo Comparator|placebo Combined With Amantadine|
11086011|NCT04173819|Experimental|Group 1|Single Agent, abdominal subcutaneous injection, 10:2 ratio for Ab:placebo
11086012|NCT04173819|Experimental|Group 2|Single agent, abdominal subcutaneous injection 10:2 ratio for Ab:placebo
11086013|NCT04173819|Experimental|Group 3|Single agent intravenous injection 10:2 ratio for Ab:placebo
11086014|NCT04173819|Experimental|Group 4|Single agent intravenous injection 10:2 ratio for Ab:placebo
11086015|NCT04173819|Experimental|Group 5|Combined agent intravenous injection 10:2 ratio for Ab:placebo
11086016|NCT04173819|Experimental|Group 6|Subcutaneous injection combined ratio 1 with loading dose 30:3 ratio of Ab:Placebo
11086017|NCT04173819|Experimental|Group 7|Subcutaneous injection in abdomen combined ratio 2 with loading dose 30:3 ratio of Ab:Placebo
11086018|NCT04173819|Experimental|Group 8|Subcutaneous injection in abdomen combined ratio 3 with loading dose 30:3 ratio of Ab:Placebo
11086019|NCT04173819|Experimental|Group 9|Subcutaneous injection in abdomen combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
11086020|NCT04173819|Experimental|Group 10|Subcutaneous injection in arm combined ratio 2 without loading dose 30:3 ratio of Ab:Placebo
11086021|NCT04173806|Experimental|Facebook group|"Participants will be included in an online classroom through a closed group of Facebook to receive an asynchronous course of telemedicine."
11086022|NCT04173806|Active Comparator|Control group|In this group the participants are exposed to the same course of telemedicine but on the Moodle educational platform.
11086023|NCT04173793|Experimental|AK102 450 mg|Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
11086024|NCT04173793|Experimental|AK102 300 mg|Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
11143670|NCT03770923|No Intervention|No intervention|No intervention
11086025|NCT04173793|Experimental|AK102 150 mg|Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
11086026|NCT04173793|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks
11086027|NCT04173793|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks
11086028|NCT04173780|Experimental|Atropine 0.01%|
11086029|NCT04173780|Placebo Comparator|Placebo|
11086030|NCT04173767|Experimental|HFNC|
11086031|NCT04173754||MSAT Group|"The MSAT group who are treated with korean medical treatment including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
11086032|NCT04173754||Control Group|"The control group who are treated with Korean medical treatment not including MSAT will be evaluated on first, second, third visit and 2weeks after baseline. And the patients will receive telephone inquires after 3months from the baseline.
~The Korean medical treatment includes acupuncture, chuna, pharmaco-acupuncture and Korean herbal medicine."
11086033|NCT04173741||Leg Rise Position - 3 Minutes|Patients who stayed in passive leg rise position for 3 minutes
11086034|NCT04173741||Leg Rise Position - 1 Minute|Patients who stayed in passive leg rise position for 1 minute
11086035|NCT04173728|Experimental|young and normal weight|20 subjects aged 20-29 years with normal body weight(18.5≤BMI<24), male:female = 1:1
11086036|NCT04173728|Experimental|normal weight|40 subjects aged 30-70 years with normal body weight(18.5≤BMI<24), male:female = 1:1
11086037|NCT04173728|Experimental|overweight or obesity|40 subjects aged 30-70 years with overweight or obesity (BMI≥24), male:female = 1:1
11086038|NCT04173728|Experimental|Mets|20 objects with Mets, male:female = 1:1
11086039|NCT04173715||General Group|All those who are over 65 years old and capable of walking by themselves.
11086040|NCT04173715||Low Physical Function Status Group.|All those who present a low physical function status will be included in this group.
11086041|NCT04173715||Medium Physical Function Status Group.|All those who present a medium physical function status will be included in this group.
11086042|NCT04173715||High Physical Function Status Group.|All those who present a high physical function status will be included in this group.
11086043|NCT04173702|Experimental|Healthy Group|Postural sway and stability limits in assessment of healthy individuals
11086044|NCT04173689|Active Comparator|Inspiratuar muscle training group|This group will be given inspiratory muscle training (IMT) at home for 15 minutes twice a day for 7 days a week with the resh Threshold IMT 'device. In the IMT group, the initial training intensity will be determined by measuring the maximal inspiratory muscle strength (MRP) with the intraoral pressure measuring device, 30% of the measured MRP value will be started at the first evaluation and the new training intensity will be determined by calculating 30% of the measured value by repeating the MRP measurement every week.
11086045|NCT04173689|Active Comparator|Exercise group|This group will perform upper extremity and trunk exercises combined with breathing exercises at home for 7 days, twice a day for 15 minutes. Patients in both groups will perform a single 15-minute session once a week at the hospital under the supervision of a physiotherapist.
11086046|NCT04173676|Experimental|use of indocyanine green|submucosal injection of ICG is by gastroscopy on the upper edge of the esophageal tumor,Dose of 0.5mg
11086047|NCT04173663|Experimental|ASSIST intervention group|This group will attend the 12 sessions of the ASSIST training program (one 2-hour session per week for 12 weeks).
11086048|NCT04173663|Other|Written materials only control group|This group will receive the ASSIST curriculum and written materials developed for the program but will not attend the in-person sessions.
11086049|NCT04173650|Experimental|AGLE 102|Treatment arm
11086050|NCT04173637|Experimental|AK101 45mg every 8 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 8 weeks
11086051|NCT04173637|Experimental|AK101 45mg - every 12 weeks|AK101 45mg on Week 0 and 4 administered subcutaneously followed by AK101 45mg administered subcutaneously every 12 weeks
11086052|NCT04173637|Experimental|AK101 90mg - every 8 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 8 weeks
11086053|NCT04173637|Experimental|AK101 90mg -every 12 weeks|AK101 90mg on Week 0 and 4 administered subcutaneously followed by AK101 90mg administered subcutaneously every 12 weeks
11086054|NCT04173637|Experimental|AK101 135mg -every 8 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 8 weeks
11086055|NCT04173637|Experimental|AK101 135mg -every 12 weeks|AK101 135mg on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously every 12 weeks
11086056|NCT04173637|Placebo Comparator|Placebo to AK101|Placebo on Week 0 and 4 administered subcutaneously followed by AK101 135mg administered subcutaneously at Week 12, 16 and then every 12 weeks
11086057|NCT04173624|Experimental|Endosonography|Endosonography is endoscopic method to diagnose pancreatic and biliary disorders. Participants randomized to this arm will undergo diagnostic endosonography under propofol sedation in supervision of trained anesthesiologists. If choledocholithiasis is diagnosed on endosonography, patient will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
11086058|NCT04173624|Experimental|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for diagnosis of pancreatic and biliary disorders. Participants randomized to this arm will undergo MRCP. If choledocholithiasis is diagnosed on MRCP, participants will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
11086059|NCT04173611|Experimental|EXPAREL®|For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
11086123|NCT04173117|Experimental|Intervention|Low energy meal replacement plan 12 weeks
11086060|NCT04173611|Active Comparator|Bupivacaine|In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.
11086061|NCT04173611|Active Comparator|Placebo|Subjects in the placebo arm will receive normal saline intrathecal injection
11086062|NCT04173598|Experimental|Intervention Group|An intervention group consisting of a dyad (patient + family carer) benefiting in addition to the usual treatment from the intervention for the family carer.
11086063|NCT04173598|Active Comparator|Control Group|A group consisting of a dyad (patient + caregiver) with usual care (control group)
11086064|NCT04173585|Experimental|Bortezomib-Gemtuzumab Ozogamicin Treatment|"one cycle of combined chemotherapy:
~Bortezomib (1.3 mg/m2) sc on day 1 and 3. Dose will be given 3 hours prior to Cytarabine on day 1 and 3
~Cytarabine (1g/m² twice daily) iv over 3 hours on day 1, 2 and 3 Gemtuzumab Ozogamicin (3 mg/m²,up to a maximum of one 5 mg vial) iv over 2 hours on day 1 after first dose of Cytarabine and day 4
~Pegfilgrastim 6 mg sc on day 8 (optional)"
11086065|NCT04173572|Experimental|Walking Group|Participants will be walking two times a week in supervised groups with the psychiatric clinic and will also participate in independent walks done at a location of their own choosing outside group participation.
11086066|NCT04173572|Active Comparator|Fitbit Alone|Participants will be provided with a Fitbit wristband and instructed how to use it. Participants will also be given information on current recommended physical activity guidelines and told that study staff may be contacting them on a weekly basis if it looks like participants are not wearing their Fitbit for a certain number of days or to troubleshoot any issues.
11086067|NCT04173559|No Intervention|Usual care|Women randomized to this group will receive no guidance regarding exercise / activity during pregnancy.
11086068|NCT04173559|Experimental|Activity Intervention|Women randomized to this group will receive detailed information and reminders about physical activity in pregnancy. .
11086069|NCT04173533|Placebo Comparator|Control Group|Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle
11086070|NCT04173533|Experimental|Experimental Group|Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle
11086071|NCT04173507|Experimental|Treatment (talazoparib, avelumab)|Patients receive talazoparib PO daily and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11086072|NCT04173494|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match danazol
11086073|NCT04173494|Active Comparator|Danazol|Participants will receive danazol plus placebo to match momelotinib
11086074|NCT04173481|Experimental|Rood's Group|Rood's sensory motor training along with CIMT
11086075|NCT04173481|Active Comparator|Conventional Physical Therapy Group|Conventional Physical Therapy including Proprioceptive Neuromuscular Facilitation technique.
11086076|NCT04173468|Active Comparator|MWM Group|This group will receive Mobilization with Movement (MWM) i.e. straight leg raised with traction,Tibial Gliding
11086077|NCT04173468|Active Comparator|Mulligan Taping Group|This group will receive Mulligan knee taping
11086078|NCT04173455|Experimental|HZ-A-018|"In the dose-escalation part, the 3+3 design will be applied. If the subject does not have a DLT during the first 28-day cycle, those who with stable or remission of disease may continue to receive treatment until disease progression, intolerable toxicity or the subject no longer benefits.
~In the dose-expansion part, HZ-A-018 will be administered for several 28-day cycles until disease progression, intolerable toxicity or the subject no longer benefits."
11086079|NCT04173442||Cohort 1: Dupilumab-Exposed Cohort|Pregnant women with approved indications exposed to dupilumab during pregnancy
11086080|NCT04173442||Cohort 2: Disease-Matched Comparison Cohort|Pregnant women with approved indications not exposed to dupilumab during pregnancy
11086081|NCT04173442||Cohort 3: Healthy Comparison Cohort|Pregnant women who are not diagnosed with any dupilumab-approved indications, and not exposed to dupilumab during pregnancy
11086082|NCT04173429|Experimental|Anticoagulation group|Warfarin orally with a initial dosage of 3mg daily for 6 months(warfarin group) or low molecular weight heparin subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months(LMWH-warfarin group) respectively.
11086083|NCT04173429|No Intervention|Control group|No anticoagulation therapy.
11086084|NCT04173416|Experimental|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
~The specific components of YORS will be refined and adapted based on feedback from interviews and focus groups with various stakeholders. However, the basic framework outlined above is expected to persists."
11086085|NCT04173403|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;
11086086|NCT04173390|Experimental|pregabalin|
11086087|NCT04173390|Placebo Comparator|placebo|
11086088|NCT04173364|Experimental|Experimental group : ropivacaine 0.1%|Interscalene block for arthroscopic shoulder surgery with small volume of low concentration (0.1%) of ropivacaine
11086089|NCT04173364|Active Comparator|control group : ropivacaine 0.5%|Interscalene block for arthroscopic shoulder surgery with small volume of standard concentration (0.5%) of ropivacaine
11086124|NCT04173104||Participants with Brain Cancer|Participants with new or suspected recurrent brain tumors
11086125|NCT04173078|Experimental|Computerized Distress Intolerance Intervention|Two, 1-hour computerized sessions that include psychoeducation about emotional avoidance, idiographic emotional exposure, and construction of idiographic implementation intentions to practice distress tolerance skills outside of session.
11086126|NCT04173078|Placebo Comparator|Computerized Healthy Behaviors Intervention|Two, 1-hour computerized sessions that focus on psychoeducation about the importance of a healthy lifestyle.
11086127|NCT04173065|Placebo Comparator|Placebo|
11086128|NCT04173065|Experimental|1.0 mg|
11086090|NCT04173351|Experimental|Intervention|Pregnant women in intervention group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Date of the next antenatal follow-up of the participants in the intervention group was recorded and they were given an appointment for the antenatal education. Women, whose date of next antenatal follow-up was unknown, were asked to inform the researchers about their appointment. Following the antenatal follow-up, the pregnant women in the intervention group were given an antenatal childbirth education and an educational brochure after the education. Also, provided telephone counseling to the intervention group one week after the education. Participants in the intervention group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
11086091|NCT04173351|No Intervention|Control|Pregnant women in control group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Participants in the control group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
11086092|NCT04173338|Experimental|Cabozantinib + Pemetrexed|Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
11086093|NCT04173325|Experimental|Nivolumab and Irinotecan|Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)
11086094|NCT04173312|Active Comparator|Infused analgesic|Patients will be assigned to receive local anesthetic through continuous infusion by pump.
11086095|NCT04173312|Placebo Comparator|Infused saline|Patients will be assigned to receive saline through continuous infusion by pump.
11086096|NCT04173299||Early Tips|Patients wtih early tips for Acute esophageal variceal bleeding
11086097|NCT04173299||stantard treatment|patients with standard treatment (medical + endoscopic) for Acute esophageal variceal bleeding
11086098|NCT04173286||short term antibiotics|< 7 days
11086099|NCT04173286||long terms antibiotics|> 7 days
11086100|NCT04173273|Experimental|Etrasimod Dose A|
11086101|NCT04173273|Experimental|Etrasimod Dose B|
11086102|NCT04173273|Placebo Comparator|Placebo|
11086103|NCT04173260|Experimental|Intervention arm - Oral Deutetrabenazine|This is the only arm for this trial. All subjects will receive oral Deutetrabanazine.
11086104|NCT04173247|Experimental|KeraStat Skin Cream Arm|Patients randomized to the KeraStat arm will be provided with KeraStat Skin Cream for application as often as needed but at least twice daily, morning and evening using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
11086105|NCT04173247|Active Comparator|Routine Skin Care Arm (RSC Arm)|Patients randomized to this arm will apply commercially available products from a list provided at least twice daily using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
11086106|NCT04173234|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
11086107|NCT04173234|Active Comparator|Control Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 5 days a week.
11086108|NCT04173221|Experimental|Intervention|
11086109|NCT04173221|Other|Control|
11086110|NCT04173208|Experimental|Fecal microbial transplant|The participants of the experimental arm will receive an oral fecal microbial transplant after delivery
11086111|NCT04173208|Placebo Comparator|Placebo group|The participants of the placebo arm will receive an oral placebo after delivery
11086112|NCT04173195|Experimental|Intervention arm|The CT intervention will be administered by the nurse in charge of the chemotherapy 5 min after the initiation. the CT content will be partially script.
11086113|NCT04173195|No Intervention|No intervention arm|Patients assigned to this arm will received current care.
11086114|NCT04173182||Inflammation on pCLE|Patients with inflammatory findings in the peridiverticular and colonic mucosa (crypt fusion and distortion, bright epithelium, and dilated-prominent branching vessels)
11086115|NCT04173182||No inflammation on pCLE|Patients with normal findings on pCLE evaluation of the peridiverticular and colonic mucosa (absence of inflammation)
11086116|NCT04173169|Experimental|Pre-IVF Treatment with 60 day course of oral GnRH antagonist|Subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day.
11086117|NCT04173169|Placebo Comparator|Pre-IVF Treatment with 60 day course of Placebo|Subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day.
11086118|NCT04173156|Experimental|Oscillating Chitosan Device|The brush bristles of the test device (Labrida BioClean®, LABRIDA AS, Oslo, Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed, thus not causing harm to the tissues.surrounding the tooth. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
11086119|NCT04173156|Active Comparator|Regular Curettes|Standard non surgical treatment of active periodontal disease includes supra and subgingival scaling and root planing with periodontal medical grade Gracey system steel curettes
11086120|NCT04173143|Experimental|Group 1|This group will receive Cranio cervical flexion training with pressure biofeedback protocol.
11086121|NCT04173143|Active Comparator|Group 2|This group will receive Cranio cervical flexion training without pressure biofeedback protocol
11086122|NCT04173130|Experimental|Injection of botulinum toxin with investigational device|
11086129|NCT04173065|Experimental|2.5mg|
11086132|NCT04173052|Experimental|Infertile Males|It represents the participants, all the participants in the study are infertile.
11086133|NCT04173039|Other|Controls|Patients with psoriasis and without psoriatic arthritis.
11086134|NCT04173039|Other|Cases|Patients with psoriatic arthritis and with personal or familial psoriasis.
11086135|NCT04173026|Active Comparator|Provider intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates.
11086136|NCT04173026|Active Comparator|Provider and Patient level intervention|A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.
11086137|NCT04173000|Experimental|Intervention|All adolescent/parent dyads enrolled at each practice will have access to the meHealth for ADHD software without medication continuity tools prior to being given access to the medication continuity tools.
11086138|NCT04172987|Experimental|Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)|EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)
11086139|NCT04172987|Experimental|EE/NGM + Tirzepatide (Period 2)|"EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)
~Tirzepatide administered by subcutaneous injection (SC)."
11086140|NCT04172974|Experimental|Treatment for depression and anxiety|Treatment
11086141|NCT04172974|Other|Usual care|Usual Care
11086142|NCT04172961|Experimental|Nanomicellular Cyclosporine 0.09 prior to surgery|50 subjects receive nanomicellular cyclosporien 0.09% prior to elective ophthalmic surgery
11086143|NCT04172961|Active Comparator|Lifitegrast 5.0%|50 subjects receive liftigrast 5.0% prior to elective ophthalmic surgery
11086144|NCT04172948|Experimental|Virtual reality arm|This arm will receive diaphragmatic breathing teaching by a medical professional and virtual reality module that teaches diaphragmatic breathing and practices this breathing technique in a series of 3 sessions.
11086145|NCT04172948|Placebo Comparator|Control|This arm will receive diaphragmatic breathing teaching by a medical professional only.
11086146|NCT04172935|Experimental|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal working distance as measured before intervention.
11086147|NCT04172935|No Intervention|Control Group|Will be deferred to receive spectacles as above, after the 4 weeks evaluation period.
11086148|NCT04172922|Experimental|Open label, topical sirolimus arm|Single arm, open label study of1% sirolimus ointment applied to affected area twice daily for the first four weeks followed by once daily for 5 months.
11086149|NCT04172909|Experimental|Child life group with LEGO bricks|Patients in this group will be prepped by a Certified Child Life Specialist with the use of LEGO bricks model MR
11086150|NCT04172909|No Intervention|Control group|Age matched controls will be found retrospectively, and will be patients of the same age, undergoing their first non-contrast brain MRI with no Child Life intervention.
11086151|NCT04172909|Experimental|Child life group with Mock MRI tube|Patients in this group will be prepped by a Certified Child Life Specialist with the use of a Mock MRI tube
11086152|NCT04172896|Active Comparator|Intraperitoneal Group|Vaginal intraperitoneal uterosacral ligament suspension group
11086153|NCT04172896|Active Comparator|Extraperitoneal Group|Vaginal extraperitoneal uterosacral ligament suspension group
11086154|NCT04172883|No Intervention|Control arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the standard device setting or MINERVA setting ( control arm)
11086155|NCT04172883|Active Comparator|Treatment arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the reduced sequence programming ( treatment arm)
11086156|NCT04172870||Group I|Healthy group ( No generalised periodontitis and no CAD)
11086157|NCT04172870||Group II|Generalised periodontitis patients without CAD
11086158|NCT04172870||Group III|CAD patients without generalised periodontitis
11086159|NCT04172870||Group IV|Generalised periodontitis with CAD
11086160|NCT04172844|Experimental|Pevonedistat Dose Escalation|This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
11086161|NCT04172844|Experimental|Dose Expansion Phase|Patients will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase.
11086162|NCT04172831|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
11086163|NCT04172831|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
11086164|NCT04172818|Experimental|Patients with diary|Evaluation the psychological impact of a diary on the patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives.
11086165|NCT04172805|Experimental|anlotinib combined with Toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks.
11086166|NCT04172792|Active Comparator|high-caloric fatty diet|intake of 405 kcal (45g fat) per day in addition to normal food intake
11086167|NCT04172792|Experimental|ultra-high-caloric fatty diet|intake of 810 kcal (90g fat) per day in addition to normal food intake
11086168|NCT04172792|Experimental|ultra-high-caloric carbohydrate-rich diet|intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake
11086169|NCT04172792|No Intervention|control|normal food intake (no intervention)
11086170|NCT04172779|Experimental|Erlotinib treatment|
11086171|NCT04172766|No Intervention|Basic|"Participants in the first (Basic) group will have the iOS version 13.2 or later shipping user interface (UI) that provides ability to review exposure level data for headphone audio levels and environmental sound levels in the Health app."
11086172|NCT04172766|Active Comparator|Advanced|"Participants in the second (Advanced) group will have a UI that includes notifications prompting personal data pattern review in the Health app and then prompting to do an abbreviated Pure Tone Audiometry module completed 0-24 hours after loud headphone audio level exposure (equivalent continuous average noise level, or LEQ, to >97 A-weighted decibels, or dBA for >30 minutes) to evaluate for a temporary threshold shift from baseline."
11086173|NCT04172753|Experimental|Rectal and anal cancer|In this arm patients with rectal and anal cancer are recruited.
11086174|NCT04172753|Experimental|Prostate cancer|In this arm patients with prostate cancer are recruited.
11086175|NCT04172753|Experimental|Head and neck cancer|In this arm patients with head and neck cancers are recruited.
11086176|NCT04172753|Experimental|Esophageal cancer|In this arm patients with esophageal cancer are recruited.
11086177|NCT04172753|Experimental|Breast Cancer|In this arm patients with breast cancer are recruited.
11086178|NCT04172753|Experimental|Central nervous system tutors|In this arm patients with tumors of the central nervous system are recruited.
11086179|NCT04172753|Experimental|Palliative treatments|In this arm patients with palliative treatments are recruited.
11086180|NCT04172753|Experimental|Other|In this arm patients with other tumors are recruited.
11086181|NCT04172753|Experimental|Imaging only|In this arm patients receive only imaging on the MR-Linac
11086182|NCT04172740|Experimental|Treatment|
11086183|NCT04172727|Active Comparator|ultrasound guided transversalis fascia plane block|20 mL of 0.25% bupivacaine
11086184|NCT04172727|Placebo Comparator|ultrasound guided sham block|20 mL of saline
11086185|NCT04172714|Experimental|Second mapping with low-dose Y90|Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy. Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
11086186|NCT04172701||Subjects with Chronic Obstructive Pulmonary Disease|
11086187|NCT04172688|Placebo Comparator|Placebo|Two 3.3g doses/day (12 kcal/dose) of maltodextrin
11086188|NCT04172688|Experimental|Prebiotic|Two 8g doses/day (12 kcal/dose) of oligofructose-enriched inulin
11086189|NCT04172675|Experimental|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ [CIS], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
11086190|NCT04172675|Active Comparator|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC)/hyperthermic MMC. Participants who are randomized to gemcitabine or MMC/hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
11086191|NCT04172675|Experimental|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
11086192|NCT04172675|Experimental|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
11086193|NCT04172662|Experimental|Music therapy group|Receive Music therapy in addition to standard treatment
11086194|NCT04172662|No Intervention|Control group|Receive standard treatment
11086195|NCT04172649|Experimental|Acu Arm|press tack needle acupuncture (ACU) and routine postoperative analgesic care
11086196|NCT04172649|Sham Comparator|SHAM Arm|press tack placebo acupressure (SHAM) and routine postoperative analgesic care
11086197|NCT04172649|No Intervention|CONTROL Arm|Patients in the control group will receive only routine postoperative analgesic care
11086198|NCT04172623|Experimental|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
11086199|NCT04172623|Active Comparator|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
11086200|NCT04172597|Experimental|Poziotinib|"Cohort 1: Patients that have HER2-positive or HER2-negative breast cancer with HER2 activating mutations
~Cohort 2: Patients that have colorectal cancer with HER2 activating mutations
~Cohort 3: Patients that have solid tumors (except NSCLC, breast cancer, or colorectal cancer) with HER2 activating mutations
~Cohort 4: Patients that have high-grade glioma with EGFR activating mutations
~Cohort 5:Patients that have solid tumors (except NSCLC or high-grade glioma) with EGFR activating mutations"
11086201|NCT04172571|Experimental|AK105 and anlotinib|
11086202|NCT04172558|Active Comparator|BTX100 group|ICI of Botox 100 U
11086203|NCT04172558|Active Comparator|Trimix group|ICI of Trimix
11086204|NCT04172532|Experimental|Phase I (hypofractionated radiation therapy, M3814)|Patients in Phase I undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
11086205|NCT04172532|Experimental|Phase II Group I (hypofractionated radiation therapy M3814)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
11086299|NCT04171843|Experimental|PBCAR269A at Dose Level 1|The starting dose of PBCAR269A will be 6 x 10^5 CAR T cells/kg body weight.
11086300|NCT04171843|Experimental|PBCAR269A at Dose Level 2|2 × 10^6 CAR T cells/kg body weight.
11086206|NCT04172532|Active Comparator|Phase II Group II(hypofractionated radiation therapy, placebo)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
11086207|NCT04172519|Experimental|Group A|Patients who before prostate cancer surgery will receive: psychological consultation, nursing consultation, physiotherapy consultation and intervention (4 visits which will be implemented pelvic floor muscle training). Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Then, 6 months after the surgery, there will also be a physiotherapy consultation.
11086208|NCT04172519|Experimental|Group B|Patients who will receive: psychological consultation, nursing consultation, physiotherapy consultation before prostate cancer surgery. Subsequently, patients will have the procedure performed laparoscopic radical prostatectomy, immediately after which they receive psychological consultation, nursing consultation. The physiotherapist consultation will be two weeks after the surgery, during which the physiotherapist will provide an instruction pelvic floor muscle training. Patients do the exercises themselves at home according to the instructions, 3 times a day for 3 months). Physiotherapeutic consultation 6 months after surgery.
11086209|NCT04172519|Experimental|Group C|Patients who will not receive any intervention before prostate cancer surgery. Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Physiotherapeutic consultation 6 months after surgery.
11086210|NCT04172519|No Intervention|Group D|Control group, patients after radical laparoscopic prostatectomy, without additional interventions
11086211|NCT04172506|Experimental|AK105|AK105 200 mg, every 2 weeks
11086212|NCT04172493|Experimental|Diagnostic|Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.
11086213|NCT04172480||acute HIV1 infection|Patient infected by HIV1, prior treatment initiation
11086214|NCT04172480||chronic HIV1 infection|Patient infected by HIV1, untreated or without treatment since at least 3 months
11086215|NCT04172480||HIV2 infection|Patient infected by HIV2, untreated or without treatment since at least 3 months
11086216|NCT04172454|Experimental|AK104|AK104 in subjects with advanced melanoma and other selected advanced solid tumor including PD-1/PD-L1 relapsed/refractory tumors)
11086217|NCT04172441|Experimental|dasiglucagon first then placebo|48 hours of dasiglucagon sc infusion starting at 10 µg/hr with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
11086218|NCT04172441|Experimental|placebo first then dasiglucagon|48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hr (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
11086219|NCT04172428||Healthy volunteers|Young healthy volunteers between the ages of 18-55.
11086220|NCT04172415||Retrospective cohort|Patients that received procedural sedation in a community Emergency Department.
11086221|NCT04172402|Experimental|NGS|"Eligible patients will receive Nivolumab 240mg on day 1, gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
~BSA < 1.25 m2: 80 mg/day
~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day
~BSA ≥ 1.5 m2: 120 mg/day The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
11086222|NCT04172376|Experimental|Minimally invasive puncture aspiration plus rt-PA|
11086223|NCT04172376|Active Comparator|Conservative medical treatment|
11086224|NCT04172363|No Intervention|Standard Care|Octenisept will be used as standard care antiseptic for dressing change
11086225|NCT04172363|Experimental|Resistance testing|Patients will be first tested on resistance to Octenisept and Serasept and will receive the appropriate antiseptic after reviewing the results
11086226|NCT04172350|Experimental|Intervention group: iCareBreast plus routine care|Participants in the intervention group will receive the routine care provided by the hospital (the same as the control group) plus the iCareBreast mobile app, which provides i) pre-surgery education and instructions; ii) post-surgery education, instructions, and recovery plan; iii) positive psychological support; and iv) social support. The total intervention period is 29 days (14 days before surgery, operation day, and 14 days after the surgery).
11086227|NCT04172350|Active Comparator|Control group: Routine care|Participants in the control group will only receive routine care provided by the attending Hospital. Participants being allocated to the control group may freely use the Internet to search for information regarding breast cancer but will not be granted to access the iCareBreast app.
11086228|NCT04172337|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display FOP labels on any products.
11086229|NCT04172337|Experimental|HCS-only|Arm 2 (termed HCS-only) displayed the HCS on eligible products, crossed referenced via the Health Promotion Board's HCS database (https://www.hpb.gov.sg/food-beverage/healthier-choice-symbol). Out of the 4,177 products available on NUSMart, 311 (7·45%) carried the HCS. This was comprised of 150 foods and 161 beverages.
11086230|NCT04172337|Experimental|HCS+PAE|Arm 3 displayed the HCS on eligible products as in Arm 2 and the PAE label on all products (termed HCS+PAE). PAE was calculated as the minutes required to burn off the calories of a single serving for a 73 kg person jogging at 8 km per hour.
11086231|NCT04172324|Experimental|Hibbot|
11086232|NCT04172324|Active Comparator|Standard Care|
11086233|NCT04172311|Experimental|Modified Atkins Diet|"Modified Atkins Diet administration
~Carbohydrates will be restricted to 10 grams per day.
~Recipes will be provided to be prepared from easy home available foods, to have 2.5 gram per meal. Along with this, a list of carbohydrate free foods will be provided.
~Fats intake will be actively encouraged. Protein intake will be unrestricted.
~Medications will be changed to carbohydrate free preparations.
~A multivitamin and calcium supplementation will be added."
11144059|NCT03768323|Experimental|2X incentive|2X airtime incentive
11086234|NCT04172311|Active Comparator|Levetiracetam|Levetiracetam will be started at a dose of 10 mg/kg/day in two divided doses and increased to 20 mg/kg/day after 1 week. Syrups will be used in children younger than 5 years of age, and tablets will be used in children > 5 years of age. Further dose titration will be done as per the seizure control, in 10 mg/kg/day increments in 2 weekly intervals, to a maximum of 60mg/kg/day.
11086235|NCT04172298|Placebo Comparator|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
11086236|NCT04172298|Experimental|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
11086237|NCT04172298|Experimental|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
11086238|NCT04172285|Experimental|Physical activity group|
11086239|NCT04172285|Experimental|Physical activity and supplementation group|
11086240|NCT04172285|Experimental|Control group|
11086241|NCT04172272|Active Comparator|Systemic multimodal analgesia only|"In the first group, patients will receive intravenous, systemic, multimodal analgesia: paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
11086242|NCT04172272|Experimental|TAP block only|In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacaine in 40 ml bilaterally. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
11086243|NCT04172272|Experimental|Combined TAP block with systemic multimodal analgesia|In the third group there will be patients who will be treated with TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
11086244|NCT04172259|Experimental|ACH-TH|Doxorubicin liposome（PLD）35 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Docetaxel（DOC）75 mg/m2 every 3 weeks
11086245|NCT04172259|Active Comparator|EC-TH|Epirubicin（EPI）90 mg/m2 Cyclophosphamide（CTX）600 mg/m2 Trastuzumab：first cycle 8mg/kg，then 6mg/kg Docetaxel（DOC）75 mg/m2 every 3 weeks
11086246|NCT04172246|Experimental|Zanubrutinib|
11086247|NCT04172233|Experimental|Phase I: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0 and 4 by subcutaneous injection
11086248|NCT04172233|Experimental|Phase I: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0 and 4 by subcutaneous injection
11086249|NCT04172233|Experimental|Phase I: AK101 270 mg|Biological: AK101 AK101 270 mg on Week 0 and 4 by subcutaneous injection
11086250|NCT04172233|Placebo Comparator|Phase I: Placebo|Biological: Placebo Placebo on Week 0 and 4 by subcutaneous injection
11086251|NCT04172233|Experimental|Phase II: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0, 4 and 16 by subcutaneous injection
11086252|NCT04172233|Experimental|Phase II: AK101 90 mg|Biological: AK101 AK101 90 mg on Week 0, 4 and 16 by subcutaneous injection
11086253|NCT04172233|Experimental|Phase II: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0, 4 and 16 by subcutaneous injection
11086254|NCT04172233|Placebo Comparator|Phase II: Placebo to AK101|Drug: Placebo Placebo on Week 1 and 4 by subcutaneous injection, and then AK101 on Week 12 16 by subcutaneous injection
11086255|NCT04172220|Experimental|PECS + Opioid-free GA|Loco-regional anesthesia with PEC I and serratus plane block with an echoguided technique and opioid-free general anesthesia
11086256|NCT04172220|Active Comparator|GA|General anesthesia
11086257|NCT04172207||Results of study groups.|
11086258|NCT04172194||PT Group|patients with hepatocellular carcinoma treated by percutaneous thermoablation alone
11086259|NCT04172194||PT+TAC group|patients with hepatocellular carcinoma treated by pecutaneous thermoablation comined in a single session with trans-arterial chemoembolization
11086260|NCT04172181||UCBT-SCID-Case|SCID patients who underwent cord blood stem cell transplantation.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.
11086261|NCT04172168||Heart rupture|Include left ventricular free-wall ruptrue after AMI
11086262|NCT04172168||Non heart rupture|AMI with non heart rupture
11086263|NCT04172142||Control group|Healthy individuals of similar age and sex who meet the inclusion criteria
11086264|NCT04172142||Pectus Excavatum|Individuals with pectus excavatum that meet the inclusion criteria
11086265|NCT04172142||Pectus Carinatum|Individuals with pectus excavatum that meet the inclusion criteria
11086266|NCT04172129||NANOS|NANOS™ Neck Preserving Hip Stem
11086267|NCT04172116||long pouch RYGB|Patients with the variation of a long and narrow pouch (hypothesis: slower transit of food)
11086268|NCT04172116||short pouch RYGB|Patients with the variation of a short and wide pouch (hypothesis: faster pouch emptying as compared with long and narrow pouch)
11086269|NCT04172090|Other|Control|2 consecutive days of standardised daily levels of moderate physical activity (PAL=1.85 reflecting their habitual levels), and matched energy (food) intake
11086270|NCT04172090|Experimental|SIT+E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst maintaining the level of food intake prescribed in the Control trial, thus creating a positive energy balance
11086271|NCT04172090|Experimental|SIT=E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst reducing food intake to match the reduction in energy expenditure induced by inactivity, thus maintaining energy balance
11086272|NCT04172064||377patients evaluated by MPS and DSE|
11086301|NCT04171843|Experimental|PBCAR269A at Dose Level 3|6 × 10^6 CAR T cells/kg body weight.
11086436|NCT04170985|Other|Single Cohort|All participants will receive cWGS testing revealed to the site PI/clinician at Day 180. Participants will all receive standard of care testing throughout the study.
11086273|NCT04172051|Experimental|Experimental Group|"Subjects will be admitted into the Tony Robbins event for free, or receive a voucher for an event in the future. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
11086274|NCT04172051|No Intervention|Control Group|"The control group will be asked to engage in gratitude journaling every day for a month. The control group will NOT attend the event. This exercise will take 10 minutes to complete. The subject will write down three things that went well each day and provide an explanation about why they went well. This will be written down in a journal. The subjects will follow these instructions:
~Give the event a title (e.g., co-worker complimented my work on a project)
~In the space below, write down exactly what happened in as much detail as possible, including what you did or said, and if other people were involved, what they did or said.
~Include how this event made you feel at the time and how this event made you feel later (including now, as you remember it)."
11086275|NCT04172051|Active Comparator|Motivated Experimental Group|"The Motivated Experimental Group (M Experimental) will consist of participants who registered and paid for Tony Robbins Date with Destiny (DWD). They are chosen as the motivated experimental as they will be paying full price for the event. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
11086276|NCT04172038|Experimental|Phase I: Physical Therapy (PT)|Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
11086277|NCT04172038|Experimental|Phase I: Move to Health (M2H)|"Initial Randomization: M2H is a key component of Army Medicine's System for Health, along with the Performance Triad. It is a person-centered, holistic, and experience-centric approach to promoting healthy behaviors (nutrition, physical activity, sleep, instrinsic factors, extrinsic factors). Precise dosage (i.e, number of M2H sessions) will be at the discretion of the health coaches. Sessions may be delivered in-person or utilize technology including text messaging, telephone, e-mail, video chat, app-based self-management etc."
11086278|NCT04172038|Experimental|Phase II: Combine PT & M2H|Sequential Randomization: Participants randomized to receive a combination of PT and M2H as a Phase II intervention will continue their Phase I treatment (either M2H or PT). The participant will begin the treatment component that was not part of their Phase I intervention.
11086279|NCT04172038|Experimental|Phase II: MORE Mindfulness|Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
11086280|NCT04172025||Patients with colonization or infections with a pathogen|All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data
11086281|NCT04172012|Active Comparator|Probiotic|Study subjects receive probiotic mixture for 4 weeks
11086282|NCT04172012|Placebo Comparator|Placebo|Study subjects receive placebo mixture for 4 weeks
11086283|NCT04171999|Experimental|Usual Care + Intervention (Case)|Cases will receive the CommunityRx Intervention.
11086284|NCT04171999|No Intervention|Usual Care (Control)|Controls will receive the usual standard care, which consists of information about hospital food resources and access to Feed1st hospital food pantries prior to discharge.
11086285|NCT04171986|Experimental|Test Group|
11086286|NCT04171973|Other|Driving an electric wheelchair in real condition|In order to be able to evaluate the feasibility of virtual reality driving training, the driving performance will be evaluated on the same 3 standardized circuits: for the control group, 3 circuits of test of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
11086287|NCT04171973|Experimental|Driving an electric wheelchair in virtual condition|In order to be able to evaluate the feasibility of driving training in virtual reality, the driving performance will be evaluated on the same 3 standardized circuits: for the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
11086288|NCT04171960||Acute Blood Biomarker Branch|"Blood draw within 12 hours of injury for i-STAT Testing then processing for storage for future use
~Blood draw between 12 to 24 hours of injury then processing for storage for future use
~In-Person Outcome Assessment"
11086289|NCT04171960||Acute Blood Biomarker Plus Follow-up Branch|"Blood draw at 2 weeks and 6 months following injury then processing for storage for future use
~In-Person Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury
~Phone Outcome Assessment at 3 months following injury
~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury"
11086290|NCT04171947|Experimental|Matuzalem|Tea extract vaginal ovule daily for 7 consecutive days
11086291|NCT04171947|Sham Comparator|Vehicle|Polyethylene glycol vaginal ovule daily for 7 consecutive days
11086292|NCT04171921|Active Comparator|Robotic ventral hernia repair|
11086293|NCT04171921|Active Comparator|Open ventral hernia repair|
11086294|NCT04171908|Active Comparator|Conventional therapy|Conventional Physical therapy for the upper limb
11086295|NCT04171908|Experimental|Leap motion plus conventional therapy|Conventional Physical therapy for the upper limb plue Leap motion
11086296|NCT04171895||informal cancer caregivers (IC)|
11086297|NCT04171856|Experimental|Motor Skill Learning (CIRCUIT)|Intervention: training on the REAplan robot with a serious game based on motor skill learning (MSkL) serious game, the CIRCUIT.
11086298|NCT04171856|Active Comparator|Motor control recovery (EASY)|Training on the REAplan robot with a serious game that requires similar type and amount of movements but does not rely on motor skill learning (EASY), a brick buster game.
11086944|NCT04167397|Experimental|Dyad training|Initial training in groups of 2
11086302|NCT04171817|No Intervention|Control|Dog-handler teams will follow established hospital and therapy dog program guidelines for infection control with no changes for eight sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
11086303|NCT04171817|Experimental|CHX Intervention A|"Dog-handler teams will follow a modified protocol for infection control, with Treatment A first for four sessions, and cross-over to Treatment B for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
~Treatment A consists of a pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine) within 24 hours prior to the session, and wiping with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival at the session and every 20 minutes during the session, or between participants if the flow of participants is structured in a way that allows this (such as visits from one room to the next to visit individual patients)."
11086304|NCT04171817|Experimental|CHX Intervention B|"Dog-handler teams will follow a modified protocol for infection control, with Treatment B first for four sessions, and cross-over to Treatment A for four sessions. Participants enrolled in the session will derive their Arm assignment from the dog-handler team with which they interact.
~Treatment B will consist of the same pre-session shampoo with a commercial veterinary chlorhexidine-based product (2-4% chlorhexidine), with a single wipe with a chlorhexidine-impregnated cloth (2-4% chlorhexidine) at arrival. This treatment will depend on the residual activity of chlorhexidine throughout the visit."
11086305|NCT04171804|Active Comparator|Active|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
11086306|NCT04171804|Sham Comparator|Sham|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
11086307|NCT04171791|Experimental|ABT-199 (Venetoclax)|Patients with Cutaneous T Cell Lymphoma (CTCL) will receive ABT-199 (Venetoclax).
11086308|NCT04171778|Experimental|Intervention|Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
11086309|NCT04171778|Other|Wait List Control|Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.
11086310|NCT04171765|Placebo Comparator|Fixed Dose: Placebo|Participants will receive a fixed dose of placebo matched to BFKB8488A.
11086311|NCT04171765|Placebo Comparator|Individualized Dose: Placebo|Participants will received a dose of placebo matched to BFKB8488A.
11086312|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose A|Participants will receive BFKB8488A.
11086313|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose B|Participants will receive BFKB8488A.
11086314|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose C|Participants will receive BFKB8488A.
11086315|NCT04171765|Experimental|Individualized Dose: BFKB8488A|Participants will receive increasing doses of BFKB8488A up to the highest tolerated dose .
11086316|NCT04171752|Experimental|Young Adults|Single oral dose of elafibranor 120mg
11086317|NCT04171752|Experimental|Elderly|Single oral dose of elafibranor 120mg
11086318|NCT04171739|Other|Cohort A|Itraconazole DDI
11086319|NCT04171739|Other|Cohort B|Rifampicin DDI
11086320|NCT04171726|Experimental|Edoxaban|
11086321|NCT04171713|Experimental|Grup 1|MBHP protocol + TAU
11086322|NCT04171713|Experimental|Grup 2|ABCT protocol + TAU
11086323|NCT04171713|Active Comparator|Grup 3|TAU
11086324|NCT04171700|Experimental|Rucaparib|"Eligible patients will be enrolled in either Cohort A or Cohort B.
~Cohort A: Up to 200 patients with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.
~Cohort B (Exploratory): Up to 20 patients with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B."
11086325|NCT04171687|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
11086326|NCT04171687|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days
11086327|NCT04171687|Experimental|Clopidogrel 75 mg + RAPA113|Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days
11086328|NCT04171674|Experimental|Patients treated with high-dose ceftobiprole|
11086329|NCT04171661|Experimental|SASS|SASS applied on chronic skin wounds as skin graft
11086330|NCT04171648|Experimental|Roasted Peanut Group 1|Arm 1 is the arm of participants that will receive the roasted peanut treatment first and then will crossover to the boiled peanut treatment.
11086331|NCT04171648|Experimental|Boiled Peanut Group 1|Arm 2 is the arm of participants that will receive the boiled peanut treatment first then will crossover to the roasted peanut treatment.
11086332|NCT04171635||Patients with transfusional iron overload|The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).
11086333|NCT04171635||Healthy subjects|Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI
11086334|NCT04171622|Experimental|Treatment (pembrolizumab, lenvatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib PO on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11086335|NCT04171609|Experimental|Cancer survivors|Adult survivors of any kind of cancer (except for minor skin cancer) are eligible to participate
11086336|NCT04171596|Experimental|Primary care coordination|
11086337|NCT04171583||mucoid S. aureus|CF patients with mucoid S. aureus
11086338|NCT04171583||non-mucoid S. aureus|CF patients with non-mucoid S. aureus
11086339|NCT04171570|Other|Distal Transradial Access|Distal Transradial Access
11086340|NCT04171570|Other|Conventional Transradial Access|Conventional Transradial Access
11086397|NCT04171206|Experimental|Free From Abuse|This is a brief internet-delivered intervention designed to boost participants' ability to recognise abusive behaviour, reduce acceptance of myths related to domestic violence and IPV, as well as decrease abuse perpetration and victimisation.
11086341|NCT04171557||Patients with diabetes at the baseline assessement in EPIC|Self-reported and confirmed diabetes (validated by a second source (at least 1), including repeated self-report, contact with physician, linkage to register later point, intake of diabetes medicine, registration of diabetic chiropody, baseline glycated hemoglobin>=6.0%, five annual blood glucose measurements or two blood glucose measurements per year for five consecutive years) cases were included in the analyses. No information is available to distinguish between type 1 and type 2 diabetes across the population but type 1 is rare by comparison.
11086342|NCT04171531|Active Comparator|Botox A® injection|A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
11086343|NCT04171531|Active Comparator|Mid-urethral sling|Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
11086344|NCT04171518||Catalys Precision Laser System|Cataract Surgery with use of Catalys Precision Laser System
11086345|NCT04171505||vaccinated women|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.
~Women who sign informed consent.
~Patients with negative results in the first post-surgery control.
~Patients who have received HPV vaccination and provide vaccination card."
11086346|NCT04171505||non vaccinated woman|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.
~Women who sign informed consent.
~Patients with negative results in the first post-surgery control.
~Patients who have NOT received HPV vaccination and provide vaccination card."
11086347|NCT04171492||Open Label|Nodify XL2 results will be reported to the investigator and available to the subject.
11086348|NCT04171492||Blinded|Nodify XL2 results will not be available to the investigative site or subject.
11086349|NCT04171479||Manual|Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.
11086350|NCT04171479||Remote Magnetic Navigation|Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.
11086351|NCT04171466|Active Comparator|Broad Spectrum Antibiotic Therapy + Microbial Consortia|
11086352|NCT04171466|Placebo Comparator|Broad Spectrum Antibiotic Therapy + Placebo|
11086353|NCT04171466|Active Comparator|No Antibiotic Therapy + Microbial Consortia|
11086354|NCT04171466|Placebo Comparator|No Antibiotic Therapy + Placebo|
11086355|NCT04171453||Open-label|This study was open-label with only one treatment group. Lyrica CR was prescribed in accordance with usual clinical practice.
11086356|NCT04171440|Experimental|Cohort A-minimally invasive pancreaticoduodenectomy|Patients randomized to Cohort A will undergo pancreaticoduodenectomy through small incisions with state-of-the-art robotic-assisted technology or endoscopic techniques.
11086357|NCT04171440|Active Comparator|Cohort B-open pancreaticoduodenectomy|Patients randomized to this arm will undergo open pancreaticoduodenectomy.
11086358|NCT04171427|Other|Lithium liposome and placebo A|• Group A : 4 patients; Lithium liposome 1 application / day (evening) on target lesions on one side of the body, placebo 1 application / day (evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
11086359|NCT04171427|Other|Lithium liposome and placebo B|Group B : 4 patients; Liposomal Lithium 2 applications / day (morning and evening) on target lesions on one side of the body, placebo 2 applications / day (morning and evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
11086360|NCT04171427|Other|Lithium liposome and placebo C|Groupe C : 4 patients; Lithium liposome 2 applications / day (morning and evening) on one side, placebo 2 applications / day (morning and evening) on contralateral target lesions.
11086361|NCT04171414|Experimental|"CT-P17 SC AI (adalimumab)"|
11086362|NCT04171401||Participants post stroke|Severly affected patients in the subacute phase post stroke that are unable to walk without the help of one or two therapists to assist for balance and weight-carrying. Participants were able to sit independently for two minutes. Participants post stroke performed limits of stability testing in sitting, and tests for trunk control and functional balance.
11086363|NCT04171401||Healthy controls|Healthy control subjects who matched patients post stroke for age and gender, and had no limitations to perform measurements. Healthy controls performed limits of stability measurements and a clinical measurements for balance.
11086364|NCT04171388|Placebo Comparator|Routine care: Placebo|"In all pregnancies presenting at all centers, routine antenatal care will be strengthened:
~Provision of iron-folic acid and tetanus toxoid vaccine
~Screening for anemia and blood pressure
~Screening/treatment of HIV, syphilis, malaria, tuberculosis
~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
11086365|NCT04171388|Experimental|Routine care: Azithromycin|Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later.
11086366|NCT04171388|Experimental|Routine care: Enhanced Infection Management Package (EIMP)|At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrhea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment.
11086367|NCT04171388|Experimental|Enhanced Nutrition Package (ENP): Placebo|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.
~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
11086368|NCT04171388|Experimental|ENP: Azithromycin|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.
~Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
11086398|NCT04171206|Placebo Comparator|Technology and crime|This is a brief internet-delivered placebo intervention designed to inform participants about how the development of technology could affect crime.
11086437|NCT04170972|Experimental|Exercise and vivo insulin stimulation in TBC1D4 gene-variants|Acute exercise and in vivo insulin stimulation in homozygote carriers of a p.ARg684T TBC1D4 gene-variant.
11086369|NCT04171388|Experimental|ENP: EIMP|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.
~At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrohea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment."
11086370|NCT04171375|Experimental|trans-spinal Electrical Stimulation (tsES)|
11086371|NCT04171362|Experimental|Migraine group|The study included patients diagnosed by migraine according to International Headache Community criteria with18-65 years of age followed by routine controls and who were volunteered
11086372|NCT04171362|Active Comparator|Control group|The study included patients diagnosed by migraine according to International Headache Community criteria with 8-65 years of age followed by routine controls and were volunteered
11086373|NCT04171349|Active Comparator|Group A|Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
11086374|NCT04171349|Experimental|Group AD|Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).
11086375|NCT04171336|Experimental|Animal-assisted group therapy|
11086376|NCT04171323|Experimental|CTa|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
11086377|NCT04171323|Experimental|CTab|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
11086378|NCT04171323|Experimental|CTac|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
11086379|NCT04171323|Experimental|CTabc|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
11086380|NCT04171323|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
11086381|NCT04171310|Experimental|SAR442168|Single oral dose of SAR442168 (as a nonsalified compound) containing (NMT) 3.7 MBq of [14C]-SAR442168
11086382|NCT04171284|Experimental|SCT-I10A plus Docetaxel|SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
11086383|NCT04171284|Active Comparator|Placebo puls docetaxel|Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
11086384|NCT04171284|Experimental|Maintenance therapy of SCT-I10A|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
11086385|NCT04171284|Placebo Comparator|Maintenance therapy of Placebo|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
11086386|NCT04171271|Experimental|Activating kinesthetic motor imagery training|
11086387|NCT04171271|Active Comparator|Relaxing kinesthetic motor imagery training|
11086388|NCT04171271|No Intervention|Control (no specific intervention)|
11086389|NCT04171258|Experimental|Botulax®|
11086390|NCT04171258|Active Comparator|Botox®|
11086391|NCT04171245|Experimental|Experimental|One minute laughter prescription 3x a day Tracking sleep using equipment
11086392|NCT04171245|Active Comparator|Control|Tracking sleep using equipment
11086393|NCT04171232|Active Comparator|Balance It (Group 1)|Children with spastic hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Balance It group. Each subject in first group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
11086394|NCT04171232|Active Comparator|Bubble Pop (Group 2)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Bubble Pop group. Each subject in second group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
11086395|NCT04171232|Active Comparator|Scoop'd (Group 3)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Scoop'd group. Each subject in third group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance
11086396|NCT04171219|Experimental|Treatment (talabostat, pembrolizumab)|Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11146889|NCT03749057|Other|rivaroxaban|15-20 mg rivaroxaban daily
11086399|NCT04171193|Experimental|ISO|Patients not taking oral medications for depression. They will receive the study intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes.
11086400|NCT04171193|Experimental|ISOAD|Patients in treatment with oral medications for depression, will receive intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes
11086401|NCT04171193|Experimental|ISOPOT|Patients that where from ISO arm, that did not respond to intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes They will now, start taking sertraline as oral medication for depression to asset the enhancement of oral treatment after Isoflurane challenge.
11086402|NCT04171180|Active Comparator|Controlled group|Controlled group: budesonide/formoterol(SYM) 160/4.5ug 1 inhalation bid* 3 months (n=250).
11086403|NCT04171180|Experimental|Study group|Study group: SYM 160/4.5ug 2 inhalation bid* 3 months (n=250).
11086404|NCT04171167|Active Comparator|Frequently treated acute rhino sinusitis|Does not meet the European position paper criteria of CRS: asymptomatic periods in between and no objective findings when entering the study.
11086405|NCT04171167|Active Comparator|CRSsNP|Meets the European position paper criteria of CRS. Zinreich modification of Lund-Mackey scoringing: Opacification score < 21 and obstruction score 0-8. No visible nasal polyps in endoscopy
11086406|NCT04171167|Active Comparator|Severe CRSsNP and CRSwNP|Meets the European position paper criteria of CRS and not included in the first two groups.
11086407|NCT04171167|No Intervention|Healthy volunteers|No nasal symptoms or complaints. No interventions done.
11086408|NCT04171154|Experimental|Expectation|Participants are asked to think of three strength which have helped them in prior stressful events. They then have to think of ways how these strength may help them in future stressful situations, i.e. a test in this experiment.
11086409|NCT04171154|Experimental|Acceptance|Participants listen to an audio-instruction on cognitive defusion. They shall observe the thoughts and feelings of stress and, with the help of the instruction, distance themselves from it.
11086410|NCT04171154|No Intervention|Control|Participants wait for the stress-test to start.
11086411|NCT04171141|Experimental|Dose Escalation|Single Agent Dose Escalation
11086412|NCT04171141|Experimental|Dose Finding Anti-PD-1 Combination|Part 1B PF-07062119 plus anti-PD-1
11086413|NCT04171141|Experimental|Dose Finding anti-VEGF Combination|Part 1B PF-07062119 plus anti-VEGF
11086414|NCT04171141|Experimental|Dose Expansion Arm A|PF-07062119 as a Single Agent in CRC
11086415|NCT04171141|Experimental|Dose Expansion Arm B|PF-07062119 in Combination with anti-PD-1 in CRC
11086416|NCT04171141|Experimental|Dose Expansion Arm C|PF-07062119 in Combination with anti-VEGF in CRC
11086417|NCT04171141|Experimental|Dose Expansion Arm D|PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
11086418|NCT04171115|Experimental|10mg of G03-52-01|8 subjects randomized to 10 mg of G03-52-01 and 2 subjects randomized to placebo
11086419|NCT04171115|Experimental|25mg of G03-52-01|8 subjects randomized to 25 mg of G03-52-01 and 2 subjects randomized to placebo
11086420|NCT04171115|Experimental|50 mg of G03-52-01|8 subjects randomized to 50 mg of G03-52-01 and 2 subjects randomized to placebo
11086421|NCT04171102|Active Comparator|Short term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-5 weeks post implantation
11086422|NCT04171102|Active Comparator|Mid term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-4 months post implantation
11086423|NCT04171102|Active Comparator|Long term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 6-8 months post implantation
11086424|NCT04171089|Experimental|Child-Safety Plan Intervention|A Child Safety Plan to prevent suicidal behavior will be developed with the children and their parents. The parents and child will complete feasibility and acceptability questionnaires.
11086425|NCT04171076|Experimental|Intervention|Intervention: non-invasive spinal cord stimulation
11086426|NCT04171063|Other|Bracing arm|Patients that will be using the thoracic compressor
11086427|NCT04171050|Active Comparator|Group 1: Local Anesthesia|Standard of care with local anesthesia used during surgery
11086428|NCT04171050|Active Comparator|Group 2: Local Anesthesia plus Pudendal Nerve Block|Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery
11086429|NCT04171037|Experimental|Arm I (oxygen via Optiflow THRIVE)|Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes prior to anesthetic induction and at a higher flow rate until the end of procedure.
11086430|NCT04171037|Active Comparator|Arm II (oxygen via non-rebreather mask)|Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3 minutes prior to anesthetic induction and maintain the same flow rate until the end of procedure.
11086431|NCT04171024|Sham Comparator|Sham Group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.
~Transcutaneous electrical stimulation settings: Frequency (2 hertz); wave length (300 µs);"
11086432|NCT04171024|Experimental|Transcutaneous diaphragm electrical stimulation group|"Two channels with two electrodes each were placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two channels with two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space.
~Transcutaneous electrical stimulation settings: Frequency (35 hertz); wave length (300 µs); Intensity to achieve a visual contraction"
11086433|NCT04171011|Experimental|Nerve Stimulation|Participants will undergo brief NVB stimulation during the esophagectomy procedure.
11086434|NCT04170998|Experimental|Evogliptin 5mg group|Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
11086435|NCT04170998|Placebo Comparator|Evogliptin Placebo group|Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
11086438|NCT04170972|Experimental|Exercise and vivo insulin stimulation in matched controls|Acute exercise and in vivo stimulation in none carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant.
11086439|NCT04170959|No Intervention|A: Observational arm|Radiotherapy as per standard of care without metformin, no additional biomarkers/imaging will be performed
11086440|NCT04170959|Other|B: Control arm|Radiotherapy as per standard of care without metformin, with additional biomarkers/imaging
11086441|NCT04170959|Active Comparator|C: Interventional arm|Radiotherapy as per standard of care with metformin, with additional biomarkers/imaging
11086442|NCT04170946|Experimental|Talazoparib in Combination with Low Dose RT|Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of RT (until day 20-23). Patient will start low dose RT on day 6-9, and will continue for 10 fractions throughout 2 weeks. Talazoparib dose levels will start at 0.5mg daily and increase to 1mg if dose limiting toxicites are not observed. Toxicities include renal impairment and other treatment related toxicities Grade ≥3. Patients will be monitored weekly during study treatment, and followed up at 3 weeks, and every 3 months after for 1 year.
11086443|NCT04170933|Experimental|Magnetic recanalization|The subjects in this group will be treated by magnetic recanalization
11086444|NCT04170920|Experimental|Mobile Health Application Intervention|"LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
11086445|NCT04170907|Other|Nicotine salt 20 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 20 mg/mL.
11086446|NCT04170907|Other|Nicotine salt 40 mg/mL|Vaping of nicotine salt e-liquids with a nicotine concentration of 40 mg/mL.
11086447|NCT04170907|Other|Free-base nicotine 20 mg/mL|Vaping of free-base nicotine e-liquids with a nicotine concentration of 20 mg/mL.
11086448|NCT04170894|Experimental|Apnea|Patients will undergo an atrial fibrillation ablation and will have induced periods of apnea throughout the procedure.
11086449|NCT04170894|Active Comparator|Control|Patients who choose not to participate in the apnea arm will have the opportunity to consent to the control arm. These patients will undergo an atrial fibrillation ablation per standard of care without periods of apnea throughout the procedure. This data will be collected to use as a comparator to the apnea arm.
11086450|NCT04170881||CHILDREN|Children from involved daycares (Paris region)
11086451|NCT04170881||WORKERS|workers in involved daycares (Paris region)
11086452|NCT04170868|Other|Video 1|Ten-day exposure to one of two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
11086453|NCT04170868|No Intervention|Video 1 Washout|Ten-day washout period between access to the first and second videos.
11086454|NCT04170868|Other|Video 2|Ten-day exposure to the second of the two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
11086455|NCT04170855|Other|Furosemide Injection|"Patients with diuretic resistance:
~The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). Fluid overload is defined as the presence of at least two of the following clinical features:
~Peripheral or sacral oedema
~Jugular venous distension ≥ 7 cm
~Radiographic pulmonary oedema or pleural effusion
~Enlarged liver or ascites
~Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea
~Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration"
11086456|NCT04170842|Experimental|Music intervention|"The music intervention used in the study will be a patient selected list of songs or other music delivered to the participant by passive listening via in-ear or on-ear headphones. They will be given the choice of using their own personal headphones or use a pair provided by the hospital. If choosing to use a hospital device, the earphones provided will be disposable to minimise infection risk from re-use.
~Patient preferred music has shown to be more effective than preselected, or prescriptive music. Prescriptive music, if not of the patient's preference, could cause further discomfort, distress or anxiety. Therefore, investigators will use streaming services to provide a bank of music containing a wide range of music and genres to suit the majority of music preferences. Music will also be curated based on feedback from age-appropriate sources to identify common and popular music in the target participant age group."
11086457|NCT04170842|No Intervention|Control|Wound dressing procedure conducted according to clinical practice
11086458|NCT04170829|Experimental|Group 1 (n=6)|will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
11086459|NCT04170829|Experimental|Group 2 (n=9)|will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
11086460|NCT04170829|Experimental|Group 3 (n=9)|will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
11086461|NCT04170816|Active Comparator|DN plus KT group|"DN plus KT therapy is going to be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy is going to be applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
~Kinesio Taping Application: Tapes is going to be left on the patient's body for 5 days."
11086462|NCT04170816|Active Comparator|DN group|DN will be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy was applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
11086491|NCT04170543|Experimental|Group 3|MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
11086492|NCT04170543|Experimental|Group 4|MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
11086493|NCT04170543|Placebo Comparator|Group 5|Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
11086494|NCT04170530|Experimental|mFOLFOXIRI|patients received FOLFOXIRI alone for 6 cycles before surgery.
11086495|NCT04170504|Experimental|Qing Re Huo Xue (QRHX) plus methotrexate (MTX)|QRHX XXmg bid and methotrexate (MTX) 10 mg once a week for 24 weeks
11086496|NCT04170504|Active Comparator|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)
11086463|NCT04170803|Experimental|True Dry Needling|"Active duty DoD beneficiaries, with shoulder pain will be recruited from Army Medical Department Center and School (AMEDDC&S) and the Brooke Army Medical Center (BAMC) Outpatient Physical Therapy Clinic who meet inclusion and exclusion criteria. The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the infraspinatus muscle using FDA approved (FDA regulation # 880.5580) disposable 0.25 x 40 mm stainless steel Seirin J-type needles (Seirin, Japan). Each shoulder will undergo this treatment. Each needle insertion will last approximately 2-3 seconds using the sparrow pecking (in and out) technique to the depth of the scapula at 3 locations in the infraspinatus muscle on the affected (painful) side. When detectable, the needle insertion will specifically target palpably painful and/or taut bands of tissue. Immediately after use, all needles will be disposed of in approved sharps containers."
11086464|NCT04170803|Sham Comparator|Sham Dry Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a blunted instrument in a needling guide tube against the skin. The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in previous studies performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants..
11086465|NCT04170790|Experimental|Healthy volunteer|Day 1: Sildenafil 50 mg single dose Day 2-Day 8: Washout period Day 9-12: Saxagliptin 5 mg Once/day Day 13: Sildenafil 50 mg+ Saxagliptin 5 mg
11086466|NCT04170777||Arm A|The CBCT imaging involved for Arm A is considered part of the study treatment. Pre and post treatment images will be acquired of the patient treated on Perfexion Gamma Knife using the 'Leksell Coordinate Frame'.
11086467|NCT04170777||Arm B|Arm B will be undergoing standard treatment on Gamma Knife Perfexion for Stereotactic Radiosurgery using the 'relocatable mask'. Patients with lesions that are >3 cm at the largest diameter will be treated with the relocatable mask for which a hypo fractionated approach may be beneficial.
11086468|NCT04170751|Experimental|group N|In group N, 16 mcg / cc of norepinephrine was infused to patients.
11086469|NCT04170751|Experimental|group V|In group V, 0.4 unit / cc of vasopressin was infused to patients.
11086470|NCT04170738|Experimental|Adderall|dosage = start at 0.25-0.50mg/kg, adjusted as necessary pills by mouth
11086471|NCT04170725|Experimental|Patients and Healthy volunteers|Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
11086472|NCT04170712||Surgical or High Risk|Patients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer.
11086473|NCT04170699|Experimental|PECS 1 Block|40 patients who had PECS 1 block for peroperative analgesia in port-a-cath replacement. All patients will receive IV Midazolam (0.05mg/kg) premedication. Standard monitorization of EKG, non- invasive blood pressure and pulseoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the intervention and in the supine positon the PECS 1 block will be done. 10 % povidone - iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done as a single injection of local anaesthetic between pectoralis major and pectoralis minor muscles at the level of the 3rd rib to anaesthetise the lateral and medial pectoral nerves. The USG probe will be replaced inferior to the clavicle. Identify the pectoralis muscles with the axillary artery and axillary vein on sonography. The brachial plexus should be visible underneath. After confirmation with 20 mL %0.25 bupivacaine will be administered.
11086474|NCT04170699|Experimental|Infiltrative Anesthesia|40 patients who had port-cath replacement will receive infiltrative anesthesia.
11086475|NCT04170686|Experimental|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
11086476|NCT04170686|No Intervention|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
11086477|NCT04170634||Patients with bone metastases at risk of fracture|Adult patients with tumor osteolytic bone lesions located in proximal femur and/or vertebrae secondary to a myeloma or a breast, lung (NSCL: Non-Small Cell Lung), bladder, thyroid or kidney cancer. The target vertebrae or femur has to be naïve of localized treatment (interventional radiology - cementoplasty, cryotherapy, radiofrequency…). Previous exposure to systemic oncological treatments (chemotherapy, targeted therapy, immunotherapy…) and bone treatments are allowed if administered for less than 3 months.
11086478|NCT04170621|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
11086479|NCT04170608|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
11086480|NCT04170595|Experimental|GB221,2mg/kg|Coprelotamab Injection, 2 mg/kg, Single dose,
11086481|NCT04170595|Experimental|GB221,6mg/kg|Coprelotamab Injection, 6 mg/kg, Single dose,
11086482|NCT04170595|Active Comparator|Herceptin,6mg/kg|Trastuzumab Injection, 6 mg/kg, Single dose,
11086483|NCT04170595|Experimental|GB221,8mg/kg|Coprelotamab Injection, 8 mg/kg, Single dose,
11086484|NCT04170595|Experimental|GB221+ Capecitabine|Multiple dose groups
11086485|NCT04170595|Active Comparator|Herceptin+Capecitabine|Multiple dose groups
11086486|NCT04170569|Experimental|Experimental Group|Yoga program was applied.
11086487|NCT04170569|No Intervention|Control Group|No yoga program.
11086488|NCT04170556|Experimental|Regorafenib plus Nivolumab|Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8, regorafenib will be continued in combination with nivolumab, until symptomatic tumor progression, unacceptable adverse events, patient decision or death
11086489|NCT04170543|Experimental|Group 1|MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
11086490|NCT04170543|Experimental|Group 2|MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
11086497|NCT04170491|No Intervention|control|The standard medical care (Control) group will receive sequential portable EEGs, performed according to clinical demand. These patients usually have 2 recordings of 20-30 minutes each within 24 or 48 hours. The studies include baseline recoding and recording after auditory, tactile and nociceptive stimulation. The EEGs will be visually reviewed and reported within 4 hours after the recording completion by a Consultant Clinical Neurophysiologist or other doctor with equivalent qualifications.
11086498|NCT04170491|Experimental|cEEG|The treatment (cEEG) group will have cEEG applied within 12 hours of RSE diagnosis, which will continue until 24 hours after cessation of clinical and electrical seizure activity. Reactivity testing with auditory, tactile and nociceptive stimulation will be repeated at least once daily. The cEEG will be visually interpreted twice daily by a Consultant Clinical Neurophysiologist and the results will be communicated within two hours of their completion to the treating clinical team.
11086499|NCT04170465|Experimental|Metformin group|Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
11086500|NCT04170465|Active Comparator|Control group|Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)
11086501|NCT04170452||Chronic Hepatitis Delta patients|Patients infected with delta virus
11086502|NCT04170439|Other|clomiphene plus N acetyle cysteine|Women who will receive clomiphene citrate plus n acetyle cysteine
11086503|NCT04170439|Other|clomiphene plus chromium|Women who will receive clomiphene plus chromium
11086504|NCT04170439|Other|clomiphen citrate|Women who will receive clomiphene
11086505|NCT04170426|Experimental|Phase 1 ARM 0|9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
11086506|NCT04170426|Active Comparator|Phase 2 ARM 1|30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
11086507|NCT04170426|Placebo Comparator|Phase 2 ARM 2|15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
11086508|NCT04170413||CeVUS Urodynamic|patients undergoing urodynamic study with CeVUS
11086509|NCT04170387|Experimental|Relaxometer fibromyalgia cases|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
11086510|NCT04170387|Active Comparator|Relaxometer controls|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
11086511|NCT04170374||Patients who initiated HIV treatment|
11086512|NCT04170374||Service providers at study facilities|
11086513|NCT04170361|Active Comparator|Control Group|Patients will be admitted to chest physiotherapy program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization.
11086514|NCT04170361|Experimental|Training Group|In addition to conventional chest physiotherapy program, patients in this group will also be taught to use Triflo ® and apply at two-hour intervals.
11086515|NCT04170348|Experimental|Daily oral vitamin D3|Oral vitamin D3, 3,333 IU
11086516|NCT04170348|Active Comparator|Monthly bolus oral vitamin D3|Bolus oral vitamin D3, 100,000 IU
11086517|NCT04170335||Bariatric surgery group|Women older than age 40 and younger than age 74 undergoing primary bariatric surgery and having a BMI of ≥35 will be enrolled in this study. Pre operative and postoperative mammograms, inflammatory markers and breast cancer risk scores will be compared.
11086518|NCT04170322|Experimental|thin pvc gasrtric calibration tube|thin pvc gastric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy.
11086519|NCT04170322|Active Comparator|thick silicone gastric calibration tube|thick silicone gastrric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy
11086520|NCT04170309||With medical condition of interest|"Participants treated with ceftobiprole with at least one of the following conditions:
~Renal Insufficiency
~Hepatic Insufficiency
~Immunosuppression"
11086521|NCT04170309||Without medical condition of interest|"Patients treated with ceftobiprole without any of the following conditions:
~Renal Insufficiency
~Hepatic Insufficiency
~Immunosuppression"
11086522|NCT04170296|Experimental|Cohort 1: Posterolateral Thigh|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
11086523|NCT04170296|Experimental|Cohort 2: Buttocks|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
11086524|NCT04170283|Experimental|Zanubrutinib (BGB-3111)|All participants to receive open-label zanubrutinib
11086525|NCT04170283|Experimental|Zanubrutinib in combination with Tislelizumab|Participants to receive the combination as in the parent study (Australia Only)
11086526|NCT04170270|Experimental|oral omeprazole|oral omeprazole in bleeding peptic ulcer after endoscopic therapy 40 mg twice daily for 72 hours
11086527|NCT04170270|Active Comparator|intravenous omeprazole|intravenous omeprazole in bleeding peptic ulcer after endoscopic therapy as continuous infusion at rate of 8 mg/hour for 72 hours
11086528|NCT04170257|Experimental|Opportunistic screening cohort|This opportunistic screening cohort is constructed among patients aged 45-69 years who undergo endoscopic examinations at the endoscopy center in any of the five hospitals included in this study. Enrolled participants are requested to complete a computer aided one-on-one questionnaire regarding demographic factors, smoking and alcohol drinking status, dietary habits，digestive tract symptoms and family history of ESCC. Then experienced endoscopists will perform the upper gastrointestinal endoscopic examination for each participant, and the entire esophagus will be visually examined with the white light, NBI and iodine staining endoscopic examination.
11086529|NCT04170244||Atopic Dermatitis|
11086530|NCT04170244||Healthy control|
11086531|NCT04170244||Psoriasis|
11086532|NCT04170192||UCBT-IBD-Case|Very early onset IBD patients who underwent Cord Blood Stem Cell Transplantation.
11086533|NCT04170179|Experimental|Systemic chemotherapy plus lenvatinib and toripalimab|Systemic chemotherapy of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
11086534|NCT04170166|Active Comparator|Anterolateral Approach|The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach
11086535|NCT04170166|Active Comparator|Posterior Approach|The randomised group of patients receiving the subacromial steroid injection via a posterior approach
11086536|NCT04170153|Experimental|Part A1: Monotherapy Dose Escalation|Participants will receive M1774 once daily under fasting condition.
11086537|NCT04170153|Experimental|Part A2 - Preliminary Food Effect Assessment|Participants in the food effect assessment will receive M1774 at the dose and schedule determined as recommended dose for expansion (RDE) in Part A1. A single dose of M1774 will be administered on Day -7 under a fed (high-fat meal) or fasted condition, followed by a 1-week washout period.
11086538|NCT04170153|Experimental|Part A3 - Monotherapy Expansion|After completion of the scheduled food effect assessments, participants will follow the same schedule as participants in Part A1. Participants will be administered M1774 at a dose and schedule determined as RDE in Part A1.
11086539|NCT04170140||Prescribers of Dengvaxia|Healthcare professionals who are current or past prescribers of Dengvaxia
11086540|NCT04170127|Experimental|Right side of the maxilla|the right side of the maxilla
11086541|NCT04170127|No Intervention|Left side of the maxilla|left side of the maxilla
11086542|NCT04170114|Experimental|Cystic Fibrosis|Children with cystic fibrosis
11086543|NCT04170114|Experimental|Bronchiectasis|Children with bronchiectasis
11086544|NCT04170101|Experimental|a continuous deep NMB (group A)|after 0,6 mg/kg LBW Rocuronium for intubation Rocuronium is given in a continuous infusion starting at 1 mg/kg/h and adapted to keep PTC below 5 and note.
11086545|NCT04170101|Placebo Comparator|non deep NMB (group B)|after 0,6 mg/kg LBW Rocuronium for intubation no extra NMB is given and depth is measured by TOF/PTC to note depth.
11086546|NCT04170088|Experimental|Tranexamic acid|"Left side of face of each participant was selected for intradermal Tranexamic acid injections.
~generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months"
11086547|NCT04170088|Experimental|0.9% Normal saline|Right side of face of each participant was selected for intradermal normal saline injections generic name : Normal Saline Dose : 0.9 % Normal Saline Dose : Frequency : every 2 weekly total 6 doses. Duration : 6 months
11086548|NCT04170075|No Intervention|Usual Care (UC)|Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
11086549|NCT04170075|Experimental|Whole body vibration (WBV)|Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
11086550|NCT04170062|Experimental|Baseline followed by intervention 1a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
11086551|NCT04170062|Experimental|Baseline followed by intervention 1b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
11086552|NCT04170062|Experimental|Baseline followed by intervention 1c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
11086553|NCT04170062|Experimental|Baseline followed by intervention 1d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
11086554|NCT04170062|Experimental|Baseline followed by intervention 1e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
11086555|NCT04170062|Experimental|Baseline followed by intervention 1f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
11086556|NCT04170062|Experimental|Baseline followed by intervention 2a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
11086557|NCT04170062|Experimental|Baseline followed by intervention 2b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
11086621|NCT04169685||without dexmedetomidine|Drugs provided moderate sedation during procedure without dexmedetomidine
11086945|NCT04167397|Experimental|Triad training|Initial training in groups of 3
11086558|NCT04170062|Experimental|Baseline followed by intervention 2c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
11086559|NCT04170062|Experimental|Baseline followed by intervention 2d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
11086560|NCT04170062|Experimental|Baseline followed by intervention 2e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
11086561|NCT04170062|Experimental|Baseline followed by intervention 2f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
11086562|NCT04170049|Experimental|Behavioral: The sensory stimulative activity interventions|
11086563|NCT04170036||Protein supplement group|The group of subjects who use protein supplements at least for the preceding three months
11086564|NCT04170036||Control group|The group of subjects who never used protein supplements
11086565|NCT04170023|Experimental|Open-label ALXN2050 Monotherapy|"ALXN2050 orally administered at a dose of 120 milligrams (mg) twice daily (every 12 hours), with potential dose titration up to 180 mg twice daily if warranted, for 12 weeks.
~Participants receiving danicopan monotherapy in study ACH471-103 will switch to ALXN2050 monotherapy
~Newly identified participants with PNH will receive ALXN2050 as monotherapy
~The treatment phase will be followed by a long-term extension phase, where ALXN2050 will continue to be administered."
11086566|NCT04170023|Experimental|Open-label ALXN2050 Combination Therapy|"ALXN2050 orally administered at a dose of 120 milligrams (mg) twice daily (every 12 hours), with potential dose titration to 180 mg twice daily if warranted, for 12 weeks. In addition to ALXN2050 administration, participants will continue their background therapy with an approved C5 inhibitor.
~Participants receiving danicopan as an add-on to an approved C5 inhibitor in Study ACH471-101 will switch to ALXN2050 as an add-on to an approved C5 inhibitor
~Newly identified participants with PNH with extravascular hemolysis on an approved C5 inhibitor will receive ALXN2050 as an add-on
~The treatment phase will be followed by a long-term extension phase, where ALXN2050 will continue to be administered."
11086567|NCT04170010||Conservatively managed group|Individuals with conservatively managed obesity
11086568|NCT04170010||Surgically managed group|Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity
11086569|NCT04169997|Experimental|IMP4297|The starting dose is 100mg QD
11086570|NCT04169997|Placebo Comparator|Placebos|The starting dose is 100mg QD
11086571|NCT04169984|Active Comparator|Myofunctional Therapy|This therapy consists of the practice of isotonic, isokinetic and isometric exercises that improve mobility and coordination and increase the muscular strength of the orofacial structures that contribute to the obstructive sleep apnea etiopathogenesis.
11086572|NCT04169984|Placebo Comparator|Placebo|The placebo group will be instructed in simulation exercises that do not alter the function or morphology of the upper airway.
11086573|NCT04169971|Experimental|Music group|Will receive music during the operation conducted under spinal anaesthesia
11086574|NCT04169971|No Intervention|Control group|Will not receive music during the operation conducted under spinal anaesthesia
11086575|NCT04169945|Experimental|Ultrasonic instrumentation and Air Polishing|All participants will receive full mouth conventional ultrasonic subgingival debridement, followed by air-polishing with erythritol powder which include activating device for 5 seconds of each surface (Petersilka 2003). Subsequently, Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm. Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm
11086576|NCT04169945|Active Comparator|Ultrasonic instrumentation|All participants will receive full mouth conventional ultrasonic subgingival debridement only. No time limit (Flemmig 2012), until dental surfaces feel smooth.
11086577|NCT04169932|Experimental|CD20 CAR-T|
11086578|NCT04169919|Active Comparator|Modified method|Povidone Iodine
11086579|NCT04169919|Active Comparator|Ordinary method|normal saline
11086580|NCT04169906|Placebo Comparator|Placebo|
11086581|NCT04169906|Experimental|TS-142 10 mg|
11086582|NCT04169906|Experimental|TS-142 20 mg|
11086583|NCT04169906|Experimental|TS-142 30 mg|
11086584|NCT04169893|Placebo Comparator|Arm Title: Placebo (fasting)|fasting
11086585|NCT04169893|Placebo Comparator|Placebo (feeding)|after meal
11086586|NCT04169893|Experimental|TS-142, 1 mg|fasting
11086587|NCT04169893|Experimental|TS-142, 3 mg|fasting
11086588|NCT04169893|Experimental|TS-142, 10 mg (fasting)|fasting
11086589|NCT04169893|Experimental|TS-142, 10 mg (feeding)|after meal
11086590|NCT04169893|Experimental|TS-142, 30 mg|fasting
11086591|NCT04169880|Experimental|HILT Group|HILT Group (n=15)
11086592|NCT04169880|Experimental|HILT & EXERCISE Group|HILT&Exercise Group (n=15)
11086593|NCT04169867||Healthy Volunteers|This cohort will consist of 1000 healthy volunteers from Poland.
11086594|NCT04169867||Melanoma|This cohort will consist of 160 patients with melanoma.
11086595|NCT04169854|Experimental|Lidocaine Patch|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked Lidocaine 5% patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
11086846|NCT04168086|Experimental|Non-Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to a non-motor area of the right cerebellum prior to completing a motor learning task.
11086596|NCT04169854|Placebo Comparator|Placebo|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked placebo patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
11086597|NCT04169841|Experimental|GUIDE2REPAIR patients|olaparib + immunotherapy (durvalumab + tremelimumab) during 4 months followed by durvalumab alone as maintenance in patients with solid cancer and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.
11086598|NCT04169828|Experimental|Ondansetron premedication|Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if <15Kg, 4 mg if 15-30Kg, 8 mg if >30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate.
11086599|NCT04169828|Active Comparator|Ondansetron as needed|Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if <15Kg, 4 mg if 15-30Kg, 8 mg if >30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion
11086600|NCT04169815||ED Setting|An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.
11086601|NCT04169802||Normal subjects|Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.
11086602|NCT04169802||Subjects with neovascular AMD|Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.
11086603|NCT04169789|Active Comparator|L. reuteri Low Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E8 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total dose of either 1x10E9 L.reuteri CFU and 400 IU of cholecalciferol per day.
11086604|NCT04169789|Active Comparator|L. reuteri High Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day.
11086605|NCT04169789|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 24 months.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day.
11086606|NCT04169776|Experimental|Steroid Sensitive Frequently-Relapsing Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid sensitive frequently relapsing idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and the level of proteinuria before and while using taVNS therapy.
11086607|NCT04169776|Experimental|Steroid Resistant Idiopathic Nephrotic Syndrome|Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
11086608|NCT04169763|Experimental|Treatment (nelfinavir, cisplatin, EBRT)|Patients receive nelfinavir PO BID for up to 8 weeks. Starting week 2, patients also receive cisplatin IV over 60-90 minutes once weekly during weeks 2-8. Patients undergo EBRT for 5 consecutive days between weeks 2-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
11086609|NCT04169750|Experimental|Exergames|
11086610|NCT04169750|Active Comparator|Adaptive COGNI-TRAcK|
11086611|NCT04169750|Sham Comparator|Sham COGNI-TRAcK|
11086612|NCT04169737|Active Comparator|Arm I (acalabrutinib, venetoclax, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Beginning cycle 3, patients receive venetoclax PO BID on days 1-28. Patients who are BM MRD4-positive or in PR also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 15 and day 1 of cycles 16-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11086613|NCT04169737|Experimental|Arm II (acalabrutinib, venetoclax, early obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 beginning cycle 2 and venetoclax PO BID on days 1-28 beginning cycle 3. Patients also receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and day 1 of cycles 2-6. Patients who are BM MRD4-positive or in PR receive obinutuzumab IV over 4-6 hours on day 1 cycles 15-20. Treatment repeats every 28 days (or 42 days for cycle 14) for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11086614|NCT04169724|Experimental|Calm|Participants will be asked to download the Calm app on their smartphone. Participants will then receive an email containing login credentials to access the Calm app. Once they receive this email and they receive their study start date, they will be asked to meditate for at least 10 minutes a day for 8 weeks. This prescription mimics how a new, paying member would use the app. Participants in the intervention group will be emailed weekly reminders.
11086615|NCT04169724|No Intervention|Waitlist|Participants randomized to the control group will be asked to maintain their normal routine for 8 weeks and to avoid using the Calm meditation app.
11086616|NCT04169711|Experimental|ARO-HIF2|
11086617|NCT04169698|No Intervention|Control group|Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
11086618|NCT04169698|Experimental|Denosumab group|Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
11086619|NCT04169698|Experimental|Alendronate group|Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
11086620|NCT04169685||with dexmedetomidine|Drugs provided moderate sedation during procedure including dexmedetomidine
11086622|NCT04169672|Experimental|Surufatinib & Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
11086623|NCT04169659|Experimental|Kyphoplasty with Titanium spheres|Patients treated with kyphoplasty with baloons and insertion of titanium microspheres inside the body vertebra.
11086624|NCT04169659|Active Comparator|Kyphoplasty with Polymethylmethacrilate|Patients treated with Kyphoplasty with baloons and insertion of Polymethylmetacrylate inside the body vertebra.
11086625|NCT04169646|Other|Intervention|Multi-component intervention
11086626|NCT04169646|Other|Control|Control
11086627|NCT04169620|Experimental|variable aquatic Ai Chi|"The 15 patients assigned to the aquatic therapy group (experimental group) received 20 twice-weekly sessions in total, during the same period of time as the control group. These 20 sessions consisted of group sessions lasting 45-minutes.
~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
11086628|NCT04169620|Placebo Comparator|variable dry land|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
11086629|NCT04169607|Experimental|individualized PEEP|"Chest computerized tomography（CT） one day before surgery
~Bacis ventilation: Volume-controlled ventilation mode with positive end expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，
~Recruitment maneuver : Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.
~PEEP-titration maneuver:At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.
~After titration:A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.
~Randomized :Subsequently patient was randomized , the PEEP was then maintained (individualized PEEP arm) until extubation.
~After discharged from postoperative anesthesia care unit：A chest CT will be performed to reassess percentage of atelectasis and compared with preoperative CT."
11086630|NCT04169607|Active Comparator|PEEP 8|"Chest computerized tomography（CT） one day before surgery
~Bacis ventilation: Volume-controlled ventilation mode with positive end expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，
~Recruitment maneuver : Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.
~PEEP-titration maneuver:At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.
~After titration:A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.
~Randomized :Subsequently patient was randomized , the PEEP was then reduced to 8cm H2O(PEEP8 arm) until extubation.
~After discharged from postoperative anesthesia care unit：A chest CT will be performed to reassess percentage of atelectasis and compared with preoperative CT."
11086631|NCT04169594||Stroke|Unilateral hemiplegic stroke patients
11086632|NCT04169594||Amputee|Unilateral transtibial amputee patients
11086633|NCT04169581||Experimental Group|The experimental group received 18F-FDG PET examination
11086634|NCT04169581||Control Group|The control group received 18F-FDG PET examination
11086635|NCT04169568||OI manuel cuff BP|Patients with diagnosis of Osteogenesis Imperfecta from ages 1 to 35 who are admitted to our institution to the inpatient, non-ICU setting, following orthopedic surgery for lower extremity realignment and IM rodding
11086636|NCT04169555|Experimental|Ultrasound|
11086637|NCT04169555|Other|Standard care|
11086638|NCT04169542||Observational (questionnaire, cost diary)|Patients complete up to 4 electronic questionnaires over 15 minutes before surgery and at 6, 12, and 24 months after surgery . Patients also complete a web-based cost diary to capture out-of-pocket expenses monthly for 12 months.
11086639|NCT04169490|Experimental|FS2 Emulsion Moisturizer|The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.
11086640|NCT04169490|Experimental|Active Comparator + FS2 Emulsion Moisturizer|The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.
11086641|NCT04169477|Experimental|cTENS-mTENS|Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form
11086642|NCT04169477|Experimental|mTENS-cTENS|Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode
11086643|NCT04169464|Other|group I|A group of HCV infected patients treated with DAA therapy including Sofospovir
11086644|NCT04169451|Experimental|letrozole group|Women will be given IUI treatment with ovarian stimulation with letrozole 5mg/day starting from day 3-5 of menstrual cycle for 5 days.
11086645|NCT04169451|No Intervention|natural cycle group|Women will be given IUI treatment without ovarian stimulation.
11086646|NCT04169438|Placebo Comparator|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Vehicle Cream Base Emulsion Moisturizer + Petrolatum
11086647|NCT04169438|Experimental|FS2 Emulsion Moisturizer + Petrolatum|FS2 Emulsion Moisturizer + Petrolatum
11086648|NCT04169425||Group 1|patients who underwent to laparoscopic TME, with elective diverting ileostomy for rectal cancer
11086649|NCT04169425||Group 2|patients who underwent to laparoscopic TME, without elective diverting ileostomy for rectal cancer
11086650|NCT04169412||Resuscitation Failure, High PCO Level, High RIPK3 Level|"Resuscitation failure was defined as lactate level ≥2 mmol/L or lactate reduction <20% hour-4 after initial sepsis recognition.
~High PCO level was defined as PCO level ≥ cut off point.
~High RIPK3 level was defined as PCO level ≥ cut off point."
11086651|NCT04169412||Resuscitation Success, Low PCO Level, Low RIPK3 Level|"Resuscitation success was defined as lactate level <2 mmol/L or lactate reduction ≥20% hour-4 after initial sepsis recognition.
~Low PCO level was defined as PCO level < cut off point.
~Low RIPK3 level was defined as PCO level < cut off point."
11086652|NCT04169399|Experimental|Toripalimab plus SBRT|Participants received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Participants recevied Stereotactic body radiotherapy. Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
11086653|NCT04169386|Experimental|AK102 75mg|AK102 75mg
11086654|NCT04169386|Experimental|AK102 150mg|AK102 150mg
11086655|NCT04169386|Experimental|AK102 300mg|AK102 300mg
11086656|NCT04169386|Experimental|AK102 500mg|AK102 500mg
11086657|NCT04169386|Placebo Comparator|Placebo|Matching placebo
11086658|NCT04169373|Experimental|Study 1: Upadacitinib|Participants will be administered upadacitinib for 104 weeks
11086659|NCT04169373|Experimental|Study 1: Placebo|Participants will be administered placebo for 14 weeks followed by upadacitinib for 90 weeks
11086660|NCT04169373|Experimental|Study 2: Upadacitinib|Participants will be administered upadacitinib for 104 weeks
11086661|NCT04169373|Experimental|Study 2: Placebo|Participants will be administered placebo for 52 weeks followed by upadacitinib for 52 weeks
11086662|NCT04169360|Experimental|ANS-6637|ANS-6637 600mg once daily for 12 weeks
11086663|NCT04169360|Placebo Comparator|Placebo arm|Placebo 600 mg once daily for 12 weeks
11086664|NCT04169347|Other|Active|This is an open label study single arm
11086665|NCT04169334|No Intervention|Control group|Group receiving care as usual
11086666|NCT04169334|Experimental|Intervention group|Intervention group receiving a standardized preventive program (5 days at the Obstetric department)
11086667|NCT04169321|Experimental|Single Arm|All participants will receive a mass dose of 30 μg or less of [68Ga]-NOTA-hGZP (radioactivity dose of 3 mCi to 15 mCi) and have a PET scan.
11086668|NCT04169308|Experimental|Experimental: Restylane-L® Filler injection|
11086669|NCT04169295|Experimental|Intervention group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's, and couple's personalized IVF-prognosis
11086670|NCT04169295|Sham Comparator|Control group|At the time of their fresh embryo transfer couples will receive a document with a photo of their transferred embryo(s) and the number of cryopreserved embryos.
11086671|NCT04169282|Experimental|nPEP Recipients|Single-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
11086672|NCT04169269|Active Comparator|Enoxaparin|enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days
11086673|NCT04169269|Active Comparator|Rivaroxaban|rivaroxaban oral 10 milligram tablet daily for 20 days
11086674|NCT04169256|Experimental|HYR-PB21 & Placebo|
11086675|NCT04169256|Active Comparator|Liposome Bupivacaine & Placebo|
11086676|NCT04169243|Experimental|Intervention|Women randomized to the New Nordic Diet meet the study dietician for 1.5 hr of individual diet treatment according to the New Nordic Diet and a cognitive behavioral approach. The diet advice include evenly distributed meals over the day, foods low in fat and rich in fibre, 500 g fruit and vegetables daily, fish 2-3 times a week and keyhole foods.
11086677|NCT04169243|Active Comparator|Control|The control women receive diet advice according to usual care.
11086678|NCT04169230|Experimental|Citalopram|Single acute oral dose 20 mg Citalopram (tablet encapsulated in opaque capsule)
11086679|NCT04169230|Placebo Comparator|Placebo|Single acute oral dose Lactose Placebo (tablet encapsulated in opaque capsule)
11086680|NCT04169217|No Intervention|Control arm|This arm will not be in the prehabilitation group- as is current standard practice
11086681|NCT04169217|Active Comparator|Group 2|This arm will be subject to a one off prehabilitation workshop and provided with a prehab booklet
11086682|NCT04169217|Experimental|Group 3- Mentored group|This arm will be subject to a one off workshop and provided with a prehab booklet- and additional mentoring by means of 1. an educational app, 2. push notifications,3. weekly communication with physiotherapy team member.
11086683|NCT04169191|Experimental|Sildenafil|
11086684|NCT04169178|Experimental|HLX55, dose finding stage, advanced solid tumor|Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.
11086685|NCT04169178|Experimental|HLX55, dose expansion stage, gastric cancer|Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.
11086686|NCT04169178|Experimental|HLX55, dose expansion stage, NSCLC|Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.
11086687|NCT04169178|Experimental|HLX55, dose expansion stage, colorectal cancer|Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.
11086688|NCT04169178|Experimental|HLX55, dose expansion stage, other solid cancer|Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.
11086689|NCT04169165||compliant patients|Patients with compliance to suggestions on metabolic evaluation and dietary/medical advices
11086690|NCT04169165||non-compliant patient|Patients without compliance to suggestions on metabolic evaluation and dietary/medical advices
11086691|NCT04169152||Internal hemorrhoids and rectal prolapse|Participants were treated with Cap-assisted endoscopic sclerotherapy (CAES).
11086692|NCT04169139|Active Comparator|MIST - minimally invasive surgical therapy|"Beginning with the papilla preservation technique (Takei et al), further improved by Cortellini et al (1995) and combined with minimally invasive approaches (Harrel et al 1995), MIST, using minimally invasive surgical approaches and micro-surgery instruments, has evolved into a decision tree guideline for treating periodontitis based on periodontal pocket morphology and papilla width/ interdental space (Cortellini P, Tonetti MS (2007) J Clin Periodontol;34(1):87-93)."
11086847|NCT04168086|Sham Comparator|Control|Participants will have the Focused Ultrasound transducer placed on their neck without stimulation as a Sham present prior to completing a motor learning task.
11086848|NCT04168073|Experimental|High sodium diet|
11086693|NCT04169139|Experimental|REPaiR - laser periodontal therapy|The REPaiR regimen is a step-by-step protocol for using the Waterlase Express Er,Cr:YSGG laser for periodontitis. The protocol steps and associated laser delivery is controlled by a computer interface that dictates laser tip, energy and associated air and water mixes. Like MIST, REPaiR uses a set, decision tree approach for periodontal therapy, with prescribed steps and laser settings to quantify and standardize treatment. Potential clinical benefit, as with MIST, are not only effective periodontal therapy with reduced recession compared with traditional surgical approaches, but also reduced patient morbidity (Arnabat-Domínguez et al (2010). Lasers Med Sci;25(3):459-64).
11086694|NCT04169126|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
11086695|NCT04169113|Active Comparator|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
11086696|NCT04169113|Active Comparator|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
11086697|NCT04169100|Experimental|Prednisone Group|These patients have CTD and QTc over 500 msec. Prednisone is administered as a preventative measure against arrhythmia via QTc shortening.
11086698|NCT04169087||General anesthesia|Patients undergoing general anesthesia
11086699|NCT04169074|Experimental|Treatment with abemaciclib|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 150 mg PO twice daily on Days 1-21 (+7 days).
11086700|NCT04169074|Experimental|Treatment with abemaciclib plus nivolumab|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Nivolumab will be administered on days 1 and 15 in arm 2 only. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery. Abemaciclib 150 mg PO twice daily on Days 1-21 (+7 days) AND Nivolumab 240 mg IV on Days 1 and 15.
11086701|NCT04169061|Experimental|All participants|"Participants receive:
~a shot of Acthar (80 units) under the skin twice a week for 12 weeks
~a shot of Acthar (40 units) twice a week for 2 weeks
~a shot of Acthar (40 units) once a week for 2 more weeks
~At each visit they will have medical tests and answer questions about their symptoms."
11086702|NCT04169048|Experimental|Intervention group (BPD)|Participants (N=60) receive the weekly conducted intervention (group training for mothers with BPD) over the period of 12 weeks (12 sessions). Assessments of each participant: T0 (pre-intervention), T1 (post-intervention) and follow-up (6 months after T1).
11086703|NCT04169048|No Intervention|waiting control group (BPD)|Members of this group (N=60) receive no intervention but treatment as usual (TAU). After completing all assessment points (T0, T1, T2), they can receive the intervention of the intervention group (group training).
11086704|NCT04169048|No Intervention|clinical control group (AD/MDD)|Mothers with anxiety and/or depression (N=60) receive no intervention. Assessment point only T0.
11086705|NCT04169048|No Intervention|healthy control group|Mothers with no actual mental disorder (N=60) receive no intervention.# Assessment points T0, T1, T2.
11086706|NCT04169035|Experimental|Odon device|The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assiste vaginal birth. Odon trained practitioner available to assist the birth.
11086707|NCT04169035|Active Comparator|Forceps or ventouse|"The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assisted vaginal birth.
~The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth."
11086708|NCT04169022|Experimental|AML patients at diagnosis|AML patients at diagnosis (except AML3)
11086709|NCT04169022|Experimental|AML patients at relapse|AML patients at relapse after chemotherapy, targeted therapy or allograft
11086710|NCT04169009|Active Comparator|ZVL >5 years previously|Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
11086711|NCT04169009|Active Comparator|ZVL 6-12 months previously|Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.
11086712|NCT04169009|Active Comparator|No previous ZVL|Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.
11086713|NCT04169009|Active Comparator|SRX >5 years previously|Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
11086714|NCT04168996|Experimental|rib fracture patients group|Individualized discharge planning in rib fracture patients with different severity of lung injury
11086715|NCT04168996|No Intervention|Control group|Patients included in control group received standard conservative treatment during hospitalization
11086716|NCT04168983|No Intervention|Control|Usual care: local anesthesia + nitrous oxide and oxygen administration
11086717|NCT04168983|Experimental|Experimental|"Usual care: local anesthesia + nitrous oxide and oxygen administration
~In this arm : sophrology is added"
11086718|NCT04168970||PSGB group|MD will perform PSGB using Lidocaine. The PGSB will be performed after the administration of the 4th shock if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. PSGB will be performed after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.).
11086719|NCT04168970||Control group|Historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Cardiac Arrest Registry of the Province of Pavia
11086720|NCT04168957|Experimental|Oraxol|Subjects in KX-ORAX-008 will begin treatment at the last oral paclitaxel dose they received in Study KX-ORAX-007.
11086849|NCT04168073|Experimental|Low sodium diet|
11086946|NCT04167397|Experimental|Tetrad training|Initial training in groups of 4
11147572|NCT03744221|Experimental|Corn protein|Corn protein powder
11086721|NCT04168944|Experimental|lenvatinib group|Participants are given the same anti-rejection therapy as the control group after liver transplantation. 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mgor 12 mg orally once a day. The initial dose was 8 mgor 12 mg orally once a day.
11086722|NCT04168944|Placebo Comparator|Placebo group|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
11086723|NCT04168931|Experimental|Interventional|Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.
11086724|NCT04168918|Experimental|Group Psychological Intervention|One topic will be discussed at each of the six sessions using some principles from cognitive behavioral therapy and psychoeducation.
11086725|NCT04168918|No Intervention|Treatment-as-usual|Participants will receive their usual care which involves being seen by a mental health professional (psychologist, psychiatrist/resident in psychiatry, or mental health nurse).
11086726|NCT04168905|Experimental|Active arm|After receiving standard treatment and AOTI Inc. TWO2 topical oxygen therapy equipment training, patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
11086727|NCT04168905|Placebo Comparator|Controlled arm|patients receive standard treatment.
11086728|NCT04168892||Female age ≤ 35 years: 150 IU of HMG|For controlling the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age ≤ 35 years, COS will be carried out by daily injections of 150 IU of Human Menopausal Gonadotropins (HMG) and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the Gonadotropin-releasing Hormone (GnRH) antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary human Chorionic Gonadotropin (hCG) 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
11086729|NCT04168892||Female age >35 years: 225 IU of HMG|In order to control the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age >35 years, the controlled ovarian stimulation will be carried out by daily injections of 225 IU of HMG and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the GnRH antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary hCG 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
11086730|NCT04168879|Active Comparator|bupivacaine group|
11086731|NCT04168879|Placebo Comparator|saline group|
11086732|NCT04168866|Experimental|Surgery|Patients in the operative group will have a surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
11086733|NCT04168866|Active Comparator|Non-operative management|If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
11086734|NCT04168853|Other|Roller pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Maquet® for the roller pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
11086735|NCT04168853|Other|Centrifugal pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Sorin® for the centrifugal pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
11086736|NCT04168840||Patient undergoing general anesthesia with intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway
11086737|NCT04168827||Relatives of severe traumatized child|Relatives of a child who has been hospitalized in intensive care of Necker hospital following a severe trauma
11086738|NCT04168814||Oncology patients (Immunotherapy alone or in combination))|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).
~Patients under targeted active treatment either exclusively or in combination with chemotherapy or radiotherapy. Targeted therapy (immunotherapy) defined with: PD1, PDL1 inhibitors. At least 12 weeks of treatment."
11086850|NCT04168060|Experimental|Crura Dissection|Participants with a visually detectable hiatal hernia at the time of sleeve gastrectomy procedure will undergo a crura dissection and hiatal hernia repair.
11087023|NCT04166890|Experimental|NS Lower left molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
11086739|NCT04168814||Oncology Patients (Chemo-Radiotherapy group).|"Outpatients, over 18 years old, with locally advanced or metastatic solid tumors (with the idea of homogenizing the sample as far as possible and in line with what has been published up to now, also stratified in line with Globocan).
~Patients under active treatment either in combination with chemotherapy or radiotherapy. At least 12 weeks of treatment."
11086740|NCT04168801|Experimental|Early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, if he did not have them, then receives diet indicated between 16 and 24 hours after admission.
11086741|NCT04168801|Active Comparator|Usual oral refeeding|usual oral refeeding (UOR) Once the attending physician decided according to his clinical judgment to restart the oral feeding
11086742|NCT04168788|Other|Nephrobalstoma or ALL|Pateints treated for a nephrobalstoma or ALL in childhood or adolescence
11086743|NCT04168775|Other|Home PIFR monitoring|Measurement of PIFR using the InCheck Dial® device and quantification of respiratory symptoms and COPD exacerbations using standardized questionnaires in the patient's home setting and during research visits in the clinic setting
11086744|NCT04168762|Experimental|TUMS and Sham Group|During the subjects two visits they will receive a TUMS stimulation and a sham (placebo) stimulation at both visits.
11086745|NCT04168762|Experimental|TUMS or Sham Group|During the subjects first of two visits they will receive either a TUMS stimulation or a sham (placebo) stimulation and at the second visit they will receive the other.
11086746|NCT04168749||local compounding group|the first 100 preterm babies born as from January 1 2015 with a birth weight between 1250-2000g that received at least 10 days of TPN.
11086747|NCT04168749||Numeta G13 group|the first 100 preterm babies as from January 1 2017 with a birth weight between 1250-2000g that received at least 10 days of TPN
11086748|NCT04168723|Experimental|Group A-MD1003|Group A=32 subjects Placebo for MD1003 on Day -1. Daily dose of 1200 mg of MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Day 9
11086749|NCT04168723|Active Comparator|Group B-Moxifloxacin|"Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.
~Subgroup B1: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Moxifloxacin 400 mg on Day 1 and Placebo for moxifloxacin on Day 9 Subgroup B2: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Moxifloxacin 400 mg on Day 9"
11086750|NCT04168710|Experimental|erector spinae plane block (ESP block) with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
11086751|NCT04168710|Placebo Comparator|ESP block with saline/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
11086752|NCT04168697|Experimental|Controls|Control subjects undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
11086753|NCT04168697|Experimental|BAD|Patients with bipolar affective disorder (BAD) undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
11086754|NCT04168684|Experimental|Attachment and Biobehavioral Catch-up (ABC)|10 sessions that focused on parental nurturance, and sensitivity
11086755|NCT04168684|Active Comparator|Developmental Education for Families (DEF)|10 sessions that focused on cognitive development
11086756|NCT04168671|Other|Asthma|Asthma and symptomatic during exercise
11086757|NCT04168671|Other|Severe asthma|Severe asthma and symptomatic during exercise
11086758|NCT04168658|Experimental|Physical activity and education intervention|
11086759|NCT04168658|Active Comparator|Education intervention|
11086760|NCT04168645|Experimental|Presence of SUD with CBT|Patients diagnosed with SUD who are randomly assigned to receive CBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
11086761|NCT04168645|No Intervention|Presence of SUD with TAU|Patients diagnosed with SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
11086762|NCT04168645|Experimental|Absence of SUD with CBT|Patients without SUD who are randomly assigned to receive CBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
11086763|NCT04168645|No Intervention|Absence of SUD with TAU|Patients without SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
11086764|NCT04168632|Experimental|Intervention|A new 4-week menu plan
11086765|NCT04168619||Transient elastography (TE)|All patients who had MTX taken
11086766|NCT04168619||Two dimensional shear wave elastography (2D SWE)|For patients who has cumulative more than 3.5g methotrexate
11086767|NCT04168619||Liver biopsy|For patients who has cumulative more than 3.5g methotrexate and had 2D SWE done
11086768|NCT04168606||Cases with placental abruption|"Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination.
~All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis."
11086769|NCT04168593|Sham Comparator|A- Placebo|Sham Acupuncture and Sham Cupping
11086770|NCT04168593|Active Comparator|B -Cupping|Sham Acupuncture and Real Cupping
11086771|NCT04168593|Active Comparator|C - Acupuncture|Real Acupuncture and Sham Cupping
11086772|NCT04168593|Active Comparator|D - Acupuncture + Cupping|Real Acupuncture and Real Cupping
11086773|NCT04168580||OA- Older Athlete|Older adults who are regularly engaged in endurance exercise
11086774|NCT04168580||OS- Older Sedentary|Older adults who are sedentary
11086775|NCT04168567|Experimental|Obese patients|Patients who have BMI higher than 30
11086776|NCT04168567|Experimental|Normal weight patients|Patients who have BMI between 20 and 25.
11086904|NCT04167670|Experimental|Vonoprazan dual therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
11086777|NCT04168554||Phase 1 and Phase 2|"20 patients studied in the emergency room with a pediatrician not presen in the ER performing the telemedicine examination from a distance (ie an office down the hall) followed directly by a face-to-face
~20 patients included in the general practitioners office, telemedicine is performed from within the hospital to the GPs office.
~Patient is then still referred to the hospital in order to check whether the telemedicine and face-to-face examination are somewhat similarce physical examination"
11086778|NCT04168541|Active Comparator|Oral Nutrition Supplement A|Product containing calories from carbohydrate, protein, and fat
11086779|NCT04168541|Active Comparator|Oral Nutrition Supplement B|Product containing calories from carbohydrate, protein, and fat
11086780|NCT04168541|Active Comparator|Oral Nutrition Supplement C|Product containing calories from carbohydrate, protein, and fat
11086781|NCT04168541|Active Comparator|Oral Nutrition Supplement D|Product containing calories from carbohydrate, protein, and fat
11086782|NCT04168541|Active Comparator|Oral Nutrition Supplement E|Product containing calories from carbohydrate, protein, and fat
11086783|NCT04168541|Active Comparator|Oral Nutrition Supplement F|Product containing calories from carbohydrate, protein, and fat
11086784|NCT04168528|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|Phase I
11086785|NCT04168528|Experimental|Part II: tumor targeting potential and correlation to ICH|Phase II
11086786|NCT04168515||Patient|
11086787|NCT04168515||Caregiver|
11086788|NCT04168515||Healthcare provider|
11086789|NCT04168502|Experimental|Experimental arm|"Induction:
~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7
~Consolidation:
~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6
~Allogeneic transplantation or Autologous transplantation according to MRD level
~Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse"
11086790|NCT04168502|Active Comparator|Standard arm|"Induction:
~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7
~Consolidation:
~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6
~Allogeneic transplantation or Autologous transplantation according to MRD level
~clinical observation"
11086791|NCT04168489|Active Comparator|active rTMS|
11086792|NCT04168489|Sham Comparator|sham rTMS|
11086793|NCT04168476|Experimental|Treatment group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:
~Visual Analogue Scale
~Range of movement
~Hand grip strength. After a first assessment, scapula mobilization techniques were performed and participants reassessed."
11086794|NCT04168476|Placebo Comparator|Control group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:
~Visual Analogue Scale
~Range of movement
~Hand grip strength. The procedure was a contralateral calcaneus abduction and adduction mobilization technique was carried out."
11086795|NCT04168463|Experimental|Immediate Intervention|This cluster of four homes will receive robot animals immediately at commencement of the eight month trial.
11086796|NCT04168463|Other|Delayed Intervention|This cluster of four homes will receive robot animals four months after commencement of the 8 month trial. The four months without robots will serve as a control period.
11086797|NCT04168450|Other|WiSAT Passive|This arm is composed of participants who meet their activity threshold over the 4-week period.
11086798|NCT04168450|Other|WiSAT Active|This arm is composed of participants who do not meet their activity threshold over the 4-week period.
11086799|NCT04168437|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report.
11086800|NCT04168437|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report following completion of the study.
11086801|NCT04168411|Experimental|Symptomatic treatment group|The patients were allocated to wear a double layered elasticated bandage for treatment 5th metatarsal base fractures (Zone 1).
11086802|NCT04168411|Active Comparator|Cast group|The patients were given a below-knee cast for treatment 5th metatarsal base fractures (Zone 1).
11086803|NCT04168398|Experimental|Plavix 75mg and juspirin 81 mg therapy|Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.
11086804|NCT04168398|Experimental|Eliquis 2.5mg and juspirin 81 mg therapy):|Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin (juspirin) 81 mg.
11086805|NCT04168385|Experimental|Maralixibat|Participants will all receive Maralixibat oral solution
11086806|NCT04168372|Experimental|High fructose meal, with fructose label|2-13C fructose incorporated into a meal with high fructose content
11086807|NCT04168372|Experimental|High fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with high fructose content
11086808|NCT04168372|Experimental|Low fructose meal, with fructose label|2-13C fructose incorporated into a meal with low fructose content
11086809|NCT04168372|Experimental|Low fructose meal, with pyruvate label|2-13C pyruvate incorporated into a meal with low fructose content
11086810|NCT04168359|Experimental|Semi-barbed Sutures Localization Group|Patients with pulmonary nodules requiring CT-guided puncture positioning before thoracoscopic surgery
11086811|NCT04168346|Experimental|Intervention|IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.
11086812|NCT04168346|Placebo Comparator|Placebo|Placebo is NaCl 0.9% solution, which is administrated in the same way as the study drug
11086813|NCT04168333|Active Comparator|T101 Group|"The study will consist of 2 cohorts:
~Single Dose (SD) Cohort:
~9 chronic hepatitis B patients will be enrolled and be divided into 3 groups, with 3 patients in each group.
~Multiple Dose (MD) Cohort:
~18 chronic hepatitis B patients will be enrolled and be divided into 2 groups, with 9 patients in each group."
11086814|NCT04168333|Placebo Comparator|Placebo Group|"The study will consist of 2 cohorts:
~Single Dose (SD) Cohort:
~3 chronic hepatitis B patients will be enrolled in this group.
~Multiple Dose (MD) Cohort:
~6 chronic hepatitis B patients will be enrolled in this group."
11086815|NCT04168320|Active Comparator|Less favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.
~SBRT-PATHY will be administered to this arm at an estimated less favorable time-Position in immune cycle."
11086816|NCT04168320|Experimental|Most favorable time-position in immune cycle|"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes). Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy.
~SBRT-PATHY will be administered to this arm at an estimated most favorable time-position in immune cycle."
11086817|NCT04168307|Experimental|Ankle trainer device|The patients were instructed in the use of a new spring loaded ankle trainer
11086818|NCT04168307|Active Comparator|Conventional physiotherapy|The patients were instructed in passive stretching exercises by the use of a non-elastic band
11086819|NCT04168294||sedation group|Patients undergo sedative esophagogastroduodenoscopy (EGD) and are intravenous injected propofol in bolus
11086820|NCT04168294||control group|patients undergo conventional EGD
11086821|NCT04168281|Experimental|PCI- free after response to radical chemoradiotherapy|Patients with no metastases will be followed-up with MRI: at the qualifying visit before MRI-1, and then every 6 months +/- 2 weeks), the patients will have a cognitive examination performed using dedicated neuropsychological tests and QoL assessment using the QLQ-C30 questionnaire. The tests will be conducted in the following order: California verbal learning test (CVLT) with a delay of 15 min, Color connection test (CTT), CVLT (after delay), Benton visual memory test (BNRT), Verbal fluency test by the certified psychologist.
11086822|NCT04168255|Other|Retinal detachment|Retinal detachment with proliferative vitreoretinopathy and inferior breaks
11086823|NCT04168242|Experimental|Experimental arm|Patients have scalp cooling during the chemotherapy period
11086824|NCT04168242|Placebo Comparator|Control arm|Patients do not have scalp cooling during the chemotherapy period
11086825|NCT04168229|Experimental|ITE Hearing Aid|The subjects will wear the ITE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
11086826|NCT04168229|Active Comparator|BTE Hearing Aid|The subjects will wear the BTE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
11086827|NCT04168203|Experimental|Extended Duration Thromboprophylaxis|apixaban 2.5 mg orally twice daily for a duration of 12 months
11086828|NCT04168203|Placebo Comparator|Control|oral placebo for a duration of 12 months
11086829|NCT04168190|Experimental|Phase 1: pPCV-1|Single intramuscular (IM) 0.5 mL vaccination on Day 1
11086830|NCT04168190|Experimental|Phase 1: pPCV-2|Single IM 1.0 mL vaccination on Day 1
11086831|NCT04168190|Active Comparator|Phase 1: Pneumovax™23|Single IM 0.5 mL vaccination on Day 1
11086832|NCT04168190|Experimental|Phase 2: pPCV|Single IM vaccination on Day 1 at dose to be determined.
11086833|NCT04168190|Active Comparator|Phase 2: Pneumovax™23|Single IM 0.5 mL vaccination on Day 1
11086834|NCT04168177|Active Comparator|control group|
11086835|NCT04168177|Active Comparator|ESP Group|
11086836|NCT04168164|Experimental|Ai Chi|Ai Chi aquatic therapy Dry land therapy
11086837|NCT04168151|Experimental|hypoxic group|hypoxic patients (hypoxic index less than 250)
11086838|NCT04168138|Experimental|Newly diagnosed AML in elderly patient|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when WBC>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
11086839|NCT04168125|Experimental|Tilapia skin|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a tilapia skin as an occlusive biological dressing for palatal wound healing.
~Device: Tilapia skin. A xenogeneic collagen dressing will be placed over palate wound and stabilized with sutures during the healing process."
11086840|NCT04168125|Active Comparator|Surgical Wound Dressing|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a surgical wound dressing as a mechanical protection during palatal wound healing.
~Device: Surgical wound dressing A surgical wound dressing will be placed over palate wound during the healing process to provide mechanical protection."
11086841|NCT04168112|Experimental|Group A|Intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days).
11086842|NCT04168112|Active Comparator|Group B|Patients are placed on standard postoperative regimen of postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: QID x1 week, TID x 1 week, BID x 1 week, and Qday x 1 week.
11086843|NCT04168099|Experimental|Cefotaxime|Cefotaxime intravenous
11086844|NCT04168099|Active Comparator|Gemifloxacin|Oral Gemifloxacin
11086845|NCT04168086|Experimental|Right Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to motor area of the right cerebellum prior to completing a motor learning task.
11087024|NCT04166890|Active Comparator|SD Lower right molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
11086851|NCT04168060|Experimental|National Practice|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 2 participants will be treated to the national practice patterns of complete dissection of the curvature of the stomach without dissection of the crura.
11086852|NCT04168060|Experimental|Standard of Care|Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 3 participants will undergo the institutional standard of care with the dissection of the crura.
11086853|NCT04168047|Other|Healthy volunteers|
11086854|NCT04168047|Other|Patients with insomnia|
11086855|NCT04168047|Other|Patients with irritable bowel syndrome|
11086856|NCT04168047|Experimental|Patients with irritable bowel syndrome and insomnia|
11086857|NCT04168034|Experimental|Experimental: iParent2Parent Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 2 to 3 months
11086858|NCT04168034|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iParent2Parent program
11086859|NCT04168021|No Intervention|Group 90 individuals, baseline assessment before intervention|Baseline Cognitive status assessment
11086860|NCT04168021|Experimental|Remote ischemic condition of the brain|Intermittent claudication induction on a daily basis for 1 month
11086861|NCT04168021|No Intervention|Late cognitive assessment|Late cognitive status assessment 6 months later
11086862|NCT04168008|Experimental|Adherence|Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for ART adherence and engagement in HIV care.
11086863|NCT04168008|Active Comparator|Parenting|Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
11086864|NCT04167995|Active Comparator|Patient with attention deficit hyperactive disorser|patients (n=40) will receive probiotic preparation once daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
11086865|NCT04167995|No Intervention|ADHD not receiving probiotics|ADHD patient (40) not receiving probiotics
11086866|NCT04167982|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid(ALA) cream for 30min. A repeat treatment was administered once weekly for a maximum of 5 times. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and after treatment.
11086867|NCT04167982|Active Comparator|conventional-dose isotretinoin group|Patients in the conventional-dose isotretinoin group were given oral isotretinoin 0.5 mg/kg daily for 6 months, and the cumulative dose was 90 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
11086868|NCT04167982|Active Comparator|low-dose isotretinoin group|Patients in the low-dose isotretinoin group were given oral isotretinoin 0.2 mg/kg daily for 6 months, and the cumulative dose was 36 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
11086869|NCT04167969|Experimental|Prostate cancer patients|Patients will receive an intravenous (IV) injection of approximately 5 mCi (+/- 10%) of PSMAtargeting C' dot tracer up to 48 hours before surgery. Patients will then undergo serial preoperative PET/MR imaging to help characterize the safety, biodistribution/pharmacokinetics, and dosimetry of this agent. To assess total radioactivity in whole blood/plasma and urine samples, as well as radioactive metabolites, blood and urine samples will be collected at approximately 30 min post-injection as well as before each imaging session
11086870|NCT04167956|Experimental|ultrasound combined with CT guided|ultrasound combined with CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
11086871|NCT04167956|Sham Comparator|CT guided|CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
11086872|NCT04167943|Experimental|indirect pulp capping|TheraCAL PT will be applied to affected dentin covering the pup.
11086873|NCT04167943|Experimental|Direct pulp Capping|TheraCAL PT will be applied to pinpoint pulp exposures surrounded by sound dentin.
11086874|NCT04167943|Experimental|Partial Pulpotomy|Pulp exposure will be enlarged to a depth of 1-3 mm by a sterile round diamond bur, and then TheraCAL PT will applied after hemostasis.
11086875|NCT04167943|Experimental|pulpotomy|complete removal of coronal pulp tissue will be attempted with the first encounter of pulp exposure. TheraCAL PT will be applied thereafter, after achieving hemostasis.
11086876|NCT04167917|Experimental|NTX-301|
11086877|NCT04167891||Patients admitted in the intensive care unit|Patients with return of spontaneous circulation after cardiac arrest regardless of initial rhythm, and admitted in intensive care unit for post cardiac arrest care
11086878|NCT04167878|Experimental|ACDF with 3D printed biodegradable cervical fusion cage|A resorbable cervical interbody cage made of PCL-TCP.
11086879|NCT04167878|Active Comparator|ACDF with PEEK cage|A structural PEEK cage with autologous bone.
11086880|NCT04167865|No Intervention|Control group|All patients will be instructed to wear the device for 1 hours for 12 weeks after being instructed on how to use the vacuum bell. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
11086905|NCT04167670|Experimental|Vonoprazan triple therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
11087059|NCT04166669|Experimental|Cohort 1|Drugs: APX001, itraconazole
11086881|NCT04167865|Active Comparator|Exercise Group|In addition to the applications to the control group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PE. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
11086882|NCT04167852|Experimental|Treatment group|Subject to receive daily short message service (SMS) text message with a link to a mindfulness intervention.
11086883|NCT04167852|Experimental|Text group|Subject to receive daily text message but without the link to the mindfulness intervention.
11086884|NCT04167852|No Intervention|Standard of Care group|Subject will not receive any text message reminders or the mindfulness meditation intervention.
11086885|NCT04167813|Active Comparator|Active Treatment|"Participants randomised to the active treatment arm will take 8-24mg/day of ondansetron.
~The dose will increase from a single daily 8mg tablet (AM) (weeks 1 and 2), to 16mg/day (8mg twice daily) (weeks 3 and 4), with a further increase to 24mg/day (8mg AM, 16mg PM) (weeks 5 and 6). Dose escalation will be guided by telephone safety monitoring prior to each dose increase, and a face to face assessment at the end of week 6."
11086886|NCT04167813|Placebo Comparator|Matched placebo|"Participants randomised to the placebo treatment arm will take 8-24mg/day of matched placebo.
~The dose will increase from a single daily 8mg tablet (AM) (weeks 1 and 2), to 16mg/day (8mg twice daily) (weeks 3 and 4), with a further increase to 24mg/day (8mg AM, 16mg PM) (weeks 5 and 6). Dose escalation will be guided by telephone safety monitoring prior to each dose increase, and a face to face assessment at the end of week 6."
11086887|NCT04167800|No Intervention|Control group|All patients will be instructed to wear the device for 23 weeks for 12 weeks after being instructed on how to use the appropriate compression orthosis. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
11086888|NCT04167800|Active Comparator|Exercise Group|In addition to the applications to the first group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PC. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
11086889|NCT04167774|Experimental|Camrelizumab +nb-Paclitaxel|Participants receive Camrelizumab 200mg(3mg/kg for underweight patients) iv and nb-Paclitaxel 260mg/m2 iv every 3 weeks until disease progression or unacceptable toxicity
11086890|NCT04167761|Experimental|Ertugliflozin|
11086891|NCT04167761|Active Comparator|Glipizide|
11086892|NCT04167748|Experimental|PGT-A transfer|Transfer of single chromosomally normal (euploid) blastocyst after PGT-A
11086893|NCT04167748|No Intervention|Untested blastocyst transfer|Transfer of single untested blastocyst based on embryo morphology criteria.
11086894|NCT04167735|Active Comparator|Hearing Aid without Reverberation Canceller (no_RevC)|Hearing Aid without Reverberation Canceller (RevC)
11086895|NCT04167735|Experimental|: Hearing Aid Reverberation Canceller enabled (RevC_1)|Hearing Aid Reverberation Canceller enabled (RevC_1)
11086896|NCT04167722||Obese patients|BMI > 25
11086897|NCT04167722||Lean patients|BMI < or = 25
11086898|NCT04167709|Experimental|Allocated CHS nurses|Primary and secondary baseline data are collected from the allocated CHS nurses before the study starts. The CHS nurses are then given the educational intervention and afterwards primary and secondary outcomes are collected again.
11086899|NCT04167696|Experimental|Dose Escalation Dose Level 1|"in case of no dose limiting toxicity (DLT) and no replacement of patients, 3 consecutive patients at the dose of 1x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.
~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.
~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
11086900|NCT04167696|Experimental|Dose Escalation Dose Level 2|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 3x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.
~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.
~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
11086901|NCT04167696|Experimental|Dose Escalation Dose Level 3|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 1x10e9 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.
~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.
~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
11086902|NCT04167683||Cohort 1 - Patients referred to myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
11086903|NCT04167683||Cohort 2 - Patients referred to non myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
11086943|NCT04167397|Experimental|Single training|Initial training individually
11086906|NCT04167670|Active Comparator|Lansoprazole triple therapy|Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
11086907|NCT04167657|Experimental|Arm1|Sintilimab monotherapy every 3 weeks, after a radiation targeting a single location no less than dose 30Gy/5f.
11086908|NCT04167644||Unfavorable outcome|80 patients with poor outcome were classified according to mRS score after discharge (mRS range from 3 up to 6).
11086909|NCT04167644||Favorable outcome|70 patients with better outcome were classified according to mRS score after discharge (mRS range from 0 up to 2) .
11086910|NCT04167631|Other|Multiparametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
11086911|NCT04167618|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).
11086912|NCT04167605||Breast cancer metastatic to bone|No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).
11086913|NCT04167605||Bone metastasis|No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins
11086914|NCT04167592|Active Comparator|Benzydamine Hydrochloride Group|Subjects who were allocated in benzydamine group would gargle with 15 of ml benzydamine hydrochloride 0.15% before sedation started.
11086915|NCT04167592|Placebo Comparator|Control Group|Subjects who were allocated in control group would gargle with 15 ml of water before sedation started.
11086916|NCT04167566|Other|Intervention Communities|All participants confirmed using rapid diagnostic test (RDTs) to be carrying the malaria parasite will be treated using artemisinin combination therapy (ACT) following the Ghana National Malaria Treatment Guidelines and followed up on days 1, 2, 3 during treatment as DOTs (Directly observed therapy) and on day 7 post treatment. The research team together with Community volunteers will be provided the treatment guidelines which specify the dosage for each treatment regimen. Participants who receive the treatment will be observed for five minutes to ensure that they retain the drug. Those who vomit within this period will have the treatment repeated.
11086917|NCT04167553|Experimental|HM15136|
11086918|NCT04167553|Placebo Comparator|Placebo|
11086919|NCT04167540|Experimental|Earlier stage PD|
11086920|NCT04167540|Experimental|Later stage PD|
11086921|NCT04167527|Experimental|Immediate mechanical thrombectomy(iMT)|Treatment initiation within 8 hours of symptom onset. Arterial puncture and revascularization will be performed using EmboTrap II Retriever. The procedure will be completed within two hours of arterial access.
11086922|NCT04167527|Active Comparator|Initial medical management (iMM)|Standard medical therapy based on current AHA (American Heart Association) guidelines. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
11086923|NCT04167514|Experimental|AAT|Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
11086924|NCT04167514|Placebo Comparator|Placebo|Albumin solution administered intravenously
11086925|NCT04167501||Non exposed|Women born between 1972 and 1982 who were not exposed to HPV vaccination
11086926|NCT04167501||exposed|Women born between 1983 and 1993 who were potentially exposed to HPV vaccination
11086927|NCT04167488|Experimental|Actigraphic measurement|
11086928|NCT04167475|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
11086929|NCT04167475|Placebo Comparator|Placebo capsule|The participants consume one placebo capsule a day for 8 weeks
11086930|NCT04167462|Experimental|Arm A:BMS-986165 oral administration|
11086931|NCT04167462|Placebo Comparator|Arm B: Placebo oral administration|
11086932|NCT04167449|Active Comparator|Hydroponic Red Ginseng|
11086933|NCT04167449|Active Comparator|Conventional Red Ginseng|
11086934|NCT04167449|Placebo Comparator|Placebo|
11086935|NCT04167436|Experimental|Prehabilitation|Patients receive multi-modal prehabilitation with exercise three times weekly, protein supplements, vitamin supplements, dietitian consultation and medical optimization prior to surgery. A minimum of four weeks.
11086936|NCT04167436|No Intervention|Standard of Care|Receives standard of care
11086937|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2017 American Thyroid Association Guideline.
11086938|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
11086939|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
11086940|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2017 American Thyroid Association Guideline.
11086941|NCT04167410|No Intervention|control group|We did not perform any intervention on the patients in the control group. These patients received routine glycaemia control and healthcare provided to diabetic patients undergoing surgical intervention in the department of general surgery.After receiving written informed consent, the first part of the data collection form on the socio-demographic and disease characteristics of the patients were completed face-to-face. The BG levels of the patients and the medications and insulin used for glycaemic control were recorded one night before surgery. The anxiety levels of the patients were evaluated on the morning of surgery using State-Trait Anxiety Inventory . The second part of the data collection form , which included information on glycaemic management, glycaemia levels and the medications and insulin used on the morning of surgery and during surgery, intensive care stay and the clinical period, was filled in by the nurse on the monitoring and anaesthesia forms.
11086942|NCT04167410|Experimental|intervention group|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. management was conducted by nurses in line with the protocol. Data on glycaemic management of the intervention group was similar to the control group.the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protoco
11086947|NCT04167384|Experimental|Hard nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
11086948|NCT04167384|Experimental|Soft nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
11086949|NCT04167371|Experimental|Biofeedback|
11086950|NCT04167371|Placebo Comparator|Placebo|
11086951|NCT04167358|Experimental|Participants receiving linerixibat|Participants will receive twice daily dose of 90 mg linerixibat from Day 1 to Month 48.
11086952|NCT04167345|Experimental|VX-814|Subjects will be randomized to receive different dose levels of VX-814.
11086953|NCT04167345|Other|Placebo|Subjects will receive placebo matched to VX-814.
11086954|NCT04167332||NMIBC|"Patients diagnosed with primary non-muscle-invasive bladder (NMIBC) cancer.
~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.
~The clinical (demographic, operative and follow-up) and pathological data, and biosamples (blood, urine, bladder cancer tissue) of the patients will be collected in a completely anonymous way."
11086955|NCT04167319||Paclitaxel|Patients scheduled to receive paclitaxel as part of their standard treatment
11086956|NCT04167319||Oxaliplatin|Patients scheduled to receive oxaliplatin as part of their standard treatment
11086957|NCT04167306|Experimental|1) Varenicline + Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Investigational medicinal product (IMP) 2: Bupropion SR 150 mg
11086958|NCT04167306|Experimental|2) Varenicline + Placebo for Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Placebo capsule for IMP 2 (bupropion)
11086959|NCT04167306|Experimental|3) Bupropion + Placebo for Varenicline|Investigational medicinal product (IMP) 2: Bupropion SR 150 mg and Placebo capsule for IMP 1 (varenicline)
11086960|NCT04167306|Placebo Comparator|4) Placebo for Varenicline + Placebo for Bupropion|Placebo capsule for IMP 1 (varenicline) and Placebo capsule for IMP 2 (bupropion)
11086961|NCT04167293|Experimental|SBRT + PD-1 Arm|Patients assigned to this arm will receive SBRT followed by sintilimab. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
11086962|NCT04167293|Other|SBRT Arm|Patients assigned to this arm will receive SBRT alone. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
11086963|NCT04167280|Active Comparator|Ipratropium bromide|20mcg bronchodilator inhaler
11086964|NCT04167280|Placebo Comparator|placebo|matching bronchodilator inhaler
11086965|NCT04167267|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
11086966|NCT04167267|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
11086967|NCT04167254|Experimental|Sit Down and Play|
11086968|NCT04167254|No Intervention|Usual Care|
11086969|NCT04167241||Patients submitted to right pneumonectomy or bi-lobectomy|Consecutive, elective surgical patients submitted to right pneumonectomy or bi-lobectomy
11086970|NCT04167228||CRE infected patients treated with ceftazidime-avibactam|Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam
11086971|NCT04167228||CRE infected patients treated with best available treatment|Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment
11086972|NCT04167215|Experimental|perforator flap augmentation|Doppler probe is used to locate perforating vessels from the superior gluteal artery. . Flaps or lumbar artery flap will be designed to allow deepithelialization and dissection laterally to medially to identify the perforator . then sketolization is performed A gluteal pocket will then create for the augmentation flaps by undermining in a plane just superficial to the gluteal muscle extending to within 5 cm of the inferior gluteal crease. The deepithelialized flaps will then transpose inferomedially , and tacked to the fascia with several sutures.to be used as autologus buttock augmentation flap
11086973|NCT04167215|Experimental|fat injection|liposuction is performed firstly to parts where excess fat is exist and we will prepare the aspirated fat for injection as a graft in subcutaneous tissue of the buttock regoin
11086974|NCT04167202|Experimental|Hydrogen-rich water|Six 30-min ankle baths with hydrogen-rich water (one hydrotherapy every 4 hours)
11086975|NCT04167202|Active Comparator|RICE protocol for acute injury|RICE protocol include: (1) rest, (2) ice packs every 20 min every 3 hours (total of 8 sessions), (3) compression with elastic bandage for 24 h, and (4) leg elevation at all possible times of the injured area above the level of the heart
11086976|NCT04167189|Experimental|ADHD|Subjects will be tested with lidocaine gel.
11086977|NCT04167176|Active Comparator|Erector spinae plane block|ultrasound guided ESP Block after anaesthesia induction
11086978|NCT04167176|Active Comparator|Port site infiltration technique|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of Local anesthetic (LA) mixture that will be divided equally between port sites
11086979|NCT04167163|Active Comparator|Treatment group|"Those with clinical osteoporosis who elect ABL treatment.
~ABL therapy will begin 3 months pre-TKA and continue for a total of 18 months. ABL will be administered by injection pen with dose of 80 mcg SC qDay."
11086980|NCT04167163|No Intervention|Comparator group|Those with clinical osteopenia who receive no treatment.
11086981|NCT04167150|Active Comparator|Dose 1|Participants consume 8 fl oz of tart cherry juice per day.
11086982|NCT04167150|Experimental|Dose 2|Participants consume 2 x 8 fl oz of tart cherry juice per day.
11086983|NCT04167137|Experimental|Arm 1: SYNB1891 Monotherapy|SYNB1891 is to be administered as an intratumoral injection in up to four 21-day cycles of escalating doses on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-4. The starting dose of SYNB1891 in the first cohort will be 1 × 10^6 live cells and will be increased in approximately 3-fold increments in subsequent cohorts until MTD determination. A de-escalation dose of 3 × 10^5 live cells is available if the starting dose is deemed not tolerable. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 on day 1 of each cycle for up to 24 months after initial dose of study treatment.
11086984|NCT04167137|Experimental|Arm 2: SYNB1891 in Combination with Atezolizumab|Once the MTD has been established in Arm 1, dosing of SYNB1891 will begin in Arm 2 at a 10-fold lower dose than the Arm 1 maximum tolerated dose (MTD) and will be increased in approximately 3-fold increments in subsequent cohorts until recommended Phase 2 dose (RP2D) determination. SYNB1891 is to be administered in the same manner and frequency as Arm 1. Atezolizumab will be administered in accordance with its recommended dose and schedule (1200 mg IV every 3 weeks) on day 1 of each of the 4 planned cycles. On days when atezolizumab and SYNB1891 are both administered, SYNB1891 will be administered first, followed by at least 1 hour of observation prior to the atezolizumab infusion. Combination doses will not be escalated above the SYNB1891 single-agent MTD established in Arm 1. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 and atezolizumab on day 1 of each cycle for up to 24 months after initial dose of study treatment.
11086985|NCT04167124|Experimental|multi-sensor lifestyle intervention|
11086986|NCT04167111|Active Comparator|Vitamin D 4000|At baseline, if subjects 25(OH)D levels are 12-19.9, they will be started on 4000 IU per day.
11086987|NCT04167111|Active Comparator|Vitamin D 2400|At baseline, if subjects 25(OH)D levels are 20-30, they will be started on 2400 IU per day.
11086988|NCT04167098|Experimental|Platelet-Rich Plasma|
11086989|NCT04167098|Active Comparator|Corticosteroid|
11086990|NCT04167098|Placebo Comparator|0.9% saline|
11086991|NCT04167085|Experimental|Doxycycline, then Placebo|Doxycycline for a period of 2 months followed by a 1-month washout period, and then placebo for a further 2 months period followed by a 1-month washout period.
11086992|NCT04167085|Experimental|Placebo, then Doxycycline|Placebo for a period of 2 months followed by a 1-month washout period, and then Doxycycline for a further 2 months period followed by a 1-month washout period.
11086993|NCT04167072|Experimental|Scheduled removal|This group involves patients who will have the LAMS removed immediately after all the stones have been cleared from the gallbladder
11086994|NCT04167072|Active Comparator|Observation|This group involves patients who will be followed closely for 1 year after all the stones have been removed from the gallbladder. These patients will keep the stent in place for 1 year and at that time the patients will be offered removal of the stent.
11086995|NCT04167059|Experimental|Waitlist-Control Group|The 'waitlist control' group will receive the 12-week non-intervention period first, followed by 12 week intervention period.
11086996|NCT04167059|Experimental|Immediate Treatment|The 'immediate treatment' group will receive the 12-week intervention period first, followed by 12 week non-intervention period.
11086997|NCT04167046||Control|Patients in this group did not receive an erector spinae block. Data are obtained retrospectively (years 2017 and 2018).
11086998|NCT04167046||Erector spinae block|Patients in this group receive an erector spinae block. Data will be obtained prospectively.
11086999|NCT04167033|Experimental|Premature ovarian insufficiency|60 patients with POI followed in the endocrinology department
11087000|NCT04167033|Other|healthy volunteers|60 healthy volunteers matched with POI's patients
11087001|NCT04167007|Active Comparator|Group I|Gemcitabine at 1000 mg/m²
11087002|NCT04167007|Active Comparator|Group II|Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²
11087003|NCT04166994|Experimental|IMPACT Intervention|Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
11087004|NCT04166994|Other|Usual Care|No exercise or diet specialization.
11087005|NCT04166981|Active Comparator|Non-instrumented arm|Decompression with concomitant non-instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft.
11087006|NCT04166981|Experimental|Instrumented arm|Decompression with concomitant instrumented posterolateral fusion with autologous(obtained from the decompression) and allogenic bone graft and supplementary pedicle screw fixation.
11087007|NCT04166968|Sham Comparator|Control Group|neuromotor training and placebo stimulation
11087008|NCT04166968|Experimental|Group 1|neuromotor training and cathodal stimulation over the unaffected hemisphere
11087009|NCT04166968|Experimental|Group 2|neuromotor training and anodal stimulation over the affected hemisphere
11087010|NCT04166955|Experimental|(Intervention)|Participants will be provided with weekly messages including information for promoting physical activity.
11087011|NCT04166955|No Intervention|(Control)|Participants will be evaluated without providing any intervention.
11087012|NCT04166942|Experimental|Normal Hepatic Function (Group 1--Control)|Matched healthy subjects with normal hepatic function
11087013|NCT04166942|Experimental|Mild Hepatic Impairment (Group 2)|Subjects with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6
11087014|NCT04166942|Experimental|Moderate Hepatic Impairment (Group 3)|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9
11087015|NCT04166942|Experimental|Severe Hepatic Impairment (Group 4)|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10 to 14
11087016|NCT04166929|Experimental|Haplo-BMT followed by NK infusion|"Haplo bone marrow transplant is follewd by a haplo-NK cell infusion (target dose ≥1*106/kg b.w.) at day 7.
~Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused"
11087017|NCT04166929|Active Comparator|Haplo BMT|Patients in this arm receive standard haplo bone marrow transplant without subsequent NK cell infusion.
11087018|NCT04166916|Active Comparator|Slow waves enhancing acoustic stimulation|During non-rapid eye movement (NREM) sleep, acoustic stimuli will be played to increase slow wave amplitude.
11087019|NCT04166916|Sham Comparator|SHAM: no application of acoustic stimuli|During NREM sleep no acoustic stimuli will be played.
11087020|NCT04166916|Active Comparator|Slow waves decreasing acoustic stimulation|During NREM sleep acoustic stimuli will be played to decrease slow waves amplitude.
11087021|NCT04166890|Experimental|NS Lower right molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
11087022|NCT04166890|Active Comparator|SD Lower Left molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
11087060|NCT04166669|Experimental|Cohort 2|Drugs: APX001, rifampin
11087025|NCT04166877|Experimental|Magnesium Group|The magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours.
11087026|NCT04166877|Placebo Comparator|Control Group|The control arm will receive the same volume and rate of saline as if they were in the experimental group.
11087027|NCT04166864|Experimental|SCC-Determined TMS|
11087028|NCT04166851|Experimental|Open contest messages|Participants will view the top PrEP-promotion messages developed via an open contest.
11087029|NCT04166851|Active Comparator|Social marketing messages|Participants will view the PrEP-promotion messages developed via social marketing.
11087030|NCT04166838|Experimental|CD19 UCAR-T|
11087031|NCT04166825|Active Comparator|Long protocol|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day
11087032|NCT04166825|Active Comparator|Short protocol|Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg
11087033|NCT04166825|Active Comparator|Clomiphene citrate|Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle
11087034|NCT04166825|Active Comparator|Letrozole|Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle
11087035|NCT04166825|Active Comparator|Gonadotropins|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).
11087036|NCT04166812||patients with early COPD|diagnosis according to current GOLD recommendations
11087037|NCT04166812||patients at risk for COPD|no current diagnosis according to GOLD recommendations, but at risk for COPD
11087038|NCT04166799|Experimental|Mepitel Film Arm|Patients randomized to the Mepitel Film arm will receive the film for the entire duration of their radiation treatment and will be worn up to 2 weeks after completion of radiotherapy.
11087039|NCT04166799|No Intervention|Standard of Care Arm|Patients randomized to the Standard of Care arm will be instructed to use the institutional standard of care skin treatments for the entire duration of their radiation treatment and up to 2 weeks after completion of radiotherapy.
11087040|NCT04166786|Experimental|Testosterone + Ethanol|Subjects receive a 3-day treatment with testosterone in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
11087041|NCT04166786|Other|Testosterone placebo + Ethanol|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
11087042|NCT04166786|Other|Testosterone + Ethanol placebo|Subjects receive a 3-day treatment with testosterone in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
11087043|NCT04166786|Placebo Comparator|Testosterone placebo + Ethanol placebo|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
11087044|NCT04166773|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11087045|NCT04166773|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11087046|NCT04166773|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11087047|NCT04166773|Placebo Comparator|Placebo|Placebo administered SC once a week.
11087048|NCT04166760|Active Comparator|WHE (regular whey protein)|Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
11087049|NCT04166760|Experimental|speWHE (specific whey protein compound)|Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
11087050|NCT04166747|Experimental|Intervention Group|The participants in this group will receive virtual reality based intervention for 15 minutes at a time, twice in a week for six weeks.
11087051|NCT04166747|No Intervention|Control Group|The participants in this group will not receive virtual reality based intervention for six weeks.
11087052|NCT04166734|Other|Initial safety cohort|Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
11087053|NCT04166734|Other|Expansion cohort|An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
11087054|NCT04166721|Experimental|DKN-01 and atezolizumab|"DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d).
~During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.
~Atezolizumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 840mg on the first day of a two week cycle. (Day 1 q 14d) from cycle 2 onwards.
~In the first cycle of treatment, patients will be treated with only DKN-01, and following this they will be treated with both DKN-01 and atezolizumab"
11087055|NCT04166695|Experimental|Monolithic / facially veneered zirconia|Participants receive one monolithic / facially veneered zirconia fixed partial denture.
11087056|NCT04166695|Other|Completely veneered CoCr|Control group. Participants receive one completely veneered metal ceramic fixed partial denture.
11087057|NCT04166682|Placebo Comparator|Control Group|Routine care
11087058|NCT04166682|Experimental|Interventional Group|Home-based cardiac rehabilitation
11087061|NCT04166656|Other|Arm A : Trumenba®: Standard vaccination|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
11087062|NCT04166656|Other|Arm B:Bexsero®: standard vaccination regimen|Two doses of 0.5 ml each at one month intervals
11087063|NCT04166656|Other|Arm C : Bexsero® Innovative vaccine strategy|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
11087064|NCT04166643|Experimental|WHHIP-PLUS|"Component I: Stakeholder Group Involvement:
~Component II: Environment Assessment:
~Component III: Organizational Changes To Reduce Job Stress:
~Component IV- Worker Health Behavior Change:"
11087065|NCT04166643|Active Comparator|Education only|Education
11087066|NCT04166630|Experimental|ICU Acquired Weakness Group|Participants with a score less than 48 on the Medical Research Council (MRC) Scale will be classified as having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
11087067|NCT04166630|Experimental|No ICU Acquired Weakness Group|Participants with a score of 48 or greater on the Medical Research Council (MRC) Scale will be classified as not having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
11087068|NCT04166617|Active Comparator|Conventional therapy|Conventional physical therapy for upper limb in stroke patients
11087069|NCT04166617|Experimental|Leap motion plus conventional therapy|Leap motion plus conventional physical therapy for upper limb in stroke patients
11087070|NCT04166604|Experimental|trifluridine/tipiracil|35mg/m² BID (PER OS) (one cycle every 4 weeks)
11087071|NCT04166591|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
11087072|NCT04166591|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
11087073|NCT04166578||Mydrane group|Patients were randomly selected to the group receiving intracameral 0.2 ml Mydrane (a solution of 1% lidocaine and 0.025% of adrenaline ) during phacoemulsification.
11087074|NCT04166578||Reference group|Patients were randomly selected to the group receiving intracameral a combination of intracameral solution of lignocaine 1% and adrenalin 0.025% (0.2 ml) during phacoemulsification.
11087075|NCT04166565|Experimental|Daratumumab/bortezomib/cyclophospamide/dexamethasone (daraVCD)|"Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
~Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
~Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).
~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
11087076|NCT04166552|Experimental|EHP-101 low dose once a day|
11087077|NCT04166552|Experimental|EHP-101 low dose twice a day|
11087078|NCT04166552|Experimental|EHP-101 high dose once a day|
11087079|NCT04166552|Experimental|EHP-101 high dose twice a day|
11087080|NCT04166539||Metallosis Patients|Patients who are being seen by surgeons for metal-related issues in the blood, pain, or revision surgery.
11087081|NCT04166539||Control Group|Patients who have had total hip or knee arthroplasty no less than 5-10 years ago, who have no symptoms.
11087082|NCT04166526||Group 1: Typically developing children|Participants of this group will not have a diagnosis of SCD. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
11087083|NCT04166526||Group 2: Children with SCD not receiving treatment|Participants of this group have a diagnosis of SCD, but do not receive chronic transfusions, gene therapy or bone marrow transplants. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
11087084|NCT04166526||Group 3: Children with SCD who have undergone gene therapy|Participants of this group have a diagnosis of SCD and have had gene therapy at least one month prior to enrollment. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
11087085|NCT04166526||Group 4: Children with SCD who have chronic transfusions|Participants of this group have a diagnosis of SCD and receive chronic transfusions. These participants will undergo an MRI, lasting approximately an hour, with simultaneous FDNIRS-DCS monitoring.
11087086|NCT04166513|Active Comparator|Active tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with anodal-tDCS for 10 therapy sessions before.
11087087|NCT04166513|Sham Comparator|Sham tDCS with Phonologic-Focused Speech Therapy|Participants will receive phonologic-focused speech therapy with sham tDCS for 10 therapy sessions.
11087088|NCT04166513|Active Comparator|Active tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with anodal-tDCS for 10 therapy sessions.
11087089|NCT04166513|Sham Comparator|Sham tDCS with Semantic-Focused Speech Therapy|Participants will receive semantic-focused speech therapy with sham tDCS for 10 therapy sessions.
11087090|NCT04166500|Experimental|Intervention|
11087091|NCT04166500|No Intervention|Control|
11087092|NCT04166487|Experimental|Pembrolizumab Cycles 1-2|"For the first two cycles, Pembrolizumab will be administered at a predetermined dose every 3 weeks.
~InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1, with return of results to the treating oncologist prior to Cycle 3 Day 1.
~At Cycle 3, patients will be re-registered per the inclusion criteria into 3 arms;
~PEMBROLIZUMAB Alone
~PEMBROLIZUMAB + Doublet Chemotherapy"
11087093|NCT04166487|Experimental|Pembrolizumab Alone, Cycle 3+|"- Following imaging assessment at Cycle 3, participants will continue pembrolizumab alone if the following responses are observed:
~Response of Partial Response/Complete Response
~Response of Stable Disease with plasma response
~Response of Progressive Disease without worsening cancer symptoms AND plasma response"
11087121|NCT04166292|Experimental|Treated face|The device will be injected on V1 (D0) in the cheekbones (upper part of the cheek) for all subjects and in the chin for 20 subjects minimum and if needed (optional areas) in the temple, and facial oval (mandibular angle and border). A touch-up is possible in one or several of these areas on V2 (M1). Optional treated areas will be at the discretion of subjects and injectors.
11087094|NCT04166487|Experimental|Pembrolizumab + Doublet Chemotherapy, Cycles 3+|"Following imaging assessment at Cycle 3, participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response, OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label, per treating oncologist.
~PEMBROLIZUMAB
~Chemotherapy multiple agents systemic
~PEMETREXED
~CARBOPLATIN
~PACLITAXEL"
11087095|NCT04166474|Experimental|Dolutegravir|
11087096|NCT04166448||Group 1: High risk IUGR patients|EPF<10th perc or PA<10th perc and Doppler ombilical IP> 95th percentile, EPF or PA<3th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW),
11087097|NCT04166448||Group 2: Low risk IUGR patients|EPF et PA>20th perc (reference curves from Collège Français d'Echographie Fœtale, between 20 et 34 GW)
11087098|NCT04166435|Experimental|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
11087099|NCT04166422|Active Comparator|Conventional group|Conventional rehabilitation treatment
11087100|NCT04166422|Experimental|Experimental group|Virtual reality plus conventional rehabilitation treatment
11087101|NCT04166409|Active Comparator|Arm I (vincristine sulfate, carboplatin)|"INDUCTION: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
11087102|NCT04166409|Experimental|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity.
11087103|NCT04166396|Experimental|A: Cystic fibrosis|Patients with CF will be randomly assigned to resveratrol or placebo.
11087104|NCT04166396|Experimental|A: Healthy Controls|Healthy controls will be randomly assigned to resveratrol or placebo
11087105|NCT04166396|Experimental|B: Cystic Fibrosis|Patients with CF will be randomly assigned to NR or placebo.
11087106|NCT04166396|Experimental|B: Healthy Controls|Healthy controls will be randomly assigned to NR or placebo
11087107|NCT04166383|Experimental|1/Arm 1|VB-111 and nivolumab
11087108|NCT04166370|Active Comparator|Standard of Practice|Current Standard of Practice
11087109|NCT04166370|Experimental|Strengthened Services and Social Behavioral Change (SBCC)|Increase referrals to health services, strengthen health services, and provide enhanced social and behavior change communication (SBCC)
11087110|NCT04166370|Experimental|Strengthened Services and SBCC plus Conditional Cash Transfer|Increase referrals to health services, strengthenhealth services, provide enhanced SBCC, as well as cash transfers that are conditional on a mother attending antenatal care (ANC) and monthly nutrition education SBCC group sessions.
11087111|NCT04166357||Respiratory and autonomic complications of GBS|"Early detection of respiratory failure is among the main challenges raised by the management of GBS. Careful monitoring by an experienced team of nurses and physicians is crucial. The classic signs of respiratory failure occur late, and the early manifestations consist only of tachypnea, tachycardia, air hunger, broken sentences, and a need to pause between sentences; later, use of the accessory respiratory muscles, paradoxical breathing, and orthopnea indicate severe diaphragmatic weakness.
~Autonomic dysfunction occurred in the affected patients, including cardiac arrhythmia, hypertension or hypotension, ileus, and urinary retention."
11087112|NCT04166344|Experimental|Intervention Group|Participants in the IG will be given free access to the HappyAir platform during a 6-month period. This platform combines online/offline content to help patients with chronic respiratory diseases monitor their symptoms and improve self-management. In addition to tailored information on their condition, participants will be encouraged to fill in daily data on their physical activity levels, symptomatology, use of rescue medication and mood. In children under 12 years, parents or caregivers will fill in this information. Patients will be asked to record their peak expiratory flow using an electronic peak flow meter twice daily and to fulfil the Asthma Control Questionnaire once a week. They will also have a device connected to their inhaler to record adherence to the medical treatment and will get daily reminders in their smartphones. Every patient will be assigned a respiratory coach who will monitor patient during the study and whom the patients can contact at any time.
11087113|NCT04166344|No Intervention|Control Group|Subjects in the CG will receive standard care consisting of periodic visitations at the Allergology or Paediatric Pulmonology Unit in their respective hospitals every 4 - 8 weeks according to their physician's criteria. In addition, patients and caregivers in both groups will receive one educational session regarding the correct use of their inhalers.
11087114|NCT04166331|Placebo Comparator|Control|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
11087115|NCT04166331|Experimental|Experimental|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
11087116|NCT04166318|Active Comparator|Arm A (standard-dose chemoradiation)|Patients undergo 28 fractions of intensity-modulated radiation therapy (IMRT). Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 and 29-32 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
11087117|NCT04166318|Experimental|Arm B (de-intensified chemoradiation)|Patients undergo 20 or 23 fractions of IMRT. Within 24 hours, patients also receive mitomycin IV over 30 minutes or less on day 1 and either fluorouracil IV over 24 hours on days 1-4 or capecitabine PO BID 5 days per week (Monday - Friday) until completion of IMRT in the absence of disease progression or unacceptable toxicity.
11087118|NCT04166305||Drug responders|60 patients are drug responders
11087119|NCT04166305||Drug resistant|60 patients are drug resistant
11087120|NCT04166305||The control|The control consists of 60 Age and gender matched healthy individual with negative past and family history of epilepsy and febrile convulsion.
11087122|NCT04166279|Experimental|Single rehabilitative Treatment|Patients treated within single rehabilitative protocol
11087123|NCT04166279|Experimental|Group rehabilitative Treatment|Patients treated within group rehabilitative protocol
11087124|NCT04166253|No Intervention|Control group|Control group of breast cancer patients will receive adjuvant AC chemotherapy
11087125|NCT04166253|Experimental|Vitamin D group|Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily
11087126|NCT04166240|Experimental|SAFER TRACKS Intervention|Each cluster starts receiving the intervention in sequence per cluster randomized control trial designs. Each cluster will participate in attending monthly coaching calls and compare their data on test results from pre-intervention to receiving the intervention.
11087127|NCT04166240|No Intervention|Non-intervention period|When the cluster is not in active intervention, they are in the non-intervention period. The amount of time that each site contributes to the intervention depends on which cluster they belong to.
11087128|NCT04166227|Active Comparator|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
11087129|NCT04166227|Active Comparator|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
11087130|NCT04166214|Experimental|tele-mentoring intervention|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
11087131|NCT04166201|Other|modified chevrel technique|hernioplasty done with double mesh modification of chevrels technique
11087132|NCT04166188|Experimental|Cadavers|"20ml of 0.01% methylene blue solution (50mg of methylene blue diluted in 0.9% saline 500ml) will be injected, simulating the LESP block technique: injection between the transverse process of the fourth lumbar vertebra (L4) and the erector muscle of the underlying spine.
~The injection will be performed with a Quincke 20G 100-150mm ultrasound-guided needle with a low-frequency curvilinear transducer (4-8 MHz - SonoSite) in the plane between the transverse process of L4 and the spinal erector muscle, bilaterally in each cadaver. by the same operator.
~After injection of the solution the cadavers will be submitted to posterior lumbar region dissection by an anatomist and analyzed the dispersion and impregnation of the blue solution. The anatomical structures with the dye dispersion will be photographed and stored."
11087133|NCT04166175|Active Comparator|group 1 botox group|48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions
11087134|NCT04166175|Active Comparator|group 2 lateral sphincterotomy group|48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position
11087135|NCT04166162|Experimental|Focus Group|The Focus Group consists of the participating parents who are BTC employees with child/children in the range of 8 to 16 years old. The Focus Group will receive a total of 6 weekly sessions of the TBD Intervention.
11087136|NCT04166162|Experimental|Social Development Strategy (SDS) Group|All participating BTC workers will be receiving SDS intervention for a minimum of 1 session.
11087137|NCT04166162|Experimental|Brief Intervention Motivational Interviewing (BIMI) Group|Participating 11 to 16 year old children of BTC employees will be receiving the BIMI intervention.
11087138|NCT04166162|Experimental|Business that Care (BTC) Coalition Group|Participating BTC employees who are selected by the respective directors of the participating companies to be part of the BTC Coalition will receive a total of 8 BTC training sessions in the space of 6 months.
11087139|NCT04166149||University of Maryland|Pancreas and pancreas kidney patients enrolled at University of Maryland. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
11087140|NCT04166149||University of Wisconsin|Pancreas and pancreas kidney patients enrolled at University of Wisconsin. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
11087141|NCT04166149||Georgetown University|Pancreas and pancreas kidney patients enrolled at Georgetown University. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
11087142|NCT04166136|Active Comparator|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
11087166|NCT04165967|Experimental|Tumor-infiltrating lymphocyte product (TIL) transfer|The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
11087167|NCT04165941|Experimental|DRI cell therapy|The only arm will receive the DRI modified gamma delta T cells following standard therapy with radiation and temozolomide chemotherapy concurrent.
11087598|NCT04163107|Experimental|Combination treatment of carfilzomib/dexamethasone/HCQ|
11087143|NCT04166136|Active Comparator|Transition from the Rearfoot to the Forefoot and Midfoot|"Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. The participants will receive verbal command Try to touch first with the middle region of the foot on the treadmill. In the last four sessions, feedback will be gradually removed. At the end of each session, participants will be asked a question about the naturalness of running the new foot touch pattern on the ground. A scale from 0 to 10 will be used, where 0 means very difficult to perform and 10 indicates easy pattern. The perception of pain will also be evaluated with the numerical scale of pain of 11 points (0 to 10), where 0 means no pain and 10 the greatest pain possible."
11087144|NCT04166136|Active Comparator|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
11087145|NCT04166110|Active Comparator|Physician's prescription|Antibiotic treatment duration according to physician, following the French national guidelines: 7 to 14 days.
11087146|NCT04166110|Experimental|Duration according to stability|"Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%).
~Minimum of duration of antibiotic treatment: 3 days."
11087147|NCT04166097|Experimental|Heart Smart Interventional Program|"Subjects participate in this 6-week intervention which include a weekly didactic session, with each week devoted to a different theme (food, exercise, etc). The intervention will follow the program outlined in the book Heart Smart for Women: Six S. T. E. P. S. in Six Weeks to Heart-Healthy Living."
11087148|NCT04166084|Active Comparator|Control Group|Patients in this group will receive active ROM exercises, 10 repeats X 3 times a day, 5 days a week for 6 weeks. All exercises will be performed at home .
11087149|NCT04166084|Experimental|Training group|I addition to active ROM exercises, patients in this group will also receive trunk stabilization exercises training for 45 minutes, 2 times a week for 6 weeks. All exercises sessions will be supervised by a physiotherapist in a clinic per week.
11087150|NCT04166071|Active Comparator|Naltrexone|
11087151|NCT04166071|Placebo Comparator|Placebo|
11087152|NCT04166058|Active Comparator|72 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
11087153|NCT04166058|Active Comparator|145 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
11087154|NCT04166058|Active Comparator|290 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
11087155|NCT04166045|Sham Comparator|Sham|Treatment at the bicep location
11087156|NCT04166045|Active Comparator|Verum|Treatment at the hand location
11087157|NCT04166019|Experimental|Peer-led self-management program|Peer-led self-management program (PLSMI) consists of 10 weekly/biweekly, 1.5-hour sessions (4 months), based on the modified Crisis-resolution-team Optimization and Relapse Prevention (CORE) program workbook/manual and psycho-education programs developed by the research team. The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being. Participants work through the workbook at their own pace, with the support from the peer support worker, to facilitate/support their recovery. They will meet in group with a trained peer support worker on 10 sessions, usually at 7-12 days intervals over 4 months.
11087158|NCT04166019|Active Comparator|Psycho-education group|Psycho-education groups (12-18 members/group; 10 two-hour sessions, weekly/biweekly), 4-month duration similar to the PLSMI, will be led by one trained advanced practice psychiatric nurse in each center experienced in psychiatric rehabilitation, and are guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psycho-education programs for psychosis.
11087159|NCT04166019|Other|Usual care only|Usual care (control) participants (and treatment groups) will receive routine psychiatric outpatient and community mental healthcare services.
11087160|NCT04166006|Experimental|Experimental|"7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by Interleukin (IL) - 2 (IL-2), at a dose of 3 Million Units (MU), given by subcutaneous injection daily for five days (days 3-7). This constitutes a treatment cycle.
~Treatment cycles are repeated every 28 days up to a maximum of six cycles."
11087161|NCT04165993|Experimental|Concurrent chemotherapy and KN026|KN026 combined with docetaxol
11087162|NCT04165993|Experimental|KN026 monotherapy|KN026 monotherapy
11087163|NCT04165993|Experimental|A combination treatment of KN026 and KN046|KN026 combined with KN046
11087164|NCT04165980|Sham Comparator|Sham transcranial direct current stimulation (sham tDCS)|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
11087165|NCT04165980|Active Comparator|Active transcranial direct current stimulation (activetDCS)|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
11087168|NCT04165902|Experimental|steroid plus hyaluronic acid|steroid plus hyaluronic acid injection, one time per week, for 3 weeks
11087169|NCT04165902|Active Comparator|dextrose plus hyaluronic acid|dextrose plus hyaluronic acid injection, one time per week, for 3 weeks
11087170|NCT04165876|Active Comparator|Primary motor cortex|
11087171|NCT04165876|Active Comparator|Dorsolateral prefrontal cortex|
11087172|NCT04165876|Active Comparator|Multi-modal stimulation (DLPFC+M1)|
11087173|NCT04165876|Sham Comparator|Sham-stimulation|
11087174|NCT04165863|Experimental|A|treatment of the surgical wound healing process with Platelet-rich-fibrin in patients undergoing total knee replacement surgery
11087175|NCT04165863|Active Comparator|B|Gold standard treatment of the surgical wound healing process without Platelet-rich-fibrin in patients undergoing total knee replacement surgery
11087176|NCT04165850|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
11087177|NCT04165837|Experimental|Active|
11087178|NCT04165837|Placebo Comparator|Placebo|
11087179|NCT04165824|Experimental|MT-1186|
11087180|NCT04165811|Experimental|Aerobic Dance based Exercise|The exercise program will be administered 60 minutes, 2 days a week for 8 weeks. The exercise program will be created by physiotherapists as a group exercise program.
11087181|NCT04165811|Experimental|Counseling of physical activity|Physical activity counseling is aimed at increasing the physical activity levels of the individuals who are waiting for bariatric surgery in the preoperative period.
11087182|NCT04165798||Prospective NSCLC Participants|Male and female participants with histologically-confirmed diagnosis of squamous or nonsquamous NSCLC will be screened for participation in 1 of 3 pembrolizumab substudies.
11087183|NCT04165785|Experimental|OPT IPL followed by MGX|"Subjects in the experimental arm will receive OPT IPL followed by MGX: OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
~Interventions:
~Device: IPL Procedure: MGX"
11087184|NCT04165785|Sham Comparator|Sham OPT IPL followed by MGX|"Subjects in the sham comparator arm will receive Sham OPT IPL followed by MGX: Sham OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
~Interventions:
~Device: Sham IPL Procedure: MGX"
11087185|NCT04165772|Experimental|Patients with rectal adenocarcinoma|Patients with clinical Stage II (T3-4, N-) or Stage III (any T, N+) MRI-staged, MSI-H or dMMR, rectal cancer will receive up to 6 months (9, 3-week cycles) of PD-1 blockade followed by standard chemoradiation (with concurrent capecitabine/ 5-FU) and then TME (total mesorectal excision). Patients will be given TSR-042 500mg flat dose Q3 weeks. Following completion of 6 months of treatment (9, 21-day cycles) with TSR-042, participants will continue neoadjuvant treatment or being follow up phase. Participants who exhibit CR will proceed to non-operative follow-up. Participants who do not have a CR after 6 months of TSR-042 treatment will received chemoradiation per standard institutional guidelines. Chemoradiation will begin 6-8 after Cycle 9 day 1 of TSR-042 treatment. After completing chemoradiation, patients will be assessed for response at 6-12 weeks. If they do not have a complete clinical response, they will undergo TME.
11087186|NCT04165759||patients|Patients with lung cancer who are candidates for surgery.
11087187|NCT04165746|Experimental|Enhanced Institutional Care|"Caregivers at institutions will participate in a caregiving training, called Video Feedback Intervention to Promote Positive Parenting (VIPP). During VIPP a trained interventionist meets with a caregiver and child in the home environment.
~The VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
11087188|NCT04165746|Experimental|Enhanced Foster Care|"Foster parents will be recruited, consented to background checks, and trained in Portuguese. Hired foster parents will supported and monitored by project social workers and psychologists from local Foster Care programs. Foster parents will received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Project social workers will consult weekly with US staff experienced in dealing with young children in foster care.
~Additionally, foster parents will participate in the VIPP caregiving training, in the same format as that described in the Enhanced Institutional Care Arm: the VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
11087189|NCT04165733||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
11087190|NCT04165720||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
11087191|NCT04165707|Experimental|Keyto intervention arm|Keyto device + app
11087192|NCT04165707|Active Comparator|Weight Watchers comparator arm|Weight Watchers app
11087193|NCT04165681|Experimental|Limbix Spark|A 5 week mobile + virtual reality CBT-based program
11087194|NCT04165668||Dispatched lay responders|Nearby mobile phone located and dispatched lay responders who reached the place of the suspected OHCA before EMS and first responders (fire and police services).
11087195|NCT04165668||Non-dispatched lay responders|Nearby mobile phone located lay responders who have neither actively, nor technically responded due to either human or technical factors.
11087196|NCT04165655|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 10-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 10-weeks. The activity sessions will include semi-structures free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
11087197|NCT04165655|No Intervention|Waitlist control group|Participants in this group will not receive the 10-week group based activity intervention throughout the duration of this study. Participants will be able to participate in the 10-week activity intervention once this research has ended.
11087198|NCT04165629||Aspirin responders|On impedance aggregometry- Multiplate analyzer, if ASPI < 600 or ASPI/TRAP < 0.5
11087199|NCT04165629||Aspirin non-responders|On impedance aggregometry- Multiplate analyzer, if ASPI > 600 or ASPI/TRAP > 0.5
11087200|NCT04165629||Clopidogrel responders|On impedance aggregometry- Multiplate analyzer, if ADP < 500 or ADP/TRAP < 0.5
11087201|NCT04165629||Clopidogrel non-responders|On impedance aggregometry- Multiplate analyzer, if ADP > 500 or ADP/TRAP > 0.5
11087202|NCT04165616||Individuals with stroke|
11087203|NCT04165603|Active Comparator|5mg/kg of ICG, 24h before surgery|5mg/kg of indocyanine green, intravenously injection 24 hours before surgery
11087204|NCT04165603|Experimental|1mg/kg of ICG, 24h before surgery|1mg/kg of indocyanine green, intravenously injection 24 hours before surgery
11087205|NCT04165603|Experimental|5mg/kg of ICG, 48h before surgery|5mg/kg of indocyanine green, intravenously injection 48 hours before surgery
11087206|NCT04165603|Experimental|1mg/kg of ICG, 48h before surgery|1mg/kg of indocyanine green, intravenously injection 48 hours before surgery
11087207|NCT04165590|Experimental|Blood-stage infection of P.vivax|This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
11087208|NCT04165577|Experimental|OCD, Active TMS|Participants with OCD who receive active rTMS
11087209|NCT04165577|Sham Comparator|OCD, Sham TMS|Participants with OCD who receive sham rTMS
11087210|NCT04165577|Other|Healthy Control, Active TMS|Healthy control participants who receive active rTMS
11087211|NCT04165577|Other|Healthy Control, Sham TMS|Healthy control participants who receive sham rTMS
11087212|NCT04165564||Group 1 - Screening|Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)
11087213|NCT04165564||Group 2 - Incidental|Participants in this group will be > 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)
11087214|NCT04165551|Experimental|Probiotic|Volunteers will take 1 capsule per day containing 6x109 cfu of Lactobacillus BSL_PS71 in maltodextrin.
11087215|NCT04165551|Placebo Comparator|Placebo|Volunteers will take 1 capsule per day containing maltodextrin.
11087216|NCT04165538|Experimental|TEG group|
11087217|NCT04165538|No Intervention|Non-TEG group|
11087218|NCT04165525|Active Comparator|HelixAR Electrosurgical Generator (HEG)|Argon gas and high frequency electrical current ablation device
11087219|NCT04165525|Active Comparator|Conventional Electrosurgical Coagulation (CEC) Systems|Standard Bovie electrosugical device without argon gas
11087220|NCT04165512|Experimental|stellate ganglion block in breast cancer related lymphedema|US-guided stellat ganglion block will be applied to the patients with breast cancer related lymphedema twice at two-week intervals.
11087221|NCT04165499|Experimental|Combination of Plant Extracts (BSL_EP026)|Volunteers will take 1 capsule twice daily with the combination of the plant extracts (BSL_EP026).
11087222|NCT04165499|Placebo Comparator|Control|Volunteers will take 1 capsule twice daily with maltodextrin.
11087223|NCT04165486|Experimental|BIIB101 Low Dose|Participants will be administered BIIB101 low dose and matching placebo via intrathecal (IT) injection at regular intervals.
11087224|NCT04165486|Experimental|BIIB101 Medium Dose|Participants will be administered BIIB101 medium dose and matching placebo via IT injection at regular intervals.
11087225|NCT04165486|Experimental|BIIB101 High Dose|Participants will be administered BIIB101 high dose and matching placebo via IT injection at regular intervals.
11087226|NCT04165473|Experimental|Intervention Group|In a 6-module course, with four 3-day modules and two 5-day modules in the timeframe of one year, participants learn ways to strengthen their personal resources to establish effective social relationships and to develop skills as a social being. In between the module courses, the participants take 5 single sessions with an instructed trainer and document 10 conversations/social situations where they successfully applied the new skills.
11087227|NCT04165473|No Intervention|Intervention Group - Close Relationship|Individuals having a close relationship to participants of the Intervention Group
11087228|NCT04165473|No Intervention|Control Group|Individuals matched to the participants of the Intervention Group
11087229|NCT04165473|No Intervention|Control Group - Close Relationship|Individuals having a close relationship to participants of the Control Group
11087230|NCT04165460|Experimental|"A Intervention"|Psychoeducation, Relaxation, Cognitive Reestructuring and Problem Solving
11087231|NCT04165460|Active Comparator|"B Intervention"|Psychoeducation, Relaxation
11087232|NCT04165447|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display the label on any products.
11087233|NCT04165447|Experimental|Within-category labeling|Arm 2 displayed the label on the 20% of products that were lowest in calories per serving within each product category (termed Within-category Labeling, WC).
11087234|NCT04165447|Experimental|Across-category labeling|Arm 3 displayed the label on the 20% of all products that were lowest in calories per serving (termed Across-category Labeling, AC).
11087235|NCT04165434|Experimental|Experimental|Untrained unilateral transtibial amputees who underwent the assessment and recommended training.
11087236|NCT04165434|No Intervention|Control|Untrained unilateral transtibial amputees who after the evaluation were not included for the recommended training.
11087237|NCT04165421|Experimental|Family intervention group|The intervention starts with a two hour group session for AF-patients and family members designed by the PhD student and the project nurses based on clinical guidelines of AF-management and theory from multifamily group intervention. Project nurses who are also Nurse specialists will facilitate knowledge to patients and family members about AF and how to support self-management in their daily living. Furthermore the (Family focused nursing) FFN intervention will consist of 3 -5 Family Strength Orientated Therapeutic Conversations (FAM-SOTC) accordingly to the needs of patient and the family. The FAM-SOTC conversations will be used as health promoting conversations and a way to enhance family health and psychological resilense
11087238|NCT04165421|No Intervention|Control group|"The control group will receive conventional care and treatment according to guidelines.
~Conventional care is characterized by ad hoc management as per usual standards of clinical care (with access to routine medical care, hospital care, and pharmacotherapy)."
11087239|NCT04165408|Experimental|Device Use|Only one arm
11087296|NCT04165031|Experimental|LY3499446 + Cetuximab Phase 1|Participants given LY3499446 orally and cetuximab intravenously (IV).
11087240|NCT04165395|No Intervention|Control group|The control group will receive the standard of care adopted at Hôpital du Sacré-Coeur de Montréal in terms of pressure ulcers prevention in the SCI population.
11087241|NCT04165395|Experimental|Intervention group|In addition to undergoing the identical standard-of-care as the control group, all patients in this group will receive a prophylactic five-layer foam dressing placed directly on the sacral area and a Heelmedix boot installed alternately on both legs
11087242|NCT04165382|Other|Pre-implementation study group|Preterm infants receiving NIV before the implementation of the guideline
11087243|NCT04165382|Other|Post-implementation study group|Preterm infants receiving NIV after the implementation of the guideline
11087244|NCT04165369||Patients with extended surgical exposures|Patients with extended surgical exposures requiring postoperative observation.
11087245|NCT04165356|Experimental|Mouth-rinse with clorhexidine|Mouth-rinse with 0.12% clorhexidine + tooth brushing twice daily
11087246|NCT04165356|Active Comparator|Mouth-rinse with bicarbonate isotonic solution|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate + tooth brushing twice daily
11087247|NCT04165343||Non-Alcoholic Fatty Liver Disease (NAFLD)|"Cohort: Patients with known Non-Alcoholic Fatty Liver Disease (NAFLD)
~All patients will undergo the following interventions:
~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood test"
11087248|NCT04165343||Healthy Control Subjects|"Cohort: Healthy controls
~All healthy subjects will undergo the following interventions:
~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood tests"
11087249|NCT04165330|Experimental|AL3818 plus nivolumab|"Part 1: All participants will be assigned to receive AL3818 capsules orally, once daily at sequential deescalating doses (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (on Day 1 and Day 15) for a single 21-day cycle. Participants may continue study treatment at the AL3818 cohort dose at investigator discretion.
~Part 2: All participants will receive AL3818 capsules orally, once daily at the RP2D determined from Part 1 (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (every 2 weeks starting on Cycle 1, Day 1) in 21-day cycles, for up to 24 cycles of total AL3818 therapy."
11087250|NCT04165317|Experimental|PF-06801591 + BCG induction and maintenance|PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
11087251|NCT04165317|Experimental|PF-06801591 + BCG induction only|PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
11087252|NCT04165317|Active Comparator|BCG induction and maintenance|Bacillus Calmette Guerin (induction and maintenance).
11087253|NCT04165304|No Intervention|control|the range of products offered by the vending machines remains unchanged
11087254|NCT04165304|Other|Intervention group 1|vending machines will be re-equipped to contain 60% drinks containing a maximum of 6.7g sugar/100ml, 20% drinks containing more than 6.7g sugar/100ml and 20% water
11087255|NCT04165304|Other|Intervention group 2|In the second intervention group, the vending machines offer 80% water and 20% products with a maximum of 6.7g sugar/100ml.
11087256|NCT04165291|Experimental|F4C|Participants randomized to the Fathers for Change (F4C) program.
11087257|NCT04165291|Active Comparator|BIP|Participants randomized to the Batterer Intervention Program (BIP).
11087258|NCT04165278|Experimental|After hyperthermic baths|On the first, third and fifth day of the first week, each subject took the HTB at the same time. They would receive subjective measures before and after HTB.
11087259|NCT04165265|Experimental|Responders and Partial/non-responders|"The definition of responders to glucocorticoids is: Bowel movements ≤ 3/day without blood and normalization of CRP. In the study, this is supported by CC.
~The definition of non-responders is: Bowel movements > 8/day or 3-8/day and CRP > 45 mg/l. The decision if the patient is a non-responder is supported by CC.
~Questionnaires in CC and FC analysis with CalproSmart are performed every day until discharge or when classified as green in CC. After discharge questionnaires in CC and FC analysis are performed once every week in the following 7 weeks and a final registration at week 52. In case of disease relapse between week 7 and 52 registration in CC and FC analysis are performed on demand. Fecal samples for future use (biobank) and FC Elisa as well as blood samples are done before administration of IFX (week 2 and 6). At follow-up (week 52) it is considered whether the patient underwent colectomy or not."
11087260|NCT04165252||Term Birth|Delivery between 37-41 weeks of gestation
11087261|NCT04165252||Preterm birth|Delivery between 24-37 weeks of gestation
11087262|NCT04165239|Experimental|Treatment A|Oral administration of 50 mg KH176 twice daily
11087263|NCT04165239|Experimental|Treatment B|Oral administration of 100 mg KH176 twice daily
11087264|NCT04165239|Placebo Comparator|Treatment C|Oral administration of matching placebo twice daily
11087265|NCT04165226|Active Comparator|Low level light therapy (LLLT)|Low level light therapy using 808/915 nm infra red diode laser
11087266|NCT04165226|Active Comparator|Fractional CO2|Fractional carbon dioxide laser 10600 nm
11087267|NCT04165226|Active Comparator|Combined fractional CO2 and LLLT|Combined fractional CO2 laser and low level light therapy
11087268|NCT04165213|Experimental|Online training site|"Ten participating Trinity PACE Organizations will participate via webinar in a brief orientation/ training to the study and project logistics. Next, Trinity Health PACE organizations will be randomized into two groups using the re-randomization procedures described in the paragraph below; 5 PACE organizations will serve as the control site in which training will be provided via the traditional high intensity face-to-face.; 5 PACE organizations will serve as the comparison and be trained through the online training site. Prior to randomization, we will carefully examine PACE organizations on important variables such as size, location (urban; rural) percent of persons with dementia, and staff: participant ratio. In each site, one occupational therapist (OT) and one nurse (RN) will be trained (e.g., 5 OTs and 5 RNs in traditional sites; 5 OTS and 5 RNS in online training sites for a total of 10 OTs and 10 RNs or 20 health providers)."
11087297|NCT04165031|Experimental|LY3499446 + Erlotinib Phase 1|Participants given LY3499446 and erlotinib orally.
11087298|NCT04165031|Experimental|LY3499446 Phase 2|Participants given LY3499446 monotherapy orally.
11087299|NCT04165031|Experimental|LY3499446 + Abemaciclib Phase 2|Participants given LY3499446 and abemaciclib orally.
11087300|NCT04165031|Experimental|LY3499446 + Erlotinib Phase 2|Participants given LY3499446 and erlotinib orally.
11087269|NCT04165213|Experimental|COPE-PACE participant outcomes with online training|The efficacy of the COPE program training on PACE participant outcomes by type of COPE training will be evaluated in this arm. Each of the PACE organizations will enroll 5 persons with dementia and their caregivers in the study. This will yield 50 family dyads or 100 subjects (25 dyads in traditional training sites and 25 dyads in online training sites). Dyads will be followed for 4 months. Non-inferiority analysis will be used to assess whether dyads will yield the same or better outcomes regardless of how PACE staff were trained.
11087270|NCT04165200|Active Comparator|Patients receiving FMT capsules and ART|"ART Start at week 0 non-stop.
~FMT. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.
~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.
~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.
~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
11087271|NCT04165200|Placebo Comparator|Patients receiving placebo capsules|"ART Start at week 0 non-stop.
~Placebo capsules. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.
~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.
~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.
~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
11087272|NCT04165187|Experimental|BAT+Home exercise program|The patients in this group will participate in BAT for 3 days a week for 6 weeks in addition to home exercise program.
11087273|NCT04165187|Active Comparator|Home exercise program|The patients in the control group will perform home exercise program, two times a day, 7 days a week for 6 weeks.
11087274|NCT04165174|Experimental|PAS|PD-1:240mg,ivdrip,Q3W,begin with SBRT Apatinib:250mg,po,QD,begin with SBRT SBRT:6-10Gy/F,5-8F
11087275|NCT04165161|Other|superior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure
11087276|NCT04165161|Other|superior with 10 cmH2O positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
11087277|NCT04165161|Other|inferior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure
11087278|NCT04165161|Other|inferior with 10 cmH2O positive tele-expiratory pressur|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
11087279|NCT04165148|Experimental|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the Intelligent Flow System (iFS) AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
11087280|NCT04165148|Active Comparator|conventional laparoscopy|conventional laparoscopy
11087281|NCT04165135||Haemophilia A Without FVIII Inhibitors|
11087282|NCT04165122|Experimental|HDIT101 + Valaciclovir placebo|"Group A:
~Patients treated with a single i.v. infusion of 2 g HDIT101 for 60 min at the randomization visit and with an episodic Valaciclovir placebo bid for 3 days."
11087283|NCT04165122|Active Comparator|HDIT101 placebo + Valaciclovir|"Group B:
~Patients treated with a single i.v. infusion of HDIT101 placebo for 60 min at the randomization visit and with episodic Valaciclovir 500 mg twice daily for 3 days."
11087284|NCT04165109||Trial Ready Cohort|Non-demented adults with Down syndrome (DS)
11087285|NCT04165096|Experimental|Pembrolizumab + MK-5890|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-5890 IV for a maximum of 35 cycles (approximately 2 years). All participants are premedicated 1.5 hours (±30 minutes) before infusion of MK-5890 with 50 mg oral (PO) diphenhydramine (or equivalent dose of antihistamine) and 500-1000 mg of acetaminophen PO (or equivalent dose of analgesic).
11087286|NCT04165096|Experimental|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years).
11087287|NCT04165083|Experimental|Pembrolizumab + MK-4830|On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years)
11087288|NCT04165070|Experimental|Pembrolizumab + MK-7684 + Carboplatin + Paclitaxel|On Day 1 of each 3-week cycle, participants with squamous NSCLC receive pembrolizumab 200 mg intravenously (IV) PLUS MK-7684 IV PLUS carboplatin Area Under the Concentration-Time Curve (AUC) 6 IV PLUS paclitaxel 200 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-7684 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
11087289|NCT04165070|Experimental|Pembrolizumab + MK-7684 + Pemetrexed|On Day 1 of each 3-week cycle, participants with nonsquamous NSCLC receive pembrolizumab 200 mg IV PLUS MK-7684 IV PLUS carboplatin AUC 5 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 1-4, followed by maintenance treatment of pembrolizumab 200 mg IV PLUS MK-7684 IV PLUS pemetrexed 500 mg/m^2 IV in Cycles 5-35 (total treatment duration: up to approximately 2 years).
11087290|NCT04165057|Active Comparator|Group OMT|Optimal muscle tension management
11087291|NCT04165057|No Intervention|Group Control|Conventional anesthetic management
11087292|NCT04165044|Active Comparator|L-PRF+CAF|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
11087293|NCT04165044|Active Comparator|CTG+CAF|Connective Tissue graft plus Coronally Advanced Flap
11087294|NCT04165031|Experimental|LY3499446 Phase 1|Participants given LY3499446 monotherapy orally.
11087295|NCT04165031|Experimental|LY3499446 + Abemaciclib Phase 1|Participants given LY3499446 and abemaciclib orally.
11087754|NCT04161924||X-ray imaging without physical grid using experimental SimGrid|
11087301|NCT04165031|Experimental|LY3499446 + Cetuximab Phase 2|Participants given LY3499446 orally and cetuximab IV.
11087302|NCT04165031|Active Comparator|Docetaxel Phase 2|Participants given docetaxel IV.
11087303|NCT04165005|Experimental|decentering group|"MBSR focused on a decentering component (i.e. individuals observe their feelings and thoughts as ephemeral events, with no reactivity, alongside with acceptance)."
11087304|NCT04165005|Experimental|guided imagery group|a group practicing in guided imagery sessions.
11087305|NCT04165005|No Intervention|control group|usual care group
11087306|NCT04164992|Experimental|not resectable pancreatic cancer patients|Patients with not-resectable pancreatic adenocarcinoma will be treated with endoscopic ultrasound radio frequency ablation
11087307|NCT04164979|Experimental|Cabozantinib and Pembrolizumab|Subjects receive Cabozantinib 40mg PO daily on days 1-21 and Pembrolizumab 200mg IV on day 1 every 21 days.
11087308|NCT04164966||New onset Type 1 Diabetes|
11087309|NCT04164966||Healthy Normal Volunteers (HNV)|
11087310|NCT04164953|Experimental|Dupuytren's|Surgical intervention as second-line surgery for the treatment of Dupuytren's disease.
11087311|NCT04164940||Age 21-30|Patients aged 21-30 when admitted to hospital and receiving brief alcohol intervention
11087312|NCT04164940||Age 31-40|Patients aged 31-40 when admitted to hospital and receiving brief alcohol intervention
11087313|NCT04164940||Age 41-50|Patients aged 41-50 when admitted to hospital and receiving brief alcohol intervention
11087314|NCT04164940||Age 51-60|Patients aged 51-60 when admitted to hospital and receiving brief alcohol intervention
11087315|NCT04164940||Age 61-70|Patients aged 61-70 when admitted to hospital and receiving brief alcohol intervention
11087316|NCT04164940||Age 71-80|Patients aged 71-80 when admitted to hospital and receiving brief alcohol intervention
11087317|NCT04164940||Age 81 and older|Patients aged 81 and older when admitted to hospital and receiving brief alcohol intervention
11087318|NCT04164927|Active Comparator|Kinesio Taping|Lymphatic correction method is applied via Kinesiotaping depending on the size of the leg two or three fan-cut tape was applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Certified Kinesio Tape practitioner applied Kinesiotaping on the second day (day 2) post-surgery and once a week.
11087319|NCT04164927|Active Comparator|Manual Lymphatic Drainage|A standardized 30-minute manual lymphatic drainage (MLD) treatment is applied to MLD group. On the second day (day 2) post-surgery, patients allocated to the MLD group underwent a standardized 30 minute MLD treatment on the operated limb by an experienced remedial massage therapist trained in delivering MLD.
11087320|NCT04164927|No Intervention|Control|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
11087321|NCT04164914|Experimental|Healthy subjects|Prebiotic administration
11087322|NCT04164901|Experimental|AG-881|AG-881 40 mg, continuous daily dosing.
11087323|NCT04164901|Placebo Comparator|Matching Placebo|Matching placebo 40 mg, continuous daily dosing. Participants who experience radiographic disease progression and who were receiving placebo will have the option to cross-over to AG-881, provided certain criteria are met.
11087324|NCT04164888|Experimental|CIVI 007, Dose A|SC injection of a PCSK9 inhibitor- low dose given twice
11087325|NCT04164888|Experimental|CIVI 007, Dose B|SC injection of PCSK9 inhibitor- dose titration
11087326|NCT04164888|Experimental|CIVI 007, Dose C|SC injection of PCSK9 inhibitor- high dose given twice
11087327|NCT04164888|Placebo Comparator|Placebo|Placebo SC injection matching PCSK9 inhibitor given twice
11087328|NCT04164862|Active Comparator|use ACCUVEIN AV400|Device to facilitate cannulation of the great saphenous vein at the ankle in infants
11087329|NCT04164862|Active Comparator|ULTRASOUND GUIDED CANNULATION|Ultrasound cannulation of the great saphenous vein in infants
11087330|NCT04164849|Experimental|5-ALA photopheresis|All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light photopheresis. The investigators will collect mononuclear cells by connecting patient to Spectra Optia with CMNC (continuous mononuclear cell collection protocol), and these cells will include active T-lymphocytes. 5-ALA will be incubated for 1 hour to produce photoactive protoporphyrin-IX (PpIX) before light exposure.
11087331|NCT04164836|No Intervention|control group|nose selection will be done by random table
11087332|NCT04164836|Experimental|rhinoscope group|nose selection will be done by rhinoscopy
11087333|NCT04164823|Experimental|Medical Taping|"Medical taping will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).
~Patients will be taped for four days. It will start at the beginning of pain associated to the menstruation."
11087334|NCT04164823|Active Comparator|Analgesic self-medication (OTC)|"Participants will use the usual analgesic self-treatment for primary dysmenorrhea.It will start at the beginning of pain associated to the menstruation.
~They will note the treatment indicating the analgesic and the dosage in a calendar."
11087335|NCT04164810|Experimental|Hydrotherapy|Hydrotherapy intervention will receive the treatment for 9 weeks (2 days per week) , resulting in a total of 18 sessions of Hydrotherapy. Each session will be held for a duration of 45 minutes to 1 hour.
11087336|NCT04164810|Active Comparator|Physical therapy|Physical therapy inthervention will have 18 standard physical therapy treatment sessions during 9 weeks. Each session will be held for a duration of 45 minutes to 1 hour.
11087337|NCT04164797|Experimental|treatment group|endostar : 7.5mg/m2/d,continuous infusion for 5 days in week 1、3、5、7, chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
11087338|NCT04164797|Active Comparator|control group|chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
11087376|NCT04164511||Patients with post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy and receiving 2 daily ice creams for 2 weeks after surgery. Standard analgesic therapy available.
11087339|NCT04164784|Experimental|therapeutic monitoring|"Based on the dietary habits from guidelines, the patients will be instructed to adjust the diet according to the ambulatory glucose profile (AGP) and the recorded log monitored by the continuous glucose monitoring system, thereby implementingtherapeutic monitoring."
11087340|NCT04164784|No Intervention|The control group|Patients will be given the basic diet, lifestyle instructions according guidelines.
11087341|NCT04164771|Experimental|Moringa Group|Participants will receive 5-7g of moringa diet daily for 6 weeks.
11087342|NCT04164771|Experimental|Aerobic training Group|Participants will receive 5-7g of moringa diet daily and will do 30 minutes of aerobic training daily for 6 weeks.
11087343|NCT04164771|Experimental|Moringa and Aerobic training|Participants will do 30 minutes of aerobic training daily for 6 weeks
11087344|NCT04164771|No Intervention|Control Group (T4)|Participants will not recieve any treatment
11087345|NCT04164758|Experimental|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
11087346|NCT04164758|Placebo Comparator|Placebo|Placebo encapsulated tablet
11087347|NCT04164758|Active Comparator|Quetiapine|Immediate release Quetiapine encapsulated tablets
11087348|NCT04164745|Experimental|Experimental: Anlotinib plus Pembrolizumab|
11087349|NCT04164732|Experimental|LCZ696 at doses of 50mg, 100mg and 200mg b.i.d|randomized in a 1:1 ratio: LCZ696 to placebo
11087350|NCT04164732|Placebo Comparator|Placebo to LCZ696|randomized in a 1:1 ratio: LCZ696 to placebo
11087351|NCT04164719|Experimental|Treatment A|TNX-102 SL 2.8 mg, under fasting conditions
11087352|NCT04164719|Experimental|Treatment B|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fasting conditions
11087353|NCT04164719|Experimental|Treatment C|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fed conditions
11087354|NCT04164706|Experimental|HumiGard (plus standard care)|HumiGard device will be used to provide warmed humidified CO2 for insufflation during laparoscopic surgery. The device will be used alongside standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
11087355|NCT04164706|Sham Comparator|Standard Care (with sham HumiGard device).|"Patients will receive standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
~A sham HumiGard device will be used in the standard care arm. This will be the same HumiGard device as is in the intervention arm. However, the sham device will be turned off so that the gas delivered to the peritoneal cavity for insufflation is not heated or humidified. The sham device will deliver CO2 (as is the case for current standard practice in the hospital) through the HumiGard tubing. The sham device will look and sound the same as the active intervention arm where the HumiGard device is switched on and is delivering warm, humidified CO2 to the peritoneal cavity."
11087356|NCT04164693|Experimental|anticoagulant therapy group|during hospitalization, patients began to use low molecular weight heparin subcutaneously after arteriovenous fistula operation, once or twice a day, 4000iu-8000iu a day. After discharge, the patients took warfarin sodium tablets orally, 1.25mg on dialysis day, 2.5mg on non dialysis day, for a total course of 4 weeks.
11087357|NCT04164693|Other|non anticoagulant therapy group|no anticoagulant was used after operation, but both groups could take antiplatelet drugs.
11087358|NCT04164680||Patients with disorders of consciousness|
11087359|NCT04164667|Active Comparator|Self-Guided|Participant's do not receive text message direction from the VA Annie Text Messaging System. Participant's create their own method for accomplishing app-based exercise and mindfulness practice without detailed instructions.
11087360|NCT04164667|Experimental|Directed Messaging|Participant's receive text message directions from the ANNIE VA messaging system. The directed messaging system provides text message details of the participant's app-based meditation and exercise instructions.
11087361|NCT04164654|Experimental|Experimental-Immediate Access to the Nod app|The experimental group will have immediate access to all content in the Nod app and will be free to engage with it as much or as little as they like for four weeks. They will retain access to the Nod app for an additional four weeks.
11087362|NCT04164654|Other|Waitlist Control-Delayed Access to the Nod app|The waitlist control group will have full access to the Nod app approximately four weeks after the experimental group gains access.
11087363|NCT04164641|Experimental|Noraxon myoRESEARCH™ Software|All participants will be assigned to this group to receive study intervention.
11087364|NCT04164628|Experimental|Experimental Group: quality of life assessment|Women's quality of life will be evaluated.
11087365|NCT04164615|Experimental|GB221+ Capecitabine tablets|test drug+capecitabine
11087366|NCT04164615|Placebo Comparator|Placebo control + capecitabine tablets|placebo+capecitabine
11087367|NCT04164602||elderly patients with newly diagnosed diabetes|"Group with exposure: patients over 60 years of age with diabetes diagnosed within six months (newly diagnosed)
~Control Group: without exposure; patients over 60 years, without diabetes."
11087368|NCT04164589|Placebo Comparator|Control|The Neuro-Adaptative Regulation will be carried out in the regime of switched off power supply in vulvo-perineal and sacral area.
11087369|NCT04164589|Experimental|Experimental|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacarl area.
11087370|NCT04164563|No Intervention|Control|Standard CAM boot treatment without Even-Up device.
11087371|NCT04164563|Experimental|Study|CAM boot treatment with Even-Up for contralateral extremity.
11087372|NCT04164537||Latina adolescents and parents|Latina adolescent young women experiencing depression and their parents will be recruited from community and primary care settings for one-time individual interviews.
11087373|NCT04164537||Healthcare providers|Primary care and mental health providers who commonly work with Latina adolescent patients will be recruited for focus groups from an integrated primary care clinic.
11087374|NCT04164524||Group; A|Open technique Hernioplasty for abdominal hernia in which 160 mg Gentamycin spray applied over the mesh
11087375|NCT04164524||Group; B|Open technique Hernioplasty for abdominal hernia in which no Gentamycin spray applied over the mesh
11087453|NCT04164108|No Intervention|Control participants|Patients admitted to the medical ICU #2 (of 2 at our hospital) will receive usual care.
11087377|NCT04164511||Patients without post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy, not receiving any ice cream for 2 weeks after surgery. Standard analgesic therapy available.
11087378|NCT04164498|Experimental|Music exposure|will be exposed to music to investigate effects on preventing noise Adverse effects
11087379|NCT04164498|No Intervention|Control|no exposure to music
11087380|NCT04164485|Experimental|Functional collagen scaffold transplantation|
11087381|NCT04164485|Experimental|Autologous adipose cell transplantation|
11087382|NCT04164472|Experimental|Friend to Friend with Coaching|Program for relationally aggressive girls and their classmates delivered by school personnel who have been coached by study team.
11087383|NCT04164472|No Intervention|Control|Referral to school counselor as needed as per standard practice.
11087384|NCT04164459|Experimental|Xalost S|
11087385|NCT04164459|Active Comparator|Xalatan|
11087386|NCT04164459|Active Comparator|Taflotan-S|
11087387|NCT04164446|Placebo Comparator|Placebo|Two capsules containing starch and glucose, once per day, 60 days duration
11087388|NCT04164446|Active Comparator|Oil Palm Phenolics 250 mg|One capsule 250 mg active compound (OPP) and one capsule containing starch and glucose, once per day, 60 days duration
11087389|NCT04164446|Active Comparator|Oil Palm Phenolics 1000 mg|One capsule containing 1000 mg active compound (OPP) and one capsule starch and glucose, once per day, 60 days duration
11087390|NCT04164446|Active Comparator|Oil Palm Phenolics 2000 mg|Two capsules, 1000 mg active compound (OPP) each, once per day, 60 days duration
11087391|NCT04164433|Experimental|Workplace-based HIV Self-Testing|"i. Explain the procedure of conducting HIVST & interpret HIV self- test result to the user.
~ii. Demonstrate how to perform the self-test and how to interpret the self-test result.
~iii. Provide appointment card including information on linkage for HIV prevention services and further testing for diagnosis among those with a reactive self-test. Participants with a non-reactive self-test will be referred to HIV prevention services.
~iv. Provide a toll free number for continued consultation"
11087392|NCT04164433|No Intervention|Workplace-based standard HIV Testing Services (HTS)|Standard of care following the HIV testing algorithm .
11087393|NCT04164420|Experimental|Oral neuromuscular training and orofacial sensory-vibration|Intensive training with oral neuromuscular training and orofacial sensory-vibration stimulation for 5 weeks. The oral neuromuscular training is performed three times per session, and three times daily before eating. Regarding the orofacial sensory-vibration stimulation, the instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal by using a toothbrush.
11087394|NCT04164420|Active Comparator|Orofacial sensory-vibration stimulation|Orofacial sensory-vibration stimulation by using an electrical toothbrush for five weeks. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
11087395|NCT04164394|Placebo Comparator|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
11087396|NCT04164394|Experimental|Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
11087397|NCT04164381|Experimental|Robotic assisted intervention|Upper limb robotic therapy using a set of robotic and sensor based devices and exercises specifically selected to train cognitive functions.
11087398|NCT04164368|Experimental|R2-CHOP|Lenalidomide combined with rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
11087399|NCT04164355||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months
11087400|NCT04164355||Control Group|Healthy controls without previous surgery of radical prostatectomy.
11087401|NCT04164342|Experimental|Single ARM|This is an observational study, all patients will be followed at 3, 6 and 12 months by phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done).
11087402|NCT04164329||Exposed group|The exposed group will be composed by the patients that undergo CRT/ICD implantation (general anesthesia).
11087403|NCT04164329||Not exposed group|The non-exposed group, or control group, will be composed by the patients undergo PM implantation (without anesthesia)
11087404|NCT04164316|Sham Comparator|Kinesio Tape No Tension|Kinesio Tape No Tension
11087405|NCT04164316|Active Comparator|Kinesio Tape with Tension|Kinesio Tape with Tension
11087406|NCT04164290|Active Comparator|treatment group 1|Jiashen tablet, 0.47g, oral, once a day
11087407|NCT04164290|Active Comparator|treatment group 2|Jiashen tablet, 0.94g, oral, once a day
11087408|NCT04164290|Active Comparator|treatment group 3|Jiashen tablet,1.88g, oral, once a day
11087409|NCT04164290|Active Comparator|treatment group 4|Jiashen tablet,2.82g, oral, once a day
11087410|NCT04164290|Active Comparator|treatment group 5|Jiashen tablet,3.76g, oral, once a day
11087411|NCT04164290|Active Comparator|treatment group 6|Jiashen tablet,4.23g, oral, once a day
11087412|NCT04164290|Placebo Comparator|control group 1|Jiashen placebo tablet,0.47g, oral, once a day
11087413|NCT04164290|Placebo Comparator|control group 2|Jiashen placebo tablet,0.94g, oral, once a day
11087414|NCT04164290|Placebo Comparator|control group 3|Jiashen placebo tablet,1.88g, oral, once a day
11087415|NCT04164290|Placebo Comparator|control group 4|Jiashen placebo tablet,2.82g, oral, once a day
11087416|NCT04164290|Placebo Comparator|control group 5|Jiashen placebo tablet,3.76g, oral, once a day
11087417|NCT04164290|Placebo Comparator|control group 6|Jiashen placebo tablet,4.23g, oral, once a day
11087454|NCT04164095|Experimental|lappg|
11087455|NCT04164095|Active Comparator|ladgbi|
11087456|NCT04164082|Experimental|Treatment (pembrolizumab, gemcitabine hydrochloride)|"INDUCTION: Patients receive pembrolizumab IV over 25-40 minutes on day 1 of cycles 1-4. Patients also receive gemcitabine hydrochloride intravesically on days 1, 8 and 15 of cycles 1 and 2. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Beginning cycle 5, patients with no evidence of disease after induction receive pembrolizumab IV over 25-40 minutes and gemcitabine intravesically on day 1. Treatment repeats every 3 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity."
11087418|NCT04164277|Experimental|Intervention|"The 16-week intervention includes three components:
~Caregiver Component. Facebook-based program including four new habit-formation tasks/week, and 3 face-to-face caregiver meetings: MSU Extension health educators will lead the meetings at Head Start centers (weeks 1, 8, & 16) to connect caregivers to each other, offer health information, and discuss behavioral change strategies.
~Caregiver-Preschooler Learning. Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent privately to each caregiver , and caregivers will be asked to respond to the letters.
~Center-based Preschooler Component. Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU Extension health educators."
11087419|NCT04164277|No Intervention|Control|Control group will receive usual Head Start activities during intervention period. After post-intervention data collection, each control caregiver will receive all intervention supplies and a mini program including a face-to-face caregiver meeting and 1-week preschooler program. The caregiver meeting will cover contents on alternative cooking ingredients, food labels, and portion sizes.
11087420|NCT04164264|Experimental|Intravenous Propofol Infusion|Quantification of the dose of propofol required to produce loss of consciousness and apnea.
11087421|NCT04164251|Experimental|Inpatient screening mammography for non-adherent and high risk|All non-adherent women were offered inpatient screening mammography during hospitalization
11087422|NCT04164238|Experimental|Arm A|Toripalimab 240mg IV, every 3 weeks;
11087423|NCT04164238|Experimental|Arm B|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Carboplatin AUC 5, IV, Q3W
11087424|NCT04164238|Experimental|Arm C|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Cisplatin 25mg/m^2 IV,d1-d3, Q3W; 5-FU 3000mg/m^2 CIV 72h, Q3W
11087425|NCT04164225|Experimental|Qigong|Qigong exercises, focused on a mind-body connection
11087426|NCT04164225|Active Comparator|P.Volve|P.Volve exercises, focused on just physical movement
11087427|NCT04164212|Other|open label|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
11087428|NCT04164199|Experimental|Tislelizumab monotherapy|
11087429|NCT04164199|Experimental|Pamiparib Monotherapy|
11087430|NCT04164199|Experimental|Tislelizumab and Pamiparib Combination Therapy|
11087431|NCT04164199|Experimental|Tislelizumab and Pemetrexed Combination Therapy|
11087432|NCT04164199|Experimental|Tislelizumab and Capecitabine Combination Therapy|
11087433|NCT04164199|Experimental|Experimental: Pamiparib and temozolomide|
11087434|NCT04164173|Experimental|EzPAP|The patient will have EzPAP postoperative respiratory therapy as 3 x 10 breaths at a 1:4 ratio four times daily
11087435|NCT04164173|Experimental|Metaneb|The patient will have Metaneb postoperative respiratory therapy as 10 minutes Continuous Positive End Expiratory Pressure (CPEP) four times daily
11087436|NCT04164173|Experimental|Intermittent Positive Pressure Breathing (IPPB)|The patient will have Intermittent positive pressure breathing (IPPB) postoperatively for 10 minutes four times daily
11087437|NCT04164160|Experimental|integrated-care-model benefiting group|Chronic patients whose clinical and social data will be added in the integrated care model application software.
11087438|NCT04164147|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
11087439|NCT04164147|Active Comparator|Persona MC Retained PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Retained PCL prosthesis
11087440|NCT04164147|Active Comparator|Persona MC Sacrificed PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Sacrificed PCL prosthesis
11087441|NCT04164134||Retinoblastoma patients (children)|Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
11087442|NCT04164134||Controls (children)|Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
11087443|NCT04164134||Retinoblastoma survivors (adults)|"Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past.
~Blood will be collected and a short questionnaire has to be filled."
11087444|NCT04164134||Controls (adults)|Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
11087445|NCT04164134||Retinoblastoma survivors with Secondary primary malignancies|"Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy.
~Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery."
11087446|NCT04164121|Experimental|FLZ-150mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
11087447|NCT04164121|Placebo Comparator|FLZ-150mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
11087448|NCT04164121|Experimental|FLZ-600mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
11087449|NCT04164121|Placebo Comparator|FLZ-600mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
11087450|NCT04164121|Experimental|FLZ-900mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
11087451|NCT04164121|Placebo Comparator|FLZ-900mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
11087452|NCT04164108|Experimental|Intermittent feed participants|Patients admitted to medical ICU #1 (of 2 at our hospital) will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
11148799|NCT03735758|Experimental|Pazopanib|Pazopanib; 800 mg; daily; oral
11087457|NCT04164069|Experimental|Prevention (dasatinib, mFOLFOX, bevacizumab)|Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
11087458|NCT04164056|Experimental|stimulation on the hippocampus|deep brain stimulation on the hippocampus
11087459|NCT04164056|Active Comparator|stimulation on the anterior nucleus of the thalamus|deep brain stimulation on the anterior nucleus of the thalamus
11087460|NCT04164043|Experimental|Recreational Therapy Wellness Recovery Program Group|All participants will enter a baseline data collection period for two weeks. They will then participate in a 12-week community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (WRP).
11087461|NCT04164030|Active Comparator|Nutrition Education Control|An evidence-based nutrition program entitled Eating Smart Being Active. Delivered in a group: Meets weekly for 2 hours for 9 weeks.
11087462|NCT04164030|Experimental|Nutrition Education +OT+Yoga|9 week group that meets twice a week for two hours each. Group occupational therapy and group yoga will be added to the nutrition program.
11087463|NCT04164017|Experimental|EUS-guided FNB with syringe suction|
11087464|NCT04164017|Active Comparator|EUS-guided FNB without syringe suction|
11087465|NCT04164004|Experimental|Early Implementation of Health Status Measurement|Patients in the early implementation arm will undergo KCCQ-12 assessment of patient-reported heart failure health status at each heart failure clinic visit beginning at the start of the trial. Assessment results will be available to clinicians when making treatment decisions during each clinic visit.
11087466|NCT04164004|Active Comparator|Delayed Implementation of Health Status Measurement|Patients in the delayed implementation will start receiving the KCCQ-12 assessment at each clinic visit beginning one year after randomization.
11087467|NCT04163991|Experimental|VIB4920 Dose1 (dosing interval 1)|Participants will receive intravenous (IV) infusion of VIB4920 Dose1 in dosing interval 1.
11087468|NCT04163991|Experimental|VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)|Participants will receive IV infusion of VIB4920 Dose1 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.
11087469|NCT04163991|Experimental|VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)|Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.
11087470|NCT04163991|Experimental|VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)|Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 4 and placebo matched to VIB4920 in dosing interval 5.
11087471|NCT04163991|Placebo Comparator|Placebo (dosing interval 1)|Participants will receive IV infusion of placebo matched to VIB4920 in dosing interval 1.
11087472|NCT04163978|Experimental|Nitric oxide releasing solution (NOSi)|DailyTopical sinus irrigation delivery of 240mL NOSi
11087473|NCT04163978|Active Comparator|Budesonide -saline|Daily Topical sinus irrigation delivery of 240 mL of 1 mg Budesonide-saline
11087474|NCT04163965|Other|Patients having a pacemaker|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology. Simultaneously standard routine ECG measurements will take place.
11087475|NCT04163952|Experimental|Treatment (talimogene laherparepvec, panitumumab)|Patients receive talimogene laherparepvec IM on day 1. Patients then receive talimogene laherparepvec IM and panitumumab IV over 30-90 minutes on day 22. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive up to 3 additional cycles of treatment per physician discretion.
11087476|NCT04163939|Experimental|Collar|This group will wear a cervical collar for at least 30 minutes per day, 5 out of 7 days of the week
11087477|NCT04163939|Placebo Comparator|Control|This group will not wear the cervical collar
11087478|NCT04163926|Experimental|Intervention group - Post op follow up by trained optometrist|Intervention group will have cataract follow up conducted by a trained optometrist 4-6 weeks after surgery in community clinic
11087479|NCT04163926|Active Comparator|Usual care group - Consultant led post op follow up|Follow-up at 4-6 weeks after surgery led by consultant ophthalmologist
11087480|NCT04163913|Experimental|Cirvo Device|The CirvoTM device (Figure 1) is a lightweight, mobile, active, intermittent leg compression device placed on the calf of the leg, using hook and loop (e.g. Velcro) straps in the similar manner as commercially available intermittent leg compression devices The system utilizes an electro-mechanical drive system to intermittently compress the calf from the ankle toward the knee for a duration and compression level prescribed by the physician. The level of compression delivered by the CirvoTM therapy will be in the same range as existing devices which corresponds to the type of pressure applied by a blood pressure cuff.
11087481|NCT04163913|Active Comparator|ActiveCare DVT|A commercially available device was previously used to assess patient satisfaction with compression therapy for DVT prophylaxis as per standard of care.
11087482|NCT04163900|Experimental|A - NUC-1031 and cisplatin|725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
11087483|NCT04163900|Active Comparator|B - gemcitabine and cisplatin|1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
11087484|NCT04163887|Other|laparoscopic liver resection|Laparoscopy allows some surgical procedures to be performed through small incisions that enable the operator to access the abdominal cavity, often at the pubic area, and surgical instruments are introduced through these small incisions. This technique avoids large abdominal incisions and significantly reduces the duration of hospitalization.
11087485|NCT04163887|Other|open liver resection|standard of care
11087486|NCT04163874|Experimental|Fiasp-plus-Placebo with Full Carbohydrate Counting|Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
11087487|NCT04163874|Placebo Comparator|Fiasp-plus-placebo with Simple Meal Announcement|Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
11087488|NCT04163874|Active Comparator|Fiasp-plus-Pramlintide with Simple Meal Announcement|Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.
11149003|NCT03734432|Experimental|Patients|IGAR-Breast TeleOp
11087489|NCT04163861||1|"31 patients diagnosed as heart failure with preserved ejection fraction per ESC guidelines 2016 on the basis of history, clinical examination and investigations presenting to the department of cardiology, BSMMU were selected inclusion criteria
~Patients with regional wall motion abnormality in 2D echocardiography.
~Patients with moderate to severe valvular heart diseases.
~Patients with prosthetic valves and pacemakers.
~Patients with congenital heart diseases.
~Patients currently having arrhythmia such as atrial fibrillation on ECG screening during enrollment of patient.
~Patients with poor echo window.
~Patients who were not interested to take part in the study."
11087490|NCT04163861||2|31 normal healthy control subjects of similar age and sex of HFpEF subjects were taken. Normal echocardiograms will be defined as normal LV size and geometry, normal LVEF >55%). patients are free from cardiovascular diseases.
11087491|NCT04163848||Desflurane|desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows
11087492|NCT04163848||Sevoflurane|sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography
11087493|NCT04163835|Experimental|Low-dose Group|The intervention is half-dose of Wenxin Granules (1/2 normal dose).
11087494|NCT04163835|Experimental|Medium-dose Group|The intervention is medium-dose of Wenxin Granules (normal dose).
11087495|NCT04163835|Experimental|High-dose Group|The intervention is twice-dose of Wenxin Granules (twice normal dose).
11087496|NCT04163835|Placebo Comparator|Placebo Group|The intervention is a placebo.
11087497|NCT04163822||group with typical imaging changes in early stages|the BPD infants with typical BPD radiographic changes within the first 14 days after birht, including fibrosis and cyst.
11087498|NCT04163822||group with typical imaging changes in late stages|the BPD infants with typical BPD radiographic changes after 14 days of birht, including fibrosis and cyst.
11087499|NCT04163822||group without typical imaging changes|the infants meet the diagnosis criteria of BPD at postmenstrual age of 36weeks, but lack of typical radiographic changes.
11087500|NCT04163809|No Intervention|Control Group (no VR)|Patients will be randomly allocated to the control group, which receives no Virtual Reality (VR) during the regional anesthesia procedure.
11087501|NCT04163809|Experimental|Experimental Group (VR)|Patients will be randomly allocated to the the experimental group, which receives VR during the regional anesthesia procedure.
11087502|NCT04163796|Experimental|UPnRIDE Training|During each session, heart rate (HR), blood pressure (BP), total session time, time in standing posture, count of sit-to-stand positioning, total distance of overground movement, and rating of perceived exertion (Borg scale) for mobility skills will be monitored. At all study visits during the training period, participants will be asked to answer general health questions about the occurrence of any pressure ulcers or infections.
11087503|NCT04163783|Experimental|Arm A|Subjects will be administered a single oral dose of 320 mg of [14C]-BGB-3111
11087504|NCT04163770|Experimental|performance of pacemaker at time of implantation|
11087505|NCT04163770|Experimental|performance of pacemaker 6 months after implantation|
11087506|NCT04163757|Placebo Comparator|placebo|
11087507|NCT04163757|Active Comparator|crocin|
11087508|NCT04163731||stable patient, referred for a VO2 peak test|All stable patients above 18 years, referred for a VO2 peak test as part of their standard management in the Louis Pradel Hospital (Hospices Civils de Lyon, Lyon) and without acute clinical event in the last 3 months. All patients who accept to participate will undergo a self-questionnaire of 10 minutes.
11087509|NCT04163718|Experimental|Treatment with Umbralisib|
11087510|NCT04163705||Gram negative|"The presence of one or more positive samples will be considered positive blood cultures.
~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.
~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
11087511|NCT04163705||Gram positive|"The presence of one or more positive samples will be considered positive blood cultures.
~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.
~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
11087512|NCT04163692|Experimental|Exercise Group|Progressive relaxation exercises (PRE) as 1 day supervised and 3 days home based program in a week, for 6 weeks
11087513|NCT04163692|No Intervention|Control Group|Information was provided about pain and its treatment and the importance of relaxing exercises without any intervention, up to 6 weeks.
11087514|NCT04163679|Experimental|Vaginal Preparation|In addition to standard care, subjects will undergo vaginal preparation (VP). A VP kit includes sponge sticks and sponges soaked in a povidone-iodine 10% solution.
11087515|NCT04163679|Sham Comparator|Standard Infection Procedures|The very staff will follow hospital protocols for the cesarean delivery. The subject and the infant will be provided care in accordance with current medical standards and be discharged at the discretion of the attending physician.
11087516|NCT04163666|Experimental|Mirror therapy group|The mirror therapy group will receive a treatment based on this therapy, combined with task-oriented motor learning.
11087517|NCT04163666|Experimental|Cognitive therapeutic exercise group|The cognitive therapeutic exercise group will receive a treatment based on this therapy, combined with task-oriented motor learning.
11087518|NCT04163666|No Intervention|Control Group|No additional intervention with the participants of this group will be completed.
11087519|NCT04163653||Fontan Group|Fontan patients operated at the two centres between 1991 and 2014.
11087520|NCT04163653||Healthy Control Group|Age, gender and weight matched healthy controls.
11087521|NCT04163640|Experimental|Intervention Group|Patients randomized to this group will receive the intra-ovarian platelet rich plasma injection
11087522|NCT04163640|No Intervention|Control Group|Patients randomized to this group will not receive the intra-ovarian platelet rich plasma injection
11150089|NCT03726866|Experimental|Sequence 4|Sequence 4
11087523|NCT04163614|No Intervention|Control|Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.
11087524|NCT04163614|Experimental|IBPS (Intradialytic Blood Pressure Slope) Arm|IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.
11087525|NCT04163588|Active Comparator|Standard therapy|intravenous loop diuretics as recommended by current guidelines plus placebo
11087526|NCT04163588|Experimental|SNB|loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
11087527|NCT04163575|Experimental|experimental:1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
11087528|NCT04163575|Experimental|experimental:2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
11087529|NCT04163575|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
11087530|NCT04163562|Experimental|INP20 (Oral Immunotherapy)|
11087531|NCT04163562|Placebo Comparator|Placebo|
11087532|NCT04163549|Experimental|Safe at Home Cycle 1|The experimental arm will receive the Safe at Home program which is a community-based discussion group series aiming to prevent and respond to intimate partner violence and child maltreatment in conflict-affected communities. It includes once weekly, single-sex discussion groups with coupled men and women and once monthly family discussion groups with couples and children. During the weekly sessions men and women reflect critically and engage in dialogue related to gender, power, and privilege, learn about the causes and consequence of violence against women and children and gain skills in stress management, psychosocial support and positive parenting strategies. Family sessions focus on improving relationship quality and shared decision-making among partners and participation of children in family decision-making.
11087533|NCT04163549|No Intervention|Safe at Home Cycle 2|During the period of the study, this group will not receive an intervention. Rather, this arm will receive the Safe at Home program after endline data collection is completed for a waitlisted group.
11087534|NCT04163536|Active Comparator|cortisteroids arm|
11087535|NCT04163536|Placebo Comparator|placebo arm|
11087536|NCT04163523|Experimental|Treatment Sequence 1|5 Subjects received Period 1- 320 mg BGB-3111 administered after an overnight fast; Period 2- 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 3 - Day 15: 320 mg BGB-3111 administered after Low Fat/Calorie Meal
11087537|NCT04163523|Experimental|Treatment Sequence 2|5 Subjects received Period 1 - Day 1: 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 2- Day 8: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 3- Day 15: 320 mg BGB-3111 administered after an overnight fast
11087538|NCT04163523|Experimental|Treatment Sequence 3|Approximately 5 Subjects receive Period 1-Day 1: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 2-Day 8: 320 mg BGB-3111 administered after an overnight fast; Period 3- Day 15: 320 mg BGB-3111 administered after High Fat/Calorie Meal
11087539|NCT04163510|Experimental|Reading Intervention Group|A group of parents and their children will participate in this single arm, pre-/post-intervention study. This 10-week study will include 10 sets of parents of low-reading elementary school children, recruited from Harlem Grown Community Center. Intervention will be implemented in a 9-week period, with data collection during the first intervention week and one week post-intervention. Three large-group sessions will be held in a central location (at Harlem Grown Community Center), to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. The reading program will help parents identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading.
11087540|NCT04163497|Experimental|Diary reading|
11087541|NCT04163497|No Intervention|No diary reading|
11087542|NCT04163484||Stable coronary artery disease|
11087543|NCT04163484||ST-elevation myocardial infarction|
11087544|NCT04163484||Non-ST-elevation myocardial infarction|
11087545|NCT04163471||VasoStat|Randomized to use of VasoStat radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
11087546|NCT04163471||TR Band|Randomized to use of TR Band radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
11087547|NCT04163458|Experimental|MENOPUR liquid|MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing can be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose will be 450 IU/day and the minimum dose will be 75 IU/day. The dosing can continue for a maximum of 20 days.
11087548|NCT04163458|Active Comparator|MENOPUR powder|MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing can be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose will be 450 IU/day and the minimum dose will be 75 IU/day. The dosing can continue for a maximum of 20 days.
11087549|NCT04163445|Active Comparator|Depuy Attune|Subjects will have been implanted with the Depuy Attune PCR TKA
11087550|NCT04163445|Active Comparator|MicroPort Medial Pivot|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
11087551|NCT04163432|Experimental|Arm A: Chemo-Immuno|ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
11087552|NCT04163432|Experimental|Arm B: Immuno-Chemo|ArmB receives immunotherapy on D1 and chemotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
11087553|NCT04163419|Experimental|Arm A (treatment)|Tanezumab 10 mg SC administered on day 1 and Day 57 (± 4 days)
11087554|NCT04163419|Placebo Comparator|Arm B (placebo then treatment)|Placebo SC (to match tanezumab SC) administered on Day 1 and tanezumab 10 mg SC on Day 57 (± 4 days)
11087555|NCT04163406|Active Comparator|ferrous fumarate|Maize-based porridge fortified with iron (5mg) as ferrous fumarate
11087556|NCT04163406|Active Comparator|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) as ferrous fumarate + GOS (3g)
11087557|NCT04163406|Active Comparator|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) as ferrous fumarate + HMOs (2'-FL (2g) + LNnT (1g))
11087558|NCT04163393|Experimental|R-One|Patients treated with robotic assistance
11087559|NCT04163380|Experimental|Early Follicular Phase (EFP)|
11087560|NCT04163380|Experimental|Late Follicular Phase (LFP)|
11087561|NCT04163380|Experimental|Early Luteal Phase (ELP)|
11087562|NCT04163380|Experimental|Late Luteal Phase (LLP)|
11087563|NCT04163367|Active Comparator|Intervention as usual|The social services standard process for families reported for violence or abuse towards children. The standard process always includes a formal investigation of the suspected violence/abuse. The investigation may or may not result in voluntary or mandatory interventions, such as family support or parent training.
11087564|NCT04163367|Experimental|Intervention as usual + Safer Kids|The procedure in this arm is exactly the same as in the active comparator arm (i.e., investigation that may be followed by interventions). In addition, the general parent training program Safer Kids is offered during the investigation to all participants in this arm.
11087565|NCT04163354|Active Comparator|NaF varnish|Application of a 5% NaF varnish (Duraphat, Colgate-Palmolive Ltd, Waltrop, Germany) on the occlusal surfaces of primary second molars and all other teeth, every 3 months during the study period;
11087566|NCT04163354|Experimental|GI sealant|Glass ionomer sealant (GC Fuji VII® (pink)) on all primary second molars included in the studies, with no further repair/replacement of the sealant
11087567|NCT04163341|Experimental|CETA protocol|
11087568|NCT04163341|No Intervention|Enhanced Usual Care|
11087569|NCT04163328|Experimental|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
11087570|NCT04163328|Placebo Comparator|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
11087571|NCT04163315|Experimental|dMRI, fMRI and electrocorticography|With this exploratory pilot study, the investigator propose a multimodal evaluation of the structural and functional connectivity of patients with brain tumours, in order to better understand the tumor-induced lesion mechanisms on brain connectivity as well as the brain plasticity mechanisms that the brain develops to maintain a level of overall function neurological. The investigator hope to obtain multimodal brain mapping of locally brain-damaged patients, with a view to improving onco-functional neurosurgical practices.
11087572|NCT04163302|Experimental|CD19+ Lymphoma|This study is to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with Relapsed/Refractory B Cell Lymphoma.
11087573|NCT04163289|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation combined with approved standard of care treatment with nivolumab and ipilimumab.
11087574|NCT04163276||Group 1|20 patients without anomaly of brain metabolism
11087575|NCT04163276||Group 2|20 patients with Alzheimer's disease
11087576|NCT04163263|Experimental|Cohorts 1-3: BOS-356|Twice daily application of BOS-356 0.1%, 0.4%, and 0.7% gel in Cohorts 1, 2, and 3, respectively
11087577|NCT04163263|Placebo Comparator|Cohorts 1-3: Vehicle|Twice daily application of vehicle gel
11087578|NCT04163263|Experimental|Cohort 4: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
11087579|NCT04163263|Placebo Comparator|Cohort 4: Vehicle|Twice daily application of vehicle gel
11087580|NCT04163263|Experimental|Cohort 5: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
11087581|NCT04163263|Placebo Comparator|Cohort 5: Vehicle|Twice daily application of vehicle gel
11087582|NCT04163250||Patients with ACS undergoing cardiac catheterization|"Adults with moderate / high risk acute coronary syndrome undergoing coronary intervention.
~The sample will be selected consecutively, including patients admitted to the Cardiac Coronary Unit and who require a radiological test with intra-arterial IC administration, for diagnostic or diagnostic / therapeutic purposes"
11087583|NCT04163237|Experimental|PD-1 & Sorafenib|
11087584|NCT04163237|Other|Sorafenib|
11087585|NCT04163211||Group 1|Patients with complicated appendicitis who had a drain inserted
11087586|NCT04163211||Group 2|Patients with complicated appendicitis who did not have a drain inserted
11087587|NCT04163198|Experimental|Insufflation optimisation|Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.
11087588|NCT04163198|Experimental|Exsufflation optimisation|Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF
11087589|NCT04163185|Experimental|AXS-07|Taken once upon migraine
11087590|NCT04163185|Placebo Comparator|Placebo|Taken once upon migraine
11087591|NCT04163172|Active Comparator|Elbow hemiarthroplasty|The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.
11087592|NCT04163172|Active Comparator|Open reduction and internal fixation|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.
11087593|NCT04163146|Experimental|Healthy children and adolescents|Healthy children and adolescents aged 6 to 18 years (N=100) for the assessment of normal PEF and FEV1 variability.
11087594|NCT04163146|Experimental|Asthmatic children and adolescents|Children and adolescents aged 6 to 18 years with diagnosed asthma (N=100) for the assessment of PEF and FEV1 variability in asthmatics.
11087595|NCT04163133|Experimental|two days delay of trigger group|Two days later of trigger than regular trigger timing day (three follicles reach 17mm) .
11087596|NCT04163133|No Intervention|regular trigger group|regular trigger timing when three follicles reach 17mm bilateral.
11087597|NCT04163120|Experimental|Intervention|In this single arm study subjects follow a low calorie mediterranean ketogenci diet
11087599|NCT04163094|Experimental|Treatment arm|Patients will receive 8 W_ova1 vaccinations before and during neoadjuvant chemotherapy and adjuvant chemotherapy.
11087600|NCT04163081|Experimental|Quit Card Intervention (QCI)|Study intervention group.
11087601|NCT04163081|No Intervention|Usual Care (UC)|Study control group.
11087602|NCT04163068||Interview with researcher|All participants will participate in an interview with a researcher
11087603|NCT04163055|No Intervention|Standard of Care|Wounds will be assessed using the Clinical Signs and Symptoms Checklist (CSSC). After initial assessment, a white-light (WL) photo will be taken of the wound. The wound bed will be prepared as indicated by clinical staff based on standard of care (SoC), including irrigation and debridement. A second WL image will be taken and a swab/biopsy will be obtained from the wound. Wounds will be dressed based on SoC.
11087604|NCT04163055|Experimental|Autofluorescence guided Standard of Care|Wounds will be assessed by autofluorescence (AF)-guided SoC. A baseline WL and AF photo will be taken of the wound. AF images will guide SoC including targeted debridement of areas of bacterial growth (AF+) and targeted sampling in areas of residual bacterial growth post-debridement. If no bacterial AF is detected, sample will be obtained from the wound center by curettage technique. If AF is detected, AF-guided debridement will be repeated and additional images will be obtained until 1) no AF is detected or 2) further debridement is not medically advised. After wound bed preparation, a second set of WL and AF images will be taken. Wounds will be dressed as per SoC. At all visits, samples will be sent for microbiology analysis. At 6- and 12-week visits (or any other scheduled visits in between), microbiology reports will be shared with clinicians if they were not collected outside of SoC.
11087605|NCT04163042|Experimental|Group A: Videoconferencing intervention|Participants allocated to group A will receive a behavioural support intervention via real-time videoconferencing.
11087606|NCT04163042|No Intervention|Group B: Usual care|Participants allocated to group B will receive usual care and will be advised to continue with their regular activities of daily living.
11087607|NCT04163029||preoperative oral care|
11087608|NCT04163016|Experimental|Pharmacokinetics Sampling|"This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label.
~From all study participants blood samples will be drawn for pharmacokinetics during the study."
11087609|NCT04163003|Experimental|TAPAS, then sleep monitoring only|Participants will participate in the TAPAS intervention first, and then will participate in sleep monitoring only. TAPAS will consist of one in-person engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the TAPAS intervention. Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
11087610|NCT04163003|Experimental|Sleep monitoring only, then TAPAS|Participants will participate in sleep monitoring only first, then participate in the TAPAS intervention. First, participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.TAPAS will consist of one in-person engagement session with a therapist and 4 weeks of web-based automated intervention prompts. The program will utilize empirically supported approaches for promoting sleep health, delivered in-person and via text-message, focusing on: tailored psychoeducation, motivation and efficacy to change sleep, extending sleep duration, and regularizing sleep timing across the week. Sleep monitoring is proposed to last the same duration as the targeted intervention.
11087611|NCT04162990|Experimental|Lifestyle remodeling|
11087612|NCT04162990|Active Comparator|Does Comparator: regular treatment|
11087613|NCT04162977|Experimental|High-risk youth|The 23-item Substance Use Risk Profile Scale (SURPS) will be used to identify high-risk adolescents who enter the intervention trial. Adolescents who score high on one of SURPS subscales (i.e., high-risk youth) will be invited to participate in two group-based intervention sessions which target their dominant personality profile. The criterion for high scores on SURPS personality traits are determined based on norms from high-risk adolescents in the same age range who participated in previous trials on personality-targeted interventions.
11087614|NCT04162951|Experimental|Ordinary approach group|The patients in this group will receive ordinary ultrasound-guided thoracic paravertebral block. by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
11087615|NCT04162951|Experimental|Retro-laminar approach group|The patients in this group will be receive real ultrasound-guided Retrolaminar thoracic paravertebral block by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
11087616|NCT04162938|Experimental|Patient-Centered Electronic App Group|Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
11087617|NCT04162938|No Intervention|Reference Group|Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.
11087618|NCT04162925|Experimental|Cancer screening cohort|"All women in this study to be evaluated for cancer screening utilization rates (breast, colon and oral cancers) and cancer screening perspectives of these hospitalized women.
~The intervention will be a cancer screening education."
11087619|NCT04162912|Experimental|Experimental group|Participants in the experimental group will receive a MotivationaI Interviewing tailored ACP programme.
11087620|NCT04162912|No Intervention|Control group|The participants in the control group will receive usual care offered by the palliative care team under study and its affiliated day care centres, home care team and outpatient clinics.
11087621|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 12.
11087622|NCT04162899|Active Comparator|Active Comparator: SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 12.
11087623|NCT04162899|Active Comparator|Placebo Comparator: Placebo|Participants randomized in this arm will receive Placebo of SHR0302 until end of study at week 12.
11087624|NCT04162886|Experimental|Exercise Group|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
11087625|NCT04162886|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
11087626|NCT04162873|Experimental|Celecoxib Arm|Patients receive celecoxib PO or via feeding tube BID starting 5 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
11087627|NCT04162873|Placebo Comparator|Placebo Arm|Patients receive placebo PO or via feeding tube BID starting 5 days prior to surgery and continues until the completion of radiation therapy (up to 6 months in total) in the absence of disease progression or unacceptable toxicity.
11087628|NCT04162860|Experimental|minimally invasive esophagectomy with preemptive ENP|Patients will undergo a standard total minimally invasive transthoracic Ivor Lewis esophagectomy with preemptive ENP. After completion of the esophago-gastric anastomosis, an Eso-SPONGE® system will be inserted via an intraoperative gastroscopy. ENP will be carried out upon completion of the esophago-gastrostomy, but no later than 12 hours after the surgical intervention. Postoperatively, secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg. ENP will remain for 4 days and will be monitored with clinical parameters.
11087629|NCT04162860|No Intervention|Standard minimally invasive esophagectomy|Patients in the control group will undergo a standard minimally invasive transthoracic Ivor Lewis esophagectomy without preemptive ENP.
11087630|NCT04162847|Experimental|Mobile Coached Intervention|This group will receive access to the mobile intervention for 6 months. They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for. If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with. They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for. After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
11087631|NCT04162847|No Intervention|Referral to Counseling Center|This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
11087632|NCT04162834|Experimental|Papaverine group|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
11087633|NCT04162834|Active Comparator|Normal saline group|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
11087634|NCT04162821|Experimental|60mg group|
11087635|NCT04162821|Experimental|90mg group|
11087636|NCT04162821|Experimental|120mg group|
11087637|NCT04162795|Experimental|BAY76-2211|Participants will receive one dose of BAY76-2211 chewable tablet to chew completely before swallowing
11087638|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod Dose A|
11087639|NCT04162769|Experimental|12-Week Double-Blind Treatment Period: Etrasimod Dose B|
11087640|NCT04162769|Placebo Comparator|12-Week Double-Blind Treatment Period: Placebo|
11087641|NCT04162769|Experimental|52-Week Open-Label Extension Period: Etrasimod Dose B|
11087642|NCT04162743|Active Comparator|Trazodone|take trazodone 100mg hs
11087643|NCT04162743|Placebo Comparator|Placebo|take placebo pill hs
11087644|NCT04162717|Experimental|The Effect of Telephone Symptom Triage Protocols|"Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles.
~Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later."
11087645|NCT04162717|No Intervention|Control group|The control group received standard nursing care applied at the hospital
11087646|NCT04162691||Malignant thymoma|
11087647|NCT04162691||Benign thymoma|
11087648|NCT04162678||Diagnostic (blood collection via fluid biopsy, lab analysis)|Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
11087649|NCT04162665|Experimental|Preoperative MR-guided Radiation Therapy|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25 Gy at 5 Gy per fraction. The clinical target volume will include the entire stomach and locoregional lymph nodes. Radiation must be delivered with MR guided radiation therapy (MRgRT) and daily adaptive planning. The stomach and OARs must be redrawn each day for the adaptive plan. Plans should be adapted to meet OAR constraints or improve coverage as needed for each day's unique anatomy
~(5) 21-day cycles of standard of care CAPOX chemotherapy following completion of radiation
~Standard of care gastrectomy or esophagogastrectomy following completion of chemotherapy"
11087650|NCT04162639|Experimental|One donor|Participants will receive skin allograft from 1 distinct cadavers.
11087651|NCT04162639|Experimental|Two donors|Participants will receive skin allograft from 2 distinct cadavers.
11087652|NCT04162639|Experimental|Three donors|Participants will receive skin allograft from 3 distinct cadavers.
11087653|NCT04162639|No Intervention|Control|Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.
11087654|NCT04162626|Experimental|Intervention|Supportive home visits by public health nurses to new parents from 28 weeks in pregnancy until the child is two years.
11087655|NCT04162626|Other|Control|Follow up as usual at the Child health center
11088317|NCT04157933|Experimental|A-2a|Part A, Arm 2 (active), Dose 2 (009-A2)
11087656|NCT04162613||Patients with ACL reconstruction in Lund and Umeå|Persons who have suffered a unilateral anterior cruciate ligament injury treated with reconstruction
11087657|NCT04162600|Experimental|Group 1|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^9 vp vaccination intramuscularly.
~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
11087658|NCT04162600|Experimental|Group 2|"Volunteers will receive a standalone dose of ChAdOx2 RabG 2.5 x 10^10 vp vaccination intramuscularly.
~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
11087659|NCT04162600|Experimental|Group 3|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^10 vp vaccination intramuscularly.
~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
11087660|NCT04162587||1)Patients with significant carotid stenosis only|Patients with significant carotid stenosis without intracranial stenosis.
11087661|NCT04162587||2) Patients with carotid and intracranial stenosis.|Patients with carotid and intracranial stenosis.
11087662|NCT04162587||3) Patients with lone intracranial stenosis.|Patients with lone intracranial stenosis.
11087663|NCT04162587||4) Patients with no significant stenosis|Patients with no significant carotid or intracranial stenosis.
11087664|NCT04162574||BEGIN Case|Enrolled participants with BN/BED will participate in a 30-day observational study.
11087665|NCT04162548||cardio-relay|"Cardio-relay is a novel collaboration model between hospital-based specialists and primary care, to provide high-quality care to frail patients, relieving their burden to attend multiple hospital specialist visits.
~Using telemedicine, it is possible to make measurements where the patient is (at the family clinic at the patient's home). Data are available for all the involved. That is, primary the patient, the relatives and caregivers that the patient wishes help from and health professionals from the family clinics and the hospital. Thereby, the hospital-based specialist supports the family clinic with expert knowledge, the need for attending the hospital facilities reduced to focus on what is strictly needed as specialized provider. Ultimately, the patient can be reached for high-quality care, relieving the patient's burden to attend multiple hospital specialist visits."
11087666|NCT04162535|Experimental|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
11087667|NCT04162535|Experimental|Total intravenous anesthesia|Patients will receive a general anesthesia with Propofol as anesthetic agent
11087668|NCT04162535|Experimental|Total intravenous anesthesia and Lidocaine|Patients will receive a general anesthesia with Propofol as anesthetic agent and will also receive a fully lidocaine infusion according to the lidocaine protocol
11087669|NCT04162535|No Intervention|Placebo|10 presumed healthy volunteers that have donated 10 ml of venous blood for serum comparison
11087670|NCT04162522|Active Comparator|escitalopram (10-20 mg)|"Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as responders or non-responders. Responders will continue on escitalopram until the study endpoint (16 weeks)."
11087671|NCT04162522|Active Comparator|brexpiprazole (0.5-2 mg)|"At week 8, participants classified as non-responders will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram."
11087672|NCT04162509|Experimental|Exposure|The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.
11087673|NCT04162509|No Intervention|Control|The control group will not receive any active treatment (untreated comparison group).
11087674|NCT04162496|Experimental|Treatment with Restylane Refyne Group 1|Treat right side with Restylane Refyne with a cannula and left side with a needle
11087675|NCT04162496|Experimental|Treatment with Restylane Refyne Group 2|Treat left side with Restylane Refyne with a cannula and right side with a needle
11087676|NCT04162470|Experimental|REGN3918|Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)
11087677|NCT04162457|Experimental|Stevia beverage|Participants receive 4 study beverages in the 4 imaging sessions in randomised and counterbalanced order.
11087678|NCT04162457|Experimental|Glucose beverage|330 ml of water with glucose (equal sweetness with the stevia beverage)
11087679|NCT04162457|Experimental|Maltodextrin beverage|330 ml of water with maltodextrin (equal amount of calories as the glucose beverage)
11087680|NCT04162457|Placebo Comparator|Water|330 ml water
11087681|NCT04162444||Cohort 1|We will study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease.
11087682|NCT04162431||non-hodgkin lymphoma|patients diagnosed with non-hodgkin lymphoma
11087683|NCT04162431||hodgkin lymphoma|patients diagnosed with hodgkin lymphoma
11087684|NCT04162431||squamous cell carcinoma|patients diagnosed with squamous cell carcinoma
11087685|NCT04162431||reactive|patients diagnosed with a reactive (non-cancerous) lymph node
11087686|NCT04162431||other|none of the above. Other cancer and non-cancer conditions
11087687|NCT04162418|Other|Intervention|Treatment with Temporary Spur Stent System and a commercially available, limus-base, drug coated balloon
11087688|NCT04162405||Patients with tinnitus and hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold >30 dB
11087689|NCT04162405||Patients with tinnitus without hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold <30 dB
11087690|NCT04162392|Experimental|Experimental group|
11087691|NCT04162392|Active Comparator|Control group|
11087692|NCT04162379|Other|Prospective quizi-pre-post oral predensolone|single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mgs for 3 successive dosing every 4th day then stop the drug totally).
11087693|NCT04162366|Experimental|Aprocitentan 25 mg|
11087694|NCT04162366|Experimental|Placebo|
11087695|NCT04162366|Experimental|Aprocitentan 25 mg or Placebo|
11088318|NCT04157933|Experimental|A-3a|Part A, Arm 3 (active), Dose 3 (009-A3)
11087696|NCT04162353|Experimental|BCMA-CD19 cCAR|Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg
11087697|NCT04162340|Experimental|CD4 CAR T cells|Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg
11087698|NCT04162327|Experimental|Ia stage - IBI315 Dose escalation|
11087699|NCT04162327|Experimental|Ib stage - IBI315 monotherapy|
11087700|NCT04162314|Experimental|Experimental|This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
11087701|NCT04162314|Placebo Comparator|Control|This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
11087702|NCT04162301|Experimental|CS3002 CDK4/6 inhibitor|
11087703|NCT04162288|Experimental|Online training on SDM in prenatal screening|
11087704|NCT04162288|Placebo Comparator|Online training on prenatal screening|
11087705|NCT04162275|Experimental|pre-trial, fasting administration|2 cases were given 150mg Finamine tablets（pre-trial，fasting administration）
11087706|NCT04162275|Experimental|pre-trial,after high fat meal|2 cases were given 150mg Finamine tablets (pre- trial，after high fat meal)
11087707|NCT04162275|Placebo Comparator|formal trial-150mg|4 cases were given 150mg Finamine tablets 2 cases were given placebo
11087708|NCT04162275|Placebo Comparator|formal trial-300mg|6 cases were given 300mg Finamine tablets 2 cases were given placebo
11087709|NCT04162275|Placebo Comparator|formal trial-600mg|6 cases were given 600mg Finamine tablets 2 cases were given placebo
11087710|NCT04162275|Placebo Comparator|formal trial-1200mg|6 cases were given 1200mg Finamine tablets 2 cases were given placebo
11087711|NCT04162262|Experimental|Stretching, Strengthening, and IASTM|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. This group will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
11087712|NCT04162262|Active Comparator|Strengthening and Stretching|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. To equalize visit time with the Stretching, Strengthening, and IASTM group, subjects will perform 15 minutes of self-paced bicycle riding at the beginning of each session. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
11087713|NCT04162262|Other|Pain-free Comparison Group|The third group is a pain-free comparison group. This group will come to the laboratory once. They will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. These measurements will be compared to the same measures from the Stretching, Strengthening, and IASTM group to examine outcome measure differences in those with and without plantar fasciopathy following a single IASTM treatment.
11087714|NCT04162249||Conventional ablation (CONTROL GROUP)|"Pulmonary veins ablation.
~Anterior aspect: power 30 W, catheter dragging (30 s per point).
~Posterior aspect: point-by-point ablation using 30 W/30 s applications. If esophageal temperature measured with two independent esophageal probes exceeded 49 ºC radiofrequency settings were modified to 20 W/ 60 s and the number of radiofrequency applications minimized in areas with esophageal temperature rise.
~Al procedures were performed with continuos intracardiac echo image and esophageal temperature monitoring."
11087715|NCT04162249||High-power and short-duration ablation|"Pulmonary veins ablation.
~Subgroup 50W: power 50 W, application duration ≤ 30 s, target lesion index: LSI ≥ 5 or Ablation Index ≥ 350 (posterior wall) or ≥400 (anterior wall).
~Subgroup 60W: power 60 W, application duration 7-10 s, contact force ≥5 g.
~Subgroup 70W: power 70 W, application duration 9 s, contact force ≥5 g.
~Intracardiac echo was not used. Esophageal temperature probes were used only in 6 patients in the subgroup 50W."
11087716|NCT04162236||High Risk of Preeclampsia|"Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they meet the following criteria:
~1)High risk for preeclampsia according to first trimester screening (maternal risk factors, blood preassure, PPAP-A, mean pulsatility index (PIm) of the uterine arteries (UtA) at 11.0 to 13.6 weeks of gestation (n=280).
~Women in this group will be subdivided in cases and controls according to the later development of preeclampsia:
~cases: women developing PE (estimated n=40)
~controls: women not developing PE (estimated n=240)"
11087717|NCT04162236||Patients with Preeclampsia|Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they develop PE. Inclusion criteria: Patients presented with clinical signs and symptoms of preeclampsia (N=60).
11087718|NCT04162236||Control group|Healthy pregnant women with at low risk PE screening at 11.0 to 13.6 weeks of gestation (n=100).
11087719|NCT04162223|Experimental|Subcutaneous Fat Vaccine Injection|Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.
11087720|NCT04162223|Experimental|Intramuscular Vaccine Injection|Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.
11087721|NCT04162210|Experimental|Participants receiving Belantamab mafodotin|Participants will receive belantamab mafodotin single agent dose of 2.5 mg/kg on Day 1 of Q3W
11087722|NCT04162210|Active Comparator|Participants receiving pom/dex|Participants will receive pomalidomide orally starting dose of 4 mg daily on Days 1 to 21 of each 28-cycle, with dexamethasone at an oral dose of 40 mg once weekly or a lower dose of 20 mg once weekly on Days 1, 8, 15 and 22.
11087817|NCT04161430|Experimental|DRBP108|Phase A (Weeks 1-24): DBPR108 100mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
11087723|NCT04162197|Experimental|Experimental 1: Gait Group (GG)|Gait Group (GG) will perform, in addition to conventional therapy, gait training using only an end effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 12 sessions/month. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/ h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
11087724|NCT04162197|Experimental|Experimental 2: Balance Group (GHG)|Balance Group (GHG) will receive, in addition to conventional therapy, a combined robotic treatment program with the same end-effector robotic system and a robotic proprioceptive platform, 3 times/week for 12 sessions/month. The time of the single session (45 minutes) is dived in gait training and balance training. The balance training will consist in static and dynamic exercises during sitting and standing position, dual-task exercises and exercises aimed to improve trunk control.
11087725|NCT04162184|Experimental|Intervention|The research assistant will connect participants assigned to the intervention condition to the linkage navigator immediately after the baseline interview, if possible. The linkage navigator will maintain a worklist with all participants randomized to the intervention and will engage participants in person at the clinic and/or by phone. This engagement process will be finalized during the formative phase and will be similar to navigator standard work across the organization. The linkage navigator will then implement the intervention (intervention manual to be revised during formative phase). The current intervention consists of 2 sessions. The linkage navigator will work to educate, understand desired family planning needs and link the patient to reproductive health services as appropriate.
11087726|NCT04162184|No Intervention|Standard Care|Participants assigned to the standard care group will receive the current standard of care for reproductive health care in the substance treatment setting. Current standard of care is to administer the state-mandated, Infectious Disease Behavioral Screen. If a patient screens at risk for HIV they are referred to the Colorado Department of Public Health and Environment (CDPHE) or the Denver Public Health (DPH) Clinic for further evaluation and follow-up. At this time, there is no standard work in place to assess pregnancy desire, contraception use and/or to provide information on contraceptive methods or referral to services. All participants will receive a reproductive health informational brochure. Standard care participants will have needed information, but will need to independently initiate and access services.
11087727|NCT04162171|Experimental|Imaging & SBRT Treatment for Ventricular Tachycardia|
11087728|NCT04162158|Experimental|Targeted drug combined with allogeneic NK cell treatment group|In addition to traditional symptomatic supportive treatment, Sorafenib, regolfinib or levabinib will be administered in combination with allogeneic NK cells (3 cycles).
11087729|NCT04162158|No Intervention|Targeted drug treatment group|Sorafenib, regolfinib or levabinib will be administered in addition to traditional symptomatic supportive care.
11087730|NCT04162145|Active Comparator|Active Device|Patients in the Active Device arm will receive placement of an active BRIDGE device.
11087731|NCT04162145|Sham Comparator|Sham Device|Patients in the Sham Device arm will receive placement of an inactive, or sham, BRIDGE device. The inactive device will be identical in appearance to the active device but will have no electrical current.
11087732|NCT04162132||DynamiCare group|Patients at Morgan Street location of BrightView who were given the DynamiCare smartphone app.
11087733|NCT04162132||Non-DynamiCare group|Patients at Colerain location of BrightView who were not given the DynamiCare smartphone app.
11087734|NCT04162119|Experimental|multiple myeloma|This study is to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with Relapsed/Refractory Multiple Myeloma.
11087735|NCT04162106|Active Comparator|Ultravision™ System|Smoke management during laparoscopic cholecystectomy performed with the Ultravision™ System
11087736|NCT04162106|Active Comparator|Airseal® iFS|Smoke management during laparoscopic cholecsystectomy performed with the Airseal® iFS
11087737|NCT04162093|Experimental|single trough|
11087738|NCT04162028|Experimental|Nebulized Ketamine|sub-dissociative dose ketamine administered prehospitally via breath-actuated nebulizer at 1.0 mg/kg for patients with acute pain
11087739|NCT04162015|Experimental|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
11087740|NCT04162002|Experimental|Restylane® Lyft Filler Injection|
11087741|NCT04161989|Other|Group I (omega-3 fatty acids group)|
11087742|NCT04161989|Other|Group II (vaginal progesterone plus omega-3 group)|
11087743|NCT04161976|Experimental|LY900027|LY900027 administered to participants with type 1 diabetes mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) in one of two dosing periods.
11087744|NCT04161976|Active Comparator|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII in one of two dosing periods.
11087745|NCT04161963||Phaco|tandard ultrasound phacoemulsification cataract surgery
11087746|NCT04161963||FLACS|femtolaser assisted cataract surgery
11087747|NCT04161963||phaco+MIGS|combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery
11087748|NCT04161950||Tested device model (EG-UR5-S50 )|Tested device model: The EG-UR5 echoendoscope manufactured by SonoSscope Medical Crop. That used with the HD-500 image processor, HDL-500X light source and S50 ultrasonic processor.
11087749|NCT04161950||Compared device model (GF-UE260-ME2)|Compared device model: The GF-UE260 echoendoscope manufactured by Olympus and its compatible light source, image processor and ME2 ultrasonic processor.
11087750|NCT04161937|Experimental|Behavioural Intervention|Half of the randomly selected participants will get behavioural intervention based on Diabetes Prevention Program module.The behavioural intervention classed will be administered by trained nurse weekly for 16 weeks.After completion of behavioural intervention both the experimental and control arm will get cafeteria intervention.
11087751|NCT04161937|Experimental|Control|Half of the participants will act as a control and will not receive any form of behavioural intervention.
11087752|NCT04161924||X-ray imaging with physical grid using conventional processing|
11087753|NCT04161924||X-ray without physical grid using conventional processing|
11087755|NCT04161911||Advanced Hepatocellular Carcinoma (aHCC) cohort|aHCC cohort selected from the Flatiron Health Oncology electronic health record (EHR) data from January 2011 to the most recent data available. The index date will be defined as the start of second or third line nivolumab therapy for aHCC between January 1, 2011 and the most recent data available.
11087756|NCT04161898|Experimental|Arm 1: Upadacitinib|Participants will be administered updadacitinib once daily (QD) along with prednisolone
11087757|NCT04161898|Experimental|Arm 2: Placebo for Upadacitinib|Participants will be administered placebo once daily (QD) along with prednisolone
11087758|NCT04161885|Experimental|Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care|Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)
11087759|NCT04161885|Experimental|Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC|Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
11087760|NCT04161885|Experimental|Part 2: Arm B - Best Supportive Care (BSC)|Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)
11087761|NCT04161872|Active Comparator|Uricemin|
11087762|NCT04161872|Placebo Comparator|Placebo|
11087763|NCT04161846|Experimental|Virtual World Program|Participants will take part in an 8 session training program delivered using a virtual world approach
11087764|NCT04161846|Active Comparator|In Person Program|Participants will take part in an 8 session training program delivered using an in person approach
11087765|NCT04161833|Experimental|OPERA|Women receiving adjuvant aromates-inhibitor with arhtralgia grade ≥ 1 (CTACAE 4.03)
11087766|NCT04161820|Experimental|Education and telephone follow ups based on the CCM|"After the pre-tests (self-management, quality of life and patient satisfaction were assessed by scales at the first interview), the patients were given discharge training with a booklet prepared based on the Chronic Care Model (CCM) and containing information and recommendations on self-management strategies during their stay in the hospital (0 months). Trainings were performed in a single session and in the patient room at the clinic, not to exceed 45-50 minutes. The patients who were included in the intervention group were followed up by phone on the 7th day, 15th day, 1st month and 2nd month after discharge. Patients were referred to the hospital in unexpected / unpredictable situations during the three-month period.
~Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later."
11087767|NCT04161807|Experimental|Nerivio device treatment|participant will receive the Nerivio device for treating their migraine attacks. Treatment will be perform as soon as the participant feel that the migraine attack started
11087768|NCT04161794|Experimental|Intervention group|2 g EPA/DHA via fish oil daily Regular dietary counselling Twice weekly strength and cardiovascular exercise
11087769|NCT04161794|No Intervention|Historical control group|Standard of Care
11087770|NCT04161781||Cohort 1|10 participants will receive one injection of 18F-BMS-986229 (370 MBq) and will then undergo whole-body PET/CT (80 mA) encompassing the vertex of the skull to the proximal thigh performed at 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging.
11087771|NCT04161781||Cohort 2|25 participants may receive 370 MBq of 18F-BMS-986229 given intravenously and will undergo a single PET/CT scan 60 minutes (within the range of 55-70 minutes) postinjection. The scan itself is expected to last about 30 minutes and participants will be asked to remain in the waiting area or dedicated room for an additional 30 minutes post scan. The total time from injection will be 120 minutes. In both cohorts, participants whose treatment includes nivolumab and who have positive tumor localization observed at baseline will be asked to undergo an additional round of imaging. If the participant agrees, they will receive a second injection while undergoing nivolumab treatment (after at least 2 cycles or 6 weeksof therapy).
11087772|NCT04161768|Active Comparator|Norfloxacin|Norfloxacin 400 mg daily
11087773|NCT04161768|Experimental|Norfloxacin and Itopride|Norfloxacin 400 mg daily and Itopride 50 mg three times daily.
11087774|NCT04161755|Experimental|Pancreatic Cancer|Radiologically resectable primary pancreatic tumors
11087775|NCT04161729|Active Comparator|Magnesium sulfate|Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
11087776|NCT04161729|Placebo Comparator|Isotonic solution 0.9%|Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
11087777|NCT04161716|Experimental|NIRS module|Each patient has a NIRS module during a diagnosis urodynamic assessment provided for by the usual practice.
11087778|NCT04161703|Experimental|focused ultrasound, diet and exercises|
11087779|NCT04161703|Experimental|diet and exercises|
11087780|NCT04161690|Active Comparator|Group IV|Dexketoprofen 50mg is given intravenous 10 min before the start of the surgery. Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
11087781|NCT04161690|Active Comparator|Group Periarticular|Dexketoprofen 50mg is given as part of the local infiltration analgesia with 300mg ropivacaine. Local infiltration analgesia is proceeded by the orthopedic surgeon.
11087782|NCT04161690|Placebo Comparator|Group P|Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
11087783|NCT04161664|Experimental|neo adjuvant Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
11087784|NCT04161651|Experimental|single arm|
11087818|NCT04161430|Active Comparator|Sitagliptin|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
11087855|NCT04161170|Active Comparator|Intervention B|apply digital integrated healthcare platform clinic visit every 3 months
11087785|NCT04161638|Experimental|High Blood Pressure|Ambulatory BP measurement was used to confirm the laboratory BP group classification according to the European Society of Hypertension. Participants were placed in the high blood pressure (HBP) group if they met any of the following criteria: 1) 19-hour average systolic BP/diastolic BP (SBP/DBP) > 130/80 mmHg, 2) daytime (awake) average SBP/DBP > 135/85 mmHg, or 3) nighttime (sleep) average SBP/DBP > 120/70 mmHg.
11087786|NCT04161638|Experimental|Normal Blood Pressure|Participants were placed in the normal BP (NBP) group if they met all of the following criteria: 1) 19-hour average SBP/DBP < 130/80 mmHg, 2) daytime (awake) average SBP/DBP < 135/85 mmHg, and 3) night-time (asleep) average SBP/DBP <120/70 mmHg.
11087787|NCT04161625|Experimental|Safe Step - digital exercise program|"All included participants will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
~Additional support to promote reach and exercise adherence will be provided in the format of technical support and try-out group exercises throughout the recruitment period."
11087788|NCT04161599|Experimental|Oral + Parenteral prophylaxis + Mechanical Bowel Preparation|"Drug: Extra dosage - cefuroxime (750mg) I.V
~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.
~Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.
~Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
11087789|NCT04161599|Active Comparator|Oral + Parenteral prophylaxis|"Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.
~Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
11087790|NCT04161573||TBI group|15 people in this group. Each should be post TBI for 6 months.
11087791|NCT04161573||Control group to TBI|15 people in this group. Their gender and age accord with TBI group.
11087792|NCT04161573||Aging group 1- 20 to 39|Normal people whose age range from 20 to 39.
11087793|NCT04161573||Aging group 2- 40 to 59|Normal people whose age range from 40 to 59.
11087794|NCT04161573||Aging group 3- above 60|Normal people whose age are above 60.
11087795|NCT04161560|Experimental|use of the cetuximab-IRDye800|four groups : control group, 1% dose group (1% of therapeutic dose; 2.5 Mg/m2) and 10% dose groups (10%of therapeutic dose ;25mg/m2) and 25% dose group (25%of therapeutic dose; 62.5mg/m2)
11087796|NCT04161547|Experimental|Cohort A1: CSPCHA115 100 mg|"CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
11087797|NCT04161547|Experimental|Cohort A2: CSPCHA115 200 mg|"CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
11087798|NCT04161547|Experimental|Cohort A3: CSPCHA115 400 mg|"CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
11087799|NCT04161547|Experimental|Cohort A4: CSPCHA115 600 mg|"CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.
~Eight subjects will receive CSPCHA115
~Two subjects will receive matching placebo"
11087800|NCT04161534|Active Comparator|Arm Sling Group|
11087801|NCT04161534|Experimental|KT Tape Group|
11087802|NCT04161521|Other|Placenta Accreta patients|of 60 pregnant female diagnosed as placenta previa accreta recuirted from Obstetrics and Gynecology Department , Menoufia University Hospital.
11087803|NCT04161508|Experimental|Sugammadex|sugammadex 2 mg/ Kg for the reversal of neuromuscular blockade at the end of surgery
11087804|NCT04161508|Active Comparator|Neostigmine|neostigmine 50 mcg/Kg + glycopyrrolate 10 mcg/kg for the reversal of neuromuscular blockade at the end of surgery
11087805|NCT04161495|Experimental|Prophylaxis|Participants will receive BIVV001 once-weekly (QW) during a prophylaxis treatment regimen for 52 weeks
11087806|NCT04161495|Experimental|On Demand|Participants will receive BIVV001 on demand for 26 weeks, followed by a switch to a prophylaxis treatment regimen with BIVV001 for 26 weeks.
11087807|NCT04161482|Experimental|Cohort One|A bi-phasic delivery over 5 hours
11087808|NCT04161482|Experimental|Cohort 2a|Continuous infusion over 2 hours
11087809|NCT04161482|Experimental|Cohort 2b|Bi-phasic delivery over 2 hours
11087810|NCT04161482|Experimental|Cohort 3|Continuous infusion over 1 hour.
11087811|NCT04161482|Experimental|Cohort 4|Continuous infusion over 30 minutes.
11087812|NCT04161469|Other|Group 1|Patients diagnosed with anal fistula treated by laser closure of the tract
11087813|NCT04161469|Other|Group 2|Patients diagnosed with anal fistula treated by laser closure of the tract with an additional surgical technique as the closure of the internal orifice with a purse-string suture using 2-0 polyglactin
11087814|NCT04161456|Experimental|Apremilast|Apremilast twice daily 30 mg
11087815|NCT04161443|Experimental|Experimental|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.
~i. MET Quadratus lumborum ii. Ultrasound iii. Gluteus medius exercises iv. Hamstring stretch Posture advice and home exercise program"
11087816|NCT04161443|Active Comparator|Comparator|"Following physiotherapy treatment will be given to the participants in this group for 4 weeks and each session last for 30 minutes.
~i. Ultrasound ii.Gluteus medius exercises iii.Hamstring stretch"
11087819|NCT04161430|Placebo Comparator|Placebo|Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg + placebo matching Sitagliptin 100 mg; Phase B (Weeks 25-52): DBPR108 100 mg
11087820|NCT04161417|Other|Biopsy Material Required for Registration|The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
11087821|NCT04161404|Experimental|Period 1|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
11087822|NCT04161404|Experimental|Period 2|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
11087823|NCT04161404|Experimental|Period 3|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
11087824|NCT04161391|Experimental|TPX-0046|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.
~A food-effect sub-study will be conducted once the RP2D has been determined.
~The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.
~Phase 2 Cohorts:
~Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)
~Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)
~Cohort III (MTC + RET mutation, RET TKI Therapy Naive)
~Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)
~Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)
~Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)"
11087825|NCT04161378||RHB-SG 01|Patients with early mobilization (< 2 days after the onset of symptoms)
11087826|NCT04161378||RHB-SG 02|Patients with delayed mobilization after AMI (>2 days after the onset of symptoms)
11087827|NCT04161365|Experimental|Urethral stricture patients|Patients suffering from urethral stricture are treated with direct visual internal urethrotomy (DVIU). Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
11087828|NCT04161339|Experimental|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
11087829|NCT04161339|Placebo Comparator|Placebo|
11087830|NCT04161313||Cystic fibrosis|children with cystic fibrosis
11087831|NCT04161313||primary ciliary dyskinesia|children with primary ciliary dyskinesia
11087832|NCT04161313||healthy controls|Age-matched healthy volunteers
11087833|NCT04161300|Active Comparator|Foam Rolling Group (FR)|
11087834|NCT04161300|Active Comparator|Orthopaedic Manual Physical Therapy Group (OMPT)|
11087835|NCT04161300|Other|Control Group (CG)|
11087836|NCT04161287||SBRT with TACE|
11087837|NCT04161287||SBRT alone|
11087838|NCT04161274|Active Comparator|Traditional method: Electrosurgery|"Local anaesthesia and excision with a scalpel connected to the electric current, according to the voltage. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
11087839|NCT04161274|Active Comparator|Traditional method: Cryotherapy|"Application of liquid nitrogen to cause freezing. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
11087840|NCT04161274|Active Comparator|Traditional method: Silver nitrate|"Excision is made with the scissors and a rod is applied containing silver nitrate with caustic power on the wound.
~Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
11087841|NCT04161274|Experimental|Moist healing environment|"Excision is made with the scissors, afterwards pressure, clorhexidine and a hydrocolloid dressing when the skin is dry.
~Photograph to the lesion before and after the intervention and in each follow-up visit.
~Follow-up visits every 3 days until the lesions cicatrization."
11087842|NCT04161261|Experimental|IntraOperative Group|The intra-operative group consists of patients who have met criteria for cochlear implants. We monitor the facial nerve EMG intraoperatively in all patients, and often get some facial nerve activation when we are testing the implant intraoperatively when we are looking to see if we are getting any hearing nerve responses from electrical stimulation of the implant. We will also measure the facial nerve responses for some other charge-balanced pulse shapes, which are asymmetric and in which either the positive or negative charge is expected to stimulate the nerve. We will only measure these for two electrodes, not for all 12-22 electrodes They will be then invited back post operatively for a second testing during a standard of care visit post switch on for other pulse shapes.
11087843|NCT04161261|Experimental|PostOperative Group|The post-operative group, are patients who are actually having facial nerve stimulation on one or more electrodes, and for whom these electrodes are turned down so much they can't hear very well, or are actually turned off because of the facial nerve stimulation. For these patients, we will slowly increase the current levels on the offending electrodes (maximum of two) until they get some facial nerve twitching, and then turn down the current until they do not have stimulation any more. We will do this for all pulse shapes and determine which shape produces the greatest loudness without stimulating the facial nerve. This will be the only testing session for the second group.
11087844|NCT04161248|Experimental|Venetoclax + R-GDP|
11087845|NCT04161235||Treatment|Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
11087846|NCT04161222|Experimental|Experimental group|The control group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
11087847|NCT04161222|Experimental|Control group|The control group will perform a typical warm-up of competitive football.
11087848|NCT04161209|Experimental|Drug: Citalopram|20mg oral dose of citalopram (tablet encapsulated in opaque capsule)
11087849|NCT04161209|Placebo Comparator|Placebo|Lactose placebo (tablet encapsulated in opaque capsule)
11087850|NCT04161196|Active Comparator|patients with post - tonsillectomy suturing tonsil pillars|
11087851|NCT04161196|Placebo Comparator|patients without post - tonsillectomy suturing tonsil pillars|
11087852|NCT04161183|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
11087853|NCT04161183|Experimental|Extracoporeal shock wave therapy|Extracoporeal shock wave therapy (shock wave probe w/ energy)
11087854|NCT04161170|No Intervention|Control A|no intervention conventional diabetes treatment and clinic visit every 3 months
11087945|NCT04160572|Experimental|Morning-evening sleep schedule|
11087856|NCT04161170|Experimental|Intervention C|apply digital integrated healthcare platform, CGMS, and medical team monitoring, and education clinic visit every 3 months
11087857|NCT04161157|Experimental|Pathways|Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
11087858|NCT04161144|Active Comparator|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
11087859|NCT04161144|Placebo Comparator|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
11087860|NCT04161131|Experimental|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
11087861|NCT04161118|Experimental|Tisagenlecleucel (CTL019)|All patients will receive a single target dose of 0.6 to 6.0 × 108 of autologous tisagenlecleucel (CTL019) transduced T-cells with a viability of at least 70% administered via IV infusion after optional bridging with chemo- or immunotherapy and lymphodepleting (LD) chemotherapy with cyclophosphamide and fludarabine.
11087862|NCT04161105|Experimental|Rectus femoris dry needling group|The rectus femoris dry needling group will have their strength assessed. They will then receive one treatment of dry needling to a trigger point in their rectus femoris muscle. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
11087863|NCT04161105|Experimental|Gluteus maximus dry needling group|The gluteus maximus dry needling group will have their strength assessed. They will then receive one treatment of dry needling to trigger points in their gluteus maximus muscle only. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
11087864|NCT04161105|No Intervention|Control|This group will receive no intervention. They will have their strength assessed at baseline and 24, 48 & 72 hour follow-up
11087865|NCT04161092|Other|Liver transplantation + best alternative care|"Patients subjected to Ltx will during the waiting time receive individualized chemotherapy, with the aim to avoid side effect that make them not transplantable.
~If possible, patients randomized to Ltx should be treated within 12 weeks after randomization.
~If the patients progress systemically they will be treated with best alternative care.
~If they progress only within the liver they continue to be transplantable until they are deemed technically not transplantable by the transplant surgeon."
11087866|NCT04161092|Other|Best alternative care|The treating physician will together with the patient decide the treatment.
11087867|NCT04161079||MAR population|Subjects, who underwent MV repair operation with successful MAR implantation in clinical investigation 2010-040
11087868|NCT04161066|Experimental|Open-label|Psilocybin with guided counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
11087869|NCT04161053|Active Comparator|Rifaximin|550 mg Rifaximin tablets twice daily for six months.
11087870|NCT04161053|Experimental|Nitazoxanide|500 mg Nitazoxanide tablets twice daily for six months.
11087871|NCT04161040|Experimental|Relapse (experimental) Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. For the Relapse (experimental) Group, the second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Then, during the third phase, the incentives will be discontinued.
11087872|NCT04161040|Experimental|Fatigue Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. The first phase will mimic pre-intervention conditions; there will be a variety of activities available. No incentives for engaging in physical activity will be provided, although such activities will be available. The second phase will mimic an incentive-based intervention in which participants can earn monetary incentives for engaging in physical activity. Participants in this arm will continue to earn incentives during Phase 3 to control reductions in physical activity due to fatigue.
11087873|NCT04161040|No Intervention|No-Incentive Control Group|Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases. Each phase will last 20 minutes. Participants in this arm will not earn incentives during any of the three phases to control for the possibility that participants will engage in some physical activity in the absence of incentives.
11087874|NCT04161027|Experimental|Pregabalin|
11087875|NCT04161027|Placebo Comparator|Placebo|
11087876|NCT04161014|Other|Treatment Arm|Nintedanib 150mg twice daily for 3 years
11087877|NCT04161001|Experimental|Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe
11087878|NCT04161001|Placebo Comparator|Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan and Rosuvastatin, Ezetimibe
11087879|NCT04161001|Placebo Comparator|Amlodpine, Olmesartan|co-administration of Olmesartan, Amlodipine
11087880|NCT04160975|Experimental|Black R/Race C/Gender C/Doctor/Standard Script|Video which contains a racially and gender concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
11087881|NCT04160975|Experimental|Black R/Race C/Gender D/Doctor/Standard Script|Video which contains a racially concordant and gender discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
11087882|NCT04160975|Experimental|Black R/Race C/Gender C/Layperson/Standard Script|Video which contains a racially and gender concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
11087883|NCT04160975|Experimental|Black R/Race D/Gender C/Doctor/Standard Script|Video which contains a racially discordant and gender concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
11087946|NCT04160572|Active Comparator|Evening-morning sleep schedule|
11087947|NCT04160559|Placebo Comparator|Control group|chemotherapy plus water
11087884|NCT04160975|Experimental|Black R/Race D/Gender C/Doctor/Empathetic Script|Video which contains a racially discordant and gender concordant actor playing a doctor and reading an empathetic script. The receiver of the message will be Black.
11087885|NCT04160975|Experimental|White R/Race C/Gender C/Doctor/Standard Script|Video which contains a racially and gender concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
11087886|NCT04160975|Experimental|White R/Race C/Gender D/Doctor/Standard Script|Video which contains a racially concordant and gender discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
11087887|NCT04160975|Experimental|White R/Race D/Gender C/Doctor/Standard Script|Video which contains a racially discordant and gender concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
11087888|NCT04160975|Experimental|COVID-19 Information, Concordant Source|Message inviting subject to receive the results of a COVID-19 vaccine review from the National Medical Association (NMA). The receiver of the message will be Black.
11087889|NCT04160975|Experimental|COVID-19 Information, Discordant Source|Message inviting subject to receive the results of a COVID-19 vaccine review from the National Medical Association (NMA). The receiver of the message will be White.
11087890|NCT04160975|Experimental|COVID-19 Information, Standard Source|Message inviting subject to receive the results of a COVID-19 vaccine review from the Food and Drug Administration (FDA). Receivers of the message will be White or Black.
11087891|NCT04160962||lappg|
11087892|NCT04160962||ladgbi|
11087893|NCT04160949||Patients|Patients who have been diagnosed with Fatty Liver.
11087894|NCT04160936|Active Comparator|study group ,infiltration with 0.25% ropivacaine post-op|At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin
11087895|NCT04160936|No Intervention|control group , no anesthesia infiltration post-op|
11087896|NCT04160910|Active Comparator|5-hydroxytryptophan|"Dosage of 5-hydroxytryptophan will be determined by weight:
~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
11087897|NCT04160910|Placebo Comparator|Placebo|"Dosage of placebo will be determined by weight:
~If subject weighs less than 100lbs: 50mg twice a day If subject weights more than 100lbs: 100mg twice a day"
11087898|NCT04160897||ETV cohort|CHB patients with entecavir naive treatment
11087899|NCT04160897||TDF cohort|CHB patients with naive tenofovir disopropyl naive treatment
11087900|NCT04160884|Active Comparator|A|0.6mg/kg of ICG, iv
11087901|NCT04160884|Experimental|B|0.2mg/kg of ICG, iv
11087902|NCT04160871|Experimental|Family Connections|Experimental group
11087903|NCT04160871|Active Comparator|Treatment As Usual|Control group
11087904|NCT04160858|Experimental|Exercise Condition|The intervention is a personalized exercise prescription based on the International Scientific Spinal Cord Injury (SCI) Exercise Guidelines. Participants begin at the Starting Level guideline: 20 min aerobic exercise, 2x/wk, at 70% of heart rate reserve (or a Borg Continuous Ratio 0-10 rating of 6), & 3 sets of 10 repetitions of strengthening exercises (each major functioning muscle group at 50-80% of 1-rep max), 2x/wk. Participants will gradually increase aerobic exercise to 30 min, 3x/wk (i.e. the Advanced Level guideline). Exercise implementation will be supported by a fitness trainer and an exercise counsellor with SCI-specific training and experience.
11087905|NCT04160858|Active Comparator|Wait-list Control|Control participants will not get an exercise prescription. They will be asked to refrain from lifestyle changes for 6 mos. After the 6-month waitlist period, Controls will receive the same resources as Exercisers.
11087906|NCT04160819|Experimental|individualized nutritional intervention programs (iNIPs)|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs. Anthropometry (i.e., body mass index, limb circumference, and subcutaneous fat thickness), blood parameters (i.e., albumin and total lymphocyte count), hospital stay, Mini-Nutritional Assessment-Short Form (MNA-SF) score, target daily calorie intake, total calorie intake adherence rate, and three-major-nutrient intake were assessed during hospitalization and 3 and 6 months after discharge. Both groups received regular follow-up through phone calls. Furthermore, the rate of readmission resulting from pneumonia was recorded after discharge.
11087907|NCT04160819|No Intervention|standard care (SC) group|SC group was only provided standard nutritional supplements according to the Kaohsiung Chang Gung Memorial Hospital Nutrition Department, and patients' family members were not provided dietary advice.
11087908|NCT04160806|Active Comparator|Active Group|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
11087909|NCT04160806|Sham Comparator|Sham Group|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
11087910|NCT04160793|Other|Genital Nerve Stimulation|Stimulation of the DNP
11087911|NCT04160780|Experimental|L-PRF as sole graft material|lateral sinus augmentation using L-PRF as sole graft material
11087912|NCT04160780|Experimental|xenograft as sole graft material|lateral sinus augmentation using xenograft as sole graft material
11087913|NCT04160780|Experimental|Xenograft mixed with L-PRF as graft material|lateral sinus augmentation using L-PRF mixed with xenograft as graft material
11087914|NCT04160767|Active Comparator|Probiotic|
11087915|NCT04160767|Placebo Comparator|Placebo|
11087916|NCT04160754|Experimental|MBRP|The experimental group will receive treatment as usual plus eight Mindfulness based relapse prevention (MBRP) therapy sessions.
11087917|NCT04160754|Active Comparator|Control (CTL)|The CTL group will receive treatment as usual plus information on the neurobiology of addiction and healthy behaviors.
11087918|NCT04160741|Experimental|Hot environment with radiation|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
11087948|NCT04160559|Experimental|Test group|chemotherapy plus green tea
11150090|NCT03726866|Experimental|Sequence 5|Sequence 5
11087919|NCT04160741|Experimental|Hot environment without radiation|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
11087920|NCT04160741|Experimental|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
11087921|NCT04160741|Active Comparator|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)
~Exposure for 03:20:00:
~rest (two hours)
~work (cycling) at 100 W (one hour)
~recovery (twenty minutes)"
11087922|NCT04160728|Experimental|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
11087923|NCT04160728|Experimental|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work.
11087924|NCT04160728|Experimental|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts.
11087925|NCT04160728|Experimental|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
11087926|NCT04160728|Sham Comparator|Business as usual scenario|No interference with the usual work day of the participants.
11087927|NCT04160728|Sham Comparator|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment.
11087928|NCT04160702|Experimental|Motivate-The-Bystander|Participants assigned to the MTB condition arm.
11087929|NCT04160702|No Intervention|Assessment only control condition|Participants assigned to the assessment only condition arm.
11087930|NCT04160689|Active Comparator|Group 1|Anyridge (Mega'Gen, Korea) 5° conical internal hexed connection
11087931|NCT04160689|Active Comparator|Group 2|Core (Bioimplant, Italy) 35° conical internal hexed connection (screw-vent style)
11087932|NCT04160676|Active Comparator|Group I|"The patients in this group will be managed only according to the surviving sepsis campaign 2016 and the surviving sepsis campaign bundle 2018 update.
~The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline I.V / 6 h, 5 ml normal saline I.V / 12 h."
11087933|NCT04160676|Experimental|Group II|The patients will receive the conventional therapy of sepsis and combined therapy of hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5 gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12 h This combined therapy will be given for 4 days or to the time of discharge if the admission period is less than 4 days
11087934|NCT04160663|Experimental|Subjects with atrial fibrillation|Subjects with atrial fibrillation that have been clinically scheduled for an electrical cardioversion procedure will have carotid ultrasound testing done before and after the procedure
11087935|NCT04160650|Experimental|Educational nursing intervention|"Patients in experimental group receive standard care and one-hour educational session. Patients are provided knowledge of
~healthy diet
~malnutrition, its prevalence and consequences for patients with CRC undergoing CT
~side effects impairing nutrition intake during CT treatment.
~prevention and self-care methods of the side effects Teach-back is used to verify participants' understanding. Empowering effect is confirmed by using active listening and asking patients' individual side effects, self-care strategies and need of additional knowledge in the beginning of the session and supporting patients' self-care methods when they have been applicable and effective. Additional knowledge of each theme is offered. To reinforce the intervention effect patients receive after the first CT a self-monitoring diary including assessment of side effects prevalence and intensity (NRS 0-10) before and after the self-care strategies. They return diaries by the 5th cycle of CT."
11087936|NCT04160650|No Intervention|Standard care|"Patients in control group receive standard care, information of
~general CT induced side effects and their self-care; nausea, diarrhoea, obstipation and sores in the mouth, peripheral neuropathy symptoms, local venous irritation, heart symptoms, mucous and skin irritation
~side-effects' self-monitoring, fluid intake, medication dose changes, effect of CT
~weight control
~taste alteration
~cold sensitivity
~variable diet
~dietary supplements
~available dietitian services
~They receive a self-monitoring diary, which includes only side effects and their intensity (NRS 0-10)."
11087937|NCT04160637||Patients with post-thyroidectomy hypocalcemia|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
11087938|NCT04160637||Patients without post-thyroidectomy hypocalcemia|Patients without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
11087939|NCT04160624|Active Comparator|Non-ECLS GROUP|For AS/R patients with normal EF, only TAVR was performed
11087940|NCT04160624|Experimental|ECLS GROUP|For AS/R patients with low EF, TAVR under ECLS-assisted was performed
11087941|NCT04160611|Experimental|Premedication with Midazolam|Patients will be randomly divided into two groups, control and midazolam. The midazolam group will receive midazolam premedication in such a way that 7.5mg midazolam will be taken orally 30 minutes before the aspiration procedure. Because midazolam causes sedation, the woman will be monitored by midazolam after medical premedication to avoid possible complications and will not be allowed to get out of bed on her own for 30 minutes. After 30 min, all women, both test and control group, will begin aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
11087942|NCT04160611|No Intervention|No Premedication with Midazolam|Women in the control group will undergo aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
11087943|NCT04160598|Placebo Comparator|Placebo group|bolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
11087944|NCT04160598|Experimental|IV Mg ++ group|continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
11087949|NCT04160546|Experimental|Ponatinib plus ASA treatment|Patients will be treated with ponatinib 15 mg/day plus 100 mg/day ASA for 104 weeks. After that, ponatinib and ASA will be stopped.
11087950|NCT04160520|Experimental|Pramipexole and half-standard dose of morphine|0.25 mg oral tablet of pramipexole in combination with 0.05mg/kg of IV morphine
11087951|NCT04160520|Active Comparator|Standard dose of morphine and placebo|0.1mg/kg of IV morphine in combination with a placebo pill
11087952|NCT04160507||Healthy black adults 50 and over|Healthy black adults age 50 and over with no known history of kidney disease will be recruited as controls in this study.
11087953|NCT04160507||black adult cases with non-diabetic nephropathy|black adult cases with non-diabetic nephropathy
11087954|NCT04160494|Experimental|D2C7-IT (6920 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (6920 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
11087955|NCT04160494|Experimental|D2C7-IT (4613.2 ng/mL) + Atezolizumab|Single D2C7-IT convection-enhanced delivery (CED) infusion (4613.2 ng/mL) plus atezolizumab (1200 mg) intravenous (IV) infusions every three weeks for up to two years
11087956|NCT04160481|Active Comparator|Tomato extract|
11087957|NCT04160481|Placebo Comparator|Placebo|
11087958|NCT04160468|Experimental|Exebacase|
11087959|NCT04160468|Placebo Comparator|Placebo|
11087960|NCT04160455||Cohort A, group A1|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase : CD4 count less than 500 cells / ml at the time of inclusion in the study
11087961|NCT04160455||Cohort A, group A2|40 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated during the chronic phase: CD4 count above 500 cells / ml at the time of inclusion in the study
11087962|NCT04160455||Cohort B|20 patients on suppressive antiretroviral therapy (HIV RNA <50 copies / ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)
11087963|NCT04160455||Cohort C, group C1|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during primary infection (within 4 months of infection)
11087964|NCT04160455||Cohort C, group C2|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells/ml at the time of inclusion in the study
11087965|NCT04160455||Cohort C, group C3|20 patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells/ml at the time of inclusion in the study
11087966|NCT04160455||Cohort D|20 patients who have undetectable plasma HIV RNA (HIV RNA <50 copies / ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers).
11087967|NCT04160429||Device feasibility (Macroduct Sweat Collection System)|Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.
11087968|NCT04160416|Experimental|mXELOXIRI|"Induction therapy is followed by the maintenance therapy. Induction treatment: XELOXIRI+CET/BEV Administered for 6 cycles (a maximum of 8 cycles).Bevacizumab (BEV): 5mg/kg (d.i.v.); Cetuximab 500mg/sq.m (d.i.v.)；Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) Irinotecan (IRI):135 mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-10) Administered every 2 weeks.
~Maintenance treatment: CAP+CET/BEV. The following CAP+BEV/CET therapy will be repeated in 2-week cycles."
11087969|NCT04160403|Experimental|factors ( SES,age, sex,severity) and progress|the relation between progress in gross motor functions
11087970|NCT04160390||Arm I (biospecimen collection)|Patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. Patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
11087971|NCT04160390||Arm II (biospecimen collection)|Patients undergo collection of blood prior to transplant and on days 0, 3, and 4. Patients also undergo collection of stool prior to and post-transplant. Donors undergo collection of blood and saliva within 8 weeks prior to donation.
11087972|NCT04160377|Experimental|melancholic depression|patients with melancholic depression undergo the treatment of Fluvoxamine
11087973|NCT04160377|Experimental|non-melancholic depression|patients with non-melancholic depression undergo the treatment of Fluvoxamine
11087974|NCT04160351|Experimental|MCO Dialyser|12 treatments (4 weeks) with Medium Cut-Off Dialyzer
11087975|NCT04160351|Active Comparator|High Flux Dialyser|12 treatments (4 weeks) with High Flux Dialyzer
11087976|NCT04160325|Experimental|3 months exclusive enteral nutrition plus azathioprine|patients underwent surgery in this arm will given 3 months exclusive enteral nutrition,and free diet after 3 months. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
11087977|NCT04160325|Active Comparator|normal diet plus azathioprine|patients underwent surgery in this arm will given free diet all through. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
11087978|NCT04160312|Experimental|Mitopure™ (Proprietary Urolithin A)|Fruit flavored food sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
11087979|NCT04160312|Experimental|Pomegranate Juice|100% Pomegranate juice equivalent to a glass of juice
11087980|NCT04160299|Experimental|Dance-based exergaming|This will be an intervention-based study with single-group design, where participants will receive VR-based dance training for ten weeks. An anticipated 20 participants with a diagnosis of mild cognitive deficits will be recruited for initial screening
11087981|NCT04160286||ECT (Work Package 1)|Group of patients receiving ECT during their hospitalization.
11087982|NCT04160286||Non-ECT (Work Package 1)|Group of patients not receiving ECT during their hospitalization.
11087983|NCT04160286||Work Package 2|Group of discharged patients who during their hospitalization received ECT. At the time of assessment, the discharged patients received their last session of ECT six months ago.
11088048|NCT04159831|Placebo Comparator|Placebo|placebo (normal saline) 6ml qd x 3 days administered intrapleurally
11150091|NCT03726866|Experimental|Sequence 6|Sequence 6
11087984|NCT04160273|Experimental|Diagnosis and follow-up arm|"Patients are informed during the 9th month pregnancy consultation consultation at Angers University Hospital by the midwife or obstetrician in charge of the consultation. They are included in the 48 hours following the delivery after their hospitalization in the maternity ward.
~During hospitalization, socio-demographic and medical data are collected and the IDP scale is completed before returning home.
~Follow-up at one month and one year is carried out by the investigators by means of a telephone call during which the patient answers the PCL-S questionnaire. Also collected during this call are information on the physical and mental state of the patient, the state of health of her newborn and the progress of the return home.
~Patients are considered at high risk of PTSD if they have a PCL-S score ≥ 44 at 1 month. A consultation with a psychiatrist is offered to these patients at risk of PTSD in order to make the diagnosis and offer them appropriate care if necessary."
11087985|NCT04160260|Experimental|Omadacycline: Omadacycline Tablets|
11087986|NCT04160247|Active Comparator|Angulated screw-retained crown|Restorations are connected to the implants by angulated screw channel system
11087987|NCT04160247|Placebo Comparator|Cemented crown|Restorations are cemented onto the implant abutment
11087988|NCT04160234||Elderly patient|Preoperative elderly patients, who are planned for a surgical intervention
11087989|NCT04160221|Active Comparator|12 hours interval|Mifepristone followed by Misoprostol treatment
11087990|NCT04160221|Active Comparator|24 hours interval|Mifepristone followed by Misoprostol treatment
11087991|NCT04160208||IUI - Insemination|Males of couples undergoing their first IUI treatment
11087992|NCT04160208||IVF - In vitro fertilisation|Males of couples undergoing their first IVF treatment. Including males of couples who have had previous IUI treatments.
11087993|NCT04160208||ICSI - Micro Insemination|Males of couples undergoing their first ICSI treatment. Including males of couples who have had previous IUI treatments.
11087994|NCT04160195|Active Comparator|1/Conditioning chemotherapy plus CAR T-cells dose escalation|All patients will be receiving escalating dose of Anti-CD19 and anti-CD20 CAR T cells/kg + conditioning chemotherapy
11087995|NCT04160195|Active Comparator|2/Conditioning chemotherapy plus CAR T-cells expansion phase|MTD dose of Anti- CD19 and anti- CD20 CAR T cells/kg + Conditioning chemotherapy
11087996|NCT04160182|Experimental|Energy Conservation Work Simplification Education|The intervention will be delivered online by an occupational therapist. The intervention consists of 6 weekly sessions; each session will be 45 minutes long. The focus of the intervention is to teach breast cancer survivors strategies to manage their fatigue.
11087997|NCT04160156||Type 1 diabetes|Subjects attending metabolic clinic who were suggested to use long term sensor due to persistent hyperglycemia and hypoglycemia
11087998|NCT04160143|Experimental|SBRT followed by pulmonary metastasectomy|SBRT+Surgery
11087999|NCT04160130|Experimental|SAPIEN 3 or SAPIEN 3 Ultra|Edwards SAPIEN 3 THV system Model 9600 TFX (20, 23, 26 and 29 mm) or SAPIEN 3 Ultra THV system Model 9750 TFX (20, 23, 26) with the associated transfemoral delivery systems.
11088000|NCT04160130|Active Comparator|any surgical bioprosthetic aortic valve|Any commercially available surgical bioprosthetic valve
11088001|NCT04160117|Experimental|Intervention|Colchicine 0.6 mg p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
11088002|NCT04160117|Placebo Comparator|Control|Matching placebo p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
11088003|NCT04160104||Training cohort|This cohort was used to establish the bowel preparation score (BPS).
11088004|NCT04160104||Validation cohort|This cohort was used to verify the bowel preparation score (BPS).
11088005|NCT04160091|Experimental|FX006 32mg in Glenohumeral OA Population|Single intra-articular (IA) injection
11088006|NCT04160091|Placebo Comparator|Normal Saline in Glenohumeral OA Population|Single intra-articular (IA) injection
11088007|NCT04160091|Experimental|FX006 32mg in Adhesive Capsulitis Population|Single intra-articular (IA) injection
11088008|NCT04160091|Placebo Comparator|Normal Saline in Adhesive Capsulitis Population|Single intra-articular (IA) injection
11088009|NCT04160078|Experimental|Mindfulness Intervention Arm|A stress reduction plus sleep education intervention to improve sleep health
11088010|NCT04160065|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:
~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator
~Route of Administration:
~Intratumoral injection of cutaneous, subcutaneous or nodal lesions
~Mechanism of Action:
~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.
~Physiological Effect:
~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
11088011|NCT04160052|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax orally PO QD on days 1-7 or 1-14 and azacitidine SC or IV over 15 minutes on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
11088012|NCT04160039|Experimental|Cycle Ergometry + Standard PT/OT|
11088013|NCT04160039|No Intervention|Standard PT/OT alone|
11088014|NCT04160026|Active Comparator|IPTp-SP|Arm 1. Standard single-day stat course of quality-assured SP (Fansidar ®) of 3 tablets (500 mg of sulphadoxine and 25 mg of pyrimethamine). SP given monthly
11088015|NCT04160026|Experimental|IPTp-DP|Arm 2. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy). DP given monthly
11088016|NCT04160026|Experimental|IPTp-DP+AZ|Arm 3. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy) plus AZ (Throza®, Universal Corporation Ltd), 2 tablets (500mg) daily for 2 days. DP given monthly. AZ given once (first ANC visit only).
11088017|NCT04160013|Experimental|Discipline education|Education about discipline using the Play Nicely program (www.playnicely.org).
11088018|NCT04160013|Placebo Comparator|Cavity prevention|Education about cavity prevention using a 2 page handout.
11088049|NCT04159818|Experimental|Control group|no induction treatment, nivolumab 240 mg flat-dose, every 2 weeks
11150092|NCT03726853|Experimental|CKD-497 200mg|CKD-497 200mg
11088019|NCT04160000|Active Comparator|Catheter Ablation|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They randomly assigned to catheter ablation as one arm. They will undergo a catheter ablation procedure within 14 days of randomization. This procedure will include isolation of all four pulmonary veins in the antrum using catheter delivered radiofrequency current, cryothermal or laser ablation energy with standard FDA approved ablation catheter systems used in atrial fibrillation ablation. Patients will be monitored for a minimum period of 12 months after the catheter ablation intervention.
11088020|NCT04160000|Active Comparator|Antiarrhythmic drug therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They randomly assigned to antiarrhythmic drug therapy for Rate or Rhythm control as one arm. They will undergo drug dose titration within 14 days of randomization. This procedure will include isolation of all four pulmonary veins in the antrum using catheter delivered radiofrequency current, cryoballoon or laser balloon ablation with standard FDA approved ablation catheter systems used in atrial fibrillation ablation. Patients will be monitored for a minimum period of 12 months after the catheter ablation intervention.
11088021|NCT04159987|Experimental|Spinal muscular atrophy patient|
11088022|NCT04159974|Experimental|Durvalumab|Treatment arm A will receive durvalumab IV in a dosage of 1500mg every four weeks for 12 months as mono therapy.
11088023|NCT04159974|Experimental|Durvalumab + Tremelimumab|Treatment arm B receives durvalumab in a dosage of 1500mg every 4 weeks (-3/+7 days) for 12 months post-surgery. In addition these patients receive tremelimumab IV in a fixed dose of 75mg for the first four months on day 1; 29; 57; 85 (-3/+7).
11088024|NCT04159961|Experimental|GroupA|Inject the Drug into submental fat and abdominal fat via subcutaneous
11088025|NCT04159961|Experimental|GroupB|Inject the Drug into submental fat and abdominal fat via subcutaneous
11088026|NCT04159961|Experimental|GroupC|Inject the Drug into submental fat and abdominal fat via subcutaneous
11088027|NCT04159948|Placebo Comparator|Water|Patients will be allowed to drink water up to 2 hours before their caesarean section.
11088028|NCT04159948|Active Comparator|Carbohydrate drink|Patients will be allowed to drink a designated carbohydrate drink up to 2 hours before their caesarean section.
11088029|NCT04159948|Active Comparator|Apple juice|Patients will be allowed to drink apple juice up to 2 hours before their caesarean section.
11088030|NCT04159935|Experimental|iLux® treatment|The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
11088031|NCT04159935|Experimental|Delayed iLux® treatment|Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.
11088032|NCT04159922||Type 2 diabetic patients with foot wounds|
11088033|NCT04159909|Experimental|VNS transcutaneous stimulation|"5 minutes of stimulation (VNS) twice a day for 4 days. Patients will receive transcutaneous stimulation (30 Hz, 300 msec.) on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days. Due to the theoretical risk that right vagus nerve stimulation could affect the heart, and to ensure consistency of the intervention, all subjects randomized to receive transcutaneous vagus nerve stimulation will receive stimulation of the auricular branch of the left vagus nerve. The subject will be blinded to their treatment arm.
~The device to be used will include a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide stimulation to the auricular branch of the afferent vagus nerve."
11088034|NCT04159909|Sham Comparator|Sham stimulation|"5 minutes of sham stimulation (no electrical stimulation) twice a day for 4 days Patients will receive sham stimulation on the auricular branch of the vagus nerve 5 minutes twice a day for 4 days.
~The subject will be blinded to their treatment arm. The specific target at the ear will be the auricular branch of the vagus nerve, which innervates the skin of a specific ear area termed Cymba Concha. Electrodes will be placed on this area to provide sham stimulation (no electrical current) to the auricular branch of the afferent vagus nerve."
11088035|NCT04159896|Experimental|Treatment (ESK981, nivolumab)|Patients receive ESK981 PO QD for 5 consecutive days per week, followed by a 2-day break. Patients also receive nivolumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11088036|NCT04159883|Experimental|app|For the App group, we installed the app from the store in their smart phone or tablets, made their account using the same email they use in their smart phone store. the participant was informed if they cannot follow the animated image in the app, they can re-launch the program and start to follow.
11088037|NCT04159883|Active Comparator|paper|For the paper group, the participants were provided with a hard copy of the exercise program; we gave one paper of all nine exercises.
11088038|NCT04159870|Experimental|Intervention Group|Rifaximin 1200 mg/day in 3 doses
11088039|NCT04159870|Active Comparator|Control Group|Norfloxacin 400 mg/day in one dose
11088040|NCT04159857|Active Comparator|One-hand|During LTCS, the fetal head traditionally is delivered by one-hand manual extraction (a surgeon inserts one hand into the uterus via the hysterotomy and lifts the fetal head out of maternal pelvis, subsequently significant abdominal pressure is required to squeeze the fetal head out of hysterotomy) along with application of significant abdominal/fundal pressure.
11088041|NCT04159857|Experimental|Two-hand|An innovative approach to manual head extraction, with surgeon's both hands formed as a pair of forceps, has been used by the PI of this study for years during the LTCS for head extraction in the difficult situations described above without complication, often time it was used after one hand approach failed to deliver the infant, vacuum/forceps and abdominal pressure usually was not needed in these cases.
11088042|NCT04159844|Active Comparator|Short stretch bandage|Application with 50% overlap in combinaison with wading
11088043|NCT04159844|Active Comparator|Multi componant bandage|Application with 50% overlap
11088044|NCT04159844|Active Comparator|Short stretch bandage bis|Application with 50% overlap in combinaison with wading
11088045|NCT04159831|Experimental|400,000 U LTI-01|400,000 U LTI-01 qd x 3 days administered intrapleurally
11088046|NCT04159831|Experimental|800,000 U LTI-01|800,000 U LTI-01 qd x 3 days administered intrapleurally
11088047|NCT04159831|Experimental|1,200,000 U LTI-01|1,200,000 U LTI-01 qd x 3 days administered intrapleurally
11088050|NCT04159818|Experimental|Cisplatin induction|Cisplatin 40mg/m2, weekly for two weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
11088051|NCT04159818|Experimental|Low dose doxorubicin induction|Low dose doxorubicin 15mg flat dose, weekly for 8 weeks, after 2 weeks followed by nivolumab 240 mg flat-dose, every 2 weeks
11088052|NCT04159805|Experimental|TAK-079 Dose 1|TAK-079 dose 1 injection, subcutaneously, once weekly for 8 weeks.
11088053|NCT04159805|Experimental|TAK-079 Dose 2|TAK-079 dose 2 injection, subcutaneously, once weekly for 8 weeks.
11088054|NCT04159805|Placebo Comparator|TAK-079 Placebo-matching|TAK-079 placebo-matching injection, subcutaneously, once weekly for 8 weeks.
11088055|NCT04159792||stroke|Those with standard treatment as usual.
11088056|NCT04159779||Venetoclax Participants|Participants for whom the treating physician has decided to treat with venetoclax before enrollment in this study.
11088057|NCT04159766|Active Comparator|NLY01 (2.5 mg)|
11088058|NCT04159766|Active Comparator|NLY01 (5.0 mg)|
11088059|NCT04159766|Active Comparator|NLY01 (10 mg)|
11088060|NCT04159766|Placebo Comparator|Placebo|
11088061|NCT04159753|Other|Spinal Cord Stimulator|Burst neurostimulation
11088062|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
11088063|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
11088064|NCT04159727|Experimental|IBD or PD patients|20 patients suffering from IBD 10 patients suffering from PD
11088065|NCT04159727|Active Comparator|Asymptomatic subjects|30 asymptomatic subjects matched to patients on age, sexe and BMI
11088066|NCT04159714|Experimental|Bandage Contact Lens (BCL) group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have a bandage contact lens soaked in antibiotic solution placed in the affected eye
11088067|NCT04159714|No Intervention|Usual Care Group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have usual care provided in the Emergency Department
11088068|NCT04159701|Experimental|LY3454738|LY3454738 administered intravenously (IV).
11088069|NCT04159701|Placebo Comparator|Placebo|Placebo administered IV.
11088070|NCT04159688|Experimental|Alcohol Challenge|Alcohol Challenge, I.V. infusion, 60 mg/dL in 6% saline (v/v), Given once
11088071|NCT04159675||control patients|Patients with idiopathic craniosynostosis
11088072|NCT04159675||HR patients|Patients with craniosynostosis due to HR
11088073|NCT04159662|Experimental|Cognitive Intervention|
11088074|NCT04159662|Active Comparator|Active Control Intervention|
11088075|NCT04159649|Experimental|letrozole, gonadotropins and fixed GnRH antagonist|letrozole (2.5 mg) will be given from the second day of the cycle and for 5 days, gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF (interventional group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
11088076|NCT04159649|Active Comparator|gonadotropins and fixed GnRH antagonist (control group).|gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF(control group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
11088077|NCT04159636|No Intervention|Fasting group|Participants will be remained fasted until surgery
11088078|NCT04159636|Experimental|Carbohydrate group|Participants will be allowed to drink carbohydrate beverage before 2 hours of surgery
11088079|NCT04159623|Experimental|Belk Device|With Belk Device
11088080|NCT04159623|Other|Standard Rehabilitative treatment|With the standard rehabilitative treatment
11088081|NCT04159610|Experimental|WO 3970|Formulation containing WO 3970 for topical application
11088082|NCT04159610|Active Comparator|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
11088083|NCT04159584|Experimental|Enrolled Subject|All subjects will undergo the medical music intervention.
11088084|NCT04159571|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
11088085|NCT04159571|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
11088086|NCT04159571|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
11088087|NCT04159571|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
11088088|NCT04159558|Experimental|experimental hypertension|The subjects with Hypertension will be trained in the use of the personalized help tool and will use it during a period of 3 months.
11088089|NCT04159558|Experimental|experimental diabetes|The subjects with Diabetes will be trained in the use of the personalized help tool and will use it during a period of 3 months.
11088090|NCT04159558|Experimental|experimental heart failure|The subjects with Heart failure will be trained in the use of the personalized help tool and will use it during a period of 3 months.
11088091|NCT04159558|Experimental|experimental copd|The subjects with COPD will be trained in the use of the personalized help tool and will use it during a period of 3 months.
11088319|NCT04157933|Placebo Comparator|A-0p|Part A, placebo comparator in all 3 arms, placebo dose (009-A0)
11088092|NCT04159558|Experimental|experimental asthma|The subjects with Asthma will be trained in the use of the personalized help tool and will use it during a period of 3 months.
11088093|NCT04159558|Experimental|experimental obesity|The subjects with Obesity will be trained in the use of the personalized help tool and will use it during a period of 3 months.
11088094|NCT04159545||Participants treated with DAAs|"Participants identified through the standard pathway of care as receiving Direct-Acting Antiviral (DAA) drugs to treat chronic hepatitis C with a history of problematic substance use.
~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.
~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
11088095|NCT04159545||Control Group|"Participants identified through the standard pathway of care as having HCV positive antibodies who spontaneously clear the infection.
~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.
~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
11088096|NCT04159532|Experimental|Monoglyceride (MAG)|Group A will receive the omega-3 fatty acids in monoglyceride formulation (MAG). Subjects will receive 1.5g per day of MAG-EPA/MAG-DHA in a proportion of 460:200 for 12 consecutive weeks.
11088097|NCT04159532|Active Comparator|Triglyceride (TG)|Group B will receive the omega-3 fatty acids in triglyceride formulation (TG). Subjects will receive 1.5g per day of TG-EPA/TG-DHA in a proportion of 460:200 for 12 consecutive weeks.
11088098|NCT04159532|Active Comparator|Ethyl Ester(EE)|Group C will receive the omega-3 fatty acids in Ethyl ester formulation (EE). Subjects will receive 1.5g per day of EE-EPA/EE-DHA in a proportion of 460:200 for 12 consecutive weeks.
11088099|NCT04159519|Experimental|Treatment reduction arm|All participants will receive Fasenra® 30 mg Q8W + SMART or Symbicort® reliever only (starting with medium-dose Symbicort® 200/6 μg ×2 inhalations BID maintenance + Symbicort® 200/6 μg reliever PRN; tapering to Symbicort® 200/6 μg reliever only, as per tapering scheme and depending on degree of asthma control). The reduction period in this arm will last 32 weeks.
11088100|NCT04159519|Experimental|Reference arm|All participants will receive Fasenra® 30 mg Q8W + high-dose Symbicort® maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm will continue on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment for 32 weeks.
11088101|NCT04159506|Experimental|The Equus Effect (TEE)|TEE is a 4-session intervention. Each session is 4 hours and includes: 1) mindfulness-based activities; 2) didactics about emotion regulation and interpersonal skills; and 3) experiential learning activities with horses that provide opportunities to practice emotion regulation and interpersonal skills. At the end of each session, Veterans debrief about what they learned and identify how they might apply this knowledge to manage their mental health concerns and function better socially.
11088102|NCT04159506|Active Comparator|Attention Control (AC)|AC will exclude equine-related activities or discussions but maintain mindfulness-based activities, emotion regulation and interpersonal skills didactics, and experiential learning activities with between-session application. Instead of experiential equine activities, AC will rely on team-building activities, which aim to enhance social relations by involving participants in collaborative tasks and providing opportunities for emotion regulation and interpersonal skills practice.
11088103|NCT04159493|Placebo Comparator|Placebo|"Subjects will be randomized to placebo.
~Placebo, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
11088104|NCT04159493|Active Comparator|Ovestin|"Subjects will be randomized or assigned to varying doses of Ovestin (500, 50, 25, 12.5, 10, 5, 2.5, 0.5, 0.25 mcg) as determined by the dose de-escalation constraints specified in the protocol.
~Active, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
11088105|NCT04159480|Experimental|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
11088106|NCT04159480|Active Comparator|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
11088107|NCT04159467|Active Comparator|Group 1- diet therapy (control)|Control group undergoing a low calorie diet will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and after 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
11088108|NCT04159467|Experimental|Grupo 2 - low calorie diet + PFMT (experimental)|"Experimental group will receive supervised pelvic floor muscle training additionally to a low calorie diet. Women will be instructed to perform daily pelvic floor muscle training at home. 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The 4 sets will be performed in 2 different positions (sitting and standing). Twice a month (once every 15 days), they will receive a supervised session using the same protocol described above except for the position that will be only sitting and standing. In addition, they will be instructed to perform the the knack maneuver."
11088109|NCT04159454|Experimental|PITA Participants|"All patients in the study are part of the PITA arm, where PITA will be on for Weeks 0-8, and off from Weeks 8-12."
11088110|NCT04159415|Experimental|Treatment A|
11088111|NCT04159415|Experimental|Treatment B|
11088112|NCT04159389|No Intervention|traditional teaching|theoretical courses and procedural simulation on airway management during rapid sequence induction
11088113|NCT04159389|Experimental|Mental visualization|traditional teaching completed by mental visualization : theoretical courses and procedural simulation on airway management during rapid sequence induction + mental visualization (theoretical courses, audioguide for individual practice and experience sharing session)
11088114|NCT04159376|Experimental|Bone Metastases Patients|
11088115|NCT04159363|Experimental|Intervention group|Participants in the intervention group will receive an interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage) in addition to routine care provided by the respective hospitals.
11088116|NCT04159363|No Intervention|Control group|Participants in the control group will receive routine care provided by the respective hospitals . The routine care includes normal consultation with their attending physician, information concerning treatment plans, such as surgical procedures and its associated risks, preoperative preparations and postoperative care, treatment after discharge and/or subsequent adjunct therapy if required.
11088117|NCT04159350|Experimental|Rectal Expulsion Device (RED)|
11088118|NCT04159324|Experimental|StroCare treatment group|Optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
11088119|NCT04159324|No Intervention|control group|routine aftercare stroke treatment
11088120|NCT04159311|Active Comparator|Treated group|"The treated group will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3."
11088121|NCT04159311|Sham Comparator|Untreated group|"The untreated group will have 4 sessions of only testing osteopathy (M0, M1, M2, M3)."
11088122|NCT04159298|Experimental|Intervention|Intervention group who will undergo the Top Spin 360 study protocol.
11088123|NCT04159298|No Intervention|Traditional|Control group who undergo traditional usual clinical care comprised of bi-weekly physiotherapy sessions and home-based exercise programs.
11088124|NCT04159285|Experimental|Group CBT|15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
11088125|NCT04159285|Experimental|Treatment as Usual|Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
11088126|NCT04159272|Experimental|Mindfulness Training|The MT programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on our ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
11088127|NCT04159272|No Intervention|Control|Participants follow their regular course curriculum.
11088128|NCT04159259|Experimental|Diet intervention|All participants will stay weight stable while undergoing 3 phases of a dietary intervention
11088129|NCT04159246||Sovaldi group|patients with a documented diagnosis of chronic hepatitis C , normal renal functions And Rheumatoid factor tests (to exclude Purtscher like retinopathy as a rare presentation of cryoglobuinemia which considered one of extra hepatic manifestations of HCV)
11088130|NCT04159233|Other|Adapted 'Brief Behavioral Therapy for Insomnia' (BBTI)|All participants will receive the same intervention in this pilot study.
11088131|NCT04159220|No Intervention|Control group|The transport will be released without a clamping of endotracheal tube before each disconnection from ventilator.
11088132|NCT04159220|Experimental|Clamping group|The transport will be released with a clamping of endotracheal tube before each disconnection from ventilator.
11088133|NCT04159207||A Longitudinal Study of Inflammatory Pathways in Depression|We target to recruit 80 patients with Major Depression Disorder diagnosis and 80 patients with Major Depression Disorder with suicidal behavior.
11088134|NCT04159194|Active Comparator|Normal CHO|
11088135|NCT04159194|Experimental|High CHO|
11088136|NCT04159181|Experimental|Day A|After an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).
11088137|NCT04159181|Experimental|Day B|After an overnight fast participants will drink 200mL of water
11088138|NCT04159181|Experimental|Day C|After an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
11088139|NCT04159168|Experimental|Arm 1: R61 FAST|Individuals in this Arm will receive the FAST intervention, as described in the Intervention section of the Clinical Trials form below, with a focus on demonstrating target (facial affect sensitivity) engagement.
11088140|NCT04159168|No Intervention|Arm 2: R61 No-Treatment Control|Individuals in this Arm will not receive any intervention.
11088141|NCT04159168|Experimental|Arm 3: R33 FAST|Individuals randomized this Arm of the R33 phase will receive the FAST intervention, with the aim of replicating FAST target engagement (as demonstrated in the R61 phase) with a new high-CU sample, and to evaluate the FAST intervention in comparison to an active control condition (Arm 4, implicit eye gaze training).
11088142|NCT04159168|Active Comparator|Arm 4: R33 Active Control|Individuals in this Arm will receive the active control component, which is an implicit gaze training intervention.
11088143|NCT04159155|Experimental|Early Stage Cohort - Arm A|Carboplatin, intravenously, once every 3 weeks for 6 cycles Paclitaxel, intravenously, once every 3 weeks for 6 cycles
11088144|NCT04159155|Experimental|Early Stage Cohort - Arm B1|"External beam radiotherapy, 5 days per week, for 4-5 weeks
~Cisplatin intravenously, on the first and fourth week of radiotherapy.
~Brachytherapy will be given if needed Then
~Carboplatin, intravenously, once every 3 weeks for 4 cycles
~Paclitaxel, intravenously, once every 3 weeks for 4 cycles"
11088145|NCT04159142|Experimental|Nab-paclitaxel + Carboplatin|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
11088146|NCT04159142|Experimental|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
11088147|NCT04159116|Experimental|Suctioned Prior to Endoscope|This group will be suctioned prophylactically after sedation but prior to introduction of endoscope.
11088148|NCT04159116|Other|Standard of Care|This group will be suctioned by anesthesia providers when clinically indicated by copious secretions, coughing, choking or desaturation.
11088149|NCT04159103|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3927
11088150|NCT04159103|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3927
11088151|NCT04159103|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3927
11088152|NCT04159103|Experimental|Experimental: Dose Expansion Phase|mRNA-3927
11088153|NCT04159090|Experimental|Prostate cancer patients|
11088154|NCT04159077|Experimental|Tamsulosin Hydrochloride (HCL)|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of tamsulosin HCL to be started 3 days prior to their date of surgery.
11088155|NCT04159077|Placebo Comparator|Placebo|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of placebo to be started 3 days prior to their date of surgery.
11088156|NCT04159064||Minimal Invasive Extracorporeal Circulation(MIECC)|"Monitoring coagulation using thromboelastometry and platelet function using impedance aggregometry. Samples at the following phases:
~Time 0: Baseline, upon arrival at the operation room (samples for thromboelastometry and impedance aggregometry), Time 2: after aortic cross clamp off (only sample for thromboelastometry), Time 2': 20 minutes post protamine administration (only sample for impedance aggregometry )."
11088157|NCT04159051|Experimental|Combined regional hyperthermia and salvage radiotherapy|
11088158|NCT04159038|Experimental|Immediate Intervention Group|Parents in the immediate intervention arm sign a study consent that is integrated into the WIC Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by EI/ECSE. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.
11088159|NCT04159038|Other|Delayed Intervention Group|6 months after the immediate intervention group receives their training, the delayed intervention group will receive the training. Prior to implementation of the training in the delayed intervention group, the study team will meet with the Stakeholder Advisory Board. It will review interim results and consider the efficacy of the intervention as a whole. Based on actual use patterns and stakeholder feedback, the investigators will make improvements to the intervention prior to implementing it in the delayed intervention group.
11088160|NCT04159025|Experimental|Endobronchial ultrasound guided miniforceps biopsy|"Standard of care convex-probe endobronchial ultrasound and transbronchial needle aspiration followed by rapid on-site evaluation. If evaluation yields a diagnosis of nonsmall cell lung cancer then EBUS-MFB will be performed.
~With the EBUS bronchoscope, 6 needle punctures will be made into the targeted lymph node with the 22 gauge aspiration needle. The needle will be removed and the 1mm miniforceps will be passed through the working channel of the EBUS-bronchoscope into the targeted lymph node through the puncture site made using the 22 gauge needle using continuous endobronchial ultrasound guidance. The miniforceps will be used to obtain a core biopsy of the targeted lymph node - 8 core biopsies will be obtained from each targeted lymph node using this technique"
11088161|NCT04159012|Experimental|Active transcranial direct current stimulation|Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
11088162|NCT04159012|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
11088163|NCT04158999||Mother milk|Step 1: Mothers who meet the sample selection criteria will be informed about the scope of the study and their written and verbal consent will be obtained. Data collection form will be applied to mothers who accept to participate in the study by using face to face interview technique. Mothers and newborns will be weighed and 4 ml breast milk sample will be taken from the mother for manual milking.
11088164|NCT04158986|No Intervention|Standard treatment|Receives standard post-discharge care with planned follow-up in the clinic for liver failure or ambulatory.
11088165|NCT04158986|Experimental|Nurse-driven post-discharge intervention|Participates in a nurse-driven post-discharge intervention program.
11088166|NCT04158973|Experimental|VTE prophylaxis based on bleeding risk assessment|Patients will undergo a bleeding risk assessment to determine their entering VTE prophylaxis. Low bleeding risk patients will have once daily sc LMWH prophylaxis. Intermediate bleeding risk patients will have q 12 h sc low dose unfractionated heparin prophylaxis. High bleeding risk patients will have mechanical prophylaxis. Assigned prophylaxis can be interrupted as clinical judgement requires, e.g., for peri-procedural reasons. When patients are discharged, if they have low risk of bleeding at the time of discharge, whatever their bleeding risk assessment at the time of randomization, will begin 5 mg rivaroxaban prophylaxis (two 2.5 mg tablets) once daily with food, starting on the day of discharge, for 15 days.
11088167|NCT04158973|Active Comparator|Routine VTE prophylaxis in local clinical practice|VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge.
11088168|NCT04158960|No Intervention|Control|Control period; no equine-assisted activities or brain-building activities occurred
11088169|NCT04158960|Active Comparator|Equine-assisted activities period|Period in which only equine-assisted activities were performed
11088320|NCT04157933|Experimental|B-1 (009-B3 -> 009-B0)|Crossover (active to placebo)
11088170|NCT04158960|No Intervention|Washout|Washout period; no equine-assisted activities or brain-building activities occurred
11088171|NCT04158960|Experimental|GaitWay period|Period in which both equine-assisted activities and brain-building activities were performed
11088172|NCT04158947|Experimental|T-DM1 + Afatinib|"Trastuzumab emtansine (T-DM1) : 3.6 mg/kg IV Day 1 every 21 days.
~Afatinib: the highest dose of Afatinib with T-DM1 found in Phase I, po every day"
11088173|NCT04158947|Active Comparator|T-DM1|Trastuzumab emtansine (T-DM1) :3.6 mg/kg IV Day 1 every 21 days.
11088174|NCT04158934||Haemophilia A Group|Participants with haemophilia A in the study will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national summary of product characteristics (SmPC).
11088175|NCT04158921|Other|The Control:Diabetes mobile app for Diabetes self-management.|This is a single arm open label pilot clinical trial that will assess patient-reported blood glucose levels before and after using the Control:Diabetes mobile app.
11088176|NCT04158908|Experimental|Oncolo_GIST Arm|Patients in this arm will receive care from a clinician that received the Oncolo-GIST Version 1.0 intervention training.
11088177|NCT04158895||Patients enrolled in differentiated service delivery models|
11088178|NCT04158895||Patients not enrolled in DSD models|
11088179|NCT04158882||Patients enrolled in differentiated service delivery models|
11088180|NCT04158882||Patients not enrolled in DSD models|
11088181|NCT04158869||Cases|Patients with pMDD, enrolled in the Investigator-initiated clinical trial IICT (ClinicalTrials.gov Identifier: NCT03167307)
11088182|NCT04158869||Controls|Controls matched to cases according to age, sex and school education
11088183|NCT04158856|Experimental|Experimental Arm|adjuvant Pyrotinib plus Trastuzumab
11088184|NCT04158843|Experimental|Radical local treatment|Radical resection is performed, and the cutting edge is negative, or radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy). Systemic endocrine therapy and targeted therapy are allowed after radical local therapy. However, whether systemic chemotherapy should be used is determined by clinicians according to clinical experience or guidelines.
11088185|NCT04158843|Active Comparator|Palliative treatment|No radical surgical resection or radical surgical resection or radiotherapy is performed in this group. But palliative internal fixation or radiotherapy for pain relief is permitted. Moreover, systemic chemotherapy, endocrine therapy and targeted therapy are allowed.
11088186|NCT04158830|Other|Group 1 - ACOG recommended dose|oral dose: 81 mg aspirin daily; designated by odd number assignment [1-001, 1-003, 1-005, etc. to 899]
11088187|NCT04158830|Active Comparator|Group 2 - Comparison Dose|oral dose: 162 mg aspirin daily; designated by even number assignment [2-002, 2-004, 2-006, etc. to 900]
11088188|NCT04158817|Experimental|Experimental Arm|All Prostate cancer patients recruited to the study will be administered 2.11 MBq/kg of 68Ga-THP-PSMA in a single dose injection.
11088189|NCT04158804|Experimental|Procalcitonin algorithm+stewardship team|antibiotic prescription guided by PCT values
11088190|NCT04158804|No Intervention|standard group|standard of care guided by current guidelines
11088191|NCT04158791||EMM-I|Group with an intact IS/OS junction
11088192|NCT04158791||EMM-D|Group with a disrupted IS/OS junction
11088193|NCT04158778|Experimental|MDMA assisted Psychotherapy|All participants receive 2 sessions of MDMA-assisted psychotherapy
11088194|NCT04158765||Infertile men|Men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
11088195|NCT04158752|Experimental|Open Label Galcanezumab|Participants will receive their 1st injectable dose during the Day 30 visit. Participants will then inject themselves at home on Day 60 and again on Day 90.
11088196|NCT04158739|Experimental|Treatment (cytarabine, flotetuzumab)|Patients receive cytarabine IT on days -6 to 0 prior to cycle 1. Patients may receive additional doses of cytarabine on day 1 of subsequent cycles per physician discretion. Patients also receive flotetuzumab IV continuously for 28 days. Treatment repeats every 29 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11088197|NCT04158713|Placebo Comparator|CTX-alone|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
11088198|NCT04158713|Experimental|CTX-DP|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.
11088199|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 1)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).
11088200|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 2)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.
11088201|NCT04158700|Experimental|LY3200882 and Pembrolizumab Expansion|Participants with urothelial carcinoma, non-small cell lung cancer, or hepatocellular carcinoma: LY3200882 administered orally twice in combination with pembrolizumab administered IV.
11088202|NCT04158687|Experimental|1 g CTP-692|Powder for oral solution, taken once daily
11088203|NCT04158687|Experimental|2 g CTP-692|Powder for oral solution, taken once daily
11088204|NCT04158687|Experimental|4 g CTP-692|Powder for oral solution, taken once daily
11088205|NCT04158687|Placebo Comparator|Placebo|Powder for oral solution, taken once daily
11088206|NCT04158674|Experimental|Levosimendan|
11088207|NCT04158674|Sham Comparator|Placebo|
11088208|NCT04158661||Tmin-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG
~age ≥ 18 years
~thymectomy ≥ three years"
11088209|NCT04158661||T0-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG
~a very long disease history OR
~age ≥ 18 years
~rejecting a thymectomy or have contraindications for thymectomy"
11088210|NCT04158661||"MGTX-group (historical control group)"|"from MGTX-trial (Randomized Trial of Thymectomy in Myasthenia Gravis)"
11088281|NCT04158193|Experimental|Sham acupuncture control group|Subjects in the sham acupuncture control group are given non-acupoint shallow acupuncture.
11088211|NCT04158648|Experimental|Emicizumab|Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
11088212|NCT04158635|Experimental|Treatment (bosentan, nab-paclitaxel, gemcitabine)|Patients receive bosentan PO BID on days -7 to 21 or 8-21 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11088213|NCT04158622|Experimental|Pneumatic Retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy + laser/cryotherapy
11088214|NCT04158622|Experimental|Pars Plana Vitrectomy|Patients with retinal detachment allocated to pars plana vitrectomy + laser/cryotherapy
11088215|NCT04158609||Group 1|Pregnant women with CPR value below 1, based on Doppler indices assessment
11088216|NCT04158609||Group 2|Pregnant women with CPR value equal to or above 1, based on Doppler indices assessment
11088217|NCT04158596|Experimental|Treatment|The applied therapeutic vibrations generated by an acoustic coil have a defined sweeping frequency range.
11088218|NCT04158596|Active Comparator|Control|A control device with a different vibration pattern will be used as comparator intervention
11088219|NCT04158583|Experimental|Part A|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682. RO7296682 will be administered by intravenous (IV) infusion in a three-weekly schedule (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
11088220|NCT04158583|Experimental|Part B|Dose-Expansion: Will start once MTD/RP2D dose is defined in Part A. Participants will receive a fixed dose of RO7296682 at the dosing regimen established in part A (Q3W schedule).
11088221|NCT04158544||Checkpoint Inhibitors|Patients with metastatic melanoma receiving systemic therapy with checkpoint inhibitors
11088222|NCT04158544||Kinase Inhibitors|Patients with metastatic melanoma receiving systemic therapy with kinase inhibitors
11088223|NCT04158531|Experimental|REC2Stim|Use electrocorticography (ECoG)-based seizure detection and cortical network stimulation upon seizure onset detection.
11088224|NCT04158518|Experimental|Toxicities reduced treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).
11088225|NCT04158518|Active Comparator|Conventional treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by concurrent cisplatin chemotherapy with standard radiation dose when responses to induction chemotherapy are less than 50% Partial Response(PR).
11088226|NCT04158505||non-interventional study|
11088227|NCT04158492|Active Comparator|Standard diagnostic tests|Patients who will undergo only the standard diagnostic procedures
11088228|NCT04158492|Experimental|Experimental + standard diagnostic tests|Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).
11088229|NCT04158479||Pulmonary Support|ECMO support for acute respiratory failure, ARDS
11088230|NCT04158479||Cardiac Support|ECMO support for heart failure, cardiogenic shock
11088231|NCT04158479||Extracorporeal Cardiopulmonary Resuscitation|ECMO support for cardia arrest
11088232|NCT04158466|Experimental|Kalifilcon A Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
11088233|NCT04158466|Active Comparator|Biotrue ONEday Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
11088234|NCT04158453|Active Comparator|AUT00201|
11088235|NCT04158453|Placebo Comparator|Placebo|
11088236|NCT04158440|Active Comparator|Toripalimab + platinum-based doublet chemotherapy|Participants receive totally 4 cycles of Toripalimab combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of Toripalimab
11088237|NCT04158440|Placebo Comparator|Placebo + platinum-based doublet chemotherapy|Participants receive totally 4 cycles of placebo combined with platinum doublet chemotherapy during perioperative period ;After surgery, participants receive consolidation therapy of placebo
11088238|NCT04158427|Experimental|Fecal transplant|A single dose fecal transplant is given (via colonoscopy) from a healthy donor
11088239|NCT04158427|Placebo Comparator|Placebo|A single dose patient's own feces is given (via colonoscopy)
11088240|NCT04158414|Experimental|Different types of cancer Patients|Lymphoma,Nasopharyngeal Cancer; Esophageal Cancer, Cervical cancer; Hepatobiliary and pancreatic cancer; Sarcoma; Prostate Cancer
11088241|NCT04158401||Control group|Pregnant patients between 12w0d and 22w0d who present for prenatal care.
11088242|NCT04158401||Cerclage group A|Patients who present for a history-indicated cerclage placement.
11088243|NCT04158401||Cerclage group B|Patients who present for an ultrasound-indicated cerclage placement.
11088244|NCT04158401||Cerclage group C|Patients who present for an exam-indicated cerclage placement.
11088245|NCT04158388|Experimental|EXPERIMENTAL DIET GROUP|
11088246|NCT04158388|Other|CONTROL GROUP|
11088247|NCT04158388|Experimental|EXPERIMENTAL MASSAGE GROUP|That group received moderate pressure digital manual therapy.
11088248|NCT04158388|Experimental|EXPERIMENTAL PLACEBO GROUP|That group was treated with a US (in off mode) without conductive gel. Placebo group.
11088282|NCT04158167|Other|oxytocin|All subjects will receive both oxytocin and placebo in a counterbalanced design
11088283|NCT04158154|Experimental|Primary Health Care Centers|Selected primary health care centers in Abuja will implement a culturally- and contextually-adapted intervention package based on the Kaiser Permanente Northern California and World Health Organization HEARTS programs for hypertension diagnosis and treatment.
11088249|NCT04158375|Experimental|Insulin Resistant Exercise Group|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Resistance training will be performed using a combination of upper and lower body exercises using machine and free weights. Upper body exercises are chest press, incline press, seated row, lat pull down, triceps extension, biceps curl and lateral raises. Major muscle groups for upper body exercises will include chest (pectoralis major and minor), arm (biceps and triceps), shoulder (deltoids) and back (latissimus dorsi and rhomboids). Lower body exercises are leg press, lunge (with body weight progressing to dumbbells), seated leg extension, seated leg curl, calf raises and abdominal crunches. Major muscle groups for the lower body exercises will be thighs (quadriceps and hamstrings), calves (gastrocnemius and soleus) and core (rectus abdominus and obliques).
11088250|NCT04158375|No Intervention|Insulin Resistant Control Group|Participants in this group will perform no exercise for the 3 month study period.
11088251|NCT04158375|No Intervention|Insulin Sensitive Lean Group|Participants in this group will have a baseline study for comparison to the insulin resistant groups.
11088252|NCT04158362|Experimental|Standard Chemotherapy regimen|"* Paclitaxel: administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle.
~OR
~* Capecitabine: given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks."
11088253|NCT04158362|Experimental|Standard Endocrine therapy (ET) regimen + Abemaciclib|"* Letrozole: continuous orally administration of 2.5 mg/day (1 tablet/day) OR anastrozole continuous orally administration of 1 mg/day (1 tablet/day) in combination with oral abemaciclib 150 mg (BID: twice a day) continuous for patients NSAI naïve or relapsing >1 year after the end of adjuvant ET.
~OR
~* Fulvestrant: 500 mg intramuscular on D1-D15-D29 (loading dose). Then 500 mg every 28 days (maintenance dose) with oral abemaciclib 150 mg BID continuous for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
~For women with a non-menopausal status at inclusion, a concomitant Luteinizing hormone-releasing hormone (LH-RH) agonist will be administered in combination with ET every 28 days. The LH-RH agonist drug to be used will be left to the investigator's choice.
~Non-menopausal women will be included as soon as the reimbursement of abemaciclib in combination with ET will be approved for this population."
11088254|NCT04158349|Experimental|Dose Level 0|Dose Level 0: 85 mg/m2 Oxaliplatin IP every 2 weeks
11088255|NCT04158349|Experimental|Dose Level 1|Dose Level 1: 95 mg/m2 Oxaliplatin IP every 2 weeks
11088256|NCT04158349|Experimental|Dose Level 2|Dose Level 2: 105 mg/m2 Oxaliplation IP every 2 weeks
11088257|NCT04158336|Experimental|Single Agent Dose Escalation|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
11088258|NCT04158336|Experimental|Single Agent Phase 2|Participants with specific types of solid tumors.
11088259|NCT04158336|Experimental|Combination with Talazoparib Phase 2|Participants with a specific type of locally advanced or metastatic breast cancer.
11088260|NCT04158336|Experimental|Combination with Pembrolizumab Phase 2|Participants with specific types of solid tumors.
11088261|NCT04158310||Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
11088262|NCT04158310||Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD.
11088263|NCT04158297|Active Comparator|ESWL|Extracorporeal shock wave lithotripsy for the treatment of pancreatic duct stones
11088264|NCT04158297|Active Comparator|SOPIL|Single Operator Pancreatoscopy and intraductal lithotripsy for the treatment of pancreatic duct stones
11088265|NCT04158271|Experimental|Prone Position|Evaluation of Techniques for tracheal tube Exchange in prone position
11088266|NCT04158271|Experimental|Laryngeal tube|Evaluation of Techniques for tracheal tube Exchange in patients with laryngeal tube (LT)
11088267|NCT04158271|Experimental|Endotracheal tube Leackage|Evaluation of Techniques for tracheal tube Exchange in critical care patients with a endotracheal tube and a high leackage
11088268|NCT04158258||Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
11088269|NCT04158258||Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
11088270|NCT04158258||Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
11088271|NCT04158258||Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
11088272|NCT04158258||Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
11088273|NCT04158258||Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
11088274|NCT04158245|Experimental|18F-fluciclovine PET Scan|Single intravenous administration of 18F-fluciclovine for PET Scan.
11088275|NCT04158232|Active Comparator|Blood clotting protocol for pulp regeneration|pulp regeneration for mature teeth using blood clotting protocol
11088276|NCT04158232|Experimental|platelet rich fibrin for pulp regeneration|pulp regeneration for mature teeth using platelet rich fibrin (PRF)
11088277|NCT04158219|Experimental|Treatment|Behavioral activation for health and depression (BA-HD)
11088278|NCT04158206|Experimental|Maternal voice|The mother's voice recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group were explored maternal voice, which start from 3 minutes before the procedure, once a day and for three consecutive days.And then recorded the process by the camera, uploaded to YouTube within 24 hours and sent to their mother.
11088279|NCT04158206|No Intervention|control group|When the premature infants undergoing heel lance procedure, the control group were under routine care.And then recorded the process by the camera for three consecutive days, uploaded to YouTube within 24 hours and sent to their mother.
11088280|NCT04158193|Experimental|Acupuncture group|Subjects in the acupuncture group are given acupuncture treatment.
11088284|NCT04158141|Experimental|Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.
~STEP 2: Patients receive no treatment."
11088285|NCT04158141|Experimental|Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.
~STEP 2: Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions IMRT or PBS proton therapy 5 days per week over 6 weeks."
11088286|NCT04158115|Experimental|Entire Spinal Mobilization|Entire Spinal Mobilization( All spinal segment from Co-C1to L5-S1 Moist heat. Soft tissue Mobilization Exercises. (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
11088287|NCT04158115|Active Comparator|Segmental Mobilization|Segmental Mobilization. (All lumbar segment from L1-L2 to L5-S1) Moist heat. Soft tissue Mobilization Exercises (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
11088288|NCT04158102|Experimental|20 mg single dose cohort|Subjects would receive a 20 mg single dose of EXPAREL®
11088289|NCT04158089|No Intervention|No intervention|"Participants in the No intervention group will receive treatment (e.g., prenatal care) as usual."
11088290|NCT04158089|Experimental|Doppler Only|"Participants in the Doppler Only group will be checked out fetal Doppler monitors at their first prenatal visit during the 2nd trimester. They will be trained on how to use the monitors and will be asked to listen to their babies' heartbeats for one minute per day over a 2-week period. They will receive daily reminders via text."
11088291|NCT04158089|Experimental|Attachment Exercises Only|"Participants in the Attachment Exercises Only group will receive daily texts over the 2-week intervention period with activities to do from home that are designed to increase feelings of attachment (e.g., read a children's book aloud; sing a nursery rhyme; picture giving the baby a bath; tell the baby a story; etc.)."
11088292|NCT04158089|Experimental|Doppler and Attachment Exercises|Participants in this group will engage in both the Doppler and Attachment exercises over the 2-week intervention period.
11088293|NCT04158076|Experimental|Co-administered of AD-2071 and AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2073(Telmisartan/Amlodipine) for 8 weeks."
11088294|NCT04158076|Active Comparator|Co-administered of AD-2071 and AD-2072|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2072(Telmisartan) for 8 weeks."
11088295|NCT04158076|Active Comparator|AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2073(Telmisartan/Amlodipine) for 8 weeks."
11088296|NCT04158063|Experimental|Dual Task Training (DTT)|
11088297|NCT04158063|Active Comparator|Single Mobility Training (SMT)|
11088298|NCT04158050||anti-IL5/IL5R-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
11088299|NCT04158050||anti-IgE-therapy group|Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy
11088300|NCT04158037|Experimental|mHealth App|Participants will receive the gambling disorder mHealth app.
11088301|NCT04158037|No Intervention|Wait List Control|Participant will be placed on a wait list for 12 weeks, after which they will be offered the gambling disorder mHealth app.
11088302|NCT04158024|No Intervention|Volatile Anesthetic Control|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.
~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
11088303|NCT04158024|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.
11088304|NCT04158011||CNS ALL at lymphodepletion|Patients with active CNS leukemia at the time of lymphodepletion
11088305|NCT04158011||CNS ALL at inclusion|Patients who were referred to CAR T-cells with CNS disease, which was cleared by the time of lymphodepletion
11088306|NCT04157998|Placebo Comparator|control|patient receive 10 ml normal saline intravenous
11088307|NCT04157998|Active Comparator|metoclopramide group|"patient receive 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.
~intravenous"
11088308|NCT04157985|Active Comparator|Continue Treatment with PD-1/PD-L1 inhibitor|Continued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
11088309|NCT04157985|Experimental|Discontinue Treatment with PD-1/PD-L1-1 inhibitor|Discontinued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
11088310|NCT04157972|Active Comparator|SIMEOX|Participants will have to perform 20 minutes of SIMEOX. Passive exhalation is required using the SIMEOX, starting from tidal volume and going until achieving residual volume.
11088311|NCT04157972|Active Comparator|PEP|Participants will have to perform 20 minutes of PEP. Active exhalation is required using a PEP device, starting from tidal volume and going until achieving residual volume.
11088312|NCT04157959|Experimental|SHR4640|SHR4640 dose1 Oral Tablet Day1~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.
11088313|NCT04157959|Experimental|Febuxostat|Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8~Day14 qd.
11088314|NCT04157946||Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
11088315|NCT04157946||Non-Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
11088316|NCT04157933|Experimental|A-1a|Part A, Arm 1 (active), Dose 1 (009-A1)
11088321|NCT04157933|Experimental|B-1 (009-B0 -> 009-B3)|Crossover (placebo to active)
11088322|NCT04157920|Other|Patients treated with Medtronic Evolut R/Pro|TAVI patients treated with Medtronic Evolut R - Evolut PRO Transcatheter Heart Valves, participated in the DIRECT trial
11088323|NCT04157920|Active Comparator|Patients treated with Acurate NEO/TF|TAVI patients treated with Symetis Acurate NEO/TF Transcatheter Heart Valve recruited prospectively.
11088324|NCT04157907||Patients with borderline personality disorder|Patients with borderline personality disorder included in the MBT program
11088325|NCT04157894||Standard LLIN|This group receives Interceptor ITNs during the mass distribution campaign.
11088326|NCT04157894||Chlorfenapyr ITN|This group receives Interceptor G2 ITNs during the mass distribution campaign.
11088327|NCT04157894||Piperonyl butoxide LLIN|This group receives PBO ITNs during the mass distribution campaign.
11088328|NCT04157881|Other|APO-Dabigatran|Single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
11088329|NCT04157881|Other|APO-Dabigatran and Rabeprazole|4-7 doses of rabeprazole followed by single dose 150mg APO-Dabigatran given with 24 hours of Pharmacokinetic (PK) testing post dose
11088330|NCT04157868|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
11088331|NCT04157868|Placebo Comparator|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
11088332|NCT04157842|Experimental|total hip replacement with subtrochanteral osteotomy|subtrochanteral osteotomy is applied during total hip replacement
11088333|NCT04157842|Sham Comparator|total hip replacement with no osteotomy|no osteotomy is applied during total hip replacement.
11088334|NCT04157829|Experimental|Scintilling lamp- Classic lamp|
11088335|NCT04157829|Experimental|Classic lamp- Scintilling lamp|
11088336|NCT04157816|Experimental|Digital Training (DGT)|Participants allocated to this arm receive a low-intensity digital program accessible by smart phone app for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
11088337|NCT04157816|Experimental|Digital Training with Coaching Support (DGT+)|Participants allocated to this arm receive a high-intensity digital program accessible by smart phone app augmented with weekly telephone coaching support for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
11088338|NCT04157816|Active Comparator|Face-to-Face Training|Participants allocated to this arm receive a traditional classroom-based (face-to-face) program hosted in community settings for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
11088339|NCT04157803|Other|Patient cohort|Patients with polyps> 5mm with suspicion of tubular, tubulovillious or serrated adenomas, found during a videcolonoscopy.
11088340|NCT04157790|No Intervention|Neutral|Suggested to follow European Society of Cardiology guidelines for NSTEMI
11088341|NCT04157790|Active Comparator|CARE score|calculation of the CARE score and prescription for troponins assays or not according to the result (score > 1: troponins assays ; score < 2: no troponins assays)
11088342|NCT04157777|Experimental|massage|Among women who applied to Maternity Hospital 350 pregnant women were assigned to massage group. Participants in massage group filled out an information form including socio-demographic characteristics. Perineum massage with olive oil in the second period of delivery was performed to massage group.In massage group when they progressed to full dilatation of the cervix, the midwife inserted two fingers inside vagina and using a sweeping motion gently stretched the perineum with lubricant 5 up to 10 minutes, in and between mother's pushing in the second stage of labour.
11088343|NCT04157777|Experimental|control|Among women who applied to Maternity Hospital 350 pregnant women were assigned to control group. Participants in control group filled out an information form including socio-demographic characteristics.And, no other interventions except for applications performed routinely in the delivery room were done.In control group just Ritgen Maneuver was applied. At last, we com-pared the rate of intact perineum, episiotomy and laceration, mean duration of the second stage of labor and Apgar score in 1 and 5 minutes be-tween two groups.
11088344|NCT04157764|Experimental|APD|
11088345|NCT04157751|Experimental|Empagliflozin|
11088346|NCT04157751|Placebo Comparator|Placebo|
11088347|NCT04157738|Experimental|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
11088348|NCT04157738|Active Comparator|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
11088349|NCT04157725|Experimental|Group A (mild stimulation protocol)|
11088350|NCT04157725|Active Comparator|Group B (conventional stimulation protocol)|
11088351|NCT04157712|Experimental|Cohort A Capsule - Fasted|ALZ-801 171 mg or matching placebo once daily Day 1, ALZ-801 171 mg or matching placebo twice daily Days 2-7, ALZ-801 256.5 mg or matching placebo once daily Days 8-14
11088352|NCT04157712|Experimental|Cohort B Capsule - Fasted|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 or matching placebo mg twice daily Days 2-7, ALZ-801 340 mg or matching placebo once daily Days 8-14
11088353|NCT04157712|Experimental|Cohort C Capsule - Fed|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 mg or matching placebo twice daily Days 2-7, ALZ-801 340 mg or matching placebo twice daily Days 8-13, ALZ-801 340 mg or matching placebo once daily Day 14
11088354|NCT04157712|Experimental|Cohort D Tablet - Fed|ALZ-801 265 mg or matching placebo once daily Day 1, ALZ-801 265 mg or matching placebo twice daily Days 2-6, ALZ-801 265 mg or matching placebo once daily Day 7
11088355|NCT04157699|Experimental|QL-007 100 mg QD + TDF|QL-007 tablet 100 mg QD was combined with TDF tablet 300mg
11088356|NCT04157699|Experimental|QL-007 200 mg QD + TDF|QL-007 tablets 200 mg QD were combined with TDF tablet 300mg
11088357|NCT04157699|Experimental|QL-007 400 mg QD+ TDF|QL-007 tablets 400 mg QD were combined with TDF tablet 300mg
11088358|NCT04157699|Experimental|QL-007 200 mg BID+ TDF|QL007 tablets 200 mg BID were combined with TDF tablet 300mg
11088359|NCT04157699|Active Comparator|TDF monotherapy|TDF tablet 300mg
11088360|NCT04157686|Experimental|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL.
11088361|NCT04157686|Experimental|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL.
11088362|NCT04157686|Experimental|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 will be injected into the LCL.
11088363|NCT04157673|Experimental|Episodic Future Thinking introduced at 6 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 8-week period following a 6-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
11088364|NCT04157673|Experimental|Episodic Future Thinking introduced at 8 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 6-week period following a 8-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
11088365|NCT04157673|Experimental|Episodic Future Thinking introduced at 10 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 4-week period following a 10-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
11088366|NCT04157660|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
11088367|NCT04157660|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
11088368|NCT04157647|Active Comparator|CytoSorb|Patients assigned to this arm group will receive hemadsorption witbhCytoSorb during the surgery and in the next 24 hours after surgery.
11088369|NCT04157647|Sham Comparator|Control|Patients assigned to this arm group will undergo to a normal CPB without the use of any hemoadsorption system.
11088370|NCT04157634|Experimental|Prognostication model|In a prospective cohort of children hospitalized in a PICU, development of a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
11088371|NCT04157621|Active Comparator|Active taVNS|
11088372|NCT04157621|Sham Comparator|Sham Stimulation|
11088373|NCT04157608|Active Comparator|Habitual Prosthesis|Participant's existing baseline prescribed prosthesis
11088374|NCT04157608|Experimental|e-MIP|Experimental ankle-foot prosthesis
11088375|NCT04157595|Experimental|Participating Couples|Reproductive Genetic Carrier Screening
11088376|NCT04157582|Experimental|Study group|will consist of 20 hemiparetic patients and will receive Pilates training in addition to conventional physical therapy program consists of (manual stretching exercises, Strengthening Exercises and Wobble board training ) for 18 sessions every other day for one and half month , 3 sessions /week ,each session for 1.30 hours (40 minutes for pilates then 10 minutes rest then 40 minutes conventional physical therapy).
11088377|NCT04157582|Experimental|Control group|will consist of 20 hemiparetic patients and will receive conventional physical therapy program only same as group I for 18 sessions every other day for one and half month, 3 sessions /week, each session for (40 minutes ).
11088378|NCT04157556|Experimental|Group of athletes|Age: 18-35 Gender: Male Basketball, volleyball, handball players who have been training regularly for at least last 3 months.
11088379|NCT04157556|Experimental|Group of sedentary people|Age: 18-35 Gender: Male Individuals with similar physical characteristics to the group of athletes and who have not exercise regularly for at least last 3 months.
11088380|NCT04157543|Experimental|electroacupuncture|electroacupuncture at points after surgery
11088381|NCT04157543|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
11088382|NCT04157543|No Intervention|Control group|only injection painkiller were used before surgery
11088383|NCT04157530|Sham Comparator|sham group|15 subjects with seeds of wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
11088384|NCT04157530|Experimental|acupuncture group|15 subjects with acupuncture applied to Qingming and Qiuhou with Der-qi
11088385|NCT04157530|Experimental|Electroacupuncture group|15 subjects wth acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi
11088386|NCT04157517|Experimental|Dose Escalation Phase: TAK-573 0.1 to 6 mg/kg|TAK-573 0.1 to 6 milligram per kilogram (mg/kg), infusion, intravenously, once on Day 1 of each 21-days treatment cycle for up to 1 year. Administration of TAK-573 on Day 1 of each 28-days treatment cycle may also be evaluated.
11088387|NCT04157517|Experimental|Dose Expansion Phase: Metastatic or Locally Advanced NSCLC|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with metastatic or locally advanced non-small cell lung cancer (NSCLC). The dose of TAK-573 for dose expansion phase will be the maximum tolerated dose (MTD) and/or pharmacologically active dose (PAD) determined in the previous dose escalation phase.
11088388|NCT04157517|Experimental|Dose Expansion Phase: CRPC|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with CRPC. The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088389|NCT04157517|Experimental|Dose Expansion Phase: MSI-high Tumors|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with microsatellite instability (MSI) high tumors with acquired resistance to checkpoint inhibitors (CPIs). The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088390|NCT04157517|Experimental|Dose Expansion Phase: Melanoma|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with melanoma with acquired resistance to CPIs. The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088391|NCT04157517|Experimental|Dose Expansion Phase: Head-and-neck Cancer|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with head-and-neck cancer with acquired resistance to CPIs. The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088392|NCT04157517|Experimental|Dose Expansion Phase: Triple-negative Breast Cancer (TNBC)|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with TNBC. The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088393|NCT04157517|Experimental|Dose Expansion Phase: Pancreatic Ductal Adenocarcinoma (PDAC)|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with PDAC. The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088394|NCT04157517|Experimental|Dose Expansion Phase: MSS Colon Cancer|TAK 573, infusion, intravenously, once on Day 1 of 21-days treatment cycle for up to 1 year in participants with microsatellite-stable (MSS) colon cancer. The dose of TAK-573 for dose expansion phase will be the MTD and/or PAD determined in the previous dose escalation phase.
11088395|NCT04157504|Experimental|Experimental Group: Physical Function|Forty patients with burn injury will be evaluated in this study. Lower extremity function, functional capacity, functional mobility, quality of life an scar tissue will be evaluated.
11088396|NCT04157491|Experimental|anlotinib and anti PD-1 antibody|
11088397|NCT04157478|Experimental|Radiation therapy, Temozolomide and anlotinib|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
11088398|NCT04157478|Active Comparator|Radiation therapy and temozolomide|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
11088399|NCT04157465|Other|Early Empiric group|Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
11088400|NCT04157465|Active Comparator|Pre-emptive group|Participants will receive standard medical therapy along with the pre-emptive strategy of treatment of invasive fungal infection (based on risk factors, clinical suspicion and radiological or mycological evidence of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
11088401|NCT04157452||proximal ureteral stone patient|
11088402|NCT04157439|Active Comparator|Control Group|Hot fermentation, Sustain pressure on trigger point, Self-stretches
11088403|NCT04157439|Experimental|Experimental Group|Integrated Neuromuscular Inhibition Technique Post isometric stretch (MET) Strain counter strain
11088404|NCT04157426|Experimental|Ultrasound-guided percutaneous electrolysis|
11088405|NCT04157426|Active Comparator|ultrasound-guided dry needling|
11088406|NCT04157413||Stunted Group|A comparative cross sectional study will compare stunted group and non-stunted group on amino acid intake, blood amino acid and intestinal permeability. Stunted group is defined as children who have LAZ <-2 SD
11088407|NCT04157413||Non-stunted Group|Non-stunted group will be those with LAZ >= 0.5 SD matching by age and sex with stunted group. Other criteria will be similar. No Intervention will be given to the groups in this proposed protocol.
11088408|NCT04157400|Experimental|Epidural Spinal Cord Stimulation|Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.
11088409|NCT04157387|Experimental|Cyriax inferior capsular stretching + Manual Therapy|"Cyriax inferior capsular stretching
~+ Electrotherapy Manual therapy : Kaltenborn grade 1 and 2 Mobilization
~Active ROM exercises :
~Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction"
11088410|NCT04157387|Active Comparator|Manual Therapy|Analgesic short-wave diathermy Manual Therapy: Kalternbon grade 1 and 2 Mobilization :, Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction.
11088411|NCT04157374|Experimental|EXPERIMENTAL GROUP|AOT and Active exercises
11088412|NCT04157374|Active Comparator|Control group|Active exercises
11088466|NCT04157023|Other|Medical Students|Simulator training of 7 patient cases adapted to medical students.
11150093|NCT03726853|Experimental|CKD-497 300mg|CKD-497 300mg
11088413|NCT04157361||Asthma|Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.
11088414|NCT04157361||Cystic fibrosis|Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.
11088415|NCT04157361||Healthy control|Healthy control children/adults without chronic or autoimmune disease
11088416|NCT04157348|Experimental|Benralizumab arm|1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
11088417|NCT04157348|Active Comparator|Mepolizumab arm|3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
11088418|NCT04157335|Experimental|Benralizumab|Benralizumab administered subcutaneously
11088419|NCT04157335|Placebo Comparator|Placebo|Placebo administered subcutaneously
11088420|NCT04157296|Experimental|CBT and computerized cognitive training (CCT)|Participants will play CCT games at home 5 times per week for two weeks before beginning CBT and for two weeks after the first CBT session. Then participants will have CCT games immediately prior to CBT for nine more weeks (one time a week).
11088421|NCT04157296|Active Comparator|Cognitive behavioral therapy|Participants will receive CBT sessions once a week for 12 weeks.
11088422|NCT04157283||Group 1|60 male patients
11088423|NCT04157283||Group 2|60 female patients
11088424|NCT04157270||Patients with acute ischemic stroke|Patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO)
11088425|NCT04157257|Experimental|QL-007 +TDF|QL-007 200 mg BID +TDF 300 mg QD
11088426|NCT04157257|Experimental|QL-007 +Entecavir|QL-007 200 mg BID +Entecavir 0.5 mg QD
11088427|NCT04157257|Active Comparator|TDF monotherapy|TDF tablet 300 mg QD
11088428|NCT04157257|Active Comparator|Entecavir monotherapy|Entecavir tablet 0.5 mg QD
11088429|NCT04157244|Experimental|Experimental: Tailored Music|4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet.
11088430|NCT04157244|No Intervention|4-week Wait-list control|4-week wait-list control (Note: participants will be crossed over to 4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet)
11088431|NCT04157231|No Intervention|Usual Care|Usual care to be provided to patients as per hospital guidelines for 3 months
11088432|NCT04157231|Other|Intervention arm|"The intervention consists of training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. This intervention will run for 3 months.
~Refresher training will be given monthly during the intervention."
11088433|NCT04157218|Active Comparator|Treatment with HIFU and immediately after insertion of threads|
11088434|NCT04157218|Active Comparator|Treatment with HIFU and 6 months later insertion of theads|
11088435|NCT04157218|Active Comparator|Treatment with lifting threads alone|
11088436|NCT04157205|Experimental|Test arm|All patients. Single arm study
11088437|NCT04157192|Active Comparator|Patients receiving real acupuncture treatment|Treatment with needle insertion
11088438|NCT04157192|Sham Comparator|Patients receiving sham acupuncture treatment|Treatment without needle insertion
11088439|NCT04157179|Active Comparator|Healthy Controls|
11088440|NCT04157179|Active Comparator|Extracorporeal Membrane Oxygenation survivors|
11088441|NCT04157179|Active Comparator|Sickle Cell Anemia participants|
11088442|NCT04157166|Other|group 1 in pair week|In pair week, patients will inclued in group1: the conventional recording followed by complementary images SPECT/CT, will be realized in first intention and the procedure of recording in camera VERITON will be recorderd in second intention
11088443|NCT04157166|Other|group 2 in odd week|in odd week, patients will inclued in group2: the procedure of recording of 25 minutes in camera VERITON-CT ™, will be realized in first intention and the procedure of conventional recording followed by complementary images SPECT/CT will be recorded in second intention
11088444|NCT04157153|Experimental|Treatment|All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 36 monts.
11088445|NCT04157140|Experimental|Anlotinib+ TACE+ RFA|Anlotinib+ TACE+ RFA
11088446|NCT04157127|Experimental|Autologous DC Vaccine Cohort 1|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2b at 1.5 mcg/kg on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 1:
~st vaccine - 0.5 million cells
~nd vaccine - 1 million cells
~rd vaccine - 2 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
11088447|NCT04157127|Experimental|Autologous DC Vaccine Cohort 2|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2b at 1.5 mcg/kg on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 2:
~st vaccine - 1 million cells
~nd vaccine - 2 million cells
~rd vaccine - 4 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
11088467|NCT04157023|Other|Ophthalmologist|Simulator training of 7 patient cases adapted to ophthalmologists.
11088468|NCT04157023|Other|Neurologist/Neurosurgeon/Neonatologist|Simulator training of 7 patient cases adapted to neurologists, neurosurgeons and neonatologists.
11088469|NCT04157010|Experimental|TCZ monotherapy|Tocilizumab (TCZ) monotherapy 8mg/kg 4-weekly for a total of 48 weeks.
11088470|NCT04157010|Experimental|TCZ+MTX combination therapy|Tocilizumab (TCZ) and methotrexate (MTX) combination therapy 8mg/kg 4-weekly for a total of 48 weeks.
11088448|NCT04157127|Experimental|Autologous DC Vaccine Cohort 3|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2b at 1.5 mcg/kg on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 3:
~st vaccine - 2 million cells
~nd vaccine - 4 million cells
~rd vaccine - 8 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
11088449|NCT04157127|Experimental|Autologous DC Vaccine Cohort 4|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2b at 1.5 mcg/kg on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 4:
~st vaccine - 6 million cells
~nd vaccine - 6 million cells
~rd vaccine - 6 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
11088450|NCT04157127|Experimental|Autologous DC Vaccine Cohort 5|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2b at 1.5 mcg/kg on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 5:
~st vaccine - 7 million cells
~nd vaccine - 7 million cells
~rd vaccine - 7 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
11088451|NCT04157127|Experimental|Autologous DC Vaccine Cohort 6|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2b at 1.5 mcg/kg on the first day of vaccination up through 14 days after last vaccination.
~DC Vaccine dose evaluated in Cohort 6:
~st vaccine - 8 million cells
~nd vaccine - 8 million cells
~rd vaccine - 8 million cells
~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
11088452|NCT04157114|Active Comparator|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
11088453|NCT04157114|Placebo Comparator|Placebo|Subjects will receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
11088454|NCT04157101|Experimental|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
11088455|NCT04157101|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
11088456|NCT04157088|Experimental|Participants treated with darolutamide|
11088457|NCT04157088|Experimental|Participants treated with enzalutamide|
11088458|NCT04157075|Placebo Comparator|No injection|
11088459|NCT04157075|Sham Comparator|Normal Saline Injection|
11088460|NCT04157075|Active Comparator|Bupivicaine Injection|
11088461|NCT04157062|Experimental|Study Group|Participants will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will receive excitatory rTMS with a stimulation frequency of 10 Hz or higher.
11088462|NCT04157049||Alpha-1 Diagnosed Individuals|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
11088463|NCT04157049||Carriers of Alpha-1|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
11088464|NCT04157036|Experimental|800mg Ibuprofen|Subject will take 800mg of Ibuprofen 45 minutes prior to anesthetic delivery.
11088465|NCT04157036|Experimental|40mg Methylprednisolone|Subject will take 40mg of Methylprednisolone 45 minutes prior to anesthetic delivery.
11088471|NCT04156997||Patients with extreme lipid phenotypes|Adult patients (age 18 years or older) diagnosed with any lipid or metabolic disorder including hyperlipidemia, dyslipidemia, hyperlipoproteinemia, low HDL levels and deranged lipoprotein metabolism
11088472|NCT04156997||Healthy volunteers|Healthy adult volunteers with normal lipid metabolism will be recruited for the purpose of comparison
11088473|NCT04156984|Other|Study arm|Subjects treated with optimized dose of golimumab, irrespective of weight: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4 weeks. In case of disease flare: discontinuation of drug.
11088474|NCT04156984|Other|Control arm|"Subjects treated according to current European Label (2019) based on body weight:
~<80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 50 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): dose optimization to 100 mg sc q4wk starting at week 6 or at any time during first year.
~≥80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): discontinuation of drug."
11088475|NCT04156971|Experimental|Intervention Group|stage-based lifestyle modification intervention and fish oil supplement (omega-3). Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring' Participants in the intervention group were also given fish oil capsules containing n-3 LCPUFA (DHA and EPA) for a duration of 16 weeks. The participants were required to consume two fish oil capsules, providing 1320 mg n-3 LCPUFA (792 mg EPA, 20:5n-3 and 528 mg DHA, 22:6n-3), and 6 IU vitamin E (D-alpha tocopherol) daily. The EPA and DHA ratio was 1.5:1.
11088476|NCT04156971|Other|Control Group|Only received Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring'
11088477|NCT04156958|Other|Fruquintinib Arm|Fruquintinib, 5 mg once daily for 21 days, followed by 7 days off (28 days/cycle) treatment until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
11088478|NCT04156945|Experimental|Intervention I: behavioural intervention|Participants will receive the behavioural Intervention in addition to standard of care.
11088479|NCT04156945|Experimental|Intervention II: home-based testing intervention|Participants will receive the home-based testing intervention in addition to standard of care.
11088480|NCT04156945|Experimental|Intervention III: combined intervention|Participants will receive the behavioural intervention and the home-based testing intervention in addition to standard of care.
11088481|NCT04156932|Active Comparator|OUC|Origin uterine artery closure
11088482|NCT04156932|Active Comparator|IUC|Cervical-isthmic uterine artery closure
11088483|NCT04156919|Experimental|Playful condition|Children in the playful and non-playful conditions will receive the fooya! intervention but will be varied in the psychological state of playfulness. Children in the playful condition will play a health game called fooya! Drawing on the playfulness literature, we will manipulate four dimensions of play. First, to manipulate the voluntariness of tasks, children in the playful condition will be asked/invited to participate in the study. Second, to manipulate adult presence, there will be little to no teacher involvement in the playful condition. Third, to manipulate the timing of the activity, children in the playful condition will be given an option to play anytime, including after school hours. Fourth, to manipulate the goal perception, the children in the playful condition will be told that their activity is not graded-i.e., autotelic.
11088484|NCT04156919|Experimental|Non-playful condition|As mentioned earlier, we will manipulate four dimensions of play. First, participation will be mandatory for children in the non-playful condition. Second, teacher presence will be more salient in this condition. Third, children in the non-playful condition will participate during school hours. Fourth, the children in the non-playful condition will be told that their activity is graded.
11088485|NCT04156919|Active Comparator|Control condition|Children in the control condition will play a video game unrelated to diet and lifestyle called Wordsearch.
11088486|NCT04156906|Experimental|D+ RH genotype matched Red Blood Cell Transfusion|Investigators will provide one red cell unit of D+ RH genotype matched RBCs at the first transfusion study visit. The remainder of units will be provided per clinical standard of care, i.e. D-, CEK-matched, and negative for all other antigens the patient is alloimmunized against. If laboratory monitoring shows no reappearance of anti-D and no signs of increased red cell hemolysis, the patient will receive one unit of D+ RH genotype matched RBCs at the 2nd transfusion study visit, and if tolerated, D+ red cell exposures will increase by one unit per study visit until all units required are D+.
11088487|NCT04156893|Experimental|RH genotype matched red cell transfusions|Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.
11088488|NCT04156867|Experimental|simple discectomy|traditional simple discectomy
11088489|NCT04156854|Experimental|Subjects with heart failure|Subjects admitted to the hospital for acute decompensation of chronic systolic heart failure will have a Quantitated Blood Volume Analysis blood test done
11088490|NCT04156841||performed SLNB using a single mapping agent|
11088491|NCT04156841||performed SLNB by combination of blue dye and radiotracer|
11088492|NCT04156841||underwent SLN surgery receiving neoadjuvant chemotherapy|
11088493|NCT04156841||underwent SLN surgery not receiving neoadjuvant chemotherapy|
11088494|NCT04156828|Experimental|Treatment (copanlisib, R-GCD)|Patients receive copanlisib IV and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone PO or IV 30-60 minutes prior to chemotherapy on day 1 and PO in AM or 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim SC on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11088549|NCT04156516|Active Comparator|HealthyMinds|Attention-matched control: Growth mindset intervention
11088550|NCT04156503|Experimental|Test fat: Palm olein|One high fat muffin will be serves together with a glass of low fat milk shake.
11088551|NCT04156503|Experimental|Test fat: Lard|One high fat muffin will be serves together with a glass of low fat milk shake.
11088552|NCT04156477|Experimental|Ketone ester|Intake of a ketogenic drink.
11088553|NCT04156477|Active Comparator|Isocaloric and -volumetric glucose drink|Intake of a taste matched glucogenic drink.
11088554|NCT04156477|Placebo Comparator|Isovolumetric tap water drink|Intake of a taste matched tap water drink.
11088495|NCT04156815|Active Comparator|1,565nm NAFL only group|Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas. A facial sheet mask (skin repair dressing, Panion & BF Biotech Inc, Zhuhai, China) was used to clean the face after laser treatment, and the face was cooled by air cooler for 10 minutes. The patients received three treatment sessions with a 6-week interval between each session.
11088496|NCT04156815|Active Comparator|Oral isotretinoin only group|Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
11088497|NCT04156815|Active Comparator|Double therapy group|The patients first received 2-4 weeks of oral isotretinoin medication (1mg/kg/d), followed by 1565nm M22-ResurFx NAFL treatment. Subjects were then given isotretinoin with a dosage of 0.5 mg/kg/d for the next 12-14 weeks. Laser treatment parameters and procedures were as same as in the group one above.
11088498|NCT04156815|Experimental|Triple therapy group|The patients received the same treatments as the subjects in group (3) with additional PBT. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
11088499|NCT04156802|Experimental|Real iTBS to the mPFC|Two sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real cTBS total) (1 train of stimulation over the mPFC (AFZ); (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
11088500|NCT04156802|Sham Comparator|Sham iTBS to the mPFC|Two sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real cTBS total) (1 train of stimulation over the mPFC (AFZ); (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
11088501|NCT04156802|Experimental|Real iTBS to the MC|Two sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real iTBS total) (20 trains of stimulation over MC; each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
11088502|NCT04156802|Sham Comparator|Sham iTBS to the MC|Two sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real iTBS total) (20 trains of stimulation over MC; each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
11088503|NCT04156789||Sarcoidosis group|Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
11088504|NCT04156789||Control group|Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
11088505|NCT04156776|Experimental|Group A (MET)|Muscle Energy Technique Conventional Treatment
11088506|NCT04156776|Experimental|Group B (AIS)|Active Isolated Stretching Conventional Treatment
11088507|NCT04156750|Experimental|LY3556050 (Part A)|LY3556050 administered orally.
11088508|NCT04156750|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
11088509|NCT04156750|Other|Iohexol (Part B)|Iohexol given intravenously (IV). (Part B is optional.)
11088510|NCT04156750|Other|Metformin (Part B)|Metformin given orally. (Part B is optional.)
11088511|NCT04156750|Experimental|LY3556050+ Iohexol (Part B)|Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)
11088512|NCT04156750|Experimental|LY3556050 + Metformin (Part B)|Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)
11088513|NCT04156737|Experimental|Investigational Lens|TECNIS Symfony plus IOL Model ZHR00V
11088514|NCT04156737|Active Comparator|Control Lens|Trifocal Intraocular Lens
11088515|NCT04156724|Experimental|HV|6MWT with helmet ventilation
11088516|NCT04156724|No Intervention|Control|6MWT alone according to ATS guideline
11088517|NCT04156711|Experimental|Remote Ischemic Preconditioning|Remote ischemic preconditioning is carried out before the induction of general anesthesia. All four cycles will be completed before general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg (if systolic blood pressures exceeds 185 mmHg, the cuff will be inflated to at least 15 mmHg above the systolic blood pressure) resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia, the cuff is deflated, and the limb is reperfused for 5 minutes. This cycle is repeated 4 times. Pulse oximetry is performed on the RIPC limb to make sure that the blood flow is completely interrupted during ischemia
11088518|NCT04156711|No Intervention|Control|Will receive no intervention, but will go through same tests at the same time-points (endothelial function measured by reactive hyperemia index, blood samples, Heart rate variability and questionaires)
11088612|NCT04156035|Experimental|Lamotrigine + Ketamine|Pretreatment with lamotrigine will occur 2 hours before the ketamine infusion
11088613|NCT04156035|Experimental|Placebo + Ketamine|Pretreatment with placebo will occur 2 hours before the ketamine infusion
11088614|NCT04156035|Placebo Comparator|Placebo + Placebo|Pretreatment with placebo will occur 2 hours before the placebo infusion
11088615|NCT04156009|Experimental|Treatment (+aromatherapy) group|
11088616|NCT04156009|Sham Comparator|Control (-aromatherapy) group|
11088519|NCT04156698|Experimental|Camrelizumab (PD-1 inhibitor) group|"Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:
~Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;
~Radical radiotherapy followed by concurrent immunotherapy:
~Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;
~Maintenance period:
~After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w and apatinib 250 mg d1-5 qw will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy)."
11088520|NCT04156685|Experimental|PartA, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
11088521|NCT04156685|Experimental|PartA, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
11088522|NCT04156685|Experimental|PartB, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
11088523|NCT04156685|Experimental|PartB, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
11088524|NCT04156659|Experimental|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.
~For subjects ≤ 50 kg, tisagenlecleucel will be administered as a single infusion of 0.2 to 5.0 x 10^6 CAR positive viable T cells per kg body weight.
~For subjects > 50 kg, tisagenlecleucel will be administered as a single infusion of 0.1 to 2.5 x 10^8 CAR positive viable T cells."
11088525|NCT04156646|Experimental|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
11088526|NCT04156646|Experimental|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
11088527|NCT04156633||conventional identification methods (controls)|Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
11088528|NCT04156633||new identification method (cases)Biofire FilmArray© BCID panel|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
11088529|NCT04156633||new identification method (cases) WGS approaches|Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.
11088530|NCT04156620|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
11088531|NCT04156620|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
11088532|NCT04156607|Experimental|Kinesio taping group (KT)|"Kinesio taping applied to plantar soles of these children with Down Syndrome. Epidermis-Dermis-Fascia technique was used for providing sensory input from soles.
~The application was performed on both feet."
11088533|NCT04156607|Sham Comparator|Sham taping group (ST)|A random taping was performed using Kinesio tape but without using Kinesiotaping techniques for sham taping. The application was performed on both feet
11088534|NCT04156607|No Intervention|Healty control group|This group took no intervention but all balance assessments once.
11088535|NCT04156581|Active Comparator|ESPB with Bupivacaine and Dexamethasone|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with 0.375% bupivacaine plus 2 mg preservative free dexamethasone, 25-30 mL total per side according to patient weight.
11088536|NCT04156581|Placebo Comparator|ESPB with saline placebo|23 complex spine surgery patients will be randomized to receive intraoperative ultrasound-guided bilateral ESPB with saline placebo, 25-30 mL total per side according to patient weight.
11088537|NCT04156568|Experimental|6INH Group|10mg/kg 6INH were used in this group.
11088538|NCT04156568|Experimental|3INH+RFT group|3INH+RFTwere used in this grroup.
11088539|NCT04156555|Experimental|Study drug|
11088540|NCT04156542|No Intervention|Control|In this school, we collected data throughout the entire study without implementing any intervention.
11088541|NCT04156542|Experimental|5-week Intervention with Post-intervention Data Collection|In this school, we collected baseline data for 5 weeks, implemented the intervention for five weeks, then removed the intervention and collected post-intervention data for five weeks.
11088542|NCT04156542|Experimental|Implement intervention for 15 weeks|In this school, we implemented the intervention on January 11, 2016, the day the study began.
11088543|NCT04156542|Experimental|Implement intervention for 12 weeks|In this school, we collected baseline data for three weeks and then implemented the intervention for the remaining twelve weeks.
11088544|NCT04156542|Experimental|Implement intervention for 9 weeks|In this school, we collected baseline data for six weeks and then implemented the intervention for the remaining nine weeks.
11088545|NCT04156542|Experimental|Implement intervention for 6 weeks|In this school, we collected baseline data for nine weeks and then implemented the intervention for the remaining six weeks.
11088546|NCT04156529|Experimental|ESU position|Firstly, the semi-elevated supine position was given to participants during tube feeding
11088547|NCT04156529|Experimental|ESRL position|Firstly, the semi-elevated right lateral position was given to participants during tube feeding
11088548|NCT04156516|Experimental|HEART|sexual health intervention that focuses on communication skills
11088555|NCT04156464|Active Comparator|Phenobarbital based treatment|"The phenobarbital group will undergo management with a phenobarbital based treatment protocol with additional symptom triggered therapies.
~On day 1, the phenobarbital group receive a loading dose of phenobarbital intravenous 10mg/kg (actual body weight) with a maximum dose of 1 g/100 mL
~On day 2 of study protocol, and no sooner than 12 hours after loading dose, phenobarbital 64.8 mg is administered every 12 hours for two doses.
~On day 3 of study protocol, patients will receive phenobarbital 32.4 mg every 12 hours for two doses.
~On day 4 of study protocol, patients will receive phenobarbital 32.4 mg once, to be given 24 hours after last scheduled dose.
~Throughout the 4 day protocol, the patient will have phenobarbital 65 mg every 6 hours as needed available either IM or IV, starting no sooner than 30 minutes after the loading dose."
11088556|NCT04156464|Active Comparator|Lorazepam based treatment|"The lorazepam group will undergo management with a lorazepam based treatment protocol with additional symptom triggered therapies.
~On Day 1, the lorazepam group will be started on scheduled lorazepam 4 mg every 6 hours
~After day 1, the scheduled lorazepam dose will be modified based on the total lorazepam requirements from the previous day and divided into 4-6 doses.
~A lorazepam infusion, at physician discretion, will be available at any point if the dose of scheduled and PRN lorazepam being given is too high or frequent to effectively be administered.
~Once symptoms are well controlled on lorazepam based therapy, the total dose given over the past 24 hours will be calculated and weaned by approximately 10-20% per day when clinically appropriate.
~Throughout the entire protocol, 2-4 mg lorazepam IV q 30 minutes PRN will be available for a goal CIWA <6 or RASS -1 to 0."
11088557|NCT04156451|Active Comparator|Central Venous Pressure 8 - 10 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 8-12 mmHg is reached
11088558|NCT04156451|Experimental|Central Venous Pressure 0 - 4 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 0-4 mmHg is reached
11088559|NCT04156438|Active Comparator|Low tidal volume ventilation|Conventional low tidal volume ventilation
11088560|NCT04156438|Experimental|Airway pressure release ventilation|Early use of airway pressure release ventilation
11088561|NCT04156425|Experimental|escitalopram + golimumab|Patients will be treated with escitalopram from the minimum dosage and golimumab according to direction for use.
11088562|NCT04156425|Experimental|escitalopram + calcium tablet|Patients will be treated with escitalopram from the minimum dosage and calcium tablet according to direction for use.
11088563|NCT04156425|Active Comparator|escitalopram|Patients will be treated with escitalopram from the minimum dosage.
11088564|NCT04156412|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
11088565|NCT04156399|Experimental|Acupuncture|All subjects will receive active acupuncture.
11088566|NCT04156386|Active Comparator|Animal Protein|
11088567|NCT04156386|Active Comparator|Vegan Protein|
11088568|NCT04156386|Placebo Comparator|Placebo|
11088569|NCT04156373|Experimental|Fuerte|This group will receive the Fuerte prevention program over the span of six to eight weeks.
11088570|NCT04156373|No Intervention|Delayed waitlist control|This group will be the delayed waitlist control group. They will not receive the Fuerte prevention program until the following semester.
11088571|NCT04156360||Healthy Volunteers|
11088572|NCT04156360||Patients With Pulmonary Nodule|
11088573|NCT04156347|Experimental|Phase I Open Label Study|Phase I Single Arm
11088574|NCT04156334|Experimental|computer-controlled intraosseous anaesthesia|Patients will receive the local anaesthetic using computer-controlled intraosseous anaesthesia (Quicksleeper 5) before the tooth extraction in general anaesthesia.
11088575|NCT04156334|Experimental|infiltrative or conductive local anaesthesia|Patients will receive a local anaesthetic using carpule before the tooth extraction in general anaesthesia.
11088576|NCT04156321|Experimental|Intervention|Group I (intervention) will receive 150 gm of Sajna shak/bora (Moringa) added with 25 gm concenstrated dal with 100 gm of rice as mid-morning snack in selected school 5 times a week for 6 months
11088577|NCT04156321|No Intervention|Control arm|Group II (Control) will rice, concenstrated dal and potato vaji. Both groups will receive calorie matched meal (411 kcal)
11088578|NCT04156308|Experimental|Combined exercises+OMT weekly|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions with a weekly frequency (with + -2 days of margin: between 5 and 9 days)."
11088579|NCT04156308|Experimental|Combined exercises+OMT once every 3 weeks|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions at the rate of one session every 3 weeks (with + -2 days of margin: between 19-23 days)."
11088580|NCT04156308|Experimental|Combined exercises|This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality.
11088581|NCT04156282|Active Comparator|classical closure.|In this group, the rectus sheath closure will be done by simple running continuous sutures with the knots beneath the subcutaneous layer.
11088611|NCT04156061|Active Comparator|CTCA - verbal report|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.
~Those in the CTCA group will be further randomised into review with or without CT images.
~The review WITHOUT images (VERBAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
11088582|NCT04156282|Active Comparator|knot burial technique|The surgeon holds the left angle of the rectus sheath incision with an Allis. Using (Polyglactin 910) suture,The needle is taken from the inside outward on the upper edge.The needle is then taken lateral to the Allis and brought back into the wound by taking it through the inferior edge from outside to inside . A square knot is tied with three or four throws. The needle is then taken out of the wound through the upper edge and continuous running stitches . As the right angle is approached, the angle is held with an Allis. the suture, will be taken through the lower edge, is brought outside the wound and passed between the blades of a closed Allis before taking it inside out on the upper edge. One more bite is taken but this time just lateral to the Allis holding the angle, and the needle is brought back into the wound and to the outside between the edges of the rectus sheath. Using the loop of polyglactin held with the Allis , an Aberdeen knot is tied after removing the Allis.
11088583|NCT04156269|Experimental|BCMA-CD33 cCAR T cells|BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs
11088584|NCT04156256|Experimental|CD123-CD33 cCAR T cells|C123-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs
11088585|NCT04156243|Experimental|CD19 CARvac T cells|CD19 CARvac T cells transduced with a lentiviral vector to express
11088586|NCT04156230|Experimental|Deep vein thrombosis|Subjects with Deep vein thrombosis will receive a single IV injection of [18F] GP1
11088587|NCT04156217|Experimental|EBV-TCR-T cells|Patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
11088588|NCT04156204|Experimental|Adolescent and Young Adult (AYA) Kidney Transplant Recipients|AYA kidney transplant recipients will receive a Medication Event Monitoring System (MEMS) in the form of a medication bottle and cap system and once daily tacrolimus XR 1-10mg
11088589|NCT04156191|Experimental|ARQ-151 cream 0.15%|Open-label study of 0.15% active concentration
11088590|NCT04156178|Experimental|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs
11088591|NCT04156165|Active Comparator|VLCD-Control|Very low calorie diet, 700 kcal pr day for eight weeks.
11088592|NCT04156165|Experimental|VLCD-Active|Very low calorie diet plus additional 25 g protein powder, 800 kcal pr day for eight weeks.
11088593|NCT04156165|Active Comparator|Maintenance-Control|"12-week weight maintenance diets: Moderate protein weight maintenance diet (MP-WMD): Recommended healthy diet including 25 g beef daily.
~The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar)."
11088594|NCT04156165|Experimental|Maintenance-Active|12-week weight maintenance diets: High protein weight maintenance diet (HP-WMD): The macronutrient distribution will be 25 energy percentage (E%) from protein, 45 E% from carbohydrate and 30 E% from fat. The diet will include 150 g beef as a daily source of protein, The diet is ad libitum and will be high in fibre (40 g/10 MJ) and whole grain (150 g/day) and allow inclusion of free/added sugar up to the recommended level (<10E% sugar).
11088595|NCT04156152|Active Comparator|Grupo I|16 patients
11088596|NCT04156152|Active Comparator|Grupo II|16 patients
11088597|NCT04156139|Active Comparator|Control group|NPPV treatment for patients will be performed for patients immediately after extubation in control group.
11088598|NCT04156139|Experimental|intervention group|HFNC treatment will be performed for patients immediately after extubation in the intervention group.
11088599|NCT04156126||Infertility - Frozen Embryo Transfer|Adult females undergoing a frozen embryo transfer
11088600|NCT04156126||Spontaneous Conception|Adult females presenting with positive pregnancy test to the Obstetrics Department
11088601|NCT04156113|Experimental|Athletes Group|"The athletes group will be composed of healthy, non obese (body mass index < 30), male basketball, volleyball and handball players aged between 18 and 35 years who have been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.
~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
11088602|NCT04156113|Experimental|Sedentary Group|"The sedentary group will be composed of healthy, non obese (body mass index < 30), male aged between 18 and 35 years who have not been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.
~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
11088603|NCT04156100|Experimental|AGEN1223|
11088604|NCT04156087|Experimental|MIMIPAC|Intervention: MIS-MWA plus immunotherapy using the combination of durvalumab with tremelimumab
11088605|NCT04156074|Experimental|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
11088606|NCT04156074|Active Comparator|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|30 mL vitamin D enriched drink consumed daily for 4 weeks
11088607|NCT04156074|Placebo Comparator|Placebo coconut oil emulsion drink|30 mL placebo drink consumed daily for 4 weeks
11088608|NCT04156074|Active Comparator|Vitamin D supplement (20 mcg/day)|Vitamin D supplement consumed daily for 4 weeks
11088609|NCT04156061|No Intervention|ASSIGN score|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.
~Patients randomised to standard care with ASSIGN score alone (n=200) will be invited back approximately 6 months after baseline assessment. The detailed questionnaire, breath test, blood pressure monitoring, and 2-week activity monitor will be repeated. Bloods will be retaken to look at change in lipid levels and HbA1c where appropriate - no more than 30mls will be required."
11088610|NCT04156061|Active Comparator|CTCA - visual report|"Those in the CTCA group will be further randomised into review with or without CT images.
~The review WITH images (VISUAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
11088618|NCT04155983|Active Comparator|High ACB|In the pre-operative cohort, the adductor canal block is administered by anesthesia staff immediately prior to patient transport to the operating room. The thigh is prepped with cholorhexidine at the midpoint between the anterior superior iliac spine and the patella and sterile drapes are applied. An ultrasound probe is then used to localize the adductor canal and confirm that the femoral artery, femoral vein and saphenous nerve can be visualized deep to the sartorious. The probe is moved proximally or distally until the neurovascular bundle is centered under the sartorius. A 20cc syringe with a blunt tip 1.5in 18ga needle is then used to inject 15cc of 0.5% ropivocaine. Following this, the wound is prepped and draped in usual sterile fashion for the arthroplasty procedure.
11088619|NCT04155983|Active Comparator|Low ACB|Surgeon Administered Group In the intra-operative cohort, the block will be administered after the final components are in place and cement debris is removed. The knee joint is irrigated with dilute hibiclens or betadine followed by pulsatile lavage per institutional protocol. A blunt tip 1.5in 18ga needle was then used to administer 15cc of 0.5% ropivocaine.. The location of the saphenous nerve as it exits the adductor canal will be estimated to be 1.5x the TEA proximal to the medial epicondyle in men and 1.3x the TEA proximal in women as described by Kavolus et al. The 60cc of the anesthetic will then injected through the vastus medialis musculature in a field extending from 1cm proximal to one cm distal to the assumed location of the nerve with the needle directed in from 20° to 45° medial. The wound is then irrigated pulsatile lavage one final time and closed in layered fashion.
11088620|NCT04155970|Experimental|Manual Therapy Arm|The group will receive manual therapy, as well as an evidence-informed home management booklet.
11088621|NCT04155970|Experimental|Non-Manual Therapy Arm|The group will receive an evidence-informed home management booklet only.
11088622|NCT04155957|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty and perform a daily 5-exercise plan autonomously.
11088623|NCT04155957|Experimental|ReHub Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty but use the telerehabilitation platform ReHub to do the exercises in their rehabilitation plan at home and to have their progress monitored.
11088624|NCT04155931||body temperature measurement|The investigators planned to perform prospectively in 80 children with ASA I according to the American Society of Anesthesia (ASA) Anesthesia Risk Scale between 6 months and 7 years of age in both sexes who underwent inguinal hernia, undescended testes and hydrocele surgery
11088625|NCT04155918|Experimental|AR882/FBX|
11088626|NCT04155918|Experimental|AR882/ALLO|
11088627|NCT04155905|Active Comparator|group A fistulotomy group|35 patients with simple anal fistula subjected to fistulotomy
11088628|NCT04155905|Active Comparator|group B marsupialization group|35 patients with simple anal fistula subjected to fistulotomy and marsupialization of fistulotomy wound
11088629|NCT04155892||URI group|This group includes participants <8 years of age undergoing elective procedures with a score of at least 3 on our pre-operative URI survey.
11088630|NCT04155892||non-URI group|This group includes participants <8 years of age undergoing elective procedures with no URI symptoms or recent URI.
11088631|NCT04155879|No Intervention|Control Group|Cardioversion without treatment with Colchicine
11088632|NCT04155879|Active Comparator|Treatment group|This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
11088633|NCT04155866||Healthy participants|Measurement of lower-limb muscle activation from healthy participants.
11088634|NCT04155866||Chronic Stroke Survivors|Measurement of lower-limb muscle activation from chronic stroke survivors
11088635|NCT04155853|Active Comparator|Interposition Arthroplasty|Fascia lata interposition arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
11088636|NCT04155853|Active Comparator|Hematoma and Distraction Arthroplasty|Hematoma and Distraction Arthroplasty for the treatment of thumb carpometacarpal joint osteoarthritis
11088637|NCT04155840|Experimental|Treatment (copanlisib, rituximab, bendamustine)|Patients receive copanlisib IV over 1 hour on days 1, 8 and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. Patients who achieve at least a partial response (MRD-positive) continue on treatment for 2 additional cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 7, patients receive copanlisib IV over 1 hour on days 1 and 15 for an additional 6 cycles in the absence of disease progression or unacceptable toxicity.
11088638|NCT04155827|Experimental|SIT for males|
11088639|NCT04155827|Experimental|SIT for females|
11088640|NCT04155814|Experimental|Iron Sucrose Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
11088641|NCT04155814|Active Comparator|Venofer Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
11088642|NCT04155801|Experimental|Salix Probiotic Blend|Participants will receive a Salix Probiotic Blend capsule orally once a day for 30 days.
11088643|NCT04155788|Experimental|Food Exposure|
11088644|NCT04155775||Best Practice Alert|Platelet transfusion orders for patients with a recent platelet count exceeding 50,000 per microliter (50k/uL) will trigger an alert in the electronic health record that displays current guidelines for platelet transfusion. The alert will allow providers to bypass the recommendation and continue with platelet ordering by selecting a clinical acknowledgement / exception to recommendation.Exclusions will be built into the alert to avoid triggering in operative or procedural settings, for neurosurgery providers, or patients on anti-platelet medications.
11088645|NCT04155775||No Best Practice Alert|For this group, no visible best practice alert will activate in the electronic health record for platelet transfusion orders and recent counts above 50k/uL.
11088646|NCT04155762|Experimental|Intervention|Both suspension systems were applied consecutively to the participants. Initially, participants used the Pin Suspension System (PSS) for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period. They then employed the Vacuum-Assisted Suspension System (VASS) for three months after a similar training period.
11088647|NCT04155749|Experimental|ARM 1|Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
11088809|NCT04154670|Experimental|Normal kidney function|MGTA-145 single dose
11088648|NCT04155736|Experimental|Renew with coaching|Users will be assigned a study staff member as a support person who is notified when the user engages with the app or if they have not engaged for 7 days. Support persons are provided with psychoeducation material including information about how to be an effective support person for the user and direct messaging capacity to respond to app notifications about user engagement (e.g., user earned X points, user achieved a new level).
11088649|NCT04155736|Active Comparator|Renew without coaching|"Same as Renew with coaching except that the users will not be assigned a study staff member as a support person."
11088650|NCT04155736|No Intervention|Wait list|No intervention is provided
11088651|NCT04155723||Phase 1 group|During phase 1, Midlines are inserted only by doctors.
11088652|NCT04155723||Phase 2 group|During Phase 2, Midlines are preferentially inserted by ICU nurses, and if needed, by doctors.
11088653|NCT04155710|Experimental|Cohort 1a|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib therapy. Patients will receive IOV-2001 + low dose IL-2.
11088654|NCT04155710|Experimental|Cohort 1b|CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
11088655|NCT04155710|Experimental|Cohort 2|CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib therapy. Patients will receive IOV-2001 + IL-2.
11088656|NCT04155710|Experimental|Cohort 3|CLL/SLL patients without del 17p who progressed or progressing on ibrutinib therapy. Patients will receive IOV-2001 + IL-2.
11088657|NCT04155697|Active Comparator|Hand washing with soap for thirdhand smoke removal|
11088658|NCT04155697|Active Comparator|Ethyl alcohol-based sanitizer for thirdhand smoke removal|
11088659|NCT04155684||HIV + with COPD|COPD will be defined as Subjects with FEV1/FVC<0.70 or FEV1 and DLco < 80% predicted
11088660|NCT04155684||HIV+ normal|Normal PFT's
11088661|NCT04155671|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
11088662|NCT04155671|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
11088663|NCT04155658|Experimental|Experimental SMFP Toothpaste|Toothpaste containing 1450ppm SMFP with additional calcium and phosphate
11088664|NCT04155658|Active Comparator|SMFP Toothpaste|Toothpaste containing 1450ppm SMFP
11088665|NCT04155658|Placebo Comparator|Negative control toothpaste|Toothpaste with no fluoride
11088666|NCT04155645|Experimental|Cohort 1|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 1 injection (8 subjects) or matching placebo (3 subjects).
11088667|NCT04155645|Experimental|Cohort 2|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 2 injection (8 subjects) or matching placebo (3 subjects).
11088668|NCT04155645|Experimental|Cohort 3|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 3 injection (8 subjects) or matching placebo (3 subjects).
11088669|NCT04155632|Experimental|N-acetylcysteine + Theta Burst Stimulation|
11088670|NCT04155632|Sham Comparator|N-acetylcysteine + Sham Theta Burst Stimulation|
11088671|NCT04155632|Placebo Comparator|Placebo + Theta Burst Stimulation|
11088672|NCT04155632|No Intervention|Placebo + Sham Theta Burst Stimulation|
11088673|NCT04155619|Active Comparator|No change in eating or light exposure habits|
11088674|NCT04155619|Experimental|Early Time-Restricted Feeding|
11088675|NCT04155619|Experimental|Timed Light Therapy|
11088676|NCT04155619|Experimental|Early Time-Restricted Feeding and Timed Light Therapy|
11088677|NCT04155606|Active Comparator|Interventional Therapy|Neurosurgery or Endovascular procedure
11088678|NCT04155606|No Intervention|Conservative Management|Monitoring with pharmacological therapy if need arises.
11088679|NCT04155580|Experimental|Part 1|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
11088680|NCT04155580|Experimental|Part 2|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
11088681|NCT04155580|Experimental|Part 3|ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
11088682|NCT04155567|Experimental|TAK-123|TAK-123 as 3.75 gram per square meter (g/m^2) of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m^2 of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 24 hours.
11088683|NCT04155554|Experimental|Bictegravir/emtricitabine/tenofovir alafenamide|Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD
11088684|NCT04155554|Active Comparator|Dolutegravir/lamivudine/abacavir|Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD
11088685|NCT04155541||VIZIMPRO(dacomitinib hydrate)|Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)
11088686|NCT04155528|Experimental|Study group|The intervention group will receive routine hospital care alongside 30 minutes of music therapy per day for three consecutive days. The music therapy will be initiated on the second day postoperatively. The assessment of baseline data and the music therapy will be applied at least three hours after analgesics administration.
11088687|NCT04155528|No Intervention|Control group|Patients in the control group will receive routine hospital care only.
11088688|NCT04155515|Other|Non-cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
11088689|NCT04155515|Other|Cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
11088810|NCT04154670|Experimental|Mild decrease in GFR|MGTA-145 single dose
11088811|NCT04154670|Experimental|Moderate decrease in GFR|MGTA-145 single dose
11088690|NCT04155502||Social media sites.|These participants will be recruited from advertisements posted on social media websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
11088691|NCT04155502||Informational sites|These participants will be recruited from advertisements posted on informational websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
11088692|NCT04155502||Dating applications|These participants will be recruited from advertisements posted on dating applications. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
11088693|NCT04155489|Active Comparator|restrictive|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started.
11088694|NCT04155489|Experimental|Liberal|In the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
11088695|NCT04155476|Experimental|Nitroglycerin exposure|
11088696|NCT04155476|Placebo Comparator|Non-Nitroglycerin exposure|
11088697|NCT04155463|Experimental|Organic Diet|Participants will be allowed to order one week's worth of food from a grocery store website (capped by price), with the restriction that they may only order foods certified by the USDA as organically grown. This food will be delivered to the researcher's laboratory, packaged, and delivered to each participants' home. Participants will log their food intake using a custom food diary phone app provided by the study.
11088698|NCT04155463|Experimental|Conventional Diet|Participants will be allowed to order one week's worth of food from a grocery store website (capped by price), with the restriction that they may only order foods NOT certified by the USDA as organically grown. This food will be delivered to the researcher's laboratory, packaged, and delivered to each participants' home. Participants will log their food intake using a custom food diary phone app provided by the study.
11088699|NCT04155450|Experimental|McKenzie Extension with External Limb Loading Protocol|"Moist Heat Pack for 10 mins
~McKenzie Extension Exercise Protocol
~Static:
~Lying Prone
~Lying prone in extension
~Sustained extension
~Posture correction
~Dynamic:
~Extension in lying
~Extension in lying with clinician overpressure
~Extension mobilization
~Extension in standing
~Limb loading for basic stabilization progression of the lumbar extensors. Begin in the quadruped position and progress the intensity by
~Flexing one upper extremity
~Extending one lower extremity with a leg slide
~Extending one lower extremity by lifting it off the mat
~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.
~Progress to prone position:
~Extending one lower extremity
~Extending both lower extremity"
11088700|NCT04155450|Active Comparator|McKenzie Extension Group|"Moist Heat Pack for 10 mins
~McKenzie Extension Protocol Sequence
~Static:
~Lying Prone
~Lying prone in extension
~Sustained extension
~Posture correction
~Dynamic:
~Extension in lying
~Extension in lying with clinician overpressure
~Extension mobilization
~Extension in standing"
11088701|NCT04155437|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities.
11088702|NCT04155437|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities.
11088703|NCT04155424|Experimental|Eculizumab|"All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly.
~After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks."
11088704|NCT04155411|Experimental|Dasatinib 70 mg|
11088705|NCT04155398||Study group|Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
11088706|NCT04155385|Active Comparator|Measurement-only|Patients will complete weekly measures of treatment progress and goals; however, the information from these measures will not be shared with clinicians or patients.
11088707|NCT04155385|Experimental|Measurement and feedback|Patients will complete weekly measures of treatment progress and goals; the information from these measures will be shared with clinicians.
11088708|NCT04155372|Experimental|30min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 30 min.
11088709|NCT04155372|Experimental|60min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 60 min.
11088710|NCT04155372|Experimental|90min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 90 min.
11088711|NCT04155346|Experimental|Facility-based prehabilitation (FBP)|"Exercise
~Three supervised exercise training sessions of aerobic and resistance exercises. Includes high-intensity interval aerobic training and whole-body resistance exercises (60 min/session)
~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery
~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist
~Nutrition
~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a Registered Dietitian (60 min/session)
~Participants will also receive 20g of protein supplementation daily
~Stress management and behavioural support
~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a psychologist (60 min/session)"
11088712|NCT04155346|Experimental|Home-based prehabilitation (HBP)|"Exercise
~Three unsupervised, home-based exercise training sessions of aerobic and resistance exercises. Includes continuous moderate-intensity aerobic training and whole-body resistance exercises (60 min/session)
~Specific exercises will also be prescribed to prepare regional and/or compensatory tissues for surgery
~Exercise session will be supervised by a Registered Kinesiologist/Exercise Physiologist
~Nutrition
~Participants will receive an individualized nutrition assessment and counselling within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a Registered Dietitian (60 min/session)
~Participants will also receive 20g of protein supplementation daily
~Stress management and behavioural support
~Participants will be scheduled for a psychoeducation session within the first week of prehabilitation and again in the week prior to surgery
~All sessions will conducted by a psychologist (60 min/session)"
11088713|NCT04155346|No Intervention|Usual Care|- This group will receive no additional intervention from the routine care.
11088714|NCT04155333|Experimental|Active anodal stimulation|active anodal stimulation at F3, cathode placed on contralateral bicep
11088715|NCT04155333|Experimental|Active cathodal stimulation|active cathodal stimulation at F3, anode placed on contralateral bicep
11088716|NCT04155333|Sham Comparator|Sham stimulation|sham stimulation that will be counterbalanced between subjects such that half will receive sham stimulation configured as condition 1 (anode F3, cathode bicep) and half will receive condition 2 (cathode F3, anode bicep)
11088717|NCT04155320|Active Comparator|Group A|Subjects are encouraged to disclose their HIV status to their partner(s) with or without a counselor present (Options 1 & 2).
11088718|NCT04155320|Experimental|Group B|Subjects may choose to notify their partners themselves, with or without a counselor present (Options 1 & 2), or choose to have one or more partners notified anonymously by project staff (Option 3).
11088719|NCT04155307|Experimental|Detection of anismus in patients with distal constipation|
11088720|NCT04155281||suspicion of intoxication|New Psychoactive Substances research in urine
11088721|NCT04155268|Experimental|Floatation-REST|Participants will float in a shallow pool of water with about 1000 pounds of epsom salt, in a light and sound attenuated device, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
11088722|NCT04155268|Active Comparator|Dark Room|Participants will lay on an air mattress in a dark and quiet room, with reduced environmental stimulation, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
11088723|NCT04155255|No Intervention|Control|Age-matched overweight and obese students were selected from control schools. The students participated in their usual health and physical education classes plus any other curriculum activities provided by the school.
11088724|NCT04155255|Experimental|Intervention|Overweight and obese students were recruited from intervention schools. Students underwent MyBFF@school intervention programme that consisted of physical activity, nutrition and psychological modules for the duration of 6 months. MyBFF@school intervention programme were conducted by trained personnel that were stationed full-time at each intervention school.
11088725|NCT04155242|Experimental|Study group|As part of the post RFA treatment follow up patients will receive a Cytosponge test followed by an endoscopy with NBI magnification and biopsies. Four endoscopies will be performed during 2 years of active follow up together with up to 2 Cytosponge procedures. Molecular biomarkers including a methylation panel on DNA and immunohistochemical markers on formalin fixed paraffin embedded samples obtained during the examinations will be assessed. Patients will be then followed up for up to 3 years with standard endoscopy to assess for relapse of Barrett's oesophagus/IM/dysplasia.
11088726|NCT04155229|Experimental|Null setting, forced entry|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at -blank-. This setting required the prescriber to enter a quantity in order to write a prescription."
11088727|NCT04155229|Experimental|5 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at 5."
11088728|NCT04155229|Experimental|10 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at 10."
11088729|NCT04155229|Experimental|15 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at 15."
11088730|NCT04155229|Active Comparator|Status quo default setting|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.
~This arm has a default setting for opioid quantity set at the status quo value for each site (20 for site 1, 12 for site 2)."
11088731|NCT04155216|Experimental|Guided imagery|Relaxation and guided imagery program
11088732|NCT04155203|Experimental|Perrigo active|
11088733|NCT04155203|Active Comparator|Reference Active|
11088734|NCT04155203|Placebo Comparator|Vehicle control|
11088735|NCT04155190|Experimental|Patidegib Topical Gel, 2%|Participants will be randomized (1:1) to receive Patidegib Topical Gel, 2% for 9 months
11088736|NCT04155190|Active Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized (1:1) to receive Patidegib Topical Gel, Vehicle for 9 months
11088737|NCT04155177||begining of curriculum|trainees in obstetrics and gynecology who have achieved less than 2 years of their hole curriculum
11088738|NCT04155177||mid curriculum|trainees in obstetrics and gynecology who have achieved at least 2 years and less than 4 years of their hole curriculum
11088739|NCT04155177||Advanced|trainees in obstetrics and gynecology who have achieved at least 4 years of their hole curriculm
11088740|NCT04155164|Experimental|Metformin|Participants will receive Metformin for 12 months.
11088741|NCT04155164|Placebo Comparator|Placebo|Participants will receive placebo for 12 months.
11088742|NCT04155151|Experimental|Single Arm|6 Minute Walking Test
11088812|NCT04154657|Experimental|biventricular conductance catheter|patients with indication for invasive assessment receive right and left heart catheter and parallel biventricular conductance catheter at rest and stress
11088813|NCT04154644|Experimental|Cervical Cytology|100 women with abnormal cervical cytology will receive cryotherapy with the experimental CryoPop device
11088842|NCT04154501|Placebo Comparator|Cohort 7 Placebo|Oral Placebo Capsule
11088743|NCT04155138|Other|Naida Hearing Aid|"Adults (> 18 years of age)
~Unilaterally implanted with an Advanced Bionics implant (CII or later)
~At least six months of CI use experience
~Limited bimodal benefit as perceived by the recipient and/or the clinician
~Participants may or may not currently be using a hearing aid in the unimplanted ear.
~Open set performance with current device configuration:
~≥40% AzBio sentence score in quiet (S0)
~If currently bimodal:
~Hearing aid ear only CNC score <50%
~AzBio Scores bimodal benefit <15%
~Unaided audiometric threshold of ≤100 dBHL up to 500 Hz
~Ability and willingness to participate in multiple sets of open speech testing (and chronically evaluate HA and CROS benefit)"
11088744|NCT04155138|Other|Naida CROS Device|The same cohort will cross over to each arm.
11088745|NCT04155125|Experimental|efepoetin alfa|"Route of administration: Subcutaneous Injection.
~The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period."
11088746|NCT04155125|Placebo Comparator|Mircera|"Route of administration: Subcutaneous Injection.
~The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL."
11088747|NCT04155112|Active Comparator|Exercise|Participants randomized to exercise will receive exercise sessions of 50 minutes twice weekly for 4 weeks led by experienced exercise instructors, thereafter once weekly with an instructor and twice weekly without an instructor (up to 6 month)
11088748|NCT04155112|Active Comparator|Mediterranean diet|Participants randomized to dietary group will be counseled by experienced dietitians to follow the Mediterranean diet with Nordic modifications with follow up sessions at biweekly intevals to reinforce changes (up to 6 month)
11088749|NCT04155099|Experimental|High dose|Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
11088750|NCT04155099|Experimental|Low dose|Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
11088751|NCT04155099|Placebo Comparator|pill quantity-matched Placebo|Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
11088752|NCT04155086|Experimental|Exposed group (patient with an autoimmunise disease)|Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
11088753|NCT04155086|Other|Non Exposed group (patient without an autoimmunise disease)|
11088754|NCT04155073|Experimental|COPD/smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking, quitting smoking, and respiratory symptoms, 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit, and if needed, 3) a home spirometry test with instructions on how to video themselves completing a lung functioning test via the device within an additional e-visit.
11088755|NCT04155073|Active Comparator|Treatment as Usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
11088756|NCT04155060||DM group , non-DM group|Septic patients were divided into the DM group and non-DM group, based on their comorbidity
11088757|NCT04155060||high lactate group,low lactate group|high lactate group (lactate > 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.
11088758|NCT04155047|Active Comparator|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
11088759|NCT04155047|Placebo Comparator|Placebo|Placebo Inhalation Solution administered by Magair
11088760|NCT04155034|Active Comparator|Arm I (PCI, MRI)|Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
11088761|NCT04155034|Experimental|Arm II (MRI)|Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
11088762|NCT04155008|Active Comparator|Patients with fair to good appetite|The patients with fair-good appetite (score on CNAQ more than 24) will not receive any pharmacological agents and will receive nutrition intervention alone.
11088763|NCT04155008|Experimental|Patients with poor to fair appetite|The patients with poor-fair appetite (score on CNAQ less than 24) will be provided nutrition intervention by the Registered Dietitian and then put into one of three pharmacological groups.
11088764|NCT04154995||Long-term ICU patients|Patients with a ICU length of stay of at least 48 hours.
11088765|NCT04154982|Experimental|Pharmacological treatment|Patients are treated with NAC prior to carrying out CAP.
11088766|NCT04154982|No Intervention|Standard procedure|Patients are not treated with NAC. No placebo treatment is performed.
11088767|NCT04154969|Experimental|intervention|daily physiotherapy session as part of the rehab plan, which includes 10 minutes of vestibular exercize.
11088768|NCT04154969|Active Comparator|control|daily physiotherapy session as part of the rehab plan
11088769|NCT04154956|Experimental|SAR408701|Administered intravenously once every 2 weeks
11088770|NCT04154956|Active Comparator|Docetaxel|Administered intravenously once every 3 weeks
11088771|NCT04154943|Experimental|Cemiplimab|Will receive IV infusion Q3W
11088772|NCT04154930|Experimental|Treatment|"Restylane-L® injected with optional touch at 1 month and optional retreatment at 12 months
~,"
11088773|NCT04154930|No Intervention|No Treatment Control|No treatment control with optional treatment at 12 months
11088814|NCT04154631|Experimental|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
11088843|NCT04154501|Experimental|Cohort 7 Drug|800 mg Oral Capsule
11088774|NCT04154917|Experimental|Experimental|HOME will be delivered by a community-based OT, who will be involved in the hospital discharge planning, trained by the PI. The HOME intervention comprises 4 phases: Phase 1 (in hospital): The clinician will focus on building a rapport with the patient and family members. Information will be gathered about the participant's home environment and functional ability. Phase 2 (± 5 days prior to expected discharge): Clinician will conduct a pre-discharge home assessment with patient and family to evaluate the environment, identify potential problems, and suggest appropriate ways to address them. Phase 3 (<1 week after discharge): Post-discharge home assessment will be conducted to provide additional in-home training and follow up on any of the patient's unmet needs. Phase 4 (2-4 weeks post-discharge): Follow-up telephone calls will be made to provide ongoing support to participant and family and encourage self-problem solving and independence.
11088775|NCT04154917|No Intervention|Usual care|Usual care group will receive the customary discharge planning assessment by a different clinician (OT). During this assessment, according to usual care, information regarding the participants' ability to perform activities of daily living and regarding their home environment is gathered and used to plan for discharge. Usual care group will not receive an OT home assessment as this is not part of usual care. If the clinician identifies a potential need for assistive equipment and home modification needs, patients will be referred to community-based homecare services as is the current practice, and a home visit may be performed following discharge, typically after an lengthy wait (weeks, months) for service.
11088776|NCT04154904|Experimental|Aerobic exercise|
11088777|NCT04154904|Experimental|Resistance exercise|
11088778|NCT04154904|Experimental|High intensity interval exercise|
11088779|NCT04154878||Pacemaker Optimization|Participants were referred for pacemaker optimization following implantation of a device. All had an intact atrial contraction either intrinsic or by device stimulation. A standard baseline echo was performed prior to programming changes with a final echo scan completed after all programming complete. Device programming consisted of adjusting atrial ventricular and right to left ventricular stimulation delays.
11088780|NCT04154878||Healthy|A brief cardiac history questionnaire and complete echocardiogram will be performed.
11088781|NCT04154865|Experimental|Enrolled, eligible|Single arm for eligible subjects
11088782|NCT04154852|Experimental|TNF-antagonist|Adalimumab, 40 mg, 2-weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
11088783|NCT04154852|Active Comparator|Placebo + MTX|Placebo, 2 weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
11088784|NCT04154839||Atopic dermatitis group|Number of subjects in atopic dermatitis group 0 - < 6 years : 50 subjects 6 - <12 years : 50 subjects 12 - <18 years : 50 subjects Adult (>= 18 years) : 150 subjects Total no. of cases: 300 cases
11088785|NCT04154839||Control group|>= 40 yrs : 150 subjects
11088786|NCT04154826|Experimental|low dose|CYT107 10µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 10µg/kg/week for 4 weeks (wk9-12)
11088787|NCT04154826|Experimental|high dose|CYT107 20µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 20µg/kg/week for 4 weeks (wk9-12)
11088788|NCT04154813|Experimental|Topiramate group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is topiramate group.During this group the initial dose of 25mg/day is rapidly increased to the target dose (100mg/day) or below the maximum tolerable dose if the patient can tolerate it.
11088789|NCT04154813|Experimental|Fluoxetine+DBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+DBT group. Group cognitive behavioral therapy was performed while fluoxetine was maintained. Target dose of fluoxetine is 60mg/day.Treatment was divided into three stages: the initial stage, the main stage and the end stage. The treatment was conducted once a week for a total of 12 times, followed by maintenance treatment for 6 months.
11088790|NCT04154813|Experimental|Fluoxetine+CBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+CBT group.Target dose of fluoxetine is 60mg/day. DBT therapy was performed while the original fluoxetine dose was maintained.The core treatment stage was 1 time per week, 12 times in total, and 6 months of maintenance treatment followed.
11088791|NCT04154800|Active Comparator|Part A: Fasting|Single ascending dose (SAD).
11088792|NCT04154800|Active Comparator|Part A: Fed|Single Ascending Dose (SAD)
11088793|NCT04154800|Active Comparator|Part B: Fasting|Multiple Ascending Dose (MAD)
11088794|NCT04154800|Active Comparator|Part B: Fed|Multiple Ascending Dose (MAD)
11088795|NCT04154787|Experimental|LNP023 Regimen A|LNP023 low dose
11088796|NCT04154787|Experimental|LNP023 Regimen B|LNP023 high dose
11088797|NCT04154787|Active Comparator|Rituximab|Rituximab
11088798|NCT04154774|Experimental|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
11088799|NCT04154774|Experimental|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
11088800|NCT04154748|Experimental|APC 90W / PPI 120mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
11088801|NCT04154748|Active Comparator|APC 90W / PPI 40mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
11088802|NCT04154748|Active Comparator|APC 60 W/ PPI 120mg|treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
11088803|NCT04154735|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with fludarabine, cyclophosphamide, mesna, and alemtuzumab. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant until engraftment. Rifaximin and tacrolimus will be administered for 6 and 12 months, respectively, beginning one day before the infusion of stem cells.
11088804|NCT04154722|Experimental|meropenum and azithromycin group|inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.
11088805|NCT04154722|Active Comparator|meropenum group|inj meropenum 20mg/kg/dose I/v in 3 divided doses
11088806|NCT04154709|Experimental|CTA101|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
11088815|NCT04154631|Experimental|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
11088816|NCT04154631|Active Comparator|UC-DT|Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
11088817|NCT04154605|Active Comparator|ClariFix|Cryotherapy of the nasal passages with the ClariFix device.
11088818|NCT04154605|Sham Comparator|Sham|Sham cryotherapy of the nasal passages with the ClariFix device
11088819|NCT04154592|Experimental|Experimental Group|In addition to the conservative treatment of the control group, humeral head depressor muscle co-activation training will be applied for 8 weeks.
11088820|NCT04154592|Active Comparator|Control Group|The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., & Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).
11088821|NCT04154579|Experimental|HeRe We Arts|This is an 8 week, arts-based session that includes educational & experiential components. Topics include: Introduction to Arts & Health; Music, Well-Being, & Resilience; Movement & Physical Activity; Art & Well-Being; Writing & Communication/Self-Expression; Theater & Socialization; Art Appreciation & a Healthy Brain; & Summary/Integration of the Arts into Daily Lives.
11088822|NCT04154579|Active Comparator|HeRe We Ed (Health Education Group)|This is an 8 week, non-arts-based health education session that includes educational & some experiential components. Topics include: Introduction to Health, Resilience, & Well-Being; Nutrition & Healthy Eating; Exercise, Chair Yoga, & Sleep; Mental Health, Stress Management, & Life Satisfaction; Holistic Approaches: Wellness, Integrative Medicine, & Complementary & Alternative Medicine; Chronic Illnesses & Chronic Pain; Health & Behaviors; Summary & Navigating the Healthcare System.
11088823|NCT04154566|Experimental|the study group|Group (A) the study group received aerobic exercise in addition to selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
11088824|NCT04154566|No Intervention|the control group|group (B) the control group received the same selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment only.
11088825|NCT04154540|Experimental|demyelinating hereditary neuropathy|adult patients with demyelinating hereditary neuropathy type CMT 1A.
11088826|NCT04154540|Experimental|demyelinating inflammatory neuropathy|adult patients with acquired demyelinating inflammatory neuropathy.
11088827|NCT04154527||postpartum women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.
~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.
~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz) curved linear array ultrasound transducer was used (LOGIQe Ultrasound,General Electric Healthcare, USA) with the ultrasound unit set in B mode."
11088828|NCT04154527||nulliparous women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.
~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.
~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz)curved linear array ultrasound transducer was used (LOGIQe Ultrasound,GE eneral Electric Healthcare, USA) with the ultrasound unit set in B mode."
11088829|NCT04154514|Experimental|Delivering FES to stroke survivors|"In stroke survivors, normal and abnormal muscle synergies will also be determined from their walk EMGs. Our proposed FES intervention involves delivering stimulations to muscles with waveforms generated from the activations of all the normal synergies not observed in each stroke survivor. We are going to employ the wearable to deliver personalized muscle-synergy-based FES stimulations to multiple groups of leg muscles on the stroke-affected side of elderly chronic stroke survivors as they walk on a treadmill for gait rehabilitation. We hypothesized that the subject will essentially be walking with his/her abnormal muscle pattern superimposed with the artificially introduced normal muscle pattern coming from FES."
11088830|NCT04154501|Placebo Comparator|Cohort 1 Placebo|Oral Placebo Capsule
11088831|NCT04154501|Experimental|Cohort 1 Drug|25 mg Oral Capsule
11088832|NCT04154501|Placebo Comparator|Cohort 2 Placebo|Oral Placebo Capsule
11088833|NCT04154501|Experimental|Cohort 2 Drug|50 mg Oral Capsule
11088834|NCT04154501|Placebo Comparator|Cohort 3 Placebo|Oral Placebo Capsule
11088835|NCT04154501|Experimental|Cohort 3 Drug|100 mg Oral Capsule
11088836|NCT04154501|Placebo Comparator|Cohort 4 Placebo|Oral Placebo Capsule
11088837|NCT04154501|Experimental|Cohort 4 Drug|300 mg Oral Capsule
11088838|NCT04154501|Placebo Comparator|Cohort 5 Placebo|Oral Placebo Capsule
11088839|NCT04154501|Experimental|Cohort 5 Drug|450 mg Oral Capsule
11088840|NCT04154501|Placebo Comparator|Cohort 6 Placebo|Oral Placebo Capsule
11088844|NCT04154501|Placebo Comparator|Cohort 9 Placebo|Oral Placebo Capsule
11088845|NCT04154501|Experimental|Cohort 9 Drug|1000 mg Oral Capsule
11088846|NCT04154501|Experimental|Cohort 8 Fasted|Participant will take 300 mg Oral Capsule in a fasting state, and then fed state.
11088847|NCT04154501|Experimental|Cohort 8 Fed|Participant will take 300 mg Oral Capsule in a fed state, and then fasting state.
11088848|NCT04154488|Experimental|Mavorixafor 400 mg|Participants will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each) orally once daily (QD) in the morning for 14 days.
11088849|NCT04154475|Experimental|yogurt diet|yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium)
11088850|NCT04154475|Active Comparator|dairy diet|dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products
11088851|NCT04154475|Active Comparator|standard diet|standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt
11088852|NCT04154462|No Intervention|No intervention|The VAMC sites randomized to the comparison arm will not have medical scribes introduced into emergency departments or specialty clinics.
11088853|NCT04154462|Experimental|Treatment|The VAMC sites randomized to the treatment arm are each expected to have four medical scribes, with two being VA employees and two being contractors, introduced into emergency departments or specialty clinics to assist providers during patient encounters.
11088854|NCT04154449||Control group.|
11088855|NCT04154449||Surgical group Received intranasal insulin.|
11088856|NCT04154449||Surgical group Received placebo.|
11088857|NCT04154436|Experimental|Sodium Bicarbonate (NaHCO3) Plus Solution|15 cc of Sodium Bicarbonate (NaHCO3) plus Solution will be sprayed on left or right side of the patient's face based on randomisation
11088858|NCT04154436|Placebo Comparator|Water (H2O)|15 cc of Water (H2O) will be sprayed on the left or right side of the patient's face based on randomisation
11088859|NCT04154423|Active Comparator|Glow! Group Prenatal Care|Group prenatal care with wrap around services.
11088860|NCT04154423|Active Comparator|Individual Prenatal Care- CPSP|Individual prenatal care with supplemental services covered by CPSP.
11088861|NCT04154397|No Intervention|error-enhancing feedback|The project of the first arm was to investigate how visualized error size affects postural training effect of the elderly, with a particular focus on error amplification strategy to optimize training benefits for postural training that favors the use of feedback mechanism on postural control and error correction. All participants were randomly assigned into the control and error amplification groups. The control group was trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. For the error amplification group, they were trained with the same postural paradigm, except that the visual guidance was virtually manipulated so that the participants visually perceived twice of the execution errors during stabilometer stance. We contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
11088862|NCT04154397|Experimental|positive cerebellar transcranial stimulation|The project of the second arm was to investigate the training benefits of using combined cerebellar transcranial direct current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance.They were randomly assigned into the control (traditional error amplification)and cerebellar transcranial direct current stimulation groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
11088863|NCT04154397|Experimental|sham cerebellar transcranial stimulation|The project of the third arm was to investigate the training benefits of using combined cerebellar transcranial random current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance. All participants were randomly assigned into the control (sham stimulation) and cerebellar transcranial random current stimulation and visual error amplification (ES) groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
11088864|NCT04154384|Experimental|Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
11088865|NCT04154371|Experimental|Single-arm or non-randomized trial|Six post-stroke patients, in the chronic recovery stage, will receive a treatment in which motor execution is promoted by virtual and augmented reality using serious gaming controlled by myoelectric pattern recognition. The aim of this treatment is to improve upper limb functionality.
11088866|NCT04154358|Experimental|HPV Testing|Will perform HPV testing with self-collected specimen
11088867|NCT04154345|Experimental|Painful exercises|The pain allowed during exercises ranges between 4 and 7 on NPRS (Numeric Pain Rating Scale)
11088868|NCT04154332||Healthy Controls|
11088869|NCT04154332||Preeclampsia Group|
11088870|NCT04154319|Active Comparator|HPV Vaccination|Mothers participated in educational/behavior change sessions to promote HPV vaccination among their 9-12 year old daughters
11088871|NCT04154319|Active Comparator|Healthy Eating|Mothers and daughters participated in educational/behavior change sessions to promote healthy eating and appropriate nutrition label interpretation
11088872|NCT04154306|Placebo Comparator|Placebo|
11088873|NCT04154306|Experimental|Red clover|
11088874|NCT04154293|Placebo Comparator|Vehicle Ointment (Control)|Topical, BID (Twice daily)
11088875|NCT04154293|Experimental|TMB-001 Ointment, 0.05%|Topical, BID ( twice daily)
11088876|NCT04154293|Experimental|TMB-001 Ointment, 0.1%|Topical, BID (Twice daily)
11088877|NCT04154280|Experimental|prostate cancer Patients|patients over the age of 18 with diagnosed prostate cancer at different stages of the disease.
11088944|NCT04153825|Active Comparator|Active TENS Group|Ten sessions of active conventional TENS and hydrocollator hot-pack.
11088878|NCT04154267|Experimental|Intervention|In addition to the routine evaluation commonly carried-out at this post-transplant period, protocol biopsies will be performed at the 10th-week post-transplantation in high-risk transplant recipients. Biopsy fragments will be evaluated for tissue immune aggression (mainly cellular and antibody-mediated rejections) and other conditions such as infections, particularly polyomavirus and cytomegalovirus and medication toxicities.
11088879|NCT04154267|No Intervention|Control|Patients will only undergo routine noninvasive evaluation at this post-transplant period
11088880|NCT04154254|Experimental|Dementia Patients|
11088881|NCT04154241|Experimental|neuroendocrine tumor Patients|A cohort of patients that were diagnosed with NET using biopsy.
11088882|NCT04154228|Experimental|Lymphoma Patients|
11088883|NCT04154215|Experimental|Dementia with Lewy Body (DLB) patients|
11088884|NCT04154202|Experimental|Bone inaction patients|Three months or more post joint replacement, or post tibial ORIF, or last surgical intervention adult patients suspected of bone infection and or mechanical loosening.
11088885|NCT04154189|Experimental|Randomization Phase: Lenvatinib + Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
11088886|NCT04154189|Active Comparator|Randomization Phase: Ifosfamide + Etoposide and Lenvatinib (Optional)|Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.
11088887|NCT04154176||POD CAM Nu-DESC|Patients undergoing surgery under general anesthesia assessed for POD with CAM and Nu-DESC
11088888|NCT04154163||Stage 1 Participants|"Blood test Day 1 DBS and venous blood
~Blood test Day 2 DBS (+/- and venous blood)
~Blood test Day 15 DBS only
~Blood test Day 16 DBS only"
11088889|NCT04154163||Stage 2 Participants|"Non-drug naive participants:
~Blood test Day 1 DBS
~Blood test Day 2 DBS
~Blood test Day 15 DBS
~Blood test Day 16 DBS
~Drug naive participants:
~Blood test Day 1 DBS
~Blood test Day 2 DBS
~Blood test Day 3, 4, or 5 DBS
~Blood test Day 4, 5 or 6 DBS
~Blood test Day 15 DBS
~Blood test Day 16 DBS"
11088890|NCT04154150|Experimental|Ketamine + Cognitive Training|
11088891|NCT04154150|Sham Comparator|Ketamine + Sham Training|
11088892|NCT04154137||Patients undergoing digestive endoscopy|"All the patients, age ranged from 18 to 90 years, referred to Digestive Endoscopy Outpatients Clinic of the Department of Gastroenterology of the University Hospital Paolo Giaccone of Palermo, Italy"
11088893|NCT04154124|Experimental|Rectal Cancer Patients|
11088894|NCT04154111|Experimental|Real cTBS to the vmPFC|Thirty sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% rMT, MagPro; 600 pulses total)
11088895|NCT04154111|Sham Comparator|Sham cTBS to the vmPFC|Thirty sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% rMT, MagPro; 600 pulses total)
11088896|NCT04154111|Experimental|Real iTBS to the dlPFC|Thirty sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
11088897|NCT04154111|Sham Comparator|Sham iTBS to the dlPFC|Thirty sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% rMT, MagPro; 600 pulses total)
11088898|NCT04154098|Experimental|NO-OA-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
11088899|NCT04154098|Experimental|NO-MA-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
11088900|NCT04154098|Experimental|OA-NO-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
11088901|NCT04154098|Experimental|OA-MA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
11088902|NCT04154098|Experimental|MA-NO-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
11088903|NCT04154098|Experimental|MA-OA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
11088904|NCT04154085|Experimental|Study Group|This study only has one arm; all patients receive the treatment intervention.
11088905|NCT04154072|Active Comparator|NLY01 (2.5 mg)|NLY01 2.5 mg injection
11088906|NCT04154072|Active Comparator|NLY01 (5.0 mg)|NLY01 5.0 mg injection
11088907|NCT04154072|Placebo Comparator|Vehicle|inactive drug, injection
11088908|NCT04154059|Experimental|Intervention Group|Patients will receive a physical therapy intervention three times per week, for 8 weeks.
11088909|NCT04154059|No Intervention|Control Group|Patients will not receive any exercise treatment but they will keep their recommended clinical treatment.
11088910|NCT04154046|Experimental|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
11088911|NCT04154046|No Intervention|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
11088945|NCT04153825|Active Comparator|Active IFC Group|Ten sessions of active interferential current and hydrocollator hot-pack.
11088946|NCT04153825|Sham Comparator|Sham TENS Group|Ten sessions of sham TENS and hydrocollator hot-pack.
11088947|NCT04153825|Sham Comparator|Sham IFC Group|Ten sessions of sham IFC and hydrocollator hot-pack.
11088948|NCT04153799|Experimental|EGFR CAR-T|Group: 3 dose levels
11088912|NCT04154033|No Intervention|Arm A: Circadian Rhythm of Itch|For the study arm A, to evaluate circadian rhythm of itching, patients will record for 7 days 6 times daily in a booklet the itch intensity on a visual analog scale (VAS) scale. These time points for itch intensity recording will be hours after time of awakening (AW), so they will be AW+2h, AW+4h, AW+6h, AW+8h, AW+10h, AW+12h. Patients are to document all their pruritus attacks at these time points. On day 8 the investigators will collect suction blisters (4-5 10mm blisters) at these 6 time points from unaffected skin on the trunk. For this purpose, the investigators will use the commercially available 47mm orifice plate (Electronic Diversities, Finksburg MD, USA) with 4-5 x10mm openings for each time point and use the 4-5 1mm blister roofs for harvesting.
11088913|NCT04154033|Experimental|Arm B: Topical Naltrexone Cream|Patients will start with placebo in week 2 and move on to naltrexone treatment in week 3. There will be a wash-in phase during week 1. Following week 2 and week 3, at visits 3 and 4, patients will be asked for the area where they are experiencing most intense itch and the investigators will take suction blisters from that area before any treatment. They will be told to bring the medication they have been using and they will apply this topically. After an hour, another suction blister will be taken from the same area. This will ensure the study is still blinded as neither the physician or the participant will know whether the medication was a placebo or not. Participants may apply their topical treatment as often as he wishes.
11088914|NCT04154033|Placebo Comparator|Arm C: Placebo Cream|Patients will start with naltrexone treatment in week 2 and move on to placebo treatment in week 3. Other than this, all procedures will be the same as in study arm B.
11088915|NCT04154020|Experimental|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
11088916|NCT04154020|No Intervention|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
11088917|NCT04154007||Adult Patients who met the diagnosis of ARDS|ARDS patients were followed for the development of AKI during their ICU stay
11088918|NCT04153994|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique.
11088919|NCT04153994|No Intervention|Erector Spinae Plane Blockade Control - Standard of Care|Patients will receive the standard of care for pediatric scoliosis surgery including multi-modal opioid pain management.
11088920|NCT04153981|Experimental|Insulin Glargine|Insulin glargine administered subcutaneously (SC).
11088921|NCT04153968|Experimental|Phase 1|Determination absorption and bioconversion kinetics of [13C14]β-cryptoxanthin and provide external validation for single-sample prediction methods.
11088922|NCT04153968|Experimental|Phase 2|Test the bioefficacy of provitamin A carotenoids (pVACs) in maize by comparing a high β-cryptoxanthin:β-carotene (βCX:βC) variety to a low βCX:βC variety in combination with external [13C]-labelled pVACs.
11088923|NCT04153955|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
11088924|NCT04153955|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
11088925|NCT04153942|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after receiving IV thrombolysis therapy per usual care
11088926|NCT04153942|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after receiving IV thrombolysis therapy per usual care
11088927|NCT04153929|Experimental|Dose group 1|
11088928|NCT04153929|Experimental|Dose group 2|
11088929|NCT04153929|Experimental|Dose group 3|
11088930|NCT04153929|Experimental|Dose group 4|
11088931|NCT04153929|Experimental|Dose group 5|
11088932|NCT04153929|Experimental|Dose group 6|
11088933|NCT04153929|Active Comparator|Dose group 7 (Semaglutide)|
11088934|NCT04153916|Other|Single use and continuous use|"Patients with a continuous unilateral facial paralysis that underwent an operation for facial reanimation will be enrolled at least one year after the operation according to review of medical records of the Department of plastic surgery.
~Patients with temporary unilateral facial paralysis secondary to Bell's palsy as was identified in the admission to the Hospital Department of Plastic Surgery or to the Department of Ear, Nose and Throat."
11088935|NCT04153903||Patients with intermediate lesions|Imaging cohort will be performed invasive angiography and optical coherence tomography (or Coronary CT angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70% stenosis)
11088936|NCT04153890|Experimental|FamPALcare|Standard Care plus FamPALcare
11088937|NCT04153890|No Intervention|Standard Care|The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
11088938|NCT04153864|Experimental|Non-specialist|Trained nurses or midwives with general health care professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
11088939|NCT04153864|Active Comparator|Specialist|Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
11088940|NCT04153864|Experimental|Telemedicine|A brief, manualized behavioral activation treatment delivered over Zoom in Toronto, via the UNC TelePsychiatry Program in Chapel Hill, and via Zoom in Chicago
11088941|NCT04153864|Active Comparator|In-Person|A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore Chicago
11088942|NCT04153851|Other|neurectomy of nasopalatine nerve|"Prophylactic preoperative antibiotic will be administered prior to surgery.
~Oral disinfection will be performed before surgery.
~Labial infiltration anesthesia and nasopalatine nerve block anasthesia.
~The nasopalatine foramen will be exposed after reflection of a palatal and buccal flap.
~Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal.
~Dental implant will be inserted in the central incisor location."
11088943|NCT04153838||Children|A group of 'typically' developing children (aged between 6 years and 16 years 11 months) from the general paediatric population will be recruited; with the sample distributed evenly across 6 age bands (i.e. ages 6-7 years, 8-9 years, 10-11 years, 12-13 years, 14-15 years, and 16 years+).
11088949|NCT04153773||Group 1|60 Patient
11088951|NCT04153760|Active Comparator|Aspirin|Aspirin 81 mg daily for six weeks post-randomization (postpartum)
11088952|NCT04153760|Placebo Comparator|Placebo|Placebo daily for six weeks post-randomization (postpartum)
11088953|NCT04153747|Active Comparator|Conventional ablation|"Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.
~Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI>=6 or Ablation index >=500.
~Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI>=5 or Ablation index >=350."
11088954|NCT04153747|Experimental|High-power and short-duration ablation|Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force > 5 g.
11088955|NCT04153734|Experimental|Immunotherapy plus chemotherapy|Combination of CDDP at 75 mg/m2 (day 1) or CBDCA at Area Under the Curve=6 (AUC=6) (day 1) + PEM at 500 mg/m2 (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, CBDCA at AUC=6 (day 1) + nab-PTX at 100 mg/m2 (days 1, 8, and 15) will be administered at 3-week intervals. If there is no progression after the 4th course of induction therapy, it will be switched to maintenance therapy. For maintenance therapy, the combination of PEM at 500 mg/m2 (day 1) + Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
11088956|NCT04153721|Experimental|Digital Solution|The proposed digital solution aims to improve the patient's preparation for his colorectal surgery and follow his rehabilitation after surgery, by reinforcing his compliance with existing protocols and enriching it with complementary practices
11088957|NCT04153708|Experimental|Retrieval by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
11088958|NCT04153708|Active Comparator|Retrieval by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
11088959|NCT04153695|Experimental|Experimental|To listen flamenco music during 30 minuts per day, during 2 weks
11088960|NCT04153695|No Intervention|Control|No intervention
11088961|NCT04153682|Active Comparator|Antimicrobial stewardship (= AMS)|Management of HAP according to current practice, including intervention of the AMS team.
11088962|NCT04153682|Experimental|Antimicrobial Stewardship + Rapid Diagnostic Testing|Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.
11088963|NCT04153669|No Intervention|Control|This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
11088964|NCT04153669|Experimental|Exercise-No NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions."
11088965|NCT04153669|Experimental|Exercise-NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions. Additionally, this group will receive neuromuscular electrical stimulation (NMES) concomitant to the strength training."
11088966|NCT04153656|Other|Nurses|Subjects will be asked to commit to reading and studying Spiritual Flow.
11088967|NCT04153630|Experimental|Haploidentical MSCs derived from bone marrow|Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
11088968|NCT04153617|Placebo Comparator|Control honey|"Orange blossom honey.
~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.
~Short term trial: 20g/day in a single day."
11088969|NCT04153617|Experimental|Modified honey with soluble fiber and polyphenols|"Honey modified with soluble fiber and polyphenols
~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.
~Short term trial: 20g/day in a single day."
11088970|NCT04153565|Experimental|PBZ @ 200 mg/m2 IV + CIS @ 75 mg/m2 IV + PMX @ 500 mg/m2 IV|PBZ @ 200 mg/m2 IV every 3 weeks (Q3W) in combination with CIS @ 75 mg/m2 IV, and PMX @ 500 mg/m2 IV for 4-6 cycles followed by monotherapy of PBZ up to 35 cycles from the first dose of the study in treatment phase (approximately 2 years)
11088971|NCT04153552||Study Participants who Suffer from Heartburn or indigestion|Subjects who meet the inclusion/exclusion criteria for the trial will be invited to participate in the trial. Subjects will be asked to sign a consent and complete screening survey. At the onset on an episode of the subject will start a symptom diary and completed and rate the symptoms using a 4-point Likert scale for each symptom. The participant will take 2 capsules per indigestion and heartburn episode. With a max of 6 capsules per day. • After taking the test product, the participant will complete a 4-point Likert scale assessment for each symptom at 15 minutes, 30 minutes, and 1 hour after taking the test product.
11088972|NCT04153539|Experimental|Walking along a busy road|Participants in this group will be asked to walk along a busy road for 4.5 hours.
11088973|NCT04153539|Active Comparator|Walking in a traffic-free park|Participants in this group will be asked to walk in a traffic-free park for 4.5 hours.
11088974|NCT04153526||Surgical Cohort|Surgical Cohort: Patients offered surgery, with or without adjuvant chemotherapy.
11088975|NCT04153526||Non Surgical Cohort|Non-Surgical Cohort: Stage I/II/IIIB patients undergoing radical radiotherapy (with or without chemotherapy) or stereotactic ablative radiotherapy (SABR).
11088976|NCT04153513|Experimental|Lanolin|
11088977|NCT04153513|Active Comparator|Mother's milk|
11088978|NCT04153500|No Intervention|Traditional Methodology|A professor/lecturer of anatomy will carry out the session in the control group. The traditional (40 minutes total) will consist of 30 minutes of lecture (75% out of the total time), where female pelvic floor will be presented throughout theory and images. In the 2nd part, during 10 min (25%), participants will review anatomical drawings /atlases.
11089084|NCT04152759|Experimental|BAT2506 injection|50mg ；subcutaneous injection
11089085|NCT04152759|Active Comparator|Sinponi(EU-licensed)|50mg ；subcutaneous injection
11088979|NCT04153500|Experimental|Pelvic+ method|The second researcher will carry out the session in the intervention group. The interventional session (40 minutes total) will consist of two parts: The 1st one is a lecture of 10 minutes (25% out of the total time) on female pelvic floor anatomy. In the 2nd part, during 30 min (75%), participants, in small groups of 4 people, will assemble the female pelvic floor interactive model, following the indications suggested by the second researcher. Pelvic+ is supported by an assembling manual that participants will be allowed to use.
11088980|NCT04153487|Experimental|ASTRALI Group|ASTRALI (AScorbic acid in TRALI) group (n=40)
11088981|NCT04153487|Placebo Comparator|Control Group|Control group (n=40)
11088982|NCT04153474|Active Comparator|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
11088983|NCT04153474|Active Comparator|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
11088984|NCT04153461|Active Comparator|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
11088985|NCT04153461|Active Comparator|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
11088986|NCT04153448||Bronchiectasis|Children with bronchiectasis
11088987|NCT04153448||Healthy Controls|Age-matched healthy volunteers
11088988|NCT04153435|Experimental|Calcium|The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.
11088989|NCT04153435|Placebo Comparator|Placebo|"The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, normal saline) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline."
11088990|NCT04153422|Experimental|Treatment (IVIG)|Patients in the treatment arm will receive 2g/kg Gammagard IVIG initially (1g/kg dose on Day 1 and 1g/kg dose on Day 2) and then 1g/kg maintenance infusions for 5 additional months (six months total).
11088991|NCT04153422|Placebo Comparator|Placebo|Patients in the placebo arm will receive 0.9% NaCl during the initial infusion and at maintenance infusions for 5 additional months (six months total).
11088992|NCT04153409|Experimental|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
11088993|NCT04153409|Placebo Comparator|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
11088994|NCT04153396|Experimental|The Treatment Group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
11088995|NCT04153396|Active Comparator|The Control group|The local infiltration solution in the control group will consist of ropivacaine.
11088996|NCT04153383||TMAD|Tissue motion annular displacement (TMAD) transesophageal echocardiography
11088997|NCT04153370|Active Comparator|intubation time airtraq|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
11088998|NCT04153370|Active Comparator|intubation time glidescope|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
11088999|NCT04153370|Active Comparator|intubation time c-mac|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
11089000|NCT04153357|Active Comparator|intubation time airtraq|intubation time of Airtraq
11089001|NCT04153357|Active Comparator|intubation time glidescope|intubation time of glidescope
11089002|NCT04153357|Active Comparator|intubation time of c-mac|intubation time of c-mac
11089003|NCT04153344||Infrared hyperreflective area|Patients with neurofibromatosis type 1 and with infrared hyperreflective areas
11089004|NCT04153344||No infrared hyperreflective areas|Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas
11089005|NCT04153344||Controls|Patients with no neurofibromatosis type 1
11089006|NCT04153331|Experimental|Patients admitted to emergency department with medical cause|Patient included in emergency with a nasal swab
11089007|NCT04153279|Experimental|CMV-TCR-T cells|The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10^6 to 1×10^6 TCR+T/Kg.
11089008|NCT04153266||Patients with oral epithelial dysplasia|"INCLUSION CRITERIA
~These include:
~Adults aged 18 or above at the time of the screening visit.
~Good command of English language both written and spoken [this is necessary as questionnaires are in English and cannot be translated unless through a cross-cultural validation study].
~Being able to consent.
~Diagnosed with OED as per current standard diagnostic criteria.
~No concurrent malignancy in the head and neck or elsewhere."
11089009|NCT04153253|Active Comparator|Group I|Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
11089010|NCT04153253|Active Comparator|Group II: Early vitrectomy.|Early vitrectomy.
11089011|NCT04153240|Experimental|Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'THERAPY' mode (ie. vibration feedback will be given in response to supine position)
11089012|NCT04153240|Sham Comparator|Sham Positional Therapy|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) - set in 'MONITOR' mode (ie. no vibration feedback will be given)
11089013|NCT04153214|Experimental|Cycling workstation|Participants will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 6 months
11089014|NCT04153214|Placebo Comparator|control|Daily activities unchanged during 3 months. Then they will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 3 months.
11089015|NCT04153201|Experimental|Hydroxychloroquine|Patients with primary antiphospholipid syndrome started on hydroxychloroquine while continuing standard care (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents, depending on primary APS subgroup)
11089016|NCT04153201|No Intervention|Standard care|Patients with primary antiphospholipid syndrome continuing standard care only (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents
11089086|NCT04152746||Adenoid group|Periostin levels in the adenoid group
11089017|NCT04153188|Experimental|Pulsed Dye Laser & Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream for 4 weeks prior to 1st of 3 monthly Vbeam® Prima PDL treatments. Subjects will continue with once daily application of Oxymetazoline HCL 1% Cream during the 6-month post-baseline study with a 3-day washout of cream prior to each of the 3 PDL treatments.
11089018|NCT04153188|Active Comparator|Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream during the 6-month study.
11089019|NCT04153175|Active Comparator|CT-010 Active Therapy|Subjects in the active comparator arm will have been randomized to receive active therapy through the implanted drug delivery system through the 3-month blinded period.
11089020|NCT04153175|Placebo Comparator|Placebo|Subjects in the placebo comparator arm will have been randomized to receive placebo therapy through the implanted drug delivery system for the 3-month blinded period.
11089021|NCT04153162|Experimental|Stereotactic body radiation therapy|In patients with HCM and refractory symptoms from LVOTO, stereotactic body radiation therapy will be delivered locally to relieve symptoms
11089022|NCT04153149|Experimental|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.
11089023|NCT04153149|Placebo Comparator|Placebo|Participants will receive placebo during the double-blind period.
11089024|NCT04153136|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
11089025|NCT04153136|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
11089026|NCT04153123|Experimental|Lidocaine with epinephrine|Peribulbar anesthesia with lidocaine and epinephrine
11089027|NCT04153123|No Intervention|Lidocaine without epinephrine|Peribulbar anesthesia with lidocaine
11089028|NCT04153110|Experimental|Real tDCS - Real tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
11089029|NCT04153110|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks).
11089030|NCT04153097||pembrolizumab-treated advanced NSCLC|Patients with advanced non-small cell lung cancer treated with pembrolizumab
11089031|NCT04153084||High volume electrolytes Polyethylene Glycol (PEG 4000) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using high volume electrolytes PEG (Bohm solution®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
11089032|NCT04153084||Low volume electrolytes PEG (PEG 3350) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using low volume electrolytes PEG (Movicol®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
11089033|NCT04153084||Sodium picosulfate cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using sodium picosulfate (Picoprep®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
11089034|NCT04153071|Experimental|Unipolar microplasma RF treatment|Single cutaneous unipolar microplasma RF treatment, with variable treatment parameters
11089035|NCT04153058|Experimental|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
11089036|NCT04153058|Active Comparator|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
11089037|NCT04153045|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
11089038|NCT04153045|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
11089039|NCT04153032|Experimental|DTZ arm|The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
11089040|NCT04153032|Experimental|MEBO arm|The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
11089041|NCT04153032|Experimental|MEBO and DTZ arm|The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
11089042|NCT04153019|Other|Cancer cachexia|Psycho-educational session: 3 weekly face-to-face consultations between a dyads (patients-caregivers) and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
11089043|NCT04153006||Chest pain patients|"Patients who are admitted to the cardiac ED because of chest pain for ruling out acute coronary syndrome by troponin analysis are eligible for participation.
~Troponin analysis will be performed according to standard protocol (0-1h protocol). From every included patient capillary blood samples and an extra venous blood sample will be drawn to evaluate HS cTnI levels obtained with the POC instrument and central laboratory (CL)."
11089044|NCT04152993|Experimental|RNS group|This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
11089045|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 3 hours.|This is a dose optimization study, different dosages will be tested, the lowest dosage that will be tested is 2,5 mg/kg/h for 3 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
11089087|NCT04152746||Control Group|Periostin levels in the control group
11089120|NCT04152499|Experimental|Phase II: • Cohort 1|Histologically documented, incurable, locally advanced or metastatic Gastric Adenocarcinoma refractory to standard therapies.
11089046|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 6 hours|The second lowest dosage that will be tested is 2,5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
11089047|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 6 hours.|The third lowest dosage, is the start dosage and the dosage that is already used in other clinical studies: 5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
11089048|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 12 hours.|The fourth dosage that is tested is 5 mg/kg/h for 12 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease..
11089049|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 18 hours.|The fifth dosage that is tested is 5 mg/kg/h for 18 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
11089050|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 24 hours.|The sixth dosage that is tested is 5 mg/kg/h for 24 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
11089051|NCT04152967|Experimental|new-designed PTFE valved conduit|In this group, new-designed PTFE valved conduits will be applied for patients.
11089052|NCT04152967|Active Comparator|Bovine jugular valved conduit|In this group, bovine jugular vein valved conduits will be applied for patients.
11089053|NCT04152954|Active Comparator|Traditional cannula|
11089054|NCT04152954|Experimental|Multi-tined cannula|
11089055|NCT04152928|Experimental|Neuroendocrine Tumors Patients|Patients with confirmed NET
11089056|NCT04152915|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (semaglutide D, test formulation)
11089057|NCT04152915|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (semaglutide reference formulation)
11089058|NCT04152902||PULL-DOWN HELLER-DOR|The PD-HD procedure aimed to restore the vertical axis of the intraabdominal portion of the oesophagus as much as possible. In brief, before performing the myotomy and the anterior fundoplication according to Dor, at least 6 cm of the mediastinal oesophagus was fully isolated; two or more U intramuscular stitches were applied on the curling of the right side of the oesophagus, pulled down and rotated towards the right side of the gastro-oesophageal junction. The PD-HD operation was performed under manometric control
11089059|NCT04152902||OESOPHAGECTOMY|OE was performed with open technique, or recently, with a minimally invasive technique. The stomach was always the oesophageal substitute, and the oesophagogastric anastomosis was preferably located at the thoracic dome or at the neck to minimize the risk of postoperative reflux oesophagitis or cancer growth in the residual dilated oesophagus
11089060|NCT04152889|Experimental|Camrelizumab+chemotherapy|
11089061|NCT04152876||Cases|Patients with rare disease
11089062|NCT04152876||controls|Healthy parents and relatives
11089063|NCT04152863|Experimental|IV V937 + Pembrolizumab|Participants receive V937 at a dose of 1 X 10^9 TCID50 by IV infusion on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
11089064|NCT04152863|Experimental|ITu V937 + Pembrolizumab|Participants receive V937 at a dose of 3 X 10^8 TCID50 by ITu injection on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
11089065|NCT04152863|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
11089066|NCT04152850|Experimental|Lifestyle Medicine Group|
11089067|NCT04152850|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
11089068|NCT04152837|Experimental|Lixivaptan|Lixivaptan oral capsules, 100-200 mg twice daily
11089069|NCT04152824|Experimental|Leader Intervention|Leaders in the intervention group will go through the Resilience-Supportive Leadership Training (RESULT)
11089070|NCT04152824|No Intervention|Control Group|Leaders in the control group will be usual practice
11089071|NCT04152811|Active Comparator|Waitlist 1|usual diabetes care
11089072|NCT04152811|Experimental|Intervention 1|6-weeks of cooking matters for diabetes classes
11089073|NCT04152811|Active Comparator|Waitlist 2|usual diabetes care
11089074|NCT04152811|Experimental|Intervention 2|6-weeks of cooking matters for diabetes classes
11089075|NCT04152798|Active Comparator|ProGrip™ mesh repair|Laparoscopic hiatal hernia repair with ProGrip™ mesh
11089076|NCT04152798|Active Comparator|Primary crural repair|Primary posterior crura repair
11089077|NCT04152785|Experimental|GHG|Information given regarding greenhouse gas emissions via a GHG score
11089078|NCT04152785|Experimental|Nutrition|Information given regarding nutrition via a nutrient profiling score
11089079|NCT04152785|Experimental|GHG+nutrition|Information given regarding GHG and nutrition via a combined score
11089080|NCT04152785|Placebo Comparator|No logo|No information given
11089081|NCT04152772|Active Comparator|Active during extinction learning / Sham during consolidation|Active tDCS stimulation will be applied during the extinction learning phase. Sham tDCS stimulation will be applied during the consolidation phase.
11089082|NCT04152772|Active Comparator|Sham during extinction learning / Active during consolidation|Sham tDCS stimulation will be applied during the extinction learning phase. Active tDCS stimulation will be applied during the consolidation phase
11089083|NCT04152772|Sham Comparator|Sham during extinction learning / Sham during consolidation|Sham tDCS stimulation will be applied during both the extinction learning phase and the consolidation phase.
11089088|NCT04152733|No Intervention|Control group|Children in the control group receive oxygen via conventional nasal cannula during deep sedation. Oxygen flow is determined to set the fraction of inspired oxygen of 50%.
11089089|NCT04152733|Experimental|High flow (HF) group|Children in the HF group receive oxygen via high flow nasal cannula during deep sedation. Fraction of inspired oxygen is set to 50%.
11089090|NCT04152720|Active Comparator|Prevention of infection Foley catheter|
11089091|NCT04152720|Active Comparator|Conventional Foley catheter|
11089092|NCT04152707|Experimental|Splendor X|
11089093|NCT04152694|Other|Ceftaroline in CRRT|Ceftaroline levels measured in patients receiving continuous renal replacement therapy
11089094|NCT04152681|Experimental|Assigned Interventions|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
11089095|NCT04152668|Active Comparator|Titanium curette and ultrasonic.|Control implants will be debrided with titanium curette and ultrasonic device without time limit.
11089096|NCT04152668|Experimental|Titanium curette, ultrasonic and air-polishing.|Test implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit also without time limit.
11089097|NCT04152655|Active Comparator|Group 1: idebenone|Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
11089098|NCT04152655|Placebo Comparator|Group 2: placebo|Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
11089099|NCT04152629|Experimental|FOQUEST adults|adult (≥18 years or older) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, or 100 mg/day)
11089100|NCT04152629|Active Comparator|VYVANSE adults|adult (≥18 years or older) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
11089101|NCT04152629|Experimental|FOQUEST pediatric|pediatric (6 to 17 years old) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg or 70 mg/day)
11089102|NCT04152629|Active Comparator|VYVANSE pediatric|pediatric (6 to 17 years old) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
11089103|NCT04152616|Experimental|Optitrack®|Instrumental evaluation of posture
11089104|NCT04152603|No Intervention|Control|Individuals in this arm will go through the partner study's standard recruitment and consent process
11089105|NCT04152603|Experimental|Intervention|Individuals in this arm will be exposed to our intervention during the partner study's recruitment and consent process
11089106|NCT04152590|Experimental|Uincare|Exercise using Uincare
11089107|NCT04152577|Experimental|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX
~R2-CHOP :
~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
~R2-DA-EPOCH:
~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
~R2-HD MTX:
~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
11089108|NCT04152577|Active Comparator|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX
~R-CHOP :
~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
~R-DA-EPOCH:
~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
~R-HD MTX:
~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
11089109|NCT04152564|Active Comparator|levo-bupivacaine continuous epidural infusion [CEI])|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
11089110|NCT04152564|Active Comparator|Levo-bupivacaine continuous preperitoneal infusion [CPI]),|At the end of surgery and after the closure of the peritoneal layer, the preperitoneal catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered.
11089111|NCT04152551|Experimental|Adult Treatment Arm|Intervention treatment arm. Adults (18+ years) with type 1 OI. Must have at least mild hearing loss. Will receive Risedronate (35mg, 0-2x/week as clinically indicated) for duration of study. Changes in hearing, quality of life, and bone density will be monitored.
11089112|NCT04152551|No Intervention|Child (Bisphosphonate Arm)|Observational (no investigational intervention) arm. Children (6-17 years) with any type of OI who are already receiving bisphosphonate treatment as standard of care treatment for orthopedic symptoms. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
11089113|NCT04152551|No Intervention|Child (Control Arm)|Observational arm. Children (6-17 years) with any type of OI who are not receiving bisphosphonate treatment. Changes in hearing, quality of life, and bone density will be observed for the duration of the study.
11089114|NCT04152538||healthy subjects|Healthy subjects matched with TKA patients
11089115|NCT04152538||TKA patients|age greater than 18 years old and a recent TKA.
11089116|NCT04152525|Experimental|experimental group|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
11089117|NCT04152525|No Intervention|control group|Routine care
11089118|NCT04152512||Whole Cohort|Whole cohort administration of questionnaire at 7 times
11089119|NCT04152499|Experimental|Phase I: Dose Escalation|Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264
11089121|NCT04152499|Experimental|Phase II: • Cohort 2|Histologically documented, incurable, locally advanced or metastatic Pancreatic Adenocarcinoma refractory to standard therapies.
11089122|NCT04152499|Experimental|Phase II: • Cohort 3|Histologically documented, incurable, locally advanced or metastatic Bladder Cancer refractory to standard therapies.
11089123|NCT04152486|Experimental|Intervention arm|The vaccine Ad26.ZEBOV (5x10^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
11089124|NCT04152473|Experimental|Proglumide|Open labelled proglumide treated
11089125|NCT04152460|Active Comparator|Thermo-Viscous preheated bulk fill resin composite|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
11089126|NCT04152460|Placebo Comparator|Conventional Bulk Fill resin Composite|GrandioSo X-tra (Voco,Cuxhaven
11089127|NCT04152447|No Intervention|Standard of care|
11089128|NCT04152447|Active Comparator|VR device|
11089129|NCT04152434||Reduction in monthly migraine days all cohorts at 4 months|Migraineurs with 15-30 headache days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly headache days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)
11089130|NCT04152434||Selection of elegible paitients|A total of 158 patients were involved in this study. 118 patients (75%), received Erenumab 140 mg., and 40 patients (25%) received 70 mg. In the Botox cohort, of 650 patients, 90 (13%) patients were eligible. In the no Botox cohort, 533 patients, 83 (15%) patients were eligible.
11089131|NCT04152434||Rate of adverse events related to Erenumab|72 adverse events were experienced during the 4 months of treatment, mostly with the 140 mg. dose. The most frequent were: constipation 34%, fatigue 19%, itching 7.5%, muscle cramps 6.3%, increased headache 4.4%, rhinitis 4.4%, injection site discomfort 3.7%, lack of energy 3.1%
11089132|NCT04152421|Experimental|Software user|
11089133|NCT04152408|Experimental|FiberSense System|6 diabetic patients will wear a FiberSense system at the upper arm for up to 30 days. and a comparator CGM system at the abdomen (replaced every 7 days).
11089134|NCT04152395||Metabolic group|Patients with metabolic syndrome undergoing EVAR
11089135|NCT04152395||Control group|Patients without metabolic syndrome undergoing EVAR
11089136|NCT04152382|Experimental|LY3462817 - Intravenous (IV)|LY3462817 administered as IV infusions.
11089137|NCT04152382|Placebo Comparator|Placebo - IV|Placebo administered as IV infusions.
11089138|NCT04152382|Experimental|LY3462817 - Subcutaneous (SC)|LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
11089139|NCT04152382|Placebo Comparator|Placebo - SC|Placebo administered as SC injections. (SC administration is discretionary/optional.)
11089140|NCT04152369|Active Comparator|24 hour prophylaxis|In this group patients received a AMP for the day of the procedure
11089141|NCT04152369|Active Comparator|72 hour prophylaxis|In this group patients received a AMP one day prior, on the day of the procedure and the following day.
11089142|NCT04152356||PD-1|
11089143|NCT04152356||Sorafenib|
11089144|NCT04152343|Experimental|RFA Physics Library- PGP|The RFA Physics Library will be used during during percutaneous liver RFA procedures.
11089145|NCT04152330|Other|Comparison between intervention and control group|"Subjects will be randomized to two groups, intervention group (IG) and Control group (CG). Each GI Parents-Baby dyad will receive 4 interventions, which will take place at predetermined dates (at 30 days, 3 months, 6 months, and 9 months) with groups of up to 5 pairs of participants. Parents is understood to be a generalist nomenclature and will be considered as parent, parent or primary caregiver.
~CG subjects will receive standard guidelines from the pediatric and pediatric cardiology outpatient clinic."
11089146|NCT04152317|Experimental|Misoprostol 200mcg|In this group, the participants will receive 200mcg of misoprostol, single dose, via the vaginal route.
11089147|NCT04152317|Active Comparator|Misoprostol 800mcg|In this group, the participants will receive 800mcg of misoprostol, single dose, via the vaginal route.
11089148|NCT04152304|Experimental|Feasibility of the SINEX for treatment of shoulder instability|Feasibility of the SINEX program for treatment and evaluation of of traumatic anterior shoulder instability eligible for surgery
11089149|NCT04152291|Experimental|E-EPA-diet group|All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.
11089150|NCT04152278||study group|The study group included 300 women presenting with unexplained spontaneous miscarriage or missed abortion during the first and early second trimester of pregnancy (8-16 weeks gestational age). The included women aged 18 to 45 years old.
11089151|NCT04152278||control group|The control group included 300 women with normal pregnancy, recruited from women attending the antenatal clinic of gestational age 8-16 weeks. The included women aged 18 to 45 years old.
11089152|NCT04152265|Other|No Intervention: Current screening practice.|Patients will be asked to complete the Food Frequency Questionnaire (FFQ) and the questionnaire about The World Health Organization Quality Of Life (WHOQOL-BREF), also and will be collected the demographic and anthropometric data
11089153|NCT04152265|Experimental|Experimental: Sequential screening strategy|People aged between 50-65, will take part in the study. Patients, which will take in a screening colonoscopy, will be divided into two groups according to the result obtained. The first group, will be constitute the patients with a positive test result, while the second group (control) will be constitute the patients with the negative test result. In addition, from the Subjects the samples of blood and faeces will be collected.
11089154|NCT04152252||Baseline|No CPR feedback during CPR
11089155|NCT04152252||Real-time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
11089156|NCT04152252||Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
11089264|NCT04151459|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy on severe obesity PCOS patients
11089157|NCT04152239||Study group|Study group includes consecutive patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy. Patients fulfilling the inclusion criteria and without exclusion criteria would undergo MSE per study protocol.
11089158|NCT04152226|Active Comparator|Cohort 1|Cohort 1 low dose of J. lividum
11089159|NCT04152226|Active Comparator|Cohort 2|Cohort 2 medium dose of J. lividum
11089160|NCT04152226|Active Comparator|Cohort 3|Cohort 3 - high dose of J. Lividum
11089161|NCT04152213|Experimental|Low GI diet group|"The components of the Low GI diet group include:
~(1) A one-off, 60-minute, face-to-face, educational session conducted by the research nurse for GI knowledge input. (2) An informational booklet will be given out during the education session. (3) Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after completing the face-to-face education session."
11089162|NCT04152213|Placebo Comparator|Control group|"The components of the control group include:
~(1) Pamphlets from the Department of Health about obesity and a balanced diet based on the food pyramid will be distributed. (2)Three follow-up telephone calls of fifteen minutes will be conducted by the research nurse at the 2nd, 5th , and 8th weeks after receiving the pamphlets."
11089163|NCT04152200|Experimental|Lumasiran|All participants will receive open-label lumasiran.
11089164|NCT04152187|Experimental|Inspiratory muscle training (IMT)|Patients will receive IMT for 30 min (15x2), 7 times per week for 8 weeks using inspiratory muscle trainer device (PowerBreathe). During training, patients will be instructed to maintain diaphragmatic breathing. Inspiratory load will be set at 40-60% of maximum inspiratory pressure. Each week, six training sessions will be held at home and a training session will be supervised with physiotherapist.
11089165|NCT04152187|No Intervention|Control|No additional intervention
11089166|NCT04152174|Experimental|Combined extracorporeal blood purification|CRRT with CVVHDF mode plus treatment with CytSorb adsorber
11089167|NCT04152174|Active Comparator|Control|CRRT with CVVHDF mode
11089168|NCT04152161|Experimental|Bacille Calmette Guerin (BCG) group|
11089169|NCT04152161|Placebo Comparator|Placebo group|
11089170|NCT04152148|Experimental|500mg BAT4306F|3 weeks of a cycle
11089171|NCT04152148|Experimental|750mg BAT4306F|3 weeks of a cycle
11089172|NCT04152148|Experimental|900mg BAT4306F|3 weeks of a cycle
11089173|NCT04152148|Experimental|1000mg BAT4306F|3 weeks of a cycle
11089174|NCT04152122||Intermittent exotropia group|Intermittent exotropia group
11089175|NCT04152122||Normal group|Normal group
11089176|NCT04152109|Other|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, an average of 8 weeks.
11089177|NCT04152109|Sham Comparator|Laying on of hands without Spiritual connection subgroup|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, an average of 8 weeks.
11089178|NCT04152109|Experimental|"Laying on of hands by Spiritual connection Passe subgroup"|"The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist pass. Patients remain in the supine bed blindfolded for 5 minutes, an average of 8 weeks."
11089179|NCT04152096|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
11089180|NCT04152096|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
11089181|NCT04152083|Experimental|Eptinezumab|Subjects will receive a single dose of 100 mg eptinezumab (IV)
11089182|NCT04152083|Placebo Comparator|Placebo (IV)|Participants will receive placebo matched to a single dose of 100 mg of eptinezumab given IV
11089183|NCT04152070||Community-dwelling older adults|Community-dwelling older adults living in the Valencia region (Spain).
11089184|NCT04152057|Experimental|Pyrotinib Combined With Albumin Paclitaxel and Trastuzumab|"Preoperative
~-Drug: Pyrotinib Maleate Tablets combined with Albumin Paclitaxel and Trastuzumab.
~Surgery:Subjects should be evaluated by tumor-enhanced MRI combined with mammary gland ultrasound during the preoperative neoadjuvant administration, and evaluated every 2 cycles. The subjects who were evaluated for CR and PR for the first time should be confirmed after at least 4 weeks. The confirmed tumor assessment cannot change the previously fixed examination time point.
~Postoperative
~Drug: Epirubicin hydrochloride combined with Cyclophosphamide
~At the same time, according to the recommendation of the clinician, choose whether to accept the same anti-HER2 treatment plan before surgery. For patients with tumors positive for estrogen receptor (ER) and/or progesterone receptor (PR), endocrine therapy should be given at the end of adjuvant chemotherapy, and if there is clinical indication at the end of adjuvant chemotherapy, radiotherapy should be given."
11089185|NCT04152044||Liver biopsy, Visceral and subcutaneous obesity|Those with histology and LFT's and quantificaiton of obesity
11089186|NCT04152018|Experimental|Dose Escalation|Single Agent Dose Escalation
11089187|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
11089188|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 2|Part 1C PF-06940434 plus anti-PD-1
11089189|NCT04152018|Experimental|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
11089190|NCT04152018|Experimental|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
11089191|NCT04152005||Control|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
11089192|NCT04152005||Periodontitis|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
11089193|NCT04152005||Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
11089194|NCT04152005||Periodontitis+Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
11089195|NCT04151966||Cardioversion Group|Subjects scheduled to undergo direct current cardioversion (DCCV) as part of the clinical plan of care
11089196|NCT04151953||Subjects with cardiac implantable electronic device (CIED)|Subjects with previously implanted cardiac implantable electronic device (CIED) who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
11089197|NCT04151940||Observational (PET/CT scan)|Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.
11089198|NCT04151927|Experimental|Normobaric Hypoxia (NH)|Overnight exposure (8 hours) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
11089199|NCT04151927|Sham Comparator|Normobaric Normoxia (NN)|Overnight exposure (8 hours) to NN conditions (~20% oxygen; achieved with nitrogen dilution, equivalent to ~1000 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
11089200|NCT04151901|Experimental|Male Rehabilitation (M-REHAB)|Disuse + resistance exercise rehabilitation
11089201|NCT04151901|Experimental|Male Control (M-CON)|Disuse + ambulatory control rehabilitation
11089202|NCT04151901|Experimental|Female Rehabilitation (F-REHAB)|Disuse + resistance exercise rehabilitation
11089203|NCT04151901|Experimental|Female Control (F-CON)|Disuse + ambulatory control rehabilitation
11089204|NCT04151875|Experimental|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
11089205|NCT04151875|Active Comparator|Non-extraction orthodontic treatment|non-extraction orthodontic treatment
11089206|NCT04151862|Active Comparator|tight eye bandage|Both eyes will be operated at two separate sessions. In the first session the first 25 patients will be bandaged postoperatively with tight eye bandage patching.
11089207|NCT04151862|Active Comparator|therapeutic contact lenses (TCL)|Both eyes will be operated at two separate sessions. In the second session the 25 patients will be bandaged postoperatively with therapeutic contact lenses (TCL).
11089208|NCT04151849||GLP-1 receptor agonist treatment|Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.
11089209|NCT04151849||SGLT-2 inhibitor treatment|Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.
11089210|NCT04151836|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity 30 minutes of exercise in week 1-4,40 minutes of exercise in 5-8 weeks,50 minutes in the 9-12 week,three times weekly in three month.We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 65%-70% of the target Maximal heart rate(HRmax).
11089211|NCT04151836|No Intervention|control group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
11089212|NCT04151823|Experimental|Postbiotic &vitamin D3, lifestyle intervention.|Postbiotics will be given at the dose of 80 mg/day (2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN; immunofos from Lactobacillus paracasei CNCM I-5220). 2 mL of product will give 1600 UI/die of VIT D3. Healthy living habits will be encouraged at t0, t1 and t2 visit.
11089213|NCT04151810|Experimental|anti-EGFR monoclonal antibody|"Single-dose Phase:This is a dose-escalation trial, all participants will receive treatment with CDP1. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.
~Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;
~Multi-dose Phase:Multiple administrations of three Cohorts of subjects were followed by continuous administration of CDP1."
11089214|NCT04151797|Experimental|Medication therapy management|Medication therapy management by pharmacist-led medication review
11089215|NCT04151784||Pulmonary Group|Pulmonary Group who have evidence of pulmonary diseases
11089216|NCT04151784||Healthy Control|Health Group who have no evidence of pulmonary diseases
11089217|NCT04151771|Experimental|LL-BFRT group|Participants randomised into intervention group are attending pulmonary rehabilitation in which strengthening exercises of the lower limb are performed using LL-BFRT.
11089218|NCT04151771|Active Comparator|Usual pulmonary rehabilitation group|Participants randomised into control group are attending usual pulmonary rehabilitation as established.
11089219|NCT04151758|Experimental|Docosahexaenoic Acid Supplementation, lifestyle intervention|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day. Physical activity and healthy eating habits will be encouraged.
11089220|NCT04151745|Other|study group|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
11089221|NCT04151719|Experimental|MNTX 450 mg QD|Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.
11089222|NCT04151706|Experimental|fTBI/Thiotepa/fludarabine|Participants will be infused on Day 0 with CD34+ selected cells and CD8+CD45RA T cells following a standard non anti-thymocyte globulin (ATG) containing regimen used for CD34 selected transplants consisting of fractionated total body irradiation (fTBI) (1375 cGy); thiotepa (10 mg/kg); and fludarabine (125 mg/m2).
11089223|NCT04151693|Experimental|Research group CFS|"Research treatment for patients with CFS (diagnosed G 93.3). CBT- based group therapy
~8 sessions in 4 months. n=35-40 patients
~Special focus on autonomic nervous system and how it affects the individual (hyperarousal, cognitive disabilities) Psychoeducation and tasks (for example abdominal respiration and mindfulness) learning new coping skills Stress management in every day life"
11089224|NCT04151693|Experimental|Control group CFS|"Control group
~6 sessions in 3 months n=35-40 patients
~Health, lifestyle and wellbeing counselling (sleep, nutrition, performance)"
11089225|NCT04151680|Experimental|Intermittent anticoagulation|Patients will be given anticoagulation if continuous electrocardiographic monitoring will detect an atrial fibrillation episode lasting more than an hour
11089226|NCT04151680|Experimental|Chronic anticoagulation|Patients will be given chronic oral anticoagulation regardless findings at continuous electrocardiographic monitoring
11150094|NCT03726853|Active Comparator|Active Comparator|compartor
11089227|NCT04151667|Experimental|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
11089228|NCT04151667|Experimental|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
11089229|NCT04151667|Experimental|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m^2 Days 1,8 and 15 of each 28 day treatment cycle.
11089230|NCT04151654|Other|assessment1|İt is assessment study. Assessment1 was evaluated for all test with and without footwear.
11089231|NCT04151641|Experimental|Sequence 1|
11089232|NCT04151641|Experimental|Sequence 2|
11089233|NCT04151628|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
11089234|NCT04151615||Patients|Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation
11089235|NCT04151602||PWUD with active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease
11089236|NCT04151602||PWUD with no active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease
11089237|NCT04151602||non-PWUD with active TB|People who do not use meth/mandrax who have active TB disease
11089238|NCT04151589|Experimental|Interventional Site|"The process below will be allocated in Interventional Sites:
~At each interventional sites, implementing full assessment of current emergency work flow of acute ischemic stroke patients who eligible for endovascular treatment. All interventional sites would undergo assessment in order to form a baseline.
~Drafting intervention approaches based on the assessment results of all interventional sites. These approaches are executable, reproducible, and measurable.
~Emergency work flow management APP would be installed on smartphones of designated personnel at each interventional sites.
~Both intervention approaches and APP would be incorporated with original work flow at each interventional site.
~Training sessions would be held in interventional sites or online every 3 month once the patient enrolment begin.
~Outcome data would be analysed and dispatched every 3 month for each interventional sites."
11089239|NCT04151589|No Intervention|Control Site|The control site would not undergo any emergency work flow modification for acute ischemic stroke patients who eligible for endovascular treatment.
11089240|NCT04151576|Experimental|Experimental|The patients received medical treatment. The intervention: An aromatic oil mixture (lavender and peppermint) was massaged for 15 minutes on the temple and root of the neck of the patients, and this application continued for three weeks
11089241|NCT04151576|No Intervention|Control|The patients received only medical treatment
11089242|NCT04151563|Experimental|Arm A: cabozantinib + nivolumab + ipilimumab|
11089243|NCT04151563|Experimental|Arm B: cabozantinib + nivolumab|
11089244|NCT04151563|Experimental|Arm C: nivolumab + ramucirumab + docetaxel|
11089245|NCT04151563|Experimental|Arm D: lucitanib + nivolumab|
11089246|NCT04151563|Experimental|Arm E: nivolumab + docetaxel|
11089247|NCT04151563|Active Comparator|Arm F: docetaxel|
11089248|NCT04151550|Experimental|Natural Emmetropic Presbyopes|Patients that did not undergo any vision correcting surgery or implantation of an intraocular lens but suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
11089249|NCT04151550|Experimental|Post Laser Vision Correction (LVC) Emmetropic Presbyopes|Patients that underwent laser vision correction procedure (e.g. LASIK) in the past and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
11089250|NCT04151550|Experimental|Pseudophakic Emmetropic Presbyopes with Monofocal IOL's|Patients implanted with a monofocal intraocular lens and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
11089251|NCT04151550|Experimental|Pseudophakic Emmetropes with Crystalens IOL's|Patients implanted with the accommodative intraocular lens Crystalens (Bausch & Lomb) and suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
11089252|NCT04151537|Active Comparator|Intervention|The intervention group is provided with a PA tracker that enables self-monitoring of PA and are instructed to obtain a personalized PA goal on a weekly basis.
11089253|NCT04151537|Active Comparator|Control|The control group is recommended to follow national PA guidelines, which can be considered as the 'intervention' offered to the public.
11089254|NCT04151511|Other|Continuous Thoracic Epidural|Continuous Thoracic Epidural Analgesia for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
11089255|NCT04151511|Experimental|Continuous Erector Spinae Plane Block|Continuous Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
11089256|NCT04151498|Experimental|Intervention Group|This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
11089257|NCT04151498|Other|Usual Care Reengagement Group|This group will complete a qualitative interview about barriers and facilitators to HIV care.
11089258|NCT04151498|No Intervention|Non-enrolling Group|This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
11089259|NCT04151485|Experimental|Mind/Body Group|All persons allocated to the intervention group will take part in a 10-week Mind/Body skills development fertility program parallel with fertility workup and treatment.
11089260|NCT04151485|Active Comparator|Support Group|All persons allocated to the comparison intervention group will take part in a 10-week fertility support program parallel with fertility workup and treatment.
11089261|NCT04151472|Experimental|90mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 30mg table by mouth, three times a day for next 3 months
11089262|NCT04151472|Experimental|270mg Idebenone|Placebo by mouth, three times a day for 1 months； Idebenone 90mg table by mouth, three times a day for next 3 months
11089263|NCT04151472|Placebo Comparator|Placebo|Placebo by mouth, three times a day for 4 months
11089265|NCT04151446|Experimental|Laser scleral microporation procedure performed|Patients suffering from presbyopia will receive bilateral Laser Scleral Microporation procedure.
11089266|NCT04151433|Active Comparator|The combined technique|First step consisting of stripping the cyst wall for 80% of the surface, followed by a second step consisting of ablation of the remaining 20% cyst surface.
11089267|NCT04151433|Active Comparator|CO2 laser vaporization only|CO2 laser vaporization only of the complete inner cystic wall after drainage of the cyst content, irrigation and inspection of its inner wall. Ablation of the inner cyst wall using the CO2 laser (Lumenis). Power settings of 30-55W for CO2 laser beam and 6-10W for CO2 fibre are used. The laser should be on the ablate function to widen the beam (e.g. Surgitouch modus). The laser should be applied in Surgitouch modus so that it can ablate the cyst surface while preserving the underlying healthy tissue.
11089268|NCT04151420||Adult IBD patients|
11089269|NCT04151407|Experimental|601 dose level 1 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
11089270|NCT04151407|Experimental|601 dose level 2 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once
11089271|NCT04151407|Experimental|601 dose level 3 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once
11089272|NCT04151407|Experimental|601 dose level 4 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
11089273|NCT04151407|Experimental|601 dose level 5 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;
11089274|NCT04151407|Experimental|601 dose level 6 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.
11089275|NCT04151407|Experimental|601 dose level 7 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.
11089276|NCT04151381|Placebo Comparator|the control group|the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .
11089277|NCT04151381|Active Comparator|Amiophylline (2mg)|Aminophylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia
11089278|NCT04151381|Active Comparator|Aminophylline(4mg)|Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
11089279|NCT04151368|Experimental|Robotic Nipple Sparing Mastectomy Arm|Patient cohort undergoing nipple sparing mastectomy with use of robotic dissection.
11089280|NCT04151355|Experimental|Atorvastatin group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) in addittion to atorvastatin (20 mg once daily)
11089281|NCT04151355|No Intervention|Control group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks)
11089282|NCT04151342||Prospective|Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR exon 20, ROS1, and BRAF, from participating sites/cancer centres across Canada.
11089283|NCT04151342||Retrospective|Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR exon 20, ROS1, and BRAF, from participating sites/cancer centres across Canada.
11089284|NCT04151342||Comparator group|All cancer patients without rare molecular alterations in their tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy.
11089285|NCT04151329|Experimental|2.4mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box, 2.4mg/kg IV infusions
11089286|NCT04151329|Experimental|3.6mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box,3.6mg/kg IV infusions
11089287|NCT04151316|Experimental|vertical group|
11089288|NCT04151316|Experimental|horizontal group|
11089289|NCT04151303||Cerclage 1|Time to delivery after cerclage removal Between 36-36.6 weeks' gestation - group 1
11089290|NCT04151303||Cerclage 2|Time to delivery after cerclage removal Between 37-37.6 weeks' gestation - group 2
11089291|NCT04151303||Cerclage 3|Between 38-38.6 weeks' gestation - group 3
11089292|NCT04151303||Cerclage 4|Time to delivery after cerclage removal Beyond 39 weeks' gestation - group 4
11089293|NCT04151277|Experimental|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first)
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1
~Folinic acid: 350 mg flat dose, IV over 2 hours, day 1
~5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours (or 48 hours as per standard practice))"
11089294|NCT04151277|Active Comparator|Abraxane and Gemcitabine|"nab-paclitaxel: 125 mg/m2 IV over 30 minutes, day 1, 8, and 15 (administered first)
~Gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 (immediately following nab-paclitaxel)"
11089295|NCT04151264|No Intervention|Control Arm|blinded HPI monitoring
11089296|NCT04151264|Active Comparator|Intervention Arm|HPI monitoring to predict hypotension
11089297|NCT04151251|Active Comparator|Sleep Kit Alone|Patients who are not randomized into the I-SLEEP intervention will receive a sleep kit that includes an eye mask, earplugs, and headphones.They will still receive the usual standard of care provided by clinicians which includes measures to reduce unnecessary nighttime disruptions and limiting excessive noise within the hospital setting.
11089298|NCT04151251|Experimental|Sleep Kit + Empowerment|"A short video will be shown on iPads and a brochure will be given that both describe the importance of good sleep and how to facilitate it with good sleep hygiene.
~The video will show a few reasons why someone might not get optimal sleep while in a hospital, and offer advice to address this from a doctor. The brochure will be kept to no higher than a 6th grade reading level, considered optimal for health education materials. Text will be kept brief and to the point. To account for vision problems, we will use >12-point font & leave a large portion of each page empty. Visual Aids & graphics will be employed when possible.
~All of this is given in addition to the usual standard of care provided by clinicians."
11089299|NCT04151238|Experimental|Exercise intervention|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary.
11089300|NCT04151225|Placebo Comparator|Participants receiving placebo|Participants will receive placebo loading dose followed by placebo for 12 weeks during Induction phase. Participants with clinical response at Week 12 will continue to receive placebo into a 40-weeks blinded maintenance period. Participants without a clinical response at Week 12 will receive a 450mg GSK2330811 SC loading dose at Week 12, followed by 150 mg SC every week from Week 13 until Week 23, followed by 150 mg SC every 2 weeks until Week 50.
11089301|NCT04151225|Experimental|Participants receiving GSK2330811 450mg loading dose/150mg Q1W|Participants will receive 450mg GSK2330811 SC as loading dose followed by 150 mg GSK2330811 Q1W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
11089302|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q2W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q2W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150mg GSK2330811 SC Q2W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
11089303|NCT04151225|Experimental|Participants receiving GSK2330811 300mg loading dose/150mg Q4W|Participants will receive 300mg GSK2330811 SC as loading dose followed by 150mg GSK2330811 SC Q4W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q4W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
11089304|NCT04151225|Experimental|Participants receiving GSK2330811 150mg Q8W|Participants will receive GSK2330811 SC 150 mg Q8W for 12 weeks during Induction period. Participants with clinical response at Week 12 will continue into a 40 weeks blinded maintenance period will receive 150 mg GSK2330811 SC Q8W. Participants without a clinical response will receive GSK2330811 150mg Q1W from Week 12 until Week 23, followed by GSK2330811 150mg Q2W until Week 50.
11089305|NCT04151212|Experimental|BAT5906 injection|Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.
11089306|NCT04151199|No Intervention|No Intervention Control|The control group does not engage in any exercise during acute testing protocol.
11089307|NCT04151199|Active Comparator|Endurance Exercise|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
11089308|NCT04151186|Experimental|TM4SF1 and EpCAM positive CAR-T cells for solid tumors|The present study is proposed to study advanced malignant solid tumors in adults, and the three escalating doses, namely, 2.0~2.5. 4.0~5.0 and 8.0~10.0 (×10 ^6/kg), will be given.
11089309|NCT04151173|Experimental|aspiration/electrocoagulation|
11089310|NCT04151173|Active Comparator|cystectomy|
11089311|NCT04151160||Case Subjects|Infants with hemodynamically significant congenital heart disease.
11089312|NCT04151160||Control Subjects|Healthy infants with no heart disease or non-hemodynamically significant congenital heart disease.
11089313|NCT04151147|Experimental|CGF application in the extraction socket|Partially impacted third molar was extracted with the help of straight elevator and third molar forceps. After extraction, any remains of the dental follicle were removed and the extraction sockets were irrigated with 60 mL of sterile saline. CGF fibrin gel was then randomly placed into one socket and wound closure was completed with silk suture.
11089314|NCT04151147|Experimental|non-CGF application in the extraction socket|Opposite side of the patient was considered as the control. After extraction of the third molar, dental follicle were removed and to prevent the flap laceration, bone contouring was also performed under sterile saline irrigation. Finally, wound closure was completed with silk suture.
11089315|NCT04151121|Experimental|Intervention|The participants will receive MBCT (Mindfulness-Based Cognitive Therapy) as 2-hourly sessions over 8-weeks including a 6-hour session at the end of 6th week. The MBCT will be adapted for chest pain.
11089316|NCT04151121|No Intervention|Control group|These participants will continue to receive any treatment (or no treatment) by their primary care physicians.
11089317|NCT04151108||Old medical patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), body composition.
~Will be assessed at admission"
11089318|NCT04151108||Geriatric patients|"Blood tests, frailty (CSHA Frailty Scale), risk of pressure ulcers (Braden Score), handgrip strength, chair-rise test, gait-speed, Orientation-Memory-Concentration test (OMC), screening for sarcopenia (SARC-F), body composition.
~Blood tests, physical function measures and body composition will be assessed at both admission and discharge."
11089319|NCT04151095|Experimental|BFR|
11089320|NCT04151095|Experimental|CTL|
11089321|NCT04151082|Experimental|Supportive care (steroid therapy)|Patients receive prednisone PO (or by feeding tube) QD on days 1-5 and then taper off over 2 weeks or methylprednisolone IV over 1 hour on days 1-5 in the absence of disease progression or unacceptable toxicity.
11089322|NCT04151069||At home group|Participants with allergy to tree nuts who follow the introduction procedure A (at home)
11089323|NCT04151069||At the hospital group|Participants with allergy to tree nuts who follow the introduction procedure B (at the hospital)
11089324|NCT04151069||Control group|Participants with allergy to tree nuts who follow strict avoidance of the offending nuts.
11089325|NCT04151056||Patients without social determinant of health|"Patients without any of the five selected social determinants of health / Patients without any of the five selected social diagnosis. Patient with a registered diagnostic  Health check (Z00.00)"
11089326|NCT04151056||"Patients with the social determinantstressful work hours"|"Patients with the selected social determinant of health. Patients with a registered diagnostic stressful work hours  (Z56.3)"
11089327|NCT04151056||"Patients with the social determinant of health living alone"|"Patients with the select social determinant of health . Patients with the selected social determinant of health . Patients with a registered diagnostic  living alone problems (Z60.2)"
11089328|NCT04151056||"Patients with the social determinant of health acculturation"|"Patients with the selected social determinant of health. Patients with a registered diagnostic difficulty acculturation  (Z60.3)"
11089329|NCT04151056||"Patients with the social determinant near surrounding"|"Patients with the selected social determinant of health. Patients with a registered diagnostic other specific problems related to the nearest surroundings (Z63.8)"
11089330|NCT04151056||"Patients with the social determinant unemployment"|"Patients with the selected social determinant of health. Patients with a registered diagnostic unemployment not specified (Z56.0)"
11089331|NCT04151043|Other|Verbal suggestion|
11089332|NCT04151043|Other|No suggestion|
11089333|NCT04151030|Experimental|Endoscopic-PEG|"The patients who are unable to undergo an endoscopic pull PEG placement, will undergo an Endoscopic introducer style Push-PEG procedure at the time of the index endoscopy"
11089334|NCT04151030|Active Comparator|IR-PEG|Patients who underwent PEG placement by interventional radiology (IR-PEG).
11089335|NCT04151017|Experimental|Autologous fibrin glue|
11089336|NCT04151017|Active Comparator|Sutures|
11089337|NCT04151004|Experimental|Patient group|Incremental cycling test to volitional exhaustion. Constant load cycling test to volitional exhaustion. Respiratory and leg muscle endurance test to volitional exhaustion. Three respiratory muscle training interventions.
11089338|NCT04151004|Active Comparator|Control group|The control group executes the same tests as the patient group.
11089339|NCT04150991|Experimental|Fiber intervention|The investigator's targeted supplemental fiber mixture (35 g total) will be composed of 6g of fiber from oligofructose + 10g from resistant maltodextrin + 12g from acacia gum + 4g from whole foods + 3g from RS2; and will be split into three meals each day.
11089340|NCT04150991|Placebo Comparator|Placebo treatment|Maltodextrin will be used as a placebo control, as it is digested in the small intestine and thus does not exert local effects in the colon.
11089341|NCT04150978|Active Comparator|5% Dextrose|the parenteral formulation as prescribed by the intensive care specialist
11089342|NCT04150978|Experimental|High Protein Polymeric Formula|"Procedure :
~The daily calorie and protein prescriptions were calculated from standard recommendations (calories 25-30 kcal/kg/d, proteins 1.2-2 g/kg/d)
~Administered as boluses via a nasogastric tube. A total of 5 aliquots were administered at 4-hourly intervals in a daily feeding period of 24 hours, with the participant positioned 30° head-up."
11089343|NCT04150978|Experimental|Oligomeric Formula|Similar to the High Protein Polymeric Formula Procedure
11089344|NCT04150965|Active Comparator|Arm A - Elotuzumab|Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.
11089345|NCT04150965|Experimental|Arm B - Anti LAG-3 Single Agent|Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.
11089346|NCT04150965|Experimental|Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.
11089347|NCT04150965|Experimental|Arm C - Anti-TIGIT Single Agent|Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.
11089348|NCT04150965|Experimental|ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.
11089349|NCT04150952|Experimental|HRV-Group|Athletes will train according to their basal HRV scores. If the resting HRV is higher tan their basal HRV, they will perform a high or moderate intensity training. If the resting HRV is lower, they will perform a low intensity training. If the resting HRV still lower, they will rest. They will not accumulate two or more days of high-moderate intensity training, nor two or more days of rest.
11089350|NCT04150952|Active Comparator|TRAD-Group|Athletes will train according to their trainer plan. Training will not be guided by their basal HRV scores.
11089351|NCT04150939|Experimental|Treatment (cryoablation)|Beginning 1 week prior to the next scheduled standard of care immunotherapy infusion, patients undergo core biopsy of the lesion to be ablated and a non-ablated lesion and also undergo cryoablation. Patients undergo a mandatory second core biopsy of the non-ablated lesion at 4 weeks after cryoablation.
11089352|NCT04150926|Experimental|Black currant puree|Black currant puree
11089353|NCT04150926|Active Comparator|Black currant-quinoa product|Black currant-quinoa product
11089354|NCT04150926|Active Comparator|Quinoa base|Quinoa base is used for the black currant-quinoa product.
11089355|NCT04150926|No Intervention|Liquid with glucose, fructose and sucrose|Liquid with glucose, fructose and sucrose
11089356|NCT04150913|Experimental|Anakinra and Axicabtagene Ciloleucel|"Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment.
~Screening
~Enrollment/Leukapheresis period
~Bridging therapy (if applicable)
~Lymphodepleting chemotherapy period
~Investigational Product (IP) treatment period
~Anakinra
~Axicabtagene Ciloleucel
~Post treatment assessment period
~Long term follow-up period"
11089357|NCT04150900|Experimental|Pembrolizumab + Bavituximab|Pembro and Bavituximab for progressive recurrent/metastatic squamous cell carcinoma of head and neck
11089358|NCT04150887|Experimental|Experimental: Cohort 2: Cusatuzumab + Venetoclax|Participants enrolled in this cohort will receive venetoclax ramp-up to 400 mg orally (as background therapy) starting on Cycle 1 Day 1 and followed by 400 mg daily dosing starting on Cycle 1 Day 4 plus cusatuzumab IV on Day 3 and Day 17 of each 28-day cycle. Cohort 2 will not be enrolled in the US.
11089384|NCT04150679|Active Comparator|group I retrospective non access loop|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy without access loop
11089385|NCT04150679|Active Comparator|GROUP II access loop group|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy with duodenojejunostomy access loop
11089359|NCT04150887|Experimental|Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA)|Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
11089360|NCT04150874|Experimental|Lumason Microbubbles|Participants will receive an IV administrative of Lumason® microbubbles, prior to radioembolization. 2 doses of 2.5mL will be administered
11089361|NCT04150861|Experimental|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
11089362|NCT04150861|Experimental|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
11089363|NCT04150861|Experimental|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
11089364|NCT04150848|Experimental|Goal Focused Emotion-Regulation Therapy (GET)|GET is a 6-session intervention delivered over 8 weeks to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses. GET has an emphasis on goal navigation skill building. This includes work on goal setting with a focus on assessing progress toward achieving specific, realistic, and measurable goals. Emotion regulation components include basic cognitive restructuring skills, cognitive distancing, and coping efficacy skills (matching the correct coping skill to specific circumstances).
11089365|NCT04150848|Active Comparator|Individual Supportive Psychotherapy (ISP)|"ISP includes 6-sessions of individual supportive psychotherapy and includes components of genuineness, unconditional positive regard, and empathic understanding through reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis. ISP emphasizes maintaining focus on the cancer experience, supporting participants in the here and now, fostering expression of emotion and discussion of difficult topics, and creating a sense of being understood."
11089366|NCT04150835|Experimental|Xingnaojing|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
11089367|NCT04150835|Placebo Comparator|Placebo|Subjects will receive intravenously administered Xingnaojing placebo, combined with guidelines-based standard care.
11089368|NCT04150809||Patients|Patients who have been diagnosed with ALS.
11089369|NCT04150796|Experimental|Enhanced-view Totally Extraperitoneal (eTEP) Hernia Repair|Initial access into the retromuscular space is achieved using an optical trocar. Insufflation of CO2 is performed under direct visualization. Multiple assistant ports will be placed medial to the semilunar line to continue developing the retromuscular space. The medial insertion of the posterior rectus sheath will be incised to enter the preperitoneal plane and facilitate reduction of hernia contents. The contralateral posterior rectus sheath will be incised and the contralateral retrorectus space will be matured. Suture will be used to close any defect in the hernia sac. The defect will be measured, as will be the retrorectus space. The fascial defect will be closed with suture. Non-barrier coated mesh will be placed in the retrorectus space and flat positioning will be confirmed. Ports will be removed under direct visualization, and the abdomen desufflated. Anterior fascia of any larger ports (8mm or greater) will be closed.
11089370|NCT04150796|Active Comparator|Intraperitoneal Onlay Mesh (IPOM) Hernia Repair|Access is achieved using an optical trocar. Insufflation of CO2 is performed. Two additional trocars are placed on the left side along the anterior axillary line. If necessary, auxiliary ports may be placed on the right side. When present, hernia contents are reduced using graspers. Adhesions between abdominal contents and the abdominal wall are lysed. The hernia defect is identified and measured internally with a sterile plastic ruler with the abdomen insufflated. Defect closure is performed using nonabsorbable suture. Mesh repair is performed using polypropylene mesh with an absorbable hydrogel barrier. Mesh is chosen to achieve a minimum 3 to 5-centimeter overlap from the edges of the closed defect. Inside the abdomen, the mesh is unrolled and positioning against the anterior abdominal wall is confirmed. Mesh edges are fixed circumferentially with permanent fixation. Ports are removed and the abdomen is desufflated. The anterior fascia of the 12mm port is closed.
11089371|NCT04150783||Unilateral Cleft Lip Nasal Deformity (uCLND)|uCLND patients who are scheduled to undergo surgical treatment for nasal obstruction as standard of care.
11089372|NCT04150783||Healthy Subjects|Existing data from healthy subjects with no prior symptoms of nasal obstruction used to create normative ranges for comparison to uCLND cohort.
11089373|NCT04150770|Experimental|Patients with Childhood Uveitis|5mg/kg/dose of infliximab IV initially two weeks, then 4 weeks and then every 6-8 weeks
11089374|NCT04150757|No Intervention|Standard Analgesia|"Patients receiving no intervention will receive no intranasal ketamine while awaiting intravenous line placement for parenteral pain control."
11089375|NCT04150757|Active Comparator|Intranasal Ketamine + Standard Analgesia|Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg).
11089376|NCT04150744|Experimental|RFA plus carrizumab|
11089377|NCT04150744|Placebo Comparator|carrizumab|
11089378|NCT04150731|Experimental|Breast cancer and FES|Only one arm: All included are patients with disseminated breast cancer and all have an experimental FES-PET/CT done
11089379|NCT04150718||Subjects with Major Depressive Disorder|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine is they meet criteria for MDD.
11089380|NCT04150718||Control|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine they do not meet criteria for MDD.
11089381|NCT04150705|Experimental|FDG PET/MRI|-Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 5 time-points at which it would normally be performed in their care for the following 1 year
11089382|NCT04150692|Experimental|Arm 1: Dara-SC Re-Escalation|-Re-escalation will include weekly dosing for two 4-week cycles (8 doses, Days 1, 8, 15, and 22 of each 28-day cycle) followed by dosing every-other-week thereafter (Days 1 and 15 of each 28-day cycle). Patients will remain on study treatment until meeting clinical progression.
11089383|NCT04150692|Active Comparator|Arm 2: Dara-SC|-Continued subcutaneous daratumumab and and hyaluronidase-fihj (1,800mg/30,000U, [Dara-SC])
11089386|NCT04150666|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 2.0 to 2.5 L of water per day (depending on sex), in addition to usual consumed beverages, for 3 months
11089387|NCT04150666|No Intervention|Control|
11089388|NCT04150653||AAA patients|"All patients enrolled in phase 1 will undergo:
~Multiphase scan CT
~Non-invasive vascular ultrasound elastography by ultrasound (NIVE)"
11089389|NCT04150640|Experimental|Cohort 1: HER2 Negative|Participants in Cohort 1 (HER2-negative) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
11089390|NCT04150640|Experimental|Cohort 2: HER2 Positive|Participants in Cohort 2 (HER2-positive)will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
11089391|NCT04150627|Active Comparator|deep breathing|
11089392|NCT04150627|No Intervention|normal breathing|
11089393|NCT04150614|Active Comparator|Arm 1|ARM 1 -transdermal granisetron plus intravenous dexamethasone
11089394|NCT04150614|Active Comparator|ARM 2|ARM 2 -intravenous ondansetron plus intravenous dexamethasone
11089395|NCT04150601|Active Comparator|Spontaneous slow vital capacity|Participants will have to perform a slow vital capacity according to the guidelines, from total lung capacity to residual volume
11089396|NCT04150601|Active Comparator|SIMEOX|Participants will have to perform a passive exhalation using the SIMEOX, starting from total lung capacity and going until achieving residual volume
11089397|NCT04150601|Active Comparator|PEP|Participants will have to perform an active exhalation using a PEP device, starting from total lung capacity and going until achieving residual volume
11089398|NCT04150588||Good reaction to Efrin test|
11089399|NCT04150588||Unsatisfied reaction to Efrin test|
11089400|NCT04150575|Experimental|HLX10|HLX10+albumin-bound paclitaxel
11089401|NCT04150562|Experimental|1- Experimental Treatment: Safety Run-in|IL-15 by CIV infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 4 cycles) with avelumab by IV infusion at a dose of 800mg on Day 8 and 22 of each cycle
11089402|NCT04150562|Experimental|2-Experimental Treatment: Doe Expansion|IL-15 by CIV infusion at 4 mcg/kg/day on days 1-5 of each 28- day cycle (max 4 cycles) with avelumab by IV infusion at a dose of 800mg on Day 8 and 22 of each cycle
11089403|NCT04150549|Placebo Comparator|Autologous Transplants|
11089404|NCT04150549|Active Comparator|Allogeneic Transplants|
11089405|NCT04150536|Experimental|Lidocaine Topical System with Moderate Exercise (Treatment A)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. Subjects are instructed to exercise 30 minutes on an exercise bicycle, achieving at heart rate of approximately 108 bpm. Exercise is performed after 2.5 hours, 5.5 hours, and 8.5 hours after topical system application.
11089406|NCT04150536|Experimental|Lidocaine Topical System with Heat Applied (Treatment B)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. A heating pad is applied for 20 minutes at 2.5, 5.5, and 8.5 hours after the product is applied.
11089407|NCT04150536|Experimental|Lidocaine Topical System under normal conditions (Treatment C)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. No heat application or exercise is performed during this period.
11089408|NCT04150510||Online Survey|Individuals who are willing to participate in this online survey
11089409|NCT04150497|Experimental|Dose Escalation|"Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified
~Dose Expansion: UCART22 administered at the MTD"
11089410|NCT04150484|Other|interventional group|dietary intervention, physical exercise and mindfulness
11089411|NCT04150484|No Intervention|control group|Group without any intervention.
11089412|NCT04150458|Experimental|Fluorocholine PET/CT|The sole study-specific procedure is a single 18F-fluorocholine positron emission tomography / computed tomography (PET/CT). Subjects will receive 9 mCi 18F-fluorocholine IV, 5 to 120 minutes prior to PET/CT. 18F-fluorocholine PET/CT studies will be performed on hybrid PET/CT scanners which combine a dedicated, full-ring PET scanner with a multi-slice spiral CT scanner.
11089413|NCT04150445|Experimental|Internet treatment for overweight and obese patients|The intervention is a treatment of overweight and obesity based on cognitive behavioural therapy provided via the Internet. The treatment lasts for six months and comprises 12 treatment modules. The patient works with each module for two weeks. The modules conclude with one or more exercise tasks to be performed before the next module is activated. The patient has written contact with the therapist via the Internet platform.
11089414|NCT04150432|Experimental|propofol|propofol general anesthesia, exhaled measurement of propofol
11089415|NCT04150419|Experimental|G1|
11089416|NCT04150419|Experimental|G2|
11089417|NCT04150419|Active Comparator|G3|
11089418|NCT04150406|Active Comparator|Flexofytol|2 capsules containing 42mg of curcumin will be administered twice a day for a duration of 4 months.
11089419|NCT04150406|Placebo Comparator|Placebo|2 capsules of the placebo, identical in appearance to Flexofytol, will be administeres twice a day for a duration of 4 months.
11089420|NCT04150393|Experimental|MaaT033 treatment|A Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule
11089421|NCT04150380|Experimental|Supplement|8 weeks of dietary augmentation with oral LGG 1.0 x 1010 colony forming units (CFU) once daily (delivered in a size 1 capsule)
11089422|NCT04150380|Placebo Comparator|Placebo|8 weeks of dietary augmentation with placebo once daily (delivered in a size 1 capsule)
11089423|NCT04150367||Study group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
11089424|NCT04150367||Control group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
11089610|NCT04149080|Placebo Comparator|Control Group|Alveolar socket post-extraction covered with polypropylene membrane
11089425|NCT04150354|Experimental|Participants allocated to Cogito Companion|Participants will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators.
11089426|NCT04150341|Experimental|TD-8236 Dose A (low dose)|TD-8236 Dose A (QD x 14 days)
11089427|NCT04150341|Experimental|TD-8236 Dose B (high dose)|TD-8236 Dose B (QD x 14 days)
11089428|NCT04150341|Placebo Comparator|Placebo|Placebo (QD x 14 days)
11089429|NCT04150315||Coronary bypass with DM type 2|
11089430|NCT04150315||Coronary bypass without DM type 2|
11089431|NCT04150276|Active Comparator|ZEEP during awakening|ZEEP will be used during emergence preoxygenation and awakening.
11089432|NCT04150276|Active Comparator|PEEP during awakening|PEEP is maintained throughout emergence preoxygenation and awakening.
11089433|NCT04150263|Other|Traditional IOL repositioning|Intraocular lens (IOL) ab externo scleral suture fixation
11089434|NCT04150263|Other|Modification of traditional IOL repositioning|Modified intraocular lens (IOL) ab externo scleral suture fixation
11089435|NCT04150250|Experimental|iOWH032|Oral iOWH032 500 mg tablets every 8 hours for 3 days
11089436|NCT04150250|Placebo Comparator|Placebo|Oral matching placebo tablets every 8 hours for 3 days
11089437|NCT04150237||Novices|Medical students
11089438|NCT04150237||Intermediates|Endoscopy (EGD) assisting nurses. No prior self-performed endoscopies
11089439|NCT04150237||Experienced|Medical doctors in medical Gastroenterology or surgery, who have self-performed more than 500 EGD
11089440|NCT04150224|Experimental|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
11089441|NCT04150224|Experimental|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
11089442|NCT04150224|Experimental|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
11089443|NCT04150224|Experimental|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
11089444|NCT04150224|Experimental|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
11089445|NCT04150224|Experimental|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
11089446|NCT04150211|Active Comparator|Exten(d)|Subjects have to take Exten(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
11089447|NCT04150211|Placebo Comparator|Placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
11089448|NCT04150198|Experimental|Patients with Alzheimer (<65 years) (AD-Y)|15 patients with a diagnostic of MA-J
11089449|NCT04150198|Experimental|Patients with posterior Cortical Atrophy (PCA)|15 patients with a diagnostic of PCA
11089450|NCT04150198|Active Comparator|Control|15 controls
11089451|NCT04150185||live liver donors|Live liver donors undergoing donor hepatectomy
11089452|NCT04150172|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.
~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
11089453|NCT04150172|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.
~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
11089454|NCT04150159|Experimental|Fasting Mimicking Diet (FMD) Arm|The ProLon® FMD diet is made up of nut bars, dehydrated soups, tea, olives, kale crackers, electrolyte beverages, and a chocolate crisp bar consumed for 5 days every 30 days for 4 months.
11089455|NCT04150159|Active Comparator|Mediterranean Diet Arm|"The Mediterranean diet is based on the traditional foods that people used to eat in countries like Italy and Greece in the 1960s.
~Eat every day: vegetables, fruits, nuts, seeds, legumes, potatoes, whole grains, breads, yogurt, dairy, fish/seafood, herbs, spices and extra virgin olive oil.
~Eat three or fewer servings each week: poultry, eggs, cheese.
~Eat two or fewer servings each week: red meat, potatoes.
~Eat two or fewer servings each week: sweets, sodas, processed meat, refined grains, refined oils and other highly processed foods."
11089456|NCT04150146|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
11089457|NCT04150146|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
11089458|NCT04150133|Active Comparator|Traditional Clear Liquid Arm|Following instructions with FDA-labeled clear liquids
11089459|NCT04150133|Experimental|Low Residue Diet Arm|Following instructions for a low residue diet along with FDA-labeled clear liquids
11089460|NCT04150120|Active Comparator|Reconstructive paediatric surgery (Area I)|The overall incidence of congenital malformations in the gastrointestinal and urinary tract needing surgical interventions is about 1:1000 (Swedish national malformation registers) with a morbidity during childhood about 20-60%. Advanced paediatric surgery for the diagnosis Hirschsprung's disease, anorectal malformations, bladder extrophy, congenital diaphragmal hernia, and esophageal atresia is from July 2018 only performed at two NCSM in Sweden. The NCSM at Skåne University Hospital (SUS) in Lund forms one context. The quality of postoperative care is of immense importance both for short and long-term outcome. Legal guardians describe their situation after leaving the hospital as extremely stressful as they have not only to take responsibility for their new-born child but also of surgical wounds, medications, treatments, and special nutritional needs.
11089611|NCT04149067||Dapagliflozin cohort|Patients diagnosed with type 2 diabetes that started dapagliflozin treatment at least 6 months before the beginning of the study.
11089461|NCT04150120|Active Comparator|Congenital heart disease (Area II)|In Sweden, about 8-10 in 1000 children per year are born with congenital heart disease (CHD). CHD is a birth defect that leads to frequent hospitalisation, long hospital stays, and extreme anxiety for parents (18). In Sweden, paediatric heart surgery is concentrated to two NCSM of which one is situated at SUS, Lund where 250-300 children have cardiac surgery every year. Children with complicated CHD require contact and follow-up visits for a long time after the heart surgery and many families have to travel long for surgery (for example from Iceland), postoperative care and follow-up visits. Telemedicine after reconstructive cardiac surgery in children is shown to be feasible, although challenging and reduced unscheduled visits.
11089462|NCT04150120|Active Comparator|Preterm born (Area III)|Most prematurely born children grow up to be healthy, but as a group, they are at a greater risk of developing cognitive, emotional and behavioural problems. Every year 7% of all children are born prematurely (gestational age of less than 37 weeks) and the numbers of preterm births are rising in Sweden as well as internationally. Preterm births often involve long hospitalisations for children and parents, and discharge from the hospital often means a difficult transition for parents in both short and long-term perspectives. Traditionally, communication with parents following discharge has been through home visits or telephone calls. By communicating through digital technology, it may be possible to improve the support to parents and thereby make the transition from hospital to home less stressful.
11089463|NCT04150120|Active Comparator|Paediatric oncology (Area IV)|For children with cancer, treatment and follow-up at home is common. At the same time, families wish to minimize the negative impact on family members' social and everyday life. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care and regular follow-up in their home with an increased need for education as well as clinical management support. At present, there are no, or limited, professional outreach support to support them and their families. Communication with parents following discharge has been through e-mail and/ or telephone calls. By communicating through digital technology, it may be possible to improve the support to children and parents.
11089464|NCT04150120|Active Comparator|Intravenous infusion therapy at home (Area V)|For children with LTI administration of intravenous infusion therapy at home is an increasingly important area. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care in their home with an increased need for educational as well as clinical management support during home infusion therapy. At present, children and adolescents with LTI at the University Hospital of Copenhagen receive home infusion therapy by a portable pump with no assistance from an outreaching team to support them and their families.
11089465|NCT04150120|Active Comparator|Children with cerebral palsy (VI)|Cerebral palsy (CP) is the most common physical disability in childhood. Approximately 2-2.5/1000 children have CP with affected muscle tone, movement and motor skills, often accompanied by pain, epilepsy and intellectual, communicational and behavioural impairment. Early detection is challenging but important for minimizing the consequences from neurodevelopmental impairment by an early and right treatment. General Movement Assessment (GMA), an observational method for classification of spontaneous movements in young infants, is currently the most accurate method for early identification of CP. Video recordings are taken with a standardised video set-up in the hospitals regular follow-up clinics when the child is 10 to 20 weeks post-term age. Performing video recordings at home by the parents at a time, which suits the family and the child, would optimize the chances for a successful recording.
11089466|NCT04150107|Experimental|Treatment A|Treatment A is 24 mg (16 mg + 8 mg capsules) Once Daily (QD) at Bedtime of ORMD-0801
11089467|NCT04150107|Experimental|Treatment B|Treatment B is 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
11089468|NCT04150094|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training without stimulus.
11089469|NCT04150094|Experimental|Pelvic floor muscle training + intravaginal vibratory stimulus|Pelvic floor muscle training with intravaginal vibratory stimulation.
11089470|NCT04150068|Experimental|Cohort 1A Lenacapavir, Failing ARV Regimen, and OBR|"Functional Monotherapy Period: Participants will receive oral lenacapavir 600 mg, 600mg, and 300 mg tablets on Days 1, 2, and 8 respectively while continuing their failing regimen (previous Antiretroviral (ARV) regimen).
~Maintenance Period: At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive subcutaneous (SC) lenacapavir 927 mg and initiate an optimized background regimen (OBR) (as prescribed by the Investigator). Participants will continue to receive SC lenacapavir 927 mg once every 6 months (26 weeks).
~Participants willing to continue beyond the study beyond Week 52 visit will receive SC lenacapavir every 6 months (26 weeks) starting at Week 52 visit, while continuing their OBR."
11089471|NCT04150068|Placebo Comparator|Cohort 1B: Placebo, Lenacapavir, Failing ARV Regimen, and OBR|"Cohort 1B:
~Functional Monotherapy Period: Participants will receive placebo on Days 1, 2, and 8 while continuing their failing regimen.
~Maintenance Period: At Day 15, participants will receive oral lenacapavir 600 mg and initiate an OBR (as prescribed by the Investigator). Participants will receive oral lenacapavir 600 mg and 300 mg at Day 16 and Day 22, respectively. At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive SC lenacapavir 927 mg while continuing their optimized background regimen. Participants will continue to receive SC lenacapavir 927 mg once every 6 months (26 weeks).
~Participants willing to continue beyond the study beyond Week 52 visit will receive SC lenacapavir every 6 months (26 weeks) starting at Week 52 visit, while continuing their OBR."
11089472|NCT04150068|Experimental|Cohort 2: Lenacapavir and OBR|"Oral Lead-in Period: At Day 1, participants will receive oral lenacapavir 600 mg and initiate an OBR (as prescribed by the Investigator). Participants will receive oral lenacapavir 600 mg and 300 mg at Day 2 and Day 8, respectively, while continuing their OBR.
~Maintenance Period: At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive SC lenacapavir 927 mg once every 6 months (26 weeks).
~Participants willing to continue beyond the study beyond Week 52 visit will receive SC lenacapavir every 6 months (26 weeks) starting at Week 52 visit, while continuing their OBR."
11089507|NCT04149834|Active Comparator|Modified Minimally Invasive Surgical Technique|Comparator: Modified Minimally Invasive Surgical Technique The defect will be gained through the tiny buccal triangular ﬂap: from the buccal 'window' the soft tissue ﬁlling the defect (i.e. the so-called granulation tissue) will be sharply dissected from the papillary supra-crestal connective tissue and from the bony walls with a micro-blade and will be removed with a mini-curette (The soft tissue will be sharply dissected from the osseous defect)
11089473|NCT04150055|Experimental|Intervention|Everyone in the study will get Mindfulness Coach and an orientation session. Mindfulness Coach is a self-guided mHealth intervention designed to help individuals learn MT, an evidence-based treatment to enhance health, wellness and mental health. The intervention will be introduced during 1 in-person session by a trained research assistant with 1-2 booster instructional phone call at 7 and 14-days to ensure that the participant knows how and is encouraged to use the app. The participant will also be provided with a laminated card that provides the basic instructions. We will encourage the participant to use Mindfulness Coach weekly for 8 weeks, or more if desired, as this treatment dose is commensurate with most in-person MT psychotherapy treatment protocols.
11089474|NCT04150042|Experimental|Chemotherapy/stem cell treatment|
11089475|NCT04150029|Experimental|MBG453+Venetoclax +Azacitidine|Patients will receive MBG453 in combination with Venetoclax and Azacitidine
11089476|NCT04150016|Experimental|Firehawk implantation|22 subjects will be enrolled to receive Firehawk™ sirolimus target-eluting stent(s).
11089477|NCT04150016|Active Comparator|XIENCE implantation|22 subjects will be enrolled to receive XIENCE™ everolimus target-eluting stent(s).
11089478|NCT04150003|Experimental|Pulmonary Rehabilitation program|10-weeks structured exercise-based intervention protocol on the restoration of lung blood flow after an acute PE
11089479|NCT04150003|Active Comparator|Usual care|Protocolized usual care for patient suffering PE
11089480|NCT04149990|Active Comparator|Entresto|Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks
11089481|NCT04149990|Placebo Comparator|Placebo|Matching placebo B.I.D. for 26 weeks
11089482|NCT04149977|Experimental|blood flow restriction therapy (pressure cuff)|The cuff will be placed around the upper thigh of the injured leg and set at a pressure that will prevent approximately 80% arterial blood flow. The machine will determine what pressure is required to reach that 80%, when placed on the leg and turned on.
11089483|NCT04149977|Placebo Comparator|blood flow restriction therapy (placebo)|Patients with a placebo pressure will have a pressure setting, 50% lower than the effective setting as stated in the experimental arm
11089484|NCT04149964|Active Comparator|Standard of Care arm|Standard of Care Post-operative pain medication, Acetaminophen 325 mg every 6 hours as needed for pain plus acetaminophen/hydrocodone 7.5 mg/325 mg 1 tab every 4 hours as needed for pain.
11089485|NCT04149964|Experimental|Study Arm|Acetaminophen 650 mg 1 tab every 6 hours round the clock plus Oxycodone 5 mg 1 tab every 6 hours as needed for breakthrough pain,.
11089486|NCT04149951|Experimental|Active|Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
11089487|NCT04149951|Placebo Comparator|Control|Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).
11089488|NCT04149938|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
11089489|NCT04149938|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.
11089490|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
11089491|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
11089492|NCT04149912||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
11089493|NCT04149899|Experimental|Study Treatment 1|WB007 Formulation 1
11089494|NCT04149899|Experimental|Study Treatment 2|WB007 Formulation 2
11089495|NCT04149899|Experimental|Study Treatment 3|WB007 Formulation 3
11089496|NCT04149899|Active Comparator|Timolol 0.5%|Timolol maleate ophthalmic solution, 0.5%
11089497|NCT04149886|Experimental|Ablation group(Ablation+pacemaker)|"The cardioneuroablation will be performed under conscious sedation. After 3-dimensional endocardial surface of the LA and pulmonary veins have been constructed by Ensite system, the GP sites can be located in LA；High frequecy stimulation（HFS）will be used to conform if there is a positive vagal response at each GP site. The upper limits of power and temperature will be set to 30-40 W and 43-60°C, respectively. And if no vagal response been induced during ablation, radiofrequency will be delivered for 30 seconds and stopped in this site. The end point of the ablation procedure will be that no vagal response could be induced by repeat HFS.
~After ablation of GPs, the participants will receive permanent pacemaker implantation(see arm of control group)."
11089498|NCT04149886|Sham Comparator|Control group(only pacemaker)|The control group only treated with permanent pacemaker without cardioneuroablation.The participants will receive permanent pacemaker implantation, the pacemaker placement will be done in accordance with standards at each center. All implanted pacemakers are provided two manufacturers (St. Jude Medical or Medtronics), His bundle pacing will be recommended in patients with a LVEF between 35%-45%. After placement of permanent pacemaker, the participants will be followed-up at 1 week, 3,6,12 months. After the permanent pacemaker implantation, the rate response function should be turned off and low pacing rate should be set at 60bpm uniformly in all the eligible participants.
11089499|NCT04149873|Placebo Comparator|Control group|Control group' has the treatment with [Physical chest care ]
11089500|NCT04149873|Placebo Comparator|Experimental group-A|'Experimental group-A' has the treatment with [Mechanical-Insufflation- Exsufflation]
11089501|NCT04149873|Experimental|Experimental group-B|'Experimental group-B' has the treatment with [Mechanical-Insufflation- Exsufflation] and [Physical chest care]
11089502|NCT04149860|Experimental|Part A|Cohorts A1-A5, 8 healthy subjects per cohort. Dose levels 1 - 5
11089503|NCT04149860|Experimental|Part B|Cohorts B1-B3, 8 healthy Japanese and Chinese subjects per cohort. Dose levels 3 - 5
11089504|NCT04149860|Experimental|Part C|Cohorts C1-C4, 8 subjects with Alzheimer's disease per cohort. Dose levels 3 - 6
11089505|NCT04149847|Experimental|Nylon darn repair|a nylon #1 suture to be used to reconstruct the posterior inguinal wall
11089506|NCT04149847|Experimental|polypropylene mesh repair|a commercially available 7.5cm x 15cm sheet of polypropylene mesh to be trimmed to fit the posterior inguinal wall
11089508|NCT04149834|Other|Non- incised papilla surgical approach|intervention: Non- incised papilla surgical approach Apical horizontal incision on the buccal mucosa, as far as possible from the interdental papillae and marginal KT will be performed. Soft tissue will be reflected apico-coronally by a full-thickness flap showing the granulation tissue filling the bony defect after exposing the coronal limit of the intra-bony component of the defect, while the marginal tissue will be kept unaltered.
11089509|NCT04149821|Experimental|Cohort A Post BTKi Therapy|Patients who progress after a BTKi containing regimen
11089510|NCT04149821|Experimental|Cohort B Post BCL-2 Therapy|"Patients who progress after BCL-2 containing regimens
~Patients who progress on a regimen containing both a BTKi and a BCL-2 inhibitor"
11089511|NCT04149808|Active Comparator|Xeroform Control|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with xeroform dressing, which is the standard of care.
11089512|NCT04149808|Experimental|Mepilex Ag Intervention|A single wound is treated with both the control (xeroform dressing) and intervention (Mepilex Ag). Approximately 50% of the wound is treated with Mepilex Ag; the product being tested.
11089513|NCT04149795||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
11089514|NCT04149782||Patients enrolled in differentiated service delivery models|
11089515|NCT04149782||Patients not enrolled in DSD models|
11089516|NCT04149769|Other|Interventional|Walking in an exoskeleton within the home and community.
11089517|NCT04149756||overweight or obese adults|overweight or obese adults who participate the trial (NCT03675191)
11089518|NCT04149743|No Intervention|Randomized Standard of Care|Standard of Care
11089519|NCT04149743|Active Comparator|Randomized Standard of Care with HEMOTAG|Standard of Care with HEMOTAG
11089520|NCT04149730||Patients with primary PEA.|Patients at St. Olavs hospital who suffer cardiac arrest and pulseless electrical activity (PEA) as primary rhythm during 2018-2021. 120 episodes from St. Olavs hospital were collected previously (2010-2013). In addition 200 cases will be available from the hospital of The University of Pennsylvania, Philadelphia, USA.
11089521|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution A and Exercise|"Subject baseline HR, BP, EKG recorded.
~Subject will ingest sucrose (150g):
~30 min later, subject will exercise on a treadmill
~Subjects will return each week to repeat the above procedures with a different test solution."
11089522|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution B and Exercise|"Subject baseline HR, BP, ECG recorded.
~Subject will ingest sucrose (150g); caffeine (400 mg)
~30 min later, subject will exercise on a treadmill
~Subjects will return each week to repeat the above procedures with a different test solution."
11089523|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C and Exercise|"Subject baseline HR, BP, ECG recorded.
~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)
~30 min later, subject will exercise on a treadmill"
11089524|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C|"Subject baseline HR, BP, ECG recorded.
~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)"
11089525|NCT04149704|Experimental|ACP video decision aid|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.
~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care
~10 minute video decision aid: describing the goals-of-care options .
~Follow telephone interview at 3 months"
11089526|NCT04149704|Active Comparator|Standard Care|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.
~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care
~Receive the verbal description of the three types of care
~Follow telephone interview at 3 months"
11089527|NCT04149691|Experimental|CPL304110|CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.
11089528|NCT04149678|Experimental|Treatment Group A - Ozanimod|Subjects will receive a single oral dose of ozanimod 0.46 mg
11089529|NCT04149678|Experimental|Treatment Group B - Ozanimod plus Cyclosporine|Subjects will receive a single oral dose of ozanimod 0.46 mg plus a single oral dose of cyclosporine 600 mg
11089530|NCT04149652|Other|Patients with COPD or fibrosis|Subjects, enrolled on either an inpatient or outpatient basis, with stable COPD or fibrosis documented by anamnestic, imaging and functional tests. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
11089531|NCT04149652|Other|Smokers with no signs of COPD|Subjects with an active smoking habit or a personal history of hard smoking dating back to maximum 5 years before, without clinical and functional signs of COPD. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
11089532|NCT04149652|Other|Healthy non-smoking volunteers|Healthy volunteers who have never smoked and who have no clinical or functional sign of COPD or other respiratory diseases. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
11089533|NCT04149639|Experimental|NeuroQ|Directions: take 2 capsules at the same time daily
11089534|NCT04149626|Active Comparator|Group A|Dexmedetomidine sedation
11089535|NCT04149626|Active Comparator|Group B|Midazolam sedation
11089536|NCT04149626|Active Comparator|Group C|Remifentanil sedation
11089537|NCT04149613||Colorectal Cancer Patients|Newly diagnosed stage IV colorectal cancer patients
11089538|NCT04149613||Controls|cancer free
11089539|NCT04149600||Bicuspid aortic valve|We wish to investigate the etiology of calcific aortic valve disease, and aortic dilation or aneurysm in patients with a bicuspid aortic valve undergoing aortic valve replacement or aortic surgery.
11089540|NCT04149600||Tricuspid aortic valve|Data and samples will be compared using a control group comprised of patients with a tricuspid aortic valve undergoing aortic surgery.
11089541|NCT04149587||Brodalumab 210 mg Q2W|Participants will receive brodalumab 210 milligrams (mg) administered as 1 subcutaneous injection at Day 1 and at Weeks 1 and 2 followed by 210 mg every 2 weeks (Q2W) thereafter until Week 26.
11089542|NCT04149574|Experimental|Arm A: nivolumab|
11089543|NCT04149574|Placebo Comparator|Arm B: placebo +BCG|
11089605|NCT04149119|No Intervention|Standard arm or arm 2|LLINs+Standard Care for MalarIA case management
11089544|NCT04149561||Cerebral Palsy|100 patients over 2 years of age with a diagnosis of cerebral palsy will be included in the study. Demographic information form prepared for the study in terms of demographic information such as age, gender, clinical type of cerebral palsy, drugs used, comorbid diseases will be completed. Communication Function Classification System and Functional Communication Classification System will be used to evaluate patients' communication skills. In addition, patients; The Gross Motor Function Classification System for cerebral palsy and based on child-initiated movements with emphasis on sitting, displacement and mobility, and to hold objects during the daily activities of children with cerebral palsy. The Manual Ability Classification System, which classifies how they use their hands, will also be completed.
11089545|NCT04149548||pregnant diabetic women|Fetal Ultrasound to diabetic pregnant women
11089546|NCT04149548||non diabetic pregnant women|Fetal ultrasound to non diabetic pregnant women
11089547|NCT04149535|Experimental|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
11089548|NCT04149535|No Intervention|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
11089549|NCT04149522|Active Comparator|Medial Breast Tissue|Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
11089550|NCT04149522|Active Comparator|Lateral Breast Tissue|Women assigned to the lateral breast tissue arm will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the lateral breast tissue only, by trained staff on day 1 of radiotherapy. The in-field ipsilateral axilla will be included with lateral breast segment to extent necessary to cover breast or chest wall only. The skin is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to skin and paper frame is removed. Multiple sheets of non-overlapping film will be used to cover the treatment area. During course of therapy, new film may be applied as often as necessary, by trained staff if film no longer adheres to skin or comes off. If there are signs of infection (e.g. redness, feeling warm or swollen), the film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or trained staff.
11089551|NCT04149509||Exposed|Infants born ≥ 37 weeks gestation with second or third trimester opioid exposure as determined by maternal urine toxicology screen at delivery; maternal history; and/or infant urine, meconium, or umbilical cord toxicology screen.
11089552|NCT04149509||Unexposed - Controls|Infants born ≥ 37 weeks gestation with no antenatal drug exposure as determined by maternal urine toxicology screen at delivery and maternal history. We will match control infants to exposed infants based on birth hospital and birth month, recruiting 1 control for every other exposed infant at each site.
11089553|NCT04149496|Experimental|All|Patients requiring IVF treatment with PCOS or a PCO pattern in their ovaries who wish to undertake IVM (as a variant of their IVF procedure)
11089554|NCT04149483|Experimental|Atorvastatin|Atorvastatin tablets, 20mg once a day, for six months.
11089555|NCT04149483|Placebo Comparator|Placebo|Same color and size coated tablet, 20mg once a day, for six months.
11089556|NCT04149470|Experimental|Omeprazole|Participants will receive high dose PPI therapy (Omeprazole 20mg twice daily) and will be evaluated for histological improvement.
11089557|NCT04149457|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
11089558|NCT04149457|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
11089559|NCT04149444|Experimental|ARM 1|"Dose escalation cohort - First 10 patients enrolled on study.
~Trifluridine/Tipiracil 30mg/m2 - to start, if no significant dose limiting side effects the dose will be increased to 35mg/m2 for the duration of the trial.
~After first 10 patients enrolled on study - Trifluridine/Tipiracil 35mg/m2
~Each cycle is 28 days. Two doses per day during days 1-5 with a two day rest for days 6 and 7. Then two doses per day for days 8-12, followed by a rest period for days 13-28 with the next cycle starting the day after day 28."
11089560|NCT04149431|Active Comparator|Derinat|nasal drops
11089561|NCT04149431|Placebo Comparator|Placebo|nasal drops
11089562|NCT04149418|Experimental|Yogurt-Control|Consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks, followed by a washout phase for 4 weeks, then consumption of 12 oz. control food (flavored soy pudding, 2 x 6 oz. servings) for 4 weeks.
11089563|NCT04149418|Experimental|Control-Yogurt|Consumption of control food (flavored soy pudding, 2 x 6 oz. servings), followed by a washout phase for 4 weeks, then consumption of 12 oz. of low-fat yogurt daily (2 x 6 oz. servings) for 4 weeks.
11089564|NCT04149405|Active Comparator|Group A|scaling and root planning, bisphosphonate therapy (zoledronic acid)
11089565|NCT04149405|Active Comparator|Group B|scaling and root planning, no bisphosphonate therapy
11089566|NCT04149405|Active Comparator|Group C|scaling and root planning and bisphosphonate therapy (zoledronic acid)
11089567|NCT04149405|Active Comparator|Group D|no scaling and root planning no bisphosphonate therapy
11089606|NCT04149106|Active Comparator|Standard|The Mali National Malaria Control program has initiated SMC for children less than 5 years since 2016 (countrywide) with SPAQ. This standard care will not change in this arm
11089607|NCT04149106|Active Comparator|SMC with SPAQ extended to older children|Within this arm, SMC with SPAQ will be extended to children 5-9 years old
11089608|NCT04149106|Active Comparator|SMC with DHAPQ|Children less than 10 years within this arm will received Dihydroartemisin piperaquin for SMC instead of SPAQ
11089609|NCT04149080|Experimental|SIM Group|Alveolar socket post-extraction filled with Simvastatin covered with polypropylene membrane
11089568|NCT04149392|Experimental|CGM intervention|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge which will be downloaded at their outpatient follow up clinic visit 6-14 days later. At the follow-up visit medications may be modified based on downloaded glucose data. During the already scheduled post-discharge follow up appointment the CGM sensor data will be downloaded by clinic staff. The diabetes medications will be reconciled and the downloaded data will be reviewed with the patient. Based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
11089569|NCT04149379|Experimental|Treatment group|One group of 6 patients undergoing 20 sessions of hyperbaric therapy at table 14/90.
11089570|NCT04149366||group 1 (Wrapround retainer)|
11089571|NCT04149366||Group 2 (Essix retainer 1mm)|
11089572|NCT04149366||Group 3 (Essix retainer 1.5 mm)|
11089573|NCT04149366||Group 3 (Essix retainer 2mm)|
11089574|NCT04149353|Experimental|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
11089575|NCT04149340|Other|Sufentanil sedation|3 microgram of Sufentanil IV
11089576|NCT04149340|Placebo Comparator|Placebo sedation|1 ml de NaCl 0,9%
11089577|NCT04149340|Other|Multimodal sedation|Clonidine, sufantil, midazolam, dihydrobenzperidol, ketamine
11089578|NCT04149327|Experimental|Antibiotics group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days plus a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
11089579|NCT04149327|Active Comparator|Control group|Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned. At the end of the final treatment session, the dental hygienist will give the patients an envelop containing a recipe for 500 ml mouthrinse (0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol, Perio-Aid®). After the final session patients will rinse their mouth using that mouthrinse twice daily during 30 seconds for 2 weeks.
11089580|NCT04149314|Active Comparator|Interventional|Interventional group (hemodynamic optimization based on HPI).
11089581|NCT04149314|No Intervention|Control|Control group (blinded HPI monitoring, standard anesthesia care).
11089582|NCT04149301||Typically developing children|Children who do not have a problem with their walking ie children who do not have cerebral palsy
11089583|NCT04149301||Children with cerebral palsy without foot deformity|
11089584|NCT04149301||Children with cerebral palsy with mild foot deformity|
11089585|NCT04149301||Children with cerebral palsy with severe foot deformity|
11089586|NCT04149288|Active Comparator|High-polyphenol olive oil|Participants will consume 40 mL of high-polyphenol olive oil each day at home for 2 weeks.
11089587|NCT04149288|Active Comparator|Low-polyphenol olive oil|Participants will consume 40 mL of low-polyphenol olive oil each day at home for 2 weeks.
11089588|NCT04149275|Experimental|Cabozantinib + Nivolumab + Ipilimumab|All recurrent carcinosarcomas
11089589|NCT04149262|Active Comparator|Fiasp/Novorapid|4 weeks on Fiasp® then crossover to 4 weeks on NovoRapid® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
11089590|NCT04149262|Active Comparator|Novorapid/Fiasp|4 weeks on NovoRapid® then crossover to 4 weeks on Fiasp® in subjects on the MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
11089591|NCT04149249|Experimental|Experimental: Intervention Group (CONNECT)|Patients complete CONNECT, the Video Doctor over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
11089592|NCT04149249|Active Comparator|Control Group|"Patients complete CONNECT assessment only over 30-45 minutes on an iPad in the waiting room before their lung cancer screening test appointment.
~Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources."
11089593|NCT04149223|No Intervention|Control|Current practice at baseline, routine cirrhosis care.
11089594|NCT04149223|Experimental|Intervention|Use of a standardized cirrhosis order set.
11089595|NCT04149223|Active Comparator|Intervention + EMR|Use of a standardized cirrhosis order set embedded within an electronic medical record.
11089596|NCT04149210|Experimental|fluorometholone|Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks
11089597|NCT04149210|Placebo Comparator|Artificial Tears|one drop two times daily for four weeks
11089598|NCT04149171|Experimental|conventional treatment|red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC)
11089599|NCT04149171|Active Comparator|conventional treatment added to Crystalloids and TXA|administration of Crystalloids and TXA
11089600|NCT04149158|Placebo Comparator|Placebo|
11089601|NCT04149158|Experimental|Verum|Sinetrol® Xpur
11089602|NCT04149145|Experimental|M4344+Niraparib|all PARP resistant, recurrent ovarian cancer
11089603|NCT04149132||Patients without sepsis|Patients admitted and hospitalized for infections without sepsis and for other reasons in departments of Internal Medicine and Intensive Care Units
11089604|NCT04149119|Experimental|Intervention arm|ATSB+LLINs+Standard Care for Malaria case management
11089612|NCT04149067||Sitagliptin cohort|Patients diagnosed with type 2 diabetes that started sitagliptin treatment at least 6 months before the beginning of the study.
11089613|NCT04149028|Experimental|PRP injection|injection of PRP inside ovary by the assistance of laparoscopy
11089614|NCT04149015|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles
11089615|NCT04149002|Other|Intervention Arm: Weekly IP3 text messages|"A narrated powerpoint presentation describing the logistical details and medical rationale for components of the IP3. Participants will view the chapters of the presentation that are relevant to their specific IP3. There are a total of 4 possible chapters (lifestyle modifications, cervix length screening/cerclage, progesterone therapy, low dose aspirin). Each chapter of the presentation is ~ 10 - 15 min in length. Each chapter also includes a 4- 5 questions pre-test and the same questions are delivered as a post-test after the presentation.
~Print materials including a letter explaining the importance of prenatal care for preterm birth prevention to employers.
~Text messages sent weekly to encourage the patient to continue with their IP3 and provide basic pregnancy information
~Formal letter of encouragement from provider at 28 weeks gestation"
11089616|NCT04149002|Active Comparator|Control Arm: General pregnancy text messages|"a pre-intervention questionnaire
~a narrated powerpoint with general information about the clinic
~a post-presentation questionnaire
~text messages sent approximately weekly with general pregnancy information (e.g. today your baby is about the size of an apple)
~an exit interview"
11089617|NCT04148989|No Intervention|Pre-implementation usual care (intervention site)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
11089618|NCT04148989|Experimental|Code Sepsis post-implementation (intervention site)|Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
11089619|NCT04148989|No Intervention|Pre-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
11089620|NCT04148989|No Intervention|Post-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
11089621|NCT04148976|Placebo Comparator|Placebo (P)|The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
11089622|NCT04148976|Experimental|Dietary Portfolio (DP)|The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
11089623|NCT04148963|Experimental|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
11089624|NCT04148963|Placebo Comparator|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
11089625|NCT04148950|Experimental|Kinesio Taping|Kinesio Taping group consisted of 29 patients with CVD. Kinesio Taping was applied once a week for a period of 4 weeks. Closed Fan and Closed Basketweave techniques were applied according to the clinical manifestations, intensity of symptoms, and the needs for the areas to be taped. Basketweave technique was used generally for the thigh, and the areas rich in lymph nodes while closed fan technique was used for cruris, and regions of less severe venous reflux or obstruction. Kinesio Taping was slowly removed by the patient 4 days after the application to prevent any allergic reactions. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
11089626|NCT04148950|Active Comparator|Compression Stockings|Compression stockings group consisted of 29 patients with CVD. Patients were recommended medium pressure (23-32 mmHg) compression stockings by the physician. Knee high or thigh high compression stockings were given according to the level of symptoms and signs. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
11089627|NCT04148937|Experimental|Cohort A LY3475070|LY3475070 administered orally.
11089628|NCT04148937|Experimental|Cohort B LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered intravenously (IV).
11089629|NCT04148937|Experimental|Cohort C1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
11089630|NCT04148937|Experimental|Cohort C2 LY3475070|LY3475070 administered orally.
11089631|NCT04148937|Experimental|Cohort D1 LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
11089632|NCT04148937|Experimental|Cohort D2 LY3475070|LY3475070 administered orally.
11089633|NCT04148937|Experimental|Cohort E LY3475070 + Pembrolizumab|LY3475070 administered orally and pembrolizumab administered IV.
11089634|NCT04148924||Patients|Anyone who is hospitalized in the palliative care service of the Lyon Sud Hospital Center.
11089635|NCT04148924||Doctors|Doctors taking care of patients in the study will be solicited by the research nurse or a study investigator.
11089636|NCT04148924||Nurses|Nurses taking care of patients in the study will be solicited by the research nurse or a study investigator.
11089637|NCT04148924||Caregivers|Caregivers taking care of patients in the study will be solicited by the research nurse or a study investigator.
11089638|NCT04148911|Experimental|Atezolizumab plus Nab-Paclitaxel or Paclitaxel|Participants will receive Atezolizumab via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle in combination with Nab-Paclitaxel or Paclitaxel on Days 1, 8, and 15 (individually selected by the investigator) until disease progression, or unacceptable toxicity, additionally until loss of clinical benefit as determined by the investigator or participant decision to discontinue treatment.
11089639|NCT04148898|Experimental|osimertinb group|Osimertinib 80 mg oral daily
11089640|NCT04148898|Experimental|osimertinb combined with bevacizumab group|"Osimertinib 80 mg oral daily;
~.bevacizumab 7.5 mg/kg intravenous every 3 weeks"
11089641|NCT04148885|Experimental|nab-paclitaxel + Carboplatin|nab-paclitaxel at 260 mg/m^2 on days 1; Carboplatin AUG=5, d1, 21 days in one cycle, 3 cycles in total
11089642|NCT04148872|Active Comparator|Neuromuscular Retraining Therapy|Neuromuscular retraining therapy alone for four months, with botulinum toxin injection added during an additional four month period.
11089643|NCT04148872|Active Comparator|Chemodenervation|Ipsilateral chemodenervation with botulinum toxin injections alone for four months (onabotulinumtoxinA/Botox, Allergan or incobotulinumtoxinA/Xeomin, Merz), with neuromuscular retraining therapy added for an additional four months.
11089644|NCT04148859|Experimental|pregnant women|women who have to undergo amnioreduction due to TTTS
11089645|NCT04148846|Active Comparator|Clinical treatment - old protocol|In group I, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache.
11089646|NCT04148846|Active Comparator|Clinical treatment - new protocol|In group II, patients will receive clinical treatment, according to the new protocol of the institution.
11089647|NCT04148846|Experimental|Sphenopalatine block|In group III patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block.
11089648|NCT04148833|Experimental|LDE-Paclitaxel|Paclitaxel carried by a lipid nanoparticle (LDE-Paclitaxel)
11089649|NCT04148833|Placebo Comparator|LDE-Placebo|Lipid nanoparticle (LDE)
11089650|NCT04148820|Experimental|Once daily drug administration|Patients will be given cardiovascular drugs once daily
11089651|NCT04148820|Experimental|Twice daily drug administration|Patients will be given cardiovascular drugs twice daily
11089652|NCT04148807|Experimental|Intervention|Participant will receive 8 gait-retraining intervention sessions.
11089653|NCT04148807|Active Comparator|Control|Participant receives 8 sessions of a graded walking program.
11089654|NCT04148794|Experimental|Intervention group|Participants who join the class of eALS
11089655|NCT04148781|Experimental|Fampridine-SR|Fampridine-SR 10 mg Orally Twice Daily for 8 weeks.
11089656|NCT04148768|Active Comparator|Inferential therapy|Interferential therapy will be given using 4 electrode methods. The 'medium frequency' currents (medium frequency in electromedical terms is usually considered to be 1KHz-100KHz). These medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross & they literally interfere with each other. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation. Pre-Post Y balance test will be used after 4 sessions to measure the improvement in balance in the population
11089657|NCT04148768|Active Comparator|Shortwave diathermy|4 sessions of treatment will be given to the participants with SWD. Pre-post Y balance test will be used to measure balance in the population
11089658|NCT04148755||Elastography guided FNA|Those patients are going to have EUS elastography guided FNA
11089659|NCT04148755||EUS. FNA|From records we are going to compare them with patients who had EUS without elastography guided FNA
11089660|NCT04148742|Experimental|daily dose of DZD9008|daily dose of DZD9008
11089661|NCT04148729|Active Comparator|bupivacaine+lidocaine|15 ml bupivacaine+ 5 ml lidocaine will use for USG guided ESP block under general anaesthesia with Sevuflurane and remifentanil. This block will perform at the T10 level bilaterally after induction of anaesthesia at the prone position. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with 11-point numerical rating scale. If the score over 4 points, rescue analgesic 0.4 mg/kg meperidine will be apply intravenously.
11089662|NCT04148729|Sham Comparator|saline|In this group, the same volume saline will apply to the block region. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with 11-point numerical rating scale. If the score over 4 points, rescue analgesic 0.4 mg/kg meperidine will be apply intravenously.
11089663|NCT04148716||patients|recruitement of 9 patients
11089664|NCT04148716||control|recruitement of 9 control person
11089665|NCT04148703|Experimental|Active group|in-office follow-up at 30 days post-implantation and after by remote monitoring (daily) without scheduled in-office follow-up during the study period (48 months). A remote FU will be planned every 9 months.
11089666|NCT04148703|Active Comparator|Control group|The patients randomized in the control group will be followed accordingto the guidelines; i.e. with an in-office follow-up at 30 days post-implantation and after followed with in-office follow-ups according to clinical practice.
11089667|NCT04148690|Experimental|Group ANC Intervention|Clinics in the group ANC intervention arm offer group Antenatal Care to women who present for their initial visit prior to 24 weeks provided that they intend to remain in the area for the duration of the pregnancy, and agree to participate in GANC. Women not enrolled in group ANC will receive standard ANC per ministry of health protocols.
11089668|NCT04148690|Active Comparator|Routine ANC|Clinics will offer only standard ANC per ministry of health protocols.
11089669|NCT04148677||Protoves M1® syrup|A combination of two alkaloid, Protopine and Nuciferine
11089670|NCT04148677||No treatment|Patients will not receive a treatment
11089671|NCT04148664|Active Comparator|Standard Catheter Settings|Group 1 - Standard RF ablation settings
11089672|NCT04148664|Experimental|High Power Short Duration (HPSD)|Group 2 - High power short duration RF
11089673|NCT04148651|Experimental|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
11089674|NCT04148625||atrial fibrillation, persistent|Subjects with documented symptomatic persistent or longstanding persistent AF (> than 3 months and < 3 years continuous AF duration) who has failed a previous PVI catheter ablation procedure and/or needs LAA exclusion; and catheter ablation or minimally surgical approach is planned.
11089675|NCT04148612|Experimental|Opti-Me|Patients in this group will be treated based on the Opti-Me algorithm recommended treatment.
11089676|NCT04148612|No Intervention|Randomization|Patients in this group will be treated by random assignment of treatment.
11089763|NCT04147949|Experimental|AV-101|1440 mg of L-4-chlorokynurenine administered twice a day orally
11089677|NCT04148599|Active Comparator|dexmedetomidine|dexmedetomidine ( precedex) infusion will be administered preoperatively and continued intraoperatively
11089678|NCT04148599|Active Comparator|lidocaine|Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively
11089679|NCT04148599|Placebo Comparator|placebo|saline infusion will be administered preoperatively and continued intraoperatively
11089680|NCT04148586|Experimental|One week Whole Breast Irradiation|WBI: 27 Gy/5 fractions/1 week. 5.4 Gy /fraction ± boost to tumor bed 5.4 Gy/ 1 fraction, 2 days after the end of WBI.
11089681|NCT04148586|Experimental|Once weekly Whole Breast Irradiation|WBI: 28.5 Gy/ 5 fractions/ 5 weeks. 5.7 Gy/fraction ± boost to tumor bed 5.7 Gy/ 1 fraction, one week after the end of WBI. WBI is given on the same day each week.
11089682|NCT04148586|Active Comparator|3 weeks Whole Breast Irradiation|WBI: 40.05 Gy/ 15 fractions/ 3 weeks. 2.67 Gy/ fraction ± boost to tumor bed 10 Gy/ 4 fraction / 4 days after the end of WBI
11089683|NCT04148573|Active Comparator|Arm NFX88 - 1|1.05 g/day NFX88
11089684|NCT04148573|Active Comparator|Arm NFX88 - 2|2.10 g/day NFX88
11089685|NCT04148573|Active Comparator|Arm NFX88 - 3|4.20 g/day NFX88
11089686|NCT04148573|Placebo Comparator|Arm PLACEBO - 4|Placebo
11089687|NCT04148560|Other|Study sample|Individuals who participate in this validation study
11089688|NCT04148547|Experimental|transcranial direct current stimulation|
11089689|NCT04148547|Placebo Comparator|Sham transcranial direct current stimulation|
11089690|NCT04148534|Active Comparator|muscle relaxant|Facial motor evoked potential monitoring in patient who will receive muscle relaxant, patients will receive rocronium infusion by (5mcg/kg/min) , twenty minutes after induction. maintain partial NMB TOF count 2 and targeting BIS = (40-60)
11089691|NCT04148534|Placebo Comparator|without muscle relaxant|Facial motor evoked potential monitoring in patient who will not receive muscle relaxant, targeting BIS = 25-35 after ending of monitoring of neurophysiology propofol dose will be dropped to 4-6 mg\kg\hr. targeting Bispecteral index 40- 60.
11089692|NCT04148521|Experimental|Behavioral Health - Virtual Patient Navigation|All patients who meet eligibility criteria at sites where the virtual patient navigation behavioral health program is offered will be considered exposed to the intervention.
11089693|NCT04148521|No Intervention|Usual care Behavioral Health|All patients who meet eligibility criteria at sites where the virtual patient navigator behavioral health program is not offered will be considered exposed to usual care.
11089694|NCT04148508|Experimental|Tailored Emotional Competence|Self-help Tailored Emotional Competence delivered via mobile app
11089695|NCT04148508|Active Comparator|Cognitive-behavioural Approach|Self-help cognitive-behavioural approach delivered via mobile app
11089696|NCT04148508|Placebo Comparator|Self-monitoring|Self-help self-monitoring delivered via mobile app
11089697|NCT04148495|Experimental|Treatment group|Morphine IV and the placebo of acetaminophen IV.
11089698|NCT04148495|Active Comparator|Control group|Morphine IV and acetaminophen IV
11089699|NCT04148482|Active Comparator|Genotype of interest group|Individuals with desired genetic susceptibility will receive a standardized and an election meal in a full-day clinic visit.
11089700|NCT04148482|Placebo Comparator|Control|Individuals without genotype of interest (i.e., carrying the opposite genotype) will receive a standardized and an election meal in a full-day clinic visit.
11089701|NCT04148469|Experimental|dry needling and TENS|A dry needling treatment was performed on trapezius trigger point number 2, and just after thar, a TENS curretn was applied. Patients will be reassed on fourth day after treatment.
11089702|NCT04148469|Placebo Comparator|Placebo|A placebo dry needling was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
11089703|NCT04148469|Experimental|dry needling|A dry needling treatment was performed on trapezius trigger point number 2. Patients will be reassed on fourth day after treatment.
11089704|NCT04148456|Other|Aortoiliac occlusive disease|This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
11089705|NCT04148443|Experimental|3 minutes period of preoxygenation|3 minutes of preoxygenation : participants in this group will receive 3 minutes of preoxygenation before intubation
11089706|NCT04148443|Experimental|5 minutes period of preoxygenation|5 minutes of preoxygenation: participants in this group will receive 5 minutes of preoxygenation before intubation
11089707|NCT04148430|Experimental|Arm 1 (CART Cell Group)|"Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.
~Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days"
11089708|NCT04148430|Experimental|Arm 2 (COVID-19 Group)|Patients will receive anakinra 100mg IV q6h for 7 days.
11089709|NCT04148417|Experimental|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
11089710|NCT04148404|Active Comparator|Group NT|1.Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).
11089711|NCT04148404|Active Comparator|Group HT|2.Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP).
11089712|NCT04148391|Placebo Comparator|Placebo|Matching placebo Capsules
11089713|NCT04148391|Experimental|NYX-458 10 mg|Single oral dose taken daily for 12 weeks.
11089714|NCT04148391|Experimental|NYX-458 30 mg|Single oral dose taken daily for 12 weeks.
11089715|NCT04148391|Experimental|NYX-458 100 mg|Single oral dose taken daily for 12 weeks.
11089716|NCT04148378||Patients|Patients who have been diagnosed with colorectal cancer.
11089717|NCT04148365||Paediatric Uveitis|Patients with Uveitis below the age of 18 years.
11089718|NCT04148352|Experimental|Dupilumab|24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab
11089764|NCT04147949|Placebo Comparator|Placebo|Matching capsules of placebo
11089765|NCT04147936|Active Comparator|AXA1665 29.4g|Dietary Supplement: AXA1665 Amino acids, food study
11089719|NCT04148352|Placebo Comparator|Placebo|24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo
11089720|NCT04148339||Patients|Patients with Elevated Cholesterol
11089721|NCT04148326||Patients|Patients who have been diagnosed with Parkinson's Disease
11089722|NCT04148313||Patients|Patients with diagnosis of Multiple Sclerosis.
11089723|NCT04148287|Experimental|APX001|APX001 IV or oral for up to 42 days
11089724|NCT04148274||Patients|Patients with Ulcerative Colitis diagnosis
11089725|NCT04148261|Active Comparator|Healthy Arm, CORT + EPI, then PLB + EPI|Healthy participant will receive cortisol pill and epinephrine infusion
11089726|NCT04148261|Active Comparator|Healthy Arm, PLB + EPI, then CORT + EPI|Healthy participant will receive placebo pill and epinephrine infusion
11089727|NCT04148261|Experimental|Depression Arm, CORT + EPI, then PLB + EPI|Depressed participant will receive cortisol pill and epinephrine infusion
11089728|NCT04148261|Experimental|Depression Arm, PLB + EPI, then CORT + EPI|Depressed participant will receive placebo pill and epinephrine infusion
11089729|NCT04148248||Patients|Patients with a diagnosis of chronic constipation
11089730|NCT04148235||Patients|Patients who have been diagnosed with Celiac Disease
11089731|NCT04148222||Patients|Patients who have been diagnosed with Lyme Disease
11089732|NCT04148209|Experimental|Treatment|Participants receiving PF-07081532
11089733|NCT04148209|Placebo Comparator|Placebo|Participants receiving Placebo
11089734|NCT04148196|No Intervention|Control group|older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.
11089735|NCT04148196|Experimental|Experimental group|Intervention group: older people's who have a Standard Mini Mental Test score of 23 and above, living in nursing homes.The researcher will perform 16 sessions of progressive relaxation exercises combined with music twice a week for 8 weeks. Each PMR exercise combined with music was conducted under the guidance of the researcher. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate and blood pressure.
11089736|NCT04148183|Experimental|Metformin Group|Metformin (850 mg/day) treatment was administered for 8 weeks
11089737|NCT04148183|Experimental|Rosiglitazone Group|Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
11089738|NCT04148183|Placebo Comparator|Placebo Group|Placebo treatment was administered for 8 weeks
11089739|NCT04148170|Active Comparator|classic intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.
11089740|NCT04148170|Active Comparator|endodiathermy probe|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
11089741|NCT04148144||Adolescents with low back pain|Adolescents aged 8-19 with low back pain.
11089742|NCT04148144||Parents of included adolescents|Parents recruited for the parallel cohort, are required to be a parent or a legal guardian of the included adolescent. Siblings, grandparents or a similar person are not eligible for inclusion in the parallel cohort.
11089743|NCT04148131||Group 1, 0-5 months old|Children which is Obstetric brachial plexus palsy and 0-5 months old age have Naracas type 2 lesion.
11089744|NCT04148131||Group 2, 6-24 months old|Children which is Obstetric brachial plexus palsy and 6-24 months old age have Naracas type 2 lesion.
11089745|NCT04148131||Group 3, 25-36 months old|Children which is Obstetric brachial plexus palsy and 25-36 months old age have Naracas type 2 lesion.
11089746|NCT04148118|Experimental|NE+50µg rPA - sprayer|
11089747|NCT04148118|Experimental|NE+50µg rPA - pipette|
11089748|NCT04148118|Experimental|NE+100µg rPA - sprayer|
11089749|NCT04148118|Experimental|NE+100µg rPA - pipette|
11089750|NCT04148118|Placebo Comparator|Saline - sprayer|
11089751|NCT04148118|Placebo Comparator|Saline - pipette|
11089752|NCT04148118|Active Comparator|BioThrax - SC|
11089753|NCT04148105|Placebo Comparator|Placebo|Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
11089754|NCT04148105|Experimental|Experimental|Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.
11089755|NCT04148066|Other|Osimertinib and Crizotinib|"Osimertinib will be administered according to label: 80 mg once daily.
~Crizotinib will only be prescribed upon detection of MET amplification using ctDNA. Crizotinib will be administered according to label: 250 mg bi-daily."
11089756|NCT04148053||Active TB|"Subjects met the following:
~Either Pulmonary or Extra-pulmonary tuberculosis patients
~TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen."
11089757|NCT04148053||Latent TB|"Subjects met the following:
~TB Contact in history.
~Chest X-ray suggestive of non-TB.
~without any symptoms suggestive of TB.
~TST and/or IGRA positive."
11089758|NCT04148040|Experimental|G-POEM for infantile hypertrophic pyloric stenosis|The procedure includes four steps: a) a transversal mucosal incision was performed at the proximal antrum. b) a submucosal longitudinal tunnel was created across the pyloric ring. c) full-thickness pyloromyotomy was performed, with a little extension of the antrum. After pyloromyotomy, an ultrathin gastroscope was used to inspect the mucosa and pyloric outlet. d) after careful hemostasis, the mucosal entry was closed by clips.
11089759|NCT04148014|Experimental|Adjunctive Emotion Regulation Skills Training|Participants will receive a 5 session once a week group emotion regulation skills training adjacent to treatment as usual provided by the eating disorder unit at the child and adolescent psychiatric clinic, Linköping, Sweden.
11089760|NCT04147988|Other|DONALD T list|adults on the DONALD T list seeking diagnostic advice on autism spectrum disorder or asperger's syndrome
11089761|NCT04147975||Patients Suspected of Bloodstream Infection|No intervention(s) to be administered.
11089762|NCT04147962||Patients with dry eye disease with meibomian gland dysfunction|"Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).
~- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light"
11089766|NCT04147936|Active Comparator|AXA1665 53.9 g|Dietary Supplement: AXA1665 Amino acids, food study
11089767|NCT04147936|Placebo Comparator|Placebo 29.4 g|Dietary Supplement: Placebo
11089768|NCT04147923|Active Comparator|Floradapt Mature Immune Defense|A multivitamin will also be consumed.
11089769|NCT04147923|Placebo Comparator|Placebo|A multivitamin will also be consumed.
11089770|NCT04147910|Experimental|KW-6356|Single oral dose of carbon-14-KW-6356.
11089771|NCT04147897|Active Comparator|Internal Facilitation|mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.
11089772|NCT04147897|Active Comparator|External Facilitation|mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.
11089773|NCT04147884|Experimental|Mitral Valve Repair|All subjects will receive mitral valve repair using the Millipede System
11089774|NCT04147871|Active Comparator|ADV7103 1.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
11089775|NCT04147871|Active Comparator|ADV7103 3.0 mEq/Kg/day|Patients receive ADV7103 twice a day.
11089776|NCT04147871|Active Comparator|ADV7103 4.5 mEq/Kg/day|Patients receive ADV7103 twice a day.
11089777|NCT04147871|Placebo Comparator|Placebo|Patients receive placebo twice a day.
11089778|NCT04147858|Experimental|NYX-2925 50 mg|NYX-2925 50 mg administered orally.
11089779|NCT04147858|Experimental|NYX-2925 100 mg|NYX-2925 100 mg administered orally.
11089780|NCT04147858|Placebo Comparator|Placebo|Placebo administered orally.
11089781|NCT04147845|Experimental|Fractional Carbon dioxide laser and triamcinolone acetonide|"Group I:Fractional Carbon dioxide laser (CO2 Laser) and triamcinolone acetonide (TrA; 10 mg/ ml) (14, 15) The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.
~Laser treatment will be given to the affected area, and immediately after the treatment, triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
11089782|NCT04147845|Experimental|Microneedling with Dermapen and triamcinolone acetonide|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.
~Triamcinolone acetonide in concentration of 10 mg/ml (0.1 ml containing 1 mg of triamcinolone) will be applied on each lesion twice, before and after performing microneedling.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
11089783|NCT04147845|Experimental|Fractional Carbon dioxide laser and Platelet-rich plasma|"The same laser parameters as group I will be used, followed by application of freshly prepared PRP. The applied PRP will be spread over the whole affected area.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
11089784|NCT04147845|Experimental|Microneedling with Dermapen and Platelet-rich plasma|"Microneedling using dermapen is performed as Group II. Microneedling is preceeded and followed by intermittent application of freshly prepared PRP. The applied PRP will be spread over the whole affected area and again rolled till pinpoint bleeding points are noticed.
~Each patient will receive four treatments, with an interval of three weeks between the treatment sessions, for a total of 12 weeks.This will be followed by a follow up period of another 4 weeks. The patients will be given no topical treatments for the alopecia areata in between the sessions. Topical post-procedure care in the form of topical antibiotics, emollient or sunscreen may be used. Each patch will be digitally macrophotographed, and evaluated clinically and by dermoscopy at baseline and at the end of the study, for signs of hair regrowth"
11089785|NCT04147832||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, seen at any AHF clinic within the last two years and whose care is documented in the AHF electronic health records system.
11089786|NCT04147819|Experimental|Dose escalation of BAY2701439|The target population consists of participants with advanced HER2-expressing/amplified breast, gastric or gastroesophageal cancer.
11089787|NCT04147819|Experimental|HER2 overexpressing breast cancer|Dose expansion of BAY2701439
11089788|NCT04147819|Experimental|HER2 low expressing breast cancer|Dose expansion of BAY2701439
11089789|NCT04147819|Experimental|Other HER2 overexpressing advanced carcinomas|Dose expansion of BAY2701439
11089790|NCT04147806|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
11089791|NCT04147806|Experimental|IGRT 24 Gy single dose|single fraction IGRT at a prescription dose of 24 Gy
11089792|NCT04147793||Controls|patients attneding for surgery with no known bladder disease
11089793|NCT04147793||Overactice sphincter|those with evidence of dysfunctional voiding
11089794|NCT04147793||Underactive sphincter|those with genuine stress incontinence
11089795|NCT04147780||Primary vulvar cancer, tumor ≥ 4cm|"Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:
~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
11089796|NCT04147780||Primary vulvar cancer, multifocal tumor|"Patients with primary squamous cell vulvar cancer, multifocal tumor:
~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
11089827|NCT04147624|Placebo Comparator|Placebo Group|Participants in the treatment group will receive 125 mL of iso-caloric placebo taken by mouth, once daily, for 12 consecutive months.
11089797|NCT04147780||Local recurrence after vulvar cancer, no earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:
~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
11089798|NCT04147780||Local recurrence after vulvar cancer, earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:
~Sentinel node biopsy if detectable, otherwise no groin treatment"
11089799|NCT04147767|Experimental|Phytosterols Arm|"The investigational food product Cholesterol Reducing Strawberry Yogurt Drink (Tesco) is a strawberry yogurt drink with added plant sterols. A 100g bottle (one serving) of cholesterol lowering strawberry yogurt drink contains 2g of free plant sterols. The magnitude of the effect given by this enriched food product, providing a daily intake of 1,5-2,4 g plant sterols/stanols, refers to the lowering/reducing blood cholesterol effects in the range 7 % to 10 % within 2 to 3 weeks of treatment, as specified by Commission Regulation (EU) 384/2010 of 05/05/2010.
~The dietary intervention will consist in 8 weeks consumption of PSS enriched Yogurt Drink, which provide a daily PSS intake of 3.4g/100g bottle plant sterols ester equivalent to 2g/100g bottle of free plant sterols."
11089800|NCT04147767|Placebo Comparator|Placebo Arm|"The investigational food product Low Fat Strawberry Yogurt Drinks (Morrisons) is a strawberry flavoured yogurt drink with sweetener and sugar, vitamin C, B6 and D, British milk.
~Placebo intervention consists in 8 weeks consumption of PSS non-enriched Yogurt Drinks. The placebo intervention is needed for the study design chosen (randomized double-blind placebo-controlled cross-over clinical trial). Placebo will be used in order to determine the efficacy of PSS intervention, comparing the effects of the two compounds (PSS and placebo) in the same experimental conditions and then avoiding bias."
11089801|NCT04147754||Epidural anesthesia|At physician discretion (observational study)
11089802|NCT04147754||Intrathecal morphine|At physician discretion (observational study)
11089803|NCT04147754||Erector spinae block|At physician discretion (observational study)
11089804|NCT04147741|Experimental|Pre-Workout Supplement|A 60 g dose of a commercially available pre-workout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine 1 g, yerba mate 0.3 g and caffeine 0.4 g. With 250 ml of water.
11089805|NCT04147741|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 250 ml of water.
11089806|NCT04147728|Experimental|SRS Combination With Anlotinib|Stereotactic Radiosurgery Combination With Anlotinib
11089807|NCT04147715|Experimental|Part 1: S-648414|Participants will be assigned to 1 of 5 ascending dose groups (10 to 1000 mg) and receive a single oral dose of S-648414 in a fasted state on Day 1.
11089808|NCT04147715|Placebo Comparator|Part 1: Placebo|Participants will be assigned to 1 of 5 ascending dose groups (10 to 1000 mg) and receive a single oral dose of matching placebo in a fasted state on Day 1.
11089809|NCT04147715|Experimental|Part 1: S-648414 Days 1 and 14|Participants will receive a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (high-fat meal) on Day 14.
11089810|NCT04147715|Placebo Comparator|Part 1: Placebo Days 1 and 14|Participants will receive a single oral dose of matching placebo in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (high-fat meal) on Day 14.
11089811|NCT04147715|Experimental|Part 2: 50 mg S-648414 + Midazolam|Participants will receive 50 mg S-648414 once a day on Days 1 through 14 and a single oral dose of midazolam 5 mg alone on Day -2 and co-administered with the S-648414 dose on Day 14.
11089812|NCT04147715|Experimental|Part 2: 30 mg S-648414 + Midazolam|Participants will receive 30 mg S-648414 once a day on Days 1 through 14 and a single oral dose of midazolam 5 mg alone on Day -2 and co-administered with the S-648414 dose on Day 14.
11089813|NCT04147715|Placebo Comparator|Part 2: Placebo + Midazolam|Participants will receive matching placebo once a day on Days 1 through 14 and a single oral dose of midazolam 5 mg alone on Day -2 and co-administered with the placebo dose on Day 14.
11089814|NCT04147715|Experimental|Part 3: Dolutegravir + Low-dose S-648414|Participants will receive dolutegravir orally once a day on Days 1 to 7, low-dose S-648414 orally once a day on Days 15 to 21, and dolutegravir coadministered with low-dose S-648414 orally once a day on Days 22 to 28.
11089815|NCT04147715|Experimental|Part 3: Dolutegravir + High-dose S-648414|Participants will receive dolutegravir orally once a day on Days 1 to 7, high-dose S-648414 orally once a day on Days 15 to 21, and dolutegravir coadministered with high-dose S-648414 orally once a day on Days 22 to 28.
11089816|NCT04147702|Experimental|Experimental Group: Balance analysis|fifty dancers will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
11089817|NCT04147702|Active Comparator|Control Group:Balance Analysis|fifty healthy subjects will be evaluated in this study.Trunk muscle endurance, pulmonary functions and balance will be assessed.
11089818|NCT04147689|Experimental|Treated labia majora|Labia majora are treated at Baseline visit (V1) and a touch-up may be performed 4 weeks after Baseline (V2) if needed
11089819|NCT04147676||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study.
~The specimens will be tested with
~Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex
~Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid
~Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid"
11089820|NCT04147650|Experimental|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
11089821|NCT04147650|Experimental|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
11089822|NCT04147650|Experimental|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
11089823|NCT04147650|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
11089824|NCT04147637|Experimental|FSL-M|FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
11089825|NCT04147637|Active Comparator|FSL-A|FreeStyle Libre alone
11089826|NCT04147624|Experimental|Treatment Group|Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 12 consecutive months.
11089862|NCT04147351|Experimental|Atezolizumab+bevacizumab+pemetrexed+carboplatin or cisplatin|
11089828|NCT04147611|Experimental|Remote Microphone (RM) Technology Group|"The RM technology group will limited to the pediatrics participants.
~Participants will be tested separately on the three following conditions:
~Bone Conduction Device (BAHA) only
~BAHA + Wireless Audio-Streaming Accessory
~BAHA + Digital Adaptive RM System"
11089829|NCT04147611|Active Comparator|Normal Hearing Controls|"The normal hearing controls will be limited to 15 adults.
~Participants will be tested separately on the six following conditions:
~Unaided
~Unilateral hearing aid with contralateral plug.
~Unilateral hearing aid + Digital Adaptive RM System (using Roger™, Sonova)
~Bone Conduction Device (BAHA) only
~BAHA + Wireless Audio-Streaming Accessory
~BAHA + Digital Adaptive RM System"
11089830|NCT04147598|Experimental|Low Fat Diet (LFD) to Standard American Diet (SAD)|Week 1 to 4 participants will receive a LFD followed by a washout period of 2 weeks and then week 6 to 10 SAD.
11089831|NCT04147598|Experimental|SAD to LFD|Week 1 to 4 participants will receive a SAD followed by a washout period of 2 weeks and then week 6 to 10 LFD.
11089832|NCT04147585|Experimental|Intervention Arm|Three cycles of a 5-day Intermittent Reduced Calorie Diet
11089833|NCT04147585|No Intervention|Control Arm|Regular Diet
11089834|NCT04147572|Experimental|Inhaler A, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type A
11089835|NCT04147572|Experimental|Inhaler B, Tiotropium Easyhaler|Placebo Tiotropium Easyhaler, type B
11089836|NCT04147572|Placebo Comparator|Reference product, Spiriva modified HandiHaler|Placebo Spiriva, hard capsule inhaled via modified HandiHaler device
11089837|NCT04147572|Experimental|Substudy Test product Placebo Tiotropium Easyhaler|The substudy subjects will demonstrate the use of the inhaler.
11089838|NCT04147572|Placebo Comparator|Substudy Reference product Placebo Spiriva® HandiHaler|The substudy subjects will demonstrate the use of the inhaler.
11089839|NCT04147546|Experimental|Intervention arm|"A full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.
~At each ANC visit, study nurses will perform an HS-RDT for participants in this arm. Reminders will be sent in this group in order to improve IPTp-SP uptake"
11089840|NCT04147546|No Intervention|Control arm|"A full course of artemether-lumefantrine (AL) over 3 days. The first dose of AL will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home.
~At each ANC visit, study nurses will perform a conventional RDT for participants in this arm if the participant have symptoms suggestive of malaria. No reminder will be sent"
11089841|NCT04147533|Experimental|initially treated patients|The dose of tyrosin kinase inhibitors (imatinib, or nilotinib, or dasatinib) in patients meeting all of the inclusion criteria and none of the exclusion criteria will be reduced in two consequent steps, during the first 6 months after study entry by 50%, during the second 6 months by 50% again; the medication is discontinued then and the patients are followed each month in the first 6 months after withdrawal, each 1,5 month in the next 6 months, and each 3 months in the next 12 months.
11089842|NCT04147520|Active Comparator|Brief Motivational Interview|Single-session in person conversation focusing on risks associated with alcohol use.
11089843|NCT04147520|No Intervention|Natural History Control|No contact.
11089844|NCT04147507|Experimental|Music Therapy|
11089845|NCT04147507|Other|Control|Life style Modification.
11089846|NCT04147494|Experimental|Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes. Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).
11089847|NCT04147481|Experimental|Group Abdominal Nerve Block|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
11089848|NCT04147481|Placebo Comparator|Group control|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
11089849|NCT04147468|Active Comparator|Virtual Reality Gaming Intervention|A newly developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child, will be used. The research team will loan the system to the family. The child will be asked to move their arms to 'pop' as many virtual objects as possible with the focus on outwards, upwards, and across midline.
11089850|NCT04147468|Experimental|Functional Strength Training|Children will receive repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises which are designed to move their arms.
11089851|NCT04147455|Experimental|RealConsent|Participants randomized to this study arm will receive adapted program of RealConsent.
11089852|NCT04147455|Active Comparator|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
11089853|NCT04147442|Experimental|Music program fine-tuned|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
11089854|NCT04147442|Active Comparator|Music program standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
11089855|NCT04147429|No Intervention|Usual care|Newborns randomized to the usual care group will receive standard education about safe sleep practices, measuring temperatures and newborn feeding needs. This information will be accompanied by printed instructions that will be added to the family's discharge instructions. This reflects current practice in the Duke Hospital Newborn Nursery.
11089856|NCT04147429|Experimental|Intervention|In addition to usual care, families randomized to the intervention group will receive an early literacy intervention, delivered by a trained research assistant. To ensure intervention and delivery fidelity, the PI will meet with research assistants at bi-weekly intervals to review procedures and perform structured observations of intervention delivery.
11089857|NCT04147416|Experimental|HSK3486|
11089858|NCT04147416|Active Comparator|Propofol|
11089859|NCT04147390|Active Comparator|usage mycophenolate mofetil|
11089860|NCT04147390|Active Comparator|usage tacrolimus|
11089861|NCT04147377|Experimental|PD with FOG|Patients with Parkinson's disease who complain of freezing of gait
11089863|NCT04147338|Experimental|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
11089864|NCT04147338|Experimental|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
11089865|NCT04147338|Experimental|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
11089866|NCT04147325||Prospective Cohort|Participants newly diagnosed with Human Immunodeficiency Virus (HIV)-1, will receive Antiretroviral Therapy (ART) in accordance with clinical practice and will be included in a Test and Treat model of care at the outpatient clinic of the center.
11089867|NCT04147325||Historical Cohort|Naive HIV-1 infected participants who had their first care visit at the outpatient clinic of the center through 2017 will be included in this cohort.
11089868|NCT04147312|Experimental|Treatment group|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
11089869|NCT04147312|Placebo Comparator|control group|Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
11089870|NCT04147299||HFrEF|Heart Failure with Reduced Ejection Fraction
11089871|NCT04147299||HFpEF|Heart Failure with Preserved Ejection Fraction
11089872|NCT04147299||Elite Athletes|Endurance athletes
11089873|NCT04147286|Active Comparator|Atorvastatin (Arm B)|12 weeks of 40 mg atorvastatin therapy per os daily
11089874|NCT04147286|Placebo Comparator|Placebo (Arm C)|Identical placebo tablet is taken per os daily
11089875|NCT04147273|Other|Evaluation of CGM compared with standard measurements|Two products were studied: white bread (Butter Toast®, Golden Toast, Wittenberg, Germany) and whole grain bread (1688 Mehrkorn®, Harry-Brot, Schenefeld, Germany). One portion (containing 50 g digestible carbohydrates) was eaten immediately before the beginning of the test in the morning after an overnight fast of at least 10 h. Before testing, participants ate as usual on the previous day without a standard meal and refrained from consuming alcohol and exercising for 72 h. A 200-ml glucose drink (Accu-Chek Dextrose O.G.-T. Saft®, Roche Diabetes Care, Mannheim, Germany), containing also 50 g of carbohydrates, was used as the reference product.
11089876|NCT04147260|Experimental|BI 730357 low dose|
11089877|NCT04147260|Active Comparator|Ciprofloxacin|
11089878|NCT04147260|Experimental|BI 730357 high dose|
11089879|NCT04147260|Placebo Comparator|Placebo|
11089880|NCT04147247|Experimental|BI 905681|
11089881|NCT04147234|Experimental|Arm A: BI 1387446|superficial lesions
11089882|NCT04147234|Experimental|Arm B: BI 1387446 in combination with BI 754091|superficial lesions
11089883|NCT04147234|Experimental|Arm C: BI 1387446 in combination with BI 754091|deep lesions
11089884|NCT04147221|Experimental|Imipenem-Relebactam|Participants will receive a single dose of intravenous imipenem-relebactam (500mg-250mg) as a 30 minute infusion.
11089885|NCT04147208|Experimental|Combination group|Subjects will receive 96 weeks of GLS4+RTV+ETV.
11089886|NCT04147208|Active Comparator|Entecavir monotherapy|Subjects received 96 weeks of entecavir treatment
11089887|NCT04147195|Experimental|Cohort 1, Arm 1|LYS006
11089888|NCT04147195|Experimental|Cohort 1, Arm 2|LYS006 + Tropifexor (LJN452)
11089889|NCT04147182|Experimental|Patient with low grade TCC|"Patients of 18 years or older able to sign informed consent
~A previous diagnosis of low grade bladder cancer
~A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion
~Serum creatinine levels ≤ 2.0 mg/dl
~Serum sodium levels <146 mg/ml
~Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months
~Patient is candidate for TURBT"
11089890|NCT04147169||Dying patients|Dying patients admitted to the Intensive Care Unit who are approaching end-of-life.
11089891|NCT04147156|Active Comparator|Epley's Maneuver|Treatment of posterior canal BPPV with Epley's maneuver in the ROTUNDUM-chair.
11089892|NCT04147156|Experimental|Semont Maneuver|Treatment of posterior canal BPPV with the Semont maneuver in the ROTUNDUM-chair.
11089893|NCT04147156|Active Comparator|360 degree vertical rotation|Treatment of posterior canal BPPV with a 360 degree vertical rotation in the ROTUNDUM-chair.
11089894|NCT04147130|Experimental|MultiPAP Plus intervention|Complex intervention with general practitioners and patients
11089895|NCT04147130|Active Comparator|Usual care|Patients will recieve the usual clinical care
11089896|NCT04147117|Experimental|Pessary Group|"A pessary certified is inserted through the vagina with the woman in recumbent position and is placed around the cervix.
~Correct placement of the pessary is assessed by ultrasound. Patients on the pessary group are specially awarded about adverse symptoms and the need of immediate report in case of pain, bleeding and symptomatic contractions.
~The pessary is not removed when symptoms of infection occur after pessary insertion, but appropriate treatment is given.
~The pessary is removed at 37 weeks of pregnancy. Indications for pessary removal before 37 weeks are: active vaginal bleeding, premature labor not responding to tocolysis or severe patient discomfort."
11089897|NCT04147117|No Intervention|Control group|Current management for the follow-up of these women in the PBPC.
11089898|NCT04147104|Active Comparator|Standard-of-care plus invasive mechanical ventilation|Invasive mechanical ventilation for lung support and to facilitate exhalation via an endotracheal tube o tracheotomy.
11089899|NCT04147104|Experimental|ECCO2R plus invasive mechanical ventilation|Low-flow ECCO2R adjunct to standard-of-care and invasive mechanical ventilation.
11089900|NCT04147091|Experimental|domestic nanohydroxyapatite gel ApaCare & Repair|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
11089901|NCT04147091|Experimental|in-office ozone therapy OzonyTron|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
11089902|NCT04147091|Experimental|both remineralizing gel and ozone therapy|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
11089903|NCT04147078|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
11089904|NCT04147065|Experimental|7-day triple therapy and 7-day bismuth quadruple therapy|7-day triple therapy is consisted of proton pump inhibitor (PPI), amoxicillin and clarithromycin for seven days 7-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for seven days
11089905|NCT04147065|Active Comparator|14-day triple therapy and 14-day bismuth quadruple therapy|14-day triple therapy is consisted of PPI, amoxicillin and clarithromycin for fourteen days 14-day bismuth quadruple therapy is consisted of PPI, bismuth, tetracycline, metronidazole for fourteen days
11089906|NCT04147052|Experimental|iSLEEPms|Participants randomized to iSLEEPms complete a 4-week online program with telephone support, based on CBT-I.
11089907|NCT04147052|No Intervention|Treatment As Usual|Participants randomized to TAU continue their usual care and are encouraged to avoid starting any new sleep treatment unless deemed necessary by a health care provider.
11089908|NCT04147039|Experimental|Intervention|Receives the MINISTOP 2.0 mobile phone app for 6 months
11089909|NCT04147039|No Intervention|Control|Receives standard care through primary child health care
11089910|NCT04147026|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from rheumatoid arthritis. Prescription of an original or biosimilar biotherapy (rituximab, adalimumab, abatacept) is possible.
11089911|NCT04147026|Active Comparator|Current practice|Prescription of biotherapy without the SinnoTest® software which corresponds to current practice (all biotherapies).
11089912|NCT04147013|Experimental|Celecoxib Group|Patients will receive the interventional drug for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
11089913|NCT04147013|Placebo Comparator|Control Group|Patients will receive the placebo for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
11089914|NCT04146987|Active Comparator|Open rotator cuff repair|Patients will be positioned in a beach chair position with the affected limb pending off the table, allowing manipulation and full range of motion range. After asepsis, antisepsis and placement of sterile surgical fields, anterolateral incision will be made in the shoulder in question; the deltoid muscle belly will be gently divided along its fibers until exposure of the subdeltoid / subacromial bursa, which will be partially excised for exposure of the subacromial space and rotator cuff tendons. After mobilization and release of the ruptured tendons and debridement of the rotator cuff footprint, the tendon repair to the bone will be performed using 5.5m metal anchors, according to the preference and technique chosen by the surgeon. In all cases, the release of the coracoacromial ligament and acromioplasty will be performed.
11089915|NCT04146987|Active Comparator|Arthroscopic rotator cuff repair|The patients will be positioned in lateral decubitus position, with the arm to be operated attached to a skin traction device, which trough a traction post and 07 kg, will maintain the shoulder in the following position: abduction of 30 to 60 and flexion of 20 to 30 degrees. After asepsis, antisepsis and placement of impermeable sterile surgical fields, a posterolateral incision will be made in the shoulder for optic introduction, with a 50 mmHg pressure pump and a 0.90 flow, and inspection of the GU joint. After joint inspection, the optic will be introduced into the subacromial space with detachment of the subacromial and subdeltoid. Using shaver blades, partial bursectomy will be performed as well as debridement of the rotator cuff footprint. The tendon will then be reinserted to the bone using metallic 5.5mm anchors. After tendon repair, the coracoacromomial ligament will be released, as well as acromioplasty.
11089916|NCT04146948||COPD group|No intervention 40 years or older, clinical diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease stages I to IV)
11089917|NCT04146948||healthy group|40 years or older, not with the clinical diagnosis of COPD
11089918|NCT04146935|Experimental|Patients with XLH|Patients will receive Burosumab monthly at visits 1,2 and 3 subcutaneously at a dose of 1.0 mg/kg. Dose may be adjusted as needed.
11089919|NCT04146922|Active Comparator|IV Group|Eligible patients randomized to complete their antimicrobial therapy course through intravenous (IV) administration.
11089920|NCT04146922|Experimental|Oral Group|Eligible patients randomized to step down to oral antimicrobial therapy for the remainder of their treatment course.
11089921|NCT04146909|Active Comparator|Breast Feeding|This group will consist of women who exclusively or mostly breast-fed for at least 4-6 months (< 6 ounces of formula/24 hours at 6-9 weeks of delivery)1 and who delivered within the past 18 months.
11089922|NCT04146909|Active Comparator|Formula Feeding|This group will consist of women who exclusively or mostly formula-fed (no breastfeeding or < 3 weeks of breastfeeding)1 and who delivered within the past 18 months.
11089923|NCT04146896|Experimental|NYX-2925|NYX-2925 50 mg
11089924|NCT04146896|Placebo Comparator|Placebo|Placebo
11089925|NCT04146883|Experimental|Post procedural antibiotics treatment|This group was treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin) and post procedural oral prophylactic antibiotics
11089926|NCT04146883|No Intervention|Pre procedural antibiotics treatment only|This group was only treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin).
11089927|NCT04146857|Placebo Comparator|Normoxia|20.9% oxygen
11089928|NCT04146857|Active Comparator|Hypoxia 1|15.0% oxygen
11089929|NCT04146857|Active Comparator|Hypoxia 2|12.8% oxygen
11089930|NCT04146831|Experimental|Sintilimab|Sintilimab is administered in this arm.
11089931|NCT04146818|Experimental|Adapted Tango Dancing arm|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months)
11089932|NCT04146818|Placebo Comparator|Control arm|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
11089933|NCT04146805|Experimental|Part 1SAD/Part 2 MAD:Active Treatment(BLD-0409)|For each cohort in both study parts, 6 subjects will be randomized to active (BLD-0409). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)
11090098|NCT04145622|Experimental|Dose expansion|All participants enrolled in the dose expansion part
11089934|NCT04146805|Placebo Comparator|Part 1SAD/Part 2 MAD:Control(Matched Placebo)|For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
11089935|NCT04146792|Experimental|body acceptance program|
11089936|NCT04146792|Active Comparator|writing creativity program|
11089937|NCT04146779|Experimental|Video and Written Yoga Instruction|Videos and written instructions on Hatha yoga will be provided
11089938|NCT04146779|Experimental|Video, Written Yoga Instruction Plus Guided Yoga Sessions|Videos and written instructions on Hatha yoga and instructor guided session on Hatha yoga will be provided
11089939|NCT04146766|Experimental|eHealth|Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
11089940|NCT04146766|Experimental|wait list control|wait list control for 3 months and then Provide home physiology measurement services, including automatic uploading of measured blood pressure values to the cloud, serial back-end education platform to provide numerical anomaly alarms and health care notifications, monthly measurement data reports, combined with mobile APP management system for immediate enquiry . In addition to the electric visit to the patient's health education guidance, the content includes: 1. Encourage the walking exercise to perform 2. Ask the walking exercise execution progress, please return the daily value of the case to facilitate the record 3. Answer the relevant questions asked during the intervention.
11089941|NCT04146740|Experimental|Structured Exercise Group|"Structured Exercise Group will receive medical and dietary interventions like insulin plus structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min The combination of Stabilization exercise (10 repetitions) and PFM training ( 20 repetitions set).
~Relaxation therapy including Mitchells physiological relaxation technique (10 repeatitions) alongwith deep breathing exercises.
~Life style modification with postural guidance and back care would also be followed.
~Exercise dosage would be twice a week for 05 weeks while exercise duration will be 45 to 50 min session under Physio supervision and home plan of 10 min exercise daily. Total 150 min per week. Data will be recorded at baseline then after treatment of 5 weeks."
11089942|NCT04146740|Active Comparator|Control Group|Control Group will receive no structured exercise regime only the group will be receiving medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist due to ethical concerns and their outcomes will be observed at the baseline and then after 05 weeks.
11089943|NCT04146727||ICU Duration|The total study duration is determined by their length of stay in the ICU.
11089944|NCT04146727||Transplant through 1 month at Home|Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
11089945|NCT04146714|Experimental|Substance use screening|Participants complete a substance use questionnaire (=intervention).
11089946|NCT04146714|Active Comparator|Physical activity screening|Participants complete a physical activity questionnaire (=control).
11089947|NCT04146701||Acute heart failure|All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089948|NCT04146701||STEMI|All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089949|NCT04146701||NSTEMI|All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089950|NCT04146701||Ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089951|NCT04146701||Non-ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089952|NCT04146701||Sepsis|All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089953|NCT04146701||Healthy controls|Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
11089954|NCT04146688|Active Comparator|Patients with neurodegenerative disease|Patients with neurodegenerative disease (AD or related disease)
11089955|NCT04146688|Active Comparator|People with no neuropathological disease|
11089956|NCT04146675|Experimental|TRICOT JERSEY VANISE DOUBLE FACE|
11089957|NCT04146675|Placebo Comparator|TRICOT JERSEY SIMPLE|
11089958|NCT04146649|Experimental|Primary Osteoarthritis|Patients with native knees and effusions will participate in this arm.
11089959|NCT04146649|Experimental|Primary TKA|Patients with total knee replacements will participate in this arm.
11089960|NCT04146636|Other|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
11089961|NCT04146623|Placebo Comparator|Normal Saline Placebo|Saline (0.9%)
11089962|NCT04146623|Experimental|CodaVax-H1N1|Live-attenuated influenza vaccine
11089963|NCT04146610|Experimental|Dp303c|Multiple dose grouping
11089964|NCT04146597|Experimental|Neural mobilization|The intervention is always performed after Jiu Jitsu practice and at the training site itself. Neural mobilization consisted of the execution of a sciatic nerve sliding technique in three sets of one minute for each lower limb with an interval of one minute between sets, twice a week, for five consecutive weeks, totaling 10 interventions (Garber et al., 2011). The order of the first lower limb to be submitted to the intervention is not standardized, being at the discretion of the subjects.
11150538|NCT03723798|Placebo Comparator|Placebo|SA001 Placebo
11089965|NCT04146584|Experimental|Sofwave Treatment|In this arm (single) patients would be treated twice with Sofwave on the face and/or submental and neck.
11089966|NCT04146558|Experimental|Internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.
~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
11089967|NCT04146558|Active Comparator|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
11089968|NCT04146545|Experimental|Cases|Community Rx-Caregiver Resources
11089969|NCT04146545|No Intervention|Control|Usual Standard Care
11089970|NCT04146532|Placebo Comparator|Placebo|Single dose of a 500mg placebo tablet.
11089971|NCT04146532|Active Comparator|Aspirin 500MG|Single dose of a 500 mg aspirin tablet.
11089972|NCT04146519|Experimental|MMSC|Autologous MMSC
11089973|NCT04146506||Male|Static Muscle stretching exercises of the knee flexors
11089974|NCT04146506||Female|Static Muscle stretching exercises of the knee flexors
11089975|NCT04146493||Vascular surgery group|Patients which are given unfractionated heparin during their vascular surgery.
11089976|NCT04146493||Thromboprophylaxis group|Patients which are given low molecular heparins as a thrombosprofylax after major surgery
11089977|NCT04146493||Cardiothoracic surgery|Patients which are given high dose unfractionated heparin during their open heart surgey
11089978|NCT04146480|Experimental|Cardiac amyloidosis patients|
11089979|NCT04146467|Experimental|Arm 1|Subjects will be treated with the Apyx Plasma/RF device.
11089980|NCT04146454|Experimental|Smartphone-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with a smartphone-based wearable telerehabilitation system.
11089981|NCT04146454|No Intervention|Paper-based balance exercises|This group will complete in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises) with typical paper-based instructions.
11089982|NCT04146441|Experimental|SonoVue|SonoVue + chemotherapy
11089983|NCT04146441|Active Comparator|control|chemotherapy
11089984|NCT04146428|Experimental|clinician-mediated JASPER|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
11089985|NCT04146428|Experimental|parent-mediated JASPER|This group will consist of the therapist assisting the parent implement JASPER on the child twice a week.
11089986|NCT04146415|Experimental|Cardiac amyloidosis patients|
11089987|NCT04146402|Experimental|SCT-I10A + Chemotherapy|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
11089988|NCT04146402|Active Comparator|Placebo + Chemotherapy|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle. Chemotherapy: cisplatin+5-FU
11089989|NCT04146376||Non-Corrector|Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
11089990|NCT04146376||Corrector|Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
11089991|NCT04146363|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Placebo arm receive two Placebo injections Q2W."
11089992|NCT04146363|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):
~Two subcutaneous (SC) injections of lebrikizumab as a loading dose at Baseline and Week 2 visits followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.
~Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q2W arm receive two lebrikizumab injections Q2W."
11089993|NCT04146363|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):
~Treatment from Week 16 to Week 52 is based on re-randomization of responders in the Induction Period. Participants re-randomized to Lebrikizumab Q4W arm receive one lebrikizumab injection Q4W, with one placebo injection 2 weeks after each lebikizumab injection."
11089994|NCT04146363|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):
~Participants who require rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
11089995|NCT04146350|No Intervention|Control|
11089996|NCT04146350|Active Comparator|PPV+/-Cat|
11089997|NCT04146350|Active Comparator|PPV+/-Cat+Gas|
11089998|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Gas|
11089999|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Oil|
11090000|NCT04146350|Active Comparator|PSR|
11090001|NCT04146350|Active Comparator|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|
11090002|NCT04146350|Active Comparator|Gas|
11090003|NCT04146337|Experimental|Fecal microbiota transplantation (FMT)|FMT regimen: Patients will be given capsulized FMT 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
11090004|NCT04146337|No Intervention|Control|Routine follow-up
11090005|NCT04146324||Adjuvant nivolumab therapy|Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
11090006|NCT04146311|Active Comparator|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) is injected into the left infrapatellar fat pad.
11090007|NCT04146311|Placebo Comparator|Isotonic saline|A bolus injection (0.25 ml) of isotonic saline (0.9 %) is injected into the left infrapatellar fat pad.
11090008|NCT04146311|Experimental|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
11090009|NCT04146298|Experimental|TCR Transduced T cell therapy|"Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine
~TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9~1e11)
~Anti-PD-1 therapy: anti-PD-1 will be administered if needed."
11090010|NCT04146285|Experimental|BAT4406F|
11090011|NCT04146272|Active Comparator|Current Feedback Mermaid|The current hearing aid that is sold and uses the current feedback cancellation system will be used as a comparator.
11090012|NCT04146272|Experimental|New Feedback Mermaid 2|The new hearing aid that is not yet sold and uses the new feedback cancellation system will be tested.
11090013|NCT04146272|Active Comparator|Current Feedback Mermaid Round 2|The current hearing aid that is sold and uses the current feedback cancellation system will be used as a comparator. The same hearing aids will be used for another arm of testing.
11090014|NCT04146272|Experimental|New Feedback Mermaid 2 Round 2|The new hearing aid that is not yet sold and uses the new feedback cancellation system will be tested. The same hearing aid will be used for another arm of testing.
11090015|NCT04146272|Active Comparator|Current Feedback Power|The current power hearing aid that is sold and uses the current feedback cancellation system will be used as a comparator. It provides more power than the other hearing aids and is specifically for those with very strong hearing loss. It will be used as a comparator.
11090016|NCT04146272|Experimental|New Feedback Power|The new power hearing aid that is not yet sold and uses the new feedback cancellation system will be tested on users with very strong hearing loss.
11090017|NCT04146259||group A|Control
11090018|NCT04146259||Group B|Post-surgical hypoparathyroidism
11090019|NCT04146246||Adult|Adults aged 18 years or older. Collect whole blood sample via venous/arterial puncture and, where possible, finger stick.
11090020|NCT04146246||Neonate|Neonates gestational age >35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
11090021|NCT04146233|Other|Orange Juice without pulp|Drink orange juice without pulp and have gastric ultrasound performed 2 hours later
11090022|NCT04146233|Other|Orange juice with pulp|Drink orange juice with pulp and have gastric ultrasound performed 2 hours later
11090023|NCT04146220|Experimental|Low dose group|Prednisolone 0.5 mg/kg/day
11090024|NCT04146220|Active Comparator|High dose group|Prednisolone 1 mg/kg/day
11090025|NCT04146207|Experimental|combination therapy|"Experimental: combination therapy There is only 1 arm. Combination therapy arm includes SHR0302 and Prednisone
~Prednisone 1mg/kg/d po，At the same time give SHR0302 QDpo；"
11090026|NCT04146181|Experimental|SCT-I10A|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
11090027|NCT04146168||VenaSeal|Complete closure of previously treated veins will be assessed via ultrasound
11090028|NCT04146155|Experimental|Liraglutide+standard-of-care treatment|Intervention: Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies.
11090029|NCT04146155|Active Comparator|standard-of-care treatment|standard-of-care treatment with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
11090030|NCT04146142|Active Comparator|Transperineal prostate biopsy with antibiotic profylaxis|Cefuroxim 1.5 g will be applied intravenously before prostate biopsy
11090031|NCT04146142|Experimental|Transperineal prostate biopsy without antibiotic profylaxis|No antibiotics will be used before or after prostate biopsy
11090032|NCT04146129|Experimental|CDX-0159|Eligible subjects will receive a single dose of CDX-0159
11090033|NCT04146129|Placebo Comparator|Normal saline|Subjects assigned to receive placebo will receive a single dose of normal saline
11090034|NCT04146116|Experimental|Nasal povidone-iodine|Intranasal povidone-iodine (PDI PROFEND) will be applied to the patients' noses before orthopedic trauma surgery and after surgery. This intranasal povidone-iodine was developed under the Tentative Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket # 75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules. However, the product need not be controlled like a pharmaceutical drug. The product may be stored and controlled similarly to an iodine or alcohol skin preparation product.
11090035|NCT04146103|Experimental|Experimental arm|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally, for 3 months.
11090036|NCT04146090|Active Comparator|Low-pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
11090037|NCT04146090|Placebo Comparator|Standard pressure|Forty patients aged 18 to 65 years, with an ASA physical status I or II, who will be scheduled to undergo laparoscopic cholecystectomy
11090038|NCT04146064||Validation cohort: NSCLC|"Patients with advanced/metastatic NSCLC planned for IO-treatment in one of the following categories
~Pembrolizumab monotherapy first-line
~Pembrolizumab or nivolumab monotherapy in second or later line"
11090039|NCT04146064||Cohort 1: NSCLC|Patients with advanced/metastatic NSCLC planned for Pembrolizumab-chemotherapy combination therapy first-line
11090040|NCT04146064||Cohort 2: Melanoma|"Patients with advanced/metastatic melanoma planned for IO-treatment in one of the following categories
~Nivolumab/ipilimumab combination treatment 1L
~Pembrolizumab or nivolumab monotherapy treatment 1L
~Ipilimumab monotherapy 2L"
11090041|NCT04146064||Cohort 3: Mixed solid tumor cohort|Patients with advanced/metastatic solid tumors such as Head&Neck tumors, kidney cancer and urothelial cancer planned for IO-treatment
11090042|NCT04146064||Cohort 4: NSCLC|Patients with advanced/metastatic NSCLC planned for treatment with Chemotherapy-only (either platinum-based combination treatment or docetaxel monotherapy)
11090043|NCT04146051|Experimental|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
11090044|NCT04146051|Experimental|Phase IIa Expansion|Generalized Myasthenia Gravis
11090095|NCT04145661|Experimental|No DR group|Participants who have no cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
11090096|NCT04145635|Experimental|Aortix Device|Aortix Pump, Aortix Delivery System, Introducer Set, Aortix Control System, Aortix Retrieval System
11090045|NCT04146038|Experimental|Treatment (salsalate, decitabine, azacitidine, venetoclax)|"CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.
~CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.
~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11090046|NCT04146025|Experimental|Nature Coach Intervention|The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.
11090047|NCT04146025|No Intervention|Control Group|Education only
11090048|NCT04146012|Active Comparator|Early Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation.
11090049|NCT04146012|Active Comparator|Normal Access|Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU.
11090050|NCT04145999|Experimental|PRP + PBM group|This group will receive both PRP application and photobiomodulation.
11090051|NCT04145999|Experimental|PRP + placebo PBM|This group will receive PRP application and placebo photobiomodulation.
11090052|NCT04145999|Experimental|PBM + placebo PRP|This group will receive placebo PRP application with a saline solution and active photobiomodulation.
11090053|NCT04145986||young ladies|Young ladies≤ 35 years old.
11090054|NCT04145973||recurrence and metastasis|breast cancer patients with recurrence and metastasis after surgery
11090055|NCT04145960||Lymph node metastasis|Axillary lymph node metastasis ≥ 4 Lymph nodes
11090056|NCT04145947||triple negative breast cancer|triple negative breast cancer patients with age ≤ 60 years old
11090057|NCT04145934|Experimental|training|The subjects receive the ADSTEP intervention
11090058|NCT04145934|No Intervention|waitlist|These subjects receive two brochures on fall prevention and walking aid selection, and a letter is sent to their care provider informing them that the subject has reported falling. Subjects in this group will be offered the ADSTEP intervention once their study participation is complete.
11090059|NCT04145921|Experimental|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
11090060|NCT04145921|Active Comparator|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
11090061|NCT04145908|Active Comparator|preperitoneal mesh|patients underwent preperitoneal mesh mesh placement
11090062|NCT04145908|Active Comparator|onlay mesh|patients underwent preperitoneal mesh mesh placement
11090063|NCT04145895|Other|Physician-directed Postoperative Activity Restriction|Postoperative activity restrictions prescribed by physician.
11090064|NCT04145895|Other|Self-directed Postoperative Activity Restriction|Postoperative activity restrictions self-determined (parent/guardian and/or patient).
11090065|NCT04145882|Active Comparator|No additional osteotomy|
11090066|NCT04145882|Experimental|varisation osteotomy addition|
11090067|NCT04145882|Experimental|supination osteotomy addition|
11090068|NCT04145882|Experimental|both (varisation + supination) osteotomies addition.|
11090069|NCT04145869|Experimental|Fluorescent cholangiography|Intraoperative fluorescent cholangiography using an intravenous injection of 5mg Indocyanine green
11090070|NCT04145869|Active Comparator|X-ray cholangiography|Intraoperative X-ray cholangiography using an intraductal (cystic duct) injection of Iohexol
11090071|NCT04145856|Placebo Comparator|Placebo|- Control arm
11090072|NCT04145856|Experimental|Probiotic|- Arm with active probiotic alone
11090073|NCT04145856|Experimental|Probiotic + Antispasmodic/Antifoam|- Arm with active probiotic combined to antispasmodic/antifoam drug
11090074|NCT04145830|Experimental|Ultrasound Cyclo Plasty (UCP)|Ultrasound Cyclo Plasty (UCP) using focused ultrasound
11090075|NCT04145817|Experimental|genetic counselling|Genetic counselling (PRS for risk estimation) and questionnaires in the participating Cancer Genetic Clinics for healthy woman relative of a person first tested in the family (index case) who received a positive genetic test result or a negative non-informative test result
11090076|NCT04145791|No Intervention|No Ice|Patients will receive standard postoperative pain control methods as defined by the participating institution
11090077|NCT04145791|Experimental|Ice|Patients will receive ice packs to the abdomen, in addition to standard postoperative pain control methods as defined by the participating institution
11090078|NCT04145778||Patient|
11090079|NCT04145778||Control|
11090080|NCT04145752|Experimental|Nurse-led femoral nerve block|"Trained nurses in ED provide ultrasound guided single-shot femoral nerve block shortly after (at arrival emergency department) the patient is diagnosed with a hip fracture.
~Drug: Ropivacaine 3 mg/kg, single-shot"
11090081|NCT04145752|Active Comparator|Standard of care|Nurses do not provide ultrasound guided single-shot FNB and the patient follows the standard of care course.
11090082|NCT04145739|Experimental|Mastectomy group|Patients undergoing mastectomy
11090083|NCT04145739|Experimental|Quadrantectomy group|Patients undergoing quadrantectomy
11090084|NCT04145726||Patients undergoing esophageal resection|All patients undergoing esophageal resection will be included and tested if frail or non-frail. Which means there is no intervention
11090085|NCT04145713|Experimental|Probiotic group|
11090086|NCT04145713|Placebo Comparator|Placebo group|
11090087|NCT04145700|Experimental|Ramucirumab + Gemcitabine + Docetaxel|Ramucirumab, Gemcitabine and Docetaxel given intravenously (IV).
11090088|NCT04145700|Active Comparator|Gemcitabine + Docetaxel|Gemcitabine and Docetaxel given IV.
11090089|NCT04145687|Active Comparator|Metformin|
11090090|NCT04145687|Placebo Comparator|Placebo|
11090091|NCT04145674|Active Comparator|25 mg d-Methadone|25 mg d-Methadone Tablet and one 0 mg Placebo Tablet
11090092|NCT04145674|Experimental|50 mg d-Methadone|2 x 25 mg d-Methadone Tablet
11090093|NCT04145674|Placebo Comparator|Placebo|2 x Non-active substance Tablet
11090094|NCT04145661|Experimental|DR group|Participants who have cochlear dead regions, identified by the thresholds equalising noise test will be placed in this group.
11090097|NCT04145622|Experimental|Dose escalation|All participants enrolled in the dose escalation part
11090099|NCT04145609|Experimental|Intensified care|Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic Participants randomized to this arm will receive multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist and dietitian. Besides intensified care, participants of this arm receive evaluation of biochemical and physiological renal function more frequently. In order to provide seamless care of this group, post-discharge acute kidney disease (AKD) clinic will also be arranged for them. Clinic visits consist of evaluation of renal function, reconciliation of medication and steering necessity of renal replacement therapy.
11090100|NCT04145609|No Intervention|Usual care|No intervention: Usual care Participants randomized to this arm will receive usual care according to the medical decisions of principal care physician. Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patient will not have access to MDT care and AKD clinic.
11090101|NCT04145596|Active Comparator|Compensated Chronic Liver Disease (Child-Pugh A)|
11090102|NCT04145596|Active Comparator|Decompensated Chronic Liver Disease (Child-Pugh B)|
11090103|NCT04145596|Active Comparator|healthy volunteers（Normal liver functions）|
11090104|NCT04145583|Experimental|HSK3486|0.4 mg/kg
11090105|NCT04145583|Experimental|voriconazole , HSK3486|400 or 200 mg; 0.4 mg/kg
11090106|NCT04145570|Experimental|Erlotinib HCl 150 mg|Crossover
11090107|NCT04145570|Active Comparator|Tarceva® 150 mg|Crossover
11090108|NCT04145557|Placebo Comparator|skaling root planing|
11090109|NCT04145557|Active Comparator|skaling root planing and diode laser|
11090110|NCT04145544|Experimental|Treatment arm|"Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.
~Post operation the subject will stay at the hospital according to site standards and physician discretion."
11090111|NCT04145544|Active Comparator|Control|"Same procedure as for the treatment arm but using a commercial dural substitute.
~Implantation of the commercial dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use."
11090112|NCT04145531|Experimental|JZP-458|"Part A (IM JZP-458) of the study will have 2 IM cohorts:
~Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and
~Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule
~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.
~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit."
11090113|NCT04145518|Active Comparator|Naproxen/Placebo Crossover|"Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill. Randomization with a block size only known by the statistician, will be programmed to be allocated out of REDcap.
~Our clinical research pharmacy will provide naproxen and an identical looking placebo in containers with codes only known to the statistician to provide a double-blinded experimental design.
~On a subsequent episode of menstrual pain (1-2 months later), participants will receive the opposite treatment and undergo the exact same assessments."
11090114|NCT04145518|Placebo Comparator|Placebo/Naproxen Crossover|Participants will receive placebo first in this arm.
11090115|NCT04145492|Active Comparator|Vitamin K2 group|15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.
11090116|NCT04145492|Active Comparator|Cholecalciferol group|15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.
11090117|NCT04145492|Active Comparator|Vitamin K2 and Cholecalciferol group|15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.
11090118|NCT04145492|No Intervention|Control group|15 patients will take the standard therapy.
11090119|NCT04145479|Experimental|low-resistance|women will perform low-resistance physical activity
11090120|NCT04145479|Experimental|aerobic|women will perform aerobic physical activity
11090121|NCT04145466|Experimental|Fat responders (1)|receiving high-fat diet
11090122|NCT04145466|Experimental|Carbohydrate responders (1)|receiving high-fat diet
11090123|NCT04145466|Experimental|Fat responders (2)|receiving high-carbohydrate diet
11090124|NCT04145466|Experimental|Carbohydrate responders (2)|receiving high-carbohydrate diet
11090125|NCT04145453|Experimental|intervention group|will receive specific (genotype-based) dietary recommendations regarding the consumption of fruit and vegetables.
11090126|NCT04145440|Experimental|MOR202|9 doses of MOR202 will be administered as an intravenous infusion at 16 mg/kg over 6 treatment cycles at 28-days each. Dosing occurs weekly in cycle 1 (C1) and every four weeks in cycles 2-6.
11090127|NCT04145427|Experimental|Low Carbohydrate Diet|This arm will be randomized to low carbohydrate diet
11090128|NCT04145427|Active Comparator|Standard Dietary Advice Control Group|This arm will be randomized to control diet
11090129|NCT04145414|Experimental|Cerebral magnetic resonance imaging x2|Cerebral MRI performed at enrolment visit and at +6 weeks (maximum)
11090130|NCT04145388|Other|Comparator 1|Participants will have their cancer risk assessed via usual care. Usual Care is defined as provider capture of family history during a clinical encounter and its entry into the electronic health record (EHR). Participants will take the a patient reported outcomes (PRO) survey once to assess participants experience, perspectives and thoughts on cancer, cancer risk, and cancer risk assessments.
11090131|NCT04145388|Experimental|Comparator 2|Participants will have their cancer risk assessed using a short, standardized web-based questionnaire that will populate validated cancer risk models (such as Breast Cancer Risk Assessment Tool/Gail model 2, PREMM and/or MMRpro) which will take 5-10 minutes to complete. Following the cancer risk assessment, participants will be asked to take a PRO survey. PRO surveys will also be administered at the time of the cancer risk assessment and then 6 and 12 months following.
11090209|NCT04144920|Other|Block 4|Participants in this arm performed the conditions in this order: HFLD, LFHD, CS
11090132|NCT04145388|Experimental|Comparator 3|Participants will have their cancer risk assessed using a more detailed, full version of the family history survey than the one comparator 2 participants take. This version is a full pedigree assessment, which entails family health history for all 1st, 2nd, and 3rd-degree relatives. Time needed for completion is 15-25 minutes, depending on family size and cancer risk. Participants will also be asked to take the PRO survey following the full cancer risk assessment and also at 6 and 12 months.
11090133|NCT04145375|Experimental|Experimental: ZEN003694 in Combination with Enzalutamide|Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
11090134|NCT04145349|Experimental|Ramucirumab + Cyclophosphamide + Vinorelbine|Ramucirumab given intravenously (IV), Cyclophosphamide given orally and vinorelbine given IV.
11090135|NCT04145349|Active Comparator|Cyclophosphamide + Vinorelbine|Cyclophosphamide given orally and vinorelbine given IV.
11090136|NCT04145336|Active Comparator|5cm PDS group|All patients in this group receive 5cm 5-Fr PDS.
11090137|NCT04145336|Experimental|7cm PDS group|All patients in this group receive 7cm 5-Fr PDS.
11090138|NCT04145323|Experimental|ICG microangiography for necrotic tissue determination|During flap procedure, the study area of the patient will be imaged with a white light digital camera prior to a 5 mg dose of ICG as per FDA approved protocol for use of SPY device in microangiography. Following ICG injection, the study area will undergo fluorescence imaging using the SPY system to obtain microangiography perfusion data (baseline imaging - Standard of Care). During the standard postoperative evaluation (approximately 4 hours after baseline) and 24 hours after baseline, the study area will undergo repeat digital photography and fluorescence imaging using SPY for necrosis avid detection of ICG (Research only session). This evaluation with digital photography and fluorescence imaging will continue every 24 hours for the first 3 days after surgery or one day prior to discharge(Research only session).
11090139|NCT04145310|Experimental|Arm A|
11090140|NCT04145310|Placebo Comparator|Arm B|
11090141|NCT04145297|Experimental|Treatment: all patients|"Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily.
~Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level. Both medications will be administered in 28-day cycles"
11090142|NCT04145258|Other|WHO TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
11090143|NCT04145258|Other|WHO TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
11090144|NCT04145258|Other|Intensified TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
11090145|NCT04145258|Other|Intensified TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d
~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
11090146|NCT04145245|Experimental|Intervention or group a|Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation
11090147|NCT04145245|Placebo Comparator|Placebo or group b|Diabetic neuropathy patients with antidiabetic treatment in addition with placebo
11090148|NCT04145232||NSCLC|This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).
11090149|NCT04145219|Experimental|Active treatment|HDM SLIT-tablet plus allergy and asthma rescue medication
11090150|NCT04145219|Placebo Comparator|Placebo|Placebo oral tablet plus allergy and asthma rescue medication
11090151|NCT04145206||experimental group|the experimental group is characterized by the practice of flamenco dance
11090152|NCT04145206||control group|not practice of flamenco dance
11090153|NCT04145193|Active Comparator|Control Arm (mFOLFOX6)|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
11090154|NCT04145193|Experimental|Durvalumab|Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
11090155|NCT04145193|Experimental|Oleclumab|Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
11090156|NCT04145193|Experimental|Monalizumab|Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
11090157|NCT04145180|Experimental|Manual Therapy|Manual Therapy-based intervention
11090158|NCT04145180|No Intervention|Control|Patients waiting list
11090159|NCT04145167||Medical Treatment|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication.
11090160|NCT04145167||Percutaneous intervention|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team.
11090161|NCT04145167||Surgical treatment|This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision.
11090162|NCT04145154|Experimental|Plasma|Subjects to whom platelet rich plasma is applied
11090163|NCT04145154|No Intervention|Advanced cure|Subjects to whom advanced healing is performed
11090164|NCT04145141||1/ Cohort 1|Subjects with a diagnosis or suspicion of PLC
11090165|NCT04145128|Experimental|AG-881|Participants will receive AG-881 10 mg, tablet orally, once in Period 1 followed by AG-881 50 mg, tablet orally, once in Period 2. Period 1 and Period 2 will be separated by a washout period of 20 days between doses.
11090210|NCT04144920|Other|Block 5|Participants in this arm performed the conditions in this order: LFHD, CS, HFLD
11090166|NCT04145115|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11090167|NCT04145102|No Intervention|negative control|restoration will applied without any treatment
11090168|NCT04145102|Experimental|hesperidine|hesperidine will be applied for remaining caries then restoration will be applied
11090169|NCT04145102|Experimental|propolis|propolis will be applied for remaining caries then restoration will be applied
11090170|NCT04145102|Experimental|silver diamine fluoride|silver diamine fluoride will be applied for remaining caries then restoration will be applied
11090171|NCT04145089|Active Comparator|C-Mac intubation|Intubation with C-MAC video laryngoscopy
11090172|NCT04145089|Active Comparator|Glidescope intubation|Intubation with Glidescope video laryngoscopy
11090173|NCT04145076|Experimental|Placebo, Citalopram, Tianeptine|Dose order: Placebo, Citalopram, Tianeptine
11090174|NCT04145076|Experimental|Placebo, Tianeptine, Citalopram|Dose order: Placebo, Tianeptine, Citalopram
11090175|NCT04145076|Experimental|Citalopram, Placebo, Tianeptine|Dose order: Citalopram, Placebo, Tianeptine
11090176|NCT04145076|Experimental|Citalopram, Tianeptine, Placebo|Dose order: Citalopram, Tianeptine, Placebo
11090177|NCT04145076|Experimental|Tianeptine, Placebo, Citalopram|Dose order: Tianeptine, Placebo, Citalopram
11090178|NCT04145076|Experimental|Tianeptine, Citalopram, Placebo|Dose order: Tianeptine, Citalopram, Placebo
11090179|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent will be placed (usually the standard of care)
11090180|NCT04145063|Active Comparator|uncomplicated ureteroscopic lithotripsy without US|Following uncomplicated uretroscopic lithotripsy no uretric stent will be placed
11090181|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US-string|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent with an extraxtion string will be placed
11090182|NCT04145050|Experimental|Carbohydrate Dose: 0 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
11090183|NCT04145050|Experimental|Carbohydrate Dose: 30 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
11090184|NCT04145050|Experimental|Carbohydrate Dose: 60 grams carbohydrate|Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.
11090185|NCT04145037|Experimental|Switch Stable|study arm will include subjects who have been receiving ERT for a minimum of 24 months immediately preceding Screening, have demonstrated clinical stability during the 6 months immediately preceding Screening, and have not been treated with substrate reduction therapy (SRT) during the 24 months immediately preceding Screening (ie, switch-stable subjects). Switch-stable subjects must discontinue ERT prior to transplantation.
11090186|NCT04145037|Experimental|treatment-naïve|will include subjects who have either never received ERT or SRT, or have not received ERT or SRT within 12 months of screening
11090187|NCT04145024||Pulmonary arterial hypertension|Group 1 PH
11090188|NCT04145024||Pulmonary hypertension due to left heart disease|Group 2 PH
11090189|NCT04145024||Pulmonary hypertension due to lung disease|Group 3 PH
11090190|NCT04145024||Chronic thromboembolic pulmonary hypertension|Group 4 PH
11090191|NCT04145024||Miscellaneous|Group 5 PH
11090192|NCT04145024||Exclusion PH|Patient with invasively excluded PH
11090193|NCT04145011|Experimental|COOLIEF Cooled Radiofrequency Probe|Cooled radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
11090194|NCT04145011|Active Comparator|Conventional (Standard) Radiofrequency Probe|Standard (non-cooled) radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
11090195|NCT04144985|Active Comparator|Eyelid Speculum|Eyelid retraction was performed with an eyelid speculum.
11090196|NCT04144985|Experimental|Cotton Tipped Applicator|Eyelid retraction was performed with the cotton tipped applicator eyelid retraction technique.
11090197|NCT04144985|Experimental|Unimanual Eyelid Retraction|Eyelid retraction was performed with the unimanual eyelid retraction method.
11090198|NCT04144972|Active Comparator|Active DBS|Chronic brain recordings and stimulation with bilateral implantations in pain-related brain regions. All participants will participate in active DBS, blinded to the participant.
11090199|NCT04144972|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. brain recordings will remain active during this period. All participants will participate in inactive DBS, blinded to the participant.
11090200|NCT04144959||Patients with lower extremity acute limb ischemia|
11090201|NCT04144946||Healthy control group (CTRL)|Sports active individuals with no history of patellar tendinopathy.
11090202|NCT04144946||Early tendinopathy group (ET)|Sports active individuals with clinical signs of early tendinopathy and debut of symptoms within 90 days.
11090203|NCT04144946||Chronic tendinopathy group (CT)|Sports active individuals with clinical signs of tendinopathy and duration of symptoms >90 days.
11090204|NCT04144933|Experimental|Opioid-free General Anesthesia (OFA)|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis.
11090205|NCT04144933|Active Comparator|Traditional Opioid-containing General Anesthesia (TOA)|Opioid-sparing preoperative medications, Opioid-containing pre-intubation medications, Opioid-containing maintenance medications, postoperative nausea and vomiting prophylaxis.
11090206|NCT04144920|Other|Block 1|Participants in this arm performed the conditions in this order: CS, HFLD, LFHD
11090207|NCT04144920|Other|Block 2|Participants in this arm performed the conditions in this order: CS, LFHD, HFLD
11090208|NCT04144920|Other|Block 3|Participants in this arm performed the conditions in this order: HFLD, CS, LFHD
11090211|NCT04144920|Other|Block 6|Participants in this arm performed the conditions in this order: LFHD, HFLD, CS
11090212|NCT04144907|Experimental|Phenylalanine intake|
11090213|NCT04144894|Other|Healthy Controls|
11090214|NCT04144894|Other|Vascular Surgery Subjects|
11090215|NCT04144881|Experimental|coronary computed tomography|
11090216|NCT04144881|No Intervention|conservative (ischemia-guided) management|
11090217|NCT04144868|Experimental|Experimental: NBO group|"For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours.
~Regular treatment is based on associated guidelines for ICH ."
11090218|NCT04144868|No Intervention|Control group|"Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours.
~Regular treatment is based on associated guidelines for ICH ."
11090219|NCT04144855|Experimental|TQB3474 injection|Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
11090220|NCT04144842|Experimental|ATOR-1017|ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent
11090221|NCT04144829|Active Comparator|HIFU|3 cycles of HIFU treatment in 6-week intervals
11090222|NCT04144829|Active Comparator|Fibrin|3 cycles of platelet-rich fibrin injection treatment in 6-week intervals
11090223|NCT04144816||Passive Birth Cohort|"This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.
~Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon."
11090224|NCT04144803||Cerebral desaturation group|absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
11090225|NCT04144803||Control group|no absolute drop of forehead cerebral oxygen saturation ≥ 10% from baseline for ≥ 5 minutes during prehospital anesthesia
11090226|NCT04144790||ADHD+RLS|Twelve participants between the ages of 5 and 18 years with a clinical diagnosis of either RLS or ADHD, and iron deficiency.
11090227|NCT04144777|Experimental|Treatment|Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
11090228|NCT04144777|No Intervention|Placebo|Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
11090229|NCT04144764|Experimental|Workplace-based exercise group|
11090230|NCT04144764|Sham Comparator|Control group|
11090231|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
11090232|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
11090233|NCT04144725||Suspected coronary artery disease|Patients hospitalized for suspected acute coronary syndrome who are referred to CCTA or patients referred to CCTA from outpatient clinics for evaluation of stable coronary artery disease.
11090234|NCT04144712|Experimental|High Dose arm|subjects will receive the high dose of the drug
11090235|NCT04144712|Active Comparator|low dose arm|subject will receive low dose of the drug
11090236|NCT04144686|Active Comparator|Group A|Vestibular participants undertaking a single-task vestibular rehabilitation
11090237|NCT04144686|Experimental|Group B|Vestibular participants undertaking a dual-task vestibular rehabilitation
11090238|NCT04144673|Experimental|Investigational Product|
11090239|NCT04144673|Placebo Comparator|Placebo|
11090240|NCT04144660||Cardiogenic Shock Treated with ECMO|This cohort of participants required clinical intervention with ECMO for treatment of their index cardiogenic shock episode while pregnant or post delivery of their infant.
11090241|NCT04144647|Experimental|Healthy adults 18-80 years old|Healthy adults 18-80 years old
11090242|NCT04144634|Experimental|Intervention/Strengthening|
11090243|NCT04144634|Sham Comparator|Control/Stretching|
11090244|NCT04144621||Normal SDF|Couples with male partners having SDF lower than 20% using TUNEL assay
11090245|NCT04144621||Abnormal SDF|Couples with male partners having SDF greater than 20% using TUNEL assay
11090246|NCT04144608|Experimental|Toripalimab Combined With Platinum-containing Dual-agent|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer
11090247|NCT04144595||Low plasma glucose|This group will be formed by women with low plasma glucose: fasting plasma glucose (<10th percentile, <65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.
11090248|NCT04144595||Normal plasma glucose|This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but < 92 mg/dL), 1 or 2-hour normal glucose (< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.
11090249|NCT04144582|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Metastatic or Non-driver Gene Mutation Non-small Cell Lung Cancer
11090250|NCT04144569|Experimental|PD-1 Combined With Pyrotinib|PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
11090251|NCT04144556|Experimental|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
11090252|NCT04144556|Active Comparator|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
11090664|NCT04141904|Experimental|Tofacitinib|Tofacitinib 5mg capsule twice a day for 7-10 days
11090253|NCT04144543|Experimental|White Noise|"The white noise used in our study is a fragment called Bebeğiniz ağlamasın-2 from Kolik album of Buzuki Orhan Osman, which was used in similar studies (Balci, 2006; Karakoc & Turker, 2014; Kucukoglu et al., 2016).Since the white noise is a continuously monotonous sound, which is in the form of a hum, it resembles the sounds in mother's womb (Balci, 2006)."
11090254|NCT04144543|Experimental|Facilitated Tucking|Facilitated tucking is the procedure of holding the baby's arms and legs in a flexed position close to the midline of the torso, and the baby is able to move his/her extremities during this procedure (Caglayan, 2011).
11090255|NCT04144543|Experimental|White Noise+Facilitated Tucking|Both applications performed together.
11090256|NCT04144517|Experimental|ALKS 4230 + pembrolizumab|
11090257|NCT04144504|Active Comparator|Plastic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given balloon dilatation and plastic stenting for treatment.
11090258|NCT04144504|Active Comparator|Retrievable metallic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given retrievable metallic stenting for treatment.
11090259|NCT04144491|Experimental|Yoghurt|Yoghurt, containing Lactobacillus rhamnosus yoba 2012, Streptococcus thermophilus C104, whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence.
11090260|NCT04144491|Placebo Comparator|Custard|Custard, containing whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence, 4% modified corn starch.
11090261|NCT04144478|Experimental|experimental|Web based education intervention
11090262|NCT04144478|No Intervention|No intervention|Normal polyclinics application
11090263|NCT04144465|Active Comparator|NORADRENALIN|NORADRENALINE INFUSION
11090264|NCT04144465|Active Comparator|PHENYLEPHRINE|PHENYLEPHRINE INFUSION
11090265|NCT04144452|Active Comparator|Patient Education Session|Educational session will be given twice a day for three months. Individualized instructional booklet about back care for each patient will be designed, reviewed and finalized by operating surgeons according to the needs of patients.
11090266|NCT04144452|Experimental|Therapeutic exercises plus educational sessions|Trunk and lower musculature strength and endurance training will be performed twice a week for three months. Therapeutic exercises incorporating mat exercises will be performed. Progression will be made according to patient status.
11090267|NCT04144439|No Intervention|Before treatment|no intervention
11090268|NCT04144439|Active Comparator|After treatment|GABA
11090269|NCT04144426|Experimental|Normal diet then modified diet|Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM. Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.
11090270|NCT04144426|Experimental|Modified diet then normal diet.|Participates in the modified diet skipped breakfast, had lunch at 12:30 PM, dinner at 5:45 PM, and a breakfast equivalent snack at 10:00 PM.Participates in the normal diet will receive 3 meals each day, breakfast at 8:00 AM,lunch at 12:30 PM and dinner at 5:45 PM.
11090271|NCT04144413|Experimental|Period 1 Open-label Ikervis|Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
11090272|NCT04144413|Experimental|Period 2 Masked Ikervis|"Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.
~IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
11090273|NCT04144413|Other|Period 2 Masked Vehicle|"Other: Vehicle Comparator. Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.
~Vehicle. Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
11090274|NCT04144400|Experimental|BRAVE Group|The BRAVE program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of quiet ego characteristics. The BRAVE intervention (delivered over four weeks) will ask study participants to use the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
11090275|NCT04144400|Active Comparator|Time Management Group|The time management program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of time management characteristics. The time management intervention (delivered over four weeks) will ask study participants to use the time management version of the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
11090276|NCT04144387|Experimental|Test group|Each patient included in the study will be followed for 5 years
11090277|NCT04144374|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 5 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
11090278|NCT04144374|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of omadacycline once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
11090279|NCT04144361|Experimental|sleeve without plication|sleeve gastrectomy on bougie 36 without plication
11090280|NCT04144361|Active Comparator|sleeve with plication|sleeve gastrectomy on bougie 42 without plication
11090281|NCT04144348|Experimental|mRNA-1653, Adult participants|
11090282|NCT04144348|Experimental|mRNA-1653 Pediatric participants|
11090283|NCT04144335|Active Comparator|Group 1: N-803 and bNAbs Only|Group 1 will receive only N-803 and the bNAbs; they will not receive the haNK™ cells
11090284|NCT04144335|Experimental|Group 2: N-803 and bNAbs with haNK™ Cells|The protocol for Group 2 will be identical to the one followed by Group 1, except that they will receive haNK™ cells on the same day as each dose of N-803.
11090285|NCT04144322|Other|Short Implant|17 patients will receive a 5 mm short implant.
11090286|NCT04144322|Other|Long Implant|17 patients will receive a sinus lift procedure, bone graft, and 10 mm implant.
11090287|NCT04144309|Active Comparator|True acupuncture group|12 sessions of acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
11090288|NCT04144309|Placebo Comparator|Sham acupuncture group|12 sessions of sham acupuncture treatment (SE+SA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
11090289|NCT04144296|Other|Study Arm|All patient will be included in this arm
11090290|NCT04144283|Experimental|NAP|The NAP group will undergo a post-learning 2-hour sleep opportunity in Experiment 1.
11090291|NCT04144283|Active Comparator|WAKE|The WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness in Experiment 1.
11090292|NCT04144270||Included patients|One-arm study. All included patients will have muscle mass and muscle function evaluated
11090293|NCT04144257|Experimental|Subjects diagnosed with Multiple Sclerosis (MS)|We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).
11090294|NCT04144244|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips will be used when preparing sperm of male partner and IUI will be made with separated sperm
11090295|NCT04144244|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and IUI will be made with separated sperm
11090296|NCT04144231|No Intervention|Treatment-as-usual (TAU)|Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.
11090297|NCT04144231|Experimental|Internet-Based Cognitive Behavioral Therapy for Insomnia|"TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks.
~HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
~During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes."
11090298|NCT04144231|Experimental|Cognitive Behavioral Group Therapy for Insomnia|TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.
11090299|NCT04144218|Placebo Comparator|Control group|
11090300|NCT04144218|Experimental|Experimental group|
11090301|NCT04144205|Experimental|Fraction of inspired oxygen setting change|
11090302|NCT04144192|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
11090303|NCT04144192|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15. The sequence in which they received patch treatment was determined by random assignment. For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
11090304|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 1|1 injection of Quadrivalent RIV containing H3 strain 1
11090305|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 2|1 injection of Quadrivalent RIV containing H3 strain 2
11090306|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 3|1 injection of Quadrivalent RIV containing H3 strain 3
11090307|NCT04144179|Experimental|Quadrivalent RIV with H3 strain 4|1 injection of Quadrivalent RIV containing H3 strain 4
11090308|NCT04144179|Active Comparator|Quadrivalent RIV Control|1 injection of Quadrivalent RIV containing 2018-19 NH recommended H3 strain
11090309|NCT04144153|Experimental|Opioid Free Anesthesia Group|
11090310|NCT04144153|Active Comparator|Opioid Anesthesia Group|
11090311|NCT04144140|Experimental|Dose Escalation: Advanced Solid Tumors or Lymphomas|
11090312|NCT04144140|Experimental|Dose Expansion: Advanced Solid Tumors or Lymphomas|Dose identified from dose escalation part for E7766 will be used in dose expansion part.
11090313|NCT04144127|Experimental|Soccer Group|Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week). They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics). During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
11090339|NCT04143971|Placebo Comparator|Continiuous Low calorie diets|Low calorie diet with daily calorie restriction
11090340|NCT04143971|Active Comparator|Intermittent Fasting|Intermittent fasting every other day, in which daily calorie intake will be up to 30% of required calorie.
11090665|NCT04141904|Placebo Comparator|Placebo|Placebo capsule twice a day for 7-10 days
11090314|NCT04144127|Active Comparator|mHealth Education Group|"The mHealth education group receive brochures on the American Heart Association (AHA) Life's Simple 7 and encouraged to visit the AHA's My Life Check website for customized lifestyle recommendations. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
~Participants will be offered (for free) 4 sessions of recreational soccer instruction on the basics of the program."
11090315|NCT04144114|Experimental|Whey + ProHydrolase®|Subjects received 250mg of ProHydrolase® along with 25g of whey protein mixed in a drink every visit for 4 weeks
11090316|NCT04144114|Active Comparator|Whey|Subjects received 25g whey protein in a drink every visit for 4 weeks
11090317|NCT04144114|Placebo Comparator|Placebo|Subjects received 25g maltodextrin in a drink every visit for 4 weeks
11090318|NCT04144101|Experimental|Etoricoxib|Etoricoxib 60 mg QD
11090319|NCT04144101|Experimental|Aceclofenac|Aceclofenac 100 mg BID
11090320|NCT04144088|Active Comparator|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
11090321|NCT04144088|Active Comparator|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
11090322|NCT04144088|Placebo Comparator|Placebo|Drug : 1/10 Wu Ling San
11090323|NCT04144075|Experimental|Mindful Self-Compassion|Protocolized training program in mindfulness and self-compassion skills.
11090324|NCT04144075|Active Comparator|Cognitive Behaviour Therapy Group|A control intervention designed to develop a control group suitable for comparison with experimental groups receiving interventions based on mindfulness and compassion.
11090325|NCT04144075|Placebo Comparator|Treatment as Usual|Es variable según las características clínicas y personales del paciente.
11090326|NCT04144062|Active Comparator|Zirconia crowns|
11090327|NCT04144062|Active Comparator|CAD/CAM crowns|
11090328|NCT04144049|Experimental|MT921|1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
11090329|NCT04144049|Placebo Comparator|Placebo|Subcutaneously administered at most 50 injections per treatment.
11090330|NCT04144036|Experimental|Neihulizumab Dose Escalation, 3 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
11090331|NCT04144036|Experimental|Neihulizumab Dose Escalation, 6 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
11090332|NCT04144036|Experimental|Neihulizumab Dose Escalation, 9 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
11090333|NCT04144036|Experimental|Neihulizumab Dose Expansion|Upon determination of the maximum-tolerated dose, an expansion cohort of 4-7 patients will be enrolled so that a total of 10 patients are enrolled at the potential Phase II dose. This will be done to preliminarily assess efficacy.
11090334|NCT04144023|Experimental|Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)|Prior to standard of care surgery, patients receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11090335|NCT04143997||PPCM with Diastolic Dysfunction & Normal Systolic Function|The patient population examined will include patients diagnosed with peripartum cardiomyopathy who have diastolic dysfunction and normal systolic function.
11090336|NCT04143984|Active Comparator|Arm-CIRT|Patients will only receive carbon-ion radiotherapy with a dose of 63-69 GyE in 21-23 fractions (the fraction size is 3 GyE).
11090337|NCT04143984|Experimental|Arm-C|Patients will receive carbon-ion radiotherapy and camrelizumab. In details, patients will receive carbon-ion radiotherapy with a dose of 63-69 GyE in 21-23 fractions (the fraction size is 3 GyE); in addition, patients will also receive camrelizumab of 200 mg (IV.), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year.
11090338|NCT04143984|Experimental|Arm-CA|Patients will receive carbon-ion radiotherapy, camrelizumab and apatinib. In details, patients will receive carbon-ion radiotherapy with a dose of 63-69 GyE in 21-23 fractions (the fraction size is 3 GyE); patients will also receive camrelizumab of 200 mg (intravenously), every 2 weeks, started with carbon-ion radiotherapy for a maximal period of 1 year; in addition, patients will receive apatinib of 250 mg (PO.) daily, started with carbon-ion radiotherapy for a maximal period of 1 year.
11090574|NCT04142437||Lung|adult patients with lung cancer
11090341|NCT04143958|Experimental|agalsidase beta|Commercially available agalsidase beta treatment at approved dose and regimen;administered once every 2 weeks as an IV infusion
11090342|NCT04143958|Active Comparator|agalsidase alfa|Commercially available agalsidase alfa treatment at approved dose and regimen; administered once every 2 weeks as an IV infusion
11090343|NCT04143945|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
11090344|NCT04143945|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
11090345|NCT04143919|Experimental|Subjects with CV risk factors|Subjects with 2 or more CV risk factors will be identified. Cardiovascular risk factors include hypertension, dyslipidemia, obesity, vascular disease, diabetes mellitus, chronic kidney disease, arrhythmia requiring therapy, moderate to severe valvular disease, history of alcohol abuse, smoking, cancer chemotherapy, or thoracic radiotherapy, and abnormal findings in the most recent ECG or thoracic X-ray.
11090346|NCT04143906|Experimental|Vinorelbine/Carboplatin|Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
11090347|NCT04143906|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1; q 3 weeks
11090348|NCT04143893||Cardiogenic shock with MCS|Patients with cardiogenic shock who underwent MCS
11090349|NCT04143893||Cardiogenic shock without MCS|Patients with cardiogenic shock who did not undergo MCS
11090350|NCT04143880|Experimental|experimental group|Progesterone
11090351|NCT04143880|Placebo Comparator|control grou|saline
11090352|NCT04143867|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
11090353|NCT04143854|Experimental|MBA-P01 24U|Experimental group; Dose: 24U
11090354|NCT04143854|Experimental|MBA-P01 12U|Experimental group; Dose: 12U
11090355|NCT04143854|Placebo Comparator|Placebo|Placebo group; normal saline
11090356|NCT04143841|Active Comparator|Single treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
11090357|NCT04143841|Sham Comparator|Single sham treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
11090358|NCT04143828|Experimental|Mobile Mindfulness Programme|The mobile mindfulness program is delivered via a mobile application.
11090359|NCT04143828|No Intervention|Wait-list control condition|When assigned to the control condition, participants will be wait-listed for 3 months during the study. After the final assessment participants will receive access to the mobile mindfulness program.
11090360|NCT04143815|Experimental|MBA-P01 30U|Experimental group, Dose: 30U
11090361|NCT04143815|Experimental|MBA-P01 20U|Experimental group, Dose: 20U
11090362|NCT04143815|Experimental|MBA-P01 10U|Experimental group, Dose: 10U
11090363|NCT04143815|Placebo Comparator|Placebo|Placebo group, Normal saline
11090364|NCT04143802|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
11090365|NCT04143802|Active Comparator|Dulaglutide|Dulaglutide administered SC
11090366|NCT04143802|Placebo Comparator|Placebo|Placebo administered SC
11090367|NCT04143789|Experimental|Tablets to be taken orally daily for 14 of 21 day cycle|AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days
11090368|NCT04143763|Active Comparator|Intervention group|receive mobile messages supporting caregivers' psychological well-being, according to the participants' preferences in intervention group.
11090369|NCT04143763|No Intervention|Control group|receive general health information through a mobile message.
11090370|NCT04143750|Experimental|[14C]Vicagrel|
11090371|NCT04143737|Other|Intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
11090372|NCT04143737|No Intervention|Control|22 women participated in the control group. They were recruited from a community center in the old city of Jerusalem and did not receive any intervention. Baseline data was collected.
11090373|NCT04143724|Experimental|Cohort 1: 12 to < 18 years - Luspatercept 0.75 mg/kg|Luspatercept 0.75 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090374|NCT04143724|Experimental|Cohort 2: 12 to < 18 years: Luspatercept 1.0 mg/kg,|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090375|NCT04143724|Experimental|Cohort 3: 6 to < 12 years: Luspatercept 0.75 mg/kg|Luspatercept 0.75 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090376|NCT04143724|Experimental|Cohort 4: 6 to < 12 years: Luspatercept 1.0 mg/kg|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090377|NCT04143724|Experimental|Cohort 5: 2 to < 6 years: Luspatercept 0.75 mg/kg|Luspatercept 0.75 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090378|NCT04143724|Experimental|Cohort 6: 2 to < 6 years: Luspatercept 1.0 mg/kg|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090379|NCT04143724|Experimental|Cohort 7: 6 months to < 2 years: Luspatercept 0.75 mg/kg|Luspatercept 0.75 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090380|NCT04143724|Experimental|Cohort 8: 6 months to < 2 years: Luspatercept 1.0 mg/kg|Luspatercept 1.0 mg/kg, administered SC once every 21 days (for up to 4 cycles)
11090381|NCT04143711|Experimental|Monotherapy DF1001 Dose Escalation|Dose escalation cohorts of DF1001 in sequential ascending order.
11090382|NCT04143711|Experimental|Monotherapy DF1001 PK/PD Expansion|Expansion cohorts of monotherapy DF1001 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
11090383|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Urothelial Bladder Cancer|Monotherapy expansion cohort enrolling up to 40 patients with urothelial bladder cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
11090384|NCT04143711|Experimental|Monotherapy DF1001 Expansion in Metastatic Breast Cancer|Monotherapy expansion cohort enrolling up to 40 patients with metastatic breast cancer using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
11090575|NCT04142437||Melanoma|adult patients with melanoma
11090385|NCT04143711|Experimental|Monotherapy DF1001 Expansion in HER-2 High Expressing Cancers|Monotherapy expansion cohort enrolling up to 40 patients with solid tumors showing documented high levels HER-2 expression using the recommended phase 2 dose (RP2D) identified in the Monotherapy Dose Escalation arm.
11090386|NCT04143711|Experimental|Combination Therapy with DF1001 and Pembrolizumab|Combination dose escalation of DF1001 in combination with a PD-1 checkpoint inhibitor in patients with select solid tumors.
11090387|NCT04143698|Active Comparator|Disposable (single-use) duodenoscope|This group will be using the disposable (single-use) duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
11090388|NCT04143698|Active Comparator|Reusable duodenoscope|This group will be using the reusable duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
11090389|NCT04143685|Active Comparator|misoprostol|misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six
11090390|NCT04143685|Active Comparator|oxytocin|Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)
11090391|NCT04143672|Experimental|study group|"The following tests will be performed on the study subjects.
~Pain catastrophizing scale
~Hospital Anxiety and Depression scale-Anxiety Subscale (HADS-A)
~Pain sensitivity questionnaire
~Pain pressure threshold using electronic digital pressure algometer"
11090392|NCT04143659|Experimental|LB injection 40mg intramuscular (IM)|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg intramuscular (IM)
11090393|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SC)|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC)
11090394|NCT04143659|Experimental|LB injection 80mg intramuscular (IM)|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 80mg intramuscular (IM)
11090395|NCT04143659|Experimental|LB injection 80mg Subcutaneous (SC)|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 80mg subcutaneous (SC)
11090396|NCT04143646|Active Comparator|Web-based prevention program|"Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts.
~In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure."
11090397|NCT04143646|No Intervention|Usual Care|Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).
11090398|NCT04143633|Experimental|FODMAP diet in Irritable Bowel Syndrome|Patients with IBS will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
11090399|NCT04143633|Experimental|FODMAP diet in Ulcerative Colitis|Patients with UC will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
11090400|NCT04143633|Active Comparator|FODMAP diet in healthy patients|Healthy patients will be randomized to standard diet or low fodmap diet. The nutritional status (body composition and clinical parameters), gut microbiota, adherence to treatment, improvement of gastrointestinal symptoms and quality of life will be evaluated for 10 weeks.
11090401|NCT04143620|Other|Neovascular glaucoma|Neovascular glaucoma patients underwent triple procedure
11090402|NCT04143607|Experimental|ASK120067+ placebo Gefitinib|ASK120067 (160 mg or 80 mg orally, twice daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
11090403|NCT04143607|Active Comparator|Gefitinib + placebo ASK120067|Gefitinib (250 mg orally, once daily) plus placebo ASK120067 (160 mg or 80 mg orally, twice daily), in accordance with the randomization schedule. Following objective disease progression according to RECIST1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label ASK120067 (crossover to active ASK120067).
11090404|NCT04143594|Experimental|Lenacapavir, F/TAF, and TAF|"Induction: Participants will receive oral lenacapavir 600 mg, 600 mg, and 300 mg at Days 1, 2, and 8, respectively. Participants will also begin oral daily emtricitabine/tenofovir alafenamide (F/TAF) 200/25mg from Day 1 onwards for a total of 28 weeks. On Day 15 participants will receive subcutaneous (SC) lenacapavir 927 mg.
~Maintenance: Participants will receive SC lenacapavir 927 mg at Week 28 and every 26 weeks. Participants will discontinue oral daily F/TAF 200/25 mg at Week 28 and begin taking oral daily TAF 25 mg.
~Participants willing to continue the study beyond Week 80 will continue to receive SC lenacapavir 927 mg every 6 months (26 weeks) and oral daily TAF 25 mg from Week 80 onwards."
11090405|NCT04143594|Experimental|Lenacapavir, F/TAF, and BIC|"Induction: Participants will receive oral lenacapavir 600 mg, 600 mg, and 300 mg at Days 1, 2, and 8, respectively. Participants will also begin oral daily F/TAF 200/25 mg from Day 1 onward for a total of 28 weeks. On Day 15 participants will receive SC lenacapavir 927 mg.
~Maintenance: Participants will receive SC lenacapavir 927 mg at Week 28 and every 26 weeks. Participants will discontinue oral daily F/TAF 200/25 mg at Week 28 and begin oral daily bictegravir (BIC) 75 mg.
~Participants willing to continue the study beyond Week 80 will continue to receive SC lenacapavir 927 mg every 6 months (26 weeks) and oral daily bictegravir (BIC) 75 mg from Week 80 onwards."
11090406|NCT04143594|Experimental|Lenacapavir and F/TAF|"Participants will receive oral lenacapavir 600 mg at Day 1 and Day 2. On Day 3, participants will begin oral daily lenacapavir 50 mg. Participants will begin oral daily F/TAF 200/25 mg from Day 1 onwards.
~Participants willing to continue the study beyond Week 80 will continue to receive oral daily lenacapavir 50 mg and oral daily F/TAF 200/25 mg from Week 80 onwards."
11090407|NCT04143594|Active Comparator|B/F/TAF|Participants will receive oral daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg at Day 1 and throughout their participation in the study.
11090408|NCT04143581|Experimental|IMP|
11090409|NCT04143568||Control|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
11090666|NCT04141891|Experimental|Driving Decision Aid|Web-based Driving Decision Aid
11090410|NCT04143568||Periodontitis|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
11090411|NCT04143555||endoscopic submucosal injection of indocyanine green|
11090412|NCT04143542|Experimental|Groups Q|"In abdominal surgeries, USG guided Quadratus Lumborum 2 blocks are performed for postoperative analgesia. For this purpose, Quadratus Lumborum Block 2 (QLB 2) are frequently used blocks.
~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
11090413|NCT04143542|Experimental|Groups T|"In abdominal surgeries, USG guided TAP blocks are performed for postoperative analgesia. For this purpose, TAP blocks are frequently used blocks.
~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
11090414|NCT04143542|No Intervention|Groups C|There was no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg, and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with the target of EtCO2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC). Anesthesia will be discontinued and tracheal extubation will be done once the patient fulfills the extubation criteria.Tramadol 100 mg i.v. Before 15 min end of surgery. The patient control analgesia device will administer all patients.
11090415|NCT04143529|Experimental|Personalized acceptance-based mindfulness exercise|The purpose of this study is to identify whether a brief 60-second acceptance based mindfulness intervention at specific time points will reduce state trait anxiety, Mini-Mental Adjustment to Cancer Scale score, pain intensity, distress, anxiety, depression and anger
11090416|NCT04143529|Placebo Comparator|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 second at specific timepoints.
11090417|NCT04143516|Experimental|Patients with Colon Cancer Liver Metastases|The standard of care thermal ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.
11090418|NCT04143503||adult critically ill patients|
11090419|NCT04143490|Experimental|UC Patients|Patient group
11090420|NCT04143490|Active Comparator|Healthy controls|Control group
11090421|NCT04143477|Experimental|Peficitinib dose-A|Participants will receive a single dose of A under fasted condition Day 1, followed by multiple doses of A under fed condition once daily in the morning from Day 8 till Day 13.
11090422|NCT04143477|Experimental|Peficitinib dose-B|Participants will receive a single dose of B under fasted condition Day 1, followed by multiple doses of B under fed condition once daily in the morning from Day 8 till Day 13.
11090423|NCT04143477|Experimental|Peficitinib dose-C|Participants will receive a single dose of C under fasted condition Day 1, followed by multiple doses of C under fed condition once daily in the morning from Day 8 till Day 13.
11090424|NCT04143464|Experimental|Intervention group|"The participants in this group will receive group kyphosis-specific exercise classes given by the certified physical trainer and kyphosis-specific exercise videos.
~The intervention arrangement is:
~Group learning and practice: a 1-hour kyphosis-specific exercise training session will be provided two times in the first week,
~Weekly follow-up: a 1-hour kyphosis-specific exercise will be conducted with reinforcement of learning and remedial teaching by a certified physical trainer once a week for five consecutive weeks after the group learning and practice,
~Self-practice: the participant will following the kyphosis-specific exercise videos doing self-practice every day for the whole intervention period lasting six weeks."
11090425|NCT04143464|No Intervention|Control group|No special arrangement
11090426|NCT04143451|Active Comparator|IQ|"Year 1: a single dose ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream
~Year 2: randomised into 3 subgroups. Group IQ1: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream Group IQ2: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IQ3: ID normal saline vaccination with pre-treatment of the injected skin with imiquimod (Aldara) cream.
~Year 3: IQ1 and IQ2 same treatment as second year. IQ3 same as first year."
11090427|NCT04143451|Active Comparator|IM|"Year 1: a single dose IM QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream
~Year 2: randomised into 3 subgroups. Group IM1: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IM2: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream. Group IM3: IM normal saline vaccination with aqueous cream pretreatment.
~Year 3: IM1 and IM2 same treatment as second year. IM3 same as first year."
11090428|NCT04143451|Active Comparator|HD|"Year 1: a single high-dose IM TIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream
~Year 2: Group HD1: IM QIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream. Group HD2: IM normal saline vaccination with aqueous cream pretreatment.
~Year 3: Group HD1 same treatment as second year. HD2 same as first year."
11090429|NCT04143438|Experimental|Undergoing EOS 3D imaging|Patients with patello-femoral instability will undergo EOS 3D Imaging protocol before and after undergoing corrective surgery
11090430|NCT04143425||Received bevacizumab treatment|Recurrent glioblastoma patients with received anti-angiogenic treatment
11090431|NCT04143412|Active Comparator|Tritace (Ramipril)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks
11090576|NCT04142437||Pediatric|all pediatric patients regardless of tumor type will be enrolled under this cohort
11090577|NCT04142437||other|patients with other tumor types
11090432|NCT04143412|Active Comparator|Eraloner (Eplerenone)|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks
11090433|NCT04143412|Active Comparator|Tritace/Eraloner (Ramipril/Eplerenone)combination therapy|25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks
11090434|NCT04143399|Active Comparator|holmium laser enucleation of the prostate|holmium laser enucleation of the prostate (HoLEP)
11090435|NCT04143399|Active Comparator|bipolar resection of the prostate|bipolar resection of the prostate (BPEP)
11090436|NCT04143373|Experimental|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
11090437|NCT04143373|No Intervention|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
11090438|NCT04143360|Experimental|New Closed Drainage Device|We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.
11090439|NCT04143360|Experimental|Traditional Closed Drainage Device|We use traditional closed drainage devices for patients with hemothorax and pneumothorax.
11090440|NCT04143347||Community Hospitals - CH|Patients with head injury managed at Community Hospitals
11090441|NCT04143347||Level 1 Trauma Center - L1TC|Patients with head injury presenting to level 1 trauma center directly
11090442|NCT04143347||Transfer|Patients with head injury presenting at a community hospital but then getting transferred to the level 1 trauma center
11090443|NCT04143334||RAAB survey|We will examine 3700 Chaonan County residents aged 50 years and older, selected via a clustered, randomized sampling with probability proportional to size (PPS). The cluster will be at the village level, 50 subjects aged 50 years and older will be examined in each cluster includes Visual acuity, torch light, and fundus review, the major cause of blindness or visual impairment will be determined.
11090444|NCT04143334||conventional survey|All the recruited participants underwent ophthalmic examination according to the RAAB protocol and then 60% of them were re-examined with instruments in a mobile eye clinic set up in a village center on the same day. Examination in the mobile clinic included standardized visual acuity (VA) tests using logarithm of the minimum angle resolution charts, refraction, slit-lamp biomicroscopy, and dilated fundal examination with a binocular indirect ophthalmoscope.
11090445|NCT04143321|Experimental|empagliflozin|following a two-week washout and complete SAQ and exercise tolerance test patients gave 25 mg empagloflozin and therafter SAQ and ETT was done
11090446|NCT04143321|Placebo Comparator|No drug|following a two-week washout and complete SAQ and exercise tolerance test patients gave placebo and therafter SAQ and ETT was done
11090447|NCT04143308|Experimental|Simultaneous training of walking and cognitive group|"Wearable technology (fitness wristband & App)
~SWATCH system (App & controller)
~3 times a week (30 mins/ each time)
~Lasts for 12 weeks
~Simultaneous walking and cognitive training"
11090448|NCT04143308|Active Comparator|Cognitive training group|"Wearable technology (fitness wristband & App)
~SWATCH system (App)
~3 times a week (30 mins/ each time)
~Lasts for 12 weeks
~Cognitive training while sitting"
11090449|NCT04143308|Active Comparator|Treatment as usual group|1. Keep treatment as usual group at health care system.
11090450|NCT04143282|Experimental|Metformin group|Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy
11090451|NCT04143282|Other|control group|Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only
11090452|NCT04143269|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the GammaCore device (ElectroCore LLC)
11090453|NCT04143269|Sham Comparator|Sham Treatment|Inactive sham vagus nerve stimulation applied by the GammaCore sham device (ElectroCore LLC)
11090454|NCT04143256|Experimental|Group I|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Virginia Tobacco and 3% Virginia Tobacco
11090455|NCT04143256|Experimental|Group II|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mint and 3% Mint
11090456|NCT04143256|Experimental|Group III|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Menthol and 3% Menthol
11090457|NCT04143256|Experimental|Group IV|Subjects with ENDS user history may be randomized to use JUUL ENDS 5% Mango and 3% Mango
11090458|NCT04143256|Experimental|Group V|Subjects with cigarette user history will be assigned to use US Cigarette, Non-Menthol Flavor (Marlboro Gold King Size)
11090459|NCT04143256|Experimental|Group VI|Subjects with cigarette user history will be assigned to use US Cigarette, Menthol Flavor (Newport King Size)
11090460|NCT04143243|Active Comparator|ACT on Life|"Acceptance and Commitment Therapy plus Education, Resources and Support ('ACT on Life').
~The ACT+ERS intervention will include: 1) Acceptance and Mindfulness Training (2-3 hours); 2) Committed Action Training (2-3 hours) involving helping Veterans clarify what matters most to them and what they want to stand for in life, how they want to behave, and what sorts of strengths and qualities they want to develop; and; 3) Education, Resources, and Support (1 hour)."
11090461|NCT04143243|Placebo Comparator|Education, Resources, and Support|Information provided in the ERS workshop was compiled from existing VHA and community resources. Veterans will be educated about 1) symptoms of depression, anxiety and PTSD and how these conditions do and do not impact daily life and functional ability; 2) common difficulties and challenges with reintegration into civilian life; 3) mild TBI, differences between civilian and Veteran TBIs, shared/crossover symptoms (for example, memory and concentration difficulties, sleep disturbance, irritability can be symptoms of depression, PTSD, and mild TBI); 4) chronic pain; how it is often often misinterpreted as on-going damage, leading to fear of physical activities and resulting in increased sedentary behavior and declines in physical functioning; and 5) treatment options and resources. Basic resource counseling will include guidance on the evidence-based treatments available at VHA. Problem solving, relaxation, and deep breathing techniques will be covered
11090462|NCT04143230|Active Comparator|Extended Screening Tool (EST)|The SIAARTI/NCCN (EST) screening tool is, in fact, an instrument validated by many scientific societies, but it is very articulated and its compilation is too much time-consuming.
11090463|NCT04143230|Experimental|Simplified Screening Tool (SST)|The Simplified Screening Tool (SST) has been created through a statistical process in order to include all the critical variables, with the advantage of being shorter and therefore easier to administer in a routinely use.
11090464|NCT04143217|Experimental|Open-Label Treatment|
11090465|NCT04143204||very preterm infants cohort|A prospective cohort of very preterm or very low birth weight infants from birth to corrected age 18 months.
11090466|NCT04143191|Active Comparator|Sorafenib|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
11090467|NCT04143191|Experimental|Sorafenib plus TACE|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.
11090468|NCT04143178|Experimental|Expressive Writing Group|Writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the disease, the transplant, and their best expectations after the operation.
11090469|NCT04143178|Other|Control Group|The control group participant has been asked to describe an objects in their room, in a neutral way, without mentioning emotions or feelings,for 3 consecutive days, 20 minutes each day.
11090470|NCT04143165|Active Comparator|Epidural block|Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
11090471|NCT04143165|No Intervention|control group|patients did not receive injection
11090472|NCT04143152||Diagnostic/prognostic cohort|Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.
11090473|NCT04143152||Surveillance Cohort|Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma
11090474|NCT04143126|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.
~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
11090475|NCT04143126|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
~Time commitment: about 2 hours per week; Location: Pittsburgh, PA only"
11090476|NCT04143113|No Intervention|Usual Care (n=20)|Control: general information about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
11090477|NCT04143113|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
11090478|NCT04143087||Withdrawal TKIs|
11090479|NCT04143087||halve TKIs|
11090480|NCT04143074|Other|intervention|multidisciplinary intervention arm - behavioral intervention by physician, dietician, psychologist and physical activity trainer
11090481|NCT04143061|Experimental|Group 1|MenACYW conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
11090482|NCT04143061|Active Comparator|Group 2|Menactra® conjugate vaccine, 1 vaccination, adults in India aged 18 to 55 years
11090483|NCT04143061|Experimental|Group 3|MenACYW conjugate vaccine, 1 vaccination, adults in India aged ≥ 56 years
11090484|NCT04143061|Active Comparator|Group 4|Quadri Meningo™, 1 vaccination, adults in India aged ≥ 56 years
11090485|NCT04143061|Experimental|Group 5|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in India aged 2 to 17 years
11090486|NCT04143061|Active Comparator|Group 6|Menactra®, 1 vaccination, children and adolescents in India aged 2 to 17 years
11090487|NCT04143061|Experimental|Group 7|MenACYW conjugate vaccine, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
11090488|NCT04143061|Active Comparator|Group 8|Menactra®, 1 vaccination, children and adolescents in RSA aged 2 to 17 years
11090489|NCT04143048||The construction of Gene detection technology flow|At this stage, a small panel targeted high-throughput sequencing process for gastrointestinal stromal tumors was established, and the association of tumor-associated mutation profiles in different patients with clinical stage was initially explored. It is planned to collect about 100 cases of gastrointestinal stromal tumors after surgery (freezing tissue or FFPE sections), DNA extraction and high-throughput sequencing of small panels, and analysis of the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging).
11090490|NCT04143048||Establishment of non-invasive gene testing technology process|In this stage, we plan to establish a small panel of peripheral blood cfDNA targeting high-throughput sequencing process, and verify the consistency of peripheral blood cfDNA and tissue gDNA in gene detection of gastrointestinal stromal tumors. About 50 patients were planned to be enrolled. Peripheral blood was collected once for each patient and the blood volume was 10mL. Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion . DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor.
11090491|NCT04143048||Prospective cohort (double-blind recommended)|Peripheral blood of about 150 patients was collected once and the blood volume was 10mL . Meanwhile, the tumor tissue samples were collected within 5mm in diameter, depending on the size of the lesion. Patients focus on the early stage of stromal tumors or those whose size under gastroenteroscopy is between 2 and 5 cm. DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutation spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutation spectrum, and compared with the real clinical data of patients.
11090492|NCT04143022|Active Comparator|group A (acupuncture press needle)|Group A subjects first receive acupuncture press needle treatment at acupoint of Jin's 3-tongue point and EX-HN25. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
11090493|NCT04143022|Active Comparator|group B (acupuncture press needle)|Group B subjects first receive acupuncture press needle treatment at acupoint of EX-CA1, EX-CA5 and EX-CA6. Then, it takes 2-week washout period. After washout period, subjects receive another course of treatment at acupoint of Jin's 3-tongue point and EX-HN25. Each subject receive 2 times a week of treatment for 4 weeks (8 times in total) in each course.
11090494|NCT04143009|Experimental|Adapted Friendship Bench (AFB)|35 women seeking ANC services at Mitundu Clinic in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Adapted Friendship Bench intervention from date of enrollment through 6 months post-partum.
11090495|NCT04143009|Experimental|Enhanced Friendship Bench (EFB)|35 women seeking ANC services at Lumbadzi Clinic in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Enhanced Friendship Bench intervention from date of enrollment through 6 months post-partum.
11090496|NCT04143009|Active Comparator|Enhanced Standard Care (ESC)|35 women seeking ANC services at Nathenje Clinic will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will received the Enhanced Standard Care intervention from date of enrollment through 6 months post-partum.
11090497|NCT04142996|Active Comparator|Unilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
11090498|NCT04142996|Active Comparator|Bilateral TBS|Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
11090499|NCT04142996|Active Comparator|Maintenance Phase: Fixed|The fixed protocol will consist of two sessions per week for the first month, followed by a weekly TBS session for two months, biweekly sessions for two months and a monthly session for the last month (total of 21 sessions over 6 months).
11090500|NCT04142996|Active Comparator|Maintenance Phase: Flexible|The flexible maintenance protocol will be based on symptom emergence. Participants will receive a fixed TBS (2x/week) schedule for the first month. For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.
11090501|NCT04142983|Experimental|Study Group|Participants will receive a single dose of Tdap vaccine (Adacel) every 3 months for a total of 5 immunizations over a period of 12 months.
11090502|NCT04142970|Active Comparator|Mild renal impairment|Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)
11090503|NCT04142970|Active Comparator|Moderate renal impairment|Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)
11090504|NCT04142970|Active Comparator|Subjects with normal renal functions|Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)
11090505|NCT04142957||Focus Groups|"The investigators will invite 13-15 participants to attend the focus groups, of which it is expected that 10-12 to attend. Participants will be asked to bring a smart phone. An Informed Consent Form will be signed by the participant and a delegated researcher before the focus groups begin.
~The current generation of COPD Pal will be downloaded onto the participants' own smart phones (see Appendix 1 for current screenshots of app), participants will then be explained the purpose of the app, and asked to interact with it for 15-60 minutes, as required.
~A semi-structured focus group will then be conducted with the participants to facilitate conversation and discussion regarding COPD Pal. Once introductions have been completed, questions will be asked relating to the usability and acceptability of COPD Pal (see the Interview Schedule, Appendix 2). The focus group will last 30-60 minutes, as required."
11090506|NCT04142944|Experimental|Dexcom G6 with predictive hypo alert|
11090507|NCT04142944|Active Comparator|Dexcom G6 without predictive hypo alert|
11090508|NCT04142931|Active Comparator|filtration of 2X PV|filtration of 2X PV through the ImmunicomAIAC
11090509|NCT04142931|Active Comparator|filtration of 3X PV|filtration of 3X PV through the Immunicom AIAC
11090510|NCT04142931|Active Comparator|filtration of 2X PV combined with Nivolumab 240mg|filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
11090511|NCT04142931|Active Comparator|filtration of 3X PV combined with Nivolumab 240mg|filtration of 3X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.
11090512|NCT04142905||Patients With Asthma|Subjects with sleep disordered breathing with asthma
11090513|NCT04142905||Patients Without Asthma|Subjects with sleep disordered breathing without asthma
11090514|NCT04142892|Experimental|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD). 3 weeks of (+/-3 days) of ONA treatment
11090515|NCT04142879||Non-Interventional Centers|"Cohort A: Viz Subjects Initially Presenting to a Non-Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a non- interventional center.
~Cohort B: Subjects Initially Presenting to a Non-Interventional Center The standard of care group will be comprised of subjects randomized to not have Viz notification and who initially present to a non-interventional center."
11090516|NCT04142879||Interventional Centers|"Cohort C: Viz Subjects Initially Presenting to an Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a interventional center.
~Cohort D: Subjects Initially Presenting to a Interventional Center The standard of group will be comprised of subjects randomized to not have Viz notification and who initially present to an interventional center."
11090517|NCT04142866|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
11090667|NCT04141891|Active Comparator|Older Drivers Website|National Institute on Aging (NIA) Older Drivers website
11090518|NCT04142866|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 milliamps [mA]) plus aphasia therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
11090519|NCT04142853|Experimental|Persons with MS, dance group|
11090520|NCT04142853|Active Comparator|Persons with MS, art group|
11090521|NCT04142840|Experimental|Dexmedetomidine Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.
~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the dexmedetomidine group will be infused with a single dose of 0.7ug/kg dexmedetomidine."
11090522|NCT04142840|Active Comparator|Propofol Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.
~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the propofol group will be infused with a single dose of 0.5mg/kg propofol."
11090523|NCT04142827|Experimental|Therapy with high flow humidification|The patients will be activated after enrollment with myAirvo2 device at home for 6 months before first observations
11090524|NCT04142827|No Intervention|Therapy with usual care|The patients will be under usual care for observational
11090525|NCT04142814|Experimental|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.
~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).
~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.
~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.
~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
11090526|NCT04142814|Active Comparator|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.
~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).
~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.
~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.
~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
11090527|NCT04142801|Experimental|MeMo group|MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
11090528|NCT04142801|Placebo Comparator|Control group|Regular follow up at the memory center without cognitive training
11090529|NCT04142788|No Intervention|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
11090530|NCT04142788|Experimental|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
11090531|NCT04142775||intracranial hemorrhage (ICH)|ARDS patients treated with ECMO developing ICH
11090532|NCT04142775||no intracranial hemorrhage|ARDS patients treated with ECMO not developing ICH
11090533|NCT04142762|Experimental|Cohort 1: ABI-H2158 + Itraconazole|Oral ABI-H2158 on Days 1 and 9; oral itraconazole once-daily (QD) on Days 6 through 13
11090534|NCT04142762|Experimental|Cohort 2: ABI-H2158 + Rifampin|Oral ABI-H2158 on Days 1 and 12; oral rifampin QD on Days 6 through 16
11090535|NCT04142762|Experimental|Cohort 3: ABI-H2158 + Esomeprazole|Oral ABI-H2158 on Days 1 and 11; oral esomeprazole QD on Days 6 through 11
11090536|NCT04142762|Experimental|Cohort 4: ABI-H2158 + Midazolam|Oral midazolam on Days 1 and 11; oral ABI-H2158 QD on Days 2 through 11
11090537|NCT04142762|Experimental|Cohort 5: ABI-H2158 + Oral Contraceptive|Cycle 1: active oral contraceptive (ethinyl estradiol/levonorgestrel) QD on Days 1 through 21 and oral placebo QD on Days 22 through 28; Cycle 2: active oral contraceptive QD on Days 1 through 21, oral placebo QD on Days 22 through 26, and oral ABI-H2158 QD on Days 11 through 24
11090538|NCT04142749|Active Comparator|Oltipraz|Oltipraz 30mg
11090539|NCT04142749|Placebo Comparator|Placebo|Placebo 30mg
11090540|NCT04142736|Experimental|Prone position|Patients with acute respiratory failure with high flow nasal oxygen therapy and prone position
11090541|NCT04142736|No Intervention|Supine position|Patients with acute respiratory failure with high flow nasal oxygen therapy and supine position
11090542|NCT04142710|Experimental|Follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements.
11090543|NCT04142710|No Intervention|Standard clinical care|Participants in this arm receive standard clinical care in accordance with their medinal needs.
11090763|NCT04141176|Experimental|Spiri+|new CPAP device
11090544|NCT04142710|Experimental|Non-randomized follow-up using telehealth solutions|Participants in this arm are followed up using a telehealth solution, as specified by the National Directorate of Health at the local centre. The actual follow-up is personalized to the individual user. All users receive a tablet, which can be used to answer questions about own health and/or transmit clinical measurements. This arm is not randomized, but otherwise identical to the randomized experimental arm.
11090545|NCT04142697|Active Comparator|Healthy subjects|
11090546|NCT04142697|Active Comparator|Vestibular Disease patients|
11090547|NCT04142671|Experimental|Individualised Gait Modification Intervention|"Patients will carry out several walking trials to test the efficacy of an individualised gait modification intervention.
~Pre-intervention over ground walking, pre-intervention treadmill walking, intervention treadmill walking with real-time biofeedback on their knee loading, intervention treadmill walking with no feedback, and post-intervention over ground walking."
11090548|NCT04142658|Experimental|Apixaban|"Apixaban 5 mg twice daily(BID) or 2.5 mg BID
~For participants randomized to apixaban, INR testing will be performed on the current warfarin dose with the following algorithm to initiate apixaban
~INR < 2; stop warfarin and start apixaban
~INR 2.0 to 3.0; hold warfarin for 2 days, start apixaban on day 3
~INR > 3.0 to 4.0; hold warfarin for 4 days, start apixaban on day 5
~INR > 4.0; hold warfarin for 2 days, recheck INR, refer to steps 1, 2, or 3"
11090549|NCT04142658|Active Comparator|Warfarin|Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)
11090550|NCT04142645|Experimental|Intervention|The intervention group (i.e. all eligible and consented residents of 2 NHs) will receive the OptiMEDs intervention: the combination of an electronic decision support tool (for the appraisal of potentially inappropriate medication use, anticholinergic use, or medications that can be de-prescribed in view of limited life expectancy) with focused nurse observations (using a list of potential medication-related symptoms based on the individual medication chart of the nursing home residents), that will serve as the basis during a multidisciplinary medication review with the input of GPs, trained community pharmacists and nurses.
11090551|NCT04142645|No Intervention|Control|The control group (i.e. all eligible and consented residents of one control NH) will receive usual care .
11090552|NCT04142632||long term evaluation of hypospadias surgery|
11090553|NCT04142619|Experimental|Dose Escalation|Several tested doses of UCARTCS1A until the Maximum Tolerated Dose (MTD) is identified.
11090554|NCT04142606||Control Group (Group 1)|Having prenatal ultrasound screening without detected abnormality
11090555|NCT04142606||Non Optimal Ultrasound Scan Group (Group 2)|Having an ultrasound examination without abnormality detected but in whom ultrasound examination is not optimal (poor technical conditions, multiple pregnancies, obese patients)
11090556|NCT04142606||Malformation Group (Group 3)|Standardized prenatal screening with ultrasound examination finding an isolated anomaly that does not currently constitute a commonly accepted indication of fetal MRI
11090557|NCT04142606||TOP Group (Group 4)|A medical termination of pregnancy, (TOP), in addition to a fetopathological examination (virtopsy)
11090558|NCT04142554|Experimental|Single Arm: Parsaclisib ( Dose De-Escalation )|Prior to their scheduled standard of care surgery or research biopsy, subjects (n = 5 per dosing cohort) will be given oral doses of parsaclisib (10, 3.0 or 1.0 mg) once daily over 14 consecutive days.
11090559|NCT04142541|Experimental|Carotid artery stenting with Neuroguard IEP System|To evaluate the safety and feasibility of the Neuroguard IEP System when used in patients with clinically significant carotid artery stenosis requiring revascularization.
11090560|NCT04142528||Parkinson's Disease|Smartwatch-based sensor assessment of PD symptoms during standard care
11090561|NCT04142502|Active Comparator|Propofol group|Using propofol as a sedation drug Infusion rate control Effect site concentration 0.3~1.0 mg/ml using target concentration infusion Bispectral index 60~80
11090562|NCT04142502|Active Comparator|Dexmedetomidine group|Using dexmedetomidine as a sedation drug First 10 minutes 1.0 mcg/kg loading After 10 minutes 0.3-1.0 mcg/kg/hr maintenance Bispectral index 60~80
11090563|NCT04142489|Other|UV and biopsy|"Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= 6.4 photoproducts, and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure."
11090564|NCT04142476|Experimental|Pharmaceutical Interview|Pharmaceutical Interview to motivate patient in his hormonotherapy's compliance
11090565|NCT04142463|No Intervention|Before-group|This arm comprises patients who are recruited in phase 3 of the study, i.e. before the implementation of the care pathway. It is intended that patients included in phase 3 serve as a control-group for patients included in phase 6.
11090566|NCT04142463|Experimental|After-group|This arm comprises patients who are recruited in phase 6 of the study, i.e. after the implementation of the care pathway.
11090567|NCT04142450|Experimental|CoolSculpting® System in Both Arms and Thighs|Each participant will undergo a single treatment session that comprises timed segments of cooling followed by 2 minutes of manual massage.Each treated arm will have up to two timed segments (or cycles) in the treatment session, each treated thigh will have one timed segment (or cycle) in the treatment session.
11090568|NCT04142450|Experimental|CoolSculpting® System in Arms Only|Each participant will undergo a single treatment session that comprises timed segments of cooling followed by 2 minutes of manual massage. Each treated arm will have up to two timed segments (or cycles) in the treatment session.
11090569|NCT04142450|Experimental|CoolSculpting® System in Thighs Only|Each participant will undergo a single treatment session that comprises timed segments of cooling followed by 2 minutes of manual massage. Each treated thigh will have one timed segment (or cycle) in the treatment session.
11090570|NCT04142437||GI|adult patients with gastrointestinal (GI) cancer
11090571|NCT04142437||H&N|adult patients with head and neck (H&N) cancer
11090572|NCT04142437||STS|adult patients with soft tissue sarcoma (STS)
11090573|NCT04142437||CNS|adult patients with primary central nervous system (CNS) cancer
11090578|NCT04142424|Experimental|Cohort 1 healthy subjects: AZD2693 Dose 1|Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090579|NCT04142424|Experimental|Cohort 2 healthy subjects: AZD2693 Dose 2|Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090580|NCT04142424|Experimental|Cohort 3 healthy subjects: AZD2693 Dose 3|Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090581|NCT04142424|Experimental|Cohort 4 healthy subjects: AZD2693 Dose 4|Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090582|NCT04142424|Experimental|Cohort 5 healthy subjects: AZD2693 Dose 5|Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090583|NCT04142424|Experimental|Cohort 6 healthy subjects: AZD2693 Dose 6|Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090584|NCT04142424|Experimental|Cohort 7 healthy Japanese subjects: AZD2693 Dose 7|Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090585|NCT04142424|Experimental|Cohort 8 healthy Japanese subjects: AZD2693 Dose 8|Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090586|NCT04142424|Experimental|Cohort 9 healthy Chinese subjects: AZD2693 Dose 9|Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1.
11090587|NCT04142411|Experimental|Insulin and Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin and 20 mg of Sodium Hyaluronate
11090588|NCT04142411|Active Comparator|Insulin Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin
11090589|NCT04142411|Active Comparator|Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 20 mg of Sodium Hyaluronate
11090590|NCT04142398||Screening (health information collection)|Participants receive a questionnaire and undergo a targeted physical and anal clinical exam at months 0, 6, and 12. Participants also undergo a penile skin cell and anal swab at months 0, 6, and 12 for cytology, HPV DNA, and CD4+ T-cell count at months 0 and 6 and HIV viral load testing at months 0 and 12. Participants also undergo HRA and penile clinical exam at month 12.
11090591|NCT04142385||Observational (health information collection)|Participants receive a questionnaire, undergo a targeted physical and anal clinical exam, undergo blood collection and urethral swab for STIs, and a penile skin cell and anal swab for cytology and HPV DNA at months 0, 6, and 12. Participants also undergo HRA and penile clinical exam at month 12.
11090592|NCT04142359||Cohort A: CIS (either study)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
11090593|NCT04142359||Cohort B: High-Grade Ta/T1 Papillary Disease (either study)|Patients with histologically confirmed presence of BCG-unresponsive high-grade Ta/T1 papillary disease
11090594|NCT04142359||Cohort C: CIS (QUILT-3.032)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
11090595|NCT04142346|No Intervention|Uninterrupted sitting|Participants remained seated throughout 7 hours. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
11090596|NCT04142346|Experimental|Sitting + moderate intensity breaks|Participants were instructed to sit throughout 7 hours, while interrupting the sitting position every 30 minutes to perform 2 minutes of moderate-intensity physical activity. The breaks consisted of walk up and down stairs and squats. Each person performed these exercise alternately. During the protocol, participants were allowed to go to the bathroom in a wheelchair and al-libitum water was granted.
11090597|NCT04142333|Other|GIA Access|All patients consented to this study will be given access to the GIA technology to share with their family members.
11090598|NCT04142320|Experimental|Closed-loop rTMS|Closed-loop rTMS will be delivered to determine the target engagement compared to open-loop rTMS. Closed loop rTMS will be applied for two consecutive days for 30 minutes to determine dose response. Closed- loop rTMS will be delivered using neuro-navigation based on participants' own MRI images. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
11090599|NCT04142320|Active Comparator|Open-loop rTMS|A series of open-loop rTMS protocols will be delivered to determine the most effective standard and individualized rTMS. Active rTMS will be delivered using neuro-navigation based on participants' own MRI images. For each clinically-utilized rTMS protocol (1Hz, 5Hz, 10Hz, 20Hz), 3000 pulses will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
11090600|NCT04142320|Placebo Comparator|Sham rTMS|Sham rTMS will be delivered for two consecutive sessions to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
11090601|NCT04142307|Active Comparator|Group A (treatment)|Each session includes 20 minutes of training each with rest as needed. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. A fixation training target (FTT) will be selected by the trainer at a perceived better fixation point. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look in the direction of the FTT and listen simultaneously to the audio feedback. As performing this task, the participant will actively control the eye movements until the audio feedback becomes more frequent and then becomes a continuous sound pattern. This continuous sound will signalize to the patient that the FTT location was reached. Participants will be given take-home efficiency reading exercises.
11090764|NCT04141163|Experimental|Metformin|Subjects randomized to metformin will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
11090602|NCT04142307|Sham Comparator|Group B (control)|"The simulated biofeedback training for Group B involves the following procedure:
~For four weeks, presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button. Participants will be given take-home efficiency reading exercises."
11090603|NCT04142294|Experimental|4 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 4 g/day.
11090604|NCT04142294|Experimental|8 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 8 g/day
11090605|NCT04142294|Experimental|12 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 12 g/day
11090606|NCT04142294|Experimental|16 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 16 g/day. The 16 g /day dose will be administered if no adverse effects are observed for doses 4-12 g/day
11090607|NCT04142268||Preeclampsia group|PE was defined as diastolic BP of at least 110 mmHg on one occasion or diastolic BP of at least 90 mmHg on two consecutive occasions more than 4 hours apart, in combination with proteinuria (≥300 mg total protein in a 24-hour urine collection and, if this was not available, ≥+2 proteinuria by dipstick analysis on two consecutive occasions at least 4 hours apart) that develops after 20 weeks of gestation in previously normotensive women
11090608|NCT04142268||Control group|Normal pregnancy group
11090609|NCT04142255|Experimental|FMT|20 subjects will be enrolled in this arm to receive FMT treatment.
11090610|NCT04142242|Experimental|Group 1: Menomune (MET49)|MenACYW conjugate vaccine single injection at Day 0 (3 years after primary vaccination) in participants who received a prior dose of Menomune vaccine in study MET49
11090611|NCT04142242|Experimental|Group 2: MenACYW conjugate vaccine (MET49)|MenACYW conjugate vaccine single injection at Day 0 (3 years after primary vaccination) in participants who received a prior dose of MenACYW conjugate vaccine in study MET49
11090612|NCT04142242|Experimental|Group 3: Menomune (MET49)|MenACYW conjugate vaccine single injection at Day 0 + 2 years (5 years after primary vaccination) in participants who received a prior dose of Menomune vaccine in study MET49
11090613|NCT04142242|Experimental|Group 4: MenACYW conjugate vaccine (MET49)|MenACYW conjugate vaccine single injection at Day 0 + 2 years (5 years after primary vaccination) in participants who received a prior dose of MenACYW conjugate vaccine in study MET49
11090614|NCT04142242|Other|Group 5: Menomune (MET44)|No vaccine injection in participants who received a prior dose of Menomune vaccine in study MET44 (NCT01732627), 6 to 7 years after primary vaccination
11090615|NCT04142242|Other|Group 6: MenACYW conjugate vaccine (MET44)|No vaccine injection in participants who received a prior dose of MenACYW conjugate vaccine in study MET44 (NCT01732627), 6 to 7 years after primary vaccination
11090616|NCT04142229|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
11090617|NCT04142229|Active Comparator|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting, and come to the clinical center twice for supervised stress assessments.
11090618|NCT04142216|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
11090619|NCT04142216|No Intervention|Control group|The patients will not chewing gum during three months.
11090620|NCT04142203||23 h surgery|Adult patients who were treated in 23 h surgical unit
11090621|NCT04142190||ELONVA|Patients stimulated with Elonva
11090622|NCT04142190||PUREGON|Patients stimulated with Puregon
11090623|NCT04142177|Active Comparator|Internet-based pain self-management program|Internet-based treatment (Step 1 Treatment)
11090624|NCT04142177|Active Comparator|Enhanced Physical Therapy|Intervention that combines the internet-based pain self-management program with tailored exercise and physical activity guided by a physical therapist (Step 1 treatment)
11090625|NCT04142177|Placebo Comparator|Continued Care and Active Monitoring (CCAM)|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management (Step 1 Treatment)
11090626|NCT04142177|Active Comparator|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive face-to-face treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months (Step 2 Treatment).
11090627|NCT04142177|Active Comparator|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT (Step 2 Treatment).
11090663|NCT04141917|Active Comparator|Point-of-care molecular testing and treatment of influenza|Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A & B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .
11090628|NCT04142177|Active Comparator|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace (Step 2 Treatment).
11090629|NCT04142164|Active Comparator|MacInfo presentation|MacInfo presentation prior to intravitreal drug injection
11090630|NCT04142164|Placebo Comparator|Placebo presentation|Placebo presentation prior to intravitreal drug injection
11090631|NCT04142151|Active Comparator|SanchiTongshu group|"Drug: SanchiTongshu The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
~Drug: Aspirin or Clopidogrel"
11090632|NCT04142151|Placebo Comparator|SanchiTongshu Placebo group|"Drug: placebo of Sanchitongshu The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
~Drug: Aspirin or Clopidogrel"
11090633|NCT04142138|Experimental|nutrition implementation|Volunteers with prehypertension, but otherwise healthy, will complete a screening visit, then be admitted to the In-Patient Unit for fourteen (14) days. Participants will be admitted for 5 days during the week and then go on pass for 2 weekend days each week with packed DASH diet meals. During hospitalization we will: 1) collect samples of blood and urine daily 2) monitor blood pressure, weight and pulse twice daily 3) collect 24-hour urine, twice during the period of two weeks 4) serve participants a menu based on DASH principles, namely low in sodium and high in potassium.
11090634|NCT04142125|Experimental|Experimental (riva + ASA)|Rivaroxaban 2.5mg bid + aspirin 81mg qd
11090635|NCT04142125|Active Comparator|Control (ASA alone)|Aspirin 81 mg qd
11090636|NCT04142112|Experimental|Ohana IVF Sperm Preparation Kit|Samples in the Ohana IVF Sperm Preparation Kit group will undergo product-specific multistep processing in the lab prior to insemination.
11090637|NCT04142112|Active Comparator|Standard IVF Preparation Kit|Samples in the Standard IVF Sperm Preparation Kit group will undergo traditional processing in the lab prior to insemination.
11090638|NCT04142099|Experimental|skin to skin contact 60 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.
~Observe the time of newborn spent in suctioning the maternal nipple in 60 minutes of skin to skin contact.
~No intervention or forced neonatal suction."
11090639|NCT04142099|Active Comparator|skin to skin contact 20 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.
~Observe the time of newborn spent in suctioning the maternal nipple in 20 minutes of skin to skin contact.
~No intervention or forced neonatal suction."
11090640|NCT04142086|Experimental|Group 1|1 injection of vYF vaccine Dosage 1
11090641|NCT04142086|Experimental|Group 2|1 injection of vYF vaccine Dosage 2
11090642|NCT04142086|Experimental|Group 3|1 injection of vYF vaccine Dosage 3
11090643|NCT04142086|Active Comparator|Group 4|1 injection of YF-VAX
11090644|NCT04142073||Children under 18 years of age|
11090645|NCT04142060|Experimental|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously
11090646|NCT04142047||HIV|Participants (ages 60 and above) with HIV
11090647|NCT04142047||Control|Participants (ages 60 and above) without HIV
11090648|NCT04142034|Active Comparator|iAmHealthy Behavorial Intervention|This intervention will receive the American Academy of Pediatrics (AAP) newsletter, group and individual sessions with the iAmHealthy behavioral intervention team via an electronic tablet provided by the sponsor.
11090649|NCT04142034|Active Comparator|NewsLetter Intervention|This intervention arm will only receive the American Academy of Pediatrics (AAP) newsletter for six months.
11090650|NCT04142021||patients with 3-vessel disease with or without left main|Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
11090651|NCT04142008|Experimental|Walk with Me app|
11090652|NCT04141995|Experimental|Treatment|Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.
11090653|NCT04141982||Suspected of having TB infection|These donors are suspected of having TB infection and live in a high endemic area for TB infection
11090654|NCT04141982||No (or minimal) TB risk factors|These donors must have no previous medical record of TB infection and live in low endemic area for TB infection
11090655|NCT04141982||low/intermediate risk of TB infection population|These donors must live in an low/intermediate endemic area for TB infection
11090656|NCT04141969|Active Comparator|RLP|ReaLife+
11090657|NCT04141969|Placebo Comparator|Inert|Inert brown powder to look similar to RLP
11090658|NCT04141969|No Intervention|Control|Not given RLP or the placebo
11090659|NCT04141943|Experimental|VR|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality
11090660|NCT04141943|No Intervention|Printed document|The patients who are allocated to the Printed document arm will receive information about radiotherapy via printed document.
11090661|NCT04141930|Other|Study Drug Eligible|Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant
11090662|NCT04141917|No Intervention|Standard influenza surveillance|Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
11090668|NCT04141878|Active Comparator|Aerobic Exercise Group|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.
11090669|NCT04141878|Active Comparator|Diet Skills Group|Participants will attend weekly classes focused on incorporating heart healthy foods (e.g., fruits and vegetables) into their existing dietary plan. We will ask them to limit the number of calories they take in and will show them how to use portion control with the goal of losing body weight. Participants will also learn hands-on skills for preparing healthy meals at home in cooking classes led by professional chefs.
11090670|NCT04141865||Xen|Patients treated with a Xen microstent for glaucoma.
11090671|NCT04141865||Aqueous shunt|Patients treated with an aqueous shunt for glaucoma.
11090672|NCT04141852|Experimental|AVF surgery with device|
11090673|NCT04141852|No Intervention|AVF surgery conventional|
11090674|NCT04141839|Other|Control|Delayed intervention: baseline and 3-month assessment prior to receiving the Safer Bars training.
11090675|NCT04141839|Experimental|Intervention|This arm with consist of bars randomized to have the Safer Bars training on their premises attended by all their liquor serving staff with assessment directly before and after training (pre/post), and at 3 and 6 months post-training follow-up.
11090676|NCT04141826|Experimental|Hydrolysed whey|Hydrolysed whey
11090677|NCT04141826|Active Comparator|Intact whey|Intact whey
11090678|NCT04141826|Placebo Comparator|Caseinate|Caseinate
11090679|NCT04141813||"Pilgrims doing the Camino de Santiago (any route)"|"In the present study we utilized the Ultreya dataset. The Ultreya study is an online longitudinal study aimed at evaluating the effects of the pilgrimage on the Way of Saint James on mental health and wellbeing (www.estudiocamino.org). This pilgrimage involves hundreds of paths around Europe with a common termination at Santiago de Compostela (Spain), and it was one of the most important Christian pilgrimages during the Middle Ages. Currently, it is walked by thousands of people (>300,000 per year)."
11090680|NCT04141800||Heart failure (HF) outpatients with reduced ejection fraction|"Heart Failure (HF) with reduced ejection fraction (REF): Patients with confirmed diagnosis of HF and with ejection fraction<40%.
~Hyperkalaemia: K+values> 5,4 mEq/L.
~Optimal doses: the maximum doses of renin-angiotensin-aldosterone related drugs that, according to the physician's judgement, the patient can receive. If any of these drugs (ACIEs, ARB-II, MRAs or sacubitril-valsartan) is de novointroducedat the initial visit, optimal doses will be not considered established.
~A previous personal history of diseases and/or outcomes will be registered according to the usual practice of every centre."
11090681|NCT04141787|Active Comparator|Ceftriaxone|Ceftriaxone 2g IV q24hvia Gravity (or q12h in the case of CNS infections) Duration dependent on site of infection, determined by treating infectious diseases (ID) clinicians based on accepted clinical guidelines.
11090682|NCT04141787|Active Comparator|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Usual Antibiotics to treat methicillin-susceptible Staphylococcal infections
~Cloxacillin 2g IV q4h via Pump (dose adjusted for renal function)
~Cefazolin 2g IV q8h via Preloaded Syringe (dose adjusted for renal function)
~Daptomycin 6-10mg/kg IV daily via Gravity (dose will be determined based on the severity of infection as per discretion of the ID clinician and in accordance with most recent evidence)
~Duration dependent on site of infection, determined by treating infectious diseases clinicians based on accepted clinical guidelines."
11090683|NCT04141774|Active Comparator|Passive FES|Subjects randomized to this control group will be asked to participate in a passive FES intervention or non-EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, and functional electric stimulation (FES) treatment.
11090684|NCT04141774|Experimental|Active FES|Subjects randomized to this experimental group will be asked to complete the active FES intervention which include EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, functional electric stimulation (FES) treatment, and EEG.
11090685|NCT04141761|Experimental|Treatment Group|
11090686|NCT04141761|Placebo Comparator|Placebo Group|
11090687|NCT04141748|Active Comparator|Hand Casting|hand cast will be taken using a circumferential plaster of Paris or fiber glass wrap of the residual limb with the subject in a seated position
11090688|NCT04141748|Active Comparator|standing hydrostatic pressure casting with a water cylinder|hand cast will be taken using a circumferential plaster of Paris wrap of the residual limb with the subject in a seated position. The residual limb is then placed into the Symphonie Aqua System while in a weight bearing standing position.
11090689|NCT04141735||patients from September 2016 to September 2018|all patients underwent allogeneic hematopoietic stem cell transplantation
11090690|NCT04141722|Experimental|Sleep|
11090691|NCT04141722|Experimental|Wake|
11090692|NCT04141709|Experimental|local ablative radiotherapy|The therapy is performed for all patients in the intervention arm using high-dose radiation therapy, either as conventional fractional irradiation with 2 Gy/fraction up to a total dose of 50 Gy or as hypofractional irradiation with a single dose of 10 Gy up to a total dose of 30 Gy.
11090693|NCT04141709|No Intervention|Observational group|"Effectiveness is measured as the rate in patients with PSA progression one year after randomization (defined as PSA nadir after randomization +2 ng/ml).
~There is a 2:1 randomization between intervention and observation group."
11090694|NCT04141696|Experimental|Ketamine|Given intravenously over 40 minutes
11090695|NCT04141696|Active Comparator|Midazolam (Placebo)|Given intravenously over 40 minutes
11090696|NCT04141670|Experimental|Low dose group|Experimental: Low dose group Group of three participants who are treated with a low dose of S48168 (ARM210) for 28 days.
11090697|NCT04141670|Experimental|High dose group|Experimental: High dose group Group of seven participants who are treated with a high dose of S48168 (ARM210) for 28 days.
11090698|NCT04141657||Group 1 (0-17 years)|We will observe the treatment course in ICU pediatric patients, register adverse events (AEs) and serious adverse events (SAEs) if occur, and assess patient health status at the end of the performed therapy.
11091404|NCT04136873|Placebo Comparator|Part A: 20 mg QD Placebo|Matching Placebo; Oral Dose
11090699|NCT04141644|Experimental|Treatment: all patients|Patients entering trial should be on stable dose of osi for ≥4 weeks. Patients will self-administer osi by mouth regardless of food once daily. Doses should be taken at about the same time every day (±6hrs) and recorded on the patient dosing diary. Doses missed outside of the dosing window should not be made up but patients should be instructed to take their next dose at their regularly scheduled time. Ipi will be administered at the assigned dose level every 21 days (±3days) for a max of 4 doses. Ipi must be infused using a volumetric pump over 90min (±10min) through an IV line. Upon completion of the ipilimumab regimen, patients will continue osimertinib daily until disease progression, initiation of new anti-cancer therapy, or death by any cause.
11090700|NCT04141631|Experimental|STOP Group|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if
~Hb < 12g/dL the day before surgery
~Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay
~Postoperative Transfusion will be guided by ScvO2 values :
~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb < 7g/dL independently of ScVO2 value"
11090701|NCT04141631|No Intervention|Control Group|"Only postoperative anemia will be managed:
~RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)
~Iron sucrose administration if Hb > 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg."
11090702|NCT04141605||SherpaPak CTS Patients|Patients whose donor heart was transported with the SherpaPak CTS
11090703|NCT04141605||Standard Transport Patients|Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years
11090704|NCT04141592||Healthy Control|non-obese individuals without fatty liver disease
11090705|NCT04141592||Non-alcoholic fatty liver disease without NASH|
11090706|NCT04141592||Non-alcoholic steatohepatitis|
11090707|NCT04141592||Obese without non-alcoholic fatty liver disease|
11090708|NCT04141579|Experimental|Treatment arm|Evolocumab (140mg) will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of 140 mg/mL Evolocumab.
11090709|NCT04141579|Placebo Comparator|Comparator arm|Placebo will be administered subcutaneously every two weeks (Q2W) on day 1 through week 12 with personal injectors, containing 1 mL deliverable volume of placebo.
11090710|NCT04141566||PCPC|pseudocontinent perineal colostomy using shmidt technique for perineal reconstruction after abdominoperineal resection
11090711|NCT04141566||PLIC|Permanenet left iliac colostomy , the standard technique after abdominoperineal resection and primary closure of the perineal wound
11090712|NCT04141553|Active Comparator|Diltiazem IV push|In the standard IV push group, diltiazem will be administered at a dose of 0.25 mg/kg, to a max dose of 25 mg, over 2 minutes. At time 0, these participants will also receive 30 mg of immediate release oral diltiazem. After 15 minutes, if adequate rate control of <110 BPM has not been achieved, an additional dose 0.35 mg/kg to a max dose of 35 mg will be administered. In order to maintain the blind, the control group will also receive 50 mL of 0.9% NS IV over 20 minutes.
11090713|NCT04141553|Active Comparator|Diltiazem IV Slow Infusion|In the slow infusion group, 50 mg of diltiazem will be diluted in 50 mL of 0.9% NS and infused over 20 minutes. Similar the other group, these participants will also receive 30 mg of immediate release oral diltiazem. In order to maintain the blind, this slow infusion group will receive the equivalent volume of IV 0.9% NS over 2 minutes as a placebo.
11090714|NCT04141540|Other|"Groupe Twin 1"|Twin 1 with psychotic symptoms (PANSS +) Molecular analyses 1
11090715|NCT04141540|Other|"Groupe Twin 2"|Twin 2 without psychotic symptoms (PANSS +) Molecular analyses 2
11090716|NCT04141527||Primiparous women|82 primiparous obstetrical patients given intrathecal sufentanil for labor pain.
11090717|NCT04141527||Multiparous women|82 multiparous obstetrical patients given intrathecal sufentanil for labor pain.
11090718|NCT04141514|Experimental|intervention group|therapeutic fasting
11090719|NCT04141514|No Intervention|control group|usual alimentation
11090720|NCT04141501|Placebo Comparator|Control: Placebo|30 Patients will receive placebo
11090721|NCT04141501|Active Comparator|Intervention: Psilocybin|30 Patients will receive psilocybin
11090722|NCT04141488|Experimental|Experimantel Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own. The experimantel group was given strengthening exercises of the upper trapezoidal, middle trapezoidal and serratus anterior muscles with extra scapula muscles.
11090723|NCT04141488|Other|Control Group|Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
11090724|NCT04141475|Active Comparator|Alpha-Lipoic Acid group|
11090725|NCT04141475|Placebo Comparator|placebo group|
11090726|NCT04141462|Experimental|Patients with a a constitutional genetic alteration|one genetic consultation and one blood test
11090765|NCT04141163|Placebo Comparator|Placebo|Subjects randomized to placebo will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
11090766|NCT04141150|Experimental|[18F]APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
11090767|NCT04141137|Experimental|TricValve® System Single-Arm|Two self-expanding biological valves for implantation into the inferior and superior vena cava.
11090727|NCT04141449|Experimental|Potlako intervention|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation
~Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer
~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.
~Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program
~Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer."
11090728|NCT04141449|Active Comparator|Enhanced Care|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation.
~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer."
11090729|NCT04141436|Experimental|Intervention|Intervention Based on Hypnofertility
11090730|NCT04141436|Active Comparator|Control|Routine clinical procedure
11090731|NCT04141423|Active Comparator|Tregopil 30 mg|Dose level cohort with a sentinel dosing design
11090732|NCT04141423|Active Comparator|Tregopil 45 mg|Dose level cohort with a sentinel dosing design
11090733|NCT04141423|Active Comparator|Tregopil 60 mg|Dose level cohort with a sentinel dosing design
11090734|NCT04141423|Active Comparator|Derived Dose level|Derived Dose level cohort with a sentinel dosing design
11090735|NCT04141397||POG patients|Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
11090736|NCT04141397||Usual care controls|Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
11090737|NCT04141384|Other|General rehabilitation+Modular Interactive Tiles System, MITS|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment. In the experimental group, external stimulation (MITS) was added, and the training time was 65 minutes. Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
11090738|NCT04141384|No Intervention|General rehabilitation|Subjects were randomly assigned to the experimental or control group after completing the Berg scale test before the experiment.In the control group, each training time was 45 minutes.Before the start of the experiment and after the training every 4 weeks, each group must carry out the Berg scale and balance assessment.
11090739|NCT04141371|Active Comparator|Molar Sodium Lactate|
11090740|NCT04141371|Placebo Comparator|physiological serum|
11090741|NCT04141358||Study group|Patients with end-stage renal disease who will undergo arteriovenous fistula (AVF) surgery will be recruited and follow-up them up to 6 weeks or until the AVF become suitable for hemodialysis.
11090742|NCT04141345||Heart failure with chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
11090743|NCT04141345||Heart failure without chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. HF patients who did not have chronic lung disease were assigned as a non-CLD group.
11090744|NCT04141332||Group 1|80 Patient
11090745|NCT04141332||Group 2|80 Control subject
11090746|NCT04141319|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
11090747|NCT04141319|Active Comparator|The control group|In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.
11090748|NCT04141293|Experimental|Eligible patients|
11090749|NCT04141280||Insomnia group|According to the inclusion and exclusion criteria, 150 patients with insomnia were selected, which were divided into five groups: liver stagnation fire syndrome, phlegm heat syndrome, yin deficiency fire dysfunction syndrome, heart spleen deficiency syndrome and heart deficiency biliary syndrome.
11090750|NCT04141280||Normal group|According to the inclusion and exclusion criteria, 30 normal people were selected.
11090751|NCT04141254|Experimental|Debriefing|"a standardized follow-up visit at one month associated with debriefing and enhanced educative component"
11090752|NCT04141254|Other|Without debriefing|"a standardized follow-up visit at one month alone (i.e.; without debriefing and educative component)"
11090753|NCT04141241|Experimental|Low Dose PH100: 800mg/day|"PH100 (Ecklonia cava Phlorotannin) 200mg/tablet
~PH100 2 tablets (400mg) and Placebo 2 tablets BID during 12wks"
11090754|NCT04141241|Experimental|High Dose PH100: 1600mg/day|- PH100 4 tablets (800mg) BID during 12wks
11090755|NCT04141241|Placebo Comparator|Placebo|"Placebo 200mg/tablet
~Placebo 4 tablets BID during 12wks"
11090756|NCT04141228||Patients receiving apixaban|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
11090757|NCT04141228||Patients receiving warfarin|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
11090758|NCT04141215|Experimental|BIOBank bone paste (PPT322)|Allogeneic bone paste derived from human living donor femoral heads
11090759|NCT04141215|Active Comparator|BIOBank cortico-cancellous bone powder (PPT6)|Allogeneic bone powder derived from human living donor femoral heads (used in current practice)
11090760|NCT04141202||Exercise group|
11090761|NCT04141189|Experimental|weekly|weekly fetal surveillance
11090762|NCT04141189|Active Comparator|bi-weekly (twice-weekly)|bi-weekly fetal surveillance
11090768|NCT04141124|Sham Comparator|Control|5 minutes of reading fictitious biological medical results that are almost normal and unrelated to the upcoming scenario. This condition reflects a likely activity in relation to other patients in charge, pending an announced critical situation.
11090769|NCT04141124|Active Comparator|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
11090770|NCT04141124|Experimental|Breathing exercise combined with HRV|5 minutes of relaxing breathing, guided by a computer helping to follow inspiration and expiration and coupled with direct biological feedback on HRV.
11090771|NCT04141111|Experimental|CGM intervention|Underwent intervention defined by the intermittent use of a continuous glucose monitoring (CGM) device.
11090772|NCT04141098|Experimental|Total Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
11090773|NCT04141085||Healthy volunteers without infertility|Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
11090774|NCT04141085||Infertile Patients|Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
11090775|NCT04141059|Experimental|Oligopin|Intervention group that will intake 100 mg of Oligopin® for 6 weeks
11090776|NCT04141059|Placebo Comparator|Placebo|Placebo group that will intake 250 mg of Maltodextrin
11090777|NCT04141046|Sham Comparator|Sham Stimulation|This is a sham/placebo arm that receives some stimulation, mimicking the skin sensations associated with tACS to enhance success of patient blinding.
11090778|NCT04141046|Active Comparator|Theta-tACS|This arm targets theta oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
11090779|NCT04141046|Experimental|Alpha-tACS|This arm targets alpha oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
11090780|NCT04141033|Other|saliva neopterin levels|assessment of saliva neopterin levels in pre and post-menopausal women
11090781|NCT04141033|Other|GCF neopterin levels|assessment of GCF neopterin levels in pre and post-menopausal women
11090782|NCT04141020|Experimental|Microsurgical Clipping Treated with Sirolimus|Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.
11090783|NCT04141020|Experimental|Endovascular Treatment Treated with Sirolimus|Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.
11090784|NCT04140994|Active Comparator|Intermittent theta burst stimulation|"Volunteers will be submitted to non-invasive parietal stimulation before a mirror drawing task.
~A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver interrmittent bursts of bipolar magnetic pulses exerting an excitation on the underlying brain tissue (iTBS). The stimulation coil will be placed over the parietal cortex. Stimulation consisted of a burst of three pulses administered at 50Hz, repeated at a frequency of 5Hz, delivered in 2 s trains followed by an 8 s interval for a total of 600 pulses12. Stimulation intensity was set at 70% of RMT.
~Each session will consist of two spaced neuronavigated iTBS applications, separated by 15 minutes."
11090785|NCT04140994|Sham Comparator|Sham intermittent theta burst stimulation|For sham iTBS, the protocol is the same, except the sham coil produces no magnetic field.
11090786|NCT04140981||group 1|difficult intubation according to antropometric measurements
11090787|NCT04140981||group 2|not difficult intubation according to antropometric measurements
11090788|NCT04140981||group 3|difficult intubation according to ultrasound measurements
11090789|NCT04140981||group 4|not difficult intubation according to ultrasound measurements
11090790|NCT04140968|Experimental|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg)by mouth,every day in the second and third menstrual cycle daily from cycle day 15 to 26.
11090791|NCT04140955|Experimental|Tapering plan and telephone counselling|Patients receive an individually customized tapering plan at discharge and telephone counselling 5-7 days after discharge.
11090792|NCT04140955|No Intervention|Control group|Patients receive standard care and treatment, i.e. no tapering plan or telephone counselling.
11090793|NCT04140942|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual, participants will participate in Virtual Reality Job Interview Training.
11090794|NCT04140942|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but not limited to vocational skill training, and social skill training.
11090795|NCT04140929|Experimental|Intervention group|In the intervention group, a range of clinical parameters are recorded and the dentists prepares an individual oral hygiene and care recommendation, based on the Oral Health Tool Box. The Box is also used for instructing the dental assistants and the nursing staff for each patient individually. It is then determined when and how the dental assistants re-evaluates the oral hygiene and care process and reinstructs and remotivates the nursing staff. If the examination reveals a need for dental treatment (possibly requiring referral and transport), this will be communicated to the nursing staff. The dental assistant will further receive a training in communication, enabling them in reinstruction and remotivation. Dentists and dental assistants will further receive a training in geriatric dentistry by the State Commissioner of the German Society for Geriatric Dentistry.
11090796|NCT04140929|No Intervention|Control group|In the control group, the residents receive care as usual. This includes the recording of the same parameters are recorded as in intervention group, a standardized form is filled out and handed over to the nursing staff. As in the case of Intervention group, the nursing staff is informed in the event of a need for treatment. No further measures are applied.
11090797|NCT04140916|Experimental|Midline catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
11090798|NCT04140916|Active Comparator|PICC-line catheter|Insertion of a Midline catheter in patients scheduled for insertion of a catheter for intravenous fluids or medicines with an expected length of treatment between 5 and 28 days will
11091405|NCT04136873|Active Comparator|Part A: 5-10-20 mg BID CVL-231|Oral Dose
11090799|NCT04140903|Experimental|Oral antibiotics|Patients will be randomised to oral antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
11090800|NCT04140903|Active Comparator|Standard treatment|Patients will be randomised to continuation of standard intravenous antibiotics after two weeks of appropriate antibiotic therapy for bacterial brain abscess since definitive aspiration/excision of brain abscess or, in case of no planned diagnostic neurosurgical procedure, since initiation of guideline recommended antibiotics for bacterial brain abscess
11090801|NCT04140890|Experimental|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
11090802|NCT04140890|Placebo Comparator|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last ~15 minutes. Control condition participants receive no further intervention.
11090803|NCT04140877|Other|Visu OD, Control OS|Contralateral eye study
11090804|NCT04140877|Other|Control OD, Visu OS|Contralateral eye study
11090805|NCT04140851|Experimental|overweight/obesity diet intervention group|Dietary fiber intervention
11090806|NCT04140851|Placebo Comparator|overweight/obese normal diet group|Normal diet
11090807|NCT04140851|No Intervention|healthy control group|Healthy people
11090808|NCT04140838|Experimental|TAU + Acceptance and Commitment Therapy (ACT)|This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.
11090809|NCT04140838|Experimental|TAU + Behavioral Activation Therapy for Depression (BATD)|Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.
11090810|NCT04140838|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
11090811|NCT04140825||Group 1|Subjects>=18 years old will measure as a minimum FOT and spirometry.
11090812|NCT04140812|Active Comparator|Term infants (≥37+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
11090813|NCT04140812|Experimental|Preterm infants (≤32+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
11090814|NCT04140786|Experimental|Daily IV Gentamicin|Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
11090815|NCT04140786|Experimental|Biweekly IV Gentamicin|Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.
11090816|NCT04140773|Experimental|D-serine group|Oral administration of 2g D-serine per day, for 6 weeks.
11090817|NCT04140773|Placebo Comparator|Placebo group|Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.
11090818|NCT04140760|Active Comparator|Probiotic|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.
~Participants will take the liquid probiotic (Symprove) daily following manufacturers guidelines for a period of 12 weeks."
11090819|NCT04140760|Placebo Comparator|Placebo|"Thirty five Parkinson's Disease patients group will be randomly assigned to this study arm.
~Participants will take the liquid placebo daily for a period of 12 weeks following the same guidelines as for the probiotic."
11090820|NCT04140747||non-pregnant women|Samples will be collected from 30 healthy, non-pregnant women in the reproductive age: blood, urine, stool, saliva, oral swabs, vaginal swabs
11090821|NCT04140747||pregnant women delivering vaginally|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:
~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; cord blood, colostrum, meconium, infant oral swabs"
11090822|NCT04140747||pregnant women undergoing C-section|"From 30 healthy, pregnant women giving vaginal birth, samples will be collected shortly before, during and after birth from maternal and newborn sites:
~maternal blood, urine, stool, saliva, oral swabs, vaginal swabs; amniotic fluid, cord blood, colostrum, meconium, infant oral swabs"
11090823|NCT04140734|Experimental|Hard Palate|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use hard palate
11090824|NCT04140734|Active Comparator|Autologous Ear Cartilage|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use autologous ear cartilage
11090825|NCT04140734|Active Comparator|Porcine Acellular Dermal Matrix|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use porcine acellular dermal matrix
11090826|NCT04140721|Experimental|Moxonidine then Placebo|After 5 days of screening/baseline evaluations, patients will be discharged home on moxonidine 0.2-0.4 mg/day PO. On days 29, 30 and 31, the patients will be re-admitted for study testing while on moxonidine. At completion of this testing, patients will start taking matching placebo once daily PO to be continued at home. On days 58, 59 and 60, the patients will be re-admitted for study testing while on placebo.
11090827|NCT04140721|Experimental|Placebo then Moxonidine|After 5 days of screening/baseline evaluations, patients will be discharged home on placebo identical to moxonidine once daily PO. On days 29, 30 and 31, the patients will be re-admitted for study testing while on placebo. At completion of this testing, patients will start taking moxonidine 0.2-0.4 mg/day PO to be continued at home. On days 58, 59 and 60, the patients will be re-admitted for study testing while on moxonidine.
11090828|NCT04140708|Experimental|Exercise--Rock Steady Boxing class|Participants will be going twice a week to a Rock Steady Boxing class for an hour/class. Participants will be going to this class for a total of three months.
11090829|NCT04140695|Experimental|Tradipitant|Oral Capsule
11090830|NCT04140695|Placebo Comparator|Placebo|Oral Capsule
11090831|NCT04140682|Experimental|PAV+ mode|Weaning with PAV+ mode
11090832|NCT04140682|Active Comparator|PSV mode|Weaning with PSV mode
11090833|NCT04140669||Fetal Surgery Procedures|All pregnant women with a fetus diagnosed with a fetal abnormality and planning to undergo a fetal surgical procedure will be included in this single arm of the study.
11090834|NCT04140656|Active Comparator|Plantar sensitive exercise group|Plantar sensitive exercises:
11090835|NCT04140656|Active Comparator|Textured insole group|Textured insole group
11090836|NCT04140643|Experimental|Ozone therapy|Oral hygiene instructions given by dental hygienist and home daily use of ozonated water delivering system.
11090837|NCT04140643|Active Comparator|Only oral hygiene instructions|Oral hygiene instructions given by dental hygienist.
11090838|NCT04140630||E-cigarette users and bystanders|Households with one e-cigarette user (adult (18 years old and above); e-cigarette exclusive user for at least 1 month; daily use of e-cigarettes inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of any tobacco products or e-cigarettes) and one bystander cohabiting with the user
11090839|NCT04140630||Conventional cigarette smokers and bystanders|Households with one smoker (adult (18 years old and above; manufactured cigarette exclusive smoker for at least 6 months; daily smoking inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the smoker
11090840|NCT04140630||Heated tobacco product users and bystanders|Households with one user of the heated tobacco product, HTP (adult (18 years old and above; • HTP exclusive user for at least 1 month; daily use of HTP inside home; cohabiting with at least one non-tobacco product nor e-cigarette user; other household members should not be users of tobacco products or e-cigarettes) and one bystander cohabiting with the user
11090841|NCT04140630||Non-smokers and non-users (control)|Smoke free households (participants should be adult (18 years old and above), non e-cigarette user (never or former e-cigarette user >1 month), non-user of any kind of tobacco product (never or former user >1 month), and other household members should not be users of tobacco products or e-cigarettes
11090842|NCT04140617|Experimental|E-cigarette aerosol exposure in a room|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a 25 m3 room.
11090843|NCT04140617|Experimental|E-cigarette aerosol exposure in a car|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a car.
11090844|NCT04140604|Experimental|Lactobacillus salivarius AP-32|AP-32 is a 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Lactobacillus salivarius subsp. salicinius AP-32 and maltodextrin.
11090845|NCT04140604|Experimental|Bifidobacterium lactis CP-9|CP-9 is a 0.5 g light-yellow capsule containing freeze-dried powder of 2.5 billion CFU of Bifidobacterium animalis subsp. lactis CP-9 and maltodextrin.
11090846|NCT04140604|Placebo Comparator|Placebo|Placebo capsules are identical to the L. salivarius AP-32 and B. lactis CP-9 capsules except for the probiotics.
11090847|NCT04140591|Placebo Comparator|Proton-pump inhibitor|PPI: Pariet EC 20 mg/QDAC
11090848|NCT04140591|Active Comparator|Propranolol+Proton-pump inhibitor|"Propranolol:
~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
~PPI: Pariet EC 20 mg/QDAC"
11090849|NCT04140578|Experimental|Antibiotic|Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
11090850|NCT04140578|No Intervention|Control|Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
11090851|NCT04140539|Experimental|Gene Therapy|Infusion OTL-101
11090852|NCT04140526|Experimental|ONC-392 Treatment as single agent|The Part A study will test ONC-392 intravenous (IV) infusion up to five predefined dose levels: 0.1 mg/kg (cohort 1), 0.3 mg/kg (cohort 2), 1 mg/kg (cohort 3), 3 mg/kg (cohort 4) and 10 mg/kg (cohort 5) of ONC-392 as monotherapy every 21 days (Q3W). The treatment will continue for up to 1 year, or discontinued upon disease progression, or unacceptable toxicity, or voluntary withdraw. The Part A study will determine the maximal tolerable dose (MTD) and the recommended Phase 2 dose in monotherapy (RP2D-M).
11090853|NCT04140526|Experimental|ONC-392 in combination with pembrolizumab|"The Part B study will test ONC-392 intravenous (IV) infusion, Q3W, in combination with fixed dose of pembrolizumab. The dose for pembrolizumab will be fixed at 200mg/cycle dosed every 21 days (Q3W).
~The phase IA trial will start at one level below RP2D-M dose for ONC-392 and 200mg of pembrolizumab. When 2 DLTs occur before 6 patients are enrolled, the ONC-392 dose will be decreased to the next dose level until ≤ 1/6 patients treated at that dose develops a DLT. This dose level will be designated RP2D-C.
~The Part B study will progress to two parallel, single arm, single stage Phase IB trials to test for efficacy in two cohorts of patients with NSCLC:
~Stage IV NSCLC anti-PD(L)-1 immunotherapy naïve with positive PD-L1 (TPS> or =1%) ;
~Stage IV NSCLC anti-PD(L)-1 refractory or resistant to immunotherapy. The treatment will continue for up to 1 year, or discontinued upon disease progression, or unacceptable toxicity, or voluntary withdraw."
11090883|NCT04140253|Experimental|Standard Duloxetine treatment with PFMT|Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
11090884|NCT04140240|Experimental|İntervention group|Experimental: İntervention group
11090854|NCT04140513|Experimental|Diagnostic (dPET)|Patients receive fludeoxyglucose F-18 via injection and undergo dPET over 20 minutes after standard of care computed tomography (CT) imaging (week -2), after receiving 20-26 Gy and 40-46 Gy of radiation (weeks 3 and 5), and 3 months after completion of treatment. Patients with concern for residual disease may receive an additional dPET 6 months after treatment.
11090855|NCT04140500|Experimental|Part A: Single-Agent Dose Escalation|Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
11090856|NCT04140500|Experimental|Part B: Tumor Specific Expansion Cohorts|Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
11090857|NCT04140487|Experimental|Treatment (azacitidine, venetoclax, gilteritinib)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11090858|NCT04140474|Experimental|Archimedes procedure|All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.
11090859|NCT04140461|Experimental|Trial|Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks
11090860|NCT04140461|Active Comparator|Control|Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks
11090861|NCT04140448||UWFA-RVO-ME|Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab
11090862|NCT04140435||TTNB group|Patients with PCLs suitable for biopsy.
11090863|NCT04140422|Experimental|Hyperosmolar Eye Drops|5% sodium chloride eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
11090864|NCT04140422|Placebo Comparator|Lubricating Eye Drops|Lubricating eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
11090865|NCT04140409|Experimental|Treatment|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
11090866|NCT04140396|Placebo Comparator|Placebo Comparator|Participants will receive placebo infusion consisting of normal saline
11090867|NCT04140396|Active Comparator|Active Comparator|Participants will receive a lidocaine infusion
11090868|NCT04140383||Group 1, patients aged 85 years and older|75 eyes of 75 patients (39 female, 36 male) Mean age: 86,8 ± 1,8 years
11090869|NCT04140383||Group 2, patients aged 65 and 85 years|77 eyes of 77 patients (34 female, 43 male) Mean age:73,3 ± 5,2 years
11090870|NCT04140344|Experimental|ARM 1: Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
11090871|NCT04140344|No Intervention|ARM 2: Control group|The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.
11090872|NCT04140331||complicated post-operative evolution|Patients with a postoperative intensive care unity length of stay ≥ 5 days after elective cardiac surgery. They will have an accelerometer.
11090873|NCT04140331||simple post-operative evolution|Patients with a postoperative intensive care unity length of stay < 5 days after elective cardiac surgery. They will have an accelerometer.
11090874|NCT04140318|Experimental|treatment|combination therapy of PD-1 and chemotherapy including: sintilimab 200mg iv, 30-60min, q3w; nab-paclitaxel 125mg/m2, iv, d1,d8, q3w
11090875|NCT04140305|Experimental|Administration of RPC-1063|Patients with relapsing MS will receive RPC-1063 orally:
11090876|NCT04140292|Experimental|Vitamin D3 + Photodynamic therapy (PDT)|Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
11090877|NCT04140292|Active Comparator|Photodynamic therapy (PDT)|PDT for treatment of actinic keratosis.
11090878|NCT04140279|Experimental|Latanoprostene Bunod|Participants will receive LBN ophthalmic solution 0.024% in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
11090879|NCT04140279|Placebo Comparator|Placebo|Participants will receive Renu MultiPlus Lubricating and Rewetting Drops (placebo) in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
11090880|NCT04140266|Experimental|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
11090881|NCT04140266|Experimental|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
11090882|NCT04140253|Active Comparator|Standard Duloxetine treatment|Peroral treatment with duloxetine at a dose of 40 mg twice a day
11090885|NCT04140240|No Intervention|Control group|Control group: No intervention
11090886|NCT04140227|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
11090887|NCT04140214|Experimental|Standard Care and HTS|Standard care and twice-daily nebulised HTS (MucoClear 6%, PARI Pharma). Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser and eTrack controller (PARI Pharma).
11090888|NCT04140214|Experimental|Standard Care and Carbocisteine|Standard care and carbocisteine (750 mg three-times-per-day until visit 3, reducing to 750 mg two times per day) over 52 weeks.
11090889|NCT04140214|Experimental|Standard Care and Combination of HTS and Carbocisteine|Standard care and combination of twice-daily nebulised HTS (MucoClear 6%, PARI Pharma) and carbocisteine. Participants will be instructed to administer a 1 x 4 mL ampoule twice daily for 52 weeks using the eFlow rapid nebuliser eFlow rapid nebuliser and eTrack controller (PARI Pharma). They will also be given carbocisteine (750 mg of three times per day until visit 3, reducing to 750 mg twice per day) over 52 weeks.
11090890|NCT04140214|No Intervention|Standard Care Only|Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
11090891|NCT04140201|Active Comparator|Receive oral hypoglycemic +omega 3|Eicosapentanoic acid + standard treatment
11090892|NCT04140201|Active Comparator|Receive oral hypoglycemic +statin|Simvastatin + standard treatment
11090893|NCT04140201|Active Comparator|Receive oral hypoglycemic +fibrate|Fenofibrate +standard treatment
11090894|NCT04140201|No Intervention|Receive oral hypoglycemic only|Standard treatment only
11090895|NCT04140188|Active Comparator|Axilla no touch|Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM
11090896|NCT04140188|Active Comparator|Axilla with previous SLNB|Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM
11090897|NCT04140175||Women with suspected or confirmed endometriosis|Women with suspected or confirmed endometriosis undergoing standard of care treatments or interventions.
11090898|NCT04140162|Experimental|Dara-Rd followed by Dara-RVd|"Induction regimen with Daratumumab, Lenalidomide and Dexamethasone (Dara-Rd) in all study subjects, weeks 1-24
~Consolidation regimen with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (Dara-RVd) in post-induction MRD+ population, weeks 25-36
~Maintenance regimen with Daratumumab and Lenalidomide (Dara-R) in all study subjects, weeks 37-88
~Maintenance regimen with lenalidomide (R) until progression or intolerance"
11090899|NCT04140149||Participants|Adults who have made a suicide attempt in the past 3 months who have been referred to, and enrolled in, the Living with Hope class.
11090900|NCT04140136|Active Comparator|Treatment group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients.The investigational product is to be administered twice daily, at a dose of 400mg per day.
11090901|NCT04140136|Placebo Comparator|Placebo group|This is a pilot randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of 24-weeks tocotrienols (Tocovid Suprabio) supplementation in ALS patients. The placebo is similar in appearance but does not contain tocotrienols and consist of palm oil.
11090902|NCT04140123|Experimental|ZSP1601-Dose 1|ZSP1601-50mg once daily
11090903|NCT04140123|Experimental|ZSP1601-Dose 2|ZSP1601-50mg twice daily
11090904|NCT04140123|Experimental|ZSP1601-Dose 3|ZSP1601-100mg once daily
11090905|NCT04140123|Placebo Comparator|Placebo|Placebo
11090906|NCT04140110|Experimental|Intervention group|Achieving SBP level of <120 mmHg within 1 hour after randomisation, and maintaining this level at least 72 hours.
11090907|NCT04140110|No Intervention|Control group|Maintaining SBP 140-180mmHg, and BP lowering treatment can be given only when BP level ≥150 mmHg in order to achieve the target of ≥140 mmHg, and maintaining this level at least 72 hours.
11090908|NCT04140097||COPD patients with acute exacerbation|
11090909|NCT04140097||COPD patients without acute exacerbation|
11090910|NCT04140084|No Intervention|Translation, Redesign and Rapid prototyping with clinicians|This step includes a translation of the tools (English to French) and a redesign work of the original tools. Then, the study will include clinicians (at least 20) from two healthcare settings (CHU Sainte-Justine, and the CISSS-CA (Hotel-Dieu de Levis). After a presentation of the two tools during the Emergency Physicians' departmental meetings, the written comments about the prototype version will be collected. A revision of the prototypes is scheduled at the end of this step.
11090911|NCT04140084|No Intervention|Rapid prototyping with patients|This step will include the assessment of the tools by patients (or parents of patients) that have had a previous mTBI at the CISSS-CA (Hotel-Dieu de Levis). The comments about the adult and pediatric prototypes (5 adult patients, 5 parents of pediatric patients) will be collected through interviews. A revision of the prototypes is scheduled at the end of this step.
11090912|NCT04140084|Experimental|Real-life clinical meetings|This step will include a presentation of the tools to 5 emergency physicians so that they can use the tools with patients (5 adults, 5 parents of pediatric patients) in a realistic setting to identify any problems of use. The clinicians and patients that had used the tools during the clinical encounters will be then met during cognitive interviews to collect their comments on the tools and to address any usability issues. A final revision of the prototypes is scheduled at the end of this step.
11090913|NCT04140084|No Intervention|Training session developement|This step includes the development of a training session on how to perform SDM with patients facing the decision to undergo head CTs for mTBI and about how to use our newly developed decision aids in this clinical setting. The content of the training session will be adapted to the needs, goals, strengths and limitations observed during the focus groups (departmental meetings) exploring health professionals' barriers to using a decision aid about head CTs in mTBI. The expertise of SAVIE (www.savie.ca) in producing online and interactive elearning programs will be mobilized in order to produce a training program that will integrate the content the investigators will have identified as the main skills, knowledge and competencies needing development among our health professionals to stimulate the use of SDM and our decision aids. SAVIE will produce a virtual elearning program adaptable to all media (PC, mobile device, tablet) and different health professionals.
11090943|NCT04139889||malignant lesions|pCLE images of malignant lesions were associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
11090914|NCT04140084|No Intervention|Retrospective analysis|This step will retrospectively analyze the medical records of traumatic brain injury adult patients (adult, 350, Hotel-Dieu de Levis) and pediatric patients (406, CHU de Sainte-Justine and Hotel-Dieu de Levis)) randomly selected throughout the year preceding this study in each of the two centers to determine the rate of head CT ordering, the head CT result and the appropriateness of having ordered the head CT based on the CCHR and PECARN criteria. One reviewer will judge the appropriateness of having done a CT scan according to the CCHR and PECARN criteria based on a structured extraction form that will previously be approved by the study's steering committee. To ensure validity, 10% of the analysis will be reviewed by an expert. The reviewer will look at prehospital data collection, triage information, physician's notes, nursing notes and head CT requisition form information to determine if any of the clinical decision rule criteria are present.
11090915|NCT04140058|Active Comparator|group O4|Patients received 4mg ondansetron.
11090916|NCT04140058|Active Comparator|group O6|Patients received 6mg ondansetron.
11090917|NCT04140058|Placebo Comparator|group C|Patients received normal saline.
11090918|NCT04140045|Experimental|Hypohydrated|Participants will be required to restrict their water intake during cycling in the heat (90-120 minutes at 35°C), in order to achieve a body mass loss of approximately 3%.
11090919|NCT04140045|Experimental|Euhydrated|Participants will be provided with water intake that matches their sweat losses during cycling in the heat (90-120 minutes at 35°C)
11090920|NCT04140032|Experimental|Intervention group|Centers in the group will participate in the A-B-C Healthy Me/Soy Saludable multi- component nutrition and physical activity preschool intervention.
11090921|NCT04140032|No Intervention|Control group|"Preschools in the group will continue with usual care practices. Control group preschools will receive intervention materials and accompanying instructions after follow-up measures are collected for each cohort."
11090922|NCT04140019||NSTEMI|
11090923|NCT04140006|Active Comparator|Alendronate Gel (ALN)|After preparation, 0.05 ml of the gel containing 100 µg of ALN will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
11090924|NCT04140006|Active Comparator|Bone Morphogenic Protein Gel (BMP)|After preparation, 0.05 ml of the gel containing 100 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
11090925|NCT04140006|Active Comparator|Mixture Gel of ALN and BMP|After preparation, 0.05 ml of mixture gel containing 50 µg of ALN and 50 µg of BMP will be injected in the osteotomy site immediately before fixture insertion (20 fixtures)
11090926|NCT04140006|Sham Comparator|Control|After preparation, the fixture will be inserted without topical application of any medication (20 fixtures)
11090927|NCT04139993|Experimental|Estrogen receptor (ER) and/or progesterone rec|RBX7455 given at least minimum 2 weeks to (maximum 4 week)s prior to surgery in patients with stage I-III breast cancer;Estrogen receptor (ER) and/or progesterone receptor (PR) positive ≥ 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression.
11090928|NCT04139993|Experimental|Human epidermal growth factor receptor 2(HER2)|RBX7455 given at least minimum 2 weeks to (maximum 4 week)s prior to surgery in patients with stage I-III breast cancer;Human epidermal growth factor receptor 2 (HER2) amplification with FISH ratio ≥ 2.0 or overexpression by immunohistochemistry 3+ with any ER and/or PR.
11090929|NCT04139993|Experimental|Triple negative.|RBX7455 given at least minimum 2 weeks to (maximum 4 week)s prior to surgery in patients with stage I-III breast cancer;Triple negative. Estrogen receptor (ER) and/or progesterone receptor (PR) negative < 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression.
11090930|NCT04139980|Experimental|Virtual Reality supported therapy|"The Virtual Reality (VR) interface will be used during patients stay at the rehabilitation center. A research employee will install the VR system in the patient's room. Participants will be comfortable sitting while in VR session. Each interface consists of a head mounted display (HMD) allowing participants to see their arms and legs represented in the virtual environment. Participants will be able to control their virtual legs using hand controllers, which will allow them to walk through several virtual environments and gather points (no additional gaming elements are included)."
11090931|NCT04139967|Experimental|Elderly rectal cancer patients|
11090932|NCT04139954||Rheumatoid arthritis and Spondyloarthritis|Patients using Biological or Targeted Synthetic DMARDs
11090933|NCT04139941||Individuals with known or unknown HCV status|
11090934|NCT04139928|Experimental|Picometer-ionic form of magnesium chloride|
11090935|NCT04139928|Active Comparator|Magnesium citrate or magnesium oxide|
11090936|NCT04139928|Placebo Comparator|Placebo|
11090937|NCT04139915|Experimental|10 mg daily RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 16 weeks
11090938|NCT04139915|Placebo Comparator|Placebo|Oral matching placebo once daily for 16 weeks
11090939|NCT04139902|Experimental|Dostarlimab (TSR-042) (singly)|"Pre-Operative Phase:
~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.
~Post-Operative Phase:
~Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
11090940|NCT04139902|Experimental|Dostarlimab (TSR-042) and TSR-022 (combination)|"Pre-Operative Phase:
~Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1 and then again on Cycle 2 Day 1.
~Post-Operative Phase:
~Dostarlimab (TSR-042) will be administered through an IV over 30 minutes for 4 doses every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks. TSR-022 will not be administered."
11090941|NCT04139889||normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
11090942|NCT04139889||non-malignant lesions|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of non-malignant lesions after intravenous injecting 10% fluorescein.
11090944|NCT04139876|Active Comparator|Minimal open hemorrhoidectomy|Patients randomized to Minimal open hemorrhoidectomy
11090945|NCT04139876|Active Comparator|LigaSure hemorrhoidectomy|Patients randomized to LigaSure hemorrhoidectomy
11090946|NCT04139863|Other|aMMP-8 chairside test|Test group. The aMMP-8 chairside mouth rinse test is performed for the test group.It identifies adolescents with poor oral hygiene at risk for subclinical periodontitis without detectable and visible manifestations of the illness, such as periodontal deepened pockets.
11090947|NCT04139863|No Intervention|No test|The other group is control group. No test administered.
11090948|NCT04139850||Korean chronic hepatitis B patients cohort|Korean patients with chronic hepatitis B with or without antiviral therapy on a regular follow-up in tertially medical institution
11090949|NCT04139824|Experimental|Cohort|Period 1: LC350189 200mg (QD) Day 1~ Day 4, Period 2: Naproxen 500 mg (BID) Day 8 ~ Day 12 , Period 3 : LC350189 200mg (QD) + Naproxen 500 mg (BID) Day 13~19
11090950|NCT04139811|Other|non-ILM peeling group|vitrectomy without ILM peeling is done to all cases
11090951|NCT04139811|Other|ILM peeling group|vitrectomy with ILM peeling is done to all cases
11090952|NCT04139798|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
11090953|NCT04139798|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.6% sodium chloride solution) 4 times daily (QID)
11090954|NCT04139785|Experimental|Intervention|Guided Cognitive Behavioural Therapy based app
11090955|NCT04139785|No Intervention|Care as usual|Care as usual
11090956|NCT04139772|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
11090957|NCT04139772|Experimental|Abiraterone or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.
~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.
~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
11090958|NCT04139759|Experimental|hand massage group|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
11090959|NCT04139759|Experimental|Foot massages group|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
11090960|NCT04139759|No Intervention|control group|The patients in the control group (n = 28) were not administered except nursing interventions in the HD unit.
11090961|NCT04139746|Active Comparator|Scleral Buckling|Scleral Buckling represents the gold standard for retinal detachment in young phakic patients.
11090962|NCT04139746|Experimental|Drainage-Injection-Pneumoretinopexy|Drainage-Injection-Pneumoretinopexy is a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (BSS) in the vitreous chamber.
11090963|NCT04139733|Experimental|Prone group|"Prone position within 6 hours after randomization.
~Prone position for at least conservative hours per days during a minimum of 5 days."
11090964|NCT04139733|Other|Supine group|1. Supine group on ECMO.
11090965|NCT04139720|Experimental|e-book|e-book learning mode of sexual harassment prevention training
11090966|NCT04139720|No Intervention|audio-visual and booklet|sexual harassment prevention audio-visual and booklet learning mode
11090967|NCT04139707|Experimental|Caring4Dementia Group|The experimental group will receive Careing4Dementia downloadable on their smartphone or tablet. Caring4Dementia will tell and show caregivers of a person living with dementia how to 1) manage difficult behaviors, 2) deal with refusal, 3) deal with tensions and 4) manage work-life demands. The app is self-administered and self-paced and contains surveys referring to the outcome measurements tools used in the study. The intervention will be for 30 days without any restriction or limitation in terms of timing, location or frequency of use.
11090968|NCT04139707|Active Comparator|White Paper Group|The White Paper group will receive a white paper on the principles of communicating efficiently with persons living with dementia.
11090969|NCT04139707|No Intervention|Control Goup|The control group will not receive any intervention.
11090970|NCT04139694|Experimental|Cinnamon with Food Plan|Group of ladies who will undergo testing, receive dietary intervention, and take cinnamon supplements.
11090971|NCT04139694|Active Comparator|Food Plan Only|Group of ladies who will undergo testing, receive dietary intervention, but will not get cinnamon supplements.
11090972|NCT04139681|Experimental|A. Vogels Sore Throat Lozenges|Each patients receives 1 glass containing 20 A.Vogel Sore Throat lozenges at inclusion visit 1. They first suck under supervision in the study centre one Vogel Sore Throat lozenge and document every 15 minutes the pain 90 minutes. Patients will receive the rest of the bottle still containing 19 Vogel Sore Throat lozenges and have to take them for 4 days (5 lozenges per day, throughout the day) and record tonsillitis pain.
11090973|NCT04139668|Experimental|Vivitrol + MET/CBT|All participants will receive three 4ml doses of extended-release naltrexone 380mg (Vivitrol), administered by intramuscular injection. Three injections will be administered to each participant; one injection every 4 weeks for 12 weeks of treatment. In addition, all participants will receive weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy for 12 weeks.
11090974|NCT04139655|Experimental|Intervention Group|Administration of oral colchicine at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
11090975|NCT04139655|Placebo Comparator|Control Group|Participants allocated to the control group will receive a placebo pill at the same dosing regimen as with treatment group. Perioperative and surgical care will not be different from standard clinical practice.
11090976|NCT04139642||Group AB|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
11091073|NCT04139005|Experimental|Awareness-Connection|
11091074|NCT04139005|Experimental|Awareness-Insight|
11090977|NCT04139642||Group BA|A block randomization scheme by clinic type will be used to assign which clinics receive the Balance+Weight device in the first 9 months and which clinics receive the Balance+Weight device in the second 9 months. The block randomization scheme is proposed instead of simple randomization because of the expected variation between clinics in the types of patients they see. At the 9-month point, OSU personnel will go to every site to reprogram each device from Balance+Weight mode to Weight Only mode or vice versa, and to move the immediate feedback kiosks to the new Balance+Weight sites.
11090978|NCT04139629|Other|antibody positive (CAT+)|patients found positive for one of the assayed antichlamydial antibodies
11090979|NCT04139629|Other|antibody negative (CAT-)|women with negative antichlamydia antibody test
11090980|NCT04139616||No ECG changes in patients without pre-existing RBBB|Patients with no new conduction disturbances on the ECG performed immediately post-TAVR (and no episodes of HAVB/CHB during the procedure) have a very low risk of developing HAVB/CHB or any conduction disturbance within the hours-days following the procedure. In these cases, temporary pacing will be discontinued at the end of the procedure. However, continuous ECG monitoring until hospital discharge is recommended. A 12-lead ECG is recommended 24 hours after the procedure. If no arrhythmic episodes and no ECG changes occur within the 24 hours post-procedure, the patient can be safely discharged (the day after TAVR) with no other monitoring measures in case of otherwise uneventful clinical course (absence of other TAVR related adverse events). If the patient has to remain hospitalized because of other reasons or TAVR complications, telemetry would be recommended (but no strictly required) for the detection of post-TAVR tachyarrhythmias or late ECG changes.
11090981|NCT04139616||Patients with pre-existing RBBB|A temporary pacing wire is recommended to be maintained for 24 hours (or at least overnight) in all patients with prior RBBB, along with telemetry and daily ECG during the entire hospitalization period (minimum of 2 days). If any ECG changes occur during the initial 2-3 days, patients can be managed according to the proposed strategy (see management strategies for groups 3 and 5). If no ECG changes or significant bradyarrythmias occur within the 2-3 days following the procedure, the patient can be discharged. Considering that the increased risk of life threatening bradyarrhythmias in these patients may extend beyond the hospitalization period, the use of continuous ECG monitoring systems (minimum of 48 hours, up to 4 weeks) may be considered.
11090982|NCT04139616||ECG changes in patients with prior conduction disturbances|"Any significant increase in PR or QRS interval will indicate to continuing the temporary pacing for 24 hrs, with daily ECG and telemetry for 1-2 days. If the ECG changes regress in <24 hrs, an earlier removal of the temporary pacing may be considered. Also, a strategy of multiple ECGs during the first 24 hrs may be considered. If ECG changes regress or no further changes occur the patient can be discharged with no PPM at 2 days post-TAVR.
~If 24 hrs post-TAVR, the PR and QRS interval remain stable but >240 or >150 ms, respectively, and ≥20 ms longer than baseline, maintaining the temporary pacing wire for another 24 hrs is recommended. If no decrease in the PR or QRS duration occurs at day 2, the patient can be considered at risk for more advanced conduction disturbances requiring PPM. The use of an EP study may be a reasonable option for deciding PPM in those patients with prior conduction disturbances with worsening of ECG changes post-TAVR"
11090983|NCT04139616||New-onset LBBB|"Temporary pacing for 24 hrs is recommended, in all patients with new-onset LBBB post-TAVR. Earlier removal of the temporary pacing and discharged at day 1 can be considered if LBBB resolves in <24 hrs.
~If LBBB persists but no further progression of the duration of the QRS or PR interval is observed at day 1, temporary pacing can be discontinued. If no further ECG changes are observed up to day 2-3 post-TAVR, the patient can be discharged. These patients are however at increased risk of HAVB/CHB requiring PPM, and continuous ECG monitoring and/or EP studies may be considered.
~If further prolongation of the QRS or PR interval is observed at day 1, the temporary pacing is recommended for an additional 24 hrs. If the prolongation of the QRS or PR intervals continues at day 2, evaluation with EP studies or PPM implantation may be considered.
~The occurrence of any episode of HAVB/CHB following TAVR in a patient with new-onset LBBB will be considered an indication for PPM"
11090984|NCT04139616||HAVB/CHB during the periprocedural period|"Maintaining temporary pacing in patients with procedural persistent HAVB/CHB, and monitoring in intensive care unit are recommended. If HAVB/CHB persists at 24 hrs, PPM is recommended. If HAVB/CHB recovers the day after TAVR, the temporary pacing can be removed and the patient can remain hospitalized for 1 day. If another episode of HAVB/CHB occurs, PPM is recommended. If no other episode of HAVB/CHB occurs, and no other features potentially justifying PPM exist the patient can be discharged.
~Temporary pacing is recommended for 24 hrs in patients with transient HAVB during the procedure, with telemetry and daily ECG for 2 days. Discontinuing temporary pacing may be considered in those cases with brief episodes of HAVB/CHB and normal ECG. If no recurrent episodes of HAVB/CHB occur, and the patient has no other potential indications for PPM the patient can be discharged at day 2. PPM would be indicated if any recurrent episode of HAVB/CHB occurs during the hospitalization period."
11090985|NCT04139603|Active Comparator|Lumbopelvic kinesio taping (LPKT)|Two I-shaped kinesio tapes in 40 cm length will be applied bilaterally, beginning from 5 cm below the spina iliaca posterior superiors (SIPSs) to the level of the 12th costae, in maximum trunk flexion position, on the paravertebral muscles, by inhibition technique of muscle correction techniques. The tapes will be placed with no tension at 5 cm of both ends, and with 15-25% tension in between. In addition, an extra I-shaped tape will be placed perpendicullar to these tapes with the ligament correction technique, while the pregnant women are in the vertical upright position, at the level of the sacroiliac joints, starting with a tensile strength of 75-100% from the middle, and then with no tension at two ends.
11090986|NCT04139603|Experimental|Abdominal supported lumbopelvic kinesio taping (ALPKT)|An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
11090987|NCT04139603|Placebo Comparator|Placebo taping|A Micropore™ surgical plaster of the same color with KT will be applied with no tension, as described in the LPKT technique.
11090988|NCT04139590|Placebo Comparator|Visual Analogue Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Visual Analogue Scale."
11090989|NCT04139590|Active Comparator|Visual Analogue Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Visual Analogue Scale."
11091075|NCT04139005|No Intervention|Wait list|
11090990|NCT04139590|Placebo Comparator|Numeric Rating Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Numeric Rating Scale."
11090991|NCT04139590|Active Comparator|Numeric Rating Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Numeric Rating Scale."
11090992|NCT04139577|Experimental|Fecal Microbiota Transplant (FMT) FOR HIGH-RISK ACUTE GVHD|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~this research study for up to 6 months. You may receive up to 2 cycles of the study treatment.
~- Fecal Microbiota Transplant ( FMT)- Oral Study Drug, predetermined dosage and timings, up to 2 cycles.
~One cycle of treatment consists of one induction week of FMT followed by three weeks of maintenance FMT.
~The maintenance weeks happen for 3 weeks after the induction week.
~All doses will be administered in the clinic.
~A second cycle of treatment as deemed appropriate"
11090993|NCT04139564|Experimental|EaseVRx group|Each subject will be asked to complete a 56-day program using the EaseVRx virtual reality headset with assigned modules each week. Each week, subjects will be asked to complete 7 modules (one per day), each approximately 5 minutes in duration, for a total of 56 modules across the program.
11090994|NCT04139564|Active Comparator|Active control group VR Sham|Each subject will be asked to complete a program accessible via VR that includes 2d visual wildlife scenes similar to some EaseVRx content
11090995|NCT04139551||OQ - 01- 1XXX Denono PD|Newly diagnosed unmedicated PD patients
11090996|NCT04139551||OQ-01- 2XXX Mild /Moderate PD|Early to moderate stage PD patients well controlled on medication(typically fewer than 8 years since diagnosis)
11090997|NCT04139551||OQ-01- 3XXX Advanced PD|Advanced PD patients (typically greater than 8 years duration)
11090998|NCT04139551||OQ-01- 4XXX DBS patients|PD patients with deep brain stimulation systems
11090999|NCT04139551||OQ-01- 5XXX PSP patients|PSP patients
11091000|NCT04139551||OQ-01- 6XXX Healthy Controls|Age-frequency matched healthy controls
11091001|NCT04139538|Experimental|Invisalign treatment|Aligner patients will be treated with Invisalign® aligners to correct malocclusion
11091002|NCT04139538|Active Comparator|selfligating bracket treatment|Multibracket patients will be treated with self ligating orthodontic brackets
11091003|NCT04139525|Experimental|unfractionated heparin and 8% trisodium citrate|Unfractionated heparin and 8% trisodium citrate.
11091004|NCT04139512|Other|guided surgery|test group, using a full digital workflow procedure
11091005|NCT04139512|Other|conventional technic|free- hand technic to place implant
11091006|NCT04139499||Adults with OSA|Adults with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
11091007|NCT04139499||Children with OSA|Children with obstruction at any or all of the four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent the experimental group.
11091008|NCT04139499||Adult control|Adult without any obstruction at four levels of interest (velopharynx, oropharynx, tongue base, epiglottis) will represent a control.
11091009|NCT04139499||Children control|Children exam will be done for all the participants. Subject without obstruction represent a control.
11091010|NCT04139486|Experimental|combined EMBOTRAP II and Contact Aspiration|
11091011|NCT04139486|Active Comparator|Contact Aspiration alone|
11091012|NCT04139473|Active Comparator|Hepaticojejunostomy|Patients undergo right lobe living donor liver transplantation will receive hepaticojejunostomy
11091013|NCT04139473|Active Comparator|Duct-to-duct anastomosis|Patients undergo right lobe living donor liver transplantation will receive duct-to-duct anastomosis
11091014|NCT04139460|Active Comparator|CRT-D|Implantation of cardiac resynchronization therapy with a defibrillator (CRT-D)
11091015|NCT04139460|Active Comparator|CRT-P|Implantation of cardiac resynchronization therapy pacemaker (CRT-P)
11091016|NCT04139447||Healthy subjects|
11091017|NCT04139434|Experimental|Cohort 1|Dose 100mg
11091018|NCT04139434|Experimental|Cohort 2|Dose 200mg
11091019|NCT04139434|Experimental|Cohort 3|Dose 400mg
11091020|NCT04139434|Experimental|Cohort 4|Dose 600mg
11091021|NCT04139434|Experimental|Cohort 5|Dose 800mg
11091022|NCT04139434|Experimental|Cohort 6|Dose 1000mg
11091023|NCT04139421|Active Comparator|Urban Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in urban green space.
11091024|NCT04139421|Experimental|Rural Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in rural green space.
11091025|NCT04139408|Experimental|Disposable Pulmonary Surgical Marker|Locate the pulmonary nodules with Disposable Pulmonary Surgical Marker before VATS.
11091026|NCT04139395|Experimental|Diagnostic 68Ga-Citrate PET/MRI Imaging|Participants will receive separate scans, first a SPECT scan following administration of the 67Ga Citrate tracer (standard of care), then a PET/MRI scan following administration of the 68Ga-Citrate tracer (investigational); some participants will also receive IV gadolinium-based contrast injection. Scans will be performed 45-60 minutes following injection of the tracer.
11091027|NCT04139382|Experimental|Intervention|Telephone Consultation for women requesting abortion
11091028|NCT04139382|Active Comparator|Control|Face-to-face consultation for women requesting abortion
11091029|NCT04139369||Type 1 Diabetes Mellitus (T1DM)|Type 1 Diabetes Mellitus (T1DM) Children and adolescents with Type 1 Diabetes Mellitus
11091030|NCT04139369||Controls (C)|Controls (C) Healthy individuals matched for gender and age without any autoimmune disease of their own or their first degree relatives
11091031|NCT04139356|Experimental|Patients with rest O2 desaturation|Patient will undergo an experimental protocol consisting of 10 deep inspirations to measure and characterize changes on pulse-oxymetry values
11091032|NCT04139343||SMA cohort|Individuals who have a diagnosis of SMA who are NOT receiving Spinraza (nusinersen).
11091033|NCT04139343||SMA Spinraza cohort|Individuals who have a diagnosis of SMA who are receiving Spinraza (nusinersen).
11091034|NCT04139343||Control cohort|Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
11091035|NCT04139330|Experimental|NPC-06 (high dose)|Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
11091036|NCT04139330|Experimental|NPC-06 (low dose)|Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
11091037|NCT04139330|Placebo Comparator|NPC-06 (placebo)|Infuse NPC-06 (placebo) over 12 minutes or 18 minutes
11091038|NCT04139317|Experimental|Combination arm|Capmatinib 400 mg twice a day Pembrolizumab 200mg every 3 weeks
11091039|NCT04139317|Active Comparator|monotherapy|Pembrolizumab 200mg every 3 weeks
11091040|NCT04139304|Experimental|Treatment (daratumumab, DA-EPOCH)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3, and on day 1 of cycles 4-6. Patients also receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuous over 96 hours on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for up to 6 cycles in absence of disease progression or unacceptable toxicity.
11091041|NCT04139291|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema
11091042|NCT04139265||Hospitalized patients aged 65 and over|- Patients aged 65 and over hospitalized in the department of Internal Medicine and Geriatry
11091043|NCT04139239||Patients with disorders of consciousness|
11091044|NCT04139226|Experimental|Administration of CC-11050|Part 1: Single Ascending Dose Part 2: drug-drug interaction/ food effect (DDI/FE)
11091045|NCT04139213|Active Comparator|Usual care|usual medication assisted treatment for maintenance care of opioid use disorder
11091046|NCT04139213|Experimental|Pharmacy MAT|pharmacy-based medication assisted treatment for maintenance care of opioid use disorder
11091047|NCT04139200|Experimental|Type 1 tele coaching group|Coaching with daily interaction with the coaching application, based on a adaptive physical activity goal
11091048|NCT04139200|Sham Comparator|Type 2 tele coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application
11091049|NCT04139187|Experimental|Experimental|Individuals randomized to experimental group.
11091050|NCT04139187|No Intervention|No Intervention Control|Individuals without quadriceps dominance randomized to no intervention group.
11091051|NCT04139174||adolescent group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).
~measurements will be done on the radiograph using digital software."
11091052|NCT04139174||adult group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).
~measurements will be done on the radiograph using digital software."
11091053|NCT04139161|Experimental|Q-Factor Intervention|Participants will progress through three increasing Q-Factors for each cycling workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated.
11091054|NCT04139148|Active Comparator|True tDCS Combined With CCAT|Ture transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including drug knowledge every week, self-evaluation every two weeks and outpatient follow-up reminder every four weeks.
11091055|NCT04139148|Sham Comparator|Sham tDCS Combined With CCAT|Sham transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including only outpatient follow-up reminder every four weeks.
11091056|NCT04139148|No Intervention|Control group|During the treatment, the participants in control group only received treatment such as education of psychology, health and judicature, physical training as well as vocational training as usual in the compulsory rehabilitation center.
11091057|NCT04139135|Experimental|HLX10|HLX10 combined with chemotherapy will be adopted in the neoadjuvant treatment phase, and HLX10 monotherapy will be administered in the adjuvant treatment phase
11091058|NCT04139135|Placebo Comparator|Placebo|Placebo combined with chemotherapy will be given in the neoadjuvant treatment phase, and chemotherapy alone will be administered during the adjuvant treatment phase.
11091059|NCT04139122|Experimental|Cohort 1-4: SJP-0132|Each cohort will receive a single dose of 1 of 4 strengths of SJP-0132
11091060|NCT04139122|Placebo Comparator|Cohort 1-4: Placebo|Single dose of placebo
11091061|NCT04139122|Experimental|Cohort 5-6: SJP-0132|Cohort 5 SJP-0132 will receive the second maximum acceptable dose from Cohorts 1-4 for 4 weeks. Cohort 6 SJP-0132 will receive the maximum acceptable dose from Cohorts 1-4 for 4 weeks
11091062|NCT04139122|Placebo Comparator|Cohort 5-6: Placebo|Multiple dose placebo for 4 weeks
11091063|NCT04139083||TVM group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with TVM
11091064|NCT04139083||LSC mesh suspension group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with LSC mesh suspension
11091065|NCT04139070|Experimental|Treátment group|8 patients are expected to be included in this study. The patients will be treated once with bleomycin in combination with elektroporation
11091066|NCT04139057|Experimental|EBV TCR-T|EBV-specific TCR-T cell with anti-PD1 auto-secreted element
11091067|NCT04139044|Experimental|Stable Ankle Training Group (SG)|Balance Exercise Training for Only The Stable Ankle
11091068|NCT04139044|Experimental|Unstable Ankle Training Group (UG)|Balance Exercise Training for Only The Unstable Ankle
11091069|NCT04139044|No Intervention|Control Group (CG)|No balance exercise training
11091070|NCT04139031||Fluid loading group|Mechanically ventilated patients with low tidal volume in the intensive care unit whom clinician decided to provide fluid for correction of hypovolemia
11091071|NCT04139018|Experimental|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
11091072|NCT04139018|Placebo Comparator|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
11091076|NCT04138992|Experimental|study group A|"bevacizumab combined with neoadjuvant chemotherapy and concurrent chemoradiotherapy：
~bevacizumab combined with neoadjuvant chemotherapy for 2 cycles: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; Docetaxel 75mg/m2, intravenous injection，once three week;
~bevacizumab combined with concurrent chemoradiotherapy: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor"
11091077|NCT04138992|Experimental|study group B|study arm: bevacizumab combined with concurrent chemoradiotherapy： Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
11091078|NCT04138992|Active Comparator|control|standard concurrent chemoradiotherapy: DDP 40mg/m2, intravenous injection，once a week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
11091079|NCT04138979||Control group|20 healthy volunteers were included in the healthy control group
11091080|NCT04138979||Disease group|First chemotherapy for breast cancer
11091081|NCT04138966||Patients undergoing general anesthesia|Patients are monitored with Nol-Index, skin conductance, and antinociception-index
11091082|NCT04138953|Experimental|TMS over premotor cortex|Noninvasive brain stimulation in the premotor cortex
11091083|NCT04138953|Experimental|TMS over primary motor cortex|Noninvasive brain stimulation in the motor cortex
11091084|NCT04138953|Sham Comparator|Sham TMS over premotor cortex|Sham brain stimulation in the premotor cortex
11091085|NCT04138940|Experimental|Distributed, Short Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 5 sentence-long script.
11091086|NCT04138940|Experimental|Distributed, Long Script|Participant practices for 1 hour, 2 days a week for 5 weeks using a 10 sentence-long script.
11091087|NCT04138940|Experimental|Massed, Short Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 5 sentence-long script.
11091088|NCT04138940|Experimental|Massed, Long Script|Participant practices for 1 hour, 5 days a week for 2 weeks using a 10 sentence-long script.
11091089|NCT04138927|Experimental|Fostamatinib|"Subjects who at any time during the C-935788-057 study achieved a hemoglobin response in the absence of rescue in the previous 4 weeks or a steroid dose greater than baseline will continue at their current dose (100mg or 150 mg) and regimen in the extension study.
~All other subjects who enter the extension study will initially receive fostamatinib 100 mg PO bid. Starting at Week 4, the initial fostamatinib dose of 100 mg PO bid will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug, based on the investigator's judgment."
11091090|NCT04138914|Experimental|Focal Cryotherapy|Focal Cryotherapy using 2 freeze-thaw cycles
11091091|NCT04138901|Experimental|Group T|Patients receiving bilateral subcostal TAP block.
11091092|NCT04138901|No Intervention|Group C|Patients not receiving bilateral subcostal TAP block.
11091093|NCT04138888|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in Period 1 and a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11091094|NCT04138888|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in Period 1 and a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11091095|NCT04138875|Active Comparator|Low Risk|Low risk patients (those in complete response (CR) after induction) will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 of 21 day cycles, for 4 cycles.
11091096|NCT04138875|Active Comparator|High Risk|High risk patients (those who do not achieve a CR after induction), will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 and bendamustine (90mg/m2) on day 1-2 of 21 day cycles for up to 8 cycles. Interim imaging will be performed in cycle 4 (days 14-21) and patients achieving CR will receive additional 2 cycles for a total of 6, patients achieving partial response (PR) will receive 4 additional cycles.
11091097|NCT04138862|Active Comparator|Sensory Matched/Unlabelled|Sensory-matched covert calorie reduction, unlabelled
11091098|NCT04138862|Experimental|Sensory Matched/Labelled|Sensory-matched explicit calorie reduction, labelled
11091099|NCT04138862|Experimental|Sensory Reduced/Labelled|Sensory-reduced explicit calorie reduction, labelled
11091100|NCT04138862|Experimental|Sensory Enhanced/Labelled|Sensory-enhanced explicit calorie reduction, labelled
11091101|NCT04138849|Experimental|BBT-877 Low Dose|
11091102|NCT04138849|Experimental|BBT-877 Mid Dose|
11091103|NCT04138849|Experimental|BBT-877 High Dose|
11091104|NCT04138849|Placebo Comparator|Placebo|
11091105|NCT04138836|Experimental|Midazolam|
11091106|NCT04138836|Experimental|Itraconazole|
11091107|NCT04138836|Experimental|Esomeprazole|
11091108|NCT04138823|Experimental|Part A: BI 891065 followed by Part B: BI 891065 + BI 754091|
11091109|NCT04138810|Experimental|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
11091144|NCT04138511|Experimental|Experimental group (ECOFISIO)|Ecofisio Group received the ECOFISIO mobile application after students had received theoretical-practical lessons about ultrasound skills in sports pathologies areas, to study the subject.
11091110|NCT04138810|Active Comparator|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
11091111|NCT04138797|Experimental|Electrophysiological exploration & ECG Biosemi|
11091112|NCT04138784|Experimental|Comprehensive Rehabilitation program|19 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks individualized comprehensive rehabilitation program administered once a day.
11091113|NCT04138784|Experimental|Aquatic training|18 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks hydrotherapy intervention once a day.
11091114|NCT04138771|Experimental|Eligible patients for AI test|Device: an artificial intelligence system for postoperative management of cataract patients. These patients are enrolled in primary healthcare units and the AI clinic at Zhongshan Ophthalmic Center.
11091115|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
11091116|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
11091117|NCT04138745||Control|Historical control patients that are matched to the surgery type
11091118|NCT04138745||Experimental|After the practice change of TTP was initiated, the future pediatric patients were put into a database.
11091119|NCT04138732|Experimental|Intervention treatment group|This arm will receive the intervention treatment aimed to help improve their health behaviors. Interventions will include nutrition workshops and personal consultation for employees at risk, environmental intervention that includes brief exercise session prior to weekly meetings, placement of sports equipment in the department, and pedometer program, and stress reduction workshops. Healthy options will be demarcated in the hospital cafeteria.
11091120|NCT04138732|Other|Control group|This arm will be the control group and not receive the intervention treatment aimed to help improve their health behaviors.Once completing their time as the control group, they will continue into another phase of the trial and receive the intervention treatment.
11091121|NCT04138719|Experimental|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
11091122|NCT04138719|Active Comparator|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；
11091123|NCT04138706|Placebo Comparator|Control: Placebo|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will receive a placebo for an additional 14 days (twice a day x 7 days, then once a day for 7 days).
11091124|NCT04138706|Active Comparator|Intervention: Extended vancomycin regimen|Following a 14-day initial vancomycin treatment (125mg QID x14 days), the participant will will receive active vancomycin for an additional 14 days (125mg twice a day x 7 days, then 125mg once a day for 7 days).
11091125|NCT04138693|Experimental|Cohort 1: 2 x 2.0 g G-PUR® oral suspension|
11091126|NCT04138693|Experimental|Cohort 2: 1 x 2.0 g G-PUR® oral suspension|
11091127|NCT04138693|Placebo Comparator|Cohort 3: Placebo oral suspension|
11091128|NCT04138680|Experimental|Active Biofeedback|The patients in the active group will receive one active biofeedback training session.
11091129|NCT04138680|Sham Comparator|Sham Biofeedback|The patients in the sham group will receive one sham biofeedback training session.
11091130|NCT04138667|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema who will undergo complex decongestive therapy
11091131|NCT04138654|Experimental|Normal nitrite levels|Processed meat products enriched with natural compounds will contain normal nitrite levels.
11091132|NCT04138654|Experimental|Reduced nitrite levels|Processed meat products enriched with natural compounds will contain reduced nitrite levels
11091133|NCT04138628|Experimental|ctDNA screening arm|Flat dose 1200 mg Atezolizumab every three weeks for up to 13 months
11091134|NCT04138615|Experimental|Morphine|Morphine will be administered intravenously
11091135|NCT04138615|Placebo Comparator|Placebo|Saline will be administered intravenously
11091136|NCT04138602|Active Comparator|Emsella Chair Active Treatment with Dietary Counseling|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%. During the visit the subject will also receive dietary counseling.
11091137|NCT04138602|Placebo Comparator|Emsella Sham Treatment with Dietary Counseling|Sham subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power). During the visit the subject will also receive dietary counseling.
11091138|NCT04138589||CF patients aged 6-18 years homozygeous for delta F508|CF patients aged 6-18 years homozygeous for delta F508 starting with lumacaftor/ ivacaftor or tezacaftor/ ivacaftor
11091139|NCT04138563||Case|Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
11091140|NCT04138563||Control|Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years
11091141|NCT04138537|Other|Acromegaly group|CCCRC test and OB volume results
11091142|NCT04138537|Other|Control Group|CCCRC test and OB volume results
11091143|NCT04138524|Experimental|interventional|All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
11091406|NCT04136873|Placebo Comparator|Part A: 5-10-20 mg BID Placebo|Matching Placebo; Oral Dose
11091145|NCT04138511|No Intervention|Control Group|Students received theoretical-practical lessons about ultrasound skills in sports pathologies areas and used traditional study models, to study the subject
11091146|NCT04138498|Experimental|Sequence 1 (ADBC)|Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
11091147|NCT04138498|Experimental|Sequence 2 (BACD)|Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
11091148|NCT04138498|Experimental|Sequence 3 (CBDA)|Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
11091149|NCT04138498|Experimental|Sequence 4 (DCAB)|Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
11091150|NCT04138485|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
11091151|NCT04138485|Placebo Comparator|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
11091152|NCT04138472|Experimental|Dexmedetomidine|Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
11091153|NCT04138472|Experimental|Fentanyl|Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
11091154|NCT04138472|Experimental|Lidocaine|Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
11091155|NCT04138459||Qualitative exploration|Ten community mental health service users will be interviewed with their most important mental health worker to explore how recovery orientation of services affects roles and collaboration.
11091156|NCT04138446|Experimental|200-3000|Day 1: 200m (above sea level) asl Day 2: 3000m asl
11091157|NCT04138446|Experimental|3000-200|Day 1: 3000m asl Day 2: 200m asl
11091158|NCT04138446|Experimental|200-5000|Day 1: 200m asl Day 2: 5000m asl
11091159|NCT04138446|Experimental|5000-200|Day 1: 5000m asl Day 2: 200m asl
11091160|NCT04138446|Experimental|3000-5000|Day 1: 3000m asl Day 2: 5000m asl
11091161|NCT04138446|Active Comparator|5000-3000|Day 1: 5000m asl Day 2: 3000m asl
11091162|NCT04138433|Experimental|Real tDCS|Behavioural anomia treatment plus anodal tDCS
11091163|NCT04138433|Sham Comparator|Sham tDCS|Behavioural anomia treatment plus sham tDCS
11091164|NCT04138420||Patients receiving Bevacizumab|Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.
11091165|NCT04138407|Experimental|Intervention|
11091166|NCT04138407|Other|Control|Usual rehabilitation exercise
11091167|NCT04138394|Experimental|Vitamin C|Patients will receive intravenous vitamin C at 200mg/kg in divided doses, every 6 hrs for 96 hrs.
11091168|NCT04138394|Placebo Comparator|Control group|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
11091169|NCT04138381|Other|selinexor as a single agent and in combination with imatinib|"This is a single-arm, two-cohort, open label phase Ib/II trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of:
~Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by en expansion phase (II) testing for safety and preliminary evidence of antitumor activity
~Cohort B: single-agent, fixed selinexor dose in the same target population"
11091170|NCT04138368|Experimental|dyadic treatment|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
11091171|NCT04138368|Active Comparator|supportive treatment|mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
11091172|NCT04138355|Experimental|Extracorporeal shock wave therapy group|. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
11091173|NCT04138355|No Intervention|conventional manual therapy|the same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy.
11091174|NCT04138342|Active Comparator|Quantum dots nanoparticles group|A group of female volunteers infected with breast cancer will receive topical Quantum dots in different dosage forms.
11091175|NCT04138342|Placebo Comparator|Topical approved placebo cream|A group of female volunteers infected with breast cancer will receive placebo cream as a negative control.
11091176|NCT04138329|Active Comparator|Lichtenstein Technique|In this arm the inguinal hernia repair was made with the Lichtenstein technique by surgeons with experience in this kind of plasty using the conventional polypropylene mesh.
11091177|NCT04138329|Experimental|Onstep Technique|In this arm the inguinal hernia repair was made with the Onstep technique by one surgeon with experience using the Bard's 3DMAX mesh.
11091178|NCT04138316||Migraine patients|
11091179|NCT04138303|Experimental|Exercise Only Group (EX)|Participants will only receive the exercise protocol without nutrition education or counseling and instructed to continue to consume their regular diet.
11091180|NCT04138303|Experimental|Exercise with CR-LC Group|Participants will receive the exercise protocol and CR-LC Diet regimen.
11091181|NCT04138303|Experimental|Exercise with Ancestral Diet (AD) Group|Participants will receive the exercise protocol and AD regimen.
11091182|NCT04138290|Experimental|Predictix Antidepressant Software tool|Predictix Antidepressant Software tool will be used when prescribed with a medication for their MDD, by their treating physician.
11091183|NCT04138277|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
11091184|NCT04138264|Active Comparator|Peroperative counseling|
11091185|NCT04138264|No Intervention|No preoperative counseling|
11091186|NCT04138251|Experimental|Treatment|Oral empaglifozin 5 mg 1x/day, increase up to 10 mg 1x/day if no 25% decrease of blood1,5-anhydroglucitol level
11091187|NCT04138238||Supraflex Cruz Sirolimus-eluting Stent|
11091188|NCT04138225||Healthy|Healthy participants are those without IBS, IBD or any other gastrointestinal disorder
11091189|NCT04138225||Irritable bowel syndrome (IBS)|Participants with Rome IV diagnosed IBS
11091190|NCT04138225||Inflammatory bowel disease (IBD)|Patients with IBD - either ulcerative colitis (UC) or Crohn's disease (CD)
11091191|NCT04138212|Active Comparator|Chemotherapy group|Patients in this group will receive neoadjuvant chemotherapy.
11091192|NCT04138212|Experimental|Chemoradiation group|Patients in this group will receive neoadjuvant chemoradiation therapy.
11091193|NCT04138199||Participants with Human Immunodeficiency Virus-1 Infection|Human Immunodeficiency Virus-1 (HIV-1) infected and clinically stable patients on dual or triple HAART including Kaletra who switched or planned to switch to generic product of lopinavir/ritonavir
11091194|NCT04138186|Experimental|2.0g G-PUR® capsules|
11091195|NCT04138186|Placebo Comparator|Placebo capsules|
11091196|NCT04138173|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
11091197|NCT04138173|No Intervention|Usual care group|Usual care
11091198|NCT04138160|Experimental|5:2 intermittent energy restriction|The 5:2 intermittent energy restriction (IER) of 70% restriction (~600 kcal) delivered for two non-consecutive days/week and no restriction (so sufficient energy to meet the requirement of participants) on the other 5 days/week.
11091199|NCT04138160|Other|Continuous energy restriction|The continuous energy restriction (CER) of 20% restriction below the estimated requirement of participants (~1600 kcal) 7 days/week.
11091200|NCT04138147|Active Comparator|Superficial cervical plexus with auriculotemporal nerve blocks|
11091201|NCT04138147|Experimental|Cervical retrolaminar with auriculotemporal nerve blocks|
11091202|NCT04138134||Group 1|Patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins
11091203|NCT04138134||Group 2|Patients with atherosclerotic obstructive disease of lower limbs
11091204|NCT04138121|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
11091205|NCT04138108|Experimental|Experimental Group|Two sessions of psychoeducation were given to the parents in the experimental group.
11091206|NCT04138108|No Intervention|Control Group|The parents in the control group did not undergo any intervention and the children of the parents in this group continued their current treatment plans.
11091207|NCT04138095|Other|Virtual Reality|As this is a within subject design, participants will act as their own control. Participants will have access to their baseline opioids and benzodiazepines for pain and anxiety. Every second day they will have access to virtual reality as an adjunct to their opioids and benzodiazepines to manage their symptoms
11091208|NCT04138082|Experimental|High-dB Environment|While performing the spinal anesthesia, the participants were exposed to a pre-recorded soundtrack of one of the investigators' operating rooms while the anesthesiology team was performing a spinal anesthesia. It included instruments noise and discussion but alarms, pulse oximetry and discussion with the patient were removed. The level of the soundtrack was set to be at 70 dB with peaks up to 100 dB, this level was recorded for every participant with Iphone™ application SoundMeter X 10.3 by Faber Acoustical, which has been both choosed in accordance with similar studies. The average noise was measured using the LEq value on a ''A'' scale (dB(A)) which correlate with frequencies perceived by the human ear. Speakers where placed at each corner of the room. Since literature describe that noise can initially enhance performance but is a transitory effect, the investigators decided to expose the experimental group to the maximum level of noise without any gradation.
11091209|NCT04138082|No Intervention|Low-dB Environment|The control group performed the same spinal anesthesia simulation scenario but without any soundtrack. The ambient noise in the room was recorded with the same method for each participant.
11091210|NCT04138069|Experimental|PLB+Aerobic Bicycling|Pursed Lip Breathing + Aerobic Bicycling
11091211|NCT04138069|Active Comparator|Aerobic Bicycling|Only Aerobic bicycling
11091212|NCT04138056|Experimental|XRSV formulation 3_dTpa Group|Subjects randomized to the XRSV formulation 3_dTpa group will receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of dTpa vaccine in the right arm and will be followed up until the study end.
11091213|NCT04138056|Placebo Comparator|XPlacebo_RSV formulation 3 Group|Subjects randomized to the XPlacebo_RSV formulation 3 group will receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of Placebo in the right arm and will be followed up until the study end.
11091214|NCT04138056|Experimental|XRSV formulation 2_dTpa Group|Subjects randomized to the XRSV formulation 2_dTpa group will receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of dTpa vaccine in the right arm and will be followed up until the study end.
11091215|NCT04138056|Placebo Comparator|XPlacebo_RSV formulation 2 Group|Subjects randomized to the XPlacebo_RSV formulation 2 group will receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of Placebo in the right arm and will be followed up until the study end.
11091216|NCT04138056|Placebo Comparator|XPlacebo_dTpa Group|Subjects randomized to the XPlacebo_dTpa group will receive a single dose of Placebo in the left arm, a single dose of dTpa vaccine in the right arm and will be followed up until the study end.
11091217|NCT04138056|Experimental|URSV formulation 3_dTpa Group|Subjects randomized to the URSV formulation 3_dTpa group will receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of dTpa vaccine in the right arm and will be followed up until the study end.
11091218|NCT04138056|Placebo Comparator|UPlacebo_RSV formulation 3 Group|Subjects randomized to the UPlacebo_RSV formulation 3 group will receive a single dose of RSVPreF3 formulation 3 vaccine in the left arm, a single dose of Placebo in the right arm and will be followed up until the study end.
11091219|NCT04138056|Experimental|URSV formulation 2_dTpa Group|Subjects randomized to the URSV formulation 2_dTpa group will receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of dTpa vaccine in the right arm and will be followed up until the study end.
11091220|NCT04138056|Placebo Comparator|UPlacebo_RSV formulation 2 Group|Subjects randomized to the UPlacebo_RSV formulation 2 group will receive a single dose of RSVPreF3 formulation 2 vaccine in the left arm, a single dose of Placebo in the right arm and will be followed up until the study end.
11091221|NCT04138056|Placebo Comparator|UPlacebo_dTpa Group|Subjects randomized to the UPlacebo_dTpa group will receive a single dose of Placebo in the left arm, a single dose of dTpa vaccine in the right arm and will be followed up until the study end.
11091222|NCT04138043|Experimental|Cohort 1: GSK2330811 450 mg (Japanese)|Japanese participants in this cohort will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter [mg/mL]).
11091223|NCT04138043|Placebo Comparator|Cohort 1: Placebo (Japanese)|Japanese participants in this cohort will receive GSK2330811 matching placebo administered as three separate SC injections.
11091224|NCT04138043|Experimental|Cohort 2: GSK2330811 150 mg (Japanese)|Japanese participants in this cohort will receive GSK2330811 150 mg administered as a single SC injection.
11091225|NCT04138043|Placebo Comparator|Cohort 2: Placebo (Japanese)|Japanese participants in this cohort will receive GSK2330811 matching placebo administered as a single SC injection.
11091226|NCT04138043|Experimental|Cohort 3: GSK2330811 150 mg (Caucasian)|Caucasian participants in this cohort will receive GSK2330811 150 mg administered as a single SC injection.
11091227|NCT04138043|Placebo Comparator|Cohort 3: Placebo (Caucasian)|Caucasian participants in this cohort will receive GSK2330811 matching placebo administered as a single SC injection.
11091228|NCT04138043|Experimental|Cohort 4: GSK2330811 300 mg (Japanese)|Japanese participants in this cohort will receive a single 300 mg SC dose of GSK2330811, administered as two separate SC injections of 150 mg/mL.
11091229|NCT04138043|Placebo Comparator|Cohort 4: Placebo (Japanese)|Japanese participants in this cohort will receive GSK2330811 matching placebo administered as two separate SC injections.
11091230|NCT04138043|Experimental|Cohort 5: GSK2330811 300 mg (Caucasian)|Caucasian participants in this cohort will receive a single 300 mg SC dose of GSK2330811, administered as two separate SC injections of 150 mg/mL.
11091231|NCT04138043|Placebo Comparator|Cohort 5: Placebo (Caucasian)|Caucasian participants in this cohort will receive GSK2330811 matching placebo administered as two separate SC injections.
11091232|NCT04138030|Active Comparator|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
11091233|NCT04138030|Active Comparator|Cold Snare Endoscopic Mucosal Resection|Cold Snare Endoscopic Mucosal Resection (EMR), if necessary, to 15-40mm laterally spreading adenomas.
11091234|NCT04138017|Experimental|ViviGen Cellular Bone Matrix|Patients will receive the vivigen cellular bone matrix
11091235|NCT04138004|Experimental|2-L PEG with LB|"PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The patients were instructed to take 250 mL every 15 min untill the entire solution was consumed.
~In this group (2-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day)."
11091236|NCT04138004|Active Comparator|4-L PEG|In this group (4-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day.
11091237|NCT04137991|Experimental|Nol-Guided Analgesia Group|In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
11091238|NCT04137991|Active Comparator|Standard Analgesia Group|Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
11091239|NCT04137978|Active Comparator|ADV7103|"Patients receive ADV7103 twice a day at optimal dose. Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
~Other Names:
~• Potassium Citrate and Potassium Bicarbonate"
11091240|NCT04137978|Active Comparator|Standard of care comparator|Alkalinising treatment (SoC) taken at the usual dose and frequency
11091241|NCT04137965||Testicular torsion group|Men having undergone surgery for testicular torsion between 01.01.2003 and 12.31.2012
11091242|NCT04137965||Control group|Men without knowledge of their fertility status and who have never had their semen analyzed
11091243|NCT04137952|Experimental|deterministic visual error gain|"Day1(Pretest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min
~Day2 to Day5:
~Exp.group:27 times of posture tracking with high visual error gain.
~Control group:27 times of posture training with normal visual error gain.
~Day6 (Posttest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min"
11091244|NCT04137952|Experimental|stochastic visual noise|"Day1(Pretest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min
~Day2 to Day5:
~Exp.group A:27 times of posture training with posture tracking signal-to-noise ratio=2:1.
~Exp.group B:27 times of posture training with posture tracking signal-to-noise ratio=4:1.
~Control group:27 times of posture training with normal visual error gain.
~Day6(Posttest):
~stabilometer stance, 3 times/1 min
~air pillow stance, 3 time/30 sec
~poture-supraposture dual task, 3 times/1 min"
11091280|NCT04137692|Experimental|Red Blood Cell Transfusion|Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
11091281|NCT04137679|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
11091407|NCT04136873|Active Comparator|Part A: 30 mg QD CVL-231|Oral Dose
11091408|NCT04136873|Placebo Comparator|Part A: 30 mg QD Placebo|Matching Placebo; Oral Dose
11091245|NCT04137952|Experimental|intermittent visual gain|"Day1 (Pretest):
~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec
~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec.
~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec
~air pillow stance, 8 times/1 min
~Day2 (training section):
~Exp. group:Posture tracking with wearing flash glasses (low frequency with opaque ratio 50%), 12 times/45 sec.
~Control group:Posture tracking with wearing flash glasses (clear), 12 times/45 sec.
~Day3 (Posttest):
~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec
~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec
~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec
~air pillow stance, 8 times/1 min"
11091246|NCT04137939|No Intervention|Control group|Ctrl group is instructed to maintain their original daily life
11091247|NCT04137939|Experimental|Smart Exercise group|SE group are instructed to perform one session of upper extremity ergometer and one session of lower extremity ergometer in a week, 30 minute per session, lasting for 12 weeks.
11091248|NCT04137926|Experimental|Alzheimer's disease|
11091249|NCT04137926|Experimental|MCI due to AD|
11091250|NCT04137926|Experimental|Normal Elderly|
11091251|NCT04137913|Experimental|Music Group|Individuals in the music group will complete two assessment visit (pre-intervention and post-intervention). After their baseline visit, they will participate in a 6-week group music class, scheduled for 2 hours a day, 3 days a week. The daily music workshops will be led by a musician associated with the Rice Shepherd School of Music. Each week will be carefully scaled in difficulty, with the workshops becoming progressively more sophisticated. For instance, the first week's listening will focus on short and more familiar works such as instrumental etudes and folk songs. Gradually, the instructor will build towards symphonic movements, as well as more unfamiliar and experimental music. The course will culminate in creating a final composition.
11091252|NCT04137913|No Intervention|Non-music group|Individuals in the non-music group will complete two assessment visits separated by 2-3 months. They will be asked not to participate in any other music-related courses during the time they are enrolled in the study. At the end of participation, participants will be given resources to seek out music classes.
11091253|NCT04137900|Experimental|0.3 mg/kg repeat dose every 21 days up to 2 years|
11091254|NCT04137900|Experimental|1 mg/kg repeat dose every 21days up to 2 years|
11091255|NCT04137900|Experimental|3 mg/kg repeat dose every 21 days up to 2 years|
11091256|NCT04137900|Experimental|10 mg/kg repeat dose every 21 days up to 2 years|
11091257|NCT04137887|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
11091258|NCT04137887|Active Comparator|Group 2: QIV-SD|QIV-SD single injection at Day 0
11091259|NCT04137874|Experimental|eSTROKE|
11091260|NCT04137874|Active Comparator|Control|Conventional prehospital care
11091261|NCT04137861|Active Comparator|Mineral Trioxide Aggregate (MTA)|Root repair material
11091262|NCT04137861|Experimental|bioceramics|Root repair material
11091263|NCT04137848|Experimental|Experimental|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
11091264|NCT04137848|Sham Comparator|Control|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
11091265|NCT04137835|Experimental|Showmotion|"Performing an analysis requires the positioning of sensors on the patient's skin in predetermined positions, according to the related protocols. Each sensor positioned on patient's skin provides both raw data (accelerometer, magnetometer, gyroscope) and the orientation matrix, representing the orientation of the local System of Reference (SoR) with respect to a fixed SoR. A proprietary sensor-fusion algorithm allows provides an accurate estimate of the orientation, as assessed by stereo-photogrammetric system-based testing.
~Data from each sensor are sampled at 50 Hz and transferred wirelessly to a laptop with a proprietary software that processes the data according to the biomechanical model chosen for the analysis."
11091266|NCT04137809|Experimental|Robot Group|1-arm study where eligible volunteers will undergo robotic testing for safety, comfort, and fit.
11091267|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
11091268|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
11091269|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
11091270|NCT04137770|No Intervention|control|Patients will receive routine post-operative analgesics
11091271|NCT04137770|Experimental|intervention|Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs
11091272|NCT04137757|Experimental|Lower Body Negative Pressure (LBNP)|Participants complete mental tasks and imaging while undergoing lower body negative pressure (LBNP).
11091273|NCT04137757|Sham Comparator|Sham Pressure|Participants complete mental tasks and imaging with pressure noise but no pressure.
11091274|NCT04137744|Active Comparator|ARM preservation ALND|ARM +ve LN PRESERVED , ALND COMPLETED LATER ON
11091275|NCT04137744|Active Comparator|conventional ALND|ARM +VE NODES MARKED AND TAKEN WITH ALND
11091276|NCT04137731|Experimental|IFC Treatment|The IFC treatment will be used for 30 minutes, twice a day for two days after the total knee arthroplasty
11091277|NCT04137731|Placebo Comparator|Placebo|One set of device is programmed to be used as Placebo, the subject will feel the vibration but will not receive a therapeutic signal.
11091278|NCT04137718||Rare driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation positive.
11091279|NCT04137718||Rare driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction(PCR)panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation negative.
11091282|NCT04137679|Active Comparator|Neoadjuvant Radiochemotherapy followed by surgery|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
11091283|NCT04137653|Experimental|nab-Paclitaxel group|749 patients will be assigned into nab-Paclitaxel group.
11091284|NCT04137653|Active Comparator|paclitaxel group|749 patients will be assigned into paclitaxel group
11091285|NCT04137640|Other|endocrine group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into endocrine group.
11091286|NCT04137640|Other|chemotherapy group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into chemotherapy group
11091287|NCT04137627|Experimental|Melatonin|The group received standard treatment with the oral administration of Melatonin
11091288|NCT04137627|Placebo Comparator|Placebo|The group received standard treatment with the oral administration of Placebo
11091289|NCT04137614|Placebo Comparator|Digital substraction angiography|
11091290|NCT04137614|Experimental|Drug-coated balloon|
11091291|NCT04137588||Group A|antiangiogenesis 7.5mg/Kg q3w+pemetrexed 500mg/m2 q3w+ platinum 75mg/m2 q3w
11091292|NCT04137588||Group B|immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
11091293|NCT04137588||Group C|antiangiogenesis 7.5mg/Kg q3w+immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
11091294|NCT04137575|Experimental|ConquerFear-Group|ConquerFear-Group is a psychological intervention developed specifically for fear of cancer recurrence
11091295|NCT04137575|Placebo Comparator|Relaxation Training|The Relaxation Training serves as a placebo comparator and is not developed specifically to target fear of cancer recurrence.
11091296|NCT04137562|Experimental|ADSTEM Inj.|ADSTEM Inj. hAD-MSC 1.0x10^8 cells
11091297|NCT04137562|Placebo Comparator|Placebo|0.9% Normal Saline Inj.
11091298|NCT04137549||Nocturnal controlled hypertension|Nocturnal blood pressure was controlled under 120/70 mmHg after aggressive anti-hypertensive therapy.
11091299|NCT04137549||Nocturnal uncontrolled hypertension|Nocturnal blood pressure was still over 120/70 mmHg after aggressive anti-hypertensive therapy.
11091300|NCT04137536|Experimental|Pancreatic Adenocarcinoma|Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.
11091301|NCT04137510|Experimental|Orsiro|
11091302|NCT04137510|Active Comparator|Resolute Onyx|
11091303|NCT04137497||Patients with disorders of consciousness|
11091304|NCT04137497||Patients with unresponsive wakefulness syndrome|
11091305|NCT04137497||Patients with minimally conscious state|
11091306|NCT04137458|Experimental|Participants|The investigator will withdraw biological samples and a biological and DNA bank will also be realized
11091307|NCT04137445|Experimental|Study Provided Diet|A group of complementary foods provided to participants by researchers.
11091308|NCT04137445|Placebo Comparator|Traditional Diet|No study foods provided to participants by researchers. Participants will eat a typical diet provided by caregivers.
11091309|NCT04137432|Experimental|Oxytocin (24 IU)|Intranasal administration of 24 international units (IU) of oxytocin (OT) 30 minutes before the start of four intervention sessions
11091310|NCT04137432|Placebo Comparator|Placebo|Intranasal administration of a placebo spray 30 minutes before the start of four intervention sessions
11091311|NCT04137419|Experimental|ProlacSan|Patient will get ProlacSan lozenges after nonsurgical treatment of periodontitis.
11091312|NCT04137419|Placebo Comparator|Placebo|Patients will get placebo lozenges after nonsurgical periodontal treatment
11091313|NCT04137406||T1 tumor with lymph node metastasis|patients with T1 tumor and lymphnode positive
11091314|NCT04137406||T2 or T3 tumor with lymph node negative|patients with T2 or T3,lymph node negative
11091315|NCT04137393|Experimental|Salvadora persica|"brush teeth with Salvadora persica Miswak"
11091316|NCT04137393|Active Comparator|tooth brush|brush with fluoridated tooth paste
11091317|NCT04137380|Experimental|Mirikizumab - Intravenous (IV)|Mirikizumab administered IV
11091318|NCT04137380|Placebo Comparator|Placebo - IV|Placebo administered IV
11091319|NCT04137380|Experimental|Mirikizumab - Subcutaneous (SC)|Mirikizumab administered SC
11091320|NCT04137380|Placebo Comparator|Placebo - SC|Placebo administered SC
11091321|NCT04137367|Experimental|Active Affective Bias Modification|Computer based Affective Bias Modification
11091322|NCT04137367|Sham Comparator|Sham Affective Bias Modification|Computer based sham Affective Bias Modification
11091323|NCT04137354|Placebo Comparator|Control Iron&Vitamin A Placebo|Children randomly assigned to the placebo iron & vitamin A control group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months).
11091324|NCT04137354|Experimental|Vitamin A & Placebo Iron Supplements|Children is this group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive a high dose vitamin A capsule (200,000IU) at baseline and after 4.5 months (at mid-line)
11091325|NCT04137354|Experimental|Intermittent Iron Supplements & Placebo Vitamin A|"Children is this group will receive weekly three tablets of iron (42mg of elemental iron once a week) for 9 months (equivalent to a one school year).
~They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months)."
11091326|NCT04137354|Experimental|Intermittent Iron Supplements & High dose Vitamin A|Combined weekly iron supplementation (42mg of elemental iron once a week) for 9 months and high dose vitamin A (200,000IU) at baseline and after 4.5 months (mid-line).
11091327|NCT04137341|Experimental|Tablet A|A single oral 300-mg dose of GLPG1972 in fasted state
11091328|NCT04137341|Experimental|Tablet B|A single oral 300-mg dose of GLPG1972 in fasted state
11091329|NCT04137341|Experimental|Tablet C|A single oral 300-mg dose of GLPG1972 in fasted state
11091330|NCT04137341|Experimental|Food effect|selected tablet B or C under fed conditions
11091400|NCT04136873|Placebo Comparator|Part A: 5 mg QD Placebo|Matching Placebo; Oral Dose
11091401|NCT04136873|Active Comparator|Part A: 10 mg QD CVL-231|Oral Dose
11091331|NCT04137328|Experimental|liraglutide group|Mecobalamin tablets (0.5mg/day, oral) and liraglutide (0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection) were used for 3 months.
11091332|NCT04137328|Active Comparator|control group|Take Mecobalamin (0.5mg/day, oral), add or adjust insulin (when basic insulin is preferred for those who do not use insulin, if insulin has been used, adjust the dose or program according to the condition, inject subcutaneously) for 3 months.
11091333|NCT04137302|Active Comparator|Topical hydrocortisone administration|dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)
11091334|NCT04137302|Active Comparator|Systemic hydrocortisone administration|tablets (once a day, 50 mg, morning, during 50 days)
11091335|NCT04137289|Experimental|BI 905711|
11091336|NCT04137276|Experimental|vitamin C and thiamine|patients who received intravenous vitamin C and thiamine
11091337|NCT04137276|Active Comparator|thiamine|patients who received thiamine
11091338|NCT04137263|Experimental|Treatment|Subjects will receive dose formulation for treatment of melasma
11091339|NCT04137250|Active Comparator|Hamstring|It is the group in which the hamstrings are surgically removed to be used as an autograft for the reconstruction of the anterior cruciate ligament. The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament.
11091340|NCT04137250|Experimental|Quadriceps tendon|It is the group in which a portion of the quadriceps tendon will be surgically removed for later use as an autograft for the reconstruction of the anterior cruciate ligament. The intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
11091341|NCT04137224|Experimental|IgPro20|20% liquid formulation of human immunoglobulin for subcutaneous use
11091342|NCT04137224|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
11091343|NCT04137211|Experimental|Prolonged sitting with social break|
11091344|NCT04137211|Experimental|Prolonged sitting with walk break|
11091345|NCT04137211|Experimental|Prolonged sitting with simple resistance activities|
11091346|NCT04137198|No Intervention|control|classic analgetic protocol
11091347|NCT04137198|Experimental|intervention|intranasal Sufentanil
11091348|NCT04137185|Experimental|rhTSH|Phase 1: 0.9mgx1d、0.9mgx2d、1.8mgx1d、1.8mgx2d, intramuscularly (IM) ; Phase 2: patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the Phase 1.
11091349|NCT04137172|Experimental|group1|underwent laparoscopic IPOM hernioplasty without repair
11091350|NCT04137172|Experimental|group2|underwent laparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
11091351|NCT04137172|Experimental|group3|underwent laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
11091352|NCT04137159|Experimental|FES rowing|Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
11091353|NCT04137159|No Intervention|Wait list|During the 12-week treatment as usual program, subjects will not participate in FES-rowing.
11091354|NCT04137146|Experimental|Sacral Nerve Stimulation|Intervention: Sacral nerve Stimulation Stimulation sites：S3 Postoperative study visits lasted approximately 3 hours and were conducted in 3 months.
11091355|NCT04137146|No Intervention|No SNS Intervention|
11091356|NCT04137133|Experimental|collection of expectoration, stools and blood|
11091357|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
11091358|NCT04137107|Experimental|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
11091359|NCT04137107|Experimental|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
11091360|NCT04137107|Placebo Comparator|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
11091361|NCT04137107|Experimental|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
11091362|NCT04137107|Placebo Comparator|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
11091363|NCT04137094|Experimental|PHCI with HIV/HCV counselor|A persuasive health communication intervention will be performed by a community HIV/HCV test counselor
11091364|NCT04137094|Experimental|PHCI with ED Medical Staff|A persuasive health communication intervention will be performed by ED medical staff
11091402|NCT04136873|Placebo Comparator|Part A: 10 mg QD Placebo|Matching Placebo; Oral Dose
11091403|NCT04136873|Active Comparator|Part A: 20 mg QD CVL-231|Oral Dose
11091365|NCT04137081|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
11091366|NCT04137068|Other|Sedentary to Active|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their normal level of physical activity. After the baseline visit, participants will reduce their step count by more than half for two weeks, and then maintain baseline activity level for two weeks. The fifth week will be maintaining baseline activity level. Participants will visit the laboratory once every week during these 5 weeks.
11091367|NCT04137068|Other|Active to Sedentary|Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their normal level of physical activity. After the baseline visit, participants will maintain their baseline level of physical activity for one week, and then reduce their step count for two weeks. The fifth week will be maintaining baseline activity level. Participants will visit the laboratory once every week during these 5 weeks.
11091368|NCT04137055|Experimental|ZSP0678-10mg (single dose)-Cohort 1|ZSP0678/Placebo 10mg
11091369|NCT04137055|Experimental|ZSP0678-30mg (single dose)-Cohort 2|ZSP0678/Placebo 30 mg Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.
11091370|NCT04137055|Experimental|ZSP0678-60mg (single dose)-Cohort 3|ZSP0678/Placebo 60mg Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.
11091371|NCT04137055|Experimental|ZSP0678-120mg (single dose)-Cohort 4|ZSP0678/Placebo 120mg Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.
11091372|NCT04137055|Experimental|ZSP0678-180mg (single dose)-Cohort 5|ZSP0678/Placebo 180mg Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.
11091373|NCT04137055|Experimental|ZSP0678-240mg (single dose)-Cohort 6|ZSP0678/Placebo 240mg Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.
11091374|NCT04137055|Experimental|ZSP0678-320mg (single dose)-Cohort 7|ZSP0678/Placebo 320mg Enrollment into Cohort 7 will begin upon assurance of safety for Cohort 6.
11091375|NCT04137055|Experimental|ZSP0678 (food effect)-Cohort FE|"Period 1: Group A and Group B receive ZSP0678/Placebo under the fasting or fed condition ,respectively on Day1.
~Period 2: Group A and Group B receive ZSP0678/Placebo under the fed or fasting condition ,respectively on Day8.
~Enrollment into Cohort FE will begin upon assurance of safety for Cohort 4."
11091376|NCT04137055|Experimental|ZSP0678 Dose1 (multiple doses)-Cohort 8|ZSP0678/Placebo Dose1 will be administrated according to the results of Cohort 2&3
11091377|NCT04137055|Experimental|ZSP0678 Dose2 (multiple doses)-Cohort 9|ZSP0678/Placebo Dose2 will be administrated according to the results of Cohort 3&4
11091378|NCT04137055|Experimental|ZSP0678 Dose3 (multiple doses)-Cohort 10|ZSP0678/Placebo Dose3 will be administrated according to the results of Cohort 4&5
11091379|NCT04137042|Active Comparator|Saline|intraoperative fluid therapy by using 0.9% saline
11091380|NCT04137042|Experimental|Balanced crystalloid|intraoperative fluid therapy by using balanced crystalloid
11091381|NCT04137029|Experimental|smoking|Healthy smoking volunteers
11091382|NCT04137029|Experimental|non-smoking|Healthy non-smoking volunteers
11091383|NCT04137016|Experimental|HIV-subjects with APP|HIV-infected patients using the App + standard clinical management (SCM)
11091384|NCT04137016|No Intervention|Control group|HIV-infected patients, who only receive Standard Clinical Management (without the App)
11091385|NCT04137003|Experimental|Rouge et Or program|Rouge et Or program group follow a detailed program that they do on their own. It is made of three cycles of four weeks each. Every cycle contains 3 training sessions by week with a minimum of 24 hours between sessions. The training volume is modulated for every cycle and every week. Each training sessions is made of 6 warm-up exercises followed by 6 training exercises. The exercises are a mix of strengthening, endurance, plyometric, neuromuscular control and dynamic stability. The exercises change every month with a progressively increasing difficulty towards the end to mimic return to sport demands.
11091386|NCT04137003|Active Comparator|CHU intervention guide|CHU intervention guide group follow the standard CHU protocol. At three months post-surgery, the protocol suggests progressing the exercises without precisely suggesting exercise, parameter or frequency.
11091387|NCT04136990|Active Comparator|Isolated ACL reconstruction|Isolated ACL reconstruction only.
11091388|NCT04136990|Experimental|ACL + LEAT|ACL reconstruction combined with Lateral Extra-Articular Tenodesis (LEAT).
11091389|NCT04136964||Patients group|Patients who have pain located in the anatomical region of the neck for more than three months due to mechanical causes; with or without radiation to the head, trunk, and upper limbs. Posteriorly, pain may be present in the neck region from the superior nuchal line to the spine of the scapula and the side region down to the superior border of the clavicle and the suprasternal notch.
11091390|NCT04136951|Experimental|Experimental phase|The PREVENT recommendation about patient homecare priority will be shared in homecare referral communication with the homecare intake coordinators. Homecare intake coordinators will be instructed to prioritize high risk patients for care.
11091391|NCT04136938||Intervention group (social marketing campaign)|People aged 60 and over will be included. They will receive a social marketing campaign.
11091392|NCT04136938||Control group|People aged 60 and over will be included.
11091393|NCT04136925||"runner participating of the Grand Raid"|
11091394|NCT04136912|Experimental|Breast Imaging Cohort|A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
11091395|NCT04136912|Experimental|Thyroid Imaging Cohort|A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
11091396|NCT04136912|Experimental|Healthy Volunteers Cohort|A total of 5 participants will be included to optimize imaging parameters.
11091397|NCT04136886|Active Comparator|IMRT and concurrent cisplatin|IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction
11091398|NCT04136886|Experimental|IMRT alone|IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction
11091399|NCT04136873|Active Comparator|Part A: 5 mg QD CVL-231|Oral Dose
11091410|NCT04136873|Placebo Comparator|Part B 30 mg QD Placebo|Matching Placebo; Oral Dose
11091411|NCT04136873|Active Comparator|Part B 20 mg BID CVL-231|Oral Dose
11091412|NCT04136873|Placebo Comparator|Part B 20 mg BID Placebo|
11091413|NCT04136860||Conservative management|Patients refused to accept any interventional treatment or patients were not suitable for any interventional treatment.
11091414|NCT04136860||Microsurgical resection|All microsurgical procedures were performed with intraoperative neuronavigation, ultrasonography, indocyanine fluorescence angiography (ICG), continuous monitoring of electroencephalogram and somatosensory evoked potential.
11091415|NCT04136860||Embolization|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Multi-stage embolization and target embolization were widely used within the embolization. Onyx was the main embolization material.
11091416|NCT04136860||Embolization+Radiosurgery|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Radiosurgery management was recommended for the residual lesions about 3 months after the embolization if necessary.
11091417|NCT04136860||Single-stage hybrid surgery|Hybrid surgery is a new surgical strategy defined as single-stage combined microsurgical resection and embolization in which embolization is performed firstly on the deep feeding artery, aneurysm, AVF, and meningeal arteries involved in blood supply of the nidus, and then, the microsurgical resection was performed immediately. Intraoperative angiography was performed repeatedly before the skull was closed, confirming complete occlusion of the malformation.
11091418|NCT04136847|Experimental|Hand Aging|Microneedling treatment of the dorsum of the hands
11091419|NCT04136834|Experimental|Pegtomarginase (PT01)|To determine the MTD of PT01 based on the toxicity observed during Cycle 1 of the Dose Escalation Phase and to investigate the safety and tolerability of PT01 when administered intravenously(IV) to subjects with advanced malignancies
11091420|NCT04136821|Placebo Comparator|Placebo|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
11091421|NCT04136821|Experimental|Oceanix™|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
11091422|NCT04136795||Conventional surgery|Patients having had esophageal atresia (type III, long gap excluded) repair by conventional surgery (right thoracotomy) or patients having had minimally invasive surgery converted to thoracotomy between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
11091423|NCT04136795||Minimally invasive surgery|Patients having had esophageal atresia (type III, long gap excluded) repair through minimally invasive surgery between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
11091424|NCT04136782|Experimental|Trial group|55 cases of triple-negative breast cancer will be assigned into a trial group.
11091425|NCT04136782|Active Comparator|Control group|55 cases of triple-negative breast cancer will be assigned into a control group.
11091426|NCT04136769|Experimental|Intervention|"After trial enrolment, patients undergo visceral debranching.
~After visceral debranching, patients proceed to neoadjuvant chemotherapy. The therapy as such is not a formal part of the trial protocol. The specific chemotherapy regimen and its duration are decided individually by treating physicians.
~Tumor resection should be performed two to four weeks after completion of chemotherapy. Prior to resection, re-staging and verification of vascular reconstruction patency are carried out. The specific procedure for tumor resection and intestinal tract reconstruction is at the choice of the treating surgeon. It should follow oncological principles and aim at complete removal of the tumor and regional lymph nodes. Usually, resection will be done as pancreatoduodenectomy with or without distal gastrectomy (Whipple's procedure or pylorus-preserving Whipple's procedure), distal pancreatectomy with splenectomy, or total pancreatectomy with splenectomy."
11091427|NCT04136756|Experimental|Dose Escalation of NKTR-255|Patients will receive intravenous (IV) NKTR-255 every 21 days (q21d) to establish RP2D.
11091428|NCT04136756|Experimental|Dose Expansion of NKTR-255 alone|The selected RP2D of NKTR-255 will be evaluated in expansion cohorts. Cohort A in patients with relapsed NHL after CAR-T therapy as a salvage regimen to further characterize safety and tolerability. Cohort B1 will evaluate NKTR-255 in patients with MM with progressive disease who have had at least 3 prior lines of therapy treatment. Cohort C1 will evaluate patients with iNHL that has progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.
11091429|NCT04136756|Experimental|Dose Expansion of NKTR-255 with Daratumumab|The selected RP2D of NKTR-255 will be evaluated in expansion Cohort B2, which will combine NKTR-255 with daratumumab in patients with MM with progressive disease who have had at least 3 prior lines of therapy treatment.
11091430|NCT04136756|Experimental|Dose Expansion of NKTR-255 with Rituximab|The selected RP2D of NKTR-255 will be evaluated in Cohort C2, which will combine NKTR-255 with rituximab in patients with iNHL that has progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.
11091431|NCT04136743|Active Comparator|Corticosteroid|Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg [triamcinolone acetonide]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.
11091432|NCT04136743|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
11091433|NCT04136730|No Intervention|Control|Usual Care
11091434|NCT04136730|Active Comparator|Home-based|Home-based resistance exercise training
11091435|NCT04136717|Other|COPD patients|Patients with acute exacerbation of COPD and respiratory acidosis under oxygen therapy.
11091436|NCT04136717|Other|Bariatric surgery patients|Obese patients after gastric surgery under CPAP.
11091612|NCT04135456|Experimental|Medium dose group|1.0g/kg of 20% mannitol administered at skin incision.
11091437|NCT04136704||Sleeve Gastrectomy in Pediatric Patients|Laparoscopic Sleeve Gastrectomy will be offered as an adjuvant to a multidisciplinary family-based program that focuses on nutrition, physical activity, and behavioral counseling.
11091438|NCT04136704||Sleeve Gastrectomy in Adult Patients|This comparison group will be composed of adult patients who undergo sleeve gastrectomy
11091439|NCT04136691|Experimental|simulation training|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed. In the research, the application of burn patient scenario was performed only with the intervention group.
11091440|NCT04136691|No Intervention|Control|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed.
11091441|NCT04136678|Experimental|treadmill back walking training|15 minutes conventional walking training, 15 minutes of treadmill back walking training, 15-minute treadmill forward walking training
11091442|NCT04136665|Experimental|Physical Activity Adapted program|
11091443|NCT04136652|Placebo Comparator|Sham|The women are randomized, by a computer program, to a sham laser-treatment with the laser not active.
11091444|NCT04136652|Active Comparator|Laser|The women are randomized, by a computer program, to a vaginal CO2 laser-treatment with 30 w.
11091445|NCT04136639|Experimental|Miswak|Miswak sticks used twice daily, every 12 hours, for three months.
11091446|NCT04136639|Experimental|Grape Seed Extract|Grape seed extract 6.5% mouthwash used twice daily, every 12 hours, for three months.
11091447|NCT04136639|Active Comparator|Fluoride Mouthwash|0.05% fluoride mouthwash used twice daily, every 12 hours, for three months.
11091448|NCT04136626|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD.
11091449|NCT04136626|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
11091450|NCT04136613|Experimental|Post placental intra uterine device insertion|There was immediate post-partum insertion of CuT 380 A intrauterine device after delivery of placenta during cesarean delivery. To overcome the considerable expulsion rate in the previous studies, we stabilize the IUD in place at the fundus be an absorbable suture; vicryl 0 that was introduced through the fundus, held the needle with sponge holder that was introduce up the fundus and taken out the vicryl through the lower uterine inscion, cutting the needle, hold the vicryl around the the T arm of the IUD and withdrawn back to be placed inside the fundus. Before closing the uterine incision, the threads were placed in the lower uterine segment, then the uterine incision was then closed routinely.
11091451|NCT04136600|Experimental|EGFR antibody arm|Participants received a dose of 500 mg/m2 Cetuximab iv on Day 1 of cycle every 3 weeks, or 400mg Nimotuzumab on Day 1 of cycle, every week, until disease progression. 12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
11091452|NCT04136600|Placebo Comparator|Placebo arm|12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
11091453|NCT04136587|Active Comparator|Healthy Controls|"Inclusion criteria:
~Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss
~Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia
~Exclusion criteria:
~Diagnosis of IBD or any other inflammatory condition of the small and large intestine
~Diagnosis of irritable bowel syndrome (IBS)
~Autoimmune disorders
~Obesity (BMI> 30)
~Regular intake of NSAIDs (> 2 tablets/ week), immunosuppressants
~Intake of antibiotics within the last 3 months
~Intestinal infection by enteric pathogens
~Probiotic therapy"
11091454|NCT04136587|Active Comparator|Crohn's disease|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)
~Inclusion criteria:
~Colonoscopy indicated by routine clinical care
~Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)
~Exclusion criteria:
~• Intestinal infection by enteric pathogens"
11091455|NCT04136587|Active Comparator|Ulcerative Colitis|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)
~Inclusion criteria:
~Colonoscopy indicated by routine clinical care
~Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)
~Exclusion criteria:
~• Intestinal infection by enteric pathogens"
11091456|NCT04136587|Active Comparator|Colorectal carcinoma|"Inclusion criteria:
~• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology
~Exclusion criteria:
~• None"
11091457|NCT04136587|Active Comparator|Colitis/Enteritis of other origin|"Inclusion criteria:
~Diagnosis of intestinal inflammation at endoscopy or histology
~E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause
~Exclusion criteria:
~• None"
11091458|NCT04136561|Experimental|CVC and Midline Catheter|Existing standard of care CVC. Midline catheter placed within 24 hours of CVC placement.
11091459|NCT04136561|No Intervention|CVC|Standard of care CVC: case-matched controls using baseline data.
11091460|NCT04136548|Experimental|Fentanyl|Fentanyl will be administered intravenously
11091461|NCT04136548|Placebo Comparator|Placebo|Placebo will be administered intravenously
11091462|NCT04136535|Experimental|Pemetrexed and Carboplatin with Anlotinib|Pemetrexed and Carboplatin with Anlotinib
11091463|NCT04136535|Active Comparator|Pemetrexed and Carboplatin without Anlotinib|Pemetrexed and Carboplatin without Anlotinib
11091464|NCT04136522|Active Comparator|conventional|The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
11091465|NCT04136522|Experimental|total mesopancreas excision with arterial first approach|The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
11091466|NCT04136509|Experimental|allograft|The filler used in sinus floor elevation is albumin impregnated allograft.
11091467|NCT04136509|Experimental|xenograft|The filler used in sinus floor elevation is anorganic bovine bone mineral.
11091468|NCT04136496|Active Comparator|Ink placed before chemotherapy (Study A)|In Study A, 0.5 mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy
11091469|NCT04136496|Active Comparator|Ink placed after chemotherapy (Study B)|In Study B, 0.5 mL of Black Eye Ink will be placed before neoadjuvant therapy
11091470|NCT04136483|Experimental|CBT-I|
11091471|NCT04136470||NSCLC|This cohort will consist of 100 patients with non-small cell lung cancer (NSCLC).
11091472|NCT04136470||MEL|This cohort will consist of 30 patients with melanoma (MEL).
11091473|NCT04136457|Experimental|Endurance|Endurance training
11091474|NCT04136457|Experimental|Resistance|Resistance training
11091475|NCT04136457|Experimental|Sprint|Sprint training
11091476|NCT04136444|Experimental|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
11091477|NCT04136444|Experimental|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
11091478|NCT04136431|Experimental|Intervention group|
11091479|NCT04136431|Placebo Comparator|Control group|
11091480|NCT04136418|Active Comparator|Usual care|Patients currently self-manage their condition using antibiotics and steroids when their disease symptoms match the criteria in information provided by a clinician
11091481|NCT04136418|Experimental|Mobile App device|Patients enter their health status onto an App which is relayed to the healthcare team, who can then provide further information or clinical intervention should they so choose
11091482|NCT04136392||Eligible Patients|The population to be enrolled in this study includes patients whose intended treatment is to receive mechanical circulatory support with the ABIOMED, Inc. hemodynamic support devices per the treating physician's discretion and best practices.
11091483|NCT04136379||Clinic monitoring|Patients who attend a warfarin clinic for management of their INR
11091484|NCT04136379||Home monitoring|Patients who undertake home monitoring of their INR using a CoaguChek POC device
11091485|NCT04136366|Experimental|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
11091486|NCT04136366|Active Comparator|Standard surgical care procedure|Standard procedure performed.
11091487|NCT04136353|Experimental|Darolutamide|"Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.
~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
11091488|NCT04136353|Placebo Comparator|Placebo|"Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.
~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
11091489|NCT04136340|Active Comparator|In-person follow-up|Due to the COVID-19 pandemic, patients originally randomized to the in-person group received telemedicine visits. Thus, the researchers will expand our sample for these interviews to include patients who have completed at least 2 telemedicine follow-up visits whether they were originally randomized to the in-person group or the home telemedicine group.
11091490|NCT04136340|Experimental|Home Telemedicine follow-up|
11091491|NCT04136327|Experimental|GLPG1972 oral and [14C]-GLPG1972 IV|GLPG1972 film-coated tablet followed by [14C]-GLPG1972 solution for infusion
11091492|NCT04136327|Experimental|[14C]-GLPG1972 oral solution|[14C]-GLPG1972 oral solution
11091493|NCT04136314|Experimental|Gain-Frame Survey [A]|
11091494|NCT04136314|Experimental|Loss-Frame Survey [B]|
11091495|NCT04136301|Experimental|Informative video arm|"Nuliparus women admitted to an induction will be exposed to informative video with data regarding labor and possible obstetric emergencies such as cesarean delivery.
~All patients will answer the State-Trait Anxiety Inventory (STAI) before and after intervention"
11091496|NCT04136301|No Intervention|control arm|no intervention. All patients will answer the State-Trait Anxiety Inventory (STAI) before and after delivery.
11091497|NCT04136288|Experimental|Males with erectile dysfunction (ED)|Males diagnosed with erectile dysfunction (ED) for over a year, but less than 5 years, will receive shock wave therapy via MoreNova device
11091498|NCT04136275|Experimental|CAR-37 T cells|"CAR-37 will be administered intravenously on day 0
~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.
~Subjects will receive 3 days of lymphodepleting chemotherapy starting Day -5, before the infusion of CAR-37 T cells on Day 0"
11091499|NCT04136275|Experimental|CAR-37 T cells Dose Escalation|"CAR-37 will be administered intravenously on day 0
~Enrolled subjects will undergo a leukapheresis procedure processing approximately two times the subject's total blood volume.
~CAR-37 will undergo dose escalation"
11091500|NCT04136262|Experimental|Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
11091501|NCT04136262|Placebo Comparator|TwHF (dummy) plus MTX|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.
11091502|NCT04136249|No Intervention|Control chimiotherapeutic arm|Standard care as comparaison procedure that includes chemotherapy
11091503|NCT04136249|Experimental|Physical over-activity|The procedure under study which includes a re-training mixing EMS and EXC with a nutrition adapted to the needs related to the physical over-activity following the chemotherapy
11091504|NCT04136236||esophageal mucosal lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
11091613|NCT04135456|Experimental|High dose group|1.5g/kg of 20% mannitol administered at skin incision.
11091505|NCT04136223||RA-ILD|"Consecutive adult patients (aged >18 years) with RA* and interstitial lung disease
~*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010"
11091506|NCT04136184|Experimental|AKCEA-TTR-LRx|AKCEA-TTR-LRx by subcutaneous injection once every 4 weeks
11091507|NCT04136184|Active Comparator|Inotersen|Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to AKCEA-TTR-LRx administered subcutaneously once every 4 weeks until the end of study
11091508|NCT04136171|Experimental|AKCEA-TTR-LRx|ACKEA-TTR-LRx by subcutaneous injection once every 4 weeks
11091509|NCT04136171|Placebo Comparator|Placebo|Matching placebo by subcutaneous injection once every 4 weeks
11091510|NCT04136145|Experimental|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
11091511|NCT04136145|Experimental|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
11091512|NCT04136132|Experimental|Biological collection|"Biological collection
~For all the patients include in the study :
~blood and tissue samples collected before and during treatment. In parallel to this biological collection, standardized clinical data will be entered into a database"
11091513|NCT04136119||healthcare professionals|doctors, pharmacists and dieticians who are involved in prescribing vitamins and micronutrients to critically ill patients
11091514|NCT04136106||Low-dose IL-2 group|Patients in this group were treated with low-dose IL-2 combined with corticosteroid and immunosuppressor, and low-dose IL-2 is defined as 100IU subcutaneously every other day for two weeks, followed by two-week break, as one treatment cycle, and at least three cycles.
11091515|NCT04136106||Non IL-2 group|Patients in this group were only treated with corticosteroid and immunosuppressor,
11091516|NCT04136093|Experimental|the MED|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the MED group
11091517|NCT04136093|Experimental|the DASH|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the DASH group
11091518|NCT04136093|Experimental|The control group|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the control group.
11091519|NCT04136080|Other|chronic hypertension group|septic patients with chronic hypertension
11091520|NCT04136080|Other|denying chronic hypertension group|septic patients without chronic hypertension
11091521|NCT04136067|Experimental|NNC0268-0965|Participants will receive NNC0268-0965
11091522|NCT04136067|Active Comparator|Insulin glargine|Participants will receive insulin glargine
11091523|NCT04136054|Experimental|Adjusted group CBT-i for Anxiety and Affective disorders|Cognitive Behavioral group intervention for sleep problems in patients with Anxiety and Affective disorders, based on Cognitive Behavioral Therapy for insomnia
11091524|NCT04136054|Active Comparator|Care as usual wait-list control group|Treatment as Usual. (After about five months, participants in this condition are offered the experimental group treatment.)
11091525|NCT04136041|Experimental|Smartphone Application|Participants watch a video using the Smartphone Application displaying positive word stimuli.
11091526|NCT04136041|No Intervention|No Intervention|No Intervention.
11091527|NCT04136028|Experimental|intervention/treatment|Anakinra (Kineret)
11091528|NCT04136015||Dasatinib group|
11091529|NCT04136015||Imatinib group|
11091530|NCT04135989|Other|Cre8 AES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.
~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
11091531|NCT04135989|Other|Cre8 AES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.
~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
11091532|NCT04135989|Other|Synergy EES and personalized DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.
~Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score."
11091533|NCT04135989|Other|Synergy EES and standard DAPT duration|"Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.
~Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention."
11091534|NCT04135963||Participants with MM|Participants diagnosed with MM from 8 investigative sites will be observed retrospectively for previous 3 years before enrollment until Day 1.
11091535|NCT04135937|Experimental|MESH|Mobile Evidence-Based Smoking Cessation for Veterans Living with HIV is an intervention that is tailored for participants. It can include cognitive behavioral therapy, relapse-prevention text messaging, and/or pharmacotherapy with nicotine replacement therapy, bupropion, or varenicline.
11091536|NCT04135924|Active Comparator|walking nordic and respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will be submitted to respiratory muscle training (TMR) associated with the Nordic walking(NC) training .
11091537|NCT04135924|Active Comparator|walking nordic group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to Nordic walking training.
11091538|NCT04135924|Active Comparator|respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to respiratory muscle training protocol.
11091539|NCT04135898|Experimental|SIBP-04|
11091540|NCT04135898|Active Comparator|Bevacizumab|
11091541|NCT04135885|Experimental|Intervention group|Intervention group: patients took 7 days of folic acid tablets before surgery (0.3mg/d for children aged 1-3, 0.4mg/d for children aged 4~5 years, dissolved in 20ml brown sugar water.)
11091542|NCT04135885|Experimental|Placebo group|Placebo group: The patient received the same dose of brown sugar water for 7 days before surgery. Folic acid dose selection is based on the maximum daily intake of children（tolerable upper intake levels，UL）
11091543|NCT04135872||hypoalbuminemia|hypoalbuminemia was classified as serum albumin level (SAL) <35g/L
11091544|NCT04135872||normal albumin level|patients with serum albumin level (SAL) of 35g/L or higher
11091545|NCT04135859|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
11091546|NCT04135859|Experimental|Fibit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
11091547|NCT04135846|Experimental|doxazosin|16 mg, or maximum tolerated dose (MTD)
11091548|NCT04135846|Placebo Comparator|placebo|matching placebo
11091549|NCT04135833|Experimental|Itraconazole and BPI-7711|BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.
11091550|NCT04135833|Experimental|Rifampicin and BPI-7711|BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.
11091551|NCT04135820|Experimental|Fasted|BPI-7711 following a period of fasting
11091552|NCT04135820|Experimental|High-fat meal|BPI-7711 following a high-fat meal.
11091553|NCT04135807|Experimental|Microdevice|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
~Patients with newly found supratentorial lesions, or patients previously diagnosed with supratentorial gliomas at time of recurrence, whose treatment plan includes partial or total resection surgery as a component of standard-of-care treatment will be included.
~- Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.
~-- The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs microdoses for intratumor release of the following 8 approved drugs: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
11091554|NCT04135781|Experimental|AS|Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles
11091555|NCT04135781|Active Comparator|XELOX|Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles
11091556|NCT04135768|Experimental|Treatment|Participants who will undergo both volar locking plate fixation of the distal radius and the study procedure (wrist joint haematoma washout)
11091557|NCT04135768|Placebo Comparator|Placebo|Participants who will undergo volar locking plate fixation of the distal radius only
11091558|NCT04135755||vertebral compression fracture|No drugs intervention
11091559|NCT04135755||older adult without spinal deformity|No drugs intervention
11091560|NCT04135755||young adults|No drugs intervention
11091561|NCT04135742|Experimental|active tACS+ Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.
~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
11091562|NCT04135742|Sham Comparator|sham tACS+Cognitive Training group|"Subjects will receive CCT for a period of 3 months, 24 times, twice a week for 20 minutes each time.
~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min."
11091563|NCT04135742|Sham Comparator|active tACS+ sham Cognitive Training group|"Subjects will watch neutral pictures on iPad for a period of 3 months, 24 times, twice a week for 20 minutes each time.
~Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P4). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have 24 tACS sessions for three months, twice a week.The active tACS group will be stimulated with a 2 mA,40Hz current for 20 minutes each time during the stimulation."
11091564|NCT04135729||Personal trainer (PT)|Cross-sectional study on mental health symptoms in personal trainers
11091565|NCT04135729||Group instructors (GI)|Cross-sectional study on mental health symptoms in group instructors
11091566|NCT04135729||Combined instructors (PT + GI)|Cross-sectional study on mental health symptoms in personal trainers
11091567|NCT04135716|Experimental|Exposed group|Patients will receive colonoscopy with assistance of Endo.Angel
11091568|NCT04135716|Sham Comparator|Non-exposed group|Patients will receive colonoscopy without assistance of Endo.Angel
11091569|NCT04135703|Experimental|SBOA +Housing|receives opioid and related prevention services intervention thru Strengths-Based Outreach and Advocacy (SBOA) and rental assistance for housing (6 months)
11091570|NCT04135690|Experimental|HAIC plus toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Toripalimab 240mg intravenously every 3 weeks.
11091571|NCT04135690|Active Comparator|HAIC plus sorafenib|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Sorafenib 400mg twice daily (Bid) oral dosing.
11091572|NCT04135677|Active Comparator|low-dosage group|rivaroxaban 10mg qd for for 3 months and continued DAPT for 6 months.
11091573|NCT04135677|Active Comparator|high-dosage group|rivaroxaban 20mg qd for for 3 months and continued DAPT for 6 months.
11091574|NCT04135677|Active Comparator|DAPT group|asprin 100mg qd together clopidogrel 75mg for 6 months
11091575|NCT04135664|Active Comparator|Patients undergoing adjuvant esophagectomy|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.
~Patients randomized into undergoing adjvant esophagectomy."
11091576|NCT04135664|Experimental|Patients undergoing adjuvant chemoradiation|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.
~Patients randomized into undergoing adjvant chemoradiation."
11091744|NCT04134533||Non-Oral Feeding Group|Children with cerebral palsy who fed non-orally according to the Functional Oral Intake Scale.
11091745|NCT04134520||Generally healthy subjects with no known cancer disorder|
11091577|NCT04135664|Active Comparator|Prospective registry of patients that cannot be randomized|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.
~Patients cannot be randomized into undergoing adjvant esophagectomy or chemoradiaton.
~This arm includes patients undergoing adjuvant esophagectomy; adjuvant chemoradiation and active surveillance."
11091578|NCT04135651|Experimental|Paralaryngeal pressure|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
11091579|NCT04135651|Active Comparator|Cricoid pressure|During the induction of anesthesia, cricoid pressure is applied by 30N force with three fingers.
11091580|NCT04135638|Other|Cover Group (CG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.
~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.
~In the Cover Group the ILM flap will be folded as a single layer to bridge tissue dehiscence during air-fluid exchange. All eyes will recive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
11091581|NCT04135638|Other|Fill Group (FG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.
~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.
~In the Fill Group, multiple layers of ILM will be deliberately folded within the loss of tissue before air-fluid exchange. All eyes will receive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
11091582|NCT04135625|Active Comparator|Full Intervention|The full intervention group will receive three egg laying chickens that will be presented as a gift to the child by their religious leader (imam or priest) during a gifting ceremony, as well as Integrated nutrition and agricultural (INA) education training sessions.
11091583|NCT04135625|Active Comparator|Education Only|The education only intervention group will receive 3 chickens given in manner similar to animal distribution programs and the INA training sessions.
11091584|NCT04135625|No Intervention|Control|The control group will receive no chickens gifted and no INA training sessions.
11091585|NCT04135612|Experimental|Smartphone group|"application installed to their smartphones. This application will be in Hebrew language, simple to use, and specifically designed to the needs of the current study.
~Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles. In addition, patients will be encouraged to use the platform to ask questions and receive immediate answers regarding any aspect lactation. As per the study protocol, medical treatment will only be initiated in a formal clinic appointment and not via the application."
11091586|NCT04135612|No Intervention|Control group|The routine prenatal care provided by our institute includes lactation consulting during the 48-72 hour postpartum hospitalization.
11091587|NCT04135599|Active Comparator|real tDCS|Participants received 1.5mA tDCS for 20 minutes in 10 consecutive days.
11091588|NCT04135599|Sham Comparator|sham tDCS|Participants received sham tDCS for 20 minutes in 10 consecutive days.
11091589|NCT04135586|Experimental|Exercise|The patients in this arm will follow an exercise program for 24 weeks (i.e., during neo-adjuvant treatment), with two sessions per week including both aerobic and resistance training. Exercise intensity will range between 65% and 100% of the maximum score in the scale of Rated Perceived Exertion (RPE).
11091590|NCT04135586|Other|Control|The patients follow their usual habits as well as a Yoga program. They will also receive educational sessions on the benefits of regular physical activity (brisk walking).
11091591|NCT04135573||New untreated GD patients|Before treatment and application of anti-thyroid drugs (methimazole) or radioactive iodine treatment
11091592|NCT04135573||Healthy control|No thyroid related diseases and other immune diseases
11091593|NCT04135560|Experimental|Part A Cohort 1 (1% Body Surface Area)|Each participant in this cohort will receive both PF-07038124 0.06% and vehicle applied to the skin (1% Body Surface Area)
11091594|NCT04135560|Experimental|Part B Cohort 1 (10% Body Surface Area)|
11091595|NCT04135560|Experimental|Part B Cohort 2 (10% Body Surface Area)|
11091596|NCT04135560|Experimental|Part B Cohort 3 (10% Body Surface Area)|
11091597|NCT04135560|Experimental|Part B Cohort 4 (10% Body Surface Area)|
11091598|NCT04135560|Experimental|Part B Cohort 5 (20% Body Surface Area)|
11091599|NCT04135560|Experimental|Part B Cohort 6 (10% Body Surface Area)|Optional cohort of Japanese participants
11091600|NCT04135547|Experimental|intra-osseous access, IO at the humeral site|the OHCA patients receiving IO at the humeral site by paramedics in the field
11091601|NCT04135547|Active Comparator|intravenous access; IV at the upper limb|the OHCA patients receiving IV at the upper limb by paramedics in the field
11091602|NCT04135534|Active Comparator|group A|mutonpain 0.05 mg/kg
11091603|NCT04135534|Active Comparator|Group B|mutonpain 0.1 mg/kg
11091604|NCT04135534|Active Comparator|Group C|mutonpain 0.2 mg/kg
11091605|NCT04135508|Experimental|BAT1406|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
11091606|NCT04135508|Active Comparator|Humira|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
11091607|NCT04135495|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
11091608|NCT04135482||CD|patients with severe crohn's disease
11091609|NCT04135469|Active Comparator|Referral for tax preparation|Participants will be given contact information on financial services, including all the free tax preparation services in the city, including Boston Medical Center.
11091610|NCT04135469|Experimental|BMC tax preparation|A navigator will help the participants with using free tax preparation services located at Boston Medical Center or a service located elsewhere in the city.
11091611|NCT04135456|Experimental|Low dose group|0.5g/kg of 20% mannitol administered at skin incision.
11091746|NCT04134520||Subjects with a pathological diagnosis of cancer|
11091614|NCT04135443|Experimental|3T Tune in! Turn on! Turn up!|The intervention is a mobile app delivered sexual health promotion program designed specifically for young black men who have sex with men or who are attracted to men. The mobile app will include more than 30 interactive activities including resource maps, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) content, and communication forums. The app helps participants to become clearer about what they do/don't want to do sexually, to communicate their choices. It also focuses on ways to increase healthy relationships, enhance sexual experience if having sex while reducing HIV/STI risk. The intervention/app is intended to be used regularly (e.g., two times per week) during the 90 day active participation period.
11091615|NCT04135443|Active Comparator|General Health App|Participants will download a general health mobile app (focused on promoting drinking water). The control mobile app is intended to be used regularly during the 90 day active participation period.
11091616|NCT04135430||Survey|Practice of an updated questionnaire at D0, D2 and D7
11091617|NCT04135417|Experimental|HAV|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. HAV for this study will be manufactured using the commercial manufacturing system.It will be implanted in the forearm or upper arm using standard vascular surgical techniques. All subjects will be required to start taking daily aspirin (75 or 325 mg) on Day 1 after surgical implantation of HAV unless they are already taking another antiplatelet agent. If low molecular weight heparin (LMWH) is administered post-operatively, aspirin or other antiplatelet agents should be initiated after stopping LMWH. Subjects who are known to be aspirin-sensitive should take another antiplatelet agent at the discretion of the Principal Investigator.
11091618|NCT04135404||Pulmonary Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; pulmonary group are those who have reported any pulmonary diseases and they will be included in this study as pulmonary group.
11091619|NCT04135404||Control Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; The control group are subjects without pulmonary diseases and they will be included as (control group).
11091620|NCT04135391|Experimental|Pre- and Post- exercise training effects|All recruited subjects received aerobic exercise training (HIIT or MICT). VO2peak, cardiac output (CO), bilateral frontal cortex blood volume (∆[THb]), oxyhemoglobin (∆[O2Hb]) and deoxyhemoglobin (∆[HHb]), ventilation efficiency, serum brain-derived neurotrophic factor (BDNF) levels, cognitive and life quality questionnaire, percentage of neuroblastic cell bearing neurites (% neurites), and cell fluorescent staining were examined before and after interventions.
11091621|NCT04135378|Experimental|student- ascorbic acid|Student that have presentation given ascorbic acid ( 500 mg per day) for one week before presentation .
11091622|NCT04135378|Placebo Comparator|Control- ascorbic acid like|ascorbic acid like placebo for one week before presentation
11091623|NCT04135365||Pediatric T1D|A sample of 20 children with Type 1 Diabetes and their caregivers will be asked to stay after their diabetes clinic appointment to complete enrollment, or they may choose to come back for a study visit. Trained study staff will describe the study in detail to interested families. They will be encouraged to ask questions before giving consent. After obtaining informed consent/assent, children and caregivers will schedule time for a neurocognitive assessment and neuroimaging assessment. Children and caregivers will complete assessments again approximately 12 months later.
11091624|NCT04135365||Comparison|Children with no known chronic medical conditions or intellectual disability will undergo the same procedure listed for the Pediatric T1D group
11091625|NCT04135352|Experimental|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
11091626|NCT04135352|Experimental|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
11091627|NCT04135352|Experimental|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
11091628|NCT04135352|Experimental|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
11091629|NCT04135352|Experimental|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
11091630|NCT04135352|Experimental|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
11091631|NCT04135352|Experimental|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
11091632|NCT04135352|Experimental|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
11091747|NCT04134507||Extended Depth of Focus IOL|Post-LASIK patients with implantation of a presbyopia-correcting IOL
11091748|NCT04134507||Monofocal IOL|Post-LASIK patients with implantation of a monofocal IOL
11091633|NCT04135352|Experimental|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
11091634|NCT04135339|Experimental|Group A. Eccentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
11091635|NCT04135339|Experimental|Group B. Concentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
11091636|NCT04135339|Experimental|Group C. Isometric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
11091637|NCT04135339|No Intervention|Group D. Control.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
11091638|NCT04135326|Experimental|Supportive care (tDCS)|Patients undergo tDCS QD over 20 minutes 5 days each week (Monday-Friday) for 3 weeks.
11091639|NCT04135313|Experimental|Neoadjuvant chemotherapy|Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy
11091640|NCT04135313|Active Comparator|Chemoradiotherpy|Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.
11091641|NCT04135300|Experimental|Arm of BBM-H901|Subjects will be dosed with single dose of BBM-H901 at 5x10·12 vg/kg via intravenous infusion.
11091642|NCT04135287|Experimental|Arm 1|Treatment with GLP-1 RA
11091643|NCT04135274||Sepsis group|
11091644|NCT04135274||Non Sepsis group|
11091645|NCT04135261|Experimental|HBM4003|Up to 4 (28 day) cycles of treatment with the potential for a higher dose to be administered in each of cycle 2 and cycle 4.
11091646|NCT04135248||IDF-DAR arm|Insulin management according to IDF-DAR guidelines (IDF-DAR arm) during the fasting period.
11091647|NCT04135248||DAFNE arm|Insulin management according to local experience (DAFNE arm) during the fasting period.
11091648|NCT04135235||TAF group|take propofol fumarate for Maternal and child blockade treatment
11091649|NCT04135235||TDF group|take difenofurate fumarate for Maternal and child blockade treatment
11091650|NCT04135209||Healthy controls|Healthy individuals of age-matched
11091651|NCT04135209||Myopic patients|Patients with myopia who meet the inclusion criteria
11091652|NCT04135196|Experimental|Low Magnitude|voluntary forearm compression by leaning onto the palm of the hand with low target strain
11091653|NCT04135196|Experimental|High Magnitude|voluntary forearm compression by leaning onto the palm of the hand with high target strain
11091654|NCT04135196|Experimental|Low Rate|"voluntary forearm compression by leaning onto the palm of the hand with low strain rate (task performed slowly and evenly)"
11091655|NCT04135196|Experimental|High Rate|"voluntary forearm compression by leaning onto the palm of the hand with high strain rate (task performed as quickly as possible, with a bump)"
11091656|NCT04135196|No Intervention|Control|observation only
11091657|NCT04135183|Experimental|Comprehensive evaluation group|The effectiveness of initial treatment and the next treatment plan were determined based on the CAP guidelines of Chinese Thoracic Society (CTS) or Infectious Diseases Society of America/American Thoracic Society(IDSA/ATS). The evaluation process was independently evaluated and documented by at least two clinicians. In case of disagreement, the final determination shall vote on the majority of votes.
11091658|NCT04135183|Experimental|PSI evaluation group|The changes of PSI scores and serum CRP were used to evaluate the therapeutic effects. If both PSI scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of PSI scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both PSI scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
11091659|NCT04135183|Experimental|Expand-CURB evaluation group|The changes of Expand-CURB scores and serum CRP were used to evaluate the therapeutic effects. If both Expand-CURB scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of Expand-CURB scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both Expand-CURB scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
11091660|NCT04135183|No Intervention|Prospective observational group|Patients' Expand-CURB scores, PSI scores and serum CRP before and after 3-5 days of initial treatment will be recorded. And the initial treatment, whether the initial treatment was changed 3-5 days of initial treatment and the final outcomes (ICU admission, 30-day mortality, average length of stay) will be recorded.
11091661|NCT04135170|Experimental|Plain bone cement|
11091662|NCT04135170|Active Comparator|Antibiotic loaded bone cement|
11091663|NCT04135157|Experimental|PECs & ESP|Pectoralis nerve block and erector spine plane block are performed 30 minutes before general anesthesia. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively.
11091664|NCT04135157|Active Comparator|Control|In the control group, patients will have only general anesthesia. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively.
11091665|NCT04135144|Active Comparator|Group 1 (printed materials),|Group 1 was given home exercise method with printed materials
11091666|NCT04135144|Active Comparator|Group 2 (video phone reminder)|Group 2 was given exercise with home exercise method with video phone reminder
11091807|NCT04133974|No Intervention|Methadone|The subjects take methadone as usual.
11091808|NCT04133974|Experimental|Methadone-10min-Extinction|The subjects were given extinction training 10 min following methadone administration.
11091667|NCT04135131|Experimental|PILATES MAT EXERCISE EFFECT ON LOW BACK PAIN|Patients were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. The evaluations were made at the beginning and end of the treatment. Outcome parameters were VAS, Oswestry Disability Index, Qubec Disability Scale, Short Form-36, Beck Depression Questionnaire, sit and reach, Modified Schöber and sit up tests. Multifidus and abdominal muscle thickness were measured by ultrasound image
11091668|NCT04135131|Placebo Comparator|HOME EXERCISE|The exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises. Patients were asked to perform three sets of exercises (10 repetitions) for three times a week for 8 weeks. Exercise training was provided by a physiotherapist. Patients were also provided an illustrated exercise brochure along with an exercise diary to record the number of days on which exercise was performed. They were followed up by phone calls every 2 weeks
11091669|NCT04135105||Normal hearing group|Right-handed, normal hearing, no reported neurological disorders
11091670|NCT04135053|Experimental|Challenge|Challenge participants will inoculated intranasallly with reconstituted lyophilised Neisseria lactamica (lyoNlac). The initial dose will be 10^5 colony-forming units (CFU) and will be escalated or de-escalated by 1/2 - 1 log depending upon the proportion of volunteers colonies with viable N. lactamica.
11091671|NCT04135040|Experimental|Lysine metabolic availability|Lysine metabolism from pure amino acids and cereal foods in children.
11091672|NCT04135027||CD group|no interventions
11091673|NCT04135014|Placebo Comparator|Midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
11091674|NCT04135014|Experimental|Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 2ug/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
11091675|NCT04135014|Experimental|Midazolam and Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 1ug.kg-1 and oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
11091676|NCT04135001|Experimental|HBM Training|
11091677|NCT04135001|Placebo Comparator|Placebo Training|
11091678|NCT04134988|Experimental|Medimoov|Bi-weekly 35-minute sessions of an adaptated physical activity administered by a psychomotor therapist for 8 weeks.
11091679|NCT04134988|Active Comparator|Standard rehabilitation|Bi-weekly 35-minute sessions of the standard psychomotor therapy for 8 weeks.
11091680|NCT04134975|Experimental|Scanner Group|lumbar spine surgical procedure with guided pedicle screw placement coupled with intraoperative scanning (BODYTOM, Samsung).
11091681|NCT04134975|Active Comparator|fluoroscopy group|lumbar spinal surgery with pedicle screw placement guided by fluoroscopy, a fluoroscopic control being performed with each set screw.
11091682|NCT04134962||Ankel surgery group|Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
11091683|NCT04134962||control foot group|"Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
~Will be retained only results of normal aligment FAO"
11091684|NCT04134949|Experimental|CBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
11091685|NCT04134949|Experimental|MCBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
11091686|NCT04134936|Experimental|Arm A|Tafasitamab in addition to R-CHOP
11091687|NCT04134936|Experimental|Arm B|Tafasitamab plus lenalidomide in addition to R-CHOP
11091688|NCT04134923|Experimental|[11C] Pittsburgh Compound-B (PIB)|Using [11C] Pittsburgh Compound-B (PIB) to look for biomarkers in preclinical and symptomatic AD.
11091689|NCT04134910|Experimental|Physical therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
11091690|NCT04134897|Experimental|Neoadjuvant chemotherapy|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
11091691|NCT04134897|Active Comparator|Neoadjuvant radiotherapy|Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
11091692|NCT04134884|Experimental|ASTX727 + Talazoparib|
11091693|NCT04134871|Experimental|Intervention group|Participants randomised to the intervention group will be invited to attend a group education session where they will be given a step counter and activity diary, they will be invited to weekly group walks and fortnightly coaching 1-1 sessions aimed at setting and reviewing goals to increase physical activity and reduce sedentary behaviour
11091694|NCT04134871|No Intervention|Control group|Participants randomised to the control group will be given an information leaflet about being more active during a one-off 1-1 consultation.
11091695|NCT04134858|Experimental|The health coaching group|The experimental group (n = 52) consisted of frequent attenders who had chosen the health-coaching program. The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
11091809|NCT04133974|Sham Comparator|Methadone-6h-Extinction|The subjects were given extinction training 6h following methadone administration.
11091696|NCT04134858|No Intervention|The control group|The control group consisted of 58 frequent attenders. They, along with the experimental group, received the usual care regarding their health problems from the physicians and nurses at the primary healthcare centres if they needed it. The usual care for frequent attenders included assessment for the need of treatment, physical examination, problem assessment, laboratory and X-ray tests, medical advice and patient support and education during their visits.
11091697|NCT04134845|Experimental|Dantrolene/Ryanodex|Dantrolene/Ryanodex; intravenous administration of dantrolene; 1 mg/ kg IV over 3 minute, one time dose
11091698|NCT04134845|Placebo Comparator|Placebo|controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
11091699|NCT04134819||Vaginally Delivered Babies- No antibiotic treatment|Adult healthy pregnant females (in total 400) as well as their infants will be recruited. It is expected 67% of babies will be vaginally delivered and that 60% will not have antibiotic treatment during pregnancy. This will be up to 161 mother/infant dyads.
11091700|NCT04134819||Vaginally Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 67% of babies will be vaginally delivered and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 107 mother/infant dyads.
11091701|NCT04134819||C-section Delivered Babies- No antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by C section and that 60% will not have antibiotic treatment during pregnancy. This will be up to 80 mother/infant dyads All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
11091702|NCT04134819||C-section Delivered Babies- antibiotic treatment|It is expected based from previous hospital statistics that 33% of babies will be delivered by c section and 40% of these women will be treated with antibiotics during pregnancy. This could be up to 52 mother/infant dyads .All C Section women (including emergency C Section) will be treated with IV Cefazolin at the time of incision, in theatre, to prevent internal wound infection.
11091703|NCT04134806||Young Adults|Neurologically healthy young adults between ages 18 and 40
11091704|NCT04134806||Older Adults|Neurologically healthy older adults between ages 60 and 85
11091705|NCT04134806||Mild Cognitive Impairment/Mild Dementia|Older adults between ages 60 and 85 with Mild Cognitive Impairment or Mild Dementia
11091706|NCT04134793||Sinus group|Six-month follow-up, by holter ECG record，the patients keep normal sinus after atrial fibrillation radiofrequency ablation.
11091707|NCT04134793||atrial fibrillation recurrence group|Six-month follow-up, by holter ECG record，the patients again suffer from atrial fibrillation after atrial fibrillation radiofrequency ablation.
11091708|NCT04134780||Breast Characterization|
11091709|NCT04134767|Experimental|Re-entry Health Linkage|In the re-entry health linkage intervention, research staff will: 1) meet with participants in jail before they are released to ask them questions about drug use and related behaviors, access to needed health and social services, and personal goals; they will provide overdose education and help develop a plan for reducing risks and accessing services after release from jail; 2) meet with participants within one week of their release to conduct urine or saliva drug testing, offer HIV and hepatitis C testing and counseling, naloxon, and harm reduction supplies, and to connect participants with needed services; 3) follow up with participants once a month for three months to help participants overcome challenges; and 4) six months after release from jail, contact participants to conduct saliva or urine drug testing. Participants will complete surveys at pre-release, and at 1 week, 3 months and 6 months weeks post-release.
11091710|NCT04134767|Other|Overdose Education|The investigators will initiate the comparison group in each county six months before the intervention begins. Research staff will conduct a pre-release overdose intervention with the comparison cohort. The comparison group participants will complete an interactive training with animated scenarios and narration on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit. As in the intervention group, comparison group participants will complete surveys at pre-release, and at 1 week, 3 months and 6 months weeks post-release. Surveys will be identical to those delivered to the intervention cohort
11091711|NCT04134754|Other|Respiratory physiology testing|Subjects will wear a nosepiece and breathe through a Y-valve that allows switching from room air to two 5-liter rebreathing bags pre-filled with 50% O2, 6% CO2, and balance N2. Ventilation and respiratory gases will be measured using a pneumotachograph and rapid gas analyzers (Ultima PFX pulmonary function/stress testing system, Medical Graphics Corp). In subjects who experience clinical seizure-like activity, we will repeat the HCVR. This repeat test will occur 2 or more hours after a generalized convulsive seizure (GCS). We will repeat the HCVR at least 30 minutes after a non-GCS. Finally, we may repeat the HCVR at least 18 hours after the last seizure (GCS or non-GCS). It is anticipated that some subjects may exhibit frequent seizures that necessitate the adjustment of this schedule. Subjects may also be asked to sniff, hold their breath, and breathe through tubes of different sizes.
11091712|NCT04134741|Experimental|Kinetic Control Group|"The players participated in the classic training and for 4 weeks (3 times a week) underwent the Kinetic Control neuromuscular training with assistance of a physical therapist.
~The duration of one training was 20-30 minutes."
11091713|NCT04134741|No Intervention|Traditional Training Group|Players participated in the classic training.
11091714|NCT04134728|Experimental|GSK3196165 90 mg|Entire treatment period (24 Weeks): GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
11091715|NCT04134728|Experimental|GSK3196165 150 mg|Entire treatment period (24 Weeks): GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
11091716|NCT04134728|Active Comparator|Sarilumab 200 mg|Entire treatment period (24 Weeks): Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
11091717|NCT04134728|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
11091718|NCT04134728|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
11091719|NCT04134728|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly. From Week 12 onwards: Sarilumab 200 mg SC injection every other week + placebo SC injection in the intervening weeks. Participants will also receive a stable dose of csDMARD(s) as SoC.
11091720|NCT04134715|Experimental|PF-06826647 alone then OC alone then OC+PF-06826647|In Period 1 (Period 1 is 2 days), participants will receive a single dose of PF-06826647 600 mg on Day 1. Period 2 (Period 2 is 14 days) will immediately follow Period 1 without any washout. In Period 2, the participants will receive OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet, orally starting from Period 2 Day 1 until Period 3-Day 16 (Period 3 is 17 Days). Period 3 will immediately follow Period 2 with no washout. In Period 3 on Day 1, the participants will receive a single dose of PF-06826647 600 mg. On Day 2 in Period 3, PF-06826647 will not be dosed. From Day 3, the participants will receive PF-06826647 600 mg QD for 14 days followed by OC in the form of 1 PORTIA (EE and LN) or equivalent tablet.
11091721|NCT04134702|Experimental|Acupuncture|30 patients will receive acupuncture additionally to standard pharmacological therapy of postoperative pain
11091722|NCT04134702|No Intervention|No intervention|30 patients will receive just standard pharmacological therapy of postoperative pain
11091723|NCT04134689|Active Comparator|DOT Selfie Intervention Arm|"The DOT Selfie Intervention will comprise a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders.
~Patients in this arm will receive detailed training (in English or Luganda) on VDOT use prior to starting treatment. Each patient will be required to record and submit daily videos as they self-administer their medication. Patients who successfully submit their videos for seven consecutive days will receive a weekly incentive in the form of social bundles of airtime minutes. A prepaid internet bundle will also be uploaded to each mobile phone weekly to allow for daily video uploads. Additionally, patients will receive text message medication reminders to encourage treatment compliance."
11091724|NCT04134689|Active Comparator|In-person DOT Control Arm.|Patients in this arm will be managed according to the usual clinical practice in Uganda i.e. community- or home-based directly observed treatment .Patients in this arm will make prior arrangements with a study nurse to determine a convenient meeting place (e.g. at the patient's work, home etc.) The study nurse will then meet the patient at this location. At each daily meeting, the patient will self-administer the TB drugs as the study nurse directly observes and documents (date, time, drug dosing etc.) At the end of each meeting, the patient and nurse will agree on a convenient meeting place for the next day's dosing. These daily meetings will continue until treatment completion. The study nurse will record patient's medication intake, as well as the time taken to reach the patient, amount of money spent on round-trip transportation, and total amount of time spent during each patient encounter.
11091725|NCT04134676|Experimental|Conditioned Medium Group|"In this group, the subjects will use Conditioned Medium topical therapy for 2 weeks The Conditioned Medium gel will be applied to the wound and closed by transparent dressing.
~The evaluation and dressing replacement will be done every week for 2 weeks."
11091726|NCT04134663|Experimental|vasoconstrictor + intranasal oxytocin group|subjects receive the vasoconstrictor followed by oxytocin
11091727|NCT04134663|Active Comparator|vasoconstrictor's placebo + intranasal oxytocin group|subjects receive the vasoconstrictor's placebo followed by oxytocin
11091728|NCT04134663|Placebo Comparator|vasoconstrictor + intranasal oxytocin placebo group|subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
11091729|NCT04134650|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5mg + metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
11091730|NCT04134650|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
11091731|NCT04134637|Experimental|PIFB group|"For carrying out PIFB bilaterally the skin on either side of the sternum will be prepared with povidone iodine solution. Then a linear ultrasound probe will be placed on the right and left sides at 2 cm from the sternal body.
~A 22 gauge, 4 inch needle will be advanced until contacting the 4th costal cartilage following the lower edge of US probe, directing the tip from the bottom of the sternum and positioning the needle tip between the pectoralis major and the external intercostal muscles. Group A will receive twenty milliliters of a solution of 0.25% bupivacaine plus epinephrine (5 mcg/ml). Boluses of 5 ml are introduced to perform hydrodissection of the interfascial plane."
11091732|NCT04134637|No Intervention|control group|the block will not be given
11091733|NCT04134624|Active Comparator|Prehospital intervention|All subjects enrolled in this study will receive a sepsis intervention bundle in the prehospital setting, including blood cultures, IV fluids, and antibiotics. These patients will be compared to historical controls.
11091734|NCT04134624|No Intervention|Control arm|Historical controls without prehospital sepsis intervention.
11091735|NCT04134611|Active Comparator|Knee arthroscopy with Hyaluronic acid injection|Those patients who received hyaluronic acid injection
11091736|NCT04134611|Active Comparator|Knee arthroscopy without Hyaluronic acid injection|Knee arthroscopy who did not Hyaluronic acid injection
11091737|NCT04134598|Experimental|Partial Breast Irradiation (PBI)|Partial Breast Irradiation (PBI)
11091738|NCT04134598|Active Comparator|Endocrine Therapy (ET)|Endocrine Therapy (ET)
11091739|NCT04134585||People aged 60|People aged 60 and over who had refused to participate in fall prevention workshops will be included. They will have semi-structured interviews.
11091740|NCT04134572||Ollier Disease and Maffucci Syndrome patients|The group comprises all patients affected by Ollier Disease and Maffucci Syndrome.
11091741|NCT04134559|Experimental|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a dose of 2mg/kg/dose (max: 200mg) with 21 consecutive days defined as a treatment cycle.
11091742|NCT04134546|Experimental|group with biliary injury|group for Early versus late intervention after biliary tract injury post cholecystectomy
11091743|NCT04134533||Oral Feeding Group|Children with cerebral palsy who fed orally according to the Functional Oral Intake Scale
11091749|NCT04134494|Experimental|Intervention|Women with biopsy-proven lichen sclerosus will be treated with the ProFractional hand piece using the sapphire plate stand-off (Sciton, Inc. Palo, Alto, CA). The laser energy is delivered in a scanning fractional pattern to ablate microchannels in tissue to allow faster healing. Treatment will be delivered in 3 sessions scheduled 4 weeks (+/- 1 week) apart
11091750|NCT04134481||low intervention group|from 0-7 clustered nursing intervention
11091751|NCT04134481||high intervention group|from 8-15 clustered nursing intervention
11091752|NCT04134468|Experimental|Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine|Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.
11091753|NCT04134455|Active Comparator|Onlay Mesh Reinforcement group|The midline fascia was closed with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis. A Lightweight polypropylene mesh was used and placed on the anterior rectus fascia with an overlap of 3 cm. The mesh was fitted in the dissected space and it was fixed with PDS 2-0 suture. Fixing points are placed taking the mesh and the anterior fascia of the rectus muscle, at a distance of 3 cm between each point until completing its circunference.
11091754|NCT04134455|Experimental|RTL reinforcement group|The RTL suture is placed parallel at a distance of 0.5 cm from the fascial margin. Ideally the thread should lie between the anterior and the posterior rectus muscle sheath; there should be no contact with the rectus muscle. A nonabsorbable monofilamental polypropylene thread and a 65-mm ½ needle are used. Around this longitudinal thread, the continuous suture for fascial closure is introduced immediately lateral to the thread; with running, slowly absorbable sutures (PDS 1-0) with a recommended suture length to wound length ratio of 4:1. An anterior plane with a width of about 8 cm was created between the anterior fascia and the subcutis
11091755|NCT04134442|Experimental|Bupivacaine Liposome|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist).
~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
11091756|NCT04134442|Active Comparator|Standard therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist).
~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 10ml 0.5% bupivacaine and epinephrine 1:200,000, and 10ml of 0.9% normal saline"
11091757|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
11091758|NCT04134416|Experimental|Anodal transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive 10 20-minute sessions while receiving REGIAplus (online). Group 1 will receive active stimulation (anodal stimulation, A-tDCS).The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
11091759|NCT04134416|Sham Comparator|Sham transcranial direct current stimulation|Group 2 will receive sham stimulation (S-tDCS). In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the assay.
11091760|NCT04134403|Experimental|Arm 1: Intervention|Arm will be those that are randomized to receive usual care plus hydrocortisone, thiamine and ascorbic acid.
11091761|NCT04134403|No Intervention|Arm 2: Usual care|Arm will be those that are randomized to receive usual care alone.
11091762|NCT04134390|Experimental|Cabozantinib|Cabozantinib 40 mg p.o. once daily in 28-day cycles.
11091763|NCT04134377|Experimental|Protein Food Snack|Provide a high protein food snack the first 2 weeks of each month for 6 months. Each participant will receive an 8 ounce food snack after dialysis for a total of 6 food snacks for each month.
11091764|NCT04134364|No Intervention|control|no medication after gastric biopsy
11091765|NCT04134364|Experimental|treatment|oral administration of sodium alginate (LaminaG) after gastric biopsy
11091766|NCT04134325|Experimental|Single Arm PD-1 Inhibitors after CD30.CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
11091767|NCT04134312|Experimental|MVA-BN-Brachyury IV|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
11091768|NCT04134299|Experimental|AXA4010|AXA4010
11091769|NCT04134273|Experimental|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
11091770|NCT04134273|Active Comparator|Clindamycin Phosphate Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
11091771|NCT04134273|Placebo Comparator|Vehicle of the test product|Placebo (vehicle of the test product), applied to the face twice a day for 84 days.
11091804|NCT04134000|Experimental|Atezolizumab + BCG|"Ten patient will be enrolled in first cohort, starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).
~The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)"
11091810|NCT04133961|Experimental|Group A (Phenylephrine)|Phenylephrine infusion started immediately after administration of spinal block
11091772|NCT04134260|Active Comparator|Arm I (hormone therapy, radiation therapy)|Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 7-8 weeks beginning within 56 days after first hormone injection if the injection is not started prior to registration or within 90 days after first hormone injection if the injection is started prior to registration in the absence of disease progression or unacceptable toxicity.
11091773|NCT04134260|Experimental|Arm II (apalutamide, abiraterone acetate, prednisone)|Patients receive standard of care hormone therapy and radiation therapy as in Arm I. Patients also receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD or BID on days 1-90. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
11091774|NCT04134247|Experimental|PD-1 combined with chemotherapy|21 days every cycle, assessment after 3-cycle
11091775|NCT04134247|Active Comparator|chemotherapy|21 days every cycle, assessment after 3-cycle
11091776|NCT04134208|Experimental|Diagnostic (fluciclovine F18, PET-CT)|Within 4 weeks before starting SST, patients receive fluciclovine F18 IV then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.
11091777|NCT04134195|Experimental|Real transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of real transcranial direct current stimulation over two distinct brain areas.
11091778|NCT04134195|Experimental|Sham transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of sham transcranial direct current stimulation over two distinct brain areas.
11091779|NCT04134182|Experimental|Nivolumab + Ipilimumab|Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.
11091780|NCT04134169||Rheumatoid arthritis|
11091781|NCT04134156|Active Comparator|Sleeve gastrectomy|5-port standard sleeve gastrectomy was conducted
11091782|NCT04134156|Active Comparator|one anastomosis gastric bypass|5-port standard one-anastomosis gastric bypass was performed
11091783|NCT04134143|Experimental|Cohort 1: One Application|Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876)
11091784|NCT04134143|Experimental|Cohort 2: Up to Five Applications|Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing
11091785|NCT04134143|Experimental|Cohort 3: Up to Ten Applications|Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing
11091786|NCT04134130|Other|GnRH antagonist + FSH + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.
~After 3 weeks: 1000 mg testosterone once."
11091787|NCT04134130|Other|GnRH antagonist + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).
~After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once."
11091788|NCT04134117|Experimental|Tisagenlecleucel|"Study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.
~- Tisagenlecleucel will be administered intravenously as a one-time rapid infusion predetermined dose following lymphodepleting chemotherapy."
11091789|NCT04134104||Bowel, Bladder, and Sexual Dysfunction group|Out of 38 patients included for surgery 12 were excluded due to poor follow up and those patients who underwent upfront surgery. Only 26 patients were included in the study. There were 20 (76.9%) males and 6 (23.1%) females respectively. The mean age of the patient was 43.577yrs (26-75) and mean BMI was 20.78. The number of patients that underwent LAR was 24 (92.30%) and those who underwent APR were 2( 7.6%) after neoadjuvant chemoradiotherapy respectively.
11091790|NCT04134091|Experimental|Treatment A|LPCN 1144 Formulation A
11091791|NCT04134091|Experimental|Treatment B|LPCN 1144 Formulation B
11091792|NCT04134091|Placebo Comparator|Treatment C|Placebo
11091793|NCT04134078|Experimental|inhaled nitric oxide|Inhaled Nitric Oxide at 40 ppm will be administered in adults who suffer in hospital cardiac arrest. The administration of inhaled nitric oxide at 40 ppm will be provided upto 24 hours once ROSC is achieved.
11091794|NCT04134065|Placebo Comparator|Control group|The physical properties such as appearance, size, color, dosage form, weight, taste and odor of placebo should be as much as possible as the test drug, but should not contain the Vitamin D (such as tablets containing lactose).
11091795|NCT04134065|Experimental|Vitamin D group|Liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL)
11091796|NCT04134052|Experimental|ketamine sedation|Sedation will be performed with ketamine dose 5-20mcg / kg / min in infusion with 100 ml Na Cl solution 0.9% during surgery
11091797|NCT04134052|Active Comparator|midazolam sedation|Sedation will be performed with midazolam dose 5 - 35mcg / kg / hr in infusion with 100 ml Na Cl solution 0.9% during surgery
11091798|NCT04134039|Experimental|Polyurethane (PU) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
11091799|NCT04134039|Experimental|Natural Rubber Latex (NRL) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
11091800|NCT04134026|Experimental|Roxadustat|Roxadustat will be dosed orally three times a week.
11091801|NCT04134026|Active Comparator|Epoetin alfa|Epoetin alfa wull be disoensed per the package insert or the country-specific product labeling.
11091802|NCT04134013|Experimental|Nutrition and Chiropractic|LBP chiropractic adjustment per protocol and 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
11091803|NCT04134013|Active Comparator|Chiropractic Adjustment ONLY|LBP chiropractic adjustment per protocol
11091805|NCT04133987|Experimental|Tetravalent live attenuated dengue vaccine admixture TV005|Tetravalent live attenuated dengue vaccine admixture TV005
11091806|NCT04133987|Placebo Comparator|placebo|Plasma-Lyte A
11091811|NCT04133961|Placebo Comparator|Group B (Saline)|Normal saline infusion started immediately after administration of spinal block
11091812|NCT04133948|Experimental|A|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks)
11091813|NCT04133948|Experimental|B|For IFN-gamma high patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
11091814|NCT04133948|Experimental|C|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + domatinostat 200 mg BID, on days 1-14 (q3weeks)
11091815|NCT04133948|Experimental|D|For IFN-gamma low patients: patients will receive pre-surgically 2 courses nivolumab 240 mg (q3weeks) + ipilimumab 80 mg (q3weeks) + domatinostat. Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200 mg, on days 1-14 (q3weeks). Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200 mg BID, days 1-14, q3weeks), a lower dosing scheme (100 mg OD, days 1-14, q3weeks), or the same dosing scheme (200 mg OD, days 1-14, q3weeks).
11091816|NCT04133935|Experimental|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment
11091817|NCT04133935|Active Comparator|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
11091818|NCT04133922|Active Comparator|GLP-1|GLP-1 infusion 1.2 pmol/kg/min for 150 min
11091819|NCT04133922|Active Comparator|GLP-1 + Insulin clamp|GLP-1 infusion 1.2 pmol/kg/min for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min
11091820|NCT04133922|Active Comparator|Saline + Insulin clamp|Saline infusion at 30 ml/hr for 150 min and insulin 1 mU/kg/min + Dextrose 20% at variable rate to maintain euglycemia for 120 min.
11091821|NCT04133909|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously once every 4 weeks over a treatment period of 52 weeks.
11091822|NCT04133909|Experimental|Mepolizumab|Participants will receive mepolizumab subcutaneously once every 4 weeks over a treatment period of 52 weeks.
11091823|NCT04133896||Group 1 Male|group 1 (22 lean men),
11091824|NCT04133896||Group 2 Male|group 2 (22 class I obese men),
11091825|NCT04133896||Group 3 Male|group 3 (22class II obese men),
11091826|NCT04133896||Group 4 Male|group 4 (22 class III obese men).
11091827|NCT04133896||Group 1 Female|group 1 (22 lean women),
11091828|NCT04133896||Group 2 Female|group 2 (22 class I obese women),
11091829|NCT04133896||Group 3 Female|group 3 (22 class II obese women),
11091830|NCT04133896||Group 4 Female|group 4 (22 class III obese women).
11091831|NCT04133883|Other|Haemophilia A patients|Treated on-demand or prophylaxis with any Factor VIII (FVIII) product, plasma derived or recombinant (conventional or extended-half life) FVIII, according to routine clinical practice.
11091832|NCT04133857|Active Comparator|Group A|undergo HIIT first then SSMIT protocol
11091833|NCT04133857|Active Comparator|Group B|undergo SSMIT first then HIIT protocol
11091834|NCT04133844||Extracorporeal membrane oxygenation|
11091835|NCT04133831|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
11091836|NCT04133831|Experimental|Condition 2: Combined plus Total|Participants randomized to Condition 2 will view combined transplant survival and total survival outcome information when making a choice between the two hospitals.
11091837|NCT04133831|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
11091838|NCT04133831|Experimental|Condition 4: Stratified plus Total|Participants randomized to Condition 4 will view stratified transplant survival and total survival outcome information when making a choice between the two hospitals.
11091839|NCT04133831|Experimental|Condition 5: Total only|Participants randomized to Condition 5 will view only total survival outcome information when making a choice between the two hospitals.
11091840|NCT04133818||Multidisciplinary program.|Patients with subacute or chronic LBP for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program was not indicated.
11091841|NCT04133792|Experimental|Simvastatin|Simvastatin 40 mg administered orally daily for 5 years.
11091842|NCT04133792|Placebo Comparator|Placebo|Placebo for Simvastatin 40 mg administered orally daily for 5 years.
11091843|NCT04133779||Group A (MS)|"Age 18-55 years;
~Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;
~Course of the disease: RR-SP-PP-CIS;
~Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;
~Not in clinical relapse (at least 30 days after the last clinical relapse);
~Subjects treated or non-treated with immunomodulatory and immunosupressive drugs;
~Signature of the informed consent."
11091844|NCT04133779||Group B (HC)|"Age 18-55 years;
~Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);
~Signature of the informed consent.
~The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study, or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres."
11091845|NCT04133779||Group C (OND)|"Aged 18-55 years;
~Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.
~Signature of the informed consent."
11091846|NCT04133779||Group D (ONDi)|"Age 18-55 years;
~subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;
~Signature of the informed consent."
11091873|NCT04133584|Active Comparator|Group 2 EV71|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) with 28 days apart
11091874|NCT04133584|Active Comparator|Group 3 SIV|Give 2 doses of seasonal influenza vaccine(SIV) simultaneously with 28 days apart
11091875|NCT04133571|No Intervention|Control group|Control group: using normal saline for bladder irrigation
11091847|NCT04133766|Experimental|Community-Based Nutrition Package|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
11091848|NCT04133766|No Intervention|Standard of care|Current standard of existing community health services.
11091849|NCT04133753|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
11091850|NCT04133753|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
11091851|NCT04133740|Active Comparator|Standard regime|Supplementary oxygen is given according to the standard regime with a fraction of inspired oxygen (FiO2) of at least 0.60 during mechanical ventilation and 3 liter/minute or more after weaning from the ventilator in the intensive care unit (ICU).
11091852|NCT04133740|Active Comparator|Oxygenation targeting|Supplementary oxygen is given to achieve a partial pressure of arterial oxygen (PaO2) within the normal range defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.
11091853|NCT04133727|Experimental|Intervention|Intervention group will wear a simulation suit in which will mimic the physical limitations experienced by older adults. In addition, they will participate in a polypharmacy workshop which allows them to communicate with older adults
11091854|NCT04133727|Active Comparator|Control|This group will participate in a polypharmacy workshop which allows them to communicate with older adults
11091855|NCT04133714|Experimental|multi-channel tDCS|"In the multi-channel tDCS stimulation group, a 1:4 (anode: cathode) approach was applied, with the central anode placed in the left dorsolateral prefrontal cortex (dlPFC) (reference 10-20 standard lead EEG), and the remaining cathode distributed around the central electrode.
~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
11091856|NCT04133714|Experimental|single-channel tDCS|"The anode electrode of the single-channel tDCS stimulation group was placed in the left dlPFC, and the cathode electrode was placed in the right orbital forehead.
~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
11091857|NCT04133714|Sham Comparator|sham stimulation|The shame stimulation group had only 30 seconds of up and down stimulation, with no intermediate stimulation.
11091858|NCT04133701|Experimental|Time-Restricted Feeding|"Control (Baseline): Blood pressure and neurovascular control will be measured.
~Post-Intervention: Blood pressure and neurovascular control will be measured."
11091859|NCT04133688|Experimental|Mobile application (ASC)|mobile app / devise
11091860|NCT04133688|Active Comparator|Paper diary|paper diary
11091861|NCT04133675|Active Comparator|Emsella Chair Active Treatment|Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
11091862|NCT04133675|Sham Comparator|Emsella Sham Treatment|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
11091863|NCT04133662|Experimental|Group 1|Restricted sleep condition first, longer sleep condition second
11091864|NCT04133662|Experimental|Group 2|Longer sleep condition first, restricted sleep condition second
11091865|NCT04133649|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
11091866|NCT04133636|Experimental|JNJ-68284528|Single group assignment- After lymphodepletion, JNJ-68284528 will be administered as a single infusion to participants in cohort A (Progressive disease after 1-3 prior lines of therapy), cohort B (Early relapse after front-line), cohort C (Relapsed/refractory multiple myeloma after proteasome inhibitor [PI], immunomodulatory [IMiD], anti-CD38, and anti-B-cell maturation antigen [BCMA] therapy) and cohort D (Less than CR after autologous stem cell transplantation [ASCT] front-line therapy; some participants will be administered JNJ-68284528 followed by lenalidomide). Participants in cohort E (Newly diagnosed multiple myeloma, transplant not planned, high risk disease) will first be administered with quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), followed by lymphodepletion and JNJ-68284528, followed by a consolidation regimen of daratumumab and lenalidomide (D+R).
11091867|NCT04133623|Experimental|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
11091868|NCT04133623|Active Comparator|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
11091869|NCT04133610|Experimental|Self-sampling device in media|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using self-sampling device in STM media. HPV will be detected by hybridization technique.
11091870|NCT04133610|Experimental|Dry self-sampling device|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using dry self-sampling device. HPV will be detected by hybridization and PCR techniques.
11091871|NCT04133597|Experimental|Interventional|Two experimental steps: baseline skin conductance measurements (step 1, three minutes) and measurements of SC after social media stimulation with Line messages or calls (step 2, three minutes). With a 5-minute rest period after these two steps completed, then each participant fill out questionnaires for assessing anxiety and problematic smartphone use.
11091872|NCT04133584|Experimental|Group 1 EV71 +SIV|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV) simultaneously with 28 days apart
11091876|NCT04133571|Experimental|Study group|Study group: using 0.05% Lidocaine normal saline solution for bladder irrigation
11091877|NCT04133545||DOAC|Direct oral anticoagulant
11091878|NCT04133545||OAC|Vitamin K anticoagulant
11091879|NCT04133532|Experimental|metoprolol-no metoprolol|After a washout period of one month following discontinuation of preceding beta-blocker medication patients will be given metoprolol 50 mg daily. The effect will be evaluated after three months of treatment. After that, another one-month washout period will commence followed by three months without metoprolol medication. Then, a final reevaluation will be performed.
11091880|NCT04133532|Experimental|no metoprolol-metoprol|After a one-month washout period following discontinuation of preceding beta-blocker medication patients will continue another three months without a metoprolol medication. After that, an evaluation will be performed. Then they will be given metoprolol 50 mg daily for three months followed by a reevaluation.
11091881|NCT04133519|Active Comparator|Arm 1|Arm 1 is an active behavioral treatment for IBS (Software as a Medical Device - SaMD).
11091882|NCT04133519|Sham Comparator|Arm 2|Arm 2 is an inactive behavioral treatment for IBS (Software as a Medical Device - SaMD)
11091883|NCT04133506||acute eczema|acute eczema patients with eczema <72 hours no drugs
11091884|NCT04133506||chronic eczema|chronic eczema with eczema > 72 hours no drugs
11091885|NCT04133506||allergic contact dermatitis|allergic contact dermatitis with a clear allergen identified no drugs
11091886|NCT04133506||psoriasis patients|patients with plaque psoriasis no drugs
11091887|NCT04133506||healthy volunteers|dithranol or DNCB (used to induce irritant or allergic eczema used safely in similar research studies for decades) aspirin to half the group to assess the effects on downstream mediators
11091888|NCT04133493|Placebo Comparator|Standard of Care Group|Fibracol Dressing covered with gauze and wrapped with kerlix and wrap. Change 3Xper week
11091889|NCT04133493|Active Comparator|Intervention Group|Kerecis affixed with steri-strips, cover with gauze and change one per week .
11091890|NCT04133480|Experimental|GWP42003-P|For the first 7 days of the treatment period, participants are to take GWP42003-P at a dose of 5 milligrams per kilogram per day (mg/kg/day), administered as 2 equally divided doses (i.e., 2.5 mg/kg in the morning and 2.5 mg/kg in the evening). On Day 8, participants are to increase the dose to 10 mg/kg/day, administered as 2 equally divided doses (i.e., 5 mg/kg in the morning and 5 mg/kg in the evening). The 10 mg/kg/day dose should be maintained for the remainder of the treatment period; however, per labeling, investigators may increase the dose to a maximum of 20 mg/kg/day if clinically warranted by titrating an additional 5 mg/kg/day each week until reaching the maximum dose. GWP42003-P will be taken b.i.d. (morning and evening).
11091891|NCT04133467||Group SB|Scalp block performed with Levobupivacaine 0.125% (total dose 2 mg/kg) in combination with intraoperative intravenous acetaminophen (15 mg/kg if body weight >10Kg, 7 mg/kg if body weight < 10 kg).
11091892|NCT04133467||Group ST|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg
11091893|NCT04133454|Experimental|subjects treated with LGT|subjects will be treated with a single dose of LGT (AAV-hTERT)
11091894|NCT04133428||Sacubitril-Valsartan cohort|Patients with severe systolic disfunction (left ventricle ejection fraction<40%) heart failure that remain functional class II, III or IV after at least 3 months of optimal treatment and after being evaluated by the cardiologist by doing an echocardiography, blood test and clinical evaluation, start Sacubitril-Valsartan treatment.
11091895|NCT04133415|Experimental|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
11091896|NCT04133389|Experimental|Growth Mindset of Personality|Experimental intervention
11091897|NCT04133389|Placebo Comparator|Growth Mindset of Athletic Ability|Control intervention
11091898|NCT04133376|Experimental|Vascular Endothelial Function|
11091899|NCT04133376|Experimental|Biomarkers of oxidative stress and inflammation|
11091900|NCT04133376|Experimental|Vascular endothelial cells|
11091901|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA Layered|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
11091902|NCT04133363|Experimental|Ridge preservation using L-PRF/ FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
11091903|NCT04133363|Experimental|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF alone
11091904|NCT04133337|Experimental|Apatinib Combined With SHR-1210 Injection|"Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery.
~Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion.
~Surgery:
~The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose."
11091905|NCT04133324||Main group|One groupe in the study
11091906|NCT04133311|Active Comparator|DE-130A|Instillation of one drop, once daily in the evening (9 pm ±1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
11091907|NCT04133311|Active Comparator|Xalatan®|Instillation of one drop, once daily in the evening (9 pm ± 1 hour) in the conjunctival sac of the affected eye(s). Both eyes will be treated unless the patient suffers from unilateral OAG/OHT
11091908|NCT04133298|Active Comparator|Tunneling with laser de-epithelized gingival graft.|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
11091909|NCT04133298|Active Comparator|Tunnelingwith subepithelial connective tissue graft.|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid.
11091910|NCT04133285||Multiple Osteochondromas patients|Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
11091911|NCT04133272||Ehlers-Danlos Syndrome patients|The group comprises all patients affected by Ehlers-Danlos Syndrome, including prenatal and fetal diagnosis of Ehlers-Danlos Syndrome
11091912|NCT04133259|Experimental|HLX10, in patients with CHB|HLX10: 1 mg/kg at 0, 4th, 8th week (maximum 3 doses). Concomitant antiviral medications: take Nucleoside/nucleotide analogues (NAs) starting from at least 2 weeks before the first dose of HLX10 until 12 weeks after the last dose of HLX10 infusion.
11091913|NCT04133246|Other|Group arm|Includes subjects enrolled in focus groups
11091914|NCT04133246|Other|Interview arm|Includes subjects with individual interviews
11091915|NCT04133233|Experimental|active treatment|"IL-2 (ILT-101) Sub-cutaneous
~1 million UI/j"
11091916|NCT04133233|Placebo Comparator|placebo|placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).
11091917|NCT04133220||Cases|Patients with acute myeloid leukemia, associated to hyper leukocytosis
11091918|NCT04133220||Control|Patients with acute myeloid leukemia, without hyper leukocytosis
11091919|NCT04133207||Patients with advanced HR-positive breast cancer|patients with histologically confirmed HR-positive, HER2-negative advanced (recurrent or metastatic) breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
11091920|NCT04133194|Experimental|1600 mg Asacol (mesalazine)|1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year
11091921|NCT04133194|Active Comparator|800 mg Asacol (mesalazine)|800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year
11091922|NCT04133181|Experimental|Guided endodontic surgery|Use of a 3D surgical guide in endodontic surgery
11091923|NCT04133181|Placebo Comparator|Conventional endodontic surgery|Use of a mock guide in endodontic surgery
11091924|NCT04133168|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the POLARx™ Cardiac Cryoablation System
11091925|NCT04133155||nab-P + GEM|Nab-paclitaxel plus gemcitabine
11091926|NCT04133142|No Intervention|Medical treatment|"Patients receive the standard medical medication for herpes pain
~Oral administration of Gabapentin
~300 mg/d on day 1 and 2
~600 mg/d on day 3 and 4 if pain persists
~900 mg/d on day 5 and 6 if pain persists
~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation"
11091927|NCT04133142|Experimental|Early block Single|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment
11091928|NCT04133142|Experimental|Early Repeated block|the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery.
11091929|NCT04133142|Experimental|Late block single|"Patients receive the standard medical medication for herpes pain
~Oral administration of Gabapentin
~300 mg/d on day 1 and 2
~600 mg/d on day 3 and 4 if pain persists
~900 mg/d on day 5 and 6 if pain persists
~Oral administration of Paracetamol up to 3 g per day at day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block . Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ration benefit risks. Choice of Block by an anesthesiologist expert in regional anaesthesia techniques. After the block performance if the pain comes back patient will receive the standard medical treatment as in the group medical treatment"
11091930|NCT04133142|Experimental|late block repeated|"Patients receive the standard medical medication for herpes pain
~Oral administration of Gabapentin
~300 mg/d on day 1 and 2
~600 mg/d on day 3 and 4 if pain persists
~900 mg/d on day 5 and 6 if pain persists
~Oral administration of Paracetamol up to 3 g per day prescription for 7 day and continue for 3 weeks after evaluation At day 7 if pain more than VAS 4 the patient will receive a regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. Local anesthetic used will be ropivacaine 0.5% dose according to the type of block and never exceeding 3mg/kg The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. The block will be repeated every 48h until the pain will reach VAS < 3 6 h after block recovery."
11091931|NCT04133129|Experimental|LV-High Intensity Interval Training|2 x 4 minutes at 85%-95% of Heart rate max.
11091932|NCT04133129|Experimental|Moderate Intensity Continuous Training|1 x 45 minutes at 65%-75% of Heart rate max.
11091933|NCT04133129|No Intervention|Control Group|They will not be prescribed any training and will be asked to continue with their normal lifestyle.
11091934|NCT04133116|Experimental|LY3471851|LY3471851 administered by subcutaneous (SC) injection.
11091935|NCT04133116|Placebo Comparator|Placebo|Placebo administered by SC injection.
11091936|NCT04133103|No Intervention|First ambulation at 24 hours after operation|
11091937|NCT04133103|Experimental|First ambulation at 4 hours after operation|
11091938|NCT04133090|Active Comparator|Autogenous block bone graft|Surgical site as control group was treated with autogenous block bone graft. Augmentation site was covered with a mixture of particulate allograft and leukocyte and platelet-rich fibrin (L-PRF) membrane.
11091939|NCT04133090|Active Comparator|i-PRF enriched allograft material+screw tent pole technique|Surgical site as test group was treated with injectable platelet rich-fibrin (i-PRF) enriched allograft material. To avoid soft tissue collapse, screws were used. Augmentation site was covered with leukocyte and platelet-rich fibrin (L-PRF) membrane.
11091940|NCT04133077|Other|Succeed PDX|Genetic analysis will be performed in patients who got a successful PDX
11091941|NCT04133064|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 10 or more cigarettes per day
11091942|NCT04133051|Active Comparator|Quadratus Lumborum Block|17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.
11091943|NCT04133051|Active Comparator|Epidural Analgesia|17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).
11091944|NCT04133038||Children consulting|Children consulting in the expert center for food difficulties.
11091945|NCT04133038||Pierre Robin sequence|Children with Pierre Robin sequence following for food difficulties.
11091946|NCT04133038||Cardiac malformations|Children with cardiac malformations followed for food difficulties.
11091947|NCT04133038||Oesophageal atresia|Children with oesophageal atresia followed for food difficulties.
11091948|NCT04133038||Cleft lip and palate|Children with cleft lip and palate followed for food difficulties.
11091949|NCT04133038||Autism spectrum disorders|Children followed for congenital pathology that cause food difficulties.
11091950|NCT04133038||Ex-prematurity < 32 AG|Children born premature followed for food difficulties.
11091951|NCT04133038||Chromosomal anomalies|Children with chromosomal anomalies followed for food difficulties.
11091952|NCT04133025|Active Comparator|Conventional vestibular rehabilitation|Conventional vestibular rehabilitation
11091953|NCT04133025|Active Comparator|Vestibular rehabilitation with software|
11091954|NCT04133012|Other|Single Arm|Single arm composed by 34 HIV-1 infected male subjects
11091955|NCT04132999|Active Comparator|Family-informed intervention (INT)|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team.
11091956|NCT04132999|Active Comparator|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
11091957|NCT04132973|Experimental|Compassion guided self-help|Participants will engage in a six-week online compassion-based self-help programme with email guidance from the researcher.
11091958|NCT04132960|Experimental|HER2 status|"Three cohorts of advanced breast cancer patients:
~Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)
~Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)
~Cohort 3: HER2 non-expressing (IHC0+)"
11091959|NCT04132947||Cohort|Cohort Study correlating self reported exercise activity and spiroergometry results
11091960|NCT04132921||Patients with AKI|Patients with AKI after joint replacement
11091961|NCT04132921||Patients without AKI|Patients without AKI after joint replacement
11091962|NCT04132908|Experimental|Sclerocarya birrea|
11091963|NCT04132908|Placebo Comparator|Placebo|
11091964|NCT04132869|Other|Experimental Group|In Fall of 2019, all 6th graders in Wave 1 intervention schools (6 schools), which include 561 total 6th graders, will be invited to participate the intervention. Of those who choose to participate in the intervention, we will randomly select 84 students to participate into the experimental group. Those in the experimental group will complete all measures according to the timeline. Those not in the experimental group will also complete the intervention, but will not participate in measurements. In Fall 2020 all 6th graders who attend the Wave 2 intervention schools (schools that were the control schools in 2019), will be invited to participate the intervention. Of those who choose to participate, 84 will be randomly selected into the experimental group. Those in the experimental group will complete all measures on schedule.
11091965|NCT04132869|No Intervention|Control group|Wave 1 comparison schools (2 Schools) have a total of 267 6th graders, and 84 students will be randomly selected to participate in the comparison group and will have measurements taken at baseline and 6 months.Wave 2 comparison schools (3 Schools) have a total of 363 6th graders, and 84 students will be randomly selected to participate in the comparison group and will have measurements taken at baseline and 6 months. These students will continue with their normal activities as usual.
11091966|NCT04132856|Experimental|Intervention Group|The Intervention group will receive the services of the Psychosocial Navigator (PSN) monthly for the full 12 months of the study. At baseline, the PSN will provide the health care providers (HCPs) and family with recommendations for mapping and triaging of resources to levels of psychosocial risk (PAT: Universal, Targeted, Clinical) and level of depression and anxiety (mild, moderate, and high mental health problems; as determined by the standardized norms for the measures). This information will be summarized in the Communication Summary Profile and shared with the treating team (oncologist, nurse, and Social Worker, core psychosocial staff involved in the child's care) and family within 48 hours of completion. The PSN will conduct follow-up psychosocial screenings on a monthly basis, using the Distress Thermometer for children and caregivers. Results of the monthly assessments and recommended resources will also be communicated to the caregiver/parent and treating team of the youth.
11091967|NCT04132856|No Intervention|Treatment as Usual Group|Current psychosocial care services will be accessible to Treatment as Usual Group (e.g., social work, child life, psychology, art and music therapy, and psychiatry).
11091968|NCT04132843|Experimental|Diagnostic (MRI, gadobutrol, gadobenate dimeglumine)|Within 21 days before standard of care chemotherapy and/or radiation therapy, patients undergo an MRI scan for the first set of images. Patients then receive either gadobutrol or gadobenate dimeglumine IV and undergo an MRI for the second set of images. All MRI scans take a total of 60 minutes to complete. Patients then repeat the MRI scans 120 days after standard of care chemotherapy and/or radiation therapy.
11091969|NCT04132830||HIV-Exposed Uninfected Dyads|Mothers who had HIV during pregnancy and their HIV-negative young adult offspring
11091970|NCT04132830||HIV-Unexposed Uninfected Dyads|Mothers and young adults without HIV
11091971|NCT04132817|Experimental|Group A Target class A-1: Nivolumab+nab-paclitaxel|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
11092006|NCT04132596|Experimental|Motor incomplete SCI|C4-T12 ASIA Impairment Scale C or D spinal cord injury tscs with activity based therapy intervention
11092118|NCT04131803|Experimental|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
11091972|NCT04132817|Experimental|Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
11091973|NCT04132817|Experimental|Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
11091974|NCT04132804|Experimental|Tai Chi Treatment|All patients in the trial will receive 1-hour Tai Chi lessons once per week for a total of 8 weeks.
11091975|NCT04132791|Other|aspirin after awakening + placebo before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.
~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study."
11091976|NCT04132791|Experimental|placebo after awakening +aspirin before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.
~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study."
11091977|NCT04132778|Experimental|Intervention - Asthmatuner|Asthmatuner (Medituner AB, Stockholm, Sweden) is a CE-marked cloud-computing-based system with a healthcare interface and a downloadable patient app (Android or iOS).The intended use of Asthmatuner is to automate asthma self-management by letting patients register symptoms and measure forced expiratory volume in one second (FEV1) with a Bluetooth spirometer (MIR, SmartOne). The patient then receives immediate feedback on the status of symptom control (controlled, partly controlled or uncontrolled), and a treatment recommendation, with an image of the correct inhaler or other type of medication and the dose. Symptom control is quantified based on lung function; litre to percentage of personalised best FEV1, using a cut-off ≤80% and symptoms during the last week based on four questions: 1) need for rescue medication more than twice due to asthma symptoms, 2) any daytime symptoms, 3) nocturnal symptoms/awakenings, and 4) limitation in physical activities.
11091978|NCT04132778|No Intervention|Control group - Traditional asthma management|Traditional self-management is defined as all other types of non-digital asthma management. This could be treatment plan written on paper or by oral communication to patient/caregiver on asthma treatment.
11091979|NCT04132765||Patients with cerebral palsy|Patients with cerebral palsy at between the ages of 4-16 years and at Gross Motor Function Classification Levels of 3,4,5
11091980|NCT04132752|Experimental|Intervention|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
11091981|NCT04132752|No Intervention|Control|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
11091982|NCT04132739|No Intervention|Control|
11091983|NCT04132739|Experimental|Exercise only|
11091984|NCT04132739|Experimental|Diet only|
11091985|NCT04132739|Experimental|Diet + Exercise|
11091986|NCT04132726|Experimental|Test|Experimental group which employed with massage treatment
11091987|NCT04132726|Placebo Comparator|Placebo|Placebo group which employed with non-effective treatment
11091988|NCT04132726|No Intervention|Control|no treatment
11091989|NCT04132713||Control group|20 healthy volunteers were included in the healthy control group
11091990|NCT04132713||Disease group|30 patients with advanced breast cancer developed hand-foot syndrome after capecitabine administration
11091991|NCT04132700|Experimental|ICU Patients|Patients admitted to the ICU will be monitored using the Q-NRG for up to 30 mins.
11091992|NCT04132687|Other|autologous blood patch|autologoust blood patch therapy
11091993|NCT04132674|Other|B/F/TAF|Switching participants who are currently on multi-tablet HIV antiretroviral therapy, including multi-tablet regimens and/or two drug combinations (dual therapy) to one oral tablet of B/F/TAF once-daily for 72 weeks
11091994|NCT04132661|Experimental|bisacodyl|5 mg bisacodyl, one tablet once
11091995|NCT04132661|Placebo Comparator|placebo|placebo, one tablet once
11091996|NCT04132648|Experimental|Curcumin|Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
11091997|NCT04132648|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
11091998|NCT04132635|Experimental|artificial dermis with growth factor|
11091999|NCT04132635|Experimental|artificial dermis only|
11092000|NCT04132622|Experimental|Experimental therapy group|Besides Traditional therapy，patients in this group will also receive thyroid replacement therapy.
11092001|NCT04132622|Sham Comparator|Traditional therapy group|Patients in Standard therapy group will receive treatments according to guideline worldwide.
11092002|NCT04132609|Active Comparator|Cognitive Bias Intervention|Complete cognitive bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
11092003|NCT04132609|Placebo Comparator|Control|Complete standard attentional bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
11092004|NCT04132596|Experimental|Motor Complete Tetraplegia|C4-T1 American Spinal Injuries Association (ASIA) Impairment Scale Classification A or B spinal cord injury tscs with activity based therapy intervention
11092005|NCT04132596|Experimental|Motor Complete Paraplegia|T2-12 ASIA Impairment Scale A or B spinal cord injury tscs with activity based therapy intervention
11092648|NCT04128202|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
11092007|NCT04132583|Experimental|First Deflox®, Then Cataflam DD®|Participants will receive a single oral dose of 50 mg Deflox® tablet in treatment period 1, followed by a single oral dose of 50 mg Cataflam DD® tablet in treatment period 2 under fasting condition. A washout period of 7 days will be maintained between 2 treatment periods.
11092008|NCT04132583|Experimental|First Cataflam DD®, Then Deflox®|Participants will receive a single oral dose of 50 mg Cataflam DD® tablet in treatment period 1, followed by a single oral dose of 50 mg Deflox® tablet in treatment period 2 under fasting condition. A washout period of 7 days will be maintained between 2 treatment periods.
11092009|NCT04132570|Experimental|Budesonide 256 mcg per Day (Treatment A)|Participants will self-administer 2 nasal sprays of Budesonide (64 microgram [mcg]/spray) in each nostril once daily (every morning) up to 10 +\- 3 Days.
11092010|NCT04132570|Placebo Comparator|Placebo (Treatment B)|Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\- 3 Days.
11092011|NCT04132557||Cohort 1 (Target): Methylphenidate Monotherapy|Participants will be analyzed for Attention Deficit Hyperactive Disorder (ADHD) who are new users of methylphenidate monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
11092012|NCT04132557||Cohort 2 (Comparator [C]): Lisdexamfetamine Monotherapy|Participants will be analyzed for ADHD who are new users of lisdexamfetamine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
11092013|NCT04132557||Cohort 3 (C): Atomoxetine Monotherapy|Participants will be analyzed for ADHD who are new users of atomoxetine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
11092014|NCT04132557||Cohort 4 (C):Amphetamine/Dextroamphetamine Combo Therapy|Participants will be analyzed for ADHD who are new users of amphetamine/dextroamphetamine combo therapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
11092015|NCT04132544|Experimental|Intervention group|"a standardized gerontological evaluation (EGS) and a fall balance performed at home by an IDEG
~the proposal for a Proposal for a personalized intervention plan (PIP) to correct potentially reversible and modifiable factors
~a close follow-up by the IDEG for the implementation of the PIP throughout the follow-up period of 24 months (6 home visits and 5 telephone follow-ups)."
11092016|NCT04132544|Active Comparator|Comparison group - usual care|Usual Care with the provision of documentation on simple recommendations for the prevention of falls and aging well.
11092017|NCT04132531||Normal weight control|Individuals who are generally healthy and have a body mass index less than 25 kg/m^2.
11092018|NCT04132531||Bariatric Surgery Group|Individuals electing to undergo bariatric surgery (generally with a body mass index between 35 and 40 kg/m^2 with an additional co-morbidity such as type 2 diabetes, or individuals with a body mass index greater than 40 kg/m^2) and who are willing to participate for 2 visits, one before and one after surgery. The intervention in this group is bariatric surgery.
11092019|NCT04132518|Experimental|Treatment Group|Each subject assigned to Treatment Group will receive up to 4 injection sessions with 5(±1) weeks intervals.
11092020|NCT04132518|No Intervention|Control Group|Subjects assigned to the Control Group will not receive treatment during the study.
11092021|NCT04132505|Experimental|Treatment (binimetinib, hydroxychloroquine)|Patients receive binimetinib PO BID and hydroxychloroquine PO BID on days 1-14. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11092022|NCT04132479|Experimental|Sequential therapy|Sequential Clarithromycin + Amoxycillin + Tinidazole + rabeprazole by mouth (Both amoxycillin 1000mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days, followed by clarithromycin 500 mg every 12 hours, tinidazole 500mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days)
11092023|NCT04132479|Active Comparator|Concomitant therapy|Concomitant clarithromycin 500mg every 12 hours + amoxycillin 1000mg every 12 hours + tinidazole 500mg every 12 hours + rabeprazole 20mg every 12 hours (all drugs by mouth for 14 days).
11092024|NCT04132466|Experimental|Treatment|Adult cardiac patients who meet eligibility criteria
11092025|NCT04132440||Observational (questionnaire, interview)|Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.
11092026|NCT04132427|Experimental|Group A: Treatment|Vancomycin, magnesium citrate, microbiota
11092027|NCT04132427|Placebo Comparator|Group B: Placebo|placebo vancomycin, real magnesium citrate (because it obviously empties the bowels) and placebo microbiota
11092028|NCT04132414|Experimental|NIRS open|Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia
11092029|NCT04132414|No Intervention|NIRS blinded|NIRS monitoring applied and masked for caregiver.
11092030|NCT04132401|Experimental|family medicine physicians|Retina reading
11092031|NCT04132401|Experimental|retina specialists|Retina reading (gold standard)
11092032|NCT04132388|Active Comparator|Standard-of-Care|Subjects will be instructed to take adalimumab according to the labeled dosing regimen. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
11092033|NCT04132388|Experimental|Electronic Reporting|"Subjects will be instructed to take adalimumab according to the labeled dosing regimen. The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.
~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
11092034|NCT04132375|Active Comparator|Stage 1 - high treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
11092035|NCT04132375|Active Comparator|Stage 1 - Low treatment arm|Subjects will receive a 1st intravenous dose of 4 mg/kg INM004 (Anti-Stx hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
11092036|NCT04132375|Placebo Comparator|Stage 1 - Placebo arm|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 24 h (± 2 h).
11092037|NCT04132375|Active Comparator|Stage 2 - Selected active treatment arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of 4 mg/kg INM004 and a 2nd intravenous dose of 4 mg/kg of INM004. Each dose will be separated by 24 h (± 2 h).
~In the case, the low treatment regime is selected subjects will receive an intravenous dose of 4 mg/kg INM004"
11092038|NCT04132375|Active Comparator|Stage 2 - Placebo arm|"In the case, the high treatment regime is selected, subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo, each dose separated by 24 h (± 2 h)
~In the case, low treatment regime is selected subjects will receive a single intravenous dose of Placebo"
11092039|NCT04132362||People living with dementia, their families and carers|The cohort consists of people living with dementia. Each of them will be accompanied, throughout the study, by a family member or friend. They will take part together in a one hour music listening session, to discover their personalised playlist. Where possible, a care home staff member will join in, in order to witness the benefits of the music to the dementia resident and learn how to provide the music, as part of their care in the care home.
11092040|NCT04132349|Experimental|Ullipristal Acetate|Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months
11092041|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 1|Participants will receive one tablet of naproxen sodium/caffeine at dose 1 plus one tablet of placebo after extraction of third molars
11092042|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 2|Participants will receive one tablet of naproxen sodium/caffeine at dose 2 plus one tablet of placebo after extraction of third molars
11092043|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 3|Participants will receive two tablets of naproxen sodium/caffeine at dose 3 after extraction of third molars
11092044|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 4|Participants will receive two tablets of naproxen sodium/caffeine at dose 4 after extraction of third molars
11092045|NCT04132336|Active Comparator|Naproxen sodium|Participants will receive one tablet of naproxen sodium plus one tablet of placebo after extraction of third molars
11092046|NCT04132336|Active Comparator|Caffeine|Participants will receive two tablets of caffeine after extraction of third molars
11092047|NCT04132336|Placebo Comparator|Placebo|Participants will receive two tablets of matching placebo after extraction of third molars
11092048|NCT04132323|Active Comparator|hypertonic glucose|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
11092049|NCT04132323|Active Comparator|0.05% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
11092050|NCT04132323|Active Comparator|0.1% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
11092051|NCT04132323|Active Comparator|0.15% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.
~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.
~to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
11092052|NCT04132310||MINT Participants|Up to 60 MINT maternal participant are linked with 60 infant participants, and 60 partner participants.
11092053|NCT04132297|Experimental|Virtual Asthma Academy Training + Telehealth Visit Group|Participants will receive the Asthma Academy Training virtually. One week after the virtual training, participants will be scheduled to complete a Telehealth visit via zoom through their smart phones or computers.
11092054|NCT04132297|Experimental|Virtual Asthma Academy Training|Participants will receive the virtual Asthma Academy Training via zoom through their smart phones or computers.
11092055|NCT04132284|Experimental|DBT IOP plus DBT PI|Standard Dialectical Behavior Therapy (DBT) delivered in the context of an intensive outpatient program (DBT IOP) for adolescents plus an 8-10 session DBT-based parenting intervention (DBT PI)
11092056|NCT04132284|Active Comparator|DBT IOP alone|No parenting intervention provided beyond what is part of the DBT IOP treatment as usual.
11092057|NCT04132271|Experimental|Personalized diet|Personalized diet during the swallowing rehabilitation
11092058|NCT04132271|Active Comparator|Control|Nutritional recommendations during the swallowing rehabilitation
11092059|NCT04132245|Experimental|obesity prevention|Families were randomized to an obesity prevention intervention arm or a general health control arm.
11092060|NCT04132245|Experimental|behavioral intervention|there are two arms in this study. An active intervention arm and a control arm
11092061|NCT04132232|Experimental|Treatment Group|"The patient will exhaled into the Smokerlyzer® device will at each visit
~Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient
~Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided."
11092062|NCT04132232|No Intervention|Control Group|"The patient will exhale into the Smokerlyzer® device at each visit.
~Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient
~No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided"
11092063|NCT04132219|Experimental|Immediate Intervention Group|"Dyads randomized to the Immediate Intervention Group will receive a Welcome Box at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on."
11092064|NCT04132219|Other|Delayed Intervention Group|"Participants assigned to the Delayed Intervention Group will receive a Welcome Box which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments."
11092065|NCT04132206||ScS patients|Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
11092066|NCT04132206||Healthy subjects|Healthy subjects will provide one stool sample at inclusion.
11092067|NCT04132180|Experimental|Early mobilization|
11092068|NCT04132180|Active Comparator|Late mobilization|
11092069|NCT04132167|Experimental|training group|perturbation balance training
11092070|NCT04132167|Active Comparator|control group|traditional physical therapy that including strengthening and stretching
11092071|NCT04132154||No Warming|Patients in this group were treated according to our institution's old protocol and did not receive any warming intervention during the surgical procedure.
11092072|NCT04132154||Active Warming|This group will include the patients treated after the implementation of the S3 Guidelines for prevention of hypothermia. For this purpose convective warming through an underbody blanket was used during the surgical procedure
11092073|NCT04132141|Other|VR intervention|each subject will be own control. subjects breaks will be randomly assigned to VR or WT until they complete 3 for each type or a total of 6
11092074|NCT04132128|Experimental|study|6 meetings with a dietician diabetes educator assimilating simple CC tool
11092075|NCT04132128|Other|control|meeting with dietician as needed with regular education of CC
11092076|NCT04132102|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
11092077|NCT04132089|No Intervention|Control|This was the control group for the messaging component of the study (push notifications). These participants only received the mobile health application called capABILITY without messages.
11092078|NCT04132089|Other|Facilitator Message Group|This group of participants received the mobile health application called capABILITY and received three facilitator messages per week. Facilitator messages are designed to help people who lack ability to do something.
11092079|NCT04132089|Other|Spark Trigger Group|This group of participants received the mobile health application called capABILITY and received three spark messages per week. Spark messages are designed to help people who lack ability to do something.
11092080|NCT04132076||Group A: Osteochondral lesion of talus (OLT)|Patients with OLT treated operatively (debridement, microfracture, allograft, mesenchymal stem cells implantation) in Department of Orthopaedic Surgery, University Medical Centre Ljubljana (UMC).
11092081|NCT04132076||Group B: Ankle joint osteoarthrosis|Patients with ankle joint osteoarthrosis treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
11092082|NCT04132076||Group C: Ankle Impingement syndrome|Patients with ankle impingement syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
11092083|NCT04132076||Group D: Ankle instability syndrome|Patients with ankle instability syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
11092084|NCT04132063||Generic levetiracetam|
11092085|NCT04132050|Experimental|R788|Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
11092086|NCT04132050|Placebo Comparator|Placebo|Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
11092087|NCT04132037||patient with multiple sclerosis|At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated
11092088|NCT04132024|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
11092089|NCT04132011|Active Comparator|Shortened interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals less than every 12 hours.
11092090|NCT04132011|Active Comparator|Standard interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals every 12 hours
11092091|NCT04131985|Experimental|Erector spina block|"After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
~All anesthesia procedure will be the same as control group"
11092116|NCT04131816|No Intervention|Control|De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
11092117|NCT04131803|Experimental|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
11092092|NCT04131985|No Intervention|Control|There were no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1-2μg/kg, propofol 2 - 4 mg/kg and rocuronium 0.6 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCO2≈ 35-40 mmHg. Anesthesia was maintained using remifentanil 0.05-0.1 mcg/kg/min and propofol 80-100 mcg/kg/min via total intravenous micro pump until the surgery was completed. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria.Tramadol 100 mg i.v. will be used before 15 min end of surgery and 20 mL of 25% bupivacaine will be infiltrated to the trochar sites at the end of the surgery. Patient control analgesia device will administer all patients.
11092093|NCT04131972|Experimental|Single arm 1|Each patient will be planned to perform 7 study visits and at the second visit excision / lumpectomy and REGENERA implant will be performed during the same surgical intervention.
11092094|NCT04131959|Experimental|Pharmacodynamic population|Single arm
11092095|NCT04131946|Experimental|Community Intervention Group/Arm 1|"Community navigators will work with local businesses (barber shop, hair salon) to identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT.
~Community navigators will attend community events to post the informational flyer and provide education about CRC to community members. At these events, they will identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT."
11092096|NCT04131946|No Intervention|Standard of Care (Control) Arm 2|"These procedures are a detailed summary of the existing lay navigation program at Mile Square Health Center (MSHC). These procedures are unrelated to our research, except to demonstrate how the existing navigation program from which we will obtain deidentified data works.
~Lay clinic navigator use clinic schedules and walk-ins to identify and screen eligible participants within the Englewood MSHC. The navigator engages with each potential participant using standard scripted language. For interested patients, the navigator documents interest and FIT dispensing as appropriate, and assists the patient in obtaining and returning their FIT.
~Lay clinic navigators attend community events as normally scheduled to provide community-based health education and referral to the MSHC. At these events, they identify and screen eligible community members within the Englewood community area."
11092097|NCT04131920||Phase 1 and 2|10 male patients with severe Hemophilia A from the Washington Center for Bleeding Disorders
11092098|NCT04131920||Phase 3|20 subjects who are also participating in the EmiMSKUS study
11092099|NCT04131907|Experimental|Optilume™ BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
11092100|NCT04131907|Sham Comparator|Sham Device|The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.
11092101|NCT04131907|Experimental|Pharmacokinetics Optilume Arm|A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System
11092102|NCT04131894|No Intervention|Control|Extraction sockets with spontaneous healing (16 sockets).
11092103|NCT04131894|Active Comparator|Dentin|Extraction sockets were filled with undemineralized autogenous dentin graft (20 sockets).
11092104|NCT04131894|Active Comparator|Dentin+PRF|Extraction sockets were filled with mixture of undemineralized autogenous dentin graft and platelet rich fibrin (PRF) (21 sockets).
11092105|NCT04131868|Experimental|Extended sleep opportunity|
11092106|NCT04131868|Active Comparator|Typical sleep opportunity|
11092107|NCT04131855|Active Comparator|Pumice prophylaxis.|Will receive pumice prophylaxis in a slurry of plain pumice and water for 5 seconds per tooth using a rubber cup in a slow contra-angle handpiece. The teeth involved will then be washed and dried prior to using the self etch primer.
11092108|NCT04131855|Experimental|No pumice prophylaxis.|Will not receive pumice prophylaxis. Teeth will be washed and dried before using the self etch primer.
11092109|NCT04131842|Experimental|ExFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive external focus of attention visual feedback.
11092110|NCT04131842|Experimental|ExFOCUS Auditory|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive auditory feedback.
11092111|NCT04131842|Experimental|InFOCUS Visual|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and will receive internal focus of attention visual feedback via video.
11092112|NCT04131842|Active Comparator|NoFeedback|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools and receive no feedback.
11092113|NCT04131829|No Intervention|Healthy Controls|The healthy control group will be an age matched sample of unmedicated healthy adults who will be recruited and imaged once at baseline and the data compared with that of OCD subjects at baseline.
11092114|NCT04131829|Experimental|OCD Group|The OCD group will comprise of unmedicated individuals with clinically significant OCD symptoms. OCD Subjects will be randomized, double-blind, to receive immediate or delayed (by 6 weeks as a placebo lead-in) pharmacotherapy.
11092115|NCT04131816|Experimental|HeartHome Intervention|Participants will be in the HeartHome program for a total of 12 weeks.
11092119|NCT04131790|Experimental|Tele-Behavioral Activation|Manualized Behavioral Activation (BA) protocol delivered via videoconferencing by a trained BA interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist guides participants in learning BA skills, focusing on strategies to decrease barriers to social connectedness (e.g., limited mobility, inadequate caregiving resources).
11092120|NCT04131790|Active Comparator|Tele-Friendly Visiting|Friendly Visitor (FV) calls delivered via videoconferencing by a trained FV interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist provides social support to participants through good listening and provision of genuine regard.
11092121|NCT04131777||Roll-in|Initial patients enrolled until optimal RF algorithm is determined
11092122|NCT04131777||Optimized|Patients treated using optimal RF algorithm
11092123|NCT04131764||Optic neuritis diagnosis only|Patients who have a diagnosis of optic neuritis, without a diagnosis of MS or NMOSD.
11092124|NCT04131764||ON and multiple sclerosis|Patients who have a diagnosis of optic neuritis AND multiple sclerosis.
11092125|NCT04131764||ON and NMOSD|Patients who have a diagnosis of optic neuritis and neuromyelitis optica spectrum disorder.
11092126|NCT04131738|Experimental|Baricitinib 2 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice
~Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100
~After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
11092127|NCT04131738|Experimental|Baricitinib 4 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice
~Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100
~After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
11092128|NCT04131725||Cardiac Function Monitoring|Subjects will wear Cardiac Performance System (CPS) non-invasive device for brief periods during procedures including assessment by Pulmonary Artery Catheter (PAC) methods.
11092129|NCT04131712|No Intervention|Ambulatory Control|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. Atrophy will not be induced and massage intervention will not be applied.
11092130|NCT04131712|Sham Comparator|Ambulatory Massage|Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. No atrophy induction. Four massage treatments will be applied every other day until the end of the study.
11092131|NCT04131712|No Intervention|Immobilization Control|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Massage intervention will not be applied.
11092132|NCT04131712|Experimental|Immobilization Massage|Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Four massage treatments will be applied every other day until the end of the study.
11092133|NCT04131699||pediatric thoracoscopic group|record hemodynamic changes and cardiac output at different intrathoracic pressures ( insufflation pressures 4, 5, 6 mmHg)
11092134|NCT04131686||Control sites|Group of patients receiving standard treatment for symptomatic acute rhinosinusitis
11092135|NCT04131686||Test sites|Group of patients receiving NAC inhalation in addition to standard treatment for symptomatic acute rhinosinusitis
11092136|NCT04131673||African Americans with MS|African American patients seen in the University of Kentucky's Multiple Sclerosis Clinic between the ages of 18 and 80 who have been diagnosed with MS
11092137|NCT04131660|Experimental|AVAPS-AE mode|A volume targeted pressure support ventilation mode
11092138|NCT04131660|Active Comparator|S/T mode|A pressure support ventilation mode
11092139|NCT04131647|Active Comparator|Weight Maintenance|Heart Healthy nutrition, walking, resistance band exercise
11092140|NCT04131647|Experimental|Weight Maintenance + Intermittent Fasting|Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
11092141|NCT04131634|Experimental|SAbR 6 measurable lesions|PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)
11092142|NCT04131621|Experimental|Nivolumab/Ipilimumab|
11092143|NCT04131608||diabetic foot ulcer (1and2)with iron defic|"50 diabetic patients with diabetic foot ulcer grade (1and2) with iron deficiency anemia will be applied TO
~cbc
~ferritin
~HBA1C
~ankle brachial index by duplex"
11092144|NCT04131608||diabetic foot ulcer grade(1and2)without iron deficiency anemia|"50 patients with diabetic foot ulcer grade (1and2) without iron deficiency anemia will be applied to
~CBC
~Ferritin,
~HBA1C
~ankle brachial index by duplex"
11092145|NCT04131595|Experimental|MVA-BN-WEV Dose 1|Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.
11092146|NCT04131595|Experimental|MVA-BN-WEV Dose 2|Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL
11092147|NCT04131595|Experimental|MVA-BN-WEV Dose 3|Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL
11092148|NCT04131582|Experimental|Empagliflozin + linagliptin + metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5 mg + metformin 850 mg every 12 hours and empagliflozin 12.5 mg + metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
11092149|NCT04131582|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the complete dose. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
11092150|NCT04131569||ESBL-E fecal carriers|Patients with a positive ESBL-E fecal carriage according to routine screening
11092151|NCT04131569||non ESBL-E fecal carriers|Patients without positive ESBL-E fecal carriage according to routine screening
11092754|NCT04127448|Experimental|Exergaming Training Group|Training was given using X-box 360 Kinect.
11092152|NCT04131556|Experimental|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
11092153|NCT04131556|Experimental|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
11092154|NCT04131556|Experimental|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
11092155|NCT04131556|Experimental|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
11092156|NCT04131556|Experimental|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
11092157|NCT04131556|Experimental|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
11092158|NCT04131556|Experimental|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
11092159|NCT04131556|Experimental|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
11092160|NCT04131556|Experimental|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
11092161|NCT04131556|Experimental|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
11092162|NCT04131543|Experimental|Cabozantinib|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
11092163|NCT04131530||Colon mucosa observed by pCLE|pCLE is used to evaluate the inflammation activity in different parts of the colon mucosa
11092164|NCT04131517|Experimental|Oral contraceptive|Participants will receive oral contraceptive in period 1 (sequence AB) and in period 2 (sequence BA) of Part 1 and Part 2.
11092165|NCT04131517|Experimental|Oral contraceptive + padsevonil|Participants will receive oral contraceptive + padsevonil in period 1 (sequence AB) and in period 2 (sequence BA) of Part 1 and Part 2.
11092166|NCT04131504||Phase I - Cross-sectional Study (CD and Suspected IBD)|150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
11092167|NCT04131504||Phase I - Cross-sectional Study (healthy volunteers)|20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
11092168|NCT04131504||Phase II - Longitudinal Study of Participants with CD|70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
11092169|NCT04131491|Other|Patients with Mild Cognitive Impairment (MCI) due to AD|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, magnetic resonance imaging (MRI), blood sample with deep genetic profiling and Apolipoprotein E (APOE) determination.
11092170|NCT04131491|Other|Healthy volunteers|Neuropsychological investigation, lumbar puncture, long term-EEG monitoring and/or MEG-EEG, MRI, blood sample with deep genetic profiling and APOE determination.
11092171|NCT04131478||Cases|Cachectic lung, pancreas, or colon cancer patients.
11092172|NCT04131478||Control|Non- cachectic lung, pancreas, or colon cancer patients.
11092173|NCT04131465|Experimental|Home HIV self-testing|Fieldworkers will visit potential participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing.
11092174|NCT04131465|Experimental|Home HIV rapid testing|Fieldworkers will visit potential participants in their homes and offer home-based HIV rapid testing and counselling.
11092175|NCT04131465|Experimental|Home HIV self-testing and rapid testing|Fieldworkers will visit participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing as well as home-based HIV rapid testing and counselling.
11092176|NCT04131452||Fresh embryo transfers|those undergoing fresh embryo transfer
11092177|NCT04131452||Frozen embryo transfers|those undergoing frozen embriyo transfer
11092178|NCT04131439||"cochlear implantation group"|"cochlear implantation group: patients undergoing cochlear implantation between December 2019 and December 2021in the ENT department of Assiut university hospital."
11092179|NCT04131426|Experimental|Remune dosed twice daily|A nutritional supplement taken twice per day each day and standard care for your cancer as prescribed by your oncologist
11092180|NCT04131426|Experimental|Remune dosed twice daily and daily exercise with EXCAP|A nutritional supplement taken twice by day each day and a home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
11092181|NCT04131426|No Intervention|Usual Care|Usual standard care as prescribed by your oncologist
11092182|NCT04131413|Other|Vaccination Arm Level 1|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; Level 1 dose of 0.3 mg
11092183|NCT04131413|Other|Vaccination Arm Level 2|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 2 at dose 1.0 mg
11092184|NCT04131413|Other|Vaccination Arm Level 3|The dose escalation of pNGVL4aCRTE6E7L2 will be conducted to evaluate the safety of three escalating doses; level 3 dose of 3.0 mg
11092185|NCT04131400||Patients with Inherited Retinal Dystrophy|known patients with a diagnosis of inherited retinal dystrophy (IRD) will be recruited to identify the type of IRD diagnosis. The comprehensive ophthalmic examinations and retinal imaging will be performed. Additionally, blood sample of all participants and their family members will be kept in our bio- bank for genetic testing.
11092186|NCT04131387|Experimental|Test Group|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
11092187|NCT04131387|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
11092188|NCT04131374|Experimental|Virtual Reality Intervention|Virtual Reality Intervention: Each Person Living with Dementia-caregiver dyad will receive 10 weekly sessions of tailored reminiscence therapy delivered via virtual reality. Each session will last for a period of 15-30 minutes.
11092189|NCT04131361|Active Comparator|Crystalloid -control group:|
11092190|NCT04131361|Experimental|Colloid- study group:|
11092191|NCT04131348|Other|CSG|patients underwent open CST (component separation group or CSG)
11092192|NCT04131348|Other|BTG|patients with preoperative BT administration and following open RSR (botulinum toxin group or BTG).
11092193|NCT04131335|Experimental|Experimental Arm|Experimental arm receives lubricant eye-drops (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks following cataract surgery (in addition to the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks).
11092194|NCT04131335|Active Comparator|Control Arm|The control arm group receive the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks after cataract surgery.
11092195|NCT04131322|Experimental|switch-cohort|Adalimumab biosimilar
11092196|NCT04131322|Active Comparator|non-switchcohort|Adalimumab original
11092197|NCT04131309|Experimental|Daratumumab|"Daratumumab monotherapy 16 mg/kg intravenous infusion (iv) or 1800 mg subcutaneous injection (sc) weekly for Cycles 1-2, every 2 weeks for Cycles 3-6 and every 4 weeks thereafter.
~Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive, in addition to daratumumab, bortezomib (for a maximum of 6 cycles) and low dose dexamethasone."
11092198|NCT04131283|Experimental|Epinephrine effect throught keratinized ginigva|1 mg/ml epniephrine vs physiologocal saline
11092199|NCT04131283|Experimental|Epinephrine effect throught gingival sulcular epithelium|1 mg/ml epniephrine vs physiologocal saline
11092200|NCT04131270|Experimental|Planning + Education|"3 education sessions + 1 planning session (integrated into the 3rd education session); delivered face-to-face over 3 weeks (after the baseline measurement), individually.
~Planning: The planning materials and forms have sections: (a) instructions of what should be included in a good plan (the when, where, and how components), (b) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties) will be formed. After forming the plans individually, experimenters will discuss the plans with the participants."
11092201|NCT04131270|Active Comparator|Education|"3 education sessions; delivered face-to-face over 3 weeks (after the baseline measurement), individually.
~The education includes extended physical activity and sedentary behavior education using participant-educator discussions and printed materials."
11092202|NCT04131257|Experimental|Continuum of care|Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.
11092203|NCT04131257|Active Comparator|Usual care|The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.
11092204|NCT04131231|Experimental|microparticles packaging methotrexate (MPs-MTX) group|"Patients are first treated with microparticles packaging methotrexate (MPs-MTX) via intrapleural infusion four times on day5,6,7,8 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.
~MPs-MTX: 5 U of MPs-MTX containing a total dose of more than 25μg of MTX dissolving in 50ml of physiological saline solution"
11092205|NCT04131231|Active Comparator|recombinant human interleukin-2(rhIL-2) group|"Patients are first treated with rhIL-2 via intrapleural infusion three times on day5,8,11 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.
~rhIL-2: 2 million IU of rhIL-2 dissolving in 50ml of physiological saline solution"
11092206|NCT04131218|Experimental|Obese group|n=8, 25≤BMI≤39.9kg/m²
11092207|NCT04131218|Experimental|Morbidly obese group|n=8, BMI≥40kg/m²
11092208|NCT04131205||Minimal Hepatic Encephalopathy|Patients with hyperammonemia and minimal hepatic encephalopathy
11092209|NCT04131205||Control|Healthy controls
11092210|NCT04131192|Experimental|z650 and Gemcitabine|Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles
11092211|NCT04131179|Experimental|Youth culturally adapted therapy (Y-CMAP)|Youth Culturally adapted manual assisted (Y-CMAP) psychological therapy
11092212|NCT04131179|No Intervention|Treatment as Usual|"TAU will be standard routine care delivered by local medical, psychiatric and primary care services according to clinical judgement. A record will be kept of any treatment received by each participant.
~Assessment will be done at 3rd,6th,9th and 12 month after randomization along with TAU"
11092213|NCT04131166|Other|Metabolically normal lean|Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
11092214|NCT04131166|Experimental|Metabolically normal obese - Mediterranean diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
11092215|NCT04131166|Experimental|Metabolically normal obese - Low-carbohydrate ketogenic diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
11092216|NCT04131166|Experimental|Metabolically normal obese - Low-fat diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
11092217|NCT04131166|Experimental|Metabolically abnormal obese - Mediterranean diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
11092218|NCT04131166|Experimental|Metabolically abnormal obese - Low-carbohydrate ketogenic diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
11092219|NCT04131166|Experimental|Metabolically abnormal obese - Low-fat diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
11092220|NCT04131153|Other|Conventional radiofrequency ablation group|Conventional radiofrequency ablation procedures
11092221|NCT04131153|Experimental|Three-step radiofrequency ablation group|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
11092222|NCT04131101|Experimental|Community Organizing|All tenants in three TCHC buildings will be invited to participate in a survey on their building conditions at baseline, 6 months and 12 months. Once baseline data collection is complete, there will be a community organizing campaign involving tenants to advocate for improved building conditions.
11092223|NCT04131075||Study group|Patients with CAD undergoing FFR-guided revascularisation. FFR, coronary flow reserve (CFR) and the index of hyperemic microvascular resistance (HMR) will be measured with the Doppler guidewire (Combowire, Volcano - Philips corporation) under steady state hyperemia.
11092224|NCT04131062|No Intervention|Control (no intervention)|Consented using the traditional, human-mediated consent process already in use for MyCode consenting.
11092225|NCT04131062|Experimental|Electronic Consent (iPad)|Consented using the Sage eConsent framework, which presents participants with an iPad that describes MyCode and allows participants to choose to learn more information at various steps along the process.
11092226|NCT04131049|Experimental|Carbohydrate Counting|The insulin doses of the breakfasts were calculated according to carbohydrate counting.
11092227|NCT04131049|Experimental|Food Insulin Index|The insulin doses of the breakfasts were calculated according to food insulin index.
11092228|NCT04131036||Arm A|Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough >1%.
11092229|NCT04131036||Arm B|Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.
11092230|NCT04131023|Experimental|Metabolic Tracking|Metabolism (indirect calorimetry) tracking was performed
11092231|NCT04131023|No Intervention|Standard Care|Metabolic (indirect calorimetry tracking was not performed
11092232|NCT04131010|Experimental|SpyGlass Pancreatoscopy|ERP with direct pancreatoscopy
11092268|NCT04130815|Active Comparator|Slow/Deep/Large|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration
11092233|NCT04130997|Experimental|Ublituximab Infusions|"All subjects who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab followed by a 1-hour infusion of 450 mg ublituximab 14 days later. Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks.
~Infusion treatment will continue for 168 weeks, or until physician or subject decision to withdraw from the study."
11092234|NCT04130984|Experimental|Group IO|Intraosseous assess will be established in group IO, using EZ-IO for drug or fuild resuscitation. Proximal tibia is the insertion site,locating at 1 cm medial tibial tuberosity. IO access should be retained for less than 1 day, and venous access should be established as soon as possible after winning rescue time to continue treatment. Other treatment measures refer to 2015 AHA guidelines.
11092235|NCT04130984|No Intervention|Group IV|Intravenous access will be established in group IV, choosing any available peripheral venous for the administration of drugs or fluids.The antecubital vein is the preferred choice. If failed, the next catheterization plan will be determined by the physician in charge of the scene.Other treatment measures also refer to 2015 AHA guidelines.
11092236|NCT04130971||Patients without neoadjuvant treatment|
11092237|NCT04130971||Patients with short course radiotherapy|
11092238|NCT04130971||Patients with long course chemoradiotherapy|
11092239|NCT04130971||Patients with short course radiotherapy and deferred surgery|
11092240|NCT04130958|Experimental|MDD and Active iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving active iTBS-TMS.
11092241|NCT04130958|Experimental|BPD and Active iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
11092242|NCT04130958|Sham Comparator|MDD and Sham iTBS-TMS|This group will consist of patients diagnosed with MDD that are receiving sham iTBS-TMS.
11092243|NCT04130958|Sham Comparator|BPD and Sham iTBS-TMS|This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.
11092244|NCT04130945|Active Comparator|group 1|patients with erector spine plane block
11092245|NCT04130945|No Intervention|group 2|patients without erector spine plane block
11092246|NCT04130932|No Intervention|Normal flooring|standard office flooring
11092247|NCT04130932|Experimental|Ergonomic flooring|Ergonomically designed flooring
11092248|NCT04130919|Experimental|GS-4875 300 mg|Participants will receive blinded GS-4875 300 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
11092249|NCT04130919|Experimental|GS-4875 100 mg|Participants will receive blinded GS-4875 100 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
11092250|NCT04130919|Placebo Comparator|Placebo|Participants will receive blinded GS-4875 placebo for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
11092251|NCT04130919|Experimental|Open-label Treatment Phase|Based on the efficacy assessment results at Week 10, participants who do not achieve MCS response will have the option to receive open-label GS-4875 300 mg for up to 50 weeks.
11092252|NCT04130906|Active Comparator|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
11092253|NCT04130906|Sham Comparator|Sham Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
11092254|NCT04130893|Experimental|A stimulation of G13 then G15|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G13 auricular stimulation At the Third session: Cold water hand immersion + G15 auricular stimulation
11092255|NCT04130893|Experimental|B: stimulation of G15 then G13|The first session is similar between the two arms: Cold water hand immersion only At the Second session: Cold water hand immersion + G15 auricular stimulation At the Third session: Cold water hand immersion + G13 auricular stimulation
11092256|NCT04130880||Children with cerebral palsy|Children with CP who aged between 18 months and 6 years will be evaluated.
11092257|NCT04130880||Children with typical development|Children with typical development who aged between 18 months and 6 years will be evaluated.
11092258|NCT04130867||Group A: Swallow Therapy Oropharyngeal Strengthening|"Participants receiving any standard of care swallow therapy with oropharyngeal strengthening as the primary goal
~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post -therapy)"
11092259|NCT04130867||Group B: Surgical Treatment Esophageal Sphincter|"Participants receiving surgical treatment for relief of upper esophageal sphincter outlet obstruction.
~Participants will undergo pHRM, videofluoroscopy (VF), diet assessment, functional reserve tests, and patient--reported outcome questionnaires at 3 standardized time points: baseline, 4 to 6 weeks (mid therapy), and 10 to -12 weeks (post therapy)"
11092260|NCT04130867||Group C: Healthy Controls|Healthy controls (n=50) will also undergo data collection at parallel time points, without completion of a treatment paradigm.
11092261|NCT04130854|Experimental|APX005M on day 3 of RT & day 3 of cycles 1-5 of mFOLFOX|On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
11092262|NCT04130854|Active Comparator|Radiation Therapy 5Gy x 5 days, mFOLFOX|Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
11092263|NCT04130841|Experimental|Spontaneous ILM peeling|
11092264|NCT04130841|Active Comparator|Active ILM peeling|
11092265|NCT04130841|No Intervention|No ILM peeling|
11092266|NCT04130828|Experimental|Thrice-weekly group|Ferrous fumarate 200 mg PO PC Thrice-weekly
11092267|NCT04130828|Active Comparator|Thrice-daily group|Ferrous fumarate 200 mg PO PC Thrice-daily
11092269|NCT04130815|Active Comparator|Slow/Deep/Small|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
11092270|NCT04130815|Active Comparator|Fast/Shallow/Large|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration.
11092271|NCT04130815|Active Comparator|Fast/Shallow/Small|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
11092272|NCT04130802|Experimental|OCS-01 1.5% mg/mL QD|eye drops
11092273|NCT04130802|Experimental|OCS-01 1.5% mg/mL BID|eye drops
11092274|NCT04130802|Placebo Comparator|Placebo (Vehicle) BID|eye drops
11092275|NCT04130789||patients with sepsis (cases)|patients who developed or were admitted with sepsis to the ICU (cases)
11092276|NCT04130789||patients without sepsis (controls)|patients who did not develop sepsis (controls).
11092277|NCT04130763|Experimental|FMT Capsule in Combination with Anti-PD-1 Therapy|
11092278|NCT04130750|Active Comparator|treatment of physician's choice|Patients in this arm will receive neoadjuvant chemotherapy according physician's choice.
11092279|NCT04130750|Experimental|treatment of drug screening|Patients in this arm will receive neoadjuvant chemotherapy according results of drug screening vitro.
11092280|NCT04130737|Experimental|TORUS Stent Graft System|The TORUS Stent Graft System (SGS) is comprised of a Stent Graft (SG) and a Stent Graft Delivery System (SGDS).
11092281|NCT04130724||Ketogenic diet|Subjects consuming either a ketogenic (<30g carbohydrate per day) or a low-carb (<100g carbohydrate per day) diet.
11092282|NCT04130724||High-carbohydrate diet|Subjects consuming a high carbohydrate (>100g carbohydrate per day) diet.
11092283|NCT04130711|Other|TEST 1: Visual virtual Conditions|"50 subjects (30 healthy volunteers and 20 patients after stroke)
~3 different situations of vibration applications, without EGG neurofeedback session"
11092284|NCT04130711|Other|TEST 2: Standard EEG|"40 subjects (20 healthy volunteers and 20 patients after stroke)
~3 separate electroencephalographic recording conditions without Neurofeedback"
11092285|NCT04130711|Other|TEST 3: Neurofeedback Trial|"21 healthy volunteers
~3 modalities of feedback during 10 minutes each (visual, vibratory, visual combination + vibratory)"
11092286|NCT04130711|Other|TEST 4: Neurofeedback Training Healthy subjects|"21 healthy volunteers
~6 neurofeedback sessions spread over 2 weeks according to the feedback modality that will be drawn (visual, vibratory, visual combination + vibratory)"
11092287|NCT04130711|Other|TEST 5: Neurofeedback Training Stroke Patients|"20 patients after stroke
~15 neurofeedback sessions spread over 5 weeks according to the feedback modality that will be drawn (visual or vibratory)"
11092288|NCT04130698|Experimental|Distress Tolerance|"Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address all 3 key factors. This condition includes both key factors in the control but introduces the third key factor distress tolerance (DT). Toward that end, modules will include: a values discussion; experiential avoidance; distress tolerance; and mindfulness-based ways to manage distress.
~Module 1: Orientation & ACT; Module 2: Avoidance; Module 3: Cognitive Fusion vs. Defusion; Module 4: Self-As-Context; Module 5: Present-Moment-Awareness; and Module 6: Values and Committed Action."
11092289|NCT04130698|Active Comparator|Active Health Control|"Treatment rationale: RAs will explain that there are 2 key factors that maintain smoking behavior and excess weight: 1) learned habits and 2) the addictive properties of smoking and food. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address both key factors. Toward that end, modules will include standard treatment on: the dangers of smoking, excess weight, unhealthy diets and sedentariness; the importance of healthy behaviors; and relaxation exercises to manage stress. These are all key aspects of standard treatment for smoking cessation and weight loss.
~Module 1: Orientation and Health; Module 2: Game Plan; Module 3: Stress and Coping Strategies; Module 4: Physical Activity; Module 5: Changes in Activities, Habits and Lifestyle; and Module 6: Long-Term Rewards."
11092290|NCT04130672|Other|Hot saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 50 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 50 ° C saline irrigation was applied.
11092291|NCT04130672|Other|Cold saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 22 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 22 ° C saline irrigation was applied.
11092292|NCT04130659|Experimental|Marial® + PPI (generic omeprazole)|Marial® + PPI (generic omeprazole) Application: following the Summary of Product Characteristics Marial®: 1 stick of Marial® twice a day after meals from day 1 to 28 Omeprazole 20 mg cps: once a day from day 1 to 28
11092293|NCT04130659|Active Comparator|PPI alone (generic omeprazole)|PPI alone (generic omeprazole) Application following the Summary of Product Characteristics Omeprazole 20 mg cps: once a day from day 1 to 28
11092294|NCT04130646|Active Comparator|Active taVNS, Active TMS|
11092295|NCT04130646|Sham Comparator|Sham taVNS, Active TMS|
11092296|NCT04130646|Sham Comparator|Active taVNS, Sham TMS|
11092297|NCT04130646|Sham Comparator|Sham taVNS, Sham TMS|
11092298|NCT04130633|Placebo Comparator|Placebo|Placebo (5mL distilled water)
11092299|NCT04130633|Experimental|Vaporized high THC alone|25mg of vaporized pure THC
11092300|NCT04130633|Experimental|Vaporized low alpha-pinene|0.5mg of vaporized alpha-pinene
11092301|NCT04130633|Experimental|Vaporized high alpha-pinene|5mg of vaporized alpha-pinene
11092302|NCT04130633|Experimental|Vaporized high THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 25mg vaporized THC
11092303|NCT04130633|Experimental|Vaporized high THC and high alpha-pinene|5mg of vaporized alpha-pinene with 25mg vaporized THC
11092304|NCT04130633|Experimental|Vaporized low THC alone|10mg of vaporized pure THC
11092305|NCT04130633|Experimental|Vaporized low THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 10mg vaporized THC
11092306|NCT04130633|Experimental|Vaporized low THC and high alpha-pinene|5mg of vaporized alpha-pinene with 10mg vaporized THC
11092307|NCT04130607|Experimental|Analytical|Students will receive brief instruction in probability, sensitivity, specificity, and likelihood ratios, with distributions and calculations. Pretest and posttest probabilities will be computed for two cases for each of the three conditions listed above.
11092308|NCT04130607|Active Comparator|Experiential|"Students will receive a brief instruction conceptually discussing sensitivity and specificity (e.g. a sensitive test will be positive at even low levels of disease. However, this can lead to a number of false positive errors, when the test is positive even when there is no disease. As a result, it is most useful for ruling out a diagnosis). They will then work through a total of 30 cases, 10 for each condition, in blocked sequence. For each brief written case they will be asked for a probability of diagnosis after the clinical information is presented. The test result will then be given and they will be asked for a post-test probability. Their estimate will be compared to the computed value based on published estimates of sensitivity and specificity and feedback provided."
11092309|NCT04130607|Placebo Comparator|No Explicit Instruction or Examples|Students will receive 3 passages from a clinical text related to each of the 3 conditions in the study and asked to study them for 15 min each.
11092310|NCT04130594|Experimental|phase 1, vaccine half dose|half dose of BVRS-GamVac vaccine single administration
11092311|NCT04130594|Experimental|phase 1, vaccine full dose|full dose of BVRS-GamVac vaccine single administration
11092312|NCT04130594|Experimental|phase 2, vaccine selected dose|selected dose of BVRS-GamVac vaccine single administration
11092313|NCT04130594|Placebo Comparator|phase 2, placebo|placebo single administration
11092314|NCT04130581|Experimental|TMS|Six 30-pulse trains of 20 Hz repetitive Transcranial Magnetic Stimulation to left primary motor cortex hand area, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
11092315|NCT04130581|Sham Comparator|Sham|Six 30-pulse trains of 20 Hz repetitive sham Transcranial Magnetic Stimulation above, but not in contact with, the head, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
11092316|NCT04130555||CELLIS Rectopexy|Rectal prolapse repair by ventral rectopexy with the CELLIS Rectopexy matrix
11092317|NCT04130542|Experimental|LVGN6051|The dose escalation phase includes 10 dose levels of LVGN6051, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
11092318|NCT04130529|Experimental|Adjusted group CBT-i for Bipolar disorder|"The experimental group receives group-CBT-i adjusted for Bipolar disorder. This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the population with Bipolar Disorder. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the Bipolar population.
~Treatment is given as 8 weekly group sessions."
11092319|NCT04130529|Active Comparator|Sleep lectures|The control group is offered a series of 3 lectures on sleep during the same time-period.
11092320|NCT04130516|Other|Active|Phase 1 open-label
11092321|NCT04130503|Experimental|PAP treatment- Acute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.
~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
11092322|NCT04130503|Active Comparator|Usual Care (HLE)|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
11092323|NCT04130503|Experimental|PAP treatment- Subacute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.
~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
11092324|NCT04130477|Experimental|Clear aligners with tunnel attachment|Participants will receive traditional clear aligner therapy with virtual set up and will be supplemented by virtually planned tunnel attachments which will be threaded by a light Nickel-Titanium wire
11092325|NCT04130477|Active Comparator|Clear aligners|Participants will receive traditional clear aligner therapy with virtual set up
11092326|NCT04130464|Experimental|Ropivacaine|Subjects will receive a continuous intraperitoneal infusion of ropivacaine
11092327|NCT04130464|Experimental|Ropivacaine + Ketorolac|Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac
11092328|NCT04130464|Placebo Comparator|Normal Saline|Subjects will receive a continuous intraperitoneal infusion of normal saline
11092329|NCT04130451|Active Comparator|Pre pleurodesis Procedure Fever Pulse rate Respiratory rate Pa|Pre pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procedure 24 hours before 16 hours before 8 hours before
11092330|NCT04130451|Active Comparator|After Pleurodesis procedure Fever Pulse rate Respiratory rate|Post pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procdure 24 hours before 16 hours before 8 hours before
11092331|NCT04130438|Active Comparator|Beta Blocker (nebivolol)|
11092332|NCT04130438|Active Comparator|Calcium Channel Blocker (diltiazem)|
11092333|NCT04130438|Placebo Comparator|Placebo|
11092334|NCT04130425|Experimental|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely & Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
11092335|NCT04130412|Active Comparator|Open release of lateral retinaculae|This group was treated by open release of lateral retinaculae after diagnosis of lateral compression syndrome by arthroscopy
11092336|NCT04130412|Active Comparator|Arthroscopic release of lateral retinaculae|This group was treated by arthroscopic release
11092755|NCT04127448|Active Comparator|Aerobic Exercise Group|Session using treadmill (model no TMX58 220).
11092337|NCT04130399|Experimental|Preoperative Chemotherapy + SBRT|"Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines.
~After 6 cycles of neoadjuvant therapy are completed, patients will undergo imaging with pancreatic protocol CT and PET-MRI to assess disease status . Patients without evidence of disease progression at the end of 6 cycles of neoadjuvant treatment will proceed to SBRT followed by surgical resection.
~Following surgery, patients will receive an additional 6 cycles of FOLFIRINOX chemotherapy."
11092338|NCT04130386|Experimental|Motivational Interviewing|Participants assigned to this arm will complete three MI sessions over 10 weeks.
11092339|NCT04130386|Active Comparator|E-education|The e-education group receives three educational modules lasting approximately 10 minutes each over a period of 10 weeks.
11092340|NCT04130373||Women receiving autologous fat grafting|Women who received breast reconstruction and autologous fat grafting.
11092341|NCT04130373||Control|Women who received breast reconstruction only.
11092342|NCT04130360|Experimental|Problem-solving|
11092343|NCT04130360|No Intervention|Control|
11092344|NCT04130347||Pancreatic resection|
11092345|NCT04130347||Liver resection|
11092346|NCT04130347||HIPEC surgery|
11092347|NCT04130347||Gynecological debulking surgery|
11092348|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to horizontal|horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
11092349|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to vertical|horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
11092350|NCT04130321|Experimental|Camu camu|
11092351|NCT04130321|Placebo Comparator|Placebo|
11092352|NCT04130308|Experimental|ACL-R|
11092353|NCT04130308|No Intervention|Control|
11092354|NCT04130295|Experimental|Wearable intensive nerve stimulation|The device will be worn on the upper calf with each session of stimulation lasting 60 minutes after which the device will turn off for 60 minutes before turning back on. Participants will be instructed to wear the device for 5 hours a day in order to receive three one our sessions of stimulation.
11092355|NCT04130282|Experimental|Group 1|8 volunteers receiving 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
11092356|NCT04130269||Patients with MCI|Patients with myocardial infarction (STEMI/NSTEMI) aged 19-90
11092357|NCT04130256|Experimental|Active Reminders|35 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will provide daily medication reminders for participants to take their pill.
11092358|NCT04130256|Experimental|Passive Adherence Monitoring|35 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will not provide medication reminders and will only track medication use.
11092359|NCT04130243||Congenital Heart disease|In patients with (a history of) pressure- and/or volume loaded right ventricle due to congenital heart disease extra blood will be withdrawn for a blood test; serumbiomarker
11092360|NCT04130243||Pulmonary Arterial Hypertension|In patients with (a history of) pressure- and/or volume loaded right ventricle due to pulmonary arterial hypertension extra blood will be withdrawn for a blood test; serumbiomarker
11092361|NCT04130230|Experimental|Neostigmine group|This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
11092362|NCT04130230|Placebo Comparator|Standard group|This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.
11092363|NCT04130217|No Intervention|Control group|patients will be intraoperatively mechanically ventilated without PEEP nor RM.
11092364|NCT04130217|Experimental|PEEP Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
11092365|NCT04130217|Experimental|PEEP and RM Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
11092366|NCT04130204|Experimental|Active|DYV700
11092367|NCT04130204|Placebo Comparator|Placebo|Placebo
11092368|NCT04130191||Participants with hereditary angioedema (HAE)|Participants who initiate treatment with lanadelumab according to current product labelling will be enrolled and followed for up to 36 months after the enrollment in the study.
11092369|NCT04130178|Active Comparator|Bupivacine injected|Half ml of Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was injected through a 27G needle at the level of the volar proximal digital crease of the 2nd and 3rd PIP on each side of the selected joint.
11092370|NCT04130178|Placebo Comparator|Bupivacine spared|Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was not injected in this group and it was considered as a control group.
11092371|NCT04130165|Experimental|Matched donor human milk|Infants randomized to the matched donor human milk arm, will receive donor human milk which is matched to their mother's secretor status.
11092372|NCT04130165|No Intervention|Standard issue donor human milk|Infants randomized to the standard issue donor human milk arm, will receive donor human milk which is prepared without consideration of secretor status as per standard practice.
11092373|NCT04130152|Experimental|Palbociclib + Letrozole|"Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
~If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues (ie, triptorelin 3.75 mg intra-muscular (IM) or Goserelin 3,6 mg SC) must be initiated at least 2 weeks before palbociclib plus letrozole administration."
11092374|NCT04130139||residents|obstetrics and gynecology residents from France with or without previous experience in oocyte pick up
11092375|NCT04130126|No Intervention|Warm showers|Participants in the warm showers condition are instructed to continue their normal warm showers throughout the study
11092376|NCT04130126|Experimental|Cold showers|Participants in the cold showers condition will be asked to take cold showers over a time period of 3 months
11092377|NCT04130100|Experimental|Low Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of low dose of mesenchymal stem cells.
11092994|NCT04125823|Experimental|Video game-based physical activity training|
11092378|NCT04130100|Experimental|High Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of high dose of mesenchymal stem cells.
11092379|NCT04130100|Active Comparator|Sodium Hyaluronate|Patients receiving intraarticular injection of Sodium Hyaluronate
11092380|NCT04130087|Experimental|Selegiline Group|27 healthy participants who will be administered a single 10mg tablet of selegiline hydrochloride.
11092381|NCT04130087|Placebo Comparator|Placebo Group|27 healthy participants who will be administered a single lactose tablet (placebo)
11092382|NCT04130061|Experimental|Randomized|
11092383|NCT04130061|No Intervention|Control|
11092384|NCT04130022|Other|Fasted Children|
11092385|NCT04130009|Active Comparator|TKA with tourniquet|This group was treated by TKA with the use of tourniquet
11092386|NCT04130009|Active Comparator|TKA without tourniquet|This group was treated by TKA without tourniquet
11092387|NCT04129996|Experimental|camrelizumab in combination with nab-paclitaxel and famitinib|
11092388|NCT04129983|Experimental|Prednisone acetate + somatosensory stimulation|Prednisone acetate 1 mg/kg body weight * 7 days and somatosensory stimulation 30 days were given to sudden deafness patients.
11092389|NCT04129983|Experimental|Prednisone acetate + hyperbaric oxygen|Prednisone acetate 1mg / kg body weight * 7 days and hyperbaric oxygen 15 days were given to sudden deafness patients.
11092390|NCT04129970|Experimental|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active iTBS.
11092391|NCT04129957||Patients who underwent placement of dental implants|The study only includes one cohort. That is the patients who underwent placement of dental implants at baseline.
11092392|NCT04129944|Placebo Comparator|Placebo|
11092393|NCT04129944|Experimental|UBX0101 0.5 mg|
11092394|NCT04129944|Experimental|UBX0101 2.0 mg|
11092395|NCT04129944|Experimental|UBX0101 4.0 mg|
11092396|NCT04129931|Experimental|Medium Chain Triglycerides (MCT)|Participants in this arm will receive Medium Chain Triglycerides (MCT) powder packets (10 g each) at each treatment visit at any point in the study. Participants will mix 1-2 packets of MCT supplement powder into liquids or semi-solid food and ingest 3 times a day during the 16-week treatment period. Participants will be randomized to the treatment sequence and will receive either the active MCT or the matching placebo first or vice versa.
11092397|NCT04129931|Experimental|Clazakizumab|Participants randomized to this arm will receive a 12.5 mg dose of Clazakizumab via a subcutaneous injection at every study visit, every 4 weeks, during the 16-week treatment period at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Clazakizumab or the matching placebo first or vice versa.
11092398|NCT04129931|Experimental|Broncho-Vaxom|Participants randomized to this arm will receive 7 mg of Broncho-Vaxom once a day on an empty stomach for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Broncho-Vaxom or the matching placebo first or vice versa.
11092399|NCT04129931|Experimental|Imatinib|At any point in the study, participants randomized to this arm will take two 100 mg Imatinib tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Participants will then take four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Participants will be randomized to the treatment sequence and will receive either the active Imatinib or the matching placebo first or vice versa.
11092400|NCT04129931|Experimental|Cavosonstat|Participants randomized to this arm will take one 50 mg Cavosonstat capsule orally twice a day for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Cavosonstat or the matching placebo first or vice versa.
11092401|NCT04129931|Experimental|Itacitinib|Participants randomized to this arm will take a JAK inhibitor for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active drug or the matching placebo first or vice versa.
11092402|NCT04129918|Experimental|experimental group|ear plugs and eye mask for 3 successive nights
11092403|NCT04129918|No Intervention|control group|without ear plugs and eye mask
11092404|NCT04129905|Experimental|Symptomatic HCM patients|30 subjects (25-26 sarcomeric, 4-5 Fabry).
11092405|NCT04129905|Active Comparator|Healthy controls subjects|10 subjects (matched in age and sex to HCM patients) to obtain reference values of endothelial dysfunction.
11092406|NCT04129892|Experimental|Course participants|Students that enroll in the Resilience-based course during their Bachelor of science or Bachelor of social studies.
11092407|NCT04129892|No Intervention|Control group- no intervention|Students in their Bachelor of science or Bachelor of social studies that did not attend the course, but agreed to fill out the study questionnaires.
11092408|NCT04129879|Experimental|1|all patients treated by conventional bare eye technique and then the use of methylene blue contrast technique to visualize endometriotic lesions perioperatively
11092409|NCT04129866|Experimental|M-IBM|M-IBM is based on a slightly modified version of the word sentence association paradigm focused on words and sentences related to common concerns among those with elevated anxiety sensitivity cognitive concerns (i.e., losing control of mental processes).
11092410|NCT04129866|Placebo Comparator|Control IBM|Control-IBM is identical to M-IBM except that the sentence that follows the cue word is not related to an anxious-threat interpretation of the cue word.
11092411|NCT04129853|Experimental|Crossover|Performing a sit to stand with the Cyberlegs Xleg and comparing with their current prosthesis.
11092412|NCT04129853|Experimental|Case study|Comparing the cyberlegs xleg with other devices.
11092413|NCT04129840|Active Comparator|Intervention 1: dual combination|dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
11092414|NCT04129840|Active Comparator|Intervention 2: triple combination|triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
11092415|NCT04129840|Placebo Comparator|Standard of care|start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point
11092416|NCT04129814|Experimental|test group|Non-surgical periodontal treatment consisted of oral hygiene instructions (OHI), single session full-mouth scaling and root planing (SRP)
11092417|NCT04129814|No Intervention|control group|no periodontal treatment was performed during the follow-up period in the control group.
11092418|NCT04129801||Prospective analysis|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
~Evaluation of Muscle Strength was used The Biodex Multi-joint System 3 dynamometer (Biodex Medical Systems, Inc., Shirley, New York, USA) to measure isokinetic extension (Ext) and flexion (Flex) MVC torques for both legs."
11092419|NCT04129788|Experimental|bisacodyl|bisacodyl 5mg tablet, once a day on three consecutive days
11092420|NCT04129788|Placebo Comparator|placebo|tablet, once a day on three consecutive days
11092421|NCT04129775|Experimental|OTO-413|
11092422|NCT04129775|Placebo Comparator|Placebo|
11092423|NCT04129762|Experimental|Diet without NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
11092424|NCT04129762|Active Comparator|Diet with NCS in irritable bowl syndrome|Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS
11092425|NCT04129762|Experimental|Diet without NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS
11092426|NCT04129762|Active Comparator|Diet with NCS in dyspepsia|Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS
11092427|NCT04129749||Real-Time Analysis Interactive Lab|walk spontaneously or at prescribed speeds of cerebral palsy patient to a standstill in a virtual and secure virtual reality environment.
11092428|NCT04129736|Other|Teriflunomide 14 mg tablets|Single arm
11092429|NCT04129723|Experimental|Perianal Crohn's patient|Stopping biological therapy
11092430|NCT04129710|Experimental|I-MRE|"Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
~Rituximab 375 mg/m2 conventional infusion d1.Etoposide 250 mg/m2 over 3 hours on day3.
~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
11092431|NCT04129710|Experimental|L-MRE|"Oral lenalidomide 25mg/day (starting dose) between days 4 and 24 of each cycle for six cycles.Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
~Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
~Rituximab 375 mg/m2 conventional infusion d1.
~Etoposide 250 mg/m2 over 3 hours on day3.
~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol."
11092432|NCT04129710|Active Comparator|MRE|"Methotrexate (standard hydration/leucovorin support) 3.5 g/m2 (0.5 g/m2 in 15 min+ 3 g/m2 in 3-hr infusion) d2.
~Rituximab 375 mg/m2 conventional infusion d1.
~Etoposide 250 mg/m2 over 3 hours on day3.
~Every 4 weeks for 1 cycle, 6 cycles will be prescribed as protocol.
~Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time will be randomly allocated to the Experimental groups."
11092433|NCT04129697|Active Comparator|Dexamethasone|
11092434|NCT04129697|Active Comparator|Methylprednisolone|
11092435|NCT04129684|Experimental|Test group|SRP+BioGaia Prodentis oil drops and lozenges
11092436|NCT04129684|Placebo Comparator|Control group|SRP+subgingival delivery of placebo and placebo lozenges
11092437|NCT04129658||Intervention|The patients are registered at PHCCs who agreed to participate into the study, the patients have provided an informed consent. The PHCCs (seventeen according to the power calculation) will receive an educational outreach visit by a cardiologist, discussing evidence-based treatment. The physician will decide afterwords if the treatment will be adjusted. Blood samples and electrocardiography will be collected before the intervention, data from the EMR will be collected before and after the intervention.
11092438|NCT04129658||Control|The control group will be the rest of the patients with heart failure in Southern Sweden. Data from the regional data base on medication and heath care consumption will be collected at base line and 6 and 12 months after.
11092439|NCT04129632|Other|IEPF intervention|Survey respondent voluntary decides to do a 4 weeks mindfulness intervention
11092440|NCT04129619|Experimental|ORP-101 50 mg|ORP-101 (50 mg) once daily
11092441|NCT04129619|Experimental|ORP-101 100 mg|ORP-101 (100 mg), once daily
11092442|NCT04129619|Placebo Comparator|Placebo|Matching placebo, once daily
11092443|NCT04129606|Other|TURBT|Transurethral resection of bladder tumour
11092444|NCT04129593|Experimental|Self Awakening|Participant will intend to wake up at a specific time before going to bed.
11092445|NCT04129593|Experimental|Snooze|Participant will set multiple alarms before bed to wake at a specific time.
11092446|NCT04129580|Experimental|Treatment-As-Usual (TAU) + reSET-O|Participants randomly assigned to this arm will receive their TAU alongside the use of the app, reSET-O.
11092447|NCT04129580|No Intervention|TAU only|Participants randomly assigned to this arm will receive their TAU only (no use of the app, reSET-O).
11092448|NCT04129567|Experimental|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
11092449|NCT04129567|Experimental|Dry air|Delivering dry air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
11092450|NCT04129567|Placebo Comparator|Humidified air|Delivering humidified air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
11092451|NCT04129567|Active Comparator|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
11092481|NCT04129424|Experimental|Pregestational diabetes mellitus_7-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092452|NCT04129554|Experimental|JNJ-73763989+ JNJ-56136379+ NA|Participants will receive fixed dose of JNJ-73763989 subcutaneous injection once every 4 weeks along with fixed dose of JNJ-56136379 tablet once daily and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) once daily up to 48 weeks.
11092453|NCT04129554|Placebo Comparator|Placebo for JNJ-73763989+ Placebo for JNJ-56136379+ NA|Participants will receive matching placebo for JNJ-73763989 subcutaneous injection once every 4 weeks with matching placebo for JNJ-56136379 once daily and NA treatment (either ETV, TDF or TAF) once daily up to 48 weeks.
11092454|NCT04129541|Active Comparator|SDD|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
11092455|NCT04129541|Active Comparator|OH|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
11092456|NCT04129528|Active Comparator|CFZ533|Randomized in a 2:1 ratio: 2 Active / 1 Placebo
11092457|NCT04129528|Placebo Comparator|Placebo|Similar in appearance to active study drug
11092458|NCT04129515|Experimental|PHASE 1: NovoTTF-200A + PEMBROLIZUMAB|"The Phase I portion of the study will have a 3 + 3 design and consist of one cohort treated
~NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.
~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
11092459|NCT04129515|Experimental|PHASE 2: NovoTTF-200A + PEMBROLIZUMAB|"NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.
~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
11092460|NCT04129502|Experimental|TAK-788 Group (Arm A)|TAK-788 160 mg, capsules, orally, once daily until the participants experience progressive disease (PD) as assessed by blinded independent review committee (IRC), intolerable toxicity, or another discontinuation criteria.
11092461|NCT04129502|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|Pemetrexed 500 mg/m^2 plus Cisplatin 75 mg/m^2, infusion, intravenously, once on Day 1 of 21-day cycle pemetrexed 500 mg/m^2 plus Carboplatin, infusion, intravenously, once at a dose calculated to produce area under curve (AUC) of 5 mg*min/mL on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/Cisplatin or pemetrexed/Carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m^2, on Day 1 of a 21-day cycle thereafter.
11092462|NCT04129489|Experimental|Sintetic Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day
11092463|NCT04129476|Experimental|Cooperative Education Program|We explore the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression.
11092464|NCT04129476|No Intervention|Control|We provide routine care for these people during pregnancy
11092465|NCT04129463|Active Comparator|SST with Iris incarceration|infants that underwent SST with iris incarceration procedure
11092466|NCT04129463|Active Comparator|Conventional trabeculotomy|infants that underwent Conventional trabeculotomy
11092467|NCT04129450|Experimental|Mindfulness Pain Program + Usual PCP Care|Participants will undergo 8 weekly 90 minute sessions of Mindfulness-Based Stress Reduction in addition to receiving usual PCP care for chronic lower back pain.
11092468|NCT04129450|Active Comparator|Usual PCP Care|Participants will receive usual PCP care for chronic lower back pain.
11092469|NCT04129437|Active Comparator|NSAID|Ibuprofen, 800 mg, one time dose
11092470|NCT04129437|Active Comparator|OMT/NSAID|Ibuprofen, 800 mg, one time dose
11092471|NCT04129437|Active Comparator|OMT alone|low velocity osteopathic manipulative medicine
11092472|NCT04129424|Experimental|Type 1 diabetes mellitus_7-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092473|NCT04129424|Experimental|Type 1 diabetes mellitus_14-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092474|NCT04129424|Experimental|Type 1 diabetes mellitus_28-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092475|NCT04129424|Experimental|Type 2 diabetes mellitus_7-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092476|NCT04129424|Experimental|Type 2 diabetes mellitus_14-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092477|NCT04129424|Experimental|Type 2 diabetes mellitus_28-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092478|NCT04129424|Experimental|Gestational diabetes mellitus_7-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092479|NCT04129424|Experimental|Gestational diabetes mellitus_14-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092480|NCT04129424|Experimental|Gestational diabetes mellitus_28-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092544|NCT04128995|Active Comparator|Bariatric Surgery|
11092545|NCT04128995|Active Comparator|Medical Therapy|
11092482|NCT04129424|Experimental|Pregestational diabetes mellitus_14-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092483|NCT04129424|Experimental|Pregestational diabetes mellitus_28-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092484|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _7-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092485|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _14-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092486|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _28-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092487|NCT04129424|Experimental|Diabetes patients in perioperative period _7-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092488|NCT04129424|Experimental|Diabetes patients in perioperative period _14-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092489|NCT04129424|Experimental|Diabetes patients in perioperative period _28-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
11092490|NCT04129411|Experimental|RFA Group|
11092491|NCT04129398|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
11092492|NCT04129385|No Intervention|Group S|Control group (Group S: 54 patients); this group will undergo the standard laparoscopic procedure (the procedure is done in Trendelenburg position). While in Trendelenburg position and prior to wound closure and with laparoscopic port valves open, the patient's abdomen will be passively deflated. The patients will be placed in supine head up position in the post anesthesia care unit (PACU).
11092493|NCT04129385|Experimental|Group T|Intervention group (Group T: 54 patients); the patients will be subject to the same maneuver as in arm 1 prior to wound closure but will be positioned in a 20 degree Trendelenburg position once fully awake and cooperative in the PACU and will remain in this position for the first 24 hours post operatively, even after they are transferred to their rooms on the American University of Beirut Medical Center (AUBMC) floors. The maximum time allowed in a straight-up position will be three 15-minute intervals over a 24-hour period (the first interval being a clear fluids intake at 12 hours postoperatively).
11092494|NCT04129372|Experimental|New Foods Take Time|"Head Start classrooms will receive New Foods Take Time, a series of five interactive weekly lessons designed to promote children's willingness to try new foods, particularly fruits and vegetables. Lessons will be delivered by nutrition educations. Children will also receive three tastings per week of the new foods discussed during the lessons."
11092495|NCT04129359|Experimental|FamilieTrivsel|Enhanced care as usual in general practice plus training in the use of the online mentalisation programme
11092496|NCT04129359|Active Comparator|control|Enhanced care as usual in general practice
11092497|NCT04129346|Experimental|Fit2ThriveMB|Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
11092498|NCT04129346|Active Comparator|Healthy Living Control|Participants in the healthy living group will receive the American Society of Cancer Oncologists smartphone app, cancer.net. They will also receive calls during the intervention period and the Fitbit following completion of 12 week assessments
11092499|NCT04129333|Experimental|Hypnosis group|A hypnosis group with standard care during the invasive procedure according to the usual practice of the care team and setting up a hypnotic accompaniment by an nurse trained beforehand and dedicated throughout the gesture. The hypnosis session will end at the same time as the invasive procedure.
11092500|NCT04129333|Placebo Comparator|Control group|A control group with standard care during the invasive procedure according to the usual practice of the care team.
11092501|NCT04129320|Experimental|Experimental Arm 1|Enoblituzumab plus MGA012
11092502|NCT04129320|Experimental|Experimental Arm 2|Enoblituzumab plus MGD013
11092503|NCT04129307|Experimental|Motor Imagery|
11092504|NCT04129307|Experimental|Double time Motor imagery|
11092505|NCT04129307|Active Comparator|Action observation|
11092506|NCT04129294|Experimental|NS-089/NCNP-02|NS-089/NCNP-02
11092507|NCT04129281|Other|Surgery|Surgery
11092508|NCT04129281|No Intervention|Active surveillance|Follow up
11092509|NCT04129268|Other|No exercise control|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
11092615|NCT04128410||T2|At 10 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092510|NCT04129268|Experimental|175kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
11092511|NCT04129268|Experimental|350kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
11092512|NCT04129268|Experimental|700kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
11092513|NCT04129255|Other|OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)|OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
11092514|NCT04129242|Active Comparator|"paired taVNS + Task Specific Training"|
11092515|NCT04129242|Active Comparator|"unpaired taVNS + Task Specific Training"|
11092516|NCT04129229|Experimental|LTR Treatment|Eligible subjects will undergo insertion of the LTR device in their tongue. Initiation of treatment will occur 7 days post insertion procedure and will be monitored over the course of 1 year.
11092517|NCT04129216|Experimental|Tamoxifen arm|for premenopausal patients
11092518|NCT04129216|Experimental|Letrozole arm|for postmenopausal patients
11092519|NCT04129216|Experimental|Exemestane arm|for postmenopausal patients
11092520|NCT04129203|Experimental|Trial arm|Mechanical thrombectomy using Versi Retriever
11092521|NCT04129190|Experimental|Single|
11092522|NCT04129164|Experimental|VIB4920 Dose 1 in Population 1|Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
11092523|NCT04129164|Placebo Comparator|Placebo in Population 1|Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
11092524|NCT04129164|Experimental|VIB4920 Dose 1 in Population 2|Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
11092525|NCT04129164|Placebo Comparator|Placebo in Population 2|Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
11092526|NCT04129151|Experimental|PALBOCICLIB and GANITUMAB|"The research study procedures include screening for eligibility and study treatment including evaluations for testing and follow up visits.
~The study treatment will be 12 months in duration and follow up will be one year from when the participant receives the last dose of study drug.
~The names of the study drugs involved in this study are:
~Palbociclib-Oral, per protocol pre determined dosage, once a day for 21 days
~Ganitumab-Intravenous, per protocol predetermined dosage, twice per cycle
~Cycle is 28 days"
11092527|NCT04129138||Observational (survey)|Participants complete a survey over 30 minutes.
11092528|NCT04129125|Experimental|ZOOM Reperfusion Catheter|
11092529|NCT04129125|Active Comparator|Trevo® Pro or Solitaire™ Stent Retrievers|
11092530|NCT04129112||Patients without body movements|Patient who, under general anesthesia without curare agents, during surgery has no body movements
11092531|NCT04129112||Patients with body movements|Patient who, under general anesthesia without curare agents, during surgery has any body movements that are no reflexes movements
11092532|NCT04129099|Experimental|CAR-T treatment group|The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
11092533|NCT04129086|Experimental|Ketamine plus Usual care|
11092534|NCT04129086|Active Comparator|Usual care|
11092535|NCT04129073||Cardiac arrest patients admitted to Intensive Care treatment|Intensive Care treatment; Utilization of neuroprognostication tools
11092536|NCT04129060|Experimental|Mecamylamine Challenge|One of the two study days will be the oral mecamylamine.
11092537|NCT04129060|Experimental|Placebo Challenge|One of the two study days will be the oral placebo.
11092538|NCT04129047|Experimental|Omnichroma (one shade universal) composite by Tokuyama|class V cavities will be made under isolation. Omnichroma (one shade universal) composite by Tokuyama will be placed according to guidelines.
11092539|NCT04129047|Active Comparator|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA)|class V cavities will be made under isolation. A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA) will be placed according to guidelines.
11092540|NCT04129034|Experimental|Treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
11092541|NCT04129021|Experimental|High-resolution retinal imaging through adaptive optics|High-resolution retinal imaging through adaptive optics, full field OCT and holographic systems
11092542|NCT04129008|Experimental|Indobufen|
11092543|NCT04129008|Active Comparator|Aspirin|
11092546|NCT04128982||Videolaryngoscopy|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
11092547|NCT04128969|Experimental|Carnitine supplementation (CS+)|Carnitine supplementation in liquid form, sugar free.
11092548|NCT04128969|Placebo Comparator|Placebo (CS-)|Placebo comparator liquid similar in appearance and taste to CS+.
11092549|NCT04128956|Experimental|Aspirin®|"To show if a combination therapy of rivaroxaban plus Aspirin® is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy.
~To demonstrate tolerability of combination therapy of Aspirin® plus rivaroxaban in long-term treatment."
11092550|NCT04128956|No Intervention|Control group|Observational study of standard of care anticoagulation (rivarobaban dosis defined in the clinical routine).
11092551|NCT04128930|Experimental|Fixed CPAP titration at home|"Patients will start CPAP treatment with a pressure that is calculated by the following formula (predicted pressure = (0.13 x BMI) + (0.16x neck circumference in cm) + (0.04 x AHI)) with a maximal pressure of 10 cmH2O. After 3 nights and after 7 nights, CPAP data will be remotely evaluated and pressure will be adapted based on the following rules:
~After 3 nights: median obstructive AHI<5/h: decrease pressure with 2 cmH2O; median obstructive AHI>5/h: increase with 2cmH2O
~After 7 nights: median obstructive AHI>5/h of 4 nights after last adaptation: increase with 2 cmH2O"
11092552|NCT04128930|Active Comparator|APAP titration at home|Patients will start CPAP treatment with an auto-adjusting CPAP device with pressure levels between 4 and 12 cmH2O. After 7 nights of titration, the optimal pressure will be determined by analyzing the median of the nightly pressure that included 95% of the periods (percentile 95). CPAP treatment will be continued with this fixed optimal pressure.
11092553|NCT04128917|Experimental|Tegoprazan 50 mg|Tegoprazan 50 mg Triple Therapy
11092554|NCT04128917|Experimental|Tegoprazan 100 mg|Tegoprazan 100 mg Triple Therapy
11092555|NCT04128917|Active Comparator|RAPAE01|RAPAE01 Triple Therapy
11092556|NCT04128904|Active Comparator|Standard in vitro fertilisation (IVF)|"Oocytes are fertilised with standard IVF. For details please see Project Description."
11092557|NCT04128904|Active Comparator|Intracytoplasmic sperm injection (ICSI)|"Oocytes are fertilised with ICSI. For details please see Project Description."
11092558|NCT04128891|Experimental|Sacubitril/Valsartan|30 participants to be administered Sacubitril/Valsartan (Entresto) tablets, minimum dose of 49/51mg or maximum dose of 97/103 mg twice daily for the duration of the study (two years).
11092559|NCT04128891|Active Comparator|Valsartan|30 participants to be administered Valsartan tablets, minimum dose 80 mg or maximum dose of 160 mg twice daily for the duration of the study (two years).
11092560|NCT04128878||Atrial Fibrillation Cohort|Adult patients with known or new diagnosis of either paroxysmal or persistent atrial fibrillation seen at the electrophysiology outpatient clinic and admitted to the electrophysiology service for initiation of anti-arrhythmic medications (dofetilide or sotalol).
11092561|NCT04128852|Other|MagnetOs Putty|MagnetOs Putty will be applied according to the latest Instructions For Use (IFU) approved in Europe. Specifically, MagnetOs Putty will be used as bone void filler.
11092562|NCT04128826|Experimental|Partial Range of Motion (PROM)|
11092563|NCT04128826|Experimental|Full Range of Motion (FROM)|
11092564|NCT04128826|No Intervention|Control (CON)|
11092565|NCT04128813|Active Comparator|Vertical whole body vibration platform.|Use of a rotational whole body vibration platform.
11092566|NCT04128813|Active Comparator|Rotational whole body vibration platform|Use of a rotational whole body vibration platform.
11092567|NCT04128813|No Intervention|Control group|No intervention.
11092568|NCT04128800|Experimental|Apatinib and S-1 group|
11092569|NCT04128787|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
11092570|NCT04128787|Experimental|Treatment Sequence BCAD|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
11092571|NCT04128787|Experimental|Treatment Sequence CABD|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
11092572|NCT04128774||GBM-dexa|Participants with clinical diagnosis of GBM, that require dexamethasone due to neurological deficits. Dose is based on the clinical judgement of the treating physician but should be given at least two weeks. Dexamethasone is given once a day.
11092573|NCT04128774||GBM-control|Participants with clinical diagnosis of GBM not requiring dexamethasone treatment.
11092574|NCT04128761|Experimental|Scarcity Narrative|Participants assigned to the scarcity group will be asked to read and consider a hypothetical narrative about a sudden loss of resources.
11092575|NCT04128761|Sham Comparator|Neutral Narrative|Participants assigned to the neutral group will be asked to read and consider a hypothetical narrative about a neutral change in resources.
11092576|NCT04128748|Experimental|Treatment (CPX-351, quizartinib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3 and 5 and quizartinib PO on days 6-19. Patients who do not respond to treatment during cycle 1 receive CPX-351 IV on days 1 and 3 and quixartinib PO on days 6-19 during cycle 2. Treatment repeats every 28 days for up 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive CPX-351 over 90 minutes on days 1 and 3 and quizartinib PO on days 4-28 of cycle 1. Treatment with CPX-351 repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive quizartinib PO on days 1-28 in the absence of disease progression or unacceptable toxicity."
11092616|NCT04128410||T3|At 15 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092577|NCT04128722|Experimental|Sirolimus 1mg/mL|Application of 1 mg/mL sirolimus solution, 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation, the experimental intervention versus usual care (no treatment), the control condition.
11092578|NCT04128722|No Intervention|Control condition|Usual care, i.e. no intervention
11092579|NCT04128709|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
11092580|NCT04128696|Experimental|Participants receiving GSK3359609 and pembrolizumab|Participants will be administered GSK3359609 (humanized anti-ICOS immunoglobulin G4 [IgG4] monoclonal antibody [mAb]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.
11092581|NCT04128696|Active Comparator|Participants receiving placebo and pembrolizumab|Participants will be administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.
11092582|NCT04128683|Experimental|Healthy Controls|Healthy Control Subjects
11092583|NCT04128683|Experimental|Anorexia Nervosa|Anorexia Nervosa Subjects
11092584|NCT04128670|Experimental|Kinesiotape (KT)|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. The tape will be applied with a tension of 10-20%.
11092585|NCT04128670|Placebo Comparator|Placebo Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
11092586|NCT04128670|No Intervention|No Tape|This group will not receive any intervention.
11092587|NCT04128644|Other|Standard of care+Thoughts & health|12 sessions of Thoughts & Health. Baseline questionnaires and follow up assessments
11092588|NCT04128644|Other|Standard of care|Baseline questionnaires and follow up assessments, intervention as usual Student Health
11092589|NCT04128631||PET/CT|group of patients will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels.
11092590|NCT04128618|Experimental|Active NMES|
11092591|NCT04128618|Sham Comparator|Modified NMES sham|
11092592|NCT04128605|Experimental|Intervention: Suprascapular nerve block (SSNB)|SSNB performed by skilled interventionist who is not blinded for safety reason. 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline.
11092593|NCT04128605|Active Comparator|Control: Intraarticular shoulder steroid injection (IAS)|"IAS performed by skilled interventionist who is blinded on patient's initial measurement.
~40 mg of Triamcenolone Acetate + 2 ml of Lidocaine 1%"
11092594|NCT04128592|Other|Wheezing|
11092595|NCT04128592|Other|Rattling|
11092596|NCT04128579|Experimental|EQ001 Type A cohort|EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg).
11092597|NCT04128579|Experimental|EQ001 for Type B cohort|EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 13 doses (up to 3 cohorts with dosing to be determined in the range of 0.8 -- 3.2 mg/kg).
11092598|NCT04128566|Experimental|Group 1: healthy subjects aged between 20 and 30 years|healthy subjects aged between 20 and 30 years
11092599|NCT04128566|Experimental|Group 2: previous ACL injury aged between 20 and 30 years|subjects with previous Anterior cruciate Ligament (ACL) injury aged between 20 and 30 years
11092600|NCT04128566|Experimental|Group 3: healthy subjects aged between 40 and 60 years|healthy subjects aged between 40 and 60 years
11092601|NCT04128566|Experimental|previous ACL injury aged between 40 and 60 years|subjects with previous ACL injury aged between 40 and 60 years
11092602|NCT04128553|Experimental|Intervention motivational interview group|Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.
11092603|NCT04128553|No Intervention|Control|The control group will be pre-tested and post-tested and the average number of steps will be calculated with a pedometer.
11092604|NCT04128540|Other|Control group|This group will receive fentanyl infusion only
11092605|NCT04128540|Active Comparator|ESPB group|This group will receive fentanyl infusion plus Ultrasound guided ESPB
11092606|NCT04128514||Enrolled subjects|"Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.
~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects."
11092607|NCT04128501|Experimental|Treatment (azacitidine, venetoclax)|Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11092608|NCT04128462|Experimental|MNK6105 + SoC|"Participants will receive standard of care (SoC), along with MNK-6105 delivered by continuous intravenous (IV) infusion as follows:
~Loading dose: 20 g infused over 6 hours
~Intermediate dose: 15 g infused over 18 hours
~Maintenance dose: 15 g infused over 24 hours for up to 4 days"
11092609|NCT04128462|Placebo Comparator|Placebo + SoC|Participants will receive SoC, along with continuous IV infusion of matching placebo for 5 days.
11092610|NCT04128449|Experimental|docosahexaenoic acid|1,66 grams/24 hours (5 dragees)
11092611|NCT04128449|Placebo Comparator|Placebo|sunflower oil (5 dragees)
11092612|NCT04128436|Other|Progesterone levels|Patients will be divided into groups according to quartiles (25/50/75) of progesterone levels. Optimal range of progesterone levels for ongoing pregnancy rate will be calculated.
11092613|NCT04128423|Experimental|AMV564|
11092614|NCT04128410||T1|At 5 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092617|NCT04128410||T4|At 20 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092618|NCT04128410||T5|At 25 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092619|NCT04128410||T6|At 30 minutes after flurbiprofen axetil injected intravenously, 14 patients' samples were required to be collected,including 7 younger patients
11092620|NCT04128410||T7|At 35 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092621|NCT04128410||T8|At 40 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092622|NCT04128410||T9|At 45 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092623|NCT04128410||T10|At 50 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
11092624|NCT04128397|Experimental|transcranial magnetic stimulation（TMS）|arm:experimental:perform TMS to patients for 5days ,3times a day(0 minute ,15 minute ,60 minute )
11092625|NCT04128384|Other|EPS arm|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
11092626|NCT04128371|Experimental|1|Subjects will receive mepolizumab 700 mg IV x 3 doses at approximately one month intervals, at predicted eosinophil nadir (2-3 weeks after peak), at study visits 4, 6, and 7.
11092627|NCT04128358|Experimental|Group on high dose dexamethasone, cyclosporin and rituximab|Egyptian patients with idiopathic thrombocytopenic purpura on high dose dexamethasone together with cyclosporine and rituximab.
11092628|NCT04128358|Active Comparator|Group on steroids only|Egyptian patients with idiopathic thrombocytopenic purpura on parenteral or oral steroids.
11092629|NCT04128358|Placebo Comparator|Placebo group|Egyptian normal healthy volunteers who share on the President Initiative (100 Million Health).
11092630|NCT04128345||SBN arm|We will evaluate the feasibility of using an integrated navigation system incorporating pre-operative MRI and intraoperative ultrasound images
11092631|NCT04128332|Other|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
11092632|NCT04128319|Experimental|T-Guard Treatment|Patients will receive T-Guard for treatment of steroid-refractory acute GVHD.
11092633|NCT04128306|Experimental|Patient group|"A total of 120 patients with brain tumors will be divided into our two groups, divided as follows:
~In the group Pre-Per, 20 patients will be included by localization of electrical stimulation (60 patients in total). A patient who would be stimulable in two different areas could be included in two different groups.
~In the group Pre-End, the subjects will be distributed by localization of the brain tumor, by lobe. A total of 20 participants will be included per lobe, corresponding to the frontal, temporal or parietal lobes (as a reminder, a tumor in the occipital lobe is an exclusion criterion), for a total of 60 participants"
11092634|NCT04128306|Active Comparator|Control group|A maximum of 120 healthy matched sex and age subjects with patients will also be included
11092635|NCT04128293|Experimental|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11092636|NCT04128293|Experimental|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11092637|NCT04128293|Experimental|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11092638|NCT04128293|Experimental|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
11092639|NCT04128280|Experimental|Test Group|Test group: Patients will receive a surgery: transurethral dilation of prostate with a columnar balloon
11092640|NCT04128280|Active Comparator|Control Group|Control group: Patients will receive a surgery: transurethral incision of bladder neck.
11092641|NCT04128267|Experimental|Response to Pain|Brain's response to pain using magnetic resonance imaging (MRI)
11092642|NCT04128254|Experimental|Apixaban|
11092643|NCT04128254|Placebo Comparator|Placebo|
11092644|NCT04128241||Panel of Spanish consumers|A panel of Spanish consumers recruited from various audited and validated internet databases.
11092645|NCT04128228|Other|Alcohol use disorder|All patients with alcohol use disorder will receive the same 8 week outpatient treatment.
11092646|NCT04128215|Active Comparator|Older Men|
11092647|NCT04128215|Active Comparator|Postmenopausal Women|
11092995|NCT04125823|Active Comparator|Conventional physiotherapy program|
11092649|NCT04128202|Experimental|Sunnyside Plus|An online intervention to better manage mood and promote and support breastfeeding during and after pregnancy.
11092650|NCT04128189|Active Comparator|Transplanted subject|In addition to receiving standard dose (2) of Shingrix prior to transplantation, participant may receive a 3rd dose several months after transplantation if they meet criteria related to no rejection.
11092651|NCT04128189|Sham Comparator|Non-Transplanted subject|Receives standard Shingrix dose (2), but not transplanted within 16 month time frame post-dose, so does not receive additional Shingrix dose.
11092652|NCT04128176|Experimental|Rituximab combined with Omalizumab|All patients will receive daily doxycycline, nicotinamide, and high-potency topical steroids. Additionally, all patients will receive rituximab combined with omalizumab.
11092653|NCT04128163|Experimental|QL1206|"QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times.
~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
11092654|NCT04128163|Placebo Comparator|Placebo|"placebo injection (1ml) by subcutaneous injectionevery 6 month for two times.
~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
11092655|NCT04128137|Experimental|fludrocortisone|FLUCORTAC® 50 μg (tablet breackable). One tablet during the first week. Then 2 tablets during the second week. Then 3 tablets during the third week and finally 4 tablets during the 4th week. Maximum of 200μg/day.
11092656|NCT04128137|Placebo Comparator|Placebo|placebo of flucortac and same diagram of administration
11092657|NCT04128124||self-extubation|patients receiving invasive mechanical ventilation who develops an episode of self-removal (voluntary) of the endotracheal tube. Excluding those accidentally removed.
11092658|NCT04128124||spontaneous breathing trial|patients who, according to the attending physician, are clinically ready to initiate and begin a protocolized test (acording to the institutions or unit) to evaluate the readiness to be liberated from mechanical ventilation.
11092659|NCT04128111||Acute Exacerbation|Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient's usual status that is sufficient to require a change in treatment.
11092660|NCT04128111||Non-acute exacerbation|Non-acute exacerbation of asthma includes chronic remission and clinical delays.Clinical remission stage refers to an absence of wheezing, chest tightness, cough and other symptoms for more than 1 year.Chronic duration refers to that symptoms, such as wheezing, chest tightness, cough and so on, attack at different frequency and different degrees every week.
11092661|NCT04128111||Healthy Volunteer|Health is not only the absence of disease or infirmity, but also a state of physical, mental, and social perfection.
11092662|NCT04128085|Experimental|TQB3804|TQB3804 tablet administered orally , once daily in 28-day cycle.
11092663|NCT04128072|Experimental|Mogamulizumab + Total Skin Electron Beam Therapy (TSEB)|"Treatment with mogamulizumab will be continued until disease progression or the occurrence of another withdrawal criterion as specified in the protocol.
~TSEB will start 28 days after mogamulizumab cycle 2 day 1 at a dose of 12 Gy in 8 fractions over two weeks (4 fractions per week)."
11092664|NCT04128059|Experimental|phase 1, component 1|component 1 of vaccine
11092665|NCT04128059|Experimental|phase 1, half dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half dose
11092666|NCT04128059|Experimental|phase 1, full dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in full dose
11092667|NCT04128059|Experimental|phase 2, selected dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in selected dose
11092668|NCT04128059|Placebo Comparator|phase 2, placebo|vaccination with placebo with an interval of 21 days
11092669|NCT04128046|Experimental|PRFM|Hemi-face injected with PRFM. PRFM was produced from 9 mL of blood (Healeon Medical, Inc).
11092670|NCT04128046|Placebo Comparator|Saline|Hemi-face injected with saline.
11092671|NCT04128033|Experimental|puncture of the RP6 point|The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
11092672|NCT04128033|Placebo Comparator|puncture of the placebo point|The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
11092673|NCT04128020|Experimental|Nivolumab|Nivolumab: 0.3, 0.5, or 1.0 mg/kg IV, days 1 & 15
11092674|NCT04128020|Experimental|Nivolumab + Azacitidine|Azacitidine 8,16, 24 mg/m^2, days 1-5 Nivolumab @MTD (1.0 mg/kg or lower), days 8 & 15
11092675|NCT04128007|Experimental|ARQ-154 foam 0.3%|
11092676|NCT04128007|Placebo Comparator|ARQ foam VehicleRQ-154 foam Vehicle|
11092677|NCT04127994|Experimental|3 meals|"Patients with type 2 diabetes will be submitted to a 3 meal regimen for 3 months.
~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
11092678|NCT04127994|Experimental|6 meals|"Patients with type 2 diabetes will be submitted to a 6 meal regimen for 3 months.
~We will compare their basal complete blood chemistry, somatometric measurements versus the same variables after 3 months. Glycemic levels and glycemic variability will also be measured."
11092679|NCT04127981|Active Comparator|Patients with cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia.
11092680|NCT04127981|Active Comparator|Patients without cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC) or pancreatic cancer without cachexia.
11092681|NCT04127968|Experimental|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
11092682|NCT04127968|Placebo Comparator|control group|Septic children with vitamin A deficiency who will receive placebo.
11092683|NCT04127955|Experimental|Intervention|"Quasi-experimental design with one-group, pre-post test
~A nurse-led Theory of Planned Behavior based Physical Activity intervention consists of five component. These are a health education, a group walking, an individually tailored counseling session grounded on motivational interview technique, having the individuals keep track their physical activity levels with a pedometer, and use of physical activity pamphlet and posters as a reminder was planned. This intervention will be completed in eight weeks."
11092996|NCT04125810|Experimental|Probiotic|Probiotic
11092684|NCT04127942|Experimental|platelet-rich plasma injection|1cc platelet-rich plasma(PRP) injection in the superior temporomandibular disk joint space by ultrasound guidance.
11092685|NCT04127942|Placebo Comparator|normal saline injection|1cc normal saline injection in the superior temporomandibular disk joint space by ultrasound guidance.
11092686|NCT04127929|Active Comparator|Glass carbomer|
11092687|NCT04127929|Active Comparator|Tokuyama Estelite Posterior|
11092688|NCT04127903|Experimental|the Length of Right Main Stem Bronchus >=15mm|
11092689|NCT04127903|Experimental|the Length of Right Main Stem Bronchus <15mm|
11092690|NCT04127890|Experimental|Intervention Arm|1.5 L of ELO Water to be drunk daily for 24 weeks
11092691|NCT04127890|Placebo Comparator|Control Arm|1.5 L of placebo bottled drinking water to be drunk daily for 24 weeks
11092692|NCT04127877|Experimental|CHRONIC HEMODIALYSIS PATIENTS, NICAS-ASSISTED MONITORING|Chronic hemodialysis patients, NICAS-assisted monitored
11092693|NCT04127877|No Intervention|Control hemodialysis patients|Chronic hemodialysis patients, conventional clinical care and monitoring.
11092694|NCT04127851|Experimental|Sodium Hyaluronate 0.15%|
11092695|NCT04127851|Active Comparator|Cyclosporin 0.05%|
11092696|NCT04127851|Other|Combination therapy|
11092697|NCT04127838|Experimental|Low Vision Occupational Therapy|The anticipated low vision occupational therapy intervention strategy includes training participants to compensate for their vision more effectively for increased participation in ADLs and IADLs.
11092698|NCT04127825|Experimental|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a blood conservation technique that entails the removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement.
11092699|NCT04127825|No Intervention|Standard of Care|Standard of care for blood volume maintenance during surgery
11092700|NCT04127812|Experimental|Savor the Flavor|"The Savor the Flavor curriculum is a series of five interactive lessons designed to teach children how to savor foods and slow down while eating by focusing on the sensory experience of eating. The intervention also teaches attention control techniques so that children are better able to delay consumption of high energy, low nutrition foods, when appropriate, as well as general mindfulness practices (e.g. breathing exercises). Lessons are delivered in the Head Start classroom by a nutrition educator."
11092701|NCT04127799|Experimental|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
11092702|NCT04127799|Active Comparator|Subjects with AF conventional treatment|Subjects with AF via conventional clinic visit according to the latest relevant guidelines
11092703|NCT04127786|Experimental|Group 1: VRVg-2|VRVg-2, 3 injections at Day 0, Day 7, and Day 28
11092704|NCT04127786|Active Comparator|Group 2: Verorab|Verorab, 3 injections at Day 0, Day 7, and Day 28
11092705|NCT04127786|Active Comparator|Group 3: Imovax Rabies|Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28
11092706|NCT04127773||NEX group|oro gastric tube placement using NEX insertion length predictor
11092707|NCT04127773||NEMU group|oro gastric tube placement using NEMU insertion length predictor
11092708|NCT04127760|No Intervention|control|Follow-up at several time frames
11092709|NCT04127760|Experimental|treatment|Radiotherapy would be carried out. Follow-up at the same time frames as the control arm
11092710|NCT04127747|Active Comparator|Standard dose group|
11092711|NCT04127747|Experimental|Individualized dose group|
11092712|NCT04127721|Experimental|Prevention (itacitinib, busulfan, fludarabine, ASCT)|"CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.
~ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.
~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor)."
11092713|NCT04127708|Placebo Comparator|sham acupuncture|Ten acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
11092714|NCT04127708|Active Comparator|acupuncture|en acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
11092715|NCT04127695|Experimental|ABBV-0805 Dose 1 or Placebo|Participants will receive ABBV-0805 Dose 1 or Placebo.
11092716|NCT04127695|Experimental|ABBV-0805 Dose 2 or Placebo|Participants will receive ABBV-0805 Dose 2 or Placebo.
11092717|NCT04127695|Experimental|ABBV-0805 Dose 3 or Placebo|Participants will receive ABBV-0805 Dose 3 or Placebo.
11092718|NCT04127695|Experimental|ABBV-0805 Dose 4 or Placebo|Participants will receive ABBV-0805 Dose 4 or Placebo. Note: This dosing group may be added after a review of data from dosing groups 1-3.
11092719|NCT04127682||Physicians|Physicians dealing with cases of pediatrics' acute URIs at PHC units either urban or rural, insurance hospitals or Assiut university hospitals.
11092781|NCT04127292|Experimental|Emotional Self Awareness Group (Clinician participants)|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
11092720|NCT04127669|Experimental|Arm A|Active substance treatment with OSU6162. Starting dose for all patients in the OSU6162 treatment group is 15 mg BID. The dose is taken orally as one circular coated tablet of 15 mg together with a light meal in the morning and one tablet around lunch unless otherwise agreed upon. In order to aim at optimal dosing of OSU6162, some flexibility is allowed. The investigators are able to modify the dose for individual patients based on how well the treatment is tolerated and how well the patients respond to it. In the case where there is no clear response, the dose can be increased to maximally 30 mg BID (intermediate dosage is allowed) after 4 weeks of treatment; it is also possible to decrease the dose to a lower level (even below 15 mg BID) if a higher dose is not tolerated and/or there is a perceived weakened therapeutic effect with the higher dose. All dose changes will be performed while retaining the blind.
11092721|NCT04127669|Placebo Comparator|Arm B|Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
11092722|NCT04127656|Experimental|Amino Acid-Based Experimental Study Formula|Not commercially available amino acid-based study formula
11092723|NCT04127643||S-ICD patients|patients who have received the EMBLEM S-ICD system
11092724|NCT04127630||mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
11092725|NCT04127617|Experimental|Osteopathic Manipulative Treatment|the treatment group will receive 5 osteopathic manipulative treatment. The treatment will last 45 - 60 minutes with the following frequency: the subjects will receive 3 OMT on a weekly basis, the two following twice weekly. The osteopathic treatment protocol will therefore last 7 weeks. Each individual patient will be taken in charge by two operators during the entire duration of the study.
11092726|NCT04127617|Active Comparator|Nursing Care|The conventional treatment consists in educational nursing care.
11092727|NCT04127604|Experimental|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
11092728|NCT04127604|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
11092729|NCT04127591||myocardial infarction group|Patients admitted with the diagnosis of myocardial infarction.
11092730|NCT04127591||Blank control group|Patients admitted without the diagnosis of myocardial infarction.
11092731|NCT04127578|Experimental|Low dose|
11092732|NCT04127578|Experimental|High dose|
11092733|NCT04127565||Pre-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2013 to March 2014.
~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units."
11092734|NCT04127565||Post-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2015 to March 2016.
~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units.
~Additionally analysis of all ambulance calls with telemedical support."
11092735|NCT04127552||Patients with non-functioning adrenal adenoma|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels lower than 50 nmol/L
11092736|NCT04127552||Patients with pACS receiving conservative management|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving conservative management
11092737|NCT04127552||Patients with pACS receiving adrenalectomy|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving adrenalectomy according to the 2016 European Society of Endocrinology guidelines
11092738|NCT04127552||Healthy controls|Patients without adrenal masses
11092739|NCT04127539|Experimental|Intervention|Will start a Strong & Steady group exercise programme immediately after baseline testing.
11092740|NCT04127526|Active Comparator|Baseline Period of 2 weeks|2 participants will be randomly allocated to a baseline of 2 weeks before commencing CONNECT intervention.
11092741|NCT04127526|Active Comparator|Baseline Period of 3 weeks|2 participants will be randomly allocated to a baseline of 3 weeks before commencing CONNECT intervention.
11092742|NCT04127526|Active Comparator|Baseline Period of 4 weeks|2 participants will be randomly allocated to a baseline of 4 weeks before commencing CONNECT intervention.
11092743|NCT04127513|Experimental|12% AMMONIUM LACTATE|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 12% ammonium lactate. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
11092744|NCT04127513|Active Comparator|10% UREA|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 10% urea. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
11092745|NCT04127500|Experimental|DEX group|use DEX
11092746|NCT04127500|No Intervention|control group|use placebo
11092747|NCT04127487||Periodontitis group|35 Generalized chronic periodontitis subjects without coronary heart diseases
11092748|NCT04127487||periodontitis with CAD group|35 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease
11092749|NCT04127474||Group I|25 Generalized chronic periodontitis subjects without coronary heart disease.
11092750|NCT04127474||Group II|25 Generalized chronic periodontitis subjects diagnosed with coronary heart disease.
11092751|NCT04127474||Group III|25 Periodontally healthy subjects diagnosed with coronary heart disease.
11092752|NCT04127461|Active Comparator|Open vessel harvesting|Arm 1 is the conventional procedure
11092753|NCT04127461|Experimental|Medtronic endoscope|Arm 2 - is the minimally invasive procedure
11092997|NCT04125810|Placebo Comparator|Placebo|Placebo
11092756|NCT04127435||High-Dose-Rate 192Ir Brachytherapy|"All patients underwent computed tomography (CT) 3-5 days before surgery. The collimation is 2.5 mm and CT Planning System.
~Delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs);
~Determination of the needle tract of the implanted insertion direction, distribution, and depth. Then calculation of the dose distribution of the target volume and OARs.
~Depending on B-TPS data, we establish a digital model for the individual template.
~Local anesthesia or intraspinal anesthesia was induced in all patients. The three-dimensional printing noncoplanar templates (3D-PNCT) was placed on the surface of the treatment area of the patient. The 3D-PNCT was aligned accurately with the outer-contour features. Through the guide hole of the 3D-PNCT, we inserted to pre-planned depths.
~Delineation of the GTV and design planning .
~Connect the source tube and 192Ir high dose rate interorganizational brinotherapy
~At the end pressed to stop bleeding."
11092757|NCT04127422||Study group|"Patients presenting with current symptoms related to the breast. Adult females aged 18-39 years presenting to the breast outpatient clinic with either mastalgia, nodularity and/or discharge.
~A questionnaire, physical examination and bilateral breast ultrasonography will be obtained for all patients.
~A- The questionnaire will contain the following items:
~symptoms related to the breast.
~other medical history.
~menstrual history.
~obstetric history.
~rapid screener for beverages and fast food consumption.
~rapid screener for vegetables and fruit consumption.
~B- Physical examination will specifically records the following:
~breast tender point(s).
~breast nodularity.
~nipple discharge.
~weight, height, body mass index (BMI).
~C- bilateral breast ultrasonography for all patients.
~D- breast biopsy when clinically indicated as per hospital policy."
11092758|NCT04127422||Control group|"Age-matched healthy volunteers with no current medical conditions. Adult females aged 18-39 years with no current breast problems. These healthy volunteers will be asked to complete the same questionnaire as per the Study group and have anthropometric measure.
~A- The questionnaire will contain the following items:
~other medical history.
~menstrual history.
~obstetric history.
~rapid screener for beverages and fast food consumption.
~rapid screener for vegetables and fruit consumption.
~B- Physical examination will specifically records the following:
~1- weight, height, body mass index (BMI)."
11092759|NCT04127409|Placebo Comparator|Control Chicken-meat & Control Eggs|Participants will be provided with control chicken-meat and control eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three control eggs/week, for 6 months.
11092760|NCT04127409|Experimental|Control Chicken-meat & Omega-3 Eggs|Participants will be provided with control chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the control chicken-meat, and to eat at least three omega-3-enriched eggs/week, for 6 months.
11092761|NCT04127409|Experimental|Omega-3 Chicken-meat & Control Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and control eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three control eggs/week, for 6 months.
11092762|NCT04127409|Experimental|Omega-3 Chicken-meat & Omega-3 Eggs|Participants will be provided with omega-3-PUFA enriched chicken-meat and omega-3-PUFA enriched eggs, and will be requested to eat at least three portions/week of the omega-3-PUFA enriched chicken-meat, and to eat at least three omega-3-PUFA enriched eggs/week, for 6 months.
11092763|NCT04127396|Experimental|lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
11092764|NCT04127396|Active Comparator|Sorafenib and TACE|Patients in Sorafenib + TACE group will take oral sorafenib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
11092765|NCT04127383|Experimental|ABCC-tool|The intervention group will use the ABCC-tool during consultation with their healthcare provider. Healthcare providers in the intervention group will receive a short instructional film about the ABCC-tool before the start of the study. Additionally, healthcare providers from 12 practices will be invited for interviews, evaluating the context and process of implementation.
11092766|NCT04127383|No Intervention|Usual care|The control group will receive usual care, and healthcare providers will not be instructed
11092767|NCT04127370|Experimental|Obese Patients With NAFALD Undergoing Bariatric Surgeries|
11092768|NCT04127357|Other|A - Control|Brushing with 1450 ppm fluoride toothpaste.
11092769|NCT04127357|Experimental|B - Test|Resin sealing (FluroShield, Dentsply, Brazil).
11092770|NCT04127344|Experimental|Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.
~Patients randomised to a music therapy intervention will receive an individualised music therapy intervention."
11092771|NCT04127344|No Intervention|Non-Music Therapy Intervention|"Patients enrolled will be randomised between two arms: Music Therapy Intervention and Non-Music Therapy Intervention.
~Patients allocated to Non-Music Therapy Intervention received standard treatment."
11092772|NCT04127331|Active Comparator|Routine|Patients who are scheduled for routine outpatient surgery.
11092773|NCT04127331|Active Comparator|Urgent|Patients who are scheduled for urgent surgery.
11092774|NCT04127331|Active Comparator|Emergent|Patients who are scheduled for emergency surgery.
11092775|NCT04127318|Experimental|Pedaling Group|During their 30 minute immunotherapy infusions, participants will pedal using a stationary cycle ergometer. Participants will be allowed to determine their pedaling intensity and cadence, however, will be encouraged to reach the established goal intensity level. A research personnel will monitor the patient's heart rate, blood pressure, and RPE at baseline and every 10 minutes throughout the pedaling session. Participants will also have treatment response biomarkers gathered at baseline and before and within 10 minutes of completing their first and fourth immunotherapy infusions. Lastly, participants will complete both a physical activity questionnaire and a quality of life questionnaire at baseline and following their fourth treatment.
11092776|NCT04127305||VA ECMO|Patients will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
11092777|NCT04127305||VA EMCO + RRT|Patients with RRT will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
11092778|NCT04127305||VV ECMO|Patients will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
11092779|NCT04127305||VV ECMO + RRT|Patients with RRT will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
11092780|NCT04127305||Control|Patients will be included within 24-48h after start of an antiinfective therapy
11092782|NCT04127292|No Intervention|Emotional Self Awareness Group (Patient participants)|Patients provided care by clinicians trained in ESA
11092783|NCT04127292|Sham Comparator|Control Group (Clinician participants)|The Control group CPs will engage in the same two VHI scenarios and will complete the TRQ-SF in response to each scenario without receiving the ESA feedback
11092784|NCT04127292|No Intervention|Control Group (Patient participants)|Patients provided care by clinicians not receiving ESA feedback
11092785|NCT04127279|Experimental|Enriched Cream|The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.
11092786|NCT04127279|Active Comparator|Placebo Cream|Cream devoid of essential oils, self-administered
11092787|NCT04127253|Experimental|transcranial direct current plus Brain training tools|20 minutes of transcranial direct current stimulation along with the application of motor imagery and action observation
11092788|NCT04127253|Placebo Comparator|Placebo transcranial direct current plus Brain training tools|A placebo intervention of direct transcranial stimulation being active during 15 seconds and then it will be turned off the rest of the time until 20 minutes. This group will also carry out the training of action observation and motor imagery.
11092789|NCT04127253|Sham Comparator|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
11092790|NCT04127240|Experimental|Meat assignment in DASH intervention|Participants consumed 3 ounces of red meat per day as a part of the DASH diet.
11092791|NCT04127240|Experimental|Meat allocation in DASH intervention|Participants consumed 6 ounces of red meat per day as a part of the DASH diet.
11092792|NCT04127227|Experimental|Sintilimab With P-GemOx|Sintilimab, 200mg, d1, intravenous drip; pegaspargase, 2000U/m2, d1, intravenous drip; gemcitabine, 1000mg/m2, d1,d8, intravenous drip; oxaliplatin, 130mg/m2, d1, intravenous drip; All patients received up to 6 treatment cycles of 21 days. Stage IV patients with localized disease will be treated with consolidative RT. Patients with CR or PR will receive Sintilimab maintenance therapy.
11092793|NCT04127201|Experimental|Online intervention, en_línea|Participants will be provided with a username and a password to acess to a website. en_línea program is an online adaptation of the LEARN program. The five treatment areas are: Lifestyle, Exercise, Attitudes, Relationships and Nutrition. We have designed and developed a website (www.programaenlinea.org) with 17 weekly treatment sessions and an exclusive mobile application for self-recording.
11092794|NCT04127201|Active Comparator|Standard group therapy|Participants in this arm will received a 10 sessions of standard primary care group therapy. Sessions 1 and 2 will be weekly and sessions from 3 to 10 will be biweekly. Sessions, between 8 and 10 participants, will be conducted by a specialized psychologist and they will last 90 minutes. Treatment areas will be the same as en_línea, beginning with nutrition and exercise and a progressive incorporation of the other topics. Material to work at home and self-recording will be provided in paper.
11092795|NCT04127201|No Intervention|Control group|Participants in the control group only will receive a biweekly newsletter by email without feedback. They will be provided with material and instructions to self-record their daily meals and exercise. The newsletter only will content basic information about nutrition and exercise.
11092796|NCT04127162||alive|
11092797|NCT04127162||dead|
11092798|NCT04127149|Experimental|Group with ultrasound|The first group consists of nine general practitioners having received a brief training on the use of ultrasound scanners in general practice. The general practitioner includes all adult patients who are consulting for one of the 8 medical conditions studied and perform an ultrasound scan. Two weeks later, he/she calls each patient to collect the necessary data.
11092799|NCT04127149|No Intervention|Group without ultrasound|The second group consists of nine general practitioners. Each physician includes all adult patients who are consulting for one of the 8 medical conditions studied and performs a standard consultation. Two weeks later, he/she calls each patient to collect the necessary data.
11092800|NCT04127136|Experimental|Study Group|The cases were analyzed for the change in the severity of binge eating disorder in the program. The data collection was performed via socio-demographic information form, binge eating disorder evaluation (BEDE) form, and progress record forms. BEDE was a structured form exclusively using DSM-5 BED diagnosis and the severity criteria. Progress record form included weekly session content that was administered by a physician, dietitian, psychologist, and the physiotherapist and the monthly individual meetings data. BEDE and progress record forms were applied before the trainings that focuses on cognitive change and repeated every four weeks for 20 weeks. The patients were planned to receive 80 hours of training by the physician, dietitian, psychologist, and the physiotherapist.
11092801|NCT04127110|Experimental|Lorlatinib|"Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
~Lorlatinib will be taken continuously on a daily basis until disease progression, unacceptable toxicity, occurrence of any withdrawal criterion, whichever comes first."
11092802|NCT04127097|Experimental|cartoon group|
11092803|NCT04127097|No Intervention|control group|
11092804|NCT04127084|Experimental|normal albuminuria|baseline urinary albumin creatinine ratio [UACR]< 30 mg/g
11092805|NCT04127084|Experimental|moderately increased albuminuria|baseline UACR 30~300 mg/g
11092806|NCT04127084|Experimental|severely increased albuminuria|baseline UACR>300mg/g
11092807|NCT04127084|No Intervention|blank Comparator|normal participant
11092808|NCT04127071|Active Comparator|Surgical I&D Procedure|The abscess cavity will be evaluated thoroughly with ultrasonography. The site will be prepared and draped. The skin surface will be infiltrated with local anesthetic with a 25-gauge needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Incision of the skin surface with a number 11-blade scalpel will be performed over the largest area of infection; the incision will be extended into the abscess cavity. A blunt instrument will then be used to break up internal loculations if present. Repeated instrumentation through the initial incision or extension of the original incision will be performed if needed. Lastly, iodoform packing will be inserted through the incision into the cavity. The decision to send the abscess contents for microbiological culture and susceptibility analysis will be at the discretion of the treating clinician.
11092841|NCT04126798||Unilateral vestibular impairment|Cross-sectional study on cognitive and motor single tasks, as well as cognitive-motor dual-tasks, in persons with unilateral vestibular impairment
11092809|NCT04127071|Experimental|Ultrasound-guided Needle Aspiration Procedure|The abscess cavity will be evaluated thoroughly with US. The site will be prepared and draped. The skin surface and anticipated needle track will be infiltrated with local anesthetic with a 25g needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Under direct US-guided visualization, a 14g 2in steel needle attached to a 40mL syringe will be advanced into the abscess cavity with manual negative pressure. The needle tract will be extended obliquely 2-3 cm between the skin and abscess to prevent fistulization. Purulent material will be aspirated until no further purulence can be aspirated. Multiple aspiration attempts on the initial visit will be permitted to maximally drain the abscess cavity. Additionally, irrigation of the abscess cavity with sterile saline will be permitted to break up internal loculations if present, as has reported previously for trunk and breast abscesses.
11092810|NCT04127058|Other|CYP2D6 non-poor metabolizers|titrated up to 24 mg daily (12 mg b.i.d.)
11092811|NCT04127058|Other|CYP2D6 poor metabolizers|titrated up to 12 mg daily (6 mg b.i.d.)
11092812|NCT04127045||IMN-Group|Patients treated with intramedullary nailing
11092813|NCT04127045||HA-Group|Patients treated with Hemiarthroplasty
11092814|NCT04127032|Experimental|Tailored ICBT for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
11092815|NCT04127019|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
11092816|NCT04127019|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
11092817|NCT04127019|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).
11092818|NCT04127006||Vision Cohort 1|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field
11092819|NCT04127006||Vision Cohort 2|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field)
11092820|NCT04127006||Vision Cohort 3|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 18 or less [approximate Snellen equivalent 20/500 or worse]
11092821|NCT04126993|Experimental|Camrelizumab+ Apatinib test group|Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
11092822|NCT04126993|Active Comparator|Apatinib single drug control group|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
11092823|NCT04126980||ED group|The ED group who had less than 72 hours of hospitalization (including the preparation period which commonly took approximately 1 day) for the surgery.
11092824|NCT04126980||Comparison group|The comparison group who were hospitalized for more than 72 hours but less than 12 days.
11092825|NCT04126967|Other|allo-PBSCT patients with no NGS text|
11092826|NCT04126954||Cinacalcet|Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet
11092827|NCT04126941||Teriparatide|Patients with hypoparathyroidism treated by teriparatide
11092828|NCT04126928|Other|Participant|Each participant will go through (i) screening using DMFT and PUFA, (ii) orthopantomography assessment using PAI, and (iii) comprehensive clinical examination to derive pulpal and periapical diagnoses
11092829|NCT04126902||late-onset preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
11092830|NCT04126902||Control|The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
11092831|NCT04126876|Experimental|Tilsotolimod (IMO-2125)|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
11092832|NCT04126876|Placebo Comparator|Placebo|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
11092833|NCT04126837|Other|Patient admitted for Ankle and foot injuries|Diagnosis and treatment of Ankle and foot injuries by an accelerated nursing branch in emergency department
11092834|NCT04126824|Active Comparator|Bupivacaine|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine and contrast to enable visualization of the nerve block under fluoroscopy.
11092835|NCT04126824|Experimental|Bupivacaine and Triamcinolone|During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine plus triamcinolone mixed with contrast to enable visualization of the nerve block under fluoroscopy.
11092836|NCT04126811|Experimental|Apatinib and Chemotherapy Test Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
11092837|NCT04126811|Active Comparator|Apatinib Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
11092838|NCT04126811|Active Comparator|Chemotherapy Group|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
11092839|NCT04126798||Healthy adults|Standardization and collecting normative age-related data for cognitive and motor single tasks, as well as cognitive-motor dual-tasks
11092840|NCT04126798||Bilateral vestibulopathy|Validation of cognitive and motor single tasks, as well as cognitive-motor dual-tasks
11092842|NCT04126785|Placebo Comparator|Control without exercise in heated water-based|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the xiphoid process level for 30 min.
11092843|NCT04126785|Experimental|High Intensity Interval Exercise in Heated Water|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
11092844|NCT04126785|Experimental|Continuous Moderate Exercise in Heated Water|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light) level of RPE.
11092845|NCT04126772||Active MS patients|10 MS patients with an active lesion of 0,5 cm diameter
11092846|NCT04126772||Healthy controls|20 healthy controls
11092847|NCT04126772||SPMS patients|10 SPMS patients
11092848|NCT04126759|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
11092849|NCT04126733|Experimental|Regorafenib + Nivolumab|
11092850|NCT04126720|Active Comparator|vitamin E|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and Vitamin E capsule (Vitamin E 400: 400 mg vitamin E capsules - Pharopharmaceuticles) daily.
11092851|NCT04126720|Placebo Comparator|Placebo|topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermapharm) four times daily and placebo capsule daily
11092852|NCT04126707|Experimental|[14C] HQP1351|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of [14C] HQP1351 to healthy Chinese male subjects.
11092853|NCT04126694|Experimental|CBT with smartphone application|12 weeks of CBT with SenseSupport smartphone application
11092854|NCT04126681|Experimental|HQP1351 therapy cohort|HQP1351 40 mg, taken orally once every other day of a 28-day cycle
11092855|NCT04126681|Active Comparator|Best Available Therapy (BAT) cohort|Best available therapy (BAT) will be selected by the investigator for each participant.
11092856|NCT04126668|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast
11092857|NCT04126668|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
11092858|NCT04126655|Experimental|Arfolitixorin.|Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU
11092859|NCT04126655|Active Comparator|Calciumfolinate.|Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU
11092860|NCT04126642|Other|Assessment only group|
11092861|NCT04126642|Experimental|Intervention group|
11092862|NCT04126629||Normotensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the normotensive group. Every attempt will be made to stratify both groups equally between second and third trimesters.
11092863|NCT04126629||Hypertensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the hypertensive group.Every attempt will be made to stratify both groups equally between second and third trimesters.
11092864|NCT04126616|Experimental|patients with COPD and PH|
11092865|NCT04126616|Active Comparator|patients with COPD without PH|
11092866|NCT04126616|Active Comparator|healthy subjects|
11092867|NCT04126603|Placebo Comparator|Group A Placebo|Metformin + Placebo.
11092868|NCT04126603|Active Comparator|Group B Active|Metformin + Placebo
11092869|NCT04126590|Experimental|KN044 0.03 mg/kg dose group|KN044 0.03 mg/kg dose group,once every 3 weeks，a total of four cycles
11092870|NCT04126590|Experimental|KN044 0.1 mg/kg dose group|KN044 0.1 mg/kg dose group,once every 3 weeks，a total of four cycles
11092871|NCT04126590|Experimental|KN044 0.3mg/kg dose group|KN044 0.3mg/kg dose group,once every 3 weeks，a total of four cycles
11092872|NCT04126590|Experimental|KN044 1 mg/kg dose group|KN044 1 mg/kg dose group,once every 3 weeks，a total of four cycles
11092873|NCT04126590|Experimental|KN044 3 mg/kg dose group|KN044 3 mg/kg dose group,once every 3 weeks，a total of four cycles
11092874|NCT04126590|Experimental|KN044 6mg/kg dose group|KN044 6mg/kg dose group,once every 3 weeks，a total of four cycles
11092875|NCT04126590|Experimental|KN044 10mg/kg dose group|KN044 10mg/kg dose group,once every 3 weeks，a total of four cycles
11092876|NCT04126577||Patients with suspected peritonitis|Secondary peritonitis, sepsis and endotoxemia
11092877|NCT04126564|Experimental|IEO Intervention Group|The Group 1 is the active study group which receives the online mindfulness intervention first.
11092878|NCT04126564|Active Comparator|Control Group|Group 2 will be asked to read a book or journal of their choice for first 30 days, and then recieve online mindfulness intervention (IEO).
11092879|NCT04126551||Lean, healthy control|Lean, healthy control subjects. Volunteers will be matched for sex and age 35-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
11092880|NCT04126551||Obese nondiabetic|Obese nondiabetic subjects. Obesity will be defined using a body mass index of greater than or equal to 30 kg/m2. Volunteers will be matched for sex and age 35-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
11093495|NCT04122040|Active Comparator|roxithromycin|roxithromycin 300 mg oral per day
11092881|NCT04126551||Type 2 diabetes|Participants with type 2 diabetes diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 35-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
11092882|NCT04126538|Experimental|Patient group|Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
11092883|NCT04126538|Experimental|Control group|Healthy subjects take pirfenidone capsule 400mg once orally
11092884|NCT04126525|Experimental|neoadjuvant pyrotinib|pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days
11092885|NCT04126512||Bedside ligation|Infants admitted to St. Orsola-Malpighi Hospital (SOM) NICU had their PDA ligated at bedside, with a timing of surgery dependent on the time schedule of the surgeons and anaesthesiologists.
11092886|NCT04126512||Referred to specialist paediatric cardiac surgery centre|Due to the unavailability of local cardiac surgery, infants admitted to the Cambridge University Hospital (CUH) NICU were referred to specialist paediatric cardiac surgical centres, where PDA ligation was performed. In these cases, the surgical timing depended on both bed availability at the referral centre and the availability of the neonatal transfer team.
11092887|NCT04126486|Other|Zio®XT Monitor Arm|
11092888|NCT04126486|No Intervention|Usual Care Arm|
11092889|NCT04126473|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
11092890|NCT04126460|Experimental|Toripalimab|Injection; dosage form: 6ml: 240mg; frequency: 240mgQ3W; duration: 17cycles (12 months) or randomization to the date of the first documented progression
11092891|NCT04126434|Sham Comparator|no masking|not wearing facemask
11092892|NCT04126434|Active Comparator|masking|wearing facemask
11092893|NCT04126421|Active Comparator|E1 Vitamin E infused HXLPE|E1 Vitamin E infused highly cross-linked polyethylene (HXLPE)
11092894|NCT04126421|Active Comparator|Marathon HXLPE|Marathon highly cross-linked polyethylene (HXLPE)
11092895|NCT04126408|Sham Comparator|Sham arm|gammaCore sham device which will not provide stimulation of the vagus nerve
11092896|NCT04126408|Active Comparator|Treatment group|Active gammaCore device that supplies non-invasive stimulation of the cervical branch of the Vagus nerve
11092897|NCT04126395||Controls|"This groups consists of children now aged 6-12y:
~Without a medical diagnosis possibly influencing motor development
~Without motor problems (M-ABC-2 and DCD-Q)
~Without social reponsiveness problems (SRS-2)"
11092898|NCT04126395||Developmental Coordination Disorder|"This groups consists of children now aged 6-12y:
~With a multidisciplinary diagnosis of DCD
~With motor problems (M-ABC-2 and DCD-Q)
~Without social responsiveness problems (SRS-2)"
11092899|NCT04126395||Developmental Coordination Disorder + Autism Spectrum Disorder|"This groups consists of children now aged 6-12y:
~With a multidisciplinary diagnosis of DCD
~With motor problems (M-ABC-2 and DCD-Q)
~With social responsiveness problems (SRS-2)"
11092900|NCT04126382|Active Comparator|INSURE|Intubate-Surfactant-Extubate(INSURE) technique is a Important treatment in premature infants with RDS.
11092901|NCT04126382|Experimental|LISA|Less invasive surfactant administration(LISA) technique is a Important treatment in premature infants with RDS.
11092902|NCT04126369|Experimental|mindfulness intervention|12 mindfulness sessions for 3 months (1 session per week)
11092903|NCT04126369|Active Comparator|Psycho educative programme|12 psycho educative sessions for 3 months (1 session per week)
11092904|NCT04126343|Experimental|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
11092905|NCT04126343|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
11092906|NCT04126343|Active Comparator|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
11092907|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Elderly|
11092908|NCT04126330|Placebo Comparator|Placebo- Elderly|
11092909|NCT04126330|Experimental|Probiotics and Omega-3/vitamin D Supplements- Obese|
11092910|NCT04126330|Placebo Comparator|Placebo- Obese|
11092911|NCT04126317|Experimental|intravitreal aflibercept injection (IAI)|"Treatment-naïve patients with neovascular wet age-related macular degeneration (nAMD) randomized in a 1:1 ratio"
11092912|NCT04126317|Experimental|High-dose aflibercept (HD)|Treatment-naïve patients with nAMD randomized in a 1:1 ratio
11092913|NCT04126304||Common cold|A cold is a clinical diagnosis.Complaints may include a stuffy nose, sore throat, cough and headache.Objective signs are rare, but may include fever, enlarged anterior cervical lymph nodes, nasal mucosa and oropharyngeal erythema, and nasal mucus.
11092914|NCT04126304||acute bronchitis|In 2011, the European society of respiratory diseases (ERS) defined acute disease in patients with non-chronic lung disease. Symptoms include cough, with or without expectoration of phlegm, and other symptoms and signs may indicate lower respiratory tract infection and cannot be explained by other diseases (e.g., sinusitis, asthma).The main symptoms of acute bronchitis are cough, may be accompanied by fever, fatigue, asthma and dyspnea.
11092915|NCT04126304||Post-infection cough|The definition in the 2013 guidelines for diagnosis and treatment of chronic cough in Chinese children: cough refers to a recent history of respiratory tract infection;The cough lasted > for 4 weeks, presenting an irritating dry cough or a little white phlegm.Chest x - ray examination showed no abnormality or only increased lung veins.The pulmonary ventilation function was normal, or presented transient high airway response.Coughs are usually self-limited, and other diagnoses should be considered if the cough is more than 8 weeks old.In addition to other causes of chronic cough.
11092916|NCT04126304||community-acquired pneumonia|According to the 2019 guidelines for the diagnosis and treatment of community-acquired pneumonia in children, it is defined as infectious pneumonia developed outside the hospital (community), including pneumonia developed after admission due to infection of pathogens with a clear incubation period outside the hospital (community).
11092993|NCT04125836|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
11093496|NCT04122040|Placebo Comparator|placebo|placebo one tablet per day
11092917|NCT04126291|Experimental|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived change in self-efficacy/ confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
11092918|NCT04126278|Experimental|Barbotage Injection|Subjects receiving barbotage with saline injection
11092919|NCT04126278|Active Comparator|Barbotage with Cortisone Injection|Subjects receiving barbotage with cortisone injection
11092920|NCT04126265|No Intervention|Routine colonoscopy group|The patient underwent routine colonoscopy.
11092921|NCT04126265|Experimental|Artificial intelligence assisted colonoscopy group|The real-time automatic polyp detection system was used to assist the endoscopist.
11092922|NCT04126252|Experimental|Group A|This arm received pharmacotherapy for erectile dysfunction.
11092923|NCT04126252|Experimental|Group B|This arm received cognitive behavior psychotherapy for erectile dysfunction.
11092924|NCT04126252|Experimental|Group C|This arm received combined treatment approach.
11092925|NCT04126252|Placebo Comparator|Group D|This arm acted as a control group and received placebo or no intervention.
11092926|NCT04126239||Participant suffering from obesity|Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2
11092927|NCT04126239||healthy volunteer|
11092928|NCT04126226|Experimental|Study group|
11092929|NCT04126226|No Intervention|Control Group|
11092930|NCT04126213|Experimental|RSV MAT formulation 2 Group|Maternal subjects randomized to RSV MAT formulation 2 Group will receive a single dose of RSVPreF3 formulation 2 vaccine in the deltoid region of the non-dominant arm and will be followed up until the study end.
11092931|NCT04126213|Experimental|RSV MAT formulation 3 Group|Maternal subjects randomized to RSV MAT formulation 3 group will receive a single dose of RSVPreF3 formulation 3 vaccine in the deltoid region of the non-dominant arm and will be followed up until the study end.
11092932|NCT04126213|Placebo Comparator|Control Group|Maternal subjects randomized to the Control Group will receive a single dose of Placebo in the deltoid region of the non-dominant arm and will be followed up until the study end.
11092933|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)|
11092934|NCT04126200|Experimental|Belantamab mafodotin+GSK3359609 dose exploration (Sub-study 2)|
11092935|NCT04126200|Experimental|Belantamab mafodotin+nirogacestat dose exploration(Sub-study3)|
11092936|NCT04126200|Experimental|Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)|
11092937|NCT04126200|Active Comparator|Belantamab mafodotin monotherapy cohort expansion|
11092938|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)|
11092939|NCT04126200|Experimental|Belantamab mafodotin+GSK3359609 cohort expansion (Sub-study 2)|
11092940|NCT04126200|Experimental|Belantamab mafodotin+nirogacestat cohort expansion(Sub-study3)|
11092941|NCT04126200|Experimental|Belantamab mafodotin+dostarlimab cohort expansion(Sub-study4)|
11092942|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
11092943|NCT04126174|Active Comparator|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
11092944|NCT04126174|Active Comparator|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
11092945|NCT04126161|Active Comparator|CT|Patients have standard of care CT prior to primary hip replacement
11092946|NCT04126161|Experimental|Ultrasound|Patients have ultrasound scans together with standard of care CT prior to primary hip replacement
11092947|NCT04126148||Age matched Healthy participants (150)|Healthy Participants Age: > 40y No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system
11092948|NCT04126148||Coronary Artery Disease (CAD) Patients (200)|Coronary Artery Disease (CAD) Patients Age > 18 y Patients with an Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.
11092949|NCT04126135|Active Comparator|Usual Care Group|Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
11092950|NCT04126135|Experimental|Treatment Group|Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
11092951|NCT04126096|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive beta lactam containing antibiotics during surgery (other than penicillin) in order to determine Negative Predictive Values and Non-Irritant Concentrations.
11092952|NCT04126083|Experimental|Lofexidine|Patients will receive lofexidine 0.54 mg 4 times daily and the baseline opioid dose will be reduced by 10% daily.
11092953|NCT04126070|Experimental|COHORT 1: DNA damage repair defects (DDRD) +/- Inflamed Tumor|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.
~Androgen Deprivation Therapy: Given per standard care for duration of study
~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage
~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
11092954|NCT04126070|Experimental|COHORT 2: Inflamed Tumor without DNA repair defects (DDRD)|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.
~Androgen Deprivation Therapy: Given per standard care for duration of study
~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage
~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6."
11092955|NCT04126070|Experimental|COHORT 3: Biomarker Negative|"After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial.
~Androgen Deprivation Therapy: Given per standard care for duration of study
~Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage
~Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6"
11092956|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method A|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A
11092957|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method B|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B
11092958|NCT04126044|Active Comparator|Reference: bevacizumab - EU|
11092959|NCT04126044|Experimental|Test: PF-06439535 (CN)|
11092960|NCT04126031|Experimental|Part A, Cohorts 1-3|Single dose pharmacokinetics. This arm will include three age cohorts.
11092961|NCT04126031|Experimental|Part B, Cohorts 1-3|Multi-dose pharmacokinetics. This arm will include three age cohorts.
11092962|NCT04126018||Mitral Valve Regurgitation|Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.
11092963|NCT04126018||Aortic Valve Regurgitation|Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.
11092964|NCT04126018||Aortic Stenosis|Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.
11092965|NCT04126018||Patients referred for CRT Implantation|Patients who meet clinical guideline criteria for CRT implantation with EF < 40%
11092966|NCT04126005||Cohort 1|"(age < 18 months)
~In-home visits every 2 months
~Clinic assessments every 6 months"
11092967|NCT04126005||Cohort 2|"(age ≥ 18 months - 3 years)
~In-home visits every 4 months
~Clinic assessments every 6 months"
11092968|NCT04126005||Cohort 3|"(age > 3 - 5 years)
~In-home visits every 6 months
~Clinic assessments every 6 months"
11092969|NCT04126005||Cohort 4|"(age > 5 years)
~In-home visits every 12 months
~Clinic assessments every 12 months"
11092970|NCT04126005||Cohort 5|"(deceased)
~• The patient's medical history records will be reviewed. In addition, a parent interview will be performed."
11092971|NCT04125992|Experimental|Distal Radial|Patients who undergo coronary catheterization by accessing the distal radial artery in the snuff-box of the hand.
11092972|NCT04125992|Active Comparator|Forearm Radial|Patients who undergo conventional coronary catheterization by accessing the forearm radial artery.
11092973|NCT04125979|Experimental|Preservation of pulmonary vagus nerve|Preservation of pulmonary branches of vagus nerve in minimally invasive surgery for lung cancer
11092974|NCT04125979|Experimental|No pulmonary vagus nerve preservation|In minimally invasive surgery for lung cancer, the pulmonary branches of vagus nerve were severed
11092975|NCT04125953|Experimental|Intervention|A 3 week intervention with Andullation will be performed, 3 times a week for 20 minutes after completion of the radiotherapy session
11092976|NCT04125953|Placebo Comparator|Control|This group will follow the same intervention protocol, but without the application of the Andullation technology
11092977|NCT04125940|Placebo Comparator|Placebo-controlled Arm|Placebo - 12oz water with food coloring
11092978|NCT04125940|Active Comparator|1 serving Resync Arm|12oz water + 7.5g Resync
11092979|NCT04125940|Active Comparator|2 servings Resync Arm|12oz water + 15g Resync
11092980|NCT04125940|Active Comparator|1 servings Resync+Collagen Arm|12oz water + 17g collagen + 2g Resync + 1g Carbohydrates
11092981|NCT04125927|Experimental|Open-label arm|
11092982|NCT04125914|Experimental|Prevention (weight management, health behavior intervention)|Participants undergo weight management and health behavior intervention with a combination of 4 components for 16 weeks. TELEPHONE COACHING: Participants receive 1 phone call each week from a coach over 30-45 minutes to discuss diet, physical activity and goal setting. EMAIL COACHING: Participants receive 1 phone call to discuss the process over 10-15 minutes and then receive 1 email each week for 16 weeks. NO COACHING: Participants receive 1 phone call the first week over 10-15 minutes to discuss the process. TEXT MESSAGING: Participants receive 7-12 text messages comprising information about diet and physical activity each week for 16 weeks. SELF-MONITORING: Participants record their food intake and weight directly into the Fitbit website or application 4-7 days each week or 1 day each week for 16 weeks. FAMILY TEAM INTERVENTION: Participants receive 2 group phone calls and join a Facebook group that is monitored by research staff where they can interact with each other and coaches.
11092983|NCT04125901|Experimental|Pain Neuroscience Education and Exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, resistance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
11092984|NCT04125901|Other|Exercise|Participants will received an 8 week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
11092985|NCT04125888||AIT Cohort|Allergic rhinitis patients with and without asthma treated with AIT
11092986|NCT04125888||Control Cohort|Allergic rhinitis patients with and without asthma not treated with AIT
11092987|NCT04125875||Patients with cirrhosis of esophageal varices|
11092988|NCT04125875||Patients with gastric polyps|
11092989|NCT04125862|Other|Fibrous Dysplasia/McCune-Albright Syndrome|20, Fibrous Dysplasia/McCune-Albright Syndrome Patients with or without pain
11092990|NCT04125862|Other|Healthy Controls|20, matched healthy controls
11092991|NCT04125849|Active Comparator|Thoraco-laparoscopic esophagectomy|Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
11092992|NCT04125849|Active Comparator|Mediastinoscopy-assisted transhiatal esophagectomy|Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
11092998|NCT04125797|Active Comparator|Adhesive 1|This arm investigates one type of silicone adhesive (3M2475P) on adult female skin.
11092999|NCT04125797|Active Comparator|Adhesive 2|This arm investigates one type of silicone adhesive (RX1449P) on adult female skin.
11093000|NCT04125797|Active Comparator|Adhesive 3|This arm investigates one type of silicone adhesive (PS-1243) on adult female skin.
11093001|NCT04125784||Lipid-profile|The cohort includes male and female patients diagnosed and confirmed HIV diagnosis who receive HIV related treatment in an extramural setting. All patients are adults (older than 18 years old) and have participated in the original study in 2014.
11093002|NCT04125771|Other|Diclofenac + HBB|Women who will receive Diclofenac + HBB
11093003|NCT04125771|Other|Diclofenav + placebo|Women who will receive Diclofenav + placebo
11093004|NCT04125758|Experimental|Mindfulness training|Participants will listen to one to two 3-30 minute audio recordings each day for 4 weeks between study visits (28 days total) through the Healthy Minds @Work smartphone app and record when they listen to each recording on a paper log. The app will also collect data on which recordings, when, and for how long participants listen.
11093005|NCT04125758|Active Comparator|Tracking time spent on mobile device|Participants will record how much time they estimate they have spent on their phone in the past 24 hours, each day for 4 weeks (28 days total) between study visits.
11093006|NCT04125745|Experimental|CXA-10|Oral CXA-10 300 mg once daily for 12 weeks
11093007|NCT04125732|Experimental|AdVEGFXC1 at 1x10^9 vp|
11093008|NCT04125732|Experimental|AdVEGFXC1 at 1x10^10 vp|
11093009|NCT04125732|Experimental|AdVEGFXC1 at 4x10^10 vp|
11093010|NCT04125732|Experimental|AdVEGFXC1 at 1x10^11 vp|
11093011|NCT04125719|Experimental|Primay PD-1 resistance|Cohort 1 will include 15 patients who progressed within 3 months (primary resistance) of starting PD-1 therapy
11093012|NCT04125719|Experimental|Secondary PD-1 resistance|Cohort 2 will include 15 patients who progressed after at least 3 months of PD-1 therapy
11093013|NCT04125706|Experimental|Mincycline hydrochloride 2% oral gel|Minocycline will be delivered locally in the periodontal pocket.
11093014|NCT04125706|Experimental|Metronidazole hylcate 0.75 % oral gel|Metronidazole gel will be delivered locally in the periodontal pocket.
11093015|NCT04125693|Experimental|Cancer patients|Patients from completed Bayer clinical trials, who received rogaratinib as monotherapy or combination therapy for the treatment of cancer.
11093016|NCT04125680|Experimental|ESL Health Literacy Classes|The intervention will last 8 weeks with classes that are held during evening hours. The curriculum will focus on using pedagogies for health literacy as a practice. Assessments will be administered pre-post intervention.
11093017|NCT04125680|Other|8 Week Wait-List Control|The adults assigned to the wait-list control group will not receive access to the classes until after 8 weeks. After the 8 weeks, adults will be given access to the classes, and the curriculum in these classes will focus on using pedagogies for health literacy as a practice. Assessments will be administered pre-post intervention.
11093018|NCT04125654|Experimental|Patients with ascites enrolled for mNGS testing|Patients with ascites will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective clinical documents).
11093019|NCT04125641||Elxaban group|AF patients taking Elxaban
11093020|NCT04125628|Experimental|Exercise with cooling|Assigned Interventions 10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise training session involved head cooling and neck wraps. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
11093021|NCT04125628|Active Comparator|Exercise without cooling|10 MS patients (aged 25----50 years) with Expanded Disability Status Scale between 2 to 6.5 have agreed to participate in this study. The exercise session performed without cooling. The exercise training session consisted of 40 min continuous cycling where the participants performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
11093022|NCT04125615|Experimental|Protected Non-Clinical Time|Protected non-clinical time
11093023|NCT04125615|No Intervention|Control Period|No protected non-clinical time
11093024|NCT04125602|Experimental|High fat low carbohydrate diet|
11093025|NCT04125602|Experimental|Low fat high carbohydrate diet|
11093026|NCT04125589|Experimental|Introduction Activity and Product Evaluation Activity|Participants will engage in an introduction activity first and a product evaluation activity second.
11093027|NCT04125589|Experimental|Product Evaluation Activity and Introduction Activity|Participants will engage in a product evaluation activity first and an introduction activity second.
11093028|NCT04125576||Burn patients|The subjects complaine of severe neuropathic pain that is rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
11093029|NCT04125576||Healthy controls|age and sex matched healthy controls
11093030|NCT04125563|Placebo Comparator|Placebo capsules|Soft gel capsules with placebo: Sorbitol and colorant.
11093031|NCT04125563|Active Comparator|Active substance - oral capsaicin in soft gel capsules|"This is a phase 2 clinical study in humans for therapeutic use of Capsicum oleoresin - (capsaicin) in CIC. The study has a randomised, double-blind and cross-over design. During 4 weeks the participants take either active capsules (Capsicum oleoresin), or matching placebo capsules. This period follows by 2 weeks of wash out and then another 4 weeks with active capsules or placebo in accordance with the trial profile below."
11093032|NCT04125550|Experimental|Group P|In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 10 mg/kg/h propofol infusion and 5 µg/kg/h fentanyl infusion will be administered.
11093033|NCT04125550|Active Comparator|Group S|In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of anesthesia.
11093034|NCT04125537||Dialysis Centers|Dialysis Center staff participating in the collaborative learning activities. These staff then implement the best practices for seriously ill patients in their setting via quality improvement activities around identifying seriously ill patients, shared-decision making/advanced care planning, palliative dialysis and dialysis withdrawal.
11093035|NCT04125537||Chronic Kidney Disease Clinics|Chronic Kidney Disease Clinic staff participating in the collaborative learning activities. These staff then implement the best practices for seriously ill patients in their setting via quality improvement activities around identifying seriously ill patients, shared-decision making/advanced care planning, and medical management without dialysis.
11093036|NCT04125511|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
11093037|NCT04125498|Active Comparator|OMT|Osteopathic manual treatment
11093038|NCT04125498|Active Comparator|OMT plus self-massage|Patients will be submitted to OMT and then they will be invited to practice a self-massage at home.
11093039|NCT04125498|Sham Comparator|Placebo|Similar to OMT without pressure.
11093040|NCT04125498|Active Comparator|Placebo plus self-massage|Patients will be submitted to placebo manual treatment and then they will be invited to practice a self-massage at home.
11093041|NCT04125485||Person with Parkinson's|"Inclusion criteria for interview/focus group with people with PD: people with PD living at home, Hoehn & Yahr stage 1-4 (Hoehn and Yahr, 1967), cognitively able to participate, able to speak a conversational level of English, and at different stages of PD (early, mid, later by years of diagnosis) and ages (younger and older).
~Exclusion criteria: any hospital admission within the last 1 year, whether for Parkinson's or anything else, that was for more than 24 hours i.e. not day surgery/brief checks in the emergency department after falls; patients diagnosed with PD less than 6 months ago to confirm the diagnosis and allowed them to have time for using the resources for people with PD; unwillingness to participate."
11093042|NCT04125485||Healthcare professional|"Inclusion criteria for interview/focus group for health professionals: Professionals from different disciplines (physician, neurologist, General Practitioners, nurses/specialist nurses, social worker, occupational therapist, mental health workers, physiotherapist, pharmacist, speech therapist) that provide support directly or indirectly to patients with PD and family carers.
~Exclusion criteria: Not involved in direct care or support of people with PD or unwillingness to participate."
11093043|NCT04125485||Family carer|"Inclusion and exclusion criteria for all are the same for Interviews and Focus Groups.
~Family carers:
~Inclusion criteria: family caregivers of PD patients at different stages (early, mid, late) or friends involved in the care process. Also, family caregivers of patients with cognitive impairment will be included.
~Exclusion criteria: not being involved in the care of the person with PD or unwillingness to participate in the project, and an ability to speak a conversational level of the English language.
~Family carers do not need to have the person they care for in the study also and vice-versa."
11093044|NCT04125485||Stakeholder|"Stakeholders:
~Inclusion criteria: non-NHS professionals or volunteers involved in policy making or working or collaborating in voluntary organisations or from different sectors; (non-NHS) Health Care, Social Services, voluntary sector, employment, food, Pharmaceutical, Education, Political, that have an impact directly or indirectly in the management of PD and development of care pathways for PD or other long-term conditions (when relevant). Exclusion criteria: unwillingness to participate in the project or lack of involvement in strategic planning or involvement in provision of community PD care."
11093045|NCT04125459||Individuals with Gout|This arm will be getting a biopsy as well as a blood draw
11093046|NCT04125459||Controls|These individuals will not be getting a joint biopsy and will just get a blood draw
11093047|NCT04125446||Cancer in pregnancy chemo treated|Patients that received at least one of the following treatments: Carboplatin, Cisplatin, Cyclophosphamide, Paclitaxel and/or anthracyclines, the latter being the most given type of CT during pregnancy
11093048|NCT04125446||Cancer in Pregnancy not chemo treated|Women who were not treated with CT during pregnancy, including those who were solely surgically treated or did not receive any treatment during pregnancy, will be included in the CT-unexposed control arm
11093049|NCT04125446||healthy pregnancies|A group of healthy pregnant women without cancer will form the second control group
11093050|NCT04125433|Experimental|Medicaid Emergency Department High Utilizers|"This Arm will include the following individuals
~Up to 400 Adults age 18 to 65
~New York State Medicaid Managed Care Members
~Have utilized emergency department services 6 or more times in a 12-month period
~Have been assigned to the Pilot Project by their Medicaid Managed Care Plan"
11093051|NCT04125407|Experimental|Interventional|"Experimental group will receive one customized pair of sensorimotor foot orthoses (insoles).
~Intervention: Other: Sensorimotor foot orthoses with any other supplementary treatment."
11093052|NCT04125407|No Intervention|Control|Control group will receive neither orthotic nor other supplementary intervention.
11093053|NCT04125394|Experimental|NaCl 5%|Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days.
11093054|NCT04125381||Exposed to high Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with high Arsenic concentration in drinking water, were enrolled
11093055|NCT04125381||Exposed to low Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with low Arsenic concentration in drinking water, were enrolled
11093056|NCT04125368|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities
11093057|NCT04125368|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities
11093058|NCT04125355|Placebo Comparator|Placebo|Placebo control
11093059|NCT04125355|Experimental|Reflexology|foot reflexology
11093060|NCT04125342|Experimental|Conditioned NIV in High Risk Patients|
11093061|NCT04125342|Active Comparator|HFOT in High Risk Patients|
11093062|NCT04125342|Experimental|Conditioned NIV in Obese Intermediate Risk Patients|
11093063|NCT04125342|Active Comparator|HFOT in Obese Intermediate Risk Patient|
11093064|NCT04125329|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
11093065|NCT04125316||Asthma|Asthma patients
11093066|NCT04125303|Experimental|Intervention Group|Based on NANDA diagnosis recommendations, entertainment-sector workers were asked to record their perceptions and the meaning of their substance-use problem in a diary. The intervention was subsequently designed based on brief motivational psychoeducational therapy (BMPT).
11093067|NCT04125277|Experimental|Imaging|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
11093068|NCT04125264|Experimental|Intense therapeutic Ultrasound|"During the trial two applications of 1000 pulses each one (day one and day thirty) will be applied. Pulse regulation could be modified from 4 to 5 joules depending the presence or not of pain.
~Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching."
11093069|NCT04125264|No Intervention|Control group|Non ITU application. Conservative treatment of plantar fasciitis include: custom made foot orthosis with the same general characteristics plus plantar fasciia and achilles tendon stretching.
11093070|NCT04125251|Active Comparator|BISP,CT & LSB to Couples|In this arm 1, the LSB intervention will be offered to the BISP-CT beneficiary women and their spouses
11093071|NCT04125251|Active Comparator|BISP,CT & LSB to Women|In this arm, the LSB intervention will be offered to the BISP-CT beneficiary women only.
11093072|NCT04125251|No Intervention|BISP,CT & No LSB|This is the control group, where neither BISP-CT beneficiary women nor their spouses will be offered the LSB intervention
11093073|NCT04125238|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at five time points in the future (1 day, 1 week, 1 month, 3 months, 1 year, 5 years, and 25 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
11093074|NCT04125238|Sham Comparator|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at five time points in the recent past (last night from 7pm-10pm, yesterday between 4pm-7pm, yesterday between 1pm-4pm, yesterday from 10am-12pm, yesterday between 7am-10am, the night before last between 7pm-10pm, and evening before last between 4pm-7pm). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
11093075|NCT04125199|Experimental|experimental group|
11093076|NCT04125199|Placebo Comparator|control group|
11093077|NCT04125186||Pilot Part|After providing consent, participants with nocturia will complete web-based baseline EpiNP survey followed by 3-day bladder diary and then a qualitative interview.
11093078|NCT04125186||Main Part|After providing consent, participants will complete web-based baseline EpiNP survey. All respondents who report greater than equal to (≥)2 voids/night, and a randomly selected cohort of respondents reporting 0 and 1 void/night will use the EpiNP 3-day web-based bladder diary.
11093079|NCT04125173|Active Comparator|1. Pneumoperitoneum pressure = 15mmHg|1. Pneumoperitoneum will be set at 15mmHg
11093080|NCT04125173|Active Comparator|2. Pneumoperitoneum pressure = 12mmHg|2.Pneumoperitoneum will be set at 12mmHg
11093081|NCT04125173|Active Comparator|3. Pneumoperitoneum set at 10mmHg|3. Pneumoperitoneum will be set at 10mmHg
11093082|NCT04125160||Type 2 diabetes and peritoneal dialysis|Case group with type 2 diabetes undergoing peritoneal dialysis for at least 3 months.
11093083|NCT04125160||Type 2 diabetes and eGFR above 60ml/min|Control group with type 2 diabetes and no nephropathy (defined as eGFR above 60ml/min and UACR below 300mg/g).
11093084|NCT04125147|Experimental|Montage Bone Hemostat|Use of Montage Settable Resorbable Hemostatic bone putty on the cut surfaces of bleeding bone at the osteotomy site
11093085|NCT04125147|No Intervention|Standard of Care: No bone hemostat|Use of no bone hemostat on the cut surfaces of bleeding bone at the osteotomy site
11093086|NCT04125134|Experimental|Hypertonic Saline Responders|Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
11093087|NCT04125134|Experimental|Hypertonic Saline Non-responders|Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
11093088|NCT04125121|Active Comparator|Sevoflurane-Propofol|"Session one: Sevoflurane as maintenance anaesthetic during general anaesthesia.
~Session two: Propofol as maintenance anaesthetic during general anaesthesia."
11093089|NCT04125121|Active Comparator|Propofol-Sevoflurane|"Session one: Propofol as maintenance anaesthetic during general anaesthesia.
~Session two: Sevoflurane as maintenance anaesthetic during general anaesthesia."
11093090|NCT04125108|Experimental|pulmonary rehabilitation group|The experimental group was to participate in a 12-week pulmonary rehabilitation program supplemented with an individualized and supervised exercise-training program.
11093091|NCT04125108|No Intervention|control group|The control group was to participate in a 12-week conventional rehabilitation program.
11093092|NCT04125095||Head Scans|Includes patients receiving proton therapy for tumors in the brain, skull, and head and neck region. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
11093093|NCT04125095||Body Scans|Includes proton irradiation to shoulders, thorax, abdomen, pelvis, spine (thoracic or lumbar), extremities, and other body sites. The same patient could potentially contribute to both cohorts if he/she receives radiation to both head and body sites.
11093127|NCT04124835|Experimental|Intervention Group|In the intervention group, the use of the Swiss Ball will be performed through active exercises of pelvic anteversion and retroversion, lateralization and circumduction according to the obstetric evaluation.
11093128|NCT04124835|Other|Control Group|The control group will receive the usual routine care of the service.
11093094|NCT04125082|Other|Type 2 Diabetics|"Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks. Participants will attend study visits at Day 0, Weeks 1, 2, 3, 4, 8, 12 and 16, where insulin titration may be performed based on CGM readings. Participants will receive instruction in carbohydrate counting and corrective insulin dose adjustments.
~Participants will wear CMG throughout the study.
~At final study visit, CGM system will be collected. A1c, FEV1 and Quality of Life Questionnaires will be collected. Pregnancy test will be collected for all females of child-bearing potential. Participants will be transitioned back to Multiple Daily Injections plus basal or may choose to continue on commercial Afrezza® inhaled insulin plus basal"
11093095|NCT04125069||Patients aged from 18 to 85 years|Cardiac surgery patients aged from 18 to 85 years,programmed for Coronary artery bypass graft requiring ECC.
11093096|NCT04125056|Experimental|test group|Hydronidone capsules (Specification: 30 mg / capsule）
11093097|NCT04125056|Placebo Comparator|Control group|Hydronidone capsules (Specification: 15 mg / capsule）
11093098|NCT04125043||RRT Group|Pediatric patients undergoing ocular screening tests
11093099|NCT04125017|Other|effect of using LASER pulse|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
11093100|NCT04125017|Other|Micro-needle Technique|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
11093101|NCT04125004|Experimental|virtual reality|Patients will use virtual reality headset during procedure
11093102|NCT04125004|No Intervention|general anesthesia|Patients will undergo general anesthesia for their procedure
11093103|NCT04124991|Experimental|Yttrium-90 Microspheres in Combination with Durvalumab|Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.
11093104|NCT04124978|Experimental|Intervention group|prospective, single armed, single centre trial study using the MyTAP device on a daily basis for a period of 3 months
11093105|NCT04124965|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized in dosage regimen 1 will receive assigned dosages of rozanolixizumab at pre-specified time points during Treatment Period.
11093106|NCT04124965|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized in dosage regimen 2 will receive assigned dosages of rozanolixizumab at pre-specified time points during Treatment Period.
11093107|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
11093108|NCT04124939|Active Comparator|10 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 10 cc of sterile saline for the purpose of 10 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
11093109|NCT04124939|Active Comparator|20 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 20 cc of sterile saline for the purpose of 20 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
11093110|NCT04124926|Experimental|Healing Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
11093111|NCT04124926|Active Comparator|Healing Phase: Lansoprazole 30 mg|Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
11093112|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 10 mg|Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
11093113|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
11093114|NCT04124926|Active Comparator|Maintenance Phase: Lansoprazole 15 mg|Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
11093115|NCT04124913|Experimental|Dydrogesterone|
11093116|NCT04124913|Active Comparator|Vaginal progesterone|
11093117|NCT04124900||patients at prostate cancer risk diagnosed|"The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:
~Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason >6).
~Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer ( No cancer o Non-significant prostate cancer (Gleason ≤6))."
11093118|NCT04124887|Active Comparator|Sodium fluoride|Duraphat Varnish containing 5% Sodium fluoride
11093119|NCT04124887|Experimental|Tricalcium phosphate|Clinpro™ White Varnish containing 5% NaF with TCP
11093120|NCT04124887|Experimental|Xylitol-coated calcium and phosphate|Embrace ™ Varnish containing 5% NaF with CXP
11093121|NCT04124887|Experimental|Casein phosphopeptide amorphous calcium phosphate|MI Varnish containing 5% NaF with CPP-ACP
11093122|NCT04124861|Experimental|Drug free|Drug：free Glucocorticoid（GC）is tapered and stopped in 8 weeks. Immunosuppressant treatment is also stopped after admission.
11093123|NCT04124861|Experimental|IS monotherapy|Drug: Immunosuppressant Glucocorticoid（GC）is tapered and stopped in 8 weeks. The same type and dosage of immunosuppressive agent before admission, including Mycophenolate mate(<= 1g/d) or Leflunomide (<=20mg/d) or Methotrexate (<=12.5mg/w) or Azathioprine (<=100mg/d)
11093124|NCT04124861|Experimental|GC combined with IS|Drug: GC+Immunosuppressant Both Glucocorticoid(GC) (no more than 7.5mg/d) and immunosuppressant are kept as maintaining dose.
11093125|NCT04124848||Somali Descent|Study participants who are of Somali origin.
11093126|NCT04124848||Non-Somali Descent|Study participants who are not of Somali origin.
11093129|NCT04124822|No Intervention|control|group 1 , is no intervention group in which root canal procedure will be done without drug as ideal protocol .
11093130|NCT04124822|Experimental|Piroxicam|group 2 is given Piroxicam 20 mg half an hour before root canal treatment to manage post operative pain.
11093131|NCT04124822|Experimental|Prednisolone|group 3 is given Prednisolone 20mg half an hour before root canal treatment to manage post operative pain.
11093132|NCT04124809|Experimental|Study group (artificially laser-collapsed blastocysts)|laser was used as an intervention before blastocyst vitrification to assist rapid blastocyst collapse with vitrification
11093133|NCT04124809|No Intervention|& control group (blastocysts were vitrified, no laser collapse|blastocyst were vitrified without laser assisted collapse
11093134|NCT04124796|Experimental|target subjects|"target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit."
11093135|NCT04124796|Active Comparator|health care team|the health care team managing these patients
11093136|NCT04124783|Experimental|Cooling Bolero|
11093137|NCT04124757|No Intervention|Standard neuromuscular blockade|Subjects will receive regular rocuronium induction dose, followed by bolus foses of 10 mg in case of insufficient conditions
11093138|NCT04124757|Experimental|Deep neuromuscular block|Subjects will receive high dose rocuronium induction dose followed by continuous rocuronium administration, to achieve a depth of neuromuscular block of 1-2 twitches post tetanic count
11093139|NCT04124744|Experimental|Intervention|Will receive the Health Champion intervention
11093140|NCT04124744|Active Comparator|Control|Treatment as usual
11093141|NCT04124731|Experimental|Sintilimab plus anlotinib|Sintilimab and anlotinib combination therapy
11093142|NCT04124731|Active Comparator|Control|Standard platinum-based chemotherapy
11093143|NCT04124718||high caries experience|80 adults will be allowed in the high caries experience group according to DMFT index DMFT>13.9
11093144|NCT04124718||low caries experience|80 adults will be allowed in the high caries experience group according toDMFT index DMFT≤4
11093145|NCT04124705|Experimental|Armour® Thyroid|Oral administration
11093146|NCT04124705|Active Comparator|Synthetic T4|Oral administration
11093147|NCT04124692|No Intervention|No-treatment control group|
11093148|NCT04124692|Experimental|Treatment group|
11093149|NCT04124679|Experimental|TAES group|In TEAS group, an experienced acupuncturist performed 30 minutes of TEAS treatment at the HT7 (Shenmen) and Neiguan (PC6) acupoints on bilateral side, which were identiﬁed in accordance with the TCM anatomic localizations on the first night before surgery by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no.: SDZ-II; Suzhou Medical Appliances Co. Ltd, Suzhou, China). And after surgery, ST36 (Zusanli) and LI4 (Hegu) acupoints were added for the effect of relieving postoperative complications. 30 minutes of TEAS treatment was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints on the first three nights after surgery
11093150|NCT04124679|No Intervention|Control group|Patients in the control group were attached the gel electrodes at the sham acupoints
11093151|NCT04124666|Experimental|Granulocytes infusion only|Fresh, non-irradiated granulocytes from ABO, Rh, CMV compatible, unrelated donors; bioactivity of anti-cancer ability meets the criteria.
11093152|NCT04124653|Experimental|PF-06842874/Placebo|Single dose administration of PF-06842874 or placebo
11093153|NCT04124653|Experimental|Relative Bioavailability|Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation
11093154|NCT04124640||treatment group|The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal
11093155|NCT04124627|Experimental|Single arm study|Ultrasound plus radiographic guidance
11093156|NCT04124614|Experimental|Brexpiprazole + Sertraline|3 pills: Dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
11093157|NCT04124614|Experimental|Sertraline|3 pills: Dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
11093158|NCT04124614|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
11093159|NCT04124601|Other|Neoadjuvant Chemoradiotherapy|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days)
11093160|NCT04124601|Experimental|Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days) with sequential Ipilimumab (1 mg/kg IV on day 7) and Nivolumab (3 mg/kg IV on day 14, 28 and 42)
11093161|NCT04124588|Experimental|Test group|"After achieving initial hemostasis only with the standard-of-care, endoscopic hemostatic therapie(s)"
11093162|NCT04124588|Active Comparator|Control gruop|"After achieving initial hemostasis only with the standard-of-care, Wrap up the first endoscopy without adding an additional procedure."
11093163|NCT04124549|Sham Comparator|Stand of Care|Patients in the control group received usual care with sham exercise.
11093164|NCT04124549|Experimental|Combined Exercise|The intervention was a 24-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours. Each exercise lasted about 40 minutes.
11093165|NCT04124536|Experimental|Intervention|In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
11093166|NCT04124536|No Intervention|Control|Standard partner notification services, regardless of HIV status.
11093167|NCT04124510|Experimental|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
11093168|NCT04124497|Experimental|DPd|"Therapy consists in cycles of the DPd combination as follows:
~Pomalidomide 4 mg once daily on days 1-21;
~Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22;
~Daratumumab 16 mg/kg intravenously at following schedule:
~cycle 1 and 2: days 1, 8, 15, and 22
~cycle 3 through 6: days 1, and 15
~from cycle 7 until disease progression: day 1."
11093169|NCT04124484|Experimental|50mg group|Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.
11093170|NCT04124484|Experimental|100mg group|Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.
11093171|NCT04124484|Experimental|200mg group|Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.
11093172|NCT04124484|Placebo Comparator|placebo group|Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg
11093173|NCT04124458|Active Comparator|Pulsed Radiofrequency Ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
11093174|NCT04124458|Active Comparator|Bilateral Occipital Nerve Block|In this arm all steps are the same as other arm, except the generator will not be on and patient will have pain relief by injecting numbing medications beside the sensory nerves.
11093175|NCT04124445|Active Comparator|Pulsed Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine with Maximum allowable temperature 50° rotation: 90.; Pulse rate: 3 Hz; pulse duration: 50 ms; 3 minutes
11093176|NCT04124445|Active Comparator|Continuous Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine, burn will be made at 80° for 60 seconds.
11093177|NCT04124432|Experimental|Active cannabis without nicotine|Smoked cannabis containing 10mg THC + No nicotine/tobacco
11093178|NCT04124432|Experimental|Active cannabis with own brand cigarettes|Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes
11093179|NCT04124432|Experimental|Active cannabis with low nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
11093180|NCT04124432|Experimental|Active cannabis with high nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
11093181|NCT04124432|Experimental|placebo cannabis with own brand cigarettes|Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes
11093182|NCT04124432|Experimental|Placebo cannabis with low nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
11093183|NCT04124432|Experimental|Placebo cannabis with high nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
11093184|NCT04124419|Experimental|Treatment Arm|Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
11093185|NCT04124406||Adults Prescribed Cologuard|Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
11093186|NCT04124393|Active Comparator|Water Exchange (WE) Colonoscopy|In the WE group, the air pump will be turned off before starting the procedure. During the insertion phase, the colon will be irrigated with warm water (32C-35C). WE entails the infusion of water to open the lumen and simultaneous suction if the endoscope has two channels, and sequentially if the endoscope has only one channel. When the cecum is reached and after most of the water is suctioned to collapse the cecal lumen, CO2 will be opened. The colonoscope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The colonoscope will then be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
11093187|NCT04124393|Active Comparator|CO2 Insufflation Colonoscopy|In the CO2 group, colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the colonoscope will be withdrawn from the cecum to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then, the colonoscope will be reinserted into the cecum by the first endoscopist. A tandem inspection of the right colon will be performed by a blinded endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
11093188|NCT04124380|Experimental|Imaginal Exposure First, then Alcohol Skills|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. After imaginal exposure, alcohol skills targeting alcohol misuse after sexual assault.
11093189|NCT04124380|Experimental|Alcohol Skills First, then Imaginal Exposure|Alcohol skills targeting alcohol misuse after sexual assault. After alcohol skills training, imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault.
11093190|NCT04124380|Active Comparator|Supportive Counseling/Telehealth|Internet-based intervention focusing on providing support.
11093191|NCT04124380|Experimental|Alcohol Skills First, no additional treatment|Alcohol skills targeting alcohol misuse after sexual assault only. No additional treatment.
11093192|NCT04124380|Experimental|Imaginal Exposure First, no additional treatment|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. No additional treatment.
11093193|NCT04124367|Active Comparator|Verum|
11093194|NCT04124367|Placebo Comparator|Control|
11093195|NCT04124354|Experimental|Immediate Experimental Group|Participants will immediately begin an experimental supervised moderate-intensity treadmill walking intervention program.
11093196|NCT04124354|No Intervention|Delayed Intervention Control Group|Participants will be asked to maintain their usual physical activity during the initial 8-week intervention period but will undergo all data collection procedures. Following the initial intervention period, these participants will be given the option to complete the 8-week intervention, with identical data collection procedures employed.
11093197|NCT04124341|Experimental|Epidural Prefrontal Cortical Stimulation (EpCS)|Stereotactically implanted bilateral EpCS
11093198|NCT04124328|Active Comparator|ALINE only group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria
11093199|NCT04124328|Active Comparator|VoM group|Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion
11093200|NCT04124315||PAD Patients Completing SET|This single-group study includes patients with peripheral artery disease (PAD) who are completing a physician-prescribed supervised exercise training (SET) program.
11093201|NCT04124302|Active Comparator|IPF|Total meal bolus will consist of insulin for carbohydrates (IC) and insulin for proteins and fats (IPF) based on individual insulin-to-carbohydrate ratio (ICR). Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
11093202|NCT04124302|Experimental|30%IC|Total meal bolus will consist of insulin for carbohydrates (IC) calculated based on individual insulin-to-carbohydrate ratio (ICR) and insulin for proteins and fats (IPF) estimated as 30% of IC. Dual bolus will be given 15 minutes before the mixed meal (toast with cheese).
11093203|NCT04124289||Pain post surgery|Patients who have completed surgery will be assessed with three types of pain scales. A new pain scale, a functional pain scale (FPS), will be compared to two pain scales that are routinely used: the FACES pain scale and the numeric rating scale (NRS).
11093204|NCT04124276|Experimental|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day) for 6 weeks
11093205|NCT04124276|Placebo Comparator|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
11093206|NCT04124263|Experimental|Medication Time Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
11093207|NCT04124263|Experimental|Educational Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
11093208|NCT04124224||Unidos Participants|In the Unidos intervention the county/community-based CHWs will: 1) support and connect participants to health promotion resources; 2) provide individual and group-based support guided by a novel framework for understanding Latino's health advantages, the sociocultural resiliency model; and, 3) leverage community resources to help individuals address SDH-related needs.
11093209|NCT04124224||Non-Unidos Participants: Comparison Group|Using propensity score matching, the investigators will use the medical records of Unidos participants and the electronic health record comparison group to compare health outcomes.
11093210|NCT04124211|Experimental|FMT Arm|10 Participants will be enrolled in this arm to receive FMT treatment
11093211|NCT04124198|Experimental|Transoral robotic surgery (TORS)|
11093212|NCT04124198|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|"Patients with clinical T1N0 stage are offered accelerated radiotherapy to 66 Gy/33fractions with concurrent nimorazole.
~Patients with clinical T2N0 stage are offered either accelerated radiotherapy to 66 Gy/33fractions with the option of weekly cisplatin to fit patients or hyper-fractionated accelerated radiotherapy to 76 Gy/56fractions both with concurrent nimorazole.
~Patients with clinical T1-T2, N1 stage are offered accelerated radiotherapy to 66 Gy/33 fractions and nimorazole with the addition of concurrent weekly cisplatin 40 mg/sqm to fit patients."
11093213|NCT04124185||Patients with Achromatopsia|
11093214|NCT04124172|Active Comparator|Real rTMS|"rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). M1 is defined like the hot spot to elucidated a motor evoked potential in the Abductor Pollicis Brevis (APB) muscle of the contralateral hand. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
11093215|NCT04124172|Sham Comparator|Sham rTMS|"Sham rTMS (Magstim Super Rapid, Magstim Company, Whitland, Wales, UK) with eight-shaped coil (1 Hz, 1500 stimuli) in M1of the contralateral hemisphere to the lesion (healthy side). Investigators will make the simulation disconnecting the coil but keeping its position during the same time as the real one. Intervention will be performed before one hour rehabilitation session of the upper limb according to our clinical protocol, completing 15 sessions."
11093216|NCT04124146||Patients with Surgery more than 10 years|Patients with surgery for spinal lumbar stenosis between 2006 and 2008 will be purposed to participate to the study.
11093217|NCT04124120|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
11093218|NCT04124120|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
11093219|NCT04124107|Experimental|Prostate biopsy with 68Ga-PSMA PET/MRI|Both targeted biopsy and 12-core systematic biopsy with positive 68Ga-PSMA PET/MRI
11093220|NCT04124094|Experimental|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg|Test Product
11093221|NCT04124094|Active Comparator|SERETIDE DISKUS 100/50|reference Product
11093222|NCT04124081|Experimental|Drug group|
11093223|NCT04124068|Experimental|GLO Science Professional Chairside Teeth Whitening|
11093224|NCT04124068|Experimental|GLO Science Professional At-Home Teeth Whitening Device|
11093225|NCT04124068|Experimental|GLO Brilliant At-Home Teeth Whitening Device|
11093226|NCT04124068|Experimental|GLO Lit At-Home Teeth Whitening Device|
11093227|NCT04124068|Experimental|GLO Lit Whitening GLO Vials|
11093228|NCT04124055|Experimental|Therapeutic drug monitoring (TDM)|Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples
11093229|NCT04124042|Placebo Comparator|Placebo|Inactive comparator
11093230|NCT04124042|Experimental|Low Dose XT-150|Low dose active, experimental treatment
11093231|NCT04124042|Experimental|High Dose XT-150|High dose active, experimental treatment
11093232|NCT04124029||Younger mild Traumatic Brain Injury|mTBI subjects aged 30-59 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the Test of Memory Malingering (TOMM) and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
11093233|NCT04124029||Older mild Traumatic Brain Injury|mTBI subjects aged 60- 90 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
11093234|NCT04124029||moderate Traumatic Brain Injury|TBI control subjects, age-, education- and sex-matched with mTBI subjects (aged 30-90) will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). Moderate TBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
11093235|NCT04124029||Mild Cognitive Impairment (MCI)|MCI control subjects, age-, education- and sex-matched with older mTBI subjects (aged 60-90) will be recruited if they meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria. Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function (i.e. will not meet diagnostic criteria for dementia). MCI subjects will be matched for their Montreal Cognitive Assessment (MoCA) score with older mTBI subjects. Of note, subjects with MCI may or may not meet diagnostic criteria for MCI due to AD. The intent of this control group is to recruit a broad range of MCI subjects without TBI as controls for subjects with cognitive impairment who have a history of mTBI.
11093236|NCT04124029||Younger Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with younger mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
11093237|NCT04124029||Older Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with older mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
11093238|NCT04124016|Experimental|Inulin|Inulin_ extract of chicory fermentable fiber
11093239|NCT04124016|Experimental|green tea extract|green tea extract_rich in tri-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursor)
11093240|NCT04124016|Experimental|grape seed|grape seed extract - rich in di-hydroxylated flavan-3-ol monomers (1 mmol of PVL precursors)
11093241|NCT04124016|Experimental|grape seed exctract|grape seed extract - rich in di-hydroxylated flavan-3-ol oligomers (1 mmol of PVL precursors)
11093242|NCT04124003|Experimental|rosuvastatin + BMS-963272|
11093243|NCT04123990|Experimental|IBD|
11093244|NCT04123951|Experimental|Home-based Exercise|Patients in this arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
11093245|NCT04123951|No Intervention|Control|"In this arm patients will continue 'as normal' with daily activities.
~Patients in this arm will be offered the exercise intervention once they have completed post 12 week assessments."
11093246|NCT04123938|Experimental|Pea Protein|Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
11093247|NCT04123938|Active Comparator|Whey Protein|Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
11093248|NCT04123938|Placebo Comparator|Maltodextrin|Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
11093249|NCT04123925|Experimental|Nivolumab|Patients will receive nivolumab at a flat dosage of 240 mg every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to +7 days
11093250|NCT04123912|Experimental|KT-FMPT group|
11093251|NCT04123912|Placebo Comparator|Control group|
11093252|NCT04123899|Experimental|IGAD→GSTD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
11093253|NCT04123899|Experimental|GSTD→IGAD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
11093254|NCT04123886|Experimental|SCB-313|
11093255|NCT04123873|Experimental|Group A|"Paracetamol 1000 mg + Ibuprofen 400 mg administered orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus placebo (matching DXM) IV administered after induction of anaesthesia"
11093256|NCT04123873|Experimental|Group B|"Paracetamol 1000 mg and placebo (matching ibuprofen) orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus DXM 24 mg IV after induction of anaesthesia"
11093257|NCT04123873|Experimental|Group C|"Placebo (matching paracetamol) + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus DXM 24 mg IV after induction of anaesthesia"
11093258|NCT04123873|Experimental|Group D|"Paracetamol 1000 mg + ibuprofen 400 mg orally 1 hour before surgery and given with 6-hour intervals to a total of 4 times the first postoperative day.
~Plus DXM 24 mg IV after induction of anaesthesia"
11093259|NCT04123860|Experimental|buccal fat pad|will undergo sinus lifting using intralift technique then placement of buccal fat pad followed by immediate implant placement.
11093260|NCT04123860|Active Comparator|prf|will undergo sinus lifting using intralift technique the prpration of PRF and immediate implant placement.
11093261|NCT04123847|Experimental|Stand, Step and Voluntary Training|
11093262|NCT04123834|Experimental|implantless Arthroscopic ACL reconstruction|implantless Arthroscopic ACL reconstruction using press-fit femoral technique
11093263|NCT04123834|Experimental|Arthroscopic ACL reconstruction with implant|ACL reconstruction with implant (hamstring autograft fixed with bioscrew and endo-button)
11093264|NCT04123821|Experimental|Group A|
11093265|NCT04123821|No Intervention|Group B|
11093266|NCT04123808|Experimental|IpsiHand Treatment|All participants will receive treatment with IpsiHand device
11093267|NCT04123795|Experimental|Cohort A - certolizumab pegol|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent 104-Week Open-Label Extension Period.
11093268|NCT04123795|Placebo Comparator|Cohort A - placebo|Enrolling study participants aged 12 to 17 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of placebo from Week 1 to 16 and certolizumab pegol to Week 52 and through the subsequent 104-Week Open-Label Extension Period.
11093269|NCT04123795|Experimental|Cohort B - certolizumab pegol|Enrolling study participants aged 6 to 11 years (inclusive). Study participants in this arm will receive weight-based subcutaneous doses of certolizumab pegol from Week 1 to Week 52 and through the subsequent 104-Week Open-Label Extension Period.
11093270|NCT04123782|Active Comparator|Group A (F-ESWT group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.12 mJ/mm2 per session)
11093271|NCT04123782|Placebo Comparator|Group B (placebo group)|3 sessions, one per week, of electromagnetic focused extracorporeal shockwave treatment (3000 impulses at 0.01 mJ/mm2 per session)
11093272|NCT04123769|Experimental|Drug group|
11093273|NCT04123743|Experimental|Experimental Group|The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.
11093274|NCT04123743|Placebo Comparator|Control Group|The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33
11093275|NCT04123730|Active Comparator|Fixed dose oxygen|O2Matic deliver the usual fixed-dose oxygen treatment during walking.
11093276|NCT04123730|Experimental|Automated oxygen titration|O2Matic deliver a variable oxygen dosage set at an SpO2-target of 90 to 94 % and a O2-flow of 0 - 15 liters/min during walking.
11093277|NCT04123717|Active Comparator|Arm1 - IV Ibuprofen|Patients will receive IV Ibuprofen 10 mg/kg to a maximum of 400 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with 100 ml normal saline.
11093278|NCT04123717|Active Comparator|Arm 2 -IV Paracetamol|Patients will receive 15 mg/kg IV Paracetamol to a maximum of 1000 mg intravenously over 15 minutes. This medication will be diluted as per manufacturer instructions with normal saline.
11093279|NCT04123717|Active Comparator|Arm 3- Both IV Paracetamol and IV Ibuprofen|Patients will receive an infusion of both IV Paracetamol and IV Ibuprofen. They will initially receive IV Ibuprofen and the IV catheter will then be flushed with 10 ml of normal saline, and the patient will receive IV Paracetamol
11093280|NCT04123717|Active Comparator|Arm 4 -PO Brufen|Patients will receive PO ibuprofen given as a 100mg/5ml syrup or 200 mg tablets to a maximum of 400 mg. The treating nurse will ask the parental preference to use syrup or tablets. If they vomit the medication within 15 minutes of administration, another full dose will be administered.
11093281|NCT04123704|Experimental|Sitravatinib|Sitravatinib 120 mg daily
11093282|NCT04123678||All|Patients attending a Medical Photography facility with at least 1 suspicious skin lesion will be approached to participate in the study. Participants will have an additional macro and dermoscopic image of each suspicious skin lesions suitable for photography. Photographs will be taken by a healthcare professional using an iPhone XR smart phone camera with a DL1 dermoscopic lens attachment. The images will be encrypted and electronically transmitted to Skin Analytics' cloud servers for analysis by DERM. The suspected diagnosis determined by DERM will be compared with dermatologist review and histologically confirmed diagnosis, where obtained. Healthcare resource utilization information and patient satisfaction data will also be collected
11093283|NCT04123665|Experimental|Experimental Test Dentifrice|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
11093284|NCT04123665|Placebo Comparator|Control Dentifrice|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate [SMFP] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
11093285|NCT04123652|Other|Lidocaine and ketamine infusion|
11093286|NCT04123626|Experimental|QR-1123 Single dose - dose level 1|Open label Single dose cohort: dose level 1
11093287|NCT04123626|Experimental|QR-1123 Single dose - dose level 2|Open label Single dose cohort: dose level
11093288|NCT04123626|Experimental|QR-1123 Single dose - dose level 3|Open label Single dose cohort: dose level 3
11093289|NCT04123626|Experimental|QR-1123 Single dose - dose level 4|Open label Single dose cohort: dose level 4
11093290|NCT04123626|Experimental|QR-1123 Single dose - dose level 5|Open label Single dose cohort: dose level 5
11093291|NCT04123626|Experimental|Repeat dose cohort 1|Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
11093292|NCT04123613|Experimental|2.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3
11093293|NCT04123613|Experimental|5.0 µg/kg, multiple dose|n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3
11093294|NCT04123587|Experimental|Sulfonylurea-dependent|Sulfonylurea is replaced by alternative oral hypoglycemic agent.
11093295|NCT04123574|Experimental|Single Arm|BXCL701 will be administered at a dose of 0.3 mg, twice daily (BID) for a total daily dose of 0.6mg to all patients for a short period of 14 days
11093296|NCT04123561|Experimental|TLC599|TLC599 (1mL) IA injection
11093297|NCT04123561|Active Comparator|Dexamethasone sodium phosphate|DSP 4mg (1mL) IA injection
11093298|NCT04123561|Placebo Comparator|Normal Saline|Normal saline (1mL) IA injection
11093299|NCT04123535|Experimental|Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|Pre-operative MRgFUS with the ExAblate 2000/2100 MRgFUS system 1-4 weeks prior to surgical resection of their tumor
11093300|NCT04123522||anterior cervical spine surgery|The patients will be enrolled for elective anterior cervical spine surgery.
11093301|NCT04123522||posterior cervical spine surgery|The patients will be enrolled for elective postieor cervical spine surgery
11093302|NCT04123496|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is 5 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093303|NCT04123496|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093304|NCT04123496|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093305|NCT04123496|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093306|NCT04123496|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093307|NCT04123496|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093308|NCT04123496|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093309|NCT04123496|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093310|NCT04123496|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 45 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093311|NCT04123496|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11093312|NCT04123483|Experimental|EnBrace HR for Acute Treatment of PMS and MRMD|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 weeks. Participants are currently experiencing clinically significant MRMD symptoms, defined as a ≥ 30% increase in the total Daily Record of Severity of Problems Scale (DRSP) score from the mid-follicular phase (average of DRSP scores for days 6-10) to the late-luteal phase (average of DRSP scores for last 5 days prior to menstrual bleeding).
11093313|NCT04123470|Experimental|Treatment|Delolimogene mupadenorepvec plus atezolizumab
11093314|NCT04123444|Experimental|Iloprost|Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
11093315|NCT04123444|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
11093316|NCT04123431||ACE Acetabular Cup System with XLPE Liner|
11093317|NCT04123431||ACE Acetabular Cup System with Ceramic Liner|
11093318|NCT04123431||ACE Acetabular Cup System with Dual Mobility Insert|
11093319|NCT04123418|Experimental|WVT078 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
11093320|NCT04123418|Experimental|WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
11093321|NCT04123405|Experimental|acetylcysteine 600 mg|600 mg acetylcysteine: one tablet test product plus three tablets placebo per day
11093322|NCT04123405|Experimental|acetylcysteine 1200 mg|two tablets test product plus two tablets placebo per day
11093323|NCT04123405|Experimental|acetylcysteine 2400 mg|four tablets test product per day
11093324|NCT04123405|Placebo Comparator|Placebo|four tablets placebo per day
11093325|NCT04123392|Experimental|Decitabine + BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, Decitabine +BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11093326|NCT04123392|Active Comparator|BUCY|For TP53+ myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11093327|NCT04123379|Experimental|Cohort A|NSCLC: Nivolumab + BMS-813160
11093328|NCT04123379|Experimental|Cohort B|NSCLC: Nivolumab + BMS-986253
11093329|NCT04123379|Experimental|Cohort C|HCC: Nivolumab
11093330|NCT04123379|Experimental|Cohort D|HCC: Nivolumab + BMS-813160
11093331|NCT04123379|Experimental|Cohort E|HCC: Nivolumab + BMS-986253
11093332|NCT04123366|Experimental|Olaparib+Pembrolizumab|Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.
11093333|NCT04123340|Experimental|Additional intraprocedural CT-scan|Additional intraprocedural CT-scan
11093334|NCT04123314|Experimental|Psilocybin|Participants will complete an 8-week course of study treatment including weekly psychological support and two moderate to high dose psilocybin administrations in weeks 4 and 6.
11093335|NCT04123301|Active Comparator|Active TBS Arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
11093336|NCT04123301|Sham Comparator|Sham TBS Arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
11093337|NCT04123288|Experimental|Test drug formulation|Test drug 60 mg single dose
11093338|NCT04123288|Active Comparator|Reference drug formulation|60 mg single dose
11093339|NCT04123262|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
11093340|NCT04123249||Group Propofol|Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation, remifentanil 0.2μg/kg/min intravenous pumping assisted analgesia
11093341|NCT04123249||Group Sevoflurane|Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation, remifentanil 0.2μg/kg/min intravenous pumping assisted analgesia
11093342|NCT04123236||Oral Health Impact Profile|To evaluate the Oral Health-related Quality of Life, Turkish version of Oral Health Impact Profile-14 was used. Responses were made on a scale 0 (never), 1(hardly ever), 2 (occasionally), 3 (fairly often),and 4 (very often).Oral Health-related Quality of Life impairment was characterized by the Oral Health Impact Profile-14 summary score (the sum of all 14 items, potential range 0-56). Higher Oral Health Impact Profile-14 scores mean worse Oral Health-related Quality of Life and vice versa.
11093343|NCT04123236||Helkimo's anamnestic dysfunction index|As a method based on patient feedback for the determination of the degree of temporomandibular disorders, anamnestic index was used. For this purpose eight questions were asked to the patients that includes answers as 'yes' or 'no'. (Table 2) The analyses of the questionnaire was done according to anamnestic scale as 0: no symptoms; I: mild symptoms (sensation of the jaw fatigue, jaw stiffness, and temporomandibular joint sounds as clicking or crepitus) and II:severe symptoms (included one or more of the following: Difficulty in the mouth opening, jaw locking, mandible dislocation and its painful movement and painful temporomandibular joint region and/or masticatory muscles)
11093344|NCT04123236||Visual analog scale (VAS) for facial pain:|Facial pain was measured by asking the patients if they had had any pain during last 12 months and made them mark the intensity of the pain on a visual analog scale which had the anchor points at the left (no pain) and right (worse pain) ends of a 10 cm horizontal line. The analyses of the facial pain was done as fallowing: if the patient marked no facial pain the Visual analog scale value was accepted as 0 and if the patient marked any level of facial pain Visual analog scale value was accepted as 1.
11093345|NCT04123236||Helkimo's clinical dysfunction index (DI):|Maximum opening of mandible, deviation during opening, dysfunction of temporomandibular joint, pain in the temporomandibular joint and pain in the masticatory muscles was evaluated
11093346|NCT04123223|Experimental|Restorative CR Intervention|The restorative remediation intervention will consist of a target of 50 hours (5 hours per week, 1 hour per day, over 3 months) of a sequence of computerized cognitive exercises designed to improve cognitive function through repeated drill-and-practice of exercises largely focused on attention, working memory and verbal episodic memory. Cognitive deficits will be directly targeted by these exercises. Exercises will be started at individually determined levels of difficulty at which each client will be successful, e.g., 80% accuracy. Task difficulty will be increased as performance improves.
11093347|NCT04123223|Experimental|Strategy CR Intervention|Participants in this intervention will be treated for 24 hours (2 hours per week, one day per week over 3 months) with Compensatory Cognitive Training (CCT). The therapy targets four cognitive domains: (a) prospective memory, (b) attention and vigilance, (c) learning and memory, and (d) executive function. The program is a group-based intervention that teaches strategies via interactive, game-like activities to maintain interest and enhance motivation and engagement.
11093348|NCT04123223|Placebo Comparator|Computer Games|Three months of 1-hour, 5-times per week, client-selected computer games.
11093349|NCT04123210|Experimental|Vitamin A supplement|Subjects receive a vitamin A supplement containing 175 or 525 micrograms of vitamin A as retinyl palmitate daily
11093350|NCT04123210|Placebo Comparator|Placebo|Subjects receive an oil placebo containing no vitamin A
11093351|NCT04123197|Other|Young Participants with Prior MI|Participants aged 60 or less who experienced a MI within the last 8 months will undergo a stress challenge to assess MSI and will then be followed for 3 years.
11093352|NCT04123171||The Three Villages Cohort|Individuals aged 60 years or more identified by means of door-to-door surveys, living in Atahualpa, El Tambo, and Prosperidad. Individuals will be interviewed with validated field instruments, and there will be invited for the practice of complementary exams to recognize markers of aterosclerosis and cerebral small vessel disease.
11093353|NCT04123158||WHITE|If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
11093354|NCT04123158||GREEN|"Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.
~If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card
~In case of negative Orange Criteria (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of positive Orange Criteria the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately."
11093421|NCT04122664|Active Comparator|RayOne® Hydrophobic lens 800C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophobic lens 800C
11093456|NCT04122352|Experimental|Exercises + ischemic compression group|volunteer patients with temporomandibular joint dysfunction with trigger points
11093355|NCT04123158||ORANGE|- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 15 days and triaged to surgery (to be performed within 30 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
11093356|NCT04123145|Experimental|CDK-ND|
11093357|NCT04123132||Patients with metabolic syndrome|
11093358|NCT04123132||Healthy controls|
11093359|NCT04123119|Experimental|Rotarix Arm|
11093360|NCT04123106|Experimental|ESP block|Ultrasound-guided, performed below erector spinae plane (ropivacaine 0.5% 20 mL each side).
11093361|NCT04123106|Active Comparator|Wound infiltration|Ropivacaine 0.5% 20-40 mL, performed by surgeon.
11093362|NCT04123093|Experimental|Healthy Volunteers|The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
11093363|NCT04123093|Experimental|Wound care|The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
11093364|NCT04123080|Experimental|EBL group|Removal of large long-stalked pedunculated colonic polyps using band ligations
11093365|NCT04123067|Experimental|Pioglitazone treatment group|oral administration of 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
11093366|NCT04123067|Placebo Comparator|Placebo group|Oral administration of placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
11093367|NCT04123054|No Intervention|Sensor-Augmented MDI Therapy|Participants will undergo their usual multiple daily injection (MDI) therapy along with a Freestyle Libre glucose sensor (Abbott Diabetes Care), and a data collection mobile application that collects insulin and meal data.
11093368|NCT04123054|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will undergo multiple daily injection (MDI) therapy with a Freestyle Libre glucose sensor (Abbott Diabetes Care) and a data collection mobile application that collects insulin and meal data. Every week, participants' insulin doses will be updated by the optimization algorithm's recommendations.
11093369|NCT04123041|Experimental|Virginia Tobacco|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Virginia Tobacco ENDS, JUUL 3% Virginia Tobacco ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
11093370|NCT04123041|Experimental|Mint|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mint ENDS, JUUL 3% Mint ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
11093371|NCT04123041|Experimental|Menthol|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Menthol ENDS, JUUL 3% Menthol ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
11093372|NCT04123041|Experimental|Mango|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mango ENDS, JUUL 3% Mango ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
11093373|NCT04123028||eosinophilic COPD patient|COPD patient with blood eosinophil equal or > 300 cells/µL
11093374|NCT04123028||non-eosinophilic COPD patient|COPD patient with blood eosinophil < 300 cells/µL
11093375|NCT04123002|Experimental|Interventional group|Miswak chewing sticks would be provided to the participants and they would be explained the method of use
11093376|NCT04123002|No Intervention|Comparison group|They would use only tooth brush and paste
11093377|NCT04122989|Experimental|MS-SUPPORT|Group receives access to an online shared decision making tool (an interactive decision aid) for multiple sclerosis.
11093378|NCT04122989|No Intervention|Control|Usual care
11093379|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
11093380|NCT04122963|Active Comparator|High power group|The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).
11093381|NCT04122963|Active Comparator|Standard group|The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)
11093382|NCT04122950|Experimental|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
11093383|NCT04122950|No Intervention|Control|Continue with normal daily routine.
11093384|NCT04122937||Ovarian cancer|Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.
11093385|NCT04122937||Colon cancer|Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).
11093386|NCT04122924|Experimental|Intervention Group|A three months home-based abdominal muscle training program.
11093387|NCT04122924|No Intervention|Control Group|The control group will have no intervention, and will be asked not to attend any specific supervised abdominal muscle training program during the 3 months intervention period.
11093388|NCT04122911|Experimental|Temozolomide|Temozolomide 75mg/m2 metronomic schedule: one week on/one week off in a cycle of 28 days
11093389|NCT04122898|Experimental|Intervention Group|Three months home-based PFM training program with weekly follow-up by a physiotherapist
11093390|NCT04122898|No Intervention|Control Group|No intervention
11093391|NCT04122885||CRS and HIPEC|Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
11093392|NCT04122885||PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
11093393|NCT04122872||Patients with bone or soft tissue sarcomas or carcinosarcomas|Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone [GCTB], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
11093394|NCT04122859|Active Comparator|Zip Skin Closure Device|The device is a class IIa device as per Annex II of the MDD 93/42EEC, as amended by Directive 2007/47/EEC. A CE-mark was affixed in 2014. The Zip device adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives. A combination of acrylic and hydrocolloid adhesives is used to provide a skin-friendly environment while providing the necessary tack to maintain skin adhesion during a maximum wear time of 14 days. In addition to the pressure-sensitive adhesives, the device's closure and force distribution components are made up of polyurethane monofilm, polyethylene tape, polyester and nylon.
11093395|NCT04122859|Active Comparator|Standard of Care Sutures|Conventional sutures used for laceration repair
11093396|NCT04122846|Experimental|Treatment (Emotional Awareness and Expression Therapy)|Internet-based Emotional Awareness and Expression Therapy
11093397|NCT04122820|Other|Presence of HV-Labile|Presence of vertical heterophoria labile with proprioceptive Maddox
11093398|NCT04122820|Other|Absence of HV-Labile|Presence of stable vertical heterophoria or stable orthophoria with proprioceptive Maddox
11093399|NCT04122807|Active Comparator|Mapping|Standard treatment involving ablation of the slow pathway with cryotherapy
11093400|NCT04122807|Experimental|Ablation|Mapping and ablation of the retrograde fast pathway with cryotherapy
11093401|NCT04122781|Experimental|with novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation and novel K-wire fixation devices
11093402|NCT04122781|Active Comparator|without novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation
11093403|NCT04122768|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
11093404|NCT04122768|Sham Comparator|Sham coaching group|Coaching with fixed physical activity goal and limited interaction with the smartphone application.
11093405|NCT04122755|Experimental|Cohort1|Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).
11093406|NCT04122755|Experimental|Cohort2|Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose
11093407|NCT04122755|Experimental|Cohort3|Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose
11093408|NCT04122755|Experimental|Cohort4|Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose
11093409|NCT04122755|Experimental|Cohort5|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose
11093410|NCT04122755|Experimental|Cohort6|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing
11093411|NCT04122742||Patients with RSTS|
11093412|NCT04122716|Active Comparator|Liraglutide + exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.
~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
11093413|NCT04122716|Other|Liraglutide + non-exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.
~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
11093414|NCT04122716|Other|Placebo + exercise|"Placebo: 3mg/day sc.
~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
11093415|NCT04122716|No Intervention|Placebo + non-exercise|"Placebo: 3mg/day sc.
~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
11093416|NCT04122703|Experimental|Percutaneous tibial nerve stimulation (PTNS)|The patients in the PTNS group will receive 1 PTNS treatments per week for 12 weeks.
11093417|NCT04122703|Sham Comparator|Transcutaneous electrical nerve stimulation (TENS)|The patients in the Sham group will receive one sham (TENS) treatment per week for 12 weeks
11093418|NCT04122690|Experimental|Partnered Dance Aerobic Exercise|Partnered Dance-Aerobic Exercise (PDAE) is an adapted form of Argentine tango, aka Adapted tango. Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
11093419|NCT04122690|Active Comparator|Walking Aerobic Exercise|Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
11093420|NCT04122664|Active Comparator|RayOne® Hydrophilic lens 600C|Patients will be randomly selected to receive the monofocal, acrylic, RayOne® Hydrophilic lens 600C
11093457|NCT04122352|Other|Exercises group|volunteer patients with temporomandibular joint dysfunction with trigger points
11093422|NCT04122651|Experimental|Experimental Arm|Patients will be receiving a toric intraocular lens with either a 2.00 or 4.00 diopter (D) correction, depending on the degree of pre-operative astigmatism, and the astigmatic refractive error will be refined with the use of adjunctive limbal relaxing incisions LRIs and/or off axis rotation of the toric IOL (based on a standardized protocol) so the full amount of corneal astigmatism can be targeted for correction for each patient.
11093423|NCT04122651|Active Comparator|Control Arm|The patient will receive a toric intraocular lens individually tailored to and ordered for each patients' precise degree of corneal astigmatism.
11093424|NCT04122625|Experimental|Debio 1143 + Nivolumab|Part A: Participants will receive Debio 1143 at a starting dose of 150 milligrams (mg) orally once daily on Days 1-10 and Days 15-24 every 4 weeks (q4w) along with nivolumab at a flat dose of 240 mg intravenously (IV) on Days 1 and 15 of a 28-day cycle, participants may be switched to 480 mg IV on Day 1 q4w, exclusively upon investigator request with the sponsor agreement. Part B: Participants will receive Debio 1143 at RP2D established in Part A in combination with nivolumab as per standard care.
11093425|NCT04122599|Other|Melatonin versus standard care|Melatonin is tested versus standard care
11093426|NCT04122586|No Intervention|health control group|
11093427|NCT04122586|Experimental|Tongxieyaofang granule group|
11093428|NCT04122573||Acute chest pain|The population in this study are characterized by acute chest pain as the first symptom for consultation within 24 hours.
11093429|NCT04122560|Experimental|Obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg
~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
11093430|NCT04122560|Active Comparator|Non-obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg
~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
11093431|NCT04122547|Active Comparator|Roflumilast|Roflumilast 500 microgram one tab oral per day
11093432|NCT04122547|Placebo Comparator|Placebo|One tablet oral per day
11093433|NCT04122534|Experimental|Treatment Group|Treatment groups receives the intervention training.
11093434|NCT04122521||Glioma|Patients suspected of glioma
11093435|NCT04122495|Experimental|Probiotic|Bifidobacterium lactis M8 at 10 log CFU/day for 4 weeks
11093436|NCT04122495|Placebo Comparator|Placebo|Intervention consists of daily administration of 1g of maltodextrin, administered daily for 4-weeks
11093437|NCT04122482|Experimental|Intervention Group|In this arm, participants will be given access to the course material shortly after eligibility criteria is confirmed. They will be asked to complete post-measures questionnaires at 4 weeks and 8 weeks following completion of the course material.
11093438|NCT04122482|Experimental|Wait-list Control|In this arm, participants will be given access to the course material 8 weeks following confirmation of their eligibility. During, the 8-week waiting period they will be asked to complete questionnaires at 4 weeks and 8 weeks. At 8 weeks they will be given access to the course material and will be asked to complete the same questionnaires 4- and 8-weeks following completion of the course material.
11093439|NCT04122469|Experimental|Intervention|Receiving SBRT.
11093440|NCT04122456|Experimental|Day Shift Work Schedule|Day shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
11093441|NCT04122456|Experimental|Night Shift Work Schedule|Night shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
11093442|NCT04122443|Active Comparator|Acetaminophen|Acetaminophen alone
11093443|NCT04122443|Active Comparator|Oxycodone/ acetaminophen|Oxycodone + acetaminophen
11093444|NCT04122430||GCT treated with first line chemotherapy|"Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT
~."
11093445|NCT04122417||Control Group|"The mothers and infants in the experimental and control groups were assigned to the groups by randomization method. Therapeutic touch didn't apllied to control group.
~Babies in the control group who took care practices in accordance with normal hospital procedures."
11093446|NCT04122417||Yakson Group|"The touch method was taught to the mothers in the Yakson group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.
~In yakson method, mother's fingers are closed, and she should touch in a way that does not apply excessive pressure. The method is applied for a total of 15 minutes in three cycles. First 5 minutes is resting the hand, 5 minutes is gentle caressing, and another 5 minutes of resting the hand."
11093447|NCT04122417||Gentle Human Touch Group|"The touch method was taught to the mothers in the Gentle Human Touch group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.
~Mother slowly places one hand on the baby's hand and the other over pelvic cavity, covering the waist and hips of the baby.
~The touch is preserved for 15 minutes. In order to ensure equal touch for the duration of gentle human touch, the mother sits on a stool and her elbows have to be at the same level with baby's bed"
11093448|NCT04122404|Other|Intervention|"Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture) + Intervention
~Intervention: LF-LAM is made available at the study site for the clinical staff to use; Training of clinical staff in national TB guidelines and LF-LAM use together with staff from the National TB Programme in Ghana"
11093449|NCT04122404|No Intervention|Standard of care|Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture)
11093450|NCT04122391||control|team will work in OR with volume of 85 dB
11093451|NCT04122391||intervention|team will work in OR with volume of 100 dB
11093452|NCT04122378|Experimental|Treatment Arm|Acupuncture will be provided up to once daily for one or more days till the day of discharge or 5 days, whichever occurs first. Patients will continue to receive their standard pain management regime including IV opioids, ketorolac and fluids. Minimum number of sessions received by the acupuncture group will be one.
11093453|NCT04122378|No Intervention|Control Arm|Standard of care for SCD patients who are hospitalized for acute pain and typically includes IV opioids, ketorolac and fluids.
11093454|NCT04122365|Experimental|Interventional group|Chest Wall Mobilization Program
11093455|NCT04122365|Other|Control Group|Routine limbs exercises and education
11093459|NCT04122326|Experimental|Posture Sequence|Participants will complete computer work on a provided monitor and keyboard for two hours. During the first hour, the research personnel will alter the workstation every ten minutes to test various different postures of the neck, shoulder, arms, and trunk. The sequence will include 3 seated postures and 3 standing postures. At the end of the first hour, the participant will be instructed to adjust the workstation independently and continue to work for 60 minutes for an observational session.
11093460|NCT04122313||Patients with Dupuytren's Contracture Disease|Patients with Dupuytren's Disease following the current treatment pathway
11093461|NCT04122300|Experimental|Euphrasia arm|Euphrasia eye drops® (Weleda AG, Arlesheim) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
11093462|NCT04122300|Placebo Comparator|Placebo arm|Placebo (0.9% NaCl) is administrated at a dose of one drop in each eye four times a day over a period of 96 hours.
11093463|NCT04122287|Experimental|levofloxacin-tetracycline-containing quadruple group|patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
11093464|NCT04122287|Active Comparator|tinidazole-tetracycline-containing quadruple group|patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.
11093465|NCT04122274|Sham Comparator|Education Sheet and Sham Intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of the sham intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
11093466|NCT04122274|Experimental|Education Sheet and Decision-based interactive intervention|Participants will be asked to fill out a pre-intervention survey to assess existing concussion knowledge, perceived norms, attitudes, and behavioral intentions. Afterward, the NCAA concussion education fact sheet will be viewed along with the viewing of a decision- based interactive concussion education platform intervention. Following the intervention, a post-intervention survey re-assessing the constructs from the pre-intervention survey will be completed. May be completed in-person or virtually.
11093467|NCT04122261|Experimental|experimental group|MicroHand S robotic surgery group
11093468|NCT04122261|Experimental|control group|da Vinci robotic surgery group
11093469|NCT04122248||M6-C|Subjects treated with an M6-C device
11093470|NCT04122248||ACDF|Subjects treated with Anterior Cervical Discectomy and Fusion (ACDF)
11093471|NCT04122235|Experimental|Intervention arm|New follow-up model
11093472|NCT04122235|No Intervention|Control arm|Usual care
11093473|NCT04122222|Active Comparator|Hemodialysis|ESRD patients treated by hemodialysis
11093474|NCT04122222|Active Comparator|Hemodiafiltration|ESRD patients treated by on-line hemodiafiltration
11093475|NCT04122209|Experimental|HIIE-First|60-min of exercise split into; firstly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest). Secondly 30-min of continuous exercise (50% peak maximal oxygen uptake).
11093476|NCT04122209|Experimental|Continuous-First|60-min of exercise split into; firstly 30-min of continuous exercise (50% peak maximal oxygen uptake). Secondly 30-min HIIE (10 x 1min of PPO, followed by 2-min rest)
11093477|NCT04122196|Experimental|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
11093478|NCT04122196|Placebo Comparator|Placebo|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
11093479|NCT04122183|Experimental|Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation) and asked to complete the iManage Program. Six months after the screening participants will be asked if they visited an audiologist.
11093480|NCT04122183|No Intervention|Delayed Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation). Six months after the screening participants will be asked if they visited an audiologist and they will be given the opportunity to complete the iManage Program.
11093481|NCT04122170|Active Comparator|PB2452|PB2452 18 g Intravenous Infusion over a 16 hour duration.
11093482|NCT04122170|Placebo Comparator|Placebo|Placebo (0.9% Sodium chloride) intravenous Infusion over a 16 hour duration.
11093483|NCT04122144|Experimental|Intervention|ENHANCED-SPS intervention implemented
11093484|NCT04122144|No Intervention|Control|Standard of care maintained. These are procedures conducted during the routine HIV care visits at the health facilities include ART card documentation as required, general/routine counseling, and adherence counseling to the non suppressors, ART drug supply based on the clinicians prescription and laboratory monitoring.
11093485|NCT04122118|Experimental|Hearth services research (pharmacist-led education)|"PHASE I: Patients' medical records are reviewed.
~PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider."
11093486|NCT04122105|Experimental|intervention|sildenafil administration perioperative to renal transplant
11093487|NCT04122105|Active Comparator|control|renal transplant recipients
11093488|NCT04122092||MM patients have curative effect at least VGPR|We will detect cfDNA CIN of multiple myeloma patients who have the curative effect at least very good partial response (VGPR) after front line therapy, and then monitoring cfDNA CIN every two treatment cycles or every three months during follow up，the result will be compared with bone marrow aspiration MFC.
11093489|NCT04122079||Clinical|Patients receiving mental health treatment at the University outpatient clinic
11093490|NCT04122079||Students|University undergraduate students
11093491|NCT04122079||Community|Members of the community
11093492|NCT04122066||respiratory symptoms reported in studied patients|If Sofosbuvir\Daclatasvir regimen has respiratory side effects or not and the factors increase incidence of respiratory complications
11093493|NCT04122053|Experimental|study group|group will receive dietary advice and genotype information
11093494|NCT04122053|Active Comparator|Control group|group will receive dietary advice
11093497|NCT04122027|Active Comparator|Control|Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
11093498|NCT04122027|Active Comparator|Intervention|Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
11093499|NCT04122014|Experimental|Control group|Usual daily activities
11093500|NCT04122014|Experimental|Training group|Each subject will participate in 2 sessions each week during 3 months.
11093501|NCT04122001|Experimental|Active HD-tDCS+word intervention then Sham+word intervention|Participants will receive active HD-tDCS + Word List Learning Intervention (WordLLI) and then receive Sham + WordLLI after a three-month washout period.
11093502|NCT04122001|Experimental|Sham+word intervention then active HD-tDCS+word intervention|Participants will receive Sham + Word List Learning Intervention (WordLLI) and then active HD-tDCS + WordLLI after a three-month washout period.
11093503|NCT04121988||Denoising MRI group|Patients suspected of Cushing disease undergoing deep learning based denoising MRI
11093504|NCT04121975|Experimental|Chemoradiotherapy|"Radiation:
~Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
~Drug: Endostar 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
~Drug: Cisplatin 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29."
11093505|NCT04121962|Experimental|Peer Mentor|Peer Mentor Training is 5 groups with a 30 day reunion session. This condition is focused on training participants with communication skills to promote HIV and STI home-based testing and treatment and pre-exposure prophylaxis (PrEP) to individuals in their social networks. Participants will also learn how to use the Star website to request home-based testing kits. Peer Mentor training is conducted by a two health educators. The sessions are held once a week and will last approximately 90 minutes.
11093506|NCT04121962|Active Comparator|Control|Participants will receive information on how to use the website to request at-home test kits
11093507|NCT04121949|No Intervention|Control group|The control group will receive standard-of-care treatment recommended by current ESC guidelines for patients with low to intermediate likelihood of stable CAD using the Diamond-Forrester (DF) score only: Rule-out if DF-score <15%; NIT if DF-score 15-85%.
11093508|NCT04121949|Experimental|Intervention group|The intervention group will undergo a modified diagnostic pathway where a CAD-score <30 rules out stable CAD in the group of patients having a DF-score <15% and a CAD-score ≤20 rules out stable CAD in the group of patients having a DF-score in the range 15-85%, and thus not tested with NIT. Otherwise NIT is performed.
11093509|NCT04121923|Experimental|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG) will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device.
11093510|NCT04121910|Experimental|Savolitinib and/or Itraconazole|Treatment Period 1: Single administration of savolitinib (200 mg) will occur on Study Day 1 after a high-fat, high-calorie breakfast followed by PK sampling for 48 hours Treatment Period 2: Itraconazole will be administered (200 mg BID) on Study Day 15, and (200 mg QD) on Study Days 16 and 17, 1 hour before breakfast (and before dinner, when applicable) Treatment Period 3: A single combination of itraconazole (200 mg) 1 hour before breakfast + savolitinib (200 mg) after a high-fat, high-calorie breakfast on Study Day 18, and a single dose of itraconazole (200 mg) on Study Day 19, 1 hour before breakfast
11093511|NCT04121897|Experimental|TEMPO|The Therapist Education and Massage for Parent-Infant Outcomes program (TEMPO) is a structured, therapist-led physical therapy program. TEMPO trains and supports parents to deliver physical therapy interventions including massage and developmental play during hospitalization and in the home setting.
11093512|NCT04121884|Experimental|ART Treatment|A broad patient representation of male and female adults; aged > 18 years; English speaking; and significant clinical symptoms of any of the following conditions: PTSD, Depression, ASD, Complicated Grief, and Alcohol Abuse.
11093513|NCT04121858|Experimental|Brain Safe App|1)Brain Safe App provides conversation starters for older adult patients on target anticholinergics. The conversation starters assist the patient to have discussions with their physicians regarding reduction in exposure to prescription anticholinergics. 2) Provides anticholinergic risk assessment.
11093514|NCT04121858|Sham Comparator|Attention Control App|1) Attention Control App provides a medication list for older patients to use but lacks the conversation starters for patient to use with there physicians aimed at reduction in exposure to prescription anticholinergics.2) No anticholinergic risk assessment.
11093515|NCT04121845|Active Comparator|Treatment group|Coronary sinus reducer implantation through right internal jugular vein.
11093516|NCT04121845|Sham Comparator|Sham group|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
11093517|NCT04121832|Experimental|Case|"25 people with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio Hospital. All patients over the age of 18 will be included.
~Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Patients with cognitive difficulties and / or diagnoses of intellectual disability and male patients will not be included in the study. In addiction to standard therapies, the sample will be treated with 10 sessions of biofeedback training."
11093518|NCT04121832|Active Comparator|Controls|25 women with fibromyalgia diagnosis corresponding to the diagnostic criteria of the American College of Rheumatology (ACR) will be taken in charge at the pain therapy centre of San Giovanni di Dio. All patients over the age of 18 will be included. Other patients with rheumatologic diagnoses in comorbidity with fibromyalgia will be considered exclusion criteria/will be excluded. Moreover, patients with cognitive difficulties and / or diagnoses of mental retardation and male patients will not be included in the study. The sample will be treated only with standard therapies without the use of biofeedback training
11093519|NCT04121819|Experimental|AraC|cytarabine 100mg/m2 d1-5 subcutaneous
11093520|NCT04121806|Experimental|Ulcerative colitis patients with mild to moderate activity|Participants will be followed for 14 days on their traditional diet followed by an 8 week intervention with the specially designed and provided treatment diet.
11093521|NCT04121793||Parkinson's Disease|Parkinson's Disease patients
11093522|NCT04121780|Experimental|Growth Hormone|Norditropin® (somatropin [rDNA origin] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).
11093523|NCT04121780|Placebo Comparator|Saline|Saline-placebo via auto-injector pens (Haselmeier Inc).
11093524|NCT04121767|Experimental|Edoxaban group|patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke
11093525|NCT04121767|Active Comparator|Warfarin group|patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke
11093526|NCT04121741|Active Comparator|Singing intervention 1|Instructional sing-a-long video. A video series will be created and recorded for the purposes of the study. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
11093527|NCT04121741|Active Comparator|Singing intervention 2|In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
11093528|NCT04121741|Sham Comparator|Control/sham intervention|"Subjects will have a 30-minute period of rest sitting upright (as they would be positioned for the singing interventions). This arm is meant to isolate the specific effects of the treatment rather than the potential incidental effects related to the research setting and measurements. During this time, subjects will undergo hearing testing. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after the 30 minute rest."
11093529|NCT04121728|Other|Group Ginkgo-Placebo|Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.
11093530|NCT04121728|Other|Group Placebo-Ginkgo|Cross-over design:In Group Placebo-Ginkgo participants are allocated first to the placebo during 6 months and after 2 months of wash-out period are allocated the IMP Symfona® for 6 months.
11093531|NCT04121715|Active Comparator|standard medication|"standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
11093532|NCT04121715|Experimental|standard medication+fastigial nucleus stimulation|"fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.
~standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
11093533|NCT04121702|Active Comparator|PEP-H|Physical exercise program at a hospital
11093534|NCT04121702|Experimental|PEP-PSC|Physical exercise program with tele-monitoring in a public sport centre
11093535|NCT04121689|Experimental|Milk Protein Concentrate|Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate
11093536|NCT04121676|Experimental|4-Week Monotherapy|Open Label 3+3 Dose escalation of AGEN2373, every 4 weeks, starting at dose level 0.03 mg/kg up to 3.0 mg/kg administered by IV.
11093537|NCT04121663|Experimental|Full seam anchor|
11093538|NCT04121663|Active Comparator|Polyether ether ketone bone anchor|
11093539|NCT04121637|Experimental|Aerobic exercise+Frenkel coordination Study group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set. Following this, an aerobic exercise of 30 minutes will be performed on the bicycle ergometer with electronic brake. Subjects will be advised not to do any exercise two days before or on that day and to eat only a light meal at least two hours before the test. The intensity of the exercise will be adjusted based on maximum oxygen consumption (VO2 max) specific to each individual.
11093540|NCT04121637|Active Comparator|Frenkel coordination exercise group - Control group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set.
11093541|NCT04121611|Experimental|Optical coherence tomography confirmed residual thrombus|Early antithrombotics
11093542|NCT04121611|No Intervention|Optical coherence tomography confirmed no residual thrombus|Best medical management
11093543|NCT04121598||Normal Weight Control|Adolescents with a BMI percentile under 85%.
11093544|NCT04121598||Overweight/Obese Control|Adolescents with a BMI percentile at 85% or higher.
11093545|NCT04121598||Overweight/Obese Experimental|Adolescents with a BMI percentile at 85% or higher, who report loss of control eating episodes.
11093546|NCT04121585||SL-PLUS™ hydroxylapatite coated cement free hip stem|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
11093547|NCT04121559|Experimental|Intervention|A&T intervention areas: adolescent-nutrition-focused behavior change interventions delivered through government primary schools and communities
11093548|NCT04121559|No Intervention|Control|Comparison areas: standard activities at government primary schools
11093549|NCT04121546|Experimental|Treatment Arm|Patients will receive the telecare intervention.
11093550|NCT04121533|Placebo Comparator|Placebo|Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
11093551|NCT04121533|Experimental|Vitamin D|Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
11093552|NCT04121533|Experimental|Vitamin D, glucosamine sulfate, and omega-3 fatty acids|Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).
11093553|NCT04121520||Observational|At time of consent and within the same day of HVPG measurement, participants will be asked to complete a pre-operative assessment. Relevant statistics will be recorded during the HVPG procedure. Post-operative complication will also be collected and the satisfaction survey will be conducted.
11093554|NCT04121507|Experimental|alloSCT|defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)
11093555|NCT04121494|Experimental|Group A|BCG-vaccinated, 1x10^9 vp, aerosol
11093556|NCT04121494|Experimental|Group B|BCG-vaccinated, 5x10^9 vp, aerosol
11093557|NCT04121494|Experimental|Group C|BCG-vaccinated, 1x10^10 vp, aerosol
11093558|NCT04121494|Experimental|Group D|BCG-vaccinated, highest tolerated dose aerosol + placebo IM; Randomized with Group E, blind
11093559|NCT04121494|Experimental|Group E|BCG-vaccinated, highest tolerated dose IM + placebo aerosol; Randomized with Group D, blind
11093560|NCT04121494|Experimental|Group F|BCG-non vaccinated, highest tolerated dose, aerosol
11093561|NCT04121481|Placebo Comparator|Placebo|Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
11093562|NCT04121481|Active Comparator|Treatment Group|Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
11093563|NCT04121468|Other|Group A|"Placebo for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.
~Metformin for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
11093564|NCT04121468|Other|Group B|"Placebo for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.
~Metformin for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
11093565|NCT04121468|Other|Group C|"Placebo for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.
~Metformin for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
11093566|NCT04121455|Experimental|200 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
11093567|NCT04121455|Experimental|400 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
11093568|NCT04121455|Experimental|600 mg Olaptesed pegol + Radiotherapy|olaptesed pegol weekly for 26 weeks administered i.v. by continuous infusion plus radiotherapy during weeks 1-6
11093569|NCT04121442|Experimental|Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor|Patients will receive specified dose of Isunakinra as monotherapy for three weeks, followed by combination with a PD-(L)1 inhibitor
11093570|NCT04121416|Experimental|Oxycodone group|
11093571|NCT04121416|Experimental|Sufentanil group|
11093572|NCT04121403|Active Comparator|Rituximab|Biosimilar rituximab concentrate for solution for infusion
11093573|NCT04121403|Active Comparator|Cladribine|Mavenclad oral cladribine tablets
11093574|NCT04121390||Newborn Parenting Class|New Mother who attended the Newborn Parenting Class
11093575|NCT04121390||New Mothers|New Mothers who expressed interest, but did not attend the Newborn Parenting Class
11093576|NCT04121377|Experimental|Resistance exercise program|Early resistance exercise sessions and home program
11093577|NCT04121364|Experimental|Tetranite|All patients enrolled in study will receive the dental adhesive with a dental implant. The robustness of the dental implant stability will be assessed at various time points.
11093578|NCT04121338|Experimental|Test group|10 patients with presumptive diagnosis of dysautonomia with chronic nausea, vomiting and food intolerance
11093579|NCT04121325||Gastroparesis patients with abdominal pain|Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain.
11093580|NCT04121312|Experimental|Facilitation Intervention|"A brief, web-based facilitation guide (called Weight Loss Your Way Kickoff Materials) that encourages initial and sustained engagement in online tracking and social network tools for weight loss.The intervention also includes 8 emails sent over 12 weeks to further motivate use of the online tools and weight loss."
11093581|NCT04121299|Experimental|Carvedilol 40mg Extended Release Once Daily|participants will be randomized to carvedilol 40 mg extended release once daily for the 1st or 2nd 4 week treatment period
11093582|NCT04121299|Active Comparator|Amlodipine 10mg Once Daily|participants will be randomized to amlodipine 10 mg once daily for the 1st or 2nd 4 week treatment period
11093583|NCT04121286|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
11093584|NCT04121273|Experimental|CAR-T cells|CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.
11093585|NCT04121260|Experimental|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase [rHuPH20] 30,000 units [U] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 [Day 1] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
11093586|NCT04121247|Experimental|Experimental: Parents in Chad will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
11093587|NCT04121247|Experimental|Experimental: Parents in Turkey will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
11093588|NCT04121221|Experimental|GA Depot|Monthly IM injection
11093589|NCT04121221|Placebo Comparator|Placebo|Monthly IM injection
11093590|NCT04121208|Active Comparator|Active drug: JNJ-40346527|"A single initial randomisation site will be set up for Part 1 that will assign participants to JNJ-40346527 300 mg Bis in die - twice a day (BID) or placebo in a 2:1 ratio.
~A second randomisation site will be setup for Part 2 depending on which scenario is adopted.
~Either a Part 2, Scenario 1 site will assign participants to JNJ-40346527 150 mg BID, JNJ-40346527 50 mg BID or placebo in a 2:2:1 ratio or a Part 2, Scenario 2 site will assign participants to JNJ-40346527 150-50 mg BID or placebo in a 2:1 ratio."
11093591|NCT04121208|Placebo Comparator|Placebo|Non-active study drug
11093801|NCT04119908|Other|Control group|Patients with moderate or severe hemophilia A or women carrying the hemophilia gene
11093592|NCT04121195|Other|Dose escalation sequence (all participants)|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
11093593|NCT04121182|Experimental|Nursing home with On-line training|"25 randomized residents will be included by nursing home Half of the institutions (randomized too) will benefit from an on-line training on the prevention and management of resident lung diseases"
11093594|NCT04121182|Active Comparator|Nursing home with usual practice|This group of Institutions continue their usual practice (routine care) and will not benefit from training during the study period.
11093595|NCT04121169|Other|Adults subjects with CDI receiving 10g a day|5 g twice a day for 10 - 14 days
11093596|NCT04121169|Other|Adults subjects with CDI receiving 20g a day|10 g twice a day for 10 - 14 days
11093597|NCT04121169|Other|Adults subjects with CDI receiving 40 g a day|20 g twice a day for 10 - 14 days
11093598|NCT04121156|Active Comparator|2 milli Amp dose of HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
11093599|NCT04121156|Sham Comparator|Sham (placebo) dose of HD-tDCS treatment|Sham (placebo) dose of HD-tDCS treatment for 20 minutes, for 5 consecutive twice daily sessions
11093600|NCT04121143|Active Comparator|Treatment group A|SHR-1314 low dose short intervals of subcutaneous injection
11093601|NCT04121143|Active Comparator|Treatment group B|SHR-1314 high dose long intervals of subcutaneous injection
11093602|NCT04121143|Active Comparator|Treatment group C|SHR-1314 high dose short intervals of subcutaneous injection
11093603|NCT04121143|Placebo Comparator|Placebo group|Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection
11093604|NCT04121130|Active Comparator|Group A (F-ESWT Group)|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
11093605|NCT04121130|Placebo Comparator|Group B (sham F-ESWT):|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
11093606|NCT04121117||Tobacco detoxication cohort|Patients appointed in a tobacco detoxication consultation
11093607|NCT04121104|Experimental|SCS off|
11093608|NCT04121104|Experimental|SCS on|
11093609|NCT04121091|Experimental|Pramipexole|
11093610|NCT04121078|Experimental|TAK-906 25 mg + Rifampin 600 mg and TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg, capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
11093611|NCT04121078|Experimental|Rifampin 600 mg and TAK-906 25 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg, capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg, capsule, orally, once on Day 1 of Study Period 2.
11093612|NCT04121065||Relapsing MS patients|Single Arm: Relapsing Multiple Sclerosis patients ADA SNPs and other biomarkers analyses in blood samples.
11093613|NCT04121052|Experimental|Treatment Sequence 1|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093614|NCT04121052|Experimental|Treatment Sequence 2|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093615|NCT04121052|Experimental|Treatment Sequence 3|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093616|NCT04121052|Experimental|Treatment Sequence 4|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093617|NCT04121052|Experimental|Treatment Sequence 5|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093663|NCT04120792|Active Comparator|Cognitive training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
11093618|NCT04121052|Experimental|Treatment Sequence 6|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093619|NCT04121052|Experimental|Treatment Sequence 7|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093620|NCT04121052|Experimental|Treatment Sequence 8|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093621|NCT04121052|Experimental|Treatment Sequence 9|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093622|NCT04121052|Experimental|Treatment Sequence 10|Participants will receive JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093623|NCT04121052|Experimental|Treatment Sequence 11|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093624|NCT04121052|Experimental|Treatment Sequence 12|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions ( low-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093625|NCT04121052|Experimental|Treatment Sequence 13|Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093626|NCT04121052|Experimental|Treatment Sequence 14|Participants will receive JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 3; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093627|NCT04121052|Experimental|Treatment Sequence 15|Participants will receive JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 1; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093628|NCT04121052|Experimental|Treatment Sequence 16|Participants will receive JNJ-64417184 oral tablet under fasted condition in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (standard meal) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11093629|NCT04121039|Experimental|Apatinib plus POF|Participants will receive apatinib in combination with POF,total 9-12 cycles.Then receive apatinib plus S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11093630|NCT04121039|Active Comparator|POF|Participants will receive POF,total 9-12 cycles.Then receive S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11093631|NCT04121013|Active Comparator|Mothership|Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center
11093632|NCT04121013|No Intervention|drip'n'ship|Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol
11093664|NCT04120792|Active Comparator|Neutral Video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
11093802|NCT04119895|Experimental|NMES and exercise|Neuromuscular electrical stimulation and core stabilization exercise
11093803|NCT04119895|Sham Comparator|Sham NMES and exercise|Sham neuromuscular electrical stimulation and core stabilization exercise
11093633|NCT04121000|Experimental|Erector Spinae Block for VATS Group|40 patients who had VATS will receive erector spinae block for postoperative pain management. All patients will receive IV Midazolam (0.05mg/kg) premediacation. Standard monitorization of EKG, non- invasive blood pressure and pulsoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the induction and in the prone positon the ESB procedure will be done. 10 % povidon- iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done at the 8th thoracic vertebra line. The USG probe will be replaced 2-3 cm lateral to the spinous process in sagittal plane. When the erector spinae muscle is identified in the USG the needle will be guided caudally.0.5-1 ml local anesthetics will be given in order to confirm the needle is in the right place. After confirmation with 20 mL %0.25 bupivacaine the procedure will be performed.
11093634|NCT04121000|Experimental|Patient - Controlled Analgesia for VATS Group|40 patients who had VATS will receive IV PCA for postoperative analgesia managemnet.
11093635|NCT04120987|Active Comparator|Lifitegrast|One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
11093636|NCT04120987|No Intervention|Control|No treatment
11093637|NCT04120974|Experimental|Optimal insulin injection|Study subjects will receive personal training from the Investigator on how to optimally inject insulin to treat their Diabetes Mellitus. In addition, each subject receives instruction how to use a web-based platform with online video training modules on optimal injection technique.
11093638|NCT04120961|Experimental|delayed continuous use of bivalirudine|A total of 165 patients are assigned to group with delayed continuous use of bivalirudin after randomization schedule.
11093639|NCT04120961|Other|bivalirudin use during ePCI|A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.
11093640|NCT04120948|Experimental|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
11093641|NCT04120948|Active Comparator|Tongue scraper|tongue scraping
11093642|NCT04120935||Cohort of CRC patients|Stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years.
11093643|NCT04120922|Other|calcium carbonate|"Calcium based P-binder - calcium carbonate: Typical dose is 500mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.
~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
11093644|NCT04120922|Other|sevelamer carbonate|"Calcium (Ca) free P-binder - sevelamer carbonate: Typical dose is 800mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.
~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
11093645|NCT04120896|Experimental|Karate group|
11093646|NCT04120896|Active Comparator|Kung Fu group|
11093647|NCT04120883|Experimental|HCQ treatment 1|In treatment arm 1, the dose of study drug will be 4 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
11093648|NCT04120883|Experimental|HCQ treatment 2|In treatment arm 2, the dose of the study drug will be 5 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
11093649|NCT04120870|Active Comparator|Etomidate|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
11093650|NCT04120870|Experimental|Ketamine|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
11093651|NCT04120857|No Intervention|Educational Control Group|Education provided for optional use
11093652|NCT04120857|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly
11093653|NCT04120844|Experimental|Intervention|Patients in the intervention group (n=117) received a four-session PEP in small groups over one month by trained nurses and doctors.
11093654|NCT04120844|Placebo Comparator|Control|The control group (n=108) received the traditional lecture-style health education on Diabetes Mellitus.
11093655|NCT04120831|Experimental|Rituximab + Abatacept + MTX|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
11093656|NCT04120831|Active Comparator|Rituximab + MTX (standard of care)|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
11093657|NCT04120818||SIOL group|aphakic children diagnosed with congenital cataract who underwent secondary IOL implantation
11093658|NCT04120818||PIOL group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and primary IOL implantation
11093659|NCT04120805|Experimental|Group 1 (Hemostatic Agents Plus +)|
11093660|NCT04120805|Active Comparator|Group 2 (Hemostatic Agents Negative -)|No Hemostatic Agent
11093661|NCT04120792|Experimental|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
11093662|NCT04120792|Active Comparator|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
11093665|NCT04120779|Experimental|The EMPOWER-SUSTAIN e-Health Intervention|The EMPOWER-SUSTAIN intervention is a multifaceted chronic disease management strategies based on the Chronic Care Model (CCM) and persuasive technology (PT) theory. It consists of training physicians and patients to use the EMPOWER-SUSTAIN web-based self-management intervention mobile apps, strengthening patient-physician relationship and reinforcing the use of relevant clinical practice guidelines for management and prescribing.
11093666|NCT04120779|No Intervention|Control|The control group will continue to receive usual care at the university primary care clinic. They will be given the EMPOWER-SUSTAIN Global CV Risks Self-Management Booklet©, as this is considered as usual care at the university primary care clinic. The EMPOWER-SUSTAIN web-based self-management tool will be made available to the control group at the end of the study. During the course of the study, there will be no limit to the number of clinic visits that a patient is allowed to make in either the intervention or control groups.
11093667|NCT04120766|Experimental|Treatment|Nicorandil 20mg qd
11093668|NCT04120766|Placebo Comparator|Placebo|Matched placebo qd
11093669|NCT04120753|Experimental|1|
11093670|NCT04120753|Experimental|2|
11093671|NCT04120753|Active Comparator|3|
11093672|NCT04120727||Patient|patients with predominant osteoarthritis of the knees
11093673|NCT04120727||Health professionals|health professionals with a link to osteoarthritis (physical and rehabilitation doctor, Rheumatologist, Physiotherapist, family doctor, pharmacist, Adapted physical activity teacher)
11093674|NCT04120714|Experimental|Active tDCS group|Active tDCS
11093675|NCT04120714|Placebo Comparator|Placebo tDCS group|Inactive tDCS
11093676|NCT04120701|Experimental|Chemotherapy|
11093677|NCT04120701|No Intervention|Follow-up within the study|
11093678|NCT04120701|No Intervention|Follow-up outside the study|
11093679|NCT04120688|Active Comparator|Effect on surgery|Duration of surgery, degree of manipulation of the transplant
11093680|NCT04120688|Active Comparator|Success of transplantation|Normal eruption and root development of the transplant
11093681|NCT04120675|Experimental|3 Arms and Interventions|"Experimental Group 50 patients on Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.
~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
11093682|NCT04120675|Active Comparator|Control group 1|50 patients on Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
11093683|NCT04120675|No Intervention|Control Group 2|50 patients will have the same dietary habits and a MeDi protocol
11093684|NCT04120662|Active Comparator|Group A: Surgery group|Surgical procedure according to the injury type
11093685|NCT04120662|Active Comparator|Goup B: Shockwave group|3 weekly sessions of Focused Shock Wave Treatment (F-ESWT), using an electrohydraulic device set to an energy flux density (EFD) of 0.21 mJ/mm2 and 2000 impulses
11093686|NCT04120649||endomterial cancer|All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
11093687|NCT04120636|Experimental|Phase I open label study|"Drug: Episcleral Celecoxib
~Other Names:
~Sequestered, Transscleral, Controlled-Release Celecoxib
~Sustained Release Transscleral Celecoxib"
11093688|NCT04120623|Experimental|Dapagliflozin combined with CSII|Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
11093689|NCT04120623|Active Comparator|CSII alone|Aspart infused by CSII alone as glucose lowering therapy.
11093690|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
11093691|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
11093692|NCT04120597|Experimental|Therapy group|
11093693|NCT04120597|Placebo Comparator|Control group|
11093694|NCT04120584|Experimental|Forma Eye treatment|
11093695|NCT04120571|Experimental|experimental|Sleep Audiological Intervention Device (SleepAID)
11093696|NCT04120571|Sham Comparator|control|no sound
11093697|NCT04120558||Through knee amputees|Community dwelling individuals with through knee amputation of all mobility levels.
11093698|NCT04120558||Above knee amputees|Community dwelling individuals with above knee amputation of all mobility levels.
11093699|NCT04120545|Experimental|Microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
11093700|NCT04120545|Placebo Comparator|Placebo microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
11093701|NCT04120532|Experimental|Education group|
11093702|NCT04120532|No Intervention|Usual care group|
11093703|NCT04120519|Experimental|TCD|thalidomide 100mg qn cyclophosphamide 300mg/m2 d1,8,15 dexamethasone 40mg d1,8,15,22
11093704|NCT04120506|Experimental|Rapid infusion of Vpriv|: Infusions at Baseline and during step-wise rate increases and End-of-study will be performed in the Shaare Zedek Medical Center (SZMC) by the Study Nurse who will monitor vital signs (see below) for a total of 8 visits at SZMC. Home therapy will be approved if the patient so desires for 5 infusions in Phase 1 and for the first 5 infusions in Phase 3. All routine hematological and biochemical tests will be performed in the SZMC clinical labs. Abdominal quantitative MR Imaging (MRI) for spleen and liver volumes will be performed at SZMC
11093705|NCT04120493|Experimental|Cohort 1|Low dose rAAV5-miHTT (6x10^12 gc/subject).
11093706|NCT04120493|Experimental|Cohort 2|High dose rAAV5-miHTT (6x10^13 gc/subject).
11093707|NCT04120493|Sham Comparator|Cohorts 1 and 2|Imitation (sham) surgery
11093708|NCT04120480|Experimental|Testing|Participants randomized to this arm will be sent a kit to collect a genetic sample from a swab of their mouths. The kit will have instructions on how to collect the genetic sample and how to send it in a postage-paid envelope to the testing laboratory (OneOme). OneOme will process the sample and The study pharmacist will scan the results and enter any related information into the participant's KPCO electronic health record. If any changes to the participant's medication(s) are recommended (for example: a dose decrease or increase, stop taking your current medication and start another), the study pharmacist will contact the participant's KPCO prescriber directly to discuss the recommendations. The prescriber may contact the participant to change the participant's medication(s).
11093709|NCT04120480|No Intervention|Usual Care|Participants randomized to this arm will NOT be tested. They will receive usual care and the research will not involve study visits or in-person contact.
11093710|NCT04120467|Experimental|Dance|Dance Standard rehabilitation post-stroke
11093711|NCT04120467|Active Comparator|Control|Standard rehabilitation post-stroke
11093712|NCT04120454|Experimental|Treatment (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11093713|NCT04120441|Experimental|Group mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
11093714|NCT04120441|No Intervention|Routine care/control|Study participants randomized to control will receive information about community resources. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
11093715|NCT04120428|Experimental|Experimental protocol|24-week aquatic exercise training program
11093716|NCT04120428|No Intervention|Control protocol|Maintain lifestyle routine as usual
11093717|NCT04120415|Experimental|Vaccine and Vedolizumab infusion|"Vaccine:
~The vaccine is MVA HIV-B which is a solution of HIV MVA vectors in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).
~Vedolizumab infusion (Entyvio):
~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)."
11093718|NCT04120415|Experimental|Placebo vaccine and Vedolizumab infusion|"Placebo vaccine:
~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).
~Vedolizumab infusion (Entyvio):
~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml)"
11093719|NCT04120415|Placebo Comparator|Placebo vaccine and placebo infusion|"Placebo vaccine:
~The placebo for MVA HIV-B to be used in this trial is a solution composed of S08 buffer (as for the MVA vaccine).
~Placebo infusion:
~Sodium Chloride (NaCl) 0.9% administered as an intravenous infusion (255ml)"
11093720|NCT04120402|Experimental|EP-104IAR 25 mg|A single use intra-articular injection containing 25 mg of EP-104IAR
11093721|NCT04120402|Placebo Comparator|Placebo (vehicle)|A single use intra-articular injection containing no active ingredients
11093722|NCT04120389|Experimental|BCL group|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)
11093723|NCT04120389|Active Comparator|control group|
11093724|NCT04120376|Experimental|Counseling Intervention|All participants will receive contraception counseling.
11093725|NCT04120363|Placebo Comparator|Placebo|single intramuscular injection of 3 mL sesame oil solution on Day 8
11093726|NCT04120363|Experimental|Testosterone|single intramuscular injection of 750 mg testosterone undecanoate on Day 8
11093727|NCT04120350|Experimental|R2-MTX-LEN|"Phase Ib：Experimental arm will be treated with R2-MTX regimen for 6 cycles as initiate induction, the dose of lenalidomide was escalated from 15mg， 20mg， 25mg to test DLT by 3+3 design, meanwhile the dose of rituximab and methotrexate is fixed. If the patients achieved CR or PR by MRI and CSF evaluation, they processed to lenalidomide maintenance for 2 years.
~Phase II: the patients will be treated by fixed dose of R2-MTX regimen (established lenalidomide dose from phase Ib study) for 6 cycles. the efficiency evaluation will be performed every 2 cycles, the patients who achieved CR or PR will finish the total 6 cycles of induction therapy, then begin the stage of lenalidomide maintenance for 2 years. Follow-ups should be taken for 5 years."
11093728|NCT04120337|Experimental|RemovAid Device + lidocaine patch|Test device with lidocaine patch for local anesthesia
11093729|NCT04120337|Experimental|RemovAid Device + lidocaine injection|Test device with lidocaine injection for local anesthesia
11093730|NCT04120337|Active Comparator|Standard removal technique + lidocaine injection|Standard technique involves a scalpel, forceps, and tweezers with lidocaine injection for local anesthesia
11093731|NCT04120324||Eligible & Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty and is discharged home on the day of surgery.
11093732|NCT04120324||Eligible but NOT Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty but is NOT discharged home on the same day as the surgery, and remains in hospital for a minimum of one night following surgery. Reasons for not being discharged same day include potential problems related to Surgery (eg. complication), Anesthesia (eg. prolonged effect), or patient factors (egs. pain, nausea, mobility difficulties, etc.).
11093733|NCT04120324||Not Eligible for Discharge Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and/or Anesthesia deems the patient to NOT be eligible for Same Day Discharge. The patient undergoes Primary Single Joint Total Hip Arthroplasty and remains for a minimum of one overnight in hospital following hip replacement surgery.
11093734|NCT04120311|Experimental|Phase I open label study|"Drug: Episcleral Dexamethasone Sequestered Transscleral, Controlled-Release Dexamethasone
~Other Names:
~• Sustained Release Transscleral Dexamethasone"
11093735|NCT04120298|Experimental|Supervised exercise group|"The intervention group will participate in a 9-month exercise intervention. The exercise program will start with a 6-month period, where patients participate in a supervised multimodal exercise program twice a week supplemented with unsupervised exercises. The multimodal exercise program comprises aerobic-, resistance- and balance components. After completing the initial six-month period, one supervised session will be replaced by one unsupervised session until month nine.
~Unsupervised exercises will be supported by an activity tracker (FitBit) and an exercise App specifically designed for the EFFECT trial"
11093736|NCT04120298|No Intervention|Control group|Patients randomized to the control group will also receive an activity tracker (like the intervention group). We will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.
11093737|NCT04120285|No Intervention|Primary Care Treatment|The participant will receive treatment as usual as prescribed by the primary care physician for MDD.
11093738|NCT04120285|Active Comparator|Primary care treatment with eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of eCBT for MDD.
11093739|NCT04120285|Active Comparator|Primary care treatment with guided eCBT|The participant will receive treatment as usual as prescribed by the primary care physician with the addition of guided eCBT for MDD.
11093740|NCT04120272||Delirium group|Group of patients with postoperative delirium
11093741|NCT04120272||Non delirium group|Group of patients without postoperative delirium
11093742|NCT04120259|Active Comparator|Group 1|Intervention: Metformin Tablet oral 750 mg OD
11093743|NCT04120259|Experimental|Group 2|Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD
11093744|NCT04120246|Experimental|Treatment (alpha-TEA, trastuzumab)|Patients receive one of 4 doses of alpha-TEA PO on days 1-14. Patients also receive trastuzumab on day 1 of cycle 1 and then every 3 weeks per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11093745|NCT04120233|Placebo Comparator|Placebo|Participants will receive placebo.
11093746|NCT04120233|Experimental|Dose 1|Participants will receive 10 mg of MW151.
11093747|NCT04120233|Experimental|Dose 2|Participants will receive 20mg of MW151.
11093748|NCT04120233|Experimental|Dose 3|Participants will receive 40mg of MW151.
11093749|NCT04120233|Experimental|Dose 4|Participants will receive 80mg of MW151.
11093750|NCT04120233|Experimental|Dose 5|Participants will receive 160mg of MW151.
11093751|NCT04120220|Experimental|Heavy Cream|Participants will receive a meal containing 30 g of fat prepared with heavy cream.
11093752|NCT04120220|Experimental|Soybean Oil|Participants will receive a meal containing 30 g of fat prepared with soybean oil.
11093753|NCT04120207|Experimental|Home-based Pilates|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
11093754|NCT04120207|Other|Delayed-Start Control|Participants randomized to Delayed-start will be instructed to maintain their pre-intervention physical activity levels during the trial and will be contacted by the lead researcher by email or telephone to ensure timely completion of the on-line outcome assessments at biweekly intervals. Following the 8-week intervention, Delayed start participants will be provided with the Pilates DVD for their own use, but no data will be collected. For both groups, participants who experience a relapse will be immediately withdrawn from the study, which will be recorded by the lead researcher.
11093755|NCT04120194|Experimental|NanoFlu|NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
11093756|NCT04120194|Active Comparator|Fluzone Quadrivalent|Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
11093757|NCT04120181||Control|The control group consists of 13 age- and gender-matched subjects who underwent CI surgery but showed no complications. The members of the control group were selected based on hospital records.
11093758|NCT04120168||DMD and Pompe Disease Cohort|The aim of this study gropu was to determine the frequency of Duchenne muscular dystrophin in boys and adolescents with unexplained transaminase elevation for at least 3 months and in late onset Pompe disease in girls and boys and to determine the demographic and clinical characteristics of these patients.
11093759|NCT04120155|Other|Dissecting the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary dessection during the upper lobe thoractomy.
11093760|NCT04120155|Other|Preserving the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary preservation during the upper lobe thoractomy.
11093761|NCT04120142|Experimental|IMT goup|Inspiratory muscle training + aerobic exercice
11093762|NCT04120142|Active Comparator|Control group|aerobic exercice
11093763|NCT04120129|Experimental|TMS treatment|participants receive TMS treatment
11093764|NCT04120129|Sham Comparator|sham TMS|participants receive control TMS treatment
11093765|NCT04120129|No Intervention|non intervention|control group
11093766|NCT04120116|Experimental|FX-322 Single Dose, Placebo Three Doses|Four intratympanic injections of a hydrogel formulation
11093767|NCT04120116|Experimental|FX-322 Two Doses, Placebo Two Doses|Four intratympanic injections of a hydrogel formulation
11093768|NCT04120116|Experimental|FX-322 Four Doses|Four intratympanic injections of a hydrogel formulation
11093769|NCT04120116|Placebo Comparator|Placebo Four Doses|Four intratympanic injections of a hydrogel formulation
11093799|NCT04119921|Active Comparator|usage of topical ketorolac in group2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval
11093800|NCT04119908|Experimental|Patients with haemorrhagic disease|Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia
11093770|NCT04120103|Experimental|Doll therapy|"Experimental: Doll Therapy Intervention A total of 30 patients were included in the study. All patients that meet the study inclusion criteria will be included in the study The patients in the intervention group will have Doll therapy for 60 days and weekly patient visits. The study will be started with control group patients. At the beginning of the study and after 60 days, Introductory Information Form, Mini Standard Mini Mental Test and Cohen-Mansfield Agitation Inventory will be applied to patients in intervention and control groups for data collection. Dementia patients will be given a baby, patients will be followed for two months. There will be monitoring once a week."
11093771|NCT04120103|Active Comparator|Routine nursing care|"The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
~There was no intervention other than routine care. The patients were followed up for two months.The patients were followed up for two months.Data collection forms were applied at the beginning, first and second months of the study."
11093772|NCT04120090|Active Comparator|Low dose|
11093773|NCT04120090|Experimental|High dose|
11093774|NCT04120077|Placebo Comparator|DSME + placebo supplement (group 1)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects be instructed to consume two capsules (canola oil soft-gels) per day in the morning and two capsules per day in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
11093775|NCT04120077|Experimental|DSME + DVS supplement (group 2)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (canola oil placebo) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
11093776|NCT04120077|Experimental|DSME + DVS supplement + omega-3 supplement (group 3)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (EyePromise EZTears) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
11093777|NCT04120064|Experimental|Large bolus|
11093778|NCT04120064|Active Comparator|Standard|
11093779|NCT04120051|Experimental|Fermented canola-seaweed supplement|Ingredients: Canola meal, seaweed, wheat, glucose, Vitamin D and lactic acid bacteria
11093780|NCT04120051|Placebo Comparator|Placebo|Ingredients: Rye flour, water, iodized salt, brown sugar
11093781|NCT04120025|No Intervention|Control Group|Subject will continue standard of care for GERD symptoms
11093782|NCT04120025|Experimental|Treatment Group|Subjects will continue with usual care but will also receive diaphragm training (belly breathing) instructions using verbal, visual and tactile cues for proper contraction of the diaphragm as a home program
11093783|NCT04119999|Active Comparator|CPAP|Continuous Positive Airway Pressure
11093784|NCT04119999|Experimental|MAD|Mandibular Advancement Device
11093785|NCT04119986|Experimental|drug coated balloon|A total of 110 patients with ISR are assigned to drug coated balloon treated group after randomization schedule.
11093786|NCT04119986|Other|drug eluted stent implantation|A total of 110 patients with ISR are assigned to drug eluted stent treated group after randomization schedule.
11093787|NCT04119947|Experimental|SY-009 dose 1|A single dose of SY-009 (0.5-40mg) taken orally.
11093788|NCT04119947|Experimental|SY-009 dose 2|A single dose of SY-009 (0.5-40mg) taken orally.
11093789|NCT04119947|Experimental|SY-009 dose 3|A single dose of SY-009 (0.5-40mg) taken orally.
11093790|NCT04119947|Experimental|SY-009 dose 4|A single dose of SY-009 (0.5-40mg) taken orally.
11093791|NCT04119947|Experimental|SY-009 dose 5|A single dose of SY-009 (0.5-40mg) taken orally.
11093792|NCT04119947|Experimental|SY-009 dose 6|A single dose of SY-009 (0.5-40mg) taken orally.
11093793|NCT04119947|Placebo Comparator|SY-009 matching placebo|from 2-40mg
11093794|NCT04119934||Control - None|A retrospective chart review will assess physician behaviour (rates of smoking cessation counselling and prescription of smoking cessation pharmacotherapy) in the one-year pre-intervention period.
11093795|NCT04119934||Intervention - Smoking cessation infographic|Throughout the intervention period, the personalized smoking cessation infographic will be provided to physicians (for eligible patients). Chart review will be conducted for the patient's physician within a three-month window of receiving the infographic to assess outcomes.
11093796|NCT04119921|Active Comparator|usage of topical ketorolac in group1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
11093797|NCT04119921|Active Comparator|usage of artificial tear in group 2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
11093798|NCT04119921|Active Comparator|usage of artificial tear in group 1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval
11093804|NCT04119882||Positive for ischaemia|Blood test for 363 patients with confirmed cardiac ischemic event
11093805|NCT04119882||Negative for ischaemia|Blood test for 283 patients with no cardiac ischemic event
11093806|NCT04119869|Experimental|iaya Smart Phone Application|"Pre-study evaluation
~Access to the smartphone intervention over the course of 12 weeks
~Post-study evaluation and interview"
11093807|NCT04119856|Other|Intervention group|"Affiliation with outgoing lung team
~Instructions and teaching by the outgoing lung team.
~Needs-based consultation at Dept. of Respiratory Diseases and Allergy.
~Contact to the outgoing lung team in case of exacerbation of COPD."
11093808|NCT04119856|No Intervention|Control group|"The usual practice
~Scheduled consultations at Dept. of Respiratory Diseases and Allergy.
~Contact to GP/doctor on call in case of exacerbation of COPD."
11093809|NCT04119843|Experimental|Mangoral|All patients will receive a single dose of Mangoral (equivalent to 800 mg Manganese (II) chloride tetrahydrate [MnCl2 4H2O]).
11093810|NCT04119830|Experimental|Treatment (rintatolimod, pembrolizumab)|Patients receive rintatolimod IV over 30 minutes on days 1-3 and pembrolizumab IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 4, patients receive rintatolimod IV over 30 minutes and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months from the first dose in the absence of disease progression or unacceptable toxicity.
11093811|NCT04119817|Experimental|Mucosave® capsules|60 healthy volunteers taking 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day after dinner before going to bed.
11093812|NCT04119817|Placebo Comparator|Placebo|40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed.
11093813|NCT04119804||septic loosening|Septic loosening of primary hip implants according to the 2014 CDC criteria (as routinely performed in the clinical setting), adding another major and necessary criterion: at least 3 positive intraoperative tissue samples (same micro-organism).
11093814|NCT04119804||aseptic loosening|aseptic loosening of primary hip implants not meeting the CDC 2014 criteria
11093815|NCT04119791|Experimental|Wild rice|Participants will consume one serving of the test food containing wild rice every day over 28 days.
11093816|NCT04119778|Experimental|Aerobic Exercise|The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
11093817|NCT04119778|Experimental|Tai chi|Our tai-chi classes will be based on a 16-form tai-chi exercise set. The classes will run twice a week for 16 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 16 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
11093818|NCT04119778|No Intervention|Self Management Group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 16 weeks and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
11093819|NCT04119752|Active Comparator|Curcumin powder|Curcumin powder - 10g
11093820|NCT04119752|Placebo Comparator|Placebo ( curcumin depleted)|Placebo- sucralose -1g
11093821|NCT04119739|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
11093822|NCT04119739|Active Comparator|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
11093823|NCT04119739|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
11093824|NCT04119726|Other|Control Group|The control group will receive a simplified tool including only the education message. The methodology will ensure that potential confounders by differences in nonspecific support and attention could be adjusted. Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behavior. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
11093825|NCT04119726|Experimental|Intervention Group|The intervention group will receive a complete social medial tool (web-based application ) installed on mobile phones including general education about coronary disease、personalized reminders and internet-based counseling. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
11093826|NCT04119713||Study Population|Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).
11093827|NCT04119700|Active Comparator|Muco-muscular endorectal advancement flap|After fistulectomy a muco-muscular endorectal advancement flap is mobilised and fixed to anoderma
11093828|NCT04119700|Experimental|Primary sphincter reconstruction|After fistulectomy the defect in anal sphincters is closed
11093829|NCT04119687|Experimental|Low Dose FX201|Single low dose FX201 injection
11093830|NCT04119687|Experimental|Mid Dose FX201|Single mid dose FX201 injection
11093831|NCT04119687|Experimental|High Dose FX201|Single high dose FX201 injection
11093832|NCT04119674|Experimental|Arm|Experimental: arm Biological: Anlotinib Drug: Temozolomide Radiotherapy:2.0 Gy/fraction ×30 fractions Monday to Friday total dose of 60Gy
11093833|NCT04119661|Experimental|Max-i-Probe|
11093834|NCT04119661|Active Comparator|NaviTip|
11093835|NCT04119648|Experimental|CAMS-4Kids|Participants will receive up to 10 sessions of CAMS-4Kids
11093836|NCT04119622|Experimental|XELOX combined with Toripalimab|
11093837|NCT04119596||Diagnosed Parkinson's disease|Patients with incident Parkinson's disease
11093838|NCT04119596||Control|Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
11093839|NCT04119583|Experimental|U-shape Automatic Electric Toothbrush|
11093840|NCT04119583|Active Comparator|Usual home toothbrushing procedure|
11093841|NCT04119583|No Intervention|No toothbrushing|
11093842|NCT04119583|Active Comparator|Conventional Electric Toothbrush|
11093843|NCT04119570|No Intervention|No intervention|Participants will have their clinic visit as per usual care.
11093844|NCT04119570|Active Comparator|CKD Report Card|Participants will receive the CKD Report Card prior to the clinic visit.
11093845|NCT04119557|Experimental|LY3471851|LY3471851 administered subcutaneously (SC)
11093846|NCT04119557|Placebo Comparator|Placebo|Placebo administered SC
11093847|NCT04119544|Active Comparator|Conventional Rehabilitation|at least 4 sessions/week for 6 weeks, from 1 hour of conventional upper limb rehabilitation by an occupational therapist.
11093848|NCT04119544|Experimental|Intensive Visual Simulation|at least 4 sessions/week for 6 weeks, of 1 hour of upper limb rehabilitation including 45 minutes of conventional rehabilitation (occupational therapy) and 15 minutes of work with a medical device allowing intensive visual digital simulation.
11093849|NCT04119531||Patients with insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
11093850|NCT04119531||Patients without insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
11093851|NCT04119518|Other|Healthy and hypertensive subjects|Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.
11093852|NCT04119492|Experimental|CO-OP Treatment Group|Participants in the treatment group will receive occupational therapy once weekly for 10 weeks using the published protocol for the CO-OP approach.
11093853|NCT04119492|No Intervention|Waitlist Control Group|Participants in the waitlist control group not receive CO-OP intervention during this time. They will receive their CO-OP intervention 12 weeks after their baseline assessment.
11093854|NCT04119466|Experimental|Protrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
11093855|NCT04119466|Experimental|Extrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
11093856|NCT04119453|Experimental|Oral rivoceranib, 700 mg daily during 28-day cycles|Subjects will be treated with oral rivoceranib, 700 mg daily during 28-day cycles. Subjects will be monitored for clinical and/or radiographic evidence of disease progression as assessed by tumor growth or the discovery of additional tumors. Restaging scans will be performed approximately every 8 weeks for the first year and then approximately every 12 weeks and at End of Treatment (EOT), or as clinically indicated. Subjects who discontinue treatment for reasons other than progression will have scans at the EOT visit (unless their previous restaging was performed within 6 weeks) and approximately every 12 weeks thereafter (or with the standard of care restaging frequency for their disease) until initiation of a new therapy.
11093857|NCT04119440|Experimental|Low Dose|Vaccination with 2x10^7 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
11093858|NCT04119440|Experimental|High Dose|Vaccination with 2x10^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
11093859|NCT04119440|Placebo Comparator|Placebo|Injection with placebo. Injections will be administered at days 0, 28 or 56, and 336.
11093860|NCT04119427|Experimental|Test Group|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
11093861|NCT04119427|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
11093862|NCT04119414|Experimental|S&S + LFLS Group|300 expecting couples totaling 600 participants will be completing the S&S program followed by the LFLS Program.
11093863|NCT04119401|Active Comparator|doppler-guided|ligation of hemorrhoidal arteries with doppler guidance
11093864|NCT04119401|Experimental|finger-guided group|ligation of hemorrhoidal arteries without doppler guidance but with finger detection
11093865|NCT04119388|Experimental|Adapted sports practice|patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.
11093866|NCT04119375|Active Comparator|Control|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
11093867|NCT04119375|Experimental|SMS-Only|"Patients in the SMS reminder group will receive a single, medication reminder SMS once daily at their indicated treatment time. The reminder message will read Please take the medication on time consistent with messages used by Liu and colleagues (2015)."
11093868|NCT04119375|Experimental|Social Behavior Change Communication (SBCC)|"Patients assigned to this intervention will have access to a mobile health platform that provides reminders, information and motivation - designed with behaviorally-informed strategies - but no follow up support from a human beyond what the standard of care allows. Further details of the intervention can be found in the study protocol section.
~The intervention will send automated motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. Clinicians can view individual or aggregate patient histories to leverage limited resources."
11093869|NCT04119375|Experimental|Keheala|"An automated system sends motivational messages and regular prompts for patients to self-verify their adherence. Messages include reminders about the community benefits of adherence, and a measure of the patient's adherence performance relative to successful peers. If a patient fails to correctly verify her compliance, the system automatically alerts the support-sponsor, who then intervenes with a supportive dialogue. Clinicians can view individual or aggregate patient histories to leverage limited resources.
~Further details of the intervention can be found in the study protocol section."
11093870|NCT04119362||Patients with pancreatic adenocarcinoma|Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
11093871|NCT04119349|Experimental|Counseling|Women are given extra 15-minute counseling on the pros and cons of all different methods for prenatal testing including no testing at all
11093872|NCT04119349|No Intervention|Standard care|Women receiving standard care by means of counseling
11093873|NCT04119336|Experimental|Nivolumab and Ixazomib|"- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.
~Oral:
~Ixazomib given weekly on days 1, 8, 15
~Dexamethasone given weekly during cycle
~Infused:
~Nivolumab given once per cycle
~Cyclophosphamide given on days 1, 8, 15 during cycle"
11093874|NCT04119310|Experimental|Lumbar thrust-mobilization|The investigator will perform a lumbar thrust-mobilization with the subject in right and then left sidelying position
11093875|NCT04119310|Sham Comparator|Sham-mobilization|No lumbar-thrust mobilization will be performed. Subject will receive simple passive inter-vertebral range of motion.
11093876|NCT04119297|Active Comparator|Control|Routine care (Irregular cold application or gauze bandages wetted with isotonic solution or once daily heparinoid cream application) of the clinic was applied.
11093877|NCT04119297|Experimental|Cold application|Cold application was applied for three days after craniotomy.
11093878|NCT04119297|Experimental|Heparinoid group|Heparinoid cream was applied for three days after craniotomy
11093879|NCT04119284|Experimental|Anterior Vertebral Tethering|Anterior Vertebral Tether Vertebral body tethering done through anterior spine surgery under anesthesia.
11093880|NCT04119271|Other|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:
~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
11093881|NCT04119258||Psychiatric patients|Psychiatric outpatient care patients with major depressive disorder, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, or illness anxiety disorder who have just completed cognitive-behavioral therapy.
11093882|NCT04119245|Experimental|study group|"after induction of general anesthesia, a proper size of Igel will be inserted after compelete muscle relaxation. In order to confirm proper positioning of the I-gel,a fiberoptic bronchoscope will be pass through the device and pushed forward up to1 cm proximal to it to obtain a glottic view, leak airway pressure test will be done.
~Afterwards the same patient will be placed in the lateral decubitus position ,confirmation of I-gel position using fiberoptic bronchoscope will be done and recorded.The leak air way pressure test will be done as previously done in supine position and recorded.
~The patient will be returned to supine position."
11093883|NCT04119232|No Intervention|Control|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
11093884|NCT04119232|Experimental|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
11093885|NCT04119219|Active Comparator|Ranibizumab|Arm 1
11093886|NCT04119219|Active Comparator|Aflibercept|Arm 2
11093887|NCT04119206||Control|Normonatremic control, no intervention.
11093888|NCT04119206||Fluid restriction|Hyponatremic patients (serum sodium <135mmol/L): restriction of fluid intake < 1L
11093889|NCT04119206||Tolvaptan 3.75mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 3.75 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
11093890|NCT04119206||Tolvaptan 7.5mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 7.5 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
11093891|NCT04119180|Experimental|Sedation|The child receives sedatives approved for use in an outpatient setting, directed by a doctor, to accomplish the dental treatment.
11093892|NCT04119180|Other|Control|The child does not receive sedatives. As s/he exhibits negative behavior for the dental procedure, s/he will be restrained by a family member and dental team.
11093893|NCT04119154|Experimental|Standard diagnosis and CEM platform|Participants will receive standard diagnostic approach and assessment by CEM platform
11093894|NCT04119141|Active Comparator|Standard Arm|the first acquisition will be carried out without a tin filter in supine position and the second with tin filter in procubitus.
11093895|NCT04119141|Experimental|Tin filter Arm|the first acquisition will be carried out with tin filter in supine position and the second without tin filter in procubitus.
11093896|NCT04119128|Active Comparator|Active tDCS|Patients in this group will receive 5 active sessions of low-intensity transcranial electrical stimulation for 20 minutes.
11093897|NCT04119128|Sham Comparator|Sham tDCS|Patients in this group will receive 5 sessions of sham transcranial electrical stimulation for 20 minutes.
11093898|NCT04119115||Interstitial Lung Disease (ILD)|CT-V and metabolite analysis of breath, saliva, urine, and serum at baseline
11093899|NCT04119115||COPD/Emphysema: Age-matched control|CT-V and metabolite analysis of breath, saliva, urine, and serum at baseline
11093900|NCT04119115||Healthy Volunteers: Age-matched + /- 10 yrs controls|Metabolite analysis of breath, saliva, urine, and serum at baseline
11093901|NCT04119102|Experimental|Open Label Duobrii|Duobrii QD
11093902|NCT04119076|Experimental|Intervention Group|Teacher delivered a 10 minute classroom-based physical activity on school days for eight weeks.
11093903|NCT04119076|Other|Control Group|Children in the control schools continued with their usual school routine
11093904|NCT04119063|Experimental|Exoskeleton Assistance|Walking with exoskeleton assistance to make walking easier.
11093905|NCT04119063|Experimental|Exoskeleton Resistance|Walking with exoskeleton resistance for functional gait training.
11093906|NCT04119050|Experimental|M281 administered every 4 weeks|
11093907|NCT04119050|Experimental|M281 administered every 2 weeks|
11093908|NCT04119050|Experimental|Placebo administered every 2 weeks|
11093909|NCT04119037|Experimental|Group I (cordotomy)|Patients undergo a cordotomy over 1-2 hours.
11093910|NCT04119037|Sham Comparator|Group II (morphine, fake cordotomy)|Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.
11093911|NCT04119024|Experimental|Treatment (chemotherapy, IL13Ralpha2, Il-2)|Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 15-30 minutes on days -4 to -1. Patients then receive IL13Ralpha2 CAR T cell IV on day 0. Patients may also receive recombinant interleukin-2 SC BID on days 1-7.
11093912|NCT04119011|Experimental|Probiotic|Probiotic in powder form containing lactobacillus and bifidobacterium strains, sugar, milk powder and flavoring, taken 2 sachets daily for 3 months
11093913|NCT04119011|Placebo Comparator|Placebo|Placebo in powder form containing sugar, milk powder, flavoring, taken 2 sachets daily for 3 months
11093914|NCT04118998|Experimental|Abduction Loading|
11093915|NCT04118998|Active Comparator|Supported Reaching|
11093916|NCT04118985|Active Comparator|Self-implementation|Individuals randomized to this group will be given all the materials about cognitive compensations techniques and brain health behavior guidelines and encouraged to implement those on their own.
11093917|NCT04118985|Experimental|Health-behavior intervention|Individuals randomized to this group will attend 10 weekly classes designed to provide information about cognitive compensation techniques and brain health behaviors as well as interventional support to implement those recommendations with homework and follow-up classes.
11093918|NCT04118972|Experimental|Functionality Mirror Exposure & Journal|"A text-based functionality gratitude journaling prompt three times weekly paired with three weeks of weekly functionality-based guided mirror exposure sessions in the lab (the IM FAB program)"
11093919|NCT04118972|Active Comparator|Pure Mirror Exposure & Gratitude Journal|Thrice weekly generic (non body-focused) gratitude text prompts and pure mirror exposure in the lab. Participants are not given instructions on how to examine body parts, only instructed to examine the same specific body parts as the Functionality group to control specifically for impacts of the body functionality focus.
11093920|NCT04118972|No Intervention|Assessment only control|Assessments at Week 1, Week 3, and 1- and 4-month follow-ups, identical to those received by participants in the active condition
11093921|NCT04118946|Active Comparator|intravesical instillation|Intravesical instillation of platelet enriched plasma every week for 6 weeks
11093922|NCT04118946|Active Comparator|submucosal injection|submucosal injectionof platelet enriched plasma
11093923|NCT04118933|Experimental|MSI-H advanced colorectal cancer|
11093924|NCT04118920|Experimental|Topical insulin|Patients will receive topical insulin eye drops.
11093925|NCT04118907|Experimental|acoustic stimulation|Pink noise in both ears is given to tinnitus patients. The pink noise is removed by notch filter from tinnitus frequencies that are 20 decibel higher than the threshold.
11093926|NCT04118907|Experimental|somatic stimulation|Three stimulation points were selected for each ear of tinnitus patients, namely ear door (CN.V), auditory Palace (CN.VII) and Yifeng (C2/3). The stimulation intensity should be needle-sensed.
11093927|NCT04118907|Experimental|vestibular stimulation|The patient sat on a rotating chair with sinusoidal harmonic acceleration and rotated without causing the greatest frequency of discomfort.
11093928|NCT04118907|Experimental|acoustic + somatic stimulation|Combination of auditory and somatic stimulation for tinnitus patients
11093929|NCT04118907|Experimental|acoustic + vestibular stimulation|Combination of auditory and vestibular stimulation for tinnitus patients
11093930|NCT04118907|Experimental|acoustic + somatic + vestibular stimulation|Combination of auditory stimulation, somatic stimulation and vestibular stimulation for tinnitus patients
11093931|NCT04118894||Foot and Ankle Devices|
11093932|NCT04118881|Experimental|treatment group|The treatment group was given intradermal needling at ear acupoints: cardia (CO3), stomach (CO4), sympathetic (HX4)
11093933|NCT04118881|Sham Comparator|control group|The control group was given intradermal needling at ear acupoints: spiral area (HX7 and HX8).
11093934|NCT04118868|Experimental|All participants|Pembrolizumab administered intralymphatically using the Sofusa® DoseConnect™device
11093935|NCT04118855|Experimental|Neoadjuvant arm|Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.
11094121|NCT04117490|Placebo Comparator|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
11094122|NCT04117477|Experimental|Xylitol wipes|
11093936|NCT04118842|Experimental|Savolitinib and/or Rifampicin|Treatment Period 1 consists of 16 days starting with admission on Study Day -1, followed by a single dose administration of savolitinib on Day 1, followed by a washout period of at least 14 days. Subjects will be discharged from the Study Centre on Study Day 3, after the last PK sample is collected Treatment Period 2 consists of 6 days, starting with admission on Study Day 14, followed by QD dose administrations of rifampicin for 5 consecutive days (Study Day 15 to Study Day 19) Treatment Period 3 consists of 4 days, starting immediately after Treatment Period 2, comprising of a single dose administration of savolitinib on Study Day 20 and QD dose administration of rifampicin on Study Day 20 and Study Day 21. Subjects will be discharged from the Study Centre on Study Day 22, after the last PK sample is collected
11093937|NCT04118829|Experimental|Group one|The Group 1 patients will be taking PER up to 14 days following surgical intervention as per discretion of the treating neurosurgeon.
11093938|NCT04118829|Experimental|Group Two|The Group 2 patients will be taking PER as part of their maintenance AED regimen and will continue on the same maintenance dosage postoperatively.
11093939|NCT04118816||Control|Healthy subjects, 7-75 y/o
11093940|NCT04118816||Study|7-75 y/o, diagnosed with Prader-Willi syndrome.
11093941|NCT04118790||Minor Stroke patients|"Clinical Assessment
~MRI scan session"
11093942|NCT04118790||TIA patients|"Clinical Assessment
~MRI scan session"
11093943|NCT04118790||Healthy Controls|MRI scan session
11093944|NCT04118777|Active Comparator|0.2 % Ropivacaine|An ON-Q pain pump will be placed into the pelvic cavity and 0.2% Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr.
11093945|NCT04118777|Placebo Comparator|Saline|An ON-Q pain pump will be placed into the pelvic cavity and saline will be continuously administered intraperitoneally at a rate of 6 mL/hr
11093946|NCT04118764|Experimental|Focused ultrasound treatment|Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with Definity Microbubbles (10 μl/kg).
11093947|NCT04118751||parents of preterm babies (born before 37 weeks of pregnancy|
11093948|NCT04118751||parents of full-term babies (over 37 weeks of pregnancy)|
11093949|NCT04118738||ZIKV-Exposed|Children born to women with documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery or the children's laboratory documentation of confirmed or presumptive in-utero ZIKV exposure within five days of birth.
11093950|NCT04118738||ZIKV-Unexposed|Children born to women without documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery and the children have no laboratory documentation of confirmed or presumptive in-utero ZIKV exposure at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.
11093951|NCT04118725|Experimental|Muscular explorations|Pulmonary function test and diaphragmatic electromyography
11093952|NCT04118699|Experimental|Rifaximin|Two tablets of the investigational product per dosing (400 mg of rifaximin) are orally administered 3 times daily for 4 weeks.
11093953|NCT04118699|Placebo Comparator|Placebo|Two tablets of the placebo are orally administered 3 times daily for 4 weeks.
11093954|NCT04118686|Experimental|Experimental group|The group receives CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
11093955|NCT04118686|Sham Comparator|Control group|The group receives CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
11093956|NCT04118673|No Intervention|Control (Standard Care)|Standard care during consultations. Advice and guidance offered by clinicians verbally and sometimes the addition of leaflets or a referral.
11093957|NCT04118673|Experimental|Intervention (Standard Care plus Lifestyle prescription - LRx)|Standard care during consultations with the addition of a physical lifestyle prescription. Advice and guidance will be offered by clinicians verbally, whilst being supported with a lifestyle prescription and a possible referral if required.
11093958|NCT04118660||Thoracic Disease|Thoracic Diseases (which includes but not limited to the following: thoracic neoplasms (masses/nodules) malignant or benign, interstitial lung diseases (ILD), chronic obstructive pulmonary disease (COPD), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.
11093959|NCT04118647|Experimental|Wu-Chu-Yu tang|
11093960|NCT04118634||Group with PE|"The criteria for confirmation of PE are:
~PE on spiral computed tomography (CT) proximal deep vein thrombosis on ultrasound (US) thromboembolic events objectively confirmed during the follow up"
11093961|NCT04118634||Group without PE|"The criteria for exclusion of PE are:
~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up low and moderate clinical probability and negative CT and negative follow up high clinical probability and negative CT, US and follow up."
11093962|NCT04118595|Experimental|Full Intervention (Video + Telecare + PCP communication)|Patients in this arm will watch an interactive pain management video; receive a pain assessment phone call and be given medication and behavioral pain management strategy recommendations; and an ED visit and telecare summary will be shared with patient's primary care provider.
11093963|NCT04118595|Experimental|Video-only Intervention|Patients in this arm will watch an interactive pain management video.
11093964|NCT04118595|No Intervention|Usual Care|Patients will receive the typical care provided by medical personnel in the ED for their acute pain.
11093965|NCT04118582||Prospective analisys|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
~Evaluation of RMR For the evaluation of the RMR, the values of VO2 and VCO2 will be collected by the indirect calorimetry (IC) method using the Ultima CPX metabolic analyzer (MedGraphics, USA), calibrated with each test."
11093966|NCT04118569|Experimental|Narrative Intervention Group|Patients in the narrative intervention group will participate in an interview and the resulting narrative will be uploaded to the electronic medical record. This group will also complete outcome measures (questionnaires) and exit interview.
11093967|NCT04118569|No Intervention|Usual Care Group|Patients in the usual care group will complete outcome measures (questionnaires) and exit interview only.
11094123|NCT04117477|Placebo Comparator|Placebo wipes|
11094531|NCT04114630|Experimental|erenumab|Solution for s.c injection. Prefilled autoinjector
11093968|NCT04118556|Experimental|Decidua Stroma Cells (DSC)|"Placenta derived decidua stroma cells (DSC). In the first phase I part, two different dose levels will be used, 1x10^6/kg and 3x10^6/kg. Two doses, one week apart, will be given. The decision to proceed to the next dose level will depend on results observed at the previous dose level.
~The dose in the randomized part will be based on the findings in the phase I part. In the Phase II study all patients will receive 2 doses, one week apart. Depending on response, up to 6 doses in total may be given. Additional doses (beyond the first 2 doses) may be given one week apart until response."
11093969|NCT04118556|Active Comparator|Best Available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
11093970|NCT04118543|Experimental|Intervention Group|The intervention group will take part in two 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
11093971|NCT04118543|Sham Comparator|Sham-Exercise Group|The shame-exercise group will complete two sham exercise group sessions per week (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
11093972|NCT04118530||Hematopoietic Stem Cell Transplant (HSCT) Patients|- Patients with incidence of AF/AFL in the first 30 days of transplant
11093973|NCT04118517|Experimental|test meal|The study comprises one arm of 12 healthy Jamaican male and female adults with normal body mass inex, aged 20 to 45 years, receiving a test meal containing the common bean that was intrinsically labelled with deuterium .
11093974|NCT04118504|Experimental|Intervention group|Lifestyle intervention on through mobile application
11093975|NCT04118504|No Intervention|Control group|Usual care
11093976|NCT04118491|Sham Comparator|sham1st|40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
11093977|NCT04118491|Active Comparator|sham second|"iii. We will divide the subjects into two groups of five. One group will receive 40 Hyperbaric Oxygen (HBO2) treatments (100% oxygen at twice normal air pressure (2 ATA)) followed by 40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
~iv. Neurological and psychologic assessments will be done prior to starting treatments, after the first block of 40 and again after the second block of 40."
11093978|NCT04118478|Experimental|Multi-component phased training program|"The intervention of the program consists of conducting a multi-component training in a neighborhood unit.
~The intervention will consist of the realization of a multi-component program in a training center adapted for the elderly. The duration of the program will be 27 weeks with a frequency of two weekly sessions and an intervention duration of 45 to 60 minutes"
11093979|NCT04118478|No Intervention|CONTROL|Older people assigned to the GC do not do any training programming. Only attend the measurement dates.
11093980|NCT04118465|Active Comparator|ECV with Full urinary bladder|ECV with Full urinary bladder
11093981|NCT04118465|Active Comparator|ECV with empty urinary bladder|ECV with empty urinary bladder
11093982|NCT04118452|Experimental|Intervention + Usual Care + Developmental Screening Results|Intervention group families will receive usual care and developmental screening results will be shared with each child's primary care provider. In addition, they will be connected via telephone to 2-1-1 prior to their scheduled well-child visit for the telephone-based early childhood development care coordination intervention.
11093983|NCT04118452|No Intervention|Usual Care + Developmental Screening Results|This group will receive usual care. In addition, developmental screening results will be shared with each child's primary care provider.
11093984|NCT04118439|Experimental|Motor Imaginery|Patients allocated in this arm will recieve a training on the first day after recruitment on a motor imaginery task and will be asked to do the task every day during 30 days until they start the usual care. Then after the physical therapy treatment with a pragmatic perspective will be meassured just inthe last session, after 1 month an.d after 3 moths of the treatment for the follow up
11093985|NCT04118439|No Intervention|Control Group|Patients allocated in this arm will be meassured at the start, again after 30 days and at the end of the physical therapy usual care with a pragmatic perspective. Then will be meassured again after 1 and 3 months.
11093986|NCT04118426||Radiotherapy group|Patients receiving radiotherapy after surgery for brain tumor
11093987|NCT04118426||No radiotherapy group|Patients NOT receiving radiotherapy after surgery for brain tumor
11093988|NCT04118413|Experimental|Erector spinae plane block|Erector spinae plane block will be administrated to this group at end of the surgery under spinal anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively and sheduled paracetamol will be given.
11093989|NCT04118413|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine and sheduled paracetamol. No block will be performed.
11093990|NCT04118400||Experimental: NIN-NAVA|"Premature>30weeks with respiratory distress
~PI to determine eligibility or exclusion
~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~Place the catheter to optimize position
~ABG or VBG to be obtained at 2 hrs. post NIV-NAVA
~NIV-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
11093991|NCT04118400||Active Comparator: Nasal CPAP or NIMV|"Premature>30weeks with respiratory distress
~PI to determine eligibility or exclusion
~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~Place the catheter to optimize position
~ABG or VBG to be obtained at 2 hrs. post Nasal CPAP or NIMV
~NCPAP or NIMV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
11094124|NCT04117464|Experimental|Behavioral activation therapy|Behavioral activation therapy was applied following the protocol designed by Martell, Dimidjian & Herman-Dunn (2013).
11093992|NCT04118387|Active Comparator|acetazolamide|To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
11093993|NCT04118387|Active Comparator|zolpidem|To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
11093994|NCT04118387|Active Comparator|buspirone|To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
11093995|NCT04118374|Experimental|Standard Carb Diet then Low Carb Diet|
11093996|NCT04118374|Experimental|Low Carb Diet then Standard Carb Diet|
11093997|NCT04118361|Experimental|Patients with AVS isolated at emergencies|Enrollment of patients with AVS isolated at emergencies
11093998|NCT04118348|No Intervention|Passive Control|Will consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
11093999|NCT04118348|Experimental|Best Practice Alert (BPA-only)|Will consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
11094000|NCT04118348|Experimental|Health Maintenance Topic (HMT-only)|Will consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
11094001|NCT04118348|Experimental|BPA+HMT|Will consist of both the BPA and HMT presented simultaneously in Epic.
11094002|NCT04118335|Experimental|Intervention Group|The individuals in the intervention group were asked to gargle with 5 ml black mulberry syrup three times a day after meals and wait average one minute in the mouth and then swallow, in addition to the standard practice of the clinic. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. The patients were followed for 15 days. The 15-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
11094003|NCT04118335|No Intervention|Control Group|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
11094004|NCT04118322|Experimental|intervention group|The patients in the intervention group applied peppermint oil (3%) on lips three times a day, during the five days following chemotherapy administration, in addition to the standard antiemetic treatments. The data were collected using a Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching (INVR), Visual Analog Scale (VAS) Patient Nausea Severity Follow-up Form, Patient Watch Chart, and Oil Application Protocol. Besides, patients in the intervention group were questioned thoughts associated with peppermint oil application using individual in-depth interview method.
11094005|NCT04118322|No Intervention|control group|The control group underwent only the routine treatment.
11094006|NCT04118309|Experimental|High-intensity interval training|Three sessions of high-intensity interval training per week for nine weeks. Following a three minute warm up, a session contained twenty minutes of alternating between a sprint (80% of maximum workload, 90-95% of maximum heart rate) and active rest (30% of maximum workload) at a one minute to one minute ratio. Every session ended with a two and a half minute cool down.
11094007|NCT04118309|Placebo Comparator|Placebo exercise group|No changes in physical activity behaviour occurred (already engaging in less than 150 minutes per week, instructed to maintain their current inactivity). They were told they needed to stay inactive since they were part of an 'acute' exercise group, aiming to see how long the effects of their baseline maximal exercise test would last. Thus, the cover story gave them the impression they were also in an exercise group, as oppose to a non-exercise control group.
11094008|NCT04118296|Experimental|Intervention|Intervention will be given in the form of the use of anti-acne combination creams that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
11094009|NCT04118283|Experimental|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
11094010|NCT04118283|Active Comparator|Health and Wellness|Health & Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health & Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
11094011|NCT04118270|Experimental|AFib 2gether(TM) App|Patients with known Atrial Fibrillation will be assigned to download and use an app targeted at determining stroke risk and increasing knowledge of Atrial Fibrillation and stroke risk along with treatment options and will use this information to facilitate a discussion with their cardiovascular provider.
11094012|NCT04118257|Experimental|Fruit Juice|Participants consumed 2 bottles of 100% fruit juice daily for 3 weeks.
11094013|NCT04118257|Experimental|Soda|Participants consumed 2 cans of caffeine-free Coca Cola daily for 3 weeks.
11094014|NCT04118257|Other|Water|Participants consumed 2 bottles of water daily for 3 weeks.
11094015|NCT04118231|Experimental|Dry needling|
11094016|NCT04118231|No Intervention|Control group|
11094017|NCT04118179||Suspected Sepsis Group|Participants suspected of potential to develop sepsis recruited at the emergency department.
11094018|NCT04118179||Surgical Group|Participants undergoing non-emergency scheduled surgery, including ear/nose and throat cases, orthopaedic surgery of the major joints including hip, knee, ankle, shoulder, and wrist.
11094019|NCT04118179||Healthy Group|Healthy participants
11094020|NCT04118166|Experimental|Ipilimumab/nivolumab+ cryotherapy|1 mg/kg with nivolumab 3 mg/kg every 3 weeks x 4 doses. (One cycle of treatment is 3 weeks). Cryotherapy (cryoablation) will be performed between investigational agent treatment Cycles 1 and 2
11094021|NCT04118153|Experimental|Abatacept|Abatacept will be given by a subcutaneous (SC) formulation weekly for three months.
11094022|NCT04118140|Experimental|True SA (Somatic Acupressure ) group|Receiving true somatic acupressure+usual care
11094023|NCT04118140|Sham Comparator|Sham SA group|Receiving sham somatic acupressure+usual care
11094024|NCT04118140|Other|Usual care group|Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)
11094025|NCT04118127|Experimental|2mg conventional tablet, once-weekly tablets|
11094026|NCT04118114|Experimental|PRL3-ZUMAB Monotherapy|
11094027|NCT04118101|Active Comparator|ESPB group|A total of 25 ml bupivacaine 0.5% willbe injected into the ESP.
11094028|NCT04118101|Placebo Comparator|Control group|The ESPB will not be performed.
11094029|NCT04118088|Experimental|Darvadstrocel|Participants who have previously received darvadstrocel would receive a single repeat dose of darvadstrocel 120 million cells (5 million cells/mL), by local injection into the fistula.
11094030|NCT04118075|Experimental|PT-CY-FK +/- ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
11094031|NCT04118062|Other|Metastatic Uveal Melanoma|Questionnaires and semi-structured individual interviews with patients with Metastatic Uveal Melanoma
11094032|NCT04118062|Other|Triple Negative Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Triple Negative Breast Cancer
11094033|NCT04118062|Other|Luminal B Breast Cancer|Questionnaires and semi-structured individual interviews with patients with Luminal B Breast Cancer
11094034|NCT04118062|Other|Pediatric Cancer|Questionnaires and semi-structured individual interviews with parents of children with cancer.
11094035|NCT04118062|Other|Expert Patients|Focus groups (or group interviews) and DELPHI consensus method with expert patients
11094036|NCT04118062|Other|Researchers and Clinicians|Focus groups (or group interviews) and DELPHI consensus method with Researchers and Clinicians
11094037|NCT04118049|Experimental|Vaginal Probiotic Arm|"BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) is offered over the counter. It contains a total of 5 billion lactobacilli: L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus.
~RestoreTM gel: moisturizing personal lubricant.
~We will recommend to participants to use the probiotic supplement and vaginal lubricant as a vaginal suppository three times weekly at night for 3 months."
11094038|NCT04118049|Other|Standard Care Arm|Women will perform standard care which includes follow up at 3 months for pessary removal/care.
11094039|NCT04118036|Experimental|Surgery Arm|"In the surgical arm participants who require reoperation and have evidence of CDKN2A/B or C loss and intact RB from a prior tumor sample will receive
~Pembrolizumab-prior to surgery, at predetermined dose and time point
~Abemaciclib: every 12 hours from the day of pembrolizumab infusion to the morning of surgery
~Post surgery Participants with receive
~Abemaciclib, twice daily oral at specified dose for 21 day cycle
~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
11094040|NCT04118036|Experimental|Non Surgery Arm|"The treatment arm will be comprised of participants not requiring surgery.
~- Participants will receive treatment with
~Abemaciclib, twice daily oral at specified dose for 21 day cycle
~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
11094041|NCT04118023||7T MRI Group|Patient group that receives 7 Tesla Magnetic Resonance Imaging
11094042|NCT04118010|Active Comparator|Vitamin D3 and Inulin|Vitamin D3 50,000 IU/week and 12 g/day chicory-derived prebiotic inulin for 12 weeks
11094043|NCT04118010|Active Comparator|Vitamin D3 and placebo Inulin|Vitamin D3 50,000 IU/week and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
11094044|NCT04118010|Active Comparator|Placebo vitamin D3 and Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day chicory-derived prebiotic inulin for 12 weeks
11094045|NCT04118010|Placebo Comparator|Placebo vitamin D3 and placebo Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
11094046|NCT04117971||Staff members|Staff members in different clinical departments at Faculty of Dentistry, Cairo University.
11094047|NCT04117971||PhD students|PhD candidates in different clinical departments at Faculty of Dentistry, Cairo University.
11094048|NCT04117971||Master's students|Master's candidates in in different clinical departments at Faculty of Dentistry, Cairo University.
11094049|NCT04117958|Experimental|Dose-exploration phase|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 199 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
11094050|NCT04117958|Experimental|Dose-expansion phase|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
11095149|NCT04110288||Paclitaxel Eluting Stent|Patients treated for PAD with implantation of Paclitaxel DES.
11094051|NCT04117945|Experimental|Arm A (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
11094052|NCT04117945|Experimental|Arm B (cetuximab, panitumumab, irinotecan)|Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
11094053|NCT04117932|Experimental|"Arm ustekinumab"|Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids
11094054|NCT04117919|Experimental|chinese medicine medicated bath|we used the leaf of paper mulberry as chinese medicine medicated bath. Two packs per day ,and the period of treatment will be two month.
11094055|NCT04117919|Active Comparator|control group|Topical steroids
11094056|NCT04117906|Experimental|STAGE course|
11094057|NCT04117906|No Intervention|Wait-list control|The wait-list control group will receive access to the STAGE course after the trial is complete.
11094058|NCT04117893|Experimental|Duloxetine combined with intra-articular injection|
11094059|NCT04117893|Active Comparator|Intra-articular injection|
11094060|NCT04117880|Experimental|Ataluren|Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
11094061|NCT04117867||Intraoperative hypotension|
11094062|NCT04117841||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
11094063|NCT04117841||Arm II: Prior treatment at centre|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
11094064|NCT04117841||Arm III: Prior treatment at outside centre|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
11094065|NCT04117828|Active Comparator|Control|50 g of glucose will be given to the individuals
11094066|NCT04117828|Experimental|1st Intervention group|50 g of Aseel dates will be given to the individuals
11094067|NCT04117828|Experimental|2nd Intervention group|50 g of Ajwa dates will be given to the individuals
11094068|NCT04117828|Experimental|3rd Intervention group|50 g of Karbala dates will be given to the individuals
11094069|NCT04117815||study group|"Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.
~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen No alopecia of any reason (up-front) No overt cognitive impairment and fluent in German Written informed consent Age 18 and older"
11094070|NCT04117815||reference group|"For the purpose of comparison, a reference sample will be included in the study applying to the following inclusion criteria:
~Patients with breast or gynecological cancer planning to undergo chemotherapy Chemotherapy can be neoadjuvant, adjuvant or palliative Up to two lines of chemotherapy are allowed. Adjuvant therapy counts as one line.
~Chemotherapy regime is associated with alopecia. Chemotherapy must be planned for at least 4 cycles of taxane or antracycline- based chemotherapy regimen Refuse to undergo scalp cooling Patients who have been excluded for the study group for the reason of migraine Written informed consent Age 18 and older
~Patients from the reference group complete the same survey as the study group. Group comparisons will be adjusted for baseline body image and reasons for refusal."
11094071|NCT04117802|Experimental|Maple|
11094072|NCT04117802|Placebo Comparator|Placebo|
11094073|NCT04117789|Experimental|Therapist-guided ICBT for depression|"Participants will receive internet-delivered CBT with therapist support. The treatment consists of 8 online chapters with interactive features as videos and illustrations, delivered over a maximum of 10 weeks. The treatment has the main focus on behavioral activation.
~The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The parent program also consists of eight chapters, including psychoeducation about depression and how to support their adolescent in treatment.
~The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support."
11094074|NCT04117789|Experimental|Self-guided ICBT for depression|The self-guided ICBT for depression is identical to the therapist-guided ICBT intervention, however without the therapist support. To ensure patient-safety, there will be clear instructions to the patients and primary caregivers how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
11094075|NCT04117789|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both. The content of TAU and the treatment techniques used, will be monitored.
11094076|NCT04117776||Patients|Patient benefiting during the same hospitalization of the loss or the gain of a central venous catheter.
11094077|NCT04117763|Experimental|Empagliflozin|Empagliflozin 25 mg once daily for 3 months
11094078|NCT04117750|Active Comparator|intervention group|55 female patients with PCO
11094079|NCT04117750|Placebo Comparator|non -intervention group|40 female patients with PCO and 50 healthy women matched to PCOS women as regard age and ethnic origin.
11094080|NCT04117737|Experimental|Intervention|Single-arm
11094081|NCT04117711|Experimental|AT-007|
11094082|NCT04117711|Placebo Comparator|Placebo Comparator|
11094083|NCT04117698|Experimental|Antitubercular treatment and local corticosteroid therapy|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:
~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months
~associated with a treatment similar to the control group."
11094084|NCT04117698|No Intervention|Local Corticosteroid Therapy Only|"Treatment of Ocular Inflammation by Local Corticosteroid Therapy Only comprising:
~Dexamethasone (DEXAFREE® eye drops) at an attack dose for one week (4 to 6 drops / d maximum and if severe inflammation 1 drop / hour) then decrease and stop over 3 weeks, with relay by fluorometholone (Flucon®) for 2 months maximum. The modalities of the decrease of the local steroids are left to the ophthalmologists own judgment. Maximum total duration of 3 months.
~Mydriatic (tropicamide) 1gx3 / d if necessary.
~Neosynephrine 5% if posterior synechiae.
~Atropine (Alcon 0.3%) if pain."
11094085|NCT04117685||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
11094086|NCT04117685||Arm II: Prior treatment at center|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
11094087|NCT04117685||Arm III: Prior treatment at outside center|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
11094088|NCT04117672|Placebo Comparator|Placebo|Egg yolk powder not enriched for antisecretory powder
11094089|NCT04117672|Experimental|Salovum|Egg yolk powder enriched for antisecretory powder
11094090|NCT04117659|Experimental|Phosphodiesterase-5 inhibitor withdrawal|In this single arm pretreatment with an oral phosphodiesterase-5 inhibitor will be discontinued
11094091|NCT04117646||Patients|Patients of 2 and 12 years of age with chronic rhinosinusitis.
11094092|NCT04117646||Controls|Subjects of 2 and 12 years of age without chronic rhinosinusitis.
11094093|NCT04117633|Active Comparator|Mesh Rectopexy|Using Laparoscopy
11094094|NCT04117633|Active Comparator|Suture Rectopexy|Using Laparoscopy
11094095|NCT04117620||Patients|Patients from 7 to 17 years of age with vestibular deficiency.
11094096|NCT04117620||Controls|Subjects from 7 to 17 years of age without vestibular deficiency
11094097|NCT04117607|Experimental|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
11094098|NCT04117607|Experimental|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
11094099|NCT04117607|Experimental|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
11094100|NCT04117607|Experimental|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
11094101|NCT04117607|Experimental|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
11094102|NCT04117607|Experimental|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
11094103|NCT04117607|Experimental|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
11094104|NCT04117607|Experimental|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
11094105|NCT04117607|Experimental|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
11094106|NCT04117607|Experimental|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
11094107|NCT04117607|Experimental|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
11094108|NCT04117607|Experimental|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
11094109|NCT04117581|Active Comparator|Vitamin D3 supplement|Participant will be asked to take one capsule of vitamin D3 supplement (5000 IU) (125 μg) daily for a total duration of 12 weeks.
11094110|NCT04117581|Placebo Comparator|Placebo|Participants will be asked to take one capsule of placebo (inert filler) daily for a total duration of 12 weeks.
11094111|NCT04117555||Control|Diagnostic Test: Pupillometry
11094112|NCT04117555||Parkinson patients|Diagnostic Test: Pupillometry
11094113|NCT04117542||Overweight/Obesity Control|Adolescents who have overweight/obesity, but do not report loss of control eating.
11094114|NCT04117542||Overweight/Obesity Experimental|Adolescents who have overweight/obesity, and report loss of control eating.
11094115|NCT04117529|Experimental|Experimental Arm|Pemphigus or other autoimmune diseases.
11094116|NCT04117516|Active Comparator|Open surgery|30 patients will be operated with an open carpal tunnel release.
11094117|NCT04117516|Experimental|Percutaneous surgery|30 patients will be operated with a percutaneous carpal tunnel release.
11094118|NCT04117490|Active Comparator|Epiitalis low dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
11094119|NCT04117490|Active Comparator|Epiitalis mid dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
11094120|NCT04117490|Active Comparator|Epiitalis high dose|Two capsules twice daily 30 mins before meals (breakfast & dinner).
11094125|NCT04117464|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment therapy was applied following the protocol designed by Hayes, Strosahl & Wilson, (2011).
11094126|NCT04117464|Experimental|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy was applied following the protocol designed by Barlow, Allen and Choate (2004).
11094127|NCT04117464|Other|Wait List Group|Participants at Wait List Group will be evaluated pre-post and 3, 6, 9 and 12 months follow up periods, like experimental groups.
11094128|NCT04117451|Sham Comparator|Chlorhexidine|Chlorhexidine mouthwash will be provided to participants for a week to rinse the mouth twice a day.
11094129|NCT04117451|Experimental|Propolis|Propolis mouthwash will be provided to participants for a week to rinse the mouth twice a day.
11094130|NCT04117425|Other|Pregnant women|"40 Pregnant women and 10 Pregnant women that have a medical interruption of pregnancy who were already treated by levetiracetam.
~Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.
~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption"
11094131|NCT04117412|Other|Patients with COPD|Patients with COPD will undergo two different one bout of exercise training after maximal exercise test.
11094132|NCT04117399|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
11094133|NCT04117399|Active Comparator|Control group|aerobic exercice
11094134|NCT04117386||Primary pterygium group|Participants who was diagnosed with primary pterygium
11094135|NCT04117386||Secondary pterygium group|Participants who was diagnosed with secondary pterygium
11094136|NCT04117386||Healthy participants as control group|Participants who have no pterygium and other inflammation disease in eyes
11094137|NCT04117373||Cohort 1|Patients from the existing Optum insurance claimed database with a confirmed diagnosis of melanoma, basal cell carcinoma, or squamous cell carcinoma who have undergone skin cancer excision surgery followed by interpolated flap repair between the years 2001-2006.
11094138|NCT04117360||Dentofacial Disharmony Patients|Dentofacial disharmony patients who are seeking jaw surgery in UNC oral and maxillofacial surgery department and are seen in UNC orthodontic dentofacial disharmony clinic.
11094139|NCT04117347|Experimental|Light therapy A via the Re-Timer®|-15 minutes/day
11094140|NCT04117347|Experimental|Light therapy B via the Re-Timer®|-30 minutes/day
11094141|NCT04117347|Experimental|Light therapy C via the Re-Timer®|-60 minutes/day
11094142|NCT04117334||Bracing AIS patients|These are patients undergoing brace treatment for AIS
11094143|NCT04117321||Pregnant women|Women who are being pregnant and plan to give birth in local hospital. Pregnant women who plan to stay in the same local area for at least 7 years post-delivery.
11094144|NCT04117321||New Born Baby|new born baby of an enrolled pregnant woman.
11094145|NCT04117321||Father of new born baby|Biological father of an enrolled new born baby.
11094146|NCT04117308|Active Comparator|Control group|Patients who received a classic information.
11094147|NCT04117308|Experimental|Educated group|Who have been educated to the active fetal movements count.
11094148|NCT04117295|Experimental|Treatment|Subjects implanted with the Carmat TAH
11094149|NCT04117282|Active Comparator|control group|15 children received the regular exercise program including classical gait training for diplegic children (30 minutes exercises + 30 minutes gait training)
11094150|NCT04117282|Experimental|study group|15 diplegic child received the same exercise program including the use of the antigravity shoes for gait training (30 minutes exercises + 30 minutes gait training)
11094151|NCT04117269|Experimental|External shoe lift|Those patients allocated in the experimental group will be supplemented with a external shoe lift in the contralateral limb in their conventional shoes to compensate the differences with the affected foot (using a offloading device to active ulcer).
11094152|NCT04117269|No Intervention|Standard of care|Those patients allocated in the control group will not be supplemented, they will be treated with a standard of care treatment.
11094153|NCT04117256|Active Comparator|Transcranial Stimulation|Transcranial stimulation on the primary motor cortex (M1) with anode located on the point C3 (10/20 EEG system), and the cathode on contralateral supraorbital zone.
11094154|NCT04117256|Active Comparator|Suboccipital Stimulation|Suboccipital stimulation with anode located at the upper cervical level and cathode was placed on the lateral part of right shoulder.
11094155|NCT04117243|Active Comparator|Tranexamic group|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).
11094156|NCT04117243|Active Comparator|Misoprostol group|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision.
11094157|NCT04117243|Active Comparator|oxytocin only group|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby
11094158|NCT04117217||Central venous lines|Patients having a central venous catheter placed at Banner University Medical Center, University of Arizona
11094159|NCT04117217||Cardiac catheterization|Patients undergoing a cardiac catheterization procedure done at Banner University Medical Center, University of Arizona
11094160|NCT04117204|Experimental|Fruits and Vegetables|This group will receive a prescribed amount of free fruits and vegetables (F&V) for 6 weeks of pick-up at a farm stand or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 6 weeks with minimal contact.
11094161|NCT04117204|No Intervention|Wait List Control|This group will not receive a prescribed amount of free fruits and vegetables (F&V) for 12 weeks. They will serve as the control group. After 12 weeks of control and data comparisons, they will be given 12 weeks of vouchers with minimal contact.
11094162|NCT04117191|Experimental|Tryptophan loading|All participants are introduced to receive tryptophan loading test.
11094163|NCT04117178|Active Comparator|Standard of care|Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.
11094294|NCT04116229||Normal-weight|Participants who have a body mass index within the normal-weight category.
11094164|NCT04117178|Experimental|Intervention arm|Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.
11094165|NCT04117165|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from chronic inflammatory rheumatism, in particular, rheumatoid arthritis. Prescription of bDMARD or their biosimilars is possible.
11094166|NCT04117165|Active Comparator|Patient Current care|Current care of patients with rheumatoid arthritis, based on the recommendations of the French Society of Rheumatology. Prescription of bDMARD or their biosimilars is possible.
11094167|NCT04117139|Other|Study Group|In addition to other standard imaging modalities in the fast track cancer program, included patients will have a PET/MRI done.
11094168|NCT04117126|Experimental|urinary incontinence|Recruitment, 3-day voiding record, initiate a individualized prompted voiding schedule based on the client's toileting needs until discharge, 1, 3 and 6 month follow-up post-discharge.
11094169|NCT04117113||Elderly, 60+ hospitalized with Invasive ExPEC Disease|Patients 60 years or older hospitalized with Invasive Extraintestinal Pathogenic Escherichia coli Disease.
11094170|NCT04117100||Endoscopic mucosal resection (EMR)|It has become the standard treatment for superficial tumors of the gastrointestinal tract, either flat or sessile: precancerous lesions and superficial cancers with no or low ganglionic risk. The pre-injection of physiological serum detaches the lesion from the deep plane and allows, with great security, the resection of the mucosa, muscularis mucosae with part of the submucosa, whatever the size and location of the lesion. Compared to other techniques, it allows a histological analysis which dictates the subsequent conduct and the possible need for a complementary surgery.
11094171|NCT04117100||Endoscopic mucosal dissection (ESD)|This technique uses submucosal injection and special knives to make a peri-lesional circumferential incision, followed by dissection through the submucosal sub-lesion.
11094172|NCT04117100||Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC)|This is a mucosal thermo-destruction technique. It uses a generator that delivers a sinusoidal current of high frequency to a probe covered with bipolar electrodes in tight network ensuring a uniform diffusion of the thermal effect. The tissue penetration is superficial on 1mm, intended to eradicate the epithelium up to the muscularis mucosae. Circumferential or focal probes are used as a function of the length of the segment to be treated.
11094173|NCT04117100||Per Oral Endoscopic Myotomy (POEM)|"This technique allows a myotomy on the 8 cm of the lower esophagus extended on the gastric side of the cardia, totally endoscopically, after having approached and tunneled the esophageal submucosa.
~Less invasive, it gradually replaces the pneumatic dilatation and surgical myotomy of Heller.
~It requires a general anesthesia, an expert operator and a trained nursing team, ESD instruments, carbone dioxide insufflation."
11094174|NCT04117087|Experimental|KRAS peptide vaccine, Nivolumab, and Ipilimumab|
11094175|NCT04117074|Experimental|Arm 1: Thoracic Epidural Analgesia with bupivicaine|Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter [mL] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
11094176|NCT04117074|Experimental|Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine|Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
11094177|NCT04117061|No Intervention|Control|Patient gets usual diagnostic path: after inconclusive ultrasound is refered to CT scan.
11094178|NCT04117061|Active Comparator|Observation|Patient after inconclusive primary evaluation is observed in emergency room for 8-12 hours and after the clinical evaluation, laboratory results and ultrasound examination is repeated.
11094179|NCT04117048|Experimental|At home INR measurement with LabPad®|All at home INR measurements will be performed with the LabPad® point-of-care
11094180|NCT04117035|Placebo Comparator|Control arm|Standard care
11094181|NCT04117035|Experimental|Intervention|
11094182|NCT04117022|Experimental|supplemented arm|Each subject will receive DVS formula, 2 softgels per day for 6 months.
11094183|NCT04117009|Experimental|Remifentanil 2 ng/mL|Following baseline echocardiographic evaluation, Remifentanil (ultiva at a concentration of 20 micg/ml) infusion will be started at a rate to reach a target plasma level of 2 ng/mL. A target Controlled Infusion pump will be used to infuse the study drug. Once the target drug concentration is reached (which is expected to reach around 10-15 minutes), the final echocardiographic examination will be performed.
11094184|NCT04117009|Experimental|Baseline|Baseline transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure and study drug infusion begins.
11094185|NCT04116983||All patients|Recruited participants will be attending a dermatology clinic with at least one skin lesion where there is a suspicion of skin cancer. All suspicious lesions suitable for photographing will be photographed six times in a single visit. A macro and dermoscopic image of each lesion will be captured by three different mobile phones: an iPhone, a Samsung and a Nokia smart phone, without (macro image) or with (dermoscopic image) a Dermlite DL1 lens attached. Dermoscopic images of healthy skin will also be captured by each camera. Images of the lesions will be analysed by DERM. The DERM results for lesions biopsied will be compared to the biopsy result; the DERM results for lesions not biopsied will be compared to the clinical assessment.
11094186|NCT04116970|Experimental|Diagnostic (bronchoscopy with EBUS-TBNA with/without vacuum)|Patients undergo bronchoscopy with EBUS-TBUA first without and then with applied vacuum.
11094187|NCT04116957|Other|Time 1|First two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
11094295|NCT04116229||Obese|Participants who have a body mass index within the obese category.
11094188|NCT04116957|Other|Time 2|Second two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
11094189|NCT04116944|Experimental|Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults with analogue-Generalized Anxiety Disorder
11094190|NCT04116944|Other|Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
11094191|NCT04116944|Experimental|Non-Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults without analogue-Generalized Anxiety Disorder
11094192|NCT04116944|Other|Non-Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
11094193|NCT04116931|Experimental|clopidogrel-600 mg-12h|clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
11094194|NCT04116931|Experimental|clopidogrel-600 mg-24h|clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
11094195|NCT04116931|Experimental|clopidogrel-75 mg-12h|clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor
11094196|NCT04116931|Experimental|clopidogrel-75 mg-24h|clopidogrel 75 mg maintenance dose（MD) 24 hours after the last MD of ticagrelor
11094197|NCT04116905|Experimental|Intensive Lifestyle Intervention|Participants in the intensive lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain a 15% weight loss.
11094198|NCT04116905|Active Comparator|Conventional Treatment|The conventional treatment arm provides group sessions on metabolic syndrome management and social support, aimed at a 5% weight loss.
11094199|NCT04116892|Active Comparator|the peeling group|the internal limiting membrane was discarded
11094200|NCT04116892|Experimental|the Cover group|the internal limiting membrane was peeled centripetally all the way up to the MH rim and the hinged ILM flap folded upside-down on top of the MH in order to bridge the entire retinal defect with a single layer.
11094201|NCT04116892|Experimental|the Fill group|"the internal limiting membrane was folded in multiple layers and deliberately stuffed or packed within the MH defect using a forceps."
11094202|NCT04116853|Experimental|ADAPTIVE Extended-Care Group|"Participants randomized to the ADAPTIVE extended-care program will receive extended-care intervention phone delivered only if either 1) an algorithm developed by our study team detects that a participant is at high risk for weight regain or 2) the participant self-initiates a request for a session."
11094203|NCT04116853|Active Comparator|STATIC Extended-Care Group|Participants randomized to the STATIC extended-care program will receive the extended-care intervention phone calls on a fixed, once-per-month schedule (the schedule currently used in gold-standard weight maintenance programs).
11094204|NCT04116840|Experimental|MT1002 for Injection|Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects
11094205|NCT04116827||Tamoxifen group|Pre-menopausal breast cancer patients who underwent proper surgical treatment, chemotherapy, or radiation therapy, and are scheduled for application of tamoxifen and goserelin
11094206|NCT04116801|Experimental|Fluorescence arm|fluorescence guided microsurgical resection (under 560 nm filter) in addition to the usual techniques, after iv injection of 200 mg (i.e. 3-4 mg/kg) of fluorescein sodium at the time of skin incision.
11094207|NCT04116801|Active Comparator|Standard excision|microsurgical resection with usual techniques
11094208|NCT04116775|Experimental|Treatment|"INITIAL TREATMENT PHASE: Patients progressing on enzalutamide will receive 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy.
~ASSESSMENT PHASE: After completion of the initial treatment phase, patients will have their disease assessed by tumor imaging. Patients who respond to treatment will become stool donors to patients who do not respond. Non-responders will move on to the retreatment phase.
~RETREATMENT PHASE: Non-responders will undergo a fecal transplant and be retreated with 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for an additional 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy."
11094209|NCT04116762|Experimental|Intervention|Placement of TissuePatchDS-P™ at time of operation. No surgical drain is used.
11094210|NCT04116762|Active Comparator|Control|No use of TissuePatchDS-P™. Wound is closed with a surgical drain (Surgeon's choice) in situ.
11094211|NCT04116749||Non-obese women|body mass index lower than 30 (kg/m^2) at term
11094212|NCT04116749||Obese women|body mass index equal or greater than 30 (kg/m^2) at term
11094213|NCT04116736||TEST Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with the ACUVUE® OASYS with Transitions™ will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
11094214|NCT04116736||CONTROL Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with spherical non-photochromic reusable marketed silicone hydrogel contact lenses (of any brand) will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
11094215|NCT04116723|Experimental|Flexible brace|The design of the flexible brace incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) artificial hinge bone for the strategical application and fixation of corrective panel, 3) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
11094216|NCT04116710|Experimental|Phase 1: HS-130 + HS-110 (viagenpumatucel-L)|Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
11094217|NCT04116697|Experimental|Acupuncture with Anti-Emetics|
11094218|NCT04116697|Experimental|Aromatherapy with Anti-Emetics|
11094219|NCT04116697|No Intervention|Control Group|
11094220|NCT04116684|Experimental|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
11094221|NCT04116684|No Intervention|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
11094222|NCT04116671|Experimental|Neuromechanical Gait Assist|All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance.
11094223|NCT04116658|Experimental|Cohort 1|Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab
11094224|NCT04116658|Experimental|Cohort 2|Multiple dose of EO2041 in combination with nivolumab
11094225|NCT04116658|Experimental|Cohort 3|Multiple dose of EO2041 in combination with nivolumab and bevacizumab (US only)
11094226|NCT04116645||Group 1|singleton pregnancies
11094227|NCT04116645||Group 2|Twin pregnancies
11094228|NCT04116632|Experimental|BMS-963272 or Placebo once daily (QD)|
11094229|NCT04116632|Experimental|BMS-963272 or Placebo every 12 hours (Q12H)|
11094230|NCT04116632|Experimental|BMS-963272 or Placebo every 8 hours (Q8H)|
11094231|NCT04116619||Individuals with Cannabis Use Disorder|Participants who meet criteria for Cannabis Use Disorder will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
11094232|NCT04116619||Light Cannabis Users|Participants who are light cannabis users (<1 joint/week) will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
11094233|NCT04116606|Active Comparator|Active JNJ-54175446|JNJ-54175446 is an unlicensed drug currently being developed by Janssen Pharmaceuticals. The drug is presented in oral capsules, each capsule containing 50 mg of JNJ-54175446. Participants will be asked to self-administer one capsule daily for 8 weeks.
11094234|NCT04116606|Placebo Comparator|Matching placebo|
11094235|NCT04116593|Experimental|Intervention|
11094236|NCT04116593|No Intervention|Control|
11094237|NCT04116580||Allergic patients to raw apple and birch|Single-group studies about 28 patients allergic to birch and no longer eating raw rosaceae for at least 6 months. Patients brought back into contact with this family of fruits via the raw golden apple according to an Ultra-Rush protocol.
11094238|NCT04116554|Active Comparator|intervention group (A)|which will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.
11094239|NCT04116554|Sham Comparator|control group (B)|which will have sham block bilaterally by injection of 20 ml of 0.9%saline will be injected on each side.
11094240|NCT04116541|Experimental|HDM201 + Ribociclib|Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
11094241|NCT04116541|Experimental|Cabozantinib|Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.
11094242|NCT04116541|Experimental|Alectinib|Patient with ALK alterations: translocation, mutation or amplification
11094243|NCT04116528|Other|Ketamine|Every eligible participant will receive 0.5mg/kg IV given over 40 minutes
11094244|NCT04116528|Active Comparator|Buprenorphine or Placebo|Buprenorphine or placebo once daily for 4 weeks
11094245|NCT04116515|Active Comparator|Care Only|A third of the participants will have standard clinical care only.
11094246|NCT04116515|Experimental|Care + AVG|A third of the participants will have the same standard clinical care plus an Xbox and active games.
11094247|NCT04116515|Experimental|Care + AVG + Narratives|A third of the participants will have the same standard clinical care, an Xbox and active games, plus the stories delivered to their Xbox consoles.
11094248|NCT04116502|Experimental|A- Ruxolitinib|Treatment with Ruxolitinib
11094249|NCT04116502|Active Comparator|B- Hydroxycarbamide OR Interferon A|Best Available Therapy (BAT), Treatment with hydroxycarbamide OR Interferon A
11094250|NCT04116489|Experimental|Wildlife Immersion Activity|We will use a crossover design in which each participant receives an introductory forest walk followed by 3 wildlife immersion activity experiences in different settings .
11094251|NCT04116476|Experimental|Moderate Hepatic Impairment|
11094252|NCT04116476|Experimental|Normal Healthy Matches|
11094253|NCT04116476|Experimental|Mild Hepatic Impairment|
11094254|NCT04116463|Experimental|CDSMP|Chronic Disease Self-Management Program (CDSMP) - a 6-week, group-based behavioral intervention delivered in a 2.5 hour session each week by a trained facilitator.
11094255|NCT04116463|Active Comparator|Financial Self-Management|Financial self-management course delivered in 3 modules, with a delivery time of approximately 1 hour per module.
11094256|NCT04116450|Other|primary congenital glaucoma|Glaucolight illuminated microcatheter trabeculotomy in primary congenital glaucoma
11094257|NCT04116437|Experimental|Zanubrutinib|Chronic lymphocytic leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), or Marginal Zone Lymphoma (MZL) previously treated with ibrutinib and/acalbrutinib
11094258|NCT04116424|Experimental|nurse training of the patient|
11094259|NCT04116424|Active Comparator|simple information of the patient by neurologist|
11094260|NCT04116411|Placebo Comparator|Placebo|Patients will receive placebo tablets with similar appearance as the active drug. Patients receive two 450 mg tablets twice daily taken per orally for 6 weeks, thereafter one 450 mg tablet twice daily for an additional 22.5 months; a total treatment time of 24 months.
11094326|NCT04116021|Active Comparator|Wound infiltration|Wound infiltration with bupivacaine 0.5 % 30 mL at the end of surgery
11094261|NCT04116411|Active Comparator|Valganciclovir|Patients will receive valganciclovir tablets with similar appearance as the placebo tablets. Patients receive two 450 mg valganciclovir tablets twice daily taken per orally for 6 weeks, thereafter one 450 mg valganciclovir tablet twice daily for an additional 22.5 months; a total treatment time of 24 months.
11094262|NCT04116398|Experimental|Ozurdex®, 700µg dexamethasone intravitreal injection|Intravitreal injection of dexamethasone (Ozurdex®)
11094263|NCT04116385||Cancer surgery patients|Adult subjects (18 years or older) undergoing an oncologic surgical procedure.
11094264|NCT04116372|Experimental|Empty Nest Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
11094265|NCT04116372|Experimental|Retirement Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
11094266|NCT04116372|No Intervention|Empty Nest Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
11094267|NCT04116372|No Intervention|Retirement Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
11094268|NCT04116359|Experimental|Non-BRD4 exploratory cohort (molibresib, cisplatin, etoposide)|Patients receive molibresib besylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive molibresib besylate, etoposide phosphate and cisplatin as in Phase I and II Cohort at the discretion of the principal investigator.
11094269|NCT04116359|Experimental|Phase I and II cohort (molibresib, etoposide, cisplatin)|Patients receive molibresib besylate PO QD on days 1-14 (may switch to days 1-21 after completion of etoposide and cisplatin cycles). Patients also receive etoposide phosphate IV over 60 minutes on days 1-3 and cisplatin IV over 60 minutes on day 1 of cycles 1-4. Treatments repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of cycle 4, patients may receive etoposide phosphate and cisplatin for up to 8 cycles total in the absence of disease progression or unacceptable toxicity at the investigator's discretion.
11094270|NCT04116346|No Intervention|Fasting group|Fasting for both solids and fluids for up to 6 hours pre-procedure
11094271|NCT04116346|Experimental|Non Fasting group|Usual meal on the day of the procedure and allowed to drink as usual
11094272|NCT04116333|Experimental|ML + ETI|Intubation with using endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
11094273|NCT04116333|Active Comparator|ML|Intubation with using the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
11094274|NCT04116320|Experimental|Cohort 1, primary regimen (Regimen 1a)|FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.
11094275|NCT04116320|Experimental|Cohort 1, secondary regimen (Regimen 2a)|FUSA therapy will be administered on day 8.
11094276|NCT04116320|Experimental|Cohort 2, primary regimen (Regimen 1b)|FUSA therapy, standard of care PD-1 blockade, and imiquimod. FUSA therapy will be administered on day 1.
11094277|NCT04116320|Experimental|Cohort 2, secondary regimen (Regimen 2b)|FUSA therapy and imiquimod. FUSA therapy will be administered on day 1.
11094278|NCT04116307|Experimental|Polymethylsiloxane|Polymethylsiloxane (Enterosgel) is given 3 x 10 g for the initial two days, and 3 x 5 g for the next three days.
11094279|NCT04116307|Active Comparator|Lactobacillus reuteri|Probiotic Lactobacillus reuteri (BioGaia) is given 3 x 20 drops (which means 3 x 400,000.000 CFU) per day for five days.
11094280|NCT04116294|No Intervention|Before|Standard of care for informatic prescription.
11094281|NCT04116294|Active Comparator|After|Computer-assisted prescription for radiological procedure
11094282|NCT04116281|Experimental|Supervised group|Supervised group
11094283|NCT04116281|Other|No supervised group|Control group
11094284|NCT04116268||Obesity|BMI >23kg/m2
11094285|NCT04116268||Control|BMI 18-22.9kg/m2
11094286|NCT04116255|Experimental|exercises group|exercises group apply regular therapeutic home exercises programme
11094287|NCT04116255|Experimental|splint group|splint group use mandibular oral occlusal splint
11094288|NCT04116242||cirrhosis of the liver, stadium Child A|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
11094289|NCT04116242||cirrhosis of the liver, stadium Child B|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
11094290|NCT04116242||cirrhosis of the liver, stadium Child C|sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
11094291|NCT04116242||cirrhosis of the liver, acutely decompensated|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
11094292|NCT04116242||acute liver failure|sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
11094293|NCT04116242||healthy controls|sampling of biological material and health related data collection on day 1 (Baseline)
11094296|NCT04116216|Active Comparator|High frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
11094297|NCT04116216|Active Comparator|Low frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
11094298|NCT04116216|Sham Comparator|Sham rTMS + physical therapy|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
11094299|NCT04116203|Other|Fish Oil|Fish oil capsules 1200mg 6 tablets/day 12 weeks
11094300|NCT04116203|Other|Metformin|Metformin tablets (500 mg) 2/day 12 weeks
11094301|NCT04116203|Other|Fish Oil and Metformin|Combo of other 2 arms
11094302|NCT04116190|Experimental|Telerehabilitation (TR)|Shortened inpatient rehabilitation mixed with home-based telerehabilitation.
11094303|NCT04116190|Experimental|Conventional rehabilitation (CR)|Traditional inpatient rehabilitation
11094304|NCT04116177|Active Comparator|Standard Stimulation|Standard stimulation using contact 3-6 to achieve best therapeutic stimulation
11094305|NCT04116177|Experimental|Flexible stimulation|Flexible stimulation using all available stimulation strategies provided by the VerciseTM system including stimulation of contacts 1-8 and variable pulse width and frequency.
11094306|NCT04116164|Experimental|Dosimetry and targeting|"Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.
~In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point"
11094307|NCT04116151|Experimental|Intervention group|Local administration of the Alantel (R) cream on the affected skin
11094308|NCT04116151|Placebo Comparator|Control group|Local administration of the Placebo cream on the affected skin
11094309|NCT04116138|Experimental|Salovum|Salovum®, an egg powder enriched for anti secretory factor.
11094310|NCT04116125|Placebo Comparator|Sentinel lymph node biopsy|Perform conventional sentinel lymph biopsy
11094311|NCT04116125|Experimental|Adjuvant radiation without Sentinel lymph node biopsy|Perform radiotherapy instead of sentinel lymph node biopsy
11094312|NCT04116112|Experimental|Higher Systolic Blood Pressure (SBP) Target|Lower systolic blood pressure to ≤180 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain ≥160 mmHg.
11094313|NCT04116112|Experimental|Lower SBP (<160 mmHg) Target|Lower systolic blood pressure to <160 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain >140 mmHg.
11094314|NCT04116112|Experimental|Lower SBP (<140mmHg) Target|Lower systolic blood pressure to <140 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain >110 mmHg.
11094315|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
11094316|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
11094317|NCT04116086|Other|PSMA PET-CT exam|Ga 68 -PSMA PET/CT scanning will be performed using a combined PET/CT protocol with a 16-detector-row helical CT scanner (Philips Gemini GXL). This scanner allows simultaneous acquisition of up to 45 transaxial PET images with interslice spacing of 5 mm in one bed position and provides an image from the vertex to the thigh in about 10 bed positions. The use of (68)Ga-PSMA HBED-CC results in a relatively low radiation exposure, delivering organ doses that are comparable to those of other (68)Ga-labelled PSMA-inhibitors used for PET-imaging. Total effective dose is lower than for other PET-agents used for prostate cancer imaging (e.g. (11) C- and (18) F-Choline).
11094318|NCT04116073|Experimental|INCMGA00012 (PD-1 antibody)|All participants will receive the interventional study drug; INCMGA00012.
11094319|NCT04116060|Experimental|Nitrate|Dietary nitrate dissolved in water (0,12 mmol sodium-nitrate/kgBW/day) Dietary Supplement: Dietary nitrate 200 ml tab water with 0,12 mmol/kgBW sodium-nitrate
11094320|NCT04116060|Placebo Comparator|Control|Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day) Dietary Supplement: Dietary sodium-chloride 200 ml tab water with 0,12 mmol/kgBW sodium-chloride
11094321|NCT04116047|Active Comparator|Arm 1 (control): chemoradiotherapy|Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.
11094322|NCT04116047|Experimental|Arm 3: Dose-escalated chemoradiotherapy|Dose-escalated chemoradiotherapy using intensity modulated radiotherapy (IMRT) 64Gy in 25F + Cisplatin 100mg/m2 day 1 of week 1 and of week 5 or weekly 40mg/m2. Neck dissection as indicated by clinical and radiological assessment at 3-months post-treatment.
11094323|NCT04116047|Experimental|Arm 5: Durvalumab + Arm 1|One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months
11094324|NCT04116034|Experimental|DSR|Up to 10 subjects will be treated with alfapump DSR system for a total treatment period of 59 days post-implantation
11094325|NCT04116021|Active Comparator|PECS block|Ultrasound-guided pectoral nerve block with bupivacaine 0.5 % 30 mL before surgical incision
11094327|NCT04116008|Active Comparator|Erector Spinae Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11094328|NCT04116008|Active Comparator|Subcostal Abdominis Plane Block|Ultrasound-guided bilateral STAP block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11094329|NCT04115982|Experimental|Cholecalciferol|Cholecalciferol (Vitamin D3) 100 000 IU/2 mL
11094330|NCT04115982|Placebo Comparator|Placebo|Placebo of Cholecalciferol (Vitamine D3) 100 000 IU/2 mL
11094331|NCT04115969||Patients with non-invasive ventilation|
11094332|NCT04115956|Experimental|Melflufen and dexamethasone in combination|Intravenous infusion of melflufen Day 1 of 28 day cycles, in combination of dexamethasone on Days 1 and 2 of each 28-day cycle.
11094333|NCT04115943|Experimental|Experimental Group|The experimental group (EG) will be submitted to a clinical method considered the gold standard for the treatment of neck pain together with a tongue muscle release protocol.
11094334|NCT04115943|Active Comparator|Control Group|The control group (CG) will only receive the gold standard method for the treatment of neck pain.
11094335|NCT04115930||Patient|Fatigue, cognition and quality of life measurements with different kind of tests and forms. EDSS and SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
11094336|NCT04115930||Control|Healthy volunteers. Fatigue, cognition and quality of life measurements with different kind of tests and forms. SFMC. Daily physical activity measurement 7days. Berg´s scale. Sit-Up 30 s and 6-minutes walking test. Length, weight and waist measurements.
11094337|NCT04115917|Experimental|Schocket Scleral Depressor|Scleral Depression with Schocket Scleral Depressor
11094338|NCT04115917|Active Comparator|Cotton Tipped Applicator|Scleral Depression with Cotton Tipped Applicator
11094339|NCT04115904|Experimental|Post-endodontic Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg takena week after. Incidence of flare ups after a single vsmultiple visits root canal treatments.
11094340|NCT04115904|Experimental|Acute pain|Acetaminophen 325 mg for Acute pain. Taken secondday after. Incidence of Post operative pain after rootcanal treatment in one vs two visits
11094341|NCT04115891|Experimental|Lavender oil group|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to tooth extractions.
~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale 2 (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
11094342|NCT04115891|Sham Comparator|Control group|"No application prior to interventions. No lavender oil inhalation.
~Anxiety scale (FIS) Pain scale 1 (FLACC) Pain scale (WBS) Vital signs 1 (systolic and diastolic blood pressure) Vital signs 2 (heart rate) Vital signs 3 (saturation)"
11094343|NCT04115878|Active Comparator|High dose ato-oxy|
11094344|NCT04115878|Active Comparator|Low dose ato-oxy|
11094345|NCT04115852||CON|Healthy Controls
11094346|NCT04115852||BED|Patients with Binge-Eating-Disorder
11094347|NCT04115839|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
11094348|NCT04115839|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 16 weeks.
11094349|NCT04115839|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
11094350|NCT04115839|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 2 years.
11094351|NCT04115839|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 2 years.
11094352|NCT04115826|Placebo Comparator|Extracorporeal Shock-Wave Lithotripsy|Stone localization will first be performed by obtaining high-quality plain films of the pancreatic area in left and right oblique positions using a two-dimensional radiologic targeting system.Depending on the stone localization, ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
11094353|NCT04115826|Active Comparator|Per-oral Pancreatoscopy-guided Lithotripsy|Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.
11094354|NCT04115813|Experimental|Intervention Arm|The intervention arm participants received the Project YES! intervention for the first phase and then after midline data collection went into a maintenance phase.
11094355|NCT04115813|Other|Comparison Arm|The comparison arm was a usual care arm during the first phase (and primary analysis). After midline data collection the comparison arm began receiving the Project YES! intervention.
11094356|NCT04115800|Experimental|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
11094357|NCT04115800|Placebo Comparator|Liposomal|Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease
11094460|NCT04115085|Experimental|Hand therapy|9 weeks of standard hand therapy including two 20 min slots per week.
11094358|NCT04115774||Osteogenesis Imperfecta patients|The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
11094359|NCT04115761|Other|Investigational Group|ADCV01 is autologous dendritic cells (DCs) stimulated by the patients' own tumor antigens. The total 10 doses (1 mL/dose; 2±0.5 × 10^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
11094360|NCT04115761|Other|Control Group|the conventional treatment (RT and chemotherapy) will be given after tumor resection, followed by subsequent evaluations by an approximately 8-week interval.
11094361|NCT04115748|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
11094362|NCT04115748|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg + PTM adalimumab for up to 16 weeks.
11094363|NCT04115748|Active Comparator|Adalimumab (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + adalimumab 40 mg injection for up to 16 weeks.
11094364|NCT04115748|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
11094365|NCT04115748|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 2 years.
11094366|NCT04115748|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 2 years.
11094367|NCT04115722||Agroup of IBD patients in activity|
11094368|NCT04115722||Normal controlled group|
11094369|NCT04115709|Experimental|Intervention: Device attached with advice activated|Beacon Caresystem device will be attached to the patients and its ventilator advice will be activated.
11094370|NCT04115709|Active Comparator|Control: standard care with device attached without advice|Beacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated.
11094371|NCT04115683|Experimental|Intervention Group|
11094372|NCT04115683|Active Comparator|Control Group|
11094373|NCT04115670|Experimental|specific intervention (experimental)|Specific intervention (experimental). The intervention group will carry out 3 sessions of specific pain education + 15 sessions of physical training.
11094374|NCT04115670|Active Comparator|control group (no intervention)|NO intervention
11094375|NCT04115657|Experimental|Starch 1|Tapioca starch
11094376|NCT04115657|Experimental|Starch 2|High amylose
11094377|NCT04115657|Experimental|Starch 3|Kithul flour
11094378|NCT04115657|Experimental|Starch 4|Sago flour
11094379|NCT04115657|Experimental|Sugar 1|Pure palatinose
11094380|NCT04115657|Experimental|Sugar 2|Blend of sucrose and palatinose
11094381|NCT04115644|Placebo Comparator|Group 1 (control)|will receive an injection of 5 cc 0.25% Marcaine without epinephrine
11094382|NCT04115644|Experimental|Group 2 (ketorolac)|will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
11094383|NCT04115644|Other|Group 3 (kenalog)|Pt will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone. Group 3 is standard of care
11094384|NCT04115631|Experimental|Arm A (bendamustine, rituximab, cytarabine)|Patients receive bendamustine IV on days 1 and 2 and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive rituximab IV on day 1 and cytarabine IV every Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11094385|NCT04115631|Experimental|Arm B (acalabrutinib, bendamustine, rituximab, cytarabine)|Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11094386|NCT04115631|Experimental|Arm C (acalabrutinib, bendamustine, rituximab)|Patients receive acalabrutinib PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11094387|NCT04115618|Experimental|SIB|Simultaneous integrated boost intensity-modulated chemoradiotherapy
11094388|NCT04115592|Experimental|Liquid oil type 1|Cocoa butter (CB)
11094389|NCT04115592|Experimental|Solid oil type 1|Cocoa butter oleogel (CBOG)
11094390|NCT04115592|Experimental|Liquid oil type 2|Sal seed oil (SL)
11094391|NCT04115592|Experimental|Solid oil type 2|Sal seed oleogel (SLOG)
11094392|NCT04115579|Experimental|Biscuit 1 Control|Consumption of control biscuit for breakfast and afternoon snack and impact on postprandial glucose and insulin
11094393|NCT04115579|Experimental|Biscuit 2 Test|Consumption of test biscuit for breakfast and afternoon snack on postprandial glucose and insulin
11094394|NCT04115553|Experimental|idiopathic intracranial hypertension|patients with idiopathic intracranial hypertension
11094395|NCT04115553|Sham Comparator|healthy subjects|Healthy subjects
11094396|NCT04115540|Experimental|TENS penile nerve stimulation group|"The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to prime their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use)."
11094397|NCT04115527|Active Comparator|Standard lymphadenectomy|Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction
11094398|NCT04115527|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).
11094399|NCT04115514|Experimental|Active treatment|Liothyronine Sodium (T3), 5-10-25-50µg instilled directly into the airways in a total volume of 10 ml (T3+0.9% sodium chloride). Progressive dosing every 24 hours for total 96 hours.
11094400|NCT04115514|No Intervention|Control arm|Standard of Care
11094401|NCT04115501|Experimental|Restrictive Oxygen|The restrictive oxygen patients' Fraction of Inspired Oxygen (FiO2) will be set at a minimum of 0.3 to maintain their oxygen saturations (SpO2) greater than or equal to 95% intraoperatively. During CPB a blended air/oxygen mixture will be titrated to arterial blood gas analysis with aim of maintenance of PaO2 between 100 and 150 mmHg. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
11094402|NCT04115501|No Intervention|Liberal Oxygen|The liberal oxygen group will consist of subjects exposed to a Fraction of Inspired Oxygen (FiO2) set at 1.0 throughout the intraoperative period, including during cardiopulmonary bypass. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
11094403|NCT04115488|Experimental|Biosimilar Natalizumab, solution for infusion|Biological: Biosimilar (INN: Natalizumab), 15 milliliter solution for infusion in a vial at a concentration of 20 milligrams per milliliter and a total dose of 300 milligrams, for intravenous (IV) infusions after dilution with 100 milliliter sodium chloride solution at a concentration of 0,9 percent, concentration of solution for infusion will be 2,61 milligrams per milliliter, total volume of solution for infusion will be 115 milliliter, a total of 12 doses of 300mg each will be administered every 4 weeks, duration of each infusion is 1 hour at a rate of 2 milliliters per minute
11094404|NCT04115488|Active Comparator|"EU licensed Natalizumab (Tysabri®)"|"Biological, EU licensed Natalizumab (INN), (tradename Tysabri®), 15 milliliter solution for infusion in a vial at a concentration of 20 milligrams per milliliter and a total dose of 300 milligrams, for intravenous (IV) infusions after dilution with 100 milliliter sodium chloride solution at a concentration of 0,9 percent, concentration of solution for infusion will be 2,61 milligrams per milliliter, total volume of solution for infusion will be 115 milliliter, a total of 12 doses of 300mg each will be administered every 4 weeks, duration of each infusion is 1 hour at a rate of 2 milliliters per minute"
11094405|NCT04115475|Active Comparator|Healthy Volunteers (HV)|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
11094406|NCT04115475|Experimental|Spinal Muscular Atrophy (SMA) patients|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;
~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
11094407|NCT04115462|Active Comparator|Morphine|Each participant will receive a single dose of 20 mg morphine tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
11094408|NCT04115462|Placebo Comparator|Placebo|Each participant will receive a single dose of an identical placebo tablet. At estimated peak-plasma concentration testing is conducted. The subject and the assessor are both blinded to the drug administrations.
11094409|NCT04115449|Experimental|Dexa group|"Spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort.
~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
11094410|NCT04115449|Placebo Comparator|Control group|"Normal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort.
~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale.Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
11094411|NCT04115436||stroke (+)|Patients experiencing thromboembolic events following a brief discontinuation of anticoagulant or having thrombus on the LAA occlusion device
11094412|NCT04115436||No-stroke|Patients remaining stroke-free months after discontinuation of anticoagulants
11094413|NCT04115423||Tocilizumab initiators|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving tocilizumab at least once from January 2013 to December 2018. Tocilizumab initiators are required to have no record of tocilizumab within 1 year prior to the first prescription of tocilizumab.
11094414|NCT04115423||Tumor necrosis factor inhibitors (TNFi) users|Patients over 18 years of age with a diagnosis of RA (ICD-10 codes: M05-06) and receiving TNFi at least once from January 2013 to December 2018. TNFi users will be patients who had no record of tocilizumab and given specific TNFi during 1 year before the first prescription of TNFi.
11094415|NCT04115410||PD-1 inhibitor|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received PD-1 inhibitors as a second line treatment from cytotoxic chemotherapy or as a third line for those received tyrosine kinase inhibitors as a first line, from August 2017 (the first month PD-1 inhibitors were reimbursed in South Korea) to September 2018.
11094461|NCT04115085|Experimental|Therapeutic ultrasound|9 weeks of standard ultra sound therapy including two 10 min slots per week.
11094462|NCT04115085|Experimental|Combined hand therapy and therapeutic ultrasound|9 weeks of standard hand therapy plus therapeutic ultrasound including two 30 min slots per week.
11094416|NCT04115410||Chemotherapy Drugs, Cancer|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received cytotoxic chemotherapy or tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) from August 2017 to September 2018. Each patient switching to PD-1 inhibitor will be matched to three reference standard chemotherapy users.
11094417|NCT04115397|Experimental|Bisphophonate|Zolendronic acid, one infusion iv
11094418|NCT04115397|Placebo Comparator|Placebo|Placebo, one infusion iv
11094419|NCT04115384|Experimental|Insulin (Novolin-R)|Regular insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril) BID
11094420|NCT04115371|No Intervention|Control|Standard emergency department care
11094421|NCT04115371|Other|Intervention|Standard emergency department are plus GEDI consult
11094422|NCT04115358|Experimental|hyaluronic acid|gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar
11094423|NCT04115358|Active Comparator|formocresol|0,1 ml to the orifice of the root canals of the primary molar
11094424|NCT04115358|Active Comparator|ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar
11094425|NCT04115345|Experimental|REACT -renal autologous cell therapy|The dose of Renal Autologous Cell Therapy (REACT) for subjects in the Phase 1 clinical trials (TNG-CL010 and TNG-CL011) was 3 x 106 SRC /g estimated kidney weight. Similarly, in the present study, each REACT injection will contain 3 x 106 cells/g. Since the concentration of selected renal cells (SRC) is 100 x 106 cells/mL of REACT, the dosing volume will be 3.0 mL for each 100 g of kidney weight. The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula (Length x width AP plane x width Transverse plan x .62).
11094426|NCT04115332|Experimental|Interventional|"EEG Recording The one-channel EEG sensor was recorded from Cz with linked-ear reference based on the International 10-20 system. EEG signals were recorded using BioGraph Infiniti software (Version 6.0.4, n.d.) with a band-pass between 1-30 Hz. The sample rate was 256 Hz with 60-Hz notch filters, and the electrode impedances were lower than 5 kΩ.
~A lead II electrocardiogram (ECG) was collected for 5 minutes at baseline using the ProComp InfinitiTM system (Thought Technology Ltd., Montreal, Canada), which was installed on a laptop. A sampling rate of 2,048/second was set in order to acquire real-time interbeat intervals."
11094427|NCT04115319|Experimental|SEP363856|SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
11094428|NCT04115319|Active Comparator|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
11094429|NCT04115306|Experimental|PMD-026|Oral PMD-026 (dose: 25 - 1000 mg), given daily until disease progression or unacceptable toxicity
11094430|NCT04115293|Experimental|0.3 mg/kg zilucoplan (RA101495)|
11094431|NCT04115293|Placebo Comparator|Placebo|
11094432|NCT04115267||Combined modality|Patients receiving radiotherapy and a molecular agent for the treatment of cancer
11094433|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Pancreatic|SMART will be administered per each individual disease site standards
11094434|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Renal|SMART will be administered per each individual disease site standards
11094435|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Lung|SMART will be administered per each individual disease site standards
11094436|NCT04115254|Experimental|PHASE 2: SBRT REDUCED MARGINS, DOSE ESCALATION-Pancreatic|SMART will be administered per each individual disease site standards
11094437|NCT04115254|Experimental|PHASE 2: SBRT REDUCED MARGINS, DOSE ESCALATION-Renal|SMART will be administered per each individual disease site standards
11094438|NCT04115254|Experimental|PHASE 2: SBRT REDUCED MARGINS, DOSE ESCALATION-Lung|SMART will be administered per each individual disease site standards
11094439|NCT04115228|Experimental|Study device|Subjects who provide informed consent, meet all inclusion criteria, and no exclusion criterion, will have a study device implanted and followed closely for 26 weeks.
11094440|NCT04115215|Experimental|Arm 1|Physical exercise (PE)
11094441|NCT04115215|Experimental|Arm 2|Transcranial current stimulation (tCS)
11094442|NCT04115215|Active Comparator|Control|Educational sessions on healthy aging
11094443|NCT04115202||posterior spinal approach group|Lumbar arthrodesis performed by a posterior spinal approach.
11094444|NCT04115202||anterior spinal approach group|Lumbar arthrodesis performed by a anterior spinal approach.
11094445|NCT04115189||Patients with Metastatic RCC|Patients diagnosed with metastatic RCC with clear cell histology who switched from a 4/2 schedule to a 2/1 schedule of sunitinib in first-line metastatic treatment between January 1, 2014 and June 30, 2018
11094446|NCT04115176||smokers + periodontitis|Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.
11094447|NCT04115176||nonsmoker + periodontitis|Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.
11094448|NCT04115163|Experimental|Treatment (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11094449|NCT04115150||self-gripping mesh|
11094450|NCT04115150||non-self-gripping mesh|
11094451|NCT04115137||Women with pelvic congestion syndrome|Women older than 18 years At least 1 birth Present symptoms
11094452|NCT04115124|Experimental|E-PAR Arm|Exposed to media, information and communication technology through ethnographic participatory action research.
11094453|NCT04115111|Experimental|Durvalumab arm|"Patients will receive Durvalumab at the dose and regimens described above every 4 weeks until evidence of disease progression or occurrence of unacceptable toxicity.
~Patients who show evidence of disease progression but appear to tolerate Durvalumab well, for whom no other treatment options exist and who, at the judgement of the investigator, may still enjoy clinical benefit, will be classified as failures and offered the possibility to continue treatment with extended follow up."
11094454|NCT04115098|Experimental|Drug order 1|
11094455|NCT04115098|Experimental|Drug order 2|
11094456|NCT04115098|Experimental|Drug order 3|
11094457|NCT04115098|Experimental|Drug order 4|
11094458|NCT04115098|Experimental|Drug order 5|
11094459|NCT04115098|Experimental|Drug order 6|
11094529|NCT04114643|Active Comparator|Prothrombin Complex Concentrate|
11094463|NCT04115072|Active Comparator|A - Single dose og PZQ|Single dose of Praziquantel 40 mg/kg Standard treatment of schistosomiasis as recommended by WHO
11094464|NCT04115072|Experimental|B - Five doses of PZQ|"Five doses of Praziquantel
~1 x 40 mg/kg Praziquantel after enrollment in the study plus two single doses (40 mg/kg) after 12 and 24 hours after the first treatment
~1 x 40 mg/kg Praziquantel five weeks following the 1st dose
~1 x 40 mg/kg Praziquantel ten weeks following the 1st dose"
11094465|NCT04115059|Experimental|Dasatinib|"-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.
~Dasatinib: Oral Study Drug(s):
~Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.
~This will continue for up to 24 cycles."
11094466|NCT04115046||Treatment Arm|Consecutive, eligible patients reporting for an ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. Each subject will undergo both procedures (FibroScan and EUS with SW Elastography).
11094467|NCT04115033|Experimental|True CES|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to cranial electrical stimulation (CES), which involves transfer of current from the alpha-stim device using earclip electrodes. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The treatments can be self administered by the participants. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
11094468|NCT04115033|Sham Comparator|Sham CES|Veterans with fibromyalgia who meet study criteria and are randomized to the sham comparator group will receive standard therapy in addition to a CES device that does not deliver active electrical stimulation. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. The rs-fcMRI evaluation of neural changes and assessment of clinical pain, function, and quality of life will be performed at the beginning and end of the study.
11094469|NCT04115020|Experimental|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
11094470|NCT04115020|Experimental|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
11094471|NCT04115007|Experimental|Arm A|Standard of care + Stereotactic Body Radiotherapy to oligometastases
11094472|NCT04115007|Active Comparator|Arm B|Standard of care
11094473|NCT04114994||Alzheimer's Disease|
11094474|NCT04114994||Mild Cognitive Impairment|
11094475|NCT04114994||Frontotemporal Dementia|
11094476|NCT04114994||Vascular Dementia|
11094477|NCT04114994||Parkinson Disease|
11094478|NCT04114994||Traumatic Brain Injury (TBI)|
11094479|NCT04114994||Multiple Sclerosis|
11094480|NCT04114994||No diagnosis|
11094481|NCT04114981|Active Comparator|Arm I (SSRS)|Patients undergo SSRS over 1 session.
11094482|NCT04114981|Experimental|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
11094483|NCT04114968||Intervention group|Eligible women residing in the Central Denmark Region will be assigned to intervention group. Women in the intervention group receive an invitation for HPV-based cervical cancer screening by attending either 1) GP-based screening or 2) HPV self-sampling. The self-sampling kit includes the dry Evalyn brush self-sampling device (Rovers Medical Devices B.V, Oss, Netherlands), written and picture-based user instructions on how to collect and mail the self-sample, and a prestamped return envelope addressed to the Department of Pathology, Randers Regional Hospital.
11094484|NCT04114968||Control group|Eligible women residing in the other five Danish regions (North, Central, South, Zealand and Capital ) will be assigned to control group. Women in the control group will receive usual care, which for 65-69 year-old women is opportunistic cervical cancer screening at the GP
11094485|NCT04114955|Active Comparator|Intervention|Intervention condition comprised of two components designed to address intersectional stigma: 1) a group-level, peer-led intervention and 2) an individual-level peer navigation program to increase uptake of HIV testing and PrEP.
11094486|NCT04114955|Other|Wait-list control|Control participants will receive the intervention after a one-year waiting period.
11094487|NCT04114942|Experimental|Constant Coach|Randomized to have coach during didactic training and internship.
11094488|NCT04114942|Experimental|Internship Only Coach|Randomized to have coach during internship only.
11094489|NCT04114942|Experimental|Never Coach|Randomized to never have coach.
11094490|NCT04114929|Experimental|Threshold-Based|Patients will be prescribed exercise based on ventilatory thresholds from a maximal cardiopulmonary exercise test
11094491|NCT04114929|Active Comparator|Standard Care|Patients will be prescribed exercise based on standard guidelines
11094492|NCT04114916|Experimental|Apigenin, luteonin, grapefruit extract and citrolive|One capsules a day. It will be consumed at breakfast for eight weeks.
11094493|NCT04114916|Placebo Comparator|maltodextrina|One capsules a day. It will be consumed at breakfast for eight weeks.
11094494|NCT04114903||Study A|Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users.
11094495|NCT04114903||Study B|Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity.
11094496|NCT04114890|Experimental|Pregnant woman with second trimester and third trimester|
11094497|NCT04114877|Experimental|attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. Attentional retraining (AR) is the most commonly used CBM intervention in the study of addiction-related attentional bias.
11094498|NCT04114877|Active Comparator|visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues.
11094499|NCT04114864|Experimental|Experimental|This arm will be receiving the 7 ME-WE sessions psycho-educational intervention. The experimental group will involve a blended approach with 'face to face' meetings in three European partner countries and online sessions (via a ME-WE mobile app) and a purely 'f2f' approach in a further three European partner countries.
11094500|NCT04114864|Placebo Comparator|Control|The control-group will be a wait-list, receiving relaxation exercises during waiting.
11094501|NCT04114851|Experimental|Active|Patients who get active monitor NoL
11094502|NCT04114851|No Intervention|control|control no NoL
11094503|NCT04114825|Experimental|RV001V|Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
11094504|NCT04114825|Placebo Comparator|Placebo|Total of 12 SC vaccinations with placebo. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
11094505|NCT04114812|Experimental|Blended learning|Participants in the blended learning group will be taught abdominal ultrasound by an e-learning platform and practical near-peer tutoring classes over 16 weeks, summing up to 5 hours of e-learning and 16 hours of near-peer tutoring classes.
11094506|NCT04114812|Active Comparator|Standard course|Participants in the standard course or control group will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training.
11094507|NCT04114799|Active Comparator|Group A invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid bolus will be applied in case of protocol defined hypotension according to the value of systolic pressure variation SPV (Aisys GE). The value of SPV (tidal volume 6 ml/kg) above 8% will be used to predict fluid responsiveness. In case of fluid responsiveness, bolus of 2ml/kg of Plasmalyte will be given within 10 minutes. Boluses will be repeated in hypotensive patients if fluid responsiveness persists. Norepinephrine will be used in hypotensive patients without predicted fluid responsiveness.
11094508|NCT04114799|Experimental|Group B non-invasive haemodynamical measurement|No continuous infusion of fluids will be used intraoperatively. A defined amount of fluid (20 ml of Plasmalyte, Baxter) will be used to flush the anesthetics and other drugs only. Fluid management and the use of norepinephrine will follow a protocol based on the values of cardiac index level, systemic vascular resistance and systolic volume variation (SVV) (ClearSight, Edwards).
11094509|NCT04114786|Experimental|3D-printed mask|Patients will undergo the standard CT SIM, and MR SIM necessary for radiation therapy, creating the masks from the MRIs. Prior to the start of their treatment, patients will have an additional CT scan with the 3D printed mask to confirm safety and treatment accuracy. Patients will then proceed with their standard radiation therapy, immobilized with the mask.The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
11094510|NCT04114786|Active Comparator|Control group|Control group that will be treated with the standard thermoplastic mask, as a comparison measure. The group will complete a mask tolerability questionnaire throughout the course of their treatment to capture the level of discomfort patients may feel with either masks.
11094511|NCT04114773|Experimental|SCARF|"The participants will take part in a rehabilitation intervention focused on the physical, mental, and social consequences of cardiac arrest with an overarching theme of managing fatigue. This will consist of:
~a 5-day residential rehabilitation stay
~followed by a 12 week home-based programme including one telephone call by a member of the clinical rehabilitation team,
~after the 12 week home intervention there will be a further 2-day rehabilitation stay."
11094512|NCT04114760|Active Comparator|Group A : defibrillator ECG to patchy-type ECG|"Group A subject will performing ECG examination to a mock patient in the ambulance.
~First ECG performance will be using defibrillator which contain 12-lead ECG checking function. And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using patchy-type wireless device.
~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
11094513|NCT04114760|Experimental|Group B : patchy-type ECG to defibrillator ECG|"Group B subject will performing ECG examination to a mock patient in the ambulance.
~First ECG performance will be using patchy-type wireless device.
~And taking a 15 minutes wash out period. Second ECG performance after wash out period, will be using defibrillator which contain 12-lead ECG checking function.
~when ECG examination performance ended, survey of patchy-type wireless ECG device usability will be collect."
11094514|NCT04114747|Experimental|Starting at high blood pressure|Patients in this arm are randomized to have high target blood pressure at MAP 80-90 mmHg during the first recordings, thereafter they will receive low blood pressure target 60-70 mm Hg
11094515|NCT04114747|Experimental|Starting at low blood pressure|Patients in this arm are randomized to have low target blood pressure at MAP 60-70 mmHg during the first recordings, thereafter they will receive high blood pressure target 80-90 mm Hg
11094516|NCT04114734|Experimental|Park Rx|Participants will be given a park prescription as part of their treatment plan
11094517|NCT04114734|No Intervention|No Park Rx|Usual care only
11094518|NCT04114708|Other|ACLR|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
11094519|NCT04114708|Other|ACLR with lateral extra-articular tenodesis|All LETs will be performed in a standardized fashion using the modified Lameire technique.
11094520|NCT04114695||Non-CKD (eGFR >60 ml/min/1.73 m2)|Patients with renal function considered normal for age (eGFR >60 ml/min/1.73 m2) without proteinuria or structural kidney disease.
11094521|NCT04114695||CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)|Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)
11094522|NCT04114695||CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)|Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)
11094523|NCT04114695||CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)|Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)
11094524|NCT04114695||CKD stage 5 (eGFR <15 ml/min/1,73 m2)|Patients with CKD stage 5 (eGFR <15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.
11094525|NCT04114669|Experimental|Regret lottery|"Will receive a lottery incentive (regret lottery) for 6 months"
11094526|NCT04114669|Placebo Comparator|Control Condition|Will complete a total of 3 in-person study visits, approximately one hour each.
11094527|NCT04114656|Placebo Comparator|Participants receiving Placebo|All participants will receive a single dose of placebo in either one or two of the three study periods, as per the randomization schedule.
11094528|NCT04114656|Experimental|Participants receiving GSK3858279|All participants will receive a single dose of GSK3858279 in either one or two of the three study periods, as per the randomization schedule.
11094532|NCT04114617|Experimental|Healthy Adults|"Participants will be asked to swallow a series of up to 54 liquid stimuli: a) liquid barium (different brands and concentrations); b) a 20% w/v concentration liquid barium thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; c) lemon-flavored water thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; and/or d) foods representative of minced and moist, soft-and-bite-sized or regular consistency."
11094533|NCT04114604|Experimental|Spinal Cord Injury|Adults who have sustained a spinal cord injury at the cervical or upper thoracic level (T6 or higher). Participants will swallow 20% w/v barium (E-Z-Paque) thickened to different consistencies using starch or xanthan-gum based food thickeners.
11094534|NCT04114591||LARS symptoms|Patient suffering from LARS as identified through LARS questionnaire
11094535|NCT04114591||No LARS symptoms|Absence of LARS symptoms
11094536|NCT04114578||Neonatal profile|ECHO in first 24 hours of life - ideally ECHO at Day 3-5 of life ECHO at 2-3 weeks of life or before discharge (whichever comes first) Data collected at each echocardiography: blood pressure at beginning of ECHO, pre and post-ductal saturation, respiratory support, use of inotropes and dosages, use of iNO and dosage and last blood gas
11094537|NCT04114578||Infant profile ( 4 month and/or 9 month)|Echocardiography Age and stage questionnaires CAT/CLAMS assessment
11094538|NCT04114578||Pediatric profile 3, 5 and/or 8years|Echocardiography Age and stage questionnaires CAT/CLAMS assessment Results from 18 months PMA Bailey will be retrieved
11094539|NCT04114578||Pre-adolescent/adolescent profile 11,14 and/or 17 years|Echocardiography Pediatric Quality of Life inventory survey
11094540|NCT04114539|Experimental|Ecopipam|
11094541|NCT04114526|Experimental|Community Health Advisor 4-step Program|
11094542|NCT04114513|Placebo Comparator|Maltodextrin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
11094543|NCT04114513|Experimental|Inulin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
11094544|NCT04114513|Experimental|Pectin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
11094545|NCT04114513|Experimental|Beta-glucan|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
11094546|NCT04114513|Experimental|Galactooligosaccharides|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
11094547|NCT04114487|No Intervention|control 1|The control 1 group will not be subjected to any application except education.
11094548|NCT04114487|Active Comparator|control 2|The control 2 group will be the control group and will be taken to the balance training in addition to normal education.
11094549|NCT04114487|Experimental|intervention|In theintervention group, dual task balance training will be applied within the scope of cognitive rehabilitation.
11094550|NCT04114461|Experimental|HL-TOF tab. 5mg|Tofacitinib freebase
11094551|NCT04114461|Active Comparator|Xeljanz tab. 5mg|Tofacitinib citrate (5mg as tofacitinib)
11094552|NCT04114448|Experimental|Therapeutic exercise|Patients will be trained to perform a therapeutic exercise intervention protocol. The program will be based on active physical activity including strength, balance an coordination exercises, among others. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
11094553|NCT04114448|Active Comparator|Usual care|Patients will be instructed to perform an usual care physical therapy intervention protocol. Participants in this group will be told to undergo gentle self-performed joint mobilization and stretching exercises. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
11094554|NCT04114435||Neonatal profile|"Echocardiography at:
~7 to 10 days of chronological age
~35 to 37 weeks post-menstrual age (PMA = corrected age);
~39 to 44 weeks PMA; Term equivalent"
11094555|NCT04114435||Infant profile ( between 4 months and 9 months)|"Echocardiography
~Ages & stages questionnaires CAT/CLAMS assessment"
11094556|NCT04114435||Pediatric profile (36 months and 5 years)|"Echocardiography
~Ages & stages questionnaires CAT/CLAMS assessment
~Results from 18 months PMA Bayley will be retrieved Figure 1: Premature population - Groups Recruited simultaneously"
11094557|NCT04114422|Experimental|Seven-day preoperative exercise training program|All patients will undergo to seven-day preoperative exercise training program that includes aerobic and resistance exercises
11094558|NCT04114409||1|OSAS and type D personality
11094559|NCT04114409||2|OSAS without type D personality
11094560|NCT04114396||Severe asthma|Untreated by anti-IL5 treatment for severe asthma at point of recruitment. To be prescribed anti-IL5 as part of their treatment following consent. Note: Anti-IL5 treatment is prescribed as per agreed multidisciplinary team meeting, outside of the decision to enrol the patient on the study, and is administered by the clinical team as part of the patient's clinical care outside of the research study.
11094561|NCT04114396||Healthy control|Control group without respiratory condition
11094562|NCT04114370|Experimental|Participants with Glioma|[F18]fluciclovine will be utilized to assess tumor viability compared with F-18 FDG PET or diagnostic MRI.
11094563|NCT04114357|Experimental|Intervention Group|This arm will consume the supplement daily for 4 weeks.
11094564|NCT04114357|No Intervention|Control Group|This arm will not receive the supplement for 4 weeks.
11094565|NCT04114344|Active Comparator|TAPP (Trans Abdominal PrePeritoneal)|Trans Abdominal PrePeritoneal approach to inguinal hernia repair
11094566|NCT04114344|Experimental|TEP (Totally Extra Peritoneal)|Totally Extra Peritoneal approach to inguinal hernia repair
11094567|NCT04114331|Experimental|Manual therapy and exercise|"The intervention (3 times a week for 4 weeks, for a total of 12 sessions) consisted primarily of manual therapy (soft tissue and joint mobilization) followed by therapeutic exercises (muscular control and coordination).
~Manual therapy:
~Joint mobilizations (Grades I-V) to cervical spine, thoracic spine and ribs Soft tissue mobilization to the pectoralis, scaleni, upper traps, thoracolumbar fascia, erector spinae, and suboccipital musculature
~Therapeutic exercises:
~Strengthening of mid and lower traps, lats, glut med, and glut max. Active & passive stretching of thoracic and lumbar rotation, hip flexors, and plantarflexors.
~The treating therapists agreed on a protocol with treatment individualized to each patient."
11094568|NCT04114318|Experimental|Cognitive-Cycling|Dual-task cognitive-cycling training; cognitive and cycling training simultaneously
11094569|NCT04114318|Active Comparator|Cycling|Single-task cycling training; stationary bicycle exercise training
11094570|NCT04114305||Intervention|HIV-infected pregnant women enrolled in ECD program implemented by m2m program; women followed during pregnancy and 18 months post-partum with their infants.
11094571|NCT04114305||Control|HIV-infected pregnant women receiving routine care in clinics without ECD program; women followed during pregnancy and 18 months post-partum with their infants.
11094572|NCT04114292|Experimental|TUDCA|1.75-2 grams daily in divided dosing
11094573|NCT04114279|Experimental|Laparoscopic Duodenal Atresia Repair|All participants will attempt a laparoscopic duodenal atresia repair on the synthetic high fidelity simulator.
11094574|NCT04114253||Liver transplant patients|Adult patients undergoing deceased donor liver transplantation.
11094575|NCT04114240||Xybilun: mild erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with mild ED (score IIEF-6 between 22 and 25) and begin treatment at 50 mg
11094576|NCT04114240||Xybilun: moderate erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with moderate ED (score IIEF-6 between 11 and 21) and begin treatment at 50 mg
11094577|NCT04114240||Xybilun: severe erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with severe ED (score between 6 and 10) and begin treatment at 50 mg
11094578|NCT04114240||Xybilun switch|Substitution dose to dose of previous treatment by Xybilun whatever the severity of ED.
11094579|NCT04114227|Active Comparator|Acceptance and Commitment Therapy|Participants will learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors.
11094580|NCT04114227|Active Comparator|Supportive Psychotherapy|Participants will talk about their experiences to date.
11094581|NCT04114214||patients with suspected infection or sepsis|All patients admitted with suspected infection or sepsis from January 2018 to February 2018 at Prince of Wales Hospital
11094582|NCT04114201|Experimental|PSI|Patients received TKA using patient-specific Instrumentation.
11094583|NCT04114201|Active Comparator|Conventional|Patients received TKA conventional Instrumentation.
11094584|NCT04114188|Experimental|Antithymocyte Immunoglobulin (Rabbit)|rATG induction on day 0 & 1 post op
11094585|NCT04114175|Active Comparator|Control Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
11094586|NCT04114175|Experimental|Spinal Stabilization Group|People with unilateral transtibial amputation. Participants will be provided from the sample group according to the randomization.
11094587|NCT04114149|Active Comparator|TENS (transcutaneous electrical nerve stimulation)|High frequency, high intensity TENS treatment. Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
11094588|NCT04114149|Active Comparator|Conventional treatment with iv opioid|Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
11094589|NCT04114149|No Intervention|Control|Patients who report postoperative pain intensity according to NRS (numeric rating scale) < 3 during the time spent in post-anesthesia care unit.
11094590|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Metformin|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
~Metformin - 500 mg by mouth twice daily"
11094591|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Rosiglitazone|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
~Rosiglitazone - 4 mg by mouth once daily"
11094592|NCT04114136|Active Comparator|Anti-PD-1 mAb (nivolumab or pembrozilumab)|nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
11094593|NCT04114123||Longitudinal|The researchers will be evaluating baseline indicators of wanting salience and liking between 2 and 6 month olds, with the goal of following up with these families at 24 months and beyond by reviewing the dyads' medical charts. The researchers will also examine direct and indirect associations between reward-driven eating, and maternal and infant characteristics and infant weight-for-length.
11094594|NCT04114123||Cross-sectional|The researchers will as the mother to answer questionnaires and participate in up to two video taped behavioral protocols when the infant is 6 months old.
11094595|NCT04114110||Admitted inpatients|no intervention
11094596|NCT04114110||Staff with RTLS badges|no intervention
11094597|NCT04114097|Experimental|Betamethasone-17-valerat + placebo ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (Betnovate, betamethasone dipropionate ointment 0.1%) and placebo"
11094598|NCT04114097|Active Comparator|Tacrolimus ointment|"Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (Protopic, tacrolimus ointment 0.1%)"
11094599|NCT04114084||A. patients with MGUS and sleep apnea|
11094600|NCT04114084||B. patients with MGUS and no sleep apnea|
11094601|NCT04114084||C. patients with MM and sleep apnea|
11094602|NCT04114084||D. patients with MM and no sleep apnea|
11094675|NCT04113577||health professionals|usablity assessment after the enrollement of all patients and unformal caregivers
11094676|NCT04113564|Experimental|IV remimazolam|IV remimazolam administration of 0.025 mg/kg body weight
11094603|NCT04114071|Experimental|Physical Activity intervention group|Older overweight or obese Black women who participate in the physical activity intervention group will receive a daily text message from the TOSS study for 12 weeks, a Fitbit device plus have access to the Fitbit community option on their Fitbit app as an opportunity for virtual peer support. They will also receive an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention.
11094604|NCT04114071|Active Comparator|Control group|The control will only receive a weekly neutral text message during the 12-week intervention. For this project, a neutral text message is defined as a message that only provides facts about a topic.They will also receive a Fitbit device, an instruction pamphlet that describes the health benefits of regular physical activity (PA), safety instructions for PA, the national PA guidelines for older adults, suggested strategies to increase number of steps and an accelerometer pre and post-intervention
11094605|NCT04114058|Active Comparator|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
11094606|NCT04114058|Active Comparator|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
11094607|NCT04114045|Experimental|Whey protein|Whey protein isolate
11094608|NCT04114045|Active Comparator|Isoenergetic control - Carbohydrate|Carbohydrate or maltodextrin
11094609|NCT04114045|Placebo Comparator|Placebo control - Water|Water - chocolate flavoured
11094610|NCT04114032||High-risk elective surgical patients|"The patient population to be studied are elective patients for non-cardiac surgery.
~Age ≥ 45 years of age.
~Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in hospital.
~With at least one of the following criteria:
~History of ischaemic heart disease or peripheral vascular disease (coronary equivalent)
~History of stroke or transient ischaemic attack
~History of congestive cardiac failure
~Diabetes currently on an oral hypoglycaemic agent or insulin
~Serum creatinine >175 µmol/L (>2.0mg/dl)"
11094611|NCT04114019||Stress urinary incontinence|Women suffering from stress urinary incontinence
11094612|NCT04113993|Experimental|Oral Bazedoxifene|Oral Bazedoxifene dosed at 40 mg daily
11094613|NCT04113993|Placebo Comparator|Placebo|Identically packaged placebo capsule daily
11094614|NCT04113980|Experimental|music group|The children in the groups were distracted by listening music 2 minutes before venipuncture, until the process was over.
11094615|NCT04113980|Experimental|kaleidescope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
11094616|NCT04113980|Experimental|video group|The children in the groups were distracted by watching cartoon 2 minutes before the blood collection, until the process was over.
11094617|NCT04113980|No Intervention|control group|No intervention was made to children in the control group
11094618|NCT04113967|Experimental|Biodanza Group|The biodanza program will consist of 12 sessions, one per week, during three months. Each session will last approximately 60 minutes and an introductory phase (10-15 minutes) and an experience phase (45 minutes) will be divided. It involves moving / dancing according to the suggestions of the monitor and the rhythm of the music.
11094619|NCT04113967|No Intervention|Treatment as usual Group|The control group will continue with its usual treatment and activities, without suffering any alteration. A measurement of the groups (control group and biodanza group) will be carried out before the start and after the end of the sessions.
11094620|NCT04113954|Experimental|Leg 1 and low dose PFNB|Right leg and 0.375% mepivacaine popliteal fossa-sciatic
11094621|NCT04113954|Experimental|Leg 1 and high dose PFNB|Right leg and 1.5% mepivacaine popliteal fossa-sciatic
11094622|NCT04113954|Experimental|Leg 2 and low dose PFNB|Left leg and 0.375% mepivacaine popliteal fossa-sciatic
11094623|NCT04113954|Experimental|Leg 2 and high dose PFNB|Left leg and 1.5% mepivacaine popliteal fossa-sciatic
11094624|NCT04113941|Experimental|Neuronox®|Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites
11094625|NCT04113941|Placebo Comparator|Placebo|Normal saline, same volume with Experimental arm
11094626|NCT04113928|Experimental|Broccoli & mustard seed soup|200ml acute feed
11094627|NCT04113928|Active Comparator|Broccoli soup|200ml acute feed
11094628|NCT04113915||Group 1|Group of ITP patients received triple therapy
11094629|NCT04113915||Group 2|Group of ITP patients received steroids
11094630|NCT04113915||Group 3|Normal control group
11094631|NCT04113902|Experimental|intervention group|Health education is given intervention group and 12 weeks follow up.
11094632|NCT04113902|No Intervention|control group|Control group takes standard health care and 12 weeks follow up.
11094633|NCT04113889|Active Comparator|Combination therapy group|Arm 1: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
11094634|NCT04113889|Placebo Comparator|Standard therapy group|Arm 2: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Placebo
11094635|NCT04113863|Active Comparator|ARM A - Anastrozole|Anastrozole at the dosage of 1 mg/die. Treatment will last 28 days
11094636|NCT04113863|Experimental|ARM B - Anastrozole + ATRA|Anastrozole at the dosage of 1mg/die in combination with ATRA at the total dosage of 45mg/m2/die (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
11094637|NCT04113850|Experimental|Sitting|Subjects will undergo acoustic startle testing in the sitting position.
11094638|NCT04113850|Experimental|Standing|Subjects will undergo acoustic startle testing in the standing position.
11094639|NCT04113837|Experimental|verum|"The food range is comprised of:
~sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)"
11094640|NCT04113837|Active Comparator|control|In the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.
11094677|NCT04113564|Experimental|Oral remimazolam|Oral remimazolam Administration of 0.14 mg/kg Body weight
11094641|NCT04113824|Experimental|trapezius motion style acupuncture treatment|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.
~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
11094642|NCT04113824|Active Comparator|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
11094643|NCT04113811|Experimental|Microwave needle thermoablation of prostate cancer|The treatment will be performed under general anaesthesia or monitored anaesthetic care using the Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France) under Organ-based Tracking® (OBT) mechanism of the Koelis Trinity® machine. Both Koelis Trinity and TATO3 are CE (European Conformity) marked in Europe. A transrectal sideview ultrasound probe is used for real-time imaging and OBT of the prostate. The TATO3® needle is inserted transperineally to the tumor under MRI-Ultrasound fusion OBT guidance with the treatment zone covering the whole tumor. The dominant MRI-visible lesion and up to 1-2 more MRI-visible or invisible lesion will be treated.
11094644|NCT04113798|Experimental|Moderate Intensity Exercise|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction
11094645|NCT04113798|Active Comparator|Control|Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction
11094646|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
11094647|NCT04113772|Active Comparator|Orfandin .5 mgm/kg mgm bid|Two participant will receive .5 mgm/kg mgm of orfadin
11094648|NCT04113772|Experimental|Nitinosine .5 mgm/kg bid|Two participant will receive .5 mgm/kg of nitinosine
11094649|NCT04113759|Placebo Comparator|Control Group|The control group will receive sham BFR, in which a non-occlusive pressure is applied with the cuff. The exercises performed will be identical to the BFR group.
11094650|NCT04113759|Experimental|BFR Postoperative Rehabilitation|The experimental group will receive BFR postoperative rehabilitation, which will involve performing a series of blood flow restriction exercises identical to the control group.
11094651|NCT04113746|Experimental|Asthma and Exercise Lifestyle Change|Participants receive asthma and lifestyle change education related to exercise
11094652|NCT04113746|Placebo Comparator|Asthma Education|No lifestyle change education
11094653|NCT04113733||Crohn's Disease|This group consists of patients with a diagnosis of Crohn's disease undergoing colonoscopy for clinical care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
11094654|NCT04113733||Control|This group will include patients undergoing screening colonoscopy as part of standard of care. Samples including tissue biopsy, blood and stool will be collected one time. In addition, patient information that may include questionnaires and medical record review will be collected.
11094655|NCT04113733||Cooperative Human Tissue Network|This group will consist of non-IBD patients and Crohn's disease patients participating in the Cooperative Human Tissue Network (CHTN). The CHTN will be utilized to obtain surgical specimens from these patients. The patients will be screened and consented via the CHTN protocol. No additional samples in the form of blood or stool will be collected. Associated clinical data will be collected through medical record review.
11094656|NCT04113720|Experimental|Group A|children will receive levobupivacaine 0.25% by peritonsillar infiltration after intubation 3- 5 min before the start of surgery.
11094657|NCT04113720|Active Comparator|Group B|children will receive levobupivacaine 0.25% plus dexmedetomidine 1µg/kg diluted in 4 ml saline 0.9% and given by peritonsillar infiltration (2 ml per tonsil), after intubation 3- 5 min before the start of surgery.
11094658|NCT04113707|Experimental|Motor Lab|Group A will receive 20 minutes of motor lab intervention daily.
11094659|NCT04113707|No Intervention|Standard of Care|Group B will receive standard of care which will be 20 minutes of reading per day.
11094660|NCT04113694|Experimental|Extended Wear Infusion Set|Each subject will be given 12 Extended Wear Infusion Sets to wear.
11094661|NCT04113681|Experimental|Geniculate Artery Embolization Arm|Single-arm prospective study of geniculate artery embolization for symptomatic knee osteoarthritis
11094662|NCT04113668|Experimental|Arm A: Single Dose (BMS-986165)|
11094663|NCT04113668|Experimental|Arm B:Diflunisal and Single Dose (BMS-986165)|
11094664|NCT04113655||acellular pertussis vaccine|Antibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202
11094665|NCT04113642||single group|healthy subjects
11094666|NCT04113629|Other|Sofosbuvir/Daclatasvir|standard DAA therapy: 12 or 24 weeks of sofosbuvir/daclatasvir
11094667|NCT04113616|Experimental|KRT-232+LDAC|KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle.
11094668|NCT04113616|Experimental|KRT-232(7-Day)+Decitabine|KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle.
11094669|NCT04113616|Experimental|KRT-232(14-Day)+Decitabine|KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle.
11094670|NCT04113603|Experimental|A_Single bolus|Single bolus computed tomography urography (CTU)
11094671|NCT04113603|Experimental|B_Split bolus|Split bolus computed tomography urography (CTU)
11094672|NCT04113590|Experimental|Transvaginal cholecystectomy under laparoscopic guidance|The removal of the gallbladder through several small incisions using a camera to see is called laparoscopic cholecystectomy. This study is being done to evaluate whether cholecystectomy can be performed through a natural orifice (the vagina) with minimal laparoscopic assistance (only one abdominal trocar versus four in the routine laparoscopic cholecystectomy).
11094673|NCT04113577||geriatric inpatients with neurocognitive disorder|usability assessment after 30 minutes to test the app
11094674|NCT04113577||unformal cargivers|usability assessment after 30 minutes to test the app with their relatives
11094678|NCT04113551||Cohort T1: Methylphenidate (MPH) (Concerta)|Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094679|NCT04113551||Cohort T2: MPH (Ritalin)|Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094680|NCT04113551||Cohort T3: MPH (Concerta and Ritalin)|Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.
11094681|NCT04113551||Cohort T4: Atomoxetine (ATO)|Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094682|NCT04113551||Cohort T5: Guanfacine (GFC)|Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094683|NCT04113551||Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
11094684|NCT04113551||Cohort T7: MPH (Concerta or Ritalin)|Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.
11094685|NCT04113551||Cohort T8: MPH (Concerta) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094686|NCT04113551||Cohort T9: MPH (Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094687|NCT04113551||Cohort T10: ATO All Exposures|Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094688|NCT04113551||Cohort T11: GFC All Exposures|Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.
11094689|NCT04113551||Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
11094690|NCT04113551||Cohort T13: MPH (Concerta or Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
11094691|NCT04113551||Cohort T14: MPH (Concerta and Ritalin) All Exposures|Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.
11094692|NCT04113538|Active Comparator|Standard|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study
11094693|NCT04113538|Experimental|Treat and Extend|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability
11094694|NCT04113525|Experimental|Active Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve active stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
11094695|NCT04113525|Sham Comparator|Sham Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve sham stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
11094696|NCT04113512|Experimental|Yoga Nasal Irrigation Group|Saline nasal irrigation using neti pot was practiced.
11094697|NCT04113512|No Intervention|Wait list Control group|Group was given usual pain medication. After trial period, they were offered the intervention.
11094698|NCT04113499|Active Comparator|Direct Endoscopic Necrosectomy|The subject will have endoscopic drainage and necrosectomy at the time of the index intervention.
11094699|NCT04113499|Active Comparator|Step-up Endoscopic Interventions|The subject will only have endoscopic drainage of the pancreatic necrotic collection at the time of index intervention.
11094700|NCT04113486||Renal cancer group|Patients which imaging studies have found renal mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
11094701|NCT04113486||Urothiasis group|Patients which imaging studies have found renal or ureteral stones, and rule out of renal mass, about 100.
11094702|NCT04113486||Renal cysts group|Patients which imaging studies have found renal cysts (simple or complex) about 100.
11094703|NCT04113486||Liver cancer group|Patients which imaging studies have found hepatic mass, plan to receive surgery (except for radiofrequency ablation, cryoablation, etc.), about 100.
11094704|NCT04113473|Experimental|Yoga Group|Experimental group received individualised yoga therapy twice a week for an hour for 12-weeks.
11094705|NCT04113473|No Intervention|Control Group|Control group were given education session and continued on usual care for 12-weeks.
11094706|NCT04113460|Experimental|Yoga Group|The yoga group received the 8-week yoga sessions at work setting once a week by trained teacher followed by self practices.
11094707|NCT04113460|No Intervention|Control Group|Participants had one introductory session on proper physical position and stretching exercises to be practiced daily during work.
11094708|NCT04113421||Anticoagulation|Inpatients diagnosed with acute PE, in whom clinical providers have elected to prescribe anticoagulation alone for treatment based on clinical grounds at BWH. In this population, a single follow-up contrast-enhanced chest CT will be performed to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
11094709|NCT04113382|Experimental|Participants aged 2 to <4 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (½ bottle [approximately 80 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL."
11094710|NCT04113382|Active Comparator|Participants aged 2 to <4 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 4 ounce (oz) for every 30 minutes, one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
11094711|NCT04113382|Experimental|Participants aged 4 to <9 years: CLENPIQ|"CLENPIQ administered using split-dose method and consists of two separate doses: the first dose (1 bottle [approximately 160 mL]) one day before colonoscopy between 5:00 PM and 9:00 PM, and the second dose (½ bottle [approximately 80 mL]) the next day, at least 5 hours prior but no more than 9 hours prior to the colonoscopy. Following each dose, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum."
11094712|NCT04113382|Active Comparator|Participants aged 4 to <9 years: MIRALAX|MIRALAX 3.4 to 4.9 g/kg up to a maximum of 238 g is reconstituted with non-carbonated, clear beverage, or water and administered in increments of 8 oz for every 30 minutes one day before colonoscopy between 5:00 PM and 9:00 PM. Following dosing, participants will consume 50 mL/kg of clear liquids, up to a limit of 1,000 mL total weight-based maximum.
11094713|NCT04113369|Sham Comparator|TENS group|30 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training program, patients will receive 30 minutes of conventional antalgic TENS (100 Hz) program as controls with electrostimulation device to the non-paretic wrist flexors.
11094714|NCT04113369|Active Comparator|EMS group|0 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training, the patients will receive 20 minutes of electrical stimulation to their non-paretic forearm upon wrist flexors by an intermittent maximum strength program (6 seconds of contraction, 10 seconds of rest) along with 5 minutes of pre and post warm-up with the same device.
11094715|NCT04113356||ST-Elevation Myocardial Infarction|Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
11094716|NCT04113343|Active Comparator|Treatment A: remimazolam|Oral administration of 360 mg remimazolam
11094717|NCT04113343|Experimental|Treatment B: remimazolam + 5% v/v alcohol|Oral administration of 360 mg remimazolam and 5% v/v alcohol
11094718|NCT04113343|Experimental|Treatment C: remimazolam + 15% v/v alcohol|Oral administration of 360 mg remimazolam + 15% v/v alcohol
11094719|NCT04113343|Experimental|Treatment D: remimazolam + 40% v/v alcohol|Oral administration of 360 mg remimazolam + 40% v/v alcohol
11094720|NCT04113343|Placebo Comparator|Treatment E: placebo + 40% v/v alcohol|Oral administration of Placebo + 40% v/v alcohol
11094721|NCT04113330||Study Group|Participant vaccinated with CYD Dengue Vaccine and classified as seronegative or undetermined at baseline in previous dengue studies in Colombia
11094722|NCT04113317|Experimental|Treatment Group|Subcutaneous injection of G-CSF with dose of 5μg/kg/day for 5 days consecutively, in addition to a single dose every 3 days up to 12 times, as well as liver cirrhosis standard regimen
11094723|NCT04113317|No Intervention|Control Group|Liver cirrhosis standard treatment only
11094724|NCT04113291|Experimental|DASH diet group|Participants randomized to receive the DASH diet will be prescribed an isocaloric DASH diet using meals (lunch, dinner, snacks) prepared by a Clinical Research Metabolic Kitchen under the direction of a registered dietician. Participants will prepare their own breakfast from a menu. The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
11094725|NCT04113291|Active Comparator|Attention Control Group|Participants randomized to attention control will continue their usual diet, but they will be instructed to limit their sodium intake to 2300 mg/day. They will be requested and voluntarily agree to not make additional diet or exercise changes during the 12-week study.
11094726|NCT04113265|Experimental|SUNEKOS ® Body|The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated 3 more times with an interval of 1 week (T2i, T3i and T4i).
11094727|NCT04113252|Experimental|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
11094728|NCT04113252|Experimental|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
11094729|NCT04113252|Experimental|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
11094730|NCT04113239||Diagnosed Type 2 Diabetes Mellitus|Patients with incident type 2 diabetes mellitus
11094731|NCT04113239||Control|Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria
11094732|NCT04113226|Active Comparator|classical rituximab-based chemotherapy|Rituximab-based physician's choice chemotherapy
11094733|NCT04113226|Experimental|rituximab plus lenalidomide|Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression.
11094734|NCT04113213|No Intervention|Control|Standard care during consultations.
11094735|NCT04113213|Experimental|Intervention|Standard care during consultations with the addition of a physical lifestyle prescription.
11094736|NCT04113200|Experimental|F+ALG|An alginate containing feed: MerMed One (Kaneka Corporation). 300mls administered nasogastrically over one hour.
11094737|NCT04113200|Other|F-ALG|A standard enteral feed commonly used in practice. Nutricomp Soy Fibre (B.Braun). 300mls administered nasogastrically over one hour.
11094738|NCT04113187|Experimental|Propranolol arm|
11094739|NCT04113187|Placebo Comparator|Placebo arm|
11094740|NCT04113174||SAIL databank|Anonymised records from around 5 million people in Wales, with linked primary care, ED attendance, hospital admissions, outpatient data, social care, Welsh Care Homes Dataset, and ONS mortality data. SAIL includes eFI summary scores and individual components.
11094741|NCT04113174||ResearchOne|Nationally representative, de-identified data from around 6 million primary care electronic health records on the TPP SystmOne clinical system. ResearchOne includes eFI summary scores and individual components.
11094742|NCT04113174||Leeds Data Model|Anonymised, linked primary, secondary, community and social care data from 810,000 patients across 108 practices in Leeds, including eFI summary scores and individual components.
11094743|NCT04113174||CARE75+|National prospective cohort study (n≈1,200) collecting detailed sociodemographic information, frailty measures (including eFI scores), simple instruments suitable for use in primary care (e.g. gait speed, timed-up-and-go test; activities of daily living; informal care; loneliness), and key outcomes at six, 12, 24 and 48 months. CARE75+ is a very rich dataset that provides a highly efficient method to investigate how simple instruments might augment eFI performance.
11094744|NCT04113161|Active Comparator|Standard Care|Standard care will consist of 1) community-based screening and referral and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
11094745|NCT04113161|Experimental|Child Behavioral Health Navigators (cbhN)|CbhNs will engage in a series of face to face and phone contacts with families to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
11094746|NCT04113148||Healthy volunteer|Physiological measurements from heel over 60 minute period
11094747|NCT04113148||At risk of Pressure Ulcer|Physiological measurements from heel over 60 minute period
11094748|NCT04113148||Confirmed Catefory I Pressure Ulcer|Physiological measurements from heel over 60 minute period
11094749|NCT04113148||Suspected Deep Tissue Injury|Physiological measurements from heel over 60 minute period
11094750|NCT04113135|Experimental|Journaling, meditations, education, yoga intervention Arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post testing will take approximately 45 minutes to one hour. Session 1 for all participants will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The intervention sessions (2-6) for the experimental group participants consist will include a group discussion of the objectives for the week, 20-30 minutes of education and journaling (Attachment B), 45-60 minutes of PA consisting of various yoga poses followed by SMART goal setting and guided relaxation..
11094751|NCT04113135|Active Comparator|Journaling, meditation, education arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post-testing will take approximately 45 minutes to one hour. Session 1 for all participants (control and experimental) will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The control group will participate in a 45-60 minute session for weeks 2-6 consisting of goal setting to facilitate behavior change, education on MS, and meditation. Session 7 will conclude the study with reassessment of all outcome measurements as listed above.
11094752|NCT04113122|Experimental|Cross-sectional study:|Testicular cancer survivors who were treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and who were extensively phenotypically mapped within two longitudinal trials (15,16) will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.
11094753|NCT04113122|Experimental|Longitudinal study - chemotherapy group|"Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited in the longitudinal part of this study. Study participation involves four study visits:
~Visit 1: before start of chemotherapy Visit 2:before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy"
11094754|NCT04113122|Other|Longitudinal study - stage I control group|"Patients with stage I testicular cancer will serve as control group with three study visits:
~Visit 1: at time of orchidectomy Visit 2: one month Visit 3: one year after orchidectomy"
11094816|NCT04112654|Experimental|Low pressure laparoscopy|Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®
11094755|NCT04113109|Experimental|placebo, icatibant, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
11094756|NCT04113109|Experimental|placebo, icatibant, icatibant, placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
11094757|NCT04113109|Experimental|icatibant, placebo, placebo, icatibant|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.
11094758|NCT04113109|Experimental|icatibant, placebo, icatibant placebo|After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.
11094759|NCT04113096|Experimental|Breast Cancer Stage IV|Stage IV Breast Cancer: Dibenzyl trisulphide capsules (20mg once daily)/6 months
11094760|NCT04113096|Experimental|Colon Cancer Stage IV|Stage IV Colon Cancer:Dibenzyl trisulphide capsules (20 mg one daily for 6 months
11094761|NCT04113096|Experimental|Cervical Cancer Stage IV|Stage IV Cancer of the Cervix: Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
11094762|NCT04113096|Experimental|Cancer of the Prostate Stage IV|Stage IV Prostate cancer:Dibenzyl trisulphide capsules (20 mg once daily) for 6 months
11094763|NCT04113070||Overweight and obesity group|"Children with BMI cutoff points greater than 25.0 or 30.0 at 18 years old were defined overweight or obesity according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.
~Willingness to comply with study requirements"
11094764|NCT04113070||Non-overweight group|"Children with BMI smaller than 25.0 at 18 years old were defined non-overweight according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.
~Willingness to comply with study requirements"
11094765|NCT04113057|Experimental|Remote Coaching|All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The remote coaching arm will receive regular provider feedback based on LIVMOR data.
11094766|NCT04113057|No Intervention|Remote health monitoring without provider feedback|"All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The no intervention arm will have access to LIVMOR data, but without provider feedback on the LIVMOR data."
11094767|NCT04113031|Experimental|Flywheel group|The players allocated to the flywheel group will perform six weeks of squat resistance exercise using a flywheel device.
11094768|NCT04113031|Experimental|Barbell free weight group|The players allocated to the barbell free weight group will perform six weeks of squat resistance exercise using a an olympic barbell and free weight of high loads.
11094769|NCT04113031|Active Comparator|Control|All players in all three groups (including control group) will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match).
11094770|NCT04113018|Experimental|1|Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
11094771|NCT04113005|Experimental|Desmopressin|Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
11094772|NCT04112979|Experimental|Auditory stimulation 1 (Music)|45 deciBel Sensation Level (dB SL), normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
11094773|NCT04112979|Experimental|Auditory stimulation 2 (Mother's lap)|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
11094774|NCT04112979|Experimental|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 deciBel (dB)
11094775|NCT04112979|No Intervention|No stimulation|Current standard of care
11094776|NCT04112966|Experimental|Early Manual Lymph Drainage|14 sessions of manual lymphatic drainage technique in the three months following surgery and received health education on the prevention of lymphedema.
11094777|NCT04112966|Other|Health education for lymphedema prevention|Only the health education for lymphedema prevention.
11094778|NCT04112953||Upcoming cardiac surgery|Subjects in this group will have an upcoming cardiac surgery with the use of cardiopulmonary bypass and no pre-existing renal insufficiency or failure
11094779|NCT04112940|Experimental|Adults with oropharyngeal cancer|Adult participants who have completed radiation therapy for oropharyngeal cancer within the past 3 months will undergo a swallowing x-ray study in which they will swallow up to 15 liquid stimuli prepared to different consistencies using starch and gum based thickeners.
11094780|NCT04112927||OSA Participants|"Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor.
~Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study."
11094817|NCT04112641|Placebo Comparator|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
11094818|NCT04112641|Experimental|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
11095527|NCT04107740|Experimental|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
11094781|NCT04112927||Healthy Controls|"Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders.
~Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording.
~Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent."
11094782|NCT04112914|No Intervention|Education as usual|Participants receive education/healthcare provider communication as usual during their visit to the ED for concussion care.
11094783|NCT04112914|Experimental|New education|Participants receive the newly developed educational materials, with their dissemination and implementation supported by the newly developed implementation toolkit
11094784|NCT04112901||People with trans-femoral amputation or knee dis-articulation|include individuals with unilateral transfemoral amputation or knee disarticulation, with ≤ K2 mobility grade OR SIGAM grade D or below; i.e. able to walk ≤ 50 meters on level ground, who have been users of either microprocessor-controlled knee or non-microprocessor-controlled knee joint for at least 6 months prior to the recruitment date.
11094785|NCT04112888|Experimental|Collagen group|"Patients will receive 3 to 5 infiltrations of collagen on the scar once a week.
~Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes."
11094786|NCT04112888|Active Comparator|Control group|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. Two rehabilitation sessions per week during four weeks. The rehabilitation sessions will last 45 minutes.
11094787|NCT04112875|Active Comparator|L-arginine|L-arginine supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
11094788|NCT04112875|Placebo Comparator|Maltodextrin|Maltodextrin supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
11094789|NCT04112862|Experimental|Intervention|three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
11094790|NCT04112849||Heart failure subjects|Subjects who have heart failure, and meet inclusion/exclusion criteria, who will be enrolled in this study and will have their heart sounds measured with Nanowear vest (NCHFMS).
11094791|NCT04112836||Normal nutritional status|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of 24-30 points.
11094792|NCT04112836||Malnourished|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of fewer than 17 points.
11094793|NCT04112823|Active Comparator|Dexamethasone 4mg|Dexamethasone 4mg, administered intravenously
11094794|NCT04112823|Active Comparator|Dexamethasone 16mg|Dexamethasone 16mg, administered intravenously
11094795|NCT04112810|Experimental|Tildrakizumab|Tildrakizumab (IluymaTM) is a humanized monoclonal antibody that specifically binds to the IL-23p19 subunit of IL-23 to neutralize its function.
11094796|NCT04112771||Penehyclidine group|Penehyclindine hydrochloride was administered before anesthesia induction.
11094797|NCT04112771||Placebo group|Penehyclindine hydrochloride was not administered before anesthesia induction.
11094798|NCT04112758|Experimental|Exercise group|The group will receive twice a week for 5 week
11094799|NCT04112758|No Intervention|Control group|The group will be maintained their normal after school activities
11094800|NCT04112745|Experimental|Experimental group|
11094801|NCT04112745|Placebo Comparator|Control group|
11094802|NCT04112732|Experimental|Multivitamin|1 multivitamin tablet administered by mouth daily for 12 weeks, to be taken with main meal.
11094803|NCT04112732|Placebo Comparator|Placebo|1 placebo tablet administered by mouth daily for 12 weeks, to be taken with main meal.
11094804|NCT04112719||Control arm/pregnant patients at term|Control arm where the term pregnant patient will be lying on the bed at 45 degrees.
11094805|NCT04112719||Experimental/Supine|Term pregnant patient will be positioned in supine. Changes in hemodynamics will be measured.
11094806|NCT04112719||Experimental/15 degrees lateral tilt|Term pregnant patient will be positioned at 15 degrees in lateral tilt. Changes in hemodynamics will be measured.
11094807|NCT04112719||Experimental/30 degrees lateral tilt|Term pregnant patient will be positioned at 30 degrees in lateral tilt. Changes in hemodynamics will be measured.
11094808|NCT04112693|Experimental|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.
~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
11094809|NCT04112680|Experimental|Intervention group 1|Audio messages in this group are focussed on providing a Plausible Alternative to the misinformation
11094810|NCT04112680|Experimental|Intervention group 2|Audio messages in this group focus on Avoiding the Misinformation and instead only provide the correct information
11094811|NCT04112680|Placebo Comparator|Control group|Audio messages in this control group are on a different topic
11094812|NCT04112667||Normal Macular Health|>=60 years old with no macular disease
11094813|NCT04112667||Early Macular Degeneration|>=60 years old with early age-related macular degeneration
11094814|NCT04112667||Young Normals|20-30 years old with normal macular health
11094815|NCT04112654|Active Comparator|Conventional laparoscopy|Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.
11095528|NCT04107740|Placebo Comparator|Placebo (0mg Taltirelin Hydrate)|BID for 24 weeks
11094819|NCT04112615||Patients and/or carers|Patients and/or their nominated carers come in to give feedback on the device and the system as a whole, from usability to design.
11094820|NCT04112615||Healthcare professionals|Healthcare professionals come in to give feedback on the device and the system, from what results they would like to see and their concerns about patients using it.
11094821|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
11094822|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
11094823|NCT04112589|Experimental|Level dose 1 - 40mg, 14 days|Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
11094824|NCT04112589|Experimental|Level dose 2 - 60mg, 14 days|Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
11094825|NCT04112589|Experimental|Level dose -1 - 60mg 7days|Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
11094826|NCT04112589|Experimental|Level dose -2 - 40mg 7 days|Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
11094827|NCT04112576||HFrEF|Participants that are diagnosed with NYHA class II or III heart failure with reduced ejection fraction.
11094828|NCT04112576||HFpEF|Participants that are diagnosed with NYHA class II or III heart failure with preserved ejection fraction.
11094829|NCT04112563|Active Comparator|WLI-LCI group|a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI
11094830|NCT04112563|Active Comparator|LCI-WLI group|a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)
11094831|NCT04112550|Active Comparator|Methadone|This cohort will receive oral methadone 15mg po tablet pre-operatively
11094832|NCT04112550|Active Comparator|Oxycodone|This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
11094833|NCT04112524||Patients from routine treatment|all 30 patients from Routine Treatment, only observational
11094834|NCT04112498|Experimental|nivolumab + relatlimab + rHuPH20|
11094835|NCT04112485|Other|Open discectomy|This group of patients are treated by open discectomy
11094836|NCT04112485|Other|Microdiscectomy|This group of patients are treated by Microdiscectomy
11094837|NCT04112472|Experimental|Examination of participants|Examination of participants by means of the investigational device as well as the comparative devices.
11094838|NCT04112446|Experimental|Study Treatment|4 mg [14C]-saroglitazar magnesium (approximately 100 μCi) oral suspension
11094839|NCT04112433||PURE EP 2 Group|Enrolled and consented patients who are indicated for and receive an elective cardiac ablation procedure using the PURE EP 2 system for monitoring and collection of intracardiac electrogram signals.
11094840|NCT04112420|Other|Group A|200 Participants more than 60 yrs old having Trans-esophageal Echocardiography examination upon admission to ICU
11094841|NCT04112407|Experimental|Control|Standard preparation of the surgical site without P. acnes pretreatment
11094842|NCT04112407|Experimental|BPO Group|Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry.
11094843|NCT04112407|Experimental|BPO and Phototherapy|2 days of benzoyl peroxide washes and 3 treatments of blue light phototherapy. Pretreatment with 10% Benzoyl peroxide body wash for two consecutive days of washes prior to surgery at home. The anterior shoulder area is wet before treatment; the wash is massaged in for 20 seconds producing a lather and washed off, patting dry. The blue light phototherapy is administered to the shoulder for 3 minutes on three occasions; 2 days before, the day before surgery and in the preoperative area by the patient.
11094844|NCT04112394|Experimental|ESP Group|In addition to routine standard perioperative and postoperative analgesia protocol patients will receive a single shot of local anesthetic injection at the erector spinae plane.
11094845|NCT04112394|Other|Control|Patients will receive standard perioperative and postoperative analgesia protocol.
11094846|NCT04112381|Experimental|Exablate Secondary Procedure|Thalamotomy
11094847|NCT04112368|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
11094848|NCT04112368|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
11094849|NCT04112355||6 months of age|"Visit 1
~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Provided a temperature diary to fill out for the next week Visit 2
~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Collect temperature diary if not already mailed in"
11094850|NCT04112355||12 months of age|"Visit 1
~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Provide a temperature diary to fill out for the next week Visit 2
~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Collect temperature diary if not already mailed in"
11094851|NCT04112355||5 years of age|"Visit 1
~This visit will take about 15 minutes and will be at the time of the next scheduled clinical vaccinations. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Provide a temperature diary to fill out for the next week Visit 2
~This visit will take about 15 minutes and will be approximately 7 days after the first visit. Study procedures at this visit include :
~Draw a blood sample based on age groups below
~Collect temperature diary if not already mailed in"
11094852|NCT04112342|Other|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin.
11094853|NCT04112342|Other|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin
11094854|NCT04112342|Other|Cohort 3|Patients who will receive palliative radiation (+/-concurrent systemic therapy) for any tumor involving the skin.
11094855|NCT04112342|Other|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin.
11094856|NCT04112329|Experimental|Exergaming|Will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks
11094857|NCT04112329|No Intervention|Control|Asked to continue with their normal daily routine
11094858|NCT04112316|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
11094859|NCT04112316|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
11094860|NCT04112303|Experimental|SOF/VEL|Participants will receive SOF/VEL for up to 12 weeks.
11094861|NCT04112264|Experimental|Monopolar radiofrequency ablation|Patients will receive ultrasound-guided monopolar radiofrequency ablation
11094862|NCT04112264|Active Comparator|Bipolar radiofrequency ablation|Patients will receive ultrasound-guided bipolar radiofrequency ablation
11094863|NCT04112251|Placebo Comparator|Placebo|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg oral placebo capsule (Cornstarch) every 12 hours for 12 weeks.
11094864|NCT04112251|Experimental|Supplement|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg capsule every 12 hours (100 mg / day of epicatechin) for 12 weeks.
11094865|NCT04112225|Active Comparator|Positive affect condition|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
11094866|NCT04112225|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11094867|NCT04112212|Experimental|IV administration of vedolizumab-800CW|The tracer will be intraveniously administrered 2 or 3 days before the colonoscopy procedure (with the near infrared fluorescence endoscopy platform).
11094868|NCT04112199|Experimental|BIV201 plus Standard of Care|BIV201 continuous infusion - treatment for two 28 day cycles.
11094869|NCT04112199|No Intervention|Standard of care|Per AASLD guidelines: diuretics and therapeutic paracentesis
11094870|NCT04112186|Experimental|Behavioral group therapy 1|8-weeks of group therapy
11094871|NCT04112186|Active Comparator|Behavioral group therapy 2|8-weeks of group therapy
11094872|NCT04112173|Experimental|Intervention|perturbation-based balance training
11094873|NCT04112160|Placebo Comparator|control|normal saline 0.9%
11094874|NCT04112160|Active Comparator|Ketorolac|30 mg of Ketorolac
11094875|NCT04112147|Experimental|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
11094876|NCT04112147|Experimental|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
11094877|NCT04112147|Placebo Comparator|Placebo oral capsule|Patients will receive 12-week of 50mg BID Antroquinonol placebo
11094878|NCT04112121|Experimental|Patients Meeting the Chaplain at the Bedside|First meeting with the chaplain, coupled with biblical readings at the bedside.
11094879|NCT04112121|Experimental|Patients Meeting the Chaplain at the Chapel|First meeting with the chaplain, coupled with biblical readings at the hospital's chapel
11094880|NCT04112121|No Intervention|Patients Not Meeting the Chaplain|In the control group we enrolled patients whose diagnoses and number of days in the hospital was similar to the intervention groups (covariate-adaptive, blocked, stratified randomization method).
11094881|NCT04112108||mitral stenosis post percutaneous mitral commissurotomy(PTMC)|successful PTMC after follow up
11094882|NCT04112095|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time every day for up to 24 weeks
11094883|NCT04112082|Experimental|Home-Based Neurofeedback Training|
11094884|NCT04112082|Active Comparator|Treatment as Usual|
11094885|NCT04112069|Active Comparator|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
11094981|NCT04111380|Experimental|Nab-paclitaxel and Cisplatin|cisplatin and nab-paclitaxel: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
11095177|NCT04110093|Experimental|Immunotherapy Combination treatment|All colorectal cancer patients received regorafenib plus PD-1 inhibitor
11094886|NCT04112069|Experimental|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
11094887|NCT04112056|Experimental|Study formula|The infants recruited are provided with the study formula named NAN Comfort producted by Nestle Deutschland AG, Werk Biessenhofen containing moderately hydrolyzed protein and low lactose for free during study, and asked to drink the study formula more than half of the total diet daily.
11094888|NCT04112043|Active Comparator|NR plus Walking Exercise|
11094889|NCT04112043|Active Comparator|Walking Exercise plus Placebo|
11094890|NCT04112043|Active Comparator|NR Alone|
11094891|NCT04112017|Experimental|YVOIRE Y-Solution 360|Maximum 5 ml including touch-up
11094892|NCT04112017|No Intervention|No-treatment|No-treatment. At 12 weeks after the assessment, treatment maximum 5 ml including touch-up
11094893|NCT04112004||Liver Transplant Recipients|All elective liver transplant recipients done between study period
11094894|NCT04111991|Active Comparator|Usual Care|Usual care in the NCH Complex Concussion Clinic
11094895|NCT04111991|Experimental|Usual Care + C-STEP|Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
11094896|NCT04111978|Experimental|Letrozole (aromatase inhibitor)|Letrozole (Femara), 2.5 mg tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease
11094897|NCT04111978|Placebo Comparator|Placebo|Placebo tablet of Femara (without aromatase inhibitor), 2.5 mg tablet, administered once daily for 5 years or progression of underlying disease
11094898|NCT04111965|Experimental|Nanodrop® (PRO-176)|- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.
11094899|NCT04111965|Active Comparator|Systane® Balance|"Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc.
~Route of administration: Ophthalmic."
11094900|NCT04111952|Experimental|Additional laser treatment|Women receiving a single laser treatment.
11094901|NCT04111952|Sham Comparator|Sham laser treatment|Women receiving sham laser treatment.
11094902|NCT04111939|Experimental|Wave 1 - Intervention|Communities in Wave 1 will receive the CTH intervention during the first 24 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence based practices to address overdose and opioid use disorder.
11094903|NCT04111939|Other|Wave 2 - Wait-list comparison|Communities in Wave 2 will continue usual care during the first 24 months of the trial. At month 25, Wave 2 communities will begin receiving the CTH intervention.
11094904|NCT04111926|Experimental|Intervention group|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
11094905|NCT04111926|Placebo Comparator|Control group|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
11094906|NCT04111913|Experimental|anlotinib and chemoradiotherapy|"anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.
~EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1~5, d29~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60~66Gy/30~33 times/6~7 weeks."
11094907|NCT04111900|Experimental|Sleep/Circadian Friendly|initiation of sleep/circadian rhythm friendly intervention the first night spent in MICU after enrollment until patient transfers/discharges, ceases participation, or meets exclusion criteria.
11094908|NCT04111900|No Intervention|Usual Care|Usual care within intensive care unit
11094909|NCT04111887|Experimental|Change Ahead|Each of the 6 weekly 1-hour sessions begins with a voluntary commitment to actively participate and to try something new in the upcoming week; includes a section devoted to selecting and publicly committing to one change focused on reducing negative/increasing positive cognitions and one change focused on increasing pleasant activities; and ends with home practice assignments. Additional exercises designed to increase dissonance induction include (a) group discussions for changing conditions, (b) roleplays to generate quick comebacks to written negative thoughts provided by other group members, (c) in-session writing exercises on the benefits of doing fun activities, (d) discussion of methods for creating internal and external accountability for positive change, (e) home practice assignment of engaging in actions to help someone else' mood, (f) writing a letter to my future self about positive intentions, and (g) providing positive feedback to other group members at the last session.
11094910|NCT04111887|Active Comparator|Blues Program|The 6 weekly 1-hour sessions begin with a review of concepts and (after Session 1) review of past home practice assignments; all sessions conclude with home practice assignments. Each session has a portion devoted to thought identification/recording and cognitive restructuring and a portion devoted to increased involvement in pleasant activities. We use motivational enhancement exercises to maximize willingness to use the new skills, behavioral techniques to reinforce use of the new skills, and group activities to foster feelings of group cohesion.
11094911|NCT04111887|Placebo Comparator|Brochure control|"NIMH brochure that describes major depression and recommends treatment for depressed youth (Let's Talk About Depression NIH Pub. 01-4162), as well as information about local treatment options."
11094912|NCT04111874|Experimental|Low-Intensity Therapist Assistance (LTA)|Parents will receive four 30-minute supportive video calls with a therapist over the 12 weeks of treatment.
11094913|NCT04111874|Active Comparator|Standard Therapist Assistance (STA)|Parents will receive ten 60-minute supportive video calls with a therapist over the 12 weeks of treatment.
11094914|NCT04111861|Experimental|Intevention|To see if singing can be used as a detractive method from patients experiencing ongoing pain.
11094915|NCT04111848|Experimental|ketamine group : group (k)|-Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour
11094916|NCT04111848|Experimental|ketamine and magnesium group: group (KM)|- Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
11094917|NCT04111835|No Intervention|Conventional exfoliative cytology/LBC|"According to current Polish guidelines:
~ASC-US: repeat Pap testing in 6 months - current standard protocol
~LSIL - repeat Pap testing in 6 months or refer for colposcopy (by the decision of cytologist) - current standard protocol
~ASC-H and higher and all glandular lesions - refer for colposcopy - current standard protocol
~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.
~If screening cytology is negative -> rescreening after 3 years."
11094918|NCT04111835|Experimental|hrHPV molecular testing|"hrHPV-positive - reflex LBC:
~Abnormal reflex LBC (ASC-US or worse) -> colposcopy
~Normal reflex LBC -> repeat LBC in 6 months
~Positive - colposcopy
~Negative -> The CINtec PLUS Cytology and The QIASURE methylation test
~The CINtec PLUS Cytology Positive -> colposcopy Negative -> rescreen in 3 years
~The QIASURE methylation test Positive -> colposcopy Negative -> rescreen in 3 years
~Colposcopy-targeted biopsies will be taken in agreement with national guidelines.
~HPV-negative - rescreen in 5 years"
11094919|NCT04111822|Active Comparator|Conventional treatment of septic shock|Conventional treatment of septic shock according to current management guidelines
11094920|NCT04111822|Experimental|Current management plus ascorbic acyd,thiamine and vitamin C|"Conventional treatment of septic shock according to current management guidelines associated with:
~i. Hydrocortisone 50 mg every 6 hours for 7 days or until discharge from the ICU with subsequent withdrawal in descending pattern for 3 days ii. Vitamin C (ascorbic acid) 1.5 gr diluted in 100 ml of 5% SG every 6 hours for 4 days (16 doses) iii. Thiamine 200 mg diluted in 100 ml of SG 5% or SF 0.9% every 12 hours for 4 days iv. Measurement of vitamin C levels prior to administration of the first dose of vitamin C"
11094921|NCT04111809||intravenous biphosphonate|Patients treated with intravenous bisphosphonate until 12 months in routine care
11094922|NCT04111796|Experimental|group in nature|they participate in nature based-program during work hours
11094923|NCT04111796|No Intervention|control group|they participate don't in nature based-program during work hours and perform their normal work schedule
11094924|NCT04111783|Experimental|POU ultrasound intervention test group|The experimental group used POU protocol ultrasound to perform a heart scan and a standard scan, a large vascular scan under the xiphoid, a body cavity scan, a standard section, and a lung scan in 10 minutes. Comprehensive preoperative circulation and assessment of systemic conditions, and guided intraoperative anesthesia management with assessment results.
11094925|NCT04111783|No Intervention|Control group|the anesthesiologist performed according to the existing preoperative evaluation program and existing experience, and guided the anesthesia management with the evaluation results.
11094926|NCT04111770|Experimental|IVUS guided PCI|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
11094927|NCT04111770|Active Comparator|QCA guided PCI|QCA will be used to determine lesion characteristics
11094928|NCT04111757|Experimental|Technolas TENEO 317 Model 2|One or both eyes of participants will undergo LASIK surgery with the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser on Day 0.
11094929|NCT04111744|Experimental|Training Group|Preoperative Exercise Training Optimal medical therapy,
11094930|NCT04111744|Other|Control Group|Optimal medical therapy, inactive control group
11094931|NCT04111731|Active Comparator|Group one|Cryoballoon pulmonary vein isolation
11094932|NCT04111731|Active Comparator|Group two|Radiofrequency pulmonary vein isolation
11094933|NCT04111718|Experimental|Viewing of preparation|The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
11094934|NCT04111718|Sham Comparator|Blinded to preparation|The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
11094935|NCT04111705|Experimental|Lorlatinib|100 mg once daily
11094936|NCT04111679|Experimental|Music|During laparoscopic task performance; participants will wear a noise cancelling headphone that plays music that is chosen by the participant.
11094937|NCT04111679|No Intervention|No music|During laparoscopic task performance; participants will wear a noise cancelling headphone that does not play music.
11094938|NCT04111666|Experimental|AL101 IV|Up to three single ascending doses of AL101 administered IV
11094939|NCT04111666|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 8 active and 3 placebo subjects
11094940|NCT04111666|Experimental|AL101 SC|A single dose of AL101 administered SC
11094941|NCT04111653|Experimental|Single arm|Healthy volunteers
11094942|NCT04111640|Experimental|Experimental group|A computer-supported cognitive training for the training of logical-executive and working-memory functions (CoRe software)
11094943|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
11094944|NCT04111627|Experimental|Aerobic exercise plus Duloxetine|Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
11094945|NCT04111614|Experimental|Arm 1|Single dose of 5 mL tofacitinib oral solution on Day 1 of Period 1 and Singe dose of 5 mg tofacitinib tablet on Day 1 of Period 2
11094946|NCT04111614|Experimental|Arm 2|Single dose of 5 mg tofacitinib tablet on Day 1 of Period 1 and Singe dose of 5 mL tofacitinib oral solution on Day 1 of Period 2
11094982|NCT04111367|Experimental|Genotype 2 and 6 Subjects|Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12
11095588|NCT04107272|Experimental|Experimental group|Real rTMS
11094947|NCT04111588||Glioma|"20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET/MRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET/MRI at baseline for comparison with 18F-FACBC.
~30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET/MRI at treatment/baseline and 1 month after radiosurgery."
11094948|NCT04111588||Brain Metastases|Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET/MRI at baseline, 1 month after surgery/stereotactic radiosurgery (St. Olavs Hospital/UNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.
11094949|NCT04111575|Experimental|music therapy group 1|The mothers in the experimental group 1 received music therapy for 30 minutes a day.They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
11094950|NCT04111575|Experimental|music therapy group 2|The mothers in the experimental group 1 received music therapy for 30 minutes twice a day. They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
11094951|NCT04111575|No Intervention|control group|the control group were made to rest in bed for 30 minutes a day for two consecutive days, considering the first day after the C-section as the beginning day.
11094952|NCT04111562|Other|polymethyl methacrylate Cranioplasty|The Cranioplastic kit used (Teknimed, Biomaterials Innovation, Gentafix 1 ®, France) a biocompatible material that is composed of powder and liquid form of polymethyl methacrylate.
11094953|NCT04111549|Experimental|Home-based telehealth GOALS|Participants in this arm will receive the GOALS intervention via in-home video telehealth.
11094954|NCT04111549|Active Comparator|In-person GOALS|Participants in this arm will receive the GOALS intervention in the traditional in-person format.
11094955|NCT04111536|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
11094956|NCT04111536|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets, dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
11094957|NCT04111523|Placebo Comparator|SY-007 dose 1|The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
11094958|NCT04111523|Placebo Comparator|SY-007 dose 2|The study will be intiated in healthy subjects at a 4mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
11094959|NCT04111523|Placebo Comparator|SY-007 dose 3|The study will be intiated in healthy subjects at a 10mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
11094960|NCT04111523|Placebo Comparator|SY-007 dose 4|The study will be intiated in healthy subjects at a 20mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
11094961|NCT04111523|Placebo Comparator|SY-007 dose 5|The study will be intiated in healthy subjects at a 30mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
11094962|NCT04111523|Placebo Comparator|SY-007 dose 6|The study will be intiated in healthy subjects at a 45mg dose. Twelve subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 5:1.
11094963|NCT04111510|Experimental|LN-145|LN-145 will be delivered as a single therapy in patients with Metastatic Triple Negative Breast Cancer.
11094964|NCT04111497|Experimental|Treatment (glasdegib)|Patients receive glasdegib PO QD on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11094965|NCT04111484|Active Comparator|Adrenomedullin|Will received 19.9 picomol/kg/min of adrenomedullin over 20 min
11094966|NCT04111484|Placebo Comparator|Saline|Saline
11094967|NCT04111471|Placebo Comparator|Placebo Arm|20 patients will receive 5.6 g of placebo product (maltodextrin) daily for a total of 21 days (7 days before and until 2 weeks after transplant)
11094968|NCT04111471|Experimental|Prebiotic (Inulin) Arm|20 patients will receive 10 g of inulin product daily for a total of 21 days (7 days before and until 2 weeks after transplant)
11094969|NCT04111458|Experimental|BI 1701963 monotherapy|
11094970|NCT04111458|Experimental|BI 1701963 + Trametinib|
11094971|NCT04111445|Experimental|ADG116|
11094972|NCT04111432|Experimental|Group I-EV71 and EPI vaccines Concomitant administration|EV71 Vaccine (intramuscular injection,0.5ml,first dose)/measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and EV71 Vaccine (intramuscular injection, 0.5ml,second dose)/ encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
11094973|NCT04111432|Active Comparator|Group II-EPI vaccine only Single injection of EPI vaccine:|measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
11094974|NCT04111432|Active Comparator|Group III-EV71 vaccine only EV71 Vaccine only|the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 andday 30 respectively
11094975|NCT04111419|Experimental|Intensive blood pressure and cholesterol control|
11094976|NCT04111419|Active Comparator|Intensive blood pressure and routine cholesterol control|
11094977|NCT04111419|Active Comparator|Routine blood pressure and intensive cholesterol control|
11094978|NCT04111419|Active Comparator|Routine blood pressure and cholesterol control|
11094979|NCT04111406|Other|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
11094980|NCT04111406|Experimental|Protocol based|Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based
11094983|NCT04111367|Experimental|Genotype 3 Subjects|Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24
11094984|NCT04111354|Active Comparator|Short-term (4-hours) immobilization.|Short-term (4-hours) immobilization after primary pacemaker implantation.
11094985|NCT04111354|Active Comparator|Long-term (16-24 hours) immobilization.|Long-term (16-24 hours) immobilization after primary pacemaker implantation.
11094986|NCT04111341|Experimental|TCM Gan-Lu-Yin (GLY)|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
11094987|NCT04111341|Placebo Comparator|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
11094988|NCT04111328|Experimental|sufentanil administration intravenously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
11094989|NCT04111328|Experimental|sufentanil administration subcutaneously|The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
11094990|NCT04111328|Experimental|hydromorphone administration intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
11094991|NCT04111328|Experimental|hydromorphone administration subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
11094992|NCT04111328|Experimental|sufentanil and dexmedetomidine intravenously|The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
11094993|NCT04111328|Experimental|sufentanil and dexmedetomidine subcutaneously|The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
11094994|NCT04111328|Experimental|hydromorphone and dexmedetomidine intravenously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.
11094995|NCT04111328|Experimental|hydromorphone and dexmedetomidine subcutaneously|The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.
11094996|NCT04111315|Active Comparator|metamizole + educational intervention|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
11094997|NCT04111315|Active Comparator|metamizole + standard care|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Standard care will be prescribed by the GP."
11094998|NCT04111315|Active Comparator|ibuprofen + educational intervention|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
11094999|NCT04111315|Active Comparator|ibuprofen + standard care|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).
~(B) Standard care will be prescribed by the GP."
11095000|NCT04111302|Experimental|IV-PCA|use IV-PCA for postoperative pain
11095001|NCT04111302|Experimental|IV-dezocine|use IV-dezocine for postoperative pain
11095002|NCT04111302|Experimental|IV-PCA+AA|use IV-PCA and AA for postoperative pain
11095003|NCT04111302|Experimental|IV-dezocine+AA|use IV-dezocine and AA for postoperative pain
11095004|NCT04111289|Active Comparator|Patient received upstream high bolus dose of tirofiban|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )
~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)
~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
11095005|NCT04111289|Active Comparator|Patients did not receive upstream high bolus dose of tirofiban|Patient receive tirofiban downstream selectively according to operator discretion
11095006|NCT04111276||Subjects diagnosed with osteoarthritis of the knee|Subjects must be diagnosed with marked unicompartimental degenerative joint space narrowing.
11095007|NCT04111263|Sham Comparator|PL+SHAM|Placebo intervention + sea level exposure
11095008|NCT04111263|Placebo Comparator|PL+HA|Placebo intervention + high altitude exposure
11095009|NCT04111263|Experimental|FP+HA|Fiber and polyphenol supplementation + high altitude exposure
11095010|NCT04111250|Experimental|Crestal sinus lift using iRasie implant|"Device: iRaise Sinus Lift implant (Maxillent, Herzliya, Israel). Procedure: crestal sinus lift augmentation.
~We tested crestal versus lateral approach to the sinus. Crestal approach is made by a novel device (iRaise, implant system). Lateral approach is made conventionally with gold standard procedure (lateral approach).
~The iRaise Sinus Lift implant is made of Titanium-6 Aluminum-4 Vanadium alloy, have a surface treated with grit blasting using an apatitic calcium phosphate media, followed by acid etching, and have an internal hexagon connection. Implants have an internal l-shape channel to allow saline and graft passage.
~This implants system is made to perform crestal sinus lift procedure at the same time of the implant placement using the same device. After implant site preparation and initial implant placement, the hydraulic system is connected to the implant to allow the injection of saline and then graft the material. Then, the implant, is inserted for its full length."
11095011|NCT04111250|Active Comparator|Lateral sinus lift|"Conventional procedure.
~Lateral approach to the sinus was made following the conventional procedure.
~A window on the lateral wall of the sinus is performed according to a conventional surgical lateral approach to the sinus cavity. Graft materials is filled inside the sinus cavity. Finally, iSure implants [Maxillent] are placed, and flap is sutured."
11095012|NCT04111237|Active Comparator|Two Finger|two finger method for performing chest compressions
11095013|NCT04111237|Experimental|Two Thumb Technique|Two Thumb Technique
11095014|NCT04111211||Individuals at high risk of developing Alzheimer's dementia|
11095015|NCT04111198||coronary artery disease in diabetic and non diabetic patients|
11095016|NCT04111185|Experimental|Receive Blood Volume Analysis Guided Treatment|The health care team will be provided with BVA results and may use the information to make decisions regarding the participant's treatment.
11095017|NCT04111185|No Intervention|Receive Standard of Care Treatment|The health care team will not be provided with the BVA results. The participant will receive the same treatment they would have received if they weren't in the study.
11095018|NCT04111172|Experimental|Arm A|Receive Ad5.F35-hGCC-PADRE vaccine at 10^11vp on Day 1 of Weeks 1, 5, and 9
11095019|NCT04111172|Experimental|Arm B|Receive Ad5.F35-hGCC-PADRE vaccine at 10^12vp on Day 1 of Weeks 1, 5, and 9
11095020|NCT04111172|Experimental|Arm C|Receive Ad5.F35-hGCC-PADRE vaccine at 5x10^12vp on Day 1 of Weeks 1, 5, and 9
11095021|NCT04111159|Experimental|HSK3486|Subjects < 65 years old:0.4mg/kg/0.15mg/kg;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
11095022|NCT04111159|Active Comparator|Propofol|Subjects < 65 years old:2mg/kg/0.75mg/kg;Subjects≥ 65 years old:75% of the dose for subjects < 65 years old.
11095023|NCT04111146||1|Liver transplant patients with severe vitamin D deficiency (<10ng/ml)
11095024|NCT04111146||2|Liver transplant patients with vitamin D insufficiency (10-20ng/ml)
11095025|NCT04111146||3|Liver transplant patients with normal vitamin D status (>20ng/ml)
11095026|NCT04111133|Experimental|Carvedilol + Ivabradine|
11095027|NCT04111133|Active Comparator|Carvedilol|
11095028|NCT04111120||Cirrhosis with variceal bleeding|Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7
11095029|NCT04111120||Cirrhosis without Bleeding|Control group of 25 subjects
11095030|NCT04111107|Experimental|Drug Administration Based on Next Gen Sequencing Report|Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.
11095031|NCT04111094||HF|Diagnosed heart failure as described by recent guidelines. Inclusion criteria will be applied: i) minimum one symptom typical of HF: positive physical examination (e.g., bilateral oedema, increased jugular pressure) or positive clinical history (e.g., orthopnoea, history of coronary vascular disease, history of arterial hypertension, exposition to cardiotoxic drug/radiation, diuretic use); b-type natriuretic peptide (BNP) or N-terminal pro-BNP levels ≥35 or ≥125 pg/ml, respectively; and iii) classification as New York Heart Association (NYHA) functional class 2 or 3. There is no prespecified inclusion criterion with respect to left ventricular ejection fraction as congestive symptoms and prevalence of kidney dysfunction are comparable in patients with HF across the left ventricular ejection fraction spectrum.
11095032|NCT04111094||Diabetes|Diagnosed diabetes mellitus, with/without treatment
11095033|NCT04111094||Hypertension|Diagnosed hypertension, with/without treatment
11095034|NCT04111081|Experimental|Auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
11095035|NCT04111081|Sham Comparator|Sham auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
11095036|NCT04111068|Experimental|Active then Sham|Participants in this arm will be exposed to active stimulation during session 1 and sham/placebo stimulation during session 2
11095037|NCT04111068|Experimental|Sham then Active|Participants in this arm will be exposed to sham/placebo stimulation during session 1 and active stimulation during session 2
11095038|NCT04111055|Experimental|Closed-loop group|The MAP of the patient will be managed by the CLV system to avoid hypotension. The MAP target selected in the closed-loop system will be the patient's MAP target ( same target as patient's MAP value preoperatively). Then the closed-loop system will have to adjust norepinephrine infusion rate to keep that MAP value within 10% of patient's target.
11095039|NCT04111029||Unresectable HCC undergoing locoregional therapy|Patients with unresectable HCC who have no curative option like tumour ablation, resection or transplantation and are being taken for locoregional therapy will be recruited
11095067|NCT04110808|Active Comparator|Nitroglycerine|Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
11095068|NCT04110808|Other|Phentolamine|Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
11095069|NCT04110795||Cases|Atypical Femur fracture cases
11095040|NCT04111016||Participants able to access the intervention|These group sessions will be delivered by government health workers, and include behavioral recommendations about responsive stimulation, nutrition, water, sanitation and hygiene, lead poisoning prevention, and maternal mental health. Pregnancy groups and caregiver-child groups will be held separately, and mothers and caregivers who attend sessions will receive simple toys and books to use during some of the intervention sessions, which they will be permitted to take home with them. In addition, mothers and caregivers who attend intervention sessions will receive 30 sachets containing 1 gm multiple micronutrient powder (MNP) per month. Beginning as soon as pregnancy is confirmed, health workers will facilitate pregnant women in receiving the Iron and Folic acid supplements already provided by the Government of Bangladesh and will continue the supplementation up to three months post-partum period.
11095041|NCT04111003|Experimental|SFRC direct filling|Restoration of endodontically treated tooth Endodontically treated molars are restored with direct composite restorations, using a short-FRC base filling.
11095042|NCT04111003|Active Comparator|CEREC endocrown|Restoration of endodontically treated tooth Endodontically treated molars are restored with indirect ceramic CAD/CAM restorations.
11095043|NCT04110977|Experimental|Standard Care supported by a Reminder App (Arm A)|Treatment with Standard Care supported by a Reminder App, starting at the beginning of radiotherapy.
11095044|NCT04110977|Active Comparator|Standard Care alone (Arm B)|Treatment with Standard Care alone, starting at the beginning of radiotherapy.
11095045|NCT04110964|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
11095046|NCT04110951|Experimental|Pranayama group|Kapalbhati, Ujjayi and Anuloma-Viloma pranayama techniques were applied to the experimental group. Within this scope, a three days of applied training program was prepared and a guide involving the steps of Pranayama breathing technique was formed. The patients in of pranayama group were trained by the researcher who had yoga trainer certificate. After completing three days of training and observations regarding their accomplishment of applications properly, a pranayama breathing technique video showing how the pranayama breathing technique is done with its details was downloaded to their smartphones and a guide including the application steps was distributed to the patients. The patients were required to apply pranayama technique, in company with the video, 20 min every day and a month in total.
11095047|NCT04110951|Active Comparator|Relaxation group|As there was not placebo breathing control treatment appropriate to yoga breathing technique, relaxation technique was decided to apply in the second group to equalize psychological effects of the treatment. Progressive relaxation technique was taught to the relaxation group during the same training span.A three days of applied training program and Relaxation Technique Application Guide, including steps of progressive relaxation technique, were prepared within this scope. After completing three days of training and observations regarding their accomplishment of applications properly, a relaxing music to listen during applications and a training video involving progressive relaxation directives were downloaded to smartphones of the patients. Also, Relaxation Technique Application Guide involving application steps were distributed to the patients. The patients were required to apply relaxation technique, in company with the video, 20 min every day and a month in total.
11095048|NCT04110925|Other|MDS patients|All Canadian MDS patients on the MDS-database to be included.
11095049|NCT04110912||Cardiac arrest|Ischaemic heart disease is the leading cause of death worldwide. However, this is a registry and no interventions are taking place
11095050|NCT04110912||Trauma|Worldwide, trauma is the number one cause of death and disability in people younger than 40 and confirmed for Canada as well for those under the age of 45. However, this is a registry and no interventions are taking place
11095051|NCT04110912||Sepsis|Sepsis is a clinical syndrome that results from dysregulation of the inflammatory response to severe infection. However, this is a registry and no interventions are taking place
11095052|NCT04110912||Stroke|Stroke is the second leading cause of death worldwide, and the leading cause of chronic disability. However, this is a registry and no interventions are taking place
11095053|NCT04110899|Experimental|Different paratracheal force|Esophageal occlusion is assessed by inserting an esophageal stethoscope under different paratracheal forces.
11095054|NCT04110886|Experimental|HSK21542 single ascending doses|
11095055|NCT04110886|Placebo Comparator|Placebo single dose|
11095056|NCT04110873|Experimental|Antroquinonol capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
11095057|NCT04110873|Experimental|Antroquinonol capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
11095058|NCT04110873|Placebo Comparator|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
11095059|NCT04110860|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
11095060|NCT04110860|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
11095061|NCT04110860|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
11095062|NCT04110847|Active Comparator|TCM OA1|"JING CEIH SHERN YUAN EXTRACT PILL CHUANG SONG ZONG 3 TABLET For 2 Times per day"
11095063|NCT04110847|Placebo Comparator|Placebo|Placebo 3 TABLET For 2 Times per day
11095064|NCT04110834|Experimental|once daily application|the gel is applied to the affected areas once daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
11095065|NCT04110834|Experimental|twice daily application|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to reassess the case. if complete cure is achieved, stop application. if not, repeat for one more week and then reassess.
11095066|NCT04110834|Placebo Comparator|placebo|the gel is applied to the affected areas twice daily for one week followed by a follow-up visit to assure that the results obtained from other arms are only due to the effects of the active ingredient in the prepared gel.
11095070|NCT04110795||Control|matched to AFF cases by race, age, length of ART use
11095071|NCT04110782||Radium223|
11095072|NCT04110769|Experimental|Responders|"The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers.
~The patients who undergo surgery after neoadjuvant chemotherapy will be included responders."
11095073|NCT04110769|Active Comparator|Non-responders|The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
11095074|NCT04110756|Experimental|ChangeGradients|100 adolescents will be enrolled in the CHANGEGRADIENTS intervention.
11095075|NCT04110756|No Intervention|Comparison, non-intervention condition|100 participants will not participate in the ChangeGradients intervention, and will continue to have treatment as usual at the clinic.
11095076|NCT04110743|Other|delayed imaging acquisition|10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
11095077|NCT04110743|Other|low FDG dose imaging|0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
11095078|NCT04110743|Other|comparison PET images reconstructed using CT-based attenuation|10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
11095079|NCT04110730||3D Prostheses Users|Children with unilateral congenital upper-limb reductions
11095080|NCT04110730||Typically Developing Children|Age- and sex-matched control group of typically developing children.
11095081|NCT04110717|Experimental|Active Device Group|25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.
11095082|NCT04110717|Placebo Comparator|Control Device Group|25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.
11095083|NCT04110704|Active Comparator|Transvaginal cerclage|
11095084|NCT04110704|No Intervention|Active monitoring|
11095085|NCT04110678|Active Comparator|NeuroEPO|The dose of NeuroEPO was a vial with a dose of 1 mL/1mg administered intra-nasally for five consecutive weeks.
11095086|NCT04110678|Placebo Comparator|Placebo|The dose of placebo was a vial with a dose of 1 mL/1mg of an intranasal inert solution administered intra-nasally for five consecutive weeks.
11095087|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
11095088|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+ Nefopam and Tramadol|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and Nefopam 120 mg intravenously were systematically administered. Tramadol 100 mg per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
11095089|NCT04110665|Active Comparator|Paracetamol+ ketoprofene and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
11095090|NCT04110665|Active Comparator|Paracetamol+ ketoprofene+Opioid delayed release and morphine|Paracetamol per os 1g every 6 hours and ketoprofene 100 mg per os every 12 hours and 20 mg of opioid delayed release (Oxycodone) were systematically administered. Opioid immediate release (morphine 10 mg) per os every 6 hours was added when pain was > 3/10 on a numeric ranking scale (0 no pain, 10 worst pain).
11095091|NCT04110652|Active Comparator|patient|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.(20-22) in addition to pulmonary rehabilitation program.
11095092|NCT04110652|Placebo Comparator|control group|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.
11095093|NCT04110639|Active Comparator|Validation Group|A validation group of 10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
11095094|NCT04110639|Experimental|Study Group|A study group of 20 patients with displaced femoral neck fracture patients (Garden 2-4) treated with open or closed reduction and internal fixation
11095095|NCT04110626||Expériences Animées Programme|The Expériences Animées programme involves supervised short movies and talks with secondary school and high school pupils about the use of psychoactive substances.
11095121|NCT04110431|Experimental|LBBP group|In this arm, An right artrial (RA) lead and an implantable cardioverter defibrillator (ICD) lead are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed. If LBBP failed, a left ventricular(LV) pacing lead is implanted instead.
11095215|NCT04109872||Mantle cell lymphoma treated with lenalidomide cohort|Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.
11095096|NCT04110613|Active Comparator|No Fast group|The NoFAST group will undergo naso- or orogastrointestinal tube feeding until 1 hour before the scheduled PEG procedure if the stomach is receiving EN, or until procedural timeout if the post-pyloric intestine is receiving EN. At the time tube feeding is stopped for the procedure, stomach contents will be aspirated by the oro- or nasogastric tube already in place. The procedure will be carried out per standard clinical practice. At completion of the procedure, tube feeding will be resumed at the preprocedure rate.
11095097|NCT04110613|No Intervention|control FAST group|The FAST group will have naso- or orogastrointestinal feeding held at least 8 hours prior to the procedure, then for 4 hours after the procedure. Tube feeding will be resumed and titrated at the appointed time per standard CRMH clinical protocol for initiating tube feeding. All other procedures including PEG placement and feeding procedure will be completed to the standard of care for both groups.
11095098|NCT04110600|Active Comparator|Coffee group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia And will have 100 ml of coffee after 2,4 and 6 hours
~Then outcomes will be assessed as per time frame"
11095099|NCT04110600|Active Comparator|Pepper mint oil group|"This group includes 300 patients who underwent cesarean delivery under spinal anaesthesia This group will have 100 ml of pepper mint oil After 2,4 and 6 hours
~Then outcomes will be assessed as per time frame"
11095100|NCT04110587|Placebo Comparator|arthroscopy|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.
11095101|NCT04110587|Active Comparator|arthroscopy plus hyaluronic Acid|Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.
11095102|NCT04110561|Other|Spinal Cord Injury patients with motor complete paralysis|
11095103|NCT04110548|Experimental|HCs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the emotion regulation task on the computer.
11095104|NCT04110548|Experimental|IGDs on Emotion Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on.They are instructed to complete the emotion regulation task on the computer.
11095105|NCT04110548|Experimental|IGDs on Craving Regulation|Participants are screened using the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Young's online Internet addiction test (YIAT), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and so on. They are instructed to complete the craving regulation task on the computer.
11095106|NCT04110535|Experimental|Remimazolam 5 mg|IV administration of remimazolam 5 mg
11095107|NCT04110535|Experimental|Remimazolam 10 mg|IV administration of remimazolam 10 mg
11095108|NCT04110535|Active Comparator|Midazolam 2.5 mg|IV administration of midazolam 2.5 mg
11095109|NCT04110535|Active Comparator|Midazolam 5 mg|IV administration of midazolam 5 mg
11095110|NCT04110535|Placebo Comparator|Placebo|Saline injection
11095111|NCT04110522|Experimental|Intervention with Direct Access to Rheumatologist|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation
11095112|NCT04110522|Experimental|Intervention with Standard of Care Referral|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist
11095113|NCT04110522|No Intervention|Control|Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire
11095114|NCT04110496|Experimental|RTX-134|Escalating doses of RTX-134 will be administered by intravenous infusion one time
11095115|NCT04110483|Active Comparator|TURBT|A step-by-step resection of a tumor. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
11095116|NCT04110483|Experimental|Tm-fiber ERBT|A circumferential incision around the tumor is made in the visually intact bladder mucosa. After that, the incision is continued deeper into the muscular layer. Than the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers.
11095117|NCT04110470|Active Comparator|Control Group|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
11095118|NCT04110470|Experimental|Treatment Group|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
11095119|NCT04110444||sildenafile group A|received sildenafil citrate orally 20mg every 8 hours based on previous studies18,21 (Respatio tablet, pharma Egypt group) in addition to low molecular weight heparin daily according to the bodyweight at the booking visit (Clexane 20,40,60 mg, Sanofi eventis company) plus small dose of aspirin 75 mg (Aspocid 75mg tablet, CID pharmaceutical) once daily
11095120|NCT04110444||control group B|received low molecular weight heparin as subcutaneous injection once daily plus low dose aspirin 75mg orally once daily in addition to placebo three times daily prepared by a local pharmacy from a domestic manufacturer
11095148|NCT04110288||Paclitaxel Coated Balloon|Patients treated for PAD with drug coated balloon angioplasty, without use of stent.
11095122|NCT04110431|Active Comparator|BivP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed. If the implantation of LV pacing lead is unsuccessful due to unavailable coronary sinus branches(venae cordis magna or venae cordis media is not recommended), capture above 3.5V/0.5ms or refractory phrenic nerve stimulation,a LBBP lead is placed instead.
11095123|NCT04110418|Active Comparator|Methylene Blue group (Group MB)|"Methylene Blue is supplied in 1 ml or 10 mL single-dose ampules. Each 1 mL ampule contains 10 mg of methylene blue as a clear dark blue solution
~Any unused product or waste material should be disposed of in accordance with local practice,
~For administration to be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the paediatric population. Use the diluted solution immediately after preparation.
~Do not mix with sodium chloride 9 mg/mL (0.9%) solution for injection, because it has been demonstrated that chloride reduces the solubility of methylene blue."
11095124|NCT04110418|Placebo Comparator|Terlipressin Group (Group TP )|"The active substance is terlipressin acetate. Each ampoule contains
~1 mg of terlipressin acetate in 8.5 ml solution for injection. This is equivalent to 0.12 mg terlipressin acetate per ml.
~The powder is to be dissolved in the enclosed solvent and slowly administered intravenously. Further dilution up to 10 ml with sterile isotonic sodium chloride solution is possible.
~Store in a refrigerator at 2-8˚C.
~Keep the ampoules in the outer carton in order to protect from light"
11095125|NCT04110405|Experimental|Stepped Care|To assess the effectiveness of the stepped care model with 420 women who have depression and potential co-occurring anxiety, recruited from 12 primary care clinics in Tajikistan.
11095126|NCT04110405|Active Comparator|Standard of Care plus Healthy Lifestyle|To compare standard of care plus healthy lifestyle materials with 210 women recruited from 6 primary care clinics in Tajikistan.
11095127|NCT04110392|Experimental|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
11095128|NCT04110379|Experimental|Virtual Reality (VR)|Child behavior management will be done using virtual reality glasses distraction (Remax Fantasy Land virtual reality glasses (Schenzen Remax Co.,Ltd))
11095129|NCT04110379|Active Comparator|Conventional Behavior Management|Child behavior management will be done using conventional behavior management techniques
11095130|NCT04110366|Experimental|Live attenuated influenza vaccine|Participants receiving live attenuated influenza vaccine (LAIV)
11095131|NCT04110353|Active Comparator|Conservative dressings|Use of simple dressings on wound post operatively - to be placed at end of operation
11095132|NCT04110353|Active Comparator|Prevena dressing|Use of Prevena(KCI) dressing on wound post operatively - to be placed at end of operation
11095133|NCT04110353|Active Comparator|ciVAC dressing|Use of closed incision VAC (vacuum assisted closure) dressing on wound post operatively - to be placed at end of operation
11095134|NCT04110340|Active Comparator|Ciprofloxacin Arm|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;
~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.
~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
11095135|NCT04110340|Other|Control arm|"Control arm adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those who cannot take it orally) for an additional 7 days.
~Control arm children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.
~Patients who start taking intravenous ciprofloxacin may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
11095136|NCT04110327||Claudication|Subjects presenting with claudication, identified as Rutherford category 1, 2, or 3
11095137|NCT04110327||Critical Limb Ischemia|Subjects presenting with rest pain (Rutherford category 4) or minor tissue loss (Rutherford category 5)
11095138|NCT04110327||Critical Limb Ischemia with major tissue loss|Subjects presenting with major tissue loss (Rutherford 6)
11095139|NCT04110314|Active Comparator|Gain-framed portal reminders + Pre-commitment Prompts|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
11095140|NCT04110314|Active Comparator|Gain-framed portal reminders + No pre-commitment prompt|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
11095141|NCT04110314|Active Comparator|Loss-framed portal reminders + Pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
11095142|NCT04110314|Active Comparator|Loss-framed portal reminders + No pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
11095143|NCT04110314|Active Comparator|No portal reminder + Pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal but do receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
11095144|NCT04110314|No Intervention|No portal reminders + No pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal and do not receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
11095145|NCT04110301|Experimental|MIL62 + Lenalidomide|MIL62 plus Lenalidomide
11095146|NCT04110288||Uncoated Balloon Treatment|Patients treated for PAD with balloon angioplasty, without use of stent.
11095147|NCT04110288||Bare Metal Stent Treatment|Patients treated for PAD with implantation of bare metal stent.
11095150|NCT04110275|Experimental|low dose group|"Recombinant human tissue-type plasminogen activator derivative(rPA) for injection: 18 mg, Intravenous injection for 2 minutes or more.
~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
11095151|NCT04110275|Experimental|high dose group|"Recombinant human tissue-type plasminogen activator derivative (rPA) for injection: the first injection of 18 mg rPA is pushed slowly for 2 minutes or more,the second injection of 9mg rtPA is pushed for 1 minute or more.The interval between the two injections should be controlled accurately about 30 minutes.
~A separate venous access should be used for bolus injection,a common venous access shared with other drugs is not allowed for injection. And no other drugs mixed with test drug during the injection."
11095152|NCT04110275|Active Comparator|comparative group|Recombinant tissue plasminogen activator for injection: continuous intravenous injection for 2 hours.
11095153|NCT04110262|Experimental|High-low dietary sodium|High sodium diet (3400 mg/day) feeding period followed by low sodium diet (2300 mg/day) feeding period
11095154|NCT04110262|Experimental|Low-high dietary sodium|Low sodium diet (2300 mg/day) feeding period followed by high sodium diet (3400 mg/day) feeding period
11095155|NCT04110249|Experimental|Diagnostic (PAI, ALTENS)|"PART I: Patients undergo PAI before the start of chemoradiation therapy, weekly during 7 weeks of chemoradiation, and again 3-4 months after completion of chemoradiation therapy.
~PART II (CANCER-FREE WITH XEROSTOMIA): Patients undergo PAI at baseline, up to twice during acupuncture-like transcutaneous nerve stimulation (ALTENS) therapy, once after ALTENS, and at 3-6 months follow up."
11095156|NCT04110236|Experimental|Immediate PriCARE|Caregiver-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
11095157|NCT04110236|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
11095158|NCT04110236|Experimental|Positive Discipline PriCARE|A subset of participants who were assigned to the immediate PriCARE group will be offered to participate in the PriCARE Positive Discipline Module if they attended at least 4 PriCARE sessions and completed both main study interviews. This module will occur 4-6 weeks after completion of the 6-week PriCARE intervention and will teach techniques related to behavior reward charts, appropriate timeout protocol, and other positive discipline techniques for handling persistent behaviors not addressed by the other PriCARE skills.
11095159|NCT04110223||non-smell cell lung cancer (NSCLC)|Advanced NSCLC patients receiving radiotherapy or chemo-radiotherapy
11095160|NCT04110223||Rectal cancer|Rectal cancer patients receiving neoadjuvant radiotherapy or chemo-radiotherapy
11095161|NCT04110223||Smell cell lung cancer (SCLC)|SCLC patients receiving radiotherapy or chemo-radiotherapy
11095162|NCT04110223||Esophageal cancer|Esophageal cancer patients receiving radiotherapy or chemo-radiotherapy
11095163|NCT04110223||Cervical cancer|Cervical cancer patients receiving radiotherapy or chemo-radiotherapy
11095164|NCT04110223||Liver cancer|Liver cancer atients receiving radiotherapy or chemo-radiotherapy
11095165|NCT04110210|Active Comparator|Group A(Ultrasound guided ESP block after indtiucon of GA).|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
11095166|NCT04110210|Active Comparator|Group B(GA with conventional analgesia)|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
11095167|NCT04110184||active systemic lupus erythematosus|
11095168|NCT04110184||inactive systemic lupus erythematosus|
11095169|NCT04110145|Other|Cohort 1|linaclotide 18 μg or matching placebo once daily for 4-week Study Intervention Period.
11095170|NCT04110145|Other|Cohort 2|linaclotide 36 μg or matching placebo once daily for 4-week Study Intervention Period
11095171|NCT04110145|Other|Cohort 3|linaclotide 72 μg or matching placebo once daily for 4-week Study Intervention Period.
11095172|NCT04110145|Other|Final Cohort|linaclotide at the highest dose tested/determined to be safe or matching placebo once daily for 4-week Study Intervention Period
11095173|NCT04110132|Active Comparator|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.
~Patient will have hemorrhoidectomy."
11095174|NCT04110132|Placebo Comparator|Ganglion impar block with Saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Patient will have hemorrhoidectomy.
11095175|NCT04110119|Active Comparator|Control: Drug-Only Group|Patients with acute lower-back pain who have undergone routine conventional drug treatment at the first visit to the emergency department (75 patients). The drug treatment consists of analgesic-anti-inflammatory (diclophenac sodium 75 mg IM) and myorelaxant (thiocolchicoside 4 mg IM), administered only once.
11095176|NCT04110119|Experimental|Case: Drug and Chiropractic Group|Patients, who received chiropractic treatment immediately after the conventional drug treatment as in the control group (75 patients). The chiropractic treatment consists of high speed and low amplitude spinal manipulation techniques, applied only once.
11095178|NCT04110080|Experimental|Enhanced recovery after surgery|Preoperatively, patients will be counseled on optimization of physical and nutritional status. They will receive carbohydrate loading drinks prior to surgery. Intraoperatively, standard ASA monitors will be utilized, and patients will receive general anesthesia. Goal directed fluid management will be enforced with bolus options based on hemodynamics. Transabdominal plane and rectus sheath block will be performed in the operating room by the regional anesthesia team. Post-operatively pain management will include multimodal analgesic medications. Regular diet will be allowed and encouraged on post-operative day 0 (POD). Lines and drains will be minimized to encourage early mobilization and bowel function. Patients will be counseled on expectations of discharge criteria POD0.
11095179|NCT04110080|Active Comparator|Standard of care|Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
11095180|NCT04110067||1|SMILE - Correction of eyes with myopia of more than -7.75 D
11095181|NCT04110054|Experimental|S-600918 50 mg|Participants will receive 50 mg S-600918 orally once a day for 28 days.
11095182|NCT04110054|Experimental|S-600918 150 mg|Participants will receive 150 mg S-600918 orally once a day for 28 days.
11095183|NCT04110054|Experimental|S-600918 300 mg|Participants will receive 300 mg S-600918 orally once a day for 28 days.
11095184|NCT04110054|Placebo Comparator|Placebo|Participants will receive placebo to S-600918 orally once a day for 28 days.
11095185|NCT04110041|Experimental|Moderate Intensity|Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
11095186|NCT04110041|Experimental|High Intensity|Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
11095187|NCT04110028|Experimental|Nicotinamide riboside 250 mg|One capsule of 250 mg each morning for three months
11095188|NCT04110028|Experimental|Nicotinamide riboside 500 mg|One capsule of 250 mg each morning and afternoon for three months
11095189|NCT04110028|Experimental|Nicotinamide riboside 1000 mg|Two capsules of 250 mg each morning and afternoon for three months
11095190|NCT04110028|Experimental|Nicotinamide riboside 2000 mg|Four capsules of 250 mg each morning and afternoon for three months
11095191|NCT04110028|Placebo Comparator|Placebo for 250 mg nicotinamide riboside|One capsule each morning for three months
11095192|NCT04110028|Placebo Comparator|Placebo for 500 mg nicotinamide riboside|One capsule each morning and afternoon for three months
11095193|NCT04110028|Placebo Comparator|Placebo for 1000 mg nicotinamide riboside|Two capsules each morning and afternoon for three months
11095194|NCT04110028|Placebo Comparator|Placebo for 2000 mg nicotinamide riboside|Four capsules each morning and afternoon for three months
11095195|NCT04110015||Neurology patients|Any patients with neurological disorders
11095196|NCT04110015||Glaucoma patients|Any patients with chronic open angle and chronic angle closure glaucoma of all stages
11095197|NCT04110015||Retina patients|Any patients with known retinal conditions
11095198|NCT04110002|Experimental|Injury Prevention Program|Those allocated to the injury prevention program will be instructed on the program, the added exercises, and the additional time commitment.
11095199|NCT04110002|No Intervention|Control|The control group will practice and perform with no change to pre-existing years' standard operating practice.
11095200|NCT04109989|Experimental|HominisTM Surgical System|Gynecological surgical procedure will be performed with the HominisTM Surgical System
11095201|NCT04109976|Experimental|Bimekizumab-SS|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
11095202|NCT04109976|Experimental|Bimekizumab-AI|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
11095203|NCT04109963|Active Comparator|RIC once per day|RIC performed once a day on one arm. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
11095204|NCT04109963|Active Comparator|RIC twice per day|RIC performed twice a day on one arm, approximately 12 hours apart. Each RIC session will consist of 4 cycles of unilateral or simultaneous bilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes. The procedure will be performed by using an electric auto-control device with cuffs that inflate to a pressure of 200 mmHg during the ischemic period.
11095205|NCT04109950|Experimental|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
11095206|NCT04109937|No Intervention|Surgery Alone|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction but will not receive any post-operative radiation therapy.
11095207|NCT04109937|Active Comparator|Surgery and Post-Operative Radiation Therapy|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction and will receive any post-operative radiation therapy.
11095208|NCT04109924|Experimental|Treatment (irinotecan, bevacizumab, TAS-102)|Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11095209|NCT04109911|Experimental|Fermented oyster extract group|This group takes fermented oyster extract for 12 weeks
11095210|NCT04109911|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
11095211|NCT04109898|No Intervention|standard I-gel insertion technique|Investigator will apply the recommended (standard) I-gel insertion technique in patients
11095212|NCT04109898|Experimental|Modified I-gel insertion technique|Investigator will apply the modified (interventional) I-gel insertion technique in patients
11095213|NCT04109885|Experimental|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
11095214|NCT04109885|Active Comparator|Standard treatment|Intravenous administration of prochlorperazine and diphenhydramine.
11095216|NCT04109859|Experimental|Methylene blue group|Before the anesthesia was intubated, the patients in the methylene blue group were given a 2 mg/Kg methylene blue 50 ml intravenously for 10 min; continuous constant speed pumping methylene blue(0.5mg/Kg/h).
11095217|NCT04109859|Placebo Comparator|Placebo group|Before the anesthesia was intubated, the placebo group was given 50 ml of normal saline for 10 min.continuous constant speed pumpingnormal saline (10ml/h).
11095218|NCT04109846|Experimental|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
11095219|NCT04109846|Active Comparator|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
11095220|NCT04109833||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation without antibiotic treatment in the first week of life
11095221|NCT04109833||ABT in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation with antibiotic treatment in the first week of life
11095222|NCT04109820|Experimental|Sickle cell patients|Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)
11095223|NCT04109820|Active Comparator|Non Sickle cell Control subjects|Normal control subjects administered oral MitoQ (20mg once a day for 14 days)
11095224|NCT04109807|Experimental|6 hour Filtered Air (FA) followed by O3 exposure|For the first exposure session, participants are exposed to filtered air (FA) for 6 hours. For the second exposure session, the same participant will be exposed to ozone for 6 hours. The ozone levels will start at 0.06ppm increasing to 0.08 ppm in the first hour and holding there for an hour, decreasing to 0.06ppm over the next hour and holding for an hour, increasing back to .08 over the next hour and holding there until the exposure is complete (a total of 6 hours).
11095225|NCT04109807|Experimental|6 hour O3 exposure followed by FA exposure|For the first exposure session, a participant will be exposed to ozone for 6 hours. The ozone levels will start at 0.06ppm increasing to 0.08 ppm in the first hour and holding there for an hour, decreasing to 0.06ppm over the next hour and holding for an hour, increasing back to .08 over the next hour and holding there until the exposure is complete (a total of 6 hours). For the second exposure session, the same participant will be exposed to FA for 6 hours.
11095226|NCT04109794|Active Comparator|E-CTG|Envelope connective tissue graft
11095227|NCT04109794|Active Comparator|SCAF|Semilunar connective tissue graft
11095228|NCT04109781|Other|Patients with Lumbar disc herniation|Patients with lumbar disc herniation with no response to conservative treatment and were treated with Microdiscectomy
11095229|NCT04109768|Experimental|Hands on Nutrition Education|Nutrition and activity intervention to improve behaviors pre to post
11095230|NCT04109755|Experimental|Experimental|Short Course Radiation Therapy (5 x 5 Gy in 1 week, SCRT) with 4 injections of Pembrolizumab starting on the first day of radiotherapy and surgery
11095231|NCT04109742|Active Comparator|Curcumin 500mg capsules|Dose will be 500mg daily phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
11095232|NCT04109742|Active Comparator|Curcumin 1000mg capsules|Dose will be1g daily of phosphatidylcholine-curcumin complex supplement, orally for 24 weeks
11095233|NCT04109742|Placebo Comparator|Placebo curcumin capsules|Dose will be matching placebo capsules daily, orally for 24 weeks
11095234|NCT04109729|Experimental|Treatment: all patients|
11095235|NCT04109716|Experimental|Interpersonal Psychotherapy-Adolescent Skills Training|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) is an indicated group depression prevention program. In IPT-AST, adolescents learn communication (e.g., using I statements, striking while the iron is cold) and interpersonal problem-solving strategies and apply these strategies to their relationships to decrease conflict, increase social support, and improve overall social functioning. IPT-AST consists of 1 or 2 individual pre-group sessions, 1 mid-group session, 8 weekly group sessions, and up to 6 individual booster sessions. Parents are invited to attend the mid-group session so the adolescents can apply the interpersonal strategies in a conversation with a parent. The purpose of the booster sessions is to monitor symptoms and apply the interpersonal strategies to current stressors. These sessions are designed to help solidify the interpersonal skills and address current problems before they result in a worsening of symptoms.
11095236|NCT04109716|Active Comparator|Services as Usual (SAU)|Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
11095237|NCT04109703|Active Comparator|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
11095238|NCT04109703|Placebo Comparator|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
11095239|NCT04109690|Experimental|CPX-351|Phase I will evaluate the safety and tolerability of CPX-351 (44mg/m2 of daunorubicin and 100mg/m2 of cytarabine) administered on 2 days (day 1 and day 5) to determine the Phase II dose. Phase II will evaluate the efficacy of the RP2D.
11095240|NCT04109677||SHE player|Female player in the top Swedish handball league
11095241|NCT04109677||Handbollsligan player|Male player in the top Swedish handball league
11095242|NCT04109664||antral preservation|The patients were grouped according to the distance of gastric division as Antral preservation group (6cm from pylorus)
11095243|NCT04109664||Antral resection|The patients were grouped according to the distance of gastric division as Antral preservation group (2 cm from pylorus)
11095244|NCT04109651|Experimental|Nursing İntervention|Intervention: Other: Nursing intervention
11095245|NCT04109651|Other|No Intervention: Control Group|Receive routine nursing care
11095246|NCT04109638|Active Comparator|Active PEMF Group|Participants will have a 1 in 2 chance to get the active treatment device post-operatively. The device will be attached to the post-operative dressing. The device is an Endonovo SofPulse that emits a pulsed electromagnetic field (PEMF). Single blind randomization.
11095313|NCT04109170||Normal Control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
11095247|NCT04109638|Sham Comparator|Placebo PEMF Group|Participants will have a 1 in 2 chance to get the placebo treatment device post-operatively. The device will be attached to the post-operative dressing. The Endonovo SofPulse placebo device does not emit a pulsed electromagnetic field (PEMF). Single blind randomization.
11095248|NCT04109625|Experimental|Non-immunized Hepatitis B|subjects non-immunized against hepatitis B (naive)
11095249|NCT04109625|Experimental|Vaccine Hepatitis B|subjects vaccinated against hepatitis B
11095250|NCT04109625|Experimental|Old or cured Hepatitis B|subjects with hepatitis B (old or cured)
11095251|NCT04109625|Experimental|Ongoing Hepatitis B|subjects with hepatitis B (ongoing)
11095252|NCT04109599|Experimental|PlaySmart|Adolescents, boys and girls, aged 16-19 will participate in the pilot testing of the adapted game.
11095253|NCT04109586|Experimental|Personalized nutrition therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
11095254|NCT04109586|No Intervention|Standard treatment|Standard treatment includes dietitian-led group session on nutrition after SCI and patient visits / consultations on request from doctor.
11095255|NCT04109573|Experimental|Anorectal function post anal laser|"Intervention:
~Device: laser"
11095256|NCT04109547|Experimental|Oral semaglutide 3mg|Subjects will remain on 3 mg for the entire treatment period (26 weeks)
11095257|NCT04109547|Experimental|Oral semaglutide 7mg|Subjects will receive 3 mg for for the first 4 weeks, 7 mg for the remainder of the treatment period
11095258|NCT04109547|Experimental|Oral semaglutide 14mg|Subjects will receive 3 mg for the first 4 weeks, 7 mg for the next 4 weeks and 14 mg for the remainder of the treatment period
11095259|NCT04109547|Placebo Comparator|Placebo (oral semaglutide)|Subjects will receive placebo tablets for the entire treatment period
11095260|NCT04109534|Placebo Comparator|Placebo|Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator
11095261|NCT04109534|Active Comparator|Verum|PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator
11095262|NCT04109521|Experimental|Trained vendors|"The intervention consists of a Training, Certification and Marketing scheme for dairy vendors operating in the informal sector. This scheme includes a 12hr training offered at the beginning of the study, followed by 2 quarterly visits where milk will be tested for microbiological quality and results will be discussed with participants.
~The training will include three main components: (i) milk hygiene and quality; (ii) business skills; (iii) milk marketing.
~Trainings will be offered free of charge. The trainings will be given by business development service (BDS) providers, who will be trained through a training of trainers ahead of the intervention. Quarterly visits will involve the collection of a milk sample from each participant in the experimental arm in an unannounced visit and results on the microbiological quality of the milk reported back individually and explained to each vendor."
11095263|NCT04109521|No Intervention|Untrained vendors|Participants in the no-intervention arm will receive the same unannounced quarterly visits, where milk will be sampled and tested for microbiological quality, but results will not be shared with the participants. The participants in this arm will only receive the training upon completion of the endline survey (i.e. when the study is finished).
11095264|NCT04109508|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
11095265|NCT04109508|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
11095266|NCT04109508|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
11095267|NCT04109508|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
11095268|NCT04109508|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
11095269|NCT04109508|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
11095270|NCT04109495|Other|Smart phone application(NOOM)|
11095271|NCT04109495|Other|Non-user|
11095272|NCT04109482|Experimental|Relapsed or Refractory BPDCN|Treatment with MB-102.
11095273|NCT04109482|Experimental|Relapsed or Refractory AML|Treatment with MB-102.
11095274|NCT04109482|Experimental|Demethylation resistant high risk MDS|Treatment with MB-102.
11095275|NCT04109456|Experimental|Part 1, Monotherapy Arm|The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.
11095276|NCT04109456|Experimental|Part 2, Combination Arm|"The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.
~A modified 3+3 design will be used."
11095277|NCT04109443|Experimental|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
11095278|NCT04109443|Active Comparator|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
11095279|NCT04109417|Experimental|osteotomy filled with PRP-gel and covered with PRP-biomembrane|the defect was filled with the previously activated autologous Platelet-rich plasma (PRP) gel and its supernatant. The site was then externally covered with the prepared bio-membrane composed of activated PRP which acted as an adjunct to the mucoperiosteal flap to stimulate tissue regeneration
11095280|NCT04109417|Sham Comparator|osteotomy site left empty|osteotomy site following the surgical intervention was left empty
11095281|NCT04109391|Experimental|Test Product|IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles
11095589|NCT04107272|Sham Comparator|Control group|Sham rTMS
11095282|NCT04109391|Active Comparator|Reference Therapy|IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles
11095283|NCT04109378|Active Comparator|Patients operated with conventional laparoscopic technique|Patients operated with conventional laparoscopic technique for colorectal DIE
11095284|NCT04109378|Active Comparator|Patients operated with NOSE laparoscopic technique|Patients operated with NOSE technique for colorectal DIE
11095285|NCT04109365|Experimental|Electrical Epidural Stimulation Test (EST)|Laboring women are given EST test initially before local anesthetic is administered and 1 hour post-anesthetic in order to measure sensory and motor responses.
11095286|NCT04109339|No Intervention|group 1 with no oxytocin|
11095287|NCT04109339|Experimental|group 2 with oxytocin 10 U IM + oxytocin 10 U IV|
11095288|NCT04109339|Experimental|group 3 with oxytocin 20 U IM + oxytocin 0 U IV|
11095289|NCT04109339|Experimental|group 4 with oxytocin 0 U IM + oxytocin 20 U IV|
11095290|NCT04109326|Experimental|Adapted Physical Activity and Dietetique|tailored PA program associated with individual nutritional counseling whilst hospitalization and at home during the 26-week duration of adjuvant treatment
11095291|NCT04109326|No Intervention|Control|Standard of care
11095292|NCT04109313|Experimental|LOU064|Participants will be asked to take selected dose of LOU064 twice daily for 52 weeks
11095293|NCT04109300|Experimental|preemptive screening|prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
11095294|NCT04109300|Active Comparator|standard of care|administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.
11095295|NCT04109287|Experimental|Two ultrasound scans and activation of NMES device|Participants will have their leg scanned using an ultrasound machine, before being asked to use the REVITIVE® device for 30 minutes. Their leg will then be scanned again.
11095296|NCT04109274|Experimental|Institution-Based Exercise and Self-Management (EXSM)|Eight session of supervised exercise within the cancer institution plus 8 self-management modules focusing on goal setting and action planning for safe and effective exercise strategies (this is based on our team's successful pilot intervention). Four booster sessions will be provided to this group.
11095297|NCT04109274|Experimental|Institution-Based Self-management only (SM)|Eight SM sessions for safe and effective exercise strategies will be provided to this group (described above). Four booster sessions will be provided to this group.
11095298|NCT04109274|No Intervention|Usual care|Participants in this group will receive care as normally provided by their treating oncologist. This can be heterogeneous between different physicians and centres, but usually includes oncologists encouraging their patients to 'stay active'
11095299|NCT04109261||Palbociclib treatment|
11095300|NCT04109235|Active Comparator|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
11095301|NCT04109235|Experimental|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
11095302|NCT04109222|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to < 36 months|0.5-mL dose of Fluzone Quadrivalent vaccine. For participants for whom 2 doses of influenza vaccine are recommended, a second dose will be administered on Day 28
11095303|NCT04109222|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to < 9 years|0.5-mL dose of Fluzone Quadrivalent vaccine. For participants for whom 2 doses of influenza vaccine are recommended, a second dose will be administered on Day 28
11095304|NCT04109222|Experimental|Fluzone High-Dose vaccine Group 3: adults ≥ 65 years|0.5-mL dose of Fluzone High-Dose vaccine
11095305|NCT04109209|Active Comparator|Usual Care Group|"60 Participants will be randomized to receive usual care for caregivers of patients with malignant gliomas
~Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician
~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
11095306|NCT04109209|Experimental|Psychosocial Intervention Group|"60 Participants of caregivers of patients with malignant gliomas will be randomized into the psychosocial intervention arm
~Caregivers assigned to the intervention arm will receive usual care and the psychosocial intervention. The intervention entails six one-on-one sessions with an interventionist (psychologist or social worker)
~Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
11095307|NCT04109196|Experimental|Intensive 5-day Cognitive Processing Therapy for PTSD|Participants who are eligible for and enrolled in the study will receive a 5-day CPT treatment for PTSD. All participants will be asked to complete clinician-rated and self-report assessments at multiple time points during the study. Participants will also be asked to provide fecal and saliva samples as part of the study, however, they may opt out of biological sample collection.
11095308|NCT04109183|Experimental|Active Comparator: FNC 2 mg+ TDF+EFV|
11095309|NCT04109183|Experimental|Active Comparator: FNC 3 mg+ TDF+EFV|
11095310|NCT04109183|Experimental|Active Comparator: FNC 4 mg+ TDF+EFV|
11095311|NCT04109183|Experimental|Postive Comparator: 3TC+ TDF+EFV|
11095312|NCT04109170||Dry Eye Group|This group of subjects were diagnosed with dry eye.
11095314|NCT04109157|Other|Study population|Women who had fulfilled the standardization of terminology of lower urinary function from ICS were diagnosed as urodynamic stress incontinence (USI) after urodynamic study (UDS) and enrolled for analysis in this study.
11095315|NCT04109144|Experimental|Large Volume Paracentesis (LVP) with Fresh Frozen Plasma (FFP)|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters of fluid are removed
11095316|NCT04109144|Active Comparator|Large Volume Paracentesis (LVP) with Albumin|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the first and third drainage participants will receive 1 bottle, or 50 ccs, of 25% albumin intravenously for every two liters of fluid removed
11095317|NCT04109131|Other|CNS metastases from solid tumours|"The study will be organised on three time-periods based on the time of the 1st CNS event:
~Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event"
11095318|NCT04109118|Other|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|"This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.
~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
11095319|NCT04109118|Other|Relaxation Therapy (RT)|"This psychosocial treatment intervention uses a combination of progressive muscle-relaxation training and psychoeducation about benzodiazepine use in OAT.
~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
11095320|NCT04109105||NHS-PEG coated collagen patch cohort|Patients diagnosed of colon adenocarcinoma that have ileocolic anastomosis after undergoing a laparoscopic right hemicolectomy surgery.
11095321|NCT04109092|Experimental|Dose Escalation: NMIBC And BCG Unresponsive NMIBC|
11095322|NCT04109092|Experimental|Dose Expansion: CIS With/Without Ta or T1|
11095323|NCT04109092|Experimental|Dose Expansion: High-grade Ta or T1, Without CIS|
11095324|NCT04109079|Experimental|No axillary treatment|Patients in this arm will not receive axillary treatment (axillary lymph node dissection or axillary radiotherapy). Supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
11095325|NCT04109079|Active Comparator|Axillary treatment|Patients in this arm will receive axillary treatment. Axillary treatment can be axillary lymph node dissection or axillary radiotherapy.
11095326|NCT04109066|Experimental|Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET|Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
11095327|NCT04109066|Placebo Comparator|Arm B: Placebo combined with neoadjuvant CT and adjuvant ET|Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
11095328|NCT04109027|Experimental|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
11095329|NCT04109027|Active Comparator|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
11095330|NCT04109014|Other|FASTLANE II Group|Participants will participate in the FASTLANE II Intervention. Counseling sessions will focus on: 1) depressive symptoms, 2) methamphetamine use, and 3) sexual risk behaviors. Three sessions will be devoted to each topic area. Trained staff will use a client-centered approach and develop a goal for each area alongside the participant. Counseling sessions will remain confidential and will not be audio recorded.
11095331|NCT04108988|Experimental|One Night Stan|One Night Stan will be adapted as a multiplayer videogame based on the card game prototype with a focus on a slightly younger age group.
11095332|NCT04108988|Placebo Comparator|Non-Health Related Game|Participants in the non-health related game group will play a multiplayer game unrelated to the content of One Night Stan.
11095333|NCT04108975|Active Comparator|Rectus muscle reapproximation group|Rectus muscle reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures
11095334|NCT04108975|Active Comparator|Rectus muscle non reapproximation group|No rectus muscle reapproximation will be done based on the fact that rectus muscle can regain its position
11095335|NCT04108962|Experimental|Treatment|Benralizumab treatment will be given by injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment
11095336|NCT04108949|Experimental|Tuning in to Kids|Eight weekly two-hour sessions delivered in groups of up to six parents.
11095337|NCT04108949|Active Comparator|Treatment as usual|Treatment as usual, may consist of any psychosocial intervention the therapist sees fit, which is the type of intervention the participants ordinarily receives in the participating clinics. No limit on number of sessions or format of delivery.
11095338|NCT04108936||Peritoneal Carcinomatosis|Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies
11095339|NCT04108936||Control group|Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis
11095340|NCT04108923|Active Comparator|Ligasure ( group A)|
11095341|NCT04108923|Active Comparator|Conventional vessel ligation (group B)|
11095342|NCT04108910||Traditional Urine Culture|Patients treated based upon traditional urine culture
11095343|NCT04108910||Guidance PCR/Pooled Sensitivity|Patients treated based upon multiplex UTI PCR/pooled sensitivity results
11095344|NCT04108897|Experimental|Doxycycline 40mg/day|Doxycycline 40mg will be administered once a day per oral for 28 days.
11095345|NCT04108897|Experimental|Doxycycline 50mg/day|Doxycycline 50mg will be administered once a day per oral for 28 days.
11095346|NCT04108897|Experimental|Doxycycline 100mg/day|Doxycycline 100mg will be administered once a day per oral for 28 days.
11095347|NCT04108897|Experimental|Doxycycline 200mg/day|Doxycycline 100mg will be administered twice a day per oral for 28 days.
11095348|NCT04108897|Experimental|Topical ivermectin(1%)|Topical ivermectin will be applied once a day for 28 days.
11095349|NCT04108897|No Intervention|Control|No intervention will be performed.
11095590|NCT04107259||Patient with diabetes|60 newly diagnosed type 2 diabetes
11095350|NCT04108884|Experimental|App Group|In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.
11095351|NCT04108884|Other|Standard Care Group|The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.
11095352|NCT04108871|Experimental|Transperineal Prostate Biopsy|The biopsy needed is inserted to the prostate through the perineal skin, with the assistance of an access system device known as PrecisionPoint. It utilises a single access needle cannula mounted directly on to the ultrasound probe, which acts as an access point traversing through the perineal skin. 4 - 5 cores are obtained from the anterior, mid and posterior zone of each side of the prostate.
11095353|NCT04108871|Active Comparator|Transrectal Prostate Biopsy|The biopsy needle penetrates through the bowel (rectum) to the prostate to obtain 12 cores of prostate tissues from the lateral and medial base, midzone and apex of each side of the prostate (1 core each).
11095354|NCT04108858|Experimental|Phase I, Phase II Arm I (copanlisib, trastuzumab, pertuzumab)|Patients receive copanlisib IV over 60 minutes on days 1 and 8. Patients also receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11095355|NCT04108858|Active Comparator|Phase II Arm II (trastuzumab, pertuzumab)|Patients receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11095356|NCT04108845|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine, 0.5 ml/dose
11095357|NCT04108832|Experimental|TCM OA2|TCM OA2 3G BID FOR 8 WEEKS
11095358|NCT04108832|Placebo Comparator|PLACEBO|PLACEBO
11095359|NCT04108819|Experimental|Ketogenic Diet|Participants will receive the ketogenic diet.
11095360|NCT04108806|Experimental|Endovascular therapy|Outcome of endovascular therapy on PAC
11095361|NCT04108793|Experimental|Intervention Arm|The Intervention group will be given a program of progressive balance and lower limb strengthening exercises twice a week for 3 months. All exercises will include 5 minutes warm-up exercises. The lower limb extensor muscle groups (hip & knee extensors and ankle plantar flexors) will be targeted with exercises designed to enhance postural control (i.e. balance) and muscle strength. The balance exercises include standing with a decreased base of support, forwards and sideways stepping/walking, and graded reaching activities in standing. Strengthening exercises will include sit-to-stand, forward and lateral step-ups onto a small block, semi squats and heel raises in standing. Standard principles governing frequency, volume, duration, intensity and progression of exercise will be applied. Cueing strategies will be used to reduce freezing. T
11095362|NCT04108793|No Intervention|Control Arm|The control arm will receive the usual standard postoperative rehabilitation after a bipolar hemiarthroplasty/ total hip arthroplasty which will include in hospital rehabilitation and a maximum of 5 visits postoperatively
11095363|NCT04108780||CBD exploration with T-tube|repair of CBD after CBD exploration over T-tube
11095364|NCT04108780||CBD exploration with primary repair|primary repair of CBD after CBD exploration
11095365|NCT04108767||Health students enrolled in the 3rd year at the University Cla|Health students enrolled in the 3rd year at the University Claude Bernard Lyon 1, aged over 18 years.
11095366|NCT04108754||Diagnosis of AIT|Patients in the neurovascular unit of the Neurological Hospital of Lyon between 01/01/2016 and 30/12/2017 with a probable diagnosis of AIT and having an MRI within 7 days of TIA.
11095367|NCT04108741|Experimental|treadmill augmented reality training|
11095368|NCT04108741|Active Comparator|treadmill training|
11095369|NCT04108728|Experimental|HIV exposed children during pregnancy|children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
11095370|NCT04108728|Other|control children|children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
11095371|NCT04108715|Active Comparator|ESPB GROUP|Erector spina plane block group
11095372|NCT04108715|Active Comparator|SAPB group|Deep Serratus anterior plane block group
11095373|NCT04108702|Experimental|VR heart|
11095374|NCT04108702|Sham Comparator|VR control|
11095375|NCT04108702|Active Comparator|Standard control|
11095376|NCT04108689|Experimental|I-ACT|I-ACT is short for Internet-Acceptance and Commitment Training
11095377|NCT04108676|Experimental|single arm|Drug: Fluzoparib Drug: Omeprazole
11095378|NCT04108663|Sham Comparator|Sham|Sham tDCS (ramp up and ramp down of electrical current before as well as after task performance to elicit physical sensations similar to verum tDCS)
11095379|NCT04108663|Active Comparator|L1A|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: anodal"
11095380|NCT04108663|Active Comparator|R1A|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: anodal"
11095381|NCT04108663|Active Comparator|L2A|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: anodal"
11095382|NCT04108663|Active Comparator|R2A|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: anodal"
11095383|NCT04108663|Active Comparator|L1C|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: cathodal"
11095384|NCT04108663|Active Comparator|R1C|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 1 mA
~polarity: cathodal"
11095385|NCT04108663|Active Comparator|L2C|"Active tDCS
~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: cathodal"
11095386|NCT04108663|Active Comparator|R2C|"Active tDCS
~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)
~intensity: of 2 mA
~polarity: cathodal"
11095591|NCT04107259||Control|60 non-diabetic control subjects
11095592|NCT04107246||Newly transplanted corneal patients|
11095387|NCT04108650|Experimental|Fit & Strong! group|The experimental group (23 participants) was enrolled in the intervention, the Fit & Strong! program. The program consists in 24 sessions each divided in two parts. The first part is the exercise component (60 minutes) and the second is the educational component (30 minutes). The program was provided in two classes, the first class took place from October to December 2017 and the second class took place from October to November 2018. The experimental group was enrolled in the intervention (8 weeks).
11095388|NCT04108650|No Intervention|Control group|To participants in the control group (8 participants) were offered the possibility of enrolling in the program the following year after posttest measurement for both the intervention and control groups was complete.
11095389|NCT04108637|Experimental|penicillin allergy assessment pathway|"Those in the PAAP intervention arm will complete stage 2&3 of the PAAP pathway:
~Stage-2 assessed for skin testing (ST) and ST done or straight to stage 3
~Stage-3 oral challenge test (OCT) All completing PAAP will receive a letter from the immunology clinic giving the results of the test. Also, patients who have tested negative will receive the Post-test Intervention Booklet and Patient Intervention Card Materials.
~Additionally, all participants in the PAAP arm will be called by the trial team at days 4-6 and 28-30 post testing to collect safety data. During the call at days 28-30 patients will complete the patient questionnaire on allergy beliefs.
~Practices will be informed of the test result and instructed to update the participant's electronic health records accordingly."
11095390|NCT04108637|No Intervention|Control Arm|The usual care arm receive no intervention but will be followed up as per intervention arm with monitoring of any symptoms following an antibiotic prescription.
11095391|NCT04108624|Experimental|MRD2STOP ARM|
11095392|NCT04108611|Experimental|systemic lupus in activity|Sixty systemic lupus patients in activity will receive conventional therapy (47 patient as cases 1) and immunadsortion (13 patients as cases 2) will be provided to the non responders
11095393|NCT04108611|Other|Control group 30 subjects|controls 1 (20 healthy volunteers, controls 2 (10 patients with glomerular diseases other than lupus) will do routine laboratory investigations
11095394|NCT04108598||Adults presenting with SSNHL|Adults presenting with SSNHL to NHS
11095395|NCT04108585||HFO group|HFO therapy
11095396|NCT04108585||CPAP group|CPAP therapy
11095397|NCT04108572|Experimental|Infant feeding intervention|The intervention will be delivered to parents by practice nurses and/or GPs in MPHC at each of the vaccination visits, prior to administration of the vaccination. These vaccination visits take place at 2, 4, 6, 12 and 13 months. This intervention consists of 1) verbally delivered pre-specified infant feeding messages, and 2) provision of additional infant-feeding resources including an information leaflet, a magnet, an infant bib and access to an informational website.
11095398|NCT04108559|Experimental|Kinesiologic Tape Group|After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
11095399|NCT04108559|Experimental|Surgical Drain Group|After routine impacted third molar surgery, plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa.
11095400|NCT04108559|Placebo Comparator|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
11095401|NCT04108546|Experimental|massage-electroacupuncture|Electroacupuncture will be applied throughout the back of the body, upper limbs and ears.Massage will follow the same paths of acupuncture points respectively
11095402|NCT04108546|Active Comparator|Epidural analgesia|Epidural analgesia will be applied using ropivacaine 0.2%, 5-7% ml and Fentanyl 25 mcg
11095403|NCT04108533|Experimental|Text-Based Support|"Text-Based Support - Women randomized to this arm will receive text-based support via the Way to Health platform as described below.
~Supportive texts - Encouraging text messages with prompts to ask questions will be sent twice weekly during the first four weeks postpartum and once weekly thereafter for the remaining two weeks of the program
~Inquiry texts - Questions regarding infant feeding with prompts to answer will be sent three times weekly during the first two weeks postpartum and twice weekly thereafter for the remaining 4 weeks of the program.
~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.
~Women in this group will also have the option to send a text with a question or concern at any time during the study. Weekdays from 8am to 5 pm these will be fielded by a trained obstetrician. If a text is received after-hours or on the weekend, women will be instructed to reach out to their primary OBGYN provider."
11095404|NCT04108533|No Intervention|Usual Care|"Usual care - Women randomized to this arm will receive usual postpartum care with the following exceptions:
~Inquiry texts- Questions regarding infant feeding with prompts to answer will be sent once weekly for all 6 weeks of the program.
~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.
~Women in this group will be directed to their physician with any questions or concerns during the study period."
11095405|NCT04108520|Experimental|Intervention Group|Exercises on respiratory muscle, 3 times per week, 1 hour peer day
11095406|NCT04108507|Experimental|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP)operation
11095407|NCT04108507|No Intervention|without posterior branch block of spinal nerve|without posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
11095408|NCT04108494|Experimental|Experimental group|D2 radical gastrectomy with partial omentectomy
11095409|NCT04108494|No Intervention|Control group|D2 radical gastrectomy with total omentectom
11095450|NCT04108208|Placebo Comparator|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
11095451|NCT04108195|Experimental|Part 1: Dose Escalation|Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
11095410|NCT04108481|Experimental|Y90-RE in combination with immunotherapy (durvalumab)|"The treatment phase starts of with the immunotherapy drug (durvalumab) - priming doses every 2 weeks prior to patient getting mapped and ready for treatment with Y90-RadioEmbolization.
~Post-Y90-RE, treatment is approximately 2 months in combination with fixed doses (750 mg) of durvalumab. The number and timing of doses of durvalumab each patient will receive will depend on the dose level the patient is assigned to (range 2-5 doses of immunotherapy).
~A single patient will be treated per dose level until the first dose limiting toxicity (DLT) is recorded. Once the first DLT is recorded, two additional patients are treated at the same dose level and the trial reverts to a standard 3+3 design. Up to 6 patients will be treated at each dose level. The maximum tolerated dose (MTD) will be defined as the highest dose level for which at most 1 out of 6 patients experience a DLT."
11095411|NCT04108468|Experimental|Golimumab & Methotrexate|
11095412|NCT04108468|Active Comparator|Methotrexate|
11095413|NCT04108455||With Diabetes|Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
11095414|NCT04108455||Controls|Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
11095415|NCT04108442|Active Comparator|Traditional|
11095416|NCT04108442|Experimental|Virtual|
11095417|NCT04108429|Experimental|Mobile self-help intervention|Participants will have open access to the IntelliCare system.
11095418|NCT04108403|Experimental|Pain Inducing Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
11095419|NCT04108403|Active Comparator|Pain Inducing Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
11095420|NCT04108403|Active Comparator|Pain Free Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
11095421|NCT04108403|Active Comparator|Pain Free Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
11095422|NCT04108390|Experimental|Intervention group|Individuals for this group will be treat with a dry needling intervention at the gluteus medius trigger point.
11095423|NCT04108390|Active Comparator|Control group|Individuals for this group will be treat with a dry needling technique at 1,5 cm from the trigger point (not in the trigger point).
11095424|NCT04108377|Experimental|Roflumilast|Roflumilast 500mcg by mouth, once daily, for 70 days (10 weeks).
11095425|NCT04108377|Placebo Comparator|Placebo|Placebo by mouth, once daily, for 70 days (10 weeks).
11095426|NCT04108364|Experimental|VoiceAdapt Intervention|PWA who train with VoiceAdapt app
11095427|NCT04108364|No Intervention|No Intervention|PWA who are on the waitlist and not training with VoiceAdapt app
11095428|NCT04108351|Experimental|Zopiclone|
11095429|NCT04108351|Placebo Comparator|Placebo|
11095430|NCT04108338||CCRT-randomized clinical trial|Trial patients receiving CCRT
11095431|NCT04108338||CCRT-real-world database|Patients receiving CCRT from real-world database
11095432|NCT04108338||IC+CCRT-randomized clinical trial|Trial patients receiving IC+CCRT
11095433|NCT04108338||IC+CCRT-real-world database|Patients receiving IC+CCRT from real-world database
11095434|NCT04108325|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
11095435|NCT04108312||Autism Spectrum Disorders|
11095436|NCT04108312||Typical Control|
11095437|NCT04108299|Placebo Comparator|wait-list control|Standard of care
11095438|NCT04108299|Experimental|SMS intervention|The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.
11095439|NCT04108286|Experimental|TEST/CONTROL|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
11095440|NCT04108286|Experimental|CONTROL/TEST|Eligible subjects that are habitual wearers of spherical soft contact lenses will be randomly assigned to 1 of 2 contralateral lens sequences (Right: TEST/ Left: CONTROL) or (Right: CONTROL/ Left: TEST).
11095441|NCT04108273|Experimental|OST Intervention|
11095442|NCT04108273|Other|Waitlist|
11095443|NCT04108260|Experimental|Single arm_Idelvion treated|
11095444|NCT04108247|Experimental|Abiraterone+SHR3162|
11095445|NCT04108234|Experimental|Treatment group A|HR071603,nasal spray,dose escalation.
11095446|NCT04108234|Placebo Comparator|Treatment group B|Placebo, nasal spray
11095447|NCT04108221|Experimental|Arm A : c-TAP Block performed by surgeon|c-TAP Block Block performed by surgeon
11095448|NCT04108221|Active Comparator|Arm B : us-TAP Block performed by anesthetist|us-TAP Block by anesthetist
11095449|NCT04108208|Experimental|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
11095593|NCT04107233|Experimental|Intervention|Audit and feedback directed at family physicians, including reports a one-on-one meeting.
11095452|NCT04108195|Experimental|Part 2: Dose Expansion|Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1 until disease progression, unacceptable toxicity, withdrawal of consent, otherwise deemed necessary by the investigator or the sponsor, or end of study.
11095453|NCT04108169|Active Comparator|Active Comparator|
11095454|NCT04108169|No Intervention|Sham Comparator|
11095455|NCT04108156|Experimental|PDS Arm|Participants randomized to the PDS arm will receive intravitreal ranibizumab injection every 4 weeks (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 24-weeks (Q24W) thereafter
11095456|NCT04108156|Active Comparator|Intravitreal Arm|Participants randomized to the intravitreal arm will receive intravitreal ranibizumab injection every 4 weeks until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
11095457|NCT04108143|Experimental|Intervention|MonitorMe device
11095458|NCT04108130|No Intervention|Usual Care|Patients in this arm will receive usual anesthetic and postoperative care as provided in each site.
11095459|NCT04108130|Experimental|Intervention|This arm will receive the bundle of interventions.
11095460|NCT04108117||Robotic nipple sparing mastectomy group/RNSM|"Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
~The estimated sample size for this arm is 300 cases."
11095461|NCT04108117||Conventional nipple sparing mastectomy group/CNSM|"Cases or Patients who underwent conventional nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Conventional nipple-sparing mastectomy should not be performed using robotic or endoscopic surgical systems. Axillary or lateral incisions that are similar to incisions in robotic nipple-sparing mastectomy are not allowed. Other than axillary or lateral incisions can be performed for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with nipple-sparing mastectomy without immediate reconstruction are excluded.
~The estimated sample size for this arm is 300 cases."
11095462|NCT04108104|Experimental|Low-dose group|Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
11095463|NCT04108104|Experimental|High-dose group|Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)
11095464|NCT04108104|Placebo Comparator|Placebo group|Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
11095465|NCT04108091||Treatment for TTR amyloidosis|Transthyretin amyloid cardiomyopathy (wild-type or variants) patients administered Vyndaqel
11095466|NCT04108078|Experimental|Intervention|This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention.
11095467|NCT04108078|No Intervention|Wait listed|Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study.
11095468|NCT04108065||Patients with gestational diabetes mellitus (GDM)|GDM diagnosed according to current Danish guidelines (plasma glucose (PG) concentration at 120 min after a 75 g oral glucose tolerance test (OGTT) ≥9.0 mM)
11095469|NCT04108065||Pregnant women with normal glucose tolerance (control group)|Pregnant women with normal glucose tolerance (fasting plasma glucose (PG) concentration ≤6.0 mM and PG concentration at 120 min after a 75 g-OGTT <7.8 mM)
11095470|NCT04108052|Other|Low dose CT scanner and Ultra low dose CT Scan|Thoracic low dose CT acquisition and Thoracic ultra-low dose CT acquisition
11095471|NCT04108039|Active Comparator|GnRH antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering.
11095472|NCT04108039|Experimental|Micronized progesterone|In the progesterone cycle, endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg) once a day at bed time, from stimulation day 1 and continuing until ovulation triggering.
11095473|NCT04108026|Experimental|Immunotherapy|Durvalumab 1500 mg every 4 weeks until the progression of disease, discontinuation due to toxicity or withdrawal of consent, for a maximum duration of 2 years.
11095474|NCT04108013|Experimental|SHR-1210+Carboplatin+Paclitaxel-albumin|Subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
11095475|NCT04108013|Active Comparator|Carboplatin+Paclitaxel-albumin|Subject will receive carboplatin AUC 5 on Day 1 of each 21 day, Paclitaxel-albumin 130mg/m2 on Day 1 and Day 8 of each 21 day, 2 cycles.
11095476|NCT04108000|Experimental|SPIRIT-Dementia|Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
11095477|NCT04108000|Active Comparator|Usual Care|Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
11095478|NCT04107987|Active Comparator|Reglicemi|Reglicemi is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
11095479|NCT04107987|Placebo Comparator|Placebo|Placebo
11095525|NCT04107753|Experimental|Intervention: Brief counseling based on the 5As model|The intervention group received a brief counseling based on the 5As model. It mainly consists of the following steps: ask, advice, asses, assist, arrange. It is performed by the nurse who take clinical care of the patient. The patients receive an information card about the Smoke cessation center's (CTT) and the patients who agree are contacted by the CTT's staff.
11095594|NCT04107233|No Intervention|Control|Usual care; may receive the intervention at the end of the study if successful
11095480|NCT04107974|Experimental|Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. Two T-fasteners are inserted into the stomach approximately 4cm apart. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate. The gastropexy/T-fastener sutures are cut after one week.
11095481|NCT04107974|Experimental|Non-Gastropexy|Percutaneous radiologic guided insertion of G-tube. The skin over the epigastrium is prepared and draped in sterile fashion. Midazolam and fentanyl are administered for conscious sedation. Lidocaine for local analgesia. The stomach is insufflated with air after insertion of an OG or NG tube. A needle is inserted into the stomach and an Amplatz wire is then inserted into the stomach. The tract is dilated with an 18Fr peel away sheath. A 14 Fr balloon retention gastrostomy tube is inserted. The balloon is inflated and bolster set as appropriate.
11095482|NCT04107961|Experimental|Vaccine arm|Vaccine in 1 ml, single dose
11095483|NCT04107961|Placebo Comparator|Placebo|1 ml normal saline , single dose
11095484|NCT04107948|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
11095485|NCT04107948|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
11095486|NCT04107935|Experimental|Intervention|
11095487|NCT04107935|Other|Usual Care|
11095488|NCT04107922|Active Comparator|Glicoset|Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
11095489|NCT04107922|Placebo Comparator|Placebo|
11095490|NCT04107909|Other|3 ports|3port operation
11095491|NCT04107909|Other|4 port|4 port operation
11095492|NCT04107896|Experimental|Silodosin|8 mg daily by mouth, 12 weeks
11095493|NCT04107896|Active Comparator|Tamsulosin|0.4 mg daily by mouth, 12 weeks
11095494|NCT04107883|Experimental|control group|Do not perform plasma transfusion during operation.
11095495|NCT04107883|Experimental|anhapetic group|Perform plasma transfusion during anhapetic phase.
11095496|NCT04107883|Experimental|neohepatic group|Perform plasma transfusion during neohepatic phase.
11095497|NCT04107870|Experimental|Virtual Reality Exposure Therapy|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
11095498|NCT04107870|Active Comparator|Psychomotor Therapy|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
11095499|NCT04107857||Smoking Cessation|"Patients enter the program through clinic appointments or community outreach programs.
~Patients will be given brief advice to quit smoking and referral options to receive evidence-based treatment through Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov dependent on the patient's preference for counseling
~Patient can also be prescribed smoking cessation pharmacotherapy"
11095500|NCT04107844||Athletes without concussion|We follow the athletes in terms of injuries and make a baseline test each season.
11095501|NCT04107844||Athletes suffering a concussion|We follow the athletes in terms of injuries and make a baseline test each season and when they suffer a concussion, then we follow them with the same test as at baseline every 14th day for 3 months, after that they will get enrolled in another study.
11095502|NCT04107831|Experimental|Pulmonary rehabilitation|Participants who are participating in a 6-week pulmonary rehabilitation program are enrolled in the study.
11095503|NCT04107805|Experimental|Dose Group 1|
11095504|NCT04107805|Experimental|Dose Group 2|
11095505|NCT04107805|Experimental|Dose Group 3|
11095506|NCT04107805|Experimental|Dose Group 4|
11095507|NCT04107805|Experimental|Dose Group 5|
11095508|NCT04107805|Placebo Comparator|Placebo|
11095509|NCT04107805|Experimental|Dose Group 6|
11095510|NCT04107805|Experimental|Dose Group 7|
11095511|NCT04107792|Experimental|Experimental|Parents of children with sensory processing issues who attend Workshop 1
11095512|NCT04107792|No Intervention|Waitlist Control|parents of children with sensory processing issues who attend Workshop 2
11095513|NCT04107779|Experimental|JUUL 5% Virginia Tobacco ENDS|JUUL 5% Virginia Tobacco flavored ENDS product [6 days] in confinement.
11095514|NCT04107779|Experimental|JUUL 3% Virginia Tobacco ENDS|JUUL 3% Virginia Tobacco flavored ENDS product [6 days] in confinement.
11095515|NCT04107779|Experimental|JUUL 5% Mint ENDS|JUUL 5% Mint flavored ENDS product [6 days] in confinement.
11095516|NCT04107779|Experimental|JUUL 3% Mint ENDS|JUUL 3% Mint flavored ENDS product [6 days] in confinement.
11095517|NCT04107779|Experimental|JUUL 5% Menthol ENDS|JUUL 5% Menthol flavored ENDS product [6 days] in confinement.
11095518|NCT04107779|Experimental|JUUL 3% Menthol ENDS|JUUL 3% Menthol flavored ENDS product [6 days] in confinement.
11095519|NCT04107779|Experimental|JUUL 5% Mango ENDS|JUUL 5% Mango flavored ENDS product [6 days] in confinement.
11095520|NCT04107779|Experimental|JUUL 3% Mango ENDS|JUUL 3% Mango flavored ENDS product [6 days] in confinement.
11095521|NCT04107779|Experimental|Dual-use of JUUL 5% and UB of Combustible Cigarette|JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette [6 days] in confinement.
11095522|NCT04107779|Active Comparator|UB of Combustible Cigarette|Usual brand combustible cigarette [6 days] in confinement.
11095523|NCT04107779|Other|Tobacco/Nicotine Abstention|Smoking abstention (no smoking) [6 days] in confinement.
11095524|NCT04107766||Population|Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
11095526|NCT04107753|No Intervention|Control group|"No other intervention than the usual care (range between the not mentioning the subject at all, to a general advice to quit without bringing any evidence or any structured counseling)."
11095529|NCT04107727|Experimental|Quizartinib|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days"
11095530|NCT04107727|Placebo Comparator|Placebo|"Induction: Cytarabine continuous IV infusion 200 mg/m2 (days 1-7), Idarubicin IV infusion 12 mg/m2 (days 1-3), oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.
~Consolidation: Cytarabine IV infusion 1,5-3 g/m2 (days 1, 3, 5), oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.
~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
11095531|NCT04107714|Experimental|Intervention (STC)|"Study participants randomized to the experimental group receive the intervention (STC). STC is a peer-led and web-based group intervention containing four two-hour sessions within four weeks plus an additional booster session one month later.
~Fidelity to manual is rated in each session by study staff."
11095532|NCT04107714|No Intervention|No intervention|Participants randomized to the control group do not receive the group program but get the accompanying workbook at the end of the study.
11095533|NCT04107688|Experimental|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
11095534|NCT04107688|Experimental|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
11095535|NCT04107675|Experimental|L-CsA 10 mg plus Standard of Care|Liposomal Cyclosporine A 10 mg bid for 12 weeks
11095536|NCT04107675|Experimental|L-CsA 5 mg plus Standard of Care|Liposomal Cyclosporine A 5 mg bid for 12 weeks
11095537|NCT04107675|Placebo Comparator|Liposomal Placebo plus Standard of Care|Liposomal Placebo 2.5 mL bid for 12 weeks
11095538|NCT04107662||Traumatic Brain Injury|
11095539|NCT04107649|Other|Arm1|Participants in this arm receive usual post-operative care and complete all basic study activities, which include: attending 2 in-clinic visits at designated time-points, wearing and returning waist-worn activity trackers at 5 time points over two years, and completing 6 study surveys.
11095540|NCT04107649|Experimental|Arm2|Participants in this arm receive usual post-operative care, complete all basic study activities, receive the wrist-based activity tracker intervention, and receive regular calls from study personnel about improving their general well being.
11095541|NCT04107649|Experimental|Arm3|Participants in this arm receive usual post-operative care, complete all basic study activities, and receive the TAC(MI)+FI and wrist-based activity tracker interventions.
11095542|NCT04107636|Experimental|Assigned Interventions|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location. After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
11095543|NCT04107623|Active Comparator|Grupp 1|Patients will be allocated to preserving the right gastric artery during the resection of GEJ cancer.
11095544|NCT04107623|Active Comparator|Grupp 2|Patients will be allocated to an extensive lymphatic resection (ligating the right gastric artery) during the resection of GEJ cancer.
11095545|NCT04107597|Experimental|Core stabilization exercises|Patients with CLBP who practice core stabilization exercises
11095546|NCT04107597|Experimental|Core stabilization exercises and paced breathing training|Patients with CLBP who practice core stabilization exercises combined with paced breathing training
11095547|NCT04107597|Experimental|Myofascial trigger point release|Patients with CLBP who receive myofascial trigger point release therapy
11095548|NCT04107597|Experimental|Myofascial trigger point release and paced breathing training|Patients with CLBP who receive myofascial trigger point release therapy combined with paced breathing training
11095549|NCT04107571||Cohort|
11095550|NCT04107558|Experimental|Painful stimuli with Hypnosis and Virtual Reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes. This session takes place under hypnosis
11095551|NCT04107558|No Intervention|Painful stimuli without Hypnosis and Virtual reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes.
11095552|NCT04107545|Experimental|athletes|48 elite athletes, 24 men and 24 women, experiencing regular weight cycling.
11095553|NCT04107532|Other|Virtual Reality Therapy for Acrophobia|There were a total of 5 treatments in the VR treatment group, followed by cliffs, cliffs, cliffs, single-plank bridges, and high-altitude rescues. The difficulty of the scene increased in turn. The frequency of treatment twice a week, about 30 minutes each time, fills in the motion sickness questionnaire before and after each treatment to understand the safety of VR treatment. In the course of treatment, physiological data such as skin electricity, skin temperature, heart rate, and blood volume were measured, and the state of the subjects was objectively evaluated. At the same time, every two minutes, participants were asked about sud values and recorded.
11095554|NCT04107532|Other|Imagination Exposure Therapy for Acrophobia|The imaginary exposure treatment program is to convert the five scenes of VR exposure treatment through language, guide the subjects through the guidance language, guide the subjects to expose, and achieve the purpose of adaptation. Both treatment groups were required to collect scales and nuclear magnetic data before, after and after six months of follow-up.
11095555|NCT04107519|Experimental|Immediate GRIT (ImT) training intervention|
11095556|NCT04107519|No Intervention|Delayed Training (DeT) control|
11095595|NCT04107220|Other|one arm|One arm study patients where NT-proBNP and BNP tests will be monitored.
11095596|NCT04107207|Active Comparator|Kombucha Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
11095654|NCT04106817|Experimental|Cohort 3|1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
11095557|NCT04107506|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
11095558|NCT04107506|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
11095559|NCT04107493|Active Comparator|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
11095560|NCT04107493|Experimental|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
11095561|NCT04107480|Experimental|Intervention|Patients in the intervention groups will be referred to one of the participating neurosurgical centers, for surgical consultation. After this consultation, the patient may choose to continue with surgery or not.
11095562|NCT04107480|Active Comparator|Standard care|Patients in the standard care groups will receive treatment as usual as described by the US Endocrine Society.
11095563|NCT04107454|Active Comparator|Active group|The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
11095564|NCT04107454|Placebo Comparator|Placebo group|Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
11095565|NCT04107441|Experimental|Part 1 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg, 10 mg, 20 mg or 40 mg AX-8 twice daily (8 hours apart, i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of treatment periods 1, 2, 3 or 4, respectively.
11095566|NCT04107441|Experimental|Part 2 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg AX-8 and one ODT with 40 mg AX-8 8 hours later (i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of the treatment period.
11095567|NCT04107428|Active Comparator|Somatostatin|
11095568|NCT04107428|Placebo Comparator|Placebo|
11095569|NCT04107415|Experimental|Yoga group|group doing yoga
11095570|NCT04107415|No Intervention|No yoga group|group not doing yoga
11095571|NCT04107402|Experimental|Septic shock|Septic shock Patients admitted to the ICU
11095572|NCT04107402|Other|Control group|Patients recruited at the central lab of the hospital, with matched age, gender and comorbidities
11095573|NCT04107402|Experimental|Covid-19|Covid-19 patients admitted to the ICU for Acute Respiratory Distress Syndrom with PaO2/FiO2 < 200
11095574|NCT04107389|Active Comparator|Intervention Group|Receives Art Therapy assessment and intervention
11095575|NCT04107389|Active Comparator|Wait List Control Group|Added to wait list to receive intervention at a later date, participant is made aware of this
11095576|NCT04107376|Experimental|Retroviewing endoscopy (RVE)|Withdrawal in every colonic segment with SFV (standard forward view) followed by another withdrawal with the retroviewing endoscope. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
11095577|NCT04107376|Active Comparator|standard forward viewing endoscopy (SFVE)|Withdrawal in every colonic segment with SFV followed by another withdrawal with SFV. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
11095578|NCT04107363|Experimental|Experimental group:|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes.
~After the oropharyngeal aspiration was completed, the patient's position was changed."
11095579|NCT04107363|Other|Control group|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
11095580|NCT04107350|Experimental|whole body vibration on|vibration machine on combined with conventional physical therapy
11095581|NCT04107350|Sham Comparator|whole body vibration off|vibration machine off combined with conventional physical therapy
11095582|NCT04107337|Experimental|Experimental group|Experimental group (N=10): this group will conduct a vocal work session based on semi-occluded vocal-tract exercises with a straw.
11095583|NCT04107337|Other|Control group|Control group (N=10): the second group acting as control group will perform a vocal work session based on open mouth exercices (vocalizations).
11095584|NCT04107324|Other|PVE (Portal vein embolisation)|Standard of care when FLR is small.
11095585|NCT04107324|Experimental|ARAPS (Portal vein embolisation and associating RFA)|Experimental arm with PVE combined with RFA to induce accelerated liver hypertrophy.
11095586|NCT04107298|Experimental|SUNDANCE™ Drug Coated Balloon|SUNDANCE™ Drug Coated Balloon
11095587|NCT04107285||Neurocognitive evaluation prior to and following CART|
11095597|NCT04107207|Placebo Comparator|Placebo Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
11095598|NCT04107194|Experimental|Tailored therapy|"Clarithromycin-sensitive strain (10 day-therapy):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)
~Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):
~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)
~Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)
~Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)"
11095599|NCT04107194|Active Comparator|Empiric therapy|"Either one of the two following 10-day regimens (according to physician's decision):
~Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)
~Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)"
11095600|NCT04107181|Experimental|Patient surveillance|The introducer will be used during annual Pap smears for cervical cancer screening.
11095601|NCT04107181|Experimental|Healthy Volunteers|There will be 2 types of healthy volunteers recruited to participate in this arm. The home study is to determine ease of use/feasibility of the introducer. The other group of healthy volunteers will be interviewed only. The goal of this study is to better understand how to improve women's health through learning about women's perceptions of their reproductive anatomy, specifically the cervix, comfort in discussing reproductive health topics with providers, and thoughts on two tools used to see the cervix.
11095602|NCT04107168||Cohort 1|"Disease: Unresectable AJCC (American Joint Committee on Cancer) stage 3 or 4 melanoma.
~Anti-PD-1 monotherapy (Nivolamab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted."
11095603|NCT04107168||Cohort 2|Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolamab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095604|NCT04107168||Cohort 3|Disease: Advance renal cell carcinoma. Nivolamab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095605|NCT04107168||Cohort 4|Disease: Advanced renal cell carcinoma Nivolamab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095606|NCT04107168||Cohort 5|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolamab, Pembrolizumab or Atezolizumab) monotherapy in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095607|NCT04107168||Cohort 6|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolamab, Pembrolizumab or Atezolizumab) + chemotherapy +/- antiangiogenic (Bevacizumab) in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095608|NCT04107168||Cohort 7|Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolamab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095609|NCT04107168||Cohort 8|Disease: Resected renal cancer Durvalumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095610|NCT04107168||Cohort 9|Disease: Resected renal cancer Durvalumab + Tremelimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
11095611|NCT04107155|Experimental|Weight Management Program|Dietary Supplement: Saffron extract and Gynostemma extract with hesperidin and a handout with suggestions for healthy eating and overall health
11095612|NCT04107155|Placebo Comparator|Placebo|Placebo and handout with suggestions for healthy eating and overall health
11095613|NCT04107142|Experimental|CAR-T Cell Therapy Group|"One arm study consisting of 3 + 3 dose escalation study design ranging from 3 x 10^8 - 3 x 10^9 cells CAR-γδ T cell.
~Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart."
11095614|NCT04107129||Known Endometriosis|Known Endometriosis undergoing IVF with PGTA
11095615|NCT04107129||Unexplained Infertility|Unexplained Infertility undergoing IVF with PGTA
11095616|NCT04107129||Low Risk Controls|Low Risk Controls undergoing IVF with PGTA
11095617|NCT04107116|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
11095618|NCT04107116|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by their local oncologists.
11095619|NCT04107103|Experimental|Single Arm|A single-arm combining nivolumab with pemetrexed
11095620|NCT04107090|Experimental|US guided lung recruitment|Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.
11095621|NCT04107090|Other|Non US guided lung recruitment|Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group.
11095622|NCT04107077|Experimental|Drug Administration Period|
11095653|NCT04106817|Experimental|Cohort 2|1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
11095623|NCT04107064|Experimental|Neurodiversity at Work (NaW) Group|Individuals in this group will receive a 6-week Autism at Work pre-employment training. Upon onboarding, each individual will be supported by a team manager, a team buddy, a peer mentor, a job/life skills coach, a vocational rehabilitation counselor, and a personal counselor. Ongoing support for members of support circles will be provided during the 12 weeks immediately after onboarding.
11095624|NCT04107064|Experimental|Neurodiversity at Work - Delayed Start (NaW-DS)|Participants in this group will receive typical orientation for neurotypical employees after onboarding. The support of peer mentor, job/life skills coach, vocational rehabilitation counselor, and a personal counselor will start 6 months after onboarding. Managers, co-workers, team buddies and mentors for all recruited and hired employees in both groups will receive the same specialized training to enhance their abilities to work with individuals with ASD.
11095625|NCT04107038|Active Comparator|General|Participants randomized to group A will receive general endotracheal anesthesia as their anesthetic procedure.
11095626|NCT04107038|Active Comparator|Sedation|Participants randomized to group B will receive monitored anesthesia care as their anesthetic procedure.
11095627|NCT04107025|Experimental|Intervention|As part of the intervention, along with legal opinions, advise and support, participants were provided counselling support during their time to help survivors with trauma of legal proceedings.
11095628|NCT04107025|No Intervention|Usual Care|Participants were scheduled for legal consultancy only.
11095629|NCT04107012|Experimental|Clear Aligner|Group 1 treated with clear aligners
11095630|NCT04107012|Active Comparator|Fixed appliance|Group 2 treated with conventional fixed appliances
11095631|NCT04106999|Placebo Comparator|Placebo|Normal Saline will be infused as per the protocol
11095632|NCT04106999|Experimental|Intervention group|Dexmedetomidine will be infused as per the protocol
11095633|NCT04106986|Experimental|PEMF and PRE|The PEMF and PRE group received 24 sessions (3 sessions/week for 8 weeks) of combined treatment group (pulsed electromagnetic field with PRE training)
11095634|NCT04106986|Experimental|PRE|The PRE group received 24 sessions (3 sessions/week for 8 weeks) of only progressive resistance exercise
11095635|NCT04106973||Pleural mesothelioma|Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.
11095636|NCT04106973||Asbestos exposed without pleural mesothelioma|Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.
11095637|NCT04106947||Patients with Hirschsprung and anorectal malformation|Patients with Hirschsprung and anorectal malformation living in Norway
11095638|NCT04106921|Experimental|Universal Health Coverage Mode|The NGOs Muso and Medic Mobile have partnered to develop Universal Health Coverage Mode, a smartphone app tool that provides visual cues to help CHWs track the quantity of household visits they have conducted at each household in a given month.
11095639|NCT04106921|No Intervention|Work as usual|For the control arm, all households within the CHW's household list in the app will have the same appearance. There will be no visual differentiation between households on the list to indicate the frequency of home visits.
11095640|NCT04106908||Eqwilate|
11095641|NCT04106895||Fibryga|
11095642|NCT04106882|Experimental|Arm 1: Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
11095643|NCT04106882|Experimental|Arm 2: Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
11095644|NCT04106882|Experimental|Arm 3: Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, the investigators will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while MRS is simultaneously used to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
11095645|NCT04106869|Active Comparator|Hyperventilation|"Ventilatory settings will be the following:
~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
11095646|NCT04106869|Placebo Comparator|Hypoventilation|"Ventilatory settings will be the following:
~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 ( 40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
11095647|NCT04106856|Experimental|Treatment (losartan, hypofractionated radiation therapy)|Beginning on day 1, patients receive losartan potassium PO QD. Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks. Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy.
11095648|NCT04106843|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30 minutes every 8-16 weeks. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
11095649|NCT04106830||NMOSD|Patients with neuromyelitis optica spectrum disorders
11095650|NCT04106830||Multiple sclerosis(MS)|Patients with multiple sclerosis
11095651|NCT04106830||Health control(HC)|Healthy people without any neuroinflammation disease
11095652|NCT04106817|Experimental|Cohort 1|1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10^6TCID50/dose)
11095655|NCT04106791|Experimental|Closed-loop|Pilot study: one single group of 10 ICU patients.
11095656|NCT04106778|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
11095657|NCT04106778|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
11095658|NCT04106765||: epileptic LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting epileptic seizures as a first symptom
~Evaluated items:
~Number of seizures
~Type of seizures
~Presence of EEG abnormalities
~Presence of IRM abnormalities
~Time before cognitive disorders"
11095659|NCT04106765||cognitive LGI1-antibody patients|"Patients affected by LGI1 antibody encephalitis presenting cognitive disorders as a first symptom
~Evaluated items:
~Presence of EEG abnormalities
~Presence of IRM abnormalities
~Time before epileptic seizures"
11095660|NCT04106752|Active Comparator|meal followed by caffeine|A standardized meal consisting of 2 slices of toast bread, organic peanut butter and jam was given to the participant. One and a half hours later, the participant ingested a caffeinated drink (3 mg per kg body weight of caffeine powder dissolved in water). After 30 mins, resting EE was measured using FM for 15 min while seated on the comfortable seat, and then for 5 min while seated on a cycle ergometer. Participants were then asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively. During cycling, EE was being measured using the FM, HR was monitored and rating of perceived exertion (RPE) was recorded in the last minute of every load cycle.
11095661|NCT04106752|Active Comparator|Caffeine followed by meal|Caffeine was given to the participant. After 1.5 hours the standardized meal was given followed by the same protocol mentioned above.
11095662|NCT04106752|Active Comparator|caffeine only|Caffeine will be given to the participant. 2 hours later the same protocol mentioned above will be applied
11095663|NCT04106752|Active Comparator|Meal only|A standardized meal will be given to the participant. 2 hours later the same protocol mentioned above will be applied.
11095664|NCT04106752|Active Comparator|meal plus caffeine|A standardized meal + a caffeinated drink (3 mg/kg of body weight of caffeine powder dissolved in water) will be given to the participant. 2 hours later resting EE is measured using a facemask (FM) for 10 min while seated on a cycle ergometer . The participant will be asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively.
11095665|NCT04106739|Active Comparator|Active Arm|Active arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate the outer auditory canal. It will deliver with a pulse width of 500 ms. The stimulation frequency pattern is 1.12Hz(hertz), 2.24Hz,4.56Hz, 9.12Hz, 100Hz then 9.12Hz, 4.56Hz,2.28Hz,1.12Hz. This cycle will keep on continuing. An input voltage will be 4.2V(volt).
11095666|NCT04106739|Sham Comparator|Sham Arm|Sham arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate centre of the left ear lobe to a pulse width of 500 ms at same pattern of stimulation frequency mentioned in active PENFS with an input voltage of 4.2V
11095667|NCT04106726|Experimental|Test: Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply cream to the affected areas of the face once daily for 12 weeks.
11095668|NCT04106726|Active Comparator|Reference: Soolantra® cream, 1%|Manufactured by Galderma Laboratories, L.P.; Apply cream to the affected areas of the face once daily for 12 weeks.
11095669|NCT04106726|Placebo Comparator|Placebo: Placebo for Ivermectin cream 1%|Manufactured by Zydus Worldwide DMCC; Apply to the affected areas of the face once daily for 12 weeks.
11095670|NCT04106713|Experimental|Individual Therapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
11095671|NCT04106713|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
11095672|NCT04106713|Experimental|Group CBT|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
11095673|NCT04106713|No Intervention|Delayed Waitlist|Participants in the Waitlist group will be recruited from those referred for psychotherapy and who are not assigned to either group or iCBT and not planned for psychotherapy at IMH for 8 weeks or more from the point of consent.
11095674|NCT04106713|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group are individuals who are not assigned to psychotherapy at IMH. They will be recruited from outpatient services and emergency services at IMH.
11095675|NCT04106700|Experimental|Apixaban (single arm)|
11095676|NCT04106687|Active Comparator|Caudal Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided caudal block wil performe with bupivacaine 1 ml/kg as 0.25%.
11095677|NCT04106687|Active Comparator|Sacral Erector Spinae Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory ultrasound guided sacral erector spinae block wil performe with bupivacaine 1 ml/kg as 0.25%.
11095680|NCT04106661|Experimental|Tai Chi Intervention 1|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
11095681|NCT04106661|Experimental|Tai Chi Intervention 2|The intervention group and control group were recruited during the same time frame. The intervention group received Tai Chi instruction via a weekly group session and home use of a DVD. The control group received no formal instruction in physical activity.
11095682|NCT04106635|Experimental|PP group|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
11095683|NCT04106635|Active Comparator|CP group|During the induction of anesthesia, cricoid pressure is applied by 30N force with three finger.
11095684|NCT04106622||Wolff Parkinson White patients|"The investigators will decide the location of the AP by:
~- Invasively: if the patient is subjected to (EPS)
~• There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF.
~The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions."
11095685|NCT04106609|Experimental|Exercise Group|Patients will complete a 60-minute exercise session once per week for 12 weeks. The exercise sessions will be individualized to the patient's needs and fitness level by a trainer. A patient will work with the same trainer throughout the study, who will plan the patient's individualized exercise regimen, and who will provide one-on-one supervision for the duration of each 60-minute session. Each 60-minute session will include cardiovascular, strength, and flexibility training. The intensity level for the aerobic exercise ranges from 30-45% of the individual's predicted VO2max, controlled by heart monitors and lasting 30 min. Strength training will involve a full body workout, with emphasis on all major muscle groups and employing machines, free weights, and resistance tubing. Patients will complete 3 sets of 10 repetitions for each strength exercise. Flexibility training will involve static stretching of all major muscle groups for 15-20 seconds at the completion of each workout.
11095686|NCT04106609|Active Comparator|Control Group|The control group will receive the current standard of care, which includes a resource guide with various options available to the cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
11095687|NCT04106596||Patients with antibodies against LGI1|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
11095688|NCT04106596||Patients with antibodies against CASPR2|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
11095689|NCT04106596||Patients with antibodies against GAD|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
11095690|NCT04106583||Single Arm|Single Arm - Patients with intracranial aneurysms treated with WAVE, as part of the Penumbra SMART COIL System
11095691|NCT04106570|Experimental|YOMH|Young obese metabolically healthy Description: Aged from 20 to 40 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l.
11095692|NCT04106570|Experimental|YOMD|"Young obese with metabolic disorders
~Description: Aged from 20 to 40 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
11095693|NCT04106570|Experimental|MAOMH|"Middle-Age obese metabolically healthy
~Description: Aged from 40 to 50 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
11095694|NCT04106570|Experimental|MAOMD|Middle-Age obese with metabolic disorders Description: Aged from 40 to 50 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l.
11095695|NCT04106570|Experimental|EOMH|"Elderly obese metabolically healthy
~Description: Aged from 50 to 70 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
11095696|NCT04106570|Experimental|EOMD|"Elderly obese with metabolic disorders
~Description: Aged from 50 to 70 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
11095697|NCT04106557|Experimental|OV101 once daily (weight-based dosing) Other Name:Gaboxadol|OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration
11095698|NCT04106557|Placebo Comparator|Placebo once daily|Matching placebo,oral, provided once daily at bedtime for 12 week duration
11095739|NCT04106271|Experimental|Experimental group|dyadic pain management program will be accessible by the intervention group
11095699|NCT04106544|Other|Acid Sphingomyelinase Deficiency (ASMD) Cohort|Patients across the full spectrum of chronic ASMD who have fulfilled the eligibility criteria and who have performed the inclusion visit
11095700|NCT04106518||cirrhosis|Patients with alcoholic liver disease without alcoholic hepatitis
11095701|NCT04106518||severe alcoholic hepatitis|Patients with severe alcoholic hepatitis ( Maddrey score ≥32)
11095702|NCT04106518||non-severe alcoholic hepatitis|Patients with non-severe alcoholic hepatitis (Maddrey score <32)
11095703|NCT04106505|Experimental|Biofeedback|The treatment comprises an app containing biofeedback training, instructions for self-delivery and a headache diary. The treatment utilizes these functionalities by a push-reminder in the app to complete a daily headache diary entry and a biofeedback session of 10 minutes duration daily. Prior to commencing treatment participants will be given basic information on the rationale behind biofeedback treatment, given instructions on how to use the equipment and software and instructions on how to complete a biofeedback session. The biofeedback is based on wireless sensors measuring muscle tension, finger temperature and heart rate.
11095704|NCT04106505|Sham Comparator|Sham-biofeedback|Sham-biofeedback will be made by disrupting the connection between input of physiological parameters and the feedback. Thus, the feedback will simply be displayed as positive feedback occurring at random intervals throughout the sessions. The looks and contents of the normal app and the sham-app will be completely similar. The participants being allocated to the sham-goup will also use exactly the same sensor setup as the biofeedback group. The only difference between the two arms/interventions is the internal software algorithm, which will be inaccessible to the user. All participants in both groups will be given the same information and instructions.
11095705|NCT04106492|Experimental|SQ3370|
11095706|NCT04106466|Experimental|Deep Brain Stimulation (DBS)|Open label active Deep Brain Stimulation (DBS)
11095707|NCT04106453|Experimental|navigated microwave ablation|microwave ablation is performed laparoscopically with navigation
11095708|NCT04106453|Active Comparator|ultrasound guided microwave ablation|microwave ablation is performed laparoscopically with ultrasound guidance
11095709|NCT04106440|Experimental|Application Use|Participants will be asked to use applications to track food intake, carbohydrate counts, insulin delivered, and blood sugar values and share the data with the study team.
11095710|NCT04106440|No Intervention|Standard of Care|The control group will receive usual care during their hospitalizations at the time of diabetes diagnosis, and during the time between hospital discharge and first visit to the UCD Pediatric Diabetes clinic.
11095711|NCT04106427|Experimental|cTBS plus SCRT|10 daily sessions of continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
11095712|NCT04106427|Placebo Comparator|Placebo plus SCRT|10 daily sessions of placebo continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
11095713|NCT04106427|Sham Comparator|Sham SCRT|16 sessions of sham social cognitive remediation therapy (SCRT) twice per week over an eight week period. Participants will engage in non-effective group activities
11095714|NCT04106414|Experimental|Nivolumab alone|Nivolumab 480 mg every 4 weeks.
11095715|NCT04106414|Experimental|Nivolumab with IDO-inhibitor, BMS- 986205|Nivolumab 480 mg every 4 weeks with BMS-986205 100 mg.
11095716|NCT04106401|Experimental|hypoxia & confinement|Participants exposed to high-altitude hypoxia and confinement during a one-year stay at Concordia station, Antarctica (3200 m)
11095717|NCT04106401|Active Comparator|confinement|Participants exposed to confinement during a one-year stay at Dumont d'Urville station, Antarctica (sea level)
11095718|NCT04106388|Experimental|Virtual Behavioral Health Integration|All patients who meet eligibility criteria at sites where the virtual behavioral health program is offered will be considered exposed to the intervention.
11095719|NCT04106388|No Intervention|Usual Care - Behavioral Health|All patients who meet eligibility criteria at sites where the virtual behavioral health program is not offered will be considered exposed to usual care.
11095720|NCT04106375|Experimental|Intervention Group|Women with a history of depression and no other mental health disorders undergoing Mindfulness Based Cognitive Therapy.
11095721|NCT04106375|No Intervention|Control|Healthy women with no prior history of depression or other mental health disorders as a control group for time-repetition effects on brain activity and task performance
11095722|NCT04106362|Active Comparator|Arm I (radiation therapy, cisplatin)|Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions. Patients also receive cisplatin IV over 1-2 hours on days 0 and 21.
11095723|NCT04106362|Experimental|Arm II (cetuximab, radiation therapy, cisplatin)|Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks. Patients also undergo radiation therapy and receive cisplatin as in Arm I.
11095724|NCT04106349||1st line|
11095725|NCT04106349||2nd line|
11095726|NCT04106349||later lines|
11095727|NCT04106336|No Intervention|non cannabis addict|30 non cannabis addict will be control group
11095728|NCT04106336|Active Comparator|cannabis addict|30 cannabis addict will undergo rTMS
11095729|NCT04106310|Active Comparator|Theranova|Patients will be receiving hemodialysis using Theranova dialyzer. The other hemodialysis parameters are kept the same.
11095730|NCT04106310|Active Comparator|High-flux|Patients will be receiving hemodialysis using a high-flux dialyzer. The other hemodialysis parameters are kept the same
11095731|NCT04106297|Experimental|GLPG3970 SAD|Single doses of GLPG3970 at up to 6 dose levels in ascending order
11095732|NCT04106297|Placebo Comparator|Placebo SAD|Single doses of placebo
11095733|NCT04106297|Experimental|GLPG3970 MAD|Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days
11095734|NCT04106297|Placebo Comparator|Placebo MAD|Multiple doses of placebo
11095735|NCT04106297|Experimental|GLPG3970 FE-rBA|Single dose of GLPG3970 in fed and fasted state
11095736|NCT04106297|Experimental|GLPG3970 FE|Single dose of GLPG3970 in fed and fasted state
11095737|NCT04106297|Experimental|GLPG3970 in psoriasis subjects|
11095738|NCT04106297|Experimental|Placebo in psoriasis subjects|
11095740|NCT04106271|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
11095741|NCT04106258|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
11095742|NCT04106258|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
11095743|NCT04106245|Experimental|Supportive care (PACK health coach, survey)|Patients are contacted once weekly by a health coach by text message, phone call, email, or a mobile application, for 3 months. The total time interacting with the health coach is about 3.5-4.5 hours across the study. Patients also complete surveys over 30 minutes each time at baseline and every 30 days for 3 months.
11095744|NCT04106219|Experimental|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
11095745|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
11095746|NCT04106219|Experimental|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
11095747|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
11095748|NCT04106206|Experimental|LY3372689|LY3372689 administered orally
11095749|NCT04106206|Placebo Comparator|Placebo|Placebo administered orally
11095750|NCT04106193|Experimental|Toolkit + Implementation as Usual|Participating clinics assigned to this arm will receive a guiding toolkit and implementation as usual regarding IPV screening practices.
11095751|NCT04106193|Experimental|Toolkit + Blended Facilitation|Participating clinics assigned to this arm will receive a guiding toolkit and blended facilitation to support IPV screening practices.
11095752|NCT04106180|Experimental|SBRT + sintilimab + GM-CSF|
11095753|NCT04106167||Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy|Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
11095754|NCT04106154|Experimental|Intervention|The kinesiology intervention will involve physical activity education appropriate to the MC&D delivered in a group format through twelve 2.5-hour weekly sessions49 (30 hours of kinesiology support). The sessions will combine participation in physical activities appropriate to the MC&D with education and goal-setting discussions. Each week, children will be guided to develop an individualized SMART (Specific, Measurable, Agreed upon, Realistic, Time-based) plan for changing their activity behaviour. Their weekly SMART plan, which will require an additional 2 hours per week, will specify the home/community activities they will do prior to the next session.
11095755|NCT04106154|No Intervention|Control|Patients in the control group will continue with clinical care as usual. To encourage their cooperation, children in the control group will be offered the intervention after all of their study visits have been completed.
11095756|NCT04106141|Other|control group|
11095757|NCT04106141|Active Comparator|intervention group|
11095758|NCT04106128|Experimental|ultrasound examination|Assess the prevalence of acute diaphragmatic dysfunction by ultrasound
11095759|NCT04106115|Experimental|Durvalumab + S-488210/S-488211|Trial treatment for up to 24 weeks of Durvalumab (1500 mg IV infusion every 4 weeks for up to 7 doses) in combination with S-488210/S-488211 vaccine (given as 2 subcutaneous injections of S-488210/Montanide and S-488211/Montanide starting day after first durvalumab dose, then weekly for the first 6 weeks, and then every 2 weeks for a further 9 doses).
11095760|NCT04106102|Active Comparator|Transcramial Direct current stimulation|Implement of Transcramial Direct current stimulation
11095761|NCT04106102|Placebo Comparator|Placebo|
11095762|NCT04106089|Experimental|Observation-Intervention-Observation|5 days of observation, 5 days of extended vitals check, 5 days returning to regular vitals checks
11095763|NCT04106089|Experimental|Observation-Observation-Intervention|5 days of observation, 5 more days of observation, 5 days of extended vitals check
11095764|NCT04106076|Experimental|Dose escalation|Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.
11095765|NCT04106063||deaf children|All Children between 7 and 17 years old attending medical appointment for temporary or persistent deafness in our Ear, Nose and Throat (ENT) department
11095766|NCT04106050|Experimental|Part A: BIIB095 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 1 capsules from Day 1 to Day 8.
11095767|NCT04106050|Experimental|Part A: BIIB095 Dose 2|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 2 capsules from Day 1 to Day 8.
11095768|NCT04106050|Experimental|Part A: BIIB095 Dose 3|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 3 capsules from Day 1 to Day 8.
11095769|NCT04106050|Placebo Comparator|Part A: BIIB095 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB095 capsules from Day 1 to Day 8.
11095770|NCT04106050|Active Comparator|Part A: Lidocaine|Healthy participants and participants with DPN will receive single injection of lidocaine for partial nerve conduction block and single injection of lidocaine for skin infiltration on Day 8.
11095771|NCT04106050|Experimental|Part B: BIIB074 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB074 Dose 1 tablets from Day 1 to Day 8.
11095772|NCT04106050|Placebo Comparator|Part B: BIIB074 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB074 tablets from Day 1 to Day 8.
11095773|NCT04106037||Legionnaires' disease|All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
11095774|NCT04106011||Patients with Neuropathic Pain|
11095775|NCT04105998|Experimental|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU) at the first visit. Then at the next visit, they will receive Intramuscular injection of (1 milliliter) saline.
11095776|NCT04105998|Experimental|Placebo, Then Oxytocin|Subjects in this arm will receive intramuscular injection of (1 milliliter) saline at the first visit. Then at the next visit, they will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU).
11095777|NCT04105985|Experimental|Kovanaze Nasal Spray (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
11095778|NCT04105985|Active Comparator|Articaine Injections (endodontics)|Adults (>18 years) who require non-surgical root canal treatment in maxillary anterior teeth
11095779|NCT04105972|Experimental|ELX/TEZ/IVA|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
11095780|NCT04105972|Active Comparator|TEZ/IVA|Subjects will receive TEZ/IVA FDC in the morning and IVA as mono tablet in the evening.
11095781|NCT04105959|Experimental|RIST4721 300mg|RIST4721 as once-daily 300mg oral solution for 6 days with a placebo crossover.
11095782|NCT04105959|Experimental|RIST4721 150mg|RIST4721 as once-daily 150mg oral solution for 6 days with a placebo crossover.
11095783|NCT04105946|Active Comparator|OFA Group|patients undergoing FESS under opiod free anesthesia
11095784|NCT04105946|Active Comparator|TIVA Group|patients undergoing FESS under total intravenous anesthesia
11095785|NCT04105933|Experimental|CS-CBT|Culturally sensitive-CBT intervention was comprised of 16 sessions of cognitive behavioral therapy focused on culturally-specific beliefs and attitude.
11095786|NCT04105933|Active Comparator|CBT|CBT intervention was comprised of 16 sessions of cognitive behavioral therapy.
11095787|NCT04105920|Experimental|hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
11095788|NCT04105920|Active Comparator|Conventional brachytherapy|Patients included in this arm will have the conventional brachytherapy.
11095789|NCT04105907|Experimental|Partial root canal treatment with the Sonendo GentleWave|
11095790|NCT04105881||Full term labor|Measured by flow cytometry and ELUSA
11095791|NCT04105881||Preterm labor|Measured by flow cytometry and ELISA
11095792|NCT04105881||Control|For comparison
11095793|NCT04105868|Experimental|Neurofeedback|Participants will receive feedback about their attention to negative distractors during each trial using activity from their brain waves, which will help them reduce their attention to distractors.
11095794|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
11095795|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
11095796|NCT04105842|Experimental|Delfilcon A|All study participants will be refit with Delfilcon A (Dailies Total 1) lenses which they will wear for 1 month.
11095797|NCT04105829|Experimental|Tooth color measurement|Tooth color changes between times (before retainer bonding, after retainer bonding, in 1 month, 3 months, 6 months and a year)
11095798|NCT04105816|Placebo Comparator|Adult Healthy Controls|Subjects included in part I of this study will be healthy adult volunteers with no known musculoskeletal injury. Exclusion criteria will be those with identified musculoskeletal injury, non-English speaking persons, and women who are pregnant.
11095799|NCT04105816|Experimental|Adult ACL Reconstruction Patients|Subjects included in part II of the study will be adult volunteers undergoing anterior cruciate ligament reconstruction at the University of Iowa. Exclusion criteria will be non-English speaking persons, women who are pregnant, patients undergoing multi-ligament repair, patients undergoing ACL reconstruction revision, patients undergoing concomitant cartilage or meniscal repair procedures, and patients undergoing bilateral ACL reconstructions.
11095800|NCT04105803||De novo HTx|"Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.
~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).
~Procedure: is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.
~Diagnostic test: Echocardiography and coronary angiography is part of the scheduled standard HTx follow-up visits."
11095801|NCT04105803||Longterm HTx|"Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).
~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.
~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
11095802|NCT04105803||PET-scan de novo HTx|"Radiation: Two PET-scans with 11C-acetate tracer will be performed.
~Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.
~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).
~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.
~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
11095803|NCT04105790|Experimental|Participants|Participants in class-based mental health intervention.
11095804|NCT04105777||Standard Low Glucose Parenteral Nutrition using Eurotubes®|Patients receive standard PN reduced in glucose in Eurotubes®.
11095805|NCT04105777||Standard Parenteral Nutrition using Eurotubes®.|Patients receive standard PN in Eurotubes®.
11095806|NCT04105777||Standard Parenteral Nutrition using 2/3-chamber bags|Patients receive PN according to the routine used by the participating site.
11095807|NCT04105764|Active Comparator|DEEP BLOCK|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
11095808|NCT04105764|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
11095809|NCT04105751|Experimental|Use of Device with post-use interview/questionnaire|All patients will be asked to utilize device and will then be asked to provide feedback on their experiences. This may be done by interview or a questionnaire. There could be up to three sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, session could last up to one hour.
11095810|NCT04105738||Difficult airways|Documented history of difficult airways.
11095811|NCT04105738||Control (Not difficult airways)|Age matched with normal airways to be used as controls
11095812|NCT04105725|Experimental|BMI+Substance-Free Activity Session|Two 50-minute text messaging sessions that discuss alcohol use and experiences related to alcohol use, as well as the individual's college, career, and personal goals. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that return to the individual's goals and progress.
11095813|NCT04105725|Active Comparator|Alcohol + Nutrition Education Session|Two 50-minute text messaging sessions the provide information on alcohol and nutrition. Additionally, there are 4 weeks of 20-30-minute booster text messaging sessions (once a week) that provide additional information and review previous information about alcohol use and nutrition.
11095814|NCT04105712|Experimental|Pre and Post Dietary Change (within subjects)|Participants do an initial call for baseline data. Then the active assessment period (pre / post dietary change) begins. Pre - dietary change procedure is 5 days of standard high HP diet while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Post - dietary change is 5 days of lower HP diet (food provided for 3 of 5 days) while completing daily electronic assessments of withdrawal, ecological momentary assessments, and a phone appointment. Daily assessments of affect, craving, and withdrawal are all virtual. On day 4-5 of post assessment, participants complete a food journal to report foods they ate to ensure compliance to low HP food diet. The pre / post-dietary change phone appointments include 1) psychosocial stress task, 2) cue reactivity task, 3) questionnaires 4) self-reported weight. Participants may also complete a follow up period of questionnaires every other day and self-report weight at the end of follow up.
11095815|NCT04105699||Device: Blood sampling|
11095816|NCT04105686|Active Comparator|Control Infant Formula|Milk-based study product
11095817|NCT04105686|Experimental|Experimental Infant Formula|Milk-based study product with oligosaccharides
11095818|NCT04105686|No Intervention|Reference Group|Human milk-fed group
11095819|NCT04105673||Shaken Baby Syndrome|Realization of a clinical examination and survey on children with a past history of a Shaken Baby Syndrome
11095820|NCT04105660|Experimental|Intervention arm|EEG monitoring in addition to standard monitoring (clinical parameters and BIS index)
11095821|NCT04105660|Active Comparator|Control arm|Standard monitoring including clinical parameters and BIS index
11095822|NCT04105647|Experimental|Experimental group|Patients in the experimental group will receive a face-to-face group session and a package of healthy lifestyle instant messages, including lifestyle-integrated exercise and physical activity.
11095823|NCT04105647|Placebo Comparator|Control group|The control group will receive a face-to-face group session and a package of healthy lifestyle instant messages, but not related to lifestyle-integrated exercise and physical activity.
11095824|NCT04105634|Experimental|Inflammation group|Patient diagnosed with Cardiac Amyloidosis
11095825|NCT04105634|Experimental|Amyloid group|Patient diagnosed with Cardiac Amyloidosis
11095826|NCT04105621||Drug addicts|This group included drug addicts lived in drug rehablitation center.
11095827|NCT04105621||Healthy population|We recruited the healthy participants from the Westlake N-of-1 Trials for Macronutrient Intake (NCT04125602) as healthy control
11095828|NCT04105608|Experimental|HFV meal|A vegetarian meal high in dietary carbohydrate and fiber
11095829|NCT04105608|Active Comparator|MED meal|A Mediterranean-like meal
11095830|NCT04105595||ASD patients|
11095831|NCT04105595||PFO patients|
11095832|NCT04105582|Experimental|Neo-antigen pulsed Dendritic cell|Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)
11095833|NCT04105569|Experimental|Healthy Volunteers|Enrolled subjects will be included in an experimental gingivitis model (SIBO) for 21 days and use an acrylic stent fabricated before and dispensed at the baseline appointment
11095834|NCT04105556|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
~Care was given when the child and his / her parents applied to the outpatient clinic for anesthesia consultation on the working day before the operation, and care was continued in the day surgery unit. On the 1st and 3rd days after discharge, the researcher provided tele-monitoring and consultancy services. In addition, communication with the parents was maintained at all times as needed. Care was terminated on the 10th day after discharge. The time of the study was approximately 12-14 days for each child and his / her parents.
~Nursing care consists of 3 types of comfort-oriented care interventions. These interventions;
~Standard maintenance interventions,
~Emotional focused comfort care interventions,
~Cognitive and functional comfort care interventions."
11095835|NCT04105556|No Intervention|Routine hospital schedule|"The researcher sincerely answered all questions asked by the control group during the perioperative period.
~After the post-discharge post-tests, the control group was given a gift of medal of courage, a story book and a training booklet prepared for the parents after the policlinic control on the 10th postoperative day, and the training was given to the intervention group."
11095836|NCT04105543|Experimental|CLR 131 Dose Escalation|"Enrollment will start at dose level 1 (first 4 participants). Participants will receive 2 doses of CLR 131 intravenously with the first dose on day 1 followed by the second dose on day 8.
~Dose Level -1 (de-escalation dose, if toxicities warrant) = 12.5 mCi/m^2 Dose Level 1 (beginning dose) = 15.6 mCi/m^2 Dose Level 2 (escalation dose) = 18.75 mCi/m^2
~Dose escalation will proceed with no limiting toxicities at each level (maximum of 8 participants at each dose level). With maximum tolerated dose confirmed, an expansion phase will proceed."
11095837|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 1|"One stimulation will be conducted using Anodal treatment.
~The Direct Current Anodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session."
11095838|NCT04105530|Active Comparator|Transcranial direct current stimulation (tDCS) on day 2|A final stimulation will be conducted using Cathodal stimulation. Direct Current Cathodal Stimulation will be applied for 20 minutes for each stimulation period. Brief neurocognitive testing will be conducted during each stimulation session.
11095839|NCT04105530|Placebo Comparator|Sham treatment|"The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes.Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial:"
11095840|NCT04105504|Experimental|Glutathione Group|Subjects were randomised to receive Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
11095841|NCT04105504|Placebo Comparator|Placebo Group|Subjects were randomised to receive Placebo capsules, which were identical in appearance and packaged in identical-looking containers with the Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
11095842|NCT04105491||Aligner Patients|Patients who decided to be treated with Invisalign® aligners
11095843|NCT04105478|Experimental|Un-cemented Comprehensive Nano stemless shoulder arthroplasty|"By using a stemless humeral component stem-related complications can be reduced. Furthermore, the canal preserving design may also facilitate further surgery should the need of a revision prosthesis arise.
~Currently, little is known about the results of the stemless design. The initial results have been promising, but as with the stemmed design migration and eventually loosening of the prosthesis can lead to poor results and, in some cases, revision"
11095844|NCT04105478|Active Comparator|Un-cemented Comprehensive stemmed total shoulder arthroplasty|A design with a metal stem in the humeral bone canal is currently regarded as the best treatment option, but complications related to the stem including humeral fractures can have devastating consequences.
11095845|NCT04105465|No Intervention|Surgery without trial (PJ) device|All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
11095846|NCT04105465|Active Comparator|Surgery with trial (PJ) device|Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.
11095847|NCT04105439||control|healthy subjects who do not have the disease
11095848|NCT04105439||patients with Behçet's disease|subjects who do have the disease ( Behçet's disease )
11095849|NCT04105426|Active Comparator|Antioxidants|This arm of patients received one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
11095850|NCT04105426|Placebo Comparator|Placebo|This arm of patients received placebo for 3 months.
11095851|NCT04105387|No Intervention|Control Group|Tracheostomy change at day 7
11095852|NCT04105387|Experimental|Treatment Group|Tracheostomy change at day 4
11095853|NCT04105374|Active Comparator|Arm I (surgery, radiation therapy, temozolomide)|Beginning on week 5 following standard of care surgery, patients undergo radiation therapy over 30 fractions 5 days per week for up to 6 weeks, and receive temozolomide PO QD for up to 49 days. At the discretion of treating physician, patients may also receive novoTTF-100A (Optune) device 0-7 weeks following radiation and temozolomide treatment. One month following completion of radiation therapy, patients continue to receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11095854|NCT04105374|Experimental|Arm II (Toca 511, Toca FC, radiation therapy, temozolomide)|Patients receive vocimagene amiretrorepvec via intracranial injection during surgery on day 1. Beginning on week 5 following surgery, patients receive extended release flucytosine PO TID for 7 consecutive days every 7 weeks. Patients also undergo radiation therapy and receive temozolomide as in arm I. After completion of radiation therapy and at the discretion of the treating physician, patients may continue to receive extended release flucytosine PO TID for 7 consecutive days every 8 weeks in the absence of disease progression or unacceptable toxicity.
11095855|NCT04105361|Experimental|Study group|We will do posterior nasal neurectomy in patients with allergic rhinitis after FESS in one side of the nose
11095856|NCT04105361|Experimental|Control group|We will do FESS only in the other side of the nose
11095857|NCT04105348||IBD with DM|
11095858|NCT04105348||IBD without DM|
11095859|NCT04105335|Experimental|Cohort 1 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 70mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
11095860|NCT04105335|Experimental|Cohort 2 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 98mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
11095861|NCT04105335|Experimental|Cohort 3 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 130mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
11095862|NCT04105335|Experimental|Expansion Cohort MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA RP2D administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
11095863|NCT04105322|Experimental|Kinesio Taping on Abdominal Muscles|
11095864|NCT04105322|Experimental|Kinesio Taping on Back Muscles|
11095865|NCT04105322|No Intervention|Control|
11095866|NCT04105309|Experimental|Implementation Intention (IMP)|"Following review of a psychoeducational packet regarding making changes for weight loss, all participants were assigned five dietary goals (e.g. avoiding high-fat foods, eating five servings of fruits and vegetables a day) and a goal to weight daily. Participants in the IMP condition formed an implementation intention for each of the goals at the baseline session. Two examples of implementation intentions were provided for each goal as a model. Participants thought about how they would best be able to achieve the outlined goals in their life on a daily basis (goal-aligned behavior), as well as when, where, and how they would initiate these new behaviors (retrieval cue). Participants then created and wrote down a unique implementation intention for each of the goals using the sentence structure If/When I _______, then I will ______. No repetitions or combinations of implementation intentions were allowed for standardization across participants."
11095923|NCT04104997|Placebo Comparator|The D group in placebo|Six administration both eyes, each 2 drop in Caucasian
11095953|NCT04104776|Experimental|Combination Therapy|CPI-0209 will be dosed once per day orally in 21 day cycles. Irinotecan iv will be dosed on day 1 of every cycle.
11095867|NCT04105309|Experimental|Enhanced Implementation Intention (IMP+)|Participants completed all tasks of the IMP group and additionally, individuals in the IMP+ condition received fluency training and text message reminders. Fluency training occurred weekly using an online survey tool. On fluency training days, participants received a survey link via email, which consisted of six multiple-choice questions for participant's unique implementation intentions. Participants had to correctly identify their matching goal-aligned behavior among three distractor behaviors as quickly as possible and were given corrective feedback if they chose incorrectly. Text messages containing all six implementation intentions as well as goal reminders that were obtained by asking participants to write down their reasons for wanting to lose weight were sent on four days each week of the intervention (16 days total). At baseline, participants chose how text messages were bundled and when they were sent. Text schedules stayed constant across the study.
11095868|NCT04105309|Active Comparator|Goal Intentions (GOL)|Participants in the GOL condition were assigned the five dietary goals and the daily weighing goal. No additional intervention was given.
11095869|NCT04105296|Experimental|EKSO+ES|6 months of exoskeleton training with spinal cord epidural stimulation.
11095870|NCT04105283|Experimental|Tc99m-MAA|"Tc99m-MAA will be administered by selective or supra-selective arterial injection via the bronchial artery or branches thereof.
~Administration will occur over a period of 30-240 seconds"
11095871|NCT04105270|Experimental|Arm A|
11095872|NCT04105270|Experimental|Arm B|
11095873|NCT04105257|Other|All patients|All patients seen at emergency with acute neurological deficit will be assessd if eligible to CTP/MRI
11095874|NCT04105244|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post-enrollment plus the current standard of care, whereby caregivers phone their healthcare providers when they have questions or concerns
11095875|NCT04105244|Experimental|Resourcefulness Training Intervention©|The Resourcefulness Training© arm will receive (a) individually tailored instruction on personal and social resourcefulness skills via the Resourcefulness Video and intervention nurse, (b) journal-writing instruction to describe resourcefulness application, (c) access to the study website with videotape vignettes and Resourcefulness Video, and (d) boosters at 2 and 4 months post-enrollment that will include reinforcement of skills learned and additional journal writing.
11095876|NCT04105231|Experimental|Cannabidiol|Cannabidiol 150 mg capsule, 2 capsules by mouth for 4 days, then increased to 2 capsules (300 mg) 2 times daily with a total treatment duration of 6 weeks
11095877|NCT04105231|Active Comparator|Risperidone|Risperidone 1 mg tablet, 2 capsules by mouth for 4 days, then increased to 2 capsules (2 mg) 2 times daily with a total treatment duration of 6 weeks
11095878|NCT04105218|Experimental|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
11095879|NCT04105218|Placebo Comparator|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
11095880|NCT04105205|Experimental|Apramycin injection in escalating doses|Apramycin, solution for infusion.
11095881|NCT04105205|Placebo Comparator|Placebo|Physiological saline, solution for infusion.
11095882|NCT04105192|Experimental|experimental group (Lippia citriodora + sabdariffa)|"Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.
~Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days."
11095883|NCT04105192|Placebo Comparator|control group Placebo (sucrose)|Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg or Placebo (sucrose) Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days.
11095884|NCT04105179|Experimental|Implant Groups|Group will receive the Smith & Nephew Journey II knee implant or the Zimmer NexGen LPS-Flex knee implant
11095885|NCT04105179|No Intervention|Healthy Control Group|Control group that will not be undergoing a total knee arthroplasty
11095886|NCT04105166|Experimental|RP-L301|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
11095887|NCT04105153||TKI-treated advanced EGFR+ NSCLC|Patients with advanced EGFR-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors
11095888|NCT04105140|Experimental|male oxytocin group|male subjects with oxytocin treatment
11095889|NCT04105140|Placebo Comparator|male placebo group|male subjects with placebo treatment
11095890|NCT04105127|Active Comparator|Anterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the palatal surfaces of central upper incisors
11095891|NCT04105127|Active Comparator|Posterior builds-ups|Intervention orthodontic - fixed orthodontic treatment in patients with overbite reduction: fixed orthodontic treatment with resin build-ups bonded to the occlusal surfaces of first or second upper/lower molars
11095892|NCT04105114|Experimental|Complete Spinal Cord Injury - Gravity Neutral Stepping|Group 1 will begin with a 3-4-month preparation phase and up to 12 sessions in the gravity neutral device (GND) will occur. The training sessions in the GND will be used to obtain the optimal stimulation parameters. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. This will be done in the GND in the presence of stimulation. Afterwards, Intervention 2 will include the same training procedures with the addition of Buspirone or Placebo in a cross-over fashion halfway through this phase.
11095893|NCT04105114|Experimental|Complete Spinal Cord Injury - Exoskeleton Assisted Stepping|Group 2 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours in the Ekso overground, in the presence of stimulation and Buspirone/placebo. The second phase will include the same training procedures except for the removal of Buspirone/placebo administration. The third phase will include sessions twice per week in the Ekso overground with stimulation and one day per week using a rolling walker with stimulation. The last phase will include 2 sessions per week using the rolling walker and one day per week in the Ekso, both in the presence of stimulation and Buspirone/placebo.
11095894|NCT04105114|Experimental|Incomplete Spinal Cord Injury - Overground Stepping|Group 3 will begin with a 3-month preparation phase and up to 12 sessions in the Ekso device stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. The first hour will be done in the Ekso overground and the second hour will use the rolling walker overground, both in the presence of stimulation. Afterwards, the second phase will include the same training procedures with the addition of Buspirone/placebo.
11095895|NCT04105101|Experimental|Prototype exoskeleon|The experimental trial will be performed with the prototype exoskeleton
11095896|NCT04105101|Experimental|Skel-Ex|The experimental protocol will be performed with the commercially available Skel-Ex 360 (Skel-Ex, Rotterdam, The Netherlands)
11095897|NCT04105101|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
11095898|NCT04105088||Randomly-Sampled|Adults aged 30+ living in one of the First Nations communities whose household was randomly-sampled.
11095899|NCT04105088||Walk-in Volunteers|Adults aged 30+ living in one of the First Nations communities who is a walk-in study volunteer, not randomly-sampled.
11095900|NCT04105075||Patients with COPD and obesity|Patients consented to have a blood sample taken
11095901|NCT04105075||Normal body weight patients with COPD|Patients consented to have a blood sample taken
11095902|NCT04105062|Experimental|Phase I: LS301 Dose Level 1 (0.05 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.
~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.
~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
11095903|NCT04105062|Experimental|Phase I: LS301 Dose Level 2 (0.075 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.
~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.
~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
11095904|NCT04105062|Experimental|Phase I: LS301 Dose Level 3 (0.1 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.
~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.
~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
11095905|NCT04105062|Experimental|Phase II: LS301 Dose determined in Phase I|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.
~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.
~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
11095906|NCT04105036||45-54 years of age|Divided into two subgroups: individuals who are and are not socially deprived
11095907|NCT04105036||54-64 years of age|Divided into two subgroups: individuals who are and are not socially deprived
11095908|NCT04105036||65-74 years of age|Divided into two subgroups: individuals who are and are not socially deprived
11095909|NCT04105036||75-85 years of age|Divided into two subgroups: individuals who are and are not socially deprived
11095910|NCT04105023|Experimental|genistein|Genistein capsules of 25 mg each, 50mg/day
11095911|NCT04105023|Placebo Comparator|placebo|Maltodextrin capsules, administered orally once every 12 hours
11095912|NCT04105010|Experimental|Group A|Group A: Open label AZD4205 dose A, once daily
11095913|NCT04105010|Experimental|Group B|Group B: Open label AZD4205 dose B, once daily
11095914|NCT04105010|Experimental|Group C|Open label AZD4205 selected dose from group A and B, once daily
11095915|NCT04105010|Experimental|Group D|Open label AZD4205 RP2D, once daily
11095916|NCT04104997|Experimental|The A group in 5% GLH8NDE|Three times administration both eyes, each 1 drop in Korean
11095917|NCT04104997|Placebo Comparator|The A group in placebo|Three times administration both eyes, each 1 drop in Korean
11095918|NCT04104997|Experimental|The B group in 5% GLH8NDE|Six administration both eyes, each 1 drop in Korean
11095919|NCT04104997|Placebo Comparator|The B group in placebo|Six administration both eyes, each 1 drop in Korean
11095920|NCT04104997|Experimental|The C group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Korean
11095921|NCT04104997|Placebo Comparator|The C group in placebo|Six administration both eyes, each 2 drop in Korean
11095922|NCT04104997|Experimental|The D group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Caucasian
11095924|NCT04104984|Experimental|control group not follow NICE guide lines|All pregnant women who fulfil the same inclusion criteria, exclusion criteria, diagnoses established as short cervix , and do not managed according to NICE guide lines will be treated and managed according to their units as a control group.
11095925|NCT04104984|Experimental|study group follow NICE guide lines|- All pregnant women will attend hospital between 14-24 weeks and fulfil inclusion and exclusion criteria will be approached for possibility to be included in the study . and will be managed according NICE guide lines
11095926|NCT04104971||with complications|children who did liver transplantation and develop complications
11095927|NCT04104971||without complications|children who did liver transplantation and do not develop complications
11095928|NCT04104958||Group 1|"Group 1 (n=50): women (age 20-40year) with PCOS who are diagnosed according to the criteria of the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003), which require two of the following 3 manifestations:
~oligo- or anovulation,
~clinical and/or biochemical signs of hyperandrogenism (> 2.08 nmol/l),
~polycystic ovaries on ultrasound examination (the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume > 10 cm)"
11095929|NCT04104958||Group 2|Group 2 (n=50): women (age 20-40 year) with male factor infertility.
11095930|NCT04104945|Experimental|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
11095931|NCT04104932||Surgical group|Patients with isolated minor rib fractures received surgical stabilization.
11095932|NCT04104932||Conservative group|Patients with isolated minor rib fractures received conservative treatment, such as NSAIDs.
11095933|NCT04104919|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
11095934|NCT04104919|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
11095935|NCT04104906|Experimental|motor control training|8-week exercise program, twice a week, with motor control training
11095936|NCT04104906|Active Comparator|exercises|8-week exercise program, twice a week.
11095937|NCT04104893|Experimental|Single Arm|This is a single-arm, open-label study of the checkpoint inhibitor, pembrolizumab, in Veterans with mCRPC who have progressed on at least 1 prior novel androgen receptor (AR) signaling inhibitor, inclusive of abiraterone acetate, enzalutamide, apalutamide, and darolutamide. In addition to progressive mCRPC, a patient must have a somatic tumor mutation characterized by dMMR or CDK12-/- detected by next generation sequencing (NGS). Patients enrolled in this study will be treated with pembrolizumab at the FDA approved dosage of 200 mg intravenously every 3 weeks (21 days) until disease progression or unacceptable toxicity. During study, patients will maintain a castrate level of testosterone, = 50 ng/dL by ongoing treatment with a GnRH analogue or prior bilateral orchiectomy. Prior to initiating treatment with pembrolizumab, patients will undergo a baseline biopsy of a metastatic lesion. An additional biopsy of a metastatic lesion at the time of progression will be encouraged as well.
11095938|NCT04104880|Experimental|Continuous Positive Airway Pressure (CPAP) group|Three-month CPAP use
11095939|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Itopride|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
11095940|NCT04104867|Placebo Comparator|Colonoscopy preparation by PEG-EL with Placebo|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
11095941|NCT04104867|Active Comparator|Colonoscopy preparation by PEG-EL with Domperidone|Regular protocol for colonoscopy preparation, no solid foods are allowed except low residue diet during three days before the procedure. On the next day, only liquid diet consumption is allowed.On the day prior to colonoscopy, the patients can have only clear liquid and ad libitum throughout the day until midnight. They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours one day befor colonoscopy.
11095942|NCT04104854|Experimental|drug coated balloon|A total of 110 patients are assigned to drug coated balloon treated group after randomization schedule.
11095943|NCT04104854|No Intervention|drug eluted stent implantation|A total of 110 patients are assigned to drug eluted stent treated group after randomization schedule.
11095944|NCT04104841|Experimental|Behaviorally Enhancing Adolescents' Mood in Schools (BEAMS)|8-session modified behavioral activation program
11095945|NCT04104841|Active Comparator|Usual Care|Referrals to usual care
11095946|NCT04104828||Grass/tree AIT with Allergovit|Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.
11095947|NCT04104828||Grass/tree AIT with Polvac|Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.
11095948|NCT04104828||Grass/tree AIT with Pollinex Quattro|Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.
11095949|NCT04104815|Experimental|Experimental Thickener|Powder thickener
11095950|NCT04104789|Experimental|Kovanaze Nasal Spray (General Practice)|Adults who require restorations in the maxillary teeth that would need local anesthesia
11095951|NCT04104789|Active Comparator|Articaine Injections (General Practice|Adults who require restorations in the maxillary teeth that would need local anesthesia
11095952|NCT04104776|Experimental|Monotherapy|CPI-0209 will be dosed once per day orally in 28 day cycles
11095954|NCT04104737|Experimental|Spire Medical Health Tag|Spire Medical Health Tag is worn by all subjects The study is open label
11095955|NCT04104724|Experimental|Self-help|Immediate access to self-help materials
11095956|NCT04104724|No Intervention|Control|Wait-list control - treatment as usual (no intervention)
11095957|NCT04104711|Experimental|Home visits+Health education group|"Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals.
~Nursing interventions were applied in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants and were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, oral care and foot care. In addition, the importance of annual monitoring of HBA1c, blood lipid, albumin/ creatinine levels, fundus examination, blood pressure monitoring, sleep hygiene, avoidance of smoking and alcohol was also explained."
11095958|NCT04104711|No Intervention|No nursing intervention group|"The participants in the control group who have standart care by other health services were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools only. They have no nursing intervention by the researcher.
~At the end of the study, for ethical statement the participants in the control group were given health training and the training booklet was distributed to them."
11095959|NCT04104698||Study Group (MDD with SIs)|25 Egyptian patients diagnosed with major depression (with suicidal ideations)
11095960|NCT04104698||Control group (MDD without SIs)|25 Egyptian patients diagnosed with major depression (without suicidal ideations)
11095961|NCT04104685|Experimental|FCD105 Foam|FCD105 Foam
11095962|NCT04104685|Active Comparator|3% Minocycline Foam|3% Minocycline Foam
11095963|NCT04104685|Active Comparator|0.3% Adapalene Foam|0.3% Adapalene Foam
11095964|NCT04104685|Placebo Comparator|Vehicle Foam|Vehicle Foam
11095965|NCT04104672|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.
11095966|NCT04104672|Experimental|Dose Expansion (AB680 + Zimberelimab + NP/Gem)|The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with Zimberelimab at the RP2D and the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.
11095967|NCT04104672|Experimental|Dose Expansion (AB680 + NP/Gem)|The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.
11095968|NCT04104659|Experimental|MK 6240|
11095969|NCT04104646|Experimental|CHF6563|Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
11095970|NCT04104646|Active Comparator|Morphine|Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.
11095971|NCT04104633|Other|Patients with breast or colorectal cancer|10 patients with invasive breast carcinoma, not otherwise specified (NOS) (Stade I to III) and 10 patients with invasive colorectal adenocarcinoma (Stade I to III)
11095972|NCT04104620||patients with neurological syndromes and GAD-Ab|This is a non-interventional study involving clinical data already stored in the database of the Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, or collected by the referral physicians the day of ordinary consultations. No biological sample is necessary to perform this study.
11095973|NCT04104607|Experimental|CC-1 therapy|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation. In case of clinical benefit, additional cycles with a total of up to six are possible.
11095974|NCT04104594|Experimental|patients with chronic rhinosinusitis with nasal polyps|
11095975|NCT04104594|Other|Patients with an indication for septoplasty = control group|
11095976|NCT04104581|Placebo Comparator|Control|Volunteers will consume a diet in which all grain foods are made from refined grains.
11095977|NCT04104581|Experimental|Low Whole Grain Oat Diet|Volunteers will consume a diet with a low level of whole grain oat incorporated into some of the foods.
11095978|NCT04104581|Experimental|High Whole Grain Oat Diet|Volunteers will consume a diet with a high level of whole grain oat incorporated into some of the foods.
11095979|NCT04104581|Experimental|Low Whole Grain Wheat Diet|Volunteers will consume a diet with a low level of whole grain wheat incorporated into some of the foods.
11095980|NCT04104581|Experimental|High Whole Grain Wheat Diet|Volunteers will consume a diet with a high level of whole grain wheat incorporated into some of the foods.
11095981|NCT04104568|Experimental|iSupport for dementia - European-Portuguese version|Access, for 3 months, to an online self-help training and support program: iSupport for dementia - European-Portuguese version. The e-program offers information, skills training and support for informal caregivers of people with dementia. It comprises five modules, including twenty-three lessons on dementia and caregiver support. In line with good practices on digital engagement, the education plan can be personalized by the caregiver. This means that it can be adjusted to the person's availability and lessons can be selected according to particular needs. Each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques including psycho-education, behavioral activation, cognitive reframing, relaxation and antecedent-behavior-consequence (ABC) analysis.
11095982|NCT04104568|Active Comparator|Education-only e-book|The control group will receive a minimal education-only intervention, consisting on an e-book. The manual contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
11096049|NCT04104178|Placebo Comparator|Placebo|
11095983|NCT04104555|Active Comparator|Usual supportive care - exercises and footwear advice|"OSTRICH main trial:
~Participants will be offered an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
11095984|NCT04104555|Experimental|Prefabricated, off-the-shelf orthoses|"OSTRICH main trial:
~A pair of prefabricated, off-the-shelf orthoses (i.e. mass produced to a generic shape but can be adapted by a clinician) plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
11095985|NCT04104555|Experimental|Custom-made foot orthoses|"OSTRICH main trial:
~A pair of custom-made foot orthoses, where the shape of the insole is made for a specific person based on a 3D impression of the patient's foot, using materials of the clinicians choosing. Plus an exercise programme and advice regarding footwear. The treating clinician will be able to prescribe appropriate exercises from a menu of exercises."
11095986|NCT04104555|Experimental|Pen arm|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will be given a pen with a picture of an ostrich on it in the OSTRICH recruitment pack.
11095987|NCT04104555|Experimental|Signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will be given signposting to multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
11095988|NCT04104555|Experimental|Pen and signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will be given a pen with a picture of an ostrich on it and signposting to multimedia trial information resources in the participant information sheet which is included in the OSTRICH recruitment pack.
11095989|NCT04104555|No Intervention|No pen and no signposting to multimedia|OSTRICH 'Pen and signposting to multimedia' Study within a trial (SWAT) Participants will not be given a pen or signposting to multimedia trial information resources in the participant information sheet, when sent to the OSTRICH recruitment pack.
11095990|NCT04104555|Experimental|Birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a standard birthday card on or shortly before their birthday to encourage completion of questionnaires..
11095991|NCT04104555|Experimental|Birthday card informed by nudge theory|OSTRICH Birthday card study within a trial (SWAT) Participants will be sent a birthday card informed by nudge theory to encourage completion of questionnaires.
11095992|NCT04104555|No Intervention|No birthday card|OSTRICH Birthday card study within a trial (SWAT) Participants will not be sent a birthday card during the trial.
11095993|NCT04104542|Experimental|Mindfulness MTHM|online mindfulness based stress reduction training
11095994|NCT04104542|Experimental|Mindfulness JBSA|online mindfulness based stress reduction training
11095995|NCT04104542|Sham Comparator|Healthy Lifestyle MTHM|online healthy lifestyle training
11095996|NCT04104542|Sham Comparator|Healthy Lifestyle JBSA|online healthy lifestyle training
11095997|NCT04104529|Experimental|Biological collection|"Biological collection
~For all the patients include in the study :
~samples of blood samples collected before and during treatment.
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11095998|NCT04104503|Experimental|Part A|
11095999|NCT04104503|Experimental|Part B group 1|"Treatment period 1: Fasted + iv;
~Treatment period 2: Fasted;
~Treatment period 3: High-fat meal"
11096000|NCT04104503|Experimental|Part B group 2|"Treatment period 1: High-fat meal;
~Treatment period 2: Fasted + iv;
~Treatment period 3: Fasted"
11096001|NCT04104503|Experimental|Part B group 3|"Treatment period 1: Fasted;
~Treatment period 2: High-fat meal;
~Treatment period 3: Fasted + iv"
11096002|NCT04104490||Severe pulmonary arterial hypertension.|"This cohort will consist of patients with severe pulmonary arterial hypertension.
~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of severe disease.
~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.
~This is an observational study with no interventions."
11096003|NCT04104490||Mild-moderate pulmonary arterial hypertension|"This cohort will consist of patients with mild-moderate pulmonary arterial hypertension.
~This is defined as mean pulmonary arterial pressure 25 mm Hg or greater and pulmonary artery occlusion pressure 15 mmHg or less measured by right cardiac catheterization and a clinical diagnosis of mild-moderate disease.
~Participants will be without signs of left heart disease, lung disease and or hypoxia, chronic thromboembolic pulmonary hypertension or pulmonary hypertension of unclear multifactorial mechanisms.
~This is an observational study with no interventions."
11096004|NCT04104490||Reference subjects without pulmonary hypertension|Reference subjects will be healthy people, age- and sex-matched to the other two cohorts, who have no pulmonary artery hypertension.
11096005|NCT04104477|Active Comparator|CMC OA Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
11096006|NCT04104477|Active Comparator|Age-Matched Control Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
11096007|NCT04104451|Experimental|Dose 1|
11096008|NCT04104451|Experimental|Dose 2|
11096009|NCT04104451|Experimental|Dose 3|
11096010|NCT04104438|Active Comparator|Basiliximab with Delayed TAC|"Basiliximab
~Dose #1: 20mg IV within 2 hours of transplant
~Dose #2: 20mg IV Post-operative day #4
~Tacrolimus (with basiliximab induction) o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to six months: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL
~Mycophenolate mofetil
~o 1000 mg po bid
~Corticosteroids (SOC): Per UCLA protocol
~Post-operative taper:
~Post-op day 1- methylprednisolone 50mg IVP Q6H
~Post-op day 2- methylprednisolone 40mg IVP Q6H
~Post-op day 3- methylprednisolone 30mg IVP Q6H
~Post-op day 4- methylprednisolone 20mg IVP Q6H
~Post-op day 5- methylprednisolone 20mg IVP Q12H
~Post-op day 6- methylprednisolone 10mg IVP Q12H until taking PO, then change to: prednisone 20mg PO QAM"
11096011|NCT04104438|Active Comparator|Basliximab, Delayed TAC with Everolimus|"Basiliximab
~Tacrolimus (with basiliximab induction)
~o Beginning day #5 post-transplant or when SCr < 1.8 mg/dl (subjects off dialysis) to POD 30: 0.03-0.1mg/kg q12h PO to maintain whole blood trough concentration of 4-6ng/mL
~Mycophenolate mofetil o 1000 mg po bid up to POD 30: reduce mycophenolate mofetil following achievement of steady state everolimus (POD 35) as clinically indicated
~Corticosteroids (SOC): Per UCLA protocol
~Everolimus (delayed)
~o Add by POD 30: 1 mg po bid and adjusted to maintain whole blood trough concentrations of 3-8 ng/ml."
11096012|NCT04104438|No Intervention|Control: standard TAC with steroids and MMF|"Tacrolimus (without basiliximab induction)
~Beginning day #1 post-transplant to six months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 5-12ng/mL
~Six months to one year: maintain whole blood trough concentration of 5-10ng/mL
~Mycophenolate mofetil
~o 1000 mg po bid
~Corticosteroids (SOC): Per UCLA protocol"
11096013|NCT04104412|Experimental|treatment group A （with mesenchymal stem cell intervention）|observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2*10^7/ml normal saline) and Low temperature plasma vaporization ablation
11096014|NCT04104412|No Intervention|control group B|observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation
11096015|NCT04104399|Experimental|XC130-A10H|single dose
11096016|NCT04104399|Placebo Comparator|Placebo|single dose
11096017|NCT04104386|Experimental|Disclosure of Telomere Length Arm|Telomere Length results were provided (personal value, means, and standard deviation of the group), and categorized as 'short' telomere length (bottom quartile) and 'not short' (above the bottom quartile) based on age related norms available from research literature.
11096018|NCT04104386|No Intervention|Non-Disclosure|Telomere Length results were not provided.
11096019|NCT04104360|Experimental|Galacto-oligosacchardies|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
11096020|NCT04104360|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks
11096021|NCT04104347|Experimental|Metacognitive training (MCT)|
11096022|NCT04104347|Active Comparator|Support group|
11096023|NCT04104334|Active Comparator|"Monitored group M (optimized controlled anesthesia)"|"Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume."
11096024|NCT04104334|Active Comparator|"Control group C (standard of care anesthesia)"|"Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100."
11096025|NCT04104321|Experimental|Aramchol|Aramchol 300 mg oral tablet
11096026|NCT04104321|Placebo Comparator|Placebo|Placebo matching oral tablet
11096027|NCT04104295|Experimental|Ultrasound following X-ray|An ultrasound scan of the abdomen within 2 hours of the routine X-ray will be performed by a physician blinded to the X-ray results.
11096028|NCT04104269||Mechanical Complications|Include free wall ventricular rupture and ventricular septal rupture
11096029|NCT04104269||Non-Mechanical Complications|Mechanical complications were not included in patients with AMI
11096030|NCT04104256|Experimental|Alert 1|Pre-op clinic physicians will respond to nudge #1 from study intervention.
11096031|NCT04104256|Experimental|Alert 2|Pre-op clinic physicians will respond to nudge #2 from study intervention.
11096032|NCT04104256|Experimental|Control|Pre-op clinic physicians will not receive interventions and perform duties as usual.
11096033|NCT04104256|Experimental|Alert 3|Pre-op clinic physicians will respond to nudge #3 from study intervention.
11096034|NCT04104243|Experimental|Power-Up|Participants randomized to this arm will undergo 16 classes tailored for men, that discuss food choices, physical activity, and managing stress over 6 months, which are called the core, and 6 classes over the following 6 months, which is called the maintenance phase.
11096035|NCT04104243|No Intervention|Standard NDPP (National Diabetes Prevention Program)|Participants randomized to this arm will undergo 16 mixed gender classes that discuss food choices, physical activity, and managing stress over 6 months which are called the core and 6 classes over the following 6 months which is called the maintenance phase.
11096036|NCT04104230||Individuals Affected With Pancreatic Cancer|Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
11096037|NCT04104230||Individuals Affected with Related Cancer|Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
11096038|NCT04104230||Individuals Affected With Pancreatic Neoplasm|Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
11096039|NCT04104230||High-Risk Individuals|Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
11096040|NCT04104230||Healthy Controls|Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
11096041|NCT04104217||patients|Participate in 30-60 minute interviews after each music therapy session.
11096042|NCT04104217||caregivers|Participate in 30-60 minute interviews after each music therapy session (ideally within 3 days).
11096043|NCT04104217||nurses|Participate in 10-15 minute interviews after initial music therapy session.
11096044|NCT04104217||music therapists|Music therapist will notify the researcher if he/she has provided music therapy for a patient who is identified as having delirium. Music therapists will also be interviewed about the clinical process after initial and follow up music sessions.
11096045|NCT04104204|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.1 mg, A sham subcutaneous injection of 0.5 ml normal saline at inguinal area
11096046|NCT04104204|Experimental|Ultrasound guided supra-inguinal fascia iliaca block|0.25% bupivacaine 40 ml
11096047|NCT04104191|Experimental|L-1000AF System|Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
11096048|NCT04104178|Active Comparator|Clindamycin|600 mg clindamycin, 3 times daily for 10 days, orally
11096050|NCT04104165|Active Comparator|Intermittent catheterization|women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours
11096051|NCT04104165|Active Comparator|Continous catheterization|women which will have an indwelling catheter inserted for 24 hours
11096052|NCT04104152|Experimental|ENDS 2.4% nicotine|Subjects will be assigned to one of four flavors variants of 2.4% ENDS products based on their preferred UB flavor.
11096053|NCT04104152|Experimental|ENDS 5.0% nicotine|Subjects will be assigned to one of four flavors variants of 5.0% ENDS products based on their preferred UB flavor.
11096054|NCT04104139|Experimental|Treatment (TAS-102, IMRT, 3D-CRT)|Patients receive TAS-102 PO BID Monday-Friday on weeks 1, 3, and 5. Patients also undergo IMRT or 3D-CRT 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX.
11096055|NCT04104126|Active Comparator|Standard of Care Physical Therapy|Patients with Achilles injury are prescribed PT for their treatment, therefore physical therapy is a standard of care treatment for patients with tendon pathology.
11096056|NCT04104126|Experimental|Blood flow restriction (BFR) therapy|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff.
11096057|NCT04104113|Experimental|XBYRT decoction|Participants assigned to receive the modifed Xiang Bei Yang Rong Tang granules
11096058|NCT04104113|Placebo Comparator|Placebo|Participants assigned to receive placebo (contains 5% of XBYRT) granules
11096059|NCT04104100||Women with nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
11096060|NCT04104100||Women without nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
11096061|NCT04104087|Experimental|deepithelializ free gingival graft|performing tunneling technique with deepithelialized free gingival graft in treating RT2 gingival recession
11096062|NCT04104087|Active Comparator|subepithelial connective tissue graft|performing tunneling technique with sub epithelial connective tissue graft in treating RT2 gingival recession
11096063|NCT04104074|Experimental|Radiotherapy Plus Sintilimab|HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.
11096064|NCT04104048||patients who were diagnosed as Anterior STEMI|"Patients who were diagnosed as Anterior STEMI according to criteria developed by the European Society of Cardiology.
~Onset of maximal intensity of chest pain within 12 hours before procedure"
11096065|NCT04104035||BCR-ABL-positive hematopoiesis|Patients with BCR-ABL-positive hematopoiesis (newly diagnosed CML patients, CML patients with leukocytosis, CML patients without a hematological and/or cytogenetic and/or molecular response, CML patients whose BCR-ABL status becomes negative and then positive) will be included.
11096066|NCT04104035||BCR-ABL activity inhibition under TKI|Patients with CML with BCR-ABL activity inhibition under TKI therapy (patients with MMR and/or deeper response) will be included.
11096067|NCT04104022|No Intervention|OAT as usual|Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12.
11096068|NCT04104022|Active Comparator|OAT+PET|In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist.
11096069|NCT04104022|Experimental|OAT+PET+|OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions
11096070|NCT04104009|Experimental|Interventional group|"In the exam group there will be group training for four meetings of one hour each.
~After completing the training program with the test group, a break of 5 weeks will follow, during which a new test and control group will be formed. The procedure will be carried out until the estimated sample size (99 subjects per group) is met."
11096071|NCT04104009|Active Comparator|Control group|In the control group there will not be any group training.
11096072|NCT04103983|Active Comparator|Sensory Retraining Interactive Device|The interactive device is a sensory retraining device. A band consisting of twelve equally spaced electrodes is placed over the residual limb. This band is connected to a handheld device which delivers an electrical current to the electrodes. The type of electrical current is similar to a TENS device. The device stimulates the skin via one of the electrodes, with either a single, or a rapid burst of pulse(s). The device touch screen then presents the questions, Which electrode (location) was stimulated? Was a single continuous or a rapid burst of pulses given (stimulation type)? The user responds via the screen and is told if they are correct. If correct, a new stimulus is delivered (different location and type) and the process repeated. If incorrect, the user is informed of the correct response, the same stimulation (location and type) is repeated once before moving onto to a new stimulus.
11096073|NCT04103983|Active Comparator|Sensory Retraining Non-Interactive Device|The non-interactive device is physically visually identical to the interactive device. There is no interaction required with this device i.e. there is no Q&A element, feedback nor response dependent progression.
11096074|NCT04103970|No Intervention|Control group|"Usual care:
~Before surgery all patients are invited to participate in a pre-surgery seminar, where they receive information and advice about the time before, during and after the LSF. The seminar will be guided by nurses, surgeons, anesthesiologist, occupational therapists and physiotherapist.
~After the surgery the patient will be hospitalized on an average of 3-4 days. During hospitalization a physiotherapist consults the patients on a daily basis to provide information, guidance on mobilization and instructions in gradually progressing movement. The patients will have no restrictions on movement after surgery and should gradually return to normal activity level.
~Three months post-operatively all patients will receive physical rehabilitation delivered by physiotherapists in a community care center."
11096100|NCT04103762|Experimental|indocyanine green|During the surgery, intraoperative cholangiography using indocyanine green will be performed
11096101|NCT04103762|Active Comparator|standard cpo|"During the surgery, intraoperative cholangiography using a contrast product gold standard will be performed"
11096555|NCT04100642|Placebo Comparator|placebo apply to 25%BSA|6 subjects use placebo apply to 25%BSA
11096075|NCT04103970|Experimental|Intervention group: Graded Activity and Pain Education (GAPE)|"Patients in the intervention-group will receive usual care and 9 sessions of GAPE, 4 sessions at the hospital, 2 sessions in the patient's home and 3 sessions by telephone.
~Pain education in GAPE is viewed as an approach which target cognitive attitudes and beliefs about pain. The pain education will target 3 overall questions: 1. What is pain and is my pain normal? 2. What can affect my pain? 3. What can I do to relieve my pain? The education will be individually adjusted to each patient, so the patient's context and concerns regarding pain and movement are included.
~The aim of Graded activity is to improve the patient's functional ability by positive reinforcement of health behaviors and activity levels. Graded activity will be based on which short-term activity-goals the patient evaluates as the most important for the treatment outcome. In close collaboration with the patient the physiotherapist will set quotas for the selected exercises/activities."
11096076|NCT04103944|Experimental|Osteonecrotic Repair Device|A biphasic osteochrondral composite method to support the regeneration of articular cartilage in vivo. With its concept that could be securely installed by press-fit without additional fixation, this approach can present an alternative to perform graft harvest and implantation in a single surgery.
11096077|NCT04103944|Active Comparator|Core Decompression|Core decompression is a common surgical procedure that aims to improve vascular inflow by decreasing intraosseous pressure in the femoral head. It is performed that involves removing a cylindrical core of bone from the proximal femur.
11096078|NCT04103931|No Intervention|Usual Care|Participants will receive usual care and will not get the decision aid to review.
11096079|NCT04103931|Experimental|Patient Decision Aid|"Participants in this arm will receive the patient decision aid, titled Treatment Choices for Aortic Stenosis to review."
11096080|NCT04103918|Other|Jalucomplex® 2|Jalucomplex® 2 (Linear Hyaluronic Acid) Injection: follow the instruction for use
11096081|NCT04103905|Experimental|MIL62|
11096082|NCT04103892|Experimental|CLE-100|"Part A: 1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 1 week.
~Part B: 1 oral tablet of CLE-100 once daily (in addition to current anti-depressant drug) for 4 weeks."
11096083|NCT04103892|Placebo Comparator|placebo|"Part A: 1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 1 week.
~Part B: 1 oral tablet of Placebo once daily (in addition to current anti-depressant drug) for 4 weeks."
11096084|NCT04103879|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen.
~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.
~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
11096085|NCT04103866|Experimental|Pressure Offloading Innersole System|Use of Juvederm Voluma in the foot for fat pad restoration
11096086|NCT04103853|Experimental|Proxalutamide|"Stage one - Dose climbing:
~Each dose cohort will assess toxicity within the 35 days following the first dose of GT0918.
~Stage two- the expansion cohort :
~30 patients will be enrolled to the 200mg cohort . 15 patients will be enrolled to the 300mg cohort."
11096087|NCT04103840||Severe alcohol- associated hepatitis|Severe alcohol associated hepatitis as defined by probable/ conformed National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria
11096088|NCT04103840||Control|Apparently healthy Family controls
11096089|NCT04103827||old patients|"During the first 24 hours of the hospitalisation in the equiped room and before the presentation of the device, A first series of questions will be asked a priori to the patients. Patient will freely use Le Qoos during all his hospitalisation. After this use, a survey concerning the usability of Le Qoos will be administered to the patient, during the 48 hours before his discharge from hospital."
11096090|NCT04103827||relatives / unformal caregivers|"Before the presentation of the device, a first series of questions will be asked a priori to the unformal caregiver. Unformal caregiver will freely use Le Qoos during the hospitalization of his relative. After this use, a survey concerning the usability of Le Qoos will be administered to the unformal caregivers, 48 hours before the discharge of his hospitalized relative from hospital."
11096091|NCT04103827||profesional caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Le Qoos will be administered to professional caregivers."
11096092|NCT04103814|Active Comparator|CBD cream|Subjects in this group will receive the active CBD cream for topical treatment of hallux valgus or hallux rigidus.
11096093|NCT04103814|Placebo Comparator|Placebo cream|Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
11096094|NCT04103801|Experimental|Sucrose group|This group received the 2 ml of sweet solution (sucrose)
11096095|NCT04103801|Placebo Comparator|Water group|This group received the 2 ml of water
11096096|NCT04103788|Active Comparator|95% Curcuminoid Powder|Curcumin powder standardized to >95% curcuminoids, single dose, used to determine standard absorptivity of unformulated powder.
11096097|NCT04103788|Experimental|BIOCURC|Highly absorbed curcumin emulsion, single dose, used to produce serum samples for analytical comparison of sample preparation methodologies.
11096098|NCT04103775|Experimental|Cognitive Remediation|Cognitive Remediation comprises of six exercises supplied by BrainHQ by Posit Science Corporation: Sound Sweeps (targets auditory processing speed): Two successive frequency-modulated tone sweeps are presented and participants indicate whether the frequency increased or decreased within each tone: Fine Tuning (targets auditory perception and processing speed): Participants indicate which one of two confusable syllables were presented; Syllable Stacks (targets auditory memory); Users report the order of presented syllables in a serial memory span task; Memory Grid (targets auditory memory); Participants match identical cards representing syllables; To do List Training (targets auditory memory): Participants see a g rid of everyday items (e.g., plant, carrots, shovel) and select the items in accordance with spoken instructions; Rhythm Recall (target auditory memory): Participants recreate auditory melodies
11096099|NCT04103775|Active Comparator|Active Control|Active Control Comprises six exercises also supplied by Post Science Corporation: A Maze Race, Reversi, Bricks Breaking Hex, Word Search II, Bricks Squasher II, and CircloO. These are all common computer games freely offered online.
11096102|NCT04103749|Experimental|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
11096103|NCT04103736|Experimental|Beet Juice Supplement|A single, acute dose of Beet It Sport Shot containing ~12.6mmol naturally occurring dietary nitrates.
11096104|NCT04103736|Placebo Comparator|Placebo juice|A single, acute dose of nitrate-depleted Beet It Sport Shot
11096105|NCT04103723||patients with premedication|Patients receiving preoperative premedication with midazolam before surgery.
11096106|NCT04103723||patients without premedication|Patients without preoperative premedication before surgery.
11096107|NCT04103697|Experimental|4xCapOx|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
11096108|NCT04103697|Active Comparator|Surgery|Patients will receive standard surgery for rectal cancer with partial or total mesorectal excision (based on exact tumor location and surgeons discretion). The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
11096109|NCT04103684|Experimental|Patients will receive steroid pulse therapy|
11096110|NCT04103684|Active Comparator|Patients will receive low dose steroids|
11096111|NCT04103671|Experimental|Group A|Prompt panretinal photocoagulation
11096112|NCT04103671|Experimental|Group B|Micro-invasive Pars-plana vitrectomy
11096113|NCT04103658|No Intervention|Standard of care (control)|This will be the standard of care group. The excision of the non-melanoma skin cancer will be based on standard visual inspection with 4-6mm margins.
11096114|NCT04103658|Experimental|NIR heating|This will be the NIR heating group, where the excision of the non-melanoma skin cancer will be based on the lesion margins based on the application of near-infrared radiation (with 4-6mm margins).
11096115|NCT04103645|Experimental|Treatment arm|Vactosertib intra-patient dose finding cohort.
11096116|NCT04103632|Experimental|Young recreational athletes (12-18 years)|"Young recreational athletes (12-18 years) of different sport disciplines:
~Indoor sports
~Outdoor sports
~Swimming
~Winter sports"
11096117|NCT04103619|Active Comparator|AccuTite|15 patients will receive AccuTite treatment only
11096118|NCT04103619|Active Comparator|AccuTite & Morpheus 8 Arm|15 patients will receive AccuTite and Morpheus8 treatment and additional 2 monthly Morpheus8 treatments
11096119|NCT04103606|Experimental|immediate-use App group (iApp group)|Participants in the iApp group start using the app immediately (Time 0; T0) for 16 consecutive days (until Time 1; T1).
11096120|NCT04103606|Active Comparator|delayed-use App group (dApp)|Participants in the dApp group start using the app at Time 1 (T1; 16 days after the iApp group) and use the app for the following 16 days (Time 2; T2).
11096121|NCT04103593|Experimental|exercise group|High-intensity circuit exercise training will be performed 3 times weekly for 12 weeks in a group setting. Circuit training is an exercise modality consisting of a series of exercises at different stations. Exercise training will be delivered by VTEL broadcast from the Salem VAMC to participants at the Atlanta VAMC and Baltimore VAMC. Rooms will be equipped with steps, hand and ankle weights, dumbbells, chairs and bands. No stationary exercise equipment will be used in either AEX or RT.
11096122|NCT04103593|No Intervention|control group|Sedentary activity (confirmed at eligibility no more than 1 structured physical activity/week) will be continued in participants randomized to the control group. Participants have the option after 12-week intervention phase to enter ?delayed? exercise training to assure that all participants can receive exercise training.
11096123|NCT04103580|No Intervention|Control|Will receive usual hospice care plus measures
11096124|NCT04103580|Experimental|Intervention|Will receive photo elicitation intervention and will join a secret Facebook group to share photos with other caregivers
11096125|NCT04103567|Experimental|Biological collection|"Fecal samples collected at different times : During inclusion consultation with surgeon, before and after surgery,
~In parallel to this fecal collection, standardized clinical data will be entered into a database"
11096126|NCT04103554|Experimental|sacubitril/valsartan|
11096127|NCT04103554|Active Comparator|Standard of care|Standard of care for treating blood pressure per center protocols
11096128|NCT04103541|Experimental|IP-Colombia|
11096129|NCT04103541|No Intervention|Waitlist control|
11096130|NCT04103528|Other|morning group(from 8:00 to 12:00)|
11096131|NCT04103528|Other|afternoon group(from 14:00 to 18:00)|
11096132|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
11096133|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
11096134|NCT04103502||MicroPort Medial Pivot|Subjects will have been implanted with the MicroPort Medial Pivot TKA
11096135|NCT04103502||DePuy Attune|Subjects will have been implanted with the DePuy Attune PCR TKA
11096136|NCT04103489|Experimental|HELLP Syndrome at less than 28 weeks gestation|Women diagnosed with HELLP syndrome at 23-30 weeks gestation will receive eculizumab.
11096137|NCT04103476|Experimental|BZA/CE|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
11096138|NCT04103476|Placebo Comparator|Placebo|Oral matching placebo
11096139|NCT04103463|Experimental|Interactive stepping exercise group|
11096140|NCT04103463|Active Comparator|Home exercise group|
11096141|NCT04103450|Experimental|Vibegron|Participants will receive 75 milligrams (mg) vibegron orally once daily (QD).
11096142|NCT04103437||recreational runners|Recreational runners (minimum of 2 running session and 20km of total mileage per week), with seasonal best on half-marathon comprised between 1h20' and 2h00'. Age > 18 and < 60 years. Free from musculoskeletal injuries from at least three months.
11096143|NCT04103424|No Intervention|Pre-training Metabolic Study Visit|Participants will first complete a pre-training metabolic study visit.
11096199|NCT04103060|Placebo Comparator|Vehicle gel|Vehicle gel applied topically twice daily
11096144|NCT04103424|Experimental|Post-training Metabolic Study Visit|Participants will complete a second, identical metabolic study visit following 2-weeks of exercise training.
11096145|NCT04103411|Experimental|High Intensity Interval Training (HIIT)|For the twelve weeks of intervention, participants will have three training sessions per week. Each session will be done on a cycle ergometer and will last approximately 40 minutes. Participants will be supervised by certified kinesiologists and their training programs will be revised every four weeks.
11096146|NCT04103411|Active Comparator|HydroChloroThiazide|For this group, participants have to take a diuretic (12,5 mg of Hydrochlorothiazide) daily prescribed by the doctor of this study, for twelve weeks. Participants should also maintain the same lifestyle habits that they had before the study.
11096147|NCT04103398|Experimental|Transarterial chemoembolization combined with sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
11096148|NCT04103398|Active Comparator|Transarterial chemoembolization alone|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
11096149|NCT04103385|Experimental|Reconnecting to Internal Sensations and Experiences|"Aims to improve interoception or connection to the body's emotions & internal sensation and reduce suicidal ideation."
11096150|NCT04103385|Active Comparator|Restoring Individual Strength and Energy|Aims to reduce life stressors and improve physical health
11096151|NCT04103372|Active Comparator|Low risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 0. (Margin Clear >0mm from the diathermy margin and Sm1/2 or Haggitt 1/2/3) Six monthly follow up from date of surgery.
11096152|NCT04103372|Active Comparator|Moderate Risk - RT&Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to receive radiotherapy (RT) and regular surveillance, with 3 monthly follow-up from the date of surgery.
11096153|NCT04103372|Active Comparator|Moderate Risk - Surveillance|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of 1. (Margin positive -0mm to the diathermy margin, or SM3 or Haggitt 4, or LVI) Patient randomized to surveillance arm with regular surveillance, with 3 monthly follow-up from the date of surgery.
11096154|NCT04103372|Active Comparator|High Risk|MR Staged >1mm muscularis preserved and technically feasible to perform local excision. Pathology assessment on sample with confirmation of adenocarcinoma. Sample assessed to be low risk based on PRESERVE Risk Score of >2. (Margin positive - 0mm to the diathermy margin, Margin positive/or unassessable due to piecemeal removal - 0mm to the tumour margin, Sm3 or Haggitt 4, Poorly differentiated/mucinous, LVI, T2) Patient is considered for surgery, receives radiotherapy and surveillance, with 3 monthly follow-up from date of surgery.
11096155|NCT04103372|Active Comparator|TME (Total mesorectal excision) Surgery|For patients where it is considered technically feasible to do LE but MR staged<1mm muscularis preserved, or it is considered not feasible to perform a local excision. Patients undergo TME surgery. Pathology assessment on sample with confirmation of adenocarcinoma. Patient receives 6 monthly follow-up from date of surgery.
11096156|NCT04103359|Experimental|MDS patients|MDS patients receiving blood transfusion
11096157|NCT04103346|Active Comparator|air filtration with hepa filter|air purifier used is the Holmes HAP8650B-NU-1 with the hepa filter inserted.
11096158|NCT04103346|Sham Comparator|air filtration with hepa filter removed|sham comparator uses the Holmes HAP8650B-NU-1 air purifier to be operated with the filter removed.
11096159|NCT04103333|Experimental|Angelman Syndrome: Group 1|Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096160|NCT04103333|Experimental|Angelman Syndrome: Group 2|Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096161|NCT04103333|Experimental|Angelman Syndrome: Group 3|Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096162|NCT04103333|Experimental|Angelman Syndrome: Group 4|Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096163|NCT04103333|Experimental|Dup15q Syndrome: Group 1|Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096164|NCT04103333|Experimental|Dup15q Syndrome: Group 2|Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096165|NCT04103333|Experimental|Dup15q Syndrome: Group 3|Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096166|NCT04103333|Experimental|Dup15q Syndrome: Group 4|Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
11096273|NCT04102618|Experimental|Cohort 5|HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
11096167|NCT04103307|No Intervention|Control: Standard of care|Participants in the control group will receive standard-of-care CRRT prescriptions, and have the returning venous blood warmed with an external blood warmer to a temperature of 37°C. The blood warmer temperature will be adjusted by the CRRT nurse as per usual practice to maintain normothermia.
11096168|NCT04103307|Experimental|Intervention: Cooling|Participants in the intervention group will receive standard of care CRRT prescriptions and have the blood warmer set to 35.5°C, as long as the nasopharyngeal temperature remains above 35.5°C.
11096169|NCT04103294|Experimental|cowpea variety #1|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
11096170|NCT04103294|Experimental|cowpea variety #2|25g of cowpea daily for days 6-10, 50g of cowpea daily for days 11-15 and then 75g of cowpea daily for days 16-20. The pregnant women will receive 50g of cowpea daily for days 6-10, 100g of cowpea daily for days 11-15 and then 150g of cowpea daily for days 16-20
11096171|NCT04103281||Sepsis Patients|
11096172|NCT04103281||Control Patients|
11096173|NCT04103268||Sepsis|
11096174|NCT04103268||Control|
11096175|NCT04103255|Experimental|High frequency and intensive prevention|"High frequency and intensive prevention program -
~Goal management training (Ariane Giguere-Rancourt et al., 2018) - is a home-based approach for PD patients with Mild Cognitive Impairment (MCI)
~Physiotherapy
~Rhythmic Music Gymnastic
~Speech therapy"
11096176|NCT04103255|No Intervention|Control group (Stepped-wedge trial)|Best Medical Treatment
11096177|NCT04103229|Experimental|10 ml sterile distilled water|The indwelling urinary catheterization was inflated with 10 ml sterile distilled water (SDW) of the balloon.
11096178|NCT04103229|Experimental|15 ml sterile distilled water|The indwelling urinary catheterization was inflated with 15 ml sterile distilled water (SDW) of the balloon.
11096179|NCT04103229|Experimental|10 ml 0.9% sodium chloride (NaCL)|The indwelling urinary catheterization was inflated with 10 ml 0.9% sodium chloride (NaCL) of the balloon.
11096180|NCT04103229|Experimental|15 ml 0.9% sodium chloride (NaCL)|The IUC was inflated with 15 ml 0.9% sodium chloride (NaCL) of the balloon.
11096181|NCT04103216|Active Comparator|Intervention arm|"Child will be receive the Nitazoxanide treatment for 3 days with probiotics (L reuteri DSM 17938 ) for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.
~L reuteri DSM 17938 will be 2×108 CFU and will receive 5 drops orally twice daily for a consecutive 7 days."
11096182|NCT04103216|Placebo Comparator|Control arm|"Child will be receive the Nitazoxanide treatment for 3 days with placebo for 7days. The doses of Nitazoxanide will be twice a day for 3 days and dosage will be 5 ml every 12 hours with food. The Nitazoxanide oral suspension contain 100mg/5ml.
~Placebo will receive 5 drops orally twice daily for a consecutive 7 days."
11096183|NCT04103203|No Intervention|New diagnostic results NOT available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.
11096184|NCT04103203|Experimental|New diagnostic results available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
11096185|NCT04103177|Experimental|Intervention group|20 participants to receive physical activity educational booklet with instructions on chair based exercises, Instructor-led training on how to perform the chair based exercises, two times a week, over a 6 week period, and motivational interviewing and prompts.
11096186|NCT04103164|Experimental|Cutera® excel V laser arm|After the PWS is be divided into five equal portions, four of those portions treated once with a different laser fluence using the multiple-pass approach (2 J/cm² vs 4 J/cm² vs 6 J/cm² vs 8 J/cm²), and one of the portions treated with single-pass approach at 8 J/cm²
11096187|NCT04103151||Febrile infants|Febrile Infants less than 3 months presenting to the emergency department with a temperature of ≥ 38oC.
11096188|NCT04103151||Afebrile infants|Afebrile Infants less than 3 months presenting to the emergency department
11096189|NCT04103138|Experimental|EEG-Guided Anaesthesia|Patients will have Sedline EEG sensor placed and anaesthesia guided by the EEG characteristics, patient state index (PSI) and suppression ratio (SR), in addition to routine clinical parameters.
11096190|NCT04103138|Active Comparator|Routine Care|Patients will have Sedline EEG sensor placed but the monitor is concealed so the clinician is blinded to the EEG response. Anaesthesia is guided by routine clinical parameters.
11096191|NCT04103125|Other|Janesse|Janesse® 20 (Cross-linked Hyaluronic Acid) Injection: follow the instruction for use
11096192|NCT04103112|No Intervention|Standard clinical care|Standard clinical care (anticoagulation) with no graduated compression stocking
11096193|NCT04103112|Experimental|Graduated compression stocking and standard clinical care|A graduated compression stocking and the standard clinical care (anticoagulation)
11096194|NCT04103099||Single (virtual) Arm|Observational one arm virtual study of HLNatural Immune supplement
11096195|NCT04103086|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol). All participants will receive the standard inhalation method training before hospital discharge.
~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
11096196|NCT04103086|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
11096197|NCT04103073||Study group|The patient with OSAS 35-70 years of age, clinically stabile, symptoms such as snoring, breathing cessations, and daytime sleepiness, and polysomnographic evidence consistent with mild (5<apnea hypopnea index (AHI)< 15) to moderate (16 < AHI < 30) OSAS.
11096198|NCT04103060|Experimental|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily
11096200|NCT04103047||SAD group|Adult surgical patients who are due to undergo general anaesthesia and requiring SAD insertion will be identified on the day of surgery.
11096201|NCT04103034|Experimental|BT200 0.18mg|Subjects will receive a single subcutaneous dose of BT200 0.18mg
11096202|NCT04103034|Experimental|BT200 0.6mg|Subjects will receive a single subcutaneous dose of BT200 0.6mg
11096203|NCT04103034|Experimental|BT200 1.8mg|Subjects will receive a single subcutaneous dose of BT200 1.8mg
11096204|NCT04103034|Experimental|BT200 6.0mg|Subjects will receive a single subcutaneous dose of BT200 6.0mg
11096205|NCT04103034|Experimental|BT200 12.0mg|Subjects will receive a single subcutaneous dose of BT200 12.0mg
11096206|NCT04103034|Experimental|BT200 24.0mg|Subjects will receive a single subcutaneous dose of BT200 24.0mg
11096207|NCT04103034|Experimental|BT200 24.0mg repeat|Subjects will receive a single subcutaneous dose of BT200 24.0mg
11096208|NCT04103034|Placebo Comparator|Placebo SAD|Subjects will receive a single subcutaneous dose of placebo
11096209|NCT04103034|Experimental|BT200 loading dose 24.0mg, maintenance doses of 12.0 mg|Subjects will receive an initial subcutaneous loading doses of BT200 24.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg
11096210|NCT04103034|Experimental|BT200 loading doses 48.0mg, maintenance doses of 24.0 mg|Subjects will receive an initial subcutaneous loading dose of BT200 48mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg
11096211|NCT04103034|Placebo Comparator|Placebo MAD|Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo
11096212|NCT04103034|Experimental|BT200 48.0mg + desmopressin challenge|Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200
11096213|NCT04103034|Placebo Comparator|Placebo + desmopressin challenge dose|Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo
11096214|NCT04103034|Placebo Comparator|Placebo infusion|Subjects will receive a single IV dose of placebo administered over 24 hours
11096215|NCT04103034|Experimental|BT200 36.0mg|Subjects will receive a single subcutaneous dose of BT200 36.0mg
11096216|NCT04103034|Experimental|BT200 48.0 mg|Subjects will receive a single subcutaneous dose of BT200 48.0mg
11096217|NCT04103021|Experimental|Port-a-cath|Ultrasound guided Port-a-cath insertion
11096218|NCT04103008||Group A|single coronary artery lesion
11096219|NCT04103008||Group B|multiple coronary artery lesions
11096220|NCT04102995|Experimental|Sepranolone (UC1010) low dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
11096221|NCT04102995|Experimental|Sepranolone (UC1010) high dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
11096222|NCT04102995|Placebo Comparator|Placebo|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
11096223|NCT04102982|Active Comparator|Microwave ablation plus camrelizumab group|Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
11096224|NCT04102982|Placebo Comparator|Camrelizumab group|Patients in the group are treated with camrelizumab alone.
11096225|NCT04102969|Experimental|Intervention group|"Intervention group will be instructed by an interventionist who is qualified in stress management and relaxation will perform the Benson relaxation technique to the intervention group to perform the Benson relaxation technique two times a day for 10 minutes during the study period ( two months).
~Training session of the technique will be repeated if necessary over one or two sessions until the interventionist confirm that the participants acquired sufficient skills. A total of two hours will be scheduled for each session and will be coordinated with the nursing manager of the hemodialysis department."
11096226|NCT04102969|Other|Control Group|A qualified nutritionist will run out a nutrition package session for hemodialysis patients in the control group. This nutrition package session will be for one session for one hour.
11096227|NCT04102956|Experimental|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
11096228|NCT04102956|No Intervention|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
11096229|NCT04102943|Experimental|Tacrolimus1|Tacrolimus tablet Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
11096230|NCT04102943|Active Comparator|Tacrolimus2|Tacrolimus Cap Orally, twice a day in the morning and night After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment.
11096231|NCT04102930||Retrospective|A patient who has a diagnosis of GCA or PMR
11096232|NCT04102930||Prospective|Patient with suspected GCA and PMR
11096233|NCT04102917||QFR group|915 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, acute myocardial infarction with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
11096234|NCT04102891|Experimental|Study arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the Flemish food-based dietary guidelines. Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
11096274|NCT04102605|Experimental|Nunap Vision|Nunap Vision , 5 days a week for 12 weeks
11096275|NCT04102605|Sham Comparator|Nunap Vision-C|Nunap Vision-C, 5 days a week for 12 weeks
11096276|NCT04102592|Experimental|Intervention Group|Participants in this arm receive Lesu (baby wrap) treated with 0.5% permethrin
11096235|NCT04102891|No Intervention|Control arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the guidelines from the newly developed microbiota modulation diet (MMD). Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
11096236|NCT04102878|Active Comparator|Transcutaneous anaesthetic|
11096237|NCT04102878|Active Comparator|Transconjunctival anaesthetic|
11096238|NCT04102865|Other|single use NPWT dressing|single use NPWT dressing
11096239|NCT04102852|Experimental|LGG regular dose|Patients taking LGG 1.2 × 10^10 CFU/day, 2 capsules a day, for 1 month
11096240|NCT04102852|Experimental|LGG double dose|Patients taking LGG 2.4 × 10^10 CFU/day, 4 capsules a day, for 1 month
11096241|NCT04102813|Experimental|Functional Therapy (FT)|The FT includes a variety of functional techniques such as diaphragmatic breathing, and thoracic and abdominal manipulation, designed to stimulate the neurofunctional interconnection between body, mind and immune system. The FT session will last 30 minutes.
11096242|NCT04102813|No Intervention|Attention Control (AC)|The AC group will listen an audiobook lasting for 30 minutes, which will be used as attention control activity
11096243|NCT04102800|Other|Treatment|Benralizumab 30mg by subcutaneous injection every 4 weeks
11096244|NCT04102787|Experimental|experimental group|Experimental group who received the Cardiac educational program and will be applied for Coronary Artery Disease patients, and measure the level of knowledge and satisfaction in pre and post test.
11096245|NCT04102787|No Intervention|control group|Control group who received the usual care and measure the level of knowledge and satisfaction in pre and post test.
11096246|NCT04102774|Experimental|myAIRVO2|Patients will receive a myAIRVO2 at home over-night with humidifier on top of standard therapy for bronchiectasis according to international guidelines (ERS 2017).
11096247|NCT04102774|No Intervention|Control|Patients will receive standard therapy for bronchiectasis according to international guidelines (ERS 2017).
11096248|NCT04102761|Placebo Comparator|Trigger Point Needling|The first group will receive a deep trigger point injection of saline into deep tissue.
11096249|NCT04102761|Active Comparator|Platelet Rich Plasma Injection|The Platelet Rich Plasma group will receive an injection of approximately 1-2 mL of Platelet Rich Plasma into the painful disc/discs.
11096250|NCT04102761|Active Comparator|Bone Marrow Aspirate Injection|The third group will receive an injection of approximately 1-2 mL of Bone Marrow Concentrate into the painful disc/discs.
11096251|NCT04102748|Active Comparator|Conventional|
11096252|NCT04102748|Active Comparator|I-incision|
11096253|NCT04102748|Active Comparator|M-flap|
11096254|NCT04102735|Active Comparator|Over-the-nose facemask|The AF541 oro-nasal mask is used with the over-the-nose mask cushion.
11096255|NCT04102735|Experimental|Under-the-nose facemask|The AF541 oro-nasal mask is used with the under-the-nose mask cushion.
11096256|NCT04102722|Experimental|Single Arm|All enrolled subjects will undergo breast cancer screening with mammography and the MUST device
11096257|NCT04102696|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.
~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
11096258|NCT04102696|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
11096259|NCT04102683|Experimental|Intervention Group|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
11096260|NCT04102683|No Intervention|Control Group|
11096261|NCT04102670|Experimental|Treatment|Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream
11096262|NCT04102657|Experimental|Intermittent Fasting with Left Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
11096263|NCT04102657|Experimental|Intermittent Fasting with Right Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
11096264|NCT04102657|Experimental|Free-living Diet with Left Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
11096265|NCT04102657|Experimental|Free-living Diet with Right Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
11096266|NCT04102644||Pregnant Women|15,000 pregnant women and their fetuses/newborns (including a pilot phase of up to 500 participant pairs)
11096267|NCT04102631|Experimental|exposed group|patients will receive colonoscopy with assistance of Endo.Angel
11096268|NCT04102631|Sham Comparator|non-exposed group|patients will receive colonoscopy without assistance of Endo.Angel
11096269|NCT04102618|Experimental|Cohort 1|HR+/HER2-neg patients who will receive pelareorep plus letrozole
11096270|NCT04102618|Experimental|Cohort 2|HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
11096271|NCT04102618|Experimental|Cohort 3|TNBC patients who will receive pelareorep plus atezolizumab
11096272|NCT04102618|Experimental|Cohort 4|HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
11096277|NCT04102592|Placebo Comparator|Control Group|Participants in this arm receive Lesu (baby wrap) soaked with water only to mimic re-treatment and mask allotment
11096278|NCT04102579|Experimental|Valbenazine|Capsule, administered orally once daily for 12 weeks.
11096279|NCT04102579|Placebo Comparator|Placebo|Capsule, administered orally once daily for 12 weeks.
11096280|NCT04102566|No Intervention|Standard of care arm|"The standard of care group will group will receive the following regimen while inpatient:
~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours
~Acetaminophen 1000mg every 8 hours standing
~Oxycodone 5mg PO every 4 hours as needed pain
~Phenazopyridine 100mg TID as needed for urinary burning
~Senna 1 tab every 12 hours
~Miralax 17g powder once daily as needed for constipation
~The standard of care group will get the following prescriptions on discharge:
~Oxycodone 5mg every 4 hours as needed pain - 15 tabs
~Acetaminophen 1000mg every 8 hours standing for two days then as needed
~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs
~Senna 1 tab every 12 hours - 10 tabs"
11096281|NCT04102566|Experimental|Multi-modal group|"The multi-modal group will receive the following regimen while inpatient:
~2% topical lidocaine gel applied to catheter tip as needed for pain, maximum dose of 600mg in 12 hours
~Acetaminophen 1000mg every 8 hours standing
~Ibuprofen 600mg every 6 hours standing
~Oxycodone 5mg PO every 4 hours as needed pain
~Phenazopyridine 100mg TID as needed for urinary burning
~Senna 1 tab every 12 hours
~Miralax 17g powder once daily as needed for constipation
~Patient Education (Figures 2 & 3)
~The multi-modal group will receive the following prescriptions on discharge:
~Acetaminophen 1000mg every 8 hours standing for two days then as needed - 30 tabs
~Ibuprofen 600mg every 8 hours standing for two days then as needed - 30 tabs
~Phenazopyridine 100mg TID as needed for urinary burning - 9 tabs
~Senna 1 tab every 12 hours - 10 tabs"
11096282|NCT04102553|Experimental|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
11096283|NCT04102553|Active Comparator|F-18-Fluorocholine|Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.
11096284|NCT04102540|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during a study visit scheduled immediately following their regularly scheduled clinic visits.
11096285|NCT04102527||Patients|Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis for at least three months in stable condition
11096286|NCT04102514|Other|Real-time Group Video|
11096287|NCT04102514|Other|Enhanced Usual Care|
11096288|NCT04102501|Experimental|RT001|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.
~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
11096289|NCT04102501|Placebo Comparator|Placebo|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.
~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
11096290|NCT04102488|Experimental|6-step hygiene technique, application time of 30 seconds|
11096291|NCT04102488|Experimental|6-step hygiene technique, application time of 15 seconds|
11096292|NCT04102488|Experimental|3-step hygiene technique, application time of 30 seconds|
11096293|NCT04102488|Experimental|3-step hygiene technique, application time of 15 seconds|
11096294|NCT04102475|Experimental|eatline group|
11096295|NCT04102475|Sham Comparator|control group|
11096296|NCT04102462|Experimental|Multiple rising dose part|
11096297|NCT04102462|Experimental|Midazolam part|
11096298|NCT04102449|Other|Treatment with Apremilast|"Single group:
~Apremilast will be prescribed according to the patient information leaflet, i.e.:
~Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment duration at the discretion of the treating physician."
11096299|NCT04102436|Experimental|1/Experimental Therapy|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Sleeping Beauty Transposed PBL + high- or low-dosealdesleukin.
11096300|NCT04102423||CCUS|All participants meeting the criteria for CCUS
11096301|NCT04102423||CHIP|Subjects will be split into four cohorts depending on specific mutations
11096302|NCT04102410|Experimental|Experimental group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program composed of two 2 training strategies.
11096303|NCT04102410|Sham Comparator|Control group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program of usual practice.
11096304|NCT04102397|Experimental|Standard plus Vojta therapy (SVT)|The physiotherapist's hands produce the activation with no need for medication or external equipment, thus guaranteeing the patient's safety.this therapy is able to change pathological patterns to painless patterns that reduce the use of energy caused by movement difficulty. The end result is to facilitate movement without strain.
11096305|NCT04102397|Active Comparator|Standard therapy (ST)|It consists of one or more of the following procedures: transcutaneous electrical nerve stimulation (TENS), ultrasound therapy, kinesiotherapy, and cryotherapy.
11096306|NCT04102384|No Intervention|Control Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using an electronically link sent via email. Additionally, participants will be asked to fill out one survey once a week during the study period.
11096307|NCT04102384|Experimental|Intervention Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using the e-PRO app. Additionally, participants will be asked to fill out one survey once a week during the study period. A subgroup of these participants will be asked to complete an additional interview to collect more information on their experiences using the mobile app.
11096331|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
11096308|NCT04102371|Experimental|Balanced fluids (BF)|Balanced fluids (BF), including Lactated Ringer's and PlasmaLyte, will be administered to patients randomized to the experimental arm. BF will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
11096309|NCT04102371|Active Comparator|"0.9% Normal Saline Fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
11096310|NCT04102358||Single injection|Patients who received an infraclavicular block with a single injection technique were included in Group-S.
11096311|NCT04102358||Triple injection|Patients who received an infraclavicular block with a triple injection technique were included in Group-T.
11096312|NCT04102345|Experimental|Lavender|1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.
11096313|NCT04102345|Active Comparator|Zolpidem|Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.
11096314|NCT04102332||Before arm|usual infusion practices (neutral solvent-purged infusers)
11096315|NCT04102332||After arm|Safe Infusion Device
11096316|NCT04102306||Temporomandibular disorder group (TMD)|"Patients with temporomandibular disorder coming at the Cabinet Saint Alexandre for orofacial rehabilitation.
~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a rehabilitation session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next rehabilitation session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 45 days).
~Questionnaires were performed during the course of the patient rehabilitation that was instructed not to perform imagined movement during the interval."
11096317|NCT04102306||Control healthy group (CTL)|"Healthy individuals with no temporomandibular disorder (i.e., no orofacial medical consultation or rehabilitation) aged-matched and gender-matched to TMD group.
~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 8 days).
~Questionnaires were performed with no additional rehabilitation and participants were instructed not to perform imagined movement during the interval."
11096318|NCT04102293|Experimental|Rotary instrumentation using MM files 1|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
11096319|NCT04102293|Active Comparator|Manual instrumentation using K-files 1|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
11096320|NCT04102293|Experimental|Rotary instrumentation using MM files 2|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Disposable syringe technique.
11096321|NCT04102293|Active Comparator|Manual instrumentation using K-files 2|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Disposable syringe technique
11096322|NCT04102280|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
11096323|NCT04102267|Experimental|Liposomal bupivacaine injection (Group 1)|Liposomal bupivacaine 266 mg via injection
11096324|NCT04102267|Experimental|Bupivacaine HCl continuous infusion (Group 2)|Bupivacaine HCl 300 mg via continuous infusion
11096325|NCT04102254|Experimental|ANT recording and stimulation|Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation. Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery. Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered. Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place. Up to three times daily, standard intermittent high-frequency stimulation [130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
11096326|NCT04102241|Placebo Comparator|Placebo|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
11096327|NCT04102241|Experimental|15mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
11096328|NCT04102241|Experimental|30mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 30mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
11096329|NCT04102241|Experimental|60mg Hemay005|Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
11096330|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Chronic|Chronic stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
11096442|NCT04101435|Active Comparator|Group B|Aged 3 to 8 years old vaccine non-naïve subject (with prior seasonal influenza vaccine exposure)
11096443|NCT04101435|Experimental|Group C|Aged 9 to 17 years old subject
11096332|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
11096333|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS - Subacute|Sub-acute stroke patients, receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
11096334|NCT04102215|Experimental|ARCI25|Robot assited Cochlear implant surgery.
11096335|NCT04102202|Experimental|BOL-DP-o-05|
11096336|NCT04102202|Placebo Comparator|Placebo|
11096337|NCT04102189|Experimental|Semaglutide|2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly
11096338|NCT04102189|Placebo Comparator|Placebo|Placebo injected s.c. once weekly .
11096339|NCT04102176|Active Comparator|Continue nucleos(t)ide analogue|patients will be given open label tenofovir alafenamide
11096340|NCT04102176|Experimental|Stopping nucleos(t)ide analogue|patients will stop nucleos(t)ide therapy (such as entecavir, tenofovir, lamivudine or adefovir)
11096341|NCT04102163||All Participants|Participants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.
11096342|NCT04102150|Experimental|DS-3201b|
11096343|NCT04102137||3|Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
11096344|NCT04102124|Experimental|SHR3680+SHR3162|Participants will receive SHR3680 combined with SHR3162 orally
11096345|NCT04102124|Experimental|SHR3680+SHR3162(Placebo)|Participants will receive SHR3680 combined with SHR3162(Placebo) orally
11096346|NCT04102124|Placebo Comparator|SHR3680(Placebo)+SHR3162(Placebo)|Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
11096347|NCT04102111|Experimental|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily for 12 weeks.
11096348|NCT04102111|Placebo Comparator|Placebo|Participants will receive oral tablets of matching placebo twice daily for 12 weeks.
11096349|NCT04102098|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.
11096350|NCT04102098|No Intervention|Arm B (active surveillance)|Active surveillance of participants.
11096351|NCT04102085||Mothers under 30|no intervention will be administered
11096352|NCT04102072|Experimental|Trendelenburg Maneuver|The Trendelenburg position is a common treatment in medicine.It is used either as a diagnostic tool to assess fluid loading response or as a therapeutic maneuver pending fluid resuscitation.With the advantage of autotransfusion readily available,the Trendelenburg position is used for expected instantaneous effect on cardiovascular performance.
11096353|NCT04102072|Experimental|dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
11096354|NCT04102020|Experimental|Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive care|Participants will be administered with venetoclax dose A once daily (QD) (Days 1-28) up to 24 cycles, azacitidine (AZA) dose A QD on Days 1-5 of each 28 day cycle up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
11096355|NCT04102020|Experimental|Part 2: Arm A: Venetoclax + Azacitidine (AZA) + BSC|Participants will be administered with venetoclax dose A QD (Days 1-28) up to 24 cycles, azacitidine (AZA) dose A, on Days 1-5 of each 28-day cycle up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
11096356|NCT04102020|Experimental|Part 2: Arm B: Best Supportive Care (BSC)|Participants will receive treatment as prescribed by their physician according to the best supportive care for up to 24 cycles (1 cycle = 28 days)
11096357|NCT04102007|Other|Risankizumab|Participants receive Risankizumab following suboptimal response to secukinumab or ixekizumab
11096358|NCT04101994|Experimental|VCT and real rTMS|In virtual cycling training and intermittent theta burst stimulation group (VCT + iTBS group), they received VCT and iTBS (80% of active motor threshold) on affected hemisphere.
11096359|NCT04101994|Experimental|VCT and sham rTMS|In virtual cycling training and sham theta burst stimulation group (VCT + iTBS group), they received VCT and sham TBS stimulation.
11096360|NCT04101994|Experimental|real rTMS|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
11096361|NCT04101994|Sham Comparator|sham rTMS|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
11096362|NCT04101994|Experimental|VCT and real TES|In virtual cycling training and transcranial electric stimulation group (VCT + TES group), they received TES stimulation over motor cortex.
11096363|NCT04101994|Experimental|VCT and sham TES|In virtual cycling training and sham transcranial electric stimulation group (VCT + sham TES group), they received VCT and sham TES stimulation.
11096364|NCT04101994|Experimental|real TES|In transcranial electric stimulation group (TES group), they received TES stimulation over motor cortex.
11096365|NCT04101994|Sham Comparator|sham TES|In sham transcranial electric stimulation group (sham TES group), they received sham TES stimulation.
11096366|NCT04101981||healthy subjects|10 subjects
11096367|NCT04101981||oncological patients|10 subjects
11096368|NCT04101968||GBA-PD|People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
11096369|NCT04101968||Asymptomatic GBA|Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
11096370|NCT04101955|Other|Incisionless Threaded Carpal Tunnel|
11096371|NCT04101955|Other|Standard Mini-Open Carpal Tunnel|
11096372|NCT04101942|Experimental|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in the experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours on weekdays
11096373|NCT04101942|No Intervention|Control condition (assessment only)|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 7 weeks.
11096374|NCT04101929|Experimental|Experimental: Apatinib + S-1+ Irinotecan|Apatinib: 250mg po qd； S-1 capsule: According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle; Irinotecan: According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks.
11096375|NCT04101916|Experimental|Paired Associative Stimulation|
11096376|NCT04101916|Sham Comparator|Sham|
11096377|NCT04101903|Experimental|Diagnostic Aid|The experimental group will use the trial diagnostic aid for all 6-week infant hip checks
11096378|NCT04101903|No Intervention|Standard of Care|The control group will assess infants according to standard practice, during the 6-week hip check. This group will receive a leaflet about the national best practice recommendation for this check.
11096379|NCT04101890|Experimental|Diaper care with Theraworx|Participants will be given a 4 week supply of Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000), to apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks.
11096380|NCT04101890|No Intervention|Routine diaper care|Participants continue their typical diaper care.
11096381|NCT04101877|Experimental|Avastin|bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
11096382|NCT04101877|Active Comparator|Eylea|aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)
11096383|NCT04101864|Experimental|Electromagnetic navigation|In the study group acetabular components in total hip arthroplasty will be placed with the help of electromagnetic image-less navigation system. Reference plane will be anterior pelvic plane.
11096384|NCT04101864|Active Comparator|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
11096385|NCT04101851|Experimental|No axillary SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery. Approximately 80% of these patients will be assigned to the single study arm (no axillary SLNB) due to breast pCR (ypT0) at the final pathology of lumpectomy.
11096386|NCT04101838|Active Comparator|Fluzone Younger|10 adults 18-50 years old, will receive a single dose of the Fluzone influenza vaccine each year for two sequential years
11096387|NCT04101838|Active Comparator|Flucelvax|10 adults 18-50 years old, will receive a single dose of the Flucelvax influenza vaccine each year for two sequential years
11096388|NCT04101838|Active Comparator|Fluzone Older|10 adults 65-80 years old, will receive a single dose of the Fluzone influenza vaccine
11096389|NCT04101838|Active Comparator|Fluzone High Dose|10 adults 65-80 years old, will receive a single dose of the Fluzone High-Dose influenza vaccine
11096390|NCT04101838|Active Comparator|Fluad|10 adults 65-80 years old, will receive a single dose of the Fluad influenza vaccine
11096391|NCT04101825|Experimental|Auralya|Auralya® 25 (Cross-linked Hyaluronic Acid) Injection
11096392|NCT04101812|Experimental|Experimental group|Experimental group Pegylated liposomal doxorubicin 40mg/m2 iv every 3 weeks, for 3 cycles; PD-1 every 3 weeks, for 3 cycles.
11096393|NCT04101812|Active Comparator|Control group|PD-1 every 3 weeks, for 6 cycles.
11096394|NCT04101799|Experimental|Intervention|Participating in the For our children's sake intervention, 10 group sessions, 2 hours each
11096395|NCT04101799|Active Comparator|Control|Participating in everyday activities that may include parenting activities in the control prisons
11096396|NCT04101773|Other|Rubber Band Ligation (RBL)|RBL is generallya simple, inexpensive procedure. It entails a ligation of haemorrhoids using rubber bands. In RBL, a disposable suction device applies a rubber band at least 2 cm proximal to the dentate line at the base of each haemorrhoidal cushion by using an anoscope. The banding process causes necrosis of the banded tissue and slough. The resultant inflammatory reaction causes refixation of the mucosa to the underlying tissue, helping to eliminate haemorrhoidal prolapse.The end result is a return of the haemorrhoidal cushions to a more normal size and configuration, with resolution of haemorrhoidal symptoms.
11096397|NCT04101773|Other|Sutured mucopexy|A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
11096398|NCT04101773|Other|Haemorrhoidectomy|Haemorrhoidectomy involves excision of the haemorrhoidal tissue. An elliptical incision is made in the external haemorrhoidal tissue extending proximally through the dentate line to the upper limit of the haemorrhoids. The base of the haemorrhoidal complex is ligated and the haemorrhoid is excised.
11096399|NCT04101760|Experimental|Study group|Patients in study group accept prophylactic treatment of long-acting granulocyte colony stimulating factor
11096400|NCT04101760|Active Comparator|Control group|Patients in control group accept regular or prophylactic treatment of short-acting granulocyte colony stimulating factor according to current guidelines
11096401|NCT04101734||Double Lumen Endotracheal Tube|Group of patients intubated with Double Lumen Endotracheal Tube.
11096402|NCT04101734||Double Lumen Video Endotracheal Tube|Group of patients intubated with Double Lumen Video Endotracheal Tube.
11096403|NCT04101721|Experimental|Aflibercept Group|Patients will receive a single intravitreal (IVT) injection per eligible eye at baseline.
11096404|NCT04101721|Experimental|Laser Group|Patients will undergo laser treatment in each eligible eye at baseline.
11096405|NCT04101708|Experimental|high dose dual group|Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d
11096406|NCT04101708|Active Comparator|half-dose clarithromycin-containing bismuth quadruple group|Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d
11096407|NCT04101695|Active Comparator|sham tDCS- washout period- anodal tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.
~For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds. At least 7 days of washout period is in between two tDCS. For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA."
11096517|NCT04100876||healthy subjects .|30 healthy age and sex matched control subjects .
11096408|NCT04101695|Active Comparator|anodal tDCS- washout period- sham tDCS|"Ybrain tDCS System (Ybrain, Korea) is used. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on ipsilateral buccinator muscle.
~For Anodal tDCS, 20 minutes of stimulation for intensity of 2mA. At least 7 days of washout period is in between two tDCS. For Sham tDCS, total stimulation lasts 90 seconds: ramp up period of 30 seconds, stimultation for intensity of 2mA for 30 seconds, and ramp down period of 30 seconds."
11096409|NCT04101682|Active Comparator|Single Shot|Patients will receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine
11096410|NCT04101682|Active Comparator|Continuous Block|Patients will have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days
11096411|NCT04101669|Experimental|EndoBarrier|Patients in ARM 1, will receive an upper endoscopy and will be treated with the EndoBarrier Liner
11096412|NCT04101669|Sham Comparator|Sham|Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the EndoBarrier Liner.
11096413|NCT04101656||Experimental: APBI (Accelerated Partial Breast Irradiation)|APBI 28 Gy in 5 fractions of 5.6 Gy, using external radiotherapy with modulated intensity technique (IMRT)
11096414|NCT04101643|Experimental|Evolocumab group|Eligible patients receive subcutaneous injections of evolocumab 420 mg
11096415|NCT04101630||Participants with Pulmonary Hypertension|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
11096416|NCT04101630||Healthy Volunteers|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
11096417|NCT04101617|Experimental|Experimental group|Participants will receive previously designed educational material with recommendations for healthy habits and oral health recommendations. Also, pediatricians will give the parents oral health education. Parents and their children will receive toothbrushes as well as toothpaste.
11096418|NCT04101617|No Intervention|Control Group|Parents and their children will receive toothbrushes as well as toothpaste.
11096419|NCT04101604||Patients with VKH, BD, DR, AMD, or PCV|Collection of blood samples and clinical information from patients with VKH, BD, DR, AMD, or PCV
11096420|NCT04101604||Healthy subjects|Collection of blood samples and clinical information
11096421|NCT04101578||Ocular MG|Patients with autoimmune MG whose symptoms restricted to extraocular muscles
11096422|NCT04101578||Generalized MG|Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
11096423|NCT04101565|Experimental|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of baby's age.
11096424|NCT04101565|No Intervention|Usual care|Usual care that is consistent with typical maternity care in involving expectant fathers.
11096425|NCT04101552|Experimental|grafted versus graft less socket shield technique|
11096426|NCT04101539|Active Comparator|Standard Ablation (PVI)|Patients in this arm will receive standard ablation for atrial fibrillation (wide-area circumferential ablation to achieve pulmonary vein isolation [PVI]).
11096427|NCT04101539|Experimental|OPTIMA Ablation|Patients in this arm will receive standard PVI ablation and supplemental ablation of reentrant driver sites identified by OPTIMA analysis as sites likely supportive of persistent atrial fibrillation.
11096428|NCT04101526|No Intervention|Pre-Intervention Qualitative Interviews|Qualitative interviews will be conducted with breast cancer survivors, survivors' caregivers, cancer support group leaders and clinicians regarding sleep disturbance in breast cancer survivors and preferences for an intervention for sleep disturbance.
11096429|NCT04101526|Experimental|Efficacy of new intervention|Behavioral: New intervention for cancer-related sleep disturbances. The modality of this intervention will be determined after pre-intervention qualitative interviews are completed.
11096430|NCT04101500|Placebo Comparator|AECOPD(P+C1)|Placebo Tablets(P) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
11096431|NCT04101500|Experimental|AECOPD(C1+C2)|Compound Sodium Chlolate and Aminophylline Tablets(C2) three times a day, one tablet at a time; combined with Compound Ipratropium Bromide Solution(C1) 2.5ml atomized inhalation twice a day.
11096432|NCT04101487|No Intervention|Control|Participants in this arm will receive routine monthly visits along with survey administration and the regular package of health services provided at the facility level and at home by community health assistants
11096433|NCT04101487|Experimental|Cash Transfers|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants and unconditional cash transfers every month
11096434|NCT04101487|Experimental|Cash Transfers and Nutrition Education|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants, unconditional cash transfers every month, and structured nutrition education provided at household level by community health assistants based on a structured nutrition education handbook.
11096435|NCT04101474|Active Comparator|Ketamine group|half of participants will take ketamine
11096436|NCT04101474|No Intervention|Placebo group|the other half of participants will not take any drugs
11096437|NCT04101461|Active Comparator|Group I: 27 mg elemental iron|will receive PharaFerro27; Devart Lab Company, Egypt; once daily starting at 12 -14 weeks until 37-38 weeks
11096438|NCT04101461|Active Comparator|Group II: 54 mg elemental iron|will receive two tablets of PharaFerro27; Devart Lab Company, Egypt; daily starting at 12 -14 weeks until 37-38 weeks
11096439|NCT04101448||Group A|COPD patients with bronchiectasis
11096440|NCT04101448||Group B|COPD patients without bronchiectasis
11096441|NCT04101435|Experimental|Group A|Aged 3 to 8 years old vaccine naïve subject (without prior seasonal influenza vaccine exposure)
11096518|NCT04100863||Individuals with Autism|Individuals who have been diagnosed with autism
11096444|NCT04101422|No Intervention|Development of Augmented Reality (AR) Application|Investigators will collaborate with an AR software specialist to develop AR stimuli that are embedded within a basic digital application.
11096445|NCT04101422|Experimental|Pilot Testing of AR Application|AR stimuli (smoking, e.g, cigarette, ashtray, lighter; and non-smoking, e.g., pen, notebook, eraser) will be piloted on a small group of smokers to receive feedback and modify as needed. Participants will answer questions from a 10 point Likert scale that will asses urge from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke) and reality/co-existence (how realistic the item looks, and it's integration into the environment), from 1 (Not at all) to 10 (Very Much). Participants will then be asked additional open-ended questions about the quality of the images following the ratings of the images.
11096446|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 1: Cue Reactivity|142 study participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
11096447|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 2: Extinction|Participants will be randomized into either the extinction or control group. 28 trials of AR cues will be presented for each group. Both groups will receive the same neutral cue in Trial 1 (to establish baseline urge) and the same smoking cue in Trial 2 (for pre-test cue-reactivity). The extinction group will receive smoking cues for trials 3-26, whereas the control group will receive neutral cues. Both groups will receive matched smoking cues for trial (27) followed by matched neutral cues for the final trial (28), for post-test cuereactivity. Each cue will be presented for 1 minute and will be shown 4 times in trials 3-26. Following each cue, participants will complete the single-item measure of urge. Following the final trial (28) for both groups, participants will be presented with one of their own cigarettes and asked to take at least one puff. Latency to smoke will later be determined using time stamps on the video recording. Session 2 is expected to last 1.25 hours.
11096448|NCT04101422|Experimental|Testing AR Application|20 Participants will be instructed to use the AR app that presents smoking-related stimuli (cigarette, ashtray, lighter) in locations/situations where they typically smoke with the goal of at least 5 uses per day for 7 days. Usage and rating data will be collected in real-time. Participants will also be asked to rate their urge to smoke on the smartphone app at selected times. Participants will then return to the lab to provide additional feedback on the app, answer questions related to smoking behavior, and receive an in-person interview on their perceptions of the app as a potential cessation tool. Participants will use the smart phone application for 7 days.
11096449|NCT04101409|Experimental|DAs group|Shared decision making using decision aids
11096450|NCT04101409|No Intervention|Control group|Standard oral explanation guided with booklets
11096451|NCT04101396|Other|4 points blood glucose monitoring|4 points of self monitoring blood glucose which comprises of fasting, 1 hour post breakfast, 1 hour post lunch and 1 hour post dinner
11096452|NCT04101396|Other|7 points blood glucose monitoring|7 points of self monitoring blood glucose which comprises of fasting,1 hour post breakfast, 1 hour pre and post lunch, 1 hour pre and post dinner, pre bed at 10 pm
11096453|NCT04101383|Experimental|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
11096454|NCT04101383|Active Comparator|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
11096455|NCT04101370|Experimental|Bosentan|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
11096456|NCT04101370|Active Comparator|Tracleer®|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
11096457|NCT04101357|Experimental|Part 1A - monotherapy dose escalation|BNT411 monotherapy
11096458|NCT04101357|Experimental|Part 1B combination dose escalation|BNT411 in combination with atezolizumab, carboplatin and etoposide
11096459|NCT04101357|Experimental|Part 2 expansion cohorts|BNT411 either as monotherapy or in combination with other anti-cancer agents
11096460|NCT04101344|Experimental|Fiber-blend|All participants will receive a two fiber-blend snack and then a four fiber-blend snack. Stool, blood, and urine will be monitored for changes throughout the study.
11096461|NCT04101331|Experimental|Cohort A|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%
11096462|NCT04101331|Experimental|Cohort B|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to <10%
11096463|NCT04101331|Experimental|Cohort C|TMF (transformed mycosis fungoides) patients with CD30 expression ≥1%
11096464|NCT04101318|Experimental|New Stoma Baseplate with Protective Layer|New Stoma baseplate with Protective layer
11096465|NCT04101318|Active Comparator|Standard of Care|1-piece and 2-piece stoma devices already on the market.
11096466|NCT04101305||Localised prostate cancer|Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
11096467|NCT04101305||Stage 3 prostate cancer|Patients with diagnosed stage 3 prostate cancer
11096468|NCT04101305||Stage 4 prostate cancer|Patients with diagnosed stage 4 prostate cancer
11096469|NCT04101305||Healthy controls|Age-matched healthy individuals free from diagnosed cancer, but with benign inflammatory prostatitis or other benign urological condition
11096470|NCT04101292|Experimental|Fluorescence characterization|
11096471|NCT04101279|Experimental|Midurethral synthetic tape with tension control mechanism|
11096472|NCT04101279|Active Comparator|midurethral tension free tape|
11096473|NCT04101266|Active Comparator|Interscalene nerve block|preoperative interscalene nerve block to be applied with ultrasound guidance.
11096474|NCT04101266|Active Comparator|suprascapular and infraclavicular nerve block|preoperative suprascapular and infraclavicular nerve block to be with ultrasound guidance
11096475|NCT04101253|Experimental|Interventional|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
11096476|NCT04101227|Experimental|Treatment Arm|AD04 (ondansetron)
11096477|NCT04101227|Placebo Comparator|Placebo Arm|Matching Placebo
11096478|NCT04101214|Experimental|Dry needling|One session of dry needling technique will be applied by a physiotherapist specialized in the technique. Dry needling technique will be performed in the muscle of the lower limb whose MMAS score is >1 by locating a sensitive point within a taut band. After that, a thin needle (0,32x40mm) is introduced directly into those muscle that present spasticity, decide by the clinician expert.
11096479|NCT04101214|Sham Comparator|Sham Dry needling|A physiotherapist specialized in dry needling technique will use a sham needle in order to simulate the active intervention. Sham acupuncture uses non-penetrating needles.The palpation and evaluation of the spastic muscle will be exactly the same that in the active group.
11096480|NCT04101201|Other|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
11096481|NCT04101201|Placebo Comparator|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
11096482|NCT04101188|Experimental|Moderate Potassium/Low Sodium|Subjects will be provided with a diet that is moderate in potassium and low in sodium.
11096483|NCT04101188|Experimental|Moderate Potassium/High Sodium|Subjects will be provided with a diet that is moderate in potassium and high in sodium.
11096484|NCT04101188|Experimental|High Potassium/High Sodium|Subjects will be provided with a diet that is high in both potassium and sodium.
11096485|NCT04101175||Request for abortion|Patient in first trimester of pregnancy in request for abortion
11096486|NCT04101162|Other|liver biopsy|
11096487|NCT04101162|Other|ATI|
11096488|NCT04101149||Group 1|Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.
11096489|NCT04101136|Active Comparator|Atorvastatin 20 mg|Study pharmacist will make code (A and B) for atorvastatin and placebo, then save the code in safe place. Pharmacist will record each subject as participant received A or B intervention.
11096490|NCT04101136|Placebo Comparator|Placebo 20 mg|The placebo tablets will be prepared by Cipto Mangunkusumo hospital pharmacist, were composed of starch and were similar to atorvastatin tablets in size, shape, and colour.
11096491|NCT04101123||Children and adolescents with cancer|Children and adolescents between 10-18 years with newly diagnosed leukemia, brain tumors, and sarcomas
11096492|NCT04101097||training group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
11096493|NCT04101097||validation group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
11096494|NCT04101084|Experimental|Rocking chair therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
11096495|NCT04101071|Experimental|Modular ketogenic enteral feed|Ketogenic enteral feed to be administered continuously for 10 days.
11096496|NCT04101071|Active Comparator|Standard enteral feed|Standard enteral feed to be administered continuously for 10 days.
11096497|NCT04101045|Active Comparator|Poorly-controlled T1D|Patients in this group will have poorly-controlled T1D (HbA1c >8.5%).
11096498|NCT04101045|Active Comparator|Controlled T1D|Patients in this group will have T1D and achieve targeted glycemic control (HbA1c <7.5%).
11096499|NCT04101045|Active Comparator|Lean controls|Patients in this group will not have T1D.
11096500|NCT04101032|Experimental|eBEfree|eBEfree is a ICT-delivery version of BEfree - eBEfree that comprises 12 online sessions, based on mindfulness,values and compassion components for women with Binge Eating.
11096501|NCT04101032|No Intervention|Waiting List|Participants will remain in a waiting list. After 12 weeks, they will be offered the same intervention.
11096502|NCT04101019|Placebo Comparator|Control|The patient will undergo the SPGB block with saline.
11096503|NCT04101019|Active Comparator|Active drug|The patient will undergo the SPGB block with the active drug which will include 10% lidocaine diluted to 5%.
11096504|NCT04100993||Patient group|60 participants ≥16 years of age with a confirmed diagnosis of a childhood-onset NMD
11096505|NCT04100993||Exploratory reference group|20 healthy adults ≥16 years of age
11096506|NCT04100980||Chronic UTI|Patients who have been diagnosed with chronic urinary tract infections (UTI).
11096507|NCT04100954|Experimental|Reinforced prosthesis|Implementation of a reinforced prosthesis with silver coating and double valve, whatever which type of prosthesis the patient previously had.
11096508|NCT04100954|Active Comparator|Standard prosthesis|Implementation of a standard prosthesis (simple valve, not reinforced), similar to the prosthesis the patient previously had.
11096509|NCT04100941|Experimental|standard suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the standard suction technique with 10ml negative pressure
11096510|NCT04100941|Experimental|slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
11096511|NCT04100941|Experimental|wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
11096512|NCT04100915||Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Patients diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
11096513|NCT04100902|Active Comparator|Odactra 12-sq HDM sublingual tablet|House Dust Mite, sublingual tablet
11096514|NCT04100902|Placebo Comparator|Placebo sublingual tablet|Placebo, sublingual tablet
11096515|NCT04100889||Alzheimer's disease patients|Patients who have been diagnosed with Alzheimer's disease
11096516|NCT04100876||primary ITP patients .|60 primary ITP patients .
11096519|NCT04100850|Experimental|Aquatic Exercises|Aquatic Exercises (AE) are water aerobics exercises and resistance exercises, classes will be supervised by a Physical Educator, in collective sessions of up to 30 people per class, twice a week, lasting 50 minutes, for two months.
11096520|NCT04100850|Active Comparator|Watsu|The Watsu (water shiatsu) will be applied by a physical therapist, in individual sessions, twice a week, lasting 50 minutes, for two months in a warn pool (± 34°C). Watsu in particular prescribes transition of movements, once they are instituted, the therapist can create and adapt according to the limitations and restrictions that are encountered.
11096521|NCT04100850|No Intervention|Control|The control group will not receive any of these treatments (aquatic exercises and Watsu).
11096522|NCT04100837||transportal group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transportal technique (femoral tunnel drilling) , before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
11096523|NCT04100837||transtibial group|swabs will be obtained from subcutaneous tissue at antromedial portal track in transtibial technique (femoral tunnel drilling), before and after the instrumentation and femoral screw insertion, a control sample will be taken at antrolateral track in both techniques, then samples will be sended to the lab to be studied.
11096524|NCT04100824|Experimental|Bupivacaine 0.5%|patient will take stellate ganglion block 10 ml bupivacaine 0.5% and nimodipine
11096525|NCT04100824|Active Comparator|Nimodipine|patient will take nimodipine 60 mg every 4 h.
11096526|NCT04100798|Experimental|Entire Papilla Preservation (EPP) technique|A minimally invasive surgical technique that involves using a vertical incision away from the defect area in order to preserve the integrity of the related interdental papilla and elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
11096527|NCT04100798|Active Comparator|Modified Minimally invasive Surgical Technique (M-MIST)|A minimally invasive surgical technique that involves using a horizontal interdental incision that extends to the buccal aspect of the two teeth adjacent to the intraosseous defect then elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
11096528|NCT04100785|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|The iCBT programme comprised of 6 online modules, delivered over 4 weeks, with 3 face-to-face sessions provided by a clinician.The face-to-face sessions were conducted at week 1, 3 and 4. The objectives of the face-to-face sessions was for participants to discuss with the clinician about the application of the content of the modules and the active therapeutic interventions were all found in the online modules.
11096529|NCT04100785|No Intervention|Delayed Wait-list control|The delayed wait-list control did not receive any therapy interventions for 4 weeks from the pre-treatment assessment and from the fifth week onwards, they received the same intervention as the iCBT experimental group.
11096530|NCT04100772|Experimental|vaccine 1A|Subjects received one dose of PCV13i at 18 to 49 years old
11096531|NCT04100772|Experimental|vaccine 2A|Subjects received one dose of PCV13i at 50 years old and above
11096532|NCT04100772|Experimental|vaccine 3A|Subjects received one dose of PCV13i at 6 to 17 years old
11096533|NCT04100772|Experimental|vaccine 4A|Subjects received one dose of PCV13i at 2 to 5 years old
11096534|NCT04100772|Experimental|vaccine 5A|Subjects received two doses of PCV13i at 7 months to 2 years old
11096535|NCT04100772|Experimental|vaccine 6A|Subjects received three doses of PCV13i at 3,4,5 months of age
11096536|NCT04100772|Experimental|vaccine 7A|Subjects received three doses of PCV13i at 2,4,6 months of age
11096537|NCT04100772|Active Comparator|vaccine 7B|Subjects received three doses of PCV13 at 2,4,6 months of age
11096538|NCT04100759|Experimental|Non-Smokers|Subjects administer one tablet of sildenafil 50 mg
11096539|NCT04100759|Experimental|Cigarette Smokers|Subjects administer one tablet of sildenafil 50mg
11096540|NCT04100759|Experimental|Cannabis Smokers|Subjects administer one tablet of sildenafil 50mg
11096541|NCT04100733|Active Comparator|Control|Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
11096542|NCT04100733|Experimental|Intervention|Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
11096543|NCT04100720|Experimental|Cardiovalve Transfemoral Tricuspid Valve|Replacement (Implant) delivered through a transfemoral access
11096544|NCT04100707|Experimental|Operated|Genicular block will aply to the patients with knee pain who was operated before
11096545|NCT04100707|Sham Comparator|Nonoperated|Genicular block will aply to the patients with knee pain who wasn't operated before
11096546|NCT04100681|Active Comparator|Active FlowOx™|The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
11096547|NCT04100681|Sham Comparator|Sham FlowOx™ (Placebo)|The application of a mild pulsating negative pressure will be up to 120 minutes long. The pulsating negative pressure used will be approximately 10 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
11096548|NCT04100668|Experimental|Data collection|Comparing radial arterial line, Sensifree's Alpha sensor and PPG sensor pressure waveforms
11096549|NCT04100655|Experimental|GM-CSF|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.
~3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice."
11096550|NCT04100655|Experimental|Control|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.
~After hysteroscopy examination, nothing was applied to the uterine cavity."
11096551|NCT04100642|Active Comparator|1% Hemay808 apply to 25%BSA|8 subjects use 1% Hemay808
11096552|NCT04100642|Experimental|3% Hemay808 apply to 25%BSA|8 subjects use 3% Hemay808
11096553|NCT04100642|Experimental|3% Hemay808 apply to 55%BSA|6 subjects use 3% Hemay808
11096554|NCT04100642|Experimental|7% Hemay808 apply to 25%BSA|8 subjects use 7% Hemay808
11096556|NCT04100642|Placebo Comparator|placebo apply to 55%BSA|2 subjects use placebo apply to 55%BSA
11096557|NCT04100629|Placebo Comparator|Control Group|The control group will receive medical facts and are not meant to support newly licensed nurses and are not known to affect stress, resilience, perceived social support, or Intention To Leave one's job.
11096558|NCT04100629|Experimental|Experimental Group|Texts sent to the experimental group will be based on nurturant support messages and are intended to decrease stress, Intention To Leave, increase resilience, and perceived sense of support.
11096559|NCT04100616||Obsese individuals|Patients with a BMI greater than or equal to 30
11096560|NCT04100603||Patients with CDI|Patients who are infected with C. diff
11096561|NCT04100590|Experimental|Active Cannabis|In this session, the participant will smoke two-thirds of one active cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
11096562|NCT04100590|Placebo Comparator|Placebo Cannabis|In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
11096563|NCT04100577|Experimental|TNT PISP intervention|Participants in TNT PISP intervention group will come to once monthly educational support group sessions and will be additionally enrolled in the community based doula program where they will receive 1 on 1 doula and lactation support throughout their pregnancy, delivery, and postpartum period. They will receive prenatal care clinical visits on their own with their prenatal care provider. In phase 2 of the study, participants will be offered on site prenatal care once per month.
11096564|NCT04100577|No Intervention|Control|Participants in control group will have no enhanced prenatal care support. They will attend visits on their own with their prenatal care provider and participation in this research study will not interfere with the prenatal care.
11096565|NCT04100564|Active Comparator|Standard airway method arm|Standard airway management strategy
11096566|NCT04100564|Experimental|Supraglottic airway method arm|Supraglottic first airway management strategy
11096567|NCT04100538|Experimental|Intervention group|The intervention group will receive the technology-assisted program by health coach twice a week during the 10-week treatment period. The health coach will be an experienced master-prepared nurse who has extensive and in-depth knowledge about fibromyalgia and has previously worked in direct contact with patients with fibromyalgia in a research project.
11096568|NCT04100538|No Intervention|control group|The control group will receive technology-assisted informational support twice a week during the 10-week treatment period. Each technology-assisted informational support will last for approximately 10-30 min consisting of 15-min questions-and-answers regarding the educational materials and 15-min debriefing.
11096569|NCT04100525|Active Comparator|Standard Care|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant received a copy of this report in the mail and a call from the psychologist to go over test findings and recommendations.
11096570|NCT04100525|Experimental|Experimental Treatment|Participant received neuropsychological testing, report detailing cognitive strengths and weaknesses, tailored recommendations to address areas of weakness (including psychological and/or physical symptoms impacting work productivity). Participant then receives in-person feedback (and a copy of the report at this visit) and two calls from a care-coordinator research nurse at approximately 1 and 6 months post feedback, who asks participant whether they completed recommendations and assist participant in completing recommendations where possible (i.e., help find a provider, explanation of importance of completing recommendations, etc).
11096571|NCT04100512|Active Comparator|Incentive spirometry|
11096572|NCT04100512|Experimental|Oscillating Positive Expiratory Pressure Device|
11096573|NCT04100486||Healthy, Able-Bodied Individuals|This study will only enroll healthy, able-bodied individuals.
11096574|NCT04100473|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
11096575|NCT04100473|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
11096576|NCT04100460|Experimental|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
11096577|NCT04100460|Experimental|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
11096578|NCT04100460|Placebo Comparator|Control - No Arabinoxylan (Maltodextrin)|Participants are given no Arabinoxylan
11096579|NCT04100447|Experimental|Treatment Arm|All subjects will receive 1 dose of study drug (split into 2 administrations), over the 12 hours prior to surgery.
11096580|NCT04100434|Experimental|the evolocumab plus statin therapy|Patients with ACS are treated with atorvastatin (20mg) daily and evolocumab (140 mg) every two weeks throughout the study period
11096581|NCT04100434|No Intervention|the statin alone therapy|Patients with ACS are treated with atorvastatin (20mg) daily throughout the study period.
11096582|NCT04100421||Mild renal injury|CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
11096583|NCT04100421||Moderate renal injury|CKD patients with eGFR between 30 ml∙min-1∙(1.73 m2)-1 to 60 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
11096584|NCT04100421||Severe renal injury|CKD patients with eGFR < 30 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
11096585|NCT04100421||Hemodialysis|uremic patients on hemodialysis therapy
11096586|NCT04100421||Peritoneal dialysis|uremic patients on peritoneal dialysis
11096587|NCT04100421||Healthy control|Healthy volunteers with no history of kidney diseases or any chronic diseases which may lead to renal injury.
11097466|NCT04094129|Placebo Comparator|Placebo|Subjects received two placebo sachets per day
11096588|NCT04100408||Ancillary-Correlative (biospecimen collection)|LCH patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal brushing will be sequenced, genotyped, and analyzed.
11096589|NCT04100382|Experimental|Laser and SLA implants|Surgical placement of short implants in maxillary posterior teeth with Laser surface treated and SLA surface treated dental implants
11096590|NCT04100356|Experimental|Normal diet|The group ingests normal diet, recommended by the health authorities
11096591|NCT04100356|Experimental|LCHF diet|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat
11096592|NCT04100356|Experimental|Normal diet + exercise|The group ingests normal diet, recommended by the health authorities in addition to exercise program 3x week.
11096593|NCT04100356|Experimental|LCHF diet + exercise|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat, in addition to exercise program 3x week.
11096594|NCT04100330|Experimental|Ficlatuzumab with HiDAC|Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.
11096595|NCT04100330|Active Comparator|HiDAC alone|Cytarabine 2 g/m2 IV per day on Days 1 through 6
11096596|NCT04100304|Other|patient under going liver resection|
11096597|NCT04100291|Active Comparator|FMT|Faecal microbiota transplantation
11096598|NCT04100291|Placebo Comparator|Placebo|Placebo mixture
11096599|NCT04100278|No Intervention|Traditional therapy group|All patients in this group will be given routine diabetes management, including lifestyle education, health guidance, monitoring blood sugar guidance and drug adjustment.
11096600|NCT04100278|Active Comparator|Shared Care group|The patients download the Shared Care mobile application and connect with the smart-glucometer Bg1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
11096601|NCT04100265|Experimental|Panel 1 - High risk for postoperative ileus|Intervention in patients at high risk to develop prolonged postoperative ileus. Monitoring postoperative gastric motility for 2 consecutive days in patients who require preventive placement of a nasogastric feeding tube due to a high risk to develop postoperative ileus. Allowing to explore associations between gastric motility and general clinical evolution.
11096602|NCT04100265|Experimental|Panel 2 - Postoperative ileus arm with investigational device|Intervention in a population of patients with clinical signs of postoperative ileus, requiring a nasogastric feeding tube for symptom relief. The investigational medical device will be applied. Allowing to explore the association of gastric motility and clinical signs of postoperative ileus in an enriched population with true postoperative ileus.
11096603|NCT04100265|No Intervention|Panel 3 - Postoperative ileus arm with standard of care|Standard of care control group of patients with clinical signs of postoperative ileus requiring a standard nasogastric feeding tube for symptom relief. Symptoms will be surveyed as control group to assess safety and tolerability of the investigational medical device.
11096604|NCT04100252||Group 1 (Women with AFI<5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI<5 were enrolled in the Group 1.
11096605|NCT04100252||Group 2 (Women with AFI≥5 cm at the time of PPROM diagnosis)|Pregnant women who were diagnosed PPROM the gestational ages of 23+0 and 33+0 were examined ultrasonographically at the first admission. Women with AFI≥5 were enrolled in the Group 2.
11096606|NCT04100239|Experimental|Intervention Arm|Open continuous recruitment of participants to trial where all participants begin the study as 'control participants' and at regular 'steps' participants are allocated to next available intervention group and cross from the control to the intervention condition, until all groups have completed the intervention.
11096607|NCT04100226|Experimental|Interstitial lung patients with low vitamin D|Arm 1:(interventional group): interstitial lung diseases patients with low vitamine D will receive Vitamin D supplementation in form of Vitamin D3 (1.25(OH)2 cholecalciferol) in dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for deficient vitamin D level patients and every month for 3 months for insufficient vitamin D level patients beside ca supplementation in form ca carbonate 600 mg oral capsule once daily for 3 months for all patients in addition to current treatment.
11096608|NCT04100226|No Intervention|interstitial lung diseases patients with low vitamin D|Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive their current treatment only without vitamin D supplementation.
11096609|NCT04100213|Experimental|TSST|
11096610|NCT04100200|Active Comparator|Mixed Berries|Strawberry and red raspberry composite served as a frozen drink
11096611|NCT04100200|Active Comparator|FOS|Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
11096612|NCT04100200|Active Comparator|Combination|Mixed berry composite + FOS served as a frozen drink
11096613|NCT04100200|Placebo Comparator|Control|Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
11096614|NCT04100187|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
11096615|NCT04100161|Experimental|Protein supplementation|20g protein supplementation twice daily for 3 months
11096616|NCT04100161|Active Comparator|Carbohydrate supplementation|20g maltodextrin supplementation twice daily for 3 months
11096617|NCT04100148|Experimental|SyncAV Arm|Treatment Arm
11096618|NCT04100148|Active Comparator|Fixed AV Delay Arm|Control Arm
11096619|NCT04100135|Experimental|Test Arm|Device PFO closure with the GORE® CARDIOFORM Septal Occluder
11096620|NCT04100135|Sham Comparator|Control Arm|Sham device PFO closure (PFO not closed)
11096621|NCT04100122||Cutaneous only|Cutaneous and mucosal involvement only; generalized hives, pruritus or flushing, swollen lips-tongue-uvula (n=15)
11096622|NCT04100122||Wheat anaphylaxis sIgElo|Anaphylaxis (using the clinical diagnostic criteria according to World Allergy Organization; WAO 2011) with specific Immunoglobulin E (sIgE) to wheat <100 kUA/L (n=15)
11096623|NCT04100122||Wheat anaphylaxis sIgEhi|Anaphylaxis (using the clinical diagnostic criteria according to World Allergy Organization; WAO 2011) with specific Immunoglobulin E (sIgE) to wheat ≥100 kUA/L (n=15)
11096624|NCT04100122||Wheat tolerant|Patients with confirmed IgE-mediated wheat allergy for more than 12 months, and a negative oral food challenge (OFC) result to wheat during the past 12 months will be include as a control group (n=15)
11096625|NCT04100109|Active Comparator|Polylactose|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
11096626|NCT04100109|Active Comparator|Placebo|Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
11096627|NCT04100096|Experimental|Intervention|2-3 mg/day tablet
11096628|NCT04100096|Placebo Comparator|Placebo|Placebo tablet
11096629|NCT04100083|Active Comparator|Group 1|Patients taking 50mg Spironolactone
11096630|NCT04100083|Active Comparator|Group 2|Patients taking 100mg Spironolactone
11096631|NCT04100083|Active Comparator|Group 3|Patients taking 200mg Spironolactone
11096632|NCT04100070|Other|Standard monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls.
~Standard technical training, maintenance and monitoring by the CSII service provider as defined by the official specifications (LPPR)"
11096633|NCT04100070|Other|Intensive monitoring|"Usual follow-up of children by pediatricians as recommended by relevant Authorities (HAS) both in terms of frequency of visits and rhythm of biological controls completed by a personalized vision of the patient glycaemic data along the study.
~Intensive technical training, maintenance and monitoring by the CSII service provider with a higher frequency of contacts during the period (additional nurse visits)."
11096634|NCT04100057|Experimental|Cognitive Behavioral Therapy for Insomina (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
11096635|NCT04100057|Active Comparator|Desensitization Therapy for Insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
11096636|NCT04100044|Experimental|Health Services Research (physical therapist, exercise)|Patients meet with a physical therapist on day 0 and at 3 and 6 months and receive a personalized home exercise intervention consisting of aerobic and resistance training for 6 months. Patients also receive face-to-face sessions, video chats, or text message check-ins with physical therapist weekly for 6 weeks and then every other week for up to 24 weeks.
11096637|NCT04100031|Experimental|BCL group|
11096638|NCT04100031|Active Comparator|control group|
11096639|NCT04100018|Experimental|Arm A: Nivolumab + docetaxel + prednisone|
11096640|NCT04100018|Placebo Comparator|Arm B: Placebo + docetaxel + prednisone|
11096641|NCT04100005||Crohn's disease|Patients who have been diagnosed with Crohn's disease
11096642|NCT04099992|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
11096643|NCT04099992|Active Comparator|Health enhancement program (HEP)|Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions with a day-long retreat.
11096644|NCT04099992|Experimental|MBSR+tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD) ."
11096645|NCT04099992|Active Comparator|MBSR+sham-tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
~Sham stimulation will be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
11096646|NCT04099992|Experimental|HEP+tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator (a registered dietician) in a group setting for 8 weekly 2.5-hour sessions.
~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD)."
11097211|NCT04095897||conventional analgesic therapy|Patient underwent mastectomy with conventional analgesic therapy
11096647|NCT04099992|Active Comparator|HEP+sham-tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions.
~Sham stimulation is be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency (0.1 Hz) biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
11096648|NCT04099979||Psoriasis patients|Patients who have been diagnosed with Psoriasis
11096649|NCT04099966|Experimental|alpha beta cell depletion|Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.
11096650|NCT04099953|Experimental|dialysis patients|Dialysis patients were evaluated by objective diagnostic tests.
11096651|NCT04099953|Experimental|Control group|Healthy individuals
11096652|NCT04099940|Experimental|Virtual Reality Avatar Therapy (VRAT)|In the VRAT, patients with schizophrenia and acoustic hallucinations design a visual and auditory recreation (avatar) of the entity to which they attribute their hallucinations. Working with a therapist over the course of several sessions, participants change the avatar from controlling to benevolent.
11096653|NCT04099940|Active Comparator|Assertiveness Training Program (ATP)|The ATP is a transdiagnostic cognitive behavioural treatment programme, which aims to increase self-confidence and social competence in patients with a psychiatric disorder.
11096654|NCT04099927|Experimental|SHR0410|Experimental: SHR0410 dose escalation.
11096655|NCT04099901|Experimental|Anakinra|Dosage form: intravenous. Dosage: 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
11096656|NCT04099901|Placebo Comparator|Placebo|Dosage form: intravenous. Dosage: not applicable. Frequency: once daily. Duration: 15 days (day -2 until day +12).
11096657|NCT04099888|Experimental|PCI treatment in conjunction with Standard of Care (SoC)|Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy
11096658|NCT04099888|Active Comparator|Standard of Care (SoC)|Arm B: Gemcitabine/cisplatin chemotherapy
11096659|NCT04099862||ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
11096660|NCT04099862||EUS-BD|Endoscopic UltraSound Biliary Drainage
11096661|NCT04099849|Experimental|Group A|"Diet-ZnBfR zinc biofortified rice-based diet
~Diet- CR conventional rice-based diet"
11096662|NCT04099849|Experimental|Group B|"Diet-ZnBfR zinc biofortified rice-based diet
~CR + Zn conventional rice-based diet plus zinc fortificant (Diet-CR+Z)."
11096663|NCT04099836|Experimental|atezolizumab and bevacizumab|Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)
11096664|NCT04099823|Other|MR brain|"Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
~Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
~Those who meet eligibility criteria for the study and have agreed to participate will be taken to the MRI suite when MR imaging of the brain will be performed."
11096665|NCT04099810|Other|Patients undergoing Cardiac MRI|Patients scheduled to undergo cardiac magnetic resonance for clinical reason will be asked if they are willing to undergo additional non invasive testing (three-dimensional echocardiography) which will take about 15-20 minutes
11096666|NCT04099797|Experimental|C7R-GD2.CAR T cells|This is a single arm study. Patients will be treated at 4 dose levels. At dose level 0, patients will only receive GD2.CART cells without C7R and they will receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
11096667|NCT04099784||Freeze-only|Children born from freeze-only group and frozen embryo transfer
11096668|NCT04099784||Fresh|Children born from fresh embryo transfer
11096669|NCT04099771|Experimental|Ketamine|A total of 20 patients identified as having suicidal ideation will receive ketamine at 0.5mg/kg infused intravenously over 40 minutes.
11096670|NCT04099758|Experimental|Mindfulness of the breath meditation|10 minute mindfulness of the breath meditation practice delivered online via audio-recording.
11096671|NCT04099758|Placebo Comparator|Audio-recording control|10 minute non-fiction audio-recording delivered online
11096672|NCT04099745|Experimental|CGM（continuous glucose monitoring）|Each diabetic patient received three CGM tests within 14 days of FGM monitoring, on days 1-3, 6-9 and 12-14, respectively.
11096673|NCT04099745|Experimental|FGM（Flash glucose monitoring）|Each diabetic patient received one FGM test for 14 days.
11096674|NCT04099732|Experimental|Part 1: Reference 1 followed by Test 1|Reference 1 - Rosuvastatin. Test 1 - Rosuvastatin + BI 1358894
11096675|NCT04099732|Experimental|Part 2: Reference 2 followed by Test 2|Reference 2 - Dabigatran etexilate. Test 2 - Dabigatran etexilate + BI 1358894
11096676|NCT04099719||Anyone (>16 years old) registered with services providing drug|retrospective data, no intervention to be administered
11096677|NCT04099706|Experimental|Intervention - Fat grafting|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the intervention group, the fat will be purified using decanting and injected into the painful areas of skin.
11096678|NCT04099706|Sham Comparator|Control - Saline|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the control group, the fat will be discarded and saline will be injected into the painful areas of skin.
11096679|NCT04099693||General Anesthesia|"All the patients will be intubated and ventilated using cisatracurium (0.15 mg/kg) as a muscle relaxant and propofol (1.5-2mg/kg) for induction. The inhalational anesthetic, sevoflurane, will be used to maintain the depth of anesthesia using 50% mix of nitrous oxide and oxygen.
~Fentanyl will be used in both groups at a rate of 1-2 microgram /kg to achieve an adequate level of analgesia in both groups."
11097467|NCT04094129|Experimental|Probiotic|Subjects received two Wismemo sachets with 1x10^10 cfu/day
11096680|NCT04099693||Anesthetist Administered sedation for ERCP|To ensure a steady level of AAS each patient in this group will be sedated using propofol. An induction bolus of propofol (0.5 - 1 mg/kg) will be administered followed by continuous infusion with variable doses depending on the patients' age, weight, and clinical condition. In addition, fentanyl 1.5 μg/kg will be used at the anesthetist discretion.
11096681|NCT04099680|Active Comparator|Partial-thickness bed preparation|Partial-thickness bed preparation for free gingival graft procedure.
11096682|NCT04099680|Experimental|Full-thickness bed preparation|Full-thickness bed preparation with bone screw placement for anchoring the sutures.
11096683|NCT04099667|Experimental|Phase 2: MYOBLOC 15,000 U, IM|Subjects will receive a single total limb dose of 15,000 Units of MYOBLOC via intramuscular (IM) injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
11096684|NCT04099667|Experimental|Phase 2: MYOBLOC 20,000 U, IM|Subjects will receive a single total limb dose of 20,000 Units of MYOBLOC via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
11096685|NCT04099667|Placebo Comparator|Phase 2: Placebo|Subjects will receive a single total dose of volume-matched placebo via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
11096686|NCT04099667|Experimental|Phase 3: recommended Phase 3 dose (RP3D)|Subjects will receive the recommended dose of MYOBLOC (determined after analysis of the Phase 2 data) via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
11096687|NCT04099667|Placebo Comparator|Phase 3: Placebo|Subjects will receive a single total dose of volume-matched placebo via IM injection into the ankle plantar flexor muscles of the affected lower limb on Day 1 with safety and efficacy monitored over the course of 13 weeks. Provided retreatment criteria has been met, subjects will be eligible to participate in open-label extension for a total of 4 additional treatments.
11096688|NCT04099654|Experimental|Core-Stabilization Exercise|
11096689|NCT04099654|Experimental|Counseling of physical activity|
11096690|NCT04099641|Experimental|bavituximab and pembrolizumab|Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks
11096691|NCT04099615||Endovascular urgent stroke treatment group|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
11096692|NCT04099602|Experimental|Massage group|Twice a day after the birth of the baby was massaged by the researcher for 5 days. Bilirubin levels were measured twice daily by the transcutaneous bilirubin meter before the morning massage and 2 hours after the evening massage for 5 days. In the morning (between 07:00-09:00 am) and in the evening (between 19:00-21:00 pm) twice a day, 15-20 minutes baby massage was applied.
11096693|NCT04099602|No Intervention|Control group|The control group who were administered standard care and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
11096694|NCT04099589|Experimental|MIBC Group|Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.
11096695|NCT04099589|Experimental|UTUC Group|Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.
11096696|NCT04099576|Experimental|Physiotherapy plus Education|The experimental group received a three-week program consisting of 15 sessions of physiotherapy and six sessions of therapeutic neuroscience education.
11096697|NCT04099576|Active Comparator|Control group|The control group received a three-week program consisting of 15 sessions of physiotherapy alone. .
11096698|NCT04099563|Experimental|PF-04965842|Following an overnight fast for at least 10 hours, participants will receive PF-04965842 oral single dose of 200 mg (2 × 100 mg tablets) on Day 1, at approximately 08:00 am plus or minus 2 hours in the morning. On Days 3 to 8, participants will receive PF-04965842 oral dose of 200 mg (2 × 100 mg tablets) QD in the morning at approximately similar clock hour as on Day 1. On Day 3 and Day 6-8, the dosing of PF-04965842 will be after collection of pre-dose blood samples (under fasted condition for at least 10 hours). On Day 8, the dosing will be under fasted condition at approximately 8:00 am plus or minus 2 hours in the morning.
11096699|NCT04099550|Active Comparator|SMBG with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
11096700|NCT04099550|Experimental|RT-CGM with lifestyle intervention|All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.
11096701|NCT04099537|Experimental|Approach cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to pull the joystick toward (approach) them when seeing skin stimuli on a computer screen.
11096702|NCT04099537|Experimental|Avoidance cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push the joystick away (avoidance) from them when seeing skin stimuli on a computer screen.
11096703|NCT04099537|Placebo Comparator|Placebo cognitive training|This training is a single session training. Each session lasts about 30 minutes where participants are to push and pull the joystick towards or away from them (no rule) when seeing skin stimuli on a computer screen.
11096704|NCT04099524|Experimental|active tDCS|We will apply the stimulation for 20 minutes using current at 1.5mA with a ramp up and ramp down period of 30 seconds at the start and end of the session.
11096705|NCT04099524|Sham Comparator|sham tDCS|tDCS will ramp up for 30 seconds with 1 mA current and then ramp off within 10 seconds. As 30 seconds is too short for tDCS to have any effects, this will be the control condition. tDCS is on for 30 seconds because that is usually the only time individuals would experience tingling and itching - a factor we aim to equate between experimental and control conditions.
11096706|NCT04099511|Active Comparator|Usual Care Occupational Therapy-Outpatient|
11096707|NCT04099511|Experimental|Cognitive Orientation to daily Occupational Performance|
11096708|NCT04099498|No Intervention|Standard Control group|This group will not partake in the intervention but will be assessed with the same protocol at the same moments.
11096709|NCT04099498|Experimental|Online-Intervention group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator.
11096710|NCT04099498|Experimental|Enhanced-online-Intervention Group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator. In addition, gamification strategies (e.g., points for each complete activity, feedback) will be implemented in order to promote engagement with the program and activities.
11096711|NCT04099485|No Intervention|Current State|Clinicians of patients randomized to this arm will have access to the Atrial Fibrillation Decision-Support Tool (AFDST) embedded in our EHR (as they do now), but will not receive BPAs alerting them to patients who might benefit significantly from a change in anticoagulation treatment.
11096712|NCT04099485|Experimental|AFDST with BPA|Clinicians of patients randomized to this arm will receive BPAs when they are in the medical record of an AF patient who might gain significantly from a change in anticoagulation treatment. In addition, clinicians will have the ability to refer patients to a pharmacist-staffed AF Thromboprophylaxis Shared Decision-Making Service based in our Anticoagulation Clinic.
11096713|NCT04099472|Placebo Comparator|Control Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. The intervention group will also receive the same pamphlet.
11096714|NCT04099472|Experimental|Intervention Group|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission. Additionally, they will receive delirium education on prevention and management of delirium.
11096715|NCT04099433|Experimental|Oral Bacteriotherapy Arm|Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
11096716|NCT04099433|Placebo Comparator|Placebo Arm|Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
11096717|NCT04099420||Italian university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
11096718|NCT04099420||Spanish university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
11096719|NCT04099407|Experimental|Antifibrotic plus standard of care treatment|Prolonged release pirfenidone formulation in combination with standard of care treatment.
11096720|NCT04099394|Experimental|Behavioral Health|Ten behavioral health classes.
11096721|NCT04099394|Active Comparator|Health Education|Ten health education classes covering healthy aging.
11096722|NCT04099381|Experimental|Group 1 Low HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
11096723|NCT04099381|Experimental|Group 2 High HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or more HLA compatibility degree in A, B, DRB1 loci will be used.
11096724|NCT04099381|Other|Group 3 Control|Patients with standard therapy as a control group.
11096725|NCT04099368|Experimental|Auditory|Group receives training on listening to musical pitch differences between sounds as the first component of a crossover trial. The intervention is the listening exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
11096726|NCT04099368|Active Comparator|Visual|Group receives training on visual differences between objects on a computer screen as the first component of a crossover trial. This is a control measure for the auditory training exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
11096727|NCT04099355|Experimental|dronabinol|active group
11096728|NCT04099355|Placebo Comparator|control|control group
11096729|NCT04099342|Experimental|A: FEAST|Focally Electrically-administered Seizure Therapy (FEAST) is a form of Electroconvulsive therapy (ECT) that combines unidirectional stimulation, control of polarity, and an asymmetrical electrode configuration.
11096730|NCT04099342|Experimental|B: RP FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Polarity (RP) utilizes the same electrode placement as FEAST but a reversed directionality of current flow.
11096731|NCT04099342|Experimental|C: RC FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Configuration (RC) utilizes the same current flow as FEAST but a reversed electrode configuration.
11096732|NCT04099329|Experimental|Pre-game Safety Huddles|Pre-game safety huddles will occur before each game and athletes and coaches will be surveyed.
11096733|NCT04099329|No Intervention|Control|No intervention will be delivered by athletes and coaches will be surveyed.
11096734|NCT04099316|Experimental|Older adults|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
11097678|NCT04092569|No Intervention|Control group|Usual care
11096735|NCT04099316|Experimental|Older adults-Control|Older adults (Over the 60 years), Subjects did not suffer from musculoskeletal or metabolic diseases.
11096736|NCT04099316|No Intervention|No intervention|Metabolic diseases, Hypertension (150/90mmHg), Myocardial infarction within 6 months. Fractures within 6 months.
11096737|NCT04099303|Experimental|Vaccine 1A|Subjects received one dose of DTaP aged 4 to 6 years.
11096738|NCT04099303|Active Comparator|Vaccine 1B|Subjects received one dose of DT aged 4 to 6 years.
11096739|NCT04099303|Experimental|Vaccine 2A|Subjects received one dose of DTcP aged 18 to 24 months.
11096740|NCT04099303|Active Comparator|Vaccine 2B|Subjects received one dose of DTaP aged 18 to 24 months.
11096741|NCT04099303|Experimental|Vaccine 3A|Subjects received three doses of DTcP at 3,4,5 months of age.
11096742|NCT04099303|Active Comparator|Vaccine 3B|Subjects received three doses of DTaP at 3,4,5 months of age.
11096743|NCT04099303|Active Comparator|Vaccine 3C|Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.
11096744|NCT04099303|Experimental|Vaccine 4A|Subjects received three doses of DTcP at 2,3,4 months of age.
11096745|NCT04099303|Active Comparator|Vaccine 4B|Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.
11096746|NCT04099303|Experimental|Vaccine 4C|Subjects received three doses of DTcP at 2,4,6 months of age.
11096747|NCT04099277|Experimental|LY3435151 Dose Escalation|LY3435151 administered intravenously (IV).
11096748|NCT04099277|Experimental|LY3435151 + Pembrolizumab Dose Escalation|LY3435151 and Pembrolizumab administered IV.
11096749|NCT04099277|Experimental|LY3435151 Dose Expansion|LY3435151 administered IV.
11096750|NCT04099277|Experimental|LY3435151 + Pembrolizumab Dose Expansion|LY3435151 and Pembrolizumab administered IV.
11096751|NCT04099264|Experimental|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
11096752|NCT04099264|Active Comparator|Control: Audio Books|Control will consist of audio books.
11096753|NCT04099251|Experimental|Nivolumab|specified dose on specified days
11096754|NCT04099251|Placebo Comparator|Placebo|placebo equivalent specified dose on specified days
11096755|NCT04099238||Subjects with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018
11096756|NCT04099238||NVAF patients with ischemic stroke|Adult subjects from the UK THIN database who were hospitalized for ischemic stroke between 01-Jul-2016 to 30-Jun-2018 and had a diagnosis of NVAF prior to ischemic stroke (Subgroup)
11096757|NCT04099212||Cases|Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
11096758|NCT04099186|Experimental|hydro-mechanical pulmonary embolism fragmentation|Those patients will undergo catheter directed fragmentation followed by injection of 200 ml saline via power injector
11096759|NCT04099173|Experimental|Brief Mindfulness Based Intervention|
11096760|NCT04099173|No Intervention|Treatment as Usual|
11096761|NCT04099147||ETHON|Subjects from the general population identified in the ETHON
11096762|NCT04099147||HEPAmet|Subjects belonging to the Spanish registry of NAFLD (HEPAmet)
11096763|NCT04099121|Other|Patients with Pelvic Organ Prolapse|Patients who meet the inclusion criteria will be recruited. Ultrasound images of the pelvic floor and vaginal cavity will be analyzed to predict pessary size and type. This will be compared against the pessary size and type being used already by the patient.
11096764|NCT04099108|Experimental|Intervention|Combined cycle ergometry and bolus amino acid supplementation, along with standard of care
11096765|NCT04099108|No Intervention|Control|Standard of care only
11096766|NCT04099095|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed
11096767|NCT04099095|Active Comparator|Delayed Appointment|Wait-list control group who receive Social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed
11096768|NCT04099082||Cases|eligible patients with 10% decline in Forced Expiratory Volume (FEV1) at 2 months
11096769|NCT04099082||Controls|eligible patients free of 10% FEV1 decline at 2 months
11096770|NCT04099069|Placebo Comparator|trachial intubation|patient was insert trachial intubation with normal frequency jet ventilation
11096771|NCT04099069|Experimental|rigid bronchoscopy|patient was insert trachial intubation with high frequency jet ventilation
11096772|NCT04099056|Active Comparator|Participants with Major Depressive Disorder (MDD)|Participants with MDD will complete computer tasks while receiving TMS.
11096773|NCT04099056|Active Comparator|Healthy Control|Participants without MDD will complete computer tasks while receiving TMS.
11096774|NCT04099043|Experimental|Continuous Monitoring|Single Arm, Randomized
11096775|NCT04099030||Opioid shortage|Patients undergoing laparoscopic cholecystectomy during time of Fentanyl drug shortage
11096776|NCT04099030||Normal Opioid supply (no shortage)|Patients undergoing laparoscopic cholecystectomy during time of normal Fentanyl drug supply
11096777|NCT04099017|Experimental|Mulligan mobilization group|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.
~The following are the brief detail of therapy
~Mulligan joint mobilization in Non-weight bearing (NWB):
~Knee strengthening
~Kinesiotaping"
11096778|NCT04099017|Experimental|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.
~The following are the brief detail of therapy:
~Trunk stabilization i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:
~Iv. lateral step up:
~Knee strengthening i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:
~Kinesiotaping:"
11096779|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.
~The following are the brief detail of therapy:
~Knee strengthening i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:
~Kinesio-taping:"
11096897|NCT04098029|Experimental|Group 1 Low HLA compatibility|The patients in the first group will receive two CBU of low-level HLA matched infusions within a 6-month interval. The low-level match is 3 or less HLA compatibility degree by A, B, DRB1 loci.
11096944|NCT04097808|Experimental|collagen peptide bovine high molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
11096780|NCT04099004||PFP Subjects|We aim to recruit approximately 30 healthy female volunteers with PFP. Only females will be recruited for this study as they are 2 to 10 times more likely to develop PFP than males. Females participants with PFP (age 7-40 years old) will be recruited from local school districts local sports clubs and teams, local colleges, adult sport leagues, and professional sports teams, through our well established network with area coaches and athletic trainers
11096781|NCT04098991||Participants with primary hypothyroidism|All participants will receive the same treatment (levothyroxine, a synthetic T4 hormone replacement) at a dose that will be titrated using serum thyrotropin (TSH) levels as a goal, according to the American Thyroid Association Task Force recommendations
11096782|NCT04098978|Experimental|Pharmacist Drug Therapy Management|
11096783|NCT04098965|Experimental|Experimental|Physical Therapy Techniques
11096784|NCT04098965|Other|Control|physician treatment
11096785|NCT04098952|Active Comparator|Control group|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and myofascial technique for the decompression of the temporals.
11096786|NCT04098952|Experimental|Experimental group|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
11096787|NCT04098939||Healthy participants|Participants without any known cardiac or pulmonary disease.
11096788|NCT04098939||Heart disease participants|Participants with heart disease.
11096789|NCT04098939||Lung disease participants|Participants with lung disease.
11096790|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN0|Lymph node negative breast cancer
11096791|NCT04098926|Experimental|Accelerated dose-integrated radiotherapy - pN1|Lymph node positive breast cancer
11096792|NCT04098913|Experimental|Reduced screen-based media use|Reducing recreational screen-based media use for a period of 2 weeks.
11096793|NCT04098913|No Intervention|Control group|Participants are asked to continue their habitual screen-based media use.
11096794|NCT04098887|Experimental|Lattice stereotactic body radiation therapy|Patients with up to 10 chondrosarcoma lesions will undergo radiotherapy to all sites of disease. For lesions less than 4.5 cm, traditional SBRT will be used. For sites 4.5 cm or greater, Lattice SBRT will be used. For Lattice SBRT, radiotherapy will be prescribed to 20 Gy in 5 fractions delivered every other day with a LATTICE simultaneous integrated boost (SIB) to 66.7 Gy in 5 fractions.
11096795|NCT04098874|Experimental|Bupropion|Participants randomized to extended-release bupropion. Once-daily
11096796|NCT04098874|Placebo Comparator|Placebo|Participants randomized to placebo. Once-daily
11096797|NCT04098861|Experimental|once daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered once daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.
~For once daily dosing, the eye drops will be instilled at 8am every morning. The IOP will be taken at 9am-12pm on study day."
11096798|NCT04098861|Experimental|twice daily group|"Latanoprost/Timolol Fixed Combination (LTFC) will be administered twice daily for 4 weeks. The IOP will be determined on Day 14 and 28. The following examinations will be performed: evaluation of conjunctiva hyperemia, anterior chamber reaction, applanation tonometry, measurement of blood pressure and heart rate.
~For twice dosing, the eye drops will be instilled at 8am and 8pm. The IOP will be taken at 9am-12pm on study day."
11096799|NCT04098848|Experimental|Intradialytic exercise|Cycling exercise 30 minutes a time, three times a week during hemodialysis
11096800|NCT04098848|No Intervention|Control group|not participate in cycling exercise during hemodialysis
11096801|NCT04098835|Experimental|ASCEND|ASCEND combines computer-based cognitive training exercises, homework exercises to enhance cognition, and coaching sessions delivered in-person and via telephone/videoconference by a neuropsychologist. ASCEND includes 24 total computer training sessions of 30 minutes each, for a total of 12 hours. ASCEND includes 8 coaching sessions of 45 minutes each. The computer exercises aim to improve attention, working memory (WM), and cognitive control through a series of engaging and interactive computer games (e.g., card games, driving simulation). The homework exercises and coaching sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to daily life and to develop further strategies to compensate for attention and WM difficulties in daily life.
11096802|NCT04098809|Active Comparator|Catheter 16 French|16 French urinary catheter
11096803|NCT04098809|Active Comparator|Catheter 20 French|20 French urinary catheter
11096804|NCT04098796|Experimental|Experimental: Anti-PD-1 antibody＋XELOX|Every patient will receive anti-PD-1 antibody (200 mg intravenous drip every 3 weeks) and XELOX regimen chemotherapy (Oxaliplatin 130 mg/m2, intravenous drip, d1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14;every 21 days). Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years. XELOX will be administered 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
11096805|NCT04098783|Experimental|Nursing interventions (home visit and health education) group|Nursing interventions group: Home visit, health education At the Intervention group; the researcher made pretest (baseline measurements) before the nursing interventions at the first home visit. The researcher offered education and guide about prevention of lymphedema after the baseline measurements at the first home visit. Second and third home visits were made three and six months after the first visit. At the second and the third home visits, the measurements were repeated, and the nursing interventions were maintained in the direction of the patients' individual needs.
11096806|NCT04098783|No Intervention|No Nursing interventions group|No Nursing interventions group; the researcher administered the pretests at first home visit. The measurements were repeated in the third and sixth months after the first home visit. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
11096807|NCT04098770|Experimental|Conventional treatment plus Allogeneic Adoptive Immune Therapy|Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
11096808|NCT04098770|No Intervention|Conventional treatment|Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received
11097722|NCT04092205|Experimental|Experimental: Treatment|28 days treatment with NBMI 600 mg/day
11096809|NCT04098757||Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
11096810|NCT04098757||acupuncture|2 sessions a week, for a total of 10 (5 weeks), performed by the same operator, repeatable if necessary, after a therapeutic interval of at least one month. Each session lasts about 20-30 minutes per patient. Tewa J Type sterile disposable needles, coated, with a Chinese-style copper wire handle, with a guide tube, of 22x13 mm (CJ 2213) and 30x25 mm (CJ 3025) will be used. Acupuncture will be carried out by same trained operator.
11096811|NCT04098744|Experimental|Artesunate vaginal insert|Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
11096812|NCT04098744|Placebo Comparator|Placebo vaginal inserts|Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4. Unblinding will take place at week 15. Participants who do not have histologic regression at week 15 will have the opportunity to cross over to the experimental arm, and start treatment with artesunate vaginal inserts within 4 weeks of the week 15 visit.
11096813|NCT04098718|Other|PO open label prednisolone (in low blood eosinophils)|Standard care Prednisolone 30mg given daily for 5 days to treat an exacerbation.
11096814|NCT04098718|Experimental|Benralizumab SC + PO placebo|Benralizumab as a single 100mg sub cut injection and oral placebo tablet daily for 5 days
11096815|NCT04098718|Experimental|Benralizumab SC + PO prednisolone|Benralizumab as a single 100mg sub cut injection and oral prednisolone 30mg daily for 5 days
11096816|NCT04098718|Active Comparator|Placebo SC + PO prednisolone|Placebo sub cut injection and oral prednisolone 30mg daily for 5 days.
11096817|NCT04098705|No Intervention|Pre-intervention|Pre-intervention period
11096818|NCT04098705|Experimental|Post-intervention|Post-intervention period
11096819|NCT04098692|Experimental|Single-Arm: Derazantinib (Part 1 and Part 2)|"Part 1: 300 mg Derazantinib oral administration followed by 100 μg [14C]-Derazantinib intravenous microdose
~Part 2: 300 mg [14C]-Derazantinib oral administration"
11096820|NCT04098666|Experimental|metformin users|Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
11096821|NCT04098666|Placebo Comparator|metformin non-users|Placebo tablets identical to dxtended release metformin 500 mg tablets up to 4 tablets a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
11096822|NCT04098653|Experimental|Decitabine + BUCY|For myeloid tumors undergoing allo-HSCT, Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10, Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11096823|NCT04098653|Active Comparator|BUCY|For myeloid tumors undergoing allo-HSCT, BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11096824|NCT04098640|Other|FMI|FoundationOne CDx will be performed using archival tumor tissue
11096825|NCT04098627|Experimental|Intervention|Once weekly 30-minute long group laughter therapy session for 8 weeks while patients are on dialysis
11096826|NCT04098627|No Intervention|Usual Care|Usual care
11096827|NCT04098614|Experimental|Recovery Coach Intervention|"Experimental: Recovery Coach Intervention Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR)
~- Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants."
11096828|NCT04098614|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
11096829|NCT04098601|Experimental|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
11096830|NCT04098601|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
11096831|NCT04098588|Experimental|BEAST|There are 3 parts to BEAST. Part 1 involves the Behavioral Nudge technique using previously collected injunctive and descriptive norms from a National Guard sample. Soldiers will be given a customized feedback form that shows norms relevant to the target behavior they selected. The soldier will be given a chance to ask any follow-up questions. Part 2 of the intervention focuses on the principle of targeting others, considering how a change would impact those closest to them. Part 3 will utilize the Reciprocal Concessions procedure combined with the Reducing Barriers technique.
11096943|NCT04097821|Active Comparator|Part 3 Arm 3: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 3
11096832|NCT04098588|Active Comparator|Descriptive Feedback|This condition will involve a presentation of descriptive data based on the soldiers' tests scores and an opportunity to ask any follow-up questions. This process is a component of some behavioral change interventions (e.g., motivational interviewing); therefore this should be a more useful control condition (mirroring parts 1 and 2 of the active condition) versus a more passive or waitlist control condition. Participants in the control condition will also be given standard referral information to the USM Psychology Clinic (mirroring part 3 of the active condition).
11096833|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
11096834|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
11096835|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
11096836|NCT04098562|Experimental|Treatment|0.5 mg/mL LL-37 cream, administered twice a week for 4 weeks
11096837|NCT04098562|Placebo Comparator|Placebo|Placebo cream, administered twice a week for 4 weeks
11096838|NCT04098549|Experimental|Rapid-Slow|"This arm will begin with intervention rapid (rapid rate of fall in plasma glucose) for the first study visit and proceed to intervention slow (slow rate of fall in plasma glucose) for the second study visit."
11096839|NCT04098549|Experimental|Slow-Rapid|"This arm will begin with intervention slow (slow rate of fall in plasma glucose) for the first study visit and proceed to intervention rapid (rapid rate of fall in plasma glucose) for the second study visit."
11096840|NCT04098536|Experimental|Diesel Exposure|
11096841|NCT04098536|Placebo Comparator|Filtered Air Exposure|
11096842|NCT04098523|Other|Epidemiologic screening|All subjects are screened by duplex ultrasound for abdominal aortic aneurysm (AAA) and carotid artery stenosis (CAS). A questionnaire is completed to obtain information on demographic information, risk factors as well as prior treatment for AAA or CAS and current medication. No treatment is given.
11096843|NCT04098510|Experimental|MitoQ|Subjects ingest 160 mg of MitoQ
11096844|NCT04098497|Experimental|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.
~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).
~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
11096845|NCT04098484|Active Comparator|Normal-weight|Subjects with a BMI of 18-25 kg/m2
11096846|NCT04098484|Experimental|Obese|Subjects with a BMI of > 30 kg/m2
11096847|NCT04098471|Experimental|single transanal loca excision|
11096848|NCT04098471|Experimental|transanal local excision following radiotherapy|
11096849|NCT04098471|Experimental|total mesorectal excision|
11096850|NCT04098458|Experimental|NDURE|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system-(care coordination), interpersonal-(social support), and individual- (health belief model [HBM]; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, enhance HNSCC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE navigation sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit, time points chosen to facilitate case identification and coordination across key care transitions.
11096851|NCT04098445||Pediatric and young adult HSCT recipients|Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).
11096852|NCT04098432|Experimental|Arm 1|4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks
11096853|NCT04098419|Experimental|Williams Implementation|
11096854|NCT04098419|Experimental|Pittsburg Implementation|
11096855|NCT04098406|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
11096856|NCT04098406|Experimental|30 mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
11096857|NCT04098393|Experimental|patients hematologic malignancies other than multiple myeloma|A. Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels. B. Melphalan (70mg/m2/day) administered on days -6 and -5. C. Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
11096858|NCT04098393|Experimental|patients with multiple myeloma|A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
11096859|NCT04098380|Active Comparator|Small bite|The needle bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
11096860|NCT04098380|Active Comparator|Large bite|The needle bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
11096861|NCT04098367|Experimental|VIVITY|VIVITY IOL implanted in the eye during cataract surgery
11096862|NCT04098367|Active Comparator|SYMFONY|SYMFONY IOL implanted in the eye during cataract surgery
11096863|NCT04098367|Active Comparator|AT LARA|AT LARA implanted in the eye during cataract surgery
11096864|NCT04098354|Active Comparator|home-based BP telemonitoring|The intervention is a working prototype of a home BP telemonitoring system whereby a patient pushes a single button on a home BP monitor to initiate measurement, and data are auto-transmitted via Bluetooth to an Android smartphone and relayed to a secured web portal for review. Patients will receive a validated electronic upper arm oscillometric BP device (A&D Ltd. UA-651BLE; San Jose, CA) and an Android smartphone. Patients will take four measurements daily for 1 week. If BP is uncontrolled (high or low), this 1-week protocol will be followed each month until BP is in the therapeutic range. Once controlled, the 1-week protocol will be repeated every 3 months. Teletransmitted BP readings will be summarized within the health portal using telemonitoring software to the study case manager, who will also review telemonitored health portal BP summaries, make protocol-based therapeutic adjustments and send summaries to participants' PCPs to inform them of treatment changes.
11096865|NCT04098354|Placebo Comparator|usual care|For the control arm (usual standard care), participants' home BP series mean, trends, and individual readings will be sent via secure electronic medical records (EMR) to their PCP along with a 1-page summary of Canadian guidelines for BP thresholds, targets, and treatments relevant for CKD.
11096866|NCT04098341|Other|Screening|All eligible migrants will be offered opt-out IGRA blood test to screen for for latent Tuberculosis infection
11096867|NCT04098302|Active Comparator|dutasteride|two 0.5 mg capsules of dutasteride daily
11096868|NCT04098302|Placebo Comparator|placebo capsule|inactive placebo matched in appearance with dutasteride capsules
11096869|NCT04098289||Hysteroscopic septum resection without in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with natural conception (without the use of in vitro fertilization techniques).
11096870|NCT04098289||Hysteroscopic septum resection with in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
11096871|NCT04098289||Natural conception, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with natural conception (without in vitro fertilization techniques).
11096872|NCT04098289||In vitro fertilization, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
11096873|NCT04098276|Experimental|Online weWomen Intervention|For first stage randomization, women in the intervention group receive the online safety planning intervention informed by culturally specific danger assessment (DA) tool.
11096874|NCT04098276|No Intervention|Online usual care or no treatment control|Women in the control group receive the non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
11096875|NCT04098276|Experimental|WeWomen Plus Text messaging only|For second stage randomization, the text messaging intervention will follow-up with non-responder group of immigrant women (those who did not improve in intervention or control arms above) on their enactment of tailored (tailored to the DA Score and priorities) safety plan provided in the online weWomen intervention or non-tailored (standard list of resources) safety recommendations provided in the usual care control arm
11096876|NCT04098276|Experimental|WeWomen Plus Text messaging and phone|Second stage randomization will involve both text (described above) and phone calls for non-responder group of women in intervention or control arm. The phone calls will draw from motivational interviewing adapted for abused women, solution focused therapy and a strengths perspective to discuss women's safety concerns and other needs, and strategies to strengthen social support networks
11096877|NCT04098263|Active Comparator|Part B: Cohort 1|300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days
11096878|NCT04098263|Active Comparator|Part B: Cohort 2|1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days
11096879|NCT04098263|Active Comparator|Part B: Cohort 3|3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days
11096880|NCT04098263|Other|Part A|3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally
11096881|NCT04098250|Experimental|Erenumab|140 mg erenumab
11096882|NCT04098250|Placebo Comparator|Placebo|placebo comparator
11096883|NCT04098237|Experimental|Standard of care treatment with Pancreaze (pancrelipase)|Pancrelipase capsules; 84,000 IU lipase units per main meal and 42,000 IU lipase units per snack; for 24 weeks
11096884|NCT04098224|Experimental|Interventional Device - Treated|
11096885|NCT04098224|No Intervention|Control Group|
11096886|NCT04098198||Participants with an Inborn Error of Metabolism|Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years
11096887|NCT04098172|Experimental|Pressure Guidewire test subject|Stable patients with suspected or known CAD, who are scheduled for diagnostic angiography and pressure wire assessment, and signed the informed consent, will be screened for enrollment in this study.
11096888|NCT04098159|Experimental|ESRD Patients have functioning or failing VAs (AVFs or AVGs).|
11096889|NCT04098146||Mandibular Reconstruction|Patients undergoing segmental mandibular defect reconstruction. The decision of one stage or two stage reconstruction is done according to the patient and treating surgeon preferences following the local standard of care
11096890|NCT04098107|Experimental|Throwing Device Phase 1|During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
11096891|NCT04098081|Experimental|galeterone|galeterone orally once daily
11096892|NCT04098081|Experimental|galeterone+gemcitabine|daily dose galeterone and weekly dose of gemcitabine
11096893|NCT04098068|Experimental|MSI (Microsatellite Unstable) Negative with Mutator Phenotype|
11096894|NCT04098055|Experimental|Custom-made foot orthoses|
11096895|NCT04098055|Placebo Comparator|Control Group|
11096896|NCT04098042||Scaffold|"Patients receiving during PCI the implantation of at least one Magnesium Made Bioresorbable Scaffold Magmaris"
11096898|NCT04098029|Experimental|Group 2 High HLA compatibility|The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
11096899|NCT04098029|Other|Standard therapy|Patients with standard therapy as a control group
11096900|NCT04098016|Experimental|Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) responsive coaching, and 4) skills training.
11096901|NCT04098003|Experimental|Rosuvastatin|rosuvastatin 20 mg daily for eight weeks
11096902|NCT04098003|Placebo Comparator|Placebo|placebo daily for eight weeks
11096903|NCT04097990|Other|healthy participants|healthy participants
11096904|NCT04097990|Other|hypertriglyceridemia without prior pancreatit|
11096905|NCT04097990|Other|hypertriglyceridemia and at least one case of|
11096906|NCT04097977|Experimental|Intervention: RENEW in a psychiatric ward|Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group that will form the basis of real user involvement.
11096907|NCT04097977|No Intervention|Conventional clinical practice in a psychiatric standard ward|The comparison group patients were admitted to a standard psychiatric ward that offered conventional care.
11096908|NCT04097964|Experimental|FaCES Intervention|Primary care providers will deliver anticipatory guidance for adolescents reporting no drug, alcohol or marijuana use in past year, an abbreviated brief intervention for adolescents who report using these substances one or twice in the past year, and a full brief intervention for adolescents who report using these substances monthly or weekly in the past year.
11096909|NCT04097964|Active Comparator|Treatment as usual|Usual care will be delivered by primary care providers during the clinic visit
11096910|NCT04097951|Experimental|Montelukast|
11096911|NCT04097951|Experimental|Bepotastine|
11096912|NCT04097951|Experimental|Montelukast + Bepotastine|
11096913|NCT04097938|Experimental|GLPG3667 SAD|Single doses of GLPG3667 at up to 6 dose levels in ascending order
11096914|NCT04097938|Placebo Comparator|Placebo SAD|Single doses of placebo
11096915|NCT04097938|Experimental|GLPG3667 MAD|Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days
11096916|NCT04097938|Placebo Comparator|Placebo MAD|Multiple doses of placebo
11096917|NCT04097938|Experimental|GLPG3667 FE fasted|Single dose of GLPG3667 in fasted state
11096918|NCT04097938|Experimental|GLPG3667 FE fed|Single dose of GLPG3667 in fed state
11096919|NCT04097938|Experimental|GLPG3667 oral suspension rBA-FE fed|Single dose of GLPG3667 oral suspension in fed state
11096920|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fasted|Single dose of GLPG3667 capsules in fasted state
11096921|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fed|Single dose of GLPG3667 capsules in fed state
11096922|NCT04097925|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks
11096923|NCT04097912||Low-dose aspirin users|Patients who receive low-dose aspirin (75-100mg) for either the primary or secondary prevention of cardiovascular disease (CVD).
11096924|NCT04097899||Group A in preimplementation phase|Patient and antibiotic related data were collected to calculate and define; ventilator associated pneumonia incidence, mean ventilation days and mean length of stay, antibiotic selection, antibiotic cost, antibiotic susceptibility pattern, antibiotic consumption.
11096925|NCT04097899||Group B in postimplementation phase|The appropriateness of antibiotic use (selection, initiation, duration & time of discontinuation) before and after implementing the educational program was compared, calculation of the change in the ventilator associated pneumonia incidence & length of ICU stay, calculation of the change in the rate of antibiotic resistance and calculation of the cost change of antibiotics used after implementing the educational program.
11096926|NCT04097886|Experimental|Morning Exercise Group|Participants perform moderate exercise in the morning.
11096927|NCT04097886|Experimental|Evening Exercise Group|Participants perform moderate exercise in the evening.
11096928|NCT04097873|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
11096929|NCT04097873|Active Comparator|Isolated high-intensity inspiratory muscle training|
11096930|NCT04097860|Experimental|Intervention group|Will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
11096931|NCT04097860|No Intervention|Control group|Will only be sent text messages that include the same general lactation information sent to the treatment group
11096932|NCT04097834||PrEP Prescription at Enrollment|
11096933|NCT04097834||No PrEP Prescription at Enrollment|
11096934|NCT04097821|Experimental|Part 1 Arm 1: Ruxolitinib + Siremadlin|Dose escalation of siremadlin added to existing stable dose of ruxolitinib
11096935|NCT04097821|Experimental|Part 1 Arm 2: Ruxolitinib + Crizanlizumab|Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib
11096936|NCT04097821|Experimental|Part 1 Arm 3: Ruxolitinib + MBG453|Safety run-in of MBG453 added to existing stable dose of ruxolitinib
11096937|NCT04097821|Experimental|Part 2 Arm 1: Ruxolitinib + Siremadlin|Siremadlin added to existing stable dose of ruxolitinib
11096938|NCT04097821|Experimental|Part 2 Arm 2: Ruxolitinib + Crizanlizumab|Crizanlizumab added to existing stable dose of ruxolitinib
11096939|NCT04097821|Experimental|Part 2 Arm 3: Ruxolitinib + MBG453|MBG453 added to existing stable dose of ruxolitinib
11096940|NCT04097821|Experimental|Part 2 Arm 4: Ruxolitinib monotherapy|Existing stable dose of ruxolitinib as control for Part 2
11096941|NCT04097821|Active Comparator|Part 3 Arm 1: Ruxolitinib + Compound X|Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib
11096942|NCT04097821|Active Comparator|Part 3 Arm 2: Ruxolitinib cessation|Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy
11096945|NCT04097808|Experimental|collagen peptide bovine low molecular weight-Water|source: bovine; standardized to 10 g provided as single dose. Orally applied in water.
11096946|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 1|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 1
11096947|NCT04097808|Experimental|collagen peptide bovine low molecular weight- food matrix 2|source: bovine; standardized to 10 g provided as single dose. Orally applied in Food matrix 2
11096948|NCT04097808|Experimental|collagen peptide fish low molecular weight-Water|source: fish; standardized to 10 g provided as single dose. Orally applied in water.
11096949|NCT04097808|Experimental|collagen peptide porcine low molecular weight-Water|source: porcine; standardized to 10 g provided as single dose. Orally applied in water.
11096950|NCT04097795||Prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which offer prehabilitation.
11096951|NCT04097795||No prehabilitation|Patients aged 70 years and above or with an American Society of Anesthesiologists (ASA) score of III, who are scheduled for colorectal cancer surgery in one of the participating hospitals which do not offer prehabilitation.
11096952|NCT04097782|No Intervention|Control Group|"Prior to the study, primiparous pregnant women presented to the outpatient clinic for routine pregnancy control were introduced with free prenatal education classes and they were invited to participate in the study.
~Primiparous women who volunteered to participate in the study and met the inclusion criteria were included in the study and they formed the experimental and control group. Control group did not receive antenatal education and they received prenatal care service routinely provided at the polyclinics of the same hospital."
11096953|NCT04097782|Experimental|Experimental Group|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
11096954|NCT04097769|Other|HX009|Study treatment: HX009 administered every 2 weeks (14 [±1] days) via intravenous infusion.
11096955|NCT04097756|Experimental|Part1：dose escalation|The investigational product for this study is LX-039 tablets,which can be administered orally. 6~8 ascending dose level until MTD and the specification included 50 mg, 100 mg, 200 mg, 400 mg, 600 mg , 800 mg,1050 mg and 1400 mg. LX-039 tablets will be administered in a therapeutic cycle of 28 days once a day orally. The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
11096956|NCT04097756|Experimental|Part 2：dose expansion|2~3 selected tolerable dose will be selected according to the tolerance and FES PET results of dose escalation phase.The subjects will continue therapy with LX-039 if good safety and tolerability were assessed by investigators after one cycle treatment. The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
11096957|NCT04097743|Experimental|Coping statement|Daily practice of pain coping statements for 7 days
11096958|NCT04097743|No Intervention|Control|No instruction about pain coping statement.
11096959|NCT04097730|Placebo Comparator|Standard Therapy|Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.
11096960|NCT04097730|Experimental|Early Steroids|Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.
11096961|NCT04097730|Experimental|Cross-Linking plus Early Steroids|Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.
11096962|NCT04097717|Experimental|Decision Aid Arm|Participants will use the web-based decision aid plus usual medical care.
11096963|NCT04097717|Other|Usual Care Arm|Participants will receive usual medical care.
11096964|NCT04097691||on subcutaneous glucose|this group was on subcutaneous glucose 0.5 ml per site around subcutaneous nerves in the foot region both on palm and sole.which is repeated every 2 weeks for 2 months.
11096965|NCT04097691||control(not receiving treatment)|the second group is considered as control.received no treatment.
11096966|NCT04097678|Experimental|Retained Sponge Group|Just prior to imaging, the surgeon will purposely place a sponge in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
11096967|NCT04097678|No Intervention|No Retained Sponge Group|No sponge will be placed in the wound. Two radiographs will be taken of the spine (AP and Lateral views).
11096968|NCT04097665||patients with expanded flaps|Patients will undergo tissue expansion. When the expanded flaps are harvested and transplanted, ICGA will be conducted intraoperatively. Meanwhile, the possible area of necrosis will be marked according to clinical experience. And then this area will be further divided into perfusion units (1*1 square centimeter for each). The center of each perfusion unit will be marked as observation point, of which the fluorescence value will be recorded. After 1 week's follow-up postoperatively, the flap tissue will be determined by superimposing digital photography over ICGA imaging results, and the outcome of each observation point will be recorded. By analyzing the fluorescence value and outcome of each observation point, a cut-off point can be further identified to achieve both higher positive and negative predictive value, improving the utility and accuracy of ICGA in predicting the postoperative skin viability of expanded flaps.
11096969|NCT04097652|Experimental|UMC119-06|Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.
11096970|NCT04097626|Experimental|experimental|This group will receive nutrition education during the first week of the study. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
11096971|NCT04097626|Active Comparator|control|This group will receive no nutrition education. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
11096972|NCT04097613|Experimental|Betadine Treatment|Study subjects will use betadine saline sinus rinse for period of 6 weeks.
11096973|NCT04097600|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
11096974|NCT04097600|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
11096975|NCT04097600|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
11096976|NCT04097600|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
11096977|NCT04097600|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
11096978|NCT04097600|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
11096979|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
11096980|NCT04097574|Active Comparator|NPO-13 0.8%|Low dose
11096981|NCT04097574|Active Comparator|NPO-13 1.6%|High dose
11096982|NCT04097574|Placebo Comparator|NPO-13 0%|Placebo
11096983|NCT04097561|Experimental|Single arm, open-label|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
11096984|NCT04097548|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care.
11096985|NCT04097548|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care.
11096986|NCT04097522|Active Comparator|real neurofeedback|Participants receive neurofeedback from a region of the brain thought to be associated with increasing pain resilience
11096987|NCT04097522|Sham Comparator|sham neurofeedback|Participants receive neurofeedback from a region of the brain thought to be unrelated with increasing pain resilience
11096988|NCT04097509|Experimental|autologous fibrin glue (AFG) group|In the test groups, polymerized AFG was applied to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
11096989|NCT04097509|Experimental|injectable platelet rich fibrin (i-PRF) group|In the test groups, polymerized i-PRF was applied to the donor area. Donor palate was closed with sterile aluminum foil and periodontal pack.
11096990|NCT04097509|Placebo Comparator|Control Group|In the control group, only moist sterile tamponade was applied following graft removal to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
11096991|NCT04097496|Experimental|Act Out! Intervention|Eligible classrooms will be randomized to attend a 1-hour ACT OUT! interactive, semi-improvisational psychodrama performance. The ACT OUT! intervention is an established theater program (https://www.claudemcnealproductions.com/act-out-ensemble/). The ACT OUT! production will include three to five vignettes paired with moderated discussions between the audience and the actors, the latter who will remain partly in character for the duration of the intervention. Vignettes will be different for each grade level included in the study (4th, 7th, and 10th). Public documentation of the guidelines for the ACT OUT! intervention will be made available as a supplemental file attached to the primary outcomes paper for the study.
11096992|NCT04097496|No Intervention|Control|Classrooms randomized to this arm will continue with their school day as normal, except that they will complete the data collection tools.
11096993|NCT04097483|Experimental|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention, centered on motivational interviewing and cognitive behavioural therapy for adherence and depression.
11096994|NCT04097483|No Intervention|Control group|Control group with treatment as usual (TAU).
11096995|NCT04097470|Active Comparator|Arm A: Decitabine|"Cycles 1-3: Decitabine 10-day; depending on day +28 bone marrow (BM) blasts after the previous cycle, next cycle consists of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks); continuation of these cycles until progression.
~Dosage for Decitabine 20 mg/m2 i.v."
11096996|NCT04097470|Experimental|Arm B: Decitabine and Midostaurin|"Cycle 1:Decitabine; 10-day schedule (start day +1) + midostaurin (start day +11). Midostaurin is given until 2 days before start next cycle of decitabine. Cycles 2-3: Decitabine 5 or 10-day schedule; depending on day +28 bone marrow blasts of the previous cycle, next cycle consist of either 5-day (BM blasts < 5%) or 10-day (BM blasts ≥5%) decitabine + midostaurin (daily, starting the day after the last dose of decitabine (i.e. day +6 or +11). Midostaurin is given until 2 days before start next cycle. Cycles 4 and beyond: 5-day decitabine (in cycles of 4-8 weeks) followed by midostaurin starting at day +6 until two days before start of next cycle of decitabine; continuation of these cycles until progression. Midostaurin is given until 2 days before start next cycle of decitabine.
~Dosage for Decitabine 20 mg/m2 i.v.
~Dosage for Midostaurin 50 mg b.i.d."
11096997|NCT04097457|Experimental|Parent mediated intervention (PMI) group|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. The protocol is administered to groups of 4 families.
11096998|NCT04097457|Experimental|Waitlist control|Families will be recruited and will fill out measure for 3 months prior to participation and will then join the active intervention
11096999|NCT04097457|Experimental|Individual|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. In this arm the protocol is administered individually to families.
11097019|NCT04097353|Experimental|Harvesting Hope for Kids (HH4K)|Eight weekly, 60-minute sessions at a university-based farm with booster sessions. Learning is structured around fun activities to provide information about the impact of cancer treatment on children's health, as well as the importance of nutrition and physical activity in survivorship. Each session is manualized and devoted to education, a behavioral strategy applied toward a weekly goal, a cooking demonstration/taste testing, and harvesting produce from the survivor garden. Modules are offered in a group format with families together.
11098228|NCT04088721|Experimental|AD17002 60μg|Intranasal weekly dosing of AD17002 for three times
11097000|NCT04097444|Experimental|Step 1 (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) oxaliplatin (OX): 100/130 mg/sq.m (d.i.v.) irinotecan (IRI):150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. OX/IRI dose is applied according to the progress of Step 1.
~[Maintenance treatment: 5-fluorouracil (FU)/Levofolinate calcium (LV)+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
11097001|NCT04097444|Experimental|Step 2 Arm A (FOLFOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment: FOLFOXIRI+BEV] Administered for 8 cycles (a maximum of 12 cycles). BEV: 5mg/kg (d.i.v.) OX: 85 mg/sq.m (d.i.v.) IRI:165mg/sq.m (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. Day1-15) Administered every 3 weeks."
11097002|NCT04097444|Experimental|Step 2 Arm B (CAPOXIRI+ BEV)|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment: CAPOXIRI+BEV] Administered for 6 cycles (a maximum of 8 cycles). BEV: 7.5mg/kg (d.i.v.) OX: 100/130 mg/sq.m (d.i.v.) IRI:150/180/200mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-15) Administered every 3 weeks. Regarding to OX/IRI dose, RD will be confirmed at Step 1.
~[Maintenance treatment: 5-FU/LV+BEV or CAP+BEV] The following 5-FU/LV+BEV therapy will be repeated in 2-week cycles, or the following CAP+BEV therapy will be repeated in 3-week cycles (Physician's choice). No change in treatment regimen will be permitted after the selection of maintenance therapy (5-FU/LV+BEV or CAP+ BEV).
~5-FU/LV+BEV: BEV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~CAP+BEV: BEV: 7.5mg/kg (d.i.v.) CAP 1,600 mg/sq.m /day (po. day1-15) Administered every 3 weeks."
11097003|NCT04097431|Experimental|Precursors as Response Chain or Class|The precursor behavior occurs as a part of a sequence, or for the same maintaining variable, leading up to the severe problem behavior.
11097004|NCT04097418|Experimental|Aerobic training in healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
11097005|NCT04097418|Active Comparator|Conventional motor training of healthy subjects|"For each healthy subject, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
11097006|NCT04097418|Experimental|Aerobic training in MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Subjects of the experimental groups (both patients and healthy controls) will carry out an aerobic training of moderate intensity (fixed time and variable intensity) on a treadmill. The training will be set individually via direct method: during the first session, the subject will be trained at an intensity that gets the heart rate (HR) corresponding to 46-63% of VO2 peak measured during the exercise test; in subsequent sessions the intensity will increase to maintain the same HR, which will be always monitored. The intensity workout identified will be maintained for 30 minutes each session, preceded and followed by a few minutes of warm-up and cool-down."
11097007|NCT04097418|Active Comparator|Conventional motor training of MS patients|"For each MS patient, the treatment will lasts 8 weeks. Each treatment will consists of 35 minutes of training, administered 3 times per week.
~Control groups of both patients and healthy subjects will follow a conventional non-aerobic physiotherapy training, structured in: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training."
11097008|NCT04097405|Active Comparator|D-0120 Dose Ascending Cohorts 1-4|D-0120 dose daily for up to 7 days.
11097009|NCT04097405|Placebo Comparator|Placebo Dose Ascending Cohorts 1-4|Placebo dose daily for up to 7 days
11097010|NCT04097405|Experimental|D-0120/Uric Acid Lowering Agent Cohort 6|D-0120 in combination with a uric acid lowering agent for up to 7 days of combination therapy
11097011|NCT04097392|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
11097012|NCT04097392|Active Comparator|Isolated high-intensity inspiratory muscle training|
11097013|NCT04097379|Experimental|LRX712|Randomized in a 1:1 ratio: LRX712 to placebo
11097014|NCT04097379|Placebo Comparator|Placebo|Randomized in a 1:1 ratio: LRX712 to placebo
11097015|NCT04097366|No Intervention|Standard of Care|Control arm, no supplementary imaging is given. Participants have mammographic screening 3-yearly as per current standard of are.
11097016|NCT04097366|Active Comparator|Abbreviated MRI (ABB-MRI)|Supplementary imaging with abbreviated MRI at study entry and 18 months after baseline mammogram.
11097017|NCT04097366|Active Comparator|Automated Breast Ultrasound (ABUS)|Supplementary imaging with automated breast ultrasound at study entry and 18 months after baseline mammogram.
11097018|NCT04097366|Active Comparator|Contrast Enhanced Mammography (CESM)|Supplementary imaging with contrast enhanced spectral mammography at study entry and 18 months after baseline mammogram.
11097212|NCT04095897||Pecs II block|Patient underwent mastectomy with conventional analgesic therapy with pre induction Pecs II block
11097020|NCT04097353|Sham Comparator|Surviving Strong for Kids (SS4K)|Families assigned to enhanced usual care (SS4K) group will receive education in the form of standardized guidelines for nutrition and physical activity for survivors of childhood cancer. In a one-hour session, they will learn about the impact of cancer treatment on health and the importance of nutrition and physical activity for survivors. Families will receive websites for other educational resources. They will not have access to harvesting, remote coaching, the web portal, or behavioral training to address their child's nutrition or activity.
11097021|NCT04097340|Active Comparator|Attentional Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
11097022|NCT04097340|Placebo Comparator|Control Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
11097023|NCT04097314|Experimental|Zibotentan|
11097024|NCT04097314|Placebo Comparator|Placebo|
11097025|NCT04097301|Experimental|MLM-CAR44.1 T-cells infusion|"PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.
~PHASE IIa: i.v. dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD)."
11097026|NCT04097288|Experimental|Single dose citalopram|A blinded single dose 40 mg citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
11097027|NCT04097288|Active Comparator|Single dose reboxetine|A blinded single dose 8 mg reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
11097028|NCT04097288|Placebo Comparator|Single dose placebo citalopram|A blinded single dose visually identical placebo pill to citalopram is administered three hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
11097029|NCT04097288|Placebo Comparator|Single dose placebo reboxetine|A blinded single dose visually identical placebo pill to reboxetine is administered two hours before urethral pressure reflectometry and anal acoustic reflectometry measurements
11097030|NCT04097275||Participants with an Inborn Error of Metabolism|
11097031|NCT04097262|Experimental|Own-Price Elasticity|"The price of fruit will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
11097032|NCT04097262|Experimental|Cross-Price Elasticity|"The price of fruit will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
11097033|NCT04097249||Healthy subjects|Participants free from any pain specific to the upper limb, chronic pain or other disease.
11097034|NCT04097236|Active Comparator|45° semirecumbent position|
11097035|NCT04097236|Active Comparator|No elevation of the upper section of the bed|
11097036|NCT04097223||Subjects with Pulmonary Disease, Chronic Obstructive|
11097037|NCT04097197|Experimental|Patients receiving information|Patients in the experimental arm will receive a brief educational intervention if they initially refuse flu vaccination. The intervention was designed towards the most common barriers to flu vaccination that were found after a brief review of the literature. After the intervention, patients will be asked again whether or not they wish to receive the flu vaccine.
11097038|NCT04097184|Active Comparator|"active tDCS group"|Patients will benefit from a series of 10 double-blind effective tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
11097039|NCT04097184|Sham Comparator|"sham tDCS group"|Patients will benefit from a series of 10 double-blind placebo tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
11097040|NCT04097171|Experimental|High Carbohydrate Diet|Participants will consume a high carbohydrate diet (65-75% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
11097041|NCT04097171|Experimental|Ketogenic Diet|Participants will consume a low carbohydrate diet (<5-10% of total energy intake). Protein intake will be standardized at 15% of total energy intake.
11097042|NCT04097158||Upper Motor Neuron predominant ALS|
11097043|NCT04097158||Lower Motor Neuron predominant ALS|
11097044|NCT04097158||Bulbar predominant ALS|
11097045|NCT04097158||Generalized ALS|
11097046|NCT04097145|Experimental|Edwards PASCAL System & OMT|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
11097047|NCT04097145|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
11097048|NCT04097132||ischemic stroke patients|all patient admitted with acute ischemic stroke either their ECG was AF or sinus rythm
11097049|NCT04097119|Other|Dietary supplement arm|Subjects to receive a specific dietary supplement
11097050|NCT04097106||Lean BMI (19-25)|
11097051|NCT04097106||Obese BMI (30-35)|
11097052|NCT04097093||Study 62005-STBSG patients treated with imatinib > 10 years|
11097053|NCT04097080|Experimental|NBTX-001|30% medical grade xenon/70% Oxygen
11097054|NCT04097080|Placebo Comparator|Standard of Care|Reconstituted air
11097055|NCT04097067|Experimental|Treatment (low-dose radiation therapy)|"Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT & IGRT).
~Blood draw for biomarker-analysis (at baseline visit/ after 4 Gy/ after 10 Gy / after 20 Gy RT/ at 3 and 6 months after RT)"
11097056|NCT04097054|Experimental|Intervention|Patients in the interventional arm are operated after augmented planning of the procedure. The plan is prepared by the surgeon and made available to the study team a day prior to the procedure and on a screen in the OR during the procedure. The plan includes the current and next operative step, the used equipment and the approximate time used as well as the estimated time of when the procedure will end.
11097149|NCT04096417|Experimental|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11097057|NCT04097054|No Intervention|Control|In the control cases no particular planning and distribution of operative plan is performed. The standard preparation only includes the distribution of information on the desired positioning of the patient, necessary special equipment and the overall estimated OR time.
11097058|NCT04097041|Active Comparator|Surgical Arm|Surgery arm - patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).Patient has routine follow up - H&P, 2 weeks after surgery and then H&P, Audiometry and Tympanometry over 12 months post surgery (3rd month, 6th month and 12th month).
11097059|NCT04097041|Active Comparator|Non-Surgery|"Non surgery arm - patient has audiological consult and fitting of masking device.
~The Patient has a routine follow up - H&P, 2 weeks after masking fitting and then H&P, Audiometry, Tympanometry over 12 months (3rd month, 6th month and 12th month). Patient cross over to change arms, at 6 months, if they have no resolution of symptoms."
11097060|NCT04097028|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1 and trifluridine and tipiracil hydrochloride PO BID on days 1-5. Treatment repeats every 14 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care chemoradiation therapy followed by surgery.
11097061|NCT04097015|Experimental|Treatment|The treatment or intervention is the use of NI-ES using a signal generator, Alpha-Stim M, with an Ocular Interface connected to one channel and a Spinal Interface to the other channel. The treatment is done at home for 40 minutes at a time, twice a day. The upper lids of the closed eyes are treated for 10 minutes and the lower lids of the closed eyes are treated for 10 minutes, alternated throughout the treatment time. The Spinal Interface is placed above the SCI for 40 minutes. The entire procedure is repeated for another 40 minutes for a second time. The participant will treat himself at home.
11097062|NCT04097002|Experimental|Phase I, Part A, Cohort 1|"Single dose-escalation of ORCA-010, Dose Cohort 1: 1x10*11 viral particles.
~Single dose of ORCA-010 will be administered for the first subject only and all relevant safety data for this subject will be reviewed by the DSMB prior to enrolling additional subjects.
~After the DSMB review, subjects will be enrolled in groups of three (including the first subject) and assessed for safety and Dose-Limiting Toxicity (DLT) after a single dose of ORCA-010.
~Group of 3 subjects.
~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
11097063|NCT04097002|Experimental|Phase I, Part A, Cohort 2|"Single dose-escalation of ORCA-010, Dose Cohort 2: 5x10*11 viral particles.
~Group of 3 subjects.
~Dose will be escalated to the next cohort based on safety and toxicity results from the 3 treated subjects to determine the Maximum Tolerated Dose, if not determined by this cohort."
11097064|NCT04097002|Experimental|Phase I, Part A, Cohort 3|"Single dose-escalation of ORCA-010, Dose Cohort 3: 1.5x10*12 viral particles.
~Group of 3 subjects.
~Dose will be considered as the Maximum Tolerated Dose based on safety and toxicity results from the 3 treated subjects."
11097065|NCT04097002|Experimental|Phase IIa, Part B, Cohort 4|"Two dose administration of ORCA-010 seperated by 2 weeks, Dose Cohort 4: The Maximum Tolerated Dose depending on Phase I/ Part A results.
~Group of 12 subjects."
11097066|NCT04096989|No Intervention|Control group|Routine care.
11097067|NCT04096989|Experimental|Experimental group|The participants accept TCM regimen-based lifestyle mobile health application intervention.
11097068|NCT04096989|Sham Comparator|Sham comparator group|The participants accept mobile health application intervention.
11097069|NCT04096976||Hospital survival|
11097070|NCT04096976||No hospital survival|
11097071|NCT04096963||The WATCHMAN FLX Delivery System|Patients who are eligible for a WATCHMAN FLX device according to current international and local guidelines (and future revisions) and per physician discretion;
11097072|NCT04096950|Experimental|MT-3921|Intravenous, single ascending dose
11097073|NCT04096937||Appalachian adults|Adults in Appalachia invested in well-being of youth.
11097074|NCT04096937||Appalachian youth|Youth from 7th through 12th grade.
11097075|NCT04096924|Experimental|Treatment Group|Experimental group is allocated to use novel interventional guidewire for the echocardiography guided percutaneous interventions for ASD.
11097076|NCT04096924|Active Comparator|Control Group|Control Group is allocated to use Cook lunderquist guidewire for the echocardiography guided percutaneous interventions for ASD.
11097077|NCT04096911|Experimental|Sintilimab and HPV Vaccine|Sintilimab 200 mg intravenously every 3 weeks ，3 doses of quadrivalent HPV vaccine intramuscularly at day 1,60,180
11097078|NCT04096885||InSurg cohort|Patients who undergo elective or emergency surgery at the Department of Visceral Surgery and Medicine, Inselspital, Bern, who gave informed consent.
11097079|NCT04096859||PremiCron®|Assessment of PremiCron suture for cardiac valve reconstruction and replacement
11097080|NCT04096833|Experimental|Intervention Group|Participants use as a distracting measure Virtual Reality glasses during the vaccination.
11097081|NCT04096833|No Intervention|Control Group|Participants use usual non-virtual distracting measures during the vaccination.
11097082|NCT04096820|Experimental|Open Label|Uromune will be taken by the participant for 90 days.
11097083|NCT04096781|Experimental|Shared Decision Making Tool (SDMT)|
11097084|NCT04096781|Active Comparator|Usual Care|
11097085|NCT04096768|Experimental|Dexmedetomidine + Ketamine|
11097086|NCT04096768|Placebo Comparator|Dexmedetomidine + Placebo|
11097087|NCT04096755||DVT group|40 patients with a confirmed deep venous thrombosis (DVT) on Duplex ultrasound will be recruited into this group. All patients will have serum and urine samples for analysis.
11097088|NCT04096755||Control Group|40 volunteers without a DVT will be recruited for the control group. They will have urine and serum samples taken for analysis.
11097089|NCT04096742|Experimental|Altreno|tretinoin 0.05% lotion (Altreno)
11097090|NCT04096742|Sham Comparator|Vehicle|Vehicle lotion not containing tretinoin
11097091|NCT04096729||patients who have consulted and need compression therapy using|1) age from 18 to 75 years; 2) compression therapy prescribed by a phlebologist. The exclusion criterion is hearing impairment, which could interfere with a telephone questionnaires.
11097150|NCT04096404|No Intervention|Control|no advice
11097151|NCT04096404|Active Comparator|Non genetic personalised advice|dietary and physical activity advice based on reported dietary intake and physical activity
11097092|NCT04096716|Experimental|Cohort 1: Tc-99m tilmanocept|"The surgeon will inject 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor
~Portable gamma camera imaging will be obtained at 3 ± 2 hour, 6 ± 1 hours (optional), and the following day after injection of Tc-99m tilmanocept."
11097093|NCT04096716|Experimental|Cohort 2A: Tc-99m tilmanocept frontal lobe injection site|"The surgeon will inject 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor
~SPECT/CT of the head and neck will be obtained at the time of peak lymph node enhancement (time to be determined by gamma camera imaging from Cohort 1). If this is found to be on Day 1 and the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
11097094|NCT04096716|Experimental|Cohort 2B: Tc-99m tilmanocept parietal lobe injection site|"The surgeon will inject 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor
~SPECT/CT of the head and neck will be obtained at the time of peak lymph node enhancement (time to be determined by gamma camera imaging from Cohort 1). If this is found to be on Day 1 and the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
11097095|NCT04096716|Experimental|Cohort 2C: Tc-99m tilmanocept temporal lobe injection site|"The surgeon will inject 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor
~SPECT/CT of the head and neck will be obtained at the time of peak lymph node enhancement (time to be determined by gamma camera imaging from Cohort 1). If this is found to be on Day 1 and the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
11097096|NCT04096716|Experimental|Cohort 2D: Tc-99m tilmanocept occipital lobe injection site|"The surgeon will inject 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor
~SPECT/CT of the head and neck will be obtained at the time of peak lymph node enhancement (time to be determined by gamma camera imaging from Cohort 1). If this is found to be on Day 1 and the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
11097097|NCT04096703|No Intervention|Expectant management of EGJOO Group|The participants randomized to this group will receive expectant management of EGJOO. Expectant management is evaluating whether symptoms improve over time without an intervention
11097098|NCT04096703|Experimental|Pneumatic dilation of EGJOO Group|The participants randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific).
11097099|NCT04096690|Experimental|Anti-PD-1 antibody plus pegaspargase|Participants will receive induction treatment for six cycles of Anti-PD-1 antibody plus pegaspargase (21-day cycle) and Anti-PD-1 antibody monotherapy maintenance treatment for about 2 years (21-cycle)
11097100|NCT04096677||hysteroscopy repair|patients with post cesarean scar defect
11097101|NCT04096677||transvaginal repair|patients with post cesarean scar defect
11097102|NCT04096664|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
11097103|NCT04096664|No Intervention|Control|Usual care
11097104|NCT04096651|Other|PSP Classic|"15 patients with a classical form of PSP are recruited to realize all the tests of the multimodal approach."
11097105|NCT04096651|Other|Caribbean PSP|"15 patients with a Caribbean PSP are recruited to realize all the tests of the multimodal approach."
11097106|NCT04096651|Other|Healthy controls|15 persons with no PSP are recruited to realize all the tests of the multimodal approach.
11097107|NCT04096638|Experimental|Part 1a: Monotherapy Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses (0.3-14 SB 11285 µg/Kg)
11097108|NCT04096638|Experimental|Part 1b: PD-L1 Combination Dose Escalation|SB 11285 weekly on Days 1, 8, 15 and 22 on repeated 28-day cycles in escalating doses (0.3-3.0 SB 11285 µg/Kg) plus 1680mg every 4 weeks (Q4W) atezolizumab
11097109|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort A)|"Cohort A: Patients with Melanoma
~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
11097110|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort B)|"Cohort B: Patients with HNSCC
~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
11097111|NCT04096638|Experimental|Part 2: Combination Expansion Cohorts at RP2D (Cohort C)|"Cohort C: Patients with tumor types other then Cohort A and B (Naïve or relapsed refractory to anti PD-1/PD-L1)
~After determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in SB 11285 plus atezolizumab combination the Part 2 with expansion cohorts will commence to further evaluate the RP2D."
11097112|NCT04096625|Experimental|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
11097113|NCT04096625|Sham Comparator|Sham tDCS|Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
11097114|NCT04096612|Experimental|Orbital decompression combined MPT|Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
11097152|NCT04096404|Experimental|Genotype- based personalised advice|dietary and physical activity advice based on genotype, reported dietary intake and physical activity
11097115|NCT04096612|Experimental|Separate MPT|MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
11097116|NCT04096599|Experimental|Test group|
11097117|NCT04096599|Active Comparator|Control group|
11097118|NCT04096586|Active Comparator|Red juice|Subjects consume 8 fl oz of red juice daily for 8 weeks
11097119|NCT04096586|Experimental|Watermelon juice|Subjects consume 8 fl oz of watermelon juice daily for 8 weeks
11097120|NCT04096573|Experimental|LC51-0255 low dose|Oral, daily, low dose for induction period, high dose for OLE period
11097121|NCT04096573|Experimental|LC51-0255 middle dose|Oral, daily, middle dose for induction period, high dose for OLE period
11097122|NCT04096573|Experimental|LC51-0255 high dose|Oral, daily, high dose for induction period, high dose for OLE period
11097123|NCT04096573|Placebo Comparator|placebo|Oral, daily, placebo for induction period, high dose for OLE period
11097124|NCT04096560|Placebo Comparator|Part A, Cohorts A1 and A2, NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT1.
11097125|NCT04096560|Experimental|Part A, Cohort A1, NT1 Participants: TAK-994 Dose 1|TAK-994, tablets, dose level 1 for 28 days, in participants with NT1.
11097126|NCT04096560|Experimental|Part A, Cohort A2, NT1 Participants: TAK-994 TBD|TAK-994 tablets, dose to be determined (TBD) based on safety and tolerability in Cohort A1, for 28 days. Based on Cohort A1 data decision will be made to enroll participants in this Cohort.
11097127|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 1|TAK-994 dose 1, tablets, for 56 days in participants with NT1.
11097128|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 2|TAK-994 dose 2, tablets, for 56 days in participants with NT1.
11097129|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 3|TAK-994 dose 3, tablets, 56 days in participants with NT1.
11097130|NCT04096560|Placebo Comparator|Part B, NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 56 days in participants with NT1.
11097131|NCT04096560|Placebo Comparator|Part C, Cohort C1, NT1 Participants in China: Placebo|TAK-994 placebo-matching tablets for 56 days, in participants with NT1 in China.
11097132|NCT04096560|Experimental|Part C, Cohort C1, NT1 Participants in China: TAK-994|TAK-994 tablets, dose TBD based on safety and tolerability in Part B, for 56 days in participants with NT1 in China.
11097133|NCT04096560|Placebo Comparator|Part D, Cohort D1 and D2, NT2 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT2.
11097134|NCT04096560|Experimental|Part D, Cohort D1, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety and tolerability in Part A , for 28 days in participants with NT2.
11097135|NCT04096560|Experimental|Part D, Cohort D2, NT2 Participants: TAK-994 TBD|TAK-994 tablets, dose TBD based on safety and tolerability in Part A, for 28 days in participants with NT2. Based on Cohort D1 data decision will be made to enroll participants in this Cohort.
11097136|NCT04096534|Experimental|Normotonic partial nephrectomy|Performing a partial nephrectomy under normal body blood pressure
11097137|NCT04096534|Active Comparator|Hypotonic partial nephrectomy|Performing a partial nephrectomy under hypotonic body blood pressure
11097138|NCT04096521||East Jakarta Cohort Study|One group included in the study was originated from mothers who participated in the first data collection pregnancy. The follow-up study included mothers and their children born as the subject in the follow-up in the study. This study also includes peer of the subjects that lived in the same neighbourhood since the first cohort study and have children in the same age with cohort participant
11097139|NCT04096508|Experimental|Group A|Patients sit comfortably in a chair for 20 min listening classic music before the procedure.
11097140|NCT04096508|Experimental|Group B|Patients sit comfortably in a chair for 20 min listening popular music before the procedure.
11097141|NCT04096508|No Intervention|Control group|Patients sit comfortably in a chair for 20 min without music listening before the procedure.
11097142|NCT04096482|Experimental|Peregrine Drivable ENT Scope Followed by Standard Endoscope|Participants will receive an endoscopy with the Peregrine Drivable ENT Scope followed by an endoscopy with the standard 30° 4mm endoscope.
11097143|NCT04096482|Active Comparator|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
11097144|NCT04096469|Experimental|Motivational Interviewing|The intervention group received a guidance regarding their diet and physical activity using the motivational interviewing strategy to improve adherence to healthy behaviors. Participants received a guide with a motivational interviewing approach, which served as the basis for the interview process. The objectives in the intervention group were to consume four vegetables and two fruits a day, seven days a week, increase fiber consumption to more than 30 g daily, reduce fat consumption to no more 20% of the total energy consumed, decrease the consumption of sugary drinks and increase protein intake. Another goal was to increase the number of steps to 4,000 additional steps to those who have already walked.
11097145|NCT04096469|Active Comparator|Traditional Education|The comparison group received a guide on medical care and nutrition with a traditional educational approach. The indication was to read and learn about the health-related topics included in the booklet that was given to them. These participants were visited in the same way as the intervention group to answer questions and monitor participation throughout the intervention.
11097146|NCT04096443|Experimental|Intervention|Fecal microbial transplant capsules
11097147|NCT04096430|Experimental|ENGAGE approach (child-oriented goal-setting)|Therapists will receive training on our principles-based goal setting approach and strategies in the goal setting toolbox. Training will include an overview of tools and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS) and the Pediatric Activity Card Sort (PACS). In addition, we will provide training on Goal Attainment Scaling and administration of the Canadian Occupational Performance Measure (COPM). We will introduce simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
11097148|NCT04096430|No Intervention|Usual care|The control group will comprise of usual care.
11097153|NCT04096391|Active Comparator|Intrathecal Drug Delivery System|Subjects randomized to the Intrathecal Drug Delivery System group will be implanted with the Prometra System under sterile technique in accordance with the Instructions for Use. The pump will be filled at the time of implantation with the prescribed medication.
11097154|NCT04096391|Active Comparator|Conventional Medical Management|Subjects randomized to the Conventional Medical Management group will continue with the standard of care procedures.
11097155|NCT04096378|Experimental|EMBRace Intervention Group|Over 13 weeks, participants will engage in a pretest (week 1) 5 weekly sessions (weeks 2-6), a posttest (week 7) and a follow-up (week 13). The intervention (Engaging, Managing, and Bonding through Race: EMBRace) seeks to reduce racial trauma for both youth and caregivers and increase family functioning via psychoeducation and therapy.
11097156|NCT04096378|Other|EMBRace Waitlist Group|Participants will wait for thirteen weeks without receiving EMBRace or alternative therapeutic sessions. The waitlist group will subsequently become the intervention group with the opportunity to participate in the EMBRace intervention protocol above.
11097157|NCT04096365|Experimental|Subcostal temporary extracardiac pacing lead|All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
11097158|NCT04096352|Experimental|Indirect+Direct method|"Indirect method: one session of information on voice function and voice hygiene.
~Direct method: three sessions of voice training using virtual reality simulations over a course of 3 weeks."
11097159|NCT04096352|Active Comparator|Indirect method|Indirect method: one session of information on voice function and voice hygiene.
11097160|NCT04096339|Active Comparator|EGD followed by Colonoscopy|Randomized to group Esophagogastroduodenoscopy followed by Colonoscopy
11097161|NCT04096339|Active Comparator|Colonoscopy followed by EGD|Randomized to group Colonoscopy followed by Esophagogastroduodenoscopy
11097162|NCT04096326|Experimental|AGN-151586|
11097163|NCT04096326|Placebo Comparator|Placebo|
11097164|NCT04096287|Experimental|PNT001|Single escalating doses of intravenous PNT001 administered as a 30 minute infusion at doses of 33mg, 100mg, 300mg, 900mg, 2700mg, and as a 60 minute infusion at 4000 mg
11097165|NCT04096287|Placebo Comparator|Placebo|Single intravenous dose of vehicle administered as a 30 minute infusion up to 2700 mg and as a 60 minute infusion at 4000 mg
11097166|NCT04096274|Experimental|LOCI (Intervention)|Agencies in the intervention group will receive leadership training and coaching in addition to training and technical assistance to implement the digital measurement based care system.
11097167|NCT04096274|Placebo Comparator|Implementation As Usual (Control)|Agencies in the control group will receive web-based leadership training in addition to training and technical assistance to implement the digital measurement based care system.
11097168|NCT04096261||Healthy controls|Healthy controls recruited through public advertisement.
11097169|NCT04096261||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement
11097170|NCT04096261||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
11097171|NCT04096261||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
11097172|NCT04096261||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
11097173|NCT04096235|Experimental|RAM Cannula|
11097174|NCT04096222||Pemphigus subjects|Subjects with the diagnosis of pemphigus and with active disease in the skin will be invited to participate. After informed consent, at the enrollment visit the following interventions will be done: 1) two 4 mm punch biopsies in a target lesion, 2) A 10 ml blood sample will be taken, 3) photographs of the subject, 4) demographic, disease, comorbidity and treatment data will be documented, 5) PDAI and ABSIS, 6) Medication adherence. The subject will come to follow-up visits every 6 weeks +- 2 weeks. In these visits we will take photographs, perform activity scales, document treatment, and medication adherence. The termination visit will take place when the subject reaches a 75% in PDAI scale or after one year of follow up and the following interventions will be done: 1) two 4 mm punch biopsies in the same target lesion, 2) A 10 ml blood sample will be taken, 3) photographs of the subject, 4) treatment data will be documented, 5) PDAI and ABSIS, 6) Medication adherence
11097175|NCT04096209|Experimental|Graft-less and grafting using xenograft and autograft|Extraction of badly decayed teeth with immediate implant placement using graft-less and grafting using autogenous bone and xenograft between the implant and labial socket bone
11097176|NCT04096196|Experimental|Game intervention group|Participants assigned to the intervention group will be given a manual containing instructions to play the Safe City game. A research assistant will provide a briefing session on the game in each participating school. A unique username and password set will be created for each user to log in the game. This login information will be provided to the student participants in a sealed envelope after the briefing session. The participants will be instructed to play the game as many times as desired within a 4-week time frame. The players ranked in the top 20 will receive a reward in the form of book coupon after the intervention ends.
11097177|NCT04096196|Active Comparator|"Health education (control) group"|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
11097178|NCT04096183|Other|Ventilation of healthy volunteers|
11097208|NCT04095923|Active Comparator|Standard self-regulation|Fitbit wearable activity monitor and brief counseling
11097209|NCT04095910|Experimental|Planet Nutrition program|multidisciplinary school- based program
11097179|NCT04096170|Experimental|IV Lidocaine|100 mg Lidocaine bolus on induction, then an infusion of 1.5 mg/kg/hr to begin prior to incision, run throughout the operation and continues into PACU for 1 hour OR until one 2gm/250mL D5W bag has been infused, whichever occurs first. The Patient will be monitored by nursing staff with the aid of continuous cardiac monitoring in the PACU for at least 30 minutes after the discontinuation of the lidocaine drip.
11097180|NCT04096170|Placebo Comparator|Placebo|Patients will receive D5W solution at the same volume and rate as the IV lidocaine.
11097181|NCT04096157|Experimental|Isavuconazonium sulfate IV solution then capsules|Participants will first receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 2.
11097182|NCT04096157|Experimental|Isavuconazonium sulfate capsules then IV solution|Participants will first receive a single dose of isavuconazonium sulfate capsules (reference formulation) for oral administration under fasting conditions on Day 1 of Period 1. After a washout period of 30 days, the participants then receive a single dose of isavuconazonium sulfate intravenous (IV) solution via nasogastric (NG) tube (test formulation) under fasting conditions on Day 1 of Period 2.
11097183|NCT04096144|Experimental|Neostigmine|This is the standard Neuromuscular reversal drug that has been in standard care for the past thirty years. Dose: -Neostigmine: 0.03-0.07 mg/kg by intravenous route.
11097184|NCT04096144|Experimental|Sugammadex|"Used for Neuromuscular reversal; Sugammadex is devoid of the parasympathetic effects caused by Neostigmine.
~Dose: -Sugammadex: 2-4 mg/kg (4 mg/kg if no twitch responses after initial stimulation), intravenous route."
11097185|NCT04096131||SURGERY|subjects with early DME undergoing cataract surgery
11097186|NCT04096131||OBSERVATION|subjects with early DME
11097187|NCT04096105|Experimental|CC-93538 in Japanese subjects|Twenty-four Japanese subjects will be randomized into 1 of 2 dose levels in a 1:1 fashion so that 12 subjects will receive a 180 mg or 360 mg dose via SC injection.
11097188|NCT04096105|Experimental|Administration of CC-93538 in Caucasian subjects|Twenty-four Caucasian subjects will be matched to Japanese subjects by weight (± 20%) and receive a 180 mg or 360 mg dose via SC injection
11097189|NCT04096079||OHCA patients|Patients who suffered an out-of-hospital cardiac arrest between 2015 and 2018 in Province of Pavia (Italy), Ticino Region (Switzerland), Wien area (Austria) and Nicosia area (Cyprus) who underwent a coronary angiography.
11097190|NCT04096066|Experimental|KRd|"Carfilzomib (K):
~20 mg/m2 IV on day 1 of cycle 1;
~56 mg/m2 IV on days 8 and 15 in cycle 1;
~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;
~56 mg/m2 on days 1 and 15 from cycle 13 and onwards.
~Lenalidomide (R):
~- 25 mg orally on days 1-21 of each cycle.
~Dexamethasone (d):
~- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle.
~Until PD or intolerance. Only patients that achieve at least a VGPR within the first year of treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib after 2 years of treatment, and will continue with lenalidomide and dexamethasone administration."
11097191|NCT04096066|Active Comparator|Rd|"Lenalidomide (R):
~-25 mg orally on days 1-21 of each cycle.
~Dexamethasone (d):
~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycles.
~Until PD or intolerance."
11097192|NCT04096053|Experimental|TEACHH|The training workshop is designed as a 3-hour session for care providers. The training will be delivered by trans women. During this training, we plan to have providers: 1) discuss human rights for trans women; 2) teach providers about common words with which to discuss gender identity and expression, and develop a basic understanding of trans healthcare, HIV prevention, and HIV treatment, and how these types of healthcare affect trans women living with and affected by HIV; 3) discuss what it means to be trans-affirming in their work and how they can make their organizations more trans- affirming; and 4) have participants complete a case study to apply what they have learned to practice. These case studies will address issues affecting trans women who are immigrants/newcomers, trans women who are living with HIV, and trans women who experience other vulnerabilities.
11097193|NCT04096040|Experimental|Device Data Engagement Assessment|This arm will assess the endpoints of investigator engagement with the device data.
11097194|NCT04096027|Experimental|Early administration|Cabergoline administered the day before egg collection.
11097195|NCT04096027|Experimental|Late administration|Cabergoline administered after egg collection.
11097196|NCT04096014|Active Comparator|Ensure Enlive|
11097197|NCT04096014|Placebo Comparator|Standard of Care|
11097198|NCT04095988|Experimental|Verum-AMR|Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy
11097199|NCT04095988|Placebo Comparator|Placebo-AMR|Patients receiving Placebo(Saline)-Infusion via gastroscopy
11097200|NCT04095975|Active Comparator|Baking Soda|Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.
11097201|NCT04095975|Active Comparator|LithoLyte|Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.
11097202|NCT04095975|Active Comparator|UrocitK|Subjects randomized to potassium citrate will be provided a prescription for 40 mEq potassium citrate and will be provided the usual instructions on how to take it (potassium citrate has been used for decades in clinical care of patients with stones; thus, standard instructions will be provided). This is usually in divided doses (such as 20 mEq twice daily) with meals
11097203|NCT04095962|Experimental|Training Group|Training protocol will be held for 6 months, twice per week/ 60 min per sessions.
11097204|NCT04095962|No Intervention|Control Group|Participants in the control group will receive monthly sessions regarding physical activity and health related topics as a complement to standard care. No specific exercise intervention will be conducted for this group.
11097205|NCT04095949|Experimental|Artichokes|1 day of artichokes intake
11097206|NCT04095936|Experimental|AMG531|
11097207|NCT04095923|Experimental|Social media game|Private Facebook group with weekly walking challenges, Fitbit wearable activity monitor, and brief counseling
11097213|NCT04095884||Urinary Tract Infection|"Inclusion criteria (one from the list below):
~Positive leukocytes, positive nitrites on dipstick
~Negative leukocytes, Positive nitrites on dipstick
~Positive leukocytes, negative nitrites, plus bacteriuria on microscopy
~Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.
~Exclusion criteria (one from the list below):
~1. No evidence of UTI on dipstick"
11097214|NCT04095884||Upper respiratory tract infection|"Inclusion criteria (one from the list below)::
~Evidence of nasal discharge AND/OR
~Inflammation throat/ tonsils on direct examination AND/OR
~Inflammation of middle or outer ear on direct examination
~History of fever AND history of stridor/ barking cough
~History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough
~Exclusion criteria (one from the list below)::
~Foreign body inserted in either nose/ ear
~Traumatic perforation of ear drum
~Allergic rhinitis i.e. good contact history
~Evidence of LRTI"
11097215|NCT04095884||Lower respiratory tract infection|"Inclusion criteria (one from the list below):
~Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry
~Fever > 38.5C AND chest recessions AND/OR raised respiratory rate
~Radiological evidence of LRTI
~Exclusion criteria (one from the list below):
~1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever"
11097216|NCT04095884||Diarrhoea/ gastroenteritis|"Inclusion criteria (one from the list below):
~Abrupt onset of 3 or more loose/liquid stools/ day
~Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting
~Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI
~Exclusion criteria (one from the list below):
~Normal breast milk stool
~Neurological cause of vomiting"
11097217|NCT04095871||Patients included|"Patients over 18 years old performed CISC for more than 1 month, exclusive or not, are included.
~At home, patients have to complete one diary on the specific duration of a 24-hour CISC and the next day a second diary on the total duration of CISC.
~The specific time of CISC described by the timed duration from the moment when the circumstances of care are combined to carry it out : isolated place, nearby equipment.
~The total time of CISC described by the timed duration from the moment of the intention to self-catheter until the return to the initial activity."
11097218|NCT04095858|Experimental|CD24Fc Treatment|CD24Fc: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted; Methotrexate: given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT.
11097219|NCT04095858|Placebo Comparator|Placebo|Placebo (Saline solution): 100ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted; Methotrexate: given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT.
11097220|NCT04095845|Active Comparator|CO THA|Computerised tomography based planning of conventional total hip arthroplasty
11097221|NCT04095845|Experimental|Mako THA|Mako robotic-arm assisted total hip arthroplasty
11097222|NCT04095832||Parturients with preeclampsia|Parturients who were diagnosed with preeclampsia
11097223|NCT04095832||Healthy parturients|Healthy full-term parturients
11097224|NCT04095819|Experimental|Middle Meningeal Artery Embolization|Middle Meningeal Artery Embolization
11097225|NCT04095819|Active Comparator|Traditional Surgery|Craniotomy/Burr hole
11097226|NCT04095793|Experimental|ampreloxetine|Participants will receive a single, oral, daily dose of active drug (TD-9855) for 182 weeks.
11097227|NCT04095780|Experimental|Advanced oral hygiene care programme|Patients with stroke will receive the advanced oral hygiene care programme (AOHCP) comprising powered tooth brushing and mouth rinsing with chlorhexidine (with a supply of standardized power tooth brushes, mouth rinse, tooth paste and oral hygiene instruction).
11097228|NCT04095780|Experimental|Oral hygiene instruction|Patients with stroke will only receive the oral hygiene instruction.
11097229|NCT04095767|Experimental|Treatment arm|The thrombectomy in eligible patients will be carried out by making use of the device under investigation.
11097230|NCT04095754|Other|Group I (control group)|Patients will be positioned supine.
11097231|NCT04095754|Experimental|Group II|patients will be positioned 10° anti-trendelenburg position.
11097232|NCT04095754|Experimental|Group III|patients will be positioned 20° anti-trendelenburg position.
11097233|NCT04095728|Experimental|Investigational Product|
11097234|NCT04095728|Placebo Comparator|Placebo|
11097235|NCT04095715||Children and adults with unexplained hemorrhagic syndrome|Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.
11097236|NCT04095702|Experimental|Weighted Pacifier|Patient will receive a weighted pacifier for 48 hours of their stay in the NICU.
11097237|NCT04095702|Placebo Comparator|Non-Weighted Pacifier|Patient will receive a standard non-weighted pacifier for 48 hours of their stay in the NICU.
11097238|NCT04095689|Experimental|Experimental|docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy and pembrolizumab plus IL-12 gene therapy followed by TAC chemotherapy and pembrolizumab plus the pan-nitric oxide synthase (NOS) inhibitor NG-monomethyl-L-arginine (L-NMMA)
11097239|NCT04095676|Experimental|VATS / surgical group|"The VATS procedure must be completed as soon as possible and no later than 48 hours after admission. The surgery is performed with the patient in a 90 degree sideways position, using general anesthesia. Preferably a uniportal access, purification and possibly decortication, and insertion of one pleural drain (sizes 24 - 32F) at the end of surgery. 20 ml Marcain is used as local analgetic and applied at the incision sites or as a nerve block. In the VATS group, suction on drain (- 15 cm H20) is applied in the first day after the procedure. Operator must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be registered and approved by the steering committee."
11097240|NCT04095676|Active Comparator|Drain and intrapleural therapy group|Pigtail is applied at a specialized department (Pulmonary or Thoracic surgery department) as soon as possible and within 48 hours of admission. Drain placement is carried out using ULS. Operators (conductors of the procedure) must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be approved by the steering committee to conduct the procedure. A pigtail catheter (minimum 10F) is inserted. Operator determines the size of drain and whether drain placement is done with one-step or Seldinger technic
11097241|NCT04095663|Active Comparator|Partial Colectomy|Elective segmental colectomy for diverticular disease involves removal of the segment of colon (most commonly sigmoid and/or left colon) where there has been disease identified by computed tomography imaging or colonoscopy. Elective colectomy usually removes the affected colon along with adjacent segments that have diverticula, with a primary anastomosis performed to reestablish bowel continuity. Most surgeons now perform the procedure using a laparoscopic approach, when possible, and sometimes use a temporary, protective stoma if the re-connection is considered high-risk. The technique for laparoscopic resection is not specified by the protocol (allows for any number of laparoscopic port sites, all incision types, hand-assistance and robotic) with details of the technique recorded. If randomized to elective colectomy, patients will be encouraged to undergo the procedure within 6 weeks of assignment.
11097242|NCT04095663|Active Comparator|Medical Management|"Medical management for diverticular disease has been used for over 30 years and includes a set of interventions, all components of which have been the subject of small, but often positive trials. All patients randomized to medical management or who select it as their treatment in the observational cohort will view a video (provided in English and Spanish) that explains each element of the medical management toolbox: diet and exercise recommendations, fiber supplementation (e.g., augmenting dietary fiber or over the counter fiber supplements), with mesalazine tablets or suppositories, probiotics and rifamycin. In consultation with their physician, they will be recommended to a regimen of diet and exercise and fiber supplementation. Clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
11097243|NCT04095650|Experimental|Intervention|Participants will engage in a 7-week chronic pain self-management program.
11097244|NCT04095637|Experimental|Mako medial UKA|Mako medial unicondylar knee arthroplasty
11097245|NCT04095637|Active Comparator|Oxford media UKA|Oxford unicompartmental knee arthroplasty with navigation control
11097246|NCT04095624|Experimental|Opioid Taper Group|Patients randomized to the taper group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive a scheduled tapering protocol, with a goal of 10-15% reduction in their weekly opioid use, along with weekly phone calls from a study coordinator assessing their ability to taper and pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
11097247|NCT04095624|Active Comparator|Control Group|Patients randomized to the control group will have baseline pain score, opioid medication use, and patient reported outcomes 4-6 weeks prior to elective thoracolumbar, lumbar, or lumbosacral spinal fusion surgery. They will receive no recommendation or guidance in their preoperative opioid pain medication use, but will received weekly phone calls from a study coordinator assessing their preoperative pain scores. After surgery, they will receive 6 weekly phone calls from the coordinator, to assess their postoperative opioid medication use and pain scores. At the 6th week phone call, and 3 month and 6 month clinic postoperative clinic visits, they will also repeat patient reported outcome measures.
11097248|NCT04095611|Experimental|SPAIRE|hemiarthroplasty surgery, the muscle-sparing modification of the posterior approach (SPAIRE).
11097249|NCT04095611|Active Comparator|LATERAL|hemiarthroplasty surgery, the standard lateral approach
11097250|NCT04095598||Syndesmotic injured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
11097251|NCT04095598||Syndesmotic uninjured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
11097252|NCT04095585||Patients presenting with WBS and ASD|patients with WBS and ASD. The diagnosis of WBS was confirmed by fluorescent in situ hybridization. All patients met formal ASD criteria.
11097253|NCT04095572|Active Comparator|intervention group A|50 ml of a sterile sodium HA (800 mg)- CS (1g) solution (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Via Martiri di Cefalonia 2, 26900 Lodi, Italy) weekly for four weeks, then every second week in the second month and four weeks later
11097254|NCT04095572|Placebo Comparator|control group B|50 ml sterile purified water weekly for four weeks, then every second week in the second month and four weeks later
11097255|NCT04095533||Sepsis|"Starting at admission to ICU, patients admitted to a mixed medical-surgical ICU will be assessed every second day to determine their muscle size as measured by ultrasound, and their muscle strength as measured clinically using the Medical Research Council strength assessment at the bedside.
~One-time Measures:
~Illness severity as measured by the SOFA score within the first 24 hours of admission.
~duration of mechanical ventilation
~duration of stay in the ICU
~duration of stay in the hospital"
11097256|NCT04095520|Active Comparator|Paste Type Traditional Composite-GC G Aenial Anterior|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with microhybrid composite
11097257|NCT04095520|Experimental|Injectable Composite- GC G Aenial Universal Injectable|Non-carious cervical lesions with shallow depth of less than 3 mm will be restored with injectable form composite
11097258|NCT04095507|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
11097259|NCT04095481||Obalon NTS|Patients who commercially purchased the NTS Compatible Obalon Balloon System
11097260|NCT04095468||Resectable rectal cancer|
11097261|NCT04095468||Rectal cancer with threatened mesorectal fascia|
11097262|NCT04095455|Active Comparator|pectoral nerves block group|modified pectoral nerves block was performed on the side of surgery
11097263|NCT04095455|Active Comparator|Ktamine plus Magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump
11097264|NCT04095455|Active Comparator|Control Group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo
11097265|NCT04095442|Active Comparator|Cepacol|
11097266|NCT04095442|Sham Comparator|Tom's Natural Mouthwash|
11097267|NCT04095429|Experimental|Expect Respect Support Group|"Experimental: Expect Respect Support Group Expect Respect is a program intended to create safe, trauma-informed space for young people who have been exposed to violence, to promote positive bystander intervention and healthy relationship skills, to alter norms that foster TDV/SV perpetration, and reduce violence perpetration through weekly support groups with students at elevated risk for such perpetration. Youth with prior history of exposure to violence are invited to in-school gender specific support groups that take place over 24 in-classroom sessions.
~Expect Respect addresses violence perpetration prevention with youth already exposed to violence by recognizing violence as a problem that is fueled by gender norms that promote dominance and challenging the need to control and exert power in relationships especially with the use of violence, while simultaneously strengthening emotion regulation, social skills, and connectedness."
11097268|NCT04095429|Active Comparator|Enhanced Usual Care|Comparator: Enhanced Usual Care The control arm will receive enhanced usual care. Enhanced care means that the investigators will ensure each school has information, resource lists, and connection to services for individual youth who are referred to the study, including warm referrals to victim service agencies, behavioral health services, as well as resources (e.g., assistance with food insecurity, and so forth).
11097269|NCT04095416|Experimental|Intervention|Bilateral lower extremity ACE compression wraps in addition to standard medical care
11097270|NCT04095416|No Intervention|Control|Standard medical care
11097271|NCT04095403|Experimental|Tarp assisted cooling|Whole body cooling in a small amount of 20'C water.
11097272|NCT04095403|Sham Comparator|Passive cooling|Supine lying
11097273|NCT04095390|Experimental|Arm A|Hormone receptor positive,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Letrozole until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11097274|NCT04095390|Experimental|Arm B|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 plus Capecitabine until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11097275|NCT04095390|Experimental|Arm C|Hormone receptor negative,HER2 positive participants will receive Pyrotinib in combination with CDK4/6 Inhibitor SHR6390 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11097276|NCT04095377||healthy|
11097277|NCT04095377||CVA|
11097278|NCT04095377||Hammorhage|
11097279|NCT04095377||TBI|
11097280|NCT04095377||Concussion|
11097281|NCT04095377||Fibromyalgia|
11097282|NCT04095377||ABD|
11097283|NCT04095377||ADHD|
11097284|NCT04095377||MCI|
11097285|NCT04095377||DEMENTIA|
11097286|NCT04095377||COGNITIVE IMPAIRMENT|
11097287|NCT04095377||COGNITIVE DECLINE|
11097288|NCT04095377||MS|
11097289|NCT04095364|Experimental|Arm I (paclitaxel, carboplatin, letrozole)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole PO QD in the absence of disease progression or unacceptable toxicity.
11097290|NCT04095364|Experimental|Arm II (letrozole)|Patients receive letrozole PO QD in the absence of disease progression or unacceptable toxicity.
11097291|NCT04095338|Active Comparator|control group|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks
11097292|NCT04095338|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks.
11097293|NCT04095338|Experimental|robotic treadmill arm|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks.
11097294|NCT04095325|Active Comparator|transversus abdominis plane block|Group 1 (n: 50): those who underwent TAP block after induction of propofol atropine and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
11097295|NCT04095325|Active Comparator|erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
11097296|NCT04095312|Experimental|pancreaticobiliary disease|10 pancreaticobiliary disease cases
11097297|NCT04095312|Experimental|Urinary tract disease|13 urinary tract disease cases
11097298|NCT04095312|Experimental|Colon disease|10 colon disease cases
11097299|NCT04095299|Active Comparator|A: Standard chemoradiotherapy|50.4 Gy to the tumor and elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays.
11097300|NCT04095299|Experimental|B: High-dose radiotherapy|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume. The dose is given in 28 fractions on weekdays concomitantly with capecitabine 825 mg/m2 twice daily on weekdays
11097301|NCT04095286|Experimental|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
11097302|NCT04095286|Experimental|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
11097303|NCT04095286|Experimental|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
11097367|NCT04094896|Experimental|Arm A: TCHP|docetaxel/carboplatin/trastuzumab/Pertuzumab
11098229|NCT04088721|Placebo Comparator|Placebo|Intranasal weekly dosing (placebo) for three times
11097304|NCT04095286|Experimental|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
11097305|NCT04095286|Experimental|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
11097306|NCT04095286|Experimental|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
11097307|NCT04095273|Experimental|Dose escalation of BAY1895344|2 dose levels of BAY1895344 are planned
11097308|NCT04095273|Experimental|Dose expansion cohort 1a of BAY1895344|Participants with advanced hormone-receptor-positive, Human epidermal growth factor receptor 2 (HER2)-negative Breast cancer (BC), known to be positive for ataxia-telangiectasia mutated (ATM) loss and/or ATM deleterious mutations who have not received prior treatment with immunotherapy.
11097309|NCT04095273|Experimental|Dose expansion cohort 1b of BAY1895344|Participants with advanced hormone-receptor-positive, HER2-negative BC, known to be DDR deficiency biomarker-positive (except ATM) who have not received prior treatment with immunotherapy.
11097310|NCT04095273|Experimental|Dose expansion cohort 2a of BAY1895344|Participants with advanced Colorectal cancer (CRC) known to be positive for ATM loss and/or ATM deleterious mutations who have not received prior treatment with immunotherapy. DDR+ MSI-H CRC subjects cannot be included.
11097311|NCT04095273|Experimental|Dose expansion cohort 2b of BAY1895344|Participants with advanced CRC, known to be DDR deficiency biomarker-positive (except ATM) who have not received prior treatment with immunotherapy. DDR+ Microsatellite instability (MSI)-H CRC subjects cannot be included.
11097312|NCT04095273|Experimental|Dose expansion cohort 3 of BAY1895344|Participants with advanced Gastric/Gastroesophageal junction (GEJ) cancer known to be positive for ATM loss and/or ATM deleterious mutations. Participants must have progressed on treatment with an anti-Programmed cell death protein 1/ligand 1 (PD-1/L1) Monoclonal antibody (mAB) administered either as monotherapy, or in combination with other checkpoint inhibitors or in combination with other therapies.
11097313|NCT04095273|Experimental|Dose expansion cohort 4 of BAY1895344|Participants with advanced Non-small cell lung cancer (NSCLC) known to be positive for ATM loss and/or ATM deleterious mutations. Participants must have progressed on treatment with an anti-PD-1/L1 mAB administered either as monotherapy, or in combination with other checkpoint inhibitors or in combination with other therapies.
11097314|NCT04095260||high school athletes|High school athletes, ages 14 to 18, who are participating in an organized sports training program.
11097315|NCT04095234|Experimental|Acupuncture|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
11097316|NCT04095234|Active Comparator|Massage|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
11097317|NCT04095221|Experimental|Prexasertib and Irinotecan|Patients will have extent of disease scans following every 2 cycles (every 6 weeks on dose levels 0-3, and every 8 weeks on dose level -1 (if required). Patients will be allowed to continue therapy as long as they do not experience dose-limiting toxicities or progression of disease.
11097318|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm A|Combination of nivolumab and relatlimab.
11097319|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm B|Treatment by nivolumab alone.
11097320|NCT04095195||Familial pancreatic cancer relatives|
11097321|NCT04095195||Peutz-Jeghers syndrome|
11097322|NCT04095195||BRCA 1/2, PALB2, p16 mutations with familiarity for PC|Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC
11097323|NCT04095195||Lynch syndrome with familiarity for pancreatic cancer|
11097324|NCT04095195||FAMMM syndrome|
11097325|NCT04095195||Hereditary and genetic pancreatitis|
11097326|NCT04095182|Experimental|Zebinix 400mg|
11097327|NCT04095182|Placebo Comparator|Placebo for Zebinix 400mg|
11097328|NCT04095182|Experimental|Zebinix 800mg|
11097329|NCT04095182|Placebo Comparator|Placebo for Zebinix 800mg|
11097330|NCT04095182|Experimental|Zebinix 1600mg|
11097331|NCT04095182|Placebo Comparator|Placebo for Zebinix 1600mg|
11097332|NCT04095169||axSpA|Patients with low back pain ≥three months who a) fulfilled the ASAS definition for a positive MRI scan of sacroiliac joints (definite inflammation) or b) were HLA-B27 positive with at least one concomitant clinical spondyloarthritis feature.
11097333|NCT04095169||non-axSpA|Patients with a) positive MRI according to the ASAS definition, but no additional clinical spondyloarthritis features, or b) positive HLA-B27 and one clinical spondyloarthritis feature.
11097334|NCT04095169||Controls|Patients with non-specific low back pain without spondyloarthritis-related features and negative MRI SIJ.
11097335|NCT04095156||Prospective cohort|Patients with biopsy-proven idiopathic MN, who are candidate to receive a B-cell depleting treatment as per center clinical practice.
11097336|NCT04095156||Retrospective cohort|Patients with biopsy-proven idiopathic MN, who already received a B-cell depleting treatment as per center clinical practice.
11097337|NCT04095156||Healthy volunteers cohort|Subjects > 18 years not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
11097338|NCT04095143||New onset of stage ≥2 acute kidney injury|"Either:
~A ≥ 2-fold increase in serum creatinine OR
~A serum creatinine ≥ 354 μmol/L with evidence of a minimum increase of 27 μmol/L OR
~Urine output < 6.0 mL/kg over the preceding 12 hours OR
~Initiation of RRT for severe acute kidney injury less than 72 hours before recruitment"
11097339|NCT04095130||Healthy subjects|those without a condition
11097340|NCT04095130||Psoriasis patients|those with a condition
11097341|NCT04095104|Experimental|Phentermine & Topiramate|"Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration:
~4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning
~+
~Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning
~+
~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
11097342|NCT04095104|Placebo Comparator|Placebo Drugs|"Placebo Phentermine- Formulation: 8mg scored tablet, Dosage/Frequency/Duration: 4mg x 7d then 8mg x 7d then 12mg x 7d then 16mg x 63d, taken once every morning
~+
~Placebo Immediate release topiramate- Formulation: 25mg tablet, Dosage/Frequency/Duration: 25mg x 7d then 50mg x 7d then 75mg x 7d then 100mg x 63d then 50mg x 7 days then 25mg x 7d, taken once every morning
~+
~Standard of Care (multidisciplinary postoperative bariatric surgery clinic visits)"
11097343|NCT04095091||Control Group|"Healthy volunteers will be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.
~A substudy including patients undergoing radiotherapy for malignancies of the abdomen and pelvis. They will also be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan."
11097344|NCT04095091||Patient Group|Patients receiving radiotherapy for malignancies of the abdomen and pelvis will be asked to complete two research visits lasting approximately one hour. Each visit will include a 30 minute combined 4D ultrasound and 4D MRI scan.
11097345|NCT04095078|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
11097346|NCT04095078|No Intervention|Control|Usual care
11097347|NCT04095065|Experimental|itMatters|Participants will have access to content focused on general knowledge and injunctive and descriptive norms for a period up to 3 weeks.
11097348|NCT04095065|Experimental|itMatters and itMatters Sexual Violence Prevention|Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
11097349|NCT04095065|Experimental|itMatters Well-being and itMatters Sexual Violence Prevention|Participants will have access to content focused on basic information related to sleep wellness and time management. In Addition, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.
11097350|NCT04095065|Experimental|itMatters Well-being|Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
11097351|NCT04095052|Experimental|Methyl Folate|Participants will receive a capsule containing 1,000 mcg methyl folate and microcrystalline cellulose orally once per day for 15 days.
11097352|NCT04095052|Placebo Comparator|Placebo|Participants will receive a microcrystalline cellulose capsule orally once per day for 15 days.
11097353|NCT04095039|Experimental|Hi Arm|Patients to allow blood serum phosphate levels to rise to 6.5 mg/dl or above
11097354|NCT04095039|No Intervention|Lo Arm|Patients to titrate blood serum phosphate levels to the standard <5.5mg/dl
11097355|NCT04095026||Patients|Patients age >18 years and <= 65 years enrolled in 11-N-0051 Epilepsy Surgery
11097356|NCT04095013|Experimental|Group BF|hyperbaric Bupivacaine 10mg with fentanyl 10micrograms
11097357|NCT04095013|Experimental|Group BD|hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
11097358|NCT04095000|Experimental|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
11097359|NCT04095000|Active Comparator|Treatment As Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
11097360|NCT04094987|Experimental|Quadratus Lumborum block|We will use the ultrasound guided anterior Quadratus Lumborum Block.A peripheral nerve block catheter will be placed between the quadratus lumborum muscle and the psoas muscle with ultrasound
11097361|NCT04094961|Experimental|ixazomib plus pomalidomide and dexamethasone|"The study drugs will be administered within a 21-day cycle
~Phase I will follow a standard 3 +3 dose escalation design: Starting with the first cohort, 3 to 6 patients will be treated at this and each subsequent dose level.
~The Phase II portion of the study will be a single-arm open-label enrollment with dosing based on the MTD determination in the Phase I portion of the study"
11097362|NCT04094948|Experimental|clenbuterol|The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
11097363|NCT04094948|Placebo Comparator|placebo|Initially, one capsule each morning for one week, followed by one capsule BID for the next 5 weeks until Week 6. If tolerated, the dose will be increased to two capsules each morning and 1 capsule each evening for one week, followed by two capsules BID for the next 5 weeks until the Week 12 visit. If two capsules BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
11097364|NCT04094922|Experimental|Intervention|Free access to the Swedish PTSD Coach smartphone app for three months.
11097365|NCT04094922|No Intervention|Waitlist|Delayed access to the Swedish PTSD Coach smartphone app. Access is given after post-intervention data collection at three months.
11097366|NCT04094909|Experimental|Rh-endostatin + chemotherapy+Pembrolizumab|The subjects are 186, including Squamous and Non-Squamous NSCLC. Squamous NSCLC receives rh-endostatin at a dose of 15mg/m2 for 5 days and 200 mg of pembrolizumab at day 1 in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. all the patients with squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and [nab]-paclitaxel (100mg/m2) for the first 4 cycles. For non-squamous NSCLC, rh-endostatin at dose of 15mg/m2 for 5 days, 200 mg of pembrolizumab at day 1 and pemetrexed (500mg/m2,d1) are given in each cycle, repeating every 3 weeks till to PD or unacceptable toxicities. Non-squamous NSCLC also receive carboplatin (5U/AUC) or cisplatin ( 75mg/m2) and pemetrexed (500mg/m2,d1) for the first 4 cycles.
11097368|NCT04094896|Active Comparator|Arm B: EC-THP|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab
11097369|NCT04094883|Experimental|4CMenB Vaccine|Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.
11097370|NCT04094870|Active Comparator|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
11097371|NCT04094870|Active Comparator|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
11097372|NCT04094857|Experimental|HBN-1 Plus Standard of Care|Subjects will receive an intravenous loading dose of HBN-1 followed by a 12 hour maintenance infusion plus standard of care targeted temperature management
11097373|NCT04094857|No Intervention|Standard of Care|Subjects will receive standard of care targeted temperature management only
11097374|NCT04094844|Active Comparator|Roadmap 2.0|"Roadmap 2.0 mobile app + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).
~Includes caregivers of adult patients and caregivers of pediatric patients"
11097375|NCT04094844|Experimental|Roadmap 2.0 with Positive Activities|"Roadmap 2.0 mobile app (patients), Roadmap 2.0 with mobile Positive Activities app (caregivers) + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).
~Includes caregivers of adult patients and caregivers of pediatric patients"
11097376|NCT04094831|Active Comparator|Intervention arm|Intervention group (Health education through CKD campaign and mHealth) technology
11097377|NCT04094831|Active Comparator|Control|No intervention
11097378|NCT04094805|Active Comparator|Rocaltrol Combining HD-DXM|Rocaltrol 0.25 μg once per day, 1 month; HD-DXM (orally at 40 mg daily for 4d )
11097379|NCT04094805|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
11097380|NCT04094792|Experimental|Intervention|For the intervention group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later). Intervention group subjects will use the Breather app twice daily, five minutes each time, for a period of 21 days.
11097381|NCT04094792|No Intervention|Control|For the control group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later).
11097382|NCT04094779|Active Comparator|Usual relational care|Isolate the patient from the group of other patients in order to propose to him a a relationship dual with the caregiver to the aim to calm the agitation
11097383|NCT04094779|Experimental|"Flash activity breath of fresh air"|Isolate the patient from the group of other patients in order to propose to him in a relationship dual with the caregiver a physical activity outside the service that promotes relaxation by focusing his attention to the environment during 15 minutes
11097384|NCT04094766|Experimental|BLLCAR-L10D treatment group|In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 2.0×10^6 CAR-T cells/kg.
11097385|NCT04094740|Experimental|Needle-free Jet Injector|Subjects will be instructed to use a needle-free syringe to inject insulin during the study period. The dosage and frequency of insulin are determined by the responsible physician according to the patient's condition.
11097386|NCT04094740|No Intervention|Conventional Insulin Pen|Patients allocated to the control group will be instructed to use conventional insulin pens to inject insulin. Except for the syringe, all of them are the same as the experimental group.
11097387|NCT04094740|No Intervention|Routine Care|Subjects can receive the education provided by health-care professionals and training in the outpatient department and inpatient departments.
11097388|NCT04094727|Experimental|Presumptive treatment and enhanced vector control|"For all eligible HRPs in intervention areas, after obtaining informed consent, presumptive treatment for malaria will be carried out using artemether-lumefantrine (AL) at two time points.
~Enhanced vector control activities will include: (1) a mop up indoor residual spraying (IRS) campaign and (2) distribution of long-lasting insecticide-treated nets (LLINs) and/or vector control packs with topical repellent.
~The intervention arm will also receive the standard of care in Namibia."
11097389|NCT04094727|No Intervention|Standard of care|The control arm will receive the standard of care in Namibia: passive case detection through health facilities and health extension workers, routine indoor residual spraying (IRS), and reactive case detection (RACD) accompanied by reactive IRS.
11097390|NCT04094701|Placebo Comparator|Control Group|"Control Group will receive the following pain medication regimen:
~Scheduled Tylenol 1g every 8 hours, meloxicam 15mg every 12 hours
~Tramadol 50mg, 20 pills
~Oxycodone 5mg, 30 pills"
11097391|NCT04094701|Experimental|Experimental Group - Opioid Reduced|"Experimental - opioid reduced: 50% less oxycodone relative to control group
~Scheduled Tylenol 1g every 8 hours, meloxicam 15mg every 12 hours
~Tramadol 50mg, 20 pills
~Oxycodone 5mg, 15 pills"
11097392|NCT04094688|Experimental|Arm I (bevacizumab, chemotherapy, high-dose vitamin D3)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV on days 1-3 or irinotecan hydrochloride IV on day 1, leucovorin calcium IV over 90 minutes on day 1, and fluorouracil IV on days 1-3. Patients also receive high-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
11097393|NCT04094688|Active Comparator|Arm II (bevacizumab, chemotherapy, standard-dose vitamin D3)|Patients receive bevacizumab and chemotherapy as in Arm I. Patients also receive standard-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
11097432|NCT04094389|Experimental|Orthotic wear during waking hours only group|Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping.
11097433|NCT04094389|Experimental|Orthotic wear only while sleeping group|In the night-wear group, participants will be told to wear their orthosis only at night.
11097434|NCT04094376|Other|Day group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00)
11098861|NCT04084457|Placebo Comparator|Placebo|Matched for macronutrients, micronutrients and fibre
11097394|NCT04094675|Experimental|Treatment arm|"There will be a clinic visit and colonoscopy at study entrance with standard of care sampling and assessment of polyps, including resection of concerning polyps. The investigators will also collect data on well-being via the SF-36 health survey (a validated questionnaire to help monitor this aspect given anecdotal patient-level reports of improvement while on therapy).
~Study subjects will then begin sirolimus 2 mg by mouth daily for 1 year.
~Laboratories will be checked at 4 days after initiation, at 2 weeks after initiation, then every 4 weeks for 3 months, then every 3 months to complete the year of therapy
~Participants will have a clinic visit at 3, 6 and 9 months and include well-being assessment with the SF-36 health survey.
~Participants will have a clinic visit with well-being assessment and perform colonoscopy at study closure at 12 months. The investigators will perform standard of care sampling and assessment of polyps, including resection of concerning polyps."
11097395|NCT04094662|Experimental|Mirogabalin|Mirogabalin 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
11097396|NCT04094662|Placebo Comparator|Placebo|Placebo (14-weeks)
11097397|NCT04094649|Sham Comparator|Sham vs Active Stimulation Positions|Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design. Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle ~2 cm away from the vagus nerve.
11097398|NCT04094649|Active Comparator|Active uVNS|Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.
11097399|NCT04094636|No Intervention|No intervention: Control|Control group
11097400|NCT04094636|Experimental|In-bed cycling|Supervised in-bed cycling
11097401|NCT04094636|Experimental|Exercise booklet|Supervised physical training with exercises from exercise booklet
11097402|NCT04094623|Experimental|NSSI-DBT|Dialectical behavior therapy, 2 hours every week for 13 weeks.
11097403|NCT04094623|Active Comparator|NSSI-SSGT|Social support group therapy, 2 hours every week for 13 weeks.
11097404|NCT04094610|Experimental|Repotrectinib (TPX-0005)|"Phase 1
~Oral repotrectinib (TPX-0005):
~Safety and tolerability at different dose levels
~Phase 2
~Oral repotrectinib (TPX-0005): 3 cohorts
~Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ALK/ROS1/NTRK alterations or fusions in tumors and ALCL"
11097405|NCT04094597|Placebo Comparator|placebo|saline is given orally in dose of 2 ml per day for one month
11097406|NCT04094597|Active Comparator|lacoferrin|Pravotin is given orally 100 mg per sachet dissolved in 5 ml water given for one month
11097407|NCT04094584|Experimental|Multimodal Intervention|"The intervention is multimodal and consists of:
~Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 6 months.
~Case Management services
~Access to telemedicine counseling services to be used as needed by study participants."
11097408|NCT04094571|Experimental|Healthy Individuals and those with Movement Disorders|Participants will perform the FES cycling protocol along with the FES angle protocol.
11097409|NCT04094558|Experimental|Single Arm|Participant swallows and retrieves capsule in stool. Capsule and stool samples are analyzed for bacterial density and composition.
11097410|NCT04094545||Nasopharyngeal carcinoma(NPC)|The patients (1) were diagnosed with NPC; 2)18< Age <75.
11097411|NCT04094545||Health adults|(1) 18< Age <75, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; None of the patients had rhinitis or used any antibiotics during the three months last 3 months.
11097412|NCT04094532|Active Comparator|ultrasound guided transverse thoracic muscle plane block|
11097413|NCT04094532|Sham Comparator|ultrasound guided sham block|
11097414|NCT04094519|Experimental|digoxin plus rosuvastatin and enzalutamide|Participants will receive a single oral dose cocktail containing digoxin and rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and enzalutamide once daily on Days 8 through 71.
11097415|NCT04094506|Experimental|Dose level A of ASP1948|Dose A of ASP1948 will be administered intravenously on Day 1 of every 2-week cycle.
11097416|NCT04094506|Experimental|Dose level B of ASP1948|Dose B of ASP1948 will be administered intravenously on Day 1 of every 2-week cycle.
11097417|NCT04094506|Experimental|Dose level C of ASP1948|Dose C of ASP1948 will be administered intravenously on Day 1 of every 3-week cycle.
11097418|NCT04094493|Experimental|A1|vit D + no hypocalcemia
11097419|NCT04094493|Experimental|A2|Vit D + hypocalcemia
11097420|NCT04094493|No Intervention|B1|NO vit D + no hypocalcemia
11097421|NCT04094493|No Intervention|B2|NO vit D + hypocalcemia
11097422|NCT04094480|Active Comparator|endoloop ligation|securing appendicular base with endoloops
11097423|NCT04094480|Active Comparator|non absorbable polymeric clips|securing appendicular base with non absorbable polymeric clips
11097424|NCT04094467|Experimental|Study group|"the antagonist protocol group where they will do intra-cytoplasmic injection using classical antagonist protocol"
11097425|NCT04094467|Active Comparator|control group|"agonist stop/antagonist protocol group where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol"
11097426|NCT04094454|Experimental|Tampon with extended vaginal dilatation|Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
11097427|NCT04094454|Active Comparator|Commercially available tampon|Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
11097428|NCT04094441|Experimental|additional pulmonary function tests|additional pulmonary function tests
11097429|NCT04094428||Intensive care unit patient|All intensive care unit patients staying for at least 72 hours on the ICU and patients dying within 72 hours
11097430|NCT04094415||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
11097431|NCT04094389|Experimental|Orthotic continuous wear group|Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance.
11097435|NCT04094376|Other|Night group|42 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
11097436|NCT04094363|Experimental|Product usage order ABCD|Subjects will use each of the 4 products (ABCD) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
11097437|NCT04094363|Experimental|Product usage order BDAC|Subjects will use each of the 4 products (BDAC) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
11097438|NCT04094363|Experimental|Product usage order CADB|Subjects will use each of the 4 products (CADB) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
11097439|NCT04094363|Experimental|Product usage order DCBA|Subjects will use each of the 4 products (DCBA) sequentially for 1 and 1/2 days during a 9 day confinement, followed by a 4 hour Test Session.
11097440|NCT04094350|Experimental|ACF with a seed-and-recruit model|Active case finding with a seed-and-recruit model to be implemented by KHANA. Target group: key populations for TB (people living with HIV, TB contacts, people with diabetes, people who use/inject drugs) and presumptive TB cases
11097441|NCT04094350|Experimental|ACF targeting household and neighborhood contacts|Active case finding targeting household and neighborhood contacts to be implemented by CENAT. Target group: household contacts, immediate neighbors of people diagnosed with TB in the last 2 years, and other presumptive TB cases
11097442|NCT04094350|Experimental|ACF targeting the older population|Active case finding targeting the older population (people aged 55 and older) using mobile screening units to be implemented by CATA. Target group: elderly above age of 55 and other presumptive TB cases
11097443|NCT04094350|No Intervention|Passive case finding|Passive case finding strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
11097444|NCT04094337|Experimental|Internet-assisted treatment|The intervention group will receive internet-assisted treatment comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
11097445|NCT04094337|No Intervention|Control group|The control group will receive treatment as usual, which is no specific treatment. The control group can however use the general health system as they like.
11097446|NCT04094324||Children and youth at obesity clinic|Children 11-18 who are patients at obesity clinics in region Skåne SUS.
11097447|NCT04094324||Children and youth at a pediatric gastrointestinal clinic|Children 11-18 who are patients at a gastrointestinal clinic i region Skåne SUS.
11097448|NCT04094311|Other|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel per the Health Authority-approved tisagenlecleucel product information in the respective country/region are considered eligible for this study . Patients will be divided into 2 groups:
~Group A: Pediatric and young adult patients with B-cell ALL (pALL) who meet the indication in Health Authority-approved tisagenlecleucel product information in the respective country/region whose final manufactured product is OOS for commercial release.
~Group B: Adult patients with r/r LBCL including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the product information for tisagenlecleucel in respective country/region but whose final manufactured product is OOS for commercial release/acceptance."
11097449|NCT04094298|Experimental|Treatment Group|Patients receiving the 32-unit injection of FX006.
11097450|NCT04094285|Experimental|1|
11097451|NCT04094285|Experimental|2|
11097452|NCT04094272||Chronic hepatitis C participants|Participants with a newly started DAA medication for HCV infection were included in the study.
11097453|NCT04094246|Experimental|Experimental Group|Participants in the experimental group will receive standard post-surgical rehabilitation protocol per their surgery in addition to Battlefield Acupuncture.
11097454|NCT04094246|Active Comparator|Control Group|Participants in the control group will receive standard post-surgical rehabilitation protocol per their surgery.
11097455|NCT04094233|Experimental|Beetroot Extract|Capsule containing 600mg of beetroot extract.
11097456|NCT04094233|Experimental|Placebo|Capsule containing 600mg of starch.
11097457|NCT04094220|Experimental|Lateral lumbar interbody fusion|Patients in this group received lateral lumbar interbody fusion alone. Patients who suffered residual neurologic symptoms postoperatively will received conservative treatment for at least 3 months.Patients were considered to have unsuccessful indirect decompression if they had less than 20% improvement according to the Oswestry Disability Index (ODI) by 3 months postoperatively.
11097458|NCT04094220|Experimental|Lateral lumbar interbody fusion plus posterior decompression|Patients in this group received lateral lumbar interbody fusion plus posterior decompression.
11097459|NCT04094207|Placebo Comparator|Control group|Equivalent Placebo will be given
11097460|NCT04094207|Experimental|Pentoxifylline group|Pentoxifylline will be given orally at 1200 mg a day for 4 months
11097461|NCT04094181||VPRIV Participants|Participants who has been transitioned from ERTs/SRTs to VPRIV will be assesed for 12 months.
11097462|NCT04094168|Experimental|Del Nido Cardioplegia solution|1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.
11097463|NCT04094168|Active Comparator|Cold blood Cardioplegia solution|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.
11097464|NCT04094155|Experimental|Retinal fundoscopy|Retinal vascular analysis by retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
11097465|NCT04094142|Experimental|Treatment arm|"Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.
~Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21"
11097468|NCT04094116|Active Comparator|ear wax syringing with pre ear oil treatment|patients in Fanling Family Medicine Centre with ear wax will be given ear oil one week before performing ear syringing.
11097469|NCT04094116|Sham Comparator|ear wax syringing without pre ear oil treatment|Patients in Wong Siu Ching Clinic and Tai Po Clinic who are found to have ear wax after physical examination will have ear syringing done, without pre-ear oil application.
11097470|NCT04094103|Experimental|Active strawberry powder|Participants will consume a 39g freeze-dried active strawberry powder beverage once per day for 4-weeks.
11097471|NCT04094103|Placebo Comparator|Placebo strawberry powder|Participants will consume a 39g freeze-dried strawberry powder placebo beverage once per day for 4-weeks.
11097472|NCT04094103|Active Comparator|Mixed active/placebo strawberry powder|Participants will consume a 39g mixed active/placebo strawberry powder beverage once per day for 4-weeks.
11097473|NCT04094090|Experimental|Pulsed, accelerated|4 mW, 10 sec on, 10 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
11097474|NCT04094090|Experimental|Pusled, accelerated|8 mW, 10 sec on, 10 sec off, 11.25 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
11097475|NCT04094077|Experimental|Aguix + Stereotactic Radiation|
11097476|NCT04094064|Experimental|CGM Use while on Hemodialysis Therapy|All subjects will use a CGM for 10 days. Subjects will continue their standard of care hemodialysis treatments during the study period.
11097477|NCT04094038|Experimental|Intervention|Intradialytic parenteral nutrition three times weekly during 16 weeks
11097478|NCT04094038|Placebo Comparator|Placebo|5% glucose three times weekly during 16 weeks
11097479|NCT04094025|Experimental|dATS patch|dATS, placebo and saline will be administered simultaneously
11097480|NCT04094012|Active Comparator|3-months weekly RPT plus INH (3HP)|weekly RPT (900 mg for participants with body weight >50.0 kg; 750 mg for 32.1-50.0 kg; 600 mg for 25.1-32.0 kg; and 450 mg for 14.1-25.0 kg) plus INH (dose: 15 mg/kg, rounded up to nearest 150 mg; maximum 900 mg) for a total of 12 doses.
11097481|NCT04094012|Experimental|1-month daily RPT plus INH (1HP)|daily RPT (dose: 600 mg for participants with body weight ≥45.0 kg; 450 mg for <45.0 kg) plus INH (dose: 300 mg) for a total of 28 days.
11097482|NCT04093999||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction with additional sensory nerve coaptation.
11097483|NCT04093999||Noninnervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction without sensory nerve coaptation.
11097484|NCT04093986||Retrospective Chart Review|Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
11097485|NCT04093986||Participant Survey and Retrospective Chart Review|Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
11097486|NCT04093973||MAC subjects|Outpatients with moderate to severe mitral annular calcification on echocardiogram who are able to perform supine bicycle exercise.
11097487|NCT04093973||Controls|Sex matched individuals who are within 5 years of age of the paired MAC subject and who have the same left ventricular wall thickness as measured by echocardiography.
11097488|NCT04093960|Experimental|escitalopram plus128|escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily)
11097489|NCT04093960|Active Comparator|escitalopram|10 mg/d of escitalopram
11097490|NCT04093934|Experimental|Intervention|Children in the intervention arm will receive sessions of psychosocial stimulation every two weeks at the community clinics for one year. The intervention includes songs, games, book and toy activities for undernourished children and nutritional and developmental messages for their mothers.
11097491|NCT04093934|No Intervention|Wait-listed control|The wait-listed controls will be only tested at baseline and after a year. Following completion of the 2nd test, they will be included in the study and receive the same intervention provided to children in the experimental arm.
11097492|NCT04093921|Experimental|Intervention|Receive motivational enhancement training based, telehealth-delivered 6-8 session intervention aimed at increasing readiness to engage in pain self-management, in addition to all recommended outpatient treatments.
11097493|NCT04093921|Active Comparator|Standard Care|Participate in all recommended outpatient pain treatments while awaiting PPRC admission.
11097494|NCT04093908||multi-center validation cohort|We collect retrospective data from several international centers containing preoperative variables (demographical and clinical) and postoperative outcome (UPDRS II, III, IV) one year postoperatively, and merge these data to one validation cohort.
11097495|NCT04093895|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept® drug administration
11097496|NCT04093882||Healthy controls|Healthy controls recruited through public advertisement.
11097497|NCT04093882||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement.
11097498|NCT04093882||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
11097499|NCT04093882||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
11097500|NCT04093882||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
11097501|NCT04093869|Experimental|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX intervention will consist of 12, 30 minute weekly sessions conducted by a respiratory therapist knowledgeable about lung transplantation and trained in motivational interviewing, Cognitive Behavioral Therapy (CBT), and exercise therapy.
11097502|NCT04093869|Experimental|Standard of Care plus Education (SOC-ED)|The SOC-ED intervention will consist of 12, 30 minute weekly sessions conducted by a health educator knowledgeable about transplantation and skilled in educational instruction.
11097503|NCT04093856||Diabetic|20 men and women with type 2 diabetes and obesity
11097504|NCT04093856||Non-diabetic|20 normoglycemic men and women with obesity matched for age and sex with diabetic group
11097505|NCT04093843|Experimental|Open label|Open label single arm study to determine safety and effectiveness of TMS for post stroke depression
11097506|NCT04093830|Experimental|pre-lingually deafened children with cochlear implant|pre-lingually deafened children with cochlear implant who continuously used bimodal hearing.
11097507|NCT04093817||on pump CABG|patients under going CABG with cardiopulmonary bypass machine
11097508|NCT04093817||off pump CABG|patients under going CABG without cardiopulmonary bypass machine
11097509|NCT04093804|Active Comparator|32mm Glenosphere|The control group will receive the standard 32mm glenosphere.
11097510|NCT04093804|Experimental|36mm Glenosphere|The experimental group will receive a 36mm glenosphere.
11097511|NCT04093791|Experimental|"Collective Intervention G"|"HAPPY MAMA intervention will follow the following steps: listening and establishing relationship phases; analysis of the problems; definition of the problem and the goal of intervention.
~The duration will be of 3.5 hours in one day and the intervention will happen in Sapienza University of Rome, in a group of 15 women.
~This group fill in an on line questtionarie for four times, the first before the intervention."
11097512|NCT04093791|Experimental|"Individual Intervention I"|"The same intervention of G group (HAPPY MAMA), but at individual level and the intervention will happen at the participants' house.
~This group fill in an on line questtionarie for four times, the first before the intervention."
11097513|NCT04093791|No Intervention|"Control group C"|The women from this group will not receive any intervention. This group fill in an on-line questtionarie for four times.
11097514|NCT04093778|Experimental|SDA intervention|Low dose high frequency training of all health workers in maternity and pediatric ward and dissemination of a Safe Delivery Application
11097515|NCT04093765|Experimental|Sustained high incidence villages|Villages classified as high incidence, low probability of elimination (P. falciparum cumulative incidence >84 cases/1000/year, in spite of >1 year of functioning malaria post) will be eligible to be included in group 1. Villages in this group will be addressed by MSAT waves of 10-15 villages. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
11097516|NCT04093765|Experimental|Seasonal focal transmission villages/locations|"This group will follow the NMCP case/and foci investigation guidelines, but use URDT instead of standard RDT for screening. MSAT group 2 locations will be cluster of houses, villages or clusters of villages selected based on the results of case or foci/outbreak investigation. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
~Village inclusion after case investigation
~Village inclusion after outbreak investigation"
11097517|NCT04093752|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly.
11097518|NCT04093752|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly.
11097519|NCT04093752|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly.
11097520|NCT04093752|Active Comparator|Insulin Glargine|Insulin glargine administered SC once daily.
11097521|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
11097522|NCT04093726|Experimental|lollipop|
11097523|NCT04093726|No Intervention|control|
11097524|NCT04093713|Other|participants|participants are subjected to a novel technique to block the inferior alveolar nerve depending on extraoral landmarks
11097525|NCT04093700||SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
11097526|NCT04093687|Experimental|Intervention Arm|"The intervention will consist of one training session, focusing on technical and non-technical aspects identified in the study Phase I (according to the evaluation questionnaire). The training will be conducted by a team consisting of (i) supervisors (researchers) and (ii) teachers experienced in the previous trial (Train-Colonoscopy-Leaders course - TCL; this methodology has already been evaluated (citation)). There will be 7 trainees per session: 1 under-, 4 average and 2 overperformers.
~The training session will be divided into two parts: theoretical and practical. During the first, theoretical part of the training, the body of research on the phenomenon of colonoscopy pain will be presented. The second, practical part of the training, will consist of a one-day session of 7 colonoscopies.
~Each average and underperforming endoscopist who underwent training in the randomized phase will receive a written, customized feedback on his/her performance during the training session."
11097527|NCT04093687|No Intervention|Control Arm|The endoscopists in the control arm will not be informed about participation in the study and will receive only tailored feedback on adjusted painful colonoscopy rate (practice as usual). They will receive a reminder, that dedicated report on painful colonoscopy rate is provided in the Polish Colonoscopy Screening Program database and they will be monitored for endpoints through Polish Colonoscopy Screening Program database.
11097528|NCT04093674|Experimental|Clinical evaluation|Clinical periodontal parameters
11097529|NCT04093674|Experimental|Laser Doppler Flowmetry|Laser Doppler Flowmetry evaluation
11097530|NCT04093674|Experimental|Patient centered outcomes|Pain and discomfort/ Esthetics
11097531|NCT04093661||Children below 1 year|Children <= 1 year for elective surgery
11097532|NCT04093648|Experimental|TEGAR T cells + Fludarabine and Cytoxan|GPC3-CAR (TEGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
11097533|NCT04093635||Group I|Those patients that will be treated by NPWT.
11097534|NCT04093635||Group II|Those patients will be treated with standard saline moist wound care and dressing.
11097535|NCT04093622||Genetically engineered NK Cell - treated|Long term follow-up of subjects who have received lentivirus-mediated genetically engineered NK Cells.
11097536|NCT04093609||cases|
11097537|NCT04093609||control|
11097538|NCT04093596|Experimental|ALLO-647, ALLO-715|
11097539|NCT04093583|Active Comparator|Simple suture|
11097540|NCT04093583|Experimental|PRGF-Endoret|
11097541|NCT04093570|Experimental|ASTX727|The recommended starting dose is the fixed-dose combination (FDC) tablet, containing 100 mg cedazuridine and 35 mg decitabine, Daily×5 in 28-day cycles. Subjects should receive ASTX727 at the same dose they received in the last cycle of their parent study; if an adjustment from that dose is required, a different total cycle dose may be employed, as guided by the dose adjustment guidelines in the parent study protocol.
11097542|NCT04093557|Active Comparator|Orton Score Cohort - High|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they score highly, they will receive an extended GoLytely bowel prep."
11097543|NCT04093557|Placebo Comparator|Prospective Orton Score Cohort - Low|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they do not score highly, they will receive a standard GoLytely (or Suprep) bowel prep."
11097544|NCT04093557|Other|Retrospective Cohort (before Orton Score)|
11097545|NCT04093544|Active Comparator|Standard Stimulation|Participants will receive stimulation using the best contact combination in ring mode.
11097546|NCT04093544|Experimental|Directional Stimulation|Participants will receive stimulation using the best segmented (steered) contacts.
11097547|NCT04093531|Experimental|Ustekinumab|All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit. 650mg acetaminophen and 60mg allegra will be given as premedication to the infusion. All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits. Subcutaneous injections do not require any premedication. Drug will be administered by qualified personnel.
11097548|NCT04093518|Active Comparator|Active Comparator|Estradiol 200µg
11097549|NCT04093518|Placebo Comparator|Placebo Comparator|Placebo
11097550|NCT04093505|Experimental|GO147_G|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
11097551|NCT04093505|Placebo Comparator|GO147_P|"GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
11097552|NCT04093505|Experimental|GO1_G|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
~_G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27"
11097553|NCT04093505|Placebo Comparator|GO1_P|"GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
~_P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27"
11097554|NCT04093492|Experimental|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention in its current form sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
11097555|NCT04093492|Active Comparator|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
11097556|NCT04093479||BMI, oxytocin|Repeteadly blood samples will be taken
11097557|NCT04093466|Experimental|Treatment (CX1003)|Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
11097558|NCT04093453|Placebo Comparator|Placebo + Fasting|Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
11097559|NCT04093453|Placebo Comparator|Placebo + Exercise|Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.
11097560|NCT04093453|Placebo Comparator|Placebo + Post-prandial|Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.
11097561|NCT04093453|Experimental|Propionate and Fasting|Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
11097562|NCT04093453|Experimental|Propionate and Exercise|Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.
11097563|NCT04093453|Experimental|Propionate and Post-prandial|Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.
11097564|NCT04093440|Other|Observation|lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
11097565|NCT04093427|Active Comparator|softSTOPP active|
11097566|NCT04093427|No Intervention|softSTOPP inactive|
11097567|NCT04093414|Active Comparator|Selective His Bundle Pacing|Pacemaker wires placed in Bundle of His
11097568|NCT04093414|Active Comparator|Left Bundle Area Pacing|Pacemaker wires placed in Left Bundle Branch
11097569|NCT04093401|No Intervention|Control|Subjects will be assigned to the control arm if their subject ID is an odd number. Control arm subjects will not receive counseling for individualized risk assessment for developing a second basal cell carcinoma.
11097570|NCT04093401|Experimental|Individualized risk assessment|Subjects will be assigned to the intervention arm (i.e., informed of their individualized risk assessment) if their subject ID is an even number. Subjects in the intervention arm will be informed of their estimated 1-year, 3-year, and 5-year risk of developing a second basal cell carcinoma.
11097571|NCT04093388|Experimental|Self-PAP|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the self-administered Papanicolaou (Pap) smear. They will be compared to each other for congruence and accuracy.
11097572|NCT04093388|Experimental|Traditional Pap|Each patient will participate in both arms of the study on the day of the clinical examination. This arm includes the traditional, healthcare provider obtained Papanicolaou (Pap) smear specimen. They will be compared to each other for congruence and accuracy.
11097573|NCT04093375|Experimental|Radical Prostatectomy|Patients with locally advanced prostate adenocarcinoma receives Radical Prostatectomy with or without enlarged lymph node dissection
11097574|NCT04093375|Active Comparator|Radical Radiotherapy|Patients with locally advanced prostate adenocarcinoma receives Radical Radiotherapy with adjuvant androgen deprivation therapy
11097575|NCT04093362|Experimental|TAS-120|TAS-120 tablets, oral; 21-day cycle
11097576|NCT04093362|Active Comparator|Cisplatin/Gemcitabine|"• On Days 1 and 8 of a 21-day cycle, patients will receive:
~Cisplatin 25 mg/m2 in 1000 mL 0.9% saline by intravenous (I.V.) infusion over 1 hour, followed by 500 mL 0.9% saline over 30 minutes; and
~Gemcitabine 1000 mg/m2 in 250-500 mL 0.9% saline by I.V. infusion over 30 minutes, beginning after completion of the cisplatin and saline infusions."
11097577|NCT04093349|Experimental|SPK-3006|All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.
11097578|NCT04093336|Active Comparator|MSCs group|The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.
11097579|NCT04093336|Placebo Comparator|control group|The people in this group will receive placebo and standardized treatment of acute ischemic stroke.
11097580|NCT04093323|Experimental|Treatment (IFNA2, rintatolimod, celecoxib, alphaDC1 vaccine)|Patients receive recombinant interferon alpha-2 IV over 30 minutes, rintatolimod IV over 2.5 hours, and celecoxib PO BID on days 1-3. Beginning cycle 2, patients also receive alpha-type-1 polarized dendritic cells ID on day 1. Treatment repeats every 3 weeks up to 4 cycles in the absence of disease progression or unacceptable toxicity. At 12 weeks, patients with progressive disease may switch to ipilimumab with or without a PD-1/PD-L1 inhibitor and patients with a complete response CR, PR, or stable disease SD may switch to a PD-1/PD-L1 inhibitor or best alternative care.
11097581|NCT04093310|Experimental|Word catheter|The abscess is incised and the Word catheter is inserted into the residual cavity to create a neo-channel to prevent recurrence. The catheter is removed after 4 weeks during a consultation
11097582|NCT04093310|Active Comparator|Incision-drainage|This procedure performed under general or loco-regional anaesthesia consists in incising the abscess, draining the pus build-up and placing a wick in the residual cavity to promote progressive healing from the inside out.
11097583|NCT04093297|Active Comparator|Group Ring|Patients in Group Ring will undergo tricuspid rigid ring annuloplasty
11097584|NCT04093297|Active Comparator|Group Band|Patients in Group Band will undergo flexible band annuloplasty
11097585|NCT04093284|Experimental|Group A|The needle-free jet injector Continuous insulin therapy for 9 days, then changed to conventional insulin pen therapy for 9 days
11097586|NCT04093284|Experimental|Group B|The conventional insulin pen therapy for 9 days, then changed to needle-free jet injector Continuous insulin therapy for 9 days
11097587|NCT04093271|Experimental|Randomized to consume Rest-ZZZ, comparator, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Rest-ZZZ dietary supplement in Study Period 1, Comparator (Diphenhydramine HCl) in Study Period 2, and Placebo in Study Period 3.
11097588|NCT04093271|Experimental|Randomized to consume comparator, placebo, then Rest-ZZZ|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume the Comparator (Diphenhydramine HCl) in Study Period 1, Placebo in Study Period 2, and the Dietary Supplement, Rest-ZZZ in Study Period 3.
11097589|NCT04093271|Experimental|Randomized to consume placebo, Rest-ZZZ, then comparator|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Dietary Supplement, Rest-ZZZ in Study Period 2, and Comparator (Diphenhydramine HCl) in Study Period 3.
11097590|NCT04093258|Experimental|Test/Control|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
11097591|NCT04093258|Experimental|Control/Test|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
11097592|NCT04093245|No Intervention|Phase I-A (Local project set-up)|An executive committee will oversee the entire project. This committee, led by the nominated PI and Director of Nursing, will meet every 4 weeks during this four-year project. The team may include, depending on the hospital site: an administrator, the ED Director, the ED Head nurse, a community and/or hospital-based geriatric nurse specialist, an ED physician, a hospitalist, a geriatrician, a family physician, a home care nurse/coordinator, an inpatient unit manager, the research coordinator, and a local patient/caregiver. Each local team will be responsible for selecting and implementing the ACE intervention(s) best suiting their milieu, and will include locally identified champions to lead the local implementation.
11097593|NCT04093245|Experimental|Phase I-B (Implementation):|The investigators will implement the context-adapted ACE program with the support of administrators and local implementation teams who will have the responsibility to roll out the different elements of the intervention within their respective hospitals. It may include a series of systematic pre-discharge, post-discharge and across transitions period interventions for eligible patients: 1) a GEM nurse to support patients during the post-discharge transition period, 2) pre- and post-hospitalization medication list reconciliation, 3) systematic discharge summaries given to patients and/or caregiver, and sent to their family physician, 4) a planned follow-up appointment with their family physician, 5) a systematic follow-up phone call, 6) access to wiki-based patient-oriented KT tools, 7) access to a community-based telemonitoring service.
11097594|NCT04093245|Experimental|Phase IC (Study description)|Results from each center will be analysed over time. Guided by previous work in healthcare governance, the investigators will analyze the impact of the sequential interventions within the context of a major health reform in Quebec aiming at implementing an integrated health system and within the PI program's overall goal of creating a Learning Health System. This will be accomplished by conducting a comparative case study across the four study sites to compare the barriers, facilitators and local solutions implemented to gain a better understanding about how the ACE program could eventually be scaled up elsewhere.
11097595|NCT04093219|Experimental|IV Acetaminophen|1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
11097596|NCT04093219|Placebo Comparator|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
11097597|NCT04093206|Experimental|EpiCor and Vitamin C|EpiCor (90mg/5ml) and Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
11097598|NCT04093206|Active Comparator|Vitamin C|Vitamin C (25mg/5ml) given at dose of 5ml to children 1-2 years old, 7.5ml to children 3-4 years old and 10ml to children 5-6 years old
11097679|NCT04092556|Active Comparator|tDCS (M1)|The participants will be submit to tDCS applied over the motor cortex (M1)
11097599|NCT04093193|Experimental|Debridement group|Patients receive routine post-operative debridement at their Day 6, 30 and 60 follow up appointments.
11097600|NCT04093193|No Intervention|Non Debridement Group|Patients will not receive debridement at any follow up visit after surgery. They will continue with saline irrigation.
11097601|NCT04093180|Experimental|Experimental group|Experimental group undergoing treatment course according to INRS
11097602|NCT04093180|Other|Control group|Wait-list delayed intervention. Control group continues usual activity and care while staying in the waiting list.
11097603|NCT04093167|Experimental|Pembrolizumab|200mg IV every 3 weeks
11097604|NCT04093154|Experimental|Virtual Reality|Standard Care + VR VR applications introduced to the child or adolescent by the researcher before the procedure. Three VR applications were used in this study; riding a rollercoaster (Rilix VR), swimming with marine animals in underwater world (Ocean Rift) and exploring the forest though the eyes of woodland species (In the eyes of animal). Children/adolescent chose one of these three applications. When the child is ready for the procedure, the researcher started the application by wearing virtual glasses to the child/adolescent. VR intervention was started 2-3 min before the procedure and continued until the procedure was completed.
11097605|NCT04093154|No Intervention|Control|Standart Care Control group children did not receive any distraction techniques.
11097606|NCT04093141|Experimental|Intervention|
11097607|NCT04093128|Experimental|adults aged 19-57|adults aged 19-57 years old living in Amman Jordan, body mass index between 19-57
11097608|NCT04093115|Experimental|CX1106|CX1106 740 mg/m2 as a 24-hour continuous infusion for 5 days every 3 weeks (3 weeks/cycle, 4-6 cycles)
11097609|NCT04093102||cases|cases with obsrtuctive sleep apnea
11097610|NCT04093102||control|cases without obstructive sleep apnea.
11097611|NCT04093089|Experimental|Test Group|
11097612|NCT04093089|Placebo Comparator|Control Group|
11097613|NCT04093076|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device.
11097614|NCT04093076|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.
11097615|NCT04093076|Placebo Comparator|Placebo Group C|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device.
11097616|NCT04093076|Placebo Comparator|Placebo Group D|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit..
11097617|NCT04093063|Experimental|Intervention Group|Subjects in the intervention group were tasked with building a micro-stellated icosahedron using a detailed instruction manual. They were each provided with a dissecting microscope and necessary materials to complete the task at home at their leisure. They were given two weeks to complete the task. They were asked to return for a second in-person meeting two weeks.
11097618|NCT04093063|No Intervention|Control Group|Subjects in the non-intervention control group were not given any task or any materials. They were asked to return for a second in-person meeting in two weeks.
11097619|NCT04093050|Experimental|TT Genotype|
11097620|NCT04093050|Placebo Comparator|AA/AT Genotype|
11097621|NCT04093037|Experimental|Patient with dry eye disease|"Patient with dry eye disease will be included. They will have:
~Time #1: LacryDiag examination without dye
~Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score
~Time #3: Standard Break-Up Time (SBUT)
~Time #4: Schirmer test
~Satisfaction questionnaire to the patient"
11097622|NCT04093024|Experimental|Nintedanib (Ofev®)|
11097623|NCT04093024|Placebo Comparator|Placebo|
11097624|NCT04092998|Experimental|Thermocautery VS scalpel circumcision|Thermocautery circumcision in comparison to circumcision with traditional scalpel
11097625|NCT04092985||Patients suspected with Cardiac Arrhythmia|iECG + 12-lead ECG recording in patients suspected with any type of cardiac arrhythmias at the time of recruitment
11097626|NCT04092972|Experimental|Atherectomy|Atherectomy and drug-coated balloon (DCB)
11097627|NCT04092972|Active Comparator|Standard care|Standard care with predilation (POBA) and DCB
11097628|NCT04092959|Experimental|Walking group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
11097629|NCT04092959|Experimental|Chinese Square Dancing group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
11097630|NCT04092959|Experimental|Control group|A total of 240 hypertensive subjects aged 40-69 years (including 126 patients complicated with diabetes) will be included in a few communities in Beijing, and will be divided into 3 groups according to the individual wishes of the subjects: walking group(n=80, including 42 patients complicated with diabetes), Chinese square dancing group(n=80, including 42 patients complicated with diabetes) and control group(n=80, including 42 patients complicated with diabetes).
11097631|NCT04092946|Experimental|Patients with chronic musculoskeletal disorders|Tailored digital programs for individuals working for organizations that enter into a commercial agreement with SWORD Health, which acts as a service provider.
11097632|NCT04092920|Experimental|laser and SLA implants|extraction of badly broken maxillary and mandibular teeth with immediate implant placement using laser surface treated and SLA surface treated dental implants
11097633|NCT04092907|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
11097634|NCT04092907|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
11097635|NCT04092894|Active Comparator|Suvorexant|Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
11097636|NCT04092894|Placebo Comparator|Placebo|Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
11097637|NCT04092881|Active Comparator|Short pulsed Nd-YAG laser treatment side|"Neodymium-Doped Yttrium Aluminum Garnet (Nd-YAG) (Fotona XP®) laser is a successful therapeutic modality and is characterized by its safe profile compared to other lasers.
~Short pulsed Nd-YAG laser (Fotona XP® Accelera mode) results in a non-ablative dermal heating with intact overlying epidermis which has shown a potential for dermal collagen remodeling in histological sections."
11097638|NCT04092881|Active Comparator|Fractional ablative CO2 laser treatment side|"Carbon dioxide (CO2) (Deka SmartXide DOT®) laser is one of the well-tolerated therapeutic modalities used for treatment of different skin disorders including striae alba.
~CO2 laser targets mainly water content in both epidermis and dermis causing vaporization of target cells.
~Fractional ablative CO2 laser creates columns of focal dermo-epidermal tissue loss known as (microablative columns) with thermal damage, hemostatic effect and incomplete coagulation of tissues. This ablation of dermal tissues (including collagen and elastin) has the potential for stimulation of new tissue formation in striae distensae."
11097639|NCT04092868||cardiac surgery with extracorporeal circulation|"during the operation
~Intervention Blood sample :
~protamine dosage: t = 5, 8, 11,14 and 17 min after protamine injection
~anti-X activity t = 0 before administration and at time 5, 8, 11,14 and 17 min then at time 1, 3, 5, 6 and 7 hours after protamine injection
~thrombin generation test (TGT) activity (thrombinography) : t = 5, 8, 11,14 and 17 min after protamine injection"
11097640|NCT04092842|Experimental|Group intervention: Silicone prothesis|Breast cancer conservative surgery will be performed by removing the tumor according to the usual technique and then the defect generated will be filled with a silicone prosthesis of the same size. Said prosthesis will be covered with fat and subcutaneous cellular tissue and then the skin will be closed.
11097641|NCT04092842|Active Comparator|Group control: Usual surgical technique|Breast cancer conservative surgery will be performed according to the usual surgical technique, that is, removing the tumor and covering the defect by mobilizing the breast tissue and then closing the skin.
11097642|NCT04092829|No Intervention|FROZEN EMBRYO TRANSFER IN NATURAL CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.
11097643|NCT04092829|Active Comparator|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|After confirming ovarian rest (follicles < 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol >100 pg/ml and serum progesterone < 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.
11097644|NCT04092816|Experimental|FAMILY|Patient-co-parent dyads will participate in the FAMILY intervention in-person.
11097645|NCT04092803|No Intervention|GA for LP|Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
11097646|NCT04092803|Experimental|VR for LP|"The patients in this study will be presented the opportunity to use VR instead of undergo GA for a LP. Patients who agree to undergo an LP with VR will be assessed by a certified child life specialist (CCLS) to determine whether the patient is an appropriate candidate for using VR.The system includes a VR headset with VR software already loaded in to it. The VR software to be used is either a game called Pebbles the Penguin or SpacePups (Weightless Studios)."
11097647|NCT04092790|Experimental|Virtual Gate Device (VGD)|The Virtual Gait Device (VGD) is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. The stocking-like device is especially useful in older patients who are acutely hospitalized and thus at risk for sarcopenia. While physical activity and physical resistance training are well-documented as preventive measures for sarcopenia, active physical exercise is an unrealistic option for most acutely hospitalized, mobility-limited, older patients. The VGD is a practical alternative that is simple to operate. One pilot study in the orthopedics department in Hadassah Medical Center in Jerusalem, Israel was performed on patients with fractured ankles with the goal of muscle wasting prevention. The VGD will be provided by the manufacturer for use in this pilot clinical study.
11097648|NCT04092777|Experimental|Strong Minds Program|This is a 10-session, culturally-adapted intervention, that includes cognitive behavioral therapy techniques combined with mindfulness exercises, led by a Community Health Worker.
11097649|NCT04092777|Other|Enhanced Usual Care|Enhanced usual care includes check in calls by a Care Manager 4 times over the course of 6 months and educational materials about depression and anxiety.
11097650|NCT04092764|Experimental|Participants Receiving Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks.
11097651|NCT04092751|Experimental|Treatment A|Single oral 20-mg dose of PRA on Day 1 AM
11097652|NCT04092751|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later.
11097680|NCT04092556|Active Comparator|tDCS (Cerebellar cortex)|The participants will be submit to tDCS applied over the cerebellar cortex
11097681|NCT04092556|Sham Comparator|Sham stimulation|The participants will be submit to sham stimulation
11097682|NCT04092543||Stroke patients|All patients diagnosed with a stroke are collected in the database.
11097653|NCT04092738|Experimental|Intervention Group|"In the intervention group, subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2. In addition, participants will be provided with an external movement sensor that will be linked to the Walk@WalkApp-Diab for Android and iOS. This App will monitor the time participants spend sitting, walking and standing during working hours. It will also provide participants with strategies to sit less and move more at work throughout 13 weeks. This mHealth intervention aims to change occupational sitting by replacing desk-based activities by active tasks."
11097654|NCT04092738|No Intervention|Control Group|Subjects will receive brief advice on occupational physical activity, sedentary behaviour and Diabetes Type 2.
11097655|NCT04092725|Experimental|Treatment A|Single oral 150-mg dose of DAB on Day 1 AM.
11097656|NCT04092725|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
11097657|NCT04092712|Experimental|Investigational Product|[14C]-CTP-543
11097658|NCT04092699|Other|patient|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
11097659|NCT04092699|Other|skulls|CBCT Dicom file of patient has been scanned will be used for measurements of maxillary sinus volume by different software
11097660|NCT04092686|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
11097661|NCT04092686|Experimental|SEP-363856 100mg|SEP-363856 100mg dosed once daily
11097662|NCT04092686|Placebo Comparator|Placebo|Placebo dosed once daily
11097663|NCT04092673|Experimental|sequential escalation|eFT226 is administered IV weekly in 21 day cycles. eFT226 doses will be escalated in sequential cohorts after subjects enrolled in a given cohort have completed the 21-day dose-limiting toxicity (DLT) evaluation period. Starting dose is 0.005mg/kg/week, potentially escalating to 0.12mg/kg/week until MTD and RP2D are established
11097664|NCT04092660|Experimental|Intervention Care Group|"The Intervention care group will receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard. Additionally, they will also receive special support in the form of behaviour change interventions. The behavior change interventions consist of motivational interviewing, will be shown a video highlighting the negative consequences of sleep apnoea.
~Booster calls at week 3,6, 18 and 12 for verbal encouragement and to resolve any technical problems with the device.
~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life."
11097665|NCT04092660|Active Comparator|Standardized Care Group|"The standardized care group will only receive the Mandibular Advancement Appliance (MAA) or the anti-snoring mouthguard along with routine care and will be called for follow up at 3rd and 6th month of treatment to assess their use and to resolve any technical problems with the device.
~Participants will be asked to complete questionnaires regarding their personality, socio-economic status, social support and quality of sleep and life at the initial visit and subsequent follow-up."
11097666|NCT04092647|Experimental|ashwagandha|Ashwagandha
11097667|NCT04092647|Placebo Comparator|placebo|Placebo
11097668|NCT04092634|Experimental|Dual mobility|Patients in this group will receive a dual mobility hip implant
11097669|NCT04092634|Active Comparator|Single bearing, traditional hip implant|Patients in this group will receive a traditional, single-bearing hip implant.
11097670|NCT04092621|Experimental|Rhythm-control strategy|The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
11097671|NCT04092621|Active Comparator|Rate-control strategy|At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
11097672|NCT04092608|Active Comparator|Low CVP group (restrictive group)|"Standard practice: the goal is to keep the CVP < 7 mmHg during surgery.
~Baseline of crystalloid of 2ml/kg/h max in all patients.
~EV 1000 monitoring device (Edwards Lifesciences, Irvine, USA) will be used but values will be blinded to the anesthesiologist in charge of the patient.
~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion
~Additionnal fluid administration is given to the patient at the end of the surgery (standard practice)
~UPi is blinded in all groups"
11097673|NCT04092608|Experimental|GDFT group|"The goal is to keep stroke volume variation below 13% during surgery with mini fluid challenge of 100 ml of balanced crystalloid using the monitoring device (Edwards Lifesciences, Irvine, USA). Of course, the values will not be blinded to the anesthesiologist in charge of the patient.
~All patients have a baseline crystalloid: 2ml/kg/h and mini fluid challenges per 100 ml as described above.
~Mean Arterial pressure (MAP) should be kept over 65mmHg during surgery (standard practice) with continuous norepinephrine infusion
~UPi is blinded in all groups"
11097674|NCT04092595|Experimental|PF-06651600 and Rosuvastatin|Period 1 is 4 days in length. On Day 1 of Period 1 participants will receive a single dose of Rosuvastatin 10 mg given as a tablet orally. Period 2 is 11 days in length and will immediately follow Period 1 with no washout. In Period 2, participants will be dosed with oral 200 mg PF-06651600 once-daily (QD) for 7 days. On Day 8 of Period 2, a single dose of 10 mg Rosuvastatin oral tablet will be administered following administration of the 200-mg dose of PF-06651600. Dosing with oral 200 mg PF-06651600 QD will continue until Day 10 of Period 2.
11097675|NCT04092582|Experimental|MTPS9579A|
11097676|NCT04092582|Placebo Comparator|Placebo|
11097677|NCT04092569|Active Comparator|Intervention group|Pre-medical consultation structured diabetes self-care education programme
11097683|NCT04092530|Experimental|Intervention|During the intervention period (20 months), staff will capture women during the first well-baby visit (WBV; typically 3-5 days after delivery) and offer to have the next visit co-scheduled for infant and contraception care. Appointments are scheduled during the discharge process at the end of each WBV. During the discharge process all women 0-6 months postpartum will be identified by clerical staff through review of each pediatric clinic beforehand and through an electronic flag alert in the infant's electronic medical record. The pre-review of pediatric clinic schedules and the use of the flag will remind staff to offer the mother a co-scheduled visit for newborn and contraceptive care at the time of the next newborn visit.
11097684|NCT04092530|No Intervention|Control|Clinics will schedule postpartum contraception using normal clinic procedures.
11097685|NCT04092517|Active Comparator|Control Corn Soya Diet|Control Corn Soya Diet will be prepared to a formulation for Corn Soya Blend (SUPER CEREAL) product adopted by the WFP as complementary food for children over than 6 months.
11097686|NCT04092517|Experimental|Test Corn Moringa Diet|Test Corn Moringa Diet will be prepared to the same formulation as Corn Soya Blend, but the Soya content will be replaced with Moringa and no micronutrient premix will be added.
11097687|NCT04092504|No Intervention|Control group|Standard care at the unit
11097688|NCT04092504|Experimental|Gero-Erat|New care pathway that is built on the concept of ERAS and CGA
11097689|NCT04092491||1 blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:
~2 PAXgene RNA tubes of 2 ml each
~1 dry tube for creatinine and IgA assay
~1 tube of NFs (5ml)"
11097690|NCT04092478||Traditional Sitting Position|We are going to use the Traditional Sitting Position on each patients.
11097691|NCT04092478||Lateral Decubitis Position|We are going to use the Lateral Decubitis Position on each patients.
11097692|NCT04092478||Abdominal Crunch Position|We are going to use the Abdominal Crunch Position on each patients.
11097693|NCT04092452|Experimental|Cohort 1|PF-06650833
11097694|NCT04092452|Experimental|Cohort 2|PF-6700841
11097695|NCT04092452|Experimental|Cohort 3|PF-06826647
11097696|NCT04092452|Placebo Comparator|Cohort placebo|placebo
11097697|NCT04092439|Experimental|Watermelon juice|100% watermelon juice
11097698|NCT04092439|Placebo Comparator|Placebo|Fructose matched control
11097699|NCT04092426||patients with keratoconus|"patients with keratoconus attending refractive surgery centers in Assiut will be subjected to the following :-
~Full history and clinical evaluation.
~collection of individual data ( residency , occupation , special habbit , chronic illness )
~Analysis of results to assess prevelance of keratoconus and its distribution geographically in Assiut"
11097700|NCT04092400||Micro-Invasive Glaucoma Surgical devices|Patients implanted With Micro-invasive Glaucoma Surgical (MIGS) devices at the National University Hospital, Singapore
11097701|NCT04092387|Experimental|RC 1 only|Research cigarettes #1
11097702|NCT04092387|Experimental|RC 2 only|Research Cigarettes #2
11097703|NCT04092387|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
11097704|NCT04092387|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
11097705|NCT04092374|Experimental|Case arm|
11097706|NCT04092361||anisometropic amblyopia|
11097707|NCT04092361||strabismic amblyopia|
11097708|NCT04092361||deprivational amblyopia|
11097709|NCT04092348||study group|children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia
11097710|NCT04092348||control group|healthy age- and sex-matched children without ahistory of any malignancies
11097711|NCT04092322||Patients with subacute chronic stroke|Patients with subacute chronic stroke between the ages of 40-80
11097712|NCT04092309|Other|ACE group|patients after bone marrow transplantation will be treated with ACE inhibitor
11097713|NCT04092309|Other|Sacubitril Valsartan group|patients after bone marrow transplantation will be treated with sacubitril valsartan
11097714|NCT04092309|Other|Control group|patients after bone marrow transplantation will be treated neither with ACE i nor with sacubitril valsartan
11097715|NCT04092296|Experimental|resin infiltration|resin infiltrant (Icon product, DMG, Hamburg,Germany)
11097716|NCT04092296|Active Comparator|remineralization|
11097717|NCT04092283|Experimental|Arm A (durvalumab, chemotherapy, durvalumab)|"STEP 1 (CONCURRENT THERAPY): Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycle 1 and day 1 of cycle 2. Patients also receive 1 of 3 treatment regimens per investigator choice: 1) etoposide IV over 60 minutes on days 1-5 and cisplatin IV over 60 minutes on days 1 and 8 every 28 days for 2 cycles; 2) pemetrexed disodium IV over 60 minutes and cisplatin IV over 60-120 minutes on day 1 every 21 days for 2 cycles; or 3) paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1 every 7 days for 6 cycles. Treatment continues in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of chemotherapy, patients receive radiation therapy 5 days a week for 6 weeks.
~STEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
11097718|NCT04092283|Active Comparator|Arm B (chemotherapy, durvalumab)|"STEP 1 (CONCURRENT THERAPY): Patients receive 1 of 3 investigator's choice treatment regimens and radiation therapy as in Arm A.
~STEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
11097719|NCT04092270|Experimental|Treatment (peposertib, PLD)|Patients receive peposertib PO BID on days 1-28 and pegylated liposomal doxorubicin hydrochloride IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11097720|NCT04092257|Experimental|VIA and thermocoagulation|Participants will undergo same day VIA and thermocoagulation
11097721|NCT04092231||1|Thirty children were between two and five years of age at the time of implantation. All were congenital pre-linguistically bilateral profound sensorineural hearing loss. Reports about basic audiological evaluation which included air and bone conduction thresholds, speech audiometry for all the study group before the implantation were obtained. They had limited benefit from consistent use of hearing aid amplification and enrolled in a rehabilitation program focused on oral communication. they underwent unilateral CI with CI experience ranged from 6 months and above.
11097723|NCT04092192|Active Comparator|Forceps|Subjects randomized to this cohort will have their IVC filter removed using a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed.
11097724|NCT04092192|Active Comparator|Snare|Subjects randomized to this cohort will have their IVC filter removed using an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.
11097725|NCT04092179|Experimental|Venetoclax and Enadisenib|"Enasidenib and venetoclax will be taken by mouth (orally), once a day, every day, continuously.
~Every 28-day period will be called a cycle. Participants will start venetoclax alone on Cycle 1 Day 1 and continue the study drug alone until Day 15. On Day 15, participants will take enasidenib and venetoclax together and will continue to take the combination of study drugs until intolerable side effects or disease worsening."
11097726|NCT04092166|No Intervention|Controlled|Participants will have no intervention.
11097727|NCT04092166|Other|Cardiac Rehab Exercise: Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
11097728|NCT04092153|Active Comparator|Mechanically aligned|Neutral limb alignment irrespective of the patient's native knee anatomy and joint mechanics
11097729|NCT04092153|Experimental|Functionally aligned|Restore the patient's own pre-arthritic knee anatomy
11097730|NCT04092140||diabetic complaining of neuropathy or not|using of ultrasound in examination and nerve conduction study
11097731|NCT04092140||carpal tunnel syndrome|using of ultrasound in examination and nerve conduction study
11097732|NCT04092127||premature infants (<32 weeks of Gestation Age)|premature babies (<32 weeks of Gestation Age) to be screened with RetCam for retinopathy of prematurity and who will be filmed during the screening procedure to evaluate pain with the PIPP score (Premature Infant Pain Profile)
11097733|NCT04092114|Other|Control|Receives Standard of Care (SOC) services established in accordance with the South African Department of Health (DoH) PrEP (Pre-exposure Prophylaxis) guidelines.
11097734|NCT04092114|Experimental|CHARISMA Intervention|"Receives SOC (Standard of care) per control arm plus provider-administration of HEART (HEAlthy Relationship Assessment Tool) and provider-administration of CHARISMA (the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence) counseling modules, as applicable:
~Module A: General Partner Communication and Relationship Skills
~Module B: Partner Disclosure and Communication around PrEP Use
~Module C: Responding to Intimate Partner Violence and Safety Planning"
11097735|NCT04092101|Experimental|RC 1 only|Research Cigarettes #1
11097736|NCT04092101|Experimental|RC 2 only|Research Cigarettes #2
11097737|NCT04092101|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1
11097738|NCT04092101|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2
11097739|NCT04092088|Active Comparator|tDCS-r+TENS-r|Real transcranial direct current stimulation (tDCS-r) + real transcutaneous electrical nerve stimulation (TENS-r)
11097740|NCT04092088|Experimental|tDCS-r+TENS-s|Real transcranial direct current stimulation (tDCS-r) + sham transcutaneous electrical nerve stimulation (TENS-s)
11097741|NCT04092088|Experimental|tDCS-s+TENS-r|Sham transcranial direct current stimulation (tDCS-s) + real transcutaneous electrical nerve stimulation (TENS-r)
11097742|NCT04092088|Sham Comparator|tDCS-s+TENS-s|Sham transcranial direct current stimulation (tDCS-s) + sham transcutaneous electrical nerve stimulation (TENS-s)
11097743|NCT04092075|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
11097744|NCT04092075|Sham Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
11097745|NCT04092062|Experimental|Treatment - ToothWave brush|Subjects using the Silk'n ToothWave, Radio frequency (RF)-utilizing toothbrush.
11097746|NCT04092062|Sham Comparator|Control - powered toothbrush|Subjects using a regular ADA-Accepted Powered Toothbrush, no RF
11097747|NCT04092049|Experimental|lollipop|
11097748|NCT04092049|No Intervention|control|
11097749|NCT04092036||Unstable patients|Patients on mechanical ventilation, 18 years or older and developing hypotension (Mean arterial blood pressure) <65 mmHg
11097750|NCT04092023|Other|Control group|Participants in control group will be received usual care. They will be gone through yearly DM complication screening. A screening report and information sheet on general DM management will be issued to participants. Therapeutic goals will be set and further conventional health care education intervention will be referred.
11097751|NCT04092023|Other|Intervention group|The interventions are designed to address the seven key self-management behaviours identified by the Association of American Diabetes Educations: (1) healthy eating, (2) being active, (3) monitoring, (4) taking medication, (5) problem solving, (6) reducing risk, and (7) healthy coping. In addition, the Chronic Care Model elements of self-management support and patient centered-care approach is embraced during the intervention process. The nursing care components provided to participants will be included (a) self-care management knowledge, (b) skill-based learning and problem solving, (c) participants' participation and engagement, (d) participants' in goal setting, and (e) coordinate care, involve participants to make decision.
11097752|NCT04092010|Experimental|Stepped-care intervention (SCI) group|In the SCI group, mothers with low baseline depressive symptoms are offered the problem-solving education (PSE) prevention intervention, and mothers with greater depressive symptoms are offered Engagement Sessions.
11097753|NCT04092010|Active Comparator|Usual care control group|Families in the control group will receive usual Head Start services.
11097754|NCT04091997||endometriosis|laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay
11097755|NCT04091997||control|diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay
11097756|NCT04091984||Prospera Arm|There is no intervention in this study. Adult patients who have received a kidney allograft from a genetically different donor within 60 days and who have been selected by their healthcare provider to receive Prospera dd-cfDNA testing according to their regular interval testing schedule as part of their clinical care will have medical records pertaining to their kidney rejection status collected at each study visit.
11097787|NCT04091737|Experimental|CSL200|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
11097757|NCT04091984||Control Arm|The control arm will consist of retrospective data review of cases where a renal allograft from a genetically different donor was performed. Data pertaining to to their kidney rejection status from a minimum of 3 time points per year post allograft (up to 5 years) or until renal allograft failure will be collected.
11097758|NCT04091971|Experimental|Depressed adults with current MDD|Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.
11097759|NCT04091958|Experimental|Post-tumourectomy reconstruction with myo-glandular flap.|Standard tumourectomy followed by reconstruction with myo-glandular flap.
11097760|NCT04091945|Active Comparator|LT3001 Drug Product|
11097761|NCT04091945|Placebo Comparator|Placebo|
11097762|NCT04091932|Experimental|Pembrolizumab treatment|Pembrolizumab dosage form:100mg/4ml dosage:2mg/kg weight frequency: once per 4 weeks duration:12 weeks
11097763|NCT04091919||ASD group|Isolated ostium Secundum ASD patients who are involving in this study have been already selected for intervention before the starting time of the study. The ASD patients who will be scheduled for transcatheter closure have either haemodynamically significant shunt fraction (Qp/Qs > 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms. 2-D TTE derived Tissue Doppler and Strain Imaging will be done for all patients at baseline, 24 hours and 1-3 month post-procedure. Correlation between the device size and echocardiographic variables will be performed. Comparison between the results of the 2D-TTE derived Strain Imaging procedures will be done between baseline data and those obtained one day after the procedure and at one month follow up.
11097764|NCT04091919||Controlled group|Age matched controlled subjects without ASD
11097765|NCT04091906|Experimental|Healthy donor|
11097766|NCT04091893|Active Comparator|Usual care/wait list|
11097767|NCT04091893|Experimental|Art Rx|
11097768|NCT04091893|Experimental|Artful Meditation|
11097769|NCT04091893|Experimental|Art Rx + Artful Meditation|
11097770|NCT04091880|Experimental|experimental group|378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
11097771|NCT04091880|Active Comparator|control group A|378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
11097772|NCT04091880|Active Comparator|control group B|378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).
11097773|NCT04091867|Experimental|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
~Cetuximab:
~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
~RT:
~6930 cGy IMRT starting D15-D18"
11097774|NCT04091854||HMS5552 treatment|
11097775|NCT04091841|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
11097776|NCT04091841|Placebo Comparator|Carbo Mass|Control patients will be received protein diet (1.2 g/kg/day) and Carbo Mass for 1 month after surgery.
11097777|NCT04091828||Biplar patients|diagnosed by DSM-5 and divided to manic,depressed and mixed last episod
11097778|NCT04091828||controlled subject|not have any medical or psychatric problem affect cognition
11097779|NCT04091815|Active Comparator|I group - general anaesthesia|General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), opioids (fentanyl and morphine), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture.
11097780|NCT04091815|Experimental|II group - combined - spinal and general anaesthesia|"Spinal anesthesia: L3-4 interspace, 27G needle, bupivacaine hyperbaric, 16 mg, morphine sulfate 0.1% - 0.1ml.
~General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture."
11097781|NCT04091802|Experimental|single layer of L-PRF|single layer of L-PRF will be put in the vertical incision
11097782|NCT04091802|Experimental|multiple layers of L-PRF|multiple layers of L-PRF will be put in the vertical incision
11097783|NCT04091789|Experimental|Test Article|Subjects will take Pure Femme sublingual tablets as directed, one tablet 2 days before, one tablet 1 day before, and then up to 3 tablets per day for 3 days (72 hours) during menstruation.
11097784|NCT04091763|Experimental|Polidocanol foam sclerotherapy|"Preparation of the polidocanol foam according to Tessari technique immediately before application (so that the microbubbles of the foam did not disintegrate);
~Application according to the Blanchard technique (Fig. 2) through a disposable transparent anoscope, with the patient in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle;
~Patients treated in a maximum of 3 sessions at 3 weeks intervals;
~Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air;
~In each session more than one hemorrhoid cushion could be treated."
11097785|NCT04091763|Experimental|Rubber band ligation|"Use of reusable metal ligation device connected to a vacuum system (McGown suction method) to apply the rubber bands above the dentated line through a disposable transparent anoscope with the patient in jackknife position;
~A maximum of 3 sessions of ligation at 3-week intervals were performed;
~More than 1 band per session could be applied."
11097786|NCT04091750|Experimental|Single Arm|"Induction phase:
~Nivolumab 3mg/kg IV plus Ipilimumab 1mg/kg IV every 3 weeks x 4 cycles (12 week period)
~Cabozantinib 40mg PO daily for 12 weeks
~Maintenance phase:
~Nivolumab 480mg IV every 4 weeks for up to 92 weeks
~Cabozantinib 40mg PO daily for up to 92 weeks
~Maintenance therapy will continue for up to 92 weeks to complete 2 years total of treatment if tolerating therapy well and disease is controlled."
11097790|NCT04091711|Experimental|ReX-C intervention|Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
11097791|NCT04091698|Active Comparator|topical Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
11097792|NCT04091698|Placebo Comparator|topical corticosteroid|will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.
11097793|NCT04091672|Experimental|All Participants (within patient control)|All subjects will receive both RECELL and skin graft. Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment (RECELL) will be randomly allocated to either Area A or Area B
11097794|NCT04091659|Active Comparator|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
11097795|NCT04091659|Experimental|Virtual Reality|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
11097796|NCT04091646|Active Comparator|ARQ-154 foam 0.3%|
11097797|NCT04091646|Placebo Comparator|ARQ-154 foam Vehicle|
11097798|NCT04091633|Active Comparator|School Mental Health Program-Conventional (cSMHP)|The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
11097799|NCT04091633|Experimental|Enhanced-School Mental Health Program (eSMHP)|The teachers of schools randomized to intervention arm will receive online training in adapted version of School Mental Health Program. The online training in adapted School Mental Health Program consists of 4-5 hour, self-paced online training course for teachers. The teachers will register themselves in the online course in the form of a group of 4-5 teachers from each school. The teachers will complete the online training course in a group, with interactive group activities and role plays. Progress to the next module in the online training is conditional upon completion of post-module mental health literacy quiz. A certificate of training completion in adapted SMHP shall be awarded to those teachers who complete the post-test. Teachers will be supported online and in-person by the trainers who are trained in SMHP in monthly supervision meeting of teachers for 9-months.
11097800|NCT04091620|Experimental|Transanal Total Mesorectal Excision|For transanal total mesorectal excision, a two team approach will be adopted. One surgical team will be performing the abdominal phase dissection using standard laparoscopic approach, while the other will be simultaneously performing the transanal dissection and total mesorectal excision in a 'down-to-up' fashion using laparoscopic instruments.
11097801|NCT04091620|Active Comparator|Robotic Total Mesorectal Excision|For robotic total mesorectal excision, a fully robotic approach will be adopted. Left-sided colonic mobilization, division of lymphovascular pedicle, and 'top-to-down' total mesorectal excision will be performed using the robotic platform.
11097802|NCT04091607|Active Comparator|Music Therapy Intervention Group|listen to preferred choice of music during the Lumbar Medial Branch Block procedure.
11097803|NCT04091607|No Intervention|Control Group|No music will be provided but will be provided earbuds. The sound environment will be standard for procedures by closing procedure room door and minimizing extraneous sounds.
11097804|NCT04091594|Experimental|Flexible orthotic|Sensory input flexible ankle foot orthotic (SIAFO) with appropriate lycra garments
11097805|NCT04091594|Active Comparator|Standard of care|Standard of care solid ankle foot orthotic (AFO)
11097806|NCT04091581|Experimental|Assessment|Instill eye drop and perform followup assessments
11097807|NCT04091568||Awake fibre-optic intubation|Awake fibre-optic intubation
11097808|NCT04091568||Asleep fibre-optic intubation|Asleep fibre-optic intubation
11097809|NCT04091542|Experimental|FiO2 group 1|FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
11097810|NCT04091542|Experimental|FiO2 group 2|FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
11097811|NCT04091542|Experimental|Duration 1|In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
11097812|NCT04091542|Experimental|Duration 2|In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
11097813|NCT04091542|Experimental|respiratory rate 1|In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
11097814|NCT04091542|Experimental|respiratory rate 2|In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
11097815|NCT04091542|Experimental|Position 1|The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
11097816|NCT04091542|Experimental|Position 2|The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
11097817|NCT04091529|Experimental|Radiofrequency myolysis of uterine fibroids|54 premenopausal participants with symptomatic uterine myomas
11097940|NCT04090749|Experimental|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
11097818|NCT04091516|Other|Low-fat plant-based diet|For 12 weeks, participants will follow a diet comprised of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
11097819|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 75 mg/M2 per day|75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
11097820|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 150 mg/M2 per day|150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
11097821|NCT04091503|Active Comparator|Intranasal Modified Temozolomide 200 mg/M2 per day|200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)
11097822|NCT04091490|Experimental|Patients with relapsed/refractory Hodgkin's lymphoma|A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
11097823|NCT04091464|Experimental|TRAIN-BW|1x/week for 8 weeks + home exercise program
11097824|NCT04091464|Active Comparator|TRAIN-FW|1x/week for 8 weeks + home exercise program
11097825|NCT04091451|Experimental|HZ/su Group|Subjects randomized to the HZ/su group will receive 2 doses of HZ/su vaccine at visit day 1 and visit month 2 and will be followed up until the study end.
11097826|NCT04091451|Placebo Comparator|Placebo Group|Subjects randomized to Placebo group will receive placebo at visit day 1 and visit month 2 and will be followed up until the study end.
11097827|NCT04091438|Experimental|TAK-925 Dose A + Placebo|TAK-925 Dose A, 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour IV infusion once on Day 3, Treatment Period 2.
11097828|NCT04091438|Placebo Comparator|Placebo + TAK-925 Dose A|TAK-925 placebo-matching 9-hour IV infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 Dose A, 9-hour IV infusion once on Day 3, Treatment Period 2.
11097829|NCT04091425|Experimental|TAK-925 Dose A|TAK-925 dose A intravenous (IV) infusion in each treatment sequence (crossover design).
11097830|NCT04091425|Experimental|TAK-925 Dose B|TAK-925 dose B IV infusion in each treatment sequence (cross over design).
11097831|NCT04091425|Placebo Comparator|Placebo|TAK-925 placebo-matching IV infusion in each treatment sequence (crossover design).
11097832|NCT04091412|Experimental|Long-term administration of Butylphthalide Soft Capsules|In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.
11097833|NCT04091412|No Intervention|Standard secondary prevention group|patients in this group take atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets as standard secondary prevention.
11097834|NCT04091399|Experimental|Patient cohort|Patients suffered from alveolar osteitis and treated using a Stomatological tamponade Contipro, composed of the Hyaluronic acid and Octenidine dihydrochloride. Firstly, the extraction wound had been irrigated with 2 ml of 3% solution of H2O2 to disinfect the site and then flushed by 2 ml of Aqua pro injectione to clear any remaining debris. After, the tested drug was applied into the extraction wound. This procedure was repeated on a daily basis for a maximum of 7 days or until the pain subsided below 20 mm and remained there for at least 2 days.
11097835|NCT04091386||Hemophilia A patients|Patients with hemophilia A who are being treated with Damoctocog alfa pegol (Jivi, BAY94-9027) in routine medical practice and are enrolled in Bayer-sponsored study NCT03932201
11097836|NCT04091373|Experimental|Sequence 1|100ug SC injection cotadutide in the upper arm on Day 1, in the lower abdomen on Day 8, and in the thigh on Day 15
11097837|NCT04091373|Experimental|Sequence 2|100ug SC injection cotadutide in the thigh on Day 1, in the upper arm on Day 8, and in the lower abdomen on Day 15
11097838|NCT04091373|Experimental|Sequence 3|100ug SC injection cotadutide in the lower abdomen on Day 1, in the thigh on Day 8, and in the upper arm on Day 15
11097839|NCT04091373|Experimental|Sequence 4|100ug SC injection cotadutide in the thigh on Day 1, in the lower abdomen on Day 8, and in the upper arm on Day 15
11097840|NCT04091373|Experimental|Sequence 5|100ug SC injection cotadutide in the lower abdomen on Day 1, in the upper arm on Day 8, and in the thigh on Day 15
11097841|NCT04091373|Experimental|Sequence 6|100ug SC injection cotadutide in the upper arm on Day 1, in the thigh on Day 8, and in the lower abdomen on Day 15
11097842|NCT04091360|Experimental|Experimental dose 1 - 100ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 1; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 100ug; Inhaler No.1 = 50ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
11097843|NCT04091360|Experimental|Experimental dose 2 - 300ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 2; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 300ug; Inhaler No.1 = 150ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
11097844|NCT04091360|Experimental|Experimental dose 3 - 1000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 3; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 1000ug; Inhaler No.1 = 500ug; Inhaler No.2 = Placebo; Inhaler No.3 =Placebo"
11097845|NCT04091360|Experimental|Experimental dose 4 - 3000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 4; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = 3000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug"
11097846|NCT04091360|Experimental|Experimental dose 5 - 6000ug|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 5; each patient will be instructed to take four puffs (inhalations) from each of Inhalers 1 through 3, for a total of twelve inhalations.
~No. of Puffs per Inhaler = 4; Total Dose = 6000ug; Inhaler No.1 = 500ug; Inhaler No.2 = 500ug; Inhaler No.3 = 500ug"
11097847|NCT04091360|Placebo Comparator|Placebo comparator - placebo|"Patients will be randomly assigned to receive a single dose of one of six possible treatments. For Treatment Arm 6; each patient will be instructed to take two puffs (inhalations) from each of Inhalers 1 through 3, for a total of six inhalations.
~No. of Puffs per Inhaler = 2; Total Dose = Placebo; Inhaler No.1 = Placebo; Inhaler No.2 = Placebo; Inhaler No.3 = Placebo"
11097848|NCT04091347|Other|Open Label Pilot Arm|Three participants will receive the intervention in the open label pilot. The participants will receive half of the visits (4 visits) and this will occur over 6 weeks.
11097849|NCT04091347|Experimental|Intervention Arm|The intervention group will receive the intervention for 12 weeks. The wait list control group will have outcomes measured but will not receive the intervention at this time.
11097850|NCT04091347|Active Comparator|Wait List Control Arm|Once the intervention group has completed the intervention the wait list control group will complete the intervention.
11097851|NCT04091334|Experimental|Serial ultrasound group|"Will received standard care and monitoring and in addition, have focused ultrasound examination of the heart and the lungs done twice.
~The investigator is supposed to titrate the treatment according to the findings on the ultrasound examinations."
11097852|NCT04091334|Active Comparator|Standard care group|Standard care and monitoring.
11097853|NCT04091321||Chronic Headache|Women who endorse chronic headache
11097854|NCT04091321||Chronic Back Pain|Women who endorse chronic back pain
11097855|NCT04091308|Active Comparator|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
11097856|NCT04091308|Experimental|Usual Care with Protein Supl.|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
11097857|NCT04091308|Experimental|Individualized Physical Exercise Training with Protein Supl.|This group is also called EXER group, and will receive individually tailored physical exercise programs, based on their strength and weaknesses from the baseline testing.
11097858|NCT04091269|Placebo Comparator|PSV-10%|PSV mode using E5 ventilator with fixed flow trigger and Esense 10%
11097859|NCT04091269|Placebo Comparator|PVS-30%|PSV mode using E5 ventilator with fixed flow trigger and Esense 30%
11097860|NCT04091269|Placebo Comparator|PSV-50%|PSV mode using E5 ventilator with fixed flow trigger and Esense 50%
11097861|NCT04091269|Experimental|PSV-auto|PSV mode using automatic adjustmen of inspiratory triger and cycling-off based on waveform
11097862|NCT04091269|Active Comparator|PSV-neuro|NAVA mode using NAVA level of 15 cmH2O/uV and pressure limit function to simulated EAdi triggered PSV.
11097863|NCT04091256|Experimental|Clinical trials with a single arm|: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
11097864|NCT04091243|Experimental|Romosozumab|Romosozumab (210mg) subcutaneously every month for 12 doses
11097865|NCT04091243|Active Comparator|Denosumab|Denosumab subcutaneously (60mg) every 6 months for 2 doses
11097866|NCT04091230|Experimental|novel needle|TRUSbx using the 18 gauge (G) 25 centimeter(cm) novel needle with 19 millimeter (mm) sample notch and a new actuator. 12 biopsies / patient.
11097867|NCT04091230|Active Comparator|standard tru cut needle|TRUSbx using a standard tru cut biopsy needle (Mermaid Medical M-biopsy 18G 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator ( Moller Medical Blue RBG-1000-10-1000). 12 biopsies/ patient.
11097868|NCT04091217|Experimental|Atezolizumab + Bevacizumab|
11097869|NCT04091204|Experimental|Olaparib|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
11097870|NCT04091191|Active Comparator|Specialized nutraceutical|Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
11097871|NCT04091191|Placebo Comparator|Placebo|Identical placebo formulated without active ingredients in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
11097872|NCT04091178|Experimental|VITAMIN D SUPPLEMENTATION ARM|"On day 1 of every chemotherapy cycle, the patient will be receive an oral solution of vitamin D (UVEDOSE/calciferol).
~In parallel,a calcium supplementation is prescribed."
11097873|NCT04091165||Study Group|"Participants will be identified for inclusion by leaders of the GI Clinic after GI surgery has been scheduled. Upon consenting, participants will be instructed how to download and use the mobile phone application My Plate Calorie Counter."
11097874|NCT04091152||old patients|"Patient will freely use Ardoiz during their hospitalisation for a maximum of 9 days.
~After this use, a survey concerning the usability of Ardoiz will be administered to the patient, before their discharge from hospital."
11097875|NCT04091152||relatives / unformal caregivers|"Unformal caregivers will freely use Ardoiz during the hospitalization of their relatives and a maximum of 9 days.
~After this use, a survey concerning the usability of Ardoiz will be administered to the unformal caregivers, before the discharge of their hospitalized relatives from hospital."
11097876|NCT04091152||profesionnal caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Ardoiz will be administered to professional caregivers."
11097877|NCT04091139|Experimental|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).
~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
11097878|NCT04091139|Active Comparator|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
11098023|NCT04090151||University Hospital Cologne|
11098024|NCT04090151||The EuroSIDA cohort|
11097879|NCT04091126|Experimental|Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.9 milligram /kilogram (mg/kg) three -weekly (Q3W) dose of belantamab mafodotin intravenously (IV) on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.9 mg/kg four-weekly (Q4W) dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.
11097880|NCT04091126|Experimental|Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.4 mg/kg six-weekly (Q6W) dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.4 mg/kg eight-weekly (Q8W) dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.
11097881|NCT04091126|Experimental|Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd|Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.9 mg/kg Q8W dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.
11097882|NCT04091126|Experimental|Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin intravenously on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.0 mg/kg Q4W dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.
11097883|NCT04091126|Experimental|Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd|Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin intravenously on Day 1 of every 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 1.4 mg/kg Q4W dose of belantamab mafodotin intravenously on Day 1 of every 28-day cycle in combination with Rd.
11097884|NCT04091126|Experimental|Cohort 6: belantamab mafodotin 1.9 or 2.5 mg/kg Q9/12W+VRd/Rd|Based on emerging data, participants will receive either 1.9 mg/kg or 2.5 mg/kg Q9W dose of belantamab mafodotin intravenously on Day 1 of every third 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive either 1.9 mg/kg or 2.5 mg/kg Q12W dose of belantamab mafodotin intravenously on Day 1 of every third 28-day cycle in combination with Rd.
11097885|NCT04091126|Experimental|Cohort7:belantamab mafodotin 1.9/2.5mg/kg Q6/8W (split)+VRd/Rd|Based on emerging data, participants will receive a total dose of either 1.9 mg/kg or 2.5 mg/kg of belantamab mafodotin intravenously (split in to two equal doses of 0.95 mg/kg or 1.25 mg/kg to be given on Day 1 and Day 8) Q6W of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive a total dose of either 1.9 mg/kg or 2.5 mg/kg of belantamab mafodotin intravenously (split in to two equal doses of 0.95 mg/kg or 1.25 mg/kg to be given on Day 1 and Day 8) Q8W of every other 28-day cycle in combination with Rd.
11097886|NCT04091126|Experimental|Cohort 8: belantamab mafodotin 2.5 mg/kg Q6/8W + VRd/Rd|Based on emerging data, participants will receive 2.5 mg/kg Q6W dose of belantamab mafodotin intravenously on Day 1 of every other 21-day cycle for the first 8 cycles in combination with VRd. From cycle 9 onwards, participants will receive 2.5 mg/kg Q8W dose of belantamab mafodotin intravenously on Day 1 of every other 28-day cycle in combination with Rd.
11097887|NCT04091113||Participants with Hereditary Angioedema|Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment
11097888|NCT04091100|Active Comparator|electroacupuncture|The individuals in the electroacupuncture group were administered the therapy by a certified acupuncturist. Two Shenlong acupuncture needles were inserted in each of the trapezius and levator scapulae muscles at intervals of 0-3 mm and clips were attached to their ends. Afterwards, an electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes.
11097889|NCT04091100|Active Comparator|myofascial release|Firstly, longitudinal stretching was done with forearm to the muscles in the person's neck in order to relax. Afterwards, the researcher placed one hand under the person's head and placed their fingertips on the muscles under the occipital bone in the neck area. The researcher applied lateral flexion to the neck with one hand while placing the other hand on the trapezius and levator scapulae muscles and then stretched the muscles with friction massage. After this step, the participant's neck was guided back into a neutral position and the pinching technique was applied to the muscles. During the administration of therapies, the trigger points on muscles were identified and friction was applied to these sites until a loosening could be felt. The myofascial release sessions concluded with the administration of the friction massage technique once again to the muscles.
11097890|NCT04091087|Experimental|crisaborole ointment|crisaborole ointment
11097891|NCT04091087|Sham Comparator|vehicle ointment|vehicle ointment
11097892|NCT04091074|Active Comparator|aspirin + ticagrelor before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + ticagrelor 90mg for 15 days before carotid stenting
11097893|NCT04091074|Active Comparator|aspirin + clopidogrel before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + clopidogrel 75 mg for 15 days before carotid stenting
11097894|NCT04091061|Experimental|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
11097895|NCT04091061|Experimental|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
11097896|NCT04091061|Experimental|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
11097897|NCT04091061|Experimental|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
11097898|NCT04091048||Primary Cohort|
11097899|NCT04091022|Active Comparator|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms twice per day and topical DFMO to bilateral forearms once per day.
11097900|NCT04091022|Placebo Comparator|Placebo + placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms twice per day and placebo for topical DFMO to bilateral forearms once per day.
11097901|NCT04091009|Active Comparator|Continue Group|Those who continue taking their standard dose of buprenorphine before, during and after surgery.
11098025|NCT04090151||Frankfurt HIV Cohort Study|
11097902|NCT04091009|Active Comparator|Reduce Group|Those who are placed on a lower dose of buprenorphine starting one day before surgery and during the time period after surgery until the pain from the surgery has decreased. Once the pain from the surgery has decreased, you will be put back on your full dose of buprenorphine.
11097903|NCT04090996|Experimental|DT patients|
11097904|NCT04090983|Active Comparator|Cognitive-behavioral therapy (Hesslinger protocol)|
11097905|NCT04090983|Experimental|Cognitive-behavioral therapy (CADDI protocol)|
11097906|NCT04090957|Experimental|Estetrol 15 mg - Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for 52 consecutive weeks.
11097907|NCT04090957|Experimental|Estetrol 20 mg - Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.
11097908|NCT04090957|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for 52 consecutive weeks.
11097909|NCT04090957|Experimental|Estetrol 20 mg - Safety Part|Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.
11097910|NCT04090944|Active Comparator|1st group (group B)|"The LMA LarySeal Multiple will be inserted using the blind technique which involves holding the LMA like a pen guided into the pharynx with the index finger of the operator at the junction of the tube and the bowl, with the operator at the head of the patient and the LMA facing caudally.
~The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
11097911|NCT04090944|Active Comparator|2nd group:(group U)|"The LMA LarySeal Multiple will be inserted under the guide of B-mode US on the anterior neck . Transverse scans , Sagittal view and Parasagittal view.
~-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading devised by Aoyama et al."
11097912|NCT04090931|Experimental|Heat-Activated Nickel-Titanium Archwires|"Heat-activated NiTi (HANT) Group (TruFlex™ Thermal Nickel-Titanium, Ortho Technology, USA):
~0.014-inch HANT
~0.016-inch HANT"
11097913|NCT04090931|Experimental|Superelastic Nickel-Titanium Archwires|"Superelastic NiTi (SENT) Group (TruFlex™ Nickel-Titanium, Ortho Technology, USA):
~0.014-inch SENT
~0.016-inch SENT"
11097914|NCT04090918||Group 1: Abdominal surgery with POAF|Twenty patients undergoing abdominal surgery with new-onset atrial fibrillation
11097915|NCT04090918||Group 2: Abdominal surgery without POAF|Twenty patients undergoing abdominal surgery without new-onset atrial fibrillation matching patients in group 1 on age, sex and comorbidities.
11097916|NCT04090905||Cohort|
11097917|NCT04090892||Persons with spasticity 4.0-20.11 years|Study personnel are not carrying out the surgical intervention but are assessing the outcomes of the surgery on gait and motor function.
11097918|NCT04090879|Experimental|RC 1 only|Research Cigarettes #1
11097919|NCT04090879|Experimental|RC 2 only|Research Cigarettes #2
11097920|NCT04090879|Experimental|RC 2 + EC 1|Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
11097921|NCT04090879|Experimental|RC 2 + EC 2|Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
11097922|NCT04090853|Other|Patient Treatment Group|Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
11097923|NCT04090840|Experimental|Intermittent Fasting|Patients will follow intermittent fasting for 16 hours with time restricted eating during an 8 hour window. The subjects are also advised to minimize sugar intake to <15g per serving.
11097924|NCT04090827|No Intervention|Control/ iheartchange Only|Access to the iHeartChange website only
11097925|NCT04090827|Experimental|Intervention|Nurse-led transition intervention and access to the iHeartChange website
11097926|NCT04090814|Experimental|Movement-Evoked Pain during TENS treatment|Participants performed several physical tasks while using the HeatTens device (HV-F311-E). During these tasks, participants needed to rate their pain.
11097927|NCT04090814|No Intervention|Movement-Evoked Pain|Participants performed several physical tasks during with their pain was assessed.
11097928|NCT04090801|Active Comparator|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|Group A applied topical minoxidil 5% in 90% ethanol and 5% propylene glycol
11097929|NCT04090801|Active Comparator|Topical minoxidil 5% in pure ethanol alone|Group B applied topical minoxidil 5% in pure ethanol alone
11097930|NCT04090801|Placebo Comparator|Placebo|Group C applied pure ethanol (placebo)
11097931|NCT04090788|Experimental|dried bitter-gourd supplements|2.4 gram per day for 4 weeks
11097932|NCT04090788|Active Comparator|dried cucumber supplements|2.4 gram per day for 4 weeks
11097933|NCT04090775|Other|Single arm. Subjects receiving treatment.|Cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
11097934|NCT04090762|No Intervention|Control|Women in the control arm will complete the baseline and follow up surveys but will not receive any intervention.
11097935|NCT04090762|Active Comparator|Risk information only|Women in the risk only arm who exhibit characteristics associated with a greater risk of a poor birth outcome will be informed that they possess these characteristics. Risk characteristics (identified from the medical and epidemiological literature) include age, prior pregnancy and birth history (e.g., previous stillbirth).
11097936|NCT04090762|Active Comparator|Conditional Cash Transfer only|Women in this arm will be eligible to receive conditional cash transfers. To receive the transfer, pregnant women must attend prenatal care and give birth in a health facility.
11097937|NCT04090762|Active Comparator|Conditional Cash Transfer and risk information|Women in this arm will be provided with risk information at the time of baseline survey administration AND be eligible to receive conditional cash transfers, pending attendance at prenatal care and delivery at a health facility.
11097938|NCT04090749|Experimental|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
11097939|NCT04090749|Other|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
11097941|NCT04090736|Experimental|Arm A: Pevonedistat plus Azacitidine|Pevonedistat 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine 75 mg/m2 subcutaneous administered on a 5-on/2-off [weekend]/2-on schedule in 28-day cycles (intravenous Azacitidine can be administered for any patients who have non-tolerated local reactions)
11097942|NCT04090736|Active Comparator|Arm B: Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle (intravenous azacitidine can be administered for any patients who have non-tolerated local reactions)
11097943|NCT04090723|Active Comparator|Waitlist Control Group|Waitlist control group participants will receive the usual care from start of study with intervention offered at 3 months.
11097944|NCT04090723|Experimental|Computer-delivered brief alcohol intervention (CBI-CC)|Participants will be offered only the Computer-delivered brief alcohol intervention with peer navigation from beginning of study to the end.
11097945|NCT04090710|Active Comparator|Standard of Care I/N alone|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
11097946|NCT04090710|Experimental|Standard of Care I/N plus primary disease SBRT|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
11097947|NCT04090697|Experimental|Oxandrolone Cohort 1|Participants randomized to Oxandrolone Cohort 1 will receive 0.1mg/kg of oxandrolone suspended in a multi-chain triglyceride (MCT) oil buccally twice per day.
11097948|NCT04090697|No Intervention|Standard of Care|Participants randomized to standard of care will receive the standard therapies provided at the institution at which they are being treated. Control subjects will receive standard therapy with no placebo and no oxandrolone.
11097949|NCT04090684|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
11097950|NCT04090671|Active Comparator|COPD Exacerbation|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
11097951|NCT04090671|Active Comparator|CHF|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
11097952|NCT04090671|Active Comparator|COPD|In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.
11097953|NCT04090671|Active Comparator|OSA|The questionnaire MDP will be administered once during the first visit in the sleep laboratory.
11097954|NCT04090658|Experimental|Group RSV_PreF3_AS01B|Subjects aged 60 to 80 years receiving 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Days 1 and 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
11097955|NCT04090658|Placebo Comparator|Group Placebo|Subjects aged 60 to 80 years receiving 2 doses of placebo as control, at Days 1 and 61, by IM injection into the deltoid region of the non-dominant arm preferably.
11097956|NCT04090645|Other|TheraShere in treatment of primary & secondary liver carcinoma|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
11097957|NCT04090632|Experimental|closed kineTic chain upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
11097958|NCT04090619||Observational (questionnaires)|Participants complete 8 questionnaires about appetite, quality of life, symptoms, history of weight loss, nutritional status, body image, and nutritional support over 30 minutes.
11097959|NCT04090606||FTC Method|
11097960|NCT04090606||Massachusetts Method|
11097961|NCT04090606||Health Canada Intense Method|
11097962|NCT04090593|Experimental|Educational Module Intervention|Intervention arm patients receive educational mobile module related to chronic condition that contributed to reason for admission.
11097963|NCT04090593|No Intervention|Hospital Practice Control|Control arm patients receive current, standard practice as related to patient education in the hospital (this does not include an educational mobile module).
11097964|NCT04090580|Experimental|Daily dosage of dapagliflozin and metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 10 mg dapagliflozin and 2000 mg metformin for 12 weeks
11097965|NCT04090580|Experimental|Daily dosage of metformin|Subjects enrolled will be randomized 1:1 to either receive a daily dosage of 2000 mg metformin for 12 weeks
11097966|NCT04090567|Experimental|Arm I (olaparib plus cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11097967|NCT04090567|Experimental|Arm II (olaparib plus ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11097968|NCT04090554|Other|Cytosponge™|Single intervention arm of feasibility study
11097969|NCT04090541|No Intervention|Control|Tests were applied with any taping.
11098026|NCT04090151||Georgian National AIDS Health Information System (AIDS HIS)|
11098027|NCT04090151||Modena HIV Cohort|
11098028|NCT04090151||San Raffaele Scientific Institute|
11097970|NCT04090541|Sham Comparator|Sham Taping|In ST stage; medical purpose, hypoallergenic OctaCare® Rigid Transparent Plaster was applied as a rigid tape. This tape is also used under rigid tapes for protecting the skin. In this study investigators didn't prefer extra rigid tape on the plaster because that was very light and less sensitive material to our knowledge so it suited our aim of placebo control.
11097971|NCT04090541|Experimental|Kinesiology Taping|In KT stage; the original Kinesio Tex® Tape Classic was applied as a kinesiology tape. In this study, investigators applied the tape with muscle activation technique and paper of tension (it was declared %10) according to Kenzo Kase's Kinesio Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
11097972|NCT04090541|Experimental|Biomechanical Taping|In BT stage; Dynamic Tape® was applied as a biomechanical tape. In this study, investigators applied the tape with offload technique and paper of tension according to Ryan Kendrick's Biomechanical Taping concept. It was implemented on both bileral Rectus Femoris and Calf muscles with same technique.
11097973|NCT04090528|Experimental|Arm 1: One DNA vaccine|"100 µg pTVG-HP (with 208 µg rhGM-CSF) administered intradermally (i.d.) days 1, 8 plus 200 mg Pembrolizumab, administered intravenously on day 1 of 21-day cycles (for 8 cycles)
~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles
~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-HP (with 208 µg rhGM-CSF) i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 of 21-day cycles x 4 cycles"
11097974|NCT04090528|Experimental|Arm 2: Two DNA vaccines|"100 µg pTVG-AR (with 208 µg rhGM-CSF) administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 1, 2, 5, and 6 alternating with 100 µg pTVG-HP (with 208 µg rhGM-CSF) administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 3, 4, 7, and 8.
~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles
~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-AR (with 208 µg rhGM-CSF) i.d days 1, 8 + 200 mg pembrolizumab IV day 1 of q 21-day cycles, for cycles 1 and 2 followed by 100 µg pTVG-HP (with 208 µg rhGM-CSF) i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 in 21-day cycles, for cycles 3 and 4"
11097975|NCT04090515|Experimental|Project Health|Project Health has three aims: 1) encourage participants to explore the costs of obesity, an unhealthy diet, and sedentary behavior and the benefits of physical fitness, a healthy diet, and regular exercise; 2) help participants gradually reduce caloric intake and increase physical activity, such that the participant reaches energy balance (i.e., is not eating more calories than they need); and 3) reduce attitudinal and behavioral risk factors for eating disorders and obesity. The intervention will be administered in Spanish.
11097976|NCT04090515|Placebo Comparator|Educational Video Control|The educational video control condition will include an educational video series on obesity in Spanish.
11097977|NCT04090502|Experimental|Grupo A. Dry needling in Trigger point|Participants will be treated in the most hyperalgesic foci within the hamstring musculature.
11097978|NCT04090502|Placebo Comparator|Grupo B. Dry needling in non-hyperalgesic areas|Participants will be treated in non-hyperalgesic areas within the hamstring muscles.
11097979|NCT04090476|Experimental|BIG for Life Exercise Group|This arm includes the entire cohort enrolled who will participate in the weekly one hour community exercise group for a total of 8 weeks
11097980|NCT04090463|Experimental|IORT group|"Intraoperative administration of 10 to 20 Gy after surgery or as an in situ treatment in case resection will not be performed"
11097981|NCT04090437|Active Comparator|Group1 - PVI first step|"Catheter ablation procedure:
~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)
~PVI as first step
~Remap to assess any change in activation
~Ablate all rotors (API) in LA until SR or DCCV
~Deployment of RA CTI line and demonstration of bidirectional block"
11097982|NCT04090437|Active Comparator|Group2 - PVI last step|"Catheter ablation procedure:
~Dipole map of RA and LA at baseline (5 times for both, each for 20sec, +/- Adenosine IV)
~Ablate all rotors (API) in LA until SR or DCCV
~Remap to assess any change in activation
~PVI as last step even when SR achieved earlier
~Deployment of RA CTI line and demonstration of bidirectional block"
11097983|NCT04090424|Experimental|NovoSorb BTM|Application of NovoSorb BTM to study lesions
11097984|NCT04090424|Active Comparator|Standard of Care|Application of the institution's standard to care to study lesions.
11097985|NCT04090411|Experimental|450 mg|PF-06480605
11097986|NCT04090411|Experimental|150 mg|PF-06480605
11097987|NCT04090411|Experimental|50 mg|PF-06480605
11097988|NCT04090411|Placebo Comparator|0 mg|
11097989|NCT04090398|Experimental|Arm I (paclitaxel, radium Ra 223 dichloride)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and radium Ra 223 dichloride IV over 1 minute on day 1. Treatment with radium Ra 223 dichloride repeats every 28 days for 6 cycles and treatment with paclitaxel repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11097990|NCT04090398|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11097991|NCT04090385|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
11097992|NCT04090385|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
11097993|NCT04090385|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
11097994|NCT04090372|Active Comparator|Control group|Control group will be assessed by standard preop planning using implants templates.
11097995|NCT04090372|Active Comparator|TraumaCad Group|TraumaCad Group will be assessed by preop planning using Traumacad
11097996|NCT04090359|Experimental|Dual Mobility|If patients are randomized to the dual mobility cohort, they will receive a dual mobility prosthesis at the surgeon's discretion. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
11097997|NCT04090359|Active Comparator|Conventional, Single-bearing hip implant|If patients are randomized to the conventional, single bearing cohort, surgeons will use their preferred implant design at their discretion using a 36 or 40mm head, depending on the diameter of the cup and manufacturer specifications. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
11097998|NCT04090346|Experimental|Clostridium difficile infection|Clostridium difficile infection (CDI) is due to a toxin-producing bacteria that causes a more severe form of antibiotic associated diarrhea. The disease ranges from mild diarrhea to severe colon inflammation that can even be fatal.
11097999|NCT04090320|Experimental|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
11098000|NCT04090307|Experimental|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
11098001|NCT04090307|No Intervention|Traditional Prenatal Care|Subjects randomized to routine care will receive their prenatal care with their primary obstetric provider. Patients are seen for 10-15 minutes every four weeks until 28 weeks' gestation, every two weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits focus on routine screening tests and prenatal care. Traditional care participants will receive a phone call once a month, until 28 weeks gestation, from a nurse practitioner to check-in on pregnancy goals, healthy eating, and exercise. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
11098002|NCT04090294|Experimental|Roflumilast -non roflumilast|"35 patients will receive Roflumilast for three months and improvement regarding dyspnea scales , Pulmonary function Test , Six minutes walking test and bronchectasis severity index (FACED) score pre and post therapy will be assessed.
~patients will receive Roflumilast 500 Mcg. Tablet Once daily for Three months and then base line assessment will be repeated to evaluate improvement."
11098003|NCT04090281|Other|Precision medicine implementation|Patients will receive a precision medicine approach, incorporating both CYP2C19 genotyping and platelet reactivity phenotyping, to guide dual antiplatelet therapy selection for patients with ACS, post PCI and followed over a 12 month period.
11098004|NCT04090268|Experimental|Children with malignant hemopathies|Children with malignant hemopathies attending a precision exercise training
11098005|NCT04090268|No Intervention|Healthy children|Healthy children
11098006|NCT04090255|Experimental|Ultrasonographic guided renal access|The use of ultrasound to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
11098007|NCT04090255|Experimental|Fluoroscopic guided renal access|The use of fluoroscopy to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
11098008|NCT04090242|Active Comparator|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
11098009|NCT04090242|No Intervention|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
11098010|NCT04090229|Experimental|ASLAN004|
11098011|NCT04090229|Placebo Comparator|ASLAN004 Placebo|
11098012|NCT04090216||Addict patients|patients with substance use disorders presented with STEMI & undergoing Primary PCI
11098013|NCT04090216||Non Addict patients|patients without substance use disorders presented with STEMI & undergoing Primary PCI
11098014|NCT04090203|Experimental|Boiled Peanut Powder|Boiled Peanut Powder
11098015|NCT04090190|Other|standard of care anticholinergic treatment|Women presenting to the Urogynecology clinic with urgency urinary incontinence symptoms will receive standard of care anticholinergic treatment and will have their urinary microbiome evaluated before and after treatment
11098016|NCT04090177|Experimental|Intervention-TEAM Wheels|The treatment group will receive the TEAM Wheels program over a 4-week period. Session 1 will be virtually delivered via MS Teams teleconference. The peer trainer is an experienced MWC user trained to deliver the TEAM Wheels program. At least 2 peers will be trained at each site to offer multiple trainer attributes; a male and female, one being at least 50 years old. Participants will pre-select a peer trainer from a biosketch to optimize training effect (e.g., preference for age, sex factors); comparability in age has been identified as preferential among older adults and influential to self-efficacy. After Session 1, participants engage in 4 weeks of eHealth home program training. They are instructed to practice for 75-150 minutes/week. Consistent with motor learning principles, we encourage training in 15-30 minute blocks 1-2 times/day, 3-5 days/week. The peer trainer arranges the remaining two virtual teleconference sessions with the participant, about 1 week apart.
11098017|NCT04090177|No Intervention|Control-Wait List|"The control group receives no specific intervention over the course of the 4-week period. This reflects usual practice/typical experience of a MWC user in their provincial context. Control group participants placed on the wait-list will receive the TEAM Wheels program following completion of the study (i.e. after post-treatment data collection). The site Research Coordinator/Assistant will make telephone or email contact with control group participants at the end of weeks 2 and 4 during the study period to deter attrition/drop-out. When contact is made at week 4, the Research Coordinator will schedule an appointment for post-treatment data collection (week 7). Any formal MWC training received during the wait-list period will be documented for potential post-hoc analysis as a confounding variable; research evidence and investigators' clinical experience confirm that in all 3 provinces formal training is not provided once MWC users are discharged from hospital."
11098018|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
11098019|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
11098020|NCT04090151||Austrian HIV Cohort Study (AHIVCOS)|
11098021|NCT04090151||The Australian HIV Observational Database (AHOD)|
11098022|NCT04090151||CHU Saint-Pierre|
11098031|NCT04090151||The ATHENA national observational HIV cohort|ATHENA: AIDS Therapy Evaluation in the Netherlands
11098032|NCT04090151||Nice HIV Cohort|
11098033|NCT04090151||Italian Cohort Naive Antiretrovirals (ICONA)|
11098034|NCT04090151||PISCIS Cohort Study|
11098035|NCT04090151||Swedish InfCare HIV Cohort|
11098036|NCT04090151||Bonn University Hospital|
11098037|NCT04090138|Active Comparator|Setria performance blend|l-citrulline + glutathione
11098038|NCT04090138|Placebo Comparator|Placebo|
11098039|NCT04090125|Experimental|Physical Activity and Symmetry (PAS) Intervention|Participants assigned to the PAS intervention will receive 4 sessions on balance training and physical activity coaching delivered by a physical therapist, in addition to their usual post-TKA physical therapy (PT) care.
11098040|NCT04090125|Placebo Comparator|Attention Control|Participants assigned to the ATT group will receive usual post-TKA physical therapy (PT) care, followed by two additional sessions with their physical therapist.
11098041|NCT04090112|Experimental|the study group (Group A)|Patients received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
11098042|NCT04090112|Active Comparator|Comparator group (Group B)|Patients received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
11098043|NCT04090099|No Intervention|Group C|PCA (Patient controlled analgesia) and morphine consumption will be monitored in the postoperative period.
11098044|NCT04090099|Active Comparator|Group ES (Erector Spina Plane)|A high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle. A dose of 0.25% bupivacaine will be injected which is shown to spread both above and below the T5 level. The same process will be implemented on the other side.
11098045|NCT04090099|Active Comparator|Group PS (Para Sternal Block)|Before the wire is inserted into the sternum, the sternotomy and mediastinal tube regions will be infiltrated with a mixture of bupivacaine and saline.
11098046|NCT04090086|Experimental|Treatment Sequence 1: Treatment ABC|Participants will receive Treatment A (JNJ-53718678 once daily for 7 days) in Treatment Period 1, followed by Treatment B (JNJ-64417184 once daily for 7 days) in Treatment Period 2, followed by Treatment C (JNJ-53718678 once daily + JNJ-64417184 once daily for 7 days) in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
11098047|NCT04090086|Experimental|Treatment Sequence 2: Treatment BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
11098048|NCT04090086|Experimental|Treatment Sequence 3: Treatment CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
11098049|NCT04090086|Experimental|Treatment Sequence 4: Treatment ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
11098050|NCT04090086|Experimental|Treatment Sequence 5: Treatment BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
11098051|NCT04090086|Experimental|Treatment Sequence 6: Treatment CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3. There will be a washout period of at least 7 days between the treatment periods.
11098052|NCT04090073|Experimental|Electroacupuncture Plus Fast-track Perioperative Program|Patients who are randomized to the intervention arm will receive Electroacupuncture combined with Fast-track program. Each session of Electroacupuncture will last for 20 minutes. The patients will undergo one session of Electroacupuncture daily from day 1 till day 4, or until the time when the primary outcome has occurred, whichever is earlier.
11098053|NCT04090073|Active Comparator|Fast-track Perioperative Program|Patients who are randomized to the control arm will receive Fast-track program alone.
11098054|NCT04090060|Experimental|Practice Self-/Companion Exams|300 individuals and 50 couples will be randomized to practice arm.
11098055|NCT04090060|Other|Control Arm|300 individuals and 50 couples will neither be encouraged nor discouraged to practice self-/companion exam.
11098056|NCT04090047|Experimental|PF-06700841 and Itraconazole|This fixed sequence, 2-period arm will consist of two treatments. Participants will receive a single oral dose of 30 milligrams (mg) PF-06700841 on Day 1 in Period 1. On Days 1-7 in Period 2, Itraconazole 200mg will be administered once daily(QD). On Day 4 of Period 2, co-administration of Itraconazole 200 mg and 30 mg PF-06700841 tablets will occur.
11098057|NCT04090034||Treated w PRRT|Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.
11098058|NCT04090021|Experimental|Genotypic resistance-guided triple therapy|"In the group of genotypic resistance-guided triple therapy, a molecular assay based on DNA-strip technology was used to determine the genotypic resistance of H. Pylori to clarithromycin (23SrRNA mutations) and fluoroquinolones (gyrA mutations) from gastric biopsy specimens. According to 23SrRNA and gyrA mutational analyses, a 7-day tailored triple therapy therapy was given as follows:
~Wild-type 23SrRNA: Clarithromycin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.
~23SrRNA mutated/wild-type gyrA: Levofloxacin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and levofloxacin 500 mg b.i.d.
~23SrRNA mutated/gyrA mutated: Rifabutin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g t.i.d. and rifabutin 150 mg b.i.d."
11098059|NCT04090021|Active Comparator|Empirical concomitant therapy|In the empirical concomitant group, patients received esomeprazole 40mg, amoxicillin 1gr, clarithromycin 500mg and metronidazole 500mg, all b.i.d., for 10-14 days.
11098060|NCT04090008|Active Comparator|PRP gel|PRP gel was applied to the ulcer twice per week after preparation and then the ulcer was covered with Vaseline gauze, few layers of sterile gauze and crepe bandage.
11098061|NCT04090008|Active Comparator|Saline dressing|daily dressing of the ulcer with normal saline was done
11098062|NCT04089995||Coats + and LCC syndrome|
11098063|NCT04089982|Active Comparator|Varenicline|Varenicline BID
11098064|NCT04089982|Placebo Comparator|Placebo|
11098065|NCT04089969|Experimental|Evaluation of Standard of care followed by CTA/FFRct|Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
11098066|NCT04089956||Extubation Success|extubation Success which defined as no need for need for ventilatory support after extubation using tracheal intubation or non-invasive mechanical ventilation during ICU stay
11098067|NCT04089956||Extubation Failure|Extubation Failure was defined as need for any ventilatory support after fist extubation during ICU stay or tracheostomy befor any extubation attempt.
11098068|NCT04089943|Experimental|Revascularization group|Participants will be randomized to either an endovascular or an open bypass procedure.
11098069|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited as control group
11098070|NCT04089930||Vaccine|Those SLE patients who had been given herpes zoster vaccine in our original RCT
11098071|NCT04089930||Placebo|Those SLE patients who had been given placebo vaccination in our original RCT
11098072|NCT04089917||Q Aspiration Catheter|mechanical thrombectomy for acute ischemic stroke
11098073|NCT04089904|Experimental|ARM 1|
11098074|NCT04089878|Experimental|PARTO/BRTO + SMT|PARTO/BRTO with SMT will be given.
11098075|NCT04089878|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
11098076|NCT04089865|Experimental|Oral Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1950 mg of oral TXA in the pre-operative area.
11098077|NCT04089865|Active Comparator|Intravenous (IV) Tranexamic Acid (TXA)|100 Total Hip Arthroplasty (THA) and 100 Total Knee Arthroplasty (TKA) patients will be randomized to receive 1 g of intravenous (IV) TXA upon transfer to the operating room.
11098078|NCT04089852|Experimental|Inhaled nitrous oxide anesthesia|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The treatment group will receive inhaled N2O/O2. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2. N2O/O2 will be administered per Boston Children's Hospital (BCH) N2O sedation protocol. Prior to speculum placement, treatment group participants will receive the inhaled gas until minimal sedation is achieved per BCH sedation guidelines, such that the patient is cooperative, oriented, and tranquil. Inhaled N2O will be administered throughout the duration of the procedure."
11098079|NCT04089852|Placebo Comparator|Inhaled oxygen placebo|"Patients will be assigned to a pre-implementation (control) group or a post-implementation (treatment) group. The first twelve participants will be the control group and the next twelve participants will be the treatment group. The control group will receive inhaled O2 alone. All participants will receive pre-procedural standard of care for IUD insertions, including 400-600 mg ibuprofen orally at least 20 minutes prior to insertion to reduce post-procedure pain. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered throughout the duration of the procedure."
11098080|NCT04089839||CP-CML participants initiating dasatinib|
11098081|NCT04089813||Metformin|Patients use metformin to control blood sugar
11098082|NCT04089813||Insulin|Patients use Insulin to control blood sugar
11098083|NCT04089800|Experimental|Intervention|For 9 months, each of the 40 women in the intervention condition will use their phones to access the multimedia-based antenatal videos and audios tailored to their pregnancy stages. Participants will use the prototype until six weeks after giving birth. The intervention implementation is estimated to take 9 months including a 6 weeks follow-up after delivery, which implies that the implementation will be completed by November/ December 2019. The investigators will install the final prototype on a phone and give each participant in the intervention group a phone with a prototype installed, and explain how it works. Women will get support in resolving technical issues that may arise with the application between March and May 2019.
11098084|NCT04089800|No Intervention|Control|The 40 women in the control condition will receive the usual standard care of antenatal check-up and counselling but no multimedia intervention.
11098085|NCT04089787|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
11098086|NCT04089787|Active Comparator|Control group|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
11098087|NCT04089774|Experimental|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
11098088|NCT04089774|No Intervention|Kiné|Standard physiotherapy treatment, at least 20 sessions, renewed at least once, spread over 12 months
11098089|NCT04089761|Experimental|Active Device|Treatment of acute migraine with an active form of Nerivio device
11098090|NCT04089748||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
11098091|NCT04089748||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
11098092|NCT04089735|Experimental|APP13007 0.05% BID|1 drop 0.05% APP13007 twice daily for 21 days to the operated eye
11098093|NCT04089735|Experimental|APP13007 0.05% Placebo BID|1 drop matching vehicle placebo for 0.05% APP13007 twice daily for 21 days to the operated eye
11098094|NCT04089735|Experimental|APP13007 0.05% BID/QD|1 drop 0.05% APP13007 twice daily followed by 1 drop once daily to the operated eye
11098095|NCT04089735|Experimental|APP13007 0.05% Placebo BID/QD|1 drop matching vehicle placebo for 0.05% APP13007 twice daily followed by 1 drop once daily to the operated eye
11098096|NCT04089735|Experimental|APP13007 0.1% BID/QD|1 drop 0.1% APP13007 twice daily followed by 1 drop once daily to the operated eye
11098097|NCT04089735|Experimental|APP13007 0.1% Placebo BID/QD|1 drop matching vehicle placebo for 0.1% APP13007 twice daily followed by 1 drop once daily to the operated eye
11098098|NCT04089722|Other|Open-Label: Deoxycholic Acid Injections|Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity. Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid. Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
11098099|NCT04089709|Experimental|Study arm|Patients randomized to this group will be provided exercises to perform with the uninjured arm once daily for 3 months.
11098100|NCT04089709|No Intervention|Control arm|"Patients randomized to this group will not be provided exercises for the well-arm and will be managed according to the current standard of care."
11098101|NCT04089696|Experimental|ExSpiron|10 patients with ALS
11098102|NCT04089683||Doctors|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
11098103|NCT04089683||Nurses|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
11098104|NCT04089683||OT Technicians|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
11098105|NCT04089683||House keeping staff and cleaners|Swabs collected from Web space, Scrub, Anterior nares before entering Operation theatre and while exit from operation theatre
11098106|NCT04089670|Active Comparator|Online Acceptance and Commitment Therapy Intervention|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Each module has a practice assignment at the end with the goal of having the participant engage in the material over the next week. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls, one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. During the call the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
11098107|NCT04089670|No Intervention|Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
11098108|NCT04089657|Experimental|Apatinib+Sintilimab|Apatinib 500mg qd p.o and Sintilimab 200mg intravenously on day 1 every 3 weeks until disease progression or intolerable toxicity or patients withdrawal of consent
11098109|NCT04089644|Active Comparator|manual group|Hypotension will be corrected by manual infusion of norepinephrine
11098110|NCT04089644|Experimental|closed-loop group|Hypotension will be corrected by closed-loop control of norepinephrine infusion
11098111|NCT04089631|Experimental|Chemotherapy|"Capecitabine mono or Capecitabine/Oxaliplatin as investigator choice:
~Patients who are positive for postoperative ctDNA (ctDNApos) and not microsatellite instable are randomized (2:1) to adjuvant chemotherapy with capecitabine or to follow up.
~Capecitabine 2 x 1250 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m^2. Treatment duration: 8 cycles (approx. 6 months)
~Capecitabine, if combined with Oxaliplatin (investigator choice):
~If the investigation decides to add oxaliplatin, the following schedule should be used:
~[Oxaliplatin 130 mg/m^2 i.v. (2 hours on d1)] Capecitabine 2 x 1000 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days) Treatment duration: 4 or 8 cycles (approx. 3 or 6 months)"
11098112|NCT04089631|No Intervention|Follow-up|Patients negative for postoperative ctDNA (ctDNAneg) are randomized (1:4) to follow-up within CIRCULATE or to routine follow up outside the Trial protocol.
11098113|NCT04089618|Experimental|Baseline 10 Days|10 days baseline before intervention starts.
11098114|NCT04089618|Experimental|Baseline 17 Days|17 days baseline before intervention starts.
11098115|NCT04089618|Experimental|Baseline 24 Days|24 days baseline before intervention starts.
11098116|NCT04089605|Experimental|intravitreal dexamethasone implant|The eyes undergo dexamethasone intravitreal implant 0.7 mg injections at baseline and every 3 or 4 months thereafter. Dexamethasone implants are re-injected in minimal 3-month interval if macular edema persisted or recurred with CFT more than 350 μm or manifestation of apparent submacular fluid and/or intramacular cysts. If DME subside with CFT less than 350 μm without accompanying fluid and cysts, repeated injection is mandatory in maximal 4-month interval.
11098117|NCT04089605|Active Comparator|intravitreal ranibizumab|As for intravitreal ranibizumab 0.5 mg (IVR), we use OCT-guided treat-and-extend protocol for DME treatment after modifying the settings of TREX-DME study.4 The regimen include 3 monthly loading doses then extending the treatment injection interval one month more if CFT less than 350 μm without obvious submacular fluid and intramacular cysts. The injection interval shorten one month if CFT more than 350 μm or presence of obvious fluid and/or cysts. The patients are intentionally injected at most every 3 months even DME not existing.
11098118|NCT04089592|Experimental|Dex Group|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
11098119|NCT04089592|Experimental|Fent Group|intravenous fentanyl at 2mcg/kg in 100ml saline
11098120|NCT04089579|Experimental|MSC|One dose of 6x10e6 cells/kg administered intravenously.
11098121|NCT04089579|Placebo Comparator|Placebo Infusion|Placebo infusion
11098122|NCT04089566|Experimental|28/28 Milligram (mg) Safety Group|Part A: Participants with later-onset SMA will receive loading doses of 28 mg of nusinersen intrathecally on Days 1, 15 and 29 followed by maintenance doses of 28 mg on Days 149 and 269.
11098123|NCT04089566|Active Comparator|12/12 mg Randomized Control Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
11098147|NCT04089371||Arm A Total Shoulder Arthroplasty / Hemiarthroplasty|Total Shoulder Arthroplasty (TSA) Humeral & Glenoid components as a Hemiarthroplasty or Total Shoulder Replacement.
11098124|NCT04089566|Experimental|50/28 mg Randomized Treatment Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 50 mg of nusinersen intrathecally on Days 1 and 15 followed by maintenance doses of 28 mg on Days 135 and 279. Sham procedure will be administered on Days 29, 64 and 183.
11098125|NCT04089566|Experimental|12/50/28 mg Titration Group|Part C: Participants who have been receiving the approved dose of 12 mg for at least 1 year prior to entry in this study, will receive a single bolus dose of 50 mg of nusinersen intrathecally on Day 1 (4 months after their most recent maintenance dose of 12 mg) followed by maintenance doses of 28 mg on Days 121 and 241.
11098126|NCT04089553|Experimental|Module 1|"Module 1 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with durvalumab in post-standard of care therapy for metastatic castration resistant prostate cancer (mCRPC) patients. In Module 1 approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635.
~Patients will receive AZD4635 75 mg PO QD monotherapy for 2 weeks (Cycle 0). Starting with Cycle 1, durvalumab 1500 mg IV Q4W will be added to continuous AZD4635 dosing."
11098127|NCT04089553|Experimental|Module 2|"Module 2 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with oleclumab in post-standard of care therapy for metastatic castration resistant prostate cancer (mCRPC) patients. In Module 2 approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635 plus oleclumab.
~Patients will receive a dose of AZD4635 75 mg PO QD and oleclumab 1500 mg IV Q2W for the first 4 doses and Q4W thereafter. Patients who began treatment at the AZD4635 50 mg dose will continue with that dose. The first dose of oleclumab will begin on Cycle 0 Day 1. For Cycle 1, oleclumab will be administered on Day 1 and Day 15. For Cycle 2 and beyond, oleclumab will be administered on Day 1 of each cycle Q4W."
11098128|NCT04089553|Experimental|Module 3|"Module 3 will investigate the safety, efficacy, and tolerability of AZD4635 in combination with durvalumab and oleclumab in post-standard of care therapy metastatic castration resistant prostate cancer (mCRPC) patients. In Module 3, approximately 30 patients will be enrolled, and biopsies will be obtained from approximately 15 patients in order to assess tumor microenvironment at baseline and after treatment with AZD4635.
~Patients will receive a starting dose of AZD4635 75 mg PO QD, durvalumab 1500 mg IV infusion on Day 1 and Q4W thereafter, and oleclumab 1500 mg Q2W for the first 4 doses and Q4W thereafter. The first dose of durvalumab will be delayed for 2 weeks in Cycle 1 only. For Cycle 2 and beyond, durvalumab will be administered on Day 1 of each cycle. The first dose of oleclumab will begin on Cycle 0 Day 1. For Cycle 1, oleclumab will be administered on Day 1 and Day 15. For Cycle 2 and beyond, oleclumab will be administered on Day 1 of each cycle Q4W."
11098129|NCT04089540|Experimental|Study group: New intubation method|In the new intubation method the respirator is connected to the tube prior to insertion into the mouth (oral intubation) or into the nose (nasopharyngeal intubation). Therefore an oxygen flow is already administered via the tube during the intubation process.
11098130|NCT04089540|Other|Control group: Conventional intubation|In the control group the respirator is connected to the tube and ventilation is started after the insertion of the tube into the trachea. Therefore there is no oxygen flow administered during the intubation process.
11098131|NCT04089527|Experimental|CC-95775|Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A.
11098132|NCT04089514||Adalimumab Therapy|Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy
11098133|NCT04089501||Inflammatory Bowel Disease (IBD)|Subjects will be asked to provide a stool sample (if no colonoscopy is to be performed) or if clinically indicated, a colonoscopy will be performed per standard medical routine. During colonoscopy, stool will be collected for analysis and 3 additional biopsies will be taken each from the ileum and colon for research purposes. Alternatively, subjects who are undergoing intestinal and/or colonic resection will provide stool prior to surgery and a portion of their pathology specimens will be used for research purposes following complete pathologic evaluation.
11098134|NCT04089501||Subjects not affected by IBD (Control Group)|Results of subjects with IBD will be compared to subjects in the control group.
11098135|NCT04089488||Observational (respond to surveys, medical record review)|Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
11098136|NCT04089462|Other|"1. Five sessions per period - Two sessions per period"|
11098137|NCT04089462|Other|"2. Two sessions per period - Five sessions per period"|
11098138|NCT04089449|Experimental|PRT811|PRT811 will be administered orally
11098139|NCT04089436||patients with encephalitis|children above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar
11098140|NCT04089410|Active Comparator|Hyperthermic Fitness Treatment|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the HFT.
11098141|NCT04089410|Placebo Comparator|Attenuated heating|Participants will fill out study questionnaires. After basic body measurements subjects will undergo the placebo-HFT.
11098142|NCT04089397|Experimental|Light therapy group|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis (at home, for patients dialyzing the afternoon, or during dialysis for patients dialyzing in the morning)
11098143|NCT04089397|No Intervention|Control group|Usual care, without light therapy
11098144|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
11098145|NCT04089384|Active Comparator|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
11098146|NCT04089384|Placebo Comparator|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment
11098262|NCT04088487|Experimental|Experimental group|Participants gain access to the internet intervention after the baseline measurement (pre-test).
11098148|NCT04089371||Arm B Reverse Shoulder Arthroplasty|Reverse Shoulder Arthroplasty (RSA) Humeral & Glenoid Components as a primary, fracture or revision total shoulder replacement
11098149|NCT04089358|Active Comparator|Control Group (educational materials, Fitbit)|Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
11098150|NCT04089358|Experimental|Intervention group (educational material, goal set, Fitbit)|See outline
11098151|NCT04089345|Experimental|Open label ustekinumab|All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from baseline through Week 4. Intravenous induction doses will be 260mg for patients <55kg, 390mg for patients between 55 and 85kg, and 520mg for patients with a body weight >85 kg.
11098152|NCT04089332|Experimental|Enrolled, eligible|Single arm for eligible subjects
11098153|NCT04089319|Experimental|Acupuncture + mindfulness|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen to a 15-minute mindfulness recording followed by music for 30 minutes. Acupuncture needles will then be removed.
11098154|NCT04089319|Other|Acupuncture control|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen music for 45 minutes. Acupuncture needles will then be removed.
11098155|NCT04089280|Experimental|Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: Sanprobi Barrier-multispecies probiotic product, 2,5 x10 9 cfu/gram or placebo, cross-over design
11098156|NCT04089280|Placebo Comparator|carrier material of Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: placebo comparator (carrier material of Sanprobi Barrier-multispecies probiotic product , not containing bacterial strains,similar appearance as the probiotic, cross-over design
11098157|NCT04089267|Experimental|experimental group 1|rhTPO injection7500 U ;one time a day; 14 times of administration
11098158|NCT04089267|Experimental|experimental group 2|rhTPO injection15000 U;one time a day;14 times of administration
11098159|NCT04089267|Experimental|experimental group 3|rhTPO injection15000 U;1 time every other day, 7 times;
11098160|NCT04089267|Experimental|experimental group 4|rhTPO injection30000 U；1 time every other day, 7 times;
11098161|NCT04089254|Active Comparator|Inpatient Psychiatry|Child and adolescent inpatient treatment
11098162|NCT04089254|Active Comparator|Outpatient Crisis Intervention Clinic|OCIC is outpatient crisis intervention clinic
11098163|NCT04089241|Experimental|all cohort|Patients will perform CTA 1 months after the EVAR procedure. Following CTA, an ultrasound examination which will include a 3D reconstruction and CEUS will be performed using SONOVIEW contrast agent. The dimensions and volume of the aorta will be compared to the measurements in CTA using the fusion method. In the case of endoleak type 1 or 3 the patient will be urgently refered to endovascular repair . In the case of endoleak type 2 or a normal exam the patient will undergo another fused exam with CEUS at 6 month . In the case of endoleak type 2 with a growth of more than 1 cm in the aneurysm diameter , the patient will be refered to endovascular repair. In the case of a normal exam or an endoleak type 2 with a shrinkage of 1 cm or more ,the patient will undergo another fused exam with CEUS at 12 months. At any case of a new endoleak type 1 or 3 the patient will undergo CTA.
11098164|NCT04089228|Experimental|Kinesiotape Group and INIT|Kinesiotaping and Integrated Neuromuscular Inhibition Technique (KT + INIT )
11098165|NCT04089228|Active Comparator|INIT Group|Integrated Neuromuscular Inhibition Technique (INIT)
11098166|NCT04089215|Experimental|JWCAR029 treatment|JWCAR029 be administrated in two dose level
11098167|NCT04089202|Active Comparator|In-person visit arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to an in-person visit with an Endocrinologist. This is currently the standard of care for patients referred for diabetes specialty care.
~Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
~Surveys will be administered to measure patient burden and self efficacy."
11098168|NCT04089202|Experimental|Freestyle Libre sensor arm|"In this arm, patients meeting eligibility criteria and consented into the study are randomized to have the Freestyle Libre Pro continuous glucose monitor (CGM) placed at their primary care clinic. The data collected from the diagnostic CGM will be utilized in conjunction with diet, exercise and medication logs provided by the patient and information from the patient's electronic medical record to complete an eConsult with treatment recommendations. Implementation of these recommendations will be per the primary care provider's discretion in conjunction with conversation with the patient in follow up visits.
~Surveys will be administered to measure patient burden and self efficacy."
11098169|NCT04089189|Experimental|IMP4297|100 subjects to receive IM4297 orally.
11098170|NCT04089176|Active Comparator|protocal A|Carbetocin versus placebo
11098171|NCT04089176|Active Comparator|protocal B|Oxytocin versus placebo
11098172|NCT04089163|Experimental|Sequential Dose Cohorts|Doses of Toca 511 will be evaluated in sequential cohorts. Toca 511 will be administered as a single intravesical instillation. Following Toca 511 administration, Toca FC will be administered orally at a dose of 220 mg/kg/day for 7 days every 6 weeks.
11098173|NCT04089150|Active Comparator|Arm A|"Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)
~Option 2: gemcitabine + nab-paclitaxel (3 cycles)
~Resectable patients receive surgery 6 weeks post completion of initial chemotherapy
~Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)
~Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist
~Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery
~For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX
~For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
11098197|NCT04088981|Active Comparator|Low-fat, vegan diet|For a 22-week period, participants will be asked to follow a low-fat vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
11098174|NCT04089150|Experimental|Arm B|"Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)
~Option 2: gemcitabine + nab-paclitaxel (3 cycles)
~Stereotactic Radiotherapy (SBRT) to commence within 3 weeks of completing initial chemotherapy: 40 Gray (Gy) in 5 fractions over 2 weeks
~Resectable patients receive surgery 6 weeks post completion of initial chemotherapy
~Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)
~Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist
~Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery
~For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX
~For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
11098175|NCT04089137|No Intervention|Control|This is an assessment only control condition.
11098176|NCT04089137|Experimental|ASAP (Alcohol and Sexual Assault Prevention)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault.
11098177|NCT04089124|Other|repair using General anesthesia ( control group)|Surgery repair zone 2 under GA
11098178|NCT04089124|Other|repair using Walant|Surgery repair zone 2 under WALANT
11098179|NCT04089111|Experimental|1.1. ASV, MV target 100%|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
11098180|NCT04089111|Active Comparator|1.2. Volume control, MV target %100|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3 Ventilation frequency will be adjusted to reach the same volume target calculated in arm1.
11098181|NCT04089111|Experimental|2.1. ASV, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
11098182|NCT04089111|Active Comparator|2.2. Volume control, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3. Ventilation frequency will be adjusted to reach the target PaCO2 level
11098183|NCT04089085|Other|One group pilot|The experimental group will receive the intervention, which is an 8-week (30 minute session per week) asthma educational and cognitive behavioral skills program.
11098184|NCT04089072|Experimental|Control group|Patients in the control group will have phenylephrine infusion starting at 50 mcg/min and titrated to maintain a MAP >65 mmHg as a third line vasopressor. Maximum dose of Phenylephrine is 300 mcg/min.
11098185|NCT04089072|Experimental|Intervention group|Patients enrolled in the intervention group will receive 2 mg/kg IBW (Ideal Body Weight) bolus, given over 15 mins, of ProvayBlue® followed by a concomitant infusion at 2 mg/kg/hr (IBW) mixed in D5W, which will continue for 24 hours. ProvayBlue® ( Methylene Blue) will be used as the third-line vasopressor.
11098186|NCT04089059|Other|Treatment Arm|Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).
11098187|NCT04089059|Other|Control Arm|"Proactive subject management according to GDMT leveraging also the vital signs collected by CHFS.
~After month 12 all data (including PAP measurements) will be available for both the subject and the clinician and the clinician will then treat the subject's HF per PAPGHFM and GDMT considering daily PAP measurements and the vital signs collected by CHFS."
11098188|NCT04089046|Experimental|TEAM-UP for Teens Intervention|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
11098189|NCT04089046|Active Comparator|Enhanced Care Comparison|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
11098190|NCT04089033||Primary Retinal Detachment 1|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pneumatic Retinopexy
11098191|NCT04089033||Primary Retinal Detachment 2|Patients presenting with primary macula-off rhegmatogenous retinal detachment being treated with Pars Plana Vitrectomy
11098192|NCT04089020|Experimental|Psychosocial intervention|Text messaging and health coaching over the telephone to address goal setting, monitoring, motivation, problem solving, and related skills, delivered over 5 weeks.
11098193|NCT04089007|Experimental|SOmNI intervention group|"Participants will receive an iPhone with the SOmNI app and will be instructed to move their bedtime earlier by 5 minutes (from their average baseline week bedtime) on each school night (Sunday to Thursday). Participants will also be given sleep hygiene information related to the embedded features of the SOmNI app. A research assistant will help the participant to enter the appropriate goal bedtime in the SOmNI app and orient them to the features of the SOmNI app. Participants will also be instructed to aim for <1 hour difference between school night and weekend bedtimes and wake times (i.e. avoid staying up late and sleeping in on weekends).
~The SOmNI application will allow the user to graphically track sleep behaviour across the four-week intervention period as recorded by the wearable sensor (e.g. bedtimes, wake times, amount of sleep achieved will all be displayed in the app)."
11098194|NCT04089007|Active Comparator|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
11098195|NCT04088994|Experimental|pathological model|The children assigned to the experimental group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a model with a similar manipulation strategy but improved with respect to the child's current abilities.
11098196|NCT04088994|Active Comparator|Healthy model|The children assigned to the control group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
11098225|NCT04088734|Experimental|ABO-102|
11098226|NCT04088721|Experimental|AD17002 20μg|Intranasal weekly dosing of AD17002 for three times
11098227|NCT04088721|Experimental|AD17002 40μg|Intranasal weekly dosing of AD17002 for three times
11098198|NCT04088981|Active Comparator|Portion-controlled diet|For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
11098199|NCT04088968|Experimental|Prehabilitation|Intervention: Patients allocated to the intervention group receive min. five counselling sessions in 6 weeks as an integrated prehabilitation program tailored to meet the individual patient's need for risk reduction at surgery. It is introduced via the surgical 'Engage in the process of change'. The smoking and alcohol cessation intervention follows the Gold Standard Programme and patients in the intervention group are introduced to a standardized exercise training programme taking individualized needs into account. Nutritional support is also individualized.
11098200|NCT04088968|No Intervention|Treatment as usual|Treatment as ususal covers shorter interventions, e.g. advice, brief counselling, and handing out the national folders on smoking and alcohol and surgery. Patients are ensured that they are free to access support to lifestyle changes in the community.
11098201|NCT04088942|Experimental|High-intensity group|"Will receive high-intensity intervention, which is a combination of pharmacological (varenicline) and behavioural support, described later."
11098202|NCT04088942|Active Comparator|Low-intensity group|Encouraged to quit smoking via own doctor and is prescribed varenicline.
11098203|NCT04088929|Experimental|CBD for Treatment of Diabetic Neuropathic Pain|Patients are instructed to take 3 total tablets a day, under the tongue, six hours apart for three weeks. Patients are to enter their pain scale score into the smartphone app as instructed during the initial site visit. Patients are to enter into the notes section of the app any additional information such as side effects (positive or negative), medication changes.
11098204|NCT04088903|Experimental|Daratumumab infusion|"Participants will receive an intravenous infusion of daratumumab weekly for 8 doses and then every other week for 2 doses.
~For this dose-escalation study, the initial patients will receive a 2 mg/kg dose of daratumumab. In subsequent patients, the dose will be uptitrated to 16 mg/kg as tolerated.
~Participants will undergo laboratory testing, including for circulating antibodies, at baseline, prior to each infusion session, and at the end of the study."
11098205|NCT04088890|Experimental|R/R ALL|"Relapsed/refractory ALL
~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:
~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3
~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3
~Autologous CD22 CAR T cells will be administered intravenously at Dose1: 3 x 10^5cells/kg (± 20%) 10"
11098206|NCT04088890|Experimental|R/R aggressive B-cell NHL|"Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
~Lymphodepletion prior to CD22 CAR T cell infusion (Day 0) will occur as follows:
~Fludarabine 30 mg/m2 per day IV for days 5, 4, 3
~Cyclophosphamide 500 mg/m2 per day IV for days 5, 4, 3
~Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) to determine MTD/RP2D.
~Dose1: 1 x 10^6 cells/kg (± 20%) Dose2: 3 x 10^6 cells/kg (± 20%) Dose3: 1 x 10^7 cells/kg (± 20%)"
11098207|NCT04088877|Experimental|Exercise and Art Sculpting Class|Participants will take part in a twelve week exercise program twice per week as well as an eight week art sculpting class once a week.
11098208|NCT04088864|Experimental|R/R B-ALL|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.
~Lymphodepletion:
~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2
~Cyclophosphamide 900 mg/m2 per day IV on day -2
~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
11098209|NCT04088864|Experimental|Lymphoma|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.
~Lymphodepletion:
~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2
~Cyclophosphamide 900 mg/m2 per day IV on day -2
~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
11098210|NCT04088851|Experimental|Metformin - T2D|Patients with type-2 diabetes and from their GP described Metformin Therapy (1 g per day) will undergo MRS and PINTA measurement.
11098211|NCT04088851|Placebo Comparator|No Metformin - T2D|Patients with type-2 diabetes and from their GP described Metformin Therapy (1 g per day) will pause the medication for 2 weeks and undergo MRS and PINTA measurement. After their visit they will continue the anti-diabetic treatment according to the GP's presription.
11098212|NCT04088851|No Intervention|No Metformin - Healthy Controls|Healhy controlls will undergo the MRS and PINTA measurments, matched in BMI and age.
11098213|NCT04088838||Patients undergoing abdominal surgery|All adult patients undergoing elective abdominal surgery are eligible. Abdominal surgery includes each operation in which the peritoneal cavity is openen, i.e. laparotomy or laparoscopy.
11098214|NCT04088812|Placebo Comparator|Placebo meat derivative + Placebo satiating compound|60 g Placebo meat derivative 25 g Placebo satiating compound
11098215|NCT04088812|Experimental|Placebo meat derivative + Satiating compound|60 g Placebo meat derivative 25 g Satiating compound
11098216|NCT04088812|Experimental|Experimental meat derivative + Placebo satiating control|60 g Experimental meat derivative 25 g Placebo satiating compound
11098217|NCT04088799||FSGS requiring LDL-apheresis|Pediatric patients with FSGS requiring LDL-apheresis with the Liposorber
11098218|NCT04088786|Experimental|Active|Cytoreductive surgery (CRS) followed by study treatment with nanoliposomal irinotecan administered intraperitoneally.
11098219|NCT04088773||Aim 1 Crohn Disease participants (B2 phenotype)|Crohn's Disease participants scheduled for ileal small bowel resection; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
11098220|NCT04088773||Aim 2 Crohn Disease participants (B1 phenotype)|Crohn's Disease participants with uncomplicated small bowel disease; No intervention; observational only; collection of blood, stool, and perform MRI; completion of Crohn's Activity Questionnaire
11098221|NCT04088773||Aim 2 Healthy Controls|No intervention; observational only; collection of blood, stool, and completion of Gastrointestinal Symptoms Rating Scale
11098222|NCT04088760|Experimental|TCRαβ+/CD19+ depleted HSCT|
11098223|NCT04088747||Fibromyalgia|Patients who display symptoms and have a history of Fibromyalgia, between 20-65 years of age.
11098224|NCT04088747||Healthy Controls|Age-matched, healthy controls, between 20-65 years of age who present no signs of chronic pain.
11098230|NCT04088708|Experimental|Aerobic Exercise Training|Progressive aerobic exercise training sessions supervised by exercise specialists who have experience training cancer survivors.
11098231|NCT04088708|Active Comparator|Attention Control|The non-aerobic exercise attention control condition will control for the effects of attention with flexibility/toning activities.
11098232|NCT04088695|Experimental|Intervention|The arm exposed to the intervention video
11098233|NCT04088695|Active Comparator|Control|The control group exposed an informative text.
11098234|NCT04088682||All hospitals|"All hospitals will take the treatment quality improvement strategies and tools into implementation.
~Intervention: Behavioral: Quality improvement strategies and tools"
11098235|NCT04088669|Experimental|Intervention group|A home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist.
11098236|NCT04088669|Active Comparator|Control group|A training session about the disease and the correct inhaler use, booklets that include breathing exercises and aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks.
11098237|NCT04088656|Experimental|Hypertension Systems Analysis and Improvement|Eight (8) health facilities will receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
11098238|NCT04088656|No Intervention|Control|Eight (8) health facilities will not receive the Systems Analysis and Improvement Approach (SAIA-HTN) intervention to optimize hypertension screening and management for people living with HIV/AIDS.
11098239|NCT04088643|Experimental|tACS group|NEXALIN ADI transcranial alternating current stimulator
11098240|NCT04088643|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
11098241|NCT04088630|Experimental|Fingolimod Group|In addition to Standard of care treatment, those participants randomized to the fingolimod group will receive a single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset.
11098242|NCT04088630|Placebo Comparator|Control Group|In addition to Standard of care treatment, those participants randomized to the control group will receive a single dose placebo pill within 24 hours of symptom onset
11098243|NCT04088617|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
11098244|NCT04088617|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
11098245|NCT04088604|Experimental|LY01610-Dose Escalation|The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
11098246|NCT04088604|Experimental|LY01610-Dose Extension|According to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 were further evaluated in 6 - 8 patients. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
11098247|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Escalation|"Dose Escalation:
~Based on the results of the first stage, three doses of low, medium and high doses were selected in combination with a fixed dose of 5-Fu to determine the DLT, MTD, PK characteristics and the preliminary efficacy. 5-Fu, 400mg/m2 will be administered intravenously on days 1, followed by 600 mg/m2 given as a 22-hour continuous infusion on day 1 and 2, every 2 weeks."
11098248|NCT04088604|Experimental|LY01610 with 5-Fu -Dose Extension|"Similarly, according to the subjects' tolerance, appropriate dose will be selected and the safety, PK characteristics and initial efficacy of LY01610 combined with a fixed dose of 5-Fu were further evaluated in additional 6 - 8 patients.
~In dose escalation and dose extension stages, both LY01610 and fixed dose 5-Fu will be given once every 2 weeks."
11098249|NCT04088604|Active Comparator|Hydrochloride Injection- pharmacokinetics comparative study|After receiving the MTD of LY01610, another 8 subjects were enrolled and given Irinotecan Hydrochloride Injection（captol ®） (180mg/m2) once every 2 weeks. Upon completion of the pharmacokinetics study, the sponsor will continue to provide the study drug treatment free of charge, and the researcher will conduct treatment and examination according to the subject's situation, without collecting any safety and efficacy data of the subject.
11098250|NCT04088591|Experimental|Treatment arm|The study drug is ascorbic acid is 200mg/kg/day divided over 4 doses per day and delivered in 50 ml of 5% dextrose in water intravenously over a total duration of 96 hours.
11098251|NCT04088591|Placebo Comparator|Placebo arm|The placebo is 50ml of 5% dextrose in water and will be administered 4 doses per day over a total duration of 96 hours
11098252|NCT04088578|Experimental|Vagus nerve stimulation (VNS)|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. VNS will be delivered when a minimum level of accuracy has been achieved.
11098253|NCT04088578|Sham Comparator|Sham stimulation|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. Sham stimulation will be delivered when a minimum level of accuracy has been achieved.
11098254|NCT04088565|Experimental|PAS+VNS|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with VNS in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
11098255|NCT04088565|Sham Comparator|PAS+Sham|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with sham stimulation in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
11098256|NCT04088552|Experimental|ActuaYa Arm|Participants will receive educational sessions, facilitated discussions and an exercise program.
11098257|NCT04088539|Experimental|Group A|"CSD participants will receive a combined intervention:
~Brief intervention using AWARD advice at baseline,
~Video-based health education"
11098258|NCT04088526|Experimental|intervention group|Through the effective intervention of risk factors for death in patients with dialysis, the effect of mortality of peri-dialysis patients was observed.
11098259|NCT04088513|Experimental|Aspirin|Drugs:Aspirin
11098260|NCT04088513|Active Comparator|Clopidogrel|Drugs:Clopidogrel
11098261|NCT04088500|Experimental|Nivolumab + Ipilimumab (combination)|Nivolumab + Ipilimumab (combination) Q3W for 4 doses
11098263|NCT04088487|Other|Waitlist control group|Participants gain access to the internet intervention 8 weeks after the baseline measurement (pre-test).
11098264|NCT04088474|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.
11098265|NCT04088474|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
11098266|NCT04088461|Experimental|Linagliptin + Metformin and lifestyle|Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
11098267|NCT04088461|Active Comparator|Metformin|Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.
11098268|NCT04088448|Placebo Comparator|Control group|Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
11098269|NCT04088448|Experimental|Metformin group|Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks
11098270|NCT04088422||B-cell lymphoma|
11098271|NCT04088409|Experimental|Baricitinib|Baricitinib given orally.
11098272|NCT04088409|Active Comparator|Adalimumab|Adalimumab given subcutaneously (SC).
11098273|NCT04088396|Experimental|Baricitinib|Baricitinib given orally.
11098274|NCT04088396|Placebo Comparator|Placebo|Placebo given orally.
11098275|NCT04088383|Other|Amnios™ RT|
11098276|NCT04088383|Placebo Comparator|Saline|
11098277|NCT04088370||Alcoholic Hepatitis|No intervention-blood draw only
11098278|NCT04088370||Healthy Controls|No intervention- blood draw only
11098279|NCT04088370||Healthy Heavy Drinkers|No intervention- blood draw only
11098280|NCT04088357|Active Comparator|5 Percent TolaSure Topical Gel|5%(w/w) TolaSure Gel
11098281|NCT04088357|Placebo Comparator|Topical Vehicle Gel|Vehicle Gel
11098282|NCT04088344|Placebo Comparator|Isocaloric diet (7 days)|Protocole A
11098283|NCT04088344|Experimental|Hypercaloric diet enriched with carbohydrate food (7 days)|Protocole B
11098284|NCT04088331||AMS 800 Artificial Urinary Sphincter Recipients|Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
11098285|NCT04088318|Experimental|OQL011 Dose I|OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks
11098286|NCT04088318|Experimental|OQL011 Dose II|OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks
11098287|NCT04088318|Experimental|OQL011 Dose III|OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks
11098288|NCT04088318|Other|Vehicle Ointment|Vehicle ointment, to be applied topically, three times a day, for up to six weeks
11098289|NCT04088305|Experimental|Study group|Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.
11098290|NCT04088305|No Intervention|Control group|Patients of control group will accept vancomycin dosages decided by attending physician.
11098291|NCT04088292|Active Comparator|USAT + low dose thrombolysis|UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization
11098292|NCT04088292|Active Comparator|Low dose thrombolysis|Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).
11098293|NCT04088292|No Intervention|Heparin alone|UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)
11098294|NCT04088266|Other|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA® sublingual film 16 mg buprenorphine with 4 mg naloxone
11098295|NCT04088253|Experimental|cirrhotic patient|cirrhotic patient with umbilical hernia to be operated
11098296|NCT04088240|Experimental|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
11098297|NCT04088240|Active Comparator|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
11098298|NCT04088240|Placebo Comparator|Placebo|"4 g/d placebo control (light olive oil)"
11098299|NCT04088227|Active Comparator|Control Group|The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
11098300|NCT04088227|Experimental|Experimental Group|The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
11098301|NCT04088214|Experimental|ArtDSTP|Arthroscopic lateral soft tissue release
11098302|NCT04088201|Experimental|Measuring glucose|Measuring glucose from interstitial fluid
11098303|NCT04088188|Experimental|Arm A (ivosidenib, cisplatin, gemcitabine)|Patients receive ivosidenib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11098304|NCT04088188|Experimental|Arm B (pemigatinib, cisplatin, gemcitabine)|Patients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11098305|NCT04088175|Experimental|Group 1 - Virginia Tobacco and Menthol|Subjects randomized to Group 1 will use JUUL ENDS Virginia Tobacco and Menthol flavors
11098306|NCT04088175|Experimental|Group 2 - Mint and Mango|Subjects randomized to Group 2 will use JUUL ENDS Mint and Mango flavors
11098307|NCT04088162|No Intervention|Standard Dressing|In case of Control group. After Ileostomy closure skin will be closed by 6 to 8 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures, and sterile standard dressing will be placed.
11098369|NCT04087668|Other|Monitored Anesthesia Care|Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.
11098308|NCT04088162|Experimental|Postoperative NPWT dressing|"In case of NPWT group. After Ileostomy closure skin will be closed by 3 or 4 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures. Between them small sponge tongues 1x 0,5x2 cm were placed and over whole incision an NANOVA (KCI USA) negative pressure dressing will be placed. In control group first dressing change was made in 48 hours after operation and then every day until suture removal at 7 postoperative day. In NPWT group NANOVA dressing was taken out at 72 hours. 3 steri-streps were placed between sutures and standard sterile dressing was placed. After it dressing was changed every 24 hours until suture removal at 7 postoperative day."
11098309|NCT04088149|Experimental|GXNPC1|"There are 2 dose levels Cohort 1: Low dose (1 ± 0.1 × 10^8 GXNPC1) of IPs will be administered in parallel.
~Cohort 2: High dose (2 ± 0.2 × 10^8 GXNPC1) of IPs will be administered sequentially."
11098310|NCT04088136|Experimental|Everyday Metacognitive Memory|Training in techniques for managing memory demands in everyday life
11098311|NCT04088136|Active Comparator|Memory Strategy Control|Trains the use of memory strategies for learning new associations and concepts
11098312|NCT04088123||Healthy Patients|The study design will involve analysis of platelet splicing/activity before and after exposure to a single, 180 mg loading dose of ticagrelor. All subjects will be cardiovascular healthy.
11098313|NCT04088110|Experimental|Pyrotinib and trastuzumab plus aromatase inhibito|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11098314|NCT04088097|Experimental|Cognitive-Behavioral Therapy|Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
11098315|NCT04088097|Other|Control Condition|Educational materials related to adolescent health and nutrition.
11098316|NCT04088084|Experimental|standard of care+palmitoylethanolamide|PEA was supplemented for 3 months to the standard of care (SOC, topical IOP lowering med)
11098317|NCT04088084|No Intervention|standard of care|patients were only on topical IOP lowering therapy (SOC)
11098318|NCT04088071||RAF Cohort|Subjects with symptomatic PAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
11098319|NCT04088058|Experimental|GXHPC1|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
11098320|NCT04088045|Experimental|Receiving PRP injections or PRP plus neural prolotherapy|"This experiment compares the effect of injecting PRP alone into the knee joint and pes anserinus complex with when dextrose solution is also injected to the genicular nerves.
~The injection of dextrose solution is to decrease the inflammation of the genicular nerves, hoping to further effectively alleviate the knee pain condition. Therefore, upon the conclusion of this study, we can see whether the inclusion of dextrose injection in addition to PRP treatment can really be effective in treating patients with more severe degrees of knee OA."
11098321|NCT04088032|Experimental|Active|Experimental treatment
11098322|NCT04088019||Observational cohort group|"Subjects: idiopathic uveitis with IGRA positive.
~Examinations:
~Clinical improvement examinations at day 0, second week, week 8, month 3, month 6 and month 12.
~Blood sampling at day 0, second week, month 6 for analysing type 1 IFN gene expression scoring using RT-qPCR methods."
11098323|NCT04088006|Experimental|Treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area treated
11098324|NCT04088006|No Intervention|Non-treated cheek and neckline area|Intra-individual study with one cheek and one side of neckline area non-treated
11098325|NCT04087993|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
11098326|NCT04087993|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
11098327|NCT04087993|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
11098328|NCT04087980|Experimental|Poseidon System Treatment|
11098329|NCT04087967|Experimental|Decitabine combined with HAAG|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
11098330|NCT04087967|Active Comparator|IA Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
11098331|NCT04087954|Experimental|Intervention vs control|
11098332|NCT04087954|No Intervention|Control|
11098333|NCT04087941|Placebo Comparator|Placebo|
11098334|NCT04087941|Experimental|VM-202|
11098335|NCT04087928|Experimental|Group Flexors (A)|Group A was treated by applying FMV to the flexor muscles of the upper limb (brachial biceps and carpal flexors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
11098336|NCT04087928|Experimental|Group Extensors (B)|Group b was treated by applying FMV to the extensors muscles of the upper limb (triceps brachial and carpus extensors). Patients will be treated with FMV for three consecutive days: each session consisted of three sessions of 10 minutes each, interspersed with one minute of rest. A vibration frequency of 100 Hz has been applied, according to the literature.
11098337|NCT04087915||High risk coronary artery disease|Participants with high risk coronary artery disease.
11098338|NCT04087863||Atopic Dermatitis|
11098339|NCT04087850|Experimental|Making Socially Accepting Inclusive Classrooms (MOSAIC)|
11098340|NCT04087850|No Intervention|Typical Practice Control|
11098341|NCT04087837|Experimental|bougie group|The bougie group: The end of the endotracheal tube was guided to the glottis using the endotracheal tube in the bougie mode under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
11098342|NCT04087837|Experimental|Nasogastric(NG) tube group|NG tube group: The end of the endotracheal tube is guided to the glottis by using the endotracheal tube in the nasogastric tube under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
11098343|NCT04087837|No Intervention|control group|Control group: The general anesthesia method of placing the endotracheal tube through the nasal cavity is used to guide the tip of the endotracheal tube to the glottis under the direct view of the electronic imaging laryngoscope.
11098344|NCT04087824|Experimental|AI monitoring colonoscopy|Patients in this group go through colonoscopy under the AI monitoring device.
11098345|NCT04087811||Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) - Interspinous Spacer
11098346|NCT04087798|Active Comparator|Control|Eligible patients enrolled from the control group clinics will be given a Control-EDI which has information about kidney disease in general (not tailored to the patient) during their clinic visit.
11098347|NCT04087798|Experimental|Intervention|Eligible patients enrolled from the intervention group clinics will be given an Intervention-EDI which has personalized information about kidney disease. There will be space on this for the provider to type in any goals or key points they want the patient to remember. Additionally, patients in this group will also receive health coaching.
11098348|NCT04087785||Positive metastasis|Positive occult lymph node metastasis pathology
11098349|NCT04087785||Negative metastasis|Without lymph node metastasis pathology
11098350|NCT04087772|Active Comparator|Mental Health-Enhanced PBIS|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
11098351|NCT04087772|Experimental|Mental Health-Enhanced PBIS + RED|PBIS-MH+RED involves the components of PBIS-MH integrated with racial/ethnic discrimination interventions (RED) to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
11098352|NCT04087759|Experimental|Treatment Sequence BAE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
11098353|NCT04087759|Experimental|Treatment Sequence CAF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet II under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
11098354|NCT04087759|Experimental|Treatment Sequence DAG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
11098355|NCT04087759|Experimental|Treatment Sequence ABE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
11098356|NCT04087759|Experimental|Treatment Sequence ACF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 2, thereafter will receive bedaquiline oral test tablet 2 under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
11098357|NCT04087759|Experimental|Treatment Sequence ADG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
11098358|NCT04087746|Active Comparator|AFLIBERCEPT|Intra-vitreal injection of AFLIBERCEPT
11098359|NCT04087746|Active Comparator|RANIBIZUMAB|Intra-vitreal injection of RANIBIZUMAB
11098360|NCT04087733|Experimental|GROUP / TREATED EYE|OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.
11098361|NCT04087733|No Intervention|GROUP / CONTROL EYE|No treatment. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
11098362|NCT04087720|Experimental|Pegloticase|Participants will receive 8 mg pegloticase by IV infusion every 2 weeks from Day 1 through Week 22
11098363|NCT04087707|Experimental|Step 1;TS-142|
11098364|NCT04087707|Experimental|Step 2;TS-142|
11098365|NCT04087707|Placebo Comparator|Step 2;Placebo|
11098366|NCT04087694|Other|Open|Open laminectomy and posterior stabilization with pedicle screws for symptomatic lumbar spine stenosis
11098367|NCT04087694|Other|Microscope|Microscopically done decompression of lumbar spine stenosis who are symptomatic
11098368|NCT04087681||Elderly 60+ preferably those with increased risk of IED|Study participants are aged 60 years or older in stable health, preferably with a history of urinary tract infection in the previous 10 years.
11098535|NCT04086550|Experimental|Investigational arm|Application of LIQOSEAL after closure of dura mater
11098370|NCT04087668|Other|General Anesthesia|Patients in this arm will receive standard general anesthesia with neuromuscular blockade.
11098371|NCT04087668|Other|General Anesthesia Without Neuromuscular Blockade|Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.
11098372|NCT04087655|Experimental|Exercise training|Eight weeks of interval exercise training
11098373|NCT04087642|Experimental|Intraoperative Crede manoeuver|"Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.
~In this group, the intraoperative Crede manoeuver will determine if a mid-urethral sling should be placed concomitantly."
11098374|NCT04087642|Active Comparator|Preoperative prolapse reduction cough stress test|"An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.
~In this group, the preoperative prolapse reduction cough stress test will determine if a mid-urethral sling should be placed concomitantly."
11098375|NCT04087629|Experimental|CTCL group|Patients with CTCL being treated with mechlorethamine gel will receive StrataXRT gel.
11098376|NCT04087629|Experimental|Skin Toxicity group|Patients with skin toxicity secondary to chemo/immunotherapy will receive StrataXRT gel.
11098377|NCT04087629|Experimental|GVHD group|Patients with acute cutaneous graft versus host disease will receive StrataXRT gel.
11098378|NCT04087616|Experimental|CBIT|ICBIT. Intervention delivered through an internet platform called Managing children's' tics (www.cbteamathome.co.il), based on CBIT protocol (Woods et al., 2008) adapted to an online parent-guided self-help format.
11098379|NCT04087616|Placebo Comparator|Waiting List|Participants initially assigned to the wait list receive no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants receive ICBIT.
11098380|NCT04087603|Experimental|Weekend Morning Bright Light & Early Bedtime|"Assigned a set sleep schedule for 2 weeks
~Receives evening time management goals to help facilitate scheduled bedtime
~Receives morning bright light from 2 light boxes (Phillips EnergyLights) on two weekend mornings."
11098381|NCT04087603|No Intervention|Healthy Control|- Sleep as usual at home for 2 weeks
11098382|NCT04087590|Experimental|PT003 treatment|
11098383|NCT04087577|Experimental|experimental group|conventional physical therapy with mirror therapy
11098384|NCT04087577|Active Comparator|control group|conventional physical therapy
11098385|NCT04087551|Experimental|Developing the list of items for BRFES|Two groups of six community-dwelling older adults will participate in a focus group session. Each focus group session will begin with a trained facilitator using a session guide welcoming the participants and introducing the participants in the group. The session will adopt a nominal group method which includes silent generation of ideas, sharing of an idea in a 'round robin' fashion, group discussion to clarify ideas and then completing the session with anonymous voting to include items into a list of items to be included in the Balance Recovery Falls-Efficacy Scale (BRFES).
11098386|NCT04087538||Patients treated using troponin T|
11098387|NCT04087538||Patients treated using troponin I|
11098388|NCT04087525|Experimental|Sequence 1|Period 1 : Fasted state + HIP1701, Period 2 : Fasted state + HGP1809
11098389|NCT04087525|Experimental|Sequence 2|Period 1 : Fasted state + HGP1809, Period 2 : Fasted state + HIP1701
11098390|NCT04087512|Experimental|Instrumented perturbation-based balance training|
11098391|NCT04087512|Experimental|Conventional perturbation-based balance training|
11098392|NCT04087512|No Intervention|Control|
11098393|NCT04087499|Sham Comparator|regular medication treatment|regular medication treatment
11098394|NCT04087499|Experimental|acupuncture and regular medication treatment|acupuncture and regular medication treatment
11098395|NCT04087473||Prior 2nd generation ALKi|
11098396|NCT04087473||Prior 1st and 2nd generation ALKi|
11098397|NCT04087460|Experimental|Low-dose Group A|Subjects received three doses of PBPV with 20μg each antigen
11098398|NCT04087460|Placebo Comparator|Low-dose Group B|Subjects received three doses of placebo
11098399|NCT04087460|Experimental|Middle-dose Group A|Subjects received three doses of PBPV with 50μg each antigen
11098400|NCT04087460|Placebo Comparator|Middle-dose Group B|Subjects received three doses of placebo
11098401|NCT04087460|Experimental|High-dose Group A|Subjects received three doses of PBPV with 100μg each antigen
11098402|NCT04087460|Placebo Comparator|High-dose Group B|Subjects received three doses of placebo
11098403|NCT04087447||Thyroidectomy group|patient undergoing thyroidectomy for simple nodular goiter
11098404|NCT04087434||Retrospective|retrospective review of 300 records of patients following concussive diagnosis to track recovery and adherence to progressive return to activity recommendations.
11098405|NCT04087434||Prospective|300 prospective patients enrolled following concussive diagnosis to track recovery, clinical diagnosis and brain gauge performance.
11098406|NCT04087434||Control Group|75-100 Healthy Controls recruited by Fort Bragg to assess performance in a healthy population for brain gauge performance.
11098407|NCT04087421|Experimental|Transanal irrigation|Participants receiving TAI will irrigate once/day with stepwise volumes; 1. month 150 ml, 2. month 300 ml, and 3. month 500 ml.
11098408|NCT04087421|Active Comparator|Glycerol suppositories|Participants treated with glycerol suppositories will administer one glycerol suppository once/day.
11098409|NCT04087408|No Intervention|control group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU
~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.
~Trigger will be done using HCG followed by OPU 36 h later.
~Retrieved oocytes will be fertilized by ICSI.
~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.
~6 - Blood sampling will be performed for progesterone 7 days after OPU.
~7-Quantative BHCG will be performed 14 days after OPU."
11098536|NCT04086550|Active Comparator|Control arm|Application of Adherus or DurSeal after closure of dura mater
11098410|NCT04087408|Active Comparator|study group|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU
~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.
~Trigger will be done using HCG followed by OPU 36 h later.
~Retrieved oocytes will be fertilized by ICSI.
~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.
~GnRH agonist 0.1 mg will be given 6 days after OPU.
~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg
~Quantative BHCG will be performed 14 days after OPU."
11098411|NCT04087382|Active Comparator|Intervention group|it included 32 patients with acute ischemic stroke beyond the time of window (more than 6 hours) assigned to mechanical thrombectomy) plus the conventional treatment (Aspirin 150 mg and atorvastatin 40 mg).
11098412|NCT04087382|Other|non-intervention group|it included 25 patients with acute ischemic stroke beyond the time of window (more than 6 hours) who received medical treatment (Aspirin 150 mg and atorvastatin 40 mg).
11098413|NCT04087369|Experimental|Bundled NCD WHO PEN Intervention|Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
11098414|NCT04087356||RMD+ Patients|Age-related macular degeneration patients with reticular macular disease
11098415|NCT04087356||RMD- Patients|Age-related macular degeneration patients without reticular macular disease
11098416|NCT04087343|Experimental|Meals plus exercise|
11098417|NCT04087343|Active Comparator|Meals only|
11098418|NCT04087330|Experimental|Group 1 Experimental group|Stretching, facilitation exercises with whole body vibration
11098419|NCT04087330|Active Comparator|Group 2 Control group|Stretching and facilitation exercises
11098420|NCT04087317|Experimental|Fixed time interval group.|Once the patient will arrive at the maternity ward the patient will receive paracetamol 1 gram and a tablet of ibuprofen 400 mg. Six hours after patient arrival and every 6 hours the patient will receive a tablet of paracetamol 500 mg and a tablet of ibuprofen 400 mg.
11098421|NCT04087317|Experimental|'On-demand' group.|Patients allocated to this group will receive the same medications in the same combinations and order as described in the 'fixed time interval' group protocol, patients in this group will receive pain treatment only following demand, and the time intervals described above will be considered as the minimal time for giving the next combination of drugs.
11098422|NCT04087304|No Intervention|Low Risk Group|
11098423|NCT04087304|No Intervention|Mild Risk Group|
11098424|NCT04087304|Active Comparator|Moderate Risk Group|
11098425|NCT04087304|Active Comparator|High Risk Group|
11098426|NCT04087291|Active Comparator|Phase 1: Low Dose (1-5 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
11098427|NCT04087291|Active Comparator|Phase 1: Higher Dose (8-12 visits)|Veterans with cLBP who will be randomly allocated to undergo a course of a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1).
11098428|NCT04087291|Active Comparator|Phase 2: CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care for 10 months.
11098429|NCT04087291|No Intervention|Phase 2: No CCPM|After Phase 1, Veterans with cLBP who will be randomly allocated again to receive no CCPM in which they will receive no chiropractic care for 10 months.
11098430|NCT04087278|Active Comparator|Metabotype A|Taking treatment
11098431|NCT04087278|Active Comparator|Metabotype B|Taking treatment
11098432|NCT04087278|Active Comparator|Metabotype 0|Taking treatment
11098433|NCT04087278|Placebo Comparator|Placebo|Taking matching placebo
11098434|NCT04087265|Other|Study Population (All Participants)|Patients who are referring for scheduled screening colonoscopy
11098435|NCT04087252|Experimental|vaccinated group|Neoantigen vaccination will be performed with 6 doses in total, once per week
11098436|NCT04087239||Pregnant women from >20 weeks gestation|1,200 pregnant women (600 HIV infected mothers and 600 HIV uninfected controls) at least 20 weeks gestation were enrolled from January 2016 to June 2019. Participants are being followed as mother-baby pairs at birth, within 10 days of life 6, 10, 14 24, 48, 72 and 96 weeks of age. At each visit clinical examinations are being used to assess health and the impact of environmental factors. In addition, questionnaires are administered and bio-samples for laboratory tests. The design of the study is non-interventional cohort but participants are being offered advice regarding health and hygiene.
11098437|NCT04087226|Active Comparator|Conventional Retraction Cord|
11098438|NCT04087226|Experimental|PTFE Retraction Cord|
11098439|NCT04087213|Experimental|The HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
11098440|NCT04087187|Experimental|Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
11098441|NCT04087187|Experimental|Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
11098442|NCT04087187|Experimental|Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration."
11098565|NCT04086394|Experimental|PECS Block|Group who was randomly selected to receive the intraoperative nerve block.
11098566|NCT04086394|Sham Comparator|Control|Patient who was randomly selected not to receive intraoperative nerve block
11098443|NCT04087187|Experimental|Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
11098444|NCT04087187|Experimental|Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration."
11098445|NCT04087187|Experimental|Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A|"Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.
~Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration."
11098446|NCT04087174|Experimental|Part A1: Capivasertib + enzalutamide|From day 1 to day 28 of this study treatment, patients will continuously enroll on a starting dose of capivasertib in combination with 160 mg enzalutamide.
11098447|NCT04087174|Experimental|Part A1: Capivasertib dose level 1 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+1 along with 160 mg enzalutamide.
11098448|NCT04087174|Experimental|Part A1: Capivasertib dose level 2 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+2 along with 160 mg enzalutamide.
11098449|NCT04087174|Experimental|Part A2: Capivasertib + abiraterone|Patients will continuously enroll on a starting dose of capivasertib in combination with 1000 mg abiraterone.
11098450|NCT04087174|Experimental|Part B1: Capivasertib + enzalutamide|This optional expansion will treat patients at the recommended dose regimen of capivasertib and enzalutamide.
11098451|NCT04087174|Experimental|Part B2: Capivasertib + abiraterone|This optional expansion will treat patients at the recommended dose regimen of capivasertib and abiraterone.
11098452|NCT04087148||patients|patients who were diagnosed as having CAH of at least 1 y duration. and On glucocorticoid replacement therapy .
11098453|NCT04087148||controls|A comparable number of age and sex matched apparently normal children will be included as control.
11098454|NCT04087135|Experimental|participant LD|
11098455|NCT04087135|Experimental|participant VL|
11098456|NCT04087135|Experimental|participant VLS|
11098457|NCT04087122|Experimental|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
11098458|NCT04087109|Experimental|Intervention: MedSafer|In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
11098459|NCT04087109|No Intervention|Control: Baseline (no MedSafer)|During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
11098460|NCT04087096|Experimental|Denosumab|Denosumab 60mg subcutaneous injection every 6 months
11098461|NCT04087096|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months
11098462|NCT04087083|Experimental|technological intervention arm|Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
11098463|NCT04087083|Active Comparator|Control arm|Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
11098464|NCT04087070||biosignal derived blood pressure|"Blood pressure is measured by an automated oscillometric device or arterial waveform from IntelliVue MX800 Bedside patient monitor (Philips Healthcare, Amsterdam, Netherlands).
~Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.
~PAT(time between R peak of ECG and beginning of the pulse of PPG)
~PEP(time between R peak of ECG and peak of accelerometer signal)
~PTT(PAT-PEP)"
11098465|NCT04087057||Observational (interview, medical records review)|Patients complete questionnaires and participate in an interview to answer questions about information patients received before starting chemotherapy, any medical problems after surgery that could have been related to the start of the chemotherapy, how chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.
11098466|NCT04087044|Experimental|Vestibular dysfunction|66 patients: 30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine
11098467|NCT04087044|Other|Control|120 aged matched controls
11098468|NCT04087031|Active Comparator|control arm|Ten traditional treatment sessions divided into 2 training sessions per week for 5 weeks
11098469|NCT04087031|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
11098470|NCT04087031|Experimental|robotic treadmill arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
11098471|NCT04087018|Experimental|TMB-H|Participants with a tumor biomarker status of TMB-H will receive Zimberelimab every 3 weeks.
11098472|NCT04087018|Experimental|Strata Immune Signature positive|Participants with a tumor biomarker status Strata Immune Signature positive will receive Zimberelimab every 3 weeks.
11098473|NCT04087005|Experimental|Hominis placental pharmacopuncture|The Hominis placental pharmacopuncture group will receive 10 sessions of Hominis placental pharmacopuncture at 2 sessions/week for 5 weeks. A trained doctor of Korean medicine with at least 2 years clinical experience will administer JHG002 pharmacopuncture with a disposable syringe (0.5ml) directly into the designated sites, using a standardized method.
11098567|NCT04086381|Active Comparator|Intervention|Oral injestion of 20 grams of creatine monohydrate daily
11098568|NCT04086381|Placebo Comparator|Placebo|Oral injestion of 20 grams of cellulose daily
11098474|NCT04087005|Active Comparator|Transcutaneous electrical nerve stimulation|The control group will receive 2 sessions/week of TENS for 5 weeks. A high-frequency, low-intensity stimulus of 50-100Hz and up to 15mA will be used, such that the patients feel a current but do not feel pain. At each treatment visit, a physiotherapist will administer the treatment to the bilateral temporomandibular joint for 15 minutes. Both centres will use the same TENS device-a BioTron-DX (D.M.C, Osan, South Korea).
11098475|NCT04086992|No Intervention|Control Group|This group will continue to receive standard care for ACTH monitoring and follow-up with includes blood pressure and blood glucose monitoring by the patient's PCP while on therapy, a one week nursing follow-up phone call, and a two-week EEG and Neurology appointment.
11098476|NCT04086992|Experimental|Intervention Group|This group will be provided remote monitoring technology where they will be able to monitor blood pressure and blood glucose at home. In addition, they will receive a nurse-led telemedicine visit at one week and three weeks of therapy. Like the control group, they will still receive a two-week EEG and Neurology appointment.
11098477|NCT04086979|Experimental|Parental Friendship Coaching (PFC)|
11098478|NCT04086979|Active Comparator|Coping with ADHD through Relationships and Education (CARE)|
11098479|NCT04086966|Experimental|Metastatic Prostate Cancer Arm|[68Ga]PSMA-11 PET/MRI or PET/CT for guiding the radiation treatment plan in patients with known or suspected locally metastatic prostate cancer
11098480|NCT04086953|Experimental|Chronic Respiratory Disease Group|"Each patient receive the same intervention : 4 visits with different exercise tests.
~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle, questionnaires and accelerometer)
~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)
~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)
~Visit 4 : Reproducibility of the WTLT (WTLT x2) Specific measures for COPD subjects : Respiratory Functional Assessment and Dyspnea questionnaire"
11098481|NCT04086953|Experimental|Cardiovascular diseases Group|"Each patient receive the same intervention : 4 visits with different tests.
~Visit 1: Inclusion Visit, Functional Assessment and TTLM Speed Determination (6-minute walk test x2, cardiopulmonary exercise testing on ergocycle,, questionnaires and accelerometer)
~Visit 2 : Functional Evaluation and Shuttle Tests (ISWT, ESWT, Speed tests on 4m, Quadriceps muscle strength)
~Visit 3 : Feasibility of the WTLT (WTLT x2 or 3)
~Visit 4 : Reproducibility of the WTLT (WTLT x2)"
11098482|NCT04086940|Active Comparator|esmolol(breviblock) group|Patients in group E received a loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline over 30 minutes before induction of anesthesia, then followed by an infusion of esmolol 10 µg/kg/min until the end of the surgery.
11098483|NCT04086940|Active Comparator|non esmolol group|Patients in group N received 50 ml of isotonic saline over 30 min, followed by an infusion of isotonic saline at same rate of group E till the end of the surgery.
11098484|NCT04086927|No Intervention|Control Group|Patients will not receive compression dressing
11098485|NCT04086927|Experimental|Experimental Group|Patients will receive compression dressing
11098486|NCT04086914|No Intervention|Non nerve block|Receives no nerve block
11098487|NCT04086914|Experimental|Nerve block|Receives nerve block
11098488|NCT04086901|Experimental|Dose escalation Arm|Chemo-radiotherapy with radiotherapy dose escalation based on Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG/PET) scans
11098489|NCT04086901|No Intervention|Standard|Standard chemo-radiotherapy
11098490|NCT04086875|Experimental|Phase 1 (focus groups)|Participants attend focus groups on adherence to hormone therapy.
11098491|NCT04086875|Experimental|Phase II Group 1 (text messages)|Participants receive text messages twice weekly for 6 months to remind and motivate participants about AHT adherence.
11098492|NCT04086875|Active Comparator|Phase II Group II (usual care)|Participants receive usual care.
11098493|NCT04086862|Active Comparator|The 1 MHz group|The 1 MHz group will receive therapeutic ultrasound at the 1 MHz setting.
11098494|NCT04086862|Experimental|The 3 MHz group|The 3 MHz group will receive therapeutic ultrasound at the 3 MHz setting.
11098495|NCT04086836||Patient suffering a late stroke after TAVR|All patients suffering a stroke after TAVR will be studied
11098496|NCT04086823|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 48 sites in the submental fat (0.05/0.1mL per site):
~Up to 120mg administered at 48 sites in a volume of 0.05 ml at each injection site (total injected volume 2.4mL)
~Up to 240 mg administered at 48 sites in a volume of 1 ml at each injection site (total volume injected 4.8mL)"
11098497|NCT04086823|Placebo Comparator|Vehicle|"Subject receive a single-treatment injection. Multiple injections of the Placebo are administered at 48 sites (0.05/0.1mL per site) into the submental fat.
~Up to a total of 2.4 mL will be injected for placebo subjects enrolled during cohort 1.
~Up to a total of 4.8 mL will be injected for placebo subjects enrolled during cohort 2."
11098498|NCT04086810|Experimental|DCCR|25 - 450 mg DCCR
11098499|NCT04086797|Experimental|IQP-AE-103|2 capsules after 3 main meals per day (total 1980 mg)
11098500|NCT04086797|Placebo Comparator|Placebo|2 capsules after 3 main meals per day
11098501|NCT04086784||3D-printed Cage|Patients undergoing posterior lumbar interbody fusion with 3D-printed Porous Titanium Alloy Cages at the lowest fusion segment
11098502|NCT04086784||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages at the lowest fusion segment
11098503|NCT04086771|Experimental|Intervention Group (Navigation)|Participants will be contacted by CHAs by phone one week after giving informed consent and completion of the baseline survey. CHAs will contact participants once a week for up to 10 weeks (a maximum of 10 attempts or until a clinic appointment is made, whichever comes first). Using the TIMS© message library, the CHAs will engage participants in conversations about breast and cervical cancer screening and navigate the participants to overcome any barriers to screening and motivate them to make a clinic appointment. Personal messages from mothers to daughters and vice versa and screening reminder notecards will be sent at 12-months (T3). At 18-months (T4), CHAs will follow-up with navigation group participants who reported completing a mammogram during the navigation process. Screening completion will be measured by self-report and confirmed via medical record check.
11098569|NCT04086368|Active Comparator|The Synthes Pediatric LCP Plate System|Open osteotomy and osteofixation with the pediatric LCP hip plate
11098570|NCT04086368|Experimental|The adolescent Lateral Femoral Nail|Percutaneous osteotomy and intramedullary nailing
11098504|NCT04086771|Placebo Comparator|Control Group (Information only)|Participants will be mailed an informational brochure on mammography and Pap testing one week after enrollment into the study. At 3-months post enrollment, CHAs will conduct a follow-up phone call with each participant to assess mammogram and/or Pap testing completion (primary outcomes). At 12-months (T3) post enrollment, CHAs will contact all control group participants by phone to confirm a scheduled appointment or screening completion. For those who completed a mammogram within the 12 months since enrollment, generic screening reminder notecards will be sent by mail. At 18-months (T4), CHAs will follow-up with those control group participants who reported scheduling a mammogram, Pap smear, or both at the 12-month (T3) time point.
11098505|NCT04086758|Experimental|Zolbetuximab|Participants will receive a loading dose-1 of zolbetuximab on Day 1 of Cycle 1, consists of 21 days, followed by subsequent lower dose-2 every 3 weeks until they meet the discontinuation criteria.
11098506|NCT04086745|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
11098507|NCT04086745|Experimental|Baricitinib High Dose|Baricitinib administered orally.
11098508|NCT04086745|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
11098509|NCT04086732|Experimental|Temporomandibular disorder|
11098510|NCT04086732|Experimental|Healthy control|
11098511|NCT04086719|Experimental|BMS- 986185 + Pyrimethamine|
11098512|NCT04086719|Experimental|BMS-986185|
11098513|NCT04086706||Consecutive Patients with complete colonoscopy|Inclusion criteria were as follows: Patients older than 18 years, with a complete colonoscopy, for CRC screening or post-polypectomy surveillance or diagnostic assessment. Exclusion criteria precluded patients with previous colectomy or an abdominal surgery in the last 6 months, patients with polyposis syndromes or inflammatory bowel diseases and if they were unfit for polypectomy or the polyp specimen was not retrieved for histology.
11098514|NCT04086693|Active Comparator|Standard IV dressing|Polyurethane dressing with clear tape
11098515|NCT04086693|Experimental|Standard IV dressing plus Adhezion SecurePortIV|Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).
11098516|NCT04086667|Experimental|Pain group|"The segment on the lower back marked as most painful"
11098517|NCT04086667|Experimental|Stiff group|"The segment on the lower back marked as most stiff"
11098518|NCT04086654|Other|International Trauma Interview (ITI)|
11098519|NCT04086641|Experimental|Crossover foot|Prosthetic foot that attaches to the proximal posterior socket. Relatively long strut length.
11098520|NCT04086641|Active Comparator|Energy Storing Foot|Prosthetic foot that attaches to the distal aspect of the socket. Relatively short strut length.
11098521|NCT04086628||Asthmatic children vaccinated|
11098522|NCT04086628||Asthmatic children unvaccinated|
11098523|NCT04086615|Experimental|NMES and exercise supplemented with high BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.
~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The High BFR group will have the pressure set at 80% of limb occlusion pressure."
11098524|NCT04086615|Sham Comparator|NMES and exercise supplemented with low BFR|"All participants receive a standard exercise rehabilitation protocol for PFPS to be performed singularly at home/work, synchronously with NMES and concurrently with NMES/BFR in-clinic. The PFPS exercises teach muscle strengthening exercises and self-management strategies to prevent recurrence. Participants will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the exercise program.
~For the BFR training, the automatic Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction (Delfi Medical, Vancouver, BC, Canada) with variable contour nylon cuff (11.5 cm × 86 cm, 2.5 mm thick) will be used. The Delfi PTS system automatically adjusts pressure around the set occlusion pressure. The Low BFR group will have the pressure set at 20 mmHg."
11098525|NCT04086602|Experimental|Single Ascending Dose|Once daily oral IZD334 or Placebo
11098526|NCT04086602|Experimental|Multiple Ascending Dose|Once or twice daily oral IZD334 or Placebo
11098527|NCT04086589||Young|Observational study without intervention
11098528|NCT04086589||Elderly|Observational study without intervention
11098529|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
11098530|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
11098531|NCT04086563|Experimental|Action observation|The patients will observe a 25 minutes clip of neurodynamic exercises of the hand.
11098532|NCT04086563|Experimental|Mirror Therapy|With a mirror glasses, the patients will execute neurodynamic movements of their non-dominant hand during 25 minutes.
11098533|NCT04086563|Active Comparator|Strength Training|Strength protocol for the dominant hand.
11098534|NCT04086563|Experimental|Neurodynamic exercise|Active neurodynamic exercises for the dominant hand.
11098537|NCT04086537||BMPR2-mutation carriers|Patients affected by pulmonary arterial hypertension (PAH) with already determined BMPR2 mutation status (hereditary PAH, HPAH) or patients with idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted positive for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
11098538|NCT04086537||non-BMPR2 mutation carriers|Patients affected by Pulmonary arterial hypertension (PAH) who resulted negative at the routinely-performed (according to current guidelines) BMPR2 analysis (Idiopathic PAH, IPAH) or patients with Idiopathic PAH (IPAH) and other forms of PAH who are newly diagnosed within the duration of the study and resulted negative for mutation at the routinely-performed (according to current guidelines) BMPR2 analysis.
11098539|NCT04086537||healthy controls|Healthy controls free of heart and lung disease or any comorbidities affecting iron metabolism. This control group will be age and gender matched to non-BMPR2 mutation carriers.
11098540|NCT04086524|Experimental|Binocular cartoon treatment at home|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL at home. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
11098541|NCT04086524|Active Comparator|Control group|"Participants will patch for 2 hours every day at home. After 2 weeks, they will be given the option to crossover to the teratment group for an additional 2 weeks (total of 4 weeks). Patching is a common treatment for amblyopia, often considered the golden standard. It is the most common comparison as a control group in amblyopia and vision therapy literature."
11098542|NCT04086524|Experimental|Binocular cartoon treatment in office|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL in office. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
11098543|NCT04086511||Children with PKU|
11098544|NCT04086511||Age- and sex-matched non-PKU comparison subjects|
11098545|NCT04086498|Experimental|ketogenic-mediterranean diet with phytoextracts|The KEMEPHY diet (Paoli et al., 2011) is a mediterranean calorie-controlled ketogenic protocol (about 900 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (Lodi et al., 2016).
11098546|NCT04086498|Active Comparator|Ketogenic Diet|The KD is a protocol in which all foods containing carbohydrate are excluded, whereas meat, eggs, fish, ham, green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants can be eat without any limit. This protocol allows the use of oil, lemon juice (2 tbs/day), spices and aromatic herbs with a limitation of the use of saturated fats like butter, margarine and lard. Coffee, tea and herbal tea could be sweetened with sweeteners
11098547|NCT04086498|Active Comparator|Mediterranean Diet|The MD is a balanced calorie-controlled diet. The calorie intake was 1200 Kcal/day of which 15% were proteins, 60% carbohydrates and 25% fat. In this protocol was highlighted the use of the typical ingredients of the mediterranean tradition, such as extravirgin olive oil, vegetables, fruits, fish, lean meat and whole grain cereals.
11098548|NCT04086485|Experimental|1/Lu-177-DOTATATE + Olaparib escalation|Lu-177-DOTATATE and escalating doses of olaparib to determine the maximum-tolerated dose (MTD)
11098549|NCT04086485|Experimental|2/Lu-177-DOTATATE + Olaparib fixed dose|Lu-177-DOTATATE and olaparib at the MTD
11098550|NCT04086472|Experimental|MK-1654 Dose 1|Participants receive a single IV infusion of MK-1654 Dose 1 on Day 1.
11098551|NCT04086472|Experimental|MK-1654 Dose 2|Participants receive a single IV infusion of MK-1654 Dose 2 on Day 1.
11098552|NCT04086472|Experimental|MK-1654 Dose 3|Participants receive a single IV infusion of MK-1654 Dose 3 on Day 1.
11098553|NCT04086472|Experimental|MK-1654 Dose 4|Participants receive a single IV infusion of MK-1654 Dose 4 on Day 1.
11098554|NCT04086472|Placebo Comparator|Placebo|Participants receive a single IV infusion of placebo on Day 1.
11098555|NCT04086459|Active Comparator|Active repetitive transcranial magnetic stimulation|
11098556|NCT04086459|Sham Comparator|Sham repetitive transcranial magnetic stimulation|
11098557|NCT04086459|No Intervention|No repetitive transcranial magnetic stimulation|
11098558|NCT04086446|Active Comparator|active tDCS|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
11098559|NCT04086446|Sham Comparator|sham tDCS|The sham transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
11098560|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
11098561|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
11098562|NCT04086420|Experimental|Mindfulness|Delivered through an audio-recording consisting of a single meditation exercise that lasted for 30 minutes
11098563|NCT04086420|Active Comparator|Heart-Rate|Given a heart rate monitor and instructed to use it to determine the intensity of their exercise
11098564|NCT04086407|Experimental|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
11098571|NCT04086355|Experimental|Effect of electrical stimulation on dysphagia in cp|the study group that was treated by selected oromotor exercise program in addition to neuromuscular electrical stimulation, Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
11098572|NCT04086355|Experimental|effect of oromotor exercise on dysphagia in cp|the control group was treated by the same oromotor exercise program in addition to placebo effect of neuromuscular electrical stimulation. Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
11098573|NCT04086342|Active Comparator|CHI-902|Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
11098574|NCT04086342|Placebo Comparator|Placebo|Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).
11098575|NCT04086329|Other|Affected MM Cases|Key eligibility criteria for MM cases includes physically-capable adults (male and females, ages 18 to 65 years, inclusive) with genetically-confirmed MM with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.
11098576|NCT04086329|Other|Healthy Controls|Adult healthy volunteers will be individually matched with corresponding MM cases based on age, biological sex, and body mass index.
11098577|NCT04086316||Depression Group|Naturally cycling women with a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
11098578|NCT04086316||Healthy Group|Naturally cycling women without a major depressive episode, assessed by Structured Clinical Interview for DSM-5 (SCID Clinical Version)
11098579|NCT04086303|Experimental|young handball players|The first group was named young players (n = 19; age = 18.05 ± 2.58 years, body mass index = 22.0 ± 2.21 kg, sport participation ≤ 10 years)
11098580|NCT04086303|Active Comparator|adult handball players|The second group was named old players (n =23; age = 28,91 ± 3.39 years, body mass index = 22.20 ± 2.75 kg, sport participation ≥ 11 years).
11098581|NCT04086290|Experimental|RARP + SBRT + ADT|Radical prostatectomy + extended pelvic lymph node dissection according to EAU guidelines followed by stereotactic body radiotherapy to osseous lesions with six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
11098582|NCT04086277|Experimental|Women in labor with continuous intrapartum support|Continuous intrapartum support was based on three basic aspects: 1) emotional support, 2) physical support and comfort measures and 3) information and advice.
11098583|NCT04086277|No Intervention|Women in labor without continuous intrapartum support.|The no intervention group received the usual obstetric care, without continuous intrapartum support.
11098584|NCT04086264|Experimental|Regimen A|IMGN632, administered intravenously on the first day of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 given for 7 days over a 28 day cycle
11098585|NCT04086264|Experimental|Regimen B|IMGN632, administered intravenously on the first day of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on the first day, 200mg on the second day, and 400 mg on the third day through the 21st day of a 21 day cycle
11098586|NCT04086264|Experimental|Regimen C|IMGN632, administered intravenously on the first day of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 given for 7 days over a 28 day cycle and venetoclax, administered orally daily at 100 mg on the first day, 200mg on the second day, and 400 mg on the third day through the 28th day of a 28 day cycle
11098587|NCT04086264|Experimental|Regimen D|IMGN632, administered intravenously on the first day of a 21 day cycle at 0.045 mg/kg, as a monotherapy for MRD+ patients
11098588|NCT04086251|Experimental|Gaido Intervention|All patients enrolled in the study will participate in the Gaido Intervention, which entails wearing the Biovotion Everion continuously and take blood pressure and oral temperature spot checks per clinician orders. Patients will also be responsible for filling out PRO surveys and any surveys that trigger as a result of their vital signs falling outside of tailored thresholds.
11098589|NCT04086238|Other|Formulation A Fasted|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
11098590|NCT04086238|Experimental|Formulation A Fed|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
11098591|NCT04086238|Other|Formulation B Fasted|EPI01 Formulation B (slow reelase): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
11098592|NCT04086238|Experimental|Formulation B Fed|EPI01 Formulation B (slow release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
11098593|NCT04086238|Other|Formulation C Fasted|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
11098594|NCT04086238|Experimental|Formulation C Fed|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
11098595|NCT04086212|Experimental|IXC Peritoneal dialysis solution|IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution
11098596|NCT04086212|Active Comparator|Icodextrin|Extraneal® (7.5% Icodextrin) Peritoneal dialysis solution
11098597|NCT04086199||Anterior discectomy|The discectomy is made by an anterior muscle sparring approach (extraperitoneal).
11098598|NCT04086199||Posterior discectomy|The discectomy is made by a posterior approach (posterior midline incision).
11098599|NCT04086186|Active Comparator|Adductor Canal Block Group|Standard method for peri-operative pain control. Adductor canal block is performed by anesthesiologist prior to surgery.
11098795|NCT04084847|Active Comparator|Barberry|Daily consumption of barberry in powder form.
11098600|NCT04086186|Experimental|Liposomal Bupivacaine Group|Experimental method for peri-operative pain control. Liposomal bupivacaine peri-articular injection is performed by surgeon during surgery.
11098601|NCT04086173|Experimental|Study group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.
11098602|NCT04086173|Placebo Comparator|Control group|Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.
11098603|NCT04086160|Experimental|schizophrenia- tDCS|
11098604|NCT04086160|Sham Comparator|schizophrenia- sham|
11098605|NCT04086160|Experimental|at risk- tDCS|
11098606|NCT04086160|Sham Comparator|at risk- sham|
11098607|NCT04086160|Experimental|healthy controls for schizophrenia- tDCS|
11098608|NCT04086160|Sham Comparator|healthy controls for schizophrenia- sham|
11098609|NCT04086160|Experimental|healthy controls for at risk- tDCS|
11098610|NCT04086160|Sham Comparator|healthy controls for at risk- sham|
11098611|NCT04086147|Experimental|Low dose tenecteplase|
11098612|NCT04086147|Experimental|High dose tenecteplase|
11098613|NCT04086134|Experimental|Intervention fruit products 1|Three servings of fruit products per day for 4 weeks.
11098614|NCT04086134|Experimental|Intervention fruit products 2|Three servings of fruit products per day for 4 weeks.
11098615|NCT04086134|Placebo Comparator|Control fruit products|Three servings of control fruit products per day for 4 weeks.
11098616|NCT04086121|Experimental|All Subjects|
11098617|NCT04086108|Experimental|Tomato|Single oral administration
11098618|NCT04086108|Experimental|GABA supplement|Single oral administration
11098619|NCT04086108|Experimental|Glutamate supplement|Single oral administration
11098620|NCT04086108|No Intervention|Placebo|Single oral administration, same volume of water that is distributed in the other arms
11098621|NCT04086095|Experimental|Intervention Group|Surfactant administration will be done via videolaryngoscopy and the application aid Neofact in neonates with respiratory distress syndrome and airway support with CPAP. Alveofact is used as Surfactant in its standard dosage of 100 mg / kg
11098622|NCT04086082|Experimental|Markerless Image Guidance Arm|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
11098623|NCT04086069|Experimental|Standard Training+Sit-to-stand trainer|Training using a sit-to-stand trainer device in addition to standard training of standing-up with the help of a physiotherapist
11098624|NCT04086069|No Intervention|Standard Training|Standard training of standing-up with the help of a physiotherapist
11098625|NCT04086056||Children with craniosynostosis|Children with craniosynostosis who will be operated in prone position.
11098626|NCT04086043|Experimental|Endovascular Denervation|
11098627|NCT04086030|Sham Comparator|Sham Postoperative Rehabilitation|Patients in this group will complete the standardized postoperative rehabilitation program with sham BFR, which is pressure of 20 mmHG. Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set. The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
11098628|NCT04086030|Experimental|BFR Postoperative Rehabilitation|Assigned intervention of BFR where exercises are performed with BFR at 80% limb occlusion pressure (LOP). Patients in this group will undergo blood flow restriction (BFR) training during their postoperative rehabilitation program (use an inflatable cuff that prevents blood flow from flowing out of the leg while patients perform physical therapy exercises). Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set.16 The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
11098629|NCT04086017|Experimental|Reiki teaching|Reiki Master will perform the teaching and attunement process for Level 1 Reiki and teach the caregiver(s) how to complete a simple 10-minute Reiki session with the patient and a 10-minute self-Reiki session for the caregiver(s). The Reiki Master will explain that Reiki sessions can be given whenever the patient and caregiver feel it is appropriate, but sessions should be at minimum twice per 24-hour period for at least 10 minutes with at least two hours between sessions. Reiki sessions may be more frequent than twice per day and/or longer than 10 minutes. Self-Reiki sessions should be performed daily for at least 10 minutes but maybe more frequent and/or longer in length. Each family caregiver will receive a copy of the book. The patient and caregiver will wear a Holter monitor continuously for 48 hours beginning when the caregiver(s) are trained in Reiki to measure HRV, a valid measure for stress.
11098630|NCT04086017|No Intervention|Usual care|Patients and caregivers will complete all measures expected of the intervention cohort including daily symptom checklist for 10 days. The patient and caregiver will wear a Holter monitor for the first 48 hours of study participation to measure heart rate variability (HRV), a valid measure for stress. The patient and/or caregiver may opt out of the Holter monitor if requested and still participate in the rest of the study.
11098631|NCT04086004|Experimental|Group I Experimental Motor Imagery|Motor imagery practice
11098632|NCT04086004|Experimental|Group II Dual Task Training|Dual-task balance training
11098633|NCT04085991|Experimental|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses
11098634|NCT04085978||Pre implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2014 - November 30, 2016 who qualify for hypoglycemia protocol
11098796|NCT04084847|Placebo Comparator|placebo|Daily consumption of placebo powder.
11098635|NCT04085978||Post implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2018 - November 30 2018 who qualify for hypoglycemia protocol
11098636|NCT04085965|Experimental|CAMP|Children randomized to CAMP were enrolled in the Boys and Girls Club Camp in one of two low-income Rhode Island communities in summer 2017 or 2018 for 7-weeks in 2017 and 8-weeks in 2018 due to a delayed end to the 2017 school year (i.e. snow days). Camp was offered daily from 8:30 to 4:30.
11098637|NCT04085965|No Intervention|Summer As Usual|Children randomized to the SAU group were asked to experience an unstructured summer as otherwise planned by their parent / guardian. They agreed to not attend structured summer programming (i.e. camp, summer school, or day care) for more than one week over the summer so as to provide an inactive control group for comparison to those in CAMP.
11098638|NCT04085952|Experimental|anterior colporrhaphy with dermal graft|Patients randomized to this arm underwent anterior colporrhaphy with dermal graft augmentation (ARUCS) during their surgery for pelvic organ prolapse.
11098639|NCT04085952|Active Comparator|anterior colporrhaphy suture based|Patients randomized to this arm underwent anterior colporrhaphy with suture based repair (native tissue) during their surgery for pelvic organ prolapse. This is and was the most common practice for anterior colporrhaphy.
11098640|NCT04085926|Experimental|Sealed shoe|"Therapeutic footwear including off-the-shelf therapeutic shoes and custom-made insoles. The shoe on the ulcerated foot is sealed, i.e., made irremovable, with a plastic band."
11098641|NCT04085926|Active Comparator|Total contact cast|A irremovable custom-made total Contact cast enclosing the foot and shin
11098642|NCT04085913|Active Comparator|Current Practice|Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
11098643|NCT04085913|Experimental|Bupivicaine HCL|Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
11098644|NCT04085913|Experimental|Exparel Injection|Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
11098645|NCT04085900||Screening cohort|All participants will be tested for EBV associated biomarkers, including EBNA1/IgA, VCA/IgA, BNLF2b/IgG et al. And in males, EBV-DNA will be tested.Screening positive people will be followed up annually. And screening negative are invited to retest every four year.
11098646|NCT04085887|Experimental|Cohort 1-0.006 Panitumumab-IRDye800|Dose: 0.006 Panitumumab-IRDye800 (mg/kg)
11098647|NCT04085887|Experimental|Cohort 2-0.25 Panitumumab-IRDye800|Dose: 0.25 Panitumumab-IRDye800 (mg/kg)
11098648|NCT04085887|Experimental|Cohort 3-0.50 Panitumumab-IRDye800|Dose: 0.50 Panitumumab-IRDye800 (mg/kg)
11098649|NCT04085887|Experimental|Cohort 4-1.0 Panitumumab-IRDye800|Dose: 1.0 (with max cap dose 50 mg) Panitumumab-IRDye800 (mg/kg)
11098650|NCT04085874|Experimental|FBR group|weekly home visit and monthly group meeting for 12 weeks
11098651|NCT04085874|Active Comparator|non-FBR group|once nutrition counseling from standard health care services
11098652|NCT04085861|Experimental|Dancers|Recruited group of professional dancers from the Norwegian University of dance
11098653|NCT04085861|No Intervention|Control|Recruited group of professional art students from the Oslo Academy of the Arts (Norway)
11098654|NCT04085861|Experimental|Dance teachers|Recruited group of dance teachers from the Norwegian University of dance
11098655|NCT04085848|Experimental|Groupe intervention|Usual care and music therapy
11098656|NCT04085848|No Intervention|Groupe contrôle|Usual care
11098657|NCT04085822|Experimental|Multiple Abdominal Injections|Ten injections per patient: 7 of SMA-001 and 3 of control device.
11098658|NCT04085809|Experimental|Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment|AmLactin® Rapid Relief, BID application for 14 days on left leg and no treatment on right leg
11098659|NCT04085809|Experimental|Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days on right leg and no treatment on left leg
11098660|NCT04085783|Experimental|endometrial PRP|In study group (75 patients), intrauterine infusion of PRP was done 48 hrs. before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5- 1 ml of PRP was infused into the uterine cavity with embryo transfer catheter (Wallace - Smiths, UK). On the other side, No PRP was done in control group. Pregnancy tests were done 12 days after ET.
11098661|NCT04085770|Experimental|Alfacalcidol|Patients allocated to the alfacalcidol group received 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay.
11098662|NCT04085770|No Intervention|Control|Control group were exposed to the same conditions as the treatment group except they were not given one-alfacalcidol.
11098663|NCT04085757|Experimental|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
11098664|NCT04085757|Active Comparator|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
11098665|NCT04085744|No Intervention|control group|In this group any drug will be applied on the cuff of the intubation tube
11098666|NCT04085744|Active Comparator|lidocaine group|10% lidocaine spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
11098667|NCT04085744|Active Comparator|steroid group|mometasone furoate spray will be applied on the cuff of the intubation tube topically and patient will be intubated.
11098668|NCT04085718||Study arm|All included patients will undergo FDGPET/CT scan
11098669|NCT04085705||Patients with diabetic foot ulcers|All patients with diabetic foot ulcers will undergo a PATCH test to determine the prevalence of contact allergies against wound dressings.
11098670|NCT04085692|Experimental|Intervention|"The intervention group begins LDHF dispatcher training with one introduction week followed by twelve weeks of LDHF training.
~During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs."
11098671|NCT04085692|No Intervention|Comparison|During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs.
11098672|NCT04085679||MMU active group|Subjects residing in nursing homes where the MMU care model has already been implemented
11098673|NCT04085679||MMU control group|Subjects residing in nursing homes where the MMU care model has not yet been implemented (ED visits performed in case of urgent clinical situations)
11098674|NCT04085666|Experimental|1st Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
11098675|NCT04085666|Experimental|2nd Confinement Period in Unit|Randomized to treatment with either CDX-6114 or matching Placebo
11098676|NCT04085640|Experimental|Obturator nerve block with Ropivacaine|Obturator nerve block will be performed before general anesthesia as descripted by Nielsen (RAPM, 2019). A linear transducer will be oriented in the transverse plane and placed in the inguinal crease. The tail of the transducer will be tilted distal in order to visualize the pectineus muscle (medial to the femoral vessels) at its insertion at the superior pubic ramus superficial to the external obturator muscle. An 80 mm nerve block needlewill be inserted in-plane from the lateral end of the transducer and advanced until the tip of the needle will be inside the interfascial plane between the pectineus and the obturator externus muscles. 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
11098677|NCT04085640|Sham Comparator|Obturator nerve block with isotonic salin|The same procedure will be performed and 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles
11098678|NCT04085627|Experimental|T Test|Test drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
11098679|NCT04085627|Active Comparator|R Reference|Reference drug(Valsartan / Amlodipine)1 tablet contains Valsartan 80mg& Amlodipine 5mg
11098680|NCT04085614|Experimental|Dynamic Coronary Roadmap group|Patients will be treated via standard of care for PCI with navigation support of Dynamic Coronary Roadmap.
11098681|NCT04085614|Active Comparator|Control group|Patients will be treated via standard of care for PCI without navigation support of Dynamic Coronary Roadmap.
11098682|NCT04085601|No Intervention|Standard of Care (SOC) excluding complement inhibitors|
11098683|NCT04085601|Experimental|1,080mg APL-2 administered subcutaneously twice weekly|
11098684|NCT04085588||Group 1|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.
~Before the skin incision, when sensorial block reached T10 dermatome level 2 μg / kg / min ketamine was started in Group 1. By the end of the operation ketamine infusion was reduced to 1 μg / kg / min."
11098685|NCT04085588||Group 2|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.
~Before the skin incision, when sensorial block reached T10 dermatome level 4 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 2 μg / kg /min and continued."
11098686|NCT04085588||Group 3|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.
~Before the skin incision, when sensorial block reached T10 dermatome level 6 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 3 μg / kg /min and continued."
11098687|NCT04085575|Active Comparator|tranexamic acid - The G1 group|The G1 group received 1 g of intra-articular tranexamic acid (TXA). The G1 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
11098688|NCT04085575|Active Comparator|tranexamic acid - The G2 group|The G2 group received 2 g of intra-articular tranexamic acid (TXA). The G2 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
11098689|NCT04085562|Experimental|Amlodipine|Hypertensive patients on dialysis receiving Amlodipine 5-10 mg tablet daily alone or as part of antihypertensive regimen.
11098690|NCT04085562|Experimental|Bisoprolol|Hypertensive patients on dialysis receiving Bisoprolol 5-10 mg tablet daily alone or as part of antihypertensive regimen.
11098691|NCT04085549|Experimental|Berry Oil Cream|Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
11098692|NCT04085549|No Intervention|Control|Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.
11098693|NCT04085549|Active Comparator|Reference cream|A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
11098694|NCT04085536|Other|Chronic maxillary sinusitis(for more than 12 weeks)|Patients for whom chronic maxillary sinusitis will be diagnosed in the first ENT consultation, will then be seen in a stomatology consultation to determine whether or not a dental cause is objective.
11098695|NCT04085523|Other|TransCon CNP 6 mcg|TransCon CNP 6 mcg CNP/kg or placebo mimicking TransCon CNP 6 mcg delivered once weekly by subcutaneous injection
11098696|NCT04085523|Other|TransCon CNP 20 mcg|TransCon CNP 20 mcg CNP/kg or placebo mimicking TransCon CNP 20 mcg delivered once weekly by subcutaneous injection
11098697|NCT04085523|Other|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
11098698|NCT04085523|Other|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
11098699|NCT04085523|Other|TransCon CNP >100 mcg|TransCon CNP >100 mcg CNP/kg delivered once weekly by subcutaneous injection (to be determined after completion of 100 mcg cohort)
11098700|NCT04085510|Experimental|Contrast-enhanced mammogram|All women will receive both 3D mammography and contrast-enhanced mammography for breast cancer screening; the order of interpretation will vary for each of two radiologists
11098701|NCT04085497|Experimental|Treatment|KT was applied once a week, 6 times in total. Exercises were performed for all patients for 5 weeks 5 days a week, 3 sets 15 repetitions each day.
11098702|NCT04085497|Placebo Comparator|Group 2|The exercise program included quadriceps set exercise, straight leg lifting, mini squat, stretching to hamstring and gastrosoleus muscle groups.
11098703|NCT04085484||Infants born between 1 Feb 2010 and 18 Feb 2012|Infants born between 1 February 2010 and 18 February 2012, before the concentrated PN regime was implemented (Original PN group: n = 81).
11098704|NCT04085484||Infants born between 19 Feb 2012 and 30 Sep 2013|Infants born between 19 February 2012 and 30 September 2013, after the concentrated PN regime was implemented (Concentrated PN group: n = 53).
11098705|NCT04085458|Other|Severe hemophilia A patients|Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.
11098706|NCT04085419|Active Comparator|denosumab|denosumab 60 mg subcutaneously every 6 months
11098707|NCT04085419|Active Comparator|zoledronic acid|zoledronic acid 5 mg intravenously once a year
11098708|NCT04085406|Experimental|Active Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label period) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
11098709|NCT04085406|Sham Comparator|Sham Stimulation|Patients will be randomized in a 1:1 ratio to one of two groups: Active Treatment (active stimulation programmed to the settings found to be optimal during the initial open-label phase) and a Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V).
11098710|NCT04085393|Active Comparator|GERSC for patients receiving highly emetogenic chemotherapy|Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
11098711|NCT04085393|Active Comparator|GERSC on patients receiving moderately emetogenic chemotherapy|Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
11098712|NCT04085367|Placebo Comparator|Vehicle|Two treatments of Day light DLT two weeks apart
11098713|NCT04085367|Active Comparator|Treatment|Two treatments of Day light DLT two weeks apart
11098714|NCT04085354|Placebo Comparator|Placebo|Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
11098715|NCT04085354|Active Comparator|Dapoxetine|Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
11098716|NCT04085354|Active Comparator|Dapoxetine and folic acid.|Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
11098717|NCT04085354|Active Comparator|Dapoxetine and vitamin B12|Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
11098718|NCT04085341|Experimental|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
11098719|NCT04085341|Experimental|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
11098720|NCT04085315|Experimental|Dose Escalation: Cohort 1|Patients will continue to receive osimertinib 80 mg PO daily as part of standard of care therapy during screening and study treatments. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose will be 30 mg twice daily (dose level 1). All patients at a given dose level must complete the DLT period before any additional cohorts can be opened.
11098721|NCT04085302|Experimental|All subjects|
11098722|NCT04085289|Experimental|Galcanezumab|Galcanezumab administered by subcutaneous (SC) injection.
11098723|NCT04085289|Placebo Comparator|Placebo|Placebo administered by SC injection.
11098724|NCT04085276|Experimental|JS001 Plus Nab-Paclitaxel|Patients will receive both JS001 and Nab-Paclitaxel.
11098725|NCT04085276|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Patients will receive both placebo and Nab-Paclitaxel.
11098726|NCT04085263|Sham Comparator|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
11098727|NCT04085263|Experimental|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
11098728|NCT04085250|Experimental|Nivolumab Consolidation|Patients in experimental group will receive Nivolumab consolidation (480 mg) via iv infusion Q4W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
11098729|NCT04085250|Active Comparator|Observation|Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
11098730|NCT04085237|Experimental|Ultrasound-guided continuous ESP block with opioid PCA|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
11098731|NCT04085237|Sham Comparator|Ultrasound-guided sham block and catheter with opioid PCA|The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.
11098732|NCT04085224|Active Comparator|1|
11098733|NCT04085224|Experimental|2|
11098734|NCT04085224|Experimental|3|
11098735|NCT04085211||Inflammatory Bowel Disease|Patients with an established diagnosis of ulcerative colitis or Crohn's Disease who require either a flexible sigmoidoscopy or colonoscopy as part of routine care (e.g. surveillance or staging disease activity)
11098736|NCT04085211||Patients with symptoms of gastro-oesophageal reflux disease|Patients with symptoms of gastro-oesophageal reflux disease requiring a gastroscopy as part of routine clinical care.
11098737|NCT04085211||Atrophic gastritis|Patients with known or suspected atrophic gastritis that require a gastroscopy to either confirm the diagnosis or surveillance for pre-cancerous changes.
11098738|NCT04085211||Neuroendocrine Tumours|Patients with an established history of gastric neuroendocrine tumours requiring surveillance
11098739|NCT04085198|Active Comparator|No-touch technique with the application of light physics rules|This procedure will be performed by the gynecologists who are familiar to the rules of the 'lights physics' and are currently 'lights physics' rules in their clinical practice. The brightness or darkness of the tissue which reflects the distance between the light source and the surrounding tissue will be used to find the correct route from the vagina introitus to the uterine cavity.
11098740|NCT04085198|Placebo Comparator|Control|Patients in this arm of the study protocol will receive standard hysteroscopy with 'no-touch' technique without the utilization of the 'lights physics' rules. The gynecologist performing this procedure will find their route from the vagina introitus to the uterine cavity by the identification of the anatomical structures on their way.
11098741|NCT04085185|Experimental|Phase Ia Dose-Escalation Stage:IBI110|Participants will be treated with escalating doses of IBI110 to determine the MTD.
11098742|NCT04085185|Experimental|Phase Ia Expansion Stage:IBI110|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.
11098743|NCT04085185|Experimental|Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab|Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.
11098744|NCT04085185|Experimental|Phase Ib Expansion Stage:IBI110+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.
11098745|NCT04085172|Experimental|Part A: Guanfacine hydrochloride (SPD503)|Participants randomized to SPD503 will receive initial dose of 1 milligram (mg), and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg SPD503 oral tablet once daily (QD) for 52 weeks.
11098746|NCT04085172|Active Comparator|Part A: Atomoxetine hydrochloride|Participants who weigh less than (<) 70 kilograms (kg) at baseline will receive active Atomoxetine hydrochloride capsule orally at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg oral capsule QD during the treatment of 52 weeks. Permitted doses of Atomoxetine hydrochloride capsule will be 10, 18, 25, 40, 60, and 80 mg QD. Participants who weigh >= 70 kg at baseline will receive Atomoxetine hydrochloride at an initial dose of 40 mg oral capsule QD which may be increased to 80 mg and then to 100 mg for 52 weeks. The total dose for participants who weigh >= 70 kg at baseline will not exceed 100 mg.
11098747|NCT04085172|Placebo Comparator|Part A: Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg tablet of placebo matched to SPD503 and aged 13 to 17 years will receive 5 to 7 mg tablets of placebo matched to SPD503 orally QD for first 18 weeks. Participants who weigh < 70 kg at baseline will receive placebo matched to Atomoxetine hydrochloride oral capsule at an initial dose of 0.5 mg/kg which may be increased to the target dose of 1.2 mg/kg QD oral capsule during the treatment of first 18 weeks. Permitted doses of placebo matched to Atomoxetine hydrochloride will be 10, 18, 25, 40, 60, and 80 mg QD and participants who weigh >= 70 kg will receive placebo matched to Atomoxetine hydrochloride at an initial dose of 40 mg QD capsule orally which may be increased to 80 mg and then to 100 mg.
11098748|NCT04085172|Experimental|Part B: Guanfacine hydrochloride (SPD503)|Participants from Part A roll over into Part B, where participants received placebo in Part A will roll over after first 18 weeks and participants received SPD503 or atomoxetine will roll over after 52 weeks of Part A. During Part B all the participants will receive SPD503 at an initial dose of 1 mg, and up titrated with weekly incremental dose of 1 mg until an optimal dose is reached. Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive 5 to 7 mg SPD503 oral tablet QD for 52 weeks of Part B.
11098749|NCT04085159|Experimental|CART/CTL/DCvac cells to treat cancer|
11098750|NCT04085146|Experimental|Optimal PEEP|Individualized optimal PEEP will be provided during the laparoscopic period of surgery. Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
11098751|NCT04085146|Active Comparator|Conventional PEEP|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
11098752|NCT04085120|Experimental|Ropivacaine/dexamethasone group|3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.
11098753|NCT04085120|Experimental|10% lignocaine injection group|4 ml of 10% lignocaine
11098754|NCT04085107||243 PwMCI|
11098755|NCT04085094||1. Healthy and pre-menopausal women without CKD|"A total of 45 healthy and pre-menopausal women (<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.
~Three visits will take place:
~V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.
~V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated
~V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).
~The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion."
11098756|NCT04085094||2. Pre-menopausal women with CKD|A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
11098757|NCT04085094||3. Post-menopausal women without CKD|Fifteen post-menopausal women will undergo the same exams as outlined above
11098758|NCT04085094||4. Healthy men|A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
11098759|NCT04085094||5.Men with CKD|Fifteen men with CKD will undergo the same exams as outlined above
11098760|NCT04085081|Experimental|Supportive care (coaching call, motivational messages)|Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
11098761|NCT04085068||Study group (group A):|15 women take cranioscaral treatment
11098762|NCT04085068||control group (group B):|shame group
11098763|NCT04085055|Active Comparator|22 Gauge FNB Needle - ProCore|The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
11098764|NCT04085055|Active Comparator|22 Gauge FNB Needle - Acquire|The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
11098765|NCT04085055|Active Comparator|22 Gauge FNB Needle - SharkCore|The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
11098766|NCT04085055|Active Comparator|22 Gauge FNB needle - EZ Shot 3 Plus|The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
11098767|NCT04085042|No Intervention|Usual Care|Usual care during peripheral venous catheterization. Nurses will continue with the normal routine practice, by preparing all needed material individually.
11098768|NCT04085042|Experimental|PIVC pack|Nurses will use a sterile pack that includes all needed devices for peripheral intravenous catheterization according to the latest evidence (eg, cannula, swabs, disposable tourniquet, antiseptic).
11098769|NCT04085016||meibography of statin group|patients with regular HMG CoA reductase inhibitor (statin) treatment
11098770|NCT04085016||meibography of non-statin group|patients with recently diagnosed dyslipidemia who were eligible to undergo 3 to 6 months of lifestyle interventions before re-evaluation for starting statin therapy
11098771|NCT04085003||Intact abdominal aortic aneurysm|
11098772|NCT04085003||Ruptured abdominal aortic aneurysm|
11098773|NCT04084990|Experimental|aPAP|Nightly use of aPAP when sleeping through the date of delivery
11098774|NCT04084990|No Intervention|No aPAP|No use of aPAP (standard of care)
11098775|NCT04084977||Sydenam Chorea (SC)|individuals with SC
11098776|NCT04084977||tonsilitis|children with tonsilitis in the past 3 months
11098777|NCT04084977||control|children wit no tonsilitis
11098778|NCT04084964|Experimental|Study group|These patients receive the home-hospitalisation platform
11098779|NCT04084951|Experimental|Dose escalation of SQZ-PBMC-HPV|In the monotherapy escalation cohorts, SQZ-PBMC-HPV is administered every 3 weeks for up to a year as a low and a high cell dose. In addition, a second high dose cell cohort will test the impact of a double-prime regimen where SQZ-PBMC-HPV is administered on two consecutive days followed by doses every 3 weeks for a maximum of a year.
11098780|NCT04084951|Experimental|Dose escalation of SQZ-PBMC-HPV + atezolizumab|In the combination escalation cohorts, SQZ-PBMC-HPV in combination with atezolizumab is given for up to a year at intervals of 3 weeks as a low and a high cell dose. In addition, a second high dose cell dose cohort will test the impact of a double-prime regimen of SQZ-PBMC-HPV given in combination with atezolizumab. Participants may continue to receive atezolizumab study drug every 3 weeks for a maximum of 1 year or until discontinuation criteria are met.
11098781|NCT04084938|Active Comparator|Prostate operation|You will have a surgery to remove the prostate gland. The surgery will be done during general anesthesia. If your prostate gland is small the surgery will be done through a catheter into the penis. If your prostate gland is large the surgery will be through an incision in your lower abdomen.
11098782|NCT04084938|Active Comparator|Prostate artery embolization|The embolization is done in the Department of Radiology. There will be placement of a catheter into the artery in one of the groins during local anesthesia. Through this catheter small particles will be injected into the arteries of the prostate gland. When finished, the hole in the artery will be closed.
11098783|NCT04084925||Diabetics with NAFLD|Diabetics whose abdominal ultrasound showed that they have NAFLD
11098784|NCT04084925||Diabetics without NAFLD|Diabetics whose abdominal ultrasound showed that they do not have NAFLD
11098785|NCT04084912|Active Comparator|Dexamethasone group|this group will receive one ampoule Intravenous injection of Dexamethasone Sodium Phosphate 2 ml . 8 mg once by the anesthesiologist immediately before skin incision
11098786|NCT04084912|Placebo Comparator|Placebo group|this group will receive one ampoule Intravenous injection of Saline once by the anesthesiologist immediately before skin incision
11098787|NCT04084899||Continuous Positive Airway Pressure|Patient treated with continuous positive airway pressure
11098788|NCT04084873|Experimental|Experimental PBrE|Participants are exposed to several words of emotional contents (positive, and negative). The differences between these words will allow the regulation and counter regulation of emotional processes (Schwager y Rothermund, 2013). The words are related to clinical and personal characteristics of the patients and they will promote an emotional identification that improve the emotional regulation (Kashdan, Barret y McKnight, 2015).
11098789|NCT04084873|Placebo Comparator|Control PBrE|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
11098790|NCT04084873|Other|Control|Participants do not receive the intervention.
11098791|NCT04084860|Experimental|CI-581a + MET/MBRP|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
11098792|NCT04084860|Experimental|CI-581a + Medication Management|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment ( no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
11098793|NCT04084860|Active Comparator|CI-581b + MET/MBRP|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
11098794|NCT04084860|Active Comparator|CI-581b + Medication Management|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
11098797|NCT04084834|Experimental|Intervention group|Participants allocated to the intervention group will be familiarized with exercise intensity levels (heart rate and Borg RPE) during the assessment at Diakonhjemmet Hospital. Further, the patients will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital. Thereafter, the participants will get access to a web-based exercise program and guided to choose the appropriate exercise-level. Weekly, based on the individual progression, all participants will receive an exercise program by email consisting of individually tailored exercise sessions and motivational messages. At the end of each week, the participants complete an electronic exercise diary for monitoring adherence. All participants will be offered the possibility to seek peer-support; however, if preferred they may also follow the exercise program by themselves.
11098798|NCT04084808|Experimental|Maple Syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
11098799|NCT04084808|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
11098800|NCT04084808|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
11098801|NCT04084808|Active Comparator|Sports drink|A commercial sports drink of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
11098802|NCT04084808|Placebo Comparator|Water|A solution containing stevia (sugar substitute) labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
11098803|NCT04084795|Active Comparator|EMDR plus MtCS|MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
11098804|NCT04084795|Placebo Comparator|EMDR plus sham-MtCS|Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
11098805|NCT04084795|No Intervention|Treatment as Usual|Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry. The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
11098806|NCT04084782||Onychomycosis group|Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
11098807|NCT04084769|Experimental|Group 1: MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection at Day 0 in participants who received a prior dose of MenACYW conjugate vaccine 3-6 years earlier
11098808|NCT04084769|Experimental|Group 2: MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection at Day 0 in participants who received a prior dose of Menveo® 3-6 years earlier
11098809|NCT04084769|Experimental|Group 3: MenACYW conjugate vaccine + Trumenba®|MenACYW conjugate vaccine single injection + Trumenba single injection at Day 0 in participants who received a prior dose of MenACYW conjugate vaccine 3-6 years earlier
11098810|NCT04084769|Experimental|Group 4: MenACYW conjugate vaccine + Bexsero®|MenACYW conjugate vaccine single injection + Bexsero single injection at Day 0 n participants who received a prior dose of MenACYW conjugate vaccine 3-6 years earlier
11098811|NCT04084756|Experimental|Couples Crisis Response Plan|
11098812|NCT04084756|Active Comparator|Mental Health Education|
11098813|NCT04084743|Experimental|Virtual reality training and Dual task intervention|Cognitive and motor Dual-task intervention and virtual reality training intervention in patients with Parkinson's disease
11098814|NCT04084743|Active Comparator|Conventional physiotherapy and Dual task intervention|The dual-task intervention without virtual reality training intervention in patients with Parkinson's disease
11098815|NCT04084730|Experimental|Participants with Breast Cancer|Participants will have unicentric pathological stage I invasive ductal breast cancer or Grade 1 or 2 DCIS measuring <3cm in longest diameter on pathology and/or mammogram that is histologically confirmed at MSKCC.
11098816|NCT04084717|Experimental|ROS1 Rearrangement|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
11098817|NCT04084717|Experimental|MET-activating Mutation (exon 14)|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
11098818|NCT04084717|Experimental|MET-amplification|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
11098819|NCT04084704|Other|Cingal injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
11098820|NCT04084691|Experimental|Single Arm|Every patient will undergo every combination of physical exercise/meal type (3x3 combinations), one following the other. Each combination is replicated three times.
11098821|NCT04084678|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose (maximum dose of 1400 mcg)
11098822|NCT04084678|Placebo Comparator|Placebo|Matching placebo tablets (oral)
11098823|NCT04084665|Experimental|Intervention|Guselkumab 200mg q4 weekly
11098824|NCT04084652|Experimental|Mycoprotein|Mycoprotein in its full food matrix
11098825|NCT04084652|Experimental|Protein Isolated from Mycoprotein|Protein from mycoprotein isolated from the food matrix
11098826|NCT04084639|Experimental|Ingestion of 20g Mycoprotein Drink|Milkshake containing 20g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
11098827|NCT04084639|Experimental|Ingestion of 40g Mycoprotein Drink|Milkshake containing 40g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
11098828|NCT04084639|Placebo Comparator|Ingestion of Isocaloric Control Drink|Milkshake containing 250ml full-fat milk, 50g glucose, 19g dried skim milk and 9g full-fat dried milk
11098829|NCT04084626|Experimental|PD-1 antibody|PD-1 antibody and lenalidomide administered in 2 week cycles for 6 cycles.
11098830|NCT04084613||Patients with uncontrolled severe eosinophilic asthma|Asthmatic patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants.
11098831|NCT04084600|Experimental|Intervention Group|Once a week for 6 consecutive weeks, this group will receive a manual therapy protocol with an approach based on Taylor et al., 1990; Schleip et al., 2012; Bienfait, 1999 and Myers, 2016, lasting 20 minutes, focused on the upper quadrant homolateral to the surgery. Shortly thereafter, this group will participate in a kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
11098832|NCT04084600|Sham Comparator|Sham Group|Once a week for 6 consecutive weeks, this group will receive a soft and shallow traditional massage, lasting 20 minutes. Shortly thereafter, this group will participate to the same kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
11098833|NCT04084587|Experimental|Treated Group|"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.
~Exams performed before and after treatment:
~BCVA (ETDRS)
~Reading speed (MNREAD)
~Contrast sensitivity (Pelli-Robson)
~Microperimetry and analysis of fixation (OCT-SLO OPTOS)
~QoL (VFQ-25)"
11098834|NCT04084587|No Intervention|Control Group|"Group B: 9 patients control group without rehabilitation.
~Exams performed twice, at the same time interval elapsed for the treated group:
~BCVA (ETDRS)
~Reading speed (MNREAD)
~Contrast sensitivity (Pelli-Robson)
~QoL (VFQ-25)"
11098835|NCT04084574|Experimental|Behavioral Diet Counseling|Groups of 4-6 participants will attend 12 weekly dietitian-led counseling sessions and receive coaching on practical strategies to enhance DASH diet adherence and reduce daily sodium intake.
11098836|NCT04084574|Other|Standard of Care|Participants will meet one-on-one with the study dietitian for a single 30- minute encounter and be advised to limit daily sodium intake per current clinical practice guidelines for hypertension in patients with CKD. Educational handouts and tip sheets about practical strategies to reduce dietary sodium will be distributed.
11098837|NCT04084561|Experimental|HRHA|High Risk, High Ancestry
11098838|NCT04084561|Experimental|LRLA|Low Risk, Low Ancestry
11098839|NCT04084561|Experimental|HRLA|High Risk, Low Ancestry
11098840|NCT04084561|Experimental|LRHA|Low Risk, High Ancestry
11098841|NCT04084548|Experimental|Lidocaine and placebo|Lidocaine and placebo
11098842|NCT04084548|Experimental|Ketamine and placebo|Ketamine and placebo
11098843|NCT04084548|Experimental|Lidocaine and ketamine|Lidocaine and ketamine
11098844|NCT04084548|Placebo Comparator|Placebo and placebo|Placebo and placebo
11098845|NCT04084535|Active Comparator|High intensity interval training|It will apply a HIIT program for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
11098846|NCT04084535|Active Comparator|Inspiratory muscle training|It will apply an inspiratory muscle training for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
11098847|NCT04084522|Placebo Comparator|Standard Treatment Group|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40 kcal. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30% from fat, a fixed amount of 50g of oil would be given and the remaining amount of fat would be met by the invisible dietary fat. The source of visible dietary fat would be refined soyabean oil. This group would not receive any fat in the form of Desi ghee or butter or any nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
11098848|NCT04084522|Active Comparator|Intervention Arm|In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40kcal and 1.2-1.5gm protein per kg ideal body weight per day. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30-35% from fat, a fixed amount of 50g of ghee would be given in 3 divided doses of 30 ml to be taken raw, 20 ml to be used for cooking and the remaining amount of fat would be met by the invisible dietary fat. The source of visible fat would be exclusively Desi ghee. This group would not receive any fat in the form of butter or any other oil or any other nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
11098849|NCT04084509||Healthy Controls|
11098850|NCT04084509||Idiopathic Parkinson's Disease|
11098851|NCT04084509||Symptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
11098852|NCT04084509||Asymptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
11098853|NCT04084496|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
11098854|NCT04084483|Experimental|Group 1|K-161 Ophthalmic Solution Dose A.
11098855|NCT04084483|Experimental|Group 2|K-161 Ophthalmic Solution Dose B.
11098856|NCT04084483|Experimental|Group 3|K-161 Ophthalmic Solution Dose C.
11098857|NCT04084483|Placebo Comparator|Group 4|Vehicle Solution Dose.
11098858|NCT04084470|Active Comparator|Bread types 1 & 2|Daily consumption of 5 slices of allocated bread type for 3 consecutive days.
11098859|NCT04084470|Active Comparator|Bread types 3 & 4|Daily consumption of 5 slices of allocated bread type for 3 consecutive days.
11098860|NCT04084470|Active Comparator|Bread types 5 & 6|Daily consumption of 5 slices of allocated bread type for 3 consecutive days.
11098862|NCT04084457|Active Comparator|Wild Blueberry Powder|Formulation of a 100% blueberry (freeze-dried whole fruit) drink
11098863|NCT04084444|Experimental|T8 tablet 0.5mg|Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week
11098864|NCT04084444|Experimental|T8 tablet 1mg|Oral T8 tablet with HARRT, 1mg, once daily for 48 week
11098865|NCT04084444|Placebo Comparator|Placebo|Oral Placebo with HARRT, once daily for 48 week
11098866|NCT04084431|Active Comparator|WBRT (10 x 2 Gy) + OSC|Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
11098867|NCT04084431|Experimental|Optimal Supportive Care (OSC) alone|Symptomatic treatment including steroids, pain medication, nutritional support, etc
11098868|NCT04084418|Experimental|Control diet followed by VLCHF diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet
~Phase 2 (6 weeks): Control diet (50% of energy from carbohydrates)
~Phase 3 (4 weeks): Washout period
~Phase 4 (6 weeks): VLCHF diet (10% of energy from carbohydrates)"
11098869|NCT04084418|Experimental|VLCHF diet followed by Control diet|"Phase 1 (1 to 3 weeks): Insulin dose optimization with usual diet
~Phase 2 (6 weeks): VLCHF diet (10% of energy from carbohydrates)
~Phase 3 (4 weeks): Washout period
~Phase 4 (6 weeks): Control diet (50% of energy from carbohydrates)"
11098870|NCT04084405|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
11098871|NCT04084405|Active Comparator|Control group|aerobic exercice
11098872|NCT04084392|Active Comparator|Usual Care|Participants randomized to this arm will receive care as usual.
11098873|NCT04084392|Active Comparator|Bridge Clinic|Participants randomized to this arm will be referred to the Bridge Clinic to facilitate identification and referral to an outpatient provider for addiction treatment.
11098874|NCT04084366|Experimental|OBI-999 Escalation phase|Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
11098875|NCT04084366|Experimental|OBI-999 Expansion Phase|Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
11098876|NCT04084353||Delivered women|Maternal and perinatal outcomes will be collected prospectively on all patients that deliver in Government Medical College (GMC) Hospital before, during and after the training over the study period (8 months) in order to evaluate the impact of the training.
11098877|NCT04084340|Experimental|Anodal tDCS + Exercises therapies|"Real transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes, 2mA"
11098878|NCT04084340|Sham Comparator|Sham tDCS + Exercises therapies|"Sham transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes (30 seconds ON), 2mA"
11098879|NCT04084314|Experimental|Erenumab|70 mg and 140 mg Erenumab
11098880|NCT04084301|No Intervention|Normal CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.4 L/min/m2 throughout the CPB period.
11098881|NCT04084301|Experimental|High CPB flow|In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.9 L/min/m2 throughout the CPB period.
11098882|NCT04084288|Experimental|Postoperative Acupuncture|"Neuraxial anesthesia (spinal or combined spinal epidural (CSE) with up to 4cc mepivacaine 1.5%) and 2 blocks for postoperative pain (IPACK and adductor canal peripheral nerve blocks). Sedation will be provided. Tranexemic acid (TXA) will be dosed per surgeon request.
~A certified medical acupuncturist will perform ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed. If an epidural is placed, it may be redosed with lidocaine as needed (up to 100mg total) and will be removed prior to transfer to the recovery room.
~A periarticular injection (PAI) will be placed by the surgeon during the surgery (timing at the discretion of the surgeon)"
11098883|NCT04084275|Experimental|experimental group|Levine's conservation model was used as the theoretical framework for this study. A literature review was used to determine the contents of the intervention program. A nursing care program which consisted of 8 sessions, the first of which was at the hospital and the others at the homes of puerpera and which were held at different times and lasted 12 weeks in total, based on Levine's Conservation Model was provided to the women in the intervention group. Each session lasted approximately 60-120 minutes, according to the educational and practical contents.The puerpera were given trainings on different subjects based on the module during each session. For these trainings, the investigators prepared, in the light of the literature data, leaflets containing information about breastfeeding, personal hygiene, fatigue, nutrition and pilates exercises
11098884|NCT04084275|No Intervention|control group|The puerpera in the control group received only the standard nursing care given after birth. Standard nursing care contain solely breastfeeding training. The puerpera in the control group were visited before they were discharged from the hospital to obtain their contact information and to administer them the pretest. A home visit at the end of postpartum month 3 was also planned and they were administered the posttest. After collecting the posttest data, the trainings given to the women in the intervention group on nutrition, sleep, fatigue and pilates exercises were also given to the women in the control group in consideration of the ethical dimension of the study; they were actively trained on pilates exercises by the investigator and the relevant leaflets were given to them by the end of their trainings.
11098885|NCT04084262||All Study Participants|Phantom® Intramedullary Nail combined with a supinating reduction technique
11098886|NCT04084249|Experimental|ctDNA guided surveillance|ctDNA analysis will be performed every 4 months postoperatively (4, 8, 12, 16, 20 and 24). At time of first positive ctDNA, patients undergo a whole-body FDG-PET/CT-scan for radiological assessment and a colonoscopy. If the initial assessment is without evidence of recurrence, patients will be offered high-intensive radiological surveillance with FDG-PET/CT-scans every 3 months, until recurrence detection or 21 months has passed. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C). At every FDG-PET/CT-scans the patients also complete the FCRI questionnaire.
11098918|NCT04084067|Experimental|Indocyanine green (ICG)|Participants will receive a single dose of 1.5 mg/kg of ICG intravenously over 15 minutes prior to surgery.
11098919|NCT04084041|Experimental|Device|Device group
11098920|NCT04084041|Active Comparator|Conventional chest physiotherapy|Control group
11098887|NCT04084249|No Intervention|Standard Danish follow-up program|Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At months 4, 12, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
11098888|NCT04084236|Active Comparator|Active TENS|
11098889|NCT04084236|Sham Comparator|Sham TENS|
11098890|NCT04084223|Experimental|Active RA patients group|"64 active RA patients (DAS28>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2) with an inadequate response to methotrexate (MTX) starting a treatment with JAKi (tofacitinib ou baricitinib) will be evaluated at baseline, 1, 3 and 6 months in 5 centres.
~A clinical joint assessment will be performed and CRP will be tested to calculate DAS28-CRP. Several PROs will be completed: RAPID3, HAQ, pain, and patient global assessment of disease activity on a VAS.
~An US exam on 40 joints and 12 tendons will be performed by an independent investigator, looking for synovitis and tenosynovitis with B-Mode and Power Doppler. A Global US score (GLOESS) will be collected at each visit."
11098891|NCT04084210|Active Comparator|Juul + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
11098892|NCT04084210|Active Comparator|Juul + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given Juul e-cigarettes for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
11098893|NCT04084210|Active Comparator|VLNC + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
11098894|NCT04084210|Active Comparator|VLNC + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given very low nicotine cigarettes (VLNCs) for four weeks; in Switch Week 1, participants also will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
11098895|NCT04084210|Other|No Product + Active Patch in Wk 1 and Placebo Patch in Wk 2|Participants will be given no alternative nicotine delivery products but in Switch Week 1, participants will use active nicotine patches; in Switch Week 2, participants will use placebo patches.
11098896|NCT04084210|Other|No Product + Placebo Patch in Wk 1 and Active Patch in Wk 2|Participants will be given no alternative nicotine delivery products for two weeks but in Switch Week 1 participants will use placebo patches; in Switch Week 2, participants will use active nicotine patches.
11098897|NCT04084197|Experimental|Sequence 1|Period 1 : Fasted state + HIP1402, Period 2 : Fasted state + HIP1801
11098898|NCT04084197|Experimental|Sequence 2|Period 1 : Fasted state + HIP1801, Period 2 : Fasted state + HIP1402
11098899|NCT04084197|Experimental|Sequence 3|High fat diet + HIP1402, Period 2 : High fat diet + HIP1801
11098900|NCT04084197|Experimental|Sequence 4|High fat diet + HIP1801, Period 2 : High fat diet + HIP1402
11098901|NCT04084184|Experimental|Sequence 1|Period 1 : Fasted state + HGP1812, Period 2 : Fasted state + HGP1602
11098902|NCT04084184|Experimental|Sequence 2|Period 1 :Fasted state + HGP1602, Period 2 : Fasted state + HGP1812
11098903|NCT04084171|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia.
11098904|NCT04084158|Experimental|Triprizumab+chemoradiation|"Induction immunotherapy: Triprizumab (JS001) 3mg/kg IV q 14 days x 2 cycles.
~Concurrent Chemoradiotherapy: Starting within 4 weeks after the first cycle induction immunotherapy. carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or paclitaxel liposome 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.
~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation and adjuvant therapy.
~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles.
~Adjuvant immunotherapy: Triprizumab (JS001) 3mg/kg IV q 14 days up to 1 year."
11098905|NCT04084158|Active Comparator|chemoradiation|"Concurrent Chemoradiotherapy: carboplatin AUC = 2 + albumin-bound paclitaxel 60 mg/m2 or Liposome paclitaxel 45 mg/m2 or paclitaxel 45 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 50.4 Gy given in 1.8 Gy fractions daily x 28 fractions.
~Progression of disease (PD): The progress of the disease will be assessed within 4 weeks after concurrent chemoradiotherapy. Patients without disease progression continue to receive consolidation therapy.
~Consolidation chemotherapy: carboplatin AUC = 6 + albumin-bound paclitaxel 260 mg/m2 or paclitaxel liposome 135 mg/m2 or paclitaxel 135 mg/m2 IV q 21 days x 6 cycles."
11098906|NCT04084145||CKD|Chronic Kidney Disease stage 1 - 4 followed up in secondary care
11098907|NCT04084132|Experimental|Early re-valving|60 patients who are assigned to early re-valving undergo pulmonary valve replacement within 3 months from randomization.
11098908|NCT04084132|Experimental|Later re-valving|60 patients who are assigned to later re-valving undergo pulmonary valve replacement when the current European guideline criteria are met.
11098909|NCT04084119|Experimental|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
11098910|NCT04084119|Active Comparator|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
11098911|NCT04084106|Experimental|phenoximethylpenicillin|phenoximethylpenicillin, tablet, 1 g 3 times daily for 5 days.
11098912|NCT04084106|Active Comparator|amoxicillin|amoxicillin, tablet, 500 mg 3 times daily for 5 days.
11098913|NCT04084106|Active Comparator|amoxicillin-clavulanic acid|amoxicillin-clavulanic acid tablet, 500/125 mg 3 times daily for 5 days.
11098914|NCT04084106|No Intervention|No intervention|No intervention
11098915|NCT04084093|Experimental|Surfactant Gel|
11098916|NCT04084080|Experimental|Exchange transfusion plus standard of care|Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
11098917|NCT04084080|Active Comparator|Standard of care|Randomized to standard of care
11098921|NCT04084028|Experimental|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.
~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
11098922|NCT04084028|Active Comparator|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
11098923|NCT04084028|Active Comparator|Demonstration classes + meal kits and recipes|Participants attend a weekly 2-hour cooking demonstration to learn how to prepare the same meals as in other groups. Students will sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Students will bring this timeline to class and discuss as a group before preparing the meal or watching the demonstration. At the conclusion of 6 weeks, students will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
11098924|NCT04084028|Placebo Comparator|Demonstration classes only|Participants will receive the same 2-hour cooking demonstration as in the other demonstration arm, but there is no further intervention after 6 weeks of cooking demos.
11098925|NCT04084015|Experimental|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
11098926|NCT04084002||Patients with subacute chronic stroke|Patients with subacute chronic stroke
11098927|NCT04084002||Control group|Healthy control group age and sex matched
11098928|NCT04083989||Multimodal treatment for AN|Adolescent patients with AN attending an integrative medicine-based inpatient treatment program
11098929|NCT04083989||Healthy controls|Healthy volunteers assessed once to collect comparative data
11098930|NCT04083976|Experimental|Erdafitinib|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, or decision by the investigator to discontinue treatment.
11098931|NCT04083963|Other|Single arm|Low dose weekly carboplatin in combination with standard neoadjuvant chemotherapy
11098932|NCT04083950|Experimental|Single group|All participants will receive the vaccine and aspirin.
11098933|NCT04083937|Active Comparator|70.0/ 2.0 Gray (RBE)|Normofractionated radiotherapy with photons (70.0/ 2.0 Gray)
11098934|NCT04083937|Experimental|57.0/ 3.0 Gray (RBE)|Hypofractionated radiotherapy with photons (57.0/ 3.0 Gray)
11098935|NCT04083937|Experimental|57.0/ 3.0 (RBE)|Hypofractionated radiotherapy with protons (57.0/ 3.0 Gray relative biological effectiveness [RBE]).
11098936|NCT04083924|Experimental|Basic cardiac ultrasound training|Single group education intervention study. No control group. Pre-post educational outcomes only.
11098937|NCT04083911|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.
11098938|NCT04083898|Experimental|Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
11098939|NCT04083898|Experimental|Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
11098940|NCT04083898|Experimental|Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
11098941|NCT04083898|Experimental|Phase II: Isatuximab + Bendamustine + Prednisone|-Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.
11098942|NCT04083885|Experimental|Virtual Reality|Participants receive 8 weeks of home-based or facility-based virtual reality training, supervised remotely and asynchronously, in addition to their Extra-Mural (homecare) rehabilitation.
11098943|NCT04083885|No Intervention|Usual Care|Participants receive their usual Extra-Mural (homecare) rehabilitation.
11098944|NCT04083872|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug"
11098945|NCT04083872|Experimental|Group 2|"Period 1: Test drug
~Period 2: Reference drug"
11098946|NCT04083859|Experimental|mPATH-Lung|Participants randomized to the mPATH arm will complete a self-survey and a brief video decision aid, and then invites them to estimate their personal risks and benefits of screening by completing 8 survey items needed to calculate their predicted risk of developing lung cancer based on the validated Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Model 2012.
11098947|NCT04083859|Placebo Comparator|Usual care (CONTROL)|Participants randomized to the control arm will see an animated video about exercise for lung health based on recommendations from the European Lung Foundation. They will not be offered the opportunity to estimate their predicted benefits and harms of screening or to request a lung cancer screening visit.
11098948|NCT04083846|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug 1
~Period 3: Test drug 2"
11098949|NCT04083846|Experimental|Group 2|"Period 1: Test drug 2
~Period 2: Reference drug
~Period 3: Test drug 1"
11098950|NCT04083846|Experimental|Group 3|"Period 1: Test drug 1
~Period 2: Test drug 2
~Period 3: Reference drug"
11098951|NCT04083846|Experimental|Group 4|"Period 1: Test drug 2
~Period 2: Test drug 1
~Period 3: Reference drug"
11098952|NCT04083846|Experimental|Group 5|"Period 1: Test drug 1
~Period 2: Reference drug
~Period 3: Test drug 2"
11098953|NCT04083846|Experimental|Group 6|"Period 1: Reference drug
~Period 2: Test drug 2
~Period 3: Test drug 1"
11098954|NCT04083833|Experimental|Treatment Arm|(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)
11098955|NCT04083833|Placebo Comparator|Control|"Treatment D:
~(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo
~Treatment E:
~(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin
~Treatment F:
~(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo
~Treatment G:
~(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin
~Treatment H:
~(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo
~Treatment I:
~(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin"
11098956|NCT04083820||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
11098957|NCT04083807|Experimental|TISSEEL Lyo|Applied once intra-operatively to the study suture line using the DUPLOJECT Fibrin Sealant Preparation and Application System.
11098958|NCT04083807|Active Comparator|Manual compression with surgical gauze pads|Treated once intraoperatively with manual compression using surgical gauze pads at the study suture line.
11098959|NCT04083794|Other|Laboratory based assessments|The current study has no arms; it is a cross-sectional assessment where all participants will undergo the same procedures.
11098960|NCT04083781|Experimental|Arm 1: No prophylaxis|Haemophilia A with inhibitors (HAwI) and haemophilia B with inhibitors (HBwI) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension part, patients in arm 1 will receive daily concizumab subcutaneous (s.c., under the skin) injections.
11098961|NCT04083781|Experimental|Arm 2: Concizumab prophylaxis|HAwI and HBwI patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
11098962|NCT04083781|Experimental|Arm 3: Concizumab prophylaxis|The HAwI and HBwI patients enrolled into the concizumab phase 2 trial (NN7415-4310) at time of transfer will be offered enrolment into this trial. It is required that these patients are on concizumab prophylaxis up until enrolment into the trial. These patients will continue concizumab prophylaxis.
11098963|NCT04083781|Experimental|Arm 4: Concizumab prophylaxis|Patients previously on prophylaxis with by-passing agents and on-demand patients who are screened at a timepoint where the required number of patients in arms 1 and 2 have been randomised. These patients will, if eligible, be enrolled into the trial and will initiate concizumab prophylaxis at visit 2a (week 0).
11098964|NCT04083768|Placebo Comparator|Supine group|After the patient completes the spinal anesthesia, the cesarean section is completed in the supine position.
11098965|NCT04083768|Active Comparator|15° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 15°, and the cesarean section was completed using the supine position after the skin was cut.
11098966|NCT04083768|Active Comparator|30° group|After the patient completed the spinal anesthesia, the preoperative preparation (about 10 minutes) was completed with a left tilt of 30°, and the cesarean section was completed using the supine position after the skin was cut.
11098967|NCT04083755|Active Comparator|Line A|One dose of Ferric carboxymaltose (1000mg) intravenous. Duration of administration 15 minutes.
11098968|NCT04083755|Other|Line B|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
11098969|NCT04083729|Active Comparator|Patients with persistent pulmonary hypertension|Patients with persistent pulmonary hypertension after balloon mitral comisseruotomy
11098970|NCT04083729|Active Comparator|Patients without persistent pulmonary hypertension|Patients without persistent pulmonary hypertension after balloon mitral comisseruotomy
11098971|NCT04083716|Experimental|Group 1|ABI-H2158 Reference Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation after a high-fat meal on Day 15 (Period 3)
11098972|NCT04083716|Experimental|Group 2|ABI-H2158 Test Formulation in a fasting state on Day 1 (Period 1), then ABI-H2158 Test Formulation after a high-fat meal on Day 8 (Period 2), then ABI-H2158 Reference Formulation in a fasting state on Day 15 (Period 3)
11098973|NCT04083716|Experimental|Group 3|ABI-H2158 Test Formulation after a high-fat meal on Day 1 (Period 1), then ABI-H2158 Reference Formulation in a fasting state on Day 8 (Period 2), then ABI-H2158 Test Formulation in a fasting state on Day 15 (Period 3)
11098974|NCT04083703|Experimental|Simple lumbar discectomy|
11098975|NCT04083703|Experimental|Lumbar discectomy with inter vertebral cage|
11098976|NCT04083690|Active Comparator|Standard CRT Programming, then ECG CRT Optimization|The control arm patients will have standard CRT programming for the first 6 months, and then will be reprogrammed based on the ECG CRT optimization information for the following 6 months
11098977|NCT04083690|Experimental|ECG CRT Optimization|The experimental arm patients will have CRT device reprogrammed based on the ECG CRT optimization information for 12 months.
11098978|NCT04083677||Control GROUP|healthy adult fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
11098979|NCT04083677||trauma GROUP|trauma patients fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
11098980|NCT04083664||Control healthy subjects without anemia.|"Adults > 18 years.
~Age and sex matched.
~No active infection or inflammation."
11098981|NCT04083664||ESRD with Hgb <11 g/dl.|"Adults > 18 years.
~ESRD patients on regular hemodialysis.
~Hgb < 11g/dl.
~No apparent infection or inflammation."
11098982|NCT04083664||ESRD with Hgb ≥ 11 g/dl|"Adults > 18 years.
~ESRD patients on regular hemodialysis.
~Hgb ≥ 11g/dl.
~No apparent infection or inflammation."
11098983|NCT04083651|Experimental|Methylnaltrexone Bromide (MNTX)|Participants will receive methylnaltrexone bromide (MNTX) 450 mg (3 tablets of 150 mg each) QD orally. If the initial interim analysis suggests a lack of efficacy, subsequent participants will receive 450 mg MNTX twice daily (BID) or three times daily (TID). Treatment will continue until participant's death or early withdrawal from study or study completion at Day 168.
11098984|NCT04083651|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX until participant's death or early withdrawal from study or study completion at Day 168.
11098985|NCT04083638||Group 1|Control group
11098986|NCT04083638||Group 2|Feeding will not stop during the transfusion
11098987|NCT04083625|Experimental|carbetocin|100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
11098988|NCT04083625|Placebo Comparator|placebo|10 cm syringe normal saline IV given just before skin incision of myomectomy.
11098989|NCT04083612|Other|Standard of care - ixekizumab|Patient will continue to receive ixekizumab according to standard of care dosing regimen, i.e. loading dose first (160 mg) at week 0; 80 mg every 2 weeks until week 12, then 80 mg every 4 weeks
11098990|NCT04083599|Experimental|Treatment Administered|GEN1042 will be administered every 21 days
11098991|NCT04083560|Experimental|Intervention group|Group A Intervention: 360 pregnant women will receive 250 mcg of B-12 daily orally from 1st trimester to 6 months postpartum
11098992|NCT04083560|Active Comparator|Control group|Group B- Control: 360 pregnant women will receive 50 mcg of B-12 daily orally from 1st trimester to 6 months post partum
11098993|NCT04083547||HIPEC group|All patients undergoing HIPEC will asked to join this prospective study.
11098994|NCT04083534|Experimental|REGN5459|Cohorts of multiple REGN5459 dose levels
11098995|NCT04083521|Experimental|Treatment|Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.
11098996|NCT04083521|No Intervention|Placebo|Subjects received a once daily dose of maltodextrin for 90-days.
11098997|NCT04083508|Experimental|Malaria challenge|Malaria Sporozoite Challenge by mosquito bites.
11098998|NCT04083495|Experimental|ATLCAR.CD30 cells|The cellular product consisting of ATLCAR.CD30 cells will be administered via intravenous injection over 5 - 10 minutes through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2 - 14 days after completing the lymphodepleting chemotherapy regimen
11098999|NCT04083482|Experimental|Septic patients require CVVH|continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .
11099000|NCT04083469|Experimental|Peer-Led Peer-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated the peer-leader.
11099001|NCT04083469|Other|Adult-Led Intervention|The e-cigarette intervention program will be administered to students by an adult educator.
11099002|NCT04083469|Other|Peer-Led Non-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated a different peer-leader.
11099003|NCT04083456|Experimental|Walking Biobehavioral Intervention (EXP)|The EXP group will receive biobehavioral training that is integrated into the conventional outpatient training component and is delivered over 5 months. There will be 10 biobehavioral sessions, 1 of which will be a combined biobehavioral/conventional outpatient session and the other 9 being telehealth sessions.
11099004|NCT04083456|Active Comparator|Attention Control (CTL)|The CTL group intervention will include the same conventional outpatient training (10 sessions) as the EXP group and receive the same computer tablets with telehealth software as the EXP group (week 3 of prosthetic training).
11099005|NCT04083443||Patients with blood stream infections|Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment. There will be an additional blood sampling for these patients, which is the only intervention in the study.
11099006|NCT04083430|Other|Vaccine|Yellow Fever Vaccine
11099007|NCT04083417|Active Comparator|Phenoxymethylpenicillin group|Patients randomized to oral phenoxymethylpenicillin 1000 mg three times daily for ten days
11099008|NCT04083417|Experimental|No antibiotic treatment group|Patients randomized to no antibiotic treatment
11099009|NCT04083391||CAI group|assessment had been done to this group that include patients with ankle sprain injury from more than one year and complain with repetitive injuries, giving way and instability feelings
11099010|NCT04083391||non injured ankle group|assessment had been done to this group that include control participants had not injured their ankle before and matched with CAI in age, gender, dominant side
11099011|NCT04083378|Active Comparator|Arm I (standard of care ablation)|Patients undergo standard of care ablation.
11099012|NCT04083378|Experimental|Arm II (standard of care ablation, software-aided imaging)|Patients undergo standard of care ablation with software-aided imaging (Morfeus).
11099013|NCT04083365|Experimental|CAPECITABINE + concomitant RT + Durvalumab|After careful staging, patients will be initiated to a standard concomitant chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks and 5040 cGy radiotherapy for 5 days per week for 5 weeks. At the end of treatment patients will undergo a lesion biopsy. One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations. From week 9 to 10 after neoadjuvant therapy will be performed re-staging with CT and MRI scan. Surgery will be performed at week 10-12 from the end of CT/RT and the surgical piece will be analyzed
11099014|NCT04083352|Experimental|6-week ketone supplementation|Participants took a ketomax ketone salt supplementation for 6-weeks. They took 2 servings per day.
11099015|NCT04083352|Placebo Comparator|6-week placebo supplement|Participants took a placebo supplement for 6-weeks. The placebo was calorie, sodium, and flavor-matched to the experimental supplement.
11099391|NCT04080687||Fallers|The patients who had fallen during the 6 months prior to the study onset
11099016|NCT04083339|Experimental|AT-001 High dose|The total daily doses will be of 3g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 3g/day of AT001 is capable of producing the maximum inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
11099017|NCT04083339|Experimental|AT-001 Low Dose|The total daily doses will be of 2g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 2g/day of AT001 is capable of producing a sufficient inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
11099018|NCT04083339|Placebo Comparator|Placebo Comparator|
11099019|NCT04083326|Experimental|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
11099020|NCT04083326|No Intervention|Conventional care group|Conventional care consists of specialist assessment in conjunction with pre-operative surgical visits and patient education. Patients in the conventional care group are provided with pre- and postoperative information face-to-face by paper-based method. Patients will be admitted and mobilised on the day of the surgery, and discharged one to three days after surgery. The follow-up visit, conducted by a physiotherapist, is conducted after 6 to 8 weeks post-discharge for patients with TKA and after 8 to 12 weeks for patients with THA.
11099021|NCT04083313|Active Comparator|Endoloop|Patients in which appendiceal stump was ligated using Endoloop
11099022|NCT04083313|Active Comparator|Endostapler|Patients in which appendiceal stump was ligated using Endostapler
11099023|NCT04083313|Active Comparator|Endoclip|Patients in which appendiceal stump was ligated using Endoclip
11099024|NCT04083287|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
11099025|NCT04083287|Active Comparator|Group I = ISCB group|In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
11099026|NCT04083287|No Intervention|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
11099027|NCT04083274|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
11099028|NCT04083274|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
11099029|NCT04083261||High daily dose users|Total Cannabinoid Daily Dose greater than 50 mg
11099030|NCT04083261||Control|"Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg"
11099031|NCT04083261||Low daily dose users|Total Cannabinoid Daily Dose less than 10 mg
11099032|NCT04083248|Experimental|Feasibility group|"Intervention components:
~Personalized group diabetes education.
~Fitbit Charge 3 wrist activity monitor for real-time monitoring of steps, active minutes and heart rate. The Fitbit will be used by the women to set activity goals, self-assess their progress and aid in motivation to be more active.
~Freestyle Libre (Abbott Labs, Alameda, CA) Personal CGM (FDA approved). The Libre CGM will be used to self-monitor glucose goals and monitor the real-time effects of activity and eating choices by the women.
~Final guided interview for study acceptability and feasibility. The interviews will be audiotaped, transcribed. Thematic content analyses will be performed."
11099033|NCT04083235|Experimental|Irinotecan liposome injection + Oxaliplatin + 5-FU/LV|Irinotecan liposome injection, oxaliplatin, 5 FU/LV, will be administered on Days 1 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
11099034|NCT04083235|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel and gemcitabine will be administered on Days 1, 8 and 15 of each 28-day cycle (until progression or unacceptable toxicity).
11099035|NCT04083222|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx administered subcutaneously once-weekly for 8 weeks
11099036|NCT04083222|Placebo Comparator|Placebo|Placebo matching solution administered subcutaneously once-weekly for 8 weeks
11099037|NCT04083209|Experimental|Counseling group|"Patients randomized into the counseling group will be given a 1-2 minute presentation over the risks of opioid pain medications during their preoperative visit."
11099471|NCT04080102|Experimental|High intensity interval training + Essential Amino Acid|
11099038|NCT04083209|No Intervention|Control group|The control group will undergo the standard preoperative evaluation by the senior author without any additional formal opioid counseling.
11099039|NCT04083196|Experimental|experiment group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
11099040|NCT04083196|Placebo Comparator|placebo group|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
11099041|NCT04083183|Experimental|Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)|Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365.
11099042|NCT04083170|Experimental|Regimen A (fludarabine, cyclophosphamide, TBI, OTS)|Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
11099043|NCT04083170|Experimental|Regimen B (fludarabine, cyclophosphamide, thiotepa, TBI, OTS)|Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive umbilical cord blood-derived hematopoietic CD34-positive progenitor cells IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
11099044|NCT04083157|Experimental|Intradermal hepatitis B vaccine with imiquimod|Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
11099045|NCT04083157|Active Comparator|Intramuscular hepatitis B vaccine with aqueous cream|Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.
11099046|NCT04083144|Active Comparator|Deep rTMS active + Varenicline|Participants undergoing deep rTMS (active) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
11099047|NCT04083144|Sham Comparator|Deep rTMS sham + Varenicline|Participants undergoing deep rTMS (sham) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
11099048|NCT04083118||Bicuspid aortic valve|80 patients with bicuspid aortic valve with or without an aortic aneurysm
11099049|NCT04083118||controls|20 healthy volunteer controls age and sex matched to 20 of the bicuspid aortic valve patients
11099050|NCT04083105|Experimental|30% Nitrous Oxide with Midazolam|30 percent nitrous oxide/70 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
11099051|NCT04083105|Experimental|70% Nitrous Oxide with Midazolam|70 percent nitrous oxide/30 percent oxygen will be administered for 5 minutes prior to intranasal midazolam.
11099052|NCT04083079|Experimental|PEG-rhG-CSF cohort|"PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once.
~Dosage: 6mg for weight ≥45kg，3mg for weight <45kg, subcutaneous injection"
11099053|NCT04083079|Experimental|rhG-CSF cohort|"rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10^9/L.
~rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10^9/L.
~Dosage: 5μg/kg/d, subcutaneous injection"
11099054|NCT04083066|Experimental|Rituximab combined with formoterol, pemetrexed, dexamethasone|Rituximab 375mg/m2D0 is soluble in 0.9% NS, concentration 1mg/ml, micro pump is pumped for 4h Fotemustine 100mg/m2 D1 dissolved in 250mL 0.9% NS, intravenously for 1h, protected from light Pemetrexed 600mg/m2 D1 dissolved in 100ml 0.9% NS, intravenously 1h Dexamethasone 40mg D1-5 Dissolved in 100 ml 5% GS, intravenously (21 days is a cycle)
11099055|NCT04083053|Experimental|Perianal Exam First|Perianal exam that is a part of anal cancer screening will be performed prior to the intraanal portion of the exam (high-resolution anoscopy with biopsy).
11099056|NCT04083053|Experimental|Perianal Exam Last|Perianal exam that is a part of anal cancer screening will be performed after the intraanal portion of the exam (high-resolution anoscopy with biopsy).
11099057|NCT04083040|Other|TAVI patients|Patient undergone TAVI
11099058|NCT04083014|Experimental|study group|The treatment regimen is a single dose anti-CD20 antibody injection (500mg iv drip，day0) combined with bortezomib injection (1.3mg/m2 subcutaneous injection，twice a week for two weeks，day1，4，8，11). The treatment course will be repeated three months later.
11099059|NCT04083001|Experimental|OTR4132MD|"one medical device (10mL) of one of the 5 available concentrations (20 μg/mL, 50 μg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL) will be administrated as a one shot-dose to the patient.
~The respective total dose of OTR4132 received by a patient will be one of the following: 0,20 mg, 0,50 mg, 1 mg, 1,5 mg and 2 mg."
11099060|NCT04082988|Other|Nivolumab|"Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.
~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation"
11099061|NCT04082975|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
11099062|NCT04082975|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
11099063|NCT04082962|Experimental|Treatment Group|Participants receiving dexamethasone implant.
11099064|NCT04082962|No Intervention|Non-treatment group (control)|Participants not receiving dexamethasone implant.
11099065|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths:5-6mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
11099066|NCT04082949|Placebo Comparator|Subgroups:control and initial pocket depths≥7mm|Control group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
11099067|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths:5-6mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths:5-6mm
11099068|NCT04082949|Experimental|Subgroups:AFG and initial pocket depths≥7mm|AFG group divided into two subgroups according to initial pocket depths and this subgroup includes initial pocket depths higher than 7mm
11099069|NCT04082936|Experimental|Part 1: Dose-Escalation Phase|Subjects will receive IGM-2323 via intravenous (IV) infusion on Days 1, 8, and 15, of 21-day cycles. Subjects will be treated with 4 cycles (3 weeks each). Subjects benefiting from therapy can receive up to 8 cycles or longer with good response. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
11099070|NCT04082936|Experimental|Part 2: Dose-Expansion Phase|Subjects will receive IGM-2323 via intravenous (IV) infusion at a RP2D dose and schedule to be determined after reviewing all available response and safety data.
11099071|NCT04082923|Other|Gastric bypass operated patients|Two test days in a randomized, patient-blinded, cross-over design
11099072|NCT04082923|Other|Gastric sleeve operated patients|Two test days in a randomized, patient-blinded, cross-over design
11099073|NCT04082923|Other|Control arm|Two test days in a randomized, patient-blinded, cross-over design
11099074|NCT04082910|Experimental|Therapeutic group|Patients with predicted experiencing ≤ grade 2 CRS after CAR T cells infusion, will be enrolled therapeutic group (metoprolol monotherapy, 12.5mg per time, bid; from the peak phase to extinction phase of CRS, up to 7 days).
11099075|NCT04082910|Experimental|Prophylactic group|Patients with predicted experiencing ≥ grade 3 CRS after CAR T cells infusion, will be enrolled prophylactic group (metoprolol plus anti-TNFα antibody. 1) metoprolol, 12.5mg per time, bid; from one day before cells infusion to extinction phase of CRS, up to 14 days. 2) anti-TNFα antibody will be used at the peak period of CRS).
11099076|NCT04082897|Experimental|Combination of Obinutuzumab, Atezolizumab and Venetoclax|"Obinutuzumab will be administered iv from cycle 1 to cycle 8 :
~cycle1: 100 mg iv (day 1) and 900 mg iv (day 2) 1000mg iv (day 8 and day 15)
~Cycle 2-8: 1000 mg iv on day 1
~Atezolizumab will be administered iv at 1.200 mg fixed dose from C1 to C18:
~Cycles 1: day 2
~Cycle 2-18: day 1
~Venetoclax will start from day 15 of cycle 1 on a weekly ramp-up basis:
~week 1: 20 mg (from day 15 cycle 1) week 2: 50 mg (from day 1 to day 7 cycle 2) week 3: 100 mg (from day 8 to day 14 cycle 2) week 4 200 mg (from day 15 to day 21 cycle 2) week 5: 400 mg (from day 1 cycle 3) venetoclax will be thereafter continued until day 21 of cycle 35"
11099077|NCT04082884|Experimental|Very Low Carbohydrate Diet|Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
11099078|NCT04082871|Active Comparator|Intervention|"All pharmacist level counseling and education regarding treatment, adherence and self-care activities were delivered to the active group patients only (planned to take 15 minutes). Patient level TRPs (any TRP that could be resolved via patient education and counseling) were resolved directly with the patient by the clinical pharmacist.
~A letter with the identified TRPs (prioritized from most important to least important) for each patient in the active group was sent to the patient's psychiatrist by the researcher in sealed envelopes. The psychiatrist either accepted or rejected the recommendations. In case the recommendations were accepted, the psychiatrist implemented the recommended changes. Patients were informed by a phone call by the pharmacist to visit their psychiatrist soon after the recommendations were approved for the changes to be applied.
~If the recommendations were rejected, the psychiatrist stated the reason of rejection and discussed it with the pharmacist."
11099079|NCT04082871|Active Comparator|Control|"Control group patients also underwent the baseline interview with the researcher at the psychiatric clinic, TRPs were identified and documented. No intervention was provided by the pharmacist and no letter was sent to the patients' psychiatrists. In case a patient was found to have a life-threatening TRP, the patient was excluded from the study and reported to the psychiatrist due to ethical considerations.
~After study completion, all patients in the control group received the MMR service, and a letter with their TRPs and recommendations to resolve them was sent by the pharmacist to their psychologist"
11099080|NCT04082858|Experimental|Ketamine|Participants will receive twice-weekly infusions of ketamine at 0.05mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
11099081|NCT04082858|Active Comparator|Midazolam|Participants will receive twice-weekly infusions of midazolam at 0.045mg/kg for the duration of treatment with ECT. All infusions will be administered by a Consultant Anaesthetist.
11099082|NCT04082845|Experimental|Experimental Group|The experimental group will be educated via a website that was created by the researchers.
11099083|NCT04082845|No Intervention|Control Group|The control group will take rutin patient care.
11099084|NCT04082832|Active Comparator|Cu(II)ATSM|Cu(II)ATSM Powder for Oral Suspension, 36 mg, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
11099085|NCT04082832|Placebo Comparator|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension, to be reconstituted with Diluent (15 mL of sugar-free flavored pharmaceutical syrup) to provide an oral suspension for immediate consumption. Specified dose is 72 mg (2 bottles) taken fasting, before breakfast each day.
11099086|NCT04082819|Other|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
11099087|NCT04082819|Other|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
11099088|NCT04082819|Other|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
11099089|NCT04082806|Experimental|healthy controls|
11099090|NCT04082806|Experimental|Major Depressive Disorder|
11099091|NCT04082793|Experimental|Photobiomodulation group|Low-level laser therapy will be given to the PTMB group along with mandibular mobilization and stabilization exercises
11099092|NCT04082793|Experimental|Sonophoresis group|Ultrasonic massage with diclofenac gel will be given to the sonophoresis group along with mandibular mobilization and stabilization exercises
11099093|NCT04082780|Experimental|Rifamycin|Rifamycin-SV MMX 600 mg PO two times a day (1200 mg) for 30 days
11099094|NCT04082780|Placebo Comparator|Placebo|Placebo PO two times a day for 30 days
11099095|NCT04082767|Active Comparator|Dexmedetomidine|
11099096|NCT04082767|Active Comparator|Midazolam|
11099472|NCT04080102|No Intervention|Control|
11099097|NCT04082754|Experimental|CSL311 Cohort A1 (SAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)
11099098|NCT04082754|Experimental|CSL311 Cohort A2 (SAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099099|NCT04082754|Experimental|CSL311 Cohort A3 (SAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099100|NCT04082754|Experimental|CSL311 Cohort A4 (SAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099101|NCT04082754|Experimental|CSL311 Cohort A5 (SAD Dose 5)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099102|NCT04082754|Experimental|CSL311 Cohort A6 (SAD Dose 6)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099103|NCT04082754|Experimental|CSL311 Cohort A7 (SAD Dose 7)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099104|NCT04082754|Experimental|CSL311 Cohort A8 (SAD Dose 8)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
11099105|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
11099106|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
11099107|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
11099108|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
11099109|NCT04082754|Placebo Comparator|Placebo|0.9% sodium chloride solution administered intravenously
11099110|NCT04082741|Experimental|Monotherapy SAD BMS-986318 or Placebo|Single Ascending Dose (SAD)
11099111|NCT04082741|Experimental|Monotherapy MAD BMS-986318 or Placebo|Multiple Ascending Dose (MAD)
11099112|NCT04082728|Active Comparator|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
11099113|NCT04082728|Placebo Comparator|Placebo|Patients in the experimental group will be instructed to take a placebo orally three times a day for four days, ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
11099114|NCT04082715|Experimental|carbidopa/levodopa+celecoxib|carbidopa/levodopa+celecoxib treatments will be effective.
11099115|NCT04082715|Placebo Comparator|placebo1+celecoxib|A placebo comparator for carbidopa/levodopa+celecoxib .
11099116|NCT04082715|Placebo Comparator|placebo1+placebo2|A placebo comparator for carbidopa/levodopa+celecoxib and placebo1+celecoxib.
11099117|NCT04082702|Experimental|Faith-enhanced DPP|A total of six churches were randomized to this arm that included 119 participants and received 10-month DPP with faith components.
11099118|NCT04082702|Active Comparator|Standard DPP|A total of five churches were randomized to this arm that included 102 participants who received the standard DPP on the church settings.
11099119|NCT04082689|Active Comparator|Assisted Infant Toilet Training-Group A|"Parents to Children randomized to group A will be instructed in how infant toilet training is performed by the investigators. They receive a book in Swedish concerning infant toilet training and a brief summary of the book made by the investigators. The parents are encouraged to begin infant toilet training as early as possible, but no later than 3 months of age.
~The parents of Children in group A will be invited to a special parental forum once a month. Participation is recommended but not obligatory.
~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
11099120|NCT04082689|Active Comparator|Assisted Infant Toilet Training- Group B|"Parents to Children randomized to group B will be instructed in how infant toilet training is performed by the co-workers doing the ultrasound measure of rectal diameter at 9 months. They receive a book in Swedish concerning infant toilet training and a brief summary of it made by the investigators.
~At the age of 9 months parents of Children in group B are invited to a special parental forum once a month. Participation is recommended but not obligatory.
~The definition of adherence to the intervention is to perform at least one attempt a day of infant toilet training (without the requirement of a successful outcome) on at least 5 out of 7 days per week."
11099121|NCT04082676|Experimental|Height and weight based group|"Patients in Height and weight based group will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)"
11099122|NCT04082676|Active Comparator|Height based group|"Patients in Height based group will receive intrathecal hyperbaric bupivacaine based on patients height i.e. (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)"
11099123|NCT04082663|Experimental|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
11099124|NCT04082650|Experimental|Vitamin D|Participants in the intervention group will be treated with vitamin D 4000IU (800IU per pill, take five pills once each day) per day for around 12 weeks (till the triggering day).
11099125|NCT04082650|Placebo Comparator|Placebo|Participants in the control group will be treated with equal amount of placebo tablets per day for the same duration.
11099126|NCT04082637|Experimental|MABT* + Medication Assisted Treatment|Mindful Awareness in Body-oriented Therapy + Medication-assisted Treatment
11099127|NCT04082637|No Intervention|Treatment as Usual|
11099128|NCT04082624|Active Comparator|Nutrition condition|Received nutrition information such as the comparison of nutritional information between orange juice and soda pop. Received intervention following measurements at baseline, week 4, and week 8.
11099129|NCT04082624|Experimental|Affective condition|Learned about the affective benefits (e.g., less depression) of reduced office sitting time through taking active breaks. Received intervention following measurements at baseline, week 4, and week 8.
11099130|NCT04082624|Experimental|Instrumental condition|Learned about instrumental benefits such as the relationship between sitting and cardiovascular disease and absenteeism at work. Received intervention following measurements at baseline, week 4, and week 8.
11099131|NCT04082624|Experimental|Self-regulation condition|Learned how to self-monitor their sedentary behavior and active breaks. They also learned how to create prompts/cues (e.g., sticky note reminder), problem solve to overcome barriers, action plan (i.e., specifying when, where, and how to do the behavior), and set goals in order to be less sedentary according to SMART (i.e., specific, measurable, attainable, relevant, time-oriented) principles. Received intervention following measurements at baseline, week 4, and week 8.
11099132|NCT04082611|Active Comparator|Group 1 - Data-driven clinical recommendations (CR)|Data-driven clinical recommendations (CR)
11099133|NCT04082611|Experimental|Group 2 - Data-driven coached multi-modal intervention (MMIC)|Data-driven coached multi-modal intervention (MMIC)
11099134|NCT04082598|Experimental|Tooth extraction and antibiotic treatment|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days
11099135|NCT04082598|Experimental|tooth extraction and antibiotic treatment + dietary supplement|Tooth extraction and Amoxicillin- clavulanic acid 875/125 mg, twice a day, for 6 days + Bifidobacterium longum and Lactoferrin twice a day for 6days
11099136|NCT04082598|No Intervention|Tooth extraction|tooth extraction without antibiotics and/or Bifidobacterium longum and Lactoferrin
11099137|NCT04082572|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who do not respond to pembrolizumab and stop the treatment after 2 doses may undergo surgery within 6 months.
11099138|NCT04082559|Other|Antibiotic treatment|"Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.
~Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks
~Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks"
11099139|NCT04082559|Other|Combination therapy (Antibiotics + diet)|"Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.
~Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks."
11099140|NCT04082559|Other|Nutritional prevention|"Patients in clinical remission will be recruited to a dietary prevention study.
~Mediterranean diet
~Control- based on the American Dietetic Association recommendations for patients with IBD
~Personalized nutrition group- based on prior results from study- NCT02858557"
11099141|NCT04082546||Surgical unroofing|Refractory angina to medical treatment (beta-blockers or calcium channels blockers)
11099142|NCT04082546||Medical treatment|Responders to medical treatment for angina relief
11099143|NCT04082533|Active Comparator|Stiffness Intravenous Hydrocortisone|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
11099144|NCT04082533|Placebo Comparator|Stiffness Intravenous Placebo|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
11099145|NCT04082533|Active Comparator|Non-stiff Intravenous Hydrocortisone|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
11099146|NCT04082533|Placebo Comparator|Non-stiff Intravenous placebo|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
11099147|NCT04082520|Experimental|Treatment (gallium Ga 68-DOTATATE PET/MRI, Lutathera)|Patients receive gallium Ga 68-DOTATATE IV and undergo a PET/MRI before cycles 1 and 4. Patients then receive lutetium Lu 177 dotatate IV over 30-40 minutes. Cycles repeat every 8 for up to 6 months in the absence of disease progression or unacceptable toxicity.
11099148|NCT04082507||Non_adherent plcenta|placenta separated within 15 minutes after delivery of fetus
11099149|NCT04082507||Adherent placenta|placenta dosenot separated within 15 minutes after delivery of fetus
11099150|NCT04082494|No Intervention|Regular Treatment|"No intervention is planned for the first period. Baseline treatment assesment."
11099151|NCT04082494|Experimental|Music|Optional music via internet and noise canceling headphones will be offered.
11099152|NCT04082494|Experimental|Music and Beverages|Additionally to the offered optional music via internet and noise canceling headphones, there will be beverages optionally offered (with and without sugar, warm or cold).
11099153|NCT04082481|Experimental|TAK-988: Part A|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety/tolerability, PK, and PD data from previous cohorts.
11099154|NCT04082481|Experimental|TAK-988: Part B|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety/tolerability, PK, and PD data from previous cohorts and Part A.
11099155|NCT04082481|Experimental|TAK-988: Part C|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
11099156|NCT04082481|Experimental|TAK-988: Part D|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to HE non-Japanese participants. Dose will be determined based on previous MRD cohorts.
11099157|NCT04082481|Experimental|TAK-988: Part E|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1, followed by a washout period of 2 days and twice daily (6- hour interval) on Day 3 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts.
11099158|NCT04082455|Experimental|carbon ion radiotherapy|carbon ion radiotherapy
11099159|NCT04082442|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in STEMI patients.
11099160|NCT04082442|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in STEMI patients .
11099161|NCT04082429|Experimental|Arm 1: No prophylaxis|Haemophilia A (HA) and haemophilia B (HB) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension phase, this group will receive treatment with concizumab.
11099162|NCT04082429|Experimental|Arm 2: Concizumab prophylaxis|HA and HB patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
11099163|NCT04082429|Experimental|Arm 3: Concizumab prophylaxis|The HA patients enrolled into the concizumab phase 2 trial NN7415-4255 (explorer 5) will be offered enrolment into this arm.
11099164|NCT04082429|Experimental|Arm 4: Concizumab prophylaxis|"Arm 4 will include patients previously on prophylaxis with factor products with a minimum of 24 weeks observation in NN7415-4322 (explorer 6) (at least 30 HA and 30 HB patients).
~In addition, arm 4 will also include: 1) Patients who were randomised to arms 1 and 2 before the treatment pause. 2) HA patients who were in NN7415-4255 (explorer 5) at the time of the treatment pause, and who have now completed explorer 5. 3) On demand patients included after arms 1 and 2 are closed."
11099165|NCT04082416|Experimental|RC18 160mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.
11099166|NCT04082416|Placebo Comparator|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 52 times.
11099167|NCT04082403|Active Comparator|Pre SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway
11099168|NCT04082403|Experimental|Post SALAD education group|Each trainee was asked to intubate a mannequin with a contaminated airway after receiving SALAD training
11099169|NCT04082390|Experimental|RELEASE Supplement|
11099170|NCT04082390|Placebo Comparator|Placebo|
11099171|NCT04082377|Experimental|Recruitment maneuver with tidal volume (RM TV)|RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW ,RR at 7 breaths/min, PEEP at 5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM. The ventilation protocol could be changed at any time when concerned about patient safety.
11099172|NCT04082377|Active Comparator|Recruitment maneuver by PEEP (RM PEEP)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia 5 cmH2O PEEP.
~RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver."
11099173|NCT04082364|Experimental|Margetuximab plus INCMGA00012|margetuximab plus INCMGA00012
11099174|NCT04082364|Experimental|Margetuximab plus INCMGA00012 plus chemo|margetuximab plus INCMGA00012 plus capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
11099175|NCT04082364|Experimental|Margetuximab plus MGD013 plus chemo|margetuximab plus MGD013 plus XELOX or mFOLFOX-6
11099176|NCT04082364|Experimental|Margetuximab plus chemo|margetuximab plus XELOX or mFOLFOX-6
11099177|NCT04082364|Active Comparator|Control Arm|Trastuzumab plus XELOX or mFOLFOX-6
11099178|NCT04082351|Active Comparator|Magnalife|the group of patients receiving the nanotechnology structured water
11099179|NCT04082351|Placebo Comparator|Ordinary water|the group of patients receiving ordinary water
11099180|NCT04082338|Experimental|VPN Toolkit+TM|The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application) format.
11099181|NCT04082338|Active Comparator|Text Messages|Receive TM respectively once a week for 5 weeks for every 6 months in the 18-month study period
11099182|NCT04082325|Experimental|Part A Lu AF88434 or Placebo|6 cohorts (cohort A1 to A6) with 9 subjects in each cohort. In each cohort 6 subjects will receive single doses of Lu AF88434 and 3 subjects will receive placebo
11099183|NCT04082325|Experimental|Part B1 Lu AF88434 Fed-Fasting-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B1. The treatment sequence for Group B1 is: Fed-Fasting-Fasting. 14C-spiked dose (Lu AF99723) will be given in the last treatment sequence.
11099184|NCT04082325|Experimental|Part B2 Lu AF88434 Fasting-Fed-Fasting|4 subjects will receive an identical oral dose of Lu AF88434 in Group B2. The treatment sequence for Group B2 is: Fasting-Fed-Fasting. 14C-spiked dose (Lu AF99722) will be given in the last treatment sequence.
11099185|NCT04082325|Experimental|Part B3 Lu AF88434 Fasting-Fasting-Fed|4 subjects will receive an identical oral dose of Lu AF88434 in Group B3. The treatment sequence for Group B3 is: Fasting-Fasting-Fed.
11099186|NCT04082312||Group 1|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
11099187|NCT04082312||Group 2|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
11099188|NCT04082312||Group 3|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI
11099189|NCT04082299||Pregnant women|pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
11099190|NCT04082299||Non pregnant women|Non pregnant women expected to be vaccinate with Tdap vaccine
11099191|NCT04082286|Experimental|Radioimmunotherapy|Children affected by high risk malignant disorders will be receiving increasing infused activity of a radio-immune conjugated antibody as part of their conditioning regimen prior to alleogeneic stem cell transplantation
11099192|NCT04082273|Experimental|Femtosecond Laser for Cataract Surgery|Capsulotomy, lens fragmentation and Clear Corneal Incisions with FEMTO LDV Z8, followed by ultrasound phacoemulsification and IOL implantation.
11099392|NCT04080687||Non-fallers|The patients who had not fallen during the 6 months prior to the study onset
11099193|NCT04082273|Active Comparator|Conventional Cataract Surgery|Clear Corneal Incisions, conventional capsulorhexis and ultrasound phacoemulsification and IOL implantation. Control treatment where the clear corneal incisions and capsulorhexis are performed manually and the lens fragmentation is performed with the phacoemulsification device.
11099194|NCT04082260||De novo patients with alemtuzumab|De novo patients prior and after alemtuzumab treatment initiation
11099195|NCT04082260||Alemtuzumab treatment|Patients under alemtuzumab treatment
11099196|NCT04082260||Extended alemtuzumab treatment|Patients requiring more than two alemtuzumab infusions
11099197|NCT04082247|Experimental|Experimental group|The education and training of early childhood educators (developed by the researchers) and their intervention on children.
11099198|NCT04082247|No Intervention|Control group|Receive the standard care.
11099199|NCT04082234|Experimental|Integrated Individualized Behavioral Parent Training|Partnering to Achieve School Success (PASS) is a personalized, enhanced behavioral intervention for ADHD that includes evidence-based behavior therapy strategies and enhancements to promote family engagement in treatment, team-based care, and high quality therapy. Caregivers engage in 9 to 12 sessions with a behavioral health provider over the course of 16 weeks that are specifically tailored to caregiver goals and values.
11099200|NCT04082234|Active Comparator|Treatment as Usual|The control condition will be TAU informed by AAP guidelines for managing ADHD and facilitated by electronic practice supports, which have been successfully incorporated into the EHR to guide primary care providers (PCPs) in implementing ADHD guidelines. At CHOP, PCPs across the primary care network were invited to participate in a distance learning, quality improvement initiative to promote implementation of AAP guidelines,including strategies to educate families about ADHD and evidence-based treatments, engage families in shared decision making, titrate medication, and monitor treatment effects. The five practices participating in this study participated in that project.
11099201|NCT04082208|Experimental|Intervention Group|High Flow nasal cannula (HF)
11099202|NCT04082208|Active Comparator|Standar Care Group|Standar Care: low flow device (LF)
11099203|NCT04082195|Experimental|Fooya mobile game|An arm that receives a mobile-app-based treatment.
11099204|NCT04082195|Active Comparator|Uno board game|An arm that receives a non mobile-app-based treatment.
11099205|NCT04082182|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIX4-LUNG autologous DC vaccine
11099206|NCT04082156|Active Comparator|Active TENS|
11099207|NCT04082156|Sham Comparator|Sham TENS|
11099208|NCT04082143|Experimental|Implant with prophylactic allograft|
11099209|NCT04082143|Active Comparator|Implant without prophylactic allograft|
11099210|NCT04082130|Experimental|(XCM)+(CAF)|"Surgical protocol for test treatment with CAF + XCM:
~Local anesthesia to anesthetize the recipient site, after that root preparation will be done. sulcular incision will be made at the recession site and will be extended horizontally into the adjacent interdental regions. Bilateral vertical releasing incisions will be made, connected to the horizontal incision, and will be extended out into the lining mucosa. A full-thickness flap will be elevated until the mucogingival junction. a periosteal release will be made to eliminate tension and advance the flap coronally, then de-epithelializing The facial aspects of the interdental papillae and Root surface conditioning will be made. After that the investigators will apply XCM (Geistlich Fibro-Gide® ) onto the surface 1-2 mm coronally of the CEJ. Finally, The mucoperiosteal flap will be coronally advanced to cover the XCM and then sutured to the de-epithelialized papillae."
11099211|NCT04082130|Active Comparator|(SCTG)+(CAF)|"The surgical protocol in the control group will be identical with test group protocol with these expectation:
~A partial thickness flap will be elevated instead of full thickness flap.
~A SCTG harvested from the palate will be used to cover the exposed denuded root surface in lieu of placement of XCM in the test group. And reabsorbable sutures will be used to stabilize it 2 mm coronally from the CEJ.
~As in the test group the mucosal flap will passively coronally advanced to completely cover the SCTG."
11099212|NCT04082117|Other|Open Label|Educational genetic counseling video
11099213|NCT04082065|Active Comparator|conventional physical therapy|Myofacial release Stretching of hamstring and Piriformis
11099214|NCT04082065|Experimental|cyriax lumber manipulation group|Myofacial Release stretching of hamstrings and Piriformis Cyriax Lumbar Manipulation Techniques
11099215|NCT04082052|Experimental|Single Session Intervention for Self-Dislike|A 30-45 minute intervention delivered in a web browser that focuses on reducing self-dislike using facts about the brain, testimonials from peers, and writing exercises.
11099216|NCT04082052|Placebo Comparator|Single Session Intervention for Feelings Disclosure|A 30-45 minute intervention delivered in a web browser that focuses on encouraging feelings disclosure using facts about the brain, testimonials from peers, and writing exercises.
11099217|NCT04082039|Active Comparator|1-channel PCA|Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
11099218|NCT04082039|Experimental|2-channel PCA|Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
11099219|NCT04082026|Experimental|Early Adolescent Skills for Emotions (EASE)|EASE has four core features: Seven group sessions for young adolescents and three for their caregivers; Delivered by non-specialists; Trans-diagnostic: addressing depression, anxiety, distress, and other problems as defined by the young people themselves; and Designed for young people and their caregivers in low- and middle-income countries living in communities affected by adversity.
11099220|NCT04082026|Placebo Comparator|Enhanced Treatment As Usual (ETAU)|The Enhanced Treatment as Usual (ETAU) consisted of a single psychoeducation individual session, jointly for eligible adolescents and their caregivers, that included information on: (i) the results of the screening; (ii) self-care strategies; and, (iii) seeking services from local health or community services offering psychosocial / mental health care support.
11099221|NCT04082000|Experimental|BOL-DP-o-04|
11099222|NCT04082000|Placebo Comparator|Placebo|
11099223|NCT04081974||Minimally invasive cardiac surgery|All consecutive patients presenting for minimally invasive cardiac surgery will be screened for participation to the study.
11099224|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
11099225|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
11099226|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
11099227|NCT04081948|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
11099228|NCT04081948|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
11099229|NCT04081935|Experimental|Reduce pain and fair|To determine whether the virtual reality as a distracting intervention could reduce pain and fear in school-age children receiving intravenous injections at an emergency department.
11099230|NCT04081935|No Intervention|Compared|Normal treatment
11099231|NCT04081922|Experimental|Regional analgesia using erector spinae plane block|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.
11099232|NCT04081922|No Intervention|Control|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.
11099233|NCT04081909|Active Comparator|Opioid Based Anesthesia(OBA)|
11099234|NCT04081909|Experimental|Opioid Free Anesthesia(OFA)|
11099235|NCT04081896||In Clinic Rehabilitation|Participants who are undergoing supervised exercise based rehabilitation in the SpineZone clinic
11099236|NCT04081896||Online Rehabilitation|Participants who will be undergoing online-based coaching and exercise as prescribed via telephone, online chat, or web-based interactions with SpineZone rehabilitation staff (physical therapists and physicians)
11099237|NCT04081883|Experimental|Biosensor algorithm|The biosensor DIABLO algorithm is compared to Continuous Glucose Monitoring Systems (CGMS) utilisation.
11099238|NCT04081870||ICSI cases|All women underwent long agonist protocol for controlled ovarian hyperstimulation The GnRH agonist was started in the previous mid-luteal phase . After the confirmation of pituitary down regulation , the HMG ampoules were started by 225 IU/day . During the follow up of overstimulation, the doses were adjusted according to the response of patient. All women underwent serial TVS until at least three dominant follicles were reached in every woman. When the dominant follicles reached 18-20 mm, HCG 10000 was administered. Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day . Five days following ovum pick up, the embryos were transferred at the blastocyst stage.
11099239|NCT04081857|Experimental|Sequence 1|Period 1 : Fasted state + HGP1810 Period 2 : Fasted state + HCP1704
11099240|NCT04081857|Experimental|Sequence 2|Period 1 : Fasted state + HCP1704 Period 2 : Fasted state + HGP1810
11099241|NCT04081844|Experimental|Fixed-Sequence|Period 1: Fasted state+HCP1306, Period 2: Fasted state+HGP0904+HGP0608, Period 3: Fasted state+HCP1306+HGP0904+HGP0608
11099242|NCT04081831||New-users of Low-dose aspirin (exposed group)|New-users of low-dose aspirin is defined as patients who did not receive any prescriptions of low-dose aspirin one year prior to the index date.
11099243|NCT04081831||Users of Paracetamol (non-exposed group)|Users of Paracetamol is defined as patients who receive first prescription of paracetamol during the study period. Since the patients receiving low-dose aspirin are potentially less healthy compared to non-users of aspirin, patients receiving paracetamol as the control group can minimise healthy user bias.
11099244|NCT04081818|Active Comparator|Intervention group (Nutritious Mushrooms)|
11099245|NCT04081818|No Intervention|Control group|
11099246|NCT04081805|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
11099247|NCT04081805|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
11099248|NCT04081805|Active Comparator|Promestriene|The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
11099249|NCT04081792|Experimental|1. Trial (Amputation) Soft tissue - short antibiotic arm|The intervention group consists of 1 day of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
11099250|NCT04081792|Active Comparator|1. Trial (Amputation) Soft tissue - long antibiotic arm|The control group consists of 4 days duration of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
11099251|NCT04081792|Experimental|1. Trial (Amputation) Bone - short antibiotic arm|The intervention group consists of 1 week of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
11099252|NCT04081792|Active Comparator|1. Trial (Amputation) Bone - long antibiotic arm|The intervention group consists of 3 weeks of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
11099253|NCT04081792|Experimental|2.Trial (soft tissue infection) - short antibiotic arm|The intervention group consists of 10 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
11099393|NCT04080674||Parkinson's disease|30 participants
11099394|NCT04080674||Essential Tremor|10 participants
11099254|NCT04081792|Active Comparator|2. Trial (soft tissue infection) - long antibiotic arm|The control group consists of 20 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
11099255|NCT04081792|Experimental|2. Trial (osteomyelitis) - short antibiotic arm|The intervention group consists of 3 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
11099256|NCT04081792|Active Comparator|2. Trial (osteomyelitis) - long antibiotic arm|The control group consists of 6 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
11099257|NCT04081779|Active Comparator|Arm I (patient-generated SCP)|Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).
11099258|NCT04081779|Experimental|Arm II (patient-generated SCP, educational counseling)|Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
11099259|NCT04081766|Active Comparator|SUGAR Handshake|"Participants assigned to the intervention group will receive an individualised, pharmacist-led patient counselling session (SUGAR Handshake package) at the inclusion visit.
~Participants will also receive a pictogram with the main instructions for easy recall of the counselling contents.
~They will also receive a glucometer and test strips with a demonstration on proper use, to measure their fasting blood glucose levels on a daily basis for 12 weeks.
~At week 6, participants will receive a phone call to reinforce the intervention and to remind them of the study protocol. For the qualitative evaluation of the intervention, a number of participants are interviewed and asked questions through the sixth week-phone call.
~Additionally, participants in this group will be provided with the usual care that is normally provided in the outpatient clinics at King Abdullah University Hospital."
11099260|NCT04081766|No Intervention|Control|"Participants within this group will receive the usual care provided by the health care professionals in the outpatient clinics at King Abdullah University Hospital.
~They will also be provided with instructions on hypoglycemia diagnosis, and treatment and a demonstration on glucometer use at the inclusion visit. They will be asked to measure their fasting blood glucose level daily for 12 weeks.
~Participants will receive a phone call at week 6 of the inclusion visit to remind them of measuring blood glucose levels and documenting hypoglycemic episodes on the diaries., plus a counselling session about hypoglycaemia recognition and treatment at the inclusion visit.
~For the qualitative evaluation of the study, a number of participants will be interviewed and asked questions through the sixth week-phone call."
11099261|NCT04081753|Experimental|TMD Group|Temperature Monitoring Device Group - The interventional group, who will be given the temperature monitoring device and will be monitored remotely.
11099262|NCT04081753|No Intervention|Historic cohort Group|Historic cohort group will be enrolled from medical record
11099263|NCT04081740||Asthma|The patients included in this group will have asthma, as specified in the inclusion criteria.
11099264|NCT04081740||COPD|The patients included in this group will have COPD, as specified in the inclusion criteria.
11099265|NCT04081740||Bronchiectasis|The patients included in this group will have bronchiectasis, as specified in the inclusion criteria.
11099266|NCT04081701||Meningioma|Cohort of 30 subjects with meningioma.
11099267|NCT04081701||Non-Meningioma|"Cohort of 60 subjects with non-meningioma:
~(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)"
11099268|NCT04081688|Experimental|Treatment (varlilumab, atezolizumab, SBRT)|Patients receive varlilumab IV over 90 minutes and atezolizumab IV over 30-60 minutes every cycle. Cycles repeat every 21 days for up to 1 year (18 cycles) in the absence of disease progression or unacceptable toxicity. Between cycle 1 and 2, patients also receive SBRT.
11099269|NCT04081662|Experimental|compACT Intervention|"At every time-point of the study, participants will complete self-reports of stress, (as measured by the PSS-4) distress (as measured by the PHQ-2), and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.
~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).
~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
11099270|NCT04081649||Cardiac surgery|Patients undergoing non-emergent cardiac surgery for coronary bypass graft and/or valvular replacement
11099271|NCT04081636|Active Comparator|Systematic Transrectal biopsy (TR-Bx)|Ultrasound guided; needle inserted through the rectum to reach the prostate
11099272|NCT04081636|Active Comparator|Targeted Transrectal biopsy (TR-Bx)|MRI-guided; needle inserted through the rectum to reach the prostate
11099273|NCT04081636|Experimental|Systematic Transperineal biopsy (TP-Bx)|Ultrasound guided; needle inserted directly through the skin to reach the prostate
11099274|NCT04081636|Experimental|Targeted Transperineal biopsy (TP-Bx)|MRI-guided; needle inserted directly through the skin to reach the prostate
11099275|NCT04081623||Clinic|This group is undergoing their scheduled visit for Non-Stress Test (NST) or Biophysical Profile (BPP)
11099276|NCT04081623||Labor and Delivery|This group is in active labor.
11099277|NCT04081610|Experimental|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
11099278|NCT04081610|Active Comparator|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
11099279|NCT04081597|Experimental|STAR-101|Doses in two of three crossover periods
11099280|NCT04081597|Placebo Comparator|Placebo|Matching placebo in one of three periods
11099281|NCT04081558|Experimental|Electronic follow-up|
11099282|NCT04081545|Active Comparator|Control Goup A- Opioid-based regimen|"Induction
~Fentanyl (50mcg IV)
~Lidocaine 1.5mg/kg IV bolus using IBW (Ideal body weight)
~Propofol 2-3mg/kg IV bolus
~Rocuronium 0.6mg/kg IV bolus
~Maintenance
~Sevoflurane, titrated to hemodynamic stability (defined parameters)
~Rocuronium intermittent boluses at discretion of anesthesiology team
~May use fentanyl to treat SBP or HR > 20% of baseline
~Emergence
~Neuromuscular reversal, dosed according to Virginia Mason protocol
~May titrate in more fentanyl to a maximum dose of 200mcg throughout the case.
~Patient extubated and brought to PACU
~PACU opioid orders per anesthesiology team
~Post-operative Nausea/Vomiting Prophylaxis
~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
11099283|NCT04081545|Experimental|Experimental Group B- Opioid-free regimen|"Induction:
~Dexmedetomidine 1mcg/kg IV bolus over 10 minutes using IBW
~Lidocaine 1.5mg/kg IV bolus using IBW
~Propofol 2-3mg/kg IV bolus
~Rocuronium 0.6mg/kg IV bolus
~Ketamine 0.5mg/kg IV bolus (based on IBW)
~Maintenance
~Sevoflurane
~Dexmedetomidine 0.4 mcg/kg/hr IV infusion using IBW (may titrate based on patient response between 0.3-0.5mcg/kg/hr)
~Lidocaine 2mg/kg/hr IV infusion using IBW
~May use esmolol as needed to treat SBP or HR > 20% of baseline
~Rocuronium intermittent boluses at the discretion of anesthesiology team
~Emergence
~Dexmedetomidine infusion turned off during laparoscopic desufflation
~Lidocaine infusion turned off at skin closure
~Neuromuscular reversal, dosed according to VM protocol
~Pt extubated and brought to PACU
~PACU opioid orders per anesthesiology team
~PACU orders to include one dose APAP 650mg oral solution
~Post-operative Nausea/Vomiting Prophylaxis
~-4mg dexamethasone, 1mg haloperidol, scopolamine patch"
11099284|NCT04081532|Active Comparator|Surgical treatment|
11099285|NCT04081532|No Intervention|No surgical treatment|
11099286|NCT04081519|Active Comparator|DLPFC-DLPFC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over DLPFC
11099287|NCT04081519|Experimental|DLPFC-LPC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over LPC
11099288|NCT04081519|Sham Comparator|DLPFC-SHAM|15 sessions of active rTMS over DLPFC + 15 sessions of sham rTMS over DLPFC or LPC
11099289|NCT04081506|Experimental|Group A|Individualized care
11099290|NCT04081506|No Intervention|Group B|Conventional care
11099291|NCT04081493|Experimental|Group 1 (BFRE)|Low-load blood flow restricted exercise 3/weekly for 8 weeks before TKR 10-min warm-up followed by unilateral leg press and unilateral knee extension
11099292|NCT04081493|No Intervention|Group 2 (CON)|No training before TKR
11099293|NCT04081480|Other|Valacyclovir oral solution|Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.
11099294|NCT04081467|Experimental|bed rest condition|Bed rest condition without any additional intervention
11099295|NCT04081454||Children with chronic pain|
11099296|NCT04081454||Caregivers of children with chronic pain|
11099297|NCT04081441|Experimental|Inyenyeri clean cookstove/fuel|A tier 4 clean Mimi-moto cookstove/pellet system
11099298|NCT04081441|Experimental|I-ACT behavioral empowerment intervention|A culturally adapted 2-day personal empowerment workshop (based on the Individual, Agency-Centered Training (I-ACT) to women and modified, condensed 1-day training for their male partners, if applicable
11099299|NCT04081441|Experimental|Cookstove and I-ACT empowerment|Access to both the clean cookstove system and I-ACT empowerment training
11099300|NCT04081441|Other|I-ACT Waitlisted control|These households include those that were offered cookstoves after 6 months (from baseline) and are waitlisted to receive the I-ACT intervention
11099301|NCT04081415||Group with FPIES|Not yet healed children with FPIES
11099302|NCT04081402|Experimental|HU-014 Inj|
11099303|NCT04081402|Active Comparator|Botox Inj|
11099304|NCT04081389|Experimental|CKM weeks 1-3, doxorubicin, cyclophosphamide)|Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
11099305|NCT04081376|Experimental|Treatment group|Subjects receive a single-dose treatment.Urine samples will be collected after administration (8 fractions: 0-4h, 4-8h, 8-12h, 12-24h, 24-36h, 36-48h, 48-60h, 60-72h post-administration).
11099306|NCT04081363|Experimental|Intervention|Single oral dose (50 mg) capsule of extended-release centanafadine
11099307|NCT04081350|Active Comparator|LY3471851|LY3471851 administered subcutaneously (SC)
11099308|NCT04081350|Placebo Comparator|Placebo|Placebo administered SC
11099309|NCT04081337|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
11099310|NCT04081337|Placebo Comparator|Placebo|Placebo administered SC.
11099311|NCT04081324|Experimental|Lasmiditan|Administered orally
11099312|NCT04081324|Placebo Comparator|Placebo|Administered orally
11099313|NCT04081311|Experimental|water flosser|patient will be provided with Waterpik Water Flosser and instructed to water floss around the implant once a day, preferably at nighttime
11099314|NCT04081311|Active Comparator|dental floss|patient will be instructed to floss with TePe Bridge and Implant Floss once a day, preferably at nighttime
11099315|NCT04081298|Experimental|Arm I (health education, FitBit, actigraph)|Patients attend 6 online nutrition and PA education classes, cooking sessions, and participate in physical activities over 90 minutes each. Patients wear a FitBit and Actigraph to monitor physical activity.
11099316|NCT04081298|Active Comparator|Arm II (text message, website, FitBit, actigraph)|Patients receive motivational text messages 2-3 times per week and access to a nutrition website for 3 months. Patients wear a FitBit and Actigraph to monitor physical activity.
11099317|NCT04081272||G6PD-normal|Donated blood from G6PD-normal subjects
11099318|NCT04081272||G6PD-deficient|Donated blood from G6PD-deficient subjects
11099319|NCT04081259|Experimental|LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle
11099320|NCT04081246|Experimental|Modified en bloc resection|For patients undergoing modified en bloc resection, piecemeal resection of the exophytic part of the bladder tumour will be performed, followed by en bloc resection of the tumour base.
11099321|NCT04081233|Experimental|Early surgical stabilization|This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
11099322|NCT04081233|Active Comparator|Usual care|This arm will be usual care only. Usual care will include pain managment.
11099323|NCT04081220|Experimental|IMG-7289|
11099324|NCT04081207|Experimental|AAC-LaRc|all participants receive the experimental treatment
11099325|NCT04081194||case group, Melanoma Patients|"15 patients of with Melanoma, Age between 40 and 90 years.
~-Withdrawal of Blood sample, Isolation of Exosomes:
~Bradford protein assay And Qubit protein assay.
~Bioanalyzer.
~Real time PCR."
11099326|NCT04081194||control group|"10 Persons without Melanoma, age > 40 years
~-Withdrawal of Blood sample, Isolation of Exosomes:
~Bradford protein assay And Qubit protein assay.
~Bioanalyzer.
~Real time PCR."
11099327|NCT04081181|Experimental|CT_ guided percutaneous microwave ablation|The procedure will be done under anaesthesia by interventional radiologist
11099328|NCT04081168|Active Comparator|Stereotactic Body Radiotherapy|Patients included will undergo Stereotactic Body Radiotherapy (SBRT) of hepatic metastases.
11099329|NCT04081168|Active Comparator|Microwave Ablation|Patients included will undergo Microwave Ablation (MWA) of hepatic metastases.
11099330|NCT04081142||acute respiratory failure group|acute respiratory failure (ARF) group: arterial oxygen partial pressure to fractional inspired oxygen ratio, PaO2/FiO2<300 mmHg and/or peripheral oxygen saturation SaO2<94% under air condition and/or severe dyspnea with respiratory rate >30bpm.
11099331|NCT04081142||control group|postoperative ICU patients without ARF were included
11099332|NCT04081129||ICU patients with early mobilization|
11099333|NCT04081116|Experimental|MI-E testing symmetric settings|Symmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
11099334|NCT04081116|Experimental|MI-E testing assymetric settings|Asymmetric settings is one of 3 different settings that will be tested on the same day but in randomized order.
11099335|NCT04081116|Sham Comparator|Settings in use|Settings in use is one of 3 different settings that will be tested on the same day but in randomized order
11099336|NCT04081103|Experimental|NEXAGON High Dose Concentration|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.
~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
11099337|NCT04081103|Experimental|NEXAGON Low Dose Concentration|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.
~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
11099338|NCT04081103|Placebo Comparator|NEXAGON Vehicle|"Applied on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.
~NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED."
11099339|NCT04081090|Experimental|Brain HQ adaptive Cognitive Therapy Modules|Brain HQ licensed modules that adapt to each individuals unique strengths and weaknesses to address deficits and improve neuroplasticity.
11099340|NCT04081090|Active Comparator|Brain HQ Active Control Modules|Participants in this arm will complete puzzles such as crossword puzzles, Sudoku, etc.
11099341|NCT04081077|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
11099342|NCT04081077|Experimental|Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
11099343|NCT04081077|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
11099344|NCT04081064|Experimental|Non-obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >18.5 and <30.0 kg/m2
11099345|NCT04081064|Experimental|Obese Qatar residents with type 2 diabetes|Newly diagnosed (e.g <5 years) Type 2 diabetics Qatar residents with a body mass index (BMI) of >30.0 to <40.0 kg/m2
11099346|NCT04081051|Experimental|Intervention|Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers
11099347|NCT04081051|No Intervention|control|Standard of care practices for acute febrile illness
11099348|NCT04081025||Adults|Age Groups 35, 50, 65, 75 and 85
11099349|NCT04081012|Experimental|N-acetyl Cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before endarterectomy or balloon angioplasty.
11099350|NCT04081012|Placebo Comparator|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals. All study medications will be prepared by the Pharmacology department, which is not involved in patient care; the name of the medication and dose of the original ampule will be erased and also an identification label will be placed with the name, registration number, bed number, date and will be indifferent for groups with the same type of ampoule, with the same type of labeling
11099351|NCT04080999|Experimental|r-TMS Group|"r-TMS Parameters International 10/20 system for the location of the target area (non-lesioned left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.
~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
11099352|NCT04080999|Sham Comparator|Sham Group|Sham stimulation and Visual scanning training
11099353|NCT04080986|No Intervention|Standard Arm|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
11099389|NCT04080726|Experimental|HGP1705+HIP1601 Placebo|HGP1705+HIP1601 Placebo for 4weeks. if not fully cured, take HGP1705+HIP1601 Placebo for addtional 4weeks
11099354|NCT04080986|Active Comparator|Double Sequential Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
11099355|NCT04080986|Active Comparator|Vector Change Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
11099356|NCT04080973|Experimental|osteopenic patients|patients with a kidney stone and osteopenic changes.
11099357|NCT04080947|Placebo Comparator|Control group|50 patients will receive placebo (Control group)
11099358|NCT04080947|Experimental|Montelukast group|50 patients will receive montelukast 10 mg/ day
11099359|NCT04080934|Experimental|Experimental Group|In the experimental group, patients allocated to the swimming/experimental group will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum. They will be asked to undergo a range of motion (ROM) assessment by a registered kinesiologist, as well as a few short questionnaires administered over the phone by a research assistant, once at the onset of the intervention and once a month for 3 months during the intervention.
11099360|NCT04080934|No Intervention|Control Group|The control group will include patients who receive standard of care. This includes the recommendation to undertake exercise and physiotherapy; however, no formal exercise program will be provided. In the control group, participants will be asked to answer a few short questionnaires administered over the phone by a research assistant once per month for 4 months.
11099361|NCT04080921|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
11099362|NCT04080908|Experimental|Ferumoxytol injection treatment|
11099363|NCT04080895|Experimental|group A|
11099364|NCT04080895|Experimental|group B|
11099365|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
11099366|NCT04080882|Placebo Comparator|placebo|placebo injected into platysma bands
11099367|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
11099368|NCT04080869|Experimental|retinyl palmitate ethosomes arm|All patients will be instructed to apply a thin film of the new formula on one side of the face
11099369|NCT04080869|Active Comparator|tretinoin arm|All patients will be instructed to apply a thin film of topical retinoid cream on the other side of the face
11099370|NCT04080856||Participants with endometriosis|Premenopausal participants with endometriosis receiving elagolix in real-world setting
11099371|NCT04080843|Experimental|Group A|"Patients in the study group will receive the following treatment:
~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).
~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression."
11099372|NCT04080830||Acute ischemic stroke/transient ischemic attack (TIA) with AF|patients with Acute ischemic stroke/TIA and Atrial fibrillation (observational -no intervention)
11099373|NCT04080817|Experimental|Neolexon Therapy|
11099374|NCT04080817|Active Comparator|Standard logopedic therapy|
11099375|NCT04080804|Experimental|Nivolumab + Relatlimab|20 patients at Nivolumab 480mg IV + Relatlimab 160mg IV D1 - optional Nivolumab 480 mg IV + Relatlimab 160mg IV D28 (D28 at clinician discretion i.e. surgery postponed)
11099376|NCT04080804|Experimental|Nivolumab + Ipilimumab|20 patients at Nivolumab 240 mg IV + Ipilimumab 1mg/kg D1 then Nivolumab 240 mg D14 and then optional Nivolumab 240 mg D28 (D28 at clinician discretion i.e. surgery postponed)
11099377|NCT04080804|Experimental|Nivolumab|20 patients Nivo 480 mg IV D1 and then optional Nivo 480 mg IV D28 (D28 clinician discretion i.e. surgery postponed)
11099378|NCT04080791|Experimental|Experimental Group- Virtual Reality (VR) Treatment|The participants in the experimental group will complete the educational/training session on how to use the VR equipment and programs (30 minutes). The following day, participants will begin the VR intervention attending a daily 30-minute sessions for 8 days or until a discharge date has been set, whichever comes first.
11099379|NCT04080791|Active Comparator|Standard of care group|The control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol. Prior to discharge, control group participants will meet with a licensed clinical therapist to complete the cognitive and physical assessments for the posttest evaluation.
11099380|NCT04080778|Experimental|MST|
11099381|NCT04080778|Active Comparator|ECT|
11099382|NCT04080765|Experimental|HIV-ASSIST + DHHS arm|Decision-making support for ARV selection through DHHS guidelines in conjunction with HIV-ASSIST
11099383|NCT04080765|Active Comparator|DHHS-alone arm|Decision-making support for ARV selection through DHHS guidelines alone
11099384|NCT04080752|Experimental|JNJ-61393215 135 milligram (mg)|Participants will receive JNJ-61393215 135 mg (3*45 mg capsules) orally once daily for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
11099385|NCT04080752|Placebo Comparator|Placebo|Participants will receive matching placebo for 6 weeks along with the prescribed standard oral antidepressants (without dose change) throughout the study.
11099386|NCT04080739|Experimental|Experimental Group|US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.
11099387|NCT04080739|No Intervention|Control Group|No regional anesthetic of any kind during the surgical procedure.
11099388|NCT04080726|Experimental|HIP1601+HGP1705 Placebo|HIP1601+HGP1705 Placebo for 4weeks. if not fully cured, take HIP1601+HGP1705 Placebo for addtional 4weeks
11099390|NCT04080713|Experimental|Budesonide|
11099396|NCT04080661|Experimental|Standard of care - secukinumab|Patients will continue to receive secukinumab according to the standard dosing schedule: subcutaneous injections once a week for 5 weeks, then every 4 weeks (300 mg).
11099397|NCT04080648|Other|Standard of case - guselkumab|Patients will continue to receive guselkumab according to the standard dosing schedule; subcutaneous injection of 100 mg at weeks 0 and 4 and then every 8 weeks
11099398|NCT04080635|Experimental|Standard of care - brodalumab|Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
11099399|NCT04080622|Placebo Comparator|Placebo|Usual care
11099400|NCT04080622|Active Comparator|Selenium|Usual care + selenium 300 µg/day (IV infusion)
11099401|NCT04080609|Experimental|Sequential arm|Dorzagliatin was administered single dose; after wash-out, rifampicin was dosed continuously for 9 days, with Dorzagliatin dosed simultaneously on day 8.
11099402|NCT04080596|Experimental|Sequential arm|Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.
11099403|NCT04080583||Usual Care|People with a chronic lung condition who are physically inactive
11099404|NCT04080570|Experimental|Remote Visit|After an initial physical in-home visit, the physician will see home hospitalized patients by facilitated video each day.
11099405|NCT04080570|No Intervention|In-Home Visit|The physician will see home hospitalized patients physically in their homes each day, as is usual care.
11099406|NCT04080557||AAA patients that went to the ICU postoperatively|An retrospective cohort study was conducted that included all patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
11099407|NCT04080544|Experimental|Follow up DLBS participants|Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
11099408|NCT04080531|Experimental|Arm I (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
11099409|NCT04080531|Experimental|Arm II (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
11099410|NCT04080518|Active Comparator|Experimental|Dapagliflozin, 10mg, oral dose, once every day
11099411|NCT04080518|Placebo Comparator|Control|Matching placebo for dapagliflozin, oral dose, once every day
11099412|NCT04080505|Active Comparator|SSKI (Potassium Iodide)|Participants randomized to receive 7 days of pre-operative SSKI
11099413|NCT04080505|No Intervention|NO SSKI|Participants randomized to not receive any drug pre-operative
11099414|NCT04080492||Inherited Cardiac Disease|Patients being seen for the first time at the Cleveland Clinic for Hypertrophic Cardiomyopathy or Thoracic Aortic Aneurysm.
11099415|NCT04080492||Non-inherited Cardiac Disease|Patients being seen for the first time at the Cleveland Clinic for Radiation-Induced Heart Disease.
11099416|NCT04080479|Experimental|Bolus enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions:
~Quadriceps Muscle Layer Fitness measurement
~Muscle Strength measurement
~Acute Physiology and Chronic Health Evaluation
~Sequential Organ Failure Assessment
~Nutritional Risk Screening
~Energy and Protein Intake"
11099417|NCT04080479|Experimental|Continuous enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding.
~The study subjects will undergo the following interventions:
~Quadriceps Muscle Layer Fitness measurement
~Muscle Strength measurement
~Acute Physiology and Chronic Health Evaluation
~Sequential Organ Failure Assessment
~Nutritional Risk Screening
~Energy and Protein Intake"
11099418|NCT04080466|Experimental|Cam Group|This group will consist of patients that are scheduled for surgery to undergo cam resection by hip arthroscopy.
11099419|NCT04080466|Active Comparator|Control Group|This group will consist of a matched cohort of control participants.
11099420|NCT04080453||Septic shock|Plasma of 100 patients presenting a septic shock will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
11099421|NCT04080453||Systemic Inflammatory Response Syndrome|Plasma of 100 patient presenting a systemic inflammatory response syndrome = SIRS will be analysed including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1
11099422|NCT04080440|Active Comparator|Standard of care|Clinicians decide whether to extubate or not following their ICU protocol
11099423|NCT04080440|Experimental|Extubation readiness clinical score|Clinicians decide whether to extubate or not following the extubation readiness clinical score
11099424|NCT04080427|Placebo Comparator|Placebo capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.
~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
11099425|NCT04080427|Experimental|Dronabinol 7.5 milligram oral capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.
~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
11099426|NCT04080414|Experimental|Home-based high-intensity interval training|
11099427|NCT04080414|Active Comparator|Home-based moderate-intensity continuous exercise|
11099428|NCT04080401|Experimental|Fun-Knee Mobile Application|Participants will use a mobile application paired to a knee sleeve with embedded inclinometer sensors. The sensor system will compute knee movement, and feed towards game-based rehabilitation exercises for Total Knee Arthroplasty rehabilitation. game-based and supported on mobile device running on Android or Inter-network Operating System platforms. The mobile apps is able to capture the angle and position data from the two inclinometers on smart knee sleeve.
11099429|NCT04080401|Active Comparator|Conventional Exercise Brochures|Participants will be guided to do their Total Knee Arthroplasty rehabilitation exercises using conventional, paper-based exercise brochures.
11099430|NCT04080388|Active Comparator|Control Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The control group (half of the patients) will be discharged without additional intervention.
11099431|NCT04080388|Active Comparator|Interventional Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The interventional group (half of the patients) will continue anti-congestive treatment while hospitalized until achieving a suitable level of decongestion.
11099432|NCT04080375|Experimental|dinoprostone 3 mg|patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery
11099433|NCT04080375|Placebo Comparator|placebo|patients will take 1 tablet of placebo 1 hour before the surgery
11099434|NCT04080362|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral vavle repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
11099435|NCT04080349|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
11099436|NCT04080349|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
11099437|NCT04080349|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
11099438|NCT04080336|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
11099439|NCT04080336|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
11099440|NCT04080336|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
11099441|NCT04080323|Experimental|dinoprostone 3 mg|60 minutes before the surgery 3 mg of dinoprostone inserted vaginally
11099442|NCT04080323|Placebo Comparator|placebo|60 minutes before the surgery 1 tablet of placebo inserted vaginally
11099443|NCT04080310|Active Comparator|combination therapy group|The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.
11099444|NCT04080310|Other|intensive statin group|The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.
11099445|NCT04080297|Experimental|100 mg Q-122|10 patients treated with Q-122, 100 mg. Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.
11099446|NCT04080297|Experimental|200 mg Q-122|11 patients treated with Q-122, 200 mg. Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
11099447|NCT04080284|Experimental|Niraparib|"Oral niraparib
~-Cohort - Uterine serous carcinoma"
11099448|NCT04080258|Experimental|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMTh). Patients in the OMTh group will receive 5 Osteopathic manipulative therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The protocol will last for three months.
11099449|NCT04080258|Sham Comparator|Light Touch Therapy|Participants to the LTT group will receive the protocol at the same date of the OMTh group.
11099450|NCT04080245|Experimental|Treatment Group|
11099451|NCT04080232|Experimental|Lung MRI|lung MRI concordance as compared to chest CT-scan for the description of morphological abnormalities necessary for the diagnosis of BOS after HSCT. It will be evaluated using lung MRI performed after inclusion (D0) using a standardized procedure
11099452|NCT04080219||Normal|Patients with Oxygen desaturation index <5
11099453|NCT04080219||Sleep-disordered breathing|Patients with Oxygen desaturation index ≥5
11099454|NCT04080206|Experimental|188-0551 Spray|Investigational Topical Spray Product
11099455|NCT04080206|Active Comparator|Reference Listed Drug (RLD)|FDA Approved Topical Cream
11099456|NCT04080193|Experimental|Intervention Group|The study will be a Smartphone-based interventional trial. To assess the effectiveness of the intervention weight- and eating-related behavior and cognitive and emotional responding as well as body-weight will be assessed using questionnaires and ecological momentary assessment (EMA) for one week at a pre- (T0), post- (T1) and two follow-up-assessments after six (T2) and 12 months (T3).
11099457|NCT04080193|No Intervention|Control Group|Members of the control group will participate at each assessment. During the intervention phase they will receive treatment as usual.
11099458|NCT04080180|Active Comparator|Contingency Management (CM)|CM is a behavioral method that employs external rewards for target behavior. Participants will receive vouchers for adhering to treatment for their first 4 clinic visits.
11099459|NCT04080180|Active Comparator|BMI+SFAS|Participants will receive the BMI+SFAS intervention at 4 timepoints.
11099460|NCT04080180|Active Comparator|CM+BMI+SFAS|CM+BMI+SFAS is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.
11099461|NCT04080167|Other|Arm 1 (InCharge Health app)|Patient receives the InCharge Health app for 6 months
11099462|NCT04080167|Other|Arm 2 (HU Toolbox app)|Provider receives the HU Toolbox app for 9 months
11099463|NCT04080154|Experimental|Anlotinib|Anlotinib p.o., qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
11099464|NCT04080141||PD+|Subjects with personality disorder
11099465|NCT04080141||PD-|Subjects without personality disorder
11099466|NCT04080128|Other|Contact lens|Depending upon the study lens proven to be the most effective in the BLINK Study, this contact lens will be used for the first two years of the study. The last year of the study, all subjects will be wearing single vision contact lenses.
11099467|NCT04080115|Experimental|Attention Training Technique (ATT)|
11099468|NCT04080115|Active Comparator|Progressive Muscle Relaxation (PMR)|
11099473|NCT04080089||Case group|Children over the age of 6 who came to the outpatient clinic of our hospital received the informed consent of the parents, and then included in the case group, conducted a self-made sleep questionnaire, established a file, and monitored the sleep on the Mofeh Time Sleep Apnea Monitor. The results were uploaded to the cloud system for analysis. 50 children with OSAHS were screened. Voluntary participation in the study; ability to complete all tests as well as magnetic resonance studies. Exclusion criteria: 1 mental retardation, generalized developmental disorders, severe physical and endocrine diseases, neurological diseases and other mental disorders; 2 visual and auditory diseases affecting the processing of cognitive information. 3 Psychiatric drugs were used in January.
11099474|NCT04080089||Control group|Children in the same age group of children with health checkups were screened for sleep and questionnaires without sleep. After receiving parental informed consent, 30 children were included in the control group. Exclusion criteria: 1 mental retardation, generalized developmental disorder, learning disabilities, conduct Disorders, severe physical and endocrine diseases, neurological diseases and other mental illnesses. 2 There are visual and auditory diseases that affect the processing of cognitive information.
11099475|NCT04080076|Active Comparator|ACTHar gel combined with Tacrolimus|ACTH gel 80 units 2er week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks
11099476|NCT04080076|Active Comparator|ACTHar gel|ACTHar gel 80 units 2 er week for 52 weeks
11099477|NCT04080063|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
11099478|NCT04080050||RGX-501|Study participants who have received RGX-501 gene therapy in a separate parent trial
11099479|NCT04080037|Experimental|Study Participants|All eligible and consented participants will be asked complete a multiple-choice opioid assessment based on the latest CDC opioid guidelines, then care for 6 online QualityIQ patient simulations and receive feedback on their care decisions. They will then all complete an other multiple-choice assessment at the conclusion of the study.
11099480|NCT04080024|Experimental|Single dose (i.v.) SN132D|
11099481|NCT04080011|Experimental|NP-PWD application|All patients enrolled into the study will have the negative pressure- platform wound device applied to their surgical incision.
11099482|NCT04079998|Experimental|Procellera® dressing|The Procellera® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use.
11099483|NCT04079998|Active Comparator|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
11099484|NCT04079985|Experimental|Experimental Group|"The experimental Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus. The experimental group also underwent AAT. We conducted a total of 12 weekly sessions of 60 minutes each with 10 participants."
11099485|NCT04079985|Active Comparator|Control Group|"The Control Group underwent a therapeutic intervention based on sessions of kinesitherapy , which is defined as a set of therapeutic procedures that use movement for the treatment and prevention of diseases of the locomotive apparatus without the presence of the therapy dog."
11099486|NCT04079972|Experimental|personalized lifestyle intervention|to provide personalized lifestyle guidance for weight loss through SNP testing
11099487|NCT04079972|Active Comparator|general lifestyle intervention|to provide general lifestyle guidance for weight loss
11099488|NCT04079959||women who are undergoing frozen embryo transfer|endometrial biopsy will be done one cycle before the frozen embryo transfer
11099489|NCT04079946|Active Comparator|patients for whom Complete mesocolic excision will be done|
11099490|NCT04079946|Active Comparator|patients had conventional surgery before|
11099491|NCT04079933|No Intervention|Group 1: Continue Smoking|Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks
11099492|NCT04079933|Experimental|Group 2: OTDN|Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint) also under ad libitum conditions
11099493|NCT04079907|Experimental|Ketone|This arm will receive a supplement with 25g ketone ester. It is a commercially available supplement and will be provided as a standard dose.
11099494|NCT04079907|Placebo Comparator|Placebo|This arm will receive an isocaloric supplement.
11099495|NCT04079894||LSS Participants|Patients with lumbar spinal stenosis
11099496|NCT04079894||Healthy Participants|Healthy Participants
11099497|NCT04079881|Experimental|Pre-prandial insulin|will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min prior the meal.
11099498|NCT04079881|Experimental|Post-prandial insulin|will give short acting insulin (Humalog, Lispro, etc) with the same regimen patient was using at home 20 min post the meal.
11099499|NCT04079868|Experimental|Bone Health Service arm|Interventional arm
11099500|NCT04079868|Experimental|PACT practice management arm|Interventional arm
11099501|NCT04079868|No Intervention|Usual care (control) arm|"This arm represents a no practice management support control group."
11099502|NCT04079855|Experimental|Diet composition 1|A diet with a specified macronutrient composition different from arms 2, 3, and 4.
11099503|NCT04079855|Experimental|Diet composition 2|A diet with a specified macronutrient composition different from arms 1, 3, and 4.
11099504|NCT04079855|Experimental|Diet composition 3|A diet with a specified macronutrient composition different from arms 1, 2, and 4.
11099505|NCT04079855|Experimental|Diet composition 4|A diet with a specified macronutrient composition different from arms 1, 2, and 3 based on the current information about the US macronutrient composition.
11099506|NCT04079803|Placebo Comparator|Placebo Cohort|Placebo oral tablets administered twice daily (BID)
11099507|NCT04079803|Experimental|PTI-125, 100 mg tablets Cohort|PTI-125, 100 mg oral tablets administered twice daily (BID)
11099508|NCT04079803|Experimental|PTI-125, 50 mg tablets Cohort|PTI-125, 50 mg oral tablets administered twice daily (BID)
11099543|NCT04079569|Experimental|Tobacco|"Participants will receive education delivered by a lay health worker on Quit Smoking For a Healthy Family. Participants will receive written information on nutrition and physical activity."
11099509|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
11099510|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
11099511|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
11099512|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
11099513|NCT04079777||Clinical diagnosis of severe acute pancreatitis|"1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation.
~2. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases.
~3. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology.
~4, can except other similar clinical manifestations of lesions."
11099514|NCT04079777||mtDNA|"Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria.
~They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother."
11099515|NCT04079764||active surveillance|Patient with Bosniak III or IV lesion that decide to be followed under active surveillance
11099516|NCT04079764||Surgery|Patient with Bosniak III or IV lesion that decide to undergo a definitive treatment such as surgery
11099517|NCT04079751|Active Comparator|Neutral Mechanical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
11099518|NCT04079751|Active Comparator|Anatomical Alignment|Total knee arthroplasty: Neutral Mechanical Alignment vs Anatomical Alignment
11099519|NCT04079738|Experimental|Phase I:TAK-659 + Ixazomib|Phase I: TAK-659 (Days 1-15) + Ixazomib dose escalation (Days 1, 8, 15)
11099520|NCT04079738|Experimental|Phase II:TAK-659 + Ixazomib|Phase II: TAK-659 at MTD (Days 1-15) + Ixazomib at MTD (Days 1, 8, 15)
11099521|NCT04079725|Experimental|Experimental : Infants with primary congenital glaucoma|
11099522|NCT04079712|Experimental|Treatment (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
11099523|NCT04079699|Experimental|Liquid Biopsy|"Experimental arm where the liquid biopsy decides whether to perform an prostate biopsy or not"
11099524|NCT04079699|Other|Standard Biopsy|Standard arm, where every patient receives a standard prostate biopsy
11099525|NCT04079686|Experimental|Cephazolin|Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours
11099526|NCT04079686|Placebo Comparator|Sterile saline|Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours
11099527|NCT04079673|Active Comparator|Patient controlled epidural analgesia|Use of patient controlled epidural analgesia (PCEA) for postoperative pain control
11099528|NCT04079673|Sham Comparator|Intravenous patient controlled analgesia|Use of intravenous patient controlled analgesia(IVPCA) for postoperative pain control
11099529|NCT04079660||Surgical patients|Diabetic patients scheduled to undergo non-cardiac surgery
11099530|NCT04079647||Patient with endocrinopathy after immunotherapy|Patient with endocrinopathy after immunotherapy
11099531|NCT04079634|Experimental|Treatment|Placement of study device (EnsoETM) for temperature management
11099532|NCT04079634|Active Comparator|Control|Placement of standard temperature probe
11099533|NCT04079621|Experimental|(P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days plus a low dose course of primaquine (PQ) (3.5mg/kg total dose) given 7 days during schizontocidal treatment
11099534|NCT04079621|Experimental|(P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (3.5mg/kg total dose) given over 7 days during schizontocidal treatment.
11099535|NCT04079621|No Intervention|Standard care (P.f)|patients with falciparum malaria will receive artemether-lumefantrine (AL) twice daily over three days (plus a single dose PQ)
11099536|NCT04079621|No Intervention|Standard care (P.v)|patients with vivax malaria will receive chloroquine (CQ) daily for three days plus a low dose course of PQ (total dose 3.5mg/kg) over 14 days
11099537|NCT04079608|Experimental|FLASH curriculum|Students who will receive the FLASH high school curriculum.
11099538|NCT04079608|Active Comparator|Sexual Health Education for Adolescents|Students will receive a five-session knowledge-based sexual health curriculum designed for classroom settings.
11099539|NCT04079595|Experimental|Open-faced head immonbilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with openings for the face
11099540|NCT04079595|Active Comparator|Closed-face head immobilization masks|Masks used for immobilization of the head (CIVCO Radiotherapy, Orange City, Iowa) during radiation therapy with the face closed
11099541|NCT04079582|Experimental|Higher dialysate magnesium|
11099542|NCT04079582|Active Comparator|Lower dialysate magnesium|
11099628|NCT04079062|Experimental|KLH+placebo (Part B)|
11099544|NCT04079569|Active Comparator|Healthy Living|"In this comparison arm, participants will receive education delivered by the lay health worker about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
11099545|NCT04079556|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
11099546|NCT04079543|Other|Strict NPO|NPO after midnight. No solids or liquids after midnight.
11099547|NCT04079543|Other|Liberal NPO|No solids after midnight. Clear liquids up to 2 hours prior to surgery.
11099548|NCT04079530|Experimental|Treatment A|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
11099549|NCT04079530|Experimental|Treatment B|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
11099550|NCT04079530|Experimental|Treatment C|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
11099551|NCT04079530|Experimental|Treatment D|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
11099552|NCT04079530|Experimental|Treatment E|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
11099553|NCT04079530|Experimental|Treatment F|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
11099554|NCT04079530|Experimental|Treatment G|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
11099555|NCT04079530|Experimental|Treatment H|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
11099556|NCT04079530|Experimental|Treatment I|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
11099557|NCT04079530|Experimental|Treatment J|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
11099558|NCT04079530|Experimental|Treatment K|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
11099559|NCT04079530|Experimental|Treatment L|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
11099560|NCT04079517|Experimental|Tamoxifen 10mg|Randomised dose of daily oral Tamoxifen 10mg, for 180 days
11099561|NCT04079517|Active Comparator|Tamoxifen 20mg|Randomised dose of daily oral Tamoxifen 20mg, for 180 days
11099562|NCT04079504|Active Comparator|Ligation|Ligation of indirect inguinal hernia sac in inguinal hernioplasty patients
11099563|NCT04079504|Experimental|Non-ligation|Non-Ligation of Indirect inguinal hernia sac/ simple inversion/reduction of indirect inguinal hernia sac in inguinal hernioplasty patients
11099564|NCT04079491||dental hygienists|all dental hygienists members in the trade union for dental hygienists
11099565|NCT04079478||AI|Artificial Intelligence colonoscopy
11099566|NCT04079478||Control|White light colonoscopy
11099567|NCT04079465|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 24 hours or until weaning from oxygen supplementation
11099568|NCT04079465|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic is used in monitoring mode to measure SpO2 continuously.
11099569|NCT04079452|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) coformulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 4 weeks
11099570|NCT04079439|Other|Intervention|Tailored e-heath support for physical activity with a focus on communication and rewards, using commercial accelerometers for measurements
11099571|NCT04079439|No Intervention|Control group|Standard care
11099572|NCT04079413|Experimental|GP40071|Subcutaneous (SC), before meals intake, up to Week 26
11099573|NCT04079413|Active Comparator|NovoRapid® Penfill®|Subcutaneous (SC), before meals intake, up to Week 26
11099574|NCT04079400||Tb group|Subjects who underwent bronchoscopy for suspicious endobronchial pulmonary tuberculosis (Tb) observed on chest computed tomography
11099575|NCT04079400||NTM-PD group|Subjects who underwent bronchoscopy for suspicious non-tuberculous mycobacterial pulmonary disease (NTM-PD) observed on chest computed tomography
11099576|NCT04079400||LC group|Subjects who underwent bronchoscopy for suspicious endobronchial lung cancer (LC) observed on chest computed tomography
11099577|NCT04079400||HM group|Subjects who underwent bronchoscopy for hemoptysis
11099578|NCT04079400||Control group|Subjects who underwent bronchoscopy to rule out endobronchial lesion observed on chest computed tomography. Endbronchial lesion should not be typical for any category of respiratory diseases including tuberculosis, NTM-TB and lung cancer.
11099579|NCT04079387|Experimental|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°."
11099580|NCT04079387|Active Comparator|ENDOTRACHEAL TUBE ALONE|The control group consists in intubating the trachea with an endotracheal tube alone (i.e, without stylet).
11099581|NCT04079374|Experimental|Etanercept|Patients receive Etanercept in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
11099582|NCT04079374|Active Comparator|Enbrel|Patients receive Enbrel in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
11099583|NCT04079361|Other|Pregnancy complication|Intervention: blood samples
11099584|NCT04079348|Active Comparator|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application Oasis Extracellular Matrix to their donor site wound.
11099585|NCT04079348|Active Comparator|Standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
11099586|NCT04079322|Experimental|Exercise|During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
11099587|NCT04079322|Experimental|Rest|"The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (<6 miles at a self-described easy pace) later in the afternoon."
11099588|NCT04079309|No Intervention|No Intervention|No mist will be diffused into the environment.
11099589|NCT04079309|Active Comparator|Lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
11099590|NCT04079309|Active Comparator|Orange|0,3 ml orange oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
11099591|NCT04079296|Experimental|Phase 1 ASP7517 Dose Escalation|Two single doses of ASP7517 will be administered intravenously at up to 3 dose levels and will be based on the assessment of safety variables, including the occurrence of dose limiting toxicities (DLTs).
11099592|NCT04079296|Experimental|Phase 2 ASP7517 Dose Expansion|Two single doses of ASP7517 will be administered intravenously at the dose levels determined from the Dose Escalation phase.
11099593|NCT04079283||Monotherapy|Patients who has received mono-therapy of immune checkpoint inhibitor.
11099594|NCT04079283||Combined therapy|Patients who has received immune checkpoint inhibitor combining chemotherapy.
11099595|NCT04079270|Experimental|Personalized algorithm-based diet|The intervention arm will be an 'algorithm-based' arm in which patients will receive personally tailored dietary recommendations, based on their microbiome, and other clinical data such as blood tests and lifestyle features.
11099596|NCT04079270|Active Comparator|standard Mediterranean low-fat diet|The control arm will receive nutritional recommendations according to the standard Israeli dietary approach Mediterranean-style low-fat diet.
11099597|NCT04079257||Patients with paroxysmal nocturnal hemoglobinuria|Patients are already treated with eculizumab. The only intervention is the collection of extra blood samples to measure peak concentrations of eculizumab
11099598|NCT04079244|Active Comparator|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.
~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children"
11099599|NCT04079244|Active Comparator|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.
~The cartoon used is L'âge de glace, an animated cartoon geared to children."
11099600|NCT04079231|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
11099601|NCT04079231|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
11099602|NCT04079218|Experimental|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
11099603|NCT04079218|No Intervention|No treatment|No intervention
11099604|NCT04079205|Experimental|Home rehabilitation using Wearable Device|Home rehabilitation using Wearable Device(exoRehab)
11099605|NCT04079205|Active Comparator|Control|Standard home rehabilitation program
11099606|NCT04079192|Experimental|Biolimus A9™ Drug Coated Balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon
11099607|NCT04079192|Active Comparator|Sequent ® Please Paclitaxel coated balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon
11099608|NCT04079179|Experimental|Patients < 30 years with recurrent LCH (Grp1)|Children and young adults (<30 years) with recurrent active LCH lesions (may also have LCH-ND).
11099609|NCT04079179|Experimental|Patients of any age with LCH-ND (Grp2)|Patients of any age with progressive LCH Neurodegenerative Disease (LCH-ND) without other sites of active LCH.
11099610|NCT04079179|Experimental|Patients <30 years with other histiocytic disorders (Grp3)|Newly diagnosed or relapsed/refractory children and young adults (<30 years) with other histiocytic disorders including juvenile xanthogranuloma, Erdheim-Chester disease, histiocytic sarcoma and Rosai-Dorfman disease.
11099611|NCT04079179|Experimental|Patients ≥ 30 years with LCH/histiocytic disorders (Grp4)|Adults (≥30 years) with LCH or other histiocytic disorder with recurrent active lesions (may also have LCH-ND).
11099612|NCT04079166|Experimental|SCIB1|SCIB1 administered using the TDS-IM v2.0 device
11099613|NCT04079153|Active Comparator|25% of maximal mandibular advancement|25% of maximal mandibular advancement of individual protrusion range
11099614|NCT04079153|Active Comparator|50% of maximal mandibular advancement|50% of maximal mandibular advancement of individual protrusion range
11099615|NCT04079140|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
11099616|NCT04079140|Placebo Comparator|placebo|one tablet of placebo self-administered by the patient 12 hours before IUD insertion.
11099617|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
11099618|NCT04079101|Experimental|BIIB104 0.15 mg|Participants will receive multiple oral doses of BIIB104 0.15 mg capsules twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10.
11099619|NCT04079101|Experimental|BIIB104 0.5 mg|Participants will receive multiple oral doses of BIIB104 0.5 mg capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
11099620|NCT04079101|Experimental|Placebo|Participants will receive multiple oral doses of placebo-matched BIIB104 capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
11099621|NCT04079088|Placebo Comparator|Placebo|Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
11099622|NCT04079088|Experimental|BIIB061 Dose 1|Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
11099623|NCT04079088|Experimental|BIIB061 Dose 2|Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
11099624|NCT04079088|Experimental|BIIB061 Dose 3|Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
11099625|NCT04079075|Experimental|Non-pharmacological intervention|"Non-pharmacological strategy, implemented in groups of 10 participants, over 10 consecutive months, based on five different interventions:
~cognitive training, physical activity; nutrition education; adaption to memory loss; detection and correction of hearing impairment."
11099626|NCT04079062|Experimental|ONO-4685 (PartA, D)|
11099627|NCT04079062|Placebo Comparator|Placebo (PartA, D)|
11099631|NCT04079049|Experimental|Surgical intervention|Surgical and oncological treatment
11099632|NCT04079049|Active Comparator|Control|Oncological treatment
11099633|NCT04079036||Underweight Adult Male|Male patients with Underweight BMI classification and more than 20 years old https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
11099634|NCT04079036||Healthy Weight Adult Male|Male patients with Healthy Weight BMI classification and more than 20 years old
11099635|NCT04079036||Overweight Adult Male|Male patients with OverWeight or Obese BMI classification and more than 20 years old
11099636|NCT04079036||Underweight Adult Female|Female patients with Underweight BMI classification and more than 20 years old
11099637|NCT04079036||Healthy Weight Adult Female|Female patients with Healthy Weight BMI classification and more than 20 years old
11099638|NCT04079036||Overweight Adult Female|Female patients with Overweight or Obese BMI classification and more than 20 years old
11099639|NCT04079036||Underweight children Male|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
11099640|NCT04079036||Healthy Weight children Male|Male patients less than 20 year old, and with Healthy Weight BMI classification
11099641|NCT04079036||Overweight children Male|Male patients less than 20 year old, and with Overweight or Obese BMI classification
11099642|NCT04079036||Underweight children Female|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
11099643|NCT04079036||Healthy Weight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
11099644|NCT04079036||Overweight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
11099645|NCT04079023||Obese|30 obese patients (12 M/ 18 F) with a mean BMI of 46 candidate to SG Alcohol drink mean volume: 158 Ml administered in 10 minutes
11099646|NCT04079010|Placebo Comparator|Control|Participants will adhere to resistance training protocol.
11099647|NCT04079010|Active Comparator|BFR (blood flow restriction)|Participants will adhere to resistance training protocol, while also applying a blood flow restriction cuff during resistance training.
11099648|NCT04079010|Active Comparator|BFR (blood flow restriction), plus Arginine|Participants will adhere to resistance training protocol, apply a blood flow restriction cuff during resistance training, and will take the clinically safe dose of arginine prior to training sessions.
11099649|NCT04078997||PCV13-vaccinated,15-24 months of age|"Recruitment for carriage surveillance (primary endpoint) will take place at randomly selected households within each of the catchment areas (zones) of the 20 selected health centers.
~Sampling: Random sampling from populations will occur preferentially around the health centers and not from the population on the zonal interfaces. Researchers will designate two geographic sampling areas within each zone around each health center that allows a buffer against zonal borders. If the recruitment target within first sampling area is not met, sampling will move into the second area."
11099650|NCT04078997||PCV13-vaccinated, 5-10 years of age|"Six schools will be selected: three located centrally in each of the 3+0 zones, and three in the 2+1 zones.
~Sampling: Children will be randomly chosen and recruited from each school. NP swab collection will occur during two surveys, starting 21 and 34 months after the switch to 2+11.
~Mapping analysis from our current surveillance activities shows good clustering of recruited children living around the school, suggesting limited movement and thus low risk of contamination between zones with different vaccination schedules."
11099651|NCT04078997||PCV13-unvaccinated HIV-infected adults on ART 18 - 40 years of|"Adults will be recruited from the Queen Elizabeth Central Hospital (QECH), Lighthouse ART clinic in Blantyre.
~Sampling: Mapping analysis from current surveillance activities shows good distribution throughout the Blantyre area, suggesting it is possible to achieve balance between those adults residing in 2+1 vs 3+0 areas. Sample collection will be on a rolling basis throughout the study period, starting 18 months after switch to 2+1."
11099652|NCT04078997||PCV13-vaccinated, 9 months of age|"Recruitment will take place at vaccination centers.
~Sampling: A convenience sample of NP swabs will be collected at the 9-month (measles-1) visit. Sample collection will occur 9 months after the switch to 2+1 schedule."
11099653|NCT04078984||Experimental|Experimental group is composed by patients that enter the weaning phase following a moderate to severe Acute Respiratory Distress Syndrome (ARDS) equiped with a nasogastric allowing measures of Electrical Activity of diaphragm (EAdi) will be included. Driving Pressure will be measured following the method used by Bellani et al. A weaning test will be conducted daily.
11099654|NCT04078971|Experimental|Ketogenic diet|Ketogenic diet: less than 30 g/day of carbohydrate. Subjects can eat beef, veal, poultry, fish, raw and cooked vegetables without restriction, cold cuts such as dried beef, eggs and seasoned cheese (parmesan), ketogenic pasta (selected with a ketogenic ratio of 4:1), fruits with the lowest glycemic index (blueberry, raspberry), raw nuts and seeds, ghee butter, plant oils and fats from avocado, coconut and olives
11099655|NCT04078971|Active Comparator|Western diet|The western diet (WD) is composed mainly of whole cereals (spelt, rye, oat) and pseudo-cereals (buckwheat, quinoa, amaranth), whole grain pasta, potatoes, meet, fish, vegetables, fruit, legumes, olive oil, milk and red wine (at most 1 glass per day). It ensure a constant energy and macronutrient balance: protein 1.8g x Kg-1 x body weight-1 x day-1, (30%), fats 20-25% and carbohydrate 50-55%.
11099656|NCT04078958|Experimental|Salmon fishmeal|5 g fishmeal in capsules, single oral dose
11099657|NCT04078958|Active Comparator|Whey|5 g whey in capsules, single oral dose
11099658|NCT04078932|Experimental|Intervention|Cohort of residents trained in the conversation script who will utilize the script at pediatric clinic visits. Will evaluate baseline feelings of comfort and self-efficacy prior to being trained in the script (pre-intervention measures). After being trained in the conversation script (the intervention), the following will be measured (post-intervention measures): frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
11099659|NCT04078932|No Intervention|Control|Cohort of residents at another clinical site with a similar community demographic make-up who do not receive the intervention. In the control group, we will measure frequency of facilitating conversations on safely navigating police encounters in clinical practice, feelings of comfort and self-efficacy.
11099660|NCT04078919|Active Comparator|Low calorie diets with nuts|Low calorie diet in which 20 percent of daily calories will be provided from nuts
11099662|NCT04078906|No Intervention|Control group|Conventional IVLE (Intralipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
11099663|NCT04078906|Experimental|Experimental group|n3-LCPUFA enriched IVLE (SMOFlipid) from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
11099664|NCT04078893|No Intervention|control group|
11099665|NCT04078893|Experimental|on need group|
11099666|NCT04078893|Experimental|communication group|
11099667|NCT04078880|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus ascorbic acid, other than the standard of care.
11099668|NCT04078880|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
11099669|NCT04078867||DeVega|The DeVega repair is performed when the patient had minimal annular dilation and lower severity of pulmonary hypertension
11099670|NCT04078867||MC3 ring|MC3 ring annuloplasty is performed in patients with severe tricuspid annular dilation and severe pulmonary hypertension
11099671|NCT04078854|Experimental|Foot amputation, sexual health|Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health
11099672|NCT04078854|Active Comparator|Foot amputation, no sexual health|Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health
11099673|NCT04078841|Active Comparator|ReaLife+ (RLP)|Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
11099674|NCT04078841|Placebo Comparator|Inert Brown Powder|"Brown powder
~Inert brown powder to look similar to RLP"
11099675|NCT04078841|No Intervention|Control|Control
11099676|NCT04078828|Active Comparator|PR|
11099677|NCT04078828|Active Comparator|Non-PR|
11099678|NCT04078802|Experimental|VNOTES ARM|treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.
11099679|NCT04078802|Experimental|Vaginal hysterectomy Arm|treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.
11099680|NCT04078776||Lean Individuals|waist circumference ≤94 cm (men) and 80 cm (women) and BMI ≥ 21.0 kg/m2
11099681|NCT04078776||Obese Individuals|waist circumference ≥102cm (men) and 88 cm (women) and BMI ≥ 30.0kg/m2
11099682|NCT04078763|Experimental|visual-auditory feedback|Patients included in this arm will follow the rehabilitation protocol with visual-auditory feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
11099683|NCT04078763|Experimental|visual feedback|Patients included in this arm will follow the rehabilitation protocol with visual feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
11099684|NCT04078750|Sham Comparator|Phase I. Control group|"The standard of care will be provided to the control group pre- and post-transplant. This does not involve any direct pre-transplant assessment of medication adherence or risk factors for non-adherence.
~Tacrolimus capsules will be dispensed in Medication Event Monitoring System (MEMS) caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.
~Patients will be asked to complete Basel Assessment of Adherence to Immunosuppressive Medication instrument (BAASIS) questionnaire and Long-term Medication Behaviour Self-efficacy Scale at 3 months after transplantation."
11099685|NCT04078750|Experimental|Phase II. Intervention group|Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial. Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules. MEMS® is designed to record the date/time of opening and closure of the drug vial. Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day. Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant.Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence. Patients will also undergo health literacy, cognition testing, self-efficacy tests, with a customized post-transplant plan.
11099686|NCT04078737|Experimental|Ticagrelor plus Aspirin Group|Ticagrelor of loading dosing of 180mg followed by 90mg bid for 3 months plus aspirin of loading dose of 75-300mg followed by 75mg daily for 21 days
11099687|NCT04078737|Active Comparator|Clopidogrel plus Aspirin Group|Clopidogrel of loading dosing of 300mg followed by 75mg daily for 3 months plus aspirin loading dose of 75-300mg followed by 75mg daily for 21 days
11099688|NCT04078724|Active Comparator|Normal subject without 5-HTP|Subjects with normal cognition will be randomly assigned to not consuming 5-HTP.
11099689|NCT04078724|Experimental|Normal subject with 5-HTP|Subjects with normal cognition will be randomly assigned to consuming 100 mg of 5-HTP.
11099690|NCT04078724|Active Comparator|MCI subject without 5-HTP|Subjects with MCI will be randomly assigned to not consuming 5-HTP.
11099691|NCT04078724|Experimental|MCI subject with 5-HTP|Subjects with MCI will be randomly assigned to consuming 100 mg of 5-HTP.
11099692|NCT04078711|Experimental|losartan & qianyangyuyin|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
11099693|NCT04078711|Placebo Comparator|Losartan & Placebo|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
11099694|NCT04078685|Active Comparator|CONVENTIONAL group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter
11099695|NCT04078685|Experimental|CONTACT-FORCE group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter
11099696|NCT04078672|Experimental|AMD|NOTAL-OCT V3.0 scan
11099697|NCT04078659|Experimental|Propofol infusion|Patients received intravenous Propofol infusion
11099698|NCT04078659|Experimental|Magnesium Sulfate infusion|Patients received intravenous Magnesium Sulfate infusion
11099699|NCT04078646|Experimental|Dietary intervention|Intervention with test meal only
11099700|NCT04078646|Experimental|Dietary intervention 2|Intervention with test meal and whey protein isolate (30 g)
11099701|NCT04078646|Experimental|Dietary intervention 3|Intervention with test meal and soy protein (30 g)
11099702|NCT04078633|Experimental|Normal Liquid Soap (250mL)|A normal hygiene kit will be distributed to the households. In addition, a liquid soap will be added to see the impact of having a liquid soap for hand washing on hygiene behaviors.
11099703|NCT04078633|Experimental|Bar soap (250gram)|A normal hygiene kit will be distributed to the households. In addition, a nice bar soap will be added to see the impact of having a nicer bar soap for hand washing on hygiene behaviors.
11099704|NCT04078633|Experimental|Mirror (50x30cm)|A normal hygiene kit will be distributed to the households. In addition, a mirror will be added to see the impact of having a mirror by the handwashing stand on handwashing behaviour. The mirror will have a plastic edge and be 30x 50cm in size.
11099705|NCT04078633|No Intervention|Control|A normal hygiene kit will be distributed to the households. No additional interventions will be given.
11099706|NCT04078633|Experimental|Nurture story for hygiene promotion|Hygiene promoters will share a story of being a good parent through teaching their children to do hand washing with soap at critical times. A story about a good mother who every day reminds her child to wash her/his hands before eating or preparing food and after going to the toilet will be shared with participants. The story ends with the child growing up healthy, happy and with a good education. This story if belived to increae handwashing with soap in the household/
11099707|NCT04078633|Experimental|Comfort story for hygiene promotion|Hygiene promoters will deliver hygiene promotion through an activity that provoke the feeling of comfort by having clean hands. Hygiene promoters will deliver this intervention to up to 5 neighbor households at the time, sharing a story about a family that keeps good hygiene behaviors and therefore are clean, healthy and happy. This story is believed to encourage families to increase handwashing with soap in the household.
11099708|NCT04078633|No Intervention|Education session for hygiene promotion|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
11099709|NCT04078633|Experimental|Hygiene Promotion Activity - Disgust|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will use 5 buckets of clean water and place them in front of households. They will then ask a member of one of the households to rinse their hands in the first bucket. Some dirt will come of their hands. Then the participant rinses their hands again in bucket number 2, then 3 and then 4. Before the 5th bucket the participant receives a bar of soap to use when they rinse their hand. When they do the water will have a dirty colour as the dirt comes of their hands. This activity is believed to encourage handwashing with soap.
11099710|NCT04078633|Experimental|Hygiene Promotion Activity - Comfort|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will bring some food oil and ask participants to cover their hands in food oil. They will then ask the participants to cover their hands in turmeric powder. The participants will then be asked to wash their hands with water only. This will have little effect on the cleanliness of their hands. Then participants will be given a bar of soap. The participants will then be asked to wash their hands again. This will leave their hands nice comfortable and clean. They will experience the comfort of clean hands and the activity hope to increase regular handwashing.
11099711|NCT04078633|No Intervention|Education Hygiene Promotion Activity|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
11099712|NCT04078607|Experimental|Distraction|Distraction during eating using the Rapid Visual Information Processing task as the distraction
11099713|NCT04078607|Placebo Comparator|Control|No distraction during eating
11099714|NCT04078594|Experimental|Experimental wards|Active sepsis e-alert
11099715|NCT04078594|No Intervention|Contol wards|"Masked sepsis e-alert.
~The wards will have masked sepsis e-alert."
11099716|NCT04078581|Experimental|healthy controls|Questionnaire and fecal sample collection
11099717|NCT04078568|Active Comparator|the standard group|"IVIG 2g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness."
11099718|NCT04078568|Experimental|the standard+prednisolone group|"IVIG 2g/kg once, given within 12 to 24 hours;
~Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and CRP is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
~Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days . If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued."
11099719|NCT04078555|Experimental|ENERGI-F703 GEL|topical application on target venous leg ulcer, twice daily
11099720|NCT04078555|Placebo Comparator|ENERGI-F703 GEL matched vehicle|topical application on target venous leg ulcer, twice daily
11099721|NCT04078542||Chronic cough|Subject complaining cough from at least 8 weeks
11099722|NCT04078529|Experimental|Intervention group|This group will complete a 5 day falls prevention training programme, followed by a 12 week home exercise programme, then a repeat 5 day training intervention.
11099723|NCT04078529|Active Comparator|Comparison group[|This group will complete the home exercise programme only.
11099724|NCT04078516||Type 1 diabetes and painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
11099725|NCT04078516||Type 1 diabetes and non-painful neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
11099726|NCT04078516||Type 1 diabetes and no neuropathy|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
11099727|NCT04078516||Matched controls without diabetes|No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.
11099728|NCT04078503||Case|All patients aspected to stay in ICU for at least 3 days who will develop delirium
11099729|NCT04078503||Control|All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).
11099730|NCT04078477|Experimental|Lateral tilt bed|Special lateral tilt bed.
11099731|NCT04078477|No Intervention|Body positioning|Standard NICU preventive strategy
11099732|NCT04078464|Experimental|Acute Physical Activity + Mindfulness training|20 minutes of walking on a treadmill at a moderate pace while listening to a pre-recorded guided mindfulness meditation.
11099733|NCT04078464|Experimental|Mindfulness training|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 20 minutes.
11099734|NCT04078464|Experimental|Acute Physical Activity|20 minutes of walking on a treadmill at a moderate pace.
11099735|NCT04078451|Experimental|the experimental group|"The experimental group operated by the left side of laparoscopic cholecystectomy preserving the main cystic artery.
~The operation area of cystic artery dissection is moved from the traditional triangular area to the gallbladder neck plane, away from the hepatic duct and hepatic portal.Only the superficial and even more minute branches of the cystic artery were isolated and coagulated."
11099736|NCT04078451|No Intervention|the control group|treated with conventional laparoscopic cholecystectomy cutting the cystic artery
11099737|NCT04078438|Experimental|neurofeedback augmentation group|The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
11099738|NCT04078438|Active Comparator|medication-only (treatment as usual, TAU) group|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
11099739|NCT04078438|No Intervention|healthy controls|The healthy controls provided blood samples using the same procedure at baseline only.
11099740|NCT04078425|Experimental|HF with preserved EF|50patients of heart failure with preserved ejection fration will receive anti.failure treatment(lanoxin,beta blocker,diuretics) for one month with follow up echocardiography before and after
11099741|NCT04078425|Experimental|HF with preserved EF recive eplernone|50 patients with heart failure with preserved ejection frationnwill receive traditional anti-failure treatment in addition to aldosterone antagonist (Eplernone) with follow up echocardiography and aldosterone level before and after
11099742|NCT04078412||NTM pulmonary disease|Cohort Description: adults NTM pulmonary disease patients diagnose by criteria of American thoracic society guideline
11099743|NCT04078399|Experimental|patients with recurrence after allogeneic transplantat|One arm
11099744|NCT04078386|Experimental|RC18 240mg|
11099745|NCT04078386|Experimental|RC18 160 mg|
11099746|NCT04078386|Placebo Comparator|Placebo|
11099747|NCT04078373||Without urinary disorders|Subacute stroke patients without urinary disorders
11099748|NCT04078373||With urinary disorders|Subacute stroke patients with urinary disorders
11099749|NCT04078360|Experimental|Mobile-based intervention (AMBIT)|This arm will receive a mobile based program delivered over messages/IVR calls.
11099750|NCT04078360|Active Comparator|Face-to-face counselling|This arm will receive a brief counselling session from a trained health worker.
11099751|NCT04078360|Active Comparator|Active control|This arm will receive an educational BI leaflet.
11099752|NCT04078347||Paravertebral block at T 4 and T 5 level|Patients scheduled for elective surgery with planned paravertebral block at T 4 and T 5 level will receive thermography measurements start at 5 min before the block and continoue to 20 min after the block. Chenges of temperature in the interested region on the chest wall will be recorded.
11099753|NCT04078334|Experimental|Group 1|PATH Tool : Prescription of exercise programs at discharge
11099754|NCT04078334|Experimental|Group 2|PATH 2.0 Tool : Prescription of exercise programs during hospitalization and discharge
11099755|NCT04078334|Experimental|Group 3|MATCH tool: Prescription of physical exercise programs during hospitalization
11099756|NCT04078334|No Intervention|Group 4|Control group: Usual care by the clinical teams
11099757|NCT04078321|Experimental|Single case design|Single case studies
11099758|NCT04078308|Experimental|Mesenchymal Stem Cells Transplantation|The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells
11099759|NCT04078308|Placebo Comparator|Placebo|The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)
11099760|NCT04078295|Experimental|Phase 1b: E7389-LF + Nivolumab|Participants will receive specified doses of E7389-LF (intravenous) and nivolumab (intravenous) on specified days.
11099761|NCT04078295|Experimental|Phase 2, Cohort-1: E7389-LF + Nivolumab|Participants with gastric cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
11099762|NCT04078295|Experimental|Phase 2, Cohort-2: E7389-LF + Nivolumab|Participants with esophageal cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
11099763|NCT04078295|Experimental|Phase 2, Cohort-3: E7389-LF + Nivolumab|Participants with small cell lung cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
11099764|NCT04078282|Experimental|Active treatment group|Patients will meet in a joint consultation with their family physician and a psychiatrist for evaluation. Then it follows three treatment sessions with the family physician before a new joint consultation with the psychiatrist. The intervention ends with three more treatment sessions with the family physician.
11099765|NCT04078282|Active Comparator|Control group|Patients belonging to family physicians who constitute the control group will be assessed and given treatment according to usual care. This may include treatment by the family physician, medication, referrals to specialized care.
11099766|NCT04078269|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIXNEO-LUNG autologous DC vaccine
11099880|NCT04077567|Experimental|TS-152 30mg SC|TS-152 30mg subcutaneously (SC) every 4 weeks
11099767|NCT04078256|Experimental|Experimental group|Group will carry out the proprioceptive exercise program during 8 weeks at the begining of the season
11099768|NCT04078256|Placebo Comparator|Control group|Control group will continue with their usual training routine
11099769|NCT04078243||CardioMEMS HF System|Eligible patients will be recruited and will attend for the implantation in line with standard of care procedures. The patient's details will be uploaded to the CardioMEMS HF system, enabling remote monitoring of their heart failure device. The patient will also be given a Fitbit activity monitor and set up with an account that is accessible to patient and physician to allowing activity to be monitored. The research team will be able to continuously monitor data remotely from the CardioMEMS HF system and Fitbit platform.
11099770|NCT04078230|Experimental|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
11099771|NCT04078230|No Intervention|Regional LymphAdenectomy|Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.
11099772|NCT04078217|Experimental|Jintronix|Jintronix Rehabilitation System uses Microsoft Kinect cameras to track patient's movements in 3D during exercises. They are programmed as games that are visualized on a TV and for which performance feedback is provided to the participant. Individualized asynchronous supervised home-base exercise program using the Jintronix System, 3 times/week for 12 weeks (36 sessions). A trained kinesiologist will install the system and supervise the exercise program, in person and remotely.
11099773|NCT04078217|Active Comparator|Control|Participants in this group will follow an individualized non-supervised home-based exercise program (booklet format). The exercise program will include 3 sessions per week for 12 consecutive weeks, as for Jintronix group. Actually, all movements of the booklet program are selected to match the exercise-games of the technology (similar movement, muscles engagement, etc.). A trained kinesiologist will explain and supervise the exercise program for the first sessions. The communication frequence will be the same as the Jintronix group.
11099774|NCT04078204|Experimental|Butylphthalide Soft Capsules|Two Butylphthalide soft capsules will be taken three times a day before meals.
11099775|NCT04078204|Placebo Comparator|Placebo Soft Capsules|Two placebo soft capsules will be taken three times a day before meals.
11099776|NCT04078191|Experimental|RA Subjects on Stable Therapy|RA subjects who are on stable treatment will receive a single dose of 150 mcg tilmanocept radiolabeled with 10 mCi Tc 99m.
11099777|NCT04078178|Other|Randomized Crossover|The primary outcome of this study will be objective measures of cognitive performance measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, crossover, and the end of study. Subjects will receive 1200 mg Niagen and PBO dispensed in randomized blocks. All subjects will receive both.
11099778|NCT04078165|Experimental|Zero-Gravity|In this group, the operator uses the Zero-Gravity protection system
11099779|NCT04078165|Active Comparator|Conventional|In this group, the operator uses conventional radiation protection
11099780|NCT04078152|Experimental|Treatment|Durvalumab Monotherapy
11099781|NCT04078152|No Intervention|Off Treatment|Follow up Only
11099782|NCT04078139|Experimental|The MP/RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 40mg methylprednisolone, plus 10ml saline;
11099783|NCT04078139|Active Comparator|The RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10ml saline;
11099784|NCT04078126|Experimental|Budesonide and formoterol fumarate (MDI BFF)|Subject treated with MDI BFF followed by washout period
11099785|NCT04078126|Active Comparator|Symbicort Turbuhaler|Subject treated with Symbicort followed by washout period
11099786|NCT04078113|Experimental|Experimental group|Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.
11099787|NCT04078113|No Intervention|Control group|"Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.
~Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not."
11099788|NCT04078100||group A|underwent mitral valve surgery through transseptal approach.
11099789|NCT04078100||group B|underwent mitral valve surgery through conventional left atrial approach.
11099790|NCT04078087||Non obese|"Non obese (whether normal weight or overweight) = Group NO"
11099791|NCT04078087||Obese|"obese = Group O"
11099792|NCT04078074|Experimental|Maxillary OSS|
11099793|NCT04078074|Experimental|Mandibular OSS|
11099794|NCT04078074|Experimental|Modified farrar splint|
11099795|NCT04078061|Active Comparator|MABA|
11099796|NCT04078061|Active Comparator|EIBI|
11099797|NCT04078048|Experimental|Vitamin C Group|Tablet Vitamin C 500 mg Once a day
11099798|NCT04078048|Experimental|Vitamin E Group|Tablet Vitamin E 600 I U Twice daily
11099799|NCT04078048|Placebo Comparator|Placebo Group|Capsule Paraffin oil 500 mg Once a day
11099800|NCT04078035|Experimental|Socio-evaluative Speech Stress, then Control|Participants will attend two laboratory sessions. At the first session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated. At the second session, participants will rest quietly for the same period as the speech task, in the absence of the stressor.
11099823|NCT04077892|Active Comparator|only intranasal budesonide|treatment with only intranasal budesonide 1 spray per nostril twice daily for 14 days (BD treatment group)
11099881|NCT04077567|Experimental|TS-152 80mg SC|TS-152 80mg subcutaneously (SC) every 4 weeks
11099882|NCT04077554||Study group|women and men with excess body mass
11099883|NCT04077554||Control group|women and men with proper body mass
11099801|NCT04078035|Experimental|Control, then Socio-Evaluative Speech Stress|Participants will attend two laboratory sessions. At the first session, participants will rest quietly for 5 minutes. At the second session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated.
11099802|NCT04078022|Experimental|Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
11099803|NCT04078022|Experimental|Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
11099804|NCT04078022|Experimental|Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
11099805|NCT04078022|Experimental|Cohort 4: Shigella Vaccine Only, No Challenge|All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.
11099806|NCT04078009|Experimental|Aquagen (Starts with Aquagen and finish with Grazax)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
11099807|NCT04078009|Experimental|Grazax (Starts with Grazax and finish with Aquagen)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
11099808|NCT04077996|Active Comparator|Peritonitis treatment with one exchange in CAPD|This group will receive peritonitis treatment with one exchange on Continuous Ambulatory Peritoneal Dialysis per day. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines; adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
11099809|NCT04077996|Experimental|Peritonitis treatment placed in APD|This group will receive peritonitis treatment placed in Automated Peritoneal Dialysis. The initial antibiotic scheme will be with ceftazidime (1500mg/day) and vancomycin (20mg/kg every 3 days); adjusting the management according to the result of the culture, completing the antibiotic scheme for 14 to 21 days.
11099810|NCT04077983|Experimental|combined therapy using nab-paclitaxel and gemcitabine chemo|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2
~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2
~Three weeks is a course of treatment with a total of 4 courses."
11099811|NCT04077970|Experimental|Intrauterine flushing follicular fluid|Women underwent intrauterine flushing with follicular fluid plus granulosa cells
11099812|NCT04077970|No Intervention|Without intrauterine flushing with follicular fluid|Women without intrauterine flushing with follicular fluid
11099813|NCT04077957|Experimental|Group 1. Experimental|Etanercept 50mg per week plus conventional synthetic DMARDs(csDMARDs, methotrexate 10mg per week, sulfasalazine 2.25g per day, hydroxychloroquine 0.2g per day) for 4 weeks when in high disease activity; etanercept 50mg per week plus csDMARDs for 2 weeks and continue with csDMARDs only for 2 weeks when in low disease activity; csDMARDs only for 4 weeks when in disease remission status.
11099814|NCT04077957|Active Comparator|Group 2. Positive Control|Etanercept 50mg per week for first 12 weeks; etanercept 50mg per ten days for second 12 weeks; etanercept 25mg per week for next 12 weeks; etanercept 25mg per two week for next 12 weeks.
11099815|NCT04077944||Preterm prelabor rupture of membranes|"The diagnosis of Preterm prelabor rupture of membranes was made in the case of apparent spontaneous leakage of AF from the cervical canal during sterile speculum inspection before the onset of active labor at 37 weeks of pregnancy. The study population consisted of 55 women with a singleton pregnancy who were diagnosed with pP-ROM between 24+0 and 36+6 weeks of gestation.
~The Amnisure test (AmniSure International LLC, Boston, MA) was used when there was inconclusive results to confirm the final diagnosis. The gestational age was determined by calculation from the last menstrual period and supported by the ultrasonography measurements at the first trimester of gestation."
11099816|NCT04077944||Control|The control cases were recruited from the healthy pregnant women with a gestational age-matched cohort who admitted for routine obstetric care to our outpatient clinic. Sixty healthy pregnant women who delivered at term were included in the study as the control group.
11099817|NCT04077931|Experimental|Aerobic exercises|She asked to start walking with the speed of the machine was adjusted at 0.8 km/hour, so her resting pulse rate increases, then we increased the speed by 0.2 km/hour gradually every 2 minute (to give a time for adjustment of heart rate) till reaching our target heart rate (not less than 60% and not more than 75% of target heart rate). So the intensity of exercises can be increase or decrease only by changing the speed of treadmill according to target heart rate [13]
11099818|NCT04077931|Experimental|Deep breathing exercises|Technique of breathing exercises: Regular aerobic exercises in a form breathing exercises included duration of 30 min. at 40-70% VO2 max. performed 2-3 per week. Each woman practiced deep breathing exercises 30 min. in the of form (diaphragmatic breathing exercises, 15 min. and lateral costal breathing exercises 15 min.) 3 times per week for 12 weeks.
11099819|NCT04077918|Active Comparator|Plant protein diet|18 g of plant protein diet added every day for 3 months , and after washout for 1 month, 18 g of animal protein diet added every day for 3 months
11099820|NCT04077918|Active Comparator|Animal protein diet|18 g of animal protein diet added every day for 3 months, and after washout for 1 month, 18 g of plant protein diet added every day for 3 months
11099821|NCT04077905|Experimental|DEP regimen|pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles
11099822|NCT04077892|Experimental|combination of budesonide and montelukast|receive treatment with either a combination of budesonide (Rhinorcort Astra Zeneca AB), 1 spray per nostril twice daily (total 256 μg/d) and 10mg oral montelukast tablet (Merck Sharp & Dohme Australia Pty Ltd) in the evening for 14 days (BD+MNT treatment group)
11099824|NCT04077879|Experimental|Single ascending dose of ASP1617|"This is composed of 5 sequential cohorts (cohorts 1.1 to 1.4). If the data from cohorts 1.1 to 1.4 are not sufficient to characterize safety, tolerability and pharmacokinetics, 1 optional cohort (1.5) may be added.
~Participants (6-9 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of ASP1617 under fasting conditions."
11099825|NCT04077879|Placebo Comparator|Single ascending dose of Placebo|Participants (2-3 for each cohort, consisting of either only non-Asians in cohorts 1.1 and 1.2; or non-Asians plus Japanese in cohorts 1.3, 1.4 and 1.5) will receive a single dose of matching placebo under fasting conditions.
11099826|NCT04077879|Experimental|Single dose of ASP1617 (Food Effect)|Participants (6 Japanese and 3 non-Asian) will receive a single dose of ASP1617 with a high-fat meal. Dosing of the Food Effect cohort will commence after having established the safety and tolerability of the dose tested in cohort 1.4.
11099827|NCT04077879|Experimental|Multiple ascending dose of ASP1617|"This is composed of 3 sequential cohorts (cohorts 2.1 and 2.2). If the data from cohorts 2.1 and 2.2 are not sufficient to characterize safety, tolerability and pharmacokinetics, 1 optional cohort (2.3) may be added.
~Participants (9 for each cohort, consisting of only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohorts 2.2 and 2.3) will receive ASP1617 for 14 consecutive days at the same dose level.
~Based on safety, tolerability and pharmacokinetic data of Part 1, once daily or twice daily dosing will be selected."
11099828|NCT04077879|Placebo Comparator|Multiple ascending dose of Placebo|Participants (3 for each cohort, consisting of either only non-Asians in cohort 2.1, or non-Asians plus Japanese in cohort 2.2 and 2.3) will receive matching Placebo for 14 consecutive days at the same dose level in cohort 2.1 to 2.3. Cohort 2.3 will be added only if the data from cohorts 2.1 and 2.2 are not sufficient to characterize safety, tolerability and pharmacokinetics.
11099829|NCT04077866|Active Comparator|Temozolomide alone|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
11099830|NCT04077866|Experimental|Temozolomide + B7-H3 CAR-T|"Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
~The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide treatment in the cycles of B7-H3 CAR-T treatment will be stopped."
11099831|NCT04077853|Experimental|study group|women will be given 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter in addition to other conservative measures of early-onset PE
11099832|NCT04077853|No Intervention|control group|No intervention will be given apart from the usual conservative measures of early-onset PE
11099833|NCT04077840||NCGS/NCWS patients|Adult patients with a definitive diagnosis of NCWS, based on DBPC wheat challenge, most of them suffering from IBS-like-clinical presentation, according to Rome IV criteria. The patients were consecutively recruited between January 2016 and October 2017 at the outpatient clinics of the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (both in southern Italy)
11099834|NCT04077840||Heathy blood donors|Consecutive healthy blood donors sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients.
11099835|NCT04077840||IBS patients|"Consecutive patients with a diagnosis of IBS unrelated to NCWS or other types of food intolerance/allergy, who were consecutively recruited during the study period and sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients."
11099836|NCT04077827|Experimental|Total intravenous anesthesia|"The patients will recieve intravenous anesthesia (propofol-remifentanyl)
~Recommended dosage:
~Propofol: Induction dosage 1,5-2,5 mg/kg Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
11099837|NCT04077827|Experimental|volatile anesthesia|"The patients will recieve volatile anesthesia (desflurane-remifentanyl)
~Recommended dosage:
~Desflurane dosage 6-7 MAC Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
11099838|NCT04077814|Active Comparator|ShamtDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Sham Transcranial direct brain stimulation (tDCS)
11099839|NCT04077814|Experimental|tDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Transcranial direct brain stimulation (tDCS)
11099840|NCT04077801||Study group (group A)|"Maximal vertical mouth opening (MIO):
~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.
~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
11099841|NCT04077801||Control group (group B):|"Maximal vertical mouth opening (MIO):
~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.
~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
11099842|NCT04077788||Study group (group A):|It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
11099843|NCT04077788||control group (group B):|It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).
11099877|NCT04077606|Active Comparator|monolithic zirconia crown|monolithic zirconia crown preparation
11099878|NCT04077580|Experimental|Methenamine hippurate|Tablets containing 1 g methenamine hippurate, dosage 1 tablet morning and evening.
11099879|NCT04077580|Placebo Comparator|Placebo|Placebo tablets containing 1 g of lactose, with identical size, shape and stamps
11099844|NCT04077775||Study group (group A):|"Study group (group ) Diagnostic Test: Study group (group A)24 women who have cyclic CPP
~I) Pelvic tilt angle:
~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
11099845|NCT04077775||Study group(group B):|"included 20 women who have non-cyclic CPP and the other 16 women of the participants were normal I)
~Pelvic tilt angle:
~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately. In contrast, the woman was in a standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer
~Diagnostic Test: Study group (group A)"
11099846|NCT04077775||Control group (group C):|"16 women of the participants were normal and considered the control group
~I) Pelvic tilt angle:
~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
11099847|NCT04077762|Active Comparator|Radial access|Radial access for cardiac catheterization. Radial access will be performed using ultrasound guidance and a micropuncture needle or catheter-over-needle system, as per the local standard of care.
11099848|NCT04077762|Active Comparator|State-of-the-art femoral access|Femoral access for cardiac catheterization. Femoral access will be obtained using state-of-the-art techniques (ultrasound and fluoroscopic guidance for arterial puncture, immediate femoral angiography after obtaining access and use of a vascular closure device whenever possible).
11099849|NCT04077749|Experimental|Probiotic|
11099850|NCT04077749|Placebo Comparator|Placebo|
11099851|NCT04077736|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
11099852|NCT04077723|Experimental|Part I|Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).
11099853|NCT04077723|Experimental|Part II|Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
11099854|NCT04077723|Experimental|Part III|Dose-Expansion Stage: Participants with r/r follicular lymphoma (FL) and r/r diffuse large B-cell lymphoma (DLBCL) will receive RO7227166 administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
11099855|NCT04077697||ITBA group|ITBA group is : invasive tracheobronchitis aspergillosis form.
11099856|NCT04077697||IPA without tracheobronchial involvement|IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement
11099857|NCT04077684|Placebo Comparator|Placebo|placebo s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
11099858|NCT04077684|Active Comparator|IL-2 at 0.2MIU|0.2 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
11099859|NCT04077684|Active Comparator|IL-2 at 0.5MIU|0.5 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
11099860|NCT04077684|Active Comparator|IL-2 at 1.0MIU|1.0 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
11099861|NCT04077671|Experimental|SAD - Cohort A - CHF6467 0.3 µg/mm2|Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.
11099862|NCT04077671|Experimental|SAD - Cohort B - CHF6467 1 µg/mm2|Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.
11099863|NCT04077671|Experimental|SAD - Cohort C - CHF6467 3 µg/mm2|Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.
11099864|NCT04077671|Experimental|SAD - Cohort D - CHF6467 6 µg/mm2|Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.
11099865|NCT04077671|Experimental|MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2|Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
11099866|NCT04077671|Experimental|MAD - Cohort F - CHF6467 1 or 3 µg/mm2|Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
11099867|NCT04077658|Experimental|HeartMath|
11099868|NCT04077658|Active Comparator|Waitlist Control|
11099869|NCT04077645|Experimental|Sun salutations|Sun salutations, breathing exercises, and relaxation, at a low to moderate intensity, for 30 minutes.
11099870|NCT04077645|Active Comparator|Aerobic exercise|Walking on a treadmill at low to moderate intensity for 30 minutes.
11099871|NCT04077645|Other|Seated rest (attentional control)|Watching educational videos for 30 minutes.
11099872|NCT04077632|Experimental|tDCS (anodal)|Real transcranial direct current stimulation tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
11099873|NCT04077632|Sham Comparator|tDCS (sham)|Sham transcranial direct current stimulation tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
11099874|NCT04077619|Experimental|Modern pain neuroscience approach|Behavioral: Modern pain neuroscience approach
11099875|NCT04077619|Active Comparator|Usual care evidence-based physiotherapy|Behavioral: Usual care evidence-based physiotherapy
11099876|NCT04077606|Active Comparator|ceramo-metallic crown|ceramo-metallic crown preparation
11099884|NCT04077541|Experimental|The experimental group|The trauma care bundles combined with the internet platform.
11099885|NCT04077541|No Intervention|The control group|Only trauma care bundles.
11099886|NCT04077515|Active Comparator|high blood concentration group|The blood concentration is maintained at 10-15ng/ml (not including 10ng/ml).
11099887|NCT04077515|Experimental|low blood concentration group|The blood concentration is maintained at 7-10ng/ml (including 10ng/ml).
11099888|NCT04077502|Active Comparator|stimulated group|The group stimulated by real coil of rTMS.
11099889|NCT04077502|Sham Comparator|controle group|The group stimulated by sham coil of rTMS.
11099890|NCT04077489|Other|MT|Macular thickness
11099891|NCT04077476|Active Comparator|Online Yoga|Participants in both groups will follow a prescription of classes the research team (including a 200-hour yoga instructor) developed, and is safe and appropriate for this study population. The yoga prescription will be based on the prescription used in the current R34 study (see reference for description), and modified based on results (i.e., participant feedback). Participants will be given instructions about how to use the online yoga class platform (Udaya) during the intake appointment.
11099892|NCT04077476|Experimental|Online Yoga + Facebook|"In addition to what is described above, participants will be provided instructions on how to join the private Facebook group. The Facebook group will be an informal platform where participants can connect with other people in the online + SN group to share their experiences with yoga as it relates to their stillbirths. Current social media intervention research suggests careful consideration must be given to the intervention. The current intervention will be designed based on results of focus groups asking stillbirth moms who have completed an online yoga intervention what they would find helpful in a Facebook intervention. For instance, preferences included having a moderator, rules about what they can post (e.g., no rainbow babies), and discussion about both stillbirth and life in general."
11099893|NCT04077463|Experimental|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
11099894|NCT04077463|Experimental|Phase 1b (combination): Lazertinib and JNJ-61186372|Participants will receive lazertinib and JNJ-61186372, after the safety of RP2D of lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of JNJ-61186372 is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
11099895|NCT04077463|Experimental|Phase 1b (expansion): Lazertinib and JNJ-61186372|This cohort will further characterize the safety, tolerability, and preliminary antitumor activity of lazertinib and JNJ-61186372-based combinations within specific NSCLC populations who have progressed after osimertinib and platinum-based doublet chemotherapy. Participants will receive at the RP2CD of lazertinib and JNJ-61186372, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
11099896|NCT04077450|No Intervention|Modified Waitlist Control Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. Two weeks later, participants will be asked to complete post-intervention data collection (T2), which consists of a questionnaire and heart rate variability assessment. After the completion of data collection, participants will be offered the online heart-focused breathing intervention.
11099897|NCT04077450|Experimental|Intervention Arm|Participants will complete the following components of baseline (T1) data collection: demographics, questionnaire, heart rate variability assessment. These participants will receive an online heart-focused breathing intervention. Participants will be asked to practice their breathing skills while monitoring their heart rate variability using the Welltory app on their smart device for the following two weeks. Participants will be instructed to maintain a log to record the date and time of each practice session. Research staff will make biweekly reminder calls to participants. After the two-week period, participants will complete post-intervention data collection (T2), which includes a questionnaire and HRV assessment.
11099898|NCT04077437|Experimental|Experimental: MDMA-assisted psychotherapy|Administration of 80 to 120 mg MDMA in combination with psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.
11099899|NCT04077437|Placebo Comparator|Placebo Comparator: Placebo|Administration of inactive placebo in combination with psychotherapy.
11099900|NCT04077424|Active Comparator|Fluzone-High Dose|FDA approved high dose inactivated influenza vaccine (HD-Fluzone)
11099901|NCT04077424|Active Comparator|Fluad|Adjuvanted (MF59) inactivated influenza vaccine (Fluad)
11099902|NCT04077424|Active Comparator|Recombinant Hemagglutinin vaccine (Flublok)|Recombinant hemagglutinin vaccine
11099903|NCT04077411||Children with severe TBI|Children with severe Traumatic Brain Injury
11099904|NCT04077398|Experimental|low volume High concentration group|1.Low Volume: 30 subjects randomized to Low Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,75% ropivacaine x 15 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
11099905|NCT04077398|Experimental|high volume low concentration|2.High Volume: 30 subjects randomized to High Volume will receive bilateral Quadratus lumborum Block II. Each block of 0,375% ropivacaine x 30 mL + dexmedetomidine 0.4 mcg/kg (max dose 30 mcg for age <70, max dose 20 mcg for age >70) + dexamethasone 4 mg
11099906|NCT04077385|Experimental|Retrieval Extinction (R-E) Training Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the R-E training group will observe 5-min of high calorie pictorial food cues during retrieval which will purportedly retrieve cue-reward associative memories. This will be followed by 60-min of extinction training to high calorie food cues. The R-E training group will only differ from the extinction control group in regards to the 5-min exposure to high calorie food cues prior to the 60-min of extinction training to high calorie food cues."
11099940|NCT04077138||In-Depth Interviews|Participants for the IDIs, 10-15 TW and TM, will be selected from among Phase 1 participants. We will create a purposive sample that represents a range of experiences that occurred during Phase 1.
11100223|NCT04075201|Experimental|Children-Experimental group|One dose of investigational vaccine
11099907|NCT04077385|Active Comparator|Extinction Control Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the extinction control group will observe 5-min of non-food-related cues (e.g., pictures of office supplies, tools) during retrieval, which will purportedly avoid retrieval of the food cue-reward associative memories that are targeted in the R-E training group. The 5-min of exposure to non-food-related cues will be followed by the same 60-min of extinction training to high calorie food cues that the R-E training group receives."
11099908|NCT04077372|Experimental|Serious illness conversation guide (SICG)|"Patients have serious illness conversation within 3 wks of randomization and every 3 months thereafter."
11099909|NCT04077372|Active Comparator|Conversations by treating team|Patients have conversations as determined by treating team (but not using SICG tool).
11099910|NCT04077359|Experimental|nephrographic phase CT|the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series
11099911|NCT04077359|Active Comparator|gold standard|all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm
11099912|NCT04077346|Experimental|Transcutaneous Spinal Stimulation- Acute and with Training.|"For Aim 1: Participants will receive transcutaneous stimulation (TcStim) in supine or side lying position at a single or multi site spinal levels to produce stepping/locomotor activity in lower limbs.
~For Aim 2: TcStim will be delivered while participants are stepping on a computerized treadmill with an overhead partial body weight support (BWS) system.
~For Aim 3: Participants will first receive activity-based locomotor training (AB-LT) alone for 60 sessions followed by a combination of AB-LT+TcStim for another 60 sessions."
11099913|NCT04077333|Experimental|MISA group|minimal invasive surfactant administration group
11099914|NCT04077333|No Intervention|EISA group|conventional treatment: endotracheal intubation surfactant administration group
11099915|NCT04077320|Experimental|Memory Self-Efficacy Training|
11099916|NCT04077320|Active Comparator|General Education Group|
11099917|NCT04077307|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
11099918|NCT04077294||Preoperative BNP used for cardiac risk stratification|Cohort of patients recruited in the pre-admission clinic who qualified for, and underwent, preoperative BNP screening according to CCS guidelines.
11099919|NCT04077294||Preoperative BNP not used for cardiac risk stratification|Cohort of patients from patient care database (SPOR) who qualified for preoperative BNP screening according to CCS guidelines, but did not receive screening due to surgery occurring before the implementation of the CCS guidelines.
11099920|NCT04077281|Experimental|Intervention Arm|Clinical Pharmacology specialist team approach starting in hospital and following up with the patient at home using telemedicine and detailed communication with them, their caregiver, family physician, community pharmacist and other specialists.
11099921|NCT04077281|No Intervention|Control Arm (Usual care)|Patients will receive a best possible medication history (BPMH) as do the intervention patients, then usual care by their primary team.
11099922|NCT04077255|Experimental|Anti-EGFR|Participants will receive intravenous GC-1118 in combination with weekly paclitaxel.
11099923|NCT04077255|Experimental|FGFR inhibitor|Participants will receive oral rogaratinib in combination with weekly paclitaxel.
11099924|NCT04077242|Active Comparator|"Parryscope-group"|"In these patients, Fallopian tube patency is assessed using the Parryscope technique. A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed."
11099925|NCT04077242|Active Comparator|"Tubal flow-group"|"In these patients, Fallopian tube patency is assessed using the flow technique. a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
11099926|NCT04077229|Experimental|Intervention|A total of 28 intervention text messages (1/day for 4 weeks) will be sent to participants following the baseline self-report assessment. After each message is sent, participants will receive a second text message asking them to rate the utility of the message. Following the 4-week intervention, participants will complete the same self-report assessments as in the baseline assessment (via phone) and will provide feedback about the program. Finally, 4 weeks later (at 8 weeks), participants will repeat the self-report questionnaires by phone.
11099927|NCT04077216|Experimental|Group A|Initially received the test meal with EVOO, then on crossover, received the meal without EVOO
11099928|NCT04077216|No Intervention|Group B|Initially received the test meal without EVOO, then on crossover, received the meal without EVOO
11099929|NCT04077203|Sham Comparator|Control|Those receiving no visual feedback because the handheld device monitor will be occluded with black tape (the control group).
11099930|NCT04077203|Experimental|Test|Those receiving the ability to visualize their glucose levels via the handheld device (the biofeedback group).
11099931|NCT04077190|Experimental|adipose-derived stem cell injection|Ultrasound guided injection of 5cc adipose derived stem cells
11099932|NCT04077190|Active Comparator|cortisone injection|Ultrasound guided injection of cortisone
11099933|NCT04077177|No Intervention|Assessment Only|
11099934|NCT04077177|Experimental|Intervention|
11099935|NCT04077164||Individuals with Chronic Pain|Individuals who identify as having a chronic musculoskeletal pain condition.
11099936|NCT04077164||Partners|Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.
11099937|NCT04077151|No Intervention|Standard of Care|PrEP prescribed with no intervention
11099938|NCT04077151|Experimental|Intervention Recipients|PrEP Demonstration Project intervention will be given
11099939|NCT04077138||Focus Groups|"Ten focus groups with transgender women and transgender men will be conducted. . The structure of the focus groups will utilize an interactive Rapid Approach, which differs from traditional focus groups by asking fewer questions and tightly focusing on specific areas of inquiry."
11100224|NCT04075201|Active Comparator|Children-Control group|One dose of control vaccine
11099941|NCT04077125||Cirrhosis no MHE|Patients with liver cirrhosis without signs of minimal hepatic encephalopathy
11099942|NCT04077125||Cirrhosis MHE|Patients with liver cirrhosis with minimal hepatic encephalopathy
11099943|NCT04077125||Controls|Healhty subjects
11099944|NCT04077112|Active Comparator|traditional PCIT|once a week parent training
11099945|NCT04077112|Experimental|intensive PCIT|every day for two weeks parent training
11099946|NCT04077099|Experimental|REGN5093|Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)
11099947|NCT04077086|Experimental|Intervention|Children at Intervention schools will receive free spectacles of a design they select, based on the child's measured refractive power and dispensed at school by the study optometrist. Additionally, teachers (but not children) in eligible classes will be informed that if 80% spectacle compliance as measured across three separate unannounced inspections was achieved, they will be given an incentive of an conditional cash transfer. The cash transfer will be deposited into the teacher's bank accounts directly.
11099948|NCT04077086|No Intervention|Control|Children at Control schools will receive a glasses prescription and letter to the parents informing them of the refractive status of their child, with free glasses provided only at the end of the trial. No teacher incentive will be offered. Service offered to the Control group exceeds standard care, in that no school-based programs of vision screening and refraction currently exist in the study area, or in most of rural China.
11099949|NCT04077073|Experimental|ReIn-hand and robot|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand and of robot to reduce the shoulder load."
11099950|NCT04077073|Active Comparator|ReIn-Hand|"The participant will practice reach, grasp, retrieve, and release (GR3) a plastic jar for 40 trials per session, with the assistance of ReIn-hand to open their paretic hand."
11099951|NCT04077060|Experimental|NIPT|Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.
11099952|NCT04077060|Other|Combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
11099953|NCT04077047|Other|Intervention pilot|
11099954|NCT04077034|Experimental|Experimental group|Probiotic DE111®
11099955|NCT04077034|Placebo Comparator|Control group|Placebo
11099956|NCT04077021|Experimental|Part 1: Dose Escalation|CCW702 is administered subcutaneously with ascending dose levels to determine maximal tolerated dose (MTD).
11099957|NCT04077021|Experimental|Part 2: Dose Expansion|CCW702 is administered subcutaneously at the recommended phase 2 dose (RP2D). Different dosing regimens will be compared.
11099958|NCT04077008|Other|Bilaterally Obstructed Kidneys by benign cause|
11099959|NCT04077008|Other|Bilaterally Obstructed Kidneys by malignant cause|
11099960|NCT04076995|Experimental|High Water intake|High water intake of 3.0 L/day in males and 2.0 L/day in females
11099961|NCT04076995|Active Comparator|Low Water Intake|Low water intake of 0.5 L/day in males and 0.4 L/day
11099962|NCT04076982|Experimental|mung bean|daily oral administration of protein supplement
11099963|NCT04076982|Placebo Comparator|biscuit|daily oral administration of control supplement
11099964|NCT04076969|Experimental|Integrated Educational Session|The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
11099965|NCT04076969|Other|Routine follow up|Routine follow up
11099966|NCT04076943|Experimental|Roxadustat (FG-4592)|
11099967|NCT04076930||ACEI/ARB users|
11099968|NCT04076930||ACEI/ARB non-users|
11099969|NCT04076891|Active Comparator|Cohort 1 - Dercum's disease|Nodule size - diameter (cm) 2-2.9 3-3.9 4-8 Total Dose of RZL-012 (mg) 10 15 20 Dose per NOAEL* 1/25th 1/18.75th 1/12.5th Number of Injections 2 3 4
11099970|NCT04076891|Active Comparator|Cohort 2 - Lipedema|Total Dose RZL-012 (mg) 60 80 Dose per NOAEL* 1/4.688 1/3.125 Number of Injections 12 16
11099971|NCT04076878|Experimental|Intervention in a Mechanism and a Clinical substudy|"Mechanism substudy: 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo). Patients and datacollectors were blinded in terms of the randomised order of the treatment at each of the 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo).
~Clinical substudy: Use of the fitted and individually set body suit, Mollii, in the home setting for 6 weeks"
11099972|NCT04076865|Experimental|EMLA|
11099973|NCT04076839|Experimental|Goal Management Training (GMT)|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Participants assigned to this group will attend 9 weeks of GMT group sessions, each 2 hours in length, occurring once per week.
11100001|NCT04076644|Active Comparator|TMS Treatment Arm|Subjects will receive either a 20min 10hz TMS treatment, or a 3min theta-burst TMS treatment at certain monthly intervals. The TMS treatment protocol they receive depends on what they received in their acute clinical treatment. Subjects in the arm will be tapered off antidepressant medication before TMS treatment begins. Subjects will be assessed monthly for depression using QIDS and PHQ9.
11099974|NCT04076839|No Intervention|Wait-list Control|Following baseline testing, participants randomly assigned to the wait-list control group will have no intervention during the 9 weeks that the GMT group attends their group sessions. Following the completion of the GMT group intervention, the wait-list control will attend a a testing session, and subsequently, a 3 month follow-up testing session, the results of which will be compared to those of the GMT group. This group will then be offered a complimentary 9-week GMT program once the final testing session is complete. Again, during these sessions participants will be required to complete questionnaires every third session in order to monitor their progress and symptoms. Following the completion of the complimentary 9-week GMT program, individuals in the WLC will complete post-intervention testing
11099975|NCT04076826|Experimental|Protocol A (Dexmedetomidine)|Dexmedetomidine will be administered in accordance with hospital standard operating procedures (SOP).
11099976|NCT04076826|Active Comparator|Protocol B (Propofol / Midazolam)|Propofol and/or Midazolam will be administered in accordance with hospital standard operating procedures (SOP).
11099977|NCT04076813||STEMI/NSTEMI|Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
11099978|NCT04076800|Experimental|Acupuncture|
11099979|NCT04076800|Sham Comparator|Sham acupuncture|
11099980|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
11099981|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
11099982|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
11099983|NCT04076774|Experimental|Wondaleaf female condom|Participants will be provided with 5 Wondaleaf condoms first at enrolment and switched to 5 FC2 condoms at the first follow up visit
11099984|NCT04076774|Active Comparator|FC2 Female condom|Participants will be provided with 5 FC2 condoms first at enrolment and switched to 5 Wondaleaf condoms at the first follow up visit
11099985|NCT04076761|Experimental|Trifluridine/Tipiracil|FTD/TPI at 35 mg/m2 (based on BSA) that is administered in tablet form, orally, twice daily, within one hour of morning and evening meals, on days 1-5 and days 8-12 of a 28 day cycle.
11099986|NCT04076748|Experimental|Experimental|"* Intra Nasal Sufentanil (50 µg.ml-1): Load dose : 0.3 µg. kg-1, Followed by bolus : 5 µg / 10 minutes with 2 bolus maximum.
~As soon as the venous route and ten minutes after the last administration of sufentanil:
~Morphine IV: 3 mg / 5 minutes.
~Objective: numeric rating scale (NRS) ≤ 3/10."
11099987|NCT04076748|Active Comparator|Control|"* EMONO : Given by respiratory administration via a face mask at a rate suitable for patient ventilation (generally at least 9l.min-1), Until a venous route is obtained and without exceeding 30 minutes.
~* Morphine IV: Load dose: 0.1mg. kg-1 as soon as possible; Then bolus: 3mg / 5 minutes.
~* Objective: NRS ≤ 3/10"
11099988|NCT04076735|Experimental|Distal femoral replacement (DFR)|"Distal femoral replacement will be performed by excising the distal portion of the femur (up to two thirds) and replacing with a prosthesis incorporating a hinged total knee replacement.
~Surgical approach and implant selection will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in arthroplasty."
11099989|NCT04076735|Active Comparator|Surgical Fixation (ORIF)|Surgical fixation of the distal femoral fracture will be performed with the goals of obtaining and maintaining anatomic reduction and stable fixation of the distal portion of the femur. Surgical approach and implant selection for the surgical fixation (ORIF) will be at the discretion of the treating surgeon and within the standard of care. Surgeons performing this procedure will be qualified by training and experience in trauma of the knee.
11099990|NCT04076722|Experimental|Weight Loss Treatment|This study arm will receive the weight loss treatment immediately following enrollment. The weight loss treatment is a brief (i.e., 8-week) intervention based on the evidence-based Acceptance-Based Treatment for weight loss.
11099991|NCT04076722|Other|Wait-List Control|This study arm will receive no treatment throughout the active 12-week study period. However, this arm will receive the identical weight loss treatment protocol as the Experimental Arm following the completion of the follow-up (i.e., 12-week) assessments. The weight loss treatment is a brief (i.e., 8-week) intervention based on the evidence-based Acceptance-Based Treatment for weight loss.
11099992|NCT04076709|No Intervention|Standard Care|
11099993|NCT04076709|Experimental|Goal directed anesthesia|Deep neuromuscular blockade (post tetanic count 1-2 twitches) and nociception guided anaesthesia
11099994|NCT04076696|Experimental|Scatter corrected s-DCT|The study scan, s-DCT and correction scan, will be performed within two weeks of the patient's clinical evaluations by chest CT and x-ray. The study scan may be done within 2 weeks prior or two weeks following standard of care imaging. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the standard of care (SOC) imaging and the s-DCT. All patients will have a breath held s-DCT scan in an anterior-posterior direction.
11099995|NCT04076683|Experimental|Algorithm (arm A)|Frequency and volume for apherisis proposed by algorithm and validated by the physician
11099996|NCT04076683|No Intervention|Usual care (arm C)|Frequency and volume for apherisis only decided by the physician (usual care)
11099997|NCT04076670|No Intervention|Control group|Group pf participants that received usual psychological attention.
11099998|NCT04076670|Experimental|Experimental group|Group of participants that received usual psychological attention plus the structured psychological intervention prosed in the study.
11099999|NCT04076657|Experimental|Brock String|Participants will receive instruction on Brock String therapy after first clinic visit (<48 hours post) injury, and will complete home therapy exercise twice daily
11100000|NCT04076657|Active Comparator|Standard of Care|Participants will receive standard of care (i.e., no Brock String therapy within the first week post injury) but will be informed they will receive any therapy deemed necessary at follow up visit 7-10 days post injury, consistent with standard of care
11100002|NCT04076644|No Intervention|No TMS Arm|Subjects will be followed and assessed for depressive symptoms at monthly time intervals similar to the active treatment arm using QIDS and PHQ9. This group does not receive TMS treatment.
11100003|NCT04076631||Hepatocellular Carcinoma|Patients with hepatocellular carcinoma undergo open hepatectomy.
11100004|NCT04076618|Experimental|Weight Loss plus Vest|
11100005|NCT04076618|Active Comparator|Weight Loss Plus Resistance Exercise Training|
11100006|NCT04076618|Active Comparator|Weight Loss|
11100007|NCT04076579|Experimental|Olaparib + Trabectedin|"There are 2 cohorts. Both cohorts receive the same treatment:
~Cohort 1: Leiomyosarcoma and liposarcoma
~Cohort 2: Other bone or soft tissue sarcoma histologies
~Treatment consists of 21-day cycles for a maximum of 18 months."
11100008|NCT04076553|Active Comparator|CBT + ICT|"Participants randomized to the ICT condition will complete a computerized ICT training at home during the first 4 weeks of treatment and ICT boosters following their treatment sessions during weeks 5-12."
11100009|NCT04076553|Sham Comparator|CBT + sham|"Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT boosters following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component."
11100010|NCT04076540|Experimental|AZD4041|
11100011|NCT04076540|Placebo Comparator|Placebo|
11100012|NCT04076527||Group 1 - Incomplete Responder|"Primary Incomplete Responder: PBC patients demonstrating an insufficient response to the standard therapy with ursodeoxycholic acid (UDCA) after a minimum of 12 months of treatment (Paris II criteria).
~Secondary Incomplete Responder: PBC patients demonstrating a satisfactory initial response to UDCA after a minimum of 12 months of treatment (Paris II criteria) followed by a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment."
11100013|NCT04076527||Group 2 - Responder|PBC patients demonstrating a satisfactory initial and contin-ued response to UDCA after a minimum of 12 months of treatment (Paris II criteria) without a re-increase of ALP ≥1.5 ULN, or AST ≥1.5 ULN, or bilirubin >1 mg/dl at any later time point during continuous UDCA-treatment.
11100014|NCT04076527||Group 3|Patients newly diagnosed for PBC receiving an approved PBC therapy for the first time. Patients are considered to be newly diagnosed if the initial diagnosis took place no later than six months prior to inclusion into the study.
11100015|NCT04076514||patients with node negative papillary thyroid carcinoma|
11100016|NCT04076501|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
11100017|NCT04076501|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
11100018|NCT04076488|Experimental|Dividat FIT: Computer based exercise|
11100019|NCT04076475|Experimental|electrical stimulation|receive daily NMES for 30 min/session for 10 days.
11100020|NCT04076475|Sham Comparator|Control|receive similar electrical stimulation (ES) procedure as those in the intervention group but with ES machine power off.
11100021|NCT04076462|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
11100022|NCT04076462|Placebo Comparator|Matching placebo|Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
11100023|NCT04076449||Cerebral Cavernous Malformation with Epilepsy|Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
11100024|NCT04076449||Cerebral Cavernous Malformation without Epilepsy|Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
11100025|NCT04076436||Fosfomycin cohort:|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous fosfomycin
11100026|NCT04076436||Quinolones or beta-lactams cohort|Cohort of patients with complicated urinary tract infection caused by Escherichia coli treated with intravenous quinolones or beta-lactams.
11100027|NCT04076423|Experimental|Experimental arm:|they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.
11100028|NCT04076423|Active Comparator|Comparator arm|they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.
11100029|NCT04076410|Experimental|5 Lenses|"The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).
~Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).
~Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK)."
11100030|NCT04076397|Other|lipofilling group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:
~Make EVA (evaluation of the pain),
~Complete DASH questionnaire
~Complete DN4 questionnaire
~Patients in the lipofilling group will also have:
~the repair of the last dressing during the consultation at J15
~Ablation of any threads
~Control of the digital and abdominal scar
~Making a photo of their finger at V1 and M6"
11100031|NCT04076397|Other|desensitization group|"Patient will conduct a total of 4 visits: D15, M1, M3, M6 during which they will have: a clinical examination as well as the following evaluations:
~Make EVA (evaluation of the pain),
~Complete DASH questionnaire
~Complete DN4 questionnaire"
11100032|NCT04076384|Experimental|Team-based consultations|Guided Self-Determination
11100033|NCT04076384|Experimental|Standard care|Standard consultation
11100034|NCT04076371|Experimental|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
11100035|NCT04076371|Placebo Comparator|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
11100036|NCT04076371|Experimental|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
11100037|NCT04076371|Placebo Comparator|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
11100038|NCT04076371|Experimental|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
11100039|NCT04076371|Placebo Comparator|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
11100225|NCT04075201|Experimental|Neonates-Experimenatal group|Three doses of investigational vaccine
11100040|NCT04076371|Experimental|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
11100041|NCT04076371|Placebo Comparator|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
11100042|NCT04076358|Experimental|Tab-CBI|The Tab-CBI group receives a tablet preloaded with the Tab-CBI application and an accelerometer. During the study period, the participants have four weekly educational sessions plus one booster session by the research assistant through a videoconferencing tool. The educational modules were developed based on the principles of cognitive behavioral therapy. The key elements of the modules include activity-pacing, adjustment of goal-setting to the current physical condition, setting priorities and structured planning of a simple walking activity and time off, and cognitive restructuring of activity demands (see attached, outline of education modules).
11100043|NCT04076358|No Intervention|Usual Care|The usual care group receives Arthritis related fatigue management which are currently offered to the participants at the recruitment sites. Participant are also instructed to maintain usual activity during the study period. The control group participants also receive an accelerometer to count steps, but without a tablet.
11100044|NCT04076345||Bacterial group|Newborns or infants less dans 3 months old with fever and positive bacterial sample.
11100045|NCT04076345||Viral group|Newborns or infants less dans 3 months old with fever and positive viral sample.
11100046|NCT04076345||Negatives Microbiological samples|Newborns or infants less dans 3 months old with fever and negatives microbiological samples.
11100047|NCT04076332|No Intervention|Controlled group|Standard oral explanation with booklet
11100048|NCT04076332|Experimental|Decision aid group|Shared decision making using decision aid
11100049|NCT04076319|Other|CAPABLE|CAPABLE Intervention
11100050|NCT04076306|Other|iSTEP Feasibility Study Protocol|All participants will be asked to undergo the entire protocol: iSTEP exercise test, 10 metre incremental shuttle walk test, myometry, accelerometry and Haemophilia Joint Health Score.
11100051|NCT04076293|Experimental|HM15912|
11100052|NCT04076293|Placebo Comparator|Placebo|
11100053|NCT04076280|Experimental|SWAP Intervention|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the Sodium Watcher Program.
11100054|NCT04076280|Active Comparator|Usual Care|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the usual care group.
11100055|NCT04076267||Patients with cancer|
11100056|NCT04076254|Experimental|albumin|albumin 5%
11100057|NCT04076254|Active Comparator|fluid|Ringer Lactate
11100058|NCT04076241|Experimental|Complementary Therapy|Complementary therapy group consisted of 16 pulmonary hypertension (PH) patients. Three different pranayama yoga breathing exercises were applied after osteopathic manipulative treatment (OMT). This complementary therapy model was applied 2 times a week for a period of 8 weeks with a total of 16 training sessions. There remained a 3-workday gap between two sessions and every session lasted 45-60 minutes. The patients trained on specific days of the week and specific time of day throughout the study protocol. Patients in this group were thought about pathophysiology of PH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
11100059|NCT04076241|Active Comparator|Osteopathic Manipulative Treatment|OMT group consisted of 16 PH patients. Six different OMT techniques were applied 2 times a week for a period of 8 weeks with a total of 16 sessions. The same osteopathic manipulative treatment techniques applied to complementary therapy group were used for this study group. There remained a 3-workday gap between two sessions and every session lasts 30-40 minutes. The patients visited the clinic on specific days of the week and specific time of day throughout the study protocol. Patients in this group were thought about pathophysiology of PH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
11100060|NCT04076241|No Intervention|Control|Control group also consisted of 16 PH patients and serves as the controls. No interventions were applied for the patients in this group. Similar with the patients in other two groups, pharmacological treatment of the patients in this group continued and they were advised for using their medication properly, Patients in this group were also thought about pathophysiology of PH, benefits of physical activity, airway clearance, oxygen therapy, and importance of proper nutrition, adequate sleep, effective breathing after baseline assessment.
11100061|NCT04076228||Pembrolizumab|Chinese lung cancer patients who will receive pembrolizumab will be enrolled in this study. Clinically, the treatment course of pembrolizumab is depended on the efficacy, but average cycle is about 3-4 weeks and patient will receive 6 treatment courses.
11100062|NCT04076215|Experimental|Pariticapnts with PTSD|
11100063|NCT04076215|Experimental|Pariticapnts without PTSD (controls)|
11100064|NCT04076202|Experimental|Cementless Vanguard DD RP|Patients receiving a total knee prosthesis
11100065|NCT04076189|Experimental|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
11100066|NCT04076189|Active Comparator|No endotracheal suctioning|Procedure includes: Initiation of positive pressure ventilation without endotracheal suctioning
11100067|NCT04076176|Active Comparator|L-amino Acids|"The specific amount and timing of L-amino acid consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.
~Consumption period: 12 weeks."
11100068|NCT04076176|Experimental|PKU Sphere|"The specific amount and timing of PKU sphere consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.
~Consumption period: 12 weeks."
11100069|NCT04076163|No Intervention|control group|group of students participating to a face-to-face learning
11100070|NCT04076163|Other|intervention group|group of students using serious game
11100071|NCT04076150|Experimental|Patients Receiving Optimum TAV|Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure
11100072|NCT04076137|Experimental|Targeted T-cell|This study is a pre-phase I immunotherapy trial in 10 people with malignant solid tumor consisting of 9 infusions of bispecific antibody armed anti-CD3-Actibated T cells(ATC) to determine safety, maximum tolerated dose (MTD), technical feasibility, immune responses.
11100226|NCT04075201|Active Comparator|Neonates-Control group|Three doses of control vaccine
11100073|NCT04076124|Experimental|Active rTMS-DLPFC|This active group will receive high-frequency repetitive TMS stimulation.
11100074|NCT04076124|Experimental|Active iTBS-DLPFC|This active group will receive intermittent theta-burst TMS stimulation.
11100075|NCT04076124|Sham Comparator|Sham TBS-DLPFC or Sham rTMS-DLPFC|Patients in the sham group will receive the same iTBS or rTMS parameter stimulation, performing by a sham coil.
11100076|NCT04076098|Experimental|Minocycline|Minocycline gel
11100077|NCT04076098|Placebo Comparator|Placebo|Similar gel without the active agent
11100078|NCT04076085|Active Comparator|Unsupported Upper extremity exercise|Specially designed unsupported Arm exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
11100079|NCT04076085|Active Comparator|Lower extremity exercise|Specially designed Lower extremity exercises will be done for the population with a rating of somewhat hard 13-14 (Original scale) will be used as a guideline for intensity
11100080|NCT04076085|No Intervention|Control|Here no active intervention will be given only standard care as prescribed by the hospital will be given
11100081|NCT04076072|Active Comparator|Alcon Advanced Ultravit High-Speed Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
11100082|NCT04076072|Active Comparator|Alcon Non-Beveled Tip Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
11100083|NCT04076059|Experimental|Double-blind treatment: Enzalutamide plus androgen deprivatio|Participants will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC ) and provided by the site's pharmacy stock.
11100084|NCT04076059|Placebo Comparator|Double-blind treatment: Placebo plus androgen deprivation ther|Participants will receive placebo once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) will be maintained during study treatment as per SOC and provided by the site's pharmacy stock.
11100085|NCT04076059|Experimental|Open-Label Phase: Enzalutamide|Participants who will receive placebo in double-blind phase and remain on study treatment until confirmed radiographic disease progression will receive enzalutamide in open-label phase.
11100086|NCT04076033|Experimental|ECF ESPIRAL|The volunteer is submitted to four-layer spiral functional compressive bandage, then performs Taylor's Jebsen manual function test with comprehensive functional bandage (ECF).
11100087|NCT04076033|Experimental|ECF OITO|The volunteer is submitted to functional compressive bandage in eight with four layers, then performs the Taylor Jebsen manual function test with the comprehensive functional bandage (ECF).
11100088|NCT04076020|Experimental|Intervention arm|Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
11100089|NCT04076020|Active Comparator|Usual care arm|"Receive a brochure on atrial fibrillation that is published by the American Heart Association and a smartphone with the WebMD application.
~Participants are directed to use the WebMD application as often as they would like."
11100090|NCT04076007|Active Comparator|Active|Nitrate rich beetroot juice (7.5 mmol nitrate in 250mls beetroot juice) once daily.
11100091|NCT04076007|Placebo Comparator|Placebo|Nitrate depleted beetroot juice (0.002 mmol nitrate in 250 ml beetroot juice) once daily.
11100092|NCT04075994|Experimental|Intervention arm|Receive the relational agent coupled with the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
11100093|NCT04075994|Active Comparator|Usual care arm|Receive a brochure on atrial fibrillation, the WebMD app and the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
11100094|NCT04075981|Experimental|Botulinum toxin|"All patients from the experimental group will receive botulinum toxin (Xeomin®, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 200 U dissolved in 4 mL of 0.9% normal saline and 50 U/1 mL will be injected at each fat pad).
~Botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
~The whole estimated dosage would be therefore 200 units of incobotulinumtoxin A,"
11100095|NCT04075981|Placebo Comparator|Placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo dissolved in 4 mL of 0.9% normal saline will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
11100096|NCT04075968||group 1|exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
11100097|NCT04075968||group 2|control group; patients will be given physical and cognitive home exercise program individually.
11100098|NCT04075955|Experimental|Study treatment group|Olanzapine in combination with ondansetron and dexamethasone
11100099|NCT04075955|Active Comparator|Standard treatment group|Aprepitant in combination with ondansetron and dexamethasone
11100100|NCT04075942|Other|Atrophic Anterior Maxillary Ridges participants|Using customized Xenograft bone shell with equal mixture of autogenous and xenograft particulate bone as a graft with the modified cortical shell technique, with atrophic anterior maxilla with less than 5 mm Bucco-lingual
11100101|NCT04075929|Other|4x8 min|4x8-min intervals with 2-min recovery periods. The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x8-min = 32 min
11100169|NCT04075448|Experimental|50 g Walnut - Control|Experimental condition followed by control condition.
11100102|NCT04075929|Other|4x(8x40/20s)|4x(12x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group:4x(12x40/20-sec) = 32 min if the 20-sec recovery is not included in the total time of HIT
11100103|NCT04075929|Other|4x(12x40/20s)|4x(8x40/20-sec) intervals with 2-min recovery periods The same accumulated duration of these three interval groups means that the total interval time is the same for each group: 4x(8x40/20-sec) = 32 min if the 20-sec recovery is included in the total time of HIT
11100104|NCT04075916|Experimental|Epclusa (sofosbuvir/velpatasvir)|Epclusa is taken by mouth for 12 weeks as per the FDA label.
11100105|NCT04075903|Experimental|Intervention|"Storytelling A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
11100106|NCT04075903|No Intervention|Control|Usual Care
11100107|NCT04075890|Active Comparator|Healthy subjects|
11100108|NCT04075890|Active Comparator|OCD subjects|
11100109|NCT04075877|Experimental|FOCUS|"Participants will complete a baseline survey battery and learn about The Hero's Journey. Starting at hospital discharge for 10 days, they will do the following: 1) identify which stage of The Hero's Journey they are experiencing; 2) take a picture of something good and write a caption describing the picture and provide advice; and 3) take a picture of something difficult or challenging during the day and write a caption for the photo and provide advice.
~Daily text messages will remind participants to take the photographs, write the advice captions, upload both to the server, as well as to take a very brief daily survey. At the conclusion of day 10, participants will be asked to review their photos and captions and provide final advice in the form of a letter to other adolescents with SCD or cancer. Finally, they will complete a post-intervention battery."
11100110|NCT04075877|No Intervention|Control|"In a 30-min visit (in person or virtual) with adolescents during hospitalizations, we will have participants complete a baseline survey battery.
~Daily text messages will remind participants to take a very brief daily survey. At the conclusion of day 10, participants will complete a post-intervention battery."
11100111|NCT04075864|Experimental|behavioral intervention to improve physical activity|"The proposed study is prospective single-arm feasibility clinical trial that will enroll 12 hospitalized patients with CF in accordance with consensus criteria.
~Standard care for an acute CF exacerbation includes i.v. antibiotics and airway clearance therapies for 10-14 days. Routine care following hospitalization is an outpatient CF clinic visit 2-4 weeks after discharge, and then regular follow up every 2-3 months.
~In addition, to standard care in the hospital, study participants will receive a 1) tailored exercise prescription, 2) daily, individual, supervised, aerobic and strength/power training, as well as 3) daily behavioral counseling focused on topics related to long-term adherence to exercise (details below)."
11100112|NCT04075851||Hashimoto or Grave's disease patients in treatment|Draw 10 ml venous blood
11100113|NCT04075851||Hashimoto or Grave's disease patients on initial treatment|10 ml of venous blood was extracted every month for three months
11100114|NCT04075851||Pregnant woman with Hashimoto or Grave's disease|10 ml venous blood was extracted every month to postpartum for 6 months
11100115|NCT04075851||Healthy crowd|Draw 10 ml venous blood
11100116|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001). The group gathered for a one-hour session once a week for 18 weeks.
11100117|NCT04075825|Experimental|Darvadstrocel|Participants who received a single dose of darvadstrocel, 120 million cells, intralesionally or darvadstrocel matching placebo previously in the ADMIRE-CD II study will be observed for efficacy and safety. No drug administration in this study.
11100118|NCT04075812|Experimental|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
11100119|NCT04075799|Experimental|training|8 weeks using stair climbing with a frequency of thrice a week. For the first week of the stair training exercise program subjects will meet at UNM's Teaching Education Building (Stair Case 2). The following 7 weeks subjects can perform the exercise program at a staircase most convenient to them and approved by the research team. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will be comprised of 6-12 x 30-seconds bout of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. After the exercise session the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks.
11100120|NCT04075786||Gynecologists|Gynecologists in active clinical practice and resident (in training) gynecologists.
11100121|NCT04075773|Experimental|Religious Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported religious identity. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
11100122|NCT04075773|Sham Comparator|Age Prompt|Participants will be provided a writing prompt that describes their self-reported drinking, then asks them to write for 5 to 10 minutes about how that drinking is associated with their self-reported age. After completing that writing assignment, participants will be shown their response, and asked to spend 5 to 10 minutes describing how their drinking behaviors in the next month might change.
11100123|NCT04075760|Experimental|EUS-guided combined therapy|Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
11100219|NCT04075227|Active Comparator|0.1% dexamethasone|This group was treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph) every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
11100220|NCT04075214|Sham Comparator|delayed-active tAN|
11100221|NCT04075214|Experimental|active tAN|
11100124|NCT04075760|Placebo Comparator|Beta Blocker (Propranolol)|o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.
11100125|NCT04075747|Experimental|Arm A|
11100126|NCT04075747|Experimental|Arm B|
11100127|NCT04075747|Experimental|Arm C|
11100128|NCT04075734|Experimental|RCT Intervention|The intervention consists of (1) online self-management educational modules and (2) weekly peer mentor calls to facilitate engagement with the modules and offer specialized support over approximately six weeks.
11100129|NCT04075734|No Intervention|RCT Usual Care|Participants receive usual care.
11100130|NCT04075721|Experimental|Part A (Dose Escalation): M3258|
11100131|NCT04075721|Experimental|Part B (Dose Expansion): M3258|
11100132|NCT04075708||Case-group|The case group will consist of women diagnosed with PE after 34 weeks of gestation.
11100133|NCT04075708||Control-group|The control group will include 165 participants who were not diagnosed with PE in their pregnancies.
11100134|NCT04075682|No Intervention|Standard cigarette packs (control)|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with the only alteration being the small health warning message on the side of the pack, whose textual content will be the same as that used for the pictorial warning label conditions.
11100135|NCT04075682|Experimental|Cigarette packs with inserts only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four different rotating messages to promote response efficacy beliefs (2 inserts on the benefits of cessation) or self-efficacy to quit (2 inserts with cessation tips).
11100136|NCT04075682|Experimental|Cigarette packs with pictorial warnings only|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include four different rotating pictorial warnings showing the consequences of smoking and that cover 50% of the front and back of the pack.
11100137|NCT04075682|Experimental|Cigarette packs with inserts and pictorial warnings|Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four rotating efficacy messages (see description above) and four rotating pictorial warnings (see above).
11100138|NCT04075656|Experimental|UrApp|Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
11100139|NCT04075656|Active Comparator|Standard of Care|Participants randomized to this study arm will use receive the standard of care for one year.
11100140|NCT04075643|Experimental|Group 1|"Period 1: Reference drug
~Period 2: Test drug"
11100141|NCT04075643|Experimental|Group 2|"Period 1: Test drug
~Period 2: Reference drug"
11100142|NCT04075617|Experimental|intervention group|electronic habit reminder will fabricated to treat thumb/finger sucking habit containing two parts: acrylic part specially fabricated for the child finger/thumb connected to the reminder in the shape of wrist watch.
11100143|NCT04075617|Active Comparator|control group|palatal crib will be cemented after impression taking and fabrication
11100144|NCT04075604|Experimental|Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)|
11100145|NCT04075604|Experimental|Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ|
11100146|NCT04075604|Active Comparator|Arm C: Palbociclib+ANZ|
11100147|NCT04075591|Experimental|Wavefront-guided Lasik Monovision Treatment|Wavefront-guided LASIK monovision treatment of myopic subjects with presbyopia using the STAR S4 IR® Excimer laser System with the iDesign Refractive Studio.
11100148|NCT04075578||female with urinary incontinence|Female ≥ 18 years, suffers from urinary incontinence by idiopathic overactive bladder, inadequately treated by 2 anticholinergic medicines during a period of 3 months for each of them or stopped for intolerance or adverse events
11100149|NCT04075565|Active Comparator|Simulated altitude|The participants are exposed to simulated altitude in a normobaric situation.
11100150|NCT04075565|Experimental|Terrestrial altitude|The participants are exposed to terrestrial altitude in a hypobaric situation.
11100151|NCT04075565|No Intervention|Control|the participants are exposed to a normoxic and normobaric environment.
11100152|NCT04075552|Experimental|Participants|Participants are students from a specialized school for children with autism.
11100153|NCT04075539|Experimental|Home-based cycling program associated to usual care|
11100154|NCT04075539|Other|Outpatient physiotherapy|
11100155|NCT04075526|Experimental|Povidone iodine and vancomycin powder|
11100156|NCT04075526|Experimental|Povidone iodine alone|
11100157|NCT04075526|Active Comparator|Vancomycin powder alone|
11100158|NCT04075526|Active Comparator|Conventional|neither povidone iodine, vancomycin powder, nor polymyxin/bacitracin irrigation
11100159|NCT04075513|Experimental|Toujeo|Toujeo (Insulin Glargine, 300U/ml) once daily for 12 weeks on top of rapid acting insulin analog
11100160|NCT04075513|Active Comparator|Tresiba|Tresiba (Insulin Degludec, 100U/ml) once daily for 12 weeks on top of rapid acting insulin analog
11100161|NCT04075500|No Intervention|Arm 1|Control arm, 24-h Holter monitoring
11100162|NCT04075500|Other|Arm 2|Interventional arms, prolonged cardiac monitoring
11100163|NCT04075487|Experimental|User experiences with MEPS-Pain|This is a pilot study to assess user experience with MEPS-Pain App, there is only one arm.
11100164|NCT04075474|Experimental|silver diamine fluoride|38% silver diamine fluoride
11100165|NCT04075474|Active Comparator|sodium fluoride|5% sodium fluoride
11100166|NCT04075461|Experimental|Undisplaced FNF + Arthroplasty|Arthroplasty is the typical surgery for a displaced femoral neck fracture
11100167|NCT04075461|Active Comparator|Undisplaced FNF + Internal fixation|Internal fixation is the typical surgery for an undisplaced femoral neck fracture
11100168|NCT04075448|Experimental|Control - 50g Walnut|Control condition followed by experimental condition.
11100170|NCT04075435|Other|All subjects|This arm will include all subjects, who will receive active drug in accordance with the following dosage schedule: for the first week of enrollment, the dose will be 0.5milliliters (mL) of the solution containing 20milligrams/milliliters (mg/mL) CBD and 0.58mg/ml THC twice daily (BID), for a daily total of 20mg CBD and 0.58mg THC. At the Week 1 visit, the dose will be increased to 1.0mL BID, for a daily total of 40mg CBD and 1.16mg THC. At the Week 4 visit, the study physician may increase the dose to 1.5mL BID, for a daily total of 60mg CBD and 1.74mg THC. This higher dose will be used if no clinical improvement is noted with the lower dose.
11100171|NCT04075422||Prospective cohort|64 patients treated with Bezlotoxumab
11100172|NCT04075422||Retrospective Cohort (Control)|All the first episodes diagnosed in each participating sites during the previous year that meet the inclusion criteria
11100173|NCT04075409|Experimental|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
11100174|NCT04075409|Experimental|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
11100175|NCT04075409|Experimental|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
11100176|NCT04075396|Experimental|Part D: Outside of Korea|Participants from outside of Korea with progressive disease and on prior epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) therapy will receive recommended phase 2 doses based on safety, tolerability, efficacy and pharmacokinetics (PK) of YH25448.
11100177|NCT04075383|Other|immediate dental implant|The implant is installed immediately after tooth extraction.
11100178|NCT04075383|Other|immediate-delayed dental implant|The implant is installed 8 weeks after tooth extraction.
11100179|NCT04075370||Single arm study|In this feasibility study, longitudinal mixed methods will be used to measure cognitive function and symptoms by objective tests, interviews, and biomarker assay in adults with brain cancer over time: prior to radiation (XRT; T1), 2-weeks post-XRT (T2), 2-3 months post-XRT (T3).
11100180|NCT04075357|No Intervention|Control|The patients underwent conventional CTS surgery
11100181|NCT04075357|Experimental|Experimental|The patients underwent conventional CTS surgery and transplantation of amniotic membrane
11100182|NCT04075344|Experimental|Experimental RCHEs staff|Experimental RCHEs staff will received a multimodal ICP regarding the NG tube feeding. Knowledge and skills of NG tube feeding will be measured before and after the multimodal ICP. In addition, 10 fingertips of RCHEs staff, enteral milk and NG tube hubs of residents will be taken for bacterial counts before and after the intervnetion.
11100183|NCT04075344|No Intervention|Control RCHEs staff|No multimodal ICP will be offered to the staff of control RCHEs.
11100184|NCT04075331|Experimental|Mepolizumab|Mepolizumab
11100185|NCT04075331|Placebo Comparator|Placebo|Saline solution
11100186|NCT04075318|Experimental|UB-312 40 ug|UB-312 40 ug by intramuscular injection at Weeks 1, 5 and 13
11100187|NCT04075318|Experimental|UB-312 100 ug|UB-312 100 ug by intramuscular injection at Weeks 1, 5 and 13
11100188|NCT04075318|Experimental|UB-312 40/300 ug|UB-312 40 ug at Week 1 and 300 ug at Weeks 5 and 13 by intramuscular injection
11100189|NCT04075318|Experimental|UB-312 300 ug|UB-312 300 ug by intramuscular injection at Weeks 1, 5 and 13
11100190|NCT04075318|Experimental|UB-312 40/1000 ug|UB-312 40 ug at Week 1 and 1000 ug at Weeks 5 and 13 by intramuscular injection
11100191|NCT04075318|Experimental|UB-312 1000 ug|UB-312 1000 ug by intramuscular injection at Weeks 1, 5 and 13
11100192|NCT04075318|Experimental|UB-312 2000 ug|UB-312 2000 ug by intramuscular injection at Weeks 1, 5 and 13
11100193|NCT04075318|Placebo Comparator|Placebo|Placebo by intramuscular injection at Weeks 1, 5 and 13
11100194|NCT04075305||Brain cancer|
11100195|NCT04075305||Lung cancer|
11100196|NCT04075305||Esophageal cancer|
11100197|NCT04075305||Breast Cancer|
11100198|NCT04075305||Head and Neck Cancer|
11100199|NCT04075305||Pancreatic cancer|
11100200|NCT04075305||Gynecological cancer|
11100201|NCT04075305||Rectal cancer|
11100202|NCT04075305||Prostate cancer|
11100203|NCT04075305||Bladder cancer|
11100204|NCT04075305||Oligometastases|
11100205|NCT04075305||Liver cancer|
11100206|NCT04075305||Other types of cancer|
11100207|NCT04075292|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
11100208|NCT04075292|Active Comparator|Rituximab and Chlorambucil|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
11100209|NCT04075266|Experimental|Cohort 1|Participants with a body weight from >/= 25 kg to < 40 kg (with at least 2 participants with a body weight from >/= 25 kg to </= 35 kg) will receive 300 milligram (mg) ocrelizumab
11100210|NCT04075266|Experimental|Cohort 2|Participants with a body weight >/= 40 kg (with at least 2 participants with a body weight >/= 40 kg but </= 50 kg) will receive 600 mg ocrelizumab
11100211|NCT04075266|Experimental|Cohort 3 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from >/= 25 kg to < 40 kg may be enrolled and receive another dose level of ocrelizumab
11100212|NCT04075266|Experimental|Cohort 4 (optional)|Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight >/= 40 kg may be enrolled and receive another dose level of ocrelizumab
11100213|NCT04075253|Experimental|VO2 peak test|All participants enrolled in the planned study on physical activity and ventricular arrhythmias and on baseline will complete an exercise treadmill test to determine VO2 peak
11100214|NCT04075240|Active Comparator|THA-control arm|Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin
11100215|NCT04075240|Experimental|THA-study arm|Total Hip Arthroplasty: 35 days of aspirin
11100216|NCT04075240|Active Comparator|TKA-control arm|Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin
11100217|NCT04075240|Experimental|TKA-study arm|Total Knee Arthroplasty: 14 days of aspirin
11100218|NCT04075227|Experimental|0.2% loteprednol etabonate|This group was treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
11100222|NCT04075201|Experimental|Adults-Experimental group|One dose of investigational vaccine
11100227|NCT04075188|Experimental|Combined therapy|Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.
11100228|NCT04075175|Experimental|S315 human monoclonal antibody|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
11100229|NCT04075175|Placebo Comparator|0.9% sodium chloride (NaCl)|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9% Sodium Chloride)) with escalation of a fixed dose of S315
11100230|NCT04075162||Low charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
11100231|NCT04075162||No charge CAC|Patients receiving CAC for Cardiovascular disease risk screening at no charge
11100232|NCT04075149|Experimental|Spironolactone|16 weeks without medication, then 16 weeks with medication, then 12 months without medication; spironolactone 50 mg tablets: 50-100 mg orally twice daily (1.7-3.3 mg/kg/24 hr)
11100233|NCT04075136|Active Comparator|Arm A: Lucentis|A standard of care treatment of 0.05ml/0.5mg Lucentis given every 4 weeks for 48 weeks.
11100234|NCT04075136|Experimental|Arm B: Lucentis & PDT Laser|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence.
11100235|NCT04075136|Experimental|Arm C: Lucentis, PDT Laser and Triescense|A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence and an intravitreal injection of 0.5ml-2mg Triescence at the time of PDT treatment.
11100236|NCT04075123||CPAP GROUP|Suggested PEEP range 5-10 cmH2O; Minimum required PEEP WILL BE 8 cm water (7 cm water if using bubble CPAP); Maximum allowable† PEEP: 12 cmH2O
11100237|NCT04075123||NIPPV GROUP|Suggested Ranges: PIP 12 to 24 cm water; PEEP 5 to 10 cm water; Rates 20-40 bpm; iTime 0.4-1.0 seconds; Minimum required settings on NIPPV: PEEP 8 cm water; Difference of pressure 6 cm water; Rate 20 bpm; Maximum allowable settings: PEEP 10 cm water; PIP 24 cm water; Rate 60 bpm
11100238|NCT04075110|Placebo Comparator|Control group|50 patients will receive metformin 2000mg/daily (Control group)
11100239|NCT04075110|Experimental|Montelukast group|50 patients will receive a combination of metformin 2000 mg/daily and montelukast (10 mg /day).
11100240|NCT04075097|Experimental|Aerobic exercise|44 minutes of moderate intensity walking on a treadmill.
11100241|NCT04075097|Experimental|Yoga|44 minutes of Iyengar yoga.
11100242|NCT04075071|Experimental|TCIT-U|Four teachers from two Head Start classrooms will be assigned to Teacher-Child Interaction Training - Universal (TCIT-U). TCIT-U occurs in two phases (6 weeks per phase): Child-Directed Interaction (CDI; focusing on relationship building) and Teacher-Directed Interaction (TDI; focusing on managing behavior problems). The TCIT-U Trainer (a licensed clinical child psychologist) will provide teachers with group didactic sessions (6 hours per phase) and individualized live coaching in their classrooms (20 minutes, once per week). Strategies include the use of PRIDE skills (Praise, Reflection, Imitation, Behavior Description, and Enthusiasm) or specific verbalizations that promote warm, responsive interactions, as well as classroom-appropriate behavior modification strategies which include using effective commands, prompts, natural consequences, differential social attention, and a modified time-out appropriate for use in a classroom.
11100243|NCT04075071|No Intervention|Usual Care|Four teachers from 2 PreK Counts classrooms will be assigned to the Usual Care (UC) group. They will continue their existing behavioral management strategies and techniques. Teachers will report on specific training in and use of other behavior management and social-emotional learning programs at baseline. At the conclusion of the study, UC teachers and staff will be offered didactic training in TCIT-U principles and strategies.
11100244|NCT04075058|Experimental|Study|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 34Gy in 10 fractions over 2 weeks.
11100245|NCT04075058|Active Comparator|Control|Patients with breast cancer post mastectomy or after breast conservative surgery to be treated with a hypofractionated radiotherapy dose of 35Gy in 15 fractions over 3 weeks
11100246|NCT04075045|No Intervention|"Group A. Standard Care (Control)"|Does not receive Wellth app.
11100247|NCT04075045|Experimental|"Group B. Wellth App (Treatment 1)"|Receives Wellth app without additional financial rewards tied to adherence.
11100248|NCT04075045|Experimental|"Group C. Wellth App (Treatment 2) with targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at local pharmacies for using the app to track adherence.
11100249|NCT04075045|Experimental|"Group D. Wellth App (Treatment 3) with non-targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at many stores for using the app to track adherence.
11100250|NCT04075032|Experimental|Pomegranate extract-1|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks
11100251|NCT04075032|Placebo Comparator|Placebo-1|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks
11100252|NCT04075032|Placebo Comparator|Placebo-2|Consumption of 2 daily capsules (900 mg microcrystalline cellulose, PLA) for 4 weeks. This arm is the previous PE-1 after crossover and one month of wash-out
11100253|NCT04075032|Experimental|Pomegranate extract-2|Consumption of 2 daily capsules (900 mg pomegranate extract, PE) for 4 weeks. This arm is the previous PLA-1 after crossover and one month of wash-out.
11100254|NCT04075019|Experimental|full intervention|students assigned to intervention classrooms in grades 1 through 4 and who remained in schools assigned to the intervention condition in grades 5 or 6
11100255|NCT04075019|Experimental|late intervention|students in intervention classrooms in grades 5 and 6 only
11100256|NCT04075019|Experimental|parent-training only|students whose parents were offered parent training only when their children were in grades 5 and 6 and no other intervention
11100257|NCT04075019|No Intervention|control|students in schools assigned to receive no intervention in grades 5 and 6 and who were not in intervention classrooms in grades 1 through 4
11100258|NCT04075006|Experimental|Ketamine Group|adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
11100259|NCT04075006|No Intervention|Control Group|Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
11100260|NCT04074993|Experimental|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
11100261|NCT04074980|Experimental|Venous only|One venous whole blood draw will be performed into two anti-coagulated collection tubes
11100262|NCT04074980|Experimental|Fingerstick and Venous|One finger-stick sample of capillary blood (~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. From each patient, one venous whole blood draw will also be performed into two anti-coagulated collection tubes.
11100263|NCT04074967|Experimental|Phase Ib ARRY-614 + nivolumab|Participants with advanced solid tumors will receive ARRY-614 in combination with nivolumab.
11100264|NCT04074967|Experimental|Phase Ib ARRY-614 + ipilimumab|Participants with melanoma will received ARRY-614 in combination with ipilimumab.
11100265|NCT04074967|Experimental|Phase II ARRY-614 + ipilimumab|Participants with melanoma will receive ARRY-614 combined with ipilimumab.
11100266|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab (melanoma)|Participants with melanoma will receive ARRY-614 combined with nivolumab.
11100267|NCT04074967|Experimental|Phase II ARRY-614 + nivolumab (RCC)|Participants with RCC will receive ARRY-614 combined with nivolumab.
11100268|NCT04074954||Cataracts present, no surgery|Adult patients undergoing bilateral cataract surgery
11100269|NCT04074954||Cataracts present, yes surgery|adult patients who have cataracts but are not undergoing cataract surgery
11100270|NCT04074941|Experimental|Low sodium diet|This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
11100271|NCT04074941|Active Comparator|Usual sodium diet|This group will get a usual sodium diet (~2 mg per kcal of energy intake).
11100272|NCT04074928|Experimental|QIVc|Cell-derived Quadrivalent Influenza Vaccine
11100273|NCT04074928|Active Comparator|Comparator QIV|Comparator Quadrivalent Influenza Vaccine
11100274|NCT04074915|Placebo Comparator|Placebo rinse|Normal saline
11100275|NCT04074915|Experimental|Chlorhexidine mouth rinse|Chlorhexidine mouth rinse
11100276|NCT04074915|Experimental|Test group|Chamomile mouth rinse
11100277|NCT04074889|Active Comparator|Group A|Patients will be given Lactobacillus & Bifidobacterium containing probiotics [Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg], to be taken 1 sachet twice daily for 6 months.
11100278|NCT04074889|Placebo Comparator|Group B|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.
11100279|NCT04074876||patients with femur fracture|"Group is composed of patients more of 65 years of age with femur fracture undergoing urgent orthopedic surgery.
~During normal pre-operative evaluation and classification based on principal scores and laboratory data, patients will be subjected to bedside pulmonary ultrasound.
~Pulmonary ultrasound will evaluate the presence of one of four patterns (normal pattern, isolated B lines, coalescent B lines and consolidation) defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient.
~These patients will be later subjected to spinal anaesthesia and orthopedic surgery.
~They will be follow for evaluation of MACE (major adverse cardiovascular events: atrial fibrillation, flutter, acute heart failure and non-fatal acute myocardial infarction)"
11100280|NCT04074863|Active Comparator|Darrach|Surgical procedure: resection of distal ulna
11100281|NCT04074863|Active Comparator|Prosthesis|Surgical procedure: ulnar head replacement
11100282|NCT04074850||TBI group|"A cohort of patients admitted to UZ Leuven from 1999 to 2019 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.
~Inclusion criteria will be: ≥ 65 years old at the time of the accident, admitted to UZ Leuven from 1999 and 2019, all injury severities, classified by the Glasgow Coma Scale (GCS) (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.
~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven in a different period from 1999-2019, diagnosis of other neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology before the TBI, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
11100283|NCT04074837|Placebo Comparator|Placebo|Placebo liquid suspension.
11100284|NCT04074837|Active Comparator|NNI-362, 10 mg|NNI-362 at 10 mg in liquid suspension
11100285|NCT04074837|Active Comparator|NNI-362, 20 mg|NNI-362 at 20 mg in liquid suspension
11100286|NCT04074837|Active Comparator|NNI-362, 60 mg|NNI-362 at 60 mg in liquid suspension
11100287|NCT04074837|Active Comparator|NNI-362, 120 mg|NNI-362 at 120 mg in liquid suspension
11100288|NCT04074824||Non-NEC|Those without NEC
11100289|NCT04074824||NEC|Those with NEC
11100290|NCT04074811|Sham Comparator|Sham rTMS|Sham rTMS will be applied over the left dorsolateral prefrontal cortex using a sham figure of 8 coil (within-subject crossover). Sham rTMS will consist of the same auditory and tactile stimuli as the active condition, but does not induce an electromagnetic field and does not affect cortical excitability.
11100291|NCT04074811|Active Comparator|Active rTMS|Active rTMS will be applied over the left dorsolateral prefrontal cortex using an active figure of 8 coil (within-subject crossover). In the active rTMS condition, the investigators will use high-frequency (10Hz) dorsolateral prefrontal cortex (dlPFC) stimulation with intensity of 110% of resting motor threshold. rTMS will consist of 120 trains with 50 stimuli per train (i.e. 5-sec long at 10 Hz) and 10-sec intertrain interval for a total of 6000 pulses. The entire protocol will last 30 min (120 trains with 5-sec on/10-sec off).
11100292|NCT04074798|Active Comparator|Patients with low back pain|
11100293|NCT04074798|Sham Comparator|Healthy controls|
11100294|NCT04074785|Experimental|Safety Run-In|Abemaciclib 150 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
11100295|NCT04074785|Experimental|Abemaciclib with Bevacizumab|Abemaciclib 100 mg po bid PLUS Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
11100387|NCT04074109|Experimental|Teleyoga|group will receive instruction via computer tablet
11100296|NCT04074772||Healthy Controls|This group will consist of healthy controls between the ages of 18 and 70-years-old. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be used to train a neural network to identify points of interest in a generalized patient population.
11100297|NCT04074772||Movement Disorder Patients|This group will consist of movement disorder clinic patients between the ages of 18 and 70-years-old with a diagnosed or putative movement disorder. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
11100298|NCT04074772||Age-Matched Controls|This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
11100299|NCT04074759|Experimental|FPT155 monotherapy|The study consists of dose escalation and cohort expansions
11100300|NCT04074759|Experimental|FPT155 in combination with pembrolizumab|The study consists of dose escalation and cohort expansions
11100301|NCT04074746|Experimental|Treatment (AFM13-NK, AFM13)|Patients receive standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -4 to -2, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.
11100302|NCT04074733||Patients with fractures|
11100303|NCT04074720|Other|Standard of Care|patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
11100304|NCT04074707|Experimental|oral iron supplementation|Participants go through 3 cycles of oral iron Supplementation (daily dosing, alternate-day dosing, every third-day dosing)
11100305|NCT04074694|No Intervention|Watchfull waiting|
11100306|NCT04074694|Active Comparator|Interventional|
11100307|NCT04074681|Experimental|Gambling Internet-based Protocol|Intervention group that carries out the Gambling Internet-based Protocol based on Cognitive and Behavioral Therapy (CBT) and receives support by the therapist (a weekly 15-minute phone call without clinical content and a daily feedback message using Ecological Momentary Assessment, EMA).
11100308|NCT04074681|No Intervention|Waiting List Control Group|Participants in a 12-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
11100309|NCT04074668||Type 1 Diabetes|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
11100310|NCT04074668||Healthy Controls|All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
11100311|NCT04074655|Experimental|Intervention Arm|Participants of the study will play the driving simulator daily (5 days/week) for 15-20 minutes/day over a period of 2 consecutive weeks.
11100312|NCT04074642|No Intervention|Non compressive adenoma|Optical Coherence Tomography Angiography without surgery
11100313|NCT04074642|Experimental|Compressive adenoma|Optical Coherence Tomography Angiography before and after neurosurgery
11100314|NCT04074629|Experimental|Skin related VOCs collected by Polydimethylsiloxane patch|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
11100315|NCT04074616|Experimental|High Dose|
11100316|NCT04074616|Other|Control|Low dose TTNS
11100317|NCT04074603|Experimental|Group A|needle-free before needle
11100318|NCT04074603|Experimental|Group B|needlebefore needle-free
11100319|NCT04074590|Experimental|LYS006|Experimental drug
11100320|NCT04074590|Placebo Comparator|Placebo|Placebo comparator
11100321|NCT04074577|Active Comparator|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. The first colonoscopy will be performed without automated polyp detection software (standard technique) followed immediately by another colonoscopy with automated polyp detection software (combination technique).
11100322|NCT04074577|Active Comparator|Combination +followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. In this arm, the first colonoscopy with be performed with automated polyp detection software (combination technique) followed immediately by another colonoscopy without automated polyp detection software (standard technique)
11100323|NCT04074564|Experimental|A group|MASCT-I A+PD1 antibody+Apatinib combination therapy
11100324|NCT04074564|Experimental|B group|MASCT-I B+PD1 antibody+Apatinib combination therapy
11100325|NCT04074551|Experimental|Experimental|HCP1701
11100326|NCT04074551|Active Comparator|Active Comparator 1|HGP0904, HGP0608
11100327|NCT04074551|Active Comparator|Active Comparator 2|HGP0608, HCP1306
11100328|NCT04074499||Group-1|"The patients were classified based on the frequency of falls in the last 12 months.
~Group-1 consists of COPD patients whose have at least one fall (fallers)"
11100329|NCT04074499||Group-2|"The patients were classified based on the frequency of falls in the last 12 months.
~Group-2 consists of COPD patients whose have no history of falls (non-fallers)."
11100330|NCT04074486||Injured and Matched Control Subjects|Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport).
11100331|NCT04074486||Healthy Volunteer Subjects|Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment.
11100332|NCT04074486||Non-Concussed Head Injured Subjects|A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0
11100333|NCT04074473|Placebo Comparator|Propranolol alone|TPropranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
11100334|NCT04074473|Active Comparator|Esophageal variceal ligation alone|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
11100335|NCT04074473|Experimental|Esophageal variceal ligation(DC inderal after EV eradication)|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
11100336|NCT04074473|No Intervention|Propranolol(Keep BB after EV eradication)|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
11100337|NCT04074460|Active Comparator|Propofol (TIVA)|Propofol-based total intravenous anaesthesia
11100338|NCT04074460|Active Comparator|Volatile|Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia
11100339|NCT04074434||All Participants|
11100340|NCT04074421|Active Comparator|Rifaximin group|Repeating treatment of Rifaximin
11100341|NCT04074421|Sham Comparator|Probiotics group|Sequential treatment of probiotics called Bacillus subtilis and Enterococcus faecium
11100342|NCT04074421|Placebo Comparator|Placebo group|Placebo control group
11100343|NCT04074408|Experimental|Cohort 1|low dose hUMSCs or high dose hUMSCs
11100344|NCT04074408|Experimental|Cohort 2|best dose of hUMSCs (from cohort 1) or placebo
11100345|NCT04074382||Prospective Cohort|Prospective cohort (Phase 1, and Phase 2 Group A: explained in detailed description earlier) We will recruit and consent patients on the ward in the first few weeks following their admission for major trauma when the consultant in charge of their care feels that they are physically and emotionally/mentally ready and appropriate to take part in the study. A member of the research team will ask whether they want to take part in the study and offer them the participant information sheet. If happy to take part, the patient will have an account set up on the online questionnaire service we will be using called QTool. The consent form will be completed online at baseline along with the initial baseline PROM questionnaires. This group of people will then be sent reminders at 3, 6, 9 and 12 months to complete follow-up questionnaires, up to 28 days before or after these timepoints. They will then enter Phase 2 (Group A).
11100346|NCT04074382||Retrospective Cohort|"Retrospective cohort (Phase 1/2):
~Patients between 1 to 10 years following their major trauma will be identified using a database. We will randomly select which of these patients to include in our study, using computer software, to reduce selection bias, and those selected will be sent a recruitment pack in the post. We have calculated that we need at least 320 patients in the retrospective cohort to show any important changes.
~This group of patients will only complete the questionnaires once in phase 1, and once per year up to 10 years after their trauma in phase 2 (Group B)."
11100347|NCT04074369||Pulmonary Tuberculosis Suspects|Individuals with suspected TB infection
11100348|NCT04074356|Active Comparator|Healthy Controls|Healthy volunteers with no known gastrointestinal complications will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
11100349|NCT04074356|Active Comparator|Achalasia subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of achalasia will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
11100350|NCT04074356|Active Comparator|Hypercontractile/spastic disorder subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of hypercontractile/spastic disorder will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
11100351|NCT04074343|Experimental|TAS-102 and Irinotecan|Patients receive TAS-102 25 mg/m2 PO twice daily on days 1-5 and and Irinotecan 180mg/m2 IV on day 1 every 14 days.
11100352|NCT04074330|Experimental|Phase 1, aNHL/iNHL: TAK-981 (10-160 mg) + Rituximab 375 mg/m^2|TAK-981 (at increasing dose levels from 10 milligram [mg] to 160 mg), infusion, intravenously, once on Days 1 and 8 of each 21 day treatment cycle in combination with rituximab 375 milligram per square meter (mg/m^2), infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to disease progression (PD) or unacceptable toxicity. Dose levels will be escalated based on available safety, pharmacokinetic (PK) and pharmacodynamic data.
11100353|NCT04074330|Experimental|Phase 2, Cohort A: r/r DLBCL Progressed to CAR T-cell therapy|TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21-day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants with r/r diffuse large B-cell lymphoma (DLBCL) progressed or relapsed after a prior chimeric antigen receptor (CAR) T-cells therapy that has received approval by a health authority for the treatment of DLBCL.
11100354|NCT04074330|Experimental|Phase 2, Cohort B: r/r DLBCL with no CAR T-cell Prior Therapy|TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21 day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants with r/r DLBCL that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy and no prior therapy with CAR T-cells.
11100388|NCT04074109|Active Comparator|In-person yoga|group will receive instruction in-person
11100494|NCT04073446|Active Comparator|Dorsal Root (DR) Perception|Use of DR Perception based programming
11100355|NCT04074330|Experimental|Phase 2, Cohort C: r/r FL Progressed to Systemic Therapies|TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21 day treatment cycle in combination with rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and then on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants with r/r follicular lymphoma (FL) that has progressed or relapsed after at least 2 but no more than 3 prior lines of systemic therapy.
11100356|NCT04074317|Experimental|PRAM9|Xeris pramlintide + insulin co-formulation
11100357|NCT04074317|Experimental|Regular Insulin + Pramlintide|Humulin® + Symlin® pen as separate injections
11100358|NCT04074317|Active Comparator|Regular Insulin|Humulin®
11100359|NCT04074304|Other|I-HoME prototype|Participants will be shown prototype of I-HoME and provide feedback as part of the user-center design process.
11100360|NCT04074278||development groups|The development groups included 150 patients derived from outpatients in Peking University First Hospital, between March 1st, 2014 and November 26th 2014.
11100361|NCT04074278||validation groups|The validation groups included 150 patients derived from outpatients in Peking University First Hospital, between November 27th 2014 and December 1st, 2015.
11100362|NCT04074265|Active Comparator|Pain injection|This group will be injected with a cocktail totaling 40mL (20mL on each side) that will be composed of ropivicaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), ketorolac 30mg/mL (0.5mg/kg).
11100363|NCT04074265|Placebo Comparator|Normal saline|The control group will receive an injection of 40mL of 0.9% sodium chloride solution.
11100364|NCT04074252|Active Comparator|Lofstrand Crutches|This group is given a set of Lofstrand crutches.
11100365|NCT04074252|Active Comparator|Axillary Crutches|This group is given a set of axillary crutches.
11100366|NCT04074239|Experimental|Video triage|The sick child will be triaged on video by the operator.
11100367|NCT04074239|No Intervention|Telephone triage|The sick child will be triaged solely on telephone by the operator.
11100368|NCT04074226|Experimental|Ultrasound-guided ESP block with liposomal bupivacaine|For the ESP block, the transducer will be placed parasagittally at the level of the tip of the scapula and the anesthesiologist will scan in a craniocaudal manner to identify the ipsilateral T10 transverse process and overlying erector spinae muscle. Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the muscle and transverse process. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site.
11100369|NCT04074226|Active Comparator|Ultrasound-guided QL block with liposomal bupivacaine|"For the QL block, the transducer will be placed transversely over the lumbar spine at the level of the iliac crest. Then, the anesthesiologist will scan laterally to identify the ipsilateral L3 transverse process, psoas muscle, and quadratus lumborum muscle to identify the Shamrock Sign (7). Following aseptic preparation of the injection site and the ultrasound probe, a 22-gauge, 10mm block needle will be introduced parallel to the ultrasound guided beam (in-plane technique) until its tip reaches the plane between the quadratus lumborum muscle and psoas muscle. After negative aspiration, 20 ml of a mixture containing 10ml 0.25% bupivacaine and 10ml 1.3% liposomal bupivacaine will be injected in 5 ml increments to separate the fascial plane between the two muscles. The investigators will observe local anesthetic spread under real-time imaging. The block will then be performed in the same manner on the opposite site."
11100370|NCT04074213||Haematologic malignancies with clozapine|Cases reported in the World Health Organization (WHO) database of patients treated by Clozapine, with a chronology compatible with the drug toxicity
11100371|NCT04074200||Open Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using an open surgical approach.
11100372|NCT04074200||Laparoscopic Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a laparoscopic surgical approach.
11100373|NCT04074200||Robotic-assisted Inguinal Hernia Repair|These subjects will undergo an inguinal hernia repair using a robotic-assisted surgical approach.
11100374|NCT04074187|Experimental|Caplacizumab|Eligible study participants will receive caplacizumab in addition to standard of care such as daily plasma exchange (PE) and corticosteroid treatment (mandatory), immunosuppressive treatment (if needed)
11100375|NCT04074174|Experimental|NNC0174-0833 treatment-free period; NNC0174-0833 treatment|During the NNC0174-0833 treatment-free period participants will receive OC tablets and acetaminophen. During the NNC0174-0833 treatment period participants will receive OC tablets and acetaminophen in addition to NNC0174-0833.
11100376|NCT04074161|Experimental|Semaglutide|Semaglutide administered s.c. (subcutaneously, under the skin) adjunct to a reduced-calorie diet and increased physical activity
11100377|NCT04074161|Placebo Comparator|Placebo (semaglutide)|Placebo (semaglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
11100378|NCT04074161|Active Comparator|Liraglutide|Liraglutide administered s.c. adjunct to a reduced-calorie diet and increased physical activity
11100379|NCT04074161|Placebo Comparator|Placebo (liraglutide)|Placebo (liraglutide) administered s.c. adjunct to a reduced-calorie diet and increased physical activity
11100380|NCT04074148|Experimental|Diabetes Prevention Education Program|Diabetes Prevention Education Program
11100381|NCT04074148|Experimental|control|Diabetes Prevention Education brochure
11100382|NCT04074135|Experimental|1/ Arm 1|Study natural history of VHL pancreatic neuroendocrine tumors with yearly 68-Gallium DOTATATE PET/CT research scans.
11100383|NCT04074135|No Intervention|2/ Arm 2|Study natural history of VHL pancreatic neuroendocrinetumors without research scans.
11100384|NCT04074122||Symptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
11100385|NCT04074122||Asymptomatic LQTS patients|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
11100386|NCT04074122||Healthy controls|Pharmacological (adenosine, epinephrine, isoprenaline) provocation, ECG-imaging and tissue-phase mapping using magnetic resonance imaging (TPM-MRI).
11100389|NCT04074096|Experimental|SRS followed by Encorafenib + binimetinib|Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID. The treatment should be started more than 2 days and less than 8 days (excluded) after the SRS
11100390|NCT04074096|Active Comparator|Encorafenib + binimetinib|Encorafenib 450 mg oral route (PO) once daily (QD) + binimetinib 45 mg PO twice daily (BID).
11100391|NCT04074083|Experimental|Intervention electronic IMCI group|15 primary health care clinics will be randomly allocated to intervention group. One IMCI trained HW will be selected in each intervention facility to be trained in electronic IMCI.
11100392|NCT04074083|Active Comparator|Control paper IMCI group|15 primary health care clinics will be randomly allocated to the control group. One IMCI trained HW will be selected in each control facility to receive an IMCI update (designed to mirror eIMCI training).
11100393|NCT04074070||Psoriasis with and without musculoskeletal complains|psoriasis with and without musculoskeletal complains
11100394|NCT04074070||Healthy individuals|
11100395|NCT04074070||Psoriatic arthritis|
11100396|NCT04074057|Other|Control arm|the control group will undergo a conventional weekly CR programme lasting 8-12 sessions. Components of each session will include warm up, aerobic training, resistance exercises and cool down. Patients are encouraged to continue their home exercises, exercising another 2 times a week at home and record down using an activity diary. The importance of CR programme and exercise advice will be explained and reinforced by the CR Physiotherapist. The submaximal exercise test and a body composition analysis will be repeated on the final assessment. Every week research coordinator will call the subject to remind them to exercise.
11100397|NCT04074057|Other|Intervention arm|"During the initial assessment, the importance of CR and regular exercise will be explained and reinforced by CR physiotherapist. A research assistant will teach the patient how to use Heart Track. The patient will then bring Heart Track home to continue their CR program. Patient will then undergo the whole CR programme to exercise for 3 times a day for 8-12 weeks using Heart Track. Each Heart Track session will include warm up, aerobic training, resistance exercises and cool down (same as the traditional CR session). After 8-12 weeks, patient will be called back to the clinic by the research assistant to complete the final assessment (sub-maximal exercise test and a body composition analysis) with the blinded assessor. Every week research coordinator will call the subject to remind them to exercise."
11100398|NCT04074044|Experimental|BHmApp users|Participants using BHmApp tor bladder education and training
11100399|NCT04074031|Experimental|minimally invasive method for performing thalamotomy|We will study patients with essential tremor with significant disability despite well-conducted drug therapy who have a contraindication to deep brain stimulation or who refuse treatment. In this population, unilateral thalamotomy of Vim by radiosurgery is already considered a valid indication and performed routinely with proven efficacy and morbidity deemed acceptable. It is therefore the population of choice to evaluate for the first time in France the efficacy and safety of a new, minimally invasive method for performing thalamotomy: targeted ultrasound thermal injury at high intensity. This same population will also make it possible to study, for the first time in humans in this indication, the potential of neuromodulation by low frequency low frequency ultrasound beams to improve the guidance before the lesion is achieved.
11100400|NCT04074018|Experimental|Experimental group|Self-rehabilitation guided program with investigator PMR specialist
11100401|NCT04074018|Active Comparator|Control group|Conventional rehabilitation with a speech therapist or physiotherapist specialized in facial rehabilitation
11100402|NCT04073992|Experimental|Cognitive behavioral treatment of insomnia (CBT-I)|Eight weeks of cognitive behavioral treatment of insomnia.
11100403|NCT04073979|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
11100404|NCT04073953|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15mg of RPQ every day for 5 days. Cohort 2 will receive 22.5 mg of RPQ every day for five days.
11100405|NCT04073953|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.
11100406|NCT04073953|Placebo Comparator|Placebo|Cohort 1 will receive placebo capsules every day for 5 days. Cohort 2 will receive placebo capsules every day for five days.
11100407|NCT04073940|Experimental|Targeted Ballet Program|A 16-week (32 sessions of 1 hour each) ballet-based intervention targeted to improve motor function in persons with multiple sclerosis.
11100408|NCT04073927|Active Comparator|Sodium butyrate|3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.
11100409|NCT04073927|Placebo Comparator|Placebo|Placebo. 6 capsules twice daily for 12 weeks.
11100410|NCT04073914|Active Comparator|Intervention|Type 1 Teamwork program
11100411|NCT04073914|No Intervention|Control|Standard of care
11100412|NCT04073901|Experimental|Endocrown|Adhesive monoblock restoration for pulpotomized primary molars
11100413|NCT04073901|Active Comparator|Zirconia crowns|Prefabricated primary full coverage crown
11100414|NCT04073888|Other|Single arm|Men with Fabry Disease
11100415|NCT04073875||Bioprosthetic aortic valve|Single 18F-GP1 PET-CT
11100416|NCT04073875||Bioprosthetic aortic valve thrombus - repeat imaging|18F-GP1 PET-CT at baseline and 3 months
11100417|NCT04073862|Other|Stepped-Care TF-CBT|The study participants will receive Stepped-Care Trauma-Focused Cognitive-Behavioral-Therapy (SC-TF-CBT).
11100418|NCT04073849|Active Comparator|Cohort A|EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
11100419|NCT04073849|Sham Comparator|Cohort B|Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
11100420|NCT04073810||Myocardial infarction|Patients with recent MI
11100421|NCT04073797|Experimental|Stable CVD - treatment|Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor
11100422|NCT04073797|Placebo Comparator|Stable CVD - placebo control|Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control
11100423|NCT04073797|Experimental|HeFH - treatment|HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor
11100424|NCT04073797|Placebo Comparator|HeFH - placebo control|HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control
11100425|NCT04073784|Experimental|Gemcitabine combined with Apatinib and Toripalimab|Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.
11100426|NCT04073771||Cohort study|Patients with septic shock undergoing continuous renal replacement therapy
11100427|NCT04073758|Sham Comparator|Remifentanil group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC). As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.
11100428|NCT04073758|Active Comparator|Dexmedetomidine group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.
11100429|NCT04073745|Experimental|Treatment (SBRT)|Beginning at least 2 weeks after surgical resection, patients undergo 1 fraction (or 5 fractions every other day if R2 resection of central tumor) of SBRT.
11100430|NCT04073732||family physician team|Family physician team in four regions (Beijing, Shanghai, Hangzhou and Xia'men), including general practitioners, nurses and public health personnel.
11100431|NCT04073719|Experimental|Apple Cider Vinegar + Coconut Water|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
11100432|NCT04073719|Experimental|Apple Cider Vinegar + Citric Soda|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
11100433|NCT04073719|Experimental|Apple Cider Vinegar + Lemonade|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
11100434|NCT04073719|Experimental|Coconut Water + Apple Cider Vinegar|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
11100435|NCT04073719|Experimental|Coconut Water + Citric Soda|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
11100436|NCT04073719|Experimental|Coconut Water + Lemonade|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
11100437|NCT04073719|Experimental|Citric Soda + Apple Cider Vinegar|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
11100438|NCT04073719|Experimental|Citric Soda + Coconut Water|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
11100439|NCT04073719|Experimental|Citric Soda + Lemonade|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
11100440|NCT04073719|Experimental|Lemonade + Apple Cider Vinegar|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
11100441|NCT04073719|Experimental|Lemonade + Coconut Water|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
11100442|NCT04073719|Experimental|Lemonade + Citric Soda|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
11100443|NCT04073706|Experimental|TH BSO with SNB|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG) (+/- omentectomy in high risk cell types)
11100444|NCT04073706|Active Comparator|TH BSO without retroperitoneal node dissection|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types)
11100445|NCT04073693|Active Comparator|BRCA|They were in treatment with BRCA and standard treatment based on nutritional intervention and physical exercise.
11100446|NCT04073693|Placebo Comparator|Placebo|They only were on standard treatment based on nutritional intervention and physical exercise.
11100447|NCT04073680|Experimental|Serabelisib|"Part 1 is dose escalation of Serabelisib Cohort 1 = 600mg; Cohort 2 = 900mg; Cohort 3 = 1200mg
~Part 2 is expansion of mutational cohorts with selected dose as follows:
~Cohort 4 = PIK3CA-mutated breast cancer; Cohort 5 = PIK3CA-mutated Non breast cancer; Cohort 6 = KRAS mutated"
11100448|NCT04073667|Experimental|Early Rehabilitation Group|The first six weeks (1st-6th) will be followed as an exercise group and the second six weeks (7th-12th) will be followed as a control group without any intervention.
11100449|NCT04073667|Experimental|Late Rehabilitation Group|The first six weeks (1st-6th) will be followed as a control group without any intervention and the second six weeks (7th-12th) will be followed by exercise.
11100450|NCT04073654|Active Comparator|SA Implants|Dental implant with sandblasted and Acid-etched (SA) surface
11100451|NCT04073654|Experimental|SOI Implants|Same dental implant with sandblasted and Acid-etched surface modified with pH buffering agent
11100452|NCT04073641||Survey population|Adults with type 1 and type 2 diabetes and caregivers of people with diabetes including parents of children and young people with diabetes.
11100453|NCT04073628|Active Comparator|Active Lighting intervention|The active lighting intervention will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, the intervention will allow us to: (1) use a light source that will stimulate the circadian system and (2) provide the participants with options as to how the light treatment will be delivered
11100454|NCT04073628|Placebo Comparator|Control Lighting Intervention|The control lighting intervention will consist of low levels of a warm light source designed not to impact the circadian system.
11100455|NCT04073615|Experimental|Rivoceranib|Rivoceranib, 700 mg po, qd
11100456|NCT04073615|Active Comparator|Trifluridine/tipiracil|35 mg/m2 po, bid
11100457|NCT04073615|Experimental|Rivoceranib and trifluridine/tipiracil|Rivoceranib, recommended phase 2 dose (RP2D) Trifluridine/Tipiracil, 35 mg/m2, po, bid
11100458|NCT04073602|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
11100459|NCT04073589|Experimental|Treatment A|Single SC injection of Dose A
11100460|NCT04073589|Experimental|Treatment B|Single SC injection of Dose B
11100461|NCT04073589|Experimental|Treatment C|Single SC injection of Dose C
11100462|NCT04073589|Experimental|Treatment D|Single SC injection of Dose D
11100463|NCT04073576|Experimental|AHCL|Advanced Hybrid Closed Loop
11100464|NCT04073576|Active Comparator|SAP+PLGM|Sensor Augmented Pump with Predictive Low Glucose Monitoring
11100465|NCT04073563|Experimental|Group #1|Investigational Infuse™ 2.1 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
11100466|NCT04073563|Experimental|Group #2|Investigational Infuse™ 4.2 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
11100467|NCT04073563|Active Comparator|Control|Local bone autograft and supplemented with cancellous allograft as needed).
11100468|NCT04073550|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
11100469|NCT04073550|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.
11100470|NCT04073537|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
11100471|NCT04073537|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m^2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
11100472|NCT04073524|Experimental|Nature-Body-Mind-Community (NBMC) + treatment as usual|9 weeks of nature-based therapy (Nature-Body-Mind-Community (NBMC)) treatment as usual
11100473|NCT04073524|Other|Treatment as usual|Treatment as usual
11100474|NCT04073511|Experimental|Eungyosan|Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
11100475|NCT04073511|Experimental|Samsoeum|3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
11100476|NCT04073511|Placebo Comparator|Placebo|Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
11100477|NCT04073498|Experimental|Part 1a - Cohort 1|A single IV infusion of 0.0003 mg/kg SerpinPC in healthy subjects.
11100478|NCT04073498|Experimental|Part 1a - Cohort 2|A single IV infusion of 0.001 mg/kg SerpinPC in healthy subjects.
11100479|NCT04073498|Experimental|Part 1a - Cohort 3|A single IV infusion of 0.003 mg/kg SerpinPC in healthy subjects.
11100480|NCT04073498|Experimental|Part 1a - Cohort 4|A single IV infusion of 0.01 mg/kg SerpinPC in healthy subjects.
11100481|NCT04073498|Experimental|Part 1a - Cohort 5|A single SC dose of 0.03 mg/kg SerpinPC and a single SC dose of placebo in healthy subjects.
11100482|NCT04073498|Experimental|Part 1b - Cohort 6|A single SC dose of 0.1 mg/kg SerpinPC and a single SC dose of placebo in patients.
11100483|NCT04073498|Experimental|Part 1b - Cohort 7|A single SC dose of 0.3 mg/kg SerpinPC and a single SC dose of placebo in patients.
11100484|NCT04073498|Experimental|Part 1b - Cohort 8|A single SC dose of 0.6 mg/kg SerpinPC and a single SC dose of placebo in patients.
11100485|NCT04073498|Experimental|Part 1b - Cohort 9|Two single SC doses of 0.6 mg/kg SerpinPC in patients.
11100486|NCT04073498|Experimental|Part 2|Up to 3 SC doses may be selected for Part 2 and each patient will be assigned a single SerpinPC dose level (and placebo). The dose for Part 2 will be determined from ongoing review of the Part 1 data. The dose in Part will not exceed 1.2 mg/kg, or the highest dose deemed safe from Part 1b.
11100487|NCT04073485|Other|Microwave ablation|The uterine fibroid will be identified and located with ultrasonography. A microwave electrode appropriate for the size of target lesion is placed into the target lesion under ultrasound guidance. Appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
11100488|NCT04073472|Experimental|mesenchymal stem cells (MSCs)|Direct injection of 60 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed.
11100489|NCT04073459|Experimental|L dose of Hexavalent|Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
11100490|NCT04073459|Experimental|M dose of Hexavalent|Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
11100491|NCT04073459|Experimental|H dose of Hexavalent|High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
11100492|NCT04073459|Active Comparator|Pentavalent+IPV|Co-administration of EupentaTM Inj and Imovax Polio
11100493|NCT04073446|Active Comparator|Dorsal Column (DC) Perception|Use of DC Perception based programming
11100495|NCT04073446|Active Comparator|Dorsal Column (DC) Sub-perception|Use of DC sub-perception based programming
11100496|NCT04073446|Active Comparator|Dorsal Root (DR) Sub-perception|Use of DR sub-perception based programming
11100497|NCT04073433|Experimental|Experimental: MDMA-assisted psychotherapy|One session of MDMA-assisted psychotherapy with a dose of MDMA 120 mg and optional supplemental dose of 60 mg 1.5 to 2 hours later
11100498|NCT04073420||Surgical Valve Replacement and/or Repair Patients|
11100499|NCT04073407|Active Comparator|AXA1957|AXA1957 20.4g
11100500|NCT04073407|Placebo Comparator|Placebo|Placebo 24g
11100501|NCT04073394|Other|Diet Intervention|
11100502|NCT04073381|Experimental|Prehabiliation Program|100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study ad participate in the prescribed prehabilitation exercise and nutrition program.
11100503|NCT04073368|Active Comparator|AXA1957 high dose|AXA1957 20.3g
11100504|NCT04073368|Active Comparator|AXA1957 low dose|AXA1957 13.5g
11100505|NCT04073368|Active Comparator|AXA1125|AXA1125 24g
11100506|NCT04073368|Placebo Comparator|Placebo|Placebo 24g
11100507|NCT04073355|Experimental|Physical Activity|Smartphone-delivered physical activity intervention
11100508|NCT04073342||Surgical Necrotizing enterocolitis|Cases of preterm infants with necrotizing enterocolitis need surgical intervention
11100509|NCT04073342||Non Necrotizing enterocolitis|babies with intestinal operations for non necrotizing enterocolitis pathologies like congenital intestinal obstruction.
11100510|NCT04073329||Plain x ray|measurement the accuracy of post operative reduction by Matta method
11100511|NCT04073329||CT|measure the accuracy of reduction by Verbeek method
11100512|NCT04073316|Experimental|"Intervention group"|
11100513|NCT04073316|Active Comparator|"Control group"|
11100514|NCT04073303|Active Comparator|Botulinum Toxin Type A (BOTOX®)|Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
11100515|NCT04073303|Placebo Comparator|Placebo|Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
11100516|NCT04073290|Active Comparator|Rifaximin and lactulose|Rifaximin 550 milligram b.i.d. combined with lactulose
11100517|NCT04073290|Placebo Comparator|Placebo and lactulose|Placebo b.i.d. combined with lactulose
11100518|NCT04073277|Experimental|SCF-N-treated needle acupuncture|For each participant, one hand was randomly assigned to the experimental group with SCF-N-treated needle acupuncture .
11100519|NCT04073277|Sham Comparator|untreated needle acupuncture|The other hand of participant in experimental group was assigned to the control group with untreated needle acupuncture.
11100520|NCT04073264|Experimental|monofilament|monofilament absorbable suture
11100521|NCT04073264|Active Comparator|polifilament|synthetic absorbable braided (polifilament) suture
11100522|NCT04073251|Experimental|KalobaTuss children|KalobaTuss children syrup 5 ml for 4 times a day supplied for 8 consecutive days.
11100523|NCT04073251|Placebo Comparator|Placebo|Placebo syrup 5 ml for 4 times a day supplied for 8 consecutive days.
11100524|NCT04073238|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
11100525|NCT04073238|Experimental|Repeated low-level red-light therapy|Single vision lens & repeated low-level red-light therapy
11100526|NCT04073225|Experimental|MindPod Dolphin Arm|Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke.
11100527|NCT04073225|Active Comparator|Hand Bike Arm|Pedal Exerciser, a single-component upper-arm aerobic play. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
11100528|NCT04073212|Experimental|Intervention 1 DN+HSLE|Patients in the intervention 1 Dry Needling (DN)+heavy Slow Load Exercise (HSLE) group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon followed by DN, HSLE and a standardized shoulder strengthening exercise program.
11100529|NCT04073212|Active Comparator|Intervention 2 Control|"Patients in the control group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon and a standardized exercise program. Dry needling nor heavy slow load exercise will not be integrated into the control plan of care."
11100530|NCT04073199|Active Comparator|Long Lever Group|This arm receive the protocolized treatment along with the long passive stretch of the Teres Major in Long Lever with the patient in supine position.
11100531|NCT04073199|Active Comparator|Short Lever Group|This arm receive the protocolized treatment along with the short lever stretch according to the Orthopaedic Manual Therapy of the Teres Major.
11100532|NCT04073199|No Intervention|Control Group|only receive the protocolized physiotherapy treatment for the Subacromial syndrome that is applied in the Rehabilitation Service, without the addition of any additional stretch technique.
11100533|NCT04073186|Experimental|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
11100534|NCT04073173|Experimental|LISA-analgesic|Less Invasive Surfactant Administration (LISA) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
11100535|NCT04073173|Experimental|LISA-no analgesic|Less Invasive Surfactant Administration (LISA) without an analgesic drug.
11100536|NCT04073173|Experimental|INSURE-analgesic|INtubation-SURfactant-Extubation (INSURE) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
11100537|NCT04073173|Experimental|INSURE-no analgesic|INSURE without an analgesic drug.
11100538|NCT04073160|Experimental|Decipher Bladder test subtype non-basal|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype non-basal
11100539|NCT04073160|Experimental|Decipher Bladder test subtype basal and cisplatin-ineligible|Subjects with localized muscle invasive urothelial carcinoma of the bladder, whose tumor is Decipher Bladder test subtype basal and the subject is cisplatin-ineligible
11100540|NCT04073147|Experimental|Dosing group 1|Venetoclax 600mg + Obinutuzumab 1000mg
11100541|NCT04073147|Experimental|Dosing group 2|Venetoclax 800mg + Obinutuzumab 1000mg
11100542|NCT04073147|Experimental|Dosing group 3|Venetoclax 1000mg + Obinutuzumab 1000mg
11100543|NCT04073134|Active Comparator|Evolocumab|Participants will receive evolocumab 140 mg subcutaneous injections once every 2 weeks.
11100544|NCT04073134|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injections once every 2 weeks.
11100545|NCT04073121|Experimental|Luminor DCB and Angiolite DES|Study Devices
11100546|NCT04073095|Active Comparator|Group T = mTLIP block group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
11100547|NCT04073095|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
11100548|NCT04073095|No Intervention|Group C = Control group|Patients in control group will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11100549|NCT04073069|Experimental|The DR group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, 0.5ml diprospan, plus 14.5ml saline;
11100550|NCT04073069|Active Comparator|The R group|Participates received peri-incisional scalp infiltration with 15ml ropivacaine 1% wt/vol, plus 15ml saline;
11100551|NCT04073056|Active Comparator|Quadratus Lumborum II Group|The QL 2 group will receive 15 mL bupivacaine 0.25% on both sides for a total of 30 mL once the surgery is done but prior to extubation under ultrasound guidance.
11100552|NCT04073056|Active Comparator|Conventional Therapy|Conventional therapy consists of the injection of 30 mL of bupivacaine 0.25% directly into the incision sites by the surgeon at the end of the procedure.
11100553|NCT04073043|Experimental|Intervention Group|The intervention group will have access to the web-based intervention along with telephone coaching. Participants in the intervention will receive 7 coach calls over a period of 12 weeks.
11100554|NCT04073043|No Intervention|Control Group|The control group will have access only to the web-based intervention without telephone support
11100555|NCT04073017|Experimental|Enterade|Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
11100556|NCT04073017|Experimental|Experimental|Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
11100557|NCT04073004|Experimental|Rapid Resolution Therapy|"RRT is a talk therapy that uses Neurolinguistic Programming Language and trance states to cause a shift in how the mind is processing incoming data.
~The understanding is that the part of the mind that is causing the disturbing emotion, thought or sensation is causing them to cause the person to take an action to ensure the organisms survival. RRT therapists employ psycho-therapeutic techniques taht are designed to cause the mind to process information differently so that the disturbing content and distorted meaning shift."
11100558|NCT04072991|Active Comparator|Low FODMAP diet|As part of their treatment for IBS participants may be randomised to a low FODMAP diet
11100559|NCT04072991|Active Comparator|Gluten Free Diet|As part of their treatment for IBS participants may be randomised to a gluten free diet
11100560|NCT04072991|Active Comparator|British Dietetic Association diet|As part of their treatment for IBS participants may be randomised to the BDA diet
11100561|NCT04072978||Intraocular lens implantation: AC IOL|"Patients who are scheduled to undergo AC IOL (anterior chamber intraocular lens) implantation for any of the following indications:
~primary or secondary aphakia
~primary or secondary lens subluxation or dislocation"
11100562|NCT04072978||Intraocular lens implantation: SF IOL|"Patients who are scheduled to undergo SF IOL (scleral fixated intraocular lens) implantation for any of the following indications:
~primary or secondary aphakia
~primary or secondary lens subluxation or dislocation"
11100563|NCT04072965|Experimental|Cross eduacation of balance|10 females with Chronic Ankle Instability will receive balance training for the non affected side for a six weeks
11100564|NCT04072965|Experimental|Traditional training|10 females with Chronic Ankle Instability will receive balance training for the affected side for a six weeks
11100565|NCT04072965|No Intervention|control|balance of 15 females with Chronic Ankle Instability will be assessed before and after six weeks of no intervention
11100566|NCT04072952|Experimental|ARV-471|
11100567|NCT04072939||Single arm|dilated fundus exam
11100568|NCT04072926|Experimental|PDT+/BIOROOT|Photodynamic therapy will bi conducted with diode laser (660nm, 50mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with BioRoot in combination with guttapercha points.
11100569|NCT04072926|Experimental|PUI/BIOROOT|This arm will only get PUI (passive ultrasound irrigation) with 2,5ml of 2,5% sodium hypochlorite, then 2ml of 15% EDTA which will be activated for 60seconds (EndoUltra MicroMega, France) and finally 2,5ml of 2,5% of sodium hypochlorite will be also activated for 30 seconds. Root canal filling in combination with BioRoot and guttapercha points.
11100570|NCT04072926|Active Comparator|PDT+/AH+|Photodynamic therapy will bi conducted with diode laser (660nm, 50mW, 60 seconds) with toluidine at the end of chemomechanical preparation. Final root canal filling will be with AH+ epoxy based cement in combination with guttapercha points.
11100571|NCT04072926|Active Comparator|PUI/AH+|This arm will only get PUI (passive ultrasound irrigation) in combination with AH+ epoxy based cement and guttapercha points.
11100572|NCT04072913|Other|Control group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
11100573|NCT04072913|Other|Low grade lesion group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
11100574|NCT04072913|Other|High grade lesions group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
11100575|NCT04072913|Other|Cancer group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
11100576|NCT04072900|Experimental|Intervention/Treatment|"Personalized NeoAntigen Cancer Vaccine- Neo-Vac-Mn (peptides + rhGM-CSF+anti-PD1+Imiquimod 5% Topical Cream)
~NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161
~Anti-PD-1 Toripalimab: 3mg/kg, ivgtt, Q2w
~rhGM-CSF: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
~Imiquimod 5% Topical Cream:topical application on the injection site 6 hours before each NeoAntigen peptides injection"
11100577|NCT04072887|Active Comparator|QBW251 450 mg|QBW251 450 mg
11100578|NCT04072887|Active Comparator|QBW251 300 mg|QBW251 300 mg
11100579|NCT04072887|Active Comparator|QBW251 150 mg|QBW251 150 mg
11100580|NCT04072887|Active Comparator|QBW251 75 mg|QBW251 75 mg
11100581|NCT04072887|Active Comparator|QBW251 25 mg|QBW251 25 mg
11100582|NCT04072887|Placebo Comparator|QBW251 Placebo|QBW251 Placebo
11100583|NCT04072874|Active Comparator|Régimen 1|"Regimen 1: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 4 weeks.
~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
11100584|NCT04072874|Active Comparator|Régimen 2|"Regimen 2: Curaleish lotion applied three times a day in combination with Curaleish cream applied two times a day for 6 weeks.
~For both treatments, the patient applies Curaleish lotion in the morning, afternoon, and evening, that is to say, three times a day. And Curaleish cream in the morning and afternoon, that is, twice a day."
11100585|NCT04072861|Other|Administer 9mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 9 mg of Stannous Protoporphyrin and be followed for 28 days.
11100586|NCT04072861|Other|Administer 27mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 27 mg of Stannous Protoporphyrin and be followed for 28 days.
11100587|NCT04072861|Other|Administer 90mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 90 mg of Stannous Protoporphyrin and be followed for 28 days.
11100588|NCT04072861|Other|Administer 27mgSnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 27 mg of Stannous Protoporphyrin and be followed for 28 days.
11100589|NCT04072861|Other|Administer 90mgSnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 90mg of Stannous Protoporphyrin and be followed for 28 days.
11100590|NCT04072861|Other|Administer 27mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 27mg of Stannous Protoporphyrin and be followed for 28 days.
11100591|NCT04072861|Other|Administer 90mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 90mg of Stannous Protoporphyrin and be followed for 28 days.
11100592|NCT04072835|Experimental|Etripamil NS 70mg|Patients will self-administer etripamil NS.
11100593|NCT04072822|Active Comparator|Prednisone|Standard of care plus prednisone 40 mg orally once daily on Days 1-30 and matching placebos for Anakinra (1 syringe s.c. once daily on Days 1-14), and zinc (matched pill once daily on Days 1-90).
11100594|NCT04072822|Active Comparator|Anakinra and Zinc|Standard of care plus Anakinra (100 mg s.c.) once daily on Days 1-14 zinc sulfate 220 mg once daily on Days 1-90, and placebo for prednisone (matched pill once daily on Days 1-30).
11100595|NCT04072809||All participants|All participants in the study will experience the same procedures.
11100596|NCT04072796||Case group|Case group reported urinary complaints
11100597|NCT04072796||Control group|Control group did not have any urinary complaints.
11100598|NCT04072783|Other|Patients with craniosynostosis|Patients with craniosynostosis will undergo pre - and post-operative imaging studies. The surgery will be performed for these patients as standard of care. They will also be tested fro neurodevelopment.
11100599|NCT04072770|Experimental|Pea|Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
11100600|NCT04072770|Active Comparator|Casein|Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
11100601|NCT04072757|Active Comparator|Intervention Group|The cooking skill building/nutrition education workshops will be led by a multidisciplinary team comprised of: a chef/instructor, a nutritionist and/or registered dietitian, MD and/or Preventive Medicine Resident, and Yale-Griffin Prevention Research Center staff. The cooking/nutrition education workshop sessions will be approximately 45 minutes and will: include a plant forward approach to healthy eating; integrate nutrition and health-related information and cooking instruction (i.e. knife skills, equipment use); show participants how to prepare meals that are simple, nutritious, affordable, and delicious; provide recipes and nutrition information aimed at improving dietary intake and health status; and provide an enjoyable program that participants will look forward to attending. Fruit and vegetable prescription vouchers will be redeemed at ShopRite grocery stores (Ansonia and Shelton locations) and Griffin Hospital's farmers market, where redemption will be tracked.
11100602|NCT04072757|Placebo Comparator|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
11100603|NCT04072744||Participants|General Study Participants
11100604|NCT04072731||thyroid cancer|the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.
11100605|NCT04072731||the adjacent thyroid tissues|the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.
11100606|NCT04072718|Other|Single arm|
11100696|NCT04072237|Experimental|Stage 7|Coagulation Factor VIIa variant, 120 µg/kg by subcutaneous route
11100607|NCT04072705||1. Poor and intermediate metabolizer group|Poor and intermediate metabolizer group: acute ischemic stroke patients with poor and intermediate metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
11100608|NCT04072705||2. Extensive metabolizer group|Extensive metabolizer group: acute ischemic stroke patients with Extensive metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
11100609|NCT04072692|No Intervention|1st part: The gliding properties of the tendons|No intervention. Subjects are measured by ultrasound under 5 different postures of the hand for forty minutes.
11100610|NCT04072692|No Intervention|1st part: The gliding properties of the median nerve|No intervention. Subjects are measured by ultrasound under under 6 different postures of the wrist and hand and 5 different movement patterns of the wrist and hand for forty minutes.
11100611|NCT04072692|Experimental|2nd part: New hybrid rehabilitation strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.
~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.
~For post-test, the same procedure is repeated again after completing all training.
~For follow-up, the same procedure is repeated again 6 months after completing all training.
~After pre-test, 8 times hybrid rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
11100612|NCT04072692|Experimental|2nd part: Traditional strategy|"The program includes pre-test, 8 times training, post-test and follow-up test.
~For pre-test, subjects perform the specific hand movement under different exerting force conditions and 4 different angles of phalangeal joints and be asked to do Phalen test, Grip strength test, Pinch test and SWMT test. It takes 40 minutes.
~For post-test, the same procedure is repeated again after completing all training.
~For follow-up, the same procedure is repeated again 6 months after completing all training.
~After pre-test, 8 times traditional rehabilitation training are asked. There are two times in a week, and all training will be completed in one month. Each time will take forty minutes."
11100613|NCT04072692|No Intervention|3rd part: The effect of carpal tunnel release|"No intervention. The program includes pre-test, post-test and two times follow-up tests.
~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.
~For post-test, subjects perform the functional assessment of both hands one week after carpal tunnel release surgery. It takes 20 minutes.
~For first follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands one month after carpal tunnel release surgery. It takes 40 minutes.
~For second follow-up, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands two month after carpal tunnel release surgery. It takes 40 minutes."
11100614|NCT04072692|Experimental|3rd part: Wearable anti-bowstringing orthosis (WABO)|"The program includes pre-test, post-test and two times follow-up tests.
~For pre-test, subjects perform the mechanical properties of the flexor tendon assessment and functional assessment of both hands before carpal tunnel release surgery. It takes 40 minutes.
~Subjects wear WABO in the morning and a splint at night within a week after carpal tunnel release surgery.
~For post-test, subjects perform the functional assessment of both hands with and without wearing WABO and a splint one week after carpal tunnel release surgery. It takes 40 minutes.
~From the third weeks after carpal tunnel release surgery, subjects wear WABO only in the morning.
~For first follow-up, the same procedure in pre-test is repeated again one month after carpal tunnel release surgery. It takes 40 minutes.
~For second follow-up, the same procedure in pre-test is repeated again two month after carpal tunnel release surgery."
11100615|NCT04072679|Experimental|Sintilimab+IBI305|Sintilimab: 200mg (D1, q3w） IBI305: 7.5mg/kg or 15mg/kg (D1, q3w）
11100616|NCT04072666|Experimental|ASSIP plus SPP|Participants in the ASSIP group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the ASSIP psychological intervention where they will receive three therapy sessions followed by regular ongoing contact through individually focused letters sent over 24 months.
11100617|NCT04072666|Experimental|CBT plus SPP|Participants in the CBT group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the CBT psychological intervention where they will receive five CBT 60-minute individual sessions.
11100618|NCT04072666|Active Comparator|SPP alone|"The Suicide Prevention Pathway (SPP) comprises seven steps:
~i) Initial screening - persons experiencing suicide ideation and who may also have a history of, or recent, suicide attempt, are placed on the pathway; ii) Assessment of suicide risk iii) Formulation of suicide risk (based on a prevention oriented approach) iv) Safety planning (collaboratively developed with the client) and Counselling on access to lethal means v) Structured follow-up (within 24-48 hrs); vi) Transition of care plan; and vii) Caring contacts - ongoing contact/support for the person for the next 2 years (through personalised letters or phone texts)."
11100619|NCT04072653|Experimental|Observation group( SLNB is spared)|In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.
11100620|NCT04072640|Experimental|voriconazole treatment|induction treatment with Voriconazole 200mg bid (IV) + 5FC (100mg/kg/d) for 14 days, consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
11100621|NCT04072640|Active Comparator|amphotericin treatment (0.7-1.0mg/kg/d)|Induction treatment with amphotericin B 0.7-1.0mg/kg/d + 5FC (100mg/kg/d) for 14 days,consolidation treatment wiht fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
11100622|NCT04072640|Experimental|amphotericin B treatment (0.4-0.5mg/kg/d)|Induction treatment with amphotericin B 0.4-0.5mg/kg/d + 5FC (100mg/kg/d) for 28 days, consolidation treatment with fluconazole 400mg/d for two months, then maintenance treatment with fluconazole 200mg/d
11100623|NCT04072601|Experimental|Atorvastatin|Atorvastatin 10-20 mg for 18 months of treatment. Start dose is 10 mg, adjusted to 20 mg after 15-30 days if no sideeffects occurs.
11100624|NCT04072601|Placebo Comparator|Control|Placebo of atorvastatin 10 mg, 1-2 tablets for 18 months of treatment. Start dose is 1 tablet (10 mg placebo), adjusted to 2 tablets (20 mg placebo) after 15-30 days if no side effects occurs.
11100625|NCT04072588||Sacrospinous Ligament Fixation patients|Patients who underwent Sacrospinous Ligament Fixation for the treatment of vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
11100626|NCT04072588||lateral suspension surgery patients|Patients who underwent lateral suspension surgery for vaginal cuff prolapse in patients who had previously undergone hysterectomy for benign causes
11100627|NCT04072575|Experimental|Paliperidone Palmitate 6 month(PP6M)|"Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level (moderate or higher) that the participant received during previous study. Participants in the moderate dose level will receive PP6M Dose 1 and higher dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months."
11100628|NCT04072562|Experimental|AZD7594 0.7 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 0.7 mg, delivered dose 1 inhalation
11100629|NCT04072562|Experimental|AZD7594 1.6 mg|The study subjects will receive AZD7594 via nebulizer, during 8 minutes: 1.6 mg, delivered dose 1 inhalation
11100630|NCT04072562|Active Comparator|AZD7594 720 μg|The study subjects will receive AZD7594 via DPI: 0.72 mg, delivered dose (792 µg nominal dose) 1 inhalation
11100631|NCT04072549|Experimental|Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
11100632|NCT04072549|No Intervention|Comparison/Control|The children in the control group will be children enrolled in the same schools as those randomized to receive summer programming. The comparison/control group will not receive a voucher to attend a summer camp.
11100633|NCT04072536|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream.
11100634|NCT04072536|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 without activated assistance, in a random order established upstream.
11100635|NCT04072523||1|Type 2 Diabetic Patients
11100636|NCT04072510|Experimental|Case: Self-esteem group + Treatment as Usual|"Self-esteem group is based on a cognitive behavioral model of low self-esteem addressing thoughts, feelings and behaviour. The self-esteem group is designed to be administered in 6 weekly sessions.
~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.Treatment as usual occurred alongside the self-esteem group."
11100637|NCT04072510|Active Comparator|Control: Treatment as Usual Only|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
11100638|NCT04072497|Experimental|Zoster vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
11100639|NCT04072497|Active Comparator|Varicella vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=3.3 LgPFU per dose)
11100640|NCT04072497|Placebo Comparator|Placebo|Placebo with no live virus
11100641|NCT04072484|No Intervention|Room Air|The reduced oxygen breathing device will be set to deliver room air. (i.e., no oxygen is removed from the gas mixture. The subject will perform CPR while breathing through mask and tubing that is connected to the device.
11100642|NCT04072484|Experimental|Hypoxia|The reduced oxygen breathing device will be set to deliver a gas mixture with15% oxygen. (Equivalent to the partial pressure of oxygen at 2,438 meters.) The subject will perform CPR while breathing through mask and tubing that is connected to the device.
11100643|NCT04072471||Zurampic®|Patients exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) (lesinurad+XOI)
11100644|NCT04072471||Control group: xanthine oxidase inhibitor monotherapy|Patients exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat).
11100645|NCT04072458|Experimental|BP1002 monotherapy|L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m^2.
11100646|NCT04072445|Experimental|Treatment (trifluridine and tipiracil, irinotecan)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and irinotecan hydrochloride IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11100647|NCT04072432|Experimental|120 mg FeS IV infusion|A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
11100648|NCT04072432|Experimental|240 mg FeS infusion|A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
11100649|NCT04072432|Experimental|360 mg FeS Infusion|A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
11100650|NCT04072419||enhanced recovery after surgery group|"weaning mechanical ventilation after surgery (less than 48h),
~no post-operative chest tube and urinary catheterization)
~Establishment of early feeding (D3 post-operative)"
11100651|NCT04072419||control group|"the time of mechanical ventilation after surgery is more than 48 hours
~routine postoperative indwelling chest tube and urinary catheterization)
~Establishment of feeding after D3 post-operative"
11100697|NCT04072237|Experimental|Stage 8|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route
11100698|NCT04072237|Experimental|Stage 9|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route
11100652|NCT04072406|Active Comparator|Arm I: Usual Care|"Participants assigned to usual care will receive a packet of instructions with information about how to complete weekly surveys via a link that will be emailed to them
~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
11100653|NCT04072406|Experimental|Arm II: Mindfulness Meditation|"Participants will listen to mindfulness meditations daily over the course of three weeks.
~Participants in both arms will be asked to complete a total of five surveys: baseline, at the end of each of three weeks, and a final survey one month later"
11100654|NCT04072393|Experimental|Cardiac rehabilitation|"The intervention consists of a prescribed course of cardiac rehabilitation: 36 sessions, three times a week, one hour each, over a period of 8 to 12 weeks.
~Each customized exercise session includes three phases:
~a 5- to 10-minute warm-up which consists of stretching, flexibility movements, and aerobic activity which gradually raises the heart rate to the desired level
~a conditioning or training phase, which consists of 20 to 45 minutes of continuous or discontinuous aerobic activity
~a cool down for 5 to 10 minutes consisting of low-intensity exercise that permits a gradual recovery from the conditioning phase"
11100655|NCT04072380|Experimental|SUVN-G3031 2mg|Orally taken once daily for 14 days
11100656|NCT04072380|Experimental|SUVN-G3031 4mg|Orally taken once daily for 14 days
11100657|NCT04072380|Placebo Comparator|Placebo|Orally taken once daily for 14 days
11100658|NCT04072367|Other|Active Treatment Group|NeVa Stent Retrievers
11100659|NCT04072367|Other|Control Device|Solitare Stent Retrievers
11100660|NCT04072354|Experimental|SEP-363856 50mg|SEP-363856 50mg dosed once daily
11100661|NCT04072354|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
11100662|NCT04072354|Placebo Comparator|Placebo|Placebo dosed once daily
11100663|NCT04072341|Experimental|Propolis Period|Hemodialysis patients will be under regular treatment of their comorbidities and using Propolis.
11100664|NCT04072341|Experimental|Control Period|Hemodialysis patients will be under regular treatment of their comorbidities, but without using Propolis.
11100665|NCT04072328|Experimental|Propofol alone|Participants who receive propofol alone during sedative endoscopy.
11100666|NCT04072328|Active Comparator|Midazolam with propofol|Participants who receive midazolam + propofol during sedative endoscopy.
11100667|NCT04072315|Experimental|PLN-74809 (high dose)|PLN-74809 (open label)
11100668|NCT04072315|Experimental|PLN-74809 (mid dose)|PLN-74809 (open label)
11100669|NCT04072315|Experimental|PLN-74809 (low dose/blinded)|PLN-74809 (double blind)
11100670|NCT04072315|Experimental|PLN-74809 (mid dose/blinded)|PLN-74809 (double blind)
11100671|NCT04072315|Placebo Comparator|Placebo|
11100672|NCT04072302|Experimental|KAF156 800 mg pre-challenge|Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
11100673|NCT04072302|Placebo Comparator|Placebo 800 mg pre-challenge|Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
11100674|NCT04072302|Experimental|KAF156 800 mg post-challenge|Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100675|NCT04072302|Placebo Comparator|Placebo 800 mg post-challenge|Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100676|NCT04072302|Experimental|KAF156 300 mg post-challenge|Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100677|NCT04072302|Placebo Comparator|Placebo 300 mg post-challenge|Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100678|NCT04072302|Experimental|KAF156 100 mg post-challenge|Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100679|NCT04072302|Placebo Comparator|Placebo 100 mg post-challenge|Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100680|NCT04072302|Experimental|KAF156 20 mg post-challenge|Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100681|NCT04072302|Placebo Comparator|Placebo 20 mg post-challenge|Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100682|NCT04072302|Experimental|KAF156 50 mg post-challenge|Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100683|NCT04072302|Placebo Comparator|Placebo 50 mg post-challenge|Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
11100684|NCT04072289|Experimental|Low cylinder (treatment)|0.25D and 0.50D cylinder treatments will be measured and treated by the laser.
11100685|NCT04072289|No Intervention|Low cylinder (no treatment)|0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.
11100686|NCT04072276||EV71 Vaccine with Adjuvant AlPO4|EV71 Vaccine Produced in Vero Cells with Adjuvant AlPO4
11100687|NCT04072276||Adjuvant AlPO4|Placebo (Adjuvant AlPO4 only)
11100688|NCT04072263|Experimental|Cohort 1|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus
~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x."
11100689|NCT04072263|Experimental|Cohort 2|"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus
~Tumor Infiltrating Lymphocytes (TIL) starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus
~Interferon Alpha 2A (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."
11100690|NCT04072237|Experimental|Stage 1|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
11100691|NCT04072237|Experimental|Stage 2|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
11100692|NCT04072237|Experimental|Stage 3|Coagulation Factor VIIa variant, 45 µg/kg by subcutaneous route
11100693|NCT04072237|Experimental|Stage 4|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route
11100694|NCT04072237|Experimental|Stage 5|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route
11100695|NCT04072237|Experimental|Stage 6|Coagulation Factor VIIa variant, 90 µg/kg by subcutaneous route
11100699|NCT04072211|Other|Vaccine arm|Engerix-B vaccine will be administered. This arm will include all those at risk of hepatitis B virus infection
11100700|NCT04072198|Experimental|FOLFOXIRI/Bevacizumab + Nivolumab|Bevacizumab 5 mg/m2 Nivolumab 240 mg Irinotecan 165 mg/m2 iv (max 8 cycles) Oxaliplatin + leucovorin 200 mg/m2 (max 8 cycles) Fluorouracil 3200 mg/m2 (max 8 cycles)
11100701|NCT04072185|Experimental|Physical activity group|
11100702|NCT04072185|No Intervention|Control group|
11100703|NCT04072172|Experimental|Female with leg spider veins|Females at the age of 20 to 45 not known diabetics or hypertensive complaining of leg spider veins.
11100704|NCT04072159|Experimental|Intervention group|For the intervention group, primary care providers will refer patients who have received the initial HPV vaccine to receive the additional doses at patients' community retail pharmacy.
11100705|NCT04072159|No Intervention|Control group|Control group participants will return to the primary care practitioner to complete the HPV vaccine series (usual care).
11100706|NCT04072146|Experimental|OC-01 (varenicline) nasal spray|
11100707|NCT04072146|Active Comparator|Chantix®|
11100708|NCT04072133|Experimental|Meditative Movement Intervention|Participants will complete the following components of baseline (T1) data collection: demographics, biometric measurements, a heart rate variability assessment, and questionnaires. Participants will be asked to provide six saliva samples via passive drool to measure cortisol levels. Participants will be assigned into hour-long meditative movement (MM) classes for eight weeks total. Participants will be asked to practice their MM skills at home for at least 30 minutes most days per week. The study will distribute hard-copy movement manuals and DVD instruction videos for guidance. Participants will be asked to provide a log of all dates and lengths of their at-home practice. After the eighth class, participants will return for post-intervention (T2) data collection, consisting of biometric measurements, a heart rate variability assessment, and questionnaires. Participants will provide six more saliva samples via passive drool method.
11100709|NCT04072120||R1|"Norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 registered in the FS-data during this period.
~Sub-sample those attending a cardiovascular health survey who later developed stroke."
11100710|NCT04072120||R2|All Norwegians born in the period 1 January 1940 to 31 December 1959 who survived to 1991.
11100711|NCT04072120||R3|Norwegian citizens aged 45 and above 1.1.2016.
11100712|NCT04072107|Experimental|Arm I|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy + capecitabine AC. All patients will receive concurrent cisplatin (100 mg/m2) every 3 weeks, in a total of three cycles. All patients will receive low-dose metronomic capecitabine (650 mg/m2 bid, oral, d1-21, q3w) until disease progression, or intolerable toxicity or 6 months.
11100713|NCT04072107|Experimental|Arm II|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy and anti-PD-1 therapy (sintilimab) + anti-PD-1 therapy (sintilimab) AC. All patients will receive concurrent cisplatin (100 mg/m2) and sintilimab (200 mg, IV drop 30-60 min) every 3 weeks in a total of three cycles. All patients will receive adjuvant anti-PD-1 therapy (sintilimab, 200 mg, IV drop 30-60 min, q3w) in a total of nine cycles until disease progression, or intolerable toxicity or 6 months.
11100714|NCT04072094|Experimental|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
11100715|NCT04072094|Active Comparator|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
11100716|NCT04072081|Experimental|Drug-coated ballon|Treatment of in suit coronary lesions with drug-coated balloon
11100717|NCT04072081|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
11100718|NCT04072068|Experimental|Edoxaban|edoxaban 60 mg daily
11100719|NCT04072055||MOTO medial|Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.
11100720|NCT04072042|Experimental|Apatinib monotherapy|patient will receive Apatinib 250mg tablet by mouth, bid.
11100721|NCT04072029||Cataract - FECD|Eyes with FECD undergoing cataract surgery
11100722|NCT04072016|Experimental|Beacon Aqueous Microshunt|
11100723|NCT04072003||IVUS-guided PCI|In this group, intravascular ultrasound(IVUS) in addition to coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
11100724|NCT04072003||CAG-guided PCI|In this group, coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
11100725|NCT04071990|Active Comparator|Family-based cognitive behavioral group therapy (FB-CBGT)|One family member of each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session.
11100726|NCT04071990|Placebo Comparator|Cognitive-behavioral group therapy (CBGT) without family|Each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, …) and homework exercises after each session., without the involvement of family members.
11100727|NCT04071977|Active Comparator|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
11100728|NCT04071977|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
11100729|NCT04071964||Groupe 1|Patients with colorectal cancer undergoing resection with anastomosis
11100730|NCT04071964||Groupe 2|Patients with colorectal cancer undergoing resection without anastomosis (Abdominoperineal resection)
11100731|NCT04071964||Groupe 3|"Patients with rectal cancer without surgery (Watch and wait)"
11100732|NCT04071964||Groupe 4|Control group consisting of patients who do not have surgical pathologies of the colon and rectum
11100733|NCT04071951|Experimental|Pharmacist Arm|Pharmacist-Led Medication Reconciliation, Regimen Review, and Adherence and Literacy Assessment and Counseling
11100734|NCT04071951|No Intervention|Usual Care|Patients in this study will receive usual care. Clinically-indicated services, including pharmacist services, may be provided to control group patients.
11100735|NCT04071938|Active Comparator|Intervention group|"Physicians: 10 GPs from 10 practices who treat patient with Spinal cord injury (SCI) and 10 SCI specialists.
~Patients: 270 people with SCI within 25 minutes vehicle driving distance to the GP practices will be in the intervention group"
11100736|NCT04071938|No Intervention|Control group|"Physicians: 20 GPs who treat patient with SCI will not receive any intervention. They will be completing the questionnaire (DOC) and assessed for satisfaction with collaboration with the SCI specialist.
~Patients: 210 people with spinal cord injury outside the catchment area of the intervention group will be receiving usual care (no intervention)"
11100737|NCT04071912||ACL|All sports patients who had a muscle evaluation at 3-4 months and 6-8 months after ACL ligamentoplasty since January 2016
11100738|NCT04071899||Patients|patients with RBD
11100739|NCT04071899||Bedpartners|Subjects which are the bedpartners of patients with RBD
11100740|NCT04071886|Experimental|Mindfulness-Based Training|Participants in the Mindfulness-Based Training arm will receive 2 weeks of Mindfulness-Based Training for at least 30 minutes every day.
11100741|NCT04071886|Active Comparator|Relaxation Training|Participants in the Relaxation Training arm will receive 2 weeks of Relaxation Training for at least 30 minutes every day.
11100742|NCT04071873|Experimental|Point-of-care HIV testing (intervention)|Participants will be offered voluntary point-of-care HIV testing during a traditional healer visit.
11100743|NCT04071873|Active Comparator|Education on community HIV resources (control)|Participants will be offered education regarding HIV testing and community resources during a traditional healer visit.
11100744|NCT04071860||discovery and learning cohort|Data from this cohort will be used to develop the software algorithms
11100745|NCT04071860||Validation|Data from this cohort will be used to validate the software algorithms
11100746|NCT04071847||Deep brain stimulation|Subjects implanted with an Abbott DBS system
11100747|NCT04071834||Diabetes mellitus group|Diabetic patients undergoing spinal anesthesia for lower extremity surgery
11100748|NCT04071834||Non-diabetic group|Non-diabetic patients undergoing spinal anesthesia for lower extremity surgery
11100749|NCT04071821|Experimental|A: Test under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fasted conditions
11100750|NCT04071821|Active Comparator|B: Reference under Fasted Condition|Reference: Single oral dose of cetirizine HCl oral tablets 10 mg, administered with approximately 240 mL of room temperature water, under fasted conditions
11100751|NCT04071821|Experimental|C: Test under Fed Condition|Test: Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with approximately 240 mL of room temperature water, under fed conditions
11100752|NCT04071821|Experimental|D: Test under Fasted Condition with No Water|Single oral dose of cetirizine HCl Gummy 10 mg, chewed, administered with no water, under fasted conditions
11100753|NCT04071821|Experimental|E: Test Swallowed Whole with Water, under Fasted Condition|Single oral dose of cetirizine HCl Gummy 10 mg, swallowed whole, administered with approximately 240 mL of room temperature water, under fasted conditions
11100754|NCT04071808||Coronary angiography group|In diabetic patients without symptoms of myocardial ischemia, coronary angiography showed no stenosis or stenosis less than 75%.
11100755|NCT04071808||Coronary angiographic stent implantation group|Coronary angiographic stenosis was more than 75% in diabetic patients without myocardial ischemia symptoms, and coronary stents were implanted.
11100756|NCT04071795|Experimental|Opt Out|Training and Academic Detailing
11100757|NCT04071795|Experimental|Opt In|Training and Academic Detailing
11100758|NCT04071782|Experimental|SELUTION Drug Coated Balloon|Study participants will undergo lower limb angioplasty using SELUTION DCB, which is coated with sirolimus.
11100759|NCT04071769|Experimental|Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
11100760|NCT04071756|Experimental|Topical Tazarotene 0.1% Gel Plus BPS|"Pharmacy teaching call
~DFCI approved teaching sheets will be provided
~20% urea applied to the palms and soles in the morning + tazarotene 0.1% gel, applied to the palms and soles nightly"
11100761|NCT04071756|Placebo Comparator|Placebo Gel Plus BPS|"A substance that has no therapeutic effect, used as a control in testing new drugs
~Pharmacy teaching call
~DFCI approved teaching sheets will be provided
~20% urea applied to the palms and soles in the morning with placebo gel applied in the evening."
11100762|NCT04071743|Active Comparator|Treatment|Treatment and Prevention with active gammacore device(vagus nerve stimulator)
11100763|NCT04071743|Sham Comparator|Sham|Treatment and Prevention with sham gammacore device(vagus nerve stimulator)
11100764|NCT04071730|Experimental|Immulina Dietary Supplementation|Immulina Dietary Supplementation - 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration
11100765|NCT04071730|Placebo Comparator|Placebo|Placebo - inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration
11100766|NCT04071717|Experimental|NIRS group|Participants with obesity, 12 sessions of NIRS feedback
11100767|NCT04071717|Sham Comparator|Sham NIRS group|Participants with obesity, 12 sessions of sham NIRS feedback
11100768|NCT04071717|Other|Healthy control group|Healthy participants, 12 sessions of NIRS feedback
11100769|NCT04071704||Patients|Patients who have been or are being treated for sarcoma.
11100770|NCT04071704||Health care professionals|Health care professionals with extensive experience in sarcoma care (medical oncologists, radiation oncologists, surgical oncologists, orthopaedic surgeons, nurse specialists, psychologists, physiotherapists)
11100771|NCT04071691||Active LVV|Patients with active LVV
11100772|NCT04071691||Stable LVV|Patients with inactive LVV
11100819|NCT04071379|Active Comparator|Hep B + Pentabio (registered)|Recombinant Hepatitis B + Pentabio (registered)
11100820|NCT04071366|Experimental|Itacitinib|
11100773|NCT04071678||A: Model A|Mode A was silent mode, back-to-back with endoscopic physicians to simultaneously display endoscopic images and record video, but did not interfere with the operation of endoscopic physicians.After the operation, the AI model automatically generates an endoscopy report, which is compared with the official report given by the endoscopy doctor in the endoscopy system. If the difference is large, video verification shall be played back immediately or endoscopic examination shall be performed again before the patient wakes up
11100774|NCT04071678||B: Model B|Mode B is a delayed reminder mode. If the lesion is found during the operation, it is required to be moved to the middle of the visual field within 5 seconds. If the lesion has been detected by the AI model (the lesion has been circled in the picture), but the doctor does not move the lesion to the middle of the visual field within 5 seconds, the AI system will give an alarm prompt
11100775|NCT04071678||C: Model C|Mode C is a real-time reminder mode, which is an alarm prompt when the focus is captured in the visual field.
11100776|NCT04071665|Experimental|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion for treatment of scoliosis
11100777|NCT04071665|Active Comparator|transforaminal lumbar interbody fusion|transforaminal lumbar interbody fusion
11100778|NCT04071652|Experimental|Mistral|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).
~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
11100779|NCT04071639|Experimental|Group 1|Mild to moderate HD patients receive medicine treatment with different doses of Haloperidol, Risperidone, Zoloft+Coenzyme Q10, according to their symptoms. The mode of administration is oral. Capsules will be swallowed whole with water. Zoloft should be taken 50mg once in the morning and Risperidone 1mg once at night. Haloperidol should be taken 0.5mg~1mg three times a day. Coenzyme Q10 should be taken 10mg three times a day. Study drug can be taken irrespective of meals. Duration:5 years.
11100780|NCT04071639|Experimental|Group 2|Mild to moderate HD patients receive only Coenzyme Q10 10mg three times a day. Duration:5 years.
11100781|NCT04071626|Experimental|Ertugliflozin Treatment Arm|Ertugliflozin 5 mg tablet once a day for 12 weeks
11100782|NCT04071626|Placebo Comparator|Placebo|Placebo tablet once a day for 12 weeks
11100783|NCT04071613|Active Comparator|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
11100784|NCT04071613|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
11100785|NCT04071600|Placebo Comparator|Placebo|Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
11100786|NCT04071600|Active Comparator|Neuropeptide Y|The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.
11100787|NCT04071600|No Intervention|Control|The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.
11100788|NCT04071587|Experimental|BCI training|Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
11100789|NCT04071587|Active Comparator|Control|Patients randomized to this control group will receive standard physiotherapy and occupational therapy for their impaired upper limb.
11100790|NCT04071574|Active Comparator|"Protocol A"|"Protocol with gonadotropins alone without agonist or antagonist:
~Gonadotropin treatment begins after spontaneous menses. The gonadotropins (e.g. Menopur, 150-225IU) are injected daily from D2/3 of the cycle (Gonadotropin dose varies based on the follicular response). The moment to trigger ovulation by administration of HCG (e.g. Ovitrelle or Pregnyl, 10.000IU) is determined by monitoring ovulation (folliculogenesis) approximately 14 days after gonadotropins regimen and the presence of at least 3 follicles with 18 mm sizes and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
11100791|NCT04071574|Active Comparator|"Protocol B"|"Short GnRH agonist protocol:
~For the short GnRH agonist protocol, the administration of gonadotropins begins at the same time as that of the agonist, which makes it possible to take advantage of the action of endogenous gonadotropins released by the flare-up effect of the agonist. A low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg/day)) is administered in parallel to gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved."
11100792|NCT04071574|Active Comparator|"Protocol C"|"Multiple-dose antagonist protocol:
~For the GnRH antagonist protocol, a low dose of GnRH antagonist (0.25 mg/day) is administered. The protocol starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU). 36 h after HCG triggering, the mature oocytes are retrieved."
11100793|NCT04071574|Active Comparator|"Protocol D"|"Long GnRH agonist protocol:
~For the long GnRH agonist protocol, a low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg)) is administered on cycle-day 21 followed by gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 after menses (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm. 36 h after HCG triggering, the mature oocytes are retrieved."
11100855|NCT04071132||Participants diagnosed with PTSD|
11100856|NCT04071132||Non-PTSD participants|
11100794|NCT04071574|Active Comparator|"Protocol E"|"Combined GnRH antagonist and agonist protocol:
~For the combined protocol, it starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till GnRH agonist injection (e.g., triptorelin (Decapeptyl 0.1mg/day)). 36 h after agonist injection, the mature oocytes are retrieved."
11100795|NCT04071561||Non-conversion|In 13 patients, 14 posterior retroperitoneal adrenalectomy procedures were successfully completed and form the non-conversion group
11100796|NCT04071561||Conversion|Conversion to lateral transperitoneal adrenalectomy was necessary in 1 patient after starting posterior retroperitoneal adrenalectomy.
11100797|NCT04071548|Experimental|HIIT Exercise|All individuals recruited in exercise portion will be on an active exercise intervention
11100798|NCT04071522||LBP|110 literate Turkish speaking patients suffering from low back pain (LBP) for over 3 months, within the age range 18-65 were included in the study.
11100799|NCT04071509|Experimental|Percutaneous Lung Biopsy|
11100800|NCT04071483|Experimental|Moderate stenosis|Moderate cervical neural foraminal stenosis is narrowest width of the neural foramen was >50% of the width of the width of the extraforaminal nerve root at the level of the anterior margin of the superior articular process.
11100801|NCT04071483|Active Comparator|Severe stenosis|Severe cervical neural foraminal stenosis is narrowest width of the neural foramen was ≤50% of the extraforaminal nerve root width
11100802|NCT04071470|Active Comparator|Standard of Care|Standard of care for pregnant women at risk of HIV seroconversion includes couples counseling and access to PrEP (women) and ART (men)
11100803|NCT04071470|Experimental|Storytelling Intervention|Participants in this group will receive the same services as those in the SOC but will also be provided three storytelling sessions for themselves and their families as a way to educate and de-stigmatize PrEP services.
11100804|NCT04071457|No Intervention|Study Entry / Screening|Study entry/screening to follow patient until Maintenance.
11100805|NCT04071457|Active Comparator|Arm 1: Lenalidomide|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment.
11100806|NCT04071457|Experimental|Arm 2: Lenalidomide + Daratumumab/rHuPH20|Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 2 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 2 years from starting treatment.
11100807|NCT04071457|Active Comparator|Arm 1a: Continue Lenalidomide|MRD+ or MRD- and randomized to Arm 1a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment.
11100808|NCT04071457|No Intervention|Arm 1b: Stop Lenalidomide|MRD- and randomized to Arm 1b: Discontinue protocol therapy.
11100809|NCT04071457|Active Comparator|Arm 2a: Continue Lenalidomide + Daratumumab/rHuPH20|MRD+ or MRD- and randomized to Arm 2a: Lenalidomide 10 mg/day, D1-28, q28 days for 3 cycles, then 15 mg/day, D1-28 for up to 7 years from starting treatment. Plus Daratumumab/rHuPH20 1800 mg/30,000 units D1, 8, 15, 22 q 28 days for 2 cycles, then D 1 and 15 q 28 days for cycles 3-6 then D1 q 28 days for subsequent cycles for up to 7 years from starting treatment.
11100810|NCT04071457|No Intervention|Arm 2b: Stop Lenalidomide + Daratumumab/rHuPH20|MRD- and randomized to Arm 2b: Discontinue protocol therapy.
11100811|NCT04071444|Experimental|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
11100812|NCT04071444|No Intervention|Control group|The control group (CG) received routine care.
11100813|NCT04071431|No Intervention|Control|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.
~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.
~The RFQ results of this group are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
11100814|NCT04071431|Experimental|Risk shown|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.
~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.
~The RFQ results of this group are known by the endoscopists before and during the endoscopy."
11100815|NCT04071418||I-125 Seeds Implantation|All the enrolled patients were treated with CT-guided radioactive I-125 seeds implantation assisted by 3D printing template. Prescription dose 140-160gy.
11100816|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.
~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
11100817|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.
~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
11100818|NCT04071379|Experimental|HepB + Penta batch 1|Recombinant Hepatitis B + DTP-HB-Hib batch 1
11100821|NCT04071353||Interferon combined with ribavirin group|Interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) in patients with chronic hepatitis C, collect basic data before antiviral therapy, and during the PR antiretroviral treatment period, Follow-up was performed every 3-6 months in March, June, September, December, DAAs antiviral treatment during January, March, and withdrawal follow-up, and clinical biochemistry, HCV RNA, and serological markers were used during follow-up ( anti-HCV), AFP and liver imaging (liver ultrasound) examination.
11100822|NCT04071353||DAAs treatment group|Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
11100823|NCT04071327||Pulmonary arterial hypertension (PAH)|Patients with newly diagnosed or established PAH, within 6 months of first outpatient visit to a PH Care Center
11100824|NCT04071327||Chronic thromboembolic pulmonary hypertension (CTEPH)|Patients with newly diagnosed or established CTEPH, within 6 months of first outpatient visit to a PH Care Center
11100825|NCT04071327||Group 3 PH due to Developmental Lung Disease|Pediatric patients with newly diagnosed or established Group 3 PH due to developmental lung disease, within 6 months of first outpatient visit to a PH Care Center.
11100826|NCT04071314||Cystic fibrosis|Children diagnosed with cystic fibrosis. Children aged between 0 and 18 years.
11100827|NCT04071314||Hirschsprung's disease|Children diagnosed with Hirschsprung's disease. Children aged between 0 and 18 years.
11100828|NCT04071314||Obstructive sleep apnoea|Children diagnosed with obstructive sleep apnoea. Children aged between 0 and 18 years.
11100829|NCT04071314||Healthy controls|Children free of any chronic health condition. Children aged between 0 and 18 years.
11100830|NCT04071301|Experimental|Investigational Device|TENA SmartCare Urine Sensor and Gateway
11100831|NCT04071288||laparoscopic burch colposuspension|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing laparoscopic burch colposuspension
11100832|NCT04071288||mid urethral sling operations|who underwent total laparoscopic hysterectomy for benign causes and had simultaneous incontinence; patients undergoing mid-urethral sling operations
11100833|NCT04071275|Active Comparator|Mirror therapy|Subjects will be asked to perform specific movements (using the unaffected limb while watching its mirrored reflection for 20 minutes per day, for 10 treatment days, completed during two weeks (every weekday, excluding weekends)
11100834|NCT04071275|Sham Comparator|Mirror therapy + sham tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, a sham tDCS treatment will be applied.
11100835|NCT04071275|Experimental|Mirror therapy + active tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, an active tDCS treatment will be applied.
11100836|NCT04071262|Experimental|Abemaciclib + Abiraterone Acetate + Prednisolone|Abemaciclib, abiraterone acetate and prednisolone given orally.
11100837|NCT04071249||Control|Patients who use symptomatic medication as therapy for their allergic rhinoconjuntivitis as recommended by their physician
11100838|NCT04071236|Active Comparator|Arm A (radium-223 dichloride)|Patients receive radium-223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11100839|NCT04071236|Active Comparator|Arm B (radium-223 dichloride, nedisertib)|Patients receive radium-223 dichloride as in Arm A and peposertib PO or BID on days 3-26. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11100840|NCT04071236|Experimental|Arm C (radium-223 dichloride, nedisertib, avelumab)|Patients receive radium-223 dichloride IV as in Arm A and peposertib PO QD or BID as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 15 of cycles 2-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11100841|NCT04071223|Experimental|Arm A (radium Ra 223 dichloride, cabozantinib s-malate)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1 of cycles 1-6 and cabozantinib S-malate PO QD on days 1-28 of every cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11100842|NCT04071223|Active Comparator|Arm B (cabozantinib s-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11100843|NCT04071210|Experimental|Experimental|Probiotic tablets (containing a mix of Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307, 1*10(9) CFU) 2 times/day for 12 weeks
11100844|NCT04071210|Placebo Comparator|Placebo Comparator|Placebo tablets 2 times/day for 12 weeks
11100845|NCT04071197|Experimental|Gastrostomy-biliary tube|The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
11100846|NCT04071197|Experimental|Other biliary diversion modalities|The control group will include those cases with other modalities of therapy as external biliary diversion, internal biliary diversion, and nasobiliary tube
11100847|NCT04071184|Experimental|Dose cohorts|"Part 1 (dose escalation): 3+3 design will be used. Alofanib (dose levels of 50, 100, 165, 250, 350 mg/m2) will be given i.v. daily (1-5 days on, 6-7 days off, every week) till progression or unacceptable toxicity.
~Part 2 (dose expansion): Afterwards the dosing regimen identified in Part 1 will be evaluated in a single-arm study focused on clinical efficacy."
11100848|NCT04071171|Active Comparator|Phoxilium®|
11100849|NCT04071171|Experimental|Biphozyl®|
11100850|NCT04071158|Experimental|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
11100851|NCT04071158|Experimental|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
11100852|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
11100853|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
11100854|NCT04071158|Placebo Comparator|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
11100859|NCT04071106|Active Comparator|Turmeric Extract group|10 psoriasis patients receiving turmeric based ointment levigated in glycerin twice daily and assessed for response and side effects weekly for 12 weeks
11100860|NCT04071106|Active Comparator|Turmeric extract + olive oil group|10 psoriasis patients receiving turmeric extract levigated in olive oil instead of glycerin. The ointment will be applied twice daily for 12 weeks & will be assessed weekly
11100861|NCT04071106|Placebo Comparator|Petrolatum group|10 Psoriasis patients will receive the base of the therapeutic ointment which is the petrolatum. Patients will apply it twice daily and will be assessed weekly clinically and dermoscopically for 12 weeks
11100862|NCT04071106|Active Comparator|NBUVB group|10 Psoriasis patients will receive two sessions of NBUVB weekly for 12 weeks and will be assessed weekly clinically and with dermoscope.
11100863|NCT04071106|Active Comparator|Established ttt group|10 Psoriasis patients will receive topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks and will be assessed on weekly basis clinically and by dermoscope
11100864|NCT04071093|Other|Telemonitoring|
11100865|NCT04071093|No Intervention|Usual Care|
11100866|NCT04071080|Experimental|100mg Fluorescein disodium|100mg Fluorescein disodium will be mixed with 500mL of Gatorade and taken orally by the participant
11100867|NCT04071080|Placebo Comparator|Placebo|500mL of Gatorade taken orally by the participant
11100868|NCT04071067||Emergency Clinical County Hospital Group|
11100869|NCT04071067||Municipal Clinical Hospital Group|
11100870|NCT04071054||Hemodialysis patients|
11100871|NCT04071041|Experimental|Standard care plus albumin|"Patients will receive human albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
~Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team."
11100872|NCT04071041|No Intervention|Standard care alone|Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team.
11100873|NCT04071028|Active Comparator|Footbath group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes,"
11100874|NCT04071028|No Intervention|Control group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
11100875|NCT04071002|Active Comparator|surgical group|distal radius fractures that treated volar plate
11100876|NCT04071002|Active Comparator|conservative group|distal radius fractures that treated plaster of paris
11100877|NCT04070989|Experimental|Posterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the posterior approach
11100878|NCT04070989|Experimental|Lateral Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the lateral approach
11100879|NCT04070989|Experimental|Anterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the anterior approach
11100880|NCT04070976|Active Comparator|Standard treatment|Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.
11100881|NCT04070976|Experimental|Experimental treatment|Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.
11100882|NCT04070963||Cohort|We propose a prospective, observational single-centre pilot study in the PAC (SGH), on participants aged 21 years and above. A HbA1c test will be added to their routine preoperative blood tests. The incidence of newly-diagnosed DM/pre-diabetes (HbA1c ≥6.1%) and poorly controlled DM (HbA1c ≥ 8%), demographic details and presence of significant comorbidities will be analysed.
11100883|NCT04070950||Single group|Interview of patients with cancer of the cervix or uterine body, or ovary between the time of diagnosis and 3 months after the end of their last cancer treatment (not the object of the study).
11100884|NCT04070937||study group|all patients at least 18 years of age who present bilateral vestibulopathy on vestibular investigations according to the Barany criteria
11100885|NCT04070937||control group|DFNA9 patients carrying the p.P51S mutation in COCH gene presenting bilateral vestibulopathy according to the Barany criteria
11100886|NCT04070924|Active Comparator|Conventional post-operative bulky soft tissue dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal
~Postoperative: Non-opioid medications only; Conventional post-operative bulky soft tissue dressing (Xeroform, 4x4s, Webril, Ace Wrap; Worn until first postoperative visit)"
11100887|NCT04070924|Experimental|Bandaid post-operative dressing|"Intraoperative: MAC-Local Anesthesia; Local anesthetic mixture will be distributed in both the subcutaneous tissue and within the carpal canal
~Postoperative: Non-opioid medications only; Bandaid over incision (Patient given an edema glove to wear starting post-operative day 1; Dressing change be changed post-operative day 2 and as needed after that)"
11100888|NCT04070911|Experimental|patients in the water group|water group: Patients in the water group were performed oral water after their accession to PACU.
11100889|NCT04070911|Experimental|patients in the ice group|ice group, Patients in the ice group were performed oral ice popsicle after their accession to PACU.
11100890|NCT04070911|No Intervention|no intervention group|control group, the control group patients have performed rutin treatment and care without any other intervention
11100891|NCT04070898|No Intervention|control group|Bladder catheter removal 24 hours after surgery
11100892|NCT04070898|Experimental|experimental group|Removal of the bladder catheter after the surgical intervention
11100893|NCT04070872|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
11100894|NCT04070872|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
11100895|NCT04070846|Experimental|[14C] LC350189|Single oral dose
11100896|NCT04070833|Active Comparator|Vitamin D + fish oil|
11100897|NCT04070833|Active Comparator|Vitamin D + fish oil placebo|
11100898|NCT04070833|Active Comparator|Vitamin D placebo + fish oil|
11100899|NCT04070833|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11100900|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fasting)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fasting condition
11100901|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fed)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fed condition
11100902|NCT04070781|Experimental|Itacitinib + Tocilizumab|"A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose:
~Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level
~Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level
~Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles."
11100903|NCT04070781|Experimental|Dose Expansion|Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.
11100904|NCT04070768|Experimental|Gemtuzumab Ozogamicin(GO) + Venetoclax|Gemtuzumab Ozogamicin(GO) + Venetoclax
11100905|NCT04070755|Experimental|FMX-101|
11100906|NCT04070742|Experimental|FMX-101|
11100907|NCT04070729|Placebo Comparator|Negative control|Placebo gel
11100908|NCT04070729|Experimental|Test group 1|Hyaluronic acid gel
11100909|NCT04070729|Experimental|Test group 2|injectable prf
11100910|NCT04070716|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
11100911|NCT04070716|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
11100912|NCT04070703|Experimental|Cognitively enhanced Tai Ji Quan|Participants in this arm will exercise a series of Tai Ji Quan-based movements with configurations that are specifically designed for older adults to improve cognitive function, dual-task ability, strength/balance, and mobility.
11100913|NCT04070703|Active Comparator|Standard Tai Ji Quan|Serving as an active comparison arm, participants in this intervention will exercise a series of Tai Ji Quan-based movements that are specifically designed for older adults to improve strength/balance, cognitive function, and mobility.
11100914|NCT04070703|Sham Comparator|Stretching|Serving as a control arm, participants in this intervention will engage in a series of light exercise activities consisting of breathing, stretching, and body relaxation.
11100915|NCT04070690|Other|Intervention-Control group|"In this group, the participants will receive intervention for 2 months first, followed by a wash-out period of 1 month and control for 2 months.
~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements.
~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients)."
11100916|NCT04070690|Other|Control-Intervention group|"In this group, the participants will receive control for 2 months first, followed by a wash-out period of 1 month and intervention for 2 months.
~In the control period, the investigators will provide the participants with dialysate HCO3 concentration of 38-40 mEq/L (as we usually provide to patients).
~In the intervention period, the investigators will provide the participants with lower dialysate HCO3 concentrations. (dialysate HCO3 to 28 mmol/L for half of the HD session and 30 to the second half of their HD session.) Besides, the investigators will give the participants with pre-HD HCO3<22 mEq/L oral Na-bicarbonate 650 mg 1#-2# three times a day as supplements."
11100917|NCT04070677|Experimental|Ziverel arm|Patients included will receive treatment with ZIVEREL®, initially 10 mL every 8 hours, 30 minutes after meals, to avoid physical entrainment by food, during a minimum of 8 weeks, recruited during a period of 12 months. The treatment will be indicated when the patient develops a radiation-induced esophagitis of degree ≥ 2.
11100918|NCT04070664||Central vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
11100919|NCT04070664||Peripheral vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
11100920|NCT04070625||Communication book group|Speech therapy with communication book
11100921|NCT04070625||Control group|Simple speech therapy
11100922|NCT04070612||children with autoimmune haemolytic anemia|A blood sample of 2 times 2 to 5 ml additional maximum
11100923|NCT04070612||Children with Evans syndrome|A blood sample of 2 times 2 to 5 ml additional maximum
11100924|NCT04070612||Children with Immune thrombocytopenic purpura|A blood sample of 2 times 2 to 5 ml additional maximum
11100925|NCT04070599|Experimental|Single arm|Study of lymphocyte subpopulations, cytokine assays, identification of autoantibodies, study of CD40 platelet ligand, thrombopoietin assay
11100926|NCT04070586||4DCBCT images|4DCBCT images are acquired and assessed offline.
11100927|NCT04070573|Active Comparator|81mg ASA|Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
11100928|NCT04070573|Active Comparator|162mg ASA|Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.
11100929|NCT04070560|Active Comparator|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table Other Name: Immediate clamping
11100930|NCT04070560|Active Comparator|Intact cord (≥ 180 seconds) resuscitation|"If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
~Other Names:
~Late cord clamping Deferred cord clamping Optimal cord clamping"
11100931|NCT04070547|Experimental|Early tVNS|First 2 weeks this group will receive transcutaneous vagal nerve stimulation 4 hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28) without any intervention. Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
11100932|NCT04070547|Experimental|Early Sham|First 2 weeks this group will receive sham stimulation 4hours a day (day 1 to day 14). Then participants will be followed for another 2 weeks (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (pre-intervention), on day 14 (post-intervention) and on day 28 (follow-up).
11100933|NCT04070547|Experimental|Late tVNS|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
11100934|NCT04070547|Experimental|Late Sham|First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive sham stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
11100935|NCT04070534|Other|PALS intervention|This arm will influence the development of a patient-directed education module using the Patient Activated Learning System (PALS)
11100936|NCT04070521|Experimental|Observational EEG Monitoring|
11100937|NCT04070495|Experimental|Clarithromycin|
11100938|NCT04070495|Experimental|Rifampicin|
11100939|NCT04070482||HIV-exposed uninfected infants|These are children to women who are living with HIV but who are not infected with the virus (HIV PCR results at 6 weeks is negative)
11100940|NCT04070482||HIV-unexposed uninfected infants|These are children born to women who are not infected with HIV
11100941|NCT04070469|Experimental|Patient reveiving amoxycillin|all patient included in this study
11100942|NCT04070456|Experimental|Intervention sites-Tablet-based SDH tool|All clinicians and primary care teams at a practice that are randomized to the intervention will receive the tablet-based SDH tool.
11100943|NCT04070456|No Intervention|Control sites|Care as usual, no tablet-based SDH tool.
11100944|NCT04070443|Experimental|Induction phase with Ponatinib followed by Imatinib|"Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda & Incyte Biosciences.
~Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)"
11100945|NCT04070430|Active Comparator|2 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
11100946|NCT04070430|Active Comparator|4 weeks of partial weight bearing on crutches|post-operative patient reported outcome (PRO) scores will be collected 6 weeks, 6 months, 12 months, and 24 months post-operatively
11100947|NCT04070417|Experimental|Treatment Group|Lifestyle Medicine Group
11100948|NCT04070417|No Intervention|CAU Group|Care-As-Usual Group
11100949|NCT04070391|Experimental|vitamin B6|One pill (100 mg) ingested daily for 4 weeks.
11100950|NCT04070391|Placebo Comparator|control|One vinegar pill ingested daily for 4 weeks
11100951|NCT04070378|Experimental|Open-label Treatment|This is an open-label pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease. During the treatment phase, eligible subjects will receive daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion over 3-5 minutes (15 mL) once weekly for 8 weeks followed by daratumumab SC 1800 mg every 2 weeks for 16 weeks.
11100952|NCT04070365||FLEX Vessel Prep followed by angioplasty|
11100953|NCT04070352||clostridium difficile infection (CDI)|This is a pilot project. Data from electronic medical records will be collected on all patients diagnosed with clostridium difficile infection and who are receiving fidaxomicin as part of their treatment. A total of 50 patients will be enrolled
11100954|NCT04070326|Experimental|Lanadelumab|Participants aged 2 years to < 6 years will receive lanadelumab at a dose of 150 milligrams (mg) for every 4 weeks (q4wks) with a total of 14 doses over 52-week treatment period and participants aged 6 years to <12 years will receive lanadelumab at a dose of 150 mg for every 2 weeks (q2wks) with a total of 27 doses over 52-week treatment period.
11100955|NCT04070313|Experimental|S-1|single-arm
11100956|NCT04070300|Experimental|Interval training group|Aerobic interval training during 12 weeks 3 times a week.
11100957|NCT04070300|No Intervention|Control group|No lifestyle recommendations. Usual daily life.
11100958|NCT04070287|Active Comparator|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
11100959|NCT04070287|Active Comparator|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
11100960|NCT04070287|Active Comparator|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
11100961|NCT04070287|Active Comparator|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
11100962|NCT04070287|Active Comparator|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
11100963|NCT04070274|Experimental|New surgery platform for calcaneal surgery|"The lateral position surgical platform for calcaneus surgery is designed with a bottom board, mats in front and at back of calf and thigh, and two sizes of cover plates, using tunnel principle according to physiological curve of lower limbs."
11100964|NCT04070274|Experimental|Traditional lateral platform|"The traditional lateral position makes the surgery platform bread-shaped arch surface by using medical mats and putting lower limbs superimpose on each other"
11100965|NCT04070261||User|
11100966|NCT04070248||Group 1|50 HIV-seropositive with spirometry confirmed COPD
11100967|NCT04070248||Group 2|50 HIV-seropositive without COPD
11100968|NCT04070248||Group 3|50 HIV-seronegative with spirometry confirmed COPD
11100969|NCT04070248||Group 4|50 HIV-seronegative without COPD
11100970|NCT04070235|Experimental|SH229/DCV 400mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks
11100971|NCT04070235|Experimental|SH229/DCV 600mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40).
11100972|NCT04070235|Experimental|SH229/DCV 800mg/60mg|HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40).
11100973|NCT04070235|Experimental|SH229/DCV|HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily
11100974|NCT04070222||Natural labour group|
11100975|NCT04070222||Cesarean scar group|
11100976|NCT04070222||Cesarean with diverticulum (PCSD) group|
11100977|NCT04070209|Experimental|Darolutamide (BAY1841788)+ SBRT|"CRPC subjects will receive LHRH agonist in combination with the new generation of hormonal therapy Darolutamide (300mg).
~Subjects who progress on LHRH + Darolutamide and develop oligometastases will receive SBRT"
11100978|NCT04070196|Other|Leucocyte testing|The PD effluent will be sent to the laboratory for leucocyte testing for patients presented with suspected PD peritonitis.
11100979|NCT04070183|Other|Attention Control (Home Safety Evaluation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family member (if they've designated one), in which he or she will provide suggestions on how to improve the safety of the patient's home.
11100980|NCT04070183|Experimental|Intervention (POST Facilitation)|A nurse will complete a home visit with the patient and their surrogate decision maker or other family (if they've designated one), in which he or she will provide education about the POST form. The POST facilitators will be nurses trained using the Respecting Choices Advanced Steps model.
11100981|NCT04070170|Experimental|Low-level laser therapy and no orthodontic force|No orthodontic force. Laser is applied on the first day and the premolars is extracted after 24 hours
11100982|NCT04070170|Experimental|Low-level laser therapy and application of orthodontic force|Orthodontic force and Laser is applied on the first day and the premolars is extracted after 24 hours
11100983|NCT04070170|Active Comparator|Orthodontic force only|Orthodontic force is applied and the premolars is extracted after 24 hours, with no laser therapy
11100984|NCT04070170|Experimental|Low-level laser therapy and orthodontic force|Orthodontic force and Laser is applied and the orthodontic tooth movement is evaluated
11100985|NCT04070170|Active Comparator|Orthodontic force with no laser therapy|Orthodontic force is applied and the orthodontic tooth movement is evaluated, with no laser therapy
11100986|NCT04070157|Experimental|Lofexidine|
11100987|NCT04070157|Placebo Comparator|Placebo|
11100988|NCT04070144|Experimental|IQ-Tip|At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
11100989|NCT04070131|No Intervention|Control Group|Regular follow ups.
11100990|NCT04070131|Experimental|Intervention Group|One weekly session (1 hour) of Horse-Assisted Rehabilitation, 24 weeks.
11100991|NCT04070118||patients with previous cesarean section|presenting to the emergency department with pain, previous cesarean section; Patients measured niche thickness before operation
11100992|NCT04070105|Active Comparator|Conventional Prosthetic Foot|In this condition, participants will walk with their standard prosthetic foot
11100993|NCT04070105|Experimental|CAESER Prosthetic Foot|In this condition, participants will walk with a new prosthesis with enhanced energy storage and return and increased range of motion. They will only wear this device in the lab for an approximately 4 hour period of time
11100994|NCT04070092||TBI group|"A cohort of patients admitted to UZ Leuven from 2019 to 2023 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.
~Inclusion criteria will be: ≥ 65 years old, admitted to UZ Leuven between 2019 and 2023 due to TBI, all injury severities (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.
~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven before 2019, diagnose of neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
11100995|NCT04070092||Control group|"A cohort of healthy volunteers with similar demographic characteristics will be recruited as a control group.
~Inclusion criteria will be: ≥ 65 years old and having signed the informed consent to participate in the study.
~Exclusion criteria will be: < 65 years old, diagnose of neurodegenerative diseases, cognitive and motor disturbances caused by any pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
11100996|NCT04070079|Other|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Dosed orally, once daily with or without food.
11100997|NCT04070066|Experimental|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
11100998|NCT04070066|Active Comparator|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
11100999|NCT04070053|Experimental|TheraPPP Pathway|"We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation.
~All mechanically ventilated patients will enter the pathway during the one month implementation and one year post-implementation periods.
~To assess Pathway feasibility we will collect patient data for approximately two years and one month: one year immediately prior to implementation, one month during, and one year following implementation.
~To assess acceptability of the pathway we will conduct a survey to clinicians who used the Pathway."
11101000|NCT04070040|Experimental|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
11101001|NCT04070027|Active Comparator|Total Hip Arthroplasty|A standard fast-track multimodal surgical program comprising patient information, optimised pain management, and early mobilisation. Total hip arthroplasty (THA) will be performed by experienced orthopaedic surgeons in accordance with the standard posterior surgical approach. Patients will receive standard postoperative rehabilitation consisting of either a standard leaflet with a hospital-specific home-based exercise program aimed at increasing hip muscle strength and range of motion or, if considered necessary, a referral to supervised hip-specific exercise therapy delivered at private physiotherapist clinics or municipal rehabilitation. Furthermore, postsurgical procedures will follow hospital-specific procedures ranging from no postsurgical control to postsurgical assessment of the hip and rehabilitation at the physiotherapy department (after six-weeks).
11101002|NCT04070027|Active Comparator|Progressive Resistance Training|"A 12-week supervised explosive-type progressive resistance training (PRT) program with two training sessions a week. All training sessions will be conducted in municipal rehabilitation centres with one-to-one supervision and ≥48 hours of rest in between sessions. The standardised PRT program will consist of warm-up on a stationary bicycle (10 min) followed by four lower extremity exercises (50 min). Exercises will be performed unilaterally with as full range of motion as possible in sets of three separated by 60 sec of rest in the following order: leg press, hip extension, hip flexion, and hip abduction. Patients will be instructed to complete the concentric phase of each repetition as fast as possible, maintain full extension for 1 sec, and perform the eccentric phase in 2-3 sec. Hip-related pain up to 5 rated on a Numerical Rating Scale (0-10) is considered acceptable during exercises. After the 12-weeks, patients will be offered three-months of optional unsupervised PRT."
11101003|NCT04070001|Active Comparator|Ibuprofen group|Ibuprofen group received 1-dose 400-mg Ibuprofen 1 hour before elastomeric separator placement
11101004|NCT04070001|Active Comparator|Laser group|Laser groups received a single irradiation of low-level laser immediately after elastomeric separator placement.
11101005|NCT04070001|Placebo Comparator|Control group|Control group received placebo lactose tablets 1 hour before elastomeric separator placement.
11101006|NCT04069988|No Intervention|Control group|The control group (CG) received routine care and was required to physical activity for thirty minutes
11101007|NCT04069988|Experimental|Baduanjin program|The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks ; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
11101008|NCT04069975||No sedation|The group of patients who did endoscopies without sedation.
11101009|NCT04069975||Sedation|The group of patients who did endoscopies with sedation.
11101010|NCT04069962|No Intervention|Control group|Patients in the control group will receive CGA coordinated by the oncology team as standard of care, including geriatric recommendations for interventions communicated to the treating physician (eg. referral to the social worker, psychologist, dietician).
11101011|NCT04069962|Experimental|Intervention group|Patients in the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching.
11101012|NCT04069949|Experimental|sorafenib plus toripalimab|"Stage I：Subjects (n=3) in cohort A received oral sorafenib (400 mg qd), in combination with intravenous toripalimab (240 mg d1, q3w). Subjects (n=3) in cohort B received oral sorafenib (400 mg bid) and the administration of toripalimab is consistent with cohort A. If dose-limiting toxicity (DLT) does not occur within 42 days of the first administration, the dose is escalated.
~Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39."
11101013|NCT04069936|Experimental|MILs™ - NSCLC plus nivolumab|Locally advanced and unresectable and metastatic NSCLC subjects previously treated with anti-programmed cell death-1 (PD-1) will be treated with MILs™ - NSCLC plus nivolumab.
11101014|NCT04069923|Experimental|Treatment (OsteoCrete)|Participants receive OsteoCrete intraoperatively to fill voids that occur in bones during surgery or to augment screw fixation.
11101015|NCT04069910|Experimental|Arm A (SRS/SRT, surgery)|Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.
11101016|NCT04069910|Active Comparator|Arm B (surgery, SRS/SRT)|Within 2-5 weeks after standard of care surgery, patients undergo 1, 5, or 10 fraction of SRS/SRT.
11101017|NCT04069897|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
11101018|NCT04069897|Placebo Comparator|Controls|Placebo injections
11101019|NCT04069884|Active Comparator|Arm I (Clinical high-risk, RecurIndex low-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
11101020|NCT04069884|Experimental|Arm II (Clinical high-risk, RecurIndex low-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
11101116|NCT04069156|Placebo Comparator|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
11101021|NCT04069884|Active Comparator|Arm III (Clinical low-risk, RecurIndex high-risk)|No Regional nodal irradiation (RNI) , whole breast irradiation (WBI) for breast-conserving patients and No Chest wall irradiation (CWI) for total mastectomy patients.
11101022|NCT04069884|Experimental|Arm IV (Clinical low-risk, RecurIndex high-risk)|Regional nodal irradiation (RNI) was given along with whole breast irradiation (WBI) or Chest wall irradiation (CWI) for breast-conserving patients and total mastectomy patients, respectively.
11101023|NCT04069871|Active Comparator|TENS|
11101024|NCT04069871|Sham Comparator|Control|
11101025|NCT04069858|Experimental|Baracle|Chronic hepatitis B patients who swiched to Baracle® 1 mg from Baraclude® 1 mg treatment as mono- or combination therapy after the development of antiviral resistance to nucleos(t)ide analogues
11101026|NCT04069845||liposomal doxorubicin treatment|
11101027|NCT04069832|Other|Intervention|SINGLE-SESSION CONSULTATION
11101028|NCT04069819|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
11101029|NCT04069819|Experimental|Cilostazol group|Escitalopram 20 mg tablet once daily for 12 week plus Cilostazol 50mg tablet twice daily for 12 weeks
11101030|NCT04069806|Experimental|Preoperative oral carbohydrate load|6 hours for solid food and 2 hours for liquids + oral carbohydrate preparation 2 hours prior to surgery.
11101031|NCT04069806|No Intervention|Standard preoperative fasting|6 hours for solid food and 2 hours for liquids.
11101032|NCT04069793|Active Comparator|Home Trial Condition A|Subject will use a pattern recognition controlled prosthesis that includes a powered wrist rotation, passive wrist flexion/extension, and a single DOF powered hand.
11101033|NCT04069793|Experimental|Home Trial Condition B|Subject will use at pattern recognition controlled prosthesis that includes a powered wrist rotation, powered flexion/extension and a single DOF powered hand.
11101034|NCT04069780|Active Comparator|Study group I : Intravitreal injection|A single intravitreal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
11101035|NCT04069780|Active Comparator|Study group II: Suprachoroidal injection of full dose|A single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
11101036|NCT04069780|Active Comparator|Study group III : Suprachoroidal injection of half dose|They will receive a single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 2 mg / 0.1 ml.
11101037|NCT04069767|Experimental|ICoreDIST|The intervention starts with an assessment by the physiotherapist to identify the patient's movement problems in order to choose among the 48 exercises in the intervention. Each session lasts for 60 minutes + exercises 5-10 minutes outside of therapy and is performed 5-6 days/per week in the rehabilitation units, and 3 sessions/week + home exercises 30 minutes 3 days per week in home based or outpatient treatment during the 12 weeks period.To allow for individualisation, each exercise contains five levels of difficulty. All exercises demand enhancement of dynamic trunk stability and functional movements.
11101038|NCT04069767|Active Comparator|Standard Care|Consists of standard inpatient rehabilitation, home-based and outpatient-based physiotherapy with the same dose as the intervention group.
11101039|NCT04069754|Experimental|Adapted Passport to Freedom Intervention Arm|The intervention consists of 5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections
11101040|NCT04069741|Other|Usual care, no depression|Participants without symptoms of depression who have the opportunity to use a Decision Aid but otherwise receive Usual care
11101041|NCT04069741|Other|Usual care, depression|Participants with symptoms of depression who are randomized to receive Usual care (in addition to the Decision Aid)
11101042|NCT04069741|Active Comparator|Toolkit, depression|Participants with symptoms of depression who are randomized to receive the Toolkit intervention in addition to Usual care
11101043|NCT04069728|Other|Standard clinic appointment|Patients who undergo a routine clinic outpatient appointment using standard explanation of their fistula with words, diagrams and MRI images, as per Consultant preference
11101044|NCT04069728|Experimental|Clinic appointment with 3D model|Patients who undergo a routine clinic outpatient appointment using a 3D printed model to assist explanation of their fistula
11101045|NCT04069715|Experimental|Farlong NotoGinseng™ (Farlong Ginseng Plus®)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
11101046|NCT04069715|Placebo Comparator|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
11101047|NCT04069702|Experimental|VR Blue|VR Blue is a protocol for patients with advanced stage colorectal cancer who experience persistent pain. Participants will complete a single 30-minute laboratory-based virtual reality underwater/sea environment (VR Blue) session. VR Blue is an immersive computer-generated environment featuring calming scenic graphics and relaxing nature music.
11101048|NCT04069689|Experimental|EPX-100|Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)
11101049|NCT04069689|Placebo Comparator|Placebo|Single and multiple doses of 20, 40, 80mg of placebo
11101050|NCT04069676||Autism Spectrum Condition (ASC)|Adults males and females with a formal autism diagnosis, without intellectual disability
11101051|NCT04069676||Typically developped (TD)|Adults males and females without any neurodevelopemental issue (or health issue which could impaired task performances)
11101052|NCT04069650||None-malnutrition|normal nutritionnal status
11101053|NCT04069650||Malnutrition|"weight loss was superior to 5% in the past month;
~a weight loss was superior to 10% in the past 6 months;
~a BMI was inferior to 18,5 kg/m² (if age inferior to 70 years old) or inferior to 21 kg/m² (if age superior to > 70 years old) - a serum albumin level inferior to 30g/L (if age inferior to 70 years old) or inferior to <35g/L (if age superior to 70 years old)."
11101120|NCT04069143|Experimental|Part 3: 18F-BMS-986327 (Distribution in Partcipants with IPF)|
11101054|NCT04069637||Early onset Scoliosis|Patients with early onset scoliosis treated with growth-sparing instrumentation (TGR, MCGR, and, VEPTR).
11101055|NCT04069637||Control group|Patients with operative fractures.
11101056|NCT04069624|Active Comparator|Services as Usual (SAU)|Substance abuse program (SAP) managed by the Kentucky Department of Corrections, with the option to initiate MOUD prior to jail release.
11101057|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth|Telehealth connection to a community MOUD provider.
11101058|NCT04069624|Experimental|MOUD Pre-Treatment Telehealth and Peer Navigator|Telehealth connection to a community MOUD provider, in addition to a peer navigator
11101059|NCT04069611|Experimental|Test Group|Subjects in the test group will receive scaling and root planing, plus the take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
11101060|NCT04069611|Placebo Comparator|Control Group|Subjects assigned to the placebo group will receive scaling and root planing, and will take lozenges exactly like the test ones but without bacteria.
11101061|NCT04069572|Experimental|Vibrotactile Stimulation|
11101062|NCT04069572|Sham Comparator|Sham Stimulation|
11101063|NCT04069559|Experimental|Intervention Group|Intervention contain education and application about refugees health.
11101064|NCT04069559|No Intervention|Control Group|Students of control group performed routine public health nursing practices.
11101065|NCT04069546|Experimental|AIS-RIC|RIC is a physical strategy performed through cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times. This group of patients received regular therapy of acute ischemic stroke plus unilateral arm of RIC intervention.
11101066|NCT04069546|No Intervention|AIS|This group of patients received regular therapy of acute ischemic stroke.
11101067|NCT04069533|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
11101068|NCT04069520|Experimental|Intervention group|Group that received the augmented biofeedback
11101069|NCT04069520|Sham Comparator|Comparator|group that only received the sham comparison feedback
11101070|NCT04069494||patients|People diagnosed with advanced lung cancer and scheduled to receive palliative RT will be invited to participate between 1st July 2019 and 31st January 2020.
11101071|NCT04069494||care giver|Patients' family caregivers will also be invited to participate
11101072|NCT04069481|Experimental|Dance intervention|Participants will receive a 1-hour group dance class twice a week for 12 weeks. Classes will include a seated warm up, dance exercises in standing, dance activities moving across the floor, throughout the space and conclude with a bow exercise. Music and dance styles will vary and personal preference of participants will also be taken into account.
11101073|NCT04069481|Active Comparator|Exercise and mindfulness meditation|Participants will receive a 1-hour group exercise class twice a week for 12 weeks. Classes will include resistance training exercises with resistance bands, stretching and range of motion exercises in seated and standing positions. Classes will also include mindfulness exercises. During active exercises music will be played and personal preference of participant will be taken into account.
11101074|NCT04069468||TheraSphere®|"Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A*(1-S)*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel [GBq]), S=Percentage of pulmonary shunt, 1 assuming that the lung mass=1 kilograms [kg]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung."
11101075|NCT04069455|Experimental|EPRO group|Clinical usual care plus ePRO App self-management online during postoperative adjuvant chemotherapy
11101076|NCT04069455|No Intervention|Control group|Clinical usual care during postoperative adjuvant chemotherapy
11101077|NCT04069442||cDC-1 positive|cDC-1 positive patients according to RNAseq and in situ analysis
11101078|NCT04069442||cDC-1 negative|cDC-1 negative patients according to RNAseq and in situ analysis
11101079|NCT04069429|Experimental|Healthy Controls|7 controls (subjects without GI symptoms and known GI disease), subjects will receive the radiopharmaceutical agent orally
11101080|NCT04069429|Experimental|Eosinophilic Esophagitis Patients|10 patients with diagnosed EoE (greater than 15 eosinophils per HPF) on esophageal biopsy will be included as the diseased population, subjects will receive the radiopharmaceutical agent orally
11101081|NCT04069416||Group I|175 patients who fall within the Milan criteria.
11101082|NCT04069416||Group II|36 patients who fall within up-to-7 criteria
11101083|NCT04069416||Group III|30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).
11101084|NCT04069403|Experimental|Intervention Arm- Automated Reports|Receives automated reports on prescription patterns monthly
11101085|NCT04069403|No Intervention|Control Arm: Usual clinical education and feedback|Receive no reports
11101086|NCT04069390|Experimental|Cardioskin-Neuronaute|
11101087|NCT04069377||Manuel chest compression|Manuel chest compressions will be handled by human efforts.
11101088|NCT04069377||Mechanical chest compression|In the study, chest compression in the mechanical cardiopulmonary resuscitation group was performed with the Lund University Cardiopulmonary Assist System (LUCAS) Chest Compression System (LUCAS 2).
11101089|NCT04069351|Experimental|Overfeeding Plus Resistance Training Arm|6-week overfeeding plus resistance training arm
11101090|NCT04069338|Active Comparator|Device Storz Modulith SLX-F2|Patients receive standard of care treatment for their urolithiasis using the Device Storz Modulith SLX-F2
11101091|NCT04069338|Active Comparator|Dornier Delta III Treatment|Patients receive standard of care treatment for their urolithiasis using the Dornier Delta III lithotripter
11101092|NCT04069325|Experimental|simiaowan 6g + febuxostat 40mg|
11101093|NCT04069325|Placebo Comparator|placebo 6g + febuxostat 40mg|
11101117|NCT04069156|Active Comparator|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
11101094|NCT04069312|Active Comparator|Roflumilast arm|Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months
11101095|NCT04069312|Active Comparator|Azithromycin arm|Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months
11101096|NCT04069299||Participants receiving PET scan|Participants with metastatic poorly-differentiated neuroendocrine carcinomas of the GI tract
11101097|NCT04069286|Experimental|Treated Group|in which dry Aroeira extract (Schinus terebinthifolius raddi, 640mg / tablet) will be administered + amoxicillin 500mg 2 tablets + clarithromycin, 500mg 1 tablet given twice daily (12/12 hours).
11101098|NCT04069286|Active Comparator|Control Group|in which 1 tablet of 20mg of omeprazole will be administered + amoxicillin 2 tablets of 500mg + clarithromycin, 1 tablet of 500mg administered twice daily (12/12 hours).
11101099|NCT04069273|Experimental|Arm A (Ramucirumab and Paclitaxel)|"All patients receive pembrolizumab monotherapy (generally once every 3 weeks). Then this is followed by ramucirumab + paclitaxel (study drug[s] are generally given once per week). As study treatment moves forward, a patient-tailored disease-specific algorithm is applied in which pembrolizumab is re-introduced and integrated with ramucirumab + paclitaxel if clinical benefit is anticipated.
~NOTE: All registered patients receive pembrolizumab, then patients are randomized to Arm A (ramucirumab + paclitaxel with patient-tailored disease-specific potential re-introduction of pembrolizumab with ramucirumab + paclitaxel) or Arm B (concurrent pembrolizumab with ramucirumab + paclitaxel)"
11101100|NCT04069273|Experimental|Arm B (Pembolizumab, Ramucirumab and Paclitaxel)|All patients receive pembrolizumab monotherapy (generally once every 3 weeks), which is followed by pembrolizumab + ramucirumab + paclitaxel (study drug[s] are generally given once per week).
11101101|NCT04069260|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
11101102|NCT04069247|Experimental|E-based cognitive behavioral therapy for insomnia (eCBT-I)|The eCBT-I will be delivered by a mobile application (eSleep) which contains a digital, self-paced, and highly interactive programme. It consists of six weekly sessions with animated elements, including an overview of sleep, sleep restriction, stimulus control, cognitive therapy, structured worry time and relapse prevention. Participants will have access to the eCBT-I treatment for 12 weeks.
11101103|NCT04069247|Active Comparator|Health education (HE)|The HE, a psychoeducation/information-approach, also consists of six consecutive sessions which contains information about general sleep knowledge, functions of human organs, nutrition, environmental health, brain health, identification and treatments of common diseases, but the contents are not related to any active therapeutic components of cognitive behavioral therapy for insomnia (CBT-I).Participants will have access to the intervention for 12 weeks.
11101104|NCT04069234|Experimental|Ticagrelor|ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily
11101105|NCT04069234|Active Comparator|Clopidogrel|clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily
11101106|NCT04069221|Experimental|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a [14C]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:
~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg [14C]-OZ439 (47 kBq [1.27 μCi]) beginning 3 hours after the oral dose administration."
11101107|NCT04069221|Experimental|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
11101108|NCT04069221|Experimental|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
11101109|NCT04069221|Experimental|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
11101110|NCT04069208|Experimental|IA14|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
11101111|NCT04069195|Active Comparator|DHA supplement|Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
11101112|NCT04069195|Placebo Comparator|corn oil: Soybean oil placebo|Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.
11101113|NCT04069182|Other|Behavioral Activation Therapy|Psychological intervention
11101114|NCT04069169|Experimental|Intravenous lidocaine|1% preservative free lidocaine 10 mg/ml in 0.9% NaCl
11101115|NCT04069169|Placebo Comparator|Intravenous saline control|0.9% sodium chloride, also known as normal saline
11101121|NCT04069130|Experimental|BIA 5|single oral dose of 400 mg as an oral capsule
11101122|NCT04069117|Active Comparator|• Study group|It contains 100 patients will undergo ovarian stimulation with letrozole 2.5mg twice daily (Femara; Novartis Pharma Services, Basel, Switzerland) for 5 days starting from the first day of menstruation in combination with low dose step up stimulation with recombinant FSH starting in the third day of menstruation.
11101123|NCT04069117|No Intervention|• Control group|It contains 100 patients will undergo ovarian stimulation with low dose step up stimulation with recombinant FSH starting in the third day of menstruation
11101124|NCT04069104||ABCD training with standard feedback|Asymmetry, Border, Color, Diameter (ABCD) training message intervention with standard dermatological feedback
11101125|NCT04069104||ABCD training with motivational feedback|ABCD training message intervention with dermatological feedback and a motivational message
11101126|NCT04069104||ABCD training with no feedback|ABCD message intervention with no feedback
11101127|NCT04069104||UDS method training with standard feedback|Ugly Duckling Sign (UDS) method message intervention with dermatological feedback.
11101128|NCT04069104||UDS method training with motivational feedback|UDS message intervention with dermatological feedback and a motivational message.
11101129|NCT04069104||UDS training with no feedback|UDS message intervention with no feedback.
11101130|NCT04069104||ABCD and UDS trainings with standard feedback|Both message interventions with dermatological feedback.
11101131|NCT04069104||ABCD and UDS trainings with motivational feedback|Both message interventions with dermatological feedback and a motivational message.
11101132|NCT04069104||ABCD and UDS trainings with no feedback|Both message interventions with no feedback.
11101133|NCT04069104||No message intervention with standard feedback|No message intervention, but with dermatological feedback.
11101134|NCT04069104||No message intervention with motivational feedback|No message intervention, but with dermatological feedback and a motivational message.
11101135|NCT04069104||No message intervention with no feedback|No message intervention and no feedback. True control.
11101136|NCT04069091|Experimental|CBT intervention|Participants in the CBT intervention arm will undergo standard antenatal care and the 'Enjoy your Bump' online self-help intervention employing elements of cognitive behavioral therapy (CBT)
11101137|NCT04069091|No Intervention|Standard care|Participants in the Standard Care arm will undergo standard antenatal care.
11101138|NCT04069078|Active Comparator|Hyoscine butylbromide|
11101139|NCT04069078|Placebo Comparator|Control|
11101140|NCT04069065|Experimental|Conversion to Once-daily Tacrolimus|Conversion to TacroBell slow-release cap.(Once-daily Tacrolimus) at least one year after liver transplantation
11101141|NCT04069052|Experimental|Inhaled Nitric Oxide|Inhaled nitric oxide administered throughout 4 min exercise protocol at 800 ppm.
11101142|NCT04069052|Placebo Comparator|Placebo|Inhaled room air administered throughout 4 min exercise protocol at FiO2 = 0.21.
11101143|NCT04069026|Experimental|Dose escalation of BAY2416964|Approximately 8 dose levels of BAY2416964 are planned
11101144|NCT04069026|Experimental|Dose expansion of BAY2416964 in tumor type specific|Patients with NSCLC, HNSCC, Urothelial cancer and Colorectal cancer MSS
11101145|NCT04069013|Active Comparator|Standard PCNL|Patients receive a standard PCNL procedure using a 24 fr tract
11101146|NCT04069013|Active Comparator|Mini-PCNL|Patients receive a mini-PCNL procedure using a 16 fr tract
11101147|NCT04069000|Active Comparator|Regular grade 3 classrooms|Students in this condition will participate in the regular grade 3 program. Educators will use their usual teaching methods to meet educational outcomes, including standards for social-emotional learning.
11101148|NCT04069000|Experimental|First time MindUP participants|Students in this condition will participate in MindUP for the first time. Their classroom teachers will receive training and implement the program during the school year.
11101149|NCT04069000|Experimental|Repeat MindUP participants|Students in this condition are in schools where MindUP has been implemented since they were in kindergarten (although some students may not have participated in those first three years, depending on when they moved to the school). Their classroom teachers will receive training and implement the program during the school year.
11101150|NCT04068987||Healthy Volunteers|"Healthy volunteers
~Recruited from the public
~Patients who have scheduled imaging scans for non-cardiac reasons and without a prior history or suspected history of cardiac disease"
11101151|NCT04068987||Children undergoing clinically indicated cardiac MRI|Patients who are scheduled to have a clinically indicated cardiac MRI
11101152|NCT04068974|Experimental|Test group|Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
11101153|NCT04068948|Active Comparator|Midazolam, Hydroxyzine, Meperidine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, Hydroxyzine 1.0mg/kg, and Meperidine 1.5mg/kg prior to their dental procedure.
11101154|NCT04068948|Experimental|Midazolam, Hydroxyzine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, and Hydroxyzine 1.0mg/kg prior to their dental procedure.
11101155|NCT04068935|Experimental|Buddy taping|Buddy taping of the fractured finger to ist neighbouring uninjured finger.
11101156|NCT04068935|Active Comparator|splint immobilization|A forearm-based palmar Hand Splint in an intrinsic plus Position, enclosing all fingers without the thumb.
11101157|NCT04068922|Experimental|Resilience Intervention|Participants will initially complete a baseline assessment assessing study eligibility. The Resilience intervention consists of seven weekly 1.5-hour group sessions guided by trained clinicians. Due to the COVID-19 pandemic, these group session may be conducted through Zoom. Skills and content will be directed toward improving pain management by enhancing positive emotions, setting goals, learning to live a life according to one's values, and boosting self-confidence in one's ability to manage pain. Self-administered activities include the identification of personal strengths, pleasant activity scheduling, expressing gratitude, values clarification, mindfulness practice, goal setting, positive reappraisal, and noting positive events.
11101158|NCT04068909||acute coronary syndrome|All patients should receive standard therapy for acute coronary syndrome and concomitant diseases. All drugs are prescribed according current guidelines and approved indications.
11101159|NCT04068896|Experimental|NGM120 Dose 1|NGM120 Subcutaneous Injection
11101160|NCT04068896|Experimental|NGM120 Dose 2|NGM120 Subcutaneous Injection
11101161|NCT04068896|Experimental|NGM120 Dose 3|NGM120 Subcutaneous Injection
11101162|NCT04068896|Experimental|NGM120 Dose 4|NGM120 Subcutaneous Injection
11101163|NCT04068896|Experimental|NGM120 Dose 5|NGM120 Subcutaneous Injection
11101164|NCT04068896|Experimental|NGM120 Dose 6|NGM120 Subcutaneous Injection
11101165|NCT04068896|Placebo Comparator|Placebo|Placebo
11101166|NCT04068883|Experimental|Collar group|group of athletes that will wear the collar device
11101167|NCT04068883|No Intervention|Non Collar group|group of athletes that will not wear the collar device
11101168|NCT04068870|Experimental|Contraceptive management program|
11101169|NCT04068870|No Intervention|Usual care|
11101170|NCT04068857|Experimental|rTMS|
11101171|NCT04068857|Sham Comparator|Sham|
11101172|NCT04068844|Experimental|Central HFpEF whole body exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to whole body cycle training.
11101173|NCT04068844|Experimental|Central HFpEF isolated single leg exercise|HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to isolated single leg training.
11101174|NCT04068844|Experimental|Peripheral HFpEF whole body exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to whole body cycle training.
11101175|NCT04068844|Experimental|Peripheral HFpEF isolated single leg exercise|HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to isolated single leg training.
11101176|NCT04068831|Experimental|Talazoparib and Avelumab (VHL-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
11101177|NCT04068831|Experimental|Talazoparib and Avelumab (FH- or SDH-deficiency)|All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles.
11101178|NCT04068805|Active Comparator|Positive affect condition|Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
11101179|NCT04068805|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11101180|NCT04068792|Other|Part 1-Observational Phase|Participants will not receive any intervention in the observation phase. All infants will be closely monitored for early signs and symptoms of Respiratory Syncytial Virus (RSV) disease using a mobile RSV application on the parent/caregiver's mobile phone, upon an alert, the RSV will be tested, if RSV negative participants (RSV [-] diagnosed at site) will return to the pre-diagnostic phase and RSV positive participants (RSV [+] diagnosed at site) can be enrolled in the interventional stage of the study after obtaining informed consent for the interventional stage at that time. RSV (+) participants whose parent(s)/caregiver(s) do not consent for enrollment in the interventional stage and participants who are screening failures in the interventional stage will enter the post-diagnostic phase of the observational stage (hospitalized or outpatients).
11101181|NCT04068792|Experimental|Part 2-Interventional Phase|Participants will be randomized to receive either JNJ-53718678 (for Age Group 1 (greater than or equal to [>=] 28 days and less than [<] 3 months): 2.5 milligram per kilogram [mg/kg]; for Age Group 2 (>=3 and <6 months): 3 mg/kg and for Age Group 3 (>=6 months): 4.5 mg/kg) or placebo (Age Group 1, 2 and 3) twice daily for 7 days.
11101182|NCT04068766|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
11101183|NCT04068766|Placebo Comparator|Paracervical block with normal saline|ck with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
11101184|NCT04068753|Experimental|Niraparib + dostarlimab|
11101185|NCT04068740||Mitral valve disease|
11101186|NCT04068740||Aortic valve disease|
11101187|NCT04068727|No Intervention|Control|Control Patients will be provided with educational materials. Control patients will receive no additional guidance.
11101188|NCT04068727|Experimental|Clinical Pharmacist Intervention|Two intervention pharmacists will deliver the intervention. First, a pharmacy technician will call the patient to ensure access and affordability. Next the clinical pharmacist will call to conduct an initial consultation and educational session, documenting the findings and recommendations related to this consultation in the Electronic Medical Record (EMR). Finally, the intervention staff will send educational materials customized to the patient preference - short video clips, print materials, or an email with links to print materials. Over the remaining weeks of the study, the intervention pharmacists will field questions from patients, perform two follow up monthly phone calls, order and follow up on renal and hepatic function lab work, and write an off-service note.
11101189|NCT04068714||Endovascular repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through endovascular repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
11101190|NCT04068714||Open repair|Observational retrospective cohort of patients consecutively submitted to elective abdominal aortic aneurysm surgery repair at a tertiary academic referral center from south Europe, between January 2009 and December 2015 through open repair. The exclusion criteria were non-elective cases, aortic intervention due to diagnosis other than infrarenal AAA and complex aortic aneurysms such as juxta-renal, thoraco-abdominal or thoracic aneurysms.
11101191|NCT04068701|Experimental|MaNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
11101192|NCT04068701|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
11101193|NCT04068688|Experimental|Caregiver-Chid Dyads with ASD (Autism Spectrum Disorder)|Participants in this arm will be caregivers and children with ASD.
11101194|NCT04068688|No Intervention|Children with typical development|Participants in this arm will be children with typical development.
11101195|NCT04068688|No Intervention|Children with developmental delay|Participants in this arm will be children with developmental delay.
11101196|NCT04068675|Experimental|Group counseling arm|There is only one(1) arm in this study. All patients that enroll in the study will receive the group counseling intervention and be compared to historical controls.
11101197|NCT04068662|Experimental|Pregnant Moms' Empowerment Program|Five session group therapy program covering safety planning, resilience and coping, infant care and parenting.
11101198|NCT04068662|Active Comparator|Nondirective Support Group|Five session nondirective support group with two co-leaders who assist in facilitating open discussion on women's self-identified discussion topics.
11101199|NCT04068649|Experimental|Arm I (palliative RT)|Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
11101200|NCT04068649|Experimental|Arm II (SBRT)|Patients undergo single fraction SBRT.
11101201|NCT04068636|Experimental|Flexible endoscopy guided SNB in larynx and pharynx cancers.|Patients with larynx and pharynx cancers will undergo sentinel node biopsy via flexible endoscopy. In this procedure, a radioactive tracer will be injected at 2-4 sites edging the tumor. A SPECT scan will be performed for visualization of the sentinel node(s).
11101202|NCT04068623||Triple negative breast cancer|
11101203|NCT04068610|Active Comparator|Control Arm (FOLFOX + Bevacuzimab)|Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only. Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle)
11101204|NCT04068610|Experimental|Exp. Arm (FOLFOX + Bevacuzimab + Durvalumab + Oleclumab)|"Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only.
~Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle) Durvalumab 1500 mg IV Q4W Oleclumab 3000mg IV Q2W x 4 then Q4W"
11101205|NCT04068597|Experimental|CCS1477 dose escalation NHL/MM|
11101206|NCT04068597|Experimental|CCS1477 dose escalation AML/High risk MDS|
11101207|NCT04068597|Experimental|CCS1477 expansion phase NHL|
11101208|NCT04068597|Experimental|CCS1477 expansion phase MM|
11101209|NCT04068597|Experimental|CCS1477 expansion phase AML/High risk MDS|
11101210|NCT04068584|Experimental|Complete Smart Angel|Smat Angel application with artificial intelligence
11101211|NCT04068584|Experimental|Basic Smart Angel|Smat Angel application without artificial intelligence
11101212|NCT04068584|No Intervention|Control|
11101213|NCT04068571|Active Comparator|I-PUSH intervention sites|Clusters with I-PUSH intervention
11101214|NCT04068571|No Intervention|No I-PUSH intervention sites|Clusters with no I-PUSH intervention
11101215|NCT04068558|Experimental|VNI-NAVA/sNIPPV|Ventilation of the child non-invasive ventilation (VNI) NAVA then sNIPPV
11101216|NCT04068558|Experimental|sNIPPV/VNI-NAVA|Ventilation of the child sNIPPV then non-invasive ventilation (VNI) NAVA
11101217|NCT04068532|Placebo Comparator|Placebo|Participants will receive matching placebo to BIIB104 on Days 1-4 in treatment periods 1 or 2.
11101218|NCT04068532|Experimental|BIIB104|Participants will receive BIIB104 on Days 1-4 in treatment periods 1 or 2.
11101219|NCT04068519|Experimental|Tislelizumab|Tislelizumab will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
11101220|NCT04068506|Experimental|Group A|Gabapentin 600 mg Tab
11101221|NCT04068506|Active Comparator|Group B|Paracetamol 1000 mg Tab
11101222|NCT04068493|Experimental|Dissonance-based obesity intervention|Participants in this arm will receive Enhanced Project Health.
11101223|NCT04068493|No Intervention|Assessment Only|Participants in this arm will only complete the baseline assessment and 2 month assessment. They will not receive Enhanced Project Health.
11101224|NCT04068480||Capsule endoscopy|Patient refered for small bowel capsule endoscopy in conventional indication.
11101225|NCT04068467|Experimental|Active|Instructed to download the app and use the app daily for 30 days.
11101226|NCT04068467|Active Comparator|Waitlist Control|Waitlist control.
11101227|NCT04068454|Active Comparator|classical rehabilitation group|
11101228|NCT04068454|Experimental|virtual reality group|
11101229|NCT04068441||Regular treatment|
11101230|NCT04068441||Treatment interruption|
11101231|NCT04068402|Experimental|Treatment|
11101232|NCT04068376|Active Comparator|Control group (C-GR)|Control group of an aerobic-balance-stretching exercise program led by a coach for 24 weeks (C-GR).
11101233|NCT04068376|Experimental|T1-GR training sessions by health professional|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health professional with a nursing background previously certified to coach SSE trainings by the Institute of Square-Stepping Exercise in Mie, Japan (Chief Tomohiro Okura and Overseas Director Professor Ryosuke Shigematsu).
11101234|NCT04068376|Experimental|T2-GR older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
11101235|NCT04068363||Matched group|Same sex of both donor and recipient
11101236|NCT04068363||Mismatched group|Sex mismatch between donor and recipient, subgroups might be added
11101237|NCT04068350||Single arm|The evaluation at 3 months of the postoperative pain will be carried out without the information collected in preoperative and immediate postoperative.
11101238|NCT04068337||Hemiarch|Patients with Freestyle aortic root implantation receiving a hemiarch replacement by open anastomosis technique with axillary cannulation and antegrade cerebral perfusion
11101239|NCT04068337||Non-Hemiarch|Patients with Freestyle aortic root implantation without hemiarch replacement with normal systemic perfusion
11101240|NCT04068324|No Intervention|8 hours fasting group|Routine preoperative fasting group undergoes 8 hours of fasting before the operation.
11101241|NCT04068324|Experimental|Clear liquid group|"30 pediatric patients drink 3ml/kg 1 hour before the surgery. Although clear liquid suggests any drinks that do not contain any solid ingredients, but in this study we define clear liquid as water."
11101242|NCT04068324|Experimental|Carbohydrate containing liquid group|"Other 30 pediatric patients drink 3ml/kg of carbohydrate containing fluid 1 hour before the surgery. The product name we have is NoNPO from NewCare (South Korean company). This fluid does not contain any solid ingredients, so consuming the fluid does not exceed Nil per Os time needed before the surgery."
11101243|NCT04068311||Pre Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
11101244|NCT04068311||Post Implementation|Adult patients >65 years of age in the Emergency Department Observation Unit.
11101245|NCT04068285|Active Comparator|High intensity interval exercise|"Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
~exercise"
11101246|NCT04068285|Active Comparator|Moderate intensity continuous exercise|"Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
~exercise"
11101247|NCT04068285|No Intervention|No Intervention: Control group|The participants with type 2 Diabetes mellitus in the control group will make stretching exercise at home
11101248|NCT04068272|Experimental|Treatment|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
11101249|NCT04068272|Placebo Comparator|Placebo|The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized
11101250|NCT04068259|Experimental|Cohort 1, Dose 1 of PBI-4547 or Placebo|Dose 1 of PBI-4547 or matching Placebo tablets by mouth
11101251|NCT04068259|Experimental|Cohort 2, Dose 2 of PBI-4547 or Placebo|Dose 2 of PBI-4547 or matching Placebo tablets by mouth
11101252|NCT04068259|Experimental|Cohort 3, Dose 3 of PBI-4547 or Placebo|Dose 3 of PBI-4547 or matching Placebo tablets by mouth
11101253|NCT04068259|Experimental|Cohort 4, Dose 4 of PBI-4547 or Placebo|Dose 4 of PBI-4547 or matching Placebo tablets by mouth
11101254|NCT04068259|Experimental|Cohort 5, Dose 5 of PBI-4547 or Placebo|Dose 5 of PBI-4547 or matching Placebo tablets by mouth
11101255|NCT04068246|Placebo Comparator|Control group|patients will receive the standard therapy (methotrexate) plus placebo tablets
11101256|NCT04068246|Experimental|Metformin group|patients will receive the standard therapy plus 1 g metformin daily.
11101257|NCT04068233|Experimental|Eligible patients - pacing mode sequence 1|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-synchronous pacing mode first, then AV-dyssynchronous pacing mode.
11101258|NCT04068233|Experimental|Eligible patients - pacing mode sequence 2|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-dyssynchronous pacing mode first, then AV-synchronous pacing mode.
11101259|NCT04068220|Other|Intraoperative FVEPs monitoring|adult patients admitted to TOH - Civic Campus, for chiasmal or pre-chiasmal lesions undergoing a first time minimally invasive endoscopic skull base surgery.
11101260|NCT04068207|Experimental|Minocycline|Tablets Minocycline 100mg po per day for 24 weeks
11101261|NCT04068194|Active Comparator|Arm A (hypofractionated RT, avelumab)|Patients undergo 5 fractions of hypofractionated RT QOD on days -17 to -7. Patients also receive avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11101262|NCT04068194|Experimental|Arm B (hypofractionated RT, nedisertib, avelumab)|Patients undergo 5 fractions of hypofractionated RT QOD on days -17 to -7. Patients also receive nedisertib PO BID on days 1-28, and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11101263|NCT04068181|Experimental|Talimogene Laherparepvec and Pembrolizumab|To evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting.
11101264|NCT04068155|Experimental|DaRT Seeds Intratumoral Diffusing alpha-emitters|An intratumoral insertion of securely fixed seeds loaded with Radium-224. The seeds release by recoil short-lived alpha-emitting atoms into the tumor.
11101265|NCT04068142|No Intervention|Clinical Personnel Safety Planning|Patients will complete a traditional written suicide safety plan with clinical personnel.
11101266|NCT04068142|Experimental|Peer Supporter Safety Planning|Patients will complete a traditional written suicide safety plan with peer supporters.
11101267|NCT04068129||Burma|Patients from remote Burma clinic
11101268|NCT04068129||Alaska|Patients in pediatric ophthalmology clinic
11101269|NCT04068116|Experimental|Postconditioning in primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention with post-conditioning by making 4 cycles of repeated occlusion & re-perfusion 30-second each by inflation/deflation of an appropriately sized PTCA (per-cutaneous trans-luminal coronary angioplasty) balloon
11101270|NCT04068116|Active Comparator|Primary percutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention without post-conditioning
11101271|NCT04068103|Active Comparator|Arm I (blood stored and tested for ctDNA later)|Patients undergo active surveillance.
11101332|NCT04067596|Experimental|epiphysiodesis|The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).
11101272|NCT04068103|Experimental|Arm II (blood tested for ctDNA at baseline)|"Patients are assigned to 1 of 2 groups.
~GROUP I (ctDNA DETECTED): At the discretion of the investigator, patients receive either oxaliplatin IV over 2 hours on day 1, leucovorin IV over 2 hours on day 1, and fluorouracil IV bolus over 2-4 minutes on day 1 and then by continuous IV over 46-48 hours repeated every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14 repeated every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity at the discretion of the investigator.
~GROUP II (ctDNA NOT DETECTED): Patients undergo active surveillance."
11101273|NCT04068090||Patients with CIPN|Patients with peripheral neuropathy after treatment with taxanes
11101274|NCT04068090||Patients without CIPN|Patients treated with taxanes and don't develop will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age, tumor stage, chemotherapy regimen or total taxane dosage
11101275|NCT04068077||Experimental|Patients with amyloidosis and other indistinguishable diseases
11101276|NCT04068064|Experimental|EABM training group|about 40 individuals with IGD will be randomly assigned to the EABM training group
11101277|NCT04068064|Placebo Comparator|Control training group|about another 40 individuals with IGD will be randomly assigned to the control training group
11101278|NCT04068051|Experimental|AXS-07|
11101279|NCT04068025|No Intervention|No Intervention: Control group|Patients in the control group were given usual care by a health professional who was not involved in the study and who worked in the Department of Urology. After the end of the study, the patients in the control group were also given structured bladder training similar to the patients in the intervention group.
11101280|NCT04068025|Active Comparator|the IMB model|Structured bladder training was applied to the patients in the intervention group via the IMB model.
11101281|NCT04068012|Experimental|Intervention|Ventilator management using the proposed protocol in both acute and weaning phases
11101282|NCT04067999||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
11101283|NCT04067986|Other|Camrelizumab + Apatinib|Camrelizumab + Apatinib
11101284|NCT04067973||patients|"Premature subjects benefit from the examinations described in the protocol, namely automated refractometry, intraocular air pressure, biometrics (with axial length and pachymetry (corneal thickness) performed by the same machine at the same time), a photo of the fundus (retinophotography) and an OCT RNFL. These examinations are necessary for the follow-up of premature children.
~All children examined at Nantes University Hospital benefit systematically from: automated refractometry, intraocular pressure in the air and a photo of the fundus."
11101285|NCT04067973||control|"controls benefit from two additional tests: RNFL OCT and biometrics. The duration of the RNFL OCT is about 2 minutes, with a total of 10 seconds per eye, the rest being computer manipulation.
~The biometrics take about 2 minutes to complete, with a total of 30 seconds per eye, the rest being computer manipulation.
~These two reviews are conducted on the same day as the initial consultation and directly following the consultation."
11101286|NCT04067960||Ancillary-correlative (pharmacogenomics testing)|Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing.
11101287|NCT04067947|Experimental|XG005|XG005 in 4 dose levels
11101288|NCT04067947|Placebo Comparator|Placebo|Placebo in all cohort
11101289|NCT04067934|Experimental|Jumping exercise|High-impact exercise intervention: 3 sessions per week for four weeks Each session will consist of three jumping-based exercises, performed for three sets of various repetitions, following a progressive protocol with increasing volume/intensity.
11101290|NCT04067908|Experimental|woman giving birth prematurely|Proteome: by liquid chromatography coupled with tandem mass spectrometry. Fibronectin: by vaginal sampling. Ultrasound of the cervix. Cytokines: ELISA kit of a panel of several cytokines.
11101291|NCT04067895||human bone graft screw|human bone graft screws will be used during the epiphysiodesis
11101292|NCT04067882||Cervix cancer|Women older than 18 years with histopathological diagnosis of cervical cancer clinical stage I2-IVA, candidates to receive standard treatment with chemotherapy followed by brachytherapy.
11101293|NCT04067869|Experimental|Single arm|Patient with confirmed HIV-1 infection
11101294|NCT04067856|Active Comparator|Bevacizumab|Intravitreal injection of 1.25mg/0.05cc bevacizumab
11101295|NCT04067856|Active Comparator|Dexamethasone implant|Intravitreal injection of 0.7mg dexamethasone implant
11101296|NCT04067843|Experimental|Photodynamic treatment|Skin microbiome after photodynamic treatment before and after skin antisepsis
11101297|NCT04067830|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
11101298|NCT04067830|Experimental|Arm II (RMT + usual care)|Patients use a power lung device to complete 3 sets of 15 RMT exercises over 30 minutes 6 days per week over 2-4 weeks for a minimum of 12 sessions prior to surgery. Patients also receive usual care consisting of attending physical therapy once weekly, receiving pre-surgical information, instruction on the use of a spirometer device, and wearing a Fitbit to track activity. Patients then undergo video-assisted thoracic surgery or laparoscopic surgery. Patients continue to track activity using the Fitbit for 3 months post-surgery.
11101299|NCT04067817|Experimental|norepinephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, norepinephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered
11101333|NCT04067583||Physicians with recent aflibercept experience|Ophthalmologists who have prescribed and/or administered aflibercept in the past 6 months
11101639|NCT04065321||Control group|250 patients will be assigned into control group.
11101300|NCT04067817|Experimental|phenylephrine|Blood pressure is generally maintained at value not less than 80% of baseline during intraoperative period. If the blood pressure is within normal range and SVV is less than 9, patient will be given a continuous infusion of crystalloid solution. However, when blood pressure drops and SVV is greater than 13, a bolus of 200mL colloid will then be quickly administered. If the blood pressure doesn't recover back to normal range within 5 minutes after bolus, phenylephrine will be given through the central venous catheter. If SVV is between 9 and 13, a bolus of crystalloid at 8mL/kg/h will be administered.
11101301|NCT04067804|No Intervention|Usual Care|Standard school disciplinary practices.
11101302|NCT04067804|Experimental|Dynamic Adaptation Process|Using the Dynamic Adaptation Process, specialist coordinators will convene and lead Implementation Resource Teams (IRTs). With the assistance of expert trainers and coaches, the coordinator-led IRTs will then engage in an iterative process of assessment and planning to build school capacity and implement restorative practices to reduce adverse student outcomes related to discipline.
11101303|NCT04067791|Experimental|Prolonged-Release melatonin then Immediate-release melatonin|
11101304|NCT04067791|Experimental|Immediate-Release Melatonin then Prolonged-Release Melatonin|
11101305|NCT04067778|Experimental|Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
11101306|NCT04067778|Other|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
11101307|NCT04067765|Experimental|Alcohol vs Neutral Cue|Within-subjects experimental manipulation of alcohol vs. neutral cues
11101308|NCT04067765|Experimental|Responsibility vs No Responsibility|Within-subjects experimental manipulation of responsibility vs. no-responsibility condition
11101309|NCT04067752|Experimental|High Dialysate Na|high dialysate sodium concentration (138 mEq/L)
11101310|NCT04067752|Active Comparator|Low Dialysate Na|Low dialysate sodium concentration (132 mEq/L)
11101311|NCT04067739||Readmission group|Readmission is defined as ICU readmission within ≤ 3 months of initial ICU discharge
11101312|NCT04067739||Non readmitted group|Non readmission is defined as no need for ICU readmission within ≤ 3 months of initial ICU discharge
11101313|NCT04067726|Experimental|Denosumab|"Subcutaneous injection of denosumab at a dose of 60 mg at two time points: baseline and 6 months
~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12-month mammographic breast density examination.
~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36-month optional assessment may also occur.
~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
11101314|NCT04067726|Placebo Comparator|Placebo|"Subcutaneous injection of the placebo at a dose of 60 mg at two time points: baseline and 6 months
~Participants will also be instructed to take calcium and vitamin D supplements daily for 12 months between baseline examination and 12 month mammographic breast density examination
~Mammographic breast density will be assessed at three time points in all participants: baseline, 12 months, and 24 months. A 36 month optional assessment may also occur.
~Biopsies and blood draws will occur for research purposes at baseline and 12 months."
11101315|NCT04067713||PARADIGM-D|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Docetaxel with androgen deprivation therapy (ADT).
11101316|NCT04067713||PARADIGM- A|Newly diagnosed metastatic prostate cancer patients starting long term therapy with Abiraterone with androgen deprivation therapy (ADT).
11101317|NCT04067700|Other|Coronary perfusion PET/CT patients|
11101318|NCT04067687|No Intervention|Control|No palliative home visit intervention
11101319|NCT04067687|Experimental|Intervention|Palliative home visit intervention
11101320|NCT04067674||Septic shock patients|Patients included in this cohort will have blood sampling for measurement of immune related biomarkers (immunophenotyping, functional tests, messenger ribonucleic acid (mRNA), circulating markers) in circulating blood and their associations with relevant clinical outcomes
11101321|NCT04067661|Experimental|Intervention|Participants and their partners will complete four couples counseling sessions focused on developing and enhancing relationship skills to decrease HIV risk behaviors.
11101322|NCT04067661|Active Comparator|Control|Participants and their partners will receive information and referrals on HIV risk and prevention strategies.
11101323|NCT04067648|Experimental|S1 group|Sufentanil 0.3 μg/kg was intravenously given during anesthesia induction
11101324|NCT04067648|Experimental|S2 group|Sufentanil 0.4 μg/kg was intravenously given during anesthesia induction
11101325|NCT04067648|Experimental|S3 group|Sufentanil 0.5 μg/kg was intravenously given during anesthesia induction
11101326|NCT04067635||Conservative Arm|Participants are followed by the research team conservatively. Participants in this arm may choose to undergo any valvular intervention at the discretion of their treating clinical team.
11101327|NCT04067635||Surgical Arm|Participants have already elected upfront to undergo surgical repair (at least, mitral annuloplasty) with their treating clinical team, just prior to enrollment into this study.
11101328|NCT04067622|Other|Exersides restraints first|Patients in this arm will wear the novel Exersides restraint during hours 1-4 on Day 1, then switched to soft wrist restrains during hours 5-8. On Day 2, patients in this arm will will wear soft wrist restraints during hours 1-4, and Exersides during hours 5-8. They will then wear Exersides during study days 3-6.
11101329|NCT04067622|Other|Traditional restraints first|Patients in this arm will wear soft wrist restraints during hours 1-4 on Day 1; they will then be switched to the novel Exersides restraint during hours 5-8. On Day 2, patients in this arm will will wear Exersides during hours 1-4, and soft wrist restraints during hours 5-8. They will then wear soft wrist restraints during study days 3-6.
11101330|NCT04067609|Experimental|patients receiving dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
11101331|NCT04067609|Placebo Comparator|placebo|100mL of normal saline (placebo) immediately upon the subjects' arrival to the Post Anesthesia Care Unit (PACU) after leaving the operating room from their scheduled c-section
11101635|NCT04065347||Group 1|A total of 150 participants taking tenofovir alafenamide will be enrolled in this cohort.
11101334|NCT04067570|Experimental|SBRT post operative|"Stereotactic Body Radiotherapy (SBRT) 30 Gy in 5 fractions, once weekly to prostate bed
~/ - 25 Gy in 5 fractions, once weekly simultaneously to pelvic lymph nodes
~/ - 6-24 months of androgen deprivation therapy (ADT)"
11101335|NCT04067544|Other|Acupuncture Treatment|All patients receive 10 acupuncture treatments over the course of 8 weeks.
11101336|NCT04067531|Other|treatment of BV|all patients be treated with first Deqularum then with clindamycin Cream,
11101337|NCT04067518|Experimental|Pegaspargase arm|
11101338|NCT04067505|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg twice daily for three weeks, then 20mg oral once daily after operation.
11101339|NCT04067505|Active Comparator|Warfarin/Nadroparin|Participants will receive nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 6 months.
11101340|NCT04067492|Experimental|RPH - 4 mg|Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
11101341|NCT04067492|Experimental|RPH - 20 mg|Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
11101342|NCT04067492|Experimental|RPH - 40 mg|Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
11101343|NCT04067492|Experimental|RPH - 80 mg|Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
11101344|NCT04067492|Experimental|RPH - 160 mg|Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
11101345|NCT04067492|Active Comparator|Voltaren® (diclofenac)|Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
11101346|NCT04067479|Experimental|Young|
11101347|NCT04067479|Experimental|Older Adults|
11101348|NCT04067466|Experimental|Fiber product|Fiber product: Inulin, maltodextrin, gum guar, plum powder
11101349|NCT04067466|Placebo Comparator|Control product|Maltodextrin, plum powder
11101350|NCT04067453||Patients undergoing fatiguing protocol|patient consulting for anorectal manometry in order to explore anorectal disorders with a voluntary command on external anal sphincter
11101351|NCT04067440||Patients|Subjects to undergo surgery including opening of the jejunum with non-inflammative condition.
11101352|NCT04067427|Active Comparator|Mental training|AF ablation followed by 3 months of a daily app-based mental training for 10 to 15 minutes per session. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
11101353|NCT04067427|No Intervention|Control|AF ablation without subsequent mental training. AF 6 questionnaire will be answered weekly via the Mental-AF webpage.
11101354|NCT04067414|Experimental|BZ019 treatment|Subjects will receive lymphodepleting chemotherapy of fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 infusion. A 3×3 dose escalation design of BZ019 will be adopted.
11101355|NCT04067401|Experimental|Wingman Connect|Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
11101356|NCT04067401|Active Comparator|Stress Management|The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.
11101357|NCT04067375||Pregnant women, HPA-1a positive|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a positive.
11101358|NCT04067375||Pregnant women, HPA-1a negative with HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and have formed anti-HPA-1a alloantibodies.
11101359|NCT04067375||Pregnant women, HPA-1a negative without HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and did not have formed anti-HPA-1a alloantibodies.
11101360|NCT04067362|Placebo Comparator|no fiber|Breakfast with hot chocolate with no fiber
11101361|NCT04067362|Experimental|chicory root flour|Breakfast with hot chocolate with chicory root flour
11101362|NCT04067362|Experimental|chicory root fiber supplement|Breakfast with hot chocolate with chicory root fiber supplement
11101363|NCT04067349|Active Comparator|laparoscopic liver resection|Patients undergoing laparoscopic liver resection
11101364|NCT04067349|Active Comparator|open liver resection|Patients undergoing open liver resection
11101365|NCT04067336|Experimental|KO-539|dose escalation study - capsules
11101366|NCT04067323|Placebo Comparator|LCT consumption|20g soy oil (containing mainly long chain triglycerides - LCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
11101367|NCT04067323|Experimental|MCT consumption|20g MCT oil (containing 100% MCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
11101368|NCT04067310|Experimental|Group Experimental|Participants who will use the spray skin protector
11101369|NCT04067310|Active Comparator|Group control|Participants who will use moisturizer containing in its composition calendula officinalis
11101370|NCT04067297|No Intervention|Control Arm|The 14 communities that are in the control arm of the trial will receive usual standard of care. The usual standard of care will follow clinical daily practice patterns provided by family physicians in Ontario for CVD prevention. This follows the periodic standard of care provided by Canadian cholesterol, hypertension, and diabetes best practice guideline recommendations utilized based on each physician's clinical judgement, physical assessment, and discretion. Patients also typically have access to existing cardiovascular prevention materials offered online through publicly available websites.
11101406|NCT04067050|Active Comparator|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
11101371|NCT04067297|Experimental|Intervention Arm|The 14 communities that are in the intervention arm of the trial will receive a multicomponent intervention that provides both physicians and patients with access to a 'toolbox' of lipid management resources. The components planned for the 'toolbox' are all evidence-based interventions and chosen after consultations with Canadian family physicians and implementation science experts based on their potential for scalability to the entire population, cost and practicality. Online tools will be used and the trial will leverage pre-existing implementation initiatives (e.g., newsletters, listservs) wherever possible to minimize study costs and increase accessibility.
11101372|NCT04067284|Active Comparator|Intervention 1|Nutrition education on dietary diversity.
11101373|NCT04067284|Experimental|Intervention 2|A combination of similar education plus daily supplementation of homemade yogurt.
11101374|NCT04067284|Active Comparator|Usual care|Control group.
11101375|NCT04067258||Beta-Thalassemia group|Patients suffering from beta thalassemia major or intermedia will be included in this group
11101376|NCT04067258||Control group|Healthy age and sex matched volunteers will be included in this group
11101377|NCT04067245|Other|Tetrasodium EDTA cathether lock solution|There is only one arm in this study where home parenteral nutrition patients who meet the inclusion criteria will receive tetrasodium EDTA catheter lock solution.
11101378|NCT04067232|Experimental|Patients with posttraumatic forearm impairment|All patients with a one-sided posttraumatic impairment of forearm pro- and/or supination at least 3 months after injury
11101379|NCT04067219|Experimental|Single arm|HIV-1 infected patients
11101380|NCT04067206|Experimental|Recorded mothers' voice group.|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
11101381|NCT04067206|Experimental|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
11101382|NCT04067206|Experimental|MiniMuffs|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
11101383|NCT04067206|No Intervention|Control Group|The control group who were administered standard care.
11101384|NCT04067193||old geriatric inpatients|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes)
11101385|NCT04067193||unformal caregivers|usability assessment after 24 to 72 hours of possible use of the device (PARADE CONNECT shoes) by their relative
11101386|NCT04067193||professional caregivers|usability assessment after the possible use of the device (PARADE CONNECT shoes) by 40 hospitalzed old patients in the geriatrics ward
11101387|NCT04067180|Experimental|Haplo SCT|Allogeneic stem cell transplantation with a haplo-identical family donor graft.
11101388|NCT04067180|Active Comparator|URD SCT|Allogeneic stem cell transplantation with a matched unrelated donor graft.
11101389|NCT04067167|Sham Comparator|WB-EMS (Sham-intervention)|Low-theshold WB-EMS combined with nutritional therapy
11101390|NCT04067167|Experimental|WB-EMS|WB-EMS combined with nutritional therapy
11101391|NCT04067167|Experimental|Free WB-EMS|WB-EMS using a mobile System combined with nutritional therapy
11101392|NCT04067167|Experimental|Flexi Band Resistance Training|Flexi band resistance Training combined with nutritional therapy
11101393|NCT04067154|Experimental|ALPE-TAC|ARDS patients on mechanical ventilation. Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O to evaluate potential for recruitment and measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
11101394|NCT04067141|Experimental|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
11101395|NCT04067141|Experimental|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
11101396|NCT04067128|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach called patients three times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
11101397|NCT04067128|No Intervention|Usual care arm|Patients assigned to usual care had access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
11101398|NCT04067115|Experimental|Trabectedin and Irinotecan|Trabectedin will be delivered by infusion on day 1 followed by 2 doses on irinotecan delivered by infusion for one hour on day 2 and day 4 of 21 day cycles. Some patients will receive an 18F-FLT Imaging scan prior to the first administration of trabectedin and once after administration of trabectedin.
11101399|NCT04067102|Experimental|Nab-paclitaxel Based Regimens|
11101400|NCT04067102|Active Comparator|Paclitaxel Based Regimens|
11101401|NCT04067089|Experimental|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
11101402|NCT04067089|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
11101403|NCT04067076||Students of IEMS of Mexico City|Students currently enrolled in the academic year 2019-2020 from the 24 IEMS centers of Mexico City
11101404|NCT04067063||Milpa Alta inhabitants|Population among 15 and 70 years old
11101405|NCT04067050|Experimental|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
11101407|NCT04067037|Experimental|Camrelizumab Combined With AVD regimen|Camrelizumab 200mg, Intravenous administration on day 1 and day 15 combined with regimen：AVD (Epirubicin, Vincristine and Dacarbazine): repeated every 4 weeks, up to 6 cycles.
11101408|NCT04067024|Active Comparator|Local anesthesia by the surgeon (LAS)|Local infiltration (ropivacaine 3,75 mg/ml) by surgeon
11101409|NCT04067024|Experimental|Regional anesthesia group (LRA):|By ultrasound, a pecs block I associated with a supraclavicular nerf block is performed. (Ropivacaine 3,75 mg/ml)
11101410|NCT04067011|Experimental|Group 1:Ciprofloxacin + AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
~Group 1 will concomitantly receive ciprofloxacin."
11101411|NCT04067011|Experimental|Group 2: Doxycycline +AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
~Group 2 will concomitantly receive doxycycline."
11101412|NCT04067011|Experimental|Group 3: AV7909|Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
11101413|NCT04066998|Experimental|Conjunctivitis|Patients treated with Dupilumab with conjunctivitis
11101414|NCT04066998|Other|No conjunctivitis|Patients treated with Dupilumab and showing no signs of ocular involvement
11101415|NCT04066985|Experimental|Growth Mindset Intervention|"Includes one online, single-session program, the Growth Mindset Program. The 30-minute, self-administered youth program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
11101416|NCT04066985|Experimental|Self-Kindness Intervention|Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
11101417|NCT04066985|Active Comparator|Supportive Therapy Intervention|Includes one online, single-session active comparator program, the Supportive Therapy Intervention. The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. The 30-minute, self-administered control group program includes: vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family; the same number of reading and writing activities as the web-based growth mindset intervention. However, the only goals of the ST intervention are to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs.
11101418|NCT04066972|Experimental|Single arm|
11101419|NCT04066959|Experimental|Question Prompt List (QPL)|A QPL is a simple, inexpensive communication tool that is comprised of list of questions related to the physical and psychosocial aspects of an illness and treatment components about which patients may want to ask their diabetes care team during a routine diabetes clinic visit.
11101420|NCT04066959|Experimental|Motivation Enhancement System (MES)|MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
11101421|NCT04066959|Experimental|Text Message Reminders (TXT)|Participants will receive 30 days of one-way text messages targeting one of three key daily diabetes care behaviors: monitoring blood glucose, insulin administration, or carbohydrate counting. Participants will set a reminder schedule, i.e., frequency and timing of text message reminders.
11101422|NCT04066959|Experimental|QPL & MES|Participants will receive the QPL and MES interventions as described above.
11101423|NCT04066959|Experimental|QPL & TXT|Participants will receive the QPL and TXT interventions as described above.
11101424|NCT04066959|Experimental|MES & TXT|Participants will receive the MES and TXT interventions as described above.
11101425|NCT04066959|Experimental|MES, QPL & TXT|Participants will receive the MES, QPL, and TXT interventions as described above.
11101426|NCT04066959|No Intervention|Standard Medical Care|Participants will receive standard medical care at one of two participating clinical sites. Clinical practices at these sites are consistent with the standards of T1D care recommended by the American Diabetes Association and will include diabetes clinic visits every 3-4 months for routine diabetes medical care provided by an endocrinologist and/or nurse practitioner.
11101427|NCT04066946|Experimental|Group 1 = Intervention group|Standard of care (hydration + silicone gel sheet) + Microcurrent
11101428|NCT04066946|Active Comparator|Group 2 = Control Group|Standard of care (hydration + silicone gel sheet)
11101429|NCT04066920|Experimental|IBER treatment arm|This is the only arm in a single-arm phase II study.
11101454|NCT04066777|Other|Hypertrophic obstructive cardiomyopathy|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
11101455|NCT04066764|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg oral twice daily for 3 weeks after operation, later rivaroxaban 20mg oral once daily until 3 months after the filter is retrieved.
11101430|NCT04066907|Experimental|Integrated Disease Management|Physicians randomized to intervention will attend a training session on the program standards and details of the IDM. Following the initial baseline interview a certified heart failure educator (CHFE) will meet with subjects to obtain a detailed history of their HF, provide education, self-care management strategies (medication adherence, symptoms monitoring, dietary adherence, fluid restriction, exercise, weight management, smoking cessation) and review immunization status. A self-management action plan will be developed with the study physician and CHFE to enable monitoring and management of HF by the participant. All participants will meet with a dietitian at all IDM appointments.
11101431|NCT04066907|No Intervention|Usual Care|Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months in person interviews will be conducted by the research assistant and the questionnaires will be completed.
11101432|NCT04066894|Experimental|Supportive Care (sacral nerve stimulator)|Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
11101433|NCT04066881|Experimental|Group A|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm
~1 tab of Truvada (0-26 weeks)"
11101434|NCT04066881|Experimental|Group B|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm
~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm
~1 tab of Truvada (0-26 weeks)"
11101435|NCT04066881|Placebo Comparator|Group C:|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48
~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.
~1 tab of Truvada (0-26 weeks)"
11101436|NCT04066881|Active Comparator|Group D|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm
~1 tab of Descovy (0-26 weeks)"
11101437|NCT04066881|Experimental|Group E|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48
~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm
~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm
~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm
~1 tab of Descovy (0-26 weeks)"
11101438|NCT04066881|Placebo Comparator|Group G|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48
~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.
~1 tab of Descovy (0-26 weeks)"
11101439|NCT04066868|Experimental|PRO active|
11101440|NCT04066868|Active Comparator|PRO not active|
11101441|NCT04066855||Chronic Kidney Disease (CKD)|patients diagnosed as CKD
11101442|NCT04066855||Renal transplant|recipients of renal transplantation
11101443|NCT04066842||1 - Controls|Control Healthy controls
11101444|NCT04066842||2 - SSc|SSc Systemic Sclerosis
11101445|NCT04066842||3 - Cardiovascular|Cardiovascular Cardiovascular disease
11101446|NCT04066842||4 - SSc+Periodontitis|SSc+ Periodontitis Systemic Sclerosis with Periodontitis
11101447|NCT04066829|Experimental|Default setting intervention|The arm will include all patients undergoing tonsillectomy at C.S. Mott Hospital by a pediatric otolaryngology faculty member at the University of Michigan.
11101448|NCT04066829|No Intervention|Control (Usual Care)|The arm will include all patients undergoing tonsillectomy at University Hospital, Brighton Center for Specialty Care, or Livonia Center for Specialty Care by a general otolaryngology faculty member at the University of Michigan.
11101449|NCT04066816|Experimental|Walnut Consumption|After screening, participants will avoid foods high in ellagic acid. These foods include pomegranates, hazelnuts, pistachios, strawberries, raspberries, blackberries, oak-aged wines, spirits, and walnuts (besides the ones given by researchers); a complete list will be provided to the subjects. Participants will then return to research facility and provide urine and stool samples, as well as a set of 3-day dietary records. Then, they will start to consume 2 ounces of walnuts per day for 21 days with their usual diet. At the end, they will collect another urine and stool sample as well as another set of dietary records, and then come in for the scheduled colonoscopy where they will be asked to provide biopsy specimens. That completes the intervention and participation in the study.
11101450|NCT04066803|Experimental|MTX group with folic acid|the group with optimal MTX dose (gradually increased from 0 to 12weeks，appropriate folic acid，and stable original other DMARDs
11101451|NCT04066803|Active Comparator|control group without folic acid|the group with stable MTX 10mg/w dose and maximum DMARDs doses（graduallly increased from 0 to 12 weeks）without folic acid
11101452|NCT04066790|Experimental|Pyrotinib in combination with nab-paclitaxel|Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
11101453|NCT04066790|Active Comparator|Trastuzumab in combination with nab-paclitaxel|Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
11101525|NCT04066244|Other|Cohort 4|Dose 4 of BLZ945
11101526|NCT04066244|Other|Cohort 5|Dose 5 of BLZ945
11101456|NCT04066764|Active Comparator|Warfarin/ Nadroparin|Participants will receive Nadroparin 1mg/kg twice daily (subcutaneous), plus warfarin 3mg oral once daily for 5 days after the operation, later warfarin(oral) at individually titrated doses(0.75mg to 18mg) to achieve a target international normalized ratio (INR) of 2.0 to 3.0, once daily until 3 months after the filter is retrieved.
11101457|NCT04066751|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
11101458|NCT04066751|Placebo Comparator|Placebo|Placebo, 150 mg PO every 12 hrs for 84 days
11101459|NCT04066738|Other|Patients with myocardial scar|Patient with previous STEMI resulting in myocardial scar, elected to CRT implant
11101460|NCT04066725|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 60 days
11101461|NCT04066725|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 60 days.
11101462|NCT04066725|Placebo Comparator|Placebo|Participants will be given a placebo orally once daily for a total of 60 days.
11101463|NCT04066712|Experimental|A: Normal (control) renal function|
11101464|NCT04066712|Experimental|B: Mild impairment renal function|
11101465|NCT04066712|Experimental|C: Moderate impairment renal function|
11101466|NCT04066712|Experimental|D: Severe impairment renal function|
11101467|NCT04066699||Localization|Electromagnetic navigation (EMN) guided percutaneous localization of suspicious lung lesion(s).
11101468|NCT04066686||Young|Participants recruited into one of two groups on age stratification. Young cohort defined as aged 18-65yrs old
11101469|NCT04066686||Elderly|Participants recruited into one of two groups on age stratification. Elderly cohort defined as over 65yrs of age.
11101470|NCT04066660|Experimental|Treatment & Oligo Fucoidan|4.4 g Oligo Fucoidan powder by six months, BID
11101471|NCT04066660|Placebo Comparator|Treatment & Placebo|4.4 g Placebo powder by six months, BID
11101472|NCT04066647|Experimental|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
11101473|NCT04066634|Experimental|Treatment|
11101474|NCT04066621|Experimental|CRO-SBT|Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)
11101475|NCT04066595|Experimental|Experimental (cohorts 1 and 2)|Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib). Both cohorts receive the same treatment.
11101476|NCT04066582||Experimental|Suspected skin inflammations or skin tumors
11101477|NCT04066569|Active Comparator|OGTT Tests and Placebo Test|Patients with acromegaly
11101478|NCT04066569|Active Comparator|OGTT Tests|age and sex matched healthy volunteers
11101479|NCT04066556||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
11101480|NCT04066543|Active Comparator|TACE group|Device: Transcatheter arterial chemoembolization(TACE)
11101481|NCT04066543|Experimental|TACE+Anlotinib group|Device: Transcatheter arterial chemoembolization Drug: Anlotinib Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
11101482|NCT04066530|Experimental|AD-203|
11101483|NCT04066530|Active Comparator|Mucosta tab.|
11101484|NCT04066517|Experimental|Open Label|Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
11101485|NCT04066504||Sonidegib|Patients with laBCC undergoing sonidegib treatment in routine clinical practice
11101486|NCT04066491|Experimental|Safety Run-In Part: Bintrafusp alfa + Gemcitabine + Cisplatin|
11101487|NCT04066491|Experimental|Double-blinded Part: Bintrafusp alfa + Gemcitabine + Cisplatin|
11101488|NCT04066491|Placebo Comparator|Double-blinded Part: Placebo + Gemcitabine + Cisplatin|
11101489|NCT04066478|Experimental|Teatment|75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
11101490|NCT04066478|Placebo Comparator|Comaprator|75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
11101491|NCT04066465||Proton Therapy|Patients receive proton Radio(chemo)therapy according to clinical standard. Proton Treatment is indicated BEFORE inclusion into the trial ans is not part of the trial. Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases. In addition to the treatment parameters of the radio(chemo)therapy protocol, further radiation doses to brain substructures and organs at risk are documented.
11101492|NCT04066465||No Radiotherapy - Surgical only group|"Patients are included AFTER surgery of their brain tumour and receive no radiotherapy due to their disease (i.e. according to clinical standard). This Treatment is not part of the trial, but stratifies the Patient in this second Group.
~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
11101493|NCT04066465||Control Group|"Healthy kids are recruited as Standard Group.
~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
11101494|NCT04066452||Single-group studies|"Patients will be informed about the study and their written informed consent will be requested.
~Once included in the study:
~A series of clinical, analytical and echocardiographic parameters will be collected and measured
~Will be performed:
~Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP)
~Analytical to rule out monoclonal protein:
~Proteinogram and serum immunoglobulins.
~Light chains free in serum -Freelite-
~Immunofixation in serum and urine.
~The number of readmissions, emergency visits and mortality in the following 12 months will be recorded to compare the readmission and mortality rates in one year of patients with and without CA.
~The prescribed pre- and post-diagnostic treatments will be described, according to clinical practice (without intervention).
~No intervention, whether diagnostic or follow-up, that is not the usual clinical practice will be applied to patients."
11101495|NCT04066426|Experimental|naproxen sodium+codeine phosphate|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Codeine phosphate is an opioid analgesic which has similar applications to those of morphine. However, it is significantly less potent as an analgesic and has only mild sedative effects. The drug's principal site of action is at the µ-opioid receptors (MOR) which are distributed in the central nervous system. Peak effect is reached within 2 hours and analgesic action continues for approximately 4 hours. Naproxen sodium (550 mg)+codeine phosphate (30 mg) was used twice daily in this study.
11101496|NCT04066426|Experimental|naproxen sodium+dexamethasone|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
11101497|NCT04066426|Experimental|naproxen sodium|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily in this study.
11101498|NCT04066426|Active Comparator|paracetamol|Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea.
11101499|NCT04066413|No Intervention|Breastfed group|Non-randomized breastfed reference group
11101500|NCT04066413|Placebo Comparator|Control formula|Group receiving standard infant formula
11101501|NCT04066413|Active Comparator|Formula with HMO|Group receiving standard infant formula supplemented with HMO
11101502|NCT04066400|Placebo Comparator|wheat-based diet|The patients continue a wheat-based diet aiming at a reduction in bodyweight.
11101503|NCT04066400|Experimental|ATI reduced diet|Patients are counselled to reduce dietary gluten uptake.
11101504|NCT04066374|Experimental|Treatment Arm|Intrathoracic placement of neurostimulation device
11101505|NCT04066361|Experimental|Chatbot|"Participant is given a pamphlet introducing genetic testing
~Participant is given information utilized for clinical, standard of care testing.
~Will receive genetic information with a virtual interactive Chatbot prior to genetic testing. After the Chatbot education, participant is asked if they would like to proceed with genetic testing.
~Participant is asked to complete an electronic family history tool"
11101506|NCT04066361|Experimental|Video Education|"Participant is given a pamphlet introducing genetic testing
~Participant is given information utilized for clinical, standard of care testing.
~Participant will watch a brief educational video that is approximately 8 minutes in length about the genetic testing process and what to expect prior to genetic testing. After the video education, participant is asked if they would like to proceed with genetic testing.
~Participant is asked to complete an electronic family history tool"
11101507|NCT04066348|Experimental|Etanercept Injection Group|Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.
11101508|NCT04066348|Placebo Comparator|Placebo Injection Group|Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.
11101509|NCT04066322||system treatment|Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
11101510|NCT04066322||system treatment and Surgery|Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
11101511|NCT04066309|Experimental|Abutment removal|At the time of surgery, customizable healing abutments will be placed on implants. These will be replaced by Pro PEEK Abutments 21 days later to placement of temporary prostheses (loading). The final abutments (Titanium Bases) and final prostheses will be inserted 2 months after loading.
11101512|NCT04066309|Experimental|Final abutment|The final abutments (Titanium Bases) will be placed at the time of the implant placement surgery and will stay at mouth during all period of the study. Temporary and final prosthesis will be placed on Titanium Bases.
11101513|NCT04066296|Active Comparator|Liposomal Bupivicaine|Treatment with liposomal bupivicaine
11101514|NCT04066296|Active Comparator|Standard Local Anesthestic|Treatment with Standard Local Anesthestic
11101515|NCT04066283||Older transgender women|This cohort will consist of transgender women aged 50-75 years old who have taken estradiol and spironolactone for at least one year.
11101516|NCT04066283||Younger transgender women|This cohort will consist of transgender women aged 18-40 years old who have taken estradiol and spironolactone for at least one year.
11101517|NCT04066270||study group|"candidates for cochlear implantation 18 years or older, who are eligible for implantation for the indication of bilateral severe hearing loss or single sided deafness.
~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
11101518|NCT04066270||control group|"Symptomatic DFNA9 patients carrying the p.P51S mutation in COCH, presenting the radiologic semicircular canal lesion(s) on CT and/or MR.
~clinical audiometric and vestibular investigations, CT and MR imaging of petrous bone"
11101519|NCT04066257|Active Comparator|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg twice daily for 7 days
11101520|NCT04066257|Active Comparator|Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
11101521|NCT04066257|Active Comparator|MTN 500 mg+TCL 500 mg+BIS 300 mg|Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg & Tripotassium bismuth dicitrate 300 mg four times daily for 7 days
11101522|NCT04066244|Other|Cohort 1|Dose 1 of BLZ945
11101523|NCT04066244|Other|Cohort 2|Dose 2 of BLZ945
11101524|NCT04066244|Other|Cohort 3|Dose 3 of BLZ945
11101528|NCT04066218||age 15-19|The investigators plan to complete 24 interviews with 12 in the age 15-19 cohort.The investigators will also ensure that at least 8 people from each sex are included in this study.
11101529|NCT04066218||age 20-24|The investigators plan to complete 24 interviews with 12 in the age 20-24 cohort. The investigators will also ensure that at least 8 people from each sex are included in this study.
11101530|NCT04066205|Experimental|SLEEPSMART PROGRAM|"Arm: Placebo Comparator (Usual care)-This treatment arm will receive usual JIA care, including annual Rheumatology clinic visits, medications, routine clinical and laboratory tests, physical therapy, follow-up appointments, and no sleep intervention.
~Arm: Experimental -Each child and parent will create a login, choose treatment goals, and interact with fields in the Web site. The modules will focus on improving sleep hygiene, relaxation, or increasing sleep duration. The intervention will last 6 to 8 weeks."
11101531|NCT04066192|Placebo Comparator|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
11101532|NCT04066192|Active Comparator|BREX 2mg|The BREX 2mg group will start at the same dose at the BREX 4mg group and titrate up at the same rate, so the BREX 2mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, and 2mg on day 5, to reach its final 2mg dose for day 5-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
11101533|NCT04066192|Active Comparator|BREX 4mg|The BREX 4mg group will start at the same dose as the BREX 2mg group and titrate up at the same rate, so the BREX 4mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, 2mg on day 5-6, and 4mg on day 7 to reach its final 4mg dose for days 7-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
11101534|NCT04066179|Experimental|Prednisolone+G-CSF|Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days
11101535|NCT04066179|Active Comparator|Prednisolone|Prednisolone 40 mg/day for 7 days
11101536|NCT04066179|Experimental|Granulocytes-Colony Stimulating Factor|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
11101537|NCT04066166||Subjects|Healthy
11101538|NCT04066127|Experimental|Non-ischemic heart preservation (NIHP)|Non-ischemic hypothermic perfusion (NIHP): The donor heart is preserved using a portable heart-lung machine. The device perfuse the heart continuously with a a new preservation solution at a temperature of 8°C.
11101539|NCT04066127|Other|Standard cold storage (SCS)|Standard cold static storage (SCS): The donor heart is preserved using a standard crystalloid cardioplegia. The heart is in then storage i a transport box containing ice to keep the temperature around 4-8°C. The device does not perfuse the heart.
11101540|NCT04066114|Experimental|lulizumab pegol + novel ISR|lulizumab pegol + novel ISR: lulizumab pegol plus immunosuppressive regimen (anti-thymocyte globulin (rabbit), steroids,) belatacept, tocilizumab, and everolimus)
11101541|NCT04066101||high caries risk|100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
11101542|NCT04066101||low caries risk|100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
11101543|NCT04066088|Sham Comparator|Placebo|
11101544|NCT04066088|Experimental|GXR|Immediately following the 8-week blinded randomized trial, an 8-week open-label continuation phase will be pursued to further define efficacy and tolerability of GXR, and to establish its safety with specific focus on metabolic profile.
11101545|NCT04066075|Experimental|Telerehabilitation with low vision provider|
11101546|NCT04066075|Experimental|Telerehabilitation w/ low vision provider plus tele-extender|
11101547|NCT04066075|Active Comparator|Usual Care (active control)|
11101548|NCT04066062||Retrospective|A total of 700 vessel from 700 patients clinically indicated CCTA and IVUS or OCT performed within 3 months.
11101549|NCT04066062||Prospective|A total of 1,000 subjects will be enrolled in this Registry. This number of subject is expected to provide a maximum of 1,300 vessels. All CCTA and IVUS/OCT will be performed within 3 months
11101550|NCT04066049|Active Comparator|Treatment|Participants in the Treatment group will receive a hybrid therapist-implemented and caregiver-implemented intervention be compared to a BAU control group. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
11101551|NCT04066049|No Intervention|Control|Participants in the BAU group will be offered 10 caregiver support sessions after completing the 12-month follow-up. These home-based sessions will emphasize shared book reading, modeling vocabulary for school readiness in play and routines, and include general information for families about options for public school language related services. Each session will last about 30 minutes and be conducted by a trained staff member. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention, and will receive a $50 gift card for participating in each assessment time point, $75 for completing all four assessments, and books and play/activity materials with target word lists in Spanish.
11101552|NCT04066036||Study Population|The study will enroll a total of 1,000 ART-experienced participants from the study sites in Uganda and South Africa who are being transitioned to TLD from non-nucleoside reverse transcriptase-based antiretroviral therapy.
11101553|NCT04066023|Experimental|C213 1.9 mg|C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch
11101554|NCT04066023|Experimental|C213 3.8mg|C213 3.8 mg administered as two 1.9 mg patches
11101555|NCT04066023|Placebo Comparator|Placebo|Placebo microneedle system administered as two placebo patches
11101556|NCT04066010|No Intervention|Control|
11101557|NCT04066010|Other|Intervention|Mobile application intervention
11101558|NCT04065997||Patients implanted with HVAD System|Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.
11101636|NCT04065347||Group 2|A total of 30 participants initiating/re-initiating tenofovir alafenamide will be enrolled in this cohort.
11101559|NCT04065984|Experimental|Neuro-Muscular electrical stimulation treatment arm|Active muscle stimulation with a view that this will lead to muscle preservation through muscle fibre recruitment
11101560|NCT04065984|Sham Comparator|Neuro-Muscular electrical stimulation Placebo arm|Stimulator set at a sub therapeutic threshold so as to not recruit muscle fibres
11101561|NCT04065971|Experimental|2LHERP® arm|Group N°1: 2LHERP® treatment (6 months of treatment)
11101562|NCT04065971|Placebo Comparator|Placebo arm|Group N°1: Placebo treatment (6 months of treatment)
11101563|NCT04065958|Experimental|Yoga-mindfulness|Yoga-mindfulness program consisting of movements/postures (asanas), breathing practices, relaxation practices and meditation practices, together with brief talks on yoga-based coping strategies. The intervention starts with a introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks, with home assignments for about 30 minutes per day, four days per week.
11101564|NCT04065958|Active Comparator|Patient education and physiotherapy|Patient education program consisting of lectures on topics related to inflammatory arthritis and pain together with mild physiotherapy. The interventions starts with an introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks. Each session consists of a lecture and a program of instructed physiotherapy. Besides the weekly sessions, home assignments consisting of 30 minutes of walking, are performed four days per week.
11101565|NCT04065945||Couples undergoing ART treatment|Couples in reproductive age undergoing ART treatment in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
11101566|NCT04065945||Couples getting pregnant naturally|Couples who get pregnant naturally and want to deliver the babies in Women's Hospital School of Medicine Zhejiang University, The International Peace Maternity & Child Health Hospital, and Changhai Hospital of Shanghai.
11101567|NCT04065932|Experimental|BMS-985165-01 prototype formulation 1|
11101568|NCT04065932|Experimental|BMS-986165 Tablet|
11101569|NCT04065932|Experimental|BMS-985165-01 prototype formulation 2|
11101570|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3|
11101571|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3 or 4|
11101572|NCT04065932|Experimental|BMS-985165-01 prototype formulation 3, 4 or 5|
11101573|NCT04065919|Active Comparator|Exparel|"administration of liposomal bupivacaine 266mg/20mL+ 40 mL bupivacaine 0.25% bupivacaine
~."
11101574|NCT04065919|Active Comparator|Standard of Therapy|administration of 0.25% bupivacaine with epinephrine at 1cc/kg total dose
11101575|NCT04065906|Experimental|NIRS group|Children with ADHD, 12 sessions of NIRS feedback, for two sessions per week.
11101576|NCT04065906|Other|Drug group|Children with ADHD, 6 weeks' treatment of either methylphenidate or tomoxetine
11101577|NCT04065906|Other|Control group|Healthy children, 12 sessions of NIRS feedback, for two sessions per week.
11101578|NCT04065893||Catheter ablation group|Patients with reduced biventricular pacing due to PVC or VT receiving catheter ablation of PVC/VT according to guidelines and clinical practices
11101579|NCT04065893||Medical treatment group|Patients with reduced biventricular pacing due to PVC or VT receiving intensified medical therapy (antiarrhythmics/betablocker) according to guidelines and clinical practices
11101580|NCT04065880|Active Comparator|TachoSil®|TachoSil® is a collagen sponge coated with the human coagulation factors fibrinogen and thrombin.
11101581|NCT04065880|Active Comparator|Neoveil®|Neoveil® sheet made of polyglycolic acid (PGA). It is a biodegradable, thermoplastic and non-antigenic polymer.
11101582|NCT04065854|No Intervention|Control|The control group will receive standard brief falls assessment and advice.
11101583|NCT04065854|Active Comparator|Intervention|Therapy intervention.
11101584|NCT04065841|Experimental|Arm A: combination therapy|tropifexor + licogliflozin
11101585|NCT04065841|Experimental|Arm B: tropifexor monotherapy|tropifexor (+ licogliflozin placebo)
11101586|NCT04065841|Experimental|Arm C: licogliflozin monotherapy|licogliflozin (+ tropifexor placebo)
11101587|NCT04065841|Placebo Comparator|Arm D: Placebo|licogliflozin placebo + tropifexor placebo
11101588|NCT04065815|Experimental|Resistance Training (RT)|Individualized, protein-rich nutritional therapy combined with resistance training
11101589|NCT04065815|Experimental|WB-EMS|Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
11101590|NCT04065815|Experimental|High-intensity interval training (HIIT)|Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
11101591|NCT04065815|Experimental|Combined HIIT and Resistance Training (Combi)|Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training
11101592|NCT04065802|Experimental|Radioablation Treatment|Patients will receive radioablation to scar regions of the heart responsible for ventricular tachycardia
11101593|NCT04065789|Experimental|Carfilzomib,Daratumumab,revlimid and dexamethasone|Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
11101594|NCT04065776|Experimental|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
11101595|NCT04065737|Experimental|Sintilimab|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
11101596|NCT04065724|Other|Physical training resistance and aerobic|Physical training as resistance and aerobic training
11101597|NCT04065711|Experimental|RAP Treatment|Each treatment area will receive 30-40 minutes (30-40 individual doses) of RAP treatment.
11101598|NCT04065698|Experimental|RV521|Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)
11101599|NCT04065685|Active Comparator|CG|control group receiving the usual care, the standardized information on anticipated directives
11101600|NCT04065685|Active Comparator|IG p+r|intervention group with patients and her/his relative
11101601|NCT04065685|Active Comparator|IG p|intervention group with patients without relative
11101602|NCT04065672|Experimental|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then twice a week for 8 weeks. All patients were followed up for 3 months after treatment.
11101637|NCT04065334|Experimental|low dose training|
11101638|NCT04065334|Active Comparator|high dose training|
11101603|NCT04065646|Experimental|Intervention|The intervention group will receive daily text messages with information on: (i) HMM stop locations and schedule; (ii) information on HMM weekly produce specials and sales; (iii) motivational messages encouraging use of the HMM; and (iv) links to produce coupons that they can exchange at HMM- $5 coupons received weekly for the four-week texting period.
11101604|NCT04065646|No Intervention|Control|The control group will receive the same dosage of daily text messages covering free activities taking place at the Hartford Public Library and other community locations. The control group will not receive incentive coupons.
11101605|NCT04065633|Experimental|Part A sequence 1|
11101606|NCT04065633|Experimental|Part A sequence 2|
11101607|NCT04065633|Experimental|Part B sequence 1|
11101608|NCT04065633|Experimental|Part B sequence 2|
11101609|NCT04065594|Experimental|PRP dressing|
11101610|NCT04065594|Experimental|conventional ordinary dressing|
11101611|NCT04065581|Experimental|Treatment A-washout-treatment B|Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
11101612|NCT04065581|Experimental|Treatment B-washout-treatment A|Subject will receive a single oral dose of 50 mg acarbose and 500 mg metformin as loose combination (Treatment B) in period 1, followed by a single oral dose of acarbose/metformin FDC (Treatment A, 50mg acarbose/500 mg metformin) in period 2. Washout interval between 2 treatment periods was at least 7 days.
11101613|NCT04065568|Experimental|Intervention group|The patient will receive conventional out patient rehabilitation after discharge to the home after stroke. In addition an individualized training program with gamified excercises for motor function will be set and followed up by clincians using video communication, as part of the DISKO-tool. Patients are instructed to train self sufficiently 5 days a week and will be supervised by the treating physiotherapist. The intervention will last for 6 weeks.
11101614|NCT04065568|No Intervention|Control group|Conventional rehabilitation in primary care after discharge to the home after stroke.
11101615|NCT04065555|Experimental|CIVO Microdose Injection of TAK-981, Cetuximab, and Avelumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one day (Cohort 1) or three days (Cohort 2) prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of TAK-981, cetuximab, avelumab, TAK-981 combined with cetuximab, or TAK-981 combined with avelumab. Each microdose is simultaneously and percutaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node. Approximately six patients will be assigned to each time point cohort. Cohort assignment is not sequential and will be selected by the Investigator based on clinic logistics and patient scheduling. Should one cohort fill in advance of the other, sites will be directed by Presage to enroll patients into the second cohort only.
11101616|NCT04065529|Experimental|Gelatin tannate (GT)|Gelatin tannate (GT)
11101617|NCT04065529|Placebo Comparator|Placebo|Placebo
11101618|NCT04065516|Experimental|Argon Plasma Coagulation of the gastroesophageal junction|Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
11101619|NCT04065503|Experimental|Healthy Adults|Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.
11101620|NCT04065490|Experimental|PBM Treatment|The Valeda™ Light Delivery System
11101621|NCT04065490|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System non-effective treatment
11101622|NCT04065477|Experimental|Experimental|The experimental group will receive treatment program designed to train strategic cognitive functions. Sessions will last 50 minutes and take place twice per week for 16 weeks.
11101623|NCT04065477|No Intervention|Control group|"The control group will receive no active treatment and will be treated as a no-contact control group."
11101624|NCT04065451|Experimental|Epinephrine|Epinephrine in the submucosal injection fluid (1:200,000)
11101625|NCT04065451|No Intervention|No epinephrine|Submucosal injection fluid without epinephrine
11101626|NCT04065438|Experimental|LIPOSORBER® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using LIPOSORBER® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
11101627|NCT04065412|Active Comparator|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed to localize the cricothyroid membrane
11101628|NCT04065412|Experimental|Modified laryngeal handshake technique|The modified laryngeal handshake is performed to localize the cricothyroid membrane
11101629|NCT04065399|Experimental|Experimental: SNDX-5613|"Phase 1:
~Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D). Patients will be enrolled in one of two dose-escalation arms:
~Arm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/ inducers.
~Arm B: Patients receiving strong cytochrome P450 3A4 inhibitors for antifungal prophylaxis.
~Phase 2:
~Oral SNDX-5613; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows:
~Cohort 2A: Patients with MLLr acute lymphoblastic leukemia (ALL)/mixed phenotype acute leukemia (MPAL).
~Cohort 2B: Patients with MLLr AML.
~Cohort 2C: Patients with NPM1c AML."
11101630|NCT04065386|Active Comparator|Active taVNS|"Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS), at the cymba conchea, the active localization.
~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and simultaneously to a neurophysiological assessment (256 channels EEG, electrocardiograph and pupillary measure)."
11101631|NCT04065386|Placebo Comparator|Sham taVNS|"Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS), at the ear lobe, the sham localization.
~It will be preceded and followed by a clinical assessment (Coma Recovery Scale- Revised) and simultaneously to a neurophysiological assessment (256 channels EEG, electrocardiograph and pupillary measure)."
11101632|NCT04065373|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored a common peripheral IV site over a 24 hour observation period.
11101640|NCT04065321||Trial group|250 patients will be assigned into trial group.
11101641|NCT04065308|Experimental|Experimental arm|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).
~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)
~dexamethasone :40mg/day D1-4, intravenous
~cyclophosphamide: 400mg/m2 D1-4, intravenous
~etoposide: 40mg/m2 D1-4, intravenous
~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
11101642|NCT04065295|Experimental|Single Rising Dose Part|
11101643|NCT04065295|Experimental|Bioavailability Part|
11101644|NCT04065282|Experimental|neoadjuvant therapy with Sintilimab plus Xelox|3 cycles of neoadjuvant therapy: Sintilimab iv d1 Q3W, Oxaliplatin 130mg/m2 iv d1 Q3W, and Capecitabine 1000mg/m2 po Bid d1-14 Q3W
11101645|NCT04065269|Experimental|1A: AZD6738|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with single agent AZD6738.
11101646|NCT04065269|Experimental|1B: AZD6738 + olaparib|"In second stage of trial, opening of this cohort depends on response rate in cohort 1A during first stage of trial.
~Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with AZD6738 in combination with olaparib."
11101647|NCT04065269|Experimental|2: AZD6738 + olaparib|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with NO loss of ARID1A expression treated with AZD6738 in combination with olaparib.
11101648|NCT04065269|Experimental|3: AZD6738 + olaparib|Women with other rare relapsed gynaecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status, treated with AZD6738 in combination with olaparib.
11101649|NCT04065256|Experimental|Personalized music intervention group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. A total treatment dosage of 560 minutes is required.
11101650|NCT04065256|Experimental|Personalized music plus earplug group|Participants will receive a personalized music session for forty minutes twice a day for consecutive seven days or until discharge from ICU. In addition, using earplug during night time sleep. The music intervention total treatment dosage of 560 minutes is required.
11101651|NCT04065256|No Intervention|Control group|The control group involves neither music intervention nor using earplug at night.
11101652|NCT04065243|Active Comparator|Control group|Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
11101653|NCT04065243|Experimental|Overfed group|Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
11101654|NCT04065230||TAF antiviral therapy group|
11101655|NCT04065217|Other|Iraqi patients with face hemangioma|Diode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.
11101656|NCT04065191|Experimental|High-intensity interval training|High-intensity interval training
11101657|NCT04065178||Level of Activity|Level of activity for all patients admitting to the inpatient neurological rehabilitation unit.
11101658|NCT04065165|Experimental|Experimental arm|Lanreotide 120 mg q4w Telotristat Ethyl 250 mg TID
11101659|NCT04065165|Placebo Comparator|Control arm|Lanreotide 120 mg q4w Placebo TID
11101660|NCT04065152|Experimental|oncolytic immunotherapy|Talimogene laherparepvec Dose: 10^6 pfu/ml at week 1 then 10^8/ml at week 4 and every 2 weeks (up to 4ml for each injection) Route: intralesional injection Duration of treatment: 6 months (12 cycles)
11101661|NCT04065139|Active Comparator|Control Arm|
11101662|NCT04065139|Experimental|Experimental Arm : PIPAC|
11101663|NCT04065126|Experimental|Physical activity Intervention|This arm receives ten two-hour group sessions with physical activity and psycho-educational components, held by a physiotherapist over a period of ten weeks.
11101664|NCT04065126|Active Comparator|Brief Psycho-education|This arm receives two brief lectures of psycho-education held by a physiotherapist.
11101665|NCT04065113|Experimental|Embolization Only|Medically managed patient receives middle meningeal artery embolization
11101666|NCT04065113|Experimental|Embolization + Evacuation|Participant receives standard of care evacuation and then undergoes MMA embolization
11101667|NCT04065113|No Intervention|Medical Management|Historical control of medically managed patients
11101668|NCT04065113|Active Comparator|Surgical Patients|Historical control of patients receiving standard surgery alone
11101669|NCT04065100|Experimental|Study group|Maternal PCOS
11101670|NCT04065100|Active Comparator|Comaprator|Non-PCOS pregnant women
11101671|NCT04065087|Experimental|GX-I7|GX-I7 administered until Progression of Disease
11101672|NCT04065087|Placebo Comparator|Placebo|Placebo administered until Progression of Disease
11101673|NCT04065074|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
11101674|NCT04065061|Experimental|Experimental|Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49.
11101675|NCT04065061|Placebo Comparator|Placebo|Placebo dietary supplement from week 0 to week 49.
11101676|NCT04065048|Other|Crohn's disease patients in remission|Crohn's disease patients will follow an identical diet intervention protocol therefore no randomization will be performed after enrollment. Participants will follow a soy-based diet for 7 days. The diet will be preceded by a 12-hr overnight fast and will be immediately followed by a wash out period for a minimum of 7 days and no longer than 14 days.
11101677|NCT04065035|Active Comparator|Topical Firming Body Moisturizer|Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
11101678|NCT04065035|Placebo Comparator|Placebo Moisturizer|Oil-in-water emulsion base containing emollients.
11101679|NCT04065022|Experimental|Head stimulation|Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
11101680|NCT04065022|Experimental|Arm stimulation|Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
11101681|NCT04065009|Placebo Comparator|Placebo|Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
11101682|NCT04065009|Experimental|Experimental|Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
11101683|NCT04064996|Active Comparator|Group A|Routine rehabilitation program patient education
11101684|NCT04064996|Experimental|Group B|Routine rehabilitation program + foot exercise training
11101685|NCT04064970||PASS Cohort|
11101686|NCT04064944|Experimental|Immunoadsorption group|patients' blood purification treatment protocal is Protain A Immunoadsorption method.
11101687|NCT04064944|Experimental|Plasma exchange group|patients' blood purification treatment protocal is Plasma exchange method.
11101688|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
11101689|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
11101690|NCT04064931||general population|Women of childbearing age in general examination.
11101691|NCT04064918|Other|Netarsudil 0.02% QD|4 weeks of Netarsudil 0.02% QD, then a 4 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
11101692|NCT04064918|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 4 Week washout, followed by 4 weeks of Netarsudil 0.02% QD
11101693|NCT04064905|Experimental|mRNA-1893|
11101694|NCT04064905|Placebo Comparator|Placebo|0.9% sodium chloride
11101695|NCT04064892|Experimental|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
11101696|NCT04064879|Experimental|Deployment of AD-SVF|Administration of autologous adipose derived SVF
11101697|NCT04064866|Experimental|PRP/Hemocyte Autograft Intervention Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to active condition will have exactly 3 cc of hemocyte autograft placed in a 3 cc syringe. The syringe barrels and tubing were covered with opaque tape so that the injector was blinded to the contents. 1-2 cc of PRP was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
11101698|NCT04064866|Placebo Comparator|Placebo Control Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to placebo condition will have exactly 3 cc of saline placed in a 3 cc syringe. 1-2 cc of saline was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
11101699|NCT04064840|Active Comparator|IVF: dual trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
11101700|NCT04064840|Placebo Comparator|IVF: hCG trigger|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
11101701|NCT04064840|Active Comparator|FET: agonist|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
11101702|NCT04064840|Placebo Comparator|FET: control|On the day of FET, normal saline will be injected subcutaneously.
11101703|NCT04064827|Experimental|Participants Receiving Paricalcitol|Participants will be administered paricalcitol three times a week (TIW) but no more frequently than every other day for 24 weeks
11101704|NCT04064814|Active Comparator|Flunarizine|flunarizine will be prescribed at a dose of 5mg once daily , orally for 12 weeks
11101705|NCT04064814|Experimental|Alpha Lipoic Acid|Alpha Lipoic Acid will be prescribed at a dose of 300mg once daily,orally for 12 weeks
11101706|NCT04064788|Experimental|Consecutive mCIMT group|
11101707|NCT04064788|Experimental|Intermittent mCIMT group|
11101708|NCT04064788|Active Comparator|Traditional physiotherapy control group|
11101709|NCT04064775|Experimental|Smart snacking intervention|In intervention 2 participants took part in a 4-week intervention on Instagram. Participants saw images of fictitious peers' snacks or beverages three times per week, and saw snack information images three times per week. Peer snack images were posted on days 2,4 and 6 of each week, and snack information images were posted on days 1,3 and 5 of each week. Images were posted between 10-11am each day. Participants also completed quizzes related to snacking at the end of weeks 1-3. Participants completed a survey at baseline and intervention end to assess their ideal portion sizes to allow for examination of the effectiveness of the intervention.
11101710|NCT04064775|No Intervention|Control|Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
11101711|NCT04064762|Experimental|Vagus Nerve Stimulation + Prolonged Exposure Therapy|Study treatment is vagus nerve stimulation (VNS) delivered during Prolonged Exposure Therapy.
11101712|NCT04064749|No Intervention|Control|Participants will receive screening (i.e. services as usual) provided by a national credit counseling program.
11101713|NCT04064749|Experimental|Intervention|Participants will receive screening services provided by the credit counseling program plus added brief intervention services by University of Maryland School of Social Work (UMSSW). Added intervention services include: 1) feedback about the individual's gambling, and 2) text messages to support the individual.
11101714|NCT04064723|Active Comparator|Stem components|Randomization between two stem components. LCU or Corail stem.
11101715|NCT04064723|Active Comparator|Cup components|Randomization between two cup components. DeltaTT or Pinnacle cup.
11101716|NCT04064710|Experimental|Biological Allograft Chain Tissue Implant|Biological Allograft Chain tissue product as a bone void filler in patients with painful vertebral compression fractures
11101717|NCT04064697|No Intervention|Control group|Patient will be treated by vedolizumab the standard of care alone.
11101718|NCT04064697|Experimental|Experimental group|Patient will be treated by vedolizumab the standard of care associated at valganciclovir.
11101719|NCT04064684|Experimental|treatment with Budesonide|
11101720|NCT04064684|Placebo Comparator|Placebo|
11101721|NCT04064658|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.
~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in Sham RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.
~Procedure: Encephaloduroarteriosynangiosis"
11101722|NCT04064658|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.
~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least five days before encephaloduroarteriosynangiosis.
~Procedure: Encephaloduroarteriosynangiosis"
11101723|NCT04064645|Experimental|Respiratory rate accuracy measurement|
11101724|NCT04064632|Experimental|RPV +DRV/cobi|The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.
11101725|NCT04064632|Active Comparator|baseline therapy (CAR)|The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).
11101726|NCT04064619|Active Comparator|sudden stopping|patients were followed up after 1 and 3 months from stopping the drug,
11101727|NCT04064619|Experimental|Weaning|patients were followed up after 1and 3 months from the end of gradual weaning
11101728|NCT04064593|Experimental|Polygraphy|
11101729|NCT04064567|Active Comparator|Enhanced Standard of Care|PrEP education and referral to a community-based PrEP provider (enhanced standard of care)
11101730|NCT04064567|Experimental|Community Health Worker Involved Enhanced Standard of Care|PrEP education, referral to a community-based PrEP provider, and referral to a CHW who will facilitate access to community-based PrEP and other healthcare and social-support services.
11101731|NCT04064554|Experimental|MicronJet600|BCG vaccination with MicronJet600
11101732|NCT04064554|Active Comparator|Conventional needle|BCG vaccination with conventional needle
11101733|NCT04064541|Other|Virtual Visit|"At the baseline visit patients will complete an in-clinic baseline visit consisting of Medical Hx review, NYHA assessment, Questionnaires (EQ-5D-5L, KCCQ, Frailty Index for Elders & Mini Cog) and Functional Assessments (Timed Up & Go and 6MWT). Patients will also receive virtual visit training and complete an in-clinic virtual visit consisting of the previously stated functional assessments.
~All follow-up visits will occur via virtual distance health visits. These f/u visits will occur at Day 7and Day 14 At the initiation of each distance health f/u visit the patient's current state of health will be assessed as well as NYHA. Patient Questionnaires(EQ-5D-5L, KCCQ & Frailty Index) and Functional Assessments(Timed Up & Go and 6MWT) will be completed."
11101734|NCT04064528|Active Comparator|Young|Young adults will be given a 10 g oral bolus of amino acids.
11101735|NCT04064528|Experimental|Older Adults|Older adults will be given a 10 g oral bolus of amino acids.
11101736|NCT04064515||Cervical Cancer|Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
11101737|NCT04064515||Control|Participants without a history of cervical cancer or high grade pre-cancer of the cervix
11101738|NCT04064502||volunteers|273 adult volunteers ranging from 18-78 years old
11101739|NCT04064489|No Intervention|neutral|No specific instructions for prescribing prophylaxis or not
11101740|NCT04064489|Active Comparator|TRIPscore|calculation of the TRIPcast score and prescription of prophylactic or not according to the result (score > or = 7 : treatment (low molecular weight heparin or fondaparinux); score < 7 : no treatment)
11101741|NCT04064463|Active Comparator|Control Group|Standard care
11101742|NCT04064463|Experimental|Experimental Group|Standard care plus contingency management
11101743|NCT04064450||Heart Failure|Individuals with asymptomatic or symptomatic heart failure
11101744|NCT04064450||Population Controls|Individuals free of heart failure and echocardiographic cardiac dysfunction
11101745|NCT04064437||Individuals with type 1 diabetes|
11101746|NCT04064437||Healthy controls|
11101747|NCT04064424|Experimental|Prevention Advertisement|Participants will be exposed to prevention videos and images through Facebook Advertising
11101748|NCT04064424|Active Comparator|No Advertisement|No prevention videos and images will be shown through Facebook Advertising
11101749|NCT04064411|Experimental|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide, which is an active synthetic peptide of parathyroid hormone, coated onto a sMTS array for transdermal administration of abaloparatide
11101750|NCT04064411|Active Comparator|abaloparatide-SC|A combination product consisting of the drug abaloparatide in a single-patient-use prefilled pen that delivers 80 μg of abaloparatide as a SC injection
11101751|NCT04064398|Active Comparator|Routine aspiration of gastric residuals|
11101752|NCT04064398|No Intervention|No aspiration of gastric residuals|
11101753|NCT04064385|Experimental|Intervention|FES cycle training will be performed on the RT300 FES cycle ideally 3 times per week for 6 weeks, each session lasting up to 90 minutes. Electrical stimulation will be delivered through up to 12 independent channels each delivering up to 140 mA current on the following muscles (both on the right and left leg): quadriceps, femoral biceps and gluteus, gastrocnemius and tibialis anterior. Abdominal and back extensor muscles may also be stimulated if the participant presents with neurological trunk weakness (SCI above T6). The FES unit will stimulate the muscles that extend the hip (gluteals), flex the knee (hamstrings) and extend the knee (quadriceps) in the correct order to bring about a cycling motion. The feet and lower legs of the participants will be strapped into the pedals and the wheelchair will be coupled in a rigid manner with the training device.
11101754|NCT04064385|No Intervention|Control|Participants in the control group will receive usual care, consistent with standard NHS care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting approximately 90 minutes. Physiotherapists provide one to one function-oriented physiotherapy session to improve balance, muscle strength and transfer skills.
11101755|NCT04064372|Experimental|Mindful Response to Adversity|"The treatment condition will be trained in techniques designed to teach a mindful approach to adversity. These techniques will include: normalizing, attention, equanimity, non-judgment, de-centering, accepting of experiences, and impermanence. Participants will be instructed on the mindset, asked to write about an instance of non-judgment and share with a partner, and then guided through a short training designed to practice each skill."
11101756|NCT04064372|Active Comparator|Strength-based approach to adversity|The control condition will be trained in techniques designed to teach a typical narrative self-analysis / strengths-based approach to adversity. These techniques will include: choosing the best approach, minimizing stress, and identifying and enhancing personal strengths. Participants will be instructed on the mindset, asked to write about an instance of personal strength and share with a partner, and then guided through a short training designed to practice each skill.
11101757|NCT04064359|Experimental|OBT076 Dose Escalation and Expansion|OBT076 administered intravenously (IV) every 3 weeks in escalating dose cohorts during Part A and OBT076 administered at or below the MTD in the Part B expansion cohort.
11101758|NCT04064346|Experimental|Lixivaptan|Lixivaptan capsules, 100-200 mg twice a day (BID)
11101759|NCT04064346|Placebo Comparator|Placebo|Matching placebo capsules BID
11101760|NCT04064333|Experimental|Slow-Stream Expiratory Muscle Strength Training|The therapy protocol consists of 12 sets of five breaths through the EMST150 device per week, in sessions of three or four sets (15 or 20 breaths). A typical schedule might be one 15 breath session four days per week, or one 20 breath session three days per week.
11101761|NCT04064320|Experimental|Intervention group|Received lullaby intervention and usual care
11101762|NCT04064320|No Intervention|Control group|No intervention other than usual care
11101763|NCT04064294||Statin Before Levodopa|Historical use of a statin (simvastatin or lovastatin) BEFORE beginning levodopa
11101764|NCT04064294||Statin After Levodopa|Historical use of a statin (simvastatin or lovastatin) AFTER beginning levodopa
11101765|NCT04064294||No Statin|No historical use of a statin (simvastatin or lovastatin)
11101766|NCT04064281|Experimental|the healthy Cantonese diet|Based on the typical Cantonese diet, the healthy Cantonese diet is developed according to the DASH diet and the balanced dietary pattern of the Chinese Dietary Guidelines 2016. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set to achieve the healthy goal. Compared with the typical Cantonese diet, the healthy Cantonese diet is increased in fruit, vegetables, low-fat dairy products, whole grains, nuts and seeds, and reduced in salt, oil and sweets.
11101767|NCT04064281|Placebo Comparator|the typical Cantonese diet|The typical Cantonese diet is a diet of what many Cantonese eat. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set at the average dietary intake levels in Guangdong.
11101768|NCT04064268|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
11101769|NCT04064268|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
11101770|NCT04064268|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
11101771|NCT04064255|Active Comparator|Case: Practical Body Image + Treatment as Usual|"The Case arm involves Practical Body Image + treatment as usual.
~Practical Body Image is based on a cognitive behavioural model of body image addressing thoughts, feelings, behaviours and misperceptions. PBI is designed to be administered over 10 weeks (6 weekly sessions over 6 weeks, followed by 8 twice weekly sessions over 4 weeks).
~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
11101772|NCT04064255|No Intervention|Control: Treatment as Usual Only|"Control arm involves treatment as usual only.
~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
11101773|NCT04064242|Experimental|CMK389|CMK389
11101774|NCT04064242|Placebo Comparator|Placebo|Placebo
11101775|NCT04064229|Experimental|Infiltrated Tissue|The ivWatch Model 400 SmartTouch and fiber optic sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
11101776|NCT04064216||Robot assisted laparoscopic surgery|This group will be consisted of patients that will undergo robot assisted laparoscopic surgery for benign gynecologic disorders
11101777|NCT04064216||Conventional laparoscopic surgery|This group will be consisted of patients that will undergo conventional laparoscopic surgery for benign gynecologic disorders
11101778|NCT04064203|Experimental|Totally pancreatectomized patients|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
11101779|NCT04064203|Experimental|Healthy controls|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
11101780|NCT04064190|Experimental|Vactosertib+Durvalumab|Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.
11101781|NCT04064177||Babies (24-42 weeks)|All babies born between 24 and 42 weeks
11101782|NCT04064177||Preterm infants|Preterm infants with fetal growth restriction
11101783|NCT04064164|Experimental|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
11101784|NCT04064164|No Intervention|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
11101785|NCT04064151|Experimental|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
11101786|NCT04064151|No Intervention|Standard Medical Care|Standard clinical care with no smartphone intervention.
11101787|NCT04064138|Active Comparator|Peritoneal block|patients will receive peritoneal block as an adjuvant analgesic technique.
11101788|NCT04064138|Active Comparator|Ultrasound guided erector spinae plane block|Patients will receive ultrasound guided erector spinae plane block
11101789|NCT04064125|Experimental|FMX-101|
11101790|NCT04064112|Experimental|S-BLR|For S-BLR, the lower horn of the LR is recessed based on near exodeviation and the upper horn is recessed based on distant exodeviation.
11101791|NCT04064112|Active Comparator|C-BLR|For C-BLR, the LR is recessed based on distant exodeviation.
11101792|NCT04064099|Experimental|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
11101793|NCT04064086|Active Comparator|Comprehensive Pre-ESRD Patient Education (CPE)|These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
11101794|NCT04064086|Active Comparator|Enhanced Usual Care|This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
11101795|NCT04064073|Experimental|1|
11101796|NCT04064073|Experimental|2|
11101797|NCT04064073|Experimental|3|
11101798|NCT04064060|Experimental|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to subjects by the study staff at the clinical site and administration will be documented in the subject's source record.
11101799|NCT04064047|Active Comparator|External Anal application - 5 minutes exposure|Anal application of lidocaine cream 5% for 5 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
11101800|NCT04064047|Active Comparator|External Anal application - 10 minutes exposure|Anal application of lidocaine cream 5% for 10 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
11101801|NCT04064047|Active Comparator|External Anal application - 20 minutes exposure|Anal application of lidocaine cream 5% for 20 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
11101802|NCT04064047|Active Comparator|External Anal plus intrarectal - 5 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 5 minutes before probe insertion.
~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
11101803|NCT04064047|Active Comparator|External Anal plus intrarectal - 10 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 10 minutes before probe insertion.
~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
11101804|NCT04064047|Active Comparator|External Anal plus intrarectal - 20 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 20 minutes before probe insertion.
~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
11101805|NCT04064047|Sham Comparator|Control group|No anal application of lidocaine cream prior to probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
11101806|NCT04064034|Experimental|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
11101807|NCT04064034|Experimental|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
11101808|NCT04064034|Experimental|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
11101809|NCT04064021|Experimental|Acupuncture|Acupuncture 12 sessions over 6 week to be given to pateints
11101810|NCT04064008||Primary Total Hip Arthroplasty|Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem
11101811|NCT04063995|Experimental|Excitatory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment with 10 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in excitation. Stimulation is planned for a total of 15 minutes and a total of 1500 beats in the form of a 5 seconds 10 Hz stimulation followed by a 25 seconds interval.
11101812|NCT04063995|Experimental|Inhibitory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in excitation. Stimulation is planned for a total of 25 minutes and a total of 1500 beats in the form of 1 Hz stimulation.
11101813|NCT04063995|Sham Comparator|Sham repetitive transcranial magnetic stimulation group|Single session of sham application for a total of 25 minutes. Sham application will be performed by holding the probe of the device vertically to the vertex. The device will be operated at the lowest operating power of 1 to produce the same stimulation sounds like the active application. The device operating at this power is not likely to give any stimulation due to the probe being held upright.
11101876|NCT04063475|Experimental|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
11102223|NCT04060927|Experimental|Group 3|Breath hold SBRT with SGRT in combination with implanted fiducials
11101814|NCT04063969||Endovascular team members|"All vascular surgeons, surgical trainees, nurses active in the hybrid angiography suite at one of the participating centers will be invited to participate in the study.
~All participating team members complete an online questionnaire containing an assessment of their perceived radiation safety climate (28 items, 5 dimensions), radiation safety behaviors(2 items, 2 dimensions), radiation safety knowledge (single item) and radiation safety motivation (single item). All data will be stored pseudonymized."
11101815|NCT04063969||Vascular surgical patients|"In each center, five patients undergoing primary elective endovascular repair for an infrarenal abdominal aortic aneurysm (EVAR) will be enrolled in the study.
~For each participating patient, a set of demographical (BMI, case difficulty, ASA-grade,etc.), procedure-related (procedure duration, contrast use, etc.) and radiation dose parameters (DAP, cumulative air kerma) will be collected and stored in a pseudonymized way.
~Participation in this study has no effect on the interventional procedure, or the chosen approach."
11101816|NCT04063956|Experimental|Cognitive training group|Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 4 x 40 minutes per week, for 12 weeks.
11101817|NCT04063956|Active Comparator|Active-control group|Fixed, primary difficulty level tasks. 4 x 40 minutes per week, for 12 weeks.
11101818|NCT04063943|Experimental|Arms|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
11101819|NCT04063930|Active Comparator|Lokelma|"Sodium zirconium cyclosilicate Lokelma® 5 g, powder (Astra Zeneca)
~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.
~Duration: 12 weeks"
11101820|NCT04063930|Placebo Comparator|Placebo|"Matching placebo (indistinguishable from the active comparator)
~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.
~Duration: 12 weeks"
11101821|NCT04063917|Experimental|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
11101822|NCT04063917|Experimental|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
11101823|NCT04063904|Experimental|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
11101824|NCT04063891|Placebo Comparator|Placebo-Controlled|Placebo group will have placebo treatment by standing on the LMHFV platform for 20 minutes/day
11101825|NCT04063891|Experimental|Vibration Group|Vibration group is treated with LMHFV at 35Hz, 0.3g, for 20 minutes/day, 5 times/week
11101826|NCT04063878|Experimental|Single tooth restorations using Acuris conometric concept|
11101827|NCT04063865|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
11101828|NCT04063865|Experimental|Study Arm|Everolimus monotherapy maintenance immunosuppression
11101829|NCT04063826|Other|PET MRI Scan|Imaging scan of the liver
11101830|NCT04063813|Experimental|40 minute up trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree incline and at 75% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
11101831|NCT04063813|Experimental|40 minute down trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree decline and at 45% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
11101832|NCT04063813|Experimental|Two 20 minute up trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 75% of maximal effort, the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h..Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
11101833|NCT04063813|Experimental|Two 20 min down trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 45% of maximal effort , the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
11101834|NCT04063813|Active Comparator|Sedentary trial|No exercise day with isocaloric meals provided at 7:00, 13:00. and 19:00 h.
11101835|NCT04063787|Experimental|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.
~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
11101836|NCT04063774|Experimental|Dengue diagnostic algorithm|single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)
11101837|NCT04063761|Experimental|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
11101838|NCT04063748|Experimental|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
11101839|NCT04063748|Placebo Comparator|Placebo|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
11101840|NCT04063735|Experimental|Experimental group|supplement was given for 3 months.
11101841|NCT04063735|Placebo Comparator|Placebo group|Placebo was given for 3 months.
11101874|NCT04063514|Experimental|Focused Ultrasound and Microbubble Infusion|The ultrasound treatment will last either 1 hour or 20 minutes total time for the DWL device. An infusion of Definity microbubbles will be infused intravenously over ten to thirty minutes as per routine approved application. Definity will be 1.3 mL added to 50 mL saline and infused no faster than 4 mL/minute.
11102224|NCT04060914|Experimental|Ticagrelor(90mg)|
11101842|NCT04063722|Experimental|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
11101843|NCT04063722|Active Comparator|webester procedure|periareolar incision with excision of the breast tissue
11101844|NCT04063709|Experimental|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
11101845|NCT04063709|Experimental|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
11101846|NCT04063709|Experimental|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
11101847|NCT04063709|Experimental|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
11101848|NCT04063683|Experimental|Anlotinib with chemotherapy|
11101849|NCT04063670|Active Comparator|Control|Routine, standard-of-care treatment
11101850|NCT04063670|Experimental|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
11101851|NCT04063657|Active Comparator|External fixation|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
11101852|NCT04063657|Active Comparator|Splinting|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.
11101853|NCT04063644|Experimental|Vis Glyc Neo|"Vis glyc eye drops is administered.
~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
11101854|NCT04063644|Active Comparator|physiological saline solution|Physiological saline solution ALVITA is administered.
11101855|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
11101856|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
11101857|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
11101858|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
11101859|NCT04063618|Experimental|Osteopathic Manipulative Therapy (OMT) Treatment Group|Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
11101860|NCT04063618|Active Comparator|Standard of care concussion treatment group|Standard of care concussion treatment without OMT
11101861|NCT04063605|Experimental|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
11101862|NCT04063605|Active Comparator|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
11101863|NCT04063592|Experimental|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
11101864|NCT04063579|Experimental|Patients with heart failure with preserved ejection fraction|
11101865|NCT04063579|Experimental|Non-heart failure patients|
11101866|NCT04063579|Experimental|Normal Volunteers|
11101867|NCT04063566|Other|Total cohort|The study will consist of one group, one arm, all receiving the same screening procedures.
11101868|NCT04063553|Other|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
11101869|NCT04063553|Other|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
11101870|NCT04063540|Other|placebo-amiloride|Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
11101871|NCT04063540|Other|amiloride -placebo|Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
11101872|NCT04063527|Active Comparator|Standard therapy|combination of paclitaxel and carboplatin
11101873|NCT04063527|No Intervention|Observation|Observation
11101875|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
11102225|NCT04060914|Experimental|Ticagrelor(90/60mg)|
11101877|NCT04063462|Experimental|Cohort 1|Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC
11101878|NCT04063462|Experimental|Cohort 2|Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC
11101879|NCT04063449|Experimental|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
11101880|NCT04063449|Active Comparator|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
11101881|NCT04063436|Experimental|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
11101882|NCT04063423||hemodialysis study session|"4h hemodialysis session using standard polysulphone dialyzer and Nikkiso dialysis monitors
~Minimal dose of unfractionated heparin (UFH) with loading dose 500IE and maintenance 500IE/h, stopped 60 minutes before session end in case of AVF use.
~Standard bicarbonate-based ultrapure dialysate. Na, K, Ca, bicarbonate concentrations according to the patient's routine dialysis prescription.
~The blood flow rate maximized as per routine nursing care.
~Dialysate flow rate fixed at 500 ml/min.
~Dialysate temperature between 35.5°C and 36.5°C.
~Ultrafiltration according to patient's dry weight and supported ultrafiltration rate.
~At the end of the dialysis session the blood will be returned (100ml/min) to the patient."
11101883|NCT04063410|Experimental|Screening (pPCA)|Patients undergo standard of care CTA and undergo pPCA MRI for up to 60 minutes before surgery.
11101884|NCT04063397||Preeclampsia with severe features|20 patients diagnosed with preeclampsia with severe features
11101885|NCT04063397||Preeclampsia without severe features|20 patients diagnosed with preeclampsia without severe features
11101886|NCT04063397||Control|Control group of patients without hypertensive disorders of pregnancy
11101887|NCT04063384|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
11101888|NCT04063384|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
11101889|NCT04063371|No Intervention|Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
11101890|NCT04063371|Experimental|Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
11101891|NCT04063371|No Intervention|Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
11101892|NCT04063358|Experimental|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
11101893|NCT04063358|Active Comparator|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
11101894|NCT04063358|Experimental|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
11101895|NCT04063345|Experimental|IVUS-guided PCI|Percutaneous intervention under IVUS-guidance
11101896|NCT04063345|Active Comparator|Angiography-guided PCI|Percutaneous intervention under angiograhy-guidance only
11101897|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
11101898|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
11101899|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
11101900|NCT04063319|Experimental|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
11101901|NCT04063319|No Intervention|Control|The participants in the control group will not receive any instructional intervention
11101902|NCT04063293|Experimental|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
11101903|NCT04063280|Experimental|Snare Tip Soft Coagulation (STSC)|
11101904|NCT04063280|Active Comparator|Argon Plasma Coagulation (APC)|
11101905|NCT04063280|No Intervention|No Treatment|
11101906|NCT04063267|Experimental|E cigarettes|
11101907|NCT04063267|Active Comparator|Nicotine Replacement Therapy|
11101908|NCT04063254|Experimental|High-Dose Stereotactic Radiotherapy|
11101909|NCT04063254|Active Comparator|Standard-Dose Stereotactic Radiotherapy|
11101910|NCT04063241|No Intervention|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
11101911|NCT04063241|Experimental|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
11102226|NCT04060914|Active Comparator|Clopidogrel(75mg)|
11101912|NCT04063241|Other|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
11101913|NCT04063228|Active Comparator|Standard of care|
11101914|NCT04063228|Active Comparator|Simple Skill Group|
11101915|NCT04063215|Experimental|HB-adMSC|HB-adMSCs will be infused three times over a six week period, spaced 14 days apart
11101916|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
11101917|NCT04063189|Experimental|First Relapsed Multiple Myeloma|
11101918|NCT04063163|Experimental|A|HLX 10+chemotherapy (Carboplatin-Etoposide)
11101919|NCT04063163|Placebo Comparator|B|Placebo+chemotherapy (Carboplatin-Etoposide)
11101920|NCT04063150|Active Comparator|IPV at 14 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 14 weeks and 9 months of age.
11101921|NCT04063150|Active Comparator|IPV at 6 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 6 weeks and 9 months of age.
11101922|NCT04063150|Active Comparator|fIPV ID at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
11101923|NCT04063150|Active Comparator|fIPV ID at 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
11101924|NCT04063150|Active Comparator|fIPV IM at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
11101925|NCT04063150|Active Comparator|fIPV 0.1mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
11101926|NCT04063150|Active Comparator|fIPV 0.2mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.2 mL) of IPV at 14 weeks and 9 months of age.
11101927|NCT04063137|Active Comparator|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
11101928|NCT04063137|Placebo Comparator|White bread|
11101929|NCT04063124|Experimental|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
11101930|NCT04063111|Active Comparator|group A|Group A will be treated with vacuum assistant closure
11101931|NCT04063111|Active Comparator|group B|Group B will be treated with conventional dressing
11101932|NCT04063098|Other|All participants|Participants scheduled for endoscopic sleeve gastroplasty
11101933|NCT04063085|Experimental|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
11101934|NCT04063085|Active Comparator|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
11101935|NCT04063085|Sham Comparator|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
11101936|NCT04063085|Active Comparator|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
11101937|NCT04063085|Active Comparator|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
11101938|NCT04063072|No Intervention|Usual care|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to current hospital clinical practice.
11101939|NCT04063072|Experimental|ERAS protocol|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to ERAS protocol.
11101940|NCT04063059|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
11101941|NCT04063059|No Intervention|Control|Usual care
11101942|NCT04063046|Active Comparator|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
11101943|NCT04063046|Experimental|peripheral nerve block|popliteal sciatic nerve block
11101944|NCT04063033|Experimental|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
11101945|NCT04063033|No Intervention|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
11101946|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
11101947|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
11101948|NCT04062994||Intervention Group|All patients scheduled for surgery at a UCLA site in the one year period after go-live
11101949|NCT04062981|Experimental|Cohort I|"Subjects ≥ 18 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
11101950|NCT04062981|Experimental|Cohort II|"Subjects 12 to <18 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
11101951|NCT04062981|Experimental|Cohort III|"Subjects 6 to <12 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
11101952|NCT04062981|Experimental|Cohort IV|"Subjects 2 to <6 years of age
~These subjects will reach maximum stable dose and continue onto YKP509C002."
11101953|NCT04062968|Experimental|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
11101954|NCT04062968|No Intervention|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
11101955|NCT04062955|Experimental|Prevention (dietary intervention)|"DIETARY INTERVENTION: Participants receive dietary counseling with a dietitian in person or via telephone to support adherence to a diet based on the AHEI guidelines once weekly for up to 12 weeks.
~DXA ONLY STUDY: Participants undergo DXA scan for breast density measurement at baseline and at 12 weeks."
11101956|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
11101957|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
11101958|NCT04062916||women with endometriosis|65 women whose main symptom was pain and who did not respond to medical treatment and underwent endometriosis surgery
11101959|NCT04062903|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
11101960|NCT04062903|Active Comparator|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
11101961|NCT04062890|Active Comparator|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
11101962|NCT04062890|Placebo Comparator|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
11101963|NCT04062851|No Intervention|GRV group|Gastric residuals will be checked prior to feeds
11101964|NCT04062851|Experimental|NO GRV group|Gastric residuals will not be checked prior to feeds
11101965|NCT04062838|Experimental|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
11101966|NCT04062825||VIH positive patients without lymphoma|200 VIH positive patients without lymphoma
11101967|NCT04062825||VIH positive patients with lymphoma|20 VIH positive patients with lymphoma
11101968|NCT04062825||healthy volunteers|20 healthy volunteers
11101969|NCT04062799||Study cohort|
11101970|NCT04062773|Experimental|TRF|Eating restricted to between midday and 6pm.
11101971|NCT04062773|Placebo Comparator|Normal timing of food intake.|Eating between 8am and 11pm.
11101972|NCT04062760|Active Comparator|Standard diuretic therapy (SDT)|Furosemide +/- spironolactone or potassium canrenoate
11101973|NCT04062760|Experimental|Early sequential nephron blockade (ESNB)|Furosemide + metolazone + acetazolamide +/- spironolactone or potassium canrenoate
11101974|NCT04062747|Active Comparator|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
11101975|NCT04062747|Active Comparator|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
11101976|NCT04062721|Experimental|Chemotherapy + RFA + in situ immunotherapy|Chemotherapy + RFA + in situ immunotherapy in patients with non resectable CRC liver-only metastases.
11101977|NCT04062708|Experimental|Treatment|Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.
11101978|NCT04062695|Active Comparator|Tofacitinib|5 mg oral BID
11101979|NCT04062695|Placebo Comparator|Placebo|matching Placebo BID
11101980|NCT04062682|No Intervention|Controls|No changes in diet or physical activity habits
11101981|NCT04062682|Experimental|Healthy Diet|Changes in dietary habits only
11101982|NCT04062669|Experimental|Low dose (Ld-) RG SAM (CNE) group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Days 1 and 61).
~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181)"
11101983|NCT04062669|Experimental|Medium dose (Md-) RG SAM (CNE) group|Healthy adults,18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) medium dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Day 1.
11101984|NCT04062669|Experimental|Lower dose (Lrd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lower dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181)
11101985|NCT04062669|Experimental|Lowest dose (Ltd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lowest dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181)
11101986|NCT04062669|Placebo Comparator|Saline Placebo group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive two intramuscular injections of saline placebo, one in each arm, according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181).
~In Part 2 of the study, healthy adults, 18 to 40 years of age will receive one intramuscular injections of saline placebo in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181)."
11102126|NCT04061564|Sham Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be administered sham stimulation to each ear (20 minutes in total)
11101987|NCT04062669|Active Comparator|RabAvert group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm and one intramuscular injection of saline solution in the other arm, according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181).
~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181)."
11101988|NCT04062656|Active Comparator|A - Flot|FLOT-chemotherapy pre- and postoperative 4 cycles (i.v., q2w)
11101989|NCT04062656|Experimental|B - Nivolumab|"Responders
~6 preoperative cycles nivolumab (i.v., 240mg, q2w)
~4 postoperative cycles nivolumab (i.v., 240mg, q2w)
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)
~Non-responders
~2 preoperative cycles nivolumab (i.v., 240mg, q2w)
~4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative
~followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
11101990|NCT04062656|Experimental|C - Nivolumab + Ipilimumab|"Responders
~6 preoperative cycles nivolumab (i.v., 240mg, q2w)
~2 preoperative cycles ipilimumab (i.v., 1mg/kg bw, q6w)
~4 postoperative cycles of nivolumab (i.v., 240mg, q2w), 2 cycles of ipilimumab (i.v.,1mg/kg bw, q6w)
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)
~Non-responders
~2 preoperative cycles nivolumab (i.v.,240 mg, q2w)
~1 preoperative cycle ipilimumab (i.v., 1mg/kg, q6w)
~4 additional cycles nivolumab (i.v.,240 mg, q2w) +FLOT (i.v., q2w) preoperative and 1 optional cycle of ipilimumab (i.v., 1mg/kg bw, q6w)
~4 additional cycles nivolumab (i.v.,240 mg, q2w) +FLOT (i.v., q2w) postoperative and 2 optional cycles of ipilimumab (i.v., 1mg/kg bw, q6w)
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
11101991|NCT04062656|Experimental|D - Nivolumab + relatlimab|"Responders
~6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)
~4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)
~Non-responders
~2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)
~4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative
~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
11101992|NCT04062643||Patients with obesity|Obesity in those with BMI ≥30 kg/m2
11101993|NCT04062643||Patients without obesity|Normal weight was considered in the patients with BMI <30 kg/m2
11101994|NCT04062630|Active Comparator|Standard care|Multilevel Lumbar Fusion Surgery
11101995|NCT04062630|Experimental|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
11101996|NCT04062604||Femur fracture|Stabilization of femur fracture according to the AO fundation guidelines
11101997|NCT04062604||Hip alloplasty|Endoprothesis
11101998|NCT04062604||Knee alloplasty|Endoprothesis
11101999|NCT04062604||Knee arthroscopy|Resection of the meniscus lesion or anterior cruciatus ligamentum reconstruction
11102000|NCT04062591|Active Comparator|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
11102001|NCT04062591|Sham Comparator|placebo|saline IM in the same dose of piroxicam
11102002|NCT04062578|Experimental|CD Oliver|Female first team players of the club that plays in the National Second Division league.
11102003|NCT04062578|Active Comparator|SD Huesca|Female first team players who play in the Aragonese Territorial First league
11102004|NCT04062565|Experimental|Experimental|Treprostinil and Riociguat
11102005|NCT04062552|Experimental|Group I (ENABLE palliative care program, phone calls, VLC)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for 15 months.
11102006|NCT04062552|Experimental|Group II (ENABLE palliative care program, phone calls, TA)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for 15 months.
11102007|NCT04062526|Experimental|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.
~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
11102008|NCT04062526|Experimental|Healthy Control|Subject must be a Healthy.
11102009|NCT04062513|Experimental|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
11102010|NCT04062513|Experimental|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
11102011|NCT04062513|Other|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
11102012|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
11102013|NCT04062487|Experimental|Lumbar pedicle screws implantation of traditional procedure|traditional method of lumbar pedicle screws implantation
11102014|NCT04062474|Experimental|Epidural Intervention with Steroids|Epidural Intervention with Steroids
11102015|NCT04062461|Experimental|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.
~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).
~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
11102016|NCT04062461|Active Comparator|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
11102127|NCT04061551|Experimental|EC Clinic Support|Whole of practice interventions delivery through nurse-led model
11102017|NCT04062448|Experimental|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
11102018|NCT04062435|Experimental|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX
~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
11102019|NCT04062435|Active Comparator|Control Group|"Peschke®TE 0.25 % application on the CORNEA
~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
11102020|NCT04062409||Sickle cell patients|
11102021|NCT04062409||Asmathic patients|
11102022|NCT04062396|Active Comparator|Eurosets REMOWELL 2 oxygenator|
11102023|NCT04062396|Active Comparator|LivaNova INSPIRE oxygenator|
11102024|NCT04062383|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
11102025|NCT04062370|Experimental|1+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 1 time ( month 1), and then IVR is required if central macular thickness (CMT) greater than 300 μm during the follow-up observation (Pro re nata, PRN, means if necessary).
~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.
~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.
~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
11102026|NCT04062370|Active Comparator|3+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 3 consecutive times ( months 1, 2 and 3 ),and then IVR is required if CMT greater than 300 μm during the follow-up observation (PRN).
~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.
~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.
~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
11102027|NCT04062357|Active Comparator|lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
11102028|NCT04062357|Placebo Comparator|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).
11102029|NCT04062344||Short oral drug provocation test|Minors performing a short (1-4 days) drug provocation test
11102030|NCT04062344||Prolonged oral drug provocation test|Minors performing a prolonged (5-8 days)drug provocation test
11102031|NCT04062331|Placebo Comparator|Placebo group|This group will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) without any frequency (device doesn't running; it means, device turned off) but the same duration of sessions.
11102032|NCT04062331|Experimental|Group under TMS 1 Hertz treatment|1 Hertz group (1 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 1 Hertz.
11102033|NCT04062331|Experimental|Group under TMS 5 Hertz treatment|5 Hertz group (5 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 5 Hertz .
11102034|NCT04062318|Experimental|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
11102035|NCT04062318|Active Comparator|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region unrelated to our primary target of interest (somatosensory cortex) during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
11102036|NCT04062305|Experimental|Diagnostic (nTMS, sensory testing)|Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
11102037|NCT04062292||Obstructive lung diseases group|"Having been diagnosed with obstructive pulmonary disease,
~No acute exacerbation or infection in the past 1 week, Being between the ages of 18 and 65,"
11102038|NCT04062292||Healthy group|Age and sex matched healthy subjects without orthopedic and chronic diseases
11102039|NCT04062279||case group|patients diagnosed with idiopathic paaarkinson's disease according to the clinical criteria.
11102040|NCT04062266|Experimental|Treatment (azacytidine, venetoclax)|Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11102041|NCT04062253||HCV or HIV negative|Individuals who test negative for HCV or HIV are given information regarding ways of transmission.
11102042|NCT04062253||HCV and HIV positive|Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.
11102043|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
11102128|NCT04061538|Experimental|Zinc sulfate|Zinc sulfate 20 mg by mouth, once a day for 10 days
11102044|NCT04062214|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
11102045|NCT04062214|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
11102046|NCT04062201|Experimental|Study Strategy|
11102047|NCT04062201|Active Comparator|Control Strategy|
11102048|NCT04062175|Active Comparator|cephalosporin arm|72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision
11102049|NCT04062175|Active Comparator|cephalosporin +azithromycin arm|72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
11102050|NCT04062162|Active Comparator|Interventional group|Walking football training
11102051|NCT04062162|No Intervention|Control group|Usual care
11102052|NCT04062149|Active Comparator|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
11102053|NCT04062149|Experimental|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
11102054|NCT04062136|Experimental|Stem cell transplantation|1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
11102055|NCT04062123|Experimental|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
11102056|NCT04062123|Experimental|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
11102057|NCT04062123|Experimental|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
11102058|NCT04062110|Active Comparator|Long plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with long plaster casts (above-elbow, Long plaster casts).
11102059|NCT04062110|Active Comparator|Short plaster casts for type AO 2R3A2.2|Closed reduction of the fracture and immobilization with short plaster casts (below-elbow, Short plaster casts)
11102060|NCT04062097||dabigatran-group|Patients with the anticoagulating therapy dabigatran and onset of clinically symptomatic intracranial hemorrhage, that is treated with idarucizumab.
11102061|NCT04062097||VKA-group|Patients under effective treatment with VKA and with intracranial hemorrhage.
11102062|NCT04062084|Experimental|Multifunctional Cataract-assisted Retractor|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
11102063|NCT04062084|Experimental|Capsule Retractor|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
11102064|NCT04062058|Experimental|Total Neoadjuvant Chemoradiotherapy|Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery
11102065|NCT04062045|Experimental|Group A - Local anesthetic group|Group A will receive a continuous infusion of ropivacaine 0,2% 5ml/h and intermittent boluses of the same local anesthetic 15ml/4h through the erector spinae catheter.
11102066|NCT04062045|Placebo Comparator|Group B - Placebo group|Group B will receive a continuous infusion of 0,9% saline 5ml/h and intermittent boluses of the same fluid 15ml/4h through the erector spinae catheter.
11102067|NCT04062032|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 7 days
11102068|NCT04062032|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 7 days.
11102069|NCT04062019|Experimental|interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 once every other day, for 3 months.
11102070|NCT04062006|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
11102071|NCT04061993|Experimental|Intervention Group OBV|Intervention Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
11102072|NCT04061993|Active Comparator|Control Group OBV|Control Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
11102073|NCT04061993|Experimental|Intervention Group SBNM|Intervention Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
11102074|NCT04061993|Active Comparator|Control Group SBNM|Control Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
11102075|NCT04061980|Experimental|Arm I (encorafenib, binimetinib)|Patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11102076|NCT04061980|Experimental|Arm II (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD and binimetinib PO BID as in arm I. Patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11102077|NCT04061967|Other|HPV self sampling test ordered|An invitation to order a HPV self sampling test through an online application will be sent by SMS
11102078|NCT04061954|Experimental|Intervention group|"Families in the intervention group received:
~Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts
~Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children
~Trauma-focused therapies
~Parents receive training regarding agriculture and micro credit projects, and financial assistance
~One child per family receives a social skill training group preparing them for returning to school
~Access to schools and school material
~If needed medical assistance is provided
~If needed legal assistance is provided"
11102079|NCT04061954|No Intervention|No intervention group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
11102080|NCT04061941||Stimulant Users|Stimulant users that fulfill SCID-5 clinician version definition for assessment on stimulant use disorder under DSM-5
11102081|NCT04061928|Experimental|Combination of toripalimab with preoperative chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive toripalimab and combined with preoperative chemoradiotherapy and operation.
~generic name：PD-1 dosage form：Injection dosage：240mg (6ml) frequency：every 3 weeks duration：4 times before operation and 4 times after operation"
11102082|NCT04061915|Experimental|Infographic Intervention|Emerging adults randomized to the online intervention arm will review the self-testing infographic. Once participants finish reviewing, they will answer comprehension and preference questions about the self-testing infographic.
11102083|NCT04061915|Active Comparator|Control|Emerging adults randomized to the online control arm will read paper-based HIV self-testing information.
11102084|NCT04061876|Experimental|Ruxolitinib combined with Corticosteroids|Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
11102085|NCT04061876|Active Comparator|Corticosteroids|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
11102086|NCT04061863|Experimental|ER+/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
11102087|NCT04061863|Experimental|ER-/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
11102088|NCT04061837|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
11102089|NCT04061824|Experimental|Patients with fixed-dose combination of 2 drugs|Medication for hypertension and dyslipidemia in these group was fixed-dose combination of 2 drugs
11102090|NCT04061824|Active Comparator|Patients with 2 separated drugs|Medication for hypertension and dyslipidemia in these group was 2 separated drugs for each disease.
11102091|NCT04061811||HF (heart failure)|Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.
11102092|NCT04061811||Control|Patients with end stage renal disease requiring dialysis without HF.
11102093|NCT04061798|Experimental|ACT guided heparinization|Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
11102094|NCT04061798|Active Comparator|5 000 IU of heparin|A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.
11102095|NCT04061785|Active Comparator|Participants in 16 week Judo Inspired Exercise program|"The subjects will participate in a 16 week judo inspired training program (45 minute sessions once a week) with the specific aim to increase physical qualities related to falls and injuries during falls.
~The subjects will be tested before and after the 16 week period"
11102096|NCT04061785|No Intervention|Control Group|The subjects will go about their normal life for 16 weeks without any intervention. The persons will be tested before and after the 16 week period.
11102097|NCT04061772|Experimental|BCHEP|Bortezomib：1.3mg/m2, intravenous drip, d1,d8, every 3 weeks； Etoposide：100mg/m2,intravenous drip, d1-3, every 3 weeks； Cyclophosphamide：750mg/m2,intravenous drip, d1, every 3 weeks； Pharmorubicin：75mg/m2,intravenous drip, d1,every 3 weeks； Prednisone：100mg,tablet by mouth, d1-5, every 3 weeks.
11102098|NCT04061759|Active Comparator|Soft tissue mobilization&stabilization exercises|"The following manual therapy techniques will be applied:
~Soft Tissue Mobilization;
~Pretzel Maneuvers;
~Pelvis Backward-Distraction;
~Trunk Rotation;
~Multifidus Mobilization; and
~Piriformis Transverse Friction Massage"
11102099|NCT04061759|Active Comparator|Kinesiotape&stabilization exercises|The Kinesio® Taping muscle technique, with 10-25% of the stretch of the tape, will be applied to the sacrospinalis, quadratus lumborum, gluteus medius/maximus and piriformis muscles, based on the the weakness that patient's muscles had. Factors interfering with tape adhesion, such as sweat or hair, will be removed before the application. The tape can stay in place for 3-5 days due to its water resistant and breathable properties
11102129|NCT04061538|Placebo Comparator|Placebo|Placebo tablet, once a day for 10 days
11102130|NCT04061525||Patients with coronary bifurcation lesions|Patients from 18 to 90-years old with coronary bifurcation lesions with significant >50% diameter stenosis artery scheduled for intervention of the main vessel (Medina types: 1x1, x11, 111)
11102131|NCT04061512|Active Comparator|DRC Arm|The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.
11102317|NCT04060277|Active Comparator|Arm II (letermovir, placebo)|Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
11102100|NCT04061759|Active Comparator|Stabilization exercises|The core stabilization exercise treatment program consisted of the following exercises: a posterior pelvic tilt exercise, lower abdominal muscle isometric strengthening, hip adductor muscle isometric strengthening, lumbar stabilization exercises with a Swiss ball, upper and lower abdominal muscle strengthening exercises with a Swiss ball, oblique abdominal muscle strengthening exercises with a Swiss ball, quadratus lumborum muscle stretching with a Swiss ball, back extensor muscle strengthening exercises with a Swiss ball, a slump exercise (sciatic nerve stretching), lumbar lordosis exercises with a Swiss ball, bridge exercises with a Swiss ball, single leg bridge exercises on a Swiss ball, posture exercises, push-up exercises with a Swiss ball, and squat exercises with a Swiss ball
11102101|NCT04061759|Active Comparator|Reflex therapy&Stabilization exercises|Mobilization of each vertebra and pulls were applied from the medial side of the toe to the medial malleolus and to the heel by hand or with the help of an apparatus, including the cervical, thoracic and lumbar spine reflex zones. Finally, the procedure was finished by making a V-shaped maneuver with a thumb in the direction of spinal nerve exits.
11102102|NCT04061746|Experimental|Group A Treatment|2.5 x 10^6 MSC per kg will be infused intravenously on Day 1
11102103|NCT04061746|Placebo Comparator|Group B Placebo|Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1
11102104|NCT04061733|Experimental|Experimental|Subjects who will receive an injection of the hydrogel
11102105|NCT04061720|Experimental|Enhanced Chronic Care|Enhanced Chronic Care provides ongoing, phone-based motivational interventions and interpersonal support to promote readiness to quit, with facilitated access to evidence-based smoking treatment.
11102106|NCT04061720|Active Comparator|Standard Care|Standard Care provides phone-based brief advice to quit once per year.
11102107|NCT04061694|Experimental|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
11102108|NCT04061694|Other|Immediate loading|Historic cohort subjected to immediate loading
11102109|NCT04061681|Experimental|Behavioral Intervention (BIPAMS)|Participants will complete a 16-week behavioral intervention to increase physical activity levels.
11102110|NCT04061681|No Intervention|Waitlist Control|Participants will have 16-weeks of no intervention or interaction.
11102111|NCT04061668|Other|single needle path PECS I and II block group(|The probe is placed inferior to the clavicle . A probe and needle is introduced with in-plane technique . The US is placed below outer third of the clavicle showing pectoralis major and minor muscles then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles is visualised . The US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle is inserted from caudal to cranial using an inclined manner, 15mL of bupivacaine 0.25% is put between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject 15 ml of bupivacaine in thel plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection will be visualized .
11102112|NCT04061668|Sham Comparator|double needle path PECS I and II block group|The probe will be placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles are visualised, then the needle is inserted in plane with probe and 15mL of bupivacaine are put into between pectoralis muscles. In the second puncture , the US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles are identified , the needle will be inserted in plane with the probe from caudal to cranial , 15mL of bupivacaine will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
11102113|NCT04061655|Active Comparator|iron therapy group|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
11102114|NCT04061655|Placebo Comparator|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
11102115|NCT04061642|Experimental|Clinical Decision Aid|
11102116|NCT04061629||Group C|Size of the cuffed ETT based on the Cole formula = (Age/4) + 4.
11102117|NCT04061629||Group D|size of the cuffed ETT based on the Duracher formula = (Age/4) + 3 + 0.5 mm.
11102118|NCT04061629||Group K|size of the cuffed ETT based on the Khine formula = (Age/4) + 3.
11102119|NCT04061616|Experimental|Participants|All the participants volunteer to participate to the study that were included.
11102120|NCT04061603|Experimental|iCLAS Ablation|Ablation of the left and right atrium with the Adagio Medical iCLAS System
11102121|NCT04061590|Experimental|Cohort A (pembrolizumab)|Patients receive 200mg pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
11102122|NCT04061590|Experimental|Cohort B (pembrolizumab, cisplatin pemetrexed)|Patients receive 200mg pembrolizumab IV over 30 minutes and chemotherapy (cisplatin/pemetrexed) IV on day 1. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 4 weeks following study treatment.
11102123|NCT04061577|Experimental|Stimulation arm|"Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers:
~Tier 1 - 1 mA, and Tier 2- 2 mA: Consist of a single stimulation cycle (20min) after the endovascular procedure (EVT) in patients with TICI<2c,3 and negative immediate post-EVT CT scan for definitive evidence of ICH.
~Tier 3 - 1 mA and Tier 4- 2mA consist of 2 treatment cycles after the EVT in patients with TICI<2c and 3, and negative immediate post-EVT CT scan for definitive evidence of ICH.
~Tier 5 - 1 mA and tier 6- 2 mA consist of 3 treatment cycles. The first cycle will be up to 20 min cycle, after initial imaging and prior to arterial puncture, the second and third cycles after EVT in patients with TICI<2c and 3 and negative immediate post-EVT CT scan for definitive evidence of ICH."
11102124|NCT04061577|Sham Comparator|Sham arm|Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without delivery of electrical stimulation.
11102125|NCT04061564|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be administered vagal nerve stimulation to each ear (20 minutes in total)
11102132|NCT04061512|Experimental|RI Arm|The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.
11102133|NCT04061499||Hip OA|Individuals with diagnosed hip osteoarthritis
11102134|NCT04061499||Control|Individuals without diagnosed hip osteoarthritis
11102135|NCT04061486||Experimental arm|One half of the oocyte cohort is microinjected with sperm selected by the Fertile technique, while the other half of the patient's oocyte cohort is microinjected with sperm selected by the MACS technique.
11102136|NCT04061473|Placebo Comparator|Pancreatectomized + Placebo|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
~Before the meal (1 h and 12 h) 1+1 placebo tablets will be administered orally."
11102137|NCT04061473|Active Comparator|Pancreatectomized + DPP-4 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
~Before the meal (1 h and 12 h) 1+1 DPP4-inhibitor tablets will be administered orally."
11102138|NCT04061473|Active Comparator|Pancreatectomized + SGLT-2 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
~Before the meal (1 h and 12 h) 1+1 SGLT-2 tablets will be administred orally."
11102139|NCT04061473|Placebo Comparator|Healthy + Placebo|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
11102140|NCT04061473|Active Comparator|Healthy + DPP-4 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
11102141|NCT04061473|Active Comparator|Healthy + SGLT-2 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
11102142|NCT04061460|Other|non smokers|patient who never smoked
11102143|NCT04061460|Other|former smoker|patient who smoked in the past
11102144|NCT04061460|Other|smoker|patient who still smoke
11102145|NCT04061447|Experimental|susceptibility-guided therapy|In the group of the empirical triple therapy, patients received rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
11102146|NCT04061447|Active Comparator|empirical clarithromycin-based triple therapy|In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
11102147|NCT04061434||Cardiac resynchronisation therapy recipients|
11102148|NCT04061434||Other cardiac implantable electronic devices recipients|
11102149|NCT04061421|Experimental|ASTX727 + itacitinib|ASTX727 and itacitinib will be taken by mouth
11102150|NCT04061421|Experimental|ASTX727 + INCB053914|ASTX727 and INCB053914 will be taken by mouth
11102151|NCT04061421|Experimental|ASTX727 + INCB059872|ASTX727 and INCB059872 will be taken by mouth
11102152|NCT04061408|Experimental|FSRT|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
11102153|NCT04061395|Experimental|Guselkumab|Guselkumab 200 mg Q4W; subcutaneous injections; duration of 16 weeks.
11102154|NCT04061382||Randomised selection of population - Group 1|Group 1 will be focusing on COVID-19, diphtheria and group C invasive meningococcal disease. The investigators are aiming to recruit around 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). PHE have generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visits. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history.The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
11102155|NCT04061382||Group 2|"Group two will focus on 0-19 year olds only. They will not be restricted to the post code sampling. Instead this will include standard recruitment methods such as social media advertisements within the normal recruiting regions for each site. The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
~A proportion of participants from this group from selected sites will also provide up to a maximum of three blood samples for separation of peripheral blood mononuclear cells (PBMCs) to evaluate T cell responses. These participants can be either seronegative or seropositive at their Visit 1."
11102156|NCT04061369|Experimental|Meal 1|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
11102157|NCT04061369|Experimental|Meal 2|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
11102158|NCT04061369|Experimental|Meal 3|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
11102159|NCT04061369|Experimental|Meal 4|"A liquid meal, similar to a smoothie, that is high (60% of energy) in fat calories."
11102162|NCT04061304|Experimental|Active rTMS (Anorexia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).
~For the second session each day the patients in the anorexia group will receive low-frequency treatment (1 Hz, 60 second cycles, 30 second inter-train interval, 20 trains, 1200 total pulses) at 120% of the resting motor threshold to the orbitofrontal cortex"
11102163|NCT04061304|Experimental|Active rTMS (Bulimia Nervosa)|"Patients in this arm will receive 40 sessions of active rTMS. Every day, the first session of rTMS for both groups will be applied to the left DLPFC using intermittent Theta Burst Stimulation (iTBS).
~For the second session each day the patients in the bulimia group will receive high-frequency (10 Hz, 5 second cycles, 50 pulses, 25 second inter-train interval, 60 trains, 3000 total) at 120% of the resting motor threshold treatment to the left dorsomedial prefrontal cortex"
11102164|NCT04061304|Sham Comparator|Sham rTMS (Anorexia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Anorexia Nervosa group however their will be no actual brain stimulation.
11102165|NCT04061304|Sham Comparator|Sham rTMS (Bulimia Nervosa)|Patients in this arm will receive 40 sessions of sham rTMS. They will be set up the same as the active Bulimia Nervosa group however their will be no actual brain stimulation.
11102166|NCT04061278|Experimental|4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy|Four cycles of neoadjuvant chemotherapy combined with radical radiotherapy
11102167|NCT04061278|Active Comparator|3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy
11102168|NCT04061265|Active Comparator|Lidocaine 2% group|lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd)
11102169|NCT04061265|Experimental|Articaine 4%|articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd)
11102170|NCT04061252|Experimental|KHK4827 210mg Q2W SC|
11102171|NCT04061252|Placebo Comparator|Placebo Q2W SC|
11102172|NCT04061239|Experimental|CPX-351 Arm|"CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
~The treatment includes up to 2 cycles of induction as follows:
~1 x CPX-351 1st induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1, 3, and 5
~1 x CPX-351 2nd induction: daunorubicin 44 mg/m² and cytarabine 100 mg/m² in liposomes on days 1 and 3
~Each induction cycle will last 28 days. Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy after induction or be discontinued from the treatment phase and transferred directly to alloHCT, if applicable. CPX-351 consolidation is with daunorubicin 29 mg/m² and cytarabine 65 mg/m² in liposomes on days 1 and 3. For patients < 60 years up to 3 consolidation cycles and for patients ≥ 60 years up to 2 consolidation cycles are allowed."
11102173|NCT04061239|Other|CCR Arm|"The conventional care regimens (CCR) arm has 2 options according to the discretion of the investigator:
~conventional 7+3 cytarabine/daunorubicin chemotherapy regimen
~treatment with s.c. Azacitidine"
11102174|NCT04061226||Central obesity group|Normal weight central obesity patients (by BMI and WHR).
11102175|NCT04061226||Without central obesity group|Normal weight patients without central obesity (by BMI and WHR).
11102176|NCT04061213||Patients with symptomatic severe aortic stenosis|Elderly patients referred for TAVR evaluation
11102177|NCT04061200|Active Comparator|Semaglutide 1,34 mg/ml|Semaglutide 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
11102178|NCT04061200|Placebo Comparator|Placebo 1,34 mg/ml|Placebo 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
11102179|NCT04061174|Experimental|Shoulder stabilization exercise and office exercise training|Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
11102180|NCT04061174|Experimental|Office exercise training|"Office-based stretching exercises will be given to other group 3 sets will be applied by waiting 15 seconds for increasing range of motion of back, shoulder and neck joints.
~In addition, isometric exercises and scapula stabilization exercises will be given to strengthen the shoulder muscles and participants will do these exercises 3 times a week and once a day in 10 repetitions (10-15 seconds) and 3 sets. Each set will be given a rest of 60-90 seconds. Total time will be 10-15 minutes.Office exercise training will last a total of 8 weeks."
11102181|NCT04061161|Active Comparator|Tiotropium respimat|Tiotropium respimat 2.5mcg two actuations once daily
11102182|NCT04061161|Placebo Comparator|Placebo respimat|Placebo respimat two actuations once daily
11102183|NCT04061148|Other|Non-Depressed Controls|"Volunteers who have screened by a clinical psychiatrist, to exclude depression and other major psychiatric and neurocognitive disorders.
~They will undergo NIRSIT testing to measure frontal blood oxygenation up to 3 times, with an interval of 3 weeks between each measurement."
11102184|NCT04061148|Active Comparator|Depressed Patients|Patients diagnosed with Major Depressive Disorder by a clinical psychiatrist. They will undergo NIRSIT testing to measure frontal blood oxygenation up to 5 times, with an interval of 3 weeks between each measurement, over the course of their clinical therapy for Major Depressive Disorder.
11102185|NCT04061135|Experimental|Treatment|Parkinson's Disease Patients receiving DBS electrodes
11102186|NCT04061135|No Intervention|Control|Control subjects will be non-Parkinson's Disease patients with essential tremor
11102187|NCT04061122||EX + / ECTS +|Patients suffering COPD exacerbation in last 7 days; active tobacco smokers
11102188|NCT04061122||EX - / ECTS +|Patients without COPD exacerbation in last 6 months; active tobacco smokers
11102189|NCT04061122||EX + / ECTS -|Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier
11102190|NCT04061122||EX - / ECTS -|Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier
11102191|NCT04061109|Experimental|Prophylactic therapy|Subjects received Recombinant Human Coagulation FVIII for prophylactic therapy with 25 - 35 IU/kg injection once every other day or three times per week for 6 months.
11102192|NCT04061096|Active Comparator|MIH-effected carious first permanent molar teeth|MIH-effected carious permanent first molar teeth were well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
11102193|NCT04061096|Active Comparator|not MIH-effected carious first permanent molar teeth|The carious not MIH-effected teeth were only carious without any hypomineralize areas and asymptomatic which meant to be without any spontaneous pain or pain during eating or drinking, percussion or palpation tenderness, formation of abcess or fistula.
11102194|NCT04061096|Placebo Comparator|MIH-effected non-carious first permanent molar teeth|MIH-effected teeth were carious permanent first molar teeth with well-demarcated white/yellow or brown/yellow enamel opacities which is a sign for hypomineralization and did not have any sign of caries.
11102195|NCT04061096|Placebo Comparator|not MIH-effected non-carious first permanent molar teeth|not any signs of being caries or hypomineralization.
11102196|NCT04061083|Experimental|Continuous Endotracheal Cuff Pressure Control|Continuous endotracheal cuff pressure control using smart cuff manager during the first 48 hours of intubation in the intensive care unit
11102197|NCT04061083|Experimental|Intermittent Endotracheal Cuff Pressure Control|Intermittent cuff pressure control through manual manometer measurement performed 3 times per day during the first 48 hours of intubation in the intensive care unit
11102198|NCT04061083|No Intervention|Standard Care|ET cuff pressure control will be provided with pilot balloon fingers during the first 48 hours of intubation in the intensive care unit
11102199|NCT04061070|Sham Comparator|No Intervention with the mix threalose plus polyphenols|The patients allocated in this arm will not treated with a mix of threalose plus polyphenols
11102200|NCT04061070|Active Comparator|Intervention with the mix threalose plus polyhenols|The patients allocated in this arm will treated with a mix of threalose plus polyphenols
11102201|NCT04061057|Experimental|IV lidocaine|Perioperative IV lidocaine infusion
11102202|NCT04061057|Placebo Comparator|Normal saline|Perioperative IV normal saline infusion
11102203|NCT04061044|Experimental|Treatment|
11102204|NCT04061031|Experimental|Parent-Child Interaction Therapy|
11102205|NCT04061031|Active Comparator|Child-Centered Therapy with Parent Education|
11102206|NCT04061018||High Cholesterol Efflux|Dallas Heart Study participants who are above the sex and ethnicity specific 90th % of cholesterol efflux
11102207|NCT04061018||Low Cholesterol Efflux|Dallas Heart Study participants who are below the sex and ethnicity specific 10th % of cholesterol efflux
11102208|NCT04061005|Active Comparator|Hot snare polypectomy (HSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). According to the randomized group, patients with HSP group were treated with HSP to excise 5-15 mm colorectal polyps. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopist carefully observed the edge of the resection to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
11102209|NCT04061005|Experimental|Cold snare polypectomy (CSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). After randomization, patients in the CSP group will be treated with CSP to remove colorectal polyps of 10-15 mm size. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopic surgeon carefully observed the resection margin to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
11102210|NCT04060992|Experimental|Early Follicular Phase|Women enrolled will be anywhere from cycle day 1 through 5 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
11102211|NCT04060992|Active Comparator|Late Follicular Phase|Women enrolled will be anywhere from cycle day 8 through 13 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
11102212|NCT04060992|Active Comparator|Luteal Phase|Women enrolled will be anywhere from cycle day 21 through cycle day 26 of their menstrual cycle and take elagolix 200mg oral tablet BID for 3 days total.
11102213|NCT04060979|Experimental|Group 1- NO treatment- dose 1|Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
11102214|NCT04060979|Experimental|Group 2- NO treatment- dose 2|Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
11102215|NCT04060979|Other|Group 3- Control treatment|Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
11102216|NCT04060966|Experimental|Cold - Pressor Task|
11102217|NCT04060953|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report.
11102218|NCT04060953|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the Health-Related Quality of Life Report following completion of the study.
11102219|NCT04060940|Experimental|Emotion Regulation Therapy: 8-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 8-session version of ERT will receive 8 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-5 will be 1 hour long, sessions 6 and 7 will be 1.5 hours long, and session 8 will be one hour long, resulting in a total required time commitment of 9 hours over the course of 8 weeks.
11102220|NCT04060940|Experimental|Emotion Regulation Therapy: 16-session version|All participants will be randomly assigned to an 8-session or 16-session version of ERT with equal probability. Participants assigned to the 16-session version of ERT will receive 16 sessions of individualized therapy, each of which is 1-1.5 hours, on a weekly basis. Sessions 1-9 will be 1 hour long, sessions 10-13 will be 1.5 hours long, and sessions 14-16 will be 1 hour long, resulting in a total required time commitment of 18 hours over the course of 16 weeks.
11102227|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 1|Participants in the first cohort will receive the CCSH Interventions for Teams during the fall session (first intervention period).
11102228|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 2|Participants in the second cohort will receive the CCSH Interventions for Teams during the spring session (second intervention period).
11102229|NCT04060888|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
11102230|NCT04060888|Placebo Comparator|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
11102231|NCT04060875||Feasibility group|First phase group will involve piloting a novel virtual reality treatment for chronic pain to investigate feasibility and safety with a smaller number of patients
11102232|NCT04060862|Experimental|Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant|
11102233|NCT04060862|Placebo Comparator|Phase 3: Placebo + Palbociclib + Fulvestrant|
11102234|NCT04060849|Experimental|Arm I (Nozin)|Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
11102235|NCT04060849|Active Comparator|Arm II (standard of care)|Patients receive standard of care.
11102236|NCT04060836|Experimental|group A|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.
11102237|NCT04060836|Experimental|group B|Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.
11102238|NCT04060823|Experimental|Easy Breathing|Easy Breathing will be implemented in participating clinics. Asthma-related sick visits will be monitored for changes.
11102239|NCT04060810|Other|grey zone hydrocephalic patients|MR CSF flowmetry CT brain Ventriculoperitoneal shunt
11102240|NCT04060797|Experimental|endovascular denervation|endovascular denervation
11102241|NCT04060784|Experimental|Immediate implant placement and provisionalization|On the control group, Implant will be placed immediately after tooth extraction. The gap between the implant and buccal bone will be filled with bone graft. Temporary crown will be attached to implant fixture.
11102242|NCT04060784|Experimental|Socket shield technique|On the test group, Implant will be placed immediately after tooth extraction. A piece of root shield will be retained intentionally at facial side. Temporary crown will attached to implant fixture.
11102243|NCT04060771|Experimental|Group P|During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
11102244|NCT04060771|Active Comparator|Group D|During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
11102245|NCT04060758|Experimental|14.7 mcg|PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.
11102246|NCT04060758|Experimental|26.6 mcg|PA5108 Latanoprost FA SR Ocular Implant which releases 26.6 mcg.
11102247|NCT04060758|Experimental|35.5 mcg|PA5108 Latanoprost FA SR Ocular Implant which releases 35.5 mcg.
11102248|NCT04060745|Experimental|Cooling|Participants will be cooled using an individualized cooling protocol with a water-perfused vest for two hours while resting. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
11102249|NCT04060745|Experimental|Thermoneutrality|Participants will rest for one hours. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
11102250|NCT04060732||Flash Glucose Monitoring Device|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid used by Diabetes Mellitus type 1 patients."
11102251|NCT04060719|Experimental|Reference (Period 1) - BI 894416 alone|Reference (Period 1) followed by Test (Period 2)
11102252|NCT04060719|Experimental|Test (Period 2) - BI 894416 + Rifampicin|
11102253|NCT04060706||Prostate Cancer|Adults suitable for radical image-guided radiotherapy for their Prostate cancer, approximately 170 patients Components from RTOG, LENT SOM(A), RMH symptom scale and UCLA PCI (prostate cancer index) questionnaires will be used.
11102254|NCT04060706||Head & Neck Cancer|Adults suitable for radical image-guided radiotherapy for their Head & Neck cancer, approximately 140 patients. Components from CTCAE v3, LENT SOM(A), EORTC QLQ H+N35 & Modified xerostomia questionnaires will be used.
11102255|NCT04060706||Central Nervous System Tumours|Adults suitable for radical image-guided radiotherapy for their CNS tumour, as many patients recruited as possible. Components from RTOG, LENT SOM(A), Folstein mini mental state examination & Generalised activites of daily living scale (G-ADL) questionnaires will be used.
11102256|NCT04060706||Lung Cancer|Adults suitable for radical image-guided radiotherapy for their Lung cancer, as many patients recruited as possible. Components from RTOG & LENT SOM(A) questionnaires will be used.
11102257|NCT04060693|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 30 days of home-based measurement, scheduled within a 40 days' time frame. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed within 3 minutes after the BG measurement using the thenar of the right hand of the subject.
11102258|NCT04060680|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
11102259|NCT04060667|Experimental|Intervention|
11102260|NCT04060667|No Intervention|control|
11102261|NCT04060654|Experimental|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator for up to 5 total injections
11102352|NCT04059952||Unipolar Depression|Patients diagnosed with Major Depressive Disorder.
11102262|NCT04060641||RDN Patients|Patients who have received renal denervation with the Medtronic SymplicitySpyral device will have DNA collected in using a buccal swab.
11102263|NCT04060615|Other|Patients with chronic total occlusion of the coronary artery|In each patient before the PCI procedure, the investigators will assess myocardial viability, functional parameters of collateral blood vessels, and quality of life. 24h and 6 months after the procedure these parameters will be reevaluated as well as functional parameters of the treated coronary artery.
11102264|NCT04060602|Experimental|Personalized Feedback and Education|This arm is provided personalized feedback concerning their cannabis use in addition to educational materials about risky cannabis use.
11102265|NCT04060602|Active Comparator|Education|This arm is provided educational materials about risky cannabis use.
11102266|NCT04060589||Cohort Observation|This is a cohort study where participating men will be asked to donate blood, urine, tissue in addition to access to standard of care tissue and medical data (including imaging files). Men will also consent to longer term healthcare data linkage.
11102267|NCT04060576|Experimental|Group A treated with a 16-gauge needle|Group A is intervened on the gastrocnemius muscle with a 16-gauge needle.
11102268|NCT04060576|Experimental|Group B treated with a 25-gauge needle|Group B is intervened on the gastrocnemius muscle with a 25-gauge needle.
11102269|NCT04060576|Experimental|Group C treated with a 32-gauge needle|Group C is intervened on the gastrocnemius muscle with a 32-gauge needle.
11102270|NCT04060563|Sham Comparator|Sham (fake) microcurrent therapy|Sham (fake) microcurrent therapy (placing the microcurrent pads on the patient and turning the microcurrent box on placebo mode )
11102271|NCT04060563|Experimental|Frequency specific microcurrent therapy|Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8),
11102272|NCT04060550||Normal controls|No history of skin disease and atopy
11102273|NCT04060550||ADEH-|Atopic dermatitis without a history of eczema herpeticum
11102274|NCT04060550||ADEH+|Atopic dermatitis with a history of eczema herpeticum
11102275|NCT04060537||Research|Patients with Renal Cell Carcinoma who have had previous systemic treatment, with adequate tissue samples and radiological data
11102276|NCT04060511|Experimental|HS-10342|Each subject will receive a single dose(C0) of HS-10342 and then repeat doses(C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
11102277|NCT04060498|Experimental|Mindfulness intervention|This arm consists of seven weekly-session mindfulness-based intervention for psychosis (MBI-p). The MBI-p is a protocol-based, low intensity intervention developed to help patients achieve a greater sense of peace and calmness, and facilitates participants in handling everyday stress and conflicts.
11102278|NCT04060498|Placebo Comparator|Psychoeducation intervention|This arm consists of seven weekly-sessions of psychoeducation. Topics to be discussed in the sessions include the signs and symptoms of psychosis, aetiology of psychosis, as well as pharmacological and non-pharmacological interventions.
11102279|NCT04060472|Experimental|albumin-bound paclitaxel + oxaliplatin|
11102280|NCT04060459|Experimental|Treatment plan|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
11102281|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
11102282|NCT04060433|Experimental|ROCKETLAUNCH project|Intensive treatment program with focusing on the implementation of evidence based family therapy
11102283|NCT04060420|Experimental|Comprehensive sexual and reproductive health services|In clusters randomised to the Yathu Yathu intervention, the comprehensive, community-based and peer-led intervention is being delivered. In addition to delivery of sexual and reproductive health services through community-based hubs, the intervention includes the Yathu Yathu prevention points cards, with which adolescents and young people can accrue points for accessing services at the Yathu Yathu hub and local health facility, and redeem rewards using these points.
11102284|NCT04060420|No Intervention|Standard of care|In the comparison arm, adolescents and young people will have access to sexual and reproductive health services at the local health facility. They will also have a Yathu Yathu prevention points card, with which they can accrue points for accessing sexual and reproductive health services at the local health facility and redeem rewards using these points.
11102285|NCT04060407|Experimental|Advanced Melanoma|Patients with advanced melanoma.
11102286|NCT04060394|Experimental|Phase I Cohort 1|LAE001 (capsules) 75mg Twice Daily (BID) + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg Once Daily (QD) will be administered in Cycles of 28 days.
11102287|NCT04060394|Experimental|Phase I Cohort 2|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 100mg QD will be administered in Cycles of 28 days.
11102288|NCT04060394|Experimental|Phase I Cohort 3|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 125mg QD will be administered in Cycles of 28 days.
11102289|NCT04060394|Experimental|Phase I Cohort 4|LAE001 (capsules) 100mg BID + prednisone (tablet) 5mg BID +afuresertib (tablet) 150mg QD will be administered in Cycles of 28 days.
11102290|NCT04060394|Experimental|Phase II Arm 1|LAE001 (capsules) + prednisone (tablet) +afuresertib at the Recommended Phase II Dose (RP2D)
11102291|NCT04060394|Experimental|Phase II Arm 2|Afuresertib 150 mg
11102292|NCT04060381||Fetuses of normal weight women|Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37
11102293|NCT04060381||Fetuses of severely obese women|Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37
11102294|NCT04060381||New-borns in need of blood transfusion|Neonates mainly receive blood due to blood loss, often because of repeated blood sampling
11102295|NCT04060381||New-borns in need for closure of the arterial duct|Neonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct.
11102296|NCT04060381||New-borns in need of treatment with catecholamines|Neonates are mainly treated with epinephrine, nor epinephrine or atropine due to compromised cardiovascular function or hypotension.
11102353|NCT04059952||Bipolar Depression|Patients diagnosed with Bipolar I or II.
11102354|NCT04059952||Healthy Control|Patients without psychiatric diagnoses.
11102297|NCT04060368|Experimental|ESG Stitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
11102298|NCT04060368|Active Comparator|LSG + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
11102299|NCT04060355|Experimental|Savvy Participants|Using an on-line survey method, each caregiver will be asked to complete the post-program fidelity monitoring survey that seeks responses to the program (feel more knowledgeable, more competent, better equipped, etc.) and asks them to assess the interventionist's performance and verify that certain key elements of the program were covered.
11102300|NCT04060355|Experimental|Interventionists|Three recorded semi-structured video interviews will be conducted with each interventionist. One will occur immediately after training; this will focus on their sense of the completeness and adequacy of the training program, including the training methods, videos, and materials, and their perceived readiness to lead the program. Another interview will be done immediately after the conduct of each of the two Savvy programs they lead, asking them to report on their own performance as interventionists, including any adaptation processes in which they might have engaged, and to reflect on ways the training might be improved to strengthen their skills, including for adaptation. In total: 18 interviews.
11102301|NCT04060355|Experimental|Organizational Leaders|Recorded semi-structured video interviews with sponsoring organizations' key contact persons will be conducted immediately after the interventionist training and then after each of two Savvy offerings. The conversation will focus on identifying ways to strengthen and improve the training, certification, and fidelity monitoring system. Information about time and resource costs of the program, caregiver demand, and caregiver recruitment and feedback (3 interviews per organization) will be also collected.
11102302|NCT04060342|Experimental|Phase 1: Regimen A - GB1275 monotherapy|GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).
11102303|NCT04060342|Experimental|Phase 1: Regimen B - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab dose escalation and expansion:
~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
11102304|NCT04060342|Experimental|Phase 1: Regimen C - GB1275 with Standard of Care (SOC)|"GB1275 with SOC dose escalation:
~GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)"
11102305|NCT04060342|Experimental|Phase 2: Cohort 1 - GB1275 with SOC|"GB1275 with SOC Basket Cohort in patients with newly diagnosed metastatic pancreatic cancer:
~GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI."
11102306|NCT04060342|Experimental|Phase 2: Cohort 2 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with MSS colorectal cancer:
~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
11102307|NCT04060342|Experimental|Phase 2: Cohort 3 - GB1275 with an Anti-PD-1|"GB1275 with pembrolizumab Basket Cohort in patients with gastric/GEJ cancer, PD-L1 positive:
~GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W)."
11102308|NCT04060329|No Intervention|Phase 1|Usual care
11102309|NCT04060329|Experimental|Phase 2|Usual care + coopeRATE Prompt intervention
11102310|NCT04060329|Other|Clinicians|After Phase 2, clinicians will be asked about their experiences with, and views about, the coopeRATE Prompt intervention.
11102311|NCT04060316|Experimental|GLS-1200|3 ml of GLS-1200 (1 mg/ml in 0.9% saline)
11102312|NCT04060316|Placebo Comparator|Sterile Saline|3 ml of 0.9% saline
11102313|NCT04060303|Active Comparator|ENRICH-US Implementation- early|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery for IBD) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.
~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
11102314|NCT04060303|Active Comparator|ENRICH-US Implementation- mid|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery for IBD) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.
~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
11102315|NCT04060303|Active Comparator|ENRICH-US Implementation- late|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery for IBD) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.
~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
11102316|NCT04060277|Experimental|Arm I (letermovir, Triplex)|Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
11102355|NCT04059939|Experimental|Reading Plus Attention Control|
11102318|NCT04060264|Experimental|BCD-148|"14 participants in BCD-148 group. During the main period (first 27 weeks), test product BCD-148 will be administered as 25- to 45-minute intravenous infusions.
~After Week 27 BCD-148 900 mg will be administered biweekly as maintenance therapy."
11102319|NCT04060264|Active Comparator|Soliris|"14 participants in Soliris group. During the main period (first 27 weeks), Soliris® will be administered as 25- to 45-minute intravenous infusions.
~After Week 27, patients be switched to BCD-148 900 mg biweekly as maintenance therapy."
11102320|NCT04060251|Experimental|Group 1, iGetBetter Group|Use only iGetBetter for the 3 months preceding surgery. After surgery, you will be given a new, Post-Op program to use for 2-3 months. For the first 3 weeks, you will only use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks.
11102321|NCT04060251|Experimental|Group 2, E-vive Group|You will use iGetBetter starting 3 months out from surgery. You will receive CyMedica's electrical-stimulation garment during the preoperative appointment. In addition to iGetBetter, you will wear the conductive garment two times each day for the last 3 weeks before surgery. After surgery, for the first 3 weeks you will only use the conductive garment, and will not use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to wearing the brace, approximately twice per week for the next 6-8 weeks. You will not need to return the brace after this time is up, and you may keep the brace, if you so choose, at no cost.
11102322|NCT04060251|No Intervention|Group 3, Physical Therapy Group|You will receive only iGetBetter for the 3 months preceding surgery. After surgery, you will receive only home physical therapy, and will not use iGetBetter. After those three weeks, you will receive outpatient physical therapy approximately twice per week for the next 6-8 weeks.
11102323|NCT04060238||Normal colour vision|Normal trichromopsia
11102324|NCT04060238||Inherited red blindness|Protanopia
11102325|NCT04060225|Experimental|Participants|Participants will be asked to participate in a single arm study with three phases (washout phase, abstinence phase, and exposure phase). These participants will first be asked to abstain from drinking any caffeinated food or beverages for 72 hours (known as the washout phase). Following the first phase, participants will then wear a blood pressure cuff to collect diastolic and systolic blood pressure for 24 hours (abstinence phase) wherein they will be asked to refrain from caffeinated products. Participants will then drink the coffee intervention and collect blood pressure measurements for 24 hours (exposure phase).
11102326|NCT04060212|Experimental|All Participants|All participant will eat 6 meals of tuna fish. All participants will take a prebiotic dietary supplement.
11102327|NCT04060199|Experimental|Viltolarsen|Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
11102328|NCT04060199|Placebo Comparator|Placebo|Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
11102329|NCT04060186|Active Comparator|Balloninflation Group|Patient who will perform a balloninflation after operation
11102330|NCT04060186|Sham Comparator|Conservative Group|Patient without performing a balloninflation
11102331|NCT04060173|Experimental|Treatment with ABP-671|Three sequential dose escalation cohorts of ABP-671 administered orally for 10 days.
11102332|NCT04060173|Placebo Comparator|Treatment with placebo|Three sequential dose escalation cohorts of ABP-671 matching placebo administered orally for 10 days.
11102333|NCT04060147|Experimental|CILO 30 mg|Participants will receive escalating doses of CILO 30 mg, 60 mg, and 100 mg.
11102334|NCT04060134||HADM|Patients who had human acellular dermal matrix used in their breast reconstruction procedure.
11102335|NCT04060108||MDMA Within Subject Cross-over|Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
11102336|NCT04060095||β1-adrenergic antagonists|Patients who have been treated for more than 3 months with β1-adrenergic antagonists
11102337|NCT04060082||Persons Diagnosed|Individuals with a diagnosis of bvFTD.
11102338|NCT04060082||Persons At Risk|Individuals with a known genetic risk factor for bvFTD: people with genetic testing that identified a disease-causing change in a gene that is known to cause bvFTD, such as in C9ORF72, MAPT, GRN, VCP, TARDBP, CHMP2B, or another gene that has been identified as causing FTD in the family
11102339|NCT04060069||Before pneumoperitoneum|Fluid administration
11102340|NCT04060043|Experimental|Goserelin acetate Injection|Pepti 10.8mg is a generic formulation of Zoladex® 10.8mg, with the same ingredients (active and excipients), the same formulation, the same dosage, the same size and route of administration.
11102341|NCT04060030|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
11102342|NCT04060030|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
11102343|NCT04060017|Experimental|L-leucovorin calcium|The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.
11102344|NCT04060017|Placebo Comparator|Placebo|The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.
11102345|NCT04060004|Other|Control group|Electrotherapy + therapeutic exercise
11102346|NCT04060004|Experimental|Experimental group 1|Electrotherapy + therapeutic exercise + dry needling
11102347|NCT04060004|Placebo Comparator|Experimental group 2|Electrotherapy + therapeutic exercise + sham dry needling
11102348|NCT04059978|Active Comparator|CBD + Remifentanil|CBD 1600 mg p.o. + Remifentanil 0.1 µg/kg/min i.v. for 30 min
11102349|NCT04059978|Placebo Comparator|Placebo + Remifentanil|Placebo p.o + Remifentanil 0.1 µg/kg/min i.v. for 30 min
11102350|NCT04059965|Experimental|Intervention Arm|This cohort of patients will receive panel management through a customize software that integrates with the electronic health record
11102351|NCT04059965|Active Comparator|Control Arm|This cohort of patients will receive usual care
11102359|NCT04059913|Other|Part 1 (2 arms) and Part 2|The purpose of Part 1 is to evaluate difference between low and standard weight-based doses and Part 2 is to evaluate the difference among dosing frequencies
11102360|NCT04059913|Other|Part 1|"Part 1:
~Arm Type: Other
~Arm Title: Low weight-based dosing
~Arm 1: Low weight-based dosing
~Arm Description: Subjects in this arm will receive roxadustat 70 mg three times a week (TIW) for body weight < 60 kg or 100 mg TIW for body weight ≥ 60 kg
~Arm Type: Other
~Arm Title: Standard weight-based dosing
~Arm 2: Standard weight-based dosing
~Arm Description: Subjects in this arm will receive roxadustat 100 mg TIW for body weight < 60 kg or 120 mg TIW for body weight ≥ 60 kg"
11102361|NCT04059913|Other|Part 2|"Part 2:
~Arm Type: Other
~Arm Title: Roxadustat
~Arm Description: Subjects in this arm will receive roxadustat at different dose frequencies"
11102362|NCT04059900|Experimental|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
11102363|NCT04059900|Placebo Comparator|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
11102364|NCT04059887|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administrated every 3 week cycle
11102365|NCT04059874|Experimental|donafenib tablets 1|This is the dose group was given once a day. donafenib tablets 1 100mg qd dose group
11102366|NCT04059874|Experimental|donafenib tablets 2|This is the dose group was given twice a day. donafenib tablets 2 100mg bid dose group
11102367|NCT04059861|Other|ultrasound assisted resection|resection of tongue cancer will be done with assistance of ultrasound to visualise the deep margin.
11102368|NCT04059848|Experimental|tDCS combined with NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
11102369|NCT04059848|Active Comparator|tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
11102370|NCT04059848|Sham Comparator|sham tDCS combined with sham NMES|In addition to conventional rehabilitation, all subjects received an additional sham tDCS combined with sham NMES protocol with a total of 15 sessions for 3 weeks (5 times per week, 30 minutes daily).
11102371|NCT04059835|Active Comparator|standard|Standard bra, soft
11102372|NCT04059835|Experimental|compression bra|experimental bra, compression and stabile
11102373|NCT04059822|Experimental|Slow and deep breathing|Daily practice of slow and deep breathing for 10 minutes per day. Breathing frequency will be 6 breaths per minute, with participants accessing a video aid to help guide their breathing. Breathing exercises will be conducted from enrolment until birth (maximum ~20 weeks if enrolment at 20 weeks gestation until ~40 weeks gestation birth)
11102374|NCT04059809|No Intervention|Usual Care|The control group will have usual care according to the orientation of the radiation therapy faculty responsible for the radiotherapy treatment the PBM device will be switched off
11102375|NCT04059809|Experimental|Photobiomodulation (PBM)|Additionally to the usual care, the patients will receive the PBM. Treatment will be done twice a week.
11102376|NCT04059796|Experimental|Study Eye|Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
11102377|NCT04059796|Active Comparator|Control Eye|approved monofocal or toric IOL after cataract extraction
11102378|NCT04059770|Experimental|single dose of L-AmB|single IV dose of 10 mg/kg of L-AmB on day 1;
11102379|NCT04059770|Experimental|2 doses of L-AmB|IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
11102380|NCT04059770|Active Comparator|2 weeks of L-AmB|IV dose of 3 mg/kg of L-AmB for 2 weeks.
11102381|NCT04059757|Experimental|Fecal Microbiota Transplantation (FMT)|"One dose of FMT equal to 30 capsules will be administered on day 1 of a 28 day cycle. Steroids and routine GVHD prophylaxis medications and antibiotics may be administered concurrently with FMT therapy.
~Participants will be followed for 28 days following completion of the FMT dose or protocol defined outcome.
~aGVHD will be treated as per standard of care."
11102382|NCT04059744|Experimental|Experimental arm|"Device: Fun-Knee Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.
~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
11102383|NCT04059731|Experimental|Surmimed®OPD Drink|Normocaloric oligomeric-hyperprotein supplement
11102384|NCT04059731|Active Comparator|Atempero® or Impact®|Inmunonutrition
11102385|NCT04059718|Experimental|Treatment|Treatment arm will be enrolled in the SCI Thrive Peer-Led Online Self-Management program and will take part in the next available group session.
11102386|NCT04059718|No Intervention|Wait-list Control|Wait-list control arm will only complete assessments during the 6 week group period. Subjects will be offered a place in the SCI Thrive Peer-Led Online Self-Management program after 6 weeks and completing the assessments.
11102387|NCT04059705|Experimental|Dual-Task Intervention|This study arm will receive the dual-task training program.
11102388|NCT04059692|Experimental|Cervical manipulation intervention|"To perform the evaluation and detect the cervical vertebral level with mobility restriction, with the patient in supine position, a cervical examination is carried out to determine the mobility restriction, both in flexo-extension, as in inclination and rotation. To check the level of restriction, the post-anterior sliding test is performed.
~The manipulation is performed following the criteria of thrust manipulations. A maximum of 3 manipulations are applied in total per subject, one for each level (high level C1-C2, medium level C3-C6, and low level C7), if necessary."
11102389|NCT04059692|Placebo Comparator|Placebo intervention|This group will receive 15 minutes of sham techniques in a supine position over the stretcher. First, a series of short-time and no pressure contact with physiotherapist´s hands is performed in several points of head and shoulders for 10 minutes. Subsequently, light touch is applied on standardized anatomic areas, for 2 minutes each time.
11102390|NCT04059679|Active Comparator|EC aspirin (81mg qd)|
11102391|NCT04059679|Experimental|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)|
11102392|NCT04059666|Active Comparator|Control|
11102393|NCT04059666|Experimental|Investigational|
11102395|NCT04059653|Experimental|Electrical stimulation|Neuromuscular electrical stimulation treatment
11102396|NCT04059653|Active Comparator|Treatment As Usual|Usual GP treatment
11102397|NCT04059640|Experimental|LiquiBand FIX8® OHMF Device|Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.
11102398|NCT04059627|Experimental|Experimental arm|"Participants were introduced to Heart-Track mobile app system and its navigational characteristics with standardised instructions. Each participant then performed a self-directed Cardiac rehabilitation session using the app."
11102399|NCT04059614|Active Comparator|"High flow nasal cannula (HFNC)"|"HFNC group: those who receive high-flow nasal cannula therapy"
11102400|NCT04059614|Experimental|conventional oxygen therapy (COT)|COT group: those who receive conventional oxygen therapy group
11102401|NCT04059601||Patients with acute cholecystitis|All patients with acute cholecystitis are included in the study cohort during year 2019. MRCP and IOC will be performed to all patients whenever feasible.
11102402|NCT04059588|Experimental|Injection of 2141-V11|Open label study drug 2141-V11 at escalating doses until MTD is determined, and expansion utilizing the MTD.
11102403|NCT04059575|Experimental|PERFORMANCE PLUS|performance plus better than GOLD TEX
11102404|NCT04059575|Active Comparator|GOLD TEX|GOLD TEX better than performance plus
11102405|NCT04059562|Experimental|Treatment|Combination of Lonsurf® and Campto®
11102406|NCT04059549|Active Comparator|A-CHESS|Patients randomized to the A-CHESS group will receive the A-CHESS app on a smartphone.
11102407|NCT04059549|Experimental|PartnerCHESS|Patients randomized to the PartnerCHESS group will receive all A-CHESS services listed above, plus learning modules and resources from Alcohol-based Couple Therapy.
11102408|NCT04059536||Roxwood Anchoring Catheters|Participants will be treated for an index procedure using Roxwood Medical device(s) as prescribed by the Investigator SOC on Day 0. All devices will be used in accordance with the Instructions for Use (IFU). Participants are to be administered SOC acetylsalicylic acid (ASA) and/or anti-platelet medications orally per physician discretion prior to the index procedure. Administration of an intravenous injection of heparin during the index procedure will also be at the discretion of the Investigator per Institutional SOC.
11102409|NCT04059523|Experimental|S6G5T-3|topical cream
11102410|NCT04059523|Active Comparator|Retin-A® 0.1% Cream|topical cream
11102411|NCT04059510||Screening for GBS|Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
11102412|NCT04059510||Sampling method optimisation|"If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).
~The sampling study will last for 12 weeks and samples collected include:
~A self-taken low vaginal swab
~A self-taken rectal swab
~Menstrual cup fluid
~Serum sample
~Urine pregnancy tests"
11102413|NCT04059510||Focus groups|"In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.
~Women may opt out of the focus groups at any time but remain in the sampling study if they choose.
~In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples."
11102414|NCT04059497|Experimental|Exercise group|The exercise group will receive a 10-minute exercise intervention.
11102415|NCT04059497|Experimental|Healthy diet group|The healthy diet group (control) will receive a 10-minute healthy-diet intervention.
11102416|NCT04059484|Experimental|SAR439859|Daily SAR439859 dose administered orally under fed or fast condition
11102417|NCT04059484|Active Comparator|Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator|"Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.
~Fulvestrant
~Aromatase inhibitors (anastrozole, letrozole, exemestane)
~Selective estrogen receptor modulator (Tamoxifen)"
11102418|NCT04059471|Active Comparator|Standard Dose|Yellow fever vaccine, Institut Pasteur, standard dose as release by manufacturer will be administered subcutaneously once.
11102419|NCT04059471|Experimental|Fractional dose (1000 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 1000IU/dose and administered subcutaneously once.
11102420|NCT04059471|Experimental|Fractional dose (500 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 500IU/dose and administered once.
11102421|NCT04059471|Experimental|Fractional dose (250 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 250IU/dose and administered once.
11102422|NCT04059458|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
11102423|NCT04059458|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
11102424|NCT04059445|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
11102425|NCT04059445|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
11102426|NCT04059419|Experimental|Experimental|30 Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
11102427|NCT04059419|Active Comparator|Control|Should remain under geriatric care after randomization.
11102428|NCT04059406|Experimental|IONIS TMPRSS6-LRx|A single injection of IONIS TMPRSS6-LRx at multiple dose levels, administered subcutaneously every 4 weeks
11102429|NCT04059393|Experimental|Group I (web-based legacy intervention)|Patients participate in a web-based legacy intervention by answering questions about themselves and uploading videos, photographs, and music to create a digital story within 2 weeks.
11102430|NCT04059393|Active Comparator|Group II (standard of care)|Patients receive standard of care. Patients have the option to participate in the web-based legacy intervention after 2 months.
11102431|NCT04059380||Patients with Hypoparathyroidism|Patients with Post-Surgical or Autoimmune Chronic Hypoparathyroidism requiring daily calcium and calcitriol therapy
11102432|NCT04059380||Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by hypoparathyroidism
11102433|NCT04059367|Experimental|NNC9204-1177 and cocktail of approved drugs|
11102434|NCT04059354|Experimental|Speech therapy|Direct speech therapy will be provided for a 12 week period with up to three one-hour sessions per week.
11102435|NCT04059341|Experimental|Active LI-ESWT|Active group receives five sessions of low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG.
11102436|NCT04059341|Sham Comparator|Sham|Sham group receives five sessions of sham low intensity extracorporeal shockwave treatment, once per week for five consecutive weeks. Treatment is initiated three weeks after radical prostatectomy and is given using DUOLITH® SD1 manufactured by STORZ MEDICAL AG with a shockwave absorbing adapter.
11102437|NCT04059328||Physicians in Haiti|7 OBGYN physicians underwent a laparoscopic training and simulation course and then were proctored as they performed 3 in vivo cases using a check list to help the participants remember all the steps of laparoscopic set-up.
11102438|NCT04059315||Retrospective cross sectional study|"This is an Epidemiological observational analytic study where the subjects sustained with oral and maxillofacial trauma will be divided into the two-time-frame;
~1st, retrospective study between 1 June 2011 to 31 May 2019"
11102439|NCT04059315||Prospective cohort study|2nd prospective study on 1 June 2019 to 1 June 2021.
11102440|NCT04059302|Experimental|Online CBT-I|Fully-automated, internet-delivered cognitive behavioral therapy for insomnia program that consists of 6 therapy cores delivered weekly over 6 weeks.
11102441|NCT04059302|No Intervention|Wait-List Control|Wait-list control group will receive no intervention until after the trial period is completed. During the trial period they will complete all study assessments, but receive no active treatment.
11102442|NCT04059289||Intraocular lens type I|Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
11102443|NCT04059289||Intraocular lens type II|Clareon IOL (Alcon Pharma. Freiburg/FRG)
11102444|NCT04059276||Patients with stroke|
11102445|NCT04059276||Healthy subjects|
11102446|NCT04059250|Experimental|Nobio flange|On the Nobio flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it the Nobio composite.
11102447|NCT04059250|Placebo Comparator|Traditional composite flange|On the traditional composite flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it a traditional composite.
11102448|NCT04059237|Experimental|Online Decision Aid|web-based psychosocial assessment questionnaires will be administered at baseline (T1; pre-intervention) and at one-month (T2) and three-month (T3) follow-up time points.
11102449|NCT04059224|Experimental|Arm A: advanced BRAF V600 wild-type/NRAS-mutant melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
11102450|NCT04059224|Experimental|Arm B: advanced BRAF V600 wild-type/NRAS wild-type melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
11102451|NCT04059198|Experimental|Arm 1 - Inarigivir Soproxil Daily|Inarigivir Soproxil Alone 400 mg Inarigivir daily for 12 weeks followed by 400 mg daily in combination with TAF 25 mg daily for 12 weeks
11102452|NCT04059198|Experimental|Arm 2 - Inarigivir Soproxil 3 Times Weekly|400 mg Inarigivir 3 times weekly for 12 weeks followed by 400 mg 3 times weekly in combination with TAF 25 mg daily for 12 weeks
11102453|NCT04059198|Experimental|Arm 3 - Inarigivir Soproxil and TAF Daily|400 mg Inarigivir daily in combination with TAF 25 mg daily for 24 weeks
11102454|NCT04059185|Experimental|Program 1|Triple P-Level 2 (TPL2), parenting education and consultation
11102455|NCT04059185|Experimental|Program 2|Play Nicely (PN), multimedia, computer-based parenting education
11102456|NCT04059185|Placebo Comparator|Control|"Our usual care control group participants receive a resource and referral list for local social services"
11102457|NCT04059172|Active Comparator|Ibuprofen|one 200 mg tablet of ibuprofen and 2 placebo tablets
11102458|NCT04059172|Experimental|Ibuprofen and acetaminophen|one 200 mg table of ibuprofen and two 325 mg tablets of acetaminophen
11102459|NCT04059172|Placebo Comparator|Placebo|3 tablets of tableting compounds with no active ingredients
11102460|NCT04059159|Experimental|Connected Catheter Users|
11102461|NCT04059146|Experimental|Pain Education + Exercise|"The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain.
~All participants will receive the same progressive Achilles tendon loading exercise program."
11102462|NCT04059146|Active Comparator|Standard Education + Exercise|"The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage.
~All participants will receive the same progressive Achilles tendon loading exercise program."
11102463|NCT04059133|Experimental|LiESWT arm|"For SUI: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.
~For OAB: The LiESWT was applied with 0.25 mJ/mm2 intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°, and the applicator was gently placed on suprapubic skin area over the bladder dome and bilateral bladder walls with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually."
11102464|NCT04059133|Sham Comparator|Sham arm|"For SUI: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). Probe be transcutaneous applied to the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 mJ/mm2 intensity and 1000 pulses of shocks individually.
~For OAB: The LiESWT was applied with 3000 pulses of shocks, frequency of 3 pulses/second but no energy, once weekly for 4-weeks (W4) and 8-weeks (W8). The applicator was gently placed on the suprapubic skin area over the bladder dome (1000 pulses) and bilateral bladder walls (each side 1000 pulses). The probe was placed on the lower abdomen with two fingers apart from the pubic symphysis, tilting to 45°."
11102465|NCT04059120|Experimental|Experimental group|The physical load will be organized as follows: The experimental group (EG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with specific stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
11102466|NCT04059120|Active Comparator|Control group|The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM in combination with single or general stretching exercises, and aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7.
11102467|NCT04059107|Experimental|Prosthetic Device|3D Printed Myoelectric Prosthetic Device
11102468|NCT04059094|Experimental|BI 1265162|
11102469|NCT04059094|Placebo Comparator|Placebo|
11102470|NCT04059081|Experimental|GC chemotherapy|"Before administration of GC chemotherapy, all patients must undergo pretreatment bone marrow biopsy. The pretreatment BM biopsy must include at least 1 long core biopsy samples and 10 cc of aspirate.
~Obinutuzumab 1000mg fixed dose will be administered intravenously (Day 1,8,15 for cycle 1 and D1 for subsequent cycles). Chlorambucil 0.5mg/kg will be administered orally (D1,15 for all cycles).
~28 days are considered as one cycle, and cycles will be repeated every 4-weeks for a total of 6 cycles."
11102471|NCT04059068||NASH (non-alcoholic steatohepatitis)|Patients diagnosed with non-alcoholic steatohepatitis.
11102472|NCT04059068||NAFLD (non-alcoholic fatty liver disease)|Patients diagnosed with non-alcoholic fatty liver disease.
11102473|NCT04059068||Control|Patients with normal liver tissue.
11102474|NCT04059068||obese / high WAT inflammation and fibrosis|Patients who are obese with inflammed white adipose tissue and evidence of fibrosis.
11102475|NCT04059068||obese / low WAT inflammation and fibrosis|Patients who are obese with no evidence of inflammed white adipose tissue and no evidence of fibrosis.
11102476|NCT04059068||non- obese controls|Patients who are not obese.
11102477|NCT04059042|Experimental|Music|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music.
~The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (~60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level."
11102478|NCT04059042|Placebo Comparator|Nature Sounds|"The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (~1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds.
~Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level."
11102479|NCT04059029||Morbidly obese patients with NAFLD|Morbidly obese patient with Nonalcoholic fatty liver disease. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance. The diagnosis of NASH would be made histologically.
11102480|NCT04059003||Sensitivity group|100 patients will be assigned into sensitivity group according to the actual situation of them.
11102481|NCT04059003||Drug resistance group|100 patients will be assigned into drug resistance according to the actual situation of them.
11102482|NCT04058990|Experimental|Agent Paclitaxel-Coated PTCA Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (Agent Paclitaxel-Coated PTCA Balloon Catheter with paclitaxel 2.0 μg/mm²)
11102483|NCT04058990|Active Comparator|SeQuent Please Drug Eluting Balloon Catheter|Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (SeQuent Please Drug Eluting Balloon Catheter with paclitaxel 3.0 μg/mm²)
11102484|NCT04058977|Experimental|Power training|Randomized to early power training with standardized exercise progression plus standard of care
11102486|NCT04058964|Experimental|Treatment (pembrolizumab, PEGPH20)|Patients receive pembrolizumab IV over 10 minutes on day 1 and pegylated recombinant human hyaluronidase PH20 SC on days 1, 8, and 15. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
11102487|NCT04058951|Placebo Comparator|High Animal Protein Diet (HAPD)|Consuming a diet high in protein primarily from animal origin.
11102488|NCT04058951|Experimental|High Plant Protein Diet (HPPD)|Consuming a diet high in protein exclusive from plant origin.
11102489|NCT04058938|Active Comparator|Control|The control group received standard of care, including standard patient counseling from the surgical teams.
11102490|NCT04058938|Experimental|Intervention|In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.
11102491|NCT04058912||PATİENCE GROUP|"To be in the range of 18-40 years
~Patients with an operation indication with >=5 cm endometrioma
~Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)
~Patients who will be followed for IVF cycle due to infertility"
11102492|NCT04058912||PATİENCE-CONTROL GROUP|"To be in the range of 18-40 years
~Patients with operation plan due to non-endometrioma ovarian pathologies
~Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)
~Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic"
11102493|NCT04058899|Active Comparator|, Dexmedetomidine group(DEX group)|dexmedetomidine group (DEX)group who will receive 0.5 µg/kg dexmedetomidine diluted in 50 ml of normal saline 0.9% to be given by IV infusion over 10 minutes after induction of anesthesa then 5ml of 0.9% normal saline IV ,
11102494|NCT04058899|Active Comparator|Nalbuphine group(NAL group)|nalbuphine group (NAL)group will receive IV infusion of 50 ml of 0,9%normal saline by IV infusion over 10 minutes then 0.1mg/kg nalbuphine diluted in 5ml of 0.9%normal saline IV after induction of anesthesia.
11102495|NCT04058886|Experimental|Telephone-delivered Mindfulness|Participating caregivers and care partners will receive mindfulness training in 8 weekly telephone sessions plus one 3.5-hour retreat. Respite care for the care recipient is provided for the retreat.
11102496|NCT04058860|Other|Study Patients|Patients undergoing open heart surgery with minimal invasive extracorporeal circulation (MiECC) according to accepted indications
11102497|NCT04058847|Experimental|Intervention|Use of Your Heart Forecast and an e-mail follow up-program.
11102498|NCT04058847|No Intervention|Control|The control group uses standard regime (business as usual).
11102499|NCT04058834|Experimental|NNC0385-0434|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo. Following safety observation, patients with hypercholesterolaemia will enter a fourth cohort. There will be 15 participants in this cohort.
11102500|NCT04058834|Placebo Comparator|Placebo (NNC0385-0434)|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo.
11102501|NCT04058821|Experimental|Adults with traumatic brachial plexus injuries|Participants will have two MRI scans before surgery (to find out the best time to scan), then two after surgery (at 6 and 12 months).
11102502|NCT04058808|Experimental|Participants with Atrial Fibrillation attending the clinic.|
11102503|NCT04058795|Experimental|Cancer Distress Coach (CaDC)|Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.
11102504|NCT04058795|Experimental|CaDC and mCoaching|Participants in this group will get both the CaDC app and weekly clinician support.
11102505|NCT04058795|Experimental|mCBT|Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).
11102506|NCT04058795|No Intervention|Control|Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.
11102507|NCT04058782||Patients with myocardial|
11102508|NCT04058769|Other|Software first|Patients that are pre-operatively assessed first software-guided and then traditional
11102509|NCT04058769|Other|Traditional|Patients that are first pre-operatively assessed in the traditional way and then with aid of the software
11102510|NCT04058756|Experimental|PDR001|All subjects in all combination will be entered in one arm
11102511|NCT04058743|Active Comparator|TKA with standard cobalt chromium components|Patients randomized to this group will receive the standard cobalt chromium components in their total knee arthroplasty
11102512|NCT04058743|Experimental|TKA with nickel free components|Patients randomized to this group will receive nickel free components in their total knee arthroplasty
11102513|NCT04058730|Experimental|LRYGBP|"Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.
~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge."
11102514|NCT04058730|Experimental|LSG|Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge
11102515|NCT04058730|Experimental|SMM|"Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.
~Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult"
11102516|NCT04058717|Experimental|NNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
11102550|NCT04058457||GPi DBS|Patients planned to undergo deep brain stimulation of the globus pallidus interna
11102517|NCT04058717|Experimental|NNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.
11102518|NCT04058717|Experimental|VLNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
11102519|NCT04058717|Experimental|VLNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid
11102520|NCT04058704|Experimental|Early intervention|Icotinib is administered orally three times per day. Radiation therapy (SRS/ WBRT/ HA-WBRT/SMART) start in 1 month since take icotinib orally.
11102521|NCT04058704|Experimental|Late intervention|Icotinib is administered orally three times per day. Until emerge the progression of the disease, then is given radiation therapy (SRS/WBRT/HA-WBRT/SMART)
11102522|NCT04058678|Sham Comparator|CONTROL|"A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term normal ovarian reserve referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve."
11102523|NCT04058678|Experimental|EXPERIMENTAL|A group of women with diminished ovarian reserve that will take an inactive substance has been included to avoik biases and to set the fertility base line for women with compromised ovarian reserve.
11102524|NCT04058665||Observational group|No intervention performed. This is the overall group that will be retrospectively assessed for different variables pertaining to blood loss.
11102525|NCT04058652|Experimental|TENS therapy|the first step would be to administer the biologic medication in one thigh without the use of TENS therapy. Biologic medications are administered in two doses, with one in each thigh. Administering the first biologic medication injection is done to establish a control, or baseline, for how painful the injection experience is. The second step would be a study team member applying two to four TENS unit pads (made of adhesive gel) to the skin of subject's other thigh approximately two centimeters from the site where injection of the biological medication takes place. There will be no extra injection of biologic medication during this procedure. The prescribed dose will be used one time, split into two legs (which is the standard protocol for administration). The device will be turned on during the injection of the medication. Immediately after both steps, the subject will be given a brief survey to determine your pain level. The subject's involvement would last roughly 10-15 minutes.
11102526|NCT04058639|Experimental|felt relief|"custom felt relief"
11102527|NCT04058639|Active Comparator|treatment as usual|standard treatment usually provided by the Surgical Outpatient Clinic
11102528|NCT04058613|Experimental|Albumin|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
11102529|NCT04058613|Placebo Comparator|Placebo|Placebo
11102530|NCT04058600|Experimental|Virtual Reality|The patients will be exposed to a virtual reality software that simulates the environment of the hospital, from admission to the operating room and the recovery room.
11102531|NCT04058600|No Intervention|Control|Patients in this group are not exposed preoperatively to the virtual reality software and are given the standard therapy and cares for their disease.
11102532|NCT04058587|Experimental|Simmitinib tablet|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.
~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.
~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
11102533|NCT04058574|Active Comparator|ACL|"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction"
11102534|NCT04058574|Placebo Comparator|Control|Control Group: 15 healthy volunteers, athletes.
11102535|NCT04058561|Experimental|6 weeks|6-week lengthening interval
11102536|NCT04058561|Active Comparator|16 weeks|16-week lengthening interval
11102537|NCT04058548|Experimental|6MWT and STS|All participates will receive 6MWT and STS test
11102538|NCT04058535|Experimental|ALT-L9|Intravitreal injection of ALT-L9 50 ul, every 4 weeks
11102539|NCT04058535|Active Comparator|Eylea|Intravitreal injection of Eylea 50 ul, every 4 weeks
11102540|NCT04058522|Experimental|Group Physiotherapy|1 class per week for 6 weeks (30 min length) aiming for 5-10 participants per class. Classes included advice on the nature of the condition and exercises for scapulo-humeral mobility, scapulo-humeral stability and specific rotator cuff rehabilitation exercises
11102541|NCT04058522|Active Comparator|Routine Physiotherapy|Individual physiotherapy sessions: 6 sessions weekly (30 min) for 6 weeks. Treatment was based on evidence-based guidelines for the treatment of shoulder impingement (CSP 2005) and consisted of mobilisation techniques, supervised exercises and stretches.
11102542|NCT04058509|Experimental|focused shockwave therapy|3 sessions of shock wave treatment.(Focused Shockwave Therapy).
11102543|NCT04058496||1|Coronary artery bypass surgery off-pump (n=20)
11102544|NCT04058496||2|Coronary artery bypass surgery on-pump (n=20)
11102545|NCT04058496||3|Coronary artery bypass surgery plus valve surgery (n=20)
11102546|NCT04058483|Active Comparator|HIP First|Participants randomized to perform the in-person hypnotizability test first. This will be followed within 1 week with the by-phone rHIP test performed by a second, randomly-assigned investigator.
11102547|NCT04058483|Active Comparator|rHIP First|Participants randomized to perform the by-phone hypnotizability test first. This will be followed within 1 week with the in-peron HIP test performed by a second, randomly-assigned investigator.
11102548|NCT04058470|Experimental|TR-CHOP|TR-CHOP: Toripalimab,Rituximab,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone
11102549|NCT04058457||STN DBS|Patients planned to undergo deep brain stimulation of the subthalamic nucleus
11102551|NCT04058457||VIM DBS|Patients planned to undergo deep brain stimulation of the ventral intermediate nucleus of thalamus.
11102552|NCT04058444|Experimental|ERAS Group|Perioperative management follows the ERAS (Enhanced Recovery After Surgery) protocol
11102553|NCT04058444|Experimental|Control Group|Perioperative management follows the conventional program
11102554|NCT04058431|Experimental|Osteopathic group|Treatment will be compromised of 8 weeks of standard care plus OMT. Each physician will maintain the same patient at recurring sessions. Osteopathic treatment is performed for 30 minutes and the techniques applied are highly individualized to the patient needs (i.e., techniques are selected based on structure/function, and techniques change over time based on treatment response). In an effort to standardize treatment, we will limit the study protocol to the following designated techniques: facilitated positional release treatment, high velocity low amplitude treatment, articulatory treatment, strain-counterstrain, muscle energy treatment, myofascial release treatment, soft tissue treatment.
11102555|NCT04058418||Familial breast cancer risk assessment services in England|All familial breast cancer risk assessment services in England
11102556|NCT04058392|Experimental|Camu Camu|Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
11102557|NCT04058379|Experimental|CT scan|During this study each patient will have 3 CT scans : D0, D1 and D3. A daily follow up during first seven days in ICU, then a follow up at D28 if still in hospital, and a phone call at M6 for neurological outcome
11102558|NCT04058366|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
11102559|NCT04058353|Experimental|Triple Combination Arm|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
11102560|NCT04058353|Active Comparator|Control Arm|Subjects will receive either IVA as mono tablet OR TEZ/IVA as FDC in the morning and IVA as mono tablet in the evening.
11102561|NCT04058340|Active Comparator|lactizole-placebo|A group of patients who will receive 3ml lactizole solution (150ppm) in nebulization twice a day for 4 weeks , and then for the next 4 weeks they will receive 2 times a day 3ml 0.9% NaCl solution in nebulization
11102562|NCT04058340|Active Comparator|placebo-lactizole|A group of patients who will receive 2 times a day for 4 weeks (0.9% NaCl solution in nebulization) for 4 weeks and will receive 3ml of lactizole solution (150ppm) in nebulization 2 times a day for 4 weeks
11102563|NCT04058327||MHE group|Patients whose MHE test are positive
11102564|NCT04058327||no HE group|Patients whose MHE test are negative
11102565|NCT04058327||overt HE group|2/3/4 HE patients
11102566|NCT04058314|Experimental|Study Eye|Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
11102567|NCT04058314|Active Comparator|Control Eye|control eyes will received an approved monofocal or toric IOL after cataract extraction
11102568|NCT04058301|No Intervention|Handout|Participants receive a generic handout about resources in Boston
11102569|NCT04058301|Experimental|Text message|Participants receive a generic handout about resources in Boston and a text message with a geographically proximate resource
11102570|NCT04058288||Stroke|People suffering from upper-limb motor dysfunction due to stroke
11102571|NCT04058275||Control|Deployed to 1990-1991 Persian Gulf War Do not meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] Good general medical and psychiatric health
11102572|NCT04058275||Gulf War Illness|Deployed to 1990-1991 Persian Gulf War Meet Kansas Criteria for Gulf War Illness [Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000 Nov 15; 152:992-1002. PubMed PMID: 11092441.] plus Center for Disease Control criteria for Chronic Multisymptom Illness (CMI) [Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, Noah DL, Barrett DH, Randall B, Herwaldt BL, Mawle AC, Reeves WC. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998 Sep 16;280(11):981-8. PubMed PMID: 9749480.]
11102573|NCT04058262|Experimental|Meditation presential|
11102574|NCT04058262|Experimental|Reiki|
11102575|NCT04058262|Experimental|Meditation (app)|
11102576|NCT04058262|Placebo Comparator|round of conversation|
11102577|NCT04058249|Experimental|Right DLPFC aiTBS stimulation|
11102578|NCT04058236|Experimental|human albumin 5%|10 patients with pancreatic cancer will receive human albumin 5% in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
11102579|NCT04058236|Active Comparator|gelofusine|10 patients with pancreatic cancer will receive gelofusine in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
11102580|NCT04058223||PPH/DST|Patients underwent hemorrhoidopexy by PPH or DST stapler.
11102581|NCT04058197|Experimental|Active|Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks
11102582|NCT04058197|Placebo Comparator|Placebo|Placebo
11102583|NCT04058184||Contact sports players|Athletes who engage in contact sports, football for example. Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
11102584|NCT04058184||Non-contact sports players|Athletes who engage in non-contact sports, swimming for example.Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
11102585|NCT04058171||LSS group|Participants with a diagnosis of lumbar spinal stenosis
11102586|NCT04058171||PAD group|Participants with a diagnosis of peripheral artery disease
11102587|NCT04058171||LBP group|Participants with a diagnosis of non specific low back pain
11102588|NCT04058158|Experimental|Treatment Sequence I|Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® at Week 26
11102589|NCT04058158|Experimental|Treatment Sequence II|Subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26
11102590|NCT04058145|Experimental|Pembrolizumab+AMD3100 q3w|"Pembrolizumab is administered intravenously on day 1 of each cycle
~AMD3 100 is administered via injection subcutaneously on day 1 of each cycle"
11102591|NCT04058145|Experimental|Pembrolizumab+AMD3100 weekly|"Pembrolizumab is administered intravenously on day 1 of each cycle
~AMD3 100 is administered via injection subcutaneously on a weekly basis"
11102592|NCT04058145|Experimental|Pembrolizumab+AMD3100|"Pembrolizumab is administered intravenously
~AMD3 100 is administered via injection subcutaneously"
11102593|NCT04058132|Other|Group 1: acute/subacute Traumatic Brain Injury|Any gender, age 18-55 years who have had a traumatic brain injury within 30 days
11102594|NCT04058132|Other|Group 2: Non-TBI healthy control (HC)|Any gender, age 18-55 years with no history of traumatic brain injury
11102595|NCT04058119|Experimental|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates)
11102596|NCT04058119|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the Functional Training Program after the experimental period (6 months).
11102597|NCT04058106||A patient who need the spine surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for spine surgery
11102598|NCT04058093|Experimental|Functional Training Program|"Functional training program (FTP) will last for 6 months and will include:
~Functional training sessions (each 45-minutes long, twice a week);
~Group nutrition counseling (each 90-minutes long, in three different moments throughout the intervention: week 1, 12 and 20)."
11102599|NCT04058093|No Intervention|Waiting list control group|Participants will not participate in any specific intervention, but will receive the FTP after the experimental period (6 months).
11102600|NCT04058080|Experimental|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6 degrees Celsius, 40% humidity). The class opened with a deep breathing exercise and continued with 50 minutes of standing asanas and 40 minutes of floor-based asanas, including a quick, forceful breathing exercise to finish. All but the last asana (i.e., spine-twisting) were performed twice. Savasana, which is a restorative and relaxation posture, was performed between asanas throughout the floor series and at the end of class. The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
11102601|NCT04058080|Active Comparator|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Selecting these classes was done in consultation with the general manager of the YMCA, who was familiar with each class type. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration.
11102602|NCT04058080|No Intervention|Waitlist|Waitlisted individuals were not able to access yoga or exercise classes throughout the intervention period but participated in the rest of the study protocol. Following the post-treatment assessment, they received access to the class type of their choosing.
11102603|NCT04058067|Experimental|Brolucizumab 6 mg|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
11102604|NCT04058067|Active Comparator|Aflibercept 2 mg|5 x every 4 weeks loading then every 8 weeks maintenance
11102605|NCT04058054|Experimental|KeraStat® Cream|KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.
11102606|NCT04058054|Experimental|KeraStat® Gel|KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.
11102607|NCT04058054|Experimental|Biafine|Wound dressing for management of partial and full thickness wounds.
11102608|NCT04058054|Active Comparator|Histamine|Histamine is provided as a solution of histamine base (6.0 mg/mL).
11102609|NCT04058054|Sham Comparator|Saline|Saline (sterile) is provided as a 0.9% NaCl solution.
11102610|NCT04058041|Experimental|Neural mobilization|passive mobilization of the median nerve by the therapist following by an active movement of the fingers of the pathology hand
11102611|NCT04058041|Active Comparator|Surgery|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will teach home exercises (no neural exercises) to the patients.
11102612|NCT04058041|Active Comparator|Surgery and Neural mobilization|the surgeon will release the median nerve in the tunnel carpal. After that the therapist will perform mobilizations of the median nerve just like the experimental group.
11102613|NCT04058028|Experimental|AMG 570, Dose A|Investigational product solution in vial
11102614|NCT04058028|Experimental|AMG 570, Dose B|Investigational product solution in vial
11102615|NCT04058028|Experimental|AMG 570, Dose C|Investigational product solution in vial
11102616|NCT04058028|Placebo Comparator|Placebo for AMG 570|Placebo Investigational product solution in vial
11102617|NCT04058015||adult patients with thoracoabdominal injuries|adult patients with moderate to severe thoracoabdominal injuries
11102618|NCT04058002|Experimental|Experimental|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
11102619|NCT04058002|Active Comparator|Control group|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
11102620|NCT04057989||Battlefield Injury with ketamine treatment|Patients who received ketamine infusions to treat pain from January 2007 to December 2013.
11102621|NCT04057976|Experimental|Patients having pre-operative DTT prior to surgery|All patients in this study will undergo DTT as part of a pre-operative MRI.
11102651|NCT04057755|Active Comparator|Botulinum toxin A|50 Allergan units (diluted in 0,5 ml sterile NaCl) will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
11102622|NCT04057963|Experimental|Conventional plus Functional Inspiratory Muscle Training Group|Conventional program plus functional inspiratory muscle training will be carried out three sessions per week during the six weeks. The content of the program will be the same as for the conventional group. Additional functional inspiratory muscle training will be began with 50% of the maximal inspiratory pressure value in a specific device and it will be progressed 5% every week according to the tolerance.
11102623|NCT04057963|Active Comparator|Conventional Physiotherapy Program|Conventional program will be carried out three sessions per week during the six weeks. Cervical mobilization techniques (glidings-grade 2) of cyriax will be applied in the direction of lateral flexion and rotation. Stretching exercises, craniovertebral flexion exercise and scapulothoracic strengthening exercises will be performed.
11102624|NCT04057950|Active Comparator|treating shampoo|treating shampoo (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo) 1144628 D cosmetic product
11102625|NCT04057950|Placebo Comparator|vehicle|1144781 cosmetic product
11102626|NCT04057937|Experimental|30 mg Apremilast twice daily (BID) from week 0 to 32|Subject will received Apremilast 30 mg BID from Week 0 to Week 32 weeks. Dose titration will be implemented in the first week of this study.
11102627|NCT04057937|Placebo Comparator|Placebo and Apremilast|Subject will receive Placebo BID from Week 0 to Week 16 and will receive 30 mg Apremilast BID from week 16 to 32. Dose titration will be implemented in the first week of subject switch to receive Apremilast.
11102628|NCT04057924||CIN 2 women|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
11102629|NCT04057911|Experimental|Real NIBS|In Real NIBS arm, active Noninvasive brain stimulation (NIBS) will be given for 20 mins.
11102630|NCT04057911|Sham Comparator|Sham NIBS|In Sham NIBS arm, sham Noninvasive brain stimulation (NIBS) will be given for 20 mins.
11102631|NCT04057898|Experimental|MN-166|Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day, along with a stable dose of riluzole, daily for 12 months.
11102632|NCT04057898|Placebo Comparator|placebo|Subjects will take up to 5 matching placebo capsules twice a day, along with a stable dose of riluzole, daily for 12 months.
11102633|NCT04057885|Experimental|Device Arm|A prospective series of 10 patients will receive sensor-guided TKA using the this special Orthosensor™ VERASENSE™ Knee System assisted surgery for optimization of soft tissue balance
11102634|NCT04057885|Active Comparator|Standard of Care|10 patients will receive standard of care. Prior to cementing final implants, VERASENSE will be utilized with the standard of care group with the surgeon blinded to the data.
11102635|NCT04057872|Active Comparator|TPE in Septic Shock|The patients in this arm will receive TPE
11102636|NCT04057872|No Intervention|Reference Population|The patients will receive the standard of care for septic shock treatment
11102637|NCT04057846|Active Comparator|Double pigtail|Plastic stent group EUS-guided drainage shall be performed as follows: a) Puncture of WON with a 19 GA Access needle (Cook Medical), b) aspiration of fluid in WON for microbiological assessment, c) insertion of guidewire (0.035 inch, 450 cm, Dreamwire (Boston Scientific), d) creation of transmural tract with needle knife over the guidewire, e) dilatation of tract to a diameter of 15 mm with dilation balloon (EZDilate, Olympus), f) insertion of two 7-Fr/6 cm double pigtail stents and a 7-Fr naso-cystic irrigation catheter.
11102638|NCT04057846|Experimental|Lumen apposing metal stent|LAMS shall be the Hot AXIOS stent with electrocautery-enhanced delivery system (Boston Scientific). The stent is a through-the-scope, fully covered, self-expandable metal stents with a diameter of 20 mm and a length of 10 mm. Before placement of the LAMS, the WON shall be punctured with a 19 GA Access needle (Cook Medical) and fluid in WON aspirated for microbiological assessment. Thereafter the LAMS shall be placed as follows: After directly puncturing the WON using the electrocautery tip (without the use of a guidewire to assist in stent insertion), the delivery catheter is advanced into the WON and the distal flange is deployed under EUS-guidance. The proximal flange is then released under EUS guidance or endoscopic view. After placement of the LAMS, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS.
11102639|NCT04057833|Experimental|E-CEL UVEC|"Patients will receive an injection of the Cell therapy vehicle into their supraspinatus muscle and tendon at the time of rotator cuff repair.
~E-CEL UVEC cells suspended in autologous plasma and combined with thrombin at the implantation site (tendon delivery).
~E-CEL UVEC cells suspended in 6.0% Dextran 40 and 10.0% human serum albumin (HSA) (infusion solution) (muscle delivery)."
11102640|NCT04057820|Active Comparator|Usual care, Finnegan Neonatal Abstinence Scoring Tool|Usual institutional care for infants with NOWS with the Finnegan Neonatal Abstinence Scoring Tool (FNAST)
11102641|NCT04057820|Active Comparator|Eat, Sleep, Console care tool|New treatment implemented at the site for infants with NOWS using the Eat, Sleep, Console (ESC) care tool
11102642|NCT04057807|Experimental|Patients receiving endotoxin|The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
11102643|NCT04057807|No Intervention|control|
11102644|NCT04057794|Active Comparator|Site-Based Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
11102645|NCT04057794|Active Comparator|Centralized Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.
11102646|NCT04057781|No Intervention|Control|
11102647|NCT04057781|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment every 2 weeks for 6 weeks (weeks 0, 2, 4, 6).
~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
11102648|NCT04057781|Active Comparator|Dry Needling with Intramuscular ES (DNES)|"Subjects will receive dry needling treatment with electrical stimulation every 2 weeks for 6 weeks (week 0, 2, 4, 6)
~Outcomes will be measured at baseline (week 0), 4 weeks after initiation of study (week 4), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
11102649|NCT04057768|Other|Intervention|Device: Venus Viva
11102650|NCT04057755|Experimental|Botulinum toxin A vs placebo|50 Allergan units (diluted in 0,5 ml sterile NaCl) or 0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance, dose and volume will be repeated after 3 months.
11102690|NCT04057469|Placebo Comparator|Placebo|
11102652|NCT04057755|Placebo Comparator|NaCl|0,5 ml of sterile NaCl will be injected in the bulbocavernosus muscle just inside the hymenal ring. The injection with the same substance and volume will be repeated after 3 months.
11102653|NCT04057742||Group A|30 participants with a positive virtual crossmatch (VXM) at the time of transplant will be monitored for 24 months and undergo protocol biopsies on months 3, 12, and 24 to detect subclinical rejection. Participants may also undergo clinically indicated biopsies for suspicion of rejection. AlloSure, AlloMap, immune cell phenotypes, and inflammatory cytokines will be measured at baseline (within 48 hours of transplant), 3 weeks, 6 weeks, 3 months (Standard of Care (SOC) biopsy), 6 months, 12 months (SOC biopsy), 24 months (SOC biopsy) and additionally at the time of any indication biopsy (5-8 time points/participant). Participants in this group will be monitored for 24 months per SOC.
11102654|NCT04057742||Group B|35 participants with De novo donor specific antibodies (dnDSA) will undergo a SOC biopsy within approximately three months to determine the incidence of Active Antibody Mediated Rejection (AMR). Immune cell phenotyping, AlloSure, and AlloMap will be measured at the time of the SOC biopsy (1 timepoint/patient). This is a single-time point study, unless participants are diagnosed with AMR and require treatment. In this case, they would be enrolled in group C (see below).
11102655|NCT04057742||Group C|35 additional participants with the diagnosis of Chronic Active Antibody Mediated Rejection (cAMR) will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months. Immune cell phenotyping, AlloSure, and AlloMap will be used at baseline (prior to index biopsy) and 3 month (follow-up surveillance biopsy) (2 timepoints/participant). Participants in this group will be monitored per SOC for three months (time between the two biopsies).
11102656|NCT04057729|Experimental|Arm 1 （IMP4297 100mg, Fasted-Fed）|Period 1: Fasted control → Period 2: Fed control
11102657|NCT04057729|Experimental|Arm 2（IMP4297 100mg, Fed- Fasted）|Period 1: Fed control → Period 2: Fasted control
11102658|NCT04057716|Experimental|Sleep restriction followed by extension|Children will spend 1.5 hours less than usual in bed for one week, engage in one week of wash-out, and then spend 1.5 hours more than usual in bed for one week.
11102659|NCT04057716|Experimental|Sleep extension followed by restriction|Children will spend 1.5 hours more than usual in bed for one week, engage in one week of wash-out, and then spend 1.5 hours less than usual in bed for one week.
11102660|NCT04057690||MCA ischemia without malignant edema|MCA ischemia without malignant edema
11102661|NCT04057690||MCA ischemia with malignant edema|MCA ischemia without malignant edema w/o surgical treatment
11102662|NCT04057677|Experimental|Exercise Recovery|Older males and females with Type 2 diabetes. We are examining the effects of a recovery exercise program for older adults with type 2 diabetes. Following 10 days of bed rest and during the first 4 weeks of recovery, participants will perform a combination of aerobic and resistance exercise training.
11102663|NCT04057677|Experimental|Non-Exercise Recovery|Older males and females with Type 2 diabetes. Participants in the ambulatory recovery group will not receive any exercise intervention or advice on exercise following 10 days of bed rest. Rather these participants will return to their regular daily routine that they engaged in prior to the bed rest intervention.
11102664|NCT04057664||Multidisciplinary Group Therapy|Multidisciplinary group therapy for women with chronic pelvic or belly pain
11102665|NCT04057651||Hip osteoarthritis waiting for surgery|
11102666|NCT04057651||Knee osteoarthritis waiting for surgery|
11102667|NCT04057638|Experimental|Treatment group|There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
11102668|NCT04057625|Other|lung ultrasound|using lung ultrasound in diagnosis and follow up of vap measuring the largest area of consolidation according to intercostal space and the direction of the probe
11102669|NCT04057612||Pediatric participants|"Participants' temperature measured at 2 places at the same time
~Esophagus
~Skin near to carotid artery"
11102670|NCT04057586|Experimental|Nonintubated|Nonintubated thoracoscopic surgery
11102671|NCT04057586|Active Comparator|Intubated|Intubated thoracoscopic surgery
11102672|NCT04057573|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
11102673|NCT04057573|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
11102674|NCT04057560||SIBO Group|
11102675|NCT04057560||Control Group|
11102676|NCT04057547|Experimental|Experimental group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
11102677|NCT04057547|Active Comparator|Control group|Mesalazine sustained-release granules, orally, 0.5g/time, 4-6 times/d Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
11102678|NCT04057534|Experimental|CB-CRT AUD group|experimental group AUD: patients receive standard clinical therapy and an add-on chess based - cognitive remediation treatment (CB-CRT)
11102679|NCT04057534|Active Comparator|Control group AUD|control group: patients with AUD receive standard clinical therapy
11102680|NCT04057534|Experimental|CB-CRT TUD group|experimental group TUD: patients receive standard smoking cessation therapy and an add-on CB-CRT
11102681|NCT04057534|Active Comparator|Control group TUD|control group: patients with TUD receive standard smoking cessation therapy
11102682|NCT04057521|Experimental|CHECK Program|Participants were offered enrollment into CHECK care coordination services.
11102683|NCT04057521|Active Comparator|Comparison Group|Participants were not offered enrollment into CHECK.
11102684|NCT04057508|Active Comparator|Stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order .
11102685|NCT04057508|Sham Comparator|Sham stimulation protocol|Each subject will be blinded and underwent 3 phases of stimulation (actives (2) and sham (1) comparators) in a randomized order.
11102686|NCT04057495|Placebo Comparator|no mango intake|No mango consumption on the study visit
11102687|NCT04057495|Experimental|white bread with same amount of calorie as mango|White bread consumption on the study visit
11102688|NCT04057495|Experimental|mango consumption|mango consumption on the study visit
11102689|NCT04057469|Experimental|Tulobuterol patch|
11102691|NCT04057456|Placebo Comparator|Placebo diet and placebo capsules|Participants taking the placebo diet and capsules
11102692|NCT04057456|Active Comparator|Placebo diet and THC/CBD capsules|Capsules will be 1:1 (2.5 mg:2.5 mg)
11102693|NCT04057456|Active Comparator|Placebo diet and high CBD Capsules|Capsules will be 1:20 (1mg:20mg)
11102694|NCT04057456|Active Comparator|Anti-inflammatory diet and placebo capsules|this meal plan will eliminate foods that have been established as pro-inflammatory (e.g. processed foods, refined sugars, refined wheat products, etc.) as well as foods that are commonly associated with even mild intolerances (e.g. cow's milk) and those that negatively impact cardiovascular health (e.g. hydrogenated oils, alcohol, coffee, refined sugars and wheat, trans fats, processed foods). In their place, the meal plan will consist of foods with established anti-inflammatory properties (e.g. (Oily fish, lean poultry, dark leafy greens, cruciferous vegetables, nuts, whole grains, most kinds of berries, etc).
11102695|NCT04057456|Active Comparator|Anti-inflammatory diet and THC/CBD capsules|capsules will be 1:1 (2.5mg:2.5mg)
11102696|NCT04057456|Active Comparator|Anti-inflammatory diet and High CBD capsules|Capsules will be 1:20 (1mg:20mg)
11102697|NCT04057443|Experimental|Intervention group|Patients in the intervention group will follow the standard treatment and follow-uo according to the clinical protocol of the institution and will participate in an intervention program with physical exercise and nutritional support during the period in which they are receiving oncological treatment or for a maximum period of 6 months.
11102698|NCT04057443|Active Comparator|Control group|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
11102699|NCT04057430|Active Comparator|String floss|
11102700|NCT04057430|Experimental|Gumchucks floss|
11102701|NCT04057417|Experimental|Urban Trail Expansion|Neighbourhoods within 400m to 800m of a neely built greenway, defined as a multi-use concrete/asphalt trail that was >4km in length)
11102702|NCT04057417|No Intervention|Control|Neighbourhoods that are located beyond 400 to 800m of a newly built greenway
11102703|NCT04057391||QT Scanner in comparison to mammography|Women who have experience with both technologies (QT Scanner/Breast mammography
11102704|NCT04057378|Active Comparator|0.5 ms pulse width stimulus|Electroconvulsive therapy initiated with 0.5 ms pulse width stimulus
11102705|NCT04057378|Active Comparator|1.0 ms pulse width stimulus|Electroconvulsive therapy initiated with 1.0 ms pulse width stimulus
11102706|NCT04057365|Experimental|DKN 01 and Nivolumab Safety Run in|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle
~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
11102707|NCT04057365|Experimental|DKN 01 and Nivolumab|"DKN-01 will be administered intravenously on day 1 and day 15 of each 28 day cycle
~Nivolumab will be administered intravenously on day 1 and day 15 of each 28 day cycle"
11102708|NCT04057352|Other|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
11102709|NCT04057339|Placebo Comparator|SOC (Standard of Care)|Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
11102710|NCT04057339|Experimental|TRE + SOC|Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
11102711|NCT04057326|Active Comparator|Oryz-Aspergillus Enzyme and Pancreatin Tablet Arm|Oryz-Aspergillus Enzyme and Pancreatin Tablet ,2 tablets/time, 3 times daily. Study drug will be administered orally.
11102712|NCT04057326|Placebo Comparator|Placebo Arm|Placebo,2 tablets/time, 3 timesdaily. Study drug will be administered orally.
11102713|NCT04057313|Active Comparator|Group 1|Group 1 will receive 80 cc of coffee in the dialysis session
11102714|NCT04057313|Placebo Comparator|Group 2|Group 2 will receive 80 cc of decaffeinated coffee in the dialysis session
11102715|NCT04057300|Experimental|Ticagrelor 90mg|Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
11102716|NCT04057300|Active Comparator|Clopidogrel 75mg|Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
11102717|NCT04057287||NASH related Cirrhosis|
11102718|NCT04057287||Healthy Controls|
11102719|NCT04057287||First Degree Relatives of NASH related Cirrhosis|
11102720|NCT04057287||HBV Disease Control|
11102721|NCT04057274|Experimental|Exercise assessment|The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
11102722|NCT04057274|No Intervention|Resting assessment|The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
11102723|NCT04057261|Active Comparator|Liraglutide|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen.
11102724|NCT04057261|Placebo Comparator|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
11102725|NCT04057248|Experimental|Individual's Quality of Life and Clinical parameters|Clinical parameters (HbA1C, weight, lipids profile, etc.)
11102726|NCT04057222||Patients included|"Patient with multiple sclerosis and anorectal symptoms, with indication to realize a anorectal manometry, age > 18
~A first record of rectal sensory function will be at strong desire to void. A second record will be after void. Rectal sensory function records consist on an anorectal manometry with 3 measures of external anal sphincter resting pressure, 5 measures of RAIR, 1 measure of perception, constant sensation to need to defecate and maximum tolerable threshold volumes."
11102727|NCT04057209|Active Comparator|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|Transoral CO2-Laser Microsurgical Cordectomy defined by European Laryngological Society (Remacle M, Eckel HE, Antonelli A, et al. Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol. 2000;257(4):227-231.)
11102920|NCT04056039|Active Comparator|"Atorvastatin"|"-Changes of troponin I in rheumatoid arthritis with atorvastatin 40 mg orally every 24 hours for four weeks"
11103074|NCT04055077|Experimental|ASA II/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11102728|NCT04057209|Experimental|Arm B: Single Vocal Cord Irradiation (SVCI)|Single Vocal Cord Irradiation defined by Kwa et al. and Al-Mamgani et al. (Kwa SLS, Al-Mamgani A, Osman SOS, Gangsaas A, Levendag PC, Heijmen BJM. Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. Int J Radiat Oncol Biol Phys. 2015;93(1):190-195. Al-Mamgani A, Kwa SLS, Tans L, et al. Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results. Int J Radiat Oncol Biol Phys. 2015;93(2):337-343.)
11102729|NCT04057196|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 12 weeks.
11102730|NCT04057170|Experimental|mulligan method|Mulligan mobilization with mowement method every three days for six weeks
11102731|NCT04057170|Experimental|accelerated protocol|accelerated rehabilitation protocol every three days for six weeks
11102732|NCT04057144|Experimental|ACT with mindfulness|4-hour weekly session of acceptance and commitment therapy (ACT) with mindfulness exercises during 8 weeks in groups of 8
11102733|NCT04057144|Experimental|ACT without mindfulness|4-hour weekly acceptance and commitment therapy (ACT) without mindfulness exercises during 8 weeks in groups of 8
11102734|NCT04057144|Active Comparator|Education program|Self-management education program during 8 weeks in groups of 8.
11102735|NCT04057131||Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
11102736|NCT04057118|Experimental|SKI-O-703 100 mg|
11102737|NCT04057118|Experimental|SKI-O-703 200 mg|
11102738|NCT04057118|Experimental|SKI-O-703 400 mg|
11102739|NCT04057118|Placebo Comparator|Placebo|
11102740|NCT04057092|Experimental|Intervention group|Eligible patients undergoing gynecologic oncology or general surgery will receive perioperative immunonutrition supplement INergy-FLD®. The operation should occur within 8 weeks from enrolment in the pilot study. Upon assessment and enrolment in the pilot study, patients will have a consultation with their physician in the preoperative clinic and will be provided with 10 days worth of INergy-FLD® beverages, 30 servings total.
11102741|NCT04057079|Experimental|Anugel|"In this arm, after the surgery a hydrogel impregnated sponge will be placed in the rectum.
~The patient is evaluated after the operation and the following day when the sponge is removed.
~A hydrogel impregnated foam pad is applied on the surface of the wound the following 5 days.
~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5
~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
11102742|NCT04057079|Active Comparator|Sponge|"Currently used treatment method i.e. insertion of gelatine sponge in to the rectum post operation.
~The patient is evaluated on post op, on day 1 (usually before discharge) and day 5
~The pain of the patients are evaluated according to the VAS scale and the use of analgesics and opioids is monitored."
11102743|NCT04057066|Experimental|Intervention|Participants receive physical activity counseling as well as an individualized exercise plan.
11102744|NCT04057053|Experimental|Netarsudil use|Patient eye undergoes cataract surgery + DWEK, immediately after surgery Netarsudil 0.02% ophthalmic 1 drop daily is used in the operative eye until corneal clearance is documented.
11102745|NCT04057053|Active Comparator|Standard of care + possible rescue drop|Patient eye undergoes cataract surgery + DWEK, no Netarsudil is used after surgery, if cornea is not cleared in time for first eye Netarsudil 0.02% ophthalmic 1 drop dailyadded daily as possible rescue drop and time to corneal clearance is documented
11102746|NCT04057040|Experimental|Experimental Dose Escalation (Part 1)|PTG-300 Subcutaneous (SC) weekly. Each subject's PTG-300 dose is increased at 4 week intervals until the subject reaches the maximum planned dose or has a prespecified decrease in hematocrit from baseline.
11102747|NCT04057040|Experimental|Blinded Withdrawal (Part 2) PTG-300 or placebo|PTG-300 or placebo Subcutaneous (SC) weekly.
11102748|NCT04057040|Experimental|Experimental Open label extension (Part 3) PTG-300|PTG-300 Subcutaneous (SC) weekly
11102749|NCT04057027|Experimental|Delayed Cord Clamping for 30 seconds|Infants whose umbilical cord clamping will be delayed for 30 secs.
11102750|NCT04057027|Experimental|Delayed Cord Clamping for 60 seconds|Infants whose umbilical cord clamping will be delayed for 60 secs.
11102751|NCT04057027|Experimental|Umbilical Cord Milking|Infants whose umbilical cord will be clamped after milking from the distance of 20 cm from mother's side to the baby for 3-4 times.
11102752|NCT04057014|Active Comparator|Extraction Only|Immediate extraction of infected tooth without antibiotic prescription.
11102753|NCT04057014|Experimental|Average Dose Antibiotic|Average dose antibiotic therapy(25 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 10 days and receive tooth extraction on day 10 (25 patients). (*given the average weight of a 12 year old is 45 kilos, we do not expect that we will reach the maximum dose in this group)
11102754|NCT04057014|Experimental|High Dose Antibiotic|High dose antibiotic therapy (45 mg/kg/day in divided doses every 12 hours (maximum 875 mg/dose)) for 5 days and receive tooth extraction on day 10 (25 patients)
11102755|NCT04057001||Patients who received a HCV+ liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
11102756|NCT04057001||Patients who received a HCV- liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.
11102757|NCT04056988|Experimental|Acute spinal cord injury patients to undergo contrast-enhanced|"Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
~A hand-held intraoperative ultrasound probe will be used to collect sagittal images of the spinal cord centered above the spinal cord injury. A bolus IV injection of DEFINITY® contrast agent (1.5ml DEFINITY®/8.5ml saline) will be given. Continuous imaging will be obtained to record contrast inflow and washout."
11102758|NCT04056975|Experimental|single arm|A-319 dosage: 0.05, 0.15, 0.03, 0.06, 0.12, 0.18, 0.24 μg/kg
11102759|NCT04056962|Experimental|patients treated with Tacrolimus ointment|
11102760|NCT04056949|Other|IBI308 + Paclitaxel/Albumin-Bound Paclitaxel|IBI308 Combined with Albumin-Bound Paclitaxe
11102962|NCT04055805||Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale|
11102761|NCT04056936||Infants diagnosed with a tongue-tie and a frenotomy|If a tongue-tie is present at the routine newborn examination, the infant can be included in the study. If the infant also has breastfeeding problems and there is a decreased tongue mobility and poor sucking ability, the pediatrician may find indication for frenotomy. If the frenotomy is performed before discharge the infant is included in this group. All Mother-infant dyads will get breastfeeding support.
11102762|NCT04056936||Infants diagnosed with a tongue-tie and no frenotomy|The infants that are recruited to the tongue-tie cohort that do not receive treatment before discharge. The pediatrician evaluates that the tongue tie does not cause any functional problems and no treatment is performed before discharge. All Mother-infant dyads will get breastfeeding support.
11102763|NCT04056936||All infants born in Telemark and Vestfold Counties|All the infants born in the study period that will contribute to the prevalence study.
11102764|NCT04056923|Experimental|3D-printed template-guided(3D-G)|Intraoperative 3D-G methylene blue dye marking in the operating room
11102765|NCT04056923|Active Comparator|CT-guided(CT-G)|Preoperative localization is performed by CT-G indocyanine green marking in the radiology department
11102766|NCT04056910|Experimental|Concurrent dosing of ivosidenib and nivolumab|Ivosidenib will be administered concurrently with nivolumab on a Q28 day schedule.
11102767|NCT04056897|Experimental|BCD-132, 125 mg|72 patients
11102768|NCT04056897|Experimental|BCD-132, 500 mg|72 patients
11102769|NCT04056897|Active Comparator|Teriflunomide|72 patients
11102770|NCT04056897|Placebo Comparator|Placebo|54 patients
11102771|NCT04056884|Active Comparator|SIBS intervention|SIBS intervention is a 5-session group intervention for siblings and parents of children with chronic illness. Sessions 1-3 are delivered in one day, and sessions 4-5 are delivered in one day one week later.
11102772|NCT04056884|No Intervention|Waitlist|Waitlist is 12 week of no intervention/usual care
11102773|NCT04056871||Fried Frailty Phenotype|This group of patients will be assess by using 5 characteristics of Frailty which are weight loss, weakness, exhaustion, low activity and physical fitness of the patients. Patients classify as frail will have more than 3 criteria, intermediate or pre-frail will be 1 or 2 criteria present and robust will not have criteria.
11102774|NCT04056871||Groningen Frailty Index|GFI is a simple questionnaire consisting of 15 items which are classified into 8 groups, consistent of 4 domains of functioning. A score of 4 or more indicates a higher risk for frailty and possible delirium.
11102775|NCT04056845|Experimental|Knee brace group|Patients in this group will receive a valgus knee brace (Medex K39-OA Corrector), to be worn for at least four hours a day, during the study period, on top of the presrciption of physiotherapy and oral analgesic (diclofenac and panadol).
11102776|NCT04056845|Active Comparator|Control Group|Patients in this group will receive physiotherapy and oral analgesic (diclofenac and panadol).
11102777|NCT04056832|Experimental|Single Strip Pericardium|Aortic Valve Replacement using single strip of patient's autologous pericardium
11102778|NCT04056832|Active Comparator|Mechanical Prosthetic Valve|Aortic Valve Replacement using mechanical prosthetic valve
11102779|NCT04056819|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack.
11102780|NCT04056806|Experimental|Group A|receiving terlipressin 2mg bolus on enrollment followed by 1mg per 6 hours. Both Terlipressin infusion and Ceftriaxone continue till 48 hours after endoscopic therapy
11102781|NCT04056806|Active Comparator|Gruoup B|receiving terlipressin 2mg bolus instituted on enrollment followed by 1mg per 6 hours. Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval. Both Terlipressin infusion and Ceftriaxone continue till 5 days after endoscopic therapy.
11102782|NCT04056793|Experimental|Parturients in situation of dystocia|Positioning of the parturients in an optimized birthing position
11102783|NCT04056780||Septic group|The septic group will be considered as patients that fulfill the 2018 ICM definition of PJI.
11102784|NCT04056780||Aseptic group|The aseptic group will be considered as patients that don't fulfill the 2018 ICM definition of PJI.
11102785|NCT04056767||Imaginal PE|
11102786|NCT04056767||Writing PE|
11102787|NCT04056754|Experimental|Abiraterone acetate group|Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
11102788|NCT04056754|Placebo Comparator|Placebo group|Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
11102789|NCT04056741|Experimental|Surfactant administered via supraglottic administration device|Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.
11102790|NCT04056728|Experimental|Eupenta Inj.|
11102791|NCT04056715||HCM Group|Eligible HCM subjects will be monitored for arrhythmias with a 2-week ECG patch.
11102792|NCT04056702||Prescribed triple combination|A group of 60 people with CF who are clinically prescribed elexacaftor-tezacaftor-ivacaftor and have chronic sinusitis
11102793|NCT04056702||Not eligible for modulators|A group of 10 patients with two class I/II mutations who are ineligible for elexacaftor-tezacaftor-ivacaftor based on their genotype and have chronic sinusitis.
11102794|NCT04056689|Experimental|DNL151 Low Dose|
11102795|NCT04056689|Experimental|DNL151 Mid Dose|
11102796|NCT04056689|Experimental|DNL151 High Dose|
11102797|NCT04056689|Placebo Comparator|Placebo|
11102798|NCT04056676|Active Comparator|Intraoperative modified PEC block only|Intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
11102799|NCT04056676|Experimental|Adding preoperative thoracic paravertebral nerve block|Preoperative thoracic paravertebral nerve block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug and intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
11102837|NCT04056364||Asthma|Asthma patients will be diagnosed according to a clinical history of wheezing, cough, chest tightness or shortness of breath, as well as the presence of BHR (cumulative dose caus¬ing a 20% decrease in FEV1), based on the GINA guidelines. None of them had a history of COPD, or previous doctor-diagnosed ACO. All subjects had not used any oral or/and inhaled corticosteroid (ICS) in the previous 12 weeks. The included patients with asthma had initial diagnosis and were under uncontrolled stage.
11103075|NCT04055077|Experimental|ASA III/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11102800|NCT04056663|Experimental|Health-Circuit mobile application|"The intervention contemplates. (i) management of unexpected events; and, (ii) empowering the patient to improve self-efficacy.
~Users of the intervention arm will have the Health-Circuit mobile application, which will offer them the possibility of contacting the case managers to notify a health event at any time and that this can be resolved by their health professionals through Health -Circuit. The improvement of the patient's self-efficacy for the management of their health problems through the use of Health-Circuit is considered through the virtual visits of follow-up with the manager, the possibility of interacting with the manager and the consultation of the shared documents reminders of the action plan agreed with the patient."
11102801|NCT04056663|No Intervention|Conventional treatment|Patients assigned to this group will follow conventional treatment. Once the three months have passed, we will contact you again to ask the pertinent questions.
11102802|NCT04056650|Active Comparator|Single caffeinated beverage/supplement|
11102803|NCT04056650|Active Comparator|Combination caffeine and L-theanine|
11102804|NCT04056637|No Intervention|Group 1: Standard of Care|Participants will be asked to complete follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider.
11102805|NCT04056637|Experimental|Group 2: Flexible Follow-Up|Participants will be offered three follow-up options, including: 1) follow-up in clinic 1-2 weeks following mifepristone administration for an ultrasound and consultation with a provider; 2) repeat serum beta-hCG testing; 3) repeat multi-level pregnancy test strategy
11102806|NCT04056624|Experimental|Low dose|1 x 12 ounce bottle of carotenoid-containing juice (29.7 mg carotenoids/bottle, 1.1c vegetable equivalents)
11102807|NCT04056624|Experimental|High dose|2 x 12 ounce bottle of carotenoid-containing juice (~2.2 c vegetable equivalents)]
11102808|NCT04056624|Placebo Comparator|Placebo|12 ounce bottle of apple juice (negligible carotenoids 0.06 mg/12 oz)
11102809|NCT04056611|Experimental|Adult cohort: JNJ-53718678 or Placebo|Participants greater than or equal to (>=) 18 to less than or equal to (<=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
11102810|NCT04056611|Experimental|Adolescent cohort: JNJ-53718678 or Placebo|Participants >=13 to <18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.
11102811|NCT04056598||Moderate to severe acne vulgaris|Determined by the acne severity grade of IGA 2 and above
11102812|NCT04056598||Mild acne vulgaris|Determined by the severity grade of IGA <2
11102813|NCT04056585|Experimental|Brachial plexus block with intermittent pneumatic compression|Hand and forearm surgery is performed after axillary brachial plexus block with intermittent pneumatic compression for 3 minutes.
11102814|NCT04056585|Placebo Comparator|Brachial plexus block|Hand and forearm surgery is performed after axillary brachial plexus block only.
11102815|NCT04056572|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally, twice daily.
11102816|NCT04056559|Experimental|SIngle arm|The research is based on a population of men and women practicing a sport at risk of oral trauma.
11102817|NCT04056533|Experimental|CMV CTLs|1x10^5 CMV-CTLs/kg
11102818|NCT04056520||Arm 1|Subjects undergoing posterior cervicothoracic fusions between C2 and upper thoracic will be enrolled
11102819|NCT04056507||ITP group|On frozen spleens of already splenectomized adult ITP patients.
11102820|NCT04056507||Control group|On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident.
11102821|NCT04056468|Experimental|Moderate HI (Child-Pugh B): Mobocertinib 40 mg|Mobocertinib 40 milligram (mg), capsule, orally, a single dose on Day 1.
11102822|NCT04056468|Experimental|Severe HI (Child-Pugh C): Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
11102823|NCT04056468|Experimental|Normal Hepatic Function: Mobocertinib 40 mg|Mobocertinib 40 mg, capsule, orally, a single dose on Day 1.
11102824|NCT04056455|Experimental|Severe RI: Mobocertinib 80 mg|Mobocertinib milligram (mg), capsule, orally, a single dose on Day 1.
11102825|NCT04056455|Experimental|Normal Renal Function: Mobocertinib 80 mg|Mobocertinib 80 mg, capsule, orally, a single dose on Day 1.
11102826|NCT04056442|Experimental|Cannabidiol|300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
11102827|NCT04056442|Placebo Comparator|Placebo|Olive Oil Solution
11102828|NCT04056429|Experimental|BHA|Subjects treated with BHA + standard of care
11102829|NCT04056429|No Intervention|Control|Subjects treated as per standard of care
11102830|NCT04056416|Experimental|HIIT Exercise Program|Exercise on a MedBIKE 3 times a week for 8 weeks with pre- and post-CPET testing, questionnaires and qualitative interviews.
11102831|NCT04056390|Active Comparator|Substrate Modification|After obtaining a voltage map of the LA, substrate modification by catheter ablation using an irrigated radio frequency current ablation catheter will be performed aiming at low-voltage areas (LVA) < 0.5mV.
11102832|NCT04056390|Active Comparator|LAA Isolation|Patients will undergo LAA-isolation using the cryoballoon (CB). Six weeks later patients will undergo re-mapping. In case of residual conduction LAA-reisolation will be performed. In case of durable LAA isolation, interventional LAA occlusion is recommended.
11102833|NCT04056377||Black boys|240 black boys were included in the study (mean age 7.5 years)
11102834|NCT04056377||Black girls|339 black girls were included in the study (mean age 7.5 years)
11102835|NCT04056377||White boys|239 white boys were included in the study (mean age 7.4 years)
11102836|NCT04056377||White girls|224 white girls were included in the study (mean age 7.4 years)
11102878|NCT04056169|Active Comparator|Rosuvastatin|rosuvastatin 20 mg once a day for 6 months
11102879|NCT04056169|Experimental|ezetimibe/rosuvastatin|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
11102880|NCT04056156|No Intervention|Control|Standard of care (no specific intervention)
11103265|NCT04053777||NIV group|Patients receiving non-invasive ventilation in the hospital or at home
11102838|NCT04056364||COPD|COPD patients were diagnosed according to the GOLD criterion, which included a post-bronchodilator spirometry to confirm airflow obstruction (FEV1 to forced vital capacity ratio [FEV1/FVC] ,70%), in a clinical context (dyspnea, chronic cough or sputum production, and a history of expo¬sure to risk factors for the disease). They had received a COPD diagnosis at least 1 year before the study. None of them had a history of asthma. All subjects had not used any oral or/and ICS in the previous 4 weeks. The included COPD patients had exacerbations. The GOLD stage of COPD was defined according to the 2019 recommendations of GOLD.
11102839|NCT04056364||ACO|ACO will be diagnosed by two steps: the first step is the identification of a history of chronic airway disease, i.e., chronic or recurrent cough, sputum production, wheezing, or repeated acute lower respiratory tract infections. In the second step, the features of asthma and those of COPD that best describe the patients
11102840|NCT04056351|Other|Cohort of 50 enrolled patients|The following visits will be performed: direct post-OP, 3 weeks, 6 weeks, 3 months and 6 months after surgery. Surgical details will be assessed from the surgical notes. Medical images will be collected according to the standard of care. A post-OP CT scan will also be acquired when the treating surgeon requests it as per standard of care, or additionally, as a study specific imaging procedure for the rest of the participants. Patient activity will be estimated based on various factors, including questionnaires on demographics, activity level, comorbidity score and contralateral grip strength. The actual post-OP shoulder activity will be measured by motion tracking by means of sensors attached to upper arm of the treated side and on the chest for 6 weeks and by grip strength assessed at the treated arm at week 6. Fixation failure status will be determined 6 months post-OP. Imaging and details regarding the fixation failure event will be sent to ARI.
11102841|NCT04056338||Delirium|Patients with delirium as assessed by the bedside nurse using Confusion Assessment Method for the ICU.
11102842|NCT04056338||Non-delirium|Patients without delirium.
11102843|NCT04056325|Experimental|Phase 2a - Arm A|2 mg Moxidectin at day 0 administered orally
11102844|NCT04056325|Experimental|Phase 2a - Arm B|4 mg Moxidectin at day 0 administered orally
11102845|NCT04056325|Experimental|Phase 2a - Arm C|6 mg Moxidectin at day 0 administered orally
11102846|NCT04056325|Experimental|Phase 2a - Arm D|8 mg Moxidectin at day 0 administered orally
11102847|NCT04056325|Experimental|Phase 2a - Arm E|10 mg Moxidectin at day 0 administered orally
11102848|NCT04056325|Experimental|Phase 2a - Arm F|12 mg Moxidectin at day 0 administered orally
11102849|NCT04056325|Placebo Comparator|Phase 2a - Arm G|matching Placebo tablet(s) at day 0 administered orally
11102850|NCT04056325|Experimental|Phase 2b - Arm A|the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) at day 0 administered orally
11102851|NCT04056325|Active Comparator|Phase 2b - Arm B|200 µg/kg ivermectin at day 0 administered orally
11102852|NCT04056325|Placebo Comparator|Phase 2b - Arm P|matching Placebo tablet(s) at day 0 administered orally
11102853|NCT04056312|Experimental|Group memory retraining|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
11102854|NCT04056312|Placebo Comparator|Placebo|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
11102855|NCT04056299|Active Comparator|AR201 powder (Hen Egg Allergen formulation)|Subjects will be randomized to active arm of AIME01 and will be administered IP (AR201) in escalating doses for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
11102856|NCT04056299|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of AIME01 and will be administered escalating doses of IP (placebo) for approximately 6 months, followed by a maintenance dose for approximately 12 weeks
11102857|NCT04056286|Experimental|Healthy + Whey|Healthy (overnight fast)
11102858|NCT04056286|Experimental|Catabolic + Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
11102859|NCT04056286|Experimental|Catabolic + 3-OHB / Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
11102860|NCT04056273|Experimental|Guide sheath group|Transbronchial biopsy with a guide sheath
11102861|NCT04056273|Active Comparator|Conventional group|Transbronchial biopsy without a guide sheath
11102862|NCT04056260|Experimental|ICG injection|ICG 0.5mg/ml x 0.5ml x 4 sites
11102863|NCT04056247||Newly diagnosed NSCLC stage IV|Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
11102864|NCT04056247||NSCLC stage IV 2nd line and further of immunotherapy|Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
11102865|NCT04056247||Malignant melanoma stage IV|Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
11102866|NCT04056247||Malignant melanoma stage IIIb-d|Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.
11102867|NCT04056247||SCLC stage IV|Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
11102868|NCT04056234||Rheumatoid arthritis group|Patients with rheumatoid arthritis
11102869|NCT04056234||Control group|Patients with osteoarthritis / joint effusion.
11102870|NCT04056221|Experimental|acupuncture|Acupuncture at the selected points.
11102871|NCT04056221|Sham Comparator|Sham acupuncture|Similar appearance to conventional acupuncture, however, without needles skin penetration.
11102872|NCT04056208|Active Comparator|Evening Pistachio Consumption|Participants will consume two ounces per day (57 g) of pistachios as an evening snack (i.e., after dinner and before sleep).
11102873|NCT04056208|Active Comparator|Usual care|Advice to consume a snack that contains 1-2 exchanges (15-30 g of carbohydrate) as an evening snack - this is consistent with the current standard of care for people with impaired fasting glucose.
11102874|NCT04056195|Experimental|SKI-O-703 200 mg|2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks
11102875|NCT04056195|Experimental|SKI-O-703 400 mg|4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks
11102876|NCT04056195|Placebo Comparator|Placebo|4 capsules of placebo during 12 weeks
11102877|NCT04056182|Experimental|Lofexidine|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
11102881|NCT04056156|Experimental|Level 1: Online dissemination of the HIV screening advice|General practitioners included at the first level receive the HIV-testing advice through a personal electronic mail by their local GP-organization coordinator containing an information message with the printer-friendly screening advice attached. The message also provides a link to the website of the Flemish umbrella organization for GPs (https://domusmedica.be), where the tool is available for download for all Flemish GPs. A reminder is sent out to all participants after 13 months.
11102882|NCT04056156|Experimental|Level 2: additional group-level training session|At the second intervention level, GPs first receive intervention condition 1 and additionally the face-to-face group-level training session. These sessions are organized as part of regular 'continuous medical education' provided by the GP organizations ('quality circles') at their usual venues and are organized a few months after receiving intervention level 1. A reminder of the advice is sent out 13 months after the initiation of intervention level 1.
11102883|NCT04056143||Dabigatran|Subjects who are receiving long-term Dabigatran for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
11102884|NCT04056143||Rivaroxaban|Subjects who are receiving long-term Rivaroxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
11102885|NCT04056143||Apixaban|Subjects who are receiving long-term Apixaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
11102886|NCT04056143||Edoxaban|Subjects who are receiving long-term Edoxaban for certain clinical conditions, and without any contraindication are enrolled for this cohort group.
11102887|NCT04056130|Experimental|Cohort SAD1|9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
11102888|NCT04056130|Experimental|Cohort SAD2|9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
11102889|NCT04056130|Experimental|Cohort MAD1|9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
11102890|NCT04056130|Experimental|Cohort MAD2|9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
11102891|NCT04056117|Experimental|NA (Non-adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the non-adjuvanted investigational product
11102892|NCT04056117|Experimental|A (adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the adjuvanted investigational product
11102893|NCT04056117|Experimental|NA (Non-adjuvanted) - low dose -infants|Infants receive 3 low doses of the non-adjuvanted investigational product
11102894|NCT04056117|Experimental|A (adjuvanted) - low dose - infants|Infants receive 3 low doses of the adjuvanted investigational product
11102895|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the non-adjuvanted investigational product
11102896|NCT04056117|Experimental|A (adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the adjuvanted investigational product
11102897|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - children|Children receive 3 medium doses of the non-adjuvanted investigational product
11102898|NCT04056117|Experimental|A (adjuvanted) - medium dose - children|Children receive 3 medium doses of the adjuvanted investigational product
11102899|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose-adults|Adults receive 2 medium doses of the non-adjuvanted investigational product
11102900|NCT04056117|Experimental|A (adjuvanted) - medium dose - adults|Adults receive 2 medium doses of the adjuvanted investigational product
11102901|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - infants|Infants receive 3 high doses of the non-adjuvanted investigational product
11102902|NCT04056117|Experimental|A (adjuvanted) - high dose - infants|Infants receive 3 high doses of the adjuvanted investigational product
11102903|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - children|Chilldren receive 3 high doses of the non-adjuvanted investigational product
11102904|NCT04056117|Experimental|A (adjuvanted) - high dose - children|Chilldren receive 3 high doses of the adjuvanted investigational product
11102905|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - adults|Adults receive 2 high doses of the non-adjuvanted investigational product
11102906|NCT04056117|Experimental|A (adjuvanted) - high dose - adults|Adults receive 2 high doses of the adjuvanted investigational product
11102907|NCT04056117|Experimental|MenACWY-Placebo|Adults receive one administration of MenACWY followed by one placebo administration
11102908|NCT04056117|Other|Rabies|Children receive three administrations of Rabies
11102909|NCT04056117|Other|MenACWY-DTaP|Infants receive two administrations of MenACWY followed by DTaP administration
11102910|NCT04056104|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters
11102911|NCT04056091|Experimental|Back rub stimulation|
11102912|NCT04056091|Active Comparator|Foot flicks stimulation|
11102913|NCT04056078||Team Handball Players Playing with Shoulder Pain|Team Elite Handball players playing with shoulder pain i their dominated shoulder for more than 3 months.
11102914|NCT04056078||Team Handball Players playing without shoulder pain|Team Elite Handball players who never have experience shoulder pain i their dominated shoulder.
11102915|NCT04056078||Team Handball Players playing with previous shoulder pain|Team Handball players who have had shoulder pain i their dominated shoulder, but currently have been playing without shoulder pain in the previous 6 months.
11102916|NCT04056065|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
11102917|NCT04056065|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
11102918|NCT04056052|Sham Comparator|Home Activity Only|Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
11102919|NCT04056052|Active Comparator|Home Activity + cooking Workshop|The 8-week cooking workshop condition incorporated all of the home activities previously described, however, this cohort also participated in two, two-hour cooking workshops held at a local cooking school.
11102921|NCT04056039|Active Comparator|"Colchicine"|"Changes of troponin I in rheumatoid arthritis with colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks"
11102922|NCT04056026|Experimental|Fecal Microbiota Transplant|The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
11102923|NCT04056013|Active Comparator|Absorbable|Wound repaired with Vicryl Rapide absorbable suture
11102924|NCT04056013|No Intervention|Nonabsorbable|Wound repaired with traditional nonabsorbable suture
11102925|NCT04056000|Experimental|Exercising following the ingestion of a high-carbohydrate br|60 minutes of cycling, with the ingestion of a high-carbohydrate breakfast and 200 mg of caffeine.
11102926|NCT04056000|Experimental|Exercising following the ingestion of caffeine only|60 minutes of cycling, with the ingestion of 200 mg of caffeine.
11102927|NCT04056000|Experimental|Exercising in the absence of breakfast or caffeine ingestion|60 minutes of cycling, without the ingestion of breakfast, or caffeine.
11102928|NCT04055987|Experimental|Congenitally deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of consonant-vowel-consonant (CVC) combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
11102929|NCT04055987|Experimental|Adventitiously deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of CVC combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
11102930|NCT04055974|Experimental|BeAMom|Low-risk (LR) women will receive a web-based intervention for the promotion of maternal mental health (the Be a Mom program). In addition, women will receive postpartum treatment as usually performed in primary care settings (TAU).
11102931|NCT04055974|No Intervention|Control|Low-risk (LR) women will receive postpartum treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
11102932|NCT04055948|No Intervention|Control - Standard of Care|- All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
11102933|NCT04055948|Experimental|Intervention|"All participants will be screened for health literacy using a 4-item Brief Health Literacy Screening Tool (BRIEF)
~Three in-person, one-on-one teaching sessions with the caregiver during radiation treatments, followed by a telephone booster contact 2 weeks post-treatment."
11102934|NCT04055935|Experimental|full thickness mucoperiosteal flap|A full thickness mucoperiosteal flap (FTMPF) was reflected on FTMPF side at the maxillary canine/premolar region by the same surgeon for all patients following the same procedures.
11102935|NCT04055935|Experimental|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length
11102936|NCT04055935|No Intervention|Control for Full thickness mucoperiosteal flap|Control for Full thickness mucoperiosteal flap, in which canine retraction was done in a conventional method
11102937|NCT04055935|No Intervention|control for Low level laser therapy group|Control for Low level laser therapy , in which canine retraction was done in a conventional method
11102938|NCT04055909|Experimental|nangibotide 1|
11102939|NCT04055909|Experimental|nangibotide 2|
11102940|NCT04055909|Placebo Comparator|Placebo|
11102941|NCT04055896|No Intervention|Control Group|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
11102942|NCT04055896|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:
~Medication reconciliation
~Identification of patient priorities for care
~Identification of medications that are potentially appropriate for discontinuation/dose reduction
~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
~Identification of medications for trial of discontinuation/dose reduction (shared decision making) Pause of medication and clinical monitoring"
11102943|NCT04055883|Experimental|DA-1229 5mg|Oral administration of DA-1229 5mg tablet once a day
11102944|NCT04055883|Experimental|DA-1229 10mg|Oral administration of DA-1229 10mg tablet once a day
11102945|NCT04055883|Placebo Comparator|DA-1229 Placebo|Oral administration of DA-1229 Placebo tablet once a day
11102946|NCT04055870||Undergone EUS-guided liver biopsy at MDMC|Undergone EUS-guided liver biopsy at MDMC
11102947|NCT04055857||NIID|NIID patients
11102948|NCT04055857||HC|healthy control
11102949|NCT04055844|Experimental|Decitabine + Ruxolitinib + DLI|Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
11102950|NCT04055831||GD1 subjects with no bone complications|1. GD1 subjects with no bone complications (n=10)
11102951|NCT04055831||GD1 patients with mild bone complication|2. GD1 subjects with mild bone complications
11102952|NCT04055831||GD1 with severe bone complications|3. GD1 subjects with severe bone complications
11102953|NCT04055831||No bone disease|Controls with no known bone disease (n=10)
11102954|NCT04055818|Experimental|Nicotinamide|Oral Nicotinamide 1000 mg twice daily
11102955|NCT04055818|Experimental|THU Decitabine|Oral 250 mg THU and 5 mg decitabine Once per week
11102956|NCT04055805||Fondazione Policlinico Universitario A. Gemelli, Roma|Polo Scienze della Salute della Donna e del Bambino
11102957|NCT04055805||Università degli Studi di Pavia|
11102958|NCT04055805||"Università di Napoli Federico II"|
11102959|NCT04055805||Università degli Studi di Siena|
11102960|NCT04055805||Azienda Ospedaliero-Universitaria Careggi Firenze|
11102961|NCT04055805||Fondazione Policlinico Universitario A. Gemelli Roma|U.O.C Chirurgia Senologica
11102963|NCT04055792|Experimental|Sintilimab combine with Anlotinib|Sintilimab 200mg intravenously on day 1 and Anlotinib 12mg per os on day 1-14 of each 3-week cycle
11102964|NCT04055792|Active Comparator|Anlotinib|Anlotinib 12mg per os on day 1-14 of each 3-week cycle
11102965|NCT04055779||Induced hypotension and arterial occlusion pressure|The patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
11102966|NCT04055779||induced hypotension and limb occlusion pressure|the patients will receive induced hypotensive anesthesia and the tourniquet pressure will be based on the LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
11102967|NCT04055766||Meningitis/Encephalitis|Patients with clinical signs and symptoms suspected of meningitis/encephalitis
11102968|NCT04055766||Stroke|Patients with clinical signs and symptoms suspected of stroke
11102969|NCT04055766||Headache|Patients with clinical signs and symptoms suspected of headache
11102970|NCT04055766||Vertigo|Patients with clinical signs and symptoms suspected of vertigo
11102971|NCT04055753||Doxorubicin|
11102972|NCT04055753||Doxil|
11102973|NCT04055740|Experimental|IVUS imaging|IVUS imaging will be used each patient undergoing transvenous lead extraction to visualize ILA
11102974|NCT04055714|Experimental|Treatment arm|Balloon dilation of the Eustachian Tube(s) with Acclarent Aera Balloon
11102975|NCT04055701|Other|dichorionic diamniotic twin pregnancy|rutin examination: the assesment of fetal thymus volume at all cases.
11102976|NCT04055688||Participants with known or suspected high grade gliomas|
11102977|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
11102978|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
11102979|NCT04055662||Cannabis users|
11102980|NCT04055662||Cannabis naive|
11102981|NCT04055649|Experimental|Treatment - ONC201 & Paclitaxel|Patients receive ONC201 PO on days 1, 8, and 15, and paclitaxel IV over 1 hour on days 2, 9, and 16. Cycles repeat every 28 days in the absence disease progression or unacceptable toxicity. If paclitaxel must be stopped for any reason, patients may continue on ONC201 alone.
11102982|NCT04055636||cancer survivors with heart failure and/or fatal arrhythmias|Patients undergoing cancer therapy for the last 3-4 years with signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
11102983|NCT04055636||Cancer survivors without complications|Patients undergoing cancer therapy for the last 3-4 years without signs of heart failure and/or life-threatening arrhythmias. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
11102984|NCT04055636||Cancer patients before chemotherapy|Cancer patients before administered chemotherapy. Interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
11102985|NCT04055636||Patients with non-toxic dilated cardiomyopathy (control).|Patients with non-toxic dilated cardiomyopathy. Administered interventions: physical examination, echocardiography with speckle tracking analysis, 48-hour ECG monitoring, blood samples analysis for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
11102986|NCT04055623|Experimental|Intravenous infusion of Treg cells + Interleukin-2 injections|For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.
11102987|NCT04055623|Placebo Comparator|Intravenous infusion w/Placebo + matching placebo injections|For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.
11102988|NCT04055623|Experimental|2nd 6-months Open Label: Treg Infusions + IL-2 injections|For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.
11102989|NCT04055610|Experimental|H-MEX|10 participants with paraplegia will participate in explorative gait training using H-MEX powered exoskeleton.
11102990|NCT04055597|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
11102991|NCT04055597|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
11102992|NCT04055584||Sputum spot|
11102993|NCT04055545|Active Comparator|MICT|
11102994|NCT04055545|Active Comparator|HIIT|
11102995|NCT04055532||Mild Cognitive Impairment|
11102996|NCT04055532||Alzheimer's Disease|
11102997|NCT04055532||Dementia with Lewy Bodies|
11102998|NCT04055532||Frontotemporal Lobar Dementia|
11102999|NCT04055532||Parkinson's Disease with Dementia|
11103000|NCT04055532||Transient Epileptic Amnesia|
11103001|NCT04055532||Temporal Lobe Epilepsy|
11103002|NCT04055532||Spinocerebellar Ataxia|
11103003|NCT04055532||HIV-Associated Neurocognitive Disorder|
11103004|NCT04055532||Amyotrophic Lateral Sclerosis|
11103005|NCT04055532||Primary Lateral Sclerosis|
11103006|NCT04055506|Experimental|Combination Therapy|
11103007|NCT04055493|Experimental|Ribociclib plus ET|Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice
11103008|NCT04055493|No Intervention|Standard-of-care chemotherapy|Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,
11103009|NCT04055480|Active Comparator|Closed-loop using standard rapid-acting insulin|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using standard rapid-acting insulin
~The CamAPS FX closed-loop system comprises
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
11103010|NCT04055480|Experimental|Closed-loop using faster insulin aspart|"Unsupervised home use of day and night hybrid closed loop insulin delivery system (CamAPS FX) for 8 weeks using faster insulin aspart
~The CamAPS FX closed-loop system comprises
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
11103011|NCT04055467|Other|[F18]-ASEM + Contingency Management|PET radiopharmaceutical 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide with incentive payments.
11103012|NCT04055454|Experimental|MV-LASV low dose: treatment group A|In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.
11103013|NCT04055454|Experimental|MV-LASV high dose: treatment group B|In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.
11103014|NCT04055454|Placebo Comparator|Placebo: treatment group C|In total 12 participants will receive placebo treatment on day 0 and 28.
11103015|NCT04055428|Experimental|Sacubitril/Valsartan|We will enroll 40 African Americans between 30-50 years of age. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
11103016|NCT04055428|Active Comparator|Valsartan|We will enroll 40 African Americans between 30-50 years of age. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
11103017|NCT04055415|Experimental|Intervention group|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml . Once every week#a total of two times. The Conventional drug therapy（expectorant，bronchodilator） is used.
11103018|NCT04055415|Other|Control group|The Conventional drug therapy（expectorant，bronchodilator） is used with the control group
11103019|NCT04055402|Experimental|EMA group|Participate in the baseline survey, 2-week ecological momentary assessments and a 1-month follow-up survey
11103020|NCT04055402|Active Comparator|Control group|Participate in the baseline survey,and a 1-month follow-up survey
11103021|NCT04055389|Experimental|AT-III treatment|
11103022|NCT04055389|Placebo Comparator|Placebo|
11103023|NCT04055376|Experimental|Daily exposure to active stimulation|Subjects in this arm will receive daily exposure to active stimulation
11103024|NCT04055376|Sham Comparator|Daily exposure to control stimulation|Subjects in this arm will receive daily exposure to control stimulation
11103025|NCT04055363|Experimental|Formula-fed infants|Infants fed exclusively with experimental formula
11103026|NCT04055363|Experimental|Mixed-fed infants|Infants receiving breastmilk and experimental formula
11103027|NCT04055363|No Intervention|Breast-fed infants|Reference group of exclusively breastfed
11103028|NCT04055337|Experimental|Flap Sliding|"noninvasive flap sliding technique for managing flap striae following laser in situ keratomileusis (LASIK)."
11103029|NCT04055311|Active Comparator|Usual care enhanced|Bladder cancer patients & caregivers receive standard instructions about post-op care from nursing staff plus the NCI published Facing forward cancer survivorship manual.
11103030|NCT04055311|Experimental|Intervention|Bladder cancer patients & caregivers receive standard instructions about post-op care from nursing staff plus access to Internet based software program, specifically designed for this research study. Software program contains relevant bladder cancer care instructions through videos, text, and graphics.
11103031|NCT04055298|Other|Patients|"The study will be performed at the Walk-in-Clinic (WIC) and Interdisciplinary Emergency Department (ED) of the cantonal hospital of Baden, Switzerland. During their stay at the WIC or ED the patients will be invited to use the triage-symptom-checker SMASS-Triage.
~In this study, the patient's self-triage using a symptom checker will be compared with the urgency assessments conducted by three interdisciplinary panels of physicians (panel A, B and C). In order to appropriately reflect the complex interaction in medical decision-making, which usually leads to a low inter-rater reliability, the cases assessed to be undertriaged by panel A, are subsequently assessed a second time by two panelist of panel B. Cases which are adjudged to be undertriaged by all panelist (panel A and B), are assessed for a risk to health or life by panel C. The risk assessments of panel C will be based on the structured reports generated by the symptom-checker and the discharge summaries of the WIC/ED."
11103032|NCT04055285|Experimental|Sympathetic Renal Denervation|Sympathetic Renal Denervation
11103033|NCT04055285|Active Comparator|Conventional treatment with drug therapy|Conventional drug therapy of resistant hypertension
11103034|NCT04055272|Experimental|Text messaging|Participants in the text messaging intervention arm receive mobile text messages communicating the risks of indoor tanning and motivating cessation on their mobile phones
11103035|NCT04055272|No Intervention|Control|Participants in the control arm receive no intervention
11103036|NCT04055259|Experimental|mobile Health and Wellness Coaching|
11103037|NCT04055259|Active Comparator|Usual Care|
11103038|NCT04055246|Experimental|Prebiotic|Participants receive prebiotics containing fiber bar to consume 2x daily for 1 week.
11103039|NCT04055246|Placebo Comparator|Placebo|Participants receive placebo bar containing no added prebiotics to consume 2x daily for 1 week.
11103072|NCT04055077|Active Comparator|ASA III/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11103040|NCT04055233|Experimental|Subcutaneous irrigation with 0.04% polyhexanide solution|"Intervention: after closure of abdominal fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml antiseptic solution (0.04% polyhexanide) will be done once for ten minutes.
~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
11103041|NCT04055233|Active Comparator|Subcutaneous irrigation with NaCl (saline)|"Intervention: after closure of fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml NaCl (saline) will be done once for one minute.
~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
11103042|NCT04055220|Experimental|Regorafenib|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib followed by a 7-day period of rest.
~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).
~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
11103043|NCT04055220|Placebo Comparator|Placebo|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo followed by a 7-day period of rest.
~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).
~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
11103044|NCT04055207|Experimental|VVC|Option to receive VA Video Connect (VVC) delivery of HIV care.
11103045|NCT04055207|No Intervention|Usual Care|All HIV care available at MEDVAMC will be delivered as usual.
11103046|NCT04055194|Active Comparator|Tranexamic acid group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
11103047|NCT04055194|Placebo Comparator|Placebo group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
11103048|NCT04055181|Active Comparator|rTMS in schizophrenia patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
11103049|NCT04055181|Sham Comparator|rTMS in schizophrenia Controls|In sham rTMS, all procedures were identical to 10Hz Schizophrenia group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
11103050|NCT04055181|Active Comparator|rTMS in major depressive disorders patients|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
11103051|NCT04055181|Sham Comparator|rTMS in major depressive disorders controls|In sham rTMS, all procedures were identical to 10Hz depression group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
11103052|NCT04055168|Experimental|Cohort 1 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
11103053|NCT04055168|Experimental|Cohort 2 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
11103054|NCT04055168|Experimental|Cohort 3 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 3 of AZD6615 (6 subjects) or matching placebo (2 subjects).
11103055|NCT04055168|Experimental|Cohort 1 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
11103056|NCT04055168|Experimental|Cohort 2 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
11103057|NCT04055155||Staff/Provider end-users|Testing usability of a technology-enabled behavioral intervention for depression among provider end-users in primary care.
11103058|NCT04055155||Patient participants|Testing acceptability, feasibility, and preliminary effectiveness of a technology-enabled behavioral intervention for depression among patients with depression in primary care.
11103059|NCT04055142|Active Comparator|Electrocoagulation|This procedure will be implemented following the Standard of Care (SoC) on weeks: 0, 8 and 16 calculated since the day the patient is included into the trial.
11103060|NCT04055142|Experimental|Sinecatechins (10%)|Topical ointment wich contains 2 grams of active principle (sinecatechins 10%) at each administration. It will be taken three times per week during 8 weeks of treatment.
11103061|NCT04055142|Experimental|cidofovir (1%)|Topical ointment wich contains 2 grams of active principle (cidofovir 1%) at each administration. It will be taken three times per week during 8 weeks of treatment.
11103062|NCT04055129||Birth Control|Hormone levels controlled with subject on birth control pill
11103063|NCT04055129||Non-Birth Control|Hormone (estrogen) levels not controlled but monitored for levels of estrogen at two points in menstrual cycle (Follicular and ovulatory phases)
11103064|NCT04055116|Experimental|Unbuffered Lidocaine, then Buffered Lidocaine|Subjects will receive an injection of non-buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
11103065|NCT04055116|Experimental|Buffered Lidocaine, then Unbuffered Lidocaine|"Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion.Subjects will receive an injection of this buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
~We will use 8.4% Sodium Bicarbonate manufactured by Hospira, Inc. Lake Forest, IL"
11103066|NCT04055103|Active Comparator|Intervention Group|Half of the participating hospitals will be in the intervention group for the first 6 months. The intervention will switch to the control group after the 6 months.
11103067|NCT04055103|No Intervention|Control Group|Half of the participating hospitals will be in the control group for the first 6 months. The control group will undergo the intervention in the second 6 months.
11103068|NCT04055090||Subjects who received VM202|
11103069|NCT04055090||Subjects who received Placebo|
11103070|NCT04055077|Active Comparator|ASA I/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11103071|NCT04055077|Active Comparator|ASA II/LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11103073|NCT04055077|Experimental|ASA I/HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11103076|NCT04055064|Experimental|Intervention|patients received nutrition education and nutritional supplements
11103077|NCT04055064|No Intervention|Control|patients did not receive any intervention
11103078|NCT04055051||Hemophilia A and B Cases|No intervention. Only patients that have undergone a liver transplant per study eligibility are in this cohort.
11103079|NCT04055051||Hemophilia A and B Controls|No intervention. Comparable patients to those in Case cohort will be put in this cohort.
11103080|NCT04055038|Experimental|Platinum-based chemotherapy|"This is an experimental arm of this study. Allowed therapeutic options:
~Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);
~Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;
~Doxorubicin 40-50 mg/m2 d 1 + carboplatin AUC5 or cisplatin 60-75 mg/m2 d 1 every 3 weeks;
~Topotecan 0.75 mg/m2 d 1-3 + cisplatin 60-75 mg/m2 or carboplatin AUC 4-5 d 1 every 3 weeks;
~Etoposide 100 mg once daily orally d 1-7 + cisplatin 60-75 mg/m2 d1 every 3 weeks.
~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
11103081|NCT04055038|Active Comparator|Non-platinum monochemotherapy|"This is a control arm of this study. Allowed therapeutic options:
~Paclitaxel 60-80 mg/m2 weekly (or day 1, 8, 15 every 4 weeks schedule);
~Gemcitabine 1000 mg/m2 d 1, 8, 15 every 4 weeks;
~Doxorubicin 50-60 mg/m2 d 1 every 3 weeks;
~Topotecan 1,2-1,5 mg/m2 d 1-5 every 3 weeks;
~Etoposide 100 mg once daily orally d 1-10 every 3 weeks.
~Up to 6 cycles of chemotherapy will be administered to study participants allocated to this arm."
11103082|NCT04055025|Other|Sleeve gastrectomy operated patients|Five test days in a randomized, patient-blinded, cross-over design
11103083|NCT04055012|Experimental|High Dose Metformin|High Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1,000mg) for the first week then increase to 3 tabs per day (1,500mg) for the remaining 6 months.
11103084|NCT04055012|Experimental|Low Dose Metformin|Low Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1 metformin tab (500mg) and 1 placebo tab in pre-packaged blister pack) for the first week then increase to 3 tabs per day (1 metformin tab (500mg) and 2 placebo tabs (in pre-packaged blister pack) for the remaining 6 months.
11103085|NCT04055012|Placebo Comparator|Placebo|Placebo Group (n=100). Subjects will receive placebo and will be instructed to take 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months.
11103086|NCT04055012|Other|Wait-List Control|"Control Group (n=100). Subjects will be told that they are in the wait-list control group. They will have a 3 month waiting period before they will be randomized again to a treatment group. They will be randomized to one of the previous groups."
11103087|NCT04054999|Experimental|Cyanokit|Single dose intraoperatively of Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
11103088|NCT04054999|Active Comparator|Methylene Blue|Single dose intraoperatively of Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
11103089|NCT04054986|Experimental|Breast Cancer|Breast cancer
11103090|NCT04054973|Experimental|L-arginine and Kuvan|Open-label single arm study, all participants will be in this group
11103091|NCT04054960|Experimental|Real tPCS|Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
11103092|NCT04054960|Sham Comparator|Sham tPCS|Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
11103093|NCT04054960|Active Comparator|Levodopa|Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
11103094|NCT04054947|Experimental|Suicide Prevention Program|
11103095|NCT04054947|No Intervention|Usual Care|
11103096|NCT04054934||Normal Circardian rhythm|Regular night sleep, with at least 7 hours length of sleep.
11103097|NCT04054934||Reversed circadian rhythm|Night/day circadian clock is opposite, with at least 7 hours length of sleep
11103098|NCT04054921|Experimental|Interventions|PTG-300
11103099|NCT04054908||Cohort A|Patients treated with oral fluoropyrimidine (Capecitabine (CAP)) as part of standard of care (SOC) chemotherapy
11103100|NCT04054908||Cohort B|Patients treated with Trifluridine/Tipiracil (TAS-102) including those receiving it in combination with Y-90 radioembolization as part of a clinical trial
11103101|NCT04054908||Cohort C|Patients receiving CAP plus immunotherapy (pembrolizumab) and bevacizumab as part of a clinical trial.
11103102|NCT04054895|Experimental|Physiological pacing|"Pacing the his-purkinje system.
~Crossover to biventricular CRT will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria [Europace. 2019 Oct 9. doi: 10.1093/europace/euz275]."
11103103|NCT04054895|Active Comparator|Biventricular resynchronization therapy|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.
~Crossover from biventricular CRT to physiological pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
11103104|NCT04054882|Experimental|Sabin-IPV and DTaP|234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
11103105|NCT04054882|Active Comparator|Sabin-IPV only|234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
11103106|NCT04054882|Active Comparator|DTaP only|234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
11103107|NCT04054869|Experimental|Bio-mechanically correct manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically correct direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
11103136|NCT04054661|Other|evaluation of a G6PD test|all participants recruited in the study will be screened with an investigational IVD- STANDARD G6PD Test. The investigational test will not be used to determine any treatment or case-management. Participants will be tested on venous and fingerstick blood. Venous blood will be sent to a clinical laboratory for confirmatory testing on a reference assay
11103108|NCT04054869|Experimental|Bio-mechanically incorrect manual therapy (received first) arm|Participants will be randomized to receive manual therapy directed at the cervical spine atlanto-axial joints in the bio-mechanically incorrect direction followed by instruction in a home program to maintain this motion. Outcome measures will be assessed. Participants will return in 2-3 days and receive the opposite treatment and home program followed by outcomes assessment. Participants will return again in 2-3 days, outcomes will be assessed and the study will conclude. Participants will then be given the option to continue in formalized physical therapy if desired.
11103109|NCT04054856|Other|Patients with Morbus Parkinson|
11103110|NCT04054856|Other|Healthy Subjects|
11103111|NCT04054843||Gestational diabetes mellitus|First trimester pregnancies with gestational diabetes mellitus
11103112|NCT04054843||Control|First trimester healthy pregnancies
11103113|NCT04054830|Experimental|Topical, preservative-free NSAID|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
11103114|NCT04054830|Active Comparator|Topical, preservative-free steroid|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
11103115|NCT04054830|Experimental|Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee
11103116|NCT04054817|Experimental|Single Arm|
11103117|NCT04054778|Experimental|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
11103118|NCT04054778|Active Comparator|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
11103119|NCT04054765|Experimental|Teens in the Invite Only VR videogame|115 adolescents playing the Invite Only VR intervention
11103120|NCT04054765|Active Comparator|Teens in an Attention/Control non-health-related VR videogame|115 adolescents playing an attention/control non-health-related VR videogame
11103121|NCT04054752|Experimental|1/Arm 1|NT-I7 administered at 720 and 960g/kg to select the OBD of NT-I7
11103122|NCT04054752|Active Comparator|2/Arm 2a|Administration of 5 vaccines according to Sequence 1 + NT-I7 administration at OBD to assess vaccine response
11103123|NCT04054752|Active Comparator|3/Arm 2b|Administration of 5 vaccines according to Sequence 2 + NT-I7 administration at OBD to assess vaccine response
11103124|NCT04054739|Experimental|Robot-assisted gait training|experimental group that applied the end-effector robot-assisted gait training
11103125|NCT04054739|Active Comparator|Treadmill gait training|control group that applied the treadmill gait training
11103126|NCT04054726|Experimental|Real tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
11103127|NCT04054726|Sham Comparator|Sham tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
11103128|NCT04054713|Active Comparator|Chromoendoscopy with acetic acid and targeted biopsies|Acetic acid is prepared at a concentration of 2.5%, after initial cleaning is done, it will be applied with a 7 French spray catheter, starting the proximal application performing a uniform application on the area of intestinal metaplasia an then will be timed for mucous visualization in search of areas of loss of acetowhitening, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the esophageal face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal (glands evenly distributed with normal or abnormal crypt density (compact crypts with increased density; focal irregularity or disorganized crypts; absence of a cryptic pattern), once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
11103129|NCT04054713|Active Comparator|Seattle protocol|Take random biopsies by quadrants every 2 centimeters biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction begins, taking tissue every 2cm from the 4 quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
11103130|NCT04054700|Experimental|distal upper rehabilitation robot|experimental group that applied the distal upper rehabilitation robot
11103131|NCT04054700|Other|proximal upper rehabilitation robot|control group that applied the proximal upper rehabilitation robot
11103132|NCT04054687|Experimental|TXA|Research participants in the experimental group will receive one dose of 100mg/mL TXA soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
11103133|NCT04054687|Placebo Comparator|Saline|Research participants in the placebo group will receive one dose of normal saline (0.9%) soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.
11103134|NCT04054674|Experimental|flat occlusal scheme restored by lithium disilicate crown|flat occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
11103135|NCT04054674|No Intervention|planar occlusal scheme restored by lithium disilcate crown|planar occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
11103137|NCT04054648|Active Comparator|Bedtime Antihypertensive Medications|The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.
11103138|NCT04054648|No Intervention|Morning Antihypertensive Medications|No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.
11103139|NCT04054635|Experimental|Regimen 1|Two applications of silver diamine fluoride (SDF) four months apart, which is the protocol frequency adopted by the Winnipeg Regional Health Authority's (WRHA) Clinical Guideline on SDF.
11103140|NCT04054635|Experimental|Regimen 2|Two applications of silver diamine fluoride (SDF) six months apart (American Dental Association recommendation)
11103141|NCT04054635|Experimental|Regimen 3|Two applications of silver diamine fluoride (SDF) one month apart, which is proposed in the American Academy of Pediatric Dentistry's clinical practice guidelines.
11103142|NCT04054609|Other|FAZA PET/MRI scan|PET/MRI scan using radiotracer 18F-Fluoroazomycin Arabinoside
11103143|NCT04054596|Experimental|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
11103144|NCT04054596|No Intervention|Controlled|During weeks 2-5, one group will undergo a memory enhancement protocol, used to improve memory functioning in individuals with neurological injuries. The other group will serve as a control group and complete memory exercises with the researcher.
11103145|NCT04054583||Residents|Residents living on a special care unit in a long-term care facility. All 60 residents residing in the unit pre- and post-renovation will be eligible, and all will have intermediate or advanced dementia.
11103146|NCT04054583||Family Members|Family members are defined as the key person who supports the resident on a regular basis. This could include a spouse, adult child, adult grandchild, niece or nephew, close friend, former neighbour, or other significant person to the resident.
11103147|NCT04054583||Staff|Staff are the people who work on the special care unit. They may work only briefly or work on the design of the renovations. Types include: managers, nurses, health care aides, recreation facilitators, social worker, occupational therapist, physiotherapist, rehabilitation assistant, speech language pathologist, physicians, designers, and cleaning staff.
11103148|NCT04054570||Adaptive servo-ventilation patients|All patients under adaptive servo-ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
11103149|NCT04054570||Barometric and Volumetric patients|All patients under barometric and volumetric ventilation in the Geneva Lake area and details of the specifics indications, population treated and venitator settings
11103150|NCT04054557|Active Comparator|Arm I (Standard of Care office Visits)|Participants receive standard of care office visits every 3 months (± 2 weeks) for one year.
11103151|NCT04054557|Experimental|Arm II (Standard of Care Office Visits, telehealth)|Participants receive standard of care as in Arm I and 4 telehealth visits over approximately 20-30 minutes every 6 weeks (± 2 weeks) at around weeks 6, 18, 30, and 42 for one year.
11103152|NCT04054544|Experimental|Gluten challenge|Participants will receive a gluten 4 g powder twice daily (BID), for 13 consecutive days
11103153|NCT04054531|Experimental|KN046 + carboplatin/paclitaxel|KN046 5 mg/kg IV every three weeks (Q3W) +Carboplatin AUC5 IV Q3W x 4 cycles + Paclitaxel 500 mg/m2 IV Q3W x 4 cycles
11103154|NCT04054531|Experimental|KN046 + carboplatin/pemetrexed|KN046 5 mg/kg IV Q3W +Carboplatin AUC5 IV Q3W x 4 cycles + Pemetrexed 500 mg/m2 IV Q3W x 4 cycles
11103155|NCT04054518|Experimental|Durvalumab|1500 mg durvalumab (MEDI4736) via IV infusion Q4W <<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48>> or <<until confirmed disease progression>> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
11103156|NCT04054505|Active Comparator|Vitamin A|Rise or fall of Vitamin A after three months
11103157|NCT04054505|Active Comparator|Vitamin E|Rise or fall of Vitamin E after three months
11103158|NCT04054505|Active Comparator|Vitamin B1|Rise or fall of Vitamin B1 after three months
11103159|NCT04054505|Active Comparator|Vitamin B2|Rise or fall of Vitamin B2 after three months
11103160|NCT04054505|Active Comparator|Vitamin B6|Rise or fall of Vitamin B6 after three months
11103161|NCT04054505|Active Comparator|Vitamin B12|Rise or fall of Vitamin B12 after three months
11103162|NCT04054505|Active Comparator|Vitamin C|Rise or fall of Vitamin C after three months
11103163|NCT04054505|Active Comparator|Vitamin D|Rise or fall of Vitamin D after three months
11103164|NCT04054505|Active Comparator|Calcium|Rise or fall of Calcium after three months
11103165|NCT04054505|Active Comparator|Iron|Rise or fall of Iron after three months
11103166|NCT04054505|No Intervention|IGF1|Rise or fall of IGF1 after three months
11103167|NCT04054505|No Intervention|FT-3|Rise or fall of FT-3 after three months
11103168|NCT04054492|Experimental|sIPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
11103169|NCT04054492|Active Comparator|sIPV+sIPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
11103170|NCT04054492|Active Comparator|sIPV+sIPV+sIPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
11103171|NCT04054479|Experimental|Penehyclidine|Patients in this arm will receive penehyclidine after anesthesia intubation.
11103172|NCT04054479|Placebo Comparator|Normal Saline|Patients in this arm will receive normal saline after anesthesia intubation.
11103173|NCT04054466|Experimental|Experimental group|Intervention with counselling designed
11103174|NCT04054466|Other|Control group|Intervention with habitual counselling
11103175|NCT04054453|No Intervention|Pre-intervention|Baseline data on neonatal encephalopathy and epilepsy before the introduction of the care bundle
11103176|NCT04054453|Experimental|Post-intervention|Baseline data on neonatal encephalopathy and epilepsy after the introduction of the care bundle
11103177|NCT04054427|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF
11103367|NCT04053049|Active Comparator|High carbohydrate/ solid|Subject will receive a high carbohydrate/solid meal.
11103178|NCT04054414|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
11103179|NCT04054414|Experimental|PMZ-1620|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
11103180|NCT04054388|Experimental|300 Randomized to re-education group|LINE re-education of colon preparation
11103181|NCT04054388|No Intervention|300 Randomized to control group|education of colon preparation 1 time in hospital
11103182|NCT04054375|Experimental|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
11103183|NCT04054362|Experimental|With Cisplatin|Paclitaxel Protein bound, Cisplatin, and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
11103184|NCT04054362|Experimental|Without Cisplatin|Paclitaxel Protein bound and Gemcitabine until stable or progressive disease, at which point Paricalcitol will be introduced.
11103185|NCT04054349|Experimental|Low FODMAP Diet Group|The parent/caregiver was given detailed nutrition education by the investigator concerning the low FODMAP diet and was asked to implement for 2 weeks.
11103186|NCT04054349|No Intervention|Control Group (Habitual Diet)|The parent/caregiver was asked to continue their child's usual dietary intake for 2 weeks.
11103187|NCT04054336|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures containing soft drinks by swiping/pulling them towards themselves, whereas pictures with alcoholic content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
11103188|NCT04054336|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon soft drinks by swiping/pulling towards themselves the picture. Pictures containing alcoholic content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
11103189|NCT04054336|Sham Comparator|Control group|This type of active control group receives the instructions to swipe alcohol pictures to the left and soft drink pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
11103190|NCT04054323|Experimental|Patient Physical Activity Arm|Patients only receive physical activity intervention.
11103191|NCT04054323|Experimental|Dyadic Physical Activity Arm|Patients and caregivers both receive physical activity intervention.
11103192|NCT04054310|Experimental|Study arm|Only one arm, so not necessary.
11103193|NCT04054297|Experimental|High GI/SFA diet|Subjects will adhere to a two-week high GI and high SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
11103194|NCT04054297|Experimental|Low GI/SFA diet|Subjects will adhere to a two-week low GI and low SFA diet. Crossover design, randomly assigned to start with either high GI/SFA or low GI/SFA. 4 week washout between the two diets.
11103195|NCT04054284|Experimental|Intervention|Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
11103196|NCT04054284|Active Comparator|Control|Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
11103197|NCT04054258|Experimental|App support programme group|In addition to the usual care, the participant and one family member will receive a CHD app and a briefing from a trained research nurse (A). The reason to invite an additional family member to install the app is to ensure that he/she can be informed automatically when the patient presses an icon during a chest pain attack. The patient may be too stressed during an angina attack and may not be able to follow the 'Things to Do List' quickly. In addition, automatic reminders of the individual's medication times and follow-up times will be pre-set in the app for individual use.
11103198|NCT04054258|Active Comparator|Telephone support group|In addition to the above usual care, bi-weekly 20-minute telephone follow-ups will be provided by a trained research nurse (B) for up to 3 months. Patients can ask about related health problems if any. The nurse will address their problem by providing advice or referring them to the ED follow-up clinic. The team has set up a telephone advice guide to support the research nurse in giving phone advice.
11103199|NCT04054245|Experimental|Treatment (LOXL2 inhibitor PAT-1251)|Patients receive LOXL2 inhibitor PAT-1251 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11103200|NCT04054232|Experimental|EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to have their primary care physician receive an electronic health record message regarding their high risk of having PAD and a recommendation will be made to have the participant referred for non-invasive testing called Ankle Brachial Index (ABI) testing to confirm diagnosis. For individuals who undergo ABI testing and are confirmed to have PAD, they and their physicians will be provided with American Heart Association Guidelines for the management of PAD. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications.
11103225|NCT04054050|Experimental|Light therapy|Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
11103226|NCT04054037||HBV-ACLF Group|Patients with HBV related acute on chronic liver failure
11103227|NCT04054024|Active Comparator|Active drug|
11103228|NCT04054024|Placebo Comparator|Placebo|
11103264|NCT04053790|Active Comparator|LB 20000|Patients in this group will receive placebo 1 tablet containing 10,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
11103201|NCT04054232|No Intervention|No EHR Alert|Twenty-five participants who are flagged by the screening tool as having high risk of undiagnosed peripheral artery disease (PAD) will be randomized to the control arm and they nor their physicians will be alerted of their status for 6 months. Each participant's medical record will be reviewed for 6 months to evaluate for referral for ABI testing, referral to cardiovascular specialists (vascular medicine, vascular surgery or a cardiologist), and for initiation of new cardiovascular related medications such as an antiplatelet, statins, or anti-hypertensive medications. At the end of 6 months of observation, the primary care physician's of control participants will receive the same alert as participants in the intervention arm.
11103202|NCT04054206|Active Comparator|Sequence 1|"Two participants will be randomly assigned to sequence 1 comprising 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart:
~Day 1-7: ER fasted; Day 8-15: ER fed Day 15-22: IR fasted"
11103203|NCT04054206|Active Comparator|Sequence 2|Two participants will be randomly assigned to sequence 2 comprising 3 treatments in a crossover design, administered one week apart: Day 1-7: ER fed; Day 8-15: IR fasted; Day 15-22: ER fasted
11103204|NCT04054206|Active Comparator|Sequence 3|"Two participants will be randomly assigned to sequence 3 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: IR fasted; Day 8-15: ER fasted; Day 15-22: ER fed"
11103205|NCT04054206|Active Comparator|Sequence 4|"Two participants will be randomly assigned to sequence 4 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: IR fasted; Day 8-15: ER fed; Day 15-22: ER fasted"
11103206|NCT04054206|Active Comparator|Sequence 5|"Two participants will be randomly assigned to sequence 5 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: ER fasted; Day 8-15: IR fasted; Day 15-22: ER fed"
11103207|NCT04054206|Active Comparator|Sequence 6|"Two participants will be randomly assigned to sequence 6 comprising 3 treatments in a crossover design, administered one week apart:
~Day 1-7: ER fed; Day 8-15: ER fasted; Day 15-22: IR fasted"
11103208|NCT04054193|Experimental|Fosaprepitant Regimen|Participants will receive 115 mg or an age-adjusted dose of intravenous (IV) fosaprepitant in combination with a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 of emetogenic chemotherapy. Following Day 1, participants will receive single-daily 80 mg or age-adjusted doses of IV fosaprepitant on Days 2 and 3 with or without a 5-HT3 antagonist. Participants may also receive dexamethasone at investigator's discretion based on the local standard of care.
11103209|NCT04054180|Experimental|CPAP S.Box associated with its 3 connected devices|S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.
11103210|NCT04054167|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
11103211|NCT04054154|Experimental|Device Feasibility (Millar Mikro-tip catheter, elastography)|Patients scheduled for an ultrasound-guided tumor biopsy undergo stiffness assessment of the tumor with shear wave elastography over 2 minutes and pressure measurements of the tumor using a Millar Mikro-tip catheter before and after the biopsy is collected.
11103212|NCT04054141|Experimental|rTMS arm|"Each patient's participation will last a maximum of 12 weeks and involves 2 sessions of neurophysiological testing (TMS) sessions and 15 neurophysiological treatment sessions (rTMS).
~Patients will have a neurophysiological testing session (TMS) at the screening visit (week 0). Patients will then return for 15 neurophysiological treatment sessions (rTMS) within 14 days of screening. Patients must complete three neurophysiological treatment sessions (rTMS) during weeks 1, 2, 3, 4 and 5. The second neurophysiological testing session will be done at the final visit (week 5). Follow-up visits will be scheduled at weeks 7 and 10 (+/- 3 days). That is, the follow-up visits will occur two and five weeks after the final rTMS session which occurs on day 15."
11103213|NCT04054128|Experimental|Sodium bicarbonate catheter lock group (SBCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with sodium bicarbonate 7.5% Injection.
11103214|NCT04054128|Active Comparator|Heparin catheter lock group (HCL)|Chronic hemodialysis patients with a catheter as a vascular access, will be lock with heparin, 1000 Units/mL injectable solution
11103215|NCT04054115|Experimental|Treatment Arm|"Baseline cardiac catheterization under GA. (Standard of Care, SOC)
~Transfer patient to MRI unit
~Baseline MRI
~Obtain ABG for pCO2 from existing femoral arterial access.
~Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.
~MRI phase contrast imaging for flow measurements(SOC).
~During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.
~Post alprostadil infusion
~1ml blood sample taken from existing femoral venous access for prostaglandin level.
~Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.
~Repeat MRI flow measurements
~7.Return to cath lab if further intervention required. 8.Recovery and monitoring for for 4 to 6 hours prior to discharge(SOC)."
11103216|NCT04054102|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
11103217|NCT04054102|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
11103218|NCT04054089|Experimental|A|B/F/TAF
11103219|NCT04054089|Active Comparator|B|DTG+3TC
11103220|NCT04054076|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
11103221|NCT04054076|Experimental|Custom-made insoles soft|Custom-made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate.
11103222|NCT04054076|Experimental|Custom-made hard|Custom-made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate.
11103223|NCT04054076|No Intervention|Control group|No intervention with therapeutic insoles and/or shoes.
11103224|NCT04054063|Experimental|HSK3486+etomidate|Cohort 1: HSK3486 0.324 mg/kg + etomidate 0.15 mg/kg Cohort 2: HSK3486 0.216 mg/kg + etomidate 0.2 mg/kg Cohort 3: HSK3486 0.432 mg/kg + etomidate 0.1 mg/kg There were an additional 2 cohorts (Cohorts 4 and 5) planned for dose escalation once the optimal ratio of the drug combination was identified from the first 3 cohorts. However, these 2 cohorts were not done as the results of Cohorts 1 to 3 suggested that dose increases would cause higher occurrence of drug-related adverse events (AEs).
11103229|NCT04054011|Experimental|deoxycholic acid|Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)
11103230|NCT04053985|Experimental|TAI+lenvatinib group|TAI combine lenvatinib
11103231|NCT04053985|Active Comparator|lenvatinib group|lenvatinib only
11103232|NCT04053972|Experimental|treatment group|adjuvant lenvatinib
11103233|NCT04053972|No Intervention|control group|no intervention
11103234|NCT04053959|Experimental|AI Group|Artificial intelligence assisted insulin titration system group
11103235|NCT04053959|Active Comparator|Control Group|Physicians decided insulin titration group
11103236|NCT04053946|Experimental|Next Science|Following amputation, SurgX™ will be applied directly to the surgical incision in the operating room under sterile conditions and covered with SOC dressing. The surgical dressing will not be removed until post-operative day 3, except if deemed necessary by the treating surgeon. At that time, direct application of the BlastX™ to the incision will be placed, then covered with a SOC dressing. BlastX™ will be applied every day and covered with SOC dressing.
11103237|NCT04053946|No Intervention|Control|Post-op SOC dressing as per treating research doctor to include dressing changes post-op day 3 and daily thereafter.
11103238|NCT04053933||Patients treated with ESA|
11103239|NCT04053933||Patients treated with 5'azacitidin|
11103240|NCT04053933||Patients treated with deferoxamine|
11103241|NCT04053933||Patients treated with deferasirox|
11103242|NCT04053933||Patients treated with transfusion only|
11103243|NCT04053933||Patients treated with lenalidomide|
11103244|NCT04053933||Patients treated with intensive chemotherapy|
11103245|NCT04053920|Experimental|Low load|Training at 30-40% one-repetition maximum (1RM)
11103246|NCT04053920|Experimental|High load|Training at 65-75% one-repetition maximum (1RM)
11103247|NCT04053907|No Intervention|CCM:Standard of Care|Community Case Management (CCM), with passively monitored malaria incidence by community health workers using standard RDTs and artemisinin-based combination therapy (ACT), artemether-lumefantrine (AL) according to national guidelines.
11103248|NCT04053907|Experimental|CCM plus weekly fever screening and treatment|CCM plus active case detection (ACD) by fever screening and treatment if positive. Trained VHW recruited for this study will carry out weekly visits of all residents and screen for fever using research-grade thermometers. A standard RDT will be performed in all individuals with a body temperature ≥37.5°C or with reported fever in the last 24 hours. RDT positive individuals will be treated with AL according to national guidelines.
11103249|NCT04053907|Experimental|CCM plus MSAT|CCM plus monthly screening for malaria infection and treatment of positive individuals, regardless of symptoms. Screening will be performed by research staff and timed to ensure a gap of 25-35 days between screening rounds; Positive individuals will be treated with AL, according to national guidelines.
11103250|NCT04053907|Experimental|CCM plus dry season MDA|CCM plus plus 3 monthly rounds of MDA with a long-acting ACT (dihydroartemisinin-piperaquine, DP) starting in the dry season (April, May, June) (tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight).
11103251|NCT04053881||Certolizumab pegol|Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
11103252|NCT04053868|Experimental|Electronic Cigarette|The participants will participate in a standardized vaping session using a JUUL E-cigarette device with a JUUL e-liquid pod.
11103253|NCT04053868|Experimental|Tobacco Cigarette|The participants will participate in a standardized smoking session using commercial tobacco cigarettes.
11103254|NCT04053855||Renal mass patients|"Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.
~They will have an urinary sample."
11103255|NCT04053855||Control patients|Control patients (without renal mass) will be included. They will have an urinary sample.
11103256|NCT04053842|Experimental|Multi-modality prostate cancer imaging|The study requires eligible patients to complete one imaging session at St. Joseph's Health Care to begin within 6 weeks of the scheduled Radical Prostatectomy. Imaging will consist of simultaneous multiparametric MRI (mpMRI), sodium MRI and positron emission tomography (PET) with a radio-labeled probe for prostate-specific membrane antigen (PSMA).
11103257|NCT04053829|Experimental|HOLOBalance|The experimental arm will use the HOLOBalance tele-rehabilitation system to provide the intervention. Participants will be required to use the HOLOBalance system on a daily basis for the duration of the 8 week study. Although participants will have daily interaction with the HOLOBalance system, they will be free to choose when to complete their exercises.
11103258|NCT04053829|Active Comparator|OTAGO Home Exercise Programme|The comparator for this study is the OTAGO home exercise programme. The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. The OTAGO is well-established and is widely used in clinical practice in the UK for the management of older adults who fall or have increased risk for falling. It has been shown to be well tolerated in older adults in community settings with good adherence rates, and reduces falls rate in older adults by 35%, with greatest effects observed in frailer older women
11103259|NCT04053816|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
11103260|NCT04053816|Active Comparator|Tight control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
11103261|NCT04053803|Experimental|Open Label|
11103262|NCT04053790|Placebo Comparator|placebo group|Patients in this group will receive placebo 1 tablet every 12 hours, during 4 weeks.
11103263|NCT04053790|Active Comparator|LB 10000|Patients in this group will receive placebo 1 tablet containing 5,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
11103266|NCT04053764|Experimental|crizanlizumab + standard of care|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.
11103267|NCT04053764|Active Comparator|standard of care|Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.
11103268|NCT04053751|Experimental|closed suctioning system|Closed suctioning system will be compared with open suctioning system
11103269|NCT04053751|No Intervention|open suctioning system|The patient will be monitored with closed system for one day and open aspiration system on the other day.
11103270|NCT04053738|No Intervention|Baseline|Participants slept in the anti-snoring bed in the laboratory, but the bed did not provide any intervention
11103271|NCT04053738|Experimental|Anti-snoring Intervention|Participants slept in the anti-snoring bed in the laboratory, and the bed moved the trunk of the participant
11103272|NCT04053712|Placebo Comparator|Single-hormone|FiAsp (R) - Saline
11103273|NCT04053712|Active Comparator|Dual-hormone|FiAsp(R) - GlucaGen(R)
11103274|NCT04053699||Patients undergoing treatment with a VWF-containing product|Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months
11103275|NCT04053686|Experimental|Intervention|The intervention group will aim to regularly break up participants' prolonged sitting time with three-minute incidental movement breaks every half hour at work. Support for behaviour change will include a lecture/workshop, electronic prompts, break logging, team competition, health champions, and email support.
11103276|NCT04053673|Experimental|RBN-2397|Dose Escalation: Multiple doses of RBN-2397 for oral administration Dose Expansion: Oral dose of RBN-2397 as determined during Dose Escalation
11103277|NCT04053660|No Intervention|Control|Periodontally healthy group
11103278|NCT04053660|Experimental|Chronic Periodontitis|Patients with chronic periodontitis
11103279|NCT04053647||Hypoparathyroid patients|Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.
11103280|NCT04053647||Control patients, without hypoparathyroidism|
11103281|NCT04053634|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
11103282|NCT04053634|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
11103283|NCT04053621|Experimental|Experimental group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and thiamine pyrophosphate (weekly dose of 1 gram administered by IV: 25 ml of thiamine pyrophosphate + 250 ml saline solution at a 60-80 drops/minute rate).
~Total duration of 12 weeks."
11103284|NCT04053621|Placebo Comparator|Placebo group|"Metformin at patient´s tolerated oral dose (maximum of 2550 mg per day) and weekly administration of 275 ml of saline solution at a 60-80 drops/minute rate).
~Total duration of 12 weeks."
11103285|NCT04053595|Experimental|Estimated Oxygen Extraction|
11103286|NCT04053595|Active Comparator|Dynamic Parameters|
11103287|NCT04053582|Active Comparator|Augmented Mindfulness Training (AMT)|Participants will receive real-time neurofeedback from the PCC during mindfulness practice in the MRI
11103288|NCT04053582|Active Comparator|Sham|Participants will receive an artificial neurofeedback signal during mindfulness practice in the MRI
11103289|NCT04053569|Experimental|Diet with table grape|Table grape (5g/Kg) administered for four weeks with dietary recommendations. A strict restriction of fruits and the limitation of other foods containing polyphenols will be necessary.
11103290|NCT04053569|No Intervention|Specific dietary advice|Dietary recommendations (such as limitation of alcohol, caffeine), and low consumption of fruits.
11103291|NCT04053543|Experimental|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
11103292|NCT04053530|Experimental|3M™ Ketac™ Universal Aplicap™|"3M™ Ketac™ Universal Aplicap™ Glass Ionomer Restorative Clean the cavity preparation with water. Rinse thoroughly and dry. Extrude the mixed ketac universal out of the capsule directly into the prepared cavity with a capsule gun. Please ensure that no air bubbles are included.
~It is recommended that the finishing and polishing can be continued after approximately 4 minutes after the start of the mixing or earlier if heat is applied for faster setting. The finishing and polishing can be done immediately after final setting with Extra-Fine, Friction Grip diamonds under water-cooling."
11103293|NCT04053530|Experimental|Filtek™ Bulk Fill Flowable composite|"Filtek™ Bulk Fill Flowable Restorative is the 3M ESPE choice in the bulk fill flowable category.
~Selective etching 15-20 s for enamel. The adhesive system (BISCO universal all bond) will be applied following the manufacturer's instructions (apply 2 coats 20 s before curing). Bulk fill flowable composite will be light cured for 40 s using a visible light curing unit."
11103294|NCT04053530|Active Comparator|ketac N100|"Ketac™ Nano Light Curing Glass Ionomer Restorative. Primer will be applied to both enamel and dentinal surfaces for 15 seconds. The prepared tooth surfaces will be wet with the primer for the full application time.
~Dispensing two clicks from the Clicker™ Dispenser will provide an adequate amount of material for most restorative filling applications.
~It will be placed with a syringe system then will be placed in 2mm increments or less, and light cured after each increment. An LED curing light will cure all shades with a 20 second light exposure.
~Finishing Ketac Nano restorative will be polished with conventional finishing and polishing instruments such as a diamond impregnated rubberized polishing system under water spray. A glaze such as Vitremer™ Finishing Gloss will be applied after polishing if desired."
11103295|NCT04053517||Observational (questionnaire administration)|Patients complete questionnaires about financial state and quality of life over 15 minutes. Patients' medical chart is also reviewed.
11103296|NCT04053504|Experimental|Intervention|Behavioral intervention delivered by parent peer leaders.
11103297|NCT04053504|No Intervention|Standard Care|Standard diabetes care
11103298|NCT04053491|Experimental|Axillary block group|Initial bolus will be given and then a perinervous catheter will be inserted by the axillary approach.
11103299|NCT04053491|Experimental|Infraclavicular block group|Initial bolus will be given and then a perinervous catheter will be inserted by the infraclavicular approach.
11103300|NCT04053478|Experimental|Myometrium + Ephedrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine (from 10 -10M to 10 -3M)
11103301|NCT04053478|Experimental|Myometrium + Phenylephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine(from 10 -10M to 10 -3M)
11103302|NCT04053478|Experimental|Myometrium + Norepinephrine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine(from 10 -10M to 10 -3M)
11103303|NCT04053478|Experimental|Umbilical artery + Ephedrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine (from 10 -10M to 10 -3M)
11103304|NCT04053478|Experimental|Umbilical artery + Phenylephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine(from 10 -10M to 10 -3M)
11103305|NCT04053478|Experimental|Umbilical artery + Norepinephrine|The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine(from 10 -10M to 10 -3M)
11103306|NCT04053465|Experimental|Exercise in heat group|Exercise in a hot environment
11103307|NCT04053465|Placebo Comparator|Exercise in cool group|Exercise in a cool environment
11103308|NCT04053452|Experimental|GBS Patients|
11103309|NCT04053452|Active Comparator|Controls|
11103310|NCT04053439||Lymphoma patients >=60 receiving cytotoxic chemotherapy|Lymphoma patients >=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.
11103311|NCT04053426||"Population before"|Patient included before implementation of care algorithm.
11103312|NCT04053426||"Population after"|Patients included after the implementation of care algorithm and training of health professionnals
11103313|NCT04053413|No Intervention|Usual care|Women in this group will undergo usual care and the complete the survey questions on knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean.
11103314|NCT04053413|Active Comparator|Decision Aid|Women in this group will receive a decision aid prior to undergoing counseling by their physician. Following completion of the decision aid and physician counseling, they will complete a series of survey questions to assess their perceptions of their knowledge and involvement in the decision for trial of labor after cesarean (TOLAC) or repeat cesarean delivery.
11103315|NCT04053400||Ketamine Group|Active duty military service member injured in theater, AEROVAC-ED out, and received ketamine.
11103316|NCT04053400||Non-Ketamine Comparison Group|Active duty military service member injured in theater, AEROVAC-ED out, and did NOT receive ketamine treatment for pain.
11103317|NCT04053387|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
11103318|NCT04053374||DMD treatment naive CIS or RRMS patients|Newly presenting Clinically Isolated Syndrome (CIS) or Relapsing and Remitting Multiple Sclerosis (RRMS) patients not treated before with Disease Modifying Drugs (DMD) Additional analysis of CSF and CSF cells will be performed in this cohort on a voluntary basis.
11103319|NCT04053374||Secondary Progressive Multiple Sclerosis (SPMS)|People with confirmed diagnosis of SPMS
11103320|NCT04053374||Primary Progressive Multiple Sclerosis (PPMS)|People with confirmed diagnosis of PPMS
11103321|NCT04053374||DMD-treated with stable disease|People with Multiple Sclerosis (MS) who are treated with DMD who have had stable disease symptoms for at least 3 months
11103322|NCT04053374||Disease controls|People who undergo lumbar puncture due to clinical suspicion of neurological condition, but brain Magnetic Resonance Imaging (MRI) and CSF examination exclude MS diagnosis.
11103323|NCT04053374||Healthy donors|Age, sex and ethnicity matched healthy donors will also be recruited from university and hospital staff and patient friends after informed consent has been obtained. Healthy donors will be asked to provide a blood sample and demographic information but will NOT be asked to provide CSF samples.
11103324|NCT04053361|Active Comparator|Group A: Clinical ablation|"Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.
~If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.
~If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.
~If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.
~If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.
~No induction protocols for other, on top of already ablated, arrhythmias will be attempted."
11103325|NCT04053361|Experimental|Group B: Clinical plus substrate-based ablation|"- The initial ablation steps will be identical to those in patients from Group A.
~Supplemental ablation will consist of:
~Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)
~AND
~Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage <0.5 mV in sinus rhythm or <0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (<20% of atrial surface) achievable to ablate.
~Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.
~Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (>5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol."
11103326|NCT04053348|Experimental|Intervention|Participants allocated to the intervention group will receive their home-based rehabilitation program using mobile app installed in the mobile device.
11103327|NCT04053348|Active Comparator|Control|Those assigned to the control group will receive the same home-based rehabilitation program but with information and instructions delivered through the use of paper-based handouts.
11103328|NCT04053335||Cohort 1: Multicomponent Physician Performance Peer-Comparison|Cohort 1 (2 groups): Runs July 2019 - December 2020 - Inova/Signature Parters and Sentara/Sentara Quality Care Network
11103329|NCT04053335||Cohort 2: Multicomponent Physician Performance Peer-Comparison|Cohort 2 (2 groups): Runs November 2019 - April 2021 - Ballad Health and Carilion Clinic
11103330|NCT04053335||Cohort 3: Multicomponent Physician Performance Peer-Comparison|Cohort 3 (2 groups): Runs March 2020 - August 2021 - Health Care Associates Virginia/Virginia Care Partners and Virginia and Commonwealth University Health System
11103331|NCT04053322|Experimental|Study Arm|
11103368|NCT04053036|Experimental|Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive MDMA (1.5 mg/kg)
11103332|NCT04053309||Males undergoing TESE or microTESE|All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.
11103333|NCT04053296||The first pregnancy with PAH group|
11103334|NCT04053296||The second pregnancy with PAH group|
11103335|NCT04053283|Experimental|Intratumoural|In the IT cohort, patients will receive a single dose of NG-641 by IT injection on Day 1. The dose given to each patient will be dependent on the size of the tumour lesion to be injected.
11103336|NCT04053283|Experimental|Intravenous|In the IV cohort, patients will receive a single cycle of study treatment, with three single doses of NG-641 on Days 1, 3 and 5 by IV infusion.
11103337|NCT04053270|Experimental|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
11103338|NCT04053270|Placebo Comparator|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
11103339|NCT04053257|No Intervention|Before intervention|HH opportunities, compliant moments and HAIs recorded before the intervention
11103340|NCT04053257|Active Comparator|After intervention|HH opportunities, compliant moments and HAIs recorded after the intervention
11103341|NCT04053244|Experimental|treatment|all participants will be assigned to the treatment, consisting of therapist-assisted iCBT.
11103342|NCT04053218|Active Comparator|Exercise and supplement|Supervised aerobic exercise three times weekly and daily omega-3 supplements
11103343|NCT04053218|Placebo Comparator|Placebo|Olive oil capsules. No supervised exercise but written recommendations for daily physical activity from the American Heart Association
11103344|NCT04053205|Experimental|1 Gentuximab+ Paclitaxel|8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
11103345|NCT04053205|Experimental|2 Gentuximab+ Paclitaxel|12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
11103346|NCT04053192||High-Gradient Aortic Stenosis (HG-AS)|(Pmean >40mmHg, AVA <1cm^2, Vmax >4m/s)
11103347|NCT04053192||Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)|(Pmean <40mmHg, AVA <1cm^2, Vmax <4m/s, EF <50%)
11103348|NCT04053192||Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)|Pmean <40mmHg, AVA <1cm^2, Vmax < 4m/s, EF >50%)
11103349|NCT04053179|Experimental|Connected patch validation|
11103350|NCT04053166|Experimental|Individualized home-based physical activity|The subjects of this arm will have a daily goal in number of steps based on the initial 2 first week evaluation of daily number of steps. They will wear connected wrists, and will be contacted twice a month by phone call by the adapted physical activity trainer to revaluate these goals.
11103351|NCT04053166|Active Comparator|Control group|The subjects of this arm will not have evaluation of daily steps and recommendations regarding physical activity and sedentary behaviour. They will be asked to live as usual.
11103352|NCT04053153|Experimental|Use of musical instrument|
11103353|NCT04053153|Sham Comparator|Use of sham musical instrument|
11103354|NCT04053140|Experimental|Routine intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.
11103355|NCT04053140|Experimental|Closed-loop control of intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
11103356|NCT04053140|Experimental|Closed-loop control of continuous infusion|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
11103357|NCT04053127|Experimental|RAVANS|Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
11103358|NCT04053127|Sham Comparator|non-RAVANS|For sessions randomized to sham stimulation, the electrodes in the ear will remain as described above, but the leads will be disconnected from the stimulator. Subjects will be instructed that for this session they may or may not feel pulsing in their ear, and that the goal is to ensure that the stimulus was not painful.
11103359|NCT04053114||Retrospective cohort|Tissue samples
11103360|NCT04053088||SAVR patients|patients undergoing surgical aortic valve replacement (SAVR) by usage of the INSPIRIS RESILIA Aortic valve™
11103361|NCT04053075|Active Comparator|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
11103362|NCT04053075|Active Comparator|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
11103363|NCT04053062|Experimental|LIGHT-PSMA-CART|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -6 to -4. Patients receive LIGH-PSMA-CART IV at split doses from day 0 on.
11103364|NCT04053049|Active Comparator|High fat/ Semi-solid|Subject will receive a high fat/semi-solid meal.
11103365|NCT04053049|Active Comparator|High carbohydrate/ Semi-solid|Subject will receive a high carbohydrate/semi-solid meal.
11103366|NCT04053049|Active Comparator|High fat/ solid|Subject will receive a high fat/solid meal.
11103369|NCT04053036|Experimental|MDMA Then Placebo|Participants first receive MDMA (1.5 mg/kg) at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
11103370|NCT04053023|Experimental|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
11103371|NCT04053010|Experimental|group 1|234 subjects; simultaneously administration of Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
11103372|NCT04053010|Active Comparator|group 2|234 subjects; Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
11103373|NCT04053010|Active Comparator|group 3|234 subjects; DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
11103374|NCT04052997|Experimental|Camidanlumab Tesirine|Camidanlumab Tesirine is administered as a 30- minute intravenous (IV) infusion on Day 1 of each cycle (every 3 weeks). Camidanlumab Tesirine will be administered at a dose of 45 μg/kg every 3 weeks for 2 cycles, then 30 μg/kg for subsequent cycles.
11103375|NCT04052984|Experimental|Intervention group|Twenty four pares of healthy mothers-newborns, with delayed clamping and immediate skin-to-skin contact after birth by caesarean section
11103376|NCT04052984|No Intervention|Control group|Twenty four pares of healthy mothers-newborns, with early clamping without skin-to-skin contact after birth by caesarean section and newborn attended in radiant warm table
11103377|NCT04052971|Experimental|Escalation phase|"Drug: ABN401
~Route of Administration: Oral
~The study will follow a single patient cohort approach for the first 3 regular dose levels followed by classic 3+3 design. The starting dose is 50mg QD."
11103378|NCT04052971|Experimental|Expansion phase|"Drug: ABN401
~Route of Administration: Oral
~Once the MTD or highest escalation cohort has been reached, or notable efficacy has been observed at a given dose level, a decision as to RP2D will be determined. Upon the establishment of RP2D, up to 4 expansion cohorts of 10-29 patients will be recruited representing various c-Met amplification or mutant tumor types of interest."
11103379|NCT04052958|Active Comparator|Group 1: Strength Training|Respiratory muscle strength training
11103380|NCT04052958|Active Comparator|Group 2: Endurance Training|Respiratory muscle endurance training
11103381|NCT04052958|No Intervention|Group 3: Control group|no training of respiratory muscles
11103382|NCT04052945|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
11103383|NCT04052945|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
11103384|NCT04052932|Placebo Comparator|Placebo|Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks
11103385|NCT04052932|Experimental|SHR4640 dose1|SHR4640 dose1 once a day, orally, for 36 weeks
11103386|NCT04052932|Experimental|SHR4640 dose2|SHR4640 dose2 once a day, orally, for 36 weeks
11103387|NCT04052932|Active Comparator|Allopurinol|Allopurinol 300mg (milligram) once a day, Orally, for 36 week
11103388|NCT04052919|Experimental|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.
~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.
~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
11103389|NCT04052906|Experimental|Intervention Group|Planned Inhaler Medication Training
11103390|NCT04052906|No Intervention|Control Group|usual care
11103391|NCT04052893|Experimental|Study group|100 patients will be assigned into a study group.
11103392|NCT04052893|Active Comparator|Control group|100 patients will be assigned into a control group.
11103393|NCT04052880|Experimental|Daratumumab with dose-attenuated VRd|SubQ Daratumumab with Dose-Attenuated VRd
11103394|NCT04052867|Experimental|Lignocaine group|20 patients undergoing elective laparoscopic donor nephrectomy will be given lignocaine infusion as part of the perioperative pain management.
11103395|NCT04052867|Active Comparator|Control group|20 patients undergoing elective laparoscopic donor nephrectomy will be receiving an equivalent volume of normal saline.
11103396|NCT04052841|Experimental|MGD-thermal pulsation group|Undergo a 15-minute Lipiflow treatment lid hygiene, then receive topical eye drops for 3 months.
11103397|NCT04052841|Experimental|MGD-IPL group|Undergo 3 times intense pulsed light therapies for each 3 weeks, then receive topical eye drops for 3 months.
11103398|NCT04052841|Experimental|MGD-manual meibomian gland expression|Warm compresses and lid hygiene per day, lid massage up to four times per day for 15 minutes for 3 months. Then receive topical eye drops for 3 months.
11103399|NCT04052841|No Intervention|Normal health subject group|Normal health subject without intervention.
11103400|NCT04052828|Experimental|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
11103401|NCT04052815|Experimental|Diabetes prevention program culturally tailored|Adult females with Hispanic background
11103402|NCT04052802|Experimental|Bioactive resin (Giomer)|"This group of patients will receive a bioactive resin Beautifil flow plus X (Shofu Dental) for treatment of their demineralized fissures"
11103403|NCT04052802|Experimental|Conventional resin|"This group of patients will receive a conventional resin Filtek Z350xt Flowable composite (3M ESPE) for treatment of their demineralized fissures"
11103404|NCT04052789|Active Comparator|Zirconia single posterior crowns veneered with ceramics|'In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
11103405|NCT04052789|Experimental|BioHpp PEEK single posterior crowns veneered with compos|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits
11103406|NCT04052776|Active Comparator|Buspirone|40mg
11103408|NCT04052776|Active Comparator|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
11103409|NCT04052776|Placebo Comparator|Placebo|Mannitol pill
11103410|NCT04052763||High-risk ACS patients|High-risk ACS patients admitted to the emergency departement witch chest pain.
11103411|NCT04052750|No Intervention|The control group|Patients in this group only received medications without daily text message reminder
11103412|NCT04052750|Experimental|The intervention group|Patients in this group received a daily short message service (SMS) reminder when medications were prescribed
11103413|NCT04052737|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
11103414|NCT04052737|Experimental|PMZ-1620 (sovateltide)|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1 (total dose/day: 0.9 µg/kg body weight), the same dosing regimen will be repeated every month for 6 months post randomization.
11103415|NCT04052724|Experimental|Intervention group LINGI|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
11103416|NCT04052724|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
11103417|NCT04052711|Experimental|FMX-101|
11103418|NCT04052698|Experimental|All patients|Patients with type 3, type 2 (except 2N), or severe type 1 VWD aged ≥6 years at screening receiving Wilate for prophylactic treatment.
11103419|NCT04052685|Experimental|Selective removal to soft dentin (SRSD)|The patients in SRSD group will be randomized into two subgroups as Group A and Group C. After caries removal to soft dentin calcium silicate based material (Biodentine) will be applied in Group A while will not be applied in Group C prior to placement of the resin composite restoration. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel.Carious tissue at the periphery of the cavity will be prepared to hard dentin using round tungsten carbide burs and/or an excavator, while soft carious dentin will remain in the pulpal aspect of the cavity to prevent pulp exposure. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration.
11103420|NCT04052685|Active Comparator|Selective removal to firm dentin (SRSD)|Procedures will be done using local anesthesia. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel. Caries tissue in the periphery including the enamel-dentinal junction will be removed using round tungsten carbide burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries tissue will be removed until hard or leathery dentin remains. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration. Restoration will be performed after caries removal to firm dentin and placement of calcium silicate based material (Biodentine).
11103421|NCT04052672|Active Comparator|Randomized Intervention|The intervention will consist of an exercise intervention, a combination of supervised exercise classes and in home exercises and open label nutritional supplement.
11103422|NCT04052672|No Intervention|Randomized - Control|The control will consist of a single group educational session which will include the discussion of general advice on health, exercise and nutrition as well as open label nutritional supplement
11103423|NCT04052659|Experimental|Sintilimab (IBI308)|200 mg IV，every 3 weeks
11103424|NCT04052633||Cholangiography success|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative success of cholangiography
11103425|NCT04052633||Cholangiography failure|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative failure of cholangiography
11103426|NCT04052620|Experimental|Diclofenac diethylamine (DDEA) 2.32%/ Placebo gel|Participants will receive 4 tubes, DDEA 2.32% gel and Placebo gel (2 each) and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2). DDEA 2.32% gel will be applied in morning and late afternoon and Placebo gel will be applied in noon and late evening for 7 days.
11103427|NCT04052620|Active Comparator|DDEA 1.16% gel|Participants will receive 4 tubes of DDEA 1.16% gel and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2) in morning, noon, late afternoon, and late evening for 7 days.
11103428|NCT04052607|Experimental|Dydrogesterone Suppression|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.
11103429|NCT04052607|Experimental|Dydrogesterone Suppression with minimal stimulation|Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.
11103430|NCT04052607|Active Comparator|Antagonist Suppression|cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.
11103431|NCT04052594|Experimental|LY3475766 - IV|LY3475766 administered intravenously (IV) to participants with dyslipidemia
11103432|NCT04052594|Placebo Comparator|Placebo - IV|Placebo administered IV to participants with dyslipidemia
11103433|NCT04052594|Experimental|LY3475766 - SC|LY3475766 administered subcutaneously (SC) to participants with dyslipidemia
11103434|NCT04052594|Placebo Comparator|Placebo - SC|Placebo administered SC to participants with dyslipidemia
11103435|NCT04052581||POEM-TIF|All participants will undergo the POEM-TIF in the same session.
11103436|NCT04052568|Experimental|Experimental psilocybin|Participants will have up to four doses of psilocybin.
11103437|NCT04052555|Experimental|Treatment (berzosertib, radiation therapy)|Patients receive berzosertib IV over 60 minutes BIW for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo RT 5 days a week for 5-6 weeks depending on the type of surgery undergone.
11103438|NCT04052542|Active Comparator|Traditional online continuing education|
11103439|NCT04052542|Active Comparator|Interprofessional education|
11103440|NCT04052542|Active Comparator|Just-in-time education|
11103441|NCT04052529|Experimental|Intervention|Participants are instructed to use a popular dietary self-monitoring application on their smartphone for one month.
11103442|NCT04052529|No Intervention|Control|Participants are not asked to use the smartphone application.
11103443|NCT04052516|Placebo Comparator|Placebo|Placebo oral capsules taken one daily for 52 weeks
11103444|NCT04052516|Experimental|Icosabutate 300mg|Icosabutate 300mg oral capsule taken once daily for 52 weeks
11103445|NCT04052516|Experimental|Icosabutate 600mg|Icosabutate 600mg oral capsules taken once daily for 52 weeks
11103446|NCT04052503|Experimental|Fully Supported Group|Meetings with knowledge broker 6 times over 10 months to design and implement knowledge translation intervention. Intervention consisted of audit and feedback, goal setting, education, reminders, documentation changes, and KB support.
11103447|NCT04052503|Active Comparator|Partially Supported Group|Meetings with knowledge broker 4 times over 10 months to design and partially implement knowledge translation intervention. Group meets 2 additional times without knowledge broker to self implement intervention. Intervention consisted of audit and feedback, goal setting and documentation changes. Group self implemented education and reminders.
11103448|NCT04052490|Experimental|flat occlusal reduction with feather edge finish|
11103449|NCT04052490|Experimental|flat occlusal reduction with shoulder finish line|
11103450|NCT04052490|No Intervention|planar occlusal reduction with shoulder finish line|
11103451|NCT04052464||endometrium biopsy only|In these cases, only endometrium biopsy is investigated for the selected biomarkers gene expression profile.
11103452|NCT04052464||endometrium lavage followed by endometrium tissue biopsy|In these cases before the endometrium tissue biopsy, an endometrial lavage is performed and from both samples, the selected biomarkers gene expression profile are investigated.
11103453|NCT04052464||serial endometrium lavage followed by endometrium biopsy|In these cases before the endometrium tissue biopsy, at different days endometrial lavage samples are taken. From all samples, the selected biomarkers gene expression profile are investigated.
11103454|NCT04052451|Experimental|Major Depression Disorder|MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
11103455|NCT04052451|Experimental|Generalized Anxiety Disorder|MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured
11103456|NCT04052438||Patients with recurrent abortion.|More than three idiopathic involuntary miscarriages.
11103457|NCT04052438||Patients with implantation failure.|More than three IVF abortions with good quality embryos or more than two abortions in oocyte donation cycles.
11103458|NCT04052425|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
11103459|NCT04052425|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
11103460|NCT04052412|Experimental|NSCLC with Immunotherapy without radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy without adjuvant radiation therapy
11103461|NCT04052412|Experimental|NSCLC with Immunotherapy with radiation|The biodistribution and kinetics of the 18F-AraG compound will be assessed in non-small cell lung cancer patients undergoing immunotherapy with adjuvant radiation therapy
11103462|NCT04052399|Active Comparator|Anodal tDCS|Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
11103463|NCT04052399|Active Comparator|Cathodal tDCS|Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)
11103464|NCT04052399|Placebo Comparator|Sham stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)
11103465|NCT04052386|Experimental|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
11103466|NCT04052386|No Intervention|Control|Participants randomized to the control group did not receive any intervention. They were an assessment-only control group.
11103467|NCT04052373|Experimental|Peri-implantitis treatment with implantoplasty|Open flap debridement with implantoplasty treatment
11103468|NCT04052373|Active Comparator|Peri-implantitis treatment without implantoplasty|Open flap debridement withput implantoplasty treatment
11103469|NCT04052360|Experimental|Cenerimod / ACT-334441|
11103470|NCT04052360|Placebo Comparator|Matching Placebo|
11103471|NCT04052347|Experimental|Shared decision-making with a patient decision-aid|
11103472|NCT04052347|Active Comparator|routine shared decision-making|control group
11103473|NCT04052334|Experimental|Infusion of Tumor-infiltrating lymphocyte|"Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB). All participants will receive not less than 10^9, and up to 1x10^12 T cells in ≥250 mL NS as an inpatient by intravenously (IV).
~Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated."
11103474|NCT04052321|Experimental|3D scan arm|This is a single arm study. Patients in this arm will receive a 3D scan just prior to, 2 weeks after, as well as 6 and 12 months after Nuss bar removal.
11103560|NCT04051645|Experimental|Breathing through a system with adjustable flow resistance|During the experiment, the volunteers will breathe through ten adjustable flow resistances and their work of breathing will be measured.
11103561|NCT04051632||Type 1 Diabetes patients treated with the Medtronic 670G|Type 1 Diabetes patients treated with the Medtronic 670G at Boston Childrens Hospital
11103475|NCT04052308|Active Comparator|Control group|"Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team.
~They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end fo the study; The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end fo the study; Answer EQ-5D-5L at baseline and at the end fo the study."
11103476|NCT04052308|Experimental|Continuous group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill at 60% of reserve heart rate), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
11103477|NCT04052308|Experimental|Interval group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill with alternating intensity between 50% and 80%) of HR, resulting in an average load of 60% ((50% 2) + 80% 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
11103478|NCT04052282||Mobile Health App - Healthy Individuals|"Mobile health App - Test
~Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants.
~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
11103479|NCT04052269|Experimental|eyes with glaucoma|patients with glaucoma will have imaging of retina post administration of Sildenafil or Tadalafil.
11103480|NCT04052269|Other|Healthy (unaffected) eyes|patients with healthy eyes who are already taking Sildenafil or Tadalafil have their imaging of retina post administration of Sildenafil or Tadalafil.
11103481|NCT04052256||Patients with intermediate coronary lesions|Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.
11103482|NCT04052243|Other|All patients|Exercise is added to resting right heart catheterization
11103483|NCT04052217|Other|Control Ring|"Normal intercourse with very thin (less than 0.5cm) ring randomised to either 3, 4 or 5 episodes of intercourse (Phase A)"
11103484|NCT04052217|Experimental|"1 RIng"|"Intercourse wearing a 1 ring. Randomised to either 3, 4, or 5 episodes of intercourse (Phase B)"
11103485|NCT04052217|Experimental|"1.5 Ring"|"Intercourse wearing a 1.5 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase C)"
11103486|NCT04052217|Experimental|"2 Ring"|"Intercourse with a 2 ring randomised to either 3, 4, or 5 episodes of intercourse (Phase D)"
11103487|NCT04052204|Experimental|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
11103488|NCT04052204|Experimental|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
11103489|NCT04052204|Experimental|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
11103490|NCT04052191|Experimental|Low Dose|Low Dose of MCRcI® stem cells.
11103491|NCT04052191|Experimental|Intermediate Dose|Intermediate Dose of MCRcI® stem cells.
11103492|NCT04052191|Experimental|High Dose|High Dose of MCRcI® stem cells.
11103493|NCT04052178|Active Comparator|Repetitive transcranial magnetic stimulation (rtMS)|"Acute repetitive transcranial magnetic stimulation on the pharyngeal sensory cortex. Applied intensity 90% of the resting motor threshold, 1250 pulses at 5 Hz.
~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
11103494|NCT04052178|Active Comparator|Intrapharyngeal electrical stimulation (PES)|"Intrapharyngeal electrical stimulation applied to an intensity of 75% of the tolerance threshold with 0.2 ms pulses at 5 Hz during 10 min.
~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized."
11103495|NCT04052178|Active Comparator|Capsaicin|"100 mL of oral capsaicin solution at a concentration of 10-5M.
~Each treatment arm was placebo/sham compared with a time separation of one week. The assignment to either active or sham was randomized"
11103496|NCT04052165|Experimental|Glaucoma drainage device in glaucoma patient|GDD is inserted in glaucoma patients
11103497|NCT04052152|Experimental|Group A|"Patients in the study group will receive the following treatment:
~21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be administered until disease progressioncor un-tolerable toxicity. Anlotinib will be administered until disease progression. If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again"
11103498|NCT04052139|Active Comparator|Low-dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
11103562|NCT04051619|Experimental|oxytocin|The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
11103563|NCT04051619|Placebo Comparator|matching placebo|The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
11103499|NCT04052139|Active Comparator|Gabapentin|Participants randomized to the gabapentin arm begin on a dose of 300 mg daily (300 mg qd). In week 2, participants will take 300 mg of gabapentin three times daily. In week 3 the dose will be titrated up to 1800 mg daily (300 mg+300 mg tid) will remain on the dose until week 8, when they will be tapered back down to 900 mg daily (300 mg tid). In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
11103500|NCT04052139|Placebo Comparator|Placebo|Participants will receive a placebo to be taken three times daily for 8 weeks.
11103501|NCT04052126|Experimental|Individualized physical activity program|
11103502|NCT04052100|Active Comparator|Usual care|Patients following the standard preoperative policies of opur institution
11103503|NCT04052100|Experimental|Prehabilitation|Patients following the standard preoperative policies of opur institution and the multimodal prehabilitation program
11103504|NCT04052074|Experimental|Intervention group. Music in palliative patient|Listening to pre-recorded and selected music preferred by the patient, half an hour for 7 days.
11103505|NCT04052074|Sham Comparator|Palliative patient.|Basic therapeutic education repetition performed to all patients through earphones, half, an hour for 7 days.
11103506|NCT04052074|Experimental|Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
11103507|NCT04052074|Sham Comparator|Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
11103508|NCT04052061|Experimental|CD19 t-haNK|CD19 t-haNK will be administered to patients with Diffuse Large B-Cell Lymphoma who have received 2 or more lines of therapy and are ineligible for transplant.
11103509|NCT04052022||1|Patients with TB who have already initiated treatment and are suspected to have paradoxical reactions, as well as patients taking TB treatment without signs of paradoxical reactions.
11103510|NCT04052009|Experimental|CT - Group|The conventional training consists of gait training during walking over ground. It includes the standard interventions therapists apply during training over ground. The aim is to achieve as many steps as possible. Three training sessions per week of intensive over ground therapy are planned, and twice a week a therapy with focus of attention isn't walking.
11103511|NCT04052009|Active Comparator|EET - Group|In the end-effector-based training participants undergo gait training in the end-effector device lyra (THERA-trainer). The principle of an end-effector is that the movement is induced at the level of participants feet. Furthermore, participants wear a harness attached to the end-effector lyra for safety purpose and for weight support. Three training sessions per week of intensive over lyra therapy are planned, and twice a week a therapy with focus of attention isn't walking
11103512|NCT04052009|Active Comparator|CETcomb:|The group with the combined training receives 5 sessions of CT and EET each. The pattern of series per week is always either two sessions of CT with one session of EET or vice versa.
11103513|NCT04051996|Experimental|DAC5|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
11103514|NCT04051996|Experimental|DAC10|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
11103515|NCT04051970|Experimental|Strategy TRI-BI|
11103516|NCT04051970|Active Comparator|Strategy Immediate BI|
11103517|NCT04051957|Experimental|Isosorbide Mononitrate|
11103518|NCT04051957|Placebo Comparator|Placebo|
11103519|NCT04051944|Experimental|Rozanolixizumab|Subjects in this arm will receive predefined subcutaneous doses of rozanolixizumab at a specified frequency.
11103520|NCT04051931||stable COPD group|include COPD patients with stable state
11103521|NCT04051931||AECOPD group|include COPD patients with acute exacerbation
11103522|NCT04051918|Experimental|Intervention|Piano training intervention
11103523|NCT04051892|Experimental|Implantation of FixNip™ NRI|Female Patients Seeking Reconstructive Surgery of the Nipple
11103524|NCT04051879||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
11103525|NCT04051879||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype.
11103526|NCT04051879||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
11103527|NCT04051866|Other|Control|Usual care (provided in Primary Health Care Centres) Oral hygiene instructions
11103528|NCT04051866|Experimental|Intervention|Usual care (provided in Primary Health Care Centres) Non-surgical periodontal treatment: Scaling and root planing (SRP) Oral hygiene instructions
11103529|NCT04051853|Experimental|Sorafenib with midazolam clearance test|"Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
11103530|NCT04051853|Experimental|Sorafenib with CYP cocktail test|"In this subgroup of 15 patients (in the Academic Medical Center Amsterdam), the midazolam test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
~Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be escalated with weekly intervals up to 400 mg BID (max dose)."
11103564|NCT04051606|Experimental|Regorafenib|160 mg regorafenib 3 weeks on/ one week off in participants with Avastin refractory Glioblastoma, continued until progression or toxicity. Participants will receive an MRI every 8 weeks.
11103565|NCT04051593|Experimental|Treatment|Exercise
11103566|NCT04051580|Experimental|Lactated Ringer's solution|For patients randomized to lactated Ringer's solution (study group), lactated Ringer's solution is used as a base solution for del Nido cardioplegia.
11103722|NCT04050501|Active Comparator|non-invasive Vagus Nerve Stimulation|non-invasive Vagus Nerve Stimulation on top of best medical practice
11103531|NCT04051840|Experimental|ClinOleic group|Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
11103532|NCT04051827|Experimental|Part A: Midazolam + TAK-788|Midazolam 3 mg, solution, orally, once on Days 1 and 24 and midazolam 1 mg, infusion, intravenously, once on Days 2 and 25 along with TAK-788 160 mg, capsule, orally, once daily from Day 3 through 30 in Cycle 1.
11103533|NCT04051827|Experimental|Part B: TAK-788|TAK-788 160 mg, capsules, orally, once daily in a 28-day treatment cycle from Cycle 2 to Cycle 24, or until progressive disease (PD), intolerable toxicity, or another discontinuation criterion is met, whichever is sooner. Eligible participants from Part A may enter into Part B. Based on the investigator's opinion, if a participant continues to experience clinical benefit, treatment with TAK-788 may be continued after PD.
11103534|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 1|
11103535|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 1|
11103536|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 2|
11103537|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 2|
11103538|NCT04051801|Experimental|Dose Escalation of VU319 - Dose 3|
11103539|NCT04051801|Placebo Comparator|Dose Escalation of Placebo - Dose 3|
11103540|NCT04051788|Experimental|Step Aerobics|Step Aerobics Training (120 to 126 foot steps per min)
11103541|NCT04051788|Active Comparator|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling
11103542|NCT04051762||Preterm neonates on HFNC|neonates extubated to HFNC (High flow nasal cannula)
11103543|NCT04051762||Preterm neonates on NCPAP|neonates extubated to NCPAP ( nasal continuous positive airway pressure)
11103544|NCT04051749||Patients submitted to VS|
11103545|NCT04051736|Experimental|group 1|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
11103546|NCT04051736|Active Comparator|group 2|180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV
11103547|NCT04051723|Experimental|The dexamethasone plus ropivacaine group|Patients in the dexamethasone plus ropivacaine group will receive a peri-incisional scalp infiltration with 0.025% dexamethasone and 0.2% ropivacaine and normal saline miscible liquids.
11103548|NCT04051723|Active Comparator|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 0.2% ropivacaine and normal saline miscible liquids.
11103549|NCT04051710|Experimental|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
11103550|NCT04051710|Active Comparator|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
11103551|NCT04051710|Placebo Comparator|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
11103552|NCT04051697|No Intervention|Usual Care arm|Participants allocated to the control group will receive their usual care. Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care. Participants in this arm do not receive the self-management intervention (SEA CHANGE).
11103553|NCT04051697|Experimental|Intervention arm|Participants in the intervention group will receive usual care and will be offered access to the self-management intervention (SEA CHANGE). Healthcare professionals within the designated sites will deliver aftercare treatment as usual, with no changes to the patient's clinical care.
11103554|NCT04051684|Experimental|TAP, Bupivacaine|This group will receive general anesthesia and at the end of the operation, but still in the operating room, a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
11103555|NCT04051684|No Intervention|No intervention|General anesthesia
11103556|NCT04051671|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
11103557|NCT04051671|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) during the first 20 mins (sham mode) of conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
11103558|NCT04051658|Experimental|Dual-tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
11103559|NCT04051658|Sham Comparator|Sham-tDCS & PT|Dual transcranial direct current stimulation (tDCS) in sham mode will be applied over C3-C4 or the motor area (M1) for 20 mins before conventional physical therapy (about 1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and cerebral hemodynamic .
11103567|NCT04051580|Active Comparator|PlasmaLyte-A|For patients randomized to PlasmaLyte-A (control group), PlasmaLyte-A (Baxter Healthcare Corporation, Deerfield, IL, USA) is used as a base solution for del Nido cardioplegia.
11103568|NCT04051567|Experimental|LDA group|
11103569|NCT04051567|No Intervention|NC group|
11103570|NCT04051554|Experimental|Neuromuscular and Proprioceptive Training|Myklebust's training program
11103571|NCT04051554|Active Comparator|Conventional Training|Running, Sprints, Agility training, and Dynamic stretching
11103572|NCT04051541|Other|Simulation arm|All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized.
11103573|NCT04051528|Experimental|combinatorial training group|Combinatorial training group will have the same procedure with the sequential training group in the first 8 sessions. After that the procedure for sessions from 9th to 16th will be 60 minutes of guiding training.
11103574|NCT04051528|Experimental|sequential training group.|Sequential training group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of computerized cognitive training. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
11103575|NCT04051515|Experimental|Intradialysis exercise guided by nursing staff|During 16 weeks subjects will exercise during the hemodialysis session, the exercise will include both aerobic and resistance training. Guidance will be provided by nursing staff
11103576|NCT04051515|Active Comparator|Home-based exercise program|During 16 weeks subjects will exercise on their own at home. A booklet will be provided, with a diary. Instructions to do resistance exercise with intervals of walking will be provided. Initial training will be provided by physiotherapy staff from the hospital.
11103577|NCT04051502||Group 1|First group of 10 participants enrolled
11103578|NCT04051502||Group 2|Second group of 10 participants enrolled
11103579|NCT04051502||Group 3|Third group of 10 participants enrolled
11103580|NCT04051489||Mobile App|Individuals with symptomatic knee osteoarthritis
11103581|NCT04051476|Experimental|3-g footbath|Footbath with 3g ginger flour per liter of water
11103582|NCT04051476|Experimental|6-g footbath|Footbath with 6g ginger flour per liter of water
11103583|NCT04051476|Experimental|12-g footbath|Footbath with 12g ginger flour per liter of water
11103584|NCT04051476|Placebo Comparator|Warm water footbath|Footbath with warm water only
11103585|NCT04051463|Active Comparator|Netarsudil|A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
11103586|NCT04051463|Placebo Comparator|Placebo|A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.
11103587|NCT04051437|Experimental|Plasma exchange|The consented patients will receive standard medical management with sessions of single volume plasma exchange with fresh frozen plasma and 5% human albumin.Plasma exchange session will be done on an alternate day to a maximum of 5 procedures.
11103588|NCT04051437|Active Comparator|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections, entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
11103589|NCT04051424|Active Comparator|ConMed bite block|Standard bite block (Conmed Bite Block; Conmed Corp., Utica NY, USA)
11103590|NCT04051424|Active Comparator|Williams Airway|Williams Airway Intubator (Williams Airway Intubator Ltd, Calgary, Canada)
11103591|NCT04051424|Experimental|McKay airway|A new device that enables maintenance of jaw thrust. (US patent application 16/098,530)
11103592|NCT04051398|Experimental|Intervention Arm (BI)|The BI participants will initially undergo simple spirometry and a 6-minute walk test and Borg scale application upon admission to the thoracic surgery department. Immediately after the exams, they will undergo a TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes. Immediately after the TENS application, the participants will be submitted to a new spirometry, a new 6-minute walk test and again to the Borg scale.
11103593|NCT04051398|Placebo Comparator|Control Arm (BC)|The BC participants will undergo the same steps as BI, however when applying TENS to these participants investigators will place the electrodes over the points without turning on the device in order to obtain the effect of a placebo.
11103594|NCT04051385|Active Comparator|stage II grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage II grade B periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
11103595|NCT04051385|Active Comparator|stage III grade B periodontitis|"GCF and serum samples were taken before and after treatment from stage III grade B periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
11103596|NCT04051385|Active Comparator|gingivitis|"GCF and serum samples were taken before and after treatment from gingivitis patients.
~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
11103597|NCT04051385|Placebo Comparator|periodontally healthy|GCF and serum samples were taken at baseline from periodontally healthy individuals.
11103598|NCT04051372||BAL group|"Adult patients with hematology disease under allo-HSCT at any phase of treatment are enrolled according to the following criteria:
~lung infiltration detection at computed tomography (CT) scan.
~Patients with fever, cough, respiratory symptoms. According to the investigators, the patients fulfilling these criteria undergo BAL as soon as possible"
11103599|NCT04051359|Active Comparator|Standard carbohydrate (200 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
11103600|NCT04051359|Experimental|Low carbohydrate (130 g) group|Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy. After, the randomization will be performed and GDM patients will be assigned to the low carbohydrate (130 g) group.
11103601|NCT04051346|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A six day wash out period will follow, during which the subject will consume the low oxalate diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
11103602|NCT04051346|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A six day wash out period will follow, during which the subject will consume the low oxalate diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
11103603|NCT04051320|Experimental|Women with a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
11103604|NCT04051320|Experimental|Women without a history of perinatal depression|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
11103605|NCT04051307|Experimental|intervention|"Vaccination with:
~PD-L1 peptide:
~PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL Dose: 100 µg PD-L1 long1 dissolved in DMSO/water - Total volume: 0,5 ml.
~Arginase1 peptide:
~ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL Dose: 200 µg ARGLong2 dissolved in DMSO/water - Total volume: 0,5 ml.
~Both vaccines are given at a treatment. Adjuvant Montanide ISA 51 0,5ml is mixed with the peptides before treatment To be administered every second week - a total of twelve times, with a possibility of additional six treatments."
11103606|NCT04051294|Experimental|Intervention group 1: commercial kombucha|8oz
11103607|NCT04051294|Experimental|Intervention group 2: brewed kombucha|8oz
11103608|NCT04051294|Active Comparator|Control group 1: tea|8oz
11103609|NCT04051294|Placebo Comparator|Control group 2: water|8oz
11103610|NCT04051281|No Intervention|Just under target control|Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.
11103611|NCT04051281|Experimental|Just under target letter|"Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
11103612|NCT04051281|No Intervention|Over target control|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent
~Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)
~Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)"
11103613|NCT04051281|Experimental|Over target letter|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
11103614|NCT04051281|Experimental|Over target letter with bar chart|"Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
11103615|NCT04051281|Active Comparator|Top 20% feedback letter control|"Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter"
11103616|NCT04051281|Experimental|Top 20% above target letter|"Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
11103617|NCT04051281|Experimental|Top 20% feedback letter with specific example of patient harm|"Targeting practices that are currently in the top 20% of prescribers
~• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)
~Randomization is stratified according to whether their prescribing had increased by > 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter."
11103618|NCT04051268|Experimental|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
11103619|NCT04051268|Experimental|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
11103620|NCT04051268|Experimental|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
11103621|NCT04051268|Active Comparator|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
11103622|NCT04051268|Active Comparator|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
11103655|NCT04051008|No Intervention|Group 1 - Control|No intervention - participants will shop in-person as they usually would. Participants will receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
11103656|NCT04051008|Experimental|Group 2 - Online|Participants will utilize online grocery shopping (shopping at a local grocery store via an online platform). Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
11103723|NCT04050501|No Intervention|Standard Care|Best medical practice alone
11103724|NCT04050488|Active Comparator|Treatment Group|Participants who receive the intervention.
11103623|NCT04051255|Experimental|Smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgingival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients has prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
11103624|NCT04051255|Experimental|Non-smokers aggressive periodontits|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
11103625|NCT04051242|Experimental|XenMatrix AB Surgical Graft|This study proposes to use XenMatrix™ AB Surgical Graft which has 510(k) approval [#K162193] intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue. This trial proposes to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after trauma
11103626|NCT04051229|Experimental|Exercise Training Group|All 20 participants will be assigned to this arm. These individuals will participate in 6 weeks of a moderate supervised aerobic exercise training program.
11103627|NCT04051216|Experimental|Supportive Care|Caregivers receive the Roadmap information system loaded on an Apple iPad® for use during the inpatient hospitalization of CART therapy. The Roadmap information system consists of 5 modules personalized to the CART patient: laboratory studies, medications, clinical trial enrollment, healthcare providers, and criteria for discharge. Patients wear an activity monitoring device on days 0-100. Patients wear the device as long as they can each day to monitor physical activity level, sleep/wake patterns, skin temperature, heart rate and respiratory rate.
11103628|NCT04051203|Experimental|Autologous Platelet Rich Plasma Injection|PRP contains high concentrations of platelets, growth factors, and anti-inflammatory molecules.
11103629|NCT04051203|Active Comparator|Standard Treatment|Steroid and anesthetic injection: the clinical standard.
11103630|NCT04051203|Placebo Comparator|Normal Saline|Placebo injection, with no known treatment effects.
11103631|NCT04051190|Experimental|VLED group|Participants will undergo a 10-week VLED.
11103632|NCT04051190|Experimental|Sleeve Gastrectomy group|Participants will undergo standard clinical practice prior to surgery.
11103633|NCT04051190|Experimental|Gatric Bypass group|Participants will undergo standard clinical practice prior to surgery.
11103634|NCT04051177|Experimental|parents living with HIV intervention group|Parents living with HIV in this group received five two-hour parent HIV disclosure intervention, delivered one session per week for five weeks in the clinics where the parents are recruited. The intervention curriculum is modeled after the TRACK program with supplemental materials from TALC.
11103635|NCT04051177|Other|Parents living with HIV control group|"Parents living with HIV in this group received five two-hour nutrition education curriculum in same delivery way. The nutrition curriculum is modeled after the Simply Good Eating: curriculum developed at University of Minnesota."
11103636|NCT04051164|Experimental|Progressive Muscle Relaxation Technique|Progressive muscle relaxation technique
11103637|NCT04051164|Active Comparator|Conventional treatment|Conventional Treatment: (Strengthening exercises of residual limb, Gait training, Deep Breathing exercise)
11103638|NCT04051151|Experimental|Gameification Arm|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game.
11103639|NCT04051151|No Intervention|Education Arm|Participants and partners that randomized to the control group will receive standard of care educational resources on the importance of physical activity in Parkinson's patients.
11103640|NCT04051112|Experimental|SCB-313|
11103641|NCT04051099|Experimental|bilateral cervical plexus block|bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 0.25% bupivacaine 16 mg)
11103642|NCT04051099|Experimental|General anesthesia|General anesthesia with endotracheal intubation under total intravenous anesthesia (TIVA)
11103643|NCT04051086|Other|Williams Beuren|Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
11103644|NCT04051086|Other|Micro-duplication 7q11.23|Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
11103645|NCT04051086|Other|Healthy Group|Subjects without cardiovascular and neurological medical history.
11103646|NCT04051073|Sham Comparator|Blinded|CNAP monitoring applied, but screen and information not visible to treating anaesthetist
11103647|NCT04051073|Active Comparator|Unblinded|CNAP monitoring applied and available in full to the treating anaesthetist
11103648|NCT04051060||Patients with Bronchial Asthma|
11103649|NCT04051060||Healthy individuals|
11103650|NCT04051047|Experimental|Gemcitabine|Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure. The surgical procedure is standard of care.
11103651|NCT04051034|Experimental|Omega 3 supplementation|12 weeks: Active: 1.25 g capsules/ [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
11103652|NCT04051034|Experimental|Placebo|12 weeks: Placebo: 1.25 g capsules/ [1.25-gram high oleic safflower oil capsule]with heat therapy increasing internal body temperature 1.2C above baseline for 90 min each bout..
11103653|NCT04051021|Other|Usual Care|
11103654|NCT04051021|Experimental|Comfort Coach|
11103684|NCT04050774|Experimental|Age group 2|15-17 years old
11103685|NCT04050774|Experimental|Age group 3|18 - 24 years old
11103657|NCT04051008|Experimental|Group 3 - Default|The default intervention will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make recipes from the provided recipe cards, and that they can modify it as they like. Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
11103658|NCT04050982|Experimental|AF CARE|Patients will interface with digital application.
11103659|NCT04050982|Active Comparator|Usual Care and Daily Weight|Usual care with daily weight entry
11103660|NCT04050969|Active Comparator|Atrial Fibrillation (AF) Catheter Ablation-Group A|Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
11103661|NCT04050969|Experimental|Bariatric surgery prior to AF Catheter Ablation-Group B|"Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.
~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation."
11103662|NCT04050956||Myocardial infarction|As it is an observational study, no intervention is planned. However, nested clinical interventional trials are planned for which a specific registration will be done
11103663|NCT04050943||CRD patients|Patients with chronic pulmonary disease like COPD, asthma, bronchiectasis, and etc.
11103664|NCT04050930|Experimental|Normal weight, normo-dented|healthy young male presenting a good oral health ad a normal weight
11103665|NCT04050930|Experimental|Obese, normo-dented|healthy young male presenting a first level of obesity, and a good oral health
11103666|NCT04050917|Experimental|Real stimulation|The smartwatch produces vibration stimulation.
11103667|NCT04050917|Sham Comparator|No stimulation|The smartwatch produces no vibration.
11103668|NCT04050904|Experimental|ExpHeart|The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
11103669|NCT04050891|No Intervention|group GA (general anesthesia)|"After pre-oxygenation general anesthesia was induced using 2mg/kg propofol, 1μg/kg of fentanyl. After loss of consciousness 0.5 mg/kg of atracurium was injected. The endotracheal tube (ETT) was placed and inflated. The patient was mechanically ventilated to adjust end tidal CO2 between 35 and 40mmHg, anesthesia was maintained using 1.2 % isoflurane diluted in 3L of 50 % oxygen mixed with air. Increments of fentanyl (0.5 μg/kg ) and atracurium 10 mg were used whenever required and the hemodynamic values were maintained within 20% of the basal values.
~At the end of surgery, residual muscle relaxant was reversed with 50µg/kg neostigmine and 0.02 mg/kg atropine."
11103670|NCT04050891|Active Comparator|group RA (regional anesthesia)|received combined supraclavicular and interscalene block.The mixture of anesthetic suolution was prepared by 20 ml isobaric bupivacaine 0.5% plus 10ml lidocaine 2% plus 10ml normal saline, total volume was 40ml which is devided into 25ml for suraclavicular block and 15ml for intersalene block
11103671|NCT04050878|Experimental|Patient with or without dental prostheses|The patient will be submitted to two facial scans, one with and another without the dental prostheses and the obtained datasets will be compared to assess the differences. Marks will be made in the face to allow for measurements (digital and conventional)
11103672|NCT04050865|Experimental|OTX-DP|
11103673|NCT04050865|Placebo Comparator|Placebo|
11103674|NCT04050852|Experimental|SMA patients receiving nusinersen treatments|
11103675|NCT04050839|Experimental|Neuroscience pain education group|Pain neuroscience education in addition medical treatment
11103676|NCT04050839|Active Comparator|Control group|Medical treatment only
11103677|NCT04050826|Experimental|Dermal Pharmacokinetic study|"Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dOFM after topical application of three lidocaine/prilocaine products in 20 participants.
~After baseline sampling (1 hour pre-dose) the three lidocaine/prilocaine products will be applied and removed after 3 hours. ISF and blood sampling will be continued for a duration of 12 hours post-dose. Additionally different physical parameters (e.g. TEWL) will be measured."
11103678|NCT04050813|Experimental|Control|"The program is performed 2 times per week using resistance equipment in a physiotherapy clinic. Each session consists of on 2-legged loaded exercises for hamstring, quadriceps, gluteus maximun and core. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 4 exercises.
~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 set of 12-repetition maximum (12RM), in week 1 and 2; 3 set of 10 RM, in week 3 and 4; 4 set of 10RM, in weeks 5 and 6; and 4 set of 8RM, in weeks 7 to 8."
11103679|NCT04050813|Experimental|Intervention|Experimental: Inertial flywheel resistance training The program is performed 2 times per week using resistance equipment in a physiotherapy clinical. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 16 repetition maximum (RM) with moment inertia 0.05 m² from week 1-2, 24 repetition maximum (RM) with moment inertia = 0.10 m² from week 3 to 4. 32 repetition maximum (RM) with moment inertia = 0.10 m² from week 5 to 6 and 32 repetition maximum (RM) with moment inertia = 0.13 m² in a flywheel hamstring curl devise.
11103680|NCT04050800|Experimental|Healthy Controls|Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
11103681|NCT04050787|Experimental|D2 Lymphadenectomy including No. 10|lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
11103682|NCT04050787|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy but without No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
11103683|NCT04050774|Experimental|Age group 1|6-9 years old
11103687|NCT04050761||Monotherapy|Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.
11103688|NCT04050748|Placebo Comparator|Early Rehabiliation|6 weeks of non-weight bearing in addition to basic stretching exercises.
11103689|NCT04050748|Active Comparator|Accelerated Rehabilitation|Patients will be non-weight bearing for 2 weeks. After 2 weeks patients were transitioned to a boot with two heel wedges and were weight bearing as tolerated. At 4 weeks, patients were transitioned to one wedge, and at 6 weeks patients were weight bearing as tolerated in a flat shoe. Each heel wedge was ¾ inch tall. After 6 weeks, patient's in both groups underwent identical rehab regimens per protocol
11103690|NCT04050735|Experimental|Alcohol, ethyl, moderate dose|0.6 gram ethyl alcohol per kilogram of body weight
11103691|NCT04050735|Placebo Comparator|Placebo|0 gram ethyl alcohol per kilogram of body weight
11103692|NCT04050722|Experimental|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent [%] of stannous fluoride] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
11103693|NCT04050722|Other|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
11103694|NCT04050709|Experimental|PD-L1 t-haNK Dose Level 1|PD-L1 t-haNK will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 1 is 3 to 6.
11103695|NCT04050709|Experimental|PD-L1 t-hanK Dose Level 2|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 2 is 3 to 6.
11103696|NCT04050709|Experimental|PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into RP2D is 4.
11103697|NCT04050709|Experimental|PD-L1 t-haNk Dose -1a (if needed)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level -1a is 3 to six, if needed.
11103698|NCT04050696|Experimental|Treatment (with PT run-in)|Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
11103699|NCT04050683|Experimental|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Right Atrial Pressure (RAP) ≥ 15mmHg or change in RAP ≥ 10 mmHg or Peak Systolic Right Ventricular (PSRV) Pressure ≥ 46 mmHg
11103700|NCT04050683|Active Comparator|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Normal hemodynamic parameters
11103701|NCT04050670|Experimental|Tirzepatide - Upper Arm|Tirzepatide administered subcutaneously (SC) to the upper arm of healthy participants in one of three study periods.
11103702|NCT04050670|Experimental|Tirzepatide - Thigh|Tirzepatide administered SC to the thigh of healthy participants in one of three study periods.
11103703|NCT04050670|Active Comparator|Tirzepatide - Abdomen|Tirzepatide administered SC to the abdomen of healthy participants in one of three study periods.
11103704|NCT04050657|Experimental|Two-week appointment interval group|Orthodontic patients who come to tighten their braces every 2-weeks.
11103705|NCT04050657|Other|Eight-week appointment interval group|Orthodontic patients who come to tighten their braces every every 8-weeks.
11103706|NCT04050644|Experimental|Preservative-free dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preservative-free dexamethasone 0.1% and diclofenac 0.1% eye drops.
11103707|NCT04050644|Active Comparator|Preserved dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preserved dexamethasone 0.1% and diclofenac 0.1% eye drops.
11103708|NCT04050631||L&D team|the first responders on L&D floor including : anesthesia, nurses and OBGYN
11103709|NCT04050618|Experimental|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
11103710|NCT04050618|Experimental|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
11103711|NCT04050605|Experimental|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
11103712|NCT04050592|Other|Group A, Abrupt Discontinuation|Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
11103713|NCT04050592|Other|Group B, Tapered Discontinuation|"Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows:
~weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days.
~weeks 10-20: placebo"
11103714|NCT04050592|Active Comparator|Group C, Control Group|Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.
11103715|NCT04050579|Other|OPIE in thin inverventricular septum|The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.
11103716|NCT04050553|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) in one of two study periods.
11103717|NCT04050553|Placebo Comparator|Placebo|Placebo administered SC in one of two study periods.
11103718|NCT04050540|Experimental|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
11103719|NCT04050540|No Intervention|Standard of Care Arm|Participants assigned to Standard of Care
11103720|NCT04050514|Experimental|H-MAD, hinge system according to Herbst|"Patients with snoring and OSAS. Therapy with MAD type H-MAD with lateral hinges according to Herbst.
~Bite elevation 2 mm interocclusal distance with a lower jaw advancement of 5 mm"
11103721|NCT04050514|Active Comparator|F-MAD, SomnoDent Fusion|Patients with snoring and OSAS,Fusion MAD with sliding side wings (F-MAD). Bite elevation 5 mm interocclusal distance with a lower jaw advancement of 5 mm
11103725|NCT04050488|Placebo Comparator|Control Group|Participants who receive the placebo.
11103726|NCT04050475|Experimental|PSY-FMD|Subjects randomized in the PSY-FMD group carried out the Functional Therapy protocol over 20 individual sessions, which were scheduled twice a week for the first two months and once a week for the last month (three months total). The treatment program was specifically manualized for treating depression with the aim to increase mood, self-esteem and quality of life. Furthermore, patients followed a Fasting Mimicking Diet (FMD) protocol consisting of 3 cycles of 5 days a month each: the first day of the diet provided 1090 kcal (10% protein, 56% fat, 34% carbohydrate), the days 2-5 were identical in the formulation and provided 725 kcal (9-10% protein, 44-56% fat, 34-47% carbohydrate). Between cycles of FMD the subjects stuck to a free diet. At the end of the treatment all patients were re-tested through the same assessment protocol and the same things was realized at the follow-up (three months later the end of the treatment).
11103727|NCT04050475|No Intervention|PSY|Subjects randomized into the control group (PSY) completed the same Functional Therapy program without practicing any diet. Specifically, at the end of the nutritional consultation the nutritionist suggested them to keep a food diary without changing their habitual diet style.
11103728|NCT04050462|Active Comparator|Nivolumab Monotherapy|
11103729|NCT04050462|Experimental|Nivolumab/BMS-986253 combination|
11103730|NCT04050462|Experimental|Nivolumab/Cabiralizumab combination|
11103731|NCT04050449||Group 1: Switch to TLD from NNRTI first-line regimen|Participants switching to TLD from a first-line regimen containing a NNRTI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 1a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 1b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
11103732|NCT04050449||Group 2: Switch to TLD from boosted PI second-line regimen|Participants switching to TLD from a second-line regimen containing a boosted PI. These participants will be divided into two subgroups based upon their HIV-1 RNA level in a sample obtained at entry, before starting TLD. Group 2a will include participants with viremia (HIV-1 RNA >1000 copies/mL at start of TLD) and Group 2b will include participants with suppressed viral load (HIV-1 RNA ≤1000 copies/mL at start of TLD).
11103733|NCT04050449||Group 3: Concomitant TLD and RIF-containing TB treatment|Participants initiating concomitant TLD and RIF-containing TB treatment, with an additional daily dose of dolutegravir (DTG) 50mg. For participants already on RIF-containing TB treatment when TLD treatment is started, TLD treatment must be started within 8 weeks (56 days) of the start of RIF-containing TB treatment. Group 1, 2, or 4 participants who start RIF-containing TB treatment after enrollment will have additional evaluations at the start and end of concomitant HIV and TB treatment but will not be co-enrolled in Group 3 (their additional evaluations will, however, be considered when analyzing data from Group 3).
11103734|NCT04050449||Group 4: ART-naive initiating TLD therapy|Antiretroviral therapy (ART)-naïve participants initiating therapy with TLD
11103735|NCT04050436|Experimental|Cemiplimab in combination with RP1|Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks
11103736|NCT04050436|Active Comparator|Cemiplimab|Cemiplimab administered intravenously as a single therapy every 3 weeks
11103737|NCT04050423||Breast Characterization|
11103738|NCT04050410|Experimental|Moxonidine|Patients will receive a single oral dose of moxonidine 0.4 mg.
11103739|NCT04050410|Placebo Comparator|Placebo|Patients will receive a single oral dose of placebo.
11103740|NCT04050397|Experimental|Supervised exercise arm|Informational initiation lecture and supervised exercise twice a week for 12 weeks followed by 12 weeks of non-supervised exercise.
11103741|NCT04050397|Active Comparator|Non-supervised exercise arm|Informational initiation lecture and only non-supervised exercise
11103742|NCT04050384|No Intervention|No vibratory stimulus before or during heel lance|Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
11103743|NCT04050384|Experimental|Vibratory stimulus before and during heel lance|Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.
11103744|NCT04050371|Experimental|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
11103745|NCT04050358|Active Comparator|1X dose of NRPT|
11103746|NCT04050358|Placebo Comparator|Placebo|
11103747|NCT04050345||Colon|Patients who have a diagnosis of large bowel cancer (in the colon) and the cancer is not metastatic.
11103748|NCT04050345||Rectal|Patients who have a diagnosis of large bowel cancer (in the Rectum) and the cancer is not metastatic.
11103749|NCT04050332|Experimental|Stair Walking|Participants in this arm will engage in four minutes of stair walking while being tracked by radio frequency identification equipment.
11103750|NCT04050332|No Intervention|Control|Participants in this arm will stand in the stairwell for four minutes while being tracked by radio frequency identification equipment.
11103751|NCT04050306||Adolescents and young adults|Participants 12-19 years old without chronic diseases.
11103752|NCT04050293|Experimental|SPN-538|Patients will be treated with SPN-538 as a single dose once a day
11103753|NCT04050293|Placebo Comparator|Placebo|Patients will be treated with Placebo once a day
11103754|NCT04050280|Experimental|CLAG-GO|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
11103755|NCT04050267|Placebo Comparator|Control group - air|Breathing air with 21 % of oxygen (0% nitrous oxide). Performing cognitive tests as per protocol.
11103756|NCT04050267|Experimental|Intervention Group - 5% nitrous oxide|Breathing 5% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
11103757|NCT04050267|Experimental|Intervention Group - 7% nitrous oxide|Breathing 7% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
11103758|NCT04050267|Experimental|Intervention Group - 10% nitrous oxide|Breathing 10% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
11103759|NCT04050267|Experimental|Intervention Group - 12% nitrous oxide|Breathing 12% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
11103760|NCT04050267|Experimental|Intervention Group - 15% nitrous oxide|Breathing 15% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
11103761|NCT04050267|Experimental|Intervention Group - 20% nitrous oxide|Breathing 20% nitrous oxide in air with 21 % of oxygen. Performing cognitive tests as per protocol.
11103762|NCT04050254|Experimental|Real tDCS + exercise|Transcranial direct current stimulation combined with therapeutic exercise
11103763|NCT04050254|Sham Comparator|Sham tDCS + exercise|Sham transcranial direct current stimulation combined with therapeutic exercise
11103764|NCT04050254|No Intervention|Control|No treatment.
11103765|NCT04050241|Experimental|Videolaryngoscope|Anesthetists performing intubation with the Glidescope videolaryngoscope.
11103766|NCT04050241|Experimental|Direct laryngoscope|Anesthetists performing intubation with the Mcintosh laryngoscope.
11103767|NCT04050228|No Intervention|Standard Neoadjuvant Chemotherapy Monitoring|
11103768|NCT04050228|Experimental|Adaptive Chemotherapy Monitoring|
11103769|NCT04050215|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 3 hours. Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent management decision.
11103770|NCT04050202|Experimental|ABC|ABC delivers therapy through 10, home-based, in-person sessions led by a trained professional. Treatment content is based on attachment theory and an understanding of children's stress neurobiology. Components aim to improve parental sensitivity, nurturance, and responsivity, as well as children's biological and behavioral reactivity through dyadic interactions between parents and children.
11103771|NCT04050189|Active Comparator|prenatal probiotic|will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery
11103772|NCT04050189|Active Comparator|postnatal probiotic|will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery
11103773|NCT04050176|Experimental|Blinded Hypnotic Medication Taper (BT)|Participants assigned to the Blinded Taper group will not know the medication dose they receive during the Structured Medication Taper (SMT) phase.
11103774|NCT04050176|Active Comparator|Open-Label Hypnotic Medication Taper (OLT)|Participants assigned to the Open-Label Hypnotic Medication Taper group will know the medication dose they receive during the SMT phase.
11103775|NCT04050163|Experimental|Low Dose|
11103776|NCT04050163|Experimental|Intermediate Dose|
11103777|NCT04050163|Experimental|High Dose|
11103778|NCT04050150|Experimental|Arm Training in Standing|Task-oriented, functional arm training completed in standing or during walking. All participants receive the same arm training intervention.
11103779|NCT04050137|Experimental|Exercise group|Exercise programme 3 times/week.
11103780|NCT04050124|Experimental|Promogran Prisma|Following standard of care split thickness skin grafting, patients randomized to the intervention group will receive Promogan Prisma as the primary contact dressing at the donor grafting site.
11103781|NCT04050124|Active Comparator|Standard of care (SOC) dressings|
11103782|NCT04050111|Experimental|SVF injection|"Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
~Interventions:
~Procedure: Liposuction Other: SVF isolation Other: Intraarticular administration of autologous SVF"
11103783|NCT04050098|Active Comparator|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
11103784|NCT04050098|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
11103785|NCT04050085|Experimental|Treatment (SD-101, radiation therapy, nivolumab)|Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
11103786|NCT04050072||Childhood Cancer Survivors (CCSS)|i. PRO-CTCAE-SCC ii.Quality of life assessment
11103787|NCT04050072||St. Jude Life (SJLIFE)|i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
11103788|NCT04050072||Community non-cancer control|i. PRO-CTCAE-SCC ii.Quality of life assessment
11103789|NCT04050059|Active Comparator|2% Lidocaine group|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited) skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal anesthesia induction.
11103790|NCT04050059|Active Comparator|EMLA cream group|In EMLA (Eutectic Mixture of Local Anesthesia- lidocaine 2.5% and prilocaine 2.5%) cream group, EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
11103791|NCT04050046|Active Comparator|Real tDCS + CBCT|20 minutes of 2.0mA of tDCS for 5 consecutive days
11103792|NCT04050046|Sham Comparator|Sham + CBCT|Sham stimulation closely imitates reals tDCS 30 second ramp-up / ramp-down
11103793|NCT04050033|Experimental|Treatment Arm|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).
11103794|NCT04050020|Active Comparator|Group A|
11103795|NCT04050020|Placebo Comparator|Group B|
11103796|NCT04050007|Experimental|1|Preventive initiation of fluid removal
11103797|NCT04050007|Other|2|Curative initiation of fluid removal
11103798|NCT04049994|Experimental|Immunomodulation|Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
11103799|NCT04049994|Placebo Comparator|Placebo|Oral placebo tablet once daily for 90 days.
11103800|NCT04049981|Experimental|Facial Engagement|This group will receive a version of Superpower Glass that targets specific areas of social deficits associated with autism.
11103801|NCT04049981|Experimental|Emotion Recognition|This group will receive a version of Superpower Glass that targets different areas of social deficits associated with autism.
11103802|NCT04049968|Experimental|Experimental group|Patients in the experimental group were individually assessed by a mobile health application (APP).
11103803|NCT04049968|Active Comparator|Control group|Patients in the control group were individually assessed by a traditional routine health care and instruction.
11103804|NCT04049955|Experimental|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
11103805|NCT04049942|Experimental|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
11103806|NCT04049942|Experimental|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
11103807|NCT04049929|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
11103808|NCT04049916|Active Comparator|Pyronaridine-artesunate (PA)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days.
11103809|NCT04049916|Experimental|PA with single low dose primaquine (PQ)|Subjects will receive pyronaridine-artesunate (PA) once daily for 3 days, and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
11103810|NCT04049916|Active Comparator|Dihydroartemisinin-piperaquine (DP)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days.
11103811|NCT04049916|Active Comparator|DP with single low dose primaquine (PQ)|Subjects will receive dihydroartemisinin-piperaquine (DP) once daily for 3 days., and a low dose of primaquine (PQ) on the first dat of treatment. PQ dose is at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
11103812|NCT04049903|Experimental|MP0310 (AMG 506)|Enrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD is exceeded, unacceptable toxicity is reached, or until the maximum protocol specified dose is delivered. Up to 12 additional patients in total may be included at selected dose levels (up to 3).
11103813|NCT04049890||Parents of children with a chronic disease with no siblings|Parents of children suffering from a chronic disease who has no brother or sister over 3 years of age
11103814|NCT04049890||Parents of children with a chronic disease with siblings|Parents of children suffering from a chronic disease who one or more sibling over the age of 3 years old
11103815|NCT04049864|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
11103816|NCT04049851|Experimental|Moxidectin|
11103817|NCT04049851|Active Comparator|Ivermectin|
11103818|NCT04049838|Active Comparator|lateral transversus abdominis block|patients will take lateral transversus abdominis plan block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
11103819|NCT04049838|Active Comparator|posterior tansversus abodominis plane block|patients will take posterior transversus abdominis plane block. The block will be done unilaterally on the same side of proposed surery with 0.25% bupivacaine at a volume of 1 ml·kg-1
11103820|NCT04049838|Active Comparator|convential analgesia|conventional analgesia in form of 1 micrograms. Kg-1 fentanyl and paracetamol 15 mg. Kg-1 suppositories
11103821|NCT04049825|Experimental|Dose Escalation Stage|The dose of OPB-111077 in the first cohort will be 200 mg/day, increasing as appropriate to 400 mg/day in the second cohort and then to 600 mg/day in the third cohort.
11103822|NCT04049825|Experimental|Dose Expansion Stage|4 days on and 3days off of 21-day cycles of OPB-111077 Day 1 of 21-days cycles of rituximab Day 2 and 3 of 21-day cycles of bendamustine
11103823|NCT04049812|Active Comparator|Pulsed electromagnetic field (PEMF) treatment Group|Group received routine hot pack, Transcutaneous electrical nerve stimulation (TENS) and PEMF treatment.
11103824|NCT04049812|Sham Comparator|Sham PEMF treatment Group|Group received routine hot pack, TENS and sham PEMF treatment.
11103825|NCT04049799||Medically-supervised withdrawal (MSW)|
11103826|NCT04049799||Opioid agonist treatment (OAT)|
11103827|NCT04049786|Experimental|Simvastatin Study|Adult patients (18-60 years old) with body mass index ≥ 35 kg/mˆ2 who have indication for bariatric surgery and do not use simvastatin are being recruited. All patients are being submitted to 3 steps: before, 4-6 months and 10-12 months after surgery. In all steps, patients are receiving oral single dose of simvastatin (40 mg). Serial blood sampling are being collected up to 24 hours after drug administration for pharmacokinetic study. The phenotype for cytochrome P450 (CYP) 3A4 phenotype is being evaluated using midazolam as probe. CYP3A4 and P-glycoprotein expression (mRNA) are being assessed in intestinal biopsies before (step 1), during and after surgery (step 3). Blood sample are being collected for DNA extraction (step 1). Patients are being genotyped for polymorphisms on genes SLCO1B1 (521 C>T) and ABCB1 (1236C>T, 2677nonG and 3435C>T).
11103828|NCT04049786|Experimental|Carvedilol Study|Adult patients (18-60 years old) with body mass index ≥ 35 kg/mˆ2 who have indication for bariatric surgery and do not use carvedilol are being recruited. All patients are being submitted to 3 steps: before, 4-6 months and 10-12 months after surgery. In all steps, patients are receiving oral single dose of carvedilol (25 mg). Serial blood sampling are being collected up to 24 hours after drug administration for pharmacokinetic study. Cytochrome P450 (CYP) 3A4 and CYP2D6 phenotypes are being evaluated using midazolam and metoprolol as probes. CYP3A4 and P-glycoprotein expression (mRNA) are being assessed in intestinal biopsies before (step 1), during and after surgery (step 3). Blood sample are being collected for DNA extraction (step 1). Patients are being genotyped for polymorphisms on genes CYP2C9 (432 C>T, 1075A>C) and ABCB1 (1236C>T, 2677nonG and 3435C>T ).
11103829|NCT04049760|Experimental|migalastat HCl 150 mg|One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl will be administered every other day (QOD) during the treatment period.
11103830|NCT04049747|Experimental|CHRONOS A - Arm 1 (Control)|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]). In patients undergoing radiotherapy a maximum of 6-months neo-adjuvant hormonal therapy will be allowed. In patients undergoing radical prostatectomy, cytoreduction of maximum 6 months with medication will be permissible, provided this is part of local practice.
11103831|NCT04049747|Experimental|CHRONOS A - Arm 2 (Intervention)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second focal therapy session in-field, or a first focal therapy session to an out-of-field progressive or de novo lesion will be allowed as part of the focal therapy intervention.
11103832|NCT04049747|Experimental|CHRONOS B - Arm 3 (Control)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second treatment in-field, or a first focal ablation to an out-of-field progressive or de novo lesion will be allowed but will be regarded as failure events for the purpose of CHRONOS-B.
11103833|NCT04049747|Experimental|CHRONOS B - Arm 4 (Intervention):|Neoadjuvant finasteride 5mg once daily for a minimum of 12 weeks followed by focal therapy (as per CHRONOS B control arm).
11103834|NCT04049747|Experimental|CHRONOS B - Arm 5 (Intervention)|Neoadjuvant bicalutamide 50mg once daily therapy for a minimum of 12 weeks followed by focal therapy (as per control arm).
11103835|NCT04049734|Active Comparator|patients received the oral losartan|50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
11103836|NCT04049734|No Intervention|patients didn't receive the oral losartan|50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs
11103837|NCT04049721|Active Comparator|Standard of Care without HBO|Intravenous access and fluid resuscitation (standard of care treatment)
11103838|NCT04049721|Experimental|HBO + Standard of Care|Ten daily treatment sessions of HBO at 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks
11103839|NCT04049695|Experimental|Exercise Intervention|This arm will receive a 12-month individually tailored phone and email-based exercise program.
11103840|NCT04049695|Active Comparator|Health & Wellness Intervention|This arm will receive a 12-month health and wellness program.
11103841|NCT04049682||Pre Time-change|Daily activity, sleep duration, subjective sleepiness, and response time before change in school start time
11103842|NCT04049682||Post Time-change|Daily activity, sleep duration, subjective sleepiness, and response time after change in school start time
11103843|NCT04049669|Experimental|Core Regimen, sub-cohort A|For patients not eligible for re-irradiation; Start with Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
11103844|NCT04049669|Experimental|Core Regimen, sub-cohort B|For patients who are eligible for partial re-irradiation; Start with indoximod plus up-front re-irradiation, using a palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
11103845|NCT04049669|Experimental|Core Regimen, sub-cohort C|For patients who are eligible for full-dose radiation; (All newly diagnosed DIPG patients and some relapsed ependymoma patients); Start with indoximod plus up-front radiation, using a palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine); Followed by Core Regimen chemo-immunotherapy (indoximod with oral temozolomide).
11103846|NCT04049669|Experimental|Salvage Regimen 1|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral metronomic cyclophosphamide and etoposide).
11103847|NCT04049669|Experimental|Salvage Regimen 2|For patients who wish to continue access to indoximod after progression on the Core Regimen; Cross-over to indoximod with oral lomustine and temozolomide).
11103848|NCT04049656|Experimental|HFVI intervention group|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
11103849|NCT04049656|No Intervention|Standard of Care Group|Subjects receiving a balanced maintenance anesthetic consisting primarily of a sevoflurane hypnotic (titrated to a BIS range of 40-60) and fentanyl analgesia. Subjects randomized to the control group (Standard Practice) will have analgesia administered as needed according to standard clinical monitoring and practice requirements based on the judgment of the clinician responsible for the case. The HFVI monitor will be applied, but the display will be masked in this control group population.
11103850|NCT04049643|Active Comparator|Audiologist-Based|In this group, the audiologist-based fitting will be used to provide hearing aids.
11103851|NCT04049643|Experimental|Service-Only|In this group, hearing aids that have minimum amplification will be fitted by audiologists.
11103852|NCT04049643|Experimental|Device-Only|In this group, hearing aids will be provided with minimum services from audiologists.
11103853|NCT04049630|Experimental|LEV 1 mg/kg|Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
11103854|NCT04049630|Experimental|LEV 1,5 mg/kg|Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.
11103855|NCT04049630|Placebo Comparator|Placebo|Tablets of placebo will be administrated to the participant in single dose only one time.
11103856|NCT04049617|Experimental|GS-4224|"Dose Escalation (Phase 1b):
~Participants will be sequentially enrolled in a dose escalation design to receive GS-4224 starting at 400 mg once a day (QD). Subsequent doses of 700 mg QD, 1000 mg QD, 1500 mg QD, and 1000 mg twice a day (BID) are planned based on the safety and tolerability of each dose level.
~Dose Expansion (Phase 2):
~Dose expansion will begin when the RP2D has been determined."
11103857|NCT04049604||1/Cohort 1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
11103858|NCT04049604||2/Cohort 2|Women undergoing active treatment or surveillance for known malignancy
11103859|NCT04049591|Active Comparator|Higher Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
11103860|NCT04049591|Active Comparator|Lower Dose Unfractionated Heparin Treatment Period|A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
11103861|NCT04049578|Experimental|Balovaptan|
11103862|NCT04049565||Procalcitonin|septic patients who will receive Procalcitonin
11103863|NCT04049565||C-Reactive Protein|septic patients who will receive C-Reactive ptotein
11103864|NCT04049552|Experimental|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
11103865|NCT04049552|Placebo Comparator|Placebo|Placebo will be applied as a control on one keloid on the subject
11103866|NCT04049539|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|Within 14-26 days after the start of previous cycle of chemotherapy, patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
11103867|NCT04049513|Experimental|WZTL002-1 (1928T2z CAR T-cells)|"A starting WZTL-002 dose of 5 × 10^4 CAR T-cells/kg has been selected with four possible dose level cohorts proposed.
~Escalation to a higher dose cohort will be based on assessment of dose limiting toxicities to determine safety at a given dose level."
11103868|NCT04049500||Clinicians|Five practices will be selected from NYULH ambulatory practice sites to represent the spectrum of provider settings within the system. These sites will be the clinical partners for the adaptation of the dDPP tool suite
11103869|NCT04049487|Active Comparator|Generalized Exercise|General wellness/exercise program designed to replicate a generic wellness program that one would find in a gym setting. Will be led by an exercise instructor.
11103870|NCT04049487|Experimental|Diastasis Specific Exercise|Diastasis specific exercise program incorporating multiple muscle groups and based on research findings of exercises that are shown to be effective for reducing size and impact of diastasis rectus.
11103871|NCT04049474|Experimental|Bronchoscopic Cryo-Immunotherapy (BCI)|BCI is performed by advancing a flexible cryoprobe through a bronchoscope to reach a peripheral tumor. The cryoprobe is activated to freeze a portion of the tumor. The cryoprobe is allowed to thaw to prevent removal of lung or airway tissue. The tumor must be located by radial EBUS and a guide sheath placed prior to cryoablation.
11103872|NCT04049461||PDAC Group|Radical operations were performed through central abdominal incisions. The postoperative pathology was pancreatic ductal adenocarcinoma.
11103873|NCT04049461||Benign Group|The abdominal midline incision was performed and the postoperative pathology was benign.
11103874|NCT04049448|Experimental|ABX464 50 mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 12 months (52 weeks)
11103875|NCT04049435||horizontal deficiency anterior maxilla|Using the titanium sheet in augmentation of horizontally deficient anterior maxilla will be efficient, time saving, accurate reconstruction
11103876|NCT04049409|Experimental|CMAB809|
11103877|NCT04049409|Active Comparator|Trastuzumab|
11103878|NCT04049396|Experimental|Berberine|Berberine (6.25 g/day)
11103879|NCT04049396|No Intervention|Control|No intervention
11103880|NCT04049383|Experimental|Dose Escalation Phase|
11103881|NCT04049383|Experimental|Dose Expansion Phase|
11103882|NCT04049370||"Retrospective data collection of the actual state"|"Retrospective data collection of the actual state 6 months prior to August 2019."
11103883|NCT04049370||Prospective data collection|Prospective data collection after implementation of the quality assurance measure for another 6 months (SOP as clinical decision tool into the electronic database of the CPU).
11103884|NCT04049357|Experimental|The intervention group|"If the FIT test is returned and positive the individual can choose either Camera Capsule Endoscopy (CCE) or Optical colonoscopy (OC) as the primary bowel investigation. If OC is chosen, it is performed as standard and the participant outcomes remains analyzed in the intervention group as intention to treat.
~If CCE is chosen an out-clinic CCE will be done at one of four regional sites. Overall and segmental bowel preparation grade (Leighton-Rex 1-4) and all pathological findings are reported. If the anal verge is identified without video blackout in the colon the transit is considered complete. Any incomplete CCE investigation will be followed by standard optical endoscopy to the extent needed to investigate the proportion of the colon not visualized by the capsule and remove any detected polyps. If the CCE is complete with complete transit and adequate preparation, individuals with more than two polyps or one polyp over 9 mm will be referred for colonoscopy."
11103885|NCT04049357|No Intervention|The control group|The control group will be invited to screening as usual. The intervention group will be informed that if the fecal test is returned and positive they can either choose to have an initial colon capsule endoscopy, and only colonoscopy if significant findings are made or an initial colonoscopy as usual.
11103886|NCT04049344|Experimental|Combination of decitabine with oxaliplatin treatment|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
11103887|NCT04049331|Experimental|1|weekly IM injections of 125mg of Testosterone cypionate
11103888|NCT04049331|Placebo Comparator|2|"weekly IM injections of clinical grade saline 0.9% sodium chloride"
11103889|NCT04049318||24 weeks|Subjects who participated in the intervention who have data available at week 24
11103890|NCT04049318||48 weeks|Subjects who participated in the intervention who have data available at week 48
11103891|NCT04049305|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
11103892|NCT04049305|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
11103893|NCT04049305|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
11103894|NCT04049292|Experimental|RTS and rehabilitation tool|Six months after ACLR, athletes will commence a standardized RTS assessment. The athlete will follow a standardized, sport-specific progression protocol designed to increase athletic confidence and trust in the knee during sports. Readiness to return to full, unrestricted practice will be determined based on 7 time-based, load-based, clinical and functional criteria. If the athlete fails any of the criteria, he or she will continue to participate in restricted practice. Depending on which of the specific criteria the athlete fails, a targeted treatment plan will be developed. Standardized protocols for effusion management, knee control and strength training will be triggered if the athlete fails the criteria for knee joint effusion, hopping and muscle strength, respectively. The RTS assessment and development of the targeted treatment plan will be repeated every 2 months until the athlete is cleared to RTS, up to a maximum of 12 months after ACLR.
11103895|NCT04049292|Active Comparator|Usual care|Athletes will receive usual care as determined by their treating health care professional
11103896|NCT04049279|Active Comparator|BiMobile standard cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
11103897|NCT04049279|Active Comparator|BiMobile larger cement|25 patients will receive a cemented THA with a BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
11103898|NCT04049279|Active Comparator|Avantage standard cement|25 patients will receive a cemented THA with an Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
11103899|NCT04049266|Experimental|KSI-301 5 mg|"Drug: KSI-301 5 mg. KSI-301 5 mg will be administered by intravitreal injection into the study eye at 12, 16, and 20 weeks intervals as specified in the study protocol.
~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
11103900|NCT04049266|Active Comparator|Aflibercept 2 mg|"Drug: Aflibercept 2 mg. Aflibercept 2 mg will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.
~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
11103901|NCT04049253|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
11103902|NCT04049253|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
11103903|NCT04049240|Active Comparator|Active Comparator: 18<BMI<30 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11103904|NCT04049240|Active Comparator|Active Comparator: 30≤BMI<35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11103905|NCT04049240|Active Comparator|Active Comparator: BMI≥35 kg/m2 - LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11103906|NCT04049240|Active Comparator|Experimental: 18<BMI<30 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11103907|NCT04049240|Active Comparator|Experimental: 30≤BMI<35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11103908|NCT04049240|Active Comparator|Experimental: BMI≥35 kg/m2 - HFNO|High Flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11103909|NCT04049227|Experimental|Treatment (letrozole, abemaciclib)|Patients receive letrozole PO QD and abemaciclib PO BID on days 1-14. Patients then undergo standard of care hysterectomy on day 15.
11103910|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
11103911|NCT04049201|Experimental|Group tablet|group T will receive interactive Tablet containing many cartoon's videos 20 minutes before parental separation until the anesthesia induction
11103912|NCT04049201|Active Comparator|Group Midazolam|group Midazolam will receive oral midazolam 0.5 mg/kg (max 20 mg) 20 minutes before the parental separation
11103913|NCT04049188|Experimental|Single-Fraction Palliative RT|Single-Fraction Palliative Radiation Therapy Adminstration
11103914|NCT04049175|Experimental|Treatment A|Administration of CHF 6532 Dose #1
11103915|NCT04049175|Experimental|Treatment B|Administration of CHF 6532 Dose #2
11103916|NCT04049175|Experimental|Treatment C|Administration of CHF 6532 Dose #3
11103917|NCT04049175|Placebo Comparator|Treatment D|Administration of CHF 6532 Placebo
11103918|NCT04049162|Experimental|Blueberry Plus Exercise (BB-EX)|BB-Ex participants will consume lyophilized blueberry powder, mixed with water (18 grams, equivalent to 3/4ths cup of blueberries) with 2 daily meals (36 g/d blueberry powder total; approx. 1.5 servings/d)
11103919|NCT04049162|Placebo Comparator|Blueberry Placebo Plus Exercise (P-EX)|Participants randomized to P-EX treatment will consume an indistinguishable placebo powder, matched for color, flavor, consistency, and caloric content, in the same manner.
11103920|NCT04049149|Other|JADE-PRISM group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
11103921|NCT04049149|Other|JADE group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
11103922|NCT04049136||Healthy pregnant women with BMI <30|
11103923|NCT04049136||Healthy pregnant women with BMI >=30|
11103924|NCT04049123|Active Comparator|Insulin Lispro (Humalog)|Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
11103925|NCT04049123|Experimental|LY900014|LY900014 administered once, SC, in two of three study periods.
11103926|NCT04049110|Experimental|Dapagliflozin first, placebo second|Dapagliflozin followed by placebo
11103927|NCT04049110|Experimental|Placebo first, Dapagliflozin second|Placebo followed by dapagliflozin
11103928|NCT04049097|Experimental|Arimoclomol|1200 mg/day arimoclomol citrate (400 mg t.i.d.)
11103929|NCT04049071||Case|Cases are patients that are prescribed tocilizumab as escalation therapy for relapsing/refractory GCA
11103930|NCT04049071||Control|Controls are those that are prescribed an alternative escalation therapy (not tocilizumab) for relapsing/refractory GCA.
11103931|NCT04049045|Active Comparator|Verum arm|25 mg tablet of empagliflozin once daily for five days
11103932|NCT04049045|Placebo Comparator|Placebo arm|one tablet of the matching Placebo once daily for five days
11103933|NCT04049032||In-Person Participants|This group received perinatal OUD treatment in-person.
11103934|NCT04049032||Telemedicine Participants|This group received perinatal OUD treatment via telemedicine.
11103935|NCT04049019|Experimental|Urine collection|"The child ́s weight and height will be registered. The children's urine will be tested for infection with a dipstick urinalysis.
~The child will be asked to perform home recordings for seven days consisting of measurements of diaper weight and first morning voided volume and a two-day frequency-volume chart."
11103936|NCT04049006|Experimental|complex-treatment benefiting group|Participants in the intervention group will receive the complex treatment and the usual clinical practice.
11103937|NCT04049006|No Intervention|complex-treatment no benefiting group|Participants in the control group will receive the care from the usual clinical practice
11103938|NCT04048980|No Intervention|Control Group|Patients with dementia or cognitive impairment and femur fracture receiving the traditional care in traumatology units.
11103939|NCT04048980|Experimental|Experimental Group|Patients with dementia or cognitive impairment and femur fracture receiving an intervention in traumatology units.
11103940|NCT04048967|Experimental|Intervention|Preschool staffs will participate in 50 hours of professional development over 7 months focused on promotion of physical activity in the preschool setting. Staffs and investigators will work together to develop models to ensure children receive 60 minutes per day of moderate-to-vigorous physical activity, 90 minutes per week of motor challenging physical activity, 90 minutes per week of cognitively engaging games/play, and 90 minutes per week of physically active learning.
11103941|NCT04048967|No Intervention|Control|Staffs receive no professional development and children will receive standard care.
11103942|NCT04048954||APPLITABAC arm|Use of a smartphone application on screening for complications related to tabagism
11103943|NCT04048941|Experimental|Verum Acupuncture with Movement|Verum acupuncture along radial side of 2nd metacarpal, following by active movement of previously painful body part x 10 minutes.
11103944|NCT04048941|Active Comparator|Verum Acupuncture without Movement|Verum acupuncture along radial side of 2nd metacarpal, following by laying on examination table x 10 minutes.
11103945|NCT04048941|Sham Comparator|Control Acupuncture with Movement|Sham/control acupuncture at acupoint LI4, following by active movement of previously painful body part x 10 minutes.
11103946|NCT04048928|Experimental|Strength group|Receives maximal strength training
11103947|NCT04048928|No Intervention|Control group|receives no active treatment
11103948|NCT04048915|Experimental|Long live drama|Primary school students watched an interactive long live drama (90 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
11103949|NCT04048915|Experimental|Short live drama|Primary school students watched an interactive short live drama (60 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
11103950|NCT04048915|No Intervention|Waitlist control|Primary school students received no intervention during the 3-month study period. After the study finished, the students watched either short or long live drama, and DVD with worksheets were distributed to students and they were invited to share with their parents.
11103951|NCT04048902|Placebo Comparator|Pilates and Shortwave placebo|In this group the patients will receive 20 minutes of short wave placebo application. The equipment will keep the timer on and the intensity will remain at zero. The patient will be informed that the dose is subsensory and therefore there will be no perception of the passage of the short waves through the body.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
11103952|NCT04048902|Active Comparator|Pilates and Shortwave active|In this group the patients will receive 20 minutes of application of the Shortwave Active continuous mode (thermal effect), with vigorous local thermal sensation.The application will be performed with two coplanar plates in parallel, arranged on the right and left side of the lumbar region, maintaining a distance of 5 to 10 cm between them, with the patient lying in the dorsal decubitus position
11103953|NCT04048889|Experimental|Popliteal plexus block and continuous femoral nerve block|
11103954|NCT04048889|Active Comparator|continuous femoral nerve block|
11103955|NCT04048876|Experimental|CC-90001 400 mg once daily (QD)|CC-90001 400 mg QD
11103956|NCT04048876|Experimental|CC-90001 200 mg once daily|CC-90001 200 mg QD
11103957|NCT04048876|Experimental|CC-90001 100 mg once daily|CC-90001 100 mg QD
11103958|NCT04048876|Placebo Comparator|Placebo once daily|Placebo QD
11103959|NCT04048863|Active Comparator|Stage 1 Baseline|Study site to use standard of care PIVC device(s) and procedure(s) on patients.
11103960|NCT04048863|Other|Stage 2 Education|RN education and training in the use of B. Braun PIVC products, devices and procedures.
11103961|NCT04048863|Other|Stage 3 Run-In|Familiarization of study RNs with the B. Braun devices and procedures in a clinical setting.
11103962|NCT04048863|Other|Stage 4 Post-Education|Study site uses B. Braun PIVC device(s) and procedure(s) on patients.
11103963|NCT04048850||Patients living with HCV +/- HIV|HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use treated with elbasvir/grazoprevir 50-100 mg fixed-dose-combination, 1 tablet by mouth daily, for 12 weeks.
11103964|NCT04048824|Experimental|Inhibitory Learning-Based Exposure|Participants will receive exposure therapy aimed at increasing inhibitory learning.
11103965|NCT04048824|Active Comparator|Habituation-Based Exposure|Participants will receive exposure therapy aimed at reducing fear responding.
11103966|NCT04048811|Experimental|HSK3486|HSK3486 induction + maintenance group
11103967|NCT04048811|Active Comparator|Propofol|Propofol induction + maintenance group
11103968|NCT04048811|Other|Propofol HSK3486|Propofol induction + HSK3486 maintenance group
11103969|NCT04048798|Active Comparator|Oxygen therapy via HFNC|Patients who will be applied high frequency nasal cannula before and after surgery
11103970|NCT04048798|Active Comparator|Oxygen therapy via face mask|Patients who will be applied O2 via face mask before and after surgery
11103971|NCT04048785|No Intervention|control|Infant sleep monitoring(actiwatch and sleep dairy) and parental surveys
11103972|NCT04048785|Experimental|infant behavioral sleep intervention|For intervention group, 5 times sleep hygiene education will be introduced to parents and behavioral approach will be given for infants with behavioral insomnia. Parents are instructed to sleep protocols, including a standardized sleep schedule and bedtime routine, as well as other support from a sleep interventionist. Behavioral procedures such as unmodified extinction; graduated extinction (ignoring the infant cries with minimal checks), or camping out
11103973|NCT04048772|Experimental|Intervention|Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.
11103974|NCT04048772|Other|Control|Standard of care in vitro fertilization patients at our institution.
11103975|NCT04048759|Other|Remote Low|
11103976|NCT04048759|Other|Remote High|
11103977|NCT04048759|Other|Personal Coach|
11103978|NCT04048746||ASTHMA|"The patient presents to the emergency department for an aggravation of his asthma. The patient later sees an emergency investigator for medical care for his aggravation of asthma. When the patient's condition is stabilized, the investigator checks his eligibility for study and offers to participate. If the patient agrees, the investigator gives him the questionnaire and possibly helps to fill it out.
~When the investigator returns to see the patient for a reassessment of his condition, he retrieves the completed questionnaire. He verifies that the patient has completed the questionnaire. Prescriptions and action plans are retrieved by the principal investigator either in digitized format from the patient's computerized medical record or in paper format. Each medication prescription and each action plan are read by the principal investigator and evaluated according to the grids."
11103979|NCT04048733|Experimental|Patchy type-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.
~Second and third 12 lead ECG will be taken using patchy-type 12-lead ECG device as a doctor's order. This device will be automatically record 12-lead ECG 3 times in 1 minutes at a time by its algorithm."
11103980|NCT04048733|No Intervention|Standard 12-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.
~Second and third 12 lead ECG will be taken using standard 12-lead ECG device as a doctor's order. Interns and ECG technicians will perform 12-lead ECG as they perform as usual."
11103981|NCT04048720|Experimental|Family Nurture Intervention (FNI)|FNI sessions will be held once a week in the afternoon for eight weeks. Participants will take part in FNI group therapy with their child alongside other mother-child pairs. One to two staff members will lead FNI sessions.
11103982|NCT04048707|Active Comparator|Midodrine/Octreotide|This arm will receive standard of care treatment of midodrine, octreotide, and albumin.
11103983|NCT04048707|Experimental|Angiotensin 2|This arm will receive the experimental treatment of angiotensin 2 infusion and albumin.
11103984|NCT04048681|Experimental|Diet Soda|12oz can of Diet Coke
11103985|NCT04048681|Active Comparator|Soda|12oz can of Coke
11103986|NCT04048681|Placebo Comparator|Carbonated Water|12oz can of carbonated (unflavored) water
11103987|NCT04048668|Active Comparator|Anodal tDCS|2mA for 20 minutes
11103988|NCT04048668|Sham Comparator|Sham tDCS|30 second ramp-up / ramp-down for 20 minutes
11103989|NCT04048655|Other|Study group|Single arm and everyone gets the same treatment according the protocol
11103990|NCT04048642|Experimental|DASH diet; plant-based diet; DASH diet|Food is provided: 7 days of an ad libitum DASH diet, followed immediately by 7 days of an ad libitum whole food, plant based diet, followed immediately by 7 days of an ad libitum DASH diet again.
11103991|NCT04048629|Experimental|Point-of-care (POC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At POC facilities, at the first antenatal visit (ANC1), all women enrolled in the intervention cohort will have a blood sample collected for VL which will be tested onsite using an existing POC device. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
11103992|NCT04048629|Active Comparator|Standard of care (SOC)|All facilities will receive a refresher training on Zimbabwe's 2018 Guidelines. At SOC facilities, at ANC1, all women enrolled in the intervention cohort will have a blood sample collected for VL which will be sent to centralized labs for testing. If a woman is virally unsuppressed (VL ≥1000 cpm), she will be given adherence counseling and, if necessary, a treatment regimen switch/infant prophylaxis per national guidelines.
11103993|NCT04048616|Active Comparator|whey protein isolate + KHCO3|1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
11103994|NCT04048616|Active Comparator|whey protein isolate + microcrystalline cellulose|1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
11103995|NCT04048616|Active Comparator|maltodextrin powder + KHCO3|isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
11103996|NCT04048616|Placebo Comparator|maltodextrin powder + microcrystalline cellulose|isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
11103997|NCT04048603||idiopathic REM sleep behavior disorder|Subjects with the diagnosis of idiopathic REM sleep behavior disorder
11103998|NCT04048603||Controls without iRBD|Healthy controls without the diagnosis of idiopathic REM sleep behavior disorder
11103999|NCT04048590|No Intervention|Control|Control subjects will receive care at a skilled nursing facility.
11104000|NCT04048590|Active Comparator|Intervention|Intervention subjects will go home from the hospital and receive care from a specialized care team.
11104001|NCT04048577|Experimental|Dose Interruption|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
11104002|NCT04048577|No Intervention|Standard Treatment|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days).
11104033|NCT04048317|Experimental|drug eluting bead trans arterial chemo embolization|the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere
11104003|NCT04048551|No Intervention|No S&D Reduction Training; PrEP and SRH only|Arm 1 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
11104004|NCT04048551|Experimental|No S&D Reduction Training; PrEP and SRH + YWHC|Arm 2 does not receive stigma and discrimination (S&D) reduction training to clinic staff, but provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
11104005|NCT04048551|Active Comparator|S&D Reduction Training; PrEP and SRH only|Arm 3 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis) and SRH (sexual and reproductive health) services to AGYW (adolescent girls and young women).
11104006|NCT04048551|Experimental|S&D Reduction Training; PrEP, SRH + YWHC|Arm 4 receives stigma and discrimination (S&D) reduction training to clinic staff and provides PrEP (pre-exposure prophylaxis), SRH (sexual and reproductive health) services, and YWHC (Young Women's Health CoOp) to AGYW (adolescent girls and young women).
11104007|NCT04048538|Experimental|Treatment Arm|Individuals who will receive access to the animated multimedia platform prior to their surgical procedure.
11104008|NCT04048538|Active Comparator|Control Arm|Individuals who will not receive access to the animated patient platform, and instead will receive the usual standard of care.
11104009|NCT04048525|Experimental|CVVHD with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
11104010|NCT04048525|Active Comparator|CVVH with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
11104011|NCT04048512||Resection with intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection with intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio Pulmonary By pass (CPB)
11104012|NCT04048512||Resection without intraoperative ECMO/CPB|Patients suffering of neoplastic thoracic disease, undergoing thoracic resection without intraoperative use of Extra Corporeal Membrane Oxygenator (ECMO) or Cardio pulmonary By Pass (CPB)
11104013|NCT04048486||CAPA-IVM|Live babies born from CAPA-IVM
11104014|NCT04048486||IVF/ICSI|Live babies born from IVF/ICSI
11104015|NCT04048486||Natural conception|Live babies born from natural conception
11104016|NCT04048473||MUH (Mansoura University Hospital)|enrolled 127 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5). Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
11104017|NCT04048473||Ocmu (Oncology center Mansoura University)|enrolled132 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5).Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
11104018|NCT04048460|Experimental|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
11104019|NCT04048434|No Intervention|Standard of care (SOC)|
11104020|NCT04048434|Experimental|Cyotosorb|
11104021|NCT04048421|Experimental|hvNOTES group|Participants will undergo hvNOTES radical colectomy.
11104022|NCT04048408||Obstructive lung diseases group|
11104023|NCT04048408||Healthy group|
11104024|NCT04048395||Follicular lymphoma arm|The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
11104025|NCT04048382|Experimental|Patient Navigation (PN)|This intervention consists of standardized health educational materials and manualized sessions that can be implemented based on a participant's stage in the PrEP continuum. The intervention will utilize bilingual peer lay navigators and also consist of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP.
11104026|NCT04048382|Other|Usual Care (UC)|Participants in this condition will receive the CDC's 2-page PrEP Information Sheet in the participant's preferred language (either English or Spanish).
11104027|NCT04048369|Experimental|Point-of-care testing arm|for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.
11104028|NCT04048369|Active Comparator|Core Lab testing arm|for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)
11104029|NCT04048356|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
11104030|NCT04048356|Active Comparator|Povidone Iodine|Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
11104031|NCT04048343|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
11104032|NCT04048330||Women of reproductive age|Women 15 to 40 years of age who are not pregnant or lactating
11104034|NCT04048317|Placebo Comparator|conventional trans arterial chemo embolization|the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol
11104035|NCT04048304|Experimental|short antibiotic therapy|3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
11104036|NCT04048304|Active Comparator|long antibiotic therapy|6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
11104037|NCT04048291|Experimental|Brisk walking and balance training|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session
~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session
~Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)"
11104038|NCT04048291|Active Comparator|Upper limb exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session
~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session
~Participants practice own upper limb and hand exercise 2-3 times/week (to aim at 150 min of exercise per week)"
11104039|NCT04048278|Experimental|Lidocaine Hydrochloride|The IV bolus and infusions of lidocaine to those patients assigned to the lidocaine group will be started in the operating room and will continue until 24 h later. The group receiving the lidocaine infusion will first be administered a 1.0 - 1.5 mg/kg loading infusion over 5 minutes followed by a 1.0 - 1.5 mg/kg/h infusion for 24 h
11104040|NCT04048278|Placebo Comparator|Saline Solution for Injection|The group receiving the saline infusion will be administered an equivalent volume of saline infused over 5 min followed by a saline infusion at the same flow rate as that used in the lidocaine group for 24 h (1.0 - 1.5 mg/kg/hr)
11104041|NCT04048265|Experimental|Pain in PD Arm one|This arm will receive a total 5 sessions of TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
11104042|NCT04048265|Sham Comparator|Pain in PD Arm two|This arm will receive a total 5 sessions of sham-TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
11104043|NCT04048252||Focus group|
11104044|NCT04048252||Workshop|
11104045|NCT04048226|Placebo Comparator|Control group|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
11104046|NCT04048226|Experimental|Dexmedetomidine-Ketamine group|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
11104047|NCT04048200|Other|Control group|Anesthesia will be induced by fentanyl 1 ug/kg, propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The patients in this group will be connected to a syringe pump before induction of anesthesia that was prepared by anesthesia resident not participating in the study and contain normal saline and adjusted at a rate of 1 ml/kg/hr till the end of the surgery.
11104048|NCT04048200|Experimental|Opioid free anesthesia group|A syringe 50 ml was prepared by anesthesia resident not participating in the study and contain 100 ug of dexmedetomidine (2 ug/ml) and 25 mg ketamine 90.5 mg/ml) and 200 mg lidocaine (4 mg/ml). The syringe will be connected to the patients before induction of anesthesia at a rate of 0.1 ml/kg/hr according to the ideal body weight. Anesthesia will be induced by propofol 2 mg/kg, and rocuronium 1 mg/kg to facilitate tracheal intubation. After endotracheal intubation, the patients will be connected to mechanical ventilator with its parameters adjusted to maint5ain etCO2 32-36 mmhg. Anesthesia will be maintained by sevoflurane 2% in a mixture of oxygen: Air 1: 1 to maintain entropy 40-60. The syringe infusion will be continued till the end of peritoneal manipulation. Patients in this group will receive magnesium sulphate preload at a dose of 40 mg/kg ideal body weight followed by maintenance infusion of 10 mg/kg/hr.
11104049|NCT04048187|Experimental|Phone Application|
11104050|NCT04048174|Sham Comparator|Saline irrigation|"Each participant performed nasal saline irrigation at 2 periods:
~Day -14 to Day 0
~Day 14 to Day 28"
11104051|NCT04048174|Experimental|Probiotic lactococcus lactis W136 irrigation|Each participant performed Probiotic lactococcus lactis W136 nasal irrigation from Day 0 to D14
11104052|NCT04048161|Experimental|Tacrolimus(Group A)|Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
11104053|NCT04048161|Experimental|Mycophenolate Mofetil(Group B)|Mycophenolate Mofetil: 250mg; Dispersible tablets; 20~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
11104054|NCT04048148|Other|Novel myopia control lenses|This group will be randomized to wear test lenses for 6 months followed by control lenses for 6 months
11104055|NCT04048148|Other|Single vision lenses|This group will be randomized to wear control lenses for 6 months followed by test lenses for 6 months
11104056|NCT04048135|Experimental|Dose 1|
11104057|NCT04048135|Experimental|Dose 2|
11104058|NCT04048135|Experimental|Dose 3|
11104059|NCT04048135|Experimental|Dose 4|
11104060|NCT04048135|Experimental|Dose 5|
11104061|NCT04048135|Experimental|Dose 6|
11104062|NCT04048135|Placebo Comparator|Placebo|
11104063|NCT04048122|Active Comparator|Standard of Care (Control Group)|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
11104097|NCT04047940|Active Comparator|Reference Drugs|Metformin XR, atorvastatin, and valsartan administered orally
11104128|NCT04047719||Intent-to-Diagnose Population|All subjects enrolled in the study that have at least one Karius Test with a valid result
11104148|NCT04047537|Other|Experimental: WBF-0011|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
11104064|NCT04048122|Experimental|MC4PD Strategy Training|This treatment focuses on improving functional performance by enhancing the generation and use of strategies-which can be internal (e.g., self-talk, planning) or external (e.g., checklist, alarm)-to circumvent cognitive processing limitations caused by PD. It uses a standardized approach across and within sessions for all clients while being tailored to each client's cognitive problems and goals.
11104065|NCT04048096|Placebo Comparator|Placebo|4g/day of mixed vegetable oil supplements
11104066|NCT04048096|Experimental|Krill|4g/day krill oil
11104067|NCT04048083|Experimental|Patients-MT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training (MT) of reaching to grasp movements
11104068|NCT04048083|Experimental|Patients-CAT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in computer-aided training (CAT) of reaching to grasp movements using virtual environment with visual-feedback.
11104069|NCT04048083|Experimental|Patients-CAMT|3 Patients with bilateral upper limb congenital transverse deficiency that participated in kinesthetic mental training of reaching to grasp movements supplemented by virtual environment (patients that received both types of training).
11104070|NCT04048083|Active Comparator|Healthy-controls|9 Healthy, age and gender-matched subjects, without any kind of training
11104071|NCT04048070|Experimental|ERAS with postoperative intravenous Flubiprofen Axetil|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
11104072|NCT04048070|Experimental|ERAS with analgesia pump|The patients was given extended perioperative counseling, shorter fasting food for 6 to 8 hours and carbohydrate water for 2 hours before surgery. Early ambulation and oral intake 2 hours after patient recovery from anesthesia. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
11104073|NCT04048070|Experimental|Traditional care with Flubiprofen Axetil|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Once a day 100mg Flubiprofen Axetil in this group for postoperative pain management.
11104074|NCT04048070|Experimental|Traditional care with analgesia pump|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
11104075|NCT04048070|Placebo Comparator|traditional care without postoperative intravenous analgesia.|Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. Intravenous saline with necessary oral analgesic for postoperative pain management.
11104076|NCT04048057|Experimental|Modarete Intensity Continous Training|
11104077|NCT04048057|Experimental|High Intensity Interval Training I|
11104078|NCT04048057|Experimental|High Intensity Interval Training II|
11104079|NCT04048044|Active Comparator|Telomere length, GigaHz exposure|Measurement of white blood cell telomeres before and yearly for 5 years
11104080|NCT04048031|Active Comparator|Nutrafol Supplement Capsules|"NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.
~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal."
11104081|NCT04048031|Placebo Comparator|Placebo Capsules|The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
11104082|NCT04048031|Other|Open Label 6 month Extension|"During the 6 month open label extension all 70 subjects will receive NUTRAFOL's Synergen Complex Plus® which is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.
~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for the six month extension with a substantial meal."
11104083|NCT04048018||Active Tuberculosis Patient|
11104084|NCT04048018||High risk for LTBI Participant|
11104085|NCT04048018||Low risk for prior TB infection Participant|
11104086|NCT04048018||NTM patient|
11104087|NCT04048018||Precision patient|
11104088|NCT04047992|Experimental|Exoskeleton Users|All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
11104089|NCT04047979|Experimental|Younger Group|Participants between the ages of 50 to 60 years will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
11104090|NCT04047979|Experimental|Older Group|Participants who are ≥70 year old will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
11104091|NCT04047966||Fetal growth restriction|63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile
11104092|NCT04047966||Control group|63 control fetuses with an estimated fetal weight about the 10th percentile
11104093|NCT04047953|Experimental|Conversion Therapy|Paclitaxel (albumin-bound) +S-1+Oxaliplatin
11104094|NCT04047940|Experimental|LY900020 Formulation 1|LY900020 Formulation 1 administered orally
11104095|NCT04047940|Experimental|LY900020 Formulation 2|LY900020 Formulation 2 administered orally
11104096|NCT04047940|Experimental|LY900020 Formulation 3|LY900020 Formulation 3 administered orally
11104127|NCT04047732|Experimental|Topical KB105|HSV1-TGM1 vector (KB105)
11104098|NCT04047927|Experimental|EpiFinder|Eligible subjects will be included to this group to receive an epidural injection of steroids to treat their chronic back pain. The investigational device will be used in conjugation to the standard practice of epidural injections, to assist the investigator to identify the epidural space.
11104099|NCT04047914|Experimental|experimental PDT group|Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 1 minute pre-irradiation time. Irradiations will be performed with a red laser diode (wavelength = 660 nm), 240 seconds and 4-point nostril application (one point on each of the 4 walls).
11104100|NCT04047914|Active Comparator|control mupirocin group|A standard treatment will be performed conventionally with topical mupirocin. Will be performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
11104101|NCT04047901|No Intervention|control group|"A group of patients who will not be trained will be evaluated at baseline (pre) and after 16 weeks.
~They are oriented to maintain lifestyle changes"
11104102|NCT04047901|Experimental|Training group|Patients will complete 16 weeks of training including 40 minutes of aerobic training, 15 minutes of resistive exercise and 5 minutes of relaxation.
11104103|NCT04047888||Intervention Group|Mothers and children in this group will have measurements, questionnaire administration. The children will have routine child care at their health center and mothers will have a 60 minute nutrition-based and non-nutrition based educational message
11104104|NCT04047888||Control Group|Mothers and babies will have measurements and questionnaire administration and children will receive routine child care at their health centers. These mothers will receive a non-nutrition based educational message only.
11104105|NCT04047875|Experimental|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Primolut-Nor® per bleeding episode)
11104106|NCT04047875|Placebo Comparator|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting (maximum use of 1 box of Placebo per bleeding episode)
11104107|NCT04047862|Experimental|Phase 1|"Cycle 1 (28 Days): A flat dose of BGB-A1217 as a single agent on Day 1. In the first cycle, 200 mg tislelizumab will be administered on Day 8.
~If BGB-A1217 is tolerated in Cycle 1, participants will receive tislelizumab + BGB-A1217 sequentially on Day 29 and every 21 days for up to 8 months."
11104108|NCT04047862|Experimental|Phase 1b Cohort 1|First line participants with metastatic squamous NSCLC will receive BGB-A1217 + tislelizumab + paclitaxel/nab-paclitaxel + Carbo once every 3 weeks (Q3W) for 4 to 6 cycles (21 days each)
11104109|NCT04047862|Experimental|Phase 1b Cohort 2|First line participants with metastatic squamous NSCLC will receive BGB-A1217 + tislelizumab + pemetrexed + Cis/Carbo Q3W for 4 to 6 cycles (21 days each)
11104110|NCT04047862|Experimental|Phase 1b Cohort 3|First-line participants with metastatic NSCLC (PD-L1 positive, [TPS] ≥ 1%) will be treated with BGB-A1217 + tislelizumab for up to 6 to 8 months
11104111|NCT04047862|Experimental|Phase 1b Cohort 4|First-line participants with extensive SCLC will be treated with BGB-A1217 + tislelizumab + etoposide + Cis/Carbo Q3W for up to 6 to 8 months
11104112|NCT04047862|Experimental|Phase 1b Cohort 5|Checkpoint inhibitor (CPI)-experienced NSCLC participants who have received 1 or 2 prior therapies including an anti-PD-(L)1 in the most recent line of treatment and progressed after a best response of CR, PR, or SD will be treated with BGB-A1217 plus tislelizumab for up to 6 to 8 months
11104113|NCT04047849|Experimental|Antibiotics|This will include those subjects randomized into the treatment arm, receiving the outpatient antibiotic course of azithromycin and amoxicillin prior to re-admission at viability (23 0/7 weeks gestation). They will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home).
11104114|NCT04047849|No Intervention|No antibiotics|This will include those subjects randomized into the control arm and will not receive outpatient antibiotics prior to re-admission at viability (23 0/7 weeks gestation).
11104115|NCT04047836|Other|Low Nicotine|Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
11104116|NCT04047836|Other|Medium or High Nicotine|The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
11104117|NCT04047810|Experimental|Subjects with Advanced Chronic Obstructive Pulmonary Disease|Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)
11104118|NCT04047797|Experimental|Treatment (ixazomib, rituximab)|Patients receive ixazomib by mouth on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of cycle 1. Beginning in cycle 3, patients receive rituximab Intravenous over 4-8 hours on day 1. Treatment repeats every 28 days up to cycle 12 in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue to receive ixazomib indefinitely in the absence of disease progression or unacceptable toxicity.
11104119|NCT04047784|Experimental|Critically Ill Patients|"Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.
~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
11104120|NCT04047784|Experimental|Patients undergoing standard of care clinical bronchoscopy|"Patients undergoing clinical bronchoscopy as a part of their standard of care.
~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
11104121|NCT04047784|No Intervention|Previously recorded patient media from standard of care clinical bronchoscopy with EBUS|"Patients who underwent a standard of care clinical bronchoscopy with EBUS previously.
~Information and media including images and videos that were previously recorded for patients who underwent a standard of care clinical bronchoscopy with EBUS will be available to the study team."
11104122|NCT04047771|Experimental|SCB-313|
11104123|NCT04047758|Experimental|Palbociclib + Letrozole group|210 patients will be randomly assigned to receive treatment with palbociclib and letrozole (palbociclib + letrozole group) .
11104124|NCT04047758|Placebo Comparator|Letrozole group|210 patients will be randomly assigned to receive treatment with letrozole (letrozole group).
11104125|NCT04047745|Active Comparator|liposomal bupivacaine|
11104126|NCT04047745|Active Comparator|ropivacaine|
11104129|NCT04047706|Experimental|Cohort I (radiation, temozolomide, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT methylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive temozolomide PO QD, IDO1 inhibitor BMS-986205 PO QD, and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins.
~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Within 4 weeks of radiation therapy completion, patients also receive temozolomide PO QD on days 1-5 of cycles 2-6. Cycles repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
11104130|NCT04047706|Experimental|Cohort II (radiation, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT unmethylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive IDO1 inhibitor BMS-986205 PO QD and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Cycles repeats every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins."
11104131|NCT04047693|Experimental|ddMVAC|4 cycles of neoadjuvant chemotherapy using dose dense MVAC with G-CSF
11104132|NCT04047680||SOF-based DAAs|Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks
11104133|NCT04047680||SOF-free DAAs|Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks
11104134|NCT04047667||CBCT guided TBCB|Patients with ILD who met the following including criteria from September 2018 to July 2019 were suggested to receive TBCB under CBCT guidance: more than 18 years old, diffuse parenchymal lung diseases without a diagnosis after integration of clinical profile, laboratory tests and HRCT features, FVC more than 50%, DLCO more than 35%, patients without acute exacerbation within one month, patients without bleeding diathesis, anticoagulant therapy, using antiplatelet drugs, patients without pulmonary hypertension, respiratory failure, liver or kidney disfunction, or cardiac insufficiency, PLT more than 50 x 109/L. All included patients signed the informed consent.
11104135|NCT04047654||Non vitamin K oral anticoagulants (NOACs)|Patients who were prescribed with apixaban, dabigatran, edoxaban, or rivaroxaban for stroke secondary prevention.
11104136|NCT04047654||Warfarin|Patients who were prescribed with warfarin for stroke secondary prevention.
11104137|NCT04047641|Experimental|Treatment (idarubicin, cladribine, cytarabine, quizartinib)|"INDUCTION: Patients receive idarubicin Intravenous over 1 hours on days 1-3, cladribine intravenous over 1-2 hours on days 1-5, cytarabine Intravenous over 3 hours on days 1-5 (or days 1-3 for patients over age 60), and quizartinib by mouth daily on days 6-19. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR or CRp after Induction receive idarubicin Intravenous over 1 hours on days 1-2, cladribine Intravenous over 1-2 hours on days 1-3, cytarabine Intravenous over 3 hours on days 1-3, and quizartinib by mouth daily on days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients who achieve CR or CRi/CRh after Consolidation receive quizartinib by mouth daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
11104138|NCT04047628|Experimental|AHSCT|"AHSCT: Myeloablative and Immunoablative therapy followed by Autologous Hematopoietic Stem Cell Transplantation
~Participants will undergo:
~Mobilization and graft collection: mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide, filgrastim, and dexamethasone. The autologous graft will be collected by leukapheresis and cryopreserved.
~Conditioning: high dose myeloablative and immunoablative conditioning with a six-day BEAM chemotherapy and rabbit anti-thymocyte globulin regimen will be initiated ≥30 days after cyclophosphamide mobilization.
~Autologous cryopreserved graft infusion: the cryopreserved peripheral blood stem cells (PBSC) graft will be thawed and infused the day following completion of the conditioning regimen. Each bag will be thawed and infused according to institutional standards consistent with the Foundation for the Accreditation of Cellular Therapy (FACT) guidelines. Participants will receive prednisone following graft infusion."
11104139|NCT04047628|Active Comparator|Best Available Therapy (BAT)|Participants randomized to BAT: Best available therapy will be selected by the Site Investigator from: natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), or rituximab (Rituxan®).
11104140|NCT04047615|Experimental|Exercise effects on Behavior|An exercise intervention programme will be implemented 3 times a week for an 8 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will be fun for the students to participate in and will involve aspects of fundamental movement skills.
11104141|NCT04047602|Experimental|Reduced Dose Stereotactic Radiosugery|Subjects will receive one SRS treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 2, 6, 9, and 12 months post SRS treatment
11104142|NCT04047589||Subjects|
11104143|NCT04047589||Providers|
11104144|NCT04047576|Experimental|sirolimus group|"Sirolimus: 2 mg/day for the first 3 days and 1 mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L.
~Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d, and by 2.5 mg every month after 15 mg/d until discontinuation."
11104145|NCT04047576|Active Comparator|corticosteroid group|Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d, and by 2.5 mg every month after 15 mg/d until 5 mg/d.
11104146|NCT04047563|Active Comparator|Normal Saline + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
11104147|NCT04047563|Experimental|PMZ-1620 (sovateltide) + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
11104149|NCT04047537|Other|Experimental: WBF-0011 (0.2X concentration)|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
11104150|NCT04047537|Other|Placebo|2 capsules/day (one in the morning and one in the evening), taken with meal for 12 weeks
11104151|NCT04047524|Other|Prehabilitation|These participants will receive a home based prehabilitation programme for a period of 2-6 weeks prior to surgery and will be provided with a Fitbit Charge 2.
11104152|NCT04047524|Other|Control|These participants will receive a Fitbit Flex and told to continue with their every day activity levels for a period of 2-6 weeks prior to surgery
11104153|NCT04047511|Experimental|Virtual Reality|"Twice a week, for a 4 consecutive weeks:
~8 sessions of VRTierOne therapy ( 20 minutes each).
~8 sessions of general fitness training (40 minutes each)
~8 sessions of psychoeducation (20 minutes each"
11104154|NCT04047511|Active Comparator|Control|"Twice a week, for a 4 consecutive weeks:
~8 sessions of general fitness training (40 minutes each)
~8 sessions of psychoeducation (20 minutes each"
11104155|NCT04047498|Experimental|Within-subjects comparison of constant and alternating DBS|
11104156|NCT04047485||Elderly Female (A)|Female subjects between 65 and 85 years old
11104157|NCT04047485||Great Elderly Female (B)|Female subjects with more than 85 years old
11104158|NCT04047485||Elderly Male (C)|Male subjects between 65 and 81 years old
11104159|NCT04047485||Great Elderly Male (D)|Men subjects with more than 81 years old
11104160|NCT04047472|Experimental|Brolucizumab 6 mg|
11104161|NCT04047472|Active Comparator|Aflibercept 2 mg|
11104162|NCT04047459||Patient undergoing prosthetic surgery|Patients undergoing surgery for the insertion of a hip prosthesis or a cruciate ligament reconstruction will be included. On those patients tissue samples collection and cells isolation will be performed
11104163|NCT04047446|Experimental|Liposomal bupivacaine & standard bupivacaine|
11104164|NCT04047446|Active Comparator|Standard bupivacaine & dexamethasone|
11104165|NCT04047433|Experimental|women with external anal sphincter injury|The study cohort will be composed of women undergoing vaginal delivery and diagnosed with external anal sphincter injury after a vaginal delivery.
11104166|NCT04047433|Experimental|women without external anal sphincter injury|The control group will be women who had a vaginal delivery without any clinically apparent perineal laceration
11104167|NCT04047420|Experimental|Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Insert|On the first dosing visit (Visit 3), participants will receive a single TAF/EVG Insert for rectal administration. On the second dosing visit (Visit 7), after a washout period of at least 7 days, participants will receive two TAF/EVG Inserts for rectal administration. Each participant will be on study for approximately 6-13 weeks.
11104168|NCT04047407||Fibromyalgia|
11104169|NCT04047407||Healthy volunteers|
11104170|NCT04047394|Experimental|PEGylated recombinant candida urate oxidase|"There are two parts (part A and part B), part A has five dose increasing groups, part B has three dose extension groups.
~Part A: Group1：2mg, Group2：3mg, Group3：6mg, Group4：9mg, Group5: 12mg. Part B: Group1：3mg, Group2：6mg, Group3：9mg."
11104171|NCT04047381||Atrial Fibrillation|Turkish patients diagnosed with atrial fibrillation
11104172|NCT04047368|Active Comparator|Rotablation|
11104173|NCT04047368|Experimental|Coronary Lithoplasty|
11104174|NCT04047355|Experimental|Group A: Propranolol first|"Participants randomly assigned to this group will receive Propranolol first. After the washout period, they will receive Placebo.
~Propranolol will be given in liquid or pill form."
11104175|NCT04047355|Placebo Comparator|Group B: Placebo first|"Participants randomly assigned to this group will receive Placebo first. After the washout period, they will receive Propranolol.
~Placebo will look identical to the study drug Propranolol."
11104176|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
11104177|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.
~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
11104178|NCT04047329||Without post-operative myocardial infarction|Patients without post-operative myocardial infarction after first admission for transurethral resection of the prostate
11104179|NCT04047329||With post-operative myocardial infarction|Patients with post-operative myocardial infarction after first admission for transurethral resection of the prostate
11104180|NCT04047303|Experimental|Administration of CC-90010|During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
11104181|NCT04047290|Experimental|AK112|AK112 IV every 2 weeks (q2w)
11104182|NCT04047277|Experimental|Treatment Right-Away|Cognitive Behavioral Therapy using exposure, relaxztion, and rescripting - Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
11104183|NCT04047277|No Intervention|Waitlist Control|Waitlist control group will complete pre and post assessments at beginning and end of wait period.
11104184|NCT04047264|Experimental|Mutant or WT tumor|Patients with suspected or biopsy-proven IDH-mutant tumor. Patients with suspected or biopsy-proven IDH-WT tumor
11104185|NCT04047251|Experimental|Cohort 1: Treatment at Dose Level 1|FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11104186|NCT04047251|Experimental|Cohort 2: Treatment at Dose Level 2|FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11104187|NCT04047251|Experimental|Cohort 3: Treatment at Dose Level 3|FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11104188|NCT04047238|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving Reminiscence Therapy or to a control group receiving treatment as usual. Participants in the intervention group will participate in two Reminiscence Therapy sessions per week for 3 months besides their treatment as usual. The sessions will be based on the Book of Past and Present and they will follow the same protocol in every participant institution.
11104189|NCT04047238|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
11104190|NCT04047225|Experimental|Analgesia Nociceptive Index (ANI)|Using ANI for guiding intraoperative opioid administration.
11104191|NCT04047225|No Intervention|No Analgesia Nociceptive Index (ANI)|Do not use ANI
11104192|NCT04047212||Smokers ≥ 10 cigarettes/day|
11104193|NCT04047212||Smokers < 10 cigarettes/day|
11104194|NCT04047212||non-smokers|
11104195|NCT04047186|Experimental|neoadjuvant PD-1 group|receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
11104196|NCT04047173|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
11104197|NCT04047173|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
11104198|NCT04047160|Experimental|OP-724|"Dose: 140, 280, 380 mg/m2/4 hrs
~Administration method:
~[Level 1] 140 mg/m2/4 hours [Level 2] 280 mg/m2/4 hours (starting dose) [Level 3] 380 mg/m2/4 hours Continuous intravenous administration will be done for 4 hours twice a week. This procedure will be as one cycle and 12 cycles (12 weeks in total) will be conducted. On 7 days prior to the first cycle administration, a dose scheduled in the first cycle will be administered with continuous intravenous for 4 hours and the safety and pharmacokinetics on the day of administration to the next day after administration will be evaluated."
11104199|NCT04047147||Enrollment in the Million Hearts CVD Risk Reduction Model|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to participate in the Million Hearts CVD Risk Reduction Model intervention.
11104200|NCT04047147||Enrollment in control provider organizations|Eligible Medicare fee-for-service (FFS) beneficiaries enrolled in provider organizations that were randomly assigned to the control group.
11104201|NCT04047134|Experimental|Experimental Group (EG)|The Experimental Group (EG) will observe and execute/repeat Activities of Daily Living (ADL) actions.
11104202|NCT04047134|Active Comparator|Control Group (CG)|The COntrol Group (CG) will observe landscapes and perform the same actions observed by their peers but after verbal instructions.
11104203|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
11104204|NCT04047095|Experimental|Intervention|"Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.
~8 a.m. - normal meal plus one sachet immune nutrients
~1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients"
11104205|NCT04047095|Active Comparator|Control|"Normal daily meals. 8 a.m. - normal meal
~1 p.m. - normal meal 6 p.m. - normal meal"
11104206|NCT04047069|Other|Control|Awareness Training
11104207|NCT04047069|Experimental|Intervention group|"Awareness Training
~Person-Centered Occupational Therapy Intervention"
11104208|NCT04047056|Placebo Comparator|Ergonomic Guidelines Manual|A manual of ergonomic occupational and daily living guidelines will be given to both control and labor kinesiotherapy groups, which is the only approach for the control group initially.
11104209|NCT04047056|Active Comparator|Labor Kinesiotherapy in group|The intervention will be performed by a physical therapist, which will consist of preparatory labor kinesiotherapy, which aims to prepare the workers' osteo-articular system for the beginning of the work activity, acting more specifically on those muscle groups that will be most required during the journey which will be identified in the evaluation. Labor kinesiotherapy will be performed in the workplace before the workday and will last 20 minutes, 3 times a week, for 12 weeks.
11104210|NCT04047043||Taurine > 30 μmol/L|serum taurine level
11104211|NCT04047043||Taurine 30-20 μmol/L|serum taurine level
11104212|NCT04047043||Taurine < 20 μmol/L|serum taurine level
11104213|NCT04047030||Injured Cohort|Approximately 300 participants treated for a fracture of the tibial plateau, pilon, ankle or calcaneus will be enrolled from METRC civilian trauma centers and military treatment facilities over an 18 month period. Participating centers treat large numbers of severe orthopaedic injuries and have a proven track record for successfully recruiting and retaining participants in prospective studies in orthopaedic trauma. Participants will be enrolled following definitive treatment of their injury.
11104214|NCT04047030||Non-Injured Volunteers|Non-injured adults of similar age and gender distribution will be enrolled at two participating centers (Carolinas Medical Center and Womack Military Medical Center). The sample of non-injured volunteers will exclude individuals with history of lower extremity injury, vascular disease, or who require use of ambulatory aides to walk.
11104215|NCT04047017|Experimental|Test group|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
11104216|NCT04047004|Experimental|High-risk gastric cancer patients|The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.
11104217|NCT04046991|Active Comparator|HD-tDCS+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of HD-tDCS for 20 minutes using a montage in which a central electrode (1.5mA) is placed over the left frontotemporal area and four surrounding cathodes (.375mA each). Subjects will participate in a modified constraint-induced language therapy.
11104218|NCT04046991|Sham Comparator|Sham+mCILT|Participants will undergo 10 daily sessions (Monday-Friday, x2 weeks) of sham for 20 minutes using a montage in which a central electrode is placed over the left frontotemporal area and four surrounding cathodes. Subjects will participate in a modified constraint-induced language therapy,
11104219|NCT04046978|Experimental|Group F|Mos3.1 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
11104220|NCT04046978|Experimental|Group G|Mos3.2 100 ug at Month 0 Mos3.1 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
11104221|NCT04046978|Experimental|Group H|Mos3.3 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.1 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
11104222|NCT04046978|Experimental|Group I|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug at Months 0, 2 and 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
11104223|NCT04046965||Region XI Head Start children and families|children (800) parents (800) classrooms/teachers (80) program directors (22) center directors (37)
11104224|NCT04046952|Active Comparator|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
11104225|NCT04046952|Experimental|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
11104226|NCT04046939|Experimental|dexpramipexole 75 mg/day|dexpramipexole 37.5 mg tablets taken orally BID
11104227|NCT04046939|Experimental|dexpramipexole 150 mg/day|dexpramipexole 75 mg tablets taken orally BID
11104228|NCT04046939|Experimental|dexpramipexole 300 mg/day|dexpramipexole 150 mg tablets taken orally BID
11104229|NCT04046939|Placebo Comparator|placebo|matching placebo tablet taken orally BID
11104230|NCT04046913|Active Comparator|Low food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
11104231|NCT04046913|Placebo Comparator|Habitual food additive diet|Dietary advice, given by a dietitian, will be discussed at trial baseline.
11104232|NCT04046900|Active Comparator|Vaginal microbiome transplant|Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor
11104233|NCT04046900|Placebo Comparator|Saline placebo|Women in this group will be randomized to receive two doses of sterile saline
11104234|NCT04046887|Experimental|Combination of lonsurf + gemcitabine + nab-paclitaxel|
11104235|NCT04046874|Other|Usual Care|All patients were referred for the study by their General Practitioner (GP). GPs were encouraged to assess and treat their patients as usual and make all the referrals they think are appropriate for their patients.
11104236|NCT04046874|Other|Stratified Model of Care|A subgrouping tool helps guide clinical decision-making about treatment and onward referral (Start Back Screening Tool). Patients in each subgroup (low, medium or high risk of chronicity) are then managed according to a targeted treatment system of increasing complexity.
11104237|NCT04046861|Active Comparator|Vitamin C|2g vitamin C (ascorbic acid) iv before cardiopulmonary bypass, 2 g vitamin C iv before removing the aortic clamp, 1g vitamin C iv 8 h after aortic clamp removal and every 8 h thereafter(2 times)
11104238|NCT04046861|Placebo Comparator|Placebo (saline)|placebo (saline) iv before cardiopulmonary bypass, placebo before removing the aortic clamp, placebo iv 8 h after aortic clamp removal and every 8 h (2 times)
11104239|NCT04046848|Experimental|Cohort 1|"50 IU/kg (n=4): single-period investigation with a single sc dose of 50 IU/kg OCTA101 profiled up to 72 hours after dosing in adult male patients with severe hemophilia A.
~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 2, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
11104240|NCT04046848|Experimental|Cohort 2|"100 IU/kg (n=4): single-period investigation with a single sc dose of 100 IU/kg OCTA101 profiled up to 96 hours after dosing in adult male patients with severe hemophilia A.
~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 3, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
11104241|NCT04046848|Experimental|Cohort 3|"200 IU/kg (n=8): two-period investigation of a single iv dose of 50 IU/kg Human-cl rhFVIII (Nuwiq) profiled for up to 72 hours after dosing followed by sc dose of 200 IU/kg OCTA101 profiled up to 120 hours in adult male patients with severe hemophilia A.
~Treatments will be administered in fixed sequence, with Human-cl rhFVIII first.
~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 4 and 5 alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
11104242|NCT04046848|Experimental|Cohort 4|400 IU/kg (n=4): single-period investigation with a single sc dose of 400 IU/kg OCTA101 profiled up to 120 hours after dosing in adult male patients with severe hemophilia A
11104243|NCT04046848|Experimental|Cohort 5|"(n=8): three-period investigation of single sc doses of 50, 100, and 200 IU/kg OCTA101 profiled up to 72, 96, and 120 hours after dosing, respectively in adult male patients with severe hemophilia A.
~Treatments will be administered in fixed dose-ascending sequence"
11104244|NCT04046822|Active Comparator|Active drug|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
11104245|NCT04046822|Placebo Comparator|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
11104246|NCT04046809|Experimental|Study Treatment|500 ml oral solution containing citicoline free acid 50 mg/ml.
11104247|NCT04046809|Placebo Comparator|Placebo|500 ml oral solution indistinguishable from active product in appearance and taste
11104248|NCT04046796||Healthy twin|
11104249|NCT04046796||Effected Twin|Twin with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location.
11104250|NCT04046783||Group A included subjects without a history of C-section|Group A consisted of 47 women without a prior a history of C-section: 24 controls and 23 subjects who used patch. These latest 23 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
11104251|NCT04046783||group B subjects who had already undergone previous C-section|Group B consisted of 46 women already undergone previous C-section: 22 controls and 24 subjects who used patch. These latest 24 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
11104252|NCT04046770|Experimental|Double-Chamber Syringe|Intravenous administration of drugs and flushing with the Double-Chamber Syringe
11104253|NCT04046770|Active Comparator|Classical Syringes|Intravenous administration of drugs and flushing with the classical syringe
11104254|NCT04046744|Active Comparator|BAX|
11104255|NCT04046744|Experimental|BAX-Asso|
11104256|NCT04046731|Experimental|Study Group|Study team is developing a new diagnostic skin testing procedure for patients who receive NMBAs during surgery in order to determine Negative Predictive Values and Non-Irritant Concentrations.
11104257|NCT04046718|Experimental|electroacupuncture|the study group received electroacupuncture stimulation at different points
11104258|NCT04046718|No Intervention|control group|a control group with no intervention
11104259|NCT04046705|Experimental|HLA matched haematopoietic stem cell transplantation|Peripheral blood stem cell from matched HLA related donor.
11104260|NCT04046705|Other|Control arm|Best standard care : Patients will receive the best standard care according to their situation and their previous treatment: initiation of Hydroxyurea, continuation or optimization of the dose of Hydroxyurea, initiation or continuation of TP, initiation of a new drug proved to improve SCD and having authorization to use in France.
11104261|NCT04046692||children in hospital school in contact with outside school|children experience school's lesson with the hospital teacher in the school's room or into their bedrooms and the investigator give before/after the lesson 2 questionnaire (PANAS-C and PH-C) and the VAS to evaluate the aim's study. Then, the investigator asks the children to make 2 paintings: one about the hospital school experience (what is for him/her the hospital school) and one about the outside school (what he/she do/did outside during school).
11104262|NCT04046692||children in hospital school NOT in contact with outside school|"it's the same of the previous group (children experiencing hospital school still in contact with outside school); the only difference of this group is that children are not in contact with the outside school."
11104263|NCT04046692||hospital teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
11104264|NCT04046692||outside teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
11104265|NCT04046692||Parents|parents have to answer some questions (qualitative interview)
11104266|NCT04046679|Experimental|Bleomycin|Bleomycin Infusion By Tattoo Machine
11104267|NCT04046679|Placebo Comparator|Saline Solution|Saline Infusion by Tattoo Machine
11104268|NCT04046666|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
11104269|NCT04046666|Other|Healthy group|This group will include 40 healthy volunteers.
11104270|NCT04046666|Other|Healthy intervention group|This group will include 40 healthy volunteers, who will receive moxibustion intervention.
11104271|NCT04046653|Experimental|Study arm 1|Allin capsules (x2) and Sulforaphane capsules (x2) once daily for 4 weeks
11104272|NCT04046653|Experimental|Study arm 2|Allin capsules (x2) and placebo capsules (x2) once daily for 4 weeks
11104273|NCT04046653|Experimental|Study arm 3|Sulforaphane capsules (x2) and placebo capsules (x2) once daily for 4 weeks
11104274|NCT04046653|Placebo Comparator|Study arm 4|Placebo capsules (x4) once daily for 4 weeks
11104275|NCT04046640||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
11104276|NCT04046640||Healthy group|This group will include 40 healthy volunteers.
11104277|NCT04046614|Experimental|nintedanib nivolumab|nintedanib-nivolumab combination therapy
11104278|NCT04046601|Experimental|Impedance|every resected tissue will measured by an impedance probe
11104279|NCT04046588|Other|COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
11104280|NCT04046588|Other|Healthy control group|This group will include 40 healthy volunteers.
11104281|NCT04046588|Experimental|Healthy intervention group|This study will include 40 healthy adults. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively.
11104282|NCT04046575|Experimental|IMRT + Carboplatin + Paclitaxel|Concurrent chemoradiation will consist of hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) for 3 weeks with carboplatin and paclitaxel for 3 cycles every 7 days. Endoscopy and (optional) PET/CT within 6-8 weeks post-completion of chemoradiation.
11104318|NCT04046354|Active Comparator|Group B|The group will use radiofrequency ablation equipment to treat benign thyroid nodules.
11104349|NCT04046120|Experimental|Heel not included|he bandage is made by leaving the heel uncovered.
11104283|NCT04046562|Active Comparator|PAW plus standard of care|Each PAW session will include handouts and worksheets to assist with new strategies as well as homework. Strategies taught within PAW will be integrated with the skills taught in weight management. For example, pain diaries will be kept along with food and exercise logs to examine relationships among pain, eating and activity.
11104284|NCT04046562|Placebo Comparator|Pain education plus standard of care|For those randomized into the information-only group, sessions will be delivered in the same manner. Sessions will cover general pediatric pain management but no behavioral or cognitive skills training will be taught.
11104285|NCT04046549|Experimental|Belatacept+VIB4920|Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.
11104286|NCT04046536|Active Comparator|Active rTMS at the LDLPFC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left dorsolateral prefrontal cortex (LDLPFC).
11104287|NCT04046536|Sham Comparator|Sham rTMS at the LDLPFC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LDLPFC.
11104288|NCT04046536|Active Comparator|Active rTMS at the LMC|Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
11104289|NCT04046536|Sham Comparator|Sham rTMS at the LMC|Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
11104290|NCT04046523|Experimental|Healthy Controls|In the first phase of the experiment, 20 healthy controls will test the VO device to determine whether the camera with a CCD or CMOS lens is the most appropriate for use in ICP patients and to synchronize the VO, ECG, PPG, IOP and respiratory signals.
11104291|NCT04046523|Experimental|Transfer Function Estimation|Subjects in the second phase of the experiment (70 subjects total) will be randomized to either Group A or Group B. We anticipate that 25 adult and 10 pediatric (ages 4-17) patients will participate in each group. Individuals in Group A will have two inter-leaved examinations (1-14 days apart). Data from the first examination will serve for SVP-ICP transfer function estimation and data from the second examination will serve for the intra-group verification for the estimated transfer function.
11104292|NCT04046523|Experimental|Intra-Group Verification|Individuals in Group B will undergo one examination. Data from Group B participants will serve as the inter-group re-test verification of the estimated transfer function.
11104293|NCT04046510|Active Comparator|High doses|the patients of this group recieved conventionnal doses of ocytocin after foetal extraction in C section: 5IU in bolus followed by 15IU in continuous infusion
11104294|NCT04046510|Experimental|Intermediate doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 10IU in continuous infusion
11104295|NCT04046510|Experimental|Low doses|the patients of this group recieved after foetal extraction in C section: 2IU in bolus followed by 5 IU in continuous infusion
11104296|NCT04046497|Experimental|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
11104297|NCT04046497|Active Comparator|Usual Care|Usual care provided at CSC clinic
11104298|NCT04046484|Active Comparator|Normal Saline (Dose: Equal volume) + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
11104299|NCT04046484|Experimental|PMZ-1620 + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
11104300|NCT04046471|Other|Individual In-Person|
11104301|NCT04046471|Other|Group Remote|
11104302|NCT04046458|Experimental|EHR Alert|Physician teams will observe the EHR alert as they perform their clinical duties in the EHR.
11104303|NCT04046458|Placebo Comparator|No Alert|Physician teams will perform their clinical duties in the EHR as usual, with no visible alert.
11104304|NCT04046445|Experimental|Cohort 1a|6 patients with stage IV CRC having failed SoC therapies
11104305|NCT04046445|Experimental|Cohort 1b|6 patients with stage IV MSS/MMRp CRC being in SD or PR after first line of SoC (6 months duration at minimum)
11104306|NCT04046445|Experimental|Cohort 2a|5 patients with stage IV MSS/MMRp CRC being in SD or PR after first line of SoC (6 months duration at minimum)
11104307|NCT04046445|Experimental|Cohort 2b|15 patients with stage IV MSS/MMRp hepatic-limited metastatic CRC
11104308|NCT04046432|Experimental|Vigiis 101-LAB|The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial 1. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101-LAB capsule II) containing 10 billion bacteria per capsule for clinical trial 2.
11104309|NCT04046432|Placebo Comparator|placebo|Maltodextrin was used as a placebo.
11104310|NCT04046406|Experimental|Pelvic pain syndromes|Patients with pelvic pain syndromes who will undergo MR neurography-guided cryoanalgesia
11104311|NCT04046393|Experimental|Traditional Chinese Medicine(TCM) group|nasal irrigation with Traditional herbal medicine(licorice) extract-saline isotonic solution
11104312|NCT04046393|Placebo Comparator|Saline control group|nasal irrigation with saline isotonic solution
11104313|NCT04046380||normal lungs|
11104314|NCT04046380||Acute respiratory distress syndrome (ARDS) group|
11104315|NCT04046367|Experimental|Intervention|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, with specific training aimed at increasing physical activity, functional capacity and conditioning of the respiratory musculature (prehabilitation by a physiotherapist)
11104316|NCT04046367|Active Comparator|Control|Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
11104317|NCT04046354|Experimental|Group A|The group will use microwave ablation equipment to treat benign thyroid nodules.
11104517|NCT04044898|Experimental|Low dose|
11104319|NCT04046341|Experimental|Behavioral Sleep Intervention|Parents attend 1-3 one-hour sessions at their primary care office or via telemedicine, where they receive sleep education and work with interventionists to develop strategies to help their child at bedtime.
11104320|NCT04046328|Experimental|"Low Dose ECC Regimen"|ECC at the 1.7 g daily dose, administered BID as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
11104321|NCT04046328|Experimental|"High Dose ECC Regimen"|ECC at the 4.25 g daily dose, administered BID as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
11104322|NCT04046302|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
11104323|NCT04046302|Placebo Comparator|placebo|one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
11104324|NCT04046289||Low Calcium|low calcium milk of 180 ml, twice daily for 24 weeks
11104325|NCT04046289||Regular Calcium|regular calcium milk of 180 ml, twice daily for 24 weeks
11104326|NCT04046289||Probiotic 1|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
11104327|NCT04046289||Probiotic 2|regular calcium milk of 180 ml + probiotic, twice daily for 24 weeks
11104328|NCT04046276|Placebo Comparator|Conventional Physical Therapy|Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
11104329|NCT04046276|Sham Comparator|Medium Intensity Aerobic exercise (50% VO2 max)|Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
11104330|NCT04046276|Experimental|High Intensity Aerobic exercise|Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
11104331|NCT04046263|Experimental|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
11104332|NCT04046250|Experimental|TK112690|TK112690 treatment
11104333|NCT04046250|Placebo Comparator|Placebo|TK112690 formulation
11104334|NCT04046237|No Intervention|Usual treatment - Control group|"The patient is referred to his treating dentist with a diagnosis report of his oral state including his periodontal status.
~The usual care usually includes the extraction of non-preservable teeth, the dental prosthesis to replace them and at least one descaling session."
11104335|NCT04046237|Experimental|Periodontal treatment - Intervention group|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit at M9.
~Briefly, the intervention group includes initial therapy with information on oral hygiene techniques, scaling and surfacing of dental roots. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
11104336|NCT04046224|Experimental|Sequential dose escalation|ST-920 is administered as a single infusion
11104337|NCT04046211|Experimental|Hydrogen exposure|The first two patients will be exposed to 2.4% hydrogen gas in medical air via HFNC for 24 hours. The second two patients will be exposed to the same gas for 48 hours. The final 4 patients will be exposed to the same gas for 72 hours.
11104338|NCT04046198|Experimental|İntervention group|Nurses working at Akdeniz University Hospital became the intervention group. The nurses who accepted to participate in the study were divided into groups of 5-15 people. Pre-test was applied to nurses who accepted the research. Nurses were given 4-hour group trainings. A booklet on the subject prepared by the researchers was given. Three interim interviews were conducted in the subsequent 3-month period. Six separate posters were posted in the clinics. Weekly reminder messages were sent via WhatsApp. At the end of the third month, post-test data were collected from the nurses.
11104339|NCT04046198|Other|Control group|The nurses working in the University of Health Sciences Antalya Training and Research Hospital constituted the control group. Pre-test was applied to nurses who accepted the research. Post test applied 3 months later. A booklet on the subject prepared by the researchers was given after the post test. Group training was conducted to nurses.
11104340|NCT04046185|Experimental|pd-1 inhibitor and progesterone|Toripalimab. 240mg intravenous injection, every 3 weeks, 4 times. Megestrol Acetate Tablets, 160mg, po, once a day.
11104341|NCT04046185|Active Comparator|progesterone|Megestrol Acetate Tablets, 160mg, po, once a day.
11104342|NCT04046172|Experimental|test group|intensive periodontal treatment (IPT)
11104343|NCT04046172|Sham Comparator|control group|Control periodontal treatment (CPT)
11104344|NCT04046159|Active Comparator|Radiotherapy arm|Radiotherapy for ipsilateral whole breast with 50 Gy/25 fractions or 40.05 Gy/15 fractions
11104345|NCT04046159|Experimental|Tamoxifen arm|Tamoxifen 5 mg QD for 10 years
11104346|NCT04046146|Experimental|NIR-ICG MRL|We may ask healthy subjects to return for up to four injection sessions for the study. The first injection session will consist of intradermal injection of ICG into the webspaces of the hand as done in our previous studies followed by NIR camera imaging. The second session will consist of intradermal gadolinium injection and intravenous (IV) iron contrast agent followed by MRI imaging approximately 1 week after the first session. The third session will occur at minimum eight weeks later and entail intra-articular ICG injection in order to evaluate drainage via the lymphatics. The MCP joints will be identified in the non-dominant hand and injected with ICG. Approximately one week later, the fourth session will compromise of intra-articular gadolinium injection and IV iron contrast to confirm lymphatic drainage. The MCP joints of the non-dominant hand will again be identified and injected with gadolinium.
11104347|NCT04046133|Experimental|pembrolizumab|Patients with locally advanced (stage IIIA/B, T3/T4, any N, M0) anal cancer will receive pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT.
11104348|NCT04046120|No Intervention|Heel included|The bandage is made by including the heel as recommended in routine.
11104518|NCT04044898|Experimental|High dose|
11104350|NCT04046107|Experimental|Cohort 1: Cemiplimab (0.3 mg/kg)|Participants will receive cemiplimab 0.3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
11104351|NCT04046107|Experimental|Cohort 2: Cemiplimab (1 mg/kg)|Participants will receive cemiplimab 1 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
11104352|NCT04046107|Experimental|Cohort 3: Cemiplimab (3 mg/kg)|Participants will receive cemiplimab 3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
11104353|NCT04046094|Experimental|IV Ascorbic Acid|IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks
11104354|NCT04046081|Other|Dichloroacetate|Open label study
11104355|NCT04046055|Sham Comparator|Sham|50% of participants will have a unilateral cerebellar montage with the anode (active electrode) three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode (return electrode) on the ipsilateral cheek. 50% of participants will have a bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned (2 mA) on for the 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
11104356|NCT04046055|Experimental|Unilateral, 2 mA|A unilateral cerebellar montage with the anode three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode on the ipsilateral cheek. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
11104357|NCT04046055|Experimental|Bilateral, 2 mA|Bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
11104358|NCT04046055|Experimental|Unilateral, 4 mA|A unilateral cerebellar montage with the anode three cm lateral to the inion on the side ipsilateral to the more PD-affected side and the cathode on the ipsilateral cheek. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
11104359|NCT04046055|Experimental|Bilateral, 4 mA|Bilateral cerebellar tDCS will have both electrodes placed 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
11104360|NCT04046042|Active Comparator|Conventional exercise time|During 12 months subjects will exercise during the first two hours of the hemodialysis session. A virtual reality exercise program will be implemented
11104361|NCT04046042|Experimental|Experimental group|During 12 months subjects will exercise during the last two hours of the hemodialysis session. A virtual reality exercise program will be implemented
11104362|NCT04046029|Experimental|Bivalirudin|
11104363|NCT04046029|Active Comparator|Heparin|
11104364|NCT04046016|Experimental|Subjects|A total of two subjects were enrolled. Those are breast cancer patients.
11104365|NCT04046003|Experimental|Tai Chi intervention|24-form Yang style Tai Chi
11104366|NCT04045990|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. rTMS will be administered in an excitatory pattern as 20Hz. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
11104367|NCT04045990|Sham Comparator|SHAM stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory or language performance, or whether practice effects or other non-specific effects are responsible for any changes in memory or language performance which may be observed.
11104368|NCT04045977|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
11104369|NCT04045977|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
11104370|NCT04045964|Experimental|Motivational advice and free NRT|
11104371|NCT04045964|Active Comparator|Quitline referral|
11104372|NCT04045951|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
11104373|NCT04045951|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
11104374|NCT04045925|Experimental|Taïso practice|6 months of biweekly practice Taïso
11104375|NCT04045912|Experimental|HIVST + AGYW-Friendly Services|"Drug shops in Arm 1 will implement AGYW-friendly services, including a sexual and reproductive health (SRH) product display, a tablet with SRH videos, and a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discretely request free SRH products. They will also provide HIV self-test (HIVST) kits to AGYW customers for free."
11104376|NCT04045912|Active Comparator|HIVST Only|Drug shops in Arm 2 will provide HIVST kits to AGYW customers for free.
11104377|NCT04045899|Active Comparator|ProSeal Laryngeal Mask Airway Group|ProSeal LMA was inserted in 50 patients
11104378|NCT04045899|Experimental|Air-Q LMA Group|Air-Q LMA was inserted in 50 patients
11104379|NCT04045899|Experimental|Ambu AuraGain LMA Group|Ambu AuraGain was inserted in 50 patients
11104380|NCT04045886|Experimental|Online Educational Modules group|anesthesia residents are randomized to watch educational videos which is the intervention.
11104381|NCT04045886|Active Comparator|Reading two research papers group|anesthesia residents are randomized to read 2 research papers which is the active comparator
11104382|NCT04045873|Experimental|ECMO plus IABP|
11104383|NCT04045873|Experimental|IABP|
11104384|NCT04045860|Experimental|CDT for head and neck lymphedema|Complete Decongestive Therapy
11104385|NCT04045860|Other|Standard of Care for head and neck lymphedema|Observation
11104386|NCT04045847|Experimental|CD147-CART|CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
11104387|NCT04045821|Placebo Comparator|Control|Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D&C procedure will be completed.
11104388|NCT04045821|Experimental|Intervention|Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D&C procedure will be completed.
11104389|NCT04045808||CAD(+) group|Participants were included in CAD (+) if they had more than 50% reduction in diameter in one or more major epicardial arteries,
11104390|NCT04045808||CAD(-) group|patients with less than 50% reduction in epicardial artery diameter were enrolled to CAD (-) group
11104391|NCT04045795|Experimental|Dose regimen 1|Isatuximab SC administration dose level 1 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
11104392|NCT04045795|Experimental|Dose regimen 2|Isatuximab SC administration dose level 2 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
11104393|NCT04045795|Experimental|Dose regimen 3|Isatuximab SC administration dose level 3 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
11104394|NCT04045795|Experimental|Dose regimen 4|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
11104395|NCT04045795|Experimental|Dose regimen 5|Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle
11104396|NCT04045782|Other|single arm|Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
11104397|NCT04045769|Experimental|Study Treatment 1|Saroglitazar magnesium 4 mg
11104398|NCT04045769|Experimental|Study treatment 2|Saroglitazar magnesium 20 mg
11104399|NCT04045769|Placebo Comparator|Placebo|Placebo
11104400|NCT04045769|Active Comparator|Active Control|Moxifloxacin 400 mg
11104401|NCT04045756|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
11104402|NCT04045743|Experimental|Bermekimab (MABp1)|
11104403|NCT04045743|Experimental|Placebo|
11104404|NCT04045730|Experimental|Patients with metastatic pancreatic ductal adenocarcinoma|Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma, and all patients must have at least 15 unstained slides of formalin fixed paraffin embedded (FFPE) tumor tissue available or a pre-treatment core needle biopsy will be required as outlined in section 7.1.2.7. All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab in 4-week cycles.
11104405|NCT04045717|Experimental|Hypo-FLAME 2.0|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
11104406|NCT04045678|Experimental|LY03003|
11104407|NCT04045678|Placebo Comparator|Placebo|
11104408|NCT04045665|Active Comparator|Antiplatelet Therapy|Antiplatelet-only strategy
11104409|NCT04045665|Active Comparator|Oral Anticoagulant|OAC-based strategy
11104410|NCT04045652||Kenyan women|Kenyan women, some HIV-infected and some HIV-uninfected, VIA negative at enrollment.
11104411|NCT04045639||Intervention arm|The AF risk prediction algorithm will be run on patient records within the Egton Medical Information Systems (EMIS) data base, in order to identify patients at risk of developing AF
11104412|NCT04045639||Control arm|Patients may be diagnosed with AF through routine clinical practice only
11104413|NCT04045626|Active Comparator|Transepithelial accelerated cross-linking|"Paracel is instilled 1 drop every 1.5 minutes for 4.5 minutes then vibex-xtra is instilled 4 drops at 5.5 minutes followed by 1 drop at 6.5 minutes for a total soak time of 11 minutes followed by ultraviolet-A UVA irradiation with intended irradiance of 45mW/cm2 for 2.4 minutes"
11104414|NCT04045626|Active Comparator|Epithelium-off accelerated cross-linking|"Vibex-rapid is instilled every 2 minutes for 10 minutes followed by ultraviolet-A UVA irradiation of 30 mW/cm2 for 4 minutes"
11104415|NCT04045613|Experimental|Derazantinib [Substudy 1]|Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib.
11104416|NCT04045613|Experimental|Derazantinib + Atezolizumab: Dose finding [Substudy 2]|Dose finding and dose expansion in patients with solid tumor.
11104417|NCT04045613|Experimental|Derazantinib +/- Atezolizumab: First line [Substudy 3]|Patients with urothelial cancer will be randomized for first-line treatment with either derazantinib alone or the recommended phase 2 dose (RP2D) for derazantinib-atezolizumab.
11104418|NCT04045613|Experimental|Derazantinib +/- Atezolizumab: Second line [Substudy 4]|Patients with urothelial cancer progressing after prior FGFR inhibitor treatment will be randomized to receive either derazantinib alone or the RP2D for derazantinib-atezolizumab.
11104419|NCT04045600|Experimental|Mult FCT/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
11104420|NCT04045600|Experimental|Mult FCT + Stimulus Fading/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
11104421|NCT04045587||Severe Asthma Participants|Participants with severe asthma classified at GINA Step 4 and uncontrolled in terms of their symptoms and exacerbations or GINA Step 5.
11104422|NCT04045574|Experimental|DAMP1 :|Single arm trial comparing a conventional technique with an experimental one, within the same patient.
11104423|NCT04045548|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 2 hours before IUD insertion.
11104424|NCT04045548|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 2 hours before IUD insertion.
11104425|NCT04045535|Experimental|Intervention group|Intervention with nurse and patients
11104426|NCT04045535|Active Comparator|Usual care|Usual clinical care based on current clinical practice guidelines.
11104427|NCT04045509|Other|Group 'young age'|Group 'young age': 18 - 30 years of age; healthy eyes
11104428|NCT04045509|Other|Group 'advanced age'|Group 'advanced age': 50 - 70 years of age; healthy eyes
11104429|NCT04045496|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
11104430|NCT04045483|Experimental|VR based cognitive training|Participants perform the VR based cognitive training under the supervision of a research nurse or psychologist for 30 min per session, twice per week, over the 6-week intervention period.
11104431|NCT04045483|No Intervention|Usual care|Participants take some medication for risk factors and cognitive impairment and receive health advice as a usual care.
11104432|NCT04045470|Experimental|Initial Cohort|"Patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma
~Mandatory skin biopsy for corollary studies will be obtained
~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)"
11104433|NCT04045470|Experimental|Expansion Cohort|"Only patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma who plan to start systemic therapy as part of standard of care
~Mandatory skin biopsy for corollary studies will be obtained
~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)
~Participants will receive standard of care therapy and clinical course followed
~Participants will undergo standard of care therapy as previously determined by treating oncologist and/or dermatologist prior to enrollment to study
~Participants will not be assigned any treatment intervention"
11104434|NCT04045457|Other|SIngle arm|Single arm, intervention All recipients were treated with dry needling technique into active myofascial trigger points They received 1 treatment weekly for three weeks.
11104435|NCT04045444|Experimental|women non active young people|women between 18 and 30 years practice less than 1h of physical activity per week
11104436|NCT04045444|Experimental|men non active young people|men between 18 and 30 years practice less than 1h of physical activity per week
11104437|NCT04045444|Experimental|women non active old people|women between 60 and 85 years practice less than 1h of physical activity per week
11104438|NCT04045444|Experimental|men non active old people|men between 60 and 85 years practice less than 1h of physical activity per week
11104439|NCT04045444|Experimental|women active old people|women between 60 and 85 years practice at least 3h of physical activity per week
11104440|NCT04045444|Experimental|men active old people|men between 60 and 85 years practice at least 3h of physical activity per week
11104441|NCT04045444|Experimental|women with parkinson's disease|women between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
11104442|NCT04045444|Experimental|men with parkinson's disease|men between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
11104443|NCT04045431|Experimental|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
11104444|NCT04045431|Active Comparator|Synvisc-One|Intra-articular injection with Synvisc-One (hyaluronic acid)
11104445|NCT04045418||COPD group|This group will include 40 patients with chronic obstructive pulmonary disease (COPD).
11104446|NCT04045418||Healthy control group|This group will include 40 healthy volunteers.
11104447|NCT04045418||Healthy intervention group|This group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
11104448|NCT04045405|Experimental|CDR132L|
11104449|NCT04045405|Placebo Comparator|Saline|
11104450|NCT04045392|Experimental|Mediterranean diet group|Mediterranean diet with calorie restriction below 1,500 kcal per day.
11104451|NCT04045392|No Intervention|Conventional diet group|Conventional diet with calorie restriction below 1,500 kcal per day.
11104452|NCT04045379|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
11104453|NCT04045379|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
11104454|NCT04045379|Active Comparator|Estriol|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
11104455|NCT04045353|No Intervention|Standard of care|Subjects will receive standard counseling on obesity as part of routine postpartum care.
11104456|NCT04045353|Active Comparator|Low carbohydrate diet education|Subjects will receive educational materials regarding a low carbohydrate diet in addition to the standard counseling on obesity as part of routine postpartum care.
11104457|NCT04045353|Active Comparator|Low carbohydrate diet education with behavioral component|Subjects will receive in person instruction regarding a low carbohydrate diet as part of a 12 week course, in addition to receiving educational materials regarding a low carbohydrate diet and the standard counseling on obesity as part of routine postpartum care.
11104458|NCT04045327|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
11104459|NCT04045327|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
11104460|NCT04045314|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the long-term effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study.
11104519|NCT04044885|Experimental|Nap|After each night with a 6.5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
11104461|NCT04045301|Experimental|Omalizumab 16 mg/kg|"Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks.
~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
11104462|NCT04045301|Experimental|Omalizumab 8 mg/kg|"Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks.
~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
11104463|NCT04045301|Placebo Comparator|Placebo|"Participants will receive placebo doses for 20 weeks. The doses will be injected every 2 or 4 weeks depending on the weight of the participant.
~Multi-food oral immunotherapy following a symptom-driven schedule will begin 8 weeks after starting study drug."
11104464|NCT04045288|Active Comparator|Standard Implementation|All schools in SWITCH receive training through webinars and an in-person conference to learn about the defining elements and school wellness programming in general. Consistent with the standard implementation, schools were added to the online content management system (CMS) and were given access to an online community of practice (CoP) to interact with other schools / teachers in the study. Schools were provided with resources and program materials (i.e. educational modules, trinkets, posters, etc.) but were given autonomy with regard to how they were used within their school. Weekly updates through the online CMS, the CoP, and via direct email correspondence provided information about the weekly corresponding weekly themes, implementation tips, recommended module activities to incorporate, upcoming evaluation needs, important SWITCH dates, and other program reminders.
11104465|NCT04045288|Experimental|Enhanced Implementation|The 'Enhanced' implementation strategy provided schools with the same training, access and resources as the standard SWITCH implementation along with more personalized, web-based training based on motivational interviewing (MI) techniques and feedback throughout the implementation process. The supplemental support was provided through participation in two online 'checkpoint sessions' that helped schools self-assess their use of the recommended quality elements and setting-specific best practices. The sessions used principles of motivational interviewing (MI) to promote autonomy and motivation for school change through the process. Schools were also provided with information about how to capitalize on support from local 4H program leaders in their county.
11104466|NCT04045275|Experimental|Calm|"The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete 7 days of Calm meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails."
11104467|NCT04045275|No Intervention|Control|This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.
11104468|NCT04045249|No Intervention|1st Group|Children were treated as per standard CMAM protocols; provided RUTF until MUAC reaches 11.5 cm
11104469|NCT04045249|Experimental|2nd Group (1st Intervention group)|Children were initially provided RUTF until MUAC reach 11 cm then 50 % calories were provided from RUTF and 50% calories from home based food
11104470|NCT04045249|Experimental|3rd Group (2nd Intervention)|Children were initially provided RUTF until MUAC reach 11 cm then 100 % calories provided from home based food
11104471|NCT04045236||Non metastatic rectal cancer|Patients receiving the diagnosis of non metastatic rectal cancer and the indication for a curative treatment will be enrolled in the registry. The study population will consist of all the patients enrolled in the participating centres from the start of the rectal cancer registry on.
11104472|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
11104473|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
11104474|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
11104475|NCT04045210|No Intervention|No Intervention|
11104476|NCT04045210|Experimental|Doula|
11104477|NCT04045210|Experimental|Psychologist|
11104478|NCT04045197|Experimental|Intervention group|In the intervention group; informed consent forms, Relaxation Focused Nursing Care and routine nursing care in the hospital were performed. Then data collection tools were applied.
11104479|NCT04045197|No Intervention|Control group|Women in the control group received routine nursing care in the hospital and data collection tools were applied at the same hours as the intervention group.
11104480|NCT04045184||B-FED|Clients of the Birmingham AIDS Outreach Food and Education Delivery (B-FED) program who are also patients at the 1917 Clinic.
11104481|NCT04045184||non B-FED|Patients at the 1917 Clinic who have chosen not to participate in B-FED at this time.
11104482|NCT04045145|Experimental|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
11104483|NCT04045132|Active Comparator|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
11104484|NCT04045132|Experimental|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
11104485|NCT04045119|Experimental|Before-and-after|54 Healthy adults 18 years of age or older at the visit or will receive the first application and will be evaluated according to the objectives defined in the study (short-term data) and to evaluate the longterm effects, two other visits will be made at intervals of 2 weeks to evaluate the impact of topical skin application according to the parameters defined in the study
11104486|NCT04045106|Experimental|PNF pattern|"PNF patterns were performed using Dynamic of reversals technique which is characterized as active motion alternating from one direction (agonist) to the opposite (antagonist) without relaxing. The cervical patterns consisted of
~Cervical flexion with right rotation followed by extension with left rotation.
~Cervical flexion with left rotation followed by extension with right rotation."
11104487|NCT04045106|Experimental|PNF stretching|PNF stretching was done using contract-relax-antagonist contract (CRAC) technique for cervical flexors, extensors, right and left lateral flexors, right rotators and left rotators.
11104488|NCT04045106|Sham Comparator|control|Participants allocated to the control group received ineffective passive ROM.
11104489|NCT04045093|Experimental|Dabigatran etexilate|Subjects randomized into this group will be prescribed with either Dabigatran 150mg or Dabigatran 110mg (twice daily) according to creatinine clearance level, twice daily) for stroke prevention.
11104490|NCT04045093|Active Comparator|Warfarin|Subjects randomized into this group will be prescribed with Warfarin with dosage adjustment according to INR level (targeting to INR 2-3) for stroke prevention.
11104491|NCT04045080|Experimental|AMADEO Training|Twenty PD patients with hand bradykinesia will be treated with the AMADEO® system. They will undergo 15 training sessions, 5 a week for 3 weeks, each session lasting about 60 minutes. During each session, both the hands will be treated using the endeffector in its active and active-assisted modality.
11104492|NCT04045080|Active Comparator|OT training|"Twenty control subjects (PD patients) will be treated with traditional rehabilitation focused on fine hand-finger movement skills. The patients in this group will undergo the same amount of treatment.
~Both the groups will be trained with conventional physiotherapy concerning postural, balance and gait."
11104493|NCT04045067||Group 1|A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
11104494|NCT04045067||Group 2|A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
11104495|NCT04045067||Group 3|A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
11104496|NCT04045054|Other|Intervention|The Link Team follows up with the participants for 6 months after they discharge from the hospital
11104497|NCT04045041|Experimental|Treatment group|10 week internet-based acceptance and commitment therapy
11104498|NCT04045041|No Intervention|Control group|Waiting-list control.
11104499|NCT04045028|Experimental|Arm A (Phase Ia)|Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg Tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).
11104500|NCT04045028|Experimental|Arm B (Phase Ia)|Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg Tiragolumab by IV infusion Q3W.
11104501|NCT04045028|Experimental|Arm C (Phase Ib)|Participants with R/R MM will receive 600 mg Tiragolumab Q3W + Daratumumab by subcutaneous (SC) injection.
11104502|NCT04045028|Experimental|Arm D (Phase Ib)|Participants with R/R NHL will receive 600 mg Tiragolumab Q3W + Rituximab by IV infusion and SC injection (optional).
11104503|NCT04045015|Active Comparator|glycyrrhizic acid 1.5 mg/kg body weight|Liqourice corresponding to 1.5 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
11104504|NCT04045015|Active Comparator|glycyrrhizic acid 3.0 mg/kg body weight|Liqourice corresponding to 3.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
11104505|NCT04045015|Active Comparator|glycyrrhizic acid 6.0 mg/kg body weight|Liqourice corresponding to 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
11104506|NCT04045002|Experimental|Intervention|Intervention group receive 'MyPinkMom' educational intervention delivered through WhatsApp application for 2 weeks and routine antenatal care.
11104507|NCT04045002|No Intervention|Control|Control group receive information on anaemia in pregnancy placed at respondents' antenatal card and routine antenatal care
11104508|NCT04044989|Experimental|Root resorption (total)|The resorption cavities on the root surface were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
11104509|NCT04044989|Experimental|Root resorption (local)|The resorption cavities on the root surface (palatal, buccal, distal and mesial root surfaces) were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
11104510|NCT04044976|Experimental|Treated infants|Infants who will receive caffeine in the delivery room.
11104511|NCT04044963|Experimental|Exercise Group|All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The exercise intervention is prescribed based on the FITT principle: frequency, intensity, time and type. The 10-point Rating of Perceived Exertion (RPE) scale, which has been well correlated to target HR levels, will be used to monitor exercise intensity levels throughout the intervention, with participants instructed to maintain their intensity level at 3-5 during exercise sessions. Participant progression will be individualized and based on their subjective perceived intensity level using the RPE scale. In person instruction, from a member of the research team with standard first aid and CPR-C training, and an instructional handout and exercise log will be provided, as well as exercise resistance bands to perform resistance exercises.
11104512|NCT04044963|No Intervention|Control Group|This will consist of regular care, which is standard procedure.
11104513|NCT04044950|Experimental|Arm 1|Approximately 3x10^8 E7 TCR T cells (based on the number of disease sites the patient has) will be injected on day 0.
11104514|NCT04044937|Experimental|Diagnostic FET PET|Participants receive F-18 fluoroethyltyrosine (FET) injected intravenously over approximately 1 minute and receive a single PET image lasting up to 40 minutes.
11104515|NCT04044911|Active Comparator|Tea making followed by stepping|Five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (CogWatch) is followed after a 3-week break by a control condition in which participants receive five 1-hour weekly stepping training sessions.
11104516|NCT04044911|Active Comparator|Stepping followed by tea making|A control condition comprising five 1-hour weekly stepping training sessions is followed after a 3-week break by five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (COgWatch)
11104520|NCT04044885|No Intervention|No nap|After each night with a 8-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead have free time.
11104521|NCT04044872|Experimental|Single Arm:Diagnosing Cardiotoxicity when on Radiation therapy|
11104522|NCT04044859|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
11104523|NCT04044846|Experimental|The recipients of the home-based physical activity program|Frail OAs will be asked to fill out the Vitality Plus Scale at the beginning of the implementation phase (baseline) by a research assistant over the telephone. At the end of the 6-month implementation phase, the research assistant will administer the survey again (post-intervention).
11104524|NCT04044833||intervention|(n=63)
11104525|NCT04044833||control|(n=65)
11104526|NCT04044820|Active Comparator|Standardized Discharge Prescription|Based on a previous study examining mean number of opioid pills used by patients undergoing elective, unilateral hand and forearm surgery
11104527|NCT04044820|No Intervention|Usual Discharge Prescription|Routine standard of care involves prescription for opioids at the discretion of the surgical team
11104528|NCT04044794|Active Comparator|Standard Care|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a monetary gift of $60 that can be used to purchase health-promoting supplies to support weight management.
11104529|NCT04044794|Experimental|Daily Self-Weighing|Participants randomly assigned to this arm will receive standardized weight management educational materials plus a commercially available wireless scale. Participants will be instructed to weigh daily and view their weight on the scale's digital display.
11104530|NCT04044781|Experimental|Test Group|Stage 1 safety assessments will be performed before and after the administration of a single, 185 MBq (5mCi) dose of T2310 in up to three healthy volunteers. Stage 2 will evaluate the relationship between plasma concentration of BPN14770, an investigational PDE4D modulator, and brain target occupancy in up to six healthy volunteers.
11104531|NCT04044768|Experimental|Autologous genetically modified ADP-A2M4|
11104532|NCT04044755|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
11104533|NCT04044755|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
11104534|NCT04044742|Experimental|Resiniferatoxin|12.5 ug of Resiniferatoxin in 5 mL volume is administered as a one-time dose, intra-articularly
11104535|NCT04044742|Placebo Comparator|Placebo|Placebo formulation in 5 mL volume administered intra-articularly
11104536|NCT04044729|Active Comparator|Cannabidiol|"Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
~Other Names:
~CBD"
11104537|NCT04044729|Placebo Comparator|Placebo|"Drug: Placebos An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
~Other Names:
~placebo"
11104538|NCT04044716|Experimental|Auricular acupressure Group|The Auricular acupressure (AA) nurses will place the acupressure pellet pads on the participant post-operatively.
11104539|NCT04044716|Active Comparator|Standard of care Group|
11104540|NCT04044703|Experimental|Model-based vancomycin dosing|Participants will receive model-based intermittent intravenous vancomycin dosing as calculated by the dosing calculator available on a web application. Participants will then have routine therapeutic drug monitoring and linear dose adjustments.
11104541|NCT04044690|Experimental|IgPro20|human immunoglobulin G administered subcutaneously
11104542|NCT04044690|Placebo Comparator|Placebo|human albumin solution administered subcutaneously
11104543|NCT04044677|Experimental|tDSC-active|"The TDCS-active will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend) during the practice of VR games, TDCS-active will be performed with a current of 1 mA and 20 min of duration (20 seconds of ramp-up and ramp-down). The stimulation target will be the M1 area, choosing the more functional side of the participant (C3 or C4).
~This group will perform the tDCS-sham after one-month washout."
11104544|NCT04044677|Sham Comparator|tDCS-sham|"The TDCS-sham will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend). However, the electrodes will be positioned at the same sites of the tDCS-active and the device will be switched on for 20 seconds (with ramp-up and ramp-down), giving the children the initial sensation of the 1 mA current, but with no stimulation administered during the rest of the time. This sham protocol is already programmed in the device prior to data collection.
~This group will perform the tDCS-active after one-month washout."
11104545|NCT04044664|Placebo Comparator|Placebo|
11104546|NCT04044664|Experimental|NYX-783 Low Dose|
11104547|NCT04044664|Experimental|NYX-783 High Dose|
11104548|NCT04044651|Experimental|Lenvatinib plus nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w+ lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
11104549|NCT04044651|Active Comparator|Lenvatinib|Lenvatinib 12 mg (or 8 mg) Po once daily
11104550|NCT04044638|Experimental|Young Group|"Young women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.
~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
11104551|NCT04044638|Experimental|Middle-aged Group|"Middle-aged women women who underwent 8 weeks of training and had their blood pressure checked at baseline and after 4 and 8 weeks of training.
~Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale."
11104552|NCT04044625|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
11104553|NCT04044625|Active Comparator|Low-intensity NPPV|The patients will receive low-intensity noninvasive positive pressure ventilation.
11104554|NCT04044612|Experimental|Medial Unloader Brace|
11104555|NCT04044599|Experimental|Study|THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS
11104556|NCT04044599|No Intervention|Control|Control group
11104557|NCT04044573|Experimental|ECHOLASER X4 Socratelite|Optic fiber of 300um will be inserted at a distance of 8-10mm from the urethra. Each ablation lasts 6 minutes. Each fiber ablates at an energy of 1800J with a power of 2-3W. Treatment lasts for about 30 minutes.
11104558|NCT04044560|Experimental|Blinatumomab Treatment|Eligible patients with detectable MRD will taper immunosuppressive medications, if applicable, and undergo treatment with blinatumomab. The duration of each cycle of blinatumomab treatment is 6 weeks. Adult and pediatric patients will be treated for 4 weeks followed by a 2-week treatment free period. Patients may receive up to 4 cycles total of blinatumomab therapy.
11104559|NCT04044547|Experimental|LY03003|
11104560|NCT04044547|Placebo Comparator|Placebo|
11104561|NCT04044534|Experimental|Intranasal insulin|Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).
11104562|NCT04044534|Experimental|Placebo|Subjects in this arm will receive placebo.
11104563|NCT04044521|Experimental|Academic detailing only|Clinicians will attend an educational meeting and receive audit and feedback reports for 18 months.
11104564|NCT04044521|Experimental|Academic detailing+practice facilitation|"Clinicians of this group will attend an educational meeting and receive a monthly audit and feedback report for 18 months.
~At month 3, clinics will be randomized to receive practice facilitation. Clinics will be asked to follow-up with the facilitators via phone or video chat monthly for months 4-6, then quarterly for months 7-18."
11104565|NCT04044521|Experimental|Academic detailing+practice facilitation+physician peer consul|Clinicians will receive academic detailing at month 0 and practice facilitation at month 3. At month 6, clinics will be randomized to receive physician peer consulting. Clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant.
11104566|NCT04044521|Experimental|Academic detailing+physician peer consulting|"Clinicians of this group will attend an educational meeting and will receive a monthly audit and feedback report for 18 months.
~At month 6, clinicians of the clinics will meet up to 4 times, quarterly, with the physician peer consultant."
11104567|NCT04044508|Active Comparator|Interventional diet|A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
11104568|NCT04044508|Placebo Comparator|Placebo diet|A placebo diet (over 100 g of carbohydrates per day)
11104569|NCT04044495|Experimental|Sample of 100 persons included in AMI / AMImage 2|Sample of 100 persons included in AMI / AMImage 2
11104570|NCT04044469|Experimental|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
11104571|NCT04044469|Experimental|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
11104572|NCT04044469|Experimental|Control group|This group does not receive additional information after the doctor's report.
11104573|NCT04044456|Experimental|GMT plus attention|GMT consists of 2-hour, 10 weekly sessions using an interactive Power Point presentations. Attention training consists of 2-hour computerized attention training using Attention Process Training III and Brain HQ.
11104574|NCT04044456|Placebo Comparator|BHW plus movies|Brain Health Workshop consists of 2-hour, 10 weekly sessions using Power Point presentations and national geographic movies (2-hour, 10 weekly sessions).
11104575|NCT04044430|Experimental|Treatment (encorafenib, binimetinib, nivolumab)|Patients receive encorafenib PO QD on days 1-28, binimetinib PO BID on days 1-28, and nivolumab IV on day 1. Cycles repeat every 28 days for a maximum of 24 cycles of treatment in the absence of disease progression or unacceptable toxicity.
11104576|NCT04044417|Placebo Comparator|open flap debridement only|surgical treatment of periodontal defects
11104577|NCT04044417|Active Comparator|curcumin and simvastatin|open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
11104578|NCT04044417|Active Comparator|EDTA, curcumin and simvastatin|open flap debridement followed by 24% EDTA root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).
11104579|NCT04044404||A on C group|Acute on Chronic Kidney Disease patients
11104580|NCT04044404||functional delayed graft function group|patients with functional delayed graft function(fDGF) after kidney transplantation
11104581|NCT04044404||Normal|without functional kidney injury
11104582|NCT04044391||Intention to Treat: Cardiac Catheterization|All patients meeting inclusion criteria and scheduled to undergo cardiac catheterization will undergo a CardioFlux magnetocardiogram (MCG) to determine presence of patterns which indicate myocardial ischemia.
11104645|NCT04044001|Experimental|Stage 2 - Arm 2 (BTZ medium)|Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
11104583|NCT04044391||Post Percutaneous Coronary Intervention|All patients found to have significant coronary artery obstruction seen via angiography +/- fractional flow reserve (FFR) or instant wave-free ratio (iFR) and who receive a catheter based intervention will have a post-procedure CardioFlux MCG scan. Follow up over the next 30 and 180 days will be performed to determine if a persistent pattern suggesting residual ischemia will correlate with an increased incidence of major cardiac adverse events (MACE).
11104584|NCT04044378|Experimental|Arm A: famitinib and camrelizumab|"In the dose-defining phase I portion, camrelizumab was given at a fixed dose of 200mg Q2W, while the de-escalated 3+3 design was used to detect the recommended dose of famitinib from an initial level of 15mg orally taken daily. Recommended phase 2 dose (RP2D) was defined as the highest dose at which no more than 30% patients experience a DLT in the first two courses.
~In the phase II portion, famitinib will be orally taken daily with RP2D together with camrelizumab intravenous infusion at a dose of 200 mg over 30 minutes, once every two weeks (Q2W), 4 weeks (28 days) as one treatment cycle."
11104585|NCT04044378|Active Comparator|Arm B: famitinib alone|Only phase II portion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle.
11104586|NCT04044378|Experimental|Arm C: Famitinib and Ifofamide|Only phase II protion (Phase I have been completed): famitinib will be 20mg orally taken daily, 4 weeks (28 days) as one treatment cycle together with ifofamide 1800 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 and 15-17 of each 28-day cycle for a total of 5 cycles.
11104587|NCT04044365||1/Project 1 Child/parent-proxy|Children age 5-7 with cGVHD and their parent/guardian, n=20 child/parent dyads
11104588|NCT04044365||2/Project 1 Child/parent-proxy|Children age 8-12 with cGVHD and their parent/guardian, n=20 child/parent pairs
11104589|NCT04044365||3/Project 1 Child/parent-proxy|Children age 13-17 with cGVHD and their parent/guardian, n=20 child/parent pairs
11104590|NCT04044365||4/Project 2 Child/parent-proxy|Children age 5-7 with cGVHD and their parent/guardian, n=40 child/parent pairs
11104591|NCT04044365||5/Project 2 Child/parent-proxy|Children age 8-12 with cGVHD and their parent/guardian, n=40 child/parent pairs
11104592|NCT04044365||6/Project 2 Child/parent-proxy|Children age 13-17 with cGVHD and their parent/guardian, n=40 child/parent pairs
11104593|NCT04044352|Experimental|Group 1|2 mL (approximately 5x10^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
11104594|NCT04044339|Experimental|TD-5202 for SAD (Part A)|6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive TD-5202
11104595|NCT04044339|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive placebo
11104596|NCT04044339|Experimental|TD-5202 for MAD (Part B)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-5202
11104597|NCT04044339|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo.
11104598|NCT04044326|Experimental|microwave ablation (MWA)|20 patients with liver cancer, considered for local treatment of liver tumors of size measuring <5 cm and without any signs of extra-hepatic metastasis, will be enrolled to be treated with microwave ablation (MWA)
11104599|NCT04044313|Experimental|HAIC plus Lenvatinib and Toripalimab|Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
11104600|NCT04044300|Experimental|Operative|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level.
11104601|NCT04044300|Experimental|Non-operative|Continued pain management and physical therapy
11104602|NCT04044287|Active Comparator|Intervention|200 micrograms of Misoprostol applied sublingually together with standard parenteral oxytocic therapy
11104603|NCT04044287|Placebo Comparator|Placebo|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy micrograms of misoprostol
11104604|NCT04044274|Experimental|IOPstim|
11104605|NCT04044261|Experimental|Study Arm|Single open-label study arm. All participants are enrolled into this arm.
11104606|NCT04044248||TIPS-obliteration|Patients undergoing combined transjugular intrahepatic portosystemic shunt (TIPS) creation plus transvenous obliteration for the treatment of gastric varices (GVs).
11104607|NCT04044235|Experimental|PrEP Cohort|AGYW HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.
11104608|NCT04044235|No Intervention|HIV Incidence|HIV Incidence Cohort: In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence.
11104609|NCT04044222|Experimental|Treatment (Sintilimab, etoposide, ifosfamide, carboplatin)|Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
11104610|NCT04044222|Experimental|Treatment (placebo, etoposide, ifosfamide, carboplatin)|Patients receive placebo IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Placebo in combination with ICE chemotherapy repeats every 21 days for 6 courses.
11104611|NCT04044209|Experimental|Patients receiving nivolumab and ivosidenib|"Patients who meet eligibility criteria will initiate therapy with the IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
~On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle. Patient will be treated until progression, transplant or unacceptable toxicity. The patient will be continually monitored on therapy and will undergo scheduled response assessments to evaluate response."
11104646|NCT04044001|Experimental|Stage 2 - Arm 3 (BTZ low)|Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
11104706|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)
~Placebo is a transdermal patch, applied weekly for 24 weeks"
11104612|NCT04044183|Experimental|Active Brains|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
11104613|NCT04044183|Placebo Comparator|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
11104614|NCT04044170|Experimental|Poziotinib|"Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC
~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"
11104615|NCT04044144|Experimental|Probiotic Dietary Supplement|Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days
11104616|NCT04044131|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
11104617|NCT04044131|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
11104618|NCT04044118|Experimental|Caloric Restriction|3-week low calorie diet
11104619|NCT04044105|No Intervention|No Education|Patients in this arm receive no education regarding how to dispose of their opiate medication
11104620|NCT04044105|Experimental|Pamphlet education|Patients receive an educational pamphlet only, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment.
11104621|NCT04044105|Experimental|Pamphlet education + texts|Patients receive an educational pamphlet, to be given at the preoperative teaching class, prior to their standard 3-week postoperative clinic appointment, and prior to their standard 6-week postoperative clinic appointment. In addition, 3 automated text messages sent at those same time points.
11104622|NCT04044092|Active Comparator|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization, Cervical Spine strengthening exercises
11104623|NCT04044092|Experimental|ELDOA stretching exercise|ELDOA stretching exercise protocol along with Conservative physical therapy
11104624|NCT04044079|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
11104625|NCT04044079|Active Comparator|misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
11104626|NCT04044079|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
11104627|NCT04044053|Experimental|Relative Bioavailability|Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state
11104628|NCT04044053|Experimental|Fasted State|Comparison of 400 mg MR in fed and fasted states
11104629|NCT04044040|Experimental|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
11104630|NCT04044027|No Intervention|Control Group|
11104631|NCT04044027|Experimental|Intervention Group|
11104632|NCT04044014|Active Comparator|Arm A|Left arm: Gellan sheet; Right arm: Mepitel One.
11104633|NCT04044014|Active Comparator|Arm B|Left arm: Mepitel One; Right arm: Gellan sheet.
11104634|NCT04044014|Active Comparator|Arm C|Left arm: Gellan fluid gel; Right arm: Mepitel One.
11104635|NCT04044014|Active Comparator|Arm D|Left arm: Mepitel One; Right arm: Gellan fluid gel.
11104636|NCT04044001|Experimental|Stage 1 - Cohort 1 (BTZ 250)|Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
11104637|NCT04044001|Experimental|Stage 1 - Cohort 2 (BTZ 500)|Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
11104638|NCT04044001|Experimental|Stage 1 - Cohort 3 (BTZ 750)|Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
11104639|NCT04044001|Experimental|Stage 1 - Cohort 4 (BTZ 1000)|Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
11104640|NCT04044001|Experimental|Stage 1 - Cohort 5 (BTZ 1250)|Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
11104641|NCT04044001|Experimental|Stage 1 - Cohort 6 (BTZ 1500)|Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
11104642|NCT04044001|Experimental|Stage 1 - Cohort 7 (BTZ 1750)|Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
11104643|NCT04044001|Experimental|Stage 1 - Cohort 8 (BTZ 2000)|Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
11104644|NCT04044001|Experimental|Stage 2 - Arm 1 (BTZ high)|Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
11104921|NCT04042064||TIVA (total intravenous anesthesia)|Patient anesthetised with total total intravenous anesthesia.
11104647|NCT04044001|Active Comparator|Stage 2 - Arm 4 (control)|"Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.
~The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening:
~participants weighing 38 - 54 kg: 3 tablets
~participants weighing 55 - 70 kg: 4 tablets
~participants weighing >70 kg: 5 tablets"
11104648|NCT04043975||Patients with metastatic RCC|Patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) with intermediate or poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, who will be treated with Nivolumab + Ipilimumab for the first time
11104649|NCT04043962|Experimental|Web-based CBT (Web-MAP)|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
11104650|NCT04043949||Normal|healthy subjects
11104651|NCT04043949||Dry eye group|patients with dry eye
11104652|NCT04043949||Dry eye after treatment|patients with dry eye after treatment
11104653|NCT04043936|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions."
11104654|NCT04043936|Sham Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a CBM task with a neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
11104655|NCT04043936|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
11104656|NCT04043923|Experimental|Norketotifen|Norketotifen oral capsules, once daily for 5 days
11104657|NCT04043923|Placebo Comparator|Placebo|Placebo oral capsules, once daily for 5 days
11104658|NCT04043910|Experimental|Single-sided deaf group|30 children will be included in this group
11104659|NCT04043910|Active Comparator|Normal hearing group|30 children will be included in this group
11104660|NCT04043897|Experimental|Drug|Patients will receive open-label rifaximin 550mg tid x 4 weeks.
11104661|NCT04043884|Experimental|sEmg Biofeedback training|8-week exercise program, twice a week, with emg biofeedback training.
11104662|NCT04043884|Active Comparator|Exercises|8-week exercise program, twice a week.
11104663|NCT04043871||Patients with renal insufficiency|
11104664|NCT04043858|Experimental|Midodrine daily|Midodrine hydrochloride 2.5 mg tab once per day
11104665|NCT04043845|Experimental|LY3214996+Ibrutinib|"LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle
~Ibrutinib will be administered by mouth once daily continuously throughout each treatment cycle."
11104666|NCT04043819|Experimental|PSC-01|All study participants will receive intraarticular injection of the investigational biological product, PSC-01.
11104667|NCT04043806|Experimental|Open-Label Triple Combination|Subjects will receive ELX/TEZ/IVA TC in the morning and IVA as mono tablet in the evening.
11104668|NCT04043780|Experimental|Decompression prototype splint|The patients of this group will wear the decompression prototype splint.
11104669|NCT04043780|Active Comparator|standard splint|The patients of this group will wear a standard splint.
11104670|NCT04043767||Pediatric patients aged between 1-8 years|Pediatric patients aged between 1-8 years who scheduled for general anesthesia in elective surgery. Additional physical examinations which were including thyromental distances, hyomental distances and neck circumferences, was performed at one day prior surgery. Intubation was done by general anesthesiologist in order to grade the laryngoscopic view.
11104671|NCT04043754|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
11104672|NCT04043754|Active Comparator|GTR treated patients|"Periodontal surgery with MEMBRANE is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers ; then, ABG will be applied alternatively with MEMBRANE into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositioned and sutures completed by interrupted sutures."
11104673|NCT04043741|Experimental|Dry Needling|Dry needling (04 Sessions) and exercises
11104674|NCT04043741|Active Comparator|Sustain Pressure|sustained pressure and Exercises
11104675|NCT04043728|Experimental|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
11105024|NCT04041310|Experimental|Cohort B. Expansion high dose|Subjects treated with RP2D of GAd20-209-FSP prime and MVA-209-FSP
11104676|NCT04043728|Experimental|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
11104677|NCT04043728|Experimental|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
11104678|NCT04043715|Other|Comparison of transcutaneous & epidural stimulation|Comparison of transcutaneous vs epidural electrical stimulation
11104679|NCT04043702||on topiramate|"topiramate, conviban® group vs no treatment ( control group)."
11104680|NCT04043702||on empagliflozine|"empagliflozine, jardiance® vs no treatment ( control group)."
11104681|NCT04043702||on topiramate plus empagliflozine|all patients' vs no treatment ( control group).
11104682|NCT04043702||no treatment|all patients' vs no treatment ( control group).
11104683|NCT04043689|Active Comparator|tACS stimulation of the right frontal region|Active tACS stimulation of the right frontal region (around the right FEF, EEG electrode FC2) at a high-beta frequency (30 Hz) with the goal of visibly training EEG recordings, frontal oscillatory activity and right fronto-parietal synchrony (FEF-IPS, or between FC2 and P4 electrodes) in the high-beta band (~ 30 Hz) which facilitates attentional orientation and visual perception in the two visual hemi-fields, but more particularly the targets present on the blind field of vision.
11104684|NCT04043689|Active Comparator|tACS stimulation of the occipito-parietal region|Active tACS stimulation of the occipito-parietal posterior contralesional region(around the right IPS, EEG electrode P4), at an alpha frequency (10 Hz) which will induce on the EEG recordings an oscillatory drive in the alpha band ( ~ 10Hz) and an increase in synchrony at this frequency band on the stimulated posterior occipital and parietal lobe (EEG electrodes P4 and 02), but also, by transcallosal push-and-pull phenomena, a desynchronization effect of the contralateral posterior occipital and parietal area (EEG electrodes P3 and 01), which will facilitate attention orientation and target detection in the blind visual field of view.
11104685|NCT04043689|Sham Comparator|TACS stimulation of the right frontal (FEF)|. Condition TACS stimulation of the right frontal (FEF) at a high-beta frequency (30 Hz) for half of the patients and unilateral occipital cortex (right / left) at an alfa frequency (10 Hz) for the other half . This condition will control the possible placebo effects of tACS stimulation and the potential effects of visual field enhancement with repetition of perimetry tests. This condition will also verify the lack of changes in cerebral rhythm activity in the case of an application without effective electrical current.
11104686|NCT04043676|Experimental|Ponatinib Treatment|Patients will be treated with 15 mg/day of ponatinib during 48 weeks. If a patient maintains MR4 throughout the 48 weeks, he/she will be eligible to start the ponatinib TFR phase. If a patient has confirmed loss of MR4 (two consecutive BCR-ABL > 0.01% IS) or loss of MMR (no confirmation needed), he/she will not be eligible for the TFR phase. Instead, he/she will restart imatinib treatment.
11104687|NCT04043663|Experimental|Virtual reality program group|Virtual reality program based on a virtual reality guided tour registered in the investigator's pediatric OR setting before surgery.
11104688|NCT04043663|Active Comparator|control group|standard perioperative care without virtual reality program
11104689|NCT04043650|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
11104690|NCT04043624|Experimental|Lidocaine group|First group (lidocaine group) will include those who receive a intraoperative lidocaine infusion.Induction bolus dose of 1.5 mg/kg body weight ( 30 minutes before incision)followed by a continous lidocaine infusion of 2mg/kg/h，until 1 hours after skin closure.
11104691|NCT04043624|Placebo Comparator|Saline group|The second group（saline group） will include those who receive a intraoperative placebo.The same dosage of saline was given according to the same method of administration in the lidocaine group.
11104692|NCT04043611|Active Comparator|Conservative physical therapy management|Tens and hot pack , Soft tissue mobilization , Maitland's Lumbar segmental mobilization, Traction, Neurodynamics, Active Stretching, McKenzie Prone Extension Exercises
11104693|NCT04043611|Experimental|ELDOA|Conservative physical therapy management + ELDOA positions
11104694|NCT04043598|Active Comparator|high sodium infusion fluid|Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
11104695|NCT04043598|Active Comparator|low sodium infusion fluid|Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
11104696|NCT04043572||Participants with Epilepsy|This group comprises pregnant patients with epilepsy who are actively using anti-epileptic drugs
11104697|NCT04043572||Healthy Controls|Healthy volunteers
11104698|NCT04043559||patients with an acute symptomatic infarction|
11104699|NCT04043559||controls with cryptogenic stroke|
11104700|NCT04043546|Experimental|Exercise intervention|
11104701|NCT04043533|Experimental|Exercises Group|
11104702|NCT04043533|No Intervention|Control Group|
11104703|NCT04043520|Experimental|Premenopausal: GnRH antagonist + estradiol|"Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection
~Estradiol is a transdermal patch 0.075 mg, applied weekly for 12 weeks"
11104704|NCT04043520|Experimental|Premenopausal: GnRH antagonist + placebo|"GnRH antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection
~Placebo is a transdermal patch, applied weekly for 12 weeks"
11104705|NCT04043520|Experimental|Postmenopausal: GnRH antagonist + estradiol|"GnRH antagonist is degarelix acetate, 80 mg, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)
~Estradiol is a transdermal patch 0.075 mg, applied weekly for 24 weeks"
11104707|NCT04043520|Placebo Comparator|Postmenopausal: placebo + placebo|"Placebo (1) is normal saline, delivered twice as a subcutaneous injection (at baseline and after 12 weeks)
~Placebo (2) is a transdermal patch, applied weekly for 24 weeks"
11104708|NCT04043494|Other|SR I/II: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~maintenance therapy"
11104709|NCT04043494|Experimental|SR I/II: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment Phase (protocol M)
~maintenance therapy"
11104710|NCT04043494|Other|SR: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
11104711|NCT04043494|Experimental|SR: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
11104712|NCT04043494|Other|"HR: R1 into Pred and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
11104713|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib)
~non-HR extra-compartment phase (protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
11104714|NCT04043494|Experimental|"HR: R1 into Pred and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone
~standard induction phase (protocol Ia-prednisone)
~consolidation phase (protocol Ib*)
~HR extra-compartment phase (intensified protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
11104715|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone
~experimental induction phase (protocol Ia-dexamethasone)
~consolidation phase (protocol Ib*)
~HR extra-compartment phase (intensified protocol M)
~reintensification phase (protocol II)
~maintenance therapy"
11104716|NCT04043468|Experimental|Improved A&F intervention|Two feedback sessions and four structured focus groups
11104717|NCT04043468|Active Comparator|Standard A&F intervention|Two feedback sessions
11104718|NCT04043455|Experimental|Olorinab low dose (Main Study)|
11104719|NCT04043455|Experimental|Olorinab medium dose (Main Study)|
11104720|NCT04043455|Experimental|Olorinab high dose (Main Study)|
11104721|NCT04043455|Placebo Comparator|Placebo (Main Study)|
11104722|NCT04043455|Experimental|Olorinab (Long-Term Extension)|Participants will receive olorinab based on their treatment assignment in the Main Study.
11104723|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 1|Custom neural anatomical target 1 defined by neuroimaging data
11104724|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 2|Custom neural anatomical target 2 defined by neuroimaging data
11104725|NCT04043442|Active Comparator|Active + Placebo rTMS for Custom Neural Target Group 3|Custom neural anatomical target 3 defined by neuroimaging data
11104726|NCT04043442|Active Comparator|Active + Placebo rTMS for Left DLPFC Neural Target|"Neural anatomical target will be the Left Dorsolateral Prefrontal Cortex identified using the 5cm from the motor hot spot rule."
11104727|NCT04043429|Experimental|Vision Restoration Training (VRT)|home-based rehabilitation program which applies intense light stimulation via a PC-monitor to areas of residual vision with a duration of 1 hour daily/six days a week, subjects are asked to respond via button press upon appearance of light stimuli without eye movements
11104728|NCT04043429|Active Comparator|Vision Exploration Training (VET)|home-based rehabilitation program to train eye movements upon visual stimuli presented via a PC-monitor with a duration of 1 hour daily/six days a week, subjects are asked to shift their gaze towards targets and respond via button press upon detection of targets
11104729|NCT04043416|Experimental|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.
~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
11104730|NCT04043416|Experimental|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program
~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
11104731|NCT04043390|Experimental|CRP and Xpert ULTRA MTB/RIF|Scheme 1 will screen all patients for HIV using rapid tests routinely used by the clinics and a rapid CRP. Patients with CRP >10 will be further tested using Xpert ULTRA. Individuals with HIV will undergo an HIV VL using Xpert HIV-1 VL.
11104797|NCT04042909|Experimental|Counter Attitudinal Advocacy|Participants in this arm will articulate ways to avoid alcohol-related consequences using self-generated protective strategies and publicly state those strategies.
11104732|NCT04043390|Experimental|CRP and Molbio Truenat MTB|Scheme 2 will screen individuals for HIV and CRP (as in scheme 1) and patients with CRP >10 will be tested using Molbio Truenat MTB. Individuals with HIV will undergo an HIV VL using Molbio Truenat HIV-VL and individuals with Truenat MTB-positive samples wil be tested with Truenat MTB RIF.
11104733|NCT04043390|No Intervention|standard test Xpert|All patients receiving in scheme 1 and scheme 2 will be tested using the standard tests used in the study context. These are rapid HIV tests, Xpert MTB/RIF and culture.
11104734|NCT04043377|Experimental|All patients|
11104735|NCT04043364|Experimental|LIVE|A multicomponent intervention focusing on Learning, Innovation, Volunteers and Empowerment organized by a local coordinator.
11104736|NCT04043364|No Intervention|Treatment as usual|Care coordination and facilitation as usual.
11104737|NCT04043338|Experimental|XC130-A10H|XC130-A10H (single dose)
11104738|NCT04043338|Placebo Comparator|Placebo|placebo (single dose)
11104739|NCT04043312|Sham Comparator|Control|Patients will receive one hour of sham stimulation.
11104740|NCT04043312|Experimental|Active|Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.
11104741|NCT04043299|Experimental|Intervention|This arm will receive 100% oxygen at a rate of 10L/min for 15 minutes
11104742|NCT04043299|Active Comparator|Control|This arm will receive medical air (21% oxygen) at a rate of 10 L/min for 15 minutes
11104743|NCT04043286|No Intervention|Control group|Healing abutments are connected on the implants on the day of surgery, which will be subjected to multiple disconnection and reconnection during the prosthetic phase
11104744|NCT04043286|Experimental|Test group|Definitive abutments connected to the implants on the day of surgery. No disconnection or reconnection during the prosthetic phase
11104745|NCT04043273||Whole cohort|The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
11104746|NCT04043260|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro algorithm. After approval by the study physician (may override the suggestions for safety reasons), the treatment plan will be sent to the subject to be followed for the following 3 weeks. The study team will follow-up with a phone call to the subject to verify the subject received the updated treatment plan.
11104747|NCT04043247|Sham Comparator|Control Group|Same as TEAS group but without electrical stimulation
11104748|NCT04043247|Experimental|TEAS Group|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
11104749|NCT04043208|Experimental|Biofeedback|
11104750|NCT04043208|Placebo Comparator|Placebo|
11104751|NCT04043195|Experimental|Nivolumab + Oxaliplatin|Cohort 1
11104752|NCT04043195|Experimental|Nivolumab + Oxaliplatin + Ipilimumab|Cohort 2
11104753|NCT04043182|No Intervention|group control|You will not receive any type of intervention
11104754|NCT04043182|Experimental|treatment group (ultrasound)|Will perform protocols of 10 sessions of ultrasound in the region of abdomen
11104755|NCT04043182|Placebo Comparator|placebo group|It will perform protocols of 10 sessions of ultrasound in the region of abdomen, but the apparatus will be with zero intensities
11104756|NCT04043156|Experimental|High-precision RT|Study Arm: 18 x 2.33 Gy of high-precision RT in 3.5 weeks.
11104757|NCT04043143|Placebo Comparator|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
11104758|NCT04043143|Experimental|Arm 2 Prescription Tool Intervention|At the time of writing the discharge prescription for a patient the provider will be informed by the best practice alert (BPA) Prescription Tool that a patient may be considered for a lower post-discharge opioid dose (no opioids for patients who did not take any opioids in the last 24 hours, and 10 oxycodone 5mg tablets, for patients having taken less than 22.5 MME, e.g. 1-3 oxycodone 5mg tablets in the last 24 hours). Final dosing decisions and drug choices will remain at the discretion of the treating provider and decisions will be tracked.
11104759|NCT04043130|Experimental|Pulse Treatment App|The treatment app is a web-based mobile health app designed for Black & Latinx women ages 18-20. Through culturally and age-appropriate content, Pulse provides information on birth control, healthy relationships, sexual health, pregnancy, & utilization of clinical services to encourage users to choose effective birth control, seek reproductive health services, and prevent unplanned pregnancies. Users access Pulse autonomously and on their own terms. The app does not require users to follow a specific sequence of content viewed. Participants randomized to the intervention condition are given access to Pulse and receive Multimedia Messaging Service (MMS) messages related to sexual health several times a week for 6 weeks. Participants receive a baseline survey, 6-week follow-up survey, and 6-month follow-up survey via an electronic survey platform (6-month survey only administered to participants recruited between November 2018-March 2019).
11104760|NCT04043130|Active Comparator|Pulse Control App|The control app, also called Pulse, is a web-based mobile health app designed by the study team for young women ages 18-20. Although Pulse control and Pulse treatment apps look and feel similar aesthetically, they contain different content. Pulse control app provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Users access Pulse autonomously, on their own terms, and in their own time and place. The app does not require the user to follow a specific sequence of content viewed; however, all users receive a monetary incentive after completing a baseline survey and registering with the app. Control participants also receive MMS messages related to general health for six weeks. Participants receive a baseline survey and a six-week follow-up which are conducted online via an electronic survey platform.
11104761|NCT04043117||Clinical Group|Group is composed by 12-19 years adolescents with a tumor (excluding brain tumor). Every patient included in the group complete the assessment including: evaluation of self-esteem (TMA test) and body image (BUT test, I-BICI test and Human Figure Drawing).
11104762|NCT04043104|Experimental|1 x 1011 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
11104763|NCT04043104|Experimental|3 x 1011 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
11104764|NCT04043104|Experimental|1 x 1012 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
11104765|NCT04043104|Experimental|3 x 1012 vg/mL|The starting dose will be at a titer of 1 x 1011 vg/mL. The viral titer used to dose each consecutive cohort of subjects will be increased as follows: 3 x 1011 vg/mL, 1 x 1012 vg/mL, 3 x 1012 vg/mL, and 6 x 1012 vg/mL. If 2 subjects experience a DLT at the 1 x 1011 vg/mL dose level (Dose Group 1; see Table 2), then a lower dose of 3 x 1010 vg/mL may be studied. Depending upon the occurrence of a protocol-defined toxicity, an additional 1-3 subjects may be enrolled into a dose group.
11104766|NCT04043091|Experimental|percutaneous coronary intervention|stable obstructive coronary artery disease (coronary artery stenosis >70%) - percutaneous coronary intervention performed in all diseased segments until 300 mL of contrast reached; preferably with drug eluting stents; along with standard medical therapy
11104767|NCT04043091|No Intervention|standard of care|stable obstructive coronary artery disease (coronary artery stenosis >70%) - no intervention (revascularization), just standard medical therapy
11104768|NCT04043078|Other|Exercise|Exercise and respiratory muscle training before surgery
11104769|NCT04043065|Experimental|LEAP-2|Liver-enriched antimicrobial peptide 2
11104770|NCT04043065|Placebo Comparator|Placebo|Saline
11104771|NCT04043052|Active Comparator|Treatment As Usual (TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination
11104772|NCT04043052|Experimental|EMA intervention assocuated to Treatment As Usual (EMA-TAU)|Evaluation of depression and anxiety disorders at 3 and 6 months post-stroke using psychological and functional examination in addition with Ecological Momentary Assessment (EMA) evaluation.
11104773|NCT04043039|Experimental|FULL THICKNESS PALATAL GRAFT|the full thickness palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
11104774|NCT04043039|Active Comparator|FREE GINGIVAL GRAFT|the Epithelialized Free Gingival Grafts palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membrane or by gelatine sponge
11104775|NCT04043026||WP1: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease
11104776|NCT04043026||WP1: AF + no CKD|Anticoagulated participants with atrial fibrillation and no chronic kidney disease
11104777|NCT04043026||WP1: no AF + CKD|Anticoagulated participants with chronic kidney disease and no atrial fibrillation
11104778|NCT04043026||WP1: no AF + no CKD|Anticoagulated participants without atrial fibrillation or chronic kidney disease
11104779|NCT04043026||WP2: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy
11104780|NCT04043013|Active Comparator|Mini-Taurus® (Rocky Mountain©) Brackets|"Brackets Mini-Taurus® (Rocky Mountain©) with:
~ORTHODONTIC BRACKET PRESCRIPTION Canines 0º First Premolar 0º Second Premolar 0º First Molar 0º"
11104781|NCT04043013|Active Comparator|Smart Clip® SL3 High Torque (3M Unitek©)|"Brackets Smart Clip® SL3 High Torque (3M Unitek©) with:
~ORTHODONTIC BRACKET PRESCRIPTION
~Canines +6º First Premolar -4º Second Premolar -4º First Molar -14º"
11104782|NCT04043013|Active Comparator|Tip-Edge Plus® (TP Orthodontics©)|"Brackets Tip-Edge Plus® (TP Orthodontics©) with:
~ORTHODONTIC BRACKET PRESCRIPTION
~Canines -4º First Premolar -7º Second Premolar -7º First Molar 0º -14º -11º -14º"
11104783|NCT04043013|Active Comparator|Victory® (3M Unitek©)|"Brackets Victory® (3M Unitek©) with:
~ORTHODONTIC BRACKET PRESCRIPTION
~Canines 0º First Premolar -7º Second Premolar -7º First Molar -14º"
11104784|NCT04043000|Experimental|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
11104785|NCT04043000|Placebo Comparator|Placebo|" The placebo without Super 13 Pro & Prebiotics was given three times a day for four weeks."
11104786|NCT04042987||Historical Control Group|Retrospective chart review
11104787|NCT04042987||Prospective QIP Group|Participants that meet eligibility criteria will be prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption.
11104788|NCT04042974|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
11104789|NCT04042974|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
11104790|NCT04042961|Experimental|Reactive balance training|
11104791|NCT04042961|Active Comparator|Aerobic and strength training|
11104792|NCT04042948|Experimental|Experimental Group|preventive use non-steroidal anti-inflammatory drugs to before the removal of drainage tube
11104793|NCT04042948|No Intervention|Control Group|without any intervention when remove the drainage tube
11104794|NCT04042935|Experimental|Alpha Lipoic Acid (ALA) during chemoradiation|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation as standard of care will receive ALA before, during, and after treatment. The drug will have dose escalation in a 3+3 design. The first group of 3 patients will receive 600 mg twice a day. If there are no DLTs, the next 3 patients will receive the highest dose of 600 mg three times a day. If one or more patients develop a DLT at any of the dosing levels, the group will either be expanded or dropped to a lower dose level.
11104795|NCT04042922|Experimental|Exposure to active stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of active stimulation
11104796|NCT04042922|Sham Comparator|Exposure to control stimulation for 30 - 60 min|Subjects in this arm will receive 30 - 60 minutes of control stimulation
11104798|NCT04042909|Active Comparator|Personalized Normative Feedback|Participants in this arm will view personalized normative feedback regarding their 1) own drinking quantity and frequency of drinking, 2) perceptions of typical drinking by same-sex students' on campus (i.e., perceived descriptive norms), and 3) actual drinking rates by same-sex students' on campus (i.e., actual descriptive norms).
11104799|NCT04042909|No Intervention|Assessment-only Control|Participants in this arm will not receive any intervention.
11104800|NCT04042896|Experimental|exergame group|"The exergame group performed exercise using the Exer Heart device (D&J Humancare, Seoul, South Korea), which consisted of a running/jumping board and a screen connected to the board. The exercise program Alchemist's Treasure, a running-based exergame, moves the avatar according to the user's motions and was used for the exercise session. Alchemist's Treasure is a game in which the user listens to stimulating music, runs with the avatar, avoiding obstacles, and wins items using the front, back, left, and right sensors on the exercise board. The subject can control the speed of the avatar movement by adjusting the walking or running speed on the board.
~This study did not enforce exercise intensity in order to allow patients to enjoy the exergame. Thus, during the training period, the patients exercised at a self-selected pace for 40 minutes per day."
11104801|NCT04042896|Active Comparator|treadmill group|The treadmill group consisted of 40 minutes of walking or jogging at 60-80% of the heart rate (HR) reserve. The exercise intensity was determined using the Karvonen method target HR = [Exercise Intensity × (HRmax - resting HR)] + resting HR. The HR was recorded during each session using an HR monitor (Polar RS400sd; Madison Height, Michigan, USA). The control group was asked to maintain their regular physical activity level for 12 weeks.
11104802|NCT04042896|No Intervention|control group|The control group was asked to maintain their regular physical activity level for 12 weeks.
11104803|NCT04042883|Active Comparator|ANH|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
11104804|NCT04042883|No Intervention|Control|No intervention
11104805|NCT04042870|Experimental|Joint Loosening Yoga|Yoga Intervention. Dose: 15 minutes, M-F for 4-weeks.
11104806|NCT04042857|Experimental|Next Science|Patients will apply Next Science treatment to the study target hallux nail for 48 weeks daily.
11104807|NCT04042844|Experimental|Active Treatment- BRTX-100|BRTX-100 consists of a population of hypoxic-cultured bone marrow mononuclear cells highly enriched in mesenchymal stem cells from autologous bone marrow with autologous platelet lysate.
11104808|NCT04042844|Placebo Comparator|Saline|Isotonic saline will be used as a control in this study. Drug: saline (0.9% sodium chloride).
11104809|NCT04042831|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
11104810|NCT04042805|Experimental|Sintilimab Plus Lenvatinib|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11104811|NCT04042792||ADA for ≥12 weeks and concomitant MTX therapy|PiRD patients with ADA for ≥12 weeks and concomitant MTX therapy (oral or subcutaneous)
11104812|NCT04042792||ADA for ≥ 12 weeks without MTX|PiRD patients with ADA for ≥ 12 weeks without MTX ≥ 12 weeks (or never exposed to MTX)
11104813|NCT04042779|Active Comparator|model-based WM training|In order to build the model-based WM training, existing tasks used to assess the different component of the Baddeley's model will be reviewed on their findings according to test-retest reliability and construct validity. For each component - phonological loop, visuospatial sketchpad, episodic buffer and central executive - the task with the highest reliability and validity will be chosen and then build the basis for the computerized training program. This procedure results in a model-based, adaptive, computerized training program for WM.
11104814|NCT04042779|Active Comparator|single-task WM training|"The basis for the single-task training administered to the second group will be the widely used dual-n-back training paradigm suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices."
11104815|NCT04042779|Active Comparator|multiple-task WM training|Verbal WM tasks - particularly letter span and digit span tasks - and a visuospatial WM task are most commonly used (e.g. Dahlin et al., 2008; Klingberg et al., 2005; Westerberg et al., 2007). Therefore, a multiple-task training including these tasks will be administered to the third group.
11104816|NCT04042779|Sham Comparator|sham intervention|Active control group that as well performs a training, however not based on WM. To exclude the involvement of WM, a motor training will be administered to the control group.
11104817|NCT04042766|Active Comparator|laser treatment|
11104818|NCT04042766|Sham Comparator|sham treatment|
11104819|NCT04042753|Experimental|Pituitary Cancer|Participants will have a pituitary adenoma/carcinoma of any histology
11104820|NCT04042740|Experimental|Glecaprevir/Pibrentasvir (G/P)|"In Step 1, participants will receive G/P FDC tablets to be taken orally once daily for 4 weeks.
~Any participant who experiences viral re-infection, suspected relapse, virologic failure, or undefined post-treatment HCV viremia may enter Step 2. In Step 2, participants may receive G/P FDC tablets orally once daily for 8-16 weeks. Some participants may also receive ribavirin (RBV) tablets orally twice daily. Alternate regimens are allowed in Step 2."
11104821|NCT04042727|Experimental|Dexmedetomidine plus Standard of Care|Dexmedetomidine hydrochloride infusion will be prepared by the investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
11104822|NCT04042727|Placebo Comparator|Placebo plus Standard of Care|Normal Saline solution will be prepared by investigational pharmacy and administered intravenously at a rate of 1mcg/kg/hr for a duration of 8 hrs to patients in rapid Afib in addition to the usual standard of care as deemed necessary by patient's ICU team.
11104823|NCT04042714|Experimental|TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
11104860|NCT04042493|Experimental|Connect for Health Program|
11104861|NCT04042480|Experimental|SGN-CD228A|SGN-CD228A administered intravenously
11104824|NCT04042701|Experimental|Part 1 (Dose Escalation)|HER2-positive breast cancer, HER2-low expressing breast cancer, HER2-expressing NSCLC, and HER2-mutant NSCLC participants who received escalating doses of DS8201a (initial dose 3.2 mg/kg Q3W) and pembrolizumab 200 mg.
11104825|NCT04042701|Experimental|HER2-positive breast cancer (Part 2 Dose Expansion)|HER2-positive breast cancer participants with prior ado-trastuzumab emtansine (T-DM1) with disease progression and who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
11104826|NCT04042701|Experimental|HER2-low breast cancer (Part 2 Dose Expansion)|HER2 low breast cancer participants with prior failed standard treatments who received DS8201a at the RDE in combination with pembrolizumab 200 mg.
11104827|NCT04042701|Experimental|HER2-expressing NSCLC (Part 2 Dose Expansion)|HER2-expressing NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
11104828|NCT04042701|Experimental|HER2-mutant NSCLC (Part 2 Dose Expansion)|HER2-mutant NSCLC participants who had not received any prior treatment with anti-PD-1, anti-PD-L1, or HER2 agents and received DS8201a at the RDE in combination with pembrolizumab 200 mg.
11104829|NCT04042688|Experimental|Treatment group|Patients were randomly allocated to one of two groups during preoperative preparation by computer-generated randomization. Treatment group; IA administration of TXA, control group; no TXA administration
11104830|NCT04042688|No Intervention|Control gorup|
11104831|NCT04042675||parkinson group|parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage.
11104832|NCT04042675||Control group|healthy individuals between the ages of 40-75 and without any neurological disorders.
11104833|NCT04042662||Meropenem Failure ( Treatment failure)|
11104834|NCT04042662||Meropenem Success ( Treatment Success)|
11104835|NCT04042649|No Intervention|pre-intervention|Critically ill patients didn't provide environmental intervention (help sleep cycle, provide comfortable environment)
11104836|NCT04042649|Experimental|post-intervention|After providing environmental intervention for critically ill patients
11104837|NCT04042636||1|Patients with Bacteremia after trauma
11104838|NCT04042636||2|Patients with non-bacteremia after trauma
11104839|NCT04042623|Experimental|Treatment with AVB-S6-500|Patients will receive AVB-S6-500 by intravenous infusion every 2 weeks for total of 6 doses.
11104840|NCT04042610|Experimental|Intervention: electronic prompt to interrupt sitting time|The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
11104841|NCT04042610|No Intervention|Control Group|The control group will be given an Amazfit BIP device to record their steps. They will submit their daily steps counts for weeks: 1,2,4, 6 and 8.
11104842|NCT04042597|Experimental|Arm A: anlotinib arm|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
11104843|NCT04042597|Active Comparator|Arm B: imatinib arm|Imatinib was given at dose of 400 mg twice daily continuously
11104844|NCT04042584|Experimental|Visio conference device evaluation|Neurological tele-evaluation by a neurologist
11104845|NCT04042571|Experimental|Cerebral oxymetry monitoring (NIRS)|Cerebral oxymetry (NIRS) -by rSO2 measurement - in order to detect vasospasm in patient with severe subarachnoid hemorrhage compare to standard monitoring tools
11104846|NCT04042558|Experimental|Cohort with Bevacizumab|"4 cycles of induction every 3 weeks with :
~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route
~Pemetrexed 500 mg/m² per IV route
~Atezolizumab 1200 mg per IV route
~Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles"
11104847|NCT04042558|Experimental|Cohort without Bevacizumab|"4 cycles of induction every 3 weeks with :
~Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route
~Pemetrexed 500 mg/m² per IV route
~Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles"
11104848|NCT04042545|Experimental|inhaled THC/CBD (PPP001)|PPP001 (pellet with THC/CBD) inhalation with a device
11104849|NCT04042545|Placebo Comparator|Placebo|Placebo inhalation with a device
11104850|NCT04042532|Active Comparator|Active group|Active group will receive active stimulation of standard intermittent TBS (iTBS) protocol.
11104851|NCT04042532|Sham Comparator|Sham group|Sham group will receive sham stimulation of the same iTBS protocol with the coil set at 90 to the skull.
11104852|NCT04042532|No Intervention|Cognitively normal control|Cognitively normal controls will be recruited for neuroimaging comparison.
11104853|NCT04042519||Healthy control|age - and sex-matched healthy individuals without lung disease
11104854|NCT04042519||Patients with mild and moderate COPD|Grading according to the GOLD guide standards
11104855|NCT04042519||Patients with severe and very severe COPD|Grading according to the GOLD guide standards
11104856|NCT04042519||The severe and very severe COPD group baseline|Severe and very severe COPD patients were in the baseline time group
11104857|NCT04042519||The severe and very severe COPD group six months|Patients with severe and very severe COPD were six months from baseline.
11104858|NCT04042519||The severe and very severe COPD group one year|Patients with severe and very severe COPD were one year from baseline.
11104859|NCT04042506|Experimental|Extracranial SBRT and Nivolumab|"Stereotactic body radiation therapy (SBRT) will be given to a single extracranial metastatic site in combination with nivolumab.
~Patients will receive nivolumab 480mg intravenously (IV) every 4 weeks (1 cycle = 8 weeks), as well as SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
~Nivolumab will be continued until confirmed progression, unacceptable toxicity, or total of 6 Cycles (whichever occurs first)."
11104862|NCT04042467|Experimental|Greenlight Plus|"Families will receive the Greenlight intervention plus a health information technology (HIT) intervention aimed at supporting family goal-setting and behavior change.
~This design allows us to determine if HIT and the asynchronous support it provides between well-child visits can promote additional behavior change and obesity prevention."
11104863|NCT04042467|Active Comparator|Greenlight|During each of the recommended well child visits from 0-24 months, pediatric residents, trained in clear health communication skills and shared goal-setting, will use the Greenlight Toolkit of low literacy, age- specific, parent education booklets to promote healthy family behaviors and obesity prevention.
11104864|NCT04042454|Experimental|Test Product|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
11104865|NCT04042454|Active Comparator|Control Product|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
11104866|NCT04042441||Ryzodeg® as per local practice|Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.
11104867|NCT04042428|Experimental|Treatment group|Subjects receive a 14-day treatment. A 450 mL blood sample is extracted 6 hours after the last administration (day 14).
11104868|NCT04042428|No Intervention|Control group|Subjects do not receive any treatment. A 450 mL blood sample is extracted at baseline.
11104869|NCT04042415|No Intervention|Free diet controls|Patients on free diet
11104870|NCT04042415|Experimental|Caloric restriction|Patients will be treated with a mild caloric restriction (15-20% caloric restriction)
11104871|NCT04042415|Experimental|Caloric restriction without cow's milk and gluten|Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten
11104872|NCT04042402|Experimental|Open Label|Open label, monthly subcutaneous injection
11104873|NCT04042389|Experimental|WhatsApp|WhatsApp reminders
11104874|NCT04042389|Experimental|Email|Email reminders
11104875|NCT04042389|Other|Control|No reminder
11104876|NCT04042376|Experimental|Ibrutinib 420 milligram (mg)|Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.
11104877|NCT04042363|Experimental|Active Transorbital electrical stimulation|Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks
11104878|NCT04042363|Sham Comparator|Sham Transorbital stimulation|Sham stimulation - 10 sessions during 2 consecutive weeks
11104879|NCT04042350||CKD patients on dialysis|Data will be analyzed from CKD patients on dialysis that participated in the AURORA study.
11104880|NCT04042337|Experimental|PRT Telehealth|Participating parents will receive 12 weekly 60-minute parent training sessions via secure videoconference to learn Pivotal Response Treatment
11104881|NCT04042337|No Intervention|Waitlist|Participants will continue stable community-based treatments
11104882|NCT04042324|Experimental|Triferic post-dialyzer; UFH via continuous infusion|Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.
11104883|NCT04042324|Experimental|UFH and Triferic admixture|"Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer heparin line. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis."
11104884|NCT04042324|Experimental|UFH via continuous infusion pre-dialyzer|Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis
11104885|NCT04042311|Experimental|High-Intensity interval training|High-intensity interval training performed for 20 minutes, 3 times weekly for a period of 6 weeks at 85-100% of maximal heart rate.
11104886|NCT04042298||5-FU Chemotherapy (Experimental)|Comprised of newly diagnosed cancer patients 21 years or older who have received 5-FU chemotherapy within the past 30 days or are scheduled to receive 5-FU chemotherapy.
11104887|NCT04042298||Non-5-FU Chemotherapy (Sub-Control)|Comprised of newly diagnosed cancer patients 21 years or older who have received chemotherapy other than 5-FU within the past 30 days or are scheduled to receive chemotherapy other than 5-FU.
11104888|NCT04042298||Age/Sex matched Control (Control)|Age, biological sex, and prior health history (excluding cancer diagnosis) matched control for cancer patients
11104889|NCT04042298||5-FU Chemotherapy Cancer Survivor (Survivor)|Cancer survivors who have not received cancer therapy during the past year but previously received 5-Fluorouracil chemotherapy.
11104890|NCT04042285|Active Comparator|Extracorporeal shockwave therapy|The shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second (17). Participants will receive 3 sessions of shockwave therapy in a 7-day period. In addition to standard wound care (dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate).
11104891|NCT04042285|Placebo Comparator|Standard wound care|Patient with a diabetic foot wound who receive standard wound care, consisting of dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate.
11104919|NCT04042077|Active Comparator|Best Available Therapy|"Cardiothoracic / related leg SSI
~Vancomycin IV
~Linezolid IV, with the option to switch to linezolid oral.
~In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice
~Abdominal SSI
~Piperacillin/Tazobactam IV, OR
~Tigecycline IV
~In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice."
11104920|NCT04042064||Inhalation|Patient anesthetised with Inhalation anesthetic agents.
11104892|NCT04042272||Healthy volunteers|Healthy volunteers group; Kidney donor groups; Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
11104893|NCT04042272||Living kidney graft recipients|Kidney transplant group; Course of the research: Course of the research: Blood samples from all groups shall be taken for S100β, NSE, and GFAP in the preoperative period, in the operating room and after 1st, 7th day and the first following month in the postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients with S100β, NSE, and GFAP. Patients' demographic data, accompanying diseases, American Society of Anesthesiology classification, main etiology, preoperative laboratory values shall be recorded accordingly. In addition, routinely taken anesthetics, duration of the operation, duration of anesthesia, duration before the reperfusion, duration of postperfusion, graft hot and cold ischemia durations, first measured central venous pressure, volume replacement therapy, blood component transfusion, and immunosuppressive drugs are given during the operation shall be recorded.
11104894|NCT04042259|Active Comparator|Negative Pressure Wound Therapy|Standardized wound closure with negative pressure therapy.
11104895|NCT04042259|Other|Historic Cohort|Historic cohort have undergone a midline laparotomy and managed with an open abdomen for at least one day and have contaminated or dirty wound classification.
11104896|NCT04042246|No Intervention|Control|No intervention is implemented among Control
11104897|NCT04042246|Experimental|Treatment (Educational Information on Vaccination)|Provide general and tailored information on vaccination and vaccination schedule at the end of the baseline survey
11104898|NCT04042233|Active Comparator|IV administration of vancomycin|Standard IV vancomycin administration protocol.
11104899|NCT04042233|Experimental|IO Vancomycin 500mg in 250 mL NS|Experimental Intraosseous administration protocol.
11104900|NCT04042220||GK + IT|Gamma Knife and immunotherapy
11104901|NCT04042220||GK + IT + GC|Gamma Knife, immunotherapy and glucocorticoids
11104902|NCT04042220||GK only|Gamma Knife without immunotherapy
11104903|NCT04042207|Active Comparator|Reference treatment (Open-Loop)|Sensor-augmented pump therapy (SAP) namely the Low Glucose Predictive Suspend system or LGPS and a blinded glucose sensor (Dexcom G6) followed by a 48-week extension period in closed-loop condition
11104904|NCT04042207|Experimental|DBLHU system (Closed-Loop)|DBLHU software (a Model Predictive Control [MPC]-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleido insulin pump followed by a 48-week extension period in closed-loop condition
11104905|NCT04042194|Experimental|Thickened with T-PRF|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and T-PRF was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
11104906|NCT04042194|Active Comparator|Thickened with CTG|Following local anaesthesia, the measurement of soft tissue thickness at three points [1) occlusal part of the alveolar crest (OAC), 2) midbuccal mucosa level (MBML), 3) over 1 mm of mucogingival junction (MGJ1)] was performed with an endodontic spreader and digital caliber. Following the mid-crestal incision, the buccal flap was raised with double layer technique, while the lingual flap was left to enable direct visibility. The implant bed was drilled according to the manufacturer's protocol. The implants (BEGO Semados® RS/RSX implant system, Bremen, Germany) were placed at the bony crest. Right after the implant placement, the randomisation procedure was performed. In this group, the implants were placed in thin tissues, and CTG was inserted in the prepared mucoperiosteal flap at the facial site and secured with horizontal mattresses.
11104907|NCT04042181|Placebo Comparator|Placebo|
11104908|NCT04042181|Active Comparator|Bifidobacterium longum|
11104909|NCT04042168|Experimental|Intervention|Inappropriate use of inhalers and medication change. Pre-post intervention data will be compared.
11104910|NCT04042142|Active Comparator|Healthy overweight subjects|MR spectroscopy verified no steatosis
11104911|NCT04042142|Active Comparator|Subjects with non-alcoholic fatty liver disease|MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy
11104912|NCT04042142|Active Comparator|Subjects with non-alcoholic steatohepatitis|MR spectroscopy verified steatosis, steatohepatitis on liver biopsy
11104913|NCT04042129||1|gynecologic operations with urologic complications
11104914|NCT04042116|Experimental|Lucitanib + Nivolumab|"Phase 1b (Dose escalation): Up to 50 patients with advanced solid tumor.
~Phase 2 (Dose expansion): Up to 182 patients with advanced gynecological malignancies."
11104915|NCT04042103|Experimental|Tapinarof (DMVT-505) cream, 1%|Tapinarof (DMVT-505) cream, 1% applied topically once daily
11104916|NCT04042090|Experimental|Intervention group: use of therapeutic virtual reality|Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. Meanwhile, participant is placed on the waiting list to receive normal chronic pain treatment.
11104917|NCT04042090|No Intervention|Control group: no use of therapeutic virtual reality|Control group: no intervention, patient is waiting to receive normal chronic pain treatment.
11104918|NCT04042077|Experimental|Delafloxacin|Delafloxacin IV, with the option to switch to delafloxacin oral
11104922|NCT04042051|Other|Single Arm|This study is a phase Ib open label, single arm, adaptive multi-centre trial. Patients with unresectable locally advanced or metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, separately or in combination, will be treated with copanlisib (as assigned at registration according to the dose escalation scheme) plus trastuzumab emtansine 3.6mg/kg IV on day 1 of a 21-day cycle.
11104923|NCT04042038|Experimental|CBT|Intensive CBT (20 sessions in 1 month)
11104924|NCT04042038|No Intervention|Waiting-list|Waiting-list
11104925|NCT04042025|Other|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec-xioi|Participants received treatment with IV onasemnogene abeparvovec-xioi in an onasemnogene abeparvovec-xioi or received treatment with IT onasemnogene abeparvovec-xioi in an onasemnogene
11104926|NCT04042012|Experimental|Eccentric group|The dancers of this group wil perform a soleus eccentric exercise
11104927|NCT04042012|Experimental|PNE group|"The dancers of this group will receive a PNE treatment, consisting of the application of galvanic current, by ultrasound.
~The approach will be performed with a transverse axis with a needle orientation that will depend on the location of the target tissue. The parameters will be 3 mA, 3 seconds, 3 impacts (3: 3: 3). The periodicity will be 1day/7day/21day"
11104928|NCT04042012|Experimental|Combined group|The dancers of this group will receive a combined treatment and will be carried out in the same way as the other two groups.
11104929|NCT04041999|Experimental|Daily Cognition Training Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.
~Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.
~Specifically we focus on tasks related to taking medication and adherence to treatment."
11104930|NCT04041999|Active Comparator|Traditional Cognitive Stimulation Program|"The intervention was administered by a qualified professional, in this case an occupational therapist. And it was always individually through specific activities or exercises.
~Tasks are performed to work various cognitive functions."
11104931|NCT04041986|Experimental|Site-Finding|Each subject will receive anodal, cathodal, and sham stimulation to both the ipsilesional and contralesional hemispheres in a series of six sessions (one condition per session), each separated by at least two days. During anodal and cathodal tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 mA using a 5x5 cm electrode. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. The participant will complete pre/post language testing at each session in order to determine if the subject is a tDCS responder and if so, which site produces the best transient language improvement in that individual. Subjects who do not respond to tDCS will not be invited to move forward to the treatment phase.
11104932|NCT04041986|Active Comparator|Real tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
11104933|NCT04041986|Sham Comparator|Sham tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
11104934|NCT04041973|Experimental|ACT arm|Artemether-lumefantrine (AL) x 3 days followed by 1 day per week
11104935|NCT04041973|Active Comparator|Multivitamin arm|Multivitamin x 3 days followed by 1 day per week
11104936|NCT04041960|Experimental|SMG|Brain region targeted with transcranial magnetic stimulation: superamarginal gyrus
11104937|NCT04041960|Experimental|MTG|Brain region targeted with transcranial magnetic stimulation: middle temporal gyrus
11104938|NCT04041960|Active Comparator|Vertex|Brain region targeted with transcranial magnetic stimulation (none associated): Vertex
11104939|NCT04041934|Experimental|cohorte 1|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.11
11104940|NCT04041934|Experimental|cohorte 2|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.07
11104941|NCT04041934|Experimental|cohort 3|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio = 0.04
11104942|NCT04041921||Chronic coronary occlusion patients|≥3 months chronic total occlusion on coronary angiography
11104943|NCT04041908|Experimental|Experimental Product|Drink mix powder
11104944|NCT04041895||Alzheimer's Disease|Those individuals who possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
11104945|NCT04041895||Control|Those individuals who do not possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
11104946|NCT04041882|Experimental|68Ga-DOTATATE PET/CT|Inject 68Ga-DOTATATE and then perform PET/CT scan
11104947|NCT04041869|Experimental|MapTrek|
11104948|NCT04041856|Active Comparator|EKC patients|Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission
11104949|NCT04041856|No Intervention|Control group|All patients will undergo observational treatments including artificial tear drop and improving hygiene level
11104950|NCT04041843|Experimental|Abixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
11104951|NCT04041830|Experimental|NW (Normal Weight)|20 to 55 years old lean adults
11104952|NCT04041830|Experimental|OBESE|20 to 55 years old adults with obesity
11104953|NCT04041817|Experimental|Trigger increasing steps|"Trigger variations will be performed following increasing steps of 2 L/min every 15 minutes. End expiratory lung volume and lung aeration will be conducted using elecrical impedance tomography. Diaphragmatic motion and thickening will be analyzed by ultrasonography. Work of breathing will be evaluated using gastric and oesophageal pressure measurements.
~Measurements will be conducted during the last minute of each step."
11105061|NCT04041011|Experimental|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|
11104954|NCT04041804|Active Comparator|Every week RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every week until getting the require expansion needed
11104955|NCT04041804|Active Comparator|Every four days RPE activation|Non-surgical semi-rapid maxillary expansion (SRME) with the time intervals activation every four days until getting the require expansion needed
11104956|NCT04041791|Active Comparator|Benzyl penicillin/ampicillin + gentamicin & IV fluids|"Participants are assigned to receive benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.
~Maintenance fluids will be given as a continuous infusion for at least 24 hours."
11104957|NCT04041791|Experimental|Ceftriaxone and IV fluids|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for a minimum of 48 hours and for up to 7 days.
~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
11104958|NCT04041791|Experimental|Amoxicillin-clavulanate and IV fluids|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for a minimum of 48 hours and for up to 7 days.
~Intravenous fluids will be given as a continuous infusion for at least 24 hours."
11104959|NCT04041791|Experimental|Benzyl penicillin/ampicillin + gentamicin & NG feeds|"Participants are assigned to receive Benzyl penicillin at 50,000 IU/kg every 6 hours or ampicillin 50mg/kg every 8 hours plus gentamicin 7.5 mg/kg once daily given intravenously (IV) or via intramuscular (IM) injection for a minimum of 48 hours and for up to 7 days.
~Nasogastric feeds will be given 3 hourly for at least 24 hours."
11104960|NCT04041791|Experimental|Ceftriaxone and NG feeds|"Participants are assigned to receive ceftriaxone at 50 mg/kg every 12 hours given IV or IM for up to 7 days.
~Nasogastric feeds will be given 3 hourly for at least 24 hours."
11104961|NCT04041791|Experimental|Amoxicillin-clavulanic acid and NG feeds|"Participants are assigned to receive amoxicillin clavulanic acid at 30 mg/kg every 8 hours given IV or IM for up to 7 days.
~Nasogastric feeds will be given 3 hourly for at least 24 hours."
11104962|NCT04041765|Experimental|Treatment Group|IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
11104963|NCT04041765|Placebo Comparator|Placebo Group|Antibiotics only
11104964|NCT04041752|Experimental|Normal weight|30 healthy normal weight adults will be involved and will realize the three conditions
11104965|NCT04041739||diabetic foot osteomyelitis|"Patients will be subjected to:
~1-History taking including duration of diabetes and ulcer . 2 Clinical examination of ulcer , including diagnosis of osteomyelitis 3- Venous blood will be withdrawn to do the following laboratory tests :
~HbA1c
~erythrocyte sedimentation rate(ESR)
~C reactive protein(CRP)
~Complete blood culture
~Serum urea and creatinine 4-culture and sensitivity test 5-Bone fragments and tissue biopsy from infected ulcers 6-Fundus examination"
11104966|NCT04041713|Active Comparator|Rett T|Rett T is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
11104967|NCT04041713|Placebo Comparator|Placebo|Placebo is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
11104968|NCT04041700|Experimental|Osia 2 system|
11104969|NCT04041674|Experimental|Group 1 (T1): DNA + MVA + Placebo (IM)|"Participants will receive 3 mg of GEO-D02 DNA by intramuscular (IM) injection at Months 0 and 2.
~Participants will also receive 1×10^8 50% tissue culture infective dose (TCID50) of MVA/HIV62B plus placebo for B63521^11 gp120 plus placebo for IHV01, each by IM injection at Months 4, 6, and 10."
11104970|NCT04041674|Experimental|Group 2 (T1): DNA + MVA + Placebo (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B by IM injection plus placebo for B63521^11 gp120 by subcutaneous (SC) injection plus placebo for IHV01 by SC injection at Months 4, 6, and 10."
11104971|NCT04041674|Experimental|Group 3 (T2): DNA + MVA + IHV01 + B63|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B plus 150 mcg of B63521^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
11104972|NCT04041674|Experimental|Group 4 (T3): DNA + MVA +IHV01 + Placebo|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 2.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B plus placebo for B63521^11 gp120 plus 150 mcg of IHV01, each by IM injection at Months 4, 6, and 10."
11104973|NCT04041674|Experimental|Group 5 (T4): DNA + MVA +IHV01 (SC)+ B63 (SC)|"Participants will receive 3 mg of GEO-D02 DNA by IM injection at Months 0 and 3.
~Participants will also receive 1×10^8 TCID50 of MVA/HIV62B by IM injection plus 150 mcg of B63521^11 gp120 by SC injection plus 150 mcg of IHV01 by SC injection at Months 4, 6, and 10."
11104974|NCT04041661|Experimental|Active tDCS plus gait training group|Participants in Active tDCS plus gait training group will execute Active tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
11104975|NCT04041661|Sham Comparator|Sham tDCS plus gait training group|Participants in Sham tDCS plus gait training group will executeSham tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
11104976|NCT04041648|Placebo Comparator|placebo|placebo group
11104977|NCT04041648|Experimental|L606 Liposomal inhalation solution|Liposomal inhalation solution
11104978|NCT04041635|Experimental|Stimuli Reduction|This group will receive reduced visual and auditory stimuli in addition to usual care during venipuncture. Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
11105025|NCT04041284|Experimental|fremanezumab|monthly 225 mg. In the open-label extension phase starting at week 12, all patients will receive active treatment with a quarterly dose of 675 mg sc
11105026|NCT04041284|Placebo Comparator|Placebo|
11104979|NCT04041635|Active Comparator|Usual Care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
11104980|NCT04041622|Other|Endoscopy and biopsy|Participants of the HUNT study with a positive serological assay for celiac disease are invited to attain a diagnostic endoscopy with duodenal biopsies
11104981|NCT04041609|Active Comparator|LYR-210 (Low Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate low dose) in the middle meatus
11104982|NCT04041609|Active Comparator|LYR-210 (High Dose)|In-office bilateral placement of the LYR-210 drug depot (mometasone furoate high dose) in the middle meatus
11104983|NCT04041609|Sham Comparator|Sham Procedure|In-office bilateral sham procedure
11104984|NCT04041583||Arm 1|Patients undergoing posterior cervical arthrodesis procedures for spondylosis supplemented with CIS involving three or more segmental levels in the subaxial cervicothoracic spine (between C2-upper thoracic)
11104985|NCT04041570|Experimental|cAd3-EBO S at 1x10^10 PU dose|Twenty (20) subjects enrolled in Group 1 will receive a 1x10^10 PU dose of cAd3-EBO S vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
11104986|NCT04041570|Experimental|cAd3-EBO S at 1x10^11 PU dose|Twenty (20) subjects enrolled in Group 2 will receive a 1x10^11 PU dose of cAd3-EBO S vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
11104987|NCT04041557||adults with CHD|Adults with congenital heart disease 18-32 years of age
11104988|NCT04041557||controls|healthy peers
11104989|NCT04041544|Active Comparator|SN1011|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
11104990|NCT04041544|Placebo Comparator|SN1011 placebo|5 Cohort for Part A:25mg once a day,50mg once a day, 100mg once a day, 150mg once a day, 200mg once a day 4 Cohort for Part B : 50mg once a day, 100mg once a day, 200mg once a day, 100mg twice a day
11104991|NCT04041518|Other|Intervention|Autotransplantation and intra-operative extraoral apicoectomy of a permanent tooth.
11104992|NCT04041505|Active Comparator|Breastfeeding|Infant consumes mother's milk directly from the breast.
11104993|NCT04041505|Experimental|Bottle-feeding|Infant consumes mother's expressed milk from a bottle.
11104994|NCT04041492|Experimental|Group 1|Vitamin D3 1000UI + Placebo (Calcined Magnesia).
11104995|NCT04041492|Experimental|Group 2|Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
11104996|NCT04041492|Active Comparator|Group 3|Vitamin D3 1000UI + Vitamin K2 100 mcg
11104997|NCT04041479|Active Comparator|Standard of Care|FDA-cleared, standard-of-care 10 Hertz repetitive Transcranial Magnetic Stimulation (10 Hz TMS) targeting the left dorsolateral prefrontal cortex (DLPFC), regardless of the depression subtype (biotype) determined by a magnetic resonance imaging (MRI) scan.
11104998|NCT04041479|Experimental|Targeted Side Arm|10 Hz rTMS targeting the area of the brain (DLPFC or dorsomedial prefrontal cortex DMPFC)) that we hypothesize will be most effective for that subject's biotype (confirmation arm).
11104999|NCT04041479|Active Comparator|Opposite Side Arm|10 Hz rTMS targeting the opposite site (DLPFC or DMPFC) than the one we hypothesize will be most effective for that subject's biotype (disconfirmation arm).
11105000|NCT04041466|Experimental|Atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
11105001|NCT04041466|Experimental|Sinus Rhythm (SR)|Patients diagnosed with SR during reference ECG
11105002|NCT04041466|Experimental|Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
11105003|NCT04041453|Active Comparator|Albendazole 400mg|Albendazole 400mg in single dose
11105004|NCT04041453|Experimental|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
11105005|NCT04041453|Experimental|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
11105006|NCT04041453|Experimental|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
11105007|NCT04041440|Experimental|Auditory Training|Pre- and post assessments of auditory training intervention
11105008|NCT04041427|Experimental|Fasting|Albendazole 400mg will be ingested by study participants with an 8-hour fasting diet.
11105009|NCT04041427|Experimental|High fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with high fat content (40 grams of fat).
11105010|NCT04041427|Experimental|Moderate fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with moderate fat content (15 grams of fat).
11105011|NCT04041414|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
11105012|NCT04041414|Active Comparator|Control schools|Students in control schools will receive a delayed onset intervention in semester 2.
11105013|NCT04041401||Children and their Caregivers|Children following discharge from PICU and their caregivers receiving a storybook intervention.
11105014|NCT04041388|Other|Tooth tipping|
11105015|NCT04041375|Experimental|iNSPiRED|Peer coaching intervention
11105016|NCT04041375|Active Comparator|Usual Care|Directory of resources and encouragement to follow-up with Primary Care Physician
11105017|NCT04041362|Active Comparator|Arm1 (Standard ART)|Standard ART
11105018|NCT04041362|Experimental|Arm 2 (ART plus UB-421)|ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks
11105019|NCT04041349|No Intervention|The standard treatment group|The standard treatment group is treated with conventional drugs and cholinesterase inhibitors
11105020|NCT04041349|Experimental|mouse nerve growth factor (mNGF)group|Conventional drugs and cholinesterase inhibitors + mouse nerve growth factor (mNGF) of 20 μg (9000 U)/day for 14 consecutive days by intramuscular injection.
11105021|NCT04041336|Experimental|All participants|All participants will have measurements taken. There are no comparators or controls in this feasibility study
11105022|NCT04041310|Experimental|Cohort A. Low dose|Subjects treated with low dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D
11105023|NCT04041310|Experimental|Cohort A. High dose|Subjects treated with high dose of GAd20-209-FSP prime and MVA-209-FSP boosts to define the RP2D
11105027|NCT04041271||Nonspecific chronic neck pain (NCNP) group|Subjects with nonspecific chronic neck pain will be included to perform clinical test and assess their jaw kinematics and muscle activation.
11105028|NCT04041271||Control group|Healthy control subjects will be included to compare the differences in jaw kinematics, muscle activation and clinical tests between healthy subjects and subjects with nonspecific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
11105029|NCT04041245||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
11105030|NCT04041245||Healthy group|This group will include 40 healthy volunteers.
11105031|NCT04041232|Experimental|PBA treatment of ATF6-/- Achromatopsia|Patients will be monitored at the baseline visit, followed by a second and third visit that will be 1 and 3 months after the initial visit. Patients will complete a standard visual functioning questionnaire and undergo a complete ophthalmic evaluation at each visit. Other visual assessments will consist of color vision testing, contrast sensitivity, retinal imaging, and macular sensitivity testing using microperimetry. Full-field electroretinogram will also be performed at the baseline visit and after 1 and 3 months of PBA use. If improvement in retinal function is observed, an additional ophthalmic evaluation will be conducted after 6 months of PBA use. A blood draw will be performed at each visit to test for any indications of adverse effects from drug use.
11105032|NCT04041219|Experimental|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
11105033|NCT04041206||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
11105034|NCT04041206||Healthy group|This group will include 40 healthy volunteers.
11105035|NCT04041193|Experimental|SIDERA^B|Behavioral: telerehabilitation activities Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) 5 sessions/week of an individualized telerehabilitation program at home. The sessions will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by the therapist weekly. Each patient's performed session will be reviewed by the therapist.
11105036|NCT04041193|Active Comparator|usual care|Behavioral: paper and pencil activities as usual rehabilitation at home Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) of a usual rehabilitation program.
11105037|NCT04041167|Active Comparator|Alpha lipoic acid|All patients will be assigned intravenous alpha lipoic acid 600mg within 24 hours of symptom onset. Patients will receive intravenous alpha lipoic acid 600mg/day for one week, followed by an oral pill of alpha lipoic acid 600mg/day for three months.
11105038|NCT04041167|Placebo Comparator|Normal saline|All patients will receive intravenous normal saline within 24 hours of symptom onset.
11105039|NCT04041154|Experimental|Cognitive Fatigue|We will use a behavioral intervention. Participants will perform a cognitively demanding task, repeatedly, to induce cognitive fatigue.
11105040|NCT04041154|Experimental|Physical Fatigue|We will use a behavioral intervention. Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
11105041|NCT04041154|Experimental|Rewarding Stimuli|We will use a behavioral intervention. Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
11105042|NCT04041141||Oral Cancer|Patients receiving curative radiation treatment for an oral cancer.
11105043|NCT04041128|Experimental|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
11105044|NCT04041115|Active Comparator|Control|personalized nutritional therapy + aerobic exercise
11105045|NCT04041115|Active Comparator|Non-alcoholic Beer|non-alcoholic beer + personalized nutritional therapy + aerobic exercise
11105046|NCT04041102||Infantile (Type 1) or Juvenile (Type 2) GM1 Gangliosidosis|This study observes one cohort: up to 40 Infantile GM1 (Type 1) or Juvenile GM1 (Type 2) subjects.
11105047|NCT04041089|Experimental|Recognition of objects|Patients will do the therapy in the following order: object location, object manipulation and object recognition
11105048|NCT04041089|Experimental|Location of objects|Patients will do the therapy in the following order: object recognition, object location, and object manipulation
11105049|NCT04041089|Experimental|Manipulation of objects|Patients will do the therapy in the following order: object manipulation, object recognition and object location
11105050|NCT04041076||Elective Surgical Patients in Tuen Mun Hospital|Patients who received elective surgical operation in Tuen Mun Hospital from 1July 2012 to 30June 2018
11105051|NCT04041063|Experimental|Nerve transfer + robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
11105052|NCT04041063|Active Comparator|Nerve transfer + delayed robotic training|Participants will receive nerve transfer surgery at Massachusetts General Hospital in Boston, MA. One year + six weeks after the surgery, participants will receive six weeks of upper limb robotic training at the Burke Neurological Institute in White Plains, NY.
11105053|NCT04041050|Experimental|Part 1: Navitoclax Monotherapy|Participants will receive various doses of navitoclax once daily (QD).
11105054|NCT04041050|Experimental|Part 2: Navitoclax + Ruxolitinib Combination Therapy|Participants will receive various doses of navitoclax once daily (QD) in combination with ruxolitinib twice daily (BID).
11105055|NCT04041050|Experimental|Part 3: Navitoclax Monotherapy|Participants will receive navitoclax Dose A once daily (QD).
11105056|NCT04041050|Experimental|Part 4: Navitoclax + Celecoxib|Participants will receive navitoclax dose A once daily (QD) from Day 3 through Day 16. Participants will also receive celecoxib singe dose on Day 1 and Day 7.
11105057|NCT04041024|Experimental|bulimia nervosa group|Patients with Bulimia Nervosa according to DSM 5 criteria aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right handed.
11105058|NCT04041024|Other|Control group|healthy participants without any history of eating disorder aged between 18 and 35 years and specifically for participants attending MRI scans in the experiments: no counter indication to MRI scans and right
11105059|NCT04041011|Experimental|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|
11105060|NCT04041011|Experimental|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|
11105062|NCT04040998|Experimental|CCT+TAU group|The participants in CCT+TAU group received compensatory cognitive training plus treatment as usual. The CCT intervention consisted of two 50-minute sessions each week for 10 weeks
11105063|NCT04040998|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as CCT+TAU group.
11105064|NCT04040985|Other|Legion Primary|Legion Primary TKA
11105065|NCT04040972|Experimental|Rebalance - Group Compassion Focussed Therapy|
11105066|NCT04040959|Experimental|Nicotinamide Riboside|Each nicotinamide riboside capsule contains 250 mg of nicotinamide riboside chloride mixed with microcrystalline cellulose. Dosage: 500 mg by mouth twice a day for 3 months.
11105067|NCT04040959|Placebo Comparator|Placebo|Matched placebo capsules.
11105068|NCT04040946|Other|TEMP-TDM with MIBI|Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
11105069|NCT04040946|Other|F18-choline PET|Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
11105070|NCT04040920|Experimental|Ozone therapy|Ozone application before pits and fissure sealants
11105071|NCT04040920|Active Comparator|Pits and fissure sealants|
11105072|NCT04040907|Active Comparator|XNW3009|
11105073|NCT04040907|Placebo Comparator|XNW3009 placebo|
11105074|NCT04040881|Experimental|Remote monitoring using Smartphone|Patients will be provided with a Global System for Mobile communications (GSM) accelerometer-equipped Android smartphone (specific model to be decided) with an installed open source, freely available pedometer application (Google Fit, Google, CA, United States) which will record their daily steps. Patients will receive daily calls from a research assistant to document the presence of clinically significant chemotherapy-related toxicity.
11105075|NCT04040868|Other|robot-assisted technique|
11105076|NCT04040868|Other|conventional fluoroscopy-assisted technique|
11105077|NCT04040855|Experimental|Intervention|Patients in the intervention groups received multi-professional medication reviews. A nurse performed a symptom evaluation, a pharmacist assessed the drug list and made adjustment suggestions and finally a physician took action and performed medication changes.
11105078|NCT04040855|No Intervention|Control|Patients were treated according to the usual routine.
11105079|NCT04040829|Active Comparator|SE + TAU|"Supported education (SE) includes a variety of services ranging from orientation, study strategies or homework help. This intervention is personalized to the need of each patient in terms of services and frequency. Previous to this randomized controlled trial, we conducted interviews with each site that will provide SE. In these interviews, we explored the fidelity of their services to the Individual Placement and Support adapted to education. Information regarding the dosage of SE (frequency, length of session, type of support) will be collected and used as covariates for each participant since intensity treatment can impact outcomes.
~Treatment as usual (TAU) consists of medication and routine contact with the clinical team. Patients will continue to receive their standard treatment, but we will collect information regarding the type of medication, the dosage, and all other relevant information and use it as covariate in our analyses."
11105080|NCT04040829|Experimental|CR + SE + TAU|"Cognitive remediation therapy (CR) will be conducted using CIRCuiTS, a computerized program designed to improve cognition (attention, memory, executive functioning) and metacognitive skills. CIRCuiTS has an integrated focus on the transfer of cognitive skills to daily living, using real-world goals and homework to facilitate in vivo use of new strategies, as well as a formulation-based approach, which takes into account the impact of cognitive strengths and difficulties with daily living skills. Each session includes about 4-8 tasks targeting a range of cognitive problems, which become more ecologically valid as the program progresses. The rate of delivery for CIRCuiTS will be two to three sessions per week, for a maximum of 40 sessions. The therapy will be provided entirely online with a therapist, using the platform Zoom.
~This arm will include our active control condition : supported education (SE) as well as Treatment as usual (TAU) as previously described."
11105081|NCT04040816|Experimental|Dose A|Dose A SAP-001 versus placebo
11105082|NCT04040816|Experimental|Dose B|Dose B SAP-001 versus placebo
11105083|NCT04040816|Experimental|Dose C|Dose C SAP-001 versus placebo
11105084|NCT04040816|Experimental|Dose D (allopurinol patients)|Dose D SAP-001 versus placebo in gout patients who remain on allopurinol
11105085|NCT04040803|Experimental|10 Hz tACS|"Stimulation will be applied at 10 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~10 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
11105086|NCT04040803|Experimental|20 Hz tACS|"Stimulation will be applied at 20 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~20 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
11105087|NCT04040803|Experimental|70Hz tACS|"Stimulation will be applied at 70 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~70 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
11105088|NCT04040803|Experimental|0.1-640Hz tRNS|"Stimulation will be applied at 0.1-640Hz tRNS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.
~0.1-640Hz tRNS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
11105089|NCT04040803|Sham Comparator|Sham|"Stimulation will be performed only for 10 s before the fade out, with 20 Hz tACS and an intensity of 1.5 mA (peak to peak).
~Sham condition will be applied over pseudo-stimulation of pharyngeal cortex region and contralateral supraorbital region."
11105090|NCT04040790|Experimental|Healthy volunteers|15 healthy volunteers for trials with passive artificial iris
11105091|NCT04040764|Experimental|Uncemented Tritanium Knee Replacement|30 participants will be randomly allocated to receive an uncemented Tritanium total knee replacement.
11105092|NCT04040764|Active Comparator|Cemented Triathlon Knee Replacement|30 participants will be randomly allocated to receive standard Triathlon cemented total knee replacements.
11105093|NCT04040751|Experimental|CARE-CITE Carepartner|This study arm consists of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
11105134|NCT04040465|Active Comparator|Overweight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
11105094|NCT04040751|Active Comparator|Control Carepartners|"Carepartners (CP) receiving customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The CP will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
11105095|NCT04040751|Experimental|CARE-CITE Stroke Survivor|This study arm consists of stroke survivors of carepartners receiving the CARE-CITE intervention. The CARE-CITE intervention will occur over 4 weeks in the dyad's home. The research interventionist will conduct two in-home visits (at orientation and during week 4), two phone call visits (at weeks 2 and 3), and one telephone follow up at week 8.
11105096|NCT04040751|Active Comparator|Control Stroke Survivors|"Stroke survivors (SS) or carepartners receiving customary care outpatient rehabilitation therapy but no CARE-CITE intervention. The CP will receive the same number of structured weekly phone calls and the booster call to answer any questions, assess helpfulness of the information and ascertain if there was any use of the web resources or social support groups."
11105097|NCT04040738|Active Comparator|Upper extremity surgery under general anaesthesia|Fentanyl 2 mcg/kg iv, propofol 2 mg/kg iv induction, 1MAC sevoflurane maintenance
11105098|NCT04040738|Active Comparator|Upper extremity surgery under regional anaesthesia|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
11105099|NCT04040725|Experimental|Rogaratinib|"Rogaratinib is administered orally twice daily
~Rogaratinib is held for 72 hours before cystoscopy/TURBT and if no complications are seen, treatment is resumed 24 hours after the TURBT"
11105100|NCT04040712|Experimental|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
11105101|NCT04040712|Sham Comparator|Sham FMT|Sham fecal microbiota transplantation
11105102|NCT04040699|Experimental|KN026 combined with KN046|"KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.
~KN046 is a PD-L1 - CTLA-4 bispecific antibody."
11105103|NCT04040686|Experimental|Injection of 99mTc-NM02|All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99mTc-NM02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection.
11105104|NCT04040686|Experimental|Injection of 188Re-NM02|Ten breast cancer patients recruited to the study will be administered 66 MBq/kg of 188Re-NM02 (188Re labeled anti-HER2 sdAb) in a single dose injection.
11105105|NCT04040673||Normal benign|participants with normal benign nodules (no cancer)
11105106|NCT04040673||Follicular thyroid cancer|participants with follicular thyroid cancer
11105107|NCT04040673||Papillary thyroid cancer|participants with papillary thyroid cancer
11105108|NCT04040673||Anaplastic thyroid cancer|participants with anaplastic thyroid cancer
11105109|NCT04040673||Medullary thyroid cancer|participants with medullary thyroid cancer
11105110|NCT04040647||colorectal surgery|50 consecutive patients scheduled to colorectal surgery in an enhanced recovery programme
11105111|NCT04040647||bariatric surgery|50 consecutive patients scheduled to bariatric surgery (gastric by-pass, sleeve gastrectomy) in an enhanced recovery programme
11105112|NCT04040634|Experimental|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP <120 mm Hg.
11105113|NCT04040634|Active Comparator|Standard Control of Systolic Blood Pressure (SBP)|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg.
11105114|NCT04040621|Experimental|Ceftazidime-avibactam|This arm includes 4 cohorts
11105115|NCT04040608||experimental group|differences in responses to visual analog scales depending on screen sizes
11105116|NCT04040595|Experimental|Adipocyte measurement|Abdominal fat biopsy
11105117|NCT04040569|Experimental|Single-fraction stereotactic partial breast radiotherapy|The primary objective is to escalate the dose of 1 fraction stereotactic partial breast radiotherapy utilizing the Gammapod or Cyberknife system to an ablative dose in the pre-operative setting to the primary tumor without exceeding the maximum tolerated dose in patients with early stage breast cancer.
11105118|NCT04040556||anesthesia residence|anesthesia residences who currently study in the department of Anesthesia and voluntarily enrolled into the study
11105119|NCT04040543|Experimental|Daily|Daily supplementation with product containing markers
11105120|NCT04040543|Experimental|Intermittent|Daily supplementation with either the product containing markers or the product not containing markers
11105121|NCT04040543|Placebo Comparator|Control|Daily supplementation with product not containing markers
11105122|NCT04040530||Cryoablation|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with CT-guided cryoablation at Odense University Hospital in the period from 1/6-2019 to 1/6-2021.
11105123|NCT04040530||Partial nephrectomy|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with partial nephrectomy at Odense University Hospital or Zealand University Hospital in the period from 1/6-2019 to 1/6-2021.
11105124|NCT04040504|Experimental|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
11105125|NCT04040504|Active Comparator|Pentax ED-34i10T Duodenoscope|Pentax ED-34i10T Duodenoscope
11105126|NCT04040491|Experimental|Newly diagnosed PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
11105127|NCT04040491|Other|Relapse/refractory PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
11105128|NCT04040478||Abdominal|80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.
11105129|NCT04040478||Vascular|20 patients undergoing femoral endarterectomy.
11105130|NCT04040465|Active Comparator|Normal Weight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
11105131|NCT04040465|Active Comparator|Normal Weight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
11105132|NCT04040465|Active Comparator|Normal Weight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
11105133|NCT04040465|Active Comparator|Overweight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
11105135|NCT04040465|Active Comparator|Overweight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
11105136|NCT04040465|Active Comparator|Obese/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
11105137|NCT04040465|Active Comparator|Obese/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
11105138|NCT04040465|Active Comparator|Obese/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
11105139|NCT04040452|Experimental|Treatment|"Description: Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte). To eliminate excess exposure and the associated side effects, all patients enrolled in the study will not be given any additional NSAIDs (except aspirin, which is standard of care in many post-operative cardiac surgery patients) during the study period.
~Dosage and Route of Administration:
~Continuous ketorolac 0.08mg/kg/hr, with a maximum of 5mg/hr for patients weighing greater than or equal to 60kg, administered intravenously by nursing staff. Study drug will infuse continuously for 48 hours.
~Intermittent Plasmalyte 0.033mL/kg (max 2mL) infusion every 6 hours for 48 hours."
11105140|NCT04040452|Placebo Comparator|Standard of care|"Description: Patients randomized to the standard of care arm of the study will receive a generically marked syringe of Plasmalyte to be infused at the same rate as the treatment medication, and will only receive intermittent dosing of ketorolac (current standard of care). As in the treatment group, no additional NSAIDs (except aspirin) are to be given during the 48 hour study period.
~Dosage and Route of Administration
~Continuous Plasmalyte infusion to match the aforementioned ketorolac dosing
~Intermittent ketorolac 0.5mg/kg IV infusion every 6 hours (max 30mg per dose)"
11105141|NCT04040439||Dexmedetomidine Hydrochloride|"Pediatric patients (45 weeks corrected gestational age to <18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation during and after mechanical ventilation in the intensive care setting"
11105142|NCT04040426|Experimental|Human split thickness skin allograft (Theraskin™)|Theraskin™ is an all-human split thickness skin allograft with a native extracellular matrix that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing. Theraskin™ is an allograft tissue and will be used in compliance with homologous use by the FDA under section 361 of the PHS Act and 21 CFR Part 1271
11105143|NCT04040426|Active Comparator|Fibracol wound dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
11105144|NCT04040400|Experimental|Treatment Arm|intraoperative radiotherapy (IORT) arm
11105145|NCT04040387|Experimental|Treatment Arm|Intervention with NightWare Therapeutic System
11105146|NCT04040387|Sham Comparator|Sham Arm|NightWare system set to not provide any interventions
11105147|NCT04040374|Experimental|AI-based diagnosis|• AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
11105148|NCT04040374|Active Comparator|Expert endoscopist diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
11105149|NCT04040361|Experimental|Pembrolizumab+Ramucirumab+Surgery|Pembrolizumab and Ramucirumab will be administered simultaneously for non small cell lung cancer patients for 2 cycles before surgery.
11105150|NCT04040348|Experimental|hMSC Treatment group|Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period.
11105151|NCT04040322|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
11105152|NCT04040322|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
11105153|NCT04040309|Experimental|Plasma rich in growth factors group|Group of patients who will receive 1 ml of PRGF 2nd fractions injections into their trigger points in the masseter muscle.
11105154|NCT04040309|Active Comparator|Lidocaine group|Group of patients who will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle.
11105155|NCT04040296|No Intervention|Usual Care|Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.
11105156|NCT04040296|Experimental|Kidney Action Team Recommendations|Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.
11105157|NCT04040270|Experimental|Live drama+DVD+Worksheets|Primary school students watched an interactive live drama in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
11105158|NCT04040270|Experimental|DVD+Worksheets|Primary school students were given DVD and worksheets and they were asked to watch the DVD and finish the worksheets with their parents. After the study finished, the students watched the live drama.
11105159|NCT04040270|No Intervention|Waitlist control|Primary school students received no intervention during the 4-week study period. After the study finished, the students watched the live drama, and DVD with worksheets were distributed to students and they were encouraged to share with their parents.
11105160|NCT04040257|No Intervention|Individual Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
11105161|NCT04040257|Experimental|Group Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
11105162|NCT04040244|Experimental|Exhaled Breath Analysis|Exhaled breathe condensate will be collected using R-tube and ReCIVA device over 5-10 minutes.
11105163|NCT04040231|Experimental|Malignant Pleural Mesothelioma (MPM)|Participants with previously treated Malignant Pleural Mesothelioma/MPM
11105164|NCT04040205|Experimental|Abemaciclib|Subjects will be treated with abemaciclib 200 mg twice daily by mouth.
11105165|NCT04040192|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied once daily (QD)
11105166|NCT04040192|Placebo Comparator|Vehicle|Vehicle ointment applied once daily (QD)
11105167|NCT04040166|Other|PET/MRI scan with 68Ga DOTATATE|PET/MRI scan with 68Ga DOTATATE of carotid arteries in in patients following head and neck radiation therapy
11105168|NCT04040153|Experimental|Guiding Good Choices|Enrollment in the intervention, Guiding Good Choices, a substance use initiation prevention program, will be recommended by the pediatrician to parents of those adolescents empaneled with an intervention arm pediatrician
11105169|NCT04040153|No Intervention|Control|Parents of adolescents empaneled with a control arm pediatrician will not be offered Guiding Good Choices
11105170|NCT04040140|Experimental|APA Treatment|Oncology patients with a pain rating of four or greater will receive APA treatment for patients' cancer-related pain. The ear points will be determined by the corresponding body points related to the patient's specific pain. Pain data will be tracked by electronic surveys and Electronic Health Records.
11105171|NCT04040127|Experimental|Cord blood stem cells|cord blood stem cells from Invitrx
11105172|NCT04040127|Placebo Comparator|0.9% sodium chloride (saline)|canal will be rinsed by saline solution.
11105173|NCT04040114|No Intervention|Lead-in phase|During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).
11105174|NCT04040114|Active Comparator|Active phase|During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.
11105175|NCT04040101|No Intervention|Healthy Adult|balance assessment
11105176|NCT04040101|No Intervention|Stroke|balance assessment
11105177|NCT04040101|Experimental|Stroke smartphone training|smartphone balance training
11105178|NCT04040101|Active Comparator|Stroke traditional training|traditional physical therapy training
11105179|NCT04040088|Experimental|Cohort A (68Ga-DOTATATE, PET/CT)|Patients with newly diagnosed neuroendocrine cancer receive 68Ga-DOTATATE intravenously (IV) and undergo PET/CT over 20-30 minutes at diagnosis (before any treatment) and at the time of radiation treatment planning.
11105180|NCT04040088|Experimental|Cohort B (68Ga-DOTATATE, PET/CT)|Patients with previously diagnosed with neuroendocrine cancer receive 68Ga-DOTATATE IV and undergo PET/CT over 20-30 minutes at the time of radiation treatment planning.
11105181|NCT04040075|Other|Open label|Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation
11105182|NCT04040062|Experimental|SCC|Subjects will be treated according to their frequency response pattern which may show one or more distinct frequencies of stimulation that generated increased SCC
11105183|NCT04040049|Experimental|FLT190|FLT190 is a replication-incompetent adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
11105184|NCT04040036|Experimental|VR-Rollercoaster|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, individuals feel as if they are getting on and riding a rollercoaster. The rollercoaster speeds up and slows down.
11105185|NCT04040036|Experimental|VR-Ocean Rift|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
11105186|NCT04040036|No Intervention|Control|They would be monitored during the procedure if their informed consent was received. Control group children did not receive any distraction techniques.
11105187|NCT04040023|Other|I Group: PBMi|Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices
11105188|NCT04040023|Experimental|C Group: PBMc|"Patient Blood Management: full program
~PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)"
11105189|NCT04040010|Experimental|Postmenopausal women colostrum supplement|
11105190|NCT04040010|Experimental|Osteoporosis patients colostrum supplement|
11105191|NCT04040010|Experimental|Osteopenia patients colostrum supplement|
11105192|NCT04040010|Placebo Comparator|Postmenopausal women placebo|
11105193|NCT04040010|Placebo Comparator|Osteoporosis patients placebo|
11105194|NCT04040010|Placebo Comparator|Osteopenia patients placebo|
11105195|NCT04039997|Experimental|Chest compression without cpr feedback device|teaching resuscitation without application of cpr feedback device
11105196|NCT04039997|Experimental|Chest compression with cpr feedback device|teaching resuscitation with application of CPRMeter - cpr feedback device
11105197|NCT04039984|Experimental|Prime Cup|The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.
11105198|NCT04039971|Active Comparator|Tendon-Bone Graft|Participants receive the Quadriceps Tendon Tendon-Bone Graft technique during ACL reconstruction.
11105199|NCT04039971|Active Comparator|All-Soft-Tissue Graft|Participants receive the Quadriceps Tendon All-Soft-Tissue Graft technique during ACL reconstruction.
11105200|NCT04039958|Experimental|T test|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
11105201|NCT04039958|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
11105202|NCT04039958|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
11105203|NCT04039932|Experimental|Intervention|
11105204|NCT04039932|No Intervention|Standard of Care|
11105205|NCT04039919|Experimental|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
11105206|NCT04039919|Placebo Comparator|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
11105207|NCT04039919|No Intervention|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
11105208|NCT04039919|No Intervention|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
11105209|NCT04039919|Experimental|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
11105210|NCT04039919|Placebo Comparator|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
11105211|NCT04039906|No Intervention|Removal of needle with existing method|Participants will remove needles from syringes with the existing method like they are already doing. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
11105212|NCT04039906|Experimental|Removal of needle with using ANDYs|Participants will remove needles from syringes with Andy. (Record the time required for the needle removal procedure by photographing during 24 hours/7 days.)
11105213|NCT04039893|Other|Node-positive breast cancer patients|All patients with positive lymph nodes for who an axillary node clearance is proposed as part of the surgical treatment
11105214|NCT04039880|Experimental|Cohort A (mass balance)|evaluation of mass balance and metabolite profiling
11105215|NCT04039880|Experimental|Cohort B (biliary evaluation)|evaluation of biliary elimination
11105216|NCT04039867|Experimental|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
11105217|NCT04039854|Active Comparator|Volatile anaesthetics arm|Patients randomised to receive volatile anaesthetics will receive either isoflurane, sevoflurane or desflurane during the surgical procedure.
11105218|NCT04039854|Active Comparator|Propofol anaesthetics arm|Patients randomised to receive propofol will not receive any volatile anaesthetics during the surgical procedure.
11105219|NCT04039841|Other|Motor imagery evaluation|cohort study
11105220|NCT04039828|Experimental|Stratum|"Stratum 1: From 3 months to <18 months= 175 Stratum 2: From 18 months to 59 months= 175
~In total, 350 participants will be enrolled"
11105221|NCT04039815|Experimental|ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group|"patients in study group, so called ABC (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days"
11105222|NCT04039815|Placebo Comparator|normal saline group|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
11105223|NCT04039802||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery
11105224|NCT04039802||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures
11105225|NCT04039789|Active Comparator|Control|Usual Care: that consists of healing the wound (assessment, cleaning, disinfection, debridement and topical treatment) and compression therapy multilayer usual practice, according to the recommendations for the treatment of cutaneous ulcers of the Region of Madrid.
11105226|NCT04039789|Experimental|Intervention|"ACTIVE LEGS: The usual care plus experimental intervention. It is a structured educational intervention, directed by nurses and carried out in the health center consultations. The intervention Active Legs has been designed based on the available evidence. It incorporates a program of lower limb exercise at home and daily walking patterns.
~Home program of lower limb exercises. The nurse will instruct the patients in the performance of 4 exercises of lower limbs of progressive difficulty that must be performed at home 5 days a week, twice a day Daily walking program. In addition, patients must ambulate progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)) .
~At the start of the study, the Active Legs diary will be provided, showing the patterns of the exercise and walking program graphically and a pedometer."
11105227|NCT04039763|Experimental|Real Time Continuous Glucose Monitoring|"Participants wear Real time continous glucose monitoring (Dexcom G6), with alarms for when their glucose is too low or too high. They will be able to view their data on the Dexcom app on their smartphones or a Dexcom receiver and share this with a nominated caregiver. Participants can chose to share data between study visits via Dexcom clarity with the research/clinical team, who will support them making changes to their insulin regime in light of the data."
11105228|NCT04039763|Placebo Comparator|Standard care|Standard care - finger prick self monitoring of blood glucose.
11105229|NCT04039750|Experimental|Antibiotic irrigation with suction|Group A: You will receive antibiotic irrigation with suction if a PA is found during surgery
11105230|NCT04039750|Active Comparator|suction only|Group B: You will receive suction alone if a PA is found during surgery
11105231|NCT04039737|Experimental|Treatment Group|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
11105232|NCT04039737|No Intervention|Control Group|
11105233|NCT04039724|Experimental|Sequence A|"Period 1 : HCP0605+HGP0816
~Period 2 : HCP1305"
11105234|NCT04039724|Experimental|Sequence B|"Period 1 : HCP1305
~Period 2 : HCP0605+HGP0816"
11105235|NCT04039711|Other|Genital infections|Women with vaginal/cervical sampling indications
11105236|NCT04039698|Experimental|Telemedicine|Sofosbuvir 400mg and velpatasvir 100mg qd for 12 weeks Telemedicine support
11105237|NCT04039685|Experimental|Aerobic exercise group|
11105238|NCT04039685|Experimental|Resistance exercise group|
11105239|NCT04039685|Experimental|Combined (aerobic+resistance) exercise group|
11105240|NCT04039685|No Intervention|Non-exercise group|
11105241|NCT04039672|Experimental|Biopsy|Skin biopsy before BRAFi/MEKi treatment
11105242|NCT04039659|No Intervention|Control Group|Patients will be cured with dressings wound everyday or before if there are complications in surgical incisions.
11105243|NCT04039659|Active Comparator|PICO group|Patients will carry the device for 7 days uninterrupted until its withdrawal.
11105244|NCT04039646|Active Comparator|Standard postoperative care group|Patients received standard postoperative care as ususal.
11105245|NCT04039646|Experimental|ERAS group|Patients received postoperative ERAS treatment.
11105246|NCT04039633|Experimental|Burst spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
11105247|NCT04039633|Sham Comparator|sham spinal cord stimulation (SCS)|following implantation of a generator that sends pulses to a thin wire (lead), which delivers pulses to nerves along the spinal cord, the patients will initially undergo four six-week long periods with either burst SCS or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.
11105248|NCT04039607|Experimental|Nivolumab + Ipilimumab|
11105249|NCT04039607|Active Comparator|Sorafenib/lenvatinib|
11105250|NCT04039594||ECMO|
11105251|NCT04039581|Experimental|Group Kinesio Taping and TENS|"The number of participants in this group is anticipated to be 30. The treatment method for this group is the conventional treatment + KT (Kinesio Taping) relaxation technique (muscle inhibition technique). In KT technique, while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.
~In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises."
11105252|NCT04039581|Active Comparator|Group TENS|The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment TENS (Transcutaneous electrical nerve stimulation) applications and therapeutic exercises on the painful area every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. The conventional therapy method will also include therapeutic exercises. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist. Therapeutic exercises will consist of active shoulder evolution, active cervical rotations, active cervical lateral flexion movement and active shoulder flexion and abduction exercises.
11105253|NCT04039581|Active Comparator|Group Kinesio Taping|The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position.
11105254|NCT04039568|Active Comparator|Active Control Group|"Ten to fifteen participants in the HEP arm will participate in the program for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.
~The Health-Enhancement Program (HEP) was designed and used as a manualized active control in meditation-based intervention trials. HEP controls for several non-specific factors found in a meditation groups, including: group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is tailored to be structurally equivalent to SSM with similar-sized groups, meeting schedule, total contact hours, amount of home practice and encouragement to keep practice logs."
11105255|NCT04039568|Experimental|Intervention Group|"Ten to fifteen participants in the SSM arm will be trained for 4 consecutive days (2hrs/day) in the 1st week, followed by 75 min/week reinforcement sessions for 11 weeks.
~This standardized, manualized therapy will be delivered by certified meditation instructors. On day 1, participants will learn the nature of meditation, and then undergo personal guided meditation. Training on days 2-4 includes understanding the nature of the mind and the thoughts arising from it, guided meditations by the instructor, and a discussion of meditation processes. Weekly 75 min reinforcement sessions will include 20 minutes of guided meditation practice, and then focus on participants' experiences with meditation during the week, additional observations, and a review of relevant knowledge to support their home practice. Participants will also be encouraged to practice twice daily at home for 20 minutes per session."
11105256|NCT04039555|Active Comparator|Active Arm - CO2 intimate|Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart
11105257|NCT04039555|Active Comparator|Active Arm - Erbium-yag|Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart
11105258|NCT04039555|Sham Comparator|Sham Arm|Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart
11105259|NCT04039542|Experimental|Compassion focused therapy (CFT)|A group programme of CFT running for 10 sessions lasting 90 minutes per session.
11105260|NCT04039529|No Intervention|CT-only guided biopsy|The current standard of care for biopsy at Temple University Hospital.
11105261|NCT04039529|Experimental|SCENERGY-guided Biopsy|The use of the SCENERGY to fuse CT and Ultrasound for biopsy
11105262|NCT04039516|Experimental|Lutathera Treatment Arm|• 4x cycles of 7.4 GBq (200mCi) of Lutathera therapy (177Lu-DOTA0-Tyr3-Octreotate) with concomitant amino acids for participants randomised onto the Lutathera therapy arm, every 8 weeks, plus long term somatostatin analogues (SSTA).
11105263|NCT04039516|No Intervention|Best Supportive Care|Somatostatin analogue treatment according to current standard, routine care
11105264|NCT04039503|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11105265|NCT04039503|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11105266|NCT04039503|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11105267|NCT04039503|Placebo Comparator|Placebo|Placebo administered SC once a week.
11105268|NCT04039490|No Intervention|Ultrasound-only Pediatric Vessel Cannulation|The standard of care for vessel cannulation currently employed at CNMC
11105269|NCT04039490|Experimental|SCENERGY-guided Pediatric Vessel Cannulation|The addition of the SCENERGY guidance combined with the ultrasound for pediatric vessel cannulations.
11105270|NCT04039477|Experimental|Arm A - KZR-616 30mg|KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks
11105271|NCT04039477|Experimental|Arm B - KZR-616 45mg|KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.
11105272|NCT04039464|Active Comparator|Monotherapy with Sildenafil Group|mono-therapy: first-line monotherapy (sildenafil alone) - in pediatric subjects with PAH.
11105273|NCT04039464|Active Comparator|Duo Therapy with Sildenafil + Bosentan Group|duo-therapy: compare two treatment strategies - first-line combination therapy (sildenafil and bosentan)
11105274|NCT04039451||people who live in rural areas in Assuit governorate|The study will performed on people who live in rural areas in Assuit governorate (all households) regardless of sex or age.
11105275|NCT04039425||cancer patient|"Recently diagnosed cancer stage 1, 2, or 3
~Assigned to receive immunosuppressive chemotherapy treatment
~Natural hair that has not been dyed or permed in the past 3 months"
11105276|NCT04039412|Active Comparator|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
11105277|NCT04039412|Active Comparator|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
11105278|NCT04039412|Active Comparator|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
11105279|NCT04039399|Experimental|Ischemic Conditioning|Study participants will receive one session of ischemic conditioning on their affected leg with cuff inflation to 225 mmHg.
11105280|NCT04039399|Sham Comparator|Sham Ischemic Conditioning|Study participants will receive one session of sham ischemic conditioning on their affected leg with cuff inflation to 10 mmHg.
11105281|NCT04039386|Experimental|Cell Phone Based Cognitive Based Therapy|Young adults with hip pain
11105282|NCT04039386|Placebo Comparator|Placebo|Young adults with hip pain
11105283|NCT04039373|Experimental|Treatment Arm|
11105284|NCT04039347|Experimental|L-CsA 5 mg plus Standard of Care|L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant
11105285|NCT04039347|Experimental|L-CsA 10 mg plus Standard of Care|L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant
11105286|NCT04039334|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 week. All exercise sessions will be performed at home.
11105287|NCT04039334|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
11105288|NCT04039321|Active Comparator|ESPB group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
11105289|NCT04039321|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
11105290|NCT04039282|Other|Patient Participant|Patients will be asked to complete an 3 days worth of an online dietary recall prior to their out patient appointment with the dietitian
11105291|NCT04039282|Other|Dietitian Participant|The Dietitian will be asked to review the patients completed dietary recalls prior to the patient attending their out patient appointment.
11105292|NCT04039269|Active Comparator|Multiple (watch > 3 times)|Preoperative video information
11105293|NCT04039269|Active Comparator|single (watch 1 time)|Preoperative video information
11105294|NCT04039269|No Intervention|conventional (do not watch)|Do not watch video
11105295|NCT04039256|Experimental|PVR implantation group|Patients enrolled receive PVR intervention
11105296|NCT04039243|Experimental|Active Treatment|Up to 12 sessions of Parent-Child CBT using an adaptation of the Being Brave protocol
11105297|NCT04039243|Active Comparator|Parent Education|Parents receive educational materials about how to help young children overcome shyness and anxiety
11105298|NCT04039243|No Intervention|Monitoring|
11105299|NCT04039230|Experimental|Sacituzumab Govitecan+Talazoparib|"Sacituzumab Govitecan is administered on days 1 and 8 of a 21 day cycle.
~Talazoparib is administered daily"
11105300|NCT04039217|Experimental|Group A|Group A will provide biological specimens 2, 48, and 96 hours after the in-clinic dose of TAF/FTC/BIC. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre- wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at 1 study timepoint.
11105301|NCT04039217|Experimental|Group B|Group B will provide biological specimens 4, 26, and 120 hours after the in-clinic dose of TAF/FTC/BIC. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre- wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at 1 study timepoint.
11105302|NCT04039217|Experimental|Group C|Group C will provide biological specimens 24, 28, and 72 hours after the in-clinic dose of TAF/FTC/BIC. Approximately 24 mL of blood will be drawn, an oral cheek swab, 1 pre- wet penile swab and 1 dry penile swab, and a urethral swab will be collected. After previous swab collections are complete, participants will be asked to provide a urine sample (some of which will be used for gonorrhea and chlamydia testing). Participants will undergo rectal biopsy collection at 1 study timepoint.
11105303|NCT04039204|Experimental|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
11105304|NCT04039204|Active Comparator|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
11105305|NCT04039204|No Intervention|Non-treatment group|This group will be followed without treatment
11105306|NCT04039191|Placebo Comparator|SMS survey|Subject to receive SMS survey.
11105307|NCT04039191|Active Comparator|SMS survey with education|Subject to receive SMS survey with education.
11105308|NCT04039178|Active Comparator|Treatment group|Real BQ treatment, 40 treatments including 20 minutes of device guided functional motor tasks.
11105309|NCT04039178|Sham Comparator|Control group|Sham BQ treatment, (zero intensity) 40 treatments including 20 minutes of device guided functional motor tasks.
11105310|NCT04039165|Experimental|Intervention Group|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. The investigators will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
11105311|NCT04039165|No Intervention|Wait-list Control Comparison Group|Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
11105312|NCT04039152||Pre- interventions group|Without clinical pharmacists recommendations to optimize antibiotics use
11105313|NCT04039152||Post - interventions group|interventions include clinical pharmacists recommendations to optimize antibiotics use
11105314|NCT04039139|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
11105315|NCT04039139|Active Comparator|Mind Body Intervention 1|Participants will receive a mind body educational-based intervention to learn the techniques comprising intervention 1.
11105316|NCT04039139|Experimental|Mind Body Intervention 2|Participants will receive a mind-body educational-based intervention to learn the techniques comprising intervention 2.
11105317|NCT04039126|Experimental|PATIENTS WITH MALIGNANT PLEURAL EFFUSION|PARTICIPANTS WITH MALIGNANT PLEURAL EFFUSIONS REQUIRING PLEURODESIS, COMBINATION OD POVIDONE IODOONE-TETRCYCLINE TO BE USED.
11105318|NCT04039126|Active Comparator|PATEINT WITH MALIGANT PLEURAL EFFUSION REQUIRNG PLEURODESIS|TO USE POVIDONE IODINE ALONE IN THIS GROUP
11105319|NCT04039113|Active Comparator|Tezepelumab|Tezepelumab, SC, Q4W
11105320|NCT04039113|Placebo Comparator|Matching Placebo|Matching placebo, SC, Q4W
11105321|NCT04039100|Experimental|Family Caregiver Ambassador Support|Intervention group: caregivers of newly diagnosed patients (n=30), former family caregivers as ambassadors (n=20)
11105322|NCT04039087|Active Comparator|Sildenafil|active sildenafil 40 mg p.o. three times per day
11105323|NCT04039087|Placebo Comparator|Placebo Arm|placebo three times per day
11105324|NCT04039074|Experimental|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
11105325|NCT04039074|Active Comparator|Iyengar yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
11105326|NCT04039074|Active Comparator|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
11105327|NCT04039061||ADPKD patients|Patients with a diagnosis, or suspected diagnosis, of ADPKD
11105328|NCT04039048|Experimental|ctDCS during Balance training|
11105329|NCT04039048|Sham Comparator|ctDCS sham during Balance training|
11105330|NCT04039022|Experimental|AXS-05 (dextromethorphan and bupropion)|
11105331|NCT04039009||Infertility patients|Infertility patients will be examined according to the pelvic organ prolapse quantification classification system during hysteroscopy.
11105332|NCT04038983||Observational|"ER2 is a simple and standardized clinical tool composed of two sequential components: an assessment followed by recommendations for intervention. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies (21-24). Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
11105333|NCT04038970|Experimental|KN019 5mg/kg|Intravenous (IV) solution, 5 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
11105334|NCT04038970|Experimental|KN019 10mg/kg|Intravenous (IV) solution, 10 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
11105335|NCT04038970|Placebo Comparator|Placebo|Intravenous (IV) solution, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
11105336|NCT04038957|Experimental|SEP-363856|SEP-363856 50mg, 75mg flexible dosing, dosed once daily
11105337|NCT04038944||Subjects with new onset atrial fibrillation|Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion
11105338|NCT04038918|Experimental|Progressive Muscle Relaxation Exercise Group|Standard postoperative physiotherapy program plus progressive muscle relaxation (PMR) exercise will be applied.
11105339|NCT04038918|Other|Control Group|Standard postoperative physiotherapy program will be applied.
11105340|NCT04038892|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. After the training given by the physiotherapist, all exercise sessions will be performed at home.
11105341|NCT04038892|Experimental|Nintendo Wii Fit Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive Nintendo Wii Fit based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
11105342|NCT04038892|Experimental|BreathingLabs Breathing Games Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive BreathingLabs Breathing Games based exercise training for 40 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised by physiotherapist in a clinic per week.
11105343|NCT04038879||Mitral/Aortic Regurgitation|Subjects identified with mitral or aortic regurgitation will be asked to undergo testing with trans thoracic echocardiogram, stress echocardiography, and cardiac MRI with and without contrast. In addition, patients will be asked to answer the KCC and EQ5DL questionnaires.
11105344|NCT04038866|Experimental|DUAL-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait with a dual-task program with secondary cognitive and upper limb motor tasks.
~In this group, the training of the tasks (walking and cognitive or motor) was performed separately and then they were trained at the same time under a progression system. Cognitive/motor secondary tasks were different from those used in the assessment of gait.
~Each training session consisted of three parts: the initial warm-up, dual-training, and back-to-calm."
11105345|NCT04038866|Active Comparator|SINGLE-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait without a dual-task program (physical and walking exercises without additional load of cognitive or upper limb motor tasks).
~Each training session consisted of three parts: initial warm-up, physical exercise in single-task condition, and back-to-calm.
~The objectives and walking exercises were the same as those performed in the experimental group."
11105346|NCT04038853|Experimental|Vitamin D|Intervention drug, containing 1,25-dihydroxy-vitamin D, comes in original packages as vials containing a total amount of 10 ml of clear solution. 5 drops accounting for 1000 IU of 1,25-dihydroxy-vitamin D will be administered orally on a daily basis.
11105347|NCT04038853|Placebo Comparator|Placebo|A placebo identical to the study intervention drug in all its characteristics (package, visual characteristics of the fluid, smell, and taste) will be administered in the same manner.
11105348|NCT04038840|Experimental|Healthy Control (HC) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
11105349|NCT04038840|Experimental|Schizophrenia (SZ) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
11105350|NCT04038814||VAP1 - historical group|Routine prevention of VAP
11105351|NCT04038814||VAP2 - study group|Modified prevention of VAP
11105352|NCT04038801|Active Comparator|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed over four visits at 1-weekly intervals using an assortment of manual periodontal curettes.
11105353|NCT04038801|Experimental|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
11105354|NCT04038801|Experimental|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
11105355|NCT04038788|Active Comparator|Active tRNS|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
11105356|NCT04038788|Sham Comparator|Sham treatment|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham group were maintained on their antipsychotic medications throughout the study period.
11105357|NCT04038775|Experimental|Volunteering|"The experimental arm will receive a volunteer prescription from their provider and assistance from a study team member to find a volunteer job."
11105358|NCT04038775|No Intervention|Control|The control arm will not be recommended to volunteer or assisted in finding a volunteer activity. They will answer the same survey questions as the intervention subjects.
11105359|NCT04038762|Active Comparator|Conventional nasal intubation|Passage of an endotracheal tube via the nare followed by video laryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
11105360|NCT04038762|Experimental|Nasotracheal Intubation with cuff inflation-deflation method|Nasotracheal intubation placed with video laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
11105361|NCT04038749|Experimental|Pharmaceutical method- Bromocriptine|
11105362|NCT04038749|Experimental|Pharmaceutical method- Cabergoline|
11105363|NCT04038749|Other|Without medications that inhibit lactation|
11105364|NCT04038736|Experimental|Healthy subjects at averge risk for CRC|All subjects are healthy who didn't have any known polyps in past colonoscopy and who arw candidates for CRC screening
11105365|NCT04038736|Experimental|Healthy subjects at high risk for CRC|Subjects who had polyps in former colonoscopy, subjects who have family history of CRC or subjects who have positive stool blood test.
11105366|NCT04038723|Experimental|Pre- and Post-HIIT|Participants will be evaluated before and after exercise training.
11105367|NCT04038710||Patients with severe disease|Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
11105368|NCT04038697|Experimental|Ischemic Conditioning + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning and treadmill training.
11105369|NCT04038697|Placebo Comparator|Ischemic Conditioning Sham + Treadmill Training|Study participants with prior history of stroke will receive both ischemic conditioning sham and treadmill training.
11105370|NCT04038697|Active Comparator|Ischemic Conditioning Only|Study participants with prior history of stroke will receive only ischemic conditioning.
11105371|NCT04038697|Active Comparator|Healthy Control - Ischemic Conditioning + Treadmill Training|Healthy control participants will receive both ischemic conditioning and treadmill training.
11105372|NCT04038684|Experimental|Mindfulness-Based Weight Control|All participants will be randomly assigned to a 16-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 90 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
11105399|NCT04038554||Acute Pancreatitis|Patients older than 18 years old diagnosed of acute pancreatitis according to Atlanta 2012.
11105373|NCT04038684|Active Comparator|Standard Behavioral Weight Control|All participants will be randomly assigned to a 16-week group-based Mindfulness-Based Behavioral Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the SBWC intervention will receive the SBWC without mindfulness components. Each of the 16 group sessions will be approximately 90 minutes. Outside of group sessions, participants will be asked to practice dietary self-monitoring at home during the week.
11105374|NCT04038671|Experimental|Activated Carbon Dressing|A low-adherent, comprised of 100% pure activated carbon and also conforms to body contours to maintain contact with the incision surface. The dressing may be used either dry or moistened with sterilized water over dry or discharging, partial and full thickness wounds.
11105375|NCT04038671|Active Comparator|Knitted Cellulose Acetate Mesh|a non-adhering dressing, comprised of a knitted cellulose acetate mesh impregnated with a specially-formulated petrolatum emulsion.
11105376|NCT04038671|Active Comparator|Antimicrobial Alginate Dressing with Silver|a non-adherent antimicrobial alginate dressing with silver
11105377|NCT04038658|Experimental|Intervention Group (MoveIt)|10-minute Qigong exercise session (video demonstration via website) delivered twice a day at set break times during the working day for 12 consecutive weeks
11105378|NCT04038658|No Intervention|Wait-list control group|No intervention for 12 weeks. Then received the MoveIt Intervention for 12 weeks.
11105379|NCT04038645|Active Comparator|Experimental Group (laser)|"The patients (n=18) will receive infrared LEDs in 6 points (3 on the right side and 3 on the left side) using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt (mW) . The LED light outputs will be positioned in direct contact with the skin. During application of the LED both patient and operator will wear goggles.
~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
11105380|NCT04038645|Placebo Comparator|Control group (Placebo)|The patients (n=18) will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days (by the same evaluator), as well as the evaluation of serum CRP.
11105381|NCT04038632|Experimental|District Hospital focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.
11105382|NCT04038632|Experimental|Primary Health Center focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.
11105383|NCT04038619|Experimental|Treatment (loperamide, colonoscopy, FMT)|Patients receive loperamide PO. After 4 hours, patients undergo FMT via colonoscopy over 15-30 minutes.
11105384|NCT04038606|Active Comparator|acceptance of mastectomy|Assess the determinants of acceptance of mastectomy based on personal background,Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
11105385|NCT04038606|Experimental|rejection of mastectomy|Assess the determinants of rejection of mastectomy based on personal background, Measured by questionnaires: self-image (Rosenberg),personal background (level of fragility, self-image),quality of life SF-36, QLQC30,pain (BPI-SF) and Big Five Inventory.
11105386|NCT04038593|No Intervention|Non interventional arm|Standard conditions of complex dressing cares, without experimental intervention. It will be a control intervention
11105387|NCT04038593|Active Comparator|Comparative arm with relaxation music from Youtube©|Standard conditions of complex dressing cares + use of non standardized music relaxation during complex dressing cares
11105388|NCT04038593|Experimental|Interventional arm with MUSIC CARE©|Standard conditions of complex dressing cares + administration of a specific music therapy program (U method) delivered through headphones from a tablet, under the direction of trained nurses.
11105389|NCT04038580|Sham Comparator|Prescribed Laminated Socket|In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
11105390|NCT04038580|Experimental|Adjustable Sockets|In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
11105391|NCT04038567|Experimental|High dose / therapist attention / introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and an introductory call from a therapist.
11105392|NCT04038567|Experimental|High dose / therapist attention / no introductory call|Will receive high dose intervention content, therapist attention to elevated symptoms, and no introductory call from a therapist.
11105393|NCT04038567|Experimental|High dose / app attention / introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
11105394|NCT04038567|Experimental|High dose / app attention / no introductory call|Will receive high dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
11105395|NCT04038567|Experimental|Standard dose / therapist attention / introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and an introductory call from a therapist.
11105396|NCT04038567|Experimental|Standard dose / therapist attention / no introductory call|Will receive standard dose intervention content, therapist-based attention to elevated symptoms, and no introductory call from a therapist.
11105397|NCT04038567|Experimental|Standard dose / app attention / introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and an introductory call from a therapist.
11105398|NCT04038567|Experimental|Standard dose / app attention / no introductory call|Will receive standard dose intervention content, app-based attention to elevated symptoms, and no introductory call from a therapist.
11105400|NCT04038554||Healthy Control|Healthy people with a proximity relationship with case patients and similar age (+/- 5 years).
11105401|NCT04038541|Other|Prebiotic/ Probiotic|These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
11105402|NCT04038541|Other|Probiotic/ Prebiotic|These subjects will be assigned to first receive probiotics (Visbiome®) for 6 weeks. Then after a 6 week wash-out period, subjects will take (Prebiotin Prebiotic Fiber Stick) for 6 weeks (followed again by a 6 week washout period).
11105403|NCT04038528||Telemedicine Group|Patients in this group monitor blood sugar levels at home and upload their data through a telemedicine systems.
11105404|NCT04038528||Control Group|The control group will attend their routine appointments scheduled by their GPs and specialists in outpatient clinics and will record blood sugar levels according to the traditional method as per GP or specialist physician's indications.
11105405|NCT04038515|Experimental|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
11105406|NCT04038515|Experimental|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
11105407|NCT04038515|Experimental|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
11105408|NCT04038515|Experimental|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
11105409|NCT04038502|Active Comparator|Treatment Arm 1 - Carboplatin to Olaparib|Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.
11105410|NCT04038502|Active Comparator|Treatment Arm 2 - Olaparib to Carboplatin|Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.
11105411|NCT04038489|Experimental|Tamoxifen and Aspirin with AC-T Chemotherapy|AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor.
11105412|NCT04038476|Other|Standard monitoring|"When assigned to the group Standard monitoring:
~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. The examiner (doctor or physicians involved in the study) are blinded to the transcutaneous CO2 measurement. An adjustment of the sedation management therefore takes place on the basis of the monitoring measures mentioned above. Transcutaneous CO2 monitoring is recorded in the background (Excel table of all registered values) and also monitored by the sedation assisting nurse and integrated into the standard sedation protocol."
11105413|NCT04038476|Other|Standard monitoring + transcutaneous CO2 monitoring|"When assigned to the group Standard monitoring + transcutaneous CO2 monitoring:
~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. In this group, the values of transcutaneous, continuous CO2 monitoring, including an alarm sound, are accessible to the treating physicians. Moreover, sedation management is adjusted on the basis of transcutaneous CO2 measurement. The above-mentioned measurements of the standard monitoring are carried out as described, in addition there is the the transcutaneous CO2 monitoring."
11105414|NCT04038463|Experimental|Early Follicular Phase (EFP)|The group will engage in the Resistance Training intervention on the fourth day of their menstrual cycle, which will correlate with the middle of the early follicular phase (EFP).
11105415|NCT04038463|Experimental|Late Follicular Phase (LFP)|The group will engage in the Resistance Training intervention on the eleventh day of their menstrual cycle, which will correlate with the middle of the late follicular phase (LFP).
11105416|NCT04038463|Experimental|Early Luteal Phase (ELP)|The group will engage in the Resistance Training intervention on the eighteenth of their menstrual cycle, which will correlate with the middle of the early luteal phase (ELP).
11105417|NCT04038463|Experimental|Late Luteal Phase (LLP)|The group will engage in the Resistance Training intervention on the twenty-fifth day of their menstrual cycle, which will correlate with the middle of the late luteal phase (LLP).
11105418|NCT04038450||Practicing Physical Therapists|licensed physical therapists currently practicing
11105419|NCT04038450||Student Physical Therapists|students currently enrolled in DPT program
11105420|NCT04038437|Experimental|CPX-351 and Venetoclax|CPX-351 and Venetoclax will be administered over 28 day cycles
11105421|NCT04038424|Experimental|Study group|The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
11105422|NCT04038424|No Intervention|Control group|The control group (n = 30) will receive only the Routine Hospital Management (RHM) and the department conventional rehabilitation activity.
11105423|NCT04038411|Experimental|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 Antibody: 240mg, d1, Chidamide: 20mg, twice a week, Lenalidomide: 25mg, d1-14 Etoposide:100mg/m2, d1-3 and 21 days made one treatment cycle.
11105424|NCT04038398|Other|FiO2 : 100% - 50% - 21%|see above
11105425|NCT04038398|Other|FiO2: 21% - 50% - 100%|see above
11105426|NCT04038385|Experimental|Intervention|This group will receive routine services provided by WIC and an intervention that will combine behaviorally-focused nutrition education with 1) the establishment of a WIC-based farmers' market (implemented in 2019 during the WIC Farmers' Market Nutrition Program voucher issuance period [June 19 to August 19]), and 2) monthly trips to an area farmers' market and local supermarket (between September 1, 2019 and November 30, 2019 [the end of the local growing season]).
11105427|NCT04038385|No Intervention|Control|This group will receive routine services provided by WIC only.
11105428|NCT04038359|Experimental|Duvelisib, Continuous and Intermittent Dosing|Duvelisib 25 mg BID continuously for 10 weeks, followed by 25 mg BID dosed two weeks on and two weeks off of each subsequent 4-week cycles.
11105429|NCT04038359|Experimental|Duvelisib, Intermittent Dosing|Duvelisib 25 mg BID dosed two weeks on and two weeks off.
11105430|NCT04038346|Experimental|NSAID|Naproxen at weight based standard dose given bid daily until symptoms resolve
11105431|NCT04038346|Active Comparator|Acetaminophen|Acetaminophen at weight based standard dose given qid until symptoms resolve
11105432|NCT04038346|Experimental|NSAID first, then Acetaminophen|Naproxen at weight based standard dose given bid for one week, then acetaminophen at weight based standard dose given qid until symptoms resolve
11105433|NCT04038346|No Intervention|Standard Care|Symptom observation only
11105434|NCT04038333||Children|Interviewees are parents or grandparents of children aged between 6 to 59 months.
11105435|NCT04038333||Elderly|Interviewees are the elderly aged 60 years old or above.
11105436|NCT04038333||Chronic disease patients|Interviewees are adult patients with chronic diseases aged below 60 years old.
11105437|NCT04038333||Vaccination and health care personnel|Interviewees are vaccination and health care personnel in each study site.
11105438|NCT04038320||HCV infected patients|All HCV infected confirmed by HCV RNA,
11105439|NCT04038307|Placebo Comparator|control|will receive 100 ml of saline
11105440|NCT04038307|Experimental|paracetamol group|will receive 1gm paracetamol (100ml)
11105441|NCT04038294|Experimental|Protein Supplementation|The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
11105442|NCT04038294|Placebo Comparator|Placebo Supplementation|Enrolled patients allocated to the control group will receive the same supplementation schedule as well as compliance verification; however, they will receive a placebo product with no supplemented protein (no nutritional benefit).
11105443|NCT04038268||Patients|Adults and children, males and females, with IgE mediated pollen, house dust mites, animal dander and moulds respiratory allergy who will initiate aeroallergen AIT, either SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice
11105444|NCT04038268||Prescribers|Doctors who are currently prescribing AIT as part of their regular clinical practice
11105445|NCT04038255|Active Comparator|Usual Care|Participants in this group will receive a brief advice to quit smoking, 6-week supplies of nicotine replacement therapy (NRT), and self-help materials to quit smoking.
11105446|NCT04038255|Experimental|Craving-to-Quit app|"Participants in this group will receive one in-person orientation session, 6-week supply of NRT, the Craving-to-Quit app, and two brief follow-up phone calls."
11105447|NCT04038255|Experimental|In-person Mindfulness Training|Participants in this group will receive twice weekly group sessions (eight total during 4 weeks) that were manualized and delivered by instructors experienced in Mindfulness Training (MT) (a single therapist with >4 years of training in MT).
11105448|NCT04038242|Experimental|Resilience promotion program|Subjects in the intervention group will participate in an eight-session resilience promotion program.
11105449|NCT04038242|No Intervention|Treatment as usual|Treatment as usual for subjects in the control group.
11105450|NCT04038229|No Intervention|Standard of care|Prospective derived data from children and adolescents undergoing spinal fusion due to idiopathic scoliosis
11105451|NCT04038229|Experimental|Enhanced recovery pathway|Children and adolescents undergoing spinal fusion due to idiopathic scoliosis using the pre -per and postoperative enhanced recovery protocol
11105452|NCT04038216||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
11105453|NCT04038216||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures.
11105454|NCT04038203||Neonates with UAC placement|Neonates with birth weight less than 1500 grams with UAC placed on admission. Raman measurements will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
11105455|NCT04038190|Experimental|Behavioral Activation Course|Behavioral activation course condition administered in a college freshman orientation seminar
11105456|NCT04038190|No Intervention|Standard Orientation Course|Standard freshman orientation seminar course condition
11105457|NCT04038177|Experimental|Superset strength training|This is the experimental group that performs strength training with sets and rest intervals programmed in a superset manner
11105458|NCT04038177|Active Comparator|Traditional strength training|This is the comparator group that engages in strength training with sets and rest intervals programmed in accordance with the recommendations from The American College of Sports Medicine
11105459|NCT04038164|Experimental|Dog-Assisted Therapy (DAT) and pharmacological treatment|The DAT program comprised 12 manualized sessions and included two phases: 1) individual intervention (6 sessions) and 2) group activity (6 sessions). Patients participated in weekly sessions for about 3 months. Each session lasted 45 minutes. The groups were formed by 3-4 patients. Sessions included the participation of two certified therapy dogs, two technicians specialized in DAT and a psychologist. Participants in this group were visited by their psychiatrist in order to monitor their adherence to medications.
11105460|NCT04038164|Active Comparator|Treatment as usual (TAU, pharmacological treatment)|Participants received their usual treatment. They were visited by their psychiatrist in order to monitor their adherence and continuation on medications as prescribed. Inclusion and exclusion criteria were the same as for the experimental group. Participants in the TAU group did not receive DAT sessions.
11105461|NCT04038151|Experimental|Condition A: Hybrid Leg|Subject will be trained on use of the experimental device, the Hybrid Leg.
11105462|NCT04038151|Other|Condition B: Passive Leg|Subject will use their currently prescribed home passive prosthesis
11105463|NCT04038138|Experimental|Patient with muscular dystrophy|
11105464|NCT04038125|Other|Ozurdex Implant|Intravitreal injection of Ozurdex implant
11105465|NCT04038112|Other|Method of Levels (MOL)|all participants will be offered intervention
11105466|NCT04038099|Placebo Comparator|Water Based Lubricating Jelly|5ml of Water Based Lubricating Jelly
11105467|NCT04038099|Active Comparator|Lidocaine 2% Jelly|5ml of Lidocaine 2% Jelly
11105468|NCT04038086|Experimental|oral glucose tolerance test|
11105469|NCT04038086|Other|circadian rhythm|
11105470|NCT04038086|Experimental|effect of insulin on peptide transport|
11105471|NCT04038073||ADHD|Attention Deficit/Hyperactivity Disorder
11105472|NCT04038060|Experimental|WhatsApp Group|Participants will be assigned to participate in a WhatsApp Group
11105473|NCT04038060|Experimental|2-way SMS|Participants will be assigned to receive weekly 2-way SMS initiated by the study team
11105474|NCT04038060|Experimental|2-way SMS and monthly counseling sessions|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions
11105475|NCT04038060|Experimental|2-way SMS and drug level feedback|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback
11105476|NCT04038060|Experimental|WhatsApp Group and monthly counseling sessions|Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions
11105477|NCT04038060|Experimental|WhatsApp Group and drug level feedback|Participants will be assigned to participate in a WhatsApp Group and drug level feedback
11105478|NCT04038047||Core|Cystic Fibrosis patients prescribed elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).
11105479|NCT04038034|Placebo Comparator|group A|35 patients treated with pressure lowering drugs and placebo
11105480|NCT04038034|Experimental|group B|35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
11105481|NCT04038021|Experimental|PEth-based CM|PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result. They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row. There is a cap at $100 for each negative result.
11105482|NCT04038021|Active Comparator|Non-contingent Control|Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol. Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
11105483|NCT04038008|Other|Sequence AB|13 subjects assigned to the sequence AB will receive a single 200 mg dose of test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 1 and a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
11105484|NCT04038008|Other|Sequence BA|13 subjects assigned to the sequence BA will receive a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in Period 1 and test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
11105485|NCT04037982|Experimental|LPD|In this group, patients will undergo laparoscopic pancreaticoduodenectomy.
11105486|NCT04037982|Active Comparator|OPD|In this group, patients will undergo open pancreaticoduodenectomy.
11105487|NCT04037969|Experimental|Nesofilcon A/Delefilcon A|Nesofilcon A randomly assigned to one eye with delefilcon A in the fellow eye.
11105488|NCT04037969|Experimental|Delefilcon A/Nesofilcon A|Delefilcon A randomly assigned to one eye with nesofilcon A in the fellow eye.
11105489|NCT04037956|Experimental|Tubeless NOSES|Patients receive Tubeless NOSES.
11105490|NCT04037956|Active Comparator|traditional laparoscopic|Patients receive traditional laparoscopic radical resection.
11105491|NCT04037943|Experimental|Low-dose group|Low-dose group will received 30 grams of walnuts everyday during the study period of 6 months.
11105492|NCT04037943|Experimental|High-dose group|High-dose group will received 60 grams of walnuts everyday during the study period of 6 months.
11105493|NCT04037943|No Intervention|Control group|Control group will received non-edible gifts during the study period of 6 months.
11105494|NCT04037917|Experimental|Synthetic Tissue Substitute|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
11105495|NCT04037904||H. pylori negative group|Subjects who have not have H. pylori infection, and had not receive H. pylori eradication
11105496|NCT04037904||H. pylorieradicated group|Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication
11105497|NCT04037891|Experimental|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
11105498|NCT04037891|Placebo Comparator|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
11105499|NCT04037878|Experimental|TAP block group|Patients in this arm will be given Transversus Abdominal Plane(TAP) block after the induction of anesthesia. They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
11105500|NCT04037878|Experimental|Local infiltration|Patients in this arm will be given local and intraperitoneal infiltration of local anesthetic before closure.They will also be given post operative patient controlled intravenous analgesia(PCIA) using tramadol.
11105501|NCT04037878|Other|Control group|These patients will be given post operative analgesia in the form of patient controlled intravenous analgesia(PCIA) using tramadol. Neither local infiltration nor TAP block will be administered
11105502|NCT04037865|Experimental|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
11105503|NCT04037865|Experimental|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
11105504|NCT04037865|Experimental|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
11105505|NCT04037865|Experimental|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
11105506|NCT04037852|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
11105507|NCT04037852|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
11105508|NCT04037852|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
11105509|NCT04037826|Experimental|L. reuteri Gastrus|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475)
11105510|NCT04037826|Placebo Comparator|Placebo|Placebo chewable tablets
11105511|NCT04037813||Laparoscopic tubal occlusion|54 patients will undergo laparoscopic tubal occlusion.
11105512|NCT04037813||Hysteroscopic tubal occlusion|54 patients will undergo hysteroscopic tubal occlusion.
11105513|NCT04037800|Experimental|SFUR-RARP|Patients in which RARP with sustainable functional urethral reconstruction (SFUR) is performed.
11105514|NCT04037800|Active Comparator|Standard RARP|Patients in which standard RARP is performed.
11105515|NCT04037787|No Intervention|Usual care|Perioperative care for colorectal cancer cancer is managed according to current hospital clinical practice.
11105516|NCT04037787|Experimental|ERAS protocol|Perioperative care for colorectal cancer surgery is managed according to ERAS protocol.
11105517|NCT04037774|Active Comparator|dex 5microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 5micrograms of dexmedetomidine.
11105518|NCT04037774|Active Comparator|dex 10microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 10micrograms of dexmedetomidine.
11105519|NCT04037774|Placebo Comparator|placebo|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of placebo.
11105520|NCT04037748|Experimental|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
11105521|NCT04037748|Experimental|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
11105522|NCT04037735|Experimental|ATTUNE|Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
11105523|NCT04037735|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
11105524|NCT04037722|Experimental|Healthy + Whey|Healthy conditions (overnight fast)
11105525|NCT04037722|Experimental|Catabolic + Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
11105526|NCT04037722|Experimental|Catabolic + 3-OHB / Whey|Catabolic conditions (36-hour fast, bed rest and inflammation (LPS))
11105527|NCT04037709|Placebo Comparator|scaling and root planing (SRP) + PDT placebo|"17 patients will receive periodontal treatment (scaling and root planing - SRP) with universal curettes and ultrasound depending on their needs. The SRP will be done in one session. Periodontal treatment will be performed by only one experienced researcher, who will not do the periodontal exams. Periodontal reassessment will be performed after 7 and 21 days.
~The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application."
11106318|NCT04032158|Active Comparator|Avonex® + Evobrutinib matched Placebo: Double-Blinded Period|
11105528|NCT04037709|Experimental|scaling and root planing (SRP) + PDT|"17 patients will receive the same scaling and root planing treatment that placebo group.
~However the PDT will be done using methylene blue 0.005% - Chimiolux 5, DMC - purified water and methylene blue.The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pocket."
11105529|NCT04037696|Experimental|Experimental group|The experimental group will receive individual face-to-face brief MI (about 5 minutes) on a health-related lifestyle practice. The experimental group will then receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up.
11105530|NCT04037696|Other|Control group|The control group will be given general brief advice and receive a self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
11105531|NCT04037683||MOLI participants pre IOL|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) after recruitment to MOLI RCT but prior to the start of the induction of labour (IOL) process
11105532|NCT04037683||MOLI participants post IOL (misoprostol/misoprostol)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/misoprostol Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
11105533|NCT04037683||MOLI participants post IOL (misoprostol/oxytocin)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
11105534|NCT04037683||Staff focus group pre and during MOLI recruitment|"A focus group in each of the 2 recruitment sites before the start of the MOLI trial (n=2) A focus group in each of the 2 recruitment sites and with each cadre of staff during the MOLI trial (n=8)
~Research assistants
~Residents
~Consultants
~Midwives"
11105535|NCT04037670|Experimental|SASI bypass|Patients with super obesity underwent SASI bypass
11105536|NCT04037657|Experimental|HSK3486|0.288 mg/kg ，0.432 mg/kg ，0.540 mg/kg ，0.648 mg/kg，0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
11105537|NCT04037657|Active Comparator|Propofol|2.5 mg propofol
11105538|NCT04037644|Experimental|Albumin|fluid loading with 200 mL of 4% albumin over a 10' interval
11105539|NCT04037644|Active Comparator|Ringer Lactate|fluid loading with 5 mL/kg actual body weight of Ringer Lactate over a 10' interval
11105540|NCT04037631||Patients without clinically significant age-related cataract|
11105541|NCT04037618|Experimental|[14C]-EYP001a|[14C]-EYP001a dose A containing 100 μCi radioactivity
11105542|NCT04037605|Experimental|Control Condition|"8 am - Saline Solution for Injection
~10 am - Placebo oral capsule
~1 pm - Saline Solution for Injection
~4 pm - Placebo oral capsule & start hourly blood sampling
~7 pm- Gonadorelin (GnRH) and Corticorelin (CRH) injections
~9 pm - Saline Solution for Injection & last blood sample"
11105543|NCT04037605|Experimental|Hypothalamic Condition|"8 am -Ganirelix
~10 am - Placebo oral capsule
~1 pm - Dexamethasone injection
~4 pm- Placebo oral capsule and start of hourly blood sampling
~7 pm - GnRH and CRH injections
~9 pm - Saline Solution for Injection and last sample blood sample"
11105544|NCT04037605|Experimental|Pituitary Condition|"8 am - Saline Solution for Injection
~10 am - Ketoconazole Pill
~1 pm - Saline Solution for Injection
~4 pm - Ketoconazole Pill & start of hourly blood sampling
~7 pm - GnRH and CRH
~9 pm - Hydrocortisone Injection and last blood sample"
11105545|NCT04037605|Experimental|Adrenal/Testis Condition|"10 pm - Ganirelix Injection & Dexamethasone Pills (night before)
~8 am - Start of hourly blood sampling
~10 am - Dexamethasone Pills
~11 am - Last hourly blood sample taken
~11:30 am - Start of blood sampling every 10 minutes
~1 pm - Recombinant Human Luteinizing Hormone (rhLH) Injection
~3 pm - rhLH Injection
~5 pm - rhLH Injection
~5 pm - Cosyntropin Injectable product
~7 pm - GnRH and CRH Injections
~9 pm - Last blood sample"
11105546|NCT04037592|Experimental|Active standardized iTBS-DMPFC|This active group will receive standardized dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
11105547|NCT04037592|Experimental|Active high-dosage iTBS-DMPFC|This active group will receive high dosage of intermittent theta-burst on dorsomedial prefrontal cortex(DMPFC)
11105548|NCT04037592|Sham Comparator|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Patients in the sham group will receive the same standardized or high-dosage iTBS performing by a sham coil
11105549|NCT04037579||Down Syndrome Cordoba Association|The participant will answer a questionnaire related to social skills and physical activity
11105550|NCT04037579||Down Syndrome Granada Association|The participant will answer a questionnaire related to social skills and physical activity
11105551|NCT04037579||Down Syndrome Malaga Association|The participant will answer a questionnaire related to social skills and physical activity
11105552|NCT04037579||Observers in Cordoba|Observers from Cordoba, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
11105553|NCT04037579||Observers in Granada|Observers from Granada, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
11105554|NCT04037579||Observers in Malaga|Observers from Malaga, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
11105555|NCT04037566|Experimental|XYF19 CAR-T cell|"One arm study consisting of 3 + 3 dose escalation study design followed by dose expansion phase at determined MTD."
11105556|NCT04037553||Group 1|Patients underwent right ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the left) was applied to the patients and ICP values were documented following 3 respiration cycles.
11106319|NCT04032158|Experimental|Evobrutinib: Open-Label Extension Period|
11105557|NCT04037553||Group 2|Patients underwent left ear surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, lateral neck rotation (approximately 60-70 degrees to the right) was applied to the patients and ICP values were documented following 3 respiration cycles.
11105558|NCT04037553||Group 3|Patients underwent left head and neck surgery: After intracuff pressure (ICP) is adjusted to 25 cmH2O at neutral position, gel pillow with the height of 4,5 cm was placed under the shoulders of patients to extend the neck. Following 3 respiration cycles, the ICPs were noted. Then, right or left lateral neck rotation was applied depending on the operation side (approximately 60-70 degree to the opposite site). After 3 respiration cycles, ICPs were documented again.
11105559|NCT04037540|Experimental|Operational approach|The patients enrolled in this arm underwent surgical treatment of the Jones fracture.
11105560|NCT04037540|Experimental|Conservative approach|The patients enrolled in this arm were treated conservatively, using fixation of the injured extremity.
11105561|NCT04037527|Experimental|Neoadjuvant Chemotherapy Plus Radiation Therapy|Up to 6 cycles (once a week) of chemotherapy with a 3+3 dose escalating plan (from 100 mg to 300 mg for Gemcitabine; 10 mg to 25 mg for Docetaxel) along with radiation (five days a week) for up to 6 weeks.
11105562|NCT04037514|Experimental|Paracetamol|Intravenous paracetamol 15 mg/kg/6h for 3 or 6 days
11105563|NCT04037514|Active Comparator|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24 h (day 1) and 5 mg/kg/24h (day 2 and 3) for 3 or 6 days
11105564|NCT04037501|Experimental|Intervention|
11105565|NCT04037501|No Intervention|care as usual|
11105566|NCT04037488||Cohort: ADT patients|"All enrolled patient data entered in single group cohort. All patient who started androgen deprivation therapy for prostate cancer can included this cohort by following inclusion and exclusion criteria. We do not planned any intervention on this cohort. We measuring changes of body composition by Inbody 320 in the planned follow-up period.
~We planned sub-group analysis for timing of intervention (Intervention 1) , ADT type(Intervention 2), LHRH agonist type(Intervention 3), patients age(Intervention 4), initial PSA level (Intervention 5) and Gleason Grade Group (Intervention 6)."
11105567|NCT04037475|Placebo Comparator|Control (placebo)|The patients will receive an agent with the same vehicle as methylene blue to mimic irrigation with the photosensitizer and the laser will be switched off at the time of application. The placebo PDT procedures will be performed on the lesion: Application of methylene blue placebo with a carpule syringe and needle (with stop and without bevel) inside the lesions; 1 minute of pre-irradiation will be expected. The irradiations will be performed with the same device positioned in the same way and at the same time of application, however, the laser will be turned off. The beep sound will be recorded and turned on during application to blind treatment to the patient. The patient will receive a catheter with acyclovir cream and will be advised to spread on the lesions four times a day for 7 days, which will be their return for reevaluation. It will be washed in abundance with saline (saline solution) until the total removal of the placebo from the photosensitizer.
11105568|NCT04037475|Experimental|experimental group|Patients will be treated with photodynamic therapy and will receive a placebo ointment simulating acyclovir cream. If the lesions are in the vesicle phase, they will be ruptured with a sterile needle. The methylene blue solution at 0.005% concentration will be gently placed on the lesions. Application of methylene blue on the lesions.1 minute of pre-irradiation will be expected. The irradiations will be performed with the Laser Duo® with a wavelength of 660 nm, with a power of 100 mW(milliwatts), the energy density of 300 J / cm², with the energy of 3 J (joules) in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each lesion with energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. Patients will receive a tube with a placebo cream simulating aciclovir and the same will be advised to spread the cream 4 times per day for 7 days.
11105569|NCT04037462|Experimental|Lead in Dexamethasone followed by immunotherapy|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
11105570|NCT04037449|Experimental|TAP block|Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
11105571|NCT04037449|Active Comparator|Conventional analgesia|Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
11105572|NCT04037436|Experimental|Intervention|"At regular intervals (the steps) one cluster (i.e., one site) is randomised to cross from the control to the intervention under evaluation. This process continues until all clusters have crossed over to be exposed to the intervention. At the end of the study there will be a period when all clusters are exposed. Four sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart."
11105573|NCT04037436|Other|Control|Each cluster contributes observations under both control and intervention observation periods.
11105574|NCT04037423||PE patients treated with CDT|Acute pulmonary embolism patients undergoing catheter-directed embolectomy.
11105575|NCT04037397|Active Comparator|Antiarrhythmic Medications|Patients randomized to the antiarrhythmic drug group are administered medications approved for treatment of AF by the regulatory bodies of each participating country. The selection of antiarrhythmic drugs and dosages is left to the discretion of the investigator, and will follow the AHA/ACC/HRS general guidelines
11105576|NCT04037397|Active Comparator|Radio Frequency Catheter Ablation|Patients randomized to radiofrequency catheter ablation will undergo isolation of the pulmonary veins with confirmation of entrance block into each vein. The CARTO TM(Biosense Webster, CA) system will be used to reconstruct the atrial geometry and assist for mapping and ablation. Ablation will be performed using approved ablation devices (Biosense Webster, CA).
11105577|NCT04037384|Active Comparator|Eye Yoga group|Eye yoga exercises
11105578|NCT04037384|Placebo Comparator|Reading Group|Passive reading
11105579|NCT04037358|Experimental|Radium-223 and SABR|First radium-223 infusion will be within two weeks of SABR
11105580|NCT04037358|Active Comparator|SABR|SABR(1-5 fractions) will be administered for all men
11105581|NCT04037345|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
11105582|NCT04037345|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
11105583|NCT04037345|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
11105584|NCT04037332||Pre-RAS roll-out . Group I|I. Children presenting directly to a referral health facility without prior administration of RAS (pre-RAS): provides a baseline assessment of artemisinin resistance marker prevalence before the introduction of RAS
11105585|NCT04037332||Post-RAS roll-out - Group II|II. Children presenting directly to a referral health facility without prior administration of RAS (post-RAS): group not receiving pre-referral RAS and hence having baseline pressure for K13 resistance markers.
11105586|NCT04037332||Post-RAS roll-out - Group III|III. Children receiving pre-referral RAS from community-based provider and successfully referred to a referral health facility: group receiving pre-referral RAS (monotherapy).
11105587|NCT04037332||Post-RAS roll-out - Group IV|IV. Children receiving pre-referral RAS from community-based provider but not completing referral to a referral health facility, followed-up at their home on day 28: children malaria-positive on Day 28 may have an increased chance of harboring a resistant infection.
11105588|NCT04037319||Main cohort|Will undergo surgery for colorectal cancer with curative intent as planned by local cancer multidisciplinary team.
11105589|NCT04037306|Active Comparator|Rapid Feedback|Participants received daily feedback on both fiber intake and stool butyrate measurements.
11105590|NCT04037306|Active Comparator|Delayed Feedback|Participants received daily feedback on fiber intake and one-time feedback on stool butyrate measurements at the end of the study period.
11105591|NCT04037280|Experimental|Isometric strenghtening 1|once a day (1RI): patients in this group will have to play 20 tonic contractions of Pelvic Floor Muscle with a duration of 5 seconds each, performed in supine position), in sitting position and in standing position.
11105592|NCT04037280|Experimental|Isometric strenghtening 2|twice a day (2RI): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
11105593|NCT04037280|Experimental|Functional strenghtening 1|once a day (1RF): patients in this group will have to play 10 times the postural passage from supine position to sitting position on a bed and 10 times the postural passage from sitting position to erect position (STS), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional act. In sequence, starting from erect position, they will have to play 10 trunk flexion bending their knees (as to pick up an object on the ground), maintaining the contraction of Pelvic Floor Muscle during the execution of each functional movement.
11105594|NCT04037280|Experimental|Functional strenghtening 2|twice a day (2RF): patients in this group will have to play the same typology of exercises in the same way just described (see above), but twice a day (in the morning and in the evening).
11105595|NCT04037267|Experimental|Endoscopic Treatment|Endoscopy was performed using a rigid endoscope. The hematoma was removed by a technique using irrigation and aspiration. The ventricular drainage catheter was placed on the surgical side. Six hours after surgery, we administered 20,000 U urokinase with 5 ml saline every 8 hours through the catheter and the catheter was closed for 1 hour to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
11105596|NCT04037267|Active Comparator|EVD Treatment|The surgeons used a soft catheter to puncture in depth of about 5 cm. The next step was to fix the drainage catheter. Postoperative CT was done immediately to confirm positioning of the soft catheter and stability of the hematoma. Six hours or more after catheter placement, we administered 20,000 U urokinase with 5 ml saline every 8 hours and the catheter was closed for 1 h to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
11105597|NCT04037254|Experimental|Phase I (niraparib, GnRH, IMRT)|Patients receive niraparib PO QD and receive standard of care GnRH agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.
11105598|NCT04037254|Active Comparator|Phase II, Arm I (GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
11105599|NCT04037254|Experimental|Phase II, Arm II (niraparib, GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
11105600|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel|"Patients in the anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
11105623|NCT04037072|Experimental|Mitomycin C|Cotton swab or strip of 2x2 cotton gauze soaked with 0.4mg/mL Mitomycin C
11105601|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|"Patients in the anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
11105602|NCT04037241|Active Comparator|2nd Line: Gemcitabine /nab paclitaxel Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
11105603|NCT04037241|Active Comparator|2nd Line: NLIR + FU/FA Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
11105604|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
11105605|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
11105606|NCT04037241|Active Comparator|3rd Line: NLIR+FU/FA Alone|Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
11105607|NCT04037241|Active Comparator|3rd Line: Capecitabine Alone|Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
11105608|NCT04037228||KneeAlign 2|Those of the group will be adopt KneeAlign 2: accelerometer-based navigation system at total knee arthroplasty.
11105609|NCT04037215|Other|COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|In order to explore the cognitive treatment of patients with early onset anorexia nervosa in front of images of silhouettes and food, it is currently used in the child psychiatry department of the Robert Debré Hospital, the eye-tracking method. Eye tracking is a non-invasive and painless method of recording the path of vision on images presented on a computer screen. In order to understand the specificities of the eye path in sick patients, we will compare the data with those of controls without eating disorders.
11105610|NCT04037202|Experimental|Study Group|"The first session of the foot massage was performed after mothers were taken to the postpartum service and after the effect of the first analgesia had elapsed (4-6 hours after birth).
~The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported."
11105611|NCT04037202|No Intervention|Control Group|Routine procedures were applied and VAS was repeated at the same time periodical as the study group mothers (0th, 20th and 50th minute) and after 20-24 hours (before discharge), at the same time intervals (0th, 20th and 50th minute) pain status was measured by using VAS and PCS was administered for the last time and analgesics administered were recorded on the DFC.
11105612|NCT04037176|Active Comparator|Omalizumab|"Omalizumab is a sterile solution in a prefilled syring for subcutaneous injection. The syrings contains 75 mg or 150 mg omalizumab.
~75 patients will have Omalizumab in doses depending of body weight and IgE every 2. or 4. week for 6 month Omalizumab is administered subcutaneously"
11105613|NCT04037176|Placebo Comparator|Placebo|"Placebo contains sodium chloride 0,9 % in a prefilled syring for subcutaneous injection.
~25 patients will have placebo depending of the body weight and IgE every 2. or 4. week in 3 month. They will subsequently get Omalizumab for 3 month if nonresponders.
~Placebo is administered subcutaneously"
11105614|NCT04037163||CCTA-FFR|Patients who underwent CCTA within 90 days before FFR measurement will be included in the present study.
11105615|NCT04037124||Cervical procedure abandoned|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is abandoned due to intraoperatively reported lymph node matestasis. Patient is referred for primary (chemo)radiation.
11105616|NCT04037124||Cervical procedure completed|Cervical procedure (hysterectomy, radical hysterectomy or fertility sparing treatment) is completed. Patient is referred for adjuvant chemoradiation.
11105617|NCT04037111|Experimental|drug treatment and active VNS|At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
11105618|NCT04037111|Sham Comparator|drug treatment and sham VNS|It received oxacillin oxalate tablets and sham VNS for 2 months.
11105619|NCT04037111|Other|drug treatment|The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
11105620|NCT04037098|Experimental|Magnesium|Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
11105621|NCT04037098|Placebo Comparator|Control|2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.
11105622|NCT04037085|Experimental|Ketamine|Ketamine - IV after cord clamping; IV infusion for 12 hours
11105624|NCT04037072|Placebo Comparator|Control|Cotton swab or strip of 2x2 cotton gauze soaked with Normal saline
11105625|NCT04037059||Spinal Deformity Patients|For patients with disabling spinal deformities, long segment fusions have been shown to improve the health related quality of life (HRQOL). A consequence of spine fusion however is elimination of range of motion especially in the lumbar spine. Even in patients who report overall improvement in pain related domains, difficulty with some ADL's in this patient group has been well documented in previous studies. Complaints such as inability to dress independently, bathing of lower halves of their body, driving a motor vehicle, getting in and out of a chair/bed and performing perineal hygiene care following toileting have been reported.
11105626|NCT04037046|Experimental|Screening HCV with DBS at primary care centers|Patients assigned to the strategy 1 will receive an invitation letter for HCV screening with DBS at the primary care center to be performed by the general practitioner
11105627|NCT04037046|Active Comparator|Screening HCV and CCR with FOT at primary care centers|Patients assigned to the strategy 2 will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
11105628|NCT04037046|Active Comparator|Self-testing at home for screening HCV and CCR|Patients assigned to the strategy 3 will receive an invitation letter for self-testing at home for HCV screening with DBS, and CCR screening with FOT
11105629|NCT04037020||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa.
11105630|NCT04037007|Active Comparator|Fistulotomy - High experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists.
11105631|NCT04037007|Active Comparator|Fistulotomy - Low experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists.
11105632|NCT04037007|Active Comparator|Conventional (guidewire) cannulation- High experience|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists.
11105633|NCT04037007|Active Comparator|Conventional (guidewire) cannulation - Low experienced.|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.
11105634|NCT04036994|Active Comparator|Experimental: Treatment group|
11105635|NCT04036994|Sham Comparator|Sham Comparator: Control group|
11105636|NCT04036981||Brachialis|Targeted muscle for BoNT A injection
11105637|NCT04036981||Biceps|Targeted muscle for BoNT A injection
11105638|NCT04036981||Brachioradialis|Targeted muscle for BoNT A injection
11105639|NCT04036981||Combinations|Targeted muscles for BoNT A injection
11105640|NCT04036968|Experimental|5 outpatient sessions|This is a within-subject study so all session procedures will be identical, however the specific medications provided as part of the double-blinded study medications may change during each session. During each session, which will last up to 8 hours a day and will be conducted on an outpatient basis, participants will be asked to complete standardized pain testing procedures, as well as questionnaires about how participants are feeling and to complete cognitive tasks.
11105641|NCT04036955|Experimental|intervention group|"The INFOSA-DEM programme consists of five, 90-minute informational/training sessions delivered consecutively over one week. Morning or afternoon groups are offered depending on the caregiver's availability. Programme content was developed for use in small groups of 6-8 caregivers. Topics covered in the sessions include basic concepts in dementia and specific issues such as nutrition, rest, medication, physical and cognitive changes, management of behavioural symptoms, affective problems in the patient and informal caregiver, verbal and non-verbal communication techniques, caregiver self-care and information on available resources and community services.
~The sessions are conducted using audio-visual material to facilitate understanding of the content and to encourage active participation among caregivers when talking about their experiences."
11105642|NCT04036955|No Intervention|usual care|Caregivers in the Group control received usual care in the centres where the follow-up was carried out. This consisted of annual or quarterly consultations with a health professional (GP, geriatrician or neurologist) and, depending on the health centre, a nurse and social worker.Currently, there is no homogenous protocol for all care centres for the patient with high levels of cognitive impairment and dependency.
11105643|NCT04036942|Active Comparator|Hybrid argon plasma.|"After diagnostic endoscopy investigators will proceed to use argon plasma probe for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will use the jet included in the argon plasma probe with effect 20 to 40 system for the injection of the background submucosa in the marking area, applying 0.9% saline solution with methylene blue, to achieve adequate Submucosal elevation for application or argon plasma with high voltages (100 watts, 1.5 liters / min) using forced coagulation mode, applying plasma argon to 1cm above the Z line in the esophageal mucosa and 2cm below it towards the gastric mucosa, argon will be applied until a carbonization effect of the mucosa is achieved, once the application of the therapy is performed mucosal lavage and immersion technique to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications"
11105644|NCT04036942|Active Comparator|Band mucosectomy|After diagnostic endoscopy investigators will proceed to use the tip of a polypectomy snare for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will perform submucosal elevation with the injection of 0.9% saline with carmine indigo and adrenaline 1:10000, after adequate submucosal elevation investigators will proceed with the help of a band ligation cap to suction and release the elastic band in the previously marked and elevated tissue, proceeding to resect the previously ligated tissue with polypectomy loop below the elastic band with forced coagulation (Effect 2, 40 W), until the marked mucosa is completely resected (average used of 5 elastic bands, reviewing the work area for complications like bleeding or perforation.
11105645|NCT04036929|Experimental|Estrogen-bazedoxifene|Tablet, once daily for 6 months.
11105646|NCT04036929|Placebo Comparator|Placebo|Closely matched tablet, once daily for 6 months.
11105679|NCT04036656|Experimental|Cohort 2:SYHA136 1 mg or Placebo matching SYHA136 1 mg|Participants will receive a single oral dose of SYHA136 1 mg or Placebo matching SYHA136 1 mg under fasted conditions.
11105680|NCT04036656|Experimental|Cohort 3:SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg|Participants will receive a single oral dose of SYHA136 2.5 mg or Placebo matching SYHA136 2.5 mg under fasted conditions.
11105647|NCT04036916|Experimental|Virtual Reality Training (Experimental)|Participants will receive multi-modal sensorimotor training interventions, including activities training the vestibular system, oculomotor control and visual perception, neuromotor control and strengthening of the cervical spine, postural control/ balance exercises, and exercises integrating the use of multiple types of sensory information for controlled motor output, including speed and accuracy. Novel headset virtual reality (VR) games/activities; compliant balance surfaces; resistance bands/weight; and biofeedback devices will be utilized to deliver the training intervention. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 12 sessions over 6 weeks.
11105648|NCT04036916|No Intervention|No Virtual Reality Training (Control)|True control.
11105649|NCT04036890|Experimental|2% minocycline hydrochloride controlled-delivery system (MHS)|Mechanical ultrasonic/ hand instrumentation and subsequent administration of MHS on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
11105650|NCT04036890|Placebo Comparator|Placebo|Mechanical ultrasonic/ hand instrumentation and subsequent administration of a placebo gel on that day (Day 0) and on Day 4, at 3 months, 6 months and 9 months
11105651|NCT04036851|No Intervention|Local standard of care|Women receive integrated antenatal and HIV services during pregnancy and are referred to general adult HIV services after delivery; no standardized peer support groups exist for this patient population.
11105652|NCT04036851|Experimental|Peer support intervention|Women will be invited to attend monthly peer support groups during pregnancy and postpartum, separate from any routine health services.
11105653|NCT04036838|Experimental|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
11105654|NCT04036825|Experimental|Liquid Nutritional Supplement from Hospital Product|This group received liquid nutritional supplement from hospital product. The product is in a form of low lactose milk ready to drink with volume 200 ml and will be given 2 times daily for 14 days. This product is consist of 1.017 kcal/ml, 10 vitamin and 9 mineral
11105655|NCT04036825|Placebo Comparator|Placebo|This group received standard liquid nutritional supplement as a placebo. Placebo will be given 2 times daily for 14 days
11105656|NCT04036812|Experimental|Superficial cervical plexus block group|
11105657|NCT04036812|Sham Comparator|Control group|
11105658|NCT04036799||Hypertrophic Cardiomyopathy|
11105659|NCT04036786|Experimental|study gorup|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
11105660|NCT04036786|Other|control group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Sixty six pregnant participants with preeclampsia risk were included in the control group and 66 pregnant participants with preeclampsia risk were included in the intervention (exercise) group.
11105661|NCT04036773|Experimental|Intervention Group|
11105662|NCT04036773|No Intervention|Control Group|
11105663|NCT04036760||Standard of Care transitional care coordination|
11105664|NCT04036760||Research transitional care coordination|
11105665|NCT04036734|Active Comparator|Transverse Ultrasound Orientation|Transverse placement of ultrasound to long axis of target lower limb vein
11105666|NCT04036734|Experimental|Longitudinal Ultrasound Orientation|Longitudinal placement of ultrasound to long axis of target lower limb vein
11105667|NCT04036721|Experimental|ARM A - PROLONGED|induction dose 1-4mg/kg of prednisone, prednisone 60mg q24h for 2-4wks, tapering not faster than 10mg each 14d, maintenance dose 10mg q24h for 8wks, withdraw of treatment during 4wks, summary of treatment time not shorter than 12-24wks.
11105668|NCT04036721|Active Comparator|ARM B - FAST REDUCTION|induction dose 1-4mg/kg of prednisone, prednisone 30-60 mg q24h, tapering not faster than 10mg each 7d, summary of treatment time 6-12wks.
11105669|NCT04036708|Experimental|MISC and WTM|Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
11105670|NCT04036708|Active Comparator|WTM only|WTM trainings only (recommended standard of care) bi-weekly for 12 months.
11105671|NCT04036695|Experimental|Reveal LINQ insertable cardiac monitoring system|In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
11105672|NCT04036682|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|CLN-081 BID in single patient dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations that either have received or never received prior EGFR TKIs.
11105673|NCT04036682|Experimental|Phase 1 Dose Escalation (Rolling Six)|CLN-081 QD or BID in Rolling Six dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations.
11105674|NCT04036682|Experimental|Phase 1 Dose Expansion(s)|CLN-081 BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Rolling Six cohorts.
11105675|NCT04036682|Experimental|Phase 2a Dose Expansion(s)|CLN-081 QD or BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Phase 1 Dose Escalation cohorts.
11105676|NCT04036669||RA patients|RA patients ( N=80; BMI= 26.4± 3.96 ) Eighty patients diagnosed with Rheumatoid arthritis according to American Rheumatology Association criteria and radiographic analysis for at least 10 years previously were randomly involved in this study
11105677|NCT04036669||Healthy control|A healthy control group ( N=80; BMI=22.3± 1.85) eighty age and sex-matched healthy controls were included in the study following the assignment of informed consent.
11105678|NCT04036656|Experimental|Cohort 1:SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg|Participants will receive a single oral dose of SYHA136 0.5 mg or Placebo matching SYHA136 0.5 mg under fasted conditions.
11105711|NCT04036487|Experimental|IH group|Inhalation anesthesia will be given during transaxillary endoscopic breast augmentation.
11105681|NCT04036656|Experimental|Cohort 4:SYHA136 5 mg or Placebo matching SYHA136 5 mg|Participants will receive a single oral dose of SYHA136 5 mg or Placebo matching SYHA136 5 mg under fasted conditions.
11105682|NCT04036656|Experimental|Cohort 5:SYHA136 10 mg or Placebo matching SYHA136 10 mg|Participants will receive a single oral dose of SYHA136 10 mg or Placebo matching SYHA136 10 mg under fasted conditions.
11105683|NCT04036656|Experimental|Cohort 6:SYHA136 20 mg or Placebo matching SYHA136 20 mg|Participants will receive a single oral dose of SYHA136 20 mg or Placebo matching SYHA136 20 mg under fasted conditions.
11105684|NCT04036656|Experimental|Cohort 7:SYHA136 35 mg or Placebo matching SYHA136 35 mg|Participants will receive a single oral dose of SYHA136 35 mg or Placebo matching SYHA136 35 mg under fasted conditions.
11105685|NCT04036656|Experimental|Cohort 1:SYHA136 50 mg or Placebo matching SYHA136 50 mg|Participants will receive a single oral dose of SYHA136 50 mg or Placebo matching SYHA136 50 mg under fasted conditions.
11105686|NCT04036643|Experimental|patient with rectal cancer|Patient with rectal cancer treated by neoadjuvant chemo-radiation therapy with clinical complete response
11105687|NCT04036630|Experimental|2kHz tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105688|NCT04036630|Sham Comparator|sham tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105689|NCT04036630|Experimental|2kHz tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105690|NCT04036630|Sham Comparator|sham tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105691|NCT04036630|Experimental|2kHz tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105692|NCT04036630|Sham Comparator|sham tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105693|NCT04036630|Experimental|env tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105694|NCT04036630|Active Comparator|time-reversed env-tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105695|NCT04036630|Sham Comparator|sham tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
11105696|NCT04036617|Experimental|NaQuinate|Initial SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150 mg
11105697|NCT04036617|Experimental|Placebo|Initial SAD cohorts will receive 1 placebo dose between 10-150 mg . MAD cohorts will receive 7 days placebo dosing between 70-150 mg
11105698|NCT04036604|Experimental|Group of pelvic floor exercise|Group of pelvic floor exercise include 47 elderly people which contains contraction and repetition of pelvic floor muscle exercises during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.
11105699|NCT04036604|No Intervention|Group of pelvic floor education|Group of pelvic floor education include 47 elderly people which contains anatomy of pelvic floor and dysfunction during once a week for 8 weeks performed by an expert pelvic health physiotherapist.
11105700|NCT04036591||Children under 24 months with ARIS|
11105701|NCT04036578|Other|Pelvic Floor Dysfunction With and Without POP|group 1(Pelvic Floor Dysfunction Without POP Stage I~II) and group 2(Pelvic Floor Dysfunction With POP Stage I~II)
11105702|NCT04036565||The experimental group|The first post-test measurements were taken right after the participants completed the sunlight therapy (two to four weeks after the start of the intervention), and the second post-test measurements were taken one month after the intervention was completed (six to eight weeks after the start of the intervention).
11105703|NCT04036565||The control group|Standard care.The first and second post-test measurements were taken two and six weeks, respectively, after they started receiving standard care.
11105704|NCT04036539|Placebo Comparator|Control (placebo)|Patients in Control will receive the photobiomodulation placebo,application, but with the laser off. Procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described: Simulations will be performed with the same laser.This will require 10 seconds of application simulation per point. As 10 points will be simulated, it will take 100 seconds for this simulation.5 points lingual and 5 points at vestibular
11105705|NCT04036539|Experimental|Experimental:|Experimental: Molar verticalization + PBM (n = 17 + 3) - patients will receive laser treatment (photobiomodulation) in order to modulate orthodontic movement and act on inflammation and pain. The procedures will be performed immediately after the application of forces (placement of elastic bandages) on the tooth, as described:The irradiations will be performed with the red diode laser ( = 660 nm) with 100 milliwatts output power The power of the device will be 100miliWatts and the wavelength used will be 808 nanometers (± 10nm). The optical fiber diameter of the device is 600 micrometer, therefore a spot (area) of 0.002826 centimeter2. The energy delivered per point will be 1Joule. This will require 10 seconds of application per point. As 10 points will be irradiated, the total application time will be 100 seconds and the total energy delivered will be 10Joule. The energy density will be 25 Joule / cm2 and the power density will be 35.38 Watt / cm2
11105706|NCT04036526|Experimental|Group 1 Drop method|Group 1 will receive vaccine/placebo by drop method.
11105707|NCT04036526|Experimental|Group 2 Nasal actuator|Group 2 will receive vaccine/placebo with nasal actuator.
11105708|NCT04036513|Experimental|MINST|"Usage of magnification loupes, specific thin and delicate tips together with piezoelectric device and specifically designed Hu-Friedy mini five, micro mini five, and after five Gracey curettes under local anaesthesia."
11105709|NCT04036513|Active Comparator|Conventional SRP|Conventional non-surgical mechanical treatment using piezoelectric device (PiezoLED, Kavo) and standard Gracey curettes under local anaesthesia.
11105710|NCT04036500|Experimental|Estradiol|Subjects will take estradiol 1 mg orally after time 0 blood draw. They will get 7 blood draws at hours 0,1,2,3,4,6,8. A wash-out period of at least one week will allow for complete clearance of the exogenous oral estradiol before testing the pharmacokinetics of sublingual estradiol on the same ten patients in the same manner. On day 2 of study, subject will take estradiol 1 mg sublingually after time 0 blood draw, supervised by a research team member to ensure proper dissolution. Blood will be drawn at hours 0,1,2,3,4,6,8 as on day 1 of study.
11105712|NCT04036487|Active Comparator|TIVA group|Total intravenous anesthesia will be given during transaxillary endoscopic breast augmentation.
11105713|NCT04036474|Experimental|Smoking Prevention Education Program|In addition to the lecture on the hazards of smoking, students received the SPEP intervention. The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. The SPEP intervention was delivered to participants in their usual classroom setting, during school hours combined with relevant school subjects such as physical education class. The duration of SPEP intervention took approximately one month.
11105714|NCT04036474|No Intervention|Control|Immediately after the collection of baseline data, students received a one-time lecture on the hazards of smoking by the research assistant.
11105715|NCT04036461|Experimental|Administration of CC-99712|CC-99712 will be administered via intravenous (IV) infusion once per 21-days on a Once every three weeks (Q3W) schedule, and once per 28-days on a Once every four weeks (Q4W) schedule
11105716|NCT04036448||Lenalidomide in IPSS Low-or intermediate-1-risk del population|For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
11105717|NCT04036448||Lenalidomide in Refractory/relapsed rrMCL population|For the Refractory/relapsed Mantle cell lymphoma (rrMCL), the recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
11105718|NCT04036435|Experimental|BMS-986165|
11105719|NCT04036422|Experimental|Computer based exercise group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week to a total of twenty hours over a four week period. In addition to this, these patients will receive half an hour of conventional occupational therapy and half an hour of Rejoyce computerized exercise seven days a week to a total of twenty eight hours over a four weeks period.
11105720|NCT04036422|Active Comparator|Conventional treatment group|The fifteen patients included in this arm of the study will receive a one hourly 'one-on-one' session of conventional physical therapy five days a week, to a total of twenty hours over a four week period. In addition to this, patients in this group will receive one hourly sessions of conventional occupational therapy seven days a week to a total of twenty eight hours over a four week period.
11105721|NCT04036409|Experimental|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP <120 mm Hg.
11105722|NCT04036409|Active Comparator|Standard Control of Systolic Blood Pressure|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg
11105723|NCT04036396|Active Comparator|Standard of Care Case Management|A client-centered assessment of priorities and needs, substance abuse-focused transitional case management, and customized prevention and testing referrals.
11105724|NCT04036396|Experimental|Mobile Enhanced Prevention Support|Standard of Care in addition to the Mobile Enhanced Prevention Support Program
11105725|NCT04036383|Active Comparator|vestibüler|vestibular exercise training
11105726|NCT04036383|Experimental|balance training|vestibular exercise training+ balance training with computerized balance system
11105727|NCT04036383|Experimental|square-step|vestibular exercise training+ square step exercise
11105728|NCT04036370|Active Comparator|PECS group|In addition to routine analgesic protocol; before anaesthesia induction; following the PECS I + II block, a continuous infusion catheter will be placed at the PECS II block level under the guidance of USG, and local anesthetic infusion will be started via the catheter at the end of the operation.
11105729|NCT04036370|Sham Comparator|Control group|Peroperative and postoperative routine analgesic protocol will be performed with no additional intervention (block).
11105730|NCT04036344|No Intervention|Control|Control participants receive treatment for a facial skin cancer with Mohs micrographic surgery (MMS), however, do not receive a peer mentor. Participants complete 3 online Skin Cancer Index (SCI) surveys at enrollment, 1 week follow-up, and 3 month follow-up.
11105731|NCT04036344|Experimental|Mentee - Preoperative Consult|Mentees are enrolled at preoperative consultation visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
11105732|NCT04036344|Experimental|Mentee - Same Day Surgery|Mentees are enrolled at same day surgery visit and paired with a peer mentor throughout their treatment of a facial cancer with MMS. Participants have regular contact with their mentor and complete 3 online SCI surveys at enrollment, 1 week follow-up, and 3 month follow-up.
11105733|NCT04036331|Active Comparator|Adolescent Participants|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
11105734|NCT04036331|Experimental|Caregivers of Adolescent Participants|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
11105735|NCT04036331|Experimental|Co-enrollment|This condition is for dyads that are co-enrolled in This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.
11105736|NCT04036305||EDS Patients|Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome
11105737|NCT04036305||Healthy Volunteers|Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome
11105741|NCT04036253|Active Comparator|Eprex/Erypo|"Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.
~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
11105742|NCT04036253|Experimental|Hemax PFS|"receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.
~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
11105743|NCT04036240|Experimental|Finger feeder|HMF supplementation will be given by finger feeder
11105744|NCT04036240|No Intervention|Control|HMF supplementation will be given by mother preference such as cup, bottle.
11105745|NCT04036227|Experimental|GS-248|"Part I (SAD): Single doses of 1 mg, 5 mg, 25 mg, 75 mg, 225 mg and 450 mg (planned doses)
~Part II (MAD): Multiple ascending doses for 10 days in four cohorts with planned doses of 25 mg, 75 mg, 225 mg and 450 mg. The doses will be finally selected based on results from Part I."
11105746|NCT04036227|Placebo Comparator|Placebo|Matching placebo oral solution
11105747|NCT04036201|Experimental|Group 1(22-24 mm)|Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.
11105748|NCT04036201|Experimental|Group 2(24.1-26 mm)|Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m
11105749|NCT04036188|Experimental|Triamcinolone Cream + Vitamin D3|This arm will continue to take Vitamin D3 at Week 16 to Week 28.
11105750|NCT04036188|Placebo Comparator|Triamcinolone Cream + Placebo|Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.
11105751|NCT04036175|Other|Group 1|Standard oxygen - High-Flow Nasal Oxygen - Non-invasive ventilation - Standard Oxygen (20 minutes for each condition)
11105752|NCT04036175|Other|Group 2|Standard oxygen - Non-invasive ventilation - High-Flow Nasal Oxygen - Standard Oxygen (20 minutes for each condition)
11105753|NCT04036162|Experimental|Young group|Young Right-handed healthy volunteers
11105754|NCT04036162|Experimental|Aged group|Aged Right-handed healthy volunteers
11105755|NCT04036149|Experimental|LUCIA|CT LUCIA 611P - Intraocular lens
11105756|NCT04036149|Active Comparator|ASPHINA|CT ASPHINA 409MP - Intraocular lens
11105757|NCT04036136|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
11105758|NCT04036136|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
11105759|NCT04036123|Experimental|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
11105760|NCT04036110|Experimental|Intervention 1|Vitamin C 500 mg taken daily for 3 months
11105761|NCT04036110|Experimental|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
11105762|NCT04036110|Placebo Comparator|Control|Placebo tablets taken daily for 3 months
11105763|NCT04036084||Patients|Patients with CADASIL disease : Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL
11105764|NCT04036084||Control|
11105765|NCT04036058|Experimental|Intervention|Enact universal gloving practices
11105766|NCT04036058|No Intervention|Control|Continue standard of care gloving practices
11105767|NCT04036019|Experimental|C-CAR066|Autologous C-CAR066 administered by intravenous (IV) infusion
11105768|NCT04036006|Experimental|Group-Based|
11105769|NCT04036006|Active Comparator|Self-Directed|
11105770|NCT04035993|Experimental|Intervention group|
11105771|NCT04035980|No Intervention|Conventional care|Screening HCV with dried blod spot (DBS) testing and referral to tertiary care hospital to evaluate disease stage and treatment of HCV RNA positive patients
11105772|NCT04035980|Active Comparator|Telemedicine care|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
11105773|NCT04035954|Active Comparator|Interventional|The control group will continue the routine physiotherapy program based on NDT: Neurodevelopmental Therapy twice a week, 2 days / 1 hour / day during 8 weeks.
11105774|NCT04035954|Experimental|Experimental|The treatment group will participate in clinical pilates exercises 2 days / 1 hour / day during 8 weeks.They will also continue their weekly routine physiotherapy programs.
11105775|NCT04035941|Experimental|Feasibility|The cycle training intervention group
11105776|NCT04035928|Experimental|3D digital scanning for maxillofacial prosthetics|
11105777|NCT04035915|Experimental|Limited driving pressure ventilation|
11105778|NCT04035915|Experimental|Conventional mechanical ventilation strategies|
11105779|NCT04035902|Experimental|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered during surgery
11105780|NCT04035902|Active Comparator|control|Ferric carboxymaltose is not administered
11105781|NCT04035889|Experimental|Group 1|Participants assigned to Group 1 will take 2 weeks of melatonin followed by 2 weeks of placebo
11105782|NCT04035889|Experimental|Group 2|Participants assigned to Group 2 will take 2 weeks of placebo followed by 2 weeks of melatonin.
11105783|NCT04035876|Experimental|Camrelizumab plus apatinib|
11105784|NCT04035863|Experimental|PBM + physiotherapy exercises|"will be submitted to active PBM and physiotherapeutic exercises.
~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated at the lesion level with a wavelength of 808 nm, 25 J per point for 12 sessions. The same laser device (Laser DMC Therapy EC).
~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
11105785|NCT04035863|Sham Comparator|SHAM PBM + physiotherapy exercises|"will be submitted to sham PBM and physiotherapeutic exercises.
~For irradiation sham, the individuals will be positioned comfortably in lateral decubitus on the examining table. The same laser device (Laser DMC Therapy EC) will be used but the device will emit sound but not light.
~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
11105786|NCT04035850|Experimental|Participants|Vortioxetine PO tablets, 5-20mg Daily
11105787|NCT04035837|Experimental|short-course combination group|Nucleoside analogue is used during the first 3 months.
11105788|NCT04035837|Experimental|full-course combination group|Nucleoside analogue is used during all the course of study.
11105789|NCT04035824|Active Comparator|Gastrodia and Uncaria granule|Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
11105790|NCT04035824|Placebo Comparator|Placebo|Placebo of Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
11105791|NCT04035798|Experimental|memantine (MM)|The participants will receive memantine 5mg (1 capsule) per day for 12 weeks.
11105792|NCT04035798|Placebo Comparator|Placebo|The participants will receive one capsule of placebo per day for 12 weeks.
11105793|NCT04035785|Experimental|Kangfu anti-inflammatory suppository|"Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.
~One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.
~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
11105794|NCT04035785|Placebo Comparator|antibiotics alone group|"One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.
~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
11105795|NCT04035772|Experimental|Wiki101 and WikiTrauma|"Wiki101, a theory-based continuing professional development (CPD) program, will train participants at the selected trauma centers to use WikiTrauma effectively and safely to create and share different types of Knowledge Transfer (KT) tools (e.g., care protocols, order sets, patient decision aids). Participants will receive Wiki101 training and then gain access to WikiTrauma with editing rights to the knowledge implementation tools (e.g. care protocols, order sets, care pathways) found in the wiki.
~WikiTrauma is the wiki we created to promote best practices in trauma care and will be implemented in four trauma centers in Quebec during 12 months. During this period, we will continue to measure the impact on the quality of care."
11105796|NCT04035759|Experimental|APPEAL Program|Participants receive the APPEAL program, consisting of three one-on-one sessions, each lasting approximately one hour, and spaced one month apart. Sessions are designed to promote positive affect. Participants receive optional weekly check-ins to support behavior change efforts. All participants continue to receive standard of care.
11105797|NCT04035759|No Intervention|Standard of care|Participants receive standard of care.
11105798|NCT04035746||Single-group study|Assessment of microcirculation, brain plasticity and clinical function
11105799|NCT04035733|Experimental|Open-label single arm study|
11105800|NCT04035720|Experimental|Quantitative risk estimation|Participants will be exposed to case-scenarios. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating the probability of risk progression (20%, 25%, 85%, 90%). This information may or may not be accurate to reflect potential errors of risk prediction tools.
11105801|NCT04035720|Active Comparator|Qualitative risk estimation|Participants will be exposed to the same case-scenarios as the intervention arm. Each case scenario provides a description of the current clinical situation (e.g. patient age, current treatment, number of relapses, current EDSS, MRI findings, etc). In addition, participants will see a squared box indicating a qualitative probability of risk progression (low, high). This information may or may not be accurate to reflect potential errors of risk prediction tools.
11105802|NCT04035707|Experimental|anaesthesia with rocuronium|rocuronium is used during anaesthesia
11105803|NCT04035707|Experimental|anaesthesia without rocuronium|during anaesthesia rocuronium is not used
11105804|NCT04035694|Experimental|Intervention|Participants will receive access to Media Aware.
11105805|NCT04035694|No Intervention|Delayed-Intervention Control|Participants will receive their regular health education programming not related to sexual health education or media literacy education.
11105806|NCT04035681|Experimental|Problem-Solving Therapy|Participants who are assigned to receive problem-solving therapy will work with a research team member for six, one-hour sessions. During each session, participants will identify a problem (big or small) and create a plan to work on that problem.
11105807|NCT04035681|Active Comparator|Stroke-Related Health Education|Participants who are assigned to receive stroke-related health education will work with a research team member who will teach them about various topics related to stroke over six, one-hour sessions. Each session will cover information about a different topic related to stroke.
11105808|NCT04035668|Experimental|LOU064 Dose 1|high orally
11105809|NCT04035668|Experimental|LOU064 Dose 2|high orally
11105810|NCT04035668|Experimental|LOU064 Dose 3|middle orally
11105811|NCT04035668|Experimental|LOU064 Dose 4|low orally
11105812|NCT04035668|Placebo Comparator|Placebo|0 mg orally
11105813|NCT04035655|Experimental|Clinical and electrophysiological evaluation of tDCS session|"In this prospective case-control study, the investigator's main goal was to evaluate the impact of a single standard-care tDCS session on brain activity (EEG).
~The effect of a single 20 minutes 2 mA tDCS session with the anode placed over the left dorsolateral prefrontal cortex and the cathode over the right supraorbital cortex administered as routine care were evaluated by combined behavioral and electrophysiological assessments immediately before and after the stimulation.
~The study consisted of the following interventions, administered immediately before and after the stimulation session:
~detailed behavioral assessment by the Coma Recovery Scale-Revised (CRS-R)
~5 minutes resting state high-density EEG recordings and 6 minutes auditory oddball paradigm immediately.
~Additionally, clinical anatomical MRI (T1) acquired as routine care were used to model the estimated tDCS-induced electric fields in the entire head of patients, based on available T1-weighted MRI."
11105814|NCT04035642|Experimental|IGRT 24 Gy Single dose|Patients will be treated using image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with a single fraction at a prescription dose of 24 Gy.
11105815|NCT04035629|Experimental|Hyperpolarized 129Xe MRI for lung diagnosis|All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung.
11105816|NCT04035616|Placebo Comparator|Placebo|placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets with active comparator and labelled as A
11105817|NCT04035616|Active Comparator|Hexbio® MCP|The treatment sample is labelled as B.This is an orange-flavoured, granulated microbial cell preparation containing 30 billion colony forming units (cfu) of Lactobacilli and Bifidobacteria strains: Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC® 02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC® 02120. The placebo sample was similar in appearance and taste, but contained no microbial cells.
11105818|NCT04035603|Experimental|D-Cycloserine Augmentation|D-cycloserine (DCS) augmentation of CET sessions
11105819|NCT04035603|Placebo Comparator|Placebo Augmentation|Placebo (PBO) augmentation of CET sessions
11105820|NCT04035590|Active Comparator|With drain|Patients undergo mastectomy with flap fixation and low vacuum drainage.
11105821|NCT04035590|Experimental|No drain|Patients undergo mastectomy with flap fixation and low vacuum drainage is omitted.
11105822|NCT04035577|Experimental|Extended usability of a mobile self-help intervention|Participants will have open access to the Intellicare Hub app for 8-weeks and be surveyed at Baseline, 4-weeks, and 8-weeks
11105823|NCT04035564|Active Comparator|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
11105824|NCT04035564|Experimental|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
11105825|NCT04035551||patients receiving home parenteral nutrition|Includes patients receiving home parenteral nutrition for any indication.
11105826|NCT04035538|Experimental|A group|
11105827|NCT04035538|Experimental|B group|
11105828|NCT04035525|Experimental|MaxSimil® fish oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g MaxSimil® fish oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
11105829|NCT04035525|Active Comparator|Rice bran oil + CoQ10|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
11105830|NCT04035525|Active Comparator|CoQ10 as powder form|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive 1 dose of 1 g rice bran oil + 200 mg CoQ10. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
11105831|NCT04035512|Experimental|Expressive writing|The expressive writing group will perform the writing task, for 3 consecutive days, 20 minutes each day
11105832|NCT04035512|No Intervention|Control group|Any intervention
11105833|NCT04035499|Experimental|Experimental Arm:single|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©® is a progressive walking and resistance exercise program
11105834|NCT04035486|Active Comparator|Osimertinib 80mg QD|"Osimertinib (AZD9291) 80mg QD.
~All patients randomized into this will only receive Osimertinib 80mg.
~Dose may be reduced to allow for the management of IP related toxicity."
11105926|NCT04034836|Active Comparator|The i.v. group|The i.v. group will receive scalp blocks with ropivacaine 20ml, plus saline 2ml with epinephrine (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously.
11106670|NCT04029688|Experimental|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
11105835|NCT04035486|Experimental|Osimertinib 80 mg QD and platinum-based chemotherapy|"Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
~Dose may be reduced to allow for the management of IP related toxicity."
11105836|NCT04035473|Active Comparator|Sequence A (Oraxol, IV paclitaxel)|"The treatment sequences will be:
~A Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2 B IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2"
11105837|NCT04035473|Active Comparator|Sequence B (IV paclitaxel, Oraxol)|"The treatment sequences will be:
~A IV paclitaxel on Day 1 of Treatment Period 1 followed by Oraxol on Days 1, 2, and 3 of Treatment Period 2 B Oraxol (paclitaxel + HM30181) on Days 1, 2, and 3 of Treatment Period 1 followed by IV paclitaxel on Day 1 of Treatment Period 2"
11105838|NCT04035460|Active Comparator|Helmet oxygenation group|Patients randomized to helmet NIPPV will receive noninvasive oxygenation and ventilation via a latex free helmet
11105839|NCT04035460|Active Comparator|High Flow Nasal Oxygen|Oxygen will be passed through a heated humidifier and applied continuously through large-bore nasal prongs
11105840|NCT04035447|Experimental|Behavioral Symptom Management for Young Adult Cancer Survivors|The proposed intervention will provide systematic training in cognitive and behavioral coping skills (e.g., activity-rest cycling, cognitive restructuring, relaxation training) delivered over the course of 8 sessions (10 therapy hours). By employing these strategies, participants learn to adjust their thoughts, behaviors, and emotions in the service of better managing symptoms.
11105841|NCT04035447|Active Comparator|Waitlist Control|Waitlist control participants will receive the intervention and receive systematic training in cognitive and behavioral coping skills approximately 6 months into their participation in the study.
11105842|NCT04035434|Experimental|CTX110|Administered by IV infusion following lymphodepleting chemotherapy.
11105843|NCT04035408||All subjects|All the enrolled subjects will be considered for the assessment of the primary and secondary outcomes.
11105844|NCT04035395|Experimental|Intervention|Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
11105845|NCT04035395|No Intervention|Control|Participants randomized to the usual care group will receive the SyV 1.0 program which includes community based program referrals (excluding intervention programs) and home-based visits from CHWs. These participants will also receive the standard follow-up from UTHealth staff such as a phone call, an information session as per their treatment plan, and /or a onetime mailing of information about the importance of following their treatment plan. Before implementation begins, additional details about standard care will be ascertained from partner organizations to better understand how these differ from the treatment conditions of the intervention group. Once the participant completes 12 months in the study, 2.0 services will be initiated.
11105846|NCT04035382|Experimental|Labor Induction|Induction of labor between 39 0/7 to 39 6/7 weeks. Cervical ripening and induction method will be left to the managing clinician. However, combination method of cervical ripening with prostaglandin or oxytocin and Foley catheter, followed by oxytocin infusion and amniotomy will be encouraged.
11105847|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - TAI|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to TAI
11105848|NCT04035369|Active Comparator|Endophthalmitis Post Intravitreal Injections - PPV|Patients 18 years and older with presumed infectious endophthalmitis after non-steroid intravitreal injections randomized to PPV
11105849|NCT04035356||HAART 300|HAART 300 Aortic Annuloplasty Device
11105850|NCT04035356||HAART 200|HAART 200 Aortic Annuloplasty Device
11105851|NCT04035343|Active Comparator|Conventional face down positioning|Patients in third arm will be treated with the current standard of care, that is, they will be kept supine in the ophthalmic surgery chair after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will transition to face down positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
11105852|NCT04035343|Experimental|Supine positioning|Patients in the second arm will be kept supine after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will maintain supine positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
11105853|NCT04035330|Experimental|etidronate in sodium hypochlorite|It comes in a capsule containing 0.9 g of etidronate powder, which should be mixed immediately with 10 mL of a NaOCl solution of choice directly before treatment, resulting in a combined irrigant containing both active chlorine and approximately 9% etidronate. Irrigation with a total volume of 25 ml for each case
11105854|NCT04035330|Active Comparator|sodium hypochlorite|irrigation with 2.5% NaOCl with a total volume of 25 ml for each case
11105855|NCT04035317|Experimental|Aesculus hippocastanum|Patients will receive extract of Aesculus hippocastanum
11105856|NCT04035317|Placebo Comparator|Placebo|Patients will receive placebo
11105857|NCT04035304|Experimental|Mindfulness Coach Mobile App|Participants in this condition will complete 3 assessments: initial, end of month two and end of month four. Each participant, following initial assessment will be provided with a link to download the Mindfulness Coach mobile app as well as with brief recommendations for how to use the app over the subsequent 16 weeks of the study. Mindfulness Coach is a mobile app for iPhone and Android, developed by the VA National Center for PTSD in collaboration with National Center for Telehealth and Technology (T2).
11105858|NCT04035304|No Intervention|No Treatment Control Group|Participants in this condition will initially be provided with links to resources for Veterans with PTSD (http://ptsd.va.gov) and will be told that they will be contacted again in 8 weeks (60 days) to complete a second assessment. Each participant will then be provided with a link to download the Mindfulness Coach mobile app and with brief recommendations for how to use the app over the subsequent 8 weeks of the study (see description above). Participants will participate in a final follow up survey 8 weeks after receiving the app.
11105859|NCT04035291|Active Comparator|Interventional|The first group (n = 25) will be asked to apply the physiotherapy program by the family at home that includes the principles of therapeutic handling-holding-positioning of NDT principles, starting at the third month for 8 weeks. And It will last for at least 45 minutes, 3 days a week. Family education will be evaluated after 4 weeks and improvements will be made in accordance with the motor development of the infant. The program will be implemented by families for 8 weeks.
11105860|NCT04035291|Experimental|Experimental|In the second study group (n = 25), family collaborative physiotherapy program will be applied by the family. This program will start from the postterm third month, and will include family trainings based on the goal-oriented active motor learning model of the baby in an 8-week in enriched environment and to include holding-carrying-positioning trainings in daily routines. Also it will last for at least 45 minutes, 7 days a week. All members of the family will be included in the family trainings and home visits will be made at 2-week intervals. Families will be encouraged to apply the physiotherapy processes of their babies in their natural environment at every moment of their daily routines (feeding, carrying on lap, gas extraction, changing the bed, sleeping, waking time, shopping moment, playing games etc.).
11105861|NCT04035291|No Intervention|control|In the third study group, families who are out of town or who cannot participate in the treatment program for other reasons will be included in the evaluations.
11105862|NCT04035278|Experimental|Dengusiil|
11105863|NCT04035278|Placebo Comparator|Placebo|
11105864|NCT04035265|Active Comparator|pain+ / synovitis +|SLE patients with inflammatory pain and synovitis determined by the practitioner during physical examination of radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP. Defining synovitis as pain and inflammation and/or deformity (present or existing over the past year) included in the clinical history
11105865|NCT04035265|Active Comparator|pain + / synovitis -|SLE patients with inflammatory pain without determined synovitis. Current (or over the past year) pain in radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP, with no synovitis
11105866|NCT04035265|Active Comparator|pain - / synovitis -|SLE patients without inflammatory pain with normal physical examination currently or over the past year
11105867|NCT04035265|Placebo Comparator|healthy|control patients (healthy participants: no pain, no SLE, no family affected by systemic inflammatory disease, a blood test with no elevation APR or autoimmunity +)
11105868|NCT04035252||1. Young healthy group|Male or female between the age of 18 and 40 years old. No presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
11105869|NCT04035252||2. Patients with an AAA|Individuals (>60 years) with a small, stable, abdominal aortic aneurysm (i.e. AAA diameter of 30-50 mm)
11105870|NCT04035252||3. Healthy older group|Healthy age- and sex- matched with group 2 with no presence of systolic blood pressure >140 and/or diastolic blood pressure >90, cardiovascular history or antihypertensive medication
11105871|NCT04035239|Experimental|BGS use|Use of BGS goggles for a 3-6 weeks period.
11105872|NCT04035226||Relapsed/refractory Multiple Myeloma|Patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody treatment will be observed.
11105873|NCT04035213|Experimental|Behavior of Sleep Course|A semester-long course focused on sleep improves college students' sleep patterns over one semester. The listed aims of this course are to: 1) provide students with a comprehensive understanding of sleep; 2) afford an overview of the multiple ways sleep impact health, performance and well-being; and 3) to assist students in discovering how their own sleep-wake patterns impact their day to day functioning.
11105874|NCT04035213|No Intervention|Control|Students from other upper level departmental courses with content that does not include a focus on or discussion of sleep
11105875|NCT04035200|Experimental|V117957 1 mg|V117957 tablets taken orally at bedtime
11105876|NCT04035200|Experimental|V117957 2 mg|V117957 tablets taken orally at bedtime
11105877|NCT04035200|Placebo Comparator|Placebo|Placebo to match V117957 tablets taken orally at bedtime
11105878|NCT04035187|Experimental|Sequence A (fast, medium, oral solution, then slow)|Participants first receive fast tablet, then medium tablet, then oral solution, and then slow tablet. Washout period is (at least) one week.
11105879|NCT04035187|Experimental|Sequence B (medium, slow, fast, then oral solution)|Participants first receive medium tablet, then slow tablet, then fast tablet, and then oral solution. Washout period is (at least) one week.
11105880|NCT04035187|Experimental|Sequence C (slow, oral solution, medium, then fast)|3, 4, 2, 1 Participants first receive slow tablet, then oral solution, then medium tablet, then fast tablet. Washout period is (at least) one week.
11105881|NCT04035187|Experimental|Sequence D (oral solution, fast, slow, then medium)|Participants first receive oral solution, fast tablet, then slow tablet, and then medium tablet. Washout period is (at least) one week.
11105882|NCT04035174|Experimental|LTS-2 DEC patch|This is a transdermal device with diethylcarbamazine (DEC) applied directly on the skin. The reading will be done 24 hours after.
11105883|NCT04035174|Active Comparator|Skin snip|A skin snip will be performed using a 2 mm Holth corneoscleral's punch. Once done, the microfilariae of Onchocerca volvulus will be counted with a microscope.
11105884|NCT04035135|Experimental|Open Label Treatment Arm|One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.
11105885|NCT04035122|Experimental|Robotic Treatment|The Lokomat is a robotic device. For treatment with the robotic system, the amount of body weight supported will initially set at 70% of every patient's weight, then decreasing in accordance with load tolerance, although not providing less than 20% support. The selected speed will be adapted to the patient's working comfort under the supervision of a trained physiotherapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
11105886|NCT04035122|Active Comparator|Conventional Treatment|The CG will perform traditional overgroung gait rehabilitation. Exercises in this program are designed with gradual increments to meet each patient's abilities and were supervised by a physical therapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
11105887|NCT04035109|Other|Anakinra (Period 1) then Placebo (Period 2)|Subjects randomized to this arm will receive a single injection of anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their first allergen challenge (Period 1), followed by the matching saline placebo after their second allergen challenge (Period 2).
11105888|NCT04035109|Other|Placebo (Period 1) then Anakinra (Period 2)|Subjects randomized to this arm will receive a single injection of saline placebo administered subcutaneously after their first allergen challenge (Period 1), followed by anakinra 1 mg/kg (max dose of 100 mg) administered subcutaneously after their second allergen challenge (Period 2).
11105889|NCT04035096|Experimental|The high-dose vitamin C with very low carbohydrate diet group|"Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.
~Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose
~Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.
~The Riordan IVC protocol (Taiwan)
~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks
~The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month
~VLCD intervention in the first 12 weeks"
11105890|NCT04035096|Active Comparator|The control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs
~Usual care"
11105891|NCT04035083|Experimental|Laser activated irrigation|Laser activated irrigation of sodium hypochlorite using a 980 nm diode laser device
11105892|NCT04035083|Active Comparator|Passive ultrasonic irrigation|passive ultrasonic irrigation of sodium hypochlorite using an ultrasonic laser device
11105893|NCT04035070|Experimental|Root canal irrigation with co-amoxiclav-clindamycin solution|Alternate irrigation with 1 mL antibiotic-containing solution followed by 4 mL 2.5% sodium hypochlorite solution between each size instrument and the consequent one. The antibiotic-containing solution will be prepared by mixing equal quantities of 1.2 gm Co-amoxiclav solution and 600 mg Clindamycin solution at a ratio of 1:1 by volume.
11105894|NCT04035070|Experimental|Root canal irrigation with MTAD|Irrigation with 5 mL MTAD irrigating solution for 5 minutes between each size instrument and the consequent one.
11105895|NCT04035070|Active Comparator|Root canal irrigation with 2.5% sodium hypochlorite|Irrigation with 5 mL 2.5% sodium hypochlorite irrigating solution between each size instrument and the consequent one.
11105896|NCT04035057|Experimental|Behaviorally Enhanced Training Strategies|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions. The two conditions will differ in their training focus during the subsequent half-day training. The Behaviorally Enhanced condition will involve therapist engagement in repeated self-exposure and partner-exposure exercises with the goal of targeting and reducing therapists' reservations about using exposure with their patients. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Behaviorally Enhanced condition will include regular sampling and feedback on therapists' remaining reservations about exposure in additional to counseling the implementation of exposure with therapists' patients.
11105897|NCT04035057|Active Comparator|Standard Didactic Training|Both training conditions will receive a 1.5 day training followed by ongoing supervision while they implement exposure therapy with patients recruited to the study. The first full day will consist of the same foundational information in both conditions.The two conditions will differ in their training focus during the subsequent half-day training. The Standard Didactic condition will involve additional didactic instruction related to common barriers and more advanced delivery concepts than will be presented in the half-day training for the Behaviorally Enhanced condition. The focus of ongoing supervision following the initial 1.5 day training workshop will also differ by condition. The Standard Didactic condition will involve counseling on the implementation of exposure with therapists' patients without explicit focus on therapists' remaining reservations about exposure.
11105898|NCT04035031|Experimental|Forxiga first, placebo second|Forxiga followed by placebo
11105899|NCT04035031|Experimental|Placebo first, Forxiga second|Placebo followed by forxiga
11105900|NCT04035018|Experimental|pharmacopuncture therapy|The physicians will select one or more pharmacopuncture therapy for each participants. The physicians will also decide dosage and frequency of treatment according to the participant's status.
11105901|NCT04035018|Active Comparator|physical therapy|The physicians will select one or more physical therapy for each participants. The physicians will also decide intensity and frequency of treatment according to the participant's status.
11105902|NCT04035005|Experimental|Ocrelizumab|Participants will receive ocrelizumab by IV infusion every 24 weeks.
11105903|NCT04035005|Placebo Comparator|Placebo|Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
11105904|NCT04034992||Retrospective CKD cohort|Retrospective (secondary) data refers to patient data extracted from existing electronic health records (EHRs)/registries/databases. It represents existing real-world data, regardless of reason for collection or location of storage and is analogous to those represented in the study protocol for which feasibility assessments are conducted. Retrospective data will be collected from registries, databases, and EHRs. The aim is to identify and extract clinical data retrospectively from a minimum of 100000 (no set maximum) CKD patients via existing databases/registries/EHRs across geographies. The retrospective data will be captured beginning 1 January 2008 through the most currently available data.
11105927|NCT04034836|Active Comparator|The control group|The control group will receive scalp blocks with ropivacaine, 20ml, plus saline 2ml with epinephrine (5 ug/mL) and i.v. saline 2ml;
11105928|NCT04034823|Experimental|KN035 in combination with trastuzumab and docetaxel|
11105929|NCT04034797|Experimental|Photo|
11105930|NCT04034797|Active Comparator|No photo|
11105931|NCT04034784|Experimental|Discrete(TM)|Intraperitoneal injection
11105905|NCT04034992||Prospective CKD cohort|Prospective (primary and secondary) data refers to manual collection/extraction of data in a de novo manner for the purpose of addressing study objectives. Collection/extraction of patient data in the prospective cohort will be done via electronic case report form, questionnaires, and mobile phone/tablet application. The initial aim is to identify and collect/extract data from a minimum of 1000 (no set maximum) CKD patients enrolled over a period of 2 years, with the possibility of prospective follow-up for a minimum of 1 year. The patient specific data in the prospective cohort will be collected by utilizing Rapid Assessment of Physical Activity (RAPA) questionnaire, Work Productivity and Activity Impairment (WPAI) questionnaire, Short Form (SF)-36 questionnaires, simple food diary, and other patient reported outcomes - including a set of questions to collect patient symptoms.
11105906|NCT04034979|No Intervention|Phase I-Baseline evaluation|The first two months of the investigator's project will be a baseline evaluation of the current decision making process about goals-of-care in a local ICU setting (Levis, Quebec). A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) dyads of physicians and newly admitted elderly patients discussing goals-of-care.
11105907|NCT04034979|Experimental|Phase II-Impact of the decision aid|The two following months will be an evaluation of the decision making process about goals-of-care in the same local ICU setting using only the decision aid without any training. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care, whether the physician chooses to use the context-adapted decision-aid or not.
11105908|NCT04034979|Experimental|Phase III- Impact of the decision aid and the|This phase will be an evaluation of the decision making process about goals-of-care in the same local ICU setting after intensivists complete the training program and using the DA. A PhD student will collect sociodemographic data (age, gender, education level, religion), observe and video record (or audio record) new dyads of physicians and newly admitted elderly patients discussing goals-of-care using the context-adapted decision aid and the new skills learned in the training program.
11105909|NCT04034966|Active Comparator|Claria|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) with the telemedicine module. The telemedicine module is the platform for storing patient information directly from the PD machine. Handling will be done according to the basic operating instructions established by the manufacturer.
11105910|NCT04034966|No Intervention|Control|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device. the device is used for automated peritoneal dialysis. Handling will be done according to the basic operating instructions established by the manufacturer.
11105911|NCT04034953|Other|Colorectal Cancer Screening|"Potential screening participants will firstly be briefed about the CRC screening pilot program launched by the Department of Health (DH).
~This project will offer screening referrals to the government pilot program or FIT screening tests for a total of 10,000 consecutive visitors."
11105912|NCT04034953|Other|Prostate Cancer Screening|A blood test for Prostate Specific Antigen (PSA) will then be performed. Subsequently, for subjects with serum PSA 4-10 ng/ml, additional blood tests for Prostate Health Index (PHI) will be performed for the further assessment of risk of prostate cancer. Subjects with serum PSA > 10 ng/ml; or PHI ≥ 35 will be referred for Trans-rectal Ultrasound-guided Prostatic Biopsy (TRUS+PB). Subjects with serum PSA < 4 ng/ml or with PHI level < 35 will be invited to repeat the prostate screening tests every 2-years. We aim to screen not more than 5,000 subjects. For all patients recruited for prostate cancer screening, the study team will continue follow the subjects, by phone or mail or other means, for the long term clinical outcome for up to 10 years.
11105913|NCT04034953|Other|Breast Cancer Screening|Up to 5,000 eligible female subjects will receive a mammography on a 2-yearly basis. Individuals with abnormal findings on mammography will be referred for subsequent follow-up by the Jockey Club Breast Health Centre (BHC) run by the Hong Kong Breast Cancer Foundation (HKBCF).
11105914|NCT04034940|Other|primary PCI STEMI patients|All Patients with AMI refered for primary PCI in single center
11105915|NCT04034927|Active Comparator|Arm I (olaparib)|Patients receive olaparib PO BID in the absence of disease progression or unacceptable toxicity.
11105916|NCT04034927|Experimental|Arm II (olaparib, tremelimumab)|Patients receive olaparib as in Arm I. Patients also receive tremelimumab IV over 60 minutes on day 1. Cycles of tremelimumab repeat every 4 weeks for 4 doses and then every 12 weeks for up to 2 years total in the absence of disease progression or unacceptable toxicity.
11105917|NCT04034914|Experimental|Yoga Therapy|
11105918|NCT04034901|Experimental|Monitoring of cardiorespiratory parameters|Monitoring of cardiorespiratory parameters with BORA Band
11105919|NCT04034888|Experimental|Home Exercise Program (HEX)|Customized home exercise program
11105920|NCT04034875|Experimental|Patients with acquired brain injury|
11105921|NCT04034862|Experimental|2DR|Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)
11105922|NCT04034862|No Intervention|3DR|Continued 3 drug regimen treatment (DTG+ABC+3TC)
11105923|NCT04034849|Experimental|Test group|Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
11105924|NCT04034849|Placebo Comparator|Placebo group|Low-Level Laser Therapy was applied in the placebo group with a Diode Laser Fox (A.R.C. Laser, Italy) turned off with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
11105925|NCT04034836|Experimental|The scalp blocks group|The scalp blocks group will receive scalp blocks with ropivacaine, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine (5 ug/mL) and i.v. saline 2ml;
11105932|NCT04034784|Sham Comparator|Control Lactated Ringer's Solution (Control LRS)|Intraperitoneal injection
11105933|NCT04034771|Experimental|propofol and melatonin|propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.
11105934|NCT04034771|Active Comparator|propofol and placebo|propofol iv infusion and a placebo tablets through a nasogastric tube once at admission
11105935|NCT04034758|Placebo Comparator|Placebo capsule arm|Oral administration of 30 placebo capsule containing edible pigmented starch together with full dose of oral 5-Aminosalicylic acid(5-ASA).
11105936|NCT04034758|Active Comparator|SQIMC-md FMT arm|Oral administration of 30 SQIMC-md capsules containing 2*10^13 copies of prepared fecal microbiota lyophilized powder from multiple healthy donors' fresh feces together with full dose of oral 5-Aminosalicylic acid(5-ASA).
11105937|NCT04034745||Standard of Care telotristat ethyl (Xermelo) Treatment|Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
11105938|NCT04034732|Experimental|Mindfulness-based Relapses Prevention (MBRP)|The MBRP program will be delivered by an instructor with training in MBSR/MBCT who has more than two years of teaching experience in MBSR/MBCT. The MBRP programme will consist of 2.5 hour weekly sessions for 8 weeks. The mindfulness curriculum will include training in mindfulness through (1) a body scan, (2) sitting meditation and (3) mindful stretching exercises.
11105939|NCT04034732|Active Comparator|Usual Care Control Group (UCCG)|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
11105940|NCT04034719|Experimental|Experimental group|"Newborn hospitalized in the neonatal department with their parent will be included.
~They will have a portage scarf to help them to keep their child skin-to-skin"
11105941|NCT04034719|Active Comparator|Control group|"Newborn hospitalized in the neonatal department with their parent will be included.
~They wont have a portage scarf."
11105942|NCT04034706||PCOS females|Females diagnosed with PCOS with a BMI between 23 and 40 kg/m2.
11105943|NCT04034706||Non-PCOS control females|Females without PCOS with a BMI between 23 and 40 kg/m2 split into 2 groups- apple shaped and pear shaped.
11105944|NCT04034693|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
11105945|NCT04034693|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
11105946|NCT04034680|Experimental|Home care services - Intervention group|Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
11105947|NCT04034680|Active Comparator|Home care services - Control group|Totally 5 municipalities (25 persons with dementia) will be included in the Control group. The municipalities in the control group will receive the same two hours lectures about dementia and NPS as the intervention group. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
11105948|NCT04034641|Experimental|probiotics plus standard therapy|
11105949|NCT04034641|Placebo Comparator|placebo plus standard therapy|
11105950|NCT04034628||Laparoscopic insertion|Individuals who undergo laparoscopic PD catheter insertion
11105951|NCT04034628||Percutaneous insertion|Individuals who undergo percutaneous PD catheter insertion by either a nephrologist or radiologist.
11105952|NCT04034615|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
11105953|NCT04034615|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
11105954|NCT04034615|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
11105955|NCT04034602|Experimental|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
11105956|NCT04034602|Active Comparator|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
11105957|NCT04034589|Experimental|Pyrotinib plus fulvestrant|Pyrotinib(400 mg once daily) + fulvestrant (500 mg, administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days)
11105958|NCT04034576|Experimental|TAU + mindfulness intervention|The mindfulness-based intervention consists of three five to ten minutes session-introducing interventions (mindful walking, body scan, breathing space). At the beginning of each of the 24 therapy sessions patients receive one of the three mindfulness interventions. Each intervention is instructed for four sessions consecutively and eight sessions in total. After completion of the mindfulness intervention, the regular therapy session begins.
11105959|NCT04034576|Active Comparator|TAU + relaxation intervention|The relaxation interventions (progressive muscle relaxation (PMR), imagery journey, walking relaxation) are parallelized to the three mindfulness-based interventions. At the beginning of each of the 24 therapy sessions, patients receive one of the three relaxation interventions. Each intervention is instructed for four sessions consecutively and eight sessions in total. After completion of the relaxation intervention, the regular therapy session begins.
11105960|NCT04034576|Other|Treatment as usual|Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions. No particular session-introductions are applied.
11105961|NCT04034563|Other|Risk of advanced neoplasia at 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy at 3-years
11106078|NCT04033601|Experimental|non-pharmacological intervention group|
11106079|NCT04033601|Experimental|control group|
11105962|NCT04034563|Other|Risk of advanced neoplasia beyond 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy beyond 3-years
11105963|NCT04034550|Experimental|hospitalized patients diagnosed with leptospirosis|hospitalized patients diagnosed with leptospirosis: 12 months of follow up with biological samples and data collection
11105964|NCT04034537|Experimental|cPSTA GROUP|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
11105965|NCT04034524||New users of GLP1 receptor agonists (exposure)|
11105966|NCT04034524||New users of basal insulin (reference)|
11105967|NCT04034511|Experimental|Medically-tailored meal delivery and medical nutrition therapy|Participants assigned to this arm will receive home-delivered, medically-tailored meals for 3 months combined with monthly individual Medical Nutrition Therapy sessions for 6 months. Participants will also receive participants' usual case management services from participants' Medicaid insurance program.
11105968|NCT04034511|No Intervention|Usual care|Participants assigned to this arm of the study will receive usual care and case management services from participants' Medicaid insurance program.
11105969|NCT04034485|Experimental|LIB003|300 mg SC Q4W
11105970|NCT04034485|Active Comparator|evolocumab|420 mg SC Q4W
11105971|NCT04034472|Other|Cardiometabolic risk in women with obesity|The use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
11105972|NCT04034459|Active Comparator|FOLFOXIRI plus bevacizumab|"One cycle (cycle duration 14 days) consists of:
~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
~Oxaliplatin 85mg/m² day 1
~5-FU 3000 mg/m² iv over 48 h days 1-2
~Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1 *1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.
~Repeat administration every 2 weeks for a maximum of 12 cycles
~Dose adaptation at the treating physician's discretion.
~Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
11105973|NCT04034459|Experimental|FOLFOXIRI plus cetuximab|"One cycle (cycle duration 14 days) consists of:
~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
~Oxaliplatin 85mg/m² day 1
~5-FU 3000 mg/m² iv over 48 h days 1-2
~Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
~Repeat administration every two weeks up to a maximum of 12 cycles.
~Dose adaptation at the treating physician's discretion.
~Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
11105974|NCT04034446|Experimental|A|Single dose of CD19-CD22 CAR-T cells
11105975|NCT04034433|Experimental|Exercise|
11105976|NCT04034433|No Intervention|Control|
11105977|NCT04034420|Experimental|Online training|To receive self-paced online training and learning materials
11105978|NCT04034407|Experimental|Damage control surgery|In the damage control surgery (DCS) group the surgeon was asked to perform rapid source control by stapling the perforated segment leaving blind ends or suturing the perforation site if possible, doing a thorough lavage of the abdominal cavity and placing an intra-abdominal negative pressure system avoiding the retraction of the abdominal wall with dynamic sutures as published. The second-look operation was scheduled for a time 24-48 hours after primary surgery that would be during regular working hours with a colorectal surgeon on hand to make the decision for either anastomosis or ostomy.
11105979|NCT04034407|Active Comparator|Control group|In the conventional treatment group (Group C), the decision to reconstruct the colon or perform a Hartmann procedure was made by the surgeon during the emergency operation. After performing the anastomosis or the Hartmann procedure, patients with advanced peritonitis received an intraabdominal negative pressure system at the discretion of the operating surgeon.
11105980|NCT04034394|Experimental|Electromoxibustion|Participants in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside (Fort Mayer, Guangzhou, China).
11105981|NCT04034394|Active Comparator|Knee health education|Participants in this group will attend 2 sessions (120 minutes each, 1-week apart) of health education related to knee OA symptom management.
11105982|NCT04034381||Port-au-Prince metropolitan area|
11105983|NCT04034381||Other urban areas|
11105984|NCT04034381||Rural areas|
11105985|NCT04034368|Experimental|Experimental Arm|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
11105986|NCT04034355|Experimental|PledOx (5 µmol/kg)|Calmangafodipir 5 µmol/kg
11105987|NCT04034355|Placebo Comparator|Placebo|0.9% sodium chloride in 20 mL vials
11105988|NCT04034329||ASVAL - group|GSV diameter ≤ 6 mm
11105989|NCT04034329||EVLA-group|GSV diameter > 6 mm
11105990|NCT04034316|Experimental|MSC|"During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:
~25% reduction of the ongoing immunosuppressive treatment following the first administration;
~50% reduction of the ongoing immunosuppressive treatment following the second administration;
~interruption of the ongoing immunosuppressive treatment following the third administration.
~In the case that the hypothesis that P ≥ 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
11105991|NCT04034290|Experimental|Stage 1 (GamFluVac intranasal drip)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated by intranasal drip
11106082|NCT04033575|Active Comparator|Colgate Total SF|Colgate Total Clean Mint White Paste 1100 ppm F Toothpaste
11105992|NCT04034290|Experimental|Stage 1 (GamFluVac with the help of a spray dispenser)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated intranasally with the help of a spray dispenser
11105993|NCT04034290|Experimental|Stage 2 Vaccine|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
11105994|NCT04034290|Placebo Comparator|Stage 2 (Controll Group)|Placebo
11105995|NCT04034277|Experimental|Lee Silverman Voice Therapy|LSVT LOUD® is a therapy program which requires four sessions per week for 4 weeks by a speech and language therapists with a certification in Lee Silverman Voice Therapy. Each session lasted 50-60 min.
11105996|NCT04034277|Active Comparator|Conventional Treatment|The content and dose of standard SLT is poorly defined within the published literature. For this reason, the standard therapy intervention will encompass all SLT techniques that are not LSVT®. Treatment will be individualized and may include any of the following: exercises targeting respiration, phonation, articulation, behavioral strategies to reduce prosodic abnormality
11105997|NCT04034264||1|Patients between 6 months and 65 years old who present with fever.
11105998|NCT04034251|Experimental|1/Arm 1|IP and IV paclitaxel administration with concomitant oral capecitabine
11105999|NCT04034238|Experimental|1. Dose escalation|LMB-100 at escalating doses plus tofacitinib
11106000|NCT04034238|Experimental|2. Dose expansion|LMB-100 at optimal dose plus tofacitinib
11106001|NCT04034225|Experimental|SNS-301 added to pembrolizumab|"SNS-301
~Pembrolizumab"
11106002|NCT04034212|Experimental|Singing for Lung Health group|Once weekly attendance at a Singing for Lung Health group for 12 weeks.
11106003|NCT04034212|No Intervention|Usual Care group|Usual care group, participants given advice on physical activity while continuing with usual care.
11106004|NCT04034199|Experimental|Denosumab group|Patients randomized into the denosumab group will receive denosumab 60mg subcutaneously every 6 months, for a total duration of 1 year. DEXA scan would be repeated at 1 year.
11106005|NCT04034199|Active Comparator|Zoledronic acid|Patients randomized into the denosumab group will receive one dose of zoledronic acid at 5mg intravenously. DEXA scan would be repeated at 1 year.
11106006|NCT04034173|Other|RAS mutations frequency <= 7%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1
~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
~Followed by FOLFIRI regimen
~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
~5-FU 400 mg/m² BSA, bolus, D1
~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
~q day 14"
11106007|NCT04034173|Other|RAS mutation frequency >7% to <=14%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1
~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
~Followed by FOLFIRI regimen
~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
~5-FU 400 mg/m² BSA, bolus, D1
~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
~q day 14"
11106008|NCT04034173|Other|RAS mutation frequency >14% to <=20%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1
~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
~Followed by FOLFIRI regimen
~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
~5-FU 400 mg/m² BSA, bolus, D1
~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
~q day 14"
11106009|NCT04034160|Experimental|burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The beef patty (Beef Patty Chuck) will be 80% lean and 20% fat.
11106010|NCT04034160|Active Comparator|vegetarian burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The vegetarian patty (Impossible Burger) will be 18% fat.
11106011|NCT04034134|Experimental|Jaktinib hydrochloride tablets 1|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 150mg qd dose group
11106012|NCT04034134|Experimental|Jaktinib hydrochloride tablets 2|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 200mg qd dose group
11106013|NCT04034121|Other|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
11106014|NCT04034108|Experimental|Experiment group|All the patients were classified as AIS-A at the time of admission to the clinical center. The MRI was performed in all cases prior to and after the surgery. Surgeries were performed between 12 hours to 30 days after trauma. At 15 days after surgery, with protection of a tailored chest-waist cast made of polyurethane 8 foam for thoracic/lumbar injuries or a neck support for cervical injuries, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers.
11106015|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.
11106016|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
11106017|NCT04034082|Experimental|IHT group|Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
11106018|NCT04034082|Active Comparator|Conventional group|Conventional phase 2 in-hospital rehabilitation program
11106019|NCT04034069|Experimental|cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
11106020|NCT04034069|Active Comparator|Sham cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
11106080|NCT04033588|Other|Freedom® Total Knee System|A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in United Kingdom
11106021|NCT04034069|Sham Comparator|Sham cTBS + sham iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
11106022|NCT04034056||Obinutuzumab|
11106023|NCT04034030|Experimental|Treatment Group|This study will be conducted over one year in 10 focal CSWS patients ranging in age from 3 to 21 years. The patients will be recruited from the large patient population that is served by the Children's Mercy Comprehensive Epilepsy Monitoring Unit (EMU) in Overland Park, Kansas. Subjects will be identified from these EMU patient population. Those meeting inclusion criteria will be approached for possible enrollment. Inclusion criteria will be defined by patients that were diagnosed with focal CSWS in accordance with the ILAE classification with SWI >85% during NREM sleep on their previous or most recent EEG. Patients and their parents/guardians will provide assent/consent for participation in the study after being briefed on the nature of the study, by reading and signing assent and assent/consent forms, respectively
11106024|NCT04034004|Experimental|Meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
11106025|NCT04034004|Experimental|meditation|"Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation."
11106026|NCT04033991||Patients with advanced RCC|Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)
11106027|NCT04033978|Experimental|Cognitive remediation arm|Participants will be enrolled in a cognitive remediation group. The program will last 10 weeks and be composed of 10 participants. This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
11106028|NCT04033978|Active Comparator|Control group|Participants will be enrolled in an information control group. They will receive information about psychosocial rehabilitation and recovery process. The program lasts 10 weeks.
11106029|NCT04033965||women <35 with early breast cancer|
11106030|NCT04033965||women>65 years old with early breast cancer|
11106031|NCT04033952|Experimental|Assigned Interventions|The OPASS program will be delivered to the intervention group. The intervention protocols of the OPASS program were developed based on the strategy training guidelines developed by Skidmore et al. and based on the findings identified from the feasibility study. Trained research therapists will take the responsibility for delivering the intervention to participants. The program consists of four critical ingredients: self-selected goals, self-evaluation of performance, strategy development, and implementation, and therapeutic guided discovery.
11106032|NCT04033952|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
11106033|NCT04033939|Experimental|HSK3486-01|Randomized to receive HSK3486 (0.016mg/kg,0.064mg/kg )as a single IV injection. HSK3486-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
11106034|NCT04033939|Placebo Comparator|Placebo-01|Randomized to receive placebo (0.016mg/kg,0.064mg/kg )as a single IV injection. placebo-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
11106035|NCT04033939|Experimental|HSK3486-02|Randomized to receive either HSK3486（0.128mg/kg,0.192mg/kg,0.288mg/kg,0.432mg/kg,0.540mg/kg,0.648mg/kg,0.810mg/kg) as a single IV injection. HSK3486-02 was open-label.(5 HSK3486-02: 1 propofol-02)
11106036|NCT04033939|Active Comparator|Propofol-02|Randomized to receive propofol (2.5mg/kg) as a single IV injection. Propofol-02 was open-label.(5 HSK3486-02: 1 propofol-02)
11106037|NCT04033926|Other|Arm A|"Treatment Period 1: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks
~Treatment Period 2: Placebo SC weekly for 16 weeks"
11106038|NCT04033926|Other|Arm B|"Treatment Period 1: Placebo SC weekly for 16 weeks
~Treatment Period 2: KZR-616 30 mg SC weekly for 2 weeks, then 45 mg SC weekly for 14 weeks"
11106039|NCT04033913||Adult patient learning self-catheterization|Patients who have successfully perform self-catheterization during a day hospital in a neuro-urology department complete a questionnaire validated by experts on the different criteria that guided the final choice of the catheter
11106040|NCT04033900|Experimental|Prewarming|Active warming is allowed prior to surgery with forced-air warming devices
11106041|NCT04033900|No Intervention|No prewarming|Non active warming is allowed before surgery
11106042|NCT04033887||HCV-only infected|"Archived frozen plasma samples from individuals that were characterised to be HCV-antibody positive or HCV-antibody negative (HCV-only infected). These samples are characterised for their HIV status (negative)."
11106043|NCT04033887||HCV/HIV co-infected|"Archived frozen plasma samples from HCV-positive or HCV-negative individuals who are HIV infected (HCV/HIV co-infected)."
11106044|NCT04033874|Experimental|Kangaroo care|"Heel stick procedure will be performed during kangaroo care.
~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
11106045|NCT04033874|Experimental|Mother's lap|"Heel stick procedure will be performed during newborns who are holding on their mother's lap.
~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
11106081|NCT04033575|Sham Comparator|Fluoride Control|Colgate Cavity Protection 0.76% as Na MFP Toothpaste
11106046|NCT04033874|Experimental|White noise|"Heel stick procedure will be performed during newborns listened to white noise.
~For the white noise; the track named do not cry your baby, pt. 2 will be played in Orhan Osman's Colic album. The white noise level will be adjusted to an average of 55 decibels. During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
11106047|NCT04033874|Experimental|Ambient sound|"Heel stick procedure will be performed during newborns listened to ambient sound.
~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
11106048|NCT04033861|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
11106049|NCT04033861|Placebo Comparator|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
11106050|NCT04033835|Experimental|MBT-I|12 sessions of MBT
11106051|NCT04033835|Active Comparator|Waiting list control|Treatment as usual
11106052|NCT04033822|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the trial will not receive accelerated cholecystectomy surgery to correct cholecystitis. No services will be taken away but patients will continue with care as originally provided by the healthcare system.
11106053|NCT04033822|Experimental|FAST Intervention|Patients diagnosed with cholecystitis and randomized to the FAST intervention arm of the study will undergo surgery as soon as possible with a goal of surgery within 6 hours of diagnosis.
11106054|NCT04033809|Active Comparator|Multigrain powder (S)|Oral high fiber multigrain supplements
11106055|NCT04033809|No Intervention|Standard care (C)|Standard care without oral high fiber multigrain supplements
11106056|NCT04033796|Active Comparator|25,000 IU|
11106057|NCT04033796|Active Comparator|50,000 IU|
11106058|NCT04033796|Placebo Comparator|Placebo|
11106059|NCT04033783|Experimental|6MWT - assessor walks behind the patient|In this experimental condition, the assessor walks behind the patient to continuously measure oxygen saturation during the test (recommended procedure)
11106060|NCT04033783|Active Comparator|6MWT - assessor does not walk behind the patient|In this experimental condition, the assessor does not walk behind the patient. The patient carries the pulse oximeter to continuously measure oxygen saturation during the test.
11106061|NCT04033770|Active Comparator|Air-charged measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS but using an air-charged instead of a water-filled measurement system."
11106062|NCT04033770|Active Comparator|Water-perfused measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS."
11106063|NCT04033757||Sub-cohort 1|1,469 participants were enrolled in 2015. Two follow-ups have been completed in 2016 and 2017, and will be asked to participate in follow-up in 2020, 2023, and 2026.
11106064|NCT04033757||Sub-cohort 2|1,267 participants were enrolled in 2018. They will be asked to participate in follow-up in 2021, 2024, 2027, and 2030.
11106065|NCT04033757||Sub-cohort 3|Plan to recruit about 1300 participants in 2019. And they will be asked to participate in follow-up in 2022, 2025, 2028, and 2031.
11106066|NCT04033744|Experimental|PRF (platelet-rich fibrin)|PRF will be used after the extraction of the third molar to prevent periodontal defects to second molar
11106067|NCT04033744|Active Comparator|spontaneous healing|after the extraction of the third molar the socket will be left to heal spontaneously
11106068|NCT04033731||Controls|Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
11106069|NCT04033718|Experimental|Inpatient testing package|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA
11106070|NCT04033692||JuggerKnot Mini Soft Anchors|Patients who have been implanted with the JuggerKnot Mini Soft Anchor who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc
11106071|NCT04033679|Experimental|Active TDCS|In the active condition, a constant current of 2 mA intensity will be applied for 20 min to the parietal regions, using P3 as the cathode and P4 as the anode.
11106072|NCT04033679|Sham Comparator|Sham TDCS|In the sham condition, stimulation will be administered using the same parameters at the site of active treatment, but the current will be turned off after 30 seconds.
11106073|NCT04033666|Active Comparator|High Flow nasal cannula|It will be administered as part of the high-flow nasal cannula treatment to reduce the symptoms of acute asthma
11106074|NCT04033666|Active Comparator|NIV noninvasive ventilation|It will be administered as part of the Noninvasive ventilation treatment to reduce the symptoms of acute asthma
11106075|NCT04033640|Other|screening with STANDARD G6PD Test|all participants recruited in the study will be screened with an investigational IVD- STANDARD G6PD Test- in addition to routine case. The investigational test will not be used to determine any treatment or case-management
11106076|NCT04033627|Experimental|In Vitro T cell depletion|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
11106077|NCT04033614|Experimental|Patients with Laparostoma|"Patients needing a laparostoma will be treated with the fasciotens abdomen device. The distance between the fasciae will be measured frequently using a ruler.
~12 months after the treatment an ultrasound measurement will be performed to assess hernia formation"
11106083|NCT04033562|Active Comparator|Lidoderm patch|Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
11106084|NCT04033562|Active Comparator|Infusion pump|Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.
11106085|NCT04033536|Active Comparator|Involved target SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined Involved Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
11106086|NCT04033536|Active Comparator|Elective target SSRS|SSRS with 16 Gy in single fraction to the defined Elective Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
11106087|NCT04033523|Experimental|High intensity-interval training (HIIT)|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
11106088|NCT04033523|No Intervention|normal counterparts|gender-matched normal counterparts (NC) did not receive any form of intervention
11106089|NCT04033510||AF/NR|Single cohort with a known or new diagnosis of atrial fibrillation, and intention attain/maintain normal rhythm. Subjects with be their own controls: Tablet-based cognitive testing to be performed while in atrial fibrillation (AF), and while they are in normal rhythm (NR). Results of both sets of cognitive testing will be compared.
11106090|NCT04033497|Experimental|TRAMs I|"Magnetic resonance imaging (MRI)-based treatment response assessment maps (TRAMs)
~Patients with an enlarging lesion in the site of a brain metastasis treated with stereotactic radiation for which neurosurgical resection is planned will undergo preoperative TRAMs"
11106091|NCT04033484|Active Comparator|Biological Mesh|Using biological mesh to recnostruct the pelvic floor following ELAPE
11106092|NCT04033484|Experimental|Biological Mesh With Negative Pressure Wound Therapy|Using biological mesh compined with negative pressure wound therapy to recnostruct the pelvic floor following ELAPE
11106093|NCT04033471|Active Comparator|BM|Bupivacaine 0.25% + midazolam 10mg in total volume 10m
11106094|NCT04033471|Active Comparator|BMM|Bupivacaine 0.25% + midazolam 10mg and morphine 5mg in total volume 10ml
11106095|NCT04033471|Active Comparator|B|bupivacaine 0.25% in total volume 10 ml
11106096|NCT04033458|Experimental|Treatment Sequence ABECD|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B), then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and, then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106097|NCT04033458|Experimental|Treatment Sequence BCADE|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and, then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106098|NCT04033458|Experimental|Treatment Sequence CDBEA|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then, JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then, JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106099|NCT04033458|Experimental|Treatment Sequence DECAB|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regiment 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106100|NCT04033458|Experimental|Treatment Sequence EADBC|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then, JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106101|NCT04033458|Experimental|Treatment Sequence DCEBA|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106102|NCT04033458|Experimental|Treatment Sequence EDACB|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106103|NCT04033458|Experimental|Treatment Sequence AEBDC|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and then JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106148|NCT04033224||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
11106671|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Venetoclax|
11106104|NCT04033458|Experimental|Treatment Sequence BACED|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106105|NCT04033458|Experimental|Treatment Sequence CBDAE|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
11106106|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 1|Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
11106107|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 2|Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
11106108|NCT04033445|Placebo Comparator|Induction Study 1: Placebo IV|Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
11106109|NCT04033445|Experimental|Induction Study 2: Guselkumab IV|Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
11106110|NCT04033445|Placebo Comparator|Induction Study 2: Placebo IV|Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
11106111|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 1|Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
11106112|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 2|Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
11106113|NCT04033445|Placebo Comparator|Maintenance Study: Placebo SC|Participants will receive matching placebo SC q4w.
11106114|NCT04033432|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay >= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.
11106115|NCT04033419|Experimental|Memantine|
11106116|NCT04033406|Experimental|VIR-2482|VIR-2482
11106117|NCT04033406|Placebo Comparator|Placebo|Placebo
11106118|NCT04033393|Experimental|Game based dual-task training group|Participants in dual-task training group will execute game based dual-task training with treadmill, 3 times per week for 8 weeks
11106119|NCT04033393|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training, 3 times per week for 8 weeks
11106120|NCT04033380|Active Comparator|Resin bloc endocrown|composite-based blocs (Grandio Blocs, VOCO)
11106121|NCT04033380|Active Comparator|Ceramic endocrown|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
11106122|NCT04033367|Experimental|Dupilumab|Dupilumab 300mg q2w
11106123|NCT04033367|Placebo Comparator|Placebo|Matching placebo
11106124|NCT04033354|Experimental|A|HLX10 + chemotherapy (carboplatin nab paclitaxel)
11106125|NCT04033354|Placebo Comparator|B|Placebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
11106126|NCT04033341|Experimental|LY3214996 + [14C]-LY3214996|A single dose of LY3214996 and [14C]-LY3214996 administered orally.
11106127|NCT04033328|Experimental|Dose Escalation|ORIC-101 dosed orally, once per day in combination with enzalutamide (160 mg) of each 28-day cycle.
11106128|NCT04033328|Experimental|Dose Expansion|RP2D dose
11106129|NCT04033302|Experimental|Single arm|Multiple CAR T cells to treat CD7-positive hematological malignancies
11106130|NCT04033289|Experimental|experimental group|
11106131|NCT04033289|No Intervention|control group|
11106132|NCT04033276|Active Comparator|Rituximab|Inj Rituximab 375mg/m2 IV given on day 0
11106133|NCT04033276|Active Comparator|Combination of high-dose IVIG and Rituximab|IV Rituximab 375mg/m2 on day 0 and IV high-dose IVIG 2g/kg on day 0
11106134|NCT04033263|Placebo Comparator|Placebo mouth rinse|Placebo: Deionized water (serving as negative control)
11106135|NCT04033263|Active Comparator|Elmex mouth rinse|commercial mouth rinse used as gold standard in erosion studies: elmex® Erosion Protection solution (which contains 800 ppm Sn2+, as SnCl2, and 500 ppm F-, as NaF and AmF)
11106136|NCT04033263|Active Comparator|Fluoride mouth rinse|Fluoride solution similar to many other commercial mouth rinses containing sodium fluoride (NaF at 500 ppm F-)
11106137|NCT04033263|Experimental|Plant extract A|Plant Extract A
11106138|NCT04033263|Experimental|Plant extract A with fluoride|Plant Extract A + Fluoride
11106139|NCT04033263|Experimental|Plant extract B|Plant Extract B
11106140|NCT04033263|Experimental|Plant extract B with fluoride|Plant Extract B + Fluoride
11106141|NCT04033263|Experimental|Plant extract C|Plant Extract C
11106142|NCT04033263|Experimental|Plant extract C with fluoride|Plant Extract C + Fluoride
11106143|NCT04033250|Experimental|Interventional arm (group A)|"Patients with risk factors for IBP who will receive intensified bowel preparation"
11106144|NCT04033250|Active Comparator|Control arm (group B)|Patients with risk factors for IBP who will receive standard bowel preparation
11106145|NCT04033250|Active Comparator|Control arm (group c)|Patients without risk factors for IPB who will receive standard bowel preparation
11106146|NCT04033237|Experimental|Very low nicotine content cigarettes|
11106147|NCT04033237|No Intervention|Usual Brand|
11106149|NCT04033211||Novosyn® CHD|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using Novosyn® CHD suture for fascia and skin closure of trocar wounds.
11106150|NCT04033211||Novosyn®|A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using either Novosyn® suture for fascia and skin closure of trocar wounds.
11106151|NCT04033198||fourth decade|appendectomy done , appendix send for histopathological examination
11106152|NCT04033198||fifth decade|appendectomy done , appendix send for histopathological examination
11106153|NCT04033198||sixth decade|appendectomy done , appendix send for histopathological examination
11106154|NCT04033198||older than 60 years|appendectomy done , appendix send for histopathological examination
11106155|NCT04033185|Active Comparator|study group|virtual reality, robot-assisted gait training, conventional treatment
11106156|NCT04033185|Other|control group|conventional treatment
11106157|NCT04033172|Experimental|Pyrotinib plus Fulvestrant|
11106158|NCT04033159|Experimental|cohort 1|DYN101 in a low dose (1.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3 subjects with a mutation in DNM2 (subcohort a) and 3 subjects with a mutation in MTM1 (subcohort b).
11106159|NCT04033159|Experimental|cohort 2|DYN101 in a middle dose (4.5 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3 subjects with a mutation in DNM2 (subcohort a) and 3 subjects with a mutation in MTM1 (subcohort b).
11106160|NCT04033159|Experimental|cohort 3|DYN101 in a high dose (9 mg/kg), (unless the IDMC advises otherwise). In each cohort, there will be 3 subjects with a mutation in DNM2 (subcohort a) and 3 subjects with a mutation in MTM1 (subcohort b).
11106161|NCT04033146|Experimental|Economical muscle dynamics|The investigators are trying to figure out how to optimize muscle contractile conditions for mobility. To do this, the investigators are systematically altering muscle contraction conditions for all participants.
11106162|NCT04033133|Experimental|Multiple Sclerosis|People with MS get tDCS with different intensities.
11106163|NCT04033133|Active Comparator|Healthy Subjects|Healthy subjects get tDCS with different intensities.
11106164|NCT04033120||Cohort 1|"Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:
~MycoF/lytic blood culture system
~Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis
~Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis
~Histoplasma antigen in urine (HAg) LFA for histoplasmosis
~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period"
11106165|NCT04033120||Cohort 2|"Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:
~CrAg LFA for cryptococcosis
~HAg LFA for histoplasmosis
~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period."
11106166|NCT04033107|Experimental|Treatment arm|Vitamin C combined with metformin
11106167|NCT04033094||MorphaBond ER|
11106168|NCT04033094||Comparator Group|
11106169|NCT04033081|Experimental|CivaSheet Treatment|Implanted with CivaSheet during tumor removal
11106170|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccinations (high dose)|14 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and day 28
11106171|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccination (low dose)|14 Participants will receive MV-ZIKA-RSP 2,5 x10E4 /dose on day 0 and day 28
11106172|NCT04033068|Experimental|One MV-ZIKA-RSP vaccination (high dose) and one placebo|12 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and placebo on day 28
11106173|NCT04033068|Placebo Comparator|Two placebo injection|8 Participants will receive placebo on day 0 and placebo on day 28
11106174|NCT04033055|Experimental|CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).
~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
11106175|NCT04033055|Active Comparator|CycloMesh™ soaked in saline solution 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).
~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
11106176|NCT04033042|Experimental|Protocol 1|RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
11106177|NCT04033042|Experimental|Protocol 2|"RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
~One group of subjects will receive training in the use of the device the other will not. Both groups will receive the instructions for use."
11106178|NCT04033029||Patients under CVVHDF with high adsorption membrane|Continuous venovenous hemodiafiltration mode (CVVHDF) using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
11106179|NCT04033016|Experimental|Facebook and motivational interviewing group|Women from this group were included in social media intervention and in two sessions of motivational interviewing.
11106180|NCT04033016|Experimental|Facebook only group|Women from this group were included in the social media intervention only.
11106181|NCT04033016|No Intervention|control group|women from this group only received the information on the benefits of physical activity during pregnancy.
11106182|NCT04033003|Experimental|Group ANC|Intervention groups consist of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
11106183|NCT04033003|No Intervention|Stand ANC|Individual standard antenatal care delivered at health facilities in Ghana
11106184|NCT04032990|Experimental|Transcutaneous spinal stimulation - Acute and Training|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while upper extremity function is assessed at 3 time points (acute) and/or in combination with activity-based upper extremity training (40 sessions, 1.5 hours/day, 5 days/week); stimulation will be applied intermittently for no more than 10 minutes at a time. Upper extremity training is based on usual care activities to challenge use of the hands and arms, e.g. reaching, grasping, manipulating objects.
11106185|NCT04032964|Experimental|Arm L19TNF + DOXO|"Patients will be treated with:
~doxorubicin 75 mg/m2 i.v. on day 1 of each 21-day cycle;
~L19TNF 13 µg/kg i.v. on day 1, 3 and 5 of each 21-day cycle"
11106186|NCT04032951|Experimental|Adominal neoplasms patients|Patients in whom EUS-FNTA is performed with a novel type of biopsy neede.
11106187|NCT04032938||the control group|30 healthy people as the control group.
11106188|NCT04032938||the case group|60 patients were admitted to intensive care unit (ICU) as the case group after cardiac surgery and extracorporeal circulation. This group should contain 30 patients with fever and/or hemodynamic instability and 30 patients with normothermia and normal hemodynamic.
11106189|NCT04032925|Experimental|PICSO therapy Group|"This will be the only treatment of the PICSO VIPER study. Within this group patients will be randomised to have cycles of 2 minutes of balloon-induced myocardial schema with PICSO device in ON vs OFF modality."
11106190|NCT04032899|Experimental|L. fermentum CECT5716 3x109 ufc|Volunteers will take 1 capsule per day with L. fermentum CECT5716 3x109 cfu mixed with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
11106191|NCT04032899|Placebo Comparator|Maltodextrin|Volunteers will take 1 capsule per day with maltodextrin from week 28-32 of gestation up to 16 weeks after delivery.
11106192|NCT04032886|Experimental|classic kinesio tape|this group will receive mechanical correction tape with classic tape plus exercise.
11106193|NCT04032886|Experimental|performance kinesio tape|this group will receive mechanical correction tape with performance tape plus exercise.
11106194|NCT04032886|Other|control|this group will receive only exercise.
11106195|NCT04032873|Other|Provider Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by the orthopaedic surgeon before the decision for immobilization has been made.
11106196|NCT04032873|Other|Research Team Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by a member of the study team after the decision for immobilization has been made.
11106197|NCT04032860|Experimental|ETV group|group in which patients take ETV as antiviral therapy after curative treatment
11106198|NCT04032860|Experimental|TDF group|group in which patients take TDF as antiviral therapy after curative treatment
11106199|NCT04032847|Experimental|Arm 1|Infusion of cell therapy product ATL001.
11106200|NCT04032834|Other|Part 1, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
11106201|NCT04032834|Other|Part 1, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
11106202|NCT04032834|Other|Part 1, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
11106203|NCT04032834|Other|Part 1, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
11106204|NCT04032834|Other|Part 1, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
11106205|NCT04032834|Other|Part 1, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
11106206|NCT04032834|Other|Part 2, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
11106207|NCT04032834|Other|Part 2, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
11106208|NCT04032834|Other|Part 2, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
11106209|NCT04032834|Other|Part 2, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
11106210|NCT04032834|Other|Part 2, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
11106211|NCT04032834|Other|Part 2, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
11106212|NCT04032834|Other|Part 3, Arm A of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask.
11106213|NCT04032834|Other|Part 3, Arm B of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece.
11106214|NCT04032834|Other|Part 3, Arm C of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask.
11106215|NCT04032834|Other|Part 3, Arm D of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece.
11106216|NCT04032821|Experimental|Alkotinib（300mg）First empty stomach, after the meal|Alkotinib（300mg），Subjects need to be fasting overnight for at least 10 hours before being warmed to 240 mL on an empty stomach Water service, lunch 4 hours later, dinner 10 hours later.
11106217|NCT04032821|Experimental|Alkotinib（300mg）After eating first, after fasting|Alkotinib（300mg），Subjects need to be fasting for at least 10 hours overnight, starting 30 min before taking the medication A standard meal (800-1000 CAL) can be taken before taking the medicine, and 240 mL warm water can be taken after the meal Lunch hours later, dinner 10 hours later.
11106218|NCT04032795|Experimental|Lycium barbarum polysaccharide (LBP)|Experimental group takes LBP tablet (300mg/day) for 6 weeks
11106219|NCT04032795|Placebo Comparator|Placebo|Placebo control group takes placebo 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
11106220|NCT04032782|Experimental|HM15136|
11106221|NCT04032782|Placebo Comparator|Placebo of HM15136|
11106222|NCT04032769|Experimental|Modified strategy MODS|"the threshold of D-dimer will depend on the YEARS rule (MODS strategy):
~If all the three items of YEARS are negative (i.e. No hemoptysis, No clinical sign of deep venous thrombosis and PE is not the most likely diagnosis), then the threshold of D-dimer will be raised at 1000 ng/ml.
~If at least one item of YEARS is positive, then the threshold will remain unchanged (>500 ng/ml for patients aged < 50 and > agex10 for patients aged 50 and over).
~A positive result of D-dimer and the absence of other obvious cause for PE will mandate a CTPA, or V/Q scan if CTPA is contra-indicated.
~A negative result of D-dimer will rule out PE."
11106223|NCT04032769|No Intervention|Control group|All included patients will be tested with D-Dimer, threshold for ordering a CTPA as usual
11106224|NCT04032756||Group 1|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
11106225|NCT04032756||Group 2|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.
11106226|NCT04032730|No Intervention|Control|Participants assigned to the control arm will undergo treatment and care for MDR/XDR-TB as per the South African Department of Health guidelines.
11106227|NCT04032730|Experimental|Intervention|Participants assigned to the intervention arm will undergo extensive counselling, participants will be provided with an electronic pillbox that monitors their adherence to one of their TB and one of their ART medication. Based on the recordings provided by the wisepill device we will determine if a participant is adherent to their medication and intervene with counselling, phone calls, home visits and relevant referrals.
11106228|NCT04032717|Experimental|Open-label Q-GRFT enema|Open-label Q-GRFT enema administered rectally once as a single dose (Arm 1)
11106229|NCT04032717|Experimental|Randomized, blinded Q-GRFT enema|Blinded Q-GRFT enema administered rectally once as a single dose (Arm 2)
11106230|NCT04032717|Placebo Comparator|Randomized, blinded placebo enema|Blinded placebo enema administered once as a single dose (Arm 3)
11106231|NCT04032704|Experimental|Ladiratuzumab Vedotin|SGN-LIV1A monotherapy
11106232|NCT04032691|Experimental|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
11106233|NCT04032678|Experimental|1 (DGT7)|"Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard Touch 7 - DGT7, Schiller Medical, France) with recommended by the manufacturer adult pads (FRED-PA1, Schiller) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.
~Other Name: DGT7"
11106234|NCT04032678|Active Comparator|2 (LP15)|"Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.
~Other Name: LP15"
11106235|NCT04032665||Stable coronary and peripheral artery disease (CAD/PAD)|Stable CAD/PAD patients with previous percutaneous coronary intervention and drug eluting stent-implantation treated with dual antiplatelet therapy (ASA+clopidogrel)
11106236|NCT04032665||Acute coronary artery disease (ACS)|Patients with troponin-positive ACS (NSTEMI/STEMI) with planned percutaneous coronary intervention and drug eluting stent-implantation treated with P2Y12 inhibitor (ticagrelor) and ASA
11106237|NCT04032652|Active Comparator|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
11106238|NCT04032652|Active Comparator|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
11106239|NCT04032639||Prader-Willi Syndrome|24 children and adolescents (7-16 years) with diagnosed Prader-Willi Syndrome will be recruited
11106240|NCT04032639||Controls|24 children and adolescents (7-16 years) without diagnosed Prader-Willi Syndrome will be matched for age, sex, and BMI-percentile to the Prader-Willi group
11106241|NCT04032626|Experimental|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
11106315|NCT04032171|Active Comparator|Avonex® + Evobrutinib matched Placebo: Double-Blinded Period|
11106242|NCT04032626|Placebo Comparator|Placebo|Placebo taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
11106243|NCT04032613|Experimental|Vascular access quality improvement program participants|All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.
11106244|NCT04032600|Other|Full paracentesis|All ascites is drained
11106245|NCT04032600|Other|Fractioned paracentesis|3 Liters are drained, then the drain is clamped and the rest of the ascites is drained on the next day
11106246|NCT04032587|Experimental|Non-treatment seeking subjects with Alcohol Use Disorder|AUD; mild vs. moderate to heavy
11106247|NCT04032587|Active Comparator|Healthy Controls|
11106248|NCT04032574|Experimental|Herbal medicinal product|three times daily two film coated tablets containing: extracts of restharrow root (Ononidis radix) 80mg,Java tea (Orthosiphonis folium) 90mg, goldenrod herb (Solidaginis herba) 180mg
11106249|NCT04032574|Placebo Comparator|Placebo|three times daily two film coated tablets
11106250|NCT04032548|Placebo Comparator|Placebo|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
11106251|NCT04032548|Experimental|Propolis|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
11106252|NCT04032548|Active Comparator|Chlorhexidine|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
11106253|NCT04032535|Experimental|SAD|"Single Ascending Dose of 2 cohorts:
~Cohort A will be administered three ascending dose levels: 0.2 mg (dose 1), 2 mg (anticipated dose 3), 8 mg (anticipated dose 5) or placebo; Cohort B will be administered three ascending dose levels: 1 mg (anticipated dose 2), 4 mg (anticipated dose 4), 14 mg (anticipated dose 6, maximum dose) or placebo."
11106254|NCT04032535|Experimental|MAD|"Multiple Ascending Dose of 4 cohorts:
~Cohort A will be administered with 2 mg (anticipated dose 1) or placebo; Cohort B will be administered with 4 mg (anticipated dose 2) or placebo; Cohort C will be administered with 8 mg (anticipated dose 3) or placebo; Cohort D will be administered with 12 mg (anticipated dose 4) or placebo;"
11106255|NCT04032535|Experimental|2way crossover|Two 28-day treatment periods (Period 1 and Period 2), separated each by 32 days (up to 40 days) wash-out period, in crossover design. The treatment period will consist in repeated administrations of CHF 6523 at one dose level or placebo.
11106256|NCT04032522||Intervention Arm (A)|Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA >1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
11106257|NCT04032522||Control Arm (B)|The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
11106258|NCT04032509||Mild TBI|Mild TBI (GCS 13-15 on admission) within 12 hours after injury
11106259|NCT04032496|Experimental|Mindfulness Intervention|Participants in this arm will participate in the Contemplative-Based Intervention for People Living with SLE intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
11106260|NCT04032496|Active Comparator|HEP Intervention|Participants in this arm will participate in the Health Enhancement Program (HEP) intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
11106261|NCT04032470||Essential Tremor|Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems
11106262|NCT04032457|Active Comparator|A1 - SiHyDD to Moist|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
11106263|NCT04032457|Active Comparator|A2 - Moist to SiHyDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
11106264|NCT04032457|Active Comparator|A3 - SiHyDD to OASDD|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of ACUVUE® OASYS 1-Day contact lenses.
11106265|NCT04032457|Active Comparator|A4 - OASDD to SiHyDD|1 week of ACUVUE® OASYS 1-Day contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
11106266|NCT04032457|Active Comparator|A5 - SiHyDD to DT1|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of Alcon DAILIES TOTAL 1® contact lenses.
11106267|NCT04032457|Active Comparator|A6 - DT1 to SiHyDD|1 week of Alcon DAILIES TOTAL 1® contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
11106268|NCT04032457|Active Comparator|B1 - HydDD to Moist|1 week of Test HydDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
11106269|NCT04032457|Active Comparator|B2 - Moist to HydDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
11106270|NCT04032457|Active Comparator|B3 - HydDD to BioTrue|1 week of Test HydDD contact lenses followed by cross over to 1 week of BIOTRUE ONEday® contact lenses.
11106271|NCT04032457|Active Comparator|B4 - BioTrue to HydDD|1 week of BIOTRUE ONEday® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
11106272|NCT04032457|Active Comparator|B5 - HydDD to AqCom+|1 week of Test HydDD contact lenses followed by cross over to 1 week of DAILIES® AquaComfort PLUS® contact lenses.
11106273|NCT04032457|Active Comparator|B6 - AqCom+ to HydDD|1 week of DAILIES® AquaComfort PLUS® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
11106316|NCT04032171|Experimental|Evobrutinib: Open-Label Extension Period|
11106317|NCT04032158|Experimental|Evobrutinib + Avonex® matched Placebo: Double-Blinded Period|
11106274|NCT04032431|Experimental|Telerehab VR intervention|The telerehab VR intervention consists of a custom-made software running on a computer connected with a commercial VR device (i.e. Oculus Rift). PwMS will be requested to reproduce several ADLs from the three main areas of self-care, dressing and meal preparation. The user can physically see his/her hands within the virtual scenario and, during the exercise, the hand coordinates are continuously recorded. Thus, data on 3D trajectory, speed, accuracy on target placement and movement smoothness, will be accessible. They will be stored in the PC and also be remotely sent to the clinical center for further analysis/processing. Both target position and task complexity will define the exercise difficulty, which can be modified automatically, on the basis of the previous performance or manually modified by the user
11106275|NCT04032431|Active Comparator|Conventional therapy|Conventional therapy will focus on task-related upper-limb treatments while in a sitting or prone position, representing the standard care in MS. Several manual techniques, therapy tools and objects of ADL will be allowed during treatment. No restrictions will be placed on the material used (ie, ADL, reaching and grasping material). Use of additional electrical or mechanical therapy devices (ie, support arm systems, splints) will be avoided. The interventions will be conducted on a one-on-one basis in the physiotherapy or occupational therapy department of each participating center. Training and therapy content will be tailored to each participant's preferences, the agreed movement aims and the motor function level of each MS patient.
11106276|NCT04032418|Active Comparator|Arm I (pembrolizumab 3 weeks)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
11106277|NCT04032418|Experimental|Arm II (pembrolizumab 12 weeks)|Patients receive pembrolizumab IV over 30 minutes every 12 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
11106278|NCT04032405|Active Comparator|CAF+CTG|the combined connective tissue graft (CTG) with coronally advanced flap (CAF)
11106279|NCT04032405|Experimental|CAF+CTG+i-prf|the combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
11106280|NCT04032392|Experimental|Autologous γδT cells|"Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions.
~Dose escalation subjects will receive 6 infusions with dose of γδT cells escalation from 1×10e9 to 6×10e9.
~Constant dose subjects will have single infusion intravenously at a target dose of 1~2×10e9 γδT cells."
11106281|NCT04032379||Certain IIH or IIH-WOP|According to revised diagnostic criteria, Friedmann, 2013.
11106282|NCT04032379||Suspected IIH|IIH is suspected, does not fulfill diagnostic criteria.
11106283|NCT04032379||IIH ruled out|Patients in whom another diagnosis is made.
11106284|NCT04032366||PEEP 5|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, without inhaled nitric oxide
11106285|NCT04032366||PEEP 10|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, without inhaled nitric oxide
11106286|NCT04032366||PEEP 10 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, with inhaled nitric oxide
11106287|NCT04032366||PEEP 5 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, with inhaled nitric oxide
11106288|NCT04032353|Other|Medical Consortium|subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)
11106289|NCT04032340||Elderly with a companion dog|elderly living at home with a dog consulting his family doctor
11106290|NCT04032340||Elderly without a companion dog|elderly living at home without a dog consulting his family doctor
11106291|NCT04032327|Active Comparator|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
11106292|NCT04032327|Active Comparator|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
11106293|NCT04032314||Healthy controls - cross-sectional project design|
11106294|NCT04032314||Patients - cross-sectional project design|
11106295|NCT04032314||Patients - longitudinal project design|
11106296|NCT04032301|Experimental|Intravenous ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
11106297|NCT04032301|Placebo Comparator|Intravenous saline infusions|Six infusions of normal saline solution over 3 weeks.
11106298|NCT04032275||Untreated chronic HBV infected person group|Enrolled in the Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Department of Liver Histology, Department of Hepatology, Chronic HBV HBV infection.
11106299|NCT04032262|Other|Parkinson's Disease Relationship to the GI track|Patients with Parkinson's.
11106300|NCT04032249|Active Comparator|Control Group (CG)|Education and modifying diet
11106301|NCT04032249|Experimental|Intervention Group (IG)|Education, modifying diet and Indications to record self-weighing with a frequency of 2 times per week
11106302|NCT04032236|Other|smoking group|35 smoking case
11106303|NCT04032236|Other|nonsmoking group|35 nonsmoking case
11106304|NCT04032223|Experimental|3D printed metal copings|3D printed primary and secondary metal copings inderctly from 3D printed resin in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
11106305|NCT04032223|Active Comparator|Cast metal copings|Cast metal primary and secondary metal copings in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
11106306|NCT04032210|Experimental|Regimen using dual Zinc plus Arginine based toothpaste|
11106307|NCT04032210|Experimental|Regimen using Zinc based toothpaste (Crest complete)|
11106308|NCT04032210|Active Comparator|Fluoride based toothpaste (Signal)|
11106309|NCT04032197|Experimental|Semaglutide|Semaglutide injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg semaglutide is reached.
11106310|NCT04032197|Placebo Comparator|Placebo|Placebo injected once-weekly. Standard dose escalations every 4 weeks will be applied, until the maximum dose of 1.0 mg placebo is reached.
11106311|NCT04032184|Active Comparator|Fluoride toothpaste|
11106312|NCT04032184|Experimental|fluoride toothpaste and chlorhexidine mouthwash|
11106313|NCT04032184|Experimental|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|
11106314|NCT04032171|Experimental|Evobrutinib + Avonex® matched Placebo: Double-Blinded Period|
11106320|NCT04032145||Observational|All participants who go to the Montreal Museum of Fine Arts will fill out an online questionnaire called: CESAM ( Self Administered Questionnaire). This questionnaire will asse participant's health condition. Moreover, the goal of the questionnaire is to evaluate if art activities may change the participants' health conditions in time.
11106321|NCT04032132|Experimental|curcumin paste in conjunction with open flap debridement surge|curcumin paste (2% circumin) in conjunction with open flap debridement surgery
11106322|NCT04032132|Placebo Comparator|open flap debridement surgery only|surgical treatment for periodontal pocket
11106323|NCT04032119|Experimental|Epinephrine|0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection
11106324|NCT04032119|Active Comparator|Non-epinephrine|No epinephrine would be added into the solution
11106325|NCT04032106|Active Comparator|Group A (standard HPV information)|Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
11106326|NCT04032106|Experimental|Group B (Outsmart HPV, unidirectional vaccine reminders)|Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
11106327|NCT04032106|Experimental|Group C (Outsmart HPV, interactive vaccine reminders)|Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
11106328|NCT04032093|Experimental|RSV dose with aluminum hydroxide|RSV vaccine with aluminum hydroxide
11106329|NCT04032093|Experimental|RSV dose without aluminum hydroxide|RSV vaccine without aluminum hydroxide
11106330|NCT04032093|Experimental|Higher RSV dose with aluminum hydroxide|Higher dose level RSV vaccine with aluminum hydroxide
11106331|NCT04032093|Experimental|Higher RSV dose without aluminum hydroxide|Higher dose level RSV vaccine without aluminum hydroxide
11106332|NCT04032093|Placebo Comparator|Placebo dose|Normal saline solution for injection (0.9% sodium chloride injection)
11106333|NCT04032080|Experimental|LY3023414 followed by prexasertib|Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 until disease progression followed by prexasertib until disease progression. Patients who achieve a confirmed clinical complete response will discontinue prexasertib, and these patients will be followed to document the durability of the complete responses. Patients whose disease does not respond to prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.
11106334|NCT04032067|Active Comparator|Control Group|"GV1001-Placebo ID injection administered every 2 weeks through Week 24
~+ Proscar PO administered once a day through Week 24"
11106335|NCT04032067|Experimental|Study Group 1|"GV1001 0.56 mg ID injection administered every 2 weeks through Week 24
~+ Proscar-placebo PO administered once a day through Week 24"
11106336|NCT04032067|Experimental|Study Group 2|"GV1001 1.12 mg ID injection administered every 2 weeks through Week 24
~+ Proscar-placebo PO administered once a day through Week 24"
11106337|NCT04032054||A|mono-axial
11106338|NCT04032054||B|poly-axial
11106339|NCT04032041||Group 1: Healthy Able-bodied Individuals (Completed)|Healthy able-bodied individuals with no history of lower extremity trauma.
11106340|NCT04032041||Group 2: Individuals Requiring AFO Use (Recruiting)|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
11106341|NCT04032015|Active Comparator|rTMS treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own MRI images. Daily treatment regiments will last 30 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
11106342|NCT04032015|Sham Comparator|Sham treatment|"Sham rTMS will be delivered for 20 sessions over 4 weeks. To maximize sham validity, both 1) a direction-sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity 10Hz electrical stimulation will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS treatment. Daily treatment regiments will last 30 minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS sessions for adverse events and/or side effects.
~Upon completing the 20 sham sessions, participants are unblinded and offered 20 treatments of active rTMS. The open-label treatment would follow the active rTMS treatment protocol."
11106343|NCT04032002|Other|Patients hereditary bradykinetic angioedema|
11106344|NCT04032002|Other|healthy volunteers|
11106345|NCT04031963||No treatment|Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.
11106346|NCT04031950||test group|Test group will wear PSG
11106347|NCT04031950||Novel wearable device|THis group will wear the novel device
11106348|NCT04031937|Active Comparator|major depressive disorder|psychometric scales psychomotor assessment
11106349|NCT04031937|Active Comparator|Control|psychometric scales psychomotor assessment
11106350|NCT04031924||Liver Transplantation|Sixteen individuals with liver transplantation were included in the study, and their physical and demographic characteristics of the individuals recorded. The Senior Fitness Test (SFT) was used to evaluate to physical fitness. The Tampa Scale for Kinesiophobia (TSK) was used to assess kinesiophobia; the Fatigue Impact Scale (FIS) and Fatigue Severity Scale (FSS) to evaluate fatigue; the Berg Balance Scale (BBS) and the Timed Up and Go test (TUG) to evaluate the balance; the International Physical Activity Questionnaire (IPAQ) to determine the level of physical activity;and the Hospital Anxiety and Depression Scale (HADS) to evaluate psychological status.
11106351|NCT04031924||Healthy Subjects|Sixteen age- and sex-matched healthy subjects were included in the study.
11106352|NCT04031911|Other|Control group|Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).
11106353|NCT04031911|Experimental|Study group|"Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."
11106354|NCT04031898||full analysis set|All eligible patients who meet all inclusion criteria and none of the exclusion criteria
11106355|NCT04031885|Experimental|Abemaciclib + Fulvestrant|Abemaciclib given orally and fulvestrant given by intramuscular (IM) injection.
11106356|NCT04031885|Active Comparator|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
11106357|NCT04031872|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine
11106358|NCT04031859|Experimental|Group A|In this group a VTE risk stratification procedure will be used
11106359|NCT04031859|No Intervention|Group B|In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)
11106360|NCT04031846|Experimental|V114|Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
11106361|NCT04031846|Active Comparator|Prevenar 13™|Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
11106362|NCT04031833|Experimental|Phase 1a single ascending dose study|Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
11106363|NCT04031833|Experimental|Phase 1b multiple day dosing|9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
11106364|NCT04031833|Experimental|Phase 2 safety and tolerability|Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.
11106365|NCT04031820|Active Comparator|unipolar cup|550 patients will receive a total hip arthroplasty with a unipolar cup.
11106366|NCT04031820|Active Comparator|Dual Mobility cup|550 patients will receive a total hip arthroplasty with a dual mobility cup.
11106367|NCT04031794||Conventional ARDS treatment group|Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.
11106368|NCT04031794||ECMO group|Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support
11106369|NCT04031781|Active Comparator|Receiving repetitive transcranial magnetic stimulation (rTMS)|This group received 5 rTMS sessions, delivered over one week over the left dorsolateral prefrontal cortex (LDLPFC ) at 5-Hz frequency and 100% motor threshold intensity.
11106370|NCT04031781|Placebo Comparator|Group receiving placebo rTMS|This group received Placebo rTMS was given with the same stimulation frequency at a fixed intensity of 50% of the machine output
11106371|NCT04031768|Other|0-2-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~0 minutes 2 minutes 5 minutes 5 minutes"
11106372|NCT04031768|Other|0-5-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~0 minutes 5 minutes 2 minutes 5 minutes"
11106373|NCT04031768|Other|2-0-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~2 minutes 0 minutes 5 minutes 5 minutes"
11106374|NCT04031768|Other|5-0-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~5 minutes 0 minutes 2 minutes 5 minutes"
11106375|NCT04031768|Other|2-5-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~2 minutes 5 minutes 0 minutes 5 minutes"
11106376|NCT04031768|Other|5-2-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:
~5 minutes 2 minutes 0 minutes 5 minutes"
11106377|NCT04031755|Experimental|Minocycline versus Placebo|"Phase 1: 4 weeks of daily minocycline 100mg BID dosing
~2-week washout period
~Phase 2: 4 weeks of daily placebo dosing"
11106378|NCT04031755|Experimental|Placebo versus Minocycline|"Phase 1: 4 weeks of daily placebo dosing
~2-week washout period
~Phase 2: 4 weeks of daily minocycline 100mg BID dosing"
11106379|NCT04031742|Experimental|Part 1: IBI306|Participants received open-label IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.
11106380|NCT04031742|Experimental|Part 2: IBI306|Participants received open-label 450mg Q4W subcutaneously for 12 weeks.
11106381|NCT04031729|Experimental|Aspirin|Low-dose (81mg) aspirin tablets
11106382|NCT04031729|Placebo Comparator|Placebo|Placebo tablets
11106383|NCT04031716|No Intervention|Control|Participants in the control group will receive present standard of care, which includes an assessment of participant/family needs by integrative care after surgery, as well as standard holistic health care by a licensed/certified holistic health specialist. They will not receive the MUSETM focused-attention meditation training or intervention protocol.
11106384|NCT04031716|Experimental|Meditation|Participants randomized to receive focused-attention meditation training will attend a preoperative training session, provided by a licensed/certified Holistic Health Specialist. The content will include an age appropriate explanation of focused-attention meditation, using breath as the focus; set-up and utilization of the MUSETM headband; and experiential practices. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions, and thoughts), provide self-regulation strategies, and promote healthy and adaptive responses to stress.
11106385|NCT04031703|Experimental|6 cycles of PC adjuvant chemotherapy|6 cycles of PC (Paclitaxel 80 mg/m2 ivgtt d1,8,15+ Carboplatin Auc = 2 ivgtt d1,8,15, 28 days per cycle).
11106386|NCT04031703|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|3 cycles of FEC (epirubicin100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
11106387|NCT04031690||patient-caregiver dyads|
11106388|NCT04031677|Other|Standard arm|Surgery alone
11106389|NCT04031677|Experimental|Experimental arm|Preoperative chemotherapy and surgery
11106433|NCT04031274||TAVI + MR no further intervention|Patients undergoing TAVI with MR more than moderate following the procedure, no further mitral valve intervention
11106390|NCT04031664|Experimental|Qianjin Capsule of Gynaecology|"On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.
~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
11106391|NCT04031664|Placebo Comparator|Antibiotics alone group|"Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.
~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
11106392|NCT04031638||Radioactive Iodine treatment for thyroid cancer|
11106393|NCT04031625||Metastatic Colorectal Cancer|
11106394|NCT04031612||Neoadjuvant Breast Cancer|Patients undergoing neoadjuvant therapy for breast cancer
11106395|NCT04031599|Active Comparator|Carbohydrate counting|Rapid acting insulin analogue with carbohydrate counting
11106396|NCT04031599|Active Comparator|Simplified qualitative meal size estimation|Rapid acting insulin analogue with simplified qualitative meal size estimation
11106397|NCT04031586||Children diagnosed with Solid Tumors|Children diagnosed with solid tumors in Managua, Nicaragua in Central America
11106398|NCT04031573|Experimental|Ivabradine (Low)|
11106399|NCT04031573|Experimental|Ivabradine (High)|
11106400|NCT04031573|Placebo Comparator|Control|
11106401|NCT04031560|Experimental|Experimental|Integrative treatment
11106402|NCT04031560|No Intervention|Control|The control group (62 patients) will not receive any type of add-on psychotherapy.
11106403|NCT04031547|Active Comparator|Active tES-fMRI|
11106404|NCT04031547|Sham Comparator|Inactive/Sham tES-fMRI|
11106405|NCT04031534|Experimental|Measure of hypoxia by F-Miso PET scan and RMI|Patient will undergo F-Miso PET scan and MRI to detect hypoxia. Imaging will be correlated with immunohistochemistry on tumour biopsy
11106406|NCT04031521||Sickle cell pain crisis|
11106407|NCT04031521||Sickle cell steady-state|
11106408|NCT04031508|Experimental|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
11106409|NCT04031508|Sham Comparator|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
11106410|NCT04031482||Ongoing or incipient targeted therapies|Ongoing or incipient targeted therapies with biologics and/or other targeted therapies (e.g. Janus kinase inhibitors)
11106411|NCT04031469||General Population|The general population will have their microbiome sequenced from stool samples provided.
11106412|NCT04031456|Experimental|Participants receiving PRP treatment|Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion
11106413|NCT04031456|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP) treatment|Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion
11106414|NCT04031430|Experimental|telemonitoring group (TM)|
11106415|NCT04031430|Active Comparator|Patient self-monitoring group (PSM)|
11106416|NCT04031430|No Intervention|control group (CC)|
11106417|NCT04031417|Other|Placebo|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
11106418|NCT04031417|Other|soy isoflavones|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
11106419|NCT04031417|Other|soy isoflavones & cocoa polyphenols|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
11106420|NCT04031404|Experimental|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
11106421|NCT04031404|Experimental|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
11106422|NCT04031391|Experimental|physical activity group|
11106423|NCT04031391|No Intervention|Control group|
11106424|NCT04031378|Active Comparator|A|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation using PET/CT imaging studies every 6 months
11106425|NCT04031378|Experimental|B|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months stratified by whether disease is castrate-sensitive (mCS-PCa) or castrate-resistant (mCR-PCa)
11106426|NCT04031365|Experimental|Acupuncture and Cognitive Behavioral Therapy|Participants will receive four sessions of a brief acupuncture therapy in addition to a brief cognitive behavioral therapy.
11106427|NCT04031365|Active Comparator|Cognitive Behavioral Therapy|Participants in this group will receive a brief cognitive behavioral therapy in addition to four telephone follow-ups.
11106428|NCT04031339||Patients diagnosed with thyroid cancer|Patients with histologically-confirmed diagnoses of papillary, follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer
11106429|NCT04031326|Experimental|LENA Home|Home visitors assigned to the intervention group will be trained to use and administer LENA Home in addition to the standard ECS curriculum during designated home visits beginning when the child is between 6- and 9-months old.
11106430|NCT04031326|No Intervention|Standard Practice|Home visitors assigned to the control group will administer the standard ECS curriculum only
11106431|NCT04031300|Experimental|RSP-20|Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 48 days.
11106432|NCT04031274||TAVI no MR|Patients undergoing TAVI with MR up to moderate following the procedure
11106434|NCT04031274||TAVI + MR undergoing TMVR/r|Patients undergoing TAVI with MR more than moderate following the procedure, underwent transcatheter mitral valve intervention
11106435|NCT04031261||National Validation|All patients must have a diagnosis of severe asthma, be taking high dose inhaled corticosteroids (GINA step 4 & 5), and be aged 16 years or over.
11106436|NCT04031261||Sensitivity to Change|Patients commencing a biologic treatment for their severe asthma (GINA step 4 & 5), as per National Institute for Health and Care Excellence (NICE) guidelines.
11106437|NCT04031248|Experimental|WBV group (experimental)|"Participants in the experimental group will follow a program that will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work.
~The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience."
11106438|NCT04031248|Active Comparator|Exercise group (control)|Control subjects will perform the same exercise program without whole-body vibration.
11106439|NCT04031235|Experimental|Safe Sleep Education|Mothers in the intervention group will receive education on American Academy of Pediatrics safe sleep recommendations using a specially-designed children's book (Sleep Baby, Safe and Snug). In addition, they will receive information on the importance of reading with their infant using a brochure created by the AAP.
11106440|NCT04031235|Active Comparator|Infant Reading Education|Mothers in the control group will receive education on American Academy of Pediatrics recommendations on reading and talking to infants using a specially-designed children's book (Read Baby, Every Day). In addition, they will receive information on safe sleep using a brochure created by the AAP.
11106441|NCT04031209||G7 G7 Acetabular System|All patients will receive G7 G7 Acetabular System
11106442|NCT04031196|Active Comparator|QLB group, Quadratus Lumborum Block group|the patient placed in the lateral decubitus position, the low-frequency convex probe of Sonosite M Turbo ultrasonography was placed in the anterior axillary line midway between subcostal margin and iliac crest to identify the abdominal muscle layers, then the probe was moved to the posterior axillary line to visualize the quadratus lumborum muscle attached to the transverse process of the L4, With the psoas major muscle placed anteriorly, the erector spinae muscle posteriorly, a 22-gauge, 80 mm needle was inserted in-plane into the posterior aspect of QL muscle (between quadratus lumborum and erector spinae muscle), and then 0.5ml/kg of 0.25% levobupivacaine local anesthetic was injected behind the muscle as a bolus dose. The block was performed bilaterally.
11106443|NCT04031196|Active Comparator|TAP block group,Transversus Abdominis Plane Block group|patient placed in the supine position, a linear multifrequency 6-13 MHz probe of Sonosite M Turbo ultrasonography was placed posterior to the midaxillary line at the midpoint between the inferior costal margin and the iliac crest, a 22-gauge, 50 mm needle was placed using an in-plane technique between the internal oblique and transversus abdominis muscle then local anesthetic was injected in a bolus dose 0.5ml/kg of 0.25% levobupivacaine, the block was done bilaterally.. after ultrasound Identification of the plane between the internal oblique and transversus abdominis muscle,
11106444|NCT04031170|Experimental|Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic Parent Training Program. It consists of twelve (12) 2-hour classes led by Dean Coffey, a senior psychologist and certified peer coach in the Incredible Years Parent Training Series.
11106445|NCT04031170|Other|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts.
11106446|NCT04031157|Experimental|PGT arm|Predictix Antidepressant-guided treatment condition
11106447|NCT04031157|No Intervention|soc arm|Standard of Care condition
11106448|NCT04031144|Experimental|Ultrafiltration|Ultrafiltration is applied at the end of cardiopulmonary bypass procedure. The amount of filtration volume is determined by an attending perfuionist.
11106449|NCT04031131|Active Comparator|Intervention Arm|topical anaesthetic gel and lubricating gel
11106450|NCT04031131|Placebo Comparator|Control Arm|lubricating gel alone
11106451|NCT04031105|Experimental|Condition 1|Priming sham TBS, followed by iTBS after an inter-stimulation-interval (ISI) of 0 minutes
11106452|NCT04031105|Experimental|Condition 2|Priming cTBS, followed by iTBS after an ISI of 0 minutes
11106453|NCT04031105|Experimental|Condition 3|Priming cTBS, followed by iTBS after an ISI of 10 minutes
11106454|NCT04031105|Experimental|Condition 4|Priming cTBS, followed by iTBS after an ISI of 20 minutes
11106455|NCT04031092|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for patients with chronic pain.
11106456|NCT04031092|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
11106457|NCT04031079|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program).
11106458|NCT04031079|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
11106459|NCT04031066|Experimental|Velmanase alfa|
11106460|NCT04031066|Placebo Comparator|placebo|
11106508|NCT04030754|Experimental|duoderm group|duoderm dressing will be applied to these patients as intervention
11106549|NCT04030494|Other|Atrial fibrillation (AF)|Group for the validation of detection of AF by the device
11106550|NCT04030494|Other|Valvular heart disease (VHD)|Group for the validation of detection of VHD by the device
11106461|NCT04031053||Intensive Pharmacokinetic Group|After receiving the first dose of ITZ, a single blood sample will be collected 12-hours post-dose. On Day 7, the blood will be collected for intensive PK study. After 7 days of combined ITZ + EFV, a blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. An identical set of intensive PK blood samples will be drawn 2 weeks after initiating the EFV based regimen.
11106462|NCT04031053||Trough Level Group|On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.
11106463|NCT04031040|Experimental|Genio(TM) system therapy|Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 9 months, 12 months and then every year for a total period of 5 years after surgery.
11106464|NCT04031014|Experimental|Active treatment|Treatment with the active treatment protocol of the BTL EMSELLA device twice per week for six treatments total
11106465|NCT04031014|Sham Comparator|Sham treatment|Treatment with the sham protocol of the BTL EMSELLA device twice per week for six treatments total
11106466|NCT04030988|Active Comparator|Active|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
11106467|NCT04030988|Placebo Comparator|Placebo|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
11106468|NCT04030975||interview|emergency physicians
11106469|NCT04030962|Experimental|AGN-242428 Cohort 1A|Administration of AGN-242428 ophthalmic solution
11106470|NCT04030962|Experimental|AGN-242428 Cohort 1B|Administration of AGN-242428 ophthalmic solution
11106471|NCT04030962|Experimental|AGN-242428 Cohort 1C|Administration of AGN-242428 ophthalmic solution
11106472|NCT04030962|Experimental|AGN-231868 Cohort 1A|Administration of AGN-231868 ophthalmic solution
11106473|NCT04030962|Experimental|AGN-231868 Cohort 1B|Administration of AGN-231868 ophthalmic solution
11106474|NCT04030962|Experimental|AGN-231868 Cohort 1C|Administration of AGN-231868 ophthalmic solution
11106475|NCT04030962|Placebo Comparator|AGN-242428 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
11106476|NCT04030962|Placebo Comparator|AGN-231868 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
11106477|NCT04030949||Ateendes STD clinics Östergötland physician appointment|"Attendees with an appointment to a physician (if she has symptoms or if she wishes a gynecological exam).
~The exam starts with an Abbot multi-collect swab taken from the anal verge, at the opening of the anal canal.
~A pediatric proctoscope (a proctoscope designed and manufactured to examine children) is used for sampling the rectal specimens using an Abbot multi-collect swab and a standard Sigma swab of Sigma virocult, followed by vaginal speculum exam. Firstly samples from the lateral fornix for wet smear are collected, secondly a swab for methylene-blue staining from the endocervical orifice followed by two Abbot multi-collect swabs for chlamydia/gonorrhoea and M.genitalium respectively from the orifice, the portio and the vaginal wall and one standard Sigma swab of Sigma virocult from the same areas. Lastly a sample is collected from the distal urethra and stained with methylene blue."
11106478|NCT04030949||Ateendes STD clinics Östergötland, nurse appointment|"The participant collects the rectal sample for chlamydia and gonorrhea (Abbot multi-collect swab) first and is instructed to try not to touch the perianal/perineal areas. Then the vaginal samples for chlamydia/gonorrhoea and M.genitalium are collected.
~There is a group of women who have been tested positive for chlamydia by self-collected vaginal swab which is sent to the patient by mail. Those are requested to attend the STD-clinic for partner tracing and are offered antibiotic treatment with doxycycline. Those accepting to participate in the study will answer the study questions and will be tested again and a nurse will collect firstly an Abbot multi-collect swab from the anal verge, at the opening of the anal canal and then two rectal swabs using a pediatric proctoscope (one Abbot multi-collect and one standard Sigma swab of Sigma virocult) and the participant will self-collect a new vaginal sample for chlamydia/gonorrhea and one for M.genitalium (two Abbot multi-collect swabs)"
11106479|NCT04030949||Ateendes STD clinics Östergötland+Jönköping partner chlamydia|"Women attending the STD clinics because of a verified chlamydia infection of their current partner. This group of patients is examined and tested by a nurse or doctor before doxycycline treatment is offered.
~Those accepting to participate in the study answer the questions about the experience of receptive anal sex and fellatio (and condom use) during the last 12 months and even additional questions regarding fellatio and whether it happened that a male partner ejaculated in oral cavity of the participant.
~The first sample is an Abbot multi-collect swab taken from the anal verge and the anal canal and two more swabs are taken under the use of a pediatric proctoscope: one Abbot multi-collect and one standard Sigma swab of Sigma virocult and finally vaginal samples are collected (one Abbot multi-collect and one standard Sigma swab of Sigma virocult)"
11106480|NCT04030923|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses on the left DLPFC for 10 consecutive sessions totally over period of 10 days.
11106481|NCT04030923|Sham Comparator|sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses with coil perpendicular on scalp over the occipital cortex for 10 consecutive sessions totally over period of 10 days.
11106509|NCT04030741|Active Comparator|Meronem and flagyl|Children in Non-operative treatment (group A) Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours. Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses) and metronidazole (20 mg/kg/day divided into 3 doses for another 8 days.
11106510|NCT04030741|Active Comparator|Surgery (appendectomy)|"Children in group B: appendectomy will b done and post operative single dose of antibiotics.
~discharge after 24hour and Follow up after 1 week."
11106584|NCT04030286||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
11106482|NCT04030910|Experimental|'LIFEView' intervention|"The 'LIFEView' session(s) involves the use of audiovisual software by Motitech AS (technology provided by and used with permission from Motitech AS). For its primary uses as Motiview, the audiovisual software was coupled to a mobile user-adapted cycle-trainer. Since a secondary benefit of the virtual cycle trip may include reminiscence which may in-turn facilitate conversation of past experiences, the audiovisual software is being adapted for use in reminiscence therapy for a palliative care population.
~As there is an extensive library available to participants and 'LIFEView' sessions could potentially be longer than feasible for research personnel to conduct, each 'LIFEView' session will be limited to up to 3 videos per session or up to 1 hour of videos per session, whichever is a shorter duration. Additional post-study 'LIFEView' sessions can be provided upon request from participants."
11106483|NCT04030897|Active Comparator|Online Programs + Information/Psychoeducation/Referral (IPR)|"Includes 2 online, one-session programs (one for youths; one for parents) and Primary Care-based IPR. The 30-min, self-administered YOUTH PROGRAM includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change. In the 15-min Qualtrics-based PARENT PROGRAM, parents read 2 scientific passages on (1) the notion that emotions are flexible in youth and adults, and (2) that failure promotes personal growth. After each passage, parents write a persuasive summary of its main arguments, directed to fellow parents who may benefit from the information."
11106484|NCT04030897|Placebo Comparator|Information/Psychoeducation/Referral (IPR; usual care control)|Information, Psychoeducation and Referral (IPR) represents usual care in the Stony Brook University Hospital's Pediatric Primary Care Division. Families of a youth with elevated MD symptoms during a PC visit receive a folder containing informational materials about the nature of depression and referrals to providers in their area. All families in this study will receive PC-based IPR.
11106485|NCT04030884|Experimental|Intervention Lap.Chol.|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a laparoscopic cholecystectomy.
11106486|NCT04030884|No Intervention|Control Lap.Chol.|The participants received standard care for their laparoscopic cholecystectomy.
11106487|NCT04030884|Experimental|Intervention Thyroidectomy|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a thyroidectomy.
11106488|NCT04030884|No Intervention|Control Thyroidectomy|The participants received standard care for their thyroidectomy.
11106489|NCT04030871|Active Comparator|Capsule Dome G-Tube|Capsule Dome G-Tube
11106490|NCT04030871|Active Comparator|Balloon Bolus feeding tube|Balloon Bolus feeding tube
11106491|NCT04030858|Experimental|Treatment group|The treatment group will eat a nutrient-dense plant-based diet and attend weekly nutrition education sessions.
11106492|NCT04030858|No Intervention|Control group|
11106493|NCT04030845||breast reconstruction|
11106494|NCT04030845||oncoplastic breast-conserving surgery|
11106495|NCT04030819|No Intervention|control group|no intervention
11106496|NCT04030819|Experimental|experimental group|schema therapy
11106497|NCT04030806|Experimental|Intervention group|"All patients will perform 60 minutes of intervention, twice a week, for six weeks. During the intervention, the patient will be positioned seated in a chair with a table in front of him and a mirror (50cm x 50cm) will be placed vertically between his upper extremity.
~The patient's paretic upper extremity will be positioned behind the mirror, allowing only the movements of his healthy upper extremity to be visualized. The reflective side of the mirror will be facing the healthy upper extremity , the patient will perform the exercises observing the movements of his healthy upper extremity through the reflection produced by the mirror, interpreting as the movement of his paretic member."
11106498|NCT04030806|Sham Comparator|Control group|All patients will perform 60 minutes of intervention, twice a week, for six weeks. The mirror will be placed in the same position as the intervention group. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm. In the control group, the patients will be submitted to the same bimanual activities of the intervention group, but without the reflecting side of the mirror. Thus, the nonreflective side of the mirror will be facing the healthy arm, the patient will perform the same exercises visualizing only the movement of the healthy member.
11106499|NCT04030793|Experimental|Individualized stimulation group|Based on transcranial direct current stimulation (tDCS) simulation, individualized stimulation on leg motor areas during 30 minutes.
11106500|NCT04030793|Active Comparator|Conventional stimulation group|Conventional stimulation on leg motor areas during 30 minutes.
11106501|NCT04030780|Active Comparator|Cohort 1FD (on-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks on-PPI+ sporebiotics (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
11106502|NCT04030780|Placebo Comparator|Cohort 1FD (on-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks on-PPI+ placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
11106503|NCT04030780|Active Comparator|Cohort 2FD (off-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks of sporebiotics (2) followed by 8 weeks of sporebiotics (open label)
11106504|NCT04030780|Placebo Comparator|Cohort 2FD (off-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks of placebo (2) followed by 8 weeks of sporebiotics (open label)
11106505|NCT04030767|Experimental|lip repositioning technique with Botox injection.|"Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity (Binder et al., 1998).
~Therefore, the technique is a useful adjunct in the esthetic improvement of the smile and provides better results when combined with resective gingival surgery(Pedron & Mangano, 2018)."
11106506|NCT04030767|Active Comparator|lip repositioning technique.|Lip repositioning aims to limit the retraction of elevator smile muscles. Lip repositioning results in a shallow vestibuler restricting of the muscle pull; Thereby limiting the gingival display during smiling.(Makkiah, 2017) It is a less invasive, viable substitute for patients, has fewer post-operative complications and provides a faster recovery compared to orthognathic surgery(Grover, Gupta, & Luthra, 2014).
11106507|NCT04030754|Experimental|amniotic membrane group|amniotic dressing will be applied to these patients
11106511|NCT04030728||Group 1: Standardized coaching arm|Patients in this group receive a continuous standardized MOATT based patient education and coaching and optional eMBSR (electronic Mindfulness-Based Stress Reduction) within the first 24 weeks of Abemaciclib treatment.
11106512|NCT04030728||Group 2: Coaching according to local practice|Patients in this group receive a patient management according local routine.
11106513|NCT04030715|Other|the successful group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
11106514|NCT04030715|Other|the failure group|divide the subject to two groups based on the success or failure of eradication, and analyze the influential factors of eradication. Build a predictive model for the success of eradication.
11106515|NCT04030689||Axis 2|Each patient diagnosed HIV positive following VihTest test will be invited to participate to ALSO-Parcours; This program aimed to decribe the link to care for this population and to make a descriptive analysis of this HIV+ patients.
11106516|NCT04030676|Experimental|QuantiFERON Test|Patient with CytoMegaloVirus (CMV) infection will be included. They will have biopsies and blood samples, composite of QuantiFERON-CytoMegaloVirus (QF-CMV) assay.
11106517|NCT04030663|Active Comparator|papaverine|
11106518|NCT04030663|Active Comparator|nitroglycerine|
11106519|NCT04030663|Placebo Comparator|xlyocaine|
11106520|NCT04030650||healthy volunteers|
11106521|NCT04030650||patients|patients with lower limb amputations
11106522|NCT04030637||CRC cases|samples will be collected from subjects with known diagnosis of colorectal cancer
11106523|NCT04030637||Healthy cases|samples will be collected from healthy subjects with normal colonoscopy findings
11106524|NCT04030637||Cases with pathologies|samples will be collected from subjects whose colonoscopies showed other pathologies (e.g. inflammatory polyps, adenomas, diverticular diseases)
11106525|NCT04030624|Experimental|Remote Electronic Patient Monitoring|"The Remote Electronic Patient Monitoring intervention will entail monitoring of vital sign data and patient reported assessments to address and manage any concerning issues identified.
~The Remote Patient Monitoring system uses algorithms that can indicate when patient vitals and patient-reported outcomes have changed.
~Automatic patient surveys are sent to the patient with results displayed on the clinician user interface (i.e., dashboard) on a computer located in the clinical area.
~Qualitative interviews with patient participants and their oncology clinicians using a semi-structured interview guide will be conducted."
11106526|NCT04030611||control group|Participants in the type 2 DM group were diagnosed with DM based on criteria recommended by the American Diabetes Association and required to have a fasting plasma glucose of ≥7mmol/L or an HbA1c of ≥6.5%, as measured on 2 separate occasions.
11106527|NCT04030611||diabetic retinopahty group|Participants in th ediabetic retinopahty group group were diagnosed according to the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales.
11106528|NCT04030598|Experimental|IONIS-PKK-LRx (Part A)|IONIS-PKK-LRx administered subcutaneously (SC) to participants with HAE-1/HAE-2 every 4 weeks for up to 12 weeks.
11106529|NCT04030598|Experimental|IONIS-PKK-LRx (Part B)|IONIS-PKK-LRx administered SC to participants with HAE-nC1-INH every 4 weeks for up to 12 weeks.
11106530|NCT04030598|Placebo Comparator|Placebo|Placebo will be administered SC to HAE-1/HAE-2 participants every 4 weeks for up to 12 weeks during Part A.
11106531|NCT04030585|Experimental|robot-assisted exercise|Robot-assisted exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
11106532|NCT04030585|Active Comparator|Home exercise|Home exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
11106533|NCT04030572|Experimental|Clonidine Pill|One week period of clonidine, 0.1 mg tabs, one by mouth daily at bedtime
11106534|NCT04030559|Experimental|Treatment (niraparib)|Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
11106535|NCT04030546|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session
11106536|NCT04030546|No Intervention|Usual care|Patient will receive usual care
11106537|NCT04030533|Experimental|Cohort 1: Guselkumab (SC): Dose 1|Participants will receive a single subcutaneous (SC) injection of guselkumab (dose 1), administered on Day 1.
11106538|NCT04030533|Experimental|Cohort 2: Guselkumab (SC): Dose 2|Participants will receive a single SC injection of guselkumab (dose 2), administered on Day 1.
11106539|NCT04030533|Experimental|Cohort 3: Guselkumab (IV): Dose 1|Participants will receive a single intravenous (IV) infusion of guselkumab (dose 1), administered on Day 1.
11106540|NCT04030533|Experimental|Cohort 4: Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2), administered on Day 1.
11106541|NCT04030533|Experimental|Cohort 5: Ustekinumab (IV): 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 milligrams per milliliter (mg/mL) solution on Day 1.
11106542|NCT04030520|Experimental|intervention|participants will receive a behavioral intervention including counseling and offer of HIV oral fluid self test and PrEP
11106543|NCT04030520|Active Comparator|comparison|participants will be not be offered HIV oral fluid self test but receive counseling, condoms and offered PrEP
11106544|NCT04030507|Experimental|Inflammatory Breast Cancer Managed with Curative Intent|"Patients will receive an initial screening magnetic resonance imaging (MRI) of the brain
~If no evidence of intracranial involvement is identified, additional screening MRIs of the brain every six months for two years and at initial systemic progression."
11106545|NCT04030507|Experimental|HR+ or HER2+ Metastatic Breast Cancer - Screening Arm|"An initial MRI screening will be conducted
~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
11106546|NCT04030507|No Intervention|HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm|No initial MRI screening will be conducted
11106547|NCT04030507|Experimental|Triple Negative Breast Cancer|"An initial MRI screening will be conducted
~If negative, patients will receive a second MRI of the brain at first systemic progression after study entry"
11106548|NCT04030494|Other|Blood pressure (BP)|Group for the validation of blood pressure measurement by the device
11106551|NCT04030481||Group A: Sevoflurane, sufentanil and rocuronium|sevoflurane (1-3%)and sufentanil (0.5-2 mcg/kg/h) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
11106552|NCT04030481||Group B: Propofol, sufentanil and rocuronium|propofol (4-12 mg/kg/h) and sufentanil (0.5-2 mcg/kg/h/) and rocuronium (0.3～0.6mg/kg/h) used intraoperatively as required
11106553|NCT04030468|Experimental|General practitioners|Educational intervention
11106554|NCT04030468|Experimental|Patients|Informative intervention
11106555|NCT04030468|Experimental|General practitioners and patients|Combined strategy
11106556|NCT04030468|No Intervention|Control|No intervention
11106557|NCT04030455|Experimental|Treatment (cisplatin, docetaxel, pembrolizumab)|Patients receive cisplatin IV over 1 hour, docetaxel IV over 1 hour (patients who develop significant adverse events to cisplatin treatment may receive carboplatin IV over 1 hour instead), and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who completely respond to the study drugs (the disease appears to go away) then receive pembrolizumab IV over 30 minutes on day 1 for 4 additional cycles in the absence of disease progression or unacceptable toxicity.
11106558|NCT04030442|Placebo Comparator|Smoked cannabidiol 0%|
11106559|NCT04030442|Active Comparator|Smoked cannabidiol 3.4%|
11106560|NCT04030442|Active Comparator|Smoked cannabidiol 12.7%|
11106561|NCT04030429|Experimental|Crizotinib arm|Crizotinib 250 mg bid orally
11106562|NCT04030403||Microbial Keratitis participants|151 participants presenting with clinically suspected microbial keratitis will be recruited from St Paul's Eye Unit, Royal Liverpool University Hospital.
11106563|NCT04030403||Healthy control participants|20 participants with no history of microbial keratitis who use no eye drop medication will be recruited.
11106564|NCT04030403||Contact-lens wearers|20 participants with no history of microbial keratitis who are contact-lens wearers will be recruited.
11106565|NCT04030403||Glaucoma eye drop users|20 participants who have no history of microbial keratitis but are on eye drop treatment for glaucoma. This group has been included to assess for changes in the corneal microbiome that could be secondary to drop treatment.
11106566|NCT04030403||Keratoconus participants|30 participants with keratoconus who are undergoing cross-linking will be recruited. These participants as part of the routine cross-linking procedure will have their corneal epithelium removed. This removed epithelium from an otherwise healthy corneal surface will allow for a direct comparison between the corneal microbiome characterised from the corneal impression membrane and that characterised directly from the epithelium.
11106567|NCT04030390|Experimental|Physical Fatigue Condition|
11106568|NCT04030390|Placebo Comparator|Control Condition|
11106569|NCT04030364|Other|Self-referral to group exercise classes|"Structured, multi-component, supervised group exercise classes are the health related intervention proposed for this study. The group classes will occur at a local CrossFit gym facility.
~For the purposes of this project, all eligible Rosemount Clinic patients with type 2 diabetes mellitus will receive an email or letter mail invitation to self-refer to a structured, facility-based, supervised aerobic and resistance exercise program. Interested patients will be invited to attend a 1-hour information session at the exercise facility at the time of implementation start up where they will complete an initial baseline survey. This session will also serve as an initial meet and greet for participants to meet exercise trainers prior to starting exercise classes and to receive a tour of the facility."
11106570|NCT04030351|Experimental|dried fruit|100 g per day of dried fruit
11106571|NCT04030351|No Intervention|no dried fruit|no intervention to be given
11106572|NCT04030338||Prostate cancer|Participants with histologically confirmed prostate cancer, that is either newly diagnosed OR progressive as defined by standard PCWG3 criteria. Patients w ill remain on study until 30 days after their last PSMA imaging timepoint required by their companion therapeutic protocol.
11106573|NCT04030325|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
11106574|NCT04030325|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
11106575|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
11106576|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
11106577|NCT04030325|No Intervention|Assessment Only Control|Participants complete baseline survey, longitudinal follow up assessments, and pre- and post- event surveys.
11106578|NCT04030312|Active Comparator|Standard Infant Formula|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of standard 20 calorie-per-ounce infant formula up to two times during the duration of the study to treat hypoglycemia.
11106579|NCT04030312|Experimental|Commercially-Sterilized Donor Human Milk|Infants in this randomized treatment arm will receive bottle supplementation of up to 15 milliliters of 20 calorie-per-ounce commercially-sterilized donor human milk up to two times during the duration of the study to treat hypoglycemia.
11106580|NCT04030299|Experimental|OTC Group|In this group, the over-the-counter fitting will be used to provide hearing aids.
11106581|NCT04030286||Control|Healthy patients
11106582|NCT04030286||Periodontitis|Patients with periodontal disease
11106583|NCT04030286||Cardiovascular|Patients with cardiovascular disease
11106585|NCT04030273||Open (laparotomic) myomectomy|Women undergoing uterine myomectomy by open surgery (laparotomy).
11106586|NCT04030273||Laparoscopic myomectomy|Women undergoing uterine myomectomy by laparoscopy.
11106587|NCT04030273||Robotic myomectomy|Women undergoing uterine myomectomy by robotic surgery.
11106588|NCT04030260|Experimental|Regorafenib and Nivolumab in Combination with Radiotherapy|
11106589|NCT04030247|Experimental|Plant Sterol|A randomized group of South Asians with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.
11106590|NCT04030247|No Intervention|Control|A randomized group of South Asians with moderate cardiovascular disease risk will receive standard of care.
11106591|NCT04030234|Experimental|Intensive treatment group|Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
11106592|NCT04030234|Active Comparator|Standard treatment group|Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
11106593|NCT04030208|Other|Sequence A|If patient is randomly assigned to Sequence A, they will be placed on a traditional ventilator for the first period. This period will be 1 hour in duration. Delivered tidal volume, respiratory rate (RR), and peak pressure will be recorded throughout the period using the ventilator. Heart rate (HR), Blood Pressure (BP), and oxygen (O2) saturation measurements will be recorded every 5 minutes. Arterial blood gas (ABG) data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing. Next, the study participant will be transitioned to the Umbulizer to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be taken every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour.
11106594|NCT04030208|Other|Sequence B|If patient is randomly assigned to Sequence B, they will be shifted to the Umbulizer for the first period. This period will be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using Umbulizer. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 30 minutes and 1 hour. Next, the study participant will be transitioned to a traditional ventilator to begin Period 2. This period will also be 1 hour in duration. Delivered tidal volume, RR, and peak pressure will be recorded throughout the period using the ventilator. HR, BP, O2 saturation measurements will be recorded every 5 minutes. ABG data will be taken at t = 1 hour if the patient is stable on the traditional ventilator. ABGs may be taken more frequently if the patient is destabilizing.
11106595|NCT04030195|Experimental|Dose Level 1 of PBCAR20A CAR T cells|"1 x 10^6 CAR T cells per kg body weight.
~In this study, PBCAR20A, allogeneic anti-CD20 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
~Route of Administration: Intravenous infusion.
~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR20A infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
11106596|NCT04030195|Experimental|Dose Level 2 of PBCAR20A CAR T cells|3 x 10^6 CAR T cells per kg body weight.
11106597|NCT04030195|Experimental|Dose Level 3 of PBCAR20A CAR T cells|6 x 10^6 CAR T cells per kg body weight.
11106598|NCT04030182||Level of vitamin D|Level in blood sample of vitamin D for each patient
11106599|NCT04030169|Experimental|Experimental: MDMA-assisted psychotherapy|Two sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
11106600|NCT04030156||ultrasonographic tonsil volume|All measurements were done by the same radiologist with over 20 years of experience. GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) was used in USG examination. The patients were viewed using a 2-9 MHz linear probe from the submental region. The examination was done while the patient was in a supine position, with a neck support. Right tonsil measurement was done by turning the neck slightly to the upper left whereas left tonsil measurement was done by turning the neck slightly to the upper right. Tonsil volume was calculated with standard ultrasonography formula (height x length x thickness x 0.52) due to its ellipsoid shape.
11106601|NCT04030156||Actual tonsil volume|Excised tonsil volumes were calculated by water replacement method.
11106602|NCT04030143|Experimental|Aripiprazole 2M LAI|"2 Months (2M) Long-acting injection (LAI).
~Participants will receive a total of 4 injections of aripiprazole 2M LAI, administered every 56 days (+/- 2 days) from Day 1.
~Participants will continue to take their current oral antipsychotic or be given 10 to 20 mg oral aripiprazole for 7 days after the first administration."
11106603|NCT04030143|Active Comparator|Aripiprazole 1M depot injection|"1 Month (1M) depot injection.
~Participants will receive a total of 8 injections of aripiprazole 1M depot, administered every 28 days (+/- 2 days) from Day 1.
~Participants will continue to take their current oral antipsychotic or be given 10 to 20 mg oral aripiprazole for 14 days after the first administration."
11106604|NCT04030130|Experimental|NDURE|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system-(care coordination), interpersonal-(social support), and individual- (health belief model [HBM]; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, enhance HNSCC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE navigation sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit, time points chosen to facilitate case identification and coordination across key care transitions.
11106638|NCT04029935|Experimental|Physical Fatigue Condition|
11106639|NCT04029935|Placebo Comparator|Control Condition|
11106605|NCT04030130|No Intervention|Usual Care|UC consists of discussions about the indications, risks/benefits/alternative, Guidelines, timing, and logistical details of adjuvant therapy. These discussions will be administered according to practice patterns of the involved providers.
11106606|NCT04030117|Experimental|ACTIVA Test arm|Treatment of decay in Class II second primary molars using ACTIVA restorative material.
11106607|NCT04030117|Active Comparator|Compomer Comparator arm|Treatment of decay in Class II second primary molars using compomer restorative material.
11106608|NCT04030104|Active Comparator|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
11106609|NCT04030104|Experimental|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
11106610|NCT04030091|Experimental|3 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 3 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
11106611|NCT04030091|Experimental|2 hour pulsatile normal insulin infusion treatment|the pulsatile insulin infusion treatment will be applied for 2 hours once a week with 10 pulses of 3 U of humulin R 100 IU/mL insulin per hour
11106612|NCT04030065|Experimental|Experimental Arm - omega 3 fatty acid|
11106613|NCT04030065|No Intervention|Control Arm - No intervention|
11106614|NCT04030052|Experimental|Untreated/minimally treated moderate HA no inhibitors|Previously untreated patients (PUPs) and minimally treated patients (MTPs) <3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.
11106615|NCT04030052|Experimental|Treated any moderate HA with existing inhibitors|Children <21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).
11106616|NCT04030039||chronic hepatitis B patients during the immune control period|Patients with chronic HBV infection during the immune control period do not have any clinical treatment intervention cohort
11106617|NCT04030039||Therapy group A|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with interferon
11106618|NCT04030039||Therapy group B|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they stopped to be treated with interferon
11106619|NCT04030039||Therapy group C|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential nucleoside analogues
11106620|NCT04030039||Therapy group D|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential interferon
11106621|NCT04030039||Therapy group E|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with the nucleoside analogues
11106622|NCT04030026|Active Comparator|Arm 1a: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 1
11106623|NCT04030026|Placebo Comparator|Arm 2a: Placebo|Placebo twice a day for Treatment Period 1
11106624|NCT04030026|Placebo Comparator|Arm 1b: Placebo|Placebo twice a day for Treatment Period 1
11106625|NCT04030026|Active Comparator|Arm 2b: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 2
11106626|NCT04030013|Active Comparator|Group education for 2 years|Patients who will receive structured diabetes education in groups , Group 1
11106627|NCT04030013|Active Comparator|One to one education for 2 years|Patients who will receive one to one structured diabetes education, Group 2
11106628|NCT04030013|No Intervention|Control group without structured education|Patients who will not receive structured diabetes education, Group 3
11106629|NCT04030000|Other|Paclitaxel/Carboplatin and radiation|"Paclitaxel 135 mg/m2 over 3 hrs on day 1 Carboplatin IP (AUC= 6.0) on day 1 Paclitaxel 60 mg/m2 IP on Day 8 Repeat q 21 days x 6 cycles
~Pelvic 6MV Photon Beam Energy, or IMRT where appropriate 1.8 Gy Dose/FX Total Dose 45 Gy
~High Dose Radiation (HDR) x 3, or IMRT where appropriate 5 Gy to 0.5cm Depth from the Vaginal Cylinder Surface Total Dose 15 Gy"
11106630|NCT04029987|Active Comparator|Trans Muscular Quadratus Lumborum fascial plane Block|"In group (Trans Muscular Quadratus Lumborum Block),will undergo ultrasound guided trans-muscular quadratus lamborum block as follows:
~A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoas Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
11106631|NCT04029987|Active Comparator|Intra Muscular Quadratus Lumborum fascial plane Block|"In group Intra Muscular Quadratus Lumborum Block ,will undergo ultrasound guided intra-muscular quadratus lamborum (QL) block as follows:
~A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg per side of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side."
11106632|NCT04029987|Placebo Comparator|group c → control|group c → control ,will receive conventional analgesia in the form of paracetamol with 15 mg\ k.g every 6 hours, and naluphin 0.1 mg \kg on demands
11106633|NCT04029974|Experimental|Treatment|Progressive elevation (0 degrees, 25 degrees, 50 degrees, 75 degrees; x2 minutes in each position) while on robotic tilt-stepper at the cadence of 0, 40, and 80 steps/minute.
11106634|NCT04029961|Active Comparator|Video Education|Participants will receive video education on radiation therapy.
11106635|NCT04029961|Experimental|VR-based Education|Participants will receive VR-based education on radiation therapy.
11106636|NCT04029948|Active Comparator|laser ERBT|Laser En Bloc Resection Of bladder Tumor
11106637|NCT04029948|Active Comparator|electro-surgical ERBT|electro-surgical En Bloc Resection Of bladder Tumor
11106640|NCT04029922|Experimental|Arm 1- Dose Escalation|"The dose escalation part of the study is aimed at determining the Recommended Phase 2 Dose (RP2D) of MT-5111.
~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
11106641|NCT04029922|Experimental|Arm 1- Dose Expansion|"The dose expansion part of the study will begin after completion of the dose escalation phase to confirm the safety and tolerability of the RP2D.
~The RP2D dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
11106642|NCT04029909|Experimental|Gimatecan 0.6mg/m2/d|Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
11106643|NCT04029909|Experimental|Gimatecan 0.8mg/m2/d|Three or six patients will be treated with the dose of 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
11106644|NCT04029909|Experimental|Gimatecan 0.4mg/m2/d|Three or six patients will be treated with the dose of 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
11106645|NCT04029883|Other|Remote BP Monitoring|Patients with uncontrolled hypertension provided with a remote BP monitor linked to their electronic health record.
11106646|NCT04029857|Active Comparator|Group I (standard of care)|Patients receive standard of care nutritional supplementation.
11106647|NCT04029857|Experimental|Group II (Impact Advanced Recovery)|Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
11106648|NCT04029844|Experimental|Colibri Device|Treatment
11106649|NCT04029831|Experimental|K61|Patients in K61 group received propofol and ketamine in a ratio of 6:1. The 6:1 ketofol mixture was made by mixing 30 mL of 1% propofol (10 mg/mL) and 1 mL of ketamine (50 mg/ml), then 19 mL of 0.9% NaCl was added until the volume of the mixture was 50 mL. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
11106650|NCT04029831|Experimental|K41|Patients in K41 group received propofol and ketamine in a ratio of 4:1. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
11106651|NCT04029818|Experimental|Probiotic|Volunteers will take a capsule with Bifidobacterium BSL_PS404 (3x109 cfu) daily.
11106652|NCT04029818|Placebo Comparator|Placebo|Volunteers will take a capsule with maltodextrin daily.
11106653|NCT04029805|Experimental|Combination of a Plant Extract and a Probiotic|Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
11106654|NCT04029805|Placebo Comparator|Placebo|Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.
11106655|NCT04029792|Experimental|Combination of Plant Extracts (BSL_EP028)|Volunteers will take twice at day for 8 weeks a capsule containing the combination of a plant extracts (BSL_EP028)
11106656|NCT04029792|Placebo Comparator|Placebo|Volunteers will take twice at day for 8 weeks a capsule containing maltodextrin.
11106657|NCT04029779|Experimental|Immediate implant placement coated with I-PRF|The test group received implants coated with injectable platelet-rich fibrin and also the sockets were injected with injectable- platelet rich fibrin
11106658|NCT04029779|No Intervention|immediate implant only|The control group received immediate dental implants only after extraction of the teeth without any local coating.
11106659|NCT04029766|Experimental|HSK3486|Initially 0.288 mg/kg or 0.540 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 1 mg/kg/h administered as a 30 minute infusion via infusion pump.
11106660|NCT04029753|Experimental|Walk out from operating room|Patients will return to the ward after surgery by walking.
11106661|NCT04029753|No Intervention|Leave operating room by transporting bed|Patients will return to the ward after surgery by lying on the transporting bed.
11106662|NCT04029740|Other|Healthy controls|40 Healthy controls matched on gender and age with no current psychopathology will have exosomal microRNAs measured twice over a 3 month period.
11106663|NCT04029740|Experimental|panic disorder receiving CBT|40 adult patients diagnosed with primary panic disorder will have their exosomal microRNAs measured 2x over 3 months.
11106664|NCT04029727|Experimental|Combination of Plant Extracts (BSL_EP025)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP025)
11106665|NCT04029727|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
11106666|NCT04029714|Active Comparator|Arm 1: Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and initiation of curative treatment are performed according to the urologist's judgement.
11106667|NCT04029714|Experimental|Arm 2: Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
11106668|NCT04029701|Experimental|Research group|"Subjects who are recruited into this group are asked to take the Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.
~P.S. Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
11106669|NCT04029701|Placebo Comparator|Control group|"Subjects who are recruited into this group are asked to take the placebo of Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.
~P.S. Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
11106672|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Cyclophosphamide/Topotecan|
11106673|NCT04029688|Experimental|AML: Idasanutlin + Venetoclax|
11106674|NCT04029688|Experimental|AML: Idasanutlin + Fludarabine/Cytarabine|
11106675|NCT04029688|Experimental|ALL: Idasanutlin + Venetoclax|
11106676|NCT04029675|Experimental|Study Group ( High dose vitamin C group )|They will receive 1.5 gm intravenous (IV) Vitamin C in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes every 6 hours daily for 4 days or until ICU discharge.
11106677|NCT04029675|Active Comparator|Control Group (Daily requirements vitamin C Group )|They will receive standard daily requirements of Vitamin C intravenously which is 75-90 mg in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes daily for 4 days or until ICU discharge
11106678|NCT04029662|Experimental|Group Valsalva Maneuver|Patients who undergo spinal anesthesia and perform Valsalva maneuver to reduce the pain intensity
11106679|NCT04029662|No Intervention|Group Control|Patients who undergo spinal anesthesia and perform nothing to reduce the pain intensity
11106680|NCT04029649|Experimental|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days
11106681|NCT04029649|Placebo Comparator|Placebo|This group received empty capsule with dose 3x1 capsule a day for 90 days
11106682|NCT04029636||Established LONIPC|The first cohort will comprise of patients with established LONIPCs and the investigative procedures in this study will provide data on the scope of abnormalities and pathology across the spectrum of these conditions.
11106683|NCT04029636||Trajectory of LONIPC|The second, prospectively followed, cohort will provide data on the sequence and temporal development of these abnormalities, and therefore provide information on the trajectory of LONIPCs
11106684|NCT04029623|Experimental|Partnered Rhythmic Rehabilitation (PRR)|Participants in this study are will receive the PRR intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
11106685|NCT04029623|Active Comparator|Group walking (WALK)|Participants in this study are will receive the WALK intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
11106686|NCT04029610|Active Comparator|Local anesthesia of lidocaine and arterial blockage on the arm|Local anesthesia of lidocaine and arterial blockage on the arm
11106687|NCT04029610|Experimental|Local anesthesia with lidocaine and adrenalin|Local anesthesia with lidocaine and adrenalin
11106688|NCT04029597|Experimental|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the Remote Patient Monitoring System.
11106689|NCT04029584|Experimental|uninduced fluvastatin rifampin study|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers in a two-period, randomized, unblinded, crossover clinical trial. On period 1 of the study, subjects will be randomized to one of two treatment groups: (i) one oral dose of fluvastatin (Lescol®) 20mg capsule (ii) one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.
~The two study periods will preferentially be separated by one day of washout. Subjects will be instructed to fast overnight the day before study periods 1 and 2, and for 3h post-dosing. In both treatments, venous blood samples (~8ml each) will be drawn at 0, 0.33, 0.67, 1,1.5, 2, 2.5, 3, 4, 6, 9, 12h after fluvastatin dosing. During Period 2, subjects will receive the second treatment, followed by blood draws at the same time points as after fluvastatin dosing alone."
11106690|NCT04029584|Experimental|induced fluvastatin rifampin study|The effect of rifampin on the disposition of fluvastatin under a hepatic enzyme induced state will be studied in a two-period, randomized, unblinded, crossover clinical trial. Subjects will be pretreated,5 days with 600mg oral rifampin for enzyme and transporter induction. In period 1, subjects will be randomized to one of two treatment groups: (i) one oral dose of fluvastatin 20mg (ii) one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. The two study periods will be separated by one day of washout. Subjects will fast overnight the day before study period 1 and period 2, and for 3h post-dosing. In both treatments, venous blood samples (8ml each) will be drawn at 0, 0.33, 0.67, 1,1.5, 2, 2.5, 3, 4, 6, 9, 12h after fluvastatin dosing. During washout, patients will pretreat with one 600mg dose of oral rifampin. In Period 2, subjects will receive the second treatment, followed by blood draws at the same time points after fluvastatin dosing.
11106691|NCT04029571|Experimental|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
11106692|NCT04029571|Active Comparator|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
11106693|NCT04029571|No Intervention|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
11106694|NCT04029558|Experimental|Combination of plant extracts (BSL_EP024)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP024)
11106695|NCT04029558|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
11106696|NCT04029545|Experimental|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
11106697|NCT04029545|Active Comparator|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
11106698|NCT04029545|Experimental|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
11106699|NCT04029532||Non-overweight/obese & normal weight|Body mass index (BMI) < 24.0 kg/m^2
11106700|NCT04029532||Overweight and obese|Body mass index (BMI) >= 24.0 kg/m^2
11106701|NCT04029519|Experimental|PN40082|All subjects in this study will receive one open-label treatment with PN40082.
11106702|NCT04029506||medical staff group|medical staff in Qilu Hospital who recieveing endoscopy for physical examination
11106703|NCT04029506||general population group|general population who recieveing endoscopy for physical examination in Qilu Hospital
11106704|NCT04029480|Experimental|Ertugliflozin 5 mg/5 mg|"All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.
~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
11106705|NCT04029480|Experimental|Ertugliflozin 5 mg/15 mg|"All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.
~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
11106706|NCT04029480|Placebo Comparator|Placebo|At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.
11106707|NCT04029467|Active Comparator|Precedex|participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
11106708|NCT04029467|Experimental|Dexmedetomidine|participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
11106709|NCT04029454|Experimental|Intervention period|Intervention : birth dose vaccination against hepatitis B strategy Birth dose of vaccine against hepatitis B + routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
11106710|NCT04029454|No Intervention|Control period|Routine Expended Programme on Imunisation (EPI) vaccination schedule starting at 8 weeks of life
11106711|NCT04029441||the successful eradication cohort|the subjects who eradicate the Hp successfully after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
11106712|NCT04029441||the failure eradication cohort|the subjects who fail to eradicate the Hp after recieving the therapy or rescue therapy based on antimicrobial susceptibility test
11106713|NCT04029428|Active Comparator|90Y DOTATATE|Therapy 90Y DOTATATE, total activity 4x3.7GBq (14.8 GBq), i.v. infusion of 90Y DOTATATE administered for 20 min. via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
11106714|NCT04029428|Experimental|177Lu DOTATATE or mix 90Y and 177Lu DOTATATE (50% each)|Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
11106715|NCT04029402||Diabetic kidney disease|Patients with archived biopsies with a pathologic diagnosis of diabetic kidney disease, interstitial fibrosis/tubular atrophy, or nephrosclerosis.
11106716|NCT04029402||Healthy controls|Potential living donors with archived biopsies performed as part of their donor workup and with no diagnostic abnormalities
11106717|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Conservational|After ESWT therapy patients suffer from extreme pain will recieve only conservational therapy (26 patients)
11106718|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Local|After ESWT therapy patients suffer from extreme pain will receive local steroid injections
11106719|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Tibial nerve|After ESWT therapy patients suffer from extreme pain will receive tibial nerve block
11106720|NCT04029350|Experimental|Anlotinib Combined With Osimertinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
11106721|NCT04029324|Active Comparator|Immediate implant placement|Implants are placed immediately after extraction
11106722|NCT04029324|Placebo Comparator|Early implant placement|Implants are placed 4-8 weeks after extraction
11106723|NCT04029311|Experimental|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
11106724|NCT04029311|Experimental|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
11106725|NCT04029298|Experimental|HBDC Intervention Group|Immediate enrollment in the 16-week, HBDC education-based intervention, followed by a 12-month observation period
11106726|NCT04029298|Other|Control/Usual Care/Delayed Intervention Group|16-week, HBDC education-based intervention will be delayed by 12 months. Following the delayed intervention, this group will be observed for an additional 12-month period
11106727|NCT04029285|Other|Traditional Gym Based exercise - Control|Twice weekly sessions of TGB exercise for six weeks.
11106728|NCT04029285|Experimental|Exergaming|Twice weekly sessions of exergames for six weeks.
11106729|NCT04029272|Active Comparator|Metformin|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)
~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d."
11106730|NCT04029272|Experimental|Metformin+EQW|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)
~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d.
~EQW: Participants will receive long-acting Exenatide once a week for 12 weeks"
11106731|NCT04029246|No Intervention|Letter only|
11106732|NCT04029246|Active Comparator|Letter plus phone call|
11106733|NCT04029246|Active Comparator|Letter plus incentive|
11106734|NCT04029220|Experimental|Parent Peer Navigation (PPN) by Family Run Organization|In this arm, families receive PPN services from a trained provider with lived experience whose role is to effectively engage parents/caregivers in necessary treatment for their children by helping them connect with assessment, treatment and community-based resources and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support once the PPN is no longer involved. PPN providers use the foundational competencies and skills to educate, inform and support families who are just entering the child-serving systems due to emerging behavioral health issues of their child.
11106735|NCT04029220|Active Comparator|Resources provided by Family Support Organization|"The active comparator is service provided by Family Support Organizations (FSOs), which provide information and resources for families about disabilities, special education and other services as well as workshops and parent support groups. Unlike PPN services, FSO staff members are not veteran caregivers of a child with mental health challenges, do not provide personalized service delivery, do not provide a comprehensive assessment of family needs, and do not prepare families to make use of services through support for their initial and continued involvement in them. Finally, whereas PPNs participate in comprehensive training and coaching, training for FSO staff tends to be more general and consists primarily of being aware of local resources to which families may be referred."
11106736|NCT04029207||African Surgical OutcomeS-2 Trial|The ASOS-2 Trial is a cluster randomised trial purposively recruiting hospitals across Africa. To be eligible for inclusion a hospital must perform at least 20 cases of adult in-patient surgery with anaesthesia per week, have local ethics approval for the trial, have local hospital management approval and have established a local hospital study team. The trial excludes hospitals with lower surgical volume. The trial aims to include all consecutive adult in-patient surgical cases at participating hospitals (both elective and emergency surgery). Patients under the age of 18 and patients who have already been recruited into the trial are excluded from recruitment. Follow-up is in-hospital, censored at 30 days.
11106737|NCT04029194|Experimental|Treatment|
11106738|NCT04029194|No Intervention|Control|
11106739|NCT04029181|Experimental|Dose finding cohort|In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval.
11106740|NCT04029181|Experimental|Feasibility cohort|The purpose of part B of the study is to analyze the PK of the anti-CD8 imaging agent in patients before and during treatment with checkpoint inhibitors.
11106741|NCT04029168||weak pelvic floor muscles|The group will consist of females with pelvic floor strength lower or equal to 26.5 measured by perineometry and/or females with lack of ability to sustain stable pelvic floor contraction at submaximal level (80% of maximal voluntary contraction) for 5 seconds.
11106742|NCT04029168||strong pelvic floor muscles|The group will consist of females with pelvic floor strength over 26.5 measured by perineometry and/or females with ability to sustain stable pelvic floor contraction at submaximal level (80% of maximal voluntary contraction) for 5 seconds.
11106743|NCT04029155|Active Comparator|TBNA with Conventional bronchoscope|patients in this arm will undergo bronchoscopy by a conventional probe
11106744|NCT04029155|Experimental|TBNA with a Ultrathin bronchoscope|Patients in this arm will undergo bronchoscopy by a ultra thin probe
11106745|NCT04029129|No Intervention|High exposure|Ambient air was allowed freely into the room.
11106746|NCT04029129|Experimental|Medium exposure|Limited air filtration was used to partially reduce levels of pollution in the room relative to outside.
11106747|NCT04029129|Experimental|Low exposure|Doors and windows were closed and sealed and full filtration was used to maximally reduce pollution in the room.
11106748|NCT04029116|Experimental|Ibrexafungerp|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
11106749|NCT04029116|Placebo Comparator|Placebo|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days
11106750|NCT04029103|Active Comparator|used m-DAKBAS|"m-DAKBAS application was downloaded to the mobile phones of the participants who met the research criteria and accepted to participate in the study; the participants were given a username and a password for the confidentiality. They were instructed how to use the application after a number of trials.
~The participants were asked to send their blood sugar levels each time they measured it and foot observations daily through the application. Using the admin panel, the researcher followed the participants' frequency of using the application and the data they sent throughout 24 weeks and tried to find solutions to the problems experienced (for example: hyperglycaemia, insulin dosage adjustments). The participants were provided with feedback in line with these data; SMS reminders were sent if the tasks were not completed."
11106751|NCT04029103|Experimental|not used m-DAKBAS|The participants who met the research criteria and accepted to participate in the study were given training via verbal instruction about the information in the content of m-DAKBAS (definition of Diabetic Foot, risk factors, protective precautions, daily foot care)
11106752|NCT04029090|Experimental|Sequence 1|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
11106796|NCT04028739|Experimental|Theracurmin CR-033P|1 Capsule with 150mL water, Single, curcumin 90mg/day
11106753|NCT04029090|Experimental|Sequence 2|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
11106754|NCT04029090|Experimental|Sequence 3|Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)
11106755|NCT04029077||Vapor group|Bronchoscopic lung volume reduction treatment using Vapor
11106756|NCT04029038|Experimental|Treatment (CD19-CD22 CAR T cells)|Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
11106757|NCT04029025|Active Comparator|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
11106758|NCT04029025|Active Comparator|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
11106759|NCT04029025|Active Comparator|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C).
11106760|NCT04029012|Experimental|Penthrox|methoxyflurane inhaler (Penthrox)
11106761|NCT04028999|Experimental|the EO31 shoulder sling|To develop and evaluate the effects of the EO31 shoulder sling for the prevention of pain, subluxation, spasticity, as well as effect on increasing functional use of the UL in activities of daily living.
11106762|NCT04028986||Surgery group|patients treated by surgery before starting the IVF/ICSI treatment
11106763|NCT04028986||Ulipristalacetate group|patients treated by ulipristalacetate before starting IVF/ICSI treatment
11106764|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 1)|
11106765|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 2)|
11106766|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 1)|
11106767|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 2)|
11106768|NCT04028960|Placebo Comparator|Placebo|No active drug
11106769|NCT04028960|Experimental|Humulin-R|Insulin
11106770|NCT04028947|No Intervention|Standard TKA|Subjects will have the standard procedure.
11106771|NCT04028947|Active Comparator|TKA with Neurectomy|Subjects will the nerve excised and protected with soft tissue.
11106772|NCT04028921||Normal weight, active|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, >=60 min/day of moderate/vigorous physical activity.
11106773|NCT04028921||Normal weight, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, <60 min/day of moderate/vigorous physical activity.
11106774|NCT04028921||Overweight/obese, active|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, >=60 min/day of moderate/vigorous physical activity.
11106775|NCT04028921||Overweight/obese, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, <60 min/day of moderate/vigorous physical activity.
11106776|NCT04028895|Other|Experimental|
11106777|NCT04028882||Non viremic HIV patients under treatment|Patients with various immune activation profiles
11106778|NCT04028869||Glycyrrhizin preparation treatment group|Clinical effect of glycyrrhizic acid preparation for 144 weeks of autoimmune liver disease and safety during treatment
11106779|NCT04028856||Continuous interferon treatment group|Patients with chronic hepatitis B treated with continuous interferon for 48 weeks
11106780|NCT04028856||Intermittent interferon treatment group|patients with chronic hepatitis B treated with intermittent interferon for 48 weeks, in which interferon therapy was intermittent for 3 months
11106781|NCT04028843|No Intervention|WIC Nutrition|Participants will receive weight management advice and care through the standard Women, Infants, and Children program. They will also receive weekly health information related to pregnancy, birth, and infant health through a closed Facebook group.
11106782|NCT04028843|Experimental|Healthy Beginnings|Participants will receive the SmartMoms smartphone application, a wireless connected scale, and a Fitbit. The Healthy Beginnings program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the SmartMoms smartphone application, personalized feedback from counselors, and evidence-based behavioral intervention delivered throughout pregnancy.
11106783|NCT04028830|Experimental|Arm 1|Medical representative presentation with the help internet tool for decision ANTIBIOCLIC
11106784|NCT04028830|Experimental|Arm 2|Medical representative presentation without presentation of the internet tool for decision support
11106785|NCT04028830|No Intervention|Arm 3|Usual practice without intervention regarding the prescription of antibiotics
11106786|NCT04028817|Experimental|group treatment|This group will receive laser treatment combined with low intensity exercises
11106787|NCT04028817|Placebo Comparator|group control|This group will receive placebo laser treatment combined with low intensity exercises
11106788|NCT04028804||FDG PET|FDG PET imagaing
11106789|NCT04028804||FLT PET|FLT PET imaging
11106790|NCT04028791|Experimental|AS and AA|Participants will be submitted to 45 minutes of exercise on ergocycle.
11106791|NCT04028778|Experimental|Gefitinib + Anlotinib|Patients will be treated with Gefitinib 250mg, p.o., qd and anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle.
11106792|NCT04028778|Placebo Comparator|Gefitinib + Placebo|Patients will be treated with Gefitinib 250mg, p.o., qd and placebo to simulate anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; take on an empty stomach (take at the same time every day as possible), every 3 weeks for a cycle
11106793|NCT04028765|Active Comparator|Oral Misoprostol|Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated
11106794|NCT04028765|Active Comparator|Oxytocin|IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol
11106795|NCT04028752||Males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
11106797|NCT04028739|Experimental|Theracurmin CR-031P|3 Capsule with 150mL water, Single, curcumin 90mg/day
11106798|NCT04028739|Experimental|Curcumin|1 Capsule with 150mL water, Single, curcumin 90mg/day
11106799|NCT04028726|Active Comparator|Cluster set Resistance Training Protocol|Cluster set configuration is the new training approach that it is being tested.
11106800|NCT04028726|Sham Comparator|Traditional Resistance Training Protocol|Traditional is commonly used in training sessions.
11106801|NCT04028713|Active Comparator|Standard dosing group|Patients will continue to receive adalimumab according to the standard dosing schedule.
11106802|NCT04028713|Experimental|Dose tapering group|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
11106803|NCT04028700|Experimental|G6DP Deficient Red Blood Cell Transfusion|Transfusion of red blood cells that have been identified by local laboratory procedures to be deficient in G6PD enzyme activity.
11106804|NCT04028700|Active Comparator|Non-G6DP deficient Red Blood Cell Transfusion|Transfusion of red blood cells that have been identified by local laboratory procedures to not be deficient in G6DP enzyme activity.
11106805|NCT04028687||Taperloc Complete Stems|Patients that have been implanted with a Taperloc Complete Stem to repair hip malfunction/disease.
11106806|NCT04028674|Experimental|Early Activation of Laryngeal Pacing device|Early Activation of the laryngeal pacing device (n=9) at one month post-implantation.
11106807|NCT04028674|Sham Comparator|Delayed Activation of Laryngeal Pacing device|Delayed activation of the laryngeal pacing device (n=3) at two months post-implantation.
11106808|NCT04028661|Experimental|Intervention group|use of 3D printed Modified Twin Block Appliance.
11106809|NCT04028661|No Intervention|Untreated control group|No treatment phase of 8 months.
11106810|NCT04028648||elderly|150 elderlies (>60 years): community dwelling or living in old
11106811|NCT04028635|Experimental|Cognitive-behavioral therapy plus VR-based body exposure|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, six sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which the they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions, until a healthy BMI value is reached.
11106812|NCT04028635|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the centre in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
11106813|NCT04028622|Experimental|TCAD (telemedicine anesthesia consultation)|Patients having a telemedicine anesthesia consultation
11106814|NCT04028609|Experimental|Intervention|Subjects receive an intervention with 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.
11106815|NCT04028609|Active Comparator|Services as Usual|Subjects receive medical services as usual.
11106816|NCT04028596|Active Comparator|Acetaminophen|Trade name: Paracetamol Pharmaceutical form: Tablet (oral use) Once 1000 mg 2h before the ECT-session. Total maximum of five times over the course of weeks
11106817|NCT04028596|Active Comparator|Nimodipine|Trade name: Nimotop Pharmaceutical form: Film-coated tablet (oral use) Once 60mg 2h before the ECT-session. Total maximum of five times over the course of weeks.
11106818|NCT04028596|No Intervention|Control|Glass of water (50cc) only. Once 2h before the ECT-session. Total maximum of five times over the course of weeks.
11106819|NCT04028583|Experimental|PIM-Check group|
11106820|NCT04028583|Active Comparator|STOPP/START group|
11106821|NCT04028570|Experimental|Radiation|This study involves a 3+3 design. The starting cohort (n=3) will receive a neoadjuvant Background dose to the affected hemithorax (starting at 0 cGy) as well as concomitant Boost dose (of at least 2100 cGy) to a part of the gross tumour volume (GTV). The radiation will be delivered over 3 alternate days over 5-7 calendar days followed by macroscopically complete extensive pleural resection (either extra-pleural pneumonectomy or extended pleurectomy decortication, at the surgeon's discretion) after 7 to 14 days. If no dose limiting toxicities (DLTs) seen, then the Background RT dose will be increased by 600 cGy (up to 1800 cGy) and the cohort (n=3) for the next dose level will be accrued. If only 1 DLT seen, then an additional 3 patients will be treated on this dose level. If 2 or more DLTs seen at any given dose level, then the previous dose level will be defined as the maximum tolerated dose (MTD). Patients will be stratified by type of resection.
11106822|NCT04028557|Experimental|Customized CDS|The customized CDS will be designed and implemented with comprehensive application of known best practice principles in CDS design. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
11106823|NCT04028557|Active Comparator|Commercial CDS|The commercial CDS is available to all institutions using the Epic electronic health record vendor, but violates some CDS design best practices, notably not being tailored to the end users of a given health system. The recommendation will be to initiate an evidence-based beta blocker for heart failure.
11106824|NCT04028544|Experimental|The Treatment Group|standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
11106825|NCT04028544|Placebo Comparator|The Control Group|standard treatment + placebo (oral use, 1 bag each time, three times a day).
11106826|NCT04028531||Sample Collection|"Blood tests required for assessment
~Specimens and data will also be collected from outside sites
~Clinical data from patients with Chronic Lymphocytic Leukemia will be gathered into a database at Dana Farber Cancer Institute"
11106827|NCT04028518|Experimental|The high-dose group|"Experimental: r-PA Dose: stick 18 mg;
~Mode of admin:
~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
11106828|NCT04028518|Experimental|The low-dose group|"Experimental: r-PA Dose: stick 18 mg;
~Mode of admin:
~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.Subjects were closely monitored during the medication and within 24 hours of administration."
11107110|NCT04026438|Experimental|Intervention Arm - potassium phosphate injection|
11106829|NCT04028518|Experimental|Active Comparator: Alteplase|"Active Comparator: Alteplase Drug: Alteplase for Injection Dose:50mg;20mg
~Mode of admin:
~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours of medication.Subjects were monitored according to the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018."
11106830|NCT04028505|Experimental|Terlipressin Continuous Infusion|Standard of care being given at AKUH + Continuous infusion of Terlipressin (Terlipressin Injectable Product) at a rate of 0.5mg/hour for the first 24 hours
11106831|NCT04028505|Active Comparator|Terlipressin Bolus Infusion|Standard of care being given at AKUH + Bolus infusion of Terlipressin (Terlipressin Injectable Product) at a frequency of 2mg every six hourly for first 24 hours
11106832|NCT04028492|Experimental|Tradipitant|Oral Capsule
11106833|NCT04028492|Placebo Comparator|Placebo|Oral Capsule
11106834|NCT04028479||Validation Cohoirt|Patients enrolled into the study to allow validation of a specific element, process, or endpoint. Validation will be done showing concordance with traditional interventional trial standards.
11106835|NCT04028479||Analysis Cohorts|Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit. Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study. Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
11106836|NCT04028466|Experimental|Vonoprazan|Patients will be randomized to receiving vonoprazan, which will be taken 30 minutes before the first meal of the day for 14 days
11106837|NCT04028466|Active Comparator|Omeprazole|Patients will be randomized to receiving omeprazole, which will be taken 30 minutes before the first meal of the day for 14 days
11106838|NCT04028453||Mother|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation questionnaire.
11106839|NCT04028440|Experimental|Autologous γδT cells|Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions, single infusion intravenously at a target dose of 1~2×10e9 γδT cells (constant dose).
11106840|NCT04028427|Experimental|Participants randomly assigned to VGI|
11106841|NCT04028427|Experimental|Participants randomly assigned to MBI|
11106842|NCT04028414|Experimental|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
11106843|NCT04028414|No Intervention|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
11106844|NCT04028401|Experimental|5 % benzoyl peroxide topical treatment|Application of 5% benzoyl peroxide
11106845|NCT04028401|No Intervention|No topical treatment|No intervention
11106846|NCT04028388|Active Comparator|Docetaxel IV|This study arm will receive docetaxel at 75 mg/m2 given i.v. as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily.
11106847|NCT04028388|Experimental|ModraDoc006/r|This cohort will receive ModraDoc006/r 30 mg oral docetaxel in combination with 200 mg ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in the evening (7-12 hours after the morning dose), on Day 1, 8 and 15 of a 21-day cycle, plus 5 mg oral prednisone twice daily.
11106848|NCT04028362||Neuromuscular blockade|Patients who will receive neuromuscular blockade during their ICU length stay will be follow until day 28 or their hospital discharge.
11106849|NCT04028349|Experimental|Single Arm|Ad26.ZEBOV/ MVA-BN-Filo Vaccines
11106850|NCT04028336|Experimental|TITRATION|"All patients hospitalized in intensive care and meeting inclusion criteria and without criteria for non-inclusion will be included in this study. All patients will benefit from Lung ultrasound (LUS) and esophageal pressure measurement (Peso) according to the habits of the service. A PEP titration pulmonary opening (PEP-OP) test using a recruitment maneuver was then performed in all patients followed by a new LUS and Peso measurement."
11106851|NCT04028323|Experimental|Experimental group|Drug: Terlipressin. Terlipressin should be administrated with an initial dose of 1-2 mg intravenously and slowly injected (over 1 minute) while monitoring the heart rate and blood pressure. The maintenance dose should be administrated every 4-6 hours. Each dose of terlipressin is 1mg. The usual duration of therapy is 3-5 days.
11106852|NCT04028323|Active Comparator|Control group|Drug: Octreotide. Octreotide should be continuously and intravenously dripped at the speed of 0.025-0.05 mg/h and could be diluted with saline with the maximum duration of 5 days. The usual duration of therapy is 3-5 days.
11106853|NCT04028310|Experimental|Phonological group|
11106854|NCT04028310|Experimental|visual-attention group|
11106855|NCT04028284|Active Comparator|Group 1|In Group 1 (control), the staff anesthesiologist will follow the traditional technique for US-guided thoracic epidural insertion. Briefly, the anesthesiologist will use the US to identify and mark the appropriate spot for placement of the thoracic epidural catheter. The US probe is then placed at rest and the anesthesiologist will proceed with thoracic epidural needle insertion following standard techniques.
11106888|NCT04027985|Experimental|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
11107111|NCT04026438|No Intervention|Control Arm|
11107112|NCT04026425|Experimental|ME/CFS|Adults with ME/CFS
11106856|NCT04028284|Active Comparator|Group 2|In Group 2 (intervention), the staff anesthesiologist will use the HoloLens tool to assist with the traditional technique as described above for Group 1. In combination with the US, a hologram image of the trajectory towards the epidural space will be generated, thereby mitigating the need to walk off the lamina. The holographic system will mark the appropriate spot for placement of the thoracic epidural catheter. Then, the needle will be inserted following the holographic trajectory overlaid on the patient's back.
11106857|NCT04028271|Experimental|experimental|local anesthesia applyed with Comfort in system
11106858|NCT04028271|Active Comparator|conventional injection|local anesthesia applyed with conventional syringe
11106859|NCT04028258|Other|Group A: study+wash out+control|Study product (3 weeks) + wash out (2 weeks) + control product (3 weeks)
11106860|NCT04028258|Other|Group B: control+wash out+study|Control product (3 weeks) + wash out (2 weeks) + study product (3 weeks)
11106861|NCT04028245|Experimental|Spartalizumab and Canakinumab|Subjects with renal cell carcinoma will receive study treatment Q4 weeks x 2 doses prior to radical nephrectomy.
11106862|NCT04028219||Transgender patients|Gender dysphoric patients undergoing hormone treatment
11106863|NCT04028206|No Intervention|Control Group|No intervention on sarcopenic subjects screened (based on the AWGS definition).
11106864|NCT04028206|Active Comparator|Exercise + HMB Group|Sarcopenic subjects on combined treatment of elastic-band exercise and HMB supplementation
11106865|NCT04028206|Active Comparator|Vibration Treatment + HMB Group|Sarcopenic subjects on combined treatment of vibration treatment and HMB supplementation
11106866|NCT04028193|Other|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
11106867|NCT04028193|Other|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
11106868|NCT04028180|Experimental|Midge Repellency|Treatment of forearm with insect repellent and exposure to midges every 1 hour for 12 hours
11106869|NCT04028167|Experimental|Sequential FLOT followed by chemoradiation|Sequential Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/Leucovorin followed by chemoradiation with concurrent carboplatin and paclitaxel
11106870|NCT04028154|Experimental|ESP Block|
11106871|NCT04028154|Active Comparator|TLIP Block|
11106872|NCT04028141||participants undergoing procedural sedation|"The study gathered observational data about participants who underwent procedural sedation according to the new standard protocol with ketofol in a 1 on 4 concentration.
~The participant was observed for complications or cardiorespiratory interventions by the sedating physician until he was fully awake. Thirty minutes after the awakening, the participant was questioned for his remembrance and perception of the sedation and procedure. He was observed for complications until discharge"
11106873|NCT04028128|Experimental|Cocoa group|The cocoa was provided in 5 g sachets. The intervention last 10 weeks. Cocoa was provided in a single daily dose of 5 g, which provided 425 mg of flavonoids
11106874|NCT04028128|Placebo Comparator|Placebo group|Maltodextrin (5 g) was supplied as placebo in sachets identical to those provided for cocoa.
11106875|NCT04028115|Experimental|Interventional|Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. In this, study no randomisation will occur. All patients will receive the same treatment.
11106876|NCT04028089|Experimental|Diet Modification Group|
11106877|NCT04028089|Other|Regular Diet Group|
11106878|NCT04028076|Experimental|Peers LEAD|8-week educational behavioral intervention
11106879|NCT04028063|Experimental|doxorubicin with AGEN1884 and AGEN2034|Doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. Doxorubicin dosing is standard at 75 mg/m2 via Bolus with prior Dexrazoxane. AGEN2034 - 300 mg IV over 60min with infusion pump. AGEN1884 - 1 mg/kg IV over 90 min (-10 /+20 min) with infusion pump, within 30 minutes (0 / +20) of completion of AGEN2034.
11106880|NCT04028050|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
11106881|NCT04028037|Experimental|FTPG treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. In Test group, the harvest of palatal graft was performed using FTPG technique. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
11106882|NCT04028037|Active Comparator|Sub-epithelial connective tissue graft (SCTG) treated patient|the recipient bed preparation was made according to langer&langer modified technique. Intrasulcular incision was performed from at least one tooth mesial and at least one tooth distal to the teeth with gingival recession. No vertical incisions were made to provide better blood supply. A partial thickness flap was created. To ensure an effective randomization only at this stage the patients were assigned to the test and to the control group.In control group trap door technique was used to obtain connective palatal graft. SCTG was adapted to recipient site in way that the first mm upon cementoenamel junction (CEJ) was covered , the flap is stabilized with interrupted sutures. The palatal graft was adapted to recipient site in order to put on exposed root the full thickness area, that having been custom designed it will fill perfectly the box of the recession. Interrupted suture was completed.
11106883|NCT04028024|Other|inhibiting systemic inflammatory response|Ulinastatin 5000U/kg in 20ml NS i.v. before occlusion of aorta
11106884|NCT04028011||PSG and novel wearable device|75 patients will wear polysomnography at the same time as the Novel wearable device
11106885|NCT04028011||PG and novel wearable device|75 patients will wear polygraphy at the same time as the novel wearable device
11106886|NCT04027998||Carpal tunnel syndrome|group of carpal tunnel syndrome patients
11106887|NCT04027998||Control group|group of healthy controls
11106889|NCT04027985|Sham Comparator|Control group|the patients will receive sham KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
11106890|NCT04027972|Experimental|Primary|6 Subjects will receive all 4 types of medication administration in random sequence
11106891|NCT04027959|Experimental|Epilation|Hair epilated prior to application of Vitamin B12 solution to skin
11106892|NCT04027959|Experimental|Oleic Acid|Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin
11106893|NCT04027959|Experimental|No Prep|Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin
11106894|NCT04027946|Experimental|Arm 1|LMB-100 administered in cycles 1 and 2. Pembrolizumab administered in subsequent cycles
11106895|NCT04027933|Active Comparator|Experimental|Education Based on Standard Patient Simulation was given to this group
11106896|NCT04027933|No Intervention|Control|Control group
11106897|NCT04027907||T2DM|
11106898|NCT04027907||healthy controls|
11106899|NCT04027894|Experimental|Rifamycin SV MMX plus ORT|
11106900|NCT04027894|Placebo Comparator|Placebo tablets plus ORT|
11106901|NCT04027881|Experimental|STAR - immediate|Receive 15-week STAR intervention immediately after pretest.
11106902|NCT04027881|No Intervention|STAR - waitlist control|No intervention for the 15 weeks after pretest.
11106903|NCT04027855|Other|collection of PBMC from healthy donors|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.
~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
11106904|NCT04027842|Experimental|Prewarming group|Participants in Prewarming group was warmed with forced air warming device (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) over the entire body for 10 minutes before anesthesia was induced in the operating theater. All participants received active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
11106905|NCT04027842|No Intervention|Non-prewarming group|In Non-prewarming group, no active warming was conducted before induction of anesthesia. Only standard care was provided with introperative active warming with forced air warming system from the initiation of anesthetic induction until end of surgery.
11106906|NCT04027829|Experimental|Dexmedetomidine|Intravenous infusion of dexmedetomidine for 50 min after surgery at intensive care unit
11106907|NCT04027803|Experimental|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
11106908|NCT04027803|Active Comparator|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
11106909|NCT04027790||Group 1 - Cancer Patients|Subjects with known colorectal cancer (i.e. AJCC/UICC stages 0, I, II, and III) who provide plasma at least 7 days after diagnosis by colonoscopy, but prior to surgery or treatment
11106910|NCT04027790||Group 2 - Screening Subjects|Prospectively enrolled subjects reporting for screening colonoscopy who provide a blood sample up to 2 weeks prior to bowel prep and prior to colonoscopy. We accept all subjects who meet the institutional criteria as average risk subjects referred for a screening colonoscopy for colorectal cancer, including subjects undergoing a colonoscopy as a follow-up to a positive (non-colonoscopic) test
11106911|NCT04027777|Experimental|Aktiia.product-P0|Single study arm including 85 subjects
11106912|NCT04027764|Experimental|Toripalimab Combined With S1 and Albumin Paclitaxel|
11106913|NCT04027751|Experimental|Tropisetron|Patients allocated to this arm will receive single dose of intravenous Tropisetron (5mg) before anesthesia induction.
11106914|NCT04027751|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of saline solution before anesthesia induction.
11106915|NCT04027738|Experimental|PRP injection|The patients received a single 3-ml injection of PRP.
11106916|NCT04027725|Experimental|Sensorimotor neurofeedback training group|"Three interventions will be administered :
~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours.
~The third intervention is the neurofeedback training sensorimotor that will be recorded at channel Cz according to the international 10-20 system."
11106917|NCT04027725|No Intervention|Control Group|"Three interventions will be administered :
~An electroencephalography recording (EEG) for 30 minutes with an electrocap of 19 scalp locations according to the international 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2hours
~The psychopedagogical care: each session will be organized using the same video material"
11106918|NCT04027699|Experimental|Mini-bolus|"First injection of 2ml/kg (saline solution)
~Second injection of 18ml/kg (saline solution)"
11106919|NCT04027686|Experimental|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
11106920|NCT04027686|Active Comparator|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
11106921|NCT04027673|Experimental|Treatment|Participants in the treatment group complete interactive modules. They will be asked to complete one module per week, for a total of eight weeks.
11106922|NCT04027673|No Intervention|Control|Participants in the control group will have no active study requirements for the eight weeks following Survey Session 1.
11106949|NCT04027465|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses of egg protein, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
11106950|NCT04027452|Experimental|Traumatic memory reactivation|Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
11106923|NCT04027660||Exposed Immediate Zirconia Implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications to be enrolled in an immediate implant.
~No Active Infection
~No loss of buccal plate
~ASA 1 or ASA 2 Patient
~Extraction of the tooth will be performed and in the same clinical act, a zirconia dental implant will be placed toghether with a provisional or an individualized customs healing abutment. The jumping gap will be filled with a xenograft biomaterial.
~Final Zirconia Crown delivered 3 month after healing.
~3 STL files will be generated - Before extraction, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion
~Measure 1,2 and 3 will be at the gingival margin(measure 1), at 2mm (measure 2) and 4 mm (measure 3) apical to gingival margin. Both palatal and buccal references are joined by a line that gives a distance.Difference on the dimensions of each line with different time of evaluation represent ridge loss."
11106924|NCT04027660||Non-exposed delayed Zirconia implants|"Group Formation : patients that require a tooth extraction and have the following clinical indications not to be enrolled in an immediate implant.
~Active Infection
~Loss of the buccal plate.
~Extraction will be performed but a classical implant approach will be made, that include a waiting period of 3 month before implant placement and 3 month after osseointegration period before place final crown.
~Implant placement with Guided bone regeneration (xenograft), if needed. Final Zirconia Crown 3 month after implant placement.
~4 STL files will be generated - Before extraction, before implant placement, at Final impression level 3 month after implant placement, at 3 month after final prosthesis insertion
~Measure 1,2 and 3 the same has the other group"
11106925|NCT04027647|Experimental|Treatment|Daily administration of oral Dacomitinib
11106926|NCT04027634|No Intervention|Control group|The control group (CG) received routine care and was required to walk during 6-7 pm.
11106927|NCT04027634|Experimental|Baduanjin program|The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
11106928|NCT04027621|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
11106929|NCT04027621|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
11106930|NCT04027582|Active Comparator|Low Fidelity Simulator - Wooden block|This simulator consists of a simple series of wooden panels with holes. The resident learns how to manipulate the fiberoptic bronchoscope through the holes.
11106931|NCT04027582|Active Comparator|High fidelity Simulator - ORSIM|The ORSIM® bronchoscopy is a virtual reality simulator (Airway Simulation Limited, Auckland, New Zealand). It consists of hardware and software components that interact to create a high-fidelity virtual reality simulation. A replica fiberoptic scope is advanced by the resident through a desktop sensor, which is connected to a laptop computer. The laptop software program provides a virtual airway in which the user must navigate the probe.
11106932|NCT04027569|Active Comparator|PSFS group|Patients in this arm will complete the patient specific functional scale (PSFS) during their visits
11106933|NCT04027569|Experimental|PROMIS PF group|Patients in this arm will complete the PROMIS Physical Function during their visits
11106934|NCT04027556|Experimental|Low dose - lean body weight|Low CT contrast media dose calculated based on lean body weight
11106935|NCT04027556|Active Comparator|Standard dose|Standard CT contrast media dose calculated based on total body weight
11106936|NCT04027543||Neoadjuvant chemoradiotherapy|Patients who had chemoradiotherapy before surgery.
11106937|NCT04027543||Neoadjuvant chemotherapy|Patients who had chemotherapy before surgery.
11106938|NCT04027543||Surgery alone|Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
11106939|NCT04027530|Experimental|Ertugliflozin 15mg once daily|Once daily treatment with oral ertugliflozin (steglatro) 15mg for 4 consecutive weeks.
11106940|NCT04027530|Placebo Comparator|Placebo|Once daily treatment with a placebo pill for 4 consecutive weeks.
11106941|NCT04027517|Experimental|JTZ-951|Oral doses once daily
11106942|NCT04027517|Active Comparator|Darbepoetin Alfa|Intravenous doses of Darbepoetin Alfa administered once weekly
11106943|NCT04027504|Experimental|Fitabisc|Participants receiving fitabisc preoperatively
11106944|NCT04027491|Experimental|Virtual reality intervention|"Participant undergo 12 treatment sessions, during a 4-week period (3 sessions per week).
~Each intervention session lasts 45 minutes."
11106945|NCT04027491|No Intervention|Observational|Participant undergo a 4 weeks observational period. No intervention are performed.
11106946|NCT04027478|Active Comparator|FMD (fasting-mimicking diet)|Over the course of three rounds of chemotherapy, patients in the FMD will consume a diet that consists of 10 cal/kg/day and includes 50% fat, 40% carbohydrates, and no more than 10% protein. The diet includes nuts, olives, vegetable broth, broccoli/cauliflower, white rice/puffed rice cake, onion, tea/coffee, almond milk. The diet prohibits meat products, dairy, alcohol, sugar, and artificial sweeteners. Patients will be instructed to drink 2 cups of water each morning, take their usual medications and limit exercise to walking.
11106947|NCT04027478|No Intervention|regular diet|Diet not influenced by a fast-mimicking diet.
11106948|NCT04027465|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
11106951|NCT04027452|Placebo Comparator|Neutral memory reactivation|Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
11106952|NCT04027439|Active Comparator|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
11106953|NCT04027439|Active Comparator|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
11106954|NCT04027426|Active Comparator|FBT (family-based behavioral treatment)|This condition will be prescribed the Traffic Light Diet (1000-1500 kcal/day, < 2 servings/day of RED [non-nutrient-dense, energy-dense] foods) and a > 60 min/day of MVPA prescription for children and > 30 min/day of MVPA for adults at least 5 days/week. FBT will receive a family-based, behavioral intervention to assist the targeted child and a participating adult caregiver with making changes in energy balance behaviors.
11106955|NCT04027426|Experimental|FBT+Variety|The FBT+Variety condition will receive FBT along with a limited variety prescription. In this prescription families will identify two RED foods, a dinner entree and snack food, and develop meal plans that reduce variety of RED foods by regularly consuming these foods and limiting consumption of other RED entrees and snack foods.
11106956|NCT04027413|Placebo Comparator|Placebo/ Control|participants in this group will receive carbohydrate product which does not include protein at all
11106957|NCT04027413|Experimental|Intervention group|Participants in this group will receive high protein product
11106958|NCT04027400|Active Comparator|Primarily visual computer exercises|Participant performs visual computer exercises 30 minutes a day, five days a week for one month.
11106959|NCT04027400|Experimental|Visual+Audio|Participant performs audio computer exercises and some visual computer exercises 30 minutes a day, five days a week for one month
11106960|NCT04027387|Experimental|TMB-365 400 mg- Group 1|Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
11106961|NCT04027387|Experimental|TMB-365 800 mg- Group 2|Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
11106962|NCT04027387|Experimental|TMB-365 1600 mg- Group 3|Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
11106963|NCT04027374||Fetal surgery group|Newborns after successful fetal surgery for MMC, delivered by elective c-section at weeks 35;0 - 37;0.
11106964|NCT04027374||Glucocorticoid control group|Healthy newborns after exposure to synthetic glucocorticoids for lung maturity during pregnancy, delivered by elective c-section between 35;0 - 40;0 weeks, matched for child sex with group 1. This group is needed to control for the effects of sGC exposure.
11106965|NCT04027374||Healthy controls|Healthy newborns, uncomplicated pregnancy, delivered at term by elective c-section between 36;0 - 39;0 weeks. Matched for child sex with group 1.
11106966|NCT04027361|Active Comparator|Amphetamine ER Tablets, 20 mg|Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline
11106967|NCT04027361|Placebo Comparator|Placebo|Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline
11106968|NCT04027348|Experimental|Treatment (octreotide, dexamethasone, metoclopramide)|IV octreotide 300 mcg TID + IV dexamethasone 4 mg BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.
11106969|NCT04027335|Experimental|Leva Arm|Subjects will undergo training in the use of a vaginal device and its associated app, to be used twice daily to perform pelvic floor muscle exercises guided by the device/app for 10 weeks.
11106970|NCT04027322|Active Comparator|Budesonide|"Drug Name: budesonide Dose: 2000mcg (2mg) of budesonide nebulizer solution is mixed with normal saline solution to make a total volume of 8mL.
~Frequency: Stat Dose Route: Nebulization"
11106971|NCT04027322|Active Comparator|Dexamethasone|"Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.
~Frequency: Stat Dose Route: Nebulization"
11106972|NCT04027322|Placebo Comparator|Control|Drug Name: Normal Saline Dose: 8ml. Frequency: Stat Dose Route: Nebulization
11106973|NCT04027309|Active Comparator|Arm A (Midostaurin)|Midostaurin (50 mg BID PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
11106974|NCT04027309|Experimental|Arm B (Gilteritinib)|Gilteritinib (120 mg QD PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
11106975|NCT04027296||suspected COPD|Patients aged >35yo and > 10Pack.Year
11106976|NCT04027283|Active Comparator|Erythritol|18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
11106977|NCT04027283|Active Comparator|Erythritol + lactisole|18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
11106978|NCT04027283|Active Comparator|D-allulose|18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
11106979|NCT04027283|Active Comparator|D-allulose + lactisole|18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
11106980|NCT04027283|Placebo Comparator|Tap water|18 volunteers receive 300mL tap water via a nasogastric tube
11106981|NCT04027283|Placebo Comparator|Tap water + lactisole|18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
11106982|NCT04027270|No Intervention|Standard of Care|These individuals will receive standard of care for post operative recovery following a prostatectomy.
11106983|NCT04027270|Experimental|Physical Therapy|These individuals will receive post operative physical therapy in addition to standard of care for post operative recovery following a prostatectomy.
11106984|NCT04027257|Experimental|STAR|Receive 15-week STAR intervention immediately after pretest.
11106985|NCT04027257|No Intervention|Waitlist Control|No intervention for the 15 weeks after pretest.
11106986|NCT04027244||Primary cohort|Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
11106987|NCT04027244||Frailty & cognitive additional assessments|Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
11106988|NCT04027244||Cardiac MRI additional assessments|Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
11106989|NCT04027244||Biomarkers additional assessments|Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
11106990|NCT04027244||Historical cohort|Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
11106991|NCT04027231||Ahlback I|
11106992|NCT04027231||Ahlback II|
11106993|NCT04027231||Ahlback III|
11106994|NCT04027231||1 year following TKA|
11106995|NCT04027231||TKA revision|
11106996|NCT04027218|Active Comparator|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.
~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
11106997|NCT04027218|Active Comparator|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.
~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
11106998|NCT04027218|Active Comparator|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.
~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
11106999|NCT04027205|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
11107000|NCT04027205|Active Comparator|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation.
11107001|NCT04027192|Experimental|Bridging part: intervention sequence ABC or BAC|10 healthy male participants will be randomly allocated to this arm. The study interventions will follow the sequence ABC or BAC: A: single dose of 50 mg BAY2328065 given as LSF in fasted state B: single dose of 50 mg BAY2328065 given as tablet in fasted state C: single dose of 50 mg BAY2328065 given as tablet in fed state (i.e. after a high caloric and high fat meal)
11107002|NCT04027192|Experimental|Multiple dose escalation part: dose 1|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day"
11107003|NCT04027192|Experimental|Multiple dose escalation part: dose 2|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
11107004|NCT04027192|Experimental|Multiple dose escalation part: dose 3|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
11107005|NCT04027192|Experimental|Multiple dose escalation part: dose 4|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by twice daily doses for 10 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
11107006|NCT04027192|Experimental|Multiple dose escalation part: dose 5|"10 participants will be randomly allocated to active drug or placebo (8 active drug, 2 placebo).
~The study intervention will be administered with a single dose on the first dosing day followed by a treatment pause of 2 days followed by twice daily doses for 1 day followed by three times daily doses for 9 days followed by a single dose on the last dosing day Midazolam is given for investigation of drug-drug interaction"
11107007|NCT04027179|Experimental|FMS chlorhexidine mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of 0.12% chlorhexidine gluconate mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with 0.12% chlorhexidine gluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
11107008|NCT04027179|Placebo Comparator|FMS placebo mouthwash|Full-mouth scaling and root planning with manual curettes, 20 ml of placebo mouthwash irrigation of each periodontal pocket of 5mm of more. Patients will rinse with placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
11107009|NCT04027179|Active Comparator|FMS no mouthwash|Full-mouth scaling and root planning with manual curettes.
11107010|NCT04027166|Experimental|administration immediate|Methadone will be administered prior to study procedures
11107011|NCT04027166|Experimental|administration delayed|Methadone will be held for four hours until the end of all study procedures.
11107012|NCT04027153|Experimental|Fee Arm|Participants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice.
11107013|NCT04027153|Active Comparator|Standard of Care Arm|Participants in this arm will pick up their medication refill at the local clinic
11107014|NCT04027127|Active Comparator|ACS GRUP|"Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared.
~GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared."
11107015|NCT04027127|Active Comparator|plasebo grup|It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.
11107016|NCT04027114|Experimental|Behavioural Physical Activity (PA) intervention|
11107017|NCT04027114|No Intervention|Wait list control|
11107018|NCT04027101|Experimental|Experimental group|Oral baricitinib 4mg/day for 12 weeks. Then, at week 12, if PMR-AS≤10, patients will receive baricitinib 2 mg for 12 weeks. If PMR-AS ≤10, the patients will not receive any treatment until W24 At W24, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1 mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) according to investigator's opinion.
11107019|NCT04027101|Placebo Comparator|Control group|Oral placebo every day during 3 months (W12). Then, at week 12, if PMR-AS ≤10, placebo for 12 weeks. If PMR-AS ≤10, the patients do not receive any treatment until a flare. If PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS<10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d or more according to investigator's opinion). Dosage of GCs will be decreased (1mg every week) or increased according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 20 increase, 10 ≤ PMR-AS ≤ 20: stable dose) and according to investigator's opinion.
11107020|NCT04027088|Experimental|Immunonutrition|Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
11107021|NCT04027088|Placebo Comparator|Standard|Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
11107022|NCT04027075|Experimental|Intervention|This group will be asked to use the Rewire app daily in the month following the baseline assessment. This group will also receive services as usual from the Department of Youth Services.
11107023|NCT04027075|No Intervention|Services as usual|This group will receive services as usual from the Department of Youth Services.
11107024|NCT04027062|Other|Diabetes Continuing Education Program|"the physicians will be assessed before and after intervention
~the intervention group will be enrolled to the intervention program proposed to be (lecture + interactive workshop + group discussion + role play)"
11107025|NCT04027049|Experimental|Supine cycle ergometry of the lower extremities|Patients will receive two 20 minute cycle ergometry sessions separated by at least 4 hours in addition to usual care. The cycle will be set to a gear of zero and will begin in passive mode, the patient will be able to actively cycle if patients are able.
11107026|NCT04027049|No Intervention|Control|Patients will receive usual care only.
11107027|NCT04027036|Active Comparator|fIPV Intramuscular|180 children will receive 0,1 ml of inactivated poliovirus vaccine intramuscularly
11107028|NCT04027036|Active Comparator|fIPV Intradermal|180 children will receive 0,1ml of inactivated poliovirus vaccine intradermally
11107029|NCT04027010|Experimental|"Healthy U tablet application"|Healthy U is a self-administered intervention implemented through a tablet app with interactive learning experiences, including videos, digital games, quizzes, and role-plays. Healthy U takes youth 3-4 hours to complete. The goals of Healthy U are to: 1) Increase male youth's perception of vulnerability to unplanned fatherhood, STDs and HIV; 2) Increase male youth's self-efficacy for negotiating condom use with their partners; 3) Increase male youth's self-efficacy for using condoms correctly and consistently every time they have sex; and 4) Increase male youth's engagement with goals and dreams for their future.
11107030|NCT04027010|No Intervention|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition. OYA does not provide much programming to youth in its facilities related to sexual health and pregnancy prevention.
11107031|NCT04026997|Experimental|Cohort 1|CIN-102 tablets by mouth twice daily for 14 days
11107032|NCT04026997|Placebo Comparator|Cohort 1 - Placebo|Placebo tablets by mouth twice daily for 14 days
11107033|NCT04026997|Experimental|Cohort 2|CIN-102 tablets by mouth twice daily for 14 days
11107034|NCT04026997|Placebo Comparator|Cohort 2- Placebo|Placebo tablets by mouth twice daily for 14 days
11107035|NCT04026997|Experimental|Cohort 3|CIN-102 tablets by mouth twice daily for 14 days
11107036|NCT04026997|Active Comparator|Cohort 3- Placebo|Placebo tablets by mouth twice daily for 14 days
11107037|NCT04026984|Experimental|Rifamycin SV MMX plus ORT|
11107038|NCT04026984|Placebo Comparator|Placebo tablets plus ORT|
11107039|NCT04026971|Experimental|Phone Application Supported Nutrition Education|Classic nutrition training and diet list is provided. Then notification was sent to obese patients for 3 months by phone application named 'MotiVe'
11107040|NCT04026971|Other|Classical Nutrition Education|Classic nutrition training and diet list is provided.
11107041|NCT04026958|Experimental|Clarithromycin|Participants in this study arm will receive clarithromycin for 14 days.
11107042|NCT04026958|Placebo Comparator|Placebo|Participants in this study arm will receive a placebo to match clarithromycin for 14 days.
11107043|NCT04026945|Other|Active Treatment (ST-CP) Group|"This study uses a dose-escalating approach in the active treatment arm. There is no comparator product. All qualifying patients receive the active treatment ST-CP as an injection in the region around the spermatic cord. The following dosing cohorts will be used:
~I: 1 x 2 mL of 140 mg/mL ST-CP (= 280 mg lidocaine) II: 1 x 3 mL of 140 mg/mL ST-CP (= 420 mg lidocaine) III: 1 x 4 mL of 140 mg/mL ST-CP (= 560 mg lidocaine)"
11107044|NCT04026932|Placebo Comparator|Unmodified music group|34 participants in Group 1 will listen to the music without any modification for at least two hours a day in total.
11107045|NCT04026932|Experimental|Modified tinnitus relieving sound group|34 participants in Group 2 will listen to the music modified according to the matched dominant tinnitus pitch for at least two hours a day in total.
11107046|NCT04026919|Experimental|to analyze the effectiveness of Ok en Casa Zaindoo|The multicomponent online programme is composed of the components explained in the detailed study description:
11107047|NCT04026906|Experimental|Skin Glue|Patients in the intervention group will receive standard peripheral intravenous catheter (PIVC) securement (with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape). In addition they will receive a drop of cyanoacrylate glue (Dermabond® topical skin adhesive) at both the PIVC insertion site and under the hub of the catheter.
11107048|NCT04026906|Placebo Comparator|Standard Care|Patients in the control group will receive standard PIVC placement with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape.
11107049|NCT04026880|Active Comparator|Treatment Arm|weekly IM administration of 25 mg Testosterone Enanthate for 12 weeks
11107050|NCT04026880|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks
11107051|NCT04026867|Active Comparator|Clinician Referral Only|"The Clinician Referral arm will serve as an active control and baseline standard of care. All individuals who test positive for HCV antibodies or are identified with untreated, active HCV will be informed of their result and receive the following information from their clinical care teams in the ED: (a) explanation of process and rationale for follow-up RNA testing; (b) delivery of simple posttest counseling (e.g., risk for liver disease, risks of transmission); and (c) provision of a list of insurance enrollment resources, as needed, along with (d) a list of HCV treatment providers and their contact information as provided in aftercare instructions. For new HCV diagnoses, patients will be instructed to access their electronic patient portal (MyChart) for their RNA test results or to call a designated results line. Post-testing counseling messages and follow-up instructions will be included on the patient discharge papers."
11107052|NCT04026867|Experimental|Clinician Referral + Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS). Individuals randomized to this intervention will be contacted by a linkage navigator either during the ED visit (if during business hours) or the following business day (if during non-business hours). If the navigator does not contact the patient at the time of ED visit, they will offer to meet with the patient in person or over the phone. For all individuals in this arm, a structured linkage navigation process will include motivational interviewing and (a) reiteration of posttest counseling messages, (b) assessment of the patient's needs for medical insurance and substance abuse treatment, c) assistance scheduling and/or rescheduling appointments for HCV treatment, and d) follow-up phone call after the first HCV treatment appointment and thereafter as needed up to 6 months after ED visit.
11107053|NCT04026854||Psychiatric nurses|Nurse with a degree in the state or psychiatric sector. Work in a psychiatric ward that offers full hospitalization, a day hospital (HdJ) or a medico-psychological center (CMP).
11107054|NCT04026841|Experimental|PD-1 Antibody Sintilimab|Patients receive the treatment of PD-1 antibody Sintilimab
11107055|NCT04026828||Periodontitis Group|Chronic periodontitis and aggressive periodontitis patients
11107056|NCT04026828||Control Group|Both periodontal and medically healthy volunteers.
11107057|NCT04026815||60 - 65 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107058|NCT04026815||65 - 69 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107059|NCT04026815||70 - 74 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107060|NCT04026815||75 - 79 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107061|NCT04026815||80 - 84 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107062|NCT04026815||85 - 89 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107063|NCT04026815||≥90 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
11107064|NCT04026802|Experimental|In--Bed Resistance Training Device|The present invention provides full body resistance training devices that attach to a planar edge, such as a footboard, headboard, or sideboard of a bed. The devices employ resistance bands for resistance training in both the incursion (force applying) and excursion (force releasing) phase of exercise.
11107065|NCT04026802|Active Comparator|Standard of Care|No resistance training device
11107066|NCT04026789|Active Comparator|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
11107067|NCT04026789|Active Comparator|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
11107068|NCT04026776|Experimental|Preterm Group|Subjects with very low birth weight (<37 completed weeks' gestation and birth weight <1500 g) at a regional perinatal center will receive a dietary intervention (high/low salt diet) and FDA approved drug, Allopurinol
11107069|NCT04026776|Active Comparator|Term-born control group|Subjects with birth weight ≥2500 g will receive a dietary intervention (high/low salt diet)
11107070|NCT04026763|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as a US guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy guided prostate biopsy.
11107071|NCT04026750|Experimental|Pitolisant|
11107072|NCT04026750|Placebo Comparator|Matching placebo|
11107073|NCT04026724||Exposed group|Chinese patent medicine combined with western medicine routine treatment
11107074|NCT04026724||Non-exposed group|Western medicine routine treatment
11107075|NCT04026711|Active Comparator|MitoQ|MitoQ 40 mg per day for 12 weeks
11107076|NCT04026711|Placebo Comparator|Placebo|placebo daily for 12 weeks
11107077|NCT04026698|Experimental|Resident and Family Engagement Intervention.|The intervention has three components: leadership coaching for managers, administrators/ directors of care in long-term care settings; a one-day in-person training session for staff and managers; and resident and family led huddles (brief, 15 minute meetings) with staff.
11107078|NCT04026685|Active Comparator|Phenylephrine infusion only|Phenylephrine infusion only
11107079|NCT04026685|Active Comparator|Phenylephrine infusion and Ringer-Acetate bolus|Phenylephrine infusion and Ringer-Acetate bolus
11107080|NCT04026659|Experimental|Multi-modal exercise programme|The 10-week multi-modal exercise programme will comprise of twice weekly supervised group-based exercise sessions. Each exercise session will last approximately 1 hour and consist of a combination of aerobic, resistance and balance and flexibility exercises.
11107081|NCT04026646|Experimental|Proprioceptive Neuromuscular Facilitation stretching exercises|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
11107082|NCT04026646|Experimental|Static stretching exercises|Passive Static Stretching exercises will be performed 2 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
11107083|NCT04026633|Experimental|Experimental: Enhanced Intervention|Participants assigned to this arm will complete a personal writing task about alcohol use.
11107084|NCT04026633|Placebo Comparator|Placebo Comparator|Participants assigned to this arm will complete a personal writing task about eating behaviors.
11107085|NCT04026620|Other|Pamphlet-only|Pamphlet-only women will be provided with two (2) informational pamphlet(s) (both in Afrikaans).
11107086|NCT04026620|Other|MET Group|MET women will be provided with a one (1) hour and 30 minute session of Motivational Enhancement Therapy (MET) and informational pamphlet(s) (both in Afrikaans).
11107087|NCT04026607|Experimental|Whey Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
11107088|NCT04026607|Experimental|Pea Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
11107089|NCT04026607|Experimental|Collagen Protein Supplement|Supplements will be consumed twice daily (25g per serving x 2 servings/day)
11107090|NCT04026594|Experimental|Mindfulness Based Stress Reduction (MBSR)|"306 participants will be randomized in the MBSR program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a MBSR recall session will be offered six month after intervention.
~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability.."
11107091|NCT04026594|Active Comparator|Progressive Muscle Relaxation Training (PMRT)|"306 participants will be randomized in a relaxation program, consisting of 8 weekly sessions lasting 2 and half hours each. In addition to this, they will be asked to complete 30 minutes of home practice each day. In order to avoid forgetting techniques and to reinforce motivation, a relaxation recall session will be offered six month after intervention.
~All the sessions may be carried out remotely, by videoconference. In this case, both programs should be conducted in this way in order to ensure comparability"
11107092|NCT04026581||Assessment|A comprehensive AAC assessment collecting clinical and personal data required to select a speech-generating device (SGD) is conducted along with a trial of three AAC technology solutions, followed by a trial for BCI access to an AAC system.
11107093|NCT04026581||Training and Treatment|AAC training and treatment services will be provided and communication performance outcomes monitored over the course of studying clinical treatment services. At monthly home visits the SLP gathers clinical and personal data on communication performance outcomes and user satisfaction of their AAC system and any alternative access methods.
11107094|NCT04026568|Experimental|Single dose 4AP|15mm opaque capsule containing 10mg of 4-AP
11107095|NCT04026568|Placebo Comparator|Placebo|Opaque capsule identical looking to the 4AP placebo pill
11107096|NCT04026555|Active Comparator|MEWS++ Monitoring|This consists of all the patients that will be receiving MEWS++ escalation monitoring and provider alerting.
11107097|NCT04026555|Placebo Comparator|Standard of Care Monitoring|Patients in the control arm will have a score calculated but no alert will be sent.
11107098|NCT04026529|Experimental|walking at incline|Subjects will walk on treadmill at slope and speed to equal 70-80% of their peak work rate as determined on baseline cardiopulmonary exercise test.
11107099|NCT04026516|Experimental|CAVA Dizziness Trial Arm|All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
11107100|NCT04026503|Experimental|Live Long Walk Strong|8 week rehabilitation program
11107101|NCT04026503|Active Comparator|8 week wait list control|8 week wait list then followed by 8 weeks of the Live Long Walk Strong rehabilitation program
11107102|NCT04026490|Experimental|Immediate intervention group|The student will have a conversation with an Interventionist.
11107103|NCT04026490|Active Comparator|Waitlist control group|These students will be approached for intervention for the months following the implementation of the immediate intervention group using the same procedures.
11107104|NCT04026477|Experimental|Immediate intervention group|Universal Trauma-Informed Care and Cultural Humility Training. After video and workshop training, staff will have ability to recognize trauma and racism and its impact on school procedures, practices, and children themselves. Staff will be able to apply core principles of cultural humility. Staff will examine their own cultural identity and how it influences their interactions and relationships with students of diverse cultural backgrounds (Principle 1). Staff will learn ways that privilege and oppression relate to their cultural identity and identify ways to flatten power hierarchies between themselves and students, including handling misbehavior from a trauma-informed, culturally humble perspective (Principle 2). Staff will problem-solve ways for their schools to be accountable for equitable discipline practices (Principle 3).
11107105|NCT04026477|Active Comparator|Waitlist control group|All staff from waitlisted schools will receive Universal Trauma-Informed Care and Cultural Humility Training at the end of the waitlist period.
11107106|NCT04026464|Active Comparator|Ibuprofen+Acetaminophen Group|Infants with PDA randomized to the combined treatment group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) and oral acetaminophen (15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses).
11107107|NCT04026464|Placebo Comparator|Ibuprofen Group|Infants with PDA randomized to the control mono therapy group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) alone.
11107108|NCT04026451|Experimental|Intervention|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.
11107109|NCT04026451|Active Comparator|Control|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SAS (1-2). SedLine® monitor will be also used in these patients but the screen will be covered.
11107113|NCT04026425|Active Comparator|Healthy controls|Healthy, low-active adults
11107114|NCT04026412|Experimental|Arm A: nivolumab + CCRT + ipilimumab|Concurrent chemoradiotherapy (CCRT)
11107115|NCT04026412|Experimental|Arm B: nivolumab + CCRT|Concurrent chemoradiotherapy (CCRT)
11107116|NCT04026412|Experimental|Arm C: CCRT + durvalumab|Concurrent chemoradiotherapy (CCRT)
11107117|NCT04026399|Experimental|stimulation + therapy|The participant receives stimulation and home therapy.
11107118|NCT04026399|Sham Comparator|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
11107119|NCT04026386|Experimental|Center Based Early Intervention Program|
11107120|NCT04026373|Experimental|modified Prolonged Exposure|
11107121|NCT04026373|Active Comparator|Treatment as usual|
11107122|NCT04026347|Experimental|Vesair|Subjects are treated with Vesair Balloon at enrollment (day 0)
11107123|NCT04026347|Sham Comparator|Sham|Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
11107124|NCT04026334|Experimental|V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline|
11107125|NCT04026321|Experimental|SQ-001 125mL/day|
11107126|NCT04026321|Experimental|SQ-001 250mL/day|
11107127|NCT04026321|Experimental|SQ-001 500mL/day|
11107128|NCT04026321|Experimental|SQ-001 625mL/day|
11107129|NCT04026321|Placebo Comparator|saline(0.9% NaCl injection)|
11107130|NCT04026308|No Intervention|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
11107131|NCT04026308|Experimental|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
11107132|NCT04026295|Experimental|Short burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
11107133|NCT04026295|Active Comparator|Traditional Locomotor Treadmill Training (TLTT)|TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
11107134|NCT04026282|Experimental|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
11107135|NCT04026282|Active Comparator|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
11107136|NCT04026269|Experimental|MOAP treatment|Chlormethine Hydrochloride Injection 10mg d1,8 iv Vindesine Sulfate for Injection 4mg d1,8 iv Doxorubicin Hydrochloride Injection 25mg/m2 d1,8 iv Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po 28 days/Cycle
11107137|NCT04026256|Active Comparator|Teriparatide only|daily subcutaneous injection teriparatide for 3 months
11107138|NCT04026256|Active Comparator|Denosumab only|one dose of subcutaneous injection denosumab
11107139|NCT04026256|Active Comparator|Denosumab and teriparatide|daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
11107140|NCT04026243|Active Comparator|QL group (n = 25)|After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
11107141|NCT04026243|Active Comparator|TF group (n = 25)|After GA, patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in midaxillary line just cephalad to the iliac crest. Scanning anteriorly will identify the three muscles of the anterior abdominal wall. The transversus abdominis typically tapers to form a hyper echoic aponeurosis that passes posterior to quadratus lumborum. Scan will be continued posteriorly to visualize solid organs or viscera deep to the transversus abdominis. The needle will be positioned such that it enters the skin anterior to the ultrasound probe and passes in-plane posterolateral through the three lateral abdominal muscles. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the transversus abdominis muscle and the transversalis fascia anterolateral to quadratus lumborum.
11107142|NCT04026230|Experimental|Atorvastatin|Capsules of atorvastatin. Daily dose of 80 mg for max. 5 years or until development of castration resistance.
11107143|NCT04026230|Placebo Comparator|Placebo|Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 5 years or until development of castration resistance
11107144|NCT04026204||Coronary cannulation after TAVR|Coronary ostia cannulation after TAVR
11107145|NCT04026191|Other|Orthovisc-T|
11107146|NCT04026178|Experimental|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients > 40 kg: 2.5mg Female patients > 40 kg: 5mg
11107147|NCT04026165|Experimental|Selonsertib|"Run-in Period (5 Weeks): Participants will receive placebo for at least one week and then SEL 18 mg for at least 4 weeks.
~Double-Blind Treatment: Participants will be randomized to receive SEL 18 mg until death, study drug discontinuation, kidney failure, or the global study end date."
11107148|NCT04026165|Placebo Comparator|Placebo|"Run-in Period (5 Weeks): Participants will receive placebo for at least one week and then SEL 18 mg for at least 4 weeks.
~Double-Blind Treatment: Participants will be randomized to receive placebo until death, study drug discontinuation, kidney failure, or the global study end date."
11107203|NCT04025749|Experimental|Immediate intervention group|Thirty children with CP aged 8 to 12 years (or fifteen with neuroimage data) will participate in a computerized executive training program from home (12 weeks, 5 days a week, 30 min a day).
11107149|NCT04026152|Experimental|Resistance training + Unified Protocol|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will also receive four weekly hour-long sessions with a therapist to learn cognitive-behavioural strategies to assist them with managing their anxiety when exercising. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
11107150|NCT04026152|Active Comparator|Resistance training|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
11107151|NCT04026152|No Intervention|Waitlist|Participants randomly assigned to this condition will maintain their usual physical activity and exercise routine and not engage in any additional exercise than they were prior to the study. These participants will fill out questionnaires (~20 minutes each time) following randomization into this condition, once per week for four weeks, and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up. After completing the last follow-up, participants in the waitlist condition will be re-randomized into either the resistance training only or resistance training + Unified Protocol conditions.
11107152|NCT04026139|Experimental|experimental group|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
11107153|NCT04026139|Active Comparator|control group|The control group underwent active joint range-of-motion exercises and isometric contraction exercises.
11107154|NCT04026126|Experimental|Heat Therapy Treatment|This study will recruit subjects to participate in heat therapy treatment at the University of Kansas Medical Center (KUMC). After pre-screening, informed consent, and enrollment, all subjects will have baseline hemodynamic assessments as well as VO2max measurements. Subjects will complete 10 heat therapy treatments over the course of 14 days. Hemodynamics will be assessed with the use of the Clearsight© fingertip blood pressure cuff. Within 24-48 hours after the last heat therapy experience, hemodynamic assessments and VO2max will be performed. Blood samples will be collected pre- and post intervention and analyzed for levels of nitric oxide mediators, heat shock protein levels and pro-anti-inflammatory markers.
11107155|NCT04026113|Experimental|Linaclotide 72 μg|Single dose, once daily at approximately the same time each day, 30 minutes before any meal
11107156|NCT04026113|Experimental|Placebo|Single dose, once daily at approximately the same time each day, 30 minutes before any meal
11107157|NCT04026100|Experimental|CTA101|
11107158|NCT04026087||patient with kidney transplant|Blood sample will be took from subjects during this research
11107159|NCT04026074|Experimental|Fentanyl i.v. (intravenously)|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
11107160|NCT04026074|Experimental|Remifentanil i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
11107161|NCT04026074|Experimental|Clonidine i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
11107162|NCT04026074|Experimental|EMLA salve|Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo
11107163|NCT04026074|Placebo Comparator|Placebo|Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)
11107164|NCT04026061|Experimental|FMA group|Receiving the FMA training and tool
11107165|NCT04026061|Placebo Comparator|control group|Receiving a simple tablet training and some websites
11107166|NCT04026048|Experimental|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
11107167|NCT04026048|Experimental|Waitlist Control Group|Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
11107168|NCT04026022|Placebo Comparator|Standard pain management|Besides the standard pain management a placebo TTS (normal wound plaster) will be administered in the Emergency Room (ER) or Post Anaesthesia Care Unit (PACU)
11107169|NCT04026022|Experimental|Modified pain management|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial i.v. treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day
11107170|NCT04026009|Experimental|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
11107171|NCT04026009|Placebo Comparator|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
11107172|NCT04026009|Experimental|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
11107173|NCT04026009|Experimental|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
11107174|NCT04026009|Placebo Comparator|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
11107175|NCT04025996||Diseased Group|Patients with type 2 diabetic retinopathy and known cardiac dysfunction.
11107176|NCT04025983|Experimental|GastimunHp Plus|1 sachet of GastimunHp Plus twice daily during or after meals.
11107177|NCT04025983|Placebo Comparator|Placebo|1 sachet of placebo twice daily during or after meals.
11107178|NCT04025970||Cancer of Unknown Primary (CUP)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for possible cancer of unknown primary (CUP).
~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
11107179|NCT04025970||Suspected CANcer (SCAN)|"Subjects referred, based on standardised criteria, for investigation and diagnosis for suspected cancer (SCAN) based on serious non-specific symptoms and signs of cancer.
~Blood samples to be investigated for presence of circulating tumor cells and circulating tumor DNA."
11107180|NCT04025957|Experimental|SHR-1501 dose escalation|SHR-1501 given subcutaneously
11107181|NCT04025957|Experimental|SHR-1501 dose expansion|SHR-1501 given subcutaneously
11107182|NCT04025944||chronic hepatitis B|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
11107183|NCT04025944||chronic hepatitis C|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
11107184|NCT04025931|Experimental|chidamide combined with Toripalimab|"chidamide 30mg orally twice a week;
~240 mg of toripalimab (fixed dose) every three weeks.
~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
11107185|NCT04025918|Experimental|vasopressor delivery automated system|vasopressor delivery automated system that administered phenylephrine and ephedrine based on data from continuous non-invasive hemodynamic monitor
11107186|NCT04025918|Active Comparator|manual vasopressor delivery|manual bolus that delivered phenylephrine and ephedrine based on data from non-invasive intermitted blood pressure monitor
11107187|NCT04025905|Experimental|Social Cognition Training Program|This program is taken from two validated cognitive remediation programs: the SCIT program and the RC2S program : perception of social situations - emotional processes and social perception;interpretation of social situations - theory of mind and attributions;acting in social situations - social skills training
11107188|NCT04025905|Sham Comparator|Informations program|Educational team Information will be given to participants about work environment, social environment, stress management, sleep management, treatments. It will also include socialization sessions with board games or cultural activities.
11107189|NCT04025892|Experimental|Tracking group|Participants will be asked to track weight daily for six weeks
11107190|NCT04025879|Experimental|Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo|
11107191|NCT04025879|Placebo Comparator|Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.|
11107192|NCT04025866|Active Comparator|Conventional rehabilitation|Conventional rehabilitation treatment for inpatients with femur fracture
11107193|NCT04025866|Active Comparator|Aerobic exercise|Addition of cycle ergometer for upper limb to conventional rehabilitation treatment for femur fracture
11107194|NCT04025840|No Intervention|Control|Patients in this group receive general anesthesia, without epidural block and perioperative dexamethasone. Patient-controlled intravenous analgesia is provided after surgery.
11107195|NCT04025840|Experimental|Epidural block|Patients in this group receive combined epidural-general anesthesia (0.375% ropivacaine for epidural block), without perioperative dexamethasone. Patient-controlled epidural analgesia is provided after surgery.
11107196|NCT04025840|Experimental|Dexamethasone|Patients in this group receive dexamethasone (10 mg) before anesthesia induction and general anesthesia, without epidural block. Patient-controlled intravenous analgesia is provided after surgery.
11107197|NCT04025840|Experimental|Epidural block+Dexamethasone|Patients this group receive dexamethasone (10 mg) before anesthesia induction and combined epidural-general anesthesia (0.375% ropivacaine for epidural block). Patient-controlled epidural analgesia is provided after surgery.
11107198|NCT04025814|Experimental|CaregiverAssist|Parents and School Mental Health Providers (SMHPs) will participate in focus groups and discussions to facilitate the build, design, and use of a digital Health (dHealth) tool to improve parent adherence sustained use of evidence-based parenting strategies. Parents will participate in a 2-month trial during which time they will use the dHealth tool in daily life contexts.
11107199|NCT04025775|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days
~The CamAPS HX closed-loop system comprises
~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump
~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
11107200|NCT04025775|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.
11107201|NCT04025762|Experimental|Day and night hybrid closed loop control|"The day and night hybrid closed-loop system (CamAPS FX) will consist of:
~Dana RS insulin pump (Sooil)
~G6 real-time CGM sensor (Dexcom)
~An unlocked android smartphone hosting the CamAPS FX app with Cambridge control algorithm"
11107202|NCT04025762|Active Comparator|Sensor augmented pump therapy|The comparator will consist of Dana RS insulin pump (Sooil) and G6 real-time CGM sensor (Dexcom)
11107204|NCT04025749|Other|Wait-list delayed intervention|Thirty children with CP (or fifteen with neuroimage data) matched by age, sex, motor and cognitive impairment severity.
11107205|NCT04025736|Experimental|Patients received Tranexamic acid|The patient was assigned as intervention group, TXA will be aspirated into a syringe. In TXA group, TXA 1000 mg (20 mL) was given intravenously 10 minutes before surgery.
11107206|NCT04025736|Placebo Comparator|Patients received same volume of saline|In the control group, the patient received 20ml saline intravenous also 10 min before surgery.
11107207|NCT04025723|Active Comparator|Young|men aged between 18 to 30 years old
11107208|NCT04025723|Active Comparator|Middle-aged|men aged between 35 to 50 years old
11107209|NCT04025710|Other|all patients|
11107210|NCT04025697|Placebo Comparator|Conventional CD|A conventional Complete denture will be constructed and the amount of denture tooth movement will be measured
11107211|NCT04025697|Active Comparator|Rapid Prototyped Denture|A digital light processed denture will be constructed and the amount of tooth movement will be measured
11107212|NCT04025684|Other|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million [ppm] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
11107213|NCT04025684|Other|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
11107214|NCT04025684|Other|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
11107215|NCT04025684|Other|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
11107216|NCT04025671|Experimental|Nasal Spray Naloxone|This arm will be randomized to administer a nasal spray naloxone device in a simulated overdose setting.
11107217|NCT04025671|Active Comparator|Intramuscular|This arm will be randomized to administer a intramuscular naloxone device in a simulated overdose setting.
11107218|NCT04025671|Active Comparator|Improvised Nasal Atomizer|This arm will be randomized to administer an improvised nasal atomizer naloxone device in a simulated overdose setting.
11107219|NCT04025658|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11107220|NCT04025658|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11107221|NCT04025658|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11107222|NCT04025658|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11107223|NCT04025658|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11107224|NCT04025658|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11107225|NCT04025645||PATIENTS WITH CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITH CHOLELITHIASIS
11107226|NCT04025645||PATIENTS WITHOUT CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITHOUT CHOLELITHIASIS
11107227|NCT04025632|Experimental|0.3 mg/kg zilucoplan|Daily subcutaneous (SC) injection
11107228|NCT04025632|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection
11107229|NCT04025619|Experimental|treatment group|the data is collected from the same participant after the intervention.
11107230|NCT04025619|No Intervention|Control group|The Collect the data from the same participant before the intervention as control
11107231|NCT04025606|Active Comparator|Thoracic epidural analgesia|Standard thoracic epidurals preoperatively at the dag of surgery.
11107232|NCT04025606|Experimental|Paravertebral block|Paravertebral block inserted at the end of the operation by the surgeons
11107233|NCT04025593|Active Comparator|RCHOP|
11107234|NCT04025593|Experimental|RCHOPX|
11107235|NCT04025580|Experimental|Flucelvax, Fluvirin, or Fluzone High Dose|Healthy Volunteer between ages 18-65 receiving Flucelvax
11107236|NCT04025567|Experimental|1/Arm 1|Oral vancomycin
11107237|NCT04025554|Experimental|1/Active treatment|Patients with MS will be assigned to the same intervention
11107238|NCT04025541|Other|COHORT 1 BREAST TUMOR/PALBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib
~BLOOD SAMPLING"
11107239|NCT04025541|Other|COHORT 2 BREAST TUMOR / RIBOCICLIB|"Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib
~BLOOD SAMPLING"
11107240|NCT04025528||Hypercapnic|Obese patients with daytime hypercapnia
11107241|NCT04025528||Eucapnic|Obese patients with normal daytime carbon dioxide levels
11107242|NCT04025502||Healthy Volunteer Subjects (HV)|"Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.
~Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
11107243|NCT04025502||Subjects with Schizophrenia (SZ)|"Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.
~Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System."
11107244|NCT04025489|Experimental|Vitamin D and Placebo|Doses of cholecalciferol (commercial name, Calcirol) 60,000IU (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose Granules) to the placebo group according to the random numbers generated by the computer.
11107247|NCT04025463|Other|Intervention|Hybrid type II effectiveness/implementation study design - pre-post design with each participant serving as his or her own control.
11107248|NCT04025450|Experimental|Chidamide plus VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
11107249|NCT04025450|Active Comparator|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
11107250|NCT04025437|Experimental|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
11107251|NCT04025437|Active Comparator|Neoadjuvant radiotherapy plus hepatectomy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
11107252|NCT04025424||Skin melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary lesion;
~2) The availability of basic clinical information about the patient and the course of his illness;"
11107253|NCT04025424||Hodgkin disease, retrospective|"1) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);
~2) The availability of basic clinical information about the patient and the course of his illness;"
11107254|NCT04025424||Uveal melanoma, retrospective|"1) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);
~2) The availability of basic clinical information about the patient and the course of his il"
11107255|NCT04025424||Skin melanoma, proscpective|"1) Clinically and morphologically verified diagnosis of metastatic melanoma;
~2) The availability of basic clinical information about the patient and the course of his illness;"
11107256|NCT04025424||Lung cancer, procpective|"1) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;
~2) The availability of basic clinical information about the patient and the course of his illness;
~3) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;"
11107257|NCT04025411|Experimental|Experimental group|Patient with stroke ischemic or hemorrhagic will be included. They will have visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device and electroencephalography (EEG).
11107258|NCT04025411|Active Comparator|Control group|Patient with stroke ischemic or hemorrhagic will be included. They will have simulation with the traditional Mirror Therapy (TM) and electroencephalography (EEG).
11107259|NCT04025398|Experimental|REHABILITUS|Réhabilitus is a cognitive remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among adults with intellectual disabilities.
11107260|NCT04025398|Active Comparator|CONTROL GROUP|The control group involves manual activities and research computer information.
11107261|NCT04025385|No Intervention|Control Group|Patients will participate in regular training units
11107262|NCT04025385|Active Comparator|HIIT Group|Patients will participate in high intensity interval training
11107263|NCT04025372|Experimental|Bicalutamide+GnRH Agonist+Radiation Therapy|"Bicalutamide is administered orally on a daily basis
~GnRH Agonist as prescribed
~Radiation therapy is administered starting 8-12 weeks after ADT"
11107264|NCT04025372|Experimental|Darolutamide+Radiation Therapy|"Darolutamide is administered orally twice daily
~Radiation therapy is administered starting 8-12 weeks after ADT"
11107265|NCT04025359|Active Comparator|Dronabinol 10mg|Dronabinol 10mg
11107266|NCT04025359|Active Comparator|Dronabinol 20mg|Dronabinol 20mg
11107267|NCT04025359|Placebo Comparator|Placebo|Placebo
11107268|NCT04025346|Active Comparator|Capsimax|
11107269|NCT04025346|Placebo Comparator|Placebo|
11107270|NCT04025320|Experimental|Group 1|"Intraneural facilitation treatment for 50-60 minutes. 50 minutes if ultrasound received.
~9 total treatment visits, 3 visits per week
~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
11107271|NCT04025320|Sham Comparator|Group 2|"SHAM treatment for 50-60 minutes. 50 minutes if ultrasound received. 9 total treatment visits, 3 visits per week
~• One 50-60 minute visit on Monday, Wednesday and Friday, for 3 weeks."
11107272|NCT04025307|Experimental|bacTRL-IL-12|single-dose, 1 mL IV infusion of bacTRL-IL-12
11107273|NCT04025294|Experimental|Students playing videogame|The experimental group will consist of our videogame intervention including the five mini-games.
11107274|NCT04025294|Active Comparator|Students receiving school climate assessment|The control group differs from the experimental group as it includes the school climate assessment tool but excludes the mini-games
11107275|NCT04025281|Active Comparator|Extra virgin olive oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
11107276|NCT04025281|Active Comparator|Refined olive oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
11107277|NCT04025268|Active Comparator|pregnant women receiving group prenatal care (GPNC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to receive the 10-session GPNC intervention.
11107278|NCT04025268|Active Comparator|pregnant women receiving standard of care (SOC)|Overweight/obese pregnant women will be recruited from the prenatal care clinic at the Lyndon B Johnson Tropical Medical Center (LBJTMC) in Pago Pago, American Samoa. These women will be randomized to continue with standard of care (SOC) prenatal care visits.
11107279|NCT04025255|Experimental|Braini|28-day oral capsules of Braini
11107280|NCT04025255|Placebo Comparator|Placebo|28-day oral capsule of placebo comparator
11107281|NCT04025229|Experimental|HIIT exercise|Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery
11107282|NCT04025229|No Intervention|No HIIT exercise|Participants will not perform exercises prior to surgery.
11107341|NCT04024813|Experimental|Seladepar 25 mg (N=25)|25 mg seladelpar for the remainder of the study
11107283|NCT04025216|Experimental|Dose Escalation Arm1: Solid Tumors|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
11107284|NCT04025216|Experimental|Dose Escalation Arm 2: Multiple Myeloma|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
11107285|NCT04025203|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
11107286|NCT04025203|Active Comparator|Ibuprofen arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
11107287|NCT04025203|Active Comparator|Gabapentin|Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
11107288|NCT04025203|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
11107289|NCT04025190||Allogeneic Transplant|All patients seen in the UNC Bone Marrow Transplant clinic who are candidates for allogeneic transplantation attending their pre-admission visit were approached to offer study participation. Study participation included completion of surveys over a time period up to 60 days after their transplant.
11107290|NCT04025177|Experimental|Neonates with an open PDA|Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.
11107291|NCT04025164|Experimental|Hypofractionated Radiotherapy|"40 Gy/15 fractions irradiation is delivered to the whole breast, 2.67 Gy per fraction, 5 fractions weekly.
~Tumor bed is boosted to 48 Gy simultaneously, 3.2 Gy per fraction, 5 fractions weekly."
11107292|NCT04025164|Active Comparator|Conventional Irradiation|"50 Gy/25 fractions irradiation is delivered to the whole breast, 2 Gy per fraction, 5 fractions weekly.
~Additional 10 Gy/5 fractions is boosted to tumor bed sequentially, 2 Gy per fraction, 5 fractions weekly."
11107293|NCT04025151|Experimental|Intervention group|Alcohol brief intervention, leaflets, regular personalized messages on ABI through IM Apps, real-time chat-based support through IM Apps
11107294|NCT04025151|Active Comparator|control group|Alcohol brief intervention, leaflets, regular messages on general health through IM Apps
11107295|NCT04025138|Experimental|female subjects involved in races over 100 km (F>100)|Female subjects involved in races over 100 km (F>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
11107296|NCT04025138|Experimental|female subjects involved in races less than 60 km (F<60)|Female subjects involved in races less than 60 km (F<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
11107297|NCT04025138|Experimental|male subjects involved in races over 100 km (H>100)|Male subjects involved in races over 100 km (H>100) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
11107298|NCT04025138|Experimental|male subjects involved in races less than 60 km (H<60)|Male subjects involved in races less than 60 km (H<60) will be included. They will have neuromuscular tests in isometric mode, Transcranial Magnetic Stimulation (TMS), neuromuscular fatigue assessment test, treadmill, blood sample and urinary sample.
11107299|NCT04025112|Experimental|Armeo|Patients group (54 patients) for robotic therapy.
11107300|NCT04025112|Active Comparator|Conventional|Patients group (54 patients) for conventional rehabilitation protocol.
11107301|NCT04025099|Experimental|Internal Cues|"Over 10 weeks, participants will be asked to participate in the following:
~Classes (held in STAR Tower 419/420 IPE Space and Conference Room 413)
~One ~60-minute Intuitive Eating class per week (total = 10 classes);
~Two ~60-minute yoga classes per week (total = 20 classes);
~Repeat one of the ~60-minute yoga classes each week on the participants' own, in a space participants feel comfortable, using a video recording (total = 10 classes).
~Assessments (held in STAR tower)
~Three ~60-minute assessments* which will include:
~Height & weight measurements (taken privately)
~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors
~Collection of participants' heart rate overnight (on their own)
~Collection of participants' saliva three times in one day (on their own)"
11107302|NCT04025099|Active Comparator|External Cues|"Over the next 10 weeks, participants will be asked to participate in the following:
~Classes (held in STAR Tower 419/420 IPE Space)
~One ~60-minute Healthy Eating class per week (total = 10 classes);
~Participants will be provided with a UD group fitness membership. Using this membership, participants will be asked to attend at least 2 cardio fitness classes per week and do an additional 30 minutes of heart-raising activity on participants' own (total = 3 exercise sessions/week).
~Assessments (held in STAR tower)
~Three ~60-minute assessments* which will include:
~Height & weight measurements (taken privately)
~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors
~Collection of participants' heart rate overnight (on their own)
~Collection of participants' saliva three times in one day (on their own)"
11107303|NCT04025099|No Intervention|Assessment Only|"Over the next 10 weeks, participants will be asked to participate in the following:
~a. Assessments (held in STAR tower)
~•Three ~60-minute assessments* which will include:
~Height & weight measurements (taken privately)
~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors
~Collection of participants' heart rate overnight (on their own)
~Collection of participants' saliva three times in one day (on their own)"
11107304|NCT04025086||Study group|"44 patient undergoing spinal surgery in prone position at Gaspare Rodolico Presidium, in which the new Perioperative Goal Directed Therapy protocol has been used"
11107339|NCT04024813|Experimental|Seladelpar 5 mg (N=25)|5 mg seladelpar daily for the remainder of the study
11107305|NCT04025086||Control group|44 patients who underwent spinal surgery in the period January 2016 - December 2017, in which was not used a Perioperative Goal Directed Therapy approach but a classical hemodynamic monitoring, according to the recommendations of good clinical practice and the international guidelines.
11107306|NCT04025073|Experimental|Intervention Group|The intervention group will be assigned to the DASH diet with moderately reduced caloric intake and will participate in a nutrition education program.
11107307|NCT04025073|Experimental|Control Group|The control group will continue to follow the standard hospital diet and will participate in the same nutrition education program as the intervention group.
11107308|NCT04025060|Experimental|Caffeine-free Soda|Consumption of caffeine-free soda daily for two weeks
11107309|NCT04025060|Experimental|Carbonated Water|Consumption of unsweetened, carbonated water daily for two weeks
11107310|NCT04025060|Active Comparator|Regular Soda|Consumption of regular soda daily for two weeks
11107311|NCT04025047||Transvaginal mesh|Patients who undergo pelvic reconstruction surgery using trans-vaginal mesh (commercial mesh kits or self-cut synthesized mesh).
11107312|NCT04025034|Experimental|Study Group|Use of SONOPET(R) to orbital surgery.
11107313|NCT04025021|No Intervention|Control group (standard fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:
~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines."
11107314|NCT04025021|Experimental|Intervention group (targeted fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:
~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study."
11107315|NCT04024982|Other|Lecture followed by Simulation|Subjects will undergo the lecture on TEE first followed by the simulation session.
11107316|NCT04024982|Other|Simulation followed by Lecture|Subjects will undergo the TEE simulation first followed by the lecture.
11107317|NCT04024969||Clinically isolated syndrome|Those presenting for diagnositic evaluation of multiple sclerosis, not currently meeting the 2017 McDonald criteria.
11107318|NCT04024956|Experimental|Sealing Device|Sealing Device applied in hepatic resection or distal pancreatectomy
11107319|NCT04024917|Experimental|Coherence cardiac|
11107320|NCT04024917|Active Comparator|Standard care|
11107321|NCT04024904|No Intervention|control group|In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
11107322|NCT04024904|Experimental|VRHD1|In the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
11107323|NCT04024904|Experimental|VRHD2|In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
11107324|NCT04024891|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye, 1 hour post medically-induced mydriasis
11107325|NCT04024891|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye, 1 hour post medically-induced mydriasis
11107326|NCT04024878|Experimental|Stanfard Platinum|"A total of 5 NeoVax immunizations will be administered over a 3-week period
~Two booster vaccinations will be given at Week 12
~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks."
11107327|NCT04024878|Experimental|Stanfard Platinum with Surgical or Core Needle Biopsy|"A total of 5 NeoVax immunizations will be administered over a 3-week period
~Two booster vaccinations will be given at Week 12
~Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.
~Will undergo required surgical or core needle biopsy at first recurrence with progression free interval"
11107328|NCT04024865||Treated with domperidone|Women who received a prescription for domperidone during the six months following delivery.
11107329|NCT04024865||Unexposed group (reference)|Women with no prescription for domperidone during the six months following delivery.
11107330|NCT04024852|No Intervention|Control group|The control group did daily mild exercise (walking) outdoors for 30 minutes, for maximum 70 days.
11107331|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes. Total study period lasted for maximum 70 days.
11107332|NCT04024839|Active Comparator|Post Isometric Relaxation|Post Isometric Relaxation was applied three times a week for the duration of three weeks.
11107333|NCT04024839|Experimental|Active Isolated stretch|Active Isolated stretch was was applied three times a week for the duration of three weeks.
11107334|NCT04024826|Experimental|Early Follicular Phase (EFP)|This group is comprised of participants at the Early Follicular Phase (EFP) of the menstrual cycle.
11107335|NCT04024826|Experimental|Late Follicular Phase|This group is comprised of participants at the Late Follicular Phase (LFP) of the menstrual cycle.
11107336|NCT04024826|Experimental|Early Luteal Phase|This group is comprised of participants at the Early Luteal Phase (ELP) of the menstrual cycle.
11107337|NCT04024826|Experimental|Late Luteal Phase|This group is comprised of participants at the Late Luteal Phase(LLP) of the menstrual cycle.
11107338|NCT04024813|Placebo Comparator|Placebo (N=25)|Placebo for the remainder of the study
11107340|NCT04024813|Experimental|Seladelpar 10 mg (N=25)|10 mg seladelpar for the remainder of the study
11107342|NCT04024800|Experimental|Arm 1|AE37 peptide vaccine every 21 days for 5 doses + Pembrolizumab every 21 days for 2 years (Maximum 35 cycles)
11107343|NCT04024787|Experimental|Immediate intervention|
11107344|NCT04024787|No Intervention|Waitlist|
11107345|NCT04024774||index cases and their parents|
11107346|NCT04024761|Experimental|CIML NK|"CIML NK will be administered intavenously on day 0
~Fludarabine will be administered as one-hour IV infusion once daily for 5 doses beginning on day 6.
~Cyclophosphamide will be administered as 2-hour IV infusion on days -5 and -4."
11107347|NCT04024748||Patients already scheduled for a FDG test|Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
11107348|NCT04024722|Experimental|Single ovary treatment|
11107349|NCT04024722|Experimental|Dual ovary treatment|
11107350|NCT04024696|Experimental|Dosing Cohorts|Three (3) dose cohorts are pre-set to include 40 mg BID, 60 mg BID and 80 mg BID,respectively.The pre-set dose group is subject to change during the study and the actual dosage increment is determined by the Data safety Monitoring Committee (DSMC).
11107351|NCT04024683||Serratus block group|Realization of a serratus block and para-vertebral catheter
11107352|NCT04024683||Control group|Realization of a para-vertebral catheter
11107353|NCT04024670|Active Comparator|HRO|brief description do not too much
11107354|NCT04024670|Active Comparator|BMT|
11107355|NCT04024670|No Intervention|HRO Standard of Care|SOC
11107356|NCT04024670|No Intervention|BMT Standard of Care|SOC
11107357|NCT04024631|Other|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.
~They will also undergo a whole body DXA (intervention) during the study day."
11107358|NCT04024618|Active Comparator|Parenteral Nutrition|Patients who have been randomized to receive PN will be started on day 5 post AHSCT. This will be if patient intake is < 80% of usual oral intake at that time. The central venous catheter required for PN administration will be already in place for AHSCT treatment, prior to admission and pre-transplant evaluation. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
11107359|NCT04024618|Experimental|Enteral Nutrition|Patients who have been randomized to receive EN will have a Nasogastric tube (NGT) inserted on day 5 post AHSCT, prior to start of Enteral feeds. This would be a polyurethane tube, 8-10 French, which will be inserted by physician or Nurse Practitioner with position confirmed by radiological examination. This will be if patient intake is < 80% of usual oral intake at that time. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
11107360|NCT04024605|Experimental|Sunflower|Biscuits containing sunflower isolate intrinsically labelled with 15N and 2H
11107361|NCT04024605|Experimental|Rapeseed|Biscuits containing rapeseed isolate intrinsically labelled with 15N and 2H
11107362|NCT04024605|Experimental|Flaxseed|Biscuits containing flaxseed isolate intrinsically labelled with 15N and 2H
11107363|NCT04024605|Experimental|Lupin|Biscuits containing lupin flour intrinsically labelled with 15N and 2H
11107364|NCT04024592|Experimental|children|
11107365|NCT04024553||bipolar disorder family|Screening priori BD-I/BD-II patients， their relatives with mental illness (including but not limited to BD) and their healthy families.
11107366|NCT04024553||health control|Group-matched non-psychiatric family history health subjects were enrolled, DSM-IV-TR is used for demographic assessment.
11107367|NCT04024540|Experimental|isocaloric dietary restriction|Very low caloric diet 400 kcal/d for a week, 600 kcal/d for another week and 800 kcal/d for 2 weeks and 1000 kcal/d for 2 months.
11107368|NCT04024540|Active Comparator|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
11107369|NCT04024527|Active Comparator|Dual therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
11107370|NCT04024527|Experimental|Metronidazole plus dual therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
11107371|NCT04024514|Experimental|Low dose|Low CT contrast media dose
11107372|NCT04024514|Active Comparator|Standard dose|Standard CT contrast media dose
11107373|NCT04024501|Experimental|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
11107374|NCT04024501|Experimental|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
11107375|NCT04024501|Experimental|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
11107376|NCT04024501|Experimental|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
11107377|NCT04024501|Experimental|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
11107378|NCT04024488|Experimental|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
11107379|NCT04024488|Active Comparator|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
11107408|NCT04024293|Experimental|All participants|All patients will be follow the same procedures and be placed the investigational device
11107380|NCT04024475||A: Opportunistic screening & benign prostate syndrome (BPS)|Asymptomatic men offered screening (PSA testing) with prostate biopsy (A1). Or patients with lower urinary tract symptoms from benign prostatic hyperplasia undergoing: no treatment (A2), medical therapy (A3), or transurethral resection of the prostate (A4)
11107381|NCT04024475||B: Localized/locally advanced PCa with curative intent|B0: Patients under active surveillance (B0, closed group); B1: radical prostatectomy (RP) or RP followed by (adjuvant) external beam radiation; B2: external beam radiation therapy (EBRT) without androgen deprivation therapy (ADT); B3: external beam radiation therapy with ADT
11107382|NCT04024475||C: Biochemical relapse|Patients with PSA progression after RP with or without systemic therapy
11107383|NCT04024475||D: Metastatic PCa but hormone sensitive|Metastatic PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical), with or without additive treatments. Oligometastatic PCa.
11107384|NCT04024475||E: Metastatic castration resistant prostate cancer (mCRPC)|Metastatic castration resistant prostate cancer (mCRPC). Oligometastatic PCa.
11107385|NCT04024462|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
11107386|NCT04024462|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of neoadjuvant chemotherapy: 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
11107387|NCT04024449||Celiac Disease|"Celiac disease with the following criteria;
~13 ≤ Age ≤20
~At least one year after menarche
~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia."
11107388|NCT04024449||Control|"The adolescent with the following criteria;
~13 ≤ Age ≤20
~At least one year after menarche
~Non-obesity or malnutrition, Non-Hyperandogenism symptoms, and blood tests, Non-Hyper or hypothyroidism, Non-Hyperprolactinemia.
~Control group; with normal menstrual period, Non-chronic diseases"
11107389|NCT04024436|Experimental|TAS-120|TAS-120 tablets, oral; 28-day cycle
11107390|NCT04024436|Experimental|TAS-120 + fulvestrant|TAS-120 tablets, oral; 28-day cycle Fulvestrant; intramuscular
11107391|NCT04024423||Related M. abscess isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
11107392|NCT04024423||Unrelated M. abscessus isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
11107393|NCT04024423||Related M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
11107394|NCT04024423||Unrelated M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
11107395|NCT04024423||Related M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
11107396|NCT04024423||Unrelated M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
11107397|NCT04024384|Experimental|Daratumumab|Daratumumab as maintenance after peripheral blood stem cell transplantation from HLA-identical or haploidentical family donor in the treatment of refractory or relapsed multiple myeloma
11107398|NCT04024371||HV|Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.
11107399|NCT04024371||SZ|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.
11107400|NCT04024371||MDD|Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.
11107401|NCT04024345|Experimental|Psychometric assessment group|Arms to whom the psychometric assessment will be administered
11107402|NCT04024332|Experimental|Group A (healthy)|On Day 1, 8 healthy subjects will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
11107403|NCT04024332|Experimental|Group B (severe renal function impairment)|On Day 1, 8 subjects with severe renal function impairment will receive a single oral dose of 25 mg ACT-541468 in fasted condition.
11107404|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
11107405|NCT04024319||Local Infiltration Analgesia|Retrospectively, the data of the patients belonging to the control group (LIA) were collected through the electronic file in the SAPP program of the internal network of the Barcelona Clinic Hospital in chronological order until completing 35 cases. To include them in the control group, the patients had to meet the same criteria as those belonging to the intervention group (GNB), therefore, the surgery should have been performed under spinal anesthesia and subsequently followed with an oral analgesia schedule meeting criteria of fast track hospitalization. The same data were obtained as in the GNBG, demographic data (age, sex, weight, height, hematocrit, hemoglobin, ASA), duration of the surgery and ischemia time, PACU VAS, AM VAS, PM VAS and finally some data of the post-operative period (hematocrit, hemoglobin, transfusion, hospital stay)
11107406|NCT04024306||ULTRAFILTRATION|
11107407|NCT04024306||DIURETICS|
11107409|NCT04024280|Experimental|Intervention arm|Patients will perform a supervised physical exercise program specifically developed for breast cancer patients, based on the guidelines of the American College of Sports Medicine. The physical exercise program comprises 3 weekly sessions of 60 minutes each. Each session will involve an initial warm-up with light mobility exercises, followed by resistance and aerobic training and ending with a return to calm phase of light stretching exercises.
11107410|NCT04024280|No Intervention|Control arm|Patients should maintain the usual physical activity
11107411|NCT04024267|Experimental|Eurythmy therapy (ERYT)|"Eurythmy therapy (ERYT) is a standardized movement therapy and for each medical condition standardized ERYT exercise (series) exist. In such, in the present study, the cancer series O-E-M-L-I-B-D that is specific and standardized for breast cancer patients will be applied. Patients can perform and maintain the postures without stress and tension. Patients are instructed by ERYT therapists in sessions with 1 to 4 patients."
11107412|NCT04024267|Active Comparator|CoordiFit|The CoordiFit program consists of standardized exercises that address physical coordination, stability, balance and dexterity. These exercises serve as a control intervention and are non-specific with respect of cancer-related fatigue and breast cancer. They mimic those of ERYT but have no mindfulness features. Patients are instructed by physical therapists in session with 1 to 4 patients.
11107413|NCT04024254|Experimental|Folic Acid|Folic Acid supplement 1 mg by mouth daily
11107414|NCT04024254|No Intervention|No Supplementation|
11107415|NCT04024241||high dose of cytarabine|high dose of cytarabine
11107416|NCT04024241||HAM|medium dose of cytarabine and mitoxantrone
11107417|NCT04024228|Experimental|Group 1: QIV-HD|QIV-HD single injection at Day 0
11107418|NCT04024228|Active Comparator|Group 2: QIV-SD|QIV-SD single injection ad Day 0
11107419|NCT04024202||Patients|"Patients with a positive DAT, a positive eluate and signs of hemolysis
~Patients with a positive DAT with complement only, negative eluate, but with hemolysis"
11107420|NCT04024202||Blood donors|Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies
11107421|NCT04024176|Experimental|Moderate hemophiliac patients|Each participant will perform a gait analysis and clinical examination
11107422|NCT04024163|Experimental|Benznidazole|Benznidazole 100 mg Tablets or Benznidazole 12.5 mg Tablets by mouth, every 12 hours for 60 days
11107423|NCT04024150||Newborns exposed|Newborns exposed in-utero to raltegravir
11107424|NCT04024150||Newborns controls|Newborns exposed to antiretroviral therapy without anti-integrase
11107425|NCT04024137|Experimental|ZSP1273-200 mg BID|Subjects will receive 10 doses of ZSP1273 200mg along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
11107426|NCT04024137|Experimental|ZSP1273-400 mg BID|Subjects will receive 10 doses of ZSP1273 400mg（200mg*2) along with placebo twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
11107427|NCT04024137|Experimental|ZSP1273-600 mg QD|Subjects will receive 5 doses of ZSP1273 600mg （200mg *3) and 5 doses of placebo respectively for 5 days.The interval between ZSP1273 and placebo is approximately 12 hour (+/- 2) .
11107428|NCT04024137|Placebo Comparator|Placebo|Subjects will receive 10 doses of matching placebo of ZSP1273 twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5 days.
11107429|NCT04024111|Experimental|KONTAKT(c)|A social skills group training
11107430|NCT04024111|Active Comparator|Super Chef|A social cooking grou
11107431|NCT04024085||Participants|adult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) < 7, consulting in a neuro-urology department
11107432|NCT04024072|Experimental|Perrigo active|Test product
11107433|NCT04024072|Active Comparator|Reference active|Azopt ophthalmic suspension
11107434|NCT04024059|Experimental|Buprenorphine Adherence and Opiate Abstinence|Participants will receive financial incentives for buprenorphine use and opiate abstinence.
11107435|NCT04024059|Experimental|Buprenorphine Adherence Only|Participants will receive financial incentives for buprenorphine use.
11107436|NCT04024059|No Intervention|Control|Participants will not receive any intervention.
11107437|NCT04024046||Control - Placebo|"Placebo Drink-Mix Daily for 180 days
~Placebo Capsules Daily for 180 days"
11107438|NCT04024046||Group 1|"Uqora Drink-Mix Daily for 180 days
~Placebo Capsules Daily for 180 days"
11107439|NCT04024046||Group 2|"Uqora Drink-Mix Daily for 180 days
~Uqora Capsules Daily for 180 days"
11107440|NCT04024033|Active Comparator|capsule|patinets receiveing pine cone extract tablets
11107441|NCT04024033|Placebo Comparator|placebo capsule|patinets receiving placebo
11107442|NCT04024020||Individuals with insomnia|Men and women with chronic insomnia (>5 years duration)
11107443|NCT04024020||Good sleepers|Men and women with a longstanding pattern of good sleep
11107444|NCT04024007||Dialysis patients|Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Dialysis performed according to the standard indications of the service. Patients are dialysed with the prismaflex system on AN69ST membranes.
11107445|NCT04023994|Experimental|Cohort 1: Dose level 1 of RO7126209 and placebo|Healthy volunteers will be administered a single intravenous dose level 1 of RO7126209 or matching placebo as per schedule specified in the respective arm.
11107446|NCT04023994|Experimental|Cohort 2: Dose level 2 of RO7126209 and placebo|Healthy volunteers will be administered a single intravenous dose level 2 of RO7126209 or matching placebo as per schedule specified in the respective arm.
11107447|NCT04023994|Experimental|Cohort 3: Dose level 3 of RO7126209 and placebo|Healthy volunteers will be administered a single intravenous dose level 3 of RO7126209 or matching placebo as per schedule specified in the respective arm.
11107448|NCT04023994|Experimental|Cohort 4: Dose level 4 of RO7126209 and placebo|Healthy volunteers will be administered a single intravenous dose level 4 of RO7126209 or matching placebo as per schedule specified in the respective arm.
11107449|NCT04023994|Experimental|Cohort 5: Dose level 5 of RO7126209 and placebo|Healthy volunteers will be administered a single intravenous dose level 5 of RO7126209 or matching placebo as per schedule specified in the respective arm.
11107535|NCT04023370|Experimental|BeGraft Peripheral Stent Graft System|Covered stent
11107536|NCT04023370|Active Comparator|Bare metal stent system|bare metal stent
11107909|NCT04020627|Experimental|BiPAP Group|Bilevel Positive Airway Pressure
11107450|NCT04023981|No Intervention|Standard care alone|Patients randomly allocated to standard care will be cared for on the appropriate mattress indicated for use in that participating centre according to local policy e.g. foam mattress or dynamic air mattress. Standard care may also include a mattress overlay or the use of a wedge or pillows to maintain the position of the participant, or pressure offloading boots on the foot if the need arises during the study period.
11107451|NCT04023981|Experimental|Parafricta bootees plus standard care|Patients randomly allocated to Parafricta plus standard care will be cared for on the appropriate mattress as above and care may possibly include a mattress overlay or the use of a wedge or pillows. Participants will in addition be issued with Parafricta bootees (one pair and up to two spare pairs). The patient and clinical staff and the patient's carers will be instructed in the use of Parafricta bootees, which are intended to be worn throughout the day and night and removed only for normal daily washing or examination of the patient's feet. Either the slip-on bootees or the Velco-closure bootees will be selected for the participant at the judgment of the clinical ward nurses.
11107452|NCT04023968|Experimental|YESplus workshop|Your Enlightened Side, plus more (YESplus) is an four-day, 15-hour integrative life skills workshop with a strong emphasis on breathing techniques and social connectedness. In addition to specific contemplative techniques such as yoga, mindfulness meditation, and compassion meditation that help cultivate inner peace, YESplus incorporates discussions and other activities to facilitate social connectedness, leadership, and community service. During the workshop, participants have ample time to learn and practice the Sudarshan Kriya Yoga (SKY) technique, as well as to ask questions. SKY has four sequential, form- and rhythm-specific breathing components interspersed with normal breathing while sitting in a relaxed position with eyes closed, followed by Yoga Nidra. A certified instructor with a minimum of 1,000 hours of SKY instruction training will lead each workshop.
11107453|NCT04023968|Active Comparator|WOW! workshop|"A comparison workshop titled Wisdom On Wellness (WOW!) will be implemented to control for potential expectancy effects, time commitment, group-based interactions, and wisdom/knowledge of YESplus that is anticipated to have beneficial effects on stress management and well-being, allowing for more rigorous evaluation of the contemplative practices and other activities unique to the YESplus workshop. This workshop differs from YESplus due to the increased focus on cognitive approaches to conceptualizing and managing stress (e.g. thoughts about the past and future versus present moment), and absence of physical or somatic activities."
11107454|NCT04023955||Intervention|Twitter messages delivered over 1 month period
11107455|NCT04023942|Active Comparator|Low carb - App-based group|Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
11107456|NCT04023942|Active Comparator|Low carb - Newsletter-based group|"Low carb is defined as 30 energy percent from carbs and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
11107457|NCT04023942|Active Comparator|Low fat - App-based group|Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. Participants assigned to the app-based group works together with a personal coach via app, providing nutritional guidance and support during the 12-month weight maintenance step.
11107458|NCT04023942|Active Comparator|Low fat - Newsletter-based group|"Low fat is defined as 25 energy percent from fat and consist of 20 energy percent from protein. The daily energy requirement is calculated for each participant individually, based on his/hers resting metabolic rate and physical activity level. Daily energy intake should be 10% lower than the calculated daily energy requirement. The newsletter intervention group gets regularly digital newsletters, in the same frequency as contacts take place in the app-based group."
11107459|NCT04023929||Term babies|Babies who are born at or after 37 gestational weeks.
11107460|NCT04023929||Preterm babies|Babies who are born between 32 and 36+6 gestational weeks.
11107461|NCT04023929||Very preterm babies|Babies who are born before 32 gestational weeks.
11107462|NCT04023916|Experimental|Sintilimab-R-CHOP|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and Sintilimab, rituximab, and CHOP during Cycles 2-6 (21-day cycle) ,Sintilimab and rituximab during Cycles 6-8 (21-day cycle) , followed by Sintilimab from Cycles 9-14 (8-week cycle) during consolidation treatment.
11107463|NCT04023903|Experimental|RTA 402 5mg 3cap at fasting|
11107464|NCT04023903|Experimental|RTA 402 5mg 3cap after meal|
11107465|NCT04023877|Experimental|E2027|Participants will receive approximately 130 microcurie (μCi) of [14C]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
11107466|NCT04023864|Experimental|Platycodon Grandiflorus Extract(GCWB107) group|Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
11107467|NCT04023864|Placebo Comparator|Placebo group|Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))
11107468|NCT04023851||Adolescent patient|"Participant between the ages of 15-18
~Participants who are taking antiepileptic drug for seizure control"
11107469|NCT04023851||Parents with epilepsy children|"Participants who have child with epilepsy (ages of 1-15)
~Participants' child who are taking antiepileptic drug for seizure control"
11107470|NCT04023838|Placebo Comparator|Right conventional radial approach|After local anesthesia on right wrist area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
11107471|NCT04023838|Active Comparator|Left distal radial approach|After local anesthesia on left anatomical snuffbox area with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After the successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by insertion of the 5Fr. radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan).
11107472|NCT04023825|Experimental|experimental group|Patients will receive loco regional anesthesia
11107473|NCT04023825|No Intervention|control group|Patients will not receive loco regional anesthesia
11107474|NCT04023812||Cohort 1|Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
11107475|NCT04023812||Cohort 2|Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
11107476|NCT04023786|Experimental|56 patients, one arm|All patients benefits of a passive leg raising test and a PEEP test to compare these two tests.
11107477|NCT04023773|Experimental|Liver perfusion|"Device: Liver Machine Perfusion (MP) Device
~The liver grafts will be preserved at hypothermic and normothermic temperature on the institutional-developed Liver MP Device, and have continuous perfusion with oxygen supply in the ex vivo organ preservation phase."
11107478|NCT04023760|Experimental|Treatment group A: Cyclosporine in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on cyclosporine as part of their immunosuppressive regimen
11107479|NCT04023760|Active Comparator|Cyclosporine in healthy subjects|"Results from Treatment group A will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of cyclosporine at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)
~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
11107480|NCT04023760|Experimental|Treatment group B: Tacrolimus in transplant recipients|A single oral dose of 10 mg apixaban will be administered to kidney or lung transplant recipients stabilized on tacrolimus as part of their immunosuppressive regimen
11107481|NCT04023760|Active Comparator|Tacrolimus in healthy subjects|"Results from Treatment group B will be compared to previously obtained data in healthy participants receiving a single dose of apixaban with a daily dose of 100 mg of tacrolimus at steady state concentration (Bashir et al. Clin Transl Sci. 2018 Jul 3. doi: 10.1111/cts.12580)
~Transplant recipients require continuous immunosuppression so it will not be possible to stop the cyclosporine or tacrolimus to serve as a control. As such PK plasma time curves will be compared to data in healthy volunteers."
11107482|NCT04023747||Cohort 1|Participants with Monoclonal B-Cell Lymphocytosis or Asymptomatic Chronic Lymphocytic Leukaemia
11107483|NCT04023747||Cohort 2|Participants with IgM Monoclonal Gammopathy or Asymptomatic Waldenstrom's Macroglobulinaemia
11107484|NCT04023747||Cohort 3|Participants with IgA or IgG Monoclonal Gammopathy or Smouldering Myeloma
11107485|NCT04023734|Experimental|Intervention|A targeted and tailored pharmacist intervention at baseline and at 1-month follow-up.
11107486|NCT04023734|Active Comparator|Control group|Usual care based on the Indonesian guideline at baseline and 1-month follow-up.
11107487|NCT04023721|Experimental|Cohort 1 - Inarigivir Soproxil Alone|Cohort 1, 400 mg Inarigivir daily for 24 weeks and after treatment discontinuation will be followed for a further 18 months.
11107488|NCT04023721|Experimental|Cohort 2 Arm A - Inarigivir Soproxil and NUC|Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
11107489|NCT04023721|Experimental|Cohort 2 Arm B - Inarigivir Soproxil and NUC|Cohort 2, Arm B, 400 mg Inarigivir daily plus prestudy nucleoside/nucleotide (NUC) analogue inhibitors for at least 24 weeks and up to 48 weeks. After treatment discontinuation of both inarigivir and the NUC, subjects will be followed off treatment up to Week 96.
11107490|NCT04023708||Cohort I: CYD-TDV exposed pregnant women and offspring|Pregnant women of any age and their offspring who were inadvertently exposed to CYD-TDV anytime during the pregnancy or in the 30 days preceding their LMP
11107491|NCT04023695|Active Comparator|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
11107492|NCT04023695|Experimental|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
11107493|NCT04023682|Experimental|Anesthesia Provider hands|Anesthesia Providers hands cultures with standard hand hygiene
11107494|NCT04023669|Experimental|A: prexasertib + cyclophosphamide|"Stratum A: Participants receive combination treatment with cyclophosphamide given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.
~Note: Only if absolutely necessary, cyclophosphamide may be given on day 16 and prexasertib may be given on day 17."
11107495|NCT04023669|Experimental|B: prexasertib + gemcitabine|"Stratum B: Participants receive combination treatment with gemcitabine given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.
~Note: Only if absolutely necessary, gemcitabine may be given on day 16 and prexasertib may be given on day 17."
11107496|NCT04023643|Experimental|CPAP + PS|Weaning from mechanical ventilation using CPAP + PS
11107497|NCT04023643|Active Comparator|SIMV + PS|Weaning from mechanical ventilation using SIMV+PS
11107498|NCT04023630|Experimental|rivaroxaban plus ticagrelor|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus ticagrelor 90 mg tablet twice daily for 12 months
11107499|NCT04023630|Active Comparator|rivaroxaban plus clopidogrel|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily for 12 months
11107910|NCT04020627|Experimental|CPAP Group|Continuous Positive Airway Pressure
11107500|NCT04023617|Experimental|Nivolumab + Docetaxel|"Nivolumab was administered at a dose of 300 mg on the first day of the 21-day cycle (every 3 weeks; q3w) when combined with docetaxel, and administered at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w) after stopping docetaxel treatment.
~On the first day of each cycle (21 days), docetaxel 75 mg/m2 was infused by IV on Day 1 of each 21-day cycle for 4-6 cycles (judged by investigator)."
11107501|NCT04023617|Active Comparator|Nivolumab|Nivolumab was administered in the monotherapy group at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w).
11107502|NCT04023604|Active Comparator|Controlled diet with beef raised without antibiotics|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in RWA (raised without antibiotics) systems for three weeks.
11107503|NCT04023604|Experimental|Controlled diet with beef produced in conventional systems|Subjects will be randomized and assigned to consume the U.S. Healthy Diet Diets with beef produced in conventional systems for three weeks.
11107504|NCT04023591||Surgery|Surgery/ Occupational Therapy
11107505|NCT04023578|Experimental|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
11107506|NCT04023565|Experimental|perindopril + moxonidine|perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
11107507|NCT04023552|Experimental|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
11107508|NCT04023552|Placebo Comparator|Placebo|Monthly subcutaneous injections.
11107509|NCT04023539|Active Comparator|Intervention group|Daily supplement of 2 g cinnamomum zeylanicum orally (capsules) for a period of 90 days
11107510|NCT04023539|Placebo Comparator|Control group|Daily placebo capsules orally (wheat flour without any active compound) for a period of 90 days.
11107511|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg|Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
11107512|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg|Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
11107513|NCT04023513|Experimental|Strength Training and Protein high|6 weeks of high protein intake (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
11107514|NCT04023513|Experimental|Strength Training and Protein low|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
11107515|NCT04023513|Other|Control|No Intervention.
11107516|NCT04023500|Active Comparator|Motivational interview|The MI-intervention is used as a part of normal dental hygienist appointment. Dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients. Dental hygienist support patients in decision making although patients were addressed as an active agent.
11107517|NCT04023500|Active Comparator|Prevailing education|In control group prevailing, more professional-centered education is used. Dental hygienist define patients educational needs and give direct instructions how to change behaviour and self-care.
11107518|NCT04023487|Experimental|Lifestyle Intervention|Resilient, Empowered, Active Living-Telehealth (REAL-T)
11107519|NCT04023487|No Intervention|Usual Care|Participants will continue to have access to routine diabetes care from the provider of their choosing; they will not receive any study-related intervention.
11107520|NCT04023474|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft in clinic at the time any pertinent post-operative complication is identified.
11107521|NCT04023474|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
11107522|NCT04023461|No Intervention|Clinical Treatment Group|
11107523|NCT04023461|Experimental|Interventional Ablation Group|
11107524|NCT04023448|Experimental|coloplasty(CP)|After purse-string suture and ligation of the head of the stapler at the colonic end, 5cm away from the colonic end, 5cm longitudinal incision was made to the proximal end of the teniae coli in the anterior wall of the colon, transverse suture was performed, and the plasmomuscular layer was embedded, then end to end colon-rectum (or anal canal) anastomosis was performed
11107525|NCT04023448|No Intervention|straight colorectal anastomosis (SCA)|End to end colon-rectum (or anal canal) anastomosis was performed routinely
11107526|NCT04023435|Experimental|PNE education|All subjects will be tested before and after receiving PNE education
11107527|NCT04023422|Active Comparator|Clinical intervention|Clinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit.
11107528|NCT04023422|Experimental|Clinical intervention AND Home Visit|Patient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics.
11107529|NCT04023422|Experimental|Clinical intervention AND Feedback|
11107530|NCT04023422|Experimental|Clinical intervention AND Home Visit AND Feedback|
11107531|NCT04023409||Severe COPD patients|Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
11107532|NCT04023396|Experimental|ABX464 50mg|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 48 weeks.
11107533|NCT04023383|Placebo Comparator|Control|The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
11107534|NCT04023383|Experimental|HyaRegen NCH gel group|In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
11107537|NCT04023357|Experimental|PEEK|"PEEKs (polyetheretherketones) are presented as alternative materials to metal and glass ceramics,1 Their elastic modulus comparable to those of cortical bone and dentin so the polymer could exhibit good stress distribution. Also they have high fracture resistance, and low abrasion to the antagonist enamel.
~Yet clinical studies are needed to evaluate their clinical performance."
11107538|NCT04023357|Active Comparator|Emax|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for Endocrowns
11107539|NCT04023344|Active Comparator|Humalog® Mix 25|Insulin Humalog® Mix 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
11107540|NCT04023344|Experimental|Insulin Lispro Biphasic 25|Insulin Lispro Biphasic 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
11107541|NCT04023331|Experimental|67Cu-SARTATE|"64Cu-SARTATE - patients will receive a bolus injection of 64Cu-SARTATE during screening, and following each 67Cu-SARTATE Therapy Cycle at a rate of 2.0 MBq/kg.
~67Cu-SARTATE - In the dose escalation phase, patients will receive a single administration of 67Cu-SARTATE as a slow IV infusion (dose will be determined based on cohort allocation). In the expansion phase, patients will receive up to 2 administrations of 67Cu-SARTATE a the MTD level as a slow IV infusion."
11107542|NCT04023318|Experimental|Integrated Lifestyle Intervention|
11107543|NCT04023305|Experimental|Nonfocal ARDS|ARDS patient with nonfocal lung imaging phenotype
11107544|NCT04023305|Experimental|Focal ARDS|ARDS patient with focal lung imaging phenotype
11107545|NCT04023292|Experimental|Arm I (2 weeks preoperative endocrine therapy))|Patients receive endocrine therapy before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
11107546|NCT04023292|Active Comparator|Arm II (4 weeks preoperative endocrine therapy)|Patients receive endocrine therapy before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
11107547|NCT04023279|Experimental|TENS|Conventional TENS of 100 Hz and 100 usec for 20 minutes
11107548|NCT04023279|Experimental|Myofascial Therapy|Conventional TENS of 100 Hz and 100 usec for 20 minutes plus myofascial release therapy in the brachial biceps; Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding
11107549|NCT04023266|Experimental|Intravenous N-Acetylcysteine arm|On arrival at the recruiting hospital, eligible and consenting STEMI patients randomly allocated to the experimental arm would be administered an intravenous N-Acetylcysteine bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours.
11107550|NCT04023266|No Intervention|Control arm|Patients randomized to this arm would receive no experimental therapies and would continue to receive all standard guideline recommended medical therapies and interventions.
11107551|NCT04023253|Experimental|mirabegron|Receive mirabegron 2 mg treatment per day
11107552|NCT04023253|Experimental|solifenacin|Receive solifenacin 5 mg treatment per day
11107553|NCT04023240|Experimental|68Ga-FAPI PET/CT|Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
11107554|NCT04023227|Experimental|Sacubitril/valsartan|"Sacubitril/valsartan 200 mg b.i.d.
~Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).
~Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug
~Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively"
11107555|NCT04023227|Active Comparator|Enalapril|"Enalapril 10 mg b.i.d.
~Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily)."
11107556|NCT04023214||ADPKD|ADPKD patients
11107557|NCT04023214||Controls|Healthy volunteers
11107558|NCT04023201||Parkinson's disease patients|Parkinson's disease patients with or without nocturnal symptoms
11107559|NCT04023175|Active Comparator|In office|Patients will undergo our standard in office preoperative counseling.
11107560|NCT04023175|Experimental|Virtual visit|Patients will undergo preoperative counseling using telemedicine virtual visits.
11107561|NCT04023162|Experimental|Biomedical group|Therapy Exercises and Back School by month, 2 times a week for 60 minutes.
11107562|NCT04023162|Experimental|Biopsychosocial group|Operant Conditioning implement in physiotherapy, Therapy Exercises and Back School by month, 2 times a week for 60 minutes.
11107563|NCT04023162|No Intervention|Usual care|Usual care and written instructions on Therapeutic Exercises and Back School for home work.
11107564|NCT04023149|Experimental|experimental group|Patients will receive rhIL-2 solution oral gargle twice per day (2 million units of rhIL-2 dissolved in 5ml normal saline for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
11107565|NCT04023149|Placebo Comparator|control group|Patients will receive placebo solution oral gargle twice per day (5ml for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
11107566|NCT04023136|Other|only one arm (resected patients)|liver resection group
11107567|NCT04023123||Anterior Cornea Striae|Eyes with anterior cornea striae present
11107568|NCT04023123||Hypotony Maculopathy|Eyes with hypotony maculopathy present
11107569|NCT04023123||Hypotony only|Eyes with intraocular pressure less than 10 without cornea striae and/or maculopathy
11107570|NCT04023110|Experimental|Carvedilol|"Carvedilol will be initiated at 3.125mg twice daily and uptitrated as tolerated in a stepwise fashion to a maximum dose of 25mg twice daily or to a systolic blood pressure (SBP) of 110-120mmHg or heart rate (HR) of 50-55 beats per minute (bpm). Patients will start carvedilol in the evening after first dose of chemotherapy and will continue on medication for 12 months.
~Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months."
11107571|NCT04023110|No Intervention|Usual Care|Clinical, echocardiographic, and biomarker data will be collected on all patients at baseline and standardized time intervals during and after therapy at approximately 3, 6, 9, 12, and 24 months.
11107572|NCT04023097|Experimental|Toothwave contraindicated subject|"the Toothwave toothbrush is contraindicated for people in certain conditions, e.g. pregnant or nursing women, people with pacemaker and more.
~This arm is assembled from contraindicated subject, who should exclude themselves from use of the device, based on the user manual and box sleeve."
11107573|NCT04023097|Active Comparator|potential users of the Toothwave device|The control arm is assembled from people who can use the toothbrush and should recognize themselves as potential users.
11107574|NCT04023084|Experimental|Atopic Dermatitis Group|Receive crisaborole intervention
11107575|NCT04023071|Experimental|FT516 Monotherapy|FT516 monotherapy in adult subjects with r/r AML.
11107576|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies|FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
11107577|NCT04023058|No Intervention|CABG/increasing MR|non-massive IMR with increasing IMR during exercise - CABG only
11107578|NCT04023058|Experimental|CABG+mitral surgery (MS)/increasing MR|non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
11107579|NCT04023058|No Intervention|CABG/non-increasing MR|non-massive IMR non-increasing IMR during exercise - CABG only
11107580|NCT04023058|Experimental|CABG+MS/non-increasing MR|non-massive IMR non-increasing IMR - CABG+ mitral surgery
11107581|NCT04023058|Other|Control 1|massive IMR at rest without increasing during exercise - CABG+ mitral surgery
11107582|NCT04023058|Other|Control 2|massive IMR at rest with increasing during exercise - CABG+ mitral surgery
11107583|NCT04023045|Active Comparator|Habitual Prosthesis|Participant's prescribed prosthesis
11107584|NCT04023045|Experimental|Assist-Knee|Experimental knee prosthesis
11107585|NCT04023019||Group 1: ITI with Nuwiq, octanate, or wilate|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery and for prophylaxis.
11107586|NCT04023019||Group 2: ITI with Nuwiq, octanate, or wilate with emicizumab|Participants receiving immune tolerance induction with either Nuwiq, octanate, or wilate, in combination with emicizumab prophylaxis. As needed, aPCC/rFVIIa will be administered to treat bleeding episodes or during surgery.
11107587|NCT04023019||Group 3: Prophylaxis with emicizumab, aPCC, or rFVIIa|Participants receiving routine prophylaxis with emicizumab, aPCC, or rFVIIa without immune tolerance induction. On-demand aPCC/rFVIIa can be used as needed to treat bleeding episodes or during surgery.
11107588|NCT04023006||Edentulous Patients|The investigational device is part of a treatment concept for edentulous patients of all ages, gender and races. The incidence for tooth loss has not declined over years, and the prevalence for edentulism is significantly higher for adults 50 years and older. For this descriptive two-part survey, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) patients will be enrolled, i.e. 10 dentures will be fabricated within this study.
11107589|NCT04022993|Active Comparator|Lantus® SoloStar®|Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
11107590|NCT04022993|Experimental|Insulin RinGlar®|Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
11107591|NCT04022980|Experimental|Stage 1|Safety Run-In
11107592|NCT04022980|Experimental|Stage 2|Expansion Cohort
11107593|NCT04022967|Experimental|Arm 1 : Dual maintenance therapy DTG+3TC|
11107594|NCT04022967|Experimental|Arm 2 : Dual maintenance therapy ATV/r+3TC|
11107595|NCT04022967|Active Comparator|Arm 3 : Reference triple therapy TDF+3TC+EFV|
11107596|NCT04022954||Inquiry™ AFocusII™ Double Loop|The Inquiry™ AFocus™ catheters are for recording intracardiac signals and cardiac stimulation during diagnostic electrophysiological studies. The Inquiry™ AFocus™ catheters are for use in mapping atrial regions of the heart.
11107597|NCT04022954||Advisor™ HD Grid, Sensor Enabled™|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart with recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
11107598|NCT04022941|Experimental|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
11107599|NCT04022941|Placebo Comparator|Placebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
11107600|NCT04022928|Experimental|PRP injection|Patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.
11107601|NCT04022915|Experimental|Acute pulmonary embolism|Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
11107602|NCT04022889|Experimental|Stage 1|Stage 1 is a randomized, 2-period crossover design. Test platelets stored for 7 days will be radiolabeled using either the BEST or Variant 1 methods (depending on the period and randomization scheme for the Test platelets) for 12 healthy subjects. The recovery and survival for Test platelets prepared with the BEST and Variant 1 methods will be compared with each other and against the fresh platelet Control.
11107603|NCT04022889|Experimental|Stage 2|Stage 2 is a single arm study in which all Test platelets will be prepared for radiolabeling using the Variant 1 methodology. The recovery and survival for Test platelets will be compared against the fresh platelet Control. Recovery and survival of INTERCEPT platelets will be assessed after Day 7, 6 or 5 days of storage for up to 24 evaluable subjects. The storage duration of the Test platelet components will be determined by Cerus based on the outcome of Stage 1.
11107604|NCT04022876|Experimental|Phase 1b|"ALRN-6924 will be administered IV on days 0-4 of every 21-day cycle
~Topotecan will be administered IV after ALRN-6924 on days 1-5 of every 21-day cycle"
11107605|NCT04022876|Experimental|Phase 2 Experimental|"ALRN-6924 will be administered IV on days 0-4 of every 21-day cycle
~Topotecan will be administered IV after ALRN-6924 on days 1-5 of every 21-day cycle"
11107606|NCT04022876|Experimental|Phase 2 Control|Topotecan will be administered IV on days 1-5 of every 21-day cycle
11107607|NCT04022863||ovarian tumor benign|all pathological proven benign ovarian tumors
11107608|NCT04022863||ovarian tumor borderline|all pathological proven borderline ovarian tumors
11107609|NCT04022863||ovarian tumor malignant|all pathological proven malignant ovarian tumors
11107610|NCT04022850|Active Comparator|Passive dissemination|Passive dissemination strategies focused on the distribution of materials, support tools and training
11107611|NCT04022850|Experimental|Intuitive de-implementation|Mindless externally imposed de-implementation strategies to discourage the non-desired behavior and to encourage the preferred/desired behavior
11107612|NCT04022850|Experimental|Reflexive de-implementation|Active de-implementation strategies targeting conscious cognition processes to discourage the non-desired behavior and to encourage the preferred/desired behavior
11107613|NCT04022837|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
11107614|NCT04022837|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
11107615|NCT04022824||OSA|
11107616|NCT04022824||Non-OSA|
11107617|NCT04022811|Experimental|Artificial tears|0.1% bromfenac VS Artificial tears
11107618|NCT04022798|Experimental|Experimental group|Neural mobilization (NM), lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
11107619|NCT04022798|Active Comparator|Control group|lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
11107620|NCT04022785|Experimental|Treatment (BRD4 Inhibitor PLX51107, azacitidine)|Patients receive PLX51107 PO QD on days 1-21 and azacitidine SC or IV over 15 minutes on days 8-14 and 22-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11107621|NCT04022772|Experimental|GROUP I (PACK Health program)|Patients participate in PACK Health program consisting of weekly contact with an assigned health coach via text message, phone call, and email for 3 months. Following the first 3 months of the program, study participants will then receive at least one touch point weekly between months 4-6 of their study enrollment, with additional engagement and frequency according to each patient's preference.
11107622|NCT04022772|Active Comparator|GROUP II (standard of care)|Patients receive standard of care support services over 6 months.
11107623|NCT04022759|Active Comparator|Treatment as Usual|Participants randomised to the 'treatment as usual' group will receive behavioural activation guided-self help intervention as routinely delivered in the service.
11107624|NCT04022759|Experimental|Treatment with Security Prime|Participants randomised to the experimental group will receive behavioural activation guided self-help intervention as is routinely delivered in the service with additional attachment security priming intervention.
11107625|NCT04022746|Experimental|Diagnostic (MRI/MRE)|Patients undergo standard of care MRI and MRE over 60-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks until disease progression.
11107626|NCT04022733|Placebo Comparator|Moderate NMB group|
11107627|NCT04022733|Experimental|Deep NMB group|
11107628|NCT04022720|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft.
11107629|NCT04022720|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
11107630|NCT04022707|Experimental|High-Velocity Resistance Circuttraining (HVRCT)|The participants will perform three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three weeks from 1 to 3 circuits.
11107631|NCT04022707|Experimental|Educational Control (CON)|A supervised program will be provided to the participants that includes lectures on health and fitness.
11107632|NCT04022694|Active Comparator|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
11107633|NCT04022694|Experimental|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
11107634|NCT04022681||Non-specific liver disease|Patients who were categorised as having a non-specific liver disease in the original BALLETS study.
11107635|NCT04022668||STEMI|Current international ECG criteria (New ST-segment elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV millivolts (mV) in all leads other than leads V2-V3; for leads V2-V3: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age) with troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia.
11107636|NCT04022668||NSTEMI|Troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia without abovementioned criteria.
11107637|NCT04022668||Normal|Emergency department admission with a clinical picture compatible with acute coronary syndrome, but no change in serial ECGs and no rise in cardiac biomarkers
11107638|NCT04022655||ANCA-associated Vasculitis|Patients with ANCA-associated vasculitis admitted to the ICU
11107639|NCT04022642|Experimental|HIIT Group|Two HIIT sessions delivered at the beginning of Physical education classes
11107640|NCT04022642|No Intervention|Control Group|Usual programmed Physical education classes
11107641|NCT04022629|Active Comparator|Treatment Group 1|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
11107642|NCT04022629|Active Comparator|Treatment Group 2|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
11107643|NCT04022616||Immediate Surgery|Adult patients with breast malignancy.
11107644|NCT04022616||Neo-adjuvant Chemotherapy|Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.
11107645|NCT04022616||Lymph Node Tissue|Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.
11107646|NCT04022616||Metastatic Breast Cancer|Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).
11107647|NCT04022603|Experimental|Optiflow nasal googles|Oxygen provided by means of high throughput nasal googles (Optiflow, Fisher&Paykel- New Zealand).
11107648|NCT04022603|Active Comparator|Venturi mask|Oxygen provided by means of a Venturi mask.
11107649|NCT04022590|Experimental|E-clothes|The participants with E-clothes do aerobic training at home
11107650|NCT04022590|Active Comparator|Home exercise|The participants with healthy consultation do aerobic training at home.
11107651|NCT04022577|Experimental|experimental group|The experimental group will participate in a eight session course of Adherence Therapy
11107652|NCT04022577|Placebo Comparator|control group|The control group received routine care
11107653|NCT04022564||The subjects are diagnosed as MS patient|The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.
11107654|NCT04022551||Observational|"At Emergency nurses will carry out a test called: Emergency Room Evaluation and Recommendation which contents the following statements:
~Being 85 years older and over (Yes/No)
~Male (Yes/No)
~Home services (Yes/No)
~Taking 5 different medication daily (Yes/No)
~Use of walking aid (Yes/No)
~Disoriented (Yes/No)"
11107655|NCT04022538|Experimental|Sandwich osteotomy with simultaneous implant placement|This group will undergo Sandwich osteotomy procedure and segment will be fixed using the dental implants placed simultaneously during the same surgical procedure. The remaining gap will be filled using xenograft.
11107656|NCT04022538|Active Comparator|Sandwich osteotomy using micro-plates fixation|This group will undergo Sandwich osteotomy procedure and segment will be fixed using micro-plates and screws, and the gap will be filled using xenograft.
11107657|NCT04022525||leflunomide responsive vs non-responsive|
11107658|NCT04022499|Experimental|Pre-NDPP|Presessions + usual care NDPP
11107659|NCT04022499|Active Comparator|Usual care NDPP|Usual care NDPP only
11107660|NCT04022486||Children admitted in the PICU for severe bronchiolitis|Children admitted in the Pediatric Intensive Care Unit (PICU) for severe bronchiolitis between January 1st, 2010 and April 30th, 2018
11107661|NCT04022473|Experimental|Bafiertam|oral capsules administered twice daily
11107662|NCT04022473|Active Comparator|Tecfidera|oral capsules administered twice daily
11107663|NCT04022434|Placebo Comparator|Placebo|"Psyllium powder is used as the placebo. A member of the research staff will package and dispense L-alanine and placebo in similar containers. A standard measuring spoon will be provided to the subject for preparing the placebo solution. Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
~Meal Placebo Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
11107664|NCT04022434|Experimental|Experimental Alanine|"L-alanine, USP (Spectrum® Chemicals and Laboratory Products, Gardena, CA) will be packaged and dispensed by one member of the research staff who will have no other role in the study. A one-month supply will be dispensed to the subjects.
~Meal L-Alanine Breakfast * 1-2 scoops Snack * .5 - 1 scoop Lunch * 1-2 scoops Snack * .5 - 1 scoop Dinner * 1-2 scoops"
11107665|NCT04022421|Experimental|hydroxychloroquine arm|
11107666|NCT04022408|Experimental|Liquid based cytology|.Liquid-based cytology (LBC), enables cells to be suspended in a monolayer. LBC makes better cytological assessment possible with improved sensitivity and specificity, since fixation is better and nuclear details are well preserved in the technique. Preneoplasticand neoplastic cells are not obscured by other cells, such as normal epithelial and inflammatory cells. LBC techniques are currently applied to cytological samples from several tissues or fluids. They include uterine cervix , endometrium, aspirates from breast , thyroid tumors, ascites and pleural effusion, and urine , LBC technology is suggested as an appropriate diagnostic method for metastatic tumors in cerebrospinal fluid .
11107667|NCT04022408|Active Comparator|Conventional cytology|It is a gold standard for histopathological diagnosis of pancreatobiliary malignancies till date
11107668|NCT04022395|Experimental|stress cardiac MRI|"To optimize the scan protocol and the sequence parameters
~To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients
~To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features"
11107669|NCT04022382|Experimental|Restylane Defyne recipient|
11107670|NCT04022369|Experimental|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. Education program based on Empowerment model. Weekly motivational telephone interviews were conducted with the patients, and the home visits and telephone interviews were repeated when belived necessary. The purpose of the study were explained to all individuals involved in the study. Body movements, balance levels, exercise durations, and strengths of individuals before exercise program and after exercise program were evaluated. A booklet demonstrating the exercises was given to the patients to enhance their understanding, and they were allowed to ask questions about the exercise program during the training.
11107671|NCT04022369|No Intervention|Control Group|The patients in the control group continued their standard treatment and care. Data collection forms were applied to the patients in the control group at the first month and 12 weeks after discharge. After the study was completed, all patients in the control group were provided with home-based exercise training booklets.
11107672|NCT04022356|Experimental|Connected soles|Number of steps recorded by the soles (activation per smartphone)
11107673|NCT04022356|Active Comparator|Gold Standard|Number of steps counted by two observers viewing the film
11107674|NCT04022343|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
11107675|NCT04022330|Other|Blood sampling|
11107676|NCT04022317|Experimental|Biocon Insulin R|0.3 IU/kg Dose per administration, subcutaneous Route of administration
11107677|NCT04022317|Active Comparator|Humulin® R (regular insulin human)|0.3 IU/kg Dose per administration, subcutaneous Route of administration
11107705|NCT04022135|Experimental|(6S)-5-methyltetrahydrofolic acid (Metafolin)|0.625 mg/d (an equimolar dose to folic acid)
11107678|NCT04022304|Experimental|Sequence: Humulin® N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
11107679|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
11107680|NCT04022304|Experimental|Sequence: Humulin® N- Humulin® N-Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N(100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
11107681|NCT04022304|Experimental|Sequence: Biocon Insulin N- Humulin® N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
11107682|NCT04022304|Experimental|Sequence: Humulin® N-Biocon Insulin N- Biocon Insulin N|"Period 1: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
11107683|NCT04022304|Experimental|Sequence: Biocon Insulin N- Biocon Insulin N-Humulin® N|"Period 1: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 2: 0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.
~Period 3: 0.4 IU/kg of Humulin® N (100 IU/mL) administered once subcutaneously.
~The treatment periods will be separated by 5-7 days"
11107684|NCT04022291|Experimental|Biocon Insulin 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
11107685|NCT04022291|Active Comparator|Humulin® 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
11107686|NCT04022265|Active Comparator|Control Site -Drill site|The control sites (Drills) will be prepared with a lanceolate drill (FS 230, Sweden / Martina), with a maximum diameter of 2.3 mm,
11107687|NCT04022265|Experimental|Test site -sonic site|test sites will be prepared with conical diamond inserts of increasing diameter (SFS99.000.014 to SFS99.000.024, Komet-Brasseler-GmbH, Germany) mounted on a sonic-air surgical instrument
11107688|NCT04022252|Experimental|Tooth Movement|Canine distalization on premolar extracted patients
11107689|NCT04022252|Experimental|Biochemistry measurements|biochemistry analysis of IL-8, OPG, RANKL
11107690|NCT04022252|Experimental|periodontal measurements|gingival and plaque index, blooding on probing, pocket depth
11107691|NCT04022239|Experimental|Schedule I (non-lymphoma)|Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
11107692|NCT04022239|Experimental|Schedule II (lymphoid malignancies)|Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.
11107693|NCT04022226|Active Comparator|Methohexital|Standard of care anesthesia that does not affect slow wave characteristics
11107694|NCT04022226|Experimental|Ketamine|Standard of care anesthesia that suppresses slow wave characteristics
11107695|NCT04022213|Experimental|Group A|Participants with DSRCT who have undergone GTR of their abdominopelvic disease and who have no definitive radiological evidence of disease in liver or outside the abd/pelvis. Patients if deemed of likely benefit to the patient after completing RIT plus WA-IMRT, or will be mandated if ANC is persistently <500/ul despite use of G-CSF for >1 week, or if patients experience life threatening febrile neutropenia.
11107696|NCT04022213|Experimental|Group B|Participants with DSRCT without GTR
11107697|NCT04022213|Experimental|Group C|Participants with tumors other than DSRCT who are B7H3-positive on immunohistochemistry
11107698|NCT04022200||Paclitaxel DCB for De Novo Coronary Lesions|we define de novo coronary artery lesions as the lesions never been treated with any interventional device, such as POBA, stent, rota ablation, laser etc.
11107699|NCT04022187||Bulbocavernosus reflex assessment|Patients over 18 years old, consulting in neuro-urology department for urinary, anorectal or genito-sexual disorders.
11107700|NCT04022174|Experimental|Moderate dosage training|
11107701|NCT04022174|Experimental|Intensive dosage training|
11107702|NCT04022161|Placebo Comparator|Nitrogen|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
11107703|NCT04022161|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled nitric oxide (iNO) will be weaned and discontinued.
11107704|NCT04022135|Active Comparator|Folic acid|0.6 mg/day
11107736|NCT04021888|Active Comparator|Control|
11107706|NCT04022122||Heart Failure patients|The study does not imply any specific therapeutic intervention, and will not imply any change in the management of the participating patients, who will follow the usual clinical controls and will receive the medical and invasive treatments usually provided to patients with HF in our health area; as well as the different modalities of specific health education for this disease. At the time of hospital discharge, patients will be handled according to the usual protocols of the center established for outpatient follow-up of HF patients.
11107707|NCT04022109||Gastric cancer patients undergoing surgery|Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management
11107708|NCT04022109||Gastric cancer patients|Patients with histologically confirmed gastric cancer (adenocarcinoma)
11107709|NCT04022109||Control group patients without gastric cancer|Patients without gastric malignant disease according to data obtained in upper endoscopy
11107710|NCT04022109||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
11107711|NCT04022109||Patients with dyspeptic symptoms|Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)
11107712|NCT04022096|Experimental|Tegoprazan 25mg QD|Tegoprazan 25mg tablet, once daily, oral administration
11107713|NCT04022096|Active Comparator|Lansoprazole 15mg QD|Lansoprazole 15mg capsule, once daily, oral administration
11107714|NCT04022070|Other|Dynamic Tape|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage in a sample of subjects affected by plantar fasciitis.
11107715|NCT04022057|Active Comparator|Pre-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
11107716|NCT04022057|Sham Comparator|Post-GA|10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
11107717|NCT04022031||Exposed group|Chinese patent medicine combined with western medicine routine
11107718|NCT04022031||Non-exposed group|Western medicine routine treatment
11107719|NCT04022018|Experimental|Adaptive radiotherapy group|Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of adaptive radiotherapy group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
11107720|NCT04022018|Active Comparator|Control group|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.
11107721|NCT04022005|Experimental|Chidamide combined with R-GemOx|Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
11107722|NCT04021992|Experimental|GVD with or without R|Gemcitabine 1000mg/m2, d1,d8, intravenous drip; Vinorelbine 50mg/m2, d1,d8, oral; Doxorubicin liposomes 30mg/m2, d1,intravenous drip; With or without rituximab 375 mg/m2, d0,intravenous drip; All patients received up to 6 treatment cycles of 21 days.
11107723|NCT04021979|Experimental|Enteral Nutritional+PEG|Enteral Nutritional Powder with low volume 1.5L PEG
11107724|NCT04021979|Placebo Comparator|Self-controlled diet+PEG|Self-controlled diet with normal amount of 2L PEG
11107725|NCT04021966|Experimental|Laser|In this arm, participants will have 3 real laser treatments first, followed by 3 consecutive sham treatments.
11107726|NCT04021966|Sham Comparator|Sham|In this arm, participants will have 3 sham treatments first, followed by 3 consecutive real laser treatments.
11107727|NCT04021953|Experimental|Intervention Group|"The online intervention comprises a series of six videos, each about 10-minutes in length, entitled the People Like Us series. The intervention was developed by gayhealth.sg and Action for AIDS Singapore in 2018. The series follow the love and sex lives of four ethnically-diverse GBQ men of varying socioeconomic backgrounds, as they negotiate issues of sexual health, mental health, and relationships throughout the six-part miniseries.
~The intervention group will also be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention."
11107728|NCT04021953|Active Comparator|Control Group|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
11107729|NCT04021940|Experimental|Dose adjusted ULOD|dose adjusted ULOD using 60J/cm3 applied to the larger ovary. The number of punctures (Np) per ovary will be calculated according to the following formula: Np = 60 J/cm3 divided by 30 W x 4 s.
11107730|NCT04021940|Active Comparator|Fixed dose ULOD|600 J for the larger ovary will be delivered through four punctures, each for 4 s and 40 W
11107731|NCT04021927|Experimental|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
11107732|NCT04021914|Experimental|EnChroma glasses|EnChroma products improve brightness and color purity of primary colors for CVD people. Each participant with CVD will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life.
11107733|NCT04021901||F21|balloon diameter F21
11107734|NCT04021901||F24|balloon diameter F24
11107735|NCT04021888|Experimental|Exercise Group|
11107737|NCT04021862|Experimental|Treatment Arm 1 (bermekimab every week)|"Loading Dose: 400 mg subcutaneous (SC) injection of bermekimab and a SC injection of placebo at week 0 (Baseline)
~Treatment Dose: 400 mg subcutaneous injection of bermekimab administered weekly (qw) from week 1 to week 15."
11107738|NCT04021862|Experimental|Treatment Arm 2 (bermekimab every other week)|"Loading Dose: Two 400 mg SC injections of bermekimab at week 0 (Baseline)
~Treatment Dose: 400 mg SC injection of bermekimab administered every other week (q2w) alternating with placebo q2w from week 1 to week 15"
11107739|NCT04021862|Placebo Comparator|Placebo|"Loading Dose: Two SC injections of placebo at week 0 (Baseline)
~Treatment Dose: Subcutaneous injection of placebo administered once weekly (qw) from week 1 to week 15."
11107740|NCT04021849|Experimental|Intervention|Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
11107741|NCT04021849|Sham Comparator|Control|Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
11107742|NCT04021836|Other|3d evaluation of naso labial changes using alar cinch suture|
11107743|NCT04021836|Other|3d evaluation of nasolabial change without Alar cinch|
11107744|NCT04021823||DBS patients|Patients with treatment resistant major depression participating in the FORESEE III study.
11107745|NCT04021823||Healthy controls|Age- and sex-matched healthy controls undergoing analyses of neurodegenerative markers (neurofilament light protein) in blood and metabolomic analyses in blood and urine.
11107746|NCT04021810|Active Comparator|CPAP only|Obstructive sleep apnea patients with CPAP treatment only
11107747|NCT04021810|Active Comparator|Mandibular Advancement Device only|Obstructive sleep apnea patients with Mandibular Advancement Device only
11107748|NCT04021810|Experimental|CPAP + Mandibular Advancement Device|Obstructive sleep apnea patients with combined CPAP and Mandibular Advancement Device
11107749|NCT04021797|Sham Comparator|Sham|For the sham condition, the electrodes will be attached to an ear location that has not been shown to engage the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the active tVNS condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
11107750|NCT04021797|Experimental|Active|For the active condition, the electrodes will be attached to the ear at a place previously demonstrated to stimulate the vagus nerve. The stimulation frequency, intensity and duration will be aligned with the same parameters presented for the sham condition (8Hz frequency, 5.0 mA electrical current and 200 ms pulse width).
11107751|NCT04021784|Experimental|Spring Distraction System (SDS)|The SDS will be placed and fits around a standard rod of 4.5 or 5.5mm.
11107752|NCT04021784|Experimental|Necker Enfants Malade OSTeosynthesis (NEMOST)|The NEMOST is a one-way-rod that uses a ratchet type of locking mechanism. Both NEMOST devices should be placed in parallel, on the two fixator rods that are connected with a cross connector
11107753|NCT04021771|Other|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
11107754|NCT04021771|Other|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
11107755|NCT04021758|Experimental|Peer to peer program intervention|The experimental condition for the proposed project is the Airman's Edge program, a peer to peer program in which peer mentors will be trained to provide a series of interventions aimed at reducing risk for suicidal behaviors both directly and indirectly through the targeting of emotion dysregulation, cognitive rigidity, and contextual risk factors (e.g., insomnia, meaning in life, social support, firearm availability).
11107756|NCT04021758|No Intervention|Wait list|
11107757|NCT04021745|Experimental|App-based mindful eating|The intervention will be delivered through a mindful eating smartphone application using the latest evidence-based mindful eating methods and behavior change theory.
11107758|NCT04021719||OnTrackNY LHS Participants and Stakeholders|OnTrackNY participants and stakeholders, including past participants, family members, clinicians, administrators, payors, and state leadership
11107759|NCT04021706|Active Comparator|anamorelin|one 100 mg tablet daily, taken one hour before breakfast
11107760|NCT04021706|Placebo Comparator|microcrystaline cellulose|one identical appearing tablet daily, taken one hour before breakfast
11107761|NCT04021693|Experimental|Handheld Ultrasound Devices|
11107762|NCT04021693|No Intervention|No Handheld Ultrasound Devices|
11107763|NCT04021667|Experimental|INDIVIDUAL BREASTFEEDING TRAINING|"Individual Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.
~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates."
11107799|NCT04021394||Low-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
11107800|NCT04021394||High-volume metastatic hormone-sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
11107764|NCT04021667|Experimental|GROUP BREASTFEEDING TRAINING|"Group Breastfeeding Training: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.
~After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates.The groups were composed of five pairs of parents."
11107765|NCT04021667|No Intervention|Control Group|Control Group: Mother and father candidates who applied to the pregnant outpatient clinic and met the study criteria were included in the study.After the informed consent was signed, the socio-demographic questionnaire including obstetric history and breastfeeding history, IOWA infant nutrition attitude scale and Breastfeeding Self-Efficacy Scale were applied to the mother and father candidates. Routine procedures were applied to the mother and father candidates.
11107766|NCT04021641||Participants with Typical Hearing|From 5 age groups from their 6 years of age to adulthood
11107767|NCT04021641||Participants with Hearing Impairment|Participants with various degree of hearing impairment
11107768|NCT04021615|Experimental|Group A (study group)|Twenty five patients will receive comprehensive rehabilitation program combined with inspiratory muscle training.
11107769|NCT04021615|Active Comparator|Group B (Control group)|Twenty five patients will receive traditional chest physical therapy combined with inspiratory muscle training.
11107770|NCT04021602|Active Comparator|Intervention 1 (Tx1) - DPP + Breastfeeding + Usual Care|Patients randomized to Tx1 will receive education in both the Diabetes Prevention Program (DPP) and in Breastfeeding. At baseline, this includes 16 DPP sessions (core curriculum), one 2-hour breastfeeding session, and participation in a professional peer support group. The 2-hour breastfeeding session is pre-recorded into four (4) 30-minute sessions and archived on a secure, private Facebook group. Participants will have access to all four breastfeeding sessions by week 24 of pregnancy and they need to complete all sessions by week 30 of pregnancy. At delivery, the patient will receive usual lactation support in the hospital, additional breastfeeding assessment and support (at day 3, day 10, week 3 and week 6), followed by 6 DPP sessions (post-core curriculum).
11107771|NCT04021602|Active Comparator|Intervention 2 (Tx2) - DPP Only + Usual Care|Patients randomized to Tx2 will receive education in only the Diabetes Prevention Program. At baseline, this includes 16 DPP sessions (core curriculum). At delivery, the patient will receive usual lactation support in the hospital, followed by 6 DPP sessions (post-core curriculum).
11107772|NCT04021602|Placebo Comparator|Intervention 3 (Tx3) - Usual Care Only|Patients randomized to Tx3 will receive only usual standard of care. At baseline, the patient will receive only regular prenatal care provided by their physician. At delivery, the patient will receive standard of care breastfeeding support provided by the hospital.
11107773|NCT04021589|Experimental|WLS-intervention group|chemotherapy + WLS
11107774|NCT04021589|Active Comparator|the control group|chemotherapy
11107775|NCT04021576|Experimental|intervention|preventative training program
11107776|NCT04021576|No Intervention|control|no such training
11107777|NCT04021563|Experimental|SR419|Ascending single and multiple doses of SR419 orally
11107778|NCT04021563|Placebo Comparator|Placebo|Ascending single and multiple doses of placebo orally
11107779|NCT04021550|Experimental|Combined Treatment|Subjects will be given 80 mg/day Telmisartan + 600 mg/day Alpha-Lipoic Acid. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
11107780|NCT04021550|Placebo Comparator|Placebo Control|Subjects will be given placebo capsules. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.
11107781|NCT04021537|Experimental|non-invasive nerve stimulation a|Electrical stimulation will be delivered to a location at the ear.
11107782|NCT04021537|Active Comparator|non-invasive nerve stimulation b|Electrical stimulation will be delivered to a location at the ear.
11107783|NCT04021524|Active Comparator|Hibiclens Soap|
11107784|NCT04021524|Experimental|BPO Soap|
11107785|NCT04021511|No Intervention|Phase A|The first one (Phase A) will occur in the emergency department with the application of OAR only by the physicians (without changing the standard of care) during 4 weeks
11107786|NCT04021511|Experimental|Phase B|The second one (Phase B) will occur after the Phase A. Nurses will apply OAR according to the protocol. This phase will also lasts 4 weeks.
11107787|NCT04021498|Placebo Comparator|Placebo|"placebo
~1 year"
11107788|NCT04021498|Experimental|Simvastatin|"40 mg
~1 year"
11107789|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 3 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.
~Interventions will include:
~Standardized neurological exam
~Morphometric measurements including height, weight, head circumference
~Blood pressure measurement
~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY subtests and KABC-II (Kaufman Assessment Battery for Children II) subtests,
~Social Relativeness, using Social Relativeness Scale parental questionnaire,
~Parental stress using PSI questionnaire"
11107790|NCT04021472|Experimental|Text message|Participants receive text messages about healthy eating or physical activity.
11107791|NCT04021459|Other|women with endometrial cancer|
11107792|NCT04021446|Active Comparator|Exercise|Will receive the exercise intervention
11107793|NCT04021446|No Intervention|Attention Control|Will not receive the exercise intervention
11107794|NCT04021433|Experimental|MDD|Treatment resistant patients will be treated with multiple doses of IM/SC ketamine [dose range 0.3-1.5mg/kg]
11107795|NCT04021420|Experimental|low intensity pulsed UltraSound|SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
11107796|NCT04021407|Active Comparator|LMA|36 patients were ventilated with LMA during dacryocystorhinostomy surgery
11107797|NCT04021407|Active Comparator|AirQ|36 patients each were ventilated with air Q airway during dacryocystorhinostomy surgery
11107798|NCT04021394||Non-metastatic, high-risk hormone sensitive prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
11107801|NCT04021394||Metastatic castrate-resistant prostate cancer|Phlebotomy collection of 2 tubes of blood then annual follow up for 5 years
11107802|NCT04021381|Experimental|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate
11107803|NCT04021381|Placebo Comparator|Placebo|Patients are treated with placebo
11107804|NCT04021368|Experimental|SEL120|The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of SEL120 to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with SEL120 to support the evaluation of the RD.
11107805|NCT04021355|Experimental|Early Sodium|Early sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for 9 days and in addition will take 2 g of sodium in the form of salt tablets with breakfast each day.
11107806|NCT04021355|Experimental|Late Sodium|Late sodium load: participants will consume a standardized diet providing 2.3 g of sodium per day for 7 days (run-in period), after which they will continue to consume the standardized diet for the next 9 days and in addition will take 2 g of sodium with dinner each day.
11107807|NCT04021342|Active Comparator|Montmorency tart cherry concentrate|Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to ~180 cherries per day).
11107808|NCT04021342|Placebo Comparator|Isocaloric cherry flavoured placebo|The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.
11107809|NCT04021329|Other|EMDR Therapy|One arm will be a group subjected to EMDR Therapy
11107810|NCT04021329|Other|CBT Therapy|other arm will be a group subjected to CBT Therapy
11107811|NCT04021316|Active Comparator|Standard care arm|Compression bandaging therapy as per standard care
11107812|NCT04021316|Experimental|DCD Arm|DCD graft plus compression bandaging therapy as per standard care
11107813|NCT04021303|Experimental|Experimental Cereal|Experimental cereal with probiotics, prebiotic fiber and low carbohydrates through all the duration of the study.
11107814|NCT04021303|Active Comparator|Conventional cereal|Conventional gluten free cereal between 4 and 6 months old, and conventional gluten cereal between 7 and 12 months old.
11107815|NCT04021290|Experimental|Participants receiving DTG/3TC FDC|Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.
11107816|NCT04021290|Active Comparator|Participants receiving CAR|Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.
11107817|NCT04021277|Experimental|ACT with chemotherapy in metastatic solid tumours|Part 1: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with solid tumours
11107818|NCT04021277|Experimental|ACT with chemotherapy in metastatic CRC|Part 2: PS101 administered together with standard of care chemotherapy (FOLFOX or FOLFIRI) and US insonation over the targeted liver metastasis in patients with metastatic colorectal cancer
11107819|NCT04021277|Experimental|ACT with chemotherapy in metastatic PDAC|Part 2: PS101 administered together with standard of care chemotherapy (Gemcitabine and nab-paclitaxel) and US insonation over the targeted liver metastasis in patients with metastatic Pancreatic Duct Adenocarcinoma (PDAC)
11107820|NCT04021264|Active Comparator|PRE-GA|14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
11107821|NCT04021264|Sham Comparator|POST-GA|14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
11107822|NCT04021251|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.
11107823|NCT04021251|Experimental|Medium term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements.
11107824|NCT04021251|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on P0.2 for four times a day for 90 days distributed over a time period of 6 months. Spectral data will be compared to standard BG measurements.
11107825|NCT04021251|Experimental|Medium term collection of IMD data, increased # of sessions|Subjects will collect spectral raman data on P0.2 four times a day for 30 days distributed over a time period of 40 days. Spectral data will be compared to standard BG measurements. The number of optical sessions performed each time measurements are done are increased compared to the investigation's second arm.
11107826|NCT04021238|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
11107827|NCT04021225|Active Comparator|Ectoin® Allergy Eye Drops 2%|"20 Patients:
~- Ectoin® Allergy Eye Drops 2% (bitop AG)"
11107828|NCT04021225|Active Comparator|Ectoin® Eye Spray Colloidal|"20 Patients:
~-Ectoin® Eye Spray Colloidal (bitop AG)"
11107829|NCT04021225|Active Comparator|Tears Again® Eye Spray|"20 Patients:
~- Tears Again® Eye Spray (Optima Pharmazeutische GmbH)"
11107830|NCT04021212||Patients with pituitary adenomas resection|Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once
11107856|NCT04021043|Experimental|Group III (nivolumab, BMS-986156, SBRT)|Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
11107831|NCT04021199|Active Comparator|T1D Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.
~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.
~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
11107832|NCT04021199|Experimental|MODY Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.
~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.
~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
11107833|NCT04021186|Experimental|Intervention|Insulin treatment using standard measurements.
11107834|NCT04021186|No Intervention|Control|Standard care.
11107835|NCT04021173|Experimental|Anfibatide|
11107836|NCT04021173|Placebo Comparator|Placebo|
11107837|NCT04021160|Active Comparator|Active Group|A total of 16, every other day sessions of rTMS at 10 Hz frequency will be applied to 4 locations along the perilesional area (see target selection). Intensity will be 100% of motor threshold, 25 trains - 40 pulses per train with 20 seconds intertrain interval and a total of 1000 pulses per session. The coil handle will be directed downwards at 45º of the sagittal plain to ensure that the induced electric field be perpendicular to the underlying gyrus.
11107838|NCT04021160|Sham Comparator|Sham Group|Sham group will receive the same sessions as above with the exact same parameters yet a sham coil identical in shape and size to the active coil will be used instead. The sham coil produces sounds and sensations very similar to the active one.
11107839|NCT04021147|Experimental|Action Observation|
11107840|NCT04021147|Experimental|Motor Imagery|
11107841|NCT04021147|Experimental|Visual mirror feedback|
11107842|NCT04021147|Active Comparator|Orofacial exercise|
11107843|NCT04021121|Experimental|High Dose RIF with LZD|Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.
11107844|NCT04021121|Experimental|Standard dose RIF with LZD|Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.
11107845|NCT04021121|Experimental|High Dose RIF|Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.
11107846|NCT04021121|Active Comparator|Standard Dose RIF|Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.
11107847|NCT04021108|Other|Cohort 1|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.
~Subjects in Cohort 1 will receive Nivolumab alone (every 2 weeks for two doses, and then every 4 weeks)"
11107848|NCT04021108|Experimental|Cohort 2|"Subjects will receive standard dose FOLFOX plus nivolumab 240mg IV every 2 weeks for 2 months. If you are responding to treatment, you will receive FOLFOX plus nivolumab for one additional month and then you will be randomized to Cohort 1 or Cohort 2.
~Subjects in Cohort 2 will receive Nivolumab (every 2 weeks for two doses, and then every 4 weeks) plus radiation therapy (total 5 sessions)"
11107849|NCT04021095|Experimental|Decompressive craniectomy|3D printed skull replacement piece will be fitted to subject.
11107850|NCT04021082|Experimental|Cohort A|Cerdulatinib dosing of patients with Peripherial T-Cell Lymphoma (PTCL) not otherwise specified (NOS); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
11107851|NCT04021082|Experimental|Cohort B|Cerdulatinb dosing of patients with nodal lymphomas of T follicular helper (TFH) phenotype origin, including angioimmunoblastic T cell lymphoma (AITL), follicular T-cell lymphoma (FTCL), and nodal PTCL with TFH phenotype; Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
11107852|NCT04021082|Experimental|Cohort C|Cerdulatinb dosing of patients with Anaplastic large cell lymphoma (ALCL) (anaplastic lymphoma kinase positive [ALK+] and negative [ALK-]); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
11107853|NCT04021082|Experimental|Cohort D|Other rare types of extranodal non-cutaneous aggressive PTCL, including hepatosplenic T-cell lymphoma (HSTCL), enteropathy-associated T-cell lymphoma (EATL type I), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, EATL type II), and extranodal NK/T-cell lymphoma (nasal type); Cerdulatinib 30 mg orally (PO) twice daily (BID) (60 mg daily total)
11107854|NCT04021043|Experimental|Group I (ipilimumab, BMS-986156, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11107855|NCT04021043|Experimental|Group II (ipilimumab, BMS-986156, SBRT, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11107857|NCT04021030|Experimental|Cognitive Behavioral Therapy (CBT)|
11107858|NCT04021017|Experimental|Treatment|"Participants randomized to the treatment arm will be divided by maturational status:
~Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months.
~o These participants will also receive progesterone (Provera 10 mg tablet) orally every 4 weeks, for 7 days during the second half of the planned menstrual cycle, in order to induce a menstrual period.
~Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches:
~3.1 mcg/day (1/8 patch) for first six-months,
~6.2 mcg/day (1/4 patch) for second six-months,
~12.5 mcg/day (1/2 patch) for third six-months, and
~25 mcg/day (full patch) for final six-months."
11107859|NCT04021017|No Intervention|No Treatment|The participants in this group will not receive the estrogen patch nor the oral progesterone.
11107860|NCT04020991||Doctors working in a tertiary hospital|Doctors working in a tertiary hospital
11107861|NCT04020978|Other|Patients with Renal Cell Carcinoma|Each patient with metastatic renal cell carcinoma will first undergo an X-ray CT scan for attenuation correction purpose. After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds. The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes. After the PET scan, the patient gets off the scanner. One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
11107862|NCT04020965|No Intervention|Control arm|This arm includes all households in villages randomized to the active control arm (double-sized) or passive control arm of the original trial. Village-level promoter visited households enrolled in the WASH Benefits Kenya study active control arm and strictly engaged in recording the child's MUAC and referring children identified as malnourished (MUAC<11.5 cm) to health clinics, for two years. These visits were also conducted in all active comparator arms. Households in active control and active comparator villages which were not enrolled in the original study did not receive such visits.
11107863|NCT04020965|Experimental|Water Treatment|This arm includes all households in villages randomized in the original WASH Benefits trial to the water treatment arm, combined water treatment with handwashing and sanitation (WASH) arm, and combined WASH + nutrition arm. Village-level promoter visited households enrolled in the original trial to promote the interventions for approximately two years.
11107864|NCT04020952|Active Comparator|"st.st 0.019×0.025 wire"|
11107865|NCT04020952|Experimental|"st.st 0.016×0.022 wire"|
11107866|NCT04020952|Experimental|"st.st 0.017×0.025 wire"|
11107867|NCT04020939|Experimental|Patients undergoing intestinal resections|"Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence
~Drug:
~Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only"
11107868|NCT04020913||Short Stature Boys|Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (defined as peak GH responses to pharmacologic stimuli <10ng/ml) or idiopathic short stature (i.e., no identifiable pathology) will be studied pre and post 12 months of GH therapy.
11107869|NCT04020913||Normally Statured Boys|A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on Growth Hormone replacement, preferably siblings (although not exclusively), will be recruited to serve as healthy controls.
11107870|NCT04020900||Children <18 years, admitted for a general anesthesia.|Children <18 years, admitted for a general anesthesia.
11107871|NCT04020887|No Intervention|Observation Phase|In the first three months of this proof-of-concept study, a telemedicine center for the PACU will monitor patients assigned to PACU bays. Both telemedicine center clinicians and nurses caring for patients in these PACU bays will independently record information on patient physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness (based on the modified Aldrete scale). During this phase of the study, clinicians in the telemedicine center will not communicate with clinicians in the PACU (nurses or physicians), unless there was a patient safety event.
11107872|NCT04020887|Experimental|Interaction Phase|In the three months following the observation phase, clinicians in the telemedicine center will interact with clinicians and patients in the two designated PACU bays using audio-visual technology. The clinicians in the telemedicine center will continue to document information on physiological derangements, treatable symptoms, situations requiring urgent medical intervention, and discharge readiness.
11107873|NCT04020874|No Intervention|Baseline|Year 1, no intervention to generate baseline, comparative data for subsequent years
11107874|NCT04020874|Experimental|HuTT-2x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 2 times each week throughout the regular season.
11107875|NCT04020874|Experimental|HuTT-4x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 4 times each week throughout the regular season.
11107876|NCT04020861|Active Comparator|PBM + TENS|The patients will be submitted to the active PBM and active TENS
11107877|NCT04020861|Active Comparator|PBM|The patients will be submitted to the active PBMT and placebo TENS
11107878|NCT04020861|Active Comparator|TENS|The patients will be submitted to the placebo PBMT and active TENS
11107879|NCT04020861|Placebo Comparator|Placebo|The patients will be submitted to the placebo PBMT and placebo TENS.
11107908|NCT04020640||Partial breastfeeding (PartBF)|provision of breast milk plus infant formula or cow milk or other solid/semi-solid complementary foods
11107880|NCT04020848||Patients with Alternating Hemiplegia of Childhood (AHC)|"Patients who fit the Aicardi Alternating Hemiplegia of Childhood clinical criteria of any age. The Aicardi Criteria are six (Heinzen et al 2015). (1) Paroxysmal hemiplegia episodes. (2) Bilateral hemiplegia or quadriplegia episodes. (3) Other paroxysmal manifestations, such as abnormal eye movements, nystagmus, strabismus, ataxia, dystonia, choreoathetosis, tonic spells, or autonomic disturbances. (4) Evidence of permanent neurological dysfunction, which can manifest as cognitive impairment, developmental delay, and/or persistent motor deficits such as spastic diplegia/quadriplegia, hypotonia, ataxia, choreoathetosis, or dystonia. (5) Sleep relieves symptoms, although attacks may resume soon after awakening. (6) First signs of dysfunction occur prior to the age of 18 months.
~Patients having some but not all the above criteria and have the mutation in ATP1A3 gene can be included."
11107881|NCT04020822|Experimental|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
11107882|NCT04020809|Experimental|Atezolizumab|Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.
11107883|NCT04020796|Active Comparator|Beetroot juice|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of beetroot juice in a single moment.
11107884|NCT04020796|Placebo Comparator|Mineral water|Randomized cross-over trial. Thirty-seven hypertension, age 40-70 years were randomized to receive a 500ml volume of mineral water in a single moment.
11107885|NCT04020783||Observation group|sequential
11107886|NCT04020770|Experimental|Vibrating Ball|Vibrating ball is held in both hands. Participants complete 5 30-second bouts of 68 Hz vibration with a 1 minute rest in between each bout.
11107887|NCT04020757|Other|Bicarb Variation|Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3
11107888|NCT04020744|Active Comparator|healthy elderly participants with rtfMRI feedback (HC)|This group consists of healthy elderly individuals, who receive feedback from their hippocampal activity.
11107889|NCT04020744|Sham Comparator|healthy elderly participants with rtfMRI feedback (other area)|This group consists of healthy elderly individuals, who receive feedback from another brain area.
11107890|NCT04020744|Experimental|patients with MCI with rtfMRI feedback (HC)|This group consists of patients with mild cognitive impairment, who receive feedback from their hippocampal activity.
11107891|NCT04020744|Sham Comparator|patients with MCI with rtfMRI feedback (other area)|This group consists of patients with mild cognitive impairment, who receive feedback from another brain area.
11107892|NCT04020731|Experimental|Right-handed healthy volunteers|Magnetoencephalography (MEG) records
11107893|NCT04020718|Experimental|Early assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 4 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
11107894|NCT04020718|Experimental|Late assessment|Patients are assessed for response to brief telephone advice plus a tailored text message program at 8 weeks post-randomization. Response is based on self-reported 7-day point prevalence abstinence. Non-responders are randomized to 4 weeks of mailed nicotine patches and/or lozenges (NRT) or 4 weeks of mailed NRT plus proactive telephone coaching.
11107895|NCT04020705|Experimental|Citicoline eye drops (OMK1)|45 patients will be treated with active treatment (OMK1)
11107896|NCT04020705|Placebo Comparator|hypromellose based ocular lubricant|45 patients will be treated with placebo (lubricant eye drops)
11107897|NCT04020692|Experimental|"intervention  group"|"Patient At D0, the patient receives his discharge drugs prescription and benefits from a pharmaceutical counselling.
~At D+3, he benefits from a telephone follow-up (good understanding of the methods of taking drugs, collection of difficulties).
~Community pharmacist At D0, he receives the discharge drugs prescription. At D+3, he is contacted to collect information relating to drugs 'dispensation.
~The attending physician At D0, he is informed of the patient's discharge and his drugs treatment
~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].
~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
11107898|NCT04020692|No Intervention|Control group|"At D0, the patient receives his discharge drugs prescription.
~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].
~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
11107899|NCT04020679|No Intervention|Control arm|Participants will not receive GOCI materials
11107900|NCT04020679|Experimental|Intervention|Participants will receive GOCI materials and clinicians will receive training.
11107901|NCT04020666||HUK group|On the basis of routine treatment for cerebral infarction, patients in the HUK group were also given Urinary Kallidinogenase at 0.15 PNA unit/day, for a 10-day course.
11107902|NCT04020666||control group|The control group were given routine treatment for cerebral infarction, including anti-platelet aggregation, anticoagulation, lipid-lowering and plaque stabilizing, free radical scavenging, nerve nutrition and brain protection.
11107903|NCT04020653|Placebo Comparator|Placebo + ACT|Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
11107904|NCT04020653|Experimental|5 ALA/SFC+placebo+ACT BID|"5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
~Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14)."
11107905|NCT04020653|Experimental|5-ALA/SFC+placebo+ACT QD|5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
11107906|NCT04020640||Exclusive breastfeeding (EBF)|provision of breast milk only, allowing only receiving oral rehydration salts (ORS), drops and syrups (vitamins, minerals, medicines) as necessary
11107907|NCT04020640||Predominant breastfeeding (PBF)|providing breast milk plus other liquids (water and water-based drinks, fruit juice) and ORS, drops and syrups (vitamins, minerals, medicines)
11107911|NCT04020614||Survey|All of the patients that enrolled in this study will be in this group.
11107912|NCT04020601|Active Comparator|PRE-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through the interscalene catheter
11107913|NCT04020601|Sham Comparator|POST-GA|10 ml of 5% dextrose injection before the start of surgery and 1% ropivacaine injection at the end of surgery through the interscalene catheter
11107914|NCT04020588|Active Comparator|Celecoxib|Celecoxib 200 mg twice a day
11107915|NCT04020588|Active Comparator|Minocycline|Minocycline 100 mg twice a day
11107916|NCT04020588|Placebo Comparator|Placebo|Placebo capsules twice a day
11107917|NCT04020575|Experimental|Dose Escalation|"Dose escalation or de-escalation is tested in cohorts of 3 patients each using standard 3+3 dose-finding."
11107918|NCT04020575|Experimental|Luminal|Dose Expansion - 15 patients will be enrolled with luminal (hormone receptor positive, HER2 negative) metastatic breast cancer.
11107919|NCT04020575|Experimental|HER2+|Dose Expansion - 15 patients will be enrolled with HER2+ metastatic breast cancer.
11107920|NCT04020575|Experimental|Triple Negative|Dose Expansion - 15 patients will be enrolled with triple negative metastatic breast cancer.
11107921|NCT04020562|Experimental|Mild Resistive Expiratory Technique|Mild resistive Expiratory Technique from EMST150- five-week training protocol.
11107922|NCT04020562|Active Comparator|Conventional Training|Breathing exercise, Assistive Coughing, ROM Exercises, Sustained stretching, Splinting, Bracing, Functional Mobility, Tilt table standing
11107923|NCT04020549|Experimental|Intervention|
11107924|NCT04020549|Sham Comparator|Study Skills Control|
11107925|NCT04020536||kala-azar group|
11107926|NCT04020536||epidemic hemorrhagic fever group|
11107927|NCT04020536||brucellosis group|
11107928|NCT04020523|Experimental|Patient with an injected breast MR exam|
11107929|NCT04020510|Active Comparator|Standard Injections|For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 30mL of injectable saline injected in 30 sites with 1mL per injection along the posterior wall of the bladder above the trigone.
11107930|NCT04020510|Experimental|Reduced Injections|"For idiopathic overactive bladder, 100 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone. For neurogenic overactive bladder, 200 units of onabotulinumtoxinA mixed in 10mL of injectable saline injected in 5 sites with 2mL per injection in an X configuration on posterior wall of the bladder above the trigone."
11107931|NCT04020497|Experimental|Ensemble + SAU (Support as usual)|The five-session Ensemble program provided to informal caregivers targeted support + SAU
11107932|NCT04020497|Active Comparator|SAU (Support as usual)|SAU alone which was chosen as a control condition.
11107933|NCT04020484|Experimental|Intervention Group|Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week.
11107934|NCT04020484|Other|Waitlist Control|Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete the Baseline and Immediate Follow-up questionnaire at comparable times to families in the intervention arm; they will not complete the Extended Follow-up questionnaire. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session.
11107935|NCT04020458|Active Comparator|Periodontitis, no kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)
~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)
~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).
~iv. Single visit intensive scaling and root planning (SRP) (full mouth)
~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)
~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations
~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
11107936|NCT04020458|Active Comparator|Experimental- chronic kidney disease|"Dental intervention i. Full mouth intraoral X-rays (FMX)
~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)
~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).
~iv. Single visit intensive scaling and root planning (SRP) (full mouth)
~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)
~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations
~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
11107937|NCT04020458|No Intervention|Control- no Periodontitis or kidney disease.|Only regular dental cleaning
11107938|NCT04020432||pregnant women|"Pregnant women are coming to their monthly consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.
~Pregnant women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
11107972|NCT04020185|Experimental|Ph II Combination Therapy (Arm B)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors.
~This arm shall include a safety run-in of 5-10 patients.
~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment."
11107939|NCT04020432||childbearing age women|"Women of childbearing age, who are coming for a gynecological consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.
~Childbearing age women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
11107940|NCT04020419|Experimental|Pediaberry group|PediaBerry™ is a proprietary blend powdered berry extracts
11107941|NCT04020419|Placebo Comparator|Placebo|Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).
11107942|NCT04020406||Antibacterial Activity of Urea|Activity of Urea Solution against Ocular Bacterial Isolates
11107943|NCT04020393||Block group|The patients that had received Sphenopalatine ganglion block(SPGB) before the surgery
11107944|NCT04020393||Control Group|The patients that had not received SPBG before the surgery
11107945|NCT04020380|Experimental|Azithromycin 250 mg|Azithromycin, 250 mg capsules once a day for a total of 3 months
11107946|NCT04020367|Other|patients with biopsy|
11107947|NCT04020354|Experimental|HABIT-ILE|Early HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
11107948|NCT04020354|Active Comparator|Usual Care|A two weeks period of usual customary care
11107949|NCT04020341|Active Comparator|Gepotidacin|Subjects will be administered oral doses of 1500 mg gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days
11107950|NCT04020341|Active Comparator|Nitrofurantoin|Subjects will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
11107951|NCT04020328|Experimental|leflunomide + low dose glucocorticoids therapy group|the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
11107952|NCT04020328|No Intervention|Basic conservative treatment group|the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy
11107953|NCT04020315|Experimental|Generalized aggressive periodontitis|Non-surgically performed scaling and root planing.
11107954|NCT04020302|Experimental|Shopping group|Participants will receive an 8-week intervention which will include weekly sessions that are delivered in an alternating group-individual format. Sessions will provide participants the opportunity to practice and apply self-monitoring techniques across a variety of shopping tasks and settings to promote generalization and transfer of learning (Phase B).
11107955|NCT04020289|Experimental|"BalancingMySwing"|"Psychoeducational Program BalancingMySwing for bipolar disorder"
11107956|NCT04020289|Other|treatment as usual (TAU)|Patients received treatment as usual
11107957|NCT04020276|Experimental|MRI-Guided SBRT Dose Escalation|"Treatment on MRI Linac with SBRT in 5 fractions with adaptive planning, maximum dose 80 Gy
~Dose Escalation Bowel Pathway, V34 < 0.5cc Dose Escalation Liver Pathway, 700 cc < 16 Gy
~Subsequent Phase 1B: CRC only for Safety and Local Control, dosage informed by Phase 1A"
11107958|NCT04020263|Experimental|Levosimendan|Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
11107959|NCT04020263|Placebo Comparator|Placebo|Control group: Patients with cardiogenic shock treated with placebo for levosimendan in addition to the conventional strategy.
11107960|NCT04020237|No Intervention|Observational arm|General counselling to particulate matter practice score.
11107961|NCT04020237|Other|Interventional arm|Active education and feedback on the particulate matter practice score that affects real life.
11107962|NCT04020224|Experimental|Treatment with pathogen reduced whole blood|Subjects will receive one amustaline/GSH treated whole blood product.
11107963|NCT04020224|Active Comparator|Treatment with Standard of Care|Subjects will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product
11107964|NCT04020211||HF10|SCS stimulation with HF10 therapy
11107965|NCT04020198||Parkinson's Disease|Subjects who have a PD diagnosis
11107966|NCT04020198||Multiple System Atrophy|Subjects who have an MSA diagnosis
11107967|NCT04020198||Age-matched controls|Subjects who do not have a diagnosed neurological disorder.
11107968|NCT04020198||Rapid Eye Movement Sleep Behavior Disorder (RBD)|Subjects who have a diagnosis of RBD
11107969|NCT04020185|Experimental|Ph I Monotherapy|"Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified.
~The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients.
~Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose [HNSTD] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg."
11107970|NCT04020185|Experimental|Ph I Combination Therapy|"Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria:
~A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).
~The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT).
~The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints.
~Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related.
~Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation."
11107971|NCT04020185|Experimental|Ph II Monotherapy (Arm A)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy
~Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment."
11107973|NCT04020185|Experimental|Ph II Combination Therapy (Arm C)|"This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA.
~This arm shall include a safety run-in of 5-10 patients.
~Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.."
11107974|NCT04020172|Experimental|Dobutamine+fluid therapy|All patients will receive a baseline infusion of Ringer's lactate at 3ml/kg/hr to satisfy maintenance fluid requirements. The intervention will commence at anesthesia induction and continue for up to 4 hours postoperatively. In addition to maintenance fluids, patients will receive 250ml fluid challenges with crystalloid as required until they are no longer fluid responsive. The absence of fluid responsiveness will be defined as the absence of a sustained rise in stroke volume of at least 10% for 20 minutes or more, at which point, the patient will be considered fluid optimized. At this point, a low-dose dobutamine infusion at a fixed rate (2.5 μg/kg/min) will be commenced and maintained until 4h postoperatively. The infusion rate will be halved and/or discontinued if the patient develops a tachycardia (heart rate ≥ 100bpm) for more than 30 minutes despite adequate anesthesia/analgesia and fluid status.
11107975|NCT04020172|No Intervention|Standard of care|Patients in the control group will also receive a baseline infusion of Ringer's lactate at 3ml/kg/hr to satisfy maintenance fluid requirements, which will be commenced upon admission to the operating room. The anesthetic management will otherwise be according to standard practice. No specific cardiac output monitoring device will be used to guide fluid therapy. Likewise, perioperative dobutamine will not be used unless clinically indicated to improve cardiac function.
11107976|NCT04020159||Participants with COL6-related dystrophy|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
11107977|NCT04020146||group 1;|healthy controls (C, n=15),
11107978|NCT04020146||group 2|periodontitis patients with stage 3 grade B; (P, n=15)
11107979|NCT04020146||group 3|peri-implantitis patients (PI, n=15).
11107980|NCT04020133|Active Comparator|the control group|this group will receive post-operative saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
11107981|NCT04020133|Active Comparator|the intervention group|this group will receive popliteal plexus block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg in addition to standard saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
11107982|NCT04020120||ADHD in professional activity|Adult ADHD patients in active employment at the time of inclusion or who were in employment within 3 months prior to inclusion
11107983|NCT04020107|Active Comparator|Compressive garment associated with physical therapy|
11107984|NCT04020107|Placebo Comparator|Low compressive garment associated with physical therapy|
11107985|NCT04020094|Experimental|Treatment: all patients|
11107986|NCT04020081|Experimental|Effect of yoga exercises in COPD patients after 12 weeks.|Yoga group
11107987|NCT04020081|No Intervention|COPD patients lung functions without yoga excercises.|Control group
11107988|NCT04020055|Experimental|migalastat HCl 150 mg|All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
11107989|NCT04020042|Experimental|Ultrasound imaging guidance|Determination of epidural needle site by using ultrasound guidance
11107990|NCT04020042|Active Comparator|Traditional landmark palpation|Depermination of epidural needle site by using traditional landmark method
11107991|NCT04020029|Experimental|Mindset Intervention|Mindset Intervention will include watching three brief ~10-25 minute films and respond to a number of short reflection activities after viewing the films.
11107992|NCT04020029|Active Comparator|Treatment As Usual (TAU)|TAU Control Arm will complete the same assessments as those participants in the Mindset Intervention Arm, but will not view the short films or complete the corresponding response activities.
11107993|NCT04020016|Experimental|Part 1 Single Ascending Dose|Impaired liver function subjects and healthy liver subjects single ascending dosing up to 162 mg BID of Nalbuphine ER
11107994|NCT04020016|Experimental|Part 2 Multiple Ascending Dose|Impaired liver function subjects will receive multiple ascending dosing up to 162 mg BID of Nalbuphine ER
11107995|NCT04020003|Other|Routine treatment|Routine treatment group: control infection, remove or control the primary disease; mechanical ventilation with low tidal volume and high PEEP mechanical ventilation strategy; strictly control volume, strengthen airway management, timely nutritional support and severe rehabilitation treatment.
11107996|NCT04019990|Other|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
11107997|NCT04019977|Experimental|Nurse Home Visiting Group|This group will be offered services from the nurse home visiting program.
11107998|NCT04019977|No Intervention|Non-intervention Group|This group will not be offered services from the nurse home visiting program.
11107999|NCT04019964|Experimental|Nivolumab in biochemically recurrent prostate cancer|"Participants with previous prostatectomy or radiation therapy who subsequently developed detectable prostate specific antigen (PSA) levels (biochemically recurrent prostate cancer)."
11108000|NCT04019951|Experimental|Propionate (1 g)|Participants will receive 1 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
11108001|NCT04019951|Experimental|Propionate (3 g)|Participants will receive 3 g of Ca-propionate in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
11108002|NCT04019951|Placebo Comparator|Placebo|Participants will receive 2.6 g of cellulose in a colon-release form. Volunteers will receive the product on visits 2, 3 and 4. Each of the visits will be separated by > 5 days. Visit 5, the end of study visit, will occur within 5 days of visit 4.
11108003|NCT04019938||Diabetic adults|
11108004|NCT04019925|Other|ADM/MDM hip prosthesis|Type of prosthesis participant received.
11108005|NCT04019912|Experimental|Gait Training plus music|Patients will be randomly assigned to the rehabilitation group through gait trainer3 with Rhythmic Auditory Stimulation (RAS). All patients will undergo a complete clinical and neurophysiological evaluation at baseline. The training program consist of 45 minutes of treadmill training with RAS. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists with 2 years of RAS training.
11108006|NCT04019912|Active Comparator|Traditional Gait Training|Patients will be randomly assigned to the non-Rhythmic Auditory Stimulation (RAS) treadmill walking group. All patients will undergo a complete clinical and neurophysiological evaluation at baseline.The daily training program consist of 45 minutes of conventional gait training using a non-RAS treadmill. The daily training program will be practiced once a day at the same time of day (from 9:00 am to 1:00 pm), five times a week for eight consecutive weeks. Non-RAS treadmill sessions will be performed individually in the same position and under the supervision of physiotherapists.
11108007|NCT04019899|Active Comparator|Control group|
11108008|NCT04019899|Experimental|Study group|
11108009|NCT04019886|Experimental|Experimental Group|"It consists following techniques-
~Peri-oral stimulation
~Vertebral pressure
~Anterior stretch -lifting posterior basal area
~Co-contraction -abdomen
~Intercoastal stretch
~Moderate manual pressure"
11108010|NCT04019886|No Intervention|Control Group|Outcome measure will be measured at baseline on first day prior to the intervention and on 5th day after the treatment.
11108011|NCT04019873||Subjects receiving 2DR treatment|Data will be collected from HIV positive male or female adult subjects who have started 2DR with an integrase inhibitor plus a reverse transcriptase inhibitor from 2014.
11108012|NCT04019860|Experimental|High Intensity Interval Training|High intensity interval training for seven weeks. Three weekly, supervised training sessions.
11108013|NCT04019860|Experimental|Time-Restricted Eating|Time-restricted eating for seven weeks. Maximal daily eating window of 10 hours.
11108014|NCT04019860|Experimental|High Intensity Interval Training & Time-Restricted Eating|
11108015|NCT04019860|No Intervention|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
11108016|NCT04019847|Experimental|STAK Tool|The STAK Tool enables patients to apply a high intensity stretch to their knee independently. Patients are asked to do this for a maximum of 60 mins per day.
11108017|NCT04019847|Active Comparator|Standard treatment|Patients are treated as per their Clinician's prescription. Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain ROM and function.
11108018|NCT04019834|Experimental|regional nerve block with local anesthesia|Treatment Arm (n=55) will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes and perform regional nerve blocks. A block needle will be passed into the fascial plane an injectate will be deposited . The injectate in the active arm will contain a local anesthestic and dexamethasone.
11108019|NCT04019834|Placebo Comparator|regional nerve block with normal saline|Placebo Comparator Arm (n=55). Patients will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue.
11108020|NCT04019821|Active Comparator|Normal Bolus|Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).
11108021|NCT04019821|Experimental|Super Bolus|Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.
11108022|NCT04019795|Sham Comparator|Non-Active REVIAN (Sham) Cap 100|Sham (Control) Group
11108023|NCT04019795|Experimental|Active REVIAN Cap 101|(625 nm and 660 nm)
11108024|NCT04019795|Experimental|Active REVIAN Cap 102|(425 nm)
11108025|NCT04019795|Experimental|Active REVIAN Cap 103|(425 nm, 625 nm and 660 nm)
11108026|NCT04019782|Experimental|Collagen-PVP|Collagen-polyvinyl pyrrolidone (collagen-PVP).
11108027|NCT04019782|Active Comparator|Hylan G-F 20|Hylan G-F 20.
11108028|NCT04019769|Experimental|1|All patients will receive L-glutamine 10-30mg daily based on weight for 3 months
11108029|NCT04019756||Patients with cancer|50 patients ultimately diagnosed with bladder cancer and 50 control patients (diagnosis of cancer reversed at cystoscopy or cystoscopy for another cause)
11108030|NCT04019743|Experimental|Group 1|"Period 1: Treatment A
~Period 2: Treatment B
~Period 3: Treatment C"
11108031|NCT04019743|Experimental|Group 2|"Period 1: Treatment C
~Period 2: Treatment A
~Period 3: Treatment B"
11108032|NCT04019743|Experimental|Group 3|"Period 1: Treatment B
~Period 2: Treatment C
~Period 3: Treatment A"
11108033|NCT04019743|Experimental|Group 4|"Period 1: Treatment C
~Period 2: Treatment B
~Period 3: Treatment A"
11108034|NCT04019743|Experimental|Group 5|"Period 1: Treatment B
~Period 2: Treatment A
~Period 3: Treatment C"
11108035|NCT04019743|Experimental|Group 6|"Period 1: Treatment A
~Period 2: Treatment C
~Period 3: Treatment B"
11108036|NCT04019730|Experimental|low carbohydrate diet|less than 10 En% carbohydrates
11108037|NCT04019730|Experimental|high carbohydrate diet|more than 50 En%carbohydrates
11108038|NCT04019717|Experimental|8 weeks|
11108039|NCT04019717|Experimental|12 weeks|
11108040|NCT04019704|Experimental|AXS-05|AXS-05 (bupropion and dextromethorphan) oral tablets
11108041|NCT04019704|Placebo Comparator|Placebo|Placebo oral tablets to match AXS-05
11108042|NCT04019691|Active Comparator|Mix-and-Match group|Cataract surgery and implantation of a Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
11108043|NCT04019691|Active Comparator|EDOF group|Cataract surgery and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
11108044|NCT04019691|Active Comparator|Trifocal group|Cataract surgery and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
11108045|NCT04019678|Experimental|Group 1: experimental|patients with micro metastatic sentinel lymph node and/or parasentinella lymph node (ypN1mi). Axillary dissection is not performed.
11108046|NCT04019678|Active Comparator|Group 2: standard|patients with negative sentinel lymph node (ypN0) or with ITC finding (ypN0 / YpN0 (i +)). Axillary dissection is not performed as standard treatment.
11108047|NCT04019678|Other|Group 3: internal control|Patients with macro metastatic sentinel and/or parasentinella lymph nodes (ypN>=1). In these patients standard axillary dissection is performed as standard treatment.
11108048|NCT04019665|Other|SAGE and MMSE score|
11108049|NCT04019652|Experimental|10 mg CS-3150 (Treatment Sequence 1)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 10-mg dose of CS-3150, a 40-mg dose of CS-3150, a 400-mg dose of moxifloxacin, followed by placebo.
11108050|NCT04019652|Experimental|40 mg CS-3150 (Treatment Sequence 2)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 40-mg dose of CS-3150, placebo, a 10-mg dose of CS-3150, followed by a 400-mg dose of moxifloxacin.
11108051|NCT04019652|Experimental|Moxifloxacin (Treatment Sequence 3)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral 400-mg dose of moxifloxacin, 10-mg dose of CS-3150, placebo, 40-mg dose of CS-3150.
11108052|NCT04019652|Experimental|Placebo (Treatment Sequence 4)|Participants will receive the following treatment sequence (1 treatment per Period): a single oral dose of placebo, 400-mg dose of moxifloxacin, 40-mg dose CS-3150, 10-mg dose of CS-3150.
11108053|NCT04019639|Experimental|CG Paste+EasyFoam|"The subjects assigned to the test group through random assignment will receive the wound treatment by applying CG Paste and EasyFoam. CG Paste is a medical device currently marketed in CGBio.It is a free-flowing, acellular allogeneic dermis processed from human tissue skin, and then granulated and homogenized. This increases the water content and viscosity of the micronized ADM particles mixed with the gelatin sol carrier to protect the wound area and maintain the wet environment by applying to the desired wound area.It contains collagen, elastin and various growth factors in the dermis and has excellent tissue compatibility compared to the heterogeneous or synthetic material, so that the immune rejection is hardly observed in the graft site.
~It also contains collagen, elastin, fibronectin, laminin, and proteoglycans, which are components of the human skin, to help the interaction between normal cells and extracellular matrix."
11108054|NCT04019639|Active Comparator|EasyFoam|"Subjects randomly assigned to the control group receive EasyFoam treatment for wound healing.
~The foam has excellent moisture permeability, absorbs a large amount of exudates, and prevents scar formation to minimize scar formation."
11108055|NCT04019626|Active Comparator|Continue-smoking|The subject's usual brand of combustible cigarette
11108056|NCT04019626|Experimental|myblu Tobacco Chill 2.5%|myblu e-cigarette system with Tobacco Chill flavor Intense Liquidpod, 2.5% nicotine
11108057|NCT04019626|Experimental|myblu Tobacco Chill 4.0%|myblu e-cigarette system with Tobacco Chill flavor Intense Liquidpod, 4.0% nicotine
11108058|NCT04019626|Experimental|myblu Honeymoon 2.5%|myblu e-cigarette system with Honeymoon flavor Intense Liquidpod, 2.5% nicotine
11108059|NCT04019626|Experimental|myblu Honeymoon 4.0%|myblu e-cigarette system with Honeymoon flavor Intense Liquidpod, 4.0% nicotine
11108060|NCT04019613|Experimental|Subjects undergoing clinical invasive hemodynamic stress test|Subjects scheduled for standard-of-care, clinically indicated, invasive hemodynamic stress test will undergo lung ultrasound and assessment of extravascular lung water by pulmonary thermodilution technique.
11108061|NCT04019587||Test of reliability and validity|
11108062|NCT04019574|Experimental|CR845 0.5 mcg/kg IV (Therapeutic Dose)|
11108063|NCT04019574|Experimental|CR845 3 mcg/kg IV (Supratherapeutic Dose)|
11108064|NCT04019574|Placebo Comparator|Placebo IV|
11108065|NCT04019574|Active Comparator|Moxifloxacin 400 mg|
11108066|NCT04019561|Experimental|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
11108067|NCT04019561|Placebo Comparator|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
11108068|NCT04019561|Experimental|MEDI0382 low dose|MEDI0382 low dose administered subcutaneoously
11108069|NCT04019561|Placebo Comparator|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
11108070|NCT04019548|Experimental|Prophylactic PEG|Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.
11108071|NCT04019548|Experimental|Reactive PEG|Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).
11108072|NCT04019522|Experimental|Hypoxia|During each session, study participants will receive a single sequence of AIH, consisting of 15 x 60-seconds periods of hypoxia alternating with 90-seconds of normoxia (21% O2), for a total of 30 minutes, whilst in a seated upright position. AIH will be applied by directing gas flow to a reservoir bag connected via plastic tubing to a non re-breathing facemask/respiratory valve system while the participants are in a seated position. Defined gas mixtures will be delivered by manual adjustment of one-way valves attached to a hypoxia generator.
11108073|NCT04019509|Active Comparator|Tg AB positive, TPO AB negative|Includes patients with only anti-thyroglobuline autoantibodies present and no anti-thyreoperoxydase antibodies at start of fertility treatment.
11108074|NCT04019509|Active Comparator|Tg AB negative, TPO AB negative|Includes patients without thyroid autoantibodies at start of fertility treatment
11108075|NCT04019509|Active Comparator|Tg AB positive, TPO AB positive|Includes patients with anti-thyroglobuline autoantibodies and anti-thyreoperoxydase antibodies at start of fertility treatment.
11108076|NCT04019496||Episodic Migraine|
11108077|NCT04019496||Healthy controls|equal to or less than 1 headache day/month
11108078|NCT04019457|Experimental|Dietary fiber 1|Participants receive cereal flakes 1 to include it in their normal diet.
11108079|NCT04019457|Experimental|Dietary fiber 2|Participants receive cereal flakes 2 to include it in their normal diet.
11108080|NCT04019444|Experimental|Arm A|One dose (1 ml (5x10^10 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
11108081|NCT04019444|Experimental|Arm B|One dose (1 ml (1x10^11 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
11108082|NCT04019444|Experimental|Arm C|Two doses (1 ml (1x10^11 vp) each) of ChAd155-RG vaccine administered intramuscularly on Day 1 (first dose) and Day 15 (second dose), and 1 ml of matching placebo administered intramuscularly on Days 8 and 22. N=10
11108083|NCT04019444|Active Comparator|Arm D|Three doses (1 ml each) of RABAVERT vaccine administered intramuscularly on Day 1 (first dose), Day 8 (second dose), and Day 22 (third dose), and 1 ml of matching placebo administered intramuscularly on Day 15. N=12 (2 sentinel, 10 non-sentinel)
11108084|NCT04019431|Experimental|Whey protein|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
11108085|NCT04019431|Active Comparator|Vegetable proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on vegetal protein derived from soya or green peas or cereals.
11108086|NCT04019431|Active Comparator|Animal proteins|VLCKD (780 kcal/day) low in carbohydrates (<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days.Patients will be given four meals per day containing natural animal protein (meat, fish, eggs, dairy products without whey protein).
11108087|NCT04019418|Placebo Comparator|No Carbohydrate Drink + Rest|Participants will consume the no carbohydrate drink (300ml water) followed by a rest session
11108088|NCT04019418|Active Comparator|No Carbohydrate Drink + Exercise|Participants will consume the no carbohydrate drink (300ml water) followed by an exercise session (75% VO2 max on a cycle ergometer)
11108089|NCT04019418|Active Comparator|Carbohydrate Drink + Rest|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by a rest session
11108090|NCT04019418|Experimental|Carbohydrate Drink + Exercise|Participants will consume the carbohydrate drink (300ml water + 75g maltodextrin) followed by an exercise session (75% VO2 max on a cycle ergometer)
11108091|NCT04019405||Frailty status|Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.
11108092|NCT04019392|Active Comparator|Wetted ice with elastic wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied to each participants' lower leg for 30 minutes using an elastic wrap. The elastic wrap will be applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half. The elastic wrap application will consist of pulling the wrap to its full tension, measuring the length of the wrap, and calculating 75% of the total length to apply to the body part.
11108093|NCT04019392|Active Comparator|Game Ready|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
11108094|NCT04019379|Experimental|Sequence A|Low Ca/High Phos crossover to Low Ca/Low Phos
11108095|NCT04019379|Experimental|Sequence B|Low Ca/Low Phos crossover to Low Ca/High Phos
11108096|NCT04019366|Experimental|Group I|The experimental group was treated with Balance Training on Biodex Stability System along with traditional exercises.
11108097|NCT04019366|Active Comparator|Group II|The Control group was treated with Traditional exercises only for Symptomatic knee osteoarthritis.
11108098|NCT04019353||cf-DNA Collection|All patients undergoing kidney allograft biopsy for suspicion of an acute rejection episode will be approached for consent into the study. Patients who consent to the study will have the cf-DNA test drawn at time of biopsy to determine levels of cf-DNA. All consented patients will be followed for biopsy outcomes. Those whose biopsy shows acute rejection leading to treatment will have cf-DNA determination at 2, 4, 6, and 8 weeks post biopsy. Recipients with persistent high cf-DNA levels will undergo repeat biopsy at ~6 weeks after end of treatment per standard of care (this is not performed for purpose of the study, but for clinical care).
11108099|NCT04019340|No Intervention|Control|Usual care for patients in the CG is defined as visiting the outpatient wound clinic as prescribed by the physician. Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses.
11108100|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient wound clinic as prescribed by the physician). Wound size measurement, wound care (including dressing and inspection), and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a pluridisciplinary educational program
11108101|NCT04019327|Experimental|Metastatic Castration Resistant Prostate Cancer|Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
11108102|NCT04019314|Experimental|Subjects with know chronic systolic heart failure|Subjects with know chronic systolic heart failure (LVEF<50%) admitted to SMH Heart Failure Medical Service for decompensated HF with clinical findings of volume overload requiring advanced diuretic therapy intervention and management will receive daily blood draws and quantitative blood volume analysis
11108103|NCT04019301|Experimental|Community-based Qigong Group|Participants randomized into this group follow one, 75 minutes class per week supplemented by home practice for 20 minutes on 3 additional days.
11108104|NCT04019301|Experimental|Internet-based Qigong Group|Participants randomized into this group follow two online sessions for 40 minutes each, also supplemented by home practice for 20 minutes on 3 additional days.
11108155|NCT04018963||Uninostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the single nostril approach.
11108156|NCT04018963||Binostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the bilateral nostril approach.
11108924|NCT04013815|Active Comparator|group I|patients receiving the intercostal nerve block
11108105|NCT04019301|No Intervention|Self-Care Control Group|The Self-care control group, will be requested not to practice any Qigong during the study. Participants will be provided with an educational book on caregiving that includes self-guided activities related to caregiving and caregiver health (The Caregiver Helpbook: Powerful Tools for Caregiving). The book's evidence-based program is designed to provide caregivers the tools to increase their self-care and their confidence to handle difficult situations, emotions, and decisions. In addition, study staff will call participants in the self-care control group once a month.
11108106|NCT04019288|Experimental|Arm I (AVB-S6-500, durvalumab)|Patients receive anti-AXL fusion protein AVB-S6-500 IV over 60 minutes on days 1, 15, and 29 of cycle 0, and on days 1 and 15 of subsequent cycles. Beginning cycle 1, patients also receive durvalumab IV over 60 minutes on day 1. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11108107|NCT04019288|Experimental|Arm II (durvalumab, AVB-S6-500)|Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive anti-AXL fusion protein AVB-S6-500 IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11108108|NCT04019275|Experimental|ENGAGE|The intervention blends social learning, guided discovery, and skill training to promote community participation after stroke. The intervention is delivered in a group format and comprises group learning activities and individual action planning activities that address barriers to community participation after stroke.
11108109|NCT04019262|Active Comparator|40 Gy in 15 fractions|Patients randomized to 40 Gy in 15 fractions will receive 75 mg/m^2 temozolomide per day for 15 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
11108110|NCT04019262|Active Comparator|25 Gy in 5 fractions|Patients randomized to 25 Gy in 5 fractions will receive 150 mg/m^2 temozolomide per day for 5 days starting the first day of radiotherapy. This treatment will be followed by standard monthly 5 day cycles at 150 mg/m^2 for upto 1 year.
11108111|NCT04019249|Experimental|Experimental: Healthy Weight Coaching|Intervention: Healthy Weight Coaching.
11108112|NCT04019236|Other|" interventional "|New other than Routine nursing care will be used.
11108113|NCT04019236|No Intervention|" Control group "|Routine care only will be done for this group
11108114|NCT04019223||anti-tissue transglutaminase group|serum IgA-tissue transglutaminase antibody (tTG) was analyzed in serum using a quantitative automated ELISA method by means of a commercially available detection kit using recombinant human tTG as antigen recommended cut-off by the manufacturer > 8 U/mL).
11108115|NCT04019223||biopsy group|upper gastrointestinal endoscopic examination will be done and the jejunal histopathological examinations will be done at the Histopathology Laboratory. The features consistent with CD included: hyperplasia of crypts, atrophy of villous, and increase of intraepithelial lymphocytes.Duodenal samples will be processed using haematoxylin/eosin staining and CD3 immunophenotyping. The number of intra-epithelial lymphocytes (IEL), the architecture of villi, and the inflammatory cell infiltration of the lamina propria will be assessed. Histopathological changes will be classified according to the Marsh-Oberhuber criteria.Lymphocytic enteropathy (Marsh 1 lesion) was defined as 25 or more IEL per 100 epithelial nuclei, and normal villous architecture.
11108116|NCT04019210|Experimental|MODIFIED TRABECULECTOMY|"Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane.
~Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm."
11108117|NCT04019197|Experimental|Participants with HIV and lipohypertrophy: semaglutide arm|Participants with HIV/lipohypertrophy will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
11108118|NCT04019197|Placebo Comparator|Participants with HIV and lipohypertrophy: placebo arm|Participants with HIV/Lipohypertrophy will receive placebo x32 weeks, then no placebo for 24 weeks.
11108119|NCT04019197|Experimental|Overweight/obese participants without HIV: semaglutide arm|Overweight/obese participants without HIV will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
11108120|NCT04019197|Placebo Comparator|Overweight/obese participants without HIV: placebo arm|Overweight/obese participants without HIV will receive placebo x32 weeks, then no placebo for 24 weeks.
11108121|NCT04019184|Experimental|Glutamine group|Intravenous infusion of 0.5 g/kg body weight (2.5 ml/kg body weight) L-alanyl-Lglutamine over 12 h after randomization
11108122|NCT04019184|Placebo Comparator|Control group|Intravenous infusion of 2.5 ml/kg body weight sodium chloride 0.9 % over 12 h after randomization
11108123|NCT04019171|Experimental|interval exercise training|
11108124|NCT04019171|No Intervention|waiting list|
11108125|NCT04019158|Experimental|Parkinson's Disease patients|Parkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality
11108126|NCT04019145|Experimental|Fiber Reinforced bulk fill resin composite|Fiber reinforced bulk fill resin composite dentine substitute, capped occlusally and proximally (closed centripetal technique) by nanohybrid resin composite.
11108127|NCT04019145|Active Comparator|nanohybrid resin composite incrementation|Nanohybrid resin composite layering to fill the whole cavity, using closed centripetal technique.
11108128|NCT04019132||Older adults|Older adults aged >65 years
11108129|NCT04019132||Young group|Younger adults between the age of 20 and 35 years
11108157|NCT04018950|Experimental|ETX2514 and 14C-ETX2514|Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.
11108158|NCT04018937|Experimental|Reduced Intensity Conditioning with FAM|Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
11108240|NCT04018391|Active Comparator|Enhanced Usual Care|Participants will be randomized two weeks post-baseline. Those randomized to the control condition will receive Enhanced Usual Care.
11108130|NCT04019119|Experimental|Intervention: digital intervention Behaviour Change Technique|The assigned participants will receive an intervention based on gamification and the use of behavior change techniques to reduce sedentary lifestyle. Thus, a new mobile application will be used for 12 weeks that proposes to the user the realization of activities with the aim of reducing their sedentary behavior. The development of the application is based on previous analyzes that propose 6 clusters that encompass 33 factors that influence sedentary behavior. In this way, the application is designed to act on the two accessible: social support and behavior. On the social support, he proposes to the user to share his achievements in social networks or in an internal network of game users. In terms of habit modification, behavior modification strategies proposed in the Michie et al. (2013) taxonomy are applied, such as the following: establishment of personalized goals, rewards and reminders, awareness of achievements achieved, among others
11108131|NCT04019119|No Intervention|Control Group|The control group will receive the usual indications about the harms of sedentary lifestyle and the benefits of physical activity, not receiving specific intervention. In case the use of the intervention applied in the experimental group is beneficial, the participants assigned to the control group will be offered the opportunity to receive the intervention outside the study to allow the benefit to be used.
11108132|NCT04019106|Experimental|Dosing Level 1|0.0625 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
11108133|NCT04019106|Experimental|Dosing Level 2|0.125 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
11108134|NCT04019106|Experimental|Dosing Level 3|0.25 mg/kg Budesonide in bovine lipid extract surfactant (BLES)
11108135|NCT04019093|Experimental|TMD patients|Individuals seeking care for temporomandibular joint and muscle disorder (TMD).
11108136|NCT04019093|Experimental|Healthy controls|Healthy social drinkers without TMD recruited as a comparison group.
11108137|NCT04019067|Experimental|MCE first group|"Patients randomized to the MCE first group will have a MCE deployed as the first detection method."
11108138|NCT04019067|No Intervention|standard of care group|For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.
11108139|NCT04019054|Experimental|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.
~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
11108140|NCT04019054|Placebo Comparator|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.
~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
11108141|NCT04019041|Experimental|bermekimab ew|2 800 mg bermekimab loading dose subcutaneous injections, followed by weekly 400 mg bermekimab injections
11108142|NCT04019041|Experimental|bermekimab eow|2 800 mg loading dose subcutaneous injections, followed by alternating weekly 400 mg bermekimab injections with matching placebo injections
11108143|NCT04019041|Placebo Comparator|placebo ew|2 800 mg placebo loading dose subcutaneous injections, followed by weekly placebo subcutaneous injections
11108144|NCT04019028|Experimental|Navigated low frequency rTMS|"Application of 1Hz low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere using a navigation system.
~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image."
11108145|NCT04019028|Experimental|only low frequency rTMS(not using Navigation System)|"Application of low frequency repetitive transcranial magnetic stimulation to the primary motor area of the dominant hemisphere not using a navigation system.
~TMS coil is fixed on the target area based on MEP hotspot."
11108146|NCT04019028|Sham Comparator|Navigated Sham rTMS|"Application of repetitive transcranial magnetic stimulation with sham mode(no stimulation) to the primary motor area of the dominant hemisphere using a navigation system.
~Using the BrainSight instrument, a navigation system, the TMS coil position can be fixed on the point precise target area based on the subject's MRI image.
~Sham stimulation is stimulated by the same frequency, intensity and time as the actual stimulus in such a way that the 8-shaped coil is placed at a 90 degree angle to the scalp in the same manner as rTMS and sounds are heard but the magnetic stimulus is not transmitted to the cerebrum"
11108147|NCT04019015|Experimental|Kcentra|"A single dose of Kcentra based on estimated body weight
~2000 U for patients with an estimated body weight ≤ 75kg
~3000 U for patients with an estimated body weight > 75kg"
11108148|NCT04019015|Placebo Comparator|Placebo|A single infusion of volume matched placebo solution (Normal Saline)
11108149|NCT04019002|Experimental|Cohort 1: Newly Diagnosed- Standard Treatment|"This arm is for patients with histologically proven newly diagnosed glioblastoma who will undergo standard treatment with radiation therapy (RT) and temozolomide (TMZ).
~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at two time points: before receiving standard treatment with RT/TMZ and at the first post-radiation follow-up scan (8 weeks later)."
11108150|NCT04019002|Experimental|Cohort 2: Recurrent- Standard Surgical Resection|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will receive surgical resection for the recurrence.
~Patients will receive one injection of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at one time point: before surgery."
11108151|NCT04019002|Experimental|Cohort 3: Recurrent- Standard Treatment|"This arm is for patients with histologically proven recurrent suspected glioblastoma who will undergo standard treatment for the recurrence.
~Patients will receive two injections of hyperpolarized 13C pyruvate for research imaging performed prior to standard imaging on the same day. Research imaging occurs at three time points: prior to treatment (baseline), approximately 7-14 days after the initiation of treatment, and 6-8 weeks after the initiation of treatment."
11108152|NCT04018976|Experimental|Heat and Vacuum|AVACEN 100 applies heat and vacuum to hand
11108153|NCT04018976|Active Comparator|Heat Only|AVACEN 100 applies heat only
11108154|NCT04018976|Sham Comparator|Sham|AVACEN 100 applies neither heat nor vacuum
11108159|NCT04018924|Experimental|T - Treated|After standard cleansing or debridement of all wounds, on wound or portion of wound selected for treatment is treated with EmoLED device. Then covered with hydro fibre medication and dressing or compressive dressing when needed on the whole wound (SOC). Treatment is repeated once a week.
11108160|NCT04018911|Active Comparator|Hearing Aid standard NR_1|Hearing Aid with standard Noise Reduction (NR) serves as reference condition.
11108161|NCT04018911|Experimental|Hearing Aid with NR_2|NR_2: Noise Reduction principle 2
11108162|NCT04018911|Experimental|Hearing Aid with NR_3|NR_3: Noise Reduction principle 3
11108163|NCT04018911|Experimental|Hearing Aid with NR_4|NR_4: Noise Reduction principle 4
11108164|NCT04018898||Observational|Each participant will be evaluated at Emergency Department based on ER2 screening tool (Emergency Room Evaluation and Recommendation Form). Six closed-ended format questions (i.e., yes versus no) composed ER2 assessment: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless its type, and temporal disorientation (inability to give the current month and/or year).
11108165|NCT04018885|Experimental|ALA 2.5% 0.5h|Topical application of 2.5% ALA for 0.5 hour
11108166|NCT04018885|Experimental|ALA 2.5% 1.5h|Topical application of 2.5% ALA for 1.5 hours
11108167|NCT04018885|Experimental|ALA 2.5% 3h|Topical application of 2.5% ALA for 3 hours
11108168|NCT04018885|Experimental|ALA 5% 0.5h|Topical application of 5% ALA for 0.5 hour
11108169|NCT04018885|Experimental|ALA 5% 1.5h|Topical application of 5% ALA for 1.5 hours
11108170|NCT04018885|Experimental|ALA 5% 3h|Topical application of 5% ALA for 3 hours
11108171|NCT04018885|Experimental|ALA 10% 0.5h|Topical application of 10% ALA for 0.5 hour
11108172|NCT04018885|Experimental|ALA 10% 1.5h|Topical application of 10% ALA for 1.5 hours
11108173|NCT04018885|Experimental|ALA 10% 3h|Topical application of 10% ALA for 3 hours
11108174|NCT04018872|Experimental|Itraconazole|Itraconazole capsule 300mg twice daily for 6-8 weeks following chemoradation.
11108175|NCT04018859|Experimental|Platelet-Rich Plasma|Participants will receive intradermal injections of 2-3mL autologous PRP to eyebrows.Three treatments will be performed 1 month apart.
11108176|NCT04018859|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of 2-3mL sterile saline to eyebrows.Three treatments will be performed 1 month apart.
11108177|NCT04018833||ranibizumab|Patients nonresponsive to bevacizumab that were switched to ranibizumab
11108178|NCT04018833||aflibercept|Patients nonresponsive to bevacizumab that were switched to aflibercept
11108179|NCT04018820|Experimental|Training program|
11108180|NCT04018807|Other|Resource Pamphlet|Participants will receive a pamphlet detailing mental health and social service providers at the local, state, and national level.
11108181|NCT04018807|Experimental|Remote Therapy|Participants will receive eight 30-minute remote therapy sessions over the course of twelve weeks.
11108182|NCT04018794|Experimental|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
11108183|NCT04018781||MR group|Patients who benefit from a full process of medication reconciliation (entrance and discharge) before being discharged to home.
11108184|NCT04018781||Control group|Patients who benefitted from a medication reconciliation at entrance only before being discharged to home.
11108185|NCT04018768||Ibuprofen + Percocet|
11108186|NCT04018768||Percocet|
11108187|NCT04018755|Experimental|treatment|anakinra 100 mg subcutaneous once daily
11108188|NCT04018742||Patients with an abscess|Patient diagnosed with a cerebral abscess at admission; and to benefit from an abscess puncture as part of routine care.
11108189|NCT04018729|Experimental|Endobronchial valve + marrow-derived mesenchymal stromal cell|
11108190|NCT04018729|Active Comparator|Endobronchial valve|
11108191|NCT04018716|Experimental|MTA|mineral trioxide aggregate
11108192|NCT04018716|Active Comparator|Dycal|calcium hydroxide cement
11108193|NCT04018703|Experimental|Dexmedetomidine|Dexmedetomidine will be used for perioperative sedation.
11108194|NCT04018703|Experimental|Midazolam|Midazolam will be used for perioperative sedation.
11108195|NCT04018690|Experimental|Experimental|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.
11108196|NCT04018690|Active Comparator|Control Group|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine
11108197|NCT04018677|Experimental|TOGETHER app users|TOGETHER app will be downloaded on smart phone. Subjects will be asked to answer questions and/or perform activities on his/her smartphone device. Project information will include responses to surveys and giving additional feedback on app user experience.
11108198|NCT04018664|Placebo Comparator|Placebo|"Placebo
~150 mL flavored beverage"
11108199|NCT04018664|Experimental|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution
~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
11108200|NCT04018664|Experimental|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution
~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
11108201|NCT04018664|Experimental|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution
~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
11108202|NCT04018664|Experimental|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution
~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
11108203|NCT04018664|Experimental|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution
~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
11108204|NCT04018664|Experimental|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution
~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
11108205|NCT04018664|Experimental|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution
~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
11108239|NCT04018391|Experimental|Stepped care for non-adherence and depression|Participants will be randomized approximately two weeks post-baseline. Those randomized to the experimental condition will receive the Intervention and Stepped Care Treatment Protocol
11108206|NCT04018651|Experimental|PrEP Master Adherence Intervention|The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
11108207|NCT04018638|Experimental|Adults with TKR Perform Home Exercise Program|Participants that have a total knee replacement will complete a home-based exercise program
11108208|NCT04018638|No Intervention|Healthy Controls Only|Participants that have no history of knee joint dysfunction will serve as age-matched uninjured controls
11108209|NCT04018625|Experimental|Intervention|Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
11108210|NCT04018625|Active Comparator|Treatment as usual|Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
11108211|NCT04018612|Active Comparator|High Dose IV Acetaminophen|High Dose IV Acetaminophen Post Op
11108212|NCT04018612|Active Comparator|Low Dose IV Acetaminophen|Low Dose IV Acetaminophen Post Op
11108213|NCT04018612|Placebo Comparator|Placebo|IV Placebo Post Op
11108214|NCT04018599|Experimental|40 mg MSB11022 via Auto-injector|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via an auto-injector on Day 1.
11108215|NCT04018599|Experimental|40 mg MSB11022 via Pre-filled Syringe|Participants will receive a single dose of 40 mg/0.8 mL of MSB11022 via a pre-filled syringe on Day 1.
11108216|NCT04018586|Experimental|Heat and Vacuum|AVACEN 100 device applies heat and vacuum to hand
11108217|NCT04018586|Active Comparator|Heat Only|AVACEN 100 device with heat only
11108218|NCT04018586|Sham Comparator|Sham|AVACEN 100 device with neither heat nor vacuum
11108219|NCT04018573|Active Comparator|Parent Support Film|Parents will watch Lead with Love, a 35-minute documentary style film designed to provide support, information, and behavioral guidance to parents with a lesbian, gay, or bisexual child. One month later, parents will look over material that reviews the major points of the film. All of this material is presented online via our webapp.
11108220|NCT04018573|Experimental|Parent Support Film + PATHS Sexual Communication Toolkit|Parents in this arm will have the option of watching Lead with Love, and then will engage with our parent toolkit, designed to increase the frequency and quality of parent-child communication about HIV and condoms. One month later, parents will engage with booster content, customized to address their self-reported barriers to communicating with their sons. All of this material is presented online via our webapp.
11108221|NCT04018560|Experimental|Intervention|
11108222|NCT04018560|No Intervention|Usual care|
11108223|NCT04018534|Experimental|Control group|The patients in control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society(BOS) educational goals.
11108224|NCT04018534|Experimental|Video assisted education group|The patients in one of the study groups received a video assisted education
11108225|NCT04018534|Experimental|Hands-on training group|The patients in other study group received a hands-on training.
11108226|NCT04018521|Active Comparator|Parent Connectors|trained and supervised PPNs deliver weekly telephone-based support for six to nine months to parents or caregivers of all newlyenrolled youth or young adults (Y/YA) in FEP services
11108227|NCT04018521|Active Comparator|Usual Care|Coordinated Specialty Care (CSC)
11108228|NCT04018508|Experimental|Massages|During routine clinic visits, subjects will receive a total of six 30-minute massages (one massage per week for 4 weeks, then one massage every two weeks for 4 weeks).
11108229|NCT04018508|No Intervention|Control|Subjects randomized to the control arm will also attend routine clinic visits at the same pre-prescribed intervals (one clinic visit per for 4 weeks, then one visit every two weeks for 4 weeks).
11108230|NCT04018495|Experimental|Interventional - Fitbit tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
11108231|NCT04018482|Experimental|Open label test arm|Subjects will have their right eye treated with 5% Povidone Iodine per standard institutional protocol prior to receiving their intravitreal injection (2 drops of PI followed by application of 3.5% non-preserved lidocaine gel for 10 minutes, followed by 1 drop of PI for 30 seconds prior to injection). Subjects will have their left eye treated with Avenova per the same application protocol as PI prior to receiving their intravitreal injection. Prior to and following disinfecting both eyes but before the injection, a physician will gently swab the inferior conjunctival fornix (white part of each eye below the lower eye lid) with an ocular brush. Swabs will be cultured to compare bacterial counts. Subjects will be asked to complete a questionnaire regarding comfort of the disinfectant and injection procedure in general immediately following the injection and 1-2 hours post-injection.
11108232|NCT04018456|Experimental|Biodentine|Intervention group: application of biodentine as pulp space barrier during regenerative endodontic treatment.
11108233|NCT04018456|Active Comparator|White MTA|Control group: application of White MTA as pulp space barrier during regenerative endodontic treatment.
11108234|NCT04018443||patients admitted ti surgical ICU after major surgery|patient admitted to surgical ICU after major surgery for post-operative close monitoring, assessment and resuscitation of the intravascular volume status
11108235|NCT04018417|Experimental|Amphotericin B|The eye bank will add amphotericin B 0.255 μg/mL to the Optisol-GS donor cornea storage solution.
11108236|NCT04018417|No Intervention|Control|The donor cornea will be stored in Optisol-GS per the eye bank's standard procedure.
11108237|NCT04018404|No Intervention|Control|Subjects will be approached for enrollment prior to or following clinic visit with physician. Only children present with a biological mother will be considered for enrollment. Charts of controls will be flagged so that they will not be able to be enrolled in the FRI clinical program if they present to a morning clinic where the program is offered.
11108238|NCT04018404|Experimental|Subject|Mothers and children will be approached by study personnel (separate from Outreach Coordinators who will obtain consent for use of information to evaluate the FRI Clinical Program) for enrollment in the FRI Research Program following completion of all FRI Clinical Program activities for that day. Both mother and child will be enrolled and contribute data and samples to the FRI Research Program.
11108241|NCT04018378|Experimental|RT|"period 1: HGP1604 1mg (reference drug, R) will be administered once orally.
~period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period."
11108242|NCT04018378|Experimental|TR|"period 1: HIP1502 1mg (test drug, T) will be administered once orally.
~period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period."
11108243|NCT04018365|Experimental|Treatment of empagliflozin|Empagliflozin 10 mg is to be continuously administered once daily for 12 weeks. Measure an HbA1c level after 12 weeks and determine the dose (Week 13 to Week 24). In case of <7.0%, 10 mg will be continued: in case of >=7.0%, it will be increased to 25 mg.
11108244|NCT04018339|Experimental|RTA 402 5mg or 10mg oral administration|
11108245|NCT04018339|Placebo Comparator|Placebo|
11108246|NCT04018326||Compliant patients|The compliant patient was defined as a patient who did not miss any follow-up visit until the end of the study period.
11108247|NCT04018326||Loss to follow-up (LTFU)|LTFU was defined as missing any follow-up visit for any interval exceeding 6 months provided that patients eventually resumed care before the end of the study period (time zero was defined as the date of the missed follow-up visit).
11108248|NCT04018313|Experimental|CT-P39 (Part 1)|150 mg/mL, Solution for injection in PFS
11108249|NCT04018313|Active Comparator|EU-approved Xolair (Part 1)|150 mg/mL, Solution for injection in PFS
11108250|NCT04018313|Experimental|CT-P39 (Part 2)|150 mg/mL, Solution for injection in PFS
11108251|NCT04018313|Active Comparator|EU-approved Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
11108252|NCT04018313|Active Comparator|US-licensed Xolair (Part 2)|150 mg/mL, Solution for injection in PFS
11108253|NCT04018300|Experimental|Ferrous sulfate|Subjects will take a 65 mg Fe capsule of ferrous sulfate, once daily for 21 consecutive days. The first treatment capsule will be consumed with a semi-purified meal (egg albumin, sugar, vanilla, maltodextrose and corn oil) and will have blood drawn hours 0, 1, 2, 3, 4, 6 and 8 post consumption. Serum will be used to determine non-transerrin bound iron, serum iron and percent saturation. Throughout the treatment period, subjects are informed to consume the capsule with food and report symptoms in an online questionnaire. Following three weeks treatment, participants return for a blood draw and oxidative stress indicators are measured. A three week washout period with placebo treatment takes place between treatment crossover.
11108254|NCT04018300|Experimental|Aspiron|AspironTM which is an iron-enriched supplement will follow the same guidelines and protocol as ferrous sulfate arm. Equivalent 65 mg Fe per capsule will be administered to participants.
11108255|NCT04018300|Placebo Comparator|Placebo|Participants will follow the same description for the other two experimental treatment groups. Capsules will be given to subjects in opaque formation, therefore will be unable to differentiate the iron supplements.
11108256|NCT04018287||HPP-Group|"genetical verified hypophosphatasia
~age >18 years
~written informed consent
~complete serological and radiological examinations"
11108257|NCT04018287||Control-Group|"healthy men and women without any history of musculoskeletal diseases
~Alkaline phosphatase (AP) in reference range
~written informed consent
~complete serological and radiological examinations"
11108258|NCT04018274|Experimental|Sequence 1|In Treatment Sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into Period 2 where they will receive PF-06651600 PO for 9 days followed by administration of a single dose of OC on the morning of Day 10.
11108259|NCT04018274|Experimental|Sequence 2|In Treatment Sequence 2, Period 1, participants will be dosed with PF-06651600 PO QD for 9 days and administered a single dose of OC on the morning of Day 10. After a washout period of at least 10 days, participants will continue into Period 2 and will receive an additional single dose of OC.
11108260|NCT04018261|Experimental|Activated T-Lymphocytes|Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.
11108261|NCT04018248|Experimental|Treatment ( BR101801):Phase Ia (dose escalation)|Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
11108262|NCT04018248|Experimental|Treatment ( BR101801):Phase Ib (dose expansion)|"Group A: Patients with diffuse large B-cell lymphoma (DLBCL) including MYC-altered DLBCL
~Group B: Patients with follicular lymphoma.
~Group C: Patients with chronic lymphocytic leukemia/small lymphocytic leukemia, other B-cell lymphoma such as, but not limited to mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, or PTCL"
11108263|NCT04018235||localized disease or locally advanced disease|"Subgroups:
~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy"
11108264|NCT04018235||metastatic disease|"Subgroups:
~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
11108265|NCT04018235||follow up disease|"Subgroups:
~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
11108266|NCT04018222||Lupus Cases|This cohort of patients will involve individuals with a confirmed medical history of Systemic Lupus Erythematosus. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
11108267|NCT04018222||Healthy Controls|This cohort of patients will involve individuals whom do not have a diagnosis of Systemic Lupus Erythematosus or any other rheumatological or auto-immune diseases. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
11108268|NCT04018196|Experimental|Experimental group|Patient aged over 80 years old will be included. They will have motor imagery training of manual task and motor imagery training of motor task.
11108269|NCT04018196|Active Comparator|Control group|Patient aged over 80 years old will be included. They will have emotionally neutral film as training of manual task and emotionally neutral film as training of motor task.
11108270|NCT04018170|Experimental|JW1601|tablet formulation
11108271|NCT04018170|Placebo Comparator|Placebo|tablet formulation identified with JW1601
11108272|NCT04018157|Active Comparator|ketodex|ketamine dexmedetomidine mixture
11108273|NCT04018157|Active Comparator|ketofol|ketamine propofol mixture
11108274|NCT04018157|Placebo Comparator|placebo|normal saline
11108275|NCT04018144||Group-1|Healthy individuals
11108276|NCT04018144||Group-2|Periodontitis patients-stage 3-grade B
11108277|NCT04018144||Group-3|Periodontitis patients-stage 3-grade C
11108278|NCT04018131|Active Comparator|Cimetidine|
11108280|NCT04018118||Eosinophilia/Hypereosinophilic syndrome|patient with eosinophilia and/or hypereosinophilic syndrome
11108281|NCT04018105|Experimental|taking metformin 30 or 60 minutes before the OGTT|
11108282|NCT04018105|Placebo Comparator|No metformin before OGTT|
11108283|NCT04018092|Experimental|Active NIR-PBM|"For transcranial stimulation, the study team will use two MedX units (1116 Rehab Console, MedX Health), whereas intranasal stimulation is delivered using the 810 Intranasal device (Vielight Inc). During each lab session, six transcranial LED clusters will be placed on the scalp in two distinct configurations guided by 10-20 EEG system. Total transcranial stimulation time is 40 minutes, 20 min per cluster. Concurrently, two 810 intranasal devices will be placed in each nostril for 25 min of total dose per nostril. For at home sessions, participants will use the standalone 810 Intranasal device only.
~Total amount of sessions:
~16 sessions of stimulation will occur in the laboratory. Each session will last approximately 90 minutes and will include two 20-minute segments of NIR stimulation.
~AND
~44 sessions of intranasal stimulation in the home. Each session will last 25 minutes and will occur on weekdays when there is no in-lab session."
11108284|NCT04018092|Sham Comparator|Sham NIR-PBM|"Participants randomized to the Sham control group will undergo identical procedures as the Active group. The only difference is that the sham NIR devices are modified not to deliver stimulation. Because NIR is invisible, participants are unable to detect whether NIR is being delivered."
11108285|NCT04018066|Experimental|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
11108286|NCT04018053|Experimental|18F-fluciclovine|"18F-fluciclovine will be administered via slow push over 10 seconds through a peripheral intravenous line
~Immediately after the injection of the radiopharmaceutical, dynamic PET/CT images of the pelvis will be obtained for 15 minutes
~Subsequently, PET/CT images will be obtained from the pelvis to the base of skull."
11108287|NCT04018040|No Intervention|Control Group|Patients will be asked to continue their usual diet patterns over an 8 week period
11108288|NCT04018040|Experimental|Intervention Group|Patients will follow a lacto-ovo vegetarian diet for an 8 week period. patients will be provided with a lacto-ovo vegetarian food box delivery service with fresh ingredients and recipes to cover four dinners per week.
11108289|NCT04018027|Active Comparator|Difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablet administered twice daily
11108290|NCT04018027|Active Comparator|Difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablet administered twice daily
11108291|NCT04018027|Active Comparator|Difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg tablet administered twice daily
11108292|NCT04018027|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
11108293|NCT04018014||< 30 kg/m2|patients with BMI < 30/kg/m2
11108294|NCT04018014||>30 kg/m2|patients with BMI > 30 kg/m2
11108295|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
11108296|NCT04017988|Experimental|Ethanol Extracts of Porphyra Tenera(PTE10) group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 2.5 g/day)
11108297|NCT04017988|Placebo Comparator|Placebo group|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal (2.512 g/day, Ethanol Extracts of Porphyra Tenera(PTE10) 0 g/day)
11108298|NCT04017975|No Intervention|Non-imaging cohort|There will be no intervention for the non-imaging group. Subjects will receive standard of care for cardiac surgery.
11108299|NCT04017975|Experimental|Imaging cohort|Up to 5mL of 1:1000 dilute fluorescite will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes. The system will be used to assist the investigator with the operative course.
11108300|NCT04017962|Experimental|Hematopoietic cell transplantation/HCT|"Participants will be hematopoietic cell transplantation (HCT) recipients with a history of CMV infection. INTERVENTIONAL COHORT: Patients receive letermovir PO QD (or IV over 1 hour for patients unable to receive PO) for 14 weeks in the absence of disease progression or unacceptable toxicity.
~OBSERVATIONAL COHORT: Patients undergo collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180."
11108301|NCT04017936|Experimental|Anakinra|100 mg/0.67 mL daily subcutaneous injection for 4 weeks
11108302|NCT04017936|No Intervention|Standard of Care|Continue standard of care treatment
11108303|NCT04017923||20-29 age group|
11108304|NCT04017923||30-39 age group|
11108305|NCT04017923||40-64 age group|
11108306|NCT04017923||65 and older age group|
11108307|NCT04017897|Experimental|Experimental|
11108308|NCT04017884|Experimental|Remin Pro Forte.|intervention
11108309|NCT04017884|Active Comparator|Remin pro.|comparator
11108310|NCT04017871|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
11108311|NCT04017871|Placebo Comparator|Control|10 days of care and classic activities
11108312|NCT04017858|Experimental|Experimental|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
11108313|NCT04017858|Active Comparator|Control|Patients will be submitted to total knee replacement.
11108314|NCT04017845|Active Comparator|Household-Open Invitation (HOI)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
11108351|NCT04017637|Experimental|Resistance Training Intervention (RT)|Those randomized to the RT group will complete baseline and post-intervention assessments at weeks 0 and 12. For the intervention, they will complete resistance training for approximately 12 minutes 2x per week for 12 weeks.
11108352|NCT04017624|Experimental|Fresh Truck with stipend|Referral to Fresh Truck mobile market
11108353|NCT04017624|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
11108884|NCT04014088|Active Comparator|facemask CPAP|facemask CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
11108315|NCT04017845|Active Comparator|Recommendation By Physician (RBP)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
11108316|NCT04017832|Experimental|Oral semaglutide 3 mg and placebo (sitagliptin)|Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
11108317|NCT04017832|Experimental|Oral semaglutide 7 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
11108318|NCT04017832|Experimental|Oral semaglutide 14 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
11108319|NCT04017832|Experimental|Sitagliptin 100 mg and placebo (oral semaglutide)|Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks
11108320|NCT04017819|Active Comparator|Healthy volunteers (Group 1)|Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
11108321|NCT04017819|Experimental|Patients with newly diagnosed lung cancer (Group 2)|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
11108322|NCT04017819|Experimental|Patients with lung cancer undergoing non-surgical tx (Group 3)|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of [18F]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a [18F]-C-SNAT4 PET/CT scan)
11108323|NCT04017793|Active Comparator|Mindfulness Based Stress Reduction Program|
11108324|NCT04017793|Active Comparator|Relaxation Group|
11108325|NCT04017780|Experimental|Single-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
11108326|NCT04017780|Experimental|Double-limb circuit with Intensive Care Unit ventilator|Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
11108327|NCT04017780|Experimental|Double-limb circuit with turbine-driven ventilator|Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
11108328|NCT04017767|Experimental|Moderate to Severe Obstructive Sleep Apnea (OSA)|Individuals with moderate to severe OSA defined as having an Apnea-hypopnea Index (AHI) that is greater than or equal to 15.
11108329|NCT04017767|Active Comparator|Without OSA|Individuals without OSA defined as having AHI less than 5.
11108330|NCT04017754||Study sample|Women with unexplained recurrent pregnancy loss.
11108331|NCT04017754||Control group|Danish female blood donors of reproductive age with unknown reproductive history.
11108332|NCT04017741|Active Comparator|Active group|The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
11108333|NCT04017741|Placebo Comparator|Placebo group|The placebo group will be administered 4mls of 0.9% saline.
11108334|NCT04017728|Active Comparator|Conventional Percutaneous Vertebroplasty|The cement is injected after the successful puncture.
11108335|NCT04017728|Experimental|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied to destroy the metastatic lesion before coment injection.
11108336|NCT04017715|Experimental|warm up|warm up exercises
11108337|NCT04017715|Experimental|cool down|cool down exercises
11108338|NCT04017715|Active Comparator|control|Following conventional protocol
11108339|NCT04017702||Pregnant women with gestational age between 32-40 weeks.|100 patients scheduled for cesarean section under neuraxial anesthesia with 150 mcg intrathecal or 3-mg epidural morphine.
11108340|NCT04017702||Patients post anesthesia care units (PACU) and surgical floor.|100 patients scheduled to receive General Anesthesia (GA) and planned to receive opioid intravenously (boluses/patient controlled analgesia (PCA).
11108341|NCT04017702||Patients in step down/ICU.|50 patients suffered from rib fracture and 50 patients after weaning from mechanical ventilation and extubation.The Expiron will provide continuous information about the respiratory status (tidal volume, respiratory rate and minute ventilation) of non-intubated patients specifically: sleeping or awake; with the use of incentive spirometry; the response to medications and other interventions (such as paravertebral/epidural block); the need for endotracheal re-intubation.
11108342|NCT04017689||Verbal Information Group|Verbal Information
11108343|NCT04017689||Photo Group|Information by photos
11108344|NCT04017689||Video Group|Information by video
11108345|NCT04017676|No Intervention|Control group|The first group will be under the usual treatment conditions (TAU)
11108346|NCT04017676|Experimental|Experimental group|The second group will be exposed to a multidisciplinary therapeutic program that has a monitoring component and after two months an intervening component will be.
11108347|NCT04017663||Public group|patients who performed cardiovascular rehabilitation in a public center
11108348|NCT04017663||Private group|patients who performed cardiovascular rehabilitation in a private center
11108349|NCT04017650|Experimental|Treatment (encorafenib, cetuximab, nivolumab)|Patients receive encorafenib PO QD on days 1-28, cetuximab IV over 1 hour on days 1 and 15, and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11108350|NCT04017637|No Intervention|Usual Care (UC)|Those randomized to the UC group will complete baseline and post-intervention assessments only. No intervention will be administered.
11108354|NCT04017611|Experimental|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
11108355|NCT04017598|Active Comparator|Ferrous Sulfate|Iron will be given orally in the form of tablets. A supplement of 60 mg will be taken daily for 12 weeks. World Health Organization standard dose and commonly used form of iron.
11108356|NCT04017598|Experimental|Ferrous Bisglycinate|Iron will be given orally in the form of tablets. A supplement of 18 mg will be taken daily for 12 weeks. Ferrous bisglycinate has a bioavailability 2-4x greater than ferrous sulfate.
11108357|NCT04017598|Placebo Comparator|Placebo|Placebo will be given orally in the form of tablets as a control made of microcrystalline cellulose.
11108358|NCT04017585|Active Comparator|patients with IBS treated with gluten|patients receiving gluten
11108359|NCT04017585|Placebo Comparator|patients with IBS treated with placebo|patients receiving placebo
11108360|NCT04017572|Active Comparator|Standard treatment|APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.
11108361|NCT04017572|Active Comparator|Optimized treatment|APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.
11108362|NCT04017559|Experimental|Intervention cohort|All participants were entered into the intervention cohort to receive the Motivational Interviewing intervention
11108363|NCT04017546|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15. Venetoclax will be taken daily on Day 1 through Day 15. One cycle will be 28 days or 4 weeks.
11108364|NCT04017533|Experimental|GMK Sphere|Patients receive a cementless GMK Sphere Total Knee Replacement
11108365|NCT04017520||Mother-infant dyads|"200 mother-infant dyads enrolled at delivery and followed longitudinally at regularly scheduled well child checks (4, 16, 24, and 48- weeks) at a primary care outpatient pediatric clinic affiliated with an academic medical center. Eligible mothers will be those who plan to breast feed for 16 weeks and infants born at term (37-42 weeks). The cohort will be divided post-hoc into atopic and non-atopic groups based on the primary outcome measure (described below).
~No intervention will be administered."
11108366|NCT04017507||Oscillating-rotating electric toothbrush|Twice daily brushing
11108367|NCT04017507||Side-to-side electric toothbrush|Twice daily brushing
11108368|NCT04017507||Manual toothbrush|Twice daily brushing
11108369|NCT04017494||Single ventricle|Patients with single ventricle lesions
11108370|NCT04017481|Experimental|Repetitive stimulating transcranial stimulation (rTMS)|Subjects receive 8 sessions M1 Neuromodulation using rTMS according to the protocol ( 80% resting motor threshold, 10 Hertz; 1000 pulses; 25 trains de 4 seconds con 25 seconds intertrain.
11108371|NCT04017481|Experimental|EEG guided Neurofeedback (NFB)|Subjects receive 8 sessions M1 EEG guided NFB with virtual reality goggles in order to modify the beta rhythm. The sessions have a duration of 20min
11108372|NCT04017481|Experimental|rTMS + NFB|Subjects receive both interventions sequentially
11108373|NCT04017481|No Intervention|No intervention|No interventions, the patient just comes to be evaluated sequentially according to the timing of experimental groups.
11108374|NCT04017468|Active Comparator|Treatment Arm|The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
11108375|NCT04017468|No Intervention|Control Arm|The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.
11108376|NCT04017455|Experimental|bevacizumab and atezolizumab|1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy
11108377|NCT04017442|Experimental|Morphine|2mg preservative free morphine
11108378|NCT04017442|Placebo Comparator|Saline|4 mL preservative free saline
11108379|NCT04017429|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
11108380|NCT04017429|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
11108381|NCT04017416||Standard Care|Audiologists in the standard care group were instructed to manage the patients in the same way as they would do in their routine clinics which were in accordance with national practice guidelines and were typical of National Healthcare Services (NHS) audiology departments across the UK.
11108382|NCT04017416||I-PLAN|Audiologists were instructed to deliver the I-PLAN in addition to standard care at the hearing aid fitting consultation.
11108383|NCT04017403|Experimental|Probiotic group|The probiotic group was treated with Bifidobacterium tripleis,one day before surgery to the sixth day after surgerythe drug is taken orally, 4 capsules at a time, 2 times a day.
11108384|NCT04017403|Placebo Comparator|Placebo group|The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
11108385|NCT04017390|Experimental|Arm 1: Theraworx Foam alone|Theraworx foam only
11108386|NCT04017390|Active Comparator|Arm 2: Theraworx Foam and night splint|Theraworx foam with a night time splint
11108387|NCT04017390|Placebo Comparator|Arm 3: Placebo foam alone|Placebo foam alone
11108388|NCT04017390|Other|Arm 4: Placebo foam and night splint|Placebo foam with a night time splint
11108389|NCT04017377|Experimental|Chemotherapy+ Radiation therapy|"Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2, Patients secondly receive weekly cisplatin (40 mg/m^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.
~Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days."
11108390|NCT04017364|Active Comparator|PTCA of coronary de novo lesion PCB|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
11108756|NCT04014764||Single group|"Documented hematologic malignancy in need of starting an active anti-cancer therapy.
~This is a non-interventional study."
11108391|NCT04017364|Experimental|PTCA of coronary de novo lesion SCB|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
11108392|NCT04017351|Experimental|Subjects with virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery will have access to artificial intelligence virtual assistance (AIVA)
11108393|NCT04017351|No Intervention|Subjects without virtual assistance|Subjects receiving current standard of care for a surgical procedure within the department of plastic surgery
11108394|NCT04017338|Experimental|Non Randomized Intervention|"Intervention description: recipients on the wait-list for lung, heart, kidney, and/or pancreas transplants will all receive antiviral treatment in the form of 8 total doses of oral tablets. Lung recipients will also receive donor lungs that are treated with normothermic EVLP (details of both described below).
~Drug: All recipients will receive glecaprevir (300mg)/pibrentasvir (120mg) supplied as three tablets per dose 6-12 hours prior to transplant, and for 7 days post-transplant. Other Names: Maviret. Patients will also receive ezetimibe (10mg), supplied as one tablet per dose to be taken at the same time as Maviret tablets (6-12 hours prior to transplant in addition to 7 daily doses post-transplant).
~Ex Vivo Lung Perfusion (EVLP): Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions. Other names: Normothermic EVLP."
11108395|NCT04017325||TOOKAD VTP TREATMENT|Subjects randomized in the treatment arm (TOOKAD VTP treatment) in the initial period of the study.
11108396|NCT04017325||Active surveillance|Subjects randomized in the control group (active surveillance) in the initial period of the study.
11108397|NCT04017312|Active Comparator|HFCWO group|Subjects in this arm of treatment will use The Vest® as their primary airway clearance modality for the duration of the study.
11108398|NCT04017312|Active Comparator|OPEP group|Subjects in this arm of treatment will use the Acapella® as their primary airway clearance modality for the duration of the study.
11108399|NCT04017299|Active Comparator|Virtual reality with computer graphics|Use of Virtual reality with computer graphics
11108400|NCT04017299|Active Comparator|Virtual reality with real movies|Use of Virtual reality with real movies
11108401|NCT04017299|Active Comparator|Music therapy (dedicated device and music scores)|Use of music therapy (dedicated device and music scores)
11108402|NCT04017299|Other|Usual device (TV radio)|usual distraction : watching TV
11108403|NCT04017286||depressive disorder group|At 21 weeks of pregnancy, women diagnosed with depressive disorder by the Hamilton depression scale and Beck depression rating scale and their offspring were enrolled.
11108404|NCT04017286||Nutrient-deficient group|Nutrients (Vitamin A,D,E) were tested at 21 weeks of pregnancy, and pregnant women with one or more nutrient deficiencies or insufficiency and their offspring were enrolled.
11108405|NCT04017286||depressive disorder and nutrient deficiency group|At 21 weeks of pregnancy, pregnant women with depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
11108406|NCT04017286||Neither group|At 21 weeks of pregnancy, pregnant women without depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
11108407|NCT04017273||Observational|The participants of this study will be seen at Emergency Department, and a nurse will perform a test called ER2 ( Emergency Room Evaluation and Recommendation).
11108408|NCT04017260|Experimental|open and closed technique|treatment of pilonidal sinus by open and closed approach
11108409|NCT04017260|Experimental|Rhomboid flap technique|treatment of pilonidal sinus by Rhomboid flap
11108410|NCT04017260|Experimental|karydakis technique|treatment of pilonidal sinus by Karydakis
11108411|NCT04017260|Experimental|open technique|treatment of pilonidal sinus by open approach
11108412|NCT04017247|Active Comparator|Intermittent treatment|Infusion of oxytocin for 6 hours at a time until patient delivers.
11108413|NCT04017247|Active Comparator|Continous treatment|Infusion of oxytocin continuously from patient admission until patient delivers.
11108414|NCT04017234|Experimental|PMP group|children received health education for eye and the intervention(which included frequency following response, eye exercise, and transcutaneous electrical nerve stimulation) a 30 minute three times per week for four weeks.
11108415|NCT04017234|No Intervention|control group|children just received health education for eye
11108416|NCT04017221||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current use of a SGLT2 inhibitor alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
11108417|NCT04017221||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current use of a DPP-4 inhibitor alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
11108418|NCT04017221||Other treatment combinations|Current use of other antidiabetic drugs, current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
11108419|NCT04017208|Experimental|ASP2713|Participants will receive a single dose of ASP2713. Up to 8 dose levels will be administered in the study.
11108420|NCT04017208|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
11108421|NCT04017195|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch using the adhesive component at the beginning of shelf life (BOSL) (Treatment A) will be applied to the right buttock of participants on Day 1 of Treatment Period 1, followed by application of a single patch of transdermal contraceptive using newly sourced adhesive component HMW PIB at the end of shelf life (EOSL) (Treatment B) to left buttock of participants on Day 1 of Treatment Period 2. The Treatment periods will be separated by a washout period of 21 days.
11108422|NCT04017195|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1, followed by Treatment A to the left buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
11108423|NCT04017195|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment B to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
11108424|NCT04017195|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1, followed by Treatment A to the right buttock on Day 1 in Period 2. The Treatment periods will be separated by a washout period of 21 days.
11108425|NCT04017169||No reflow phenomenon|"Those that during procedure experience no reflow phenomenon
~To define no reflow requires:
~• Angiographic evidence of reopening of occluded coronary artery and successful stent placement with no evidence of flow-limiting residual stenosis (<50%), dissection, vessel spasm, or thrombus burden
~and
~Angiographic documentation of a TIMI flow grade ≤II, or
~A TIMI flow grade III with a myocardial perfusion grade 0 or I, at least 10 min after the end of PCI procedure."
11108426|NCT04017169||No NRP|Normal angiographic coronary flow/blush post patent culprit vessel.
11108427|NCT04017156|Experimental|Test site (torque of <10 Ncm)|The test sites (<10 Ncm) will be over-prepared with drills of larger diameter
11108428|NCT04017156|Other|Control site (torque of ~30 Ncm)|the standard sites (~30 Ncm)will be prepared with the corresponding drills suggested by the manufacturer
11108429|NCT04017143|Experimental|HPV App group|Participants will be assigned to receive an HPV app.
11108430|NCT04017143|No Intervention|Usual Care|This is a usual care group that receives a brochure that is usually distributed by a clinic.
11108431|NCT04017130|Experimental|Part 1: TAK-169 50 mcg/kg Once Weekly|TAK-169 50 microgram per kilogram (mcg/kg), infusion, intravenously, once weekly on Days 1, 8, 15, and 22 in a 28-day treatment cycle until progressive disease (PD), unacceptable toxicity or withdraw from the study for other reasons.
11108432|NCT04017130|Experimental|Part 1: TAK-169 100 mcg/kg Once Weekly|TAK-169 100 mcg/kg, infusion, intravenously, once weekly on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD, unacceptable toxicity or withdraw from the study for other reasons.
11108433|NCT04017130|Experimental|Part 1: TAK-169 200 mcg/kg Once Weekly|TAK-169 200 mcg/kg, infusion, intravenously, once weekly on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD, unacceptable toxicity or withdraw from the study for other reasons.
11108434|NCT04017130|Experimental|Part 1: TAK-169 335 mcg/kg Once Weekly|TAK-169 335 mcg/kg, infusion, intravenously, once weekly on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD, unacceptable toxicity or withdraw from the study for other reasons.
11108435|NCT04017130|Experimental|Part 1: TAK-169 500 mcg/kg Once Weekly|TAK-169 500 mcg/kg, infusion, intravenously, once weekly on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD, unacceptable toxicity or withdraw from the study for other reasons.
11108436|NCT04017130|Experimental|Part 1: TAK-169 665 mcg/kg Once Weekly|TAK-169 665 mcg/kg, infusion, intravenously, once weekly on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD, unacceptable toxicity or withdraw from the study for other reasons.
11108437|NCT04017130|Experimental|Part 1: TAK-169 TBD Once Every Two Weeks|TAK-169 TBD, infusion, intravenously, once every 2 weeks on Days 1 and 15 in a 28-day treatment cycle until PD, unacceptable toxicity or withdraw from the study for other reasons. Dose escalation of TAK-169 will be based on the investigator and sponsor review of available safety, PK, pharmacodynamic, efficacy data in the previous cohort.
11108438|NCT04017130|Experimental|Part 2, Daratumumab RR: TAK-169 TBD Once Weekly|TAK-169 TBD, infusion, intravenously, once weekly in participants who are relapsed or refractory (RR) to daratumumab until PD, unacceptable toxicity or withdraw from the study for other reasons. Dose for Part 2 will be determined based on the review of the available safety, efficacy, PK, and pharmacodynamic data from Part 1 of this study.
11108439|NCT04017130|Experimental|Part 2, Daratumumab RR: TAK-169 TBD Once Every Two Weeks|TAK-169 TBD, infusion, intravenously, once every 2 weeks in participants who are RR to daratumumab until PD, unacceptable toxicity or withdraw from the study for other reasons. Dose for Part 2 will be determined based on the review of the available safety, efficacy, PK, and pharmacodynamic data from Part 1 of this study.
11108440|NCT04017130|Experimental|Part 2, Anti-CD38 Therapy Naive MM: TAK-169 TBD Once Weekly|TAK-169 TBD, infusion, intravenously, once weekly in participants with MM who have never received anti-CD38 therapy until PD, unacceptable toxicity or withdraw from the study for other reasons. Dose for Part 2 will be determined based on the review of the available safety, efficacy, PK, and pharmacodynamic data from Part 1 of this study.
11108441|NCT04017117|Experimental|Custom Made Poly Ether Ether Ketone Mesh|Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
11108442|NCT04017117|Active Comparator|Conventional Titanium mesh|Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
11108443|NCT04017104||18F-FDG PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-FDG PET/CT procedure.
~18FFDG is considered standard care and has been approved by Health Canada."
11108444|NCT04017104||68Ga-DOTATOC PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 68Ga-DOTATOC PET/CT procedure.
~The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
11108445|NCT04017104||18F-DCFPyL PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-DCFPyL PET/CT procedure.
~The 18F-DCFPyL radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
11108446|NCT04017091|Experimental|VR Group|ABI Patients Twenty-one patients with ABI participated in this pilot study (Figure 1): 9 diagnosed with stroke (43%), 6 with TBI (29%), 2 with anoxic injury (10%), 3 with brain tumor (14%), and 1 with amyloid angiopathy (5%).
11108447|NCT04017091|No Intervention|Control Group (Standard Care)|The 12 Controls were age- and gender-matched (and etiology when possible) patients who had previously received traditional neurorehabilitation and completed the same measures as the VR group prior to onset of the study, but they did not receive VR treatment.
11108448|NCT04017078||Patients who referred for periodontal therapy|Patients who referred to Baskent University, Faculty of Dentistry, Department of Periodontology, during 2016-2018
11108449|NCT04017065||Patients treated with the MAXFRAMETM system|Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system
11108450|NCT04017052|Other|Booster vaccination|Intervention = one i. m. TBE booster vaccination (FSME-Immun) at visit 1.
11108451|NCT04017039|No Intervention|Phase 1|Phase I is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 6.5 hr/night (short sleep)
11108921|NCT04013828||Patients|Patients with recurrent high-grade glioma
11108452|NCT04017039|Experimental|Phase 2|Phase II is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep less than 6.5 hr/night (Specific Aims 3).
11108453|NCT04017026||6 mm implants|Patients were treated with 6mm short implants (Straumann, SLA, SLActive, 4.1 or 4.8 mm in diameter).
11108454|NCT04017013|Active Comparator|Epidural Analgesia|"The placement of the thoracic epidural catheter will be located depending on surgical incision as follows:
~Surgery of the upper abdomen: T7-T8.
~Surgery of lower abdomen: T8-T9. The epidural catheter placement technique will be determined by the treating anesthesiologist. However, once the epidural space is located and the respective catheter is inserted, the correct location of the catheter should be tested with lidocaine at 2% CE 5 cc and a sensitivity test with temperature should be performed on the target dermatomes. A negative test for an adequate location of the catheter indicates that the procedure should be repeated until the epidural space is correctly located. Once this is achieved, the catheter will be left 4 cm away from the skin. The catheter will be fixed according to the institutional protocol."
11108455|NCT04017013|Experimental|Lidocaine Infussion|Intravenous lidocaine
11108456|NCT04017000|Active Comparator|BlaST study|"Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.
~The participants Urodynamic clinic will run according to routine care."
11108457|NCT04017000|Other|Calibration Sub Study|"Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.
~Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.
~Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change."
11108458|NCT04016987|Experimental|Automated, Individualized Education|Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
11108459|NCT04016987|No Intervention|Routine care|Subjects only receive the education provided by health-care professionals in the outpatient department
11108460|NCT04016974|Experimental|Oral semaglutide|
11108461|NCT04016974|Placebo Comparator|Placebo|
11108462|NCT04016961|Experimental|Animal Assisted Therapy - Dog Session|Therapy dog added to PT and OT session
11108463|NCT04016961|Active Comparator|Treatment as usual - No Dog session|No dog added to PT and OT session - PT and OT session as usual standard of care
11108464|NCT04016948|Experimental|Probe-based confocal laser endomicroscopy(pCLE)|Confocal laser endomicroscopy optical biopsy will be performed in surgery for patients assigned to this group
11108465|NCT04016948|Active Comparator|Intra-operative frozen section(IFS)|Intra-operative frozen section will be performed for patients assigned to this group
11108466|NCT04016935||Patients with primary invasive ER+ HER2- breast cancer|Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy
11108467|NCT04016922||Group A|Patients with mild anemia (Hb concentration: 9.0-10.9 g\dl).
11108468|NCT04016922||Group B|Patients with moderate anemia (Hb concentration: 7.0-8.9 g\dl).
11108469|NCT04016922||Group C|Patients with severe anemia (Hb concentration: >7.0 g\dl).
11108470|NCT04016909|Experimental|aerobic exercise plus calorie restriction|"The experimental intervention: both exercise and calorie restriction, as described below:
~Exercise intervention. 6 months, 72 supervised aerobic exercise training sessions on cycle ergometers, including 3 sessions of training per week. A warm-up procedure consisting of 5 min of low-intensity stretching was completed by all women before the aerobic training. Subsequently, a 50 min aerobic training at an intensity between 60% and 70% of the maximum heart rate (HR) was performed. Thereafter, a cool-down consisting of 5 min of low-intensity stretching and breathing exercises was completed. HR was recorded continuously throughout the training sessions using an HR monitor (S625X, Polar Electro, Kempele, Finland).
~Calorie restriction intervention. The CR intervention was designed to create a 12.5% energy deficit, with the goal of reducing body weight by 5%-10% over 6 months."
11108471|NCT04016909|No Intervention|Control|No intervention and participants were instructed to maintain their regular physical activity and diet regime for 6 months; they were also prohibited from participating in any weight-loss or exercise program.
11108472|NCT04016896|Experimental|Widowed Elders' Lifestyle after Loss (WELL)|digital monitoring of sleep, meals, physical activity; motivational health coaching; personalized feedback
11108473|NCT04016896|Active Comparator|Enhanced Usual Care|enhanced usual care
11108474|NCT04016883|Sham Comparator|Conventional web platform|Participants asked to review the web platform for 4 weeks.
11108475|NCT04016883|Experimental|Problem Solving Therapy offered through a web platform|4 sessions with cognitive behavioral therapy, offered through a web platform. Each session will be offered per week.
11108476|NCT04016870|Active Comparator|New Device|New pacemakers will be sourced from pacemaker manufacturers.
11108477|NCT04016870|Experimental|Reconditioned Device|Donated devices are inspected according to specific protocols that evaluate physical and electrical (battery longevity) suitability for future use. Devices deemed to be acceptable are shipped to a third-party vendor (NEScientific) for disassembly, cleaning and re-sterilization.
11108478|NCT04016857|Experimental|RIPC Group|Remote ischemic preconditioning
11108479|NCT04016857|Sham Comparator|Control Group|Sham remote ischemic preconditioning
11108480|NCT04016844|Active Comparator|tDCS effects on glucose uptake in leg muscles|tDCS Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time tDCS will be applied to the motor cortex (M1) corresponding to the more-affected leg.
11108481|NCT04016844|Placebo Comparator|Sham effects on glucose uptake in leg muscles|Sham Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time SHAM will be applied to the motor cortex (M1) corresponding to the more-affected leg.
11108482|NCT04016831|Other|Mapping Enhanced Counseling (MEC) only|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
11108483|NCT04016831|Experimental|Mapping Approaches to Prepare for Implementation Transfer|an implementation intervention to explore and address agency preparation needs in order to promote implementation success (includes MEC training)
11108484|NCT04016818|Experimental|18-F FDG Study using Breast-Dedicated PET Camera|Breast-Dedicated PET Camera will be used with standard PET 18-F FDG tracer dose
11108485|NCT04016805|Experimental|ublituximab + umbralisib + ibrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
~umbralisib: 800 mg; to be administered daily
~ibrutinib: dose tolerated by subject; to be administered daily"
11108486|NCT04016805|Experimental|ublituximab + umbralisib + venetoclax|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
~umbralisib: 800 mg; to be administered daily
~venetoclax: dose tolerated by subject; to be administered daily"
11108487|NCT04016805|Experimental|ublituximab + umbralisib + acalabrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
~umbralisib: 800 mg; to be administered daily
~acalabrutinib: previously tolerated dose; to be administered every 12 hours"
11108488|NCT04016792|Placebo Comparator|Placebo|Placebo qd
11108489|NCT04016792|Experimental|SPN-812|200 mg SPN-812
11108490|NCT04016779|Placebo Comparator|Placebo|Placebo qd
11108491|NCT04016779|Experimental|SPN-812|SPN-812 qd
11108492|NCT04016766|Experimental|Prepartying mobile app intervention|Mobile app intervention
11108493|NCT04016766|No Intervention|Control|Control participants receive a personalized attention control task (i.e., listing and ranking favorite movies, music, and books), which controls for the time needed by the intervention group to view the intervention material.
11108494|NCT04016753|Experimental|Monotherapy|
11108495|NCT04016740|Experimental|Multimodal General Anesthesia|"Intraoperative
~The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.
~Routine anesthetic induction
~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision
~Ketamine (0.06 to 0.12 mg.kg/hr)
~Remifentanil (0.05-0.2 mcg/kg/min)
~Dexmedetomidine (0.2-1.0 mcg/kg/hr)
~Rocuronium intermittent bolus (TOF)
~Propofol infusion ± Sevoflurane titrated based on EEG monitoring
~Postoperative
~Standard pain management protocol
~Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)
~Infusion continued till extubation
~Propofol infusion may be added/used for sedation based on the treating physician's discretion"
11108496|NCT04016740|Other|Standard Practice with EEG monitoring|The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
11108497|NCT04016727|Experimental|PRP group|patients in which 60 units of prp was injected
11108498|NCT04016727|No Intervention|Control group|patients not given any intervention
11108499|NCT04016714|Experimental|V114|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2 and 4 (approximately 3, 5, and 12 months of age).
11108500|NCT04016714|Active Comparator|Prevnar 13®|Infant participants will receive a single 0.5 mL IM injection of Prevnar 13® at Visit 1, 2 and 4 (approximately 3, 5, and 12 months of age).
11108501|NCT04016701|Experimental|VR Intervention|Eight weeks of training with Floreo's VR Joint Attention Module with two sessions per week
11108502|NCT04016701|Active Comparator|Treatment as Usual|Regularly scheduled therapy
11108503|NCT04016688|Active Comparator|ES Erector Spinae Plane Block|"bilateral ESP block at the level of T9 by a linear ultrasound (US) transducer (Phillips Saronno Italy) placed vertically 3cm lateral to the midline to visualize the back muscles superior to the transverse process.
~A 22-G short bevel needle (spinocan, B.Braun, melsungen AG, Germany) will be inserted in cranial-caudal direction until it make contact with the transverse process. Confirmation of the correct position of the tip of the needle is by injection of 1 ml saline causing hydrodisscetion between the erector spinae muscle and the transverse process. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected.The same procedure is done on the other side of the back."
11108504|NCT04016688|Active Comparator|TAP Transversus Abdominis Plane Block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.
~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.25 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
11108505|NCT04016675|Experimental|Study Group|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
11108506|NCT04016675|Active Comparator|Control Group|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
11108507|NCT04016662|Active Comparator|Hybrid Closed Loop Control (HCL)|The HCL intervention arm will utilize the Tandom t:slim X2 with Control-IQ Technology and Dexcom G6 CGM
11108508|NCT04016662|Active Comparator|Predictive Low-Glucose Insulin Suspension (PLGS)|The PLGS intervention arm will utilize the Tandom t:slim X2 with Basal-IQ Technology and Dexcom G6 CGM
11108509|NCT04016662|No Intervention|Sensor-Augmented Pump (SAP)|The SAP arm will utilize the Tandem t:slim X2 without HCL or PLGS features turned on and Dexcom G6 CGM
11108594|NCT04015986|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
11108595|NCT04015973|No Intervention|Group A: Control|Standard Care
11108510|NCT04016636||Single Group Study. Patients with CLL receiving ibrutinib.|"In this study the investigator does not assign specific interventions to the study participants. Participants will receive interventions as part of routine medical care, and the investigator will observe the effect of the intervention.
~This study will collect prospective real-world data to describe the quality of life (QOL) in patients with CLL receiving ibrutinib in routine Argentinian clinical practice over a 12-month follow-up period.
~The primary data source for this observational study will be the medical records of each enrolled patient, as well as questionnaires concerning quality of life. Data will be collected at baseline and on months 1,3,6 and 12 during a prospective period."
11108511|NCT04016623|Experimental|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
11108512|NCT04016623|Active Comparator|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
11108513|NCT04016610|Experimental|ASR Treatment|Single and/or multi-treatment ASR device applied to the keloid scar for a period of 2 minutes for each 3 cm.
11108514|NCT04016597||Lung diffusing capacity measurements|Participants perform single-breath lung diffusing capacity measurements in random order during one study visit.
11108515|NCT04016584|Experimental|Latino adults with type 2 diabetes|"Participants of the Diabetes Pueblo Education Program will include adults with T2D from the Santa Barbara Latino community whose diabetes is poorly controlled, defined as -
~hemoglobin A1c > 8% at or prior to enrollment, or
~hemoglobin A1c < 8% (within the last 3 months), AND with at least one of the following (also within the last 3 months):
~Fasting plasma glucose > 130 mg/dL
~2-hour post-prandial or random blood glucose > 180 mg/dL
~> 1 hypoglycemic event (blood glucose < 70 mg/dL) , or
~adults with T2D from the community who are new to insulin or being considered for insulin therapy by their healthcare provider."
11108516|NCT04016571||Adults with Cystic Fibrosis|"All Adults with a confirmed diagnosis of Cystic Fibrosis being admitted for Intra-Venous Antibiotic Treatment of a Pulmonary Exacerbation
~This study is observational so no intervention will be carried out."
11108517|NCT04016558|Experimental|StreamLine|Diabetes education, behavioral management
11108518|NCT04016558|Experimental|TunedIn|Diabetes distress reduction, emotion regulation techniques.
11108519|NCT04016558|Experimental|FixIt|Unified program combining diabetes education, behavioral management, diabetes distress reduction, and emotion regulation techniques.
11108520|NCT04016545||Treated patients|
11108521|NCT04016532|Other|Patient malnourished or at risk of undernutrition|Dietary follow-up at home: 4 visits (D15, D30, D60, D90)
11108522|NCT04016532|Other|Not undernourished patients|Dietary follow-up at home: 3 visits ( D30,D60, D90)
11108523|NCT04016519||Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.
~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
11108524|NCT04016506||Pancreas injury|children with Pancreas trauma
11108525|NCT04016493||Control group (CAF+CTG; N=20)|
11108526|NCT04016493||Test group (TUN+CTG; N=20)|
11108527|NCT04016480|Active Comparator|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
11108528|NCT04016480|Active Comparator|Conventional Oxygen Therapy|Conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
11108529|NCT04016467|Experimental|Thoracic Manipulation (ThM)|Will undergo spinal manipulation between pain assessment pre and post.
11108530|NCT04016467|Sham Comparator|Sham thoracic treatment (ThS)|Sham manipulation between pain assessment pre and post
11108531|NCT04016454|Experimental|Intervention group|No handover of anesthesia care
11108532|NCT04016454|No Intervention|Control group|Complete handover of anesthesia care
11108533|NCT04016441||Subjects|Subjects who are capable of completing an online, English survey.
11108534|NCT04016428|Experimental|OPTIMISM Intervention|Participants will receive online delivery of a mindfulness-based program for improving sleep in pregnancy, along with the usual care they would receive from their provider.
11108535|NCT04016428|Active Comparator|Sleep Education|Participants will receive online delivery of an education program on sleep in pregnancy, along with the usual care they would receive from their provider.
11108536|NCT04016415|Experimental|Mindfulness Based Stress Reduction|
11108537|NCT04016415|Active Comparator|Stress Management Education|
11108538|NCT04016402||Study Group|All participants enrolled in the study
11108539|NCT04016389|Experimental|Neo-Adjuvant Chemotherapy, Surgery, and Adjuvant Chemotherapy|"Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles.
~After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done.
~Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done."
11108540|NCT04016376|Experimental|PVB|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
11108541|NCT04016376|Experimental|PVB + PECS-1|"Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
~For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor."
11108596|NCT04015973|Experimental|Group B: High energy diet|High energy diet for 8-12 weeks pre-surgery
11108542|NCT04016376|Experimental|Serratus + PECS-1|"For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor.
~For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior."
11108543|NCT04016363|Experimental|ProbeFix arm|The echocardiography probe is fixated on the patient's thorax using the ProbeFix
11108544|NCT04016363|Active Comparator|Controll arm|The sonographer manually holds the probe on the patient's thorax
11108545|NCT04016350|Experimental|Exercise Training with Inulin Propionate Ester|Study participants underwent 4 week supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation at doses of 10g / day.
11108546|NCT04016350|Experimental|Exercise Training with Placebo|Study participants underwent 4 week supervised moderate intensity exercise training combined with cellulose as placebo at doses of 10g / day.
11108547|NCT04016337|Experimental|Intervention with beverage added with sucralose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with sucralose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.
~Concentrations of lemon and maqui extract are under industrial secret. The sweetener sucralose was added within the ranges established by law as maximums.
~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.
~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
11108548|NCT04016337|Experimental|Intervention with beverage added with saccharose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with saccharose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.
~Concentrations of lemon and maqui extract are under industrial secret. The sweetener saccharose was added within the ranges established by law as maximums.
~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.
~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
11108549|NCT04016337|Experimental|Intervention with beverage added with stevia|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with stevia extract was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.
~Concentrations of lemon and maqui extract are under industrial secret. The sweetener stevia was added within the ranges established by law as maximums.
~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.
~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
11108550|NCT04016324|Other|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
11108551|NCT04016311|Experimental|Mindful Drinking/Eating Group|
11108552|NCT04016311|No Intervention|Wait list control|
11108553|NCT04016285|Experimental|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
11108554|NCT04016285|Active Comparator|Standard of Care: Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
11108555|NCT04016272|Experimental|Active tDCS|
11108556|NCT04016272|Placebo Comparator|Sham tDCS|
11108557|NCT04016259|Experimental|Self-CES|
11108558|NCT04016259|Placebo Comparator|Sham-CES|
11108559|NCT04016246|Experimental|Propofol|"Propofol (Propofol LIPURO 1% 100mL), Pharmacologic form: 10mg/ml. Considering the birthweight of most preterm babies, Propofol will be diluted to a final concentration of 1mg/ml by the nurse.
~Treatment initiation: the 1st dose will be injected following usual management of LISA procedure included the installation of the newborn and the atropine and caffeine injections and sugar solution administration Dose per administration: 0.5mg/kg per dose of Propofol. Number of administrations: Several administrations of 0.5 mg/kg are possible, according the level of sedation achieved, as evaluated by the FANS score. If the FANS score is ≥6, a new dose will be injected up to a total of two (before 28 wGA) or 3 (between 28 - 31 wGA) administrations of the drug. (See paragraph 5.3)"
11108560|NCT04016246|Placebo Comparator|medialipide|"Name of treatment for placebo: Medialipide® (B. BRAUN) Pharmacological form: 20g/100ml Medialipide 20% will be used as the placebo. This is an emulsion of medium and long triglycerides based on soya oil and having same appearance organoleptic characteristics as Propofol.
~Dose per administration: Same volume as for the Propofol administration
~Number of administrations: according the same protocol that for the Propofol administration.
~Modalities of preparation : The same dilution procedure as Propofol lipuro 1% SPC (Summary of Product Characteristics):1 part of Medialipide 20% with 9 parts of 5% w/v glucose solution or 0.9% w/v sodium chloride solution as shown in parenteral nutrition which is in accordance with medialipide 20% SPC"
11108561|NCT04016233|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, each with 3 douches. Sequence A will be 3 sequential doses of TFV douche; Sequence B will be one dose of TFV douche followed by 2 sequential non-medicated douches; Sequence C will be 2 sequential non-medicated douches followed by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by various specimen collections over 8 days according to individual sampling schedule assigned to each participant. Specimens will be collected on Days 1, 2, 4, and 8 post sequence administration.
11108562|NCT04016220|Experimental|Budesonide group|The experimental group received a first nebulization of 5 mg of terbutaline(solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
11108563|NCT04016220|Placebo Comparator|normal saline|The control group received a nebulization of 2 ml normal saline at baseline, 20, 40, 60 and 120 min as placebo comparator in association with nebulized terbutaline . All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
11108564|NCT04016207||Guanfacin regular treatment|
11108565|NCT04016168||Patients with DILD|Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
11108566|NCT04016155|Active Comparator|SMBG|Patients use their own glucometers as control
11108567|NCT04016155|Experimental|Flash CGMS|
11108568|NCT04016142|Experimental|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients
~will be registered in the first part of the study at diagnosis and will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).
~will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage (no progression during Part 1 of the study and no medical contra-indication to the study treatment)."
11108569|NCT04016129|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
11108570|NCT04016116|Experimental|Pembrolizumab (Cohort 1)|Pembrolizumab IV every 3 weeks (Cohort 1: Advanced progressive MPNs)
11108571|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 1: Advanced progressive MPNs)
11108572|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib (Cohort 2)|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 2, unresponsive to PD-1)
11108573|NCT04016103|Experimental|MY01 Device|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
11108574|NCT04016090|Placebo Comparator|Placebo treatment|Participant will be asked to ingest a placebo capsule.
11108575|NCT04016090|Experimental|Folic Acid|Participant will be asked to ingest a capsule containing 5 mg of folic acid.
11108576|NCT04016077|Experimental|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
11108577|NCT04016077|Experimental|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
11108578|NCT04016077|Experimental|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.
~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
11108579|NCT04016064|Other|group 1;|Er:YAG laser
11108580|NCT04016064|Other|group 2|Nd:YAG laser
11108581|NCT04016064|Other|group 3|Electrosurgery
11108582|NCT04016051|Experimental|Clarithromycin DST|"Participants received oral administration of Clarithromycin DST twice a day:
~125.0 mg straw, participants with body weight between 12 and 19 kg (approximate age 2-4 years).
~187.5 mg straw, participants with body weight between 20 and 29 kg (approximate age 4-8 years).
~250.0 mg straw, participants with body weight between 30 and 40 kg (approximate age 8-12 years).
~For oral intake of DST granules, the lower end of the straw was to be dipped into a glass with a clear, cool or lukewarm, preferably flavored beverage of participant choice. Suitable beverages were lemonade (carbonated or not), clear fruit juices without pulp, tea or water. The beverage was to be sipped smoothly through the straw."
11108583|NCT04016051|Active Comparator|Clarithromycin Syrup|"Participants received oral administration of Clarithromycin Syrup twice a day:
~2.5 ml (125 mg) participants with body weight between 12 and 19 kg (approximate age 2-4 years).
~3.75 ml (187.5 mg) participants with body weight between 20 and 29 kg (approximate age 4-8 years).
~5 ml (250 mg) participants with body weight between 30 and 40 kg (approximate age 8-12 years)."
11108584|NCT04016038||QualiPas Observational|Prospective qualitative study through a participant observation procedure with 8 care teams practicing within Palliative Care Units, Palliative Care Mobile Team or Territorial Palliative Care Team.
11108585|NCT04016038||QualiPas clinical interview|Qualitative study retrospective research interviews with the doctor and another carer involved in the care of the patient, and close relatives of patients who had sedated before their death. The interviews will be based on 50 cases of patients who have been sedated.
11108586|NCT04016038||QualiPas Focus|Qualitative study by group focus group interviews with clinical teams participating in the project.
11108587|NCT04016025|Active Comparator|cream|Treatment with topical Methylprednisolone aceponate 0,1% cream (Advantan®) plus Basic care (Bepanthen® Sensiderm)
11108588|NCT04016025|Active Comparator|fatty ointment|Treatment with topical Methylprednisolone aceponate 0,1% fatty ointment (Advantan®) plus Basic care (Bepanthen® Sensiderm)
11108589|NCT04016012|Experimental|Intervention arm|Participants in the intervention group will receive local zambian foods and standard health care for eight (8) weeks.
11108590|NCT04016012|No Intervention|Control arm|The control group will have their usual (standard) diet in their home and receive standard health care for eight (8) weeks.
11108591|NCT04015999|Experimental|Intervention arm|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
11108592|NCT04015999|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
11108593|NCT04015986|Experimental|Intervention arm|MDCF-2 prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth).
11108685|NCT04015310||PSC patients attending outpatient|Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
11108597|NCT04015947|Experimental|Active treatment|This is an open label, single-institution pilot study to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.
11108598|NCT04015921||Inpatients|Patients admitted with various psychiatric disorders
11108599|NCT04015921||Age-matched control group|
11108600|NCT04015908|Experimental|multi-modal|"3 Different Non-opioid pain medication taken every 6 hours
~Celecoxib 100mg
~Acetaminophen 325mg
~Pregabalin 50 mg
~Plus, for breakthrough pain
~oxycodone 5-10 mg will be taken every 4 hours as needed for pain."
11108601|NCT04015908|Active Comparator|Control|7 day supply of Percocet (oxycodone 5mg/acetaminophen 325 mg) to be taken 1-2 by mouth every 4 hours as needed for pain.
11108602|NCT04015895||Patient with cancer|Patient with cancer will be included. They will have to answer at DEFCO tool.
11108603|NCT04015882|Active Comparator|exercise|the exercise group will applied virtual reality exercises by Nintendo Wii Fit Plus System Game Console.
11108604|NCT04015882|No Intervention|control|No exercise applied the control group.
11108605|NCT04015869|Active Comparator|allopregnanolone|allopregnanolone
11108606|NCT04015869|Placebo Comparator|placebo|placebo
11108607|NCT04015856|Experimental|Full TP intervention including emphasized social norms change|Participants in this study arm will receive the full TP intervention, including emphasized social norms change, for 18 months.
11108608|NCT04015856|Active Comparator|Light TP intervention without emphasized social norms change|Participants in this study arm will receive the light TP intervention, without emphasized social norms change, for 18 months
11108609|NCT04015856|No Intervention|Control|The control group will not have any study interventions.
11108610|NCT04015830|Experimental|Older Adults with HIV (N = 60)|African Americans and Whites age 50 and older
11108611|NCT04015817|Experimental|Etude longitudinale|Work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, support from the mobile palliative care team
11108612|NCT04015804|Experimental|Clinical database|
11108613|NCT04015791||Match Group|Surgery conducted at the disc level corresponding with the highest level of NOCISCORE value in the subject and that is classified as either NOCI + or NOCI mild
11108614|NCT04015791||Miss Group|Surgery conducted at a disc that: (a) corresponds with a low relative NOCISCORE value in the subject and that is classifies as NOCI - or (b) excludes the disc level with the highest NOCISCORE value in the subject and that is classifies as NOCI+ or NOCI mild
11108615|NCT04015778|Experimental|Nivolumab Mono|In arm A, 24 participants will be enrolled into this arm according to PD-L1 expressing level (≥50%).Arm A consists of 3 cycles of neoadjuvant nivolumab (240mg every 2 weeks), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
11108616|NCT04015778|Experimental|Nivolumab Plus Chemo|In arm B, up to 12 participants will be enrolled into each subgroup according to PD-L1 expressing level (<1% and 1%-49%).arm B consists of 3 cycles of neoadjuvant nivolumab (360mg every 3 weeks) with nab-paclitaxel and carboplatin(nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every three weeks ), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
11108617|NCT04015765|Experimental|Group treatment h-APC and EMR|Standard endoscopic mucosal resection (EMR) technique will be used for primary removal of all polyps. Submucosal injection will be used to lift the polyp from the muscularis propria. Injection is used as per the current standard of care using a contrast agent and a lifting agent (e.g. NaCl 0.9% or Voluven). Snare electrocautery resection will be facilitated until complete visible removal of the complete polyp. Electrocautery snare technique is facilitated using standard microprocessor controlled electrocautery (e.g. ERBE VIO Endocut 3-1-6). Ablation of the margin after visibly complete removal of the polyp is routinely applied. For thermal ablation hybrid APC (Erbe Hybrid APC) will be applied using standard settings on the margin and resection base. Once resection and thermal ablation is considered complete the mucosal defect can be closed with clips or another preventative measure applied to reduce the risk for post-polypectomy bleeding.
11108618|NCT04015752||diabetics|"Full history with special attention to:
~Causes of admission to ICU . Duration of DM when present, medication used, controlled or not.
~Complete physical examination with special attention to :
~Vital signs ( MAP, pulse, temp, RR). Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).
~Laboratory investigations includes :
~CBC , Liver and kidney functions → baseline and follow up. Arterial Blood Gases (ABG). Lactic acid level. HBA1C. ESR, CRP →baseline and follow up.
~Culture :
~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
11108619|NCT04015752||non diabetics|"Full history with special attention to:
~Causes of admission to ICU . Duration of DM when present medication used, controlled or not.
~Complete physical examination with special attention to :
~Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).
~Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.
~Culture :
~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
11108620|NCT04015752||patients devoloped hyperglycemia in ICU only|"Full history with special attention to:
~Causes of admission to ICU . Duration of DM when present medication used, controlled or not. 2. Complete physical examination with special attention to : Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, CVP,..). 3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.
~Culture :
~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
11108621|NCT04015739|Experimental|Bevacizumab, Olaparib and Durvalumab|Single arm study
11108622|NCT04015713||TB HIV-negative|"Patients will receive standard TB treatment and will be followed according to the national procedures.
~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.
~All participants will be followed 24 weeks."
11108686|NCT04015297|Experimental|control|healthy controls
11108687|NCT04015297|Experimental|patient|patients diagnosed with endometriosis
11108623|NCT04015713||TB HIV-positive|"Patients will receive standard TB treatment and will be followed according to the national procedures.
~In addition, plasma samples will be collected at baseline, Week 1, Week 2, Week 4 and Week 8 to measure IL-1Ra, sCD163 and IP-10. Baseline will be the initiation of TB treatment.
~All participants will be followed 24 weeks."
11108624|NCT04015700|Experimental|Vaccine (GNOS-PV01 + INO-9012)|"Standard radiation therapy will be administered per standard of care and is outside the scope of this study.
~GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2 for a total of 6 cycles or until intolerance or progression"
11108625|NCT04015687|Experimental|AG-881 (Group 1)|On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.
11108626|NCT04015687|Experimental|AG-881 (Group 2)|Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
11108627|NCT04015687|Experimental|AG-881 (Group 3)|Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
11108628|NCT04015674|Experimental|Exercise group|Patients will remain in supine position for 5 minutes to measure their vascular caliber of the AVF by echography. After, will be instructed to perform 30 minutes on stationary bicycle (Model Monark). The AVF vascular caliber will be measured during aerobic exercise. Because it is a cross-over trial, participants will perform the other arm after 7 days.
11108629|NCT04015674|Active Comparator|Control group|The patients will perform 30 minutes of rest in a chair and the measurements will be performed in the same moments established by the exercise group. Because it is a cross-over trial, participants will perform the other arm after 7 days.
11108630|NCT04015661|Experimental|Nab-paclitaxel+Nedaplatin|induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
11108631|NCT04015661|Active Comparator|Paclitaxel+Nedaplatin|induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
11108632|NCT04015648|Experimental|Group 1|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^9 vp vaccination intramuscularly.
11108633|NCT04015648|Experimental|Group 2|Volunteers will receive standalone dose of ChAdOx1 Zika 2.5 x 10^10 vp vaccination intramuscularly.
11108634|NCT04015648|Experimental|Group 3|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^10 vp vaccination intramuscularly.
11108635|NCT04015648|Experimental|Group 4|Volunteers will receive co-administration dose of ChAdOx1 Zika 5 x 10^9 vp vaccination and ChAdOx1 Chik 5 x 10^9 vp intramuscularly.
11108636|NCT04015648|Experimental|Group 5|Volunteers will receive co-administration dose of ChAdOx1 Zika 1.25 x 10^10 vp vaccination and ChAdOx1 Chik 1.25 x 10^10 vp intramuscularly.
11108637|NCT04015648|Experimental|Group 6|Volunteers will receive co-administration dose of ChAdOx1 Zika 2.5 x 10^10 vp vaccination and ChAdOx1 Chik 2.5 x 10^10 vp intramuscularly.
11108638|NCT04015648|Experimental|Group 7|Volunteers will receive co-administration dose of ChAdOx1 Zika 5 x 10^10 vp vaccination and ChAdOx1 Chik 5 x 10^10 vp intramuscularly.
11108639|NCT04015635||Study group|"120 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.
~Clinical and laboratory assessment. NO intervention."
11108640|NCT04015635||Control|"120 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring.
~Clinical and laboratory assessment. NO intervention."
11108641|NCT04015622|Experimental|A: Biomarker directed Therapy (BT)|ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
11108642|NCT04015622|Active Comparator|B: Clinician's Choice (CC)|Enzalutamide or docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
11108643|NCT04015609|Experimental|Meaning Centered Psychotherapy for Latinos (MCP-L)|
11108644|NCT04015609|Active Comparator|Control|
11108645|NCT04015596|Experimental|Intervention|Participants receive Naproxen Sodium.
11108646|NCT04015596|Placebo Comparator|Placebo|Participants receive placebo.
11108647|NCT04015583|Experimental|exergaming group|"The exergaming group (EXG) performed exercise using Exerheart® devices (D&J Humancare, Busan, South Korea) composed of a running/jumping mat [730(W) × 730(D) × 130(H)] and a tablet PC on a stand (can be adjusted to any height between 70 and 155 cm) (Supplemental Figure 1A). Exerheart® is an exergaming developed for in-situ running along with the video game called Alchemist's Treasure (D&J Humancare, Busan, South Korea). To play this game, the subject has to run or jump on a spot on the mat to move a virtual avatar on the screen of the tablet PC to the front, back, left, and right along with music. The subject can control the speed of avatar movement by running or jumping speed on the mat."
11108648|NCT04015583|Active Comparator|treadmill exercise group|The treadmill exercise group (TEG) performed exercise using commercial treadmills (MOTUS, Gyeonggi-do, South Korea). Each subject walked or ran on the treadmill at a comfortable speed.
11108649|NCT04015570|Experimental|High Volume Plasma Exchange with SMT|"PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity.
~Standard Medical Treatment (Albumin + High Caloric Diet)"
11108650|NCT04015570|Active Comparator|Standard Medical Treatment|Standard Medical Treatment (Albumin + High Caloric Diet)
11108755|NCT04014777|Experimental|NGM621 Cohort 4 Multiple Dose|NGM621 multiple IVT injection Cohort--Dose 4
11108651|NCT04015557|Experimental|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
11108652|NCT04015557|Experimental|Acetaminophen + N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose.
11108653|NCT04015544|Experimental|Watermelon|Watermelon puree 710 mL per day for six weeks
11108654|NCT04015544|No Intervention|Control|No intervention
11108655|NCT04015531|Active Comparator|Conventional radiotherapy|"50 Gy in 25 fractions to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla), followed by tumor bed boost of 10 Gy in 5 fractions in case of breast conserving surgery.
~Total time: 5-6 weeks."
11108656|NCT04015531|Experimental|Hypofractionated radiotherapy|"40 Gy in 15 fractions (2.67 Gy each) to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla).
~Patients undergoing breast conserving surgery will receive concomitant boost with total dose of 48 Gy in 15 fractions (3.20 Gy each) to tumor bed.
~Total time: 3 weeks."
11108657|NCT04015518|Experimental|Dose group 1|
11108658|NCT04015518|Experimental|Dose group 2|
11108659|NCT04015518|Experimental|Dose group 3|
11108660|NCT04015518|Experimental|Dose group 4|
11108661|NCT04015518|Placebo Comparator|Placebo only|
11108662|NCT04015505|Experimental|Intervention|Participants will receive 5 sessions of a psychological (talking therapy) intervention based on the wisdom enhancement 'timeline technique' within cognitive behavioural therapy for older adults.
11108663|NCT04015492|Experimental|BAY94-9027 / Adynovi|Treatment sequence A-B with washout before each treatment
11108664|NCT04015492|Experimental|Adynovi / BAY94-9027|Treatment sequence B-A with washout before each treatment
11108665|NCT04015479|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
11108666|NCT04015479|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
11108667|NCT04015466||Cases|Patients with high diagnostic suspicion of advanced GC diagnosis
11108668|NCT04015466||Control|Patients with confirmed absent of GC
11108669|NCT04015440|Experimental|HBMT|
11108670|NCT04015440|Placebo Comparator|Placebo|
11108671|NCT04015427|Active Comparator|screw-retained|Patients in group A will receive a screw-retained implant crown. Following this first period of 16 weeks, the screw-retained implant crown will be replaced by a new intraorally cemented implant crown. Cement removal will be preformed according to best clinical procedure. These implant crowns will again be left for another period of 16 weeks and followed up for the harvesting of microbiological samples every 8 weeks. After the second 16-week the implant crowns will be removed to evaluate any excess cement. All patients will be fitted with the original screw-retained implant crown. Clinical parameters for inflammation and probing depths will be obtained after each 16 week-period.
11108672|NCT04015427|Active Comparator|cement-retained|In group B the implant crowns will be incorporated in a reverse pattern. During the first 16 weeks a cemented implant crown will be inserted and any possible cement residues will be removed according to best clinical procedure, while for the second period of 16 weeks patients will be fitted with a screw-retained single implant crown. Again, microbiological and clinical parameters will be obtained at the same intervals as in Group A.
11108673|NCT04015414|Active Comparator|Varenicline (Champix)|Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
11108674|NCT04015414|Active Comparator|Cytisine (Tabex)|Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
11108675|NCT04015388||Diabetes Mellitus / Hyperglycemia|iPro Continuous Glucose Monitoring on subjects with blood sugar value >140 mg/dL upon admission to the intensive care unit or who have been diagnosed with type 1 or type 2 diabetes or have glycosylated hemoglobin A1C (HbA1C) values > 6.5% prior to admission.
11108676|NCT04015375|Experimental|Dapsone gel, 7.5% (Torrent Pharmaceuticals Ltd.)|Topical, once daily for 84 days
11108677|NCT04015375|Active Comparator|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical, once daily for 84 days
11108678|NCT04015375|Placebo Comparator|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical, once daily for 84 days
11108679|NCT04015362|Experimental|Pulsed magnetic stimulation of the spinal cord|Sub-threshold intermittent pulsed magnetic stimulation of spinal cord
11108680|NCT04015362|Sham Comparator|Sham magnetic stimulation|Sham - patient and machinery placed in same position as intervention arm but no magnetic stimulation delivered
11108681|NCT04015336|Experimental|Arm 1|Up to 3x1010 E7 TCR T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
11108682|NCT04015323|Experimental|IFC Therapy 2 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 2 kHz
11108683|NCT04015323|Experimental|IFC Therapy 4 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 4 kHz
11108684|NCT04015323|Experimental|IFC Therapy 8 kHz Arm|Subjects in this group will receive interferential current to their knees with a carrier frequency of 8 kHz
11108922|NCT04013828||Relatives|Close relatives of patients with recurrent high-grade glioma
11108688|NCT04015284|Experimental|SSNB + PCB|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL ropivacaine 0.5%, then single shot US-guided posterior cord block (PCB) with 10 ml ropivacaine 0.5%.
11108689|NCT04015284|Active Comparator|ISBPB|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL ropivacaine 0.5%.
11108690|NCT04015271|Experimental|Action Observation + Repetitive Task Practice|Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
11108691|NCT04015271|Placebo Comparator|Placebo Video + Repetitive Task Practice|The control placebo videos (PV) will be 6 minutes, and will include a series of changing static images without animals, human beings, or sound (i.e. pictures of buildings, trees, cruise ships, mountains, beach umbrellas, beds, and tables). A Repetitive Task Practice (RTP) therapy regimen will be completed immediately after observing the PV, which emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task. These tasks include putting on a shirt, picking up a sandwich and bringing it to mouth, eating food with a spoon, or cutting meat with knife and fork. The PV + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
11108692|NCT04015258|Experimental|Blueberries|Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day
11108693|NCT04015258|Experimental|Blueberry powder|Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries
11108694|NCT04015258|Placebo Comparator|Blueberry components capsules|Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption
11108695|NCT04015245|Experimental|SNMC|
11108696|NCT04015245|No Intervention|non-SNMC|
11108697|NCT04015232|Experimental|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
11108698|NCT04015232|Active Comparator|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
11108699|NCT04015219|Experimental|Treatment Arm|PROKERA SLIM + Standard of Care
11108700|NCT04015219|Active Comparator|Control Arm|Standard of Care
11108701|NCT04015206|Experimental|IPT-G+UCT|12 sessions of Group Interpersonal therapy added to pharmacotherapy + clinical management plus one individual session pre-group and one session pos-group
11108702|NCT04015206|Active Comparator|Usual treatment (UCT)|Pharmacotherapy + Clinical management once a month
11108703|NCT04015193||Full responders|Full responders: no signs or symptoms of Raynaud's phenomenon (RP) in Raynaud condition score, no RP during cooling-recovery experiment.
11108704|NCT04015193||Partial responders|Partial responders: at least 25% reduction in Raynaud condition score and finger ischemia time during cooling and recovery.
11108705|NCT04015193||Non-responders|Non-responders: no or less than 25% reduction in Raynaud condition score and/or finger ischemia time during cooling and recovery.
11108706|NCT04015180|Experimental|Aflibercept arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
11108707|NCT04015180|Active Comparator|Laser photocoagulation arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
11108708|NCT04015167||T2 Alpha Tibia|Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.
11108709|NCT04015154||T2 Alpha Femoral Nail PF|Subjects in the clinical investigation will undergo placement of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the piriformis fossa, according to the Instructions for Use and Operative Technique Manual
11108710|NCT04015141|Experimental|Perampanel|Participants age 1 month to less than 18 years with pediatric epileptic syndrome (Cohort 1) or age 1 month to less than 2 years with POS with or without secondary generalization (Cohort 2) will receive perampanel oral suspension or perampanel tablets, once daily up to 56 weeks.
11108711|NCT04015128||T2 Alpha Femoral Nail GT|Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.
11108712|NCT04015115|Experimental|Youth Opioid Recovery Support service model|The components of the Youth Opioid Recovery Support service model includes 1) home-delivery of standard-of-care medication and individual/family counseling services; 2) assertive outreach efforts by the treatment team; and 3) contingency management incentives upon receipt of medication treatment.
11108713|NCT04015089|Experimental|Partially hydrolyzed formula (pHF)|Infants fed exclusively with a infant formula based on partially hydrolyzed serum cow's milk proteins.
11108714|NCT04015089|Active Comparator|Standard formula (SF)|Infants fed exclusively with a standard formula based on intact cow's milk proteins
11108715|NCT04015076|Experimental|Single Ascending Dose|Inzomelid or Placebo
11108716|NCT04015076|Experimental|Multiple Ascending Dose|Inzomelid or Placebo
11108717|NCT04015076|Experimental|Patients with CAPS|Inzomelid Open Label
11108718|NCT04015063|Other|Primary Subjects|Women subjects 40-65 years of age that meet the specified inclusion/exclusion criteria taking P29429-01 as a skin care product per the protocol.
11108719|NCT04015050|Experimental|Test product|Cow's milk based infant formula containing prebiotics and postbiotics
11108720|NCT04015050|Active Comparator|Control product|Cow's milk based infant formula without prebiotics and postbiotics
11108721|NCT04015037|Experimental|Group A|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
11108722|NCT04015037|Experimental|Group B|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
11108723|NCT04015024|Experimental|SKLB1028 150mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs.
11108724|NCT04015024|Experimental|SKLB1028 200mg bid|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
11108725|NCT04015024|Experimental|SKLB1028 300mg qd|Repeated oral administration until there is no longer clinical benefit from therapy,or until unacceptable toxicity occurs
11108726|NCT04015011|Experimental|Low Calorie Diet (LCD) diet intervention|In person or video conference
11108727|NCT04014998|Experimental|Virtual Reality|Virtual Reality + Exercise
11108728|NCT04014998|Other|Exercise|Exercise Only
11108729|NCT04014985|Other|Girls with RETT syndrome|100 girls over 18 years old with RETT syndrome
11108730|NCT04014972||Patients with Myocardial Infarction|
11108731|NCT04014959|Experimental|All Participants|All participants follow the same procedures.
11108732|NCT04014946|Other|ICD implantation|Implantation of a Lumax 540 single/dual chamber ICD or successor according to local practice within 3 months after enrolment. The patient will be implanted with a single or dual chamber device according to ESC guidelines.
11108733|NCT04014933||open-angle glaucoma|patients with a diagnosis of open-angle glaucoma, i.e. untreated IOP >21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
11108734|NCT04014933||normal tension glaucoma|patients with a diagnosis of normal tension glaucoma, i.e. untreated IOP </=21mmHg plus glaucomatous disc changes and/or visual field defects typical for glaucoma
11108735|NCT04014933||healthy controls|individuals with normal optic disc and IOP </21mmHg and normal visual fields
11108736|NCT04014920|Active Comparator|Oxygen Group|Patient will receive standard oxygenotherapy
11108737|NCT04014920|Experimental|NIV Group|Patient will receive non invasive ventilation
11108738|NCT04014894|Experimental|CD19+ Leukemia and Lymphoma|The trial will enroll 9 leukemia and 9 lymphoma. Each disease has 3 groups by infusion dose level. Each dose group has 3 patients.
11108739|NCT04014881|Experimental|CD123+ Acute Myeloid Leukemia|Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial. Each dose group has 3 patients and the the maximum dose can be extended.
11108740|NCT04014868|Experimental|Nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with active nasal high-flow :
~Flow : 30 L/min; Temperature : 34°C;
~The device will be out of sight of the patient. The device allow for oxygen supplementation (fitting on the back of the device). Usual oxygen prescription (if any) will be adjusted to reach a transcutaneous oxygen saturation superior to 90%. A second fitting will be placed just before the nasal canula to allow for oxygen supplementation during the sham nasal high-flow (device turned OFF) test.
~Due to the cross-over design of the study, all patients will perform both interventions."
11108741|NCT04014868|Sham Comparator|Sham nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with a sham nasal high-flow :
~The procedure will be exactly the same but the device (out of sight of the patient) will be turned OFF. Oxygen supplementation will be possible through the fitting placed just before the nasal canula.
~Due to the cross-over design of the study, all patients will perform both interventions."
11108742|NCT04014855|Active Comparator|obese children 1|iron supplementation
11108743|NCT04014855|Active Comparator|obese children 2|lactoferrin supplementation
11108744|NCT04014842|Other|RapidShock|
11108745|NCT04014829||Control|Preoperative assessment with questionnaires, Mechanical Temporal Summation, and Pain-Pressure Threshold. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 4 and 6 months.
11108746|NCT04014829||Chronic Post-Hysterectomy Pain (CPHP)|Preoperative assessment with questionnaires, Mechanical Temporal Summation, and Pain-Pressure Threshold. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if significant pain is noted during the follow up evaluations at 4 and 6 months.
11108747|NCT04014816||Group I|Patients who had GI dysfunction (Group I) for one or more occasions.
11108748|NCT04014816||Group II|Patients who had normal GI function (Group II) for one or more occasions.
11108749|NCT04014803|Active Comparator|Prasugrel plus Aspirin arm|"Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily* will be given for one year.
~* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement."
11108750|NCT04014803|Active Comparator|Clopidogrel plus Aspirin arm|Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.
11108751|NCT04014790|Experimental|RGI-2001|Subjects will be administered RGI 2001 in combination with standard of care treatment
11108752|NCT04014777|Experimental|NGM621 Cohort 1 Single Ascending Dose|NGM621 single IVT injection Cohort-Dose 1
11108753|NCT04014777|Experimental|NGM621 Cohort 2 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 2
11108754|NCT04014777|Experimental|NGM621 Cohort 3 Single Ascending Dose|NGM621 single IVT injection Cohort--Dose 3
11108757|NCT04014751||Symptom Monitoring Cohort|This cohort will include up to1,050 cancer patients being seen at regional Northwestern Medicine (NM) cancer centers for their cancer care. Patients who have recently completed an on-line, EHR-integrated patient-reported symptom and needs assessment as part of their regular care will be invited to complete a survey at baseline, 6- and 12-months targeting the assessment of their symptoms, healthcare experiences and utilization. Patients may also be invited to participate in a one-time interview or focus group designed to help study investigators better understand the value of the symptom and needs assessment from the patient perspective.
11108758|NCT04014725|Experimental|Eligible patients for AI test|
11108759|NCT04014712|Experimental|acute BH4/Tetrahydrobiopterin treatment|Oral supplement, Pill, 10 mg/kg of body weight
11108760|NCT04014712|Placebo Comparator|Placebo|Oral supplement, Pill, Placebo pill with inert excipient
11108761|NCT04014699|Experimental|modified 2.2mm micoincision|
11108762|NCT04014699|Active Comparator|conventional 2.2mm microincision|
11108763|NCT04014686|Sham Comparator|Control group|No exercise intervention
11108764|NCT04014686|Experimental|Exercise intervention group|Exercise intervention group (resistance band exercise training for 12 weeks, 3x per week, for 60 minutes per day).
11108765|NCT04014673|Other|Patients with a PGRN gene mutation|Symptomatic patients with a PGRN gene mutation
11108766|NCT04014673|Other|Presymptomatic individuals|Asymptomatic 'At-risk' individuals with a PGRN gene mutation
11108767|NCT04014673|Other|healthy volunteers|'At-risk' individuals without a PGRN gene mutation
11108768|NCT04014660|Active Comparator|Probiotic group|The participants in this group are provided with a dietary supplement (capsules) containing freeze dried bacteria (active lactobacilli culture) mixed with corn starch, for daily intake (1 capsule per day).
11108769|NCT04014660|Placebo Comparator|Placebo group|The participants in this group are provided with a dietary supplement (capsules) containing corn starch only, for daily intake (1 capsule per day).
11108770|NCT04014647||Event-free|Patients who have had no negative events (as described in group 2)
11108771|NCT04014647||Negative event|"Group 2 - patients with one or more of the following negative events post-operatively:
~Whether the patient has been prescribed inotropic support
~Wound infection by assessing use of antibiotics.
~Length of stay in hospital >1 week
~Reduced renal function assessed by having any AKI alert during hospital stay
~Cardiac event within 31 days following surgery
~Death within 31 days following surgery"
11108772|NCT04014634|Placebo Comparator|Placebo|Injection of NaCl
11108773|NCT04014634|Experimental|Verum|
11108774|NCT04014621|Active Comparator|Treated|Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
11108775|NCT04014621|Sham Comparator|Control|Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
11108776|NCT04014608||Baseline Control|Standard Practice before the intervention was introduced
11108777|NCT04014608||Intervention initiative|Standard Practice plus Admission Surveillance for toxigenic C. difficile.
11108778|NCT04014595||Rotational atherectomy + Cutting Balloon|Rotational atherectomy in combination with cutting balloon in severely calcified coronary lesions
11108779|NCT04014582|Experimental|Communal Coping Intervention|This group will participate in diabetes education + a communal coping based intervention.
11108780|NCT04014582|Active Comparator|Control|This group will participate in diabetes education and an individual intervention.
11108781|NCT04014569|Experimental|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA algorithm
11108782|NCT04014556|Active Comparator|Aflibercept plus micropulse laser (group A)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
11108783|NCT04014556|Active Comparator|Aflibercept monotherapy (group B)|Overall 40 patients were included in the study; they were randomized into either group A (Aflibercept + Micropulse; 20 patients) or group B (Aflibercept monotherapy; 20 patients).
11108784|NCT04014543|Experimental|Gastrostomy|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.
~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
11108785|NCT04014530|Experimental|Phase I dMMR and pMMR|2-4 groups of 3 patients treatment with 200mg i.v. Pembrolizumab q3w and dose escalation of Ataluren in order to determine the Ataluren MTD. These patients can either be pMMR/dMMR CRC and dMMR EC patients.
11108786|NCT04014530|Experimental|Phase II dMMR|Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
11108787|NCT04014530|Experimental|Phase II pMMR|Mismatch repair proficient CRC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
11108788|NCT04014517|Active Comparator|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
11108789|NCT04014517|Experimental|Immunonutrition|Impact
11108790|NCT04014504||study group|The results of the hearing screening test of the beats of the patients who have undergone pethidine in the active phase of labor will be examined. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at.
11108791|NCT04014504||control group|In the active phase of labor, hearing screening test results of beats of pediatric patients will be evaluated. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at. control group.
11108792|NCT04014491|Experimental|Scapula control exercise|Subjects will perform three exercises with EMG biofeedback and verbal cues. Three exercises are elevation in scapular plane, sidelying external rotation and dynamic hug plus
11108793|NCT04014491|Experimental|Scapula strengthening exercise|The subjects in the scapular strengthening group will be asked to perform the three exercises the same as scapula control exercise group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
11108794|NCT04014491|Other|Healthy subject group|Healthy subjects will be included to compare the differences in corticospinal system between healthy subjects and subjects with shoulder impingement syndrome, so this group will not receive any treatment.
11108795|NCT04014478|Experimental|Endovascular Denervation|
11108796|NCT04014465||patients with radiotherapy|The patients of lung cancer or esophagueal cancer, who received definitvie RT, should included in this Cohort.
11108797|NCT04014452|Experimental|Microwave ablation group|Microwave ablation is used for the treatment of Complicated Monochorionic Pregnancies
11108798|NCT04014452|Active Comparator|Radiofrequency ablation group|Radiofrequency ablation is used for the treatment of Complicated Monochorionic Pregnancies
11108799|NCT04014439||Normal Diaphragm|Diaphragm thickness is 2 mm or more
11108800|NCT04014439||Thinning Diaphragm|Diaphragm thickness is less than 2 mm
11108801|NCT04014426|Other|Exposed|Healthcare workers participating at two PIPAC
11108802|NCT04014426|Other|Non-exposed|Healthy volunteers unexposed to chemotherapy
11108803|NCT04014413|Experimental|Crohn's disease|Fecal Microbiota Transplant will be performed.
11108804|NCT04014413|Experimental|Ulcerative colitis|Fecal Microbiota Transplant will be performed.
11108805|NCT04014413|Experimental|Celiac disease|Fecal Microbiota Transplant will be performed.
11108806|NCT04014413|Experimental|Irritable bowel syndrome|Fecal Microbiota Transplant will be performed.
11108807|NCT04014413|Experimental|Functional dyspepsia|Fecal Microbiota Transplant will be performed.
11108808|NCT04014413|Experimental|Constipation|Fecal Microbiota Transplant will be performed.
11108809|NCT04014413|Experimental|Metabolic disease (diabetes mellitus or obesity)|Fecal Microbiota Transplant will be performed.
11108810|NCT04014413|Experimental|Multidrug-resistant infection|Fecal Microbiota Transplant will be performed.
11108811|NCT04014413|Experimental|Hepatic encephalopathy|Fecal Microbiota Transplant will be performed.
11108812|NCT04014413|Experimental|Multiple sclerosis|Fecal Microbiota Transplant will be performed.
11108813|NCT04014413|Experimental|Pseudo-obstruction|Fecal Microbiota Transplant will be performed.
11108814|NCT04014413|Experimental|CRE infection|Fecal Microbiota Transplant will be performed.
11108815|NCT04014413|Experimental|VRE infection|Fecal Microbiota Transplant will be performed.
11108816|NCT04014413|Experimental|Multiple organ dysfunction|Fecal Microbiota Transplant will be performed.
11108817|NCT04014413|Experimental|Dysbiotic bowel syndrome|Fecal Microbiota Transplant will be performed.
11108818|NCT04014413|Experimental|MRSA enteritis|Fecal Microbiota Transplant will be performed.
11108819|NCT04014413|Experimental|Pseudomembranous enteritis|Fecal Microbiota Transplant will be performed.
11108820|NCT04014413|Experimental|Alopecia|Fecal Microbiota Transplant will be performed.
11108821|NCT04014413|Experimental|Autism|Fecal Microbiota Transplant will be performed.
11108822|NCT04014413|Experimental|Graft-versus-host disease|Fecal Microbiota Transplant will be performed.
11108823|NCT04014413|Experimental|Idiopathic thrombocytopenic purpura|Fecal Microbiota Transplant will be performed.
11108824|NCT04014413|Experimental|Atopy or allergy|Fecal Microbiota Transplant will be performed.
11108825|NCT04014413|Experimental|Liver disease|Fecal Microbiota Transplant will be performed.
11108826|NCT04014413|Experimental|Alcohol dependence|Fecal Microbiota Transplant will be performed.
11108827|NCT04014413|Experimental|Antibiotic-associated diarrhea|Fecal Microbiota Transplant will be performed.
11108828|NCT04014400|Experimental|Suprathel|Once hemostasis is obtained, the Suprathel material will be handled with a new pair of sterile gloves. It will be cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The Suprathel will be secured with a protective layer of Rylon extending 1-2 cms beyond the margins of the Suprathel. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze). The outer dressing will be changed 7-10 days post-op. The Suprathel and Rylon will remain in place until they can be easily peeled off. To facilitate the pain-free and easy removal of the primary Suprathel dressing, practioners will apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Suprathel (and Rylon) are removed, but they may continue to be seen until the STSG is fully healed.
11108829|NCT04014400|Active Comparator|Xeroform|After hemostasis occurs, the Xeroform dressing will be handled with a new pair of sterile gloves and cut so that the material extends 1-2 cm beyond the donor site margins, then applied to the donor site. The primary dressing will be covered with cotton gauze (4x4 fluff gauze pads) and wrapped with rolled gauze (Kerlix). The outer dressing will be changed 7-10 days post-op. The Xeroform will remain in place until it can be easily peeled off. To facilitate the pain-free and easy removal of the Xeroform dressing, practioners may apply Vaseline or lotion to saturate and loosen the material. The patients will be followed on average about once per week in an outpatient clinic until the Xeroform is removed, but they may continue to be seen until the STSG is fully healed.
11108830|NCT04014387|Active Comparator|Zolpidem Arm|Participants will be given one week of Zolpidem.
11108831|NCT04014387|Active Comparator|Suvorexant Arm|Participants will be given one week of Suvorexant.
11108832|NCT04014387|Placebo Comparator|Placebo Arm|Participants will be given one week of a placebo pill.
11108833|NCT04014374||Transplant Arm|Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT
11108834|NCT04014374||Control Arm|Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT
11108835|NCT04014361|Experimental|LY3154885 - Part A|LY3154885 administered orally in two of three study periods.
11108836|NCT04014361|Placebo Comparator|Placebo - Part A|Placebo administered orally in one of three study periods.
11108837|NCT04014361|Experimental|LY3154885 - Part B|LY3154885 administered orally alone.
11108838|NCT04014361|Placebo Comparator|Placebo - Part B|Placebo administered orally alone.
11108883|NCT04014088|Active Comparator|helmet CPAP|helmet CPAP administer to patient diagnosed as acute cardiogenic pulmonary edema
11108839|NCT04014361|Experimental|LY3154885 + Itraconazole - Part B|LY3154885 administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. LY3154885 co-administered with itraconazole, orally, once.
11108840|NCT04014361|Placebo Comparator|Placebo + Itraconazole - Part B|Placebo administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. Placebo co-administered with itraconazole, orally, once.
11108841|NCT04014361|Experimental|LY3154885 - Part C|LY3154885 administered orally on consecutive days.
11108842|NCT04014361|Placebo Comparator|Placebo - Part C|Placebo administered orally on consecutive days.
11108843|NCT04014361|Experimental|LY3154885 - Part D|LY3154885 administered orally once in each of three study periods.
11108844|NCT04014348||Female|Diagnostic
11108845|NCT04014335|Experimental|IONIS-FB-LRx|
11108846|NCT04014322|Experimental|E-cigarette|All participants will be instructed to start using e-cigarettes as much as they like for the first 2 weeks, and then, to switch completely from combustible cigarettes to e-cigarettes for the next 4 weeks. They will be assessed at baseline, 2 weeks, 4 weeks, and 10 weeks.
11108847|NCT04014309|Experimental|Supportive and survivorship care program|Routine distress screening will be conducted using the Distress Thermometer (DT) and an accompanying problem list. Participants will complete the screening tool before their consults with oncologists and the results will be stored in their medical records. During the consult, oncologists will review the DT scores and problem list with each participant to provide the corresponding educational materials, advice or referrals. Highly distressed participants may be referred by oncologists to the supportive care nurses (SCN) for further triage and review.
11108848|NCT04014309|Placebo Comparator|Usual care|No routine distress screening will be performed.
11108849|NCT04014296|Experimental|High Protein Diet|
11108850|NCT04014296|Experimental|Resistance Training|
11108851|NCT04014283|Active Comparator|BRCA(+) Selenium deficiency|Placebo: 100 Supplement: 100
11108852|NCT04014283|Active Comparator|BRCA(+) Selenium excess|Diet modification: 500 Observation: 500
11108853|NCT04014283|Active Comparator|BRCA(-) Selenium deficiency|Placebo: 900 Supplement: 900 Diet modification: 900 Observation: 900
11108854|NCT04014283|Active Comparator|BRCA(-) Selenium excess|Diet modification: 1100 Observation: 1100
11108855|NCT04014283|Active Comparator|BRCA(+) Selenium excess, age > 50|Diet modification: 200 Observation: 200
11108856|NCT04014270|Experimental|Self modulated functional electrical stimulation (SM-FES)|Patients will receive self-modulated functional electrical stimulation SM-FES
11108857|NCT04014270|Active Comparator|Standard care (SC)|Patients will receive standard care, dose matched to the experimental group therapy
11108858|NCT04014257|Experimental|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
11108859|NCT04014244|Experimental|Corticosteroids vs. Dextrose|In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance.
11108860|NCT04014244|Experimental|Corticosteroids or Dextrose vs. Surgery|In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. Surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
11108861|NCT04014231||Observational (single wave assessment)|Patients undergo placement of a single wave application near the carotid region of the neck.
11108862|NCT04014218|Experimental|Inhalation sedation|
11108863|NCT04014218|Active Comparator|Propofol|
11108864|NCT04014205|Experimental|ICP-022 (Lower Dose)|100 mg, Once a day (QD)
11108865|NCT04014205|Experimental|ICP-022 (Higher Dose)|150 mg, QD
11108866|NCT04014192|Experimental|Dapagliflozin Group|10mg/d for one week
11108867|NCT04014192|Experimental|Empagliflozin Group|10mg/d for one week
11108868|NCT04014192|Experimental|Canagliflozin Group|100mg/d for one week
11108869|NCT04014192|No Intervention|Normal Glucose Tolerance Group|
11108870|NCT04014179|Experimental|Immediate Intervention (Dried Blood Spot)|Blood samples will be tested for HCV RNA from dried blood spot cards.
11108871|NCT04014179|Experimental|Immediate intervention (Point-of-care testing)|Blood samples will be tested for HCV RNA using the Xpert HCV Viral Load Fingerstick point-of-care assay.
11108872|NCT04014179|Active Comparator|Delayed intervention (Dried Blood Spot)|There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing from dried blood spots.
11108873|NCT04014179|Active Comparator|Delayed intervention (Point-of-care testing)|There will be a period of business as usual, that is, sites will continue with standard of care for HCV RNA testing, then switch to intervention for HCV RNA testing using the point-of-care assay.
11108874|NCT04014166|Experimental|15 refractory ITP patients|15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose.
11108875|NCT04014153||Group 1 (5-year prognosis)|
11108876|NCT04014153||Group 2 (1-year prognosis)|
11108877|NCT04014140||Patients with multi-vessel coronary artery disease (MVCAD)|iFR measurements will be taken pre-operatively during the invasive coronary angiography.
11108878|NCT04014127||Controls|25 controls with preserved renal function
11108879|NCT04014127||Kidney Donors|25 living kidney donors who have donated a kidney at least 12 months prior to enrollment in the study.
11108880|NCT04014127||Pre-dialysis|25 patients with pre-dialysis chronic kidney disease stage 5
11108881|NCT04014127||Peritoneal dialysis|25 patients with chronic kidney disease stage 5 undergoing peritoneal dialysis
11108882|NCT04014101|Experimental|SHR-1210+ apatinib|SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
11108885|NCT04014075|Experimental|All participants|Participants who have centrally confirmed HER2-positive gastric or gastro-esophageal junction cancer will be treated with trastuzumab deruxtecan by intravenous (IV) infusion every 3 weeks, until progression of disease or withdrawal from treatment for other reasons.
11108886|NCT04014062|Experimental|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
11108887|NCT04014062|Active Comparator|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
11108888|NCT04014036|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
11108889|NCT04014036|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
11108890|NCT04014023|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
11108891|NCT04014023|Experimental|DWP16001 Bmg|DWP16001 Bmg, Tablets, Orally, Once daily
11108892|NCT04014023|Experimental|DWP16001 Cmg|DWP16001 Cmg, Tablets, Orally, Once daily
11108893|NCT04014023|Placebo Comparator|Placebo|Placebo, Tablets, Orally, Once daily
11108894|NCT04014010||Cohort|Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
11108895|NCT04013997|Experimental|Exoskeletal-assisted walking training group|Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study.
11108896|NCT04013997|No Intervention|Matched control group|"Twenty inpatients with SCI were identified as the matched control group through reviewing an acute inpatient rehabilitation database of Uniform Data System for Medical Rehabilitation by a person blinded to the study.
~The control group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. The control groups received the same amount of acute rehabilitation time per week as the intervention group."
11108897|NCT04013984|Experimental|Accupuncture|"Acupuncture twice a week during the preceding cycle and the ovarian stimulation by GnRH agonist stopped protocol."
11108898|NCT04013984|No Intervention|Non-accupuncture|"Ovarian stimulation by GnRH agonist stopped protocol without intervention."
11108899|NCT04013971|Other|Game without AR, Game with AR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without AR, game with AR, traditional interface
11108900|NCT04013971|Other|Game without AR, Traditional Interface, Game with AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game without AR, traditional interface, game with AR
11108901|NCT04013971|Other|Game with AR, Game without AR, Traditional Interface|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with AR, game without AR, traditional interface
11108902|NCT04013971|Other|Game with AR, Traditional Interface, Game without AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: game with AR, traditional interface, game without AR
11108903|NCT04013971|Other|Traditional Interface, Game without AR, Game with AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game without AR, game with AR
11108904|NCT04013971|Other|Traditional Interface, Game with AR, Game without AR|Post-stroke participants randomized to receive the three gait training biofeedback interfaces in the order of: traditional interface, game with AR, game without AR
11108905|NCT04013958|Active Comparator|IV Ketamine|IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
11108906|NCT04013958|Experimental|IM Ketamine|IM Ketamine group will receive IM Ketamine with IV morphine.
11108907|NCT04013945|Active Comparator|Superba Boost capsules|1000 mg krill oil concentrate per capsule
11108908|NCT04013945|Placebo Comparator|Placebo capsules|1000 mg capsule composed of mixed vegetable oil.
11108909|NCT04013932|Experimental|KUPAA Intervention + Standard of Care|Patient/caregiver dyads will be assigned to a KUPAA group composed of approximately 6 patients and 6 matched caregivers. The dyads will first participate in 1-2 joining sessions with a provider, followed by a 1-day group educational workshop. Participants will then attend weekly family psychoeducation group sessions (~1.5-2 hours) for 12 weeks.
11108910|NCT04013932|No Intervention|Control - Standard of Care|Patients will receive the standard of care.
11108911|NCT04013919||Type 1 Diabetes|
11108912|NCT04013919||Type 2 Diabetes|
11108913|NCT04013906|Experimental|Rotational atherectomy|Patients will undergo rotational atherectomy
11108914|NCT04013906|Experimental|Intravascular lithotripsy|Patients will undergo intravascular lithotripsy
11108915|NCT04013880|Experimental|Treatment (ASTX727, FT-2102)|Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11108916|NCT04013854|Active Comparator|Arm A: Adjuvant Nivolumab (Complete Pathological Response)|480 mg IV for up to one year
11108917|NCT04013854|Active Comparator|Arm B: Adjuvant Nivolumab (Less than Complete Response)|480 mg IV for up to one year
11108918|NCT04013854|Experimental|Arm C: Adjuvant Combination (Less than Complete Response)|ipilimumab (1mg/kg) plus nivolumab (3mg/kg) for 4 doses and then nivolumab (480 mg) alone for a total of one year
11108919|NCT04013841|Experimental|Oral preparation|The bowel preparation prior to colorectal resection will be conducted using oral-agents
11108920|NCT04013841|Experimental|Enema preparation|The bowel preparation prior to colorectal resection will be conducted using rectal enema
11108925|NCT04013802|Experimental|HLA-matched VSTs|"Partially HLA-matched VSTs will be thawed and given by intravenous injection. Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused with agreement of the principal investigator, patient and/or guardian and the treatment team
~Additional doses may be from the same donor or a different donor based on available cell lines and patient/disease factors. Decision to switch to a different donor can be made by the principal investigator based on factors that include sequential treatment of different viral infections, concerns for immune escape of the targeted virus and/or availability of a better matched or otherwise superior VST line. Additional treatments will only be given following the agreement of the patient, treating physician, and investigator. This process can be repeated as needed."
11108926|NCT04013789|Other|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
11108927|NCT04013789|Other|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
11108928|NCT04013776|Active Comparator|Phosphate supplemented diet|All participants will undergo phosphate testing after following a phosphate supplemented diet for 5 days
11108929|NCT04013776|No Intervention|Low phosphate diet|All participants will undergo phosphate testing after following a low phosphate diet for 5 days
11108930|NCT04013763|Experimental|Atopic dermatitis with stop using product|case wheat allergy with atopic dermatitis and stop using wheat containing skin care products
11108931|NCT04013763|Experimental|Atopic dermatitis with containing using product|case wheat allergy with atopic dermatitis and continue using wheat containing skin care products
11108932|NCT04013763|Experimental|Non atopic dermatitis with stop using product|case wheat allergy with normal skin and stop using wheat containing skin care products
11108933|NCT04013763|Experimental|Non atopic dermatitis with continue using product|case wheat allergy with normal skin and continue using wheat containing skin care products
11108934|NCT04013763|No Intervention|Atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and has atopic dermatitis
11108935|NCT04013763|No Intervention|Non atopic dermatitis with no product use|case wheat allergy who does not use wheat containing skin care products and no atopic dermatitis
11108936|NCT04013750|Experimental|left hemiplegia|Patients in the left hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
11108937|NCT04013750|Experimental|right hemiplegia|Patients in the right hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
11108938|NCT04013750|No Intervention|control|10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme.
11108939|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Qualitative evaluation and co-design of interventions. Prospective evaluation of intervention.
11108940|NCT04013737||Prescribers|Quantitative and qualitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
11108941|NCT04013724|Experimental|Intervention group|"The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' Supporting Smoking Cessation Guide for Health Professionals17 and the World Health Organization's Strengthening Health Systems for Treating Tobacco Dependence in Primary Care training package.18
~The topics that were explored during the group sessions include:
~Introduction to the Program and Reasons to Quit
~Benefits of Quitting and Understanding Why We Smoke and Ways of Quitting
~Withdrawal Symptoms and Social Support
~Dealing with Stress and Anxiety and Coping with Depression
~Assertiveness Training and Anger Management
~Tobacco-Free Lifestyle and Dealing with High Risk Situations"
11108942|NCT04013724|No Intervention|Control|The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT.
11108943|NCT04013711|Experimental|Thermal Imaging|Patients will undergo non-invasive, thermal imaging of their whole breast or head and neck cancer site, during the course of the radiotherapy treatment, at weekly time intervals.
11108944|NCT04013698|Experimental|PEEP level 5 cmH2O to 15 cmH2O|
11108945|NCT04013698|Experimental|PEEP level 15 cmH2O to 5 cmH2O|
11108946|NCT04013685|Experimental|Subjects with Acute Leukemia or Myelodysplasic Syndrome|"This is a non-randomized, single-arm study. Patients will be grouped based on their underlying disease:
~Group 1 will enroll subjects planning to undergo myeloablative allogeneic hematopoietic cell transplantation (MA-alloHCT) for the treatment of either acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi), and with no known minimal residual disease positivity.
~Group 2 will enroll subjects Subjects planning to undergo MA-alloHCT for acute myeloid, lymphoid or mixed phenotype leukemia that is either:
~not in morphologic CR with bone marrow infiltration by leukemic blasts of <= 10%, or
~in morphologic CR with evidence of minimal residual positivity by either multiparameter flow cytometric analysis or by a nucleic acid-based technique.
~Group 3 will enroll subjects planning to MA-alloHCT for high or very high risk myelodysplasic syndrome (MDS) myelodysplastic syndromes."
11108947|NCT04013672|Experimental|Arm A - Have not received immunotherapy|Arm A is patients with first recurrence of glioblastoma who have failed prior chemotherapy and radiation but have not received any immunotherapy.
11108948|NCT04013672|Experimental|Arm B - Have failed prior anti-PD1 therapy|Arm B is an exploratory arm of 10 patients who have failed prior anti-PD1 therapy.
11108986|NCT04013425|No Intervention|Spontaneous Healing|Spontaneous Healing after Atraumatic Extraction
11108949|NCT04013659|Experimental|G1 - Permanence of the Whitening Gel|Permanence of the Whitening Gel (Biological Product: 35% Hydrogen Peroxide) on the tooth enamel during the 15 minutes of dental-bleaching
11108950|NCT04013659|Experimental|G2 - Renewal of the Whitening Gel|3 Whitening Gel (Biological Product: 35% Hydrogen Peroxide) renewal every 5 minutes during the 15 minutes of dental-bleaching
11108951|NCT04013646|Experimental|UCB infusion and EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
11108952|NCT04013646|Experimental|UCB infusion and placebo EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
11108953|NCT04013646|Placebo Comparator|Placebo UCB infusion and placebo EPO injection group|Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
11108954|NCT04013633|Experimental|Lifesaver virtual reality (VR) training|Training using the Lifesaver VR application. Lifesaver VR is an interactive game that can be played on smartphones allowing users to 'resuscitate' a victim of cardiac arrest, while wearing VR-goggles showing a filmed CPR-scenario
11108955|NCT04013633|Active Comparator|Face-to-face training|A short face-to-face CPR training based on international guidelines provided by certified instructors
11108956|NCT04013620|Experimental|transient belatacept|
11108957|NCT04013607|Experimental|Fiber drink|A drink high in fructo- and galacto-oligosaccharides.
11108958|NCT04013594|Experimental|carbohydrate group(CHO group)|
11108959|NCT04013594|No Intervention|control group|
11108960|NCT04013581|Experimental|TZD group|Pioglitazone added to Metformin, DPP-4 inhibitors, Sulfonylurea
11108961|NCT04013581|Active Comparator|SGLT-2 inhibitor group|Empagliflozin added to Metformin, DPP-4 inhibitors, Sulfonylurea
11108962|NCT04013568|Active Comparator|Group 1 - Agree to Exercise Program|"12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific.
~Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students"
11108963|NCT04013568|No Intervention|Group 2 - Declines Exercise Program|Same biometric and biomarker assessment at as Group 1 (at baseline and after 12 weeks) however they will not participate in the exercise sessions
11108964|NCT04013555|Experimental|N-acetylcysteine & Tryptophan|N-acetylcysteine 140 mg/kg up to a maximum of 15 g. Thirty minutes after N-acetylcysteine administration participants will receive Tryptophan, 6 grams.
11108965|NCT04013555|Placebo Comparator|Placebo & Tryptophan|Placebo 140 mg/kg up to a maximum of 15 g. Thirty minutes after placebo administration participants will receive Tryptophan, 6 grams.
11108966|NCT04013542|Experimental|Treatment (nivolumab, ipilimumab, radiation therapy)|"CONCURRENT THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 8 cycles, and treatment with ipilimumab repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 1 day of starting nivolumab and ipilimumab, patients also undergo radiation therapy 5 days a week (Monday-Friday) over 6-7 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
11108967|NCT04013529|Placebo Comparator|Control|Participate in technology-enabled care without regret lottery
11108968|NCT04013529|Experimental|Experimental|Participate in technology-enabled care with regret lottery
11108969|NCT04013516|No Intervention|Pure Control|Respondents received New Incentives' normal program.
11108970|NCT04013516|Placebo Comparator|Reminder Call|Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives.
11108971|NCT04013516|Experimental|Small Additional Incentive|Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
11108972|NCT04013516|Experimental|Large Additional Incentive|Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
11108973|NCT04013490|Placebo Comparator|Placebo capsule|Subject receive the Placebo product for 4 weeks.
11108974|NCT04013490|Active Comparator|Cassava dietary fiber capsule 1.5 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
11108975|NCT04013490|Active Comparator|Cassava dietary fiber capsule 3 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
11108976|NCT04013477|Experimental|Cohort1|"drug : DA-5207 80mg/40cm²
~placebo : 40cm²"
11108977|NCT04013477|Experimental|Cohort2|"drug : DA-5207 120mg/60cm²
~placebo : 60cm²"
11108978|NCT04013477|Experimental|Cohort3|"drug : DA-5207 160mg/80cm²
~placebo : 80cm²"
11108979|NCT04013477|Active Comparator|Cohort4|drug : Aricept
11108980|NCT04013464|Experimental|MDD and Health Control|MDD in open label
11108981|NCT04013451|Experimental|Intervention Group|Participants allocated to the intervention group will participate in the intervention (acts of kindness).
11108982|NCT04013451|No Intervention|Control Group|Participants allocated to the control group will not participate in the intervention and will act as the comparison condition.
11108983|NCT04013438|Experimental|FET cycle, discontinue estradiol after 6 gestational weeks|In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
11108984|NCT04013438|Active Comparator|FET cycle, continue estradiol till 12 gestational weeks|Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.
11108985|NCT04013425|Experimental|Ice Cream Cone Technique|Atraumatic extraction followed by addition of barrier membrane and xenograft in the socket.
11108987|NCT04013412|Experimental|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
11108988|NCT04013412|No Intervention|Control|Ad libitum diet for four days immediately before surgery
11108989|NCT04013399|Experimental|Continuous Positive Airway Pressure|Women will receive Continuous Positive Airway Pressure (CPAP) for one month.
11108990|NCT04013399|No Intervention|Control|Women will receive standard prenatal care.
11108991|NCT04013386|Active Comparator|Aprepitant/Dexamethasone Group|
11108992|NCT04013386|Active Comparator|Mertazepine /Dexamethasone Group|
11108993|NCT04013386|Active Comparator|Dexamethasone Group|
11108994|NCT04013373||BIS home-based monitoring|
11108995|NCT04013360|Active Comparator|Breath Stacking|Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes.
11108996|NCT04013360|Active Comparator|Expiratory Positive Airway Pressure|Therapeutic technique consisting of a face mask, a one-way valve and an expiratory resistor, responsible for resistance to expiratory flow, which will determine the level of pressure in the airway.
11108997|NCT04013347||Early Surgery|Surgery after ≤ 42 days from the end of neoadjuvant radio-chemotherapy
11108998|NCT04013347||Late Surgery|Surgery after 43-56 days from the end of neoadjuvant radio-chemotherapy
11108999|NCT04013347||Very Late Surgery|Surgery after 57 or more days from the end of neoadjuvant radio-chemotherapy
11109000|NCT04013334|Experimental|MTG201 plus Nivolumab|Single arm, open-label, patients receive both MTG201 and nivolumab
11109001|NCT04013321|Experimental|Test intervention group|Chronic insomniacs will track their sleep with the SleepScore Max device and will receive feedback and coaching from the Smartphone app associated with the device.
11109002|NCT04013321|Active Comparator|Active control|Chronic insomniacs in the active control group will be tracking their sleep with the device, without feedback or coaching. But they will also undergo online cognitive behavioral therapy for insomnia (CBTi).
11109003|NCT04013321|No Intervention|Passive control|Chronic insomniacs in the passive control group will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
11109004|NCT04013321|No Intervention|Healthy control|Healthy sleepers will track their sleep using the SleepScore Max device, but without the feedback or coaching feature.
11109005|NCT04013308|Experimental|10 iontophoresis treatments with potassium iodide|
11109006|NCT04013308|No Intervention|10 iontophoresis treatments with placebo|
11109007|NCT04013295|Experimental|Prize-linked savings intervention|Participants in the intervention group will be assisted with opening bank accounts at the partner bank and will be eligible for monetary rewards linked to the amount they save in these project accounts. During the intervention period, information about participants' savings activities will be shared with the study team at regular intervals by the bank. Winners will learn of their prize via text message and will have their prize money deposited into their accounts. Respondents who did not win the lottery will also receive a text message, which will remind them to save.
11109008|NCT04013295|No Intervention|Control|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.
~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
11109009|NCT04013269|Active Comparator|CytoSorb-Therapy|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber
11109010|NCT04013269|No Intervention|Standard of care|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy
11109011|NCT04013256|Experimental|Dermal Exposure to Thirdhand Cigarette Smoke|Participants will wear clothing that has been exposed to cigarette smoke, for 3 hours while breathing filtered, temperature and humidity controlled air.
11109012|NCT04013256|Active Comparator|Inhalational Exposure to Thirdhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 22 hours, for 3 hours while wearing clean clothing.
11109013|NCT04013256|Active Comparator|Inhalational Exposure to Secondhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 30 minutes, for 3 hours while wearing clean clothing.
11109014|NCT04013256|Sham Comparator|Clean Air Exposure|Participants will breathe filtered, temperature and humidity controlled air while wearing clean clothing for 3 hours.
11109015|NCT04013243|Active Comparator|Magnesium Sulfate group|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
11109016|NCT04013243|Placebo Comparator|Placebo group|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
11109017|NCT04013230|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic.
11109018|NCT04013230|Active Comparator|Web-COP|Usual care plus group sessions and a web-based treatment program
11109019|NCT04013217|Experimental|Eribulin ORA|To determine the MTD of Eribulin ORA (oral eribulin mesylate and HM30181A) when administered on Day 1 and Day 8 of a 3 weeks cycle.
11109020|NCT04013204|Experimental|Intervention group|Intervention group: Before the patient returns to the doctor and the prescription is issued, the EDCM system will feed back the EndoPAT test results to the responsible doctor through the automatically generated information on the doctor's mobile phone, but will not let the patient know the endothelium test results (blinded to the patient).
11109021|NCT04013204|No Intervention|Control group|Control group: The EDCM system will not report the EndoPAT test results to the responsible doctor (the doctor cannot see the final EFT results), nor can the patients know the EFT results.
11109022|NCT04013191|Experimental|Adult study participants|Participants will receive assigned single and multiple doses of padsevonil.
11109023|NCT04013191|Experimental|Elderly study participants|Participants will receive assigned single and multiple doses of padsevonil.
11109024|NCT04013178|Experimental|Accentuated eccentric loading + electromyostimulation|This group will undertake a supervised 12-week intervention involving accentuated eccentric loading and electromyostimulation of the knee extensors, dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
11109025|NCT04013178|Active Comparator|Traditional resistance training|This group with undertake a supervised 12-week intervention involving volume matched dynamic resistance training of the knee extensors, and dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
11109026|NCT04013165|Active Comparator|Active control|Usual care of the Community Mental Health Service
11109027|NCT04013165|Experimental|Village-based intervention|Individual-based case management + group-based program
11109028|NCT04013152|Experimental|clinical database|
11109029|NCT04013139||CKD Stage 3|CKD patients with GFR between 30-60cc/min
11109030|NCT04013139||CKD Stage 4|CKD Patients with GFR 15-30 cc/min
11109031|NCT04013126|Experimental|endometriosis|Women who undergoing surgery for removal of endometriosis implants
11109032|NCT04013126|Active Comparator|non-endometriosis|Women who undergoing surgery for removal of benign masses in the pelvis
11109033|NCT04013113|Active Comparator|Standard Medical Treatment|Group A will be given standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
11109034|NCT04013113|Experimental|Hemoadsorption plus standard medical therapy|
11109035|NCT04013113|Experimental|Plasma Exchange plus standard medical therapy|
11109036|NCT04013087|Experimental|Test Formula|Feihe Stage 1 infant formula
11109037|NCT04013087|Active Comparator|Control formula|A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used)
11109038|NCT04013087|Other|Breast feeding|Breast fed of human milk
11109039|NCT04013074|Experimental|TIPS+Standard Medical Treatment|TIPS along with standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
11109040|NCT04013074|Active Comparator|Standard Medical Treatment|standard medical therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
11109041|NCT04013061||Standard consultation|
11109042|NCT04013061||Pharmacist-anesthesiologist consultation|
11109043|NCT04013048|Experimental|[14C]-Fluzoparib|Patients will receive single dose of [14C]- Fluzoparib.
11109044|NCT04013022||Young|Healthy young subjects (age 18 - 30 )
11109045|NCT04013022||Old Sedentary|Healthy and sedentary old subjects (age 65 - 75)
11109046|NCT04013022||Old Endurance Trained|Healthy old subjects ( age 65 - 75) who participated in endurance sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
11109047|NCT04013022||Old Strength Trained|Healthy old subjects ( age 65 - 75) who participated in resistance training/sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
11109048|NCT04012996|Experimental|Investigational|Two-level prodisc C SK and/or prodisc C Vivo
11109049|NCT04012996|Active Comparator|Control|Two-level Mobi-C device
11109050|NCT04012983||diabetic patients with periodontitis|
11109051|NCT04012983||periodontitis patients|
11109052|NCT04012983||healthy control|
11109053|NCT04012970|Experimental|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
11109054|NCT04012970|Experimental|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
11109055|NCT04012957|Experimental|Darbepoetin Alfa Injection|Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.
11109056|NCT04012957|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
11109057|NCT04012944|Experimental|Cordella™ Pulmonary Artery Sensor System|The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
11109058|NCT04012931|Experimental|Rilpivirine (RPV) (25 mg or adjusted weight-based dose)|Participants will receive rilpivirine (RPV 25 milligram [mg], adjusted weight-based dose) orally once daily in combination with an investigator selected background regimen (that is investigator-selected antiretrovirals [ARVs] such as nucleoside/nucleotide reverse transcriptase inhibitor [N{t}RTIs] and integrase inhibitors) for 48 weeks.
11109059|NCT04012918|Experimental|A.I. + Capeciabine|Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
11109060|NCT04012918|Active Comparator|A.I|Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.
11109061|NCT04012905|Experimental|Short tapering corticosteroids|Corticosteroid taper over 28 weeks
11109062|NCT04012905|Active Comparator|Long tapering corticosteroids|Corticosteroid taper over 52 weeks
11109063|NCT04012892|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
11109064|NCT04012879|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
11109101|NCT04012606|Experimental|TORIPALIMAB|
11109102|NCT04012606|Active Comparator|Chemotherapy|
11109103|NCT04012593||premenopausal women|diary
11109065|NCT04012866|Experimental|SEQ (sequential training group)|The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
11109066|NCT04012866|Experimental|DUAL (dual training group)|The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
11109067|NCT04012866|Active Comparator|CI (control intervention group)|The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
11109068|NCT04012853|Experimental|treatment arm|tDCS treatment group
11109069|NCT04012853|No Intervention|control arm|Sham tDCS
11109070|NCT04012827|Experimental|Apatinib Mesylate Combined With Doxorubicin and Ifosfamide|A course of treatment every 21 days. For patients with disease control (CR+ PR+SD) and tolerable adverse reactions after 6 courses of treatment, continuous drug use was considered by the researchers as inappropriate for patients to continue drug use or when the efficacy was assessed as disease progression (PD).No other antitumor treatment can be given during the treatment.
11109071|NCT04012814|Experimental|Subject treatment group|Treatment group receiving up to 4 diode treatments and up to 8 RF treatments.
11109072|NCT04012788|Active Comparator|probiotic arm|inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
11109073|NCT04012788|Placebo Comparator|placebo arm|placebo powder, 15 g
11109074|NCT04012775|Active Comparator|Insulin Humulin® NPH|Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
11109075|NCT04012775|Experimental|Insulin Rinsulin® NPH|Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
11109076|NCT04012762|Active Comparator|Moderate-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 25 Hz for training frequency in moderate-intensity group.
11109077|NCT04012762|Active Comparator|Vigorous-intensity group|WBVT application was 2-4 mm for vibration amplitude value and 40 Hz for training frequency in vigorous-intensity group.
11109078|NCT04012749|Active Comparator|Advance directive|Messaging and advance directive distribution. All arms receive physician advance care planning education at the clinic level.
11109079|NCT04012749|Active Comparator|Advance directive and Prepare|Messaging and advance directive distribution plus introduction to the Prepare For Your Care website. All arms receive physician advance care planning education at the clinic level.
11109080|NCT04012749|Active Comparator|Advance directive, Prepare and Facilitator|Messaging and advance directive distribution, introduction to the Prepare For Your Care website, plus patient engagement from a trained facilitator who also can interact with the primary care physician. All arms receive physician advance care planning education at the clinic level.
11109081|NCT04012736||Celiac disease|Celiac disease subjects enrolled after diagnosis and before gluten free diet initiation
11109082|NCT04012736||Control|Healthy controls with no chronic condition
11109083|NCT04012723|Experimental|MY01 Device|"Device: MY01 Device
~Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure"
11109084|NCT04012710|Active Comparator|Laparoscopy|Abdominal conventional laparoscopy for salpingo-oophorectomy
11109085|NCT04012710|Active Comparator|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
11109086|NCT04012697|Experimental|Peer Support|Peer support services from a peer support worker in the emergency department.
11109087|NCT04012697|No Intervention|Usual care|Usual care in the emergency department.
11109088|NCT04012684|Experimental|rTMS: left first|One-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
11109089|NCT04012684|Experimental|rTMS: right first|"One-session rTMS is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session rTMS is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
~After at least two weeks, stimulations of the same parameters are given over left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well."
11109090|NCT04012684|Sham Comparator|Sham: left first|One-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
11109091|NCT04012684|Sham Comparator|Sham: right first|One-session sham stimulation is applied to right IFG. Pre-stimulation and post-stimulation MMN is recorded and compared. After at least two weeks, one-session sham stimulation is applied to left IFG. Pre-stimulation and post-stimulation MMN is recorded and compared as well.
11109092|NCT04012658||Patients with the genetic diagnosis of Wilson's Disease|
11109093|NCT04012658||Asymptomatic Wilson's Disease carriers|
11109094|NCT04012658||Relatives of Wilson's Disease patients or carriers|
11109095|NCT04012658||Unrelated healthy controls|
11109096|NCT04012645|Experimental|experimental group|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used during the surgeries.
11109097|NCT04012645|Active Comparator|control group|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
11109098|NCT04012632||cases|Early puberty cases of Han Chinese
11109099|NCT04012632||controls|Controls were matched to cases at 1:1 by age (± 3 months)
11109100|NCT04012619|Experimental|Anlotinib Hydrochloride Combined With AP|Patients receive pemetrexed (500mg/m2) with cisplatin (75mg/m2)/carboplatin (area under the curve 5) once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14 of a 21-day cycle. Anlotinib with AP will be administrated up to 4 cycles followed by maintenance treatment with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.
11109104|NCT04012580|Experimental|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the program, participants will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact provided on a weekly basis.
11109105|NCT04012580|No Intervention|Treatment as usual control|Participants will not receive access to the transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) program for 12-weeks. Participants will be permitted to access community resources (e.g., support groups). After 12-weeks, participants will be offered the program although their treatment data will not be included in the current study.
11109106|NCT04012567|Experimental|The Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
11109107|NCT04012567|Active Comparator|The BIOSURE HA Interference Screw|The Biosure HA Interference Screw, an absorbable screw made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
11109108|NCT04012554|Experimental|avoiding chest drainage tube placement after resection of lung|This group of patients underwent avoiding chest drainage tube placement after VATS of the lung.
11109109|NCT04012554|Other|indewlling chest drainage tube after resection of lung|This group of patients underwent indewlling chest drainage tube after VATS of the lung.
11109110|NCT04012541|Experimental|treatment group|"post-myocardial infarction management
~basic periodontal examinations
~active dental procedure"
11109111|NCT04012541|Active Comparator|control group|"post-myocardial infarction management
~basic periodontal examinations"
11109112|NCT04012528||"the before group"|75 teenagers after scoliosis surgery before ERAS program implementation
11109113|NCT04012528||"the after group"|75 teenagers after scoliosis surgery after ERAS program implementation
11109114|NCT04012515|Experimental|CAVA Electrode Pad Appraisal Trial Arm|All trial participants are within this arm. All participants will wear the same selection of electrode pads and follow the same replacement schedules.
11109115|NCT04012502|Active Comparator|conventional treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
11109116|NCT04012502|Experimental|Toxicities reduced treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
11109117|NCT04012489|Active Comparator|Breath Stacking|Breath stacking: patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
11109118|NCT04012489|Experimental|Air Stacking|Air stacking: the same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
11109119|NCT04012476|Experimental|ICG|Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green
11109120|NCT04012450|Active Comparator|Epidural Anesthesia|Women in labor receiving epidural anesthesia
11109121|NCT04012450|Active Comparator|Spinal-epidural|Women in labor receiving spinal-epidural anesthesia
11109122|NCT04012437|Experimental|Experimental|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a mobile app and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter. The groups use of a masturbation aid device called Myhixel I from the spanish company New Wellness Concept SL.
11109123|NCT04012437|Active Comparator|Control|.The groups completed Sphincter Control Training over 8 weeks. The SCT consists of 8 different exercises into a video tutorial and an educational videos. Its objective is to provide patients with greater knowledge, awareness, and control of the external urethral sphincter.
11109124|NCT04012424|Experimental|Drug (400mg Curcumin) Curcumin is apice|"Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .
~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .
~patients will take 400mg capsule curcumin one hour before endodontic treatment and study its effect on post endodontic pain immediately and after 8,12,24,48 hours after completion of endodontic treatment"
11109125|NCT04012424|Placebo Comparator|Starch(400mg starch) starch is sometype of carbohydrates|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
11109126|NCT04012411|Active Comparator|Patient with LP|Huntington's disease patients who agreed to have LP
11109127|NCT04012411|Active Comparator|Patient without LP|Huntington's disease patient with contraindication to LP or refusal to have LP
11109128|NCT04012411|No Intervention|Control Group|Retrospective study with biologic samples of patients without Huntington's disease
11109129|NCT04012385|No Intervention|Control|Subjects assigned to control group receives only a booklet including the recommendations for a correct diet by the Italian National Institute for Research on Food and Nutrition (INRAN), presently called (CRA-NUT) .
11109158|NCT04012151||Pregnant cohort|Parturients of gestational age >= 32 weeks will have measurements of arm length, MAC, proximal arm circumference, distal arm circumference, finger circumference to generate the conicity index.
11109421|NCT04010175|Experimental|Experimental group 2|High frequency cognitive distance training
11109130|NCT04012385|Experimental|Intervention|"Subjects assigned to the intervention group will follow a nutritional pathway based on a Mediterranean diet pattern for 4 months and receive suggestions on the regular practice of physical activity, under the guide of some nutritionists, who will propose individualized diets for each subject.
~All subjects of both groups will undergo urologic examination, measurement of weight, height and abdominal circumference, an interview on demographic data and lifestyle variables, and will provide blood and semen samples in fasting conditions, at the enrollment (baseline), at the end of the intervention phase (after 4 months) and at the end of follow-up (after 8 months)."
11109131|NCT04012372|Experimental|ROSA water|Ad libitum hydration with ROSA oligomineral water
11109132|NCT04012372|Active Comparator|Control water|Ad libitum hydration with other waters
11109133|NCT04012359||Bullous emphysema|Participants with known bullous emphysema will undergo lung ultrasound according to standard of care clinical practice during a regular follow-up consultation or scheduled hospitalization.
11109134|NCT04012359||Pneumothorax|Participants hospitalized in pulmonary medicine units for the treatment of a pneumothorax will undergo lung ultrasound according to standard of care clinical practice.
11109135|NCT04012346|Active Comparator|Active Comparator: MCI patients with real iTBS|Patients will receive real iTBS in a week-long sessions.
11109136|NCT04012346|Sham Comparator|Sham Comparator: MCI patients with sham iTBS|Patients will receive sham iTBS in a week-long sessions.
11109137|NCT04012333|Experimental|Intervention|Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: >2.2g/kg/day
11109138|NCT04012333|No Intervention|Standard Care|Patients will receive standard care (enteral nutrition only) to stay below the protein level: <1.2g/kg/day
11109139|NCT04012320||Pamidronate therapy|
11109140|NCT04012320||Zoledronate therapy|
11109141|NCT04012307|Other|Sequence AB|20 subjects assigned to the sequence AB will receive a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in Period 1 and a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11109142|NCT04012307|Other|Sequence BA|20 subjects assigned to the sequence BA will receive a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in Period 1 and a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11109143|NCT04012294|Experimental|allopurinol|150 mg daily for a month then 300 mg daily for the rest of the study (5 months)
11109144|NCT04012281||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured fractional flow reserve after PCI
11109145|NCT04012268|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
11109146|NCT04012268|Sham Comparator|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
11109147|NCT04012255|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
11109148|NCT04012255|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
11109149|NCT04012242||NAFLD patients who are scheduled for liver biopsy|
11109150|NCT04012229||Patients treated by chemotherapy for an early breast cancer|Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
11109151|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
11109152|NCT04012203||Healthy subjects|Participants free from any pain specific to the upper limb during the past 3 months, chronic pain or other disease.
11109153|NCT04012177|No Intervention|Control Arm|Arm-A: Standard antenatal care (ANC) counseling, service provision and nutrition counseling (World Health Organization (WHO) standard)
11109154|NCT04012177|Experimental|Nutrition only Arm|Arm-B:Balanced-energy protein (BEP), ready-to-use utrition supplement for at least 6 months + Standard ANC counseling, service provision and nutrition counseling (WHO standard)
11109155|NCT04012177|Experimental|Nutrition plus Azithromycin Arm|Arm-C:Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + 2000 mg of Azithromycin at week 20 and 28 of pregnancy + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
11109156|NCT04012177|Experimental|Nutrition plus Choline and Nicotinamide Arm|Arm-D: Balanced-energy protein (BEP), ready-to-use nutrition supplement for at least 6 months + Choline 450 and Nicotinamide 100 mg (1 each once daily orally starting from week 20 until birth outcome) + Standard ANC counseling, service provision and nutrition counseling (WHO standard).
11109157|NCT04012164|Experimental|Microbiological, anthropological and historical study|"30 adult participants will be recruited to self-report daily activities and contacts with domesticated and wild animals for a five month period. Following the five months of data collection, we will collect 5ml blood and 2g stool from each participant.
~From the fifth month of investigation, an additional 30 adult participants will participate in oral anthropological, historical interviews to develop the socio-historical context of their changing activities and relations with selected domesticated and wild animals. No other intervention will be performed."
11109159|NCT04012138|Experimental|Salbutamol|Patients in this experimental group will receive : 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air);
11109160|NCT04012138|Active Comparator|Insuline + dextrose|Patients in the experimental group will receive : 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period
11109161|NCT04012138|Experimental|Insuline + Dextrose + Salbutamol|"Patients in the experimental group will receive either:
~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR
~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
11109162|NCT04012125|Experimental|Prospective, single-arm trial|
11109163|NCT04012112|Experimental|single-arm trials|longitudial study of the thoracolumbar brace in the neuromuscular scoliosis for 6 months
11109164|NCT04012099|Experimental|BMT101|BMT101 injection (treatment)
11109165|NCT04012099|No Intervention|control|Un-treated control
11109166|NCT04012086|Experimental|physical therapy (PT)|The physical therapy program consisted of 6 individual sessions/week, each lasting 60 minutes for 4 weeks in addition to their usual pharmacological therapy
11109167|NCT04012086|No Intervention|No physical therapy (CT)|Subjects in CT group received only standard medication.
11109168|NCT04012073|Experimental|IPERPEEP|"End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial.
~Set PEEP will be ≥5 cmH2O and chosen to ensure the maximum recruitment, with a maximum plateau pressure of 30 cmH2O. Recruitment across two adjacent PEEP levels will be normalized to the changes in applied PEEP: Recruitment/cmH2O (Rec) will be computed as the ratio of recruitment and PEEP difference.
~Rec ≥ 19 ml/cmH2O will lead to the higher PEEP value.
~Rec< 7 ml/cmH2O will lead to lower PEEP value.
~19 ml/cmH2O >Rec≥7ml/cmH2O: the choice among two adjacent PEEP levels will be left to the attending physician.
~In patients with airway closure, no PEEP lower than airway opening pressure will be tested or used (due to interferences with EELV measurement) for the whole duration of treatment. A 5-step PEEP trial will re-assess EELV at different PEEP levels every 12-24 hours,after body position or ventilator settings changes."
11109169|NCT04012073|Active Comparator|EXPRESS|PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O
11109170|NCT04012060|Active Comparator|Conventional group|All patients undergoing aortic valve replacement through full sternotomy.
11109171|NCT04012060|Experimental|Limited access group|All patients undergoing aortic valve replacement through partial upper hemisternotomy.
11109172|NCT04012060|Other|Registry group|"All patients unwilling or unable to participate in the randomized part of the trial.
~All patients will undergo aortic valve replacement through median full sternotomy."
11109173|NCT04012047|Active Comparator|Levcromakalim|
11109174|NCT04012047|Placebo Comparator|Saline|
11109175|NCT04012034|Experimental|Radiofrequency A|Treatment with radiofrequency
11109176|NCT04012034|Placebo Comparator|Placebo|Treatment with radiofrequency without energy
11109177|NCT04012021|Experimental|EX-VIVO SPECIMENS|"Three groups of ex-vivo surgical specimen:
~Group A: native livers in transplant recipients Group B: liver grafts excluded for donation Group C: primary pancreatic cancer"
11109178|NCT04012008|Active Comparator|Standard care|"Regular follow-up by internists every 3 month
~May consult nephrologists case-by-case"
11109179|NCT04012008|Experimental|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month
~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
11109180|NCT04011995|Experimental|Intermittent caloric restriction|
11109181|NCT04011995|Active Comparator|Low carbohydrate diet|
11109182|NCT04011969||Colorectal cancer suspects|Patients suspected with colorectal cancer who come to our hospital to conduct colonoscopy procedure will be recruited for this study and will undergo a series of examinations.
11109183|NCT04011956||Retrospective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures from 2002 to Feb 28th 2019 were recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
11109184|NCT04011956||Perspective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures after Mar. 1st 2019 will be recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
11109185|NCT04011943|Experimental|Participants with bowel diseases|Treatment by transplantation of fecal microbiota
11109186|NCT04011943|Experimental|autologous transplantation of fecal microbiota - healthy|Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)
11109187|NCT04011943|Experimental|Both autologous and heterologous transplantation - healthy|Healthy volunteers will receive both autologous and heterologous transplantation (capsules)
11109188|NCT04011943|Placebo Comparator|placebo capsules - healthy|Healthy volunteers will receive placebo capsules
11109189|NCT04011930|Active Comparator|Experimental study|"vitamin D Generic name -cholecalciferol (40,000IU)Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks.
~Drug cholecalciferol- ingredients -cholecalciferol (40,000 IU) Microcrystalline cellulose(58.1 gm),hydroxy toluene (.2mg),magnesium stearate(3mg0,gelatin capsule shell(1mg)
~other name D-rise"
11109190|NCT04011930|Placebo Comparator|Experimental control|"Placebo oral capsule Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks
~placebo oral capsule-ingredients-microcrystalline cellulose,butylated hydroxy toluene
~,magnesium stearate
~other name D-rise"
11109191|NCT04011917||Caseload group|
11109192|NCT04011917||Prediction group|
11109193|NCT04011904|Experimental|Traditional Inuit Diet|This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%).
11109194|NCT04011904|Placebo Comparator|Westernized Diet|This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%).
11109195|NCT04011891|Active Comparator|Robotic Partial Nephrectomy|Partial nephrectomy performed using the DaVinci robotic surgical system.
11109196|NCT04011891|Active Comparator|Open Partial Nephrectomy|Partial nephrectomy performed using the open approach.
11109197|NCT04011878|Experimental|isolated trabeculodysgensis|etiology of primary congenital glaucoma
11109198|NCT04011865|Active Comparator|Robotic-assisted surgery|
11109199|NCT04011865|Sham Comparator|Laparoscopic surgery|
11109200|NCT04011813||"Control arm, H-"|semen treated without hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
11109201|NCT04011813||"Experimental arm, H+"|semen treated with a 50mM hypotaurine supplementation in density gradient centrifugation, washing and cryopreservation media
11109202|NCT04011800|Active Comparator|Catheter ablation|Patients will undergo catheter ablation of atrial fibrillation.
11109203|NCT04011800|Experimental|Risk factor modification|Patiemt will undergo risk factor intervention (dietary intervention, physical intervention, alcohol reduction or abstinence)
11109204|NCT04011787|Active Comparator|Intervention|bolus NGT feeding
11109205|NCT04011787|Other|Control|Continuous NGT feeding (standard care)
11109206|NCT04011774|Experimental|PLANI-REV|Persons with schizophrenia who will benefit from the fifteen weekly sessions of PLANI-REV group program
11109207|NCT04011774|Active Comparator|RELAXATION|Persons with schizophrenia who will benefit from a non cognitive stimulation, namely RELAXATION, in a day-care clinic or day-care therapeutic activities center during fifteen weekly sessions. This activity will be 15 groups sessions of relaxation.
11109208|NCT04011761|Active Comparator|Experimental Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
11109209|NCT04011761|No Intervention|Control Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the control arm will receive treatment prescribed by pediatricians.
11109210|NCT04011748|Experimental|Haire regrowth by SCE and minoxidil therapy|AA subjects will receive Stem Cell Educator therapy combined with oral minoxidil. Hair regrowth will be evaluated during one-year follow-up studies.
11109211|NCT04011735||Respimat SMI-experienced|patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry
11109212|NCT04011735||Respimat SMI-naïve|patients who have not previously used a Respimat SMI product and receive their first prescription at study entry
11109213|NCT04011722|Experimental|Portico™ NG valve, FlexNav™ Delivery System|Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)
11109214|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2A|Subjects who carried out 3 attempts at Visit 1, failed to achieve nebulization success and subsequently were included in Test Arm 2A for Visit 2
11109215|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2B|Subjects who carried out 3 attempts at Visit 1, achieved nebulization success and were subsequently included in Test Arm 2B for Visit 2
11109216|NCT04011670|Active Comparator|Caffeine group|Participants will receive a caffeine tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
11109217|NCT04011670|Placebo Comparator|Placebo group|Participants will receive a placebo tablet and all electrical stimulations in a random order (tACS 140 Hz at 1 mA and sham tACS). Participant's vigilance status will be monitor based on active vigilance condition or passive vigilance condition.
11109218|NCT04011657|Experimental|Voluntary CDSS|Voluntary use of computerized decision support with prospective review and feedback
11109219|NCT04011657|No Intervention|Compulsory CDSS|Compulsory use of computerized decision support with prospective review and feedback
11109220|NCT04011644|Active Comparator|Self monitored|"Patients of this group will continue receiving regular care from their physician with no interference from the two experimental groups. Patient subjects will download the app on their Android or Apple smart phone that will direct them to external information hosted on the internet that may help reduce their drinking (e.g., NIAAA resources). For the first 12 weeks, once a week patients can set a weekly goal related to their alcohol use or other health related behaviors (e.g., I will only drink on Friday this week.). At the end of the week subjects will be prompted to take a weekly survey, which will include questions such as a variation of the brief alcohol monitor (BAM) and timeline followback. Patients will then receive feedback on the amount of drinks they had compared to their goal. Then the patient will set a new goal for the following week. Patients will complete quarterly surveys on the A-CHESS app to assess study outcomes."
11109221|NCT04011644|Experimental|Peer supported|Patients will be asked to take the same surveys and have the access to the same information as the self-monitoring group. Patient subjects in this group will have access to discussion boards where they can talk to one another and have the ability to share and see stories of other patients. The only involvement of someone other than patients themselves in the peer-supported group will be by a sponsor (i.e., a dedicated user from the area with a sustained history of successful alcohol reduction). The sponsor will participate in discussion groups and encourage use of the system. Patient-reported feedback will be presented directly to the patient.
11109222|NCT04011644|Experimental|Clinically integrated|Patients in the clinically integrated group will receive the same intervention as the peer-supported group aside from three differences: 1) patients have the option to share selected elements of their app data with the University of Wisconsin (UW) Health health coach, 2) the health coach will replace the role of the sponsor in the peer-support group, and 3) patients will have the option to attend an initial 60- to 90-minute and two 30-minute follow-up consultations with the health coach in-person, via phone, or via video chat.
11109223|NCT04011631|Experimental|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
11109224|NCT04011618|Placebo Comparator|Placebo|16 patients to receive 1 homologated placebo capsule (calcinated magnesia 500 mg) every 12 hours along 12 weeks
11109225|NCT04011618|Experimental|Ellagic acid|16 patients to receive 1 homologated intervention capsule (ellagic acid 500 mg) every 12 hours along 12 weeks
11109226|NCT04011592|Experimental|Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
11109227|NCT04011592|Experimental|Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)
11109228|NCT04011579|Experimental|MSFIT|The MSFIT group will self-manage Pilates exercises at-home through a tool based on XBox Kinect for 12 weeks, performing at least 3 sessions/week for a total of 30 minutes of exercises for each session(also distributed during the day with a minimum slot of 10 minutes). No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
11109229|NCT04011579|No Intervention|CTRL|No rehabilitative interventions except sphincter and speech rehabilitation and psychological support, are admitted for the 12 weeks of participation to the project and the following 6 weeks before Follow-up evaluations (a total of 18 weeks). The execution of unspecific physical activities, if not already practiced, will be suggested to the participants.
11109230|NCT04011566||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
11109231|NCT04011553|Experimental|Virtual group|This virtual realtiy was implemented with MarVAJED® (Marmara Visual Auditory Joint Education Device) system which was developed by Marmara University, Department of Physiotherapy and Rehabilitation, Istanbul,Turkey. MarVAJED® is a system that evaulates the range of motion of the joints, analyzes the sensation of joint position, provides biofeedback support to increase joint control and the same time allows exercises to be controlled. This device analyzes the joint motion with the help of small sensors (Figure 2). The obtained data transfers to your mobile phone, to the tablet or to your personal computer. It stores the data by downloading it to the central server via internet for storage.
11109232|NCT04011553|Active Comparator|Control group|Conventional physiotherapy consists of electrotherapy and exercise programs. Hotpack or coldpack, therapeutic ultrasound (US) and conventional TENS were applied as electrotherapy program.
11109233|NCT04011540|Experimental|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
11109234|NCT04011540|No Intervention|Usual Care|Usual care
11109235|NCT04011527||Patients with Coronary Artery Disease|Patients with Coronary Artery Disease undergoing a Rotational Atherectomy in Coronary Lesion/s
11109236|NCT04011514||Baseline period|Usual care. Stroke patients admitted to the ED during the 3-month baseline inclusion period.
11109237|NCT04011514||Intervention period|Intervention: 2 month implementation period of specialized stroke nurses allocated to ED for nurse specific treatment of stroke patients specific observations and care
11109238|NCT04011501|Experimental|Continuous unilateral ESP block|Erector spine block and catheter placement will be performed for continuous analgesia on this group of patients undergoing minimally invasive cardiac surgery. Initially a volume of 20 ml of Levobupivacaine 0.25% will be administered and subsequently a 22G catheter will be introduced and fixed 10-12 cm from the skin. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
11109239|NCT04011488|No Intervention|Standard patient information data sheet|
11109240|NCT04011488|Experimental|SDM Tool|A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).
11109241|NCT04011475||Subjects with Tiotropium and Olodaterol|
11109242|NCT04011475||Subjects treated with other LABA/LAMA therapy|
11109243|NCT04011475||Subjects treated with LAMA therapy|
11109244|NCT04011462|Experimental|Prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
11109245|NCT04011462|Experimental|Prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
11109246|NCT04011462|No Intervention|Standard care|warming with cotton sheet and blanket for 20 minutes.
11109247|NCT04011449|Experimental|Device Implantation|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
11109248|NCT04011436|Experimental|Core, Hip and knee.|Physical Exercises to strengthen the core, hip and knee.
11109249|NCT04011436|Sham Comparator|Hip and Knee|Physical Exercises to strengthen the hip and knee.
11109250|NCT04011423|Experimental|Unstable shoes|Wearing unstable shoes during the whole-body vibration training
11109251|NCT04011423|Active Comparator|Stable shoes|Wearing stable shoes during the whole-body vibration training
11109252|NCT04011410|Experimental|Hydroxychloroquine|"Hydroxychloroquine (HCQ)
~DOSAGE FORM: 200 mg tablet, oral route
~DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg
~FREQUENCY: HCQ is taken twice daily (morning and night) with food.
~DURACTION OF HCQ: 90-days"
11109253|NCT04011397|Experimental|Intervention group|Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment. [low recruitment prohibited control arm]
11109254|NCT04011384|No Intervention|Control Group|Participants in this arm will view the typical web-based ordering system platform (usual care group).
11109255|NCT04011384|Experimental|Behavioral Economic Intervention Group|Participants in this arm will be exposed to the web-based ordering system with multiple behavioral economic interventions applied, including healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
11109256|NCT04011371|Experimental|Cyanoacrylate closure|Subjects enrolled in the study will undergo ultrasound guided vein closure using the VenaSealTM cyanoacrylate delivery device.
11109257|NCT04011358|Other|Patient|Patient with Retinal Vein Occlusion
11109258|NCT04011358|Other|Patient control|Patient with no Retinal Vein Occlusion
11109259|NCT04011345|Other|Folic Acid Supplement [Phase 1]|Phase 1: Folic acid supplement (1 mg per day) for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Placebo for 12 weeks
11109260|NCT04011345|Other|Placebo [Phase 1]|Phase 1: Placebo for 12 weeks; Phase 2: Wash-out period (no supplement or placebo) for 12 weeks; Phase 3: Folic acid supplement (1 mg per day) for 12 weeks
11109261|NCT04011332|Experimental|Intervention Group|
11109262|NCT04011332|No Intervention|Control Group|
11109263|NCT04011319|No Intervention|convention culture|Each droplet separate culturing an individual embryo.
11109264|NCT04011319|Experimental|group culture|Embryos were cultured in the same droplet.
11109265|NCT04011306|Experimental|Lumina24 BLU|Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.
11109266|NCT04011293|Experimental|A|Single dose of CNCT19
11109267|NCT04011280|Experimental|Low Dose Varenicline|0.5 mg twice daily with 0.5 mg daily titration over one full week
11109268|NCT04011280|Active Comparator|Standard Dose Varenicline|1.0 mg twice daily with standard titration
11109269|NCT04011267|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in the SOPeD software three times/week at home via web-software. In the follow-up period, patients will follow the same schedule set by the project till the end of the study.
11109270|NCT04011267|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
11109271|NCT04011254||Healthy Control|Healthy control
11109272|NCT04011254||Haemodialysis %IDWG >4%|Patient on regular haemodialysis with average IDWG >4%
11109273|NCT04011254||Haemodialysis %IDWG <4%|Patient on regular haemodialysis with average IDWG <4%
11109274|NCT04011241|Experimental|Reference - BI 1323495 alone|Reference followed by Test
11109275|NCT04011241|Experimental|Test - BI 1323495 + Itraconazole|
11109276|NCT04011228||Type 2 diabetic patients|
11109277|NCT04011228||Prediabetic patients|
11109278|NCT04011228||Women with gestational diabetes|
11109279|NCT04011228||Healthy control subjects|
11109280|NCT04011228||Pregnant women without gestational diabetes|
11109281|NCT04011215|Experimental|wool-first (wool X standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing
11109282|NCT04011215|Active Comparator|standard-first (standard X wool)|standard clothing to be worn for 6 weeks followed by 6 weeks of superfine merino wool clothing
11109283|NCT04011202|Experimental|VR Group|Receives the VR protocol
11109284|NCT04011202|No Intervention|Control Group|Receives regular care
11109285|NCT04011189|Experimental|Videotaping|"Upon successful recruitment of the study, patients will be asked to complete 2 questionnaires and rate their pre-surgical pain on the numerical rating scale in the pre-anaesthetic evaluation clinic. Their face and body pose from a frontal view will be videotaped.
~The general anaesthesia technique and type of analgesia administered intra-operatively will be according to standard practice and is at the discretion of the attending anaesthesiologist. After surgery, patients will be reviewed at 12-36 hrs, 36 hrs till before discharge post-operatively in the ward. They will be asked to rate their pain scores and videotaping will be done from a frontal view."
11109286|NCT04011176|Placebo Comparator|Standard treatment + placebo|Placing the microcurrent pads on the patient but not turning on the microcurrent box for 30 minutes once a week for 6 weeks
11109287|NCT04011176|Experimental|Standard treatment + Microcurrent Therapy|100-300µA microcurrent delivered for 20-300 minutes, once a week for 6 weeks
11109288|NCT04011163|Experimental|VPIA analgesia|VPIA pump will be connected to patients after surgery for up to three days. The vital signs (oxygen saturation, respiratory rate, heart rate) will be closely monitored when patients are using VPIA pump. Intravenous medication (morphine) will be given intravenously.
11109289|NCT04011150|Experimental|Variable volume Automated Mandatory Bolus (VVAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
11109290|NCT04011150|Active Comparator|Automated mandatory bolus (AMB) of variable-frequency (VAMB)|The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.
11109291|NCT04011137|No Intervention|Control|No exercise - 30-min of rest
11109292|NCT04011137|Experimental|High-intensity interval training|8 x 60 s intervals at 70% peak power output (intersperesed with 60 s recovery intervals at 10% peak power output)
11109293|NCT04011137|Experimental|Moderate-intensity continous training|25 min at 45% peak power output
11109294|NCT04011124|Experimental|Rifampicin + Fluzoparib|
11109295|NCT04011098|Active Comparator|Control Group (No Additional Epidural Fentanyl Bolus)|The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
11109296|NCT04011098|Experimental|Fentanyl bolus group|The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
11109297|NCT04011085||Group1|Patients currently undergoing treatment for early breast cancer (either targeted HER2 therapy and chemotherapy OR targeted HER therapy alone)
11109298|NCT04011085||Group2|Patients with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving locoregional treatment, chemotherapy or targeted HER2 therapy; patients may still be receiving hormone therapy)
11109299|NCT04011085||Group3|Patients receiving treatment for metastatic breast cancer
11109300|NCT04011072|Active Comparator|Infrared treatment arm|Far infrared radiation will be given for 40 minutes on the skin above the patients fistula in each dialysis session for one year
11109301|NCT04011072|No Intervention|Control arm|The control group will not receive any intervention, but will be followed with the same data as the treatment group
11109302|NCT04011059|Placebo Comparator|Comparison/control group|Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.
11109303|NCT04011059|Active Comparator|Experimental group|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed.
11109304|NCT04011033|Experimental|TACE+iNKT for unresectable HCC|TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TACE will be performed at 0th and 4th week. 5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
11109305|NCT04011033|Other|TACE for unresectable HCC|TACE will be conducted at 0th week and 4th week.
11109306|NCT04011020|Experimental|Treatment of T1D with Stem Cell Educator therapy|Recruited T1D subjects will receive one treatment with SCE therapy.
11109307|NCT04011007|Active Comparator|vitrectomy without ILM peeling|vitrectomy without ILM peeling
11109308|NCT04011007|Active Comparator|vitrectomy with inverted ILM flap technique|vitrectomy with inverted ILM flap technique
11109309|NCT04010994|Other|rtACS|repetitive transorbital ACS
11109310|NCT04010981|Experimental|study grup-Virtual reality- Nintendo Wii Fit exercise group|in this group patients will complete 12 sessions of virtual reality exercise - Nintendo Wii Fit Plus, 30-minute training sessions with strengthening exercises for the lower extremities and upper extremities, aerobic and balance exercises, two days a week. They will do 5 minute warm-up exercises before stretching, stretching exercises and 5 minute cooling exercises at the end of the session, as well as breathing exercises and will attend a total of 50 minutes of treatment.
11109311|NCT04010981|Active Comparator|control group-home based video exercise group|Patients will be join home based exercises two days a week during 12 sessions .we will prepare for the lower and upper extremity features similar to Nintendo Wii Fit exercises 30 minutes of video game exercise practices, 5 minutes warm-up exercises, 5 minutes cooling exercises and complete the 50-minute training session with the breathing exercises we will teach them. In addition to exercise sessions, patients will record their activities (walking, cycling, swimming ına) in daily life schedules with their pedometers. Thus, changes in physical activity levels will be monitored.
11109312|NCT04010968|Active Comparator|FCR|"FCR :
~rituximab (R): 375 mg/m² IV D1 cycle 1 and 500 mg/m² IV D1 cycles 2 to 6.
~fludarabine (F): 40 mg/m² orally, D2 to D4 - cycles 1 to 6.
~cyclophosphamide (C): 250 mg/m² orally, D2 to D4 - cycles 1 to 6."
11109313|NCT04010968|Experimental|venetoclax and ibrutinib (I+VEN)|"ibrutinib: 420 mg/d orally, continuously from Month 1 to the end of treatment, either Month 15 or Month 27
~venetoclax: stepwise weekly dose ramp-up beginning at Month 4 from a starting dose of 20 mg/d to the final dose of 400 mg/d (20, 50, 100, 200 and then 400 mg) over a 5 weeks, and then 400 mg/d continuously from Month 5 to the end of treatment, either Month 15 or Month 27."
11109314|NCT04010955||Edoxaban Monotherapy|"edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.
~However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians."
11109315|NCT04010955||Edoxaban and antiplatelet combination|edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.
11109316|NCT04010942|Active Comparator|Vitamin D|"Group V : number of 60 women will receive 100000 IU Cholecalciferol Intramuscular every month + 2000 mg Metformin (oral: 2 tablets 1000 per day) for 5 months .
~-after two months from the start:
~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day,from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
11109317|NCT04010942|Placebo Comparator|Control|"Group C: number of 60 patients will receive Metformin 2000mg (oral: 2 tablets1000 mg per day) for months .
~-after two months from the start:
~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day, from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
11109318|NCT04010929|Experimental|Laser+MTA group|before the MTA condensation, Er, Cr: YSGG laser was applied to the exposure area
11109319|NCT04010929|Active Comparator|MTA group|MTA was applied to the exposed area
11109320|NCT04010916|Active Comparator|Group Pre = preoperatively before inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
11109321|NCT04010916|Active Comparator|Group Pre-T = preoperatively after inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
11109322|NCT04010916|Active Comparator|Group Post = Postoperatively group|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
11109323|NCT04010903|Experimental|HEALTHY SUBJECTS|SUBJECTS WITH BMI<27 and HOMA<4
11109324|NCT04010903|Experimental|OVERWEIGHT NON INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA<4
11109325|NCT04010903|Experimental|OVERWEIGHT INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA>4
11109326|NCT04010890|Experimental|Culturally adapted CBT|Ca_CBT will be delivered to the experimental group using the newly developed manual . The intervention will be delivered over 8-12 sessions. The Control group will receive standard CBT
11109327|NCT04010890|Active Comparator|Standard CBT|Participants in this group will receive standard CBT
11109328|NCT04010877|Experimental|Multiple CAR T cells to treat AML|Multiple CAR T cells to treat AML
11109329|NCT04010864||SHARP-2|ShangHai At Risk for Psychosis-Phase 2
11109351|NCT04010669|Placebo Comparator|Control group|The control group includes participants who will receive placebo (a 24 hours infusion of 1000ml Normal Saline solution 0.9%) postoperatively (after liver resection).
11109422|NCT04010162||Group-1: King's College Hospital|Doctors in King's College Hospital, London, The United Kingdom (Excluding Urology and Gynecology)
11109330|NCT04010851|Experimental|Peer co-led educational group|The intervention delivered in a group format is added to treatment as usual. After the parents participate in the one day-intervention, they can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence.
11109331|NCT04010851|Other|Control group|The control goup will receive treatment as usual.
11109332|NCT04010838|No Intervention|Conventional treatment|
11109333|NCT04010838|Experimental|Spinal cord stimulation and conventional treatment|
11109334|NCT04010825|Experimental|Hypnosis Arm|"In parallel with an inpatient pulmonary rehabilitation program, nine visits will be carried out :
~V0 : an inclusion visit
~V1 : a randomization visit
~V2 to V6 : five visits with hypnosis sessions
~V7 : a end-stay visit
~V8 : a 6-month post-rehabilitation visit ( by phone call)
~The five hypnosis sessions (V2 to V6) will be spread over three weeks of rehabilitation program (1 to 2 hypnosis sessions per week).
~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
11109335|NCT04010825|No Intervention|Control Arm|"In parallel with an inpatient pulmonary rehabilitation program, no additional intervention will be carry out and four visits will be carried out :
~V0 : an inclusion visit
~V1 : a randomization visit
~V7 : a end-stay visit
~V8 : a 6-month post-rehabilitation visit ( by phone call)
~For V1, V7 and V8 : questionnaires will be filled about : quality of life (CAT questionnaire), the three dimensions of dyspnea (mMRC, LCADL and MDP questionnaires), anxiety and depression (HADS questionnaire), post-traumatic stress ( PCLS questionnaire), sedentarity and physical activity (SIMPAQ questionnaire). Other data will be also collected on : previous experiences with hypnosis, self-hypnosis and relaxation, number of exacerbations and hospitalizations in the past 6 months, drug treatment, psychotropic drug use and dosage and psychological follow-up."
11109336|NCT04010799|Experimental|CHF6333|"CHF6333 Active (part I - SAD). Once daily inhaled single dose of CHF6333 at each period (three dose level).
~CHF6333 Active (part II -MD). Once daily inhaled multiple dose of CHF6333 for 7 consecutive days."
11109337|NCT04010799|Placebo Comparator|CHF6333 Placebo|"Part I (SAD): Single dose of placebo matching CHF6333 at each period
~Part II (MD): Once daily multiple doses of placebo matching CHF6333 for 7 consecutive days"
11109338|NCT04010786|Experimental|Active treatment NNC0247-0829|Up to 6 single dose cohorts are planned with 10 subjects in each; 8 will receive active treatment. Up to 2 multiple dose cohorts are planned with 12 subjects in each; 8 will receive active treatment
11109339|NCT04010786|Placebo Comparator|Placebo|In each of the 6 single dose cohorts, 2 subjects will receive placebo. In the 2 multiple dose cohorts, 4 subjects will receive placebo
11109340|NCT04010760||PE confirmed|Patients admitted with confirmed pulmonary embolism.
11109341|NCT04010760||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
11109342|NCT04010760||Controls|Healthy controls same gender and age (within af range of 10 years) as PE patients
11109343|NCT04010747|Experimental|Motivational Interviewing for Loved Ones (MILO)|"MILO consists of four sessions of coaching in communication skills called motivational interviewing. Participants meet with a trainer/therapist for each session. At the first session, participants learn about the ideas behind motivational interviewing. In the second session, participants practice motivational interviewing skills. In the third and fourth sessions, the participant and therapist discuss the participant's efforts to communicate with their loved one using MI skills. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one."
11109344|NCT04010747|Active Comparator|Mental Health Services Consultation|This consultation will consist of a 30-45 minute appointment in which participants can meet with a clinician knowledgeable about psychosis treatment resources in their area. He/she can recommend specific programs, educational websites, and/or support groups that might be relevant for the participant's family. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one.
11109345|NCT04010734|Active Comparator|peroral Cholangioscopy examination|"Patient with suspected malignant biliary stricture (SMBS) is allowed:
~to the peroral Cholangioscopy examination with both visual and tissue diagnosis. The visual diagnosis is based on morphological and vascular patterns (presence or not of nodular or papilary masses, irregularity of the surface, morphology of the vessels and the fragility of mucosa). The tissue diagnosis consists on cytopathological evaluation after tissue sampling using minuature biopsy forceps (SpyBite). During this, 5-8 samples are taken under visual control, from different parts of the lesion."
11109346|NCT04010734|Active Comparator|ERCP examination with sampling|"Patient with suspected malignant biliary stricture (SMBS) is allowed:
~to ERCP examination with both sampling by brushing and forceps biopsy, with subsequent pathological evaluation and an additional fluorescence in situ hybridization(FISH) examination of the specimens.
~ERCP (Endoscopic retrograde cholangiopancreatography) is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Brushing and endocanal forceps biopsies were the most used techniques, both with different specificity and sensitivity. It was demonstrated that Fluorescence in Situ Hybridization (FISH) improved the diagnostic yield of routine cytology. That is the reason why the investigators will combine FISH with the sampling methods to maximize the chance to make early diagnosis of the biliary stenosis."
11109347|NCT04010721|Other|Experimental : experiment 1,2 and 3|"One user included participates all experiments:
~Visit 1 : experiment 1
~Visit 2 : experiment 2
~Visit 3 : experiment 3"
11109348|NCT04010708||IOMUM|Pregnant women
11109349|NCT04010695|Other|screening with STANDARD G6PD Test|all participants recruited in the study will be screened with an investigational IVD- STANDARD G6PD Test. The investigational test will not be used to determine any treatment or case-management
11109350|NCT04010669|Active Comparator|Study group|The study group includes participants who will receive somatostatin postoperatively (after liver resection).
11109419|NCT04010175|Active Comparator|Control group|
11109352|NCT04010656|Experimental|PVR-based home self-catheterization|Patients will learn to self-catheterize preoperatively prior to urogynecology surgery requiring trial of void. First post-operative void will be used to collect basic information about voiding function. All participants will leave the hospital and self-catheterize until they achieve two sequential voids with post-void residual (PVR) less than half the volume voided. The cases of urinary retention captured with abnormal PVR will be used to compare the diagnostic accuracy of several commonly-used, pre-defined parameters for trial of void.
11109353|NCT04010643|Active Comparator|online cognitive behavioural therapy (oCBT)|"20 hours of online engagement with the oCBT programme over 5 weeks, distributed as follows.
~Each week, the participants complete 1 hour of of the MoodGym program, followed by 2 hours of practical online CBT homework. To equate time and type of engagement spent in doing oCBT and oCBT+NCRT, 1 final hour per week is dedicated to completing online puzzles."
11109354|NCT04010643|Experimental|online neurocognitively-enhanced CBT (oCBT+oNCRT)|"20 hours of online engagement with the oCBT+oNCRT programme over 5 weeks, distributed as follows.
~Each week, the participants complete 1 hour of the MoodGym program, followed by 1 hour of practical online CBT homework & 3 hours of the online NCRT programme Cognifit targeting attention, memory, and planning ability."
11109355|NCT04010630|No Intervention|control group|The physicians will resuscitate the patients according to the current critical care medicine guidelines.
11109356|NCT04010630|Experimental|Sodium bicarbonate group|Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion
11109357|NCT04010617|Experimental|Pharyngeal Electrical Stimulation|Orotracheal intubated patients at high risk of extubation failure will receive open-label PES
11109358|NCT04010604||SMA type I|
11109359|NCT04010604||SMA type II|
11109360|NCT04010604||SMA type III|
11109361|NCT04010604||Asymptomatic carriers of SMA|
11109362|NCT04010604||Relatives of SMA patients and carriers|
11109363|NCT04010604||Unrelated healthy controls|
11109364|NCT04010591||UDS group|All enrolled patients with urodynamic study
11109365|NCT04010578|Experimental|Vitamin K2 supplementation|Patients will receive a daily vitamin K2 supplementation for 3 months.
11109366|NCT04010578|Placebo Comparator|Placebo|Patients will receive a daily placebo for 3 months.
11109367|NCT04010565|Experimental|Extract of aged black garlic|Participants will consume a tablet of 550 mg daily with 250 mg of aged black garlic extract and 300 mg of excipients (microcrystaline cellulose 90 mg; dicalcium phosphate 157 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg) .
11109368|NCT04010565|Placebo Comparator|Placebo|Participants will consume a tablet of 550 mg daily with 550 mg of excipients (microcrystaline cellulose 342.5 mg; dicalcium phosphate 154.5 mg; crosscamellose sodium 10 mg; magnesium stearate 7 mg; sodium alignate 3.06 mg; stearic acid 0.03 mg; oleic acid 1.54 mg; medium chain triglycerides 2.80 mg; ethylcellulose 13.17 mg; hydroxypropylcellulose 4.86 mg; hydroxypropylmethylcellulose 4.86 mg; talcum 2.88 mg; titanium dioxide 1.80 mg; vanilla aroma 1.00 mg).
11109369|NCT04010552|Experimental|NALIRINOX treatment|Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.
11109370|NCT04010539|Active Comparator|Gepotidacin|Subjects will receive Gepotidacin orally at the study site during the Baseline (Day 1) visit followed by self-administration of a second oral dose as an outpatient 6 to 12 hours after the first dose.
11109371|NCT04010539|Active Comparator|Ceftriaxone plus Azithromycin|Subjects will receive a single IM dose of Ceftriaxone plus a single oral dose of Azithromycin at the study site during the Baseline (Day 1) visit.
11109372|NCT04010526|Experimental|treatment|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
11109373|NCT04010526|Placebo Comparator|placebo|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
11109374|NCT04010513|Experimental|Hypnosis|
11109375|NCT04010513|Active Comparator|Standard of Care|
11109376|NCT04010500|Experimental|Rugby Players|
11109377|NCT04010487||Endometrial carcinoma arising in adenomyosis|Patients pathologically conformed endometrial carcinoma arising in adenomyosis (EC-AIA)
11109378|NCT04010487||Adenomyosis without malignancy|Patients pathologically diagnosed with adenomyosis
11109379|NCT04010461|Experimental|TMS to dlPFC, without a concurrent task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are in a resting state
11109380|NCT04010461|Experimental|TMS to vertex, without concurrent task|TMS (intermittent theta burst stimulation) will be applied to the cerebral vertex, when subjects are in a resting state
11109381|NCT04010461|Experimental|TMS to dlPFC, during task|TMS (intermittent theta burst stimulation) will be applied to the dlPFC, when subjects are engaged in the n-back working memory task
11109382|NCT04010448|Experimental|TV P2-VP8|
11109383|NCT04010448|Active Comparator|Rotarix®|
11109384|NCT04010435|Active Comparator|Group A (r TMS group)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises.
11109385|NCT04010435|Active Comparator|Group B (Galvanic stimulation)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo galvanic vestibular stimulation; in addition to designed vestibular rehabilitation exercises.
11109386|NCT04010435|No Intervention|Control (Group C)|Twenty randomly assigned patients with unilateral peripheral vestibular disorders will undergo designed vestibular rehabilitation exercises.
11109420|NCT04010175|Experimental|Experimental group 1|Moderate frequency cognitive distance training
11109387|NCT04010422||ASD group|"Inclusion Criteria:
~Having a clinical diagnosis of autism spectrum disorder
~Aged over 20 years; able to read and sign an informed consent form.
~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.
~Exclusion Criteria:
~Unable to cooperate with the examinations.
~Younger than 20 years old"
11109388|NCT04010422||TD Group|"Inclusion Criteria:
~Aged over 20 years; able to read and sign an informed consent form.
~Clear conscious and can follow the instruction of opening eyes and movement toward all direction.
~Exclusion Criteria:
~Unable to cooperate with the examinations.
~Younger than 20 years old.
~Having a clinical diagnosis of autism spectrum disorder"
11109389|NCT04010409||ASD Group|Autism spectrum disorder participants, no intervention
11109390|NCT04010409||TD Group|Typically developmental controls,no intervention
11109391|NCT04010396||Recipients of Bovine Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
11109392|NCT04010396||Recipients of Mechanical Graft|Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
11109393|NCT04010383||normal visual field subjects|"Cataract yes or no
~Age range 40 - 80 years
~normal visual field (MD: < +2 dB)
~Refractive error within ±5 dpt. spherical equivalent
~Astigmatism of < -3 dpt.
~Visual acuity of ≥0.3 logMar (decimal ≥0.5)
~Experience in perimetry (history of at least one perimetry examination)
~False positive or negative errors each less than 20% in each examination"
11109394|NCT04010383||Glaucomatous subjects|"Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma
~Early to moderate visual field loss (MD: +2 to +12 dB)
~Refractive error within ±5 dpt. spherical equivalent
~Astigmatism of < -3 dpt.
~Visual acuity of ≥0.3 logMar (decimal ≥0.5)
~Experience in perimetry (history of at least one perimetry examination)
~False positive or negative errors each less than 20% in each examination
~Cataract yes or no
~Age range 40 - 80 years"
11109395|NCT04010357|Experimental|Abemaciclib|"Subjects will receive Abemaciclib (200 mg), orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.
~Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment."
11109396|NCT04010344|Experimental|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
11109397|NCT04010344|Active Comparator|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
11109398|NCT04010331|Experimental|Nokyong Mixture Extract(CME-PI) group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
11109399|NCT04010331|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
11109400|NCT04010318||Corrected group|The patients in which the PVI will corrected by fluid to level below 15
11109401|NCT04010318||Uncorrected group|Patients in which intravenous fluid administration didn't result any change in PVI or changed but still higher than 15
11109402|NCT04010305|Placebo Comparator|Placebo|Sublingual Film with no active drug; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
11109403|NCT04010305|Experimental|20 micrograms|Sublingual Film containing 20 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
11109404|NCT04010305|Experimental|60 micrograms|Sublingual Film containing 60 micrograms BXCL501; single administration with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
11109405|NCT04010305|Experimental|120 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501; single administration of 2 films with the possibility of repeating dose after 1 hour in case of lack of significant efficacy
11109406|NCT04010305|Experimental|180 micrograms|2 Sublingual Films, each containing 60 micrograms BXCL501.
11109407|NCT04010292|Experimental|Patient education card|
11109408|NCT04010292|No Intervention|Control|
11109409|NCT04010279|Active Comparator|spontaneous breathing|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the spontaneous position.
11109410|NCT04010279|Active Comparator|spontaneous breathing with APL 5 cmH2O|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the 5 cmH2O position.
11109411|NCT04010279|Active Comparator|CPAP 5cmH2O PEEP|volunteers will breath via an anesthesia face mask spontaneously on the CPAP mode of the anesthesia workstation with 5 cmH2O PEEP.
11109412|NCT04010266|Active Comparator|Standard of care group|Receive standard of care for pain management, do not receive RelieVRx headset
11109413|NCT04010266|Experimental|Standard of care + RelieVRx group|Receive standard of care for pain management, plus RelieVRx headset
11109414|NCT04010253|Experimental|SIMEOX|
11109415|NCT04010253|Active Comparator|Autogenic Drainage|
11109416|NCT04010240||Retrospective cohort|For eligible subject, tumor material will be tested by immunohistochemistry (Pan-Trk ICH testing with mAb EPR17341).
11109417|NCT04010227|Experimental|Acceptance and Commitment Therapy|Patients and caregivers in the ACT arm will learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
11109418|NCT04010227|Active Comparator|Education/Support|Patients and caregivers in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
11109423|NCT04010162||Group-2: Uludag University Hospital|Doctors in Uludag University Hospital, Bursa, Turkey (Excluding Urology and Gynecology)
11109424|NCT04010162||Group-3: The United States|Doctors from The United States (Excluding Urology and Gynecology)
11109425|NCT04010162||Group-4: The World|Doctors from all over the world (Excluding Urology and Gynecology)
11109426|NCT04010149|Experimental|Active tDCS|During cognitive training in the first 2 weeks, participants will also received brain stimulation. The investigators will use a total current intensity of 2mA for 20 minutes, preceded by 30 seconds ramping up and followed by 30 seconds ramping down (total stimulation time = 21s).
11109427|NCT04010149|Sham Comparator|SHAM tDCS|During sham stimulation, concurrent with the cognitive training, The investigators will use the same setup as in the active condition but after ramping up, the current will be brought back to zero and the process repeated 30 seconds before the end of the 21 minutes time interval (total sham stimulation time = 21s).
11109428|NCT04010136|No Intervention|Control group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will be given no intervention
11109429|NCT04010136|Experimental|Identification tool group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive access to the Identification tool Supportive and Palliative Care Indicators Tool (SPICT-PT) with a brief training on how to use it.
11109430|NCT04010136|Experimental|Standard Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training according to the Center Healthcare Administrative Region standard model of training.
11109431|NCT04010136|Experimental|Clinical cases based Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training using a clinical cases based model.
11109432|NCT04010110||Patients on hydroxychloroquine|A data collection sheet was used to collect patient's information. All patients underwent a complete ophthalmic examination including assessment of visual acuity, anterior segment examination looking for corneal verticillata and a dilated fundus examination looking for retinal pigment epithelium (RPE) depigmentation either in a para-foveal or extra-macular distribution within the retina. Ancillary tests were done which included: visual field testing (10-2), spectral domain ocular coherence tomography (SDOCT). Fundus auto-fluorescence and mf-ERG were done if further ancillary testing was needed in doubtful cases or to confirm findings.
11109433|NCT04010097|Experimental|Horton group|The test involves chewing a chewing gum for 4 minutes plus a standard Horton disease diagnostic
11109434|NCT04010097|Active Comparator|N Horton Group|The test involves chewing a chewing gum for 4 minutes
11109435|NCT04010084|Placebo Comparator|Control group|
11109436|NCT04010084|Active Comparator|Laser group|
11109437|NCT04010071|Experimental|axitinib plus toripalimab|"Axitinib (Inlyta, Pfizer Inc.) is a novel oral angiogenesis inhibitor that selectively targets vascular endothelial growth factor (VEGFR) 1, 2 and 3.
~Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody."
11109438|NCT04010032|Experimental|PIEB (Programmed intermittent epidural bolus)|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)
11109439|NCT04010032|Active Comparator|CEI (Continuous epidural infusion)|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device
11109440|NCT04010019|Experimental|Enhanced Facebook Condition|The enhanced Facebook group will be moderated by clinicians and offer psychosocial pain management techniques.
11109441|NCT04010019|Active Comparator|Control Facebook Condition|In the control condition, there will be no outside intervention; rather, the investigators will instruct participants to offer mutual support for the duration of the group and will not comment further.
11109442|NCT04010006|Experimental|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
11109443|NCT04010006|Active Comparator|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
11109444|NCT04009993|Experimental|A-BIRTHPERFORM digital tool|interactive partogram that maternity care professionals of the experimental group use, in interactive and device will guide the professional thought the NICE guidelines on labour care
11109445|NCT04009993|No Intervention|control group with conventional partogram use|Conventional care in each participant hospital, with conventional partogram in each centre
11109446|NCT04009980|Experimental|OMK2 group|Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day
11109447|NCT04009980|Placebo Comparator|Placebo group|Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day
11109448|NCT04009967|Experimental|Prostate Cancer|Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
11109449|NCT04009954||Delayed transit|CRC patients with delayed gut transit recovery( first time defecation >3 day )
11109450|NCT04009954||Normal transit|CRC patients with normal gut transit recovery( first time defecation <=3 day )
11109451|NCT04009941|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
11109452|NCT04009928|Experimental|Active followed by sham stimulation|2 weeks of active stimulation of the medial forebrain bundle or subcallosal cingulate at the optimized stimulation settings derived during the open-label phase. After 1 week of washout period (with no stimulation), subjects undergo 2 weeks of sham stimulation
11109453|NCT04009928|Sham Comparator|Sham followed by active stimulation|"2 weeks of sham-stimulation, followed by 2 weeks of active stimulation, separated with 1 week washout period.
~This is a crossover study, patients will undergo both arms, the order of which they do is randomized."
11109454|NCT04009915|Experimental|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer
11109455|NCT04009915|Active Comparator|open surgery|Patients undergo a standard open operation for stage II-III lung cancer
11109456|NCT04009889|Active Comparator|verum|probiotic bland with 5 different lactobacilli
11109457|NCT04009889|Placebo Comparator|placebo|Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
11109458|NCT04009876|Experimental|Chemotherapy + Surgery|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection
11109459|NCT04009876|Experimental|Chemotherapy + Watch-and-wait|"Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and watch-and-wait surveillance protocol."
11109460|NCT04009863|Active Comparator|HIFU on NMNG|The patients with non-toxic multinodular goiter are assigned to have high intensity focused ultrasound treatment.
11109461|NCT04009863|Active Comparator|RAI on NMNG|The patients with non-toxic multinodular goiter are assigned to have radioactive iodine (i131) treatment.
11109462|NCT04009850|Experimental|Menthol e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a menthol flavored e-cigarette
11109463|NCT04009850|Experimental|Tobacco e-cigarette|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes and a tobacco flavored e-cigarette
11109464|NCT04009837|Experimental|HIP+|Hip-focused rehabilitation intervention
11109465|NCT04009837|Active Comparator|SFR|Spine-focused rehabilitation intervention
11109466|NCT04009824|Placebo Comparator|Group 1: Saline Placebo|Participants will receive placebo on Days 1 and 22.
11109467|NCT04009824|Experimental|Group 2: AGS-v PLUS Non-Adjuvanted|Participants will receive 1012 µg of unadjuvanted AGS-v PLUS vaccine on Days 1 and 22.
11109468|NCT04009824|Experimental|Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo|Participants will receive 1012 µg of AGS-v PLUS + Montanide ISA-51 on Day 1 and placebo on Day 22.
11109469|NCT04009824|Experimental|Group 4: AGS-v PLUS + Montanide ISA-51|Participants will receive 1012 µg of AGS-v PLUS + Montanide ISA-51 on Days 1 and 22.
11109470|NCT04009824|Experimental|Group 5: AGS-v PLUS + Alhydrogel® Adjuvant|Participants will receive 1012 µg of AGS-v PLUS + Alhydrogel® on Days 1 and 22.
11109471|NCT04009811|Experimental|Suersen obturator then membraneous obturator|
11109472|NCT04009811|Experimental|Membraneous obturator then Suersen obturator|
11109473|NCT04009772|Active Comparator|"Cefepime , Maxipime® 1 gm"|"Patient will receive Cefepime ,Maxipime® 1 gm IV during cesarean section just before skin incision"
11109474|NCT04009772|Active Comparator|"Cefuroxime, Zinnat® 1gm plus metronidazoleFlagyl® 500"|"Patient will receive Cefuroxime, Zinnat® 1gm ,and metronidazoleFlagyl® 500 IV; just before skin incision for emergency cesarean section"
11109475|NCT04009759|Active Comparator|Morphine|Morphine group (n=700), where patients will be treated with i.v. injection of Morphine 2,5 mg diluted in 10 ml of NaCl 0,9%. The treatment will be given during CPR as soon as possible.
11109476|NCT04009759|Active Comparator|Ketamine|Ketamine group (n=700), where patients will be treated with i.v. injection of Ketamine 50 mg diluted in 10 ml of NaCl 0,9%. The treatment will be given during CPR as soon as possible.
11109477|NCT04009759|Placebo Comparator|Saline|Control group (n=700), where patients will be treated with i.v. 10 ml of NaCl 0,9%. The treatment will be given during CPR as soon as possible.
11109478|NCT04009733|Experimental|Osteogenesis imperfecta type 1|Patients with OI type 1
11109479|NCT04009733|Experimental|Osteogenesis imperfecta type 3|Patients with OI type 3
11109480|NCT04009733|Active Comparator|Control population|The control population corresponds to a pre-existing serum collection of osteoarthritis cohorts (OFELY and MODAM for women, STRAMBO for men).
11109481|NCT04009707||patients with alcool use desorders|Patient cared for in the addictology department of the University Hospital of Nîmes
11109482|NCT04009694|Experimental|Pelvic Floor Muscle Training|"Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist.
~Participants will be assessed at weeks 0 / 4 / 10 & 16 and the outcome measures will be recorded at week 0 & week 16.
~During each assessment, participants will be educated regarding the anatomy of pelvic organ prolapses and the pelvic floor muscles. They will be taught how to contract their pelvic floor, offered a vaginal examination, given a personalised pelvic floor muscle training programme (including the Knack) - up to a ten second hold long contractions (x 10 repitations) and up to 10 quick contractions. They will also be taught a sub max contraction for up to 30 seconds, offered lifestyle management advice including avoiding heavy lifting or straining. A leaflet explaining the aforementioned information will also be provided at the initial assessment."
11109483|NCT04009681|Experimental|THOR-707 Monotherapy, Q2W|Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.
11109484|NCT04009681|Experimental|THOR-707 Monotherapy, Q3W|Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
11109485|NCT04009681|Experimental|THOR-707 in combination with a checkpoint inhibitor, Q3W|Dose Escalation: THOR-707 will be administered in sequential ascending doses in combination with a checkpoint inhibitor via IV administration Q3W until unacceptable toxicity, disease progression, or withdrawal of consent.
11109486|NCT04009681|Experimental|THOR-707 in combination with an anti-EGFR antibody, Q3W/QW|Dose Escalation: THOR-707 will be administered in sequential ascending doses in combination with an anti-EGFR antibody via IV administration Q3W/QW (respectively) until unacceptable toxicity, disease progression, or withdrawal of consent.
11109487|NCT04009668|Experimental|adalimumab|Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously
11109488|NCT04009655|Experimental|music therapy|The infant will receive music therapy over 3 consecutive days and will obtain standard care as usual
11109489|NCT04009655|No Intervention|control|The infant does not receive any sound emission because the headphone will be turned off and will obtain standard care as experimental
11109490|NCT04009642||Type 2 Diabetes|
11109491|NCT04009642||Non Diabetic|
11109492|NCT04009629|Experimental|Exercise|A single 15 minute bout of moderate intensity aerobic exercise.
11109493|NCT04009616|Experimental|Aloe Vera mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving aloe vera mouthwash by studying plaque, gingival and bleeding indices.
~the plaque will be accumulated for 3 days accumulation phase before applying aloe vera mouthwash for 5 days rinsing phase."
11109525|NCT04009395||Midwives|One-on-one in-depth interviewing or focus group discussions
11109494|NCT04009616|Experimental|Chlorhexidine mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving chlorhexidine mouthwash by studying plaque, gingival and bleeding indices.
~the plaque will be accumulated for 3 days accumulation phase before applying chlorhexidine mouthwash for 5 days rinsing phase."
11109495|NCT04009616|Placebo Comparator|Placebo mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving placebo mouthwash by studying plaque, gingival and bleeding indices.
~the plaque will be accumulated for 3 days accumulation phase before applying placebo mouthwash for 5 days rinsing phase."
11109496|NCT04009603|Active Comparator|Metformin|Group no 1(26 patients) Metformin tablets at a dose of 500mg BD for 12 weeks
11109497|NCT04009603|Experimental|Probiotic|Group no 2(26 patients): will be given probiotics alone at a dose of 180mg B.D for 12 weeks
11109498|NCT04009603|Experimental|Metformin and Probiotic|Group no 3(26 patients): will be given metformin 500mg B.D and probiotics 180mgram O.D. for 12 week
11109499|NCT04009590|Experimental|GROUP I (Quit4Health)|Participants utilize Quit4Health intervention that includes interactive features, coping strategies and games related to cigarettes and other tobacco products for 1 month.
11109500|NCT04009590|Active Comparator|Group II (educational booklet)|Participants read an educational booklet about cigarettes and other tobacco products for 1 month.
11109501|NCT04009577|Experimental|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
11109502|NCT04009577|Experimental|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
11109503|NCT04009577|Experimental|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
11109504|NCT04009564|Experimental|Date seeds filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 45 g of date seeds coffee in 280 ml of boiled water, coffee flavour and brown food colouring ( made using a filter coffee machine). it will be served in a paper cup with lid
11109505|NCT04009564|Experimental|Normal filtered coffee|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 6 g of coffee in 280 ml of boiled water (made using a filter coffee machine) it will be served in a paper cup with lid
11109506|NCT04009564|Placebo Comparator|Placebo|Each participant will consume this arm in a visit has been allocated by Latin Square randomisation order: 280 of boiled water, coffee flavour and brown food colouring it will be served in a paper cup with lid
11109507|NCT04009538|Experimental|COPD patients participated PR program|COPD patients participated first and second PR program
11109508|NCT04009525|Experimental|MSD-HSCT|matched sibling donors hematopoietic stem cell transplantation
11109509|NCT04009525|Experimental|URD-HSCT|unrelated donor hematopoietic stem cell transplantation
11109510|NCT04009525|Experimental|haplo-HSCT|haplo-identical hematopoietic stem cell transplantation
11109511|NCT04009512|Experimental|Primary Study Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
11109512|NCT04009512|Experimental|Expanded Use Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments. The expanded use arm provides broaden inclusion criteria to include select patients excluded from the primary study arm.
11109513|NCT04009499|Experimental|Bimekzumab dosage regimen|Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
11109514|NCT04009486|Experimental|Obstructive Sleep Apnea|Subjects will undergo 6 weeks of whole body vibration.
11109515|NCT04009473|Experimental|SEGOVA Intervention Group|Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.
11109516|NCT04009460|Experimental|Part A dose escalation|ES101 will be escalated in patients with advanced solid tumors.
11109517|NCT04009460|Experimental|Part B expansion|Subjects with solid tumors will be treated with single-agent ES101 at either specified dose levels or RP2D.
11109518|NCT04009447|Other|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) 6 sessions of Cognitive Behavioral Training for Insomnia (1 hour each).
11109519|NCT04009434|Other|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy
11109520|NCT04009434|Experimental|TAVI/MitraClip|Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.
11109521|NCT04009421||High and low coronary artery plaque burden|Patients with high plaque burden defined as plaque in >=4 segments of the coronary tree and low plaque burden as plaque in <4 segments of the coronary tree assessed by postprocessing of CT coronary angiography images and cardiovascular events and mortality.
11109522|NCT04009408|Experimental|EMST therapy|Participants use the EMST device as per study protocol, set to 50% of the patient's maximal expiratory pressure, as measured by handheld manometer.
11109523|NCT04009408|Sham Comparator|Sham EMST therapy|Participants use a sham EMST device that has the spring removed as per study protocol, with no significant airflow resistance.
11109524|NCT04009395||Pregnant women|One-on-one in-depth interviewing
11109526|NCT04009382|Experimental|Baduanjin Group|This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
11109527|NCT04009382|Active Comparator|Control Group|This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
11109528|NCT04009369|No Intervention|Emergency Physician Group|Usual care by the EP without the intervention of the ED PT.
11109529|NCT04009369|Experimental|Physical Therapist Group|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
11109530|NCT04009343|Active Comparator|Artemether-lumefantrine|Standard 6-dose regimen
11109531|NCT04009343|Experimental|Dihydroartemisinin-piperaquine|Standard 3-dose regimen
11109532|NCT04009330||Adults in the Intensive Care Setting|Adults in the Intensive Care Setting
11109533|NCT04009317|Experimental|TQ-B3139|TQ-B3139 tablet 600mg administered orally , twice daily in 28-day cycle.
11109534|NCT04009317|Active Comparator|Crizotinib|Crizotinib tablet 250mg administered orally, twice daily in 28-day cycle.
11109535|NCT04009304|Experimental|In-person|OSNAP intervention delivered to afterschool sites using an in-person train-the-trainer model implementation strategy
11109536|NCT04009304|Experimental|Online|OSNAP intervention delivered to afterschool sites using an online training model implementation strategy
11109537|NCT04009304|No Intervention|Control|
11109538|NCT04009291|Experimental|TransCon PTH 15 mcg|TransCon PTH 15 mcg delivered once daily by subcutaneous injection
11109539|NCT04009291|Experimental|TransCon PTH 18 mcg|TransCon PTH 18 mcg delivered once daily by subcutaneous injection
11109540|NCT04009291|Experimental|TransCon PTH 21 mcg|TransCon PTH 21 mcg delivered once daily by subcutaneous injection
11109541|NCT04009291|Placebo Comparator|Placebo|Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
11109542|NCT04009278|Experimental|1. Self-compression arm|Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
11109543|NCT04009278|No Intervention|2. Control arm|The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.
11109544|NCT04009265|Experimental|Chemotherapy|Docetaxel 75mg/m2, 3w, 2cycles. DDP 75mg/m2, 3wl, 2cycles.
11109545|NCT04009265|Experimental|Chemoradiotherapy|5040cGy, 180cGy/d, 28F Concurrent Docetaxel 60mg/m2, 3w, 2cycles DDP 60mg/m2, 3w, 2cycles
11109546|NCT04009265|No Intervention|Surgery alone|Surgery alone, no adjuvant treatment.
11109547|NCT04009252|Experimental|Intervention Group|3D model to be printed and used as teaching tool to discuss injury with patient as well as its associated long-term outcomes and potential complications. The operative plan will also be reviewed with the patient using the model as well as post-operative course (ie rehabilitation)
11109548|NCT04009252|No Intervention|Control Group|The CT image will be shown to the patients along with teaching
11109549|NCT04009239|Experimental|Early Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 1 hour after habitual wake time.
11109550|NCT04009239|Experimental|Mid-day Time Restricted Feeding|Consume meals for 7 days during an 8 hour window starting 6 hours after habitual wake time.
11109551|NCT04009226||Participants with GNE|
11109552|NCT04009213|Experimental|LiquiBand FIX8®|LiquiBand FIX8® is an n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
11109553|NCT04009213|Active Comparator|AbsorbaTack™|AbsorbaTack™ is an absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2
11109554|NCT04009200||circumcision|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.
~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
11109555|NCT04009200||inguinal hernia|"Modified Yale Preoperative Anxiety Scores (m-YPAS), Visual Analogue Scale Anxiety (VAS-anxiety) will be evaluated when patients are taken to the preoperative waiting room.
~After awakening, patients will be taken to the postoperative wake-up room where Pediatric Anesthesia Recovery Delirium Scores (PAED), Recovery Agitation 5-point Scores (EA), FLACC scores will be evaluated every 5 minutes and mean arterial pressure, pulse, SPO2 values will be recorded. Duration of stay in recovery unit will be recorded"
11109556|NCT04009187|Active Comparator|Training group|Training group will first receive 30 minutes of education about biomechanically efficient propulsion techniques. They will be tested on this knowledge to make sure participants understand the material. The participant then will be asked to come into the lab for 6 sessions of training, two times per week for three weeks. The training is an hour of the proper wheelchair propulsion techniques broken into 5 parts, 7 minutes each with breaks. Based on the motor learning principles, we gradually increase the components of the training by focusing either hand reaching toward the back of the wheel or hands reaching down toward the axle.
11109557|NCT04009187|Active Comparator|Control group|Control group will first receive 30 minutes of education about the biomechanically efficient propulsion. They will be tested on this knowledge to make sure participants understand the material. No further training will be implemented with this group.
11109558|NCT04009174|Experimental|Imaging Panel|Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.
11109559|NCT04009148||Successful Cascade Testing|Genetic counselor contacts relatives and offers participation in study. Relative accepts and genetic testing in performed.
11109560|NCT04009148||Relative Declines Genetic Testing|Genetic counselor contacts relatives and offers participation in study. Relative declines and genetic testing is not performed.
11109600|NCT04008953||Sixteen patients having end stage renal disease|Intravascular volume assessment in 16 pediatric patients under going renal transplant surgery using ultrasonography, CVP and echocardiography
11109561|NCT04009135|Experimental|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
11109562|NCT04009135|Experimental|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind & acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
11109563|NCT04009135|Placebo Comparator|Attention Control (AC)|Patients in the control condition will be given access online psychoeducation about depression and chronic pain. They will be provided weekly phone calls to query symptoms and well-being.
11109564|NCT04009122|Experimental|IGEN-0206|a sachet after each meal, preferably (3 sachets per day)
11109565|NCT04009122|Placebo Comparator|Placebo|a sachet after each meal, preferably (3 sachets per day)
11109566|NCT04009122|No Intervention|group C|standard treatment
11109567|NCT04009109|Experimental|Lenalidomide|12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
11109568|NCT04009109|Experimental|Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone|12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
11109569|NCT04009096|Experimental|Group 1|3 volunteers receiving one dose of 5 x 10^10 vp ChAd63 PvDBP and one dose of 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2 weeks later.
11109570|NCT04009096|Experimental|Group 2|12 volunteers receiving one dose of 5 x 10^10 vp ChAd63 PvDBP and one dose of 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen, followed by blood-stage CHMI 2 weeks later.
11109571|NCT04009083|Other|Standard of Care|
11109572|NCT04009083|Experimental|18F-Fluciclovine PET Scan|
11109573|NCT04009070|Active Comparator|Acupuncture|"Group A: Acupuncture group:Group A: Acupunctur will be applied to the Acupunctur group 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally on the tibia) . The tape (Needle Press) will stay for 24 hours.
~Needle Press: Pres Needle: 0.22x1.5 mm needle"
11109574|NCT04009070|No Intervention|Control Group|Group C: Control group
11109575|NCT04009057||B/F/TAF|HIV-1 infected adults who initiate B/F/TAF therapy
11109576|NCT04009044|Experimental|Treatment (afimoxifene)|Patients apply afimoxifene gel topically QD to both breasts for 4 weeks and then undergo core needle biopsies of both breasts.
11109577|NCT04009031|Experimental|Bootle Blast|"Bootle Blast is a series of 13 mini-games targeting different upper limb motor therapy goals. Bootle Blast is designed with many of the features of mainstream video games known to be appealing to young people. Game rewards are linked to meeting therapeutic objectives, such as daily play targets that are customizable to each child. Bootle Blast is played through movements of the upper limbs tracked via a low-cost camera/sensor (Microsoft Kinect, no hand-held controls needed). The movements required to play are customizable to each child's range of motion. Some of the mini-games are mixed reality, where children interact and manipulate real-life objects (e.g. musical instruments, coloured building blocks) to play the game. The use of skeletal tracking and mixed reality enables both gross and fine motor skills to be practiced in line with each child's therapy goals and motor abilities."
11109578|NCT04009018|Other|Psycometric analyses|It will be a validation study of the Perioperative Satisfaction Scale in Regional Anesthesia. This study is not experimental research. This is a psychometric assessment study of a questionnaire and data will collect pencil-paper survey and face to face from the patients who will get regional anesthesia in the postoperative second day.
11109579|NCT04009005|No Intervention|Usual care|Participants will receive usual care from their treating neurologist
11109580|NCT04009005|Experimental|Therapeutic Lifestyle|Participants will be trained via videos from a three day in-person seminar that teaches the public about the use of a therapeutic diet and lifestyle to reduce multiple sclerosis related fatigue and improve quality of life.
11109581|NCT04008992|Experimental|Part A SAD - A1 Cohort|Single Ascending Dose
11109582|NCT04008992|Experimental|Part A SAD - A2 Cohort|Single Ascending dose
11109583|NCT04008992|Experimental|Part A SAD- A3 Cohort|Single Ascending dose
11109584|NCT04008992|Experimental|Part A SAD- A4 Cohort|Single Ascending dose
11109585|NCT04008992|Experimental|Part A SAD - A5 Cohort|Single Ascending dose
11109586|NCT04008992|Experimental|Part A SAD- A6 Cohort|Single Ascending dose
11109587|NCT04008992|Experimental|Part B MAD- B1 Cohort|Multiple Ascending Dose
11109588|NCT04008992|Experimental|Part B MAD - B2 Cohort|Multiple Ascending Dose
11109589|NCT04008992|Experimental|Part B MAD - B3 Cohort|Multiple Ascending Dose
11109590|NCT04008992|Experimental|Part B MAD - B4 Cohort|Multiple Ascending Dose
11109591|NCT04008992|Experimental|Part C JMAD - C1 Cohort|Japanese Multiple Ascending Dose
11109592|NCT04008992|Experimental|Part C JMAD - C2 Cohort|Japanese Multiple Ascending Dose
11109593|NCT04008992|Experimental|Part C JMAD - C3 Cohort|Japanese Multiple Ascending Dose
11109594|NCT04008979|Experimental|PL-ASA 325 mg|Novel aspirin formulation being tested
11109595|NCT04008979|Active Comparator|IR 325 mg|Immediate release aspirin
11109596|NCT04008979|Experimental|PL-ASA-650|Novel aspirin formulation being tested
11109597|NCT04008979|Active Comparator|IR 650|Immediate release aspirin
11109598|NCT04008966|Active Comparator|single trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
11109599|NCT04008966|Active Comparator|Dual trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously
11109601|NCT04008927|Other|All patients|All participants recruited during the RDS survey.
11109602|NCT04008927|Other|HCV infected patients|HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL)
11109603|NCT04008927|Other|Patients with hepatitis C|Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.
11109604|NCT04008914||readmission at 30 days|
11109605|NCT04008914||readmission at 90 days|
11109606|NCT04008901|Active Comparator|Treatment group|The randomly assigned target was given a Lonicera Flos extract (BST104) 175 mg/day for eight weeks.
11109607|NCT04008901|Placebo Comparator|Placebo group|The randomly assigned target was given a placebo for eight weeks.
11109608|NCT04008888|Experimental|A:Allogeneic Stem Cell Transplant Group|Fludarabine+Melphalan followed by Allogeneic SCT.
11109609|NCT04008888|Experimental|B:Autologous Stem Cell Transplant|Melphalan followed by Autologous SCT.
11109610|NCT04008888|Experimental|C:Non-Transplant|Consolidated Chemotherapy for Patients Unable to Receive Transplantation
11109611|NCT04008875||Successful weaning/extubation|"Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.
~Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation."
11109612|NCT04008875||Failed weaning/extubation|"Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.
~Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy."
11109613|NCT04008862|Experimental|Partnership-based care|Each patient will serve as his/her own control
11109614|NCT04008849||Subjects treated with MGTA-456|MGTA-456 is an investigational expanded CD34+ cell therapy
11109615|NCT04008797|Experimental|Hepatocellular Carcinoma (HCC) Part|Participants with HCC will receive E7386 tablets, alone orally, once daily (QD) for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386 tablets, orally, QD in combination with lenvatinib capsules, orally, QD in 28-day treatment cycles until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
11109616|NCT04008797|Experimental|Other Solid Tumor (ST) Part|Participants with ST (except for HCC) will receive E7386 tablets, alone orally, QD for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386 tablets, orally, QD in combination with lenvatinib capsules, orally in 28-day treatment cycles until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 and lenvatinib will be based on the available safety data from the previous cohorts.
11109617|NCT04008784||Crisaborole 2% Topical Application Ointment [EUCRISA]|Crisaborole 2% Topical Application Ointment [EUCRISA] applied twice a day for 8 weeks
11109618|NCT04008784||Crisaborole 2% plus Triamcinolone Acetonide 0.1%Ointment|Crisaborole 2% plus Triamcinolone Acetonide 0.1% Ointment applied twice a day for the first 2 weeks, followed by Crisaborole 2% alone applied twice a day for the following 6 weeks
11109619|NCT04008771|Experimental|Severe Disease|Subjects with baseline BCVA between 20/16000 and hand motion (HM). Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
11109620|NCT04008771|Experimental|Moderate to Severe Disease|Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten [10]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
11109621|NCT04008758|Experimental|sono group|Evaluate the participant's lung condition using ultrasound and do recruitment maneuver if it is necessary
11109622|NCT04008758|No Intervention|control group|If participants need recruitment maneuver (decreasing saturation, peak airway pressure > 35 mmHg) by clinical judgement, do recruitment maneuver not using lung ultrasound
11109623|NCT04008745|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in an educational booklet three times/week at home. In the follow-up period, patients will follow the same schedule set by the project till the end of the study (16-weeks).
11109624|NCT04008745|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
11109625|NCT04008732|Experimental|MED2005 (0.6 mg)|MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study
11109626|NCT04008732|Experimental|MED2005 (1.2 mg)|MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study
11109627|NCT04008732|Experimental|MED2005 (1.8 mg)|MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study
11109628|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 1|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
11109629|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 2|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
11109630|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 1|MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study
11109631|NCT04008732|Active Comparator|Intravenous (I.V.) dose of GTN (0.3 mg)|GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study
11109632|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 2|MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study
11109633|NCT04008719|Other|Patients|Assessments are made by a psychiatrist
11109691|NCT04008251|Experimental|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
11109634|NCT04008706|Experimental|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive (TN) cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory (R/R) cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior Bruton tyrosine kinase inhibitor (BTKi) therapy cohort, up to 70 to 100 participants with Prior BTKi therapy will be enrolled.
11109635|NCT04008693|Active Comparator|Kyolic® Hi-Po Formula - Kyolic|Aged garlic extract
11109636|NCT04008693|Placebo Comparator|Placebo|Maltodextrin
11109637|NCT04008680|Other|Low response burden|36 item short form survey is placed 1st in a list of 7 questionnaires given.
11109638|NCT04008680|Other|Low to medium response burden|36 item short form survey is placed 3rd in a list of 7 questionnaires given.
11109639|NCT04008680|Other|Medium to high response burden|36 item short form survey is placed 5th in a list of 7 questionnaires given.
11109640|NCT04008680|Other|High response burden|36 item short form survey is placed 7th in a list of 7 questionnaires given.
11109641|NCT04008667|Experimental|Intervention arm|"Receiving the acupoint application and optimal supports.
~The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
11109642|NCT04008667|Placebo Comparator|Placebo arm|"Receiving the fake acupoint application and optimal supports.
~The fake acupoint is
~The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
11109643|NCT04008667|No Intervention|Control arm|"Receiving the optimal supports.
~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
11109644|NCT04008654|Active Comparator|ERAS group|This groups will receive ERAS protocol
11109645|NCT04008654|Placebo Comparator|Conventional care|This group will not receive the ERAS protocol.
11109646|NCT04008641||Parents after pediatric antenatal consultation|Survey after pediatric antenatal consultation, for both members of couple if possible
11109647|NCT04008628|Active Comparator|Nitrous oxide|Inhalation of a 50%/50% mixture of nitrous oxide and oxygen. Reassurance of the child during procedure
11109648|NCT04008628|No Intervention|Standard care|Infants will be reassured as currently performed in routine clinical practice
11109649|NCT04008615||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.
~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test.
~For the purpose of this study, patients will be offered to participate in an additional exercise session in which they will repeat the same procedure (two 6-minute stepper test) but but monitoring cardiopulmonary parameters and gaz exchanges using a face mask, a pneumotachograph and a gaz analyser (indirect calorimetry)."
11109650|NCT04008602|Active Comparator|Experimental: Quick Icing|Group receiving the application of cold on the ventral side of the thigh (bilaterally) for 30 seconds, using the technique of ice beakers dynamically.
11109651|NCT04008602|Active Comparator|Experimental: Prolonged Cold|"Group receiving the intervention of ice bag for a period of eight minutes n the ventral side of the thigh (bilaterally)."
11109652|NCT04008602|No Intervention|Control:|Group that does not receive intervention and that will rest for ten minutes.
11109653|NCT04008589|Experimental|rtACS|repetitive transorbital ACS
11109654|NCT04008589|Experimental|tDCS/rtACS|Sequential tDCS - tACS
11109655|NCT04008589|Sham Comparator|Sham stimulation|
11109656|NCT04008576|Other|Group Blended Transdiagnostic treatment|
11109657|NCT04008563|Experimental|Bariatric Surgery and Progestin Intrauterine Device|This group will receive a progestin intrauterine device and be offered to undergo bariatric surgery.
11109658|NCT04008563|No Intervention|Progestin Intrauterine Device Alone|This group will receive a progestin intrauterine device alone.
11109659|NCT04008550|No Intervention|No Pulmonary Arterial Hypertension before TAVI|No intervention has been done in this group of patients.
11109660|NCT04008550|Other|Pulmonary Arterial Hypertension before TAVI|In this group, a right heart catheterization is done 3 months after TAVI in order to evaluate PAH (persistence or regression).
11109661|NCT04008537|Experimental|Halcyon kV CBCT imaging|-Each patient will undergo five Halcyon kV CBCT imaging sessions that will then be utilized to simulate the CBCT-guided online ART workflow. Halcyon imaging will be scheduled as per the patient's schedule and availability, with intent but not mandate for imaging on the same days as clinical treatments, preceding clinical treatment. Multiple images may be acquired in one session but no more than 6 Halcyon kV CBCT images will be acquired per day. No more than 6 additional Halcyon kV CBCT images will be acquired in one imaging session and no more than 10 total additional Halcyon kV CBCT images for the duration of the study
11109662|NCT04008511|Experimental|Phase Ib: Regorafenib plus XELOX|"Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:
~Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)"
11109663|NCT04008511|Experimental|Phase II: Regorafenib plus XELOX|Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
11109664|NCT04008511|Active Comparator|Phase II: XELOX|Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
11109692|NCT04008238|Experimental|Biomarker analysis|This study is a single arm study with biomarker analysis
11109693|NCT04008225||ARDS group|Inpatients hospitalized in medical intensive care with a table of ARDS defined according to the Berlin criteria and requiring an BAL for a diagnostic purpose under a suspicion of pneumopathy acquired under mechanical ventilation.
11109665|NCT04008498|Experimental|AEEG monitoring|"Babies whose families consent to involvement will have their head cleaned, EEG leads attached, the monitor set up, and observations.
~Babies will be recorded continuously for the entire duration of their time on the intensive care unit.
~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.
~Before being discharged home, the babies will have additional follow-up. They will receive magnetic resonance imaging (MRI) of the brain on a 1.5T scanner at the University of Sheffield. They will also have a standardised examination of their neurological system performed by a physiotherapist (The Hammersmith Neonatal Neurological Examination)."
11109666|NCT04008485|Experimental|Asymptomatic high-risk women|Women will be scheduled to attend for MIS measurement at 20-22 weeks, to be repeated at 26-28 weeks. This measurement will be taken at the same time as the routine examination which they receive when they attend the prematurity clinic. At each study visit the patient will undergo a vaginal examination. Triple high vaginal swabs will then be taken for bacteriology and fetal fibronectin. The sterile magnetic impedance probe will then be introduced, data being captured automatically by pressing the data capture button on the handle of the device. A transvaginal scan will also be performed to measure CL.
11109667|NCT04008485|Experimental|Symptomatic pregnant women|These women (≥ 16 years of age) will be approached when they attend the labour delivery room or triage with symptoms of preterm labour as detailed above. As a matter of clinical routine these women receive a speculum examination, triple vaginal swabs taken, and fetal fibronectin and cervical length scans as indicated. The study will be explained to them and study materials provided. They will be asked to contact research staff by telephone or through their clinical midwife if they wish to participate. They will be given time to decide. If they agree to take part, written informed consent will then be obtained by research staff who will also conduct the MIS study. If clinical assessments have not already been performed by the time of obtaining consent they will be carried out at the same time
11109668|NCT04008472|Experimental|Telemedecine|Patients benefiting from telemedicine
11109669|NCT04008472|No Intervention|Control|routine care without telemedecine
11109670|NCT04008459||Degenerative musculoskeletal spinal conditions|Participants are included who are enrolled in a 6-week physiotherapy exercise class aimed at improving function in people with degenerative spinal conditions.
11109671|NCT04008433|Experimental|Lidocaine pre-intravenous injection|The initial dose of lidocaine for pre-injection was set at 0.5mg /kg according to previous literature and preliminary test results. The dose of lidocaine was according to the patients' pain level. If there is no pain (negative reaction), the dose of lidocaine in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of lidocaine will be increased in the next patient until the patient is painless.
11109672|NCT04008420||Adults who are scheduled to undergo robotic esophagectomy|Adults who are scheduled to undergo robotic esophagectomy
11109673|NCT04008407|Active Comparator|ESD|Lesion with overt stigmata of SMIC or those with high risk (=> 10%) for covert SMIC.
11109674|NCT04008407|Active Comparator|EMR|Lesion with no overt or a low risk for (<10%) for covert SMIC
11109675|NCT04008394|Experimental|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
11109676|NCT04008381|Experimental|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
11109677|NCT04008368|Other|1|patients with HLA-matched sibling donors
11109678|NCT04008368|Other|2|patients with haploidentical donors
11109679|NCT04008355|Experimental|60mg/day/84 days|Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
11109680|NCT04008355|Experimental|80mg/day/10 days followed by 50mg/day/74 days|Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
11109681|NCT04008355|Placebo Comparator|Placebo/84 days|Patients randomized in this arm will receive placebo solution once daily during 84 days.
11109682|NCT04008342|Experimental|Intervention group|The intervention group (IG) was submitted to 16 multisensory sessions that followed the protocol.
11109683|NCT04008342|No Intervention|Control group|The control group (CG) received usual care with routine interventions and services in the LTC, such as bath, hygiene care, watching TV and so on.
11109684|NCT04008316|Experimental|colchicine 1mg/day|Colchicine per os: 1 tablet (1mg) / day during 6 months
11109685|NCT04008316|Placebo Comparator|placebo|placebo 1 tablet / day during 6 months
11109686|NCT04008303||Patients with migraines|"Patients seen in clinic and assessed with Migraine Headache Diagnostic Criteria to ensure diagnosis.
~Patients track the characteristics of migraine headaches for one month before surgery.
~After this month, patients receive surgery in the operating room for migraine.
~After surgery, patients track the characteristics of migraine headaches for 3 months.
~Patients will then be asked to track the characteristics migraine headaches again at 1 year and 2 years and 5 years after surgery. For these time periods, patients only have to keep track of the characteristics for 1 month intervals."
11109687|NCT04008290|Experimental|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl containing 0.6 mg liraglutide.
11109688|NCT04008290|Placebo Comparator|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl saline (0.9%) solution.
11109689|NCT04008264||Standard post operative pain regimen|There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
11109690|NCT04008264||Scopolomine group|During the observational phase, patients will be on scopolamine for a total 6 day course (one patch applied at time of surgery, prescription for one patch), and patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery. The patients who incorporate scopolamine into their post operative analgesia regimen will be eligible for inclusion in the study.
11109694|NCT04008225||Control group|The control group will be made up of patients with an BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: < 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (< 20%), neutrophils: < 5%, eosinophils: < 2%.
11109695|NCT04008212||EVAR aneurysm|
11109696|NCT04008212||Stenosis|
11109697|NCT04008199|No Intervention|Control|Control group will not receive any intervention. Households in this group will only be surveyed.
11109698|NCT04008199|Experimental|Treatment|Treatment group will receive an invitation to join Super Abbu in addition to identical surveys to those in the control group.
11109699|NCT04008186|Experimental|Omaveloxolone and Multiple Drugs (Part 1)|Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27
11109700|NCT04008186|Experimental|Omaveloxolone & Gemfibrozil (Part 2)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
11109701|NCT04008186|Experimental|Omaveloxolone and Itraconazole (Part 3)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
11109702|NCT04008186|Experimental|Omaveloxolone and Verapamil (Part 4)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.
11109703|NCT04008173||Male|
11109704|NCT04008173||Female|
11109705|NCT04008173||Kidney Disease|
11109706|NCT04008173||Diabetes|
11109707|NCT04008173||Elderly|
11109708|NCT04008160||healthy persons|
11109709|NCT04008160||individuals with paraplegia|
11109710|NCT04008147|Active Comparator|No GDM, non-anemic|12 women with no gestational diabetes who are not anemic
11109711|NCT04008147|Active Comparator|No GDM, anemic|12 women with no gestational diabetes who are anemic
11109712|NCT04008147|Experimental|GDM, non anemic|12 women with gestational diabetes who are not anemic
11109713|NCT04008147|Experimental|GDM, anemic|12 women with gestational diabetes who are anemic
11109714|NCT04008134|No Intervention|Standard recommendation (ORS)|Participants received the standard recommendation on oral rehydration solution use
11109715|NCT04008134|Experimental|mHealth with no home visits|Participants received the health facility delivery of CHoBI7, plus bi-weekly mHealth (voice and text) reminders for 12 months
11109716|NCT04008134|Experimental|mHealth with home visits|Participants received the health facility delivery of CHoBI7, plus two home visits and bi-weekly mHealth (voice and text) reminders for 12 months
11109717|NCT04008121|Experimental|Adult participants with normal or diseased eyes|500 mg dose of intravenous fluorescein sodium followed by ocular angiography; after a minimum of 3 days, participants will receive a single intravenous dose of MB-102 at 4 μmol/kg followed by ocular angiography
11109718|NCT04008108|Experimental|Patient with urinary incontinence|Patient with urinary incontinence
11109719|NCT04008082||Lenvatinib|Lenvatinib capsules 12 milligram (mg) for participants with body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg for participants with body weight less than (<) 60 kg, orally, once daily as per routine clinical practice.
11109720|NCT04008069|Experimental|Study drug|sarilumab 200 mg subcutaneously every two weeks
11109721|NCT04008069|Placebo Comparator|placebo|placebo subcutaneously every two weeks
11109722|NCT04008056||Patients undergoing chemotherapy|
11109723|NCT04008043|Experimental|Dexamethasone|Participants in this arm will take a 6mg dexamethasone tablet the day before surgery, a 6 mg tablet the day of surgery, a 4mg tablet the day after surgery and a 2mg tablet the second day after surgery. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
11109724|NCT04008043|Active Comparator|Vicodin|Participants in this arm will take a vicodin tablet every 4-6 hrs as needed to a maximum of 8 tablets after surgery. Each tablet has 300 mg acetaminophen and 5 mg hydrocodone. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
11109725|NCT04008030|Experimental|Arm A: Nivolumab Monotherapy|Specified dose on specified days
11109726|NCT04008030|Experimental|Arm B: Nivolumab + Ipilimumab Combination|Specified dose on specified days
11109727|NCT04008030|Active Comparator|Arm C: Investigator's Choice Chemotherapy|Specified dose on specified days. Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress
11109728|NCT04008017||stable Chronic obstructive pulmonary disease|clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
11109729|NCT04008017||acute exacerbation of Chronic obstructive pulmonary disease|patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
11109730|NCT04008004|Experimental|EDP-514 HV SAD Cohorts|EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
11109731|NCT04008004|Experimental|EDP-514 HV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
11109732|NCT04008004|Placebo Comparator|EDP-514 HV SAD Placebo Cohort|Matching placebo, orally, once daily in one single administration
11109733|NCT04008004|Placebo Comparator|EDP-514 HV MAD Placebo Cohort|Matching placebo, orally, once daily for 14 days
11109734|NCT04008004|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
11109735|NCT04008004|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days
11109736|NCT04007991|Experimental|Ecopipam 2 mg/kg/day|Ecopipam HCl 12.5-, 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings
11109737|NCT04007991|Placebo Comparator|Placebo|Matching Placebo tablets taken orally in the evening
11109738|NCT04007978|Experimental|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
11109739|NCT04007965|Experimental|Opacified posterior capsule|PCO
11109740|NCT04007965|Active Comparator|Clear posterior capsule|CPC
11109741|NCT04007952|No Intervention|Intervention 1 (Control)|No anterior gastropexy will be performed.
11109742|NCT04007952|Experimental|Intervention 2 (Treatment)|Anterior gastropexy will be performed.
11109743|NCT04007939||Employee population|Subject comprised of employees of Metagenics but later will be expanded to those recruited from practitioner practices
11109744|NCT04007926|No Intervention|Control Group|Participants assigned to the control arm of the study will be asked to maintain their normal dietary and exercise habits.
11109745|NCT04007926|Experimental|Aerobic exercise group|Participants randomised to the aerobic exercise intervention will undertake a 12-week aerobic exercise training programme.
11109746|NCT04007926|Experimental|Resistance exercise group|Participants randomised to the resistance exercise intervention will undertake a 12-week aerobic exercise training programme.
11109747|NCT04007913|Experimental|teleCBIT|Patient receive eight sessions of individual teleCBIT, in accordance with Woods et al's (2008) protocol, from a licensed psychologist.
11109748|NCT04007900|Experimental|Positive Affect Treatment|Individuals randomized to the intervention will participate in 20 therapy visits. Before each therapy visit, the participant will meet briefly with a member of the research staff, who will measure weight (blind to the participant) and administer the CHEDS, PANAS, and a pre-session feedback form that will assess how helpful the skills learned in the prior session had been over the past week. After the session, the participant will complete the post-session feedback form, which will assess how helpful the skills he or she perceived the skills from this session to be. These procedures will take approximately 10 minutes. Each intervention session will take approximately 50 minutes to complete. Therefore, each intervention visit will be approximately 1 hour long. Therapy sessions will take place either in the private office of a study therapist or in a consultation room of the Ambulatory Research Center.
11109749|NCT04007900|No Intervention|Waitlist|For participants randomized to the waitlist control, the opportunity will be offered to participate in the intervention following the second assessment (20 weeks following their Baseline assessment).
11109750|NCT04007887|Experimental|Intervention|Post-MI patients attending an adult education program designed to inform and motivate them on how to best control cardiovascular risk factors as a means to offer optimized secondary prevention of cardiovascular events
11109751|NCT04007887|No Intervention|Controls|Usual care for post-MI patients
11109752|NCT04007874|Experimental|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
11109753|NCT04007874|Active Comparator|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
11109754|NCT04007861||Patients with pain|"This will be the group of patients in whom pain is a significant enough problem, that they have been referred to the specialist Pain Management Team. These patients will be identified retrospectively.
~Patients seen in Pain Management Clinics between 1st of January 2016 and 31st of December 2018, who have consented to be included in the Pain Management database and have a clinician specified pain diagnosis of pain persistent post-surgical pain following breast cancer treatment will be identified. If these patients have an unclear pain diagnosis, they will not be included."
11109755|NCT04007861||Patients without pain|"This will be the group of patients in whom pain is deemed not to be a significant problem.
~Once again, these patients will be identified retrospectively. Appropriately matched patients to the 52 patients in the patients with pain will be identified using records of hospital operating lists by the peri-operative medicine team.
~Patients will be matched based upon the following details:
~Age (within 5 years of matched case)
~Surgical procedure (matched for the following elements:
~Surgery to breast tissue (biopsy, lumpectomy, wide-local excision or mastectomy)
~+/- Sentinal lymph node biopsy or axillary dissection
~+/- Reconstruction
~Surgical procedure within 3-months of matched case.
~Provided these individuals have not had an appointment with or referral to the Pain Management Team, they will be included in the matched controls."
11109756|NCT04007848|Experimental|Cobimetinib|Experimental group : 36 histiocytoses's patients without or with BRAF V600E will be randomised in cobimetinib group
11109757|NCT04007848|Placebo Comparator|Placebo|Control group : 18 histiocytoses's patients without or with BRAF V600E will be randomised in the placebo group
11109758|NCT04007835|Experimental|Anlotinib Hydrochloride combined with EGFR-TKI|Patients receive anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of following EGFR-TKIs: Gefitinib is administered 250 mg once per day. Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
11109759|NCT04007822||Physiotherapists|Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
11109760|NCT04007809|Experimental|New-onset Type 1 diabetes|
11109761|NCT04007796|Experimental|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
11109762|NCT04007796|Active Comparator|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
11109763|NCT04007770|Experimental|Acupuncture|
11109764|NCT04007770|Sham Comparator|Sham Acupuncture (SA)|
11109765|NCT04007770|Other|Wait-List Control|
11109766|NCT04007757||1|Participants who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study who live in the area of University of Cincinnati, Massachusetts General Hospital, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of participant or legal representative to provide informed consent. Racial/ethnic category of Caucasian, African American or Hispanic.
11109767|NCT04007744|Experimental|Treatment (sonidegib, pembrolizumab)|Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11109768|NCT04007731|Experimental|High protein, high fibre and creatine load bar (DrRip)|1 new protein bar (260 kcal) after training every day
11109769|NCT04007731|Active Comparator|Voltage energy bar|1 control commercially available protein bar (260 kcal) after training every day
11109770|NCT04007718|Experimental|Active|
11109771|NCT04007718|Sham Comparator|Control|
11109772|NCT04007705|Experimental|Anti-inflammatory and low FODMAPs diet|The anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy and processed food, for three months. During the first month, a low FODMAPs diet will be implemented, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Additionally, some potentially anti-inflammatory foods will be promoted: Omega-3 through specific fish (tuna fish, salmon, sardine, horse mackerel) and nuts, antioxidant rich foods, such as fruit and vegetables, and the maintenance of glycemic index.
11109773|NCT04007705|Active Comparator|Control|Dietary counselling based on general recommendations for healthy eating according to the World Health Organization
11109774|NCT04007692||Simple interrupted suture group|Participants will have a simple interrupted suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
11109775|NCT04007692||Triangular suture group|Participants will have a triangular suturing pattern, determined by care provider, at the time of esophageal stent placement for esophageal stent fixation as part of standard care and will have an endoscopy at 3-4 weeks after the stent placement as part of a routine follow-up.
11109776|NCT04007679|Experimental|Pain education group|Pain education was conducted in physical conditions similar to the university classrooms where the study was performed for all participants.
11109777|NCT04007666|Experimental|Cognitive Processing Therapy (CPT)|CPT is a gold-standard evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms. It can be delivered in group and individual formats, but will be delivered in a group format in this project due to feasibility in the setting. Structure will be based on feedback obtained during completion of Aim 2 while remaining within the range evaluated in prior research (i.e., 8-12 sessions, 1-2x per week, each lasting 1.5-2 hours).
11109778|NCT04007666|Active Comparator|Coping Skills Group|The Coping Skills Group will match for attention and dose, without adding any cost to the system. Exact content will be determined during completion of Aim 2; however, project sites already provide coping-focused programming and coping-skill approaches to trauma treatment are a common alternative to evidence-based therapies for PTSD, such as CPT, that deal more directly with the index trauma. To provide an enhanced standard of care, the investigator will review treatment materials (workbooks, handouts) already used in prison settings and arrange a curriculum of skills similar to those in coping-focused trauma-informed interventions (e.g., psychoeducation, assertiveness).
11109779|NCT04007653||Patients treated with heparin+edoxaban for VTE|Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
11109780|NCT04007653||Patients treated with heparin+VKA for VTE|Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
11109781|NCT04007640|Other|Volunteer patient|1st stage: To adjust the transducer, test and validate pancreatic MRI sequences on volunteers without history of known pancreatic disorders. Adjustment of MRI parameters is needed to optimize data acquisition, especially in obese patients. Moreover, an external material (transducer) has to be applied on the abdomen. The right position has to be tested and specified before stages 2 and 3 of the study. We aim to include volunteers without history of known pancreatic disorders for the Stage 1, meaning volunteers without personal history or symptoms suggesting pancreatic disorders.
11109782|NCT04007640|Other|Obese volunteers with indication for hepatic MRI|2nd stage: To validate and assess pancreatic MRI sequences on obese volunteers with indication for hepatic MRI , in relation with acceptable resolution and field of view criteria applicable to the typical anteroposterior diameters found in obese persons. For Magnetic Resonance Elastography (MRE), the amplitude setting of the MRE transducer will be adapted to the size of obese patients, in addition to the aforementioned adjustments to spatial resolution and field of view sizes. The effect of frequency on MRE data quality will be investigated. The effects of respiratory motion will be investigated; indeed in obese patients respiration amplitude is typically low and this enables to acquire data in free breathing mode over long periods of time, which offers more possibilities (notably in terms of averaging, spatial resolution, mechanical wave sampling rate) than when constraining acquisition parameters with a maximum breath hold time of less than 20s.
11109783|NCT04007640|Other|Obese patient|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
11109784|NCT04007640|Other|Non obese patients|3rd stage: To assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients validated at the microscopic level. We will analyze MRI of obese patients and non-obese patients with a planned pancreatic surgery. It will be possible to compare imaging with histology performed on resected parenchyma
11109785|NCT04007614||Patients|Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
11109786|NCT04007601|Active Comparator|Active tDCS|Remotely delivered active tDCS + cognitive training
11109787|NCT04007601|Placebo Comparator|Sham tDCS|Remotely delivered sham tDCS + cognitive training
11109788|NCT04007588|Experimental|Nivolumab+BMS-986205|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
~BMS-986205 will be administered orally on a daily basis"
11109789|NCT04007588|Experimental|Nivolumab|-Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
11109790|NCT04007588|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
~Ipilimumab will be administered intravenously every 6 weeks"
11109853|NCT04007146|Experimental|Cardiac Output Measurement|Subject will have a usual cardiac output
11109791|NCT04007562||Lipin-1 deficiency|Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
11109792|NCT04007549|Experimental|Individual brief motivational intervention|Individual brief motivational intervention (IBMI) on tobacco/alcohol risk reduction for the breast cancer patient; the partner receive e-mail or postal brief advices.
11109793|NCT04007549|Active Comparator|Couple-based brief motivational intervention|Couple-based brief motivational intervention (CBMI) on tobacco/alcohol risk reduction.
11109794|NCT04007536||Part 1|Patients from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
11109795|NCT04007536||Part 2|Patients from 2 through 30 years of age who have MPS II will be enrolled; Part 2 will entail a single collection of CSF, urine, and blood. Clinical assessments are optional in Part 2.
11109796|NCT04007523|No Intervention|Usual Care Group|Usual care per surgical ward standards
11109797|NCT04007523|Experimental|HELP Support System|This arm will receive the HELP Support System intervention only
11109798|NCT04007523|Experimental|Family Support System|This arm will receive the Family Support system intervention only
11109799|NCT04007523|Experimental|Combined Support Systems|Participants randomized to this arm will receive both HELP- and family-based support system interventions
11109800|NCT04007510|Experimental|EPI-CAL mHealth data network|"This arm of the study involves the use of the mobile health technology (app) to measure outcomes within an early psychosis (EP) program."
11109801|NCT04007510|Experimental|DUP Evaluation|A subset of individuals will participate in interviews to validate a tool to determine the duration of untreated psychosis in community settings
11109802|NCT04007484|Experimental|HP+CPB/DHCA group|For patients randomized into the intervention group, a hemoperfusion device will be connected in series to the extracorporeal circulation machine in advance to ensure that every single patient will undergo continuous hemoperfusion from the beginning to the end of CPB.
11109803|NCT04007484|No Intervention|CPB/DHCA group|For patients randomized into the CPB/DHCA group, no hemoperfusion device will be connect to the extracorporeal circulation machine. Patients will undergo CPB and DHCA without continuous hemoperfusion.
11109804|NCT04007458|Active Comparator|Letter|Patients will receive a letter reminding them that they are overdue for repeat annual screening.
11109805|NCT04007458|Experimental|Community Health Worker phone call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
11109806|NCT04007445|Active Comparator|Formally Directed Group (Exercise Group)|A group performing a 12 - week guided exercise program at an accessible Community Health and Wellness Center
11109807|NCT04007445|Placebo Comparator|Self-Directed Group (Control Group)|A group receiving educational information about physical activity and exercise at home and then self-directing a 12 - week exercise program on their own.
11109808|NCT04007432|Experimental|Older patients with hip fracture|Older patients admitted for hip fracture surgery
11109809|NCT04007419|Experimental|Single Arm|The Promotoras de Donación eLearning module will be launched and 40 participating lay health educators trained. Access to the module will be provided via a link to the website embedded in an announcement email. To assess the impact of the Promotoras de Donación eLearning module on lay health educators' knowledge of organ donation and the need for Hispanic donors, and confidence communicating about donation and promoting the act of donor registration, participating lay health educators will complete a brief online survey upon enrollment (pre) and after completing the module (post). Then, trained lay health educators will hold at least 2 small group sessions with mature Latina (6-8 per session); in all, 80 sessions are anticipated with 480 to 640 mature Latina. Participating mature Latina will complete anonymous paper-pencil surveys before and after each session to assess changes in attitudes toward organ donation and donor registration and intent to register as posthumous organ donors.
11109810|NCT04007406|Experimental|DP13 low|DP13 for 8 weeks
11109811|NCT04007406|Experimental|DP13 middle|DP13 for 8 weeks
11109812|NCT04007406|Experimental|DP13 high|DP13 for 8 weeks
11109813|NCT04007393|Other|LSMT x 12 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=12 weeks: if body mass index (BMI) is down 5% at T=12 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 36 weeks); if BMI is not down 5% at T=12 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=24 weeks. At T=24 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 24 weeks); if BMI is not down by 5% at T=24 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 24 weeks).
11109814|NCT04007393|Other|LSMT x 24 weeks|Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
11109815|NCT04007380|Other|CPAP-therapy arm|This single-arm clinical trial will examine the effects of 4-month period CPAP therapy in individuals living with SCI. The CPAP will be adjusted according to the results of the auto-titrating CPAP testing for each participant.
11109816|NCT04007367|Experimental|SAGE-217|
11109817|NCT04007367|Placebo Comparator|Placebo|
11109818|NCT04007354|No Intervention|Intubated|The patient was intubated with a left-sided double-lumen endobronchial tube. The protective ventilation was performed as follows: a tidal volume of 6 mL/kg predicted body weight, I:E ratio of 1:2, a respiratory rate to maintain PaCO2 within 35 to 45 mmHg, and positive end-expiratory pressure at 5 cmH2O. If the airway pressure exceeded 25 cmH2O, tidal volume was adjusted.
11109854|NCT04007133||Diabetic patients|Patients with non-insulin-dependent diabetes, taking statins for at least 1 month
11109819|NCT04007354|Experimental|Non-intubated|The patients were oxygenated via facial mask with O2 5~10 L/min during the whole procedure. The end-tidal carbon dioxide (EtCO2) was measured by insertion of a detector inside one of the nostrils. Respiration rate was maintained between 12 and 20 breaths/min with adjustment of anesthetics.
11109820|NCT04007341|No Intervention|Saline group|Patients in the saline group were infused with an identical volume of normal saline.
11109821|NCT04007341|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.
11109822|NCT04007328|Experimental|methylprednisolone|20 mg of methylprednisolone IV Q12H for 5 days
11109823|NCT04007328|Placebo Comparator|Placebo|normal saline IV Q12H for 5 days
11109824|NCT04007315|Experimental|SaeboGlove Therapy + usual care|Use for 6 weeks - given an individualised self-management training programme involving repetitive grasping and releasing movements.
11109825|NCT04007315|Active Comparator|Usual care|Usual NHS rehabilitation care based on National Clinical Guidelines for 6 weeks + 2 study visits and one study phone call
11109826|NCT04007302|Experimental|walking with distraction|the patient walks in front of a screen with virtual reality simulation
11109827|NCT04007302|Active Comparator|Walking without distraction|the patient walks on a treadmill without virtual reality simulation
11109828|NCT04007289|Active Comparator|APIXABAN|Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.
11109829|NCT04007289|Placebo Comparator|PLACEBO|Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.
11109830|NCT04007276|Experimental|Lumify Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
11109831|NCT04007276|Sham Comparator|Control Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
11109832|NCT04007263|Placebo Comparator|Placebo|Placebo intravenous infusion over 30 minutes, five days of once daily dosing
11109833|NCT04007263|Experimental|NP10679 25 mg|NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
11109834|NCT04007263|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
11109835|NCT04007263|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing
11109836|NCT04007250||FENIX participants|Individuals being treated with the FENIX™ Continence Restoration System.
11109837|NCT04007237|Experimental|Selsun Shampoo (SeS2 shampoo)|Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
11109838|NCT04007237|Active Comparator|Ketoconazole shampoo|Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
11109839|NCT04007224|Active Comparator|Oxytocin|Intranasal Oxytocin
11109840|NCT04007224|Experimental|Autologous umbilical cord blood|Intravenous administration of autologous umbilical cord blood
11109841|NCT04007211|Experimental|ABT13107|
11109842|NCT04007211|Active Comparator|Hyalobarrier|
11109843|NCT04007198|Experimental|EQ001|EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
11109844|NCT04007198|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
11109845|NCT04007185||Control group|30 patients undergoing biopsy for brain tumour. They have the effect of the tumour but not the impact of surgery. Changes in QoL will inform the RCI measures planned
11109846|NCT04007185||Surgery Group|The main test group. This group have been determined by their treating surgeon to undergo a resection of the tumour so will be different from the control arm by undergoing a safe, maximal resection of their tumour
11109847|NCT04007172|Experimental|Neural Therapy & home exercise program|"Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
11109848|NCT04007172|Experimental|Physical Therapy & home exercise program|"Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
11109849|NCT04007159|Experimental|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
11109850|NCT04007159|Experimental|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
11109851|NCT04007159|Experimental|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
11109852|NCT04007159|Placebo Comparator|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
11109855|NCT04007120|Experimental|RVT-1601 Low Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
11109856|NCT04007120|Experimental|RVT-1601 Mid Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
11109857|NCT04007107|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
11109858|NCT04007107|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
11109859|NCT04007094|Experimental|Study Arm|Participants will be entered into the single armed study in which one side of the fusion will be coated with milled local autograft bone and the opposite fusion side will be supplemented with an equal volume of Depuy Synthes ViviGen.
11109860|NCT04007081|Experimental|Participants with Xerostomia|Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration
11109861|NCT04007055|Experimental|Experimental: screening/treating for HPR|Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
11109862|NCT04007055|No Intervention|Control: guideline based therapy|Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
11109863|NCT04007029|Experimental|Treatment (fludarabine, cyclophosphamide, CD19/CD20 T-cells)|"CONDITIONING CHEMOTHERAPY: Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes 5, 4, and 3 days before cell infusion.
~T-CELL INFUSION: Patients receive CD19/CD20 CAR-T cells IV on day 0. Patients with cytokine release syndrome may also receive tocilizumab IV on day 2 at the discretion of the clinical investigator."
11109864|NCT04007016||Pemberton osteotomy （PO）|PO group received Pemberton osteotomy
11109865|NCT04007016||"inner L shaped iliac osteotomy (ILSO)"|"ILSO group received inner L shaped iliac osteotomy"
11109866|NCT04007003|Experimental|optimal injection technique|Subjects will be trained on site regarding optimal insulin injection technique, including avoiding injections in lipohypertrophy areas and proper rotation. Furthermore subjects are provided with access codes to watch online training modules on the Becton Dickinson (BD) and Me(TM) platform
11109867|NCT04006990|Experimental|Intervention|Subjects are given recliner chairs and education on the dangers of bedrest
11109868|NCT04006990|No Intervention|Control|Subjects are treated with standard care
11109869|NCT04006977|Placebo Comparator|Arm 1: placebo plus standard therapy|placebo plus standard therapy
11109870|NCT04006977|Experimental|Arm 2: DSF plus standard therapy|DSF (4 sachets/day) plus standard therapy
11109871|NCT04006964||Identification Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
11109872|NCT04006964||Validation Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
11109873|NCT04006951|Experimental|Biological collection|"For all the patients include in the study :
~Paraffin tissue samples (if applicable) collected during pre-therapeutic rectal biopsy
~Blood samples collected at different times : Before any treatment and Before surgery if the patient received pre-operative radiochemotherapy
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11109874|NCT04006938|Experimental|Single Bout ('S') - 30 minutes of moderate intensity cycling|Subjects will perform a single 30-minute bout of moderate intensity cycling before breakfast
11109875|NCT04006938|Experimental|Multiple Bout ('M')|Subjects will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
11109876|NCT04006925|Active Comparator|Sodium Oxybate (SXB) arm|Sodium Oxybate (SXB) will be dispensed to the participants.
11109877|NCT04006925|Placebo Comparator|Placebo (PBO) arm|Placebo will be dispensed to the participants.
11109878|NCT04006912|Experimental|Minimal residual theoretical astigmatism group|
11109879|NCT04006912|Active Comparator|Steep meridian incision design group|
11109880|NCT04006899||subj 1|Three commercially available BIA devices vs SBIS device
11109881|NCT04006873|Active Comparator|Tezacaftor/Ivacaftor in combination with Ivacaftor|"A film-coated tablet containing 100mg tezacaftor and 150mg ivacaftor will be taken in the morning.
~A film-coated tablet containing 150mg ivacaftor will be taken in the evening.
~Participants will take these tablets for 28 days.
~All tablets are licensed for use in the EU."
11109882|NCT04006873|Placebo Comparator|Placebo|A visually matched placebo to the active drugs will be taken in the morning and in the evening for 28 days.
11109883|NCT04006860|Experimental|SHC014748M: Fast + Fed|Participants will receive a single oral dose of SHC014748M capsules in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fed condition on Day 8 of treatment period 2.
11109884|NCT04006860|Experimental|SHC014748M: Fed + Fast|Participants will receive a single oral dose of SHC014748M capsules in fed condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fasted condition on Day 8 of treatment period 2.
11109885|NCT04006847|Experimental|Eicosapentaenoic Acid (EPA)|"Phase I: TKI with escalating/de-escalating doses of EPA to determine MTD.
~Phase I dose levels: Dose Level 1 = EPA 1500 mg orally once per day; Dose Level 2 = EPA 2000 mg orally once per day; Dose Level 3 = EPA 3000 mg orally once per day; Dose Level -1 = EPA 1000 mg orally once per day; Dose Level -2 = EPA 500 mg orally once per day.
~Phase II: TKI administered in combination with the recommended Phase II dose of EPA"
11109886|NCT04006834||MDD with hypersomnia|Patient with a history of MDD and ESS >10
11109887|NCT04006834||MDD without hypersomnia|Patient with a history of MDD and ESS <=10
11109888|NCT04006821|Experimental|PD-1 antibody + Apatinib mesylate|Every patient will receive PD-1 antibody 200mg iv every 2 weeks and apatinib 250mg or 500mg (according to the patient's tolerance) orally every day. PD-1 antibody will be administered until disease progression or lasts for two years. Apatinib mesylate will be administered until disease progression.
11109889|NCT04006808|Experimental|PED-HZ/su 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)
11109890|NCT04006808|No Intervention|Control 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care
11109891|NCT04006808|Experimental|PED-HZ/su 1-11 Group|"Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su).
~Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin."
11109892|NCT04006808|No Intervention|Control 1-11 Group|Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care
11109893|NCT04006795|Experimental|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
11109894|NCT04006795|Experimental|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
11109895|NCT04006795|Experimental|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
11109896|NCT04006795|Placebo Comparator|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
11109897|NCT04006782|Other|Narrow dental implants in multiple fixed prosthesis|
11109898|NCT04006769|Experimental|Entacapone & Imatinib mesylate|"Entacapone 200mg tablet by mouth, three times a day and then increasing to 400mg tablet by mouth, three times a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.
~And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first."
11109899|NCT04006756|Experimental|Online cognitive training 1|Eight-week, three times a week during 45 minutes cognitive training
11109900|NCT04006756|Active Comparator|Online cognitive training 2|Eight-week, three times a week during 45 minutes cognitive activities
11109901|NCT04006743|No Intervention|The routine care group|In the routine care group, while a neonatal nurse performed the OGT insertion procedure, physiological measurements of the highest value of heart rate and the lowest value of oxygen saturation were recorded by one researcher (the first author) 1 min before the procedure, during the process and after the process in 1st and 2nd minutes acquired for each infant in the unit with an individual monitor.
11109902|NCT04006743|Experimental|The swaddling group|In this group, preterm infants were given swaddling method.
11109903|NCT04006743|Experimental|The expressed breast milk group|In this group, preterm infants were given expressed breast milk method.
11109904|NCT04006743|Experimental|The facilitated tucking group|In this group, preterm infants were given facilitated tucking method.
11109905|NCT04006743|Experimental|The swaddling and expressed breast milk group|In this group, preterm infants were given combined swaddling and expressed breast milk method.
11109906|NCT04006743|Experimental|The facilitated tucking and expressed breast milk group|In this group, preterm infants were given combined facilitated tucking and expressed breast milk method.
11109907|NCT04006717|No Intervention|Control|Routine root canal treatment
11109908|NCT04006717|Placebo Comparator|Low-Level Laser Placebo|Patient informed that laser will be applied but device won't be turned on
11109909|NCT04006717|Experimental|Low-Level Laser Therapy|Low-Level Laser Therapy following root canal treatment
11109910|NCT04006717|Experimental|Intracanal Cryotherapy|Cold saline irrigation before obturation
11109911|NCT04006717|Experimental|Combination of LLLT and ICCT|Both cold saline irrigation before obturation and Low-level laser Therapy after root canal treatment
11109947|NCT04006405||Cohort 2|up to 140 patients with a minimum follow-up of 12 months
11109948|NCT04006392|Experimental|Erchonia FX-635|The Erchonia FX-635 is administered to the foot 12 times over 6 weeks (2 times each week) for 15 minutes per foot.
11109912|NCT04006704|Experimental|D/C/F/TAF (Whole Placebo Tablet then Split Placebo Tablet)|Participants will receive scored film-coated 10 milligram (mg) FDC matching placebo tablets (Intake period 1) swallowed whole followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed as a split tablet on Day 1. Both the intakes will be separated by at least 15 minutes.
11109913|NCT04006704|Experimental|D/C/F/TAF (Split Placebo Tablet then Whole Placebo Tablet)|Participants will receive scored film-coated 10 mg FDC matching placebo tablets (Intake period 1) swallowed as a split tablet followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed whole on Day 1. Both the intakes will be separated by at least 15 minutes.
11109914|NCT04006691|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml. 3-6 once weekly intravesical instillations for the ablation treatment.
11109915|NCT04006678|Experimental|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
11109916|NCT04006678|Active Comparator|conventional sandwich osteotomy|:conventional segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla.
11109917|NCT04006665||Lung Ultrasonography prior to docking Robotic arms|Base line Lung ultrasonography will be performed in three basal zones for Right and Left lung -Post intubation and prior to docking robotic arms .
11109918|NCT04006665||Lung Ultrasonography after removal of robotic arms|Lung Ultrasonography will be performed to assess degree of atelectasis after removal of robotic arms and before extubation in three basal zones for Right and Left lung .
11109919|NCT04006652|Experimental|Recipient|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician
~Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines"
11109920|NCT04006652|No Intervention|Donor|-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)
11109921|NCT04006639|Active Comparator|Bilateral superficial cervical plexus block with Bupiv|Patients, who will have tracheostomy procedure, might receive bilateral superficial cervical plexus block with 10 mL of Bupivacaine 0.5% (20 mL spuit with 25 G 1.5 inch needle) on each side before tracheostomy procedure.
11109922|NCT04006639|Active Comparator|Local infiltration of Lidocaine 2%|Patients, who will have tracheostomy procedure, might receive local infiltration of Lidocaine 2% (5 mL spuit with 25 G 1.5 inch needle) before tracheostomy procedure.
11109923|NCT04006626||PET group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT
11109924|NCT04006626||FES group|the staging and management of newly diagnosed ER+ Breast Cancer Patients based on 18F-FDG PET/CT and 18F-FES PET/CT
11109925|NCT04006613|Experimental|Circuit Training|Structured intervention to improve aerobic capacity, balance and strength
11109926|NCT04006613|Active Comparator|Usual Care|Unstructured intervention to improve mobility and balance
11109927|NCT04006587|Experimental|IS intervention|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
11109928|NCT04006587|No Intervention|control|standard care without IS intervention
11109929|NCT04006574|Experimental|core stabilization training|Patient with hip dysplasia aged between 20-60, non-operated
11109930|NCT04006574|Active Comparator|traditional physiotherapy and core stabilization|Patient with hip dysplasia aged between 20-60, non-operated
11109931|NCT04006561||newly-diagnosed patients with primary CNS lymphoma|
11109932|NCT04006522|Experimental|Cohort 1|Patients with Localized RCC prior to nephrectomy.
11109933|NCT04006522|Experimental|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
11109934|NCT04006509|Experimental|Antenatal Education Group|Patients will receive a prenatally delivered lactation educational program.
11109935|NCT04006509|No Intervention|Standard of Care Group|Patients will receive standard of care and not a prenatally delivered lactation educational program.
11109936|NCT04006496|Experimental|Experimental: Intervention|In-patient, Chemotherapy patients in this arm will receive the expressive writing intervention twice each week for two weeks. These writing samples will be reviewed and analyzed. These patients will receive coaching from an expert expressive writing coach and will be allowed to ask questions and receive guidance. All patients will receive standard of care treatment in addition to the intervention.
11109937|NCT04006496|No Intervention|Control|Patients in the control group will not interface with the expressive writing coach for guidance nor have their writing samples reviewed and analyzed. All patients in the control arm will still receive standard care
11109938|NCT04006483||Stannous Fluoride Dentifrice|Twice daily brushing
11109939|NCT04006483||Positive control dentifrice|Twice daily brushing
11109940|NCT04006483||Negative control dentifrice|Twice daily brushing
11109941|NCT04006470||Stannous Fluoride Dentifrice|Twice daily use
11109942|NCT04006470||Positive control dentifrice|Twice daily use
11109943|NCT04006470||Negative control dentifrice|Twice daily use
11109944|NCT04006457|Experimental|Treatment sequence 1|"Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 given QD for 23 months.
~Patients participating in the vaccine sub-study will receive the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 21 visit of the main B7981032 study."
11109945|NCT04006457|Experimental|Treatment sequence 2|"Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 given QD for 24 months.
~Patients participating in the vaccine sub-study will receive the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 21 visit of the main B7981032 study."
11109946|NCT04006405||Cohort 1|140 patients with a minimum follow-up of 12 months
11109949|NCT04006392|Sham Comparator|Placebo Laser|Noise and appearance of output is the same but no active therapy applied. Treatment administration procedure is the same as with the experimental arm.
11109950|NCT04006366|Other|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
11109951|NCT04006353|Experimental|Group 1: ABT|Intravenous infusion of 320 mg ABT on Day 1, 2, 3, and 8.
11109952|NCT04006353|Experimental|Group 2: ABT+RIF|600mg Rifampicin once daily from Day 1 to 16. Intravenous infusion of 320 mg ABT on Day 7, 8, 9 and 14.
11109953|NCT04006340|Placebo Comparator|Empirical group|Patients receive conventional triple therapy containing esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days
11109954|NCT04006340|Active Comparator|Genotypic resistance-guided tailored group|"Patients receive triple or quadruple therapy by resistance-associated mutations in 23S ribosomal RNA which are identified by polymerase chain reaction (PCR).
~Triple therapy contains esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days and quadruple therapy contains esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days."
11109955|NCT04006327||Palliative care patients and their family caregivers|The present study is a cross-sectional study with single group study design. Only palliative care patients and their family caregivers will be recruited.
11109956|NCT04006314|Other|Receiving PRP injections or PRP plus neural prolotherapy|PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
11109957|NCT04006301|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
11109958|NCT04006301|Experimental|Part 2: Dose Expansion|Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1.
11109959|NCT04006288|Active Comparator|Aspirin and clopidogrel|aspirin 81 mg/qd plus clopidogrel 75mg/qd for 30 days
11109960|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and clopidogrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
11109961|NCT04006288|Active Comparator|Aspirin and prasugrel|aspirin 81 mg/qd plus prasugrel 10mg/qd for 30 days
11109962|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and prasugrel|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
11109963|NCT04006288|Active Comparator|Aspirin and ticagrelor|aspirin 81 mg/qd plus ticagrelor 60mg/bid for 30 days
11109964|NCT04006288|Experimental|Aspirin and rivaroxaban from aspirin and ticagrelor|aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
11109965|NCT04006275|Experimental|Sonovue and Sonazoid Group|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.
~Contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
11109966|NCT04006275|Experimental|Sonazoid and Sonovue Group|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at observing room for at least 30min.
~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
11109967|NCT04006262|Experimental|Experimental arm|"Neo-adjuvant treatment (6 cycles - 12 weeks)
~Surgery
~Adjuvant treatment (9 cycles - 9 months)"
11109968|NCT04006249|Other|diagnostic test|
11109969|NCT04006236|Experimental|Experimental Infant Formula|extensively hydrolyzed casein protein
11109970|NCT04006236|Active Comparator|Control Infant Formula|extensively hydrolyzed casein protein
11109971|NCT04006223||11C-PIB or 18F-florbetapir PET/MR|Patients suspected of or diagnosed with systemic amyloidosis will be scanned by 11C-PIB or 18F-florbetapir PET/MR twice. One is before biopsy and treatment, and the other is after at least half a year of treatment.
11109972|NCT04006210|Experimental|Group A|ND0612 SC infusion + placebo IR-LD/CD + active IR-LD/CD (Carbidopa Levodopa USP tabs 25mg/100mg), for 24 hours.
11109973|NCT04006210|Active Comparator|Group B|Placebo for ND0612 SC infusion + placebo IR-LD/CD + active IR-LD/CD (Carbidopa Levodopa USP tabs 25mg/100mg), for 24 hours.
11109974|NCT04006184||Endovenous Thermal Ablation|Limbs treated with either radiofrequency ablation or endovenous laser ablation
11109975|NCT04006184||Cyanoacrylate Closure|Limbs treated with cyanoacrylate closure system
11109976|NCT04006171|Active Comparator|women with polycystic ovary syndrome|30 patients with PCOS
11109977|NCT04006171|Active Comparator|Healthy women of reproductive age|30 patients with regular normal menstrual cycle
11109978|NCT04006158|Experimental|LightStim LED Bed|Full body LED bed device.
11109979|NCT04006145|Experimental|Elobixibat|Elobixibat 5 mg once daily
11109980|NCT04006145|Placebo Comparator|Placebo|Placebo
11109981|NCT04006132|Experimental|Ponto 3 SuperPower sound processor|All patients will be fitted with two bone-anchored sound processors (Ponto 3 SuperPower), unilaterally and bilaterally.
11109982|NCT04006119|Experimental|Ad-RTS-hIL-12 + veledimex in combination with cemiplimab-rwlc|Intratumoral Ad-RTS-hIL-12 and oral veledimex (activator ligand, 20mg) given in combination with cemiplimab-rwlc via infusion.
11109983|NCT04006093|Experimental|participants with normal renal function|
11109984|NCT04006093|Experimental|participants with end-stage renal disease|
11109985|NCT04006080|Experimental|Vedolizumab|
11109986|NCT04006067|Experimental|Group A|
11109987|NCT04006067|No Intervention|Group B|
11109988|NCT04006054|Experimental|Dexmedetomidine treatment group|Dexmedetomidine will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
11109989|NCT04006054|Active Comparator|Midazolam treatment group|Midazolam will be administrated at a dose of 0.25-0.75 µg/(kg*h) for 5 days
11110065|NCT04005521|Experimental|Preventive intervention|Patient will perform daily exercise: jaw and swallwing exercises, as well as are encouraged to eat and drink for as long as possible during treatment
11109990|NCT04006041|Experimental|Toripalimab group|All patients will receive standard fractionation radiation therapy (RT) scheme: 44Gy in 20 fractions over 4 weeks, concurrently with 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 and 2 cycles of toripalimab 240 mg on days 1, 22. Esophagectomy is performed 6-8 weeks after CRT completion.
11109991|NCT04006015||Main study group|31 people with COPD and 31 controls in the main study group.
11109992|NCT04006015||six-minute walk substudy|We will aim to have 40 participants participating in the 6 minute walk sub-study.
11109993|NCT04006015||Qualitative dance substudy|We will aim for 20 participants.
11109994|NCT04006002||Endoscopic Sleeve Gastrectomy|This group includes all patient who undergo Endoscopic Sleeve Gastrectomy for weight loss
11109995|NCT04006002||Laproscopic Sleeve Gastrectomy|This group includes all patient who undergo Laproscopic Sleeve Gastrectomy for weight loss
11109996|NCT04005989|Placebo Comparator|PLACEBO GROUP|injection of saline solution
11109997|NCT04005989|Active Comparator|Low dose group|hASC injection (1x10e6 / kg body weight)
11109998|NCT04005989|Active Comparator|Intermediate Dose|injection of hASC (2x10e6 / kg of body weight)
11109999|NCT04005989|Active Comparator|High dose group|injection of hASC (4x10e6 / kg body weight)
11110000|NCT04005976||Patients with heritable thoracic aortic disease (H-TAD)|Patients with heritable thoracic aortic disease (H-TAD) with causal mutations in the known H-TAD genes.
11110001|NCT04005950||medical doctors|
11110002|NCT04005950||paramedics|
11110003|NCT04005937|Experimental|H-reflex|H-reflex with different interstimulus interval of the plegic side soleus muscle were tested
11110004|NCT04005924|No Intervention|Control|Bread and sugar-free blackberry jam breakfast
11110005|NCT04005924|Experimental|Low dose|Bread and sugar-free blackberry jam breakfast with 6 g arabinogalactan
11110006|NCT04005924|Experimental|High dose|Bread and sugar-free blackberry jam breakfast with 21 g arabinogalactan
11110007|NCT04005911||Post-Surgical|Patients who underwent surgery and were admitted to the PACU
11110008|NCT04005898|Experimental|Experimental: near-infrared cholangiography|Each subject included in the study will be subjected to a fluorescence cholangiography. The control group will be the same patient. The study consists of knowing if fluorescence is able to visualize structures that are not seen with the naked eye. For this purpose the structures are visualized with normal light and then with infrared light of the same patient. During laparoscopic cholecystectomy it will change between normal and infrared light.
11110009|NCT04005885|Experimental|comfilcon A, then somofilcon A, then stenfilcon A contact lens|Participants will be fitted and wear the comfilcon A lens on a daily wear, reusable basis for 1 month, then fitted and wear the somofilcon A daily disposable test lens for 1 week of daily wear, then fitted and wear the stenfilcon A daily disposable test lens for 1 week of daily wear.
11110010|NCT04005885|Experimental|comfilcon A, then stenfilcon A, then somofilcon A contact lens|Participants will be fitted and wear the comfilcon A lens on a daily wear, reusable basis for 1 month, then fitted and wear the stenfilcon A daily disposable test lens for 1 week of daily wear, then fitted and wear the somofilcon A daily disposable test lens for 1 week of daily wear.
11110011|NCT04005872|Experimental|Nano Silver Fluoride|2 drops of nano silver fluoride (NSF) applied on the last soft carious layer using micro brush
11110012|NCT04005872|Active Comparator|Calcium Hydroxide|Calcium hydroxide placed on the last soft carious layer approaching the pulp
11110013|NCT04005859|Active Comparator|CONTROL: IV Lido|CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)
11110014|NCT04005859|Experimental|EXPERIMENTAL: Exparel|EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)
11110015|NCT04005846|Other|Active tDCS first / Sham tDCS second|Receiving active tDCS during the first visit followed by sham tDCS on the next visit
11110016|NCT04005846|Other|Sham tDCS first / Active tDCS second|Receiving sham tDCS during the first visit followed by active tDCS on the next visit
11110017|NCT04005833||COPD exacerbation|COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)
11110018|NCT04005820|Experimental|children and young adults supported in one of SFCE's centers|
11110019|NCT04005807|Experimental|Cohort 1 (fasted condition)|10 mg BPN-14967 or placebo
11110020|NCT04005807|Experimental|Cohort 2 (fasted condition)|25 mg BPN-14967 or placebo
11110021|NCT04005807|Experimental|Cohort 3 (fasted condition)|50 mg BPN-14967 or placebo
11110022|NCT04005807|Experimental|Cohort 4 (fed condition)|10 mg BPN-14967 or placebo
11110023|NCT04005807|Experimental|Cohort 5 (high-fat fed condition)|10 mg BPN-14967 or placebo
11110024|NCT04005794|Active Comparator|VR Social Skills Training|Participants will undergo a virtual reality social skills training program for 10 sessions. Each session takes about an hour. Participants visit the lab twice a week. Therefore, the training duration is 5 weeks.
11110025|NCT04005794|Other|Cognitive training game|If there is a significant improvement in social skills for the active treatment condition, the reason might be that the participants were exposed to social environment by coming to the lab and interacting with the research staff twice a week for 5 weeks and/or they used a computerized training tool twice a week for 5 weeks. In order to control for these potential confounds, we included a cognitive training arm. Participants will undergo a commercially available brain fitness program (Posit Science) for ten 1-hour sessions (twice a week for 5 weeks).
11110026|NCT04005794|No Intervention|Healthy Controls|Healthy controls are recruited to yield comparison data. They do not undergo training.
11110027|NCT04005781|Experimental|Hydroxychloroquine sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
11110028|NCT04005781|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
11110029|NCT04005768|Experimental|Hydroxychloroquine Sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
11110030|NCT04005768|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
11110066|NCT04005521|No Intervention|Control group|No intervention, only encouragement to eat and drink for as long as possible during treatment
11110258|NCT04004182|Active Comparator|Fruit bar|Fruit bar Plus Oral Glucose Tolerance test (OGTT)
11110031|NCT04005755|Experimental|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
11110032|NCT04005742||Healthy|Participants recruited to the healthy arm of the BORICC Study (BORICC1) at baseline.
11110033|NCT04005742||Polyp|Participants recruited to the polyp arm of the BORICC Study (BORICC2) at baseline, with a prior history of polyps.
11110034|NCT04005729|Experimental|Cangrelor + Ticagrelor|Bolus of cangrelor (30 mcg/kg) and immediately afterwards a continuous intravenous infusion of 4 mcg/kg/min at the start of the primary percutaneous coronary intervention. Crushed and dissolved ticagrelor tablets (180 mg) will be given via inserted enteral tube.
11110035|NCT04005729|No Intervention|Ticagrelor|Crushed and dissolved ticagrelor tablets (180 mg) will be given via enteral tube (standard care).
11110036|NCT04005716|Experimental|tislelizumab plus etoposide and platinum|
11110037|NCT04005716|Active Comparator|Placebo plus etoposide and platinum|
11110038|NCT04005703||Pediatric Hodgkin's lymphoma|Children with newly diagnosed Hodgkin's lymphoma
11110039|NCT04005690|Experimental|Arm I (cobimetinib)|Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
11110040|NCT04005690|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery.
11110041|NCT04005677||lung cancer|
11110042|NCT04005677||benign lung nodule|
11110043|NCT04005677||lung nodule|
11110044|NCT04005664|No Intervention|Bolus group|Hypotension occurring under spinal anaesthesia (SBP < 90mmHg) requires pharmacological treatment. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. The dose within this range will be decided by the attending anaesthetist. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
11110045|NCT04005664|Active Comparator|Phenylephrine coload group|Phenylephrine 500ug will be added to the first litre of ringer's lactate infused on initiation of spinal anaesthesia. If the phenylephrine infusion protocol is being used, and the mean arterial pressure (MAP) rises to greater than 20% of the initial MAP, and where this rise in MAP is not due to a recent bolus of either phenylephrine or ephedrine (within 2 minutes), the Ringers Lactate infusion will be switched off. The pharmacological management of hypotension, once diagnosed, will be the same regardless of the protocol being used. If the heart rate is greater than 70 beats per minute, phenylephrine will be administered in a dose of 50-100 mcg as an intravenous bolus. If the heart rate is less than 70 beats per minute, ephedrine will be administered in a dose of 5-10 mg. In both arms, Ringers Lactate fluid should run fast if hypotension occurs.
11110046|NCT04005651|Experimental|POD L GF|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the POD L GF arm. Subjects will be implanted bilaterally with the European Conformity (CE) marked POD L GF trifocal IOL and assessed according to the study visit schedule.
11110047|NCT04005651|Active Comparator|Symfony®|Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
11110048|NCT04005651|Active Comparator|AcrySof®|Approximately 50 subjects who are scheduled for monofocal IOL implantation and enrolled in the study will be placed in the AcrySof® arm. Subjects will be implanted bilaterally with the CE marked AcrySof® IQ monofocal IOL and assessed according to the study visit schedule.
11110049|NCT04005638||Autoimmune Cytopenia|
11110050|NCT04005612|Experimental|vitamin d3 group|weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks
11110051|NCT04005612|Experimental|omega3-Fatty Acid group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
11110052|NCT04005612|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily
11110053|NCT04005612|No Intervention|Control group|NO INTERVENTION
11110054|NCT04005599|Active Comparator|Remifentanil group|Intravenous anesthesia with propofol and remifentanil
11110055|NCT04005599|Experimental|Magnesium group|Intravenous anesthesia with propofol and magnesium sulfate
11110056|NCT04005573|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
11110057|NCT04005573|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
11110058|NCT04005573|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
11110059|NCT04005573|Other|control group|no intervention was given
11110060|NCT04005560|Other|patient|Score of PedSQL who is the Pediatric Quality of Life Questionnaire
11110061|NCT04005547|Experimental|Program+survey|
11110062|NCT04005547|No Intervention|Survey-only|
11110063|NCT04005534|Placebo Comparator|Regular group|Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 0.5% levobupivacaine with adrenaline 1:200,000 plus 5 ml 2% lidocaine with adrenaline 1:200,000) and sedation ( midazolam 3 mg, fentanyl 50 µg and dexmedetomidine 1 µg/kg (infusion lasting 10 min) followed by 0.5 µg/kg/min).
11110064|NCT04005534|Experimental|Preemptive group|Patients from this group will undergo ultrasound-guided brachial plexus blockade, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 0.5% levobupivacaine with adrenaline 1:200,000 plus 5 ml 2% lidocaine with adrenaline 1:200,000) and sedation ( midazolam 3 mg, fentanyl 50 µg and dexmedetomidine 1 µg/kg (infusion lasting 10 min) followed by 0.5 µg/kg/min).
11110721|NCT04000997||Success group|Patients with a successful endotracheal extubation
11110067|NCT04005508||OSA (Watch PAT AHI >/= 15 events per hour)|Patients found to have OSA by an overnight sleep study
11110068|NCT04005508||Non-OSA (Watch PAT AHI < 15 events per hour)|Patients found NOT to have OSA by an overnight sleep study
11110069|NCT04005495|Experimental|Teaching kitchen program|The teaching kitchen model is an innovative, multidisciplinary approach for motivating and establishing healthful habits and behaviors. The program combines didactic information with experiential learning in nutrition, culinary arts, exercise, yoga, and mindfulness.
11110070|NCT04005469|Experimental|Trepostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
11110071|NCT04005456|Other|N of 1 Tent|Personalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
11110072|NCT04005456|Other|Wellness Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
11110073|NCT04005456|Other|Elevated Homocysteine Bucket|Personalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
11110074|NCT04005456|Other|Dental Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
11110075|NCT04005456|Other|Immune Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
11110076|NCT04005456|Other|Elevated Anti-Nuclear Antibodies (ANA) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
11110077|NCT04005456|Other|Autoimmune Conditions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
11110078|NCT04005456|Other|Symptomatic Fatigue/Myalgias Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
11110079|NCT04005456|Other|Gastrointestinal Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
11110080|NCT04005456|Other|Irritable Bowel Syndrome (IBS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
11110081|NCT04005456|Other|Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
11110082|NCT04005456|Other|Wellness Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
11110083|NCT04005456|Other|Metabolic Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
11110084|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket C/S Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
11110085|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket R/I Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
11110086|NCT04005456|Other|Ketogenic Product Development Exploratory Group|Subgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
11110087|NCT04005456|Other|Reproductive Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
11110088|NCT04005456|Other|Perimenopausal and Menopausal Transitions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
11110089|NCT04005456|Other|Premenstrual Syndrome Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
11110188|NCT04004715|Active Comparator|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
11110090|NCT04005456|Other|Polycystic Ovary Syndrome (PCOS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
11110091|NCT04005456|Other|Andropause/Late Onset Hypogonadism Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
11110092|NCT04005443|Other|PET at 68Ga-NODAGA-RGD|The first PET scan will be performed within a maximum of one month following the initial ophthalmologic assessment including OCT and measurement of visual acuity (M0);
11110093|NCT04005430|Experimental|Phase 1|Phase I open label study
11110094|NCT04005417||Stannous fluoride dentifrice|Twice daily brushing
11110095|NCT04005417||Positive control dentifrice|Twice daily brushing
11110096|NCT04005417||Negative control dentifrice|Twice daily brushing
11110097|NCT04005404|Experimental|intertrochanteric femoral fractures|
11110098|NCT04005404|Experimental|neck femur fractures|
11110099|NCT04005404|Experimental|subtrochanteric femoral fractures|
11110100|NCT04005391|Experimental|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
11110101|NCT04005391|No Intervention|Routine Care offered to Control Clusters|Women will receive routine postpartum care
11110102|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
11110103|NCT04005378|Other|Usual Care|Usual care provided by CSC center
11110104|NCT04005365|Experimental|Prop+neochemo|
11110105|NCT04005352|Experimental|Brolucizumab|Intra-vitreal injection
11110106|NCT04005352|Active Comparator|Aflibercept|Intra-vitreal injection
11110107|NCT04005339|Experimental|Single Arm|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.
11110108|NCT04005326|Experimental|QLB Group|this group will receive ultrasound-guided transmuscular quadratus lumborum block; (Anterior QLB or QLB III)
11110109|NCT04005326|Experimental|FIB Group|this group will receive suprainguinal fascia iliaca block
11110110|NCT04005313|Experimental|Comparison between unisensory and multisensory stimulation|The same person receive unisensory and multisensory stimulation on separate day.
11110111|NCT04005313|Experimental|The treatment effect of multisensory stimulation|The persons living in long-term care facility would receive multisensory stimulation for one month.
11110112|NCT04005313|Experimental|Multisensory stimulation and virtual reality.|The subjects would receive vibroacoustic therapy or virtual reality.
11110113|NCT04005313|Experimental|Vibroacustic therapy on neck pain.|The subjects would receive either vibroacustic therapy or music therapy.
11110114|NCT04005300|Experimental|low calorie feeding group|Enteral nutrition was fed at 10-20kcal/kg/d for the first three days before identifying the refeeding syndrome
11110115|NCT04005300|Active Comparator|standard calorie feeding group|Enteral nutrition was fed at 500-750kcal/d for the first three days before identifying the refeeding syndrome
11110116|NCT04005300|No Intervention|RFS group|The definition of RFS is that serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded. And it is divided into three sub-group that is Group 1 that a drop of >0.16 mmol/L from any previous measurement, to below 0.65 mmol/L within 72 h after starting nutritional support, Group 2 that their serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded, and Group 3 that their serum phosphate concentration decreased to below 0•32 mmol/L within 72 h after starting nutritional support.
11110117|NCT04005300|No Intervention|nRFS group|It is not up to the RFS definition
11110118|NCT04005287|Placebo Comparator|Placebo Low Dose|WST-057 Matching placebo 2 mL volume
11110119|NCT04005287|Placebo Comparator|Placebo High Dose|WST-057 Matching placebo 4mL volume
11110120|NCT04005287|Experimental|Active Low Dose|WST-057 2mL volume
11110121|NCT04005287|Experimental|Active High Dose|WST-057 4mL volume
11110122|NCT04005261||patients with type 2 diabetes treated with insulin|"Patients with type 2 diabetes who have been using insulin for at least six months.
~They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital"
11110123|NCT04005248|Other|Testing for HCV|HCV IgG test and questionnaire; both at visit to the sexual health clinic
11110124|NCT04005222|Other|SELENIUM|The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
11110125|NCT04005222|Other|MELATONIN|The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
11110126|NCT04005209|Active Comparator|Pain management without ketamine infusion|Pain management without ketamine infusion. No other restrictions on pain management or medications.
11110127|NCT04005209|Experimental|Pain management with ketamine infusion|Pain management that includes a ketamine infusion. No other restrictions on pain management or medications.
11110128|NCT04005183||All patients|Patients undergoing nephrectomy at the University Health Network are eligible for enrolment. All histological subtypes and stages are eligible. Tumor, blood and urine samples are acquired at the time of nephrectomy.
11110129|NCT04005170|Experimental|PD-1 group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50.4 Gy in 28 fractions over 5-6 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 and 2 cycles of toripalimab 240 mg on days 1, 22 followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
11110189|NCT04004702|Experimental|Levetiracetam|All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
11110130|NCT04005157|Experimental|Patients undergoing bronchoscopic MWA|Patients meeting the inclusion criteria will be enrolled in the study and undergo ENB guided MWA. Chest CT will be performed at 1 day after the procedure to confirm the complications and then at 1 month, every 3 months for 2 years, and every 6 months for 3 years thereafter after the procedure. PET/CT will be performed 3 months after MWA to assess the treatment response.
11110131|NCT04005144|Experimental|Treatment (brigatinib, binimetinib)|Patients receive brigatinib PO QD and binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11110132|NCT04005131|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 10 weeks
11110133|NCT04005131|Active Comparator|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 weeks
11110134|NCT04005118||preoperative preparation on microbiome composition|Mechanical Bowel Preparation + oral antibiotics group: receiving mechanical bowel preparation only MBP will be prepared with 4 liters of Polyethylene glycol (PEG) solution to be started 24 hours before the planned surgery. 500mg of Metronidazole will be administrated 3 times one day before the surgery at 2 pm, 3 pm and 10 pm.
11110135|NCT04005105|Active Comparator|Intensive management|"Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure. Intra-surgical values of ± 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group
~1 based on cardiac index and MPP will be followed for 24 hours."
11110136|NCT04005105|No Intervention|Standard management|MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.
11110137|NCT04005092|Active Comparator|Helmet Continuous Positive Airway Pressure(hCPAP)|Helmet CPAP produce a better physiological outcomes after 1-hour intervention
11110138|NCT04005092|Active Comparator|High Flow Nasal Cannula(HFNC)|HFNC produce a better physiological outcomes after 1-hour intervention
11110139|NCT04005079|Experimental|Treatment Group|2% pilocarpine and standard of care post op drops ( Prednisolone acetate and Ofloxacin)
11110140|NCT04005079|Active Comparator|Control Group|Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine
11110141|NCT04005066|Other|Cohort 1|metastatic colorectal cancer patients who are accordance with Elunate® package insert
11110142|NCT04005066|Other|Cohort 2|other patients suitable for according to investigator's judgement
11110143|NCT04005053|Experimental|Low-Dose NAC|3600 NAC mg/day
11110144|NCT04005053|Experimental|High-Dose NAC|5400 NAC mg/day
11110145|NCT04005053|Placebo Comparator|Placebo|Placebo
11110146|NCT04005040|Active Comparator|Mobile X-ray|Intervention: X-ray examination in the patients own home
11110147|NCT04005040|Placebo Comparator|X-ray at the Hospital|Control: X-ray at the hospital
11110148|NCT04005027|Experimental|Intermittent graded exercise (INT)|The intermittent graded exercise test (INT) increase treadmill speed incrementally using three minute stage duration on a motorised treadmill. However, the speed within each three minute exercise bout will vary every 30 s between the target speed, and a complete pause for 30 s. The acceleration of the treadmill belt will be set to its maximum capability.
11110149|NCT04005027|Active Comparator|Continuous graded exercise (CONT)|The continuous graded exercise test (CONT) will increase treadmill speed incrementally using three minute stage duration on a motorised treadmill
11110150|NCT04005014|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SE and presence of high myopia in the subsequent 10 years.
11110151|NCT04005014|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
11110152|NCT04005001|Experimental|Experimental|The experimental arm will involve patients monitored by HindSight.
11110153|NCT04005001|Active Comparator|Control|The control arm will involve patients monitored by InSight.
11110154|NCT04004988|Experimental|Tirzepatide Test|Tirzepatide administered subcutaneously (SC) to healthy participants via an autoinjector (AI) in one of two study periods.
11110155|NCT04004988|Experimental|Tirzepatide Reference|Tirzepatide administered SC to healthy participants via a prefilled syringe (PFS) in one of two study periods.
11110156|NCT04004975|Experimental|anlotinib|12 mg daily from day 1 to 14 of a 21-day cycle
11110157|NCT04004949||study group (high scapular dyskinesia )|group A (30 patients): with high scapular dyskinesia scores
11110158|NCT04004949||control group (low or no scapular dyskinesia )|group B (30 patients): with low or no scapular dyskinesia scores. (30 patients): with low or no scapular dyskinesia scores.
11110159|NCT04004936|Active Comparator|Active Feedback|EQUIPPED with active provider feedback, implementing one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
11110160|NCT04004936|Active Comparator|Passive Feedback|EQUIPPED with passive provider feedback, implementing monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
11110161|NCT04004923|Active Comparator|Monopolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
11110162|NCT04004923|Active Comparator|Bipolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
11110163|NCT04004910|Experimental|Immunopheresis|All patients will receive up to 16 weeks of initial treatment as per study arm assignment, which will include up to 48 LW-02 device-based immunopheresis treatments over a 4-month period (up to 3 procedures per week). Each patient assigned to the treatment with LW-02 device-based immunopheresis will require central vascular access for the procedure. In general, a cuffed,tunneled dual-lumen catheter will be inserted into a central vein and remain in situ throughout the treatment phase or longer if additional treatments are clinically indicated.Immunopheresis will be performed using the LW-02 device used in-line with the Terumo BCT Spectra Optia Apheresis System® (or alternate centrifugal apheresis device) with a secondary plasma processing system such as the Secondary Processing Device [SPD].
11110223|NCT04004468|Active Comparator|Conjugate Training|Utilization of conjugate strength model
11110164|NCT04004910|Experimental|Immunopheresis combined with weekly chemotherapy|All patients will receive up to 16 weeks of treatment as per study arm assignment, which will include up to 48 LW-02 device-based immunopheresis treatments over a 4-month period (up to 3 procedures per week). Each patient will require central vascular access for the procedure. Immunopheresis will be performed using the LW-02 device used in-line with the Apheresis System with a secondary plasma processing system. Patients will be treated with immunopheresis combined with iv chemotherapy regimen administered iv on a weekly basis (every 7 days) in doses: 80 mg/m2 of paclitaxel and carboplatin AUC2 (Calvert formula). Patients will be administered their chemotherapy following the last LW-02 device-based immunopheresis procedure of each week. Chemotherapy infusion will follow immunopheresis, but will be initiated not earlier than 90 minutes after completion of the procedure in the absence of any immunopheresis-related side effects (i.e. hypotension).
11110165|NCT04004910|Active Comparator|Chemotherapy|Patients who are assigned chemotherapy arm of the study will be treated with paclitaxel+carboplatin chemotherapy alone. The chemotherapy regimen will be administered intravenously on a weekly basis (every 7 days) in doses: 80 mg/m2 of paclitaxel and carboplatin AUC2 (Calvert formula).
11110166|NCT04004897|Other|Preeclampsia group|Patients with preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
11110167|NCT04004897|Other|Pregnants without preeclampsia|Pregnant women without preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
11110168|NCT04004884||UPA Treatment|Women who had completed a full 12-week treatment course of Ulipristal Acetate for symptomatic uterine fibroids since September 2018
11110169|NCT04004871|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.
11110170|NCT04004858|Active Comparator|Standard margin|Patient cohort planned with the current standard PTV margin
11110171|NCT04004858|Experimental|Reduced margin|Patient cohort planned with the reduced margin validated from the retrospective study
11110172|NCT04004845||Pregnant women|We are including only women who are age 18 or over, who have a single baby (not twins), with the baby's head down, and are between 36 weeks 6 days and 42 weeks 0 days of pregnancy.
11110173|NCT04004819|Experimental|Rituximab group|Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
11110174|NCT04004819|No Intervention|Control group|Patients will receive usual care and drug use.
11110175|NCT04004806|No Intervention|Pre-Intervention|Phase 1 (Observational phase): All residents and staff physicians rotating through the inpatient medicine services during the first three (3) months, who agreed to be a part of the study, will be provided with Hill Rom tracking devices to quantify the time spent at the patient's bedside by each member as part of the daily practice.
11110176|NCT04004806|Experimental|Intervention|Phase 2 (Intervention phase): The interventional phase will be six (6) months duration. During this period, the recorded time spent by the individual study participants at the patient's bedside will be compared to their respective peers, and percentile scores will be generated. Based on these percentile scores, the study participants will receive emails notifying them of the results. Participants whose scores fall in the lower 50th percentile will be encouraged to increase patient interaction times. Participants with scores in the top 50th percentile will receive congratulatory emails to encourage them to keep up the performance.
11110177|NCT04004806|No Intervention|Post-Intervention|Phase 3: (Post Intervention observation phase): The final phase of the study will be again three (3) months. The intervention of feedback emails and text pages will be discontinued and the study participants will only be monitored to see if the past intervention made an impact on their daily clinical practice in terms of time spent with the patients.
11110178|NCT04004793|Experimental|Dapagliflozin plus intensive lifestyle intervention|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
11110179|NCT04004793|Placebo Comparator|Placebo plus intensive lifestyle intervention|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
11110180|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
11110181|NCT04004754||Complicated CL in Gondar|Patients treated with miltefosine in Gondar will be followed up to see outcomes of treatment
11110182|NCT04004754||Complicated CL in Boru Meda|Patients treated with miltefosine in Boru Meda hospital will be followed up to see outcomes of treatment
11110183|NCT04004741|Experimental|Osteopathic Manipulative Treatment|Group A will receive osteopathic treatment by NMM/OMM board certified attending physicians. The protocol for the OMT intervention group is based on the guidelines set forth previously in textbooks. The protocol will last 25 minutes total, with 10 minutes for the evaluation and 15 minutes for treatment. The protocol will start in ribs so as to not exacerbate any tachyarrhythmias with rib raising, thoracic myofascial release, and a pectoralis lift. The investigator will then proceed with opening the thoracic inlet, cervical myofascial release, suboccipital release, and then end by checking for and treating Chapman's points. The physician will submit their osteopathic evaluation and fill out a form in order to determine if certain arrhythmias have an associated trigger point.
11110184|NCT04004741|Sham Comparator|Light Touch Treatment|Group B will receive a light touch treatment, based on previous research done studying heart rate variability and OMM, where sham treatment was utilized. The protocol consisted of contacting the right ankle, left knee, right hip, diaphragm, right shoulder, neck, and cranium for precisely two minutes each, with the goal of preventing placebo autonomic nervous system stimulation. The protocol is 25 minutes long, with 10 minutes for the evaluation and 15 minutes for treatment.
11110185|NCT04004728|Other|laser, leg veins, sclerotherapy|to compare laser and sclerotherapy on treating leg veins
11110186|NCT04004715|Experimental|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
11110187|NCT04004715|Active Comparator|Whey Protein|commercially available whey protein isolate
11110190|NCT04004689||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join the rehabilitation program.
~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
11110191|NCT04004676|Active Comparator|Placebo|isocaloric carbohydrate - only containing drink will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
11110192|NCT04004676|Experimental|Ketone_CHO|Ketone - Carbohydrate supplementation will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
11110193|NCT04004663|Experimental|Treatment Sequence 1|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D).
11110194|NCT04004663|Experimental|Treatment Sequence 2|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment D); Period 3 (Treatment A); Period 4 (Treatment C).
11110195|NCT04004663|Experimental|Treatment Sequence 3|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment C); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment B).
11110196|NCT04004663|Experimental|Treatment Sequence 4|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment D); Period 2 (Treatment C); Period 3 (Treatment B); Period 4 (Treatment A).
11110197|NCT04004650|No Intervention|Primary closure|Primary perineal closure after extralevator abdomino perineal resection
11110198|NCT04004650|Experimental|Gluteal turnover flap|Gluteal flap reconstruction of the pelvic floor after extralevator abdomino perineal resection
11110199|NCT04004637|Experimental|CD7 CAR-T cells Infusion|
11110200|NCT04004624|Active Comparator|Study Arm|The left ventricle is mapped during atrial and right or left ventricular pacing (site close to the infarct) at a similar cycle length of 600ms. Radio-frequency ablation is performed selectively in areas of activation slowing (defined as ≤40ms per 5mm while voltage abnormalities and late potentials were not specifically targeted.
11110201|NCT04004624|No Intervention|Control|Patient who underwent ablation using similar technology and irrigated catheters guided by standard substrate mapping techniques.
11110202|NCT04004611|Experimental|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) and Subcutaneously (SC). Participants >40 kilograms (kg)
11110203|NCT04004611|Experimental|Mirikizumab Dose 2|Mirikizumab administered IV and SC. Participants ≤40 kg
11110204|NCT04004611|Experimental|Mirikizumab Dose 3|Mirikizumab administered IV and SC. Participants ≤40 kg
11110205|NCT04004598|Experimental|golf training|12-week golf training program
11110206|NCT04004585|Experimental|Intervention|This was a single arm study with all participants receiving the same intervention. Participants will receive a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour.
11110207|NCT04004572|Experimental|LEAP Regimen|Pegaspargase, 2500IU/m2, im, day 1 Sintilimab, 200mg, iv day1 Anlotinib, 8mg, oral, day 1-14 The LEAP regimen will be repeated every 3 weeks.
11110208|NCT04004559||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|Cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the training cohort.
11110209|NCT04004559||Sun Yat-sen University Cancer Center|Cohort of Sun Yat-sen University Cancer Center is validation cohort 1.
11110210|NCT04004559||Tungwah Hospital of Sun Yat-Sen University|Cohort of Tungwah Hospital of Sun Yat-Sen University is validation cohort 2.
11110211|NCT04004546|Experimental|Intervention group|At baseline: video and education booklet. 2-weeks after enrollment: telephone call by nurse.
11110212|NCT04004546|No Intervention|Control group|Usual care
11110213|NCT04004533||Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
11110214|NCT04004520|Experimental|Virtual Reality with Meditation|Participants will receive a virtual reality and audio guided mindfulness meditation program available at (https://guidedmeditationvr.com/)
11110215|NCT04004520|Other|Virtual Reality Control|Participants will receive a virtual reality of historic photographs and written narratives program (https://lookingglassvr.com/)
11110216|NCT04004520|Other|Audio Control|Participants will receive an online audio-only guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations).
11110217|NCT04004507|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye (QD) for one day.
11110218|NCT04004507|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye (QD) for one day.
11110219|NCT04004494|Experimental|3D Reconstruction|Chest contrast-enhanced computed tomography will be performed preoperatively, and 3-dimensional reconstruction will be formed based on the data of chest CT. Video-assisted segmentectomy will be performed guided by the image of 3-dimensional CT. IPS-lung software (Shenzhen Yorktal Digital Medical Imaging Technology Company, Shenzhen, China) will be used preoperatively to construct a 3D-image to ascertain the position and structure of targeted segmental blood vessels and bronchi.
11110220|NCT04004494|No Intervention|Chest computed tomography|Chest contrast-enhanced computed tomography will be performed preoperatively. Video-assisted segmentectomy will be performed based on the image of preoperative chest CT
11110221|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
11110222|NCT04004468|Active Comparator|Standard Periodization Training|Utilization of traditional periodization strength training model
11110224|NCT04004455||Childhood cancer|Children with an established cancer diagnosis (any type) between 8-18 years old that are currently being treated for cancer (not necessarily hospitalized) in the University Hospital Brussels or Ghent.
11110225|NCT04004455||Healthy controls|Healthy children between 8-12 years old, selected based on age and sex.
11110226|NCT04004442|Experimental|Avelumab + AVB-S6-500|
11110227|NCT04004429|Experimental|50 mg AP1189|50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
11110228|NCT04004429|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.
11110229|NCT04004429|Placebo Comparator|Placebo|Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.
11110230|NCT04004416|Placebo Comparator|Healthy Controls|
11110231|NCT04004416|Experimental|Early Psychosis patients|
11110232|NCT04004416|Experimental|Schizophrenia or Schizoaffective disorder patients|
11110233|NCT04004416|Experimental|Bipolar disorder patients|
11110234|NCT04004403|Experimental|Alternate day fasting|"These participants will consume 25% of their baseline energy needs on the fast day and eat ad libitum at home on alternating feed days."
11110235|NCT04004403|Experimental|Exercise|These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session.
11110236|NCT04004403|Experimental|Combination alternate day fasting plus exercise|"These participants will consume 25% of their baseline energy needs on the fast day and eat ad libitum at home on alternating feed days. They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session."
11110237|NCT04004403|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.
11110238|NCT04004377||acoustic neuroma monitored radiologically|patient with an acoustic neuroma (vestibular schwannoma) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, monitoring by radiology
11110239|NCT04004377||acoustic neuroma whose treatment is surgical|patient with an acoustic neuroma (vestibular schwannoma or) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, resection surgery planified
11110240|NCT04004325|Experimental|Cohort A|
11110241|NCT04004325|Experimental|Cohort B|
11110242|NCT04004312|Experimental|Single Fraction SBRT in the treatment of prostate cancer|Prior to treatment, a hydrogel spacer will be inserted between the recutm and prostate. A urinary catheter will also be inserted in the bladder. A single dose of 19Gy will be delivered with an IMRT technique. The treatment should last approximately 30 minutes. After the treatment, the urinary catheter will be removed.
11110243|NCT04004299|Other|HCV self-test intervention|Diagnostic intervention: participant performs capillary blood sampling at home in between outpatient clinic visits (3 months after) and sends the sample to the investigator's laboratory by regular post mail for HCV RNA analysis. This is on top of standard of care ALT measurement at every 6-monthly outpatient clinic visit, followed by HCV RNA testing if ALT is elevated. Follow-up period is 2 years, in which participants will perform and send in 4 self-tests, in combination with filling out 4 questionnaires into sexual risk behavior.
11110244|NCT04004273|Experimental|Exercise|Participants randomised to the exercise training intervention will complete 24 moderate-intensity exercise training sessions over the subsequent six weeks (four times per week; ~50 min per session). Each week, three exercise training sessions will be supervised by the research team (visits three to 20), whilst one session will be unsupervised but monitored objectively using a heart rate monitor.
11110245|NCT04004273|No Intervention|Control|Participants randomised to control will receive no interventions and will be requested to maintain their habitual lifestyle during the six week intervention phase
11110246|NCT04004260|Experimental|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
11110247|NCT04004260|Other|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
11110248|NCT04004247|Experimental|Experimental group|"10-12 young healthy volunteers. Placed on semi-sitting position on the bed (40 deg.elevation). Calibration of electrical impedance tomography (EIT) on defined tidal volume 500ml, done with 500ml syringe connected to closed breathing circuit using full face mask as an interface.
~Insertion an esophageal and nasopharyngeal catheter for pressures measurement. In the first phase - spontaneous breathing with full face mask at 0, 5 and 10 cm H20 levels of PEEP.
~In the second phase - high flow oxygenation through nasal cannula, start with flow rate 10 L/min with gradual increase up to 60 L/min.
~Spirometry to determine functional residual capacity (FRC) before and after procedure is planed."
11110249|NCT04004234|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
11110250|NCT04004221|Experimental|Tislelizumab|200mg intravenously (IV) every 3 weeks(Q3W)
11110251|NCT04004208|Experimental|Aflibercept arm|Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
11110252|NCT04004208|Active Comparator|Laser photocoagulation arm|Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
11110253|NCT04004195|Experimental|Healthy participants|
11110254|NCT04004195|Experimental|Participants with mild renal impairment|
11110255|NCT04004195|Experimental|Participants with moderate renal impairment|
11110256|NCT04004195|Experimental|Participants with severe renal impairment|
11110257|NCT04004182|Active Comparator|OGTT session|Oral Glucose Tolerance test (OGTT)
11110259|NCT04004182|Experimental|Fruit bar with bilberry|Fruit bar with addition of 600 mg bilberry anthocyanins Plus Oral Glucose Tolerance test (OGTT)
11110260|NCT04004182|Experimental|Fruit bar with bilberry and apple|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols Plus Oral Glucose Tolerance test (OGTT)
11110261|NCT04004169|Experimental|Arm 1: Intervention (stimulation ON)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
11110262|NCT04004169|Sham Comparator|Arm 2: Control (stimulation OFF)|This is a crossover trial. Each patient will receive 6 wks of stimulation ON (arm 1) and stimulation OFF (arm 2) in random order. After 6 months of intervening therapy, this 2-period crossover study will be repeated.
11110263|NCT04004156|Experimental|Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
11110264|NCT04004143||Cross-sectional|a cross-sectional study.
11110265|NCT04004117|Experimental|Fentanyl s/l|Sublingual fentanyl will consist in liquid fentanyl at a concentration of 25 mcg/mL, with preparation by the pharmacist of pre-dosed syringes of 12,5 mcg (0,5 mL).
11110266|NCT04004117|Placebo Comparator|Placebo|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
11110267|NCT04004104|Active Comparator|Control - Upright Exercise|Participants will perform upright exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
11110268|NCT04004104|Experimental|Intervention - Supine Exercise|Participants will perform supine exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
11110269|NCT04004091|Experimental|24-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
11110270|NCT04004091|Experimental|26-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
11110271|NCT04004091|Experimental|28-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
11110272|NCT04004091|No Intervention|24-Day Non Spermine Group|Subjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
11110273|NCT04004091|No Intervention|26-Day Non Spermine Group|Subjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
11110274|NCT04004091|No Intervention|28-Day Non Spermine Group|Subjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
11110275|NCT04004078||Group A|Non-gene directed group：Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）. Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）.
11110276|NCT04004078||Group B|Gene directed group（UMs and EMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs，EMs.
11110277|NCT04004078||Group C|Gene directed group（IMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with IMs.
11110278|NCT04004078||Group D|Gene directed group（PMs）： Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 100mg . Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
11110279|NCT04004065|Experimental|Part A: SRP-5051|Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051, monthly, via intravenous (IV) infusion for at least 12 weeks during Part A. Once the maximum tolerated dose (MTD) has been determined in Part A, all patients who have completed Part A will transition to Part B.
11110280|NCT04004065|Experimental|Part B: SRP-5051|Patients will receive SRP-5051 at the MTD determined in Part A, monthly, via IV infusion, for 24 weeks. This includes the patients who roll over from Part A, as well as the expansion cohort of approximately 15 patients who will enroll in the study at the beginning of Part B.
11110281|NCT04004052|Active Comparator|Group 1|Blockade of the LFCN is performed for therapeutic management of MP in group 1.
11110282|NCT04004052|Active Comparator|Group 2|Ten sessions of conventional TENS were applied to the group 2 daily 20 minutes per session, 5 days per week, for 2 weeks.
11110283|NCT04004052|Sham Comparator|Group 3|Sham TENS was applied to the group 3 with the same protocol.
11110284|NCT04004026||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform 3 m backwards walk test.
11110285|NCT04004013|Active Comparator|Lifenol|50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
11110286|NCT04004013|Placebo Comparator|Placebo|50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
11110287|NCT04004000|Experimental|Treatment|FSHD1 patients with genetic confirmation with receive 15 mg of losmapimod twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for for up to approximately 52 weeks.
11110288|NCT04003987|Active Comparator|ESP Block|For the ESP block the ultrasound is positioned in a parasagittal fashion, 2-3 inches lateral to the spinous process. This approach visualizes the transverse process. The needle is inserted cranial-to-caudal to make contact with the shadow of the transverse process, with the needle tip deep to the fascial plane of the erector spinae muscle. Injection of saline confirms the location of the needle, and the anesthetic is injected (40 ml into each side; 20 ml injected at T8 and 20 ml injected at T12)
11110350|NCT04003558||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is a training cohort.
11110289|NCT04003987|Active Comparator|TAP Block|For the TAP block, the ultrasound probe is placed transverse to the abdominal wall, between the iliac crest and the costal margin. The needle is placed in the plane of the probe and advanced until it is between the internal oblique and the transversus abdominis muscles. Once in the plane, 2 mL of saline is injected to confirm needle position, then the local anesthetic solution is injected (40 ml into each side; 20 ml injected for subcostal TAP and 20 ml injected for posterior TAP).
11110290|NCT04003974|Experimental|Treatment|FSHD1 patients with genetic confirmation will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
11110291|NCT04003974|Placebo Comparator|Placebo|FSHD1 patients with genetic confirmation will receive a Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily for 48 weeks.
11110292|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
11110293|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
11110294|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
11110295|NCT04003948|Experimental|Fixed dose|Ibogaine Hydrochloride 100 mg on each administration.
11110296|NCT04003948|Experimental|Ascending dose|Ibogaine Hydrochloride on ascending doses (100-200-300-400-500-600).
11110297|NCT04003935||Control|Continuing habitual diet and lifestyle.
11110298|NCT04003935||Active 1|Ingestion of a macro- and micro-nutrient rich shake, otherwise continuing habitual diet and lifestyle.
11110299|NCT04003935||Active 2|Ingestion of an encapsulated vitamin and phytonutrient supplement, otherwise continuing habitual diet and lifestyle.
11110300|NCT04003909|Experimental|ESP group|patients will have ultrasound guided ESP block before spinal anesthesia.
11110301|NCT04003909|Experimental|Control group|patients will have spinal Anesthesia without ESP block
11110302|NCT04003896|Experimental|Abemaciclib|Abemaciclib will be given as a single oral agent Approximately up to 27 subjects may be enrolled to attain at least 24 evaluable participants. The starting dose will be 200 mg twice daily. Dosing will continue daily for 28 days, this being one cycle. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.
11110303|NCT04003883||Emergency physicians|Emergency physicians doing shifts at the Medical University of Vienna's emergency response car will recieve a thorough cardiac pretesting. During shifts they will be attached to a Holter-ECG to detect changes in ST-T Segment and other ECG changes. Furthermore surrogate parameters of stress will be measured
11110304|NCT04003870|Experimental|Runner|Subject will undergo an assessment wearingeither the CASO or the HL. Sequence of CASO of HL will be randomly allocated.
11110305|NCT04003857|Experimental|PNEUMOSTEM®|A single intratracheal administration of Pneumostem® (10.0 x 10^6 cells/kg)
11110306|NCT04003857|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
11110307|NCT04003844|Experimental|Experimental|Investigational product (IP)
11110308|NCT04003818|Experimental|Teicoplanin|teicoplanin, administered orally 100-200 mg, twice a day
11110309|NCT04003805|Experimental|Switching from Smoking Cigarettes to SREC|
11110310|NCT04003805|Experimental|Switching from Smoking Cigarettes to Nicotine Mini-Lozenge|
11110311|NCT04003805|No Intervention|Usual Brand Cigarettes|
11110312|NCT04003792|Experimental|single arm prospective trial|
11110313|NCT04003779|Other|Participant stability with various room configurations|Single-arm. Ergonomically exploring patient stability moving around various configurations of a hospital room.
11110314|NCT04003766|Active Comparator|Percutaneous Biopsy|"The subject would undergo the standard of care procedure for a percutaneous biopsy of the liver.
~All percutaneous biopsies will be performed after administration of local anesthetic. No pre-procedure antibiotics will be administered. Subcostal or subxyphoid area will be cleaned and draped in the standard manner. 2% lidocaine solution will be injected subcutaneously using a 25-gauge needle and then administered into the subcutaneous tissue up to the liver capsule. A 16-gauge biopsy needle is inserted into the liver parenchyma under US or CT-guidance, with the location of needle placement left to the discretion of the performing radiologist. One or two core biopsy samples will be obtained. All procured specimens will be placed in a single specimen container of 10% formalin for tissue processing. When biopsy samples have been obtained, the patient will be taken to the recovery area for post-procedure monitoring."
11110315|NCT04003766|Active Comparator|Endoscopic-guided Ultrasound Biopsy|"The subject would undergo the standard of care procedure for an endoscopic-guided biopsy of the liver.
~The left lobe of the liver is identified from the gastric lumen, EUS-guided fine needle biopsy (FNB) will be performed using a 19-gauge FNB needle, with the choice of needle type at the discretion of the performing endoscopist. Stylet will only be used to puncture the liver at the time of the first pass and then subsequently removed. No suction will be used. Fanning technique will not be used. A total of 10 to-and-fro needle movements will be performed during each pass. A total of two passes will be performed.All tissue specimens procured will be placed in a single specimen container of 10% formalin for tissue processing. When two passes are complete under EUS-guidance, the echoendoscope will be withdrawn from the patient and the patient will be taken to the recovery area for post-procedure monitoring."
11110316|NCT04003753|Experimental|Exposure|"Study phase 1: The experimental intervention in the experimental group consists of three 20-minutes VR exposures (total duration in VR: 60 minutes).
~Study phase 2: The experimental intervention in the experimental group consists of six 30-minutes VR exposures as home training (total duration in VR: 3 hours) within two weeks."
11110317|NCT04003753|No Intervention|Control|"Study phase 1: The control group will not receive any active treatment. Instead they will use an App to make virtual tours (three times 20 minutes, total duration in VR: 60 minutes).
~Study phase 2: The control group will not receive any active treatment (untreated comparison group)."
11110318|NCT04003740|Experimental|Active tDCS|The anode will be placed over the right dorsolateral prefrontal cortex (DLPFC) and the cathode over the left DLPFC. Stimulation will be performed for 30 minutes with a current intensity of 2 mA. A ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero will be used.
11110319|NCT04003740|Sham Comparator|Sham tDCS|The same montage will be used. Sham stimulation will have the same ramp-up and ramp-down time in three different moments (beginning, middle and at the end of the session).
11110320|NCT04003727|Active Comparator|Neutral Position|Head and neck will be on neutral position.
11110321|NCT04003727|Active Comparator|Sniffing Position|Head and neck will be on sniffing position
11110322|NCT04003727|Active Comparator|Head Extension position|Head will be on simple extension position
11110323|NCT04003714|Experimental|Repetitive Transcranial Magnetic Stimulation Group|Patients in r-TMS group received r-TMS 20-min (1000 pulses) daily session, 5 days per weeks, for a total of 10 sessions.
11110324|NCT04003714|Sham Comparator|Sham Group|Control group received sham r-TMS with the same protocol.
11110325|NCT04003701|Active Comparator|Usual care group (control group)|Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head supported by the table (cancer patients) or stretched out and lying down along the body (CID patients), with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.
11110326|NCT04003701|Experimental|Robot-assisted puncture procedure (experimental group)|During the experimental intervention, the child, a nurse, one of the parents/guardians, a researcher and the humanoid robot NAO (H25 Academic Edition, Aldebaran Robotics, Paris, France) will be present in the same room. The child will sit down in the same position as with the usual care. Next to the patient a humanoid robot of three-foot tall will sit on eye level on a slanted reading table, at the non-puncture side. The nurse will carry out the puncture procedure as performed as usual. The robot is programmed to distract the child during the entire procedure (before, during and after the puncture) by playing a game with the child based on his/her interests. The child can therefore choose between a number of games in different themes. In the end the robot tells the child that he/she did very well. During the whole intervention, the robot will be re-activated for each phase only when the child and the nurse are ready.
11110327|NCT04003688|Placebo Comparator|Placebo group|Patient will be administered saline solution followed by venous general anesthesia.
11110328|NCT04003688|Experimental|Magnesium sulfate through real weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's actual weight followed by venous general anesthesia.
11110329|NCT04003688|Experimental|Magnesium sulfate through ideal corrected weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's ideal corrected weight followed by venous general anesthesia.
11110330|NCT04003675||Adolescent elite athletes|Adolescent boys and girls elite athletes over 16 years of age studying at elite sport high schools in Norway.
11110331|NCT04003675||Adolescent controls|Adolescent boys and girls over 16 years of age studying at regular high schools in Norway.
11110332|NCT04003675||Trainers and leaders|Trainers (with more than 20 percent employment status) at elite sport high schools, and leaders/principals at elite sport high schools and regular high schools.
11110333|NCT04003662||inpatients|Vital signs measurement - standard of care and prototype
11110334|NCT04003662||outpatients|Vital signs measurement - standard of care and prototype
11110335|NCT04003662||Healthy controls|Vital signs measurement - standard of care and prototype
11110336|NCT04003649|Experimental|Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)|Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
11110337|NCT04003649|Experimental|Arm II (nivolumab, IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
11110338|NCT04003636|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
11110339|NCT04003636|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
11110340|NCT04003623|Experimental|Pemigatinib|
11110341|NCT04003610|Experimental|Pemigatinib + Pembrolizumab|Combination of pemigatinib plus pembrolizumab.
11110342|NCT04003610|Experimental|Pemigatinib|Pemigatinib alone.
11110343|NCT04003610|Active Comparator|Standard of Care|Chemotherapy or pembrolizumab.
11110344|NCT04003597|Placebo Comparator|Usual-salt diet|Usual-salt diet followed for 5 weeks
11110345|NCT04003597|Active Comparator|Reduced-salt diet|Reduced-salt diet followed for 5 weeks
11110346|NCT04003584||Minimally Invasive Cardiac Bypass patients|
11110347|NCT04003584||Traditional Sternotomy Cardiac Bypass patients|
11110348|NCT04003571|Experimental|Augmented reality with functional electrical stimulation group|Ten participants in group A will undergo 30 minutes interactive augmented reality with functional electrical stimulation intervention and 30 minutes traditional physiotherapy per day, 3 days a week for 8 weeks.
11110349|NCT04003571|Active Comparator|Traditional physiotherapy group|Ten participants in group B will undergo 30 minutes treadmill and balance training as well as 30 minutes traditional conventional physiotherapy a day, 3 days a week, for 8 weeks.
11110351|NCT04003558||Sun Yat-sen University Cancer Center|The cohort of Sun Yat-sen University Cancer Center is a validation cohort.
11110352|NCT04003558||Tungwah Hospital of Sun Yat-Sen University|The cohort of Tungwah Hospital of Sun Yat-Sen University is a validation cohort.
11110353|NCT04003558||Shunde hospital of southern medical university|The cohort of Shunde hospital of southern medical university is a validation cohort.
11110354|NCT04003545|Active Comparator|Active group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
11110355|NCT04003545|Placebo Comparator|Placebo group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
11110356|NCT04003506|Experimental|Group LB|local infiltration of analgesia (LIA) with adductor canal block (ACB) will be given using 10ml of 1.33% liposomal bupivacaine
11110357|NCT04003506|Active Comparator|group bupivacaine|LIA with ACB will be given using 15ml 0.25% bupivacaine
11110358|NCT04003493|Experimental|Intervention group of nutrition|On the basis of a blood test, Mini Nutritional Assessment, food diary and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the caregivers. If the caregivers seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
11110359|NCT04003493|No Intervention|Control group of nutrition|The control group has the same examinations as the intervention group, they do not get dietary counseling.
11110360|NCT04003493|Experimental|Intervention group of oral health|After the dental hygienist interview and oral health examination, the caregivers in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions.
11110361|NCT04003493|No Intervention|Control group of oral health|The control group has the same examinations as the intervention group, they do not get oral health counseling.
11110362|NCT04003480|Experimental|FRAME|Vein graft to be treated with FRAME
11110363|NCT04003467|Experimental|EBP05 1.5mg|6 subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
11110364|NCT04003467|Experimental|Placebo for EBP05 0.5mg (3 or 5)|18 subjects will be randomly assigned to receive 3 or 5 tablets of matching EBP05 placebo orally each day for 6 months
11110365|NCT04003467|Experimental|EBP05 2.5mg|36 subjects will be randomly assigned to receive 5 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
11110366|NCT04003454|Other|Nontargeted Screening|The nontargeted HCV screening arm will consist of implementing non-risk-based rapid opt-out HCV screening.
11110367|NCT04003454|Other|Targeted Screening|"The targeted HCV screening arm will consist of implementation of risk-based rapid opt-out HCV screening using current recommendations for HCV screening by the CDC, USPSTF, and AASLD-IDSA. Targeted HCV screening will consist of offering HCV testing to those identified with the following specific risk characteristics, adapted from the above recommendations: born between 1945 - 1965 (birth cohort); injection drug use (IDU); intranasal drug use;tattoo or piercing in an unregulated setting; or blood transfusion or organ recipient before 1992."
11110368|NCT04003441|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
11110369|NCT04003441|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
11110370|NCT04003428|Experimental|Per-caesarean HIFU shots|Adjuvant treatment with High Intensity Focused Ultrasound (HIFU) performed the day of the scheduled childbirth, after confirmation of placenta accreta, and after fetal extraction by caesarian section.
11110371|NCT04003415|Experimental|Investigational Device Arm|Once consented for the study, participants will undergo testing with the investigational device for a one hour period. Testing will entail the participant wearing an EKG monitor, a respiratory rate monitor, a pulse oximeter, and being positioned next to the investigational device. The investigational device is contactless and captures chest movement of participants which allows it to estimate real time heart rate and respiratory rate. Additional data collected with the EKG monitor, respiratory rate monitor, and the pulse oximeter will be used to validate the vital sign data collected by the investigational device. After data collection is complete, participant involvement will then be over. Participants will have the option to return on a later date for additional testing (up to a maximum of three sessions total), within the six month window of the study. Participants will continue their standard of care therapies for their respiratory condition.
11110372|NCT04003402|Experimental|Sequence 1: Participants receiving treatment sequence A,B,C,D|"Eligible participants will received treatment sequence A, B, C, D. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~A= ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol"
11110373|NCT04003402|Experimental|Sequence 2: Participants receiving treatment sequence B,D,A,C|"Eligible participants will received treatment sequence B, D, A, C. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~B= ASP8062 with Placebo Alcohol; D = Placebo ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol; C= Placebo ASP8062 with Alcohol"
11110374|NCT04003402|Experimental|Sequence 3: Participants receiving treatment sequence C,A,D,B|"Eligible participants will received treatment sequence C, A, D, B. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~C= Placebo ASP8062 with Alcohol; A= ASP8062 with Alcohol; D = Placebo ASP8062 with Placebo Alcohol; B= ASP8062 with Placebo Alcohol"
11110375|NCT04003402|Experimental|Sequence 4: Participants receiving treatment sequence D,C,B,A|"Eligible participants will received treatment sequence D, C, B, A. Each participant will receive a single oral dose and each treatment period has a minimum of a 14 day washout period between investigational product administration.
~D = Placebo ASP8062 with Placebo Alcohol; C= Placebo ASP8062 with Alcohol; B= ASP8062 with Placebo Alcohol; A= ASP8062 with Alcohol"
11110376|NCT04003389|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
11110377|NCT04003389|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
11110378|NCT04003389|Placebo Comparator|placebo|Participants will receive placebo for 52 weeks.
11110379|NCT04003376|Active Comparator|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata
11110380|NCT04003376|Experimental|fractional carbon dioxide laser and triamcinolone acetonide|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide (10mg/ml)
11110381|NCT04003376|Experimental|fractional carbon dioxide laser and platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
11110382|NCT04003376|Experimental|fractional carbon dioxide laser and vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
11110383|NCT04003363||Participants with Myotonic Dystrophy|
11110384|NCT04003350|Active Comparator|Opioid Regimen|"Weeks 1-4
~Oxycodone 5 mg PRN q4h (30 tablets)
~Tramadol 50 mg PRN q6h (30 tablets)"
11110385|NCT04003350|Experimental|Multimodal pain regimen with PRN opioids|"Weeks 1-4
~Tylenol 1000 mg q8h (standing)
~Meloxicam 15 mg qD (standing).
~Gabapentin 200 mg BID (with morning and evening Tylenol dose)
~Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)
~Esomeprazole 20mg daily if not already on another H2 blocker or PPI
~Oxycodone 5 mg PRN q4h (30 tablets)
~Tramadol 50 mg PRN q6h (30 tablets)"
11110386|NCT04003337|No Intervention|GROUP A: Morphological embryo selection|Patients enrolled in group A will receive an embryo transfer according to classical morphological criteria.
11110387|NCT04003337|Active Comparator|GROUP B: Morpho-kinetics embryo selection|Patients enrolled in group B will receive an embryo transfer according to new morphokinetics criteria.
11110388|NCT04003324|Experimental|Intervention group|Self-monitoring tool (Activator) and general information
11110389|NCT04003311||Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
11110390|NCT04003298|Experimental|Electric toothbrush and power interdental device|Electric toothbrush and power interdental device
11110391|NCT04003298|Active Comparator|Electric toothbrush|Electric toothbrush
11110392|NCT04003285|Experimental|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
11110393|NCT04003285|Experimental|ALLO 50 nM|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
11110394|NCT04003285|Experimental|ALLO 150 nM|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
11110395|NCT04003272||Comprehensive Reverse Versa-Dial Titanium Glenosphere|Patients who have an allergy to typical cobalt chrome or other metal allergies had surgery to repair shoulder malfunction/disease.
11110396|NCT04003259|Experimental|Overweight and obese subjects|1-year lifestyle programme
11110397|NCT04003246|Experimental|Single Arm: Therapeutic Intervention|
11110398|NCT04003233|Experimental|Spring Distraction System|The SDS device will be implanted during a scoliosis correction operation.
11110399|NCT04003233|Experimental|Minimal Invasive Deformity Correction system|The MID-C device will be implanted during a scoliosis correction operation.
11110400|NCT04003220||MyeloDysplastic Syndrome|platelets <150 G/l and diagnosis of myelodysplasia according to the WHO classification (abnormal bone marrow features).
11110401|NCT04003220||Idiopathic Chronic Thrombocytopenia of Unknown Significance|Acquired thrombocytopenia lasting>6 months, without feature of dysimmunity (antiplatelet Ab, or anti nuclear Ab, anti ENA Ab, ANCA, anti-CCP Ab, cryoglobulinemia), normal bone marrow examination, absence of other thrombocytopenia in the family. All ICTUS patients included in the study will thus have a bone marrow aspiration.
11110402|NCT04003220||Immune Thrombocytopenic Purpura|Diagnosis of Immune Thrombocytopenic Purpura (ITP) is made according to the international ITP consensus (diagnostic criteria of Rodeghiero){Provan, 2010 #18}, knowing that a presumptive diagnosis of ITP is made when the history, physical examination, complete blood count, and examination of the peripheral blood smears do not suggest other etiologies for the thrombocytopenia
11110403|NCT04003220||healthy volunteers undergoing cardiac surgery|patients with normal blood counts undergoing cardiovascular surgery for valve replacement, or healthy bone-marrow donors
11110404|NCT04003207|Experimental|Phelan-McDermid syndrome|Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy
11110405|NCT04003194|Experimental|Pinto beans|1/2 cup pinto beans eaten daily by free-living individuals for 12 consecutive weeks.
11110406|NCT04003194|Active Comparator|Green beans|1/2 cup green beans eaten daily by free-living individuals for 12 consecutive weeks.
11110407|NCT04003181|Active Comparator|Positive breath test|Patients with a positive breath test are treated with antibiotics.
11110408|NCT04003181|Active Comparator|Positive SeHCAT scan|Patients with a positive SeHCAT scan are treated with a bile acid binder.
11110409|NCT04003181|No Intervention|No intervention|Patients with a normal breath test and a normal SeHCAT scan receive no intervention.
11110410|NCT04003168|Experimental|Human BCMA targeted T Cells Injection|"A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10^6 CAR T +cells/kg. The classic 3+3 dose escalation will be applied."
11110411|NCT04003155|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
11110412|NCT04003155|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
11110413|NCT04003155|Placebo Comparator|placebo|Participants will receive placebo for 12 weeks, after 12 weeks participants will be re-assigned to either low dose or high dose fezolinetant for 40 weeks.
11110414|NCT04003142|Experimental|low dose fezolinetant|Participants will receive low dose fezolinetant for 52 weeks.
11110415|NCT04003142|Experimental|high dose fezolinetant|Participants will receive high dose fezolinetant for 52 weeks.
11110416|NCT04003142|Placebo Comparator|placebo|Participants will receive placebo for 12 weeks, after 12 weeks participants will be re-assigned to either low dose or high dose fezolinetant for 40 weeks.
11110417|NCT04003116|Experimental|Supplementary oxygen|Supplementary oxygen added to conventional anticoagulant treatment.
11110418|NCT04003116|No Intervention|Standard medical therapy|Standard management.
11110419|NCT04003103|Experimental|Islatravir 60 mg|60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
11110420|NCT04003103|Experimental|Islatravir 120 mg|120 mg islatravir administered once monthly, orally in capsule form for 24 weeks
11110421|NCT04003103|Placebo Comparator|Placebo|Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks
11110422|NCT04003090|Experimental|Citicoline eyes|Patients had to administer 3 drops/day of an ophthalmic solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride for 14 days before surgery and 2 hours prior to surgery.
11110423|NCT04003077|Experimental|Laser meridian massage|They are treated with laser meridian massage on the back including Bladder meridian and Governor vessel three times a week for 4 weeks.
11110424|NCT04003077|No Intervention|Control|A control group of participants without laser meridian massage treatment are matched by age.
11110425|NCT04003051|Experimental|Supportive Care (Project Prepare website)|Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
11110426|NCT04003038|Active Comparator|Group I (wound care with a standard dressing)|Patients receive wound care with a standard dressing (bandage) after surgery for 7 days.
11110427|NCT04003038|Experimental|Group II (NPWT)|Patients receive NPWT after surgery for 7 days.
11110428|NCT04003012|Active Comparator|EMLA|The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
11110429|NCT04003012|Active Comparator|Lidocaine|The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
11110430|NCT04002999|Active Comparator|Ceramic braces, directly placed|Patients in this group will be treated with directly-bonded traditional tooth-colored ceramic brackets
11110431|NCT04002999|Experimental|Ceramic braces, indirectly placed|Patients will be treated with the same brackets from treatment group 1 but using the indirect bonding technique
11110432|NCT04002999|Experimental|3D printed customized ceramic braces|Patients will be treated using indirectly bonded 3D-printed ceramic (tooth-closed) brackets
11110433|NCT04002986|Experimental|Women at intermediate/high risk of breast cancer|Women age 35 years old identified at intermediate/high risk of breast cancer will receive genetic testing
11110434|NCT04002973|Experimental|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
11110435|NCT04002960|Experimental|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
11110436|NCT04002947|Experimental|1|Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with > or = to 25% tumor reduction, treat with DA-EPOCH-R or RCHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with <25% tumor reduction, treat with DA-EPOCH-R or RCHOP alone for 6 cycles
11110437|NCT04002934|Experimental|Group A|"Group A is the early-start group and will receive a total of 6 months of BZA -- 3 months of BZA, followed by 3 months BZA"
11110438|NCT04002934|Experimental|Group B|"Group B is the delayed-start group and will receive a total of 3 months of BZA -- 3 months of placebo, followed by 3 months of BZA"
11110439|NCT04002921||Right colectomy|Patient with scheduled right colectomy and with a documented preoperative scan.
11110440|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
11110441|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
11110442|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain & milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.
~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
11110443|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
11110444|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.
~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
11110445|NCT04002895|Experimental|Foliglurax|
11110446|NCT04002882||Subjects with Cystic Fibrosis|n=60 patients with CF ages 16-30
11110447|NCT04002882||Healthy Controls|n=30 healthy controls matched to participants with CF for age, sex, BMI, and race.
11110448|NCT04002869||Active TB suspicion|This study will include both adults and children with suspicion of different degrees of severity of active TB (pulmonary and extrapulmonary) to bring the investigator's study population into line with the routine clinical practice and to avoid the spectrum bias
11110449|NCT04002869||Latent TB infection|Individuals with latent TB infection (adults and children), with positive TST and/or IGRAs; without any sign or radiological evidence of TB disease or any clinical picture compatible with the criteria defined in the section TB cases.
11110450|NCT04002869||NTM infection|Adult and pediatric patients with lymphadenopathies caused by NTMs or individuals with chronic respiratory diseases with a NTM microbiologically confirmed by culture isolation.
11110451|NCT04002869||Uninfected control|Both adult and children without active TB and no immunologic evidence of M. tuberculosis infection, with negative TST and/or IGRAs
11110452|NCT04002869||Other respiratory diseases|Subjects with ARIs, and subjects with lung cancer; without any clinical picture compatible with the criteria defined in TB cases section. Patients with ARIs will be identified as individuals with clinical signs, symptoms and radiology of respiratory infections, and microbiological confirmation of non-TB origin. Patients with lung cancer will be identified as those with a high clinical suspicion, a suggestive chest X-ray/computed tomography scan, and a confirmed histopathological/cytological diagnosis
11110453|NCT04002856|Experimental|Profhilo®|"The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated after 1 month (T1).
~2 mL of Profhilo® was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 vertical-lines (3-4-3 ). The amount of product injected was 0.2 ml for each injection point."
11110454|NCT04002843|Experimental|- Virgin patients with Botulinum Toxin, first injection|"Experimental: - Virgin patients with Botulinum Toxin, first injection
~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.
~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)
~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of the elbow flexor muscle chosen (biceps brachialis, anterior brachialis), located ultrasonographically.
~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
11110455|NCT04002843|Experimental|- Injected group: Patients already injected|"- Injected group: Patients already injected
~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.
~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)
~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of in one elbow flexor muscle (biceps brachialis, anterior brachialis), located ultrasonographically.
~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
11110456|NCT04002843|Other|Control|healthy patient matched in age and sex to included patients
11110457|NCT04002830|Experimental|Taliglucerase Alpha|Intravenous infusion of Taligluucerase alfa (Elelyso) in treatment-naive patients with type 3 Gaucher disease
11110458|NCT04002804|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
11110459|NCT04002791|Placebo Comparator|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
11110460|NCT04002791|Active Comparator|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
11110461|NCT04002778|Active Comparator|ROSE by endosonographer|Submitted to fine-needle aspiration. Endosonographer's on-site evaluation of sample adequacy and categorization
11110462|NCT04002778|Other|non-ROSE|Submitted to fine-needle aspiration.
11110463|NCT04002765|Other|New RA patients|"Adults aged 18 to 90 years-old
~Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria
~Onset of disease duration at least 1 year and at most 10 years prior to inclusion"
11110464|NCT04002752|Experimental|Panel A: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 1) or matching placebo as single subcutaneous injection.
11110465|NCT04002752|Experimental|Panel B: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 2) or matching placebo as single subcutaneous injection.
11110466|NCT04002752|Experimental|Panel C: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 3) or matching placebo as single subcutaneous injection.
11110467|NCT04002739|Experimental|Patients with Acute Coronary Syndrome (ACS)|Patients admitted to a Coronary Care Unit (CCU) with a new diagnosis of ST Elevation Myocardial Infarction (STEMI) or Non ST Elevation Myocardial Infarction (NSTEMI). Patients are eligible within 72 hours from the admission in CCU. All patients admitted to CCU are going to perform the following procedures/exams as standard clinical practice: coronary angiogram, blood samples, echocardiogram, 24-hour Holter EKG Monitoring. The experimental arm will also perform a polygraphy during CCU stay, a bioelectrical impedance and will complete baseline questionnaires assessing daytime sleepiness such as Epworth Sleepiness Scale (ESS), STOP-BANG and Mallampati score. After the discharge from CCU, patients that had a diagnosis of Obstructive Sleep Apnea Syndrome are going to complete a follow up visit in 90 days undergoing a new polygraphy, bioelectrical impedance, questionnaires (ESS, STOP-BANG and Mallampati Score), echocardiogram.
11110468|NCT04002726|Active Comparator|Group Aa|Allocated to do the app-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
11110469|NCT04002726|Active Comparator|Group As|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
11110470|NCT04002726|Active Comparator|Group Sa|Allocated to do the slide-based training. Allocated to do the app-based classroom IGA test first, and the slide-based test second.
11110471|NCT04002726|Active Comparator|Group Ss|Allocated to do the app-based training. Allocated to do the slide-based classroom IGA test first, and the app-based test second.
11110548|NCT04002219|Experimental|Active arm|Subjects will receive treatment with active beverage containing the active ingredient
11110472|NCT04002713||ALT&AMT free flap reconstruction|Patients who underwent ALT or AMT free flap reconstruction after head and neck cancer surgery between March 1, 2008 and February 28, 2017
11110473|NCT04002700||Target Cohort 1|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years without a recent dementia diagnosis.
11110474|NCT04002700||Target Cohort 2|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years without a recent dementia diagnosis.
11110475|NCT04002700||Target Cohort 3|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged greater than or equal to (>=) 65 years.
11110476|NCT04002700||Target Cohort 4|Participants will be analyzed for stroke-risk who are new users of haloperidol aged >= 65 year.
11110477|NCT04002700||Target Cohort 5|Participants will be analyzed for stroke-risk who are new users of typical antipsychotics aged 18 to 64 years.
11110478|NCT04002700||Target Cohort 6|Participants will be analyzed for stroke-risk who are new users of haloperidol aged 18 to 64 years.
11110479|NCT04002700||Comparator Cohort 7|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years without a recent dementia diagnosis.
11110480|NCT04002700||Comparator Cohort 8|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged >= 65 years.
11110481|NCT04002700||Comparator Cohort 9|Participants will be analyzed for stroke-risk who are new users of atypical antipsychotics aged 18-64 years.
11110482|NCT04002687|Experimental|ATV-PG 1000-400 mg + AQ 612 mg|T1 (n=16) - Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.
11110483|NCT04002687|Active Comparator|ATV-PG 1000-400 mg + AQ unmatched placebo|T 2 (n=12) - Atovaquone (ATV)-Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) unmatched placebo on days 1,2, 3.
11110484|NCT04002687|Active Comparator|ATV-PG unmatched placebo + AQ 612 mg|T 3 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + Amodiaquine (AQ) 612 mg on days 1,2, 3.
11110485|NCT04002687|Placebo Comparator|ATV-PG unmatched placebo + AQ unmatched placebo|T 4 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + AQ unmatched placebo on days 1,2, 3.
11110486|NCT04002674|Placebo Comparator|Placebo|"Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
11110487|NCT04002674|Active Comparator|200 mg Nilotinib|Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
11110488|NCT04002661|Active Comparator|Arm 1 - Active|Participants will take flibanserin 100mg orally every night for approximately 3 months.
11110489|NCT04002661|Placebo Comparator|Arm 2 - Placebo|Participants will take a placebo orally every night for approximately 3 months.
11110490|NCT04002648||MT-Right|
11110491|NCT04002648||Sternotomy|
11110492|NCT04002635|Active Comparator|Hormonal Replacement Therapy|Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.
11110493|NCT04002635|Experimental|Letrozole|Using letrozole for ovulation induction before planning the frozen embryo transfer
11110494|NCT04002622|Experimental|TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
11110495|NCT04002609||Group A, Active comparator|Patients in this group did not receive any rountine oxygen supplementation during the procedure. Rescue supplemental oxygen through nasal cannual was provided if clinically significant desaturation could be observed during bronchoscopy. This significant desaturation was defined as systemic oxygen saturation ≤90% on pulsoxymetry or a relative change of ≥ 4% lasting for 1 minute. N=31 patients
11110496|NCT04002609||Group B, Active comparator|Supplemental oxygen was provided for the patients through nasal cannula by a flow rate of 2 l/minutes throughout the procedure. N= 31 patients
11110497|NCT04002609||Group C, Active comparator|Supplemental oxygen administration through nasal cannula by a flow rate of 4 l/minutes throughout the procedure. N= 30 patients
11110498|NCT04002596|Experimental|ExAblate MRgFUS treatment|Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
11110499|NCT04002583|Experimental|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
11110500|NCT04002570||GROUP I/GROUP I bis|20 breast cancer patients who performed radiotherapy treatment
11110501|NCT04002570||GROUP II|maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.
11110502|NCT04002570||CONTROLS GROUP|healthy women with +/- 5 years compared to breast cancer patients age
11110503|NCT04002557||Focus group|"This is a qualitative study using focus group discussions with young people aged 12-18 who are receiving consultation summaries.
~Patients attending a single diabetes service will be invited to enrol. This service serves a population from a wide geographic area and socio-economic backgrounds.
~Interviews will be conducted by a qualitative researcher with relevant experience. They will be held on the day of a participant's clinic appointment within the same hospital or on the day agreed with the participant."
11110504|NCT04002544|Active Comparator|NTG group|In this group, nitroglycerin patch will be applied near the radial artery pulsation covered with a gauze.
11110505|NCT04002544|Placebo Comparator|Control group|In this group, no patch as applied to the patient. However, a gauze will be applied to confirm blinding
11110506|NCT04002531|Other|Single Visit|"General and neurological examination
~Vital signs including height, weight, blood pressure, pulse, temperature
~12 lead ECG
~2 hour Holter monitor for heart rate variability
~Echocardiogram
~Renal function will be assessed by the eGFR. The eGFR will be calculated from serum creatinine using CKD-EPI equation.
~CBC with differential
~Complete metabolic panel
~Urinalysis
~Urine Albumin/creatinine ratio.
~Urine and plasma samples for biomarkers (Gb3, lyso-Gb3) that will be stored in -80 freezer and assayed in our lab.
~Brief Pain Inventory questionnaire.
~Quality of Life Questionnaires (SF36)"
11110507|NCT04002518||3.0mm and 4.0mm|Patients who have surgically been treated with a 3.0mm or 4.0mm screw.
11110508|NCT04002518||5.0mm|Patients who have surgically been treated with a 5.0mm screw.
11110509|NCT04002518||6.5mm and 8.0mm|Patients who have surgically been treated with a 6.5mm or 8.0mm screw.
11110510|NCT04002505|Experimental|Head Injury Subject|Subjects that present to the Emergency Department with a blunt head injury within the past 24 hours, determined to be low risk by the Canadian CT Head Rules (CCHR), and are being considered for a head CT by the treating provider will use the shared decision making tool Concussion and Brain Bleed app (CBC) with their clinician
11110511|NCT04002492|Experimental|Addition of bodyweight training|All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
11110512|NCT04002479|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11110513|NCT04002466||Children (6-59 months)|
11110514|NCT04002466||Women of Reproductive Age (15-49 years)|
11110515|NCT04002466||Adult Men (15-49 years)|
11110516|NCT04002453||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
11110517|NCT04002440|Active Comparator|AMIA with SHARESOURCE|For this arm, dialysis nurses will review those patients using the AMIA with SHARESOURCE connectivity platform twice a week and will contact patients who meet certain triggers. They will then offer patients interventions, ie. a change in the preset AMIA ultrafiltration program, in order to achieve prescribed dry weight.
11110518|NCT04002440|Placebo Comparator|HomeChoice PRO|For this arm, routine standard of care for peritoneal dialysis patients will continue using the HomeChoice PRO device. Data regarding treatments will be captured on a chip to be analyzed at the end of 6 months to evaluate compliance with treatments.
11110519|NCT04002427|Experimental|Only one study arm|"[14C]AZD7594 Solution for Infusion 5 µg/mL (1.1 kBq/mL)
~AZD7594 Inhalation Powder, SD3FL Inhaler"
11110520|NCT04002414|Active Comparator|Usually Active- Decrease|Participants who usually meet or exceed recommended levels of physical activity who will be asked to minimize activity during stimulation.
11110521|NCT04002414|Experimental|Usually Active- Maintenance|Participants who usually meet or exceed recommended levels of physical activity who will be asked to maintain usual level of activity during stimulation.
11110522|NCT04002414|Experimental|Usually Insufficiently Active- Increase|Participants who are usually insufficiently active (do not meet recommended levels of physical activity) who will be asked to increase activity to the recommended level during stimulation.
11110523|NCT04002414|Active Comparator|Usually Insufficiently Active- Maintenance|Participants who are usually insufficiently active (do not meet recommended levels of physical activity) who will be asked to maintain current level of activity.
11110524|NCT04002414|Experimental|Usually Inactive- Increase|Participants who are usually inactive who will be asked to try to increase activity to the recommended level during stimulation.
11110525|NCT04002414|Active Comparator|Usually Inactive- Maintenance|Participants who are usually inactive who will be asked to maintain inactivity during stimulation.
11110526|NCT04002401|Experimental|Axicabtagene Ciloleucel and Rituximab Combination|Participants will receive rituximab, and fludarabine and cyclophosphamide conditioning chemotherapy, followed by axicabtagene ciloleucel and additional rituximab.
11110527|NCT04002388|Experimental|Activity Monitor Group|This arm will receive a FitBit and will be asked to wear this for one year
11110528|NCT04002388|Active Comparator|Usual Care Group|The usual care group will NOT receive a FitBit
11110529|NCT04002362|Experimental|Children receiving triamcinolone acetonide|Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks.
11110530|NCT04002349|Placebo Comparator|A: Placebo group|Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning
11110531|NCT04002349|Experimental|B: Budesonide Nasal Spray (Rhinocort)|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning
11110532|NCT04002349|Experimental|C: Levocabastine Nasal Spray (Livostine)|Treated by Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
11110533|NCT04002349|Experimental|D: Combined Treatment|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
11110534|NCT04002336|Active Comparator|Traditional Voice Therapy|Standard of care (traditional) voice therapy.
11110535|NCT04002336|Experimental|App Group|Voice therapy using a smartphone app.
11110536|NCT04002323||HIV-1 ART-Naive|Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)
11110537|NCT04002310|Experimental|BI 754132|
11110538|NCT04002297|Experimental|zanubrutinib plus rituximab|
11110539|NCT04002297|Active Comparator|bendamustine plus rituximab|
11110540|NCT04002284|Experimental|anlotinib|anlotinib 12mg qd p.o. d1-14/21day/cycle
11110541|NCT04002271|Active Comparator|Group SA|Patients in Group SA will undergo spinal anaesthesia.
11110542|NCT04002271|Active Comparator|Group GAS|Patients in Group GAS will undergo general inhalational anaesthesia using sevoflurane.
11110543|NCT04002271|Experimental|Group TIVA|Patients in Group TIVA will undergo general anaesthesia using propofol total intravenous anaesthesia.
11110544|NCT04002245|Experimental|Go back|Application of a compress impregnated with alcoholic Betadine® by movement of return
11110545|NCT04002245|Experimental|Technique of snail|Application of a compress impregnated with alcoholic Betadine into a single movement from the center towards the periphery and covering the end surface of followed by spontaneous drying time 30 seconds.
11110546|NCT04002232|Experimental|CPP-ACP-NaF|Dental varnish that contains calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
11110547|NCT04002232|Placebo Comparator|Placebo|Dental varnish base that does not contain calcium phosphoprotein stabilized amorphous calcium phosphate and sodium fluoride (CPP-ACP-NaF) is applied to the teeth with orthodontic brackets on one side of the mouth immediately after the teeth have received the bracket.
11110549|NCT04002219|Placebo Comparator|Placebo arm|Subjects will receive treatment with placebo beverage not containing the active ingredient
11110550|NCT04002206|Experimental|Muscle Energy Technique|Post isometric relaxation technique was used in experimental group
11110551|NCT04002206|Active Comparator|Static Stretch|Static stretching was given in control group
11110552|NCT04002180||Vedolizumab 300 mg|Vedolizumab (Genetical Recombination) 300 mg, IV infusion, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
11110553|NCT04002167|Experimental|Neurofeedback|The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
11110554|NCT04002167|Active Comparator|Cognitive Training|The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
11110555|NCT04002167|No Intervention|Waitlist|Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
11110556|NCT04002154|Experimental|A - papilocare alternative days|Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
11110557|NCT04002154|Experimental|B - papilocare semiintensive|Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
11110558|NCT04002154|No Intervention|C - standard of care|Arm C: usual clinical practice: no treatment
11110559|NCT04002141|Experimental|Endometriosis Letrozole|Participants will be asked to take 5mg letrozole daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to letrozole. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
11110560|NCT04002141|Placebo Comparator|Endometriosis Placebo|Participants will be asked to take one tablet placebo daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to placebo. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
11110561|NCT04002141|No Intervention|No Endometriosis Control|Participants will be asked to complete surveys during their ovarian stimulation and up to 12 weeks following retrieval to evaluate symptoms of pelvic pain. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
11110562|NCT04002128|Placebo Comparator|Group air|"Group air was mechanically ventilated using 35% oxygen in 65% air during the whole surgical procedure.
~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
11110563|NCT04002128|Active Comparator|Group nitrous oxyde (N2O)|"Group N2O was mechanically ventilated using 35 % oxygen and 65 % of nitrous oxyde during the surgical procedure.
~Nitrous oxyde may increase cuff pressure during the general endotracheal anesthesia and result in the respiratory symptoms like sore throat, hoarseness and postoperative cough.
~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
11110564|NCT04002115|Experimental|Clofarabine 30 mg/m^2|"Clofarabine 30 mg/m^2 IV once a day for 5 days prior to the initiation of the standard conditioning regimen for the stem cell transplant infusion (Day 0). In the event of excessive toxicities related to the clofarabine, a dose de-escalation to 20 mg/m^2 will occur for the next cohort of subjects.
~Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest (no scheduled conditioning medications), Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV, Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV, Day - 4 Fludarabine 40 mg/m^2 IV, Day - 3 Fludarabine 40 mg/m^2 IV, Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF"
11110565|NCT04002102|Experimental|OLP treatment|Participants randomized to the treatment group will receive: 1) educational materials; 2) positive expectancy; 3) 2 placebo pills twice a day for 21 days.
11110566|NCT04002102|Other|Usual care|Participants randomized to the no treatment group will remain in standard care alone for 21 days and receive educational materials.
11110567|NCT04002102|Active Comparator|Expectancy Group|Participants receive educational materials and positive expectancy orientation via Zoom or telephone
11110568|NCT04002089|Experimental|Cohort 1 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.
11110569|NCT04002089|Experimental|Cohort 2 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.
11110570|NCT04002089|Experimental|Cohort 3 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only
11110571|NCT04002089|Active Comparator|Cohort 4 -|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.
11110572|NCT04002076|Experimental|Robot-assisted hand combined with occupational therapy|Ten participants in group A will undergo robot-assisted hand (with visual feedback) combined with occupational therapy. They will receive 60 minutes a day and 3 days a week robot-assisted hand and occupational therapy for six weeks.
11110573|NCT04002076|Active Comparator|Traditional occupational therapy|Another 10 participants allocated to the group B will receive 60 minutes a day and 3 days a week traditional occupational therapy for six weeks.
11110599|NCT04001907|Placebo Comparator|exercise combined with placebo|Resistance exercise ( 3d/week) and placebo as 3g/d maltodextrin as three 1g capsules orally, for 9 weeks
11110574|NCT04002063|Experimental|CBT-D augmented with CBT MobileWork-V|Patients randomized to this condition will receive CBT-D as usual plus access to CBT MobileWork-V, a comprehensive tailored smartphone app for CBT skills practice for OEF/OIF Veterans.
11110575|NCT04002063|Active Comparator|CBT-D|Patients randomized to CBT-D will receive CBT-D as usual only.
11110576|NCT04002050|Active Comparator|CBTm Course Intervention|Participants placed in the intervention group will receive the CBTm Course. The CBTm Course consists of 5 classes, 90 minutes each, and held in-person on a weekly basis.
11110577|NCT04002050|No Intervention|Comparison Group|Participants in the comparison group will not receive the intervention during the study, but will be offered intervention once the study has been completed (i.e. 3 month waiting-period). However, in the event that a stressful situation arises while a participant is placed in the comparison group, the participant may seek assistance from the usual mental health supports offered through their respective occupational organizations, EAP programs, and other programs in the community. Following completion of the study, participants in the comparison group will be invited to attend the CBTm Course.
11110578|NCT04002037|Active Comparator|Triamcinolone 40mg/mL|A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
11110579|NCT04002037|Active Comparator|Triamcinolone 10mg/mL|A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
11110580|NCT04002037|Active Comparator|Soluble dexamethasone 4mg/mL|A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.
11110581|NCT04002024|Active Comparator|Placebo and Treatment Arm A|The patients in treatment arm A group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the right side of their face and placebo which is moisturizer without those active ingredients on the left side of their face.
11110582|NCT04002024|Active Comparator|Treatment and Placebo Arm B|The patients in treatment arm B group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the left side of their face and placebo which is moisturizer without those active ingredients on the right side of their face.
11110583|NCT04002011|Active Comparator|Group VKA|"103 patients. First intake at postoperative day 1 or later when anticoagulation is secondary indicated.
~Dosage adapted to INR = [2.0-3.0], parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) until INR > or = 2.0.
~Daily INR during hospital stay, then management by familial doctor. Duration: 3 months"
11110584|NCT04002011|Active Comparator|Group DOAC|"103 patients - One drug among the 4 DOAC according the morbidity of each patient (preoperative DOAC, oral nutrition recovery).
~First intake at hospital discharge - parenteral (subcoutaneous low-weight molecular or intravenous unfractionated heparin) during hospital stay.
~Regular daily dosages according the drug, its indication (atrial fibrillation/flutter or biological mitral replacement/repair or biological tricuspid replacement versus venous thromboembolism) and the morbidity of each patient (age, weight, creatinine ou its clearance).
~Validation by one referent pharmacist. No biological monitoring. Duration: 3 months"
11110585|NCT04001998|Experimental|Tablet vs Capsule Formulation|Single oral dose of BLD-2660 capsule or tablet formulation
11110586|NCT04001998|Experimental|Dose Proportionality|Single oral dose of BLD-2660 tablet formulation
11110587|NCT04001985|Active Comparator|Immediate NG tube removal|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
11110588|NCT04001985|Active Comparator|NG tube clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
11110589|NCT04001972|Experimental|Intervention group|Brief advice (AWARD model) + NRT-S + IM Apps and Chatbot
11110590|NCT04001972|Active Comparator|Control group|Brief advice (AWARD model) + regular SMS
11110591|NCT04001959|Active Comparator|Silver Diamine Fluoride|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Next, dry the tooth for 30 seconds with air jet followed by a drop of 30% Diamino Fluoride Silver with a disposable applicator brush for 3 minutes and after that time washing for 1 minute.
11110592|NCT04001959|Experimental|Silver Diamine Fluoride with Potassium Iodide|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Then the tooth is dried for 30 seconds with an air jet and applied one drop of the Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the surface treated with Diamino , until the formed creamy white color becomes transparent. After these steps have been completed, rinse with water for 1 minute.
11110593|NCT04001946|Other|G-button Securement Device|Subjects will be provided instructions and a 12-week supply of test devices, sufficient to change the gauze dressing at least once per day.
11110594|NCT04001946|No Intervention|Standard Dressing|Subjects will be provided instructions and a 12-week supply of tape and gauze (current standard of care), sufficient to change the gauze dressing at least once per day.
11110595|NCT04001933|Experimental|Intervention Arm|CPOP Intervention (see below).
11110596|NCT04001933|No Intervention|Control Arm|Usual care.
11110597|NCT04001920|Experimental|Training program|12-week strength and endurance training program
11110598|NCT04001907|Experimental|exercise combined with β-hydroxy-β-methylbutyrate (HMB)|Resistance Exercise ( 3d/week) and HMB: 3g/d as three 1g capsules orally, for 9 weeks
11110923|NCT03999606|Experimental|Music Training|Participants in the experimental group will be assigned to a online based choir program.
11110600|NCT04001894|Experimental|Ticagrelor|To observe the safety and efficacy of standard-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
11110601|NCT04001894|Active Comparator|Clopidogrel|To observe the safety and efficacy of standard-dose clopidogrel in Chinese patients with Stable Coronary Artery Disease
11110602|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
11110603|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
11110604|NCT04001868|Experimental|Experimental Group|Application of the sub occipital inhibition technique.
11110605|NCT04001868|Placebo Comparator|Placebo Group|Hand contact in the sub occipital region without executing any technique.
11110606|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach bath|Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.
11110607|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach gauze soaks|Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.
11110608|NCT04001842|Experimental|Axially vascularized constructs|Reconstructing a mandibular defect using an axially vascularized bone substitute using the arteriovenous loop (AVL)
11110609|NCT04001829|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel IV over 3 hours once weekly. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive trastuzumab and/or pertuzumab per institution routine care per treating physician's discretion.
11110610|NCT04001829|Experimental|Arm B (docetaxel)|Patients receive docetaxel IV over 1 hour once every 3 weeks. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity. Patients may also receive cyclophosphamide, doxorubicin, trastuzumab, and/or pertuzumab per institution routine care per treating physician's discretion.
11110611|NCT04001803|Experimental|Subjects with HIV infection|HIV-infected subjects receiving CAB LA+RPV LA will be included in this arm.
11110612|NCT04001790|Experimental|Project Search + ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center where they rotate through three 10-12 week internships within the business learning marketable skills, social communication, and adaptive behavior in the business setting. In order to meet the unique needs of youth with ASD, Wehman, et al. (2014) enhanced the Project SEARCH model by adding autism supports to the original model. Those added supports were: 1) on-site, intensive, systematic instruction using the principles of applied behavior analysis, 2) on-site support and consultation from a behavior/autism specialist, and 3) intensive staff training in ASD and the Project SEARCH Model.
11110613|NCT04001790|No Intervention|Business as Usual|Business as Usual means these youth remain in their high school programs as determined on their individualized education plans
11110614|NCT04001777|Experimental|APG-1252 plus Osimertinib (AZD9291)|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase; Dose of osimertinib will be fixed at 80mg QD based on approved label.
11110615|NCT04001764|Active Comparator|The first group|The radial artery catheterization with ultrasound-guided short axis out of plane intervention will be performed over 2 cm of the wrist for this group.
11110616|NCT04001764|Experimental|The second group|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
11110617|NCT04001764|Experimental|The third group|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
11110618|NCT04001751|Experimental|Therapeutic educational postural yoga program|Daily 15-min yoga sessions at home during 12 weeks. One 90-min yoga-therapeutic education session/week (during 6 weeks).
11110619|NCT04001738|Active Comparator|Direct Transfer to Angio Suite|After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
11110620|NCT04001738|No Intervention|Direct Transfer to CT Scan|After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
11110621|NCT04001725|Active Comparator|A (Dexamethasone)|Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route (control arm). The total dose can either administered once a day or through a refracted schedule
11110622|NCT04001725|Experimental|B (Dexamethasone and Metformin)|"Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route.The total dose can either administered once a day or through a refracted schedule.
~The same patients subjected at a metformin. Metformin initial dosage will be 850 mg per day, and will be escalated based on patient tolerability up to a maximum of 2550 mg daily (experimental arm)."
11110623|NCT04001712|Experimental|early caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support
11110651|NCT04001465|Active Comparator|Volumetric methacholine challenge|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer
11110624|NCT04001712|Active Comparator|late caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support
11110625|NCT04001699|Experimental|Intervention|Preoperative assessment conducted by an interprofessional team
11110626|NCT04001699|Active Comparator|Usual care|Usual care
11110627|NCT04001673|Active Comparator|Pharmacist's intervention|Evaluation of knowledge and adherence of patients treated by bDMARDs before and after the intervention of a pharmacist that will give information concerning bDMARDs management.
11110628|NCT04001673|No Intervention|Control|Evaluation of knowledge and adherence of patients treated by bDMARDs who did not receive pharmacist's intervention.
11110629|NCT04001660|Experimental|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
11110630|NCT04001647|Experimental|TUDCA|Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
11110631|NCT04001647|Placebo Comparator|Placebo|Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
11110632|NCT04001634||Dual anti-HER2 group|Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy
11110633|NCT04001621|Experimental|Pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
11110634|NCT04001608|Experimental|Seraprevir and sofosbuvir|Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
11110635|NCT04001595||Participants with FKRP genetic mutation|
11110636|NCT04001582||Participants with FSHD|
11110637|NCT04001569|Experimental|AZD8186 in combination with paclitaxel|
11110638|NCT04001556|Experimental|Patients reporting subjective sicca symptoms|HAQ(Health Assessment Questionnaire) Score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
11110639|NCT04001556|Experimental|Patients without subjective sicca symptoms|HAQ(Health Assessment Questionnaire) score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
11110640|NCT04001543|Experimental|Immunomodulating oral supplementation|"The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3.
~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
11110641|NCT04001543|Active Comparator|Sip feed control|"The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control.
~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
11110642|NCT04001530|Experimental|Half-normal saline|Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters
11110643|NCT04001530|Active Comparator|Normal saline|Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters
11110644|NCT04001517|Experimental|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
11110645|NCT04001517|Placebo Comparator|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
11110646|NCT04001504|Experimental|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV during index ACS hospitalization
11110647|NCT04001504|Active Comparator|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV 30 days after hospital discharge
11110648|NCT04001478||Control group|Patients who are attending hospital for a gastroscopy as part of their routine clinical care as a 2 week wait rule referral and those on Barrett's surveillance , will be asked to give a sample of their breath prior to the procedure.
11110649|NCT04001478||Early oesophageal cancer (T1)/ Barrett's high grade dysplasia|Patients who have known pre-diagnosed T1 oesophageal adenocarcinoma or HGD attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation. Patients will be sampled upon return for follow up endoscopy to assess breath profile changes and correlation with endoscopy findings.
11110650|NCT04001478||Advanced Oesophageal cancer (T2/3/4)|Patients who have been diagnosed with oesophageal adenocarcinoma attending hospital as part of their clinical care will be asked to give a breath sample prior to their endoscopy resection/ cancer operation.
11110652|NCT04001465|Active Comparator|Methacholine challenge with spirometer|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer fitted with an ultrasonic spirometer
11110653|NCT04001452||Level of experience in interventional cardiology|"Total cohort will be grouped according to experience in interventional cardiology, as defined by a single choice questionnaire:
~Yearly personal PCI volume Less than 75 / Between 75 and 150 / Between 151 and 250 / More than 250"
11110654|NCT04001452||Level of experience with intravascular ultrasound|"Total cohort will be grouped according to experience with intravascular ultrasound, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
11110655|NCT04001452||Level of experience with optical coherence tomography|"Total cohort will be grouped according to experience with optical coherence tomography, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
11110656|NCT04001452||Level of experience with fractional flow reserve|"Total cohort will be grouped according to experience with fractional flow reserve, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
11110657|NCT04001452||Level of experience with non-hyperaemic pressure ratios|"Total cohort will be grouped according to experience with non-hyperaemic pressure ratios, as defined by a single choice questionnaire:
~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years
~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
11110658|NCT04001439|Other|Clinical trial|the study design is an open-label, single-arm propective clinical trial. In this proof-of-concept study we will assess feasibility safety and potential efficacy of an intervention of FMT in SZ subjects with MD.
11110659|NCT04001426|Experimental|Monitoring during activation of the FemPulse System|Subjects will undergo non-invasive monitoring during activation of the FemPulse System.
11110660|NCT04001413|No Intervention|Arm A: Observational|No intervention, observational arm.
11110661|NCT04001413|Experimental|Arm B: Durvalumab Alone|Durvalumab will be administered as an IV Infusion.
11110662|NCT04001413|Experimental|Arm C: MEDI0457 and Durvalumab|MEDI0457 is an injection. Durvalumab will be administered as an IV Infusion.
11110663|NCT04001400|Experimental|High-dose rabeprazole|Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
11110664|NCT04001400|Active Comparator|Standard-dose rabeprazole|Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks
11110665|NCT04001387||Spinal anesthesia|
11110666|NCT04001374||Ticagrelor|Ticagrelor 90mg tablet bid for 12 months
11110667|NCT04001374||Ticagrelor + ASA|Ticagrelor 90mg tablet bid for 12 months and enteric coated aspirin 81mg-100mg daily p.o. for 12 months
11110668|NCT04001361|Sham Comparator|Sham|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser inserted into knee joint but not turned on.
11110669|NCT04001361|Experimental|Laser Only|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser fiber is inserted into knee over an 18 gauge needle and micro-channels are made into the damaged cartilage.
11110670|NCT04001361|Experimental|Laser plus Marrow|Under conscience sedation, a 10mL marrow aspiration is performed. Laser fiber is inserted into the knee over an 18 gauge needle and micro-channels are made into the damaged cartilage. After the channels are made, marrow aspirate is injected over the same 18 gauge needle.
11110671|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 610|
11110672|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
11110673|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 430|
11110674|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 520|
11110675|NCT04001335||CL suspicion|Patients with skin lesions suspected to be cutaneous leishmaniasis
11110676|NCT04001322|Experimental|14 Intervention LGAs|Various target beneficiaries will receive broadcast, targeted and individualized SMS messages on immunization.
11110677|NCT04001322|Other|7 Control LGAs|This arm will not receive any SMS messages on immunization
11110678|NCT04001309|Experimental|Infectious diseases physician led|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly
~Also including standard of care
~infectious disease consultant on demand
~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
11110679|NCT04001309|Experimental|Multiprofessional team|"Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention
~Also including standard of care
~infectious disease consultant on demand
~hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)"
11110680|NCT04001296|Experimental|21 day Brush Day and Night intervention|The 21 day Brush Day and Night programme aims to instruct on and encourage twice a day brushing with a fluoridated toothpaste.
11110681|NCT04001296|No Intervention|Control schools|Schools / children who receive only toothpaste / toothbrushes, no 21 day Brush Day and Night intervention
11110682|NCT04001283|Experimental|sodium nitrite 24hours before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
11110683|NCT04001283|Experimental|sodium nitrite 30minutes before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
11110684|NCT04001283|Placebo Comparator|0.9% sodium chloride|Intravenous normal (0.9%) sodium chloride infused at 1ml/min
11110685|NCT04001270||Patients anti leucine rich glioma inactivated-1 encephalitis|Biomarkers from patients with anti-leucine rich glioma inactivated 1 encephalitis (anti LGI1-E) will be studied. This is a non-interventional study involving biological samples (CSF biomarkers) already stored in biobank repositories. All stored samples were collected as part of the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population.
11110720|NCT04000997||Failure group|Patients with a failure endotracheal extubation
11110686|NCT04001244||Endometriosis (EAP)|Surgical diagnosis of endometriosis (aim equal distribution of stage I/II and stage III/IV disease); at least one pelvic pain >3/10; pain not perceived by the patient as arising from the bladder; no urinary symptoms (e.g. urge, frequency)
11110687|NCT04001244||Bladder Pain Syndrome (BPS)|Bladder pain syndrome (as defined by ESSIC criteria: pelvic pain, pressure or discomfort for greater than 6 months, perceived to be related to the urinary bladder accompanied by at least one other urinary symptom like persistent urge to void or frequency); no history of endometriosis
11110688|NCT04001244||Endometriosis and Bladder Pain (EABP)|Surgical diagnosis of endometriosis; at least one pelvic pain >3/10; pain perceived by the patient as arising from the bladder AND from other area(s) of the pelvis; at least one urinary symptom (e.g. urge, frequency)
11110689|NCT04001244||Controls|No endometriosis; No pelvic pain (or dysmenorrhea; NRS <3/10)
11110690|NCT04001231|Experimental|Single arm of exenatide once-weekly suspension|Exenatide once-weekly suspension via subcutaneous (SC) injection
11110691|NCT04001218|Experimental|Painful condition|Participants will be injected with 0.5ml hypertonic saline (5.8%) into a neck muscle
11110692|NCT04001218|Experimental|Control condition|Participants will be injected with 0.5ml Isotonic saline (0.9%) into a neck muscle
11110693|NCT04001205||No oral anticoagulation|Patients without oral anticoagulation for AF
11110694|NCT04001205||Oral anticoagulation|Patients with long term oral anticoagulation
11110695|NCT04001192|Experimental|exercise|exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
11110696|NCT04001179||Presence of pulmonary embolism|≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy
11110697|NCT04001179||No pulmonary embolism|Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy
11110698|NCT04001153||Upper primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
11110699|NCT04001153||Lower primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
11110700|NCT04001153||Upper primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
11110701|NCT04001153||Lower primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
11110702|NCT04001140|Active Comparator|Intervention group|The intervention group will take part in the sessions of the intervention, in which they learn different skills for the purpose of emotion regulation. All participants will complete the questionnaires and take part in the experiment again. This group prevention program, which is short-term, entailing 7 sessions, synthesizes techniques from three therapeutic models: Cognitive-Behavioral Therapy, Dialectical-Behavioral Therapy and Acceptance and Commitment Therapy.
11110703|NCT04001140|No Intervention|Waiting-list group|The waiting-list group will receive the intervention 7 weeks after the intervention group finishes. The intervention group will finish the research in week 7, while the waiting-list group will start to attend the intervention. They will complete the questionnaires and the experiment.
11110704|NCT04001127|Experimental|High Intensity Functional Training|Intervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
11110705|NCT04001114|Other|Smokers with schizophrenia|This is a diagnostic group, defined independently from this study.
11110706|NCT04001114|Other|Smokers without schizophrenia|This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
11110707|NCT04001101|Active Comparator|RT and Anti-PD-1|"In the pembrolizumab + RT arm, pembrolizumab will be started on study within 7 days (+/- 7 days) of start of RT.
~Pembrolizumab will be given as standard of care in both arms"
11110708|NCT04001101|Placebo Comparator|Anti-PD-1|anti-PD-1 therapy alone Pembrolizumab will be given as standard of care in both arms
11110709|NCT04001088|Experimental|Probiotic|Probiotics in a capsule.
11110710|NCT04001088|Placebo Comparator|Placebo|Non active ingredients in a capsule.
11110711|NCT04001075|Experimental|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
11110712|NCT04001062|Active Comparator|Non-operatively|"Adults 18 and older
~Native English-speaker
~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
11110713|NCT04001062|Active Comparator|Surgical|"Adults 18 and older
~Native English-speaker
~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
11110714|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX15|Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
11110715|NCT04001036|Experimental|Experimental peritoneal dialysis solution IPX07|Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
11110716|NCT04001023|Experimental|PDS|18F-EF5 PET/CT and 18F-FDG PET/CT scan prior to primary cytoreductive surgery and targeted sample collection during primary cytoreductive surgery
11110717|NCT04001023|Experimental|IDS|"18F-EF5 PET/CT and 18F-FDG PET/CT scans prior to diagnostic laparoscopy and after neoadjuvant chemotherapy before interval cytoreductive surgery .
~Targeted sample collection during diagnostic laparoscopy and interval cytoreductive surgery"
11110718|NCT04001010|Experimental|inhaled THC/CBD (PPP011)|PPP011 (synthetic THC/CBD) inhalation with mighty medic device
11110719|NCT04001010|Placebo Comparator|Placebo|Placebo inhalation with mighty medic device
11110722|NCT04000984|Experimental|Mindfulness-Based Intervention|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.
11110723|NCT04000984|Active Comparator|Cognitive Rehabilitation Training|Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
11110724|NCT04000984|No Intervention|Treatment As Usual|Participants in the Treatment As Usual group were only required to attend baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. Participants in this group will not receive an intervention for the duration of the study. They received treatment as usual which is 6 months to 1-year follow up visits with their attending neurologist of psychologist.
11110725|NCT04000971|Active Comparator|Integrated Stroke Practice Unit (ISPU)|ISPU personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge. This will be supplemented by a more integrated model designed to increase coordination through team-based initiatives across the continuum of care for stroke - from acute and in-hospital care through 12 months post-discharge. Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, increase understanding, and build positive behavior change for patients and caregivers. Primary outcomes will be assessed by phone at 3, 6, 12, and 24 months; secondary outcomes will be assessed at 3, 6, and 12 months.
11110726|NCT04000971|Active Comparator|Comprehensive or Primary Stroke Center (CSC/PSC)|CSC/PSC personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge, follow-up clinic visits as recommended by their outpatient provider, and other clinic visits initiated by the patient when issues arise. Primary outcomes will be assessed by phone at 3, 6, 12, and 24 months; secondary outcomes will be assessed at 3, 6, and 12 months.
11110727|NCT04000958|Experimental|PIFR group|
11110728|NCT04000958|Active Comparator|control group|
11110729|NCT04000945|Experimental|BTL-899 Therapy Arm|
11110730|NCT04000945|Sham Comparator|Sham Arm|
11110731|NCT04000932|Experimental|Platelet rich plasma (PRP) -T lab PRP kit|A single 1ml PRP extract injection will be will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel. performed once into the carpal tunnel in the wrist . PRP will be obtained by centrifugation of autologous anticoagulated whole blood.
11110732|NCT04000932|Active Comparator|Diprospan ®, Schering Plough|A single steroid injection (1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel.
11110733|NCT04000919|Sham Comparator|Effects of single-dose of carbidopa (50mg) on CNS excitability|Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
11110734|NCT04000919|Placebo Comparator|Effects of single-dose placebo on CNS Excitability|Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
11110735|NCT04000919|Active Comparator|Effects of single-dose 5HTP/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
11110736|NCT04000919|Active Comparator|Effects of single-dose L-DOPA/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
11110737|NCT04000906|Experimental|Experimental Arm|Pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration of Nab paclitaxel and cisplatin
11110738|NCT04000893|Experimental|Resistance exercise session|Acute isometric session, about 20 minutes.
11110739|NCT04000893|Active Comparator|Aerobic exercise session|Acute aerobic session, about 20 minutes.
11110740|NCT04000880|Experimental|Project 1: Diet-Exercise|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
11110741|NCT04000880|Experimental|Project 2: Exercise-Diet|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
11110770|NCT04000685|Active Comparator|aerobic walking exercise group|Aerobic walking exercise program applied all patients in this group accompanied by physiotherapist.
11110771|NCT04000672|Active Comparator|HTO with navigation|High Tibial Osteotomy is offered to patients with symptomatic medial compartment knee osteoarthritis (OA)
11110772|NCT04000672|Experimental|HTO with navigation + PSI jig|"3D printed patient specific metal jigs (PSI jig) are created based on the pre-operative CT image. After that, calibrated osteotome is used to achieve the desired correction with the use of navigation for overall lower limb alignment, which is the same as the Active Comparator group."
11110742|NCT04000880|Experimental|Project 3: Wait-list Control- Combined Diet and Exercise|For the first six months of the study, participants will be in the wait-list control group, where they receive health information on topics other than diet and exercise. Participants will then join the intervention, receiving the diet and exercise content simultaneously in combined web-based sessions. Participants will receive and participate in web-based sessions that focus on diet and exercise for 12 months. Participants will be encouraged to track their diet, weight and physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
11110743|NCT04000867|Active Comparator|real TCMS treatment|Subjects with DN located in their bilateral feet that have been previously identified and have a graded average baseline score of at least 5 in each foot will receive either TCMS treatment or Sham treatment on clinic day-1 according to the contents of a sealed opaque envelope corresponding to the subject's number in the series and opened immediately before treatment on day 1. (Our statistician will have generated these envelopes and their contents in advance.) Subjects and staff evaluating the subject's response will remain blinded to treatment assignment; only the staff member setting the treatment mode will know whether it is active or sham.
11110744|NCT04000867|Sham Comparator|Sham TCMS treatment|Patients in the sham treatment group, will use the same device. The device will be switched into sham mode by the clinician by pressing a small, non-descript button on the backside of the pulse generator. The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
11110745|NCT04000854|Active Comparator|Calcium hydroxide|Root canal dressing with Ca(OH)2 (Calasept)
11110746|NCT04000854|Active Comparator|Chlorhexidine|Root canal dressing with clorhexidine digluconate 2 % gel
11110747|NCT04000841|Experimental|Intervention|Intervention participants receive access to the Mindful You app for 12 weeks. They will use the app to listen to guided meditations and to receive notifications, messages, and reminders that they select and ones sent to all participants by the app.
11110748|NCT04000841|No Intervention|Waitlist Control|Waitlist control participants will continue business as usual with regards to stress-management and reduction.
11110749|NCT04000828|Other|single Arm|all patients receive the measurement with Sensimed Triggerfish
11110750|NCT04000815|Active Comparator|Reproductive age women|The healthy women between 18-40 years old.
11110751|NCT04000815|Active Comparator|Perimenopausal women|The healthy women between 40-49 years old.
11110752|NCT04000815|Active Comparator|Postmenopausal women|The healthy women that has been in to menopause more than a year
11110753|NCT04000789|Experimental|NPDR|
11110754|NCT04000789|Active Comparator|NPDR Comparator|
11110755|NCT04000789|Experimental|PDR|
11110756|NCT04000789|Active Comparator|PDR Comparator|
11110757|NCT04000763|Experimental|Transcutaneous Nerve Stimulator(TENS)|Adult females who have difficulty emptying their bladder due to non-obstructive urinary retention or because of an under-active bladder will be given transcutaneous nerve stimulation (TENS) therapy.
11110758|NCT04000750|Experimental|Time Restricted Eating (16:8)|Participants will consume all calories within an 8 hour window each day.
11110759|NCT04000750|Active Comparator|Control|Participants will consume all calories within a ~12 hour window each day (4 separate meals + needed snacks).
11110760|NCT04000737|Experimental|Sorafenib + YIV-906|Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
11110761|NCT04000737|Active Comparator|Sorafenib + Placebo|Patients in the placebo arm will be given sorafenib with placebo
11110762|NCT04000724|Experimental|Text+Step|The TechStep Text+Step messaging intervention is a six-month technology-based culturally competent theory-based text messaging intervention that sends three automated text messages to participants daily to reduce HIV risk and increase PrEP uptake and adherence.
11110763|NCT04000724|Experimental|WebApp+Step|The TechStep WebApp+Step website intervention is a six-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV sexual risk reduction and PrEP uptake and adherence.
11110764|NCT04000724|Experimental|Information|The Information/No Step intervention includes nothing more than access to a website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
11110765|NCT04000711|Experimental|Outpatient oral antibiotic treatment group.|After randomization, participants assigned to receive outpatient treatment with oral cefixime at a dose of 8 mg/kg/day were discharged. Treatment was provided by the researchers. Subjects were evaluated daily at the outpatient clinic of the hospital. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed in the outpatient group, they were re-admitted to the hospital to receive intravenous antibiotics. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
11110766|NCT04000711|Active Comparator|Inpatient intravenous antibiotic treatment group.|After randomization, participants continued intravenous inpatient antibiotic with cefepime 150 mg/kg/day according to local standard of care guidelines. Subjects were evaluated daily. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed, treatment was changed according to clinical guidelines. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
11110767|NCT04000698|Experimental|intervention/treatment|"Preparative chemotherapy before allogeneic HSCT
~Fludarabin
~Cytarabine
~Venetoclax
~Daratumomab
~Vecanoid
~treosulfan
~fludarabine
~thiophosphomide
~Venetoclax
~Plerixafor
~abatacept
~tocilizumab
~rituximab
~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
11110768|NCT04000685|Active Comparator|Yoga exercise group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing, warm up and relaxation exercises.
11110769|NCT04000685|Active Comparator|Spinal stabilization exercise group|Spinal stabilization exercise with three different progressive phases were applied all patients in this group accompanied by physiotherapist.
11110958|NCT03999320|Other|Control group|usual care
11110773|NCT04000659|Experimental|Episealer Knee System|The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.
11110774|NCT04000659|Placebo Comparator|Microfracture|The control arm will comprise of subjects that will receive a Microfracture surgery.
11110775|NCT04000646|Other|standard care|Standard care non-pharmacologic interventions during anesthesia induction
11110776|NCT04000646|Experimental|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
11110777|NCT04000633|Active Comparator|lidocaine group|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
11110778|NCT04000633|Placebo Comparator|Placebo group|the patients of this group will recieve nebulization of 5 ml of normal saline prior to induction of general anesthesia
11110779|NCT04000620||cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as positive for cancer cell involvement by imaging based deep learning.
11110780|NCT04000620||no cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as negative for cancer cell involvement by imaging based deep learning.
11110781|NCT04000607|Experimental|Edwards Transcatheter Atrial Shunt System|
11110782|NCT04000594|Experimental|Dose level 1 of RO7234292 (RG6042)|Participants will receive dose level 1 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
11110783|NCT04000594|Experimental|Dose level 2 of RO7234292 (RG6042)|Participants will receive dose level 2 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
11110784|NCT04000594|Experimental|Dose level 3 of RO7234292 (RG6042)|Participants will receive dose level 3 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
11110785|NCT04000581|Active Comparator|Arm I (usual care)|Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
11110786|NCT04000581|Experimental|Arm II (additional mobility)|Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
11110787|NCT04000568||Study Population|All the infants enrolled in the study will receive 1 h of NAVA-NIV and 1h PC-NIV in a cross-over study design
11110788|NCT04000555|Experimental|Study drug|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
11110789|NCT04000555|Placebo Comparator|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
11110790|NCT04000542|Experimental|Eligible Participants|Eligible Participants that consent will receive the pharmacist intervention.
11110791|NCT04000529|Experimental|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
11110792|NCT04000529|Experimental|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
11110793|NCT04000516|No Intervention|Control|The control group was asked to continue their usual eating schedule and pattern.
11110794|NCT04000516|Experimental|Evening Fasters (EF)|Evening fasters were asked to not consume food after 3 pm until the next morning.
11110795|NCT04000516|Experimental|Morning Fasters (MF)|Morning fasters were asked to not consume food from the time they woke until 11 am.
11110796|NCT04000503|Experimental|Community Health Worker Self-Collection|Door-to-door recruitment of women for self-collected HPV testing
11110797|NCT04000503|Experimental|Community Health Meeting Self-Collection|Community health meeting recruitment of women for self-collected HPV testing
11110798|NCT04000490||patient with a chest pain|adult patient with a chest pain calling for urgency center
11110799|NCT04000477|Experimental|Kevorkian curette|
11110800|NCT04000477|Experimental|Cytobrush|
11110801|NCT04000464|Experimental|Single Arm|24 Week Lifestyle Modification intervention
11110802|NCT04000451|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
11110803|NCT04000451|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
11110804|NCT04000438|Experimental|Experimental DF01 high dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
11110805|NCT04000438|Experimental|Experimental: DF01 medium dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
11110806|NCT04000438|Experimental|Experimental: DF01 low dose|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
11110807|NCT04000438|Placebo Comparator|Placebo comparator: PL1|The subject receives sc injections once daily for up to 7 days until labor induction or spontaneous onset of labor.
11110808|NCT04000425||ctDNA detection|The blood samples for ctDNA and other tumor markers (such as CEA, et al.) will be first collected within 7 days before surgery, and then be tested after radical gastrectomy in scheduled interval.
11110809|NCT04000412||CASE GROUP|patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias
11110810|NCT04000399|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinician trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.
~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE.; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
11110811|NCT04000386|Experimental|zinc oxide nanoparticles coated socks|62 patients with zinc oxide nanoparticles coated socks
11110812|NCT04000386|Placebo Comparator|placebo|62 patients with placebo socks
11110813|NCT04000373|Other|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
11111100|NCT03998397|Experimental|patients without alcohol use disorders|
11110814|NCT04000360|Experimental|High-Intensity Exercise Group|Mild to moderate Parkinson's disease patients: The exercise group will be asked to cycle 3x/week for 12 months on a Peloton bicycle which will be delivered to their home.
11110815|NCT04000360|No Intervention|Usual and Customary Care Group|Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
11110816|NCT04000347|Active Comparator|2.5% benzoyl peroxide|43 patients with 2.5% benzoyl peroxide gel
11110817|NCT04000347|Active Comparator|5% benzoyl peroxide|43 patients with 5% benzoyl peroxide gel
11110818|NCT04000334|Experimental|Cerebral hypoperfusion (group A)|Cerebral hypoperfusion will be defined by an abnormal TCD at inclusion (t0) when two of the three measured values are abnormal using the following thresholds: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4.
11110819|NCT04000334|Active Comparator|Normal cerebral perfusion (group B)|Normal cerebral perfusion will be defined by a normal TCD at inclusion (t0) when two of the three measured values are normal using the following thresholds: Vm > 30 cm/s, Vd > 20 cm/s, PI < 1.4.
11110820|NCT04000321|Experimental|Windmill group 30 Mins|In the Windmill Group, the Windmill technique is carried out after 30 minutes. The windmill technique of the umbilical cord for placental development is performed by a trained obstetrician or midwife with a doctor presence. In a frustrated attempt to develop placenta using the Windmill technique, a manual removal is performed according to the clinic standard.
11110821|NCT04000321|Active Comparator|Control Group|In the control group, after a total of 45 minutes of unsuccessful application of the traditional and customary measures, the Windmill technique is used. If unsuccessful, a manual placenta removal is performed according to hospital Standards.
11110822|NCT04000308|Experimental|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
11110823|NCT04000308|Active Comparator|Wound Infiltration|Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
11110824|NCT04000295|Experimental|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
11110825|NCT04000295|Active Comparator|Weekly Paclitaxel|Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
11110826|NCT04000282|Experimental|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
11110827|NCT04000282|Experimental|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
11110828|NCT04000269|Experimental|Treatment Group|Treatment with 'Soterix MxN Neuromodulation device (high definition transcranial direct current stimulator) using HD-Targets for optimal neural targeting will be provided to participants and will include 20 minutes of stimulation coupled with conventional OT treatment during and after the intervention. There will be a total of 10 sessions over about a 2 week period.
11110829|NCT04000269|Sham Comparator|Sham group|Sham stimulation will consist of using the devices auto-sham feature. The exact same setup/device will be used during both groups. This is considered a control for the experiment. Both groups will receive similar physical occupational and speech therapy
11110830|NCT04000256||Spinal Cord Injury|The data during the first visit involves questionnaires, performance and observational measures for baseline evaluation. The 2nd to 8th visit involves feedback survey and interview data collection based on experiences of participants undergoing activity-based training using upper extremity rehabilitation equipment.
11110831|NCT04000230|Experimental|TCIT|Teachers in the intervention group receive TCIT in the first half of the school year and booster coaching is provided throughout the second half of the school year as the Waitlist Control group is trained.
11110832|NCT04000230|Active Comparator|Waitlist Control|Waitlist Control teachers do not receive any intervention for the first half of the school year. They then receive the same TCIT training as the intervention group in the second half of the school year.
11110833|NCT04000217|Active Comparator|Written Exposure Therapy|Written exposure therapy (Sloan et al., 2012) is a brief evidence-based treatment for PTSD (US Dept. of VA & DoD, 2017), wherein patients are asked to write about their trauma memories for 30 minutes, with therapist instruction and feedback before and after each writing exercise.
11110834|NCT04000217|Active Comparator|Imaginal Exposure Therapy|Imaginal exposure therapy will involve verbal recounting of trauma memories for 30 minutes with therapist instruction and feedback before and after each recounting exercise.
11110835|NCT04000204|Experimental|HYAJOINT Plus|
11110836|NCT04000204|Active Comparator|Durolane|
11110837|NCT04000191|Active Comparator|Usual monitored anesthesia care (MAC)|Monitored anesthesia care (MAC) administered by anesthesiology and injection of local anesthesia by the operating surgeon.
11110838|NCT04000191|Experimental|MAC and perianal ice|Monitored anesthesia care (MAC) administered by anesthesiology, application of ice to the perianal area after it is prepared with betadine, and injection of local anesthesia by the operating surgeon.
11110839|NCT04000178|Other|group A|patients who received polyurethane stents
11110840|NCT04000178|Experimental|group B|patients who received silicone stents
11110841|NCT04000165|Experimental|SC|subjects with SCD
11110842|NCT04000152|Active Comparator|Control group (group 1)|Deferred single blastocyst transfer with blastocyst selection according to morphology.
11110843|NCT04000152|Experimental|Intervention group (group 2)|Deferred single blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).
11110844|NCT04000139|Active Comparator|Standardized anthocyanin rich extract|3 doses of 2x 500mg in capsules daily
11110845|NCT04000139|Placebo Comparator|Placebo|3 doses of 2x 500mg in capsules daily
11110846|NCT04000126|Active Comparator|Control C|This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)
11110847|NCT04000126|Experimental|Lignocaine group L|This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
11110848|NCT04000126|Placebo Comparator|Placebo P|This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation
11110849|NCT04000113|Experimental|laser acupuncture treatment|Subjects accept low-dose near-infrared laser acupuncture (10mWx10) treatment for 5 minutes in each trial.
11110850|NCT04000113|Sham Comparator|Sham laser acupuncture treatment|Subjects accept the sham (blank) laser acupuncture treatment for 5 minutes in each trial.
11110851|NCT04000100|Placebo Comparator|Control group|This group received supraclavicular block using 25mL of 0. 5% bupivacaine and 1 mL normal saline
11110852|NCT04000100|Active Comparator|Neostigmine group|This group received 25 mL 0. 5% bupivacaine and 1 mL neostigmine (0.5 mg)
11110853|NCT04000087|Experimental|Intervention|Care teams randomized to intervention will have access to the screening tool.
11110854|NCT04000087|No Intervention|Control|Care teams randomized to control will continue routine practice.
11110855|NCT04000074|Experimental|Telephonic Services - Intervention|Persons in this group are linked with a telephonic case manager to help address their social needs.
11110856|NCT04000074|No Intervention|Telephonic Services - Control|Persons in this group are similar in risk to those in the 'Telephonic Services - Intervention' arm, but are not linked with a case manager.
11110857|NCT04000074|Experimental|In-Person Services - Intervention|Persons in this group are linked with an in-person case manager who makes home visits to help address their social needs.
11110858|NCT04000074|No Intervention|In-Person Services - Control|Persons in this group are similar in risk to those in the In-Person Services - Intervention' arm, but are not linked with a case manager.
11110859|NCT04000061||acute coronary syndrome (ACS)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed.
11110860|NCT04000061||acute heart failure (AHF)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed.
11110861|NCT04000035|Experimental|HealthAtWork|The interdisciplinary HealthAtWork intervention consists of three information sessions over the course of one year, with work place processes in between. In the meetings, structured health information about musculoskeletal- and mental disorders is given and put in the context of working and the specific workplace. It is an integrated intervention where information is given together by both healthcare- and NAV-personnel.
11110862|NCT04000035|Active Comparator|Regular work place measures|Regular work place measures offered by NAV workplace service. Those are interventions given by NAV personnel without healthcare involvement and can be varying.
11110863|NCT04000022||Non-Treatment Resistant Patients|
11110864|NCT04000022||Treatment-Resistant Patients|The group of patients from NCT03944213
11110865|NCT04000009|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
11110866|NCT03999996|Experimental|Takeda's Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once at Month 15.
11110867|NCT03999996|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once at Month 15.
11110868|NCT03999970|Active Comparator|Phlebotomus papatasi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus papatasi fed on blood twice in the laboratory prior to human exposure.
11110869|NCT03999970|Active Comparator|Phlebotomus duboscqi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus duboscqi fed on blood twice in the laboratory prior to human exposure.
11110870|NCT03999957|Other|Interventional Arm|Telehealth conferencing
11110871|NCT03999931||schizophrenia with positive symptoms|schizophrenia with positive symptoms
11110872|NCT03999931||schizophrenia with negative symptoms|schizophrenia with negative symptoms
11110873|NCT03999931||bipolar disorder|bipolar disorder
11110874|NCT03999931||depression|depression
11110875|NCT03999931||panic disorder|panic disorder
11110876|NCT03999931||obsessive-compulsive disorder|obsessive-compulsive disorder
11110877|NCT03999931||control|
11110878|NCT03999918|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
11110879|NCT03999918|Placebo Comparator|Placebo|Placebo tablets
11110880|NCT03999905|Experimental|Intervention Arm|Online training on Oral anticoagulant counseling.
11110881|NCT03999905|No Intervention|Control Arm|No counseling training
11110882|NCT03999892|Experimental|Consumers with SMI|Consumers with serious mental illness who attend a psychiatric rehabilitation program (PRP) will participate in a group-based diet and physical activity program.
11110883|NCT03999892|Other|Staff at PRP|Staff and peer leaders who work at a psychiatric rehabilitation program (PRP) will observe sessions of a group-based diet and physical activity program for consumers with SMI.
11110884|NCT03999879||Cognitively Normal|having 30 participants with normal cognition
11110885|NCT03999879||Amnesic MCI|aMCI Group having 15 participants with a CDR of 0.5-1 and a Mini-Mental State Examination (MMSE) of 20-25.
11110886|NCT03999866|Active Comparator|satisfaction of instructor|visual analogy scale of the satisfaction of the instructor was recorded
11110887|NCT03999866|Active Comparator|satisfaction of the patient|visual analogy scale of the satisfaction of the patient was recorded
11110888|NCT03999866|Active Comparator|duration of view|duration of the visualization the vocal cords was recorded
11110889|NCT03999853|Experimental|Conventional Therapy / Butyrate|This arm will be receiving usual therapy for the first study period then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) after washout and cross-over
11110922|NCT03999606|Active Comparator|Mindfulness Training|Participants in the control group will be assigned to a online based mindfulness training.
11110890|NCT03999853|Experimental|Butyrate / Usual Therapy|This arm will be receiving 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) placebo for the first study period then usual therapy after washout and cross-over
11110891|NCT03999840|Experimental|IMP|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
11110892|NCT03999840|Placebo Comparator|Placebo|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
11110893|NCT03999827|Experimental|Immediate Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning immediately after randomisation.
11110894|NCT03999827|Active Comparator|Delayed Diet Group|Adhere to Low Glycaemic Index diet for 52 weeks, beginning 12 weeks after randomisation.
11110895|NCT03999801||All|All subjects that previously received RGX-314 in a parent study are enrolled into this arm.
11110896|NCT03999788|Experimental|multiple sclerosis patients|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
11110897|NCT03999788|Experimental|control subjects|lumbar puncture, microRNAs quantification in CSF samples, SNPs analysis in blood samples
11110898|NCT03999788|Experimental|multiple sclerosis patients with spasticity and selected SNPs|iTBS therapeutic protocol
11110899|NCT03999775|Active Comparator|Calcium, vitamin D and bioactive collagen peptides supplement|In this arm, all patients received a sachet containing 5mg bioactive collagen peptides, 500 mg calcium lactate and 400 IU vitamin D3 per day.
11110900|NCT03999775|Active Comparator|Calcium and vitamin D supplement|In this arm, all patients received a chewable tablet containing 500 mg calcium carbonate and 400 IU vitamin D3 per day.
11110901|NCT03999762|Active Comparator|Density gradient sample prep|Standard density gradient sample preparation
11110902|NCT03999762|Experimental|Automated sample prep|Automated experimental sample preparation
11110903|NCT03999749|Experimental|Induction Phase, Maintenance Phase|"Induction Phase: 2 induction treatment cycles of 42 days (6 weeks) each, of which the first cycle of 6 weeks is the DLT period.
~Maintenance Phase: Consists of treatment cycles of 84 days (12 weeks) each, and may extend up to 1 year."
11110904|NCT03999736|Experimental|Treatment|"14 sessions x 30 minutes of 2mA transcranial direct current stimulation to the dorsolateral prefrontal cortex.
~10 x sessions over the course of the initial two weeks (e.g. 5 x per week with flexibility).
~4 x sessions over the course of a two week maintenance treatment."
11110905|NCT03999723|Experimental|Vitamin C|Oral vitamin C (ascorbic acid) will be given in a dose of 1000 mg daily (two capsules of 500 mg once daily) starting day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier.
11110906|NCT03999723|Placebo Comparator|Placebo|Placebo will be administered orally as two capsules once daily that look and taste identical to the capsules containing vitamin C. Treatment will start day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier. The content of the placebo capsules is glucose monohydrate, potato starch, gelatin, magnesium stearate and talc.
11110907|NCT03999710|Experimental|Non-Small Cell Lung Cancer|All participants have locally-advanced non-small cell lung cancer, Stage II-III. Treatment will consist of durvalumab administered concurrently with thoracic radiation consisting of 60 Gy in 30 fractions. Patients will be monitored weekly during on-treatment visits. Durvalumab will then be continued up to 1 year as maintenance or until disease progression or unacceptable toxicity. Optional Research MRIs (Does not apply to the Alliance Sites. Research MRIs will only be done at MSKCC)
11110908|NCT03999697|Experimental|CAR-CD22 Cell immunotherapy|Enrolled patients will receive CAR-CD22 cell immunotherapy with a novel specific chimeric antigen receptor targeting CD22 antigen by infusion.
11110909|NCT03999684|Experimental|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
11110910|NCT03999671|Experimental|INSTRUMENT SF 36|Instrument SF36 Spanish version, validated in Spain, translated in several languages and applied to multiple studios in Mexico. The 36 items explore 8 dimensions: the state of physical health, physical function, physical role, body pain, general health, vitality, social function, emotional role and mental health: considering depression, anxiety, self-control, and general well-being.
11110911|NCT03999671|Active Comparator|Checklist|Verify that the interventions of both groups were carried out
11110912|NCT03999658|Experimental|Extranodal NK/T-cell lymphoma (ENKTL)|Intravenous STI-3031 (anti-PD-L1 antibody)
11110913|NCT03999658|Experimental|Peripheral T-cell lymphomas (PTCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
11110914|NCT03999658|Experimental|Diffuse large B-cell lymphoma (DLBCL)|Intravenous STI-3031 (anti-PD-L1 antibody)
11110915|NCT03999658|Experimental|Biliary tract cancers (BTC)|Intravenous STI-3031 (anti-PD-L1 antibody)
11110916|NCT03999645|Active Comparator|Group E: Early LC (n=60)|Early laparoscopic cholecystectomy (within 72h from symptom onset)
11110917|NCT03999645|Active Comparator|Group L: Late LC (n=60)|Late laparoscopic cholecystectomy (after 72h up to seven days from symptom onset)
11110918|NCT03999632|Experimental|Mankai Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group A (Wolffia Globosa) will be allowed to have two meals a day and one protein shake (Wolffia Globosa) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Wolffia Globosa) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
11110919|NCT03999632|No Intervention|Control Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group B (Control) will be allowed to have two meals a day and one protein shake (Control) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Control) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
11110920|NCT03999619|Experimental|Experimental|Children will enter into the Move 2 Learn program immediately following their first assessment (between week 0 to 10)
11110921|NCT03999619|Other|Wait-list Control|Children will not participate in the program until after their second assessment (between week 11 to 21). Their control period will take place between week 0 and 10.
11110924|NCT03999580|Experimental|Experimental Arm:|"Experimental: Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day
~3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UI/day as maintenance therapy for 48 weeks.
~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)."
11110925|NCT03999580|Active Comparator|Control Arm:|"Active Comparator: Vitamin D3 600 UI/day then 600 UI/day
~600 UI/day as induction therapy for 4 weeks, then 600 UI/day as maintenance therapy for 48 weeks.
~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
11110926|NCT03999567|Experimental|Pen and Paper vs. Mobile Digit Symbol Substitution Test|This validation study will assess the convergent validity of the mobile DSST application with the pencil version of the DSST. Correlations between performance on app-based version of the DSST and paper-based version of DSST will be measured.
11110927|NCT03999554|Experimental|Low dose Sing2016 M2SR|Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
11110928|NCT03999554|Experimental|Medium dose Sing2016 M2SR|Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
11110929|NCT03999554|Experimental|High dose Sing2016 M2SR|High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
11110930|NCT03999554|Active Comparator|Low dose Bris10 M2SR|Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
11110931|NCT03999554|Placebo Comparator|Placebo|Saline will be administered intranasally on days 1 and 29
11110932|NCT03999541|Experimental|Freeze-all|Good quality embryos (either day 3 or 5) will be frozen and subsequent frozen embryo transfer will be arranged within three months of the egg retrival.
11110933|NCT03999541|No Intervention|Fresh embryo transfer|Women will undergo fresh embryo transfer at the cleavage (day 3) or blastocyst stage (day 5).
11110934|NCT03999528||study group|RA Patients
11110935|NCT03999528||control group|normal control
11110936|NCT03999515|Experimental|Treatment (abiraterone acetate, enzalutamide, erdafitinib)|Patients receive abiraterone acetate orally PO QD or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
11110937|NCT03999502|Experimental|Intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
11110938|NCT03999476|Experimental|ambu scope2|intubation of cancer tongue patients with ambu scope2 device
11110939|NCT03999476|Active Comparator|fiberoptic|intubation of cancer tongue patients with fiberoptic device
11110940|NCT03999450|Experimental|Behavioral intervention|Patients admitted to Strong Hospital with opioid use will be given 1 to 3 brief motivational interventions and computer based cognitive behavioral therapy
11110941|NCT03999437|Experimental|Treatment # 1|
11110942|NCT03999437|Experimental|Treatment # 2|
11110943|NCT03999437|Placebo Comparator|Placebo Control|
11110944|NCT03999424|Experimental|Autologous human Schwann cells|All participants will receive autologous human Schwann cells harvested from their own sural nerve.
11110945|NCT03999411|Placebo Comparator|Usual Care|Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.
11110946|NCT03999411|Active Comparator|Smoking cessation only intervention|"Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the Crave-to-Quit app, and two brief follow-up phone calls."
11110947|NCT03999411|Experimental|Combined smoking cessation and HIV intervention|Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.
11110948|NCT03999398||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
11110949|NCT03999398||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
11110950|NCT03999385|Experimental|Immediate Training Group|8 weeks of training in Mindful Self-Compassion.
11110951|NCT03999385|Other|Waitlist Control Group|No intervention for approximately 12 weeks. After this waiting period, participants will complete 8 weeks of training in Mindful Self-Compassion.
11110952|NCT03999372|Experimental|PICSI procedure|PICSI procedure: PICSI dishes are conventional plastic culture dishes pre-prepared with 3 microdots of powdered. The powdered HA is re-hydrated by adding 5 μL droplets of fresh culture medium to each of the three microdots. A 2 μL droplet with suspension of treated spermatozoa is then connected with a pipette tip to these culture medium droplets. The PICSI dish is incubated under oil; within 5 minutes the bound spermatozoa are attached by their head to the surface of the HA-microdots and are spinning around their head. An ICSI injecting pipette is used to pick the best motile HA-bound sperm up and inject them one by one into an oocyte. The ICSI injecting pipette can be previously loaded with viscous medium (PVP or Sperm Slow) to facilitate sperm micromanipulation.
11110953|NCT03999372|Active Comparator|ICSI procedure|ICSI procedure: following sperm preparation as described before, samples were incubated until time of injection. Each oocyte was injected with a single morphologically abnormal and immobilized in polyvinyl Pyrolidone (PVP) spermatozoon. Individual sperm subjected to ICSI was examined and evaluated. The injection procedure was carried out in a sterilized dish using holding pipette and injection needle. Intra cytoplasmic sperm injection was performed according to the protocol of Van Steirteghem.
11110954|NCT03999359|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
11110955|NCT03999359|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
11110956|NCT03999333|Experimental|Virtual Reality|Every participant is provided with a VR headset
11110957|NCT03999320|Experimental|Sophrology group|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
11110959|NCT03999307|Experimental|Low-Level Laser Therapy (LLLT)|In the LLLT group, a low-level laser with wavelength of 808 nm, output of 250 mW, energy of 4 Joules per point and application time of 16 seconds per point will be applied on each tooth of the six maxillary anterior teeth according to this protocol: the root will be divided theoretically into 2 halves; gingival and cervical, and laser will be applied in the center of each half from both buccal and palatal sides which means 4 application points and a total energy of 16 Joules per tooth.
11110960|NCT03999307|Experimental|Flapless Corticopuncture|In the flapless corticopuncture group, 3 interdental punctures located between the roots of the six maxillary anterior teeth from both the buccal and palatal sides, will be done using a 1-mm diameter round surgical Tungsten bur with 1 mm depth and 1.5 mm space between each puncture. These punctures start 2 mm from the free gingiva. Besides, an additional 2 parallel set of punctures with the same dimensions of the interdental ones will be done in the extraction sockets from both the buccal and palatal sides.
11110961|NCT03999307|Experimental|Control|Patients in control group will undergo typical orthodontic treatment only with no LLLT or flapless corticopuncture application.
11110962|NCT03999294|No Intervention|Control Group|
11110963|NCT03999294|Experimental|Experimental Group|
11110964|NCT03999281||Diabetic Foot Ulcers (DFU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
11110965|NCT03999281||Venous Leg Ulcer (VLU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
11110966|NCT03999268|Experimental|Intervention|Participants assigned to the intervention group will receive insulin administration education according to standard procedures plus have access to the I-START app. Over the course of the study period, participants will be able to use I-START as much or as little as they prefer.
11110967|NCT03999268|Active Comparator|Usual Care|Participants in the usual care group will receive insulin administration education according to standard procedures. They will not have access to the I-START app.
11110968|NCT03999255|Experimental|Patients undergoing intrarenal surgery|
11110969|NCT03999229|Active Comparator|Blood transfusion with SNO agent|"Autologous blood transfusion packed red blood cells (RBCs) while inhaling S-nitrosylating agent (SNO)
~A single intra venous blood transfusion of one unit of packed Red Blood Cells (RBCs) will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.
~Inhalation of SNO agent, 20-40 parts per million will occur during the transfusion."
11110970|NCT03999229|Placebo Comparator|Normal Saline with SNO agent|"Normal Saline Transfusion while inhaling S-nitrosylating agent (SNO)
~A single intra venous infusion of one unit of normal saline, will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.
~Inhalation of the SNO agent at 20-40 parts per million, will occur during the transfusion."
11110971|NCT03999216|Active Comparator|Loop only|Participants will receive a loop diuretic for up to the first 72 hours of hospitalization. The specific drug, dose and route are left to the treating providers.
11110972|NCT03999216|Active Comparator|Loop + Thiazide|Participants will receive a loop+thiazide diuretic for up to the first 72 hours of hospitalization. The specific drugs, doses and routes are left to the treating providers.
11110973|NCT03999203||A - T2 High Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL and consistently high FeNO levels ≥30 ppb.
~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
11110974|NCT03999203||B - T2 Low Severe Asthmatics|"Severe asthmatic patients with consistent eosinophil count ≤ 0.2x10^9/mL and consistently low FeNO levels <30 ppb.
~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
11110975|NCT03999203||C - Mild/Moderate Asthmatics|mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
11110976|NCT03999203||D - T2 Intermediate|"Severe asthmatic patients with consistent eosinophil count ≥ 0.3x10^9/mL OR consistently high FeNO levels ≥30 ppb.
~Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling"
11110977|NCT03999190||30 subjects with schizophrenia|
11110978|NCT03999190||30 healthy controls|
11110979|NCT03999177|Experimental|Kinect-TOLF prototype|
11110980|NCT03999164|Experimental|Moderate to Severe Traumatic Brain Injury|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
11110981|NCT03999151|Active Comparator|Arm A: Reference Group|Arm A will receive print educational materials about the benefits of exercise and diet for men with prostate cancer, with recommendations geared at men living with prostate cancer, mailed around the date of surgery. They also receive a 9-week text messaging program focused on recovery after radical prostatectomy surgery.
11110982|NCT03999151|Experimental|Arm B (Arm A + Exercise)|Arm B receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise habits and various tools, such as the ability to track exercise; additional educational print materials on exercise; additional text messages over 2 years that supports healthy exercise habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years.
11110983|NCT03999151|Experimental|Arm C (Arm A + Diet)|Arm C receives the following: Arm A material plus access to an online portal with additional educational materials to help improve diet habits and various tools, such as the ability to track diet; additional educational print materials on diet; additional text messages over 2 years that supports healthy diet habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
11110984|NCT03999151|Experimental|Arm D (Arm A + Exercise + Diet)|Arm D receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise and diet habits and various tools, such as the ability to track exercise and diet; additional educational print materials on exercise and diet; additional text messages over 2 years that supports healthy exercise and diet habits; a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
11110985|NCT03999138||Single Arm|
11110986|NCT03999125|Active Comparator|Group 1|Aflibercept intravitreal injection for CSME
11110987|NCT03999125|Other|Group 2|Ranibizumab Intravitreal Injection for CSME
11110988|NCT03999125|Experimental|Group 3|Dexamethasone Implant for CSME
11110989|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 4 week|Standard MERIT + 4 week baseline period
11110990|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 6 week|Standard MERIT + 6 week baseline period
11110991|NCT03999112|Experimental|Metacognitive Reflection and Insight Therapy (MERIT) 8 week|Standard MERIT + 8 week baseline period
11110992|NCT03999099|Placebo Comparator|Placebo|
11110993|NCT03999099|Experimental|Suvorexant 10mg|Suvorexant 10mg oral dose
11110994|NCT03999099|Experimental|Suvorexant 20mg|Suvorexant 20mg oral dose
11110995|NCT03999086||Control Group|Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.
11110996|NCT03999086||Intervention arm|Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.
11110997|NCT03999073||Subjects with coarctation|
11110998|NCT03999073||Controls|
11110999|NCT03999060|Experimental|Electric Stimulation|
11111000|NCT03999034|Experimental|Patients|experimental, cognitive test, no treatment investigated. 140 patients (90 relasping remitting and 50 progressive multiple sclerosis)
11111001|NCT03999034|Experimental|Healthy controls|experimental, cognitive test, no treatment investigated. 400 healthy controls divided into 20 groups, due to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not).
11111002|NCT03999021|Experimental|Experimental Arm|All participants to receive study intervention.
11111003|NCT03999008|Active Comparator|Budesonide|"Oral viscous budesonide will be given in apple sauce according to body weight at inclusion:
~< 10 kg: 250 mcg BID in 5 ml apple sauce 10 kg to <15 kg: 500 mcg BID in 5 ml apple sauce >15 kg: 1000 mcg BID in 5 ml apple sauce"
11111004|NCT03999008|Placebo Comparator|Placebo|Placebo: 5 ml apple sauce BID plus 1 mL saline
11111005|NCT03998995|Experimental|IVR rehabilitation game intervention|Clinical trial patients' use the IVR rehabilitation game for two 15 minute sessions during one physical therapy session with their usual practitioner, with support from the physiotherapist and the game expert on the team.
11111006|NCT03998982|Active Comparator|glycyrrhetinic acid Combining HD-DXM|Compound glycyrrhizin tablets 75mg three times per day, 1 month, and HD-DXM (orally at 40 mg daily for 4d )
11111007|NCT03998982|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
11111008|NCT03998969|Experimental|Pantoprazole and DA-5204|Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks
11111009|NCT03998969|Active Comparator|Pantoprazole and placebo|Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks
11111010|NCT03998956|Active Comparator|Circumferential PV isolation|Circumferential PV isolation only
11111011|NCT03998956|Experimental|Circumferential PV and BOX isolation|Circumferential PV and BOX isolation
11111012|NCT03998956|Experimental|circumferential PV and BOX isolation with substrate ablation|Atrial substrate ablation apart from circumferential PV and BOX isolation
11111013|NCT03998930|Experimental|brain injuried patients|"Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R),
~15-minute break between the two evaluations.
~Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task (imagine moving the right or left wrist)."
11111014|NCT03998917||Chronic Kidney Disease (CKD) Patients|Patients with chronic kidney disease and a glomerular filtration rate less than 60 ml/min of creatinine. Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
11111015|NCT03998917||Control cohort|The control cohort will consist of a group of people from the same age group as the CKD group but without chronic kidney disease. The exclusion criteria apply to this group. They will be selected from the spouses and other volunteers. This group will also perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
11111016|NCT03998904|Experimental|Muscle preservation|Muscle preservation for hamsting graft
11111017|NCT03998904|Active Comparator|None preservation|No muscle preservation for hamstring graft
11111018|NCT03998891||salt restricted diet|In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
11111019|NCT03998891||normal salt diet|In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
11111020|NCT03998878|Experimental|Low-Carbohydrate Diet|Participants will be instructed to consume less than 30 grams of carbohydrates per day.
11111021|NCT03998878|Experimental|Intermittent Energy Restriction|Participants choose 2 non-consecutive days per week in which they will consume 500-650 calories.
11111022|NCT03998878|Experimental|Hunger Training|Participants monitor their hunger symptoms and blood glucose, and eat only when blood glucose is below a certain threshold level.
11111023|NCT03998865|Experimental|PEEK Provisional Abutment|The provisional crown will be fixed onto a PEEK abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
11111024|NCT03998865|Active Comparator|Titanium Provisional Abutment|The provisional crown will be fixed onto a titanium abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
11111025|NCT03998852|Experimental|Molecular imaging|Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
11111026|NCT03998839||Intervention|Children tested will live within an area targeted for community IPTp distribution for pregnant women.
11111027|NCT03998839||Control|Children tested will live within an area NOT targeted for C-IPTp, but will live in an area nearby.
11111028|NCT03998826|Experimental|Piroxicam drug|20 mg piroxicam
11111029|NCT03998826|Placebo Comparator|Placebo|placebo
11111030|NCT03998813|Experimental|Locoregional analgesia by femoral triangle catheterization|
11111031|NCT03998813|Active Comparator|Tissue infiltration|
11111032|NCT03998800|Experimental|L-arginine and L-citrulline|10 days of supplementation with 1.5 g of L-arginine and 1.5 g of L-citrulline per day
11111033|NCT03998800|Experimental|L-arginine|10 days of supplementation with 3 g of L-arginine per day
11111034|NCT03998800|Placebo Comparator|Placebo (corn-starch)|10 days of supplementation with corn-starch
11111035|NCT03998787||Patients with Parkinson's disease|Patients with Parkinson's disease
11111036|NCT03998787||Healthy Subjects|Healthy subjects
11111037|NCT03998761|Active Comparator|Micronized progesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening).
11111038|NCT03998761|Active Comparator|Micronized progesterone plus dydrogesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening).
11111039|NCT03998748|Experimental|Experimental|This group of participants will receive the feedback that they have a genetic vulnerability to depression.
11111040|NCT03998748|Active Comparator|Control|This group of participants will receive the feedback that they do not have a genetic vulnerability to depression.
11111041|NCT03998735|Experimental|Group 1 (N=15)|160 µg/g herbal snuff, median level found in commercial moist snuff
11111042|NCT03998735|Experimental|Group 2 (N=15)|70 µg/g herbal snuff, lowest level found in commercial moist snuff (rounded)
11111043|NCT03998735|Experimental|Group 3 (N=15)|3.5 µg/g herbal snuff, 5% of the lowest level found in commercial moist snuff
11111044|NCT03998735|Active Comparator|Group 4(N=10)|0 µg/g herbal snuff, control group will use unmodified herbal snuff
11111045|NCT03998722|Experimental|Vagivital|Vagivital once Daily for 12 weeks
11111046|NCT03998709|Other|Elevation of fasting FFA and Glucose|People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
11111047|NCT03998709|Other|Lowering of fasting FFA and glucose|People with elevated fasting glucose and elevated fasting FFA (Impaired fasting glucose / impaired glucose tolerance - IFG / IGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive insulin to lower fasting glucose and fasting FFA. Subsequently (on either study day) they will undergo a hyperglycemic clamp for 2 hours. After this somatostatin will be infused acutely to inhibit endogenous insulin secretion and observe clearance of beta-cell polypeptides.
11111048|NCT03998696|Active Comparator|Weekly Cisplatin|Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
11111049|NCT03998696|Experimental|Three weekly Cisplatin|Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
11111050|NCT03998683|Experimental|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
11111051|NCT03998683|Placebo Comparator|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
11111052|NCT03998670|Experimental|Prism Group|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by prism and alternate cover test (PACT) at distance or near) equally divided between the 2 lenses will be prescribed to the participant
11111053|NCT03998670|Placebo Comparator|Non-Prism Group|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism will be prescribed to the participant
11111054|NCT03998657|Experimental|Exablate Treated Arm|Treatment with Exablate Prostate 2100 Type-3 System
11111055|NCT03998644||healthy|Subjects without colorectal disorders.
11111056|NCT03998644||precancerous|Subjects with risk factors that may contribute to the carcinogenesis.
11111057|NCT03998644||colorectal cancer|Patients who were identified by standard procedures to suffer with colorectal cancer.
11111058|NCT03998631|Placebo Comparator|Saline Flush|This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
11111059|NCT03998631|Experimental|Carbon Dioxide and Saline Flush|Carbon dioxide flush of the TEVAR or TAVI device followed by saline flush.
11111060|NCT03998618|Experimental|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
11111061|NCT03998618|Active Comparator|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
11111062|NCT03998605|Experimental|Abuse Prevention Program Condition|"The abuse prevention program will address: (1) BEFORE -- (a) Learning about problem of abuse and what abuse is; (b) Knowing about types of abuse, who the abusers are and where abuse happens; (c) Planning ahead and identifying safe people; (2) DURING -- (a) Rejecting abuse by saying no; (b) Getting away if possible/staying safe and paying attention, (c) Staying calm and getting home; and (3) AFTER -- (a) Telling your safe person, (b) Knowing what to do and what not to do, and (c) Reporting the abuse and getting help to cope with the event."
11111063|NCT03998605|Active Comparator|Control condition|During the study the control group will receive 12 activity sheets from the ESCAPE-NOW curriculum. Six activity sheets will be given at the initial meeting and half way through the study the remaining activity sheets will be mailed to the dyads. We chose these activity sheets because they provide abuse information that was designed for individuals with ID.
11111064|NCT03998592|Experimental|Low-dose vaccine|
11111065|NCT03998592|Experimental|Mid-dose vaccine|
11111066|NCT03998592|Experimental|High-dose vaccine|
11111067|NCT03998592|Placebo Comparator|Placebo|
11111068|NCT03998579|Experimental|Individualized exercise|The intervention group get a referral to physiotherapist in Primary Health Care in Stockholm County Council, close to where they live. Within the third week after discharge, the patients begin twelve weeks of biweekly exercise. The physical exercise is individually targeted aerobic and strength exercises, based on international recommendations for persons with cancer disease. The program is approved by resposible surgeons.
11111069|NCT03998579|Active Comparator|Active control group|Oral and written information of a home-based exercise programme and information of supportive techniques to improve physical activity
11111070|NCT03998566|Experimental|TraceIT Tissue Spacer|
11111071|NCT03998540||Patients with myopathy suspected of titinopathy|Patients with myopathy in which one or more potentially pathogenic TTN variants have been previously identified (index cases and related cases affected). Muscle biopsy performed previously
11111072|NCT03998527|Experimental|Non-Disabled (ND) and Spinal Cord Injured (SCI) controls|The ND Control group (n=6) and SCI Control group (n=6) will be used to assess related values as acute effects of transcutaneous electrical spinal cord stimulation (TcESCS) itself and will not receive any training intervention. The ND group will receive baseline assessments, then up to 12 (4-Respiratory function, 4-Arm function, and 4-Trunk function) TcESCS mapping experiments, followed by repeating the assessments in the presence of TcESCS. The investigators will decide which stimulation type should be used for the post-mapping assessments.
11111073|NCT03998527|Experimental|Spinal Cord Injured (SCI) intervention groups|The respiratory training (RT) group (n=6) will receive the respiratory training intervention only); the transcutaneous electrical spinal cord stimulation (TcESCS) group (n=6) will receive transcutaneous spinal cord stimulation only; TcESCS + RT group (n=6) will receive TcESCS combined with RT; TcESCS + Arm Training (AT) group (n=6) will receive TcESCS combined with AT; and TcESCS + Trunk Training (TT) group (n=6) will receive TcESCS combined with TT.
11111074|NCT03998514|Experimental|Group A1 single ascending dose (SAD)|CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
11111075|NCT03998514|Experimental|Group A2 SAD|CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
11111076|NCT03998514|Experimental|Group A3 SAD|CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
11111077|NCT03998514|Experimental|Group A4 SAD|CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
11111078|NCT03998514|Experimental|Group A5 SAD|CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
11111079|NCT03998514|Experimental|Group A6 SAD|CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
11111080|NCT03998514|Experimental|Group B1 multiple ascending dose (MAD)|CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
11111081|NCT03998514|Experimental|Group B2 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
11111082|NCT03998514|Experimental|Group B3 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
11111083|NCT03998514|Experimental|Part C|CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
11111084|NCT03998501|Experimental|Active|5-week CBTm
11111085|NCT03998501|No Intervention|Waitlisted|Waitlisted (will receive 5-week CBTm 3 months after).
11111086|NCT03998488|Experimental|Investigational FMT|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy.
~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
11111087|NCT03998488|Active Comparator|Investigational FMT + psyllium fiber|"Participants will be blindly randomized to receive a single dose of investigational FMT during the week 0 colonoscopy. They will also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.
~Additionally, participants will blindly receive a single dose of placebo FMT during the week 8 by flexible sigmoidoscopy."
11111088|NCT03998488|Placebo Comparator|Placebo FMT +/- psyllium fiber|"Participants will be blindly randomized to receive a single dose of placebo FMT during the week 0 colonoscopy. They may or may not also receive fiber supplementation of 1 teaspoon 2x/day for 8 weeks.
~Additionally, participants will blindly receive a single dose of investigational FMT during the week 8 by flexible sigmoidoscopy."
11111089|NCT03998475|Experimental|Transition preparation program|Transition preparation intervention for young adults with type 1 diabetes (T1D)
11111090|NCT03998462|Active Comparator|Mindfulness Based Stress Reduction|MBSR consists of 6-8 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
11111091|NCT03998462|Placebo Comparator|Psychoeducational/Supportive Care|Psychoeducational/Supportive care consists of 6-8 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
11111092|NCT03998449|Experimental|Cholera vaccination|Two doses of the vaccine against cholera
11111093|NCT03998436|Active Comparator|Galnobax® 14% gel plus SoC|Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
11111094|NCT03998436|Sham Comparator|SoC Only|Only Standard of Care will be administered twice daily (150 subjects)
11111095|NCT03998436|Placebo Comparator|Vehicle plus SoC|Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)
11111096|NCT03998423|Experimental|1 dose fecal microbiota transplant|This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
11111097|NCT03998423|Experimental|2 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
11111098|NCT03998423|Experimental|3 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
11111099|NCT03998397|Experimental|patients with alcohol use disorders|
11111101|NCT03998384|Active Comparator|group of autoserum|One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
11111102|NCT03998384|Placebo Comparator|group of placebo|The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
11111103|NCT03998371||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology and FISH.
11111104|NCT03998371||Non-cancer participants group|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
11111105|NCT03998358||High Fatigue|TBI patients with significant fatigue as calculated by a score of >= 5.5 on the Fatigue Severity Scale
11111106|NCT03998358||Low Fatigue|TBI patients without significant fatigue as calculated by a score of < 5.5 on the Fatigue Severity Scale
11111107|NCT03998345|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance
11111108|NCT03998319|Experimental|Tenecteplase|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/3 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
11111109|NCT03998319|Placebo Comparator|Water for injection|Water for injection will be prepared to 20mL over an equivalent time period to the reconstitution time of the experimental arm, in order to maintain the blind, and administered by intracoronary infusion over 3 minutes.
11111110|NCT03998306|Experimental|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive probiotic lozenge before falling asleep for12 weeks. They will receive hygienic and dietetic instructions. examination will be conducted before study and after 12 weeks.
11111111|NCT03998306|Sham Comparator|CONTROL|no intervention
11111112|NCT03998293|Other|proinsulin clearance|all participants will be studied once where somatostatin will be used to block endogenous insulin secretion
11111113|NCT03998267|Active Comparator|Intervention arm|"For the subjects using the app (intervention group): The mobile app team shall do the following:
~Educate/train patients on app usage
~Patients will be subscribed to the app and their profile on the app will be created
~Subjects will log in their blood sugar readings and communicate with the mobile app team (educators and physician) via the app
~Additionally patients will be placed on a diet and lifestyle plan as agreed upon by the patient and health care provider team, best suited towards the patient's needs
~Throughout the study, patient will receive notifications and advice on how to follow diet and lifestyle changes
~Throughout the study; patient interaction and app usage will be tracked
~Patients will additionally be interviewed by the research team together with Droobi to capture app experience at 3 months and 6 months"
11111114|NCT03998267|Placebo Comparator|Standard of care arm|"For the subjects not using the app (the standard of care group):
~At time 0, will be seen by the dietician and diabetes educators at HGH endocrine clinics as part of standards of care
~The educators contact number and diabetes hotline number will be provided to the patients
~o The diabetes hotline number #16099 is a new service provided to diabetes patients at the national diabetes center to help communicate with the diabetes educators with questions relating to their diabetes management, medication adjustment such as dose titrations etc.
~Appointments thereafter with the educator and/or dietician will be decided and scheduled according to the individual patient needs, with a minimum visit every 3 months during the study period"
11111115|NCT03998254|Experimental|V503|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
11111116|NCT03998254|Active Comparator|Gardasil|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
11111117|NCT03998215|Experimental|Diphtheria booster vaccination|One booster dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
11111118|NCT03998202||Adults 65-74 years|
11111119|NCT03998202||Adults >= 75 years|
11111120|NCT03998189|Experimental|Female Participants|45 female patients will be screened to participate.
11111121|NCT03998189|Experimental|Male Participants|45 male patients will be screened to participate
11111122|NCT03998176|Experimental|B/F/TAF|Participants will receive B/F/TAF for 48 weeks
11111123|NCT03998163|Experimental|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
11111124|NCT03998150|Active Comparator|HoLEP holmium laser enucleation of the prostate|holmium laser enucleation of the prostate
11111125|NCT03998150|Active Comparator|BPEP bipolar plasmakinetic enucleation of the prostate|bipolar plasmakinetic enucleation of the prostate
11111126|NCT03998137||Autograft|Standard Rigid Fixation plus autograft
11111127|NCT03998137||AUGMENT® Injectable|Standard rigid fixation plus AUGMENT® Injectable Bone Graft
11111128|NCT03998124|Experimental|Peer-led intervention|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
11111129|NCT03998124|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
11111130|NCT03998111|Experimental|Trial|Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
11111131|NCT03998098||Oxygen Saturation (Oximetry)|Arm to determine the performance of the Oxygen Saturation measurement in LifeLight First
11111132|NCT03998098||Heart Rate (Pulse)|Arm to determine the performance of the Heart Rate measurement in LifeLight First
11111133|NCT03998098||Respiratory Rate|Arm to determine the performance of the Respiratory Rate measurement in LifeLight First
11111134|NCT03998098||Blood Pressure|Arm to determine the performance of the Blood Pressure measurement in LifeLight First
11111135|NCT03998085|Experimental|anlotinib|
11111136|NCT03998072|Experimental|Intervention|
11111137|NCT03998072|No Intervention|Treatment as usual (waiting list control)|
11111253|NCT03997240|Experimental|Immediate intervention|Immediate treatment group
11111254|NCT03997227|Active Comparator|Block group|
11111138|NCT03998059||30 immune thrombocytopenia(ITP) patients|A total of 30 cases. The investigators plan to take 20ml of peripheral blood (PB) of these 30 ITP patients at 6 time points, including 1 day before surgery, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery
11111139|NCT03998059||20 normal controls|A total of 20 cases.18 age- and gender- matched healthy donor will also be enrolled as controls and taken 20ml of peripheral blood.
11111140|NCT03998059||Spleens of the 30 cases patients(ITP)|These 30 ITP patients agree to have splenectomy.The investigators will take a small amount of spleen tissue during surgery.
11111141|NCT03998059||Spleens of the 10 cases patients(normal controls)|The investigators also plan to take splenic tissue from 10 patients who have splenectomy due to hereditary spherocytosis or trauma.
11111142|NCT03998046|Active Comparator|Basic Resources and Services|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, and information about linkages to extant intensive lifestyle interventions in the community
11111143|NCT03998046|Experimental|Coordinated Primary Care Population Management (C3PO)|Patients will receive outreach engagement in goal setting via MyChart, an electronic scale, telemonitoring of self weighing, information about linkages to extant intensive lifestyle interventions, and outreach MyChart messages that are tailored to each individual's pattern of self-weighing and progress towards their weight goal, and more intensive support from a primary care nurse based on self-weighing behavior and weight loss success.
11111144|NCT03998033|Experimental|ET140202 T cells|ET140202 Receptor (+) T Cells
11111145|NCT03998020|Other|chronic sleep disorders|Subjects with chronic sleep disorders responsible of hypersomnolence measured by a scale of severity of sleep disorder, and blood parameters (blood sample)
11111146|NCT03997994|Experimental|Experimental: DCB Treatment|Stricture patients treated by DCB
11111147|NCT03997981||Breast cancer patients with weekly/biweekly paclitaxel regimen|
11111148|NCT03997981||Breast cancer patients receiving docetaxel regimen|
11111149|NCT03997981||Lymphoma patients receiving vincristine regimen|
11111150|NCT03997968|Experimental|Experimental: Active treatment|This is an open label study. All patients will receive single agent CYT-0851 administered orally.
11111151|NCT03997955|Experimental|Experimental group|Myofascial induction
11111152|NCT03997955|Sham Comparator|Control group|Sham myofascial induction
11111153|NCT03997942||proprioceptive neuromuscular facilitation|PNF will be applied to randomly selected patients.
11111154|NCT03997942||Mirror therapy|Mirror therapy will be applied to randomly selected patients.
11111155|NCT03997942||Standart therapy|Standard treatment will be applied to randomly selected patients.
11111156|NCT03997929||CASE (intra abdominal candidiasis)|Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection
11111157|NCT03997929||CONTROL (bacterial intra abdominal infection)|Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)
11111158|NCT03997916|Other|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG), also known as sleep study, in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient. There will be no separate arm to test a different device.
11111159|NCT03997903|Experimental|Imatinib Intervention|
11111160|NCT03997890|Experimental|Symfony group|The subjects who underwent cataract surgery with binocular implantation of either Symfony or Symfony toric IOLs
11111161|NCT03997877|Active Comparator|Control|"The usual physical activity valued by the YPAS questionnaire (Yale Physical Activity Survey) will be maintained. The questionnaire allows to calculate the time in physical activity expressed in hours / week, the energy expenditure expressed in MET-h / week and the summary index of physical activity that takes into account the frequency and duration of physical activity and oscillates from 0 to 137. A value below 51 identifies sedentary patients. Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.
~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
11111162|NCT03997877|Experimental|Intervention|"It is intended that the exercise program have a duration of 6 months and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule and without the need for instruments or special facilities. In this sense the walk is adjusted to these assumptions and the goal of 10.000 steps / day can encourage compliance.
~The subjects assigned to the intervention group will be supervised and trained by a physiotherapist who will explain the training program and resolve the doubts raised by the patient.
~Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.
~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
11111163|NCT03997864|Active Comparator|Treatment - prazosin|Participants randomized to this group will receive the medication prazosin.
11111164|NCT03997864|Placebo Comparator|Control - placebo|Participants randomized to this group will receive placebo .
11111165|NCT03997851|Experimental|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
11111166|NCT03997851|Experimental|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
11111255|NCT03997227|No Intervention|control group|
11111256|NCT03997214|No Intervention|Control group|as usual care
11111257|NCT03997214|Experimental|experimental group|The intervention of inspiratory muscle strength training
11111167|NCT03997851|Experimental|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
11111168|NCT03997851|Placebo Comparator|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
11111169|NCT03997838|Experimental|VVZ-149 Injections|
11111170|NCT03997838|Placebo Comparator|Placebo|
11111171|NCT03997812|Experimental|VVZ-149 Injections|
11111172|NCT03997812|Placebo Comparator|Placebo|
11111173|NCT03997799|Experimental|uniportal transcervical approache|Uniportal lobectomy with complete lymphadenectomy - transcervical approach with elevation of the sternum
11111174|NCT03997799|Experimental|uniportal intercostal approache|Uniportal lobectomy with complete lymphadenectomy - intercostal approache
11111175|NCT03997786|Placebo Comparator|Part B - Placebo|
11111176|NCT03997786|Active Comparator|Part B - Etanercept|
11111177|NCT03997786|Experimental|Tildrakizumab|
11111178|NCT03997773|Experimental|Intervention|Will receive the intervention
11111179|NCT03997773|No Intervention|Usual care|Will receive usual care - will be the control group
11111180|NCT03997760|Experimental|Part A|Participants with baseline SCD receive a single dose of SHP655 or placebo matching to SHP655 intravenous (IV) infusion at 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner for 12 days.
11111181|NCT03997760|Experimental|Part B|Participants with SCD and acute VOC requiring hospitalization will receive standard of care VOC treatment along with either SHP655 or placebo as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg for 12 days.
11111182|NCT03997747||comprehensive genomic analysis group|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. The therapy patients received would not be based on the results of the genomic analysis.
11111183|NCT03997734|Experimental|Treatment A-AB001|Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
11111184|NCT03997734|Experimental|Treatment B-AB001|Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
11111185|NCT03997734|Active Comparator|Treatment C|Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
11111186|NCT03997734|Placebo Comparator|Treatment A-Placebo|Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
11111187|NCT03997734|Placebo Comparator|Treatment B-Placebo|Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
11111188|NCT03997721||Perforation|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal perforation or ( small intestine, large intestine), perforated ventricular or duodenal ulcer
11111189|NCT03997721||Obstruction|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of intestinal obstruction
11111190|NCT03997721||Anasomotic leak|Patients undergoing primary emergency laparotomy/laparoscopy due to suspicion of anastomotic leak following elective surgery.
11111191|NCT03997708|Active Comparator|Group A|MED-LFD Diet (diet A) for 2 - 6 weeks. After this period there will be a reintroduction phase protocol that will last 4-6 weeks.
11111192|NCT03997708|Active Comparator|Group B|Diet according to guidelines from the National Institute for Health and Care Excellent (mNICE) Managing IBS (diet B) for 14 weeks.
11111193|NCT03997695|Active Comparator|Core stabilization exercise group|"Core stabilization exercise (CSE):
~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional."
11111194|NCT03997695|Experimental|Core stabilization exercise plus kinesio taping group|"Core stabilization exercise (CSE):
~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
~Kinesio Taping:
~The Kinesio Taping was carried out 2 days a week for 6 weeks (12 sessions) by experienced and certificated physiotherapist. Kinesio taping was applied to spinal region."
11111195|NCT03997682|Experimental|Hands-Up Program|Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
11111258|NCT03997201|Other|Ripple Mapping guided ischaemic VT ablation|Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.
11111259|NCT03997188|Experimental|Hepilor arm|patients received ZLC solution. The prescribed dose was 10 ml, in the morning and evening, between meals.
11111196|NCT03997682|No Intervention|Standard Care|The control group will receive usual care after a distal radius fracture. The standard care for a distal radius fracture will receive an assessment related to whether casting or surgery is necessary. The participant may be in a cast for 6 weeks with routine check up and x-rays to monitor the healing, at 3 months, 6 months and 12 months. The participant should receive some physical therapy related to restoring function of the hand and wrist.
11111197|NCT03997669||experimental group|patients with malignant pleural effusion
11111198|NCT03997669||control group|patients with benign pleural effusion
11111199|NCT03997656|Experimental|MyDipp|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program. Each lesson will take 30 to 60 minutes to complete. The lesson will be considered complete if the participants clicked through all of the pages and answered multiple choice questions to indicate engagement and understanding.
11111200|NCT03997656|Other|Control|Participants in the control group (usual care) will receive standard health education from primary care providers in the clinic. In addition, they also will be provided with pamphlets and booklets about various health topics. They will be given a diary to record their weights, diet, physical activities and blood test result.
11111201|NCT03997643|Active Comparator|Standard Radiotherapy|Radiotherapy to all dissected areas
11111202|NCT03997643|Experimental|Radiotherapy to smaller treatment area|Omit radiation to pN0 neck
11111203|NCT03997630|Experimental|Interventional group|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
11111204|NCT03997630|Active Comparator|Control group|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
11111205|NCT03997617|Other|Personalized Functional Profiling|
11111206|NCT03997591||Conventional therapy|Group doing conventional rehabilitation was assessed at T0 and then after 6 weeks of conventional therapy (occupational therapy, physical therapy, aquatic therapy, musicotherapy, others)
11111207|NCT03997591||Ready2E.A.T. therapy|Group doing Ready2E.A.T. program received a mean of 1 hour per week and was assessed at T0 and then after 6 weeks of this program implementation.
11111208|NCT03997578|Active Comparator|NIPSA|Patients will be treated with only NIPSA technique.
11111209|NCT03997578|Experimental|NIPSA plus Connective tissue graft|Patients will be treated with NIPSA technique associated to a connective tissue graft.
11111210|NCT03997565||Patients TKR|
11111211|NCT03997565||Healthy subjects|
11111212|NCT03997552|Experimental|Non-incised papillae surgical approach (NIPSA)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the enamel matrix derivates will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
11111213|NCT03997552|Active Comparator|marginal approach by palatal incision|A small incision in the palatal aspect and a limited papila elevation to the buccal aspect will be made for treating isolated periodontal defect. Enamel matrix derivates will be applied on the debrided root surfaces.
11111214|NCT03997552|Active Comparator|Minimally invasive surgical technique (MIST)|The incision of the defect-associated papilla will be performed according to the principles of the papilla preservation techniques. Enamel matrix derivates will be applied on the debrided root surfaces. Stable primary closure of the flaps will be obtained with internal modified mattress sutures.
11111215|NCT03997539|Experimental|pyrotinib 320mg + vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
11111216|NCT03997539|Experimental|pyrotinib 400mg + vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
11111217|NCT03997539|Experimental|Pyrotinib + vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
11111218|NCT03997539|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
11111219|NCT03997526||3C Patch treatment|Medicare beneficiaries with diabetes and hard-to-heal non-healing ulcers of the foot will receive usual care (i.e., care consistent with the IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes) supplemented by the application of the 3C Patch (A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process)
11111260|NCT03997188|Placebo Comparator|Placebo arm|Patients received a placebo solution. The prescribed dose was 10 ml, in the morning and evening, between meals
11111261|NCT03997175|Experimental|Intervention|The children were in daily contact with biodiversity sand 5 days a week for two weeks.
11111262|NCT03997175|Placebo Comparator|Placebo|Children were in contact with normal but colored sand that looked as it were the biodiversity sand. All the other details were as above.
11111220|NCT03997513|Experimental|Pulmonary Telerehabilitation Intervention Group|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
11111221|NCT03997513|No Intervention|Usual Care Group|Participants randomized to the usual care arm will also be enrolled in our institution's telehealth program, will receive an automatic blood pressure monitor, portable pulse oximeter, and scale and will be in regular contact with a telehealth provider. A study team member will meet with participants randomized to the usual care arm to discuss the importance of exercise and will encourage exercise (strength training, light aerobic activity such as walking or cycling) a minimum of 20-40 minutes three times per week at discharge.
11111222|NCT03997500|Placebo Comparator|Normal saline|Simultaneous with subarachnoid block, a bolus of normal saline was given followed by normal saline infusion
11111223|NCT03997500|Experimental|Norepinephrine|Simultaneous with subarachnoid block, a bolus of norepinephrine was given followed by norepinephrine infusion
11111224|NCT03997487|Experimental|Children examined|All children examined for clinical signs of trachoma will be invited to participate to have photos of conjunctivae taken with the TOFTEE smartphone app and a DSLR camera.
11111225|NCT03997474|Experimental|Arm 1|Infusion of ATL001
11111226|NCT03997461|Experimental|BPro vs Oscar 2|Blood pressure measurement with BPro and Oscar 2 simultaneously during 24 hours under ambulatory conditions
11111227|NCT03997448|Experimental|Abemaciclib and Pembrolizumab|Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
11111228|NCT03997435|Experimental|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy
11111229|NCT03997435|Experimental|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy
11111230|NCT03997422|Experimental|Vertical Sleeve Gastrectomy (VSG)|Bariatric surgical procedure
11111231|NCT03997409|Experimental|Low Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the LCD intervention will consume 25-35% of total daily intake from carbohydrates, 45-65% from fat and 10-30% from protein.
11111232|NCT03997409|Active Comparator|Standard Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the SCD intervention will consume 45-65% of total daily caloric intake from carbohydrates, 25-35% from fat and 10-30% from protein.
11111233|NCT03997409|No Intervention|No Dietary Recommendations|This group will serve as a control that receives the same number of education sessions as LCD and SCD group to teach general diabetes management but without specific dietary recommendations.
11111234|NCT03997396||the DGM group|The subject recruitment was implemented in the obstetrics department of the First People's Hospital of Chongqing Liangjiang New Area, China. 255 pregnant women diagnosed with GDM by IADPSG2010 standard and their children will be enrolled into the GDM group.
11111235|NCT03997396||the Non-GDM group|In the obstetrics department of Chongqing First People's Hospital of Liangjiang New Area,China,the healthy pregnant women and delivery children in the same period were enrolled into the non-GDM group in a 1:1 ratio.
11111236|NCT03997383|Experimental|Patisiran|Participants will be administered multiple doses of patisiran in the double-blind and open-label extension period.
11111237|NCT03997383|Placebo Comparator|Placebo|Participants will be administered multiple doses of placebo in the double-blind period. In the open-label extension period, participants will be administered multiple doses of patisiran.
11111238|NCT03997370|Experimental|Treatment (iohexol, standard care carboplatin, blood samples)|Patients receive iohexol IV over 30-60 seconds. Patients then receive standard of care carboplatin IV. Patients also undergo collection of 7-8 blood samples for analysis.
11111239|NCT03997344|Experimental|Nature hiking|Group hikes in a natural setting (e.g., park, wilderness area)
11111240|NCT03997344|Active Comparator|Urban hikes|Group hikes in a urban setting (e.g., downtown area)
11111241|NCT03997331|Experimental|Intervention|"Subjects in the Intervention arm will receive the following:
~Automated in-app messages containing behavioral and educational content that is tailored to each subject based on an assessment of their entry survey results and on their adherence and glucose data. (Behavioral Support Engine).
~Targeted in-app messages and phone calls from clinicians or as designated by the Investigator (through the CRx Care app) based on the subject's adherence and glucose data.
~Push notifications that alert the subject that it is time to complete a regimen event (ie take medication or take a fasting blood glucose reading).
~Push notifications that alert the subject that they have missed a scheduled regimen event.
~In-app messages containing adjustments to the subject's insulin glargine dose when the Investigator(s) approves an adjustment in the CRx Care App. (Treatment Support Engine)."
11111242|NCT03997331|Active Comparator|Control|Subjects in the Control arm will receive the CRx Health solution for self-management of chronic conditions.
11111243|NCT03997318|Experimental|AMDC-USR|AMDC-USR is the study product (Autologous Muscle Derived Cells for Urinary Sphincter Repair).
11111244|NCT03997318|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
11111245|NCT03997292||Alteplase group|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion
11111246|NCT03997292||Urokinase group|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End
11111247|NCT03997279|Experimental|S.boulardi|Quadruple eradication therapy with S. boulardi
11111248|NCT03997279|Placebo Comparator|Placebo|Quadruple eradication therapy without S. boulardi
11111249|NCT03997266|Active Comparator|Empiric antibiotics|Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
11111250|NCT03997266|Placebo Comparator|Placebo|Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.
11111251|NCT03997253|Experimental|blood and urine samples|blood and urine samples at D0, D7, D14, M1, M3, M6 and M12
11111252|NCT03997240|Other|Wait-list control|Six-week wait list control
11111263|NCT03997162||Observational (ERAS protocol)|Participants complete standard of care early recovery after surgery protocol beginning the day before surgery to day 6 after surgery.
11111264|NCT03997149|Experimental|Stress Condition|The stress condition involved the Trier Social Stress Test (TSST), a standardized laboratory stressor designed to elicit psychological stress and cortisol responses. Following the TSST, participants were brought to a separate room, instructed to rest and given the option to eat at their leisure. Books and magazines were included in the room for the participant to utilize.
11111265|NCT03997149|Placebo Comparator|Rest Condition|Participants completed a control condition on a separate day. This condition followed the same sequence of events as the stress condition with the exception that the 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
11111266|NCT03997123|Experimental|Capivasertib + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.
~Capivasertib: Oral tablets. 400 mg of Capivasertib (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
11111267|NCT03997123|Placebo Comparator|Placebo + Paclitaxel|"Paclitaxel: Intravenous infusion. 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.
~Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle."
11111268|NCT03997110|Active Comparator|Arm A Or Control Arm- Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
11111269|NCT03997110|Experimental|Arm B or Experimental Arm-Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
11111270|NCT03997097|Experimental|sildenafil|• Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent and adult patients, and for a period of 6 months.
11111271|NCT03997097|Placebo Comparator|placebo|• Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6 months. To guarantee the double blind, capsules will be similar in size and colour and will be differentiated only by a vial number regarding to the randomization list
11111272|NCT03997058|No Intervention|Control group|
11111273|NCT03997058|Experimental|Auricular acupoint pressing group|
11111274|NCT03997058|Active Comparator|Oral estazolam group|
11111275|NCT03997058|Active Comparator|Combined treatment group|
11111276|NCT03997045|Experimental|Intervention group|Pregnant women receiving usual care and participating in supervised physical exercise program.
11111277|NCT03997045|No Intervention|Control group|Pregnant women that are receiving usual care but are not participating in supervised physical exercise program.
11111278|NCT03997032|Experimental|Patients with Diabetes|Patients with Type 1 or Type 2 Diabetes
11111279|NCT03997019|Active Comparator|group A|opioid analgesia
11111280|NCT03997019|Active Comparator|group B|ESP block
11111281|NCT03997006|Active Comparator|Group A (n=30)|Aminophylline group
11111282|NCT03997006|Active Comparator|Group NA (n=30)|Neostigmine/Atropine group
11111283|NCT03996993||Hormone Therapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.
11111284|NCT03996993||Salvage Radiotherapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.
11111285|NCT03996980|Experimental|Custom-made foot orthoses|treatment intervention custom-made polypropylene foot orthoses for a period of 4 weeks
11111286|NCT03996980|Placebo Comparator|Placebo|a flat insole for a period of 4 weeks
11111287|NCT03996967||BA Group|The bacterial group: Patients will be assorted to this group if he/she has a bacterial pathogen culture of fluid from a normally sterile site (e.g. blood, pleural fluid)
11111391|NCT03996213|No Intervention|supine group|induction of anesthesia will be initiated while patient in supine position
11111288|NCT03996967||VI Group|"The viral group: Patients will be assigned to this group if they have negative bacteria microbiological tests, negative malaria blood slides, X-rays without endpoint pneumonia, no evidence of fungal infection, and positive PCR for a viral pathogen from nasopharyngeal swabs."
11111289|NCT03996967||MA Group|The malarial group: Patients will be assigned to this group if they have normal X-rays, no bacterial infection and >0 asexual P. falciparum parasites if they are aged < 1 year, or > 2,500 asexual parasites/µl of blood if they are aged > 1 year
11111290|NCT03996954|Active Comparator|Normal ECGs|Patients with normal ECGs
11111291|NCT03996954|Active Comparator|Abnormal ECGs|Patients with different kinds of abnormal heart rhythms will be enrolled in order to compare whether Alivecor can accurately differentiate between these abnormal heart rhythms and normal sinus rhythm/sinus tachycardia. Also, Alivecor diagnostic accuracy in differentiating between different kinds of arrhythmias will be assessed.
11111292|NCT03996941||seguiPrEP|MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
11111293|NCT03996928|Experimental|Eccentric exercise by physiotherapist|"A physiotherapist will apply (in this order) a plan of stretching exercises, warm-up exercises and eccentric exercises of epicondylar muscle,according to a program of 10 sessions of 20 minutes each, during two weeks.
~Before exercise, ultrasounds will be applied at intensity of 0.1 wat/cm2, which is considered as a placebo, in order to achieve greater adherence and monitor the treatment."
11111294|NCT03996928|Active Comparator|Illustrated booklet|A physiotherapist will train the patient an exercise plan equivalent to the one above explained with the help of illustrations. Now, in order to achieve palmar flexion at the same time the patients will contract their epicondylar muscles (the eccentric effect), and elastic band is used.
11111295|NCT03996915|Experimental|experimental PDT group|G1-20 patients Photodynamic therapy with methylene blue as photosensitizer device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point (6 points) and radiant 90 seconds. Photosensitiser (PS) will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.Six points with the distances of 1 cm between them will be irradiated.
11111296|NCT03996915|Active Comparator|control tongue scrapper group|G2-20 patients Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum in order to promote the mechanical removal of tongue coating
11111297|NCT03996902|Experimental|Tailored intervention|Brief Motivational Smoking Intervention
11111298|NCT03996902|Experimental|Control|Intervention consistent with standard clinical practice (Control)
11111299|NCT03996889||Popliteal aneurysm patients with GORE VIABAHN®|The study population will include all popliteal aneurysm patients treated with GORE VIABAHN® stent graft in scheduled elective surgery, whether symptomatic or asymptomatic.
11111300|NCT03996876|Active Comparator|Threat ABM Training|Attention Bias Modification Training with threatening words
11111301|NCT03996876|Placebo Comparator|Neutral Attention Training|Non-active version of ABM Training
11111302|NCT03996863|Experimental|Otoband efficacy on CINV|"Participants will wear the Otoband during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.
~The Otoband will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the OtoBand is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the OtoBand 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
11111303|NCT03996863|Placebo Comparator|Placebo device efficacy on CINV|"Participants will wear the placebo device during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.
~The placebo device will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the device is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the device 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
11111304|NCT03996850||Health service research (MIBI SPECT/CT, questionnaire)|Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
11111305|NCT03996837|Experimental|Fresh embryo transfer with intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
11111306|NCT03996837|No Intervention|Fresh embryo transfer without intra uterine infusion of PRP|In IVF-ICSI cycles, ovulation will be stimulated through the standard protocol using a gonadotropin-releasing hormone agonist for all patients. 48 hours after the oocyte retrieval and ensuring that at least 3 good quality embryos are formed, patients will be randomized into two groups of with and without PRP intrauterine injection. For all patients, 2 embryos in the blastocyst stage with excellent or good quality will be transferred. One milliliter PRP will be injected into the patients' uterine cavity using an embryo transfer catheter (Labotect Gmbh, Labor-Technik-Gottingen Kampweg 12, 37124 Rosdorf, Germany) 48 hours before embryo transfer. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
11111307|NCT03996837|Experimental|Freeze embryo transfer with intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
11111308|NCT03996837|No Intervention|Freeze embryo transfer without intra uterine infusion of PRP|In frozen embryos transfer cycles, the endometrium of all patients will be prepared through the standard protocol using a gonadotropin-releasing hormone agonist. Following this process, 2 embryos in the blastocyst stage with good or excellent quality will be transferred. It is worth mentioning that in 48 hours prior to the embryo transfer; 1 mL of PRP will be injected into the uterine cavity using an embryo transfer catheter. In order to eliminate the effects of catheter insertion, the same catheter will be applied to the patients in the control group 48 hours before the embryo transfer without any injections.
11111309|NCT03996824||AAV viral transduction|Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
11111310|NCT03996811|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity for 40 min, three times a week on non-dialysis days. We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the target heart rate, as determined by the Karvonen method, and 12-13 on the RPE.
11111311|NCT03996811|No Intervention|usual-care group|Hospital routine care
11111312|NCT03996798|Experimental|Jessa Hospital, Herk-de-Stad|"Back to Work methodology: a revalidation trajectory with standard revalidation therapy in combination with an early focus on back to work, using a Disability Case Manager"
11111313|NCT03996798|No Intervention|Revalidation and MS Clinic Overpelt|"Standard revalidation therapy without explicit focus on back to work"
11111314|NCT03996785|Active Comparator|Urban|"Patients will go for a silent 60-minute walk in an urban setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.
~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology). The urban walk will be located on Boulevard de la Vérendrye with large arteries with three to four lanes."
11111315|NCT03996785|Experimental|Nature|"Patients will go for a silent 60-minute walk in a nature park setting. The walk will take place in the months of June, July, August and September between 10:00 to 11:00 am.
~Participants will walk in groups of two to three participants accompanied by two research assistants trained in mental health (doctoral students in psychology).
~The nature walk will take place at Parc Angrignon, an area of 96 hectares, one of Montreal's largest green and biodiverse spaces with a forest of 20 000 trees and a pond surrounded by willow trees."
11111316|NCT03996772|Experimental|Direct Oral Anticoagulant|"If the patient is randomized in this arm, a direct oral anticoagulant (DOAC) included:
~Direct thrombin inhibitor: Dabigatran
~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban will be prescribed to the patient. Choice and dose of DOAC treatment as well as the use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the spectrum of licensed doses labelled for stroke prevention in atrial fibrillation patients in Europe following the Summary of Product Characteristics."
11111317|NCT03996772|No Intervention|No Anticoagulant|If the patient is randomized in this arm investigators will use their best judgment to decide upon the prescription of an antiplatelet drug of their choice or no such therapy
11111318|NCT03996759||Critically ill patients|Patients admitted in ICU
11111319|NCT03996746||Non-dialysis Group|non-dialysis patients with CKD 2-5
11111320|NCT03996746||Hemodialysis Group|patients with CKD 5 under hemodialysis for more than 3 months
11111321|NCT03996733|Active Comparator|GControl|Participants will attend the lecture for 20 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
11111322|NCT03996733|Experimental|GModel|"Participants will attend the lecture for 20 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
~Participants in this group will also practice jugular vein puncture on our homemade jugular central venous catheterization training model."
11111323|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
11111324|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
11111325|NCT03996707|Other|Immediate protected weight-bearing|Immediate protected weight-bearing
11111326|NCT03996707|Other|Traditional non weight bearing|Strict non-weight-bearing
11111327|NCT03996694|Experimental|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
11111328|NCT03996694|Experimental|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
11111329|NCT03996694|Experimental|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
11111330|NCT03996694|Active Comparator|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
11111331|NCT03996694|Active Comparator|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
11111332|NCT03996694|Placebo Comparator|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
11111333|NCT03996681|Experimental|TACE plus methylcantharidimide tablets|Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
11111334|NCT03996668|No Intervention|Control|Subjects received standard operating room dress including sequential compression devices.
11111335|NCT03996668|Experimental|Experimental|Subjects wore thigh high compression stockings in addition to standard operating room dress including sequential compression devices.
11111336|NCT03996655|Experimental|Group S|Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
11111337|NCT03996655|Active Comparator|Group N|Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
11111338|NCT03996642|Other|Patients with Active Cancer|Eligible participants will undergo an unknown number of Avatar-life review sessions depending on acceptability of the intervention to subjects and the capacity of the team to provide the intervention.
11111339|NCT03996629|Experimental|Pharmacist-managed anticoagulation service|
11111340|NCT03996629|No Intervention|Usual medical care|
11111341|NCT03996616|No Intervention|Control Group|"During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.
~The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor."
11111342|NCT03996616|Active Comparator|Assigned Intervention|During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
11111343|NCT03996603|Experimental|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
11111344|NCT03996603|No Intervention|Control Cohort|No intervention will be given.
11111345|NCT03996577|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
11111346|NCT03996577|Experimental|Experimental: lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
11111347|NCT03996564|Active Comparator|Acupuncture Group|"Battlefield Acupuncture (BFA) has a structured administration sequence that was utilized to limit any variability between investigators administering the treatment. The BFA technique has been suggested that the needles are placed not just in an acupoint but actually acupoint zones. BFA utilizes one to ten (maximum five points per ear) ASP semi-permanent gold needles® placed in one or both ears. The ASP Gold needle® is a sterile device which inserts a small 2 mm needle into the auricle. It is comprised in single-needle applicator ensuring ease of insertion combined with excellent precision. The needles remain in the ear and fall out spontaneously as early as two hours and up to seven days. After administration of the BFA, if subjects felt that their pain was not controlled based on verbal response, rescue medication could be administered to control pain to a tolerable level for discharge."
11111348|NCT03996564|Active Comparator|Standard Care Group|Participants randomized to the standard care group were treated with one, or a combination of selected medications to include oral Acetaminophen 500mg-1000mg, Diclofenac 50mg-75 mg orally, Diazepam 5mg-10 mg intravenous or oral, Hydrocodone 5mg/325mg-10mg/650mg mg oral, or intramuscular Ketorolac 30mg-60 mg, as deemed appropriate by the treating investigator (medical provider). Standard treatment was administered by the investigators based on the patient's presentation and driving status as many of the medications cannot be administered if the subject would operate a vehicle. No standardized algorithm was specified and the route and dose of medications was administered at the provider's discretion. After administration of the traditional standard care medications, if subjects felt their pain was not controlled based on verbal responses, rescue medication would be given to control pain to a more tolerable level for discharge.
11111349|NCT03996551|Experimental|Intervention Group|This group will receive access to the 12-week kidney transplant specific weight gain prevention online resource (ExeRTiOn online resource). After the 12 weeks, they will be offered the option to continue using the website up until the completion of the study (12 months)
11111350|NCT03996551|No Intervention|Control group|This group will not receive the online resource. They will receive the standard encouragement to follow a healthy diet and perform physical activity during routine transplant follow up appointments.
11111351|NCT03996538|Experimental|Metformin Hydrochloride Extended Release Tablets|Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
11111352|NCT03996538|Placebo Comparator|Placebo|Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
11111353|NCT03996525|Experimental|Electrical Stimulation|"Electrical Stimulation
~The patient will receive active electrical stimulation."
11111354|NCT03996525|Placebo Comparator|Sham Treatment|"No Electrical Stimulation
~The patient will receive sham electrical stimulation."
11111355|NCT03996512|Experimental|Post scaphoid fracture with screw fixation|Post surgical rehabilitation using an early active controlled wrist motion rehab protocol that limits the amount of proximal carpal row loading forces
11111356|NCT03996499|Experimental|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).
~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.
~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
11111357|NCT03996486|Experimental|Hemophilia|Dose escalation starting with 200 mg of BAY1093884
11111358|NCT03996473|Experimental|Phase 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
11111359|NCT03996473|Experimental|Phase 2 Cohort 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
11111360|NCT03996473|Active Comparator|Phase 2 Cohort 1: Pembrolizumab alone|Participants will receive pembrolizumab every 3 weeks
11111361|NCT03996473|Experimental|Phase 2 Cohort 2: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
11111362|NCT03996460|Placebo Comparator|Placebo|"Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1). Fifteen (15) patients in arm 1 (group 1) will receive the matching placebo (8 x Placebo capsules) (sugar pill) orally once daily for 12 weeks (90 days)."
11111363|NCT03996460|Active Comparator|96 mg of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 2 (group 2) will receive the 96 mg of K0706 (4 x 24 mg K0706 and 4 Placebo capsules) orally once daily for 12 weeks (90 days).
11111364|NCT03996460|Active Comparator|192 mg of K0706|Forty five (45) participants will be recruited and randomized into 3 arms (1:1:1) .Fifteen (15) patients in arm 3 (group 3) will receive 192 mg of K0706 (8 x 24 mg K0706 capsules) orally once daily for 12 weeks(90 days).
11111365|NCT03996447|Other|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
11111366|NCT03996447|Other|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI
11111367|NCT03996434|Experimental|Coasting group|Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
11111368|NCT03996434|Active Comparator|Antagonist group|"Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration.
~GnRH agonist will be discontinued at the start of antagonist administration.
~E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given."
11111369|NCT03996421|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
11111370|NCT03996421|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
11111371|NCT03996408|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11111372|NCT03996395||Infants|Infants, 4-4.5 months of age at enrollment
11111373|NCT03996382|Other|Suspicion of cardiac amyloidosis|Patients who display signs of cardiac amyloidosis will be referred for further diagnosis.
11111374|NCT03996369|Experimental|Etrasimod 2 mg|
11111375|NCT03996369|Placebo Comparator|Placebo|
11111376|NCT03996343|Experimental|Endotracheal intubation|
11111377|NCT03996343|Experimental|Laryngeal mask airway|
11111378|NCT03996317|No Intervention|Standard care|Standard practice where 10L/min O2 is delivered to patient by mask when any fetal tracing abnormalities are identified.
11111379|NCT03996317|Experimental|Room air|O2 will be withheld at times when fetal tracing abnormalities are identified. Patient will continue to breath room air.
11111380|NCT03996291|Experimental|SAR442168|"SAR442168 : Experimental - Part A: Double-blind period of continued treatment with the respective SAR442168 dose administered in the DRI15928 study until selection of Phase 3 dose.
~Part B: Open-label period of a single-group treatment with SAR442168 selected Phase 3 dose of 60 mg. All participants will be switched to this 60 mg dose."
11111381|NCT03996278||Patients in the Grafalon group|Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database
11111382|NCT03996278||Patients in the Thymoglobulin group|Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database
11111383|NCT03996265|Experimental|Arm I (bupropion hydrochloride controlled-release)|Patients receive bupropion hydrochloride controlled-release PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
11111384|NCT03996265|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for up to 13 weeks in the absence of disease progression or unacceptable toxicity.
11111385|NCT03996252|Experimental|Combination treatment arm|Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.
11111386|NCT03996239|Experimental|patients with clonal hematopoiesis|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
11111387|NCT03996239|Experimental|post treatment patients with breast or colorectal cancer|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
11111388|NCT03996239|Experimental|men with localized prostate cancer undergoing active surveillance|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
11111389|NCT03996226|Experimental|E7386: Fed + Fast|Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
11111390|NCT03996226|Experimental|E7386: Fast + Fed|Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
11111392|NCT03996213|Active Comparator|head down|induction of anesthesia will be initiated while patient in head down position
11111393|NCT03996213|Active Comparator|leg elevation|induction of anesthesia will be initiated while patient in leg elevation position
11111394|NCT03996200|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
11111395|NCT03996161|Active Comparator|Supine position|After the induction of anesthesia, mask ventilation is performed in the supine position.
11111396|NCT03996161|Experimental|Semi-sitting position|After the induction of anesthesia, mask ventilation is performed in the semi-sitting position.
11111397|NCT03996148|Active Comparator|Remifentanil, Propofol, and Desflurane|Study group A: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
11111398|NCT03996148|Active Comparator|Remifentanil, Dexmedetomidine, and Desflurane|Study group B: no midazolam given; maintenance drugs started immediately after induction and airway is secured.
11111399|NCT03996148|Active Comparator|Remifentanil and Desflurane|Study group C (control group): no midazolam given; maintenance drugs started immediately after induction and airway is secured.
11111400|NCT03996135|Experimental|Experimental : Cannulation with AccuVein AV400|Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
11111401|NCT03996135|No Intervention|Control|Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
11111402|NCT03996122||resistant patients with schizophrenia|Age 18 - 60 years No MRI contraindication
11111403|NCT03996109|Experimental|Aim2Be|Youth-parent dyads randomized to Aim2Be
11111404|NCT03996109|Active Comparator|BnLt|Youth-parent dyads randomized to BnLt
11111405|NCT03996096||Group with the TKI withdrawal syndrome|There is no intervention. Patients will stop their tyrosine kinase inhibitor yielding to 2 subsets: patients with or without the TKI withdrawal syndrome.
11111406|NCT03996096||Group without the TKI withdrawal syndrome|As abovementioned.
11111407|NCT03996083|Experimental|Multicomponent exercise intervention|The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
11111408|NCT03996083|Experimental|Walking intervention|Participants assigned to the walking group walked with the research staff two days per week; additionally, they walked partially supervised by LTNH staff, family members or caregivers the rest of the week. Daily walking goals were set follows: walking between 5 to 10 minutes on the first month, up to 15 minutes on the second, and finally 20 minutes per day on the third month. The final goal was to get as close as possible to the recommendations of engaging in 150 minutes of aerobic exercise per week from the World Health Organization (WHO). Participants were asked to walk as fast as they could and rest was allowed whenever needed. Walking goals were achieved in one or multiple sessions, depending on each participant´s capacities. Those participants that met the walking goals without any rest were encouraged to walk at a faster pace.
11111409|NCT03996070|Active Comparator|Treatment arm|Therapeutic dose regime
11111410|NCT03996070|Placebo Comparator|Sham arm|Sub-therapeutic dose regime
11111411|NCT03996057|Experimental|Methenamine augmentation|2g methenamine hippurate twice daily for 90 days added to a baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
11111412|NCT03996057|Active Comparator|No methenamine augmentation|Baseline regimen of low dose vaginal estrogen (two to three times per week) and d-mannose (1000 mg twice daily)
11111413|NCT03996044|Experimental|Group 1|Thirteen patients who will receive treatment with teeth brushing, dental floss and tongue scraper.
11111414|NCT03996044|Experimental|Group 2|Thirteen patients who will receive treatment with teeth brushing, dental floss and antimicrobial photodynamic therapy applied to the back and middle third of the tongue.
11111415|NCT03996044|Experimental|Group 3|Thirteen patients who will receive treatment with teeth brushing, dental floss and probiotics.
11111416|NCT03996044|Experimental|Group 4|Thirteen patients who will receive treatment with teeth brushing, dental floss, antimicrobial photodynamic therapy applied to the back and middle third of the tongue and probiotics..
11111417|NCT03996031||Study Sample|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests. Following the baseline assessment, participants will engage with the Plan to Thrive app for a 90-day period.
11111418|NCT03996018||group 1(HIV Uninfected)|Participant is HIV negative per antibody screen conducted on premises and participant is enrolled on HPTN 083 study
11111419|NCT03996018||group 2 (HIV Infected)|Participant has initiated ART therapy as a patient at St Jude Children's Research Hospital, newly diagnosed HIV and prolonged HIV
11111420|NCT03996005|Experimental|MRI Guided Transurethral Ultrasound|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
11111421|NCT03995992|Active Comparator|multi sport|During 10 days, each morning, from 9 am to 12 pm, participants had sporting activities: mountain walking, mountain biking, climbing, canyoning and collective orienteering running. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
11111422|NCT03995992|Experimental|diving|During 10 days, each morning, from 9 am to 12 pm, participants had diving activities. From 3 pm, they had individual and collective practical workshops based on PTSD psychoeducation, human resources competences and coaching, including a curriculum vitae workshop. During their free time, they could take part in collective activities like table football, pool, party games or have a rest. Relaxation exercises were proposed every day after the sporting activity and before dinner.
11111423|NCT03995979|Experimental|Protein Restriction Group|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided.
11111424|NCT03995966|Active Comparator|Subtype 2 Automatically Maintained SIB|
11111425|NCT03995966|Active Comparator|Subtype 3 Automatically Maintained SIB|
11111426|NCT03995953|No Intervention|Control|2 control zones with no intervention at the clinic or community level
11111427|NCT03995953|Experimental|SHIELD: Community-based behavioral intervention|2 clinic zones where participants attend modules designed to educate and empower adolescent girls and young women (AGYWs) and their families, along with attendance at community-based youth clubs to foster peer support.
11111428|NCT03995953|Experimental|SHIELD: Community- based behavioral intervention & IWC Clinic|2 clinic zones where participants receive the Support for HIV Integrated Education, Linkages to care, and Destigmatization (SHIELD) intervention along with the coupled benefits of having an integrated wellness care (IWC) clinic within health facilities where adolescent girls and young women (AGYWs) can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and human papilloma virus (HPV) vaccination.
11111429|NCT03995927||Data collection/questionnaire|Data collection for patient medical charts and patient fill out questionnaires first visit and post-treatment visits
11111430|NCT03995901|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
11111431|NCT03995901|No Intervention|Control|"Standard induction therapy followed by a maintenance regimen of tacrolimus, mycophenolate, and corticosteroids after kidney transplant.
~Control donors are not followed beyond randomization."
11111432|NCT03995888|Experimental|Healthy Volunteers|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
11111433|NCT03995888|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
11111434|NCT03995862||Patients in care, at high risk of HIV infection|Patients in care, at high risk of HIV infection, according to the criteria defined by the French Ministry Of Health for the use of FTC / TDF in PreP (men who have sex with men, transgender, heterosexual women migrants or not, sex workers (sexual intercourse in exchange for money, drugs, housing, food), intravenous drug users) HIV-negative, exposed by their sexual practices to a high risk of HIV infection.
11111435|NCT03995836||Obstructive Sleep Apnea|
11111436|NCT03995836||Non Obstructive Sleep Apnea|
11111437|NCT03995810|Experimental|Carnosine|Carnosine, capsulle, 2 g/day, 8 weeks
11111438|NCT03995797|Active Comparator|Treatment arm|Treatment with erbium YAG laser
11111439|NCT03995797|Placebo Comparator|Sham arm|Sub therapeutic procedure with erbium YAG laser
11111440|NCT03995784|Experimental|Intravenous Loading Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
11111441|NCT03995784|Experimental|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
11111442|NCT03995771||Children and adolescents with knee pain|Children and adolescents (8-19 years old) presenting to general practice for knee pain
11111443|NCT03995758|Active Comparator|Standard laser lithotripsy|standard of care for stone fragmentation in ureteroscopy
11111444|NCT03995758|Active Comparator|MOSES laser lithotripsy|MOSES technology used for stone fragmentation in ureteroscopy
11111445|NCT03995745|Experimental|adherence based financial incentives|Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
11111446|NCT03995745|No Intervention|control|Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
11111447|NCT03995732|Experimental|40 mg treatment group|PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
11111448|NCT03995732|Experimental|80 mg treatment group|PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
11111449|NCT03995732|Experimental|160 mg treatment group|PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
11111450|NCT03995732|Placebo Comparator|placebo control group|placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
11111451|NCT03995719|Other|Preoperative education|Each patient had individual consultation several days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
11111452|NCT03995719|Other|Postoperative education|Each patient had individual consultationseveral days before surgery with the stoma nurse specialist, following standard ostomy teaching plans
11111453|NCT03995706|Experimental|Breast Brain Metastasis and Glioblastoma|Sacituzumab Govitecan treatment will be initiated with a 10mg/kg standard dose without any dose escalation on day-1, prior to surgery. Sacituzumab govitecan and will continue to be administered by IV infusion over 3 hours on Days 1 and 8 of a 21 day cycle post-operatively until progression.
11111485|NCT03995550|Experimental|Multiple ascending dose Cohort M|Multiple doses of LEO 142397 or placebo.
11111486|NCT03995550|Experimental|Multiple ascending dose Cohort N|Multiple doses of LEO 142397 or placebo.
11111487|NCT03995550|Experimental|Multiple ascending dose Cohort O|Multiple doses of LEO 142397 or placebo.
11111454|NCT03995693|Experimental|Concentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of CONCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
11111455|NCT03995693|Experimental|Concentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of concentric cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
11111456|NCT03995693|Experimental|Eccentric cycling with placebo ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A PLACEBO solution (water with a non-caloric sweetener) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
11111457|NCT03995693|Experimental|Eccentric cycling with glucose ingestion|Participants will complete 45 minutes of arm cranking at an intensity corresponding to 30% of the concentric cycling VO2max, followed by 35 minutes of ECCENTRIC cycling on a recumbent ergometer at the same VO2. A GLUCOSE solution (glucose with a trace amount of 13C) will be ingested 30 min prior to starting exercise and every 15 min thereafter, until the exercise is completed. Indirect respiratory calorimetry, expired gas sampling, blood sampling will occur will be performed 4 minutes before each ingestion.
11111458|NCT03995680|Experimental|Chewable tablet of mebendazole|"3-5 year olds allocated to the swallowable tablet arm will be given the crushed tablet on a spoon mixed with a small amount of clean water;
~6-12 year olds allocated to the swallowable tablet arm will be given the whole tablet to swallow with a glass of clean water;"
11111459|NCT03995680|Active Comparator|Swallowable tablet of mebendazole|"3-5 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and swallow it without water; if they cannot chew it then a small amount of water will be added to the tablet in a spoon;
~6-12 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and then swallow it without water."
11111460|NCT03995667|Experimental|Prevention (TTFields therapy, questionnaire)|Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
11111461|NCT03995641|No Intervention|Surgery Alone|Patient will receive sacrospinous ligament suspension surgery without any additional interventions
11111462|NCT03995641|Experimental|Surgery Plus Trigger Point Injection|Patient will have sacrospinous ligament suspension procedure with addition of a trigger point injection (9cc of 0.5% marcaine and 1 cc kenalog) over area of suture placement
11111463|NCT03995628|Experimental|Steroid Group|Participants will receive a one-time dose of oral dexamethasone at 0.5 mg/kg on the third post-operative day
11111464|NCT03995628|No Intervention|No Steroid Group|Participants will not receive dexamethasone
11111465|NCT03995615|No Intervention|Group I (Control)|• Group I (Control) - 15 periodontally healthy patient with probing depth< 3mm and ≤ 10% sites with bleeding on probing.
11111466|NCT03995615|No Intervention|• Group II|• Group II - 15 systemically healthy chronic periodontitis patient who had presented >25% of sites with gingival bleeding ,surface demonstrating supra-gingival plaque accumulation and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm
11111467|NCT03995615|No Intervention|• Group III|• Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1with out scaling and root planing
11111468|NCT03995615|Active Comparator|• Group IV|• Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed
11111469|NCT03995602|Experimental|Dragon fruit first then placebo|2 weeks of dragon fruit juice intake or placebo with crossover to the other
11111470|NCT03995602|Experimental|Placebo first then dragon fruit|2 weeks of dragon fruit juice intake or placebo with crossover to the other
11111471|NCT03995589|Experimental|Walking Group|
11111472|NCT03995589|Active Comparator|Control|
11111473|NCT03995563|Active Comparator|D group|0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days
11111474|NCT03995563|Placebo Comparator|N group|0.19% Ropivacaine 8mL only every other day injection during 10 days
11111475|NCT03995550|Experimental|Single ascending dose Cohort A|Single dose of LEO 142397 or placebo.
11111476|NCT03995550|Experimental|Single ascending dose Cohort B|Single dose of LEO 142397 or placebo.
11111477|NCT03995550|Experimental|Single ascending dose Cohort C|2 single doses, separated by a washout of ≥7 days.
11111478|NCT03995550|Experimental|Single ascending dose Cohort D|2 single doses, separated by a washout of ≥7 days.
11111479|NCT03995550|Experimental|Single ascending dose Cohort E|Single dose of LEO 142397 or placebo.
11111480|NCT03995550|Experimental|Single ascending dose Cohort F|Single dose of LEO 142397 or placebo.
11111481|NCT03995550|Experimental|Single ascending dose Cohort G|Single dose of LEO 142397 or placebo.
11111482|NCT03995550|Experimental|Single ascending dose Cohort H|Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.
11111483|NCT03995550|Experimental|Multiple ascending dose Cohort K|Multiple doses of LEO 142397 or placebo.
11111484|NCT03995550|Experimental|Multiple ascending dose Cohort L|Multiple doses of LEO 142397 or placebo.
11111488|NCT03995550|Experimental|Multiple ascending dose Cohort P|Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.
11111489|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
11111490|NCT03995511|Experimental|Bilateral sagittal split|
11111491|NCT03995498|Active Comparator|Individualized carbohydrate intake|"Based on glucose sensor level, carbohydrate (orange juice, Oasis classic) will then be given as follow:
~If sensor glucose level is under < 4.5 mmol/L, the camp staff will treat hypoglycemia according to the camp procedure, If sensor glucose level is between 4.5 and 7.0 mol/L, 0.5g of CHO/kg body weight will be given, If sensor glucose level is between 7.1 and 10.0 mmol/L, 0.25g of CHO/kg body weight will be given, If sensor glucose level is between 10.1 and 15.0 mmol/L, no CHO will be given, If sensor glucose level is > 15.1 mmol/L, the camp staff will treat hyperglycemia according to the camp procedure."
11111492|NCT03995498|Active Comparator|Usual camp protocol|As per camp routine care, there will be no mandatory glucose level measurement before the start of physical activity if no symptoms of hypoglycemia or hyperglycemia appear.
11111493|NCT03995485|Experimental|KW-136+SOF|Treatment-naive and experienced subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
11111494|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose escalation|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
11111495|NCT03995472|Experimental|SHR-1501 and SHR-1316 dose expansion|SHR-1501 given subcutaneously with different doses. SHR-1316 given intravenously.
11111496|NCT03995472|Experimental|SHR-1501 and SHR-1316 Indication expansion|SHR-1501 given subcutaneously with a recommended dose. SHR-1316 given intravenously.
11111497|NCT03995446|Experimental|low-level laser therapy|808nM wavelength, power density of 300mW
11111498|NCT03995446|Sham Comparator|Sham laser acupuncture treatment|received the same manner except for joule.
11111499|NCT03995420|Experimental|Virtual Reality Therapy (V-NeST)|Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
11111500|NCT03995420|Other|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) only.
11111501|NCT03995407|Active Comparator|Control|"Participants in the control arm will receive usual care."
11111502|NCT03995407|Experimental|100% Whey Protein|Participants will receive 100% Whey Protein oral nutritional supplements.
11111503|NCT03995394|Experimental|Positive Reinforcement Group|"In the intervention group, participants will receive two text messages weekly. The first text message will ask if participants completed the recommended activity. If the participants respond yes, the participant will receive a positive reinforcement response. If the participants respond no, the participant will receive a text message stating, Thank you for your response."
11111504|NCT03995394|No Intervention|Control Group|"For the control group, participants will receive two text messages weekly. The first text message will ask if the participants completed the recommended activity. When the participant responds, the participant will receive a second text message stating, Thanks for your response."
11111505|NCT03995381|Experimental|DAs group|Shared decision making using decision aids
11111506|NCT03995381|No Intervention|Control group|Standard oral explanation guided with booklets
11111507|NCT03995368|Experimental|People with Schizophrenia|People who have been diagnosed with schizophrenia and meet the investigators' research criteria for symptoms indicative of schizophrenia within their lifetime.
11111508|NCT03995368|Experimental|People with TBI|People who have been diagnosed with a mild or moderate traumatic brain injury (TBI) and meet research criteria indicative of TBI within their lifetime.
11111509|NCT03995368|Experimental|Healthy Controls|People without a history of psychiatric illness or TBI and who do not meet research criteria for a psychiatric illness or TBI.
11111510|NCT03995342|Experimental|exprimental: Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
11111511|NCT03995342|Placebo Comparator|Active comparator: maltodextrin|Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.
11111512|NCT03995329|Other|healthy non smokers|"Healthy non smokers males, aged 18-55years,receiving no medications
~Intervention: the use of an IQOS Examination of pulmonary function, exhaled CO, blood pressure, heart rate and O2 saturation immediatly after IQOS"
11111513|NCT03995316|Other|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
11111514|NCT03995316|Other|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
11111515|NCT03995303|Active Comparator|NCP and home-delivered meals|Preventing malnutrition with NCP by a registered dietician and home-delivered meals
11111516|NCT03995303|No Intervention|Current practice|Current practice after discharge from the University Hospital of Iceland.
11111517|NCT03995277|Other|Healthy cohort - high dose|Apparently healthy subjects, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
11111518|NCT03995277|Other|Hypothyroid cohort|Subjects under thyroid medication, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
11111519|NCT03995277|Other|Healthy cohort - low dose|Apparently healthy subjects, who take 50 µg/d of biotin at the same time each morning for 20 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), after 20 days of biotin supplementation (day 20), and 10 days after participants stopped taking biotin (day 30).
11111520|NCT03995264|Experimental|Ultrasound group|Ultrasound-guided radial artery cannulation
11111521|NCT03995264|Placebo Comparator|Palpation group|Radial artery cannulation with palpation technique
11111522|NCT03995251|Experimental|Standard Medical Treatment +Intramuscular Testosterone + Exerc|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
11111523|NCT03995251|Active Comparator|Standard Medical Treatment+Exercise|Standard Medical Treatment +Exercise
11111524|NCT03995238|Experimental|Error-augmentation training|A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
11111525|NCT03995238|Experimental|Error-correction training|A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
11111526|NCT03995238|Active Comparator|Supervised waking|A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
11111527|NCT03995225|Experimental|Smokers|This study involves wearing a smartband to monitor, record and notify smokers of smoking events and deliver real-time brief mindfulness exercises by smartphone app.
11111528|NCT03995212|Active Comparator|CR845 1.0 mg|Oral CR845 1.0 mg tablet administered twice daily
11111529|NCT03995212|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
11111530|NCT03995199||Furlow group|All cleft palate patients surgically treated with a modified Furlow technique since January 2012
11111531|NCT03995199||Furlow + Sommerlad group|All cleft palate patients surgically treated with a modified Furlow technique in combination with an intravelar veloplasty by Sommerlad
11111532|NCT03995186|Experimental|Behavioural activation group|
11111533|NCT03995186|Active Comparator|Activity monitoring group|
11111534|NCT03995186|No Intervention|Waiting list control group|
11111535|NCT03995173|Active Comparator|active|active rTMS
11111536|NCT03995173|Placebo Comparator|placebo|placebo rTMS
11111537|NCT03995160|Active Comparator|Total knee replacement with use of closed suction drainage|Use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
11111538|NCT03995160|Active Comparator|Total knee replacement without use of closed suction drainage|Without the use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
11111539|NCT03995147|Experimental|Treatment Arm|
11111540|NCT03995134||Propofol and Remifentanil|Procedural sedation in Dentistry provided by a Target Controlled Infusion pump using propofol as the sedative/hypnotic agent and Remifentanil as the opioid analgesic agent.
11111541|NCT03995121||Schizophrenia and other psychotic disorders|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
11111542|NCT03995121||Cannabis Use Disorder|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
11111543|NCT03995121||Healthy Control|For each [11C]APP311 PET scan, up to 20 mCi of [11C]APP311 will be administered by infusion pump, followed by up to 120 minutes of dynamic PET data acquisition.
11111544|NCT03995108|Experimental|Mavorixafor|Participants will receive mavorixafor 400 milligrams (mg) once daily orally for 52 weeks in the Randomized Period. Participants who complete the Randomized Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent adjudication committee (AC), will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
11111545|NCT03995108|Placebo Comparator|Placebo|Participants will receive placebo matching to mavorixafor once daily orally for 52 weeks in the Randomized Period. Participants who complete the Randomized Period or are granted Early Release due to recurrent or significant infections, as adjudicated by a blinded, independent AC, will be offered the opportunity to enroll in the Open-Label Period and receive treatment with mavorixafor 400 mg once daily orally until commercial availability or study termination by the Sponsor.
11111546|NCT03995095|No Intervention|Control group|Group of participants that received usual psychological attention.
11111547|NCT03995095|Experimental|Experimental group|Group of participants that received usual psychological attention plus attention of spiritual needs following the Kibo protocol (intervention).
11111548|NCT03995082|Experimental|Experimental Group|Patients will receive the results from the PROM survey in graphical form each time they complete a survey.
11111549|NCT03995082|No Intervention|Normative Control|These patients will complete the PROM surveys, but will not be presented with the results of the survey.
11111550|NCT03995069|Experimental|3D|The participant's voluntary grip forces in all 3 dimensions will be shown to the participant via computer screen.
11111551|NCT03995069|Active Comparator|1D|The participant's voluntary grip force in 1 dimension will be shown to the participant via computer screen.
11111552|NCT03995056|No Intervention|Control-group|Subjects diagnosed with NAFLD and a sedentary lifestyle will have no changes in their habits and diets.
11111553|NCT03995056|Experimental|Exercise-group|This group with diagnosed NAFLD patients will perform a high-intensity aerobic interval exercise training without changing their diets.
11111554|NCT03995043|Experimental|Control Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.
~Personal Support from community peer mentor to access counselling services through SRH"
11111555|NCT03995043|Experimental|Case Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.
~Personal Support from community peer mentor to access counselling services through SRH
~Access to Contraception and counselling and service provision will be provided by the mobile reproductive health team at contraceptive access points."
11111556|NCT03995017|Experimental|Safety Lead In|"Rucaparib 600 milligrams twice daily
~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
~Nivolumab 480 milligrams intravenous every 4 weeks
~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
~One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients
~1 cycle= 28 days"
11111557|NCT03995017|Experimental|Cohort A|"Rucaparib 600 milligrams twice daily
~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
~Nivolumab 480 milligrams intravenous every 4 weeks
~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
~1 cycle= 28 days"
11111558|NCT03995017|Active Comparator|Cohort B|"Rucaparib 600 milligrams twice daily
~Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
~Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
~1 cycle= 28 days"
11111559|NCT03995004|Experimental|Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.
~IV Normal Saline (1mL) on induction and continued q12h for 4 more doses."
11111560|NCT03995004|Active Comparator|Dexamethasone|"Placebo capsules at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.
~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
11111561|NCT03995004|Experimental|Dexa_Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.
~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
11111562|NCT03994991|Experimental|Active TMS|Patients in the active TMS group will receive active TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
11111563|NCT03994991|Sham Comparator|Sham TMS|Patients in the shamTMS group will receive sham TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
11111564|NCT03994978||Surgical group|Patients with uncomplicated recurrent diverticulitis undergoing elective sigmoid resection
11111565|NCT03994978||Conservative group|Patients with uncomplicated recurrent diverticulitis with conservative treatment
11111566|NCT03994965|Experimental|Patients|"40 antipsychotic-free, first-episode schizophrenia spectrum patients will receive 6 weeks of treatment with a selective serotonin 2A Receptor (2AR) blockade.
~Before initiation of treatment patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR binding potential using the radioligand [¹¹C]Cimbi-36; magnetic resonance spectroscopy (MRS) of cerebral glutamate levels; structural Magnetic Resonance Imaging (MRI), including diffusion tensor imaging (DTI); cognitive and psychopathological examinations; Electrocardiography (ECG), and blood sampling for genetic- and metabolic analyses.
~(Full description will be updated on approval)."
11111567|NCT03994952||Uninjured Physically Active Young Adults|"This is a group of physically active, and currently uninjured young adults. They will complete a single balance assessment, the modified balance error scoring system protocol, as outlined by the Sway Balance application.
~There is no comparison group for this investigation."
11111568|NCT03994939|Experimental|Intervention|Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
11111569|NCT03994939|No Intervention|Control|Parents randomized to the control group did not receive any intervention sessions and only completed assessment questionnaires.
11111570|NCT03994926|Experimental|Experimental|Directed smoking of about 3.6% THC cannabis cigarette
11111571|NCT03994913|Experimental|CAR-CD19-T Cells|The subjects are enrolled into 3 dose levels cohorts in sequence.
11111572|NCT03994900|Experimental|Blood sampling for HbNO assessment|
11111573|NCT03994887|Experimental|Experimental group|Patients under general anesthesia will be included.
11111574|NCT03994874|Experimental|PolyCore PUF|PolyCore peritoneal ultrafiltration (PUF) (over the top of patient's prescribed heart failure medications), for 6 months.
11111575|NCT03994874|Active Comparator|Control|Patients in the control arm (receiving no PUF therapy) will remain on their prescribed heart failure medications.
11111576|NCT03994861|Active Comparator|Patients with musculoskeletal disorders|Patients with either shoulder pain, knee pain, hip pain, low back pain, pelvic pain or neck pain as their primary pain complaint, lasting for 6 weeks or longer
11111577|NCT03994861|Sham Comparator|Healthy controls|Age- and gender-matched healthy controls (without musculoskeletal pain)
11111578|NCT03994848|No Intervention|Control|
11111579|NCT03994848|Experimental|Spirometry Group|
11111580|NCT03994822|Experimental|pRESET Thrombectomy Device|Mechanical Thrombectomy using the pRESET Thrombectomy Device
11111581|NCT03994822|Active Comparator|Solitaire Revascularization Device|Mechanical Thrombectomy using the Solitaire Revascularization Device
11111582|NCT03994796|Experimental|Arm I (CDK gene mutation)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11111583|NCT03994796|Experimental|Arm II (PI3K gene mutation)|Patients receive PI3K inhibitor GDC-0084 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11111584|NCT03994796|Experimental|Arm III (NTRK/ROS1 gene mutation)|Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11111585|NCT03994783|Active Comparator|Standard of Care (SOC)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants)
11111586|NCT03994783|Experimental|Standard of Care plus Rituximab (SOCR)|Intravenous Methylprednisolone (500 mg (600 mg/m2 for paediatric participants), n=3) Plasma Exchange (PEX) (60 ml/kg max 4 l (1 - 1.5 plasma volumes for paediatric participants), n=7) Intravenous Immunoglobulin (high dose: 2 g/kg total, or low dose: 100 mg/kg n=7 after each PEX, no dose adjustment for paediatric participants) Rituximab (375 mg/m2 max 1 g (no dose adjustment for paediatric participants), n=2 14 days +/- 2 days apart)
11111587|NCT03994770|Other|STR|Older people who have suffered a stroke
11111588|NCT03994757|Experimental|MRBI group|
11111589|NCT03994757|Sham Comparator|Control group|
11111590|NCT03994744|Experimental|Sintilimab and Metformin|"Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).
~The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up."
11111591|NCT03994731|Experimental|Pegloticase with methotrexate (MTX)|Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period and Run-in Period, then pegloticase (every 2 weeks) with MTX (weekly) for 52 weeks
11111592|NCT03994731|Placebo Comparator|Pegloticase with placebo for methotrexate (MTX)|Participants will receive MTX (15 mg) (weekly) during the Tolerability Assessment Period, placebo for MTX (weekly) in the Run-in Period, then pegloticase (every 2 weeks) with placebo for MTX (weekly) for 52 weeks
11111593|NCT03994718|Experimental|Music|The musician will either offer music that can either be played for the participant or an instrument so they can experience playing themselves. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. The outpatient music intervention will consist of providing a recording of similar music for the participant to listen to for at least 30 minutes per week, along a with telephone call session with the music therapist.
11111594|NCT03994718|Experimental|Visual art|The creative visual artist will assess interest in spending time using the materials provided. Participants will be offered watercolor painting, drawing, or adult coloring. There will be a guided activity based on their art making preference. A standardized prompt will be utilized for both writing and visual art sessions. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For remote follow-up sessions, participants will be supplied with a small art kit to use at home.
11111595|NCT03994718|Experimental|Creative writing|The writer will ask the participant about their interests and experiences in writing or storytelling. The following options are offered; introduction to journaling, storytelling or writing exercises with prompts to get started, interactive writing or storytelling activities. For participants who are unable to write or prefer not to, the writer can scribe their words on a laptop and print them out. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For follow-up sessions, participants will be supplied with a journal.
11111596|NCT03994705|Experimental|Dose-Escalation|
11111597|NCT03994692|Experimental|PEEK eminoplasty|"CT scan with bony window for facial bones and DICOM files on CD .then, Using cad cam software (mimics 15) , the virtual design and surgery will be done.
~under general anathesia The TMJ will be exposed using the endural incision line and the articular eminence will be identified then blunt dissection so that the front wall of the articular capsule can be exposed completely.
~The patient specific PEEK eminence will be inserted and secured with two to three pre-planed screws .
~Functional mandibular movements were reproduced to confirm absence of subluxation and then closure"
11111598|NCT03994692|Active Comparator|autogenous onlay grafting eminoplasty|"under general anesthesia , chin graft was taken Layered Endural approach to TMJ making wedge in eminence by mallet & chisel (green stick fracture), then wedging piece of chin graft to increase the height of the eminence creating an obstacle to treat dislocation by manipulation of patient mandible intra operative.
~- Functional mandibular movements were reproduced to confirm absence of subluxation then closure"
11111599|NCT03994679||cleft patient requiring bone graft|Patients presenting at the division of maxillofacial surgery at the AZ Sint-Jan Brugge-Oostende av (Belgium) or the 1st department of pediatrics at the USemmelweis (Hungary) for bone graft surgery of the unilateral cleft receive a complete routine work-up, including a cone-beam CT (CBCT).
11111600|NCT03994666|Experimental|simple dose|
11111601|NCT03994666|Experimental|double dose|
11111602|NCT03994666|Placebo Comparator|placebo|
11111603|NCT03994653||Cases|Participants diagnosed with ovarian cancer
11111604|NCT03994653||Controls|Participants without ovarian cancer
11111605|NCT03994640|Experimental|Cannabis cream|Cannabis cream topical skin application in experimental group
11111606|NCT03994640|Placebo Comparator|Placebo cream|Placebo cream topical skin application in control group
11111607|NCT03994614|Experimental|the Acupuncture intervention group|Patients in this group will be given acupuncture treatment for 12 weeks prior to COS.
11111608|NCT03994614|No Intervention|No intervention group|Patients in this group will not be given any intervention for 12 weeks prior to COS.
11111609|NCT03994601|Experimental|Arm A BMS-986288|Specified dose on specified days
11111610|NCT03994601|Experimental|Arm B BMS-986288 in combination with Nivolumab|Specified dose on specified days
11111611|NCT03994588|Active Comparator|study arm|In this arm a light weight, wide pore, soft polypropylene mesh will be used for intraperitoneal hernia repair
11111612|NCT03994588|Active Comparator|control|in this arm a double mesh (vicryl + polypropylene mesh) will be used for intraperitoneal hernia repair.
11111613|NCT03994549|Active Comparator|ZP7570|Single subcutaneous injection
11111614|NCT03994549|Placebo Comparator|Placebo|Single subcutaneous injection
11111615|NCT03994536|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
11111616|NCT03994536|Experimental|Comparison group: Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
11111617|NCT03994510|Other|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
11111618|NCT03994497|Other|Patient in need of a kidney transplant|
11111619|NCT03994484|Experimental|HA121-28 tables|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
11111620|NCT03994471|Experimental|XyloCore peritoneal dialysis solution|Patients will receive 2 to 3 daily (short-dwell) exchanges with XyloCore of an osmotic strength comparable to their pre-randomization prescription of glucose peritoneal dialysis solution (XyloCore Low, Medium and High Strenght have an osmotic strength comparable to Physioneal, Fixioneal or Dianeal 1.36%, 2.27%, 3.86% glucose, respectively, and Balance, Bicavera, Bicanova or Equibalance with 1.5%, 2.5%, 4.25% glucose, respectively). All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
11111621|NCT03994471|Active Comparator|Glucose peritoneal dialysis solution|Patients randomized to glucose solution will continue the 2 to 3 daily (short-dwell) exchanges of Physioneal 40 or 35, Fixioneal 40 or 35 or Dianeal (1.36%, 2.27%, 3.86% glucose), Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.5%, 4.25% glucose) with the same osmotic strength of their pre-randomization prescription. All patients will receive Extraneal (7.5% Icodextrin) for nocturnal (long-dwell) exchange.
11111622|NCT03994458|Experimental|Experimental|Participants get the full program for 6 weeks.
11111623|NCT03994458|Placebo Comparator|Placebo|Participants get the placebo program for 6 weeks.
11111624|NCT03994445|Experimental|Intervention group|Intervention group will be enrolled to the intervention program proposed to be (pharmacotherapy + counseling+ motivator phone messages).
11111625|NCT03994445|No Intervention|Control group|Control group will receive the standard treatment of the Ministry of the Health program (pharmacotherapy + counseling) only.
11111626|NCT03994432|Experimental|Intervention group|"patients with symptomatic endometriosis in therapy with estro-progestins or progestins, who will be asked to follow a mediterranean diet and to practice an aerobic physical exercise according to the 7-minutes workout model"
11111627|NCT03994432|No Intervention|Control group|patients with symptomatic endometriosis in therapy with estro-progestins or progestins.
11111628|NCT03994406|Experimental|CLM2 Topical Gel|CLM2 topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
11111629|NCT03994406|Placebo Comparator|Placebo Topical Gel|Placebo topical gel to be applied dermally to forehead twice daily, in the morning and at bedtime.
11111630|NCT03994393|Active Comparator|Cohort 1|Participants with no evidence of T790M
11111631|NCT03994393|Active Comparator|Cohort 2|Participants with evidence of T790M
11111632|NCT03994380|Experimental|Intervention|rhDNAse 2.5 mg nebulizer daily for 4 weeks
11111633|NCT03994367|No Intervention|Standard protein (control)|
11111634|NCT03994367|Experimental|High animal protein isolate|
11111635|NCT03994367|Experimental|High animal protein whole food|
11111636|NCT03994367|Experimental|High plant protein isolate|
11111637|NCT03994367|Experimental|High plant protein whole food|
11111638|NCT03994354||1,2|"J-P drain group
~Penrose drain group"
11111639|NCT03994341||NEC Group|Infrared images of the abdomen, timed at handling. A FLIR Thermovision a320M thermal IR camera bound with an Microsoft Kinect RGB-D sensor system connected to a laptop will be used. Both imaging technologies are non-invasive and represent no risk to the subject. The thermal images record the temperature distribution, the Kinect sensor will acquire color image and depth image that will be used to segment the subject from the background bedding surface. All three sets of images will be collected in synchronization. Thermography requires period of slight cooling of the skin surface to stabilize the body surface temperature. The room temperature will be maintained slightly below thermoneutrality. Thermographic camera will be positioned about 60-70 cm above the baby.
11111640|NCT03994341||Normal Group|Same procedure for both experimental and active comparator.
11111641|NCT03994328||Group 1|500 patients already receiving safinamide (50 or 100 mg/day) as add-on to L-dopa for no more than 2 months.
11111642|NCT03994328||Group 2|500 patients receiving rasagiline 1 mg/day as add-on to L-dopa for no more than 2 months.
11111643|NCT03994328||Group 3|235 patients receiving other SoC drugs as add-on to L-dopa for no more than 2 months.
11111644|NCT03994315|Experimental|B. infantis EVC001 + LNT (3 g/L then 8 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 1 [B. infantis + LNT (3 g/L then 8 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 3 g/L for 2 weeks followed by 8 g/L for the next 2 weeks, without a washout period in between.
11111645|NCT03994315|Experimental|B. infantis EVC001 + LNT (6 g/L then 12 g/L)|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days. Group 2 [B. infantis + LNT (6 g/L then 12 g/L)] will also receive two dose-escalated concentrations of the prebiotic supplement (LNT) mixed with their infant formula for every formula preparation during the 28-day supplementation period. They will receive a concentration of 6 g/L for 2 weeks followed by 12 g/L for the next 2 weeks, without a washout period in between.
11111646|NCT03994315|Active Comparator|B. infantis EVC001 alone|Infants will receive a once-daily oral feeding of B. infantis EVC001 (8.0 x 10^9 CFU) mixed with infant formula for 28 consecutive days.
11111679|NCT03994068|Experimental|VIVO mapping pre-procedure|15 patients with structurally normal heart and indication for PVC/VT catheter ablation, who will undergo pre-procedural non invasive mapping with VIVO mapping system.
11111647|NCT03994302||Immune toxicity induced by drugs and chemotherapies|Immune toxicity induced by drugs and chemotherapies Case reported in the World Health Organization (WHO) of immune toxicities(such as Antiphospholipid syndrome) of patient treated by a drug, with a chronology compatible with the drug toxicity
11111648|NCT03994289|No Intervention|Control|Participants remain seated for 2 hours after the intake of a standardized breakfast.
11111649|NCT03994289|Experimental|Motor-assisted cycling|Participants will perform 3 bouts of motor-assisted cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
11111650|NCT03994289|Experimental|FES cycling|Participants will perform 3 bouts of FES cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
11111651|NCT03994276|Placebo Comparator|Phase 1: Control|oral glucose tolerance test (OGTT): 58g Dextrose in 330ml water
11111652|NCT03994276|Active Comparator|Phase1: Chickpea Control|"sub-cellular Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring"
11111653|NCT03994276|Experimental|Phase1: Chickpea Powder|Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring
11111654|NCT03994276|Active Comparator|Phase 2: Control|Wheat bread: breakfast consisting of a 100% wheat bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
11111655|NCT03994276|Experimental|Phase 2: 30%Chickpea Powder|Wheat bread: breakfast consisting of a 70% wheat / 30% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
11111656|NCT03994276|Experimental|Phase 2: 60%Chickpea Powder|Wheat bread: breakfast consisting of a 40% wheat / 60% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
11111657|NCT03994263|Experimental|iTind arm|ITind device implant
11111658|NCT03994250|Active Comparator|Kinematic Arm|Kinematic Alignment for TKR surgery
11111659|NCT03994250|Placebo Comparator|Control Arm|Mechanical alignment for TKR surgery
11111660|NCT03994237||ALZHEIMER CAREGIVER|Caregiver available to accompany the patient to the consultation, helping calling for the first time the memory center, aidant who noticed a cognitive disorder help, having a family link identified with the patient
11111661|NCT03994211|Experimental|Arm A (core phase)|
11111662|NCT03994211|Experimental|Arm B (core phase)|
11111663|NCT03994211|Experimental|Extension phase|
11111664|NCT03994198|Experimental|Alpha-lactalbumin|Participants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
11111665|NCT03994198|Active Comparator|Collagen peptides|Participants will consume 60 g of collagen peptides for 3 training days.
11111666|NCT03994185|Experimental|Group Treated with stent graft|This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
11111667|NCT03994172|Experimental|teriparatide (TPTD) + the calcimimetic cinacalcet|Combination arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a 30-mg tablet of cinacalcet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
11111668|NCT03994172|Placebo Comparator|teriparatide (TPTD) + placebo|Monotherapy arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a placebo tablet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
11111669|NCT03994159|Experimental|PARO emotional robot|"Quasi-experimental before after study of the impact of the PARO robot on team dynamics among caregivers in geriatric wards caring for patients with dementia.
~Pre intervention period: no PARO robot. Post-intervention period: with the PARO robot."
11111670|NCT03994146|Experimental|Remifentanil tapering / Placebo abrupt cessation|Syringe one contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1 and Syringe two contains 40 ml NaCl 9 mg.ml-1 at an identical infusion rate. According to randomisation syringe one will then be tapered towards the end of surgery and syringe two abruptly stopped.
11111671|NCT03994146|Placebo Comparator|Placebo tapering / Remifentanil abrupt cessation.|Syringe one contains 40 ml NaCl 9 mg.ml-1 and Syringe two contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1. According to randomization syringe one will be tapered towards the end of surgery and syringe two abruptly stopped.
11111672|NCT03994133||Daily Home Dialysis patients|Daily Home Dialysis patients with low-flow dialisate for more than 3 months in France
11111673|NCT03994120|Active Comparator|Motor Cortex rTMS|Motor Cortex rTMS
11111674|NCT03994120|Active Comparator|PPC rTMS|PPC rTMS
11111675|NCT03994120|Placebo Comparator|vertex rTMS|vertex rTMS
11111676|NCT03994107|Experimental|PLD/albumin-bound paclitaxel/Trastuzumab|"First phase
~PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.
~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
~Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.
~Second phase
~PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.
~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
~Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6."
11111677|NCT03994081|Experimental|transcranial alternating current stimulation (tACS) at alpha|10 Hz tACS with an amplitude of 1 mA for 40 minutes. Uses tACS device.
11111678|NCT03994081|Sham Comparator|sham stimulation|Will include 20 seconds of ramp-up, 40 seconds of 10 Hz tACS at 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation. Uses sham tACS device.
11111741|NCT03993522|Experimental|CTO Exerciser|"2x Symptom limited cardiopulmonary exercise tests
~1x Sub-maximal cardiopulmonary exercise test (20 minutes)"
11111680|NCT03994055|Experimental|Anti-inflammatory Diet|"Dietary intervention providing:
~Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).
~This group will include the consumption of foods that contain immune modulating nutrients:
~Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area."
11111681|NCT03994055|Active Comparator|Low residue Diet|"Dietary intervention providing:
~Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction."
11111682|NCT03994042|Experimental|Mental imagery neurofeedback training|Complete intervention with mental imagery neurofeedback training. Patients recruited by physioterapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
11111683|NCT03994029|Experimental|Polyphenol supplementation|120mg per day of powder polyphenol for 60 days
11111684|NCT03994029|Placebo Comparator|Placebo|1 tab PO QD per day of placebo for 60 days
11111685|NCT03994016|Experimental|WiseGuyz Participant|Individuals in this arm will receive the WiseGuyz program in their grade 9 year.
11111686|NCT03994016|No Intervention|Comparison Participant|Individuals in this arm will not receive any intervention in their grade 9 year, and will be used to create a matched comparison group for individuals in Arm 1 (WiseGuyz Participants).
11111687|NCT03993990|Experimental|Experimental group|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation).
11111688|NCT03993990|No Intervention|Control group|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
11111689|NCT03993977|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
11111690|NCT03993977|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
11111691|NCT03993964|Experimental|Experimental: Pyrotinib + SHR6390|Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd
11111692|NCT03993938|Experimental|Patients for TMVR|Patients with severe mitral regurgitation scheduled for TMVR procedure at Henry Ford Hospital - main campus.
11111693|NCT03993912|Experimental|Arm 1: Experimental group|"Daratumumab SC 1800 mg
~once every week for 8 weeks
~then once every other week for 16 weeks
~thereafter once every 4 weeks, until progression Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of a 28-day cycle, for the first 2 cycles, then discontinued"
11111694|NCT03993912|Sham Comparator|Arm 2: Control group|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
11111695|NCT03993899|Active Comparator|Cochlear implant (CI) with FineHearing Strategy then HDCIS|cochlear implant with FineHearing strategy first during 15 days then with HDCIS strategy during 15 days
11111696|NCT03993899|Active Comparator|CI with HDCIS Strategy then FS4|cochlear implant with HDCIS strategy first during 15 days then with FS4 strategy during 15 days
11111697|NCT03993886|Other|Arm 1|Adult (≥ 18 years of age) ambulatory patients diagnosed with heart failure and/or undergoing cardiac management.
11111698|NCT03993886|Other|Arm 2|Adult (≥ 18 years of age) patients undergoing chronic hemodialysis.
11111699|NCT03993886|Other|Arm 3|Adult (≥ 18 years of age) patients (i) implanted with the CardioMEMS HF device and (ii) diagnosed with heart failure and/or undergoing cardiac management.
11111700|NCT03993886|Other|Arm 4|Adult (≥ 18 years of age) patients diagnosed with heart failure and/or undergoing cardiac management.
11111701|NCT03993873|Experimental|Phase 1 TPX-0022|"The dose-escalation part of the study will determine the safety, tolerability, MTD, and RP2D of TPX-0022.
~A food-effect sub-study will be conducted once the RP2D has been determined.
~The dose-expansion part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.
~Dose expansion cohorts: Cohort I (NSCLC, METΔex14, MET Target Therapy Naive), Cohort II (NSCLC, METΔex14, MET Target Therapy Pre-treated), Cohort III (MET-amplified NSCLC, Hepatocellular Carcinoma (HCC), Gastric Cancer, or GEJ, Cohort IV (MET KD Mutations or MET Fusions)"
11111702|NCT03993860|Experimental|Intervention arm|Infants will be given fish powder called Chisense (Potamothrissa acutirostris) for a period of 6 months from the time they are 6 months up to the time they are 12 months.
11111703|NCT03993860|Placebo Comparator|Control arm|Infants will be given fish powder called sorghum powder for a period of 6 months from the time they are 6 months up to the time they are 12 months.
11111704|NCT03993847||Prospective Cohort of Undiagnosed Back Pain|"All consecutive patients referred to a rheumatologist with current undiagnosed back pain of ≥3 months duration with onset ≤45 years of age will comprise the prospective cohort.
~This is a classification study; no intervention will be administered"
11111705|NCT03993834||Normal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test ≤ 15 seconds
11111706|NCT03993834||Abnormal modified Allen Test|Patients undergoing transradial coronary angiography with a modified Allen-Test > 15 seconds
11111707|NCT03993821|Experimental|Burosumab|Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
11111742|NCT03993509|Experimental|1 Hz Arm|Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered. Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
11111817|NCT03992989|Active Comparator|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
11111708|NCT03993808|Experimental|Educational/behavioral support for hypertension self efficacy|On-site monitoring of pulse, blood pressure, weight, and surveys, at Months 0,1,3,6; Four educational sessions to address: 1) basics about blood pressure (BP); 2) training in home BP monitoring with personal Omron 10 device; 3) information about Dietary Intervention to lower Systemic Blood Pressure (DASH) eating plan, recipes and cooking demonstrations; 4) education about BP medication adherence. Interventions occur on the background of Carter Burden Network's implementation of a DASH-congruent menus for congregant meals for all seniors attending the sites, including those not enrolled in the protocol.
11111709|NCT03993795|Experimental|A19010-W, B19010-F Use Group|Use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
11111710|NCT03993795|Experimental|B19010-F, A19010-W Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
11111711|NCT03993782|Experimental|A19010-R, B19010-O Use Group|Use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
11111712|NCT03993782|Experimental|B19010-O, A19010-R Use Group|Use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
11111713|NCT03993769|Experimental|A19010-F, B19010-F Use Group|Use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
11111714|NCT03993769|Experimental|B19010-F, A19010-F Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
11111715|NCT03993743|Experimental|CD147-CART|Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
11111716|NCT03993730|Other|Device Implantation|A prospective, blocked, randomised, controlled trial of primary prophylaxis ICD therapy or ILR insertion in patients with LVEF <45% and LGE on CMR.
11111717|NCT03993730|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF <45% and no LGE on CMR.
11111718|NCT03993717|Experimental|Three to six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine three to six months after kidney transplant
11111719|NCT03993717|Experimental|Twelve to thirty-six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine twelve to thirty-six months after kidney transplant
11111720|NCT03993704|Experimental|Active|450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days
11111721|NCT03993704|Placebo Comparator|Placebo|Placebo to match LHF-535 given once daily for 14 days
11111722|NCT03993691|Experimental|All Participants|Participants that have undergone standard of care, conventional 2D radiographic imaging of wrist for presumed or known scaphoid, wrist or distal radius fractures will receive the Tomo-E scans within two weeks.
11111723|NCT03993678|Experimental|Ablation + IP-001|"Ablation + IP-001 will be administered every 4 weeks for up to 6 treatment visits.
~Trial treatment will stop in case of tumor progression according to RECIST 1.1 or iRECIST or unacceptable toxicity.
~In all cases, toxicity assessment will continue for at least 100 days after discontinuing the last treatment of Ablation + IP-001 or until resolution of Ablation + IP-001-associated toxicity."
11111724|NCT03993665||affected|All patients with a histologically confirmed squamous cell carcinoma in the head and neck region
11111725|NCT03993665||control|Whartin tumour or pleomorphic adenoma of the parotid gland without malignant transformation
11111726|NCT03993652|Experimental|Screen-time and Snacking|Aim: to reduce both screen-time and unhealthy snacking
11111727|NCT03993652|Experimental|Screen-time only|Aim: to reduce screen-time only
11111728|NCT03993652|Experimental|Snacking only|Aim: to reduce unhealthy snacking only
11111729|NCT03993652|No Intervention|Control|Control
11111730|NCT03993639|Experimental|KRN125|Single SC administration
11111731|NCT03993626|Experimental|CXD101 and Nivolumab combination|"CXD101 will be presented as 10mg HPMC capsules and will be taken orally for 5 consecutive days repeated every three weeks on an outpatient basis.
~Nivolumab will be presented as a 10 mg/mL solution in a single-dose vial, administered as iv infusion over 60 mins, repeated every two weeks.
~CXD101 in combination with nivolumab will be administered in the Phase II component of the trial at doses determined in the Phase Ib component."
11111732|NCT03993613|Experimental|human apotransferrin|Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.
11111733|NCT03993600|Sham Comparator|Healthy volunteers|sweat test and skin biopsy
11111734|NCT03993600|Experimental|Patients with Cystic fibrosis|sweat test and skin biopsy
11111735|NCT03993600|Experimental|Heterozygotes subjects|sweat test and skin biopsy
11111736|NCT03993574|Other|Standard Care|The standard care group will receive baseline testing #1, standard care, baseline testing #2 and follow up testing approximately 8 weeks later.
11111737|NCT03993574|Experimental|Experimental|Experimental group will baseline testing #1, standard care, baseline testing #2 however then participate in a 6-week self-management intervention (either generic or vision specific self-management based) and then get 8 week follow up testing.
11111738|NCT03993561|Experimental|TSSP Group|A one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists will be provided
11111739|NCT03993548|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
11111740|NCT03993535|Other|SSRI or cognitive behavioral therapy|selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine) or cognitive-behavioral therapy, depending on availability and patient preference
11111743|NCT03993509|Experimental|10 Hz Arm|Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI. Stimulation will occur while subjects are doing the Sternberg WM paradigm. The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
11111744|NCT03993496||EVAR Patients|Patients with infrarenal abdominal aortic aneurysm scheduled for elective endovascular aneurysm repair (EVAR) surgery will undergo intraoperative assessments of aneurysm wall pulsatility using ultrasound M-Mode.
11111745|NCT03993483|Experimental|Higher Load|One arm and one leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
11111746|NCT03993483|Experimental|Lower Load|The other arm and leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
11111747|NCT03993470|Experimental|experimental|The short foot exercise daily for 4 weeks
11111748|NCT03993470|Placebo Comparator|Control|A placebo excercise daily for 4 weeks
11111749|NCT03993457|Other|CRP<1, CRP consistent antidepressant selection|Participants with CRP<1 will be prescribed escitalopram
11111750|NCT03993457|Other|CRP> or equal to 1, CRP consistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed bupropion XL
11111751|NCT03993457|Other|CRP<1, CRP inconsistent antidepressant selection|Participants with CRP< 1 will be prescribed bupropion XL
11111752|NCT03993457|Other|CRP> or equal to 1, CRP inconsistent antidepressant selection|Participants with CRP> or equal to 1 will be prescribed escitalopram
11111753|NCT03993444|Experimental|communication and problem solving|Three smal group sessions (separate for employees (length 2 hours each) and for supervisors (length 2,5 hours each)) focused on training communication and problem solving skills.
11111754|NCT03993444|Active Comparator|psychoeducation|Two, 1 hour, lectures, one on the topic of pain and one on the topic of stress (for employees and supervisors combined).
11111755|NCT03993431|Experimental|Bio-active cement|Bio-active cement dispensed into the crown, and the crown was properly positioned over the tooth, cement was allowed to self-set for 20 seconds while maintaining gentle pressure on the crown, then flash cured using a light curing unit to remove excess cement, buccal and lingual surfaces were light cured for extra 10 seconds each.
11111756|NCT03993431|Active Comparator|Packable glass ionomer|Dentin conditioner was applied to the prepared crown surfaces for 20 sec, then rinsed, and dried. Capsule was activated, mixed for 10 seconds in an amalgamator, then loaded into the capsule applier to extrude cement directly into the crown, the crown was properly positioned over the tooth, cement was allowed to self-set for 2 minutes while maintaining gentle pressure on the crown, excess cement was removed before complete setting of cement.
11111757|NCT03993418|Experimental|Stevia arm|stevia drops
11111758|NCT03993418|No Intervention|Control arm|No change in diet
11111759|NCT03993405|Active Comparator|Control group:young|Sixty older subjects will be evaluated in this study.
11111760|NCT03993405|Active Comparator|Control Group:Middle-aged|Sixty middle-aged subjects will be evaluated in this study.
11111761|NCT03993405|Experimental|Experimental group:older|Sixty older subjects will be evaluated in this study.
11111762|NCT03993392|Experimental|TM buprenorphine followed by SUBLOCADE injection|Subjects with a diagnosis of OUD will stop use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, subjects will be administered TM buprenorphine. Depending on their response after 1 hour, the investigator will either administer additional TM buprenorphine, ask the subject to return to the clinic on another day or administer SUBLOCADE.
11111763|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-front line|histologically or cytologically confirmed solid tumor who have received no prior treatment
11111764|NCT03993379|Experimental|CX-072 in combination with ipilimumab|histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
11111765|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Progressed|histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
11111766|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Neoadjuvant|neo-adjuvant study in subjects with histologically confirmed solid tumor
11111767|NCT03993366|Experimental|Simple Meal Announcement|Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.
11111768|NCT03993366|Active Comparator|Full Carbohydrate counting|The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.
11111769|NCT03993353|Experimental|Tadalafil and Pembrolizumab|Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
11111770|NCT03993340||1|Rescue stenting group
11111771|NCT03993327|Experimental|Diagnostic (iodine I 124 monoclonal antibody M5A, PET scan)|Patients receive iodine I 124 monoclonal antibody M5A IV on day 0 and undergo PET scan on days 2 and 6.
11111772|NCT03993314|Active Comparator|Bupivacaine|
11111773|NCT03993314|Experimental|Chloroprocaine|
11111774|NCT03993301|Experimental|Probiotic A formula|Infant Formula with Lactobacillus salivarius AP-32.
11111775|NCT03993301|Experimental|Probiotic B formula|Infant Formula with Bifidobacterium lactis CP-9.
11111776|NCT03993301|Placebo Comparator|Regular formula|The infant formula without any probiotic.
11111777|NCT03993288|Experimental|Ferrum Lek|Patients will receive Ferrum Lek® 2 tablets daily (200 mg), during 12 weeks
11111778|NCT03993288|Active Comparator|MALTOFER|Patients will receive MALTOFER® 2 tablets daily (200 mg) during 12 weeks
11111779|NCT03993275||Patients with Stroke|30 Patients suffering a stroke will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 4 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
11111848|NCT03992729||Tildrakizumab-Exposed Cohort|Exposure to tildrakizumab for the treatment of an approved indication
11111780|NCT03993275||Patients with Multiple Sclerosis|50 Patients suffering multiple sclerosis will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 3 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
11111781|NCT03993262|Experimental|Interventional|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
11111782|NCT03993262|Placebo Comparator|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
11111783|NCT03993249|Other|Chemoradiotherapy|standard of care chemo-radiotherapy
11111784|NCT03993249|Experimental|Combination|standard of care chemo-radiotherapy + Nivolumab
11111785|NCT03993236|Experimental|Rosuvastatin/Ezetimibe 10/10mg|The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
11111786|NCT03993236|Active Comparator|Rosuvastatin 20mg|The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days
11111787|NCT03993223||MTrP group|Healthy overhead athletes with upper trapezius myofascial trigger point
11111788|NCT03993223||Control group|Healthy overhead athletes without upper trapezius myofascial trigger point
11111789|NCT03993210|Experimental|MR Fingerprinting and QTI|"QTI or MRF will be run along with the routine standard of care MRI.
~MR Fingerprinting and QTI will not require intravenous contrast agent"
11111790|NCT03993197|Experimental|Patients suffering from severe endometriosis and chronic pain|Patients suffering from severe endometriosis and chronic pain that have been identified during a gynecological consultation (individual or during a multidisciplinary team meetings) or during a pain consultation on the same site of the Croix-Rousse Hospital and having signed a consent form
11111791|NCT03993184|Experimental|90-minute Hot Yoga Classes|This group will complete 3, 90-minute hot yoga classes weekly for 12 weeks.
11111792|NCT03993184|Experimental|60-minute Hot Yoga Classes|This group will complete 3, 60-minute hot yoga classes weekly for 12 weeks.
11111793|NCT03993184|No Intervention|Control|This group will maintain their current physical activity for 12 weeks.
11111794|NCT03993171|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11111795|NCT03993171|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11111796|NCT03993171|Experimental|Second dose determined by results of Cohort 1 of CNM-Au8|Second dose determined by results of Cohort 1 of CNMAu8 suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11111797|NCT03993171|Experimental|Dose determined by results of Cohort 1 of CNM-Au8|Dose determined by results of Cohort 1 of CNMAu8 suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11111798|NCT03993145|Experimental|Web-based lifestyle intervention|participants will be provided access to web-based lifestyle intervention program with personalized coaching from a clinical dietician
11111799|NCT03993132||Patients with type 2 diabetes|
11111800|NCT03993119||patients with NVAF|
11111801|NCT03993106|Experimental|Study Drug|All study participants will receive sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. All study participants will receive two doses of study drug on Days 1 and 15 of each 4 week cycle.
11111802|NCT03993093||HIV with OIs|Treatment naive HIV patients with OIs
11111803|NCT03993080|Experimental|Virtual reality relaxation|Virtual reality relaxation using virtual landscape and audio features and sound
11111804|NCT03993080|No Intervention|Treatment as usual|Seated in similar environment as experimental group for same time
11111805|NCT03993067|Active Comparator|Standard Treatment|Fibrin glue and Tabotamp on cut surface
11111806|NCT03993067|Experimental|Hemopatch|Hemopatch on cut surface
11111807|NCT03993054|Active Comparator|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
11111808|NCT03993054|Experimental|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
11111809|NCT03993041|Experimental|Cognitive-behavioral therapy (CBT)|Individuals in the CBT arm are expected to participate in a phone screen + baseline phase (one assessment) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
11111810|NCT03993041|Active Comparator|Waitlist Control|Individuals in the Waitlist Control arm are expected to participate in a phone screen + baseline phase (two assessments, 12 weeks apart) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
11111811|NCT03993015||Patients attending the Obstetrical Emergency Unit|Patients attending the Obstetrical Emergency Unit of CHU Montpellier during 2018
11111812|NCT03993002|Active Comparator|Normoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40"
11111813|NCT03993002|Active Comparator|Normoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60"
11111814|NCT03993002|Active Comparator|Hyperoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40"
11111815|NCT03993002|Active Comparator|Hyperoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.
~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60"
11111816|NCT03992989|Experimental|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
11111910|NCT03992287|Experimental|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
11111818|NCT03992976||Teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
11111819|NCT03992976||Parents of teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
11111820|NCT03992963|Active Comparator|Hearing Aid without frequency lowering enabled|
11111821|NCT03992963|Experimental|Hearing Aid with frequency lowering enabled|
11111822|NCT03992950|Experimental|Cricoid pressure|Cricoid pressure is applied during direct and video laryngoscopies
11111823|NCT03992950|Experimental|Paratracheal pressure|Cricoid pressure is applied during direct and video laryngoscopies
11111824|NCT03992937|Experimental|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
11111825|NCT03992937|Active Comparator|LNG-IUS|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.
11111826|NCT03992924|Active Comparator|angiography-guided PCI|
11111827|NCT03992924|Experimental|FFR-guided PCI|
11111828|NCT03992924|Experimental|OCT-guided PCI|
11111829|NCT03992911|Experimental|FOLFSIM Plus Teripalimab|Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab
11111830|NCT03992911|Active Comparator|EP/EC|Etoposide plus Cisplatin or Carboplatin
11111831|NCT03992898||Chronic hepatitis cohort|In this cohort, patients were defined as type A acute-on-chronic liver failure (ACLF) patients who have chronic liver disease but without cirrhosis.
11111832|NCT03992898||Cirrhosis cohort|In this cohort, patients were defined as type B and type C ACLF patients with cirrhosis.
11111833|NCT03992885|Experimental|combination therapy with ectiecinib, pemetrexed and platinum|ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally;Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle, a total of 6 cycles.Maintenance therapy: ectinib: ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally, pemetrexed 500mg/m2,d intravenous infusion, day 1,21 days for a cycle
11111834|NCT03992859|Experimental|serratus catheter|Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine
11111835|NCT03992859|No Intervention|standard treatment|Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine
11111836|NCT03992846|Experimental|Linzagolix 75 mg|
11111837|NCT03992846|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
11111838|NCT03992846|Placebo Comparator|Placebo|
11111839|NCT03992833|Experimental|lung cancer screening|"Participants will undergo a chest CT scan in the Department of Radiology at Tianjin Cancer Hospital. All scans will be performed using the same CT system: Definition AS. Two readings of the images will be performed. In the first image reading, the CT images will be read by specially trained Chinese resident radiologist and checked by one of two senior Chinese radiologists. Lung Cancer Screening (version 2. 2018) Guidelines of the National Comprehensive Cancer Network (NCCN) will be used for the management of lung nodules. This guideline recommends management of lung nodules based on diameter. In the second reading, a semi-automated volumetry software will be used to measure the volume and evaluate the other parameters of lung nodules.
~At baseline and one year after baseline, data about general characteristics, risk factors of lung cancer, and health status of the participants will be collected."
11111840|NCT03992820|Experimental|TENS arm (trial arm)|The trial group will have the TENS (transcutaneous electrical nerve stimulator) to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.
11111841|NCT03992820|Other|EMLA arm (Control arm)|The control group will have EMLA (Eutatic mixture of local anaesthetic) applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution.
11111842|NCT03992807|Experimental|A patient decision aid|A patient decision aid that includes not only the standard general information, but also the quantitative risk information on the possible outcomes of cataract surgery as well as value clarification exercise.
11111843|NCT03992807|Active Comparator|A usual education booklet|A traditional booklet with standard general information developed by the National Eye Institute (NEI) to help patients understand cataract.
11111844|NCT03992794||Total patients|Consecutive patients presenting to the ED with either a suspected or documented infection in which blood samples were taken during routine. An extra blood sample was taken to measure PCT & MR-proADM using the Samsung IB10 point of care assay.
11111845|NCT03992755|Experimental|LIQ861 Inhaled Treprostinil|LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg. LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg capsule strength to 200 μg capsule strength treprostinil four times a day (QID) in individual patients. Titrating to dose levels beyond 200 μg capsule strength QID, under clinical investigator supervision, requires review and approval from the Medical Monitor.
11111846|NCT03992742|Experimental|Intervention Group (subgroup A+B+C)|Personalized instant messaging (PIM) + optional cocktail interventions (OCI) + AWARD advice + referral card + warning leaflet+ COSH booklet
11111847|NCT03992742|Experimental|Control Group (subgroup D+E+F)|Regular instant messaging (RIM) + personalized instant messaging (PIM) + AWARD advice + referral card + warning leaflet+ COSH booklet
11111849|NCT03992729||Disease-Matched Comparison Cohort|No exposure to tildrakizumab at any time in the current pregnancy
11111850|NCT03992716|Experimental|SmofKabiven® extra Nitrogen|Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
11111851|NCT03992716|Active Comparator|Olimel N9E|Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
11111852|NCT03992703||Standard strategy|This group has been treated with antibiotic susceptibility testing on a conventional Mueller-Hinton medium with reading after 24 hours of incubation (Period 1: from July 1, 2015 to December 31, 2016)
11111853|NCT03992703||Rapid strategy|This group has been treated with antibiotic susceptibility testing on a rapid Mueller-Hinton medium after 8 hours of incubation (period 2: January 1, 2017 to June 30, 2018)
11111854|NCT03992690|Experimental|WANR protocol|Including training with Brain-machine interfaces, visuo-tactile feedback and assisted locomotion
11111855|NCT03992690|Active Comparator|Classical physiotherapy protocol|Training with classical physiotherapy protocol
11111856|NCT03992677||Brugada VF|Confirmed Brugada Syndrome by either Spontaneous or drug induced Type 1 ECG, confirmed cardiac arrest or appropriate ICD therapy for potentially lethal arrhythmia.
11111857|NCT03992677||Brugada relative|Relatives of Brugada syndrome patients with proven no pathology by Ajmaline challenge
11111858|NCT03992677||Ventricular ectopy|Patients undergoing ablation with ECGi system for other arrhythmias -these patients will be similar to our original controls and provide a repeat set of controls.
11111859|NCT03992677||AF|Patients with AF undergoing ablation with ECGi system (n=10). These patients will be older and have varying RR intervals which may cause a falsely low V-CoS.
11111860|NCT03992677||Ischaemic VF|Out-of-hospital cardiac arrest primary PCI with full recovery of left ventricular function and full revascularisation (n=10) - the purpose of this group is to confirm that the changes detected in our SCD group are not secondary to the SCD event. These are patients who have had a cardiac arrest secondary to coronary occlusion, but have made a full recovery with normal LGE-MRI and no indication for ICD.
11111861|NCT03992677||Athletes|Athletic Hypertrophy (n=10) - Elite athletes often have physiological LVH and abnormal ECGs at rest. It is unclear if these variations in activation will lead to a decrease in V-CoS.
11111862|NCT03992664|Experimental|EDUCATION|If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
11111863|NCT03992664|No Intervention|NON-INTERVENTION|The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
11111864|NCT03992651|Experimental|Experimental group|One single group of healthy subjects
11111865|NCT03992638|Experimental|L-PRF membrane|Periodontal plastic surgical procedures (coronally advanced flap, CAF) in combination with a double layer autologous leucocyte and platelet-rich fibrin (L-PRF) membrane.
11111866|NCT03992638|Active Comparator|Control|CAF
11111867|NCT03992612|Experimental|CBT for chronic pain|"Cognitive-behavioral treatment with twelve group sessions (6-8 subjects) with a duration of between 90 and 120 minutes and a weekly periodicity (total hours1080).
~components of the intervention are: reducing pain and emotional discomfort, increasing adaptive behaviors, changing irrational thoughts associated with pain, increasing self-efficacy, reducing anxiety, decreasing catastrophic thoughts and increasing healthy habits"
11111868|NCT03992612|Experimental|MBPM- Minfulness- Based Pain Management|"Psychological intervention with 8 group sessions ( 8 -10 subjects) with a duration of 2 and a half hours per session and a weekly periodicity (total hours 1080).
~It is centered on training on the awareness of physical, cognitive and emotional sensations, and the attentional processes to become an observer of one's own thoughts and emotions. With the aim to provide greater flexibility to manage pain"
11111869|NCT03992599||Laparoscopic modified central mesocolic excision|Patients receiving laparoscopic colectomy with the concept of modified complete mesocolic excision for right-sided colon cancer
11111870|NCT03992586|Experimental|Pink lenses|Pink-colored lenses
11111871|NCT03992586|Placebo Comparator|Clear lenses|Clear lenses
11111872|NCT03992573|Experimental|Study group|
11111873|NCT03992573|No Intervention|Control group|
11111874|NCT03992560|No Intervention|Standard CRT implantation|
11111875|NCT03992560|Experimental|MRI guided CRT implantation|
11111876|NCT03992547|Experimental|robot assisted gait traing|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks.
11111877|NCT03992534|Experimental|LACTIN-V|"Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)
~Dosage: LACTINV is a powder formulation of Lactobacillus crispatus CTV-05 provided in a prefilled vaginal applicator at a dose of 2 x 10^9 CFU of L. crispatus CTV-05. Route of Administration: LACTIN-V powder is administered vaginally using a specially designed applicator.
~Formulation: LACTIN-V is supplied as a pre-filled, single-use applicator. Each applicator contains LACTIN-V powder at a dose of 2 x 10^9 CFU. The LACTIN-V powder formulation contains L. crispatus CTV-05 and a preservation matrix containing inactive excipients of non-animal origin."
11111878|NCT03992508|Other|complex decongestive treatment|In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
11111911|NCT03992287|Placebo Comparator|Placebo|Placebo for 12 weeks
11111912|NCT03992274|Active Comparator|Standard implementation|During Standard Implementation, sites will use standard Yunnan CDC strategies to introduce HIV prevention innovations.
11111879|NCT03992508|Experimental|intermittent pneumatic compression|In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
11111880|NCT03992495||Neck pain|People suffering from neck pain at the time of recruitment
11111881|NCT03992495||Healthy|Participants with no significant past neck pain, chronic pain or other relevant medical disorders.
11111882|NCT03992482|Experimental|IVIG-Eye Drop|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
11111883|NCT03992482|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl)
11111884|NCT03992469|Experimental|BFAHF-2|Low dose BFAHF-2 (29 mg/kg/d divided two times a day) for 2 weeks followed by a full dose (71mg/kg/d divided two times a day) for 6 weeks
11111885|NCT03992469|Placebo Comparator|Placebo|tablets are identical in appearance to BFAHF-2 tablets
11111886|NCT03992456|Experimental|Arm A (panitumumab)|Patients receive panitumumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
11111887|NCT03992456|Active Comparator|Arm B (regorafenib, trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12, or regorafenib PO QD on days 1-21, at the discretion of the treating physician. Treatment repeats every 28 days for a maximum of 24 cycles in the absence of disease progression or unacceptable toxicity.
11111888|NCT03992443|Experimental|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 milligrams (mg) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose, if needed, at min 90. Assessments were performed at min 30, 60, 90, 120, 150, and 180.
11111889|NCT03992430|Experimental|Part 1: Eteplirsen|Patients will receive high dose level 1 of eteplirsen once weekly for at least 4 weeks, followed by high dose level 2 of eteplirsen once weekly for at least 4 weeks. Patients will continue treatment with the selected high dose as a distinct cohort for up to a maximum of 144 weeks.
11111890|NCT03992430|Active Comparator|Part 2: Eteplirsen 30 mg/kg|Patients will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.
11111891|NCT03992430|Experimental|Part 2: Eteplirsen-High Dose Level 1|Patients will receive high dose level 1 of eteplirsen once weekly before the selection of high dose occurs and then the selected high dose once weekly for up to 144 weeks.
11111892|NCT03992430|Experimental|Part 2: Eteplirsen-High Dose Level 2|Patients will receive high dose level 2 of eteplirsen once weekly before the selection of high dose occurs and then the selected high dose once weekly for up to 144 weeks.
11111893|NCT03992417||Participants with AD|Adult participants with AD initiating treatment with Dupixent® for AD according to the country-specific prescribing information, as part of their usual care as determined by their physician
11111894|NCT03992404|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.
~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
11111895|NCT03992404|Placebo Comparator|Placebo|"Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.
~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
11111896|NCT03992391|No Intervention|Qualitative Interviews|Qualitative Interviews with adolescents, their parents and clinicians.
11111897|NCT03992391|Experimental|Open Pilot|Open-label pilot group of adolescents (n=10) in a suicide prevention intensive outpatient program
11111898|NCT03992391|Experimental|Open-label trial|Open-label trial of adolescents (n=40) in a suicide prevention intensive outpatient program
11111899|NCT03992378|Experimental|Active Treatment|Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
11111900|NCT03992378|Sham Comparator|Sham Control|Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
11111901|NCT03992365|Experimental|Quiklean®|Quiklean® (32 tablets)
11111902|NCT03992365|Active Comparator|GroKlean-Prep with Dulcolax®|2 sachets of Klean-Prep with 1 tablet of Dulcolax®
11111903|NCT03992352||Age 60+ with planned HCT for Hematologic Malignancy|Subjects 60 years or older with a planned allogeneic transplantation for a hematologic malignancy.
11111904|NCT03992339|Experimental|ATG-010|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.
11111905|NCT03992326|Experimental|TIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
11111906|NCT03992313|Experimental|Facility-based testing intervention|Community Health Workers (CHWs) will provide information inside their groups on the possibility to be tested in health centers for HCV infection. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center that will be in charge to give result to the participant and to refer to care in case of active infection.
11111907|NCT03992313|Experimental|Community-based testing intervention|After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the village of participants. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS and sent to Phnom Penh for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center of each cluster and CHWs will be in charge to give result to the participant and to refer to care in case of active infection.
11111908|NCT03992300|Experimental|Intraoral scanning|An intraoral scanning is taken. An auxiliary device is used to achieve better accuracy. A zirconia framework is produced
11111909|NCT03992300|Active Comparator|Conventional scanning|A conventional elastomeric impression is taken and a zirconia framework is produced
11111913|NCT03992274|Experimental|Enhanced implementation|During Enhanced Implementation, sites will transition to receive enhanced Implementation Support to plan and implement PrEP.
11111914|NCT03992261|Experimental|Halobetasol Propionate Foam|2 weeks of application, 2 times daily
11111915|NCT03992248|Experimental|Time Restricted Feeding|Participants are instructed to eat within a limited time frame during the day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
11111916|NCT03992248|Other|Control|Participants are instructed to spread their habitual food intake over at least 14hrs per day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
11111917|NCT03992235|Experimental|Study Group|Chest physiotherapy + educational material
11111918|NCT03992235|Other|Control group|Chest physiotherapy
11111919|NCT03992222|Experimental|administration of a physical exercise programme|administration of a Physical exercise program for 24 weeks.
11111920|NCT03992222|No Intervention|control|
11111921|NCT03992209|Other|Standard handwashing by anesthesia provider|Anesthesia provider will conduct patient care per their usual standard practice in the operating room.
11111922|NCT03992209|Active Comparator|Protocolized hand washing by anesthesia provider|Anesthesia provider will conduct patient care using a personal hand washing device to optimize hand washing and captures hand washing events in real time.
11111923|NCT03992196|Experimental|Rotigotine|Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
11111924|NCT03992170|Experimental|Single Arm|"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).
~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."
11111925|NCT03992157|Experimental|holter-ECG|Implementation of an ECG Holter during hospitalisation patient.
11111926|NCT03992157|No Intervention|Crontrole|No implementation of an ECG Holter
11111927|NCT03992144|Experimental|amoxicillin|single preoperative oral 500 mg dose of Amoxicillin before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
11111928|NCT03992144|Experimental|metronidazole|single preoperative oral 400 mg dose of metronidazol before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
11111929|NCT03992144|Active Comparator|conventional group|conventional therapy for prevention of dry socket post operative; 400mg metrinidazol 3 times a day for 5 days 500mg of amooxicillin 2 times a day for 5 days painkiller 48 hours after extraction then sos
11111930|NCT03992131|Experimental|Arm A: Oral rucaparib and oral lucitanib|"Phase 1b (Dose escalation): Up to 55 patients with advanced or metastatic solid tumors.
~Phase 2 (Dose expansion): Up to 80 patients with High Grade Ovarian Cancer."
11111931|NCT03992131|Experimental|Arm B: Oral rucaparib and IV sacituzumab govitecan|"Phase 1b (Dose escalation): Up to 55 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, platinum resistant Ovarian Cancer, or a tumor with a BRCA1, BRCA2, PALB2, RAD51C, or RAD5/1D mutation
~Phase 2 (Dose expansion): Up to 139 patients with metastatic Triple Negative Breast Cancer, metastatic Urothelial Cancer, or platinum resistant Ovarian Cancer"
11111932|NCT03992118|Experimental|Feeding Challenges|Parents will be coached to implement strategies to address factors contributing to feeding challenges based on a multidisciplinary assessment using the medico-oral-behaviour-sensory-environment (MOBSE) approach.
11111933|NCT03992105|Other|historical cohort|150 homeless patients in crisis, identified from an extraction of the database of psychiatric emergencies of the same territory, and matched for age, sex, and main diagnosis.
11111934|NCT03992092|Experimental|C-Mac VS|Intubation using the C-MAC Video Stylet
11111935|NCT03992092|Active Comparator|FB|Intubation using the Flexible Bronchoscope
11111936|NCT03992079|No Intervention|Control|The control group will receive standard preoperative and postoperative directions, with the anesthesiologist and surgeon's preferences for analgesia during and after surgery.
11111937|NCT03992079|Experimental|Experimental|The experimental group will receive routine directions for surgery and a ReCOVER patient education document on the Enhanced Recovery protocol, with instructions on preoperative preparation, postoperative wound care, pain management, preventing and managing constipation, activity limitations, and return precautions. The information sheet will be provided to patients in clinic and reviewed with a member of the healthcare team to ensure an understanding of the plan.
11111938|NCT03992066|Experimental|Vadadustat 600 mg|Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
11111939|NCT03992066|Experimental|Vadadustat 750 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
11111940|NCT03992066|Experimental|Vadadustat 900 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
11111941|NCT03992066|Other|Erythropoiesis-stimulating agent|Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
11111942|NCT03992053|Active Comparator|Group 1|conventional 2-D fluoroscopy guidance as the first choice of guidance
11111943|NCT03992053|Active Comparator|Group 2|3-D CT guidance as the first choice of guidance
11111944|NCT03992040||Reinforced SSIAD (SSIADR arm )|"Reinforced Home Nursing Care Services: Patients with a score between 11 and 21 on the regional public health authorities (ARS) score.
~This arm will benefit from better coordination and delivery of care, which can reduce hospitalizations and visits to emergency departments"
11111945|NCT03992040||Classic SSIAD (Control arm)|Classic Home Nursing Care Services. For this arm, no direct benefit is expected since taking care, even for the heaviest patients, corresponds to current practice.
11111946|NCT03992027|Experimental|Immediate CF-CBT Intervention|This group will enter immediately into the 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT).
11112110|NCT03990870|Experimental|Experimental Treatment|dCBGT + WASABI
11111947|NCT03992027|Other|Waitlist control|This group will enter into the same 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT) 3 months after enrollment.
11111948|NCT03992014|Experimental|Linerixibat + [14C]-linerixibat|Subjects will receive a single oral dose of linerixibat 90 milligram (mg) (2*45 mg) tablets concomitantly with [14C]-linerixibat 100 microgram (approximately 9.25 kilobecquerel; 250 nano curie) IV infusion for 3 hours, after an overnight fast that continues for 2 hours after the oral dose/start of IV infusion, small standard high-fat meal will be given on Day 1 in treatment Period 1; followed by a single oral dose of [14C]-linerixibat 90 mg (approximately 4.96 megabecquerel; 134.1 micro curie) solution on Day 1 in treatment Period 2. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
11111949|NCT03992001|Experimental|Sequence A-B|Patients in this arm will receive blood component A for 6 months and blood component B for the next 6 months
11111950|NCT03992001|Experimental|Sequence B-A|Patients in this arm will receive blood component B for 6 months and blood component A for the next 6 months
11111951|NCT03991988|Experimental|Montelukast Group|Montelukast (10, 20, or 40 mg)
11111952|NCT03991988|Placebo Comparator|Placebo Group|Matched placebo pill
11111953|NCT03991975|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11111954|NCT03991962|Experimental|mFOLFIRINOX followed by SBRT|Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
11111955|NCT03991949|Experimental|Experimental Infant Formula|Ready-to-feed, milk-based formula
11111956|NCT03991936|Placebo Comparator|Placebo|Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
11111957|NCT03991936|Experimental|Triamcinolone Acetonide 2.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
11111958|NCT03991936|Experimental|Triamcinolone Acetonide 5.0 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
11111959|NCT03991936|Experimental|Triamcinolone Acetonide 7.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
11111960|NCT03991936|Experimental|Triamcinolone Acetonide 10 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
11111961|NCT03991923|Experimental|Non-ischemic heart preservation (NIHP)|Continous cold cardioplegic perfusion of hearts
11111962|NCT03991923|Active Comparator|Ischemic cold static storage (ICSS)|Standard preservation technique
11111963|NCT03991910|Placebo Comparator|control|control patients will be given a placebo
11111964|NCT03991910|Experimental|treatment|Ramipril 5 mg treatment group
11111965|NCT03991897|Experimental|Ketogenic diet|"the intervention will consist of 3 phases: a one week run-in period, 24 weeks strict KD and 24 weeks Modified Atkins Diet.
~Every day, 40 g of KetoCal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals and to ensure ketosis during the night (some patients drink some sips of the shake during the night). During this run-in period, patients will become familiar with their diet and, in particular, they will learn which foods are allowed and which are not."
11111966|NCT03991897|Active Comparator|Isocaloric diet|During the run-in period, the dietician will discuss the diet and maintenance of an isocaloric diet with the patients. As such, the diet of the control group will not change from their normal dietary pattern, unless a patient is following an Atkins-like diet. In the latter case, the patient will be asked to change the diet to a normal Belgian diet.
11111967|NCT03991884|Experimental|Dose -1 (0.3 mg/m^2)|Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11111968|NCT03991884|Experimental|Dose 1 (0.3 mg/m^2)|Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11111969|NCT03991884|Experimental|Dose 2 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11111970|NCT03991884|Experimental|Dose 3 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11111971|NCT03991871|Placebo Comparator|Control Group|35 hours ECP treatment, initial treatment pressure is 75 mmHg
11111972|NCT03991871|Experimental|Intervention Group|35 hours ECP treatment, initial treatment pressure is 300 mmHg
11111973|NCT03991858|Other|Phone follow-up|Phone follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
11111974|NCT03991858|Experimental|Telerehabilitation follow-up|Telerehabilitation follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
11111975|NCT03991845|Experimental|Low dose Vit D|All Patients belonging to arm 1 will be treated with low dose oral Vit D (2000 IU/day) for 12 weeks
11111976|NCT03991845|Active Comparator|High dose Vit D|All patients in this group will be treated with high dose oral Vit D (60,000 IU/week) for 12 weeks
11111977|NCT03991845|No Intervention|Placebo|No Vit D supplementation will be given to patients in this group
11111978|NCT03991832|Experimental|Cohort A: IDH mutated glioma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
11111979|NCT03991832|Experimental|Cohort B: IDH mutated cholangiocarcinoma|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
11111980|NCT03991832|Experimental|Cohort C: Other IDH mutated solid tumors|Olaparib, by mouth (orally), twice a day, every day. Durvalumab, by vein (intravenously), on Day 1 of every 28 day cycle.
11111981|NCT03991819|Experimental|Phase 1|"Cycle 1 = 28 days and Cycle 2 and Future Cycles = 21 days
~Binimetinib, by mouth (orally): Level 1: 45 mg, twice a day, continuously; Level -1: 30 mg, twice a day, continuously; Level -2: 30 mg, twice a day, for Days 1-14 of each cycle only
~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 8 of Cycle 1, then Day 1 of Cycle 2 and future cycles."
11111982|NCT03991819|Experimental|Phase 1b|"All Cycles = 21 days
~Binimetinib, by mouth (orally), at the best dose found in Phase 1 of the study, twice a day, continuously.
~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 1 of every cycle."
11111983|NCT03991793||Sepsis|Severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
11111984|NCT03991793||Control|Absence of severe sepsis or septic shock (2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference)
11111985|NCT03991780|Experimental|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib (tablet taken orally) twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
11111986|NCT03991767|Experimental|period 1|"Period 1: Retrospective period:
~Collection of data from the 12 months preceding the start of the research of hospitalized patients:
~number of hospitalizations,
~number of HIV serologies performed,
~number of patients with socio-demographic criteria justifying HIV screening.
~Start of research: Implementation of the POP-UP electronic alert
~Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.
~Six possibility to answer:
~Patient accept to participate: patient is include and receive HIV serology during their hospitalization.
~Not time to answer to the alert
~Patient already has a serology less than 3 months old
~Patient followed for a known HIV infection.
~Patient who refused the test
~Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization."
11111987|NCT03991754|Experimental|Amiodarone|Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
11111988|NCT03991754|Placebo Comparator|Control|Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
11111989|NCT03991741|Experimental|melanoma|
11111990|NCT03991741|Experimental|head and neck cancer|
11111991|NCT03991728||Alloplastic total TMJ replacement|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
11111992|NCT03991715|Experimental|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
11111993|NCT03991689|Experimental|the six weeks solution-focused pain management groups|
11111994|NCT03991676|Experimental|Values-Based Behavioral Treatment|
11111995|NCT03991650||Control|"n=30 healthy participants will be recruited using social networks and leaflets of information distributed by the research team at the Hospital Cliníc de Barcelona.
~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants' data will also be monitored with a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
11111996|NCT03991650||Experimental|"The recruitment process will be carried out in patients of external consultations and the day hospital of the Addictions Unit at the Hospital Clinic of Barcelona.
~n=30 patients with Anxiety and Alcohol Use Disorder.
~The participants will be monitored over the course of one month using the humanITcare app U-Shine, which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants will also be monitored using a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit."
11111997|NCT03991637|Experimental|NICMP Spectral Reading|Non-invasive spectral data is collected from this arm to function as the intervention of interest.
11111998|NCT03991637|Active Comparator|Venipuncture CMP|"A standard CMP blood draw is performed to function as the gold standard reference value.
~Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method."
11111999|NCT03991624|Other|Alzheimer's patients (lack of executive functions)|
11112000|NCT03991624|Other|control (lack of executive functions)|
11112001|NCT03991624|Other|Alzheimer's patients (lack of working memory)|
11112002|NCT03991624|Other|control (lack of working memory)|
11112003|NCT03991624|Other|Alzheimer's patients (lack of episodic memory)|
11112004|NCT03991624|Other|control (lack of episodic memory)|
11112005|NCT03991611|Experimental|IPREA3 program|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for at least 5 months
11112006|NCT03991611|Other|Intermediate group|Application of the IPREA 3 program (multicomponent intervention to reduce perceived discomforts in critically ill patients) for less than 5 months
11112007|NCT03991611|Active Comparator|Standard care|Standard care
11112008|NCT03991598|Experimental|intervention|EDs 1 to 7 will then be randomly phased-in INT every 3 months.
11112009|NCT03991598|No Intervention|control|During the first 6 months and throughout CTRL time
11112111|NCT03990870|Active Comparator|Active Comparator|dCBGT Only
11112010|NCT03991585|Experimental|Three times a week MCRF|Participants in this arm will participate in the MCRF intervention sessions three times a week for 12 consecutive weeks.
11112011|NCT03991585|Experimental|One time a week MCRF|Participants in this arm will participate in the MCRF intervention sessions one time a week for 12 consecutive weeks.
11112012|NCT03991572|Active Comparator|Real Stimulation|The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
11112013|NCT03991572|Sham Comparator|Sham Stimulation|The procedure of Sham Stimulation protocol was performed by a placebo coil,lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
11112014|NCT03991559|Active Comparator|Dose-Escalation, intranasally|With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
11112015|NCT03991559|Active Comparator|Dose-Escalation, inhalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
11112016|NCT03991546|Experimental|Acceptance and Commitment Therapy|Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy.
11112017|NCT03991546|No Intervention|Control group|Subjects randomizing into this arm did not receive the text message study intervention.
11112018|NCT03991533||affected|patients with a histologically confirmed head and neck tumour
11112019|NCT03991533||control|histologically confirmed Whartin tumour or pleomorphic adenoma of the parotid gland, without malignant transformation
11112020|NCT03991520|Experimental|Active Treatment with Anakinra|10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
11112021|NCT03991520|Placebo Comparator|Standard Comparison|10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
11112022|NCT03991494|Experimental|Pamiparib|
11112023|NCT03991481|Experimental|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
11112024|NCT03991481|Active Comparator|Liquid-stored platelets|Platelets that have been liquid stored, with an expiry of 5 days.
11112025|NCT03991455|Other|Apyx device treatment|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.
11112026|NCT03991442|Experimental|BR1010 and Fimasartan/Amlodipine placebo|BR1010 or Fimasartan/Amlodipine
11112027|NCT03991442|Active Comparator|BR1010 placebo and Fimasartan/Amlodipine|BR1010 or Fimasartan/Amlodipine
11112028|NCT03991429||Group 1|Patients with BPH and significant improvement in storage symptoms after BOO procedures
11112029|NCT03991429||Group 2|Patients with BPH who have persistent storage symptoms after BOO procedures
11112030|NCT03991429||Group 3 (Control group)|Men without LUTS who are planning to undergo radical prostatectomy
11112031|NCT03991416|Experimental|Understanding Your Baby|Understanding Your Baby plus postnatal care as usual
11112032|NCT03991416|Active Comparator|Care As Usual|Postnatal care as usual
11112033|NCT03991403|Experimental|Atezolizumab group|
11112034|NCT03991403|Active Comparator|Control group|
11112035|NCT03991390|Experimental|Core stability and feedback visual laser exercises|"Two complementary protocols for the treatment of balance after stroke in patients with pusher syndrome were designed, including multidimensional physiotherapy exercises. Both protocols differentiate 3 levels of difficulty: Second level requires maintenance of balance sitting 5, if the patient does not succeed, stays in level 1. To move to L3 patients must stay seated 10''. Each exercise is repeated 5 times, always considering patients' levels of fatigue and safety.
~Visual feedback with laser (Motion Guidance Clinical Kit, approved for therapeutic use): Through visual aid, patients' verticality is achieved by encouraging their active participation in correcting the imbalance while performing the exercises.
~Core stability: The exercises have to be adapted for the pusher patient avoiding overuse of the less affected side of the body, and strengthening the muscles that stabilize the trunk."
11112036|NCT03991390|Active Comparator|Control stroke|Rehabilitation program is based on a comprehensive approach, where the patient follows a personalized plan of exercises according to the deficits, the previous situation and personal concerns.
11112037|NCT03991377|Experimental|EMDR therapy|Patients in the psychotherapy intervention will receive up to 20 individual sessions of EMDR, weekly sessions, of 60 minutes each, using the standard EMDR therapy protocol developed by Shapiro to treat both current and past trauma-related symptom.
11112038|NCT03991377|Active Comparator|Treatment as usual|Multidisciplinary approach that includes pharmacological treatment and psychological support.
11112039|NCT03991364|Experimental|Constant gait speed group|experimental group that applied the speed of the robot-assisted gait training constantly
11112040|NCT03991364|Other|Increasing gait speed group|control group that applied the gradual increase of the speed of the robot-assisted gait training
11112041|NCT03991351||Men aged 18-34|Participants will be males aged 18-34. Each individual will be exposed to images of men with either a muscular, skinny or overweight physique or the control images of landscapes.
11112042|NCT03991325||difficult laryngoscopy|group of patients with Cormack and Lehane grade III or IV
11112043|NCT03991325||easy laryngoscopy|group of patients with Cormack and Lehane grade I or II
11112044|NCT03991312|Experimental|Part 1|"Period 1: Day 1, participants will receive 20 milligrams (mg) of mitapivat sulfate.
~Period 2: Day 1 to Day 9, participants will receive 200 mg of itraconazole, once daily and 20 mg of mitapivat sulfate on Day 5."
11112045|NCT03991312|Experimental|Part 2|"Period 1: Day 1, participants will receive 50 milligrams (mg) of mitapivat sulfate.
~Period 2: Day 1 to Day 12, participants will receive 600 mg of rifampin, once daily and 50 mg of mitapivat sulfate on Day 8."
11112046|NCT03991299|Experimental|Botox Arm|Botox will be injected into duodenums of subjects via endoscopy.
11112047|NCT03991286|Placebo Comparator|Placebo|"Drug: Placebo
~Ovulatory Agent:
~Clomiphene Citrate"
11112048|NCT03991286|Experimental|experimental|"Drug: Astaxanthin 4mg
~Drug: Ovulatory Agent Clomiphene Citrate"
11112049|NCT03991273|Experimental|Y-M2M©|a group-based M2M© program conducted onsite at a local YMCA
11112050|NCT03991273|Experimental|B-M2M©|a blended program that provides Y-M2M© and a home-based M2M© via videoconferencing
11112051|NCT03991260||The tested injected doses of 99mTc- ADAPT6 500 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 500 µg. Subjects withdrawn from the study for any reason will be replaced.
11112052|NCT03991260||The tested injected doses of 99mTc- ADAPT6 1000 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 1000 µg. Subjects withdrawn from the study for any reason will be replaced.
11112053|NCT03991247|Experimental|Internet Behavioral therapy program + spa therapy|Patient following a program of computerized behavioral therapy for insomnia management during a 3 weeks spa treatment.
11112054|NCT03991247|Active Comparator|Internet Behavioral therapy program at home|Patient following a program of computerized behavioral therapy for insomnia management during 3 weeks at home.
11112055|NCT03991234|Experimental|Coordinated Reading and Math Intervention|Coordinated intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction addressing similar skills as those addressed in the reading intervention arm & similar skills as the math intervention arm.
11112056|NCT03991234|Active Comparator|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction designed to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
11112057|NCT03991234|Active Comparator|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge, counting strategies, and arithmetic skill.
11112058|NCT03991234|No Intervention|Business-as-usual Control|Participation in the school's typical reading and math classroom instruction and, if designated by the school, its supplemental program.
11112059|NCT03991221|Other|Dental exam by orthodontic non-specialists|Detection of the presence of at least one malocclusion by orthodontic non-specialists with the graphic chart
11112060|NCT03991221|Other|Dental exam by orthodontic experts|Detection of the presence of at least one malocclusion by orthodontic experts
11112061|NCT03991208|Experimental|Rest|Pharmacokinetics of Single Dose Malarone at Rest
11112062|NCT03991208|Experimental|Exercise|Pharmacokinetics of Single Dose Malarone under exercise in a heat chamber
11112063|NCT03991195|Experimental|Probiotic supplemented group with aMCI|Thirty participants in this group will take Bifidobacterium for three months.
11112064|NCT03991195|Placebo Comparator|Placebo group with aMCI|Thirty participants in this group will take placebo for three months.
11112065|NCT03991182|Experimental|Community-based parenting group|The community-based parenting group will include 39 health zones and 585 caregiver-child dyads
11112066|NCT03991182|Active Comparator|Control group|The control group will include 39 health zones and 585 caregiver-child dyads
11112067|NCT03991169|Experimental|Oral Iron therapy|Participant will receive oral iron therapy.
11112068|NCT03991169|No Intervention|No oral iron therapy|Participant will not receive oral iron therapy for 3 months.
11112069|NCT03991156|Experimental|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|
11112070|NCT03991143|Experimental|ATH3G10|Phosphorylcholine human monoclonal antibody (ATH3G10)
11112071|NCT03991143|Placebo Comparator|Placebo|Placebo to ATH3G10, 0.9% sodium chloride
11112072|NCT03991130|Experimental|High Dose IL-2 and Nivolumab|
11112073|NCT03991117|Experimental|80 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
11112074|NCT03991117|Experimental|80 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 80 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
11112075|NCT03991117|Experimental|30 %1RM, Regular Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of three seconds per repetition.
11112076|NCT03991117|Experimental|30 %1RM, Slow Tempo|Participants performed three sets of unilateral knee extension with a load that was 30 % of their one-repetition maximum (1RM) at a tempo of seven seconds per repetition.
11112077|NCT03991104|Experimental|SOX-based Chemoradiotherapy|IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
11112078|NCT03991091|Experimental|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm
11112079|NCT03991091|Active Comparator|continuation of oxytocin administration|Standard care in France, i.e. when oxytocin is started during the latent phase of the 1st stage, administration of oxytocin is continued during the active 1st stage and during the 2nd stage if the fetal heart rate is reassuring.
11112080|NCT03991065|Experimental|with endoscopy|high digestive endoscopy
11112081|NCT03991065|No Intervention|without endoscopy|no endoscopy
11112268|NCT03989804|Experimental|Targeted follow-up|
11112269|NCT03989804|No Intervention|Usual practice|Usual practice at the fitness center is self-directed use
11112082|NCT03991052|Active Comparator|EV1000 monitor|MAP management will be done as usual (adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
11112083|NCT03991052|Experimental|EV1000 monitor + closed-loop system|Fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
11112084|NCT03991039|Active Comparator|Gamma knife group|Patients selected to be treated with gamma knife radiosurgery
11112085|NCT03991039|Active Comparator|MVD Group|Patients treated with microvascular decompression
11112086|NCT03991026|Experimental|Healthy food and Education/Cooking Classes|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, healthy eating attitudes, and demographics. Every week for 6 weeks, participants will pick-up a healthy food bag (e.g. fresh vegetables) for a $3 co-pay and attend an hour-long education classes at East Baltimore Medical Center. All participants will complete a survey at healthy food bag pick-up or an education class. Surveys at bag pick-up will ascertain outcomes like vegetable consumption. Surveys at education classes will ascertain outcomes like healthy eating attitudes. At 6 weeks, all participants will complete a follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again at 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
11112087|NCT03991026|No Intervention|Control Group|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, cooking habits, food security, healthy eating attitudes, and demographics. As a control group, participants will not partake in the healthy food bag pick-ups or cooking classes therefore they will not fill out those associated surveys. After the 6 weeks of the intervention, control participants will be given the follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again after 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
11112088|NCT03991013|Active Comparator|Supplementary dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.
11112089|NCT03991013|Placebo Comparator|Placebo dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.
11112090|NCT03991000|Experimental|Intravenous iron|Intravenous iron administration in the form of ferric carboxymaltose will be carried out according to summary of product characteristics. Bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks (up to a total of 2000 mg which is in-label) according to approved dosing rules, followed by administration of 500 mg ferric carboxymaltose at months 4 and 8, except when haemoglobin is > 16.0 g/dL or ferritin is > 600 µg/L. To avoid unblinding in these patients a saline infusion will be administered.
11112091|NCT03991000|Placebo Comparator|Placebo|Administration of i.v. NaCl according to the dosing rules for intravenous iron.
11112092|NCT03990987||Day group|patients in Day group accept operation from 8：00～12：00
11112093|NCT03990987||Night group|patients in Night group accept operation from 18：00～22：00
11112094|NCT03990974|Experimental|Postoperative antimicrobial prophylaxis|Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.
11112095|NCT03990974|Sham Comparator|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.
11112096|NCT03990961|Experimental|Pembrolizumab Treatment|
11112097|NCT03990948||Patients with obesity|In 100 patients with obesity, blood samples will be collected.
11112098|NCT03990948||Patients with a Sleeve Gastrectomy|In 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
11112099|NCT03990948||Patients with a Roux-en-Y Gastric Bypass|In 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
11112100|NCT03990935|Active Comparator|sodium fluoride varnish|"The fluoride varnish will be bifluorid 10 single use by voco (Germany). It Contains 5 % sodium fluoride (equal to 22,600 ppm fluoride).
~A thin coat will be applied on the tooth surface by using a brush. 10-20 s are sufficient for the varnish to be absorbed and then dry with air. Participants will be informed that they should not brush their teeth for 12-24 hours after the application and not to eat, or drink for at least 30 minutes after use to get the best results."
11112101|NCT03990935|Experimental|Ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
11112102|NCT03990922|Experimental|CTPVB with ropivocaine|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
11112103|NCT03990922|Placebo Comparator|CTPVB with saline|Continuous Paravertebral block with saline and Patient-controlled analgesia with morphine
11112104|NCT03990909|Experimental|BCAAs|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
11112105|NCT03990909|Placebo Comparator|Rice Protein|Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
11112106|NCT03990909|Placebo Comparator|Microcrystalline Cellulose|Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
11112107|NCT03990896|Experimental|Talazoparib|-Talazoparib will be provided as capsules for oral administration daily
11112108|NCT03990883|Other|Treatment of device 1 on left side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to left NLF, Comparator is assigned to right NLF
11112109|NCT03990883|Other|Treatment of device 1 on right side|Treatment of nasolabial folds (NLF) with both Investigational Device and Comparator; Princess Filler Lidocaine is assigned to right NLF, Comparator is assigned to left NLF
11112112|NCT03990857|Experimental|Intervention|Group of participants with a recent DM2 debut (less than 5 months) treated according to the comprehensive care protocol in DM2 with comorbidities attended in Primary care nurse office
11112113|NCT03990857|No Intervention|comparison group|Participants in the study that do not receive the intervention. usual care.
11112114|NCT03990844|Placebo Comparator|0% Okra seed noodle|In this arm, subjects will consume noodles made with 0% okra seed. This serves as a control arm for the study.
11112115|NCT03990844|Experimental|10% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
11112116|NCT03990844|Experimental|20% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
11112117|NCT03990831|Other|burn injury and normal patient|HbO2 PFC perfusion using fNIRS
11112118|NCT03990805|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
11112119|NCT03990805|Placebo Comparator|saline|saline
11112120|NCT03990792|Experimental|e-predictD intervention|In this arm, patients will receive a personalized intervention to prevent depression based on ICTs, risk predictive algorithms and decision support systems (DSS) for patients and General Practitioners (GPs).
11112121|NCT03990792|Active Comparator|m-Health control|In this arm, patients will continue receiving the usual care from their GPs. In addition, they will use an App with the same appearance as the e-predictD App but it will only send weekly messages about physical and mental health management. This intervention is not personalized and does not include GP training and GP-patient interview.
11112122|NCT03990779||Children with congenital cardiac disease|Children with congenital cardiac disease who undergoing surgery
11112123|NCT03990766|Experimental|Theophylline saline irrigation|Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
11112124|NCT03990766|Placebo Comparator|Placebo saline irrigation|Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
11112125|NCT03990753||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.
11112126|NCT03990740||Cases|Patients suffering from keratoconus and requiring a first optical corneal transplant
11112127|NCT03990740||Controls|Patients with an indication of orbital exenteration operation due to an orbital tumor
11112128|NCT03990727||Retinitis pigmentosa|Any type of retina dystrophy with pigment / retinitis pigmentosa
11112129|NCT03990727||Usher Syndrome|Retina dystrophy or retinitis pigmentosa associated with audition problems
11112130|NCT03990727||Cone>rod syndromes|Retina dystrophy diagnosed or started in central vision.
11112131|NCT03990727||Retinitis pigmentosa sx|Retinitis pigmentosa with any type of other features
11112132|NCT03990714|Experimental|Intracorporeal anastomosis|The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
11112133|NCT03990714|Experimental|Extracorporeal anastomosis|The mobilized colon was externalized preferentially via a transverse or midline incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed.The incision for the extraction of the right colon and the realization of the anastomosis is sutured in two layers by absorbable suture. Drains were not used routinely.
11112134|NCT03990701|Experimental|Single Arm|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 150 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease.
11112135|NCT03990688|Experimental|AK3280 (Cohort 1)|Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.
11112136|NCT03990688|Experimental|AK3280 (Cohort 2)|Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.
11112137|NCT03990688|Experimental|AK3280 (Cohort 3)|Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
11112138|NCT03990688|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.
11112139|NCT03990675|Experimental|FNA, FNB|
11112140|NCT03990662||TMD|Patients (aged ≥18 years) with a diagnosis of Temporomandibular Disorders
11112141|NCT03990649|Experimental|Part A: TAK-935|Part A (Double blind titration period): Tablets, TAK-935, 100 mg, orally, twice daily (BID) for Week 1, followed by tablets, TAK-935, 200 mg, orally, BID for Week 2, further followed by tablets, TAK-935, 300 mg, orally, BID for Week 3. Dose will be uptitrated every week based on safety and tolerability. Part A (Double blind maintenance period): Tablets, TAK-935 300 mg, orally BID for 12 weeks. Dose adjustments during maintenance period may take place due to safety and tolerability. Taper period (if participant does not continue to Part B): Dose of TAK-935 to be reduced to next lower dose every 3 days (maximum 6 days) till TAK-935 is discontinued.
11112270|NCT03989791|Active Comparator|Absolute diet|
11112271|NCT03989791|Experimental|Normal diet|
11112142|NCT03990649|Placebo Comparator|Part A: Placebo|TAK-935 placebo-matching tablets, orally, BID for Weeks 1, 2 and 3 in Double blind titration period. TAK-935 placebo-matching tablets, orally BID for 12 weeks in Double blind maintenance period. Taper period (if participant does not continue to Part B): Dose of TAK-935 placebo-matching tablets to be reduced to next lower dose every 3 days (maximum 6 days) till TAK-935 is discontinued.
11112143|NCT03990649|Experimental|Part B: TAK-935|Part B (Optional, Open label extension: titration period all participants to receive TAK-935): Tablets, TAK-935, 200 mg, orally, BID up to 1 week followed by tablets, TAK-935, 300 mg, orally, BID for up to 1 week. Dose will be uptitrated every week based on safety and tolerability. Part B (Open label extension: maintenance period): Tablets, TAK-935 300 mg, orally BID for 12 weeks. Dose adjustments during maintenance period may take place due to safety and tolerability. Taper period: Dose of TAK-935 to be reduced to next lower dose every 3 days (maximum 6 days) till TAK-935 is discontinued.
11112144|NCT03990636|Experimental|Metil 5-aminolevulinate arm|Metil 5-aminolevulinate arm with photo activation.
11112145|NCT03990636|Placebo Comparator|Placebo arm|Placebo (without metil 5-aminolevulinate) arm with photo activation.
11112146|NCT03990623|Experimental|Diagnostic (CT perfusion scans, liver biopsy)|Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.
11112147|NCT03990610|Experimental|Treatment (vascularized lymph node transfer)|Patients undergo vascularized lymph node transfer during standard of care breast reconstructive surgery.
11112148|NCT03990597|Experimental|Supportive care (StrataXRT, placebo)|Beginning first day of CSI proton radiation therapy, caregivers apply StrataXRT gel to half of the patient's forehead and one ear and placebo to the other half of the forehead and the other ear BID until the last day of radiation therapy.
11112149|NCT03990584|Experimental|three irrigation activation methods|"Manual dynamic irrigation was performed using a well-fitting gutta-percha cone inserted to WL with in-and-out vertical strokes of 5 mm at a rate of approximately 100 strokes per minute in order to hydrodynamically displace the irrigant.
~Passive ultrasonic irrigation was performed using a non-cutting size 25 file attached to a piezoelectric ultrasonic unit.
~Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm."
11112150|NCT03990584|Active Comparator|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
11112151|NCT03990571|Experimental|Treatment (axitinib, avelumab)|Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11112152|NCT03990558||Primary ICH|Subject with acute brain injury will have data collected, including EEG, behavioral, clinical, and outcome measures.
11112153|NCT03990545||Cases with stroke|
11112154|NCT03990545||Controls without stroke|
11112155|NCT03990532|Experimental|treatment group|
11112156|NCT03990519|Experimental|Cohort1: JNJ-2636682/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
11112157|NCT03990519|Experimental|Cohort 2: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
11112158|NCT03990519|Experimental|Cohort 3: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.
11112159|NCT03990506|Experimental|Epi-on PiXL|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
11112160|NCT03990506|Active Comparator|Epi-off PiXL|Photorefractive intrastromal corneal crosslinking with epithelium debridement.
11112161|NCT03990493|Experimental|PV-001-DV in Combination with PV-001-DC|Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
11112162|NCT03990480|Active Comparator|valsartan|Group I treated with valsartan (160 mg/d, n = 100)
11112163|NCT03990480|Active Comparator|amlodipine|Group II amlodipine (10 mg/d, n = 100).
11112164|NCT03990480|No Intervention|Control|30 healthy subjects are enrolled as control group (Group III).
11112165|NCT03990467|Experimental|Patients treated by amikacin and piperacillin|ICU patient with a sepsis treated by amikacin and piperacillin/tazobactam
11112166|NCT03990454|Experimental|Dose escalation/expansion|"The starting dose will be 25 mg/day and subsequent doses will be determined after an internal review by Data Review Committee of all available safety, PK and PD data from the minimum required number of subjects who complete cycle 1. All dose-escalation decisions and the rationale for progressing to the next cohort will be documented.
~A subject may continue treatment with SLC-391 in 21-day cycles until the treatment discontinuation criteria are met.
~Subjects with certain tumour types (e.g., NSCLC or ovarian) may be enrolled in expansion cohorts of up to 12 subjects at doses less than or equal to the MTD to better characterise the activity and safety of SLC-391 and define the Recommended Phase 2 Dose (RP2D) dose."
11112167|NCT03990441|Experimental|Intervention|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
11112168|NCT03990441|Placebo Comparator|Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
11112169|NCT03990428||Caregivers of Patients|This is an observational study of informal caregivers (ICs) of patients with Erdheim-Chester Disease (ECD) and other histiocytic diseases. That will collect data cross-sectionally, at a single time point. Caregiver-reported data will be completed in the form of online surveys by the participants themselves using the Research Electronic Data Capture Platform [RedCAP] platform.
11112170|NCT03990415|Experimental|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
11112171|NCT03990415|Active Comparator|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
11112172|NCT03990415|No Intervention|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
11112173|NCT03990402||Malawi group|500 young people with asthma symptoms in Malawi
11112174|NCT03990402||South Africa group|500 young people with asthma symptoms in South Africa
11112175|NCT03990402||Uganda group|500 young people with asthma symptoms in Uganda
11112176|NCT03990402||Nigeria|500 young people with asthma symptoms in Nigeria
11112177|NCT03990402||Zimbabwe group|500 young people with asthma symptoms in Zimbabwe
11112178|NCT03990402||Ghana group|500 young people with asthma symptoms in Ghana
11112179|NCT03990389|No Intervention|Usual Care Group|"Subjects will undergo screening including Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Edinburgh Postnatal Depression Scale (EPDS) and a few additional questions.
~Eligible subjects randomized to usual care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.
~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
11112180|NCT03990389|Experimental|Chabot Care Group|"Subjects will undergo screening including REALM-R and EPDS and a few additional questions.
~Eligible subjects randomized to chatbot care will receive monthly reminder phone calls from a research coordinator. Subjects will receive an email with a link to surveys for the purpose of collecting information on depression severity, medication adherence, self-efficacy, side-effect burden, and maternal functioning.
~In addition to the above procedures, eligible subjects randomized to chatbot care will receive weekly messages from the chatbot asking them to complete a depression severity measure and side-effect burden assessments. Within week 1 subjects will receive a check-in call from a study coordinator to answer any questions regarding use of the chatbot.
~All participants will be asked to participate in a semi-structured debrief interview upon study completion."
11112181|NCT03990389|No Intervention|Provider Subject Cohort|20 provider subjects from each study site will be enrolled to ensure they understand the study and consent to have their patients enrolled in the study
11112182|NCT03990376|Other|Blood volume assessment with Blood Volume Analyzer|Injections of 1 mL of I-131-labeled serum albumin based on each patient's height and weight - 1 pre-surgical and 1 post-surgical
11112183|NCT03990363|Experimental|High Dose|High Dose (mg) (verinurad/allopurinol) Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 12/300
11112184|NCT03990363|Experimental|Intermediate Dose|Intermediate Dose (mg) verinurad/allopurinol Step 1 - titration_ 3/100 Step 2 - titration_ 7.5/200 Step 3 - target dose_ 7.5/300
11112185|NCT03990363|Experimental|Low Dose|Low Dose (mg) verinurad/allopurinol Step 1 - titration_3/100 Step 2 - titration_3/200 Step 3 - target dose_3/300
11112186|NCT03990363|Experimental|Allopurinol alone (0/300 mg)|Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose_0/300
11112187|NCT03990363|Placebo Comparator|Placebo (0/0 mg)|Placebo (mg) in 3 steps_0/0
11112188|NCT03990350||Hispanic children with obesity|
11112189|NCT03990350||Hispanic children without obesity|
11112190|NCT03990350||Caucasian non-Hispanic children with obesity|
11112191|NCT03990350||Caucasian non-Hispanic children without obesity|
11112192|NCT03990337|No Intervention|Control group (CPG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage using finger palpation without ultrasonography
11112193|NCT03990337|Active Comparator|Ultrasound group (USG, n=65)|cricoid pressure applied by the OR nurse on the cricoid cartilage after localization with ultrasonography
11112194|NCT03990324|No Intervention|Control group|The control group did not received intervention and sat on a table for approximately 5 minutes
11112195|NCT03990324|Experimental|Stretching group|The stretching group received a standardized manual stretching protocol
11112196|NCT03990311|Experimental|Intervention|The experimental arm receives 2 months of sodium restricted prepared meals plus dietary counseling followed by 3 months of counseling alone.
11112197|NCT03990311|Placebo Comparator|Control|The control arm receives 5 months of usual care followed by 2 months of receipt of sodium restricted prepared meals.
11112198|NCT03990298|Other|All subjects|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.
11112199|NCT03990285|Other|[18F]Fluciclovine in glioblastoma|Axumin is a positron emitting radiopharmaceutical that has been studied in vivo in humans in a number of tumor types with positron emission tomography (PET/CT). 18F-Fluciclovine is a fluorine-18 labeled synthetic amino acid analog that is FDA approved as a PET imaging agent for prostate cancer recurrence, however, it has also been tested in other tumors. Investigators will use a typical dose of 18F-fluciclovine that is used for clinical studies in glioblastoma. This will be 5 mCi (approximate range for most studies is anticipated to be 5 mCi +/- 20%), but a lesser dose may be injected if, in the opinion of a Nuclear Medicine Authorized User, complete imaging data could be generated.
11112200|NCT03990272|Experimental|artemisia annua allergen extract drops|
11112201|NCT03990272|Placebo Comparator|Placebo drops|
11112202|NCT03990259||Male|The male individuals of the study population
11112203|NCT03990259||Female|The female individuals of the study population
11112204|NCT03990246|Experimental|Acid stable emulsion with solid droplets|Acid stable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
11112205|NCT03990246|Experimental|Acid stable emulsion with liquid droplets|Acid stable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
11112206|NCT03990246|Experimental|Acid unstable emulsion with solid droplets|Acid unstable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
11112207|NCT03990246|Experimental|Acid unstable emulsion with liquid droplets|Acid unstable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
11112208|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts A|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
11112209|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts B|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
11112210|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C1|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous patients with selected advanced solid tumours (e.g. Non-small Cell Lung Carcinoma, Triple Negative Breast cancer, Pancreatic cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Renal cell carcinoma, Urothelial Carcinoma, Small Cell Lung Cancer, Gastric cancer, Colorectal Cancer and Ovarian cancer)
11112211|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C2|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with selected advanced solid tumours (e.g. Non-small Cell Lung Carcinoma, Triple Negative Breast cancer, Pancreatic cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Renal cell carcinoma, Urothelial Carcinoma, Small Cell Lung Cancer, Gastric cancer, Colorectal Cancer and Ovarian cancer)
11112212|NCT03990220||Treatment|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of yoghurt containing Lactobacillus rhamnosus, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
11112213|NCT03990220||Control|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of milk, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
11112214|NCT03990207|Experimental|PowerSpiral Enteroscopy System|Subjects who have a medical indication for antegrade enteroscopy
11112215|NCT03990181|Experimental|Meal & natural polyphenol supplement (NPPS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
11112216|NCT03990181|Experimental|Drink & natural polyphenol supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with the natural polyphenol supplement
11112217|NCT03990181|Placebo Comparator|Meal & control supplement (CS)|A meal, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
11112218|NCT03990181|Placebo Comparator|Drink & control supplement|A drink, labelled with stable iron isotope as ferrous sulphate, consumed with a control supplement
11112219|NCT03990168|Experimental|Experimental|Participants will receive one anodal tDCS at 1 mA intensity over the left superior temporal gyrus (T3 in 10-20 international system) and the cathode tDCS over the right orbitofrontal area (Fp2 in 10-20 international system). tDCS will be delivered for 20 minutes during fluency intervention for six consecutive days.
11112220|NCT03990168|Sham Comparator|Sham Comparator|Participants will receive sham tDCS while the one anode electrode will be positioned over the left superior temporal gyrus and the cathode will be placed over the right orbitofrontal similar to the active mode. The sham stimulation will break down after 30 seconds at the beginning of 20 minutes of fluency intervention for six consecutive days.
11112221|NCT03990155|Experimental|HFNCOT+ECCO2R|Patients on NIV+ECCO2R who have reached at least for 4 consecutive hours, a RR <25 bpm + pH >7.35 + absence of clinical signs of respiratory distress after treatment with NIV+ECCO2R
11112222|NCT03990142|Experimental|Group 1: patients without intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
11112223|NCT03990142|Experimental|Group 2: patients with intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
11112224|NCT03990129|Other|Study population|All participants
11112225|NCT03990116|Experimental|Lateral kangaroo|Placing the infant in lateral on the parents chest, keeping the head neutral and limbs flexed towards body midline
11112226|NCT03990116|Active Comparator|Prone Kangaroo|placing the baby in upright and ventral position between mother's breasts or over the father chest, in skin-to skin contact with no clothes in between and with lower limbs flexed
11112227|NCT03990103|Experimental|Experimental arm|S1+Paclitaxel (IV&IP)+Bevacizumab (IP)
11112228|NCT03990103|Active Comparator|Control arm|S1+Oxaliplatin (IV)
11112229|NCT03990090|Experimental|TG103|Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.
11112230|NCT03990090|Placebo Comparator|Placebo|Placebo administered SC once in healthy participants.
11112231|NCT03990077|Experimental|dose escalation of HL-085 plus Docetaxel|"HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).
~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects."
11112232|NCT03990064|Experimental|musicotherapy|daily sessions of music listening during 2 months, associated with their standard treatment,
11112233|NCT03990064|No Intervention|waiting list|waiting list
11112234|NCT03990051|Experimental|Pro-ocular™|Pro-ocular™ 1% topical gel applied dermally to forehead twice daily, morning and before bedtime.
11112235|NCT03990051|Placebo Comparator|Placebo|Vehicle topical gel without active ingredient applied dermally to forehead twice daily, morning and before bedtime.
11112236|NCT03990038|Active Comparator|Group C|"Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter.
~They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery"
11112237|NCT03990038|Active Comparator|Group U|"Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down.
~They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total"
11112238|NCT03990025|Other|Linked Color Imaging - White Light Imaging|Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging
11112239|NCT03990025|Other|White Light Imaging - Linked Color Imaging|Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging
11112240|NCT03990012|Experimental|Patients referred for breast biopsy|Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.
11112241|NCT03989999|Experimental|TCD Group|Transcranial Doppler within 8 hours of traumatic injury
11112242|NCT03989999|No Intervention|CONTROL Group|Mild TBI management with SFMU recommandations
11112243|NCT03989986|Experimental|iPeer2Peer Mentorship|In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
11112244|NCT03989986|No Intervention|Waitlist Control Group|The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.
11112245|NCT03989973||Cirrhosis patients|Patients were diagnosed by liver biopsy, CT or ultrasound
11112246|NCT03989960|Experimental|LISA+SNIPPV group|receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation
11112247|NCT03989960|Active Comparator|InSurE group|receives intubation-surfactant- extubation technique and selects CPAP ventilation
11112248|NCT03989947|Experimental|Active BMN 111|Age-appropriate daily subcutaneous injections of BMN 111 as determined by the 111-206 study
11112249|NCT03989934|Experimental|The Mind in Action|The Mind in Action is a mindfulness intervention developed by the Holistic Life Foundation (HLF), a Baltimore-based non-profit organization. The curriculum will be delivered over approximately 40 sessions and will follow HLF's typical program modifications for high school students (i.e., sustained focus on breath work and meditation). Each program session will include an initial exercise of focusing on the breath to center oneself, followed by the introduction and practice of different breathing techniques (e.g., rhythmic breathing) that enhance calmness and reduce physiological arousal, and concluding with a brief guided meditation. Instructors will describe benefits of the practices for health and stress management. Participants are given assignments between sessions to reinforce lessons (e.g., breathing exercises or periods of meditation).
11112250|NCT03989934|Active Comparator|Healthy Topics|Adapted from the Glencoe Health Curriculum (McGraw Hill), Healthy Topics is designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
11112251|NCT03989921||normo responders|that have an AMH dosage greater than or equal to 1.2 ng/mL
11112252|NCT03989921||poor responders|with a dosage of less than 1.2 ng/mL
11112253|NCT03989908|Experimental|Co-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the same direction in the production of the microfluidic noodle.
11112254|NCT03989908|Experimental|Counter-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the opposite direction in the production of the microfluidic noodle.
11112255|NCT03989908|Placebo Comparator|Mee Sua|Mee Sua is used as a control to compare the outcome due to its similarity in textural properties
11112256|NCT03989895|Experimental|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
11112257|NCT03989882|Experimental|Wheat germ|Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
11112258|NCT03989882|Placebo Comparator|Control|Control energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
11112259|NCT03989869|Experimental|VEMA|Immediate medical abortion treatment
11112260|NCT03989869|No Intervention|Standard of Care|Delayed care until an intrauterine pregnancy has been confirmed with ultrasound.
11112261|NCT03989856|Experimental|Suturing group|"The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
~The running suture starting from central area, around the ovarian hilus to peripheral tissue, will be performed with intraovarian knots to re-approximate the edges to achieve satisfying hemostasis. Knots will not be detectable on the ovarian surface for prevention of adhesion. Mean time for hemostasis of ovary was recorded in a form. The cyst wall will be removed from the abdomen by means of an endobag. All resected cyst walls will be sent to the pathology laboratory, to confirm the histopathology of endometriosis."
11112262|NCT03989856|Active Comparator|Bipolar group|In bipolar coagulation group, after stripping the ovarian cyst wall, bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). In laparoscopic suturing group, no bipolar coagulation will be performed during or after stripping the ovarian cyst wall.
11112263|NCT03989843||Frozen embryo transfer|Frozen embryo transfer
11112264|NCT03989843||Fresh embryo transfer|Fresh embryo transfer
11112265|NCT03989830|Experimental|Second-line chemotherapy combined with Endostar|Second-line chemotherapy+Endostar
11112266|NCT03989817|Active Comparator|VIP|To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.
11112267|NCT03989817|Placebo Comparator|Saline|To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.
11112272|NCT03989778|Experimental|Vitamin D supplement|he intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas
11112273|NCT03989778|No Intervention|Control|control group will receive Metformin treatment during the study period.
11112274|NCT03989765|Experimental|Intervention arm|Municipalities in the intervention arm will, in Stage 1, be part of developing the intervention to reduce the rate of compulsion. In Stage 2 they will implement the intervention through their services.
11112275|NCT03989765|No Intervention|Control municipality|As all outcome measures will be collected from the National Patient Register, there will be treatment as usual.
11112276|NCT03989752|Experimental|Wearable robotic exoskeleton-assisted walking program|Total of 34 training sessions (60 min/session) during 16 weeks (1-3 session/week). Session intensity will be individualized and safely progressed thereafter (standing time, number of steps) to maintain a moderate-to-vigorous intensity (Borg rate of perceived exertion ≥12/20).
11112277|NCT03989739||robotic distal pancreatectomy|
11112278|NCT03989739||laparoscopic distal pancreatectomy|
11112279|NCT03989726|Experimental|High density voltage and fractionation map guided group|"Complex fractionated atrial electrogram (CFAE), voltage and fractionation map will be performed with a multielectrode mapping catheter.
~The mapping should be performed in AF.
~First, low-voltage zone is defined as an area with bipolar peak-to-peak voltage amplitudes < 0.5mV.
~A voltage-map guided segmental PV isolation is performed. Radiofrequency energy is applied in the antral regions of the PVs. High voltage zone over 0.5mV in the antral region is targeted. IF PV isolation in not achieved by voltage-guided segmental ablation, additional Lasso catheter guided segmental antral ablation is performed.
~Radiofrequency energy is delivered at target sites for 15-30 sec guided by contact force, lesion size index (LSI) and local electrogram elimination.
~If the patient is still in AF after PV isolation, additional fractionation map guided ablation is performed. The fractionation area within low voltage area (<0.5mV) should be targeted."
11112280|NCT03989726|Active Comparator|Circumferential PV isolation|A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
11112281|NCT03989713|Experimental|MRD-triggered arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.
~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)
~Consolidation therapy: Patients receive one cycle of HAM and are further allocated based on the MRD-results assessed by flow cytometry with a cut of level of 0.1%: if the MRD is negative they remain in the MRD-triggered arm, whereas MRD positive patients cross over to the prophylactic arm.
~(Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)
~Observation: No treatment will be given in the MRD-triggered arm. (Duration: 48 weeks in total.)
~Safety follow-up and observational follow-up"
11112282|NCT03989713|Experimental|Prophylactic Arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.
~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)
~Consolidation therapy: Patients may receive up to two cycle of Q-HAM. (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)
~Maintenance therapy: Quizartinib will be given as single-agent therapy. The dose of quizartinib is aimed to be increased during maintenance therapy. (Up to 12 cycles. Duration: four times three cycles á 28 days, 48 weeks in total.)
~Safety follow-up and observational follow-up"
11112283|NCT03989700|Experimental|Low dose|Low dose of thiamin supplementation
11112284|NCT03989700|Experimental|High dose|High dose of thiamin supplementation
11112285|NCT03989700|Placebo Comparator|Placebo|placebo supplementation
11112286|NCT03989687|Experimental|glass ionomer sealant|glass ionomer sealant
11112287|NCT03989687|Experimental|isolation|isolation type either rubber dam or cotton roll isolation
11112288|NCT03989674|No Intervention|White bread|
11112289|NCT03989674|Experimental|Anthocyanin-fortified bread (2% w/w)|
11112290|NCT03989674|Experimental|Anthocyanin-fortified bread (4% w/w)|
11112291|NCT03989661||Test group|This group corresponds to patients who had undergone preoperative embolization (with resorbable material) before myomectomy.
11112292|NCT03989661||Control group|This group corresponds to patients with myomectomy without embolization.
11112293|NCT03989648|Active Comparator|Esmarch bandages|
11112294|NCT03989648|Active Comparator|simple leg elevation|
11112295|NCT03989635|Experimental|QAW039|QAW039 450mg
11112296|NCT03989635|Placebo Comparator|Placebo|Placebo to QAW039
11112297|NCT03989622|Experimental|evaluation of the visual field on the ground|evaluation of the visual field on the ground followed by 10 reeducation sessions
11112298|NCT03989622|No Intervention|usual care|control session followed by 10 re-education sessions
11112299|NCT03989609|Experimental|Dexmedetomidine Group|patients will receive dexmedetomidine as sedative
11112300|NCT03989609|Active Comparator|Midazolam|patients will receive midazolam as sedative
11112301|NCT03989596|Experimental|Radiotherapy with hyperthermia|10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)
11112302|NCT03989583||Children's feet temperature|The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
11112303|NCT03989570|Experimental|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
11112304|NCT03989570|Active Comparator|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
11112305|NCT03989570|Placebo Comparator|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
11112306|NCT03989557|Experimental|Monitoring Arm|Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
11112307|NCT03989557|Experimental|Conventional Arm|Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.
11112308|NCT03989544|Experimental|Tezepelumab via Vial-and-syringe|Participants will be randomized to a single dose of tezepelumab via SC administration with Vial-and-syringe
11112309|NCT03989544|Experimental|Tezepelumab via APFS|Participants will be randomized to a single dose of tezepelumab via SC administration with APFS
11112310|NCT03989544|Experimental|Tezepelumab via AI|Participants will be randomized to a single dose of tezepelumab via SC administration with AI
11112311|NCT03989531|Experimental|Adrecizumab on top of standard of care|8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion
11112312|NCT03989531|Placebo Comparator|Placebo on top of standard of care|100 mL saline as single dose infusion
11112313|NCT03989518|Experimental|Simple stimuli|Two perceptually simple stimuli are used during all experimental phases (geometrical figures).
11112314|NCT03989518|Experimental|Complex stimuli|Two complex stimuli are used in all experimental phases. Stimuli consist of photographs of real objects of the same size and shape as the simple stimuli, but include perceptually more complex patterns, details and colors.
11112315|NCT03989505||Cohort|214 consecutive patients undergoing contrast-enhanced diagnostic and/ or therapeutical intervention in the cath lab of the University Heart Center Hamburg
11112316|NCT03989492|Experimental|Autonomic responses to stressors|Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
11112317|NCT03989479|Active Comparator|Conventional Toothbrush|Brushing with conventional Kid's Soft Toothbrush, Colgate (5-9-year-old)
11112318|NCT03989479|Experimental|T-shaped Toothbrush|Brushing with T-shaped toothbrush (Denson™, Malaysia)
11112319|NCT03989466|Experimental|Treatment (itacitinib, alemtuzumab)|"CYCLE 1: Patients receive itacitinib PO QD on days 1-28 and alemtuzumab IV over 2 hours on days 15, 17, 19, 21, 23, 25, and 27 in the absence of disease progression of unacceptable toxicity.
~CYCLE 2 AND BEYOND: Patients receive itacitinib PO QD on day 1-28 and alemtuzumab IV over 2 hours on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients who achieve a response (CR/CRi or PR) may receive itacitinib for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity."
11112320|NCT03989453|Experimental|Chi Kung group|This group receives physical training based on Chi Kung.
11112321|NCT03989453|No Intervention|Control Group|This group does not receive any treatment.
11112322|NCT03989440|Experimental|AXER-204|Part 1 - Single ascending doses; Part 2 - Repeated dose
11112323|NCT03989440|Placebo Comparator|Placebo|Part 2 only - Repeated dose
11112324|NCT03989427|Experimental|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
11112325|NCT03989427|Experimental|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
11112326|NCT03989414|Experimental|CC-92480 in combination with bortezomib and dexamethasone|"Subjects in cohorts A, D and G will receive following:
~Oral CC-92480 at specified cohort dose administered over a 21-day cycle
~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle
~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (>75 years old) administered over a 21-day cycle"
11112327|NCT03989414|Experimental|CC-92480 in combination with daratumumab and dexamethasone|"Subjects in cohorts B and E will receive following:
~Oral CC-92480 at specified cohort dose administered over a 28-day cycle
~Intravenous (IV) daratumumab 16 mg/kg administered over a 28-day cycle
~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
11112328|NCT03989414|Experimental|CC-92480 in combination with carfilzomib and dexamethasone|"Subjects in cohort C and F will receive following:
~Oral CC-92480 at specified cohort dose administered over a 28-day cycle
~Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle
~Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects >75 years old) administered over a 28-day cycle"
11112329|NCT03989401|Experimental|Multimedia video education|The experimental group conducted multimedia video education while admission.
11112330|NCT03989401|No Intervention|None multimedia video education|The control group conducted usual nursing of oral face-to-face education on admission.
11112331|NCT03989388|Experimental|Intervention Group|Occupational Self-Analysis Programme
11112332|NCT03989388|Active Comparator|Control group|Vocational guidance or usual rehabilitation (in the case of ABI participants)
11112333|NCT03989375|Experimental|experiment group|
11112334|NCT03989375|No Intervention|control group|
11112335|NCT03989362|Experimental|LM1|Phase 2 study of vopratelimab by intravenous (IV) infusion administered in combination with ipilimumab by IV infusion in NSCLC
11112336|NCT03989362|Experimental|LT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in NSCLC
11112337|NCT03989362|Experimental|UM1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
11112338|NCT03989362|Experimental|UT1|Phase 2 study of vopratelimab by IV infusion administered in combination with ipilimumab by IV infusion in urothelial cancer
11112339|NCT03989362|Experimental|LM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
11112340|NCT03989362|Experimental|LT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in NSCLC
11112341|NCT03989362|Experimental|UM2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
11112342|NCT03989362|Experimental|UT2|Phase 2 study of vopratelimab by intravenous (IV) infusion in administered in sequence with ipilimumab by IV infusion in urothelial cancer
11112343|NCT03989349|Placebo Comparator|Placebo|Placebo administered via subcutaneous injection
11112344|NCT03989349|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
11112345|NCT03989336|Experimental|Manganese primed Sintilimab plus nPP chemotherapy|Subject received Manganese continuously for 3 cycles, stopped for 2 cycles, then followed with the schedule of 2 weeks of administration then 2 weeks of rest. The combination of Sintilimab, nab-paclitaxel and platinum chemotherapy is given continuously for every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
11112346|NCT03989336|Active Comparator|Sintilimab plus nPP chemotherapy|Subject received Sintilimab, nab-paclitaxel and platinum chemotherapy every 3 weeks until achieving a second assessable complete response or progressive disease, development of unacceptable toxicity, or withdrawal of consent.
11112347|NCT03989323||Patients treated with immunotherapy|Patients receiving for the first time an immunotherapy treatment for their cancer (Checkpoints inhibitors, such as PD-1 or PD-L1 or CTLA4…). Patients will be enrolled before starting the immunotherapy treatment and will be followed up for 5 years or until the permanent discontinuation of the immunotherapy treatment to describe the arm.
11112348|NCT03989310|Experimental|ed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
11112349|NCT03989297||NPC patients|Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
11112350|NCT03989284|Experimental|Peer counseling group|Peer counselors performed 1-hour home visits weekly to their assigned clients for three months.
11112351|NCT03989284|Experimental|Social engagement group|Senior citizens joined 3-hour weekly social events held at the OSCA Center for three months.
11112352|NCT03989284|Experimental|Combination group|Senior citizens in this group underwent both peer counseling and social engagement interventions mentioned above.
11112353|NCT03989284|No Intervention|Control group|Senior citizens in this group had access to usual or standard care from health and aged care services that were usually available.
11112354|NCT03989271|Active Comparator|Quercetin|Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.
11112355|NCT03989271|Placebo Comparator|Placebo|"Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.
~Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months."
11112356|NCT03989258|Active Comparator|Cohort 1|High monogenic breast cancer risk
11112357|NCT03989258|Active Comparator|Cohort 2|High polygenic breast cancer risk
11112358|NCT03989258|No Intervention|Cohort StMG|Standard mammography screening in age 50-69
11112359|NCT03989245||Target arm: UCC (Cognitive Behavioural Unit)|Patients receiving care in Cognitive Behavioural Unit (UCC )
11112360|NCT03989245||Control arm: SSR (Geriatric Follow-up and Rehabilitation Unit)|Patients receiving care in Geriatric Follow-up and Rehabilitation Care Unit (SSR)
11112361|NCT03989232|Experimental|Semaglutide 2.0 mg|All participants will receive one injection per week during a 12-week dose escalation period, until the target dose for semaglutide 2.0 mg is reached. From week 13 to week 40, semaglutide will be given in two weekly injections of 1.0 mg each.
11112362|NCT03989232|Active Comparator|Semaglutide 1.0 mg|All participants will receive one injection per week during a 12-week dose escalation period. From week 13 to week 40, the 1.0 mg group will receive an additional injection of semaglutide placebo in order to maintain the blinding.
11112363|NCT03989219|Experimental|lung nodules were found by CT scanning|Plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
11112364|NCT03989206|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
11112365|NCT03989193|Experimental|Computer guided alveolar ridge splitting technique|Computer guided alveolar ridge splitting using piezo electric device and a 3D printed surgical guide. An L shaped splitting pattern with one crestal and one distal cut will be performed.
11112366|NCT03989167|Experimental|Intervention group|Group receiving the Clinical decision support
11112367|NCT03989167|No Intervention|Control group|
11112368|NCT03989141|Experimental|Repeated cannulation Buttonhole|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
11112369|NCT03989141|Active Comparator|Single cannulation Buttonhole|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
11112370|NCT03989128||Observational (survey)|Participants complete a survey over 5-10 minutes
11112371|NCT03989115|Experimental|RMC-4630 and Cobimetinib|RMC-4630 and Cobimetinib for oral administration
11112372|NCT03989115|Experimental|RMC-4630 and Osimertinib|RMC-4630 and Osimertinib for oral administration
11112373|NCT03989102|Experimental|Arm 1|Arm 1: (n= 100) will receive 3 doses of PfSPZ Vaccine (9 x10(5)) via direct venous inoculation (DVI) at 1, 8, 29 days.
11112374|NCT03989102|Experimental|Arm 2|Arm 2: (n= 100) will receive 3 doses of PfSPZ Vaccine (1.8 x10(6)) via DVI at 1, 8, 29 days.
11112375|NCT03989102|Placebo Comparator|Arm 3|Arm 3: (n=100): will receive 3 doses of normal saline (placebo) injection via DVI at 1, 8, 29 days.
11112376|NCT03989089|Experimental|Pembrolizumab single agent|Pembrolizumab 200 mg will be given intravenously every 3 weeks , on Day 1 on each 3 week cycle. Pembrolizumab can be given up to 35 adminstration (2 years).
11112377|NCT03989063|Experimental|Amputees (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
11112378|NCT03989063|Active Comparator|Amputees (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
11112379|NCT03989063|Experimental|Diabetes (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
11112380|NCT03989063|Active Comparator|Diabetes (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
11112381|NCT03989063|Active Comparator|Non-diabetic controls (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. This group serves the purpose to investigate how the presence of diabetes interacts with attentional focus to affect motor learning. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
11112382|NCT03989063|Active Comparator|Non-diabetic controls (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. This group serves the purpose to investigate how the presence of diabetes interacts with attentional focus to affect motor learning. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
11112383|NCT03989050||Melanoma patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for melanoma
11112384|NCT03989050||Non-small cell lung cancer (NSCLC) patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for NSCLC
11112385|NCT03989050||other malignancy patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for other malignancy
11112386|NCT03989037|Experimental|SIBP-01 & Docetaxel & Carboplatin|SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
11112387|NCT03989037|Active Comparator|Herceptin & Docetaxel & Carboplatin|Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
11112388|NCT03989024|Experimental|Pulsatile Gonadotropin-releasing Hormone|Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
11112389|NCT03989024|Experimental|Clomiphene|Use Clomiphene for 3 months to treat PCOS
11112390|NCT03988998|Experimental|Radiofrequency ablation with radiotherapy|Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.
11112391|NCT03988998|Active Comparator|Radiofrequency ablation alone|Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.
11112392|NCT03988985|Experimental|PATIENT-GP-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
11112393|NCT03988985|Active Comparator|GP-FEEDBACK|Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
11112394|NCT03988985|No Intervention|NO-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.
11112395|NCT03988972|Experimental|diathermy group|"Diathermy incisions will be carried out using monopolar blade pen electrode, set on cutting mode and delivering a 35 continuous current. Electrosurgical cutting was performed without pressure or mechanical displacement.
~'Bleeders' will be controlled by using diathermy, on coagulating mode, and will be applied to a hemostat on the vessels"
11112396|NCT03988972|Active Comparator|scalpel group|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
11112397|NCT03988959|Other|Control|Standard resection
11112398|NCT03988946|Experimental|Transcatheter Mitral Valve Replacement|Replacement valve delivered through a transfemoral access and transseptal approach
11112399|NCT03988933|Experimental|Intervention Arm 1|Two months of daily self-administered rifampin at 20 mg/kg (maximum 1200 mg/day).
11112400|NCT03988933|Experimental|Intervention Arm 2|Two months of daily self-administered rifampin at 30 mg/Kg (maximum 1800 mg/day).
11112401|NCT03988933|Active Comparator|Control Arm|Four months of daily self-administered rifampin at a dose of 10mg per kg per day (maximum 600mg per day).
11112402|NCT03988920|Experimental|Tenapanor w/Sevelamer|Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
11112403|NCT03988920|Experimental|Sevelamer w/Tenapanor|Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed
11112404|NCT03988907|Experimental|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
11112405|NCT03988907|Experimental|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
11112406|NCT03988894|No Intervention|Control: Usual Care|All participants will (a) receive a general hypertension health education booklet from the Heart and Stroke Foundation of Ontario;(b) be encouraged to see their family physicians or primary health care providers regarding their blood pressure status; those who do not have a primary health care provider will be referred to a walk-in clinic or a community health centre; and (c) have access to family physicians, tele-health, emergency care, hospital and other health care facilities in the Greater Toronto Area as required.
11112407|NCT03988894|Active Comparator|Intervention: mDASHNa-CC app use|In addition to usual care, those participants randomized to the intervention group will be offered use of the app.Then, they will load the app in their smartphones and be requested to review educational contents, conduct dietary self-assessment, and monitor blood pressure for 8 weeks.By the end of eight weeks post randomization, seniors will be prompted by phone using an audible alert to complete the app Evaluation Questionnaire on the smartphone, which ascertains likes and dislikes with the app.
11112408|NCT03988881||1 PCI Group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with positive dobutamine stress echocardiography and positive Fractional Flow Reserve recieving revascularization (PCI or CABG) Drug: Standard of care after acute myocardial infarction
11112409|NCT03988881||Group 2 OMT group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with negative dobutamine stress echocardiography and negative Fractional Flow Reserve or the mismatching cases Standard of care after acute myocardial infarction
11112410|NCT03988855|Experimental|Part 1|10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days.
11112411|NCT03988855|Experimental|Part 2|30 subjects with severe CDI will be enrolled and randomized in a 2:1 ratio to receive DNV3837 or standard of care. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days
11112412|NCT03988842|Experimental|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
11112413|NCT03988842|Active Comparator|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
11112414|NCT03988829|Active Comparator|Low-C|In an experimenter-designed simulation game, participants will be trained on predictable low attentional control shifts during working memory.
11112415|NCT03988829|Experimental|High-C|In an experimenter-designed simulation game, participants will be trained on unpredictable high attentional control shifts during working memory.
11112416|NCT03988829|Experimental|High-C+|In this commercially-available video game, in addition to unpredictable shifts of attentional control in working memory, task switching and resource planning will be trained.
11112417|NCT03988816|Experimental|Roflumilast|Roflumilast tablets will be supplied at a concentration of 500 mcg. Each tablet contains 500mcg of the active ingredient in addition to the excipients: lactose monohydrate, corn starch, povidone and magnesium stearate. The coating contains hypromellose, macrogol, titanium dioxide, yellow iron oxide. Patients should take 1 tablet once daily, before, during or after meals, at the same time each day.
11112418|NCT03988816|Placebo Comparator|Placebo (control)|Roflumilast placebo-containing tablets will look similar to active roflumilast tablets and will be supplied to patients in packs identical to those of the active drug.
11112419|NCT03988803|Experimental|All subjects|
11112420|NCT03988790|Experimental|VOC analysis|VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
11112421|NCT03988777||Prospective Magseed|This cohort includes patients with an impalpable breast lesion that are scheduled for breast conserving surgery with Magseed localisation after September 2018. Their data will be prospectively collected and analysed.
11112422|NCT03988777||Retrospective hooked-wire|This cohort includes patients with an impalpable breast lesion that were scheduled for breast conserving surgery with hooked-wire before September 2018. Their data will be retrospectively collected and analysed.
11112423|NCT03988764||Antibody-negative|"Patient has been found negative for at least three T1D antibodies.
~The investigators will proceed with whole exome sequencing"
11112424|NCT03988764||Antibody-positive|"Patient has been found to be positive for at least one T1D autoantibody.
~No further studies will be performed as part of the main study."
11112425|NCT03988751|Active Comparator|Continuous Ambulation|The total distance will be 40 meters. Study team members will walk, support, and coach the subject to walk as slow as he/she wants
11112426|NCT03988751|Active Comparator|Interval Ambulation|The subject will walk a total distance of 40 meters. This distance will be divided into four intervals of 10 meters to equal the same measured distance as the continuous group. The subject will receive two minutes of rest between each interval and will be supported and coached to walk as fast as they can.
11112505|NCT03988244|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
11112427|NCT03988738|Experimental|Intervention|Participants will receive messages regarding blood donation promotion and campaigns through social media once or twice a week for six months.
11112428|NCT03988738|Sham Comparator|Control|Participants will receive a message regarding blood donation at the beginning of the study through social media. After four months they will receive another message including information about upcoming blood donation campaigns.
11112429|NCT03988725|Experimental|Vitamin E intervention|All study participants receive Vitamin E 800 IU once daily for 6 months
11112430|NCT03988712||Iron deficiency anaemia with bowel symptoms|Patients with IDA presenting with bowel symptoms like change in bowel habits, weight loss and abdominal mass other than rectal bleed
11112431|NCT03988712||Iron deficiency anaemia with no bowel symptoms|Patients with IDA with no bowel symptoms
11112432|NCT03988712||Iron deficiency anaemia with rectal bleeding|Patients with IDA and rectal bleeding
11112433|NCT03988699|Experimental|Subject with severe tinnitus|Subjects diagnosed with severe tinnitus for at least six months, and it has not responded to conventional management will have surgical implantation of the device Tinnitus Implant System.
11112434|NCT03988686|Experimental|Intervention Group|Radical prostatectomy plus standard care
11112435|NCT03988686|Active Comparator|Comparator Group|Standard care, currently ADT +/- other systemic therapies.
11112436|NCT03988673|No Intervention|decision aid with information only (control)|decision aid with information only, without values clarification method (VCM)
11112437|NCT03988673|Active Comparator|decision aid with implicit VCM|decision aid with information plus an implicit VCM
11112438|NCT03988673|Active Comparator|decision aid with explicit VCM|decision aid with information plus an explicit VCM
11112439|NCT03988660||Healthy controls|Healthy individuals
11112440|NCT03988660||Histologically confirmed appendicitis|Patients who have diagnosis of appendicitis on histology
11112441|NCT03988660||Histologically normal appendix|Patients who have diagnosis of a normal appendix on histology
11112442|NCT03988660||Alternative diagnosis group|Patients who diagnosed with a condition other than appendicitis
11112443|NCT03988647|Experimental|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
11112444|NCT03988634|Experimental|sacubitril/valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.
~Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by patient's previous dose of ACEi/ARB immediately prior to hospital admission for acute decompensated heart failure. Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).
~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril/valsartan and one tablet of valsartan matching placebo pack)."
11112445|NCT03988634|Active Comparator|valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.
~Initial dose at randomization will be based on patient's previous dose of or lack of ACEi/ARB immediately prior to current hospital admission for ADHF, or at the time of out-of-hospital randomization.
~Study treatment will be titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).
~Patients will be required to take a total of two tablets twice daily (one tablet of active valsartan and one tablet of sacubitril/valsartan (LCZ696) matching placebo pack)."
11112446|NCT03988621|Experimental|Intervention|Caregivers randomized to the intervention ViCCY will receive 10 front-loaded sessions of virtual health coaching by trained registered nurses over 6 months with content based on the theoretical framework (based on the Transactional Model of Stress and Coping) and prior research. Sessions are provided using tablets. Initially, sessions are weekly but the frequency decreases over time as needed. We help caregivers gain the knowledge and skills needed to achieve self-identified health goals through self-care using motivational interviewing. We focus on identifying personal values, solving problems, and transforming goals into action. ViCCY is standardized in a treatment manual. Because stress does not affect all people equally, the intervention is tailored to individual appraisals and the factors most likely to influence demand and perceived burden.
11112447|NCT03988621|No Intervention|Health Information|The Health Information (HI) group will receive health resource information delivered through the internet.
11112448|NCT03988608|Experimental|Eltrombopag|Subjects will start eltrombopag treatment at 25 mg/day since Day 1.
11112449|NCT03988595|Experimental|aerobic training 90 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
11112450|NCT03988595|Experimental|aerobic training 150 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
11112451|NCT03988595|Experimental|aerobic training 225 mins/wk|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
11112506|NCT03988231|Active Comparator|Enoxaparin 40mg once daily|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
11112452|NCT03988595|Experimental|aerobic training 300 mins/week|Exercise sessions will consist of individualized, walking delivered following a non-linear(i.e., exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
11112453|NCT03988582|Experimental|HCT (hematopoietic cell transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
11112454|NCT03988582|Experimental|SOT (solid organ transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
11112455|NCT03988582|Experimental|Other immune competent or immune compromised patients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
11112456|NCT03988569|Experimental|Intervention Group|Will view audiovisual decision aid (AVDA) and then have opportunity for questions with physician before signing consent forms
11112457|NCT03988569|No Intervention|Control Group|Will undergo standard verbal informed consent with physician before signing consent forms
11112458|NCT03988556|Experimental|Cohort A1 - Head & neck cancer - Prophylactic intent|"Patients with head & neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent).
~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.
~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis.
~."
11112459|NCT03988556|Experimental|Cohort A2 - Head & neck cancer - Curative intent|"Patients with head & neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent).
~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).
~The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions."
11112460|NCT03988556|Experimental|Cohort B1 - Breast cancer - Prophylactic intent|"Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent).
~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.
~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis."
11112461|NCT03988556|Experimental|Cohort B2 - Breast cancer - Curative intent|"Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent).
~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).
~The device will be used on each lesion. All existing lesions will be treated."
11112462|NCT03988543|No Intervention|Usual Care|Patients will receive current standard care of EHR-integrated symptom monitoring.
11112463|NCT03988543|Experimental|Enhanced Care|Patient will receive current standard care of EHR-integrated symptom monitoring, plus patient self-management intervention.
11112464|NCT03988530|Active Comparator|DPI-386 Nasal Gel|DPI-386 Nasal Gel (0.2 mg / 0.12 g)
11112465|NCT03988530|Placebo Comparator|Placebo Nasal Gel|placebo nasal gel (0.12 g)
11112466|NCT03988517|Active Comparator|levothyroxine at Iftar|Patients took levothyroxine 30 minutes before breaking the fast at sunset (iftar)
11112467|NCT03988517|Active Comparator|Levothyroxine at Suhour|Patients took levothyroxine 30 minutes before an early morning meal before sunrise (suhour)
11112468|NCT03988491||End stage renal disease on maintanance hemodialysis|End-stage renal disease due to any etiology on maintenance hemodialysis and consented to participate in the study.
11112469|NCT03988478|Experimental|Behavioral, detoxificaiton & psychotherapy|Providing treatment as usual (detoxificaion) & psychotherapy
11112470|NCT03988465||Cardiac Surgery Patients|Patients undergoing cardiopulmonary bypass surgery, including placement of a ventricular access device.
11112471|NCT03988452|Active Comparator|Darunavir/r Zidovudine Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
11112472|NCT03988452|Experimental|Darunavir/r Tenofovir Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
11112473|NCT03988452|Experimental|Dolutegravir Zidovudine Lamivudine|Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
11112474|NCT03988452|Experimental|Dolutegravir Tenofovir Lamivudine|Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
11112475|NCT03988439|Experimental|IDP-118 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 4 to 11 years 11 months) will apply IDP-118 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
11112476|NCT03988426|Experimental|Octanorm|Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center [during first training sessions and then for every 4th administration] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
11112477|NCT03988413|Experimental|25mg|Tablets, Oral, 25mg, single dose
11112478|NCT03988413|Experimental|50mg|Tablets, Oral, 50mg, single dose
11112479|NCT03988413|Experimental|100mg|Tablets, Oral, 100mg, single dose
11112480|NCT03988413|Experimental|200mg|Tablets, Oral, 200mg, single dose
11112481|NCT03988413|Experimental|400mg|Tablets, Oral, 400mg, single dose
11112482|NCT03988413|Experimental|800mg|Tablets, Oral, 800mg, single dose
11112483|NCT03988400|Experimental|Sensory augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
11112484|NCT03988400|Active Comparator|Random vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
11112485|NCT03988387|Experimental|Peer Support PS)|Participants randomized to the PS arm will be assigned a trained peer supporter (PSr) to enhance adherence to PrEP.
11112486|NCT03988387|Experimental|Reminders and Resource Transfer (RRT)|Participants randomized to the RRT arm will receive weekly SMS text messages and resource transfers to enhance adherence to PrEP.
11112487|NCT03988374|Active Comparator|0% Baking Soda Dentifrice|
11112488|NCT03988374|Active Comparator|20% Baking Soda Dentifrice|
11112489|NCT03988374|Active Comparator|35% Baking Soda Dentifrice|
11112490|NCT03988361||Control group|Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
11112491|NCT03988361||Study group|"Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS.
~The sperm used in this group is considered to be enriched in non apoptotic cells."
11112492|NCT03988348|Experimental|study group|infraumbilical transverse incision will be done
11112493|NCT03988348|Active Comparator|control group|Direct intraumbilical transverse incision will be done
11112494|NCT03988335|Experimental|RIST4721|RIST4721 as once-daily 300mg oral solution for 28 days.
11112495|NCT03988335|Placebo Comparator|Placebo|Placebo as once-daily 300mg oral solution for 28 days.
11112496|NCT03988322|Experimental|Quantitative assessment of imaging biomarkers|This is the intervention arm. In this arm, the participants will be scanned with low-dose CT with pre-defined scanning parameters for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the volume of the nodule. The quantitative assessment of imaging biomarkers of lung cancer, COPD and cardiovascular disease will be recorded.
11112497|NCT03988322|Active Comparator|Visual assessment of imaging biomarkers|This is the control arm. In this arm, the participants will be scanned with low-dose CT with routine scanning parameters used for lung cancer screening in the hospital for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the diameter of the nodule. The imaging biomarkers related to lung cancer, COPD and cardiovascular disease will be visually assessed.
11112498|NCT03988309|Active Comparator|"Test, subjects categorised as low risk or Not low risk"|"A clinical risk factor nomogram risk classification will be used in this study. The nomogram categorizes subjects as either low risk or not low risk categories. Low risk subjects satisfy all conditions and not low risk satisfies at least one of the conditions.The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Subjects categorised as not low risk will be evaluated as per standard of care. Note that Cxbladder test results will be available for eventual analysis for these subjects."
11112499|NCT03988309|No Intervention|Control|Subjects on the control arm will be on standard of care. Trial nomogram clinical risk factor categorization for control arm subjects will not be provided to the physician (but appropriate information will be collected on the CRF to enable sub-group analysis) No Cxbladder test results will be provided for control arm subjects. Note that Cxbladder test results will be available for eventual analysis for these subjects.
11112500|NCT03988283|Experimental|Personalized neoantigen DNA vaccine|Patients will receive the vaccine on a 28-day cycle. It will be given weekly (+/- 3 days) during Cycle 1 (i.e., C1D1, C1D8, C1D15, C1D22) as a priming phase followed by booster injections on Day 1 (+/- 7 days) of each subsequent cycle (i.e., C2D1, C3D1, etc.). Vaccine administration will continue indefinitely until development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression.
11112501|NCT03988270|Experimental|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
11112502|NCT03988270|No Intervention|Control|Participants in the control group will not receive any pre-surgical instructions for exercise in the access arm
11112503|NCT03988257|Experimental|Experimental group|Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day.
11112504|NCT03988257|Placebo Comparator|Control group|A vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight.
11112507|NCT03988231|Placebo Comparator|Placebo|All patients will have enoxaparin prophylaxis or placebo initiated at 8 hours after surgery. Prophylaxis or placebo will be provided every 24 hours and will be continued for the duration of inpatient stay.
11112508|NCT03988218|Experimental|Anorexia|Subjects with anorexia nervosa
11112509|NCT03988218|Active Comparator|Control|Subjects without eating disorders
11112510|NCT03988205|Experimental|Intervention|The study intervention is the application of a prescribed outpatient care model including a nurse teacher educational program and quality of life surveys for both subjects and caregivers. Induction therapy and medical follow up are performed without prophylactic admission to an inpatient facility. Subjects will also receive CPX-351 according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
11112511|NCT03988192|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.
11112512|NCT03988166|Other|Chronic Total Occlusion Percutaneous Coronary Intervention|CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
11112513|NCT03988153|Experimental|Probiotic Milk Formula (PMF)|Twenty subjects should drink 200 mL of PMF (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
11112514|NCT03988153|Placebo Comparator|Skimmed Milk Formula|Twenty subjects should drink 200 mL of skimmed milk drink (30 gm mixed with 200 mL of water) before breakfast and dinner (2 times/day) for 10 weeks
11112515|NCT03988140|Experimental|Implant placed at supra crestal level (SL)|Implants were placed at supra crestal level (SL)
11112516|NCT03988140|Other|Implant placed at crestal level (CL).|Implants were placed at crestal level (CL)
11112517|NCT03988114|Experimental|Abemaciclib + NSAI|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.
11112518|NCT03988101|Experimental|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
11112519|NCT03988101|Placebo Comparator|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
11112520|NCT03988088|Experimental|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
11112521|NCT03988075|Active Comparator|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
11112522|NCT03988075|Experimental|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
11112523|NCT03988062|Experimental|TrelliX Embolic Coil System|
11112524|NCT03988049|Active Comparator|Right Side 1,550 laser Left Side 755 laser|All subjects on this arm will be treated on this split-faced. The Right side of their face will be treated with the 1,550-nanometer Fracionated Photothermolysis laser, and the left side of their face will be treated with the 755-nanometer alexandrite picosecond laser.
11112525|NCT03988049|Active Comparator|Left Side 1,550 laser Right Side 755 laser|All subjects on this arm will be treated on this split-faced. The left side of their face will be treated with the 1,550-nanometer Fracionated Photothermolysis laser, and the right side of their face will be treated with the 755-nanometer alexandrite picosecond laser.
11112526|NCT03988036|Experimental|HER2-enriched|"Trial treatment is defined as neoadjuvant therapy only. The Investigational Medicinal Products (IMPs) are pembrolizumab, trastuzumab biosimilar and pertuzumab.
~Trastuzumab Biosimilar (Trazimera®) - Investigational Medicinal Product
~Loading dose: 8 mg/kg bodyweight at initial administration infusion over 90 min; monitor patient for at least 6 h afterwards.
~Maintenance dose: 6 mg/kg bodyweight, over 30-90 min; monitor patient for 2 h afterwards.
~Route: Intravenous infusion.
~Schedule: Every 3 weeks during the neoadjuvant phase.
~Pertuzumab (Perjeta®) - Investigational Medicinal Product
~Loading dose: 840 mg, initial administration.
~Maintenance dose: 420 mg.
~Route: Intravenous infusion.
~Schedule: Every 3 weeks during the neoadjuvant phase.
~Pembrolizumab (Keytruda®) - Investigational Medicinal Product
~Dose: 200 mg.
~Route: Intravenous infusion.
~Schedule: Every 3 weeks during the neoadjuvant phase."
11112527|NCT03988023|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
11112528|NCT03988023|Placebo Comparator|Saline|Saline solution, 4 mL, single intra-articular injection
11112529|NCT03988010|Experimental|Amantadine Sulphate|200 mg ıv Amantadine Sulphate in 500 cc solution
11112530|NCT03988010|Placebo Comparator|Placebo group|iv 500 cc %0.9 sodium chloride
11112531|NCT03987997|Active Comparator|Association electrical muscle stimulation with cyclo-ergometer|Randomized leg with receive electrical muscle stimulation of the quadriceps in addition to early mobilization of lower limbs with cyclo-ergometer.
11112532|NCT03987997|Other|Cyclo-ergometer only|This control group correspond to the leg which don't receive electrical muscle stimulation (as usually supported)
11112533|NCT03987971|Experimental|Deep acupuncture on GB26|
11112534|NCT03987971|Sham Comparator|Superficial acupuncture on GB26|
11112535|NCT03987971|No Intervention|waiting list|
11112536|NCT03987958||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for AML.
~The decision to treat with venetoclax has been made independently from this observational study before participants are offered the opportunity to participate in this study."
11112537|NCT03987945||Left atrial appendage occlusion|Patients with non-valvular atrial fibrillation who have received left atrial appendage occlusion procedure.
11112538|NCT03987932|Experimental|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
11112539|NCT03987932|Experimental|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
11112540|NCT03987932|Other|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
11112541|NCT03987919|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11112542|NCT03987919|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11112543|NCT03987919|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11112544|NCT03987919|Active Comparator|Semaglutide|Semaglutide administered SC once a week.
11112545|NCT03987906|Experimental|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
11112546|NCT03987906|No Intervention|Standard Oncology Care|The control arm receives standard oncology care, which includes routine symptom screening at every outpatient visit.
11112547|NCT03987893|Experimental|PEG+Lactulose|this arm will recieve PEG3350 in addition to standard of care
11112548|NCT03987893|Active Comparator|Lactulose alone|this arm will recieve only standard of care for management of hepatic encephlaopathy with ACLF
11112549|NCT03987880|Active Comparator|4.0 mm zone|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
11112550|NCT03987880|Experimental|3.5 mm zone|PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
11112551|NCT03987867|Experimental|Arm: CIK+PD-1 inhibitor+chemotherapy|"CIK cell, IBI308, Pemetrexed, Liposome paclitaxel, Carboplatin
~IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Liposome paclitaxel intravenous infusion 135mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
11112552|NCT03987854|Experimental|complete diet and lifestyle program|
11112553|NCT03987841|Experimental|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. Single-arm study, a group of participants meeting eligibility requirements will be invited to participate.
11112554|NCT03987815|Experimental|Study Arm|Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
11112555|NCT03987802||Fiasp®|Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.
11112556|NCT03987789|Active Comparator|Low PEEP group|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
11112557|NCT03987789|Experimental|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers
11112558|NCT03987776|Experimental|Anti-inflammatory diet|energy-reduced diet with the use of low glycemic foods, wholegrain products, legumes, colorful vegetables and fruit, nuts, seeds, marine fish, olive oil, green/black tea, and multiple spices and herbs
11112559|NCT03987776|Experimental|Control energy-resticted diet|isocaloric to anti-inflammatory diet, energy restricted diet (55-60% carbohydrates, 25% fat, 15-20% protein) used in a standard obesity management
11112560|NCT03987763|Experimental|IDP-122 Lotion|Two cohorts of pediatric participants (1 cohort of participants age 12 to 16 years 11 months and 1 cohort of participants age 6 to 11 years 11 months) will apply IDP-122 Lotion to Investigator identified lesions affecting a minimum of 10% body surface area (BSA) once daily for 8 weeks.
11112561|NCT03987750|Experimental|Safinamide 100mg|Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
11112562|NCT03987750|Experimental|Safinamide 150mg|Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
11112563|NCT03987750|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
11112564|NCT03987737|Experimental|small catheter|In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ.
11112565|NCT03987737|No Intervention|control group|In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet without small catheter in situ.
11112566|NCT03987724|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
11112567|NCT03987711|Experimental|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
11112568|NCT03987711|Active Comparator|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
11112569|NCT03987711|Active Comparator|No oral anticoagulation|Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.
11112570|NCT03987698|Experimental|Arm 1: CIK+PD-1i|"SHR-1210 & CIK cells
~SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
11112571|NCT03987698|Active Comparator|Arm 2: Control|SHR-1210,200mg/d,intravenous infusion,d1; Q3W.
11112572|NCT03987685|Experimental|Oratopo|To determine the Maximum Tolerated Dose (MTD) of oral topotecan with HM30181A administered once daily for 5 consecutive days every 21 days.
11112632|NCT03987230|Placebo Comparator|Sensitive Eyes® Plus Saline Solution|Participant cleans eyelids with Sensitive Eyes® Plus Saline Solution
11112573|NCT03987672|Other|Assess Nutritional Effects of Nutritional Formula|Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.
11112574|NCT03987659|Active Comparator|Root Canal Treatment without dECMs release|Two visit non-surgical root canal therapy with conventional irrigation protocols
11112575|NCT03987659|Experimental|Root Canal Treatment with dECMs release|Two visit non-surgical root canal treatment with irrigation protocols that optimise release of soluble dentine extracellular matrix components (dEMCs)
11112576|NCT03987646|Experimental|xenograft cortical flexible sheet|a-traumatic tooth removal , socket lavage and curettage, performing a vestibular access horizontal incision corresponding to the socket 3-4 mm apically from the muccogingival junction , a tunnel is then created from the socket office and extended apically till it connects with the vestibular access incision, a computer guided surgical template is then used to deliver the implant in its optimal position, a slowly resorbable membrane shield is then introduced through the tunnel and stabilized with a membrane tac , it is a sturdy fixable membrane barrier placed above the labial plate
11112577|NCT03987633||Displaying trait of interest|There are 19 disease areas under investigation. Enrolled patients are segmented into cohorts based on data collected through questionnaires and medical histories. This data-driven approach does not allow for precisely predefined cohorts for the diseases under investigation. Therefore, as a default, the two general predefined cohorts are set as either displaying or not displaying a trait that would form the basis of an investigation.
11112578|NCT03987633||Not displaying trait of interest|Please see above.
11112579|NCT03987620|Experimental|Ibrexafungerp (SCY-078)|300 mg BID for one day
11112580|NCT03987620|Placebo Comparator|Placebo|Matching Placebo
11112581|NCT03987607||Patients scheduled for elective surgery|Patients scheduled for elective surgery requiring neuromuscular blockade
11112582|NCT03987594|Placebo Comparator|TUF|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
11112583|NCT03987594|Experimental|TUF+HD|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
11112584|NCT03987581|Experimental|CBT + mCM + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.
11112585|NCT03987581|Experimental|CBT + mCM + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.
11112586|NCT03987581|Experimental|CBT alone + incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
11112587|NCT03987581|Active Comparator|CBT alone + no incentive|Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.
11112588|NCT03987568|Experimental|Diagnostic (MRI biospecimen collection)|Patients undergo MRI over 15 minutes before standard of care surgery. Patients also undergo collection of blood samples during MRI and at the time of surgery.
11112589|NCT03987542||Exposed|Patients who had their asparaginase treatment truncated or had no asparaginase enzyme activity.
11112590|NCT03987542||Unexposed|Patients who did not have their asparaginase treatment truncated and had measurable asparaginase enzyme activity
11112591|NCT03987529||Sevoflurane+Remifentanil|Using inhalent agent(Sevoflurane), continuous infusion of Remifentanil
11112592|NCT03987529||Propofol+Remifentanil|Using continuous infusion of Propofol and Remifentanil
11112593|NCT03987516|Experimental|Active intervention|Patients will be included in an active intervention.
11112594|NCT03987516|No Intervention|Control group|Patients in the control group will not receive any intervention
11112595|NCT03987503|Experimental|at Point-of-Diagnosis HCV treatment|At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
11112596|NCT03987503|Active Comparator|Passive observation|Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
11112597|NCT03987490|Experimental|Parents of Girls|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
11112598|NCT03987490|Experimental|Parents of Boys|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
11112599|NCT03987477|Experimental|Experimental group|The experimental group will be exposed to a brief online program aimed at the modification of negative emotional cognitive biases. The program consists of an introduction and four 1-hour sessions, in video format. In each session, participants are required to complete some open questions and scales about the type of cognitive bias addressed in each session. All sessions are structured in four parts: 1) description and examples of some specific cognitive biases; 2) information about negative consequences of each bias; 3) explanation of adaptive strategies to modify cognitive biases (i.e., the four-questions approach used in standard Cognitive behavioral therapy); and 4) use of some practices to familiarize participants with the use of those strategies.
11112600|NCT03987477|Other|Waiting list group|The control group will be composed of individuals waiting for the treatment. Participants will not be exposed to the experimental program or any other between the pre-evaluation and the post-evaluation sessions. Participants in this group will have access to the potential benefits of the intervention after the post-evaluation of both groups.
11112601|NCT03987464|Experimental|Patients with MCI|Participants diagnosed with mild cognitive impairment (MCI) and their study partners
11112602|NCT03987451|Experimental|Semaglutide|Dose escalation to 2.4 mg of semaglutide once-weekly
11112603|NCT03987451|Placebo Comparator|Placebo|Semaglutide placebo once-weekly
11112706|NCT03986684||NAFLD|
11112604|NCT03987438|Experimental|Behavioral intervention|Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
11112605|NCT03987438|No Intervention|Control group|Participants randomized to the control group have regular care in their local hospitals. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
11112606|NCT03987425|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
11112607|NCT03987425|No Intervention|Conservative measures|Group of patients who will receive conservative treatment based on hygienic-dietetic measures
11112608|NCT03987412|Experimental|Behavioral intervention|Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
11112609|NCT03987412|No Intervention|Control group|Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
11112610|NCT03987399|Experimental|Tailored educational intervention|The intervention will be based on previous research and results from baseline (T1). The intervention will be a one-day educational day and includes lectures and workshops with main focus on the lowest competence in pediatric postoperative pain management. Healthcare providers at the included surgical wards will be invited to participate on this educational day. As a supplement, there will be provided clinical supervision in pediatric postoperative pain management and reminders (such as lectures and posters) over a period of six months after educational day.
11112611|NCT03987386|Active Comparator|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy daily over 6.5 weeks after standard of care surgery.
11112612|NCT03987386|Experimental|Arm II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy over 4.5 weeks after standard of care surgery.
11112613|NCT03987334|Experimental|Experimental Group (VRT)|Subjects in the experimental group (VRT) will undergo 30 minutes of motor control exercises using a virtual reality-based sensorimotor rehabilitation provided using the Virtual Reality Rehabilitation System (VRRS) of Khymeia Group. The equipment includes a computer workstation connected to a 6 degrees of freedom (DOF) motion-tracking system (Polhemus G4, Vermont, US), a high-resolution LCD displaying the virtual scenarios on a large screen and a software processing the motion data coming: from the receiver of the sensors end-effectors placed on the sternum and on the head through a helmet. The system has been found to reliably record head position and cervical range of motion among asymptomatic people as well as persistent neck pain patients. The VRRS allows the participant to perform the requested motor tasks, while the movement of the system's end-effector is simultaneously represented in a virtual scenario.
11112614|NCT03987334|Active Comparator|Control Group (CT)|Control group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
11112615|NCT03987321|Experimental|Denali Group|Those who received Denali filter placement
11112616|NCT03987321|Experimental|Celect Group|Those who received Celect filter placement
11112617|NCT03987308|Experimental|Beinaglutide|Five-week Beinaglutide pump treatment group
11112618|NCT03987308|Experimental|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
11112619|NCT03987295|Experimental|AL001|AL001 every 4 weeks for up to 96-weeks
11112620|NCT03987282|Active Comparator|Enhanced usual care (EUC)|The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
11112621|NCT03987282|Experimental|Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model|The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
11112622|NCT03987269|Active Comparator|Intervention, Virtual Reality Group|The intervention group to experience the virtual reality embodied narrative experience.
11112623|NCT03987269|Placebo Comparator|Control, Narrative Video Group|The control group to watch the same narrative video content that has been formatted for standard television
11112624|NCT03987256|Experimental|ECRB needling with adjuvant PRP infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy
~Second step: one single tendon needling with PRP"
11112625|NCT03987256|Active Comparator|ECRB needling with adjuvant NaCl 0.9% infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy
~Second step: one single tendon needling with Saline solution"
11112626|NCT03987243|Other|Intervention|Two interventions will be provided. The first intervention is a structured education regarding pressure ulcer prevention through weight shifts at start of study. The second intervention is the use of a mobile seat interface pressure map (IPM), which will occur during two intervention phases.
11112627|NCT03987230|Active Comparator|Oust™ Demodex® Wipes™|Participant cleans eyelids with Oust™ Demodex® Wipes™
11112628|NCT03987230|Active Comparator|I-LID N LASH PLUS® Eyelid Cleanser|Participant cleans eyelids with I-LID N LASH PLUS® Eyelid Cleanser
11112629|NCT03987230|Active Comparator|Blephadex Lid Wipes|Participant cleans eyelids with Blephadex Lid Wipes
11112630|NCT03987230|Active Comparator|Eye Cleanse Lid Wipes|Participant cleans eyelids with Eye Cleanse Lid Wipes
11112631|NCT03987230|Active Comparator|Blephademodex|Participant cleans eyelids with Blephademodex
11112633|NCT03987217|Experimental|Group I (resistance training)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minute each for 12 weeks.
11112634|NCT03987217|Experimental|Group II (resistance training, creatine supplementation)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minutes each for 12 weeks and receive creatine monohydrate supplementation given orally 4 times daily during week 1, and then QD (once per day) during weeks 2-12.
11112635|NCT03987204|Experimental|Ivabradine|Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.
11112636|NCT03987191|Active Comparator|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
11112637|NCT03987191|Experimental|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
11112638|NCT03987178|Experimental|Head Dunk|Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
11112639|NCT03987178|Placebo Comparator|No Head Dunk|Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
11112640|NCT03987165|Experimental|Music Therapy|Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
11112641|NCT03987165|No Intervention|Control|
11112642|NCT03987152|Other|Sirolimus|Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
11112643|NCT03987139|Other|All patients|Patients included in the study.
11112644|NCT03987126|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.
~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)"
11112645|NCT03987126|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.
~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
11112646|NCT03987087|Experimental|Radiotherapy group|Thoracic intensity modulated radiation therapy (IMRT) concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.Cisplatin Thoracenteral infusion chemotherapy。 Thoracic intensity modulated radiation therapy (IMRT) concomitant with Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations.
11112647|NCT03987087|Active Comparator|Chemotherapy group|"EGFR-TKI on paticipants with known sensitive EGFR mutations,Cisplatin Thoracenteral infusion chemotherapy.
~Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations."
11112648|NCT03987074|Experimental|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) for 24 weeks
11112649|NCT03987074|Experimental|Semaglutide + Firsocostat|Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + firsocostat 20 mg for 24 weeks
11112650|NCT03987074|Experimental|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + cilofexor 30 mg for 24 weeks
11112651|NCT03987074|Experimental|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + cilofexor 100 mg for 24 weeks
11112652|NCT03987074|Experimental|Semaglutide + Firsocostat + Cilofexor|Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
11112653|NCT03987061|Experimental|MOTIV bioresorbable vascular scaffold|MOTIV bioresorbable vascular scaffold for below-the-knee artery disease
11112654|NCT03987048||Cirrhotic patients with septic shock|All consecutive adult cirrhotic patients admitted to the ICU with septic shock from 2002 to 2013.
11112655|NCT03987035|Experimental|BGP Stent Graft System|BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms
11112656|NCT03987022|Experimental|"ICE-T"|"Regimen #1 ICE-T Opioid Sparing Regimen At the end of surgery patients will receive 30mg of intravenous (IV) toradol. Once out of the post anesthesia care unit (PACU) patients will receive
~ICE PACKS applied to the surgical sites every hour for 20 minutes Around the clock (ATC) until discharge.
~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.
~Once out of the PACU will receive 1 gram of Tylenol per os (PO) every 6 hours for a total of 4 grams daily ATC until discharge
~Patients will receive dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain.
~Patients will be discharged home with (PO) Tylenol and PO toradol as needed (PRN)."
11112657|NCT03987022|Active Comparator|Standard of care|"Regimen #2 STANDARD Postoperative Regimen
~Once out of the PACU patients will receive Standard postoperative regimen
~Motrin 600mg PO every 4 hours PRN pain scale 1-3 pain
~Percocet 1 tab PO every 4-6 hours PRN pain scale 4-6 pain
~Percocet 2 tabs PO every 7-10 hours PRN pain scale 7-10 pain
~Patients will receive dilaudid 0.2mg IV every 3 hours PRN for breakthrough pain.
~Patients will be discharged home with Motrin and Percocet for pain PRN."
11112658|NCT03987009|Experimental|Without RAMP and without video|Sniffing position and a standard Macintosh laryngoscope
11112659|NCT03987009|Experimental|With RAMP and with video|Ramped position and a McGrath Mac videolaryngoscope
11112660|NCT03987009|Experimental|Without RAMP and with video|Sniffing position and a McGrath Mac videolaryngoscope
11112661|NCT03987009|Experimental|With RAMP and without video|Ramped position and a standard Macintosh laryngoscope
11112662|NCT03986996|Active Comparator|Group 1 -|triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.
11112663|NCT03986996|Experimental|Group 2 -|double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.
11112664|NCT03986983|Experimental|Experimental group of Aerobic exercise|The participants perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
11112665|NCT03986983|Experimental|Experimental group of Shockwave therapy and Aerobic Exercise|"The participants do the Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position.
~In addition, the participants also perform the Aerobic exercise protocol - The entire protocol was monitored through the Polar® brand heart rate monitor and watch."
11112666|NCT03986983|No Intervention|Control group|The participants do not perform any type of intervention.
11112667|NCT03986970|No Intervention|Arm 1: Control|No PrEP.
11112668|NCT03986970|Experimental|Arm 2: FTC-TDF|FTC-TDF one day, 5 hours before circumcision.
11112669|NCT03986970|Experimental|Arm 3: FTC-TDF|FTC-TDF one day, 21 hours before circumcision.
11112670|NCT03986970|Experimental|Arm 4: FTC-TDF|FTC-TDF two days, 5 hours before circumcision.
11112671|NCT03986970|Experimental|Arm 5: FTC-TDF|FTC-TDF two days, 21 hours before circumcision.
11112672|NCT03986970|Experimental|Arm 6: FTC-TAF|FTC-TAF one day, 5 hours before circumcision.
11112673|NCT03986970|Experimental|Arm 7: FTC-TAF|FTC-TAF one day, 21 hours before circumcision.
11112674|NCT03986970|Experimental|Arm 8: FTC-TAF|FTC-TAF two days, 5 hours before circumcision.
11112675|NCT03986970|Experimental|Arm 9: FTC-TAF|FTC-TAF two days, 21 hours before circumcision.
11112676|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
11112677|NCT03986944|Experimental|Linzagolix 75 mg|
11112678|NCT03986944|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
11112679|NCT03986944|Placebo Comparator|Placebo|
11112680|NCT03986931|Experimental|Pharmacist-Bidirectional Texting Group|Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
11112681|NCT03986931|Active Comparator|Control Group|Patients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.
11112682|NCT03986918||Ovation and Ovation Tribute|All patients having undergone a total hip arthroplasty that received the Ovation® or Ovation Tribute® (Ortho Development, Draper, Utah) Hip system will be sent the survey.
11112683|NCT03986905|Experimental|Scopolamine Nasal Gel|DPI-386 Nasal Gel + placebo patch
11112684|NCT03986905|Placebo Comparator|Placebo|placebo nasal gel + placebo patch
11112685|NCT03986905|Active Comparator|TDS Patch|placebo nasal gel + TDS patch
11112686|NCT03986892||COmPLETE-Health|No intervention
11112687|NCT03986892||COmPLETE-Heart|No intervention
11112688|NCT03986866|No Intervention|No Video|Patients are not shown the informational video on the safe usage of opioids.
11112689|NCT03986866|Experimental|Video|Patients are shown an informational video on the safe usage of opioids.
11112690|NCT03986853|Experimental|Blood sample|Blood sampling Under general anesthesia
11112691|NCT03986840|Experimental|Exercise program|The exercise program was applied for 6 weeks. A total of 18 sessions were distributed in 3 weekly sessions. The participants performed a resistance exercises: leg press at an intensity of 40%-60% with 10 repetitions, 12 repetitions of steps with their bodyweight and a plantar flexion followed by a cardiovascular HIIT exercise walking on a treadmill.
11112692|NCT03986840|Active Comparator|Daily activities|The patients who belongs to this group will continue to perform their daily routines.
11112693|NCT03986827|Experimental|Cool Kids Anxiety Program - Social Enhanced (CK-E)|CK-E is a G-CBT treatment developed specifically for treatment of youth SAD. The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session.
11112694|NCT03986827|Active Comparator|Cool Kids Anxiety Program (CK)|"The standard Cool Kids Anxiety Program is a treatment program based on generic CBT techniques such as cognitive restructuring and gradual exposure.
~The program consists of 10 2-h group sessions with four to five adolescents and their parents in each group. 9 sessions with the adolescents and parents together and one parents-only session (session 5). Three months after ending treatment participant will be offered a 1-h booster group session."
11112695|NCT03986801|Experimental|PASS pharmaceutical interview|
11112696|NCT03986801|No Intervention|Usual management out of hospital|
11112697|NCT03986788|Other|Weightlessness|Weightlessness measurements during flight
11112698|NCT03986775|Active Comparator|citrus drink with isomaltulose|
11112699|NCT03986775|Placebo Comparator|citrus drink with sucrose|
11112700|NCT03986762|Experimental|Open Label Clav|
11112701|NCT03986749|Experimental|ARCR-BursaSeries|Tendon healing in the reconstruction of the rotator cuff, taking advantage of augmentation potential of the subacromial bursa.
11112702|NCT03986736||Patients with major trauma|Patients with major trauma will be included in the study.
11112703|NCT03986697|Active Comparator|Bictarvy|Intervention group: those randomised to switch antiretroviral therapy to Bictegravir, Emtricitabine and Tenofovir Alafenamide fixed dose combination.
11112704|NCT03986697|No Intervention|Usual therapy|Control group: those randomised to continue their usual antiretroviral regime
11112705|NCT03986684||Non-NAFLD|
11112707|NCT03986671|Experimental|EMG Testing|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
11112708|NCT03986658|Experimental|Adolescents|Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
11112709|NCT03986645|Experimental|4DFLOW|Acquire MR 4DFLow data.
11112710|NCT03986632|Experimental|Tundra gifts program|
11112711|NCT03986632|No Intervention|Comparison|
11112712|NCT03986606|Experimental|Open-label Dose Escalation and Expansion Study of PSB205|"Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.
~Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts."
11112713|NCT03986593|Other|Cryoablation +- cementoplasty treated patients|cone beam computed tomography guided cryoablation +- cementoplasty
11112714|NCT03986580|Other|BARRICAID device|Single arm study; all patients treated with BARRICAID device
11112715|NCT03986567|Active Comparator|control|Providing with a paper notification card to the STI diagnosed young person
11112716|NCT03986567|Experimental|intervention web app|providing to the STI diagnosed young person, with a code number to enter into the app to notify sexual partners
11112717|NCT03986567|Experimental|intervention game|providing to the STI diagnosed young person, with a code number to enter into the app and play a game to get motivated to notify sexual partners
11112718|NCT03986554|Other|Randomization Visit A|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Each sequence will be use VFSS to visualize swallows.
11112719|NCT03986554|Other|Randomization Visit B|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Sequences 1 and 3 will use videofluoroscopy only, while sequence 2 will use VFSS with simultaneous pharyngeal high resolution manometry in order to visualize swallows.
11112720|NCT03986541||Retrospective cohort|Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
11112721|NCT03986541||Prospective cohort|Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
11112722|NCT03986528|Experimental|Kanglaite Injection + Chemotherapy|Participants receive Kanglaite Injection PLUS first-line chemotherapy.
11112723|NCT03986528|Active Comparator|Chemotherapy|first-line chemotherapy.
11112724|NCT03986515|Experimental|treatment group|"apatinib 250mg orally once a day until disease progression of occurrence of intolerable adverse events.
~SHR-1210 200mg every two weeks until disease progression of occurrence of intolerable adverse events.
~(the first dose of SHR-1210 is set on the 3-5 days after apatinib"
11112725|NCT03986502|Experimental|Arm I (financial navigation program)|Patients and caregivers watch a web-based financial literacy video and receive information about financial counseling, direct medical cost and healthcare coverage assistance, and indirect and non-medical cost assistance.
11112726|NCT03986502|Active Comparator|Arm II (usual care)|Patients and caregivers participate in usual clinic procedures and utilize any available clinic or community-based financial resources.
11112727|NCT03986489|Experimental|Mindfulness-based dance/movement therapy|Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.
11112728|NCT03986489|Active Comparator|Chronic pain social support group|Participants assigned to the control condition will participate in a 12-session (90-minute session/week) social support group.
11112729|NCT03986476|Experimental|Lactobacillus reuteri strain 1|Probiotic compound
11112730|NCT03986476|Experimental|Lactobacillus reuteri strain 2|Probiotic compound
11112731|NCT03986476|Placebo Comparator|Placebo|Placebo
11112732|NCT03986463||Cohort 1|"Stage III NSCLC as per the American Joint Committee on Cancer 8th edition (AJCC 8th ed.)
~Appropriate to undergo concurrent chemotherapy and radiation
~Planned radiation dose must be between 54 and 66 Gy
~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine
~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2
~No prior system chemotherapy (induction) for their stage III NSCLC, any adjuvant chemotherapy given for resected disease must have been at least 100 days prior to enrollment"
11112733|NCT03986463||Cohort 2|"Stage IV NSCLC or stage III NSCLC, as per the AJCC 8th ed.
~Planning to start systemic cytotoxic chemotherapy, without concurrent radiation
~Previous treatment with tyrosine kinase inhibitors or immunotherapy (PD-1, PD-L1, CTLA4 directed antibodies) is allowed as long as no cytotoxic chemotherapy was given concurrently
~Previous palliative radiation is permitted, but must have been completed at least at least 21 days prior to the initiation of treatment
~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine
~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2
~If cytotoxic chemotherapy was previously given for adjuvant or stage III NSCLC it must have been at least 100 days prior to enrollment"
11112734|NCT03986463||Cohort 3|"Patients with advanced NSCLC set to undergo palliative radiation to the primary or regional or distant metastatic lesion(s), including intracranial lesions
~Radiation dose scheduling must be 2.5 to 4.0 Gy on days 1 through 3 for extracranial treatment, ideally 40 Gy in 15 fractions, 20 Gy in 5 fractions, or 30 Gy in 10 fractions.
~Radiation dose for brain lesions must be 6 to 9 Gy per dose, ideally 30 to 35 Gy in 5 daily fractions or 27 Gy in 3 fractions on alternating days
~No plans for concurrent chemotherapy to be given
~Five patients in cohort 3 will receive radiation to the primary tumor and five patients will receive radiation to brain lesions"
11112735|NCT03986450|Active Comparator|ERAS group|Patients in this group will receive ERAS protocol preoperatively, perioperatively and postoperatively.
11112736|NCT03986450|No Intervention|Control|This group of patients will not receive ERAS care and will undergo a standard laparoscopic hysterectomy.
11112737|NCT03986424|Experimental|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg once daily
11112738|NCT03986424|Active Comparator|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg twice daily
11112739|NCT03986411|Other|Feasibility study of physiotherapy for UI in athletic women|A mixed methods study with 3 distinct but related phases to explore the feasibility of conducting an RCT of physiotherapy as management of urinary incontinence in athletic women
11112740|NCT03986398|Experimental|Prophylactic efficacy of Urell®|Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty
11112741|NCT03986385|Experimental|A(apatinib Xelox)|Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
11112742|NCT03986385|Active Comparator|B(Xelox)|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles
11112743|NCT03986372|Experimental|PRP injection, once|PRP injection, once
11112744|NCT03986372|Experimental|PRP injection, twice|PRP injection, twice, 2 weeks apart
11112745|NCT03986372|Experimental|PRP injection, 3 times|PRP injection, 3 times, 2 weeks apart
11112746|NCT03986359|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
11112747|NCT03986359|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
11112748|NCT03986346|Experimental|Laser group|Participants in this group receive pulsed dye laser to treat the scar.
11112749|NCT03986346|Active Comparator|Control group|Participants in this group receive standardized care.
11112750|NCT03986333||Control|Children whose drooling was expected to remain relatively stable over 1 month
11112751|NCT03986333||Intervention|Children receiving a treatment to reduce their drooling
11112752|NCT03986320|Experimental|Keeogo™ Dermoskeleton|Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
11112753|NCT03986307|Experimental|Omega-3|Elderly supplemented with omega-3.
11112754|NCT03986307|Placebo Comparator|Placebo|Elderly supplemented with corn oil.
11112755|NCT03986294|Experimental|S1 and liposomal irinotecan|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
11112756|NCT03986294|Experimental|Liposomal irinotecan, Leucovorin and 5-fluoracil|Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
11112757|NCT03986281|Active Comparator|Omron HeartGuide Smartwatch|Readings from the Omron HeartGuide Smartwatch
11112758|NCT03986281|Active Comparator|Arterial Line|Readings from the arterial line
11112759|NCT03986268|Active Comparator|study group|The patients measured a total of 25 OH vitamin D3 levels, initial, 3'th month and 6'th month of neoadjuvant therapy with replacement treatment with vitamin D3 at least weekly 50000 IU for eight weeks.
11112760|NCT03986268|Other|control group|The patients had measured a total of 25 OH vitamin D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamin D3.
11112761|NCT03986255|Experimental|Lumbar Puncture|Participants will undergo Lumbar puncture procedure
11112762|NCT03986242|Experimental|static stretchin|Static extremity muscles of the lower extremities, including: gluteal muscles (major muscle group: gluteus maximus), anterior thigh muscles (strand rectus, medial femoral muscle, lateral femoral muscle, medial femoral muscle), posterior thigh muscles (main muscle) Group: semimembranosus, semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). 4 groups per muscle group, 30 seconds/group
11112763|NCT03986242|Experimental|non- vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each leg of each pair performs 30 seconds/group for a total of 4 groups for a total time of 20 minutes.
11112764|NCT03986242|Experimental|Vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each muscle group of each foot performs 30 seconds/group, a total of 4 groups, the vibration frequency is 28 Hz, and the total time is 20 minutes.
11112765|NCT03986229|Active Comparator|With compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
11112766|NCT03986229|Active Comparator|Without compression garments|"Evaluation of the variation in the travel speed of the center of pressure with compression garments and the standing static balance."
11112767|NCT03986216|Experimental|Home based group|This group will involve 2-4 randomly selected participants who have already completed the lab based sessions. They will use the developed ReIn-Hand device to assist them to practice 'reach-grasp-retrieve-release' movements at home, 1 hours per day (20 trials), 7 days per week for 12 weeks.
11112768|NCT03986203|Experimental|Active|Subjects in this group will receive the active treatment for each daily treatment session.
11112769|NCT03986203|Sham Comparator|Sham|Subjects in this group will receive the sham treatment for each daily treatment session.
11112770|NCT03986190|Experimental|Healthy Juntos Intervention Condition|Parent-adolescent dyads randomized to the Healthy Juntos intervention condition will access a program that includes didactic, behavioral, and positive parenting content from their smartphones for 8 weeks.
11112771|NCT03986190|No Intervention|Control Group|This group will not receive any form of intervention in the study.
11112772|NCT03986177|Experimental|Intervention|The intervention arm will receive a multi-faceted self-management intervention package.
11112773|NCT03986177|No Intervention|Enhanced care|The control arm will receive usual care plus basic asthma education from a trained nurse educator.
11112774|NCT03986164|Active Comparator|Guided surgery (GS)|Installation of dental implant with the aid of the virtually planned guide by means of specific software
11112775|NCT03986164|Active Comparator|Conventional surgery (CS)|Installation of dental implant performed freehand using a conventional surgical guide made by study models
11112776|NCT03986151|Active Comparator|Conventional radial access|
11112777|NCT03986151|Experimental|Distal radial access|
11112778|NCT03986138|Experimental|gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI|Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
11112779|NCT03986138|Experimental|gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI|Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
11112780|NCT03986125|Experimental|Emotional Awareness & Expression Therapy|Participants will attend three individual sessions focused on becoming aware of and expressing avoided or conflicted emotions.
11112781|NCT03986125|Experimental|Mindfulness Meditation Training|Participants will attend three individual sessions focused on increasing equanimity and compassion and reducing self-judgement.
11112782|NCT03986125|No Intervention|Wait-List Control|Participants will receive the intervention of their choice following assessment at four and eight weeks after randomization.
11112783|NCT03986112||hypertensive group|Evaluation of the ability of carotid sonography and inferior vena cava sonography for the post-induction hypotension in hypertensive patients undergoing general anesthesia
11112784|NCT03986099|No Intervention|Standard of care|SOC viral load
11112785|NCT03986099|Active Comparator|Near point of care|POC viral load
11112786|NCT03986086|Experimental|MPH966|Participants receive MPH966 at RP2D tablet orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
11112787|NCT03986086|Placebo Comparator|Placebo|Participants receive MPH placebo tablet matching MPH966 orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
11112788|NCT03986073|Experimental|Low dose group|Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
11112789|NCT03986073|Experimental|High dose group|Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
11112790|NCT03986073|Active Comparator|Positive drug control group|Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.
11112791|NCT03986073|Placebo Comparator|Placebo group|Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
11112792|NCT03986047|Experimental|Thermal care|Participants will be asked to wear a heat wrap over the lower lumbar spine, during the day for 8 hours on 7 consecutive days. The Thermal care group will also receive education by a physiotherapist on acute low back pain management.
11112793|NCT03986047|Experimental|Thermal care + exercises|In addition to heat wrap and pain management education as for Thermal care group, participants of this group will be asked to perform exercises at home over 7 days, targeted on functional capacity, lumbar mobility, and slight contraction of trunk muscle (posture and/or cognitive).
11112794|NCT03986047|Sham Comparator|Control|Participants in the control group will receive the same education program as those of the two other groups. A sham non-heating wrap will be used to control for potential supportive and sensory influence of the heat wrap.
11112795|NCT03986034|Experimental|Relapsed/Refractory CLL pts|Ages 18 and older
11112796|NCT03986021||Post-menarche girls|Healthy, early post-menarchal girls age 10-14
11112797|NCT03986008|Experimental|Benaglutide|Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
11112798|NCT03986008|Active Comparator|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
11112799|NCT03985995|Active Comparator|CBD 800 mg p.o.|The study Investigational Medical Product (IMP) is a cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration.
11112800|NCT03985995|Placebo Comparator|Placebo p.o.|Participants in the control arm will be receiving a single dose of oral placebo solution 8 ml matched to the active comparator.
11112801|NCT03985982|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
11112802|NCT03985982|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
11112803|NCT03985969|Experimental|DDI|Period 1: study of elafibranor's pharmacokinetics Period 2: study of elafibranor's pharmacokinetics under CHRONO-INDOCID® (indomethacin) at steady state
11112804|NCT03985943|Placebo Comparator|Placebo|Placebo
11112805|NCT03985943|Experimental|Nemolizumab|Nemolizumab Active
11112806|NCT03985930|Experimental|Distraction Group|Children between the ages of 3 and 6 years will be distracted using virtual reality content delivered through goggles. Since exposure to video screens has been previously discouraged by various scientific and professional medical organizations in children under 3 years of age, these children will be distracted using video projections of the same content.
11112807|NCT03985930|Active Comparator|Treatment as Usual|Children randomized to this group will receive the usual medical care.
11112950|NCT03984890|Other|Control Group|Traditional treatment of CGD and TB without Vitamin D Supplementation
11112808|NCT03985917|Experimental|Intervention Singing Group Program|Singing group intervention program that includes six components: (1) vocal warm-up exercises; (2) vocal technique; (3) rehearsal of repertoire; (4) break for socialization; (5) creation and presentation of a show; (6) assessment of participants performance (vocal tuning).
11112809|NCT03985917|Active Comparator|Alternative Social and Leisure Activities|While the experimental group is participating in the intervention program, the control group will participate in the other activities proposed by the day care centers, which will be registered.
11112810|NCT03985904|Experimental|Art Therapy|Participants will attend art therapy group sessions for three months in a designated museum.
11112811|NCT03985904|No Intervention|Control|Participants will NOT attend art therapy group sessions but will continue with usual care during the three months
11112812|NCT03985891|Experimental|JS001 in combination with Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks) in combination with JS001 (3mg/kg, Q2W). Patients will receive 6 cycles treatment in pre-operation and same cycles after operation.
11112813|NCT03985891|Active Comparator|Folfox|Patients who meet the enrollment criteria will receive Folfox(Oxaliplatin 85mg/m2 iv Day1; Leucovorin 400mg/m2 iv Day1; 5-FU 400mg/m2 iv bolus on Day1, then1200mg/m2/d x 2days(total 2400mg/m2 over 46-48 hours) iv continuous infusion repeat every 2 weeks). Patients need to receive 6 cycles treatment in pre-operation and same cycles after operation.
11112814|NCT03985878|Experimental|Eteplirsen|Patients will receive eteplirsen via intravenous (IV) infusions, once weekly, for up to 284 weeks.
11112815|NCT03985865|Experimental|Intragastric quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
11112816|NCT03985865|Experimental|intragastric denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
11112817|NCT03985865|Placebo Comparator|Intragastric placebo|0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
11112818|NCT03985865|Experimental|Intraduodenal quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
11112819|NCT03985865|Experimental|Intraduodenal denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
11112820|NCT03985865|Placebo Comparator|Intraduodenal placebo|0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
11112821|NCT03985852|Active Comparator|Patient Directed Standard of Care|Patients receive pre-test genetic counseling and, if relevant, post-test counseling for a negative result from an automated genetics education assistant.
11112822|NCT03985852|No Intervention|Enhanced Standard of Care|Patients receive standard counseling from a genetic counselor.
11112823|NCT03985839||MICRORAPTOR™ REGENESORB™ Suture Anchor|MICRORAPTOR™ REGENESORB™ Suture Anchor
11112824|NCT03985839||MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
11112825|NCT03985839||MICRORAPTOR™ Knotless PEEK Suture Anchor|MICRORAPTOR™ Knotless PEEK Suture Anchor
11112826|NCT03985826||Childhood ALL survivors|The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
11112827|NCT03985826||Comparison cohort|A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
11112828|NCT03985813|Experimental|Screening Wizard|Youth and parents receiving Screening Wizard will be screened for depression and suicidal risk within their pediatric primary care provider's office. Screening will be analyzed in real-time to produce a decision support tool meant to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
11112829|NCT03985800|Active Comparator|TEAM-care as usual approach|Patients will be triaged based on their physical health (PH) and behavioral health (BH) complexity to determine the frequency of in-person visits and how much of these visits will be devoted to medical versus BH issues
11112830|NCT03985800|Active Comparator|TECH-telehealth approach|Each patient will have an initial face-to-face visit with the core treatment team described above and undergo the same triage process to determine their PH/BH care needs. Each TECH patient will participate in one face-to-face treatment team visit per year unless more frequent visits are deemed to be medically necessary; however, all other interactions will be conducted via technology-supported modalities
11112831|NCT03985787|Experimental|All Participants|
11112832|NCT03985774||Patients requiring carotid revascularization|Symptomatic patients, male or female, with atherosclerotic extracranial internal carotid stenosis (ICA) with or without involvement of the contiguous common artery (CCA), that require carotid revascularization.
11112833|NCT03985761|Experimental|Home Telerehabilitation_Motivation Enhanced HTme|The Home Telerehabilitation Motivation Enhanced (HTme) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTme group will use three simulations that will provide the user with eight to twelve levels of gradually increasing difficulty and complexity. A screen announces each level change and the graphics for each new level change substantially. Scoring opportunities increase at each new level.
11112860|NCT03985579|Experimental|Standard care and Kinesiology taping Group|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders.
11112861|NCT03985579|No Intervention|Standard care Group|Assistance in baby feeding, manual of device-assisted (lactator) milk expression, cold compress, ibuprofen, gentle breast massage, breathing and shoulder girdle exercise.
11112862|NCT03985566|Experimental|Fibre Grains|Fibre grains were used to partially replaced Jasmine white rice in this arm.
11112834|NCT03985761|Active Comparator|Home Telerehabilitation_Unenhanced (HTu)|The Home Telerehabilitation Motivation Enhanced (HTu) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTu group will use three simulations. Difficulty will be increased utilizing an adaptive control algorithm that increases difficulty based on performance. Difficulty changes are extremely incremental making them imperceptible for most subjects. Graphics and scoring do not change as difficulty level changes.
11112835|NCT03985748|Experimental|Breath Actuated Nebulizers (BAN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
11112836|NCT03985748|Active Comparator|Standard Nebulizer (SN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
11112837|NCT03985735||Group good sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).
~Sleeping time are more than six hours."
11112838|NCT03985735||Group poor sleepers|"Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 20:00pm to 06:00am).
~Sleeping time are less than two hours."
11112839|NCT03985722|Experimental|Unlimited cycles of Olaratumab and Trabectedin|"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label,.
~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."
11112840|NCT03985709|Experimental|Probiotcal group|Probiotic (Lactobacillus casei) once daily taken by 3 months
11112841|NCT03985696|Experimental|patients with DLBCL|
11112842|NCT03985696|Active Comparator|Healthy volunteers|
11112843|NCT03985683|Active Comparator|Control group|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
11112844|NCT03985683|Experimental|Experimental (Nutritional Interventional)|In experimental group athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively. Average carbohydrates required for athletes are 6 to 10 gram per kilogram per day. T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test will use as baseline assessment and after 6 days of intervention.
11112845|NCT03985670|Experimental|treatment group|teripalimab 240mg d1 paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1
11112846|NCT03985670|Active Comparator|chemotherapy followed by immunotherapy|paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1 teripalimab 240mg d3
11112847|NCT03985657|No Intervention|Baseline Sleep Study|Baseline sleep polysomnography will involve collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure and pleural pressure during sleep with no CPAP.
11112848|NCT03985657|Experimental|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep disordered breathing
11112849|NCT03985644||Fulfilling Hangzhou criteria|"Patients flfilling Hangzhou critieria:
~Without macrovascular invasion Tumor burden <=8 cm Preoperative AFP level <=400 ng/mL Histopathologic grades I, II"
11112850|NCT03985644||Exceeding Hangzhou criteria|Patients exceeding Hangzhou critieria
11112851|NCT03985631|Experimental|Telerehabilitation|Tai Chi intervention by telerehabilitation (3-month intervention, three sessions per week: two supervised session and one unsupervised session).
11112852|NCT03985618|Active Comparator|Randomized Caesarean section|Randomized to planned pre-labour Caesarean section
11112853|NCT03985618|Active Comparator|Randomized Induction of Labour|Randomized to planned induction of labour
11112854|NCT03985618|Active Comparator|Preference Caesarean section|Preference for planned pre-labour Caesarean section
11112855|NCT03985618|Active Comparator|Preference Induction of Labour|Preference for planned Induction of Labour
11112856|NCT03985592|Other|Educational Intervention for ICU-Based Clinicians|ICU-based clinicians (e.g. physicians and RNs) will be provided with educational modules related to bereavement support for family members. Following the modules a survey will be provided to participants to assess their perceived usefulness of the modules.
11112857|NCT03985592|Experimental|Educational material and personalized letter of condolence|Clinicians who participated in the educational modules will be asked to send a letter of condolence to family members listed as the primary contact of the diseased ICU patient.
11112858|NCT03985592|Experimental|Meeting with the care team to address unmet needs|At 8-12 weeks post-death, we will contact FMs and invite them to meet with the care team. Our observational studies indicated that the most common need reported by bereaved FMs was the desire to meet with the care team to review events during the ICU stay and particularly the events that led to death, and that this was the type of support that ICU clinicians were most comfortable providing.
11112859|NCT03985592|Experimental|Identifying FMs at high risk of SGRs|At 10-12 weeks post-death, we will contact FMs and administer the Inventory of Complicated Grief-Revised (ICG-r), Brief Grief Questionnaire (BGQ), Impact of Events Scale - Revised (IES-r), Patient Health Questionnaire-9 (PHQ-9), and the Bereavement Dependency Scale (BDS). If these results suggest a 10% or greater risk of developing Complicated Grief (CG), we will offer and encourage the FM to participate in a 1-2 hour narrative exploration of their grief and bereavement experience. Narrative interventions require specialized resources and are less scalable than components #1 and #2, but the results of Barnato et al., as well as the response to our qualitative interviews, suggest that this intervention may be helpful for selected FMs. Narrative interventions have been shown to reduce healthcare utilization and improve subjective health following a traumatic experience.
11112863|NCT03985566|Placebo Comparator|Jasmine white rice|Jasmine white rice is used as a control to compare the outcome.
11112864|NCT03985553|Other|Parenting Self-Management Program|Participants were provided a Parenting Self -Management Program booklet with the twenty-four fact sheets at the beginning of the four-week program on topics such as adaptive babycare techniques, advocacy in the courts, emergency planning, safety in the community, talking to children about disability, managing pain/fatigue, connecting to other parents with SCI/D, and wheelchair adjustment/management during and after pregnancy. Sessions included topic introduction, participant interaction, goal setting, resource utilization, and program evaluation. Participants were allowed to choose which resources they wanted and what tips to incorporate into their parenting roles. Participants were asked to develop a weekly goal to encourage achievement, allowing individuals to identify what they wanted or decided to do that could be related to parenting directly or indirectly, such as health and wellness goals that gave them more energy or strength to complete parenting tasks.
11112865|NCT03985540|Experimental|memory experimental group|Experimental group will receive memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
11112866|NCT03985540|Placebo Comparator|Placebo comparator memory|Placebo controlled group will receive placebo memory retraining exercises administered on a lab top computer twice a week for 5 weeks.
11112867|NCT03985540|Experimental|Processing speed|Processing speed group will receive processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
11112868|NCT03985540|Placebo Comparator|Processing speed placebo|Placebo controlled group will receive placebo processing speed training exercises administered on a lab top computer twice a week for 5 weeks.
11112869|NCT03985527|Experimental|Transvenous nerve stimulation|
11112870|NCT03985514|Active Comparator|Antibiotic treatment|Patients will receive in-hospital intravenous antibiotics (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3). Surgery if no symptom relif occur.
11112871|NCT03985514|Other|Clinical observation|"Patients are followed by in-hospital Active observation (watchful waiting) according to clinical routine. Patients are observed until either, recovery and dismissal from hospital, or decision for intervention (surgery) is taken."
11112872|NCT03985501||newborn screening for sickle cell disease|Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon
11112873|NCT03985488||Eview Fluoroscopy Machine|The Eview Fluoroscopy Machine is the standard of care fluoro machine used in endoscopy.
11112874|NCT03985488||Fluoroshield Device|The FluoroShield technology (Omega Medical Imaging) has been developed in an effort to further reduce the degree of radiation exposure to patients and provides. This technology is an additional component that can be fitted to the preexisting Eview fluoroscopy machines, in order to further filter radiation that has passed through the pre-existing machine.
11112875|NCT03985475||Person with a skin infection|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
11112876|NCT03985462|Experimental|VSEL Max|A total of 300,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a high dose group
11112877|NCT03985462|Experimental|VSEL Medium|A total of 200,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a middle dose group
11112878|NCT03985462|Experimental|VSEL Mini|A total of 100,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a low dose group
11112879|NCT03985462|No Intervention|Control|5 mL plate-rich plasma with no cells inside were injected into the bilateral fallopian tubes as a control group
11112880|NCT03985449|Other|Active Implementation phase|See the 'detailed description' section to read about the intervention(s) clinicians will use during the active implementation phase of the randomized stepped-wedge design.
11112881|NCT03985436|Experimental|Trek for Surgical Success|Cognitive behavioral therapy for pain
11112882|NCT03985423|Experimental|Emapalumab|
11112883|NCT03985410|Experimental|Treatment Sequence ABC|Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
11112884|NCT03985410|Experimental|Treatment Sequence ACB|Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
11112885|NCT03985410|Experimental|Treatment Sequence BAC|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
11112886|NCT03985410|Experimental|Treatment Sequence BCA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
11112887|NCT03985410|Experimental|Treatment Sequence CAB|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
11112888|NCT03985410|Experimental|Treatment Sequence CBA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
11112951|NCT03984877||Amyloidosis|TAVI patients with diagnosis of amyloidosis
11112889|NCT03985397|Experimental|Experimental group (EG)|At the first interview, after the application of the scales to the intervention group patients, planned discharge training and the manual prepared by the researcher were given. The second interview was performed 4 weeks later and the same scales were reapplied.
11112890|NCT03985397|No Intervention|Control group|In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
11112891|NCT03985384|Active Comparator|Semaglutide|Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
11112892|NCT03985384|Placebo Comparator|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
11112893|NCT03985371|Experimental|Drops Used|
11112894|NCT03985358|No Intervention|Control Group|Patients randomized to the Control Group will not receive opioid counseling and will only receive their standard of care instructions for preoperative and postoperative care.
11112895|NCT03985358|Experimental|Treatment Group|Patients randomized to the Treatment Group will have opioid counseling plus standard of care instructions given by the same counselor (investigator on the study) using the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher).
11112896|NCT03985345|Experimental|EMY Probe|
11112897|NCT03985319|Experimental|YYD601 20mg|Esomeprazole IR 10mg + esomeprazole SR 10mg
11112898|NCT03985319|Active Comparator|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca
11112899|NCT03985306|Experimental|Feasibility trial group|Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
11112900|NCT03985293|Placebo Comparator|Placebo|
11112901|NCT03985293|Experimental|PF-06882961 2.5 milligrams (mg)|
11112902|NCT03985293|Experimental|PF-06882961 10 mg|
11112903|NCT03985293|Experimental|PF-06882961 40 mg|Participants will be titrated up to 2 weeks to reach desired dose level
11112904|NCT03985293|Experimental|PF-06882961 80 mg|Participants will be titrated up to 4 weeks to reach desired dose level
11112905|NCT03985293|Experimental|PF-06882961 120 mg|Participants will be titrated up to 6 weeks to reach desired dose level
11112906|NCT03985280|Experimental|Cooled radiofrequency|The procedure will be performed under regimen of major ambulatory surgery, it will be done under guidance of combined X-ray and ultrasound. . The nerves will be located b, after applying AL (Lidocaine 1%), a RF needle will be placed in the objective position.After verifying the positive sensitive and negative motor responses the cooled radiofrequency will proceed (previous application of local anesthesia (lidocaine 2%)). Cooled RF will be performed for 2:30 minutes at 60 degrees.
11112907|NCT03985280|Active Comparator|Intraarticular local anesthetic and steroids injections|An intraarticular injection will be done in ambulatory surgery regimen with a 22 Gauge needle. Intraarticular injection will be done under Fluoroscopic guidance (X-rays) with intra articular position confirmation by infusion of iodine contrast (Omnipaque 240). Once the needle position has been verified we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.
11112908|NCT03985267|Experimental|The Swinging Effect Intervention|Standard guided imagery combined with Mindfulness and breathing technique will be applied. Additionally, the directives will be given to participants to imagine themselves swinging in a green peaceful environment where they will face no harm but healing and full of wellness. Every time they imagine their swing goes up, patient will be asked to physically take a deep breath (taking the breath will be physically (actually) done, not imagining), and when going down patient will be asked to physically release their breath (releasing breath will be physically (actually) done, not imagining).
11112909|NCT03985267|Active Comparator|Standard Treatment|Participants will receive a session of standard psycho-social care for anxiety (50 minutes length). The standard psycho-social care interventions involve the most well-known talking therapy approach of Cognitive Behavioural Therapy (CBT).
11112910|NCT03985254|Active Comparator|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).
~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
11112911|NCT03985254|Experimental|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
11112912|NCT03985241|Experimental|Functional Assessment of Myocardial Ischemia by icECG|Evaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
11112913|NCT03985228|Experimental|Fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks.
11112914|NCT03985228|Placebo Comparator|Placebo milk|The subjects assumed daily 250 ml of placebo milk for 12 weeks.
11112915|NCT03985202|Experimental|Structured Exercise Programme|"An initial 45 min exercise counselling incorporating behaviour modification techniques.
~Participants will be offered three sessions per week of aerobic interval exercise on a cycle ergometer over nine weeks. Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
~Following this:
~Participants will be encouraged to comply with current physical activity recommendations: 150 min of moderate intensity aerobic exercise per week (brisk walking / cycling). They will also be sign posted to local exercise facilities."
11112916|NCT03985189|Experimental|ME-401|ME-401 administered orally
11112917|NCT03985176||Aneurysmal SAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
11112918|NCT03985137||HIV-infected patients|Male patient presenting at a follow-up consultation for HIV infection or following a Sexual Viral Exposure (EVA) accident, pre-exposure prophylaxis (PrEP) or screening for a Sexually Transmitted Infection (IST).
11112919|NCT03985124|Experimental|Intervention TIK-T|24 kindergartens will receive the full intervention. Dosage: 1 3 hour implementation session for kindergarten leaders; 1 x 2-day training workshop for kindergarten leaders and a lead resource person in each kindergarten who will support teachers in learning and implementing Emotion Coaching with children; 2 full training days for all teachers/childcare workers in Emotion Coaching; 2 x booster sessions for all teachers with the resource person in their kindergarten to assist them in using Emotion Coaching with children in their kindergartens.
11112920|NCT03985124|No Intervention|wait list control|24 kindergartens will be in the 12-month wait list condition
11112921|NCT03985111||No CVC inserted|Patients undergoing major elective colorectal resection without central venous catheter inserted pre-operatively
11112922|NCT03985111||CVC inserted|Patients undergoing major elective colorectal resection with a central venous catheter inserted pre-operatively
11112923|NCT03985098|Experimental|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
11112924|NCT03985098|No Intervention|Control|usual care
11112925|NCT03985085|Experimental|Intervention arm|
11112926|NCT03985072|Experimental|Andes-1537|There will be 6 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, colorectal cancer, gastric cancer, pancreatic cancer, and clear call renal cancer). All patients will receive a dose of 400 mg of Andes-1537 twice a week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression.
11112927|NCT03985059||Cases|Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
11112928|NCT03985059||Controls|Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
11112929|NCT03985046|Experimental|Sintilimab plus chemotherapy|
11112930|NCT03985033|Experimental|L-PRF|Post-extraction sockets will be filled with autologous leucocyte and platelet-rich fibrin (L-PRF) clot.
11112931|NCT03985033|No Intervention|Control|Post-extraction sockets will be left to heal spontaneously with natural blood clot.
11112932|NCT03985020|No Intervention|Standard of Care|The control group will receive standard of care dietary advice for their solid food and beverage intake.
11112933|NCT03985020|Active Comparator|Water Intervention|We will order and deliver bottled water to the homes of subjects in the treatment group. We will provide each participant with a weekly supply of about 36 16.9 fl oz single-serving containers. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously.
11112934|NCT03985020|Experimental|Stevia Intervention|We will order and deliver a commercially-available stevia-sweetened soft drink Zevia (Los Angeles, CA) to each participant in the treatment group. We will provide each participant with a weekly supply of 24 12 fl oz single-serving containers. Zevia will be provided in an assortment of flavors for the first week, then catered to the preference of the participant for the remainder of the study. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously. Participants will also be asked to keep track of how many containers they consume using a sticker chart, and we will also phone parents weekly to verify the sticker charts
11112935|NCT03985007|Experimental|CDIAG|Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.
11112936|NCT03984994|Experimental|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
11112937|NCT03984994|Active Comparator|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
11112938|NCT03984968|Experimental|CAR-T infusion|CAR-T cells and feeding T cells were infused into remission patients sequentially,with 5*10e6/kg and 1*10e7/kg respectively for each cycle. Each patient underwent 3 cyles of CAR-T consolidation therapies and was followed up for 2 years.
11112939|NCT03984955|Active Comparator|Group A PRP injection|"Platelet-Rich Plasma injection Single therapeutic injection of Platelet-Rich Plasma performed under ultrasound guidance.
~This group will also undergo a class-based physiotherapy intervention. This outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and those receiving the sham injection."
11112940|NCT03984955|Active Comparator|Group B Ostenil Tendon|Sodium hyaluronate with mannitol (Ostenil Tendon) Single therapeutic injection of sodium hyaluronate with mannitol (marketed under the device name Ostenil Tendon) under ultrasound guidance. This group will also undergo a class-based physiotherapy intervention.
11112941|NCT03984955|Sham Comparator|Group C control group|Subcutaneous sham injection. This group will also undergo a class-based physiotherapy intervention. The outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and to those receiving PRP injection.
11112942|NCT03984929|Experimental|Localized Information Resource Intervention|
11112943|NCT03984929|Active Comparator|Generic Information Resource Intervention|
11112944|NCT03984916|Active Comparator|Hesperidin Pharma|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The approximate particle size is less than 100 µm for the 90% of the extract, and of 10 µm for 10% of the extract.
11112945|NCT03984916|Active Comparator|Hesperidin Pharma_M|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The size of 90% of particles is less than 10 µm.
11112946|NCT03984916|Experimental|Cardiose|500 mg of sweet orange extract with more than 90% of the isomer -S. The size of the 90% of particles is less than 10 µm.
11112947|NCT03984903|Active Comparator|Face-to-face Learning Group|
11112948|NCT03984903|Experimental|Multimedia Learning Group|
11112949|NCT03984890|Experimental|Vitamin D Group|Vitamin D3 Supplementation plus traditional treatment of CGD and TB
11112952|NCT03984877||Non-Amyloidosis|TAVI patients without diagnosis of amyloidosis
11112953|NCT03984864|Experimental|Exercise therapy Chosen|
11112954|NCT03984864|Active Comparator|Exercise therapy no Chosen|
11112955|NCT03984851||Group A: Surgicel Group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
11112956|NCT03984851||Group B: Bipolar Cautery group|a retrospective cohort study. Two groups were assigned, the first under the care of the author [AA], in which patients of his group underwent cold dissection tonsillectomy and achieved hemostasis via surgicel (without bipolar cautery). While group B patients (consisted of 2 surgeons) underwent cold dissection tonsillectomy and attained hemostasis with bipolar cautery. The main outcome that was pursued was postoperative tonsillectomy bleeding
11112957|NCT03984838|Experimental|Subjects receiving Dolutegravir and Rilpivirine FDC|Subjects will receive Dolutegravir/Rilpivirine 50mg/25mg fixed dose combination (FDC) tablet as a single oral dose in a fed state.
11112958|NCT03984825|Experimental|Portia followed by Portia co-administered with GSK3640254|Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
11112959|NCT03984812|Experimental|Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO|GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.
11112960|NCT03984812|Experimental|Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO|GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts.
11112961|NCT03984812|Experimental|Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
11112962|NCT03984812|Experimental|Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO|GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
11112963|NCT03984812|Experimental|Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
11112964|NCT03984812|Experimental|Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO|GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts.
11112965|NCT03984812|Experimental|Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts.
11112966|NCT03984812|Experimental|Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO|GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts.
11112967|NCT03984812|Experimental|Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
11112968|NCT03984799|Experimental|Bronchoscopy|Research bronchoscopy
11112969|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.
~Participants randomized to this arm will then receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
11112970|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/No Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.
~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
11112971|NCT03984786|Experimental|ICBT alcohol misuse: No Assessment Interview/Guidance|"The client will not receive any assessment interview during the telephone screen.
~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
11113008|NCT03984513|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
11113035|NCT03984331|Experimental|Fish skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.
11113064|NCT03984110|Active Comparator|Eylea Monotherapy|Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
11112972|NCT03984786|Experimental|ICBT for alcohol misuse: No Assessment Interview/No Guidance|"The client will not receive any assessment interview during the telephone screen.
~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
11112973|NCT03984773|No Intervention|Control|Clinicians will receive current standard communications regarding serious illness performance.
11112974|NCT03984773|Experimental|Mortality Estimates and Nudges|Clinicians will receive a weekly email with upcoming patients that have high mortality estimates to consider for a serious illness conversation. Clinicians will have the opportunity to review the list and pre-commit (using an opt-out design) to patients appropriate for a conversation. They will receive a nudge on the day of the patient visit through a text message reminding them of their pre-commitment to conduct a serious illness conversation
11112975|NCT03984760|Experimental|Ferric Citrate Capsule|Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion & BF Biotech Inc.
11112976|NCT03984760|Active Comparator|Sevelamer Carbonate Tablet|Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited
11112977|NCT03984747||Adult Transplant Patients|Adult subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
11112978|NCT03984747||Pediatric Transplant Patients|Pediatric subjects between ages 2-17 who have undergone at least one organ transplant prior to enrollment and are willing to provide assent/LAR is willing to provide consent.
11112979|NCT03984747||Pregnant Transplant Patients|Pregnant subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
11112980|NCT03984734|Active Comparator|Control group|Patients undergoing pancreatoduodenectomy with antrectomy
11112981|NCT03984734|Experimental|Study group|Patients undergoing pancreatoduodenectomy with pylorus-preserving pancreatoduodenectomy
11112982|NCT03984721|Experimental|Amylose typing|Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed
11112983|NCT03984708|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
11112984|NCT03984708|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
11112985|NCT03984695|No Intervention|Control|"15 minute discharge planning session with health educator
~Health education booklet containing SHE-Women intervention content in print form(N~100)
~access to health educator via text message"
11112986|NCT03984695|Experimental|Intervention|"Deliver text-Web intervention to (N ~100) women
~Researchers will deliver the integrated, multimedia electronic women's health literacy intervention arm of SHEWomen in text-Web format for individuals recently released from jail. Two health educators will be responsible for delivering content to participants, with an estimated contact time of ~10 hours pushed to participants over approximately a 5-day period."
11112987|NCT03984682|Experimental|Experimental group|Patients will benefit from regular care + Joint Crisis Plan
11112988|NCT03984682|No Intervention|Control group|Patients will benefit from regular care
11112989|NCT03984656|Active Comparator|AL group|patients will receive a local infiltration of 10 mL Lidocaine without epinephrine 20 mg/mL
11112990|NCT03984656|Experimental|Serratus group|patients will receive ultrasound guided serratus plane block injection of 30 mL Ropivacaine 4.75 mg/mL
11112991|NCT03984643|Experimental|Deep Brain Stimulation|Subjects in this study will have been implanted with a DBS lead in the VIM as part of their routine clinical care and have an existing set of brain MRI's.
11112992|NCT03984630|No Intervention|Control Arm|Participants were informed to continue to receive usual care by their Obstetrician and were asked to send in body weights weekly.
11112993|NCT03984630|Experimental|Intervention Arm|Received snacks high in fiber, attended weekly phone calls, recorded daily food intake and reported weekly body weight for 12 weeks.
11112994|NCT03984604|Active Comparator|CHI-921|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (CHI-921) for 3 weeks, followed by another 3 weeks of treatment at 1.0 mL for and another 3 weeks of treatment at 2.0 mL.
11112995|NCT03984604|Placebo Comparator|Placebo|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (placebo) for 3 weeks, followed by another 3 weeks of placebo treatment at 1.0 mL for and another 3 weeks of placebo treatment at 2.0 mL.
11112996|NCT03984591|Active Comparator|Spironolactone|Spironolactone used according to heart failure guidelines
11112997|NCT03984591|Active Comparator|Eplerenone|Eplerenone used according to heart failure guidelines
11112998|NCT03984578|Experimental|Colon cancers|Pre-operative CAPEOX 1 cycle Pre-operative Pembrolizumab 2 cycles with cycle 1 on Day 1 (concurrent with start of CAPEOX) and cycle 2 on Day 22
11112999|NCT03984578|Experimental|Rectal Cancers|Following completion of neo-adjuvant chemo-radiotherapy, 2 cycles of pre-operative Pembrolizumab administered 3 weeks apart.
11113000|NCT03984565|Experimental|Cannabidiol Treatment Arm|20mg/ml CBD sublingual product administered twice daily for 6 weeks
11113001|NCT03984565|Placebo Comparator|Placebo Treatment Arm|Placebo sublingual product administered twice daily for 6 weeks
11113002|NCT03984539|Active Comparator|CBT-E|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). CBT-E will occur over the course of 25 weeks and be delivered as it typically is in the clinic setting of the investigators.
11113003|NCT03984539|Experimental|CBT-T|Participants will be randomly assigned to one of two conditions (CBT-E or CBT-T). Participants who agree to participate will receive 10 weeks of CBT-T.
11113004|NCT03984526|Placebo Comparator|Control group|intravenous normal saline pretreatment
11113005|NCT03984526|Experimental|Atropine group|intravenous atropine 0.5mg pretreatment
11113006|NCT03984526|Experimental|Ephedrine group|intravenous ephedrine 8mg pretreatment
11113007|NCT03984513|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
11113009|NCT03984500|Other|Education|"During phase 1 of this study parents who attend in person education sessions will be recruited to have their standard sessions video-taped, timed, and reviewed by the SCTaware Team. Subjects will complete before and after education questionnaires that will then be reviewed to see how much participants learned about SCT, how education was not clear and/or appropriate (too much medical jargon). The SCTaware education will then be created based on review of these videos and participants' survey responses.
~For phase 2 of the study, the same recruitment strategy will be utilized. Participants will receive SCTaware and complete before and after questionnaires for evaluation. Participants in this phase will also complete follow-up questionnaires at 1 and 6 months."
11113010|NCT03984487|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
11113011|NCT03984487|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
11113012|NCT03984474||Single bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
11113013|NCT03984474||Double bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
11113014|NCT03984461|Active Comparator|Group A - PRP plus Lipoaspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate). Total Volume varies by joint.
11113015|NCT03984461|Active Comparator|Group B - PRP plus Bone Marrow Aspirate|Equal proportions of PRP plus bone marrow aspirate. Total Volume varies by joint.
11113016|NCT03984461|Active Comparator|Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate) plus bone marrow aspirate. Total Volume varies by joint.
11113017|NCT03984448|Active Comparator|Arm 1 (R-CHOP, DA-EPOCH-R)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen consisting of rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen consisting of rituximab IV on day 1, doxorubicin hydrochloride IV on days 1-4, etoposide IV on days 1-4, vincristine sulfate IV on days 1-4, prednisone PO BID on days 1-5, and cyclophosphamide IV on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
11113018|NCT03984448|Experimental|Arm 2 (R-CHOP, DA-EPOCH-R, venetoclax)|"DEL: Patients with DEL receive R-CHOP chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~DHL: Patients with DHL receive DA-EPOCH-R chemotherapy regimen as in Arm 1. Patients also receive venetoclax PO QD on days 4-8 of cycle 1 and days 1-5 for cycles 2-6. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
11113019|NCT03984435||Patients|Patients with a diagnosed malignancy who have been referred for radiotherapy with extended treatment time (>10 minutes)
11113020|NCT03984435||Radiographers|Radiographers from radiotherapy departments in the UK who deliver radiotherapy
11113021|NCT03984422||Raynaud phenomenon|Use of smartphone application
11113022|NCT03984409|Active Comparator|Group 1|Potassium citrate x 7days Off therapy x 7 days 500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Return to potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
11113023|NCT03984409|Active Comparator|Group 2|500 mL low calorie orange juice beverage x 7 days 1000 mL low calorie orange juice beverage x 7 days Off therapy x 7 days Potassium citrate x 7days Continue on potassium citrate therapy Litholink urine collection to be performed after each 7 days treatment
11113024|NCT03984396|Experimental|Intervention - Patient and Clinician|Intervention educational materials provided to patient and family and clinician
11113025|NCT03984396|No Intervention|Delayed Intervention|Usual care
11113026|NCT03984383||Lung-derived endothelial cells|Every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.
11113027|NCT03984383||Umbilical cord-derived endothelial cells|Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.
11113028|NCT03984370|Experimental|80 ug of sc dasiglucagon|80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
11113029|NCT03984370|Experimental|200 ug of sc dasiglucagon|200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
11113030|NCT03984370|Placebo Comparator|0.4 mL of sc saline (placebo)|0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
11113031|NCT03984357|Experimental|PD-1 blocking antibody combined with IC+IMRT|All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blocking antibody (360 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of PD-1 blocking antibody are administrated concurrently with IC and IMRT, respectively. After 4 weeks of the completion of IMRT, adjuvant PD-1 blocking antibody (480 mg per cycle) will begin every 4 weeks for 6 cycles.
11113032|NCT03984344|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
11113033|NCT03984344|Experimental|Active cTBS|Continuous TBS will be delivered at 80% of RMT and will be applied as 600 pulses in a 40-second train of uninterrupted 50Hz bursts to the right dorsolateral prefrontal cortex.
11113034|NCT03984344|Sham Comparator|Sham TBS|Sham stimulation will be given at the right or left dorsolateral prefrontal cortex (counterbalanced) for 40 seconds or 3 minutes and 9 seconds (counterbalanced), at the same frequency as active TBS (50Hz), however a sham coil will be used.
11113036|NCT03984331|Active Comparator|Cadaver skin|All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.
11113037|NCT03984318|Experimental|patient treated with immune checkpoint targeted monoclonal AB|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
11113038|NCT03984305|Experimental|PKG+ Group|"For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is controlled or uncontrolled based on scores provided by the PKG."
11113039|NCT03984305|Placebo Comparator|PKG- Group|For subjects in the PKG- Group (SOC control group), participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
11113040|NCT03984292|Experimental|Mass Learning|Single teaching session of 3 hours shall be provided
11113041|NCT03984292|Experimental|Distributed Learning|Three teaching sessions of 1 hour each shall be provided.
11113042|NCT03984279||Sequentiel group (SEQ)|
11113043|NCT03984279||Siral group (SPI)|
11113044|NCT03984253||Severe Asthma|All patients with severe asthma who will be treated in the participating centers should be continuously enrolled in the register.
11113045|NCT03984240|Experimental|Brain eloquent area glioma group|The brain eloquent area glioma will be diagnosed by MRI scan.
11113046|NCT03984240|Active Comparator|control group|Healthy volunteers without intracranial diseases.
11113047|NCT03984227||SLE patient group|SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
11113048|NCT03984227||control group|The control group will include age and sex matched healthy volunteers
11113049|NCT03984214|Active Comparator|Dronabinol|BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)
11113050|NCT03984214|Placebo Comparator|Placebo|Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets
11113051|NCT03984201|Active Comparator|iTBS over L-DLPFC to dACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the dorsal anterior cingulate cortex (dACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.
~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
11113052|NCT03984201|Active Comparator|iTBS over L-DLPFC to sgACC|"Participants will receive iTBS (intermittent theta burst stimulation) to the left dorsal lateral prefrontal cortex (L-DLPFC) with high connectivity to the subgenual cingulate cortex (sgACC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.
~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
11113053|NCT03984201|Sham Comparator|Sham iTBS over L-DLPFC|"Participants will receive sham iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system.
~Sham stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
11113054|NCT03984188|Experimental|Low-dose Theophylline|Participant in this group will receive low-dose theophylline.
11113055|NCT03984188|Placebo Comparator|Placebo|Participant in this group will receive a placebo.
11113056|NCT03984175|Experimental|Patients with ARDS at three Intermountain tertiary hospitals|
11113057|NCT03984149||FH pediatric patients|1000 clinically diagnosed FH pediatric patients (age <18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
11113058|NCT03984136|Experimental|Intervention group|Men will be required to exchange the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends conditionally.
11113059|NCT03984136|Active Comparator|Control group|Men will share the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends freely without conditional exchange requirement.
11113060|NCT03984123|Other|Double cuff inflation|The first arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end-diastolic volume of left ventricle
11113061|NCT03984123|Other|Single cuff inflation|The second arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
11113062|NCT03984123|No Intervention|Standard treatment|The third arm utilizes no cuff inflation to cause remote conditioning and serves as control group. Follow up echocardiography is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
11113063|NCT03984110|Experimental|Combination of Ozurdex and Eylea|Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
11113065|NCT03984097|Experimental|TAK-079 and LenDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with lenalidomide, orally, once daily for 21 days and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until progressive disease (PD) or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to Month 36. The dosage of dexamethasone can be reduced for participants who are greater than (>) 75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
11113066|NCT03984097|Experimental|TAK-079 and VRd|TAK-079 subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter, along with bortezomib, subcutaneously, once on Days 1, 8, and 15, for a maximum of 8 cycles, lenalidomide, orally, once daily for 21 days, and dexamethasone, orally or intravenously, once on Days 1, 8, 15 and 22 in each 28-day treatment until PD or unacceptable toxicity, withdrawal of consent, death, or termination of the study by sponsor for up to Month 36. The dosage of dexamethasone can be reduced for participants who are >75 years, have poorly controlled diabetes, or had prior intolerance to or AE from corticosteroid therapy.
11113067|NCT03984084||externally recruited participants|Self-referred affected and non-affected participants responding to advertisements
11113068|NCT03984084||In-house patients|Patients seeking treatment in the outpatient clinic of the Max-Planck-institute of Psychiatry
11113069|NCT03984058|Other|Study Arm 1|All enrolled participants will have participants' PAP usage monitored by Fusion Health using the ResMed AirView Remote Monitoring system. Fusion Health will provide individual care for each participant by monitoring daily PAP usage by all study participants. This assessment ensures routine follow-up of PAP adherence during the study. The responsibility for patient care during the study, however, will fall on clinical site staff with any needed assistance by the Fusion Health staff. An intervention will be required when PAP adherence decreases or if any other issues are identified that require a face-to-face visit.
11113070|NCT03984045|Experimental|SPG block|SPG block performed by using qtip applicator soaked in 2% lidocaine and placed posteriorly into nasal cavity where it dwells for up to 30 min
11113071|NCT03984045|Active Comparator|Control|Delivered through IV access obtained in all patients.
11113072|NCT03984032|Experimental|LMA Protector Cuff Pilot|
11113073|NCT03984032|Active Comparator|LMA Supreme|
11113074|NCT03984019|Other|A|Radiotherapy; SBRT Additional cardiac diagnostics
11113075|NCT03983993|Experimental|Treatment (niraparib, panitumumab)|Patients receive 200 or 300 mg niraparib orally once daily on days 1-28 and 6 mg/kg panitumumab intravenously over 60-90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11113076|NCT03983980|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
11113077|NCT03983980|Placebo Comparator|Vehicle Cream Group|Vehicle cream applied once daily
11113078|NCT03983967|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Cytokine-Induced Killer cells; Immuncell-LC) 3 times(3 treatments at a frequency of once per week) or 6 times(3 treatments at a frequency of once per week followed by 3 treatments every 2 weeks)
11113079|NCT03983954|Experimental|Naptumomab estafenatox 2 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 2 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113080|NCT03983954|Experimental|Naptumomab estafenatox 5 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 5 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113081|NCT03983954|Experimental|Naptumomab estafenatox 10 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113082|NCT03983954|Experimental|Naptumomab estafenatox 15 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113083|NCT03983954|Experimental|Naptumomab estafenatox 20 µg/kg and durvalumab|NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113084|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 10 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 10 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113144|NCT03983499|No Intervention|Usual Care|Participants randomized to the Usual Care (UC) arm continue to see their primary care provider and receive referrals to health education. At the discretion of the provider, UC patients are screened and referred to behavioral health (BH) care.
11113145|NCT03983473|Other|Crohn's disease|Patients suffering from established Crohn 's disease without spondyloarthritis
11113146|NCT03983473|Other|Spondyloarthritis|Patients with established spondyloarthritis without Crohn 's disease
11113085|NCT03983954|Experimental|Dose escalation, obinutuzumab pretreatment followed by NAP 15 µg/kg and durvalumab|Obinutuzumab (1000 mg/day) will be administered on days 13 and 12 prior to the first day of NAP. NAP is to be administered on the first four days of each 21-day cycle, at daily doses of 15 µg/kg. Durvalumab (1120 mg, IV, 1- 1.5 hours after completion of the administration of NAP) will be administered on the second day of each 21-day cycle. After cycle 3, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113086|NCT03983954|Experimental|MTD expansion, obinutuzumab pretreatment with NAP at MTD and durvalumab|NAP at MTD and durvalumab (1120 mg) will be given for 6 cycles after pre-treatment of obinutuzumab (1000 mg/day) on D-13 and D-12. After cycle 6, patients will continue to receive durvalumab alone at a dose of 1500 mg delivered once every 28 days, until confirmed disease progression or unacceptable toxicity for a maximum of up to 24 months.
11113087|NCT03983941|Active Comparator|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
11113088|NCT03983941|Experimental|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
11113089|NCT03983928|Experimental|TQB2450 Combined with Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11113090|NCT03983915|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
11113091|NCT03983915|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
11113092|NCT03983902|Active Comparator|Delayed cord clamping|Delayed cord clamping
11113093|NCT03983902|Active Comparator|Umbilical cord milking|Umbilical cord clamping
11113094|NCT03983902|Active Comparator|Immediate cord clamping|Immediate cord clamping
11113095|NCT03983889|Experimental|F|Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
11113096|NCT03983889|Experimental|DR|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
11113097|NCT03983889|Experimental|DF|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
11113098|NCT03983889|Experimental|PR|Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
11113099|NCT03983876|Experimental|AVT02 100mg/mL in PFS|Prefilled Syringe Arm
11113100|NCT03983876|Experimental|AVT02 100mg/mL in Autoinjector|Autoinjector Arm
11113101|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
11113102|NCT03983850|No Intervention|Donor Arm|Collection of bone marrow and/or PBSC (Up to 40 donors)
11113103|NCT03983850|Experimental|Phase I Dose De-escalation|PTCy at deescalating doses (25 mg /kg/day on days +3 and +4, and PTCy 25 mg/kg on day +4) to assess forsafety and determine Phase II dose (up to 12 evaluable patients)
11113104|NCT03983850|Experimental|Phase I Pilot for Comparative Data|Standard PTCy 50 mg/kg/day on days +3 and +4, in asmall pilot (up to 5 evaluable patients) for comparativedata
11113105|NCT03983850|Experimental|Phase II Efficacy|PTCy at shortest duration, safe dose (from Phase I) toassess efficacy at providing adequate protection from grade 3-4 acute GVHD (up to 14 additional patients)
11113106|NCT03983837|Experimental|1|Participants will be on this diet for 4 weeks. The amount per serving will be determined on the basis of the participant s weight and caloric needs, as determined by a staff dietician.
11113107|NCT03983824|Experimental|Treatment (M3814, mitoxantrone, etoposide, cytarabine)|Patients receive M3814 PO BID on days 2-21, mitoxantrone IV over 15 minutes, etoposide IV over 60 minutes and cytarabine IV over 60 minutes on days 1-5 in the absence of disease progression or unacceptable toxicity.
11113108|NCT03983811|Experimental|Chemotherapy+Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
11113109|NCT03983811|Placebo Comparator|Chemotherapy+Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
11113110|NCT03983798||Simulation training in psychiatry|Convenient sample of 72 voluntary medical students, allocated among 6 groups of around 12 students, will be recruited at Paris Descartes, Paris Diderot and Brest Universities between september of 2018 and June of 2019.
11113111|NCT03983785|Experimental|Pilates|
11113112|NCT03983785|Experimental|Elastic Taping|
11113113|NCT03983785|No Intervention|Wait List Control|
11113114|NCT03983772|Experimental|RS10-10-10|First 2 weeks is for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 10 g RS blend. Fourth 2 weeks is 10 g RS blend.
11113115|NCT03983772|Experimental|RS10-20-20|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 20 g RS blend.
11113116|NCT03983772|Experimental|RS10-20-30|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g resistant starch (RS) blend. Third 2 weeks is 20 g RS blend. Fourth 2 weeks is 30 g RS blend.
11113117|NCT03983772|Placebo Comparator|Placebo10-10-10|First 2 weeks are for baseline variability measurement (no product). Second 2 weeks is 10 g placebo. Third 2 weeks is 10 g placebo. Fourth 2 weeks is 10 g placebo.
11113147|NCT03983473|Other|Crohn + spondyloarthritis|Patients suffering from both spondyloarthritis and Crohn 's disease
11113148|NCT03983473|Other|healthy controls|Patients without spondyloarthritis and Crohn 's disease
11113230|NCT03982849|Active Comparator|Hydroquinone group|Hydroquinone 4% cream Cream applied once daily at night on affected areas for 3 months.
11113118|NCT03983759|Experimental|treatment group|"phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events.
~the dose of sintilimab is fixed dose of 200mg every three weeks"
11113119|NCT03983746|Experimental|traditional physical therapy program (control group)|fifteen children with DS received a traditional exercises program with instructions to the children for 60 minutes aiming to improve posture control and balance
11113120|NCT03983733|Experimental|Dietary Intervention|Dietary intervention using standardised test meals, on up to 8 days within the study period.
11113121|NCT03983720|Experimental|Patient with multiple sclerosis and lowly fatigued|"Patient with multiple sclerosis and lowly fatigued will be included.
~They will have:
~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
11113122|NCT03983720|Experimental|Patient with multiple sclerosis and highly fatigued|"Patient with multiple sclerosis and highly fatigued will be included. They will have:
~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
11113123|NCT03983720|Active Comparator|Healthy subjects|"Healthy subjects will be included. They will have:
~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue"
11113124|NCT03983694||BabyLux device|Cerebral haemodynamics of neonates undergoing erythrocyte transfusion according to the local clinical guidelines are monitored with BabyLux device before and after transfusion and with traditional NIRS during itself.
11113125|NCT03983681|Experimental|Experimental|The experimental group will receive memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
11113126|NCT03983681|Placebo Comparator|Control group|The control group will receive placebo memory enhancement exercises administered twice a week for 4 weeks (8 training sessions).
11113127|NCT03983668|Experimental|CMP-001 plus pembrolizumab|Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab
11113128|NCT03983655|Experimental|Real High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.
11113129|NCT03983655|Sham Comparator|Sham High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
11113130|NCT03983642|Experimental|Intervention group|The intervention group received a session of 40min for an 8 weeks' period. Both games requested the participants to stand on a balance board in front of the television, without shoes, while trying to control their avatars by shifting their body weights.
11113131|NCT03983642|No Intervention|Control group|Participants in the control group were followed-up by an assessor, who made sure that they will not get involved in any type of training program during the eight weeks' period of the trial.
11113132|NCT03983629||CDA patients|
11113133|NCT03983603|Experimental|Plant stanol group|This arm receives soft chews containing 0.5g of plant stanols (delivered as plant stanol esters).
11113134|NCT03983603|Placebo Comparator|Placebo group|This arm receives soft chews that do not contain 0.5g of plant stanols (delivered as plant stanol esters).
11113135|NCT03983577|Experimental|Point of service delivery model|After the informed consent is signed, the participant will watch a standardized video on the principles of genetic testing. At the end of the video, the provider will return to answer any remaining questions. The participant will receive pre- and post- surveys for evaluation of the delivery model.
11113136|NCT03983564||All patients|Patients in this group will serve to validate the cutoff of the combination of the DES-OSA and BOSTON scores derived in the retrospective group.
11113137|NCT03983551|Experimental|Dipeptidyl peptidase 4 inhibitors|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
11113138|NCT03983551|Active Comparator|Sulfonylureas|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
11113139|NCT03983538||Patients receiving chemotherapy|Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference.
11113140|NCT03983525|Experimental|Goji berry|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
11113141|NCT03983525|Active Comparator|Lutein + zeaxanthin supplementation|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
11113142|NCT03983512|Experimental|PULSTA TPV|PULSTA Transcatheter Pulmonary Valve (TPV) System
11113143|NCT03983499|Experimental|Special Intervention|The special intervention (SI) arm addresses glycemic control, medication adherence, control of modifiable CVD risk factors, health behavior change, and psychosocial and cultural barriers to self-management. The SI arm consists of a collaborative care team approach with four main elements including: 1) Specialized clinical care by a medical provider; 2) Specialized behavioral health care by a behavioral health provider; 3) Group-based chronic disease self-management education by peer-leaders; 4) Intensive, proactive care coordination facilitated by a patient registry and electronic health records.
11113149|NCT03983460|Experimental|Dupimulab arm|"At Day 0, patients will receive Dupilumab treatment. The recommended dose of Dupilumab for adult patients is an initial dose of 600mg followed by 300mg given every two weeks administered as subcutaneous injection. Dupilumab could be self-administered by subcutaneous injection into thigh or abdomen or injected in the upper arm in case of administration by the patient's caregiver. It is recommended to rotate the injection site with each injection.
~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
11113150|NCT03983460|Active Comparator|Optimized TCS treatment arm|"At Day 0, patients will receive topical corticosteroid treatment (TCS) adapted to the AD severity (potent and very potent TCS) with a personal therapeutic education for treatment optimization. It will be asked to perform, every day, an application of topical corticosteroid (TCS) (betamethasone valerate cream 0.1%, and if not active, clobetasol propionate cream 0.05%) on active lesions. Once the AD lesion is cleared, the patients will continue to apply TCS on healed lesions, twice a week until the end of the treatment period to prevent relapse.
~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
11113151|NCT03983447|Experimental|School-based intervention to promote Physical Activity (PA)|"This intervention included :
~Physical (Environmental) adaptation of playground
~Time adaptation of lunch breaks
~Curriculum-based program of children
~Workshops and newsletters for parents
~Meetings for teachers"
11113152|NCT03983447|No Intervention|Control|Nothing has changed in the school.
11113153|NCT03983434||Healthy volunteers|Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.
11113154|NCT03983434||Irritable Bowel Syndrome Patients with Diarrhea|Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS
11113155|NCT03983434||Irritable Bowel Syndrome Patients with Constipation|Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS
11113156|NCT03983421|No Intervention|Treatment as Usual|Treatment as usual enhanced with a brief psychosis literacy training (45-60 minutes) for the counselors at the university's student health and counseling center
11113157|NCT03983421|Other|Screening|Implementation of the Prodromal Questionnaire - Brief, which is a screening tool to detect risk of psychosis.
11113158|NCT03983421|Other|Screening Plus Warm Hand-Off|Addition of a warm hand-off to coordinated specialty care (CSC) for those determined eligible on the screening tool.
11113159|NCT03983408|Active Comparator|KRG group|"Enrollment: 60 patients
~Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)"
11113160|NCT03983408|Placebo Comparator|Placebo group|"Enrollment: 60 patients
~Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks"
11113161|NCT03983395|Experimental|Part 1: Cohort 101 - ISB 1302 250 ng/kg|Cohort 101, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
11113162|NCT03983395|Experimental|Part 1: Cohort 201 - ISB 1302 325 ng/kg|Cohort 201, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
11113163|NCT03983395|Experimental|Part 1:Cohort 301- ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Cohort 301, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
11113164|NCT03983395|Experimental|Part 1:Cohort 401- ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Cohort 401, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
11113165|NCT03983395|Experimental|Part1Cohort501-ISB1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Cohort 501, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
11113166|NCT03983395|Experimental|Part1Cohort601-ISB1302 325ng/kgD1;550 ng/kg D8;900 ng/kgD15,22|Cohort 601, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
11113167|NCT03983395|Experimental|Part 1 Cohort 701- ISB 1302 escalating doses,1200 ng/kg D15,22|Cohort 701, subjects will be administered ISB 1302 by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
11113168|NCT03983395|Experimental|Part 2 (Dose Expansion) -ISB 1302 at the MTD and/or RP2D dose|Subjects treated with ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
11113169|NCT03983382||HER2-Positive Breast Cancer|
11113170|NCT03983369|Experimental|"preventive treatment with LLLT (Laser group)"|
11113171|NCT03983369|Placebo Comparator|control group with a placebo intervention|
11113172|NCT03983356|Experimental|Group of GPs receiving training|GPs, psychologists and social workers in the intervention regions will receive a training program.
11113173|NCT03983356|No Intervention|Group of GPs receiving no attention|GPs, psychologists and social workers in the control regions will not receive information about the intervention.
11113174|NCT03983343|No Intervention|control group|Standard technique: Suturing the perineal skin with fast-absorbable running sutures (Vicryl Rapide 3-0).
11113175|NCT03983343|Active Comparator|intervention group|Closing the perineal skin using adhesive glue- dermabond®
11113228|NCT03982862|Active Comparator|control group|0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume
11115265|NCT03968614|Active Comparator|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
11113176|NCT03983330|Experimental|Intervention group|"The trained RA will deliver brief MI to each subject individually via WeChat or WhatsApp in the smart phones throughout the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once per 2-3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering message through WeChat or WhatsApp will be interactive, depended on subjects' actions and responses.
~Start from 6 months, minimal messages by merely following the subjects' progress and responding to their questions to maintain contact will be provided to subjects till one-year follow-up.
~The readiness of quitting smoking will be assessed at 3-month follow-up. For those who are willing to take further actions to promote their health, i.e. with an intention to quit smoking, health advice on smoking will be given with more emphasis on the health benefits of quitting. The whole intervention will be given through WeChat/WhatsApp."
11113177|NCT03983330|Other|Control group|Subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months
11113178|NCT03983317|No Intervention|Baseline|For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
11113179|NCT03983317|Experimental|Active treatment|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
11113180|NCT03983304|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
11113181|NCT03983291|Experimental|FaReWell Depression|Physiotherapeutic exercises for the relaxation of facial muscles associated with the expression of negative emotions and for the activation and strengthening of facial muscles associated with the expression of positive emotions 15 minutes daily
11113182|NCT03983291|Placebo Comparator|Resting exercise|Resting 15 minutes daily
11113183|NCT03983278|Experimental|School Model|School Model (n=47 schools): Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.
11113184|NCT03983278|Experimental|Referral Model|Referral Model (47 schools): Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary.
11113185|NCT03983278|Experimental|Referral Model + Cost Recovery|"Referral Model + Cost Recovery (47 schools): Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles (which was shown to be appealing to families in the recent PRICE study. These spectacles have scratch-proof coatings and designs selected to appeal to local children. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary."
11113186|NCT03983265|Other|computer guided condylar reposition device|surgical procedure : under general anesthesia after BSSO condyle will be repositioned by computer guided repostioning device
11113187|NCT03983252|Experimental|Relapsing Remitting Multiple Sclerosis starting Alemtuzumab|"Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (defined by International Panel Criteria), age 18-60 years, enrolled to start treatment with alemtuzumab.
~Subjects will undergo [F-18]PBR06 PET scans at baseline, 6 months and 18 months."
11113188|NCT03983239|Experimental|Fedratinib plus Rifampin|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of rifampin. On Day 17, a single dose of fedratinib will be concomitantly administered with rifampin.
11113189|NCT03983239|Experimental|Fedratinib plus Efavirenz|A single dose of fedratinib on Day 1. On Days 9 through 18, once-daily (QD) doses of efavirenz. On Day 17, a single dose of fedratinib will be concomitantly administered with efavirenz.
11113190|NCT03983226|Experimental|Surgery|"Intervention:
~Procedure: Maximum effort cytoreductive surgery combined with Niraparib maintenance Drug: Platinum-based chemotherapy and Niraparib"
11113191|NCT03983226|Active Comparator|No surgery|Intervention: Drug: Platinum-based chemotherapy and Niraparib
11113192|NCT03983213||Pat. after mpfl reconstruction|All 45 subjects operated with mpfl reconstruction included to chek-up after follow-up.
11113193|NCT03983200|Sham Comparator|Control group|Mecobalamine 0.5mg, tid
11113194|NCT03983200|Experimental|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid
11113195|NCT03983187|No Intervention|Control|
11113196|NCT03983187|Experimental|Rotating Magnetic Therapy group|
11113197|NCT03983174|Experimental|Drainage seton with flap|Drainage seton will be put around the external anal sphincter with mucosal advancement flap
11113198|NCT03983174|Experimental|EAS sparing seton|Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done
11113199|NCT03983161|Experimental|Fedratinib in moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to subjects with moderate hepatic impairment
11113200|NCT03983161|Experimental|Fedratinib in severe hepatic impairment subjects|A single dose of 200 mg of fedratinib will be given to subjects with severe hepatic impairment
11113201|NCT03983161|Experimental|Fedratinib in healthy vs moderate hepatic impairment subjects|A single oral dose of 300 mg of fedratinib will be given to healthy subjects with normal hepatic function.
11113202|NCT03983161|Experimental|Fedratinib in healthy vs severe hepatic impairment subjects|A single oral dose of 200 mg of fedratinib will be given to healthy subjects with normal hepatic function.
11113203|NCT03983148|Experimental|Motivational interviewing|Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
11113229|NCT03982862|Experimental|botox group|4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume
11115566|NCT03966196|Other|Healthy Volunteers|oxymetry and finger pressure in Healthy subjects
11113204|NCT03983148|Placebo Comparator|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.
~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
11113205|NCT03983135|Experimental|Study group|Patients who undergo revisional bariatric surgery
11113206|NCT03983122|Experimental|Study group|Patients who undergo laparoscopic sleeve gastrectomy
11113207|NCT03983109|Experimental|Detection by EpiFaith syringe with air|
11113208|NCT03983109|Experimental|Detection by EpiFaith syringe with saline|
11113209|NCT03983096||test group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used Pegylated liposomal doxorubicin for treat.
11113210|NCT03983096||control group|Patients with invasive breast cancer diagnosed by menstrual histology in 2014-2018 and receiving neoadjuvant chemotherapy, or patients with invasive breast cancer diagnosed by menstrual histology in 2014-2016 and receiving adjuvant chemotherapy. That used epirubicin for treat.
11113211|NCT03983083|Experimental|Intervention|Aspects of the HEALED intervention are based on various components of successful interventions for breast cancer survivors and older adults, NCI funding priorities, CPS-3 survivor preferences discussed in prior focus groups and survivorship research from other cohorts. As such, HEALED participants will receive monthly motivational e-mails, based on prior studies of the most effective delivery time intervals for interventions involving cancer survivors, with links to a web-based platform which will provide: physical activity information (largely consisting of publicly available evidence-based resources), at-home exercise demonstrations/videos for survivors of all fitness levels, personal survivor stories, physical activity/sitting recommendations (based on National Guidelines and ACS guidelines for survivors), positive messaging, a space for SMART goal setting, a platform for physical activity tracking, a discussion board, etc.
11113212|NCT03983083|No Intervention|Wait-list control|"Wait-listed control group will be instructed to continue behavior as-usual. They will receive access to the HEALED website at the end of the 12-week intervention period."
11113213|NCT03983070|Active Comparator|Control Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
11113214|NCT03983070|Experimental|Blood Flow Restriction and Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include the application of blood flow restriction during two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 40% maximal Watts, and deadlifts at 30% of one-repetition maximum. Blow flow restriction will be applied at 80% occlusion during both exercise modalities.
11113215|NCT03983057|No Intervention|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
11113216|NCT03983057|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 3mg/kg
11113217|NCT03983005||Patients with suspected lung cancer|Patients with pulmonary parenchymal lesions suspected for malignancy in contact or adjacent to the esophagus which can be sampled by EUS-B-FNA
11113218|NCT03982992|Experimental|DLI-TARGET|"14d screening period: methotrexate, cytarabine, dexamethasone infusion i.th.
~Cycle 1 (all patients): d1-28: blinatumomab continuous infusion i.v., d4: allogeneic donor lymphocyte single infusion i.v., d29: methotrexate, cytarabine, dexamethasone infusion i.th.
~Cycle 2 (only patients with toxicity ≤ grade 2 CTCAE in cycle 1): d43-d70: blinatumomab continuous infusion i.v., d46: allogeneic donor lymphocyte single infusion i.v., d71: methotrexate, cytarabine, dexamethasone infusion i.th."
11113219|NCT03982966|Experimental|Omega 3|Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)
11113220|NCT03982966|No Intervention|Control|20 patients will not take omega 3 fatty acids.
11113221|NCT03982953||PD patients with STN-DBS|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus
11113222|NCT03982953||Controls - PD patients with medical treatment|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.
11113223|NCT03982940|Experimental|BGP+ Stent Graft System|Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms
11113224|NCT03982901|Experimental|women with chest pain|women with chest pain and coronary artery stenosis less than 50%
11113225|NCT03982901|Sham Comparator|healthy women|women without chest pain and coronary artery stenosis less than 50%
11113226|NCT03982888|Experimental|DBS Treatment|Deep brain stimulation of both limbic and dysfunctional reward processing circuits for treatment of repetitive self injurious behaviours in children with ASD
11113227|NCT03982875|Experimental|SmartBag arm|"The Alfred SmartBag System will be placed on the ostomy site during surgery. The system will be used to wirelessly monitor ostomy function in the hospital setting and the patient will otherwise receive the standard of care. At discharge the patient will continue to use the Alfred SmartBag System and ostomy function will be monitored by the research and clinical teams remotely.
~If participant's output is (i) less than 50mL or greater than 1500mL per day or (ii) greater than 1200mL in two days; the mobile app will alert not only the participant but also the clinical staff (nurse).
~Participants will also receive support from a 'Patient Coach', a trained health coach who is also an ostomy patient to provide quality of life support."
11113231|NCT03982849|Experimental|Silymarin group|Silymarin 0.7% cream Cream applied twice daily on affecectec areas for 3 months.
11113232|NCT03982836|Experimental|Fructooligosaccharide|All the 25 volunteers received the sandwich containing 20 grams of fructooligosaccharide
11113233|NCT03982836|Experimental|Partially hydrolyzed guar gum|All the 25 volunteers received the sandwich containing 20 grams of partially hydrolyzed guar gum
11113234|NCT03982836|Placebo Comparator|Maltodextrin|All the 25 volunteers received the sandwich containing 20 grams of Maltodextrin
11113235|NCT03982823|Experimental|Hand-Sewn Sleeve Gastrectomy|
11113236|NCT03982823|Active Comparator|Stapled Sleeve Gastrectomy|
11113237|NCT03982810||Surgical Site Infections|Patients equal or greater than 18 years of age undergoing non-emergent non-cardiac surgical procedures involving a skin incision will be included in the study.
11113238|NCT03982797|Experimental|treated with IMUNO BCG Moreau RJ adjuvant.|
11113239|NCT03982784|Experimental|single-injection TQLB(transmuscular quadratus lumborum block)|Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
11113240|NCT03982784|Active Comparator|Control|postoperative IPCA is given alone
11113241|NCT03982771|Experimental|BCD regimen|Bortezomib, cyclophosphamide and dexamethasone (the BCD regimen) would be utilized in newly diagnosed iMCD (idiopathic Multicentric Castleman's disease) patients
11113242|NCT03982758|Experimental|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
11113243|NCT03982758|Experimental|isometric of lower limbs|Isometric session for lower limbs: 4 series with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute.
11113244|NCT03982732||Women vaccinated at less than 24 weeks|Women receiving a pertussis containing vaccine at less than 24 weeks
11113245|NCT03982732||Women vaccinated at 24-27+6 weeks|Women receiving a pertussis containing vaccine at 24-27+6 weeks
11113246|NCT03982732||Women vaccinated at 28-31+6 weeks|Women receiving a pertussis containing vaccine at 28-31+6 weeks
11113247|NCT03982719|Experimental|Brief protocol|4 intervention sessions with the occupational therapist of 30 minutes duration.
11113248|NCT03982719|Active Comparator|Intense Protocol|6 intervention sessions with the occupational therapist of 60 minutes duration.
11113249|NCT03982706||MRI-US Fusion|patients undergoing MRI targeted prostate biopsy
11113250|NCT03982706||Focal|patients undergoing focal treatment for localized prostate cancer (HIFU, NanoKnife, Cryotherapy)
11113251|NCT03982693|Active Comparator|Active|edetate disodium (EDTA)dff active infusion
11113252|NCT03982693|Placebo Comparator|Placebo|Placebo infusion
11113253|NCT03982680|Experimental|Toripalimab combined with Gem/5-FU|All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.
11113254|NCT03982667|Experimental|PCT group|For patients randomly assigned to the PCT-guided group, measurements of serum PCT concentrations (Day 1, 3, 7, and 9) will be taken and made available to the attending physicians. This means 3 ml of whole blood will be sampled from the arterial line of the patients for each measurement the serum PCT in plain tubes. The samples will be immediately assayed for the PCT measurement using the available device and the results will be ready in next 30 minutes after running the system.
11113255|NCT03982667|No Intervention|Standard-of-care group|
11113256|NCT03982654|Experimental|Bloomlife|
11113257|NCT03982641||Colon surgery|patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
11113258|NCT03982641||Rectal surgery|patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
11113259|NCT03982628||Sepsis|Adults admitted to a mixed medical/surgical ICU for sepsis with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
11113260|NCT03982628||Trauma|Adults admitted to a mixed medical/surgical ICU for trauma (without sepsis) with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
11113261|NCT03982615|Experimental|Laser-Lok abutment|Laser-etched abutment
11113262|NCT03982615|Active Comparator|Standard Healing abutment|Standard abutment which is not laser-etched
11113263|NCT03982602|Experimental|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 [fat]: [protein + carbohydrate] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
11113264|NCT03982576|Experimental|CS Relapse Prevention|"Participants will receive 4 group sessions of a novel culturally specific, CBT-based intervention. They will also receive Path2Quit, a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Notably, CS relapse prevention will incorporate surface and deep structure elements,17 including race-matched interventionists, religion/spirituality, discussion of race-related stress, traditional values (e.g., collectivism), culturally specific recipes, etc.
~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
11113265|NCT03982576|Active Comparator|Standard Relapse Prevention|"Participants will receive 4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov. Participants will also receive SmokefreeTXT, the NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7.
~All participants will receive 4 weeks of nicotine replacement therapy (NRT; transdermal nicotine patches or nicotine gum)."
11113266|NCT03982563|Experimental|Growth Mindset|
11113267|NCT03982563|Experimental|Gratitude|
11113268|NCT03982563|Experimental|Behavioral Activation|
11113269|NCT03982563|Sham Comparator|Study Skills|
11113697|NCT03979547|No Intervention|Standard of Care|Subjects are instructed to maintain their current activity level.
11113270|NCT03982550|No Intervention|Control Period|Participants will serve as their own controls. All 12-week control periods will take place before the RT intervention to ensure that results are not confounded by detraining effects or long-term cognitive benefits of RT. In addition, a control period equal in duration to the intervention allows direct within-subjects statistical comparisons, accounting for each participants' baseline and rate of aging - i.e. age-associated cognitive decline and arterial stiffening. Participants will not be monitored, but may be contacted for scheduling.
11113271|NCT03982550|Experimental|Intervention Period|Participants will perform a periodized and progressive total-body RT program emphasizing development of lower and upper body strength. All 36 training sessions (3 days per week for 12 weeks) will be performed at the CERC, supervised by an exercise specialist. Participants will be encouraged to continue normal activities of daily living and eating routines outside the RT program of the present study. Because this is a proof-of concept study on normal aging, participants may be contacted for scheduling, but will not be monitored outside of training.
11113272|NCT03982537|Experimental|Nature's Blend N-Acetyl-L-Cysteine 600 mg with Chemotherapy|The treatment with NAC will be given twice daily for at least 10 days with the goal to cover the window of opportunity time between the treatment decision for CRT and the beginning of treatment (usually 14-21 days).
11113273|NCT03982537|Other|Standard of Care Chemotherapy (CONTROL)|Patients will receive definitive or adjuvant concurrent chemotherapy and radiotherapy as per standard of care
11113274|NCT03982524|Experimental|CBT complemented with emotion regulation training|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
11113275|NCT03982524|Active Comparator|Cognitive behavior therapy (CBT)|"This arm is based on conventional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
11113276|NCT03982511|Experimental|PCIT-Health|Participants assigned to the PCIT-Health arm will receive the intervention.
11113277|NCT03982511|No Intervention|Wait list control|Participants in the wait list control will receive an invitation to participate in the intervention 10 months after baseline data collection.
11113278|NCT03982485|Experimental|Arm I|Apatinib+Paclitaxel+Cisplatin
11113279|NCT03982485|Active Comparator|Arm II|Paclitaxel+Cisplatin
11113280|NCT03982472|Experimental|TENS right side|TENS stimulation at the right side
11113281|NCT03982472|Experimental|TENS left side|TENS stimulation at the left side
11113282|NCT03982472|No Intervention|sham stimulation|Sham stimulation
11113283|NCT03982459|Experimental|Decision support tool|Patients in this single-arm study all receive training in use of a decision support tool by a trained coordinator.
11113284|NCT03982446||Patients with germline mutations|This group will comprise of patients with pancreatic cancer who carry pathogenic mutations in genes associated with a predisposition to cancer.
11113285|NCT03982446||Patients without germline mutations|This group will comprise of patients with pancreatic cancer who did not carry pathogenic mutations in any of the genes tested, that have been previously shown to be associated with a predisposition to cancer.
11113286|NCT03982433|Experimental|Intervention|participants all receive the intervention
11113287|NCT03982407|Experimental|Ga68 PSMA PET-MR|68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan
11113288|NCT03982394||Participants treated with Risankizumab|Treatment decision independently made of study enrollment
11113289|NCT03982394||Participants treated with other approved biological therapies|Treatment decision independently made of study enrollment
11113290|NCT03982381|Active Comparator|Metformin|Metformin 1000-3000 mg per day according to clinical guidelines. Split into 2-3 doses per day.
11113291|NCT03982381|Experimental|Dapagliflozin|Dapagliflozin 10 mg once daily
11113292|NCT03982368|Experimental|rhNGF 20 μg/ml TID|One drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
11113293|NCT03982368|Experimental|rhNGF 20 μg/ml BID + vehicle OD|One drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily (BID) plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (OD) (every 6-8 hours)
11113294|NCT03982368|Placebo Comparator|Vehicle TID|Vehicle eye one drop will be instilled in both eyes three times daily (every 6-8 hours)
11113295|NCT03982355||Breast Cancer|Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
11113296|NCT03982355||Rectal Cancer|Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
11113297|NCT03982342|Active Comparator|Catheter-closure of PDA|Infants randomized to this group will undergo a catheter procedure to close hemodynamically-significant patent ductus arteriosus (HSPDA).
11113298|NCT03982342|Active Comparator|Conservative management of PDA|"Infants randomized to this group will be treated to reduce the symptoms of a hemodynamically-significant patent ductus arteriosus (HSPDA), in the hopes that over time the HSPDA will become reduced in size (to the point of no longer meeting criteria for being hemodynamically significant) or close naturally. Infants in this group with declining health status attributable to a PDA which meet qualifying criteria may receive catheter closure (intervention) if deemed medically necessary."
11113299|NCT03982329|Active Comparator|nrTMS group|15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days
11113300|NCT03982329|Sham Comparator|sham group|15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days
11113334|NCT03982186|Experimental|Arm 5: Placebo + JNJ-56136379 + NA|Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
11113301|NCT03982316|Experimental|Telehealth Behavioral Migraine Management|Participants will receive weekly online education sessions in the following categories: Relaxation, Early Warning Signs, Triggers, Medication Adherence, Reducing Migraine Impact, Stress Management, Biofeedback, and Relapse Prevention. Participants will receive four monthly 50-minute telehealth sessions with a doctoral psychology student in a clinical health psychology program covering these topics, and three check-ins to enhance adherence to behavior change strategies. Participants will complete a daily headache diary throughout the course of treatment.
11113302|NCT03982303|Experimental|Hemay102 at the dosage of 5mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 5mg/m2.
11113303|NCT03982303|Experimental|Hemay102 at the dosage of 10mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 10mg/m2.
11113304|NCT03982303|Experimental|Hemay102 at the dosage of 20mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 20mg/m2.
11113305|NCT03982303|Experimental|Hemay102 at the dosage of 40mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 40mg/m2.
11113306|NCT03982303|Experimental|Hemay102 at the dosage of 60mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 60mg/m2.
11113307|NCT03982303|Experimental|Hemay102 at the dosage of 90mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 90mg/m2.
11113308|NCT03982303|Experimental|Hemay102 at the dosage of 120mg/m2|Hemay102 will be administered to patients through i.v. drip for 4hrs at the dosage of 120mg/m2.
11113309|NCT03982290|Active Comparator|Lactobacillus plantarum PS128 (PS128)|Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks.
11113310|NCT03982290|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks.
11113311|NCT03982290|No Intervention|Normal Control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
11113312|NCT03982277|Experimental|High dose Rifampin + DTG|High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
11113313|NCT03982277|No Intervention|Standard dose Rifampin + DTG|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
11113314|NCT03982277|Experimental|High dose Rifampin + EFV|High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
11113315|NCT03982277|No Intervention|Standard dose Rifampin + EFV|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
11113316|NCT03982264|Active Comparator|ESD group|In ESD group, enrolled patients will receive the treatment modality of ESD to remove the rectal NET
11113317|NCT03982264|Experimental|EMR-C group|In EMR-C group, enrolled patients will receive the treatment modality of EMR-C to remove the rectal NET
11113318|NCT03982251|Experimental|High frequency whole body vibration|This group will receive a single 8-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
11113319|NCT03982251|Active Comparator|low frequency whole body vibration|This group will receive a single 12-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
11113320|NCT03982238|Active Comparator|Control group|continuous subcutaneous insulin infusion therapy
11113321|NCT03982238|Experimental|Metformin|metformin therapy
11113322|NCT03982238|Experimental|Dapagliflozin|Dapagliflozin
11113323|NCT03982225|Experimental|2.5% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 2.5% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11113324|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.2 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11113325|NCT03982225|Experimental|5.0% Polyene Phosphatidylcholine Injection 0.4 mL/1.0 cm|Participants receive 5.0% polyene phosphatidylcholine administered in 0.4 mL injections, 1.0 cm apart, up to 20.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11113326|NCT03982225|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants receive placebo administered in 0.2 mL injections, 1.0 cm apart, up to 10.0 ml per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11113327|NCT03982212|Experimental|Intratumoral Copaxone|Eligible subjects receive at least 1 and up to 3 doses of Copaxone® 40 milligrams (mg) intratumorally prior to standard of care surgery. The doses will be administered at least 48 hours apart. The last dose will be given within 96 hours of standard of care surgery.
11113328|NCT03982199|Experimental|Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. A subset of participants will receive Ad26-based RSV vaccine as re-vaccination on Day 365 (1 year after the first vaccination).
11113329|NCT03982199|Placebo Comparator|Group 2: Placebo|Participants will receive a single IM injection of placebo control on Day 1. A subset of participants will receive Ad26-based RSV vaccine as re-vaccination on Day 365 (1 year after the first vaccination).
11113330|NCT03982186|Experimental|Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA|Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]) up to 48 weeks.
11113331|NCT03982186|Experimental|Arm 2: JNJ-73763989 (high dose) + Placebo + NA|Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
11113332|NCT03982186|Experimental|Arm 3: JNJ-73763989 (medium dose) + Placebo + NA|Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
11113333|NCT03982186|Experimental|Arm 4: JNJ-73763989 (low dose) + Placebo + NA|Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
11113335|NCT03982186|Placebo Comparator|Arm 6 (Control): Placebo + Placebo + NA|Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
11113336|NCT03982173|Experimental|previously treated patients with solid tumors|previously treated patients with solid tumors harboring a high mutational load.
11113337|NCT03982160|Experimental|L-arginine|Intravenous infusion of L-arginine (250-350 mg/kg) will be performed for 30 minutes.
11113338|NCT03982160|Placebo Comparator|Saline|Saline will be infused for 30 minutes
11113339|NCT03982147||Stroke patients|Patients with recent ischaemic stroke
11113340|NCT03982134|Experimental|PDR001 with Panobinostat|All enrolled patients will be treated with a combination of PDR001 at 400mg every 4 weeks and panobinostat. Dose and frequency of Panobinostat will vary depending upon the dose-level cohort of the study participants. Each participant will be assigned to a particular dose-level cohort.
11113341|NCT03982121|Experimental|A|FOLFOX IV + NIVOLUMAB IV
11113342|NCT03982121|Experimental|B|FOLFOX IV + GLA IT
11113343|NCT03982121|Experimental|C|FOLFOX IV + IPILIMUMAB IT
11113344|NCT03982121|Experimental|D|FOLFOX IV + NIVOLUMAB IV + GLA IT
11113345|NCT03982121|Experimental|E|FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT
11113346|NCT03982121|Experimental|F|LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT
11113347|NCT03982108|Experimental|Knotless suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knotless suture-bridge technique.
11113348|NCT03982108|Active Comparator|Knot-tying suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knot-tying suture-bridge technique.
11113349|NCT03982082|Experimental|Device feasibility (MuscleSound technology)|Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.
11113350|NCT03982069|Active Comparator|FluMist live attenuated influenza vaccine|Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
11113351|NCT03982069|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
11113352|NCT03982056||Main study group|"Assessments performed:
~Height
~Mass
~Body fat density
~Bone density
~Lean muscle density
~Lung volume measurements
~Floating technique
~Buoyancy"
11113353|NCT03982056||Validation group|"Assessments performed:
~Height
~Mass
~Body fat density
~Bone density
~Lean muscle density
~Lung volume measurements
~Floating technique
~Buoyancy"
11113354|NCT03982043|Experimental|Text2Connect|Participants receiving Text2Connect (T2C) personalized messages aimed at increasing motivations in at-risk adolescents and their parents. The most salient of the following behavior change techniques will be selected and targeted messaging will be deployed on the participants' phone: psychoeducation, cued mood monitoring, adolescent-parent communication prompts, cognitive bias modification, and cues to action. Intervention material will be tailored to baseline characteristics and T2C will generate reports to providers.
11113355|NCT03982030|Experimental|Dalbavancin|Participants with susceptible gram-positive infections requiring prolonged parenteral antibiotic therapy will be treated with dalbavancin.
11113356|NCT03982017|Active Comparator|Usual care|Consists of routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
11113357|NCT03982017|Experimental|Application|Participants will be provided a special link to navigate to the online content and resources.
11113358|NCT03982004|Experimental|Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF|"Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-15 (every 2 weeks for the first 2 treatments, then every 3 weeks until week 15)
~Topical imiquimod will be applied 5 days per week (5 days on, 2 days off from weeks 1-15)
~Pembrolizumab will be given every 3 weeks for a minimum of 4 cycles starting at Week 3 until disease progression or unacceptable toxicity.
~Intra-lesional GM-CSF 250 mcg every 2 weeks x 2 doses then every 3 weeks for 3 doses"
11113359|NCT03981965|Experimental|Focus guidelines|"Participants enrolled in a 2-phase physical activity program divided in 2 phases as described above. Briefly, The activity consisted in a 1-h set of exercises twice per week. The first 12-week phase was performed in group under the direct supervision of a health monitor. The second 12-week phase was autonomous, and consisted of the same physical performance while maintaining virtual link through a social network based on the mobile phone.
~The FOCUS guidelines provided 2 features, the participation in monthly health talks provided by the principal investigator and the availability of a virtual mailbox to transmit any comment or suggestion."
11113360|NCT03981965|Active Comparator|Active group|Participants enrolled in a 2-phase physical activity program divided into 2 phases as described above. This group lacked the monthly talks and did not have access to the virtual mailbox.
11113361|NCT03981965|No Intervention|Inactive|Women of similar clinical characteristic who did not participate in the PA program.
11113362|NCT03981952|Experimental|Cohort A (Step 1)|Individuals receive one dose of either 6.25 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
11113363|NCT03981952|Experimental|Cohort B (Step 2)|Individuals receive one dose of either 12.5 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
11113364|NCT03981952|Experimental|Cohort C (Step 3)|Individuals receive one dose of either 25 µg of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
11113365|NCT03981952|Experimental|Cohort D|Individuals receive one or two doses of the highest, well-tolerate dose among Cohorts A-C of the trivalent vaccine or placebo. Subsequent blood samples are taken for immunological testing.
11113366|NCT03981939||CD Participants with PAF|Participants diagnosed with CD and PAF from The Ottawa Hospital (TOH) will be observed retrospectively for 5 years.
11113367|NCT03981939||CD Participants without PAF|Participants diagnosed with CD and without PAF from the TOH will be observed retrospectively for 5 years.
11113397|NCT03981718|Active Comparator|Group: Standard|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive fat grafting procedure per standard of care during their 2nd stage breast reconstruction.
11113398|NCT03981718|Experimental|Group: Experimental|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive their fat grafting procedure until 6 months after their 2nd stage breast reconstruction.
11113368|NCT03981926|No Intervention|In-Person|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek atopic dermatitis care from primary care practitioners or dermatologists, just as they would in the real world.
11113369|NCT03981926|Experimental|Team-Based Connected Health (TCH)|The intervention arm is the team-based connected health (TCH) model, which purports to increase access to specialists and improve outcomes. Specifically, TCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. TCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
11113370|NCT03981913||Healthy control (HC)|Participants without neurological or psychiatric disturbance (n= 30)
11113371|NCT03981913||Parkinson's disease (PD)|Participants with idiopathic Parkinson's disease but without other neurological or psychiatric disturbance (n= 30)
11113372|NCT03981900||Rheumatoid arthritis|All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib
11113373|NCT03981887|Experimental|Nafithromycin 200 mg as IV infusion|Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
11113374|NCT03981887|Placebo Comparator|placebo administered as IV infusion|Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
11113375|NCT03981874|Experimental|Telephonic interview|Parents or patients will be contacted by phone in order to precise whether there are persistent sequelae or not
11113376|NCT03981861|Experimental|Treatment|Treatment with Metformin and Spironolactone
11113377|NCT03981848||Relapse|Relapse of tumor within two years after liver transplantation
11113378|NCT03981848||Non-relapse|Non-relapse of tumor within two years after liver transplantation
11113379|NCT03981835||Post -PCI Patients scheduled for Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Cardiac Surgery. No intervention will be administered.
11113380|NCT03981835||Post -PCI Patients scheduled for Non- Cardiac Surgery|Post -PCI Patients (PCI within the last 2 years) who are currently on Dual- Antiplatelet (DAPT) Medication or have a current indication for DAPT, who will be undergoing Non-Cardiac Surgery. No intervention will be administered.
11113381|NCT03981822|Active Comparator|Part A & B 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
11113382|NCT03981822|Placebo Comparator|Part A & B 2 hour-Placebo|For part A. Placebo will be applied for 2 hours and removed. If 2 hour is selected as a dose regimen for Part B, Placebo will be applied for 2 hours and removed.VP-102 is applied every 21 days for 4 treatments.
11113383|NCT03981822|Active Comparator|Part A & B 6 hour-Active|For part A, VP-102 will be applied for 6 hours and removed. If 6 hours is selected as a dose regimen for Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
11113384|NCT03981822|Placebo Comparator|Part A & B 6-hour-Placebo|For part A, Placebo will be applied for 6 hours and removed. If 6 hours is selected as a dose regimen for Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
11113385|NCT03981822|Active Comparator|Part A & B 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
11113386|NCT03981822|Placebo Comparator|Part A & B 24-hour-Placebo|For part A, Placebo will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
11113387|NCT03981796|Active Comparator|Dostarlimab plus Carboplatin-paclitaxel|Participants will be administered dostarlimab 500 milligram (mg) every 3 weeks (Q3W) as 30-minute infusion intravenously (IV) from Cycle 1 (each cycle is 21 days) to Cycle 6 and dostarlimab 1000 mg every 6 weeks (Q6W) (Cycle 7 until progression of disease, toxicity, withdrawal of consent, Investigator's decision, or death, whichever occurs first); followed by Carboplatin 5 mg/milliliter (mL)/minute (min) and paclitaxel 175 mg per square meter (mg/m^2) Q3W as 30-minute infusion IV from Cycle 1 to Cycle 6.
11113388|NCT03981796|Placebo Comparator|Placebo plus carboplatin-paclitaxel|Participants will be administered placebo Q3W as 30-minute infusion IV from Cycle 1 to Cycle 6 and placebo Q6W (Cycle 7 until progression of disease, toxicity, withdrawal of consent, Investigator's decision, or death, whichever occurs first); followed by carboplatin 5mg/mL/min and paclitaxel 175 mg/m^2 Q3W as 30-minute infusion IV from Cycle 1 to Cycle 6.
11113389|NCT03981783|Active Comparator|Best available care (BAC)|
11113390|NCT03981783|Experimental|Telerehabilitation (TH)|
11113391|NCT03981770||Group good sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are more than four hours.
11113392|NCT03981770||Group poor sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are less than four hours.
11113393|NCT03981757|Experimental|NeurOS Group|Apply the single use NeurOS cerebral oximetry sensor adhesive onto patients' head who are going to have CEA surgery in the operating room before anesthesia induction.
11113394|NCT03981744|Experimental|Group 1: Ustekinumab + Placebo|Participants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
11113395|NCT03981744|Placebo Comparator|Group 2: Placebo + Ustekinumab|Participants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
11113396|NCT03981731|Experimental|Cardiac coherence|
11113399|NCT03981692|Active Comparator|Consecutive Dual Task|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. Immediately after these trainings, they should expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week etc. Attention, memory and arithmetic training will be given the ability to run.
11113400|NCT03981692|Active Comparator|Integrated Dual Task|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
11113401|NCT03981679|Experimental|Biological collection|"For all the patients include in the study :
~- Blood samples collected before the colonoscopy In parallel to this biological collection, standardized clinical data will be entered into a database"
11113402|NCT03981666|Experimental|Patients with insomnia|adult outpatients with a localized or metastatic breast, colorectal, pulmonary or urological cancer
11113403|NCT03981640|Experimental|Black Adults|Black adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
11113404|NCT03981640|Experimental|White Adults|White adults will undergo the interventions of acute exercise, a cold pressor test, and a mental stress test while beat-to-beat renal blood flow velocity, mean arterial blood pressure, and heart rate are recorded.
11113405|NCT03981627|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation
11113406|NCT03981627|Active Comparator|NovoRapid®|Subcutaneous injection of insulin aspart
11113407|NCT03981614|Experimental|Arm A (binimetinib, palbociclib)|Patients receive binimetinib PO BID on days 1-28 and palbociclib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11113408|NCT03981614|Experimental|Arm B (trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may optionally crossover to Arm A.
11113409|NCT03981601|Active Comparator|lovastatin 40 mg with bone graft|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
11113410|NCT03981601|Active Comparator|without drug with bone graft|after tooth extraction, put the bone graft wifin tooth socket
11113411|NCT03981575||Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months
11113412|NCT03981562|Experimental|1000 IU Vitamin D|
11113413|NCT03981562|Experimental|4000 IU Vitamin D|
11113414|NCT03981562|Placebo Comparator|Placebo|
11113415|NCT03981549|Active Comparator|Immediate Cellular Therapy / Deferred Sham Therapy|"At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.
~At 6 months: Sham bone marrow aspiration and sham intravitreal injection."
11113416|NCT03981549|Sham Comparator|Immediate Sham Therapy / Deferred Cellular Therapy|"At baseline: Sham bone marrow aspiration followed by sham intravitreal injection.
~At 6 months: Bone marrow aspiration followed by intravitreal injection of CD34+ cells."
11113417|NCT03981536|Experimental|AP-101: Dose Level 1|Single dose of AP-101
11113418|NCT03981536|Experimental|AP-101: Dose Level 2|Single dose of AP-101
11113419|NCT03981536|Experimental|AP-101: Dose Level 3|Single dose of AP-101
11113420|NCT03981523|Experimental|BZN-60|150 mg twice a day for 60 days.
11113421|NCT03981523|Experimental|BZN-30|150 mg once a day for 30 days.
11113422|NCT03981523|Experimental|BZN-90|150 mg once a day for 90 days.
11113423|NCT03981523|Experimental|NFX-60|240 mg twice a day for 60 days.
11113424|NCT03981523|Experimental|NFX-30|240 mg twice a day for 30 days.
11113425|NCT03981523|Experimental|NFX-90|240 mg once a day for 90 days.
11113426|NCT03981510|Experimental|Children being investigated with 3D-transit|"4 groups of each 20 children will be investigated with respectively one or two capsules:
~Healthy children (1)
~Children with chronic constipation (2)
~Children with neurofibromatosis type 1 (2)
~Children with cancer receiving treatment with Vincristine (1)"
11113427|NCT03981497||Small Renal Tumors|Subjects with small renal tumors (SRT) ad described by current ESMO (European Society for Medical Oncology) guidelines who are candidates for MWA
11113428|NCT03981497||Primary and Secondary Liver cancer|Primary liver tumors: subjects who are candidates for MWA with nodules ≤ 3 cm Liver metastases: subjects who are candidates for MWA with nodules less than ≤ 3 cm
11113429|NCT03981484|Experimental|PCC|single dose of 4-Factor PCC in addition to standard resuscitation methods
11113430|NCT03981484|Active Comparator|Standard of Care|standard resuscitation methods only
11113431|NCT03981471|Other|Elderly without fall history|Elderly people in the community who have no fall history
11113432|NCT03981471|Other|Elderly with fall history|Elderly people in the community who have fall history
11113433|NCT03981458|Active Comparator|Hyalofemme|Hyalofemme is a cream/gel containing hyaluronic acid, designed to be applied vaginally. This is primarily used in treatment of atrophic vaginitis and is applied by the patient once every three days. We intend treatment to continue for 6 months.
11113434|NCT03981458|Active Comparator|Ialuril|Ialuril is a bladder instillation designed to be delivered to the bladder via catheter. This is primarily used in patients suffering from recurrent UTI and acts to help rebuild the lining of the bladder, reducing irritation. Ialuril is applied weekly for 6 weeks, followed by every 2 weeks for 6 weeks, then once monthly for maintenance. Treatment will be continued for 6 months.
11113463|NCT03981276||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.
11113761|NCT03978975|Active Comparator|normal weight women|20 women with a body mass index ranging between 18,5 and 24,9 kg.m2
11113435|NCT03981445|Experimental|On-site Integrated Care with Adherence Counseling|Participants randomized to the on-site integrated care with adherence counselling arm will be prescribed pre-exposure prophylaxis (PrEP) (Truvada®) and, if indicated, Hepatitic C (HCV) treatment (Epclusa®) at the OAT clinic or SAP from which they were recruited. In addition to PrEP and, if indicated, HCV care, participants in the on-site integrated care arm will receive any required health care services as per local standard of care. Addiction treatment, OAT, and mental health services will be provided, if necessary and available. Participants recruited at syringe access programs (SAP) will be offered addiction counseling and treatment, including OAT when in the integrated care arm in addition to site standard of care.
11113436|NCT03981445|Experimental|Off-site Referral to Specialized Care with Patient Navigation|Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
11113437|NCT03981432|Experimental|Constitutional leanness|Constitutional leanness
11113438|NCT03981432|Experimental|Normal weight|Normal weight women
11113439|NCT03981432|Experimental|Anorexia nevrosa|women presenting Anorexia nevrosa
11113440|NCT03981419|Experimental|GRF6021|"Subjects will receive GRF6021 per the following schedule:
~On the day before surgery
~On the day of surgery within 4 hours before surgery start (first incision)
~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)
~On the day after surgery"
11113441|NCT03981419|Placebo Comparator|Placebo|"Subjects will receive Placebo per the following schedule:
~On the day before surgery
~On the day of surgery within 4 hours before surgery start (first incision)
~On the day of surgery upon arrival in the postoperative care unit (within 5 hours after the first incision)
~On the day after surgery"
11113442|NCT03981406|Experimental|Palliative Care|Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings.
11113443|NCT03981406|Placebo Comparator|Standard of Care|Standard of care for idiopathic pulmonary fibrosis
11113444|NCT03981393||Early ECMO|Patients who were cannulated <48hrs after intubation.
11113445|NCT03981393||Delayed ECMO|Patients who were cannulated >48hrs after intubation
11113446|NCT03981380|Experimental|MESA study participants|Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
11113447|NCT03981341|Experimental|Post menopausal sleep apnea|Post menopausal women with severe sleep apnea
11113448|NCT03981341|Experimental|Post menopausal non sleep apnea|Post menopausal women without sleep apnea
11113449|NCT03981328|Active Comparator|self-monitored blood glucose|The control group participants will perform self-monitored blood glucose testing with a study-provided blood glucose meter, including testing supplies. They will perform capillary blood glucose monitoring as routinely used for patients with GDM i.e. at least four capillary blood glucose values daily including measurements at fasting as well as 1h after starting each meal by using a routinely available blood glucose measurement device.
11113450|NCT03981328|Experimental|Continuous glucose monitoring|Patients randomized to the intervention group will be equipped with a real-time CGM sensor (Dexcom G6 sensor, a small flexible device that records interstitial glucose levels every five minutes). The sensor will be inserted into the subcutaneous tissue of the anterior abdomen wall. Additionally, patients will be advised to record capillary blood glucose values if glucose alerts or readings do not match with symptoms or expectations. Participants will be educated how to exchange the sensor (has to be exchanged every ten days) and will be equipped with a real-time CGM monitor and instructed in its use. The monitor provides the user with information about current glucose levels and notifies the patient before she reaches her upper or lower glucose threshold and when glucose levels change rapidly. All patients in the intervention group will specifically trained how to use the system.
11113451|NCT03981315||Lithogenic bile in symptomatic patient|Patients who are performed a cholecystectomy as a treatment of their gallbladder disease
11113452|NCT03981315||Lithogenic bile in asymptomatic patient|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found
11113453|NCT03981315||Non-lithogenic bile|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones
11113454|NCT03981302|Experimental|Family nursing conversations|The intervention will consist of structured family nursing conversations between a nurse, the patient and their selected family members. The patients will receive the intervention and usual treatment.
11113455|NCT03981302|No Intervention|Usual treatment|The patients will receive usual treatment.
11113456|NCT03981289||CAPN3 (LGMD2A)|Clinical Assessments, Biomarkers
11113457|NCT03981289||DYSF (LGMD2B)|Clinical Assessments, Biomarkers
11113458|NCT03981289||ANO5 (LGMD2L)|Clinical Assessments, Biomarkers
11113459|NCT03981289||DNAJB6 (LGMD1D)|Clinical Assessments, Biomarkers
11113460|NCT03981289||Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)|Clinical assessments
11113461|NCT03981276||Primary participant:|"Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.
~Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques."
11113462|NCT03981276||Secondary participant/ First or second-degree|First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.
11113859|NCT03978247|Experimental|NASHMIR group|Validation of the NASHMIR Test
11113464|NCT03981263|Other|MEAVANTI + Standard protheses|The patients will benefit from the experimental prothesis (MEAVANTI), after a wash-out period of 15 days, they will benefit from the standard non-adherent prothesis.
11113465|NCT03981263|Other|Standard + MEAVANTI protheses|The patients will benefit from the standard non-adherent prothesis, after a wash-out period of 15 days, they will benefit from the experimental prothesis (MEAVANTI).
11113466|NCT03981250|No Intervention|Control Group|The control group will be asked to keep their lifestyle behaviour and not increase their physical activity levels during the study period.
11113467|NCT03981250|Experimental|Exercise Group|The exercise group will engage in a home-based resistance exercise intervention for 12 weeks. They will perform 6 exercises, one each day for one minute, for 6 days a week.
11113468|NCT03981237|Experimental|Root canal treatment with laser-activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of a pulsed erbium laser. The canals are then dried and obturated.
11113469|NCT03981237|Active Comparator|Root canal treatment with ultrasonically activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of an ultrasonically driven instrument. The canals are then dried and obturated.
11113470|NCT03981224||plasma EBV DNA detectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
11113471|NCT03981224||plasma EBV DNA undetectable|the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
11113472|NCT03981211|Experimental|Cohort A: 8 weeks G/P standard therapy|8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).
11113473|NCT03981211|Experimental|Cohort B: 4 weeks SOF/G/P shortened therapy|4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).
11113474|NCT03981198|Other|RAP treatment|Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.
11113475|NCT03981185|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
11113476|NCT03981172||Non-obese/HED|Non-obese women given 60 gram portions of high energy density snack foods to consume daily for two weeks.
11113477|NCT03981172||Non-Obese/LED|Non-obese participants that were given 60 gram portions of low energy density foods to consume daily for two weeks.
11113478|NCT03981172||Obese/LED|Obese participants that were given 60 gram portions of low energy density snack foods to consume daily for two weeks.
11113479|NCT03981172||Obese/HED|Obese participants that were given 60 gram portions of high energy density snack foods to consume daily for two weeks.
11113480|NCT03981159|Experimental|Active group (under physical training)|Subjects belonging to this arm underwent physical training for three months, twice per week (60 minutes per session).
11113481|NCT03981159|No Intervention|Passive group (no physical training)|Subjects served as controls.
11113482|NCT03981146|Experimental|Nivolumab|Patients will receive 480mg of Nivolumab on a four weekly cycle for a maximum of two years.
11113483|NCT03981133|Experimental|A: unrestricted pacifier|recommendation to offer a pacifier at the facility providing maternity and newborn services the first days of life
11113484|NCT03981133|Active Comparator|restricted pacifierr|recommendation not to offer a pacifier to normal new born infant at the maternity thre first days of live
11113485|NCT03981120|No Intervention|Standard Care Group|Patients in the control arm will not undergo laser and acupuncture treatment. The treatment and control group will be compared to the baseline pregnancy rate of women meeting the same inclusion and exclusion criteria from the clinic through a chart review over the two years prior to initiation of the study.
11113486|NCT03981120|Experimental|Laser and Acupuncture Group|"The patients in the treatment arm will have 7 treatments before transfer (2-4 sessions a week), for the 3 weeks from starting estrace leading to the day before embryo transfer, then one (before and after transfer) on the day of transfer (total 8 sessions). Each treatment leading up to transfer day treatment consists of:
~Traditional Acupuncture at points Sp9 to SP6 EA2Hz Milliamp (Pantheon device), ST-36 B, LI4 unilateral, LV3 unilateral and/or LU7 unilateral, K6 unilateral.
~Bioflex Array (Photobiomodulation) - simultaneously array placements with each treatment over the sacrum (points BL-31, BL 32, BL 33 BL 34, DU2, DU3) and lower Abdomen above uterus (Ren 2 to Ren 6)
~Laser acupuncture over ST-9, ST10, SJ 17, ST-11. Ren 3 and Ren 4. 6.75 J per point at ST 9, ST10 (over carotid) and SJ17 (vertebral artery).
~On the day of FET on site at IVF clinic there will be a before and after traditional and laser acupuncture treatment."
11113487|NCT03981107|Experimental|Chest Compression Only CPR (CO-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform CO-CPR with chest compressions only.
11113488|NCT03981107|Active Comparator|Standard CPR (S-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform S-CPR with chest compressions and rescue breaths in a 30:2 ratio.
11113489|NCT03981094|Experimental|BMS-986278|
11113490|NCT03981094|Experimental|Pirfenidone|
11113491|NCT03981094|Experimental|BMS-986278 + Pirfenidone|
11113492|NCT03981081|Experimental|eosinophil-guided group|patients will receive prednisone at a dose of 1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days, only if the eosinophil count is> 2%
11113493|NCT03981081|Active Comparator|control group|a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days
11113494|NCT03981068|Experimental|Re-Irradiation with protons|60 Gy in 50 fraktions, 10 weekly with protons
11113495|NCT03981055|Experimental|Active tDCS and Active TUS|Active tDCS and Active TUS for 20 min
11113496|NCT03981055|Sham Comparator|Sham TDCS and Sham TUS|Sham TDCS and Sham TUS for 20 min
11113497|NCT03981042|No Intervention|Control group|waiting for a 3-minute delay after injection of the atracurium before laryngoscopy
11113498|NCT03981042|Experimental|Monitoring group|waiting for the TOF ratio at 0 at the corrugator supercilli before laryngoscopy
11113499|NCT03981029||FACT High-dose folic acid treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily high-dose folic acid supplementation during pregnancy.
11113860|NCT03978234|Experimental|Single group|Single group
11113500|NCT03981029||FACT Placebo treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily placebo supplementation during pregnancy.
11113501|NCT03981016|Experimental|Biological collection|"For the patients include in the study :
~blood samples collected at different times : Before surgery and during the post-operative visit and
~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
11113502|NCT03981003||MS Patients|
11113503|NCT03980990|Experimental|Metformin Continuation|Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.
11113504|NCT03980990|No Intervention|Metformin Interruption|Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.
11113505|NCT03980977|Other|skin and/or tumor Biopsy and blood sample|
11113506|NCT03980964|Experimental|Active NMES|Treatment arm receives an active NMES therapy including a conductive garment with NMES therapy, electrodes, and mobile app.
11113507|NCT03980964|Sham Comparator|Inactive NMES|Control arm receives inactive NMES therapy including a conductive garment (no NMES and no electrodes), and mobile app.
11113508|NCT03980951|Active Comparator|combined spinal epidural group|Bupivacaine 2.5 mg
11113509|NCT03980951|Active Comparator|dura puncture epidural group|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
11113510|NCT03980951|Active Comparator|epidural|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
11113511|NCT03980938|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
11113512|NCT03980938|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
11113513|NCT03980925|Experimental|Nivolumab + platinum-doublet chemotherapy|"Induction Phase: Nivolumab 360 mg IV plus Carboplatin IV (AUC=5) plus Etoposide 10mg/m2/day on days 1-3D, all every 3 weeks up to 6 cycles followed by Nivolumab 480mg for 24 months or until PD, death or toxicity.
~Order of administration: Nivolumab, Carboplatin, Etoposide
~Maintenance Phase Nivolumab 480 mg IV will be administered every 4 weeks (±3 days) for 2 years."
11113514|NCT03980899||Patients with PPI|
11113515|NCT03980873|Experimental|Experimental|An experimental group. The psychological treatment includes 10 sessions of cognitive-behavioural treatment ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders
11113516|NCT03980873|No Intervention|Control|Three-month waitlist
11113517|NCT03980860|Active Comparator|HIIT (High Intensity Interval Training)|Subjects are undergoing high intensity interval training
11113518|NCT03980860|Active Comparator|Low intensity training long duration|Subjects are undergoing a lower intensity training program for a long duration
11113519|NCT03980860|No Intervention|Control|No exercise program intervention (usual care)
11113520|NCT03980847|Active Comparator|Alendronate 20 mg with bone graft|after tooth extraction, put teh Alendronate 20mg with bone graft within teh tooth socket
11113521|NCT03980847|Active Comparator|bone graft alone|after tooth extraction, put the bone graft within the tooth socket
11113522|NCT03980834|Active Comparator|Professional Learning, Program Training and Coaching|
11113523|NCT03980834|Active Comparator|Program for Parents of Pre-K Students|
11113524|NCT03980834|Active Comparator|Program for Pre-K Students|
11113525|NCT03980821|Experimental|AZD4635 monotherapy|Dose escalation of AZD4635 monotherapy for patients with advanced solid malignancies
11113526|NCT03980808|Experimental|ASL-ADE Intervention Arm|One-half of enrolled participants will view the ASL-ADE video intervention.
11113527|NCT03980808|Sham Comparator|Control Arm|One-half of enrolled participants will view a non-health related video approximately the same length as the video intervention.
11113528|NCT03980795|Experimental|Intervention|The intervention (I) group received monthly exercise physiologist consultations, exercise prescription (resistance and aerobic exercise program using exercise bands) and weekly phone calls over 12 weeks.
11113529|NCT03980795|No Intervention|Control|Usual care
11113530|NCT03980782|Experimental|Music Intervention|Each participant will receive a 30 minute individual music intervention twice daily.
11113531|NCT03980782|No Intervention|Care as usual|Each participant will receive care as usual.
11113532|NCT03980769|Experimental|Treatment (chemotherapy, transplant)|Patients receive thiotepa IV BID on days -7, treosulfan IV on days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.
11113533|NCT03980756|Experimental|Group A1|Period 1: Test Drug(AD-206 20mg) Period 2: Reference Drug(Esomeprazole 20mg)
11113534|NCT03980756|Experimental|Group A2|Period 1: Reference Drug(Esomeprazole 20mg) Period 2: Test Drug(AD-206 20mg)
11113535|NCT03980756|Experimental|Group B1|Period 1: Test Drug(AD-206 40mg) Period 2: Reference Drug(Esomeprazole 40mg)
11113536|NCT03980756|Experimental|Group B2|Period 1: Reference Drug(Esomeprazole 40mg) Period 2: Test Drug(AD-206 40mg)
11113537|NCT03980743|Active Comparator|iOTA text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly meetings with a study health coach to develop reasonable health goals and interactive text messaging to provide daily support and self-monitoring of behavior change goals between in-person visits. Participants may receive phone calls between visits from their health coach for additional support if needed. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
11113538|NCT03980743|Placebo Comparator|Health Education text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly in-person visits with a health coach to learn about healthy eating and activity behaviors, including developing readiness for health behavior change. Participants will not set specific health goals, but will receive weekly text messages about general health tips related to their in-person visits. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
11113539|NCT03980730|Experimental|Azeliragon|Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
11113540|NCT03980730|Placebo Comparator|Placebo|Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)
11113541|NCT03980717|Experimental|Fetal Endotracheal Occlusion (FETO)|Placement and retrieval of the GoldBAL4 or GoldBAL2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
11113542|NCT03980717|No Intervention|non-FETO|The control group will consist of patients who did not undergo the FETO procedure who fit the same fetal inclusion/exclusion criteria as our FETO subjects and will be matched by variables including maternal age, body mass index, gestational age, severity of CDH and site of CDH (left- or right-sided).
11113543|NCT03980704|Active Comparator|High Protein|Provision of 400 ml per day of high protein oral nutritional supplements
11113544|NCT03980704|Experimental|Immuno ONS|Provision of 400 ml per day of immunostimulating oral nutritional supplements
11113545|NCT03980691|Experimental|Chidamide combined with CAR-T or TCR-T cell therapy|Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
11113546|NCT03980691|No Intervention|without intervention|Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
11113547|NCT03980678|Active Comparator|Mineral Rich Algae with orange flavoring|Participants will consume the Aquamin Soluble (Mineral Rich Algae) equivalent of 1000mg Calcium in 250 ml of orange flavoured water.
11113548|NCT03980678|Placebo Comparator|Water with orange flavoring|Participants will consume a placebo of maltodextrin in 250 ml of orange flavoured water (40mg Calcium).
11113549|NCT03980665|Experimental|Arsenic trioxide combined with cART|Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
11113550|NCT03980665|No Intervention|Without arsenic trioxide therapy|Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
11113551|NCT03980652|Other|Intervention|Change of gloves and use of separate, sterile instruments before closing the abdominal wall
11113552|NCT03980652|No Intervention|Current routine hospital practice|No change of gloves or use of separate, sterile instruments before closing the abdominal wall
11113553|NCT03980639||abatacept|patients with abatacept prescription
11113554|NCT03980639||others bDMARDs|patients with at least one bDMARD prescriptions
11113555|NCT03980626|Experimental|Walking Intervention|Walking participants will engage in the 3-times weekly walking program for 12 weeks.
11113556|NCT03980626|No Intervention|Usual Care|Usual care participants will be offered two personalized exercise sessions with a trained exercise specialist after all post-intervention data have been collected.
11113557|NCT03980613||Spontaneous subarachnoid haemorrhage|Patients with verified spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
11113558|NCT03980613||Controls|Patients without spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
11113559|NCT03980600|Experimental|Donor site treatment with NFC dressing/FibDex®|"Patients requiring skin graft donor site treatment were enrolled in the investigation. Patients were selected based on clinical evaluation by a plastic surgeon.
~Of the total 33 patients enrolled in the study, nine patients were treated during the optimization phase with experimental NFC dressing Types 1-3. The remaining 24 patients were treated with the final product Type 4 (FibDex®). The mean age of patients treated with NFC dressing/FibDex® was 50 ± 18 years, in the range of 21-74 years.
~Suprathel® was used to treat donor sites in the same patients as a reference material. During the optimization phase, Suprathel was intra-individually compared with NFC dressing types 1-3 in five patients out of nine. From the remaining 24 patients, Suprathel was intra-individually compared with FibDex® in 17 patients."
11113560|NCT03980574||Crossover Group|The crossover group will be further randomly assigned (1:1) with 20 patients in each group. The two crossover arms of the study will follow the patients for 8 weeks. At the end of week 8, all crossover patients will have a 1 week wash out period. Thereafter, patients will be crossed-over to the opposing arm of the study for an additional 1+8 weeks (R Drink 8 oz 3-5x/day versus a placebo drink 8 oz 3-5x/day).
11113561|NCT03980574||Non-crossover Group|The non-crossover group of the study will follow 20 patients for the entire 17 weeks and participants in this arm will not be crossed over, will not have a washout period, and will consume R Drink for the total duration of the study. If patients in this arm wish to continue on the R Drink, for 6 additional months they may do so. At the end of the optional 6 months these patients will have a repeat research transthoracic echocardiogram. Data collection will occur at baseline, week 8, and week 17. An additional 6 month data collection time point will occur for patients in the third arm opting to continue R Drink.
11113562|NCT03980561|Experimental|Varenicline|2 mg daily
11113563|NCT03980561|Placebo Comparator|Placebo|2 mg daily
11113564|NCT03980548||CABG patients|
11113565|NCT03980548||PAD patients|
11113566|NCT03980548||Healthy volunteers|
11113567|NCT03980548||Patients with CAD|
11113568|NCT03980535|Experimental|Device Feasibility (MRI, MRSI)|Patients undergo an additional investigational MRI or MRSI sequence along with the standard MRI or MRSI. Healthy volunteers undergo an investigational MRI or MRSI sequence. Healthy volunteers may also undergo an additional standard sequence if there is one that can be compared to the investigational sequence. All MRI or MRSI procedures, including the standard MRI or MRSI, are no longer than 60 minutes.
11113569|NCT03980522|Experimental|KPL-914|KPL-914 (rilonacept)
11113570|NCT03980509|Experimental|Curcumin|Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.
11113571|NCT03980496|Active Comparator|omeprazole infusion (OI) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
11113572|NCT03980496|Active Comparator|omeprazole bolus (OB) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.
11113573|NCT03980483|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and more than or equal to (>=)5 mg/week folic (or folinic) acid as standard of care (SoC).
11113574|NCT03980483|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
11113575|NCT03980483|Active Comparator|Tofacitinib|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC.
11113576|NCT03980483|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
11113577|NCT03980483|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
11113578|NCT03980483|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable oral dose of MTX and >=5 mg/week folic (or folinic) acid as SoC throughout.
11113579|NCT03980470|Experimental|Low-dose|The experimental intervention is an additional CT scan with a lower dose (about 20 to 50% decrease) and a similar contrast agent administration that is reconstructed with a deep-learning image reconstruction immediately after the clinical CT scan. The additional time required is about 5 minutes.
11113580|NCT03980470|No Intervention|Normal-dose|The control intervention consists of the routinely performed cardiac CT datasets reconstructed with a standard iterative reconstruction algorithm (ASIR-V). Median radiation dose is about 0.5 mSv, range between about 0.2 and 1.2 mSv; median contrast agent administration about 45 mL, range between 35 and 55 mL.
11113581|NCT03980457|Experimental|Exo-group|Standard rehabilitation plus use of Exoskeleton
11113582|NCT03980457|Placebo Comparator|Control-Group|Standard rehabilitation
11113583|NCT03980444|Experimental|control group, no basket of wire|"The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.
~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.
~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
11113584|NCT03980444|Sham Comparator|using a basket of wires|In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
11113585|NCT03980431|Experimental|FBY in suspected malignant brain tumor|This arm investigates the metabolic characteristics of FBY in suspected malignant brain tumor patients who consider for surgical operations. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operations, if recommended after multiple examination, will be carried out within 1 week after FBY PET scan.
11113586|NCT03980431|Experimental|FBY in suspected recurrent glioma|This arm investigates the value of FBY to differentiate tumor progression from pseudoprogression. A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later. Surgical operation, MRI follow up or change of treatment strategy, according to specific conditions, will be recommended for the definitive diagnosis as well as the management of patients.
11113587|NCT03980418|Experimental|all included patients will have the same procedure|After the conventional DaTSCAN SPECT/CT scintigraphy, all included patients will have a DaTSCAN SPECT/CT exam in the semiconductor CZTcamera with focus striatum mode recorded and then, they will have a DaTSCAN SPECT focused on the total brain
11113588|NCT03980405|Experimental|Group 1|Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
11113589|NCT03980405|Experimental|Group 2|6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
11113590|NCT03980392|Experimental|Facility-based Intervention|A group will consist of 5 or 10 persons depending on the size of the study center. Exercise training will be guided by study exercise therapists at a gym and consist of programs for progressive muscle strength training, aerobic exercise, and exercises to improve postural balance and flexibility using elastic bands, floor plate and chairs (three times per week, 60 min per session).The cognitive training program is a program including tasks to be effective in episodic memory, executive function, attention, working memory, calculation, and visuospatial function (twice per week, 60 min per session). The nutritional intervention is conducted by study nutritionists (three individual sessions and seven group sessions). Management of metabolic and vascular risk factors will include additional meetings with the study nurse (at 0, 4, 8, 16, and 20 weeks), and the study physician (at 0 and 12 weeks). Motivational training is conducted by psychologist (four group session).
11113655|NCT03979846|Experimental|Arm II (computer-based symptom reporting, usual care)|Participants use a computer based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
11113656|NCT03979833||1|Individuals currently living, over the age of 18 years and known carriers of a pathogenic variant in the VHL gene.
11113657|NCT03979820|Experimental|BI 1467335 low dose|
11113658|NCT03979820|Experimental|BI 1467335 high dose|
11113659|NCT03979820|Active Comparator|Phenelzine sulfate|
11113591|NCT03980392|Experimental|Home-based Intervention|The nutritional intervention, management of metabolic and vascular risk factors, social activity, and motivational training in the home-based intervention are similar to the facility-based intervention. The physical exercise programs consist of one group session (60 min) and two home-based sessions (60 min per session) per week in the first 2 months of the trial. During the remaining months of the 6-month study, participants in the home-based intervention attend a 1-h physical exercise group session per two weeks and two or three exercise sessions (60 min per session) alone at home per week. The cognitive training programs consist of one group session (60 min) and one home-based sessions (60 min per session) per week in the first 2 months of the trial. For the remainder of the 6-month study, participants in the home-based intervention attend a 1-h group cognitive training session per two weeks and one or two cognitive training sessions (60 min per session) alone at home per week.
11113592|NCT03980392|No Intervention|Controls|They are waiting list controls. They will receive the multi-domain intervention after this study.
11113593|NCT03980379|Experimental|experimental group|304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL
11113594|NCT03980379|Active Comparator|control group|Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.
11113595|NCT03980366|Experimental|ECT to treat self-injurious behaviors in adults with ASD|After initial exams and pre-screening, participants will receive bilateral Electroconvulsive Therapy (ECT) for 12 treatments sessions over the course of 4 weeks, plus non-ECT follow-up sessions at 1, 2, 6, and 12 months post-ECT treatment.
11113596|NCT03980353||Children before entrance in primary school|Children with type 1 diabetes, who are too young to go to primary school at the start of the school year 2018-2019, followed in the Diabetology Department of Lyon Pediatric Hospital.
11113597|NCT03980327|Experimental|probiotic|Lactobacillus rhamnosus (5 billion colony forming units per day) and Lactobacillus johnsonii (200 million colony forming units per day) given orally or through a gastrostomy tube daily for 3 months
11113598|NCT03980327|Placebo Comparator|control|1 mL of pure medium chain triglyceride oil given orally or through a gastrostomy tube daily for 3 months
11113599|NCT03980314|Experimental|Arm A (Process C)|"Participants will receive nivolumab specified dose on specified days"
11113600|NCT03980314|Experimental|Arm B (Process D)|"Participants will receive nivolumab specified dose on specified days"
11113601|NCT03980288|Experimental|CAR-GPC3 T Cells|The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
11113602|NCT03980262|Experimental|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
11113603|NCT03980262|Active Comparator|MoneySmart|A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.
11113604|NCT03980249|Experimental|Carvedilol + Standard Treatment|Subjects will receive carvedilol starting at 6.25 mg orally (PO) twice daily for 1-2 weeks and if tolerated will then be increased to 12.5 mg PO twice daily starting on day 1 of concurrent chemoradiotherapy and continue daily until the end of adjuvant cycle 6 of temozolomide and Tumor Treated Fields.
11113605|NCT03980236|Experimental|Livongo-Insulia Study App Arm|Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
11113606|NCT03980223|Experimental|Doxy PEP|Doxycycline 200mg in addition to standard of care STI testing and treatment
11113607|NCT03980223|No Intervention|Control|The control arm will consist of standard of care STI testing and treatment
11113608|NCT03980210|Experimental|Hyperbaric oxygen therapy|"Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)
~Five successive steps:
~FiO2 0.21 - 1 ATA
~FiO2 1 - 1 ATA
~FiO2 1 - 2.5 ATA
~FiO2 0.21 - 2.5 ATA
~FiO2 0.21 - 1 ATA"
11113609|NCT03980197|Experimental|Intervention|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
11113610|NCT03980197|Active Comparator|Control|No active surveillance test and preemptive isolation performed. Only standard precaution is needed, and if clinical isolates reveals MDRO, start contact precaution.
11113611|NCT03980184|Experimental|Guanfacine|guanfacine 3mg/day (GUA)
11113612|NCT03980184|Placebo Comparator|placebo|placebo (PBO)
11113613|NCT03980171|Experimental|Obinutuzumab+venetoclax+lenalidomide|Patients in both dose escalation and dose expansion will receive 6 cycles of induction treatment consisting of obinutuzumab (flat dose of 1000mg) and protocol defined dose levels of venetoclax and lenalidomide.
11113614|NCT03980158||Upper airway stimulation group|
11113615|NCT03980158||OSA group with conservative / no treatment|
11113616|NCT03980158||Test group without OSA|
11113617|NCT03980145|Active Comparator|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training.40-43 Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
11113660|NCT03979820|Placebo Comparator|Placebo|
11113661|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
11113698|NCT03979534|Experimental|Diet group|"Diet follow-up to personalize a low-protein diet for each patient. All patients following a low protein diet one month or more compose the diet group."
11113618|NCT03980145|Experimental|End-Effector Robotic Training|G-EO training: Using the G-EO System, participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system, with feet secured to pressure sensitive footplates. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence ~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking and stair climbing for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.
11113619|NCT03980132|Experimental|Preoperative Lugol Solution preparation|Patients will receive Lugol Solution preparation for 10 days before thyroidectomy
11113620|NCT03980132|No Intervention|No preparation|Patients will not receive preparation before thyroidectomy
11113621|NCT03980119|Experimental|HITSystem 3.0 Intervention|All HIV-positive children and their caregivers attending health facilities randomized to the HITSystem intervention arm will be monitored by the HITSystem. In the event that the child misses an appointment or a scheduled laboratory test, or the child's laboratory results suggest ART treatment failure, an automated SMS text message and alert will be generated in the HITSystem that will notify the child's health care provider. The child's caregiver will also receive a text message asking them to return to the clinic with the child. If the child is 16 years of age and considered an independent adolescent without a caregiver, the same process will be implemented, with the text messages being sent directly to the child. If the child's caregiver, or the independent adolescent, does not have a mobile phone, the health care provider will notify the community health worker (CHW) to trace the individual and visit them in their home.
11113622|NCT03980119|No Intervention|Control|All HIV-positive children and their caregivers attending health facilities randomized to the Control arm will receive HIV/AIDS standard of care.
11113623|NCT03980106|Experimental|Experimental RI-PI|They receive the Reciprocal Inhibition (RI) technique in the first stage and then the Post-isometric Inhibition (PI) technique in the second stage.
11113624|NCT03980106|Experimental|Experimental PI-RI|They receive the Post-isometric Inhibition (PI) technique in the first stage and then the Reciprocal Inhibition (RI) technique in the second stage.
11113625|NCT03980093|Experimental|Education plus Values|
11113626|NCT03980093|Active Comparator|Education|
11113627|NCT03980080|Experimental|OSE-127: Part 1 (SAD), Cohort A & Cohort B|
11113628|NCT03980080|Placebo Comparator|Placebo: Part 1 (SAD), Cohort A & Cohort B|
11113629|NCT03980080|Experimental|OSE-127: Part 2 (MAD)|
11113630|NCT03980080|Placebo Comparator|Placebo: Part 2 (MAD)|
11113631|NCT03980067|Experimental|Virtual Reality Group|The children in the experimental group will receive the standard of care (access to in room activity including television (TV) distraction if desired, parent support and distraction at bedside, and quiet time) in addition to our intervention, an interactive virtual reality game, played for a minimum of 5 minutes prior to procedural sedation.
11113632|NCT03980067|No Intervention|Standard of Care|The children in the control group receiving standard of care will have access to in room activity including TV distraction if desired, parent support and distraction at bedside, and quiet time.
11113633|NCT03980054|Experimental|Arm Pyrotinib|Intervention: Drug: Pyrotinib
11113634|NCT03980054|Placebo Comparator|Arm Placebo|Intervention: Drug: Placebo
11113635|NCT03980041|Experimental|IPI-549 + Nivolumab|Participants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
11113636|NCT03980041|Active Comparator|Placebo + Nivolumab|Participants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks
11113637|NCT03980015||erythema migrans|patients with erythema migrans
11113638|NCT03980002|Experimental|FCR/BR alternating with ibrutinib|FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
11113639|NCT03979989|Experimental|Tapentadol IR|A single oral dose of tapentadol IR was administered in a fasted state (Treatment A).
11113640|NCT03979989|Experimental|Omeprazole, Tapentadol IR|Oral doses of omeprazole were administered once daily in a fasted state on 4 consecutive days (Days -3 to 1), plus 1 capsule of CG5503 IR administered 2 hours after the administration of omeprazole on Day 1 (Treatment B).
11113641|NCT03979976|Active Comparator|ramipril group|Use of ramipril 10mg/day per 12 weeks
11113642|NCT03979976|No Intervention|Control Group|Without ramipril
11113643|NCT03979924|Other|Interventional Step|The interventional step will comprise the same follow-up as the observational step, except for the addition of an early and preventive care, conducted by a specialized physiotherapist using an active exercise handbook elaborated with the patient's therapeutic education transversal Unit (Utep). This aims at increasing the patient's adhesion to the program and to limit the reduction of mouth opening and its consequences ( Trismus rehabilitation)
11113644|NCT03979898|Experimental|Astrostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells
11113645|NCT03979885|Other|Goal-Directed Incentives|
11113646|NCT03979885|Other|Outcome-Based Incentives|
11113647|NCT03979885|Other|Enhanced Usual Care|
11113648|NCT03979872|Active Comparator|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
11113649|NCT03979872|Experimental|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
11113650|NCT03979872|Experimental|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
11113651|NCT03979872|Experimental|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
11113652|NCT03979859|Experimental|WCK 4873|200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study
11113653|NCT03979859|Placebo Comparator|Placebo|Visually matching placebo
11113654|NCT03979846|Experimental|Arm I (usual care, computer-based symptom reporting)|Participants receive usual care for 3 weeks, then use a computer based symptom reporting system for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
11113662|NCT03979794|Experimental|Be-WEL Intervention|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
11113663|NCT03979794|No Intervention|Standard Care|Standard Care consists of the standard care patients typically receive from their medical team.
11113664|NCT03979781|Experimental|Treatment Group|Intervention group
11113665|NCT03979781|Active Comparator|Control Group|Standard of Care group
11113666|NCT03979768|Experimental|Risk Assessment Only pharmacies (RTO-group)|Offered a diabetes risk assessment service without any blood sample testing.
11113667|NCT03979768|Experimental|HbA1c-group /pharmacies|Offered a diabetes risk assessment service including a measurement of Haemoglobin A1c (HbA1c) to the people with a high risk of developing type 2 diabetes on the risk assessment form (The Finnish Diabetes Risc Score (FINDRISC) to those with a western background, and Leicester Risk Assessment (LRA) form for those with a non-western background.
11113668|NCT03979755||Study Group|Women cancer survivors living in Campo Belo, Minas Gerais.
11113669|NCT03979755||Control Group|Women in routine follow-up in the public health system in Campo Belo, Minas Gerais.
11113670|NCT03979742|Experimental|MC001 + lithium|UCBMNC (MC001) transplant + oral lithium carbonate x 6 weeks
11113671|NCT03979742|Experimental|MC001 + placebo|UCBMNC (MC001) transplant + oral placebo x 6 weeks
11113672|NCT03979742|Placebo Comparator|No treatment|No surgery, no transplant, no lithium
11113673|NCT03979729||3D + 2D-Mammogram Recipients (Patient Group A)|Women presenting for mammographic screening who selected 3D + 2D- mammogram. These women will undergo in-person or telephone interviews.
11113674|NCT03979729||2D-Mammogram Recipients (Patient Group B)|Women presenting for mammographic screening who selected 2D- mammogram alone (declined 3D + 2D- mammogram). These women will undergo in-person or telephone interviews.
11113675|NCT03979729||Women Who Have Never Received a Mammogram (Patient Group C)|Women who have never undergone recommended mammographic screening. These women will participate in a onetime facilitated focus group.
11113676|NCT03979729||Providers|Primary care providers (physicians, physicians assistants, and advanced nurse practitioners) working in clinics providing primary care for underserved patient populations in New Mexico, including primary care providers at a RIOSNET-affiliated and UNM-affiliated clinics
11113677|NCT03979716|Experimental|Anosmic patients|
11113678|NCT03979716|Experimental|Hyposmic patients|
11113679|NCT03979716|Experimental|Normosmic patients|
11113680|NCT03979703|Experimental|Intervention group|Intervention will be a 12 week yoga class
11113681|NCT03979703|No Intervention|Control group|Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.
11113682|NCT03979690|Experimental|Subjects Receiving Colonoscopy|Subjects receiving tandem colonoscopies using the NISInspire-C System followed by a Conventional Colonoscopy
11113683|NCT03979664|Active Comparator|Active Iontophoresis|One active iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
11113684|NCT03979664|Sham Comparator|Inactive Iontophoresis|One inactive iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
11113685|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 1)|Patients with NRAS Melanoma receiving the 1st dose of the treatment (400 milligrams)
11113686|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 2)|Patients with NRAS Melanoma receiving the 2nd dose of the treatment (800 milligrams)
11113687|NCT03979651|Experimental|Patients with NRAS Melanoma (Dose 3)|Patients with NRAS Melanoma receiving the 3rd dose of the treatment (600 milligrams twice a day)
11113688|NCT03979638|Experimental|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
11113689|NCT03979638|Placebo Comparator|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
11113690|NCT03979599|Active Comparator|magnesium sulphate& levobupivacaine|Levobupivacaine add to magnisum sulphate
11113691|NCT03979599|Placebo Comparator|levobupivacaine|levobupivacaine
11113692|NCT03979586|Experimental|Patient phototype I to IV|The study will be conducted in the Laser Dermatological and Plastic Center of the Conception Hospital in Marseille. It will be a prospective, controlled, hemiface, single-blind, independent-evaluator pilot study of 20 patients, 30 to 70 years old, with phototype I to IV (Fitzpatrick scale). By this study in hemiface, each patient will be his own witness. Neither the patient nor the examining doctor will know the choice of the hemiface of application of hyaluronic acid. This will be a single-blind study with independent evaluator. Patients will be included for 3 months, and followed for a period of 3 months.
11113693|NCT03979573|Other|Intervention Arm|"PSA testing
~Multiparametric MRI (mp-MRI)
~Radiomics
~MR-guided biopsy (MR-guided and systematic US-guided)
~Molecular Markers (Histological analysis of biopsy cores)"
11113694|NCT03979560|No Intervention|Control|"The control group will benefit from the usual support (depending on the practices of the department, prescription or not of oral nutritional supplements and physiotherapy at home, but without home intervention of adapted physical activity professionals or dieticians).
~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
11113695|NCT03979560|Experimental|Nutrition intervention with appropriate physical activity|"Intervention at home of professionals:
~Patients in this arm will benefit from 14 home interventions
~7 home nutrition support (NS) sessions in 3 months or 1 session every 10 days (+/-4 days). These sessions will be conducted by a dietician from the company Saveurs et Vie.
~7 home sessions of adaptive physical activity (APA) in 3 months, one session every 10 days (+/-4 days). These sessions will be conducted by professionals from association group Siel Bleu.
~In addition to screening/inclusion visits (D0), three follow-up home visits are scheduled at D7, D45 and D90 for both study groups."
11113696|NCT03979547|Experimental|Exercise intervention|The exercise program will be similar to the Exercise in All ChemoTherapy (ENACT) study which combines in-person and home-based strength training and aerobic exercise five days a week.
11113699|NCT03979534|No Intervention|Control group|Patients who accepted to take part of the study but refused the low protein diet and patients who discontinued the diet on the first month compose the control group.
11113700|NCT03979508|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection.
11113701|NCT03979495|No Intervention|Standard of care|standard of care
11113702|NCT03979495|Active Comparator|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
11113703|NCT03979495|Active Comparator|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
11113704|NCT03979495|Active Comparator|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
11113705|NCT03979482||PAH patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. PAH patients presenting with metabolic syndrome (MS).
11113706|NCT03979482||Sedentary healthy patients|Male and female subjects, aged between 20 and 60 years old. Absence of obesity/diabètes. Healthy but sedentary subjects.
11113707|NCT03979469|Experimental|opiod free general anesthesia|In group A opioid free anesthesia is administered. Anesthesia and analgesia were achieved with ketamine(1mg/kg, bolus), dexmedetomidine(1mcg/kg, over 10 minutes), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg). Anesthesia induction with ketamine(1mg/kg), propofol 1% 2-3mg/kg, rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
11113708|NCT03979469|Active Comparator|opioid based general anesthesia|In group B opioid based anesthesia is administered.Anesthesia and analgesia were achieved with remifentanil(0.3mcg/kg/minute), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg).Anesthesia induction with propofol 1% 2-3mg/kg,fentanyl(2mcg/kg), rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
11113709|NCT03979456|Active Comparator|6-month dosing interval|This arm is receiving standard dose rituximab 500 mg every 6 months
11113710|NCT03979456|Experimental|12-month dosing interval|This arm is receiving the comparator dose rituximab 500 mg every 12 months
11113711|NCT03979443|No Intervention|Inpatient|patients staying in the hospital for 1-3 nights after surgery
11113712|NCT03979443|Active Comparator|Outpatient|discharge on the day of the surgery, usually within 6-8 hours after procedure
11113713|NCT03979430|Other|Intervention|There is only one arm with the intervention.
11113714|NCT03979417||Liver fibrosis F0-F1|Blood draw and liver resection at the liver surgery
11113715|NCT03979417||Liver fibrosis F2-F3|Blood draw and liver resection at the liver surgery
11113716|NCT03979417||Liver Fibrosis F4|Blood draw and liver resection at the liver surgery
11113717|NCT03979404|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
11113718|NCT03979391|Experimental|Children with CIS or RIS|The detection of supernumerary oligoclonal bands (OCBs) in tears will be performed
11113719|NCT03979365|Active Comparator|Tacrolimus twice-daily|Subjects assigned to this arm will take tacrolimus two times daily by mouth, at the clinically prescribed dose.
11113720|NCT03979365|Active Comparator|Envarsus XR|Subjects assigned to this arm will take Envarsus XR one time daily by mouth, at the clinically prescribed dose.
11113721|NCT03979352|Active Comparator|Empagliflozin arm|"Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.
~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.
~Participant and research staff is blinded to arm assignment."
11113722|NCT03979352|Placebo Comparator|Placebo arm|"Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.
~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.
~Participant and research staff is blinded to arm assignment."
11113723|NCT03979339|Experimental|blood sample collection|For all participants whatever the group Groups 0 and 4: Healthy volunteers Group1: Metastatic HER2-positive breast cancer Group 2: Advanced CA-125 positive ovarian cancer Group 3: Metastatic PSA-positive castrate-resistant prostate cancer Participants will receive the following interventions because they are enrolled in the study: blood sample collection of 32mL (4x8mL in EDTA tubes)
11113724|NCT03979326|Experimental|Young women during various of phases of menstrual cycle.|The group of 40 young women will have their hamstring muscle stretched in different phases of the menstrual cycle: follicular, ovulatory and luteal. Static stretching will last 3x 45 seconds with a 15 second break between repetitions. Before and after the intervention a series of tests will be performed.
11113725|NCT03979313|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
11113726|NCT03979313|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline
11113727|NCT03979287|Experimental|IFC and Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour. Participants will receive treatment with Interferential current therapy plus a program of therapeutic exercise focused on the neck region
11113728|NCT03979287|Active Comparator|Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour.This group will only receive the same therapeutic exercise program.
11113729|NCT03979274|Experimental|Reference Eutirox®, then Test Eutirox®|Participants will receive single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 1 followed by single oral dosing of Test Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 2. Each treatment period will be separated by a 35-day wash-out period.
11113760|NCT03978988|No Intervention|Thrombectomy alone|"Endovascular procedure:
~Intracranial thrombectomy alone (carotid angioplasty may be performed)"
11113730|NCT03979274|Experimental|Test Eutirox®, then Reference Eutirox®|Participants will receive single oral dose of test Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 1 followed by single oral dosing of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) in treatment period 2. Each treatment period will be separated by a 35-day wash-out period.
11113731|NCT03979261||sex ratio evaluation|Valvular surgery is performed in 30-40% of cases. The Cardiology and Cardiac Surgery De la Timone services 1000 patients as part of their valvulopathy and 450 benefit from cardiac surgery. On the other hand, transcriptomic analysis by microarray will only be done on 40 patients because the analysis costs 150 € / patients.
11113732|NCT03979248|Experimental|BMS-986165 + Rabeprazole|
11113733|NCT03979235||Heahlthy people|perform motor function assessment by using scales, sEMG, and inertia sensors
11113734|NCT03979235||People with motor deficits|perform motor function assessment by using scales, sEMG, and inertia sensors
11113735|NCT03979235||Patients with dysphagia|perform motor function assessment by using scales, sEMG, and inertia sensors
11113736|NCT03979209|Experimental|Mometasone 1mg|1mg capsule dissolved in 240mg saline solution nasal irrigation
11113737|NCT03979209|Experimental|Mometasone 2mg|2mg capsule dissolved in 240mg saline solution nasal irrigation
11113738|NCT03979209|Experimental|Mometasone 4mg|4mg capsule dissolved in 240mg saline solution nasal irrigation
11113739|NCT03979196|Active Comparator|Inpatient Management|Women in this arm will follow the standard of care for admission to high-risk units at Sunnybrook Health Sciences Centre or North York General Hospital.
11113740|NCT03979196|Active Comparator|Outpatient Management|Women in this arm will be encouraged to follow the standard of care established in the high-risk clinics at Sunnybrook Health Sciences Centre or North York General Hospital.
11113741|NCT03979183|Experimental|Intervention|Therapeutic exercise
11113742|NCT03979183|No Intervention|Control|Usual care
11113743|NCT03979157|Experimental|Healthy Volunteers|Multispectral Optoacoustic Tomography (MSOT) of proximal and distal leg muscles (total of 12 sites: left and right, 3 measurement points of Musculus quadriceps, and 3 measurement points of Musculus triceps surae) before and after the 6-Minute-Walk-Test by to independent investigators. Repetition of the same protocol after 14 days.
11113744|NCT03979131|Experimental|Resectable GC and GEJC+avelumab+FLOT preoperative treatment|Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year.
11113745|NCT03979105||Ketamine infusion|Ketamine infusion treatment for acute pain in adult population in all type of surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 48 hours.
11113746|NCT03979092|Experimental|IP-ACLS|
11113747|NCT03979092|Other|Waitlist|
11113748|NCT03979066|Active Comparator|Atezolizumab|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
11113749|NCT03979066|Experimental|Atezolizumab in combination with PEGPH20|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery in combination with PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
11113750|NCT03979053||Patients with AIH|60 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at KCH NHS FT and are either being investigated for AIH or have confirmed AIH
11113751|NCT03979040|Experimental|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
11113752|NCT03979040|Active Comparator|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant?s principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
11113753|NCT03979027|No Intervention|No Breakfast|Fasting. Ad libitum water intake permitted.
11113754|NCT03979027|Experimental|Breakfast|Ad libitum intake of ready-to-eat-cereal with milk. Participants were given a choice of four commercially available RTECs with 1.8% fat cow's milk. Ad libitum water intake was also permitted. The four ready-to-eat-cereals were corn flakes, toasted rice, shredded whole wheat pieces with a sugar topping, and wheat, corn and oat shapes.
11113755|NCT03979014|Experimental|Vaccinated Arm|Add vaccine
11113756|NCT03979014|No Intervention|Control|No intervention
11113757|NCT03979001||Patients|Patients referred for polysomnography diagnosis of obstructive sleep apnea syndrome
11113758|NCT03979001||Controls|Person without obstructive sleep apnea syndrome
11113759|NCT03978988|Experimental|Thrombectomy + Carotid Stenting|"Intravenous thrombolysis will be administered if possible. Standard mechanical thrombectomy(MT) will be performed with a balloon Guide Catheter. MT technique will be left at the discretion of the operators.
~Concerning the cervical disease, emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion. An intravenous bolus of 250mg of Aspirin (up to Imaging 24H) will be given at the end of the procedure in case of absence of complication.
~Intravenous sedation or general anesthesia will be permitted.A second antiplatelet agent is used if a thrombus is formed : IV or nasogastric tube (choice by operator) A dual antiplatelet therapy is administered after 24H imaging follow-up excluding intracranial hemorrhagic complications (discretion of the local practice)"
11113762|NCT03978975|Experimental|overweight women|20 women with a body mass index ranging between 25 and 29,9 kg.m2
11113763|NCT03978962||Study population|Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure
11113764|NCT03978949|Experimental|Probiotics|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
11113765|NCT03978949|Placebo Comparator|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
11113766|NCT03978936|Experimental|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
11113767|NCT03978936|Active Comparator|EAM only|Electronic Adherence Self-Management [EAM] only
11113768|NCT03978923||the drill-inserted implants (G1)|
11113769|NCT03978923||the ultrasonic device- inserted implants (G2)|
11113770|NCT03978910|Experimental|Weigthlessness|during a flight
11113771|NCT03978897|Experimental|Blood flow restriction with physical/occupational therapy|physical/occupational therapy including use of blood flow restriction tourniquet over 6 visits (within a twelve week period).
11113772|NCT03978897|Active Comparator|Evidence based physical/occupational therapy|evidence based physical/occupational therapy program over 6 visits (within a twelve week period) without use of blood flow restriction tourniquet
11113773|NCT03978884|Experimental|Mild Hypertensive|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg
11113774|NCT03978884|Experimental|Mild Hypertensive with Diabetes|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg and diabetes.
11113775|NCT03978884|Experimental|Severe Hypertension|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg
11113776|NCT03978884|Experimental|Severe Hypertension with Diabetes|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg with diabetes
11113777|NCT03978871|Experimental|Growth Mindset|Persuasive education about emotions, brain development, and teenagers' ability to learn how to manage emotions
11113778|NCT03978871|Active Comparator|Brain Education|Neutral education about functions of different parts of the brain
11113779|NCT03978845|Experimental|Phrenic Nerve Blockade|All patients will be submitted to bilateral phrenic nerve block on its cervical portion.
11113780|NCT03978832|Experimental|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
11113781|NCT03978819||Patients with large CPA tumors|Patients with large cerebellopontine angle tumors (>2 x 2cm) undergoing elective surgery
11113782|NCT03978806|Active Comparator|peer navigator|The first PN visit will take place within 1-2 weeks of consent. Each of the 5 subsequent PN visits will take place every 1-2 weeks. We expect patients to complete the intervention within 2-3 months of consent. The function of the initial visit is to establish trust and ensure a more personal approach with participants. The community-based PN intervention is grounded in core Latino values (e.g. trust, personalized relationships). The core elements of the PN intervention include patient motivational interviewing as well as patient activation, empowerment (e.g. help with scheduling of healthcare appointments and re-scheduling of missed HD sessions), education (e.g. education of ESKD and need for renal replacement therapy), and social challenges (e.g. access to resources for transportation, benefits, immigration issues). The duration, individuals present during the visit, and content discussed will be documented in the visit form.
11113783|NCT03978806|Placebo Comparator|Control Arm (standard of care)|Standard of care
11113784|NCT03978793|Active Comparator|MyTPill|Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill
11113785|NCT03978793|Active Comparator|Wisepill|Participants receive Wisepill for three months, have a 2-week washout, then switch to digital pills
11113786|NCT03978780|Experimental|Serratus Plane Block|"The target fascial plane superficial to the serratus anterior (superficial) muscle will be identified and the path of the block needle will be determined. After local anaesthetic infiltration of the skin with 1% lidocaine, a 50-90mm mm 22G insulated block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 0.4 ml/kg (max. 30 ml) of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
~In patients randomised to the serratus plane block group, using ultrasound guidance a sham subcutaneous injection of 0.5ml sterile normal saline injection will be performed at the same site of the ESP block to stimulate a real block procedure."
11113787|NCT03978780|Experimental|Erector spinae plane block|The interfascial plane deep to the erector spinae muscle will be identified and the path of the needle determined. The path of the needle will be visualised to target the area between the erector spinae muscle and the T3 transverse process. Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T3 transverse process. Once the needle tip is in the correct position, 0.4 ml/kg (max. 30 ml) of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed. After injection, patients will be closely monitored until they are transferred to the OR.
11113788|NCT03978767|Experimental|NSAID Analgesic bundle|Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery
11113789|NCT03978767|Active Comparator|NSAID free analgesic bundle|Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.
11113790|NCT03978754||patients with lymphedema|
11113791|NCT03978741|Experimental|Test Device|Yōni.Fit Test Device
11113792|NCT03978741|Active Comparator|Comparator Device|Yōni.Fit Comparator Device
11113793|NCT03978728||ECMO patients|Patients with ECMO support
11113794|NCT03978702|Experimental|Indication for pancreatectomy|Blood sampling at different time points before and after pancreatectomy
11113795|NCT03978689|Experimental|CUE-101 dose escalation and expansion|Part A&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)
11113796|NCT03978689|Other|Pembrolizumab and CUE-101|Part C&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
11113797|NCT03978663|Experimental|Neoadjuvant radiotherapy|3 doses of stereotactic radiotherapy administered prior to neoadjuvant chemotherapy in high-risk breast cancers.
11113798|NCT03978637|Experimental|Itacitinib 300 mg|Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
11113799|NCT03978637|Experimental|Itacitinib 400 mg|Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
11113800|NCT03978637|Experimental|Itacitinib 600 mg|Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
11113801|NCT03978637|Experimental|Itacitinib|Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
11113802|NCT03978624|Experimental|A: Pembrolizumab alone|Subjects will be administered pembrolizumab alone 200 mg IV on day 1 and day 22
11113803|NCT03978624|Experimental|B: Pembrolizumab plus Entinostat|Subjects will be administered pembrolizumab on day 1 and day 22 and entinostat 5 mg given orally on day 1, day 8 and day 15
11113804|NCT03978611|Experimental|Part 1: Dose Escalation Phase|
11113805|NCT03978611|Experimental|Part 2: Dose Expansion Phase|
11113806|NCT03978598|Experimental|Immediate insertion group|Immediate insertion in the first 24 hours after delivery ENG implant insertion Intervention.
11113807|NCT03978598|Active Comparator|Standard Postpartum Insertion Group|Insertion of the Etonogestrel implant 4-6 weeks postpartum Intervention.
11113808|NCT03978585|Experimental|HTEMS Arm|High tone therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
11113809|NCT03978585|Active Comparator|TENS Arm|TENS therapy (home based) daily for 30 minutes on at least 5 of 7 days per week
11113810|NCT03978572|Active Comparator|Resistance Training|12 weeks of whole-body progressive resistance training, three days per week, lower-extremity focused (60% of exercises targeting lower extremities)
11113811|NCT03978572|Active Comparator|Moderate-intensity continuous cycling|12 weeks of progressive endurance cycling on a stationary bicycle at a target heart rate, three days per week.
11113812|NCT03978572|Experimental|High-intensity interval cycling|12 weeks of progressive high-intensity interval cycling on a stationary bicycle, three days per week.
11113813|NCT03978559|Experimental|CAS with TMP/SMZ|
11113814|NCT03978559|Active Comparator|TMP/SMZ|
11113815|NCT03978546|Experimental|Non-Glaucoma Patient Arm|All participants will complete the same assessments
11113816|NCT03978546|Experimental|Glaucoma Patient Arm|All participants will complete the same assessments
11113817|NCT03978533|Experimental|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
11113818|NCT03978520|Experimental|Group 1: Upadacitinib and Elsubrutinib|Participants will be administered with elsubrutinib dose A and upadacitinib dose A.
11113819|NCT03978520|Experimental|Group 2: Upadacitinib and Elsubrutinib|Participants will be administered with elsubrutinib dose A and upadacitinib dose B.
11113820|NCT03978520|Experimental|Group 3: Elsubrutinib and Placebo for Updadacitinib|Participants will be administered with elsubrutinib dose A and placebo for upadacitinib.
11113821|NCT03978520|Experimental|Group 4: Upadacitinib and Placebo for Elsubrutinib|Participants will be administered with placebo for elsubrutinib and upadacitinib dose A.
11113822|NCT03978520|Experimental|Group 5: Placebo for Elsubrutinib and Placebo for Upadacitinib|Participants will be administered with placebo for elsubrutinib and placebo for upadacitinib.
11113823|NCT03978507|Experimental|DeFOG group|feedback number of steps + cueing
11113824|NCT03978507|Active Comparator|Control group|feedback number of steps
11113825|NCT03978494|Experimental|Period 1: Advagraf®; Period 2: Generic tacrolimus|In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
11113826|NCT03978494|Experimental|Period 1: Generic tacrolimus; Period 2: Advagraf®|In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
11113827|NCT03978481||Eradicated group|Gastric cancer patients received subtotal gastrectomy, with Helicobacter pylori eradication
11113828|NCT03978481||Negative group|Gastric cancer patients received subtotal gastrectomy, without Helicobacter pylori eradication or Helicobacter pylori negative
11113829|NCT03978468|Active Comparator|Usual Care Group|Children will receive usual care.
11113830|NCT03978468|Experimental|Interagency Collaboration (ICollab Group)|Subjects of this arm will receive ICollab intervention in addition to usual care which consists of communication with Home Health Nurse (HHN) , Collaborative meetings, and communication with Primary Care Physician (PCP)
11113831|NCT03978455||Patients Who Smoke|"This group will consist of up to 100 English-speaking adult smokers recruited from their primary care clinic who are willing to complete a brief phone-based interview about their experience in using the Learn, Connect, and Quit (LCQ) tablet-based mobile application. The LCQ app presents smoking and cessation-related educational and motivational content in an easily accessible manner (i.e., via videos) and provides avenues for smokers to connect to evidence-based treatment."
11113900|NCT03978026|Experimental|nap in an armchair|the participants take a nap of 30 min in a car sit in a bedroom
11113901|NCT03978026|Experimental|nap in teh Sombox|the participants take a nap of 30 min in the micro-hotel Sombox
11113832|NCT03978455||Clinic Staff|"Rooming staff and physicians from the primary care clinic (where Patients Who Smoke group participants are recruited) will be asked to participate in interviews about the feasibility of implementing the LCQ app including implementation burden, impact on clinical workload, and clinical utility of the app (i.e., Did patients ask more questions about smoking treatment? How challenging was it to try to give all smokers the app to explore?)."
11113833|NCT03978442|Experimental|CPT-SMART|COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) - an intervention that combines evidence-based PTSD treatment with guideline-concordant cognitive-behavioral smoking cessation counseling, bupropion, and intensive behavioral therapy through CM.
11113834|NCT03978442|Active Comparator|Combined Contact Yoked Control|COMBINED CONTACT YOKED CONTROL (CCYC) - an intervention that is identical to CPT-SMART for PTSD and smoking treatment, except for using non-contingent payment (i.e., yoked CM) to control for compensation and monitoring.
11113835|NCT03978429|Experimental|Intervention Arm|"Community-based Pre-eclampsia/Eclampsia Detection and Management
~Strengthened Referral Network from Community to Referral hospital levels
~Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.
~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.
~Antenatal Care Nurses will receive bluetooth blood pressure monitors.
~Community Health Workers within the intervention arm facilities will receive training in pre-eclampsia features and will be provided with smart phones and access to a smart phone application that will prompt them to initiate follow ups with pregnant women within the community and they will receive SMS/text messages reminders about pregnant women within the community who require follow up."
11113836|NCT03978429|No Intervention|Enhanced Usual Care|"Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.
~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.
~Antenatal Care Nurses will receive bluetooth blood pressure monitors."
11113837|NCT03978416|No Intervention|Focus groups|"Information on practical and cultural barriers and promoters of successful weight management will be collected through focus groups. This will include include food access, dietary patterns, physical activity, time and financial constraints, and additional psychosocial and cultural factors.
~A total of 30 participants will be recruited for the focus groups."
11113838|NCT03978416|Experimental|Pilot behavioral intervention|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests with 5 participants per test (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery.
11113839|NCT03978403|Experimental|M207 3.8 mg (two 1.9 mg Patches in foil pouches, Treatment A)|M207 3.8 mg (Zolmitriptan Microneedle System) administered as two 1.9 mg disposable titanium microneedle patches packaged in a foil pouch (Treatment A)
11113840|NCT03978403|Experimental|M207 3.8 mg (two 1.9 mg Patches in cups, treatment B)|M207 3.8 mg (Zolmitriptan Microneedle System) administered as two 1.9 mg disposable titanium microneedle patches packaged in cups (Treatment B)
11113841|NCT03978403|Experimental|M207 3.9 mg (two 1.9 mg Patches in cups (Treatment C)|M207 3.8 mg (Zolmitriptan Microneedle System) administered as two 1.9 mg disposable titanium microneedle patches packaged in cups (Treatment C)
11113842|NCT03978403|Active Comparator|Zolmitriptan Nasal Spray (Treatment D)|Zolmitriptan 2.5 mg/0.1 ml nasal spray (Zomig® Nasal Spray)
11113843|NCT03978390|Experimental|Superhero images, Reward at the beginning,|Also, Showing superhero images for 5 minutes before starting the dental procedure. Also, providing the children with reward before begging the dental procedure and telling them that they can only keep it if they cooperate during the treatment procedure.
11113844|NCT03978390|Experimental|Superhero images, Reward at the end|Universally-accepted positive reinforcement to increase children cooperation in dental settings
11113845|NCT03978390|Experimental|No Superhero Images, Reward at the beginning|Showing superhero images for 5 minutes before starting the dental procedure
11113846|NCT03978390|Active Comparator|No Superhero Images, Reward at the end|Showing no picture before starting the dental procedure
11113847|NCT03978364|Experimental|azacitidine|"azacitidine
~azacitidine 75mg/m2，iH，qd， d1-7"
11113848|NCT03978364|Active Comparator|azacitidine combined HHT|azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3
11113849|NCT03978338|Experimental|Intervention group|The experimental group will take the brain polypeptide solution .
11113850|NCT03978338|Placebo Comparator|Control group|The control group was treated with the same package of placebo .
11113851|NCT03978325|Active Comparator|Control|This arm will complete a standard prehabilitation intervention.
11113852|NCT03978325|Experimental|HIIT Intervention|This group will complete a pre-operative high intensity interval training programme.
11113853|NCT03978299||Positive PSA result|"Men with a positive PSA test defined as:
~Serum total PSA concentration is over 10 ng/ml.
~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is under 25%, in at least in two determinations."
11113854|NCT03978299||Negative PSA result|"Men with a negative PSA test defined as:
~Serum total PSA concentration is under 10 ng/ml.
~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is over 25%."
11113855|NCT03978286|Experimental|Vortioxetine therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
11113856|NCT03978286|Experimental|Sertraline therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
11113857|NCT03978273|Experimental|Night-time brace + virtual-brace|Patients are conventionally treated with night-time brace. Additionally, they use the new developped virtual-brace (MD).
11113858|NCT03978273|Active Comparator|Night-time brace only|Patients are conventionally treated with night-time brace only.
11113861|NCT03978221|Experimental|diaphragmatic tissue doppler evaluation|A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
11113862|NCT03978208|Active Comparator|Placebo Comparator|ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days
11113863|NCT03978208|Active Comparator|ATB-346 mid-dose|ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days
11113864|NCT03978208|Active Comparator|ATB-346 standard dose|ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days
11113865|NCT03978208|Placebo Comparator|Active Comparator|Overencapsulated placebo tablet taken by mouth once daily for 14 days
11113866|NCT03978195|Experimental|Treatment|
11113867|NCT03978195|No Intervention|Control|
11113868|NCT03978182|Active Comparator|active accelerated deep rTMS|Stimulation: We will use a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil, which includes a sham option. In analogy to our former accelerated rTMS studies (2, 3), all patients will receive 20 dTMS sessions (5 sessions per day; 4 consecutive days) with a stimulation intensity of 120% of the subject's resting MT, as reported by Levkovitz et al.(4). Furthermore, we selected these FDA approved dTMS parameters, so that for one session each dTMS repetition includes 2-sec pulse trains separated by 20-sec inter-train intervals. Patients will receive 55 trains in each treatment session, for a total of 1980 pulses per session. This makes 9900 pulses/day, and in total 39600 pulses per treatment.
11113869|NCT03978182|Sham Comparator|sham|Built-in sham in the H1 Helmet (same device as active treatment)
11113870|NCT03978169||General anaesthesia with orotracheal intubation|surgery patients under general anaesthesia with orotracheal intubation
11113871|NCT03978169||General anaesthesia with laryngeal mask|surgery patient under general anaesthesia with laryngeal mask
11113872|NCT03978169||Spinal anaesthesia|surgery's patients under Spinal anaesthesia
11113873|NCT03978156|Experimental|Patient on intervention|"Dronabinol capsules are supplied as oblong, soft gelatin capsules containing 2.5 mg of dronabinol.
~For masking, one intact active dronabinol capsule will be placed in a capsule shell, back filled with sufficient quantity of microcrystalline cellulose, and closed. The capsules are visually inspected and packed into high density polyethylene (HDPE) bottles."
11113874|NCT03978156|Placebo Comparator|Patient on placebo|Matching placebo will be compounded, using a matching empty capsule filled with sufficient quantity of microcrystalline cellulose. The capsules are visually inspected and packed into HDPE bottles.
11113875|NCT03978143|Other|Sequence 1|Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G
11113876|NCT03978143|Other|Sequence 2|Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G
11113877|NCT03978143|Other|Sequence 3|Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G
11113878|NCT03978143|Other|Sequence 4|Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H
11113879|NCT03978143|Other|Sequence 5|Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H
11113880|NCT03978143|Other|Sequence 6|Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H
11113881|NCT03978130|Experimental|mHealth-CR|
11113882|NCT03978130|Active Comparator|Usual Care|
11113883|NCT03978117|Experimental|Watercress Preparation|
11113884|NCT03978117|Placebo Comparator|Placebo|
11113885|NCT03978104|Experimental|Okara biscuits|Subjects will consume their habitual diet with daily okara biscuit consumption accounting to 20 grams/ day of dry okara powder for 21 days.
11113886|NCT03978104|Experimental|Bio-okara biscuits|Subjects will consume their habitual diet with daily bio-okara biscuit consumption accounting to 20 grams/ day of dry bio-okara powder for 21 days.
11113887|NCT03978104|Experimental|Control biscuits|Subjects will consume their habitual diet with daily control biscuit consumption for 21 days.
11113888|NCT03978091|Experimental|Arm 1|2.5g dose of ceftazidime-avibactam (AVYCAZ) administered intravenously as a 2-hour infusion, every 8 hours for 7 days. N=8
11113889|NCT03978091|Experimental|Arm 2|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion once, then 0.32g dose per hour daily as a continuous infusion (7.5 g/day) for 7 days. N=8
11113890|NCT03978091|Experimental|Arm 3|2g dose of aztreonam (ATM) administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
11113891|NCT03978091|Experimental|Arm 4|2g of ATM administered intravenously as a 2-hour infusion once, then 0.33g dose administered intravenously per hour, daily as a continuous infusion (8 g/day) for 7 days. N=8
11113892|NCT03978091|Experimental|Arm 5|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion, every 8 hours for 7 days, and a 1.5g dose of ATM administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
11113893|NCT03978091|Experimental|Arm 6|2.5 g dose of AVYCAZ administered intravenously as a 2-hour infusion every 8 hours for 7 days, and a 2g dose of ATM as a 2-hour infusion every 6 hours for 7 days. N=8
11113894|NCT03978078|Experimental|Biological collection|"For all the patients include in the study :
~- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11113895|NCT03978052|Experimental|1|"EGCG + multimodal intervention (n=50) Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~+ personalized intervention"
11113896|NCT03978052|Active Comparator|2|"Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~non personalized intervention"
11113897|NCT03978052|Placebo Comparator|3|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~+ personalized intervention"
11113898|NCT03978052|Sham Comparator|4|"Placebo Font-Up 49 to 98 gr Font-up (260-520mg EGCG)/day (If participant weight is ≤ 50kg will take 1 sachet each day, if participant weight is >50kg will take 2 sachets each day)
~non personalized intervention"
11113899|NCT03978026|Experimental|nap in a bed|the participants take a nap of 30 min in a bed in a bedroom
11115567|NCT03966196|Experimental|COPD patients|oxymetry and finger pressure in COPD patients
11113902|NCT03978026|Sham Comparator|no nap in a bed|the participant stay awaked for 30 min in a bed in a bedroom
11113903|NCT03978013|Experimental|Pomegranate|
11113904|NCT03978013|Active Comparator|Apple|
11113905|NCT03978000|Active Comparator|IBP-9414|
11113906|NCT03978000|Placebo Comparator|Placebo|
11113907|NCT03977987||The treatment group|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
11113908|NCT03977987||The control group with high HBV DNA level|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
11113909|NCT03977987||The control group with low HBV DNA level|Pregnant women with high HBV DNA level < 2*10^6 IU/ml
11113910|NCT03977974|Experimental|LY3526318 - Part A|LY3526318 administered orally once.
11113911|NCT03977974|Placebo Comparator|Placebo - Part A|Placebo administered orally once.
11113912|NCT03977974|Experimental|LY3526318 - Part B|LY3526318 administered once orally on consecutive days.
11113913|NCT03977974|Placebo Comparator|Placebo - Part B|Placebo administered once orally on consecutive days.
11113914|NCT03977961||DDD Patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) with a diagnosed DDD fulfilling the inclusion criteria and scheduled for surgery will be considered for this study.
11113915|NCT03977935|No Intervention|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
11113916|NCT03977935|Experimental|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
11113917|NCT03977922|Experimental|Diet group|"The diet group will be involved in a 12-week pilot nutrition program based on the anti-inflammatory diet studied by Allison and Ditor (2015). The nutrition program will entail:
~Once per week (Monday mornings), nutrition program members will come to Power Cord to pick up their box of ingredients for their meals that week (Monday to Friday). Recipe cards will accompany the ingredients, and enough food will be provided for 3 meals and 2 snacks per day. The meals will be based on the anti-inflammatory diet previously studied in Allison and Ditor (2015).
~10-12 online videos that cover basic kitchen/cooking skills, how to prepare the meals in the program, how to shop for healthy foods at the grocery store, etc.
~At the beginning of the program each member will be provided with a few pieces of accessible kitchen equipment that will made food preparation and cooking much easier.
~Once per month, we will be offering a live cooking class."
11113918|NCT03977922|No Intervention|Control group|The control group will eat their usual diet for the 12-week period.
11113919|NCT03977896|Experimental|11C-MET PET/MRI|
11113920|NCT03977870||patients with Venous thromboembolism (VTE)|
11113921|NCT03977857||28-day nonsurvival or transplantation|patients who died or underwent liver transplantation within 28 days since admission
11113922|NCT03977857||28-day transplantation-free survival|patients who survived without liver transplantation at 28 days since admission
11113923|NCT03977844|Active Comparator|Technical Assistance|Technical Assistance. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security.
11113924|NCT03977844|Experimental|Community Engagement and Planning|Community Engagement and Planning. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security. In addition, community agencies will be invited to meet with one another to develop novel and investigator supported coalitions using principles of community partnered participatory research that will adapt toolkits and other local assets to seek to enhance community resilience related to threats of disaster risk, financial insecurity, housing insecurity, mental health, or other coalition-determined domains.
11113925|NCT03977844|Active Comparator|Community Resources (CR)|Community Resources (CR). At the Individual level of randomization, individuals in the Community Resources (CR) arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security.
11113926|NCT03977844|Experimental|Community Resources (CR) + eBT|Community Resources + eBT. At the Individual level of randomization, individuals in the CR+eBT arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security, along with an interactive component to support CBT-informed coping with mood and stressors at the individual level.
11113927|NCT03977831|Active Comparator|Open Radical Cystectomy (ORC)|Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.
11113928|NCT03977831|Active Comparator|Robot-assisted Radical Cystectomy (iRARC)|Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.
11113929|NCT03977805|Experimental|Hetrombopag Olamine|Hetrombopag Olamine (5 mg, 100 uCi)
11113930|NCT03977792|Experimental|Experimental treatment|"Subjects treated with BOR15001L7.
~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
11113931|NCT03977792|Active Comparator|Comparator treatment|"Subjects treated with Docosanol 10%.
~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
11113932|NCT03977779|Experimental|Prophylactic biodegradable pancreatic stent placement|
11113933|NCT03977766|Experimental|nurse then patient digital prevalidation of chemotherapy|"Outpatient Chemotherapy prevalidation will done
~with the help of a nurse, using the digital application, for cycle 2 and 3.
~by the patient alone, using the digital application, for cycle 4 and 5."
11113934|NCT03977753|Experimental|2LVERU®/2LVERU® JUNIOR|Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)
11113935|NCT03977753|Placebo Comparator|Placebo|Group N°2: Placebo treatment (6 months of treatment)
11113936|NCT03977740|Experimental|chest PNF|"participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.
~Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow."
11113937|NCT03977740|Active Comparator|Conventional|participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
11113938|NCT03977727|Experimental|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
11113939|NCT03977727|Experimental|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
11113940|NCT03977714|Experimental|Group A - test implant and abutment|Zirconia implant and G3-coated abutment (test implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
11113941|NCT03977714|Experimental|Group B - test implant and control abutment|"Zirconia implant and control abutment (test implant, negative control abutment).
~Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons."
11113942|NCT03977714|Experimental|Group C - control implant and test abutment|Titanium implant and G3-coated abutment (control implant, test abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
11113943|NCT03977714|Active Comparator|Group D - control implant and abutment|Titanium implant and control abutment (negative control implant and abutment). Dental sites that potentially qualify for dental implant rehabilitation will be randomly assigned to either the test group (zirconia implants) or the control group (titanium implants). Also, G3-coated and control (non-coated) abutments will be equally distributed on test and control implants, to discriminate between peri-implantitis prevention due to the G3-coating or due to the specific implant characteristics. This is a split-mouth study so that each participant can act as his or her own control and to allow between and within group comparisons.
11113944|NCT03977714|Experimental|Group E - test and control implants|"Zirconia implant and titanium implant for histological and histomorphometric evaluation.
~This study will be performed in the area of the wisdom teeth (a non useful site that will not interfere with the rest of the study or with the patient's life), so it can only be performed in patients who no longer have these teeth. The procedure will match the procedures described for Groups A-B-C-D. Group E implants will only remain in the mouth for 2 months, after which they will be removed for further analysis. The removal of these implants, for the patient, has exactly the same implications as a normal molar extraction."
11113945|NCT03977701|Experimental|Mono-morphemic Singleton PD|Speech sound treatment on mono-morphemic singleton consonants for children with PD.
11113946|NCT03977701|Experimental|Mono-morphemic Singleton PD-SLI|Speech sound treatment on mono-morphemic singleton consonants for children with PD-SLI.
11113947|NCT03977701|Experimental|Mono-morphemic Cluster PD|Speech sound treatment on mono-morphemic consonant clusters for children with PD.
11113948|NCT03977701|Experimental|Mono-morphemic Cluster PD-SLI|Speech sound treatment on mono-morphemic consonant clusters for children with PD-SLI.
11113949|NCT03977701|Experimental|Bi-morphemic Singleton PD|Treatment on singletons in bi-morphemic contexts for children with PD.
11113950|NCT03977701|Experimental|Bi-morphemic Singleton PD-SLI|Treatment on singletons in bi-morphemic contexts for children with PD-SLI.
11113951|NCT03977701|Experimental|Bi-morphemic Cluster PD|Treatment on bi-morphemic consonant clusters for children with PD.
11113952|NCT03977701|Experimental|Bi-morphemic Cluster PD-SLI|Treatment on bi-morphemic consonant clusters for children with PD-SLI.
11113953|NCT03977701|Experimental|Bi-morphemic Singleton SLI|Treatment on singletons in bi-morphemic contexts for children with SLI.
11113954|NCT03977701|Experimental|Bi-morphemic Cluster SLI|Treatment on bi-morphemic consonant clusters for children with SLI.
11113955|NCT03977688||none Cyto|septic shock, refractory, without Cytokin-adsorption therapy
11113956|NCT03977688||cyto|septic shock, refractory, treated with Cytokin-adsorption therapy
11113957|NCT03977675|Experimental|Ketamine 0.3 mg/kg|Subjects are assigned to receive a dose of 0.3 mg/kg of Ketamine.
11113958|NCT03977675|Experimental|Ketamine 0.5 mg/kg|Subjects are assigned to receive a dose of 0.5 mg/kg of Ketamine.
11113959|NCT03977675|Experimental|Ketamine 0.7 mg/kg|Subjects are assigned to receive a dose of 0.7 mg/kg of Ketamine.
11113960|NCT03977662|Experimental|PTG with adult pancreatic islet co-transplantation|People with Type 1 (c-peptide negative) diabetes with stable kidney or liver allografts on chronic immunosuppression who receive study intervention, which is co-transplantation of allogeneic parathyroid (PTG) with adult pancreatic islets in people with Type 1 diabetes in the intramuscular (IM) site
11113961|NCT03977649|Experimental|erenumab|monthly subcutaneous erenumab 140 mg for 12 weeks
11113962|NCT03977649|Placebo Comparator|placebo|monthly subcutaneous masked placebo for 12 weeks.
11113963|NCT03977610|Experimental|Ga68-PSMA ligand|Glass vial with 4~20 mCi(148-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), more than 0.33 mCi/mL @ EOS; One time dose of 2-5 mCi (74-185 MBq) for PET Imaging ; i.v. injection
11113964|NCT03977584|Experimental|[^18F]GTP1 in Mutation Carriers: Crenezumab|Mutation-carrying participants receiving crenezumab in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
11113965|NCT03977584|Placebo Comparator|[^18F]GTP1 in Mutation Carriers: Placebo|Mutation-carrying participants receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
11113966|NCT03977584|Placebo Comparator|[^18F]GTP1 in Non-carriers of Mutation: Placebo|Non-carriers of the mutation receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
11113967|NCT03977571|Experimental|Deferred nephrectomy|Surgery after induction therapy (Nivo + Ipi), followed by maintenance therapy (Nivo)
11113968|NCT03977571|Active Comparator|No surgery|Induction therapy (Nivo + Ipi), followed by maintenance therapy alone (Nivo).
11113969|NCT03977558|Experimental|Intervention group|Isocaloric diet, based on individual energy requirements calculated from indirect calorimetry and physical activity adjustment Participants will be asked to eat daily ~50g canola oil
11113970|NCT03977558|Active Comparator|Control group|Standard dietary advice that is used as current best practice in the treatment of lipid disturbances of European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias)
11113971|NCT03977545|Other|Newborn with risk of neonatal opioid abstinence syndrome|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 7 days
11113972|NCT03977545|Other|Eutrophic term newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
11113973|NCT03977545|Other|Term newborn with low birth weight|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
11113974|NCT03977545|Other|Eutrophic premature newborn|The newborns will have actigraphy during 30 minutes and Lipsitz scoring system twice a day during 2 days
11113975|NCT03977532|Experimental|patients with sickle cell disease|
11113976|NCT03977519|Experimental|MA group|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used at EX-B8,BL32,SP8,and SP6.
11113977|NCT03977519|Active Comparator|TENS group|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used to stimulate the area along the lower borders of the ribs and the upper borders of the hip crests on both sides.The parameters of the electric acupuncture apparatus：Continuous wave,the frequency is 100Hz, the current intensity is 2.5mA-5mA.
11113978|NCT03977506|Experimental|Behavoiral|The evaluation will be realized on two different assessment grids during the test on the road
11113979|NCT03977493|Active Comparator|Xeomin®|Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).
11113980|NCT03977493|Placebo Comparator|Placebo concentrate|Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).
11113981|NCT03977480|Active Comparator|Hemay007 400 mg BID group|Patients will orally take Hemay007 tablets 400 mg BID for 12 weeks.
11113982|NCT03977480|Active Comparator|Hemay007 800 mg QD group|Patients will orally take Hemay007 tablets 800 mg QD for 12 weeks.
11113983|NCT03977480|Active Comparator|Hemay007 600 mg BID group|Patients will orally take Hemay007 tablets 600 mg BID for 12 weeks.
11113984|NCT03977480|Placebo Comparator|placebo group|Patients will orally take placebo tablets for 12 weeks.
11113985|NCT03977467|Experimental|Arm A (Chemo + Atezolizumab)|Arm A consists of patients with advanced NSCLC who received first-line PD-1-monotherapy, who have subsequent disease progression. In Arm A, patients with NSCLC will be randomized 1:1 to either chemotherapy plus atezolizumab at a flat dose of 1200 mg IV every 3 weeks or chemotherapy alone until progression or unacceptable toxicity. Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
11113986|NCT03977467|Experimental|Arm B (Atezolizumab Only)|Arm B consists of approximately 10-15 patients per disease type (renal cell carcinoma [RCC], triple negative breast cancer [TNBC], small cell lung cancer [SCLC], squamous cell carcinoma of the head and neck [SCCHN], melanoma, microsatellite instability-high [MSI-high] solid tumors {as determined by local testing for MSI/mismatch repair (MMR)}), as well as patients with NSCLC who were treated with a PD-1 antibody in ≥ second-line setting and who have had subsequent disease progression and NSCLC patients who have progressed after pembrolizumab plus chemotherapy in the first-line setting. In Arm B, patients with advanced solid tumors will be treated with an atezolizumab flat dose of 1200 mg IV every 3 weeks until progression or unacceptable toxicity.
11113987|NCT03977454|Experimental|Group 1 patients will receive nerve block per standard of care|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.
~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and
~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI."
11113988|NCT03977454|Active Comparator|Group 2 will NOT receive any nerve blocks.|Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
11113989|NCT03977441|Placebo Comparator|control group|treated with Pramipexole 0.75mg/d（0.25mg tid)+placebo 25mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+placebo 50mg qn * 10 weeks
11113990|NCT03977441|Experimental|experimental group|treated with Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine25 mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine 50mg qn * 10weeks
11113991|NCT03977415||RA with no ILD|"Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.
~Study Assessments Include:
~Medical history and Physical exams
~Quality of Life Questionnaires
~Collection of Sputum and Blood
~Radiology (HRCT)
~Lung Function Test"
11113992|NCT03977415||RA with ILD|"Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.
~Study Assessments Include:
~Medical history and Physical exams
~Quality of Life Questionnaires
~Collection of Sputum and Blood
~Radiology (HRCT)
~Lung Function Test
~Spirometry"
11113993|NCT03977389||Population of the study|"Patient undergoing total wrist denervation between January 1995 and December 2013 at Brest CHRU, performed by the same senior surgeon.
~Total wrist denervation is a routine procedure in orthopedic surgery for wrist arthritis."
11113994|NCT03977376|Experimental|Intervention|Valuation instruments were two validated scales: ESAS y HADS. Experimental nursing instrument: Guide of hosting.
11113995|NCT03977376|No Intervention|Control|Valuation instruments were two validated scales: ESAS y HADS. Without Guide of hosting.
11113996|NCT03977363||Anticoagulated patients|Patients receiving anticoagulation treatment
11113997|NCT03977350||Patients over 65 years undergoing heart surgery|Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored
11113998|NCT03977324|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
11113999|NCT03977324|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
11114000|NCT03977311|Experimental|MR-HIFU|-The study team will determine the tumor volume to be treated per standard-of-care diagnostic MRI or CT imaging. An array of scans will be used to align the participant with the HIFU system, optimize heat delivery to the patients, and/or monitor aspects related to the participant such as motion. Vendor-provided software will be used with the participant in each position to create a customized treatment plan for heat delivery. The HIFU device will then be used to apply clinical levels (41-42°C) of heat to the tumor volume. Regions will be heated to the 41-42°C for up to 60 minutes in one session (either before or after radiation) on one day per five to ten standard radiation therapy fractions, with a maximum of 6 days of hyperthermia over the course of their standard, indicated radiation therapy treatment.
11114001|NCT03977298|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine
11114002|NCT03977298|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
11114003|NCT03977285|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
11114004|NCT03977285|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
11114005|NCT03977285|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
11114006|NCT03977272|Active Comparator|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
11114007|NCT03977272|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 200mg.
11114008|NCT03977259|No Intervention|Standard fortification|Standard of care fortification with multicomponent human milk fortifier (24 kcal/oz) and liquid protein (0.27 g/dL); additional protein and/or calories added only for growth faltering.
11114009|NCT03977259|Experimental|Individually targeted fortification|"Standard of care fortification plus extra protein and/or calories to ensure that base milk has protein 1 g/dL and calories 67/dL."
11114010|NCT03977246|Experimental|Open-placebo|The open-placebo intervention session
11114011|NCT03977246|Placebo Comparator|Control|The control session
11114012|NCT03977233|Experimental|SingleArm: FOLFIRINOX|Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.
11114013|NCT03977220|Experimental|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
11114014|NCT03977207|Experimental|Levothyroxine|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.
~The intervention period is 24 weeks. Patients will undergo up to two subsequent dose titrations after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points. Patients whose TSH levels are higher or lower than the therapeutic TSH target of 0.5-3.0mIU/L will undergo a dose adjustment (+/- 25mcg), while those whose TSH levels are in target range will continue the prior dose."
11114045|NCT03976934|Placebo Comparator|Placebo group|administration of placebo 24 and 6 hours before surgery
11114015|NCT03977207|Placebo Comparator|Placebo|"Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (>3.0-5.0 and 5.0-10.0mIU/L) to ensure treatment balance across TSH levels. The study medications will be prepared in pill form. In the treatment arm, initial L-T4 doses will be 25mcg vs. 50mcg among patients whose TSH is >3.0-5.0mIU/L vs. 5.0-10.0mIU/L, respectively. Patients in the placebo arm will receive an equivalent number of placebo pills daily depending upon TSH level.
~The intervention period is 24 weeks. Patients in the placebo arm will undergo an equivalent titration in placebo pills (as that of the experimental arm) after 8- and 16-weeks of treatment, based on interim TSH measurements at these time points."
11114016|NCT03977194|Active Comparator|Arm A : standard treatment|Carboplatine + paclitaxel (4 cycles of 28 days)
11114017|NCT03977194|Experimental|Arm B : standard treatment + immunotherapy|Carboplatine + paclitaxel (4 cycles of 28 days) + atezolizumab (every 21 days) until progression or toxicity
11114018|NCT03977181|Experimental|Health Club|A group-based community health club akin to an ART adherence club
11114019|NCT03977181|Experimental|One-on-one|One-on-one adherence counselling and support
11114020|NCT03977181|No Intervention|Medication pick-up|Community-based medication dispensary
11114021|NCT03977155|Experimental|High dose of BOS-589|Participants will receive a high dose of BOS-589 orally twice a day (BID).
11114022|NCT03977155|Experimental|Low dose of BOS-589|Participants will receive a low dose of BOS-589 orally BID.
11114023|NCT03977155|Placebo Comparator|Placebo|Participants will receive matching placebo orally BID.
11114024|NCT03977129|Experimental|QFR group|
11114025|NCT03977129|Active Comparator|CAG group|
11114026|NCT03977116|Experimental|heart failure patients with diabetes treated by SGLT2 drugs|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
11114027|NCT03977116|Placebo Comparator|heart failure patients with diabetes treated by placebo|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
11114028|NCT03977103|Experimental|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
11114029|NCT03977090|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
11114030|NCT03977077|Experimental|Albumin binding taxol|
11114031|NCT03977064|Experimental|Intensive treatment group|The intensive treatment group will pass a life-style intervention program including consequent escalation of measures to reach sustained reduction of 10% of initial body weight at minimum.
11114032|NCT03977064|No Intervention|Standard treatment group|Patients will be taken care of by general physician without lifestyle program.
11114033|NCT03977051||Focus group|Focus group to explore immunosuppressant medication adherence in kidney transplant patients
11114034|NCT03977038||TRD sample|Individuals in the treatment resistant depression (TRD) sample suffer from the condition called TRD. The intervention that will be administered to this group is the standardized rTMS treatment using High Frequency dTMS (HF-dTMS) stimulation over L-DLPFC, at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks.
11114035|NCT03977038||Healthy Controls (HC) sample|Individuals in the HC sample are age-, sex-, education-matched to the individuals in the TRD sample. HC sample does not receive any therapeutic treatment and are solely examined as a comparative measure of normal cognitive capabilities.
11114036|NCT03977012||Patients with CRPS Type I|"Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care.
~-drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks"
11114037|NCT03976999|Experimental|Biological collection|"For all the patients include in the studie :
~Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)
~Tissue samples (tumor tissue and healthy tissue) collected during the surgery
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11114038|NCT03976986|Experimental|cPOC - pPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
11114039|NCT03976986|Experimental|pPOC - cPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by pPOC (pulsed-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by cPOC (continuous-flow).
11114040|NCT03976973|Experimental|Intervention|Patients with inoperable pseudomyxoma peritonei or peritoneal mucinous tumour that meet the entry criteria and consent to the intervention will receive intratumoural or intraperitoneal treatment/s with the combination experimental drug treatment BromAc. The drug will be injected directly into the tumour or free intraperitoneally via a percutaneously radiologically placed drain.
11114041|NCT03976960|Experimental|Biological collection|"For all the patients include in the study :
~samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11114042|NCT03976947||Before group|"The before group is the control group. We collect retrospective data in consecutive patients operated before the implementation of lung recruitment maneuvers protocol"
11114043|NCT03976947||After group|We collect data in consecutive patients operated after the implementation of lung recruitment maneuvers protocol. This lung recruitment maneuvers will be realised along the surgery, (After tracheal intubation, per-CPB, post-CPB). Each recruitment maneuver consisted of applying a continuous positive airway pressure of 30 cm of water for 30 seconds
11114044|NCT03976934|Active Comparator|Tamsulosin group|administration of 0,4mg of tamsulosin 24 hours before surgery and 0,4mg 6 hours before surgery
11114046|NCT03976921|Experimental|CCTA Strategy|CCTA will be performed with one of the latest generation scanners. A stenosis > 50% will be considered as significant from an anatomical point of view. For coronary stents, degree of intrastent restenosis will be evaluated by visual assessment of intraluminal contrast density. ISR > 50% will be considered as significant from an anatomical point of view. For CABG, each graft will be visually evaluated and scored as patent, non-significant stenosis ≤ 50%, significant stenosis > 50%, or occluded. For patients with positive CCTA results, additional stress CTP will be performed subsequently. If indicated, vasodilatation will be induced with i.v. adenosine injection or regadenoson. Static or dynamic CTP will be performed according to local practice and scanner technology available. For all patients with previous history of MI the presence of reversible ischemia will be obtained by the comparison between rest and stress perfusion.
11114047|NCT03976921|Active Comparator|Standard of care Strategy|Patients randomized to this group will be evaluated according to current clinical guidelines with the following approaches: (a) stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET; (b) direct referral to ICA.
11114048|NCT03976908|Experimental|ON-OFF|Patients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
11114049|NCT03976908|Experimental|OFF-ON|Patients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
11114050|NCT03976895|Other|Supine position (SP)|Supine position (SP) combined with HFNC
11114051|NCT03976895|Experimental|Prone position (PP)|Prone position (SP) combined with HFNC
11114052|NCT03976882|Experimental|Hetrombopag treatment|Study is 2:1 randomization ratio (hetrombopag to placebo).
11114053|NCT03976882|Placebo Comparator|Placebo treatment|Study is 2:1 randomization ratio (hetrombopag to placebo).
11114054|NCT03976869|Experimental|Cohort 1|The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
11114055|NCT03976856|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
11114056|NCT03976843|Experimental|1/18F-DCFPyL PET/CT + radical prostatectomy|18F-DCFPyL PET/CT with radical prostatectomy andlymphadenectomy
11114057|NCT03976830||Children diagnosed with cancer|Patients diagnosed with childhood cancer in participating sites in Central American countries
11114058|NCT03976817||SA-AVR group|Patients who underwent the supra-annular aortic valve replacement (SA-AVR) technique in our institution between December 2010 and December 2017 were retrospectively reviewed.
11114059|NCT03976804|Experimental|atherosclerotic cardiovascular event associated with tobacco|
11114060|NCT03976791|Experimental|Enlarged internal incision|enlarged the internal incision about 0.4mm
11114061|NCT03976791|Placebo Comparator|Regular 2.2mm incision|regular 2.2mm corneal incision for microincision coaxial phacoemulsification
11114062|NCT03976778|Other|a pre-post interventional study|intervention consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
11114063|NCT03976765||Hospital discharge at day 7|
11114064|NCT03976752|No Intervention|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
11114065|NCT03976752|Experimental|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
11114066|NCT03976752|Experimental|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
11114067|NCT03976752|Experimental|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96hrs after taking the medication in the clinic (visit 5).
11114068|NCT03976752|Experimental|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
11114069|NCT03976739||chronic gastritis|patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results
11114070|NCT03976739||precancerous lesion|patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results
11114071|NCT03976739||gastric cancer|patients with gastric cancer according to histopathological results
11114072|NCT03976726||i-gel size #3|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
11114073|NCT03976726||i-gel size #4|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
11114074|NCT03976726||i-gel size #5|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
11114075|NCT03976713|Experimental|Bufei Yishen granule plus Western medicine|Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
11114076|NCT03976713|Placebo Comparator|Placebo Bufei Yishen granule plus Western medicine|Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
11114077|NCT03976700|Experimental|Bufei Jianpi granule|Patients in this arm will receive Bufei Jianpi granule.
11114078|NCT03976700|Placebo Comparator|Placebo Bufei Jianpi granule|Patients in this arm will receive placebo Bufei Jianpi granule.
11114079|NCT03976687|Experimental|1: EYP001a Dose A|Dose A once daily morning dose
11114080|NCT03976687|Experimental|2: EYP001a Dose B|Dose B once daily morning dose
11114081|NCT03976687|Experimental|3: EYP001a Dose C|Dose C twice daily - first dose morning dose and second dose 3 hours post first dose
11114082|NCT03976674|Experimental|Patients in preparation for bariatric surgery|Patients in preparation for bariatric surgery in the endocrinology department will follow a cognitive behavioural therapy
11114083|NCT03976674|No Intervention|Control group|Standard practice
11114117|NCT03976401|Experimental|EFX Dose 3|Main Study
11114084|NCT03976661||DIAPASON 92 arm|Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
11114085|NCT03976661||Control arm|Arm will be constituted by people residing at the EHPAD (retirement home)
11114086|NCT03976648|Experimental|GLPG1690|
11114087|NCT03976635|Active Comparator|Removable Mandibular Retractor|Patients in this group will be treated by the Removable Mandibular Retractor (RMR) in order to get rid of the anterior cross bite. This appliance is removable.
11114088|NCT03976635|Experimental|Bone-anchored intermaxillary Traction|Patients will be treated using bone-anchored intermaxillary traction. Class III elastics will be extended from the Adam's clasps placed in the upper removable appliance towards the heads of mini-implants placed between the permanent canine and lateral incisors on either side of the lower dental arch.
11114089|NCT03976622||vitiligo|Patients aged 18 to 75 years with non-segmental vitiligo;
11114090|NCT03976622||psoriasis|Patients aged 18 to 75 years with plaque psoriasis;
11114091|NCT03976622||atopic dermatitis|Patients aged 18 to 75 years with atopic dermatitis;
11114092|NCT03976622||alopecia areata|Patients aged 18 to 75 years with alopecia areata sclerosis;
11114093|NCT03976583|Active Comparator|Cpp-acp|MI paste Self-administration of the product by the patient once in the evening. A pea-size amount of the product should be applied per arch, using a dry finger or cotton pellet to distribute it evenly across all teeth and to work it into the interdental spaces. The product was then retained in the mouth for 1-3 min, and manipulated around the teeth using the tongue, before being expectorated and patient should not rinse it until 30 min.
11114094|NCT03976583|Experimental|Pearl powder|Pure pearl powder in the form of gel Self-administration of the product should be used once daily (in the evening), after a 2 min manual tooth brushing. .Participants were explicitly instructed to apply the gel by his finger allover the teeth and not to rinse their mouths after application and not to eat or drink for at least 30 min.
11114095|NCT03976570|Experimental|Occupational Therapy|Occupational Therapy
11114096|NCT03976557|Experimental|BIP CVC|Polyurethane CVC with noble metal coating
11114097|NCT03976557|Active Comparator|Standard CVC|Standard CVC made of polyurethane
11114098|NCT03976544|No Intervention|Natural cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.
~The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.
~Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge."
11114099|NCT03976544|Experimental|Hormone replacement therapy cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.
~In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation."
11114100|NCT03976518|Experimental|ATEZOLIZUMAB|Atezolizumab will be administered at a flat dose of 1200 mg by intravenous route. Atezolizumab will be delivered in 250-mL 0.9% NaCl (sodium chloride) intravenous (IV) infusion bags. The administration will be repeated every 3 weeks (21 [± 3] days). The initial dose will be delivered over 60 (± 15) minutes. In case the first infusion is tolerated without any infusion-associated AEs the second infusion may be delivered over 30 (± 10) minutes. If the second 30 minutes infusion is well tolerated all the subsequent infusions may be administered over 30 (± 10) minutes. The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
11114101|NCT03976505|Active Comparator|textual prescription healthy volunteers|
11114102|NCT03976505|Active Comparator|table prescription healthy volunteers|
11114103|NCT03976505|Experimental|textual prescription Parkinson's disease patients|
11114104|NCT03976505|Experimental|table prescription Parkinson's disease patient|
11114105|NCT03976492||Normal group|normal population
11114106|NCT03976492||Brain injury group|patients with traumatic brain injury within 24 hours
11114107|NCT03976492||Non-brain injury group|Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
11114108|NCT03976466|Experimental|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
11114109|NCT03976466|Active Comparator|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
11114110|NCT03976453||Group A|Women who underwent caesarean hysterectomy
11114111|NCT03976453||Group B|Women who underwent lower segment caesarean section
11114112|NCT03976453||Group C|Women who underwent spontaneous Vaginal delivery
11114113|NCT03976427|Experimental|Guided Imagery|Participants will listen to a guided imagery recording
11114114|NCT03976414||eMOM website users|"Any woman who visits the research tab on the eMOM website will see an invitation to participate in a research study about the impact of the website on her bladder and bowel symptoms. Women may use the intervention (the website) regardless of whether they opt to participate in the research study.
~The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence."
11114115|NCT03976401|Experimental|EFX Dose 1|Main Study
11114116|NCT03976401|Experimental|EFX Dose 2|Main Study
11114121|NCT03976388|Experimental|Clinical virtual simulator|A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
11114122|NCT03976388|Active Comparator|Standard educational session|A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
11114123|NCT03976375|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
11114124|NCT03976375|Active Comparator|Docetaxel|Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
11114125|NCT03976375|Experimental|Lenvatinib Monotherapy|Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
11114126|NCT03976362|Experimental|Pembrolizumab + Carboplatin + Taxane + Olaparib|"For the Induction Phase, participants receive 4 cycles:
~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.
~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
11114127|NCT03976362|Active Comparator|Pembrolizumab + Carboplatin + Taxane + Olaparib Placebo|"For the Induction Phase, participants receive 4 cycles:
~Pembrolizumab 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.
~For the Maintenance Phase, participants receive pembrolizumab IV on Day 1 of each 21-day for up to 31 cycles PLUS matching maintenance olaparib placebo twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib placebo until progressive disease, physician decision or intolerable toxicity."
11114128|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 during Part A [Single Ascending Dose (SAD)].
11114129|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 2|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
11114130|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 3|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
11114131|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 4|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
11114132|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 5|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
11114133|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 6|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
11114134|NCT03976349|Experimental|Part B (MAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 on multiple days during Part B [Multiple Ascending Dose (MAD)].
11114135|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 2|Participants [Non leucine-rich repeat kinase 2 (Non LRRK2)] will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
11114136|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 2|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
11114137|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 3|Participants (Non LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
11114138|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 3|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
11114139|NCT03976349|Placebo Comparator|Part A (SAD): Matching Placebo|Participants will receive matching placebo during Part A [Single Ascending Dose (SAD)].
11114140|NCT03976349|Placebo Comparator|Part B (MAD): Matching Placebo|Participants will receive matching placebo on multiple days during Part B (MAD).
11114141|NCT03976336|Experimental|Berberine|
11114142|NCT03976336|Placebo Comparator|Identical Placebo|
11114143|NCT03976323|Experimental|Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib|"For the Induction Phase, participants receive 4 cycles:
~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of 21-day cycle (Cycles 1 through 4).
~If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy.
~For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21-day cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. In the Maintenance Phase, the participant continues to receive maintenance olaparib until progressive disease, physician decision or intolerable toxicity."
11114166|NCT03976232|Experimental|CST- Group|Participants of this arm will receive CST and Conventional therapy for 2 weeks.
11114167|NCT03976232|Active Comparator|combination of tDCS and CST|Participants of this arm will receive CST+ tDCS and Conventional therapy for 2 weeks.
11114168|NCT03976219|Experimental|Evoked potentials of ECAPs and SSEPs|Patients implanted with a spinal cord stimulator. In this arm, we are measuring the evoked potentials of electric compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs).
11114169|NCT03976206|Experimental|VSEL Max|We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
11114144|NCT03976323|Active Comparator|Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed|"For the Induction Phase, participants receive 4 cycles:
~Pembrolizumab 200 mg intravenous (IV) on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Pemetrexed 500 mg/m^2 IV on Day 1 of each 21-day cycle (cycles 1 through 4) PLUS Platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of 21-day cycle (Cycles 1 through 4) OR cisplatin 75 mg/m2 IV on Day 1 of 21-day cycle (Cycles 1 through 4). If the participant has a complete or partial response or stable disease to induction therapy, the participant is randomized to maintenance therapy. For the Maintenance Phase, participants receive Pembrolizumab IV on Day 1 of each 21 day-cycle for up to 31 cycles PLUS maintenance pemetrexed IV 500 mg/m^2 on Day 1 of each 21-day cycle. In the maintenance phase, the participant continues to receive maintenance pemetrexed until progressive disease, physician decision or intolerable toxicity."
11114145|NCT03976310|Other|The study population|The study population corresponds to severe eosinophilic asthma patients (see eligibility criteria).
11114146|NCT03976297|Experimental|Control Tower Intervention|For participants in the intervention arm, the results of the prediction model will be presented through a GUI interface hereby known as the Control Tower. Participants receive scores from Control Tower (0-100; higher score indicating increased need) for palliative care and are subsequently ranked from highest to lowest. Red (7 or greater) is considered high risk. The intervention will include a Control Tower operator who will interact with the inpatient palliative care consult service. The operator will monitor the Control Tower during weekday normal business hours and select daily a cohort of participants in the intervention units with the highest need of palliative care review. The final list of participants will then be sent to palliative care. The palliative care team who is on service will also assess the need for each participants, and those participants which they agree could benefit they will approach the attending clinical team to suggest a palliative care referral.
11114147|NCT03976297|No Intervention|Standard of Care|For participants who are not in an intervention period they will receive the standard of care commensurate with their clinical unit. This is feasible given that this is a pragmatic clinical trial where the investigators can easily control the communication between the control tower operator and palliative care team to prevent any contamination between clusters. In addition to the usual source of care control the investigators intentionally have calibrated the prediction model and the Control Tower review to match the average capacity of the palliative care service, knowing that that the team will still receive palliative care consults through the traditional pathway i.e. the attending care team consulting palliative care directly.
11114148|NCT03976284|Experimental|Garden-fresh produce and exercise (GFPE)|Participants are encouraged to double their consumption of minimally processed fiber-rich plant foods, especially garden-fresh produce from the church community garden. Participants are also encouraged to limit pro-inflammatory foods rich in saturated fat, sodium and added sugar. Participants are also encouraged to engage in 150 minutes of moderate to vigorous physical activity per week, most likely in the form of brisk walking.
11114149|NCT03976271|Active Comparator|T1DM poor glycaemic control|patients with type 1 diabetes and poor glycaemic control (HbA1c >8% / >64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
11114150|NCT03976271|Active Comparator|T1DM impaired awareness|patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
11114151|NCT03976271|Active Comparator|T1DM Normal awareness|patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
11114152|NCT03976271|Active Comparator|T2DM + Insulin|patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
11114153|NCT03976271|Active Comparator|Healthy control T2DM|healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
11114154|NCT03976271|Active Comparator|Healthy control T1DM|Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
11114155|NCT03976258||HIV-infected adults actively using heroin|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.
11114156|NCT03976258||HIV-infected adults never having used heroin|HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.
11114157|NCT03976258||HIV-infected adults initiating buprenorphine/naloxone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
11114158|NCT03976258||HIV-uninfected adults initiating buprenorphine/naloxone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.
11114159|NCT03976258||HIV-infected adults initiating methadone|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone
11114160|NCT03976258||HIV-infected adults initiating Vivitrol|HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
11114161|NCT03976258||HIV-uninfected adults initiating methadone|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.
11114162|NCT03976258||HIV-uninfected adults initiating Vivitrol|HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.
11114163|NCT03976245|Active Comparator|etanercept|etanercept 50 mg subcutaneously injected per week
11114164|NCT03976245|Active Comparator|tofacitinib|tofacitinib 5 mg orally daily
11114165|NCT03976232|Experimental|tDCS-Group|Participants of this arm will receive tDCS and Conventional therapy for 2 weeks.
11114283|NCT03975361|Other|Bliss-Believe|Patients included in the BLISS-BELIEVE study (NCT03312907).
11114170|NCT03976206|Experimental|VSEL Medium|We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
11114171|NCT03976206|Experimental|VSEL Mini|We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
11114172|NCT03976206|No Intervention|Control|Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group
11114173|NCT03976193|Placebo Comparator|BfitBwell program|BfitBwell is a 3-month supervised exercise program for cancer survivors delivered at the Anschutz Health and Wellness Center. This program has demonstrated effectiveness for improving physical fitness, fatigue, and depression among participants
11114174|NCT03976193|Active Comparator|BfitBwell + 6, bi-weekly PA Behavior Change counseling session|Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
11114175|NCT03976180|Active Comparator|standard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
11114176|NCT03976180|Experimental|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
11114177|NCT03976180|Experimental|HFNO with intermediate FiO2 (50%)|HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
11114178|NCT03976180|Experimental|HFNO with high FiO2 (100%)|HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
11114179|NCT03976167|Active Comparator|Common nasal cannula|Oxygen administration up to 4 liters according defined protocol
11114180|NCT03976167|Experimental|High flow nasal cannula|Oxygen administered with high flow nasal cannula according child weight and protocol designed for this study
11114181|NCT03976154|Experimental|Dermabond|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
11114182|NCT03976154|Active Comparator|Mastisol|Catheter fixation will be performed after appropriate placement of a thoracic epidural with Mastisol spray. The investigator performing the epidural placement will distribute Mastisol spray both in close proximity to the catheter insertion site as well as around the insertion site. Once the Mastisol is allowed to dry, a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team with a goal rate of 6ml/hr.
11114183|NCT03976154|Active Comparator|Grip-lock|Catheter fixation will be performed after appropriate placement of a thoracic epidural with a Grip-Lok fixation bandage. The investigator performing the epidural placement will place the fixation bandage one centimeter caudal from the insertion site. Mastisol will be applied to the surrounding skin and a clear Tegaderm will then be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia team in the operating room with a goal rate of 6ml/hr.
11114184|NCT03976141||a|
11114185|NCT03976128|Experimental|Nordic Walking training|20 sessions of 45 minutes x 2 times/week x 10 weeks using NW
11114186|NCT03976128|Active Comparator|Conventional endurance training|20 sessions of 45 minutes x 2 times/week x 10 weeks using treadmill and cycloergometer training.
11114187|NCT03976115|Experimental|1. healthy volunteers|3x single dose of DDO-3055 and placebo
11114188|NCT03976115|Experimental|2. Patients with chronic kidney disease|3x single dose of DDO-3055 and placebo
11114189|NCT03976102|Experimental|Arm A: DRL_RI|DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36
11114190|NCT03976102|Active Comparator|Arm B: MabThera®|MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36.
11114191|NCT03976089|Experimental|Recipe 4 Success intervention|10 lessons delivered across 10 successive weeks within Early Head Start infrastructure by families' regular Early Head Start home visitors. Lessons involved active coaching in which parents and children prepared healthy snacks or meals. Lessons also included information on children's self-regulation skills and healthy eating habits.
11114192|NCT03976089|Active Comparator|Treatment as usual Early Head Start|Regular Early Head Start home visitors continued to implement evidence-informed developmentally appropriate curriculum designed to promote children's physical health, cognitive skills, and social-emotional functioning as well as parents' capacities to support their children's development.
11114193|NCT03976076|Experimental|JBPOS0101 (investigational product)|
11114194|NCT03976063|Active Comparator|Nifedipine|
11114195|NCT03976063|Placebo Comparator|Placebo|
11114284|NCT03975348|Other|Baseline conventional facemask|The patients will receive oxygen therapy through conventional facemask for 10 minutes
11114196|NCT03976050|Experimental|Dose escalation|Subjects in the dose escalation cohorts will receive ascending doses of HL-085 until the MTD is determined. The first three subjects will receive twice-daily doses (BID) of HL-085 6 mg. Additional cohorts may receive doses of HL-085 9, 12 or 18 mg BID respectively and sequentially. If DLTs are observed in <33.3% of subjects at the 18 mg dose.
11114197|NCT03976037|Active Comparator|Vaginal Misoprostol in combination with foley bulb|"Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.
~Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
11114198|NCT03976037|Active Comparator|Buccal Misoprostol in combination with foley bulb|"misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.
~Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
11114199|NCT03976024|Experimental|DHBN-FN arm|"Recruitment is planned in traditional hospitalization for DHBN-FN patients. Evaluation of streptococcal carriage by swab, pharyngeal, anal and perineal in patients hospitalized for a DHBN-FN at the end of hospitalization and 1 month after discharge from hospital during the reassessment consultation. Swabs made by the dermatologist.
~The carriage of streptococcus in patients living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index"
11114200|NCT03976024|Active Comparator|Control arm (Erysipelas)|"Recruitment is planned in traditional hospitalization for patients with erysipelas.
~The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission)."
11114201|NCT03976011|Experimental|Transcutaneous Laryngeal Ultrasonography|All patients operated on endocrine surgery in the three referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. The gold standard NF will be performed between D1 and D15, as usually performed after these surgeries. TLU will be performed during the same time period by an investigator blind to the NF results. The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
11114202|NCT03975998||Aymptomatic patients with severe mitral regurgitation|Watchful waiting Early Surgery
11114203|NCT03975985|Experimental|Core stability exercises|This group will be divided in two: core stability exercises (CSE) plus conventional therapy (CP) and CSE with transcutaneous electrical nerve stimulation (TENS) plus CP.
11114204|NCT03975985|Active Comparator|Conventional physiotherapy (CP)|CP consists in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
11114205|NCT03975972|Experimental|Occupational Therapy Based Literacy Intervention|For the intervention group, the results from the Inventory of Reading Occupations will be utilized to determine a prescriptive weekly intervention for each participant in the intervention group that will be provided to teachers based on student interest and literacy need. For the intervention group, each participant will be provided with a list of 12 questions that will be used to inform the intervention plan based on the interests of each participant within the intervention group. Collectively, the information from the 12 questions and the results of the Inventory of Reading Occupations will be used to determine a 9-week intervention plan for each participant within the intervention group. The researchers will work with the subjects twice per week, 30 minutes per session in the classroom using the prescriptive intervention that was determined from the assessments utilized.
11114206|NCT03975972|No Intervention|Standard Classroom Based Literacy Intervention|The control group will receive the standard reading instruction provided within the school. With the control group, the researchers will provide occupational therapy support to classroom teachers. But, will provide this support using the materials that are standardly provided within the classroom for literacy instruction. The researchers will provide support to the classroom teachers to students in the control group twice per week for 30 mintues per session in the classroom.
11114207|NCT03975959|Other|GLIOBLASTOMA|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
11114208|NCT03975959|Other|glioma|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
11114209|NCT03975959|Other|breast cancer|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
11114210|NCT03975959|Other|HIV|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
11114211|NCT03975959|Other|healthy|"One visit with collection :
~demographical data clinical data QMRP questionnaire HADS questionnaire MFI questionnaire MoCA test FAB test"
11114212|NCT03975946|Active Comparator|the rheopheresis group|
11114213|NCT03975946|Placebo Comparator|the shamapheresis group|
11114214|NCT03975933|Experimental|Free pregnancy tests at baseline but not for the future|We offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
11114215|NCT03975933|Experimental|Free pregnancy tests at baseline and for the future|We offer free pregnancy test service at baseline and a free pregnancy test for future use.
11114216|NCT03975933|Experimental|Free pregnancy tests at baseline and future use (random price)|We offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
11114217|NCT03975933|No Intervention|Control Group|Control group. No intervention is implemented.
11114218|NCT03975933|Experimental|Pregnancy test for the future use|No free pregnancy tests at baseline, but receive a free pregnancy test for the future.
11114219|NCT03975933|Experimental|Pregnancy test for the future with random price|No free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
11114220|NCT03975920|No Intervention|Usual Care (UC)|The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.
11114221|NCT03975920|Experimental|Experimental Care (EC)|The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block.
11114222|NCT03975907|Experimental|CAR-BCMA T Cells|Phase I: The subjects are enrolled into 2 dose level cohorts in sequence. Phase II: Single arm
11114223|NCT03975894|Experimental|Intervention|Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of <30%.
11114224|NCT03975894|No Intervention|Control|Symptom directed blood transfusion during pregnancy.
11114225|NCT03975881|Experimental|Open Label|Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).
11114226|NCT03975855||Suspicious axillary lymph nodes|All patients with histologically confirmed breast cancer or highly suspicious breast lesions presenting with suspicious axillary lymph nodes
11114227|NCT03975829|Experimental|Dabrafenib and/or trametinib|"Patients in this study may receive one of the following treatments received in the parent study which are:
~Patients who received monotherapy of either of dabrafenib or trametinib
~Patients who received combination of dabrafenib and trametinib
~Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up"
11114228|NCT03975790||Truven Health MarketScan Research Database|Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX
11114229|NCT03975777|Experimental|low-intensity exercise - high-intensity exercise|low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
11114230|NCT03975777|Experimental|high-intensity exercise - low-intensity exercise|high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
11114231|NCT03975764||Preterm birth|Delivery between 24-32 weeks of gestation
11114232|NCT03975764||Term delivery|Delivery between 37-41 weeks of gastation
11114233|NCT03975738||A GP Surgery|A selection of healthcare workers from a GP Surgery to be recruited
11114234|NCT03975738||A Patient and Public Involvement and Engagement Group|A selection of healthcare workers from a Patient and Public Involvement and Engagement Group to be recruited
11114235|NCT03975738||Young Person's Steering Group|A selection of patients from a Young Person's Steering Group to be recruited
11114236|NCT03975738||An Acute Trust|A selection of healthcare workers from an Acute Trust to be recruited
11114237|NCT03975738||Hayward Hospital Social Care Team|A selection of healthcare workers from the Hayward Hospital Social Care Team to be recruited
11114238|NCT03975738||A Hospice|A selection of healthcare workers from a Hospice to be recruited
11114239|NCT03975738||West Midlands Cares|A selection of healthcare workers from a the West Midlands Cares Group to be recruited
11114240|NCT03975738||CRN Clinical Research Speciality Leads (CRSL)|A selection of healthcare workers from a group of CRN (Clinical Research Network) Clinical Research Speciality Leads (CRSL) to be recruited
11114241|NCT03975738||CRN Sub Speciality Leads (SSL)|A selection of healthcare workers from a CRN Sub Speciality Leads (SSL) to be recruited
11114242|NCT03975738||A District General Hospital|A selection of healthcare workers from a A District General Hospital to be recruited
11114243|NCT03975725|Experimental|witcard|
11114244|NCT03975699||Patients in centre 1: Louis-Mourier Hospital|All SCD follow-up consultations were conducted jointly by a paediatrician and a clinical psychologist.
11114245|NCT03975699||Patients in centre 2: Evry hospital|All SCD follow-up consultations were conducted by a paediatrician alone. The unit had close links with the local psycho-medical paediatric care centre when specialized referrals were necessary.
11114246|NCT03975699||Patients in centre 3: Clamart hospital|All SCD follow-up consultations were conducted by a paediatrician alone.
11114247|NCT03975686|Experimental|intervention|
11114248|NCT03975686|No Intervention|control|
11114249|NCT03975673|Active Comparator|Conventional Total Hip Replacement (cTHR )|"Osteoarthritic patient undergoing the conventional technique
~medializing the hip center of rotation
~obtain a standing acetabular cup position fitting the Lewinneck recommendations (inclination 40°±10°, version 15°±10°)"
11114250|NCT03975673|Experimental|Kinematically Aligned Total Hip Replacement (KATHR )|"Osteoarthritic patient undergoing the kinematically aligned technique
~restoring the acetabular center of rotation
~restoring the constitutional acetabular anteversion by using the transverse acetabular ligament (TAL) as a reference landmark.
~making personalized choice for the hip component design
~considering additional spine surgery based on the assessment of the individual spine-hip relation."
11114251|NCT03975660|Experimental|Dural puncture epidural (DPE)|Patients will receive dural puncture epidural (DPE) and will have pain levels monitored by ROPA System (CereVu Medical, Inc. San Francisco, CA) during labor.
11114252|NCT03975660|Experimental|Combined spinal-epidural (CSE)|Patients will receive combined spinal-epidural (CSE) and will have pain levels monitored by ROPA System (CereVu Medical, Inc. San Francisco, CA) during labor.
11114253|NCT03975647|Experimental|Tucatinib + T-DM1|
11114254|NCT03975647|Active Comparator|Placebo + T-DM1|
11114255|NCT03975634|Experimental|Transcutaneous spinal stimulation|Safety and feasibility outcome measures are collected during application of transcutaneous spinal stimulation while trunk control is assessed at 3 time points (acute) and/or while transcutaneous stimulation is applied in combination with activity-based locomotor training (40 sessions, 1.5 hours/day, 5 days/week; stimulation will be applied intermittently for no more than 10 minutes at a time during training)
11114256|NCT03975621|Experimental|Immediate Intervention|The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months. Patients will receive the tablet, a pedometer and an exercise band. Patients will use Nurse AMIE while receiving weekly phone calls from a patient navigator. After 90 days of the intervention observation will take place for 90 days, the patient will be asked to continue using Nurse AMIE without a patient navigator's presence.
11114257|NCT03975621|Experimental|Delayed Intervention|The delayed intervention group will receive the intervention 3 months after consent (6 months of intervention with 3 months delay total of 9 months); the patient will then follow the same pattern as listed above. The only difference is we will ask the delayed intervention group to wear a FitBit device for 1 week following consent in order to gain baseline data as to their activity/movement.
11114258|NCT03975608|Experimental|"Adaptation of CALM"|"This is the patient group that receives the intervention (IG), i.e., the psychotherapeutic treatment, i.e., the adapted version of the psychotherapeutic program Managing Cancer and Living Meaningfully (CALM) which was originally designed for patients with cancer."
11114259|NCT03975595|Active Comparator|Meditation Group A|A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).
11114260|NCT03975595|Active Comparator|Meditation Group B|A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).
11114261|NCT03975595|Active Comparator|Meditation Group C|A brief meditation intervention involving guided breathing and/or attention exercises (further information withheld to preserve blinding).
11114262|NCT03975569|Experimental|vulvovaginitis patients- lactobacillus gel|Daily use of vaginal gel containing lactobacilli by patients. Probiotic vaginal gel.
11114263|NCT03975556|Experimental|Intervention|Intervention group consisting of culturally-appropriate foods and diet advice in an initial individual session followed by daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
11114264|NCT03975556|Active Comparator|Control|Control arm of standard portion-control general nutritional and cooking advice at the initial individual session, followed by text messages for 2 months. A reinforcement phase of 2-months will follow to repeat the education and text messages.
11114265|NCT03975530|Experimental|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it. At 6 months postpartum, and upon completion of the intervention, participants in the treatment group will be asked to participate in brief semi-structured phone interviews.
11114266|NCT03975530|Active Comparator|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
11114267|NCT03975504|Other|LDCT Screening|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
11114268|NCT03975491|Experimental|Aerobic Exercise|Moderate-intensity aerobic exercise
11114269|NCT03975491|Sham Comparator|Control|Wait-list control
11114270|NCT03975478|Active Comparator|Gastric bypass|Bariatric surgery by gastric bypass (GB)
11114271|NCT03975478|Experimental|Sleeve gastrectomy|Bariatric surgery by sleeve gastrectomy (SG)
11114272|NCT03975465|Experimental|Expiratory Muscle Strength Training|Patients randomized to the EMST arm will use the EMST150 device as packaged, i.e. following package instructions
11114273|NCT03975465|Active Comparator|Pharyngeal Muscle Strengthening Exercises|Patients randomized to Standard Care will receive swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion
11114274|NCT03975452|Experimental|Primary resectable cT2-low lying-T3, N0-N1 rectal tumour|Primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes.
11114275|NCT03975426||conservative group|received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture.
11114276|NCT03975426||absorbable screws|received open reduction and internal fixation with fixation by absorbable screws.
11114277|NCT03975413||N=1 MS patient|"Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention.
~Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development."
11114278|NCT03975400|No Intervention|Pre-Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States prior to campaign initiation.
11114279|NCT03975400|Active Comparator|Active Campaign|Investigators will measure the duration of untreated psychosis and rates of referrals to OnTrackNY programs throughout New York States during the active campaign initiation.
11114280|NCT03975387|Experimental|ASTX295|
11114281|NCT03975374|Experimental|Tobramycin/Dexamethasone opthamic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
11114282|NCT03975374|Active Comparator|Tobradex Opthalmic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
11114285|NCT03975348|Experimental|HFNC 40 L/min up|The patients will receive oxygen/air mixture through high flow nasal cannula at incremental, then decremental flows, starting at 40 L/min for 10 minutes
11114286|NCT03975348|Experimental|HFNC 60 L/min up|High flow nasal cannula at 60 L/min for 10 minutes
11114287|NCT03975348|Experimental|HFNC 80 L/min up|High flow nasal cannula at 80 L/min for 10 minutes
11114288|NCT03975348|Experimental|HFNC 100 L/min|High flow nasal cannula at 100 L/min for 10 minutes
11114289|NCT03975348|Experimental|HFNC 80 L/min down|High flow nasal cannula at 80 L/min for 10 minutes
11114290|NCT03975348|Experimental|HFNC 60 L/min down|High flow nasal cannula at 60 L/min for 10 minutes
11114291|NCT03975348|Experimental|HFNC 40 L/min down|High flow nasal cannula at 40 L/min for 10 minutes
11114292|NCT03975348|Other|Washout conventional facemask|Again, the patients will receive oxygen therapy through conventional facemask for 10 minutes, to reduce the influence of HFNC on CPAP therapy
11114293|NCT03975348|Active Comparator|CPAP|The patients will receive CPAP at 10 cmH2O for 10 minutes
11114294|NCT03975335|Experimental|Intervention group|Health education on NCDs and behavioral risk factors was delivered through motivation and observational learning session.
11114295|NCT03975335|Placebo Comparator|Control group|Control group received session on carrier guidance.
11114296|NCT03975309||Previous DHS Participants|Observational
11114297|NCT03975296|Experimental|TMQLB group|
11114298|NCT03975296|Active Comparator|TPVB group|
11114299|NCT03975283|Experimental|Exparel (Liposomal Bupivicaine)|20 ml vial of liposomal bupivacaine containing 266 mg (maximum dose), will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
11114300|NCT03975283|Active Comparator|0.25% Bupivicaine HCL|Two 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes and levels via laparoscopy. Medication will be given just below the last rib and extend to below the lowest incision.
11114301|NCT03975270|Experimental|Sintilimab in Combination With Nab-paclitaxe|Sintilimab 200 mg intravenous drip, first day Nab-paclitaxe120 mg/m2, intravenous drip, first day and eighth day
11114302|NCT03975257|Experimental|Preventive application of EHT02|application of one Ectoin Lozenge before SLIT-initiation
11114303|NCT03975257|Experimental|Therapeutic application of EHT02|application of one Ectoine Lozenge after SLIT-initiation
11114304|NCT03975257|No Intervention|No application of EHT02|SLIT-Initiation without Ectoin Lozenge
11114305|NCT03975244|Experimental|Exercise group|Three months of semi-supervised exercise program in patients awaiting bariatric surgery. Body composition, cardiovascular risk factors, physical fitness, physical activity levels and quality of life will be assessed before and at the end of the study. In addition, surgery time, hospital length of stay and operative complications also will be evaluated.
11114306|NCT03975244|No Intervention|Control group|The control group only will perform the evaluations of the study.
11114307|NCT03975231|Experimental|Treatment (dabrafenib, trametinib, IMRT)|See Detailed Description
11114308|NCT03975218||Patients with stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
11114309|NCT03975205|Active Comparator|Doxil|This group of patients will receive Intravenous Doxil of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
11114310|NCT03975205|Experimental|doxorubicin|This group of patients will receive Intravenous Doxorubicin of 50mgm/m2 over 15 minutes and plasma concentration will be measured at time Frame: 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours. Cycle is defined as 28 days
11114311|NCT03975192|Experimental|Intervention Group|50% of subjects will be randomized to the Intervention group and will receive percutaneous electric nerve field stimulation (PENFS) through the BRIDGE Device for 120 hours to treat withdrawal symptoms in patients following opiate exposure in the PICU.
11114312|NCT03975192|No Intervention|Standard of Care Group|50% of subjects will be randomized to the Standard of Care group and will receive be started on the standardized PICU Methadone wean for patients following opiate exposure in the PICU.
11114313|NCT03975179|Experimental|Frozen section omission|
11114314|NCT03975179|Active Comparator|Frozen section|
11114315|NCT03975166|Experimental|Test Product|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11114316|NCT03975166|Active Comparator|Reference Product|ADVAIR DISKUS® 100/50
11114317|NCT03975153|Experimental|guselkumab treatment|Treatment with guselkumab for 20 weeks
11114318|NCT03975140|Experimental|Hypersensitive acupoint group|
11114319|NCT03975140|Active Comparator|Hyposensitive acupoint group|
11114320|NCT03975127|No Intervention|Routine|women will routinely be invited to attend for cervical screening via the SCCRS application.
11114321|NCT03975127|Experimental|SMS|Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast
11114322|NCT03975114|Active Comparator|Chemo first|Standard chemotherapy followed at progression by durvalumab
11114323|NCT03975114|Experimental|Immuno Monotherapy first|Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
11114324|NCT03975114|Experimental|Immuno Combination Therapy first|experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy
11114325|NCT03975101|Experimental|VSEL Max|A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient
11114326|NCT03975101|Experimental|VSEL Medium|A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient
11114327|NCT03975101|Experimental|VSEL Mini|A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient
11114328|NCT03975101|No Intervention|Control|A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient
11114382|NCT03974685|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
11114329|NCT03975088|Other|Persistent Diabetic macular edema|Authors defined refractory DME as eyes with persistent DME despite receiving at least 6 monthly Ranibizumab injections of anti VEGF, and then switched to Aflibercept, receiving at least three monthly injections.
11114330|NCT03975075|Experimental|Biofeedback|Participants (n=15) will undergo psychophysiological monitoring while also participating in traditional resonance frequency training for a total of eight 30-minute sessions. Prior to beginning the heart rate variability (HRV) training session, participants will be introduced to the two channels (PPG and RSG) of the Thought Technology ProComp 2 Encoder and the Biograph Infinity software. Participants will receive further instruction explaining how physiological information will be displayed and used as a means of training to induce a relaxed state while receiving real time PPG and RSG feedback. Participants will be instructed on using controlled breathing to assist with reaching this relaxed state.
11114331|NCT03975075|Active Comparator|Control Group|"The control arm (n=15) participants will undergo physiological monitoring for eight 30-minute sessions. Before the initial session, a trained study staff will provide participants with an introductory explanation of the associated equipment. The equipment will then be attached to the participants and they will be provided with the following instructions: You will be monitored with this equipment for 30 minutes. During this time frame, please try to limit movement and conversation as much as possible."
11114332|NCT03975062|Experimental|Abbreviated course group (ACG)|The patients receiving 3-days course of dabigatran etexilate during pre-cardioversion period. After cardioversion has been performed the patients continue with dabigatran etexilate until 30 days after cardioversion
11114333|NCT03975062|Active Comparator|Conventional course group (CCG)|The patients receiving 3-weeks course of dabigatran etexilate before cardioversion of AF. After cardioversion has been performed the patients will continue with dabigatran etexilate until 30 days after cardioversion
11114334|NCT03975049|Active Comparator|5-Fu + RT|5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX * 6-8
11114335|NCT03975049|Experimental|mFOLFOXIRI|mFOLFOXIRI * 4 --- TME --- mFOLFOXIRI * 4
11114336|NCT03975049|Experimental|mFOLFOX|mFOLFOX * 9 --- TME --- mFOLFOX * 3
11114337|NCT03975036|Experimental|Anlotinib&pd-1 antibody|Anlotinib 10mg/d,q.d.,p.o.&pd-1 antibody 200mg/d.q.3w.d.l.v
11114338|NCT03975023||hockey players|"During each study visit, the participants will undergo the following procedures:
~NeuroCatch Platform (NCP) assessment (only if participant meets NCP-specific criteria)
~RightEye's eye-tracking battery
~Highmark Interactive's EQ application
~Cambridge Brain Science's neuropsychological tests"
11114339|NCT03975010|Experimental|BUP TDS 20 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.
11114340|NCT03975010|Experimental|BUP TDS 40 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.
11114341|NCT03975010|Experimental|BUP TDS 40 mg for 4 day|Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.
11114342|NCT03974997|Other|serum concentration changes in cytokine TWEAK|We will perform a prospective study in which 50 patients with multiple sclerosis in the isolated clinical syndrome stage will be included over a 12-month period. Mental Cerebral MRIs will be performed for each patient at baseline (T0), month 6, and month 12. Serum dosages of TWEAK will be performed each month for each patient for one year. Patients will also be treated with soluble TNF, the leader in the TNF family of ligands, anti-TWEAK antibodies (which may interfere with the activity and dosage of TWEAK) as well as C-reactive Protein C ( search for intercurrent infectious episode). These dosages will be correlated with the clinical evolution (appearance or not of an inflammatory flare) as well as the data of the imagery (number of lesions raised or not by the gadolinium).
11114343|NCT03974984||"The Hvidovre population:"|We will include patients undergoing laparoscopic hemicolectomy for cancer scheduled for anesthesia with total intravenous anesthesia combined with epidural anesthesia and perioperative NSAID on Hvidovre Hospital.
11114344|NCT03974984||"The Zealand University Hospital population"|"The immunological and oxidative stress in relation to abdominal surgery (IMOX) study is ongoing at Zealand University Hospital, Roskilde. It is a prospective explorative study cohort that consists of 60 patients undergoing laparoscopic colorectal cancer surgery.
~The population has been anesthetized according to the standard operating procedure with either total intravenous anesthesia with propofol and remifentanil or volatile anesthesia with sevoflurane combined with a fast acting opioid (remifentanil or sufentanil). Patients anaesthetized with other techniques including epidural or other regional blocks will be excluded from the analysis."
11114345|NCT03974971||BPDCN diagnosis group|By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018
11114346|NCT03974958|Experimental|AAA patients|Patients with abdominal aortic aneurysm (AAA)
11114347|NCT03974958|Experimental|PAOD patients|patients with peripheral arterial obstructive disease (PAOD)
11114348|NCT03974945||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-60 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
11114349|NCT03974932|Experimental|Cohort 1|HTX-011 + MMA
11114350|NCT03974932|Experimental|Cohort 2|HTX-011 + MMA
11114351|NCT03974932|Experimental|Cohort 3|HTX-011 + MMA
11114352|NCT03974932|Experimental|Cohort 4|HTX-011 + MMA
11114353|NCT03974906|Experimental|GDT group|The fluid in GDT group (Goal-directed fluid therapy) will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the LiDCO monitoring system.
11114354|NCT03974906|No Intervention|Control group|Patients in the control group received conventional fluid therapy, decided by the attending anesthesiologists based on the patient's hemodynamic condition and responses, to maintain MAP >65 mm Hg, heart rate 50-100 bpm, and urine output >0.5 ml/kg/h.
11114355|NCT03974893||Vegetarian Diet|Includes children following a vegetarian diet.
11114356|NCT03974893||Non-Vegetarian Diet|Includes children following a non-vegetarian diet.
11114357|NCT03974880||patency group|Freedom from restenosis or clinically driven re-intervention in the treated lesion at 1,3,6,12 months after procedures
11114383|NCT03974672||T drain|Patients treated with a T drain approach
11114384|NCT03974672||Stoma|Patients treated with a stoma
11114358|NCT03974880||restenosis group|Restenosis was defined as a reduction in the luminal diameter of more than 50 percent according to any imaging examinations such as duplex ultrasound, CTA, MRI or DSA Re-intervention in the treated segment for the clinical progression at 1,3,6,12 months after procedures
11114359|NCT03974880||the second adverse events group|a composite of all-cause death, myocardial infarction, and stroke and any amputation at 1,3,6,12 months after procedures
11114360|NCT03974867|Experimental|Oral Prednisone Group|36 participants in Group 1 will receive oral prednisone 1mg/kg/d (maximum daily dosage is no more than 60mg) for 7 days, followed by a 7-day taper.
11114361|NCT03974867|Experimental|Intratympanic Methylprednisolone Group|36 participants in Group 2 will receive 7 intratympanic 40mg/ml methylprednisolone injections in 14 days, one injection every other day.
11114362|NCT03974854|Experimental|Arm A: XELOXIRI-3|capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days
11114363|NCT03974854|Active Comparator|Arm B: Gemcitabine|1000 mg / m2 on D1, D8 and D15, every 28 days
11114364|NCT03974828|No Intervention|Non-Contact|Participants in the non-contact group will be monitored by anesthesia control tower clinicians who will utilize AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes predictions, but who will not contact the postoperative provider unless it is clinically necessary for patient safety purposes.
11114365|NCT03974828|Experimental|Brief contact|PACU and ward providers caring for participants in the brief contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a brief summary of the patient's forecast risk of major adverse events.
11114366|NCT03974828|Experimental|Full contact|PACU and ward providers caring for participants in the full contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.
11114367|NCT03974815|Experimental|ACTIVE|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
11114368|NCT03974815|Sham Comparator|SHAM|Sham stimulation (tDCS) will be used in the dose of 0mA /30 min per day, for 6weeks. (minimum 5 times per week)(total of 30~42 sessions)
11114369|NCT03974802|Experimental|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
11114370|NCT03974789||Suspected Cushing Disease|
11114371|NCT03974776|Experimental|PF-06946860|Single subcutaneous administration of PF-06946860
11114372|NCT03974776|Placebo Comparator|Placebo|Single subcutaneous administration of placebo
11114373|NCT03974763||Test Group|Patients with acute, unilateral, facial paralysis (Bell's Palsy)
11114374|NCT03974763||Control Group|A group of age- and sex-frequency matched 'normal' controls. Based on past research, gender and age are possible confounders of facial movement/function. Thus, the control group will be frequency-matched to the patient group on gender and age.
11114375|NCT03974750|Experimental|intervention|Training on the rehabilitation robot REAplan(R) to learn complex, coordinated bimanual movements
11114376|NCT03974737||Adolescents with POTS|"Adolescents with Postural Orthostatic Tachycardia Syndrome (POTS) who meet diagnostic criteria for an orthostatic heart rate increase of >30, between ages 12-21 are eligible for this group. They will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.
~Interventions performed:
~Urine specific gravity measurement
~CRI measurements, orthostatic vitals measurements
~Survey administration"
11114377|NCT03974737||Adolescents without POTS, Control Group|"Adolescents without Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21 are eligible for this group. This group of subjects will have a urine specific gravity conducted at the beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and their urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.
~Interventions performed:
~Urine specific gravity measurement
~CRI measurements, orthostatic vitals measurements
~Survey administration"
11114378|NCT03974737||Adolescents diagnosed with POTS who do not meet HR|"Adolescents diagnosed with Postural Orthostatic Tachycardia Syndrome (POTS) between ages 12-21, who do not meet diagnostic heart rate criteria, are eligible for this group. This group of subjects will have a urine specific gravity conducted at beginning of the clinic visit to assess hydration status. If the urine specific gravity shows adequate hydration, subjects will proceed with orthostatic measurements with concomitant CRI measurements (via a non-invasive pulse oximetry monitor). (Subjects who are dehydrated will be given electrolyte drinks for rehydration and urine specific gravity will be rechecked after survey completion and before CRI and orthostatic measurements.) Following the CRI and orthostatic measurements, subjects and their parents will be asked to complete a series of surveys via REDcap.
~Interventions performed:
~Urine specific gravity measurement
~CRI measurements, orthostatic vitals measurements
~Survey administration"
11114379|NCT03974711||All study subjects|"Note: No interventions are administered under this evaluation.
~This is a real-world population. The determination to undergo a lateral lumbar interbody fusion procedure is made outside of this evaluation and is a standard of care, on-label procedure."
11114380|NCT03974698|Active Comparator|Anterolateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
11114381|NCT03974698|Active Comparator|Lateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
11114385|NCT03974659|Active Comparator|Theta Burst Stimulation|"Intervention group: ten consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation.
~Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
~The stimulation intensity was 80% Rest Motor Threshold.According to the patients' condition, age and tolerance,the intensity should be adjusted."
11114386|NCT03974659|Sham Comparator|sham Theta Burst Stimulation|sham group: we flip coil to make fake stimulation, the stimulation will also make sounds, but no magnetic field effect, the stimulation mode is the same as the intervention group.
11114387|NCT03974646|Experimental|intervention group|Participants assigned to the intervention group will receive both will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up , and a 12- weeks self-management intervention delivered by two dedicated and trained renal nurse educators. The intervention will involve three group-based sessions, CKD booklet and three follow-up phone calls.
11114388|NCT03974646|No Intervention|control group|Participants randomized to the control group in this study will receive usual care (standard clinical and medical services) provided to individual with CKD stages 3-4 who attend the CKD clinic at medical outpatient department on their clinic follow up. Usual care consisted of brief verbal information (2-5 minutes) about taking medications, reducing salt, smoking cessation and reducing alcohol consumption. There will no structured program but only the provision of written material to patients.
11114389|NCT03974633|Placebo Comparator|Control|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, without administering any type of non-invasive analgesic
11114390|NCT03974633|Experimental|Vibration|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, while applicating a vibrating device on the skin below the injection site, before and during injection.
11114391|NCT03974633|Experimental|Cold|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a bag of 50mL of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds
11114392|NCT03974633|Experimental|Anesthetic cream|subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a uniform thickness of 2mm of the anesthetic cream EMLA covered with an adhesive transparent plastic dressing for 30 minutes
11114393|NCT03974620|Experimental|Individual Placement and Support (IPS)|IPS is a vocational support program to facilitate return to employment in individuals with severe and enduring mental illnesses.
11114394|NCT03974620|Experimental|Cognitive Remediation Therapy (CRT)|CRT will be delivered twice weekly individual computerised CRT with therapist input. This therapy will be delivered by a CRT trained assistant psychologist.
11114395|NCT03974620|Experimental|IPS and CRT|A combination of IPS and CRT will be provided to participants in this arm.
11114396|NCT03974620|No Intervention|Treatment as usual|Continued input as normal with treating psychiatrist.
11114397|NCT03974607|Experimental|Physical Activity|Physical Activity Programme (PAP) was planned for the promotion of PA and other healthy habits in inactive adolescents as an agent of change intervention, in which a trained staff actively disseminates effective practices to improve the PA's habits of adolescents.
11114398|NCT03974607|No Intervention|No Physical Activity|The control group will be selected in a targeted manner according to the availability of the center. You will not be given any information about healthy habits nor will any physical training program be applied to you, so that you do not give indications that may produce a variation of your habitual behavior.
11114399|NCT03974594|Experimental|Trifluridine and Tipiracil Tablets|
11114400|NCT03974594|Active Comparator|TAS-102|
11114401|NCT03974581||Pharmacoinvasive strategy|Patients whom received pharmacoinvasive strategy (fibrinolysis and subsequently PCI) as reperfusion treatment.
11114402|NCT03974581||Primary PCI|Patients whom primary PCI as reperfusion treatment.
11114403|NCT03974542|Experimental|telephone outreach|
11114404|NCT03974542|No Intervention|control|
11114405|NCT03974529|Experimental|Intensive running arm|20 patients will be assigned randomly to intensive running arm (intervention arm). They will be required to complete a designed training protocol.
11114406|NCT03974529|Active Comparator|Physiotherapy arm|10 patients will be assigned randomly to physiotherapy arm. They will be required to complete a designed training protocol.
11114407|NCT03974516|Experimental|Careseng 1370|"Four dose cohorts are employed for Careseng 1370 oral administration in healthy volunteers:
~Level A (1 sachet): 1 sachet before breakfast;
~Level B (2 sachets): 1 sachet before breakfast, 1 sachet before lunch;
~Level C (3 sachets): 1 sachet before breakfast, 2 sachets before lunch;
~Level D (4 sachets): 2 sachets before breakfast, 2 sachets before lunch"
11114408|NCT03974503|Experimental|Exposure, Relaxation, and Rescripting Therapy (ERRT)|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
11114409|NCT03974503|Active Comparator|Sleep and Nightmare Management|This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
11114410|NCT03974490|Experimental|Intervention Group|"2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
~3 Times a week, intervention: Start with global body warming, 15 minutes, following the rhythm marked by the metronome. Central part of the session, 60 minutes, with rhythmic auditory stimulation exercises and music. Closure of the session, 15 minutes, round of impressions."
11115823|NCT03964558|Other|100 mg [14C]-acebilustat|a single oral dose of 100 mg [14C]-acebilustat
11114411|NCT03974490|No Intervention|Historical control group|2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
11114412|NCT03974477|Experimental|Intervention|"The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about The new Food Wheel, a guide to the daily food choice!."
11114413|NCT03974477|No Intervention|Control|"No intervention will be carried out except the provision of a leaflet on The new Food Wheel, a guide to the daily food choice! to the participants."
11114414|NCT03974451|Experimental|IOL implantation experimental|Implantation of the PhysIOL FineVision POD F® IOL
11114415|NCT03974451|Active Comparator|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL.
11114416|NCT03974438|Experimental|Intervention - Acupunture (SDN)|Patients allocated to the intervention arm will receive SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain.
11114417|NCT03974438|Sham Comparator|Control - Sham acupunture|Patients allocated to the control arm will receive sham-SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain. The sham procedure consists of a blunted needle, that does not penetrate the skin.
11114418|NCT03974425|Other|Diabetic macular edema resistant to Bevacizumab|Patients resistant to 6 monthly Bevacizumab injection were switched to Aflibercept.
11114419|NCT03974412|Experimental|All eligible participants|All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.
11114420|NCT03974399|Other|study enrollment|all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months
11114421|NCT03974386|Experimental|Blood Purification|Patients will receive resuscitation and treatment according to current guidelines for septic shock. In addition to standard care, the patients will receive continuous venovenous hemofiltration and adsorption with oXiris blood purification set.
11114422|NCT03974386|No Intervention|Conventional Treatment|Patients will receive standard care, including resuscitation and treatment according to current guidelines for septic shock.
11114423|NCT03974373|Experimental|BFP removal|this will be the group evaluated in this study, individuals who performed the BFP removal procedure.
11114424|NCT03974360|Experimental|Erenumab|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
11114425|NCT03974347||Acute kidney injury, no acute kidney injury|Acute kidney injury after cardiac surgery will be defined by KDIGO criteria, Creatinine rise from baseline and or urine production.
11114426|NCT03974347||No Acute Kidney Injury|No Acute kidney Injury after Cardiac surgery, according to KDIGO AKI definition
11114427|NCT03974334|Experimental|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
11114428|NCT03974308|Experimental|Study group 1|Patients with spine osteoarthritis who will be treated in polish spas in Subcarpathian Region. Comprehensive physiotherapy including balneotherapy will be applied.
11114429|NCT03974308|Active Comparator|Study group 2|Patients with spine osteoarthritis who will be treated in outpatient treatment. Comprehensive physiotherapy without balneotherapy will be applied.
11114430|NCT03974308|Other|Control group|Patients with spine osteoarthritis who will not have applied physiotherapy nor balneotherapy.
11114431|NCT03974295|Experimental|Intercourse Group|unlimited unprotected vaginal intercourse starting 24 hours after the frozen embryo transfer
11114432|NCT03974295|No Intervention|Pelvic Rest Group|pelvic rest after frozen embryo transfer until positive pregnancy test
11114433|NCT03974282|Other|Virginia Commonwealth University|Enrolled at VCU
11114434|NCT03974269|Active Comparator|Hypnosis arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
11114435|NCT03974269|Placebo Comparator|Sedation arm|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
11114436|NCT03974256|No Intervention|Group standard method|Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
11114437|NCT03974256|Experimental|Group automated method|Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
11114438|NCT03974243|Experimental|treatment group|"In this arm, patients would be given the regimen composed of Chiauranib and Chidamide orally.
~Intervention: Drug: Chiauranib and Chidamide"
11114439|NCT03974230||Patients with Fuchs Endothelial Corneal Dystrophy (FECD)|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of datas and a blood sample.
11114440|NCT03974230||Control group|Witness will be included in control group. They will have a blood sample and slit lamp examination.
11114441|NCT03974217|Experimental|Talazoparib|"Talazoparib is administered orally on a daily basis
~Hydroxyurea is allowed for up to two cycles per institutional guidelines"
11114442|NCT03974204|Experimental|Cerebrospinal fluid and Blood sample collection|"Collection of cerebrospinal fluid and blood samples:
~At initial diagnostic assessment;
~1 month and 3 months after initial diagnostic assessment, for patients classified possible, probable or confirmed according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;
~In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified lack of evidence according to EANO-ESMO classification."
11114443|NCT03974191||131 participants with chronic low back pain|All the participants (n=131) with chronic low back pain (CLBP) from the cross-sectional study in 2006 are invited to participate in the present 13-year follow-up. The same examination battery used in the cross-sectional study plus a supplementary Chair Stand Test will be used.
11114444|NCT03974178|Experimental|Fexinidazole|"Patients with a body weight ≥ 35 kg:
~1800 mg (3 tablets) from day 1 to 4
~1200 mg (2 tablets) from day 5 to 10
~Patients with a body weight ≥ 20 and < 35 kg:
~1200 mg (2 tablets) from day 1 to 4
~600 mg (1 tablet) from day 5 to 10"
11114445|NCT03974165|Experimental|Cereal-legume product 1|Treatment with cereal-legume product-1
11114446|NCT03974165|Experimental|Cereal-legume product 2|Treatment with cereal-legume product-2
11114447|NCT03974165|Experimental|Cereal product|Treatment with cereal product
11114448|NCT03974165|Active Comparator|Reference food|Treatment with reference food
11114449|NCT03974152|Active Comparator|Own brand cigarette|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
11114450|NCT03974152|Experimental|ENDS: Subox Mini C with 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
11114451|NCT03974152|Experimental|ENDS: Subox Mini C with 18 mg nicotine regular (unprotonated)|Participants will be instructed to take one puff of the tobacco product (cigarette or ENDS) every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
11114452|NCT03974139|Experimental|Obese patients|Patients with body mass index >30
11114453|NCT03974126|Experimental|40 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
11114454|NCT03974126|Experimental|80 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
11114455|NCT03974113|Experimental|Fitusiran|Participants will receive a selected dose of fitusiran on regular intervals, as per study protocol
11114456|NCT03974100|Experimental|GP2411|60 mg /mL subcutaneous injection every 6 months
11114457|NCT03974100|Active Comparator|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
11114458|NCT03974087|Active Comparator|MCI patients with real transcranial direct current stimulation|Patients will receive 2mA stimulation in 10 consecutive sessions.
11114459|NCT03974087|Sham Comparator|MCI patients with sham transcranial direct current stimulation|Patients will receive sham stimulation in 10 consecutive sessions.
11114460|NCT03974074|Experimental|Albumin infusion group|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
11114461|NCT03974074|No Intervention|Empty control|Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
11114462|NCT03974061|Experimental|Brief Acceptance and Commitment Therapy|Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
11114463|NCT03974061|Active Comparator|Brief Alcohol Intervention|Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.
11114464|NCT03974048||Trauma patients|All trauma patients admitted to Rigshospitalet's trauma center will have a blood sample taken during the initial treatment and 30 days after the trauma.
11114465|NCT03974048||Patients admitted for elective orthopedic surgery|The patients will have a blood sample taken before and after surgery and again 30 days after the surgery.
11114466|NCT03974035|No Intervention|Control Group|Patients undergoing elective bimaxillary osteotomy who receive a preincisional infiltration of lidocaine and adrenaline.
11114467|NCT03974035|Experimental|Study Group|Patients undergoing elective bimaxillary osteotomy who receive two infiltrations (firstly pre-incision with lidocaine and adrenaline, secondly pre-extubation with ropivacaine).
11114468|NCT03974022|Experimental|DZD9008|
11114469|NCT03974009|Experimental|Calcaneal taping and Conventional therapy|Calcaneal Taping Technique along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
11114470|NCT03974009|Active Comparator|Sham taping and Conventional therapy|Sham taping along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
11114471|NCT03973996|Experimental|Green Tea|Participants consuming gummy confections with catechin-rich green tea extract daily for 4 weeks
11114472|NCT03973996|Placebo Comparator|Placebo|Participants consuming matched gummy confections formulated without green tea extract daily for 4 weeks
11114473|NCT03973983|Experimental|Ultrasound-guided pudendal nerve injection group|Patients who received Ultrasound-guided pudendal nerve injections
11114474|NCT03973983|Experimental|Finger-guided pudendal nerve injection group|Patients who received Finger-guided pudendal nerve injections
11114475|NCT03973970||Test Arm 1- T-SPOT.TB assay|Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
11114476|NCT03973970||Test Arm 2-QuantiFERON-TB Gold Plus assay|Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
11114477|NCT03973957|Active Comparator|Control Arm|If undergoing talc slurry in the control arm, the patient will undergo IPC placement in the pulmonary procedure unit on day one of admission. The IPC will then be connected to a pleur-evac as standard of care protocol for chest tube drainage. At 1-2 hours post-IPC placement a chest x-ray will be obtained to assess for full lung re-expansion. If the lung does not fully expand the patient will be excluded from the study. Once full lung re-expansion has occurred, talc slurry will be ordered and the patient will be given 25 mcg of IV fentanyl. Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will be administered via the IPC. The patient will remain in the hospital, with continuous drainage measured daily for 2-5 days, depending on drainage of the effusion.
11114478|NCT03973957|Active Comparator|Intervention Arm|"An indwelling pleural catheter (IPC) will be placed during this visit. After complete drainage of the effusion, a chest x-ray will be done to determine if full lung reexpansion occurs. If there is lack of full lung re-expansion the patient will be excluded from the study at this time. If full lung re-expansion is present, the patient will receive an intravenous line (IV) by our nursing staff for analgesia prior to talc administration and will be pre-treated with 25 mcg of IV fentanyl.
~Talc slurry (5 g sterile talc, brand name Steritalc, mixed with 50 cc or sterile normal saline in a syringe, per Cooper University Pharmacy protocol) will then be administered through the IPC. The IPC will then be connected to a circuit that will consist of the IPC connected to a 4-liter fluid drainage collection bag via a one-way Heimlich valve (picture of set up included in additional documents)."
11114479|NCT03973944|Other|Cardiac resynchronization therapy|AV coupling by atrio-biventricular pacing
11114480|NCT03973931|No Intervention|Usual Care|This group will not receive an intervention. We have included a usual care group to demonstrate the impact of the text messaging interventions above and beyond usual care given that many prior medication adherence interventions have demonstrated small to negligible effects.
11114481|NCT03973931|Experimental|Generic Nudge|A generic reminder text will be delivered to patients to refill their medication at days 1, 3, 5, 7 and 10 after they been labeled as non-adherent.
11114482|NCT03973931|Experimental|Optimized nudge|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1, 3, 5, 7 and 10 after they have been labeled as non-adherent.
11114483|NCT03973931|Experimental|Optimized nudge plus AI Chat Bot|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1 and 3 after they have been labeled as non-adherent. If the patient has not filled their medication on days 5 and 7, in addition to receiving an optimized nudge text, an AI will conduct interactive chat via a chat bot to assess barriers filling the medication as described in Aim 1 above. If they still have not filled the medication, they will receive another message on day 10.
11114484|NCT03973918|Experimental|Treatment Cohort 1 AA & GBM|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
~Research Bloods"
11114485|NCT03973918|Experimental|Treatment Cohort 2 anaplastic PXAs|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
~Research Bloods"
11114486|NCT03973918|Experimental|Surgical Arm|"Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery
~Tumor; research blood; CSF samples
~post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle"
11114487|NCT03973918|Experimental|Treatment Cohort 3 Other Tumors|"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
~Research Bloods"
11114488|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).
~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
11114489|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).
~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
11114490|NCT03973879|Experimental|PVSRIPO + Atezolizumab|Single PVSRIPO infusion at a dose of 5x10^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.
11114491|NCT03973866|Experimental|Alfapump|Implantation of Alfapump
11114492|NCT03973853|Experimental|Active group with virtual reality stimulation|The subjects in this arm will undertake 14 sessions of virtual reality stimulation. The program will be delivered by a nurse, trained to the use of such a tool, and familiar with cognitive remediation techniques. Before and after these 14 sessions, social autonomy, daily life skills, cognitive domains and self-esteem will be measured
11114493|NCT03973853|Placebo Comparator|Treatment as Usual group (TAU)|Patients in this group will carry on benefiting from their usual care with no additional program. They will be assessed before and after a 3 month period for social autonomy, daily life skills, cognitive domains and self-esteem.
11114494|NCT03973840|Experimental|healthy men treatment arm|Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.
11116010|NCT03963219|Active Comparator|Standard Bolus Calculator|Standard bolus calculator
11114495|NCT03973827|Experimental|ProTrans-Repeat|"Patients 1-3: 25 x10e6 cells Patients 4-6:100 x10e6 cells Patients 7-9:200 x10e6 cells
~Control group 9 patients= non treated"
11114496|NCT03973814|Active Comparator|Prior to Thermax Warming|Baseline temperature
11114497|NCT03973814|Active Comparator|During warming|Temperature during Thermax warming
11114498|NCT03973814|Active Comparator|Post warming|Temperature after cessation of Thermax warming
11114499|NCT03973801|Experimental|Auricular acupressure|
11114500|NCT03973788|Experimental|Intervention|repetitive transcranial magnetic stimulation
11114501|NCT03973775|Experimental|Test Drug Treatment Arm|Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC
11114502|NCT03973775|Active Comparator|Reference Drug Treatment Arm|Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.
11114503|NCT03973762|Experimental|DR Grading with CAD|DR Grading with CAD
11114504|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
11114505|NCT03973749|Experimental|Group 1|Low salycilate diet on day one and High salycilate diet on day 7
11114506|NCT03973749|Experimental|Group 2|High salycilate diet on day one and Low salycilate diet on day 7
11114507|NCT03973736||PDAC patients diagnosed in 2008-2011|
11114508|NCT03973736||PDAC patients diagnosed in 2013-2016|
11114509|NCT03973723||Patients with NPC after treatment|All patients with NPC without distant metastases who receiving adequate RT dose
11114510|NCT03973710|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
11114511|NCT03973710|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
11114512|NCT03973697|Experimental|Single dose of PMT|
11114513|NCT03973697|Experimental|Two doses of PMT|Administered within 24 hours
11114514|NCT03973684|Active Comparator|aPDT group|G1- 40 patient 40 patients will be included in this group. One section of Pdt will be performed with the photosensitizer (PS). PS will be applied in sufficience quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated. The apparatus shall be precalibrated at wavelength 660nm for 90 seconds per point.
11114515|NCT03973684|Experimental|experimental tongue scrapper group|40 patients will be included in this group. Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
11114516|NCT03973671||UC patients|"Patients diagnosed with primary or recurrent non-muscle-invasive bladder (NMIBC) cancer.
~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.
~The clinical (demographic, operative and follow-up) and pathological data of the patients will be collected in a complete anonymous way."
11114517|NCT03973658||First time users of hearing aids|Hearing aid fitting and usage
11114518|NCT03973632|Experimental|Group A|Fasting at last 10h before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
11114519|NCT03973632|Experimental|Group B|Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Fasting at last 10h before taking 200mg（two pills） of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
11114520|NCT03973619|Active Comparator|Labial|Patients who received a labial graft as replacement of urethral tissue
11114521|NCT03973619|Active Comparator|Jugal|Patients who received a jugal (inner cheek) graft as replacement of urethral tissue
11114522|NCT03973606|Experimental|Arab Women health literacy focus groups|Arab women in East Jerusalem will be part of focus groups. investigators will be administrating pre-prepared questions. The focus groups will be recorded and analyzed by the researchers.
11114523|NCT03973580|Active Comparator|Attentional Bias Modification (ABM) group|Participants in this arm will participate in a six-session ABM task, one session per week.
11114524|NCT03973580|Placebo Comparator|Control group|Participants in this arm will participate in a six-session control task, one session per week.
11114525|NCT03973567|Experimental|refractory FD patients using antidepressants|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori（HP） treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
11114526|NCT03973567|Placebo Comparator|refractory FD patienTS using conventional treatment|Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.
11114527|NCT03973567|No Intervention|normal control|Age, sex and education matched, right-handed 30 normal people.
11114528|NCT03973554|Experimental|pearl powder|natural product, support bone and joint health
11114529|NCT03973554|Active Comparator|CPP-ACP|product for professional use containing the active ingredient (CPP-ACP), a special milk-derived protein that has a unique ability to release bio-available calcium and phosphate to tooth surfaces.
11114530|NCT03973541|Experimental|Virtual Reality Exposure Therapy|VRET will include 360° videos with three scenarios a) riding a bus, b) going to a school cafeteria and c) a job interview. These scenarios were chosen based on clinical experience and frequently reported difficult situations in the literature . The order of the scenarios is jointly decided by the patient and therapist. In the videos the patients can make choices which determine the further course of the exposure scenario. For example, in the bus scenario the information system is out of order. Therefore, the patient has to ask the driver to announce, when they are at a particular stop. Depending on whether or not the patient decides to do so, the video will skip to one of two alternative continuations of the scenario. During the exposures the therapist will also motivate the patient towards acting in ways they consider unacceptable to provoke fear of ridicule, and make the patient act against him or her excessively rigid rules for social interaction to observe the consequences.
11115266|NCT03968601||cohorte 1|Severe primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
11114531|NCT03973541|Active Comparator|In Vivo Exposure Therapy|In vivo exposure consists of role-playing and guided exposure either inside or outside the therapist's office with active modelling from the therapist in early sessions. Staff members are called upon to conduct exposure. Similarly to the VRET during in vivo exposure the therapist will motivate the patient towards acting in ways they consider unacceptable.
11114532|NCT03973541|Placebo Comparator|Virtual Reality Relaxation Therapy|VR relaxation therapy will consist of a VR scenario of swimming with dolphins, created by the dolphin swim club (www.thedolphinswimclub.com). Swimming with real wild dolphins has been shown to have a positive effect on anxiety, although not specifically on SAD
11114533|NCT03973528|Experimental|traditional Chinese medicine|The experimental group use traditional Chinese medicine
11114534|NCT03973528|No Intervention|non- traditional Chinese medicine|The no intervention group no use traditional Chinese medicine.
11114535|NCT03973515|Experimental|PB-201 50/50mg by mouth,every morning and noon for 7 days|
11114536|NCT03973515|Experimental|PB-201 100/50mg by mouth,every morning and noon for 7 days|
11114537|NCT03973515|Experimental|PB-201 100/100mg by mouth,every morning and noon for 7 days|
11114538|NCT03973515|Placebo Comparator|placebo|
11114539|NCT03973502|Experimental|18F-DOPA PET|PET/CT
11114540|NCT03973489|Experimental|Wild Type (WT) Group|Wild Type (WT) Group: individuals who are WT for the TAAR1 gene
11114541|NCT03973489|Experimental|Common Variant (CV) Group|Common Variant (CV) Group: individuals who are hetero-or homozygous for the V288V SNP on the TAAR1 gene
11114542|NCT03973476|Experimental|Intervention group|Mothers received a phone support service with their midwife during the 8 weeks after childbirth.
11114543|NCT03973476|No Intervention|Control group|Mothers received standard postpartum care
11114544|NCT03973463|Sham Comparator|Low fat diet,12 weeks low oil balance 1200 kcal / day|12 weeks low oil balance 1200 kcal / day
11114545|NCT03973463|Experimental|12-week resistance exercise 3 times a week|12-week stretch with resistance exercise, 3 times a week
11114546|NCT03973463|Experimental|12 weeks low oil balance and resistance exercise|12 weeks low oil balance 1200 kcal / day and 12-week stretch with resistance exercise, 3 times a week
11114547|NCT03973450||Pituitary tumours|Patients affected by pituitary tumours and followed-up at the Neuroendocrinology Unit over a 5 yrs period (2014-2018)
11114548|NCT03973437|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
11114549|NCT03973437|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
11114550|NCT03973424|Experimental|Simple|This arm uses a simplified form of dietary tracking that involves tracking only high-calorie, high-fat foods, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
11114551|NCT03973424|Experimental|Standard|This arm uses standard calorie tracking, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
11114552|NCT03973411|Active Comparator|Ondansetron group|Patients will receive intravenous ondansetron before spinal anesthesia
11114553|NCT03973411|Placebo Comparator|Control group|Patients will receive intravenous saline before spinal anesthesia
11114554|NCT03973398|Active Comparator|Quadratus Lumborum Block anterior subcostal (QLa)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
11114555|NCT03973398|Active Comparator|Quadratus Lumborum Block posterior (QLp)|Patients in this group will receive Posterior Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
11114556|NCT03973398|Placebo Comparator|Quadratus Lumborum Block anterior subcostal control (QLca)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
11114557|NCT03973398|Placebo Comparator|Quadratus Lumborum Block posterior control (QLcp)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
11114558|NCT03973385|Experimental|cryotherapy group|cryotherapy by vapocoolant spray is applied on skin for 4 to 10 seconds ( or up to skin whitening) to 15 centimeters distance with sweeping action before ABG
11114559|NCT03973385|Placebo Comparator|control group|water spray is applied on skin for 4 to 10 seconds to centimeters distance with sweeping action before ABG
11114560|NCT03973359|No Intervention|Epidemiology|HCMV-seropositive pregnant women receiving standard care
11114561|NCT03973359|Experimental|Prevention|HCMV-seropositive pregnant women receiving hygienic information
11114562|NCT03973346|Experimental|Intervention group|Encounters at primary care clinics with the risk screening tool
11114563|NCT03973346|No Intervention|Comparison group|Propensity score matched comparison encounters
11114564|NCT03973333|Experimental|IMC-C103C - Arm A1|n= approximately 28 patients to establish the MTD/RP2D
11114565|NCT03973333|Experimental|IMC-C103C and atezolizumab Arm A2|n=approximately 12 patients to establish the MTD/RP2D
11114566|NCT03973333|Experimental|IMC-C103C - Arm B1|Patients will be enrolled n=9-24 metastatic/unresectable tumors of interest patients treated at the RP2D of IMC-C103C to assess preliminary anti-tumor efficacy
11114567|NCT03973333|Experimental|IMC-C103C and atezolizumab Arm B2|Patients will be enrolled n=9-24 metastatic/unresectable tumors of interest patients treated at the RP2D of IMC-C103C to assess preliminary anti-tumor efficacy
11114568|NCT03973320||Primary Total Hip Arthroplasty|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty
11114569|NCT03973307||Participants with bladder cancer|50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
11114570|NCT03973307||Participants without bladder cancer|50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
11114627|NCT03973008|Experimental|Adujvant CT+CRT|Four to six weeks after D2 radical surgery, adjuvant chemotherapy was initiated with SOX regimen , repeated every three weeks, and adjuvant radiotherapy was started at the end of two cycles of adjuvant chemotherapy , with synchronous tegiol single drug chemotherapy. And the original SOX regimen was continued for 4 cycles after 3-4 weeks of radiotherapy.
11114571|NCT03973294|Active Comparator|Supraglottic jet ventilation|Ventilation of the patient is performed over a steel laryngoscope or a thin catheter by means of jet ventilation (JV) using the TwinStream jet ventilator (C. Reiner Corp, Vienna, Austria). The driving pressure of the device is 1.5-3 bar and respiratory rates of 10-900 per min can be provided. In superimposed high frequency jet ventilation (SHFJV), jet ventilation of normal frequency and high frequency is conducted simultaneously and enables ventilation at two different pressure levels through the steel jet laryngoscope. It is equipped with two jet nozzles, which are placed at the distal end of the jet laryngoscope.
11114572|NCT03973294|Active Comparator|Subglottic jet ventilation|"Subglottic HFJV is performed through the LaserJet catheter. It is characterized by the delivery of small tidal volumes from a high pressure jet at very high frequencies (100-400) followed by passive expiration for a very short period before delivering the next jet, creating an auto-PEEP."
11114573|NCT03973281|Active Comparator|Materna Prep Device|Materna Prep Device
11114574|NCT03973281|Active Comparator|Materna Sham Device|Materna Sham Device
11114575|NCT03973268|Experimental|1|Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.
11114576|NCT03973268|Experimental|2|Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.
11114577|NCT03973268|Experimental|3|Individuals in Arm 3 will receive doubleblinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.
11114578|NCT03973255|Placebo Comparator|Home based vestibular rehabilitation program|Home-based vestibular rehabilitation program including vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises was given to each group in the form of a booklet. All exercises were demonstrated and performed first time at hospital under supervision. Booklet with descriptions and pictures of each exercise were given to patients in order to enable them to perform exercises at home. Vestibular rehabilitation exercises were prescribed as once daily with 10 repetitions at home for one month and wanted to mark a chart if the exercises were performed daily. A diary was used to monitor adherence with the program.
11114579|NCT03973255|Active Comparator|Biofeedback training|"Biofeedback training was performed five days a week during a month for 20 minutes for a total of 20 sessions with Tetrax ® (Sunlight Medical Ltd) static posture analysis device. Biofeedback training including catch, speedball, sky ball, gotcha exercises which requires following a visual target during weight transfer movements, capturing fast-moving objects by changing the center of gravity or quickly escaping from incoming objects, were applied to the patients in biofeedback training. There is a 30 seconds pause between each exercise."
11114580|NCT03973255|Active Comparator|Whole body vibration|Whole body vibration training was also performed five days a week during a month for 20 minutes for a total of 20 sessions with Power Plate Pro 5 (MDD CE 0086). In whole body vibration, single leg, squat and deep squat positions were applied respectively with 35 Hz frequency, including rest periods of 30 seconds between each application.
11114581|NCT03973242|Active Comparator|DF-NBI|Initially, gastric mucosa is observed by conventional wight light endoscopy. Then, converting to dual-focus mode with narrow band imaging is done. Gastric mucosa is observed once again by DF-NBI mode.
11114582|NCT03973242|Placebo Comparator|WL|Conventional white light endoscopy use It is routine practice for the upper gastrointestinal endoscopy.
11114583|NCT03973229|Experimental|Cohort 1: PTSD Receiving Estradiol then Placebo|Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
11114584|NCT03973229|Experimental|Cohort 1: PTSD Receiving Placebo then Estradiol|Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
11114585|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
11114586|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
11114587|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
11114588|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
11114589|NCT03973229|Experimental|Cohort 2: PTSD Receiving Estradiol then Placebo|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
11114590|NCT03973229|Experimental|Cohort 2: PTSD Receiving Placebo then Estradiol|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
11114591|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Estradiol, then Placebo|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
11114628|NCT03973008|Active Comparator|Adujvant CT|The adjuvant chemotherapy was started 4-6 weeks after D2 radical operation. The SOX regimen was repeated every 3 weeks for 8 cycles.
11115375|NCT03967691|Placebo Comparator|Saline infusion|Subjects will be infused with saline (placebo) on study day 1
11114592|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Placebo then Estradiol|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
11114593|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
11114594|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
11114595|NCT03973216|Experimental|A primary care group-based therapeutic yoga program|A primary care care group-based therapeutic yoga program that consists of 9 sessions.
11114596|NCT03973203|Experimental|Niacin in controls|The arm includes healthy controls supplemented with niacin.
11114597|NCT03973203|Experimental|Niacin in mitochondrial myopathy patients|The arm includes mitochondrial myopathy patients supplemented with niacin.
11114598|NCT03973190|Placebo Comparator|RET Group|Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).
11114599|NCT03973190|Active Comparator|SBC Group|Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).
11114600|NCT03973190|Active Comparator|PRO Group|Alveolus sealing by a temporary ovoid pony of acrylic resin.
11114601|NCT03973177|Experimental|Treatment Group: Phenol injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites
11114602|NCT03973177|Other|Control Group: Methylprednisolone injection|Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site
11114603|NCT03973151|Experimental|HL-085|HL-085 will be administered as BID with specified dose.
11114604|NCT03973138|Experimental|Treatment group|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab under the pro re nata (PRN) treatment regimen.
11114605|NCT03973125|Experimental|Treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
11114606|NCT03973112|Experimental|HLX10+HLX04|
11114607|NCT03973099|Experimental|Placebo|Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
11114608|NCT03973099|Experimental|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner.
11114609|NCT03973086|Experimental|Citruslim (Low dose)|
11114610|NCT03973086|Experimental|Citruslim (High dose)|
11114611|NCT03973086|Placebo Comparator|Microcrystaline Cellulose- 400mg|
11114612|NCT03973073|Experimental|camouflage group|Topical applications and/or NB-UVB plus Capulin TM on-demand treatment period
11114613|NCT03973073|Other|blank group|Topical applications and/or NB-UVB on-demand treatment
11114614|NCT03973060|Experimental|Concentric muscular work|4 series of 12 repetitions of concentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
11114615|NCT03973060|Experimental|Eccentric muscular work|4 series of 12 repetitions of eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
11114616|NCT03973060|Experimental|Concentric-eccentric muscular work|4 series of 12 repetitions of concentric-eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
11114617|NCT03973060|Experimental|Isometric muscular work|6 seconds of contraction, with 20 seconds of rest with 24 repetitions, for a total working time of 12 minutes.
11114618|NCT03973047|Placebo Comparator|Group 1: BMT plus placebo|1 dose of BMT 1.75 mg via autoinjector plus placebo (dosed 30±5 minutes prior to BMT dosing) on Day 1.
11114619|NCT03973047|Active Comparator|Group 2: BMT plus Zofran|1 dose of BMT 1.75 mg via autoinjector plus Zofran 8 mg (dosed 30±5 minutes prior to BMT dosing) on Day 1.
11114620|NCT03973034||Normal people|
11114621|NCT03973034||Benign breast disease patients|
11114622|NCT03973034||Breast cancer patients in early stage|
11114623|NCT03973021|Experimental|VSEL Max|Each treatment: 120,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
11114624|NCT03973021|Experimental|VSEL Medium|Each treatment: 90,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
11114625|NCT03973021|Experimental|VSEL Mini|Each treatment: 60,000 VSELs each time, suspending with 20 mL platelet-rich plasma(PRP), transfusion for 3 times with a interval of 1 month, intracavernous injection
11114626|NCT03973021|No Intervention|Control|In this group, the patients will receive 20 mL platelet-rich plasma(PRP) treatment and as a control group.
11114629|NCT03972982|Experimental|Simplified regimen group|Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
11114630|NCT03972982|Active Comparator|Routine group|Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.
11114631|NCT03972969|Experimental|In-person exercise group|facility-based structured exercise program
11114632|NCT03972969|Experimental|Remote exercise group|home-based structured exercise program
11114633|NCT03972969|Active Comparator|Control group|health education
11114634|NCT03972956||Colorectal cancer or gastric cancer patient|Patients suffering from CRC or gastric cancer scheduled to have surgical resection of colon/rectum or stomach.
11114635|NCT03972956||Non-malignant disease patient|Patients suffering from non-malignant disease scheduled to have surgery.
11114636|NCT03972943|Active Comparator|Cohort I (observation)|Patients not diagnosed with OSA undergo observation for 6 months.
11114637|NCT03972943|Experimental|Cohort II: (CPAP treatment)|Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.
11114638|NCT03972930|Experimental|Hypofractionated Radiotherapy for Soft Tissue Sarcoma|Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
11114639|NCT03972917||ulipristal acetate based therapy|Fertile women under ulipristal acetate treatment
11114640|NCT03972904|Experimental|Intervention group|The Light-Fat Rice® group
11114641|NCT03972904|Placebo Comparator|Control group|The comparable energy staple food group
11114642|NCT03972891|Experimental|12-weeks intervention break|The intervention break starts as soon as 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy. The intervention break will last for 12 weeks.
11114643|NCT03972891|No Intervention|traditional therapy|After 70 - 80 % of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations during therapy, the children will maintain their traditional therapy until more than 90% of the target phoneme / target consonant cluster can be pronounced correctly in spontaneous speech situations (max. 12 weeks).
11114644|NCT03972878|Active Comparator|control snack|control snack
11114645|NCT03972878|Experimental|control cream|control spreadable cream
11114646|NCT03972878|Experimental|cream version 1|control spreadable cream, version 1
11114647|NCT03972878|Experimental|cream version 2|control spreadable cream, version 2
11114648|NCT03972878|Experimental|cream version 3|control spreadable cream, version 3
11114649|NCT03972878|Experimental|control chocolate bar|control chocolate bar
11114650|NCT03972878|Experimental|chocolate bar version 1|control chocolate bar version 1
11114651|NCT03972865|Experimental|Participants of the race|Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
11114652|NCT03972839||D-Dimers patients|population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)
11114653|NCT03972826|Other|1|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
11114654|NCT03972813|Experimental|cervical cancer - sexually transmitted (STD) - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
11114655|NCT03972813|Experimental|cervical cancer - STD - 12 years old (y.o.)|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
11114656|NCT03972813|Experimental|cervical cancer - STD - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
11114657|NCT03972813|Experimental|cervical cancer - infectious - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
11114658|NCT03972813|Experimental|cervical cancer - infectious - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
11114659|NCT03972813|Experimental|cervical cancer - infectious - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
11114660|NCT03972813|Experimental|cervical cancer - blank - standard|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
11114661|NCT03972813|Experimental|cervical cancer - blank - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
11114662|NCT03972813|Experimental|cervical cancer - blank - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
11114663|NCT03972813|Experimental|many cancers - STD - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
11115376|NCT03967691|Active Comparator|Tocilizumab infusion|Subjects will be infused with tocilizumab on study day 2
11114664|NCT03972813|Experimental|many cancers - STD - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
11114665|NCT03972813|Experimental|many cancers - STD - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
11114666|NCT03972813|Experimental|many cancers - infectious - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
11114667|NCT03972813|Experimental|many cancers - infectious - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
11114668|NCT03972813|Experimental|many cancers - infectious - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
11114669|NCT03972813|Experimental|many cancers - blank - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
11114670|NCT03972813|Experimental|many cancers - blank - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
11114671|NCT03972813|Experimental|many cancers - blank - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.
~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
11114672|NCT03972787|Experimental|Proactive Social Robot (Intervention)|Participants will have the opportunity to use ElliQ for a total of 8 weeks to determine the impacts of the system on participants' loneliness, mood, technology use, and quality of life.
11114673|NCT03972787|No Intervention|Waitlist Control|Participants will not receive any intervention for a total of 8 weeks to determine whether any impacts noted for participants' loneliness, mood, technology use, and quality of life are unique to ElliQ or are influenced by other factors.
11114674|NCT03972774|Other|Cardiac PET stress testing and test-dependent management|Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not).
11114675|NCT03972774|Other|Management without stress-imaging|Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up.
11114676|NCT03972761|Active Comparator|Group exposed to cognitive remediation|Computerized cognitive remediation program. Program performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
11114677|NCT03972761|Placebo Comparator|Group not exposed to cognitive remediation|Standard remediation performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
11114678|NCT03972748|Experimental|Itraconazole|Oral Itraconazole capsules, 200 mg
11114679|NCT03972735|Experimental|NECT + follow up|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.
11114680|NCT03972735|Placebo Comparator|TAU|"Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder
~Support in day-care hospital
~No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)"
11114681|NCT03972722|Experimental|GLS-010|Full-human anti-pd-1 monoclonal antibodies
11114682|NCT03972709|Experimental|RG6147 Q4W|Participants will receive RG6147 every 4 weeks (Q4W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in an open-label extension study (GR42558) and receive open-label RG6147 injections.
11114683|NCT03972709|Sham Comparator|Sham Control Q4W|Participants will receive Sham-control Q4W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in an open-label extension study (GR42558) and receive open-label RG6147 injections.
11114684|NCT03972709|Experimental|RG6147 Q8W|Participants will receive RG6147 every 8 weeks (Q8W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in an open-label extension study (GR42558) and receive open-label RG6147 injections.
11114685|NCT03972709|Sham Comparator|Sham Control Q8W|Participants will receive Sham-control Q8W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in an open-label extension study (GR42558) and receive open-label RG6147 injections.
11114686|NCT03972696|Active Comparator|BA3S|Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
11114687|NCT03972696|Experimental|BA2|RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
11116011|NCT03963206|Other|Cabozantinib group|patients will receive Cabozantinib (within the framework of its MA) (an ECG is added)
11114688|NCT03972683|Experimental|Handgrip Exercise Training Intervention|"Participants will visit the lab for baseline measurements designed to evaluate signaling mechanisms that regulate blood flow. A physician will place a catheter in the brachial artery for pharmacological infusions. The following drugs will be administered to each participant: acetylcholine, adenosine triphosphate, atropine, phenylephrine, and sodium nitroprusside (see Interventions for further details regarding each drug). The order of infusions will be randomized and blood flow will be allowed to return to baseline between each infusion (~15 min) with the exception of atropine, which will be administered last owing to its longer half-life.
~Following baseline measurements, participants will complete a 7 week handgrip exercise training intervention, then they will return to the laboratory for post-training measurements. The post-training assessments will be performed in the same manner as the baseline visit; thus, the same drugs will be infused as described above."
11114689|NCT03972657|Experimental|Dose Escalation Cohorts|In a series of dose escalation cohorts, patients will receive a 3-week monotherapy lead-in of 3 weekly doses of REGN5678 followed by REGN5678 and cemiplimab in combination.
11114690|NCT03972657|Experimental|Dose Expansion Cohorts|In a series of dose expansion cohorts, patients will receive combination therapy of REGN5678 at the recommended phase 2 dose (RP2D) and cemiplimab
11114691|NCT03972644|Active Comparator|Early intervention|Patients will undergo aortic valve replacement immediately
11114692|NCT03972644|No Intervention|Watchfull waiting|Patients will be followed and treated as recommended by guidelines.
11114693|NCT03972631|Placebo Comparator|Lifestyle education|The participants in this group will be provided usual recommendation, including the diet principles, activity guideline and behavioral strategies at baseline. In addition, the participants will have access to an APP, with which the participants could learn more information of body weight management, and keep records of diet, activity and body weight during the study.
11114694|NCT03972631|Experimental|Intensive Lifestyle Intervention|The participants in this group will be provided a comprehensive intervention, including goal setting, one to one support by the lifestyle counselors, and meal replacement products, in addition to the information and APP which are provided to the Lifestyle education group.
11114695|NCT03972618|Experimental|School and village|Simultaneous installation of filters in schools and the village
11114696|NCT03972618|Experimental|School only|Initial installation in school only
11114697|NCT03972618|Experimental|Village only|Initial installation in village only
11114698|NCT03972618|No Intervention|Control|Control group. No filter installation initially.
11114699|NCT03972592|Experimental|Topical sirolimus|The experimental group will consist in one area of the CMLM (almost half of it) that will receive 0.1% sirolimus preparation. This product will be applied 1/day on the randomly allocated area, by a nurse at home, during 12 weeks.
11114700|NCT03972592|Placebo Comparator|Vehicle|The control group will consist in the other half area of the CMLM, that will receive the same vehicle than the one used in the topical 0.1% sirolimus preparation. It will be applied 1/day in the corresponding area by a nurse, at home, during 12 weeks.
11114701|NCT03972579|Active Comparator|Graded exposure therapy|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
11114702|NCT03972579|Active Comparator|Pacing + mindfulness|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
11114703|NCT03972566||CREST with Calcinosis cutis|
11114704|NCT03972566||CREST without Calcinosis cutis|
11114705|NCT03972553|Other|Sugarbaker|For the Sugarbaker group, the bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
11114706|NCT03972553|Other|Keyhole|For the Keyhole group the stoma will be taken down and rematured through a cruciate incision (keyhole)
11114707|NCT03972540|Experimental|Mindful eating intervention|The mindful eating intervention was taught by a mindfulness-based stress reduction instructor certified by the Center of Mindfulness at the University of Massachusetts Medical School.
11114708|NCT03972527|Active Comparator|Active Device Treatment Cohort|The MuReva Phototherapy System consists of Light Control Unit and a Mouthpiece Cable Assembly. Subjects will begin device treatment photobiomodulation sessions on the first day of radiotherapy (RT) treatment. They will receive once-daily investigative device photobiomodulation treatments prior to radiation therapy (RT) with their assigned Mouthpiece for 5 days per week for the duration of their CRT treatment. Each device treatment session will last up to 5 minutes, not including up to 5 additional minutes for treatment breaks. All subjects will visit the study site once during the Screening period (Days -28 to 1) and an anticipated 30 to 40 times during the treatment period. Each patient will be assigned their own Mouthpiece Cable Assembly.
11114709|NCT03972527|Sham Comparator|Sham Device Treatment Cohort|The MuReva Phototherapy System (or sham control) is a Light Control Unit and a Mouthpiece Cable Assembly. The sham control Mouthpiece Cable Assembly will appear identical to the active Mouthpiece Cable Assembly, and will be used in the same manner as the active cohort. However, the sham control device will be configured where the mouthpiece will not emit any light at any time during the study. The same Light Control Unit will be used with sham and active Mouthpiece Cable Assemblies. Each patient will be assigned their own Mouthpiece Cable Assembly.
11114710|NCT03972501|Placebo Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
11114711|NCT03972501|Experimental|AZR-MD-001 Active Dose|AZR-MD-001 Active Dose will be dosed up to once daily.
11114712|NCT03972488|Experimental|Lutathera plus long-acting octreotide|
11114713|NCT03972488|Active Comparator|high dose long-acting octreotide|
11114714|NCT03972462|Experimental|NPC-12G Gel 0.2% (Period 1)|A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.
11114715|NCT03972462|Active Comparator|Rapamune Tablet (Period 2)|Rapamune® (sirolimus) 2 mg tablet for oral dosing.
11114716|NCT03972449|Experimental|Beatboxing: BEAT-Speech|
11114717|NCT03972449|Experimental|Traditional Articulation Approach|
11114718|NCT03972423||IRCTC group|- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
11114719|NCT03972423||CONTROL group|- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
11116157|NCT03962166||Cohort|consecutive adult patients undergoing first-time elective open-heart surgery
11114720|NCT03972410|Experimental|Eye Movement Desensitization and Reprocessing (EMDR)|The EMDR treatment will follow the EMDR Recent Birth Trauma Protocol. This protocol was recently developed by some of the colleagues collaborating in this research project (Catteneo et al., 2018). This EMDR protocol can be used to intervene immediately after birth, or at later times. The main purposes of early intervention is to prevent the onset and development of PTSD and Post-partum Depression in the mother during the months following childbirth and to facilitate mother-newborn bonding.
11114721|NCT03972410|Active Comparator|Supportive Expressive Dynamic Psychotherapy (SEDP)|The SEDP treatment (Luborsky 1984; Book, 1998) is one of the most widespread treatments and can be considered the treatment as usual in Italian maternity wards. This intervention includes both supportive techniques (to create a positive, helpful and empathic relationship with the patient) and expressive techniques (aimed at helping the patient to express and to understand and change problems).
11114722|NCT03972397|Experimental|Intercostal Nerve Cryoablation plus SOC Pain Control|Standard of Care (SOC)
11114723|NCT03972397|Active Comparator|Standard of Care (SOC) Pain Control|
11114724|NCT03972384|Experimental|Post-ICU Problem Solving|The PIC-UPS intervention focuses on self-regulation activities and environmental cues to overcome problems with memory, planning and decision-making. The interventionist uses guided discovery, reviews progress, and emphasizes generalization and transfer to other patient-identified problems. This approach may be more acceptable to participants because they can see the relevance of tasks to everyday life. Activities such as goal-setting, self-evaluation and reflective thinking behaviors enhance self-efficacy and increase the likelihood that the individual will engage in self-management behaviors. The first session of PIC-UPS will be delivered after enrollment to those participants randomized to the intervention group. Weekly intervention sessions will be conducted by a trained interventionist and supplemented by telephone reminders to complete daily homework. Follow-up data collection will be conducted in the home by a blinded data collector three months post-enrollment.
11114725|NCT03972384|No Intervention|Control Group|Participants in the control group will complete several surveys upon enrollment and randomization. Follow-up data collection will be conducted in the home for all participants control group by a blinded data collector three months post-enrollment.
11114726|NCT03972371|Experimental|Treatment Group|The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms
11114727|NCT03972358|Experimental|Medical menstrual regulation|"Mifepristone 200 mg orally on day 1.
~Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone)."
11114728|NCT03972345||Paediatric patients with iGHD or SGA|Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)
11114729|NCT03972332||Sensitised|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
11114730|NCT03972332||Non-sensitised|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
11114731|NCT03972319|Experimental|Omega-3 Supplementation|Proof of Concept and Safety Study of 4 weeks of Omega-3 supplementation pre- Bariatric Surgery
11114732|NCT03972306|Experimental|Group A: Cohorts A1-A4|"Participants (participants pretreated with ocrelizumab) will receive a single injection of subcutaneous (SC) ocrelizumab co-mixed with rHuPH20 in the abdomen. For every new dose level, recruitment will be staggered by enrolling 1 participant in each cohort followed by a 48-hour waiting period to review safety and tolerability data by the Safety Monitoring Committee (SMC) prior to enrolling subsequent participants in the same cohort. Currently, the planned dose escalation steps for patients who enroll in Group A are as follows:
~Cohort A1: 40 mg of SC ocrelizumab
~Cohort A2: 200 mg of SC ocrelizumab
~Cohort A3: 600 mg of SC ocrelizumab
~Cohort A4: 1200 mg of SC ocrelizumab"
11114733|NCT03972306|Experimental|Group A: Cohort A5|In the non-randomized subphase, participants will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
11114734|NCT03972306|Experimental|Group A: Cohort AA|Participants will receive a single 600-mg dose ocrelizumab by intravenous (IV) infusion
11114735|NCT03972306|Experimental|Group B: Cohorts B1-B4|"Ocrelizumab treatment- naive participants will receive a minimum of 3 patients in Cohort B will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.
~Cohort B1: 40 mg of SC ocrelizumab
~Cohort B2: 200 mg of SC ocrelizumab
~Cohort B3: 600 mg of SC ocrelizumab
~Cohort B4: 1200 mg of SC ocrelizumab"
11114736|NCT03972293|Experimental|Within-participant Micro-randomization|"Each week in the study, with probability .25 for each, a participant is randomized to receive either a week of mood notifications, activity notifications, sleep notifications, or no notifications.
~If the participant is assigned to receive mood, activity, or sleep notifications on a given week, then, for every day of that week the participant is randomized to: send notification on that day (with probability .5), or to not send a notification on that day (with probability .5)."
11114737|NCT03972293|Experimental|No intervention|Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
11114738|NCT03972280|Experimental|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
11114739|NCT03972280|Experimental|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
11114740|NCT03972280|Experimental|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
11114741|NCT03972280|Experimental|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
11114742|NCT03972280|Experimental|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
11114743|NCT03972280|Experimental|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
11114772|NCT03972033|Experimental|Eye Movement Desensitization and Reprocessing|EMDR manualized protocol is DEPRend (Hofmann, Ostacoli, et al., 2015), based on the eight-phase protocol by Shapiro (2001) adapted for the treatment of Depression by the European Depression EMDR Network and used in previous studies (Hase et al., 2015; Hofmann et al., 2014). EMDR targets were selected following the Adaptive Information Processing model that looks for stressful events linked with the depression and for specific developments of resources.
11114744|NCT03972267|Sham Comparator|Control Group - Free Gingival Graft|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the Control Group will not receive any kind of treatment in the palatal region.
11114745|NCT03972267|Experimental|Test Group - Free Gingival Graft + EMD|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. EMD will be applied immediately after the graft removal surgical procedure on the palatal donor area, leaving it in contact with the wound for 5 min. In sequence, it will be covered with an individualized acetate plate that will extend throughout the palatal area and be in position for 2 hours after the procedure
11114746|NCT03972254|Experimental|Intervention|Caregivers and their child will interact for 10 minutes while being observed and videotaped. Psychoeducation will be provided and goal setting will occur to ensure dyad specific relationship gains are made.
11114747|NCT03972241|Experimental|Intervention|different interventions including foot insole or kinetic training
11114748|NCT03972241|No Intervention|control|No intervention
11114749|NCT03972228|Experimental|Microdevice Intervention|The intervention to be administered is the placement of the microdevice containing 19 FDA-approved drugs into the lung lesion and the device's subsequent surgical resection. All study subjects will receive this same intervention; there is only one arm.
11114750|NCT03972215|Experimental|Berberine treatment|
11114751|NCT03972215|Placebo Comparator|Placebo control|
11114752|NCT03972202|Experimental|Patients with cerebellar ataxia (CA)|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
11114753|NCT03972202|Active Comparator|Matched controls|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI)
11114754|NCT03972202|Experimental|Additional healthy volunteers|Behavioral testing including various speaking tasks Magnetic resonance imaging (MRI) Transcranial magnetic stimulation (TMS)
11114755|NCT03972189|Experimental|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
11114756|NCT03972163|Experimental|SPECTORx Educational Intervention|The program intervention is based on a combination of 3 existing, complementary, educational programs that, together, equip hospice staff to create a comprehensive, patient-centered, medication management care plan.
11114757|NCT03972163|Active Comparator|Attention Control|"As the attention control, we will refer staff in control offices to the National Institute of Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
11114758|NCT03972150|Experimental|Part I: BI 836880 alone|Part I followed by Part II
11114759|NCT03972150|Experimental|Part II: BI 836880 and BI 754091|
11114760|NCT03972137|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
11114761|NCT03972124|Active Comparator|CBD 50 mg BID|The lower dose CBD group will start with CBD capsules 5 mg BID, then increase the dose every 4 days until on the target dose of 50 mg BID.
11114762|NCT03972124|Experimental|CBD 100 mg BID|The higher dose CBD group will start with CBD capsules 5 mg BID and will increase every 4 days until on a target dose of 100 mg BID.
11114763|NCT03972124|Placebo Comparator|Placebo|
11114764|NCT03972098||ra patients|The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young.
11114765|NCT03972098||healthy control|healthy person, similar population
11114766|NCT03972085|Experimental|Group 1|Patient received neural gliding exercises in addition electrotehrapy sessions.
11114767|NCT03972085|Active Comparator|Group 2|Patient received only electrotherapy sessions
11114768|NCT03972072|Experimental|Single Intervention Arm|daily imaging for MR-IGRT once weekly offline plan adaptation subjective/objective LENT-SOMA xerostomia-evaluation including flow measurements at baseline, 6 month-, 12 month- and 24 month-follow up EORTC-QoL questionnaires at baseline, 6 month-, 12 month- and 24 month-follow up
11114769|NCT03972059|Experimental|Experimental group|A 12-week high intensity interval circuit training program for weight management in overweight adults.
11114770|NCT03972059|No Intervention|Control group|No intervention for 12 weeks, participants perform all tests.
11114771|NCT03972046|Experimental|T-Vec + BRAF/MEK|"Participants will begin taking the following 3 medications:
~BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10^6 PFU/mL; Dose #2: 10^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10^8 PFU/mL every 14 (+/-3) days).
~Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.
~May stop earlier than 3 months at physician discretion depending on side effects and response.
~Ultrasound of tumor nodal basin(s) monthly.
~Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.
~PET CT or brain MRI as needed at discretion of the investigator.
~Manual tumor measurement in office prior to each injection."
11114834|NCT03971630|No Intervention|Standard care group|These patients will be followed by standard protocol in the Unit of HMV of the University Hospital of Santa María- University Hospital Arnau de Vilanova.
11114773|NCT03972033|Active Comparator|Cognitive Behavioral Therapy|CBT is based on the principles described by Beck (Beck et al., 1979) and included behavioral activation and cognitive restructuring according to a session-by- session protocol with homework assignments.
11114774|NCT03972020|Experimental|Mindfulness Based Intervention|8 group sessions lasting 2.5 hours each, on a weekly basis.
11114775|NCT03972020|Active Comparator|Cognitive Behavioral Therapy|8 group sessions lasting 2.5 hours each, on a weekly basis.
11114776|NCT03972007|Experimental|Immediate LEDT Group|The 940nm LED blanket will be positioned across the full length of the biceps brachii muscle in the dominant limb immediately before the muscle fatigue protocol.
11114777|NCT03972007|Experimental|LEDT Group 15Min|The 940nm LED blanket will be positioned across the length of the biceps brachii muscle in the dominant limb 15 minutes before the muscle fatigue protocol.
11114778|NCT03972007|Sham Comparator|Immediate Sham Group|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, immediately prior to the muscle fatigue protocol.
11114779|NCT03972007|Sham Comparator|Sham Group 15Min|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, 15 minutes before the protocol of muscle fatigue.
11114780|NCT03971994|Active Comparator|Young adults|Participants aged between 18 and 40 years old.
11114781|NCT03971994|Active Comparator|Healthy old adults|Participants aged between 65 and 95 years old.
11114782|NCT03971994|Experimental|Patients with Alzheimer's Disease|Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.
11114783|NCT03971981|Experimental|100% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
11114784|NCT03971981|Experimental|22% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
11114785|NCT03971968||Group 1 = Intervention group|Group 1 suffered from third degree full thickness burns in the face/neck and received a surgical procedure with Integra Artificial Skin in the past
11114786|NCT03971968||Group 2 = Control Group|Group 2 is the healthy skin of a comparable and/or contralateral skin-site of the face/neck
11114787|NCT03971955||Adult Onset Autoimmune Diabetes/Latent Autoimmune Diabetes|
11114788|NCT03971955||Type 2 Diabetes|
11114789|NCT03971955||Type 1 Diabetes|
11114790|NCT03971955||Healthy Normal Volunteers (HNV)|
11114791|NCT03971942|Experimental|Neutral ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
11114792|NCT03971942|Experimental|Positive ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
11114793|NCT03971929|Experimental|SHR0532 tablet|up to 3 cohorts of subjects will receive multiple dose of oral tablets
11114794|NCT03971929|Placebo Comparator|SHR0532 placebo|up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo
11114795|NCT03971929|Active Comparator|Hydrochlorothiazide|up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg
11114796|NCT03971916|Experimental|HBM9161 340mg|
11114797|NCT03971916|Experimental|HBM9161 510mg|
11114798|NCT03971916|Experimental|HBM9161 680mg|
11114799|NCT03971916|Placebo Comparator|Placebo|
11114800|NCT03971903|Experimental|Attention bias modification treatment|12-session of ABMT
11114801|NCT03971903|Placebo Comparator|Placebo controls|12-session of placebo(i.e.,sham) training
11114802|NCT03971890|Experimental|DanceTherapy Group|The experimental group will receive a dance treatment.
11114803|NCT03971890|Experimental|Control Group|The control group will be subjected to a educational treatment.
11114804|NCT03971877||Patients admitted in ICU or oncohaematology ward|
11114805|NCT03971851||Low frailty|Frailty risk score less than 5
11114806|NCT03971851||Intermediate Frailty|Frailty risk score 5-15
11114807|NCT03971851||High frailty|Frailty risk score 15 and above
11114808|NCT03971838|Experimental|Intervention Arm|Women with a history of gestational diabetes will be offered 4-6 months of a diabetes prevention program.
11114809|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Healthy Subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
11114810|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Psoriasis subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.
11114811|NCT03971812||Patient with high grade astrocytoma|Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
11114812|NCT03971799|Experimental|CD33CART|All patients who receive CD33CART cell infusion
11114813|NCT03971773|Experimental|Patient ongoing hypnosis sessions|
11114814|NCT03971760|Active Comparator|Group 1: 30cc/24h|This group represents the currently used value of drain output used to determine the timing of drain removal
11114815|NCT03971760|Experimental|Group 2: 50cc/24h|This group represents the experimental value of drain output used to determine the timing of drain removal
11114816|NCT03971747|Experimental|C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
11114835|NCT03971630|Experimental|MyVENT group|These patients will be followed up using the telemedicine (MyVENT System and APP)
11114867|NCT03971409|Experimental|Arm II (anti-OX40 antibody PF-04518600, avelumab)|Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11114817|NCT03971734|Experimental|Arm 1 regadenoson 0.05mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose.
~Regadenoson 0.05mg"
11114818|NCT03971734|Experimental|Arm 2 regadenoson 0.1mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
11114819|NCT03971734|Experimental|Arm 3 regadenoson 0.2mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
11114820|NCT03971734|Experimental|Arm 4 regadenoson 0.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
11114821|NCT03971734|Experimental|Arm 5 regadenoson 0.7mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
11114822|NCT03971734|Experimental|Arm 6 regadenoson 1.0mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
11114823|NCT03971734|Experimental|Arm 7 regadenoson 1.4mg|"Approximately 10 minutes prior to undergoing the research MRI, patients will be administered a single dose of regadenoson at their assigned dose level, under the supervision of a cardiologist.
~The research MRI scan will be performed immediately following administration of regadenoson and appropriate monitoring of vital signs and 12-lead electrocardiography on a similar machine as the pre-enrollment eligibility MRI scan, using the same administered dose of gadolinium and acquisition parameters.
~The research MRI will consist of DCE perfusion MRI for estimation of Ktrans and will be performed with co-administration of standard doses of gadolinium following regadenoson dose."
11114824|NCT03971708|Other|Ropivacaine|This is the control where patients will receive ropivacaine via the TAP block infusion post-operatively.
11114825|NCT03971708|Active Comparator|Lidocaine|This is the study arm where patients will receive lidocaine via the TAP block infusion post-operatively.
11114826|NCT03971695|Experimental|BI 706321|
11114827|NCT03971695|Placebo Comparator|Placebo|
11114828|NCT03971682|Experimental|Experimental - PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP is a structured individual program for detained youth. This program is based on Compassion Focused Therapy (CFT), which conceptualizes antisocial behavior and psychopathic traits as evolutionary rooted responses to deal with harsh rearing scenarios. The ultimate goal of the PSYCHOPATHY.COMP is to develop a compassionate motivation in these youth.
~PSYCHOPATHY.COMP consists of 20 individual sessions, each lasting about 60 minutes, which run on a weekly basis. Sessions must be carried out by therapists skillful in CFT. Sessions are grouped into four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse prevention, and finalization.
~The treatment group attended the PSYCHOPATHY.COMP program in addition to the Treatment As Usual (TAU) delivered at Portuguese juvenile detention facilities."
11114829|NCT03971682|Active Comparator|Treatment As Usual - TAU|"Treatment As Usual:
~Subjects in this group received Treatment As Usual in Portuguese juvenile detention facilities (school frequency, token economy system for behavior control, frequency of a structured cognitive-behavioral group program, as well as individualized counseling sessions delivered by psychologists from the juvenile justice system) and did not attend the PSYCHOPATHY.COMP program."
11114830|NCT03971669|Experimental|Vaccination with Oral Typhoid Vaccine (Vivotif)|Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.
11114831|NCT03971656|No Intervention|Control|Standard care
11114832|NCT03971656|Experimental|Intervention|Three-Fold Nutritional Intervention
11114833|NCT03971643|Experimental|IFX-1|Exploratory, Proof of Concept with a total of 15 doses of IFX-1.
11114980|NCT03970707|Experimental|Large Number of Players training protocol B|Small Sided Game: 8 vs 8
11114836|NCT03971617|Experimental|Hydrogen tablets|The ingredient in the tablet producing H2 is magnesium. Each tablet contains 80 mg magnesium, a safe level well below the recommended daily dietary allowance of 420 mg for men/ 320 mg for women. Dissolving one tablet in 250 mL of water will achieve a saturating H2 concentration of approximately 1.6 ppm. Twice a day subjects will dissolve a tablet into water and drink the effervescent water.
11114837|NCT03971617|Placebo Comparator|Placebo tablets|effervescent placebo tablets will also contain 80 mg magnesium but do not generate hydrogen-enriched water
11114838|NCT03971604|Experimental|group 1|treated with VA
11114839|NCT03971604|Experimental|group 2|treated with VE
11114840|NCT03971604|Experimental|group 3|treated with VA+VE
11114841|NCT03971604|No Intervention|group 4|No intervention
11114842|NCT03971591|Experimental|Guided Lifestyle program|The Intervention will be conducted in cohorts of 15-20. We anticipate there will be 5-6 cohorts over the course of the study. Men assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies, the second hour will be supervised exercise with strength training. The second weekly session will be a one-hour supervised exercise session with strength training. Men will also receive 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
11114843|NCT03971591|Active Comparator|Self-Guided Lifestyle program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
11114844|NCT03971578||Autism Spectrum Disorders Group|Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old
11114845|NCT03971578||Normal Control Group|Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old
11114846|NCT03971565||Patients with chronic lymphocytic leukemia|Patient with a minimum period of 90 days without treatment
11114847|NCT03971539|Experimental|Single Rising Dose|
11114848|NCT03971539|Experimental|Multiple Rising Dose|
11114849|NCT03971513|No Intervention|usual practice|Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations
11114850|NCT03971513|Experimental|TAP block|In addition of usual practice, patients receiving a TAP block at the beginning of the surgery
11114851|NCT03971500|Experimental|IVUS-guidance|In the IVUS-guided DES implantation group, optimal stent deployment criteria included: 1) the MLA in the stented segment is >5.0 mm^2, or 90% of the MLA at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is <55%; and 3) absence of >=Type B edge dissection. Further treatment will be required if any of those 3 criteria was not met.
11114852|NCT03971500|Active Comparator|Angiography-guidance|In the Angiography-guided DES implantation group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of >Type B dissection.
11114853|NCT03971500|Experimental|SAPT group|Ticagrelor + aspirin for 1 month followed by ticagrelor plus matching placebo for an additional 11 months.
11114854|NCT03971500|Active Comparator|DAPT group|Ticagrelor + aspirin for 12 month.
11114855|NCT03971487|Active Comparator|Ocrelizumab|Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.
11114856|NCT03971487|Placebo Comparator|Placebo|Two placebo intravenous infusions will be administered two weeks apart.
11114857|NCT03971474|Active Comparator|Arm A (docetaxel, gemcitabine, ramucirumab, pemetrexed)|Patients receive docetaxel IV over 10-30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 or ramucirumab IV over 60 minutes and docetaxel IV over 10-30 minutes on day 1. Patients with non-squamous NSCLC receiving docetaxel and gemcitabine hydrochloride, also receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11114858|NCT03971474|Experimental|Arm B (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11114859|NCT03971461|Experimental|Lutathera|
11114860|NCT03971448|Active Comparator|Fiberglass above-knee walking cast (AKWC)|The standard treatment arm will be a posterior splint placed in the ED by the ED clinical team (nurse/physician) and then a fiberglass AKWC to be placed ideally within 72 hours in the fracture clinic. This AKWC will be in place for 3 weeks, which is currently the most common strategy to manage TF.
11114861|NCT03971448|Experimental|Landmark Pediatric Walker Boot (LPWB)|The Landmark Pediatric Walker Boot (LPWB) will be placed in the ED and will be kept on for a minimum of one week, and then for a duration dictated by the patient's comfort.
11114862|NCT03971435||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360)
11114863|NCT03971422|Experimental|Dosage Regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
11114864|NCT03971422|Experimental|Dosage Regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
11114865|NCT03971422|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo.
11114866|NCT03971409|Experimental|Arm I (binimetinib, avelumab)|Patients will receive a 15-day lead-in of binimetinib, followed by binimetinib PO BID and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11116056|NCT03962855|Placebo Comparator|Placebo|Matching placebo administered once daily for a minimum of 4 weeks.
11114868|NCT03971409|Experimental|Arm III (utomilumab, avelumab)|Patients will receive a 15-day lead-in of utomilumab, followed by utomilumab IV over 60 minutes every 4 weeks and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11114869|NCT03971383|Experimental|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
11114870|NCT03971383|Placebo Comparator|Placebo|3 tablets one time, 3 times a day(tid)
11114871|NCT03971370|Experimental|Experimental 1|
11114872|NCT03971370|Experimental|Experimental 2|
11114873|NCT03971370|Active Comparator|Positive Control|
11114874|NCT03971357|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
11114875|NCT03971357|Placebo Comparator|Placebo|Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
11114876|NCT03971344||Family members of newborns extremely premature|Parents and siblings (if any) of infants born at 30 weeks gestational age or less, or with a birthweight less than 1500 grams.
11114877|NCT03971344||Family members of new pediatric oncology patients|Parents and siblings (if any) of patients with new onset (not relapses) pediatric oncologic diagnoses including liquid, solid, and brain cancer.
11114878|NCT03971344||Family members of critical congenital heart defect patients|Parents and siblings (if any) of newborns with critical congenital heart defects who typically undergo surgery by 12 months of life.
11114879|NCT03971344||Family members of children with severe neurological impairment|Parents and siblings (if any) of patients with severe neurologic impairments, associated with substantial functional impairment, relentless progressive deterioration, or substantially shortened life-spans.
11114880|NCT03971331|No Intervention|control group|Patients in control group received usual care that was decided by attending.
11114881|NCT03971331|Experimental|study group|Patients in study group who had been placed the PAC were performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately.
11114882|NCT03971292||Validation phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
11114883|NCT03971292||Prospective phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
11114884|NCT03971266|Experimental|Prevention (Fitbit, PRO diary)|Patients participant in movement assessment during 2 clinical trial visits. Patients also wear a Fitbit to track movements and complete a smartphone based PRO diary over 5-10 minutes to measure physical function, fatigue, sleep disturbance, social isolation, appetite, and body weight for up to 180 days.
11114885|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
11114886|NCT03971240|Experimental|outcome of surgically evacuated traumatic ASDH|we will operate patients with traumatic acute subdural hematoma with some criteria and evaluate the outcome of surgery
11114887|NCT03971227|Experimental|Acuity 200 contact lens|Rigid gas permeable contact lens for daily wear, fluoroxyfocon A
11114888|NCT03971227|Active Comparator|Acuity 100 contact lens|Rigid gas permeable contact lens for daily wear, hexafocon A
11114889|NCT03971214|Experimental|PD-1 inhibitor JS-001 consolidation for SCLC|The extensive-stage SCLC patients will receive PD-1 inhibitor JS-001 treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
11114890|NCT03971201|Experimental|Surgery plus sorafenib|surgical resection followed by adjuvant sorafenib
11114891|NCT03971201|Active Comparator|sorafenib only|sorafenib only
11114892|NCT03971188|Experimental|Internal Brace|Patients will undergo Internal Brace procedure for thumb CMC OA.
11114893|NCT03971188|Active Comparator|LRTI|Patients will undergo ligament reconstruction tendon interposition (most commonly performed surgery for thumb CMC OA) and serve as control group.
11114894|NCT03971175|Active Comparator|Forceps group|
11114895|NCT03971175|Experimental|Cryobiopsy group|
11114896|NCT03971162|Experimental|Group A|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 3 months. Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
11114897|NCT03971162|Experimental|Group B|patients were given intravitreal injection of Conbercept 0.5mg every month repeated for 6 months.Thereafter, intravitreal Conbercept 0.5mg injections should be administered in case CNV persisted or recurred (based on the assessment of defined criteria for retreatment) at a maximum frequency of once every 4 weeks through 12 months
11114898|NCT03971149|Experimental|Behavorial intervention|
11114899|NCT03971136|Other|Children with sickle cell disease|Child from 12 months to 18 years old admitted for vaso-occlusive crisis
11114900|NCT03971123|Experimental|AC-SD-03 (for Part 1)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
11114901|NCT03971123|Experimental|AC-LMP-01 (for Part 1)|Tricaprilin LMP formulation, single dose (20g tricaprilin). Administered orally.
11114902|NCT03971123|Experimental|AC-SD-03P (for Part 1)|Placebo formulation, single dose. Administered orally
11114903|NCT03971123|Experimental|AC-1202 (for Part 2)|Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
11114904|NCT03971123|Experimental|AC-SD-03 (for Part 2)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
11114905|NCT03971110|Experimental|Zoladex and Casodex|Subjects who are diagnosed with advanced prostate cancer at clinical stage of T3 and T4 (N0 or N1, M0 or M1 with five or fewer extra-pelvic lesions) are the target population of this study. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
11114906|NCT03971097|Active Comparator|Control Group (TAU)|Participants of the study who will receive the normal programming schedule or treatment as usual (TAU).
11114907|NCT03971097|Experimental|Experimental Group (TAU plus self-forgiveness model)|Participants of the study who will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Everett L. Worthington.
11114908|NCT03971084|Placebo Comparator|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
11114909|NCT03971084|Active Comparator|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
11114910|NCT03971071|Placebo Comparator|Placebo|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
11114911|NCT03971071|Active Comparator|Erenumab 70 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
11114912|NCT03971071|Active Comparator|Erenumab 140 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
11114913|NCT03971058|Active Comparator|young individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
11114914|NCT03971058|Active Comparator|elderly individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
11114915|NCT03971045|Experimental|Pembrolizumab and metronomic cyclophosphamide|.Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
11114916|NCT03971032|Other|Women undergoing hysteroscopy|Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
11114917|NCT03971019|Experimental|Statin therapy (experimental group)|"On the basis of guiding patients to control their diet and improve their lifestyle, etc.
~Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)"
11114918|NCT03971019|Other|Dietary intervention group (control group)|Guiding patients to control diet, improve lifestyle, etc.
11114919|NCT03971006||Immunocompetent ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) and no immunosuppression (excluding patients with HIV infection, solid tumor or hematological malignancies, organ transplant or taking steroids since more than 4 weeks).
11114920|NCT03971006||Immunosuppressed ARDS patients|(n=50) Patients with moderate-to-severe pneumonia-associated Acute Respiratory Distress Syndorme (ARDS) (Berlin definition (2)) and previously known immunosuppression (as listed above). These patients will allow comparing the cell defects observed in the study population to those observed in immunosuppressed patients.
11114921|NCT03971006||Controls|(n=10) Patients undergoing a bronchoscopy with Bronchoalveolar Liquid (BAL) as part of routine care but having neither ARDS nor active lung infection, infiltrating lung disease or immunosuppression. These patients will allow quantifying normal levels of the studied biomarkers in the alveolar and blood compartments.
11114922|NCT03970993|Experimental|Group 1a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart and an optional booster vaccination 12 months after the third dose
11114923|NCT03970993|Experimental|Group 2a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
11114924|NCT03970993|Experimental|Group 3a|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart, followed by CHMI by sporozoite challenge (mosquito bite) 4 weeks later. If protected from malaria, volunteers will receive an optional booster vaccination 28 days prior to malaria rechallenge
11114925|NCT03970993|Experimental|Group 4a|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
11114926|NCT03970993|Experimental|Group 5|Volunteers will receive 2 doses of 10μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 2μg R21/50μg Matrix-M at 24 weeks. This is followed by optional CHMI by sporozoite challenge (mosquito bite) 4 weeks later
11114927|NCT03970993|No Intervention|Group 6|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
11114928|NCT03970993|No Intervention|Group 7|They are infectivity control volunteers for the sporozoite challenge procedures: these volunteers are not vaccinated.
11114929|NCT03970993|Experimental|Group 1b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M, 4 weeks apart followed by an optional vaccination booster 12 months after the third dose.
11114930|NCT03970993|Experimental|Group 2b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M at 0, 4 and 24 weeks.
11114931|NCT03970993|Experimental|Group 3b|Volunteers will receive 3 doses of 10μg R21/50μg Matrix-M 4 weeks apart.
11114932|NCT03970993|Experimental|Group 4b|Volunteers will receive 2 doses of 50μg R21/50μg Matrix-M 4 weeks apart and a 3rd fractional dose of 10μg R21/50μg Matrix-M at 24 weeks.
11114933|NCT03970980|Experimental|FIO2 >90% group|This group receives FIO2 >90% during the surgery.
11114934|NCT03970980|Active Comparator|FIO2 <70% group|This group receives FIO2 <70% during the surgery.
11114935|NCT03970967|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11114936|NCT03970954|Experimental|1|Low-dose IL-2
11114937|NCT03970941||CERAMENT|Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.
11114938|NCT03970941||NO CERAMENT COMPARATIVE COHORT|Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.
11114939|NCT03970928|Active Comparator|goal-directed fluid management (GDFM)|A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
11114940|NCT03970928|No Intervention|Conventional fluid management group (CFMG)|This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
11114941|NCT03970915|Experimental|ON (standard warming process + body warmer)|Patients included during the ON periods will constitute the experimental group. Warming will be provided by the body warmer in addition to the standard warming procedure (survival blanket and heating in the emergency vehicle).
11114942|NCT03970915|Sham Comparator|OFF / Control group (standard warming process )|Patients included during the OFF periods will constitute the control group. Warming will be provided by the standard warming procedure : survival blanket and heating in the emergency vehicle.
11114943|NCT03970902||Integrated Osteoporosis Care|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis in whom a complex patient-tailored intervention is provided.
11114944|NCT03970902||Care As Usual|Group of formal and informal primary caregivers and non-institutionalized postmenopausal women with osteoporosis receiving care as usual for the management of osteoporosis.
11114945|NCT03970889|No Intervention|Standard Care|Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
11114946|NCT03970889|Experimental|Klue|Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
11114947|NCT03970876|Experimental|ATGC-100 (Phase I/II)|ATGC-100 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
11114948|NCT03970876|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
11114949|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Males|Arm 1 - Urine from males subjects
11114950|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Females|Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects
11114951|NCT03970850|Active Comparator|Multi-arm - FDA cleared NAATs (Comparator)|Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)
11114952|NCT03970837|Experimental|GSK3196165 90 mg|Entire treatment period (52 Weeks): GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as standard of care (SoC).
11114953|NCT03970837|Experimental|GSK3196165 150 mg|Entire treatment period (52 Weeks): GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
11114954|NCT03970837|Active Comparator|Tofacitinib 5 mg|Entire treatment period (52 Weeks): Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
11114955|NCT03970837|Placebo Comparator|Placebo sequence 1|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 90 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
11114956|NCT03970837|Placebo Comparator|Placebo sequence 2|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: GSK3196165 150 mg SC injection once weekly + placebo cap twice daily. Participants will also receive a stable dose of csDMARD(s) as SoC.
11114957|NCT03970837|Placebo Comparator|Placebo sequence 3|From Week 0-11: Placebo SC injection once weekly + placebo cap twice daily. From Week 12 onwards: Tofacitinib 5 mg cap twice daily + placebo SC injection once weekly. Participants will also receive a stable dose of csDMARD(s) as SoC.
11114958|NCT03970824|Experimental|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
11114959|NCT03970824|Active Comparator|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
11114960|NCT03970824|Active Comparator|EU approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
11114961|NCT03970811|Experimental|Immediate implants with immediate temporization|Immediate implants with simultaneous immediate placement of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
11114962|NCT03970811|Active Comparator|Immediate implants without temporization|Immediate implants without the use of temporary crown and placement of the final restoration (loading) will be done 3 months postsurgical
11114963|NCT03970798|Experimental|KW-6356/Healthy Japanese adult male subjects|Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
11114964|NCT03970772|Experimental|Glucagon injection|Dilute Glucagon (1 mg/ml)
11114965|NCT03970772|Active Comparator|Glucose tablets|Dextrose glucose tablets
11114966|NCT03970759||Stannous Fluoride Dentifrice|Twice daily brushing
11114967|NCT03970759||Positive Control Dentifrice|Twice daily brushing
11114968|NCT03970759||Negative Control Dentifrice|Twice daily brushing
11114969|NCT03970746|Experimental|Cohort A1|PDC*lung01 Low Dose
11114970|NCT03970746|Experimental|Cohort A2|PDC*lung01 High Dose
11114971|NCT03970746|Experimental|Cohort B1|PDC*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment
11114972|NCT03970746|Experimental|Cohort B2|PDC*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment
11114973|NCT03970733|Experimental|VLA15 Dose 1|VLA15 with Alum lower selected Dose
11114974|NCT03970733|Experimental|VLA15 Dose 2|VLA15 with Alum higher selected Dose
11114975|NCT03970733|Placebo Comparator|Placebo|
11114976|NCT03970720|Experimental|T1DM - Unaware: Metoclopramide|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
11114977|NCT03970720|Placebo Comparator|T1DM - Unaware: Placebo|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
11114978|NCT03970720|Placebo Comparator|T1DM - Aware: Placebo|T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
11114979|NCT03970707|Experimental|Small Number of Players training protocol A|Small Sided Game: 4 vs 4
11114981|NCT03970707|No Intervention|Control|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
11114982|NCT03970694|Experimental|Neoadjuvant chemoradiotherapy group|Neoadjuvant chemoradiotherapy（XELOX * 4 + radiotherapy）→ Surgery (if possible) → post-surgery chemotherapy.
11114983|NCT03970694|Other|Neoadjuvant chemotherapy group|Arm Type: control. Neoadjuvant chemotherapy（XELOX * 4）→ Surgery (if possible) → post-surgery chemotherapy.
11114984|NCT03970668||Linagliptin plus insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment with linagliptin plus insulin
11114985|NCT03970668||Insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment only with insulin
11114986|NCT03970655|Experimental|Epinephrine Group|FESS patients who receive a single injection into the pterygopalatine fossa bilaterally of 0.5% Bupivacaine with epinephrine
11114987|NCT03970655|No Intervention|No Epinephrine Group|FESS patients who receive a single injection into the pterygopalatine fossa bilaterally of 0.5% Bupivacaine without epinephrine
11114988|NCT03970642|Experimental|Intervention group|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will receive the video directly observed therapy smartphone app. Research staff will be able to monitor these medication adherence video on a password protected server linked to the app. Upto 50 patients will be randomly assigned to this group.
11114989|NCT03970642|No Intervention|Control|The control group will receive current standard of care. Upto 50 patients will be randomly assigned to this group.
11114990|NCT03970629|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA via ROSA Robot
11114991|NCT03970629|Active Comparator|Conventional TKA|Conventional TKA
11114992|NCT03970616|Experimental|Tivozanib in Combination with Durvalumab|Tivozanib in Combination with Durvalumab
11114993|NCT03970603|Active Comparator|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
11114994|NCT03970603|Active Comparator|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
11114995|NCT03970590|Experimental|CTC|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
11114996|NCT03970590|Active Comparator|Control|6-month HTN management assessment text messages without narrative component
11114997|NCT03970577|Experimental|Rituximab treatment|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
11114998|NCT03970577|Active Comparator|Oral steroid treatment|"The patients will continue exclusive oral steroid treatment, that will be progressively tapered, for a total of 24 weeks (by taking into account the initial oral steroid therapy administered during 8 weeks and the oral steroid treatment given after randomization).
~Each patient will be followed up until 18 months after randomization. The patient will have study visits at inclusion, 4 weeks and 8 weeks after inclusion. At the time of randomization, patients who will have reached CR of MCNS will be allocated in test or control group and will be followed up similarly: visits at 1, 4, 16, 24 weeks, 12 and 18 months after randomization."
11114999|NCT03970564||Suspected lung cancer|Suspected and later on confirmed lung cancer with evidence of mediastinal lymphadenopathy on computerised tomography
11115000|NCT03970551|No Intervention|No Physical Intervention|The participant will actively stand up from a seated position without performing any physical counter-maneuvers either prior to or following the stand.
11115001|NCT03970551|Experimental|Supine Knee Raises|The participant will perform 30 seconds of raising their knees to their chest while sitting down before actively standing.
11115002|NCT03970551|Experimental|Leg Crossing|The participant will actively stand and then immediately cross their legs and tense their leg muscles for 60 seconds.
11115003|NCT03970551|Experimental|Cold Pressor Test|The participant will submerge their hands in ice water for approximately 45 seconds.
11115004|NCT03970551|Experimental|Serial 7's Stress Test|The participant will perform a mental arithmetic stress test for 30 seconds prior to standing.
11115005|NCT03970551|Experimental|Functional Electrical Stimulation|The participant will have their quadriceps passively contracted using mild electrical stimulation for approximately 30 seconds prior to standing.
11115006|NCT03970538|Experimental|Treatment Arm|Treated with the LimFlow System
11115007|NCT03970525||Venturi pump|This cohort will receive femtosecond laser cataract surgery with Venturi pump.
11115008|NCT03970525||Peristaltic vacuum pump|This cohort will receive femtosecond laser cataract surgery with peristaltic pump.
11115009|NCT03970499|Experimental|glial cerebral tumor|patient with an indication of glial cerebral tumor surgery
11115010|NCT03970486|Active Comparator|Needle Manipulation|Participant will receive dry needling intervention with manipulation.
11115011|NCT03970486|Active Comparator|In Situ|Participant will receive dry needling intervention without manipulation.
11115012|NCT03970473|Active Comparator|PRM 30 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 30 cm H2O in the semi-fowler position.
11115013|NCT03970473|Active Comparator|PRM 15 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 15 cm H2O in the semi-fowler position.
11115014|NCT03970460|Active Comparator|45-54 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
11115015|NCT03970460|Active Comparator|55-59 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
11115016|NCT03970460|Experimental|45-54 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
11115017|NCT03970460|Experimental|55-59 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
11115018|NCT03970447|Active Comparator|Control Arm|"Newly Diagnosed GBM: Radiation therapy (XRT) 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 2-6 weeks from the last day of radiation, and the start of the first cycle of Maintenance Therapy 2-6 weeks after the last day of radiotherapy. The start of all subsequent maintenance therapy cycles (2-12) every 4 weeks + 7 days after the first daily dose of temozolomide of the preceding cycle. Total number of cycles should comply with institutional or country standards. During maintenance therapy, the first cycle of temozolomide will be at 150 mg/m2 for Days 1-5 of a 28-day cycle. Second and subsequent cycles of maintenance therapy will be at 200 mg/m2 for Days 1-5 of a 28-day cycle.
~Recurrent GBM: Lomustine started at 110 mg/m2/day on Day 1 of a 42-day cycle as per local standards. Treatment will continue for up to 6 total cycles."
11115019|NCT03970447|Experimental|Regorafenib Treatment Arm|"Newly Diagnosed GBM: XRT 60 Gy for 6 weeks. Temozolomide 75 mg/m2 orally daily during radiation therapy. Rest Period 4 weeks from the last day of radiation. Maintenance period: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
~Recurrent GBM: Regorafenib (Dosage Form: Tablet for oral administration; Strength: 40 mg) 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)."
11115020|NCT03970434|Experimental|Metformin|
11115021|NCT03970421||patients without anticoagulant and / or antiplatelet treatment|Patients older than 16yo with no anticoagulant or antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
11115022|NCT03970421||patients on antiplatelet therapy (ASA and / or clopidogrel|Patients older than 16yo on antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
11115023|NCT03970421||patients on treatment with acenocoumarol and INR <2|Patients older than 16yo on acenocumarol and with INR <2 attended at ED because of Head Injury and with a Head CT performed.
11115024|NCT03970421||Others|patients on anticoagulant therapy with acenocoumarol and INR> = 2 or patients on treatment with direct thrombin inhibitors (dabigatran), or inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or patients on treatment with low molecular weight heparins (LMWH) attended at ED because of Head Injury and with a Head CT performed.
11115025|NCT03970408||Carpal tunnel syndrome|"Patients with CTS who fulfill the following eligibility criteria:
~Inclusion criteria
~Females and male patients referred with a CTS diagnosis confirmed by nerve conduction studies and positive Tinel and Phalen tests.
~Age ranging from 30-50 years old.
~The selected patient will be able to tolerate the entire standard neurodynamic technique.
~Exclusion criteria
~Symptoms referred to the neck.
~Sever CTS
~More than 10% limitation of neck flexion, rotation, and side bending ranges.
~History of disease, trauma, or surgery to neck, thorax, or upper limbs.
~Presence of peripheral neuropathy or cervical radiculopathy.
~History of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity."
11115026|NCT03970408||Healthy control|Asymptomatic healthy age-matched control with no symptoms or history of upper quadrant disease, dysfunction, trauma or surgery.
11115027|NCT03970395|Experimental|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).
~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
11115028|NCT03970395|Sham Comparator|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)
~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
11115029|NCT03970382|Experimental|NeoTCR-P1|Single dose of NeoTCR-P1
11115030|NCT03970382|Experimental|NeoTCR-P1 plus nivolumab|Single dose of NeoTCR-P1 plus nivolumab 480mg IV every four weeks for up to 6 doses.
11115031|NCT03970382|Experimental|NeoTCR-P1 plus IL-2|Single dose of NeoTCR-P1 plus IL-2 500,000 IU/m2 SC twice daily (BID) for 7 days.
11115032|NCT03970369|Experimental|Monitor|Activity monitoring with feedback. Participants in the Monitor group will wear a step counter to track if the activity prescription is being met.
11115033|NCT03970369|Active Comparator|Usual care|All children will receive the usual care, which includes personalized goals and an activity prescription. Participants in the usual care group will not receive a step counter.
11115034|NCT03970356|Experimental|intervention|The antibiotic stewardship intervention will encourage to prescribe according to the latest relevant UTI guidelines which promote more restrictive use of antibiotics in case of non-specific symptoms.
11115035|NCT03970356|No Intervention|control|Usual care
11115036|NCT03970330|Experimental|Low-Dose Naltrexone|12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
11115037|NCT03970330|Placebo Comparator|Placebo|12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
11115038|NCT03970317|Experimental|Broad Band Light|Broad Band Light (BBL) motion treatment
11115039|NCT03970304|Experimental|Vaccination, Colonoscopy|Individuals receive immunization with Vivotif typhoid vaccine prior to routine colonoscopy examination. During colonoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings will also be obtained.
11115040|NCT03970304|Experimental|Colonoscopy, Vacciniation, Colonoscopy|Individuals receive immunization with Vivotif typhoid vaccine after initial colonoscopy exam and specimen collection and prior to a routine follow up colonoscopy examination during which additional specimens will be collected.
11115041|NCT03970304|No Intervention|Colonoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during colonoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum).
11115042|NCT03970291|Experimental|Nociceptive-Level (NOL)|Analgesic component of anesthesia (fentanyl) will be guided using NOL
11115043|NCT03970291|No Intervention|Standard Clinical Care (SCC)|Standard Clinical Care guided fentanyl administration
11115044|NCT03970278||All Participants|All participants enrolled in study 401GSDIA02 will have received a single IV dose of DTX401 during their participation in study 401GSDIA01 (NCT03517085).
11115267|NCT03968588|Experimental|reduced-dose tacrolimus + standard-dose MMF|Tacrolimus dose was individually adjusted with a target trough blood level of between 3ng/mL and 8ng/mL throughout the study period (6 months after transplantation). MMF started within 72 hours after transplantation and the dose of MMF was 1.5~2.0g per day.
11115045|NCT03970252|Experimental|Treatment (nivolumab, mFOLFIRINOX)|Patients receive nivolumab IV over 60 minutes on day 1. Patients also receive fluorouracil IV over 10 minutes and over 46 hours, irinotecan hydrochloride IV over 90-120 minutes, leucovorin calcium IV over 120 minutes, and oxaliplatin IV over 120 minutes on days 1 and 15. Treatments repeat every 28 days for 3-6 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients with resectable disease undergo surgery. Within 8-12 weeks after surgery, patients with successful resection may receive 6 additional cycles of fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin in the absence of disease progression or unacceptable toxicity.
11115046|NCT03970239|Experimental|Parkinson's Disease patients|"All study participants undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). [11C] -DASB is a highly specific PET radiotracer which binds to the serotonin transporter (SERT).
~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
11115047|NCT03970239|Experimental|Imaging of healthy volunteers|"All healthy volunteers undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [18F]-altanserin.
~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
11115048|NCT03970226|Experimental|Tocilizumab Administration: Phase 0 and Feasibility Phase|"In Phase 0, patients will receive one dose of tocilizumab prior to surgery.
~During the Feasibility Phase, patients will receive tocilizumab every 2 weeks for up to 26 cycles (approximately 2 years). Patients will be followed for up to 5 years."
11115049|NCT03970213|Placebo Comparator|Control Group|Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
11115050|NCT03970213|Experimental|TXA Group|One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 4 hours later
11115051|NCT03970200|Active Comparator|No investigational product|Participants who receive the antibiotics usually prescribed for C diff infection.
11115052|NCT03970200|Experimental|Upper gastrointestinal FMT|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor
11115053|NCT03970200|Experimental|Lower gastrointestinal FMT|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).
11115054|NCT03970187|Experimental|Exposure|Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks
11115055|NCT03970187|No Intervention|Control|"Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention.
~Phase 2 (home training): waitlist"
11115056|NCT03970174|Experimental|Intervention|Two of the 4 Medicine wards will have implemented the care transition module of Care Connector
11115057|NCT03970174|No Intervention|Control|Remaining 2 of 4 Medicine wards will use all other aspects of Care Connector (except for care transition module)
11115058|NCT03970161|Experimental|T2DM Patients|Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
11115059|NCT03970161|Experimental|healthy control subjects|All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
11115060|NCT03970148|Experimental|Nd: YAG laser treatment|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
11115061|NCT03970135|Experimental|Fasting|
11115062|NCT03970122|Experimental|GFB-887 SAD active|GFB-887 single dose active
11115063|NCT03970122|Placebo Comparator|GFB-887 SAD placebo|GFB-887 single dose placebo
11115064|NCT03970109|Active Comparator|ANS-6637 - 200mg|200 mg ANS-6637 (given as 2 x 100 mg tablet) once a day
11115065|NCT03970109|Active Comparator|ANS-6637 - 600mg|600 mg ANS-6637 (given as 2 x 300 mg tablet) once a day
11115066|NCT03970109|Placebo Comparator|Matched Placebo|2 placebo tablets once a day
11115067|NCT03970096|Experimental|Arm A (TnD)|Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
11115068|NCT03970096|Experimental|Arm B (CD34+ ATG)|Patients undergo TBI BID on days -9 to -6, and receive thiotepa IV over 3 hours on days -5 and -4, anti-thymocyte globulin IV over 6-8 hours on days -4 and -3, cyclophosphamide IV over 1 hour on days -3 and -2, and CD34+ enriched PBSC IV on day 0.
11115069|NCT03970096|Experimental|Arm C (PTCy, tacrolimus)|Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 hour on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
11115337|NCT03968016|Active Comparator|Stable heart disease|Stable heart disease and non-hospitalized
11115070|NCT03970096|Experimental|Arm D (tacrolimus, methotrexate)|Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid).
11115071|NCT03970083||Oxygen Levels in Tumors|-Quantitative oxygen measurements will be obtained in a single field of view using T1 sequences
11115072|NCT03970070|Experimental|Health service research (Periop-OSMT)|Patients and/or support persons/family caregivers complete Periop-OSMT session in-person or via telephone over 20-40 minutes before surgery and before hospital discharge and group telehealth session over 1.5-2 hours at weeks 1-3, 4, 5, 6, and 7 post discharge
11115073|NCT03970057|Experimental|MoodUP|
11115074|NCT03970057|Placebo Comparator|HealthyMUM|
11115075|NCT03970044|Experimental|Exenatide 2 mg plus Dapagaliflozin 10 mg|Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
11115076|NCT03970044|Active Comparator|Exenatide 2 mg|Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment
11115077|NCT03970044|Active Comparator|Dapagaliflozin 10 mg|Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
11115078|NCT03970031|Active Comparator|MSDC-0602K|MSDC-0602K one tablet per day taken orally
11115079|NCT03970031|Placebo Comparator|Placebo|Placebo one tablet per day taken orally
11115080|NCT03970018||Autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease (ADPKD) patients starting peritoneal dialysis for end stage renal failure will be included in this study.
11115081|NCT03969992|Other|nCPAP alone|Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary
11115082|NCT03969992|Experimental|Drug: Low Dose AeroFact|AeroFact-low dose SF-RI 1
11115083|NCT03969992|Experimental|Drug: High Dose AeroFact|AeroFact-high dose SF-RI 1
11115084|NCT03969979||testis with epididymo-orchitis|The patients' previously inflamed testis with epididymo-orchitis
11115085|NCT03969979||healthy testis|The patients' non inflamed testis
11115086|NCT03969953|Experimental|Rivaroxaban|Rivaroxaban 2.5mg, twice daily.
11115087|NCT03969953|Placebo Comparator|Placebo|Matched placebo, twice daily.
11115088|NCT03969940||Thermo|Buruli ulcer patients receiving thermotherapy
11115089|NCT03969940||Chemo|Buruli ulcer patients receiving chemotherapy
11115090|NCT03969927|Experimental|Low-Fidelity PDS Training|
11115091|NCT03969927|Active Comparator|High Fidelity Fixed-Base Simulator Training|
11115092|NCT03969914||Critically ill ventilated patients|Patients admitted to ICU with expected mechanical ventilation >48h
11115093|NCT03969901|Experimental|IMI/REL|Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
11115094|NCT03969901|Active Comparator|Active Control|Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.
11115095|NCT03969888|Experimental|Part 1: ABBV-3067 + Placebo|Participants will receive various dosing regimens for ABBV-3067 plus placebo ABBV-2222 taken orally depending on arm assignment.
11115096|NCT03969888|Experimental|Part 1: ABBV-3067 + ABBV-2222|Participants will receive fixed dose of ABBV-3067 plus various dosing regimens for ABBV-2222 taken orally depending on arm assignment.
11115097|NCT03969888|Placebo Comparator|Part 1 and Part 2: Placebo|Participants in Part 1 and Part 2 will receive placebo ABBV-3067 plus placebo ABBV-2222 taken orally.
11115098|NCT03969888|Experimental|Part 2: ABBV-3067 + ABBV-2222|Participants will receive various dosing regimens for ABBV-3067 plus a fixed dose of ABBV-2222 taken orally depending on arm assignment.
11115099|NCT03969862||Patient with an allergen-mediated IgE allergy|Patients with a clinical history consistent with an allergen-mediated IgE allergy & with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
11115100|NCT03969862||Patient without an allergen-mediated IgE allergy|Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
11115101|NCT03969849|Experimental|Part A: Cohort 1|Part A: Cohort 1 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
11115102|NCT03969849|Experimental|Part A: Cohort 2|Part A: Cohort 2 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
11115103|NCT03969849|Experimental|Part A: Cohort 3|Part A: Cohort 3 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
11115104|NCT03969849|Experimental|Part A: Cohort 4|Part A: Cohort 4 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
11115105|NCT03969849|Experimental|Part B|Part B: Randomized 1:1 will receive REGN5713-5714-5715 or matching placebo in Healthy Participants with birch pollen allergy
11115106|NCT03969836|Experimental|NeurOS Group|All patients will have both INVOS and NeurOS systems placed before and during cardiac surgery for monitoring cerebral oxygenation and brain blood volume.
11115107|NCT03969823|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
11115191|NCT03969147|Experimental|Tolerability Comparison|Healthy volunteers will self-place either the ManMaxAirway oropharyngeal airway adjunct or the Guedel Oropharyngeal airway adjunct, which will be left in place for an interval of one minute, while supervised by research staff. After completing a questionnaire and resting for a timed interval, they will then self-place the other airway adjunct, which will be left in place for the same length of time as the first, before completing another questionnaire. The order in which the devices are placed by each subject will be determined in advance via computer randomization.
11115108|NCT03969810|Experimental|Rounding Summary|"Surrogates who are assigned to the intervention group will receive a written rounding summary every day or every other day that the patient is in the ICU. The summary will be organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
~For patients assigned to the intervention group, the investigators will forward the previous day's summary to the ICU nurse at the beginning of each day shift. After participating in morning rounds, ICU nurses will be asked to modify the summary based on the plan for the day. Nurses will be asked to use the written summary to guide communication with surrogates that day."
11115109|NCT03969810|No Intervention|Usual Care|Usual ICU care
11115110|NCT03969784|Experimental|colorectal cancer patient with peritoneal carcinosis|
11115111|NCT03969784|Active Comparator|colorectal cancer patient without metastasis|
11115112|NCT03969771|Experimental|Frequently Absent|8 weeks of training in Mindfulness-Based Stress Reduction
11115113|NCT03969771|Active Comparator|Normal Attendees (Controls)|8 weeks of training in Mindfulness-Based Stress Reduction
11115114|NCT03969758|Active Comparator|Ciprofloxacin plus Metronidazole therapy|Will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks. Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
11115115|NCT03969758|Active Comparator|Cefixime plus Metronidazole Therapy|Will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks.Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
11115116|NCT03969745|Experimental|Time restricted feeding (TRF)|Participants restricted their daily energy intake window to between 8 am and 4 pm for two weeks. They were encouraged to not alter the quantity and composition of their diet or alter physical activity patterns.
11115117|NCT03969745|Active Comparator|Caloric deficit|The investigators observed significant weight loss in the TRF group with participants reporting to consume ~400 kilocalories less per day. Therefore the investigators added a caloric deficit group to control for the effects of weight loss on metabolism. Total energy expenditure was measured for one week and was used to prescribe a 400 kilocalories/day energy deficit diet to follow for two weeks.
11115118|NCT03969732|Experimental|amyloid PET、T807 PET|PET/CT
11115119|NCT03969719|Placebo Comparator|Placebo|Palacebo
11115120|NCT03969719|Experimental|Low Dose|150 mg
11115121|NCT03969719|Experimental|High Dose|300 mg
11115122|NCT03969706|Experimental|Single Arm|Abemaciclib 200mg tablet PO twice daily administered on 28-day cycles Subjects remain on treatment until tumor progression or unacceptable toxicity.
11115123|NCT03969693||The patients with mediastinal malignant lymphoma|Patients whose radiation therapy field essentially encompasses anterior mediastinum; namely, the majority of malignant lymphoma patients with mediastinal involvement.
11115124|NCT03969680|Experimental|BMSCs plus PRP group|Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
11115125|NCT03969680|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
11115126|NCT03969667||healthy young adults|healthy young adults
11115127|NCT03969654|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA
11115128|NCT03969654|Active Comparator|Conventional TKA|Conventional TKA
11115129|NCT03969641|Experimental|RIV4|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
11115130|NCT03969641|Active Comparator|IIV4|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
11115131|NCT03969628|Experimental|Multivariate risk assessment group (ICCMS®)|Multivariate risk assessment group (ICCMS®): multivariate caries risk assessment based on International Caries Classification and Management System (ICCMS™) guide
11115132|NCT03969628|Experimental|Simplified risk assessment group (dental caries experience)|Simplified risk assessment group (dental caries experience): simplified caries risk assessment based on dental caries experience (WHO criteria)
11115133|NCT03969615|Active Comparator|Supplemental oxygen|5lpm of supplemental oxygen via a nasal cannula or face mask
11115134|NCT03969615|Experimental|SuperNO2VA nasal positive airway pressure device|Intervention arm will receive the SuperNO2VA nasal positive pressure device at 10lpm
11115135|NCT03969602|Experimental|Experimental Group|Participants randomized will receive six individual 1-hour sessions of CBT: two sessions before the operation and four after, delivered by a psychologist trained in CBT for chronic pain. The CBT intervention is tailored to reduce pain catastrophizing. Main techniques are: pain education and the influence of cognitions, emotions and behavior on pain and pain disability; identification of catastrophizing cognitions and replacing them with more adaptive cognitions; stress/anxiety reduction by diaphragmatic breathing and progressive muscle relaxation; emotion regulation skills training; cognitive restructuring; coping skills training to combat helplessness and foster a sense of control and self-efficacy for dealing with acute post-operative pain. The four postoperative sessions build on and further extend the skills learned preoperatively. Each session ends with specific homework assignments. All patients receive a homework book and an individually tailored instruction manual.
11115338|NCT03968003|Experimental|Inulin|Group A (intervention group) will receive inulin 10 g.
11115136|NCT03969602|Active Comparator|Control Group|Participants will have six meetings with members of the research team (in person or through telephone). In a first preoperative meeting a member of the team provides verbal information on the preparation for surgery, surgery itself and recovery from surgery, stressing the importance of postoperative exercise. Any questions raised by the patient are discussed. A booklet is provided with information about: structure of the spinal column and spinal diseases; examinations before surgery; the operative environment; surgical procedures; anesthetic procedures; postoperative care and postoperative pain reduction. A second preoperative (telephone) meeting is scheduled to answer any remaining questions. During the postoperative phase, instructions and an exercise manual are provided, Patients keep a diary to record their training activity. Three, six and eight months after discharge patients are contacted by telephone and their training progress is discussed.
11115137|NCT03969602|No Intervention|Observational Group (low catastrophizing)|Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
11115138|NCT03969589|Experimental|Reproductive Life Planning-Mental Health Intervention|Reproductive Life Planning-Mental Health (RLP-MH) intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
11115139|NCT03969589|Other|Written materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
11115140|NCT03969576|Experimental|DEB-TACE|172 subjects in this study group will be receive the treatment of drug-eluting bead TACE
11115141|NCT03969576|Active Comparator|cTACE|172 subjects in this study group will be receive the treatment of conventional TACE
11115142|NCT03969563|Experimental|MBSR|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
11115143|NCT03969563|Active Comparator|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
11115144|NCT03969537||Telemedicine|The patients selected to participate in the study are cervical dystonia (CD) patients who receive treatment at Vanderbilt University Medical Center, where the study takes place.
11115145|NCT03969511|Experimental|Direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is then performed as well as intravenous thrombolysis when contraindications are excluded.
11115146|NCT03969511|Active Comparator|Standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
11115147|NCT03969498||1- Obstetric APS women (oAPS)|No intervention, pure observational study.
11115148|NCT03969498||2-Women positive for F5rs6025 or F2rs1799963 polymorphis|No intervention, pure observational study.
11115149|NCT03969498||3-Women with negative thrombophilia screening (Control group|No intervention, pure observational study.
11115150|NCT03969485|Experimental|Hybrid Fractional Laser|Hybrid Fractional Laser Treatment
11115151|NCT03969472|Experimental|probiotic group|apply probiotic after surgery
11115152|NCT03969472|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery without probiotic
11115153|NCT03969472|No Intervention|control|without electrophysiologic therapy and probiotic after surgery
11115154|NCT03969446|Experimental|Cohort I (pembrolizumab, decitabine)|Patients with AML receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine IV over 1 hour on days 1-10. Patients who achieve a CR receive decitabine on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
11115155|NCT03969446|Experimental|Cohort II (pembrolizumab, decitabine)|Patients with MDS receive pembrolizumab IV over 30 minutes on days 1 and 22 and decitabine over 1 hour on days 1-5. Treatment repeats every 42 days for up to 8 cycles or 1 year from start of therapy, whichever comes first, in the absence of disease progression or unacceptable toxicity.
11115156|NCT03969433|Experimental|Phase I|Data collections are performed with TMSi Porti system and CTG (reference)
11115157|NCT03969433|Experimental|Phases II-III-IV|Data collections are performed with the Bloomlife sensor and CTG (reference)
11115158|NCT03969420|Experimental|Stage 1: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
11115159|NCT03969420|Experimental|Stage 1: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
11115160|NCT03969394|Experimental|Heart Failure Patients|Patients with Heart Failure
11115161|NCT03969381||1 lymphoma patients|pre therapy and post therapy of lymphoma patients
11115162|NCT03969368|Experimental|Treatment Group|Treatment with the investigational device - rPMS
11115163|NCT03969368|Active Comparator|Control Group|Control group
11115164|NCT03969355||Paediatric patients 2008-2012|Paediatric patients admitted to intensive care in 2008-2012 who died during PICU stay
11115165|NCT03969355||Paediatric patients 2013-2017|Paediatric patients admitted to intensive care in 2013-2017 who died during PICU stay
11115166|NCT03969342|Experimental|Trainees|Local mid-level providers who undergo five day training on point of care ultrasound for diagnosing pediatric pneumonia
11115167|NCT03969329|Experimental|Etelcalcetide|Patients will receive etelcalcetide in addition to standard of care
11115339|NCT03968003|Placebo Comparator|Maltodextrin|Group B will receive placebo of isocaloric maltodextrin.
11115168|NCT03969316|Active Comparator|Quadratus Lumborum Block|After the premedication with ketamine and/or midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane.If the patient has the unilateral undescended testis, 0.4 ml/kg %0.25 bupivacaine, if the patient has the bilateral one, in every side 0.2ml/kg %0.25 bupivacaine will be administrated with ultrasound at the posterior border of quadratus lumborum muscle with 16 or 18 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
11115169|NCT03969316|Active Comparator|Transversus Abdominis Plane Block|After the premedication with ketamine and/or midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane.If the patient has the unilateral undescended testis, 0.4 ml/kg %0.25 bupivacaine, if the patient has the bilateral one, in every side 0.2ml/kg %0.25 bupivacaine will be administrated with ultrasound between internal oblique and transversus abdominis muscle with 16 or 18 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
11115170|NCT03969303||NOTAL OCT v.2.5 and Commercial OCT on AMD Patients|OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).
11115171|NCT03969290|Experimental|Sequence 1|Verofilcon A contact lens in the right eye (OD), with etafilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
11115172|NCT03969290|Active Comparator|Sequence 2|Etafilcon A contact lens in the right eye (OD), with verofilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
11115173|NCT03969277|Experimental|Graded Motor Imagery|Each subject in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, and home exercises.
11115174|NCT03969277|Active Comparator|Standard Rehabilitation|Each subject in the Standard Rehabilitation group will receive a treatment protocol consisting of stretching and strengthening exercises, cold therapy, and home exercises.
11115175|NCT03969264|Active Comparator|Carb Snacks|Will follow study diet based on the Dietary Guidelines and consume study carbohydrate snacks between meals.
11115176|NCT03969264|Experimental|Tree Nut Snacks|Will follow study diet based on the Dietary Guidelines and consume study tree nut snacks between meals.
11115177|NCT03969251|Experimental|Transcranial Magnetic Stimulation (rTMS)|repetitive transcranial magnetic stimulation
11115178|NCT03969251|Sham Comparator|Sham (SS)|repetitive sham rTMS
11115179|NCT03969238||Patients/Providers|Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
11115180|NCT03969212|Experimental|Baloxavir Marboxil|Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.
11115181|NCT03969212|Placebo Comparator|Placebo|Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.
11115182|NCT03969199|Experimental|MANNA Food Delivery Service|MANNA will deliver meals to patients randomized to the intervention arm of the study every week on the same day for 90 days. Each delivery will include: 7 breakfast meals, 7 lunch meals, 7 dinner entrees, health desserts, and fresh fruit. Meals will be delivered frozen and can be stored in a freezer until ready to eat. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
11115183|NCT03969199|No Intervention|Standard of Care Counseling|Patients randomized to the control arm will receive standard or care dietary counseling from either their physician or a dietician. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
11115184|NCT03969186|Experimental|Daily telehealth follow-up|The intervention arm will receive a simple telehealth intervention utilizing the Way to Health Platform engineered at the University of Pennsylvania. This platform will be used to send daily SMS messages to patients for 90 days following discharge and alert the research team to changes in patients' status. In addition, the patients in the intervention arm will receive a weekly phone call administered by members of the research team to assess their overall progress and well-being.
11115185|NCT03969186|No Intervention|Standard of care follow-up|Standard of care
11115186|NCT03969173|Active Comparator|PEEP3|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
11115187|NCT03969173|Active Comparator|PEEP6|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
11115188|NCT03969173|Active Comparator|PEEP9|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
11115189|NCT03969160|Experimental|Imaginal exposure|The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
11115190|NCT03969147|Active Comparator|MRI Comparison|MRI images will be obtained of the airways of healthy volunteers both with the ManMaxAirway oropharyngeal airway adjunct and with no airway adjunct in place in order to observe any changes to the airway anatomy caused by placement of the airway adjunct. The order of the scans (with and without airway adjunct) will be determined by randomization software in advance.
11115261|NCT03968640|Active Comparator|CoQ10 group|The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
11115192|NCT03969147|Active Comparator|Forced Oscillation|Volunteers from the tolerability comparison arm will also be invited as a subset of subjects to participate in a measurement of resistance to forced oscillation. The volunteers will be subject to forced oscillations in a pulmonary function lab with the ManMaxAirway oropharyngeal airway adjunct in place and with no airway adjunct in order to observe changes in resistance to oscillatory airflow
11115193|NCT03969134|Active Comparator|Vaccine arm|ChAd63 KH 7.5x1010 vp, single dose, by IM injection
11115194|NCT03969134|Placebo Comparator|Placebo|Normal Saline, single dose, by IM injection
11115195|NCT03969121|Active Comparator|Placebo + Endocrine therapy|Endocrine therapy for 16 weeks plus placebo
11115196|NCT03969121|Active Comparator|Palbociclib + Endocrine therapy|Endocrine therapy for 16 weeks plus Palbociclib
11115197|NCT03969108|Experimental|Indocyanine Green|
11115198|NCT03969095|Experimental|Immediate|Participants in the immediate intervention arm will begin a 4-week intervention tongue pressure resistance training protocol within 10 days of their baseline Videofluoroscopic Swallowing Evaluation assessment, with 2 face-to-face 1-hour visits per week under direct supervision of a speech-language pathologist. These treatment sessions will be supplemented by daily home practice of the intervention.
11115199|NCT03969095|Active Comparator|Delayed|Participants in the delayed intervention arm will begin their involvement with a 4-week waiting period after the baseline Videofluoroscopic Swallowing Evaluation. Treatment will commence after the second Videofluoroscopic Swallowing Evaluation and will follow the same schedule for the tongue pressure resistance training, supplemented by daily home practice.
11115200|NCT03969082|Experimental|Bibliotherapy|"Students will read to patients receiving active treatment using the read aloud method. This will be performed in a 1: 1 relationship for half an hour for 8-10 times during a period of six months."
11115201|NCT03969069||Fistula/chronic perianal conditions|Participants symptomatic of FI with chronic perianal disease
11115202|NCT03969069||Obstetric injury <12 months|Participants symptomatic of FI < 12 months following obstetric injury.
11115203|NCT03969069||Obstetric injury >12 months|Participants symptomatic of FI >12 months following obstetric injury.
11115204|NCT03969069||Neurogenic|Participants symptomatic of FI with evidence/history of neurological condition.
11115205|NCT03969056|Experimental|Artificial Intelligence (AI) Activity group|Participants in this group receive an AI based intervention (automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning and message)
11115206|NCT03969056|Active Comparator|Control group|Participants in this group receive a standardized and fixed 10,000 daily steps goal intervention.
11115207|NCT03969043|Experimental|Young volunteers|"Volunteers between 18 ans 45 years old
~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
11115208|NCT03969043|Experimental|Older Volunteers|"Volunteers between 60 ans 85 years old
~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
11115209|NCT03969030|Experimental|Intervention|"Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:
~ART Refill
~SMS notifications
~Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery."
11115210|NCT03969030|No Intervention|Control|Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club).
11115211|NCT03969017|Experimental|NAs+Peg IFN Group|NAs+Peg IFN Group will receive the treatment of NAs (patients previously treated with telbivudine will be changed to entecavir) plus pegylated interferon (Peg IFN)α-2b.
11115212|NCT03969017|Other|NAs Group|NAs Group will be treated with NAs as before enrollment.
11115213|NCT03969004|Experimental|Cemiplimab|
11115214|NCT03969004|Placebo Comparator|Placebo|
11115215|NCT03968991|Active Comparator|Healthy volunteer group|male or female healthy volunteers
11115216|NCT03968991|Experimental|Subjects with acquired visual impairment|visual acquired disability
11115217|NCT03968991|Experimental|Subjects with congenital visual impairment|Visual congenital disability
11115218|NCT03968978|Experimental|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
11115219|NCT03968978|Experimental|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
11115220|NCT03968965|Experimental|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
11115221|NCT03968965|Other|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
11115222|NCT03968952|Active Comparator|SMARThealth Pregnancy|"The components of the SMARThealth Pregnancy intervention include:
~Educational and Training component on high-risk pregnancy conditions, focusing on; Anaemia, Hypertensive Disorders of Pregnancy (HDPs) and Gestational diabetes mellitus (GDM).
~An mHealth platform providing clinical decision support, lifestyle advice, recall and reminder system for Community Health Workers (CHWs) and Primary Care Physicians (PCPs).
~Pregnant women in the intervention group will receive 3 visits at home by their CHW, in addition to their standard antenatal and postnatal care. One visit during the third trimester of pregnancy; one during Week 1 postpartum and; one visit during Week 6 postpartum."
11115262|NCT03968640|Placebo Comparator|Placebo|Allocation-concealed placebo will be used as an appropriate control.
11115263|NCT03968627||Protocol application|The study describes the method and the criteria used in the development of the protocol, the steps followed in its implementation in two Don Gnocchi Foundation Pilot Hospitals
11115264|NCT03968614|Experimental|Electrical Dry Needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
11115223|NCT03968952|No Intervention|Enhanced Standard Care|"The control group will receive enhanced standard antenatal and postnatal care, involving:
~An awareness programme for pregnant women, Community Health Workers (CHWs) and Primary Care Physicians (PCPs), held at the villages within the control group Primary Health Centre (PHC) cluster (Enhanced Standard Care). The community and health professionals will receive information on the high-risk conditions of anaemia in pregnancy, HDPs and GDM as part of the awareness programme.
~Standard antenatal and postnatal care (consisting of free monthly antenatal care, and up to 7 postnatal visits), delivered by CHWs in partnership with their PHC doctor."
11115224|NCT03968939|No Intervention|Control group (Usual Care)|Usual care
11115225|NCT03968939|Active Comparator|Sleep Hygiene Education|Sleep Hygiene Education
11115226|NCT03968939|Active Comparator|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin)|Over-the-counter sleep aids (25 mg Benadryl + 3mg melatonin) and Sleep Hygiene Education
11115227|NCT03968926||Vasoplegic ECMO|All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2
11115228|NCT03968913|Placebo Comparator|Control|Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
11115229|NCT03968913|Active Comparator|One dose Anakinra, one dose placebo|Subjects will receive one injection of sterile saline and one injection of anakinra after ACL injury, prior to surgery
11115230|NCT03968913|Active Comparator|Two doses Anakinra|Subjects will receive two injections of anakinra after ACL injury, prior to surgery
11115231|NCT03968900|Experimental|Sleep Restriction|4 hours time in bed (1 am to 5 am)
11115232|NCT03968900|Experimental|Sleep Extension|10 hours time in bed (10 pm to 8 am)
11115233|NCT03968887||Case group|Patients with postoperative delirium.
11115234|NCT03968887||Control group|Patients who have not had postoperative delirium.
11115235|NCT03968874|Experimental|Light box|Commercially available lightbox emitting 10,000 lux of light. Subjects asked to use lightbox everyday for an hour for 4 weeks upon waking.
11115236|NCT03968874|Sham Comparator|Negative Ion Generator|Commercially available negative ion generator. Subjects asked to use everyday for an hour for 4 weeks upon waking.
11115237|NCT03968861||Standard care with moderate hypothermia|Surviving children allocated to standard care with moderate hypothermia in the TOBY-Xe trial
11115238|NCT03968861||30% Xenon for 24 hours combined with moderate hypothermia|Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial
11115239|NCT03968848|Experimental|Subjects with Severe Hepatic Impairment|Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
11115240|NCT03968848|Experimental|Matched-Control Subjects|Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
11115241|NCT03968835||Biological Dressings|Bacitracin will be applied and covered with xeroform and gauze
11115242|NCT03968835||Artificial Dressings|the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft
11115243|NCT03968822|Experimental|Intralipid 20% IV Bolus|
11115244|NCT03968822|Placebo Comparator|Saline|
11115245|NCT03968809||Standard Coronary Artery Disease Screening|All patients presenting for standard coronary artery disease screening will undergo additional imaging with CardioFlux MCG. These patients will be followed longitudinally for short and long term MACE.
11115246|NCT03968796|Active Comparator|Group 1|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.
~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
11115247|NCT03968796|Active Comparator|Group 2|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.
~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
11115248|NCT03968796|Active Comparator|Group 3|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.
~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
11115249|NCT03968796|Placebo Comparator|Group 4|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.
~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
11115250|NCT03968783|Experimental|Monofilament suture|continuous double-layer unlocked suturing with 1.0 monofilament synthetic absorbable suture
11115251|NCT03968783|Active Comparator|Multifilament suture|continuous double-layer unlocked suturing with 1.0 multifilament synthetic absorbable suture
11115252|NCT03968770|Experimental|Experimental group|Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
11115253|NCT03968770|Placebo Comparator|Control group|Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
11115254|NCT03968757||Obese patients eligible for laparoscopic RYGB surgery.|
11115255|NCT03968744|Experimental|Safinamide|PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day
11115256|NCT03968731|Experimental|ZEST treatment|The study subjects will receive the ZEST treatment protocol (Zocular Eyelid System treatment) to treat Meibomian Gland Dysfunction causing Contact Lens discomfort symptoms.
11115257|NCT03968718|Experimental|Systematic ePROMs Assessment|"Intervention: The intervention is constituted by a Systematic ePROMs Assessment in routine cancer care in a comprehensive cancer centre.
~This will involve preliminary sensitization and training of both clinicians and patients towards the use of ePROMs.
~Data filled in by patients through electronic devices will be prompt made available to the clinician during the patient examination."
11115258|NCT03968679|Experimental|Unilateral elective nodal irradiation|Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.
11115259|NCT03968666||Gynecological surgery with ERAS protocol|Patients scheduled for benign gynecological surgery under ERAS protocol
11115260|NCT03968653|Experimental|Debio 0123|Participants will receive Debio 0123 as monotherapy (Day -3), orally, in the morning and once daily for 3 days during Cycle 1 then in combination with carboplatin intravenous infusion from Cycle 2 onwards.
11115268|NCT03968588|Active Comparator|standard-dose tacrolimus + reduced-dose MMF|Control group, target trough blood level was between 5ng/mL and 15ng/mL throughout the study period. MMF dose was 0.5~1g per day and MMF started within 72 hours after transplantation.
11115269|NCT03968575|Experimental|Laser|
11115270|NCT03968562|Active Comparator|2% Doxycycline Cream in Generic Aquaphor|2% Doxycycline Cream in Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Placebo Comparator
11115271|NCT03968562|Placebo Comparator|Generic Aquaphor|Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Active Comparator.
11115272|NCT03968549|Placebo Comparator|Placebo|These patients will receive capsules containing vegetable oil and corn starch
11115273|NCT03968549|Active Comparator|Probiotic|These patients will receive capsules containing Lactobacillus acidophilus
11115274|NCT03968523|Active Comparator|TAP block|TAP block technique.
11115275|NCT03968523|Experimental|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
11115276|NCT03968510||parathyroidectomy cases|patients who will be operated for primary hyperparathyroidism
11115277|NCT03968497|Other|Postoperative pain assessment|Postoperative pain evaluation by a female and a male investigator, respectively at approximately 15-minute intervals.
11115278|NCT03968484|Experimental|<50.000/µl|Transfusion of platelets starting with a platelet count <50.000/µl
11115279|NCT03968484|Experimental|<20.000/µl|Transfusion of platelets starting with a platelet count <20.000/µl
11115280|NCT03968458|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions.
11115281|NCT03968445|Experimental|Recent Myocardial Infarction|
11115282|NCT03968445|Experimental|undergoing elective percutaneous coronary intervention|
11115283|NCT03968432|Sham Comparator|Standard Care|Be Sweet to Babies Videos and Pamphlet. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of the sweet solution during vaccination will be used.
11115284|NCT03968432|Active Comparator|Intervention|Be Sweet to Babies Videos, pamphlet, and MIAS&Q. MIAS&Q includes five questions and statements based on MI approach which was developed by the researcher and was reviewed further by a panel of parent representatives and HCPs representatives and the research team consisting of the supervisor and two Ph.D. committee members. This MIAS&Q intervention consists of four scaled questions and two open-ended questions and presents brief informative and affirmative questions and statements. This aims to help the parents reflect on their own thoughts, and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
11115285|NCT03968419|Experimental|canakinumab monotherapy|All patients will receive canakinumab (ACZ885) prior to surgery
11115286|NCT03968419|Experimental|canakinumab + pembrolizumab|All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery
11115287|NCT03968419|Experimental|pembrolizumab monotherapy|All patients will receive 2 doses of pembrolizumab prior to surgery
11115288|NCT03968406|Experimental|Treatment (talazoparib, radiation therapy)|Patients receive talazoparib PO QD beginning on days -10 to -7 and continuing for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy 5 days a week (Monday-Friday) for up to 7 weeks.
11115289|NCT03968393|Experimental|Non-vitamin K oral anticoagulant (NOAC)|
11115290|NCT03968393|No Intervention|No anticoagulation|Patients allocated to the no anticoagulation arm are not allowed to receive oral anticoagulation, unless the patient develops an indication for its use during follow-up.
11115291|NCT03968380||Population in Quito|720 randomly chosen people living in District 17D06, Quito (Ecuador)
11115292|NCT03968380||Population in Esmeraldas|720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador)
11115293|NCT03968367|Experimental|Magnetic activated sperm cell sorting for infertile man|A 0.5 mL aliquot of spermatozoa suspended in HTF-modified HEPES buffer, obtained either after sperm wash to remove the seminal plasma or after DGC, was centrifuged and the pellet (maximum of 107 cells) was resuspended in 80 uL of binding buffer with 20 uL of Annexin V-conjugated microspheres, both from the Annexin V microbead kit (Miltenyi Biotec, Huburn, CA, USA), for 15 min at room temperature. After addition of 400 lL of binding solution, the suspension was placed in the separation column (MiniMACS, Miltenyi Biotec). Labeled (apoptotic) cells were retained on the column and non-labeled (viable) cells passed through the column.
11115294|NCT03968354||Steatosis group - Experimental1|Steatosis group
11115295|NCT03968354||NASH group without fibrosis - Experimental 2|NASH group without fibrosis
11115296|NCT03968354||Moderate fibrosis - Experimental 3|Moderate fibrosis
11115297|NCT03968354||Advanced fibrosis - Experimental 4|Advanced fibrosis
11115298|NCT03968354||Control group - Active Comparator|Control group
11115299|NCT03968341|Experimental|intraocular antibiotic concentrations determination|"In the event that the patient develops unfavourably, the ophthalmologist include the patient in the trial.
~The patient is reviewed at 48 hours after the introduction of probabilistic antibiotic therapy for clinical reassessment and the return of microbiological test results. Following this inclusion, the new samples will be taken when the patient passes through the operating room for the treatment of his pathology as part of the care. Ophthalmologists may have to adapt the patient's management (i.e. adjustment of antibiotic therapy) as part of their usual care routine. An anterior chamber puncture and a vitrectomy are performed. Eye fluids collected as part of the treatment are sent for analysis."
11115300|NCT03968328||Observational (interview, survey)|Patients respond to a survey and participate in an interview with study staff about their fever and when they started feeling unwell.
11115301|NCT03968315|Experimental|Diagnostic (MRI, diaphragm fluoroscopy)|Patients undergo an MRI scan over 45-60 minutes and a diaphragm fluoroscopy 30 days before surgery.
11115302|NCT03968302|Experimental|ARM A|The triple regimen, amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole 40 mg twice a day
11115303|NCT03968302|Experimental|ARM B|The quadruple regimen,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day, omeprazole 40 mg twice a day dose and colloidal bismuth subcitrate 240 mg twice daily
11115340|NCT03968003|Active Comparator|Dietary fiber|Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.
11115304|NCT03968276|Experimental|use of digital tablet|"if the patient is included in the study, an educational tablet (digital tablet) is given to the patient.
~The first connection to the tablet and then to the My medication protects my vessels application is made by the investigator in the presence of the patient. The application is configured by the investigator with the choice of the vascular pathology(s) corresponding to the patient included and the prescribed anti-thrombotic treatments. Thus, for each patient, the content of the tablet is adapted and personalized according to his vascular profile.
~After discharge from hospital, the patient has the educational tablet at his disposal for 1 month at home. The application offers patients various information supports (tools, questionnaires and pill box). Throughout its use, it may contact the investigating physician via a telephone number available within the application if it encounters a problem related to the study."
11115305|NCT03968263|Active Comparator|Hycon device(Routine protocol)|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions.
11115306|NCT03968263|Active Comparator|Hycon device(Modified protocol)|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise.
11115307|NCT03968263|Active Comparator|Hycon device(Routine protocol) and Vibration|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
11115308|NCT03968263|Active Comparator|Hycon device(Modified protocol) and Vibration|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
11115309|NCT03968250|Experimental|Cognitive Behavioral Therapy for Treating Fatigue|This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
11115310|NCT03968224|Experimental|Metformin/Dapagliflozin|Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.
11115311|NCT03968224|Active Comparator|Metformin|Metformin 1,700 mg/day
11115312|NCT03968211|Experimental|Vaccine|Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine
11115313|NCT03968198|Experimental|ASC (Adipose-derived Stem/Stroma Cells)|Patients administrated with autologous ASC in their ischemic inferiors limbs
11115314|NCT03968185||Interfascial infiltration|Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.
11115315|NCT03968185||Standard medical treatment|Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.
11115316|NCT03968172|Experimental|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
11115317|NCT03968172|Active Comparator|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
11115318|NCT03968159|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
11115319|NCT03968159|Placebo Comparator|Placebo|Placebo tablets
11115320|NCT03968146|Active Comparator|Group E|patients will receive Erector Spinae plane block in addition to intravenous fentanyl
11115321|NCT03968146|Other|Group C|Control group will receive only intravenous fentanyl.
11115322|NCT03968133|Experimental|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5*10^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10^9 CFU/gram) per day.
11115323|NCT03968133|Placebo Comparator|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
11115324|NCT03968120|No Intervention|Group Fix:One-lung ventilation with constant PEEP|Controll group: lung protective one-lung ventilation with fix positive end-expiratory pressure (PEEP)
11115325|NCT03968120|Active Comparator|Group Variable:One-lung ventilation with variable PEEP|Variable group: lung protective one-lung ventilation with variable positive end-expiratory pressure (PEEP)
11115326|NCT03968107||Women with a singleton pregnancy over 28 weeks|All pregnant women with a singleton pregnancy over 28 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures , will be proposed inclusion in the study.
11115327|NCT03968081|Experimental|Social exclusion|Participating at the cyberball game in exclusion condition in wich they will receive 2 time the ball in the 10 first throw then none of them in the last 20 throw.
11115328|NCT03968081|Active Comparator|Social inclusion|Participating at the cyberball game in inclusion condition in wich they will receive 33% of the throw : 10 in a total of 30
11115329|NCT03968068|Experimental|Exercise|
11115330|NCT03968068|Experimental|Remote Ischaemic Conditioning|
11115331|NCT03968042|Placebo Comparator|Regular treatment (RT)|Combination of vitamin B1, B6, C, E and mecobalamine
11115332|NCT03968042|Experimental|RT with NGF|Nerve growth factor adding to regular treatment
11115333|NCT03968042|Experimental|RT with EDV|Edaravone adding to regular treatment
11115334|NCT03968029|Experimental|Suturing meniscal augmented|Non-vascularised area meniscus tear was sutured and bone marrow was injected under a protective collagen membrane (ChondroGide)
11115335|NCT03968029|Active Comparator|Suturing meniscal|Non-vascularised area meniscus tear was only sutured
11115336|NCT03968016|Placebo Comparator|Healthy|Control group
11115341|NCT03967990|Experimental|refined-50/50-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
11115342|NCT03967990|Experimental|50/50-whole-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
11115343|NCT03967990|Experimental|whole-refined-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
11115344|NCT03967990|Experimental|refined-whole-50/50|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
11115345|NCT03967990|Experimental|50/50-refined-whole|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
11115346|NCT03967990|Experimental|whole-50/50-refined|48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
11115347|NCT03967977|Active Comparator|Tislelizumab in combination with chemotherapy|Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
11115348|NCT03967977|Placebo Comparator|Placebo in combination with chemotherapy|Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
11115349|NCT03967964|Experimental|Group 1: AVD|Vaginal ring with 2.2 grams dehydroepiandrosterone (DHEA), wearing time 72 hours
11115350|NCT03967964|Experimental|Group 2: AVT|Vaginal ring with 35 mg testosterone, wearing time 72 hours.
11115351|NCT03967964|Experimental|Group 3: AVD+T|Vaginal ring with 1.5 grams DHEA and 25 mg testosterone, wearing time 72 hours.
11115352|NCT03967964|Active Comparator|Group 4: DHEA capsule|Capsules with 25 mg DHEA, oral administration every 8 hours for a 72-hour period.
11115353|NCT03967964|Active Comparator|Group 5: Testosterone transdermal gel|Testosterone transdermal gel with dosing valve (pump): administration of 3 pump actuations (equivalent to 5 mg of testosterone each) per day (total daily dose 15 mg), on 3 consecutive days (72 hours).
11115354|NCT03967938|Experimental|Olaparib|tablets of 300mg twice daily until disease progression
11115355|NCT03967925|Active Comparator|Belimumab|Weekly 200mg SC injections of belimumab for 12 months
11115356|NCT03967925|Placebo Comparator|Belimumab placebo|Weekly SC injections of belimumab placebo for 12 months
11115357|NCT03967912|Experimental|MOVE UP for Caregivers|12-week lifestyle intervention focusing on diet and activity
11115358|NCT03967886|Experimental|YYD601 20mg|Esomeprazole magnesium Dihydrate.
11115359|NCT03967886|Active Comparator|Nexium 20mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
11115360|NCT03967847|No Intervention|Control|
11115361|NCT03967847|Experimental|Ketorolac|
11115362|NCT03967834|Other|Patient with Soft Tissue Sarcoma|
11115363|NCT03967821||Intervention|
11115364|NCT03967795|Other|All patients|"Citrulline genration test before starting enteral nutrition
~At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration"
11115365|NCT03967782|Experimental|cohorte 1|18 adolescents with obesity are involved and will perform the three conditions.
11115366|NCT03967769|No Intervention|Standard Practice|Infants will have high Flow nasal cannulae placed into the nares before induction. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
11115367|NCT03967769|Experimental|Low Flow oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 0,2L/kg/min of oxygen flowing through the cannulae in this group during the study.
11115368|NCT03967769|Experimental|High Flow Oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 1L/kg/min of oxygen flowing through the cannulae in this group during the study.
11115369|NCT03967756|Experimental|AI-assisted withdrawal group|A deep learning-based automatic polyp detection system was used to assist the endoscopist.
11115370|NCT03967756|No Intervention|Routine withdrawal group|Routine withdrawal without any assist.
11115371|NCT03967743||Infants with rare genetic disorders|This is a prospective, registry study of infants with genetic disorders being seen clinically in the NICU GraDS program.
11115372|NCT03967730|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
11115373|NCT03967717||Patients with edematous states|Patients with edematous states receive standard of care diuretic.
11115374|NCT03967704|Experimental|Life quality evaluation|"Patients consulting the Emergency Department (SAU) or the rheumatology department of the GHPSJ (referred by a colleague orthopaedic surgeon, rheumatologist, radiologist or other) for a recent symptomatic osteoporotic dorsal or lumbar vertebral fracture, are called for a rheumatology consultation, vertebral fracture consultation.
~Patients consulting in the rheumatology department during a spinal fracture consultation at the GHPSJ as well as patients hospitalized in the rheumatology department at the GHPSJ are selected consecutively.
~- Arm 1 (intervention): two additional consultations with the rheumatology"
11115377|NCT03967691|Other|Saline infusion under tocilizumab influence|Subjects will be infused withsaline (but still under the influence of tocilizumab) on study day 3
11115378|NCT03967678|Placebo Comparator|Beef from standard supply|
11115379|NCT03967678|Experimental|n-3 enriched beef from dietary supplement finished cattle|
11115380|NCT03967678|Active Comparator|n-3 enriched beef from grass finished cattle|
11115381|NCT03967665|Experimental|Treatment arm|NAC 400 mg three times per day from -14D pre-HSCT to +2 months
11115382|NCT03967665|No Intervention|Control arm|No-NAC concurrent control according to a 2:1 schedule.
11115383|NCT03967652||cancer|Patients with definitively diagnosed of solid tumors
11115384|NCT03967652||Benign disease|Patients with definitively diagnosed of benign disease or precancerous lesion
11115385|NCT03967652||Normal|Healthy volunteers
11115386|NCT03967639||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
11115387|NCT03967639||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
11115388|NCT03967626|Experimental|Cerebral temperature target|CCT performed by the external cooling device with cerebral temperature target, measured by a intracranial sensor (coupled to the intracranial pressure device)
11115389|NCT03967626|Active Comparator|Systemic temperature target|CCT performed by the external cooling device with systemic temperature target, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol).
11115390|NCT03967613|Experimental|FES|Functional Eletrical Stimulation
11115391|NCT03967600||Hidradenitis Suppurativa Patients|Patients with physician diagnosed Hidradenitis Suppurativa
11115392|NCT03967600||Healthy Volunteers|Healthy volunteers without any skin conditions or recent history of antibiotic use.
11115393|NCT03967587|Experimental|Neosense Umbilical Catheter|
11115394|NCT03967574|Experimental|Real tDCS|Participants received the full tDCS intervention for a total of 20 minutes, one time, two weeks following the CSI
11115395|NCT03967574|Sham Comparator|Sham tDCS|The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
11115396|NCT03967574|No Intervention|Control|Participants received no further intervention two weeks following their CSI
11115397|NCT03967561|Experimental|Progressive aerobic training|Water-based aerobic training performed with progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
11115398|NCT03967561|Experimental|Non-progressive aerobic training|Water-based aerobic training performed without progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
11115399|NCT03967548|Experimental|0.004% single-dose|96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).
11115400|NCT03967535||Control|Individuals between 45-85 years old with no diagnosis of dementia. No intervention used
11115401|NCT03967535||Dementia|Individuals between 45-85 years old with a diagnosis of dementia. No intervention used
11115402|NCT03967522|Experimental|Cabozantinib treatment|All participants will be treated by 60 mg of cabozantinib once daily.
11115403|NCT03967509|Experimental|Behavioral teacher training|Behavioral preschool teacher training (BPTT) delivered in an educational group format during nine 2,5-hour biweekly sessions with training at sessions and in between followed by supervisor's feedback on the practice and two optional coaching occasions on the spot.
11115404|NCT03967509|No Intervention|Waiting list control group|Preschool teachers worked with children as usual.
11115405|NCT03967496||No Delirium|No Delirium: CAM-ICU score of less than 3 throughout Post-Anesthesia Care Unit stay
11115406|NCT03967496||Initial Delirium|Initial Delirium: CAM-ICU score of 3 or more at 15 minutes following end of anesthesia and/or at 30 minutes following end of anesthesia
11115407|NCT03967496||Delirium|Delirium: CAM-ICU score of 3 or more immediately prior to discharge from Post-Anesthesia Care Unit
11115408|NCT03967470|Placebo Comparator|Placebo arm|Placebo spray used during one month
11115409|NCT03967470|Active Comparator|Treatment arm|Bacteria spray used during one month
11115410|NCT03967444|Other|Restylane Kysse|Hyaluronic acid
11115411|NCT03967444|Other|Restylane Kysse with other HA|Hyaluronic acid
11115412|NCT03967431|Experimental|Narrative Enhancement and Cognitive Therapy group|The patients in the experimental group received narrative enhancement and cognitive therapy which contains 20 times group meetings.
11115413|NCT03967431|No Intervention|Control group|The patients in the control group received routine care.
11115414|NCT03967418|Other|Patients with behavioral addictions|Patients suffering from behavioural addiction (sexual addiction, excessive use of video games and eating disorders with bulimia episodes) will be recruited
11115415|NCT03967418|Other|Healthy volunteers|Healthy volunteers will be matched on gender, age and education level to patients
11115416|NCT03967392|Active Comparator|GROUP X(xylocaine)|20 ml bupivacaine 0.5% + 20 ml normal saline.
11115417|NCT03967392|Active Comparator|GROUPX(Dxylocaine and dexamethasone)|20 ml bupivacaine 0.5% + 18 ml normal saline + 8 mg dexamethasone 2 ml
11115418|NCT03967379|Experimental|Mobile app plus enhanced standard care|"Patients will received enhanced standard care in addition to access to the sexual health mobile app.
~The app will also prompt patients to engage their partners with specific exercises."
11115419|NCT03967379|Other|Enhanced Standard Care|"Patients will receive Enhanced Standard Care
~Patients will meet with a transplant clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or vulvovaginal GVHD
~Patients will not have access to the sexual health mobile app"
11115420|NCT03967366||plasma melatonin 1|Quartile 1 of plasma melatonin
11115421|NCT03967366||plasma melatonin 2|Quartile 2 of plasma melatonin
11115422|NCT03967366||plasma melatonin 3|Quartile 3 of plasma melatonin
11115423|NCT03967366||plasma melatonin 4|Quartile 4 of plasma melatonin
11115424|NCT03967353|No Intervention|Routine Treatment Group|Routine treatment group(6 months treatment regimen-2HRZE/4HR); Routine health education; Dose-taken supervised by family members
11115425|NCT03967353|Experimental|Intervention Group|Using mobile technology management means to manage newly treated smear-positive tuberculosis patients, to guide patients'treatment, infection control, doctor-patient communication, and to strengthen health education on infection control of patients.
11115426|NCT03967340||Lung transplant|
11115427|NCT03967327|Active Comparator|MOR SR|"This arm includes MOR SR and placebo for BUP TDS, detailed information is as below:
~Treatment dosage form dosage frequency duration MOR SR Tablet 10,30,60mg q12h 8 weeks
~Placebo for Patch -- every 3-4 days 8 weeks BUP TDS"
11115428|NCT03967327|Experimental|BUP TDS|"This arm includes BUP TDS and placebo for MOR SR, detailed information is as below:
~Treatment dosage form dosage frequency duration Placebo for Tablet -- q12h 8 weeks MOR SR
~BUP TDS Patch 20/30/40mg every 3-4 days 8 weeks"
11115429|NCT03967314|Active Comparator|Group T = TLIP block group|After the induction of anesthesia and placement of the patient in a prone position, US-guided mTLIP block was performed via the lateral approach in group T. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
11115430|NCT03967314|Active Comparator|Group W = Wound infiltration group|After the induction of anesthesia and placement of the patient in a prone position wound infiltration was performed in group W. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
11115431|NCT03967301|Experimental|Probiotic isolated intestinal bacteria (active)|Patients randomized to active arm, will consume 5ml every 12 hours per day of a suspension of probiotics (Bioflora ® Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis y Bifidobacterium brevis) for 14 days.The content of each bottle is reconstituted up to 50 ml (10 doses) with drinking water The prescription of the intervention will be carried out and monitored through the electronic medical record. In the hospital setting, the probiotic is reconstituted by the nursing staff. If the patient is discharged before this period the patient and family will be instructed to perform the reconstitution at home.
11115432|NCT03967301|Placebo Comparator|Placebo|Patients randomized to the placebo arm, will consume 5ml every 12 hours per day of a suspension of placebo for 14 days. The prescription of the intervention will be carried out and monitored through the electronic medical record.
11115433|NCT03967288|Experimental|Chloroprocaine|50 mg of 1% spinal chloroprocaine (5 mL) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
11115434|NCT03967288|Active Comparator|Bupivacaine|10.5 mg of spinal hyperbaric bupivacaine (1.4 mL of 0.75% bupivacaine hydrochloride in 8.25% dextrose) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
11115435|NCT03967262|Experimental|Intervention|
11115436|NCT03967262|No Intervention|Control|
11115437|NCT03967249|Experimental|IONIS GHR-LRx + SRL|IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.
11115438|NCT03967223|Experimental|Substudy 1: letetresgene autoleucel|Participants with previously untreated advanced metastatic synovial sarcoma will receive letetresgene autoleucel, administered as a single intravenous (IV) infusion.
11115439|NCT03967223|Experimental|Substudy 2: letetresgene autoleucel|Participants with advanced metastatic synovial sarcoma who have progressed following treatment with anthracycline-based chemotherapy will receive letetresgene autoleucel, administered as a single IV infusion.
11115440|NCT03967197|Experimental|Lidocaine|Patients randomized to the lidocaine intervention will receive 2 sprays of lidocaine hydrochloride 10% in each nostril 3-5 minutes before their test.
11115441|NCT03967197|Placebo Comparator|Placebo (Saline)|Patients randomized to placebo will receive 2 sprays of physiological saline in each nostril 3-5 minutes before their test.
11115442|NCT03967171|Experimental|before uterine incision oxytocin group|IV infusion of 20 IU of oxytocin started before uterine incision
11115443|NCT03967171|Active Comparator|after clamping the umbilical cord oxytocin group|IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord
11115444|NCT03967158||Consecutive percutaneous coronary intervention|
11115445|NCT03967132|Active Comparator|Control Infant Formula|Milk-based infant formula
11115446|NCT03967132|Experimental|Experimental Infant Formula|Milk-based Infant Formula with oligosaccharides
11115447|NCT03967132|Other|Reference Group|Human-milk fed
11115448|NCT03967119||Laparoscopic surgery|"The following parameters are assessed and recorded at the following time points in all participants.
~The parameters assessed: mean arterial pressure, heart rate, pulse oxygen saturation, SVV, PPV, PWV, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, respiratory rate (all dynamic variables are assessed at two levels of tidal volume- 6 ml/kg and 12 ml/kg).
~The time points: T0, before anesthetic induction; T1, immediately after anesthetic induction; T2, immediately after pneumoperitoneum; T3, 10 min before desufflation; T4, immediately after desufflation.
~The desufflation-induced hypotension is defined as more than 20 % decrease in MAP at T4 from MAP at T3."
11115449|NCT03967106|Experimental|Remote Ischaemic preconditioning|Remote IPC (RIPC) intervention daily for six weeks.
11115450|NCT03967106|Sham Comparator|Sham|Remote sham intervention daily for six weeks.
11115451|NCT03967093|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
11115452|NCT03967093|Experimental|Part 2: Ependymoma Patients|Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
11115453|NCT03967093|Experimental|Part 2: Brain Tumor Patients|Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
11115454|NCT03967093|Experimental|Part 2: DIPG Patients|Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
11116158|NCT03962127||First time ischemic stroke|Patients with a first event of ischemic stroke admitted to hospitals in Central Norway.
11115455|NCT03967093|Experimental|Part 2: Other Solid Tumor Patients|Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
11115456|NCT03967054|Experimental|Ivermectin mass drug administration|Ivermectin given monthly from July-October (4 times) as a 3-day course of 300 µg/kg/day to all eligible persons per exclusion/inclusion criteria. Per package insert, dosing of IVM will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
11115457|NCT03967054|Placebo Comparator|Placebo mass administration|Placebo given monthly from July-October (4 times) as a 3-day course to all eligible persons per exclusion/inclusion criteria. Dosing of placebo will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
11115458|NCT03967041||Sarcopenic patients|
11115459|NCT03967041||Non-sarcopenic patients|
11115460|NCT03967028||Study group|primigravida scheduled for cesarean section
11115461|NCT03967015|Experimental|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will receive MUAC training and nutritional education at enrollment. A short message service (SMS) message will be sent at 7 days following enrollment asking them to measure and send their child's MUAC. Weekly SMS messages asking for the child's MUAC measurement will be sent every 7 days until the last study visit at 180 days following enrollment.
11115462|NCT03967015|No Intervention|Standard of care (SOC)|Participants randomized to the standard of care (SOC) arm will receive the same MUAC training and nutritional education as mothers in the MAMMS arm. To accurately simulate community malnutrition outreach programs, no SMS message will be sent to participants in this arm.
11115463|NCT03967002|Experimental|Test group with corticotomy surgery|Orthodontic treatment and minimally invasive corticotomy surgery with piezoelectric device and surgical guide
11115464|NCT03967002|No Intervention|Control group without corticotomy surgery|Standard orthodontic treatment without surgery
11115465|NCT03966989|Experimental|Performance Feedback|Feedback offline either via email or text
11115466|NCT03966989|No Intervention|Control|Standard practice control
11115467|NCT03966976|Experimental|Vitaphone Arm|Follow-up via VITAPHONE in addition to conventional monitoring.
11115468|NCT03966976|Active Comparator|Conventional Arm|Conventional follow-up
11115469|NCT03966963|Experimental|Eye Movement Desensitization Reprocessing (EMDR)|Subjects with trauma-related symptomology resultant from CSA will undertake EMDR; they will be systematically observed through use of their quantitative treatment outcome measures at both pre- and post- treatment alongside one-month follow-up interview data to determine outcomes of interest (namely emotional, behavioural and neuropsychological functioning).
11115470|NCT03966950|Experimental|melatonin group|for the melatonin group, 10 mg of melatonin will be taken per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
11115471|NCT03966950|Placebo Comparator|placebo group|For the placebo group, placebo will be administered per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
11115472|NCT03966937|Experimental|Dry needling|The experimental group will receive dry needling over trigger points of Quadriceps muscles along with therapeutic exercises.
11115473|NCT03966937|Active Comparator|Control|The control group will only receive standardized therapeutic exercises for Patellofemoral pain syndrome.
11115474|NCT03966924|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
11115475|NCT03966911|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) over 7 days and participate in FSTs.
11115476|NCT03966898|Experimental|SHR6390, Letrozole or Anastrozole|SHR6390, Letrozole or Anastrozole
11115477|NCT03966898|Placebo Comparator|Placebo, Letrozole or Anastrozole|Placebo, Letrozole or Anastrozole
11115478|NCT03966885|Experimental|Brief Intervention (BI)|30 minute alcohol brief intervention delivered by lay provider during HIV clinic visit.
11115479|NCT03966885|Experimental|Brief Intervention + CETA|30 minute alcohol brief intervention delivered by lay provider during clinic visit followed by 6-12 weekly sessions of CETA.
11115480|NCT03966872|Experimental|Integrated Illness Management and Recovery (I-IMR):|Participants assigned to I-IMR will receive 2 individual sessions to discuss principles of recovery and set personally meaningful goals, with the remainder of the 14 I-IMR sessions delivered in groups of 8-10 (to enable individual tailoring)
11115481|NCT03966872|Experimental|Stanford Chronic Disease Self-Management Program (CDSMP):|Participants randomly assigned get a 6-session group-based educational program co-delivered by two peers (lay people who have successfully managed a chronic illness) or a peer and a professional
11115482|NCT03966859|Placebo Comparator|Placebo|Participants will receive lactose placebo tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
11115483|NCT03966859|Experimental|Atorvastatin|Participants will receive 20mg atorvastatin tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
11115484|NCT03966846|Experimental|Kefir Group|Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
11115485|NCT03966846|Placebo Comparator|Control Group|Control group received one bottle of milk (180 ml) daily for 12 weeks.
11115526|NCT03966560|No Intervention|Healthy|Healthy volunteers who do not have systemic disease that may affect the choroidal thickness and have no ocular features that may affect test measurements.
11115527|NCT03966547|Experimental|Local anesthetic|
11115528|NCT03966547|Placebo Comparator|Isotonic NaCl|
11115529|NCT03966534|No Intervention|Control Group|Blood culture obtained as first test after venipuncture and prior to biochemistry test
11115530|NCT03966534|Experimental|Diversion Group|Biochemistry test obtained as first test after venepuncture and prior to blood culture
11115531|NCT03966508|Experimental|hyperalgesia measurement|
11115486|NCT03966833|Experimental|group-based interpersonal therapy (IPT-G)|14 weeks of group-based interpersonal therapy (IPT-G): StrongMinds is focused on treating depression in Uganda by training community members (in this case ELA club mentors) to act as mentors in IPT-G techniques. This intervention will be offered to 13-19 year old young women who score a 10 or higher on the PHQ-8. These adolescents who take up the offer will then be enrolled in the 14 weeks of therapy. Group therapy sessions build bonds between young women and encourage them to actively engage in the healing process and to support each other in the exploration of their depression triggers. With new healthier patterns and skills, women can learn to manage their current depression and ensure future depressive episodes can be quickly identified and resolved before the onset of any long-term consequences.
11115487|NCT03966833|Experimental|IPT-G + Unconditional Cash Transfer:|A one time lump sum of 200,000 UGX (~$54) be provided to all study participants in a random sub-set of intervention (IPT-G) clusters near or at the conclusion of the 14-week therapy. This treatment variation will allow for determination of whether complimentary income support enhances the effects of IPT-G on psychological wellbeing and other outcomes of interest.
11115488|NCT03966833|No Intervention|control|ELA clubs function as normal
11115489|NCT03966807||Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
11115490|NCT03966807||traditional-based support +nicotine replacement therapy(NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
11115491|NCT03966794|Experimental|Epidural Electrical Stimulation|
11115492|NCT03966794|Experimental|Functional scaffold & Epidural Electrical Stimulation|
11115493|NCT03966781|Active Comparator|ESWL followed by ERCP|Patients enrolled in the active treatment group will be subjected to ESWL followed by ERCP and pancreatic duct stenting.
11115494|NCT03966781|Sham Comparator|Sham ESWL followed by sham ERCP|Patients enrolled in the sham treatment group will be subjected to sham ESWL followed by sham ERCP with no pancreatic duct intervention.
11115495|NCT03966768|Experimental|Duramesh suturable mesh for laparotomy closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be closed with Duramesh suturable mesh.
11115496|NCT03966768|Experimental|Conventional suture closure for laparotomy closure|Patients randomized to conventional laparotomy closure will be closed using size 1 slowly-absorbing polydiaxonone (PDS) single strand or looped suture, based on surgeon preference.
11115497|NCT03966768|Experimental|Open abdomen group closed in delayed fashion with Duramesh|Patients undergoing delayed primary closure of an open abdomen will also be studied. 20 study patients undergoing delayed primary closure of an open abdomen will be closed with Number 1 or Number 2 Duramesh
11115498|NCT03966755|Experimental|UFA dietary recommendations|Dietary intervention aimed at increasing UFA consumption.
11115499|NCT03966755|No Intervention|Standard dietary recommendations|Standard of care dietary recommendations as currently performed in the clinic (2015-2020 United States Department of Agriculture (USDA) Dietary Guidelines for Americans)
11115500|NCT03966742|Experimental|Treatment|Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
11115501|NCT03966729||HFrEF|"HFrEF (Heart failure with reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF < 40%.
~LVEF = Left ventricular ejection fraction"
11115502|NCT03966729||HFmrEF|"HFmrEF (Heart failure with mid-range reduced ejection fraction): ESC Guideline heart failure 2016: patients with LVEF 40-49%.
~LVEF = Left ventricular ejection fraction"
11115503|NCT03966729||HFpEF|"HFmrEF (Heart failure with preserved ejection fraction): ESC Guideline heart failure 2016: patients with LVEF > 50%.
~LVEF = Left ventricular ejection fraction"
11115504|NCT03966716|Experimental|Arthroplasty|Arthroplasty, hemi or total depending on patient characteristics and surgeon's choice
11115505|NCT03966716|Active Comparator|Internal Fixation|Internal fixation with 2-3 screws or pins, or sliding hip screw device, depending on each hospital's routine
11115506|NCT03966703|Experimental|conventional denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
11115507|NCT03966703|Experimental|implant fixed denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
11115508|NCT03966690|Experimental|leg curl device starters|Group A randomly assigned to start with legcurl device
11115509|NCT03966690|Experimental|legpress device starters|Group A randomly assigned to start with legpress device
11115510|NCT03966677||P-GHR|Patients with persistent severe pain after groin hernia repair.
11115511|NCT03966677||NP-GHR|Patients without pain after groin hernia repair.
11115512|NCT03966677||NP|Healthy non-operated controls
11115513|NCT03966664||Septic patients|Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
11115514|NCT03966664||Healthy controls|Age and sex matched healthy volunteers.
11115515|NCT03966664||Non septic patients|Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
11115516|NCT03966651|Experimental|PRRT with 177Lu-DOTATATE|
11115517|NCT03966638||Patients receiving platelet rich plasma|The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.
11115518|NCT03966599|Active Comparator|Lateral position|The patient position was changed to lateral during surgery
11115519|NCT03966599|Active Comparator|prone position|The patient position was changed to prone during surgery
11115520|NCT03966586|Experimental|Enhanced Care|Usual clinical care + intervention components
11115521|NCT03966586|Active Comparator|Usual Care|Usual clinical care and counseling
11115522|NCT03966573|Other|Evaluating function|tests for lower extremity function
11115523|NCT03966573|Other|Radiographic imaging|Evaluating arthritis of hip and knee, leg length discrepancy and axis deviation
11115524|NCT03966573|Other|Forms|Evaluating quality of life, function and pain
11115525|NCT03966560|Experimental|Primary open-angle glaucoma|"Participants over 40 years of age and diagnosed with primary open-angle glaucoma.
~Medical treatment was initiated for the diagnosed participants."
11115532|NCT03966495||PRisM program|"Pluriprofessional primary care offices with the PRiSM RM program:
~Nine of the pluriprofessional primary care offices which implemented the RM program tested in the PRiSM study (2015-2017). The program consisted in: 1) Training on RM in the context of primary care; 2) The appointment of a RM referent in the office; 3) The conduct of six incident review meetings.
~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.
~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
11115533|NCT03966495||Control|"Pluriprofessional primary care offices without the PRiSM RM program:
~Nine of the offices pluriprofessional primary care offices which didn't implement the RM program tested in the PRiSM study (2015-2017). They belonged to the PRisM study control group.
~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.
~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
11115534|NCT03966482|Experimental|Group before-after|Speech therapy with Semiocluded vocal tract exercise.
11115535|NCT03966469||Support Person Present|Participants who bring a support person with them to their preoperative appointment.
11115536|NCT03966469||Patient Present Only|Participants who present by themselves to their preoperative appointment.
11115537|NCT03966456||nivolumab|Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
11115538|NCT03966456||pembrolizumab|Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
11115539|NCT03966456||toripalimab|Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
11115540|NCT03966456||sintilimab|Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
11115541|NCT03966430|Experimental|damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the damage control surgery group.
11115542|NCT03966430|Sham Comparator|non-damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the non-damage control surgery group.
11115543|NCT03966417|Active Comparator|Exercise training group|"Patient to be randomized to exercise training group will have exercise training sessions 2 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 75% of Vo2max."
11115544|NCT03966417|No Intervention|Usual care group|"Patient to be randomized to usual care group will undergo standard care fo 12 weeks."
11115545|NCT03966391|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/ fear/fainting mitigation interventions from CARD during vaccination)
11115546|NCT03966391|No Intervention|Control (standard care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
11115547|NCT03966378|Experimental|Grape seeds extract|Every week the grape seeds extract (gel) put into the tray and apply it to the upper teeth of the participant.
11115548|NCT03966378|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste apply to the teeth twice daily.
11115549|NCT03966365|Experimental|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
11115550|NCT03966365|Active Comparator|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
11115551|NCT03966339|Experimental|GH group|Growth Hormone adding to controlled ovarian hyperstimulation
11115552|NCT03966339|No Intervention|control group|regular controlled ovarian hyperstimulation
11115553|NCT03966326|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
11115554|NCT03966326|Active Comparator|PECS II group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
11115555|NCT03966300|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination)
11115556|NCT03966300|No Intervention|Control (standard/usual care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
11115557|NCT03966274||Delirium positive|
11115558|NCT03966274||Delirium negative|
11115559|NCT03966248|Experimental|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
11115560|NCT03966248|Active Comparator|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
11115561|NCT03966235|Experimental|Melatonin group|drug: melatonin tablets (Sigma-Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.
11115562|NCT03966235|Placebo Comparator|Control group|drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.
11115563|NCT03966222|Active Comparator|Open vein harvest|For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.
11115564|NCT03966222|Experimental|Endoscopic vein harvest|We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.
11115565|NCT03966209|Experimental|treatment|JS001（PD-1 inhibitor）, 240mg I.V. Q3W,
11115568|NCT03966183||UVFP patients post thyroplasty|Patients in this group are adults who have undergone type I medialization thyroplasty (with Montgomery implant, silicone implant, follow-up of more than 3 months) as a definitive procedure following unilateral vocal fold paralysis.
11115569|NCT03966183||Control participants|The people in this group are control subjects of the same age, sex and manual laterality as the patients.
11115570|NCT03966170|Experimental|Citicoline|Citicoline as neuroprotector
11115571|NCT03966170|Placebo Comparator|Placebo drug|Placebo
11115572|NCT03966157|Experimental|Nasal Bridle|Patients randomized to have nasal bridle.
11115573|NCT03966157|No Intervention|Standard|Patients randomized with adhesive tape.
11115574|NCT03966144|Experimental|RoboHear Device|Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words.
11115575|NCT03966131|Experimental|patients with complete denture for the first time|Arm that allows to follow the adaptation of this population to the new complete denture during the tasks of speech production and swallowing.
11115576|NCT03966131|Experimental|patients with complete denture used to their complete denture.|Arm that allows a descriptive cross-sectional study of tongue pressure measurements during the tasks of speech production and swallowing
11115577|NCT03966118|Experimental|Ramucirumab + Avelumab + Paclitaxel|Single-Arm
11115578|NCT03966105||Patients with CTS surgery indication|
11115579|NCT03966105||Patients with LSS surgery indication|
11115580|NCT03966092|No Intervention|Usual practice|Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations
11115581|NCT03966092|Experimental|QLB block|"Patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.
~In addition, patients receiving a bilateral QLB at the end of the surgery"
11115582|NCT03966079|Experimental|Intervention arm|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
11115583|NCT03966066|Experimental|low dose erythromycin group|Erythromycin 3-5mg/kg.d orally for 6 months
11115584|NCT03966066|No Intervention|Non-erythromycin treatment group|systemic treatment
11115585|NCT03966053|Experimental|Cohort A|"Cohort A: Three subjects will receive Trifluoperazine (TFP) 1 mg PO daily.
~If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort B will start.
~If 1/3 subjects in Cohort A demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort A.
~If 2 or more of the 6 subjects in Cohort A demonstrate toxicity Grade 3, the trial will be stopped; no MTD will be declared.
~If less than 2 of the 6 subjects in Cohort A demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort B will start."
11115586|NCT03966053|Experimental|Cohort B|"Cohort B: Three subjects will receive TFP 2 mg PO daily.
~If there is no non-neurologic toxicity Grade 3 at the end of the 21 days, Cohort C will start.
~If 1/3 subjects in Cohort B demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort B:
~If 2 or more of the 6 subjects in Cohort B demonstrate toxicity Grade 3, the study will be stopped, and 1 mg/day will be declared the MTD.
~If < 2 of the 6 subjects in Cohort B demonstrate toxicity Grade 3 within 21 days of starting therapy, Cohort C will start."
11115587|NCT03966053|Experimental|Cohort C|"Cohort C: Three subjects will receive TFP 5 mg PO daily.
~If there is no non-neurologic toxicity ≥ Grade 3 at the end of the 21 days, Cohort D will start.
~If 1/3 subjects in Cohort C demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort C:
~If 2 or more of the 6 subjects in Cohort C demonstrate toxicity Grade 3, the study will be stopped, and 2 mg/day will be declared the MTD.
~If < 2 of the 6 subjects in Cohort C demonstrate toxicity Grade 3 within 21 days of starting therapy, cohort D will start."
11115588|NCT03966053|Experimental|Cohort D|"Cohort D: Three subjects will receive TFP 10 mg PO daily.
~If 0/3 subjects in Cohort D demonstrates toxicity Grade 3, the study will be stopped, and 10 mg/day will be declared the MTD.
~If 1/3 subjects in Cohort D demonstrates toxicity Grade 3, an additional 3 subjects will be enrolled in Cohort D.
~If 2 or more of the 6 subjects in Cohort D demonstrate toxicity Grade 3, the study will be stopped, and 5 mg/day will be declared the MTD.
~If <2 of the 6 subjects in Cohort D demonstrate toxicity > Grade 3 within 21 days of starting therapy, 10mg/day will be declared the MTD."
11115589|NCT03966040|Experimental|Immunization schedule of day 0-3-7|Three doses of schedule given at day 0, 3 and 7.
11115590|NCT03966040|Experimental|Immunization schedule of day 0/0-3-7|Four doses of schedule given at day 0/0, 3 and 7.
11115591|NCT03966040|Experimental|Immunization schedule of day 0/0-7|Three doses of schedule given at day 0/0 and 7.
11115592|NCT03966040|Experimental|Immunization schedule of day 0/0-7-14|Four doses of schedule given at day 0/0, 7 and 14.
11115593|NCT03966027|Experimental|Hindfoot Offloading Braces / Immediate Weight-bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
11115594|NCT03966027|Placebo Comparator|No Hindfoot Offloading Braces / Delayed Weight-Bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
11115595|NCT03966014|Active Comparator|EM-amoxicillin 3 x 10 days|
11115596|NCT03966014|Active Comparator|EM-amoxicillin 3 x 14 days|
11115597|NCT03966014|Active Comparator|EM-amoxicillin 2 x 14 days|
11115598|NCT03966014|Other|Controls|
11115599|NCT03966001||Planned Cesarean Group|Pregnant women undergoing a planned cesarean section at 38-42 gestational week.
11115600|NCT03966001||Emergency Cesarean Group|Pregnant women who are planning to give normal birth between 38-42 weeks of gestation but have to been performed an urgent cesarean section due to an emergency such as acute fetal distress, cephalo-pelvic disproportion or another obstetrical condition.
11115601|NCT03965988|Experimental|Docosahexaenoic Acid|Docosahexaenoic acid
11115602|NCT03965988|Placebo Comparator|Placebo drug|Placebo
11115635|NCT03965858|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115603|NCT03965975|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated urine cups. The urine sample was then sent the Lab and tested sequentially; first by the golden standard techniques used by the Lab (first intervention) and by the S-There device (comparative device - second intervention).
11115604|NCT03965962|Experimental|Group 1: VRVg-2 + HRIG|VRVg-2 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28 + Human Rabies Immunoglobulins (HRIG) single injection at Day 0
11115605|NCT03965962|Active Comparator|Group 2: Verorab + HRIG|Verorab 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28 + HRIG single injection at Day 0
11115606|NCT03965962|Active Comparator|Group 3: Imovax Rabies + HRIG|Imovax Rabies 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28 + HRIG single injection at Day 0
11115607|NCT03965962|Experimental|Group 4: VRVg-2|VRVg-2 5 injections at Day 0, Day 3, Day 7, Day 14 and Day 28
11115608|NCT03965949||Group 1|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support
11115609|NCT03965949||Group 2|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)
11115610|NCT03965949||Group 3|Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)
11115611|NCT03965949||Group 4|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
11115612|NCT03965936|Placebo Comparator|lipofilling|subcutaneous injection of lipoaspiate (microfat) in one temporal region
11115613|NCT03965936|Active Comparator|lipofilling enriched with adipose tissue derived stem cells|subcutaneous injection of lipoaspiate enriched with adipose tissue derived stem cells in one temporal region
11115614|NCT03965923|Experimental|Cohort 1: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115615|NCT03965923|Experimental|Cohort 1: Truvada Tablet|Participants in Cohort 1 (36 0/7 weeks - 37 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115616|NCT03965923|Experimental|Cohort 2: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115617|NCT03965923|Experimental|Cohort 2: Truvada Tablet|Participants in Cohort 2 (30 0/7 weeks - 35 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115618|NCT03965923|Experimental|Cohort 3: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 3 (20 0/7 weeks - 29 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115619|NCT03965923|Experimental|Cohort 3: Truvada Tablet|Participants in Cohort 3 (20 0/7 weeks - 29 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115620|NCT03965923|Experimental|Cohort 4: Dapivirine (DPV) Vaginal Ring (VR)|Participants in Cohort 4 (12 0/7 weeks - 19 6/7 weeks) will use one DPV VR continuously for approximately one month, replacing the DPV VR each month. Participants will use the DPV VR until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115621|NCT03965923|Experimental|Cohort 4: Truvada Tablet|Participants in Cohort 4 (12 0/7 weeks - 19 6/7 weeks) will take one Truvada oral tablet daily. Participants will take Truvada until their pregnancy outcome but no later than 41 6/7 weeks of gestation.
11115622|NCT03965910|Other|group 1|Group 1:Early rehabilitation
11115623|NCT03965910|Other|group 2|Group 2:Late rehabilitation
11115624|NCT03965897|Active Comparator|Attention Control (AC)|The primary purpose of this workshop is to provide attention and education to participants. Topics of discussion will include: a) the pathophysiology of postoperative pain and how it differs from preoperative pain, b) the role of contextual factors (e.g., depressive or anxiety symptoms, expectation) on the experience of pain, d) the role of inflammation in pain and healing, e) types of pain medications and other pain relief strategies provided following surgery, and f) goals of pain medications. Additionally, deep (diaphragmatic) breathing strategies will be taught and a progressive muscle relaxation exercise will be performed in the workshop at strategic times to maintain Veteran engagement.
11115625|NCT03965897|Experimental|Acceptance and Commitment Therapy (ACT)|"The ACT intervention will include: 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts such as I can't take this pain anymore or This is unfair) and learning how to willingly face experiences that cannot be changed; and 2) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise. The workshop will also include information on pain and pain control post-TKA."
11115626|NCT03965884|Experimental|lumbal stabilization exercise group|
11115627|NCT03965884|Experimental|connective tissue massage group|
11115628|NCT03965884|No Intervention|control group|
11115629|NCT03965871|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115630|NCT03965871|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115631|NCT03965871|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115632|NCT03965871|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115633|NCT03965858|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115634|NCT03965858|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115636|NCT03965858|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
11115637|NCT03965845|Experimental|Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg|
11115638|NCT03965845|Experimental|Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg|
11115639|NCT03965845|Experimental|Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg|
11115640|NCT03965845|Experimental|Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg|
11115641|NCT03965845|Experimental|Part 2: Expansion|The recommended phase 2 dose (RP2D) determined from Part 1 will be the treatment for all cohorts in expansion Part 2.
11115642|NCT03965832|Experimental|HFNT|Patients who meet the eligibility criteria will be randomized to receive HFNT and then crossover to other device during the study procedures.
11115643|NCT03965832|Experimental|Standard oxygen|Patients who meet the eligibility criteria will be randomized to receive Standard oxygen and then crossover to HFNT during the study procedures.
11115644|NCT03965819|Experimental|Randomized to consume Pain Bloc-R, Acetaminophen, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Investigational Natural Health Product in Study Period 1, Comparator in Study Period 2, and Placebo in Study Period 3.
11115645|NCT03965819|Experimental|Randomized to consume Acetaminophen, Placebo, then Pain Bloc-R|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Comparator in Study Period 1, Placebo in Study Period 2, and the Investigational Product in Study Period 3.
11115646|NCT03965819|Experimental|Randomized to consume Placebo, Pain Bloc-R, then Acetaminophen|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Investigational Product in Study Period 2, and Comparator in Study Period 3.
11115647|NCT03965793|Active Comparator|Manual management of hypotension|Fluid and vasopressor will be managed as standard practice ( manually infusion of both fluid and vasopressors) following the investigators manual individualized hemodynamic protocol.(objective being to keep both stroke volume and MAP within 90 % of the target values)
11115648|NCT03965793|Experimental|Automated management of hypotension|Fluid and vasopressor will be managed with a novel active clinical decision support system to guide fluid administration and automated closed-loop system to maintain MAP within 90% of patient' baseline.
11115649|NCT03965780|Experimental|Training group|Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.
11115650|NCT03965780|No Intervention|Wait-list control group|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above.
11115651|NCT03965767|Placebo Comparator|control|
11115652|NCT03965767|Active Comparator|local group|
11115653|NCT03965767|Active Comparator|systemic group|
11115654|NCT03965767|Active Comparator|combined local and systemic|
11115655|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
11115656|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
11115657|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
11115658|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
11115659|NCT03965741||Men with Prostate Cancer (PCa)|
11115660|NCT03965741||Men without PCa|
11115661|NCT03965728|Experimental|Dose group 1 of BAY1830839|Period 1: Dose 1, single dose Period 2: Dose 1, once daily over 10 days.
11115662|NCT03965728|Experimental|Dose group 2 of BAY1830839|Period 1: Dose 2, single dose Period 2: Dose 2, once daily over 10 days.
11115663|NCT03965728|Experimental|Dose group 3 of BAY1830839|Period 1: Dose 3, single dose Period 2: Dose 3, once daily over 10 days.
11115664|NCT03965728|Experimental|Dose group 4 of BAY1830839|Period 1: Dose 4, single dose Period 2: Dose 4, twice daily over 10 days.
11115665|NCT03965728|Experimental|Dose group 5 of BAY1830839|Period 1: Dose 5, single dose Period 2: Dose 5, twice daily over 10 days.
11115666|NCT03965728|Placebo Comparator|Placebo|Placebo tablets matching BAY1830839
11115667|NCT03965715|No Intervention|Gait analysis with barefoot|Participants walk without assistance under gait detection.
11115668|NCT03965715|Experimental|Gait analysis with AFOs|Participants walk with AFOs under gait detection.
11115669|NCT03965715|Experimental|Satisfaction questionnaire|User feedback from the participants was obtained by questionnaire, the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and SF-36, to compare the satisfaction of AFOs
11115670|NCT03965702|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
11115671|NCT03965702|Experimental|EV1000 monitoring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
11115672|NCT03965689|Experimental|Treatment (paclitaxel, carboplatin, pevonedistat)|Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30-60 minutes on day 1, and pevonedistat IV over 1 hour on days 1, 3, and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
11115673|NCT03965676|Other|Adult patients with a tophaceous gout|Adult patients with a tophaceous gout but no urate-lowering treatment or treatment but target not reached (target = uricemia < 360µmol/L).
11115674|NCT03965663|Experimental|Trans-tibial Amputees|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living
11115675|NCT03965663|Experimental|Trans-tibial Amputees with TSR|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living. The subjects underwent a functional nerv-transfer surgery prior to participation, where the proximal part of the sural nerv was to the distal part of the saphenous nerv.
11115676|NCT03965650|Experimental|Intervention group: video coaching exercises|Video coaching exercises group: patients will perform physical exercises according to a video coaching program 3 times weekly during 6 months. The on-line program has been designed especially for this study.
11115677|NCT03965650|Active Comparator|Control group: routine exercises|Routine method advising and encouraging patients to perform physical activities according to the WHO recommendations during 3 months then to follow the video coaching physical exercises program during 3 months.
11115678|NCT03965637|Experimental|vitamin C|Intervention patients will be received double dose of Ascorbic acid via intravenous injection
11115679|NCT03965637|No Intervention|Control|Control patients will not be received any intervention
11115680|NCT03965624|Experimental|Ixazomib|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see below) or de-escalation in case of response and severe adverse events.
11115681|NCT03965611||Patients with isolated severe traumatic brain injury (TBI)|TBI with initial Glasgow Coma Scale (GCS) ≤ 8 and AISextrahead score ≤3. Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
11115682|NCT03965611||Patients with severe trauma without TBI|Patients with severe trauma without TBI (AISextrahead score > 3). Oropharyngeal and rectal swabs will be performed for each patient within the first 24 hours after ICU admission (day 0), then 48 hours (day 2) and 7 days (day 7) after ICU admission and weekly thereafter until ICU discharge.
11115683|NCT03965611||Healthy Controls|"Persons who have not had the conditions being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements.
~Oropharyngeal and rectal swabs will be taken only once, at inclusion, after that the participation of the control individual in the trial will be completed."
11115684|NCT03965598||Ultra-high risk for psychosis (UHP)|"Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia.
~Inclusion Criteria: age of 13-30 years; meet the diagnostic criteria of COPS prodromal syndrome by SIPS clinical interviews; have not received any psychiatric medication; be in good health, without major mental illness or physical illness; normal intelligence, can be operated on a clinical scale; volunteer to participate in the study and sign the written consent form.
~Exclusion criteria: exclusion of current or previous psychiatric disorders by SCID interview; meet the diagnostic criteria for substance abuse and substance dependence in DSM-IV; contraindications for MRI; pregnant or lactating women."
11115685|NCT03965598||Healthy controls|"Inclusion Criteria: the gender, age, and education level of the group are matched with the Ultra-high risk group; 13 to 30 years old; right-handed; no history of mental illness; no mental disorder consistent with DSM-IV diagnostic criteria within two or three generations; No contraindications for MRI; volunteer to participate in the study and sign the written consent form.
~Exclusion criteria: history of disturbance of consciousness over 5 minutes; history of brain organic disease or head injury; history of alcohol and drug dependence; history of coma; history of endocrine disease; abnormity in examination of blood, heart, liver, or renal function; pregnant or lactating women."
11115686|NCT03965585||Primary Infertility|Women with a diagnosed primary infertility undergoing hysteroscopy before IVF.
11115687|NCT03965585||Secondary Infertility|Women with a diagnosed secondary infertility undergoing hysteroscopy before IVF.
11115688|NCT03965585||Recurrent miscarriages|Women with recurrent miscarriages undergoing hysteroscopy before IVF.
11115689|NCT03965572||Postpartum women who requested cabergoline|A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression.
11115690|NCT03965572||Control group|An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression.
11115691|NCT03965559||plasmapheresis group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the plasmapheresis during January 2006 to October 2015
11115692|NCT03965559||double filtration plasmapheresis (DFPP) group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the double filtration plasmapheresis (DFPP) during January 2006 to October 2015
11115693|NCT03965546|Experimental|ET140202-T cell combine with Sorafenib|Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion
11115694|NCT03965546|Experimental|ET140202-T cell combine with TAE|TAE treatment ahead every two times of autologous ET140202-T cell administered by intravenous (IV) infusion
11115695|NCT03965546|Experimental|solo ET140202-T cell|autologous ET140202-T cell administered by intravenous (IV) infusion
11115696|NCT03965533|Placebo Comparator|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
11115697|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
11115698|NCT03965533|Placebo Comparator|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
11115699|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
11115700|NCT03965533|Placebo Comparator|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
11115701|NCT03965533|Experimental|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
11115817|NCT03964636||combined 1st/2nd generation oral contraceptives intake|
11115818|NCT03964636||3rd/4th generation combined oral contraceptives intake|
11115702|NCT03965533|Experimental|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
11115703|NCT03965520|Active Comparator|usual training|exercise intensity arranged by cardiopulmonary exercise test results
11115704|NCT03965520|Experimental|Novel exercise training|exercise intensity monitor by near-infrared spectrometer
11115705|NCT03965507||The group with sacroiliac joint dysfunction|The patient with sacroiliac joint dysfunction in lumbar disc hernia
11115706|NCT03965507||The group without sacroiliac joint dysfunction|The patient without sacroiliac joint dysfunction in lumbar disc hernia
11115707|NCT03965494|Experimental|AXL inhibitor BGB324 then surgery|Participants receive AXL inhibitor BGB324 PO QD on days 1-5, then undergo surgery 3-6 hours after last dose. Within 45 days, participants receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11115708|NCT03965494|Experimental|Surgery then AXL inhibitor BGB324|Participants undergo surgery, then within 45 days receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11115709|NCT03965481|Experimental|Diagnostic (CECT, PET-MRI)|Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.
11115710|NCT03965468|Experimental|Immunotherapy, chemotherapy, radiotherapy and surgery|"Durvalumab 1500 mg administered intravenously every 3 weeks for the first 4-6 cycles (during chemotherapy);
~4-6 cycles of chemotherapy, carboplatin AUC5 every 3 weeks plus paclitaxel 175 mg/m2, every 3 weeks;
~Stereotactic body radiotherapy (SBRT) of all oligo-metastatic lesions, in a maximum of 10 treatment fractions over 2 weeks, starting after week one of chemotherapy cycle 1 and completed within four weeks after start of durvalumab treatment;
~Restaging at 3 months; if no disease progression, proceed to definitive local treatment (surgical resection of primary tumour or radiotherapy at a minimum dose of 60-66Gy to the primary tumour). Durvalumab continues at 1500 mg intravenously every 4 weeks until progression of disease or for a maximum of 1 year from start of treatment."
11115711|NCT03965455||conventional group|
11115712|NCT03965455||diode laser group|
11115713|NCT03965442||Control|"Patients who underwent mastectomy under standard general anesthesia
~Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump."
11115714|NCT03965442||Esmolol|Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
11115715|NCT03965429||Donor|In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.
11115716|NCT03965429||Receiver|Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used
11115717|NCT03965416|Experimental|Doctor with white coat|Doctor during consultation is wearing a white coat
11115718|NCT03965416|Experimental|Doctor without white coat|Doctor during consultation is not wearing a white coat
11115719|NCT03965403|Experimental|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
11115720|NCT03965390|No Intervention|Classical care pathway|"Patients are following classical care pathway. Before brain surgery patients will be included after oral, medical and life quality evaluation.
~After randomization in the control group, patients will be evaluated at 6, 12 and 24 months after surgery, during classical follow up visits."
11115721|NCT03965390|Experimental|Oral education|"Patients are following classical care pathway but combined at each visit with an oral education Before brain surgery patients will be included after oral, medical and life quality evaluation.
~After randomization in the experimental group, patients will be evaluated at 6, 12 and 24 months after surgery, during classical follow up visits. At each timepoint an oral education will be realized in parallel."
11115722|NCT03965377|Experimental|Home Safety Hero game play|Home Safety Hero is parental psychoeducational computer game to prevent childhood injuries
11115723|NCT03965364||INCRAFT|Endovascular abdominal aortic aneurysm repair
11115724|NCT03965351|Experimental|Single Left Ventricle|We will be recruiting 11 individuals who have a dominant left ventricle. Subjects will receive both the study medication (probenecid) as well as a placebo.
11115725|NCT03965351|Experimental|Single Right Ventricle|We will be recruiting 11 individuals who have a dominant right ventricle. Subjects will receive both the study medication (probenecid) as well as a placebo.
11115726|NCT03965338|Other|fMRI brain activity|screening
11115727|NCT03965312|Experimental|Temperature monitoring (1) and incubator test (2) groups|"In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.
~In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator."
11115728|NCT03965299|Experimental|VERUM transcutaneous tibial nerve stimulation (TTNS)|
11115729|NCT03965299|Sham Comparator|SHAM transcutaneous tibial nerve stimulation (TTNS)|
11115730|NCT03965286||Patients with chronic HCV will be on direct antiviral drugs|is defined as the presence of detectable viral replication for at least six months diagnosed by quantitative HCV RNA polymerase chain reaction (PCR)
11115731|NCT03965273|Experimental|Full TP|Full TP intervention including emphasized social norms change
11115732|NCT03965273|Experimental|Light TP|Light TP intervention without emphasized social norms change
11115733|NCT03965273|No Intervention|Pure control|Pure control
11115734|NCT03965260||Bacteria-infected cirrhotic patients|All kind of etiologies for cirrhosis and all kind of bacterial infections (spontaneous bacterial peritonitis, urinary tract infections, pneumonia, skin and soft tissue infections and spontaneous bacteremia)
11115819|NCT03964623||smokers|
11115735|NCT03965247|Experimental|Lithium|Increasing amounts of lithium for 11 plus or minus 1 day. Day 1: 400 mg at night Day 2: 600 mg at night Day 3-11: 800 mg at night. The lithium intervention was prepared from 200mg Priadel prolonged release tablets. The intervention was provided in blue and white gelatine capsules to be taken orally.
11115736|NCT03965247|Placebo Comparator|Rayotabs|The placebo intervention was 200mg Rayotabs. The intervention was provided in blue and white gelatine capsules to be taken orally - same as the lithium intervention to maintain blinding.
11115737|NCT03965234|Experimental|Prevention (cisplatin, metastasectomy)|Patients undergo pulmonary suffusion consisting of cisplatin via infusion. Patients the undergo metastasectomy. Beginning 4-8 weeks, patients with unresectable sarcoma may receive chemotherapy.
11115738|NCT03965221|Experimental|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
11115739|NCT03965221|Experimental|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
11115740|NCT03965221|No Intervention|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
11115741|NCT03965208|Active Comparator|Unfractionated heparin|Patients randomized to this group will receive anticoagulation with unfractionated heparin
11115742|NCT03965208|Experimental|Bivalirudin|Patients randomized to this group will receive anticoagulation with bivalirudin
11115743|NCT03965195|Experimental|RIV4|Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff
11115744|NCT03965195|Active Comparator|IV4|Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff
11115745|NCT03965182|Active Comparator|PEG group|Patients in the PEG group were instructed to take the first sachet of PEG at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
11115746|NCT03965182|Active Comparator|PEG plus SPMC group|Patients in the PEG plus SPMC group will be instructed to take the SPMC sachet at 19:00 hours the day before colonoscopy and the PEG sachet at 6:00 hours on the morning of the day of colonoscopy.
11115747|NCT03965182|Active Comparator|SPMC group|Patients in the SPMC group were instructed to take the first sachet of SPMC at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
11115748|NCT03965169|Experimental|Patients undergoing prone spinal surgery|Patients undergoing elective spinal surgery in prone position under general anesthesia, which is performed by neurosurgeons in Seoul National University Hospital
11115749|NCT03965156|Active Comparator|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
11115750|NCT03965156|Active Comparator|transversus abdominis plane block|Ultrasound guided transversus abdominis plane block
11115751|NCT03965143||3D talar group|Patients that will undergo a 3D custom talar augment
11115752|NCT03965130|Experimental|Glucagon|Participants will receive glucagon or saline during the PINTA study
11115753|NCT03965117|Experimental|norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect.
11115754|NCT03965104|Experimental|Intervention pharmacists|Will receive the HC-PCP prior to starting enrollment, and then will provide care to their patients, which will include risk assessment, prescribing of antihypertensive medications, and follow-up monthly according to the Hypertension Canada Guidelines.
11115755|NCT03965104|No Intervention|Control pharmacists|Will provide usual pharmacist care. All patients with blood pressure above target will be entered into the study database and serve as the control group. No specific interventions or follow-up will be mandated other than usual pharmacist care, although all patients will be assessed at 3 months to determine change in BP since enrollment (the primary outcome).
11115756|NCT03965091|Experimental|Fremanezumab - Dose A|
11115757|NCT03965091|Experimental|Fremanezumab - Dose B|
11115758|NCT03965091|Placebo Comparator|Placebo|
11115759|NCT03965078||CMO without epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery without evidence of epiretinal membrane at the time of diagnosis.
11115760|NCT03965078||CMO with epiretinal membrane|Subject diagnosed with CMO within 12 weeks of cataract surgery with evidence of epiretinal membrane at the time of diagnosis.
11115761|NCT03965065|Experimental|Sutureless Aortic Valve Prosthesis|Patients receiving sutureless aortic valve prostheses
11115762|NCT03965065|Active Comparator|Conventional Aortic Valve Prosthesis|Patients receiving conventional biological aortic prostheses
11115763|NCT03965052|Experimental|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
11115764|NCT03965052|Active Comparator|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
11115765|NCT03965039|Active Comparator|Marketed stannous fluoride toothpaste|Brush twice daily
11115766|NCT03965039|Active Comparator|Marketed potassium nitrate toothpaste|Brush Twice Daily
11115767|NCT03965039|Placebo Comparator|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
11115768|NCT03965039|Experimental|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
11115769|NCT03965013|Experimental|Part 1 (healthy): NNC0268-0965|A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)
11115770|NCT03965013|Placebo Comparator|Part 1 (healthy): placebo|A single dose of placebo (NNC0268-0965) given s.c.
11115771|NCT03965013|Experimental|Part 2 (type 1 diabetes): NNC0268-0965|A single dose of NNC0268-0965 given s.c.
11115772|NCT03965013|Active Comparator|Part 2 (type 1 diabetes): insulin glargine|A single dose of insulin glargine given s.c.
11115773|NCT03965000||Patients|Patients carrying one or both mutations.
11115820|NCT03964623||vapers|
11115821|NCT03964623||non smokers/non vapers|
11115774|NCT03965000||Controls|Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.
11115775|NCT03964987||Control group|Women with normoevolutionary gestation.
11115776|NCT03964987||Problem group|Patients with GDM.
11115777|NCT03964974|Experimental|CBTi-CB|Cognitive Behavioral Therapy for Insomnia in Cannabis Users
11115778|NCT03964974|Placebo Comparator|Sleep Education|Psycho-education on sleep and sleep hygiene
11115779|NCT03964961|Experimental|Functional massage|
11115780|NCT03964961|Active Comparator|Conventional massage|
11115781|NCT03964948|Other|Healthy Volunteers|20 healthy volunteers will be recruited and will receive a kidney MRI and the same blood and urine labs that are collected for the other arms. Results will be compared to the disease groups.
11115782|NCT03964948|Other|Kidney Transplant|20 subjects that have received a kidney transplant that have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
11115783|NCT03964948|Other|Stage 2-5 CKD|20 subjects that have been diagnosed with stage 2-5 CKD and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
11115784|NCT03964948|Other|Lupus nephritis|"20 subjects that have that have active lupus nephritis and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
~Subjects that are post-lupus treatment will receive an additional MRI at the time of the next biopsy."
11115785|NCT03964935|Experimental|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.
~After scaling, root planing, and polishing (SRP), the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
11115786|NCT03964935|Active Comparator|Minocycline HCL|Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
11115787|NCT03964935|Placebo Comparator|Distilled water|Used to irrigate periodontal pockets after SRP
11115788|NCT03964922|Experimental|immune escape mecanims|Cohort study with a representative sample of patients
11115789|NCT03964909|Experimental|Diagnostic (fMRI, CVR MRI, rs-fMRI)|Patients undergo standard of care fMRI, CVR MRI over 3 minutes, and rs-fMRI over 6 minutes 1 month before and within 6 weeks after standard of care surgery.
11115790|NCT03964896|Experimental|Supportive Care (telephone intervention)|During standard of care chemotherapy, patients receive up to 18 telephone calls from a nurse using a standardized triage call script over 20 minutes.
11115791|NCT03964857|Other|Refined olive oil (ROO)|Control
11115792|NCT03964857|Experimental|Blended Oil 1|BO1, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 2
11115793|NCT03964857|Experimental|Blended Oil 2|BO2, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 1
11115794|NCT03964844||CASE|Patients who had an episode of diarrhoea caused by C. difficile in an hematological unit (2003-2018)
11115795|NCT03964844||CONTROL|Patients who have had an episode of diarrhoea not caused by C. difficile in an hematological unit (2003-2018)
11115796|NCT03964844||PROSPECTIVE COHORT|All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019.
11115797|NCT03964805|Active Comparator|group A|Embryo culture at 20% O2
11115798|NCT03964805|Active Comparator|group B|Embryo culture at 5% O2
11115799|NCT03964805|Active Comparator|group C|Embryo culture at 5% O2 and at 20% O2
11115800|NCT03964792|Experimental|DREPAGLOBE drug product|The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.
11115801|NCT03964779||Anovulatory women|40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility
11115802|NCT03964779||Tubal factor women|40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility
11115803|NCT03964779||male factor couple|40 women with exclusive male factor of infertility and will be used as a control group
11115804|NCT03964766|Experimental|rotary instrumentation|endodontic treatment will be performed with the use of pedo rotary files that will be activated by engine
11115805|NCT03964766|Active Comparator|hand istrumentation|endodontic treatment will be performed with the use of conventional hand files
11115806|NCT03964753|Experimental|Neo-adjuvant chemotherapy group|"cisplatin and nab-paclitaxel: Nab-paclitaxel, 125mg/m(2), d1,d8, Cisplatin, 75mg/m(2), d1, 3 week, 2 cycles.
~Surgery:
~4-6weeks after Neo-adjuvant chemotherapy"
11115807|NCT03964753|Active Comparator|Surgery alone|Surgery alone
11115808|NCT03964740|Experimental|Intervention|Mobile App intervention group
11115809|NCT03964740|No Intervention|Control Group|No intervention group
11115810|NCT03964727|Experimental|IMMU-132|IMMU-132/Sacituzumab govitecan will be administered at 10 mg/kg as an intravenous infusion on days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.
11115811|NCT03964688|Experimental|Vitamin C|vitamin C intravenous during hospitalization, followed with vitamin C oral
11115812|NCT03964688|Experimental|Placebo|placebo intravenous during hospitalization, followed with placebo oral
11115813|NCT03964675|Experimental|Respiratory rate measurement|Simultaneous measurement of respiratory rate using SenseGuard and Capnography
11115814|NCT03964662|Experimental|Patients with stroke|Rehabilitation of patients with stroke using a new technological device: WeReha
11115815|NCT03964649||Truven Health MarketScan Research Database|To compare RA-related costs among patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs (individually, as well as to TNFi and to non-TNFi each combined as groups).
11115816|NCT03964636||no contraceptive intake|
11115824|NCT03964545|Experimental|EFP neurofeedback|Ten sessions of EFP neurofeedback training. EEG is picked up with scalp electrodes, processed in real-time and returned to patients. One session lasts 30 min.
11115825|NCT03964545|No Intervention|Treatment as usual|Like patients from the treatment arm, these patients are on current residential treatment.
11115826|NCT03964532|Experimental|Phase I/Phase II|Talazoparib (1mg by mouth [PO] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously [IV] D1 every 2 weeks) will be added to talazoparib.
11115827|NCT03964519|Experimental|20% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
11115828|NCT03964519|Experimental|40% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 40% less compared to the first repetition.
11115829|NCT03964519|Placebo Comparator|Control group|This group will be just tested as a control group.
11115830|NCT03964506|Experimental|Hyperbaric Oxygen Therapy|Patients will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
11115831|NCT03964493|Experimental|TNP-2092|TNP-2092 300 mg intravenous every 12 hours
11115832|NCT03964493|Active Comparator|Vancomycin|vancomycin 1 g intravenous every 12 hours
11115833|NCT03964467|Experimental|Experimental|Transcranial Direct Current Stimulation.1) Scalp measurements of the scalp will be taken using the 10-20 EEG measurement system to determine anode and cathode placement. 2) One 1x1 Bicarbon electrode with wires attached will be placed in the center of each 5 cm x 7 cm sponge electrode dampened with 8 ml of saline. 3) One sponge electrode will be placed over the ipsilesional PMd (F3) and the other sponge electrode over the contralesional supraorbital region(Fp2). 4) Each sponge electrode will be secured under the plastic EZ strap 5) The current from the Actividose II will be turned up to 2 MA. The current will ramp up/down in 15 seconds. We will observe for adverse effects and hit the pause button, then turn the machine off, if a participant does not tolerate the stimulation. Individuals in this arm will have the stimulation stay in current until the full dose is delivered. Each participant will then engage in the UE TRT as outlined below.
11115834|NCT03964467|Sham Comparator|Control|Individuals in this arm will have the stimulation cycled off after 2-3 minutes. All will be part of the Circuit-Based, UE Task Related Training. Each participant will engage in the training program for 1.5 hours; rotating through 5 stations at about 15 minute intervals, participating in standing as tolerated, but stations can be adapted to sitting. The goal is for each participant perform > 225 movements with the affected arm per session, at the highest functional level. Rest breaks given as needed. Examples of stations are: Reach-to-grasp tasks to objects of various weight, texture and dimension at different distances and table heights. Practice opening simulated locks and containers. Shoulder wheel involving grasping plastic plates with varied grip patterns and sliding them up and over the wheel from the unaffected to the affected side encouraging shoulder abduction, external rotation and supination. Bimanual/unimanual ball toss: catching, releasing.
11115835|NCT03964454|Experimental|SC + BFI|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives contingent on observed breastfeeding.
11115836|NCT03964454|Active Comparator|SC|Participants randomized into Standard Care (SC) will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
11115837|NCT03964441||control|fetus with at least 2 ultrasound abnormalities and both parents
11115838|NCT03964441||comparison|fetus with at least 2 ultrasound abnormalities with ES diagnosis on invasive fetal sampling
11115839|NCT03964428||periodontitis|
11115840|NCT03964428||periodontitis with T2DM|
11115841|NCT03964428||control|
11115842|NCT03964415|Experimental|Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine|Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).
11115843|NCT03964415|Placebo Comparator|Group 2: Placebo|Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).
11115844|NCT03964402||Control|Control arm, i.e., as per standard procedures
11115845|NCT03964402||Experimental|Experimental arm, i.e. investigational product
11115846|NCT03964389|Experimental|Intervetion group|"A sessions of Therapeutic Neuroscience Education (TNE) joint a physical exercises programs"
11115847|NCT03964389|No Intervention|Control group|Only a therapeutic physical exercises programs
11115848|NCT03964376|Experimental|Nasal High Flow Group|Nasal High-Flow oxygen delivery will be applied starting at airflow of minimum 20 Litre/minute. It will be titrated in 15Litre/minute increments to 35 Litre/minute and a maximum 50 Litre/minute as determined by patient comfort. O2 supplementation will be managed by the anesthesia and surgical health care team to maintain the oxygen saturation level in the blood between 92-95%. In the Nasal High-Flow group, when SPO2 is in the range of 92-95%, air will be given instead of oxygen for the 1st 3 nights and during the day, if required, till discharge, whichever is earlier.
11115849|NCT03964376|Other|Usual Care Group|In the usual care, patients will receive oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via facemask titrated to keep SpO2 level in the range of 92-95%. When SpO2 level reaches in the range of 92-95%, oxygen delivery will be discontinued.
11116159|NCT03962114|Experimental|Intervention group|treatment with vitamin B3
11115850|NCT03964363|Experimental|Prehabilitation|Participants are scheduled for elective surgery and follow the home-based prehabilitation for 11-17 days
11115851|NCT03964363|Experimental|Prehabilitation + TAVI|Study participants who will undergo a TAVI form a subgroup with a modified enrolment procedure and longer duration of the intervention. The prehabilitation period is extended to 30 days.
11115852|NCT03964363|No Intervention|Control|Participants are initially evaluated for frailty prior to scheduled surgery but subsequently receive regular care without a prehabilitation program. All pre- and postsurgical evaluations will be identical to the prehabilitation group.
11115853|NCT03964363|No Intervention|Control+TAVI|The subgroup of participants who undergo a TAVI will be compared to a group of patients who will have had the same procedure. Hence the control group will also receive a screening via phone but then receive regular care. Follow-up after surgery will be identical in all groups.
11115854|NCT03964350|Experimental|Ethanol|Subjects will receive ethanol (0.4 or 0.8 g/kg) which will be administered in a gelatin vehicle.
11115855|NCT03964350|Placebo Comparator|Placebo (gelatin vehicle)|Subjects will receive placebo of black cherry sugar-free jello.
11115856|NCT03964337|Experimental|Cabozantinib Followed by Prostatectomy (Arm A)|Experimental group will received cabozantinib for 4 weeks, followed by a 2 week drug washout before a prostatectomy.
11115857|NCT03964337|Active Comparator|Immediate Prostatectomy (Arm B)|Control group will receive an immediate prostatectomy.
11115858|NCT03964324|Experimental|Severe snorers|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are noninvasive.
11115859|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2).
11115860|NCT03964285|Active Comparator|Rumination group|The patients will receive rumination induction. Rumination induction will follow a relevant activity for our patients: climbing steps. Rumination induction will be done right after climbing the steps.
11115861|NCT03964285|Experimental|distraction group|Distraction will follow a relevant activity for our patients: climbing steps. Distraction induction will be done right after climbing the steps.
11115862|NCT03964272|Experimental|ExAblate 4000 System|Exablate bilateral treatment for Parkinson's Disease Motor Features
11115863|NCT03964259|Active Comparator|Standard Hydration Regimen|In the standard intravenous fluid (IVF) protocol, following completion of HDMTX infusion, post HDMTX IVF will be initiated at 125 mL/m2/hr (no maximum mL/hr total rate).
11115864|NCT03964259|Experimental|Reduced hydration regimen|The reduced intravenous fluid (IVF) protocol, post HDMTX IVF will be initiated at 62.5 mL/m2/hr following completion of HDMTX infusion.
11115865|NCT03964246|Experimental|Compassion Meditation (CM) intervention group|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
11115866|NCT03964246|Active Comparator|Psychoeducational healthy aging group|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
11115867|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091 + BI 754111|All neoplasms
11115868|NCT03964233|Experimental|Dose Expansion - Cohort 1-Arm A -BI 907828+BI 754091+BI 754111|NSCLC
11115869|NCT03964233|Experimental|Dose Expansion - Cohort 1 - Arm B - BI 754091 + BI 754111|NSCLC
11115870|NCT03964233|Experimental|Dose Expansion - Cohort 1 - Arm C - BI 907828 + BI 754091|NSCLC
11115871|NCT03964233|Experimental|Dose Expansion - Cohort 2 - BI 907828 + BI 754091 + BI 754111|Melanoma
11115872|NCT03964233|Experimental|Dose Expansion - Cohort 3 - BI 907828 + BI 754091 + BI 754111|Liposarcoma
11115873|NCT03964233|Experimental|Dose Expansion - Cohort 4 - BI 907828 + BI 754091 + BI 754111|Hepatocellular carcinoma
11115874|NCT03964220||Patients with Asthma|
11115875|NCT03964207|Experimental|T1 followed by T2|
11115876|NCT03964207|Experimental|T2 followed by T1|
11115877|NCT03964181||Students Grades 3-12|
11115878|NCT03964181||Parents of Students Grades K-12|
11115879|NCT03964181||School Based Teachers and Staff Grades K-12|
11115880|NCT03964168||Biologic Therapy|Patient's who received and discontinued a biologic therapy
11115881|NCT03964155|Experimental|Patients with SDRA|Patients within 24 hours from meeting the Berlin criteria for moderate or severe ARDS and receiving inhaled sedation with sevoflurane
11115882|NCT03964142|Experimental|Cardiac Rehabilitation|Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
11115883|NCT03964142|No Intervention|Conventional management|Patients with conventional management and physical activity recommendation
11115884|NCT03964129|Experimental|Avance Nerve Graft with autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.
11115885|NCT03964116|Other|AYA|Questionnaires set all 3 months and psychological interviews if needed
11115886|NCT03964103|Experimental|gQ-lab daily|
11115887|NCT03964103|Placebo Comparator|Placebo|
11115888|NCT03964090|Experimental|1|Temozolomide, etoposide, doxil, dexamethasone, andrituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
11115889|NCT03964064|Experimental|I125 Seed Implantation|3D-printing Template-assisted CT-guided I125 Seed Implantation Prescription dose: gtv140-160gy ctv100-140gy Particle activity: 0.4-0.5mCi
11115890|NCT03964064|Experimental|Stereotactic Radiotherapy|According to the tumor volume, location, organ function and other factors, the dosage of stereotactic directional radiotherapy was determined. The range of BED value of radiotherapy was 80-100 for tumors above 5 mm from gastrointestinal tract and 60-80 for tumors below 5 mm from gastrointestinal tract.
11115891|NCT03964051|Experimental|Omalizumab 300 mg for s.c.injection|Omalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
11115892|NCT03964038|Active Comparator|gilteritinib|Participants will receive a single dose of gilteritinib under fasting conditions.
11115893|NCT03964038|Experimental|gilteritinib mini-tablet oral suspension|Participants will receive a single dose of gilteritinib oral suspension with water under fasting conditions.
11115894|NCT03964038|Experimental|gilteritinib mini-tablet|Participants will receive a single dose of gilteritinib mini-tablets under fasting conditions.
11115895|NCT03964025|Experimental|Cardioskin™ and 3-lead Holter recorder|This is single-arm study. All subjects will receive the investigational device (Cardioskin™) and comparator device (3-lead Holter recorder).The subject will be wearing both the Cardioskin™ and 3-lead Holter recorder for a period of 24 hours, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
11115896|NCT03964012|Experimental|NmCV-5|"Subjects in this arm will receive polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.
~A single dose of 0.5 mL will be administered intramuscularly."
11115897|NCT03964012|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.
~A single dose of 0.5 mL will be administered intramuscularly."
11115898|NCT03963999|Experimental|Patients Undergoing HCT|All patients enrolled will undergo grayscale US, Doppler US, US SWE and CEUS at specific time points as outlined in the protocol based on disease course.
11115899|NCT03963986|Active Comparator|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
11115900|NCT03963986|No Intervention|STANDARD group|The STANDARD group participants dont receive an access to an online digital platform but they receive an adapted advice sheet.
11115901|NCT03963973|Experimental|RDN-929|low, medium and high dose of RDN-929 capsules
11115902|NCT03963973|Placebo Comparator|Placebo|Matching placebo capsules
11115903|NCT03963960|Experimental|Hemodialysis with low dialysate flow|
11115904|NCT03963960|Active Comparator|Conventional triweekly high-flow hemodialysis|
11115905|NCT03963934|Experimental|Women with uncontrolled hypertension|Women with uncontrolled hypertension and unsatisfactory medication adherence
11115906|NCT03963921|Experimental|F4 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
11115907|NCT03963921|Experimental|F3 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
11115908|NCT03963908|Experimental|Intervention|AtEase is a mobile app designed to promote pain self-management, healthy sleep habits, and effective stress management. It includes a tailored Newsfeed that updates regularly with articles, activities, videos, and quizzes chosen for the user; a chat feature that asks questions and provide tailored feedback; a Message Center; and a Pain Tracker. Users can interact with AtEase as often as they like for six months.
11115909|NCT03963908|Active Comparator|Comparison|Chronic Pain Education for Veterans is a VA-endorsed pain management online educational curriculum that provides CBT pain self-management materials. Users randomized to the comparison condition will have unlimited access for 6 months.
11115910|NCT03963895|Experimental|AB002 (E-WE-thrombin)|
11115911|NCT03963895|Placebo Comparator|placebo|
11115912|NCT03963882|Experimental|Group A|Patients in group A don't receive neoadjuvant chemotherapy
11115913|NCT03963882|Experimental|Group B|Patients in group B receive neoadjuvant chemotherapy and achieve imaging response
11115914|NCT03963882|Experimental|Group C|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy
11115915|NCT03963882|Experimental|Group D|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy
11115916|NCT03963869|Experimental|Arm A: New Malaria Camp (MC) village|"Receives MC intervention in year 1 and year 2.
~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
11115917|NCT03963869|Active Comparator|Arm B: No Malaria Camp (MC) village|"Receives Standard Malaria Control in Year 1 and MC intervention in Year 2.
~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual) in the 2 year time frame of phase 1."
11115918|NCT03963869|Active Comparator|Arm C: Old Malaria Camp (MC) village|"Villages already in receipt of MCs prior to study initiation to study longer term effects.
~Each individual will be followed up 3 times (baseline and follow-ups 1, 2, and 3; 4 visits per individual)) in the 2 year time frame of phase 1."
11115919|NCT03963843|Experimental|SCI internet delivered cognitive behavioural therapy|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
11116117|NCT03962439|Experimental|High-Demand Photography|A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
11115920|NCT03963843|Active Comparator|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
11115921|NCT03963830|Experimental|MOVE UP-Sustainability|12-week lifestyle intervention focusing on diet and activity
11115922|NCT03963817||Normals|Imaging normal subjects for equipment refinement
11115923|NCT03963817||Subjects with AMD|Imaging subjects with AMD
11115924|NCT03963804||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
11115925|NCT03963804||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
11115926|NCT03963791|Experimental|Eggshell powder gel|prepared from eggshell powder. applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
11115927|NCT03963791|Active Comparator|CPP-ACP crème|CPP-ACP crème (GC Tooth Mousse). applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
11115928|NCT03963765|Active Comparator|DL-PDT isolated (Standard procedure)|Two sessions 4 weeks apart. Each daylight PDT session will consist of: application of pure chemical sunscreen for 15 minutes; curettage with a dermatological curette, followed by topical application of photosensitizer (MAL - Metvix, Galderma ®), for 30 minutes, before exposure to daylight for 2 hours.
11115929|NCT03963765|Experimental|DL-PDT + TED with microdermabrasion (aluminum oxide crystal)|The standard protocol of daylight PDT will be maintained; however, after curettage and before MAL application, microdermabrasion will be performed through three strands of skin in different directions (vertical, horizontal and oblique).
11115930|NCT03963765|Experimental|DL-PDT + TED with microneedles|Passage of an electronic pen (Dermapen Beauty®- Korea) with disposable needle tip containing 17 needles 0.5 mm in length. This instrument will be applied to the skin after the MAL to push the photosensitizer into the skin, without causing bleeding. The rest of the daylight TFD protocol will be the same as the default.
11115931|NCT03963765|Experimental|DL-PDT + TED with CO2 laser|AFXL CO2 laser: roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60W, 15 mJ / pixel, 125μm / pixel, 2mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®). Fractionated CO2 ablative laser will be applied after curettage of the lesions and immediately prior to the application of MAL. As in microdermabrasion, the laser precedes the application of MAL, forming microchannels for the penetration of the photosensitizer. The rest of the daylight TFD protocol will be the same as the default.
11115932|NCT03963752|Experimental|Ziyinxiehuo Granules and Megestrol Acetate|Experimental：Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.
11115933|NCT03963752|Active Comparator|Gonadotrophin|Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
11115934|NCT03963739||Race: Non-Hispanic African American|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
11115935|NCT03963739||Race: Non-Hispanic White|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
11115936|NCT03963739||Income: Low Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
11115937|NCT03963739||Income: Moderate to High Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
11115938|NCT03963726|Experimental|Stereotactic radiotherapy|In this study, the liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
11115939|NCT03963726|Experimental|Microwave ablation therapy|In this study, 3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
11115940|NCT03963713|Experimental|Stereotactic radiotherapy|"In this study, the metastases were treated with Stereotactic radiotherapy（SBRT）.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
~Stereotactic radiotherapy"
11116118|NCT03962439|Active Comparator|Moderate-Demand Photography|A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
11115941|NCT03963713|Experimental|Conventionally-fractionated image- guided Intensity modulated|In this study, the metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
11115942|NCT03963700||Cancer patients with Paraneoplastic neurological syndromes|"Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies:
~Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer
~anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration
~anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis
~anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors
~anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors
~anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
~without antibodies (50 patients)."
11115943|NCT03963687|Active Comparator|Control Group|Participants will receive the Standard Nursing Education Intervention first
11115944|NCT03963687|Experimental|Intervention Group|Participants will receive the New Nursing Education Intervention first
11115945|NCT03963674|Experimental|Diacutaneous fibrolysis|
11115946|NCT03963674|No Intervention|Control|
11115947|NCT03963661|Experimental|c-SIGHT|SIGHT requires participants to grasp and lift rods with their less impaired arm.
11115948|NCT03963648|Experimental|CRSwNP|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are non-invasive.
11115949|NCT03963635||Lyme Infected|Subjects presenting with suspected Lyme Disease
11115950|NCT03963635||Controls|Subjects with no known Lyme Disease, past or present
11115951|NCT03963622|Active Comparator|Control|Standard ventilation strategy.
11115952|NCT03963622|Experimental|Respiratory Mechanics|The goal of this arm is to individualize tidal volume (VT) and PEEP according to respiratory mechanics.
11115953|NCT03963596|Active Comparator|Ranibizumab|Arm 1
11115954|NCT03963596|Active Comparator|Aflibercept|Arm 2
11115955|NCT03963583|Experimental|HEROIC Intervention Group|This group will receive the HEROIC intervention.
11115956|NCT03963583|Experimental|Waitlist Control Group|The waitlisted group will receive usual care for caregivers for the first 16 weeks, which is normally limited to inclusion in some clinical assessment and teaching during patient visits. Waitlisted participants will receive monthly study postcards to encourage retention. After 16 weeks, they will begin the intervention.
11115957|NCT03963570|Experimental|Safe Step - digital exercise program|Participants randomized to the experimental group will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.
11115958|NCT03963570|Other|Control group|During 1 year, the participants randomized to the control group will receive an email every month with general falls prevention information in a short video.
11115959|NCT03963557||Healthy participants|BMI 5th percentile to less than the 85th percentile
11115960|NCT03963557||Overweight/Obese participants|BMI 85th percentile or more
11115961|NCT03963518||Control|chemotherapy
11115962|NCT03963518||Experimental|immune-checkpoint inhibitor
11115963|NCT03963492|Active Comparator|Continuous Walking|Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks
11115964|NCT03963492|Experimental|Interval Walking|Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk
11115965|NCT03963479|Active Comparator|Magnesium-Vitamin B6|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
11115966|NCT03963479|Placebo Comparator|Placebo|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
11115967|NCT03963466|Experimental|group 1|(left side of cheek) 1064-nm Q-Switched fractional laser+drug Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
11115968|NCT03963466|Experimental|group 2|(right side of cheek) 1064-nm Q-Switched laser+drug Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
11115969|NCT03963466|Experimental|group 3|(left side of cheek) 1064-nm Q-Switched fractional laser Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24
11115970|NCT03963466|Experimental|group 4|(right side of cheek) 1064-nm Q-Switched laser Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24
11115971|NCT03963453||Interventional|Regular physical exercise group
11115972|NCT03963453||Control|Standards of care treatment
11115973|NCT03963440|Experimental|Cohorte 1|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).
~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.
~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
11115974|NCT03963427|Other|Irradiated women|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap.
11115975|NCT03963427|Other|Non-irradiated women|Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
11115976|NCT03963414|Experimental|Cohort 1|Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
11115977|NCT03963414|Experimental|Cohort 2|Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.
11115978|NCT03963401|Experimental|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
11115979|NCT03963401|Experimental|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
11115980|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
11115981|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
11115982|NCT03963401|Placebo Comparator|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
11115983|NCT03963401|Placebo Comparator|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
11115984|NCT03963388|Experimental|Intervention group|Speech therapy, right after T0 (baseline measurement).
11115985|NCT03963388|No Intervention|Control group|Patients will be on a waiting list for 8 weeks. After the primary endpoint (T1), patients will receive speech therapy.
11115986|NCT03963375|Other|Group 1: LP at Baseline and Week 5|Group 1: LP at Baseline and end of Week 5. Week 5 is the optimal time point for assessing cladribine concentrations in CSF
11115987|NCT03963375|Other|Group 2: LP at Baseline and Week 10|"Group 2: LP at Baseline and end of Week 10. Week 10 is the expected nadir time for lymphocyte and monocyte levels in CSF"
11115988|NCT03963375|Other|Group 3: LP at Baseline and End of Year 1|Group 3: LP at Baseline and end of Year 1. To assess if cladribine effects on CSF markers are maintained at the end of the first treatment cycle
11115989|NCT03963375|Other|Group 4: LP at Baseline and End of Year 2|Group 4: LP at Baseline and end of Year 2. To assess if cladribine effects on CSF markers are maintained at the end of the last treatment cycle
11115990|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 60~89 mL/min|Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)
11115991|NCT03963362|Experimental|Administration of GLA5PR 75 mg over 90 mL/min|Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
11115992|NCT03963362|Experimental|Administration of GLA5PR 150 mg as 60~89 mL/min|Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)
11115993|NCT03963362|Experimental|Administration of GLA5PR 150 mg over 90 mL/min|Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
11115994|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 30~59 mL/min|Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)
11115995|NCT03963336|Active Comparator|Group A|12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
11115996|NCT03963336|Active Comparator|Group B|12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
11115997|NCT03963336|No Intervention|Control group|24 healthy subjects for whom serum D-dimer was assessed by ELISA.
11115998|NCT03963323|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
11115999|NCT03963323|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
11116000|NCT03963271||Patients with unexplained polymorphic VT and/or VF|"Unexplained polymorphic VT and/or VF patients.
~Patients with VF and the DPP6 risk haplotype, reported by the AUMC team.
~The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+"
11116001|NCT03963271||Family members|Family members of index patients of group(s) mentioned above
11116002|NCT03963271||Control group|Control subjects with structurally normal hearts with an indication for a cardiac CT,
11116003|NCT03963258|Active Comparator|control group|Over a 3-week period, the subjects in the control group received 1 hour daily of conventional upper limb training 5 times a week,including compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
11116004|NCT03963258|Experimental|whole-body vibration group|Subjects in the whole-body vibration group received half an hour of daily conventional upper limb training, followed by whole-body vibration training for an additional half hour per day,5 days per week during a 3-week period
11116005|NCT03963245|Experimental|Intervention group|MA&R - an eight months rehabilitation intervention in addition to standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
11116006|NCT03963245|Active Comparator|Control group|Standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
11116007|NCT03963232|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
11116008|NCT03963232|Placebo Comparator|Placebo|Placebo administered SC.
11116009|NCT03963219|Experimental|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
11116012|NCT03963193|Experimental|Etoposide plus Cisplatin|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
11116013|NCT03963193|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
11116014|NCT03963180|No Intervention|control group|the control group received 3 cups hot water on the 6th, 12th and 18th hours after the operation
11116015|NCT03963180|Experimental|study group|drank 3 cups of caffeinated coffee on the 6th, 12th and 18th hours after the operation.
11116016|NCT03963167||Patient in treatment with BDP/FF/G fixed combination|
11116017|NCT03963154|Experimental|Implantation of a therapeutical patch|All the patients will receive a single central subretinal implantation in one eye of a monolayer of Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE). The implanted eye will be the one with the worst visual acuity.
11116018|NCT03963128|Active Comparator|Supplemented Vitamin D3|
11116019|NCT03963128|Placebo Comparator|Placebo|
11116020|NCT03963115|Active Comparator|Coated syringe with epinephrine|Epinephrine was coated syinge before drawing the allergen to filled in.
11116021|NCT03963115|Placebo Comparator|placebo|Normal saline was coated syinge before drawing the allergen to filled in.
11116022|NCT03963102|Active Comparator|Control Group 3 hours|Application of Ameluz for 3 hours.
11116023|NCT03963102|Experimental|Trial Group 4 hours|Application of Ameluz for 4 hours.
11116024|NCT03963089|Experimental|Study group|"Measure pulse pressure variation and systolic pressure variation after each set of tidal volume to 6mL/kg, 10mL/kg and 14mL/kg. Measure respiratory variation of aortic blood flow peak velocity via transesophageal echocardiography at tidal volume of 10mL/kg.
~Measure stroke volume index via transesophageal echocardiography before and 5 min after fluid loading with 10mL/kg of crystalloid."
11116025|NCT03963076|Experimental|allergic rhinitis|administration of a nasal hypertonic spray twice a day for one month
11116026|NCT03963063|Active Comparator|Non Goal-directed Care Group|
11116027|NCT03963063|Experimental|Goal-directed Care Group|
11116028|NCT03963050|Experimental|CF|30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
11116029|NCT03963050|Experimental|PF|30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
11116030|NCT03963037||Patients|The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.
11116031|NCT03963037||Controls|The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.
11116032|NCT03963024|Experimental|Single Arm Treatment|"Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;"
11116033|NCT03963011|No Intervention|Arm A: AXR Only|Infants randomized to Arm A will obtain an abdominal x-ray (AXR) as per standard of care
11116034|NCT03963011|Active Comparator|Arm B: AXR + Bowel US|Infants randomized to Arm B will obtain an abdominal x-ray (AXR) as per standard of care and a bowel ultrasound (BUS) as the intervention
11116035|NCT03962998|Active Comparator|Lactulose/Rhamnose|1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
11116036|NCT03962998|Experimental|MB-102|4 μmol of MB-102/kg body weight administered orally as a solution
11116037|NCT03962985|Other|Intervention|The 41 participants will attend the guided tours at the Montreal Museum of Fine Arts.
11116038|NCT03962959|Active Comparator|Healthy Controls|"Healthy Controls: Participants who are matched for age and gender. No cognitive impairment supported by the following measures of general cognitive function: (a) Mini-Mental State Exam (MMSE) > 27; (b) Montreal Cognitive Assessment (MoCA) > 26; and (c) Clinical Dementia Rating Scale score of 0.
~This group will undergo the Transcranial Magnetic Stimulation (TMS) protocol. Intervention: Device: TMS"
11116039|NCT03962959|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment (MCI) clinical criteria: (a) self- or informant-reported cognitive complaint; (b) preserved independence in functional abilities; and (c) absence of dementia.
~Objective cognitive impairment supported by the following measures of general cognitive function: (a) Mini-Mental State Exam (MMSE) 24-27 (inclusive); (b) Montreal Cognitive Assessment (MoCA) 18-26 (inclusive); or (c) Clinical Dementia Rating Scale score of 0.5. Intervention: Device: TMS"
11116040|NCT03962933|No Intervention|Flexcystoscopy|Control cystoscopy every 3 months as a standard procedure
11116041|NCT03962933|Active Comparator|Uine biomarker|Urine test every 3 months
11116042|NCT03962920|Active Comparator|Surgical treatment + antibiotics|
11116043|NCT03962920|Placebo Comparator|surgical treatment + placebo|
11116044|NCT03962907|Experimental|Carrier group - intervention|BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
11116045|NCT03962907|No Intervention|Carrier group - control|
11116046|NCT03962907|Experimental|Non - carrier group - intervention|Lifo-Scrub sol 4%®, 500ml, B. Braun
11116047|NCT03962907|No Intervention|Non - carrier group - control|
11116048|NCT03962894||Early Prehospital Systemic Corticosteroids|Children with asthma attacks who receive systemic corticosteroids in the prehospital environment by emergency medical services
11116049|NCT03962894||Usual Care|Children with asthma attacks treated by emergency medical services who receive usual care en route to emergency departments, where in the ED they then receive systemic corticosteroids
11116050|NCT03962881|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11116051|NCT03962881|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
11116052|NCT03962881|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
11116053|NCT03962868|Experimental|Endoscopic submucosal dissection (ESD)|
11116054|NCT03962868|Active Comparator|Endoscopic Mucosal Resection (WF-piece meal EMR)|
11116055|NCT03962855|Active Comparator|Ifetroban|Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.
11116057|NCT03962842|Experimental|Pilates group|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
11116058|NCT03962842|No Intervention|Control group|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
11116059|NCT03962829|Placebo Comparator|Placebo condition|Participants receive placebo capsule
11116060|NCT03962829|Active Comparator|mCPP condition|Participants receive active (mCPP) capsule
11116061|NCT03962816|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11116062|NCT03962816|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
11116063|NCT03962816|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
11116064|NCT03962803|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11116065|NCT03962803|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
11116066|NCT03962803|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
11116067|NCT03962790|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
11116068|NCT03962790|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
11116069|NCT03962777|Experimental|oil pulling|patients used oil pulling therapy for 4 days
11116070|NCT03962777|Active Comparator|chlorhexidine|patients used chlorhexidine digluconate for 4 days
11116071|NCT03962764||Incarcerated|Incarcerated fathers include fathers recruited in re-entry centers, detention facilitation and in county jails.
11116072|NCT03962764||Community|Community fathers include fathers who are recruited through community partners and self-referrals.
11116073|NCT03962751|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
11116074|NCT03962751|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
11116075|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
11116076|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
11116077|NCT03962751|No Intervention|Baseline Assessment Only|Participants complete baseline survey and conclude participation.
11116078|NCT03962738|Experimental|Lasmiditan Low Dose|Lasmiditan given orally and placebo given orally to maintain the blind.
11116079|NCT03962738|Experimental|Lasmiditan Mid Dose|Lasmiditan given orally and placebo given orally to maintain the blind.
11116080|NCT03962738|Experimental|Lasmiditan High Dose|Lasmiditan given orally and placebo given orally to maintain the blind.
11116081|NCT03962738|Placebo Comparator|Placebo|Placebo given orally.
11116082|NCT03962725|Active Comparator|Control Group (C)|Endotracheal intubation would be facilitated by either Rocuronium (0.6-1mg kg-1) or Succinylcholine (1-1.5mg kg-1) and further dosing of Rocuronium would be left at the discretion of the anesthesia team members. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Neuromuscular blockade would be reversed with either Sugammadex or Neostigmine (based on institutional availability) and trachea would be extubated once patient meets criteria per attending anesthesiologist.
11116083|NCT03962725|Experimental|No Relaxant Group (NR)|Endotracheal intubation would be facilitated by Succinylcholine (1-1.5mg/kg) or Remifentanil (1-2mcg kg-1) if Succinylcholine use is contraindicated. No non-depolarizing NMBA would be administered to the patients randomized to the NR group. Choice and technique of induction and maintenance of anesthesia, use of vasopressors, perioperative antibiotics, analgesics/adjunct regional techniques, prophylaxis for postoperative nausea and vomiting, fluid and blood component therapy would be left at the discretion of the anesthesia team. Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine) either as boluses or infusion would be recommended in case of sustained high peak airway pressures (>35mm Hg), high intra-abdominal pressure, involuntary patient/diaphragmatic movement hindering surgical exposure and dissection. Choice and dose of adjunct/s to optimize operating conditions would be left to the discretion of the anesthesia team.
11116084|NCT03962712||Low-Wage Workers from Minneapolis, MN|Low-wage workers from Minneapolis, MN, where the minimum wage will be increased to $15-an-hour over the study period.
11116085|NCT03962712||Low-Wage Workers from Raleigh, NC|Low-wage workers from Raleigh, NC, where the minimum wage will not be significantly changed over the study period.
11116086|NCT03962699||Obese patients selected for bariatric surgery|Normospermic obese patients ((BMI>40), aged 20-50 years) who will undergo Bariatric surgery.
11116087|NCT03962699||Control Group: Non obese volunteers|Normospermic obese patients ((BMI>40), aged 20-50 years
11116088|NCT03962686||normoglycemics|In this cohort will be enrolled 30 normoglycemics patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
11116089|NCT03962686||patients with diabetes mellitus (DM)|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel.
11116090|NCT03962686||patients with diabetes mellitus (DM) plus metformin|In this cohort will be enrolled 23 DM patients affected by carotid artery atherosclerotic and evidence of atherosclerotic plaque causing an endolumninal stenosis > 60%. These patients will receive a surgical intervention to remove the atherosclerotic plaque and to revascularize the obstructed coronary artery vessel. These patients were treated before the surgical intervention by metformin 1000 mg daily.
11116091|NCT03962673|Experimental|UVB- exposure|Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.
11116092|NCT03962660|Experimental|HaRTS-TRENDS|See description below.
11116093|NCT03962660|Active Comparator|Standard Care (SC)|See description below.
11116094|NCT03962647|Experimental|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
11116095|NCT03962634|Experimental|Kovanaze Nasal Spray (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
11116096|NCT03962634|Active Comparator|Articaine Injections (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
11116097|NCT03962621|Active Comparator|2940 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
11116098|NCT03962621|Active Comparator|1064 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 1064 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
11116099|NCT03962621|Experimental|Combined treatment group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm or 1064 nm laser (Fotona, Slovenia, EU) alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
11116100|NCT03962608|Experimental|Yaq-001|Standard medical treatment + Yaq-001 (8 g/ day)
11116101|NCT03962608|Placebo Comparator|Placebo|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
11116102|NCT03962582|Experimental|Supportive Back Comparison|Motion Concepts matrx back to be attached to individual's wheelchair in place of the individual's back. It will be adjusted for size and to support the spinal curves as compared to a fabric back
11116103|NCT03962556||Non-Trigger Point|
11116104|NCT03962556||Trigger Point|
11116105|NCT03962543|Experimental|Mirdametinib (PD-0325901)|Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m^2 (maximum dose of 4 mg) by mouth twice daily
11116106|NCT03962517|Experimental|Training with GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.
~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with the device."
11116107|NCT03962517|Active Comparator|Training without GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.
~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without the device."
11116108|NCT03962504|Experimental|written exposure therapy|The WET condition consists of 5 weekly treatment sessions, with the first session lasting 1 hour and each subsequent session lasting approximately 40 minutes. The first session consists of education about common trauma reactions and the WET rationale. The participant is then given general instructions for completing the trauma narratives and specific instructions for completing the first 30-minute narrative writing session. All WET sessions begin with the therapist reading the specific writing instructions, clarifying any questions the person has, and leaving the instructions with the participant during the 30-minute writing session. Writing instructions begin with a focus on the details of the trauma and then shift to the meaning of the trauma event. After 30 minutes of writing, the therapist stops the writing and conducts a 5-10 minute check-in regarding how the writing session went for the participant.
11116109|NCT03962504|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a 8-15, 90 minute trauma-focused treatment which consists of imaginal and in vivo exposures
11116110|NCT03962491|Other|Daily Self-Monitoring Surveys|Asked to complete daily self-monitoring surveys.
11116111|NCT03962491|Experimental|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete daily self-monitoring surveys, with opportunity for monetary rewards.
11116112|NCT03962478|Experimental|Stent with high-intensity focused ultrasound ablation|Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.
11116113|NCT03962478|Active Comparator|Stent without high-intensity focused ultrasound ablation|Patients undergo stent insertion on day 1.
11116114|NCT03962465|Experimental|3-drug re-induction regimen with inotuzumab|"One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.
~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.
~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
11116115|NCT03962465|Experimental|4-drug re-induction regimen with inotuzumab|"One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.
~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.
~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
11116116|NCT03962452|Other|Mitochondrial disease|Unresolved index patients with suspected mitochondrial disease
11116119|NCT03962439|Placebo Comparator|At-Home Engagement Group|Participation, alone at home, in tasks that are relatively low in intellectual engagement.
11116120|NCT03962426|Active Comparator|Social Cognitive Training (SCT)|10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week
11116121|NCT03962426|No Intervention|Treatment as usual (TAU)|This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy
11116122|NCT03962413|Active Comparator|The middle meatal antrostomy approach.|"The middle turbinate will be gently moved medially. Then uncinectomy is the next step which will be performed in numerous ways. Once the natural ostium will be identified, an ostium seeker will be placed through the ostium and then carefully will be pushed posteriorly to widen the ostium.
~Using a through-cutting forceps, the ostium will be enlarged."
11116123|NCT03962413|Active Comparator|The endoscopic prelacrimal recess approach|A curved incision will be made between the anterior aspect of the IT and the posterior end of the nasal vestibule.the mucoperiosteum will be lifted posteriorly.Bone removal will be achieved. the anterior bony portion of the medial wall of the MS will be removed, .then the IT-NLD flap will be formed.The prelacrimal recess will be opened
11116124|NCT03962413|Active Comparator|The canine fossa approach.|"It will be done either transnasally or transorally:
~** The transoral approach through a sublabial incision : CFA consist in a trocar placed in the canine fossa.After removal of the trocar a 4-mm microdebrider blade will be placed through the passage created by the trocar.
~** The transnasal approach: A curved incision will be made between the anterior aspect of the Inferior Turbinate and the posterior end of the nasal vestibule,the mucoperiosteum will be lifted posteriorly Then the investigators will reach the anterior wall of the maxillary sinus through bone removal which will be achieved using a gauch and hammer and a high-speed electric drill."
11116125|NCT03962400|Active Comparator|Control|Subjects will have warfarin dose determined in the usual fashion by a health care provider.
11116126|NCT03962400|Experimental|Treatment|Subjects will have warfarin dose determined using a reinforcement learning computer model.
11116127|NCT03962387||Atopic Dermatitis|
11116128|NCT03962374|Experimental|Frova|Frova will be used to facilitate the endotracheal intubation.
11116129|NCT03962374|Active Comparator|Stylet|Stylet will be used to facilitate the endotracheal intubation.
11116130|NCT03962361||Sudden cardiac death of ischemic cause|Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS < 8 points).
11116131|NCT03962348|Experimental|Targeted Educational Campaign (TEC) for Correction Officers|The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails at New York City's Rikers Island. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
11116132|NCT03962348|Experimental|Specialized Early Engagement Team|The investigators will implement a Specialized Early Engagement Team (SEET) in the same three jails. The SEET will increase the likelihood that referred individuals found to have first-episode psychosis enroll in Coordinated Specialty Care upon release.
11116133|NCT03962335|Experimental|VD group|Group that starts with Vegetarian diet (VD)
11116134|NCT03962335|Experimental|MD+Bt group|Group that starts with Mediterranean diet with oral supplementation with butyrate (MD+Bt)
11116135|NCT03962335|Active Comparator|MD group|Group that starts with Mediterranean diet (MD)
11116136|NCT03962322|Experimental|Weaning TDI|A tissue doppler evaluation, using a sector transducer, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration in the modality of ventilation which precedes the trial, during the SBT and after extubation.
11116137|NCT03962309||Patients in charge of the participating GPs|In the study will be included patients in charge of the participating GPs aged 40-70 years
11116138|NCT03962296|Experimental|Entelon|Three daily oral doses of 50mg tablets were administered to patients
11116139|NCT03962296|Active Comparator|Doxium|Three daily oral doses of 250mg tablets were administered to patients
11116140|NCT03962296|Placebo Comparator|Placebo|Three masking tablets were administered to patients
11116141|NCT03962283|Active Comparator|Rifaximin|ASA daily + misoprostol + Rifaximin (Rifaximin group)
11116142|NCT03962283|Placebo Comparator|Rifaximin Placebo|ASA daily + misoprostol + Placebo Rifaximin (Placebo group)
11116143|NCT03962270|Experimental|Treatment group|
11116144|NCT03962270|Sham Comparator|Control group|
11116145|NCT03962257|No Intervention|Conventional|This group will have standard of care infertility counseling and consent processes.
11116146|NCT03962257|Experimental|Engaged MD|This group will have standard of care infertility counseling and access to online teaching modules and the ability to sign consents online.
11116147|NCT03962244||SEMS Group|The outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy
11116148|NCT03962244||EVT Group|The outcome of using endoscopic vacuum therapy (EVT) in the treatment of postoperative leakage after esophagogastrostomy
11116149|NCT03962231|Active Comparator|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid re-education exercises, assisted arm elevation and scapula control exercises.
11116150|NCT03962231|Active Comparator|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises with focus on lateral rotation, medial rotation and arm elevation.
11116151|NCT03962218|Experimental|Early Aquatic Therapy (EAT)|Aquatic physiotherapy treatment at time 1 (week 1)
11116152|NCT03962218|Other|Late Aquatic Therapy (LAT)|Control for Group 1 for the 5 first weeks of Group 1 treatment. Aquatic physiotherapy treatment at time 2 (week 6).
11116153|NCT03962205|Experimental|Cognitive Behavioral life-style and well-being intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification and then 4 group-based 2-hour weekly sessions of the well-being intervention in addition to the treatment as usual.
11116154|NCT03962205|Placebo Comparator|Cognitive Behavioral life-style intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification in addition to the treatment as usual.
11116155|NCT03962192|Experimental|Survey tools|Survey instruments are shared with reviewers.
11116156|NCT03962179|Experimental|VACStent Group|Patient s who received a VACStent
11116160|NCT03962101|Experimental|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
11116161|NCT03962075|Other|laparoscopic paravaginal repair|"patient enrolled in this arm were offered laparoscopic paravaginal repair by Using a 10mm laparoscope, video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique All cases received diclofenac potassium 100 mg and meperidine hydrochloride 50 mg intramuscular with anesthesia recovery and 12 hours later second dose of diclofenac potassium was given. Also 40-60 mg Enoxaparin was given 6-12 hours postoperatively as subcutaneous injection.
~Foley's catheter was removed 6 hours postoperative"
11116162|NCT03962062|Experimental|Cohort 1: 12-17 years|Moxidectin 8mg per oral, single dose
11116163|NCT03962062|Experimental|Cohort 2: 8-11 years|Moxidectin 8mg (or lower dose) per oral, single dose
11116164|NCT03962062|Experimental|Cohort 3: 4-7 years|Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2
11116165|NCT03962049|Experimental|Normal Hepatic Function|Healthy participants with Normal Hepatic Function
11116166|NCT03962049|Experimental|Mild Hepatic Impairment|Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)
11116167|NCT03962049|Experimental|Moderate Hepatic Impairment|Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)
11116168|NCT03962049|Experimental|Severe Hepatic Impairment|Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)
11116169|NCT03962023||Patient cohort|Routine follow-up of patients in the Cardiological Functional Explorations department - Valve Disease Centre for their primary mitral insufficiency by prolapse
11116170|NCT03962010|Experimental|Dose level 1|
11116171|NCT03962010|Experimental|Dose level 2|
11116172|NCT03962010|Experimental|Dose level 3|
11116173|NCT03962010|Experimental|Dose level 4|
11116174|NCT03962010|Placebo Comparator|Placebo|
11116175|NCT03962010|Active Comparator|Dulaglutide|
11116176|NCT03961997|Other|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
11116177|NCT03961997|Other|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
11116178|NCT03961997|Other|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
11116179|NCT03961984||Complex anal fistula|Patients with complex transsphincteric anal fistulas were treated with Biodesign® plug.
11116180|NCT03961971|Experimental|Treatment (MBG453, spartalizumab, stereotactic radiosurgery)|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11116181|NCT03961958|No Intervention|No protocolled propofol reduction|In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.
11116182|NCT03961958|Experimental|Two protocolled propofol reductions|In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness-reduction calculated using a predefined formula, and (2) before positioning-reduction equal to the average percentage decrease in CO after knee-chest position in phase
11116183|NCT03961945|Other|Screening Population|Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
11116184|NCT03961945|Other|Upper endoscopy - Barrett's Esophagus|Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
11116185|NCT03961945|Other|Upper endoscopy - No Barrett's Esophagus|Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
11116186|NCT03961932|Experimental|Normal Renal Function|Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m^2)
11116187|NCT03961932|Experimental|Mild Renal Impairment|Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m^2)
11116188|NCT03961932|Experimental|Moderate Renal Impairment|Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m^2)
11116189|NCT03961932|Experimental|Severe Renal Impairment|Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m^2), not on hemodialysis
11116190|NCT03961932|Experimental|End-Stage Renal Disease|Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis
11116191|NCT03961919|Experimental|FLAT-Auto|Treosulfan in a combination regimen with ARA-C and fludarabine as conditioning therapy prior to autologous PBSCT
11116192|NCT03961906|Active Comparator|Tübingen physiotherapy concept|Will receive our therapy concept and perform self-trainings on a regular basis.
11116193|NCT03961906|No Intervention|controls|Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.
11116194|NCT03961893|Experimental|Arm A: Standard colonoscopy then colonoscopy with G-EYE|Arm A: Standard colonoscopy then colonoscopy with G-EYE
11116195|NCT03961893|Experimental|Arm B: G-EYE colonoscopy then standard colonoscopy|Arm B: G-EYE colonoscopy then standard colonoscopy
11116196|NCT03961867|Experimental|DS|D2 resection -- S1 * 1 cycle + DS * 6 cycles + S1 * 9 cycles
11116197|NCT03961867|Active Comparator|SOX|D2 resection -- S1 * 1 cycle + SOX * 6 cycles + S1 * 9 cycles
11116198|NCT03961854|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
11116199|NCT03961854|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
11116200|NCT03961841|Active Comparator|Chemoradiation|weekly 5-Fu and oxaliplatin
11116201|NCT03961841|Experimental|FLOT|Eight perioperative chemotherapy cycles
11116202|NCT03961841|Experimental|FOLFOX|Twelve perioperative chemotherapy cycles
11116203|NCT03961828|Experimental|Thalassemia with HCV|The study was carried out upon 50 β-thalassaemic children infected with hepatitis C virus who attended for a medical check-up at the Hematology Unit, Pediatric Department, Tanta University Hospital. Hepatitis C virus infection was diagnosed by serological detection of HCV-Ab, and quantitative detection of serum HCV RNA by polymerase chain reaction (PCR).
11116204|NCT03961815|Experimental|Brazikumab Induction Dose|Intravenous Brazikumab on Days 1, 29, and 57 followed by subcutaneous Brazikumab every 4 weeks through Week 52
11116205|NCT03961815|Experimental|Brazikumab Maintenance Dose|Subcutaneous Brazikumab every 4 weeks through Week 52 starting at Day 1
11116206|NCT03961802|Experimental|systematic early rehabilitation|systematic early rehabilitation
11116207|NCT03961802|No Intervention|without systematic rehabilitation|without systematic rehabilitation
11116208|NCT03961789||cohorte 1|patients undergoing opioid replacement therapy
11116209|NCT03961776||non-metastatic rectal adenocarcinoma nRCT indicated|Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.
11116210|NCT03961763|Active Comparator|omega-3 supplement|This group will receive a daily dose of 4g EPA+DHA (which is the recommended safe tolerable upper intake level of omega-3 supplements for healthy individuals) for eight weeks.
11116211|NCT03961763|Placebo Comparator|Placebo|This group will receive a daily dose of 4g olive oil placebo for eight weeks.
11116212|NCT03961750|Experimental|Intervention|A feasibility study examining a single patient group undertaking a 12 week, student-led, OTAGO exercise class for community dwelling older adults at Glasgow Caledonian University. OTAGO consists of progressive strength and balance exercises.
11116213|NCT03961737|Experimental|prostatic explants|A first series of biopsies will be performed during the procedure to place the gold grains prior to radiotherapy. Explants will be performed from these biopsies. Half of these explants will be irradiated with a research irradiator at a dose of 2 Gy then placed for 24 hours in an appropriate culture medium. The other half will be directly cultured for 24 hours. After 24 hours of incubation, half of the irradiated explants and half of the explants will be used to study the transcriptome. The tissues will be stored in RNAlater solution and then frozen at -80°C. The remaining half explants will be used for immunohistochemical analysis. Two years after the end of radiotherapy, a new series of biopsies will be performed for research, in order to verify histologically the effectiveness of radiotherapy.
11116214|NCT03961724||ESRD group|
11116215|NCT03961724||Control group|
11116216|NCT03961711|Experimental|Telemedicine encounter|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
11116217|NCT03961711|Active Comparator|In-person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
11116218|NCT03961698|Experimental|Cohort A (TNBC)|"IPI-549 in combination with front-line treatment. Cohort A will include two sub-cohorts: Cohorts A1 and A2.
~Cohort A1: Approximately 30 patients with locally advanced and/or metastatic TNBC with programmed death-ligand 1 (PDL1) positive disease based on immunohistochemistry (IHC) defined as IC1/2/3.
~Cohort A2: Approximately 30 patients with locally advanced and/or metastatic TNBC with PDL1 negative disease based on IHC defined as IC0."
11116219|NCT03961698|Experimental|Cohort B (RCC)|"IPI-549 in combination with front-line treatment. Cohort B will include two sub-cohorts: Cohorts B1 and B2.
~Cohort B1: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 positive disease based on IHC defined as IC1/2/3.
~Cohort B2: Approximately 15 patients with locally advanced and/or metastatic RCC, with PDL1 negative disease based on IHC defined as IC0."
11116220|NCT03961672|Experimental|Treatment (duvelisib)|"INDUCTION: Patients receive duvelisib PO BID on days 1-28. Cycles repeat every 28 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive duvelisib PO BID on days 1-2, 8-9, 15-16, and 22-23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11116221|NCT03961659|Active Comparator|Liraglutid|Liraglutid will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutid could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
11116222|NCT03961659|Active Comparator|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but dapagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
11116223|NCT03961659|Active Comparator|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to100mg three times daily if appropriate. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but acarbose could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
11116224|NCT03961633|Experimental|AWARE intervention|"This arm is the treatment group, which receives the intervention, and is the only arm in the study. See the intervention column for more descriptions."
11116225|NCT03961607|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
11116226|NCT03961607|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 50 J/cm2) after applying 5% 5-aminolevulinic acid cream for 1.5h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
11116227|NCT03961594|Other|volume expansion in the ventilated patient|Including 51 patients, ventilated, under vasopressors suffering from septic shock. GLS, cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders. Patients with a 15% increase in cardiac output 20minutes after the end of volume expansion will be classified as persistent responders.
11116228|NCT03961581|Experimental|car|Children who will use cars to go from the double-door entrance of the block to the operative room.
11116229|NCT03961581|No Intervention|bed|Children who will use bed to go from the double-door entrance of the block to the operative room.
11116230|NCT03961568|Experimental|Core Study Placebo|Subjects who did not receive Cenobamate in the Core Study will receive Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks.
11116231|NCT03961568|Experimental|Core Study Active|Subjects who received cenobamate in the Core study will continue to receive the same daily dose (150 mg or 200mg).
11116232|NCT03961555|Experimental|SYN023+Rabies vaccine|"SYN023:
~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
~SYN023 is an equal mass mixture of CTB011 and CTB012, two monoclonal antibodies that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.
~Dosage form: 6mg/2mL, liquid,
~Dosage: 0.3 mg/kg of SYN023
~Frequency/duration: at Day 1
~Rabies vaccine (RabAvert/Rabipur):
~Interventions: should be administered in deltoid muscle
~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use
~Dosage: 1 mL after reconstitution
~Frequency/duration: at Day 1, 4, 8, 15, 29"
11116233|NCT03961555|Active Comparator|HRIG+Rabies vaccine|"HRIG:
~Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
~Dosage form: 150 IU/mL or 300 IU/mL, liquid,
~Dosage: 20 IU/kg of HyperRab (HRIG)
~Frequency/duration: at Day 1
~Rabies vaccine (RabAvert/Rabipur):
~Interventions: should be administered in deltoid muscle
~Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 1mL before use
~Dosage: 1 mL after reconstitution
~Frequency/duration: at Day 1, 4, 8, 15, 29"
11116234|NCT03961542|Experimental|Intervention Group|"This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.
~Differences in fasting glucose and longitudinal changes over the study period should be additionally examined."
11116235|NCT03961542|No Intervention|Control Group|Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).
11116236|NCT03961529|Experimental|0.3% OPA-15406 ointment|Twice daily
11116237|NCT03961529|Experimental|1% OPA-15406 ointment|Twice daily
11116238|NCT03961516||Cystic Fibrosis, Pancreatic Sufficient|CF patients with exocrine pancreatic sufficiency
11116239|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, No Insulin|CF patients with exocrine pancreatic insufficiency but not treated with insulin therapy
11116240|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin|CF patients with exocrine pancreatic insufficiency who are treated with insulin therapy for CFRD
11116241|NCT03961503||Daptomycin (DAP)|DAP : Cohort of patients who received daptomycin as the first line treatment for at least 48 hours for the defined indication
11116242|NCT03961503||Vancomycin (VAN)|VAN : Cohort of patients who received vancomycin as the first line treatment for at least 48 hours for the defined indication
11116243|NCT03961477|Active Comparator|IF group|Interferential therpapy
11116244|NCT03961477|No Intervention|Placebo|No intervention
11116245|NCT03961464|Experimental|d-cycloserine|oral, capsule, 250 mg
11116246|NCT03961464|Experimental|Placebo|oral, capsule, lactose
11116247|NCT03961451||Group With Recommendations (GAR)|Patients in the GAR group will receive several recommendations and will have access to an online tool to increase motivation to engage in physical activity.
11116248|NCT03961451||Control Group (GC)|No recommendation given
11116249|NCT03961438|Active Comparator|Group A|HIV-uninfected participants
11116250|NCT03961438|Active Comparator|Group B|HIV-uninfected participants
11116251|NCT03961425|Active Comparator|NO CO2|Traditional De Airing maneuver
11116252|NCT03961425|Active Comparator|CO2 Cannula|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by non specific needle cannula
11116253|NCT03961425|Active Comparator|CO2 Cardia|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by commercial diffuser Cardia
11116254|NCT03961412|Experimental|family-based intervention + education materials|The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
11116255|NCT03961412|Active Comparator|women only intervention + education materials|Only the participants will attend the 1.5-2 hour face-to-face intervention on cervical cancer and screening.
11116256|NCT03961399|Active Comparator|biventricular stimulation (BiV) group|patients with Abbott Medical® CRT implanted with only biventricular stimulation (BiV).
11116257|NCT03961399|Experimental|SyncAVTM stimulation group|patients with Abbott Medical® CRT implanted and SyncAVTM stimulation activated
11116258|NCT03961386|Experimental|FallsTalk-C|FallsTalk CG intervention
11116259|NCT03961386|Active Comparator|FallsTalk|FallsTalk intervention
11116260|NCT03961386|No Intervention|PostCardOnly|Postcard only- Control group
11116261|NCT03961373|Active Comparator|Standard Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
11116262|NCT03961373|Experimental|Experimental Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
11116263|NCT03961360|Experimental|162 mg/day Aspirin|
11116264|NCT03961360|Active Comparator|81 mg/day Aspirin|
11116265|NCT03961347|Active Comparator|Probiotic Group|The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
11116266|NCT03961347|Placebo Comparator|Placebo Group|The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
11116267|NCT03961334|Experimental|DOACs|Direct oral anticoagulants
11116268|NCT03961334|Active Comparator|Antiplatelets|Antiplatelets
11116269|NCT03961308|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
11116270|NCT03961308|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
11116271|NCT03961295|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
11116272|NCT03961295|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
11116273|NCT03961282|Experimental|Parkinson Disease Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
11116274|NCT03961282|Experimental|Healthy Participant Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
11116275|NCT03961256|Experimental|Exenatide SR Intervention Group|Subjects will receive, in addition to standard care, Exenatide SR 2 mg subcutaneous (SQ) weekly for 24 months.
11116276|NCT03961256|No Intervention|Standard of Care|Subjects will receive standard post-transplant care as per Mayo Clinic usual practice.
11116277|NCT03961243|Experimental|YUVA-GT-F901|Gene transfer to treat Hemophilia B
11116278|NCT03961230|Experimental|Oral Chinese medicine|Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.
11116279|NCT03961230|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.
11116280|NCT03961217||Gynecological Cases|"Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy at
~Radiumhemmat, Karolinska University Hospital and
~Jubileumskliniken at Sahlgrenska University Hospital in Sweden."
11116281|NCT03961217||Prostate Cases|Prostate Cancer survivors treated with radiotherapy for localized prostate cancer at Sahlgrenska University Hospital, Gothenburg, Sweden
11116282|NCT03961217||Gynecological Rehab Cases|Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy
11116283|NCT03961204|Experimental|Cladribine|
11116284|NCT03961191||Benign group|Patients with benign cervical histology, including normal findings, inflammation and LSIL
11116285|NCT03961191||HSIL group|Patients with cervical histology of HSIL
11116286|NCT03961191||Cancer group|Patients with cervical histology of cancer
11116287|NCT03961165|Experimental|Treatment arm|1mL 20 mg/mL butylscopolamine bromide i.v.
11116288|NCT03961165|Placebo Comparator|Placebo|1mL 9mg/mL NaCl
11116289|NCT03961152|Experimental|PainCoach-app group|In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
11116290|NCT03961152|No Intervention|Control group|The control group received usual care.
11116291|NCT03961139|Experimental|Continuous feeding (CF)|"Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.
~Feed volume increment per day is as per departmental protocol and same as comparator arm."
11116292|NCT03961139|Active Comparator|Bolus feeding (BF)|"Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.
~Feed volume increment per day is as per departmental protocol and same as experimental arm."
11116293|NCT03961126|Experimental|Group autologous platelet-rich plasma injection|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
11116294|NCT03961126|Active Comparator|Group Control|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
11116295|NCT03961113||assessment by questionnaire|
11116331|NCT03960853|Experimental|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
11116332|NCT03960853|Placebo Comparator|volume controlled ventilation|patients will be allocated to volume controlled ventilation in operation
11116296|NCT03961100|Experimental|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
11116297|NCT03961100|Experimental|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
11116298|NCT03961087|Active Comparator|case group|patients with liver cirrhosis and frequent hepatic encephalopathy received coenzyme Q10 and Meclofenoxate in addition to usual hepatic support
11116299|NCT03961087|No Intervention|control group|patients with liver cirrhosis and frequent hepatic encephalopathy received usual hepatic support only
11116300|NCT03961074||Exposure group|Chinese women with iron deficiency anemia (IDA) during pregnancy.
11116301|NCT03961074||Control group|Chinese women without iron deficiency anemia (IDA) during pregnancy.
11116302|NCT03961061|Active Comparator|Brenner FIT (Standard Care)|Adolescents will participate in Brenner Families in Training along with their caregiver. They will receive all components of standard Brenner FIT treatments.
11116303|NCT03961061|Experimental|Brenner mFIT (standard care plus mobile health components)|"Adolescents will participate in Brenner Families in Training along with their caregiver.
~Brenner mFIT (Families in Training + mobile health) includes all components of the standard Brenner FIT"
11116304|NCT03961048|Experimental|Bilateral catheters|patients receiving bilateral catheters (such as for patients undergoing sternotomies/midline incisions or with planned bilateral thoracotomy incisions)
11116305|NCT03961048|Experimental|Single catheter|patients who only have one catheter in place (such as in patients who have unilateral thoracotomies and not midline sternotomies)
11116306|NCT03961035||25% cycle ratio|Patients group treated with CPCTSI at a 25% cycle ratio
11116307|NCT03961035||31.3% cycle ratio|Patients group treated with CPCTSI at a 31.3% cycle ratio
11116308|NCT03961022|Active Comparator|ReWin(d)|Subjects have to take ReWin(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
11116309|NCT03961022|Placebo Comparator|placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
11116310|NCT03961009|Experimental|Kedrion IVIG 10%|Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.
11116311|NCT03960996|Experimental|Dacryocystorinostomy with bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy with bicanalicular intubation.
11116312|NCT03960996|Experimental|Dacryocystorinostomy without bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy without bicanalicular intubation.
11116313|NCT03960983|Experimental|Elderly pacients with complete dentures and Tongue Scraper|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of repeated before these steps
11116314|NCT03960983|Active Comparator|Elderly pacients with complete dentures and PDT|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
11116315|NCT03960970|Active Comparator|One-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once
11116316|NCT03960970|Experimental|Two-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once
11116317|NCT03960957|Experimental|Experimental|AbobotulinumtoxinA
11116318|NCT03960957|Placebo Comparator|Placebo|
11116319|NCT03960944|Experimental|Yoga in School Group|30-mins yoga sessions were conducted in schools for 8-weeks
11116320|NCT03960944|No Intervention|Control Group|Usual Activities in school
11116321|NCT03960931|Experimental|Aquatic rehabilitation|
11116322|NCT03960931|Experimental|Land based physical activities|
11116323|NCT03960931|Other|Conventional rehabilitation|
11116324|NCT03960918|No Intervention|usual neuro-rehab training|stroke patient under usual neuro-rehab training
11116325|NCT03960918|Experimental|Novel exercise training|stroke patient under aerobic exercise training
11116326|NCT03960905||Children with the usage of anti-infective drugs|in conformity with the clinical practice
11116327|NCT03960892|Experimental|E-CAU with Group Problem Management Plus (PM+)|"190 participants will be randomly assigned to E-CAU with Group PM+. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
~The participants in the experimental arm will receive Group PM+ by trained, non-specialist peer-refugees in addition to E-CAU."
11116328|NCT03960892|No Intervention|Enhanced care as usual (E-CAU) only|190 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a leaflet which will include information on the services that they can get from RASASA and other public services. ), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
11116329|NCT03960866|Experimental|Nyxol Ophthalmic Solution 1%|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
11116330|NCT03960866|Placebo Comparator|Nyxol Ophthalmic Solution Vehicle|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
11116333|NCT03960840|Experimental|CLL/SLL|Dose escalation and expansion of YTB323 in combination with ibrutinib
11116334|NCT03960840|Experimental|DLBCL|Dose escalation and expansion of YTB323 single agent in DLBCL
11116335|NCT03960840|Experimental|Adult ALL|Dose escalation and expansion of YTB323 single agent in adult ALL
11116336|NCT03960827|No Intervention|Sedentary control|The control group does not engage in any acute exercise testing protocol.
11116337|NCT03960827|Active Comparator|Sedentary EE|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
11116338|NCT03960827|Active Comparator|Sedentary RE|Participants randomized to RT first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
11116339|NCT03960827|No Intervention|Highly Active EE|A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
11116340|NCT03960827|No Intervention|Highly Active RE|A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
11116341|NCT03960814||Cohort 1|New users of basal insulins glargine and detemir
11116342|NCT03960801|Experimental|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
11116343|NCT03960801|Active Comparator|Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
11116344|NCT03960788|Experimental|MRI with Gadoxetate Sodium|Subjects will receive Gadoxetate Sodium during MRI.
11116345|NCT03960775|Experimental|Group A (dexmedetomidine)|dexmedetomidine infusion group
11116346|NCT03960775|Placebo Comparator|Group B (saline)|normal saline infusion group
11116347|NCT03960762|Active Comparator|Group A = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
11116348|NCT03960762|Active Comparator|Group B = SAP group|SAP block (Group SAP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
11116349|NCT03960749|Experimental|Sprotte 25G needle, stylet reinserted|
11116350|NCT03960749|Experimental|Sprotte 25G needle, stylet not reinserted|
11116351|NCT03960749|Experimental|Sprotte 22G needle, stylet reinserted|
11116352|NCT03960749|Experimental|Sprotte 22G needle, stylet not reinserted|
11116353|NCT03960749|Experimental|Spinocan 25G needle, stylet reinserted|
11116354|NCT03960749|Experimental|Spinocan 25G needle, stylet not reinserted|
11116355|NCT03960736|Active Comparator|Group ESPB = Erector spinae plane block group|ESP block (Group ESP) will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
11116356|NCT03960736|Active Comparator|Group TEA = Thoracic epidural analgesia group|TEA will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
11116357|NCT03960736|No Intervention|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
11116358|NCT03960710||Neuronal network Training group|"The following radiological variables, related to each CT examinations, will be collected for each patient:
~Injection modalities (without injection, injected)
~Major hepatectomy surgery
~Importance of hepatic dysmorphia
~Presence of intraperitoneal fluid effusion
~Presence of renal polycystosis (especially on the right side)."
11116359|NCT03960710||Neuronal network Validation group|"The following radiological variables, related to each CT examinations, will be collected for each patient:
~Injection modalities (without injection, injected)
~Major hepatectomy surgery
~Importance of hepatic dysmorphia
~Presence of intraperitoneal fluid effusion
~Presence of renal polycystosis (especially on the right side)."
11116360|NCT03960697|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
11116361|NCT03960697|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
11116362|NCT03960684|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System
11116363|NCT03960671|Experimental|Anxiolytics|Pediatric patients treated with sedation using anxiolytics
11116364|NCT03960658|Experimental|Ketamine and PE|ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.
11116365|NCT03960645|Experimental|B/F/TAF|B/F/TAF for up to approximately 38 weeks
11116366|NCT03960619|Experimental|in-person & mHealth coping skills training|hybrid in-person and mHealth coping skills training and activity coaching intervention is to reduce physical disability and decrease pain, fatigue and stress while enhancing patients' abilities to cope with symptoms that interfere with activity.
11116367|NCT03960606|Experimental|10 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
11116368|NCT03960606|Experimental|20 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
11116369|NCT03960606|Experimental|35 mg PUR1900|Study drug (PUR1900) will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
11116370|NCT03960606|Placebo Comparator|Placebo|Placebo will be administered orally, using a Dry Powder Inhaler (DPI) specific to the study (RS01 Monodose inhaler)
11116932|NCT03956472|Sham Comparator|Control group|Sham PEEP and fake osteopathic protocol
11116371|NCT03960593||Patients with cancer and / or hematological|The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.
11116372|NCT03960580|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
11116373|NCT03960580|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
11116374|NCT03960580|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
11116375|NCT03960554|Active Comparator|Active drug|Denosumab 60 mg subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
11116376|NCT03960554|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
11116377|NCT03960541|Experimental|CD24Fc Treatment|The intervention drug will be CD24Fc (IV infusion). Patients with HIV on antiretroviral therapy will be administered 3 doses of CD24Fc (240mg IV infusion) q2w during a 4-week window, followed by a 24-week follow-up window to assess safety and changes in LDL.
11116378|NCT03960541|Placebo Comparator|Placebo|The intervention drug will be CD24Fc (IV infusion). Patients with HIV on antiretroviral therapy will be administered 3 doses of normal saline solution (150 ml, IV infusion) q2w during a 4-week window, followed by a 24-week follow-up window to assess safety and changes in LDL.
11116379|NCT03960528|Active Comparator|Under direct vision erector spinae plane block|"20 ml bupivacaine 0,25%+ lidocaine 1% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
11116380|NCT03960528|Sham Comparator|Control group|"20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
11116381|NCT03960502|Experimental|AG881|On Day 1, after fasting for 10 hours participants, will receive an oral capsule of [14C]AG-881 followed 2 hours later by a single intravenous (IV) infusion of [13C315N3]AG-881.
11116382|NCT03960489|Experimental|Treatment Sequence 1 (ABCD)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
11116383|NCT03960489|Experimental|Treatment Sequence 2 (BDAC)|Participants will receive 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 1 followed by single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
11116384|NCT03960489|Experimental|Treatment Sequence 3 (CADB)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 2 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
11116385|NCT03960489|Experimental|Treatment Sequence 4 (DCBA)|Participants will receive single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 3 followed by 100 mg of roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
11116386|NCT03960476|Experimental|Access to Web-Based Intervention|All study participants will be given access to the web-based study intervention, PlanYourLifespan.org.
11116387|NCT03960463|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
11116388|NCT03960463|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
11116389|NCT03960450|Experimental|Part A: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
11116390|NCT03960450|Placebo Comparator|Part A: Vehicle cream|Daily application of vehicle cream
11116391|NCT03960450|Experimental|Part B: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
11116392|NCT03960450|Placebo Comparator|Part B: Vehicle cream|Daily application of vehicle cream
11116393|NCT03960437|Other|Study Participant|Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.
11116394|NCT03960424|Experimental|Diabetes Telemonitoring (DTM)|"Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for Type 2 Diabetes (T2D), uses smart devices to share information between patients, caregivers, and clinicians. DTM includes:1) weekly real time virtual visit between patient and clinician 2) vital signs monitoring/interpretation 3) diabetes management 4) patient interactive educational videos and teach back quizzes, reinforcing self-management strategies 5) a caregiver app with supportive capability."
11116395|NCT03960424|Active Comparator|Comprehensive Outpatient Management (COM)|"Comprehensive Outpatient Management (COM) is the most realistic evidence-based comparator, in that it is the most frequently recommended and used option for US T2D patients. COM, like DTM, is consistent with the 2018 American Diabetes Association (ADA) Standards which include, but are not limited to, past medical and family history, social history, medications, screening, physical examination, laboratory evaluation, etc.Patients are instructed to monitor blood glucose (within physician recommendations), and have routine or well visits every 3 months. Patients can set appointments with a T2D educator. COM patients will receive monthly calls from the study Registered Nurse (RN) to collect data."
11116396|NCT03960411|Experimental|Doxycycline|Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI
11116397|NCT03960411|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI
11116398|NCT03960398||Patients concerned by iatrogenic diseases|Patients living in the South-East of France and consulting in the emergency department of Toulon La Seyne sur Mer hospital for iatrogenic diseases
11116399|NCT03960385||Hospitalized and controls|Age-matched case of hospitalized dengue and non-dengue control
11116400|NCT03960385||Outpatient and controls|Age-matched dengue case and non-dengue control
11116401|NCT03960359||Episodic viral wheezers (EVW)|EVW: Wheezing during discrete time periods (exacerbations), absence of symptoms between exacerbations Among which SIW: EVW with ≥ 2 exacerbations over the last 6 months Clinical, microbiological and inflammatory phenotype
11116402|NCT03960359||Multiple trigger wheezers (MTW)|MTW : wheezing during exacerbations but also symptoms between episodes. Clinical, microbiological and inflammatory phenotype
11116403|NCT03960346|Other|Esophageal Effects|To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
11116404|NCT03960333||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
11116405|NCT03960333||Overweight/Obese|Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
11116406|NCT03960333||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
11116407|NCT03960307||Septic patients|ICU patients with resuscitated sepsis, based on the sepsis-3 criteria. (n=30)
11116408|NCT03960307||Healthy controls|Apparently healthy controls (n=10)
11116409|NCT03960294|Experimental|DOZE Users|Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
11116410|NCT03960281||Single implant crowns in the anterior maxilla|No drugs to be administered. Patients who have had a single implant crown placed since more than one year in the anterior maxilla (second premolar to second premolar) will be invited for a review session for dental examination and to fill the Oral Health Impact Profile (OHIP) questionnaire.
11116411|NCT03960268|Experimental|Intervention|Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks
11116412|NCT03960255||Normal adiposity group|Body fat < 25% and <32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
11116413|NCT03960255||High adiposity group|Body fat ≥ 25% and ≥32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
11116414|NCT03960229|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips (for ICSI) will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
11116415|NCT03960229|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
11116416|NCT03960216|Sham Comparator|Minimal Periodontal Treatment (MPT)|Once the hopeless teeth have been extracted, randomized patients will receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and, after the last session, placebo capsules (one every 24 h for three days).
11116417|NCT03960216|Experimental|Intensive Periodontal Treatment (IPT)|Once the hopeless teeth have been extracted, randomized patients will receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and after the last session, systemic antibiotics (azithromycin 500 mgrs, every 24 h for three days).
11116418|NCT03960203|Experimental|Comparator|The comparator arm will involve patients monitored by InSight.
11116419|NCT03960190|Experimental|1K expression kit|Subjects will be using the breastpump with the with 1K expression kit.
11116420|NCT03960190|Experimental|2K expression kit|Subjects will be using the breastpump with the with 2K expression kit.
11116421|NCT03960177|Experimental|Supportive care (glucarpidase)|Patients receive standard of care HDMTX intravenously (IV) on day 1 of weeks 4, 5, 9, and 10 as part of a standard osteosarcoma chemotherapy regimen. 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes.
11116422|NCT03960164|Experimental|Patient group|The group of patients included in the study following inclusion criteria with local (wound) and systemic test values prior and after to the application of the DRPM.
11116423|NCT03960151|Experimental|Rolapitant|Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone
11116424|NCT03960138|Experimental|Intermittent Theta-burst stimulation (iTBS)|Cross-over design - participants will receive both experimental treatments.
11116425|NCT03960138|Experimental|Continuous Theta-burst stimulation (cTBS)|Cross-over design - participants will receive both experimental treatments.
11116426|NCT03960125|Experimental|4% Imipramine Cream on Upper Forearm Site|Base cream will be applied to the lower forearm site.
11116427|NCT03960125|Experimental|4% Imipramine Cream on Lower Forearm Site|Base cream will be applied to the upper forearm site.
11116428|NCT03960112|Experimental|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
11116429|NCT03960099|Active Comparator|Pictograph in Banner and Verification Alert|Patient Pictograph displayed in the banner (at the top of the screen) AND Pictograph displayed in a verification alert when placing electronic orders.
11116430|NCT03960099|No Intervention|No Pictograph|No patient Pictographs displayed in the electronic health record.
11116467|NCT03959839|Experimental|Minimally Invasive Laparoscopic Local Surgical Treatment|Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)
11116431|NCT03960086|Experimental|Custom-made foot orthoses|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.
~Treatment period of 12 weeks"
11116432|NCT03960086|Active Comparator|Heel Lifts|"Children in the experimental group received as treatment intervention custom-made polypropylene foot orthoses (Podoactiva®, Spain). They were advised pragmatically to wear the orthoses at least 8 to 10 hours per day for the daily life and during sport activity.
~Treatment period of 12 weeks"
11116433|NCT03960073|Experimental|MitoQ|20mg daily oral dose of MitoQ
11116434|NCT03960073|Placebo Comparator|Placebo|Oral TTP placebo
11116435|NCT03960060|Experimental|CCT301-59|The safety and preliminary therapeutic efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation rule. Three dose levels of CAR T will be administered in this study: 1x10^6, 3x10^6, 1x10^7 CCT301-59 CAR positive T cells/kg weight, intravenous infusion.
11116436|NCT03960047|Experimental|Intervention: Virtual Reality Training|Uses virtual reality to train children to cross streets
11116437|NCT03960047|Experimental|Intervention: Streetside Training|Train children to cross streets using real traffic in curbside locations
11116438|NCT03960047|No Intervention|Control|Receives no intervention
11116439|NCT03960021|Experimental|Single arm|Each patient is treated with 2 RFA interventions.
11116440|NCT03960008|Other|Stereotactic Body Radiation Therapy (SBRT)|Radiation Therapy
11116441|NCT03960008|Other|Trans-Arterial Chemoembolization (TACE)|Procedure/Surgery - Chemoembolization Drug: Doxorubin
11116442|NCT03959995|Experimental|exercise|Exercise group
11116443|NCT03959995|Sham Comparator|control|active control group
11116444|NCT03959982|Experimental|HHHFA Randomized Group|Subjects will be randomized to use the HHHFA device during bedtime for at least 4 hours. Subjects will complete MRC, SGRQ, CAT, CASA-Q and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
11116445|NCT03959982|Active Comparator|Control Group|Subjects will complete MRC, SGRQ, CAT, and PSQI questionnaires. They will do spirometry, 6-minute walk, and CT scan. These interventions will be done at baseline and at the completion of their study (6 weeks). Spirehealth Device will be worn by subject daily for 12 weeks.
11116446|NCT03959969|Experimental|Educational Video Recipients|Participants will be shown educational video on pain management after cesarean delivery on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
11116447|NCT03959969|Active Comparator|Standard of Care Recipients|Participants will be given standard of care discharge instructions for pain management on day of discharge. Upon discharge, participants will be given twenty tablets of oxycodone 5 mg by mouth every four hours as needed for pain and forty tablets of ibuprofen 600 mg by mouth every six hours as needed for pain.
11116448|NCT03959943||Innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction with additional sensory nerve coaptation.
11116449|NCT03959943||Non-innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction without sensory nerve coaptation.
11116450|NCT03959930|Experimental|Interventional arm|Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
11116451|NCT03959904|Active Comparator|Small Stitch|Small stitch for wound closure
11116452|NCT03959904|Active Comparator|Large Stitch|Large Stitch for wound closure
11116453|NCT03959891|Experimental|Fulvestrant + Ipatasertib|"Ipatasertib will be administered orally on a daily basis
~Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles."
11116454|NCT03959891|Experimental|Aromatase Inhibitor + Ipatasertib|"Ipatasertib will be administered orally on a daily basis
~Aromatase inhibitors will be administered orally on a daily basis"
11116455|NCT03959891|Experimental|Fulvestrant + Ipatasertib +Palbociclib|"Ipatasertib will be administered orally on a 3 week on and 1 week off schedule
~Fulvestrant would be administered as intra-muscular injection twice a month for the first cycle, and then monthly for all other cycles.
~Palbociclib will be administered orally on a 3 week on and 1 week off schedule"
11116456|NCT03959878|Experimental|Gastrostomy Tube|Non-hospitalized outpatients undergoing placement of a gastrointestinal gastrostomy tube (GIG tube) or GI jejunostomy tube (GIJ tube) will receive the usual Standards of Care related to the placement of a GIG or GIJ tube and the Constant Pressure Skin Disk.
11116457|NCT03959865||Long-acting GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide once weekly or dulaglutide)
11116458|NCT03959865||Short-acting GLP-1RA|Patients who have been treated with daily GLP-1RA (exenatide bid or liraglutide or lixisenatide)
11116459|NCT03959865||Human GLP-1 based GLP-1RA|Patients who have been treated with GLP-1RA based on human GLP-1 (dulaglutide or liraglutide)
11116460|NCT03959865||Exendin-based GLP-1RA|Patients who have been treated with weekly GLP-1RA (exenatide or lixisenatide)
11116461|NCT03959865||Fixed ratio combination of BI/GLP-1RA|Patients who have been treated with a fixed ratio combination of GLP-1RA and basal insulin (BI), such as IdegLira (insulin degludec / liraglutide) or IglarLixi (insulin glargine / lixisenatide)
11116462|NCT03959865||Flexible combination of BI/GLP-1RA|Patients who have been treated with any GLP-1RA in combination with any basal insulin (BI)
11116463|NCT03959852|Active Comparator|Sub-Dissociative Ketamine alone|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
11116464|NCT03959852|Active Comparator|Fentanyl alone|1 mg/kg of Fentanyl IV administered over at least 1 minute
11116465|NCT03959852|Experimental|Sub-dissociative Ketamine and Fentanyl|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute
11116466|NCT03959839|Experimental|Endoscopic Treatment|Rectal Endoscopic Submucosal Dissection
11116468|NCT03959826|Active Comparator|Job activity contracting|Standard services plus job activity contracting
11116469|NCT03959826|Experimental|Reinforcement for completing activities|Standard services plus job activity contracting plus reinforcement for completing job-related activities
11116470|NCT03959787|Experimental|Educational pamphlet and standard care|patients randomized to the educational pamphlet arm will receive the educational pamphlet
11116471|NCT03959787|No Intervention|control group - standard care|Patients randomized to control arm, will receive the standard care.
11116472|NCT03959774|Experimental|breast or colorectal or lung cancer, age 70 or older|breast or colorectal or lung cancer, age 70 or older
11116473|NCT03959761|Experimental|Treatment Group|Intraperitoneal (IP) nivolumab treatment, after extensive debulking surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
11116474|NCT03959748||PAH adults|Patients with pulmonary arterial hypertension who are at least 18 years old at study entry
11116475|NCT03959748||PAH children|Patients with pulmonary arterial hypertension who are at least 3 months old and are less than 18 years old at study entry
11116476|NCT03959748||CTEPH|Patients with chronic thromboembolic pulmonary hypertension who are at least 18 years old at study entry
11116477|NCT03959735|Experimental|High Intensity Interval Training (HIIT)|"50% of participants (inpatients with a diagnosis of severe mental illness) will be randomised to HIIT. HIIT will be conducted twice a week for 12 weeks using a stationary bike. Each session will have the following structure: 4-minute warm-up, followed by 5X1 minute intervals at 85-95% of maximum heart rate, interspersed with active pauses of 90 seconds cycling at approximately 60-70% of maximum heart rate, and a 4-minute cool-down. Each exercise session will take 19 minutes to complete (11 minutes of HIIT + warm-up and cool-down). However, the amount of HIIT will be adapted for people who may be unable to complete the above target and gradually build up until they can complete the recommended amount.
~All exercise sessions will be conducted in a 1:1 environment with a participant and a member of the research team who will supervise the exercise session."
11116478|NCT03959735|No Intervention|Treatment As Usual (TAU)|50% of participants will be randomised to TAU. They will be provided with details of the local hospital gym availability and instructed to maintain their usual dietary habits
11116479|NCT03959722|Experimental|Probiotics:Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a multispecies probiotics: Ecologic® PERFORMANCE ( 1*1010 CFU(Colony forming units)/daily dose, Winclove Probiotics B.V., Amsterdam).
11116480|NCT03959722|Placebo Comparator|Placebo: Healthy male endurance athletes with GI symptoms|14 weeks of supplementation with a placebo comparator (Winclove Probiotics B.V., Amsterdam)
11116481|NCT03959709|Experimental|Prepectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.
11116482|NCT03959709|Active Comparator|Subpectoral implant placement|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement.
11116483|NCT03959696|Active Comparator|Notification only arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening.
11116484|NCT03959696|Experimental|Training and Notification arm|Clinician participants will be notified of their patients aged 76-85 with an upcoming visit who are due for colorectal cancer screening and will complete a two-hour shared decision making communication skills training course that includes case studies, interactive exercises, and lecture content.
11116485|NCT03959683|Active Comparator|Trilogy device|Trilogy Lithotrite to fragment urinary tract calculi in the kidney, ureter and bladder
11116486|NCT03959683|Active Comparator|ShockPulse-SE|ShockPulse-SE Lithotripsy System to fragment urinary calculi in the kidney, ureter and bladder
11116487|NCT03959670||extensive TAAA|including Crawford extent I and II TAAA
11116488|NCT03959670||Crawford extent III TAAA|
11116489|NCT03959670||supra-renal aortic aneurysms|Crawford extent IV TAAA and para-renal abdominal aortic aneurysms.
11116490|NCT03959631|Experimental|Intervention group|The intervention group will be offered participation for 6 months in a Virtual Communities of practice based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
11116491|NCT03959631|No Intervention|Control group|The control group will not receive any specific intervention. They receive usual care according to actually clinical practice guidelines.
11116492|NCT03959618||dietary supplements group|dietary supplements questionary
11116493|NCT03959592|Active Comparator|Lutein, zeaxanthin and mesozeaxanthin|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain 22 mg total of the carotenoids lutein (10 mg), zeaxanthin (2 mg), and mesozeaxanthin (10 mg).
11116494|NCT03959592|Placebo Comparator|Placebo|Patients will be asked to consume 1 pill daily with a meal, for six months. The pills will contain only sunflower oil (placebo).
11116495|NCT03959579||"1st cohort = derivation cohort:"|"1st cohort = derivation cohort: 1990-1998: cardiac echo + simultaneous systematic endomyocardial biopsy"
11116496|NCT03959579||"2nd cohort = validation cohort"|"2nd cohort = validation cohort: 1999-2016: only cardiac echo with same protocol (endomyocardial biopsy only in case of doubt)"
11116497|NCT03959566|Active Comparator|Arm 1 (U0)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily"
11116498|NCT03959566|Experimental|Arm 2 (U600)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~600 mg Sutezolid orally once daily"
11116499|NCT03959566|Experimental|Arm 3 (U1200)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~1200 mg Sutezolid orally once daily"
11116642|NCT03958617|Sham Comparator|Off condition|Switched off thalamic deep brain stimulation, sham stimulation
11116500|NCT03959566|Experimental|Arm 4 (U600BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~600 mg Sutezolid orally twice daily"
11116501|NCT03959566|Experimental|Arm 5 (U800BD)|"Participants receive the following medication for the duration of 12 weeks (with Bedaquiline, Delamanid and Moxifloxacin as per licensed dose):
~400 mg Bedaquiline orally once daily for the first 14 days, then 200 mg three times a week.
~200 mg Delamanid orally in two daily doses of 100 mg.
~400 mg Moxifloxacin orally once daily
~800 mg Sutezolid orally twice daily
~2 mg Midazolam orally once per day on day-1 and day 14"
11116502|NCT03959553|Placebo Comparator|Placebo|Placebo SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
11116503|NCT03959553|Experimental|GV1001 0.56 mg|GV1001 0.56 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
11116504|NCT03959553|Experimental|GV1001 1.12 mg|GV1001 1.12 mg SC injection administered once weekly for 4 weeks then every 2 weeks through Week 24
11116505|NCT03959540||Cohort 1|Standard of care (including L-DOPA) + starting opicapone
11116506|NCT03959540||Cohort 2|Standard of care (including L-DOPA)
11116507|NCT03959527|Experimental|zoliflodacin|Participant in this arm will receive a single dose of zoliflodacin.
11116508|NCT03959527|Active Comparator|ceftriaxone and azithromycin combination|Participant in this arm will receive a single dose of comparators combination (ceftriaxone and azithromycin).
11116509|NCT03959514|Experimental|AT247|Single subcutaneous injection 0.3 U/Kg
11116510|NCT03959514|Active Comparator|NovoRapid|Single subcutaneous injection 0.3 U/Kg
11116511|NCT03959514|Active Comparator|Fiasp|Single subcutaneous injection 0.3 U/Kg
11116512|NCT03959501|Experimental|Dapagliflozin|Dapagliflozin 10mg daily PO for 24 weeks
11116513|NCT03959501|Active Comparator|Sitagliptin|Sitagliptin 100mg daily PO for 24 weeks
11116514|NCT03959488|Experimental|MEDI8897|anti-RSV monoclonal antibody with an extended half-life
11116515|NCT03959488|Active Comparator|Palivizumab|anti-RSV monoclonal antibody
11116516|NCT03959475||Saint-Etienne Hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116517|NCT03959475||Firminy hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116518|NCT03959475||South Lyon hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116519|NCT03959475||Bordeaux hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116520|NCT03959475||Saint-Chamond hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116521|NCT03959475||Angers hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116522|NCT03959475||Clermont Ferrand hospital|All people aged 75 years and over hospitalized in short-stay geriatric care via a hotline in this hospital
11116523|NCT03959462|Experimental|Real tDCS|20 min of 1 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
11116524|NCT03959462|Sham Comparator|Sham tDCS|30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
11116525|NCT03959449|Experimental|Action Observation and Motor imagery|
11116526|NCT03959449|Active Comparator|Motor Imagery|
11116527|NCT03959449|Experimental|Exercise plus motor imagery and action observation|
11116528|NCT03959423|Experimental|Subjects 7-75 years of age|Subjects who have been diagnosed with type 1 diabetes
11116529|NCT03959410||HPV-positive patients|Patients who are positive for HPV DNA test
11116530|NCT03959397|Experimental|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
11116531|NCT03959384|Experimental|Surfactant replacement (Curosurf)|"Broncho-alveolar lavage (BAL) with 25 mg / kg of Curosurf, diluted 1:10 with physiological solution, divided in two aliquots administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).
~Following supplementation of a dose of 25 mg / kg of Curosurf, diluted with physiological solution 1: 2 (1 ml = 40 mg of surfactant), given in two aliquots with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
11116532|NCT03959384|Placebo Comparator|Ambient Air|"Broncho-alveolar lavage (BAL) with air, administered with a endotracheal tube in two different postures (1st BAL on right decubitus, 2nd BAL on left decubitus).
~Following supplementation of air given with endotracheal tube in two different postures (1st on right decubitus, 2nd on left decubitus). The treatment assigned may be repeated at least 12 hours later and in any case within 24 hours from the first treatment, at the same dosage and with the same method of administration"
11116533|NCT03959358|Experimental|Lenalidomide|"Participants will only receive lenalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.
~Participants will first be given a low dose of lenalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.
~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with lenalidomide at."
11116558|NCT03959202|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants in this group will also receive a Go4Life program book from the National Institute on Aging.
11116559|NCT03959189|Experimental|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
11116534|NCT03959358|Experimental|Pomalidomide|"Participants will only receive pomalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.
~Participants will first be given a low dose of pomalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.
~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with pomalidomide at."
11116535|NCT03959345|Experimental|Combination therapy group|intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
11116536|NCT03959345|Active Comparator|Standard therapy group|intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment
11116537|NCT03959332|Experimental|Baloxavir Marboxil 40 mg|
11116538|NCT03959332|Experimental|Baloxavir Marboxil 80 mg|
11116539|NCT03959319|Experimental|Movement Pattern Training|Focus will be on task-specific training to improve lower extremity movement patterns during basic daily tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Tasks will be prioritized based on patient-report of activity limitations during the baseline examination. For example, during the first visit, the treating physical therapist will begin with the daily and patient-specific tasks that the patient reported as being most bothersome. Exercises will include repeated practice of functional tasks using optimized movement patterns. Based on the participant's performance, the difficulty of the task-specific activities will be progressed by varying the repetitions performed, increasing the load or changing the support surface. The home program will consist of repeated practice of tasks performed during the supervised sessions.
11116540|NCT03959319|Active Comparator|Manual Therapy (Joint Mobilization)|Focus will be on reducing pain and improving pain-free range of motion using manual techniques provided by the physical therapist and exercise performed in the home program. Patient education will include instruction to the benefits of manual therapy and the proposed effects on pain and joint mobility. Joint mobilizations to be used with each patient will be prioritized based on the restrictions, defined as stiffness or pain that is limiting joint range of motion, noted on the patient's baseline examination. For example, during the first visit, the treating physical therapist will begin with the two most restricted motions noted in the baseline exam and perform a standard assessment to determine treatment parameters. The home program will include joint range of motion and stretching exercises to complement techniques performed during the supervised sessions.
11116541|NCT03959306|Experimental|Group I|this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months
11116542|NCT03959306|Active Comparator|Group II|this group of patients will receive their standard anti-diabetic treatment only
11116543|NCT03959293|Experimental|FOLFIRI plus durvalumab|"Durvalumab: 1500 mg by 1-hour IV infusion. Every 4 weeks until progression
~FOLFIRI (1 course every 2 weeks, until progression):
~Irinotecan: 180 mg/m² by 2-hour IV infusion,
~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,
~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,
~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
11116544|NCT03959293|Experimental|FOLFIRI plus durvalumab plus tremelimumab|"Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.
~Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).
~FOLFIRI (1 course every 2 weeks, until progression):
~Irinotecan: 180 mg/m² by 2-hour IV infusion
~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion
~5-FU bolus: 400 mg/m² by 10-minutes IV bolus
~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
11116545|NCT03959280|Experimental|Tailored intervention|"In this group, participants will receive a comprehensive lifestyle program in addition to CPAP therapy which will include a supervised exercise program, diet interventions and behavioural counselling during 12 weeks.
~Then, participants will follow a real-world maintenance program from weeks 12 to 24. It will include one telephone-based contact per month with the study coordinator. Participants will be encouraged to maintain their lifestyle modification during this phase."
11116546|NCT03959280|Active Comparator|Control|Participant in this group will benefit from routine CPAP therapy management from week 0 to 24.
11116547|NCT03959267|No Intervention|Usual Care|Participants will continue with their usual medical care. Usual care may vary at different sites. Based on the investigator's preliminary data usual care can result in not GCRA referral, referral directly to testing, or referral to genetic counseling with an interpreter. The investigators will document usual care for participants from the sites randomized to usual care.
11116548|NCT03959267|Other|Telephone Genetic Counseling|Participants will receive telephone genetic counseling with the culturally adapted protocol and booklet
11116549|NCT03959254|Experimental|Intervention Group|Application of a protocol of active exercises for recovery after arthroscopic hip surgery, adapted to the femoroacetabular shock characteristics.
11116550|NCT03959254|Active Comparator|Control Group|Usual post-surgical general guidelines for hip interventions described by Gocen et al
11116551|NCT03959241|Active Comparator|Tacrolimus/Methotrexate|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
11116552|NCT03959241|Experimental|Tacrolimus/MMF/PTCY|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
11116553|NCT03959228|No Intervention|referencial diet|0.8 g/kg/day of protein
11116554|NCT03959228|Experimental|protein very poor diet with additional keto-analogs|0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.
11116555|NCT03959215|Experimental|Usual care + Back in the Game|Smartphone-delivered cognitive behavioural therapy to support confidence to return to sport + usual post-operative physiotherapy rehabilitation
11116556|NCT03959215|Active Comparator|Usual care|Usual post-operative physiotherapy rehabilitation
11116557|NCT03959202|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
11116560|NCT03959189|Experimental|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
11116561|NCT03959176|Experimental|Group 1|"The right eye will receive a sham drop followed by 1 drop of Tropicamide 1%/Phenylephrine 2.5% five minutes after the sham drop is administered. A one minute wait will occur followed by a second drop of Tropicamide 1%/Phenylephrine 2.5%.
~The left eye will receive 2 drops of Brimonidine 0.2% followed by a five minute wait time. One drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a one minute wait time. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered."
11116562|NCT03959176|Experimental|Group 2|"The right eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered followed by a 15 second wait after which a sham drop will be administered.
~The left eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a 15 second wait after which 2 drops of Brimonidine will be administered."
11116563|NCT03959163|Other|DMSA/Quick MRI|All participants will go through DMSA and Quick MRI scan to help determine the validity of the Quick Renal MRI in pediatric kidney disease.
11116564|NCT03959150|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 po qd
11116565|NCT03959150|No Intervention|Observation|Observation
11116566|NCT03959137||Primary study group|Stage IV untreated NSCLC
11116567|NCT03959124|Experimental|AD with DBS|Alzheimer's disease subjects with optimal medication therapy and with DBS treatment
11116568|NCT03959124|Active Comparator|AD without DBS|Alzheimer's disease subjects with optimal medication therapy and without DBS treatment
11116569|NCT03959124|No Intervention|Normal control|Matched aged and demographics subjects
11116570|NCT03959111|Experimental|Ear stimulation (Location 1)|
11116571|NCT03959111|Experimental|Ear stimulation (Location 2)|
11116572|NCT03959085|Experimental|Arm I (HR-FAV B-ALL)|See detailed description for Arm I
11116573|NCT03959085|Active Comparator|Arm II (HR B-ALL CONTROL)|See detailed description for Arm II.
11116574|NCT03959085|Experimental|Arm III (HR B-ALL EXPERIMENTAL)|See detailed description for Arm III.
11116575|NCT03959085|Experimental|Arm IV (MPAL)|See detailed description for Arm IV.
11116576|NCT03959085|Experimental|ARM V (B-LLY)|See detailed description for Arm V.
11116577|NCT03959072||Robotic Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
11116578|NCT03959072||Conventional (manual) Chronic Total Occlusion PCI|The procedure will be randomized in a 1:1 fashion to either CorPath GRX robotic-assisted Chronic Total Occlusion PCI or conventional manual Chronic Total Occlusion PCI.
11116579|NCT03959059|Experimental|PKP of traditional procedure|traditional method of PKP
11116580|NCT03959046|Experimental|GIST|"GIST is an alternative way of speaking to patients. In order for patients to get the gist, Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved."
11116581|NCT03959046|No Intervention|Usual Care|These are physician and patient participants that will communicate in their normal, unchanged way.
11116582|NCT03959020||Patients, undergoing anti-reflux surgery|Patients having undergone anti-reflux surgery at the Department of Surgery, Kolding Hospital, a part of Hospital Lillebaelt, from 1th January 2002 - 31th December 2013
11116583|NCT03959007|Active Comparator|Control|Usual therapy and complete 3 questionnaire at 3 times during hospitalization : Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status
11116584|NCT03959007|Experimental|Experimental|9 consultations (3 x 3 sessions during hospitalization) of aesthetic care will be provided to patient include in experimental arm and 3 times questionnaires (Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status)
11116585|NCT03958981|Experimental|castor oil group|60 mL of castor oil in 140 mL of orange juice
11116586|NCT03958981|Placebo Comparator|placebo group|Patients will receive sunflower oil as a placebo
11116587|NCT03958955|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
11116588|NCT03958955|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
11116589|NCT03958942|Active Comparator|quadratus lumborum block|received pre-emptive ultrasound-guided quadratus lumborum block with 25 mL of 0.25% bupivacaine on each side of the abdominal wall before induction of GA.
11116590|NCT03958942|Active Comparator|lumbar epideural block|received pre-emptive lumbar epidural block with 15 mL of 0.25% bupivacaine before induction of GA.
11116591|NCT03958929|Experimental|Education group|Subjects will be asked to watch a 5-10 min education film two times (pre-op one day and post-op one day).
11116592|NCT03958929|No Intervention|Control group|Standard patient procedure that includes a pre-operative discussion with an ophthalmologist about glaucoma surgery, during which the surgeon gains the patient's informed consent. Subjects will not be asked to watch education film..
11116593|NCT03958903|Experimental|Neurophysiological recording and stimulation of amygdala|Recording and stimulation of amygdala using Neuropace RNS devices at certain points through out the behavioral tasks.
11116594|NCT03958890|Experimental|HLX10|
11116595|NCT03958890|Placebo Comparator|placebo|
11116596|NCT03958877|Experimental|BIIB017 (peginterferon beta-1a)|Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
11116597|NCT03958877|Active Comparator|Avonex|Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
11116598|NCT03958864|Experimental|CC-90001 100 mg|100 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
11116599|NCT03958864|Experimental|CC-90001 200 mg|200 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
11116600|NCT03958864|Experimental|CC-90001 400 mg|400 mg of CC-90001 (once daily [QD] x 7 days) will be given orally
11116601|NCT03958851||patients with lupus nephritis|Lupus nephritis is diagnosed by either the presence of proteinuria (>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.
11116602|NCT03958851||systemic lupus patients without lupus nephritis|The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group
11116603|NCT03958851||healthy individuals|a group of age and sex matched healthy individuals will be taken as a control group.
11116604|NCT03958838|Experimental|Intervention Group|"Subjects will receive usual care from community health center staff. In addition, they will also receive a variety of community-level and individual-level interventions, categorized broadly into three levels.
~At the community level, subjects will receive the 5 Key Diabetes Messages that Everyone Should Know and the 6 Modules of Basic Diabetes Education. At the individual level, subjects and their families will be invited to participate in group activities, co-organized by community health staff, CHC staff, and CSMG peer leaders. Subjects will receive in-person peer support through these group activities, with follow up through telephone calls and text messaging. For subjects that have poorly controlled diabetes or are experiencing emotional distress related to their diabetes, CSMG peer leaders will work closely with them to help them solve problems around their diabetes."
11116605|NCT03958838|No Intervention|Control Group|Subjects in the control group will receive usual care from community health center staff.
11116606|NCT03958825|Active Comparator|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
11116607|NCT03958825|Experimental|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
11116608|NCT03958812||Gastric cancer|patients with definitive diagnosis of gastric cancer by pathology
11116609|NCT03958812||Breast cancer|patients with definitive diagnosis of breast cancer by pathology
11116610|NCT03958812||Benign gastric diseases|Gastritis or gastric ulcer
11116611|NCT03958812||Benign breast diseases|Hyperplasia of mammary glands or mastitis
11116612|NCT03958812||Normal|healthy volunteers
11116613|NCT03958799|Experimental|Group 1: Investigational Product (IP) Formulation A|IP Formulation A administration, participation in Stage 1 and Stage 2
11116614|NCT03958799|Experimental|Group 2: IP Formulation A|IP Formulation A administration, participation in Stage 1
11116615|NCT03958799|Experimental|Group 3: IP Formulation B|IP Formulation B administration, participation in Stage 1 and Stage 2
11116616|NCT03958799|Experimental|Group 4: IP Formulation B|IP Formulation B administration, participation in Stage 1
11116617|NCT03958799|Experimental|Group 5: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
11116618|NCT03958799|Experimental|Group 6: IP Formulation C|IP Formulation C administration, participation in Stage 1 and Stage 2
11116619|NCT03958799|Experimental|Group 7: IP Formulation D|IP Formulation D administration, participation in Stage 1 and Stage 2
11116620|NCT03958799|Active Comparator|Group 8: Tdap|TdaP administration, participation in Stage 1 and Stage 2
11116621|NCT03958799|Active Comparator|Group 9: Tdap|TdaP administration, participation in Stage 1
11116622|NCT03958786|Experimental|single arm|500 HIV-1 infected patients, aged 70 years and older
11116623|NCT03958773|Experimental|Cardiovalve treatment|
11116624|NCT03958760||Diabetic patients with CVD, CKD or at risk|The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
11116625|NCT03958760||Diabetic patients without CVD, CKD or at risk|The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
11116626|NCT03958760||Non-diabetic patients with CVD, CKD or at risk|The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk.
11116627|NCT03958760||Health controls|The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk.
11116628|NCT03958747|Experimental|Ultrasound|Undergo peripheral nerve ultrasound
11116629|NCT03958734|Other|Low physical activity/fitness|Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
11116630|NCT03958734|Other|High physical activity/fitness|Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
11116631|NCT03958721|Experimental|Concurrent Adjuvant Capecitabine and Radiotherapy|
11116632|NCT03958708|Experimental|Treatment Arm|
11116633|NCT03958695|Active Comparator|Tunable-tension transobturator tape (TTT)|
11116634|NCT03958695|Active Comparator|Transobturator mid-urethral tape (TOT)|
11116635|NCT03958682|Experimental|experimental group|During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.Patients can receive timely diagnosis and appropriate treatment
11116636|NCT03958669||Sorafenib treated HCC patients|No intervention is performed. This is an observational study.
11116637|NCT03958656|Experimental|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Patients will receive escalating doses (up to 4 planned) of Anti-SLAMF7-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
11116638|NCT03958656|Experimental|2/Conditioning chemotherapy plus CAR T-cells expansion phase|MTD dose of Anti-SLAMF7- CAR T Cells + Cyclophosphamide: 300 mg/m^2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
11116639|NCT03958643||1|In a population of adult patients with SCD we will comprehensively evaluate renal function
11116640|NCT03958630|Experimental|PET scan|Healthy and Patients
11116641|NCT03958617|Active Comparator|On condition|Ongoing thalamic deep brain stimulation
11116643|NCT03958604|Experimental|Burst Spinal Cord Neurostimulation|Burst spinal cord stimulation. When this fails, tonic stimulation targeting the DRG wil be applied
11116644|NCT03958591|Experimental|Intensive-de-escalation group with intelligent management|
11116645|NCT03958591|Experimental|Intensive-de-escalation group without intelligent management|
11116646|NCT03958591|Active Comparator|Traditionally upgrading group|
11116647|NCT03958565||Actionable driver oncogene|One group will have an actionable driver oncogene and initiate treatment in any line with a TKI as standard of care and concurrent to participation to this study; expected to have an objective response rate in ≥40% who have not previously seen anti-bone resorptive therapy.
11116648|NCT03958565||No Actionable Mutations|The other group will not have actionable mutations and initiate treatment with chemotherapy/immunotherapy along with new onset therapy with IV zoledronic acid 4mg Q4 weeks or subcutaneous denosumab 120 mg Q12 weeks for bone disease, which is standard of care and would be concurrent to participation in this study.
11116649|NCT03958552|No Intervention|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
11116650|NCT03958552|Experimental|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
11116651|NCT03958539|Active Comparator|Intervention arm|6 sites out of a total of 12 will act as the intervention sites. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to be provided with bespoke 3-D printed insoles.
11116652|NCT03958539|No Intervention|Control|6 sites out of a total of 12 will act as the control sites providing standard care. 450 Patients with high risk of primary DFUs defined by peripheral sensory neuropathy and callus formation or critical limb ischaemia or on renal replacement therapy will be cluster randomised to standard care
11116653|NCT03958526|Active Comparator|Active|Active stimulation over M1
11116654|NCT03958526|Placebo Comparator|Sham|Sham stimulation over M1
11116655|NCT03958513|Placebo Comparator|Placebo|0.9% normal saline, 1.5 ml for 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
11116656|NCT03958513|Experimental|Intervention|0.25% Bupivacaine, 1.5 ml per 1 inch incision, before closure of ports in patients undergoing Laparoscopic Cholecystectomy
11116657|NCT03958500|Experimental|Comprehensive anastomotic testing|"All patients undergo:
~Indocyanine green fluorescent angiography intraluminally and intraperitoneally
~Air leak test
~Methylene blue test"
11116658|NCT03958487|Experimental|executive/monitoring training|All participants will be part of the same group and their performance after treatment will be compared to their own performance prior to treatment (baseline)
11116659|NCT03958474|Experimental|Active treatment followed by placebo treatment|Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
11116660|NCT03958474|Experimental|Placebo treatment followed by active treatment|Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.
11116661|NCT03958461|Other|Calculus removement|Anti-infective treatment of teeth
11116662|NCT03958448|Experimental|Short Group|In each side of the posterior region of the maxilla, one tissue level implant, 4 mm long and 4.1 mm in diameter, will be installed
11116663|NCT03958448|Experimental|Standard group|sinus floor elevation with will be performed using natural bovine bone graft as filler material and porcine dermis collagen membrane to cover the antrostomy. After 4 months of healing, one bone level implant, 10 mm long and 4.1 mm in diameter, will be installed into each augmented sinus.
11116664|NCT03958422|Experimental|Myocardin test group|Patients in cardiomyopeptidin group are given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) and intravenous infusion of cardiomyopeptidin was performed 3 days after primary PCI.
11116665|NCT03958422|No Intervention|Blank test group|Patients in blank test group aren't given the injection of cardiomyopeptidinl before primary percutaneous coronary intervention (PCI) .
11116666|NCT03958409|Experimental|Rigorous evaluation|Participants will be evaluated for the rigorous evaluation received.
11116667|NCT03958409|Active Comparator|Standard care|The participants will be evaluated for the standard of care received.
11116668|NCT03958396|Active Comparator|OSA Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea
11116669|NCT03958396|Active Comparator|Control (non-OSA) Group|a) Children 8-14 years old, b) ASA physical status 1or 2, c) no known obstructive sleep apnea presenting for any procedure requiring general anesthetic
11116670|NCT03958383|Experimental|Experimental Groups|"PHASE IA: As described above. Participants receive hu14.18-IL2 fusion protein intratumorally (IT).
~PHASE IB: As described above. Participants undergo palliative RT and hu14.18-IL2 fusion protein IT as in phase IA.
~PHASE IC: As described above. Participants undergo palliative RT, receive nivolumab, and hu14.18-IL2 fusion protein IT as in phase IA.
~PHASE ID: As described above. Participants undergo palliative RT, receive nivolumab in combination with ipilimumab, and hu14.18-IL2 fusion protein IT as in phase IA."
11116671|NCT03958370||Fitbit|
11116672|NCT03958357||Treatment arm|Single arm study, 40 participants will undergo brachytherapy with the Advanced Gynecological Applicator Venezia Configuration
11116673|NCT03958344|Experimental|Intraorbital injection of steroid|"2 mL of steroid will be ready for each injection session:
~1 mL Triamcinolone (40 mg) + 1 mL Betamethasone (6 mg) = 2 mL
~For Dacryoadenitis without myositis , 1 mL of this compound will be injected at lacrimal gland through 1 site of injection.
~For Dacryoadenitis plus 1 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at the rectus muscle through 2 separate sites of injection.
~For Dacryoadenitis plus 2 rectus muscles myositis 1 mL of this compound will be injected at lacrimal gland and 0.5 mL of this compound will be injected at either recti muscles through 3 separate sites of injection."
11116728|NCT03957941|Active Comparator|Standard Pumping|Pump three times while away from infant, not watching baby via FamilyLink.
11116729|NCT03957928|Active Comparator|Low fat cookies|Subjects consume 100 kcal of low fat cookies daily for 12 weeks.
11116674|NCT03958344|Active Comparator|Oral Steroid|"Each patient will receive oral Prednisolone, 1 mg/kg, for 5-7 days, followed by tapered dose in 12 weeks (according to a pre-defined table of oral administration dose).
~Daily Omeprazole 40mg p.o and daily Calcium Supplement will also be recommended to avoid complications."
11116675|NCT03958331|Active Comparator|Control Group|Automated reminders and individualized adherence feedback reports
11116676|NCT03958331|Experimental|Treatment Group|Automated reminders and individualized adherence feedback reports with social norms comparisons
11116677|NCT03958318|Experimental|Exercise|Multi-modal exercise program
11116678|NCT03958318|Experimental|Exercise plus nutritional suplementation|Multi-modal exercise program plus nutritional suplementation
11116679|NCT03958318|No Intervention|Control|No interventions
11116680|NCT03958305||LAPAROTOMY|Radical hysterectomy by laparotomy
11116681|NCT03958305||MINIMALLY INVASIVE SURGERY|Radical hysterectomy by minimally invasive surgery (Laparoscopy or Robotics)
11116682|NCT03958292|Experimental|Patients undergoing routine cataract surgery|"Two eye drops containing PVP-Iodine instillation in the eye undergoing cataract surgery three times for three days before surgery.
~Each patient was evaluated for conjunctival flora variation by means of two conjunctival swabs before starting the treatment and at the end of the treatment before the surgery."
11116683|NCT03958279||primipara giving birth|"The investigators involve every primipara giving birth in a period of two years.
~Exclusion criteria:
~a) Unwilling to participate
~b) Minors (under 18 years old)
~c) Foetus mortus or perinatal death of the newborn
~d) Admission of the newborn to the ICU
~e) Unfamiliar with slovak language
~f) Multiple pregnancy"
11116684|NCT03958266||MyIBD Care - Study Group|Will have traditional face to face outpatient contacts replaced with a novel mobile phone application supported via a digital clinician portal
11116685|NCT03958253|Experimental|Lung Cancer Screening Toolbox|"WU Staff will train local screening staff using a train-the-trainer model three months prior to the intervention and will provide technical assistance on an ongoing basis.
~During the 3 hour train-the-trainer session, the selected staff from the referral sites will learn about the program, receive an orientation to the toolbox elements, and discuss how to adapt the elements of the toolbox to their referral sites."
11116686|NCT03958240|Other|Patient with local and/or metastatic solid malignant tumor|Patient receiving an anticancer treatment in the context of their standard care.
11116687|NCT03958227|Experimental|''Manuel Therapy group''|This treatment group will be received Manuel Therapy techniques and exercise interventions.
11116688|NCT03958227|Experimental|''Exercise group''|This treatment group will be received only exercise interventions.
11116689|NCT03958214|Experimental|Recipe 4 Success|For 12 weeks, home visitors will stop delivering the usual practice Early Head Start home visits and deliver the Recipe 4 Success curriculum instead. At the end of 12 weeks, home visitors will resume usual practice Early Head Start home visits.
11116690|NCT03958214|Active Comparator|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
11116691|NCT03958201|Other|Protocol|Patients will have perioperative neuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed objectively at adductor pollicis with quantitative neuromuscular monitoring.
11116692|NCT03958188||Patients|"Patients who have undergone pre-operated computerized tomography (CT) imaging for a subsequently operated Neuro-endocrine tumor (NET).
~Clinical data collected for each patients:
~Age
~Sex
~Symptomatology (abdominal pain, diarrhea, carcinoid flush, digestive bleeding, weight loss, occlusive syndrome)
~Blood Chromogranine A and urinary 5-hydroxyindoleacetic acid (5-HIAA)
~Carcinoid valvulopathy"
11116693|NCT03958175||Patients with Parkinson's Disease|Patients with Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
11116694|NCT03958175||Patients without Parkinson's Disease = control group|Patients without Parkinson's Disease (PD) were evaluated for reading disorders using a screening method validated for dyslexia.
11116695|NCT03958162|Experimental|uniportal and tubeless video assisted thoracic surgery|lung biospy by the uniportal and tubeless video assisted thoracic surgery
11116696|NCT03958162|Experimental|transbronchial lung cryobiopsy|transbronchial lung cryobiopsy
11116697|NCT03958149|Other|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
11116698|NCT03958136|Experimental|Patients HR + and HER2-|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
11116699|NCT03958136|Experimental|Patients HER2 + with or without HR+|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
11116700|NCT03958136|Experimental|Patients triple negative (HR- and HER2-)|"At each disease progression, patient will have specific interventions :
~Metastasis biopsy
~Biomarkers blood, urine and microbiota samples
~Patient Reported Outcome (PRO)"
11116701|NCT03958123|Experimental|Treatment Group 1: Cebranopadol|"Supratherapeutic dose (1600 μg) of cebranopadol:
~Participants received placebo once a day for 2 days (Days -3 and -1); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 3 days; 900 μg once a day for 3 days; 1300 μg once a day for 3 days; 1600 μg once a day for 14 days; and placebo once a day on the last dosing day.
~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
11116702|NCT03958123|Experimental|Treatment Group 2: Cebranopadol|"Therapeutic dose (600 μg) of cebranopadol:
~Participants received placebo once a day for the first 11 days (Days -3, -1 and 1-9); 200 μg of cebranopadol once a day for 3 days; 400 μg once a day for 3 days; 600 μg once a day for 14 days; and placebo once a day on the last dosing day.
~Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days. Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
11116703|NCT03958123|Experimental|Treatment Group 3A: Placebo and Moxifloxacin|"Placebo / Moxifloxacin:
~Participants received placebo once a day for 31 days (Days -3, -1 and 1-29) and moxifloxacin 400 mg once on the last dosing day. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.
~Participants received 4 encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
11116704|NCT03958123|Experimental|Treatment Group 3B: Moxifloxacin and Placebo|"Moxifloxacin / Placebo:
~Participants received placebo once a day for 2 days (Days -3 and -1); moxifloxacin 400 mg once for 1 day; and placebo once a day for the following 29 days. Participants received capsules under fasting conditions on Days -3, -1, 1, 29 and 30, and under fed conditions on all other dosing days.
~Participants received four encapsulated cebranopadol/ placebo tablets and 1 encapsulated moxifloxacin/ placebo tablet (5 capsules in total) on Day -3, Day -1, and from Day 1 to Day 30. Capsules were taken with 240 mL of water."
11116705|NCT03958097|Experimental|NK cell combined with PD-L1 antibody|"Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16), total NK cells infused at least 3×10^9 .
~200mg PD-L1 antibody(Sintilimab Injection) will be given on D14, 1 hour after NK cells infusion.
~NK cells and PD-L1 antibody will be infused every 21 days until disease progression or unacceptable adverse events."
11116706|NCT03958084|Experimental|Massage group|The deep massage will be applied for three minutes in the ischiotíbial muscles, only in the left limb, towards the muscular fibers. The volunteers will be placed in a ventral decubitus position on the stretcher.
11116707|NCT03958084|Experimental|Ventosa therapy group|The negative pressure ventosa therapy slide winds will be applied for three minutes in the oval direction in the posterior region of the thigh to contemplate the full extent of the ischiotíbial muscles, only in the left limb. The volunteers will be placed in a ventral decubitus position on the stretcher.
11116708|NCT03958084|Experimental|Foam roller group|The foam roller is a self-applied intervention for three minutes where the volunteers will be positioned on bench press on the floor of the room, with the left thigh posteriorly on the foam roller and the leg extended, the right lower limb will be in flexion of hip and knee, only the right foot and the right and left hands will touch the ground. Volunteers will be instructed to move so that they move forward and backward, causing the roller to travel the full length of the hamstring muscles.
11116709|NCT03958084|Experimental|Lumbar mobilization group|Unilateral lumbar mobilization of grade III at the frequency of 2Hz at the joint L4 / L5 of the ipsilateral side of the limb tested. The frequency was guaranteed by a metronome set at 120 beats per minute. Three sets of 1 minute of mobilization were performed with a 30 second interval, totaling a time of 4 minutes and 30 seconds of intervention. The technique was performed with the patient in the ventral decubitus position.
11116710|NCT03958084|Experimental|Proprioceptive neuromuscular facilitation group|Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
11116711|NCT03958084|No Intervention|Control group|The patient remained lying down in the ventral position for 4 minutes. the patient remained lying down in the ventral position for 4 minutes.
11116712|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
11116713|NCT03958058||Anti-borrelial antibiotic therapy|
11116714|NCT03958058||No antibiotics|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
11116715|NCT03958045|Experimental|Patients with Stage IV SCLC|Patients with extensive stage (IV) SCLC (small cell lung cancer)
11116716|NCT03958032||Participants with gastric cancer|All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
11116717|NCT03958019|Experimental|Intervention Group|12 week multidisciplinary program consisting of; i) supervised and home-based aerobic and resistance training, ii) 1:1 dietary counselling, and iii) group education sessions.
11116718|NCT03958019|No Intervention|Control|Usual care control group
11116719|NCT03958006|Experimental|Cochlear implantation|Simultaneous cochlear implantation with tumor resection
11116720|NCT03957993|Experimental|Occupational Therapy via Telehealth|Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
11116721|NCT03957993|Active Comparator|Standard of Care Occupational Therapy|Participants in the standard of care model will undergo occupational therapy treatment via traditional in- person encounters in an outpatient clinic setting for the entire episode of care (generally 10-12 weeks). These children will receive routine occupational treatment via in-person sessions with an occupational therapist conducted in an outpatient clinic setting.
11116722|NCT03957980|Other|Telehealth Intervention First|The participants in this arm of the study received occupational therapy via telehealth in the first 12 weeks of enrollment, then received no other intervention for the duration of the study.
11116723|NCT03957980|Other|No Intervention First|The participants in this arm of the study did not receive an intervention in the first 12 weeks of enrollment, but received occupational therapy via telehealth during the second 12 weeks of enrollment.
11116724|NCT03957967||acute pain|Patient with acute pain
11116725|NCT03957954|Experimental|Cultivated Limbal Stem-Cells (cLSC)|One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.
11116726|NCT03957954|Active Comparator|Scleral Contact Lens Device (SCL)|Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.
11116727|NCT03957941|Experimental|FamilyLink Pumping|Pump three times while away from infant, while watching baby via FamilyLink.
11116730|NCT03957928|Experimental|Mango fruit|Subjects consume 100 kcal of mango fruit daily for 12 weeks.
11116737|NCT03957876|Experimental|intravenous CPX-351 with potential maintenance therapy|Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
11116738|NCT03957850|Experimental|Cognitive Reappraisal Training Group|Cognitive Reappraisal Training group will perform 4 training sessions in Cognitive Reappraisal during which, behavioral responses, event-related potentials (ERPs) and eye-tracking data are collected.
11116739|NCT03957850|Active Comparator|Control Training Group|Control Training Group will perform 4 control sessions without Cognitive Reappraisal Training during which behavioral responses, ERP and eye-tracking data are collected.
11116740|NCT03957837||Steep Trendelenburg|Patients undergoing elective laparoscopic prostatectomy in steep Trendelenburg position (25 degrees head down position)
11116741|NCT03957837||Healthy controls|Healthy awake volunteers undergoing steep Trendelenburg position (25 degrees head down position)
11116742|NCT03957811|No Intervention|Controls|Subjects under treatment for diabetes will receive the standard treatment for their condition.
11116743|NCT03957811|Experimental|Intervention|Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.
11116744|NCT03957798|No Intervention|Control (Treatment as Usual)|TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment. For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center. For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service. For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service. For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
11116745|NCT03957798|Experimental|Intervention (Treatment as usual + game)|
11116746|NCT03957785|Experimental|Alter G treatment|All participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.
11116747|NCT03957785|Active Comparator|Traditional Gait Training|All participants practiced one session a day TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using FAC-tailored physiotherapist assistance, to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). Physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions.
11116748|NCT03957785|Active Comparator|Healthy Control|ll participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.The HC initially practiced the device at the same BWS and S administered to the patients. BWS and S were reduced progressively and increased, respectively, across the AlterG sessions in keeping with patients progresses.
11116749|NCT03957772|Active Comparator|Extrafascial injection|"Extrafascial injection of local anesthetic
~Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic"
11116750|NCT03957772|Experimental|Intrafascial injection|"Intrafascial injection of local anesthetic
~Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic"
11116751|NCT03957759||COPD patients|
11116752|NCT03957746|Experimental|3 sets of resistance exercise|
11116753|NCT03957746|Experimental|6 sets of resistance exercise|
11116754|NCT03957746|Experimental|9 sets of resistance exercise|
11116755|NCT03957746|No Intervention|Rest|
11116756|NCT03957733|Experimental|Experimental arm|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and surgery. Consolidation chemotherapy will start 2-4 weeks after the end of CRT. Surgery will be performed 2-4 weeks after the last chemotherapy cycle. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (4 cycles of modified FOLFOX6 or 3 cycles of XELOX).
11116757|NCT03957733|No Intervention|Standard arm|Long course CRT will be followed by surgery 10-12 weeks after the end of CRT. After surgery, patients with pT0-2 N0 will not receive adjuvant chemotherapy. Patients with higher pathological stage will receive adjuvant chemotherapy (8 cycles of modified FOLFOX6 or 6 cycles of XELOX).
11116758|NCT03957720|Experimental|homo-R778L|When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
11116759|NCT03957720|Experimental|R778L+truncation mutation|"When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment.
~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
11116817|NCT03957330|Experimental|No Reflection Questionnaire|In this arm, no reflection questions will be asked of clients receiving ICBT.
11116760|NCT03957720|Experimental|Homo-P992L|"When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment.
~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
11116761|NCT03957720|Experimental|P992L+truncation mutation|"When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment.
~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
11116762|NCT03957720|Experimental|T935M+other point mutations|When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
11116763|NCT03957720|Experimental|Presymptomatic patients with Wilson's disease|"According to different age group, they receive various dosage of Zinc Gluconate treatment.
~Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;"
11116764|NCT03957707|Experimental|stereotactic surgery with drugs treatment|
11116765|NCT03957707|Sham Comparator|drugs treatment alone|
11116766|NCT03957694|Experimental|AMG531|
11116767|NCT03957681|Experimental|KHK4827|
11116768|NCT03957681|Placebo Comparator|Placebo|
11116769|NCT03957668|Experimental|PEG 3350|The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.
11116770|NCT03957668|Active Comparator|Lactulax|15 ml of Lactulax syrup (containing 10 g of lactulose) is drunk with 240 ml of water once daily at bedtime, for a duration of 14 days
11116771|NCT03957655|Experimental|SHED group|SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.
11116772|NCT03957655|No Intervention|Control|Standard medication for viral hepatitis and cirrhosis
11116773|NCT03957629|Active Comparator|TDF group|93 patients would receive treatment of oral medication of tenofovir disoproxil fumarate (TDF) 300mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
11116774|NCT03957629|Active Comparator|Combination group|93 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg once per week and meanwhile oral medication of tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
11116775|NCT03957616||Paraneoplastic neurological syndromes patients|Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
11116776|NCT03957603|Experimental|TPF-DM Combined with Medical Nutrition Therapy Intervention|Participants in the experimental group will be provided with an individualized dietary, nutrition recommendation and the additional Enteral Nutrition Suspension (TFP-DM, Diason 0.75 kcal/ml). Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
11116777|NCT03957603|Active Comparator|Medical Nutrition Therapy Intervention|Based on the standard care, Participants will receive an individualized dietary, nutrition recommendations with the application of food exchange porting. Participants are required to schedule the first follow-up visit one week after receiving the individualized recommendations. Afterward, the regularly scheduled follow-up visit will be scheduled every two to four weeks.
11116778|NCT03957590|Experimental|Arm A: Tislelizumab （BGB-A317）combined with chemoradiotherapy|Tislelizumab(BGB-A317) will be administrated at dose of 200 mg intravenous dosing (IV) once every cycle (Q3W), Paclitaxel 135 mg/m² will be administered as an intravenous infusion on Day 1 of every cycle (3 weeks)， total 2 Cycle; Cisplatin 25 mg/m² will be administered as an intravenous infusion on Day 1 to 3 of every cycle (3 weeks) Total 2 Cycle. Radiotherapy total dose of 50.4 Gy in 28 fractions
11116779|NCT03957590|Placebo Comparator|Arm B: Placebo combined with chemoradiotherapy|Placebo will be administrated at does of 200 mg intravenous dosing (IV)once every cycle (Q3W); Paclitaxel 135 mg/m² will be administered as an intravenous infusion on Day 1 of every cycle (3 weeks) ， total 2 Cycle; Cisplatin 25 mg/m² will be administered as an intravenous infusion on Day 1 to 3 of every cycle (3 weeks), total 2 Cycle. Radiotherapy total dose of 50.4 Gy in 28 fractions.
11116780|NCT03957577||All subjects|Subjects will not receive any study drug as intervention in this study. Subjects will continue to use medications prescribed by their regular treating physician and will continue to visit their regular treating physician for their healthcare during the study.
11116781|NCT03957564|Experimental|Patients receiving neoadjuvant chemotherapy.|"Compare the monitoring of CTC, ctDNA and cfDNA with the results of CT scan and the blood level of CEA ,CA19-9 and CA72-4 tumor markers to explore the clinical value of dynamic detection of CTC, ctDNA and cfDNA in neoadjuvant chemotherapy and operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer.
~Explore the clinical value of different types of CTC in neoadjuvant chemotherapy and Operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer. CTC can be classified into three types: epithelial CTC, mesenchymal CTC, hybrids CTC.
~Explore the consistency between plasma ctDNA and tumor related DNA in pathological tissues after operation.
~To explore the relationship between the dynamic changes of plasma CTC, ctDNA and cfDNA levels and the prognosis of patients after operation."
11116782|NCT03957551|Experimental|Cabozantinib and pembrolizumab|Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
11116783|NCT03957538|No Intervention|Standard care|Standard consent and explanation
11116785|NCT03957525|Experimental|Orthopaedic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
11116786|NCT03957525|No Intervention|Orthopaedic Control group|Gets written and oral preparation for surgery
11116787|NCT03957525|Experimental|Urologic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
11116788|NCT03957525|No Intervention|Urologic Control group|Gets written and oral preparation for surgery
11116789|NCT03957525|Experimental|General Paediatric Surgery Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
11116790|NCT03957525|No Intervention|General Paediatric Surgery Control group|Gets written and oral preparation for surgery
11116791|NCT03957499|Placebo Comparator|the control group|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
11116792|NCT03957499|Active Comparator|Group dexamethasone/Bupivacaine:|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml).(
11116793|NCT03957499|Active Comparator|Group Magnesium sulphate/Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
11116794|NCT03957486|Experimental|Same group|arterial cannulation on same arm of continuous hemoglobin monitoring
11116795|NCT03957486|Placebo Comparator|Different group|arterial cannulation on different arm of continuous hemoglobin monitoring
11116796|NCT03957473||Single Arm|Single Arm - Use of Indigo Aspiration System with CAT RX Aspiration Catheter (mechanical thrombectomy) in high thrombus burden acute coronary vessel occlusions
11116797|NCT03957460||continuous and noninvasive hemoglobin monitoring|Group receive the continuous and noninvasive hemoglobin monitoring during laparoscopic gastrectomy.
11116798|NCT03957447||patients exhibiting skin wounds|Within the framework of Taabo HDSS Cross-sectional community and health services surveys are performed before wound management intervention (main study and substudy 1) is implemented (baseline) and are continued at 6 monthly intervals thereafter. Surveys are done door-to-door. All patients with skin lesions (broken skin barrier) are enrolled, lesions are documented with help of a questionnaire and photographic documentation.
11116799|NCT03957447||patients identified in the survey and willing to participate|Each patient with a wound will be enrolled. Presumptive clinical diagnosis and empirical treatment, as well wound assessment, will be recorded at enrollment and at each follow-up visit. Additional laboratory testing done within the framework of the local health system will also be recorded.
11116800|NCT03957447||patients exhibiting Buruli ulcers < 2cm|Buruli ulcer patients fulfilling inclusion criteria will be offered thermotherapy instead of standard antibiotic treatment. Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
11116801|NCT03957434|Experimental|Physiotherapy|12-weekly physiotherapy treatment sessions.
11116802|NCT03957434|No Intervention|Standard usual care|Participants will be asked to continue the usual care established during the regular follow-up with their medical doctor for 12 weeks.
11116803|NCT03957421|Experimental|Aquatic exercise is more beneficial than land based exercise|use of aquatic exercise will be evaluated for individuals with stroke
11116804|NCT03957408|Experimental|Visual Stimuli|Participants will be presented various visual stimuli in which accommodative response is measured.
11116805|NCT03957395|Experimental|scs high-frequency|high-frequency stimulation
11116806|NCT03957395|Experimental|scs tonic|tonic stimulation
11116807|NCT03957395|Experimental|scs burst|burst stimulation
11116808|NCT03957395|Placebo Comparator|scs off|off stimulation
11116809|NCT03957369||Adult naive HIV positive individuals|HIV-diagnosed subjects, older than 18 years, with no prior exposure to any antiretroviral drug.
11116810|NCT03957356|Experimental|HLBLS-200|HLBLS-200, absorbent hemostactic powder, will be applied intraoperatively to stop blood oozing during hepatic resection.
11116811|NCT03957343|Experimental|Pacing and Planning App|The Pacing and Planning Program is a points system to aid individuals with an acquired brain injury/concussion in planning daily activities and managing symptoms. Activities are allotted various points, depending on the energy the task requires and the symptoms they create. Activities can include anything from grocery shopping to driving or watching TV, etc. Patients are allotted a number of points for a day, and therefore learn to sparingly perform activities. This results in a reduction of symptoms and improved recovery time.
11116812|NCT03957330|Experimental|Community Mental Health Clinic|In this arm, clients will be assigned to therapists working in a community mental health clinic in Saskatchewan where the focus of the setting is primarily on face-to-face treatment and ICBT makes up a small component of the workload in the clinic.
11116813|NCT03957330|Experimental|Once a week therapist contact|In once a week treatment, therapists will email their clients once a week on a pre-determined day.
11116814|NCT03957330|Experimental|Reflection Questionnaire|"In the reflection questionnaire, patients will be asked to complete the following questions five times during the treatment period (beginning lesson 2-5 and then at the point they complete post-questionnaires):
~How much of the lesson were you able to review?
~How much effort were you able to put into the lesson?
~How difficult was the lesson?
~Please share any difficulties you had with the lesson.
~How understandable was the lesson?
~How helpful did you find the lesson?
~Please describe an example of what you learned.
~To what extent have you continued to use strategies from previous lessons
~If applicable, please provide an example of what you are working on from previous lessons
~Please indicate which Additional Resources you reviewed this week.
~If applicable, please share any skills you are working on from the Additional Resources."
11116815|NCT03957330|Experimental|Specialized Internet Therapy Clinic|In this arm, clients will be assigned to therapists working in a specialized internet therapy clinic where the therapists only deliver ICBT.
11116816|NCT03957330|Experimental|Twice a week therapist contact|In twice a week treatment, therapists will email their clients twice a week on pre-determined days.
11116818|NCT03957317|No Intervention|Control|Subjects in this group do not receive an eye mask or ear plugs, and receive standard of care (including pain control modalities). The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
11116819|NCT03957317|Experimental|Intervention|Subjects in this group receive an eye mask and ear plugs in addition to standard of care for pain control. The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
11116820|NCT03957304|Experimental|Dexmedetomidine 1 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 1 mcg/kg (max 100 mcg or 1 mL).
11116821|NCT03957304|Active Comparator|Dexmedetomidine 2 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 2 mcg/kg (max 100 mcg or 1 mL).
11116822|NCT03957304|Active Comparator|Dexmedetomidine 3 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 3 mcg/kg (max 100 mcg or 1 mL).
11116823|NCT03957304|Active Comparator|Dexmedetomidine 4 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 4 mcg/kg (max 100 mcg or 1 mL).
11116824|NCT03957291|Active Comparator|Povidine-Iodine|patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye before operation
11116825|NCT03957291|Active Comparator|chlorhexidine|patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye before operation
11116826|NCT03957278|Experimental|DAISe System|The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.
11116827|NCT03957265|Experimental|Syncone|Tapered abutment connection
11116828|NCT03957252||Training Cohort|1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than 3 ng/mL and no greater than 10ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
11116829|NCT03957252||Validation Cohort|Up to 1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than 3 ng/mL and no greater than 10ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.
11116830|NCT03957239|Experimental|Cranberry Beverage|Four prepackaged juice boxes (4.23 oz each) containing a whole milled cranberry beverage for 2 weeks
11116831|NCT03957239|Placebo Comparator|Placebo Group|Four prepackaged juice boxes (4.23 oz each) containing a cranberry-flavored beverage for 2 weeks
11116832|NCT03957226|Experimental|Trasnhumeral e-OPRA Implant|This arm includes patients with transhumeral amputation that will receive the e-OPRA implant system.
11116833|NCT03957213|Experimental|Active IH + CT|Acute intermittent hypoxia will be provided to the subject by delivering 15 brief exposures (~60 seconds) of hypoxic air alternated with 15 brief exposures (~60 seconds) of room air. The amount of oxygen delivered during hypoxic exposures may range from 15%-9% fraction of inspired oxygen, compared to 21% oxygen in normal atmospheric air. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training.
11116834|NCT03957213|Sham Comparator|Sham IH + CT|A sham protocol will be administered in which 21% fraction of inspired oxygen will be delivered by the hypoxicator during hypoxic intervals, and room air will be delivered through the four-way valve during room air intervals. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training (Posit; Brain HQ).
11116835|NCT03957174|Experimental|Reboxetine|Single dose of 4mg
11116836|NCT03957174|Experimental|Rivastigmine|Single dose of 3mg
11116837|NCT03957174|Placebo Comparator|Placebo|Single dose of placebo
11116838|NCT03957161|Experimental|ACEi/ARB continuation|Intervention group will continue or start to take ACEi and/or ARBs
11116839|NCT03957161|No Intervention|ACEi/ARB withdrawal|The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
11116840|NCT03957148|Experimental|SSB Education|The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
11116841|NCT03957148|Sham Comparator|Food Safety Education|The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
11116842|NCT03957135|Experimental|Laparoscopic distal pancreatectomy|Patients receiving laparoscopic distal pancreatectomy for pancreatic tail and body cancer
11116843|NCT03957135|Active Comparator|open distal pancreatectomy|Patients receiving open distal pancreatectomy for pancreatic tail and body cancer
11116844|NCT03957122|Experimental|individualized rTMS|Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
11116845|NCT03957122|Active Comparator|standard rTMS in responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
11116846|NCT03957122|Active Comparator|standard rTMS in non-responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
11116847|NCT03957109|Other|general anesthesia|general anesthesia
11116848|NCT03957109|Other|spinal anesthesia|spinal anesthesia
11116849|NCT03957096|Experimental|SGN-CD47M|
11116850|NCT03957083|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11116851|NCT03957083|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11116852|NCT03957083|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11116853|NCT03957083|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11116933|NCT03956459|Other|Patients with a cancer|
11116854|NCT03957083|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11116855|NCT03957083|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11116856|NCT03957070|Experimental|Liver Incyte|Patients with successfully treated HCV, or NASH Healthy volunteers with no history of liver disease. Patients and Volunteers will be scanned with FibroScan and Liver Incyte.
11116857|NCT03957057|Experimental|Iron carboxymaltose group|Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight > 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
11116858|NCT03957057|Experimental|Iron isomaltoside group|Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight > 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.
11116859|NCT03957057|Active Comparator|Iron sulphate group|Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.
11116860|NCT03957044|Experimental|sensory integration group|This group was given the education of sensory integration with vestibular education.
11116861|NCT03957044|No Intervention|Control group|The control group was given the education of sensory integration without vestibular education.
11116862|NCT03957031||Cases|Patients with a pathological confirmation of GC diagnosis
11116863|NCT03957031||Control|Patients with confirmed absent of GC
11116864|NCT03956992|Experimental|Mouth gel|A mouth gel with hydroxyapatite
11116865|NCT03956979|Experimental|JM-010 group A|As JM-010 4/0.8mg dose fixed combination drug(tablet) +Placebo 2
11116866|NCT03956979|Experimental|JM-010 group B|As JM-010 8/0.8mg dose fixed combination drug(tablet) + Placebo 1
11116867|NCT03956979|Placebo Comparator|Placebo|Double-dummy - 2 tablets = Placebo 1 +Placebo 2
11116868|NCT03956966|Placebo Comparator|saline|bilateral quadratus lumborum block using 0.9% normal saline
11116869|NCT03956966|Active Comparator|Bupivacaine|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25%
11116870|NCT03956966|Active Comparator|Bupivacaine and dexamethasone|bilateral quadratus lumborum block using Bupivacaine hydrochloride 0.25% and dexamethasone
11116871|NCT03956953|Experimental|Group 1: BMS-986165 Dose 1|Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
11116872|NCT03956953|Experimental|Group 2: BMS-986165 Dose 2|Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
11116873|NCT03956953|Placebo Comparator|Group 1: Placebo Dose 1|Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
11116874|NCT03956953|Placebo Comparator|Group 2: Placebo Dose 2|Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
11116875|NCT03956940|Experimental|Intplex test|In vitro diagnostic device
11116876|NCT03956927||patients|Insulin-dependent diabetic patients who have participated in a full TPE program (3 sessions)
11116877|NCT03956914|Experimental|DSW (deep sea water) group|DSW, 440 ml/day for 8 weeks
11116878|NCT03956914|Placebo Comparator|Placebo group|Placebo, 440 ml/day for 8 weeks
11116879|NCT03956901|Experimental|Liberal Fluid Management|liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
11116880|NCT03956901|Experimental|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after
~2 ml \ kg crystalloid infusion to be started
~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.
~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.
~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
11116881|NCT03956888|Experimental|N-acetylcysteine treatment|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
11116882|NCT03956875|Active Comparator|yoga|Yoga treatment
11116883|NCT03956875|Placebo Comparator|massage|massage
11116884|NCT03956862|Experimental|GB001|GB001 Oral administration. Once per day (QD)
11116885|NCT03956862|Placebo Comparator|Placebo|Matched Placebo; Oral administration QD
11116886|NCT03956849||Professionals working with children|The studypopulation for this mixed-methods study is consisting of healthcareprofessionals working with children (with overweight or obesity), such as pediatric residents, paediatricians and youth health care professionals. Also other professionals working with children, not working in the field of healthcare, such as teachers, can be included in the study population.
11116887|NCT03956823|Experimental|Telmisartan|generic name：telmisartan；dosage form：80 mg；dosage：80 mg；frequency：once a day；duration：June , 2019-June , 2021
11116888|NCT03956823|Active Comparator|Amlodipine|generic name： amlodipine；dosage form：5mg；dosage：5mg；frequency：once a day；duration：June , 2019-June , 2021
11116889|NCT03956810|Experimental|On-demand transportation|Women randomized to the intervention group will be able to contact the transportation broker via telephone, web portal, or the broker's mobile application. In addition to the current trips provided by their Medicaid managed care organization , women assigned to the intervention group will be provided with extra trips to the pharmacy and grocery store or food bank.
11116890|NCT03956810|Active Comparator|Usual transportation|Women assigned to the usual care group will receive the usual transportation services from their Medicaid managed care organization.
11116891|NCT03956797|Experimental|-15 degrees Celsius for 10 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds.
11116892|NCT03956797|Experimental|-15 degrees Celsius for 15 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds.
11116893|NCT03956784|Experimental|E-assessed follow up|Patients undergoing colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric, for whom an early discharge has been programmed, and followed by a connected application and a nursing logistics platform at home.
11116894|NCT03956784|Other|Standard home follow-up care|Patients undergoing surgery for colorectal surgery (colectomy, sigmoidectomy, proctectomy, digestive stoma closure), bariatric or gastric surgery, for whom an early discharge has been programmed, and followed by usual way.
11116895|NCT03956771|Experimental|Real neurofeedback|Two sessions of neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
11116896|NCT03956771|Sham Comparator|Sham neurofeedback|Two sessions of placebo/control neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
11116897|NCT03956732|Experimental|High protein yoghurt and vitamin D supplement|Subjects will receive high protein yoghurt and vitamin D tablets.
11116898|NCT03956732|Experimental|High protein yoghurt and placebo supplement|Subjects will receive high protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
11116899|NCT03956732|Experimental|Medium protein yoghurt and vitamin D supplement|Subjects will receive medium protein yoghurt and vitamin D tablets.
11116900|NCT03956732|Placebo Comparator|Medium protein yoghurt and placebo supplement|Subjects will receive medium protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
11116901|NCT03956719|Experimental|Autologous adipose-derived mesenchymal stem cells|Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells
11116902|NCT03956706|Experimental|Dose Escalation (18Gy)|Receive additional dose of 18Gy to the subventricular zone
11116903|NCT03956706|Experimental|Dose Escalation (20Gy)|Receive additional dose of 20Gy to the subventricular zone
11116904|NCT03956706|Experimental|Dose Escalation (22Gy)|Receive additional dose of 22Gy to the subventricular zone
11116905|NCT03956693|Experimental|HEADS: UP|HEADS: UP is group-based mindfulness intervention based on the original mindfulness based stress reduction course, but adapted for people affected by stroke.
11116906|NCT03956680|Experimental|BMS-986301 followed by Nivolumab and Ipilimumab therapy|
11116907|NCT03956667|Experimental|Experimental: Live Music|Live Music will be played during the required Emergency Department procedure.
11116908|NCT03956667|No Intervention|Control: No Live Music|There will be no music played during the required Emergency Department procedure.
11116909|NCT03956641|Experimental|experimental: observational cohort|Evaluation of the physical condition and the quality of life
11116910|NCT03956628|Experimental|experimental group|participants in experimental group receive intervention and experimental group consists of two sub groups, teachers and students.
11116911|NCT03956628|No Intervention|control group|participants in control group does not receive intervention and control group consists of two sub groups, teachers and students.
11116912|NCT03956602|Active Comparator|Pretzels|Subjects consume pretzels to examine postprandial response
11116913|NCT03956602|Experimental|Brazil nuts|Subjects consume Brazil nuts to examine postprandial response
11116914|NCT03956602|Active Comparator|Potato chips|Subjects consume potato chips to examine postprandial response
11116915|NCT03956602|Experimental|Mixed nuts|Subjects consume mixed nuts to examine postprandial response
11116916|NCT03956589|Experimental|Orkambi open-label arm|Open-label study: all subjects will receive Orkambi during 3 months.
11116917|NCT03956576|Active Comparator|Chronic Kidney Disease patients|"Forearm blood flow studies
~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.
~Renal clearance studies
~Two standard para-aminohippurate (PAH) / inulin clearance studies with infusion of either apelin or placebo on each day.
~Dose of PAH / inulin dependent on renal function. Continuous infusion lasting 7hours in total.
~[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.
~Crossover design, so patients will receive both apelin and placebo infusion."
11116918|NCT03956576|Active Comparator|Healthy volunteers|"Forearm blood flow studies
~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.
~Renal clearance studies
~Two standard para-aminohippurate (PAH) / inulin clearance studies with infusion of either apelin or placebo on each day.
~Dose of PAH / inulin dependent on renal function. Continuous infusion lasting 7hours in total.
~[Pyr1]apelin-13 infusion initial rate 30nmol/min for 1 hour; subsequently 300nmol/min for 2 hours.
~Crossover design, so patients will receive both apelin and placebo infusion."
11116919|NCT03956563|Active Comparator|Active treatment arm|Youlaser MT: sequential 10600+1540 nm with vaginal (2 passes) and intritus (1 pass) treatment
11116920|NCT03956563|Sham Comparator|Control arm|Youlaser MT: no laser emission with vaginal (2 passes) and intritus (1 pass) treatment
11116921|NCT03956550|Experimental|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
11116922|NCT03956550|Experimental|REGN5069 High Dose|Randomized in a 1:1:1 ratio
11116923|NCT03956550|Experimental|Matching Placebo|Randomized in a 1:1:1 ratio
11116924|NCT03956537||Pedicle screw system alone|
11116925|NCT03956537||Pedicle screw system with cages|
11116926|NCT03956524|Experimental|Test group|Single dose of EuTCV will be administered intramuscularly
11116927|NCT03956524|Active Comparator|Comparator group 1|Single dose of Typbar-TCV™ will be administered intramuscularly
11116928|NCT03956524|Active Comparator|Comparator group 2|Single dose of Typhim Vi® will be administered intramuscularly
11116929|NCT03956498|Other|Patients with cervix or vaginal cancer|
11116930|NCT03956472|Experimental|Osteopathic group|LCS Drainage before altitude exposure
11116931|NCT03956472|Experimental|PEEP 10 cmH2O|10 min at rest
11116934|NCT03956446|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
11116935|NCT03956446|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
11116936|NCT03956446|Other|Healthy controls|Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
11116937|NCT03956433|Experimental|Docosahexaenoic Acid enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) to be consumed daily for 4 weeks.
11116938|NCT03956433|Experimental|Beta-glucan enriched pancakes|One portion of pancakes enriched with 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
11116939|NCT03956433|Experimental|Anthocyanin enriched pancakes|One portion of pancakes enriched with 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
11116940|NCT03956433|Experimental|DHA+BG enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
11116941|NCT03956433|Experimental|DHA+AC enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
11116942|NCT03956420||Study group|Implemented ERAS (Early Recovery After Surgery) elements
11116943|NCT03956420||Control group|The control group will consist of patients treated during the study in accordance with the current standards used in the Department
11116944|NCT03956407|Active Comparator|Active, subacute stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
11116945|NCT03956407|Sham Comparator|Sham, subacute stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
11116946|NCT03956407|Active Comparator|Active, chronic stroke|Repetitive peripheral electrical stimulation (RPES) + Motor Training. Active RPES will be administered for 2 hours. After active session of RPES, the patient will receive motor training.
11116947|NCT03956407|Sham Comparator|Sham, chronic stroke|Sham Comparator: Sham + Motor Training. Sham will be administered for 2 hours. After sham, the patient will receive motor training
11116948|NCT03956394|Other|Active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
11116949|NCT03956394|Other|Non-active Takayasu disease|UltraFast ultrasound will be performed in the usual health care, with the evaluation of carotid artery disease by Doppler ultrasound in patients hospitalized for Takayasu Arteritis Assessment.
11116950|NCT03956381||THR with OPS system-TriFit TS/Trinity combination|Hip prosthesis combination: TriFit TS stem/ Trinity cup implanted by Surgeon 1 via a posterolateral approach according to their standard of practice.
11116951|NCT03956381||THR with OPS system-MetaFix/Trinity combination|Hip prosthesis combination: MetaFix stem/ Trinity cup implanted by Surgeon 2 via a direct anterior approach according to their standard of practice.
11116952|NCT03956368|Experimental|Treatment Group|Randomised on the day of admission to receive oral Atorvastatin 20mg daily for 8 weeks.
11116953|NCT03956368|Placebo Comparator|Control Group|Randomised on the day of admission to receive placebo 20mg daily for 8 weeks.
11116954|NCT03956355|Experimental|Tapinarof (DMVT-505)|Tapinarof (DMVT-505) Cream Group
11116955|NCT03956355|Placebo Comparator|Vehicle Cream|Vehicle Cream Group
11116956|NCT03956342||Pediatric Clinicians - Group 1|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.
~This cohort will complete a first round of interviews to assess measure content."
11116957|NCT03956342||Pediatric Clinicians - Group 2|"Pediatric clinical care clinicians who work with patients who are sedated for diagnostic or therapeutic procedures. May included, MDs, DOs, PharmDs, Nurse Practitioners, or nurses with a BSN or higher level nursing degree.
~This smaller cohort will be a randomized subset of the original cohort and will complete interviews to assess changes made based on the feedback from the first cohort."
11116958|NCT03956329|No Intervention|Usual care, control arm|Usual care in which participants will not see a video intervention. This group will attend their influenza vaccination appointment as usual, without intervention. Participants will receive Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
11116959|NCT03956329|Experimental|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
11116960|NCT03956329|Experimental|Individualised Digital Intervention|Similar to the standardised digital intervention, however participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
11116961|NCT03956303|Active Comparator|Plain Levobupivacaine (Chirocaine (% 0.5)|Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain
11116962|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 40|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40
11116963|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 60|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60
11116964|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 80|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80
11117001|NCT03956030|Experimental|Control|Control group will receive educational handout on nutrition.
11116965|NCT03956290|Experimental|TREAT pilot study|Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.
11116966|NCT03956277|Experimental|Observational PUG|Patients receive gastrostomy via percutaneous ultrasound gastrostomy.
11116967|NCT03956264|Experimental|VR|"VR Installation 5 min before the drain removal and stop 10 min after the procedure.
~If Pain assessed by verbal rating scale (VRS) > 4, administration of morphine."
11116968|NCT03956264|Active Comparator|Kalinox®|"Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.
~If Pain VRS > 4, administration of morphine."
11116969|NCT03956251|Experimental|Combined Mineralized/Demineralized Putty Allograft|Ridge preservation with a Mineralized/Demineralized Putty allograft
11116970|NCT03956251|Active Comparator|Demineralized Putty Allograft|Ridge preservation with Demineralized Putty allograft
11116971|NCT03956238|Experimental|Males and Alcohol Intoxication|Men assigned to alcohol intoxication arm (target BAC .08%)
11116972|NCT03956238|Placebo Comparator|Males and Placebo Control|Men assigned to placebo control arm
11116973|NCT03956238|Experimental|Females and Alcohol Intoxication and Objectifying Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and objectifying gazes arm
11116974|NCT03956238|Experimental|Females and Alcohol Intoxication and Eye Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and eye gazes arm
11116975|NCT03956238|Experimental|Females and Placebo Control and Objectifying Gazes|Women assigned to placebo control arm and objectifying gazes arm
11116976|NCT03956238|Placebo Comparator|Females and Placebo Control and Eye Gazes|Women assigned to placebo control arm and eye gazes arm
11116977|NCT03956225|Experimental|iLux|Single treatment with 12-month follow up
11116978|NCT03956225|Active Comparator|LipiFlow|Single treatment with 12-month follow up
11116979|NCT03956212|Experimental|erythema migrans patients treated with doxycycline|adult patients with erythema migrans will be treated with oral doxycycline
11116980|NCT03956199|Experimental|experimental pulpotomy|
11116981|NCT03956199|Active Comparator|Root canal treatment|
11116982|NCT03956186||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
11116983|NCT03956186||Non-hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
11116984|NCT03956173||Clamp group|24 patients with type 1 diabetes.
11116985|NCT03956160|Experimental|Intervention group|"For 12 months from the return home, patients in the intervention group will benefit from telephone support by a trained case-manager (number and frequency of contacts defined according to the patient's needs) and access to an Internet platform.
~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon return home, including identifying and requesting the necessary health or social resources."
11116986|NCT03956160|No Intervention|Control group|"Patients randomized to the control group will receive the usual practices. As part of the study, they will be contacted for data collection upon their return home, at 6 months and 12 months by a clinical research associate.
~Access to the internet platform and an interview with the case-manager will be offered at the end of the study to patients in the control group."
11116987|NCT03956134|Experimental|Tapentadol Test Product 1 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
11116988|NCT03956134|Experimental|Tapentadol Test Product 2 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
11116989|NCT03956134|Experimental|Tapentadol Test Product 1 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
11116990|NCT03956134|Experimental|Tapentadol Test Product 2 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
11116991|NCT03956134|Active Comparator|Tapentadol PR Reference Product|Tapentadol PR tablet formulation given as single oral dose with 240 mL of still mineral water under fasting condition.
11116992|NCT03956121||Exposed group|Exposed group( with magnesium sulfate): fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for neuroprotective purposes, with decision of extraction or spontaneous or induced labour
11116993|NCT03956121||Control group|Control group (without magnesium sulfate) : fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision or spontaneous or induced labour
11116994|NCT03956108|Experimental|MRI/Fusion biopsies|Stockholm3+MRI+targeted biopsies
11116995|NCT03956108|Active Comparator|Systematic biopsies|PSA+systematic biopsies
11116996|NCT03956095||Ensure Surgery Immunonutrition Shake supplements|Participants will be provided with and instructed to drink three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
11116997|NCT03956082|Other|This is a prospective single arm study|"The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. Surgical smoke refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments."
11116998|NCT03956056|Experimental|Neoantigen Peptide Vaccine|The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.
11116999|NCT03956043||Patients with suspected sepsis in Emergency Department|Patients with suspected sepsis treated by the sepsis emergency team or the medical emergency team in the Emergency Department of Oslo University Hospital Oslo are included prospectively.
11117000|NCT03956030|Experimental|Intervention|Intervention group will receive educational handout on contraception.
11117002|NCT03956017|Experimental|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
11117003|NCT03956017|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
11117004|NCT03956004|Experimental|Experimental|Full decision aid, consisting of education on osteoarthritis and treatment options, preferences and values elicitation, and personalized risk/benefit estimates based on patient's response to patient-reported outcome measures.
11117005|NCT03956004|Active Comparator|Control|Education component of the decision aid only.
11117006|NCT03955991|Experimental|R-CBSM|10 weeks of group intervention convene by a broadband connection for approximately 75-90 minutes. Intervention given prior to Influenza Vaccine.
11117007|NCT03955991|Active Comparator|Wait List Condition (WLC)|Persons assigned to this group will receive R-CBSM approximately 28 days after receiving the Influenza Vaccine.
11117008|NCT03955978|Experimental|TSR-042 and Brachytherapy|"Patients will receive four doses of TSR-042. The first dose is given 21 days prior to the first brachytherapy fraction. The second dose is given at the time of fraction #1. The third dose is given at the time of fraction #4. The final dose is given 1 week after fraction #6.
~Brachytherapy will consist of 6 weekly fractions of 6 Gy per fraction (total 36Gy)"
11117009|NCT03955965||Emergency patients with medication reconciliation|All patients who beneficiated from medication reconciliation in the emergency department between November 2017 and April 2018
11117010|NCT03955952||Bariatric Surgery|Patients with type 2 diabetes with BMI >=30 that underwent bariatric surgery
11117011|NCT03955952||Non-Surgical Control|Matched non-surgical controls with type 2 diabetes and BMI >=30
11117012|NCT03955939|Experimental|LY3295668 Erbumine Part A|"LY3295668 erbumine administered orally (Part I).
~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
11117013|NCT03955939|Experimental|LY3295668 Erbumine Part B|"LY3295668 erbumine administered orally (Part I).
~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
11117014|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Cohort 1|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).
11117015|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Continuation Part C|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
11117016|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Switch Part D|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
11117017|NCT03955926|No Intervention|Control group|kept fasted from midnight until surgery
11117018|NCT03955926|Experimental|NO-NPO group|drink carbohydrate beverage until 2 h before surgery
11117019|NCT03955913||Participants with Urothelial Cancer,selected FGFR aberrations|Participants with urothelial cancer (UC) will be evaluated for the prevalence of positive results of selected fibroblast growth factor receptor (FGFR) aberrations and will be assessed for eligibility status for erdafitinib studies. The primary data source for this study will be the medical records of each participant.
11117020|NCT03955900||Participants with Multiple Myeloma (MM)|Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
11117021|NCT03955887||Experimental|Patients with severe acute lung disease requiring mechanical ventilation
11117022|NCT03955887||Control|Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection
11117023|NCT03955874||INITIAL SBT|Patients who underwent an Spontaneous Breathing Trial prior to extubation. This cohort will be further subdivided into initial patients who initially pass an SBT successes and those who initially fail an SBT.
11117024|NCT03955874||DIRECT EXTUBATION|Patients that were directly extubated without conduct of a prior SBT or tracheostomy
11117025|NCT03955874||DIRECT TRACHEOSTOMY|Patients who underwent a direct tracheostomy without conduct of a prior SBT or extubation
11117026|NCT03955874||No attempt at mechanical ventilation discontinuation|Patients who died without conduct of a prior SBT, extubation or tracheostomy
11117027|NCT03955848|Experimental|ARM 1|NK cell infusion
11117028|NCT03955848|No Intervention|ARM 2|Follow up without treatment
11117029|NCT03955835|Other|ACUTE|Patients with acute ischemic stroke and proven large vessel occlusion (e.g. intracranial internal carotid artery or middle cerebral artery) with unsuccessful recanalization after endovascular treatment with mechanical thrombectomy and suspected underlying stenosis of the occluded intracranial artery amenable to stenting based on judgment by the treating neurointerventionalist.
11117030|NCT03955809|Active Comparator|Ketamine 0.5 mg/kg|ketamin 0.5 mg/kg intraarticular
11117031|NCT03955809|Active Comparator|Ketamine 1 mg/kg|ketamin 1 mg/kg intraarticular injection
11117032|NCT03955809|Sham Comparator|% 0.9 Saline|% 0.9 NaCL intraarticular injection
11117033|NCT03955796|Experimental|RayOne Hydrophobic Aspheric|Patient will receive the hydrophobic IOL during cataract surgery
11117034|NCT03955796|Experimental|RayOne Aspheric|Patient will receive the non-hydrophobic IOL during cataract surgery
11117035|NCT03955783|Experimental|Treatment (venetoclax, selinexor)|Patients receive venetoclax PO QD on days 1-28. Patients with DLBCL receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Venetoclax naïve AML patients receive selinexor on days 8, 15, and 22 of cycle 1, followed by days 1, 8, 15, and 22 of subsequent cycles. Venetoclax refractory AML patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11117036|NCT03955770|Experimental|HFOT first then LFOT|
11117037|NCT03955770|Experimental|LFOT first then HFOT|
11117038|NCT03955757|Experimental|Boot Camp Translation|Intervention communities will undergo the Boot Camp Translation process.
11117039|NCT03955757|Active Comparator|Control|Control communities will behave as usual
11117040|NCT03955744|Experimental|3D translabial ultrasound|3D translabial ultrasound with concurrent vaginal manometry
11117041|NCT03955731|Other|Single study arm|STEMI Patients treated with Magmaris resorbable magnesium scaffold
11117042|NCT03955718|Experimental|Motherly App|A smartphone app with an automated intervention that provides strategies to prevent maternal depression and to promote child development: (1) behavioral activation, (2) sleep hygiene, (3) physical activity, (4) social support, (5) nutrition, (6) prenatal care schedule, and (7) educational content.
11117043|NCT03955718|Active Comparator|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
11117044|NCT03955705|Experimental|Nefopam|Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day
11117045|NCT03955705|Placebo Comparator|Normal saline solution|Normal saline or 0.9% Sodium Chloride (NaCl) or NSS
11117046|NCT03955692|Active Comparator|Active tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
11117047|NCT03955692|Sham Comparator|Sham tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
11117048|NCT03955666|Experimental|Cohort A (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
11117049|NCT03955666|Experimental|Cohort B (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
11117050|NCT03955653|Active Comparator|RAO projection|Patients will be randomized to right anterior oblique (RAO) projection by fluoroscopy for the access to the femoral artery
11117051|NCT03955653|Active Comparator|AP projection|Patients will be randomized to anterior-posterior projection by fluoroscopy for the access to the femoral artery
11117052|NCT03955640|Experimental|Treatment (olaparib, hyperthermia)|Patients receive olaparib PO BID. Treatment continues for 4 weeks in the absence of disease progression and unacceptable toxicity. Beginning week 2, patients also undergo hyperthermia treatment over 1 hour twice weekly for 3 weeks in the absence of disease progression and unacceptable toxicity.
11117053|NCT03955627|No Intervention|Enhanced Standard Care|Participants will receive standard care, plus a brochure about hormonal therapy use.
11117054|NCT03955627|Experimental|Treatment (Education plus Exercise)|Participants will receive the same materials as the standard care group, plus participate in group exercise and group discussion sessions.
11117055|NCT03955614|Experimental|St Marys Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
11117056|NCT03955614|Experimental|University College Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
11117057|NCT03955614|Experimental|Chelsea and Westminster Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
11117058|NCT03955601|Experimental|TBI free Haploidentical HSCT|Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.
11117059|NCT03955588||Women undergoing invasive prenatal diagnostic procedures|For women requiring invasive prenatal diagnosis by chorionic villus sampling or amniocentesis, they will be offered the options of having either conventional cytogenetics or aCGH.
11117060|NCT03955575|Active Comparator|Liraglutide/placebo-colesevelam|Liraglutide as active and colesevelam as placebo
11117061|NCT03955575|Active Comparator|Placebo-Liraglutide/colesevelam|Liraglutide as placebo and colesevelam as placebo
11117062|NCT03955562|Experimental|Intervention|Communities that receive a pedestrian footbridge.
11117063|NCT03955562|Experimental|Comparison|Communities that do not receive a pedestrian footbridge.
11117064|NCT03955549|Experimental|Insight Enhancement Program (IEP)|The insight enhancement program is a dynamo-cognitive therapeutic modality with the main target of improving insight in psychotic patients as a means of improving their overall outcome.
11117065|NCT03955549|Experimental|Metacognitive Training for Psychosis (MCT)|The metacognitive training program, developed by Moritz et al. (Moritz & Woodward, 2007) targets cognitive biases putatively involved in the formation and maintenance of psychotic symptoms.
11117066|NCT03955549|Active Comparator|Treatment As Usual (TAU)|"Treatment as usual will be used as a control condition to assure ethicality of our procedure.
~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
11117067|NCT03955536|Active Comparator|Group A|Routine cardiac rehabilitation program (RCRP)atient education
11117068|NCT03955536|Experimental|Group B|routine cardiac rehabilitation program + virtual reality
11117069|NCT03955536|Experimental|Group C|RCRP + inspiratory muscle training
11117070|NCT03955523|Experimental|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
11117071|NCT03955523|Experimental|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
11117072|NCT03955523|No Intervention|Control (doing nothing)|Non-exercise trial day The protocol of the non-exercise trial day is identical to that of the exercise trial day, except that exercise is substituted by 30 min of quiet sitting in a lounge area (e.g. reading, working or watching a movie on an electronic device) without further engagement with other people.
11117093|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 320 mg|320 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
11117073|NCT03955510|Other|"Right-time eating / no alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will be asked to not drink alcohol for 1 week. Subjects will randomly be assigned to each eating pattern during the study period."
11117074|NCT03955510|Other|"Right-time eating / with alcohol"|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
11117075|NCT03955510|Other|"Delayed-eating / no alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Subjects will be asked to not drink alcohol for 1 week."
11117076|NCT03955510|Other|"Delayed-eating / with alcohol"|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Moderate alcohol drinking means 0.3-0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 1 alcohol intervention week. The order of conditions will be random."
11117077|NCT03955497|Experimental|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
11117078|NCT03955497|Placebo Comparator|sodium hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
11117079|NCT03955484||Patients who had benign prostatic hyperplasia|"Male patients presenting with lower urinary tract symptoms to urology outpatient clinic
~According to the European Association of Urology Guidelines:
~International prostate symptom score> 8 Prostate volume> 40 ml Q max <15 ml /sn Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time Patients who have not undergone lower urinary tract surgery"
11117080|NCT03955471|Experimental|Niraparib+TSR-042|Participants will receive both Niraparib and TSR-042 to evaluate the efficacy and safety of the combination of both drugs. Niraparib will be administered once daily (QD) continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) will be administered via a 30-minute intravenous (IV) infusion on Day 1 every 3 weeks (Q3W) during Cycles 1 through 4. Beginning at Cycle 5, dostarlimab (TSR-042) will be administered via a 30-minute IV infusion on Day 1 of each 6-week cycle until PD or toxicity, for a maximum of 3 years.
11117081|NCT03955458|Experimental|FICB with EXPAREL|Group 1: Suprainguinal Fascia Iliaca Compartment Block (FICB) with EXPAREL and bupivacaine HCl
11117082|NCT03955458|Active Comparator|FICB with Standard of Care: ropivacaine|Suprainguinal FICB with continuous infusion of local anesthetic (ropivacaine) via catheter placed in the FIC.
11117083|NCT03955445|Experimental|Open Label LNP023|LNP023 capsules formulation
11117084|NCT03955432|Experimental|LINQ ICM|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.
11117085|NCT03955419|No Intervention|Control group|Participants in the control group will be fasted from midnight until surgery.
11117086|NCT03955419|Experimental|Study group|Participants will receive 800 mL of carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg). They will drink this beverage freely, starting from the evening before surgery until 2 hours before surgery.
11117087|NCT03955406|Active Comparator|Conventional group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min.
11117088|NCT03955406|Active Comparator|Fixed Fresh Gas Flow Rate group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC.
11117089|NCT03955393||LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter>10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.
11117090|NCT03955380|Active Comparator|Active Comparator: Contraloid 160 mg|160 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
11117091|NCT03955380|Active Comparator|Active Comparator: Contralod 320mg|320 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
11117092|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 160 mg|160 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
11118050|NCT03948685|Experimental|Carvedilol SR|Carvedilol SR 8mg, 16mg, 32mg
11117094|NCT03955367|Active Comparator|Pelvic Irradiation|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.
11117095|NCT03955367|Experimental|Prophylactic EFI|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.
11117096|NCT03955354|Experimental|experimental arm|SHR1210 plus apatinib
11117097|NCT03955341|No Intervention|conventional selective caries removal without disinfection|After collecting the first sample of dentin, the cavity will be restored
11117098|NCT03955341|Other|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
11117099|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
11117100|NCT03955328|Experimental|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
11117101|NCT03955315|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells)
11117102|NCT03955315|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
11117103|NCT03955315|Sham Comparator|Sham|Sham needle puncture (outside disc)
11117104|NCT03955302|Experimental|Exercise|Patients in this group will perform the water exercise protocol, 3 times a week, for 12 weeks.
11117105|NCT03955302|No Intervention|Control|Patients in this group will not perform any type of exercise during the 12 weeks of the treatment.
11117106|NCT03955276||Matched Therapy|Targeted therapy matched to each patient's genomic/immunophenotypic tumor profile (whereby oncogenic alterations are matched with targeted agents)
11117107|NCT03955276||Unmatched Therapy|General, unmatched therapy (standard of care)
11117108|NCT03955250|Experimental|Mobile After-Care Support (MACS) app|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and intervention.
11117109|NCT03955250|Active Comparator|Mobile app attention control|All participants download the app to their mobile phone. The app runs through a third-party software platform. It is designed to provide ecological momentary assessment and psychoeducation about illness.
11117110|NCT03955237|Active Comparator|non glucose infusion group|Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.
11117111|NCT03955237|Active Comparator|Drug:1% Dextrose infusion group|Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,
11117112|NCT03955237|Active Comparator|2% Dextrose infusion group|Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,
11117113|NCT03955224|Active Comparator|Basic Oral Care + active LLLT (experimental arm)|
11117114|NCT03955224|Placebo Comparator|Basic oral Care + inactive LLLT (control arm)|
11117115|NCT03955224|Other|Basic Oral Care (control arm)|
11117116|NCT03955211|Experimental|Treatment Group 1|A single dose of HTX-011 administered via instillation into the surgical site.
11117117|NCT03955211|Experimental|Treatment Group 2|A single dose of HTX-011 administered via instillation into the surgical site and a scheduled non-opioid multimodal analgesic (MMA) regimen.
11117118|NCT03955198|Other|Arm A (control arm)|
11117119|NCT03955198|Experimental|Arm B (Experimental arm)|
11117120|NCT03955185|Experimental|Minimally invasive surgery|The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
11117121|NCT03955185|Active Comparator|Open abdominal surgery|The patients will receive traditional radical hysterectomy.After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
11117122|NCT03955172|Experimental|Everolimus|
11117123|NCT03955159|Experimental|Experimental: Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
11117124|NCT03955159|Placebo Comparator|Placebo comparator|The placebo that will be used in the present study is maltodextrin, which is a food supplement based on carbohydrate powder.
11117125|NCT03955146|Experimental|Pamrevlumab|
11117126|NCT03955146|Experimental|Placebo|
11117127|NCT03955133|Experimental|intervention|This is a single arm before and after study with data collection at 4 time points.
11117128|NCT03955120|Experimental|Sleep Apnea- Dayzz|The intervention group is also provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the adherence to CPAP. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device. The intervention group meets a CPAP technician at the sleep clinic, as detailed below in the Sleep Apnea TAU group
11118051|NCT03948685|Placebo Comparator|Placebo|Placebo
11117129|NCT03955120|Active Comparator|Sleep Apnea- Treatment as Usual|"The treatment as usual [TAU] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial."
11117130|NCT03955120|Experimental|Insomnia - Dayzz|The intervention group is provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the insomnia concerns, sleep symptoms, and achieve sleep goals. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device.
11117131|NCT03955120|Active Comparator|Insomnia - Treatment as Usual|"The treatment as usual [TAU] group, will receive standard treatment recommendations for their insomnia, including sleep hygiene suggestions, referral for supportive/non-medical treatments [e.g. relaxation therapies], and if needed hypnotics or other medications prescribed by the sleep clinic physician."
11117132|NCT03955107|Other|Continuous Glucose Monitoring System|
11117133|NCT03955094|Experimental|AMBU® AURAGAIN™ device|Assess feasibility of AMBU® AURAGAIN™ as an intubating device in paediatrics
11117134|NCT03955068|Other|Strict Classic Ketogenic Diet Arm|The classic ketogenic diet is individually calculated for each patient based on age, weight, and nutritional needs. The diet is typically administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates. The basis of calculations is first on the amount of required protein needed to meet RDA to insure adequate growth. Fine tuning of ketogenic diet therapy is based on serum beta-hydroxybutyrate levels (target levels of 3.5-6.5 mmol/L), tolerance of the diet, and response to treatment.
11117135|NCT03955055|Experimental|Early Capsule Group|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the clinical decision unit. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
11117136|NCT03955055|No Intervention|Standard of Care Work-up|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
11117137|NCT03955042|Experimental|Pemetrexed|Pemetrexed
11117138|NCT03955029|Experimental|Conventional Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow conventional Interval Training
11117139|NCT03955029|Experimental|Progressive Interval training|It is a split-type workout that alternates periods of intensity between 60% -95% of the maximum effort (depending on the modality) and periods of passive or active rest between 20-30% of the maximum effort. The experimental group will follow progressive Interval Training
11117140|NCT03955016|Experimental|Rehabilitation group|15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
11117141|NCT03955016|No Intervention|Control group|Usual care
11117142|NCT03955003|Experimental|Group Drumming|6 week one hour/week drumming sessions. The detailed intervention protocol was created in collaboration with board-certified music therapists. The music used in the intervention will include both recorded percussion music and the use of percussion instruments.
11117143|NCT03955003|Other|Attention Control Entertaining Educational Series|6 week one hour/week educational series. The educational group is largely intended to create an attention group control so group effect and time of the drumming intervention can be controlled.
11117144|NCT03954990|Placebo Comparator|Control Arm|Placebo tablets oral, 4 tablets once.
11117145|NCT03954990|Active Comparator|Treatment Arm|Will receive 4 tablets (2g) of metronidazole oral once.
11117146|NCT03954977|Experimental|Ultrasound vs Radiograph|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
11117147|NCT03954964|No Intervention|Control Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement.
11117148|NCT03954964|Experimental|Intervention Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement will receive additional education about the disposal of opioids.
11117149|NCT03954951|No Intervention|Control group|The clinicians in the control group will continue usual care without intervention. They will not receive the online course or performance feedback reports.
11117150|NCT03954951|Active Comparator|Intervention group|The primary care physicians will receive access to an online course on hypertension management based on the ACC/AHA and ESC guidelines. They will also receive feedback reports on their performance on hypertension management for 16 weeks.
11117151|NCT03954938|Sham Comparator|Neutral-Look|Subjects will be instructed to look at cocaine associated images and respond naturally.
11117152|NCT03954938|Experimental|Positive|Subjects will be instructed to look at cocaine associated images and anticipate the positive aspects of engaging with the items shown.
11117153|NCT03954938|Active Comparator|Negative|Subjects will be instructed to look at cocaine associated images and anticipate the negative aspects of engaging with the items shown.
11117154|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with short hamstring|Anatomic anterior cruciate ligament with short hamstring graft
11117155|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with standard hamstring|Anatomic anterior cruciate ligament with standard hamstring graft
11117156|NCT03954912|Active Comparator|MAKO robotic assisted UKA|image base (MAKO) robotic assisted UKA
11117157|NCT03954912|Active Comparator|NAVIO robotic assisted UKA|imageless (NAVIO) robotic assisted UKA
11117158|NCT03954899|Experimental|MCI+ Melatonin 5mg|MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months
11117159|NCT03954899|Placebo Comparator|MCI+ placebo|MCI+ individuals receiving placebo for a period of 9 months
11117160|NCT03954899|Experimental|MCI- Melatonin 5mg|MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months
11117161|NCT03954899|Placebo Comparator|MCI- placebo|MCI- individuals receiving placebo for a period of 9 months
11117162|NCT03954886|Experimental|Induced myopic defocus|Subjects will view a television through a lens that induces blur to the retina for one hour. Images of the eye will be captured every 10 minutes
11117163|NCT03954886|No Intervention|No defocus|Subjects will view a television through a lens that induces no blur to the retina for one hour. Images of the eye will be captured every 10 minutes
11117164|NCT03954873|Experimental|Hyperglycaemia + GLP-2|Glucose + GLP-2
11117165|NCT03954873|Active Comparator|Hyperglycaemia + Placebo|Glucose + saline
11117166|NCT03954873|Experimental|Hypoglycaemia + GLP-2|Insulin + glucose + GLP-2
11117167|NCT03954873|Active Comparator|Hypoglycaemia + Saline|Insulin + glucose
11117168|NCT03954873|Experimental|Euglycaemia + GLP-2|GLP-2
11117169|NCT03954873|Active Comparator|Euglycaemia + Placebo|
11117170|NCT03954860|Experimental|No Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
11117171|NCT03954860|Active Comparator|Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
11117172|NCT03954847||Lung cancer patients|Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment
11117173|NCT03954834|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11117174|NCT03954834|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11117175|NCT03954834|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11117176|NCT03954834|Placebo Comparator|Placebo|Placebo administered SC once a week.
11117177|NCT03954821||control group|control group in which all of them present pronated foot without tratment
11117178|NCT03954821||experimental group|Group in which they have been treated with prefabricated plantar insoles to stop pronation
11117179|NCT03954808|Experimental|Motor imagery training group|Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
11117180|NCT03954808|Active Comparator|Cerebral Palsy control group|Children with Cerebral Palsy. Traditional physiotherapy control group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
11117181|NCT03954808|No Intervention|Typically developing control group|Age matched healthy individuals, with no treatment.
11117182|NCT03954795|Active Comparator|Group 1: TAP Block|TAP Block performed from the petit triangle ( anterior axillary line and iliac crest.)
11117183|NCT03954795|Active Comparator|Group 2: OSTAP Block|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
11117184|NCT03954795|No Intervention|No Block|No interventions
11117185|NCT03954782|Experimental|Nintedanib|Oral treatment of Nintedanib 150 mg soft capsule
11117186|NCT03954782|Placebo Comparator|Placebo|Oral treatment of placebo soft capsule
11117187|NCT03954769||Inpatients|Patients admitted to Stanford Hospital and Clinics medical and surgical units
11117188|NCT03954756|Experimental|apatinib and PD-1|Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
11117189|NCT03954743|Experimental|HRV Liq group|Subjects aged 6 to 10 weeks at the time of first vaccination who receive two oral doses of liquid HRV vaccine according to a 0, 1-2-month schedule.
11117190|NCT03954743|Active Comparator|HRV Lyo group|Subjects aged 6 to 10 weeks at the time of first vaccination who receive two oral doses of lyophilized HRV vaccine according to a 0, 1-2-month schedule.
11117191|NCT03954730|Experimental|Eccentric Training Group|Eccentric training will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
11117192|NCT03954730|Active Comparator|Active Release Technique Group|Active release technique will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
11117193|NCT03954717||Participants in the Shepherd CAN DO Program|24 people with MS enrolled into the Shepherd CAN DO Program.
11117194|NCT03954717||Control Group-Shepherd (CG-S)|24 people with MS who are current patients of the MS Institute at the Shepherd Center.
11117195|NCT03954717||Control Group-iConquerMS (CG-iCMS)|24 iConquerMS members
11117196|NCT03954717||Support partners of CAN DO|24 support partners of the participants in the Shepherd CAN DO Program group
11117197|NCT03954717||CG-S support partners|24 support partners of the people with MS in the CG-S group.
11117198|NCT03954717||CG-iCMS|24 support partners of the people with MS in the CG-iCMS group
11117199|NCT03954704|Experimental|Phase 1a, Part A - Dose Escalation|Part A will consist of dose escalation by an accelerated dosing design and a 3+3 dose escalation scheme. Participants will receive escalating dose levels GS-1423 of up to 45 mg/kg on Day 1 of each 2-week cycle (Q2W) until the participants meets study treatment discontinuation criteria or for up to 1 year.
11119079|NCT03941548|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
11117200|NCT03954704|Experimental|Phase 1a, Part B - Flat Dose Regimen|Part B will consist of 3 adaptive cohorts. Based on PK, pharmacodynamics, and safety results from the Part A study, participants will be administered a flat dose of GS-1423 on Day 1 of each cycle QW, Q2W and/or every 3 weeks (Q3W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
11117201|NCT03954704|Experimental|Phase 1b, Cohort 1 (Gastric Cancer)|"Safety run-in: A standard 3+3 dose escalation design will be used to determine the DLT and MTD or RP2D of GS-1423 in combination with mFOLFOX6. The planned starting dose of GS-1423 will be targeted to achieve the exposure at -1 dose of RP2D monotherapy (Q2W) determined from Phase 1a. GS-1423 will be administered in combination with mFOLFOX6.
~Post safety run-in: Approximately 70 participants will be enrolled to receive GS-1423 at the dose level determined from the safety run-in period, in combination with mFOLFOX6 regimen.
~Participants will receive GS-1423 on Day 1 of each 14-day cycle up to 2 years until PD, or unacceptable toxicity, substantial noncompliance with study procedures or study drug, study discontinuation or withdrawal from study. Participants will also receive mFOLFOX6 regimen Q2W for up to 12 cycles."
11117202|NCT03954704|Experimental|Phase 1b, Cohort 2 (Paired Biopsy)|Participants will receive GS-1423 at the dose level determined from Phase 1a Q2W until the participants meets study treatment discontinuation criteria or for up to 1 year.
11117203|NCT03954678|Experimental|Exercise Group|Participants randomized to the activity intervention will aim for taking 10,000 steps per day and completing strength training exercises three times per week.
11117204|NCT03954678|Active Comparator|Nutrition Group|Participants randomized to the nutrition intervention will consume a liquid over-the-counter nutrition supplement two times per day.
11117205|NCT03954665|Active Comparator|Baseline Testing|Baseline testing for a 10km cycle time trial and a 30s Wingate cycle test.
11117206|NCT03954665|Experimental|Dietary Supplement: Exogenous Ketone Salt|Ketone salt supplementation (0.6-0.8g•kg-1•d-1) 7-days. Participants will perform two exercise performance tests (a 10km cycle time trial and a 30s Wingate cycle test on separate days) after supplementation.
11117207|NCT03954652|Other|Cohort 1: Intellectual disability|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
11117208|NCT03954652|Other|Cohort 2 Retinal diseases|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
11117209|NCT03954652|Other|Cohort 3: Rare tumors in childhood|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
11117210|NCT03954639|Experimental|Cohort 1, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.
~EXPAREL will be mixed with Bupivacaine
~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
11117211|NCT03954639|Active Comparator|Cohort 1, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.
~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
11117212|NCT03954639|Experimental|Cohort 2, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.
~EXPAREL will be mixed with Bupivacaine
~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
11117213|NCT03954639|Active Comparator|Cohort 2, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.
~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
11117214|NCT03954626|Experimental|RTH258|Intravitreal injection
11117215|NCT03954613|Experimental|Group A|Donepezil/Memantin Combination
11117216|NCT03954613|Experimental|Group B|Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
11117217|NCT03954613|Active Comparator|Group C|Donepezil Mono
11117218|NCT03954613|Active Comparator|Group D|Donepezil Mono + Cognitive Exercises (BEYNEX Software)
11117219|NCT03954613|Active Comparator|Group E|Memantine Mono
11117220|NCT03954613|Active Comparator|Group F|Memantine Mono + Cognitive Exercises (BEYNEX Software)
11117221|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Unfed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
11117222|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Fed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Fed.
11117223|NCT03954600|Other|NPT520-34 - SAD Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT520-34: 250 mg OR Single dose of orally administered placebo capsule(s) to match dose.
11117224|NCT03954600|Other|NPT520-34 - SAD Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT520-34: 500 mg OR Single dose of orally administered placebo capsule(s) to match dose.
11117225|NCT03954600|Other|NPT520-34 - SAD Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT520-34: 1000 mg OR Single dose of orally administered placebo capsule(s) to match dose.
11117226|NCT03954600|Other|NPT520-34 - MAD Cohort 1, Dose 1|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
11117227|NCT03954600|Other|NPT520-34 - MAD Cohort 2, Dose 2|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
11117228|NCT03954600|Other|NPT520-34 - MAD Cohort 3, Dose 3|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
11117229|NCT03954587||Artificial (HRT) Cycles|"Commence estradiol valerate (E2) 4mg from day 2 or 3 of period for 3 days
~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.
~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.
~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.
~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 7 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.
~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily).
~Embryo transfer is scheduled on the 5th full day of progesterone administration."
11117550|NCT03952351|Experimental|CTCA with standard care|Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
11117230|NCT03954587||Spontaneous natural cycles:|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.
~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.
~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).
~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5ng/mL confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
11117231|NCT03954574||Retrospective patient cohort|
11117232|NCT03954574||Prospective patient cohort|
11117233|NCT03954561|Experimental|endoscopist group|endoscopist-administered abdominal compression group
11117234|NCT03954561|Active Comparator|assistant group|assistant-administered abdominal compression group
11117235|NCT03954548|Experimental|With CB-17-08 CADe|
11117236|NCT03954548|No Intervention|Without CB-17-08 CADe|
11117237|NCT03954535|Experimental|Intervention|9 sessions and website with entertainment features and resources
11117238|NCT03954535|Placebo Comparator|Control|website with entertainment features and resources
11117239|NCT03954522|Experimental|Expérimental|psychologist interview and psychometrics scales
11117240|NCT03954509||semi-structured interview|"Screening and inclusion of patients hospitalized or seen in day hospital to conduct semi-structured interviews according to the interview grid. This interview schedule was established after review of the literature and identification of primary and secondary objectives.
~Identification of key ideas through content analysis of the interviews conducted and based of the anchored theory.
~This step is performed until the results are saturated (approximately 15 patients). The principle of saturation is based on the fact that from a threshold, the diversity of the elements collected decreases. Much more than an end signal, this principle is a methodological guarantee since it allows the possibility of comparing divergent or contradictory data and thus validating the data."
11117241|NCT03954509||questionnaires|"From the previous results: elaboration of a written questionnaire built according to the results obtained thanks to the previous interviews. In order to apply the simple correspondence factor analysis method, this questionnaire will be constructed on a Likert scale. The objective is twofold:
~to reduce the observer's bias by considering both the literature reviews but also the points of view of patients to develop the questionnaire;
~reach a larger patient population (more than 100 patients) compared to the previous qualitative analysis (15 patients planned), in order to generalize the results. This methodology combines both qualitative and quantitative study to minimize bias induced by both types of study.
~Dissemination of the questionnaire and filling by the patient independently. The health professional who submitted the questionnaire will remain available to answer any questions the patient may have."
11117242|NCT03954496|Experimental|Active tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2.5mA, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
11117243|NCT03954496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
11117244|NCT03954483|Experimental|Buspirone|Participants will receive buspirone 10 mg prior to experiments.
11117245|NCT03954483|Experimental|Triazolam|Participants will receive triazolam 0.25 mg prior to experiments.
11117246|NCT03954483|Placebo Comparator|Placebo|Participants will receive a placebo prior to experiments.
11117247|NCT03954457|Experimental|A-CWS Intervention|Participants received A-CWS Intervention.
11117248|NCT03954457|Active Comparator|Standard Care Control|Participants received standard care.
11117249|NCT03954444|Active Comparator|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
11117250|NCT03954444|Active Comparator|RHOFADE Cream, 1%|RHOFADE Cream, 1%
11117251|NCT03954444|Placebo Comparator|Vehicle Cream|Vehicle cream
11117252|NCT03954431|Experimental|CE-BCT|All subjects will undergo contrast-enhanced breast CT (CE-BCT)
11117253|NCT03954418|Experimental|Intervention group|Participants will drink an artificially sweetened drink 2-4 hours before elective caesarean section.
11117254|NCT03954418|No Intervention|Control group|Participants in the control group will refrain from intake of artificial sweeteners.
11117255|NCT03954392|Experimental|CBT+SCT|Cognitive behavioral therapy plus social cognitive skills training (SCT)
11117256|NCT03954392|Active Comparator|CBT-only|Cognitive behavioral therapy only (without SCT)
11117257|NCT03954379|Active Comparator|Group C ( Comparator Group )|Standard of care: Adductor Canal Block(ACB), Spinal Anesthesia (SA) and Peri-op Pain management
11117258|NCT03954379|Experimental|Group S ( Study Group )|iPACK and multi-modal analgesic regimen
11117259|NCT03954366|Other|Arm A - rucaparib and oral rosuvastatin|
11117260|NCT03954366|Other|Arm B - rucaparib and oral contraceptives|
11117261|NCT03954340|Active Comparator|1 iRemember Treatment|Subjects randomized to this arm of the study will undergo 20 EEG NFB treatments with the iRemember System for the treatment of MCI
11117262|NCT03954340|Sham Comparator|2 Sham Treatment|Subjects randomized to this arm of the study will undergo 20 SHAM treatments
11117263|NCT03954327|Experimental|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir|
11117264|NCT03954327|Placebo Comparator|Placebo|
11117265|NCT03954314|Active Comparator|Topical Tranexamic Acid/Placebo|Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
11117266|NCT03954314|Active Comparator|Intravenous Tranexamic Acid/Placebo|Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.
11117267|NCT03954288||chronic otitis media|patients with chronic otitis media without cholesteatoma
11117268|NCT03954288||cholesteatoma|patients with chronic otitis media whose cholesteatoma
11117269|NCT03954288||control|patients scheduled to operation with diagnosis of other causes
11117551|NCT03952351|No Intervention|Standard care|
11117270|NCT03954275||Critically ill patients with a CrCl24h|Patients admitted to any intensive care unit (surgical, medical or cardiac) and having at least one 24h creatinine clearance measurement available.
11117271|NCT03954262||TCI group|Group I received TCI at 5-6 ug/ml target effect concentration (Ce)
11117272|NCT03954262||bolus group|groups II received an induction bolus of propofol (2-2.5mg/kg).
11117273|NCT03954249|Experimental|Erector Spinae nerve block group|Receive multimodal analgesia and in addition erector spinae plane block
11117274|NCT03954249|Active Comparator|Multimodal Analgesia group|Receive standard multimodal analgesia
11117275|NCT03954236|Experimental|topical ruxolitinib BID to left side of face/body|And topical moisturizer BID to right side of face/body.
11117276|NCT03954236|Experimental|topical ruxolitinib BID to right side of face/body|And topical moisturizer BID to left side of face/body.
11117277|NCT03954223|Experimental|LSC + blinded CGM|Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
11117278|NCT03954223|Experimental|LSC+TLE + blinded CGM|Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
11117279|NCT03954223|Experimental|LSC+TLE+ real time feedback via CGM|Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
11117280|NCT03954210|Experimental|Six-Week CBT-I Program|"CBT-I, six sessions, forty-five to sixty minutes in duration.
~Session 1: set up sleep restriction and stimulus control, discuss strategies for how to stay awake to a prescribed hour and what to do with wake after onset sleep time, provide sleep hygiene education.
~Session 2: determine if upward titration of total sleep time is warranted, review sleep hygiene.
~Session 3: continue upward titration of total sleep time, cognitive therapy for negative sleep beliefs if indicated.
~Session 4: continue upward titration of total sleep time, follow-up regarding negative sleep beliefs.
~Session 5: continue upward titration of total sleep time, discuss relapse prevention.
~Session 6: assess global treatment gains, discuss questions regarding relapse prevention."
11117281|NCT03954210|Active Comparator|Six-Week Active Control|"Active Control, six sessions, forty-five to sixty minutes in duration.
~Sessions will include: stretching and thinking activities (i.e., playing board games, puzzle games, or Nintendo Wii)."
11117282|NCT03954197|Experimental|Without injection group|no injection used as priming
11117283|NCT03954197|Active Comparator|hCG group|hCG used as priming
11117284|NCT03954197|Active Comparator|GnRHa group|GnRH agonist used as priming
11117285|NCT03954184|No Intervention|TAU/Control|Sites in the Treatment as Usual (TAU)/Control Arm will receive product training/online support. Sites in the TAU/Control Arm will participate in a one-day product implementation or training session.
11117286|NCT03954184|Experimental|NIATx-TI Framework|Sites in the NIATx-TI Arm will receive product training/online support, and training in the NIATx-TI framework. The NIATx-TI framework will include a pre-implementation (planning) phase, and post-implementation (problem-solving) phase, with training delivered by a NIATx-TI coach.
11117287|NCT03954171|Other|Patients treated with platinum based-chemotherapy|
11117288|NCT03954158|Experimental|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
11117289|NCT03954158|Experimental|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
11117290|NCT03954145|Active Comparator|PUMICING GROUP|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.
~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle.Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors"
11117291|NCT03954145|Experimental|SANDBLASTING GROUP|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.
~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
11117292|NCT03954132||Subject with Chronic Obstructive pulmonary disease|
11117293|NCT03954106|Experimental|Defibrotide|"Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.
~After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose."
11117294|NCT03954093|Sham Comparator|Sham stimulation|
11117295|NCT03954093|Active Comparator|Motor cortex stimulation|
11117296|NCT03954093|Experimental|MEG-localized stimulation|
11117297|NCT03954080|Experimental|ISS|
11117298|NCT03954067|Experimental|Dose Escalation - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
11117299|NCT03954067|Experimental|Dose Escalation - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
11117300|NCT03954067|Experimental|Dose Expansion - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
11117301|NCT03954067|Experimental|Dose Expansion - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
11117302|NCT03954054||Former therapeutic education patients|Patients that followed the therapeutic education program that will be interviewed (semi-directed interviews).
11117792|NCT03950687|Experimental|Experimental group B|intravenous administration, 0.5μg/kg, once a week, for 32 weeks
11117303|NCT03954054||Current therapeutic education participants|Administration of socio-economic questionnaires and of the neurological BEARNi test (Brief Evaluation of Alcohol-Related Neuropsychological Impairment test) before, and 6 months after inclusion in the therapeutic education program.
11117304|NCT03954054||Control AUD (Alcohol Use Disorder) patients|Administration of socio-economic questionnaires and of the neurological BEARNi test twice with a 6 months interval.
11117305|NCT03954041|Experimental|BIIB093 3 mg|Participants will be administered BIIB093 3 mg/day as a bolus followed by rapid and slow intravenous (IV) infusions for 96 hours.
11117306|NCT03954041|Experimental|BIIB093 5 mg|Participants will be administered BIIB093 5 mg/day as a bolus followed by rapid and slow IV infusions for 96 hours.
11117307|NCT03954041|Placebo Comparator|Placebo 3 mg|Participants will be administered matching placebo to BIIB093 as a bolus followed by rapid and slow IV infusions for 96 hours.
11117308|NCT03954041|Placebo Comparator|Placebo 5 mg|Participants will be administered matching placebo to BIIB093 as a bolus followed by rapid and slow IV infusions for 96 hours.
11117309|NCT03954028|Active Comparator|CTG Group|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the autogenous connective tissue graft (CTG) material will be randomized to transplant to one side of the arch.
11117310|NCT03954028|Active Comparator|ADM Group|The patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the commercial acellular dermal matrix (ADM) materials will be transplanted to the opposite side of the arch with CTG transplants.
11117311|NCT03954015|Other|patients over age 30 with suspicious BIRADS 4/5 Lesions|Patients who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with CEDM, CEMR and CEUS.
11117312|NCT03954002|Experimental|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.
~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
11117313|NCT03953989|Experimental|Patients with hypertrophic cardiomyopathy|"Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid).
~V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply.
~V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety.
~Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die"
11117314|NCT03953976|Experimental|PET-CT at 3 months and ENT evaluation|Treatment to the gross primary and nodal disease (70 Gy), with suspicious nodes treated to 66.5 Gy, all in 35 fractions. CT and PET-CT are required for nodal assessment. Restaging PET-CT must be performed between 11-14 weeks from the completion of treatment. The patient must see an otolaryngologist after the PET-CT to decide on post-treatment neck dissection per the surgeon's judgement. Patients will then be seen every 3 months (+/- 2 weeks) for the first year, and then at least every 6 months (+/-2 weeks) until the 36 month. Subsequent and intervening follow-up visits will be made per physician preference
11117315|NCT03953963|Experimental|Intra-Abdominal Mesenteric Fat Extraction Group|All enrolled patients will undergo the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery.
11117316|NCT03953950|Experimental|Combination of spironolactone and losartan|
11117317|NCT03953950|Active Comparator|Losartan Alone|
11117318|NCT03953937||ICP cohort|Patients with idiopathic pancreatitis
11117319|NCT03953924|No Intervention|Control group|No interventions were performed for the control patients during the study. While those in the control group were given conventional care ( nursing procedure, education about diet, exercise and so on)
11117320|NCT03953924|Experimental|Intervention group|The patients in intervention group received conventional care, transtheoretical model-based (TTM-based) intervention and motivational interviewing (MI).
11117321|NCT03953911|Active Comparator|Control: Mobile Clinic Only|The middle school assigned to the control arm will receive a visit by a mobile clinic every 6 months only. The school will follow normal protocol for HPV vaccination awareness. Parents will be made aware of the mobile clinic per normal school newsletters and mailers.
11117322|NCT03953911|Experimental|Mobile Clinic plus Educational Sessions|The middle school assigned to the Mobile Clinic every 6-mos or month plus Educational Sessions arm will receive visitation of a mobile clinic providing free HPV vaccination among other school-related vaccines once every 6-months or once a month. Parents will be made aware of the mobile clinic per normal school newsletters and mailers. In addition, parents will be provided with free weekly educational sessions about the HPV Vaccine as a cancer-prevention effort.
11117323|NCT03953898|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11117324|NCT03953885|Experimental|Fire needle group|Participants in experimental group will receive Fire needle therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
11117325|NCT03953885|Placebo Comparator|Fire needle placebo group|Participants in experimental group will receive Fire needle placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
11117326|NCT03953872||ARB|Group of angiotensin receptor blockers(ARB) monotherapy users. A subject was considered as an ARB user when the total prescription days of ARB monotherapy was at least 30.
11117327|NCT03953872||combination of CCB and ARB|Group of calcium channel blockers(CCB) and angiotensin receptor blockers(ARB) combination users. A subject was considered as a CCB and ARB combination user when the total prescription days of CCB and ARB combination therapy was at least 30.
11117328|NCT03953872||CCB|Group of calcium channel blockers(CCB) monotherapy users. A subject was considered as a CCB user when the total prescription days of CCB monotherapy was at least 30.
11117329|NCT03953872||No treatment|Group of nonusers of antihypertensives. A subject was considered as a nonuser never received regular antihypertensive treatment or total prescription days of antihypertensives was less than 30.
11117330|NCT03953859||Gamete donors|healthy male and female game donors to undergo routine gamete donation process
11117331|NCT03953859||Infertile Couple|Couples undergoing routine IVF to treat their infertility
11117332|NCT03953833|Experimental|recombinant anti-HER2 humanized monoclonal antibody conjugate|Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R & D code: B003 Drug Type : Biological Products
11117333|NCT03953820|Experimental|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
11117334|NCT03953820|Experimental|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
11117335|NCT03953820|Experimental|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
11117336|NCT03953807|Experimental|Ozurdex|OZURDEX implant 700 μg
11117337|NCT03953794||Patients with inflammatory bowel disease|"Patients who have...
~a diagnosis of ulcerative colitis or Crohn's disease as confirmed by a clinician
~experienced a flare within the past 24 months as determined by a clinician
~had quiescent disease for at least 3 months as determined by a clinician"
11117338|NCT03953781||group 1|25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years
11117339|NCT03953781||group 2|25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
11117340|NCT03953768|Experimental|Patients undergoing device implantation|Patients undergoing device implantation with vagal nerve stimulator (VNS) for epilepsy
11117341|NCT03953755|No Intervention|Control 1|no/mild tricuspid regurgitation - left-side surgery alone
11117342|NCT03953755|No Intervention|moderate TR - left-side surgery|moderate tricuspid regurgitation - left-side surgery alone
11117343|NCT03953755|Experimental|moderate TR - left-side surgery+TVS|moderate tricuspid regurgitation - left-side surgery+tricuspid valve surgery
11117344|NCT03953755|No Intervention|Control 2|tricuspid regurgitation - left-side surgery +tricuspid valve surgery
11117345|NCT03953742|Experimental|CPI-200|"Dose Escalation Group: CPI-200 will be administered via intravenous infusion once every 3 weeks for up to 7 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
11117346|NCT03953729|Experimental|Group 1:Ibuprofeno|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
11117347|NCT03953729|Placebo Comparator|Group 2: Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
11117348|NCT03953716|Experimental|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
11117349|NCT03953716|Placebo Comparator|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
11117350|NCT03953716|Experimental|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
11117351|NCT03953716|Active Comparator|Marvelon|1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
11117352|NCT03953703|Experimental|Experimental: Levocarnitine, Placebo|990 mg of levocarnitine twice per day for four weeks, a two week washout period, 990mg of placebo twice per day for 4 weeks
11117353|NCT03953703|Experimental|Experimental: Placebo, Levocarnitine|990 mg of placebo twice per day for four weeks, a two week washout period, 990mg of levocarnitine twice per day for 4 weeks
11117354|NCT03953677|Experimental|Dexmedetomidine|
11117355|NCT03953677|Placebo Comparator|Placebo|
11117356|NCT03953664|Experimental|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
11117357|NCT03953664|Experimental|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
11117358|NCT03953664|Experimental|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
11117359|NCT03953651||Patients|Patients admitted in the emergency department presenting a myocardial oxygenation imbalance and are therefore at risk for Myocardial Infarction (MI) type 2.
11117360|NCT03953625|No Intervention|no delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.
~if the patient is included and depending on the week of inclusion, he will then be randomized to either the no booklet or the booklet group.
~If it is randomized to the arm 1 no booklet group, the patient will have classic management.
~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
11117361|NCT03953625|Experimental|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.
~If the patient is included and depending on the week of inclusion, the patient will then be randomized to either the no booklet or the booklet group.
~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.
~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
11117362|NCT03953612|Experimental|patients receiving PREG|Eligible participants will then be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) and randomly assigned to 2 doses of PREG (300/500 mg/day)over 8 weeks.
11117363|NCT03953612|Placebo Comparator|patients receiving placebo|Eligible participants will then be admitted to the Clinical Neuroscience Research Unit (CNRU) at the CMHC and randomly assigned to a placebo (PLA) treatment (N=20/group) over 8 weeks.
11117364|NCT03953599|Experimental|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
11117365|NCT03953586||bubble suction test and peristalsis in hydrosalpnix|. Group A: Women with unilateral or bilateral blockage of the distal end of the fallopian tubes with tubal distension.
11117366|NCT03953586||bubble suction test and peristalsis in normal tubes|Group B: Women with normal appearance of the fallopian tubes by HSG.
11117367|NCT03953573||Women post-delivery|
11117368|NCT03953560|Experimental|Screening|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.
~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.
~In all patients, the following tests will be performed:
~Pulsioximetry.
~Electrocardiogram.
~Blood sample with determination of NT-ProBNP.
~Echocardiography. Only an echocardiography indicative of PH warrants further evaluation
~V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.
~Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis"
11117369|NCT03953547||search for antiplatelet resistance|Patients who were hospitalized in the vascular medicine department and who benefited from a search for antiplatelet resistance between April 2014 and November 2017.
11117370|NCT03953521|Experimental|navigated|Positioning of the coil according to neuronavigation (Mylius et al., 2013, Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: Inter-rater reliability, accuracy, and influence of gender and Age, NeuroImage 78, 224-232).
11117371|NCT03953521|Active Comparator|F3|Positioning of the coil according to EEG (electroencephalography) electrode Position F3 (marking this Position on a head cap).
11117372|NCT03953508|Other|Menthol|Participants will smoke and rate several puffs of a menthol Camel Crush cigarette
11117373|NCT03953508|Other|Non-menthol|Participants will smoke and rate several puffs of a non-menthol Camel Crush cigarette
11117374|NCT03953495|Experimental|Better Together|Participants will be recruited with e-mail, print, and social media announcements and advertisements distributed through the professional contacts and networks of the investigators. The experimental group will consist of randomly assigned volunteers who meet the eligibility requirements (i.e., same-sex female couple over the age of 18 who lives in Central Appalachia).
11117375|NCT03953469|No Intervention|Placebo Group|"(a) Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating, or caffeine consumption.
~b) will be given 1/4 tsp of blackstrap molasses placebo. Subjects may not consume caffeine or eat food during this time.
~(c) blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
11117376|NCT03953469|Active Comparator|Group II|"Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating food, or caffeine consumption.
~15 minutes after examination - will be given 1/8 tsp (900mg) of Passiflora incarnata solid extract by Wise Woman Herbals mixed with 1/8 tsp of blackstrap molasses to mask the taste.
~blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
11117377|NCT03953456|Experimental|elafibranor 120mg followed by placebo|Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
11117378|NCT03953456|Placebo Comparator|placebo followed by elafibranor 120mg|Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
11117379|NCT03953430||study group|Patients with clubfoot recurrence undergoing Tibialis Anterior tendon transfer with a minimum age of three years from a prospective, consecutive database of patients with clubfoot treated with the Ponseti method.
11117380|NCT03953430||control group|healthy children of employees of our hospital
11117381|NCT03953417|Experimental|Bilateral accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
11117382|NCT03953404||septic shock|
11117383|NCT03953404||severe sepsis|
11117384|NCT03953404||sepsis|
11117385|NCT03953404||sirs positive, not septic|
11117386|NCT03953391|Experimental|Tea-water|Tea before water
11117387|NCT03953391|Experimental|Water-tea|Water before tea
11117388|NCT03953378||"Group RA patients"|Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.
11117389|NCT03953378||"Group PsA patients"|Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.
11117390|NCT03953378||"Group Healthy donors"|Anonymous healthy donors from the Etablissement Français du Sang.
11117391|NCT03953365|No Intervention|without mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh
11117392|NCT03953365|Other|with mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh
11117393|NCT03953352|Other|Radiotherapy treatment|
11117394|NCT03953339|Active Comparator|no release|no release of the suprascapular nerve during arthroscopic repair of a rotator cuff tendon repair
11117395|NCT03953339|Experimental|release|arthroscopic release of the suprascapular nerve according to the established, standard technique during arthroscopic repair of a rotator cuff tendon repair
11117396|NCT03953326|Experimental|HeartPhone Intervention|Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.
11117397|NCT03953300|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
11117398|NCT03953300|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
11117399|NCT03953287|Experimental|Pharmacokinetic Study of Paracetamol.|"Detailed Description:
~Twelve healthy young volunteers are recruited, and the experiments begin at 07:45 after an overnight fast. BMI and blod pressure are recorded and a catheter is inserted in an antecubital vein for blood samples.
~At 08.00 participants take 500 mg paracetamol as a tablet with 200 ml tap water or a Paracetamol1523 capsule in random order. Subsequently, blood samples are taken every minute for 3 minutes the first hour, then every 10 minutes the following two hours. In addition, blood pressure and puls rate are measured every 20 minute the first hour, and then every 30 minutes.Side effects and time to the participants registrate any effect of the drugs are assessed in a prefabricated scheme.
~The disadvantages associated with the experiment are sought monitored by adverse event registration which ends at the end of the trial. The trial day lasts 2 hours in which blood samples are taken as described above, and blood pressure and records are stored ."
11117400|NCT03953261|Experimental|Curcumin|
11117401|NCT03953261|Placebo Comparator|Placebo|
11117402|NCT03953248|No Intervention|Non L-Carnitine|Subjects in this arm will receive standard treatment only (without LC). It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment
11117403|NCT03953248|Active Comparator|L-Carnitine|Subjects in this arm will receive standard treatment in addition to LC IV, as a dose of 1 g/8 hours
11117404|NCT03953235|Experimental|Phase 1|"GRT-C903
~GRT-R904
~nivolumab
~ipilimumab"
11117405|NCT03953235|Experimental|Phase 2|"GRT-C903
~GRT-R904
~nivolumab
~ipilimumab"
11117406|NCT03953222|Experimental|Experimental|A single group of people with Parkinson's disease will undergo real-time feedback intervention.
11117407|NCT03953209|Experimental|spironolactone 50 mg|Oral administration of spironolactone 50 mg once daily for 12 weeks
11117408|NCT03953209|Experimental|spironolactone 100 mg|Oral administration of spironolactone 100 mg once daily for 12 weeks
11117409|NCT03953209|Experimental|spironolactone 200 mg|Oral administration of spironolactone 200 mg once daily for 12 weeks
11117410|NCT03953196|Experimental|Cohort 1: Vaccine Challenge Imvanex|Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
11117411|NCT03953196|Experimental|Cohort 2: Vaccine Challenge Shingrix|Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
11117412|NCT03953196|Experimental|Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)|Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
11117413|NCT03953196|Experimental|Cohort 4: Antigen Challenge Candin|Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
11117414|NCT03953196|Experimental|Cohort 5: Skin Wounding Challenge|3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
11117415|NCT03953183|Other|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
11117416|NCT03953183|Other|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
11117417|NCT03953170|Active Comparator|Teduglutide|Teduglutide 0.05 g/kg/day
11117418|NCT03953170|Placebo Comparator|Placebo|Placebo
11117419|NCT03953157|Experimental|Arm I (dietary intervention)|Patients receive a controlled anti-inflammatory diet over 12 weeks.
11117420|NCT03953157|Experimental|Arm II (exercise intervention)|Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
11117421|NCT03953144|Experimental|VisiblePatient™ 3D Lung Modelling + IC-GREEN Segmentectomy|Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Visible Patient™ to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
11117461|NCT03952871||Intensive care patient with hemodynamic instability|The study group is composed of intensive care patients which already need an invasive monitoring of the cardiac output because of a shock state.
11117422|NCT03953131|Experimental|Diagnostic (gallium Ga 68-DOTATATE PET/CT)|Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.
11117423|NCT03953118|Placebo Comparator|Placebo|
11117424|NCT03953118|Active Comparator|Azithromycin|
11117425|NCT03953105||Resusci Baby|Resusci Baby used for the simulated emergency scenario
11117426|NCT03953105||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
11117427|NCT03953092|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
11117428|NCT03953092|Experimental|SAD Cohort 2|10 mg YG1699 or placebo
11117429|NCT03953092|Experimental|SAD Cohort 3|25 mg YG1699 or placebo
11117430|NCT03953092|Experimental|SAD Cohort 4|50 mg YG1699 or placebo
11117431|NCT03953092|Experimental|SAD Cohort 5|100 mg YG1699 or placebo
11117432|NCT03953092|Experimental|MAD Cohort 1|5 mg YG1699 or placebo
11117433|NCT03953092|Experimental|MAD Cohort 2|20 mg YG1699 or placebo
11117434|NCT03953092|Experimental|MAD Cohort 3|50 mg YG1699 or placebo
11117435|NCT03953079|Experimental|GB-102 Dose 2 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
11117436|NCT03953079|Experimental|GB-102 Dose 3 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
11117437|NCT03953079|Active Comparator|Aflibercept 2 mg Dose|Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
11117438|NCT03953066|Active Comparator|women with vaginal delivery|30 women with spontaneous vaginal delivery will be included in group 1 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
11117439|NCT03953066|Active Comparator|women with emergency cesarean section|30 women with emergency cesarean section will be included in group 2 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
11117440|NCT03953066|Active Comparator|women with elective cesarean section|30 women with elective cesarean section will be included in group 3serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
11117441|NCT03953053|Experimental|FLACS Group|Femto Laser treated (anterior Capsulotomy and Fragmentation of lens body before phaco emulification)
11117442|NCT03953053|Active Comparator|Manual Group|Gold Standard Method with manual rhexis with pinzette and phaco emulsification
11117443|NCT03953027||Health Services Research (surveys about drug shortages)|At baseline, practice sites complete a Baseline Drug Shortage Survey and Pharmacy Baseline Survey; Drug Shortage Incident Reports are completed in real time as cancer care delivery problems occur; and the Quarterly Follow-Up Survey Number Treated Report every 3 months for one year (4 total).
11117444|NCT03953001|Experimental|Buzzy|Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
11117445|NCT03953001|Active Comparator|Control|Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.
11117446|NCT03952988|Experimental|Probiotic|
11117447|NCT03952988|Placebo Comparator|Placebo|
11117448|NCT03952975|Other|follicular phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as <15 adjusted days, group A).
11117449|NCT03952975|Other|luteal phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) [14]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).
11117450|NCT03952962|Experimental|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
11117451|NCT03952962|Experimental|Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
11117452|NCT03952949|Experimental|Default|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
11117453|NCT03952949|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read a brief education brochure before online grocery shopping.
11117454|NCT03952936|Other|Mobility|Self comparison of data from pre-post intervention.
11117455|NCT03952923|Experimental|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
11117456|NCT03952910|Experimental|Experimental group|Online pain education program will be accessible by the intervention group
11117457|NCT03952910|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
11117458|NCT03952897||Group 1|Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.
11117459|NCT03952884|Active Comparator|Leucine|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
11117460|NCT03952884|Experimental|Leucine Peptide (Dileucine)|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
11119080|NCT03941548|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
11117462|NCT03952858|Experimental|Telerehabilitation Group|Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
11117463|NCT03952858|Active Comparator|Community Center group|"The Community Center Group will receive the traditional exercise programs offered in a Community Center for older people. The exercise program can vary dependent on the offer in the individual community center. Often the training consists of exercises carried out in a range of different training equipments such as exercise bikes, steppers, rowing machines etc. often supervised by a physiotherapist. At some community centers the training will be performed in groups on appointed times. Some citizens are offered one or two times instruction and hereafter they have to train on their own. Some times the citizens are offered few times of training in their own home and hereafter follow the offer at the community center for older people. Before discharge, at the hospital, their plan for rehabilitation will be completed.
~Participants in the Community Center Group will be tested by the same instruments at baseline and after 4 and 8 weeks and at 6 months of follow-up."
11117464|NCT03952845|Experimental|Intranasal Capsaicin|Separate patients will be given escalating doses of intranasal capsaicinoid spray
11117465|NCT03952832|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11117466|NCT03952819||Diabetic group,|The study was designed with 28 chronic hemodialysis patients (17 men, 11 women) receiving treatment at our hospital. Of the 28 hemodialysis patients, 14 had Type 2 diabetes mellitus. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
11117467|NCT03952819||Non-Diabetic group,|Of the 28 hemodialysis patients, the other 14 were not diabetic. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
11117468|NCT03952819||Control group,|The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
11117469|NCT03952806|Experimental|Arm 1: BHV-3241- Experimental|
11117470|NCT03952806|Placebo Comparator|Arm 2: Placebo Comparator|
11117471|NCT03952793|Experimental|Experimental|Extended biopsy
11117472|NCT03952767|Experimental|Digital Physical Measures and Survey Assessments|Digital physical measure data will be collected in clinic and at home and survey assessments will be collected
11117473|NCT03952754|Experimental|Group 2: Hip Hop Nutrition-Math Curriculum|The intervention group will receive an tailored program for ten weeks, meeting twice a week.
11117474|NCT03952754|Active Comparator|Group 1: Food Explorers Program|The control group will receive the usual care for nutrition program provided by the schools, called Food Explorers. The group will also be conducted ten weeks, meeting twice a week.
11117475|NCT03952741|Experimental|Cognitive Functional Therapy|The intervention is a targeted cognitive functional therapy and will be based on examination findings. It is behaviorally directed with a focus on normalizing mal-adaptive pain, cognitive and movement behaviors in a graduated manner. In the evaluation process it is considered whether the patient has adjusted to the back complaints in a positive way (confrontation, active coping, minimal avoidance behavior) or in a negative way (passive coping, fear and avoidance behavior). Work related issues will be a particular focus, with the aim of achieving close co-operation between the worker, the workplace and the worker's responsible health care provider.
11117476|NCT03952741|Active Comparator|Cognitive Patient Education and PT|The intervention in the second group will receive much training in cognitive coping techniques after the COPE LBP trial principles (Werner et al. 2010). The educational part of the COPE for new instructors with a PT background takes 2 days supervised by Werner and his group, with regular follow-up meeting with the project leaders, together with a psychologist trained in cognitive therapy
11117477|NCT03952728||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention, consented to administrative data linkages, and were successfully linked to Medicare databases.
11117478|NCT03952728||Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education control arm, consented to administrative data linkages, and were successfully linked to Medicare databases.
11117479|NCT03952715|Experimental|Evoked pain training|
11117480|NCT03952715|Experimental|Control|
11117481|NCT03952689|Experimental|Post cardiac surgery patients|For all patients, readings of the urine output from both the Serenno system and the collection bag (urinometer) (by camera) will be recorder every 10 minutes, for the duration of 24 hours.
11117482|NCT03952676|Experimental|Moving cupping intervention|Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
11117483|NCT03952676|Placebo Comparator|Moving cupping placebo control|Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
11117484|NCT03952663|Experimental|Group I|inferior alveolar nerve lateralization for dental implant placement ,and platelet rich fibrin membrane is placed around the nerve.
11120243|NCT03933033|Active Comparator|Group C|treated with both line of treatments
11117485|NCT03952663|Active Comparator|Group II|inferior alveolar nerve lateralization for dental implant placement without placement of platelet rich fibrin membrane around the nerve.
11117486|NCT03952650|Experimental|1a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
11117487|NCT03952650|Experimental|1b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
11117488|NCT03952650|Experimental|2a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
11117489|NCT03952650|Experimental|2b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
11117490|NCT03952650|Experimental|3a|Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
11117491|NCT03952650|Experimental|3b|Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
11117492|NCT03952650|Placebo Comparator|4a|Receiving normal saline with 75 mg pyrimethamine day 0 post injection
11117493|NCT03952650|Placebo Comparator|4b|Receiving normal saline with 75 mg pyrimethamine days 2&amp;3 post injection
11117494|NCT03952650|Placebo Comparator|4c|Receiving normal saline with weekly chloroquineibuprofen (if necessary)
11117495|NCT03952650|Experimental|5a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
11117496|NCT03952650|Experimental|5b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
11117497|NCT03952650|Experimental|6a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
11117498|NCT03952650|Experimental|6b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
11117499|NCT03952637|Experimental|1|In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg /kg of the gene transfer agent, and asentinel Type II subject will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transferagent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
11117500|NCT03952637|Experimental|2|Following the last Stage 1 subject s 6 months visit, data will be reviewed, and Stage 2 dosing andassessments will be determined. If Stage 2 dosing is toproceed, it will be reflected in a protocol amendment.
11117501|NCT03952624||Control|FNS <= 3
11117502|NCT03952624||Fatigued|FNS >= 4
11117503|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
11117504|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Reveal®|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
11117505|NCT03952611|Active Comparator|High-Definition White-light Colonoscopy With Endocuff Vision|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
11117506|NCT03952598|Experimental|1/Arm 1|Monitoring of quantitative levels of 2-hydroxyglutarate (2- HG) via proton magnetic resonance spectroscopy (1H-MRS)
11117507|NCT03952585|Active Comparator|Arm I (IMRT, IGRT, cisplatin)|Patients undergo IMRT or IGRT over 6 fractions per week and receive cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
11117508|NCT03952585|Experimental|Arm II (IMRT, IGRT, cisplatin)|Patients undergo reduced dose IMRT or IGRT QD over 5 fractions per week and receive cisplatin IV over 30-60 minutes on days 1 and 22. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
11117509|NCT03952585|Experimental|Arm III (IMRT, IGRT, nivolumab)|Beginning 1 week prior to radiation, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks (14 days) for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo reduced dose IMRT or IGRT over 6 fractions per week for 5 weeks in the absence of disease progression or unacceptable toxicity.
11117510|NCT03952572|Experimental|CDOP regimen|cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
11117511|NCT03952572|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
11117512|NCT03952559|Experimental|Baricitinib Open Label High Dose|Baricitinib administered orally.
11117513|NCT03952559|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11117514|NCT03952559|Experimental|Baricitinib Mid Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11117515|NCT03952559|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11117516|NCT03952559|Placebo Comparator|Placebo|Placebo administered orally. Matching placebo administered orally to maintain the blind.
11117517|NCT03952546|Experimental|Treatment Arm|Saline-coupled bipolar sealer
11117518|NCT03952546|Active Comparator|Control Arm|Unipolar electrocautery
11117519|NCT03952533|Experimental|ALA|"ALA Group will be composed of women allocated to the Treatment Group. These women will receive 2 tablets of Alpha lipoic Acid (ALA) as Dav® food supplement 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy) daily until delivery."
11117520|NCT03952533|No Intervention|Control|"Control Group will be composed by women allocated in the Control Group and will not receive any supplementation but the standard care."
11117521|NCT03952520|Active Comparator|Standard Approach (SA)|The Standard Approach is a one-size-fits-all multifaceted implementation strategy that was systematically developed using Intervention Mapping.
11117522|NCT03952520|Experimental|Tailored Approach (TA)|The Tailored Approach includes an implementation strategy that will be tailored to match site-specific barriers to implementation of SNaP at that site.
11117523|NCT03952507|Experimental|Group 1: JNJ-64417184|Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11117524|NCT03952507|Experimental|Group 2: JNJ-64417184|Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11117525|NCT03952507|Experimental|Group 3: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11117526|NCT03952507|Experimental|Group 4: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11117527|NCT03952507|Experimental|Group 5: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11117528|NCT03952507|Experimental|Group 6: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11117529|NCT03952494|Experimental|Intervention group|Intervention group will have the PGx test results available via Epic, three days after the biospecimen is received.
11117530|NCT03952494|Experimental|Control group|"The control group will be considered in TAU(treatment as usual) group but will have the PGx test results available after 24 weeks.
~Note: Patient in both the groups will be followed for 24 weeks and will take questionnaires every other week."
11117531|NCT03952481|Experimental|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
11117532|NCT03952468|Active Comparator|TMS + Brief Cognitive Behavioral Therapy|Combined transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
11117533|NCT03952468|Sham Comparator|Sham TMS + Brief cognitive behavioral therapy|Sham Transcranial magnetic stimulation and brief cognitive behavioral therapy for suicide
11117534|NCT03952455|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
11117535|NCT03952442|Active Comparator|control group|
11117536|NCT03952442|Experimental|experimental group|
11117537|NCT03952429|Active Comparator|Active Cognitive Bias App|Participants will receive the Anti-Alcohol App with the Active Cognitive Bias modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
11117538|NCT03952429|Placebo Comparator|Inactive Cognitive Bias Modification|Participants will receive the Anti-Alcohol App with the Inactive Cognitive Bias Modification, as well as participant diaries assessing alcohol consumption and several questionnaires.
11117539|NCT03952416|No Intervention|Standard of Care (SOC)|The control group for this study will receive rehabilitation therapy that is recommended and provided by the current healthcare structure. The SOC group will receive therapy only from four therapists who are not trained and supervised in EMR. These therapists will be monitored (videotaped or observed) but will not be not asked to do anything differently with their patients. The investigators recognize that spillover of therapist EMR training to untrained therapists is a concern. Thus, the investigators will ask therapists in the EMR group to agree not to share any of the training with non-trained therapists over the course of the study, and the investigators will provide free EMR training to the non-trained therapists once the treatment phase of the study is complete.
11117540|NCT03952416|Experimental|Enhanced Medical Rehabilitation (EMR)|Patients in the EMR group will also receive the recommended rehabilitation therapy, but they will receive therapy only from four therapists who are trained and supervised in EMR. The therapy sessions will follow EMR protocol. EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation.
11117541|NCT03952403|Experimental|Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
11117542|NCT03952403|Experimental|Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
11117543|NCT03952403|Experimental|Part 2-Arm B (HLX10+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
11117544|NCT03952403|Active Comparator|Part 2-Arm C (Carboplatin+Pemetrexed)|Participants will receive IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
11117545|NCT03952390||control|healthy volunteers
11117546|NCT03952390||sepsis|patients with sepsis
11117547|NCT03952377|Placebo Comparator|0.9% Sodium Chloride for Injection|
11117548|NCT03952377|Experimental|12.5 mg SX600|Low Dose
11117549|NCT03952377|Experimental|25.0 mg SX600|High Dose
11120244|NCT03933020|Experimental|Exercise Group|
11117552|NCT03952338|Experimental|Nutrition Coupons|Participants in the FMNCP group will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets. To ensure participants receive all 16 coupon sheets, community partners will provide two coupon sheets per household during the first 1-6 weeks of the intervention. Participants in the FMNCP group will also be invited to participate in nutrition skill-building activities (e.g., cooking classes) offered by community partners throughout the intervention period, however participation is not required (this is consistent with the existing FMNCP).
11117553|NCT03952338|No Intervention|Control|No intervention provided. Participants will be eligible to participate in the BC Farmers' Market Nutrition Coupon Program during the next farmers' market season (i.e. one year following the current intervention).
11117554|NCT03952325|Experimental|Cohort 1, Arm A: Tesetaxel plus nivolumab|
11117555|NCT03952325|Experimental|Cohort 1, Arm B: Tesetaxel plus pembrolizumab|
11117556|NCT03952325|Experimental|Cohort 1, Arm C: Tesetaxel plus atezolizumab|
11117557|NCT03952325|Experimental|Cohort 2: Tesetaxel|
11117558|NCT03952312|Experimental|"OncoTool Intervention"|
11117559|NCT03952312|Active Comparator|"Oncotool Control"|
11117560|NCT03952299|Active Comparator|Oral administration|"Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.
~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital."
11117561|NCT03952299|Experimental|Transdermal administration|Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.
11117562|NCT03952286|Experimental|Intervention|ED-Dispensing with home and school supervision
11117563|NCT03952286|No Intervention|Control|ED-Dispensing with home supervision
11117564|NCT03952273|Active Comparator|Combo|PCI with COMBO stent
11117565|NCT03952273|Active Comparator|BioMatrix Alpha|PCI with BioMatrix Alpha stent
11117566|NCT03952260|Active Comparator|Fasting clear fluid for 1 hour prior to anaesthesia|Fasting clear fluid for 1 hour prior to anaesthesia
11117567|NCT03952260|No Intervention|Fasting clear fluid for 2 hours prior to anaesthesia|Fasting clear fluid for 2 hours prior to anaesthesia
11117568|NCT03952247|Experimental|Single Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
11117569|NCT03952247|Active Comparator|Conventional Multi Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
11117570|NCT03952234|Other|Dose finding safety study|In this study, the highest acceptable dose of an amino acid called citrulline will be established in people who have a mitochondrial disorder. Previous research conducted by several groups including our center at Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in people affected with MELAS.
11117571|NCT03952221|Active Comparator|Usual physiotherapy and continuous ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and continuous ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
11117572|NCT03952221|Active Comparator|Usual physiotherapy and pulsed ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and pulsed ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle) every working day for two weeks (10 occasions).
11117573|NCT03952221|Active Comparator|Usual physiotherapy and sonotens therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sonotens therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 0,5 W/cm2 SATA intensity, transcutanous electrical nerve stimulation) every working day for two weeks (10 occasions).
11117574|NCT03952221|Placebo Comparator|Usual physiotherapy and sham ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sham ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 0 MHz frequency, 0 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
11117575|NCT03952208|Experimental|Concussion Group|Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
11117576|NCT03952208|Experimental|Matched Subjects Group|Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
11117577|NCT03952182|Active Comparator|Spinal Orthosis (LSO, TLSO, etc)|Patient's in this arm will be given an orthosis for the treatment of their injury (TLSO for thoracic or upper lumbar injury, LSO for lumbar injury)
11117578|NCT03952182|Experimental|No Spinal Orthosis|the patient's in this arm will not be given an orthotic. They will be given a bending restriction and otherwise remain activities as tolerated.
11117579|NCT03952169|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
11117580|NCT03952169|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
11117581|NCT03952156|Experimental|Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
11117582|NCT03952156|Experimental|Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
11117583|NCT03952156|Experimental|Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
11117584|NCT03952156|No Intervention|Delayed Treatment Control|Control subjects will generally have the same assessments as treated subjects. Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102.
11117585|NCT03952143|Experimental|LY900014|LY900014 given subcutaneously (SC) with either insulin glargine given SC or insulin degludec given SC.
11117586|NCT03952143|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) given SC with either insulin glargine given SC or insulin degludec given SC.
11117587|NCT03952130|Experimental|LY900014|LY900014 given subcutaneously (SC) with either insulin glargine given SC or insulin degludec given SC.
11117588|NCT03952130|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) given SC with either insulin glargine given SC or insulin degludec given SC.
11117589|NCT03952117|Active Comparator|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
11117590|NCT03952117|Sham Comparator|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
11117591|NCT03952104|Experimental|Experimental-Low Intensity Strength Training|Strength training (low intensity)
11117592|NCT03952104|Experimental|Experimental-Moderate Intensity Strength Training|Strength training (moderate intensity)
11117593|NCT03952104|Experimental|Experimental-High Intensity Strength Training|Strength training (high intensity)
11117594|NCT03952104|No Intervention|Control|No intervention
11117595|NCT03952091|Experimental|TJ202, Lenalidomide and Dexamethasone|
11117596|NCT03952091|Active Comparator|Lenalidomide and Dexamethasone|
11117597|NCT03952078|Experimental|CPI-818 Dose Escalation|Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for >2 months or if dose determined to be unsafe.
11117598|NCT03952078|Experimental|CPI-818 Dose Expansion phase|"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.
~CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for > 2 months."
11117599|NCT03952065|Experimental|Toripalimab infusion via neck artery|
11117600|NCT03952065|Experimental|Toripalimab infusion via peripheral vein|
11117601|NCT03952052|Other|Patient enrolled|Recurrent mutations determination
11117602|NCT03952039|Experimental|Fedratinib 400mg/day|Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
11117603|NCT03952039|Active Comparator|Best Available Therapy (BAT)|Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.
11117604|NCT03952026||isolated pelvic fracture|Patients with an isolated pelvic fracture
11117605|NCT03952026||combined abodominal/pelvic injury|Patients with a combined injury of a pelvic fracture and an abdominal injury.
11117606|NCT03952013||Study group|"All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE
~LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),
~HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)
~HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)"
11117607|NCT03952000|Experimental|Experimental: Exercise|Exercise: Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1.
11117608|NCT03952000|No Intervention|No Intervention: Control|Participants will rest on day 1.
11117609|NCT03951987|Experimental|Treatment A: 4 ml CG5503|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) was administered as a 2 minutes infusion.
11117610|NCT03951987|Experimental|Treatment B: 4 ml CG5503; 5 g charcoal powder|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) with oral co-administration of charcoal (5 g charcoal were co-administered orally at 1, 0.5 hours and 10 minutes before the start of CG5503 infusion and 0.5, 1, 1.5, 2 and 4 hours thereafter)
11117611|NCT03951974|Experimental|Experimental|Participants in the experimental group will receive training in utilizing social regulation of emotion strategies in an individualized format. They will meet with an interventionist for 5 weeks (1 in-person session and 4 telephone sessions) for 1-1.5 hours each week, and keep a journal documenting their emotion challenges and regulation strategy use.
11117612|NCT03951974|Other|Control|Participants in the control group will not receive training in utilizing social regulation of emotion strategies. While they will still meet with the interventionist on the same schedule and for approximately the same length of time, they will simply be asked to report the emotion regulation strategies that they naturally employ. They will also keep a journal documenting their emotion challenges and regulation strategy use.
11117613|NCT03951961|Experimental|Midostaurin|50 mg Midostaurin bid for 12 months
11117614|NCT03951935||sLSS|patients diagnosed with sLSS scheduled for decompression surgery
11117615|NCT03951935||control subjects|healthy, age-matched control subjects
11117616|NCT03951922|Experimental|Therapeutic Horticulture Group|The therapeutic horticulture group will participate in a 6-week horticulture program meeting twice a week for an hour led by an occupational therapist incorporating plant-based activities and education on pain management techniques at a community farm.
11117617|NCT03951909|Experimental|Active intervention|Either Physiotherapy activity and awareness intervention (PAAI) or Teaching recovery techniques (TRT)
11117618|NCT03951909|Experimental|Waiting list|The same interventions as above will be hold for waiting lists participants, but after 6 to 8 weeks
11117619|NCT03951896|Experimental|PRP|"Interventions:
~A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects."
11120245|NCT03933020|Active Comparator|Control Group|
11117620|NCT03951896|Placebo Comparator|Placebo|For the control group, same amount of blood was sampled and they were given a same amount of waiting time with the other group, with the resulting injection preparate being 2 ml's of 0,9% saline instead.
11117621|NCT03951883|Active Comparator|Typical Diet (TD)|Participants will be instructed to continue habitual dietary intake.
11117622|NCT03951883|Experimental|Increased Egg Consumption (IE)|Participants will be prescribed an additional 2 eggs per day to their diet.
11117623|NCT03951870|Experimental|Mesolimbic Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects will participate in four fMRI-NF sessions, up-regulating activation of three mesolimbic reward nodes:
~ventral tegmental area, and bilateral ventral striatum. ROIs are 5 mm spheres around peak activations in funcitonal localizer task (Monetary Incentive delay, reward anticipation contrast), within a predifned meta-analytic anatomical masks of the three regions.
~anatomical masks: VTA (Midbrain): -4 -24 -10 Right Nac: 12 10 -4 Left Nac: -10 10 -6 Oldham, Stuart, et al. Human brain mapping (2018).
~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
11117624|NCT03951870|Active Comparator|Control Neurofeedback|"Neuromodulation via fMRI Neurofeedback task: subjects will participate in four fMRI-NF sessions, up-regulating activation of regions comprising one of 4 control networks (5mm spheres around MNI coordinates):
~Motor Imagery (Hétu, Sébastien, et al. Neurosci. & Biobehav Rev (2013)) R. Cerebellum: 32 -62 -28 L. Cerebellum: -32 -56 -30 L. Precentral Gyrus: -26 -2 58; Auditory imagery (McNorgan, Chris.Front in Human Neurosci 6 (2012)) R STG:64 -30 9 L IFG:-48 24 -5 L precentral Gyrus: -52 1 47; Arithmetic processing (Arsalidou, Marie, and Margot J. Taylor. Nuroimage (2011)) R. SPL: 29 -66 49 L. MFG (dlpfc): -45 32 29 L. precuneus: -28 -71 33; Spatial Navigation (Kühn, Simone, and Jürgen Gallinat. Human Brain Map. (2014)) R. hippocampus 26 -35 -11 L. hippocampus -26 -47 -9 L. Post. cingulate -15 -59 19
~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
11117625|NCT03951870|Other|Natural history|"No brain manipulation (Assesment of natural history immune response).
~Hepatitis B vaccination: subjects will receive vaccination against Hepatitis B."
11117626|NCT03951857|No Intervention|Young men|Range of age is 20-35 years, young men (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
11117627|NCT03951857|No Intervention|Young women|Range of age is 20-35 years, young women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
11117628|NCT03951857|Experimental|Elderly women (control)|Range of age is 65-80 years, Elderly women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
11117629|NCT03951857|Experimental|Elderly obese women|Range of age is 65-80 years,Elderly obese women (BMI ≥25 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
11117630|NCT03951844|Experimental|Experimental group|Each participant is evaluated while wearing or not wearing the device.
11117631|NCT03951831|Experimental|ADT Followed by Chemoimmunotherapy|"REGN2810 followed by chemoimmunotherapy:
~Initiate degarelix 240mg SC once, followed by leuprolide acetate 22.5mg SC every 3 months.
~Week 4 start cemiplimab (REGN 2810) 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
~Week 10 start docetaxel 75 mg/m2 every 21 days for up to 6 cycles."
11117632|NCT03951805|Experimental|Insulin 287 algorithm A|Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
11117633|NCT03951805|Experimental|Insulin 287 algorithm B|Controlled on metformin with or without DPP4i and with or without SGLT2i.
11117634|NCT03951805|Experimental|Insulin 287 algorithm C|Controlled on metformin with or without DPP4i and with or without SGLT2i.
11117635|NCT03951805|Active Comparator|Insulin Glargine algorithm D|Controlled on metformin with or without DPP4i and with or without SGLT2i.
11117636|NCT03951792||Colorectal Cancer Subjects|Subjects under going colorectal resection with colorectal cancer will have tissue and stool collected
11117637|NCT03951792||Benign Colon Resection Subjects|Subjects under going colorectal resection without colorectal cancer will have tissue and stool collected
11117638|NCT03951779|Experimental|Subjects with unexplained but suspected cardiac dyspnea|Subjects with unexplained but suspected cardiac dyspnea who are being scheduled for right heart catheterization will undergo an exercise cardiac magnetic resonance imaging (eCMR).
11117639|NCT03951766|Other|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
11117640|NCT03951753|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
11117641|NCT03951753|Active Comparator|Semaglutide|Semaglutide administered SC
11117642|NCT03951753|Placebo Comparator|Placebo|Placebo administered SC
11117643|NCT03951740|Experimental|Group of cardiac patients|All patients completed the study wearing two wrist-worn activity trackers and the Oxycon mobile as reference method during a laboratory activity protocol.
11117644|NCT03951727|Other|Endovascular treatment for PAD|Single group study (1 arm)
11117645|NCT03951714|Other|Reference|Control experience using marketed application to record medication intake without reminders from the app
11117646|NCT03951714|Experimental|Intervention|Full experience using marketed application, with all functionalities enabled
11117647|NCT03951701|Experimental|observation cohort|Questionnaire to assess the supportive care needs
11117648|NCT03951688|Experimental|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.
~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
11117649|NCT03951688|No Intervention|Control Group|No intervention
11117650|NCT03951675||Individuals Living with DMD|90 patients/parents
11117651|NCT03951675||Healthcare Providers to Patients with DMD|40 healthcare providers
11117652|NCT03951662||With alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.
11117653|NCT03951662||Without alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.
11117654|NCT03951649|Experimental|Occipital Nerve block|"Trained OB/GYN providers will perform a physical exam to access location of occipital nerve injection based on palpation of bony landmarks.
~Site of injection will be cleaned with an alcohol swab.
~5cc of 0.5% bupivacaine will be injected into both right and left occipital nerves using a 2.5 inch 25 gauge needle. The needle will be changed between injecting sites.
~After injection is completed sterile gauze will be held on injection sites for 2-3 min or until bleeding is resolved."
11117655|NCT03951649|Active Comparator|Oral Acetaminophen/Caffeine Group|Acetaminophen 650mg PO and Caffeine 100mg PO (both Level A treatments for acute headache)
11117656|NCT03951636|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant/abutment surface will be cleaned by copious irrigation with Chlorhexidine
11117657|NCT03951636|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant/abutment surface.
11117658|NCT03951636|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant/abutment surface.
11117659|NCT03951623|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks and 16 weeks open-label treatment.
11117660|NCT03951623|Placebo Comparator|placebo arm|Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks and 16 weeks open-label treatment.
11117661|NCT03951610|Experimental|Test lens|Subjects wearing the test lens for one week, either randomized as the first or second pair.
11117662|NCT03951610|Active Comparator|Control lens|Subjects wearing the control lens for one week, either randomized as the first or second pair.
11117663|NCT03951597|Experimental|Combined therapy using Gemox, Lenvatinib and PD1|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.
~Lenvatinib (8mg/d), continuous use for 1 year.
~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
11117664|NCT03951584||ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study cohort. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset, to evaluate the damage and prognosis of vestibular function.
11117665|NCT03951571|Experimental|Anlotinib Gruop|
11117666|NCT03951571|Placebo Comparator|Placebo Group|
11117667|NCT03951558|Experimental|Diet for calciuria prevention|placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.
11117668|NCT03951558|Placebo Comparator|hydrochlorothiazide for calciuria prevention|recommendations for water intake and decrease in salt intake will be given.
11117669|NCT03951545|Active Comparator|Mechanical group|Group of patients whose tibial sections will be performed using extramedullary mechanical sighting
11117670|NCT03951545|Experimental|Gyroscopic group|Group whose tibial sections will be performed using gyroscopic and accelerometric navigation (I-Assist) will be randomized
11117671|NCT03951532||children with hyperthyroidism|children and adolescents (6 months -17 years included) whose data are present in the SNIIRAM database (DCIR data) and beneficiaries of the general health insurance scheme during the study period (01/01/2006-31/12/2017)
11117672|NCT03951519|Experimental|Water|
11117673|NCT03951519|Active Comparator|Physiological serum|
11117674|NCT03951506|Experimental|Experimental-Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
11117675|NCT03951506|Experimental|Experimental-conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
11117676|NCT03951493|Experimental|RSHF + zoledronic acid|Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).
11117677|NCT03951493|Active Comparator|RSHF|Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.
11117678|NCT03951480|Experimental|Manual medicine|
11117679|NCT03951480|Active Comparator|Corticosteroids infiltration|
11117680|NCT03951467|Experimental|Interventional arm|
11117681|NCT03951467|No Intervention|Controlled arm|Patients within this arm will be follow as usual care of the cardiologic unit
11117682|NCT03951454|Experimental|Conexiones|5 telephone sessions of Conexiones, with each session delivered 2 weeks apart across a total period of 8 weeks
11117683|NCT03951454|Other|Taking Time|1 telephone session consisting of a scripted protocol guiding participants through the NCI's Taking Time Booklet.
11117684|NCT03951428||All Participants|
11117685|NCT03951415|Experimental|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
11117686|NCT03951402|Experimental|CG5503 PR 100 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 100 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 1 tablet CG5503 PR and 1 placebo-tablet, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin 400 mg.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
11117793|NCT03950687|Experimental|Experimental group C|"intravenous administration,
~1μg/kg, once every two weeks, for 32 weeks"
11117865|NCT03950063||Patients with Cutibacterium acnes bone infections|Patients with Cutibacterium acnes orthopedic material infections
11117687|NCT03951402|Experimental|CG5503 PR 200 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 200 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
11117688|NCT03951402|Placebo Comparator|Placebo|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
11117689|NCT03951402|Active Comparator|Moxifloxacin 800 mg single dose|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); and 2 placebo-capsules, matching moxifloxacin on days 1 and 2; In the morning of Day 3, each participant received additionally 2 capsules each containing 1 tablet moxifloxacin.
~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
11117690|NCT03951376|Experimental|Intervention|"The schools in this arm will implement the UPRIGHT programme (18 skills related to Mindfulness, Coping, Efficacy and Social and emotional learning) during a minimum of 18 sessions and a maximum of 24 in a period of 6 months, which will be conducted by teachers to adolescents of 1st grade (12-14 years of age).
~Teachers will be trained by the UPRIGHT team at the beginning of the school year (3 months) and families will have a combination of face to face training and online training throughout the UPRIGHT platform."
11117691|NCT03951376|No Intervention|Control|Schools in the control arm have their usual curricula and are not provided of any intervention resources or support, apart from those in the common daily activities.
11117692|NCT03951363|No Intervention|Qualitative Interview|Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
11117693|NCT03951363|Other|Pilot Testing|Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
11117694|NCT03951350|No Intervention|Control (TAU)|Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
11117695|NCT03951350|Experimental|Lifestyle Modification Program (LMP)|It will consist of 6 weekly group sessions (lasting 90 minutes each).
11117696|NCT03951350|Experimental|Lifestyle Modification Program (LMP) + ICTs|It will consist of 6 weekly group sessions (lasting 90 minutes each).
11117697|NCT03951337|Experimental|64Cu ATSM|pretherapeutic 64Cu-ATSM PET/CT scan
11117698|NCT03951324||Expert Endoscopists|Experienced Endoscopists with significant user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
11117699|NCT03951324||None-Expert Endoscopists|Experienced Endoscopists with non-significant or beignner user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
11117700|NCT03951298||Wolfram Syndrome Patients|Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
11117701|NCT03951298||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
11117702|NCT03951285|Experimental|NR|"One intervention includes healthy BMI-discordant monozygotic twin pairs, which both are treated with NR. With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background.
~The final dose for NR will be 1 g/day. The daily NR dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full NR dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
11117703|NCT03951285|Placebo Comparator|Placebo|"The second intervention includes monozygotic twins concordant for body weight. It's randomized which member of the twin pair is treated with NR while the other co-twin gets placebo.
~The final dose for placebo will be 1 g/day. The daily placebo dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full placebo dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
11117704|NCT03951272|Experimental|Lyoplant® Onlay|All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
11117705|NCT03951272|Active Comparator|DURAFORM™ Dural Graft Implant|All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
11117706|NCT03951259|Experimental|SM934 10mg|SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids
11117707|NCT03951259|Experimental|SM934 30mg|SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids
11117708|NCT03951259|Experimental|SM934 50mg|SM934 10mg（5 tablet）p.o. qd in combination with steroids
11117709|NCT03951259|Placebo Comparator|Placebo|Placebo（5 tablets）p.o. qd in combination with steroids
11117710|NCT03951246|Experimental|Training Group|"Training Group recieved cognitive and Motor training included 6 sessions using the following training devices.
~Dynavision D2 ® (USA) (https://products.dynavisioninternational.com/products/d2) presents a panel with 64 bulbs which take the form of five circles. The task of a participant is to press the bulb that is glowing as quick as possible. In the trial 8 modes will be used; they have different instructions which are aimed at visual-motor co-ordination, processing speed, inhibition, and shifting.
~Fitlight Trainer ® (Canada) (https://www.fitlighttraining.com) consists of 7 clickers, and the tasks are similar to Dynavision ones.
~NeuroTracker ® (Canada) (https://neurotracker.net) includes a task of multiple object training for working memory and attention enhancement."
11117711|NCT03951246|No Intervention|Control Group|Control Group didn't recieved any cognitive and motor training. They visited swimming pool and physical therapy.
11117712|NCT03951233||K-RAS and EGFR mutated|
11117713|NCT03951233||Wild type|
11117863|NCT03950076|Experimental|Edoxaban 60/30mg daily|Edoxaban 60/30 mg daily (lower dose depending on clinical criteria)
11117714|NCT03951220||Group 1- Myeloma|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.
~This will be repeated at 6 months."
11117715|NCT03951220||Group 2- MGUS|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.
~This will be repeated at 6 months."
11117716|NCT03951220||Group 3- Healthy Volunteers|Participants will have the experimental combined MR imaging.
11117717|NCT03951207|Experimental|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
11117718|NCT03951207|Experimental|Rosuampin 20/5mg|Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks
11117719|NCT03951207|Active Comparator|Amlodipine/Atorvastatin 5/20mg|Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks
11117720|NCT03951194|Experimental|Participants receiving PRP treatment|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
11117721|NCT03951194|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP)|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
11117722|NCT03951181|Experimental|LEAP-MS Intervention|This is a single arm study.
11117723|NCT03951168|Other|Routine Management|The patients were divided into routine diabetic health education management model group. Patients who meet the criteria for admission and discharge.
11117724|NCT03951168|Experimental|Standardized Management|The patients were divided into standardized diabetes health education management model group. Patients who meet the criteria for admission and discharge.
11117725|NCT03951155|Experimental|ADHD Group|Muscle Relaxation technique for behavioral management
11117726|NCT03951155|No Intervention|Tell Show Do Group|Tell Show Do Technique for behavioral management
11117727|NCT03951142|Experimental|Study A: Recurrent glioblastoma (denoted 'AR')|"Patients with recurrent glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 12 cycles will be administered for a total of 6 weeks (42 days) to 24 weeks (168 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.
~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy (temozolomide or lomustine tablets)."
11117728|NCT03951142|Experimental|Study A: Newly diagnosed glioblastoma (denoted 'AN')|"Patients with newly diagnosed glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 17 cycles will be administered for a total of 6 weeks (42 days) to 34 weeks (238 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.
~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving adjuvant chemotherapy (Temozolomide tablets)."
11117729|NCT03951142|Experimental|Study B: Brain metastases (denoted 'BM')|"Patients with brain cancer from non-small cell lung cancer (N=45) with all receive a dose of 50mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 3 months (90 consecutive days) defined as a treatment cycle. A minimum of one cycle and a maximum of three cycles will be administered for a total of 3 months (90 days) to 9 months (270 days), respectively.
~A stepped-wedge randomized design (ratio 1:1:1 over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy alone (carboplatin in combination with vinorelbin or pemetrexed or equivalent analogs) or in combination with pembrolizumab (2mg/kg/3rd week)."
11117730|NCT03951129||verbal group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal informing before hemodialysis catheter insertion
11117731|NCT03951129||verbal and video group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal and video informing before hemodialysis catheter insertion
11117732|NCT03951116|Experimental|Dose escalation cohort of FCN-437c|"The dose-escalation cohort:
~Participants will receive FCN-437c monotherapy once daily (QD) for 21 days followed by a 7 day rest period (28-day cycle).
~FCN-437c will be administered orally.
~Participants with histologically or cytologically confirmed advanced unresectable/metastatic solid tumor will participate in this cohort."
11117733|NCT03951103||Hemophili A patients|Patients treated with rFVIIIFc for ITI
11117734|NCT03951090|Experimental|GARRT Arm|Participants in this arm complete an brief geriatric assessment, and the results of these assessments are given to providers with recommendations to address deficits identified by the geriatric assessment
11117735|NCT03951090|Active Comparator|Control Arm|Providers of participants of this group will not receive the results of the brief geriatric assessments. These participants will receive standard of care treatment
11117736|NCT03951077|Experimental|Various doses of Elagolix plus matching placebo|Various dosing regimens for Elagolix taken orally plus matching placebo taken orally depending on arm assignment.
11117737|NCT03951077|Placebo Comparator|Placebo|Placebo taken orally twice a day (BID)
11117738|NCT03951064|Experimental|Optimal PEEP|The waveforms of airway pressure (Paw), esophageal pressure (Pes), and transpulmonary pressure (Ptp) will be visualized on the ventilator. Ptp is obtained from Paw - Pes. PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP). Measurements will be obtained daily and adjustments to PEEP will occur daily. PEEP will be reduced below Optimal PEEP in the setting of hemodynamic compromise (requiring increasing vasoactive medications for blood pressure support).
11117739|NCT03951064|Active Comparator|ARDSNet High PEEP|PEEP in the control group will be determined by High PEEP ARDSnet PEEP/FiO2 table. Titration of PEEP will occur when clinically indicated by partial pressure of oxygen (PaO2) or oxygen saturation (SpO2), and FiO2. The investigators chose the High PEEP table based on the clinical suspicion that obese patients may require higher PEEP levels on average than non-obese patients to balance the additional pressure of their chest wall. In addition, EPVent2, a study of esophageal balloon PEEP titration in patients with ARDS utilized the High PEEP table. Patients with moderate and severe ARDS benefit from higher levels of PEEP.
11117740|NCT03951051|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11117741|NCT03951051|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11117742|NCT03951038|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with saline added up to a volume of 80ml in total ) and the equal volume of 0.9% normal saline will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
11117743|NCT03951038|Experimental|Lateral TLIPB group|Participants in this group will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine, and combined with PCIA post-operatively. The regimen of the Lateral TLIPB is 0.2% 20 ml ropivacaine respectively and the regimen of PCIA is same with PCIA group.
11117744|NCT03951025|Active Comparator|Melatonin oral administration|Consumption of one tablet with 1 mg of melatonin orally
11117745|NCT03951025|Experimental|Melatonin sublingual administration|Consumption of one tablet with 1 mg of melatonin sublingually
11117746|NCT03950999|Experimental|Study arm|Each subject underwent baseline assessment of pain reporting accuracy (FAST). Thereafter, the placebo response was assessed using tonic heat stimuli delivered at fixed temperature of 44, 46.5, and 48°C which evoke mild, moderate and severe pain sensations (in accordance). The stimuli were given in a pseudo-random order twice, once before receiving the placebo pill (a sugar pill) and once after, maintaining the same order as before.
11117747|NCT03950986|No Intervention|Control|Providers assigned to the control group will receive unmodified vaccine reminders (as they already appear in the VA EHR system). Separate reminders will appear for the different vaccines of interest.
11117748|NCT03950986|Experimental|Treatment|Providers in the treatment group will receive modified clinical reminders for the vaccines of interest. Reminders for the different vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
11117749|NCT03950973|Experimental|CareAvenue|Participants receive access to CareAvenue, an e-health tool, and receive one weekly automated telephone call and 4-5 text messages per week for 52 weeks.
11117750|NCT03950973|Active Comparator|Guest Assistance Program|Participants receive information about the Guest Assistance Program (GAP) and receive 3-4 text messages per week related to diabetes management and resources for 52 weeks.
11117751|NCT03950960|Experimental|BMS-986256 +Itraconazole|
11117752|NCT03950947|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis and randomization to the intervention group, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug, CE0086).
11117753|NCT03950947|Sham Comparator|Sham-Control|In the presence of a significant right coronary artery stenosis, and randomization to the sham-procedure: right IMA will be selectively intubated using an appropriate catheter. Angiography of the RIMA and the pericardiacophrenic branch will be performed.
11117754|NCT03950921|Experimental|Patient Safety Display Arm|Patient Safety Display in patient room
11117755|NCT03950921|No Intervention|Control Arm|Usual Care
11117756|NCT03950908|Other|Single bite|The single bite technique involved removing the forceps with its specimen after each individual biopsy.
11117757|NCT03950908|Other|Double bite|The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
11117758|NCT03950882|Experimental|Group 1|PXL770 Dose 1 or placebo
11117759|NCT03950882|Experimental|Group 2|PXL770 Dose 2 or placebo
11117760|NCT03950869|Experimental|Negative Expectations|Expectations on the severity and frequency of intrusions are increased while expectations on the controllability of intrusions are decreased.
11117761|NCT03950869|Experimental|Positive Expectations|Expectations on the severity and frequency of intrusions are decreased while expectations on the controllability of intrusions are increased.
11117762|NCT03950869|No Intervention|No Expectation Manipulation|Expectations on the severity and frequency of intrusions and on the controllability are neither increased nor decreased.
11117763|NCT03950856|Experimental|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
11117764|NCT03950856|Experimental|V114 Lot 2|Single IM dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
11117765|NCT03950856|Experimental|V114 Lot 3|Single IM dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
11117766|NCT03950856|Experimental|Prevnar 13®|Single IM dose at 0.5 mL of Prevnar 13® at Visit 1 (Day 1)
11118107|NCT03948256|Active Comparator|Control intervention|Prompt closure, based on best available scientific data
11117767|NCT03950843|Experimental|Experimental Group|"Patients assigned to this group are treated with 1 capsule of CKD-825 and 2 placebo capsules(the placebo of CKD-825)
~The necessity of a dose titration is adjudicated every 2 weeks.
~After unblinding at the end of Administration Period, only patients in experimental group are treated with 1 capsule of CKD-825 for additional 4 weeks of Extension Period."
11117768|NCT03950843|Placebo Comparator|Placebo Group|"Patients assigned to this group are treated with 3 placebo capsules (the placebo of CKD-825)
~The necessity of a dose titration is adjudicated every 2 weeks"
11117769|NCT03950830|Experimental|Treatment arm|Cisplatin 50mg/m2 day 1 and 2, every 3 weeks, Disulfiram 400mg daily, continuously
11117770|NCT03950817|Active Comparator|0.75 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 0.75 mg/kg sub-dissociative dose ketamine (SDK) to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
11117771|NCT03950817|Active Comparator|SDK: 1 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses 1 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
11117772|NCT03950817|Active Comparator|SDK: 1.5 mg/kg.|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 1.5 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
11117773|NCT03950804||CHAPLE patients, without eculizumab treatment|Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
11117774|NCT03950804||Control subjects- no intervention|Healthy subjects with no history of any chronic disease. All investigational analyses are performed on both the case and the control subjects. Therefore, the same type of biological specimens collected from the case group are collected from the control group simultaneously.
11117775|NCT03950804||Non-CHAPLE PILs|PIL patients with intact CD55 on flow-cytometry assesment undergo genetic testing to exclude a potential missense mutation in the CD55 gene that impairs its function while retaining protein expression. Overall, patients and their parents undergo exome sequencing as trios, and examined for potential gene mutations underlying their disease. Non-CHAPLE PILs are also examined by high-throughput investigation similarly to CHAPLE patients.
11117776|NCT03950804||CHAPLE patients on eculizumab|Among CHAPLE patients, there is a subgroup who receive eculizumab treatment. These patients are prospectively followed and biological samples collected at baseline as well as periodically under therapy. Eculizumab (Soliris) is being provided for CHAPLE patients on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to manufacturer's recommendations based on the weight of the patients.
11117777|NCT03950791|Experimental|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials.
11117778|NCT03950791|Placebo Comparator|Health Education|A 2-hour in-person informational session about general health education. Participants receive a list of resources in the community.
11117779|NCT03950778|Active Comparator|Septic patients receiving albumin replacement|Septic patients receiving albumin replacement 20 ml Inj Human Albumin 20% -3x100 ml- 3 day
11117780|NCT03950778|No Intervention|Septic patients not receiving albumin replacement|
11117781|NCT03950765|Experimental|Ecological Momentary Intervention|This group will receive three intervention prompts and three assessment prompts on their smartphone each day.
11117782|NCT03950752|Experimental|Bagels with optimized composition in fatty acids|Participants will consume three bagels with an optimized composition in fatty acids and without oil palm in only one day.
11117783|NCT03950752|Active Comparator|Bagels with conventional composition in fatty acids|Participants will consume three bagels with a conventional composition in fatty acids in only one day.
11117784|NCT03950739|Experimental|Tyvaso to TreT|Each subject will receive a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
11117785|NCT03950726||Study Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection through the same incision
11117786|NCT03950726||Control Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection who underwent standard laparoscopic resection
11117787|NCT03950713|Experimental|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|Participants in the intervention group received the MBSR-T in addition to routine care.
11117788|NCT03950713|No Intervention|Routine care|The control group received the routine care provided in facilities, including routine check-ups at diabetes clinics as necessary.
11117789|NCT03950700|Experimental|Bupivacaine solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
11117790|NCT03950700|Placebo Comparator|Saline solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
11117791|NCT03950687|Active Comparator|Control group A|intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
11117794|NCT03950674|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression (up to 35 treatment administrations; up to approximately 2 years).
11117795|NCT03950674|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression (up to 35 treatment administrations; up to approximately 2 years).
11117796|NCT03950661|Experimental|Forest|"Each subject is exposed to a 50 minute walk in a green location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
11117797|NCT03950661|Experimental|Urban|"Each subject is exposed to a 50 minute walk in a gray location at some point during the crossover experiment. The psychological and physiological measurements taken during these walk location weeks are compared to the measurements from the other location. In addition a 'control' day is assigned for each location (ADL)."
11117798|NCT03950648|Experimental|Spatial Cognitive Training|map reading and route-learning skills
11117799|NCT03950635|Experimental|Group I (fiber-rich diet)|Patients consume a whole-foods, fiber-rich diet for 6 weeks.
11117800|NCT03950635|Experimental|Group II (ketogenic diet)|Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
11117801|NCT03950622|Experimental|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
11117802|NCT03950622|Active Comparator|Prevnar 13®|Single IM dose at 0.5 mL of Prevnar 13® at Visit 1 (Day 1)
11117803|NCT03950609|Experimental|Treatment (lenvatinib, everolimus)|Patients receive lenvatinib PO daily and everolimus PO daily on days 1-28. Treatments repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11117804|NCT03950596|Active Comparator|One acute resistance load exercise|One hundred volunteers will participate in one acute resistance load exercises to their quadriceps
11117805|NCT03950596|Active Comparator|Three acute resistance load exercises|One hundred volunteers will participate in three acute resistance load exercises to their quadriceps
11117806|NCT03950596|Active Comparator|Control Group|One hundred volunteers will participate in study as a control group
11117807|NCT03950570|Experimental|Phase 1: Dose Escalation|"Advanced solid tumors or metastatic breast cancer: Treatment with a single oral agent, ORIN1001.
~Relapsed, refractory metastatic breast cancer: Treatment with a combination of ORIN1001 and paclitaxel."
11117808|NCT03950570|Experimental|Phase 2: Dose Expansion|Relapsed refractory metastatic breast cancer that are Triple negative, ER+ or HER2- and treated with a single agent (ORIN1001) or in combination of ORIN1001 and Paclitaxel.
11117809|NCT03950544|Experimental|only meropenem therapy,|this group is only meropenem therapy as a single antibiotic treatment
11117810|NCT03950531||COPD exacerbation without Bronchiectasis|COPD patients who have been in exacerbation period and have no bronchiectasis
11117811|NCT03950531||COPD exacerbation with Bronchiectasis|COPD patients who have been in exacerbation period and have bronchiectasis
11117812|NCT03950518|Experimental|One-drug Regimes|Drug: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
11117813|NCT03950518|Experimental|Two-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride
11117814|NCT03950518|Experimental|Three-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride Levamisole Hydrochloride
11117815|NCT03950505|Experimental|1|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
11117816|NCT03950492|Experimental|OUD DBS|This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.
11117817|NCT03950479||primiparous group|women who will give birth to their first baby
11117818|NCT03950453|Experimental|Parenting Mindfully for Health Nutrition (PMH)|Parenting Mindfully for Health (PMH) + nutrition and physical activity counseling to promote healthy eating and physical activity in parent and child.
11117819|NCT03950453|Active Comparator|Contact Control Nutrition (C+N)|Contact control intervention (C) + nutrition and physical activity counseling (N).
11117820|NCT03950427|Active Comparator|Videogame-based Physical Activity Group|"The videogame-based physical activity group, will play active videogames using the Kinect for Xbox 360 game system. Each videogame group will be facilitated by the study coordinator, the principal investigator or other study staff.
~Participants in this group will also receive bupropion and counseling for smoking cessation."
11117821|NCT03950427|Placebo Comparator|Sedentary Videogame Group|"The sedentary videogame group will play videogames while seated using the Xbox 360 game system (without the Kinect sensor). Each sedentary videogame group will be facilitated by study staff.
~Participants in this group will also receive bupropion and counseling for smoking cessation."
11117822|NCT03950414|Experimental|Tier 1|3 participants enrolled at dose level 5x10^3 cells/kg of CMV viral specific T-cells
11117823|NCT03950401|Active Comparator|Monocryl|Closure of the skin at the completion of surgery by interrupted subcuticular technique with absorbable Monocryl suture.
11117824|NCT03950401|Active Comparator|Nylon|Closure of the skin at the completion of surgery by interrupted technique on top of the skin with non-absorbable Nylon suture. These will be removed at the first postoperative visit.
11117825|NCT03950388|No Intervention|Treatment as Usual|
11117826|NCT03950388|Experimental|Intervention|
11117827|NCT03950375||cochlear implantation|"cochlear implantation group : patients undergoing cochlear implantation between December 2018 and June 2019 in the ENT service of Reims universitary hospital."
11117864|NCT03950076|Active Comparator|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy: no antithrombotic therapy or antiplatelet monotherapy (at discretion of local investigator)
11117828|NCT03950362|Experimental|Radiotherapy associated to immunotherapy|"Radiotherapy: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
~Concomitant administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)"
11117829|NCT03950349||"Anterior cervical discectomy group"|
11117830|NCT03950336|Other|"Prebiotics + Low n-6 PUFA Diet"|A combination of beta-fructans (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
11117831|NCT03950336|Other|"Prebiotics + Control Diet"|A combination of beta-fructans (12g/day) and a control diet following the guidelines of Canada's Food Guide.
11117832|NCT03950336|Other|"Placebo + Low n-6 PUFA Diet"|A combination of maltodextrin (12g/day) and a diet with reduced intake of n-6 PUFAs and higher intake of n-3 PUFAs.
11117833|NCT03950336|Other|"Placebo + Control Diet."|A combination of maltodextrin (12g/day) and a control diet following the guidelines of Canada's Food Guide.
11117834|NCT03950323|Experimental|patients operated on for parotid tumor|All consecutive patients operated on for parotid tumor.
11117835|NCT03950310|Experimental|ELCA|On the antegrade delivery of the laser catheter after wiring, we used safe laser techniques and injected saline before and during the laser procedure at a 0.5 mm/sec catheter advancement rate. Whether to perform a retrograde laser method depended on each operator. After ablation by ELCA, patients undergo balloon dilation via standard techniques, and as appropriate, receive drug-eluting stent deployment.
11117836|NCT03950310|No Intervention|non ELCA|In non ELCA group, the conventional PCI procedure, including thrombus aspiration, POBA, and stent implantation was performed. The indication for aspiration was at the discretion of the physician based on angiographic, intravascular ultrasound, or optical coherence tomography/Optical Frequency-Domain Imaging.
11117837|NCT03950297|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6;
11117838|NCT03950284|Experimental|immediate loading with all on four technique in FFF|immediately loaded dental implants with the all-on-four technique in free vascularized fibular grafts
11117839|NCT03950271|Experimental|SHR-1210+ Trastuzumab + Oxaliplatin + Capecitabine|trastuzumab + SHR-1210 + capecitabine + oxaliplatin for neoadjuvant chemotherapy 4-cycle.Then D2 radical surgery. The patients continued to receive capecitabine plus oxaliplatin for adjuvant therapy, and the total number of chemotherapy cycles was 8 cycles.
11117840|NCT03950258|Experimental|endovascular embolization|patients under the age of 18 years with arteriovenous shunts manifested by systemic or neurological manifestations will undergo endovascular embolization
11117841|NCT03950245|Other|Gastric bypass operated patients|Four test days in a randomized, patient-blinded, cross-over design
11117842|NCT03950245|Other|Sleeve gastrectomy operated patients|Four test days in a randomized, patient-blinded cross-over, design
11117843|NCT03950245|Other|Un-operated controls|Four test days in a randomized, patient-blinded cross-over, design
11117844|NCT03950232|Experimental|Etrasimod 2 mg|
11117845|NCT03950219||Intervention, Centre for Diabetes or local setting|Group-based course in diabetes education including 6 sessions of approximately 3 hours. Sessions are constructed around themes such as; diabetes knowledge and complication, mental health, diet, physical activity, Ramadan, medicine and include practical exercises such as blood sugar measurements, walking etc.
11117846|NCT03950219||Usual care|Usual care in 5 municipalities in the west area of Copenhagen
11117847|NCT03950206|Other|Women with endometriosis|Women undergoing laparoscopic surgery for endometriosis
11117848|NCT03950193||premature child|Premature children evaluated during their 24 months follow up consultation
11117849|NCT03950180|Active Comparator|PCCI group|In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.
11117850|NCT03950180|No Intervention|Standard care|Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.
11117851|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
11117852|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
11117853|NCT03950154|Experimental|Arm 1:CIK|"Bevacizumab & Oxaliplatin & Capecitabine & PD1-T cells
~Bevacizumab,7.5mg/kg,intravenousinfusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; PD1-T cells, 1x10^10 (10 billion),intravenous infusion,17; Q3W,after 6 cycles; Bevacizumab, 7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2;Oral administration,d1-14; PD1-T cells,1x10^10(10 billion),intravenous infusion,d17; Q3W, maintenance treatment."
11117854|NCT03950154|Active Comparator|Arm 2: Control|"Bevacizumab & Oxaliplatin & Capecitabine
~Bevacizumab,7.5mg/kg,intravenous infusion,d1; Oxaliplatin,130mg/m2,intravenous infusion,d1; Capecitabine,1g/m2,oral administration,d1-14; Q3W,after 6 cycles; Bevacizumab,7.5mg/kg,intravenous infusion,d1; Capecitabine,1g/m2, Oral administration,d1-14; Q3W, maintenance treatment."
11117855|NCT03950141|Experimental|Apatinib and S1 group|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
11117856|NCT03950128|Experimental|Mindfulness-Based Skills Training|This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.
11117857|NCT03950128|Active Comparator|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions.
11117858|NCT03950115|Active Comparator|Group 1|
11117859|NCT03950115|Active Comparator|Group 2|
11117860|NCT03950102|Experimental|SBRT|SBRT will be used as the primary bridging therapy for HCC patients on waitlist
11117861|NCT03950089||Patients with Central Serous Chorioretinopathy|
11117862|NCT03950089||Healthy patients|
11117866|NCT03950050|Experimental|Ambroxol|"Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.
~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
11117867|NCT03950037|Experimental|Medical intervention|Participants are hospitalized for 15-30 days while they receive the antiparasitic drug albendazole along with supportive drugs including dexamethasone and omeprazole.
11117868|NCT03950024|Experimental|with arthrogenic Muscle Inhibition|
11117869|NCT03950024|Active Comparator|without arthrogenic Muscle Inhibition|
11117870|NCT03950011||ERP|Any patient requiring oncologic surgery, including hysterectomy or curettage, posterior pelvectomy, conventional laparoscopic or assisted robotic surgery, or laparotomy for cervical or cervical cancer or ovarian cancer, body or cervix uterus and ovaries as well as benign pathologies or borderline malignancy.
11117871|NCT03949998|Experimental|Dry Needling|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals.
11117872|NCT03949998|Active Comparator|Dry Needling + Manual Therapy|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals IN ADDITION TO manual therapy of the above muscles and/or cervical joint traction and/or mobilization as indicated.
11117873|NCT03949998|Active Comparator|Manual Therapy|Participants will receive manual therapy of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals and/or cervical joint traction and/or mobilization as indicated.
11117874|NCT03949985||Estrogenic contraceptive users|
11117875|NCT03949985||Non-estrogenic contraceptive users|
11117876|NCT03949972||A - Pediatric Cohort|Pediatric patients until 18 years of age presenting with or diagnosed with idiopathic nephrotic syndrome or a biopsy-proven diagnosis of MCD or FSGS.
11117877|NCT03949972||B -Adult Cohort|Adult patients 18 years and above with a biopsy-proven diagnosis of primary or secondary FSGS or MCD.
11117878|NCT03949959|Experimental|Physiotherapy (PRPt)|The 6-week exercise program (2 sessions in each of weeks 1-4 and 1 session in each of weeks 5 and 6) will comprise specific individually-tailored exercises to improve the movement and control of the neck and shoulder girdle. The exercises will be of a low load nature and designed to be pain free. At the same time, the physiotherapist will provide pragmatic multimodal physiotherapy to facilitate ability to pursue exercises and guide the participant's return to normal activities. This specific treatment program has been described in detail (Jull et al., 2008; Ritchie et al., 2015b) and focuses on activating and improving the coordination and endurance capacity of the neck flexor, extensor and scapular muscles in specific exercises and functional tasks. Participants will also perform the exercises at home, once per day. Written and illustrated exercise instructions will be provided. The exercise program follows Australian guidelines for the management of chronic whiplash (TRACsa, 2008).
11117879|NCT03949959|No Intervention|Wait and See (PRPu)|"Individuals randomized to usual care will be provided with an advice booklet Whiplash Injury Recovery: A Self Help Guide (MAIC, Qld, 2nd edition). It provides information about whiplash; assurance about prognosis; advice to stay active and resume working as well as information on correct posture; pictorial descriptions of specific exercises for the neck and upper limbs and information on resuming functional daily activities. The booklet is based on the recommendations of the current Australian Guidelines for Whiplash Management (SIRA, 2014).
~Usual care involves a 'wait and see' approach (in combination with provision of home exercises) and will include weekly review appointments with a medical doctor, primarily to review the information in the booklet and progress the 'general' exercises and activity recommendations within the booklet. No hands-on physiotherapy will be provided. Education regarding PRP and associated healing cycles will also be provided during this time period."
11117880|NCT03949946||High-risk|Female participants confirmed to be BRCA1/2 or TP53 gene carriers
11117881|NCT03949946||Patients|Female participants confirmed to have invasive ductal carcinoma of the breast
11117882|NCT03949933|Experimental|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
11117883|NCT03949907|Other|Nutritional counseling alone|Nutritional counseling consists of a personalized dietary prescription with regular consultation by a registered dietitian and telephone interviews, as well as of the use of oral nutritional supplements, when necessary.
11117884|NCT03949907|Experimental|Supplemental parenteral nutrition plus nutritional counseling|Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.
11117885|NCT03949894|Experimental|tolvaptan|
11117886|NCT03949881|Experimental|FEMJA transplatation|"FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing.
~The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation."
11117887|NCT03949868|Experimental|High Mindfulness|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about memory performance) twice daily for six days.
11117888|NCT03949868|Experimental|Low Mindfulness|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to memory performance) twice daily for six days.
11117889|NCT03949868|Active Comparator|Active control|All participants in this condition will complete all measures online and over the phone at two points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about memory performance) twice daily for six days.
11118108|NCT03948256|Experimental|Experimental intervention|Gradual weaning, based on best available scientific data
11118109|NCT03948243|Experimental|G.Glabra|single arm
11117890|NCT03949855|Experimental|Part A: Low Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.
~Ten participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
11117891|NCT03949855|Experimental|Part A :High Proteinuria Group - Belimumab and Rituximab|"Open-label pharmacokinetics (PK) phase.
~Ten participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~An adjustment (increase) in prescribed weekly dose may occur, per protocol, if indicated by pharmacokinetics (PK) assay results.
~High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day)."
11117892|NCT03949855|Experimental|Part B: Low Proteinuria Group - Belimumab and Rituximab|Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
11117893|NCT03949855|Placebo Comparator|Part B: Low Proteinuria Group - Placebo and Rituximab|Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
11117894|NCT03949855|Experimental|Part B :High Proteinuria Group - Belimumab and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~A higher dose of belimumab, per protocol, will be prescribed in high proteinuria participants, if indicated in Part A."
11117895|NCT03949855|Placebo Comparator|Part A :High Proteinuria Group - Placebo and Rituximab|"Participants in the high proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive will receive belimumab placebo weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
~A higher dose of belimumab placebo, per protocol, will be prescribed in high proteinuria participants, if indicated in Part A."
11117896|NCT03949842|Experimental|Subjects who inhaled non-ELLIPTA MITT|Subjects with moderate or severe exacerbation in the past year and history of use of inhaled non-ELLIPTA MITT of ICS/LABA/LAMA within a routine clinical practice setting in the 52-week retrospective pre-switch period.
11117897|NCT03949842|Experimental|Subjects receiving TRELEGY ELLIPTA SITT|Subjects will receive FF/UMEC/VI (100 microgram [mcg]/62.5 mcg/25 mcg), inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) in the 52-week prospective post-switch period.
11117898|NCT03949816|Experimental|patient-centered communication style|The patient-centered style is characterized by features such as empathetic communication, open questions, and uses an easily understandable language.
11117899|NCT03949816|Experimental|doctor-centered communication style|The doctor-centered style is defined by an authoritarian and goal-oriented communication. The doctor uses medical terms instead of lay language.
11117900|NCT03949816|Active Comparator|information letter|In the active control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
11117901|NCT03949803|Experimental|Morning Chocolate|Test the if Chocolate Timing in the morning changes the metabolism
11117902|NCT03949803|Experimental|Evening Chocolate|Test the if Chocolate Timing before bedtime changes the metabolism
11117903|NCT03949803|Experimental|No Chocolate (Control)|Test the if no Chocolate Timing may affect the metabolism
11117904|NCT03949790|Active Comparator|Intercostal block with ESPB|Performed ESPB in VATs with intercostal nerve block
11117905|NCT03949790|Active Comparator|Intercostal block without ESPB|Not Performed ESPB in VATs with intercostal nerve block
11117906|NCT03949777|Experimental|Study Cohort|61 subjects will undergo colonoscopy
11117907|NCT03949764|Experimental|HCV Positive Study Participants|Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
11117908|NCT03949764|No Intervention|Control (Pike County)|After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
11117909|NCT03949751|No Intervention|Control group|The participants of the control group will not get the local therapy in the investigator's preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.
11117910|NCT03949751|Experimental|Therapy group|30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae.
11117911|NCT03949738||Adult patients with ARDS|Adults patients fulfilling the Berlin criteria for ARDS
11117912|NCT03949725|Experimental|Hans Kai program|
11117913|NCT03949725|No Intervention|Wait list control|
11117914|NCT03949712|Experimental|Right motor cortex (M1) tSMS|tSMS will be applied to the right motor cortex for 30 minutes.
11117915|NCT03949712|Experimental|Left motor cortex (M1) tSMS|tSMS will be applied to the left motor cortex for 30 minutes.
11117916|NCT03949712|Sham Comparator|Sham tSMS|Sham tSMS will be applied to the left or right motor cortex (randomized) for 30 minutes.
11117949|NCT03949478|Placebo Comparator|Placebo|Patients will receive placebo for at least five days prior to the first blood flow study. They will continue to receive placebo until the baseline study is obtained after the postictal study has been completed.
11117950|NCT03949478|Experimental|Ibuprofen|Patients will receive ibuprofen 400 mg by mouth three times a day (po tid) for at least five days prior to the first blood flow study. They will continue to receive ibuprofen until the baseline study is obtained after the postictal study has been completed.
11117917|NCT03949699|Other|Resistance Training|. Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down. Performance during exercise sessions will be monitored by study staff who will progress the participant to exercises of greater intensity (increasing number of repetitions, sets, or resistance load; on an individual basis over the 8-week intervention period according to the participant's level of readiness). This progression will also be guided by a strength training protocol. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise
11117918|NCT03949686|Sham Comparator|Saline + Placebo|Ultrasound guided 0.5 ml/kg saline injection to erector spinae plane
11117919|NCT03949686|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection to erector spinae plane
11117920|NCT03949673|Other|Knee or Hip Joint Arthroplasty|Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study
11117921|NCT03949660|Experimental|Epidural stimulation for blood pressure without stand|To assess whether epidural stimulation, used for regulating blood pressure without standing, is neuromodulatory for bowel motility after motor complete SCI
11117922|NCT03949660|Experimental|Epidural stimulation for blood pressure with stand|To assess whether epidural stimulation, used for regulating blood pressure with standing, is neuromodulatory for bowel motility after motor complete SCI
11117923|NCT03949660|Experimental|Epidural stimulation for trunk and core without stand|To assess whether epidural stimulation, used for activating the trunk and core musculature without standing, is neuromodulatory for bowel evacuation after motor complete SCI
11117924|NCT03949660|Experimental|Epidural stimulation for trunk and core with stand|To assess whether epidural stimulation, used for activating the trunk and core musculature with standing, is neuromodulatory for bowel evacuation after motor complete SCI
11117925|NCT03949647||1|Healthy males and females aged 18 years and older
11117926|NCT03949634|Experimental|PLD plus CTX sequential docetaxel or PTX|pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
11117927|NCT03949634|Active Comparator|DOX plus CTX sequential docetaxel or PTX|doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
11117928|NCT03949621|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
11117929|NCT03949621|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
11117930|NCT03949608|Experimental|BASIC|"mon cœur, mon BASIC video viewing and installation in the own smartphone or tablet of the patient"
11117931|NCT03949608|No Intervention|Control|Usual care
11117932|NCT03949595||cases|women suffering from severe/massive obesity
11117933|NCT03949582|Experimental|Mycoprotein as in Soup|24 will be randomised to soup (12 caucasian and 12 south asian) in order to test raw mycoprotein. Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
11117934|NCT03949582|Experimental|Mycoprotein as in Mince|24 will be randomised to mince (12 caucasian and 12 south asian) in order to test processed mycoprotein (Quorn). Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
11117935|NCT03949569|Experimental|Arm 1|In this condition, children will interact with the therapy dog prior to the psychosocial stress task and with the stuffed toy dog prior to the prosocial behavior tests.
11117936|NCT03949569|Experimental|Arm 2|In this condition, children will interact with the stuffed toy prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
11117937|NCT03949556|Experimental|Intervention program - stress management program|This intervention program on stress management is developed to prevent suicidal ideation in medical students and residents.
11117938|NCT03949556|Active Comparator|Intervention program - health promotion program|This intervention program on health promotion is developed to prevent suicidal ideation in medical students and residents.
11117939|NCT03949556|Placebo Comparator|Control condition - general information|Participants will receive weekly emails and SMSs, over the same periods of time, with general information about health except mental health, e.g. prevention of melanoma, dental care….
11117940|NCT03949543|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with large lunch intervention
11117941|NCT03949543|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with large dinner intervention
11117942|NCT03949530|Experimental|IDL-2965 Oral Capsule|IDL-2965 oral capsule, single and multiple doses
11117943|NCT03949530|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single and multiple doses
11117944|NCT03949517|Experimental|68-Ga RM2+68-Ga PSMA11|68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
11117945|NCT03949517|Experimental|68-Ga PSMA11+68-Ga RM2|68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
11117946|NCT03949504||General population|Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
11117947|NCT03949504||Patients with type 2 Diabetes|Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed
11117948|NCT03949491|Experimental|3-D virtual planning and medical modeling of breast|"3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction.
~Preoperative CT-Angiogram of the abdominal wall
~Volumetric analysis preformed
~3D printed models made
~Pre operative BREAST-Questionnaires given
~Free tissue transfer performed: Operative/Dissection Time Recorded
~Flap/Abdominal donor site complications recorded
~Standard Digital Photography and Harris Scoring
~BREAST-Questionnaires given at 3, 6 months"
11117951|NCT03949478|Experimental|Nifedipine|Patients will receive nifedipine 10 mg po tid for 2 days, then 20 mg po tid, thereafter for at least five days prior to the first blood flow study. They will continue to receive nifedipine until the baseline study is obtained after the postictal study has been completed.
11117952|NCT03949465|Experimental|Open label iTBS rTMS|Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
11117953|NCT03949452|Active Comparator|Subcostal Transversus Abdominis Plane catheter|This group includes patients who will receive subcostal Transversus abdominis plane block analgesia
11117954|NCT03949452|Placebo Comparator|Epidural catheter|This group includes patients who will receive epidural analgesia using a catheter technique
11117955|NCT03949439||Non-Frail|non-frail (frailty score 1~3) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
11117956|NCT03949439||Pre-Frail|Pre-frail (frailty score 4) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
11117957|NCT03949426|Experimental|KPG-818|Dose escalation
11117958|NCT03949426|No Intervention|Placebo|Matching placebo
11117959|NCT03949413|Experimental|Pediatric balance scale|The Pediatric Balance Scale (PBS) includes fourteen items. Each item of subsets scored as 4, 3, 2, 1 or 0. Finally, the total test score was calculated
11117960|NCT03949400||Patients diagnosed with knee OA|Patients diagnosed with knee OA and assigned to undergo exercise therapy and education.
11117961|NCT03949387|Experimental|FES Cycling Exercise|FES cycling will involve systematic, transcutaneous electrical stimulation of the leg muscles to produce leg-cycling movement. The intensity and duration of training will be prescribed based on guidelines for aerobic exercise training for persons with MS and from the American College of Sports Medicine, and will progressively increase across 24 weeks. Participants will be encouraged to actively cycle at a minimum cadence of ~40-50 rpm, at 40-60% VO2peak for between 10-50 minutes. The intensity of stimulation will be adjusted per leg muscle group based on sensory tolerance with the goal of maintaining pedaling action and target heart rate over the entire session. At each session, we will record the distance traveled, energy expended, power output, resistance, heart rate and rating of perceived exertion (RPE).
11117962|NCT03949387|Placebo Comparator|Passive Leg Cycling|Passive leg cycling will involve movement of the participant's legs by the cycle ergometer motor without electrical stimulation. The duration of training will follow the same schedule as the FES cycling condition and the same data will be recorded at each session. The passive cycling condition will include the same exposure with the training facility, the exercise equipment (i.e. RT300 cycles), and the research staff (i.e. social contact and attention) as with the FES cycling condition.
11117963|NCT03949374|Active Comparator|10mg of the generic formulation (rosuvastatin, ROVASRO®)|Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
11117964|NCT03949374|Active Comparator|10mg of the reference formulation (rosuvastatin, CRESTOR®)|Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)
11117965|NCT03949361||Patients starting glucocorticoids|Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.
11117966|NCT03949361||Patients stopping glucocorticoids|Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.
11117967|NCT03949348|Active Comparator|autologous fascia|Patients who underwent a transobturator sling placement using autologous rectus fascia
11117968|NCT03949348|Active Comparator|synthetic mesh|Patients who underwent a transobturator sling placement using synthetic mesh
11117969|NCT03949322|Experimental|Adapted Physical Activity Program|Patients in the experimental group take part in a program of Adapted Physical Activity lasting 6 weeks, with 2 sessions per week.
11117970|NCT03949309||Eligible patients|All eligible patients discharged from hospital for Acute Myocardial Infarction (AMI) or acute decompensation of Chronic Heart Failure (CHF)
11117971|NCT03949296|Active Comparator|Mindfulness Intervention|Mindfulness-Based Treatment for Insomnia intervention led by a certified instructor. It is adapted from the Mindfulness-Based Stress Reduction Curriculum developed by the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School. It introduces the concept of mindfulness and provides the opportunity to practice it within sessions and during home practice. Participants learn about stress, and explore habitual behavioral, physical, emotional and cognitive patterns, as well as more effective responses to challenges and demands of everyday life. Each class includes mindfulness practice, group discussions, and practices and exercises related to the class topics. Participants receive home assignments with guided meditation and yoga practices.
11117972|NCT03949296|Placebo Comparator|Sleep Hygiene|Control group participants attend a 30-minute group counseling session on sleep hygiene. The session includes a handout from the Centre for Clinical Intervention in Australia that provides 15 sleep hygiene tips.
11117973|NCT03949283|Active Comparator|Physician Choice Treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the physician from the provided list).
~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
~Liposomal Doxorubicin;
~Docetaxel;
~Paclitaxel;
~Carboplatin;
~Cisplatin;
~Gemcitabine;
~Topotecan;
~Carboplatin, Gemcitabine;
~Cisplatin, Gemcitabine;
~Carboplatin, Liposomal Doxorubicin;
~Carboplatin, Paclitaxel;
~Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
11118047|NCT03948737|Placebo Comparator|Control|Placebo is the drug with the same shape and color as the alpha-tocopherol supplementation.
11118048|NCT03948724|Experimental|Therapeutic patient education|Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize
11117974|NCT03949283|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.
~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:
~Liposomal Doxorubicin;
~Docetaxel;
~Paclitaxel;
~Carboplatin;
~Cisplatin;
~Gemcitabine;
~Topotecan;
~Carboplatin, Gemcitabine;
~Cisplatin, Gemcitabine;
~Carboplatin, Liposomal Doxorubicin;
~Carboplatin, Paclitaxel;
~Carboplatin, Docetaxel.
~The treating physician will receive the ChemoID assay results from the ChemoID lab."
11117975|NCT03949270|No Intervention|Usual Care|Patients in the usual care arm will not receive any text messages.
11117976|NCT03949270|Experimental|BETA-Text Intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
11117977|NCT03949257|Experimental|colonic TET and FMT|gut microbiota will be collected through the colonic TET after FMT
11117978|NCT03949244|Active Comparator|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
11117979|NCT03949244|Experimental|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
11117980|NCT03949244|Placebo Comparator|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
11117981|NCT03949231|Experimental|Toripalimab hepatic artery infusion|Interventional technique to place microcatheter in hepatic artery to infuse Toripalimab in 30 minutes.
11117982|NCT03949231|Experimental|Toripalimab vein infusion|Regular IV infusion of Toripalimab in 30 minutes.
11117983|NCT03949218||bipolar disorder(BD)|hospitalized patients BD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F31 bipolar disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
11117984|NCT03949218||major depressive disorder（MDD）|hospitalized patients MDD patients in SMHC from 2009 to 2018; meet ICD-10 diagnosis of F32 depressive disorder criteria and its subtype (mental examination was conducted by three levels of doctors including at least one attending physician and one chief physician in psychiatric); available relevant HIS system biochemical data; hospitalized patients need to the first admission; age and gender is not limited
11117985|NCT03949205|Experimental|Leg Extension Isometric Training|Experimental group will perform leg extension isometric exercise.
11117986|NCT03949205|No Intervention|Control Group|Control group will be advised to maintain their work habits and not to change their routine activities, especially diet and physical activities.
11117987|NCT03949179||Pain and Disability Drivers Management model|Participating clinicians will use the PDDM model to guide assessment and treatment of their patients for a 6-weeks period.
11117988|NCT03949166|No Intervention|Fasting|After completion of an epidural block patients that agreed to participate in the study and were randomised to the fasting arm will be allowed to drink water and clear fluids during labor and delivery as accepted by the institute protocol.
11117989|NCT03949166|Experimental|Eating|After completion of an epidural block patients that agreed to participate in the study and were randomized to the eating arm will be allowed to eat during their labor and delivery. They will be provided with the list of food that was approved and accepted by the anesthesia team. They will be asked to try eating every 2 hours but if they feel lack of need to eat or any side effects preventing them to eat they can choose not to eat. When reaching full dilatation of 10cm they will ber asked to stop eating.
11117990|NCT03949153|Experimental|Experimental arm|Single Nivolumab 240 mg infusion at D0, followed by cryotherapy using interventional radiology of metastatic lymphadenopathy at D1 and in situ injection with ipilimumab at D2.
11117991|NCT03949140|Experimental|Laser hair removal treatment|Patients who choose to enroll will plan to undergo a total of up to 8 laser hair removal sessions every 4-6 weeks. If patients develop abscess or infection during this time, they will undergo I&D and/or antibiotics, consistent with standard therapy for infection or abscess. If patients have 2 or more infections in 1 year, pain or drainage for more than 1 month, or miss more than 1 week of school or work due to ineffective treatment of pilonidal disease, these patients will undergo surgical excision and subsequent follow-up at surgeon's discretion. Patients will follow up at 2-4-week intervals for 3 months, then at 6, 9, and 18 months after conclusion of the laser therapy sessions. At all follow-up sessions, patients will be given the DQLI, CDQLI, and Promis 3A Pain survey. Unscheduled visits such as unplanned clinic visits, emergency department encounters, and hospitalizations, will be included in data collected for analysis of primary and secondary outcomes.
11117992|NCT03949127|Experimental|Exercise Group|The group who will exercise to manage pain.
11117993|NCT03949127|No Intervention|Control Group|The group who will not take part in any exercises and only have to do assessments.
11117994|NCT03949114|Experimental|test group|"1) Performing a weak debilitating phenotype screening on the patients before surgery;
~(2) Do the early rehabilitation intervention process:"
11117995|NCT03949114|Active Comparator|Control group|1) Performing a weak debilitating phenotype screening on the patients before surgery; (2) Patients in the control group were treated according to the general nursing routine after neurosurgery;
11117996|NCT03949101|Experimental|combined use of 1% atropine and 0.01% atropine|first week, use atropine sulfate 1% ophthalmic ointment every night before sleep; then use atropine sulfate 1% ophthalmic ointment once every week(Friday night before sleep is recommended) for half a year; then use atropine sulfate 0.01% eye drop every night before sleep for one year and a half.
11117997|NCT03949101|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years.
11117998|NCT03949088|Experimental|Linear descending UF profile|2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)
11117999|NCT03949088|Experimental|Run-in & washout phases|constant Na concentration, constant UF rate 3 weeks (6+3 sessions)
11118000|NCT03949088|Experimental|Ascending/descending UF profile|2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)
11118001|NCT03949075|Experimental|Enalapril treatment|
11118002|NCT03949075|Placebo Comparator|Placebo treatment|
11118003|NCT03949062|Experimental|iR2|Participants received six 21-day cycles of ibrutinib, lenalidomide, and rituximab (iR2) treatment (21-day cycles).
11118004|NCT03949049|Experimental|Citacoline|Citacoline as neuroprotector
11118005|NCT03949049|Placebo Comparator|Placebo|Placebo
11118049|NCT03948724|Active Comparator|Standard Care|Patient receive usual informations
11118006|NCT03949036|Experimental|target of Stroke Volume Variation ≤ 6%|The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 6%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
11118007|NCT03949036|Active Comparator|target of Stroke Volume Variation ≤ 12%|The rate of intraoperative fluid administration will be adjusted to achieve the target of Stroke Volume Variation ≤ 12%. A crystalloid bolus of 200 ml will be repeatedly administered every 20 min until the target was achieved. The basal rate of fluid administration will be 3 ml/kg/hr.
11118008|NCT03949023||Standard of Care Cerebral Angiogram Group|Participants undergoing a standard of care cerebral angiogram.
11118009|NCT03949010|Experimental|Kinesiotaping with space correction technique|
11118010|NCT03949010|Experimental|Kinesiotaping with muscle inhibition technique|
11118011|NCT03949010|Active Comparator|Home exercise program|
11118012|NCT03948997|Experimental|Treatment group|Patients with port wine stains receive PDL (1.5-10ms, 11-12.5J/cm2) with a treatment range of approximately 10*10cm2
11118013|NCT03948997|No Intervention|No treatment group|Patients with port wine stains have not been treated with PDL treatment
11118014|NCT03948984|Experimental|Therapeutic Music Session|
11118015|NCT03948971|Other|Venogram Group|Participants in this group have a scheduled clinically indicated a cerebral angiogram procedure and will undergo a Venogram.
11118016|NCT03948958|Experimental|TIVAD evaluation|TIVAD evaluation at port removal evaluation of catheter function, visualization of catheter tip, presence of thrombus material and sleeve and any device damage during linogram (contrast injection via TIVAD), tip and chamber content microbiological culture, macroscopic catheter and port chamber evaluation PROM: patient reported outcome measurements regarding TIVAD insertion, presence and removal
11118017|NCT03948945|No Intervention|before treatment|The patient with facial and neck photoaging did not receive laser treatment.
11118018|NCT03948945|Experimental|after treatment|The patient with facial and neck photoaging received Profile HaloTM mixed fractional laser treatment
11118019|NCT03948919|Active Comparator|FMT Treatment|Fecal microbiota - 1.0-3.0 x 10^11 CFU / day (2 capsules per day for 8 weeks).
11118020|NCT03948919|Placebo Comparator|Placebo|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
11118021|NCT03948893|Experimental|MORE|
11118022|NCT03948893|Active Comparator|CBT|
11118023|NCT03948867|Experimental|Elevated Initial Screening TCD|Those who have an elevated initial screening TCD (either conditional or abnormal TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule.
11118024|NCT03948867|Experimental|Normal Initial Screening TCD|Those who are found to have a normal TCD at enrolment are a part of the observation/control cohort and will undergo repeat TCD every 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant will be reassigned to the elevated initial screening TCD arm and can begin study treatment (hydroxyurea), but will not be included in the primary endpoint analysis.
11118025|NCT03948854|Experimental|Registered dietitian education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in person by a registered dietitian
11118026|NCT03948854|Experimental|On-line video program education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet using an on-line video program
11118027|NCT03948854|Experimental|Handout education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet by a printed handout
11118028|NCT03948854|Experimental|Dietitian-led group education|Subjects with irritable bowel syndrome (IBS) will receive education on FODMAP diet in a dietitian-led group setting
11118029|NCT03948841||Neuroendocrine tumor|Patients with liver metastasis from neuroendocrine tumor
11118030|NCT03948828|Other|Conventional treatment group|GnRHa combained with reverse addition therapy
11118031|NCT03948828|Experimental|Conventional treatment and Autologous NK cells therapy|GnRHa combained with reverse addition therapy and NK cell combined treatment group
11118032|NCT03948815|Experimental|Intervention room|An adaptable, person-centered, birthing room that is specially designed.
11118033|NCT03948815|Other|Control room|A regular standard birthing room
11118034|NCT03948802||STROKE GROUP|Cerebral ischemic stroke patients treated.
11118035|NCT03948802||CONTROL GROUP|Ambulatory healthy patients
11118036|NCT03948789|Active Comparator|A Myomectomy|Removement of uterine fibroids by myomectomy
11118037|NCT03948789|Experimental|B MRgFUS-TUF|Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)
11118038|NCT03948776||Healthy volunteers|Adults without HF or prior heart transplantation
11118039|NCT03948776||Participants in our existing LVAD body composition study|Currently-enrolled LVAD body composition participants, who chose to participate in this study on the same day as a DXA scan already scheduled for study #12026
11118040|NCT03948776||Patients with heart failure, an LVAD or heart transplantation|Any patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation
11118041|NCT03948776||Inpatients with heart failure, LVAD, heart transplantation|Patients with a current diagnosis of HF, with or without an LVAD, or prior HF now status post heart transplantation, currently admitted as inpatients at Tufts Medical Center. The 6/20/2019 protocol update includes these patients who will participate without a DXA scan (which can only be performed as an outpatient).
11118042|NCT03948763|Experimental|V941 Monotherapy|V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles
11118043|NCT03948763|Experimental|V941 + Pembrolizumab|V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles
11118044|NCT03948750||Patients with Ocular Toxoplasmosis|
11118045|NCT03948750||Patients without Ocular Toxoplasmosis|
11118046|NCT03948737|Active Comparator|Alpha-Tocopgerol|"Alpha-Tocopherol supplementation will be given orally for 4 weeks with doses adjusted by age.
~5-8 years old: 200 mg daily, 9-13 years old: 400 mg daily and 14-18 years old 600 mg daily."
11118052|NCT03948672|Active Comparator|Control-then-Intervention|In each intensive care unit assigned to the Control-then-Intervention arm, all participants who regularly access the ICUs will wear the wristband while at work for 5 months. The functionality of the wristband will not be disclosed to the healthcare providers. Handwashing compliance data will be automatically collected, but data will not be shared with the healthcare providers or hospital management teams. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from the sensor system. Then, all healthcare providers will be educated on the functionalities of the CleanHands system with real time reminders now turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection reduction. This phase will last for 5 months.
11118053|NCT03948672|Active Comparator|Intervention-then-Control|In each intensive care unit assigned to the Intervention-then-Control arm, all participants who regularly access to the ICUs will be educated on the functionalities of the CleanHands system with real time reminders turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection control. This phase will last for 5 months. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from sensor system installation and implementation. Then, the real-time reminder functionality of the wristband will be turned off and no more education will be provided. Handwashing compliance data will be automatically collected but will not be shared with the healthcare providers. This process will last for 5 months.
11118054|NCT03948659||Cirrhotic patients in intensive care unit|
11118055|NCT03948646|Experimental|Active|Sofpironium bromide, 15% gel, once per day
11118056|NCT03948646|Placebo Comparator|Vehicle|Vehicle gel, once per day
11118057|NCT03948633|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination).
11118058|NCT03948633|No Intervention|Control|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting).
11118059|NCT03948620||Children whose mother prescribed antibiotics during pregnancy|"Children whose mother were prescribed an only monotherapy of macrolides or penicillins from 5 gestational weeks (GW) to delivery. A monotherapy is defined as one or more consecutive prescriptions for a single antibiotic (i.e. same drug substance) separated by no more than 30 days and uninterrupted by prescriptions for other antibiotic drug substances.
~The investigators will also build a negative control cohort which includes children whose mother were prescribed an only monotherapy of macrolides or penicillins from 50 to 10 weeks before conception."
11118060|NCT03948607||Adult ADHD|Adult ADHD patients without current comorbidity and treatment.
11118061|NCT03948607||Healthy controls|Healthy controls without ADH, paired in age and gender.
11118062|NCT03948594|Placebo Comparator|plain water|subject drink 250cc plain water
11118063|NCT03948594|Active Comparator|resource|subject drink 1 packet resource(237ml)
11118064|NCT03948581|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
11118065|NCT03948581|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
11118066|NCT03948568|Active Comparator|Concurrent Endocrine Therapy and Radiotherapy|Concurrent endocrine therapy and radiotherapy. Concurrent endocrine therapy will be defined as, the commencement of endocrine therapy around 2 weeks before (a minimum of 1 week before to a maximum of 4 weeks) commencement of radiotherapy and continued throughout radiotherapy.
11118067|NCT03948568|Active Comparator|Sequential Endocrine Therapy after Radiotherapy|Sequential endocrine therapy after radiotherapy. Using the pragmatic definition sequential endocrine therapy should commence around 2 weeks (minimum 1 week, maximum 4 weeks) after the last fraction of radiotherapy.
11118068|NCT03948555||Acute aortic dissection|stable patients with confirmed diagnosis of acute AD.
11118069|NCT03948555||Chronic aortic dissection|patients with diagnosis of chronic AD, being followed up in outpatient aortic clinic.
11118070|NCT03948542||Outcome|Nerve conduction studies (NCV) Functional assessment according to Daniels and Worthingham
11118071|NCT03948529|Experimental|eltrombopag|Eligible patients will receive the investigational drug eltrombopag
11118072|NCT03948503|Experimental|Mobilization with movement (MWM) group|Application of the Mulligan concept
11118073|NCT03948503|Placebo Comparator|Sham group|Sham treatment
11118074|NCT03948490|Other|Arm 1 Cohort 1: Interventional arm/In-person rehab|"The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
~n = 20 patients"
11118075|NCT03948490|Experimental|Arm 1 Cohort 2: Interventional arm/ReMind iPad app|"The ReMind iPad-based cognitive rehabilitation was developed with collaborators at Tilburg University, The Netherlands, and is an evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors. Brain plasticity-based computerized cognitive training is a newly developing field of therapeutics for neurological and psychiatric disorders that uses frequent game-like training sessions to drive improvements in cognitive functions.
~n = 20 patients"
11118076|NCT03948490|Experimental|Arm 1 Cohort 3: Interventional arm/Healthy SMS texting|"The mobile phone texting intervention was developed with collaborators at Zuckerberg San Francisco General Hospital and is currently being studied in individuals with depression and traumatic brain injury. Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
~n = 20 patients"
11118077|NCT03948490|No Intervention|Arm 2 Cohort 4: Longitudinal arm/Upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
11118078|NCT03948490|No Intervention|Arm 1 Cohort 5: Longitudinal arm/No upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
11118079|NCT03948490|Other|Arm 1 Cohort 1A: Telehealth Cognitive Rehabilitation|"The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning. During treatment implementation, patients acquire, apply, and adapt evidenced based strategies based on neuropsychological testing and conjointly developed treatment planning goals.
~N=20"
11118080|NCT03948477|Other|Pantoprazole/Placebo|Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
11118081|NCT03948477|Other|Placebo/Pantoprazole|Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
11118082|NCT03948464|Experimental|Slow release oral morphine (SROM)|Daily witnessed ingestion of SROM (24-hour formulation) for 24 weeks as per provincial and national guidelines for opioid use disorder.
11118083|NCT03948464|Active Comparator|Methadone|Daily witnessed ingestion of methadone for 24 weeks as per provincial and national guidelines for opioid use disorder.
11118084|NCT03948451|Experimental|[14C]AZD5718 Oral Suspension|One 200 mg dose of [14C]AZD5718 Oral Suspension
11118085|NCT03948425|Experimental|Stroke|Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms):Intervention 'spectral CT'
11118086|NCT03948412|Experimental|Closed Incision Negative Pressure Wound Therapy (Prevena)|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
11118087|NCT03948412|Active Comparator|Standard Dressings|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. Standard care wound dressings are applied for patients in this arm. These are changed as clinically appropriate whilst in hospital.
11118088|NCT03948399||STROKE GROUP|150 patients admitted to Stroke Unit with a diagnosis of acute ischemic stroke (IS) or transient ischemic attack (TIA)
11118089|NCT03948399||CONTROL GROUP|50 individuals admitted to hospital without diagnosis of acute cerebrovascular disease; with diagnosis of dizziness, epilepsy, sclerosis multiplex.
11118090|NCT03948386|Active Comparator|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for > 74 height"
11118091|NCT03948386|Active Comparator|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for > 74 height"
11118092|NCT03948386|Active Comparator|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for > 74 height"
11118093|NCT03948373|Experimental|CPAP treatment|Group of patients who will receive CPAP treatment
11118094|NCT03948373|No Intervention|Conservative measures|Patients who will receive conservative treatment based on hygienic-dietetic measures
11118095|NCT03948360|Experimental|LIMB Phototherapy with SOC|Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
11118096|NCT03948360|Experimental|LIMB Phototherapy without SOC|Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
11118097|NCT03948347|Active Comparator|active|Active patients will receive liraglutide injections
11118098|NCT03948347|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
11118099|NCT03948334|Experimental|ZPL389 Dose 1 + TCS and/or TCI|Dose 1 of ZPL389 + TCS and/or TCI
11118100|NCT03948334|Experimental|ZPL389 Dose 2 + TCS and/or TCI|Dose 2 of ZPL389 + TCS and/or TCI
11118101|NCT03948321|Experimental|Painless Photodynamic Therapy（P-PDT）|The painless photodynamic therapy（P-PDT）group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 400 J/cm2) after applying 20% 5-aminolevulinic acid（ALA）cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
11118102|NCT03948321|Active Comparator|Conventional Photodynamic Therapy（C-PDT）|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 100 J/cm2) after applying 20% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
11118103|NCT03948308|Experimental|Interventional arm|blood sample before, during and after treatment for infection
11118104|NCT03948295|Experimental|Lipid Challenge Intervention|Participants of all weights will receive the lipid challenge intervention.
11118105|NCT03948269|Experimental|Internet- and mobile-based group treatment|the therapy consists of 10 modules (15 hours in total) in groups of 8 participants each over a period of 10 weeks and one follow-up meeting (2 hours) 12 weeks after the 10th module (week 22). Each module is adapted from the previous literature on CBT rationale and will be conducted online on WeChat, a mobile social networking software with 1 billion users in 2018. First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging.
11118106|NCT03948269|Active Comparator|Face-to-face group treatment|10 modules will be conducted every weekend in the psychological counseling room of The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University.
11118110|NCT03948230|Active Comparator|Sodium chloride / Water|300mg sodium chloride consumed in a capsule on two occasions with 300ml water
11118111|NCT03948230|Active Comparator|Sodium chloride / no water|300 mg sodium chloride consumed
11118112|NCT03948230|Active Comparator|Sodium chloride / colored water|300mg sodium chloride consumed in a capsule on two occasions with 300ml coloured water
11118113|NCT03948230|Placebo Comparator|Placebo / water|Placebo consumed in a capsule on two occasions with 300ml water
11118114|NCT03948230|Placebo Comparator|Placebo / no water|Placebo capsule consumed
11118115|NCT03948230|Placebo Comparator|Placebo / coloured water|Placebo consumed in a capsule on two occasions with 300ml colored water
11118116|NCT03948217|Active Comparator|L1|regimen L1 has overall higher intensity, higher color temperature and less light fluctuations
11118117|NCT03948217|Active Comparator|L2|regimen L2 has lower intensity, lower color temperature and more light fluctuations.
11118118|NCT03948204||Prostate cancer|Men diagnosed with prostate cancer
11118119|NCT03948204||Men without prostate cancer|Men without prostate cancer matched for age and county
11118120|NCT03948191|Active Comparator|Methylprednisolone(ivMP)|Methylprednisolone(ivMP) 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
11118121|NCT03948191|Experimental|99Tc-MDP|99Tc-MDP 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
11118122|NCT03948178|Experimental|Levosimendan|Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
11118123|NCT03948165||Distal Radial Approach|Distal transradial access will be performed on patients above 18 years of age, undergoing diagnostic and/or therapeutic coronary angiography, with palpable pulse at the level of the radial fossa, and these patients will be also subjected to the following tests: Allen maneuver and Barbeau maneuver; a positive Allen test was indication to perform the transradial access, while a type D Barbeau test will be a contraindication for it.
11118124|NCT03948152|Active Comparator|Standard of Care|
11118125|NCT03948152|Experimental|Mask Advice Tool|
11118126|NCT03948139|Other|Functional Bracing Group|In a presented abstract, the functional brace group has been to shown equivalent outcomes to the hip spica cast. Subject will be administered the functional brace without going to the operating room to be put under full anesthesia. Most cases will not require any sedation in this group (in some cases, light sedation may be needed). Brace will be used for up to 8 weeks post-administration, until adequate callous formation is confirmed.
11118127|NCT03948139|Other|Spica Cast Group|If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
11118128|NCT03948126||travel medicine|Healthy adults originating from Sub-Saharan Africa, South America and the Caribbean and attending a travel medicine and international vaccination consultation in France.
11118129|NCT03948100|Experimental|Group I (dyadic yoga)|Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions.
11118130|NCT03948100|Active Comparator|Group II (dyadic education)|Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions.
11118131|NCT03948087|Experimental|Vacuum Removable Rigid Dressing (VRRD)|Application of a Vacuum Removable Rigid Dressing (VRRD)
11118132|NCT03948087|No Intervention|Soft Dressing Control Group|Application of standard of care soft dressing (SD) intra-operatively.
11118133|NCT03948074|Experimental|High THC/Low CBD Cannabis Oil|THC+THCa ≥ 500 mg CBD+CBDA≤ 5 mg Total cannabinoids = 505 mg (0.83mg/drop) Dried marijuana equivalent = 2.5g
11118134|NCT03948074|Experimental|Low THC/High CBD Cannabis Oil|THC+THCa ≤25 mg CBD+CBDA≥ 500 mg (0.83mg/drop) Total cannabinoids = 525 mg Dried marijuana equivalent = 2.5g
11118135|NCT03948074|Experimental|Equal amounts of THC/CBD Cannabis Oil|THC+THCa ~ 250 mg (0.415mg/drop) CBD+CBDA~ 250 mg (0.415mg/drop) Total cannabinoids ~ 500 mg (0.83mg/drop) Dried marijuana equivalent = 2.5g
11118136|NCT03948074|Placebo Comparator|Placebo Oil|A 2:1 mixture of Rosemary oil + Unrefined Coconut oil
11118137|NCT03948061|Experimental|Cherry juice followed by placebo|Sweet cherry juice concentrate will be consumed twice daily for 6 weeks, followed by consumption of placebo beverage twice daily for 6 weeks.
11118138|NCT03948061|Experimental|Placebo beverage followed by cherry juice|Placebo beverage will be consumed twice daily for 6 weeks, followed by consumption of sweet cherry juice concentrate twice daily for 6 weeks.
11118139|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
11118140|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
11118141|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
11118142|NCT03948035|Experimental|E-KRd/ Arm A|Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
11118143|NCT03948035|Active Comparator|KRd/ Arm B|Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
11118144|NCT03948022|Active Comparator|intramuscular progesterone|progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.
11118145|NCT03948022|Active Comparator|vaginal progesterone|crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.
11118146|NCT03948022|Experimental|oral dydrogesterone|oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)
11118147|NCT03947996|Experimental|Stretching|Stretching
11118148|NCT03947996|Experimental|Walking|Walking
11118149|NCT03947983|Experimental|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
11118150|NCT03947983|Active Comparator|Control group|The control group will receive only the weight monitoring and physical activity sensors
11118151|NCT03947970|Experimental|[14C] CR845|Subjects will receive a single dose of [14C] CR845 IV solution administered as an IV bolus on Day 1.
11118153|NCT03947944|Active Comparator|manifest refraction planning group|The subjects underwent SMILE using manifest refraction planning.
11118154|NCT03947944|Active Comparator|vector planning group|The subjects underwent SMILE using vector planning.
11118155|NCT03947931||General group|Patient with extremely severe ulcerative colitis
11118156|NCT03947918|Experimental|Short sleep|No more than 8 hours of sleep for 4 consecutive nights.
11118157|NCT03947918|Experimental|Long sleep|At least 10 hours of sleep for 4 consecutive nights
11118158|NCT03947905|Experimental|Type of visit|Single arm, non-randomized crossover design. All patients will receive both types of visits virtual and physical, and after assessments are made, participants will be classified by physicians into low, moderate or high risk for intervention.
11118159|NCT03947879|Experimental|L-glutamine|Treatment with L-glutamine for 3 months.
11118160|NCT03947879|Experimental|No L-glutamine|No L-glutamine for 3 months.
11118161|NCT03947827|Active Comparator|Active|Minocycline will start at an oral dose of 100mg daily and will be increased after one week to 100mg twice daily.
11118162|NCT03947827|Placebo Comparator|Placebo|Placebo capsules will start at one capsule daily, and will be increased after one week to one capsule twice daily
11118163|NCT03947814|Experimental|Part A: Normal renal function (control group)|Participants with normal renal function (glomerular filtration rate [GFR] greater than or equal to [>=] 90 milliliters per minute [mL/min]) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
11118164|NCT03947814|Experimental|Part A: Severe renal impairment or ESRD|Participants with severe renal impairment (GFR >=15 to less than [<]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR <15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
11118165|NCT03947814|Experimental|Part B (Optional): Mild renal impairment|Participants with mild renal impairment (GFR >=60 mL/min to <90 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
11118166|NCT03947814|Experimental|Part B (Optional): Moderate renal impairment|Participants with moderate renal impairment (GFR >=30 to <60 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
11118167|NCT03947801|Experimental|Greek Yogurt condition|One week when players will consume 175g of 0% Plain Greek yogurt (~110 Kcals, 18g protein, 10g carbs)
11118168|NCT03947801|Placebo Comparator|Isoenergetic condition - Carbohydrate|One week when players will consume an isoenergetic CHO supplement (~110Kcal, 0g protein, 27.5g carbs) 3 times per day (at breakfast, immediately post-exercise and before bed)
11118169|NCT03947788|Experimental|Interventional Practices|These clinics, including physicians, clinical and administrative staff, will receive the One Key Question training program, delivered by Power to Decide, via an in-person group training session.
11118170|NCT03947788|No Intervention|Control Practices|These clinics will not receive the OKQ training program during the study period. They will have the opportunity to receive the training after the study period is over.
11118171|NCT03947775|Experimental|Immediate Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at baseline visit, dose #2 at month 2, and dose #3 at month 6.
11118172|NCT03947775|Active Comparator|Delayed Vaccination|Administration of dose #1 of 9-valent HPV vaccination will be given at month 24, dose #2 at month 26, and dose #3 at month 30.
11118173|NCT03947749||Patients with HICMP|Patients with PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized into this group.
11118174|NCT03947749||Patients without HICMP|Patients without PROMIS Pain Interference-6b scores one standard deviation above the national average will be categorized will be categorized into this group.
11118175|NCT03947749||Patients at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
11118176|NCT03947749||Patients not at risk for opioid abuse or misuse|The Opioid Risk Tool and PROMIS Short Form v1.0-Prescription Pain Medication Misuse will be used to categorize patients at risk.
11118177|NCT03947736||patients with positive HER2 amplification|
11118178|NCT03947736||patients with negative HER2 amplification|
11118179|NCT03947723|Experimental|Low power|"These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of low."
11118180|NCT03947723|Experimental|1 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
11118181|NCT03947723|Experimental|1.5 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
11118182|NCT03947723|Experimental|2 power|These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
11118183|NCT03947710|Experimental|High-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume high protein meals during their dialysis sessions for one week.
11118184|NCT03947710|Experimental|Low-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume low protein meals during their dialysis sessions for one week
11118185|NCT03947710|Experimental|No meals|Patients with End Stage Renal disease on maintenance hemodialysis will not consume meals during their dialysis sessions for one week
11118186|NCT03947697|Placebo Comparator|Control|Participants will receive stimulation only up to sensory level.
11118187|NCT03947697|Experimental|NMES|Participants will receive stimulation up to maximum tolerable level.
11118188|NCT03947697|Placebo Comparator|Resistance Training|Participants will receive exercise training with stimulation up to sensory level.
11118189|NCT03947697|Experimental|Resistance Training + NMES|Participants will receive exercise training with stimulation up to maximum tolerable intensity.
11118190|NCT03947684|Experimental|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
11118191|NCT03947671|Experimental|Body wrap|This group will receive the body wraps post surgery to maintain normothermia.
11118192|NCT03947671|Active Comparator|Tylenol|This group will receive the standard of care of monitoring temperature and administering Tylenol if a fever develops.
11118193|NCT03947671|Experimental|Tylenol with body wrap|This group will receive the standard of care of monitoring temperature but will be administered Tylenol and body wraps if a fever develops.
11118194|NCT03947658|Experimental|Six weeks group|Prosthetic restoration started 6 weeks after surgical crown lengthening
11118195|NCT03947658|Experimental|Fourteen weeks group|Prosthetic restoration started 14 weeks after surgical crown lengthening
11118196|NCT03947645|Experimental|Ipsilesional stimulation|Ipsilesional stimulation
11118197|NCT03947645|Experimental|Contralesional stimulation|Contralesional stimulation
11118198|NCT03947619|Experimental|Experimental|"Subjects randomized to the experimental arm will have their heart unloaded for 30 minutes on the Impella CP® device prior to PCI.
~Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
11118199|NCT03947619|No Intervention|Control|"Primary PCI. Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
11118200|NCT03947606|Experimental|Basic social support + communication + Ottawa guide|3 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
11118201|NCT03947606|Experimental|Basic social support + communication|2 in-person/telephone weekly sessions on providing decision social support and tips for good communication
11118202|NCT03947606|Experimental|Basic social support + Ottawa guide|2 in-person/telephone weekly sessions on providing decision social support and decision support tools
11118203|NCT03947606|Experimental|Basic social support only|1 in-person/telephone weekly session on providing decision social support
11118204|NCT03947606|Experimental|Advanced social support + communication + Ottawa guide|5 in-person/telephone weekly sessions on providing decision social support, tips for good communication, and decision support tools
11118205|NCT03947606|Experimental|Advanced social support + communication|4 in-person/telephone weekly sessions on providing decision social support and tips for good communication
11118206|NCT03947606|Experimental|Advanced social support + Ottawa guide|4 in-person/telephone weekly sessions on providing decision social support and decision support tools
11118207|NCT03947606|Experimental|Advanced social support only|3 in-person/telephone weekly sessions on providing decision social support
11118208|NCT03947593||Households with children under 13|Interviews conducted with the parent or guardian of a child or children under age 13.
11118209|NCT03947593||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
11118210|NCT03947593||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
11118211|NCT03947593||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
11118212|NCT03947580|Experimental|Use of the Dvectis Single pad|The Dvectis Single Dynamic-directional pad is a basic model of the Dvectis product range that provides full functionality based on the dynamic-directional seating principle. The Dvectis Single pad is designed to steer muscle tension during sitting in deep-seated muscles. The Dvectis Single pad is intended to eliminate chronic lumbar spine pain by strengthening the stabilizing muscles.
11118213|NCT03947580|Experimental|Use of the Dvectis Double pad|The Dvectis Double Dynamic-directional pad is based on the Dvectis Single model, but in addition to its dual-chamber design, it provides seating with a more balanced load and a higher dynamic-directional effect. The Dvectis Double pad is designed to create and route muscle tension during sitting in deep-seated muscles. The Dvectis Double is also suitable for soft substrates (sofa, soft chair, etc.). The Dvectis Double Pad is intended to remove chronic lumbar spine pain by strengthening the stabilizing muscles.
11118214|NCT03947580|No Intervention|Use of no pad|Description is not needed
11118215|NCT03947567|Experimental|Recombinant Human Coagulation FVIII|
11118216|NCT03947554|Experimental|HRG80 Panax ginseng|Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
11118217|NCT03947554|Active Comparator|Panax ginseng|Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
11118218|NCT03947554|Placebo Comparator|Placebo|Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
11118219|NCT03947541|Active Comparator|No Brace|Patients randomized to the no-brace group will not be required to wear a brace, postoperatively.
11118220|NCT03947541|Experimental|Brace|Patients randomized to the brace group will wear the brace when out of bed and will be allowed to remove the brace when in bed. This intervention will continue through their 6-week postoperative visit, after which point, patients will be allowed to wear the brace for comfort.
11118221|NCT03947528|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
11118222|NCT03947528|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
11118223|NCT03947515|Experimental|cancer group|
11118224|NCT03947515|Experimental|control group|
11118225|NCT03947502|Experimental|Intervention Group with|Educational intervention in neurobiology of pain
11118226|NCT03947502|No Intervention|Control group|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
11118227|NCT03947489|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
11118228|NCT03947489|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
11118229|NCT03947463|Experimental|PECS block group|20ml of 0.25% bupivacaine was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualised on the ultrasound screen. similarly, in Serratus plane block, ultrasound probe was placed over the mid-axillary region of the thoracic cage in a sagittal plane. Ribs were identified inferiorly and laterally, until the identification of the 3rd rib in the mid axillary line. 10 ml of 0.25% bupivacaine was infiltrated in between Serratus anterior muscle and Latissimus Dorsi muscle
11118230|NCT03947463|No Intervention|Control group|Patient were given multimodal analgesia without the regional block
11118268|NCT03947216|Placebo Comparator|PLACEBO|In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.
11120351|NCT03932266|Other|Control group|Drug: Cisplatin Drug: Docetaxel Radiation
11118231|NCT03947450|Experimental|Autologous skin fibroblasts|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives autologous skin fibroblast whole stump injections.
~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives autologous skin fibroblasts."
11118232|NCT03947450|Placebo Comparator|Control|"For whole stump participants: The investigators will be comparing whole stump injection sites that receive autologous skin fibroblasts to vehicle (placebo) injections. This subject receives vehicle (placebo) whole stump injections.
~For localized injection participants: The investigators are comparing two injection sites in the same individual. This site receives a placebo."
11118233|NCT03947437|Experimental|Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
11118234|NCT03947437|Experimental|High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
11118235|NCT03947437|Experimental|TBD dose in patients|TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.
11118236|NCT03947437|Placebo Comparator|Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
11118237|NCT03947424|Experimental|Experimental 1|Long-pulse (LP) Er:YAG laser snoring treatment.
11118238|NCT03947424|Experimental|Experimental 2|Fotona SMOOTH mode Er:YAG laser snoring treatment.
11118239|NCT03947424|Sham Comparator|Control|Sham laser snoring treatment with no energy applied.
11118240|NCT03947411|Experimental|Oseltamivir Phosphate+Xiyanping injection|Oseltamivir Phosphate+Xiyanping injection treatment for 7-10 days
11118241|NCT03947411|Active Comparator|Oseltamivir Phosphate treatment only|Oseltamivir Phosphate treatment for 7-10 days
11118242|NCT03947398|Experimental|Treatment with BLIMP first|
11118243|NCT03947398|Active Comparator|Treatment with low-profile balloon first|
11118244|NCT03947385|Experimental|Dose Escalation Monotherapy|IDE196 dosed orally, twice daily (BID) for each 28-day cycle
11118245|NCT03947385|Experimental|Dose Expansion Monotherapy|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)
11118246|NCT03947385|Experimental|Dose Escalation Combination|IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle
11118247|NCT03947385|Experimental|Dose Expansion Combination|RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)
11118248|NCT03947385|Experimental|Tablet PK Substudy|IDE196 dosed orally, once on Cycle 1 Day 1; thereafter, twice daily (BID) for each 28-day cycle
11118249|NCT03947372|Active Comparator|OA (open Appendectomy)|Open Appendectomy
11118250|NCT03947372|Experimental|LA (Laparoscopic Appendectomy)|Laparoscopic Appendectomy
11118251|NCT03947359|Other|Participants with a thoracic diameter < 75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
11118252|NCT03947359|Other|Participants with a thoracic diameter >75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
11118253|NCT03947346||survivors of neuroblastoma treated with nephrotoxic therapy|Upon enrollment, all subjects will receive a urine collection kit by mail. Participants will bring in a first-morning urine specimen on the day of their routinely scheduled long-term follow-up visit, and will then have an additional blood and urine sample drawn with their other clinical care labs upon arrival to MSK.
11118254|NCT03947333|Experimental|Intervention|Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the My Diabetes Care.
11118255|NCT03947333|No Intervention|Control|Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the My Diabetes Care (i.e., usual care).
11118256|NCT03947320|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
11118257|NCT03947307|Experimental|Experimental Intervention (treatment / medical device)|Patients in the experimental group will receive lymphtaping using Easytape® according to common practice on day 1 after surgery by specifically trained physiotherapists. The tape has an elasticity of 150%. The material is moisture- and air-permeable with a hypoallergenic adhesive coating that is activated by body temperature to increase durability of contact. If possible the taping will be left for 7 days, in case of insufficient adhesion taping will be repeated.
11118258|NCT03947307|Active Comparator|Control Intervention (compression treatment )|Patients in the control group will be treated with manual lymphatic drainage followed by compression treatment using compressive stockings if accepted or compressive bandaging in cases with pronounced swelling depending on medical necessity.
11118259|NCT03947307|Sham Comparator|Control Intervention (sham taping)|Patients in the control group will be treated by sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
11118260|NCT03947281|Experimental|Almond snack|The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
11118261|NCT03947281|Experimental|Cereal-based snack|The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
11118262|NCT03947268|Experimental|Short-course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.
11118263|NCT03947255|Experimental|Brentuximab vedotin|
11118264|NCT03947242|Experimental|Pyrotinib + trastuzumab +Vinorelbine|Pyrotinib in Combination With Trastuzumab Plus Vinorelbine
11118265|NCT03947229|Active Comparator|Clopidogrel mono-therapy|After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.
11118266|NCT03947229|Active Comparator|Dual-antiplatelet therapy|Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.
11118267|NCT03947216|Experimental|PIMAVANSERIN|In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.
11118269|NCT03947203|No Intervention|Pamphlet|Provided with only a pamphlet containing educational material about oral health
11118270|NCT03947203|Experimental|Social media|Provided pamphlet containing educational material about oral health and will have access to a private Facebook group, where we will share informational messages and content relating to oral health
11118271|NCT03947190|Experimental|Group 1|Group 1 adults (n=20) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
11118272|NCT03947190|Experimental|Group 2|Group 2 adults (n=20) will be receiving 5x10^10 vp ChAd63 ME-TRAP and 2x10^8 pfu MVA ME-TRAP vaccines, 8 weeks apart, and then a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge, 4 weeks later.
11118273|NCT03947190|Experimental|Group 3|Group 3 adults (n=10) will be receiving, 4 weeks apart, three doses of 10µg R21 /50µg Matrix M vaccine, and a CHMI intravenously (DVI) by inoculation of 3,200 PfSPZ Challenge.
11118274|NCT03947190|Experimental|Group 4|Group 4 adults (n=14) will be the control group receiving no vaccine, only a CHMI intradermally (ID) by inoculation of 22,500 PfSPZ Challenge.
11118275|NCT03947177|Placebo Comparator|Control|GMIT
11118276|NCT03947177|Experimental|Intervention|Modified GMIT + Parenting support groups
11118277|NCT03947164|Other|Case group|"Case :
~- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.
~POPs will be classified in stages 2-4 using the ICS classification;
~Without urinary incontinence associated effort (eliminated by the interrogation);
~Registered to a health insurance system;
~Having received information on the protocol and giving informed written consent."
11118278|NCT03947164|Other|Control group|"Control:
~Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.
~No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.
~Registered to a health insurance system;
~Having received information on the protocol and giving informed written consent."
11118279|NCT03947151|Other|one arm|one arm
11118280|NCT03947138|Experimental|GC3107_Part1|Part 1 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
11118281|NCT03947138|Experimental|GC3107_Part2|Part 2 GC3107(BCG Vaccine) Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
11118282|NCT03947138|Active Comparator|BCG SSI_Part1|Part 1 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
11118283|NCT03947138|Active Comparator|BCG SSI_Part2|Part 2 Intradermal BCG SSI inj Single intradermal Injection of 0.05 mL into the end of deltoid muscle in outer aspect of upper arm
11118284|NCT03947125||knee applied group|the patients with buprenorphine patch applied to painful knee joint in knee osteoarthritic patients
11118285|NCT03947125||chest applied group|the patients with buprenorphine patch applied to anterior chest wall in knee osteoarthritic patients
11118286|NCT03947112||Norwegian population with Duchenne Muscular Dystrophy (DMD)|Boys with DMD.
11118287|NCT03947086|Active Comparator|Active TDCS Group|Participants will receive active Transcranial Direct Current Stimulation (TDCS) (1.5 mA). Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
11118288|NCT03947086|Sham Comparator|Sham tDCS Group|Participants will receive sham TDCS. The protocol is identical for placebo stimulation, but the current will stop after 30 seconds from the start of stimulation. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
11118289|NCT03947073|No Intervention|Standard of Care|Subjects with newly diagnosed gestational diabetes are randomized to standard of care diabetes education.
11118290|NCT03947073|Experimental|Interactive Educational Application|Subjects with newly diagnosed gestational diabetes are randomized to standard of care plus an interactive educational application.
11118291|NCT03947060||Nasal & Frontal sensor position|One group of participants with two modes of measurement. First mode is standard frontal placement of the SedLine® sensor. Second mode is alternative nasal placement of the SedLine® sensor.
11118292|NCT03947047||Placenta Accreta|Women found to have abnormal placentation (any degree of placenta accreta) during the cesarean section.
11118293|NCT03947047||No Placenta Accreta|Women found to have normal placenta separation during the cesarean section.
11118294|NCT03947034||Metabolic toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
11118295|NCT03947021|Experimental|BSPM-only group|Participants will only receive body-surface potential mapping (BSPM) with an extensive electrode set (256 electrodes).
11118296|NCT03947021|Experimental|CT+BSPM group|Participants will receive body-surface potential measurements (BSPM) and a CT scan. These data will allow for non-invasive reconstruction of electrical potentials at the heart surface.
11118297|NCT03947008|Experimental|First Intuitive Eating Group (IE1)|IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
11118298|NCT03947008|Experimental|Second Intuitive Eating Group (IE2)|IE2 will be the second group to will participate in an intuitive eating program and will be required to attend 5 intuitive eating classes. The classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted on the same day as IE1 but they will take the 5 week course once the first group completes the class. This group will have an additional initial assessment on the day they begin their curriculum. The initial assessment will occur during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. During assessments, they will complete a questionnaire that will ask about body satisfaction and eating attitudes, and have their height and weight measured.
11118588|NCT03944889|Active Comparator|Low Dose, Topical|Capsaicin Cream- low dosage, applied topically to trapezius
11118299|NCT03946995|Experimental|Dry needling|Dry needling will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
11118300|NCT03946995|Active Comparator|Graston|Graston Technique will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
11118301|NCT03946982|Experimental|Low thoracic epidural|theoretically better catheter/incision congruency
11118302|NCT03946982|Active Comparator|Lumbar epidural|the conventional obstetric epidural technique
11118303|NCT03946969|Experimental|Sintilimab + Liposome Paclitaxel + Cis-Platinum + S-1|Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
11118304|NCT03946956|Active Comparator|Prebooking|Participants randomised to this arm receives a prebooked appointment to screening
11118305|NCT03946956|Placebo Comparator|Web based booking|Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
11118306|NCT03946956|Active Comparator|Pictured invitation|Participants randomised to this arm receives a pictured invitation to screening
11118307|NCT03946956|Placebo Comparator|Texted invitation|Participants randomised to this arm receives a classical texted invitation to screening
11118308|NCT03946943|Experimental|anlotinib + Toripalimab|Concurrent anlotinib and Toripalimab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies
11118309|NCT03946917|Experimental|JS001/regorafenib|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with regorafenib tablet
11118310|NCT03946904|Experimental|preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. The lesion in this case was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
11118311|NCT03946904|Experimental|no preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG.the lesion in this case was prepared with high power laser setting first to ablate the enamel, dentin, and caries.
11118312|NCT03946891|Experimental|Arm A|
11118313|NCT03946891|Experimental|Arm B|
11118314|NCT03946878|Experimental|Treatment (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11118315|NCT03946865|Experimental|Hospitalized hematology/oncology cancer subjects|Hospitalized hematology/oncology cancer will participate in Reiki Therapy
11118316|NCT03946852|Experimental|ARP arm|Patients will receive DCD after therapy after the abdominal reperfusion protocol.
11118317|NCT03946839||ICU Survivors|Patients with high risk of cognitive impairment who discharge from ICU
11118318|NCT03946839||Healthy Control|The control group have to be medically and cognitively healthy(MMSE ≥ 28). These individuals are recruited from the community and all attempts will be made to match them on age,sex and education to individuals recruited for groups of ICU Survivors.
11118319|NCT03946826|Experimental|PDL+ Halometasone Cream group|PDL+ Halometasone Cream Halometasone Cream, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
11118320|NCT03946826|Experimental|PDL+Vaseline group|PDL+Vaseline Vaseline, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
11118321|NCT03946826|Active Comparator|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
11118322|NCT03946826|Placebo Comparator|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
11118323|NCT03946813|Experimental|Poor ovarian reserve|Infertile women with poor ovarian reserve
11118324|NCT03946800|Experimental|MEDI1191 escalation in combination with durvalumab|MEDI1191 escalation in sequential and concurrent combination with durvalumab
11118325|NCT03946800|Experimental|MEDI1191 expansion in combination with durvalumab|MEDI1191 expansion in concurrent combination with durvalumab
11118326|NCT03946787|Active Comparator|EMDR Therapy + TAU|"Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU).
~It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life.
~Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma."
11118327|NCT03946787|Placebo Comparator|TAU (Treatment as Usual)|"Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months.
~Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses."
11118328|NCT03946774|Active Comparator|High protein|Subjects getting high protein shake
11118329|NCT03946774|Active Comparator|Low protein|Subjects getting low protein shake
11118363|NCT03946475|Other|Intervention group|4 schools in 4 subdistrict which are divided into north and south Malang District. North area (Lawang and Singosari) and South area (Kepanjen and Gondanglegi).
11118364|NCT03946475|No Intervention|Control group|4 schools in 4 subdistrict which are divided into north (Sumberpucung), south (Lawang and Singosari), and east (Tumpang) Malang District.
11118365|NCT03946462|Experimental|NO Group|
11118366|NCT03946462|Placebo Comparator|Placebo Group|
11118589|NCT03944889|Active Comparator|High Dose, Topical|Capsaicin Cream- higher dosage, applied topically to trapezius
11118330|NCT03946761|Experimental|Cancer goggle system|"The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG & visualization of biliary/liver anatomy using the cancer goggles system
~The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG & will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.
~Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles."
11118331|NCT03946748|Experimental|REGN3918|"Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A.
~Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B."
11118332|NCT03946735|Experimental|Intervention study|Cognitive Behavioural Therapy for social anxiety
11118333|NCT03946735|Experimental|Social anxiety|
11118334|NCT03946722|Other|Standard downregulation with GnRH analogue|"Participants in this arm will be assigned to the routine IVF protocol currently being used in the investigators' IVF unit, as outlined below, with two weeks of downregulation. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.
~Start progesterone (Norethisterone 5mg twice daily orally) on day 14 of downregulation cycle and continue for 11 days. Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed. Baseline scan on day 1 - 5 of bleed and start oestrogen (Progynova 2mg three times daily orally). Serial scanning from day 10 until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
11118335|NCT03946722|Experimental|Prolonged downregulation with GnRH analogue|"Participants in this arm will be exposed to an additional four weeks of downregulation using a GnRH analogue. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.
~Baseline scan on day 1-5 of bleed and administer GnRH analogue (Triptorelin acetate 3.75 mg subcutaneously single injection). 28 days later administer second dose of GnRH analogue (Triptorelin acetate 1.875 mg subcutaneously), and 21 days later start oestrogen (Progynova 2 mg three times daily orally). Serial scanning from day 10 of oestrogen until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
11118336|NCT03946709|Other|Muscle strength condition|
11118337|NCT03946709|Other|Muscle weakness condition|
11118338|NCT03946709|No Intervention|Control|
11118339|NCT03946696||Dementia|Observations of communication and interactions between people with dementia living in a care home and therapy-animals.
11118340|NCT03946683|Experimental|Cyberknife for Early Stage Breast Cancer|Cyberknife Robotic Radiosurgery will be utilized as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer.
11118341|NCT03946670|Experimental|MBG453 + hypomethylating agents|Patients will take MBG453 plus hypomethylating agents
11118342|NCT03946670|Placebo Comparator|Placebo + hypomethylating agents|Patients will take placebo plus hypomethylating agents
11118343|NCT03946657|Active Comparator|The Inhalation Group|Sevoflurane (1 minimum alveolar concentration [MAC]) were used in the Inhalation group for the maintenance of anesthesia.
11118344|NCT03946657|Active Comparator|The TIVA (total intravenous anesthesia) Group|Propofol infusion (4-8 mg/kg of total body weight/h) were used in the TIVA group.
11118345|NCT03946644|Active Comparator|EVLA with keeping of security distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
11118346|NCT03946644|Experimental|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
11118347|NCT03946631|Other|Blood Glucose Test - 2hour GTT|Only one arm: intervention group. The intervention is fasting 2 hour glucose tolerance test in the immediate postpartum period. The screening test consists of fingerstick blood glucose testing after a glucose drink. First, a fasting blood glucose finger stick will be performed. Second, the glucose drink is orally ingested containing 75g glucose. The drink is to be orally ingested over 60 seconds. Lastly, fingerstick blood glucose testing is completed at 1 hour post drink and 2 hours post drink.
11118348|NCT03946618|Experimental|Epilepsy|Patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy
11118349|NCT03946592|Placebo Comparator|Placebo group|Inject the Drug into submental fat via subcutaneous
11118350|NCT03946592|Experimental|DWJ211 group|Inject the Drug into submental fat via subcutaneous
11118351|NCT03946579|Other|Patient treated by adjuvant therapy|Self questionnaires of sexual health and quality of life (FSFI, QLQ-C30, BR23, ELD 15, HADS, GDS 15, BIS, FACIT)
11118352|NCT03946566||Acupuncture group|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
11118353|NCT03946566||Basic treatment group|Use basic treatments, such as western medicine.
11118354|NCT03946553||Allergic Rhinitis Group|Individuals with allergic rhinitis
11118355|NCT03946553||Control Group|Individuals without allergic rhinitis
11118356|NCT03946540||L-FED sample|All young people treated in Maudsley Child and Adolescent Eating Disorder Service between 1/8/2009 and 31/1/2014.
11118357|NCT03946527|Experimental|lanreotide arm|Patients with a histopathologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability who meet the inclusion/exclusion criteria. Approximately 40 patients will be enrolled.
11118358|NCT03946514|Experimental|losartan/hydrochlorothiazide group|
11118359|NCT03946514|Active Comparator|amlodipine/hydrochlorothiazide group|
11118360|NCT03946501||clinical research visit|
11118361|NCT03946488|No Intervention|Inactive neuroprosthesis|
11118362|NCT03946488|Experimental|Active neuroprosthesis|
11118367|NCT03946449|Experimental|ARO-AAT Cohort 1|"Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.
~Extension Cohort (optional enrollment): Administered every 12 weeks for 4 additional doses."
11118368|NCT03946449|Experimental|ARO-AAT Cohort 2|"Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.
~Extension Cohort (optional enrollment): Administered every 12 weeks for 4 additional doses."
11118369|NCT03946436|Experimental|I-AVI|The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
11118370|NCT03946436|Active Comparator|NO-AVI|The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
11118371|NCT03946423|Experimental|Sleeve Gastrectomy & Lifestyle Intervention|
11118372|NCT03946423|Active Comparator|Lifestyle Intervention|
11118373|NCT03946410|Active Comparator|Screening|Invitation to cardiovascular screening
11118374|NCT03946410|Placebo Comparator|Control|No invitation to cardiovascular screening
11118375|NCT03946397|Experimental|Multisensory massage|
11118376|NCT03946397|No Intervention|Control|
11118377|NCT03946384||patients|Hemophilia B with p.Ile112Thr mutation on factor IX gene
11118378|NCT03946371||Extubation Success|Patients who do not require re-intubation, upto 48 hours after a planned extubation in the adult intensive care unit.
11118379|NCT03946371||Extubation failure|Patients who required re-intubation within 48 hours after a planned extubation in adult intensive care unit.
11118380|NCT03946358|Experimental|Atezolizumab and UCPVax|"Induction phase:
~Atezolizumab 1200 mg intravenous (IV) every 3 weeks since day 1
~UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).
~Boost phase:
~UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)
~Atezolizumab 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
11118381|NCT03946332|Experimental|Physical exercise arm|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization. Furthermore, SMS will be regularly sent to remind them to practice
11118382|NCT03946332|Active Comparator|controlled arm|patients will be hospitalized in the same conditions than the experimental group and will be able to practice if they want.
11118383|NCT03946319|Experimental|Personalized, Transdiagnostic Assessments|One or more times per day, participants in the Experimental Arm will be presented with a variable-length assessment based on the personalization algorithm. The assessment will include a dynamic number of questions based on personalized relevancy, engagement level, and assessment completion metrics. Questions are scored immediately upon submission, regardless of how many questions are answered. As questions are scored, the personalization algorithm takes the previous responses and response times into consideration when determining what and when to ask additional questions.
11118384|NCT03946319|Active Comparator|Monotopic Assessments|Once daily, participants in the Control Arm will be presented with the standard of care mental health surveillance assessments identified as relevant upon intake. The assessments will be scored in totality or not at all and have a fixed, predefined number of questions. No personalization of assessment will take place.
11118385|NCT03946306|Active Comparator|Group 1|5,25% NaOCl with syringe needle irrigation alone
11118386|NCT03946306|Active Comparator|Group 2|5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)
11118387|NCT03946293|Active Comparator|White bread|White bread 3 x 30 g, single serving
11118388|NCT03946293|Active Comparator|Wholegrain|Standard wholegrain, 3 x 30 g, single serving
11118389|NCT03946293|Experimental|Wholegrain Enzyme|Enzyme-treated wholegrain, 3 x 30 g, single serving
11118390|NCT03946280|Other|Fluoroscopy Group|Patient undergoing common flutter (AFL) ablation procedure using conventional X-ray based fluoroscopy for for catheter tracking
11118391|NCT03946280|Experimental|3D Group|Patient undergoing common flutter (AFL) ablation procedure using the low X-ray 3D navigation technique for for catheter tracking
11118392|NCT03946267|Experimental|IFCG = Infracyanine Green stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 ml of low-concentration (0.5 mg/mL, 0.05%) IFCG injected over the macular area with the infusion line closed.
11118393|NCT03946267|Experimental|BBG = Brilliant Peel stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 mL BBG at a concentration of 0.25 mg/mL (0.025%) injected over the macular area with the infusion line closed.
11118394|NCT03946254|Experimental|Intervention|THE EXPERIMENTAL GROUP WILL DEVELOP 20 WEEKS OF TRAINING TO IMPROVE THE MUSCLE CAPACITY. FOR THIS, FORCE EXERCISES WILL BE DEVELOPED IN GUIDED MACHINES.
11118395|NCT03946254|Experimental|Control|THE CONTROL GROUP WILL DEVELOP 20 WEEKS OF BALANCE AND BREATHING EXERCISES.
11118396|NCT03946241||Pre-reform study populations|Children from 1st to 9th grade (n ~ 2,600) from four different school-based studies collecting objective physical activity data. The four studies are 1) The European Youth Heart Study (EYHS) conducted in 1997-98, 2003-04 and 2009-10, 2) When Cities Move Children (WCMC) conducted in 2010 and 2012, 3) Childhood Health, Activity, and Motor Performance School Study Denmark (CHAMPS-DK) conducted in 2009, 2010 and 2012, and 4) School site, Play Spot, Active transport, Club fitness and Environment (SPACE) conducted in 2010 and 2012. A total of 44 schools where included in the studies.
11118428|NCT03946020|Experimental|Augmentation with DBBM|A layer of DBBM was placed on the implant surface and thereafter covered with a collagen membrane. Care was taken to make both augmentations as comparable as possible by weighting the used amount of graft material.
11118590|NCT03944889|Placebo Comparator|Placebo, Intrafascial|Injection placebo(saline)- injected intrafascially into trapezius
11118397|NCT03946241||Post-reform study population|Children from 1st to 9th grade in 2017-18 from the same schools as included in the pre-reform research studies (n ~ 2,600). Two of the pre-reform research studies (CHAMPS-DK and SPACE) introduced PA promoting initiatives as part of the study. To minimize any influence from participation in these interventions we chose only to include and recruit participants from control schools from these studies. A total of 36 schools where invited and 31 subsequently accepted to participate. Parents and teachers of the children were included as well.
11118398|NCT03946228|Experimental|Behavioral Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
11118399|NCT03946228|No Intervention|Control Condition|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
11118400|NCT03946215|Experimental|well-trained athletes|A cardiorespiratory stress test
11118401|NCT03946202|Experimental|Radiotherapy + radiation sensitiser|Patients randomised to the test group will receive standard radiotherapy for breast cancer + a radiation sensitiser
11118402|NCT03946202|No Intervention|Radiotherapy alone|Patients randomised to the control group will receive standard radiotherapy for breast cancer alone
11118403|NCT03946189||P/F less than 100|Patients receiving mechanical ventilation with paO2/FiO2 less than 100
11118404|NCT03946189||P/F between 100 and 200|Patients receiving mechanical ventilation with paO2/FiO2 between 100 and 200
11118405|NCT03946189||P/F between 200-300|Patients receiving mechanical ventilation with paO2/FiO2 between 200 and 300
11118406|NCT03946176|Experimental|Symbiotic|HD patients with 7 weeks symbiotic administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
11118407|NCT03946176|Placebo Comparator|Placebo|HD patients with 7 weeks placebo administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
11118408|NCT03946163|Experimental|first group|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
11118409|NCT03946163|Placebo Comparator|second group|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
11118410|NCT03946150||P/FP Ratio|P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
11118411|NCT03946150||P/F ratio|P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
11118412|NCT03946137|Experimental|Sample|"30 patients of both sexes aged between 0 and 6 years with chronic neurological involvement with respiratory complications.
~Individual sessions of chest therapy every fifteen days for three months, in total 6 respiratory physiotherapy sessions of 30 minutes each were performed. And the postural hygiene workshops were given to the parents, this educational intervention was carried out at the beginning of the study, at 3 months and at 6 months from the beginning. Each intervention lasted 4 hours with theoretical and practical part."
11118413|NCT03946124|Other|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
11118414|NCT03946111|Experimental|Naltrexone/Bupropion|
11118415|NCT03946111|Placebo Comparator|Placebo|
11118416|NCT03946098|Experimental|iCBT for Gambling Disorder|Treatment will consist of a 1+10 module internet delivered CBT program targeting problem gambling, newly developed. A bottom-up procedure was used to develop the treatment protocol, inspired by Clark's (2004) method for developing novel CBT treatments. We developed a clinical model delineating what factors contribute to the persistence of problem gambling behavior, and aligned these with targeted treatment interventions; based on behavioral upon research on the learning and maintenance processes of gambling behavior (Ramnerö et al, in press), theoretical models of gambling and comorbidity (Blaszczynski & Nower, 2002); as well as qualitative interviews with treatment seeking gamblers with or without comorbidity.
11118417|NCT03946085|Experimental|Lumega-Z group|Participants assigned the study supplement Lumega-Z.
11118418|NCT03946085|Active Comparator|AREDS2 group|Participants assigned the AREDS2 supplement
11118419|NCT03946085|No Intervention|Control|Participants are determined ocular normal after clinical examination and do not have retinal drusen.
11118420|NCT03946072|Active Comparator|Transseptal Group|Transseptal Aortic Approach Catheter Ablation Procedure
11118421|NCT03946072|Active Comparator|Retrograde Group|Retrograde Aortic Approach Catheter Ablation Procedure
11118422|NCT03946059|Experimental|iTBS over superior frontal cortex|intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.
11118423|NCT03946059|Active Comparator|cTBS over superior frontal cortex|continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered.
11118424|NCT03946046|Experimental|Clinical targeting|Clinical localization method (observation and palpation of target muscles)
11118425|NCT03946046|Experimental|Ultrasonography targeting|Ultrason-guided method
11118426|NCT03946033|Other|Single arm|All participants are included in the same arm. Immunoscore Colon Test is applied on a tumor sample and the result is kept secret. In the Multidisciplinary Meeting evaluating the adjuvant therapy of the participant, a first therapeutic decision is taken, then Immunoscore result will be disclosed and the Multidisciplinary Meeting will take a second decision.
11118427|NCT03946020|Active Comparator|Augmentation with autologous bone + DBBM|A layer of autogenous bone chips was placed on the implant surface. On top of this a layer of DBBM (Bio-Oss™, Geistlich®, Wolhusen, Switserland) was placed, thereafter covered with a collagen membrane.
11118429|NCT03946007||Patients with melanoma or NSCLC|Patients (age ≥18 years) with melanoma or NSCLC ≥2 years since treatment with at least one cycle of immune checkpoint inhibitor (CTLA-4 inhibitor, PD-(L)1 inhibitor, or both) within the Department of Medical Oncology or Pulmonary Oncology of the UMCG.
11118430|NCT03945994|No Intervention|Connecting People Control Group|CMHTs (Community Mental Health Teams) will continue to support people with mental health problems using their standard care.
11118431|NCT03945994|Experimental|Connecting People Intervention Group|CMHTs will receive training on how to implement Connecting People programme. They will receive implementation toolkit to improve their practice in contrast to standard care.
11118432|NCT03945981|Experimental|Participants receiving Dolutegravir + Lamivudine FDC|Participants will receive DTG 50mg and 3TC 300 mg FDC tablet orally once daily (OD) with or without food
11118433|NCT03945955|Experimental|Melatonin|
11118434|NCT03945955|Placebo Comparator|Placebo|
11118435|NCT03945942|Other|Pediatric liver transplant patients|Using somatic and cerebral Near infrared spectroscopy devices
11118436|NCT03945929|Experimental|Distraction1 group|Distraction-1 Group (Cards containing optical illusion pictures)
11118437|NCT03945929|No Intervention|Control|Control
11118438|NCT03945929|Experimental|Distraction 2 group|Distraction-2 Group
11118439|NCT03945916|Experimental|Dark chocolate|180g/d dark chocolate
11118440|NCT03945916|Placebo Comparator|Placebo|180g/d of artificial dark chocolate
11118441|NCT03945877||English-speaking Community Members|Survey respondents
11118442|NCT03945877||Spanish-speaking Community Members|Survey respondents
11118443|NCT03945877||Arabic-speaking Community Members|Survey respondents
11118444|NCT03945864|Experimental|antimicrobial synthetic bone graft|This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
11118445|NCT03945864|Active Comparator|parenteral antibiotics with pure synthetic bone graft|This group will have parenteral antibiotics and pure synthetic bone graft
11118446|NCT03945851|Experimental|VNS + Rehabilitation|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The experimental arm for that study includes subjects whose stroke treatment via Vagal Nerve Stimulation (VNS) delivered during rehabilitation.
11118447|NCT03945851|Active Comparator|Control VNS|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The active control arm for that study included subject whose stroke treatment is rehabilitation (standard-of-care) with only a minimal amount of VNS at the start of each rehabilitation session.
11118448|NCT03945838||Breast cancer related lymphedema|All patients were included in the complete decongestive therapy programme. This therapy includes patient education, skin care, exercises, manual lymphatic drainage (self), and compression bandage therapy.
11118449|NCT03945825|Experimental|Group 1|0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
11118450|NCT03945825|Experimental|Group 2|0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
11118451|NCT03945825|Experimental|Group 3|0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
11118452|NCT03945825|Experimental|Group 4|0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
11118453|NCT03945825|Experimental|Group 5|0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
11118454|NCT03945825|Experimental|Group 6|0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
11118455|NCT03945812|Active Comparator|Granulocyte Colony Stimulating Factor Arm|"Women in this group will receive G-CSF with conventional hormonal therapy:
~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
11118456|NCT03945812|Active Comparator|Platelet Rich Plasma Arm|"Women in this group will receive PRP with conventional hormonal therapy:
~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
11118457|NCT03945812|Placebo Comparator|Saline|"Women in this group will receive saline with conventional hormonal therapy:
~Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed."
11118458|NCT03945799|Experimental|Anlotinib|Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
11118459|NCT03945773|Experimental|Cohort A|Subjects who radiographically progressed after one prior line by CPI therapy with ipilimumab and nivolumab.
11118460|NCT03945773|Experimental|Cohort B|Subjects who radiographically progressed after one prior line by CPI therapy combined with VEGF-targeted therapy.
11118461|NCT03945760|Experimental|Subjects Taking Baricitinib 2 mg|Subjects will be taking Baricitinib 2mg
11118462|NCT03945760|Placebo Comparator|Subjects Taking Placebo|Subjects will be taking placebo
11118463|NCT03945747||Control group|Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
11118464|NCT03945747||Hybrid closed-loop artificial pancreas system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
11118465|NCT03945747||Predictive low glucose suspend system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
11118490|NCT03945552|Experimental|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
11118466|NCT03945734|Experimental|Expressive Helping|Participants complete four 20-minute writing/voice-recording sessions spaced one week apart. During the first week, the instructions will explain that cancer patients and survivors benefit from learning about other cancer survivors' experiences. They are told that the first three weeks of writing/voice-recording (writing/talking about their stress and coping at Week 1, deepest emotions about cancer at Week 2, self-affirmation and benefit finding at Week 3) are exercises designed to help them think about their cancer experiences and to prepare them to write/record the narrative they would share on Week 4. During Week 4, they are asked to write/record a narrative as if they are speaking to another Chinese person with cancer, adding advice and encouragements, and reminded that their writing/recording would be shared with other Chinese American cancer patients and survivors.
11118467|NCT03945721|Experimental|Niraparib|"Niraparib will be administered orally on a daily basis
~Radiation Therapy will be administered concurrently with Niraparib"
11118468|NCT03945708|Experimental|Treatment|Addition of whole blood adsorber to CPB circuit
11118469|NCT03945708|No Intervention|Control|Standard treatment
11118470|NCT03945695|Experimental|Pneumatic Vitreolysis|All included eyes will receive one intravitreal injection of filtered sulfur hexafluoride gas (SF6).
11118471|NCT03945682|Experimental|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
11118472|NCT03945682|No Intervention|Usual Standard of Care|Participants continue with usual care and existing therapy recorded in study diary
11118473|NCT03945669|Active Comparator|Intramedullary Nail|Intramedullary Nailing: Alignment will be obtained by closed or limited open reduction of the fracture. A standard reamed intramedullary nail is inserted. Access through the patella tendon or parapatellar access is used according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. Patients are administered preoperative antibiotics (Dicloxacillin) 15 minutes before surgery commences. Postoperative antibiotics is administered by discretion of the surgeon based on individual patient considerations.
11118474|NCT03945669|Experimental|External Ring fixator|External Ring fixation: Closed or limited open reduction of the fracture is performed. A circular frame is attached on both sides of the fracture. Connection to the bone is obtained by hydroxyapatite coated half pins and/or k-wires with olives as needed according to surgeon preferences. One or more cortical screws may be used if deemed appropriate due to fracture pattern. After applying the ring fixator alignment is assessed radiologically and corrected both peri- and postoperatively. Patients are administered preoperative antibiotics (Dicloxacillin) preoperatively 15 minutes before surgery commences. Following surgery antibiotics are continued until wounds, pin- and wire perforations are dry.
11118475|NCT03945656|Experimental|Insulin 287 followed by insulin glargine|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.
~After run-in, participants will receive insulin 287 once a week (OW) for 6 weeks.
~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 12 days."
11118476|NCT03945656|Active Comparator|Insulin glargine followed by insulin 287|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.
~After run-in, participants will receive insulin glargine U100 OD for 12 days.
~After insulin glargine treatment, participants will receive insulin 287 OW for 6 weeks."
11118477|NCT03945643|Active Comparator|Sildenafil administration|Administration of 50mg sildenafil one time, one hour prior to measurements
11118478|NCT03945643|Placebo Comparator|Placebo administration|Administration of 50mg placebo one time, one hour prior to measurements
11118479|NCT03945630|Experimental|anterior Quadratus Lumborum Block (QLB)|"Anterior QLB will be performed in the sitting position. This block is also known as TQL- Transmuscular QLB or QLB 3. A convex transducer will be placed in a transverse position, in the posterior axillary line and tilted caudad until the 'shamrock sign' at L4 level will be obtained. An 80-110 mm SonoTAP (PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the needle tip will be inside the interfascial plane between the Quadratus Lumborum and the Psoas muscles. The successful needle placement will be confirmed by observing the spread of 5 mls 0,9%NaCl. Subsequently, 30 ml 0.5% ropivacaine with 100 mcg dexmedetomidine and adrenaline 1:200,000 will be injected. Satisfactory interfascial spread will be assessed by longitudinal probe orientation.
~Following QLB, a spinal anaesthetic will be sited and a THA via posterior approach will be performed."
11118480|NCT03945630|Active Comparator|Standard of Care (no QLB)|A spinal anaesthetic will be sited and a THA via posterior approach will be performed.
11118481|NCT03945617|Experimental|Unified treatment protocol|This intervention group receives 16 sessions of CBT-based, individual psychotherapy using to the Unified Treatment Protocol for the treatment of emotional disorders by Barlow et al. (2011).
11118482|NCT03945617|No Intervention|Waitlist Control Group|Participants in the waitlist control group gain access to the Unified Treatment after a waiting period of 16 weeks
11118483|NCT03945604|Experimental|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity
11118484|NCT03945591|Experimental|Cyclophosphamide and Bortezomib|
11118485|NCT03945578|Active Comparator|Control Group|This group will receive one protocol of exercises designated to the strengthen of pelvic floor muscles. This protocol will be based on Progressive Perineal Education (EPP) as proposed by Luz and collaborators (2011) and will be made in groups of five women with supervision of a physiotherapist, twice a week, for five consecutive weeks.
11118486|NCT03945578|Experimental|Intervention Group|This group will receive the same protocol of the control group destinated to the to strengthen of the pelvic floor muscles, but this group will also receive, once a week for five consecutive weeks, a visceral manual therapy protocol destinated to the abdominal and pelvic viscera. This protocol will be based on the approach proposed by Vanderheyden- Busquet (2009, 2014).
11118487|NCT03945565|Active Comparator|FiO2 0.3|Patients allocated to this group are going to receiving FiO2 of 0.3 during surgery
11118488|NCT03945565|Active Comparator|FiO2 0.8|Patients allocated to this group are going to receiving FiO2 of 0.8 during surgery
11118489|NCT03945552|No Intervention|Control|Care as usual
11118522|NCT03945318|Experimental|Part 3: BION-1301|Up to 2 cohorts of subjects will receive multiple doses of BION-1301 at a dose and frequency to be determined by IV infusion.
11118804|NCT03943420||Positive Control Group|Therapy C : Basic treatment + Donepezil
11118491|NCT03945539|Experimental|JNJ-56136379 and Itraconazole|Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single dose of JNJ 56136379 on Day 38 in Treatment Period 2. JNJ-56136379 intake in Treatment Period 1 and the first intake of itraconazole in Treatment Period 2 will be separated by a washout period of at least 33 days. Study drug (JNJ-56136379 and itraconazole) intakes will be taken orally and under fed conditions.
11118492|NCT03945526|Active Comparator|Astaxanthin|Astaxanthin supplementation will be given at 2 x 8mg for 7 days.
11118493|NCT03945526|Placebo Comparator|Control|A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation
11118494|NCT03945513|Experimental|LPRI424|
11118495|NCT03945500|Experimental|Standardized Home Spirometry (SHS) Method|"The Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet & FDA approved spirometer & pulse oximeter.
~Participants will be trained with the SHS method & perform an initial home spirometry test session & a laboratory-based spirometry test.
~Pre-surveillance Phase:Daily SHS Testing for 4 to 10 weeks to enable the Mobile Medical software application to generate volunteer specific normal range calibration.
~Surveillance Phase: At least twice weekly SHS Testing.If a variance (outside of the participant's normal range) is detected, the participant will be prompted to complete a short symptom survey on the Android Pad. Participants will be directed to intentionally induce variances, symptoms, etc., in order to fully test and assess the functionality of the Mobile Medical software neural pathways as directed by the study team. Volunteers will document this testing on a test log"
11118496|NCT03945487|Experimental|Comprehensive treatment plus UC-MSC treatment|
11118497|NCT03945487|Other|Comprehensive treatment|
11118498|NCT03945474|Experimental|OMT|Patients will receive a standardized protocol of: condylar decompression, Still's technique for the sternocleidomastoid, hyoid rebalancing and thoracic inlet myofascial release.
11118499|NCT03945474|Sham Comparator|Sham|Patient will be treated in the supine position, with hands gently applied without pressure to the four areas: occiput, lateral cervical spine, hyoid area and thoracic inlet.
11118500|NCT03945461|Experimental|Gum chewing|Chew xylitol based, peppermint flavored gum for 30 minutes every two hours during the hours of 7 am to 9 pm, for the first 24 hours after your surgery
11118501|NCT03945461|No Intervention|Standard Care|Standard hospital management with no deviations from usual care
11118502|NCT03945448|Experimental|Single dose liposomal Amphotericin and fluconazole|"Experimental:
~Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)"
11118503|NCT03945448|Active Comparator|fluconazole (standard of care)|Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months
11118504|NCT03945435||Normal Glucose Tolerance|Blood glucose level of less than 140 mg/dL at the 2 hour timepoint.
11118505|NCT03945435||Impaired Glucose Tolerance|Blood glucose level of greater or equal to 140 mg/dL at the 2 hour timepoint.
11118506|NCT03945422|Experimental|Treatment Arm|Subject will receive AccuTite/FaceTite and Morpheus8 treatment
11118507|NCT03945396|Experimental|Multidisciplinary intervention + homeopathic medication|"Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c.
~A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation."
11118508|NCT03945396|Active Comparator|Multidisciplinary intervention + homeopathic placebo|"Multidisciplinary intervention (diet, exercise program, motivational support) and placebo.
~Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation."
11118509|NCT03945383|Experimental|Treatment with IPL device|The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
11118510|NCT03945370|Active Comparator|Intervention sequence 1|Ketone drink first - Placebo drink secondly
11118511|NCT03945370|Placebo Comparator|Intervention sequence 2|Placebo drink first - Ketone drink secondly
11118512|NCT03945357|Active Comparator|Saline Irrigation|Normal saline is to be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional saline irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure.
11118513|NCT03945357|Active Comparator|Antibiotic Irrigation|Antibiotic solution is prepared consisting of 240 mg gentamicin and 600 mg clindamycin in 500 ml saline to ensure proper concentration. This solution should be placed into the dissected retromuscular space AFTER placement and fixation of mesh. This should fill the cavity completely to the level of the skin. Irrigant is to be left to stand for a total of three minutes and then evacuated. Additional irrigation with saline PRIOR to the randomization is permitted at the surgeons' discretion for hemostasis with no requirement for duration. Additional antibiotic irrigation of the subcutaneous space after fascia closure should be performed prior to skin closure. This second irrigation is not timed.
11118514|NCT03945344|Experimental|Treatment A|Tiotropium with concomitant charcoal
11118515|NCT03945344|Experimental|Treatment B|Tiotropium without concomitant charcoal.
11118516|NCT03945331|Experimental|TESS|Transcutaneous Electrical Spinal Stimulation (TESS), used during all training sessions.
11118517|NCT03945331|Experimental|EES|TESS, used during the initial 6-month training period, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
11118518|NCT03945318|Experimental|Part 1: BION-1301|Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
11118519|NCT03945318|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of placebo administered by IV infusion.
11118520|NCT03945318|Experimental|Part 2: BION-1301|Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
11118521|NCT03945318|Placebo Comparator|Part 2: Placebo|Subjects will receive placebo by IV infusion.
11118523|NCT03945305|Experimental|RIC+ antihypertensive treatment|Baseline blood pressure and heart rate are measured 2 times a day for 3 days. And then the blood pressure and heart rate are measured before and after remote ischemic conditioning. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 30±2 days.
11118524|NCT03945292|Experimental|ARO-AAT|"Part A: administered on Days 1, 29 and 113 and every 84 days thereafter until dose selected for Part B
~Part B: minimum of 6, maximum of 9 doses"
11118525|NCT03945292|Placebo Comparator|Placebo|"Part A: administered on Days 1, 29 and 113 and every 84 days thereafter until dose selected for Part B
~Part B: minimum of 6, maximum of 9 doses"
11118526|NCT03945279|Experimental|Cohort 1: BIIB100 Dose 1|Participants will receive single oral dose of BIIB100 on Day 1.
11118527|NCT03945279|Experimental|Cohort 2: BIIB100 Dose 2|Participants will receive single oral dose of BIIB100 on Day 1.
11118528|NCT03945279|Experimental|Cohort 3: BIIB100 Dose 3|Participants will receive single oral dose of BIIB100 on Day 1.
11118529|NCT03945279|Experimental|Cohort 4: BIIB100 Dose 4|Participants will receive single oral dose of BIIB100 on Day 1.
11118530|NCT03945279|Experimental|Cohort 5: BIIB100 Dose 5|Participants will receive single oral dose of BIIB100 on Day 1.
11118531|NCT03945279|Experimental|Cohort 6: BIIB100 Dose 6|Participants will receive single oral dose of BIIB100 on Day 1.
11118532|NCT03945279|Placebo Comparator|Cohort 1-6: Matching Placebo|Participants will receive single oral dose of matching placebo on Day 1.
11118533|NCT03945266|Experimental|Intervention group|Participants receive the allocated intervention to help manage gestational weight gain that includes education on weight regulation, healthy eating, physical activity, and goal setting.
11118534|NCT03945266|Active Comparator|Control group|Participants do not receive the allocated intervention but self-monitor their behaviors, complete study tasks and receive prenatal care as normal.
11118535|NCT03945253|Experimental|ASP8374-dose A|Participants will receive dose A of ASP8374 solution intravenously on day 1 of every 3-week cycle.
11118536|NCT03945253|Experimental|ASP8374-dose B|Participants will receive dose B of ASP8374 solution intravenously on day 1 of every 3-week cycle.
11118537|NCT03945240|Experimental|Group 1 (Pinnacle, lower dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
11118538|NCT03945240|Experimental|Group 2 (Pinnacle, higher dosimetry parameters)|Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
11118539|NCT03945240|Experimental|Group 3 (Phoenix)|Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
11118540|NCT03945227|Placebo Comparator|Arm A (consolidation only arm)|Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
11118541|NCT03945227|Experimental|Arm B (concurrent arm)|Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
11118542|NCT03945214|Experimental|Meditation group|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
11118543|NCT03945214|Experimental|Healthy eating group|Participants in the healthy eating group will be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
11118544|NCT03945214|Experimental|Mediation + Healthy eating group|Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
11118545|NCT03945214|No Intervention|Waitlist control condition|Waitlist control group participants will continue their normal activities and not add any form of mediation during the study period.
11118546|NCT03945201|Active Comparator|Standard of care|"Participants receive normal cardiac rehabilitation according to approved standard of care. They use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session."
11118547|NCT03945201|Experimental|Virtual walking trails|"Participants use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session. The treadmill is positioned in front of a vertically oriented high definition television screen showing Bionautica Trails, virtual walking trails created by Plas.md."
11118548|NCT03945188|Experimental|Etrasimod 2 mg|
11118549|NCT03945188|Placebo Comparator|Placebo|
11118550|NCT03945175|Experimental|Treatment|During the first two week lead-in, if the subject has a ≥30% decrease in the AISRS, they will not move into the 4-week treatment period of the study.
11118551|NCT03945162|Experimental|0.7 mg/cm^2 TLD-1433 Bladder infusion and Photodynamic Therapy|A single instillation of TLD-1433 (at the therapeutic dose of 0.7 mg/cm^2) will be infused intravesically into the bladder for approximately 60 minutes. Photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. Two treatment procedures will be performed, a primary treatment at Day 0 and a secondary treatment at Day 180 post primary treatment.
11118552|NCT03945149|Active Comparator|Turmipure Gold™|30 subjects will be randomized under active arm and will receive Active Product at V1 and until V2 (5 weeks of treatment).
11118553|NCT03945149|Placebo Comparator|Placebo|30 subjects will be randomized under Placebo arm and will receive placebo Product at V1 and until V2 (5 weeks of treatment).
11118554|NCT03945123|Experimental|Ginseng trial|compare experimental group to controlled group
11118555|NCT03945110|Experimental|Arm A|Patients in this Arm will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later.
11118556|NCT03945110|No Intervention|Arm B|Patients in this Arm will receive usual bladder care only.
11118557|NCT03945110|Experimental|Arm C|Patients in this Arm will be Spinal Urology Outpatients or Inpatients who are eligible for inclusion and experiencing significant urinary tract infection recurrence and/or complications. Patients will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later. Patients will be encouraged and supervised to self-administer iAluRil® intravesical instillations.
11118558|NCT03945097||Letters|Education program focuses on learning letters.
11118559|NCT03945097||Language|Education program focuses on language comprehension.
11118560|NCT03945084|Experimental|Experimental Arm|Patients assigned to experimental arm will receive Niraparib 300 mg or 200 mg daily (based on weight and platelet count) plus best supportive care (BSC), in 28-day cycles, until disease progression or unacceptable toxicity or death.
11118561|NCT03945084|Other|Control Arm|Patients assigned to control arm will receive best supportive care alone, until disease progression or death.
11118562|NCT03945071|Active Comparator|Puntal plug|Subjects will receive temporary punctal plug after intravitreal injection
11118563|NCT03945071|No Intervention|Non-Punctual plug|Subjects will not receive temporary punctal plug after intravitreal injection
11118564|NCT03945058|Experimental|Experimental|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
11118565|NCT03945058|Sham Comparator|CONTROL|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.
11118566|NCT03945045|Experimental|SCV|TIVAD implanted through subclavian vein under real-time ultrasound guidance
11118567|NCT03945045|Experimental|IJV|TIVAD implanted through internal jugular vein under real-time ultrasound guidance
11118568|NCT03945032|Experimental|8 parents of a childhood cancer survivor|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
11118569|NCT03945019|Experimental|CT-P13 SC|
11118570|NCT03945019|Placebo Comparator|Placebo SC|
11118571|NCT03945006||Multiple Sclerosis Patients with Incontinence|Multiple Sclerosis with incontinence 24-58 years of age and being volunteered.
11118572|NCT03945006||Multiple Sclerosis Patients without incontinence|Multiple Sclerosis without incontinence 24-58 years of age and being volunteered.
11118573|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on dominant leg.
11118574|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Non-dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on non-dominant leg.
11118575|NCT03944993|Sham Comparator|Sham Therapy (Control)|Inactive Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes.
11118576|NCT03944980|Experimental|Arm 1: CIK|"Docetaxel & PD1-T cells
~Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
11118577|NCT03944980|Active Comparator|Arm 2: Control|"Docetaxel
~Docetaxel,60mg/m2,intravenous infusion,d1; Q3W."
11118578|NCT03944954|Experimental|Excitatory TMS|Combinations of THC and excitatory TMS.
11118579|NCT03944954|Experimental|Inhibitory TMS|Combinations of THC and inhibitory TMS.
11118580|NCT03944941|Active Comparator|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
11118581|NCT03944941|Experimental|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
11118582|NCT03944915|Experimental|ARM 1|Induction Therapy
11118583|NCT03944915|Experimental|ARM 2|Radiation therapy with chemotherapy
11118584|NCT03944902|Experimental|Cohort 1: Dose Escalation using Niraparib and CB-839|The first phase will be a 3+3 design, 3 participants will be enrolled in the first cohort with a fixed dose of Niraparib and CB-839, 600 mg. If there are no dose limiting toxicities (DLT), 3 additional participants will be enrolled in the next cohort (CB-839, 800mg). If 1 of the 3 in the first cohort experiences DLT's, then the additional participants will be enrolled in the same cohort (CB-839, 600mg).
11118585|NCT03944902|Experimental|Cohort 2: Dose Escalation using Niraparib and CB-839|If there are no DLT's, 3 additional participants will be enrolled in the next cohort with a fixed dose of Niraparib and CB-839, 800mg.
11118586|NCT03944902|Experimental|Cohort 3: Expansion with Maximum Tolerated Dose (MTD)|Patients in this expansion cohort will continue study treatment with the MTD until they experience disease progression, unacceptable toxicity or withdraw consent. Patients who discontinue study treatment for reasons other than Progressive-Free Survival (PFS) will continue to have PFS follow-up visits every 2 months for the first 6 months after treatment, and every 3 months until disease progression, death, or start of another anticancer therapy.
11118587|NCT03944889|Placebo Comparator|Placebo Topical|Placebo Cream, applied topically to trapezius muscle
11118591|NCT03944889|Active Comparator|Low Dose, Intrafacial|Injection Capsaicin formulation low dose- injected intrafascially into trapezius
11118592|NCT03944889|Active Comparator|High Dose, Intrafascial|Injection Capsaicin formulation higher dose- injected intrafascially into trapezius
11118593|NCT03944889|Placebo Comparator|Placebo, Intramuscular|Injection placebo (saline) - injected intramuscularly into trapezius
11118594|NCT03944889|Active Comparator|Low Dose, Intramuscular|Injection Capsaicin formulation low dose - injected intramuscularly into trapezius
11118595|NCT03944889|Active Comparator|High Dose, Intramuscular|Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius
11118596|NCT03944876|Experimental|Botox injections towards SPG|Botulinum Toxin type A injections
11118597|NCT03944876|Placebo Comparator|Controls|placebo injections
11118598|NCT03944863||POEM + Antibiotic prophylaxis|Cefazolin: 2g or Amoxicillin - clavulanic acid: 1g x 3 during 7 days
11118599|NCT03944863||POEM + No antibiotic prophylaxis|
11118600|NCT03944850|Experimental|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
11118601|NCT03944837|Experimental|Severe fetal congenital heart disease (CHD)|Mothers whose fetuses have a diagnosis of CHD will be exposed to 10-15 L/minute of oxygen while undergoing echocardiogaphy and MRI scanning
11118602|NCT03944824|Experimental|Exercise (Intervention) Arm|The 25 patients in this arm will receive an interventional exercise plan using resistance bands and once weekly visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
11118603|NCT03944824|Placebo Comparator|Control|The 25 patients in the control arm will not receive an interventional exercise plan or visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
11118604|NCT03944811|Active Comparator|Transcrestal sinus floor elevation using Summers technique|
11118605|NCT03944811|Experimental|Transcrestal sinus floor elevation using piezoelectric surgery|
11118606|NCT03944798|Active Comparator|Surveillance Arm I|Clinical assessment and chest radiograph (CXR) every six months for two years
11118607|NCT03944798|Experimental|Surveillance Arm II|Clinical assessment and CXR every three months for two years
11118608|NCT03944798|Experimental|Surveillance Arm III|Clinical assessment and chest computed tomography (CT) every six months for two years
11118609|NCT03944798|Experimental|Surveillance Arm IV|Clinical assessment and chest CT every three months for two years
11118610|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
11118611|NCT03944772|Experimental|Module 1: Osimertinib + Savolitinib|The patients in this group will receive osimertinib taken in combination with savolitinib
11118612|NCT03944772|Experimental|Module 2: Osimertinib + Gefitinib|The patients in this group will receive osimertinib taken in combination with gefitinib
11118613|NCT03944772|Experimental|Module 3: Osimertinib + Necitumumab|The patients in this group will receive osimertinib taken in combination with necitumumab
11118614|NCT03944772|Experimental|Module 4: Carboplatin + Pemetrexed + Durvalumab)|The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
11118615|NCT03944772|No Intervention|Observational Cohort: No study drug|"Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.
~With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib."
11118616|NCT03944772|Experimental|Module 5: Osimertinib + Alectinib|The patients in this group will receive osimertinib taken in combination with alectinib
11118617|NCT03944772|Experimental|Module 6: Osimertinib + Selpercatinib|The patients in this group will receive osimertinib taken in combination with selpercatinib
11118618|NCT03944759|Active Comparator|GBM:( bupivacaine/magnesium sulphate)|"serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.
~GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate"
11118619|NCT03944759|Active Comparator|GBN: ( bupivacaine/nalpuphin)|serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg.
11118620|NCT03944746||SAMMC Emergency Medicine Residents|Emergency Medicine Residents from San Antonio Military Medical Center in San Antonio, Texas.
11118621|NCT03944746||University Hospital Emergency Medicine Residents|Emergency Medicine Residents from University Hospital in San Antonio, Texas.
11118622|NCT03944733|Active Comparator|Iron Intervention|IDA mothers will receive a 65 mg of iron (ferrous sulfate) daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
11118623|NCT03944733|Placebo Comparator|Placebo|IS mothers will receive 600 mg of gelatin daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
11118624|NCT03944707|Experimental|LOU064 treatment|45 subjects will be randomized to take LOU064 experimental dose
11118625|NCT03944707|Placebo Comparator|placebo group|30 subjects will be randomized to take LOU064 matching placebo
11118626|NCT03944694||Delirious|Patients were delirious if CAM-ICU was positive within 24 hours from admission due to acute ischemic stroke.
11118627|NCT03944694||Non-delirious|Patients were delirious if CAM-ICU was negative within 24 hours from admission due to acute ischemic stroke.
11118628|NCT03944681|Other|Droperidol group|Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus
11118629|NCT03944668|Experimental|Intervention|Exercise intervention
11118630|NCT03944655|Active Comparator|Strepsils|
11118631|NCT03944655|Placebo Comparator|Placebo|
11120592|NCT03930680|Experimental|50mg/m2 or 500 mg/m2|one dose of either 50 mg/m2 or 500 mg/m2 dexrazoxane
11118632|NCT03944642|Experimental|Intervention|Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
11118633|NCT03944642|No Intervention|Standard Care|This group will receive the standard pre and postnatal regular care, for mother and child. Professionals who provide direct care will maintain their usual attention.
11118634|NCT03944616|Active Comparator|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
11118635|NCT03944616|Experimental|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
11118636|NCT03944577|Experimental|Treatment Arm|Patients who will receive the study drug.
11118637|NCT03944564|Active Comparator|Condition 1: sitting|Four hours of sitting condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
11118638|NCT03944564|Active Comparator|Condition 2: static standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
11118639|NCT03944564|Active Comparator|Condition 3: dynamic standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
11118640|NCT03944551|Experimental|Bubble CPAP|
11118641|NCT03944551|Other|Standard Therapy|
11118642|NCT03944538|Experimental|Lifestyle Physical Activity|"The primary content of the website will be delivered through interactive video courses. The courses will be released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.
~The website Tracker feature will allow for tracking of daily step counts as well as setting goals and monitoring progress.
~The one-on-one video chats will be conducted face to face through Zoom and will be semi-scripted. The chats will consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral changes based on social cognitive theory and current website content. The chats will occur at the same frequency as the video course release. For the second 6 months of the study, participants will be asked to maintain their usual activities."
11118643|NCT03944538|Active Comparator|General Wellness|The general wellness condition will focus on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the National Multiple Sclerosis Society. The delivery of the Internet materials and chat sessions will occur on the same schedule and frequency as the intervention condition, and will have a comparable time commitment. This condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. For the second 6 months of the study, participants will be asked to maintain their usual activities.
11118644|NCT03944525|Active Comparator|Intervention|Intervention consists of HFA using standard equipment at the department. A gas flow of 60L/min and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the pati ent or indication for intubation.
11118645|NCT03944525|Active Comparator|Control|Control consists of non-invasive CPAP ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine. A positive airway pressure of 5cm H2O and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.
11118646|NCT03944512|Experimental|Pravastatin|20 mg pravastatin daily
11118647|NCT03944512|Placebo Comparator|Placebo|Identical appearing daily placebo
11118648|NCT03944499|Experimental|FS-1502|
11118649|NCT03944486|Other|On-Track|One arm feasibility study
11118650|NCT03944473|Active Comparator|neostigmine|Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers [8]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
11118651|NCT03944473|Experimental|sugammadex|Sugammadex is a modified gamma-cyclodextrin, the first of a new class of drugs called selective relaxant binding agents, with an unusually high affinity for rocuronium. This medication offers an alternate mechanism of action to antagonize the effects of steroidal neuromuscular blockade agents.
11118652|NCT03944460|Active Comparator|Contraloid 4 mg|4 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118653|NCT03944460|Active Comparator|Contraloid 12 mg|12 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118654|NCT03944460|Active Comparator|Contraloid 36 mg|36 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118655|NCT03944460|Active Comparator|Contraloid 108 mg|108 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118656|NCT03944460|Active Comparator|Contraloid 320 mg|320 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118657|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 4 mg|4 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118658|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 12 mg|12 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118659|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 36 mg|36 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118660|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 108 mg|108 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118661|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 320 mg|320 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
11118662|NCT03944447|Experimental|Cannabis users|"Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is cannabis-naïve, defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution."
11118663|NCT03944447|Experimental|Cancer prevention|Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance.
11118664|NCT03944447|Experimental|Life-Threatening Conditions|"Opioids are a class of drugs naturally found in the opium poppy plant. Opioids are often used as medicines because they contain chemicals that relax the body and can relieve pain. Prescription opioids are used mostly to treat moderate to severe pain. Opioids can also make people feel very relaxed and high - which is why they are sometimes used for non-medical reasons. This can be dangerous because opioids can be highly addictive, and overdoses and death are common.
~From 1999 to 2017, more than 700,000 people have died from a drug overdose. Around 68% of the more than 70,200 drug overdose deaths in 2017 involved an opioid.
~In 2017, the number of overdose deaths involving opioids was 6 times higher than in 1999.
~On average, 130 Americans die every day from an opioid overdose.
~This study will focus on examining outcomes of patients that have been treated with cannabis as a replacement or alternative to life-threatening opioids or other prescription drugs."
11118665|NCT03944447|Experimental|COVID-19 / SARS-CoV-2|Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted through respiratory droplets, with potential for aerosol and contact spread. It uses receptor-mediated entry into the human host via angiotensin-converting enzyme II (ACE2) that is expressed in lung tissue, as well as oral and nasal mucosa. Modulation of ACE2 levels in these gateway tissues may prove a plausible strategy for decreasing disease susceptibility. Cannabis sativa, especially one high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been proposed to modulate gene expression and inflammation and possess anti-cancer and anti-inflammatory properties. Covid-19 infection rates in cannabis users will be compared to rates in the general population. Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population.
11118666|NCT03944434|Experimental|single arm|"patients will receive anastrozole tablets (1 mg once daily) or letrozole tablets (2.5 mg once daily) + ribociclib tablets (600 mg day 1 to 21 in a 28 day cycle). Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, physician's decision, patient's refusal/consent withdrawal, or lost to follow-up.
~A LHRH agonist (triptorelin 3,75 mg or leuprolide 3,75 mg or goserelin 3,6 mg, as injectable intramuscular (i.m.) or subcutaneous (s.c.) implant every 28 days) will be used in men."
11118667|NCT03944421|Experimental|Red and Processed Meat|240 grams (raw weight) of red and processed meat every day for 2 weeks
11118668|NCT03944421|Experimental|Quorn|240 grams (uncooked weight) of Quorn every day for 2 weeks
11118669|NCT03944408|Experimental|A metal bare stent with 125I seeds|125I seeds fixed on the metal bare stent, then stent implantation
11118670|NCT03944408|Other|A metal bare stent|A metal bare stent implantation
11118671|NCT03944395|Other|Assisted Partner notification services|Voluntary assisted partner notification (VAPN) services will be offered at facilities according to a stepped wedge design. Once VAPN services are activated at a facility, HIV positive individuals will be offered four options (3 voluntary assisted partner notification options and 1 standard of care option) for inviting their contacts, which they can choose to accept or decline.
11118672|NCT03944369|Other|Observational Control|The observational control arm is an observational control group.
11118673|NCT03944369|Other|KB109|KB109 is a novel glycan.
11118674|NCT03944343|Sham Comparator|Reference product|Commercial cereals and a commercial yogurt
11118675|NCT03944343|Experimental|Test product A|Specific designed cereals A and yogurt
11118676|NCT03944343|Experimental|Test product B|Specific designed cereals B and yogurt
11118677|NCT03944343|Experimental|Test product C|Specific designed cereals C and yogurt
11118678|NCT03944343|Experimental|Test product D|Specific designed cereals D and yogurt
11118679|NCT03944330|Active Comparator|a treatment group|All study participants were provided with a standard hospital diet that provided B25-30 kcal/kg/day
11118680|NCT03944330|No Intervention|control group|All study participants were not intervened with diet
11118681|NCT03944317|Active Comparator|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
11118682|NCT03944317|Active Comparator|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
11118683|NCT03944304|Experimental|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
11118684|NCT03944291|Active Comparator|Unilateral PNB|Unilateral Pudendal Nerve Block
11118685|NCT03944291|Active Comparator|Bilateral PNB|Bilateral Pudendal Nerve Block
11118686|NCT03944278|Experimental|Thulium Device|1927 Laser Treatment
11118687|NCT03944265|Experimental|Supportive care (treatment decision counseling session)|Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
11118688|NCT03944252|Experimental|A (avelumab)|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
11118689|NCT03944252|Experimental|B (cetuximab + avelumab)|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
11118690|NCT03944239|Experimental|retinal pigment epitheliums transplantation|Transplant clinical-grade hESC derived retinal pigment epitheliums into subretinal of patients with retinitis pigmentosa.The dosage is 150000.
11118691|NCT03944226|Experimental|Beetroot|16 patients confirmed with a diagnosis of invasive ductal carcinoma who will undergo wide local excision surgery or mastectomy. All patients in the single arm will undergo a 5 day intervention drinking concentrated beetroot juice and 2 magnetic resonance imaging scan sessions pre and post intervention. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
11118692|NCT03944213||MDD patients|
11118693|NCT03944213||Healthy controls|
11118694|NCT03944200|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
11118695|NCT03944200|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
11118696|NCT03944174||Single Trans-sacral Screw|
11118697|NCT03944174||Two Iliosacral Screws|
11118698|NCT03944161|Experimental|Intervention group|Participants in the intervention group will receive an oral nutrition supplement bottle (200/220 ml) with >20 % of protein and 1.5 Kcal/ml without fibre twice a day during 12 weeks and nutritional advice.
11118699|NCT03944161|Active Comparator|Control group|Participants in the control group will receive nutrition advice
11118700|NCT03944135|Experimental|Experimental group|The sample consisted of 40 people: 20 in an experimental group. There were 5 men and 15 women.
11118701|NCT03944135|Active Comparator|Control group|The sample consisted of 40 people: 20 in a control group. There were 5 men and 15 women.
11118702|NCT03944122|Experimental|continuous ultrasound|continuous ultrasound were applied to the patients
11118703|NCT03944122|Experimental|pulsed ultrasound|pulsed ultrasound were applied to the patients
11118704|NCT03944122|Experimental|placebo|placebo (sham) ultrasound were applied to the patients
11118705|NCT03944109|Experimental|SHR-1209|Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
11118706|NCT03944109|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
11118707|NCT03944096|Experimental|FMT+MTX|"FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient.
~Drug: Methotrexate (MTX) Weekly methotrexate"
11118708|NCT03944096|Placebo Comparator|autologous FMT+MTX|"autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself.
~Drug: Methotrexate (MTX) Weekly methotrexate"
11118709|NCT03944083||ADHD with and without DMDD|ADHD with DMDD versus ADHD without DMDD. Observational study at referral and after 6 and 12 months.
11118710|NCT03944070|Active Comparator|Intensive Treatment|The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
11118711|NCT03944070|Active Comparator|Standard Treatment|The participants will continue their preoperative treat and extend protocol .
11118712|NCT03944057|Experimental|ATG-010 + Dexamethasone|Open-label ATG-010 80mg plus Dexamethasone 20 mg
11118713|NCT03944044|Other|Subcutaneous route first|The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
11118714|NCT03944044|Other|Intravenous route first|The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.
11118715|NCT03944031|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.
11118716|NCT03944018|Experimental|Intervention with rehabilitation coordinator|
11118717|NCT03944018|No Intervention|Control|
11118718|NCT03944005|Active Comparator|Study Group|Spinal Anesthesia + ACB continuous catheter+ iPACK + Sham LIA
11118719|NCT03944005|Sham Comparator|Comparator Group|Spinal Anesthesia + LIA + Sham Blocks
11118720|NCT03943992|Experimental|YYD601 40mg|Esomeprazole magnesium Dihydrate.
11118721|NCT03943992|Active Comparator|Nexium 40mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
11118722|NCT03943979|Sham Comparator|Active Control group|This group will receive CT and sham tDCS each day, for four days.
11118723|NCT03943979|Active Comparator|Active group|This group will receive both CT and tDCS, each day, for four days.
11118724|NCT03943966|Experimental|Myocardial Infarction|
11118725|NCT03943966|Active Comparator|Stable coronary disease with intracoronary stent insertion|
11118726|NCT03943966|Active Comparator|Deep vein thrombosis and Pulmonary embolus|
11118727|NCT03943966|Active Comparator|Surgical and Transcatheter Aortic valve replacement|
11118728|NCT03943966|Active Comparator|Transient ischaemic attack and stroke|
11118805|NCT03943407|Experimental|Zyclara/vehicle|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.
11118729|NCT03943953|Experimental|Facial Palsy - Trial of ITG|In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
11118730|NCT03943953|Experimental|Friends or relatives - Trial of ITG|In this arm of the trial friends or relatives of individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
11118731|NCT03943940|Experimental|BM-MNC and UC-MSC|30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.
11118732|NCT03943940|Other|Stand medicines|30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines.
11118733|NCT03943927|Experimental|Pharmacogenetic-guided metoprolol management|
11118734|NCT03943914|Experimental|"An early NIV strategy associated with HFNC-O2"|
11118735|NCT03943914|Active Comparator|"A late NIV strategy associated with COT"|
11118736|NCT03943901|Experimental|Split Dose R-CHOP|"Each cycle is 28 days and consists of one A treatment on Day 1 and one B treatment on Day 15 for 6 cycles
~Day 1 (A part of cycle)
~Rituximab 375 mg/m2 IV
~Cyclophosphamide 375 mg/m2 IV
~Doxorubicin 25 mg/m2 IV
~Vincristine 1 mg IV
~Prednisone 50 mg (Days 1-5) PO
~Pegfilgrastim 6 mg on Day 2 (24 hours after completion of chemotherapy) or filgrastim daily for a minimum of 7 days (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor.
~Day 15 (B part of cycle)
~Cyclophosphamide 375 mg/m2 IV
~Doxorubicin 25 mg/m2 IV
~Vincristine 1 mg IV
~Prednisone 50 mg (Days 15-19) PO
~Pegfilgrastim 6 mg on Day 16 (24 hours after completion of chemotherapy) or Filgrastim daily for a minimum of 7 days (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor."
11118737|NCT03943888|Experimental|Sugammadex 2mg|Administer 2mg/kg of sugammadex 15 minutes after rocuronium administration
11118738|NCT03943888|Experimental|Sugammadex 4mg|Administer 4mg/kg of sugammadex 15 minutes after rocuronium administration
11118739|NCT03943888|Experimental|Sugammadex 8mg|Administer 8mg/kg of sugammadex 15 minutes after rocuronium administration
11118740|NCT03943888|Active Comparator|Conventional reversal|Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) 15 minutes after rocuronium administration
11118741|NCT03943875|Active Comparator|Females, 3 dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
11118742|NCT03943875|Experimental|Females, 2 dose with delayed 3rd dose|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
11118743|NCT03943875|Active Comparator|Males, 3 dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
11118744|NCT03943875|Experimental|Males, 2 dose with delayed 3rd dose|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
11118745|NCT03943862|Experimental|Intervention (2Share) + treatment as usual|"Study participants randomized to the experimental group receive the intervention (2Share) while maintaining their current treatment (treatment as usual). 2Share is a peer-led group intervention containing three two-hour sessions within two weeks plus an additional booster session four weeks later.
~Fidelity to manual is rated in each session by study staff."
11118746|NCT03943862|No Intervention|Treatment as usual|Participants randomized to the control group do not receive the group program but maintain their current treatment (treatment as usual).
11118747|NCT03943849|Experimental|Particulate bone graft plus autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside. The isolated dental pulp will be mixed with hydrated particulate bone graft, and the mixture will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
11118748|NCT03943849|Active Comparator|Particulate bone graft|Hydrated particulate bone graft will be placed in the debrided extraction socket. The socket will be covered by a resorbable collagen membrane and sutured.
11118749|NCT03943836|Experimental|Music Group|
11118750|NCT03943836|No Intervention|No Music group|
11118751|NCT03943823|Active Comparator|Estrogen vaginal cream|
11118752|NCT03943823|Active Comparator|Trimo-San vaginal gel|
11118753|NCT03943797|Experimental|Cultivated oral mucosal epithelial cell transplantation|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
11118754|NCT03943784||Endoscopic Variceal Ligation|From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
11118755|NCT03943784||Propranolol Group|Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.
11118756|NCT03943771|Experimental|Virtual modelization group|Patients having their kidney modelized in three dimensions on a software
11118757|NCT03943771|Experimental|Printed modelization group|Patients having their kidney modelized and printed in three dimensions
11118758|NCT03943771|Sham Comparator|Control group|No kidney model
11118759|NCT03943758|Experimental|prepackaged Low-residue diet group|The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
11118760|NCT03943758|Active Comparator|self-prepared Low-residue group|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
11118761|NCT03943732|No Intervention|control|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays
11118832|NCT03943264|Experimental|3.0 mg/kg XPro1595|3.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
11118762|NCT03943732|Experimental|Intervention|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
11118763|NCT03943706||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
11118764|NCT03943706||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
11118765|NCT03943693|Active Comparator|Single Shock Group|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only.
11118766|NCT03943693|Active Comparator|Double Shock Group|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized.
11118767|NCT03943680|Experimental|PRGF|Post-extraction socket grafted with PRGF-Endoret
11118768|NCT03943680|Active Comparator|ABB|Post-extraction socket grafted with anorganic bovine bone (ABB)
11118769|NCT03943667|Experimental|GEMPAX|Gemcitabine + Paclitaxel until progression
11118770|NCT03943667|Active Comparator|Control|Gemcitabine alone until progression
11118771|NCT03943654||Children living within study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live within the mobile pharmacy delivery area will receive illness assessments and treatment recommendations over the phone. Immediately following calls a nurse will conduct household visits to complete in-person assessments of the children. Illness progression will be tracked with a 8-12 day follow up call. The phone and in-person assessments will be compared to evaluate safety and accuracy of the healthline.
11118772|NCT03943654||Children living outside study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live outside the delivery area will receive illness assessments and treatment recommendations over the phone. Illness progression will be tracked with a 8-12 day follow up call.
11118773|NCT03943654||Children who are identified as having danger signs|Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
11118774|NCT03943641||Population-based|Population-based cohort of participants registered with a SAIL-contributing practice.
11118775|NCT03943628|Experimental|Familias Unidas|Consists of eight parent group sessions and four family sessions with the adolescent.
11118776|NCT03943628|Other|Community Practice|Consists of community practice.
11118777|NCT03943602|Experimental|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
11118778|NCT03943589|Experimental|Imlifidase|"One (1) dose of imlifidase, 0.25 mg/kg, will be administered IV over 30 minutes, Day 1.
~IVIg, 0.4 g/kg, will be administered for 5 consecutive Days, starting on Day 3 at least 48 h after imlifidase administration."
11118779|NCT03943576|Experimental|GXCPC1|GXCPC1 contains 6.7×10^6 or 4×10^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL
11118780|NCT03943576|Active Comparator|hyaluronic acid|Hya Joint Plus synovial fluid supplement 3mL
11118781|NCT03943563|Other|single cohort|"There is only one cohort where each patient experiment the classic sequences as the standard of care and the DIXON sequences for the study."
11118782|NCT03943550|Experimental|RO7049665|Participants will receive a subcutaneous (SC) dose of RO7049665 every 2 weeks for 4 doses.
11118783|NCT03943550|Placebo Comparator|Placebo|Participants will receive a SC dose of matching placebo every 2 weeks for 4 doses.
11118784|NCT03943537|Experimental|Intranasal Insulin (40 IU)|40 IU Novolin-R insulin will be administered one time using the ViaNase intranasal delivery device.
11118785|NCT03943524|No Intervention|DrApp Without Interax-AI|There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
11118786|NCT03943524|Experimental|DrApp With Interax-AI|"There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (Interax-AI).
~Intervention: Device: Medication Interaction System of Dr App (Interax-AI)"
11118787|NCT03943511|Active Comparator|Group 1|Oral Antibiotics
11118788|NCT03943511|Active Comparator|Group 2|Standard of Care
11118789|NCT03943498|Experimental|Treatment (Fingolimod)|"Patients receive 0.5 mg dose of Fingolimod PO QD for 4 weeks.
~Take your Fingolimod approximately every 24 hours"
11118790|NCT03943485|Active Comparator|Uterien Manipulator Arm|Patients in this group will receive a uterine manipulator during abdominal hysterectomy.
11118791|NCT03943485|No Intervention|Control|Patients in this group will receive standard abdominal hysterectomy without adoption of a uterine manipulator.
11118792|NCT03943472|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA CAR-T cells to patients with multiple myeloma
11118793|NCT03943472|Experimental|anti-BCMA CAR-T+ Immune inhibitors|Administration of anti-BCMA CAR-T cells + Immune inhibitors to patients with multiple myeloma
11118794|NCT03943459|No Intervention|Control|20 Patients on placebo
11118795|NCT03943459|No Intervention|Atorvastatin|20 patients treated with atorvastatin 80 mg/day
11118796|NCT03943459|Experimental|Quercetin|20 patients treated with quercetin 500 mg/day
11118797|NCT03943446|Experimental|TAK-018 0.30 g Low Dose|TAK-018 3*0.10 gram (g), tablets, orally, twice daily (BID) for up to 26 weeks.
11118798|NCT03943446|Experimental|TAK-018 1.5 g High Dose|TAK-018 3*0.50 g, tablets, orally, BID for up to 26 weeks.
11118799|NCT03943446|Placebo Comparator|Placebo|TAK-018 placebo-matching 3*0 g tablets, orally, BID for up to 26 weeks.
11118800|NCT03943433|Active Comparator|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration at specific time points.
11118801|NCT03943433|Experimental|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration at specific time points.
11118802|NCT03943420||Experimental Group|Therapy A : Basic treatment + Qianyang Yuyin Granules
11118803|NCT03943420||Negative Control Group|Therapy B : Basic treatment
11118806|NCT03943407|Experimental|Zyclara/Doxepin|All subjects will be treated with the topical antihistamine cream (Prudoxin, containing 5% doxepin hydrochloride, Healthpoint, San Antonio, TX) or a placebo cream. After removal, subjects will be treated with Zyclara cream
11118807|NCT03943407|Experimental|Zyclara/Histamine/Cowage|All subjects will be treated with Zyclara cream, vehicle cream, histamine and cowhage
11118808|NCT03943407|Experimental|Zyclara/L-menthol/trans-cinnamaldehyde|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle. After removal, subjects will be treated with L/menthol and trans-cinnamaldehyde
11118809|NCT03943394||Denovo MDS/ AML|"Patients with de-novo myeloid neoplasm either myelodysplastic syndrome and/ or acute myeloid leukemia which are diagnosed by complete blood count , blood film, bone marrow aspirate, bone marrow biopsy , immunophenotyping and bone marrow biopsy with these inclusion criteria • Myelodysplastic syndromes: the diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy : blast count must be < 20%;
~• Acute myeloid leukemia with multilineage dysplasia: the diagnosis of AML-TLD must be confirmed by a bone marrow aspirate and/or biopsy NOTE: there must be evidence of >= 20% blasts on the review of the bone marrow aspirate and/or biopsy;"
11118810|NCT03943394||therapy related MDS/ AML|PCM1-JAK2 fusion gene detection in patients with therapy related Myelodysplastic syndrome / Acute myeloid leukemia patients
11118811|NCT03943368|Experimental|Experimental: Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11118812|NCT03943368|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11118813|NCT03943355||Nonoperative management protocol with angioembolization|The nonoperative management (NOM) protocol with angioembolization (AE) presents a trend in dealing with trauma patients with blunt splenic injury (BSI). This study was designed to explore the adverse events and associated risk factors before and after protocol-based NOM of BSI over a 12-year period.
11118814|NCT03943342|Experimental|Treatment (venetoclax, ibrutinib)|"OBSERVATION COHORT: Patients who are taking ibrutinib enter observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort.
~INTERVENTION COHORT: Patients receive venetoclax PO daily and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve MRD negative CR after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity."
11118815|NCT03943329|Active Comparator|Standard of Care|
11118816|NCT03943329|Experimental|Distal Targeting Treatment|
11118817|NCT03943303|Experimental|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. The natural gamma radiation doses of the monazite sands will be monitored, the radiation measurements gamma will be associated with the atmospheric and climatic measurements of each group. It is understood here as atmospheric measurements, level of solar radiation, spectrum of sunlight at the time of exposure, humidity, wind speed, ultraviolet radiation level, amount of ions present in the air and measurements of the magnetic field in the place.
11118818|NCT03943303|Placebo Comparator|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day. To ensure the absence of radiation, mesuaraments of possible radiation will be monitored.
11118819|NCT03943290|Experimental|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
11118820|NCT03943290|Experimental|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
11118821|NCT03943290|Experimental|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
11118822|NCT03943290|Experimental|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
11118823|NCT03943290|Experimental|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
11118824|NCT03943290|Experimental|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
11118825|NCT03943290|Experimental|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
11118826|NCT03943290|Experimental|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
11118827|NCT03943290|Experimental|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
11118828|NCT03943277||patient with infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:
~A group with an inflammatory syndrome and infection; infection being defined as:
~Viral infection confirmed by nasopharynx swab for: influenza, RSV, parainfluenza, rhinovirusses, coronavirusses.
~Bacterial infection confirmed with positive blood culture, positive articular punction, positive expectorations, pneumonia on chest radiograph, or infection documented by abdominal imagery (CT or echo), a positive urine culture with a confirmed pyelonephritis with a renal echography or a DMSA scintigraphy or specific clinical symptoms for pyelonephritis and positive hemoculture. A positive urine culture alone is not considered as urine infection because of the high prevalence of asymptomatic bacteriuria in geriatric patients."
11118829|NCT03943277||patient without infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:
~=> B) A group with inflammatory syndrome and inflammatory diseases without infection: defined as:
~Confirmed pulmonary embolism (PE) by CT or ventilation-perfusion scintigraphy
~Microcrystalline arthritis diagnosed by articular punction
~Crush syndrome or rhabdomyolyses defined by history of a fall and raised creatine kinase in blood sample."
11118830|NCT03943264|Experimental|0.3 mg/kg XPro1595|0.3 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
11118831|NCT03943264|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
11118833|NCT03943251|Experimental|HEC113995PA•H2O tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
11118834|NCT03943251|Placebo Comparator|placebo tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
11118835|NCT03943238|Experimental|Combined kidney/stem cell transplants and recipient's Tregs|Preparatory regimen including TLI, ATG after kidney transplantation followed by infusion of donor CD34+, T cell and recipient Tregs
11118836|NCT03943212|Experimental|Blood Flow Rate Reduction|Participants will have their hemodialysis blood flow rate reduced on their regular schedule.
11118837|NCT03943212|Sham Comparator|Control|Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.
11118838|NCT03943199|Active Comparator|Metamizole sodium|1 gram intravenous, will be diluted in 0.9% physiological solution of 100 ml, applied for 30 minutes
11118839|NCT03943199|Active Comparator|Ketorolac|60 milligrams intravenously, it will be added to 20 ml with 0.9% physiological solution, it will be applied for 5 minutes
11118840|NCT03943199|Active Comparator|Lysine Clonixinate|100 milligram intravenously, diluted in 5% glucose solution of 100 ml, applied for 30 minutes
11118841|NCT03943199|Placebo Comparator|Placebo|20 milliliters of 0.9% physiological solution, will be applied for 5 minutes.
11118842|NCT03943186||Ectoin Lozenges Honey Lemon|application of 1 Lozenge every three hours or as often as required, not more than 10 lozenges per day
11118843|NCT03943186||Hyaluronic acid/Icelandic moss Lozenges|application as often as required, not more than 6 lozenges per day
11118844|NCT03943173|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After treatment, patients either undergo surgery then receive standard chemotherapy for up to 4 cycles or receive standard chemotherapy within 14 days for up to 4 cycles then undergo surgery in the absence of disease progression or unacceptable toxicity at the discretion of the treating physician.
11118845|NCT03943147|Experimental|Dose 1|Specified Dose on Specified Days
11118846|NCT03943147|Experimental|Dose 2|Specified Dose on Specified Days
11118847|NCT03943147|Placebo Comparator|Placebo|Specified Dose on Specified Days
11118848|NCT03943134||Avive® Soft Tissue Membrane|Subjects with utilization of Avive® Soft Tissue Membrane on an impacted but intact nerve during a surgical procedure for one of the following targeted acute upper extremity traumas (selected injuries): Spaghetti Wrist, Distal Radius Fracture, Medial Epicondyle Fracture, Flexor Tenolysis at Wrist, and Ballistic Injuries in the Forearm and/or Hand.
11118849|NCT03943134||Standard Surgical Procedures - Control Arm|Subjects who have undergone surgical procedures for the same selected injuries, but without placement of a surgical implant on an impacted but intact nerve.
11118850|NCT03943121|Experimental|Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. Steroid-eluting stent were implanted in one side of ethmoid sinus and frontal sinus randomly.
11118851|NCT03943121|Sham Comparator|Without Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. The side without the stent is defined as the control side.
11118852|NCT03943108||Obese teenagers within the PAIDOS clinic|Obese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
11118853|NCT03943108||Healthy children|Healthy children living in Mexico City, Mexico.
11118854|NCT03943108||Children with Type 2 Diabetes|Chjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
11118855|NCT03943095|Experimental|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million [ppm] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
11118856|NCT03943095|Active Comparator|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
11118857|NCT03943082|Active Comparator|Cohort A : Usual Care (FRP Only)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent.
11118858|NCT03943082|Experimental|Cohort A: Usual Care + Intervention (FRP + Follow-up)|Patients or parents/legal guardians of patients receive FRP brochure at the time of iMPACT consent and a follow-up phone call on day 3 after iMPACT consent.
11118859|NCT03943082|Experimental|Cohort B: Non-Randomized|Patients or parents/legal guardians of patients currently enrolled in a cancer therapeutic clinical trial (TCT) or who recently completed a TCT within 90 days, and were offered, received, or are receiving benefits from the Lazarex FRP will be asked to complete assessments for exploratory endpoints.
11118860|NCT03943069|Experimental|Patient with PSP|Patient who will be admitted with primary spontaneous pneumothorax.
11118861|NCT03943056|Experimental|Single Ascending Dose (SAD): Cohort 1A|Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
11118862|NCT03943056|Experimental|(SAD): Cohort 2A|Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
11118863|NCT03943056|Experimental|(SAD): Cohort 3A|Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
11118864|NCT03943056|Experimental|(SAD): Cohort 4A|Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
11118865|NCT03943056|Experimental|(SAD): Cohort 5A|Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
11118866|NCT03943056|Experimental|Multiple Ascending Dose (MAD): Cohort 1B|Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
11118867|NCT03943056|Experimental|(MAD): Cohort 2B|Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
11118868|NCT03943056|Experimental|(MAD): Cohort 3B|Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
11118869|NCT03943043|Experimental|gemcitabine oxaliplatin nab-paclitaxel|combination at different dose of gemcitabine, oxaliplatin and nab-paclitaxel
11118870|NCT03943030|Experimental|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
11118871|NCT03943030|No Intervention|Group control|The group will not receive pulmonary rehabilitation intervention. Patients will be guided and maintain their daily and routine lives normally during the evaluation process. However, a baseline evaluation will be performed, which will be repeated after 9 weeks: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes commonly used in the assistance to assess PR will also be measured.
11118872|NCT03943004|Experimental|DFP-14927|DFP-14927: weekly IV infusion, 28 day treatment cycle
11118873|NCT03942991|Active Comparator|2% Mepecaine-L|infiltration injection of 2% Mepivacaine
11118874|NCT03942991|Experimental|4% Artpharmadent|infiltration injection of 4% Articaine
11118875|NCT03942978|Active Comparator|Longitudinal Equity Action Plan (LEAP)|Heart failure patients admitted with a principal diagnosis of heart failure to general medicine service and admitted to a general medicine pod that is randomized to the intervention arm.
11118876|NCT03942978|No Intervention|Standard Care|Heart Failure patients admitted to a general medicine pod at our institution, which is not randomized to intervention arm. Patients will be treated for their heart failure as per standard of care while admitted to the hospital.
11118877|NCT03942952||CNS demyelinating diagnosis|"Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody.
~3T and 7T MRI
~Neuropsychological testing
~Optical Coherence Tomography
~Questionnaires: Quality of Life and Behavior scales
~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year later"
11118878|NCT03942952||Healthy Control|"3T and 7T MRI
~Neuropsychological testing
~Optical Coherence Tomography
~Questionnaires: Quality of Life and Behavior scales
~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year later"
11118879|NCT03942939|Experimental|A - TKA with short tourniquet time|50 arms: subjects will receive a tourniquet with a short tourniquet time during TKA surgery. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
11118880|NCT03942939|Active Comparator|B - TKA with tourniquet|50 arms: subjects will receive a tourniquet during TKA surgery.
11118881|NCT03942926|Experimental|Sirolimus|Patients in sirolimus group will receive sirolimus for 6 months.
11118882|NCT03942913||dual therapy|including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC.
11118883|NCT03942913||triple therapy|"including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC.
~In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran."
11118884|NCT03942900||Cohort LAND|Patients enrolled in OPTIMANAL clinical trial
11118885|NCT03942887|Active Comparator|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg.
11118886|NCT03942887|Active Comparator|Rituximab plus low-dose cyclophosphamide|5.1.2. Cyclophosphamide Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
11118887|NCT03942874|Experimental|Treatment|Participants will complete baseline sessions and then complete treatment right away.
11118888|NCT03942874|Experimental|Waitlist Control|Participants will complete a baseline session and then wait for 10 weeks before starting treatment.
11118889|NCT03942861||Severe Ulcerative Colitis|Consecutive patients admitted as in-patients to the Department of Gastroenterology at four University Hospitals in Denmark, with acute severe UC defined as an affirmed diagnosis of UC according to well established criteria, combined with a Mayo score of 8 or more (i.e. severe disease activity) and the need for intravenous corticosteroid treatment will be screened for participation in the study after informed consent.
11118890|NCT03942848|Experimental|intrathecal Ziconotide followed by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
11118891|NCT03942848|Placebo Comparator|intrathecal Ziconotide preceded by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
11118892|NCT03942835|Experimental|Healthy participants aged from 6 to 90 year-old|
11118893|NCT03942835|Experimental|patients with ADHD with no treatment|patients with ADHD aged from 6 to 90 year-old with no treatment
11118894|NCT03942835|Experimental|patients with ADHD with treatment|patients with ADHD aged from 6 to 90 year-old with psychostimulant treatment (Methylphenidate)
11118895|NCT03942822|Experimental|Chia supplemented group|8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
11118896|NCT03942809|Experimental|Effectiveness|Evaluate the Effectiveness in insertion success, insertion times, influence of respiratory, cardiac and cerebral circulation
11118897|NCT03942796|Active Comparator|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin
11118898|NCT03942796|Active Comparator|pulsed radiofrequency ablation of the dorsal root ganglion und|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion
11118899|NCT03942783|Active Comparator|Control Group|"The control group will receive a written work self-help information pack plus usual care. The pack includes published arthritis patient information booklets about work; a decision-tree flowchart; information about the UK Equality Act. The self-help information pack is mailed to the participants by the CTU following randomisation.
~Usual care consists of: prescribed medication; attending Rheumatology clinics; referral to rehabilitation, as and when deemed necessary from the Rheumatology clinic, but not including work advice. Any rehabilitation required will be provided as normal, e.g. provision of exercise, self-management education, activities of daily living advice, psychosocial support."
11118900|NCT03942783|Experimental|WORKWELL Group|The same as the Control Group (i.e. self-help information pack, plus usual care) PLUS the WORKWELL intervention. This consists of, on average, 4.5 hours contact, including: a structured work assessment; identification of work-related barriers and priority problems; collaborative treatment planning with the participant; a range of self-management, work advice and job modifications appropriate to the individual participant's problems; goal setting and action planning; and a 30 minute telephone review to identify progress with goals at the end of treatment.
11118901|NCT03942770|Active Comparator|Active Comparator: Group A (Intensive incentives)|"Group A will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will also have the opportunity to earn more incentives for providing negative results. For the first 3 weeks, these additional incentives will scale based on the number of consecutive days of sustained negative samples. For the remaining weeks incentives will be based on a randomized prize drawing."
11118902|NCT03942770|Active Comparator|Active Comparator: Group B (Prize-based incentives)|"Group B will have the opportunity to earn payments based on the results of their breathalyzer screens. Participants will receive a compliance incentive per submitted sample regardless of the results, but will only have the opportunity to earn more incentives based on a randomized prize drawing if they submit a negative sample."
11118903|NCT03942770|Sham Comparator|Sham Comparator: Group C (Intensive incentives)|Group C serves as a direct control group to Group A and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
11118904|NCT03942770|Sham Comparator|Sham Comparator: Group D (Price-based incentives)|Group D serves as a direct control group to Group B and will follow the same incentive procedures, however participants will receive incentives regardless of the results of their samples.
11118905|NCT03942770|No Intervention|No Intervention: Group E (no incentives)|Group E will have no monitoring intervention, they will only complete assessment sessions.
11118906|NCT03942757||observation before educational program|100 preterm infant medical records will be studied in a first part of this observational study
11118907|NCT03942757||Observation after educational program|An educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
11118908|NCT03942744|No Intervention|high-flux hemodialysis|high-flux hemodialysis cut-off membrane above 50
11118909|NCT03942744|Active Comparator|on-line hemodiafiltration|postdilutional on-line hemodiafiltration with a convective transport above 21 liters
11118910|NCT03942731||Experimental|83 adult outpatients at CHR Metz-Thionville with penicillin allergy label
11118911|NCT03942718|No Intervention|Control group|Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.
11118912|NCT03942718|Experimental|Aerobic exercise group|Participants will obtain aerobic exercise only.
11118913|NCT03942718|Experimental|Anaerobic exercise group|Participants will obtain aerobic and anaerobic exercise respectively
11118914|NCT03942705||Kenyan Women|Women living in western Kenya will be asked to complete a self collected vaginal sample for HPV DNA screening and asked to undergo a second screening by VIA. As per Kenyan standard of care, vaccination against HPV will be offered to children/grandchildren (boys and girls) of women, and to the women themselves if age 26 or younger. The second vaccine dose (for children ages 9 through 14) and third doses (for children and adult women ages 15 through 26) will be administered at subsequent visits. There will be no requirement for HPV vaccination (of children or mothers up to 26 years of age) for participation in the study. Results of the screening will be returned to participants and they will be referred to receive standard care as applicable.
11118915|NCT03942692||Children with anaphylactic reaction|Children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in Paediatric Emergency Department of Femme-Mère-Enfant Hospital in Lyon in France.
11118916|NCT03942679|Other|PRPinjection group|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 201
11118917|NCT03942679|Other|physiotherapy group|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks
11118918|NCT03942666|Experimental|Treatment A|Single administration of CHF 6532 Dose #1
11118919|NCT03942666|Experimental|Treatment B|Single administration of CHF 6532 Dose #2
11118920|NCT03942666|Experimental|Treatment C|Single administration of CHF 6532 Dose #3
11118921|NCT03942666|Experimental|Treatment D|Single administration of CHF 6532 Dose #4
11118922|NCT03942666|Placebo Comparator|Treatment E|Single administration of CHF 6532 Placebo
11118923|NCT03942666|Other|Treatment F|Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.
11118924|NCT03942653|Experimental|Goserelin Acetate + Pembrolizumab|Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV
11119009|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Tablet|LY3154207 tablet (test) administered orally, once.
11118925|NCT03942640|Other|perineural injection group|"perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years
~Buffered glucose preparation :
~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.
~Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :
~Suprascapular nerve.."
11118926|NCT03942640|Other|deepprolotherapy group|Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
11118927|NCT03942627|Experimental|Mindfulness Program|The intervention consists of an introductory video in which a mindfulness expert explains the program's approach and models practices to increase women's comfort with the material, four audio-recorded mindfulness practices for mothers' use when the baby is in the NICU, each available in 5- and 10-minute versions, and a brief video and four additional audio mindfulness practices (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
11118928|NCT03942627|Placebo Comparator|Infant Health Education Program|The intervention consists of an introductory video explaining the program's approach, four audio recordings providing education about infant health and development, each available in 5- and 10-minute versions, and a brief video and four additional educational recordings (each available in briefer and longer versions) for use by mothers during and following the transition home with the baby.
11118929|NCT03942614|Experimental|Nordic pole walking|walking with a pair of poles customized to an individual's height and stride length
11118930|NCT03942614|No Intervention|Control|usual daily routine and activities of daily living
11118931|NCT03942601|Active Comparator|Group 1 - temsirolimus injection|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
11118932|NCT03942601|Active Comparator|Group 2 - temsirolimus and dexamethasone injection|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
11118933|NCT03942588|Experimental|High-intensity interval training|Twice-weekly supervised high-intensity interval treadmill training in a laboratory setting for 10 weeks.
11118934|NCT03942588|No Intervention|Control|Usual activities for 10 weeks
11118935|NCT03942575|No Intervention|No negative pressure wound therapy|Historical cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage and where negative wound pressure therapy has been omitted
11118936|NCT03942575|Experimental|Negative pressure wound therapy|Prospective cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage with negative wound pressure therapy
11118937|NCT03942549||MUS Cohort|This cohort will undergo midurethral sling placement.
11118938|NCT03942536||MNH Emergency Cohort|Participants will be either patients who have experienced a critical pregnancy-related, obstetric, or neonatal health emergency.
11118939|NCT03942536||Birth Planning cohort|Pregnant women who complete an initial Birth Plan through the HN program within Mfangano Island East and South Sub-locations.
11118940|NCT03942523|Experimental|School Children|School children will be administered with behavioral change communication sessions as an intervention
11118941|NCT03942510|Experimental|High intensity eccentric training|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
11118942|NCT03942510|Experimental|High intensity eccentric training with blood flow restriction|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week.
11118943|NCT03942510|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
11118944|NCT03942510|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week.
11118945|NCT03942484|Experimental|Treatment Group|Treatment with the investigational device - rPMS
11118946|NCT03942471|Other|Intervention Mindfulness Based Stress Reduction|Six Modules each delivering an important principle of Mindfulness Based Stress Reduction
11118947|NCT03942471|No Intervention|Control Group|Wait Group - received no mindfulness teaching
11118948|NCT03942458|Experimental|Vicagrel|Vicagrel 24mg loading followed by 6mg/day for 6 days
11118949|NCT03942458|Active Comparator|Clopidogrel|Clopidogrel 300mg loading followed by 75mg/day for 6 days
11118950|NCT03942445|Experimental|Control patients|
11118951|NCT03942445|Experimental|Chronic ischemia|
11118952|NCT03942445|Experimental|Acute ischemia|
11118953|NCT03942432|Experimental|Patients with dysmetabolic iron overload syndrome|
11118954|NCT03942419|Experimental|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
11118955|NCT03942419|Experimental|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
11118956|NCT03942419|Placebo Comparator|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
11118957|NCT03942406|Experimental|BPZE1 Intranasal Prime, BPZE1 Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
11118958|NCT03942406|Experimental|BPZE1 Intranasal Prime, Placebo Boost|Individual will receive an intranasal dose of BPZE1 via the VaxINator atomization device and a dose of intramuscular (I.M.) placebo. Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
11118959|NCT03942406|Experimental|Boostrix IM Prime, BPZE1 Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal BPZE1 via the VaxINator™ atomization device.
11118960|NCT03942406|Active Comparator|Boostrix IM Prime, Placebo Boost|Individual will receive an intranasal dose of placebo via the VaxINator atomization device and a dose of intramuscular (I.M.) Boostrix (aP vaccine comparator). Individuals will receive a boost dose of intranasal placebo via the VaxINator™ atomization device.
11118961|NCT03942380|Other|Cell-free tumor DNA|The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
11118962|NCT03942380|Other|Identifying recurrence|The aim is to identify recurrence through serial monitoring patients with blood samples.
11118963|NCT03942367|Experimental|Group A (Active Device Group)|Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient.
11118964|NCT03942367|Sham Comparator|Group B (Sham Device Group)|Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient.
11118965|NCT03942354|Experimental|Intervention arm|A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.
11118966|NCT03942354|Active Comparator|Standard therapy|72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.
11118967|NCT03942341||Adult subjects with Down syndrome and Alzheimer Disease|"Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS.
~All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity."
11118968|NCT03942328|Experimental|Treatment (EBRT, autologous dendritic cells, Prevnar)|Patients undergo standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8, and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
11118969|NCT03942315||Liver transplant in Hereditary Hemorrhagic Telangiectasia|Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
11118970|NCT03942289|Experimental|Healthy controls|
11118971|NCT03942289|Experimental|Parkinson disease|
11118972|NCT03942276|Placebo Comparator|Control|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
11118973|NCT03942276|Experimental|Alternative training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
11118974|NCT03942276|Experimental|Conventional training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training
11118975|NCT03942263||Newly Diagnosed and RR cHL Participants|Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
11118976|NCT03942263||Newly Diagnosed and RR sALCL Participants|Participants diagnosed with RR sALCL at the time of enrollment and RR sALCL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed sALCL, or RR sALCL at the time of enrolment, or RR sALCL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
11118977|NCT03942250|Experimental|Treated|Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks
11118978|NCT03942237|Experimental|single-injection QLB (quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
11118979|NCT03942237|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
11118980|NCT03942224|Experimental|Arm I (DId)|"INDUCTION: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2 and on days 1 and 15 of cycles 3-8, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.
~MAINTENANCE: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
11119010|NCT03942029|Experimental|Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole|LY3154207 (dose 1) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
11119011|NCT03942029|Experimental|Cohort 1 Part B - Placebo + Fluconazole|Placebo administered alone, orally, once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
11119012|NCT03942029|Experimental|Cohort 2 - LY3154207 (Dose 2) + Fluconazole|LY3154207 (dose 2) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
11119157|NCT03941002|Placebo Comparator|Clinical pressure support|The level of inspiratory pressure support will be selected by the attending physician
11118981|NCT03942224|Experimental|Arm II (DVd, DId)|"INDUCTION CYCLES 1-3: Patients receive dexamethasone IV and PO on days 1, 8, and 15, daratumumab IV on days 1, 8, and 15, and bortezomib subcutaneously (SC) on days 1, 4, 8, and 11. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
~INDUCTION CYCLES 4-8: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1 and 15, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.
~MAINTENANCE: Patients receive dexamethasone IV on day 1, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
11118982|NCT03942211|Experimental|Selexipag 200 micro gram (μg)|Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) bid/qd. Dosing frequency will be bid, except for participants with moderate hepatic impairment (Child-Pugh B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention qd. The dose will be up-titrated by the investigator/delegate in 200 μg bid/qd increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg bid/qd.
11118983|NCT03942211|Placebo Comparator|Placebo|The comparator will be administered similarly to the experimental intervention.
11118984|NCT03942198|Experimental|Oral Chinese medicine|Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
11118985|NCT03942198|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
11118986|NCT03942185|Experimental|Psoriasis with Blood heat syndrome group|Participants in Psoriasis with Blood heat syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Clearing heat and Cooling blood, such as Cool blood detoxification Decoction I，Cool blood and activating blood prescription compound, Cool blood detoxification Decoction II, Cool blood activating blood Decoction, Tufu drink, Xiaoyin Decoction and etc., two times per day for 8 weeks.
11118987|NCT03942185|Experimental|Psoriasis with Blood stasis syndrome group|Participants in Psoriasis with Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Promoting blood circulation and Removing blood stasis, such as Huoxue Sanyu Xiaoyin Decoction, Cool blood detoxification Decoction III and etc., two times per day for 8 weeks.
11118988|NCT03942185|Experimental|Psoriasis with Non-Blood heat or Blood stasis syndrome group|Participants in Psoriasis with Non-Blood heat or Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of syndrome differentiation therapy two times per day for 8 weeks.
11118989|NCT03942185|No Intervention|Healthy control group|No Intervention.
11118990|NCT03942172|Experimental|SpotOn Balance|SpotOn Balance Glasses
11118991|NCT03942159||Donors|HLA-matched or haploidentical nursing relative donors
11118992|NCT03942159||Patients|recipients of allogeneic HSCT
11118993|NCT03942146|No Intervention|Control group|No information on smoking cessation
11118994|NCT03942146|Active Comparator|Written information, GynOp|"When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
11118995|NCT03942146|Active Comparator|Doctor informed|"The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation"
11118996|NCT03942146|Active Comparator|Written information, GynOp + doctor informed|A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
11118997|NCT03942133|Experimental|entrance placement of adductor canal catheter|
11118998|NCT03942133|Experimental|middle point placement of adductor canal catheter|
11118999|NCT03942120||Participants with Crohn's Disease|Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.
11119000|NCT03942107|Active Comparator|Group 1: RCT+post+core in 1 visit|the root canal treatment will be completed with 2Shape NiTi system as well as post and core application in the same visit prior to postoperative pain evaluation.
11119001|NCT03942107|Active Comparator|Group 2: after RCT, post and core in 2nd visit|after root canal treatment conducted with 2Shape NiTi system, the postoperative pain evaluation will be completed prior applying post and core for coronal restoration.
11119002|NCT03942094|Experimental|Nilotinib|
11119003|NCT03942081|Experimental|Ulcer Measurement and Photo Group|Diabetic patients with foot ulcers being seen in clinic.
11119004|NCT03942068|Experimental|albumin-bound paclitaxel+apatinib|albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po
11119005|NCT03942055||B-line score ≥7|"Patients with B-line score ≥7 at the end of the surgical procedure.
~The Sonosite Edge II Ultrasound device will be used.
~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
11119006|NCT03942055||B-line score <7|"Patients with B-line score <7 at the end of the surgical procedure.
~The Sonosite Edge II Ultrasound device will be used.
~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
11119007|NCT03942042|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC).
11119008|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Capsule|LY3154207 capsule (reference) administered orally, once.
11119050|NCT03941795|Active Comparator|Axitinib alone|
11119013|NCT03942029|Experimental|Cohort 2 - Placebo + Fluconazole|Placebo administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
11119014|NCT03942029|Experimental|Cohort 3 - LY3154207 + Fluconazole|LY3154207 (dose 2) administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
11119015|NCT03942029|Experimental|Cohort 3 - Placebo + Fluconazole|Placebo administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
11119016|NCT03942003|Experimental|Rhomboid|When applying the Rhomboid nerve block, the patient is tilted to the side position so that the corresponding breast is at the top. After T7 up to T10 sterile preparation of the C7 spinous projection, the convex probe shows a rhomboid muscle at the level of T5 and block is applied with 0.25% bupivacaine (20 cc), 2% lidocaine (10 cc) and 10 cc SF mixture.
11119017|NCT03942003|Experimental|Pectoral|The PEC I field block is performed by administering 10 cc of local anesthetic between the pectoralis minor and the major at the 2nd costal position. PEC II field block is performed using linear USG probe visibly in 3rd and 4th ribs while the patient is in supine position. In this block, a total of 20 cc 0.25% bupivacaine (10 cc), 2% lidocaine (5 cc) and 5 cc SF mixture were used to block the area between the pectoralis minor muscle and the serratus muscle
11119018|NCT03942003|Sham Comparator|Control|Infiltration analgesia was performed.
11119019|NCT03941990|Experimental|Nitrous oxyde|will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)
11119020|NCT03941990|Placebo Comparator|Placebo|will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)
11119021|NCT03941977|Experimental|Surgery|Group evaluated with MRI and submitted to the percutaneous introduction of cannula for bone grafting
11119022|NCT03941964|Experimental|Ventoclax + azacitidine or decitabine|Venetoclax (daily for 28 days), in combination with azacitidine or decitabine, beginning on Cycle 1 Day 1. Depending on investigator's choice, participants will receive either azacitidine for 7 days beginning on Day 1 of each 28-day cycle or decitabine for 5 days beginning on Day 1 of each 28-day cycle, as per institutional practice.
11119023|NCT03941951|No Intervention|Pre-intervention Cohort|Cohort of patients who have received either empirical or targeted treatment with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2016 to December 2019 will be included.
11119024|NCT03941951|Other|Intervention cohort|Cohort of patients with complex infections treated with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2010 to June 2021.
11119025|NCT03941951|No Intervention|Safety cohort|Cohort of patients with bacteremia due to carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, carbapenem-resistant enterobacteria, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus occurred in participating hospitals from 2017 to 2021 will be collected.
11119026|NCT03941938|Experimental|Cyanoacrylate|the anastomotic reinforcement with nebulized cyanoacrylate glue using the special short catheter device for open surgery or the laparoscopic catheter.
11119027|NCT03941938|Active Comparator|No reinforcement|No reinforcement will be applied on the anastomosis line
11119028|NCT03941925|Experimental|Prebiotic fructans|Prebiotic fructans. Prebiotic will be mixed into foods or drinks and consumed twice daily.
11119029|NCT03941925|Placebo Comparator|Maltodextrin|Maltodextrin. Maltodextrin will be mixed into foods or drinks and consumed twice daily.
11119030|NCT03941899|Other|QLB II|Quadratus Lomborum Blocck II type will be performed before robot-assisted laparoscopic radical prostatectomy
11119031|NCT03941886|No Intervention|Non-intervention group|Participants receive routine prenatal care
11119032|NCT03941886|Experimental|Intervention group|Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.
11119033|NCT03941873|Experimental|Sitravatinib monotherapy|Two dose levels of sitravatinib as monotherapy, 80 mg once daily and 120 mg once daily, will be evaluated in participants with unresectable locally advanced or metastatic HCC or G/GEJ cancer. A modified 3+3 design will be used in the dose escalation to confirm recommended Phase 2 dose (RP2D)
11119034|NCT03941873|Experimental|Sitravatinib plus Tislelizumab|The combination dose escalation of sitravatinib (80 mg once daily and 120 mg once daily; modified 3+3 design) with tislelizumab (200 mg every 3 weeks, in both cohorts) will be evaluated in unresectable locally advanced or metastatic HCC or G/GEJ cancer participants . If the combination dose of 80 mg sitravatinib and 200 mg tislelizumab has been declared tolerable, the dose of sitravatinib will be escalated to 120 mg and tislelizumab will remain fixed at 200 mg. Approximately 12 to 24 evaluable participants will be treated. The dose of tislelizumab during dose escalation for the combination will be kept fixed at 200 mg
11119035|NCT03941873|Experimental|Anti-PD-1/PD-L1 Antibody Naïve or R/R HCC (Monotherapy)|
11119036|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive HCC(Combination)|
11119037|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant HCC|
11119038|NCT03941873|Experimental|Anti-PD-1/PD-L1 antibody naive G/GEJ cancer|
11119039|NCT03941860|Experimental|Arm A (lenalidomide, ixazomib citrate)|Patients receive lenalidomide PO QD on days 1-21 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11119040|NCT03941860|Active Comparator|Arm B (lenalidomide, placebo)|Patients receive lenalidomide PO QD on days 1-21 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11119041|NCT03941847|Experimental|music|The experimental group will benefit from musical listening during a classic period of induction of anesthesia
11119042|NCT03941847|No Intervention|silence|The control group will have a usual care.
11119043|NCT03941834|Active Comparator|BHV3000|
11119044|NCT03941834|Placebo Comparator|Placebo|
11119045|NCT03941821||G/P treatment|Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment
11119046|NCT03941808|Experimental|Drug|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
11119047|NCT03941808|Placebo Comparator|Placebo|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
11119048|NCT03941795|Experimental|JS001(Toripalimab Injection) Combined With Axitinib|
11119049|NCT03941795|Experimental|JS001 alone|
11119051|NCT03941769|Experimental|Supportive care (recombinant interleukin-7)|Within 60-180 days after CBT, patients receive recombinant interleukin-7 IM or SC once per week for 3 weeks.
11119052|NCT03941756|Experimental|Group I (LVB)|Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.
11119053|NCT03941756|No Intervention|Group II (no intervention)|Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.
11119054|NCT03941743|Experimental|Prevention (fingolimod hydrochloride)|Patients receive fingolimod hydrochloride PO QD starting the day before chemotherapy, the day of chemotherapy, and 1 day after chemotherapy for 12 weeks.
11119055|NCT03941730|Experimental|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11119056|NCT03941717|Experimental|Mindfulness-Based Condition|Parents and children in the mindfulness intervention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of a mindfulness activity. There is a parent and child version of the mindfulness intervention. Both scripts were developed by Siegel and Bryson (2011), and include a parent and child version of a mindfulness activity targeting worries and anxiety. Adjustments to the child script were informed by the work of Petter and colleagues (2013). Adjustments to the parent script were informed by the work of Garland and colleagues (2015). This activity will last 5-minutes.
11119057|NCT03941717|Sham Comparator|Unfocused attention Condition|Parents and children in the unfocused attention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of an unfocused attention activity. There is a parent and child version of this activity. The parent version has been validated in other research with healthy adults as a control for a mindfulness intervention (Garland, Hanley, Farb, & Froeliger, 2015). This script was condensed in time from the original reading. The child version of the activity was developed for the current study, and was adapted from a mind-wandering script used for children aged 7-12 in past research (Spann, 2016). It was also informed by the unfocused attention script used for parents (Garland, Hanley, Farb, & Froeliger, 2015), and work by Cahn and Polich (2009). This activity will last 5-mintues.
11119058|NCT03941704|Experimental|Low Glycemic Index|Pulse-based diet
11119059|NCT03941704|Active Comparator|Moderate Glycemic Index|Regular diet
11119060|NCT03941691|Experimental|Treatment Group|Experimental group is allocated to use novel fully degradable ventricular septal defect closure system manufactured by Shanghai shape memory alloy materials co. LTD.
11119061|NCT03941691|Active Comparator|Control Group|Control Group is allocated to use Interposition conveying device for ventricular septal defect closure produced by Shanghai shape memory alloy material co. LTD.
11119062|NCT03941678|Experimental|Creatine|0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
11119063|NCT03941678|Placebo Comparator|Placebo|0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
11119064|NCT03941665|Experimental|Gelronate|Tested new medical device
11119065|NCT03941665|Active Comparator|Aloevera|Current product used by the medical center
11119066|NCT03941652||Women with gestational diabetes without a prior GDM|The investigators will evaluate the usability of the sensors and define what features the application should have and how the data should be presented to the users. Participants (n=up to 10) use the sensors for one week and fill out logbooks for physical activity, sleep and diet. Participants fill questionnaires before and after the usage period, and take part in semi-structured interview.
11119067|NCT03941652||Women with gestational diabetes with or without a prior GDM|The investigators define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. GDM women (n=up to 10) will use the available version of the application for one week, and afterward the participants with GDM will take part in semi-structured interview.
11119068|NCT03941652||General pregnant women|The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week.
11119069|NCT03941626|Experimental|CAR-T/TCR-T cells immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
11119070|NCT03941613|Experimental|Anterior temporal lobectomy|surgical treatment for mTLE
11119071|NCT03941613|Active Comparator|SEEG guided RF-TC|SEEG recording and minimal invasive treatment for mTLE
11119072|NCT03941600|Active Comparator|Community-based Exercise Intervention group (CBEI)|A group performing a 12-week guided exercise program at an accessible community health and wellness center
11119073|NCT03941600|Placebo Comparator|Exercise Education Control group (EEG)|A group receiving educational information about physical activity and exercise at home and then self-direction a 12-week exercise program on their own.
11119074|NCT03941587|Active Comparator|Brolucizumab Monotherapy|Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with a dose of 6mg/ 0.05ml of Brolucizumab through an intravitreal injection, at baseline. A minimum of 1 injection(baseline) followed by PRN with minimum retreatment interval of 4 weeks ( from Baseline to week 8) and then minimum of 8 weeks retreatment thereafter ( week 12-52). Primary endpoint at week 52. At each visit, subjects will be assessed based on BCVA, opthalmic examination, Optical Coherence Tomography (OCT) and Optical Coherence Tomography-Angiography (OCT-A).
11119075|NCT03941587|Active Comparator|Aflibercept Monotherapy|Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with a dose of Aflibercept 2mg/0.05ml through an intravitreal injection,at baseline. A minimum of 1 injection(baseline) followed by Pro re nata (PRN) with minimum retreatment interval of 4 weeks ( from baseline to week 8) and then a minimum of 8 weeks retreatment thereafter ( week 12-52). Primary endpoint at week 52. At each visit, subjects will be assessed based on Best Corrected Visual Acuity (BCVA), opthalmic examination, Optical Coherence Tomography (OCT) and Optical Coherence Tomography-Angiography (OCT-A).
11119076|NCT03941574|Experimental|HLX10|
11119077|NCT03941561|Experimental|S-1 for 9 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 9 months after D2 resection
11119078|NCT03941561|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
11119081|NCT03941535|Experimental|Decreasing Daily Dose of Vitamin K|"This group of patients will receive a decreasing dose of Vitamin K IV:
~Days 1-2 = 10mg/day (standard of care) Days 3-4 = 5mg/day Days 5-90 (or date of discharge, death, etc) = 2mg/day"
11119082|NCT03941535|Active Comparator|Standard of Care Dose of Vitamin K|This group of patients will be reviewed retrospectively and would have received Vitamin K IV at 10mg/day during their entire hospital course
11119083|NCT03941522|Experimental|Intervention group (23-hour stay)|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
11119084|NCT03941522|No Intervention|Control group (conventional hospitalization)|Patients randomized to the group conventional hospitalization will be hospitalized as per the current conventional care after ileostomy closure.
11119085|NCT03941509|No Intervention|Control|All facilities will receive usual care during the control phase of the trial.
11119086|NCT03941509|Experimental|Antimicrobial stewardship|Implementation of the nurse-led bundled antimicrobial stewardship intervention
11119087|NCT03941496|Experimental|AZA Treatment|"In Phase Ib dose escalation stage, participants will receive subcutaneous (SQ) AZA once daily x 5 days. Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). All participants receive standard of care antibiotics against tuberculosis.
~Dose Escalation Strategy to identify the lowest dose of AZA that decreases DNA methylation and restores immune function is listed below. Proceeding to Phase IIa will proceed if stopping criteria are met at any of the steps below and FDA/IRB approval is obtained:
~30 mg/m^2 subcutaneous (SQ) once daily x 5 days for 8 individuals
~50 mg/m^2 SQ once daily x 5 days for 8 individuals
~75 mg/m^2 once daily x 5 days for 8 individuals"
11119088|NCT03941483|Experimental|ASP1128|Participants will receive ASP1128 solution intravenously once daily for 3 days.
11119089|NCT03941483|Placebo Comparator|Matching placebo|Participants will receive matching placebo solution intravenously once daily for 3 days.
11119090|NCT03941483|No Intervention|Observational cohort|Participants will be followed-up after the surgery up to Day 90.
11119091|NCT03941470||unexplained recurrent pregnancy loss|peripheral blood sample examined by flowcytometry
11119092|NCT03941470||control fertile multipara|peripheral blood sample examined by flowcytometry
11119093|NCT03941457|Experimental|anti-tumor response of BiCAR-NK cells (ROBO1 CAR-NK cells)|Patients with relapsed and refractory pancreatic cancer of ROBO1 expression will be treated with BiCAR-NK cells (ROBO1 CAR-NK cells).
11119094|NCT03941444|Experimental|Active arm|ANAVEX2-73 liquid oral solution
11119095|NCT03941444|Placebo Comparator|Placebo arm|Placebo liquid oral solution
11119096|NCT03941431|Experimental|Chinese medicine internal treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks.
11119097|NCT03941431|Experimental|Chinese medicine external treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks.
11119098|NCT03941431|Experimental|Chinese medicine treatment group|Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks.
11119099|NCT03941431|Experimental|Western medicine treatment group|Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks.
11119100|NCT03941431|Experimental|Integrated Chinese and Western Medicine Treatment Group|Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks.
11119101|NCT03941418|Experimental|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
11119102|NCT03941418|Placebo Comparator|Placebo|Patients will be administered with placebo as an addition to their standard therapy.
11119103|NCT03941405|No Intervention|No treatment|No treatment.
11119104|NCT03941405|Experimental|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days.
11119105|NCT03941392||Healthy children between 1 and 9 years old|A sample of 1500 apparently healthy children between 1 to 9 years old from urban areas from different regions of Spain.
11119106|NCT03941379||Patients previously participated in an Aura Biosciences study|Patients with Choroidal Melanoma or Indeterminate Lesions.
11119107|NCT03941366|Other|Neoadjuvant Chemotherapy and Follow-up Surgery|All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
11119108|NCT03941340|Experimental|[14C]-AST2818 80mg (oral solution)|Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.
11119109|NCT03941327|Placebo Comparator|Control|Patients who provide consent for implant placement but do not receive the implant.
11119110|NCT03941327|Experimental|Interventional|Patients who provide consent for implant placement and do receive the implant.
11119111|NCT03941314|Experimental|Supera® Peripheral Stent System|Femoro-popliteal arterial stenting with Supera® Peripheral Stent System as CE-marked by the manufacturer Abbott
11119112|NCT03941314|Active Comparator|EverFlex™ Self-Expanding Peripheral Stent System|Femoro-popliteal arterial stenting with EverFlex™ Self-Expanding Peripheral Stent System with Entrust™ Delivery System or as Protégé™ EverFlex™
11119113|NCT03941301|Active Comparator|Bright treatment light|
11119114|NCT03941301|Placebo Comparator|Red light|
11119115|NCT03941288|Active Comparator|Pharmacodynamics and clinical effects of cannabidiol|"Cannabidiol will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.
~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
11119158|NCT03941002|Active Comparator|Reduced pressure support|The level of inspiratory pressure support will be reduced by 25%
11119116|NCT03941288|Placebo Comparator|pharmacodynamics and clinical effects of placebo|"Placebo will be administered orally twice daily in equally divided doses starting at 2.5mg/kg per day and increasing by 2.5 to 5.0mg/kg every other day until the target dose of 20mg/kg is reached.
~Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days."
11119117|NCT03941275||Subjects undergoing bi-plane fluoroscopy|
11119118|NCT03941262|Experimental|Cohort 1 - Low dose SNK01|SNK01 (low dose) administered once a week for five weeks.
11119119|NCT03941262|Experimental|Cohort 2 - Medium dose SNK01|SNK01 (medium dose) administered once a week for five weeks.
11119120|NCT03941262|Experimental|Cohort 3 - High dose SNK01|SNK01 (high dose) administered once a week for five weeks.
11119121|NCT03941262|Experimental|Cohort 4 - SNK01 with avelumab|SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
11119122|NCT03941262|Experimental|Cohort 4 - SNK01 with pembrolizumab|SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
11119123|NCT03941236|Experimental|Dasiglucagon open-label|Dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
11119124|NCT03941223|Experimental|pectoral PECS II block|Ultrasound-guided PECS II block with ropivacaine 0.75% 20 ml (patients N = 75) + Parasternal ultrasound-guided block at T2, T4 levels with ropivacaine 0.375% 10 ml
11119125|NCT03941223|Active Comparator|Paravertebral nerve block|Ultrasound-guided paravertebral block with ropivacaine 0.75% 20 ml at T1-T2 and T3-T4 levels (10 ml each) (patients N = 75)
11119126|NCT03941210||HIV+/TB+|"Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm
~All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation"
11119127|NCT03941210||HIV+/TB-|"Participants included in this study arm will be HIV+ and TB-
~One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis"
11119128|NCT03941210||HIV-/TB+|"Participants included in this study arm will be HIV- and TB+
~Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment"
11119129|NCT03941210||HIV-/TB-|"Participants included in this study arm will be HIV- and TB-
~Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB."
11119130|NCT03941197|Experimental|Ready and Healthy for Kindergarten Family Literacy Program|Ready and Healthy for Kindergarten Family Literacy Program- 8 weekly parent child workshops with text message reminders
11119131|NCT03941184||SCAD cases|SCAD cases will be identified based on presence of at least one diagnosis code for SCAD followed by manual verification by a trained individual, OR, inclusion in the previously validated SCAD cohort (Tweet 2012).
11119132|NCT03941184||Controls without SCAD|Potential controls will be identified based on absence of any SCAD diagnosis codes.
11119133|NCT03941171|Experimental|Group 1|PAO+usual+PRT
11119134|NCT03941171|Active Comparator|Group 2|PRT
11119135|NCT03941145|Experimental|Exercise|Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
11119136|NCT03941145|No Intervention|Control|The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
11119137|NCT03941132|Experimental|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.
~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.
~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.
~Total of 11 visits"
11119138|NCT03941132|Placebo Comparator|Saline Solution - Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.
~Week 0: Loading dose of 6mg/kg saline intravenously.
~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.
~Weeks 28, 52, 78: Non-dosing visits where a Mixed Meal Tolerance Test will be administered.
~Total of 11 visits"
11119139|NCT03941119|Experimental|Intervention|The intervention arm will receive a VR-therapy session every 24-72 hours of their stay in the hospital. Participants will view specially designed 360-degree VR films using a Virtual Reality head mounted display for a maximum of 20 minutes per session.
11119140|NCT03941119|No Intervention|Control|The control arm will not receive any VR-therapy sessions during their hospital stay.
11119141|NCT03941106|Experimental|Left aTMS|
11119142|NCT03941106|Experimental|Right aTMS|
11119143|NCT03941093|Experimental|Arm A|Pamrevlumab + Gemcitabine + Nab-paclitaxel
11119144|NCT03941093|Placebo Comparator|Arm B|Placebo + Gemcitabine + Nab-paclitaxel
11119145|NCT03941080||GIMICC|Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.
11119146|NCT03941067|Experimental|Pre-event massage|
11119147|NCT03941067|No Intervention|Control|
11119148|NCT03941054|No Intervention|Control arm|No intervention
11119149|NCT03941054|Experimental|Pressure Release|Digitopressure treatment of the Myosfascial Trigger Points
11119150|NCT03941041|Experimental|Prenatal Yoga Practice|Pregnant women participating in a yoga course at least 12 session, each session in duration of 90 minutes.
11119151|NCT03941041|No Intervention|Regular Prenatal Care|Pregnant women being treated according to national guidelines
11119152|NCT03941028|Experimental|bone defects caused by trauma|Large bone defects (>6cm) caused by trauma
11119153|NCT03941028|Experimental|bone defects caused by infection|Large bone defects caused by chronic osteomyelitis
11119154|NCT03941028|Experimental|bone defects caused by tumor|Large bone defects caused by benign tumor
11119155|NCT03941015||low renal oximetry group|infants experienced renal oxygen saturation (SkO2)<80% baseline at least for 20 minutes
11119156|NCT03941015||normal renal oximetry group|infants did not experience SkO2< 80% baseline at least for 20 minutes
11119159|NCT03941002|Active Comparator|Lowest pressure support|The level of inspiratory pressure support will be reduced by 50%
11119160|NCT03940989|Experimental|3-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, 5 days/week for three weeks.
11119161|NCT03940989|Experimental|15-Week Camp|Subject will participate in a HABIT-ILE camp format for 6-hours/day, one day/week for 15 weeks.
11119162|NCT03940976|Experimental|Afatinib|
11119163|NCT03940963|Active Comparator|AxoGuard® Nerve Cap|"Porcine derived extracellular matrix (ECM) based Nerve Termination Device
~Implantation of appropriate diameter of AxoGuard® Nerve Cap at the time of surgery"
11119164|NCT03940963|Active Comparator|Standard Neurectomy|Standard surgical treatment for symptomatic neuroma entailing neuroma excision.
11119165|NCT03940950|Experimental|SVF (Stromal Vascular Fraction) Group|Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
11119166|NCT03940950|Placebo Comparator|Placebo Group|Subjects with knee osteoarthritis (OA) will be treated with a placebo
11119167|NCT03940924|Experimental|High Intensity Interval Training (HIIT) + Resistance Training|Subjects perform three sessions of training during 12 weeks. Session are composed of 20min HIIT program : 60 cycles of speeding up for 8s and pedaling slowly for 12s. (Intensity between 85 and 90% HRmax) + a single set circuits including 10 exercises with a load of 8-12 repetition at around 80% of maximal repetition (1RM)
11119168|NCT03940924|No Intervention|Control Group|Subjects don't have training program. They keep their life style.
11119169|NCT03940911|Other|anti-TNFα treatment and severe fatigue (FSS)|"See bellow (section Interventions) the full description for
~Measurement of aerobic exercise on cycloergometer
~Measurement of muscle mass by two-photon absorptiometry: specific study
~Measurement of Isometric Muscle Strength
~Blood sampling for measurement of cytokine levels in the blood
~Measurement of sedentarity
~Psychological impact
~Fatigue mesurement
~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
11119170|NCT03940911|Other|anti-TNFα treatment and with mild fatigue (FSS <4)|"See bellow (section Interventions) the full description for
~Measurement of aerobic exercise on cycloergometer
~Measurement of muscle mass by two-photon absorptiometry: specific study
~Measurement of Isometric Muscle Strength
~Blood sampling for measurement of cytokine levels in the blood
~Measurement of sedentarity
~Psychological impact
~Fatigue measurement
~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
11119171|NCT03940898|Active Comparator|study group-active rTMS|Participants in the study group received 100%MT(motor threshold) repetitive transcranial magnetic stimulation with the intermittent theta burst stimulation paradigm.
11119172|NCT03940898|Sham Comparator|control group-shame rTMS|Participants in the control group received rTMS pseudo-stimulation intervention. The stimulation head was inverted by 180 degrees or 90 degrees according to the model of the stimulation device to achieve pseudo-stimulation and the remaining stimulation parameters were consistent with the study group.
11119173|NCT03940885|Active Comparator|Erector spinea plane block group|this group is planned for ultrasound-guided Transversus abdominis plane block
11119174|NCT03940885|Active Comparator|Transversus abdominis plane block|this group is planned for ultrasound-guided Transversus abdominis plane block
11119175|NCT03940885|Placebo Comparator|Control group|standard general anesthesia
11119176|NCT03940872|Experimental|3PDQ self-questionnaire validation|200 patients will be included for this step in 10 French Parkinson expert centers.
11119177|NCT03940859||DEMAT|Patients with intramural hematoma in intracranial dissecting aneurysm treated by endovascular treatment will be recruited.
11119178|NCT03940846||Maastro (Lung1)|Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
11119179|NCT03940846||UCSF|A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
11119180|NCT03940846||Radboud|A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
11119181|NCT03940846||Stanford|Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
11119182|NCT03940833|Experimental|anti-tumor response of BCMA CAR-NK-92|Patients with relapsed and refractory MM of BCMA expression will be treated with BCMA CAR-NK 92 cells.
11119183|NCT03940820|Experimental|anti-tumor response of ROBO1 CAR-NK cells|Patients will receive a single dose of ROBO1 CAR-NK cells without any conditioning chemotherapeutic regimen.
11119184|NCT03940807|Experimental|Ultra-long protocol group|All women will receive one intra-muscular administration of 11.25 mg Gonadotropin Releasing Hormone (GnRH) agonist (triptorelin acetate) on luteal phase of their menstrual cycle. Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period. Ovarian stimulation will be started after 90 days desensitization.
11119185|NCT03940807|Active Comparator|Long protocol group|All women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous application of 0.1mg of GnRH agonist (triptorelin acetate) started on luteal phase of their menstrual cycle. Ovarian stimulation will begin after 15 days desensitization.
11119186|NCT03940794|Experimental|Verbal instruction|"The participants will be instructed to contract the pelvic floor muscle with the following verbal instruction: (1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.Those who will not be able to contract will be taught by the ultrasound as biofeedback."
11119187|NCT03940781|Experimental|intervention group|We conducted a twice a week, 12-week-intervention of 'comprehensive rehabilitation'
11119188|NCT03940781|No Intervention|control group|We kept the patients for the waiting list until after completing baseline and 12-week measurement
11119189|NCT03940768|Experimental|Lactobacillus plantarum 299v receivers|Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
11119190|NCT03940768|Placebo Comparator|Placebo receivers|Sanprobi IBS placebo 2 capsules per day for 4 weeks.
11119191|NCT03940755||Critical Illness Survivors|Those intensive care unit(ICU) patients who survive from critical illness.
11119192|NCT03940742|Experimental|Tirzepatide Control|Tirzepatide administered subcutaneously (SC) to participants with normal hepatic function
11119193|NCT03940742|Experimental|Tirzepatide Mild|Tirzepatide administered SC to participants with mild hepatic impairment
11119371|NCT03939520|Experimental|Combined therapy|
11119194|NCT03940742|Experimental|Tirzepatide Moderate|Tirzepatide administered SC to participants with moderate hepatic impairment
11119195|NCT03940742|Experimental|Tirzepatide Severe|Tirzepatide administered SC to participants with severe hepatic impairment
11119196|NCT03940729|Other|PWID colonized with S aureus|Repeated chlorhexidin showers for PWID colonized with S aureus
11119197|NCT03940716|Experimental|IntERact|"Participants randomized to this condition will receive behavioral therapy comprised of motivational interviewing, cognitive behavioral skills therapy, and care management. Youth will receive a total of six sessions, one delivered in the emergency department at the time of recruitment and five delivered over the five subsequent weeks after the ED visit (i.e., baseline). Participants will also receive a smartphone APP that will deliver intervention content between therapy sessions, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
11119198|NCT03940716|No Intervention|Enhanced Usual Care Condition|Participants randomized to this condition will receive a pamphlet with violence, mental health, and substance use resources.
11119199|NCT03940703|Experimental|Tepotinib and Osimertinib|Participants will receive a combination of tepotinib and osimertinib. The combination will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
11119200|NCT03940703|Experimental|Tepotinib Mono-therapy|Participants will receive once daily dose of tepotinib. The mono therapy will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
11119201|NCT03940690|Experimental|Anti-VEGF injections (bevacizumab)|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9
11119202|NCT03940690|Active Comparator|Arm : laser only|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
11119203|NCT03940677|Other|Parkinson's disease patient|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination for motor and non motor symptoms
11119204|NCT03940677|Other|Healthy controls|Brain functional MRI, robotic TMS + EEG, neuropsychological evaluation, neurological examination
11119205|NCT03940664||neovascular group|patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
11119206|NCT03940664||non-neovascular group|patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
11119207|NCT03940651|Experimental|Knee Arthroplasty|Surgery to replace the knee joint with prothetic joint
11119208|NCT03940651|Experimental|Hip Arthroplasty|Surgery to replace the hip joint with prothetic joint
11119209|NCT03940638||Patients with septic non-union of the tibia|
11119210|NCT03940612|Experimental|STP4 (product with probiotics)|Dietary Supplement: STP4
11119211|NCT03940612|Experimental|Placebo (product without probiotics)|Dietary Supplement: Placebo
11119212|NCT03940599|Experimental|Fitbit with visible screen|The first group will receive a FitBit with the screen visible, displaying their daily step count (the Step-Counter group).
11119213|NCT03940599|Experimental|Scale group|The second will receive a BodyTrace scale that will display and record their weight in kilograms and a FitBit with the screen covered as it was for the run-in period so their physical activity can be measured, but the only feedback they will receive is from the scale (the Scale group).
11119214|NCT03940599|Experimental|Step counter and scale|The third group will receive a BodyTrace scale and a FitBit with the screen visible (the Step-Counter and Scale group).
11119215|NCT03940599|Sham Comparator|Fitbit with screen covered|The remaining 5 participants will serve as normal controls and continue wearing the FitBit with the screen covered as it was during the run in period for the duration of follow up.
11119216|NCT03940586|Experimental|Letermovir|Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
11119217|NCT03940573|Experimental|Treatment|All patients fitted with the device.
11119218|NCT03940560|Experimental|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
11119219|NCT03940547|Experimental|Experimental - provision of flour|This arm will receive infant and young child feeding education performed by community health workers and very-low aflatoxin (AF) pre-blended porridge flour, ratio 4:1 maize to groundnut. Provision of this pre-blended flour will be 50 grams/day for 6-8 month olds, 60/day grams for 9-11 months and 75 grams/day for 12-18 month olds (with 10-15 grams added per day to account for any loss). Participants will also receive 1 kg of low-AF groundnut flour each month for 6-18 month olds. Finally, participants will receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
11119220|NCT03940547|Active Comparator|Control - promotion of flour|This arm will receive infant and young child feeding education performed by community health workers and promotion of porridge made from maize and groundnut to match what is provided to the intervention arm. Participants will also receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
11119221|NCT03940534|Active Comparator|Start with Mobile Device|
11119222|NCT03940534|Active Comparator|Start without Mobile Device|
11119223|NCT03940521||HIV-A infected patients|
11119224|NCT03940508|Experimental|MCI + IPT-A|Participants will receive the Making Connections Intervention (MCI) in addition to IPT-A for depression.
11119225|NCT03940508|Active Comparator|IPT-A Only|Participants will receive IPT-A for depression.
11119226|NCT03940482|Experimental|Single Arm|Subjects will act as their own controls
11119227|NCT03940469|Placebo Comparator|Control group|received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block.
11119228|NCT03940469|Active Comparator|Dexamethasone group|received 35ml levobupivacaine+8mg dexamethasone
11119229|NCT03940469|Active Comparator|Dexmeteomidine group|received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.
11119230|NCT03940456||Inception cohort, former Elsinore pupils|640 former Elsinore pupils (330 female, 310 male). Aged 14 in 1965. Two earlier cross-sectional studies have been done in this group (in 1990 and 2000).
11119231|NCT03940443||Ground Emergency Medical Services|Patients suffering TBI or acute MI and has been treated by GEMS dispatched by an emergency dispatch centre.
11119232|NCT03940430|Active Comparator|Lactoferrin in iron deficiency anemia|lactoferrin ( pravotin) 100mg twice daily
11119233|NCT03940430|Active Comparator|Ferrous sulfate in iron deficiency anemia|ferrous sulphate (hemojet)
11119234|NCT03940430|Active Comparator|Lactoferrin and ferrous sulfate in iron deficiency anemia|Lactoferrin 100 mg twice daily and ferrous sulfate
11119235|NCT03940404||experiment|The patients whose treatment strategy containing anlotinib.
11119236|NCT03940391|Experimental|antihistamine combination|Participants in this group will get combination chlorpheniramine and midazolam injection for sedative endoscopy.
11119237|NCT03940391|Placebo Comparator|midazolam|Participants in this group will get only midazolam injection for sedative endoscopy
11119238|NCT03940378|Experimental|One-drug Regimes|Basic drug : Anlotinib Hydrochloride Capsules
11119239|NCT03940378|Experimental|Two-Drug Regimens|Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
11119240|NCT03940365|Experimental|Study Group|As detailed above, a single group will be used for the study to compare the output of the study device with the output of the standard device in each patient.
11119241|NCT03940352|Experimental|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
11119242|NCT03940352|Experimental|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
11119243|NCT03940339|Experimental|Suboccipital myofascial release|Treatment will be given for 3 minutes, 3 days per week for 4 weeks.
11119244|NCT03940339|Active Comparator|Coventional Physiotherapy|Treatment will be given for 3 days per week for 4 weeks
11119245|NCT03940326|Experimental|Levetiracetam|
11119246|NCT03940326|Active Comparator|Valproate|
11119247|NCT03940313||Subjects|Participants >18 years old who meet inclusion and exclusion criteria, and have findings on physical exam and ultrasound that suggest potential benefit from prolotherapy.
11119248|NCT03940313||Controls|Participants >or =18 years old who do not complain of lower back pain, but consent to have physical examination testing and musculoskeletal ultrasound of the lower back to evaluate these areas.
11119249|NCT03940300|Experimental|Adults with or risk for Type 2 Diabetes|All adult individuals with (non-insulin treated) or at risk for type 2 diabetes are in the treatment group and will receive prescriptions of fresh organic vegetables on a weekly basis for 10 weeks.
11119250|NCT03940287|Experimental|Muscle Energy Technique and Conventional Physiotherapy|Muscle Energy Technique will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks, where each session of Muscle Energy Technique will be repeated for 3-5 repetitions.
11119251|NCT03940287|Experimental|Kinesiotaping and Conventional Physiotherapy|Kinesiotape application will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks
11119252|NCT03940274|Experimental|Intervention|Participants will undergo a walking program using a treadmill, a body-weight support system, and an assistive device.
11119253|NCT03940261|Experimental|High Intensity Interval Training|
11119254|NCT03940261|Active Comparator|Continuous Moderate Intensity Training|
11119255|NCT03940248|Experimental|Early Stage Breast Cancer|Patients to be treated with Accelerated Partial Breast Irradiation utilizing pencil beam scanning proton therapy. Treatment will be delivered twice a day, at least 6 hours apart, over 5 treatment days.
11119256|NCT03940235|Experimental|Stereotactic body Radiotherapy (SBRT) only|ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.
11119257|NCT03940235|Active Comparator|Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)|ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.
11119258|NCT03940222|Experimental|I-BiT group|Amblyopic patients will play I-BiT games without patching.
11119259|NCT03940222|Placebo Comparator|Placebo group|Amblyopic patients will patch their dominant eye and they will play placebo I-BiT games.
11119260|NCT03940209|No Intervention|Usual care|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan including access to a physician network, case management resources, and other educational and health-focused resources and activities.
11119261|NCT03940209|Experimental|Basic needs navigation|Medicaid beneficiaries in this arm will have all the usual resources available to them through their health plan (usual care) as well as a navigator for 6 months to address any unmet basic needs, provide instrumental and emotional social support, and improve self-management capabilities.
11119262|NCT03940196|Experimental|NovoTTF-100L(O)|Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
11119263|NCT03940196|Active Comparator|Best Standard of Care|Patients receive best standard of care with weekly Paclitaxel
11119264|NCT03940183|Experimental|Trelagliptin succinate 100 mg|Tablets,100mg per tablet,oral, once a week, 100mg each time, continuous medication for a total of 24 weeks
11119265|NCT03940183|Placebo Comparator|Placebo Oral Tablet|Tablets,N/A,oral, once a week, one tablet each time, continuous medication for a total of 24 weeks
11119266|NCT03940170||vistacam|
11119267|NCT03940170||ICDAS II|
11119268|NCT03940170||Fissurotomy|
11119269|NCT03940157|Experimental|Oh Happy Day Class - Still I Rise|The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
11119270|NCT03940144|Experimental|goal-directed fluid therapy|Stroke Volume variation (SVV)-guided fluid therapy
11119271|NCT03940144|Active Comparator|Conventional fluid therapy|Conventional fluid therapy such as CVP, MAP and urine-output guided fluid therapy
11119272|NCT03940131|Experimental|Single Arm|Panitumumab with FOLFOX6/FOLFIRI
11119372|NCT03939520|Active Comparator|Switch monotherapy|
11119273|NCT03940118|Active Comparator|Catheter secretion suctioning|Secretions are aspirated with a catheter at -120 to -150 mBar
11119274|NCT03940118|Experimental|Secretion suctioning + hypertonic saline|Hypertonic saline is nebulized prior to aspiration of secretions.
11119275|NCT03940118|Experimental|Ins-exsufflation|Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg
11119276|NCT03940118|Experimental|Ins-exsufflation + Hypertonic Saline|Mechanical insufflation-exsufflation and hypertonic saline
11119277|NCT03940105|No Intervention|Control|For 3 days during the control snack pattern, the participants will be asked to complete dietary recalls concerning their afternoon and evening snacking behavior. The participants will use the Automated Self-Administered 24-hour Recall (ASA24) system which was developed by the National Cancer Institute.
11119278|NCT03940105|Active Comparator|Standard Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch.
11119279|NCT03940105|Active Comparator|Large Package Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that the package sizes of all the foods are larger (though food amount remains the same).
11119280|NCT03940105|Active Comparator|Variety Packout|This packout contains a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. It differs from the Standard Packout in that there is about twice as much snack variety (though food amount remains the same).
11119281|NCT03940092||Healthy Volunteers|Healthy volunteers will be scheduled for an 23Na-MR examination
11119282|NCT03940092||Breast cancer patients (primary surgery)|Patients scheduled for primary surgery will undergo a single MR examination, involving 23Na-imaging prior to their planned surgery.
11119283|NCT03940092||Breast cancer patients (neoadjuvant chemotherapy)|Patients undergoing neo-adjuvant therapy will undertake up to two (2) combined PET/MR examinations with FDG. Examinations will be conducted at baseline and after 3-4 cycles of chemotherapy.
11119284|NCT03940079|Experimental|gross-motor group (GMG)|"The participants of GMG received motor-cognitive dual-task training. The sensors used by the participants were four different colored buttons. The participants wear a suit with two buttons on the shoulders and the other two fasten on the knees by velcros. To accomplish the tasks, the participants had to slap the correct colored buttons. The stretching of upper or lower limbs was demanding while slapping, so the participants of GMG received a training which required cognitive and motor functions at the same time.
~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
11119285|NCT03940079|Active Comparator|fine-motor group (FMG)|"The participants of FMG received cognitive training only. Four colored sensors used by the participants were the keys on the keyboard of the laptop. The participants simply pressed correct colored keys by fingers to complete the tasks.
~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
11119286|NCT03940066|Other|Monitoring group|
11119287|NCT03940066|Other|Standard Care|
11119288|NCT03940053|No Intervention|Observation|Subjects only accept the routine treatment for underlying diseases.
11119289|NCT03940053|Experimental|Intervention|Based on the routine treatment for underlying diseases, subjects were administrated by arginine.
11119290|NCT03940040|Active Comparator|Usual Care|Patients will under go usual care ( pulmonary rehabilitation on room air or with nasal oxygen supplementation)
11119291|NCT03940040|Experimental|High flow nasal oxygen|Patients will undergo pulmonary rehabilitation with high flow nasal oxygen
11119292|NCT03940027|Experimental|ropivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% ropivacaine with 10ml anhydrous alcohol
11119293|NCT03940027|Active Comparator|bupivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% bupivacaine with 10ml anhydrous alcohol
11119294|NCT03940014||Pulmonary arteriovenous malformations|"Patients with hereditary haemorrhagic telangiectasia (HHT)-related Pulmonary Arteriovenous Malformations (PAVMs). For all patients, the final diagnosis of certain HHT the diagnosis can be made depending on the presence of four criteria known as the Curaçao criteria: 1) Spontaneous recurrent epistaxis 2) Multiple telangiectasias in typical locations 3) Proven visceral Arteriovenous Malformations (AVM) (lung, liver, brain, spine) 4) First-degree family member with HHT. If conditions three or four are met, a patient has definite HHT, while condition two is considered as possible HHT. All patients had a molecular diagnosis and all follow-up clinical assessments were available in the database."
11119295|NCT03940001|Experimental|arm|"Biological: Sintilimab For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
~Drug: Paclitaxel 50 mg/m^2 IV Q3W day 1, day 8 and day 15
~Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15
~Radiotherapy:
~1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy"
11119296|NCT03939988|Active Comparator|Experimental group|In this study, immediately after the installation of the separators, the subjects of the experimental group will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
11119297|NCT03939988|Placebo Comparator|Placebo group|In the placebo group, the same procedures will be made, but the laser will be switched off.
11119298|NCT03939975|Experimental|Study arm|"Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely.
~Others with complete or partial responses would keep on going with mono-ICIs therapy."
11119299|NCT03939962|Experimental|treatment group|SHR1210 combined with FOLFOX repeat every 14 days for a total of 4 cycles.
11119373|NCT03939507|Experimental|Intervention group|AEP score results were made available to the treating physician at each assessment visit.
11119300|NCT03939949|Experimental|High Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions (all including questions about pain) twice daily for six days.
11119301|NCT03939949|Experimental|Low Mindfulness|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (some related to pain) twice daily for six days.
11119302|NCT03939949|Active Comparator|Active control|All participants in this condition will complete all measures online at four different points in time, including one narrative response at T1. They will also be instructed to respond to diary-type text messaging questions (none about pain) twice daily for six days.
11119303|NCT03939936|Active Comparator|Test Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.
~Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
11119304|NCT03939936|Placebo Comparator|Control Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.
~Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
11119305|NCT03939923|Active Comparator|Group One|Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).
11119306|NCT03939923|Active Comparator|Group Two|Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).
11119307|NCT03939910|Active Comparator|Control arm|bupivacaine 0.25% for pudendal block
11119308|NCT03939910|Experimental|Intervention arm|ropivacaine 0.2 % for the pudendal block
11119309|NCT03939897|Experimental|Phase I (FAC) (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level) and abemaciclib PO BID on days 2-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive fulvestrant IM on days 2 and 16 of cycle 1, and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11119310|NCT03939897|Experimental|Phase II, Arm I (FAC) (copanlisib, abemaciclib, fulvestrant)|Patients receive copanlisib hydrochloride as in phase I. Patients also receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11119311|NCT03939897|Active Comparator|Phase II, Arm II (FA) (abemaciclib, fulvestrant)|Patients receive abemaciclib PO BID on days 1-28 and fulvestrant IM on days 1 and 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11119312|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on with MSM|
11119313|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on without MSM|
11119314|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment with MSM|
11119315|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment without MSM|
11119316|NCT03939884|Active Comparator|Voltaren Emulgel|
11119317|NCT03939884|Placebo Comparator|Non-medicinal Placebo|
11119318|NCT03939871|Experimental|Single arm|Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
11119319|NCT03939858||Cognitive Function Analysis|Cognitive function will be evaluated using a customized cognitive battery designed for brain tumor patients. Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
11119320|NCT03939845|Active Comparator|TACE|
11119321|NCT03939845|Experimental|TACE+RT|
11119322|NCT03939832|Active Comparator|FiO2 0.5|
11119323|NCT03939832|Active Comparator|FiO2 1.0|
11119324|NCT03939819|Experimental|ViSiGi® 3D suction calibration device|"The ViSiGi® 3D is the first calibration system specifically intended for use during sleeve gastrectomy.ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
~Advantages of ViSiGi® 3D device include simplification of sleeve calibration in addition to suctioning the stomach and performing leak tests all with one device making operative steps simpler for both the anesthesiology team and surgeons. Since it is single patient use it does not require reprocessing."
11119325|NCT03939819|Active Comparator|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope, similar to The ViSiGi device, have suction, calibration, and leak testing capabilities.
11119326|NCT03939806||Oxytocin|This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
11119327|NCT03939806||Carbetocin|This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
11119328|NCT03939793|Placebo Comparator|Usual Clinical Support|Participants will continue with their usual diabetes care provided by their clinic. Participants will receive a free wireless glucometer on the day of enrollment if they do not already have one.
11119374|NCT03939507|No Intervention|Control group|AEP scores were only made available at the end of follow-up.
11119329|NCT03939793|Active Comparator|DFI Alone|Participants will receive a free wireless glucometer on the day of enrollment if they don't already have one. To encourage habit formation, for the first 6 weeks of the trial, participants will be eligible for a daily lottery incentive for every day that they use their glucometer. Investigators will use an approach similar to what we have used in prior DFI trials: the lottery will provide infrequent large payoffs (a 1 in 100 chance of a US$50 reward) and more frequent small payoffs (an 18 in 100 chance of a US $5 reward). Participants who draw the winning lottery number, but did not check their glucose the day prior will receive an automated text or e-mail message informing them what earnings they would have won had they used their glucometer. After 6 weeks, investigators will terminate the lottery but continue to monitor patients' adherence to glucose self-monitoring.
11119330|NCT03939793|Experimental|Hybrid DFI CHW|Participants in the hybrid intervention will receive a wireless glucometer if they don't already have one and financial incentives just as in the DFI intervention. However, any individuals who have low adherence (no self-monitoring) or elevated glucose readings (>300 mg/dL) for >30% of days over any 2 week period in the first 12 weeks of the study will be assigned to receive ongoing community health worker (CHW) support for the duration of the 24-week study period.
11119331|NCT03939780|Experimental|Cohort 1|Subjects will be scanned twice (once with each of the tracers [18F]RO-948 and [18F]MK-6240)
11119332|NCT03939780|No Intervention|Cohort 2A|No PET scans will be done. Previous [18F]AV-1451 scans of selected aged matched older cognitively healthy controls (OC) subjects from the Baltimore Longitudinal Study of Aging (BLSA) study (IRB00047185) will be reanalyzed.
11119333|NCT03939780|Experimental|Cohort 2B1 - AD [18F]RO-948 and [18F]AV-1451|Alzheimer's Disease (AD) subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
11119334|NCT03939780|Experimental|Cohort 2B2 - AD [18F]MK-6240 and [18F]AV-1451|AD subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
11119335|NCT03939780|Experimental|Cohort 2B3 - OC [18F]RO-948 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
11119336|NCT03939780|Experimental|Cohort 2B4 - OC [18F]MK-6240 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
11119337|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
11119338|NCT03939754||Adult attendance to Dedalo activities|Adult attended one Dedalo's activity
11119339|NCT03939754||Adult living in Vercelli|Adult aged 40-75
11119340|NCT03939741|Experimental|Group A|"Participants having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) more than 1 x 10^6.
~Genetic: SVF containing Autologous Non Expanded ADSC."
11119341|NCT03939728||Chest radiography and lung ultrasound|All patients will be enrolled, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
11119342|NCT03939715|Active Comparator|DermaPure|
11119343|NCT03939715|Active Comparator|Native Tissue|
11119344|NCT03939702|Active Comparator|Non-Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
11119345|NCT03939702|Active Comparator|Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
11119346|NCT03939689|Active Comparator|Enzalutamide|
11119347|NCT03939689|Experimental|I-131-1095 in combination with enzalutamide|
11119348|NCT03939676||Major Depressive Disorder or Bipolar Disorder|All eligible participants will be included in this single study arm.
11119349|NCT03939663|Placebo Comparator|placebo group|2 tablets vaginally
11119350|NCT03939663|Experimental|misoprostol group|400 mcg vaginally
11119351|NCT03939650|Experimental|Diaana|"The patient fulfill Diaana
~The resident physician reads the Diaana summary
~The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)
~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
11119352|NCT03939650|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)
~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
11119353|NCT03939637|Experimental|Eltrombopag|Patients randomized to eltrombopag will be treated for 12 weeks, with the possibility to continue therapy for up to 1 year depending on response.
11119354|NCT03939637|Active Comparator|Standard first-line therapy|"Subjects randomized to the standard therapy arm will receive one of three treatments at the discretion of the treating physician. Patients who previously failed standard management prior to study entry must be treated with a different agent than their original failed agent. e.g. Patient who failed steroids could receive either IVIg or anti-D if randomized to the standard treatment arm.
~Standard therapy will be administered as commercially available drug.
~Investigator may choose amongst the following:
~IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
~Steroids: Prednisone/Prednisolone 4 mg/kg/day (Max 120 mg/day) x 4 days
~Rho(D) Immune Globulin: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)"
11119355|NCT03939624||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Patients who received a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
11119356|NCT03939624||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Patients who received a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
11119357|NCT03939611|Experimental|Foot Reflexology Group|Foot reflexology was performed to the reflexology group infants. Foot reflexology application (FRA) involved relaxation for the first 3-5 minutes and the last 2 minutes; the remaining 12-15 minutes included stimulation of the brain and digestive system organs. To ensure relaxation, rotation was performed by using the thumbs of the hand under the feet, cephalocaudally. The session of FRA included stimulating the brain and medulla spinalis (2 min), the solar plexus (1min), the stomach (2min), the liver (2min), the pancreas (2min), the gallbladder (1min), and the ileocecal valve and intestine (5min) reflex points. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
11119358|NCT03939611|Placebo Comparator|Placebo Foot Reflexology Group|Placebo foot reflexology was performed to the placebo group infants. Placebo foot reflexology application (PFRA) was constrained to ineffective touch without any stimulation and pressure. The aim of the PFRA was to create only a touch effect. It was applied by patted the foot by using the thumbs of the hand, for 20 minutes with the same rotation and to the same points as FRA. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
11119359|NCT03939585|Experimental|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.
~27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).
~Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.
~Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.
~Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
11119360|NCT03939572|Active Comparator|Accurate step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will simply display their accurate step count."
11119361|NCT03939572|Experimental|Deflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will display a deflated step count."
11119362|NCT03939572|Experimental|Inflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will display an inflated step count."
11119363|NCT03939572|Experimental|Accurate feedback + mindset intervention|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.
~In this arm, participants' Apple Watches will display their accurate step count. Additionally, participants in this arm will receive a meta-mindset intervention."
11119364|NCT03939559|Experimental|Balance Exercises Group|Balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session
11119365|NCT03939559|Experimental|Dual Task Based Balance Exercises Group|Dual task based balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
11119366|NCT03939546|No Intervention|Control|The Control Arm will not receive any study intervention or placebo. The infants in this arm will receive standard NICU care.
11119367|NCT03939546|Active Comparator|B. infantis EVC001|Infants in the B. infantis arm will receive a once daily enteral feed of Evivo with MCT oil (8B CFU B. infantis EVC001) from Study Day 0 (by Day 10 of life) to hospital discharge, except on days when the infant is NPO.
11119368|NCT03939533|Experimental|Increased Volume Cohort - Cohort 1|Increased volume at each infusion site - patients will receive CUTAQUIG weekly and increase infusion volumes every 4 weeks
11119369|NCT03939533|Experimental|Increased Infusion Rate Cohort - Cohort 2|Increased infusion rate - patients will receive CUTAQUIG weekly and increase infusion rates every 4 weeks
11119370|NCT03939533|Experimental|Every Other Week Dosing Cohort - Cohort 3|Every other week dosing - patients will receive CUTAQUIG every other week at the equivalent of twice their body-weight dependent [mg/kg] weekly dose
11119375|NCT03939494|Experimental|Telehealth Intervention|This arm receives 26 hours of telehealth encounters with a registered dietitian in conjunction with their normal clinic/program care.
11119376|NCT03939494|No Intervention|Standard of Care Control|This arm will participate in their normal clinic/program routine.
11119377|NCT03939481||Observational (non-study chemo, questionnaire, assessments)|Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
11119378|NCT03939468||Observational Cohort|Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)
11119379|NCT03939455|Experimental|Experimental|Participants will complete a brief tablet-based intervention, which includes watching a 5 minute educational video on the importance of HIV testing, and respond via tablet computer to the offer of an HIV test.
11119380|NCT03939455|No Intervention|Treatment as usual|Participants will be offered an HIV test by hospital staff, and will respond face-to-face.
11119381|NCT03939429|Experimental|QPX2015|QPX2015, antibiotic
11119382|NCT03939429|Placebo Comparator|Placebo|Matched placebo
11119383|NCT03939416|Experimental|POLD concept treatment|Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment
11119384|NCT03939416|Active Comparator|CONTROL|Patients treated with the standart treatment
11119385|NCT03939403|Experimental|7-days pill free interval|
11119386|NCT03939403|No Intervention|5-days pill free interval|
11119387|NCT03939390|No Intervention|follicular phase stimulation|
11119388|NCT03939390|Experimental|luteal phase stimulation|
11119389|NCT03939377|Experimental|Osteopathy|Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.
11119390|NCT03939377|Placebo Comparator|Simulate|The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.
11119391|NCT03939364|Experimental|0.1% SBS-101|
11119392|NCT03939364|Experimental|0.3% SBS-101|
11119393|NCT03939364|Experimental|0.2% SBS-101|
11119394|NCT03939364|Placebo Comparator|Placebo|
11119395|NCT03939338||Participates|
11119396|NCT03939325||first group|patient who exposed to frequency 60 shock wave per min
11119397|NCT03939325||second group|patient who exposed to frequency 80 shock wave per min
11119398|NCT03939325||third group|patient who exposed to frequency 100 shock wave per min
11119399|NCT03939312|Other|Atogepant 60mg|Taken orally once daily
11119400|NCT03939299|Experimental|OCT group|Patients, whose coronary chronic total occlusion lesion was successfully implanted stent, received optical coherence tomography imaging immediately and at 9-12 months after index procedure.
11119401|NCT03939286|Other|movement group|intensified training (equipment, coordination, balance)
11119402|NCT03939286|Other|control group|continuation of physical activity as usual
11119403|NCT03939273|Active Comparator|Active group|A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
11119404|NCT03939273|Placebo Comparator|Control group|A preoperative seven day course of placebo, consisting of pills and capsules identical in appearance and number to the active group
11119405|NCT03939247|Other|"Conventional PT treatment (CPT)"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching;
11119406|NCT03939247|Experimental|"CPT + Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an active Tecaretherapy is also provided during the sessions
11119407|NCT03939247|Sham Comparator|"CPT + Placebo Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an inactive Tecaretherapy is also provided during the sessions
11119408|NCT03939234|Experimental|Vaccination|Untreated CLL patients with unmutated IgHV gene with a cut of at maximum of 2 % mutations. According to guidelines from the European Research Initiative on CLL (ERIC).
11119409|NCT03939221|Experimental|intervention of infrared lamp and acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6(neiguan) and ST36(zusanli) for one minutes) for our patient for the cold limbs, pain control and constipation problems.
11119410|NCT03939208|Experimental|Intervention (BRISC) Group|Clinicians randomly assigned to BRISC will implement a flexible intervention that, over four sessions, aims to assess and engage student clients, and identify and address student identified difficulties that are distressing and impacting academic performance/behavior, social, and overall functioning. BRISC uses an explicit, problem-solving structure and a range of techniques common to evidence-based practices (EBP) tailored to the identified needs of the student.
11119411|NCT03939208|Active Comparator|Services as Usual (SAU) Group|"Clinicians in the SAU condition will use a diverse array of treatment as usual strategies over four sessions that may include some directive, skill-building techniques common in EBPs, but, given findings from pilot studies and studies of mental health services as usual in community and school settings, are likely to be provided at an overall lower rate, and at lower intensity, than in BRISC or other EBP."
11119412|NCT03939182|Experimental|Abexinostat and Ibrutinib|The investigational agents to be used in this study are ibrutinib and abexinostat. Ibrutinib will be administered once daily on a 28-day cycle. Abexinostat will be administered orally twice daily (approximately 4-6 hours apart) for 7 days a week given every other week on a 28-day cycle.
11119413|NCT03939169|Other|Skin-to-skin support|The newborn is dressed in one layer of clothing with a hat, he is placed in the ventral position directly on the mother's chest, covered with a warm blanket and held in place with a band during the insertion of the naso-gastric feeding tube.
11119414|NCT03939169|Other|Holding|The newborn is held in his mother's arms during insertion of the naso-gastric feeding tube.
11119415|NCT03939169|Other|Four hands care|Carried out by two professionals: one health-care professional supports the child and helps stabilize the newborn whilst the other professional inserts the naso-gastric feeding tube.
11120593|NCT03930667|Active Comparator|clips|Closure of the appendix stump with hem-o-lok clips
11119416|NCT03939169|Other|Containing support with equipment|Carried out by one healthcare Professional, who places the newborn in such a manner that he will be held in the optimum position (using a soft sheet) during the insertion of the naso-gastric feeding tube.
11119417|NCT03939156||Group 1 - before starting ET|women candidate to receive ET and interviewed before starting treatment
11119418|NCT03939156||Group 2 - within 1 year of ET|women interviewed within 1 years from beginning of ET
11119419|NCT03939156||Group 3 - between 4 and 6 years of ET|women interviewed after more than 4 years but no more than 6 years of ET
11119420|NCT03939143|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
11119421|NCT03939143|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
11119422|NCT03939130|Experimental|Fructose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
11119423|NCT03939130|Active Comparator|Glucose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive glucose based beverage, prepared as a solution with 10% glucose, water and flavoring powder, totaling 1.0g / kg of body mass / day of glucose.
11119424|NCT03939130|Experimental|Fructose-rich diet and exercise|The subjects will perform the same protocol described in the intervention Fructose-rich diet, except for the inclusion of the physical exercise. During the 4-week intervention, participants will perform three sessions a week of 60 minutes of aerobic exercise at 60% of VO2 peak on cycle ergometer.
11119425|NCT03939104|Active Comparator|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
11119426|NCT03939104|Active Comparator|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|Triple ACTs
11119427|NCT03939104|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
11119428|NCT03939104|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs.
11119429|NCT03939091|Other|Ultrasonography|Renal Ultrasonography
11119430|NCT03939078||Vaginal Laser Intervention|Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.
11119431|NCT03939065|Experimental|Insulin Pump and CGM|
11119432|NCT03939065|Other|Standard of Care and CGM|
11119433|NCT03939052|Experimental|Protein intake|Free amino acids vs. Glycomacropeptide (GMP)
11119434|NCT03939039||Dyslipidemia|Genotype/phenotype correlation in patients with dyslipidemia
11119435|NCT03939026|Experimental|ALLO-647, ALLO-501|
11119436|NCT03939013|Experimental|Xpert HCV VL, sof/dac (local standard of care therapy)|Use of Cepheid GeneXpert HCV VL device as diagnostic tool to test for HCV RNA for diagnosis of chronic hepatitis C infection, for assessment of sustained virological response at 12 weeks post treatment completion
11119437|NCT03938987|Experimental|CAR T cells|Patients with relapsed/refractory B-cell ALL or NHL.
11119438|NCT03938948|Experimental|Treatment Arm|62 participants shall be enrolled
11119439|NCT03938922|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
11119440|NCT03938909||Patients with Multiple Sclerosis|200 patients and 200 control
11119441|NCT03938909||Patients with dementia|100 patients and 100 control
11119442|NCT03938909||Patients with Parkinson's disease|50 patients and 50 control
11119443|NCT03938896|Other|platelet rich plasma|It started with puncture of the vein and taking specific amount of autologous blood from the participantnearly a sample of 20 ml of venous blood (Co AY, 2012).The blood sample was put in a sterile tube containing an anticoagulant as sodium citrate.Then the blood sample wascentrifuged for 15 minutes at 1800 rpmwhich leads to separation of the plasma at the top layer from the packed RBCs at the bottom layer. The RBCs layer is removedthenanother centrifugationwas done at 3500 rpm for 10 minuteswhich leads to formation of a more concentratedplatelet layer after removal of PPP(Anitua et al., 2012).Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area.
11119444|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle.
11119445|NCT03938883|Experimental|Ocular Bandage Gel (OBG)|Cross-linked Hyaluronic Acid 0.75%, regulated through CDRH (device). EyeGate Ocular Bandage Gel will be applied topically to both eyes (OU) four times a day. Ocular Bandage Gel use is discontinued once complete re-epithelialization has occurred in that eye.
11119446|NCT03938883|Other|Bandage Contact Lens (BCL)|standard-of-care post-operative intervention following PRK. BCL (Acuvue® Oasys plano lens) applied OU. Bandage contact lens use is discontinued once complete re-epithelialization has occurred in that eye.
11119447|NCT03938870||Experimental: Group 1|30 Young Normal Controls(YNC) ages 18 & Older will enroll to evaluate leucine infusion methods of labeling, vs. the oral method. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
11119448|NCT03938870||Experimental: Group 2|Group 30 CDR > 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
11119582|NCT03937882|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
11119449|NCT03938870||Experimental: Group 3|Group of 40 CDR = 0 Age Matched. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
11119450|NCT03938857|Placebo Comparator|Fen. SOC+saline placebo (bolus+infusion)|Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
11119451|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
11119452|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
11119453|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
11119454|NCT03938844||TLH with BURCH Colposuspension|the patients who underwent simultaneous burch copying with TLH was evaluated. In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
11119455|NCT03938844||TLH with Transobturatuar Tape (TOT)|In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
11119456|NCT03938831|Experimental|dexmedetomidine group|dexmedetomidine mixture with fentanyl-based PCA infusion for 2 days
11119457|NCT03938831|Placebo Comparator|control group|Fentanyl-based PCA infusion for 2 days
11119458|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures
11119459|NCT03938818|Experimental|Tu'Washindi intervention|"Standard of care will include PrEP delivery according to the usual DREAMS procedures. The Tu'Washindi intervention includes the following components:
~PrEP sensitization for men (community level).
~Buddy Days (partner level).
~Adherence support clubs (individual and peer levels)."
11119460|NCT03938805|Experimental|I-CBT|Internet-based cognitive behavioral therapy program including 1-week introduction, 2 weeks psycho education on Cardiovascular disease/insomnia, 6 weeks of sleep hygiene, stimulus control and sleep restriction
11119461|NCT03938805|Active Comparator|Control group|3 weeks internet-based sleep hygiene education
11119462|NCT03938792|Experimental|PF-06741086|Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
11119463|NCT03938779|Experimental|Pelvic Floor Muscle Training (PFMT)|Experimental group will perform for 4 months a PFMT
11119464|NCT03938779|Experimental|Pad test|The experimental and control group will perform the pad test twice. At the beginning of the evaluation and 4 months after the PFMT. The modified pad test, has the durability of a workout (2h30min)
11119465|NCT03938779|No Intervention|Kings Health Questionnaire|Kings Health Questionnaire to assess the impact of urinary incontinence on quality of life of women. Both groups will complete the questionnaire.
11119466|NCT03938779|No Intervention|perineometer|Both groups will perform perineometry at baseline and 4 months after
11119467|NCT03938766|Other|PSMA PET/CT|Repeat PSMA PET/CT after ADT
11119468|NCT03938753|Experimental|Phonak Audéo M90-T|The Phonak Audéo M90-T is a Receiver-in-the-canal Hearing aid with direct connectivity functionality and a T-Coil from Phonak which will be fitted to the participants individual Hearing loss.
11119469|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
11119470|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
11119471|NCT03938714|Active Comparator|CH( Conventional Hemorrhoidectomy)|Closed Conventional Hemorrhoidectomy
11119472|NCT03938714|Experimental|HS( Harmonic Scalpel)|Harmonic Scalpel Hemorrhoidectomy
11119473|NCT03938701|Experimental|Fluorescence imaging with OTL38|"Fluorescence imaging with OTL38 in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) patients. A non-randomised, non-blinded, prospective, feasibility study.
~- Administration of 0.0125 mg/kg OTL38 to a total of 30 patients: 10 with Crohn's disease, 10 with ulcerative colitis and 10 with rheumatoid arthritis."
11119474|NCT03938688|Other|Transfascial sutures for mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. Full thickness transfascial sutures will be placed circumferentially to secure the mesh using slowly absorbable no. 1 sutures. A total of at least six transfascial sutures will be placed universally for all patients with additional sutures allowed according to each surgeon's discretion. Additional bone or ligament sutures for mesh fixation will be allowed according to each surgeon's discretion.
11119475|NCT03938688|No Intervention|No mesh fixation|Mesh will be placed in the retromuscular space, with wide overlap on all sides. No fixation method will be used. Bone or ligament sutures for mesh fixation will not be allowed.
11119476|NCT03938675||Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
11119477|NCT03938675||No Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
11119478|NCT03938662|Experimental|S-Adenosyl methionine and choline|Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.
11119479|NCT03938662|Placebo Comparator|Placebo|Patients in will be administered with placebo once daily for 24 weeks.
11119480|NCT03938649|Experimental|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).
~38 fractions of daily treatment, Monday to Friday"
11119481|NCT03938649|Experimental|SBRT|"RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)
~5 fractions of weekly treatment. Once fraction per week."
11119482|NCT03938636|Experimental|Subjects Free of Inflammatory Disease|The first arms is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
11119483|NCT03938636|Experimental|RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment, respectively, are designed to apprise the image re-image and/or test re-test (i.e., repeat dose) consistency of joint-specific and global TUVs across a variety of image acquisition intervals
11119484|NCT03938636|Experimental|Candidates for Initiation of, or Change to,|The third arm is designed to assess the efficacy of TUV global in clinically diagnosed subjects with active RA who are candidates for initiation of, or change to, a new anti-TNFα bDMARD therapy.
11119485|NCT03938623||Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
11119486|NCT03938623||Control|General Practitioners not using the patient-centered approach
11119487|NCT03938584|Experimental|Vitamin C|
11119488|NCT03938584|Placebo Comparator|Placebo|
11119489|NCT03938571|Experimental|Standard DS|"Standard duodenal switch:
~Sleeve gastrectomy over a 35 Fr bougie
~Division of the duodenum 2-3 cm distally of the pylorus
~Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.
~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.
~Entero-entero-anastomosis linear stapled and handsewn.
~Division between the two anastomosis.
~Closure of the mesenteric defects."
11119490|NCT03938571|Active Comparator|SADI-DS|"Duodenal switch with Single anastomosis duodeno-ileostomy:
~Sleeve gastrectomy over a 35 Fr bougie
~Division of the duodenum 2-3 cm distally of the pylorus
~Measurement of the small bowel. 250 cm alimentary limb/common channel.
~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.
~Closure of the mesenteric defects."
11119491|NCT03938558|Experimental|Dance intervention group|"Dancers at beginners level
~Dancers at advanced level"
11119492|NCT03938558|Active Comparator|Art intervention group|"Paint artists
~Word artists
~Film artists
~Photographers"
11119493|NCT03938545|Experimental|Regimen A-RVT-1401|Regimen A= RVT-1401 680 mg weekly for 12 weeks
11119494|NCT03938545|Experimental|Regimen B-RVT-1401|Regimen B= RVT-1401 340 mg weekly for 12 weeks
11119495|NCT03938545|Experimental|Regimen C-RVT-1401|Regimen C= RVT-1401 255 mg weekly for 12 weeks
11119496|NCT03938545|Placebo Comparator|Placebo|for 12 weeks
11119497|NCT03938532|Active Comparator|Control Arm|Infant will receive pressure regulated breaths, 40-60 breaths/min, PiP of 20-24cm of water as recommended by 2017 Neonatal Resuscitation Program (NRP) guidelines. Reading of the TV will be blinded from the providers as in routine clinical situations
11119498|NCT03938532|Experimental|Intervention Arm|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
11119499|NCT03938506||intubation using the endotracheal tube size of 6.0 or 8.0|Adult male patients who require endotracheal intubation using the endotracheal tube size of 6.0 or 8.0
11119500|NCT03938493||endotracheal intubation under general anesthesia|Adults who require endotracheal intubation for head and neck surgery under general anesthesia
11119501|NCT03938467|Experimental|Antiseptic Cleanser|Standard prophylaxis will be administered by Irrisept patients as would individuals in the control group. In addition, these Irrisept study subjects will be supplemented with the use of Irrisept irrigation by the study surgeon during the patient's surgical procedure. Standard times for irrigation will include immediately after incision through the dermal layer, and immediately prior to implantation of any prosthetic components. Final irrigation will be performed just prior to closure of the deltopectoral interval.
11119502|NCT03938467|No Intervention|Standard of Care Prophylaxis|Standard prophylaxis includes use of chlorhexidine wipes (Sage cloth) the night before and morning of surgery on the surgical site over the anterior shoulder.
11119503|NCT03938454|Experimental|Crizanlizumab|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51
11119504|NCT03938441|Experimental|Intermittent Fasting|Modified 5:2 intermittent fasting
11119505|NCT03938415|Experimental|Acupuncture|Acupuncture
11119506|NCT03938415|Active Comparator|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone
11119507|NCT03938402|Experimental|PEEP 5|
11119508|NCT03938402|Experimental|PEEP 10|
11119509|NCT03938402|Experimental|PEEP 15|
11119510|NCT03938389|Active Comparator|Valsartan|Valsartan 160 mg twice daily for 26 weeks
11119511|NCT03938389|Experimental|Sacubitril/Valsartan|Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks
11119512|NCT03938389|Placebo Comparator|Placebo|placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)
11119513|NCT03938376||Potential Prostate Cancer|Biopsy naïve patients with rising Prostate Specific Antigen (PSA) results referred by their Urologist for a standard of care (SOC) biopsy.
11119514|NCT03938363|Experimental|Cervical Dystonia (CD)|Patients with cervical dystonia
11119515|NCT03938363|Placebo Comparator|Healthy Control CD|CD age- and sex-matched healthy control subjects
11119516|NCT03938363|Experimental|Blepharospasm (BS)|Patients with blepharospasm
11119517|NCT03938363|Placebo Comparator|Healthy Control BS|BS age- and sex-matched healthy control subjects
11119518|NCT03938350|Experimental|Dialectical Behavior Therapy (DBT) Skills Training|Participants in this group will receive 8 weeks of Dialectical Behavior Therapy (DBT) Skills Training.
11119519|NCT03938350|No Intervention|Treatment as Usual|Participants in this study arm will receive treatment as usual consisting of routine prenatal care with any mental health assessment, social work involvement or mental health service provision based on clinician referral or self-referral.
11119520|NCT03938337|Experimental|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
11119521|NCT03938337|Experimental|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
11119522|NCT03938324|Experimental|PiCASO Intervention Group|Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
11119523|NCT03938324|Sham Comparator|Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
11119524|NCT03938311|Experimental|very early rehabilitation|early mobilization initiates within 24h from the onset of the disease
11119525|NCT03938311|Experimental|relative early rehabilitation|early mobilization initiates between 24-72h from the onset of the disease
11119526|NCT03938311|Experimental|early rehabilitation|early mobilization initiates after 72h from the onset of the disease
11119527|NCT03938298|Experimental|Intervention group|
11119528|NCT03938298|Active Comparator|Control group|
11119529|NCT03938285|Active Comparator|High Flux Hemodialysis|High Flux Hemodialysis with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment.
11119530|NCT03938285|Active Comparator|Extended Hemodialysis|Extended Hemodialysis with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment.
11119531|NCT03938285|Active Comparator|On Line Hemodiafiltration|On Line Hemodiafiltration with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
11119532|NCT03938285|Active Comparator|On Line Hemodiafiltration with an MCO membrane|On Line Hemodiafiltration with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
11119533|NCT03938272|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes Strain HC-1
11119534|NCT03938259||Control group; patients without obstructive sleep apnea|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
11119535|NCT03938259||Patients with known obstructive sleep apnea|Children with OSA having adenotonsillectomy for obstructive apnea will receive opioids with evaluation of respiratory changes
11119536|NCT03938246|Experimental|TVB-2640|Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours). Two dose cohorts of TVB-2640 are planned.
11119537|NCT03938246|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.
11119538|NCT03938233|Active Comparator|DSME program delivered by community health volunteers|Randomisation will happen in 21 primary care units to offer DSME delivered by lay health workers to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
11119539|NCT03938233|Active Comparator|DSME program delivered by nurses|Randomisation will happen in 21 primary care units to offer DSME delivered by nurses (for comparative effectiveness) to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
11119540|NCT03938233|No Intervention|Usual care(no DSME program)|Randomisation will happen in 21 primary care units where no DSME will be offered to those newly diagnosed with diabetes and/or those having difficulties with self-managing their diabetes.These patients will continue with usual care and will be assessed as the control group.
11119541|NCT03938220||fluid responders|fluid responder if stroke volume increases by > 10% after the fluid challenge
11119542|NCT03938220||fluid non responders|fluid responder if stroke volume increases by <= 10% after the fluid challenge
11119543|NCT03938207||Dry eye syndrome|Dry eye syndrome patients were extracted from Taiwan Biobank.
11119544|NCT03938207||Health subjects|Health subjects were extracted from Taiwan Biobank.
11119545|NCT03938207||Sjögren's syndrome|Sjogren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
11119546|NCT03938194|Experimental|Aquablation|Surgery of benign prostatic hyperplasia by waterjet ablation
11119547|NCT03938168||Pain patients|30 patients eligible for adhesiolysis because of chronic adhesion-related pain. Patients are recruited at the RadboudUMC, MUMC+ and Pantein hospital departments of surgery. These are patients with chronic pain after previous abdominal surgery who have been selected for operative treatment after evaluated with CineMRI. CineMRI is used to map adhesions. This technique has been established to provide insight in localization of adhesions in relation to the pain, and risk of bowel injury based on extensiveness of adhesions.
11119548|NCT03938168||Control group|The control group will comprise of 30 patients undergoing an abdominal reoperation during which adhesiolysis has to be performed for reasons other than chronic adhesion-related pain.
11119549|NCT03938142||patients with chronic pain|
11119550|NCT03938129||Group 1|Pregnant women and their baby
11119551|NCT03938116|Experimental|Healing Hearts Together|
11119552|NCT03938116|No Intervention|Usual Care|
11119553|NCT03938103|Experimental|Enhanced Go NAPSACC|Enhanced delivery model
11119554|NCT03938103|Active Comparator|Basic Go NAPSACC|Basic delivery model
11119555|NCT03938090|Placebo Comparator|Standard biventricular pacing|Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings
11119556|NCT03938090|Active Comparator|Optimised MultiSite Pacing (MSP)|Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.
11119557|NCT03938077|Experimental|S4E App intervention|"Youth will receive the S4E intervention via provided iPads. The intervention will last approximately 60. Content includes: (a) storytelling scenarios, (b) drug use and HIV/STI knowledge, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual and drug use risk behaviors and increase HIV self-testing, (e) Near Peer-youth communication, and (f) highlighting prevention principles. The youth will participate in a Near Peer-initiated prevention and risk reduction encounter which includes (a) reinforcement of HIV solutions that youth learned in the S4E app, (b) promotion of HIV self-tests, and (c) linkage to care and prevention services.
~Youth have the option to take a HIV self-test. We will determine the acceptability of youth disclosing their results to their Near Peer and linkage to resources.
~The research staff will also conduct in-depth qualitative interviews with both youth and Near Peer participants to assess feasibility and acceptability of S4E."
11119558|NCT03938064|Active Comparator|Group Early start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries from the day of ovum retrieval (OR).
11119559|NCT03938064|Placebo Comparator|Group Late start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries 2 days after OR.
11119560|NCT03938051|Experimental|Experimental group|Multi-component intervention
11119561|NCT03938051|Experimental|Control group|treadmill walk
11119562|NCT03938038|Active Comparator|Serial ultrasound assessments for GDT|
11119563|NCT03938038|Active Comparator|Usual care|
11119564|NCT03938012||Lung and head and neck tumours|"Age 18 years or older
~Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region
~No other active malignancy within the past 24 months
~Refractory disease"
11119565|NCT03937999|Experimental|Bezlotoxumab Arm|Single dose of Bezlotoxumab 10mg/kg iv over 60 minutes on Day 0
11119566|NCT03937999|No Intervention|No Bezlotoxumab|Control group who are eligible as per the inclusion/exclusion criteria to the Bezlotoxumab arm, but not given Bezlotoxumab (Day 0) .
11119567|NCT03937986|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11119568|NCT03937986|Experimental|Suvorexant Dose 1|Subjects will be maintained on oral suvorexant dose 1. Cocaine will be administered acutely during suvorexant dose 1 maintenance. Placebo will be administered acutely during suvorexant dose 1 maintenance.
11119569|NCT03937986|Experimental|Suvorexant Dose 2|Subjects will be maintained on oral suvorexant dose 2. Cocaine will be administered acutely during suvorexant dose 2 maintenance. Placebo will be administered acutely during suvorexant dose 2 maintenance.
11119570|NCT03937986|Experimental|Suvorexant Dose 3|Subjects will be maintained on oral suvorexant dose 3. Cocaine will be administered acutely during suvorexant dose 3 maintenance. Placebo will be administered acutely during suvorexant dose 3 maintenance.
11119571|NCT03937973|Experimental|Social rejection by in-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone of their own race/ethnicity (e.g., African American rejected by another African American).
11119572|NCT03937973|Experimental|Social rejection by out-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone not of their own race/ethnicity (e.g., Caucasian American rejected by another African American).
11119573|NCT03937960|Active Comparator|Carbohydrate restricted group|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose. It will provide a fixed amount of carbohydrate, and a total calorie goal - with proteins and fats to satiety. During the first two weeks of the intervention, carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day. At week three, additional CHO sources will be added back to the diet prescription including nuts, unsweetened yogurt, and low-glycemic fruits such as apples and berries.
11119574|NCT03937960|Active Comparator|Standard/Low fat diet group|The control, low-fat diet will contain 55:25:20 %energy from CHO: protein: fat based on the United States Department of Agriculture (USDA) My Plate Daily Food Plan and our groups previous work. For example, an 1800 kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
11119575|NCT03937934|Experimental|Subjects with long term health condition|Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton
11119576|NCT03937921||Group 1 - Dotarem|Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study
11119577|NCT03937921||Group 2 - Gadavist|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.
11119578|NCT03937908|Experimental|2g CAP|Single administration of 2g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
11119579|NCT03937908|Experimental|4g CAP|Single administration of 4g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
11119580|NCT03937895|Experimental|Experimental: single arm|"Biological: 'SMT-NK' Inj. (allogeneic Natural Killer cell) weekly administration for 2 weeks. After that, 1 week is a withdrawal period. (Phase 1: up to *cycle 3, Phase 2a: up to cycle 9)
~Drug: Pembrolizumab administration of Pembrolizumab 200mg/m2 at first week during cycle.
~Cycle: 1 cycle is 3 weeks in total.'SMT-NK' Inj is administered at first and second week, and Pembrolizumab is administered at first week. The third week is a withdrawal period."
11119581|NCT03937882|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
11119583|NCT03937869|Other|Single dose Solosec (secnidazole) 2g oral|Solosec 2 grams, oral
11119584|NCT03937856|Experimental|Intervention group|Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
11119585|NCT03937856|No Intervention|Control group|Usual care participants.
11119586|NCT03937843|Experimental|Arm with 2 cohorts|"Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:
~Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday.
~Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:
~Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday."
11119587|NCT03937830|Experimental|1/ Arm 1|Durvalumab, bevacizumab and tremelimumab
11119588|NCT03937830|Experimental|2/ Arm 2|Durvalumab, bevacizumab, tremelimumab and TACE
11119589|NCT03937817||1|Healthy volunteers and patients with hemolytic diseases, including sickle cell disease andmalaria, or other diseases involving inflammation or endothelial dysfunction.
11119590|NCT03937804||asthmatics|persons with asthma
11119591|NCT03937804||control|persons without asthma
11119592|NCT03937791|Experimental|Arm 1|1x1011 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
11119593|NCT03937778|Experimental|1/Blocked Arm|Arm with applied deep pressure block
11119594|NCT03937765|Experimental|PRP|Intervention group will receive PRP instead of the standard of care for skin grafts. PRP Group-will remove surgical dressing post operative day 5. Donor site will be cleaned with soap and water daily and dressed with gauze daily until drainage stops.
11119595|NCT03937765|No Intervention|Control|Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.
11119596|NCT03937752||Anal fistula|Patients with anal fistulas, no previous fistula procedures. Ultrasound investigation done as a part of surgical treatment, such as loose seton or fistulotomy.
11119597|NCT03937739||Group 1: Case group,|The patients who admitted to the general surgery for operation with inguinal hernia were the case group of this study.
11119598|NCT03937739||Group 2: Control group,|The patients who were admitted to the same hospital with such as eye, ear/nose/throat, dermatologic diseases or elective surgeries and did not have any inguinal hernia complaints, constipation and other chronic disease which could increase the intra abdominal pressure selected as control group.
11119599|NCT03937726|Experimental|Boiled peanut Oral Immunotherapy|Desensitisation using boiled peanut
11119600|NCT03937726|Active Comparator|Conventional Oral immunotherapy|Desensitisation using defatted peanut flour
11119601|NCT03937713|Experimental|BBTI plus eszopiclone|participants randomized to the combination therapy will receive eszopiclone 2 mg orally at bedtime or placebo starting with the BBTI sessions for a period of 2 weeks in combination with 4 sessions of BBTI over 4 weeks.
11119602|NCT03937713|Active Comparator|BBTI|participants randomized to BBTI will receive 4 sessions of BBTI over 4 weeks.
11119603|NCT03937700|Experimental|CPWalker Robotic-Assisted Gait Training|Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours
11119604|NCT03937687|Placebo Comparator|Placebo|300 mg cellulose
11119605|NCT03937687|Experimental|Caffeine|300 mg caffeine
11119606|NCT03937687|Experimental|Caffeine Combination|150 mg caffeine with 100 mg Dynamine and 50 mg TeaCrine
11119607|NCT03937674|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
11119608|NCT03937661|Experimental|Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.
11119609|NCT03937661|Placebo Comparator|Control Group: participants receiving Platelet Free Plasma|Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period
11119610|NCT03937648|Experimental|COL-144 50mg|
11119611|NCT03937648|Experimental|COL-144 100mg|
11119612|NCT03937648|Experimental|COL-144 200mg|
11119613|NCT03937648|Experimental|COL-144 400mg|
11119614|NCT03937648|Placebo Comparator|Placebo|
11119615|NCT03937635|Experimental|Arm I (daratumumab, lenalidomide, dexamethasone)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11119616|NCT03937635|Experimental|Arm II (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11119617|NCT03937609|Other|Standard dosing|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The control group will continue with 5 mg/kg IFX at week 2 and 6, followed by every 8 weeks.
11119618|NCT03937609|Experimental|Intervention group|All eligible patients will receive an intravenous infusion of IFX at 5 mg/kg IFX at week 0. The intervention group will receive model based dosing of infliximab with 5mg/kg at various timepoints based on the dashboard model.
11119619|NCT03937596|Experimental|D-Cycloserine|Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
11120594|NCT03930667|Experimental|knotting|Closure of the appendix stump with intracorporal knotting.
11119620|NCT03937596|Placebo Comparator|Placebo|Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for the first 2 weeks of rTMS treatment (10 sessions), followed by 2 weeks of rTMS without adjunctive medication.
11119621|NCT03937583|No Intervention|Limited screening|Complete clinical history, along with routine physical, analytical examination (creatinine, sodium, potassium, red series, white series, liver and calcium profile) and chest x-ray.
11119622|NCT03937583|Experimental|Extended screening|Limited screening plus positron emission tomography / computed tomography with 18 FDG (18FDG PET-CT).
11119623|NCT03937570|Experimental|EO GROUP|Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.
11119624|NCT03937570|No Intervention|CONTROL GROUP|Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.
11119625|NCT03937557|Active Comparator|men's hair count|
11119626|NCT03937557|Placebo Comparator|women's hair count|
11119627|NCT03937544|Experimental|CD19 CAR-T CELLS|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
11119628|NCT03937531|Experimental|Retrograde-fill void trial (RVT)|Subjects will leave the operating room with a urinary catheter inserted. Subjects should be recovered from anesthesia effects (2-3 hours after surgery) before voiding trial. First, the bladder will be completely drained into the Foley bag then the bag will be detached from the catheter. The bladder will be back-filled with sterile water (300 mL). After the catheter is removed, subjects are expected to void at least 2/3 (200 mL) of the total instilled amount within 30 minutes of filling. Post-void residual (PVR) will be measured by both subtraction of the voided volume from 300cc and by using a bladder scanner.
11119629|NCT03937531|Active Comparator|Spontaneous void trial (SVT)|"Subjects will leave the operating room without a urinary catheter. Participants are allowed up to 6 hours after surgery for spontaneous voiding. After voiding, the voided volume will be noted. PVR will be measured using a bladder scanner.
~In both groups, if PVR >=100 mL on a bladder scanner, an indwelling urinary catheter will be placed and the actual PVR will be documented. Subjects who failed voiding trial will be instructed to return to clinic within 2-4 days for the second void trial. Prophylactic antibiotics will NOT be given. The time to discharge will be measured for each subject. This will be determined by calculating the time between arrival to the PACU and the time of discharge using documentation from EPIC."
11119630|NCT03937518|Other|strontium ranelate|included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years,
11119631|NCT03937518|Other|physiotherapy|included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years
11119632|NCT03937505|Experimental|Dose-escalation|Dose-cohort escalation of single intravenous injection of IS-001 starting with 20 mg (n=8), escalating in 20 mg increments until optimal dose is determined.
11119633|NCT03937505|Experimental|Optimal dose-characterization|Single intravenous injection of IS-001 at the optimal dose will be administered to subjects assigned to the treatment group. Safety control subjects will not receive any study drug but will undergo robotic surgery and all associated safety assessment clinical trial procedures.
11119634|NCT03937492|Experimental|A group|In this group patients follow standard treatment after radius fracture plus GMI procol
11119635|NCT03937492|Active Comparator|B group|In this group patients follow standard treatment after radius fracture
11119636|NCT03937479|Experimental|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
11119637|NCT03937479|Experimental|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
11119638|NCT03937479|Experimental|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
11119639|NCT03937479|Experimental|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
11119640|NCT03937479|Placebo Comparator|Placebo twice daily|Placebo twice daily
11119641|NCT03937466|Experimental|Experimental Cooling Mattress Pad|Subjects will use a cooling mattress pad nightly for approximately 8 weeks
11119642|NCT03937453||New-Onset Diabetes Mellitus|Diabetes Mellitus diagnosed within the past 12 months
11119643|NCT03937440|Experimental|Deep neuromuscular block group|
11119644|NCT03937440|Experimental|Moderate neuromuscular block group|
11119645|NCT03937427||CRS with Asthma|
11119646|NCT03937427||CRS without Asthma|
11119647|NCT03937414|Experimental|SLNs were tested by the OSNA assay Intraoperatively|SLNs were tested by the OSNA assay Intraoperatively
11119648|NCT03937401|Experimental|Patients treated with oxytocin during MRI-HIFU|
11119649|NCT03937388|Experimental|Cochlear implant recipients|
11119650|NCT03937375||High PEEP|Use of high levels of PEEP with recruitment maneuvers
11119651|NCT03937375||Low PEEP|Use of low levels of PEEP without recruitment maneuvers
11119652|NCT03937362||Clinical Response Evaluation|"Patients with operable esophageal squamous cell carcinoma who are planned to undergo neoadjuvant chemoradiotherapy according to the CROSS regimen (intravenous carboplatin AUC 2 mg/mL/min and intravenous paclitaxel 50 mg/m2 on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery.
~Patients will undergo a first clinical response evaluation (CRE-1) 4-6 week after completion of nCRT. In patients without histological evidence of residual tumor surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy."
11119653|NCT03937349||sPTx group|Patients underwent subtotal parathyroidectomy due to severe secondary hyperparathyroidism
11119654|NCT03937349||TPTx+AT group|Patients underwent total parathyroidectomy with immediate autotransplantation of parathyroid tissue due to severe secondary hyperparathyroidism
11119655|NCT03937349||Control group|Patients with severe SHPT on conservative treatment (calcimimetics, active vitamin D analogues, phosphate-binders) who are likely to undergo surgery in a period of 12 months
11119656|NCT03937336|No Intervention|Control Group|
11119657|NCT03937336|Experimental|Bike Intervention Group|A 1-month bike-based program (1 session/week)
11119658|NCT03937323||Group 1: Pancreatitis group|Patients with biliary pancreatitis
11119659|NCT03937323||Group 2: Control group,|Healthy volunteers
11119660|NCT03937310||Surgical intervention for non-union|The investigation group will consist of cases undergoing surgical intervention for non-union
11119661|NCT03937310||Acute fracture fixation|The control group will consist of cases undergoing acute fracture fixation
11119662|NCT03937297|Experimental|Arm 1|Six Arts intervention
11119663|NCT03937297|Experimental|Arm 2|Cognitive Stimulation Therapy (CST)
11119664|NCT03937297|Active Comparator|Arm 3|Usual care (control group)
11119665|NCT03937284||Parkinson's patients|Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
11119666|NCT03937284||Control group|Subject matched for sex, age and BMI
11119667|NCT03937271||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
11119668|NCT03937271||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 revised Systemic lupus erythematosus criteria
11119669|NCT03937271||Rheumatoid Arthritis|Rheumatoid Arthritis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria
11119670|NCT03937271||Systemic Sclerosis|Systemic Sclerosis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1980 ACR eSystemic Sclerosis criteria
11119671|NCT03937271||Ankylosing spondylitis|Ankylosing spondylitis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1984 Ankylosing spondylitis Modified New York criteria
11119672|NCT03937271||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min
11119673|NCT03937258|Other|PF-04965842 single dose|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
11119674|NCT03937258|Other|PF-04965842 multiple doses|In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions.
11119675|NCT03937258|Other|Probenecid and PF-04965842|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
11119676|NCT03937245||HA-BSI|Patients with HA-BSI treated in an ICU
11119677|NCT03937232|Active Comparator|Cross-Education|Cross education has been defined as the unilateral training of a limb with resisted exercise for the benefit of transferring strength to the contralateral (often injured or immobilized) limb. Participants randomized to cross-education will be provided with a hand-grip strengthener, adjusted to provide resistance at 70-80% of their maximum grip strength. They will be given written, illustrated instructions for performing grip strengthening exercises for their uninjured hand in a seated position with both forearms comfortably supported; this will be demonstrated during the teaching session. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
11119678|NCT03937232|Active Comparator|Mirror Visual Feedback|Mirror visual feedback is the performance of movements with an uninjured hand in front of a mirror hiding the injured hand, thus creating the illusion of bilateral movement. Participants randomized to mirror visual feedback will be provided with a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization of exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete a three sets of 10 repetitions for finger flexion and extension (mimicking the fisting motion of the grip strengthening exercises) twice daily. A diary for tracking exercise completion and attendance for usual care will also be provided.
11119679|NCT03937232|Experimental|Cross-education + Mirror Visual Feedback|In this group, participants will perform the cross-education resistance exercise in front of the mirror, visualizing the performance of the resistance exercises. Participants randomized to cross education with mirror visual feedback will be provided with both a hand-grip strengthener and a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization hand grip strengthening exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
11119680|NCT03937232|Active Comparator|Usual Care|Participants randomized to usual care will be encouraged to attend the recommended rehabilitation, and provided with a diary for frequency of rehab attendance, and tracking any exercises completed at home.
11119681|NCT03937219|Experimental|Experimental Arm|Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab
11119682|NCT03937219|Active Comparator|Control Arm|Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab
11119683|NCT03937206|Experimental|Low Dose|Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
11119788|NCT03936413|Active Comparator|Native Terason group|In this arm, medical residents will use the native Terason machine to perform an echocardiogram.
11119684|NCT03937206|Experimental|Mid Dose|Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
11119685|NCT03937206|Experimental|High Dose|High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
11119686|NCT03937206|Placebo Comparator|Placebo|Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
11119687|NCT03937193||Non-SMAS group|subjects in this group are not clinically diagnosed as superior mesenteric artery syndrome(SMAS).
11119688|NCT03937193||SMAS group|subjects in this group are clinically diagnosed as superior mesenteric artery syndrome(SMAS).
11119689|NCT03937180|Other|Usual care|Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
11119690|NCT03937180|Experimental|Blended care|Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
11119691|NCT03937167|No Intervention|Control|Standard treatment at Hospital Infanta Leonor with Endocrinology and Psyquiatry
11119692|NCT03937167|Experimental|Completers|Randomized to treatment AND complete treatment 14 sessions are needed
11119693|NCT03937167|No Intervention|Drop-out|Randomized to treatment BUT do not assist or do not complete treatment Less than 14 sessions
11119694|NCT03937154|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
11119695|NCT03937154|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
11119696|NCT03937141|Experimental|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
11119697|NCT03937128|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
11119698|NCT03937128|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
11119699|NCT03937115|Experimental|Group S1|High level jump practice : more 4000 hours of practice during the last five years
11119700|NCT03937115|Experimental|Group S2|Amateur jump practice : less 4000 hours of practice during the last five years
11119701|NCT03937115|Experimental|Group C1|High level cycling practice: more 4000 hours of practice during the last five years
11119702|NCT03937115|Experimental|Group C2|Amateur cycling practice: less 4000 hours of practice during the last five years
11119703|NCT03937115|Experimental|Group T|Sedentary : less two hours of recreationally practice of sport by week
11119704|NCT03937089||Patients|Patients with persistent AF, who underwent a CA procedure in the Nancy hospital between January 2011 and April 2017, will be included in this retrospective study.
11119705|NCT03937076|No Intervention|intercostal block|patients will get intercostal block at the end of the surgery, control group
11119706|NCT03937076|Experimental|PECS II block|patients with get PECS II block at the end of the surgery, research group
11119707|NCT03937050|Experimental|Intervention|A package of three interconnected educational/behavioural film-based interventions will developed for delivery at the cluster (clinic) level. The aim of the three components will be as follows: a) improving knowledge of GDM guidelines and skills among health providers involved in GDM management, b) raising awareness of GDM and the importance of screening among pregnant women and their family members, and c) improving confidence and skills in self-management of GDM among women diagnosed.
11119708|NCT03937050|No Intervention|Control|Usual care practices.
11119709|NCT03937037|Experimental|Saline irrigation|CBD stone removal after routine ERCP procedure,100ml saline irrigation after a balloon occlusion cholangiogram confirming the absence of stones.
11119710|NCT03937037|No Intervention|None saline irrigation|CBD stone removal after routine ERCP procedure, a balloon occlusion cholangiogram confirms the absence of stones.
11119711|NCT03937011||Stratafix Arm|The single study arm would comprise of two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure).
11119712|NCT03936998|Experimental|vancomycin plus VE416 before PNOIT|active vancomycin plus VE416 before PNOIT
11119713|NCT03936998|Experimental|Vancomycin plus VE416 with PNOIT|active vancomycin plus active VE416 with active PNOIT
11119714|NCT03936998|Experimental|Placebo plus VE416 with PNOIT|placebo vancomycin plus active VE416 with active VE416
11119715|NCT03936998|Active Comparator|Placebo plus placebo with PNOIT|placebo vancomycin and placebo VE416 with active peanut oral immunotherapy
11119716|NCT03936972||ilizarov circular frame|46 participants with open tibia fracture Gustillo type III only
11119717|NCT03936972||Ex. Fix|47 participants with open tibia fracture Gustillo type III only
11119718|NCT03936959|Experimental|LY3434172|LY3434172 administered IV
11119719|NCT03936946|Experimental|Group 1--October Start Audio Content 1|This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention
11119720|NCT03936946|Other|Group 2--November Start Audio Content 1|This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.
11119721|NCT03936946|Sham Comparator|Group 3--October Start Audio Content 2|This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.
11119722|NCT03936933|Experimental|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
11119723|NCT03936933|Active Comparator|ZOLADEX® 3.6mg Injection.|3.6 mg, Subcutaneously at every 28 days
11119724|NCT03936907|Experimental|Orally Disintegrating MGC-ODT Tablet|Administration of a single tablet of Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5mg THC and 5 mg CBD
11119725|NCT03936907|Active Comparator|Sativex®|Sativex® spray X 2 actuations (1 under the tongue and 1 inside the cheek administered within 2 min) - Reference Product [Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 5.4 mg THC and 5.0 mg CBD]
11119726|NCT03936894|Experimental|Treatment|Canakinumab treatment
11119727|NCT03936868||Tendon transfer for irreversible radial nerve palsy patient|Tendon transfer for irreversible radial nerve palsy patient who had irreversible damage to radial nerve due to trauma with different mechanism especially gun shot injury
11119728|NCT03936855|Active Comparator|Incremental filling technique|Glass ionomer in the pulp chamber and incremental filling technique using composite resin
11119729|NCT03936855|Experimental|Bulk Fill|Bulk fill composite resin filling all the cavity
11119730|NCT03936842|Experimental|Single Arm|"Eligible patients who are referred to the one-stop diagnostic clinic with breast pain alone and have completed a clinical assessment will be given a patient information sheet inviting them to participate in the study. They will be met by the interviewing clinician at the same visit."
11119731|NCT03936829|Experimental|Interventional|Drug:Cyclophosphamide Dosage form: intravenous infusion Dosage: 500 mg/m2 of BSA Frequency: every 4 weeks Duration: 24 weeks
11119732|NCT03936816||GBS screened positive|150 patients that were screened positive by culture at 35-37 weeks gestational age.
11119733|NCT03936816||GBS unknown with risk factors|150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
11119734|NCT03936803|Active Comparator|exercise group|Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD) and taking their standard medications in addition to aerobic interval training exercise .Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with heart rate (HR) at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum heart rate HR. The exercise session was terminated by 5 minutes cool-down
11119735|NCT03936803|Active Comparator|electro-acupuncture group|"Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD), and taking their standard medications In addition to electro acupuncture (EA) of (2 Hz, 4 mA) was applied at points of: liver 3 (LR3) ,liver 14 (LR14), gall bladder 34 (GB 34) and stomach 36 (ST36) .
~Duration of the session was 15 min / each, three sessions per week for six weeks"
11119736|NCT03936790|Other|Ropi_dosing|The dose of ropivacaine for each parturient is determined by the response of the previous participant to a higher or lower dose according to the sequential distribution algorithm (up-down sequential allocation).
11119737|NCT03936777|Experimental|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
11119738|NCT03936764|Other|Group 1|5 Preoperative Pulmonary Rehabilitation sessions / week during 3 weeks.
11119739|NCT03936764|Other|Group 2|3 Preoperative Pulmonary Rehabilitation sessions / week during 5 weeks.
11119740|NCT03936751|Active Comparator|CPAP|Continuous positive airway pressure
11119741|NCT03936751|Sham Comparator|Nasal strips|Nasal Strips
11119742|NCT03936725||Chronic and non specific low back pain patients|Chronic and non specific low back pain patients
11119743|NCT03936712|Experimental|Red Bull drink (RB)|Over the study, three participants were unable to complete all test sessions due to muscle pain or injury . Thus, 19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg) completed all test sessions
11119744|NCT03936712|Placebo Comparator|Placebo drink|19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg)
11119745|NCT03936699|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
11119746|NCT03936699|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
11119747|NCT03936686|Active Comparator|Children in grades 4 or 5|This group was comprised of participants that were in grades 4 or 5 in school.
11119748|NCT03936686|Active Comparator|Adolescents in grades 10 or 11|This group was comprised of participants that were in grades 10 or 11 in school.
11119749|NCT03936686|Active Comparator|College Age Participants|This group was comprised of participants that were sophomores or juniors in college/university that were non-health career majors.
11119750|NCT03936686|Active Comparator|Cardiac Rehab Adults|This group was comprised of participants that were adults over the age of 40 that had completed a phase II cardiac rehabilitation program.
11119751|NCT03936686|Active Comparator|General Adults|This group was comprised of participants that were adults over the age of 40 that had never attended an outpatient cardiac rehabilitation program before.
11119752|NCT03936673|Experimental|atrophic kidney|Patients diagnosed with unilateral obstructed kidney with RRF 10% or less underwent application of percutaneous nephrostomy tube on affected side.
11119753|NCT03936660|No Intervention|Control|Clinics in the control arm will be encouraged to follow guideline-based care.
11119789|NCT03936400|Experimental|Randomized controlled trial|Experimental group receiving a couple-based intervention
11119754|NCT03936660|Active Comparator|Intervention|The cardiology clinics in the intensive educational intervention arm will receive guidance to develop an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
11119755|NCT03936647|Active Comparator|Standard conventional treatment (surgical or endovascular)|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
11119756|NCT03936647|Experimental|WEB embolization device|Endovascular treatment with WEB, including standard management of thrombo-embolic risk
11119757|NCT03936634||Newly Diagnosed (ND)|Recruited within 6 weeks of type 1 diabetes diagnosis. Age between 1 and <45 years
11119758|NCT03936634||Unaffected Family members (UFM)|"Participants who are not diabetic but have a first degree relative with type 1 diabetes diagnosed < 45 years of age.
~Age between 1 and <45 years"
11119759|NCT03936621|Active Comparator|Group 1: Omega 3 Fatty Acid|Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. In the first 6 months, you will be asked to take one capsule of Omega 3 fatty acids with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks. In the next 6 months (Months 7 to 12), you will have a blood test for markers of inflammation at the end of Month 7 and at Month 9 and 12 to determine if the anti-inflammatory effects of Omega 3 acids are still there after you have stopped taking it.
11119760|NCT03936621|Placebo Comparator|Group 2: Control Arm|No Omega 3 fatty acids for the first 6 months followed by Omega 3 fatty acids for the next 6 months. You will be asked to have a blood test for markers of inflammation at Month 1, 3 and 6 for markers of inflammation to determine the natural variation of the levels of these markers without Omega 3 fatty acid supplements. In Month 7, you will be asked to take one capsule of Omega 3 with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks.
11119761|NCT03936608|Experimental|Individualized RV-LV Pacing Offset|
11119762|NCT03936608|Active Comparator|No RV-LV Pacing Offset|
11119763|NCT03936595|Experimental|Core exercises protocol|Participants will perform 4 core exercises
11119764|NCT03936595|Experimental|Structural exercises protocol|Participants will perform 4 structural (Olympic lifting) exercises
11119765|NCT03936595|Experimental|Accentuated eccentric load exercises protocol|Participants will perform 4 exercises with eccentric loading
11119766|NCT03936595|Other|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
11119767|NCT03936582|Experimental|Treatment|All owners/managers of small businesses in 10 treatment neighborhoods will receive a request to support youth physical activity. The owners/managers will be able to direct support to specific programs, get recognized for their support, receive added information on the benefits of supporting such programs, have the oversight of an advisory board and interface with a local program representative
11119768|NCT03936582|Active Comparator|control|All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
11119769|NCT03936569|Experimental|Marketed Stannous Fluoride Toothpaste|Brush twice daily
11119770|NCT03936569|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
11119771|NCT03936556|Experimental|Marketed Stannous Fluoride Paste|Brush twice daily
11119772|NCT03936556|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
11119773|NCT03936543|Experimental|Extended axillary midline|Operator stands at the bedside on extended midline of the patient's lt. axilla during lt. internal jugular vein catheterization
11119774|NCT03936543|Active Comparator|Extended head midline|Operator stands at the bedside on extended midline of the patient's head during lt. internal jugular vein catheterization.
11119775|NCT03936517|Other|Prednisolone first; hydrocortisone second|Participant will receive 4 months of prednisolone in the first study period and 4 months of hydrocortisone in the second study period.
11119776|NCT03936517|Other|Hydrocortisone first; prednisolone second|Participant will receive 4 months of hydrocortisone in the first study period and 4 months of prednisolone in the second study period.
11119777|NCT03936504|Active Comparator|Control Group|Group received conventional exercise rehabilitation
11119778|NCT03936504|Experimental|Experimental Group|Group received Tai Chi cardiac rehabilitation program
11119779|NCT03936491|Experimental|Methylphenidate|The subjects will receive methylphenidate according to their clinical symptoms
11119780|NCT03936491|Active Comparator|Atomoxetine|The subjects will receive atomoxetine according to their clinical symptoms
11119781|NCT03936478|Experimental|8.2 Gy Radiation Therapy|Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
11119782|NCT03936465|Experimental|Cohort A|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
~Patients with unselected relapsed or refractory solid tumors or lymphoma"
11119783|NCT03936465|Experimental|Cohort B|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.
~Patients with relapsed or refractory solid tumors, lymphoma, or CNS tumors that have defined molecular features predicted to increase sensitivity to BET inhibition"
11119784|NCT03936452|Experimental|Treatment arm|Sintilimab 200mg ivdrip D1 Peg-aspargase 2500U/m2 im D1 Anlotinib 12 mg po D1-14 repeat every three weeks
11119785|NCT03936439||Consecutive stroke patient|All consecutive stroke patients from five time points, i.e. 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018 are selected for analysis.
11119786|NCT03936426|Experimental|SARTATE|All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
11119787|NCT03936413|Experimental|Bay Labs EchoGPS group|In this arm, medical residents will use the Bay Labs EchoGPS system to perform an echocardiogram.
11119790|NCT03936400|Active Comparator|Active comparator: control group|A control group that receives same but delayed couple-based intervention
11119791|NCT03936387|Experimental|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
11119792|NCT03936374|Experimental|BMS-986205 + Omeprazole|
11119793|NCT03936361|Active Comparator|Statin|The same statin agent and dose that subjects were using at the time of ICH onset.
11119794|NCT03936361|No Intervention|No-statin|Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects.
11119795|NCT03936348|Experimental|FB group|Participants who performed an exercise training program for 8 weeks using a nasal restriction device for inspiratory muscle training, called Feelbreathe®
11119796|NCT03936348|Experimental|ONB group|Participants who performed an exercise training program for 8 weeks with oronasal breathing without FB
11119797|NCT03936348|No Intervention|control group (CG)|Participants who received the standard medical recommendations for patients with COPD, but not participated in the exercise intervention program
11119798|NCT03936335||Dupilumab cohort|"Exposed to dupilumab during the relevant exposure window:
~First trimester
~Pregnancy"
11119799|NCT03936335||Other systemic therapy or phototherapy cohort|"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:
~First trimester
~Pregnancy"
11119800|NCT03936335||Unexposed cohort|"Not exposed to systemic medications (including dupilumab) or phototherapy; and
~Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:
~First trimester
~Pregnancy"
11119801|NCT03936322|Experimental|Pregnant women diagnosed with fetal myelomeningocele|Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.
11119802|NCT03936309|Experimental|Scar Deactivation Surface Release|Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
11119803|NCT03936309|Experimental|Scar Infiltration with 0.25-1% Lidocaine|Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
11119804|NCT03936309|Experimental|Physical Therapy|Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
11119805|NCT03936296|Active Comparator|fusion arm|Patients in this arm will be undertaken standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy
11119806|NCT03936296|Other|Standard arm|Patients in this arm will be undertaken only standard transrectal prostate biopsy
11119807|NCT03936283|Experimental|Lifestyle Intervention|
11119808|NCT03936283|No Intervention|Usual Care|
11119809|NCT03936270|Experimental|Palbociclib 125mg + Letrozole 2.5mg|Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment).
11119810|NCT03936257|Placebo Comparator|Breast milk|group receiving breastfeeding
11119811|NCT03936257|Active Comparator|infant formula conventional BIO|infant formula with conventional whey BIO
11119812|NCT03936257|Active Comparator|infant formula BIO TrueGreen|infant formula with whey BIO TrueGreen
11119813|NCT03936244|Active Comparator|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
11119814|NCT03936244|Experimental|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
11119815|NCT03936218|Experimental|Inj. Goserelin (Test) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
11119816|NCT03936218|Active Comparator|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
11119817|NCT03936205|No Intervention|Control|
11119818|NCT03936205|Experimental|Dexmedetomidine|
11119819|NCT03936192|Experimental|glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)|glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
11119820|NCT03936192|Active Comparator|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.
11119821|NCT03936192|Placebo Comparator|Placebo|Placebo administered once daily for 12 weeks
11119822|NCT03936179|Experimental|high dose radiochemotherapy|A total dose of 86 Gy to residual metabolic disease with concurrent chemotherapy
11119823|NCT03936166|Experimental|Single Ascending Dose (Part 1)|
11119824|NCT03936166|Experimental|Multiple Ascending Dose (Part 2)|
11119825|NCT03936166|Placebo Comparator|Elderly Cohort (Part 3)|
11119826|NCT03936153|Experimental|Abexinostat 80 mg bis in die (BID)|Abexinostat 80 mg BID
11119827|NCT03936140|Experimental|Iloprost 10|"Iloprost 10μg of inhaled iloprost (Ventavis®)
~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
11119828|NCT03936140|Experimental|Iloprost 20|"Iloprost 20μg of inhaled iloprost (Ventavis®)
~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
11119829|NCT03936140|Placebo Comparator|Distilled water|"Distilled water
~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
11119830|NCT03936127|Experimental|Transperineal (TP) Ultrasound (US) Targeted Fusion Biopsy|Transperineal (TP) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
11119831|NCT03936127|Active Comparator|Transrectal (TR) Ultrasound (US) Targeted Fusion Biopsies|Transrectal (TR) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
11119832|NCT03936114|Experimental|SMART|
11119833|NCT03936101||Prenatally Sequenced Group|750 trios with fetal structural anomalies who receive prenatal sequencing from the study
11119834|NCT03936101||No Prenatal Sequencing (Unsequenced) Group|350 trios with fetal structural anomalies who do not have prenatal sequencing
11119835|NCT03936088|Experimental|Intervention with Mindfulness App (Headspace)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the mindfulness (intervention) app.
11119836|NCT03936088|Active Comparator|Control with Water App (My Water Balance)|Patient education regarding osteoarthritis, its natural history, and common treatments plus the My Water Balance (control) app and provided an in-person demonstration on how to use it.
11119837|NCT03936075|Experimental|intervention|treatment with the provision of 6 individual sessions of the Guided Imagery and Music method as a psychological supportive intervention, and psychometric questionnaires collection
11119838|NCT03936075|Placebo Comparator|control|standard care treatment with psychometric questionnaires collection and two individual counselling sessions, at baseline (week 1) and at the end (week 6)
11119839|NCT03936062||2nd Generation SUs|Reference group
11119840|NCT03936062||Sitagliptin|Exposure group
11119841|NCT03936049||DPP-4 inhibitor|Reference group
11119842|NCT03936049||Liraglutide|Exposure group
11119843|NCT03936036||2nd generation sulfonylureas|Reference group
11119844|NCT03936036||Linagliptin|Exposure group
11119845|NCT03936023||2nd Generation SUs|Reference Group
11119846|NCT03936023||Saxagliptin|Exposure Group
11119847|NCT03936010||DPP4i|Reference group
11119848|NCT03936010||Canagliflozin|Exposure group
11119849|NCT03935997|Experimental|Step 1|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
11119850|NCT03935997|Experimental|Step 2|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
11119851|NCT03935997|Experimental|Step 3|Within this step 6 long-term care homes will receive the SPA-LTC program: 2 in Ontario; 2 in Saskatchewan and 2 in Manitoba.
11119852|NCT03935984|Experimental|Treatment Group|All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging
11119853|NCT03935971|Experimental|Subjects with Allergic Contact Dermatitis|Dupilumab 600 mg/4 mL subcutaneously once, then 300 mg/2 mL every 2 weeks for 10 weeks
11119854|NCT03935958|Experimental|Curcumin Arm (Arm 1)|20 subjects will be randomized (1:1) to this arm and receive curcumin for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood and urine samples and questionnaires.
11119855|NCT03935958|Placebo Comparator|Placebo Arm (Arm 2)|20 subjects will be randomized (1:1) to this arm and receive placebo for a year. In addition, subjects will have four study visits at Day 0, and 3, 6 and 12 months post-transplant. These study visits also include blood and urine samples and questionnaires.
11119856|NCT03935945|Experimental|Personalized Feedback Intervention (PFI)|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes.
11119857|NCT03935945|No Intervention|Attention-Control|Attention control information will be comparable in focus on health-related behaviors (e.g., nutrition, exercise). We will use behaviors in the attention control feedback that are not associated with study outcomes. Attention control feedback will have text and graphs that are similar in appearance and length (i.e., 20-30 minutes) to intervention feedback.
11119858|NCT03935932|Experimental|baseline followed by intervention|Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
11119859|NCT03935932|Experimental|intervention followed by baseline|Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
11119860|NCT03935906|Experimental|Reach Pathway|Community pharmacist will explain the risks of contracting HCV from current or historical intravenous drug use. OST patients will then meet with an outreach hepatology nurse specialist who will perform a diagnostic point-of-care (PoC) HCV test along with venepuncture for safety blood tests and confirmatory HCV RNA on the pharmacy premises. The nurse will return for a subsequent visit to prescribe (in the UK; in Australia prescribing is undertaken by qualified medic) and deliver HCV medication for participants who test positive, which will be dispensed alongside their OST schedule by their community pharmacist. The outreach nurse will return after approximately 14 days to confirm negative results, dispense medication for new patients with positive results (PCR positive but below limit of detection of POC test) and confirm follow up appointments where required. The RNA and PoC test will also be administered for sustained viral response at 12 weeks post treatment (SVR12).
11119914|NCT03935503||Total Extraperitoneal Repair|Laparoscopic Total Extraperitoneal (TEP) method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
11119861|NCT03935906|Experimental|Education-only Pathway|The community pharmacist will discuss the risks of contracting HCV through current or historical intravenous drug use. The community pharmacist will then advise participants on the nearest centre for HCV testing and treatment, as is standard of care for the countries included in this study. If they are referred from a REACH pharmacy, they will present a reply slip and/or the Patient Information Sheet to the nurse who will then consent the participant, perform HCV and safety blood tests, and complete the study paperwork. The participant's medication will be delivered to, and dispensed from, their community pharmacy alongside their OST. Participants will return to the local BBV clinic for an SVR12 test after completing treatment.
11119862|NCT03935893|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic gastric/esophagogastric, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal squamous cell, Merkel cell, cancers refractory to systemic therapy, and those with deficient mismatch repair and/or microsatellite instability cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused through a central vein catheter and administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
11119863|NCT03935880|Active Comparator|Cartiva Hemiarthroplasty|Cartiva implant
11119864|NCT03935880|Active Comparator|Cheilectomy|Bone spur removal
11119865|NCT03935867|Experimental|C-PROFET group|Community-dwelling, older adults participating in a home-based program -- C-PROFET, our adaptation of Prevention Of Falls in the Elderly Trial (PROFET).
11119866|NCT03935854|Experimental|Ketogenic Diet 16 Week Group|
11119867|NCT03935841|Experimental|3-OHB orally|36 gram 3-OHB salt consumed orally
11119868|NCT03935841|Active Comparator|3-OHB intravenously|Variable amounts of 3-OHB salt given i order to replicate the same individual plasma concentrations measured during the experimental arm.
11119869|NCT03935828|Experimental|Topical Sinonasal Antibiotics|For topical antibiotics, the compounding pharmacy will use pre-determined doses using data extrapolated from oral and intravenous doses and data that has detailed the effect of the medication on solubility, pH, and particle properties. Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml, all to be prescribed for 21 days, applied twice a day. Although the dosing schedule for these topical antibiotics has not been definitively studied, the majority of the data supports a range from two to three times daily for three to four weeks. Patients will be instructed by the pharmacist how to dissolve the cream, powder, or vial of antibiotic in saline, and to irrigate each nostril with 120 ml total. Doses will not be varied during the study period.
11119870|NCT03935828|Active Comparator|Oral Antibiotics|Oral antibiotics will be prescribed for 21 days, as available (albeit limited) evidence recommends antimicrobial therapy in CRS for at least 3 weeks. For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours, Levofloxacin 500 mg once daily, or Clindamycin 300 mg every 6 hours, as these are standard of care for treatment of Chronic Rhinosinusitis.
11119871|NCT03935815|Active Comparator|Intervention|"Standard of care pain management plus quadratus lumborum nerve block.
~Ropivicaine 0.25% 60 mL will be injected in the fascial plane between the quadratus lumborum muscle and transverses abdominus muscle."
11119872|NCT03935815|Sham Comparator|Control|Standard of care pain management plus a sham procedure.
11119873|NCT03935802||primary non-metastatic breast cancer|primary non-metastatic breast cancer
11119874|NCT03935789|Experimental|BLAST|All participants in this study will be assigned to this group to participate in the BLAST intervention. The intervention will be a self-guided web-based platform using a self-management model to help support better engagement in everyday life activity
11119875|NCT03935776|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend a 12-week intensive lifestyle programme.
~The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.
~Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes."
11119876|NCT03935776|Active Comparator|Standard Healthcare|The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
11119877|NCT03935750|Experimental|BPTB + LET|Patients will undergo anterior cruciate ligament reconstruction (ACLR) using a bone patellar bone tendon (BPTB) autograft with lateral extra-articular tenodesis (LET).
11119878|NCT03935750|Active Comparator|BPTB alone|Patients will undergo ACLR using a BPTB autograft without LET.
11119879|NCT03935750|Experimental|QT + LET|Patients will undergo ACLR using a quadriceps tendon (QT) autograft with LET.
11119880|NCT03935750|Active Comparator|QT alone|Patients will undergo ACLR using a QT autograft without LET.
11119881|NCT03935737||Full dose Chest X-Ray|Subjects will receive a full (standard) dose chest X-ray at Day 1.
11119882|NCT03935737||Low dose Chest X-Ray|Subjects will receive a follow up X-ray at at a lower dose within 3 months after the first dose.
11119883|NCT03935724|Experimental|1A Intervention group 8 patients|Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident). N=8
11119884|NCT03935724|Placebo Comparator|1B Placebo group 8 patients|Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=8
11119885|NCT03935724|Experimental|2A Intervention group 27 patients|Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident) N=27
11119886|NCT03935724|Placebo Comparator|2B Placebo group 27 patients|Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=27
11119887|NCT03935698|Experimental|Physiotherapy|12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises.
11119888|NCT03935685|Experimental|mirtazapine in glioma patients treated with Temozolomide|Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
11119889|NCT03935672|Other|All trial participants|"Baseline plasma and saliva tests for future translational analysis
~Baseline planning FDG PET CT scan
~Patients will start their 6 weeks of CCRT within two to three weeks following the planning scans. Cisplatin chemotherapy will be administered. 33 daily fractions of radiotherapy will be delivered over 6 weeks.
~A second FDG-PET-CT scan (iPET) and repeat plasma and saliva tests will be carried out after 2 weeks of CCRT (on RT days 9 - 12) and the iPET assessed for residual FDG-avid disease. The biological GTV will be re-outlined based on the residual avid region of the tumour on the second PET-CT (bGTV_iP)
~At the end of treatment, plasma and saliva tests will be carried out at 4 weeks post treatment and again at the 3 month post-treatment PET-CT
~Swallowing and QoL assessments will be repeated 4 weeks (+/- 2 weeks) after treatment and will be repeated at 6, 12 and 24 months post-treatment. The plasma and saliva samples will be repeated at 12 and 24 months"
11119890|NCT03935659|Active Comparator|Standard gauze therapy|The control group will receive a standard sterile gauge dressing over the groin incision. The dressing will be removed on post-operative day #2 and the wound will be inspected for any complications, followed by daily dressing changes and wound inspections until discharge.
11119891|NCT03935659|Experimental|Negative Pressure wound therapy|The intervention group will receive a negative pressure dressing which will be applied in the operating room under sterile conditions. The brand of negative pressure dressing will be based on surgeon preference or center availability. The NPWT dressing will be removed on day 5 postoperatively or at discharge, whichever occurs first, and the groin wound inspected for any evidence of infection or dehiscence, and daily thereafter until discharge.
11119892|NCT03935646|Experimental|Stimulant Medication|Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
11119893|NCT03935633|Experimental|First Dosage|The dose of CN128 is 20 mg/kg bw， bid.
11119894|NCT03935633|Experimental|Second Dosage|The dose of CN128 is 15 mg/kg bw， bid.
11119895|NCT03935620|Experimental|EMT|After a period of stable baseline performance (3 to 5 sessions) for parents and children the interventionists will apply the EMT Language Intervention.
11119896|NCT03935607||Normal amniotic fluid index|Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
11119897|NCT03935607||Oligohydramnios|Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
11119898|NCT03935594|Experimental|PRP injection right half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.
~After finishing the VSS and POSAS, the area inside the control half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL normal saline into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.
~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
11119899|NCT03935594|Experimental|PRP injection left half|"The scar to be treated will first be wiped with an alcohol swab, then measured and marked out with a marking pen such that the entirety of the scar will fit into a symmetric ellipse that is drawn, and the ellipse is filled entirely with the scar tissue. A ruler will be used to measure the scar in its greatest horizontal span, and the midway point will be marked with a vertical line. A coin flip will determine if the PRP injection (the experimental half) will be on the right half of the scar (as opposed to the left half). The half of the scar that will not receive PRP will be the control half.
~After finishing the VSS and POSAS, the area inside the experimental half of the ellipse will then be subdivided with a marking pen into 1cm x 1cm square boxes, with the plan of injecting 1mL PRP into each 1 square cm box at 0 months, 1 month, 4 months, and 6 months.
~Punch biopsies from each scar will be will be obtained at both six months and one year from enrollment."
11119900|NCT03935581|Experimental|ExAblate 4000 System|ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
11119901|NCT03935568|Experimental|Single Dose Placebo|Patients randomized to receive Placebo
11119902|NCT03935568|Experimental|Single Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
11119903|NCT03935568|Experimental|Multiple Dose (Placebo)|Patients randomized to receive Placebo
11119904|NCT03935568|Experimental|Multiple Dose Active (PU-AD)|Patients randomized to receive Active (PU-AD)
11119905|NCT03935555|Experimental|Oral - 50mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
11119906|NCT03935555|Experimental|Oral -100 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
11119907|NCT03935555|Experimental|Oral - 200 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
11119908|NCT03935555|Experimental|Oral - 300 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
11119909|NCT03935542||MPI arm|For the MPI arm, patients with severe jailed diagonal branch disease with available MPI in 3 months were selected from the Seoul National University Hospital Cardiac Catheterization and MPI database.
11119910|NCT03935542||CCTA arm|For the CCTA arm, patients from a previous multicenter prospective CCTA registry were retrospectively reviewed for a post-hoc analysis.
11119911|NCT03935529|Experimental|Behavioural Acitivation|Behavioural Activation. Originally a component of cognitive behavioural therapy, Behavioural Activation is a structured psychotherapeutic approach which aims to (a) increase engagement in activities associated with pleasure or mastery, (b) decrease engagement in activities that maintain depression, and (c) problem solve barriers limiting access to reward or maintain aversive control. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
11119912|NCT03935516|Experimental|Flexed Elbow|The first group will be placed in a cast with the elbow bent.
11119913|NCT03935516|Experimental|Extended Elbow|The second will be placed in a cast with the elbow straight.
11120042|NCT03934489|Experimental|PERSIST|Participants will receive Partnered Emotion Regulation Skills Intervention and Support.
11119915|NCT03935503||Lichtenstein repair|Lichtenstein method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
11119916|NCT03935490||e-TREPP|Patients with strangulated inguinal hernia treated with e-TREPP
11119917|NCT03935477||High risk surgery|those undergoing elective and emergency, high-risk surgery receiving arterial cannulation and urethral catheterisation as standard
11119918|NCT03935477||Critical Care|Emergency admissions to UCLH critical care unit receiving arterial cannulation and urethral catheterisation as standard
11119919|NCT03935464|Experimental|Intervention Arm|POC adherence testing by a urine TFV assay with feedback
11119920|NCT03935464|No Intervention|Standard of Care|Follow Kenya's PrEP guidelines on standard adherence counselling
11119921|NCT03935451|Placebo Comparator|Placebo|The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.
11119922|NCT03935451|Experimental|Experimental|The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.
11119923|NCT03935438|Experimental|Patients after ACS|Patients after acute coronary syndrome undergoing cardiac rehabilitation.
11119924|NCT03935425|Experimental|FitMi Plus|"Participants will perform targeted movement exercises by interacting with the FitMi Plus Functional modules at least 50% of the time they spend exercising.
~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
11119925|NCT03935425|Active Comparator|FitMi Basic|"Participants will perform targeted movement exercises by interacting with the FitMi Basic pucks, as described and monitored on a computer.
~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
11119926|NCT03935412|Active Comparator|ES Erector Spinae Plane Block|By the end of surgery parturient in the ESPB underwent bilateral ESPB at the level of T9 using a linear ultrasound (US) transducer (Phillips Saronno Italy) the transducer was placed vertically3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine 22-G short bevel needle (spinocan, B.Braun melsungen AG, Germany) was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml 0.5% bupivacaine was done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
11119927|NCT03935412|Sham Comparator|intrathecal morphine ITM|participant in the ITM group intrathecal injection of 10mg of hyperbaric bupivacaine 0.5 % in addition to 100 mcg of preservative-free morphine. Then, the parturient immediately placed in the supine position with 15° left tilt, and an oxygen mask was applied at 2 l.min-1. After ensuring sufficient anesthesia level, the surgical procedure was done with continuous hemodynamics monitoring and recording. While participants in the ITM group underwent sham blocks; Sham blocks consisted of a non-invasive ultrasound scan, while a blunt needle was gently pressed on both sides.
11119928|NCT03935399|Active Comparator|Oxytocin|Intramuscular injection of oxytocin (Pitocin®), 10 IU
11119929|NCT03935399|Placebo Comparator|Placebo|Intramuscular injection of (1 ml) of saline
11119930|NCT03935386|Active Comparator|Standard Compression|Standard multi-layer compression dressing with no graft or biologic material added
11119931|NCT03935386|Active Comparator|Standard Compression with application of human allograft|standard compression with application of a cryopreserved skin allograft (TheraSkin)
11119932|NCT03935373||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) primary or secondary SS; (2) aged between 20 and 75 years; (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG); (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; or (3) steroid pulse therapy within three months prior to the commencement of our study.
11119933|NCT03935373||Health subjects|Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 41 and 63 years (which the age could match the SS patients enrolling in the SS-1 trial); (2) had no chronic inflammatory illness. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; (3) abnormal findings of immune, liver, kidney, or blood function evaluations; (4) total sleeping time insufficiency less than 6 hours before one day of enrollment; (5) ever took the conventional medicine or hormone within one month; (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
11119934|NCT03935347|Experimental|Treatment (cyclophosphamide, fludarabine, pembrolizumab)|Patients receive cyclophosphamide IV over 2 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -2, and pembrolizumab IV over 30 minutes on day -1. At least 24 hours later, patients receive autologous tumor infiltrating lymphocytes LN-145 IV on day 0, and receive aldesleukin IV over 30 minutes for up to 6 doses on days 1-4. Patients then continue receiving pembrolizumab IV over 30 minutes beginning on day 21. Cycles of pembrolizumab repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity.
11119935|NCT03935334|Experimental|Eptacog alfa, biosimilar (AryoSeven)|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
11119936|NCT03935334|Active Comparator|Novoseven|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
11119937|NCT03935321|Active Comparator|Patients with acute cervical spinal cord injury: NG-101|
11119938|NCT03935321|Placebo Comparator|Patients with acute cervical spinal cord injury: Placebo|
11120677|NCT03930121|Sham Comparator|Control group|Placebo stimulation (using sham-tDCS) combined with SLT
11119939|NCT03935308|Experimental|MR-guided SBRT With SIB to the DILs to Prostate Cancer|Dose escalation to the DIL(s) will be performed in the traditional Phase I 3+3 design. Patients will be treated in four cohorts (three patients per dose level) starting with a dose of 9 Gy to the DIL(s). If no dose limiting toxicity (DLT), defined below, is observed after 90 days, then an additional three patients will be entered at the next dose level. Dose to the DIL(s) will be escalated at 1 Gy increments until DLT is observed or if maximum dose level (60 Gy in 5 fractions of 12 Gy) is reached with no observed DLT. If one of the three patients experience a DLT at a particular dose level an additional three patients will be enrolled at that level. If two or more patients experience a DLT a lower dose level will be explored to define the maximum tolerated dose (MTD). The three patients within any cohort can be enrolled simultaneously or sequentially without any waiting period among them.
11119940|NCT03935295|Experimental|Botulinum Toxin|"The investigators plan to administer approximately 1000 U Dysport ® in the concave-sided paraspinal musculature of the major curve, based on an estimated total dose of 1000 U, the maximum allowable dose. The total dose per treatment session will not exceed 15 units/kilogram or 1000 units, whichever is lower. If two curves are equivalent within 3˚, both will be treated, however, the dosing (described above) will be divided equally across both curves.
~There will be two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
11119941|NCT03935295|Placebo Comparator|Placebo|"Control patients will receive an injection of placebo specifically prepared as a control for this study. The same volumes as indicated in the experimental arm description will be injected.
~These will be administered during two cycles of injections. Patients will be treated at time 0 (baseline) and 4 months."
11119942|NCT03935282|Experimental|Intervention - AH-HA tool|With assistance from the study team, the clinic will implement the AH-HA tool in the clinics' EPIC EHR. Providers at the intervention sites will be trained to use the tool during routine follow-up care with survivors. During a routine follow-up care appointment, the provider will use the AH-HA tool with enrolled patients.
11119943|NCT03935282|No Intervention|Usual Care|Usual care practices will conduct routine follow-up care visits for enrolled survivors following typical clinic practice, without use of the AH-HA tool.
11119944|NCT03935269|Experimental|Intervention with Ambulatory Therapy|Caregivers of participants with high-grade glioma will undergo standard Cereset Research Office (CRO) in-office treatment for a total of five (5) treatments. Ambulatory therapy with the Cereset Research Wearable (CRW) will be available to caregivers while they are attending routine radiation therapy with glioma patients.
11119945|NCT03935256|Experimental|Full Dose Chemo, Reduced Dose Chemo + RT, Full Dose Chemo|Week 1 : Cycle 1: Full Dose Carboplatin and Paclitaxel Week 4: Pelvic Radiotherapy Begins Cycle 2: Dose reduced Carboplatin and Paclitaxel Week 7 : Cycle 3: Dose reduced Carboplatin and Paclitaxel Weeks 10,13,16: Cycle 4-6: Full Dose Carboplatin and Paclitaxel
11119946|NCT03935243|Experimental|equine assisted therapy|In the active intervention phase, patients participate twice a week in a equine assisted group therapy, while during the control phase they participate twice a week in a group that includes a non-specific and general activity program. After 15 therapy units in a study phase, the subjects will complete the 15 units of the other study phase (within-subject-design). All participants complete both study phases, with the order being randomized.
11119947|NCT03935243|Active Comparator|activating control phase|"In the present study, the interventions in the control phase are based on the sub-program Social Skills of the Integrated Psychological Treatment Program (IPT) for schizophrenic patients (Brenner et al., 1994, Roder et al., 1988, 2002)."
11119948|NCT03935217|Experimental|Solosec (containing 2 grams of secnidazole)|Orally administered as a single dose with applesauce. Upon completion of primary phase patients will receive the opposite treatment (placebo)
11119949|NCT03935217|Placebo Comparator|Placebo|Orally administered as a single dose with applesauce. Upon completion of primary phase patients will receive the opposite treatment (Solosec (containing 2 grams of secnidazole)
11119950|NCT03935204|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
11119951|NCT03935204|Placebo Comparator|Placebo|Participants in this arm would receive 1.0ml aluminium adjuvant.
11119952|NCT03935191||Group|Device: Dexcom CGM System
11119953|NCT03935165|Experimental|Indocyanine Green arm|"All the patients to be enrolled have to meet the inclusion criteria. All enrolled patient is subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions are described.
~Subsequently, 0.25 mg /(kg BW) Indocyanine Green is administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision is made, in order to identify the fluorescent lesions. All the lesions are described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged."
11119954|NCT03935152|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 8 hours until delivery
11119955|NCT03935152|Placebo Comparator|Placebo|placebo by mouth every 8 hours until delivery
11119956|NCT03935126|Experimental|All patients|
11119957|NCT03935113|Experimental|KT group|The paretic upper limb is a common consequence of stroke that increases activity limitation.
11119958|NCT03935100|Experimental|Treatment Group|All visible diverticula clipped during index colonoscopy
11119959|NCT03935100|Placebo Comparator|Control Group|5 clips fired at random into colon lumen. No diverticula closed.
11119960|NCT03935074||group 1|Patients who received intra-arterial chemotherapy as a first line treatment
11119961|NCT03935074||group 2|Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
11119962|NCT03935061|Experimental|Mulberry juice|Two bottles (600 ml/bottle) of sanitized mulberry juice are delivered to the patients of the experimental group 20 days before the next clinic visit, with instruction to consume 50 ml of juice diluted with drinking water at room temperature. A reminder of the next clinic visit for continuous treatment is attached.
11119963|NCT03935061|No Intervention|Controlled|Patients of the controlled group are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
11120043|NCT03934489|Active Comparator|Facilitated Peer Support|Participants will undergo a 12-week group intervention, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
11119964|NCT03935048|Experimental|Higher Protein, Low Glycemic Load with Potatoes|Higher Protein, Low Glycemic Load with Potatoes (HPLG-P): low- to moderate- glycemic load meals containing white potatoes. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
11119965|NCT03935048|Active Comparator|Higher Protein, Low Glycemic Load with Processed Potatoes|Higher Protein, Low Glycemic Load with Processed Potatoes (HPLG-PP): low- to moderate- glycemic load meals containing processed white potato products. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
11119966|NCT03935048|Placebo Comparator|Higher Protein, Low Glycemic Load - Control|Higher Protein, Low Glycemic Load (HPLG-C): low- to moderate- glycemic load meals containing control carbohydrate (e.g. rice, pasta). Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing control carbohydrate sources.
11119967|NCT03935035|Experimental|internet-Cognitive Therapy for PTSD|This is a single-arm study. All participants will receive the same therapist supported, internet-delivered intervention.
11119968|NCT03935022|Experimental|Black rice Venere|Healthy volunteers will receive the black rice Venere in a cross-over randomized clinical trial (after 7 days wash-out).
11119969|NCT03935022|Experimental|Black rice Artemide|Healthy volunteers will receive the black rice Artemide in a cross-over randomized clinical trial (after 7 days wash-out).
11119970|NCT03935022|Sham Comparator|Complete white rice|Healthy volunteers will receive the complete white rice in a cross-over randomized clinical trial (after 7 days wash-out).
11119971|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°1|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and will be instructed to use them for six weeks.
11119972|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°2|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
11119973|NCT03935009|Active Comparator|Electric toothbrush N°1 with electric toothbrush N°2|Participants will receive an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
11119974|NCT03934996|No Intervention|Assesment Runners|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week.
11119975|NCT03934996|Experimental|Runners with educational training|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week with educational training about pelvic floor muscles.
11119976|NCT03934983||Trauma patients|Subject experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
11119977|NCT03934970||Diabetic Neuropathy|Thirty Egyptian patients with type 2 diabetes mellitus complaining of symptoms suggestive of peripheral neuropathy including 12 males and 18 females with a mean of 50.90 ± 9.18.
11119978|NCT03934970||Healthy Control Subjects|Fifteen normal healthy Egyptian volunteers including10 males and 5 females with a mean age of 45.67±7.77 years.
11119979|NCT03934944|Experimental|Phone application arm|Participants will have access to a educational video and foot alerts at weekly intervals to supplement usual Podiatry care and education.
11119980|NCT03934944|Other|Usual care|Participants will have Podiatry care and education.
11119981|NCT03934931|Experimental|Facilitated Directly Observed Therapy (DOT)|Facilitated DOT arm participants will attend the Mulago Immune Suppression Syndrome (ISS) clinic on a weekly basis to ingest 3HP medication under direct observation. DOT will be defined as a designated clinic staff member observing ingestion of each dose of 3HP. Additionally, participants randomized to facilitated DOT will receive: 1) DOT cards with instructions to present directly to the pharmacy for a pharmacy-only visit, without the need to wait in the general queue; 2) Automated short message service (SMS) or phone call reminders at no cost to participants the day before each appointment, 3) A fixed level of reimbursement (~$5/visit) for each weekly visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
11119982|NCT03934931|Experimental|Facilitated Self-Administered Therapy (SAT)|Facilitated SAT participants will take their 1st dose of medication under direct observation and be given a 4-week 3HP supply to take weekly via self-administration. Participants will return to the Mulago ISS clinic after completing their 5th dose to review adherence data with the clinic pharmacy technician and receive 5 additional 3HP doses (doses 7-11). At the scheduled refill visit (dose 6) and end-of-treatment visit (dose 12) participants will ingest 3HP via direct observation. Participants will also receive: 1) Free automated SMS reminders or phone call reminders before each scheduled dose; 2) Weekly check-ins inquiring about side effects via two-way SMS with a follow-up phone call depending on participant response, 3) Fixed level of reimbursement (~$5/visit) for the refill/end-of-treatment visit, conditional on either directly observed therapy or evidence of an adverse event that would preclude further treatment.
11119983|NCT03934931|Experimental|Patient Choice between facilitated DOT and facilitated SAT|Participants randomized to the Patient Choice between facilitated DOT and facilitated SAT arm will be offered a choice between arms 1 and 2. A research nurse will review each section of the decision aid with participants, discuss values and preferences, and, after addressing any questions, ask participants to select facilitated DOT or facilitated SAT. Participants will have the option to switch between DOT and SAT at any time. The reason for switching and time spent under each strategy will be recorded.
11119984|NCT03934918|Experimental|Treatment|Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
11119985|NCT03934918|No Intervention|Control|Patients for IOL admitted to Labor and Delivery
11120044|NCT03934476|Experimental|Ketogenic diet|"Ketogenic diet:
~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)
~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.
~fat type intake recommendation:
~natural fats
~trans-FA reduction"
11120678|NCT03930108||Mortality outcome|
11119986|NCT03934905|Active Comparator|sulforaphane|Processed SFN-rich extract will be purchased in form of caplets from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts from Nutramax Labs will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Size of the caplet will be about 2 cm in length. Dosing will be based on weight and will be dosed daily for 12 weeks.
11119987|NCT03934905|Placebo Comparator|Placebo|Placebo caplets will comprise of microcrystalline cellulose from Nutramax Labs and will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Placebo pills will be identical in appearance to the sulforaphane pills and will be dosed in a similar manner (identical number of pills based on weight, daily dosing and for 12 weeks)
11119988|NCT03934892||lactate during CPB|check lactate levels routinely during cardiac operations with cardiopulmonary bypass, choose the peak lactate data
11119989|NCT03934879|Experimental|Gateway Academy|For this study, Gateway Academy students will participate in the FitClub intervention. They will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
11119990|NCT03934879|Active Comparator|Control School|Other comparable school will be added as a control school, in which regular school activities will be provided.
11119991|NCT03934866||Group A (LDCT)|"25,000 individuals who are at high-risk for lung cancer due to a significant smoking history.
~Participants will receive at least 1 LDCT scan at baseline."
11119992|NCT03934853|Other|No arm|There is no arm for this study.
11119993|NCT03934840|Experimental|Carboplatin, Cabazitaxel and Abiraterone|
11119994|NCT03934827|Experimental|Part A|"Open label, preliminary phase
~20 participants"
11119995|NCT03934827|Experimental|Part B|"Randomised, double blinded phase
~100 participants"
11119996|NCT03934814|Experimental|Part 1A - TJ011133 Monotherapy|TJ011133 alone will be administered at up to 6 dose levels (0.3, 1, 3, 10, 20, or 30 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level)
11119997|NCT03934814|Experimental|Part 1B - Combination therapy of TJ011133 with pembrolizumab|TJ011133 will be administered Q1W, starting at one dose level below MTD or MAD in monotherapy arm, in combination with pembrolizumab
11119998|NCT03934814|Experimental|Part 1C -Combination therapy of TJ011133 with rituximab|TJ011133 will be administered Q1W, starting at one dose level below MTD or MAD in monotherapy arm, in combination with rituximab
11119999|NCT03934814|Experimental|Part 2 - Dose Expansion|20 subjects (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 subjects with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.
11120000|NCT03934801||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.
~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
11120001|NCT03934788|Experimental|Oxysoft|olifilcon C, daily disposable soft contact lens, 1 month
11120002|NCT03934788|Active Comparator|SiHy|olifilcon B, dialy disposable soft contact lens, 1 month
11120003|NCT03934775||Patients with acute illness|Patients admitted to the acute medical/emergency department and/or Cardiology department at Bispebjerg Hospital.
11120004|NCT03934762|Active Comparator|Placebo|A placebo solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
11120005|NCT03934762|Experimental|Natural aloe vera|A natural aloe vera solution (peel and leaf) will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
11120006|NCT03934762|Experimental|Aloe vera soup|An aloe vera soup solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
11120007|NCT03934749||standard mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
11120008|NCT03934749||Lowenstein mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
11120009|NCT03934736|Experimental|HEPLISAV-B®|A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).
11120010|NCT03934723|Active Comparator|Control|This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms.
11120011|NCT03934723|Experimental|Antidpressants|This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year.
11120012|NCT03934710|Placebo Comparator|Placebo|Placebo
11120013|NCT03934710|Experimental|Serotonin agonist|13ug of serotonin agonist
11120014|NCT03934697|Experimental|Imaginal Exposure Session|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
11120015|NCT03934684|Experimental|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone
~Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.
~Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
11120143|NCT03933696|Placebo Comparator|Placebo Lighting Intervention|The placebo condition light source will be a warm yellow - white (2700 - 3000 K) source providing 50 -100 lux at the eye. The lighting intervention will be in place for 24 weeks.
11120016|NCT03934684|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone
~Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.
~Lenalidomide 25 mg is taken orally on days 1 to 21.
~Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
11120017|NCT03934671|Experimental|Antioxidant dressing (active product)|
11120018|NCT03934671|Active Comparator|Usual care dressing (standard clinical practice)|
11120019|NCT03934658|Experimental|Active Treatment Arm|Intervention with the NightWare Therapeutic System every night.
11120020|NCT03934658|Sham Comparator|Sham Arm|NightWare Therapeutic System every night with interventions not-enabled.
11120021|NCT03934645||Not In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)=0
11120022|NCT03934645||In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)≥4
11120023|NCT03934632|Active Comparator|Postabsorptive|Saline infusion to mimic postabsorptive circulating amino acid concentrations
11120024|NCT03934632|Active Comparator|Postprandial|Amino acid infusion to mimic postprandial circulating amino acid concentrations
11120025|NCT03934619|Experimental|Intervention|Convenient cohort, non-randomized group will be enrolled to examine the effects of the Dolores One on improving the ease of communication and intelligibility
11120026|NCT03934593|Experimental|Faith-Based (FB, BHT DSMS)|The BHT DSMD intervention strategies adapted Stanford DSMP in a spiritual context is used in this group. Participants in the FB group will participate in BHT DSMS, which includes a Health Sermon, a 6-session Health Bible Study with cooking demonstrations, the Stanford DSMP and a Diabetes Resource Seminar delivered by two trained church lay leaders.
11120027|NCT03934593|Active Comparator|Faith-Placed (FP, Stanford DSMP)|The traditional Stanford DSMP is conducted in this control group. Participants in the FP group will first attend a 7-session community health and safety curriculum as a partial attention control intervention, followed by the Stanford DSMP and Diabetes Resource Seminar facilitated by the local public health department.
11120028|NCT03934580|Experimental|hallucinated meal|A breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated under hypnosis by participants for 15 minutes
11120029|NCT03934580|Active Comparator|real meal|A real meal (white bread plus ham and cheese with 250 ml still water) is consumed by participants in 15 minutes
11120030|NCT03934567|Experimental|Abexinostat 80 mg bis in die (BID)|Experimental: Abexinostat 80 mg BID
11120031|NCT03934541|Experimental|Group 1 (Treatment 1): MPER-656 Liposome Vaccine|Participants will receive 500 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
11120032|NCT03934541|Placebo Comparator|Group 1 (Control 1): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
11120033|NCT03934541|Experimental|Group 2 (Treatment 2): MPER-656 Liposome Vaccine|Participants will receive 2000 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
11120034|NCT03934541|Placebo Comparator|Group 2 (Control 2): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
11120035|NCT03934528|Experimental|Pilot Study|
11120036|NCT03934515||Group A - etCO2|"At the end of the anaesthesia , as usual, the secretions are aspirated with a suction tube of 18 Fr of caliber (diameter 6 mm). When the tube is inserted into the endotracheal tube, before proceeding with the aspiration of the secretions, a capnometer is attached to its outer end, measuring the etCO2 value for 10-15 seconds. At the end of the measurement, authors proceed with the aspiration of the secretions as usual.
~Authors then proceed with the laying of a NGT according to local protocols. Also in this case, once the NGT has been inserted, the etCO2 is measured at the end of the probe for 10-15 seconds. At the end of the measurement, the capnometer can be detached, as a standard procedure, and the NGT can be used as usual.
~At the end of the procedure, therefore, for each patient, two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values recorded at the endotracheal level and the one recorded at the oesophageal level."
11120037|NCT03934515||Group B - pH|"At the end of the anaesthesia , once the NGT is inserted, the pH is measured by aspirating the gastric contents and measuring on specific litmus paper the pH values, both at a distance of 25 cm from the mouth (oesophageal site) and at a distance of 40 cm (gastric site).
~At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at oesophageal level and a value at the gastric level."
11120038|NCT03934502|Experimental|Evobrutinib: Treatment Sequence A, B, C, D|Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.
11120039|NCT03934502|Experimental|Evobrutinib: Treatment Sequence B, D, A, C|Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
11120040|NCT03934502|Experimental|Evobrutinib: Treatment Sequence C, A, D, B|Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.
11120041|NCT03934502|Experimental|Evobrutinib: Treatment Sequence D, C, B, A|Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.
11120045|NCT03934476|Experimental|Exercise HIIT (High-Intensity Interval Training)|"Exercise intervention:
~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:
~Cycle 1
~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)
~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)
~Cycle 2
~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)
~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)
~Cycle 3
~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)
~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
11120046|NCT03934476|Experimental|Ketogenic diet + Exercise HIIT|"Ketogenic diet:
~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)
~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.
~fat type intake recommendation:
~natural fats
~trans-FA reduction
~Exercise intervention:
~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:
~Cycle 1
~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)
~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)
~Cycle 2
~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)
~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)
~Cycle 3
~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)
~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
11120047|NCT03934476|No Intervention|Control Group|The study subjects in this arm will undergo no dietary changes and no exercise intervention.
11120048|NCT03934450|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days
11120049|NCT03934450|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days
11120050|NCT03934450|Active Comparator|Primaquine Phosphate|Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days
11120051|NCT03934450|Placebo Comparator|Placebo|Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days
11120052|NCT03934437|Experimental|mLTCR|The mLTCR intervention consists of two smartphone applications (app), one for patients and one for linkage officers (who are members of the community), to help facilitate communication.
11120053|NCT03934437|Active Comparator|LTC|Existing linkage to care (LTC) service which is standard-of-care
11120054|NCT03934424|Experimental|Weight Stigma|Weight stigma, read a weight stigma article for 5-10 minutes on one day
11120055|NCT03934424|Other|Ethnic stigma|Ethnic stigma, read an ethnic stigma article for 5-10 minutes on one day
11120056|NCT03934411|Experimental|Tramadol treatment|
11120057|NCT03934411|Placebo Comparator|Placebo treatment|
11120058|NCT03934398||ReNEW Clinical Cohort|Individuals evaluated in the ReNEW Clinic at Johns Hopkins University who join the ReNEW Clinic Cohort Study are eligible for this cross-sectional study. Tests will be done for all participants which includes Cardiovascular Assessments, Actigraphy and Laboratory assessments.
11120059|NCT03934385|Experimental|Mental Rehearsal|Between-session rehearsal/retrieval exercises focused upon consolidating non-fear learning gained from exposures by prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditioned stimulus (i.e., spider) and unconditioned stimulus (e.g., bite/attack).
11120060|NCT03934385|Active Comparator|Control Rehearsal|Between-session rehearsal/retrieval exercises focused upon an unrelated, recent academic experience.
11120061|NCT03934372|Experimental|Ponatinib|Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.
11120062|NCT03934346|Other|Zinc transport kinetics|Three different amounts of dietary zinc are used in the creation of a standard curve for determining zinc absorption kinetics: 4 mg, 7 mg, and 15 mg of zinc.
11120063|NCT03934333|Experimental|A/B (BDA MDI/Pulmicort)|For each participant, the BDA MDI/Pulmicort Flexhaler DPI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP will be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
11120064|NCT03934333|Experimental|B/A (Pulmicort/ BDA MDI)|For each participant, the Pulmicort Flexhaler DPI / BDA MDI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP should be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
11120065|NCT03934320|Other|FAMCAT|
11120066|NCT03934307|Experimental|Part A: SAD: ALN-AGT01|Participants will be administered a single dose of ALN-AGT01.
11120067|NCT03934307|Placebo Comparator|Part A: SAD: ALN-AGT01-Matching Placebo|Participants will be administered a single dose of ALN-AGT01-matching placebo.
11120068|NCT03934307|Experimental|Part B: SD: ALN-AGT01|Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
11120069|NCT03934307|Placebo Comparator|Part B: SD: ALN-AGT01-Matching Placebo|Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
11120070|NCT03934307|Experimental|Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo|Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
11120071|NCT03934307|Active Comparator|Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan|Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
11120072|NCT03934307|Experimental|Part E: Open Label: ALN-AGT01 + Irbesartan|Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
11120144|NCT03933683||Pathologic Group|Patients affected by Fecal Incontinence
11120145|NCT03933683||Control Group|Healty volunteers cohort
11120146|NCT03933670|Experimental|Diagnostic (HP C-13 MRI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.
11121490|NCT03924258|Experimental|HEART FAILURE|Patients with Heart Failure diagnosis
11120073|NCT03934294|Experimental|Treatment group: specific acupuncture group(Acu)|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.
~Acupuncture doctor will disinfect the acupoints with alcohol and will perform acupuncture on the marked points with needle Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor."
11120074|NCT03934294|Placebo Comparator|Control group: non-specific acupuncture group (Con-Acu)|"Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related pathologies, and are not reported to improve digestive function.
~Acupuncture doctor 1 will disinfect the marked acupoints with alcohol and will perform acupuncture on the marked points. Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor"
11120075|NCT03934281|Active Comparator|HAS dressing|"Patients included in the HAS dressing arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) ."
11120076|NCT03934281|Experimental|Honey dressing|"the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%).
~The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months)."
11120077|NCT03934268||infants with seizure with KCNQ2 gene mutation.|Infants who met the inclusion criteria were enrolled in this study. The infants will get their own DNA sequencing results by WES technology. The researchers found that some of them carried mutations in the KCNQ2 gene. so they wanted to compare whether there were differences with or without KCNQ2 gene mutations in the efficacy of anticonvulsants or long-term neurodevelopment in different exposure groups.
11120078|NCT03934255|Experimental|Constant Routine Protocol|Participants will be kept in constant conditions for 30 hours to observe circadian physiology in the absence of light, physical activity, and meals.
11120079|NCT03934242||New born group 1|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, before nurses formation on the newborn's bedding
11120080|NCT03934242||New born group 2|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, after nurses formation on the newborn's bedding
11120081|NCT03934229|Experimental|Group Active|Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day
11120082|NCT03934229|Placebo Comparator|Group Placebo|Placebo
11120083|NCT03934216|Experimental|BMS-986165|Specified Dose on Specified Days
11120084|NCT03934216|Placebo Comparator|Placebo|Specified Dose on Specified Days
11120085|NCT03934203|Experimental|Treatment 1|
11120086|NCT03934203|Experimental|Treatment 2|
11120087|NCT03934203|Experimental|Treatment 3|
11120088|NCT03934203|Experimental|Treatment 4|
11120089|NCT03934177|Experimental|Blueberry powder|4 weeks of supplementation of 21 g whole blueberry powder
11120090|NCT03934177|Placebo Comparator|Placebo powder|4 weeks of supplementation of 21 g placebo powder (maltodextrin)
11120091|NCT03934151||intracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with intracorporeal technique
11120092|NCT03934151||extracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with extracorporeal technique
11120093|NCT03934138|Active Comparator|Educated open label placebo|These subjects will undergo all the same procedures as in the control group. But before the placebo CTP, they will watch a short movie explaining placebo mechanisms. While applying the placebo cream, they will be told that the cream is inert (placebo), efficient to decrease pain caused by cold and the mechanisms seen in the movie will take place.
11120094|NCT03934138|Placebo Comparator|Conventional placebo|These subjects will watch a video on hand washing. While applying the placebo cream, they will be told that this cream is effective to decreased pain caused by cold.
11120095|NCT03934099|Experimental|LC350189 50mg|LC350189 50mg, QD
11120096|NCT03934099|Experimental|LC350189 100mg|LC350189 100mg, QD
11120097|NCT03934099|Experimental|LC350189 200mg|LC350189 200mg, QD
11120098|NCT03934099|Placebo Comparator|Placebo|Placebo, QD
11120099|NCT03934073|Experimental|DEXTRAIN|The DexTrain group sessions will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting dexterity components.
11120100|NCT03934073|Active Comparator|CONVENTIONNELLE|Conventional training involving stretching of the spastic muscles as well as a set of exercises conventionally used in the protocols of post-stroke rehabilitation (repeated movements, manipulation of objects).
11120101|NCT03934073|Other|CONTROLE|To compare the results of SMT and functional MRI.
11120102|NCT03934060|Experimental|Intervention|Supervised exercise training including specific strength training tools and general exercise contents (standard care), 2-3 times per week, 30 minutes per session
11120103|NCT03934060|No Intervention|Control|Supervised exercise training regarding general exercise contents (standard care), 2-3 times per week, 30 min per session
11120104|NCT03934047|Experimental|Group A|Group A: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
11120105|NCT03934047|No Intervention|Group B|Group B: No Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
11120147|NCT03933657|Experimental|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System-Peripheral is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions via atherectomy.
11120148|NCT03933644|Other|Ambu Aura Gain TM with gastric tube|
11120149|NCT03933644|Other|Ambu Aura Gain TM without gastric tube|
11121529|NCT03923972||Nephrologists|physicians treating patients with chronic kidney disease
11120106|NCT03934021||Acute stroke patient group|"Consecutive patients diagnosed with acute ischaemic stroke during hospitalization in Prince of Wales Hospital will be recruited.
~After an informed consent, stool will be collected from enrolled patients in their first bowel opening after hospitalization and stored in a freezer (-80 degree Celsius) within 24 hours for analysis. If a subject develops constipation, stool sampling will be facilitated by stool softener or laxatives. Stools samples will be stored at -80 degrees Celsius within 24 hours once it is collected.
~Subjects will be followed up at 3 and 6 months after trial entry. NIHSS and mRS will be performed at each visit. Stool sample collection will be repeated in 6 months visit only."
11120107|NCT03934021||Control group|Age and disease matched subjects will be invited to join the study as the control. Stool will also be collected for the comparison of gut microbiota with acute stroke patients to look for evidence of gut dysbiosis in acute stroke. We shall match the control cohort with the stroke cohort in terms of age, gender, smoking status, medical co-morbidities including hypertension, hyperlipidaemia, diabetes, (atrial fibrillation), use of medications in particular metformin, proton pump inhibitors and aspirin.
11120108|NCT03934008||Historical Control Group|All pediatric patients 0-6 years of age seen in the clinic within one year prior to the start of the intervention period
11120109|NCT03934008||Post-Intervention Group|All pediatric patients 0-6 years of age seen in the clinic for one year following the implementation of the motivational interviewed based tool
11120110|NCT03933995||Mesenchymal stem cell|Long-term follow up of Mesenchymal stem cell group
11120111|NCT03933982|Experimental|Pyrotinib plus Vinorelbine|
11120112|NCT03933956|Experimental|Empagliflozin-treated|Oral empagliflozin tablets 10mg daily, taken for 30 days.
11120113|NCT03933943|Experimental|LY3361237|LY3361237 administered subcutaneously (SC)
11120114|NCT03933943|Placebo Comparator|Placebo|Placebo administered SC
11120115|NCT03933930|Experimental|Lactate-directed therapy|
11120116|NCT03933930|Experimental|Goal-directed therapy|
11120117|NCT03933917|Experimental|Large Volume Acute Normovolemic Hemodilution|All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
11120118|NCT03933904|Experimental|Sirolimus|Oral sirolimus: loading dose of 7.5 mg/m^2, rounded to the nearest mg, on day 1. Starting on day 2, oral sirolimus daily at 2.5 mg/m^2/day (rounded to the nearest mg), target trough level 5-15 ng/mL by HPLC, for 12 months.
11120119|NCT03933891||Decompensated liver cirrhosis with TIPS|
11120120|NCT03933878||Post-transplant recipient BAL samples|No intervention will be administered
11120121|NCT03933878||Donor BAL samples|No intervention will be administered
11120122|NCT03933865|Other|Buprenorphine Maintained Patients|All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
11120123|NCT03933839|Experimental|PainCOACH|This group will take part in an 8-week pain coping skills training (PCST) intervention.
11120124|NCT03933839|No Intervention|Wait List Control|The other group will be the wait list group and will receive the pain CST program after completing all study measures.
11120125|NCT03933826||Patients who have selected radical cystectomy|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected radical cystectomy as their second-line treatment
11120126|NCT03933826||Patients who have selected medical management|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected medical management as their second-line treatment
11120127|NCT03933826||Caregivers|Caregivers of patients enrolled in CISTO will be approached for participation in caregiver-specific assessments
11120128|NCT03933813|Experimental|IV Iron Sucrose|Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period
11120129|NCT03933800|Experimental|High flow nasal cannula (HFNC)|High flow nasal cannula therapy
11120130|NCT03933800|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure therapy
11120131|NCT03933787|Placebo Comparator|mannitol in a tablet|two tablets containing mannitol in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
11120132|NCT03933787|Active Comparator|Saxagliptin in a tablet|two tablets containing each 5 mg of Saxagliptin in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
11120133|NCT03933774|Experimental|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
11120134|NCT03933774|Placebo Comparator|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
11120135|NCT03933761|Experimental|Pamiparib (BGB-290)|Drug: Pamiparib Oral capsules 60mg twice daily continuously Although treatment is continuous, a cycle is defined as 4 weeks or 28 days.
11120136|NCT03933735|Experimental|Arm A: Dose Escalation|9 cohorts of subjects receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
11120137|NCT03933735|Experimental|Arm B: Dose Expansion|An expansion cohort will be enrolled after recommended phase 2 dose is established.
11120138|NCT03933722||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
11120139|NCT03933709|No Intervention|Follow-up Group (FG)|dietary surveillance and conventional therapy
11120140|NCT03933709|Active Comparator|Control Group (CG)|deworming and WHO diet
11120141|NCT03933709|Experimental|Intervention Group (IG)|deworming and the Nutritional Support System (NSS)
11120142|NCT03933696|Active Comparator|Active Lighting Intervention|"The TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, TLI will allow us to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The investigators will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater).
~The lighting intervention will be in place for 24 weeks"
11120241|NCT03933033|Active Comparator|Group A|treated with platelet rich plasma
11120150|NCT03933631|Experimental|Pilocarpine, Prednisolone acetate and Ofloxacin|This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
11120151|NCT03933631|Active Comparator|Prednisolone acetate and Ofloxacin (standard of care)|This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.
11120152|NCT03933618|Other|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
11120153|NCT03933618|Other|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
11120154|NCT03933618|Other|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
11120155|NCT03933618|Other|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
11120156|NCT03933618|Other|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
11120157|NCT03933618|Other|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
11120158|NCT03933605|Active Comparator|midazolam and palonosetron|0.05 mg/kg of midazolam i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
11120159|NCT03933605|Active Comparator|palonosetron|the same volume (0.05 mg/kg) of normal saline i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
11120160|NCT03933592|Active Comparator|Thoracic epidural|thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
11120161|NCT03933592|Experimental|Serratus plane block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
11120162|NCT03933566||Ultrasound-Guided|Ultrasound-Guided Superficial Cervical Plexus Block
11120163|NCT03933566||Landmark-Based|Landmark-Based Superficial Cervical Plexus Block
11120164|NCT03933553|Experimental|Easy sleep complex essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
11120165|NCT03933553|Active Comparator|Lavender essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
11120166|NCT03933540||Pediatric Asthma Patients|"Participants are ages 8 years through 17 years and have partially controlled or uncontrolled asthma.
~No intervention is included in this study."
11120167|NCT03933527|No Intervention|control group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).
11120168|NCT03933527|Experimental|coffee group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make coffee rinses for 30 seconds, four times daily.
11120169|NCT03933527|Experimental|tea group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make tea rinses for 30 seconds, four times daily.
11120170|NCT03933514||GAgP parents|Parents diagnosed with Generalized Aggressive Periodontitis
11120171|NCT03933514||GAgP children|Children from parents diagnosed with Generalized Aggressive Periodontitis
11120172|NCT03933514||Health parents|Parents diagnosed as periodontally healthy
11120173|NCT03933514||Health children|children from parents diagnosed as periodontally healthy
11120174|NCT03933501|Experimental|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
11120175|NCT03933501|Placebo Comparator|FMUD|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
11120176|NCT03933501|Experimental|SRP + AM|Four sessions (1/week) of scaling and root planning, plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the last session of treatment and taken every 8 hours for 7 days.
11120177|NCT03933501|Placebo Comparator|SRP|Four sessions (1/week) of scaling and root planning, plus two distinct placebo pills prescribed on the last session of treatment and taken every 8 hours for 7 days.
11120178|NCT03933488|Experimental|TAK-994: Part A|TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
11120179|NCT03933488|Experimental|TAK-994: Part B|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
11120180|NCT03933488|Experimental|TAK-994: Part C|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
11120242|NCT03933033|Active Comparator|Group B|treated with Erbium Yag Laser
11120181|NCT03933488|Experimental|TAK-994: Part D|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
11120182|NCT03933488|Experimental|TAK-994: Part E|TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
11120183|NCT03933475|Experimental|Intendu Active Brain Trainer Telerehabilitation Games|Use of telerehabilitation Games within the home environment
11120184|NCT03933462|Experimental|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
11120185|NCT03933462|Active Comparator|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
11120186|NCT03933449|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 2 years).
11120187|NCT03933449|Active Comparator|Chemotherapy|Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 2 years).
11120188|NCT03933436|Experimental|Iodine|Iodine swabs.
11120189|NCT03933436|Active Comparator|Normal Saline|Saline flush.
11120190|NCT03933423|Active Comparator|Intervention|Educational session of pregnant mothers, blood grouping of parents and identifying risk factors for developing jaundice, screening newborns for neonatal jaundice, glucose 6-phosphate dehydrogenase deficiency and illness, Home based phototherapy and referral.
11120191|NCT03933423|No Intervention|Control|No intervention will be deliver
11120192|NCT03933410|Experimental|KB195|KB195 is a novel glycan
11120193|NCT03933397|Experimental|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home, what was needed during their past hospital and emergency department visits to treat pain and doses that have been effective and safe in the past.
11120194|NCT03933397|Experimental|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight.
11120195|NCT03933384|Active Comparator|Tenofovir alafenamide group|Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).
11120196|NCT03933384|Active Comparator|Entecavir group|Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).
11120197|NCT03933358||Euthyroid|
11120198|NCT03933358||Low T3|low triiodothyronine syndrome
11120199|NCT03933345||People who use illicit opioids|The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.
11120200|NCT03933332||Ventilator length of use|measured in days
11120201|NCT03933319|Experimental|PLD in combination with trastuzumab|"Trastuzumab: administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
~pegylated liposomal doxorubicin(PLD):administered at dose of 35mg/m2 IV once every 21 days."
11120202|NCT03933306|Placebo Comparator|Placebo+routine blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is managed according to routine practice.
11120203|NCT03933306|Experimental|Dexmedetomidine+routine blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is managed according to routine practice.
11120204|NCT03933306|Experimental|Placebo+goal-directed blood pressure management|Placebo (normal saline) is administered during anesthesia. Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
11120205|NCT03933306|Experimental|Dexmedetomidine+goal-directed blood pressure management|Dexmedetomidine is administered during anesthesia (0.6 mcg/kg for 10 min, then 0.5 mcg/kg/h). Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
11120206|NCT03933293|Experimental|AK102|450mg AK102, Q4W, subcutaneous injection
11120207|NCT03933293|Placebo Comparator|placebo|Placebo, Q4W, subcutaneous injection
11120208|NCT03933280|Active Comparator|Group P|nalbuphine/propofol group
11120209|NCT03933280|Active Comparator|Droup D|Nalbuphine/dexmedetomidine group
11120210|NCT03933267|Experimental|Group I|This group of participant will receive Cervical sensorimotor control training exercises. In addition to it conventional physical therapy protocol will be given.
11120211|NCT03933267|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol.
11120212|NCT03933241|Experimental|experiment group|nasal irrigation after transsphenoidal surgery for pituitary tumor
11120213|NCT03933241|No Intervention|matched group|without nasal irrigation after transsphenoidal surgery for pituitary tumor
11120214|NCT03933228||Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
11120215|NCT03933228||Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
11120216|NCT03933215||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
11120217|NCT03933202||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
11120218|NCT03933189|Active Comparator|Biomedical (BIOM) physical therapy|Six 60 minute PT sessions consisting of 15 minutes of education on topics such as ideal postural alignment (sitting, sleeping), maintenance of normal spinal curves, body mechanics, proper lifting techniques, home pain control via anti-inflammatory modalities such as ice; 15 minutes of manual therapy to region of pain (soft tissue and/or joint mobilization); 30 minutes of region specific exercises to address identified muscle imbalances -stretching and strengthening of the muscles local to the area of pain.
11120219|NCT03933189|Active Comparator|Biopsychosocial (BPS) physical therapy|"Six 60 minute PT sessions consisting of 15 minutes of pain neuro-science education, 15 minutes of Graded Motor Imagery (GMI) techniques, (a progressive program of visual and mental exercises consisting of laterality exercises, motor imagery and mirror therapy); 30 minutes of a general conditioning exercise program individualized for each participant based on initial examination findings and participant presentation consisting of:
~A cardiovascular component which may include walking on a treadmill, stationary cycling, or a seated stepping machine.
~A muscle strengthening component for extremities and trunk. A flexibility component for upper and lower extremity musculature."
11120220|NCT03933176|Experimental|Simplified restorative procedure|After selective carious tissue removal, the universal adhesive (Adper Universal; 3M ESPE, St. Paul, MN, EUA) will be applied on the cavity walls. The cavity will be restored using a single increment of Filtek One Bulk Fill (3M ESPE, St. Paul, MN, EUA).
11120221|NCT03933176|Active Comparator|Control|A thin layer of resin-modified glass ionomer (Ionoseal (Voco America Inc., Briarcliff Manor, NY, EUA) will be placed on the pulpal floor of the cavity. Then, the adhesive and composite will be used following the same directions defined for the experimental condition.
11120222|NCT03933163|Other|Resveratrol followed by placebo|1g micronised resveratrol twice daily for 24 weeks, a wash-out period of 4 weeks, followed by twice daily placebo for 24 weeks.
11120223|NCT03933163|Other|Placebo followed by Resveratrol|Twice daily placebo for 24 weeks, a wash-out period of 4 weeks, followed by 1g micronised resveratrol twice daily for 24 weeks
11120224|NCT03933150|Other|ultrasoun guided caudal epidural injection|A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.
11120225|NCT03933150|Other|fluoroscopy guided caudal epidural injection|B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
11120226|NCT03933137||Not prolonged length of stay|Living donor patients who had ≤ 6 days length of stay after laparoscopic nephrectomy procedure
11120227|NCT03933137||Prolonged length of stay|Living donor patients who had > 6 days length of stay after laparoscopic nephrectomy procedure
11120228|NCT03933124|Experimental|Virtual Reality Intervention group|"The intervention group includes 60 patients who will use Virtual Reality for postoperative pain. Participants will use Virtual Reality minimal 10 minutes, minimal 3 times a day on the second, third and fourth day after surgery, on the general ward.
~20 participants will receive an Oculus Go immersive 3D nature videos, games, meditation videos, google earth experiences and sports games.
~20 participants will receive a Relaxmaker with 2D nature videos
~20 participants will receive CareVRx with 3D nature videos and meditation videos."
11120229|NCT03933124|No Intervention|Control group|The control group receives standard postoperative care.
11120230|NCT03933111|Experimental|patients with pancreatic solid neoplasms|Patients with pancreatic solid neoplasms are enrolled in this study and accept the test.
11120231|NCT03933098|Experimental|Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
11120232|NCT03933098|Experimental|Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
11120233|NCT03933098|Experimental|Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
11120234|NCT03933098|Active Comparator|Test group D: Typbar TCV|"One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0).
~MR for age group at 9-15 months."
11120235|NCT03933085|Experimental|MCI Group|A within-subject, multiple baseline design, with each subject serving as their own control,4 will be implemented to get the maximum number of participants trained in the use of the MSS during the proposed funding period. This 2-year study will involve four phases: a 4-month translation and cultural adaptation development phase, a 12-month recruitment and treatment implementation phase, a 6-month post data collection only phase, and a 2-month data analysis and result writing phase. Data analyses will be conducted using the Statistical Package for the Social Sciences (SPSS) program.
11120236|NCT03933072|Experimental|patients with complete spinal cord injury|the planned interventions have been described in the section below
11120237|NCT03933059|Active Comparator|R&R Park City, Utah|This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
11120238|NCT03933059|Active Comparator|R&R Salt Lake City, Utah|This group will receive 12 daily individual sessions of CPT at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
11120239|NCT03933059|Active Comparator|Weekly Treatment Salt Lake City, Utah|This group will receive 12 individual sessions of CPT on a weekly basis at the National Center for Veterans Studies located on the University of Utah campus in Salt Lake City, Utah.
11120240|NCT03933046|Experimental|children referred to PSG due to suspected SDB|
11120246|NCT03933007|Other|Pharmacokinetic study|all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)
11120247|NCT03932994|Experimental|ACT on Health Intervention|Those assigned to ACT on Health will use the program over the next 8 weeks, completing weekly modules and coaching calls.
11120248|NCT03932994|No Intervention|Waitlist|Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
11120249|NCT03932981|Experimental|Temozolomide|Chemotherapy by temozolomide
11120250|NCT03932968||Symptomatic pain|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry during 24 hours will be performed.
11120251|NCT03932968||Control|patients after a sleeve gastrectomy without symptomatic pain
11120252|NCT03932955|Experimental|MC-19PD1 CAR-T Cells|
11120253|NCT03932942|Experimental|Point-of-care testing of respiratory pathogens on admission|Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
11120254|NCT03932942|No Intervention|Routine ED protocol|Diagnostic tests for respiratory pathogens will be obtained according to clinical judgement and tested on microbiological laboratory. The results are ready on the next office day.
11120255|NCT03932929|Experimental|Scotchbond universal adhesive (etch-and-rinse)|Acid etch (enamel&dentin)+adhesive agent Intervention: Device: Adhesive agent
11120256|NCT03932929|Experimental|Scotchbond universal adhesive (selective-etch)|Acid etch (only enamel)+adhesive agent Intervention: Device: Adhesive agent
11120257|NCT03932929|Experimental|Scotchbond universal adhesive (self-etch)|Adhesive agent Intervention: Device: Adhesive agent
11120258|NCT03932916|Experimental|experimental group 1|HHT201 17mg injection
11120259|NCT03932916|Experimental|experimental group 2|HHT201 34mg injection
11120260|NCT03932916|Active Comparator|experimental group 3|Donepezil Hydrochloride oral tablet 5mg
11120261|NCT03932903|Experimental|Contextually-tailored Mobile Messages for Adherence|All participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
11120262|NCT03932903|No Intervention|No messages|All participants will also be micro-randomized to not receive messages on some days of the intervention (~40% of the time).
11120263|NCT03932890|Active Comparator|Lower Volume fluid bolus arm|The 'lower volume' (LV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the LV arm, the trigger will deliver 50mls over 10 mins at a rate of 300ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
11120264|NCT03932890|Experimental|Higher Volume fluid bolus arm|The 'higher volume' (HV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the HV arm, the trigger will deliver 200mls over 10 mins at a rate of 1200ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
11120265|NCT03932877||late-onset preeclampsia, group1|30 late-onset preeclampsia patients as group1 (gestational age≥34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
11120266|NCT03932877||Control, group 2|33 patients with normal pregnancies as group2 (gestational age≥34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
11120267|NCT03932877||early-onset preeclampsia, group 3|31 early-onset preeclampsia patients as group3 (gestational age<34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg considered mild, and higher values considered to being severe.
11120268|NCT03932877||Control, group 4|31 patients with normal pregnancies as group 4 (gestational age<34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
11120269|NCT03932864|Placebo Comparator|Single Ascending Dose of MTGA-145 or placebo|MGTA-145 or placebo dose escalation as single agent, single dose
11120270|NCT03932864|Placebo Comparator|Single Dose MGTA-145 or placebo plus plerixafor|MGTA-145 or placebo in combination with plerixafor, single dose
11120271|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor for 2 sequential d|MGTA-145 in combination with plerixafor on two consecutive days; single dose per day
11120272|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis
11120352|NCT03932253|Experimental|FCN-159|Preset 6 dose groups during the dose-escalation phase, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, and 6 mg, orally, continuous once a day for 21 days, followed by a 7-day break, 28 days is a cycle.
11120273|NCT03932851||HBsAg(+) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). The newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact of HBV mother-to-child transmission.
11120274|NCT03932851||HBsAg(-) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA).
11120275|NCT03932838|Experimental|clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
11120276|NCT03932825|Placebo Comparator|Air oxygen mixture|participants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%).
11120277|NCT03932825|Experimental|Nitrous oxide|Participants in this group inhale mixed 50% nitrous oxide and 50% oxygen.
11120278|NCT03932812|Experimental|Options Counselor Health Educator Intervention Group|These individuals will receive the Options Counselor Health Educator Intervention
11120279|NCT03932812|No Intervention|Control|These individuals will receive the typical standard of care treatment from clinics
11120280|NCT03932799||Washington|Workers in the Washington Department of Labor and Industries state fund insurance system.
11120281|NCT03932799||Ohio|Workers in the Ohio Bureau of Workers' Compensation state fund insurance system.
11120282|NCT03932786||Retrospective(biospecimens, vision assessment, questionnaires)|
11120283|NCT03932786||Prospective (biospecimens, vision assessment, questionnaires)|
11120284|NCT03932773|Sham Comparator|Sham rTMS + CPT|30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session
11120285|NCT03932773|Active Comparator|Active rTMS + CPT|30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
11120286|NCT03932773|Active Comparator|Active rTMS Alone|30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks
11120287|NCT03932760|Experimental|UPLIFT Program|Weekly one-hour group sessions for 10 weeks facilitated by a mental health professional.
11120288|NCT03932760|Active Comparator|Pregnancy Skills Group|Weekly one-hour group sessions for 10 weeks facilitated by a registered nurse.
11120289|NCT03932747|Placebo Comparator|Placebo Creams|Measuring the skin before the application of the cream without urea (placebo), wait 3 hours and re-measure the hydration
11120290|NCT03932747|Active Comparator|Urea 5%|Measuring the skin before the application of the cream with urea (5%), wait 3 hours and re-measure the hydration
11120291|NCT03932747|Active Comparator|Urea 20%|Measuring the skin before the application of the cream with urea (20%), wait 3 hours and re-measure the hydration
11120292|NCT03932734||survey|
11120293|NCT03932721|Active Comparator|Evolocumabe|Patients with T2DM treated with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure) AND evolocumab (anti-PCsk9).
11120294|NCT03932721|No Intervention|Control|Patients with T2DM treated exclusive with the standard of care (SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose and blood pressure).
11120295|NCT03932708|Experimental|Urgent Care Antibiotic Stewardship Intervention|All 38 urgent care clinics will implement CDC Core Elements of outpatient antibiotic stewardship as described above.
11120296|NCT03932695|Active Comparator|High dose Milk peptides|2800mg of whey protein hydrolysates single dose
11120297|NCT03932695|Active Comparator|Low dose Milk peptides|1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
11120298|NCT03932695|Placebo Comparator|Placebo|maltodextrin
11120299|NCT03932682|Experimental|Seqirus QIVc|Cell-derived Quadrivalent Influenza Vaccine
11120300|NCT03932682|Active Comparator|Comparator|Non-influenza Comparator (NesiVac-C)
11120301|NCT03932669|Experimental|Nilotinib group|Patients with SCA and taking nilotinib treatment
11120302|NCT03932656||Females with borderline personality disorder|
11120303|NCT03932643|Experimental|ONC201 treatment|A 3+3 dose escalation design will be followed. Given the safety profile in prior trials, A dose of 250 mg weekly will be the starting dose. The first 12-15 patients are expected to receive escalating doses of ONC 201, the remaining patients will go on the expansion cohort.
11120304|NCT03932630|Experimental|Study intervention|
11120305|NCT03932630|Active Comparator|Control intervention|
11120306|NCT03932617||fluid responders|
11120307|NCT03932617||fluid non responders|
11120308|NCT03932604|No Intervention|Atrial sensing OFF mode|VDD-ICD programmed as atrial sensing Off mode
11120309|NCT03932604|Active Comparator|Atrial sensing ON mode|VDD-ICD programmed as atrial sensing ON mode
11120310|NCT03932591|Experimental|intervention|Inhibitory kinesio taping method will be used for intervention group. Y shaped, 34-40 cm length, 5 cm width, skin color kinesio tape will be applied on spastic gastrocsoleus muscle. The base of Y shaped tape will be strapped on calcaneus ( no stretch for first 5 cm) and the both legs of Y shaped tape will be strapped on gastrocnemius muscle medial and lateral head with 15% stretch.
11120311|NCT03932591|Sham Comparator|Control|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be applied on achilles tendon without stretch.
11120312|NCT03932578|Active Comparator|Atropine group|Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
11120452|NCT03931577|Experimental|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the use of C-reactive protein rapid testing.
11120313|NCT03932578|Active Comparator|Metoclopramide group|Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
11120314|NCT03932565|Experimental|The fourth-generation CAR-T therapy|Clinical trial study of Interventional therapy sequential with the fourth-generation CAR-T cells (IL7 and CCL19 or / and IL12) targeting Nectin4/FAP in the treatment of advanced malignant solid tumors with Nectin4-positive .
11120315|NCT03932552|Active Comparator|Control|Personalized nutritional therapy
11120316|NCT03932552|Experimental|Exercise|Aerobic exercise + Personalized nutritional therapy
11120317|NCT03932539||Twenty-five de-novo heart transplant recipients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs, either Everolimus or Sirolimus.
11120318|NCT03932526|Active Comparator|Vinorelbine + placebo group|92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
11120319|NCT03932526|Experimental|Vinorelbine + Apatinib group|92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
11120320|NCT03932513|Experimental|Treatment A: inarigivir soproxil|Inarigivir 400 mg once per day for 6 weeks (2800mg/week).
11120321|NCT03932513|Experimental|Treatment B: inarigivir soproxil|Inarigivir 400 mg three times per week for 6 weeks (1200mg/week).
11120322|NCT03932487||AITD group|Thyroid antibody positive and hypothyroidism
11120323|NCT03932487||normal group|Thyroid antibody negative and hypothyroidism
11120324|NCT03932474|Experimental|SAMEUp|SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
11120325|NCT03932474|Placebo Comparator|Placebo|Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
11120326|NCT03932461|Active Comparator|Vacuum assisted closure|At the index operation after the source of fecal or diffuse peritonitis has been treated there will be placed a Vacuum assisted closure system VAC® (San Antonio, TX) to temporarily close the abdomen. After 48-hours the system will be changed and potential complications will be treated. The process will be repeated until the peritonitis condition is under control, whereafter the abdomen can be closed according to Isrealsson's principles. The process will be repeated 8 days after the index operation with extension if needed. If needed the system can be changed earlier than 48-hours. All patients are routinely observed by clinical examination and SOFA-score.
11120327|NCT03932461|Active Comparator|"Relaparotomy on-demand"|At the index operation after the source of fecal or diffuse peritonitis has been treated the abdomen will be closed according to Isrealsson's principles. Patients will be reevaluated for potential relaparatomy every 48-hours based on clinical and paraclinical parameters by a surgeon. The process will be repeated continue 8 days after the index operation with extension if needed. If needed relaparotomy can be done earlier than 48-hours. All patients are routinely observed by clinical examination and SOFA-score.
11120328|NCT03932435|Experimental|TWLO_C → TWLO|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
11120329|NCT03932435|Experimental|TWLO → TWLO_C|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
11120330|NCT03932422||Controlled Hypertensive Patients (CHP)|Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
11120331|NCT03932422||Resistant Hypertensive Patients (RHP)|Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
11120332|NCT03932409|Experimental|Pembrolizumab + Radiation Therapy|Pembrolizumab given 7 days prior to radiation therapy (e.g., vaginal cuff brachytherapy)
11120333|NCT03932396||Single group of subjects who fulfill the inclusion criteria|All the population condemned to a non-custodial sentence that is presented in the Service of Management of Penalties and Alternative Measures of the Center of Social Insertion (CIS) José Hierro CP Dueso during the study period (March 2019 and March 2021) , with ages between 18 and 79 years (approximately 1000 people / year) and willing to participate (signs the IC).
11120334|NCT03932383|Experimental|Modified CPAP|Single arm cohort study of modified mask
11120335|NCT03932370||f-URS|
11120336|NCT03932370||mini-PCNL|
11120337|NCT03932344||SJIA patients on Kineret treatment|SJIA patients on Kineret treatment enrolled in the Pharmachild JIA registry
11120338|NCT03932331|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
11120339|NCT03932318|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).
~Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles.
~Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles.
~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
11120340|NCT03932305|Placebo Comparator|Control|Patients taking inactive placebo tablets
11120341|NCT03932305|Experimental|Lutein|Patients taking lutein supplement
11120342|NCT03932292|Active Comparator|Ectoin Mouth Wash|30 patients obtaining EML03 treatment
11120343|NCT03932292|Active Comparator|Supersaturated solution of calcium and phosphate ions|20 patients taking standard treatment (calcium phosphate mouth wash)
11120344|NCT03932279||Stage IA-IIA cutaneous T cell lymphoma|
11120345|NCT03932279||Stage IIB and above cutaneous T cell lymphoma|
11120346|NCT03932279||CD30+ lymphoproliferative disorders|
11120347|NCT03932279||Plaque psoriasis with BSA>5% on routine phototherapy|
11120348|NCT03932279||Moderate to severe atopic dermatitis on routine bleach bath|
11120349|NCT03932279||Healthy controls|
11120350|NCT03932266|Experimental|Experimental group|Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
11120353|NCT03932240|Experimental|Fibrinogen Concentrate (FC)|"After separation from bypass, patients will receive platelets and FC. The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
11120354|NCT03932240|Active Comparator|Cryoprecipitate|"After separation from bypass, patients will receive platelets and cryoprecipitate. Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL.
~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
11120355|NCT03932227|Other|Cardioskin-Holter|Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.
11120356|NCT03932227|Other|Holter-Cardioskin|Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.
11120357|NCT03932214|Experimental|Infrared illumination group|The nurse uses the Accuvein® device to identify the veins before puncture.
11120358|NCT03932214|No Intervention|Control group|The nurse proceeds as usual (visual identification in the light of the room and palpation)
11120359|NCT03932201||Previously treated patient (PTPs) with hemophilia A|Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
11120360|NCT03932188||Control|Individuals between 13-25 years old that do not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or Cluster A personality disorder diagnosis
11120361|NCT03932188||Prodromal/Early psychosis|Individuals between 13-25 years old that meet diagnostic criteria for a prodromal syndrome or early psychosis
11120362|NCT03932175|Experimental|Intervention group|The multicomponent intervention will comprise three aspects on-top of usual care: i) Motivational interview to assess patient's adherence profile and to raise the compromise with the behaviour change towards NIV, physical activity and nutritional habits; ii) Bi-directional interaction between the study participants and clinical staff delivered by the MyPathway app, where specific clinical problems regarding NIV will be addressed as they arise; and iii) Motivational messages and educational material delivered via the MyPathway app regarding changes in physical activity and/or nutritional habits. As part of the behavioural intervention, goal setting for NIV adherence and life-style changes will be introduced to the MyPathway app in order for the participants to follow the advice.
11120363|NCT03932175|No Intervention|Control group|Patients will receive usual care according to guidelines on management of chronically ventilated patients, without any mHealth tool or behavioural intervention
11120364|NCT03932162|Placebo Comparator|Young Adult|One small area of skin will undergo treatment with a small amount of UVB.
11120365|NCT03932162|Active Comparator|Geriatric Adult|Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injectiosn with saline. Then the injected areas will be treated with a small amount of UVB.
11120366|NCT03932149|Experimental|Experimental Group|Real stimulation
11120367|NCT03932149|Sham Comparator|Control Group|Sham stimulation
11120368|NCT03932136|Active Comparator|SFN group|The intervention duration with SFN tablet is 52 consecutive weeks. The dosage is six active tablets (411 μmol GR) per day.
11120369|NCT03932136|Placebo Comparator|Placebo group|The intervention duration with placebo tablet is 52 consecutive weeks. The placebo group will be given six placebo tablets per day.
11120370|NCT03932110|Other|psoriasis vulgaris,|patients who have only psoriasis vulgaris
11120371|NCT03932110|Other|psoriatic arthritis|patients who have psoriatic arthritis
11120372|NCT03932110|Other|healthy control|healthy people
11120373|NCT03932097|Experimental|Parenting Now|Preventive Parenting Now digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
11120374|NCT03932097|Active Comparator|Active Control Materials|SAMHSA alcohol prevention materials for parents
11120375|NCT03932084|Experimental|Control group|"During hospitalization:
~Monitor subjects' blood glucose;
~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;
~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.
~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.
~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
11120376|NCT03932084|Experimental|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
11120377|NCT03932071|Experimental|experimental group|
11120378|NCT03932071|No Intervention|control group|
11120379|NCT03932058||osteosarcoma|
11120380|NCT03932058||chondrosarcoma|
11120381|NCT03932058||enchondroma|
11120382|NCT03932045|Experimental|SYB Filler (SF-01)|
11120383|NCT03932045|Active Comparator|Ellansé M|
11120384|NCT03932032|Experimental|Attention Bias Modification Treatment|Attention Bias Modification Treatment is a computer-based attention training program.
11120385|NCT03932032|Sham Comparator|Neutral Control Task|Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.
11120386|NCT03932019|Experimental|High dose group|Jitongning tablet,3tablets,bid,po
11120387|NCT03932019|Experimental|Low dose group|Jitongning tablet,2tablets,bid,po Jitongning tablet placebo,1tablet,bid,po
11120388|NCT03932019|Placebo Comparator|Placebo Comparator controlled group|Placebo Comparator: Jitongning tablet placebo,3tablets,bid,po
11120389|NCT03932006|Experimental|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
11120390|NCT03932006|Experimental|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
11120391|NCT03932006|Active Comparator|Imrecoxib|Imrecoxib 0.1g twice a day,orally
11120392|NCT03931993|Placebo Comparator|Treatment Group 1|Six 1.0mL placebo injections (2% w/v L-tyrosine)
11120393|NCT03931993|Experimental|Treatment Group 2|Six 1.0mL injections of Grass MATA MPL 900, 2700, 8000, 8000, 8000, and 8000 SU
11120394|NCT03931980|Experimental|Robotic surgery|Patients undergoing robotic surgery for removal of rectal cancer.
11120395|NCT03931980|Experimental|Laparoscopic surgery|Patients undergoing laparoscopic for removal of rectal cancer
11120396|NCT03931967||MR-proADM|
11120397|NCT03931954||Study population|Patients completing the inclusión criteria
11120398|NCT03931941|Experimental|Active|RBX2660 is an enema of a microbiota suspension
11120399|NCT03931928|No Intervention|Control group (Group 1)|All patients receive Placebo
11120400|NCT03931928|Experimental|Group 2|"Patients will receive (Z)-endoxifen dosed according to CYP2D6 genotype"
11120401|NCT03931928|Experimental|Group 3|Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening
11120402|NCT03931915|Experimental|TAK-385|TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks
11120403|NCT03931915|Active Comparator|Leuprorelin acetate|TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks
11120404|NCT03931902|Experimental|Laryngeal Mask Airway (LMA)|Using laryngeal mask airway as the airway device during general anesthesia
11120405|NCT03931902|Active Comparator|Endotracheal Tube (ETT)|Using endotracheal tube as the airway device during general anesthesia
11120406|NCT03931889|Active Comparator|Vitamin D3|Cholecalciferol 80,000 IU (2 capsules of 40,000 IU) per oral per week for consecutive 26 weeks.
11120407|NCT03931889|Placebo Comparator|Vitamin D3 placebo|Placebo (2 capsules) per oral per week for consecutive 26 weeks.
11120408|NCT03931876|Placebo Comparator|Placebo|placebo
11120409|NCT03931876|Active Comparator|Active|AV-006
11120410|NCT03931863|Active Comparator|Group A|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
11120411|NCT03931863|Active Comparator|Group B|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
11120412|NCT03931863|Placebo Comparator|Group C|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
11120413|NCT03931850|Experimental|Dual guidance (ultrasound and neurostimulation)|This arm : patients will be received pudendal nerve block by dual guidance technique ( ultrasound and neurostimulation)
11120414|NCT03931850|Active Comparator|ultrasound-guided only|This arm : patients will be received pudendal nerve block by ultrasound-guided only.
11120415|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 75 mmHg|Before skin incision
11120416|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 100 mmHg|Before skin incision
11120417|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 150 mmHg|Before skin incision
11120418|NCT03931824|Experimental|PRP group|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).
~Injections were done every two weeks, for a total of 3 times."
11120419|NCT03931824|Sham Comparator|Placebo group|Injections containing saline were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used. To provide blindness, all injections were done using injectors coated with non transparent tape. All of the PRP injections were done by the same physician each time, with compliance to preventive measures against complications such as infections. Patients and the physician who applied the injection were blinded to the groups, and the solution was prepared by another researcher who was not blind to the groups.
11120420|NCT03931811|Experimental|Short wave diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.
~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.
~SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device). Both groups took injections in the beginning of the therapy, 3rd week and 6th week, a total of 3 times. SWD or sham SWD therapy was given right after the injections, also for a total of 3 times."
11120453|NCT03931577|Experimental|Enhancement of communication skills|Continuous (on-site and monthly online training) illness-focused intervention with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
11120488|NCT03931382|Active Comparator|Booklet|In this arm, participants will receive 45 minutes of preparation using the standard of care MRI Preparation Booklet for non-sedated MRIs.
11120421|NCT03931811|Sham Comparator|Sham diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.
~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.
~Sham SWD group took 20 minutes of SWD therapy with device not working(Enraf-Nonius, Curapuls 970 Short wave diathermy device)."
11120422|NCT03931798|Experimental|Treatment|Healthy participants were administered the Visual Scanning Test
11120423|NCT03931785|Experimental|MD-7246 300 μg|
11120424|NCT03931785|Experimental|MD-7246 600 μg|
11120425|NCT03931785|Experimental|MD-7246 1200 μg|
11120426|NCT03931785|Placebo Comparator|Placebo|
11120427|NCT03931772|Other|Automated Self-Hypnosis Intervention|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health. Participants will be provided the Amazon Alexa device to take home (necessary for using the program). After the lab visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they feel the urge to smoke). Furthermore, participants will be taking an at-home 15 minute survey at baseline, and then 1, 3, 6, 12 and 24 month follow-ups.
11120428|NCT03931759|Active Comparator|Diabetes mellitus|patients with diabetes mellitus
11120429|NCT03931759|No Intervention|non-Diabetes mellitus|patients without diabetes mellitus
11120430|NCT03931746|Experimental|Porcine Xenograft placement|Porcine xenograft will be placed on the wound.
11120431|NCT03931746|No Intervention|No porcine xenograft|The wound will be allowed to heal via second intention.
11120432|NCT03931733|Active Comparator|Music Therapy Intervention|Receiving one thirty minute music therapy intervention.
11120433|NCT03931733|No Intervention|Usual Care|Receiving usual care for a patient in the ICU during a 30 minute intervention.
11120434|NCT03931720|Experimental|anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
11120435|NCT03931707||Sick Neonatal Cohort, Sequencing|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
11120436|NCT03931694||All patients with chronic pain follow in pain clinic|
11120437|NCT03931681|Experimental|Experimental: Phase 1 - Dose Escalation|Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose. Alternatively, patients may take OKI-179 orally (PO) daily on Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
11120438|NCT03931668|Experimental|0.125mg single dose|single dose of TPN-672 0.125mg, 2 subjects
11120439|NCT03931668|Experimental|0.25mg single dose|single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
11120440|NCT03931668|Experimental|0.5mg single dose|single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
11120441|NCT03931668|Experimental|1mg single dose|single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
11120442|NCT03931668|Experimental|2mg single dose|single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
11120443|NCT03931668|Experimental|3mg single dose|single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
11120444|NCT03931668|Experimental|4mg single dose|single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
11120445|NCT03931655|Experimental|Spectroscopic photoacoustic imaging|Any suspicious lymph nodes identified through ultrasound will be imaged with spectroscopic photoacoustic imaging, which is a diagnostic test to measure saturated oxygen in the nodes.
11120446|NCT03931642|Experimental|R-CHOP- blinatumomab|"Patients will first undergo a prior debulking therapy including 2 cycles of R-CHOP.
~At Day1 (D1) : Rituximab 375 mg/m² Intravenous (IV) + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.
~From D1 to D5 : Prednisone 60 mg/m² Per Os (PO). Patients with CR and no measurable lesion left will not be treated further in the setting of the present trial. All the remaining patients will be continuing and treating on study with a single cycle of blinatumomab induction therapy : Blinatumomab at 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/d from day 15-56.
~Patients who achieve an objective response after induction are eligible to receive one further optional cycle of blinatumomab consolidation : blinatumomab 9 μg/d IV by continuous vein infusion from day 1-7, 28 μg/d from day 8-14 and 112 μg/day IV from day 15-28."
11120447|NCT03931629|Active Comparator|CONVENTIONAL PHACO|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
11120448|NCT03931629|Active Comparator|FEMTOSECONDLASER (FLACS)|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
11120449|NCT03931616|Experimental|STEMO deployment|STEMOs are specialized stroke ambulances providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
11120450|NCT03931616|Active Comparator|Regular care|Regular prehospital care consists of normal ambulance care. In suspected life-threatening cases, an emergency physician is sent to the emergency scene in parallel.
11120451|NCT03931590|Experimental|Healthy Male Subjects|Single oral dose of 150 mg of [14C] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.
11120489|NCT03931369|Experimental|Tolvaptan test|15 MG pill administered tolvatan once, one day
11120454|NCT03931577|Experimental|C-reactive protein + communication skills|Continuous (workshop and monthly web-based training) disease-focused intervention with C-reactive protein rapid testing and on-site and continuous (monthly online training illness-focused intervention) with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
11120455|NCT03931577|No Intervention|Usual care|Usual care.
11120456|NCT03931564|Active Comparator|PRESERFLO Microshunt (formerly InnFocus Microshunt (IMS))|The intervention group will undergo PRESERFLO (formerly InnFocus) Microshunt implantation (IMS).
11120457|NCT03931564|Active Comparator|Trabeculectomy|The usual care/control group will undergo a standard trabeculectomy.
11120458|NCT03931551|Experimental|Interventional Arm|Olaparib tablet 300mg bd po + Herceptin (IV 4 mg/kg body followed by weekly doses of 2 mg/kg, or SC 600 mg every 3 weeks) until progression or unacceptable toxicity.
11120459|NCT03931538|Active Comparator|Culture Only|Physician receives only culture result
11120460|NCT03931538|Active Comparator|Guidance 4.0 PCR test only|Physician receives Guidance report only
11120461|NCT03931538|Active Comparator|Culture and Guidance 4.0 PCR test Group|Physician receives both results, gets Culture report immediately before Guidance
11120462|NCT03931538|Active Comparator|Guidance 4.0 PCR test and culture group|Physician receives both results, gets Guidance report immediately before culture
11120463|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
11120464|NCT03931525|Active Comparator|Radiofrequency Therapy without drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
11120465|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 15 days|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
11120466|NCT03931525|Active Comparator|Radiofrequency therapy without drug delivery 15 days|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
11120467|NCT03931512|Experimental|transcranial direct current stimulation|"20 minutes of transcranial direct current stimulation
~1 mA on bi-hemispheric colocation with cathode on the left M1 and anode on the right M1"
11120468|NCT03931512|Sham Comparator|sham transcrial direct current stimulation|20 minutes positioning the electrodes on the scalp. Whith an initial increasing of the current intensity by 10 seconds, until 1mA and a ramp down from 20 seconds to reach zero.
11120469|NCT03931499||Study cohort|Patients undergoing surgery under cardiopulmonary bypass
11120470|NCT03931486||Operatively treated patients with Achilles tendon rupture|Cohort of operatively treated patients with acute Achilles tendon rupture.
11120471|NCT03931473|Experimental|Interceptor G2|Chlorfenapyr/alpha-cypermethrin
11120472|NCT03931473|Experimental|Royal Guard|Pyriproxyfen/alpha-cypermethrin
11120473|NCT03931473|Active Comparator|Interceptor|Alpha-cypermethrin
11120474|NCT03931447|Experimental|Cohort 1: JNJ-72537634 Dose 1 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a single day (SD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1.
11120475|NCT03931447|Experimental|Cohort 2: JNJ-72537634 Dose 2 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a SD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1.
11120476|NCT03931447|Experimental|Cohort 3: JNJ-72537634 Dose 1 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a multiple day (MD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1 for 14 consecutive days.
11120477|NCT03931447|Experimental|Cohort 4: JNJ-72537634 Dose 2 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a MD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1 for 14 consecutive days.
11120478|NCT03931434|Active Comparator|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
11120479|NCT03931434|Placebo Comparator|Placebo|The Placebo does not contain any Aged Garlic Extract (AGE)
11120480|NCT03931421|Experimental|experiment group|In this arm, patients are treated with B Cell Maturation Antigen (BMCA)-targeted CAR-T cells and the safety and efficacy will be observed.
11120481|NCT03931408|Experimental|Gentamicin|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of gentamicin mixed with saline, 2 times per day. A formulation derived from 480 mg gentamicin sulfate diluted in 1 L normal saline will be used for instillation. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
11120482|NCT03931408|Placebo Comparator|Placebo instillation (saline alone)|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of saline alone. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
11120483|NCT03931408|Other|No instillation|Participants will be randomized into one of three groups. In this arm participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
11120484|NCT03931395|Experimental|Honey Plus Standard of Care|The Honey standard of care group will receive treatment as usual, alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic, plus 1 tsp of honey with every dose of acetaminophen. The Honey standard of care group will receive the first dose of honey in the recovery room with the administration of acetaminophen and will be provided with honey upon discharge.
11120485|NCT03931395|Active Comparator|Standard of Care|The standard of care group will receive treatment as usual (alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
11120486|NCT03931382|Experimental|Virtual Reality|In this arm, participants will receive 45 minutes of preparation using a simulated virtual reality experience designed in collaboration with Medical Imaging and Child Life Specialists.
11120487|NCT03931382|Active Comparator|Mock MRI|In this arm, participants will receive 45 minutes of preparation using the standard of care simulator, conducted by a Child Life Specialist
11120490|NCT03931343|Experimental|Thoracolumbar interfascial plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
11120491|NCT03931343|Active Comparator|Erectro spinae plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
11120492|NCT03931330|Experimental|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
11120493|NCT03931317|Other|Latanoprostene bunod 0.024% QD|4 weeks of Latanoprostene bunod 0.024% QD, then a 2 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
11120494|NCT03931317|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 2 Week washout, followed by 4 weeks of Latanoprostene bunod 0.024% QD
11120495|NCT03931304||Cases group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
11120496|NCT03931304||Control group|Cytoreductive surgery alone
11120497|NCT03931291|Experimental|Experimental arm: APR-246 + azacitidine|APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 cycles
11120498|NCT03931278|Other|persons with Multiple Sclerosis (MS)|
11120499|NCT03931278|Other|Healthy controls|
11120500|NCT03931252|Experimental|High fat|Boost VHC (Very High Calorie), Nestle, 8 ounce can
11120501|NCT03931252|Experimental|High protein|Ensure High Protein 8 ounce can
11120502|NCT03931239|Experimental|Vaccination|DTPw-HB-Hib vaccine
11120503|NCT03931226||Departmental cohort|Department level of the Haute-Garonne through the use of the 'POMME' cohort (PrescriptiOns Medicines Mother Children)
11120504|NCT03931226||National cohort|"National level through the use of the EGB database (General Sample of Beneficiaries)"
11120505|NCT03931187|Experimental|Women intervention arm|Intervention will be applied to the women within the couple.
11120506|NCT03931187|Experimental|Couple intervention arm|Intervention will be applied to the couple, both men and women.
11120507|NCT03931187|No Intervention|Control arm|The couple will receive the normal nursing care.
11120508|NCT03931174|Active Comparator|Addiction Technology Transfer Center (ATTC) Training|Half of the opioid treatment centers will receive the ATTC training strategy.
11120509|NCT03931174|Experimental|Enhanced ATTC (E-ATTC) Training Strategy|Half of the opioid treatment centers will receive the E-ATTC training strategy.
11120510|NCT03931161|Placebo Comparator|Placebo|Matching Placebo.
11120511|NCT03931161|Active Comparator|Evolocumab|Evolocumab Auto-Injector [Repatha]
11120512|NCT03931148|Experimental|Intervention|"After first consultation for diagnosis of neurodegenerative disorder :
~Geriatric Assessment with specific neuropsychologic tests of decision making
~fRMI
~EEG High Resolution"
11120513|NCT03931135|Active Comparator|Dexamethasone|
11120514|NCT03931135|Active Comparator|Cyclizine|
11120515|NCT03931122|No Intervention|Group A - Weight Based Method|"Body Weight Based method: This is the conventional method for LMA size selection. The patient will be weighed and LMA size corresponding to their weight will be used as follows.
~(LMA Size - 1 for up to 5 kg of body weight) (LMA Size - 1.5 for 5 to 10 kg of body weight) (LMA Size - 2 for 10 to 20 kg of body weight) (LMA Size - 2.5 for 20 to 30 kg of body weight) (LMA Size - 3 for 30 to 50 kg of body weight)"
11120516|NCT03931122|Experimental|Group B - Ear Size Based Method|"Ear Size Based method: External ear size will be measured by using a paper ruler and will be recorded in cm as follows:
~Vertical length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.
~Horizontal length (width): from the tragus to the furthest part of the helix horizontally.
~Dimension(cm2): Vertical length (L) × Horizontal length (width-W )
~Based on these ear measurements, nearest smaller LMA size will be selected."
11120517|NCT03931109||PHPT w/ Osteoporosis|Primary hyperparathyroidism patients with osteoporosis undergoing parathyroidectomy
11120518|NCT03931109||PHPT w/o Osteoporosis|Primary hyperparathyroidism patients without osteoporosis undergoing parathyroidectomy
11120519|NCT03931109||Thyroid w/ Osteoporosis|Thyroid disease patients with osteoporosis undergoing thyroidectomy
11120520|NCT03931096||children with congenital heart disease|Groupe 1: case: children with congenital heart disease aged 5 to 7 years.
11120521|NCT03931096||control children|Groupe 2: control children recruited in schools aged 5 to 7 years.
11120522|NCT03931083||Portable magnification device (Gynocular™)|The Gynocular™ examination will be performed following the steps involved in colposcopy as described in the IARC colposcopy manual. These steps include: visualization of the vagina, vulva and cervix following insertion of a speculum, magnified assessment after application of normal saline, examination of cervical vessel patterns using the red-free mode (or green filter), application of 5% acetic acid for 1 minute and finally assessment following application with Lugol's iodine. The findings of the live examination will be documented using the parameters of the Swede score. Each parameter is scored between zero and two. Treatment will be based on the results found at histopathology, unless the woman is also VIA positive in which case, after biopsy she will undergo routine treatment as per local guidelines. The results will be used to determine the optimal threshold for treatment in WLHIV.
11120523|NCT03931083||Testing for high risk HPV (HRHPV)|To reduce the number of examinations undergone by the study participant during the same day, HRHPV testing will be carried out at the time of the first gynecological examination by the VIA nurse (see next arm). Using specific single-use cervical cytobrush provided by GeneXpert, a specimen will be collected immediately prior to VIA examination. Cervical cytobrush specimens will be placed into ThinPrep PreservCyt (Cepheid, Sunnyvale, CA) immediately after collection. The HR-HPV testing of cervical specimens will be conducted by a GeneXpert™ machine (Cepheid, Sunnyvale, CA), which will be placed at the health facility and will be operated by a trained nurse in accordance with the manufacturer's instructions. Additionally, as part of the baseline clinical characteristics of the study participant, the study participant will undergo an STI test at the same time. The sample will be collected and tested using the same GeneXpertTM platform.
11120524|NCT03931083||Visual inspection with acetic acid (VIA)|VIA, which is standard of care for cervical cancer screening in Zambia, will be carried out using the methodology described by IARC. This is summarized as follows: visualization of the vagina, vulva and cervix following insertion of a speculum; assessment with the naked eye after application of normal saline; and further assessment after application of 5% acetic acid for 1 minute. This will be recorded as normal or abnormal by the assessor.
11120525|NCT03931083||Histopathological examination of tissue biopsies|All acetowhite lesions will be biopsied. When no lesion is seen, one biopsy is taken from each quadrant at the squamocolumnar junction. Biopsies will be sent and examined in a South African based lab. All histological slides will also be verified independently by an IARC trained pathologist at the end of the study. Histological endpoints are defined by the CIN classification system: CIN 1 affects only the lower third of the epithelium (mild dysplasia), CIN 2 involves two thirds of the epithelium and CIN 3 involves the full thickness (severe dysplasia and carcinoma in situ). These findings can be dichotomized by the Lower Anogenital Squamous Terminology into low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). All patients with CIN grade 2 that stained diffusely positive for p16 are considered as HSIL, all patients with CIN 3 are considered as HSIL. Expression of p16 will be visually assessed by immunohistochemistry.
11120526|NCT03931070|Experimental|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
11120527|NCT03931070|Placebo Comparator|Placebo|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
11120528|NCT03931057|Experimental|ADV6209|ADV6209 (= gamma-cyclodextrin-Midazolam) 0.25 mg/kg p.o. once 30 min. before anesthesia
11120529|NCT03931057|Active Comparator|Midazolam|Midazolam (in orange flavored syrup) 0.25 mg/kg p.o. once 30 min. before anesthesia
11120530|NCT03931044|Experimental|Image-Guided Robotic Gastrectomy|"The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).
~A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.
~The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.
~Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence."
11120531|NCT03931044|No Intervention|Robotic Gastrectomy|Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.
11120532|NCT03931031||Cardiac Surgery Patients|Patients taking antiplatelet medication who are scheduled for elective cardiac surgery.
11120533|NCT03931018|Experimental|70 grams alcohol|"Males and Females: Alcohol 70 grams (220 ml Vodka Absolut®), single dose, oral administration
~- 70 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
11120534|NCT03931018|Experimental|100 grams alcohol|"Males: Alcohol 100 grams (312 ml Vodka Absolut®), single dose, oral administration
~- 100 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
11120535|NCT03931005|Experimental|Decision-Support|An electronic copy of a collaboration decision-support guide.
11120536|NCT03931005|Active Comparator|General Support|An electronic copy of general collaboration supports (a list of collaborative implementation strategies and their definitions)
11120537|NCT03930992|Experimental|1 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
11120538|NCT03930992|Active Comparator|2 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
11120539|NCT03930992|Experimental|3 Arm: Experimental|Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
11120540|NCT03930992|Active Comparator|4 Arm: Active comparator|Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
11120541|NCT03930979||Clearsight measurements|All patients presenting to the ED who have a painful condition for which procedural sedation is required will undergo Clearsight measurements
11120542|NCT03930966|Experimental|PDEQ, PCL-5 and demographic survey|State of the patient evaluated with questionnaires to make the connection between peri-traumatic dissociation and the occurrence of post-traumatic stress disorder
11120543|NCT03930953|Experimental|Administration of CC-99282|Escalating doses of CC-99282 administered orally once daily on intermittent schedules up to 2 years.
11120544|NCT03930953|Experimental|CC-99282 + rituximab|CC-99282 administered orally once daily on intermittent schedule with rituximab intravenously (IV) 375 mg/m2 weekly in Cycle 1, every 28 days in C2-6, then every 8 weeks through 2 years.
11120545|NCT03930940|Experimental|RIC group|RIC treatment and regular treatment.
11120546|NCT03930940|Other|Control group|Regular treatment alone.
11120547|NCT03930927|Experimental|Self Assembling peptide|intervention
11120548|NCT03930927|Experimental|Fluoride|Comparator
11120549|NCT03930914|Other|Active Treatment to Sham|Subjects randomized to the sequence Active Treatment/Sham Treatment arm will be instructed to first use the Parasym (TM) TENS device as active treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as sham treatment for the second phase of the study.
11120550|NCT03930914|Other|Sham to Active Treatment|Subjects randomized to the sequence Sham Treatment/Active Treatment arm will be instructed to use the Parasym (TM) TENS device as sham treatment for the first phase of the study. Next, they will be instructed to use the Parasym (TM) TENS device as active treatment for the second phase of the study.
11120551|NCT03930901|Other|Intervention|Children in this group were examined for intestinal parasites and then treated accordingly. Then, health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), & nail clipper).
11120552|NCT03930901|No Intervention|Control|Children in this group were examined for intestinal parasites and then treated accordingly. They were follow up for 6 months.
11120553|NCT03930888||Patients with nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients nutritionally supported by nutritional supplements.
11120554|NCT03930888||Patients without nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients without special nutritional supplements.
11120555|NCT03930875||Control - No Obstructive Sleep Apnea with Aspirin|"The control group consist of patients with a negative diagnosis of OSA (based on a negative home sleep apnea test (REI) < 5 and attended sleep study, AHI < 5; or attended NPSG with an AHI < 5) and the patient is taking aspirin at a dose of 81 mg/day for at least a week prior to inclusion.
~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
11120556|NCT03930875||Arm 1- Obstructive Sleep Apnea with CPAP therapy and Aspirin|"Arm 1 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old, CPAP has been started within the last 2 years, and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.
~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
11120557|NCT03930875||Arm 2 -Obstructive Sleep Apnea with no CPAP & Aspirin|"Arm 2 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.
~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
11120558|NCT03930862|Active Comparator|ball and socket|It is an attachment retaining implant overdentures to increase retention and stability of the denture
11120559|NCT03930862|Experimental|Locator attachment|attachment retaining implant overdentures
11120560|NCT03930849|Experimental|AIMS Intervention|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol.
11120561|NCT03930849|No Intervention|No Intervention|Participants randomized to the no intervention arm will not be enrolled in the Annie text messaging program.
11120562|NCT03930849|Experimental|AIMS Intervention Plus|Participants randomized to the AIMS Intervention Plus arm will be enrolled in VA's Annie text messaging program/study protocol and receive a weekly phone call.
11120563|NCT03930836|Active Comparator|control group|high/low dosage intervention, intensive or not (motor function rehabilitation)
11120564|NCT03930836|Experimental|interface group|high/low dosage intensive intervention using the interactive interface (motor function rehabilitation)
11120565|NCT03930823|Other|Interview|One to one interviews with older people from Turkish origin in Belgium
11120566|NCT03930810||FIC1-deficiency and Bsep-deficiency|
11120567|NCT03930797|Experimental|Intimacy Enhancement|Participants attend four sessions (60-75 minutes) consisting of education and skills training to enhance physical and emotional intimacy.
11120568|NCT03930797|Active Comparator|Living Healthy Together|Participants attend four sessions (60-75 minutes) consisting of information and support across a range of breast cancer-related topics.
11120569|NCT03930784||Participants|Divided for analysis as having suffered post-operative complications or not
11120570|NCT03930771|Experimental|All Patients|"All subjects will receive:
~Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
~Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14.
~After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity)."
11120571|NCT03930758|Experimental|Uphill exercise before the meals|40 minutes of uphill treadmill exercise at +6o slope completed 1 hour before eating the meal
11120572|NCT03930758|Experimental|Uphill exercise after the meals|40 minutes of uphill treadmill exercise at +6o slope started 1 hour after eating the meal
11120573|NCT03930758|Experimental|Downhill exercise before the meals|40 minutes of downhill treadmill exercise at -6o slope completed 1 hour before eating the meal
11120574|NCT03930758|Experimental|Downhill exercise after the meals|40 minutes of downhill treadmill exercise at -6o slope started 1 hour after eating the meal
11120575|NCT03930758|Sham Comparator|Sedentary trial|A trial with no exercise
11120576|NCT03930745|Experimental|Arm 1|TOL-463 insert administered vaginally twice a week for twelve weeks. N=125
11120577|NCT03930745|Placebo Comparator|Arm 2|Matching placebo insert administered vaginally twice a week for twelve weeks. N=125
11120578|NCT03930732|Experimental|Dupilumab|Dupilumab administered every 2 weeks
11120579|NCT03930732|Placebo Comparator|Placebo|Placebo dose administered every 2 weeks
11120580|NCT03930719||PSD|Patients fulfilling DSM-5 criteria of PSD within 7 days of admission.
11120581|NCT03930719||No PSD|Patients NOT fulfilling DSM-5 criteria of PSD within 7 days of admission.
11120582|NCT03930706|Experimental|Group A|Group A will include all the patient that will start with progesterone ((P), Utrogestan®) supplementation after 7 days of E2 (Progynova®) intake and that will perform the FET (after 13 days of E2 and 6 days of P).
11120583|NCT03930706|Active Comparator|Group B|Group B will include the patients that will perform 14 days of E2 intake (Progynova®, 6 mg per day (2 mg every 8 hours) those patients will be asked to perform a supplementary blood test and ultrasound on day 14 of E2 intake, afterwards, they will start with P supplementation (Utrogestan®, 800 mg per day, 400 mg every 12 hours) from day 15 of E2 for 6 days and they will get their FET day 20 of the cycle (after 14 days of E2 and 6 days of P)
11120584|NCT03930693|Experimental|Normotensive pregnant women|Normotensive pregnant women
11120585|NCT03930693|Experimental|Hypertensive pregnant women|Hypertensive pregnant women
11120586|NCT03930693|Experimental|Normotensive non-pregnant women|Normotensive non-pregnant women
11120587|NCT03930693|Experimental|Hypertensive non-pregnant women|Hypertensive non-pregnant women
11120588|NCT03930680|Experimental|100mg/m2|one dose of 100mg/m2 dexrazoxane
11120589|NCT03930680|Experimental|200mg/m2|one dose of 200mg/m2 dexrazoxane
11120590|NCT03930680|Experimental|300 mg/m2|one dose of 300mg/m2 dexrazoxane
11120591|NCT03930680|Experimental|400 mg/m2|one dose of 400mg/m2 dexrazoxane
11120595|NCT03930654|Experimental|iPrEP Intervention|"iPrEP Intervention:
~Women will receive the iPrEP intervention on an iPAD Air tablet device
~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument
~iPrEP uses qualitative themes
~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence
~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument
~Scales were modified (in some cases) for cultural competency and tailoring to women"
11120596|NCT03930654|Active Comparator|Usual Care|"Control Intervention:
~Women will receive usual care
~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use
~Social worker will offer a list of substance abuse treatment referral agencies"
11120597|NCT03930641|Experimental|RTH258|brolucizumab 6 mg in a prefilled syringe
11120598|NCT03930615|Experimental|Letermovir|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.
11120599|NCT03930615|Placebo Comparator|Placebo|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.
11120600|NCT03930602|Experimental|BMS-986165+Fluvoxamine|
11120601|NCT03930602|Experimental|BMS-986165 only|
11120602|NCT03930602|Experimental|Fluvoxamine only|
11120603|NCT03930589|Placebo Comparator|Standard of care|no intervention will occur in the standard of care arm
11120604|NCT03930589|Active Comparator|Remote Ischemic Conditioning|Remote ischemic conditioning using BP cuff on left arm
11120605|NCT03930576||Early Legal Terminations|Participants who receive a legal termination at <10 weeks gestation at a recruiting facility.
11120606|NCT03930576||Late Legal Terminations|Participants who receive a legal termination at 10+ weeks gestation at a recruiting facility.
11120607|NCT03930576||Turn-aways: Termination outside Legal Setting|Participants who receive a termination at another facility or outside the formal healthcare sector.
11120608|NCT03930576||Turn-aways: Birth|Participants who ultimately carry the pregnancy to term
11120609|NCT03930563|Experimental|Beetroot Juice Low|Subjects will consume beetroot juice containing 250mg inorganic nitrate and 20mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
11120610|NCT03930563|Experimental|Beetroot Juice High|Subjects will consume beetroot juice containing 500mg inorganic nitrate and 40mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
11120611|NCT03930563|Active Comparator|Beetroot Juice Placebo|Subjects will consume beetroot juice devoid of inorganic nitrate and nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
11120612|NCT03930550|Experimental|Infrared guidance first|"In this arm the infra red guidance is applied to the first passage of the flexible scope to the trachea.
~The second passage of the flexible scope is without the infrared light"
11120613|NCT03930550|Active Comparator|Infrared guidance last|"In this arm NO infra red guidance is applied to the first passage of the flexible scope to the trachea.
~The second passage of the flexible scope is with the infrared light as guide"
11120614|NCT03930537|Active Comparator|Hip replacement with cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of cemented femoral component of hip prothesis.
11120615|NCT03930537|Active Comparator|Hip replacement with non-cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of non-cemented femoral component of hip prothesis.
11120616|NCT03930524|No Intervention|Assessment Only|Control
11120617|NCT03930524|Experimental|Early-college Universal|Prior to beginning their first semester of college, incoming students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
11120618|NCT03930524|Experimental|Early-college No Coach (automated email)|Students from the early-college universal arm, who flag on one of the self monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
11120619|NCT03930524|Experimental|Early-college Coach|Students from the early-college universal arm, who flag on one of the self monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
11120620|NCT03930524|Experimental|Later-college Universal|After beginning their first semester of college, students will receive personalized normative feedback (PNF) comparing their experiences to other college students their age, as well as up to 4 self-monitoring surveys over the course of the semester.
11120621|NCT03930524|Experimental|Later-college No Coach (automated email)|Students from the later-college universal arm, who flag on one of the self monitoring surveys are invited to engage in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
11120622|NCT03930524|Experimental|Later-college Coach|Students from the later-college universal arm, who flag on one of the self monitoring surveys are invited to correspond with an online health coach who will use motivational interviewing strategies to encourage engagement in a web-based resource or in-person consultation to improve well-being, with a particular emphasis on alcohol use.
11120623|NCT03930511|No Intervention|PADL at the beginning of PR|First assessment of patients starting Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
11120679|NCT03930095|Experimental|Acceptance-Based Behavior Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
11120680|NCT03930095|Active Comparator|Non-directive Supportive Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
11120624|NCT03930511|Experimental|PADL at discharge of PR|Assessment of patients at discharge of Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
11120625|NCT03930511|No Intervention|PADL at 6 months follow-up|Half-a-year reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
11120626|NCT03930511|No Intervention|PADL at 1 year follow-up|Yearly reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
11120627|NCT03930498|Experimental|PD-1 antibody plus chemoradiotherapy|
11120628|NCT03930472|Experimental|Voucher intervention F&V|Receiving $20 in vouchers at each of up to 4 markets ($80 total) that are good for F&V only
11120629|NCT03930472|Experimental|Voucher intervention SNAP|Receiving $20 vouchers at each of up to 4 markets that are good for any foods that SNAP/EBT benefits can be used for
11120630|NCT03930472|No Intervention|Waitlist control|Delayed intervention/waitlist control (who, at the final data gathering, will receive 5 x $20 in vouchers good at the WFfT 2019 and 2020 markets).
11120631|NCT03930459|Experimental|Static cold storage (SCS)|Traditional method of organ preservation which involves flushing of cold preservation solution following complete dissection and interruption of blood supply to the donor organ. Although cold preservation slows metabolism by 10- to 12-fold, substantial anaerobic activity continues even at ice temperature. This lead to the generation of reactive oxygen species that are the basis of ischaemia-reperfusion injury, when the organ is re-exposed to oxygenated blood at the time of transplantation. This damage, exacerbated by any prior injury, limits the maximum safe preservation time of the donor organ.
11120632|NCT03930459|Experimental|Normothermic machine perfusion (NMP)|The main goal of NMP is to optimize graft preservation by mimicking physiological conditions. The perfused organ is supplied with nutrients and oxygen to maintain metabolic hemostasis. Under these conditions, ATP and glycogen reserves can be maintained or actively restored. At the same time, toxic products from the cellular milieu are continuously eliminated, so the cell-mediated injury phase of reperfusion injury can be minimized. Thus, ischemic injury is avoided and the activation of cell death cascades is prevented. This allows both hepatocellular and biliary protection.
11120633|NCT03930446|Experimental|Ethanol|Subjects will receive 4 color-coded beverages in green or blue cups, containing ethanol (0.2 g/kg per dose, total dose 0.8 g/kg).
11120634|NCT03930446|Placebo Comparator|Placebo (Juice)|Subjects will receive 4 color-coded beverages in green or blue cups, containing placebo (Juice).
11120635|NCT03930433|Active Comparator|Nebivolol group|Oral Nebivolol 5mg / day (2 weeks) -> 10mg / day (10 weeks)
11120636|NCT03930433|Placebo Comparator|Diltiazem group|Oral Diltiazem 90mg / day (2 weeks) -> 180mg / day (10 weeks)
11120637|NCT03930433|Placebo Comparator|Nebivolol+Diltiazem group|Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
11120638|NCT03930420|Active Comparator|Standard|Local health department staff in the standard arm will receive Connect to Wellness intervention materials, multiple real-time training sessions delivered via webinar, access to a web-based platform that includes all intervention and training materials and has features allowing them to communicate with each other and with research staff, and a monthly group technical assistance call.
11120639|NCT03930420|Experimental|Enhanced|Local health department staff in the enhanced arm will receive all the Connect to Wellness intervention materials, training, and support as described for the standard arm. In addition, the participants in the enhanced arm can telephone research staff at will to receive additional technical assistance. Research staff will also contact participants monthly, if they do not request assistance proactively.
11120640|NCT03930407||Hayman group|Who had undergone cesarean section within the last 6 months and received a The Hayman uterine compression suture for uterine atony.
11120641|NCT03930407||Control|Who had undergone cesarean section within the last 6 months and did not experience neither any complication nor any additional intervention
11120642|NCT03930381|Experimental|Intervention Arm|This group will download the ASTHMAXcel application and use it for the duration of the study
11120643|NCT03930381|No Intervention|Usual Care Arm|This group will just receive normal provider care
11120644|NCT03930368|Experimental|Intervened arm|as in a single-arm before-and after study, the only one arm will receive intervention of low GI diet with supplementation of RCS.
11120645|NCT03930355||Transfused|Patients who received blood transfusion in the perioperative period
11120646|NCT03930355||Non transfused|Patients who did not receive blood transfusion in the perioperative period
11120647|NCT03930342|Experimental|Native CHOICES Intervention|Native-CHOICES will comprise usual care plus 2 MI sessions delivered over 4 weeks; a contraception counseling session at a local clinic; and 3 months of electronic messaging to boost the effects of MI and counseling by increasing perceptions of social connection and social support for behavior change. Contraception counseling will be completed within 2 weeks after the second MI session, so the maximum duration of MI and counseling for each participant will be 6 weeks. Electronic messaging will include positive motivational content consistent with alcohol and contraception use goals set in the MI sessions.
11120648|NCT03930342|No Intervention|Wait-list Control Group|The control condition will comprise usual care for the 6-month study period, with a wait-list design that offers women the Native- CHOICES program after they have completed the 6-month data collection.
11120649|NCT03930329|Experimental|MBRP group|The mindfulness-based relapse prevention program consists of eight weekly 2-hour sessions. It combines mindfulness with evidence-based cognitive behavioural techniques that help participants to recognize internal and external triggers of their substance abuse, including smoking. Each session consists of mindful practices with cognitive exercises. The standardized treatment manual was published
11120820|NCT03929003|Experimental|Contingent|Participants in this arm will be required to meet CO goals in order to earn game-based rewards.
11120650|NCT03930329|No Intervention|usual care|All participants in this trial will receive usual care, which consists of 8-12 weeks of counselling and drug treatment to help smokers quit. Data from the centre shows that approximately 50% of smokers are successfully abstinent from smoking at end of the program, as confirmed by the carbon monoxide breath test. This trial will only recruit those who successfully quitted smoking. During this 8-12 week program, written information about relapse prevention is given, including information for maintaining healthy lifestyles (e.g. diet/sleep/exercise/emotional control). Participants will receive follow-up phone interviews by trained smoking cessation counsellors at end of the program (week 8-12)
11120651|NCT03930303|Active Comparator|Multimedia Arm|
11120652|NCT03930303|No Intervention|Control|
11120653|NCT03930290||Pregnant patients|Pregnant patients in their 2nd trimester.
11120654|NCT03930277||Pregnant women in labor.|Pregnant women in labor during the 2nd stage of labor.
11120655|NCT03930264|Active Comparator|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
11120656|NCT03930264|Experimental|Jayempi™|"Generic name : Azathioprine
~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
11120657|NCT03930251|No Intervention|Treatment as Usual|This is the standard coordinated specialty care treatment (without cognitive remediation) that is provided to OnTrackNY clients. This treatment involves psychiatric treatment, employment and educational support, substance abuse treatment, family education and support, CBT-informed individual psychotherapy, and cognitive health support services as needed.
11120658|NCT03930251|Experimental|Clinic-Based Cognitive Remediation|Clinic-based cognitive remediation consists of twice weekly group-based and clinician-led sessions.
11120659|NCT03930251|Experimental|Partial-Remote Cognitive Remediation|Partial-Remote cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
11120660|NCT03930238|Experimental|VA MapTrek|Veterans in the intervention group receive a Fitbit and access to VA MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required to enroll). Each week, Veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. Throughout each race, participants will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
11120661|NCT03930238|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to VA MapTrek or simply by giving the Veterans a Fitbit.
11120662|NCT03930225|Experimental|study group|"In the study group, both patients and their family members will be required to attend a weekly 1 hour long psycho-educational sessions. Moreover assessment sessions will be attended also.
~The stigma directed intervention program"
11120663|NCT03930225|Other|control group|"In the control group, only Patients will attend the psycho-educational sessions.
~Family members and patients will be required to attend the assessment sessions."
11120664|NCT03930212|Experimental|Progesterone|received rectal progesterone suppositories 400 mg once daily
11120665|NCT03930212|Placebo Comparator|Control group|received placebo suppositories rectally once daily.
11120666|NCT03930199|Experimental|Not Meeting Mobility Goals|After the first three months of sensor monitoring, participants not meeting goals will receive an intervention (others will be removed from the study). The intervention assigned is not pre-determined, but will be assigned by an expert panel based on the individual needs determined from the assessment results and monitoring data. The intervention may include prosthetic care, physical therapy, motivational interviewing or other related psychological interventions, or a combination thereof. After three months of intervention, assessments are performed again and if improvement in prosthesis use is determined, participants are monitored for another three months to assess maintenance of prosthesis use (participants showing no improvement are removed from the study before these final three months of monitoring).
11120667|NCT03930186|Experimental|Administration of Apremilast|Apremilast tablets will be taken orally twice daily (BID), approximately 12 hours apart, through the last treatment visit.
11120668|NCT03930173|Experimental|18F-fluciclovine PET/CT of the brain|"Arm includes participants with a known diagnosis of brain metastases who have undergone prior intracranial SRS and whose MRI brain scan is equivocal for radiation necrosis versus tumor progression.
~Participants will undergo 18F-fluciclovine PET/CT of the brain. Qualitative and quantitative metrics will be documented at the time of image acquisition. Qualitative image assessment will be performed independently by 3 separate physicians."
11120669|NCT03930160||Mortality outcome|
11120670|NCT03930147|Experimental|Passive phase, Pressure-Control Ventilation / ASV order|90 minutes of Pressure-Control Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Control Ventilation mode at the end of the intervention.
11120671|NCT03930147|Experimental|Passive phase, ASV / Pressure-Control Ventilation order|90 minutes of ASV, change to Pressure-Control Ventilation mode with 15 to 30 minutes of washout, 90 minutes of Pressure-Control Ventilation.
11120672|NCT03930147|Experimental|Active phase, Pressure-Support / ASV order|90 minutes of Pressure-Support Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Support Ventilation at the end of the intervention.
11120673|NCT03930147|Experimental|Active phase, ASV / Pressure-Support order|90 minutes of ASV, change to Pressure-Support Ventilation with 15 to 30 minutes of washout, 90 minutes of Pressure-Support Ventilation.
11120674|NCT03930134|Experimental|sparse uterine suture|women who had a french ambulatory casarean section including a sparse uterine closure
11120675|NCT03930134|Active Comparator|one layer uterine closure|women who had a misgav ladach caesarean section section, including a one layer classical uterine closure
11120676|NCT03930121|Experimental|Experimental group|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)
11120681|NCT03930069|Active Comparator|misoprostol group|20 cases received 400 microgram prostaglandin E1 analogue, misoprostol, (Misotac®, 200 microgram, by SIGMA pharmaceutical industries, Alexandria, Egypt), intra-vaginally, 2 hr before operation.
11120682|NCT03930069|Active Comparator|vasopressin group|20 patients who had hysteroscopic guided intralesional vasopressin injection before hysteroscopic myomectomy
11120683|NCT03930056|Experimental|C-Brace II Group|Subjects will be assigned a C-Brace II orthotic for use.
11120684|NCT03930056|Active Comparator|Traditional Group|Subjects will continue with their own KAFO (non C-Brace II) use.
11120685|NCT03930043||Health Control|
11120686|NCT03930043||Non-gastrointestinal Lymphoma|
11120687|NCT03930043||Gastric Lymphoma|
11120688|NCT03930043||Intestinal Lymphoma|
11120689|NCT03930004||Type 1 diabetic patients|"Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease.
~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
11120690|NCT03930004||Control - Healthy subjects|"Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease.
~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
11120691|NCT03929991||Case|"All women admitted or already hospitalized with suspected or confirmed infection after C/S will be screened for inclusion in the study as a case. Case confirmation will be clinically established by an infectious disease expert.SSI post C/S will be classified as:
~Superficial incisional surgical site infection,
~Deep incisional surgical site infection,
~Organ/space surgical site infection."
11120692|NCT03929991||Control|For each case, 3 patients undergoing the C/S on the same day and admitted to the same ward but not presenting Surgical Site Infection
11120693|NCT03929965|Experimental|advanced solid tumors with FGFR alteration|
11120694|NCT03929952|Experimental|Chronic low back pain|
11120695|NCT03929939|Experimental|Lifestyle Modification Group|
11120696|NCT03929939|No Intervention|Control Group|
11120697|NCT03929926|Active Comparator|Group 1 (usual care)|receive usual care
11120698|NCT03929926|Experimental|Group II (outreach contact)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Eligible and interested patients receive an office visit at the JLCSP for shared decision-making and possible lung cancer screening.
11120699|NCT03929926|Experimental|Group III (outreach + Decision Counseling Program)|Patients receive educational materials in the mail about lung cancer screening with a cover letter from their physician. A week later, they receive a phone call from the study staff to assess their eligibility. Patients then undergo a decision counseling session through a semi-structured Decision Counseling Program that includes a review of the mailed educational materials and completion of an interactive exercise intended to clarify personal preference related to screening options (to have LDCT or not to have LDCT). Patients interested in screening schedule an office visit at JLCSP for possible screening or are referred to their primary care physician for consultation.
11120700|NCT03929913|Experimental|Study Arm #1|The Transcatheter Mitral Cerclage Annuloplasty implant is attached to a guidewire and pulled through the internal jugular sheath, along the coronary sinus, through the basal septum, through the tricuspid valve, and back out of the internal jugular sheath. The position of the TMCA implant is adjusted so that the coronary protection element lies directly over any underlying branch of the left coronary artery.
11120701|NCT03929887||KORNERSTONE|"Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)
~Participants enrolled in KORNERSTONE with a biopsy proven GN.
~Eligible participants must be scheduled for a clinically indicated renal biopsy."
11120702|NCT03929874||18 ≤ age ≤ 40|18 ≤ age ≤ 40
11120703|NCT03929874||age ≥ 60|age ≥ 60
11120704|NCT03929861|Experimental|Fluconazole, period 1|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
11120705|NCT03929861|Experimental|Fluconazole, period 2|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours
11120706|NCT03929848||female|female patient who is scheduled for laryngomicrosurgery
11120707|NCT03929848||male|male patient who is scheduled for laryngomicrosurgery
11120708|NCT03929835|Experimental|Avidekel Oil|The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
11120709|NCT03929835|Placebo Comparator|Placebo|Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.
11120710|NCT03929822|Experimental|Contrast-Enhanced Spectral Mammography (CESM)|Women called back from an abnormal screening mammogram/tomosynthesis exam will be offered CESM as part of their diagnostic work up. The radiologist will interpret the low energy images and record their findings.
11120711|NCT03929809||Adult Single-sided deafness|Adult subjects with unilateral single-sided deafness at least 6 months (to ensure stability of hearing loss), but no greater than 10 years will be implanted with a MED-EL Synchrony Cochlear Implant.
11120712|NCT03929783|Experimental|Diagnostic (CEM)|Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
11120713|NCT03929770|Active Comparator|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
11120714|NCT03929770|Experimental|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
11120715|NCT03929757|Experimental|Arm 1: Ad26.ZEBOV, MVA-BN-Filo|Participants will be administered 0.5 mL of Ad26.ZEBOV vaccine (5*10^10 viral particles [vp]) on Day 1 by intramuscular (IM) injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 infectious units [Inf U]) vaccine by IM injection on Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
11120716|NCT03929757|Active Comparator|Arm 2: MenACWY|Participants will be administered 0.5 mL of MenACWY vaccine by IM injection on Day 1 and Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
11120717|NCT03929744|Experimental|LY3502970 (Part A)|Single dose of LY3502970 administered orally.
11120718|NCT03929744|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally.
11120719|NCT03929744|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
11120720|NCT03929744|Placebo Comparator|Placebo (Part B)|Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
11120721|NCT03929744|Experimental|LY3502970 (Part C)|Single dose of LY3502970 administered orally in each of two study periods.
11120722|NCT03929744|Experimental|LY3502970 (Part D)|Single dose of LY3502970 administered orally.
11120723|NCT03929744|Placebo Comparator|Placebo (Part D)|Single dose of placebo administered orally.
11120724|NCT03929744|Experimental|LY3502970 Formulation 1 (Part E)|Multiple doses of LY3502970 - formulation 1 administered orally.
11120725|NCT03929744|Experimental|LY3502970 Formulation 2 (Part E)|Multiple doses of LY3502970 - formulation 2 administered orally.
11120726|NCT03929731||Polypoidal Choroidal Vasculopathy RCT|Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T&E studies
11120727|NCT03929718|Active Comparator|Standard Therapy|subjects undergoing CTI ablation
11120728|NCT03929718|Experimental|Interventional Therapy|subjects treated with an aldosterone antagonist after CTI ablation
11120729|NCT03929705||Test Arm 1- T-SPOT.TB assay|T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
11120730|NCT03929705||Test Arm 2 -QuantiFERON-TB Gold Plus assay|QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
11120731|NCT03929692|Other|Intervention Group|Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
11120732|NCT03929692|Other|Control Group|Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
11120733|NCT03929679||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
11120734|NCT03929666|Experimental|ZW25 + FP|ZW25 plus fluorouracil (5-FU) and cisplatin
11120735|NCT03929666|Experimental|ZW25 + mFOLFOX6|ZW25 plus 5-FU, leucovorin, and oxaliplatin
11120736|NCT03929666|Experimental|ZW25 + XELOX|ZW25 plus capecitabine and oxaliplatin
11120737|NCT03929653||Advanced Refractory Solid Tumors|Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).
11120738|NCT03929640|Placebo Comparator|Ibuprofen and placebo|Oral administration of ibuprofen 600 mg tablet and placebo tablet every 6 hours
11120739|NCT03929640|Active Comparator|Ibuprofen and acetaminophen|Oral administration of ibuprofen 600 mg tablet and acetaminophen 650 mg tablet every 6 hours
11120740|NCT03929627||Group 1 - Medical personnell|Group 1 consists of 70 participants belonging to medical staff of the Medical University of Vienna/University Hospital of Vienna and is divided into subgroups consisting of medical technical assistants, nurses, assistant physicians and physicians.
11120741|NCT03929627||Group 2 - Control|Group 2 consists of 70 participants and is recruited from the General non-medical staff of the Austrian Federal Ministry of Defence and Sports, Austrian Armed Forces.
11120742|NCT03929601|Experimental|Rituximab followed by Abatacept|"Rituximab will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 1 of the study.
~Abatacept will be given by a subcutaneous formulation weekly for 2 years, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL)."
11120743|NCT03929588|Experimental|Refraction with a Hand-held Device Supported by Mobile App.|BCVA with handheld device with app.
11120744|NCT03929588|Active Comparator|Manual Refraction|BCVA with phoropter
11120745|NCT03929588|Active Comparator|Automated Refraction|BCVA with autorefractoer
11120746|NCT03929575|Placebo Comparator|Placebo of calcium|Participants will consume 250 mg of calcium
11120747|NCT03929575|Experimental|Rhodiola|Participants will consume 250 mg of Rhodiola
11120748|NCT03929575|Experimental|Rhodiola and Cordyceps|Participants will consume a combination of 250 mg of Rhodiola and 225 mg of Cordyceps
11120749|NCT03929562|Active Comparator|Brief advice|One brief advice session, resource brochure, standard of care, and an infographic about alcohol and surgical health at patient's pre-existing pre-operative clinical visit.
11120750|NCT03929562|Experimental|Health coaching|Two health coaching sessions, resource brochure, standard of care
11120751|NCT03929549|Experimental|RCMP titration|Remotely Controlled Mandibular Positioner
11120752|NCT03929523|Experimental|HOPE group|hypothermic oxygenated perfusion
11120753|NCT03929523|Active Comparator|Control group|classic static cold storage
11120754|NCT03929510|Experimental|Period A|Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
11120821|NCT03929003|Active Comparator|Non-contingent|Participants in this arm will submit CO verifications but will earn game-based rewards independent of meeting CO goals.
11120822|NCT03928990|Experimental|Experimental arm|
11120755|NCT03929510|Experimental|Period B|Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
11120756|NCT03929497|Experimental|Lu AF11167|
11120757|NCT03929484|Experimental|Group A|Each patient will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula alone (Period 2).
11120758|NCT03929484|Experimental|Group B|Each patient will receive oxygen for 1 hour using a standard nasal cannula alone (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).
11120759|NCT03929471|Experimental|Intervention group|Patients to be subjected to a fluid overload correction protocol.
11120760|NCT03929471|No Intervention|Control group|Patient will be followed but no fluid overload correction protocol will be applied.
11120761|NCT03929445|Active Comparator|AIR-Q group|the group which selected randomly to try AIR-Q device
11120762|NCT03929445|Active Comparator|I-LMA group|the group which selected randomly to try I-LMA device
11120763|NCT03929432|Active Comparator|Active tDCS (with Speech-Language Treatment)|tDCS Stimulation Dose: 1.5 mA for 20-mins
11120764|NCT03929432|Sham Comparator|Sham tDCS (with Speech-Language Treatment)|No tDCS stimulation
11120765|NCT03929419|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
11120766|NCT03929419|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
11120767|NCT03929406|Experimental|Brain Tissue Imprint|Evaluation and validation of the samples collected during the brain tissue imprint procedure using a CE marked Medical Device in patients presenting one of the following five disorders: Parkinson's disease (PD), essential tremor (ET), dystonia (DYS), Obsessive compulsive disorder (OCD) and Tourette Syndrome (TS).
11120768|NCT03929393|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
11120769|NCT03929393|Active Comparator|Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
11120770|NCT03929380|Experimental|10x10 squat protocol|
11120771|NCT03929380|Experimental|As Fast As Possible 100 squat protocol|
11120772|NCT03929367|Other|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
11120773|NCT03929354|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend the 12-week intensive lifestyle programme which includes healthy lifestyle change such as smoking cessation, healthy food choices and increasing physical activity levels, as well as management of cholesterol, diabetes, and blood pressure.
~The 12-week programme will consist of 12 sessions of 2.5 hours each per week.
~Each of the weekly sessions will incorporate an individualised meeting between the multidisciplinary healthcare team and each patient to review the progress and health goals.
~The weekly sessions will also include a one-hour group exercise programme and an educational workshop."
11120774|NCT03929354|Active Comparator|Standard Care|Standard care is defined as giving information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
11120775|NCT03929341|Experimental|CCTA first approach with Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
11120776|NCT03929341|Experimental|CCTA first approach without Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
11120777|NCT03929341|Active Comparator|Usual Care with Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
11120778|NCT03929341|Active Comparator|Usual Care without Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
11120779|NCT03929328|No Intervention|Spontaneous breathing trial with T-piece|Patients were randomized to undergo a spontaneous breathing trial with T-piece that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
11120780|NCT03929328|Experimental|Spontaneous breathing trial with high flow oxygen therapy|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
11120781|NCT03929315||Non-spaced learning|Learning/testing sessions will take place within 30 minutes of one another
11120782|NCT03929315||Spaced learning|Learning/testing sessions will take place 1 week after one another
11120783|NCT03929302|No Intervention|Brain Energy Metabolism and Sleep on cognition|In the phase-1 of the study, the investigator will be investigating the basic science of the relationship of sleep abnormalities, genes, brain energy metabolites variables with cognitive performance in three cohorts: cognitively normal adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
11120784|NCT03929302|Experimental|Dental Intervention to improve sleep and cognition|To investigate if MyTAP oral airway management with mouth shield will improve sleep and cognition in three cohorts: cognitively healthy adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
11120785|NCT03929289|Experimental|Social Facilitation|Cognitive tasks during functional Magnetic Resonance Imaging (fMRI) observed or not by a subject's known peer.
11120786|NCT03929276|Experimental|high-intensity laser therapy & exercises|High-intensity laser therapy application with iLux Laser device + exercise program
11120787|NCT03929276|Placebo Comparator|Shame laser & exercises|Sham high-intensity laser therapy application with iLux Laser device + exercise program
11120788|NCT03929276|Active Comparator|control - exercises only group|exercise program
11120789|NCT03929263|Experimental|Real-time fMRI neurofeedback|All participants will receive neurofeedback from the target region (no sham condition).
11120790|NCT03929250|Experimental|2g CAW Dose|2g of Centella asiatica water extract in a standardized product.
11120791|NCT03929250|Experimental|4g CAW Dose|4g of Centella asiatica water extract in a standardized product.
11120823|NCT03928977|Other|Confirmed TIA|Confirmed TIA at 3 months with standardized neurological expertise
11120792|NCT03929224|Active Comparator|Bacitracin|Standard care: BAHA abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
11120793|NCT03929224|Experimental|Medicinal honey and bacitracin|Standard care + MediHoney: Medi-Honey will be applied to the abutment site immediately after surgery in addition to the bacitracin. The healing cap will be placed on the BAHA site. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment and MediHoney daily to the area for 2 weeks.
11120794|NCT03929211|Experimental|CPI-613 and hydroxychloroquine|The initial phase of the study will be a dose escalation of hydroxychloroquine from 600 mg to 1,200 mg orally flat dose given 2 hours before the CPI-613 infusion on days 1-5 of every 28 days. CPI-dose will be 2,000 mg/m² and will not be escalated.
11120795|NCT03929198|Experimental|Intervention|The intervention group participated in a 6-week Pritikin diet, exercise program, and behavioral modification.
11120796|NCT03929198|No Intervention|Control|This group did not receive any intervention.
11120797|NCT03929185||Tumor affected|Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
11120798|NCT03929185||Control|Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
11120799|NCT03929172|Experimental|AAVLP-HPV Vaccine Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
11120800|NCT03929172|Placebo Comparator|Placebo Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
11120801|NCT03929159||Group A (biospecimen collection)|Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
11120802|NCT03929159||Group B (biospecimen collection)|Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
11120803|NCT03929146|Experimental|Liposomal Bupivacaine|Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
11120804|NCT03929146|Other|Interscalene Nerve Block|Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
11120805|NCT03929120|Experimental|Interstitial Lung Disease with Connective Tissue Disorder|Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
11120806|NCT03929107|Experimental|Intervention group|In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.
11120807|NCT03929094|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
11120808|NCT03929081|Experimental|Inference Based Approach (IBA)|The IBA treatment, a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly. The IBA model is based on the assumption that patients with OCD feel the need to perform compulsive acts because they misjudge the actual state of affairs, for example fearing that an appliance is on when it is visibly off. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the patient's attention from observable reality. IBA teaches patients how to defend themselves against the absorbing and confusing effect of obsessive reasoning processes and how to stay in touch with reality by actively relying on the sensory information of the very moment. As a consequence, the patient realizes that any compulsive act is superfluous and feels able to omit it.
11120809|NCT03929081|Active Comparator|Cognitive Behavior Therapy (CBT)|In the control condition, the patients will receive twenty 45-minutes sessions of CBT consisting of self-guided exposure in vivo with response prevention (ERP) and cognitive therapy (CT), both standardized according to evidence-based session-by-session protocols, containing standardized forms for exercises and homework assignments.
11120810|NCT03929081|No Intervention|No intervention (healthy controls)|The healthy control group will receive no intervention.
11120811|NCT03929068|Active Comparator|carbidopa-levodopa|Each tablet of carbidopa-levodopa in this study will be equivalent to half of a standard carbidopa-levodopa 25/100mg tablet. Participants will take one tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
11120812|NCT03929068|Placebo Comparator|Placebo|Participants will take one placebo tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
11120813|NCT03929055|Active Comparator|venturi mask|oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92%
11120814|NCT03929055|Active Comparator|HFNC|HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min
11120815|NCT03929055|Active Comparator|CPAP|Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step
11120816|NCT03929042|Experimental|Posture Correction Girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
11120817|NCT03929029|Experimental|Nivolumab+Ipilimumab+NeoVax plus Montanide|"Run in period will begin within 2 weeks of metastatic tissue biopsy, once the following criteria
~Patients will receive Nivolumab at a flat dose I.V. infusion every 4 weeks (28 days)
~Patients will receive Ipilimumab injection on weeks 12, 15, 18, and 21
~Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21"
11120818|NCT03929016|Experimental|Active DNDI-0690|Single dose starting from 10 mg for the first cohort. Dose for following cohorts to be decided by the Safety Review Committee
11120819|NCT03929016|Placebo Comparator|Placebo|Single dose placebo
11121530|NCT03923972||Nephrology nurses|nurses caring for patients with chronic kidney disease
11120824|NCT03928977|Other|Confirmed non-TIA|Not-confirmed TIA at 3 months with standardized neurological expertise
11120825|NCT03928951||Patients suffering from urinary infection|Patients consulting in one of Toulon - La Seyne sur Mer hospital emergency departments because of urinary infection
11120826|NCT03928938|Experimental|Electronic follow-up|Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
11120827|NCT03928925|Active Comparator|BOUGIE|"For patients randomized to use of a bougie, the operator will use a bougie on the first attempt at intubation. If successful, an assistant will load an endotracheal tube over the bougie, and the operator (without removing the laryngoscope from the mouth) will guide the tube through the vocal cords to the desired depth in the trachea.
~If the bougie is not successfully placed in the trachea or the endotracheal tube cannot be successfully advanced over the bougie on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
11120828|NCT03928925|Active Comparator|Endotracheal Tube with Stylet|"For patients randomized to use of an endotracheal tube with stylet, the operator will use an endotracheal tube containing a removeable, malleable stylet, on the first attempt at intubation.
~Manipulation of the shape/curve of the endotracheal tube with stylet is at the discretion of the operator, however a straight-to-cuff shape and a bend angle of 25° to 35° is encouraged. The stylet will be left in place until the tube is advanced to the trachea.
~If the endotracheal tube with stylet is not successfully placed in the trachea on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
11120829|NCT03928912||without fracture nonunion|The patients who undergone surgery after tibial shaft fracture did not exist fracture nonunion
11120830|NCT03928912||with fracture nonunion|The patients who undergone surgery after tibial shaft fracture existed fracture nonunion
11120831|NCT03928899|No Intervention|old guideline group|"Women randomized to the old guideline group will be followed up once-weekly by electronic fetal heart rate monitoring and biophysical profile until 40 weeks 0 days (unless a medical indication arises), when induction of labor was then offered."
11120832|NCT03928899|Experimental|new procedure group|"Women randomized to new procedure group will first undergo fetal weight ultrasound estimation at 38 weeks 0 days to 38 weeks 6 days of gestation, if the fetus is estimated to be LGA/macrosomia by ultrasound, women should have an elective induction of labor immediately (at 38 weeks 0 days to 38 weeks 6 days of gestation). On the contrary, if the fetus is estimated to be normal size, the pregnant women were then given a cervical assessment. If the Bishop score ≥6, women will have at least weekly follow-up visits with their doctors and unless a medical indication is present, continue pregnancy and have selective induction at 40 weeks 0 days of gestation. Whereas, if the Bishop score <6, women will be followed up until 41 weeks 0 days of gestation with a close assessment of fetal wellbeing through the cardiotocographic trace. And women who will not deliver by this gestational age will be admitted for labor induction. Certainly, medical indication should warrant delivery without delay."
11120833|NCT03928886|Experimental|Senographe Pristina patient-assisted compression model|Senographe Pristina is a commercial mammography medical device consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). Senographe Pristina includes the hardware and software components required for multi-modality functioning and is designed to improve patient experience, patient throughput, and radiographer experience. The system offers two compression modes - standard mode and the optional patient-assisted compression. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
11120834|NCT03928886|Active Comparator|Senographe Pristina standard compression mode (usual care)|Senographe Pristina standard mode
11120835|NCT03928873|Experimental|Low energy ESWT|"Low energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks)"
11120836|NCT03928873|Experimental|High energy ESWT|"High energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks)"
11120837|NCT03928873|Sham Comparator|Sham treatment|All participants will receive sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks.
11120838|NCT03928860|Experimental|OMT Session and Doppler Ultrasonography|"OMT Session Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
~Doppler Ultrasonography Femoral artery diameter and flow evaluated by radiologist.
~In the evaluation, the wall contour characteristics of the vessel to be examined were evaluated and the diameter was measured. Color doppler examination was performed to determine whether the vessel contained color filling, patency, flow direction and turbulence.
~Peak systolic and end diastolic flow rates and flow pattern and flow rate were measured by spectral examination"
11120839|NCT03928847|Experimental|EGCG treatment|"Healthy volunteers: 450 mg, 600 mg, or 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
~Patients: 600 mg EGCG capsules once daily by mouth for two weeks"
11120840|NCT03928834|Experimental|Adapted Nzira Itsva Intervention|Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
11120841|NCT03928834|No Intervention|Standard of Care( SOC)|Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents
11120842|NCT03928821|Experimental|Group 1: PGT121 + VRC07-523LS|Participants will receive PGT121 and VRC07-523LS administered sequentially in this order at Day 0.
11120843|NCT03928821|Experimental|Group 2: PGDM1400 + VRC07-523LS|Participants will receive PGDM1400 and VRC07-523LS administered sequentially in this order at Day 0.
11120844|NCT03928821|Experimental|Group 3: 10-1074 + VRC07-523LS|Participants will receive 10-1074 and VRC07-523LS administered sequentially in this order at Day 0.
11120845|NCT03928821|Experimental|Group 4: PGDM1400 + PGT121 + VRC07-523LS|Participants will receive PGDM1400, PGT121, and VRC07-523LS administered sequentially in this order at Day 0 and Month 4.
11121594|NCT03923478|Placebo Comparator|Placebo|"Cohort A: 1 capsule one time a day
~Cohort B: 1-5 capsules one time a day"
11120846|NCT03928808|Experimental|FMT for SE-AN|Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.
11120847|NCT03928795||neonates with acute acidosis|neonates with Cord blood gases measured immediately after birth inferior to 7.15
11120848|NCT03928795||neonates with a normal ph|neonates with Cord blood gases measured immediately after birth of at least 7.15
11120849|NCT03928769||Control Group|Patients with traumatic vascular injury, ultimately corresponding to control patients
11120850|NCT03928769||Atheroma Group|"Patients will be included either in the atheromatous group (patients with atheromatous pathology) or in the control group (patients without atheromatous pathology), according to the clinical evaluation.
~In the atheromatous group, subjects must have a clinically significant atheromatous pathology.
~The investigator must specify the site (s) affected by the atheroma: carotid artery, coronary artery, aorta, renal artery, mesenteric artery or lower limb artery."
11120851|NCT03928756|Experimental|Within-participant randomization|Each day, each available participant will be randomly assigned to receive either: a push notification with tailored intervention content; a push notification with engaging, nontherapeutic content; or no push notification.
11120852|NCT03928743|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
11120853|NCT03928743|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
11120854|NCT03928730|Other|Group I|Inflammatory swellings
11120855|NCT03928730|Other|Group II|Cystic swellings
11120856|NCT03928730|Other|Group III|Lymph node swellings
11120857|NCT03928730|Other|Group IV|Benign swellings
11120858|NCT03928730|Other|Group V|Malignant swellings
11120859|NCT03928717|Experimental|Text-Based Adherence Game|Participants in the experimental condition will receive the Text Based Adherence Game. They will receive semi-automated text messages sent by study staff throughout the trial period.
11120860|NCT03928717|Active Comparator|Standard of Care (SOC)|SOC participants will receive the Standard of Care Intervention which includes receiving a brief adherence counseling session and access to clinic resources, including counseling services, throughout the trial period.
11120861|NCT03928704|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
11120862|NCT03928704|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
11120863|NCT03928691||Study group|pregnant women admitted to Women's Health Hospital , Assiut university during 2019-2020 will be counseled to participate in the study
11120864|NCT03928678|Active Comparator|thefast track (FTS group)|
11120865|NCT03928678|Placebo Comparator|Thecontrolgroup|
11120866|NCT03928665||Control group|
11120867|NCT03928665||Sleep apnea using CEPAP|
11120868|NCT03928665||Sleep apnea not using CEPAP|
11120869|NCT03928665||Glaucoma control group|
11120870|NCT03928639||Cohort 1|All patients undergoing consultation for structural and valve interventional procedures are invited to participate in this registry protocol.
11120871|NCT03928626|Active Comparator|CRAVING REGULATION|"In the CRAVING REGULATION condition, participants will first read a brief essay about the adverse consequences of drinking alcohol. Then, participants may complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will be trained to use the information to inform the strategy they will use in the regulation of craving training (ROC-T). A single trial in the regulation of craving training will have two possible instructions: (a) STRATEGY: implement the strategy (bring to mind the negative facts from the essay) and (b) LOOK: to merely observe the image and allow natural responses to come. Participants will follow the instructions; followed by an alcohol-related picture, a brief delay, and will then rate their craving. Participants will then be instructed to use this strategy in daily life situations when they might drink."
11120872|NCT03928626|Placebo Comparator|CONTROL (NO REGULATION)|In the CONTROL condition, participants will first read a brief essay about a non-alcohol-related topic (e.g., color perception). Then, participants will complete a comprehension check consisting of questions to ensure that they understood and encoded the content of the essays. Participants will view images of objects that are unrelated to alcohol. Furthermore, participants in the control condition will not practice any strategy in the regulation of craving task (ROC-T). That is, in the CONTROL condition, participants would merely observe the image and allow natural responses to come (i.e., LOOK instruction) and rate how colorful is each item (this controls for task time and experiment setting).
11120873|NCT03928613|Experimental|Mild Cognitive Impairment|"Clinical dementia rating 0 or 0.5
~Diagnosed by physicians as mild cognitive impairment according to the criteria of International Working Group on Mild Cognitive Impairment"
11120874|NCT03928600|Experimental|Combined method induction group|"25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)
~After 4 hours of last misoprostol initiate oxytocin.
~Cervical Foley will be removed after 12h of placement or when fails out."
11120875|NCT03928600|Placebo Comparator|Current department guidelines group|"Following current department guidelines, as usual, with the method considered more suitable.
~If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.
~If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place."
11120876|NCT03928587|Experimental|Active|A lozenge containing 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine 2% to be taken once daily
11120877|NCT03928587|Placebo Comparator|Placebo|An identical lozenge except for the absence of probiotics and arginine to be taken once daily.
11120878|NCT03928574||Ultrasound-Guided|Ultrasound-Guided Plane Block
11120879|NCT03928574||Conventional|Conventional Block
11120880|NCT03928561|Experimental|1 - Active air cleaner then Placebo|Exposure to cat allergen in the presence of active air cleaners then placebo. 3-week wash-out period between the two exposures.
11122553|NCT03916939|Placebo Comparator|simulated osteopathy|simulated osteopathic treatment
11120881|NCT03928561|Experimental|2 - Placebo then active air cleaner|Exposure to cat allergen in the presence of placebo then active air cleaners. 3-week wash-out period between the two exposures.
11120882|NCT03928548||Low Risk Malnutrition|Participants who are determined to be at low risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
11120883|NCT03928548||High Risk Malnutrition|Participants who are determined to be at high risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
11120884|NCT03928535|Other|High-Flow Nasal Cannula|High-flow oxygen was applied immediately after extubation through specific nasal cannula.
11120885|NCT03928535|Other|Noninvasive Ventilation|Noninvasive Ventilation was applied immediately after extubation.
11120886|NCT03928522|Active Comparator|Pre-mixed tobramycin|patients will receive pre-mixed tobramycin cement
11120887|NCT03928522|Active Comparator|hand mixed tobramycin|patients will receive hand mixed tobramycin cement
11120888|NCT03928522|Active Comparator|hand mixed vancomycin|patients will receive hand mixed vancomycin cement
11120889|NCT03928522|Experimental|hand-mixed vancomycin and tobramycin|patients will receive hand mixed vancomycin and tobramycin
11120890|NCT03928509||Estrie CIUSSS|Subjects from the Estrie's Integrated Health and Social Services Centre
11120891|NCT03928509||Saguenay-Lac-Saint-Jean CIUSSS|Subjects from the Saguenay-Lac-Saint-Jean's Integrated Health and Social Services Centres
11120892|NCT03928509||CHUDGLD|Subjects from Dr. Georges-L.-Dumont University Hospital Centre
11120893|NCT03928496|Experimental|Abobotulinumtoxina|300 units of abobotulinumtoxinA was reconstituted with 2.4 ml of 0.9% preservative free sterile saline so that each 0.1 ml contained 12.5 units of Abobotulinumtoxina 0.1 ml were injected into 31 sites of the head and neck
11120894|NCT03928496|Placebo Comparator|Placebo|0.9% preservative free sterile saline. 0.1 ml were injected into 31 sites of the head and neck
11120895|NCT03928483|Experimental|Modified WW Food program|Participants will be assigned to a SmartPoints budget and number and types of ZeroPoint foods.
11120896|NCT03928470|Experimental|EsoDuo Tab. 20/800mg|EsoDuo Tab. 20/800mg
11120897|NCT03928470|Active Comparator|Nexium Tab. 20mg|Nexium Tab. 20mg
11120898|NCT03928444|Experimental|stem cells|one side of the face to be treated with intradermal stem cells
11120899|NCT03928444|Placebo Comparator|control|one side of face treated with intradermal saline
11120900|NCT03928431|No Intervention|vaginally delivered|A non-randomized reference group of vaginally delivered infants.
11120901|NCT03928431|Active Comparator|CS intervention|"A piece of gauze soaked with saline (0.9%) will be placed in the birth canal 2 hours before the CS by the study midwife, using sterile glows. Before the CS procedure begins, the gauze will be removed from the vagina and then immediately contaminated by a swab carrying maternal fecal microbiota. The swab is contaminated by introducing it 3 cm into the anal canal and by rotating it for 10-20 s.
~Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding."
11120902|NCT03928431|Placebo Comparator|CS placebo|See above - the gauze will be exchanged to a clean gauze (soaked with saline). Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding.
11120903|NCT03928418|Experimental|Live Phone Call Booster Arm|The live phone call arm will include in-person counseling during 2 quarterly clinic visits plus live booster phone calls every three weeks in the interim.
11120904|NCT03928418|Experimental|Technology Booster Arm|The technology booster arm will include in-person counseling during 2 quarterly clinic visits plus tech (choice of SMS or IVR) boosters once to twice weekly in the interim.
11120905|NCT03928418|No Intervention|Standard of Care (SOC) Arm|The standard of care (SOC) control (brief unstructured advice, with a wait-listed intervention).
11120906|NCT03928405|Experimental|Virtual reality group|The subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT). The virtual reality group was trained with games selected from different categories such as balance and aerobic exercises with Nintendo Wii virtual reality device for 6 weeks, 1 session 30 min, 2 times a week. In the control group, no treatment was performed during this period and routine medical treatments were continued. In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control.
11120907|NCT03928405|No Intervention|Control Group|The sociodemographic characteristics of the subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT).the control group was reevaluated at the end of the 6th week after the initial evaluation. After the study was completed, training was given to the volunteers from the control group.
11120908|NCT03928392|Experimental|SCUBA Dive with OT|Two SCUBA dives in conjunction with occupational therapy intervention. The occupational therapy intervention will take place on the beach or on the boat before/after the SCUBA dive. The intervention will consist of learning 3 different breathing techniques. Participants will also be educated about mindfulness principals. Additionally, participants will complete journaling activities between dives.
11120909|NCT03928392|Active Comparator|SCUBA Dive without OT|The group will engage in two SCUBA dives.
11120910|NCT03928379|Experimental|LY3305677|LY3305677 administered SC
11120911|NCT03928379|Placebo Comparator|Placebo|Placebo administered SC
11120912|NCT03928366|Experimental|Volunteers recibing propofol and remifentanil|Volunteers receive propofol to the loss of consciousness. Then they receive remifentanil during 12 min (pain stimuli in their finger also)
11120913|NCT03928353|Experimental|1: 18 g PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
11121625|NCT03923231||BMI < 18.5|Adults with a BMI of <18.5 kg/m2 who are receiving atazanavir as part of clinical care
11120914|NCT03928353|Experimental|2: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
11120915|NCT03928353|Experimental|3: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
11120916|NCT03928353|Experimental|4: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
11120917|NCT03928353|Experimental|5: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
11120918|NCT03928340|Active Comparator|combined metformin and insulin|
11120919|NCT03928340|Other|Insulin only|
11120920|NCT03928327|Experimental|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
11120921|NCT03928327|Experimental|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
11120922|NCT03928314|Experimental|Dose Escalation (Part I)|ORIC-101 dosed orally, once per day, for 5 or 7 days/week in combination with nab-paclitaxel (75 or 100 mg/m2 on Days 1, 8, and 15) of each 28-day cycle.
11120923|NCT03928314|Experimental|Dose Expansion (Part II)|RP2D dose
11120924|NCT03928301|Active Comparator|Wholetones Intervention|"Wholetones music to help participants sleep. Data collected after listening to the Wholetones music was compared to that collected both at Baseline, and after listening to the other music condition (i.e. Classical music).
~Wholetones® 2Sleep is music that is designed to lull the listener into a deep, delta sleep, using frequency-enhanced music and precise tempos. Wholetones® differs from other musical genres in that it employs a proprietary method of tuning and layering the music with a unique frequency underlayment."
11120925|NCT03928301|Active Comparator|Classical Intervention|"Classical music was the additional music condition used to compare to both Baseline data and Wholetones data.
~The classical music was selected based on the Mayo Clinic and NIH music recommendations for better sleep. More specifically, the classical music consisted of the following six pieces: Beethoven (i.e., Moonlight Sonata, first movement), Marconi Union (i.e., Weightless), Chopin (i.e., Nocturne No.2, Op.9), Ravel (i.e., Piano Concerto in G major, 2nd movement), and J.S. Bach (i.e., Prelude No.1)."
11120926|NCT03928288|Experimental|Intervention|Cabergoline 0.5 mg PO twice weekly for 6 months
11120927|NCT03928288|Placebo Comparator|Placebo|Placebo capsule PO twice weekly for 6 months
11120928|NCT03928275|Experimental|Intralesional IL-2 Treatment|CMM patients will received 4 treatments of intralesional Interleukin-2 two weeks apart over an eight week period.
11120929|NCT03928275|Experimental|Combination therapy: Intralesional IL-2 and BCG Treatment|CMM patients will receive 4 treatments of combination therapy intralesional Interleukin-2 and Bacillus Calmette Guerin two weeks apart over an eight week period.
11120930|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 1|Benralizumab single dose administration subcutaneously
11120931|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 2|Benralizumab single dose administration subcutaneously
11120932|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 3|Benralizumab single dose administration subcutaneously
11120933|NCT03928249|Active Comparator|Grupo A|Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks
11120934|NCT03928249|Placebo Comparator|GRUPO B|group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks
11120935|NCT03928236|Experimental|Limited Benzodiazepine Policy|Policy of no routine use of any intraoperative benzodiazepines.
11120936|NCT03928236|Active Comparator|Liberal Benzodiazepine Policy|Policy for the administration of benzodiazepine as per clinical guidelines but no lower than 0.03 mg/kg (ideal body weight midazolam equivalent) to all patients undergoing cardiac surgery. Any benzodiazepine may be used.
11120937|NCT03928210|Experimental|Digoxin|
11120938|NCT03928197|Other|Healthy Volunteers|
11120939|NCT03928197|Other|Volunteers with Venous Insuficiency|
11120940|NCT03928184|Experimental|0.07 mg lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 ml vehicle
11120941|NCT03928184|Placebo Comparator|Vehicle|One intra-articular injection of 0 mg lorecivivint in 2 ml vehicle
11120942|NCT03928171|Experimental|Intra-abdominal pressure of 8 mmHg|The laparoscopy insufflator is set to a pressure of 8 mmHg
11120943|NCT03928171|Experimental|Intra-abdominal pressure of 12 mmHg|The laparoscopy insufflator is set to a pressure of 12 mmHg
11120944|NCT03928171|Experimental|Intra-abdominal pressure of 16 mmHg|The laparoscopy insufflator is set to a pressure of 16 mmHg
11120945|NCT03928158|Experimental|LCZ 696|Initial dose - 50 mg twice daily, up-titration to 200 mg twice daily. Patients will also receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
11120946|NCT03928158|Active Comparator|Valsatran|Initial dose - 40 mg twice daily, up-titration to 160 mg twice daily. Patients also will receive standard therapy for heart failure (β-blockers, diuretics, MRAs)
11120947|NCT03928145|Experimental|Chlorthalidone 25 mg + amiloride 20 mg|Chlorthalidone 25 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
11120948|NCT03928145|Active Comparator|Chlorthalidone 25 mg + amiloride 10 mg|Chlorthalidone 25 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
11120949|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 20 mg|Hydrochlorothiazide 50 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
11120950|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 10 mg|Hydrochlorothiazide 50 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
11120951|NCT03928132|Experimental|CPD Workshop on Depression and Diabetes|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
11120952|NCT03928132|Sham Comparator|CPD Workshop on Depression and Diabetes II|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
11120953|NCT03928119|Experimental|public education and network construction|"Public education was conducted to evaluate the effectiveness on patients delay of ST-Segment Elevation Myocardial Infarction treatment.
~Network construction was conducted to evaluate the effectiveness to minimize the medical delay of ST-Segment Elevation Myocardial Infarction treatment."
11120954|NCT03928106|Other|intervention|pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
11120955|NCT03928106|Other|control|pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
11120956|NCT03928093|Experimental|Pregabalin followed by placebo|The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.
11120957|NCT03928093|Experimental|Placebo followed by Pregabalin|Participants will receive placebo during the first treatment period of the study(10 weeks) followed by 10 weeks of pregabalin treatment . The dose will depend on the participant's weight and phase of the treatment period . Each treatment period consists of 3 phases: 4 weeks of escalating dose until the desired maximum, 4 weeks of active treatment and 2 weeks of titrating down.
11120958|NCT03928080||Experimental cohort|Primary study to assess diagnostic accuracy
11120959|NCT03928080||Confirmation cohort|Second cohort to confirm results from the first study on independent population
11120960|NCT03928067|Experimental|TREK Study Abroad Program|On-screen personalized normative feedback (PNF) will contain information on the drinking behavior and attitudes about gender- and country-specific study abroad peers. Participants will view text-based tips and strategies and watch clips of prior student abroad students discussing how they met their cultural engagement goals while abroad (Sojourner Adjustment Feedback or SAF). Content focuses around the four aspects of positive sojourner adjustment (social interaction with host nationals, cultural understanding and participation, language development and use, host culture identification) and the two negative sojourner adjustment factors while abroad (i.e., social interaction with co-nationals, homesickness/feeling out of place). The intervention will also contain text- and video-based tips and strategies for protective strategies used abroad to limit experience of risk sex and sexual violence victimization.
11120961|NCT03928067|No Intervention|Control|"Control participants will receive a link to a general website offering study abroad advice (www.studyabroad.com) and will be asked to spend at least 20 to 30 minutes reviewing their institution's study abroad website content, including policies for drinking abroad. This control condition was selected as a form of treatment as usual as our conversations with study abroad personnel indicate this is the extent of typical information students receive about alcohol use abroad."
11120962|NCT03928054|Experimental|"group 1 Kinesio Taping® KT"|Kinesio Taping® KT
11120963|NCT03928054|Experimental|" Kinesio Taping® with therapeutic alliance KT+AT"|Kinesio Taping® with therapeutic alliance
11120964|NCT03928041|Other|single prospective study|All subjects who are entered into this trial will receive the EVOS Lumbar Interbody System (EVOS- HA).
11120965|NCT03928028|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
11120966|NCT03928028|Experimental|FBT w/ Parent-focused Cognitive Remediation Therapy|Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
11120967|NCT03928028|Experimental|FBT w/Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.
11120968|NCT03928015|Experimental|Adjunctive dronabinol|Dronabinol 5mg BID and adjusting within the range of 2.5mg - 10mg BID, as an adjunct to systemic analgesics
11120969|NCT03928015|Active Comparator|Systemic analgesics|Systemic analgesics only
11120970|NCT03928002|Experimental|4DFlow magnetic resonance imagery|2D MRI, essential for diagnosis and monitoring of PAH, with an additional 8 minutes for 4D flow
11120971|NCT03928002|Active Comparator|Cardiac catheterization|cardiac catheterization procedure using the Fick method; gold standard
11120972|NCT03927989|Experimental|Treatment Arm|Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients
11120973|NCT03927989|Active Comparator|Standard Care|Advice to quit and brief discussion of tobacco use
11120974|NCT03927976|Experimental|Path2Quit|After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
11120975|NCT03927963|Placebo Comparator|propofol|
11120976|NCT03927963|Active Comparator|dexmedetomidine|
11120977|NCT03927950|Experimental|Escitalopram bupropion open-label|No comparator
11120978|NCT03927937|Experimental|AUTOTRANSPLANTATION TOOTH|
11120979|NCT03927924|Experimental|High-intensity focused ultrasound|
11120980|NCT03927911|Active Comparator|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
11120981|NCT03927911|Active Comparator|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
11121016|NCT03927677|Experimental|Cohort|Period 1: LC350189 200mg Day 1~ Day 4 qd, Period 2: Colchicine 0.6 mg Day 8 ~ Day 15 bid, Period 3 : LC350189 200mg (qd) + Colchicine 0.6 mg (bid) Day 16~ 19
11120982|NCT03927911|Active Comparator|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
11120983|NCT03927898|Experimental|SBRT+Toripalimab|Participants received SBRT (BED>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.
11120984|NCT03927885|Experimental|Arm I (open labeled placebo)|Patients receive open labeled placebo PO BID for 4 weeks in the absence of disease progression.
11120985|NCT03927885|Active Comparator|Arm II (waiting list, open labeled placebo)|Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.
11120986|NCT03927872||cardioembolic stroke|
11120987|NCT03927872||non cardioembolic stroke|
11120988|NCT03927859|Active Comparator|Mailing Letter|Patients assigned to this arm, in which a letter is mailed out will receive 2 pamphlets in the mail. One pamphlet described the teleophthalmology program and the other pamphlet was designed by the Canadian Association of Ophthalmologists and describes what DR is and why screening is important. The letter will also contain contact information about the closest TOP to the area of the PCP practice.
11120989|NCT03927859|Active Comparator|Phone call|"Administrative staff on site of each practice will contact all patients assigned to this arm by a phone call.
~The patient will be informed that they are calling from the family health practice that the patient belongs to. The reason for the call will be that the patient has been identified as somebody who is likely overdue for a screening test. Patients will be asked if they have had a screening test done recently, and if not, they will be offered an appointment. Patients that refuse an appointment, will be politely probed for reasons and attempts will be made to provide them with information on potential solutions to these barriers (e.g. patients working 9-5 on weekdays will be informed that they can access TOP on evenings). The call will also be used as an opportunity to inform patients about the importance of screening.Three attempts will be made to reach each patient. Only a single voicemail message will be left, when the possibility is available."
11120990|NCT03927859|Active Comparator|Mail + Phone call|Patients assigned to this arm will first have letters mailed out to them (identical to the ones mailed out in the letter only arm). A week later, the letter will be followed up by a phone call as per the phone only arm. Patients will be asked if they have already booked, and if not, will be provided with information about the program as per the phone call script in the phone only arm.
11120991|NCT03927859|No Intervention|Control|No intervention will be offered to patients in this arm.
11120992|NCT03927846|Active Comparator|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
11120993|NCT03927846|Active Comparator|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
11120994|NCT03927833|Active Comparator|Continuous Phototherapy|Continuous phototherapy
11120995|NCT03927833|Experimental|Cycled Phototherapy|Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels.
11120996|NCT03927820||Patients Using Inhalers|Adult patient admitted to Vanderbilt University Medical Center (excluding surgery services) on a long acting inhaler or prescribed a long acting inhaler during admission.
11120997|NCT03927807|Experimental|repetitive hourly dose of oral misoprostol|The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.
11120998|NCT03927807|Experimental|two hourly dose of oral misoprostol|The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.
11120999|NCT03927794|Experimental|Self-Assembling Peptide P11-4|"24 teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed as baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife Camera.
~Then they will receive Self-Assembling Peptide P11-4 at Day 0. 12 teeth will receive a re-application at Day 180 and re-assessment will be done."
11121000|NCT03927794|Active Comparator|Fluoride Varnish|"24 teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed as baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife Camera.
~Then they will receive Topical Fluoride Varnish at Day 0. 12 teeth will receive a re-application at Day 180 and re-assessment will be done."
11121001|NCT03927781|Experimental|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
11121002|NCT03927768||200 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
11121003|NCT03927768||50 women undergoing clinical breast MRI|At time of previously scheduled clinical breast MRI, 60 second postcontrast imaging sequence will be added to the clinical breast MRI. MRI will be interpreted according to usual departmental protocols.
11121004|NCT03927755||Sub-xyphoid|Ultrasound views of the heart obtained using the sub-typhoid approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
11121005|NCT03927755||Para-sternal Long|Ultrasound views of the heart obtained using the parasternal long approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
11121006|NCT03927742|Experimental|Shade and application with UV message activated|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging activated
11121007|NCT03927742|Active Comparator|Shade and application without UV messaging|wearable device (wrist) and associated mobile application; UV sensor exposure display and messaging not activated
11121008|NCT03927729|Experimental|Penthrox|Patients with moderate to severe post-traumatic acute pain will be included in the emergency room.
11121009|NCT03927716|Experimental|SB206 12%|SB206 12% topically once daily
11121010|NCT03927716|Placebo Comparator|Placebo|Placebo topically once daily
11121011|NCT03927703|Experimental|SB206 12%|SB206 12% topically once daily
11121012|NCT03927703|Placebo Comparator|Placebo Comparator|Placebo topically once daily
11121013|NCT03927690|Experimental|LKA651|LKA651 IVT
11121014|NCT03927690|Experimental|LKA651/Lucentis|LKA651/Lucentis IVT
11121015|NCT03927690|Active Comparator|Lucentis|Lucentis IVT
11121108|NCT03926988|Other|Intervention|NeVa Stent Retriever
11121017|NCT03927664||Peritoneal Tuberculosis|Patients diagnosed with peritoneal tuberculosis and who have undergone a computed tomographic examination
11121018|NCT03927651|Experimental|Administration of ICG|ICG will be injected intravenously to assess ovarian perfusion in the presence or absence (control) of pathology. Near infrared fluorescence imaging will be used to illuminate the ICG. The extent of perfusion will be determined using digital imaging software. ICG will be stored at the NM Investigational Pharmacy and administered intravenously by the anesthesiologist at the direction of the surgeon during surgical procedure.
11121019|NCT03927638||Normal Weight|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
11121020|NCT03927638||Overweight/Obese|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
11121021|NCT03927625|Experimental|Cohort 1|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.16 g/min for 60 minutes.
11121022|NCT03927625|Experimental|Cohort 2|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.31 g/min for 60 minutes.
11121023|NCT03927625|Experimental|Cohort 3|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The second cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.63 g/min for 60 minutes.
11121024|NCT03927625|Experimental|Cohort 4|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The third cohort of patients will receive ascorbate-meglumine at a dose administration rate of 1.25 g/min for 60 minutes.
11121025|NCT03927612|Experimental|Alternate Perspective|After experiencing VR scenarios, participants will experience the interactions again from the virtual counterpart's perspective within the VR system.
11121026|NCT03927612|Placebo Comparator|Control Perspective|After experiencing VR scenarios, participants will experience the interactions again from the same perspective in the VR system.
11121027|NCT03927599||Advanced refractory tumor solid tumors patients|Patients with advanced refractory solid tumors carrying TP53 mutations and receive PARP-inhibitors in combination with the VEGFR-inhibitors therapy
11121028|NCT03927586|Experimental|cognitive training (COG group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each cognitive intervention session will last for 90 minutes. The COG group received computerized cognitive based training which include memory, executive function, visuospatial , language and attention trainings.
11121029|NCT03927586|Experimental|physical exercise training (PE group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each physical exercise intervention session will last for 90 minutes. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The PE group received multimodal exercise program which includes aerobic exercise, balance and muscle strength training.
11121030|NCT03927586|Experimental|sequential training (SEQ group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the SEQ group will first undergo physical exercise training for 45 minutes followed by 45 minutes of cognitive-based training. The participants will first perform 10 minutes of warm-up followed by 25 minutes of physical exercise, and end with 10 minutes of cool-down. The exercise intensity will be similar to the PE group. Following the physical exercise, the participants will take part in 45 minutes of cognitive training. The same tasks used in the COG group will be practiced.
11121031|NCT03927586|Experimental|dual-task training (Dual group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the DUAL group will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance. The 90 minutes of training session will be break up into 2 to 3 parts, and the participants can rest as needed.
11121032|NCT03927573|Experimental|GEM3PSCA|Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells
11121033|NCT03927560|Experimental|Robotic Assisted Percutaneous Coronary Intervention|
11121034|NCT03927547|Experimental|Inclined Sleep|Inclined mattress at 15 degrees
11121035|NCT03927547|No Intervention|Flat Sleep|Plane mattress
11121036|NCT03927534|Experimental|Experimental|Mindful Eating program is apply face to face 7 sessions of 120 minutes/session. ME is apply in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
11121037|NCT03927534|No Intervention|Control|Treatment As Usual (TAU) in Primary Care (PC) is any kind of treatment administered by the GP to the patient with overweight and obesity. According to nutritional status, overweight or obesity, as well as the presence of co-morbidity, different actions can comprise the treatment offered at a PC level. For individuals presenting with overweight (BMI 25-29.9 kg/m2) but with no co-morbidities, PC teams organise care plans to enable them to achieve a normal BMI range (BMI 18.5-24.9 kg/m2). In case of suicide risk, severe social dysfunction or worsening of symptoms, it is recommended that patients are referred to mental health facilities.
11121038|NCT03927521|Experimental|Focal HIFU guided by PET-MRI/68Ga-PSMA imaging|Patient with local/focal prostate cancer recurrence after radiotherapy and no distant metastasis (negative PET-Choline imaging confirmed by PET-MRI/68Ga-PSMA) will be treated by Focal-HIFU
11121039|NCT03927508|Experimental|BEC Treatment|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
11121040|NCT03927495|Experimental|Concurrent chemoradiotherapy and KN046|Participants in the Arm I will receive chemoradiotherapy and concurrent KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
11121041|NCT03927495|Experimental|chemoradiotherapy and sequential KN046|Participants in the Arm II will receive chemoradiotherapy and sequential KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
11121042|NCT03927482|Experimental|CARES mobile app|Participants in this arm will receive 12 weeks of text messages and use of the smart phone mobile app that provides support for alcohol risk reduction.
11121043|NCT03927482|Active Comparator|Alcohol Education|Those randomized to the control arm will be given access to an online alcohol education intervention; Check Your Drinking (CYD: www.CheckYourDrinking.net). CYD provides normative feedback on the user's drinking habits relative to his/her peers.
11121044|NCT03927469||Hospitalisation group|The patients who were hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
11121045|NCT03927469||Re-hospitalisation group.|The patients who were re-hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
11121046|NCT03927456|Experimental|SHR6390 + Fulvestrant|Intervention Drug: SHR6390, Fulvestrant
11121047|NCT03927456|Placebo Comparator|Placebo + Fulvestrant|Intervention Drug: Placebo, Fulvestrant
11121048|NCT03927443|Experimental|Test|
11121049|NCT03927443|Active Comparator|Reference|
11121050|NCT03927404|Experimental|Adaptive Vacuum test Prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
11121051|NCT03927391|Active Comparator|reference (normal) dose|Normal dose of enzalutamide (160mg once daily)
11121052|NCT03927391|Experimental|test (reduced) dose|Reduced dose of enzalutamide (120mg once daily)
11121053|NCT03927378|Experimental|S-katamine group|Low-dose s-ketamine (0.2 mg/kg in 20 ml normal saline) is intravenously infused in 40 minutes after childbirth.
11121054|NCT03927378|Placebo Comparator|Placebo group|Placebo (20 ml normal saline) is intravenously infused in 40 minutes after childbirth.
11121055|NCT03927365|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
11121056|NCT03927365|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
11121057|NCT03927352|Experimental|SCT630|"Participants received 80 mg SCT630 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~Participants with a PASI 50 response at week 16 continued to receive 40 mg SCT630 until week 48."
11121058|NCT03927352|Active Comparator|adalimumab-EU source|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to SCT630 until week 48"
11121059|NCT03927339||pre and post excercise group|
11121060|NCT03927326|Experimental|Local infiltration|Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
11121061|NCT03927326|Experimental|Transversus abdominis plane block|Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
11121062|NCT03927313|Active Comparator|Standard of care anti-tubercular therapy|Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
11121063|NCT03927313|Experimental|Intensified anti-tubercular therapy|"Standard of care anti-TB therapy as described in Arm 1,
~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days)."
11121064|NCT03927313|Experimental|Intensified anti-tubercular therapy plus aspirin|"Standard of care anti-TB therapy as described in Arm 1,
~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),
~Plus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)"
11121065|NCT03927300||Patients without Telemonitoring with ApTelecare Software|
11121066|NCT03927300||Patients with implementation of Telemonitoring with ApTelecare|
11121067|NCT03927287||Radical prostatectomy (RP cohort)|Our institutional prostate cancer database was queried for all patients between 2000-2017 who had a biochemical recurrence (BCR) after radical prostatectomy (RP) (Total PSA>=0.2 ng/ml) and had at least one post-BCR free PSA ratio (FPSAR) blood test (RP cohort). FPSAR ascertainments were performed incidentally or reflexively (e.g. PSA in the range of 4-10 ng/ml, as per Institutional policy). If multiple FPSAR tests were performed, only the first FPSAR test was analyzed. otal PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
11121068|NCT03927287||Radiotherapy cohort|Our institutional database was queried or all patients between 2000-2017 who had a rising PSA after radiotherapy (RT) for intermediate- and high-risk prostate cancer, and at least one post-treatment free PSA ratio (FPSAR) blood test (RT cohort). As in the RP cohort, FPSAR was performed either incidentally or reflexively, and the first FPSAR test was used for the analyses. Total PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
11121069|NCT03927287||Biobank surgical cohort|To validate our findings in the two retrospective cohorts (RP and RT), we analyzed a third cohort of prospectively collected biobank specimens of patients who underwent RP and developed biochemical recurrence(Biobank cohort). The retrieved samples were batched and tested for FPSAR levels to determine the results in lower PSA ranges and also to account for intrinsic analyte measurements variability in the retrospective cohorts. For his cohort we used the Roche Elecsys analytical platform, according to the instructions of the manufacturer.
11121070|NCT03927274|Experimental|Cleveland Multiport Catheter (CMC) + Topotecan|For predominantly enhanced tumors with volume of 8 cc or less, only 1 Cleveland Multiport Catheter (CMC) will be placed and convection-enhanced delivery (CED) will be performed over a 4-hour period within an MRI scanner, with the goal of complete tumor coverage (as evidenced by tracer distribution on MRI). The initial rate will be 1.20 ml/hour (5.0 microliters/minute/microcatheter) and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 5 microliters/minute/microcatheter based upon the tumor coverage and safety characteristics of the previously treated patients.
11121071|NCT03927261|Experimental|Dose Escalation and Dose Expansion of PRGN-3006|Participants will be treated in dose escalation phase to identify the safety and maximum tolerated dose (MTD) of PRGN-3006.
11121072|NCT03927248|Experimental|Nivolumab and PAC-1|Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.
11121073|NCT03927235|Sham Comparator|the freezing time of 3s|Transbronchial cryobiopsy in the freezing time of 3s
11121074|NCT03927235|Experimental|the freezing time of 4s|Transbronchial cryobiopsy in the freezing time of 4s
11121075|NCT03927235|Experimental|the freezing time of 5s|Transbronchial cryobiopsy in the freezing time of 5s
11121076|NCT03927235|Experimental|the freezing time of 6s|Transbronchial cryobiopsy in the freezing time of 6s
11121077|NCT03927222|Experimental|DC vaccination with Td preconditioning and GM CSF|This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant GM-CSF on overall survival of newly diagnosed GBM patients who have undergone definitive resection, are unmethylated, and completed standard temozolomide and radiation treatment. All enrolled patients will undergo a leukapheresis for the generation of DCs. Patients will then receive approximately 6 weeks of standard of care radiation therapy (RT) and concurrent TMZ. A single post-RT cycle of dose intensified TMZ (100 mg/m2/day for 21 days) will then be given. On day 23 (± 2 days) of the cycle, patients will receive the first of 3 pp65 DC vaccines every 2 weeks. All patients will receive up to a total of 10 DC vaccines
11121078|NCT03927209|Experimental|BI 1467335 (low dose)|
11121079|NCT03927209|Experimental|BI 1467335 (high dose)|
11121080|NCT03927196|Experimental|extended statin counseling group|Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.
11121081|NCT03927196|No Intervention|convetional statin counseling group|Сounseling on the prevention of cardiovascular diseases and the use of drugs for this purpose
11121082|NCT03927183|Other|Person-centred practice|Person-centred care
11121083|NCT03927170|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
11121084|NCT03927170|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
11121085|NCT03927157|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
11121086|NCT03927157|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
11121087|NCT03927144|Experimental|Erenumab|Escalate to Erenumab Dose 2 OR Switch to Oral prophylactic
11121088|NCT03927144|Active Comparator|Oral Prophylactic|Switch Oral Prophylactic
11121089|NCT03927131|Experimental|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
11121090|NCT03927131|Active Comparator|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
11121091|NCT03927131|Active Comparator|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
11121092|NCT03927131|Experimental|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
11121093|NCT03927131|Experimental|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
11121094|NCT03927131|Experimental|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
11121095|NCT03927105|Experimental|Nivolumab + Cabiralizumab|Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.
11121096|NCT03927092||Multiple Sclerosis patients|Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
11121097|NCT03927066|Experimental|Healthy Volunteer|All Volunteers will be studied at rest and during experimental condition (lower body negative pressure)
11121098|NCT03927053||HIV infected youth who use marijuana only|
11121099|NCT03927053||HIV infected youth who use tobacco only|
11121100|NCT03927053||HIV infected youth who use tobacco and marijuana|
11121101|NCT03927053||HIV infected youth with no substance use|
11121102|NCT03927040|Experimental|TEMT Administration|Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
11121103|NCT03927027|Active Comparator|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
11121104|NCT03927027|Experimental|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
11121105|NCT03927014||Preeclampsia|The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
11121106|NCT03927014||Control|The control groups' samples will obtain during the routine obstetrical care examination in the third trimester of pregnancy.
11121107|NCT03927001|Other|Intervention|NeVa Stent Retrievers
11121109|NCT03926975|Experimental|Experimental: Scleral Lens|One eye will be randomly selected to wear a scleral lens for a 6-hour testing period.
11121110|NCT03926975|Active Comparator|Control: no lens|The contralateral eye will not wear a lens.
11121111|NCT03926962|Experimental|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
11121112|NCT03926962|Placebo Comparator|Placebo|Visually matching placebo
11121113|NCT03926949|Active Comparator|Intervention group|Participants will receive parenteral nutrition (Olimel 7.6% E 1000 ml), infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
11121114|NCT03926949|Other|Control group|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively
11121115|NCT03926936|Experimental|Low-grade uterine sarcoma|
11121116|NCT03926936|Experimental|low-grade endometrial carcinoma|
11121117|NCT03926936|Experimental|sex cord stromal tumors|
11121118|NCT03926936|Experimental|low-grade serous ovarian cancer|
11121119|NCT03926910|Experimental|VESAP|patient receiving stimulation test to detect hypovolemia
11121120|NCT03926884|Experimental|Tea1 group|"This is the treatment group. This group will be taking 2 grams of the three-seeds mixture twice a day for three weeks."
11121121|NCT03926884|Placebo Comparator|Tea2 group|"This is the control group. This group will be taking 0.02 grams of the three-seeds mixture once a day for three weeks."
11121122|NCT03926871|Experimental|Novices|They received ergonomic training after 1-2 days of hiring to do the work in the cutting room, and packaging sectors. They did not have experience in the refrigerator or butchers, so they had the minimum of information about tasks and risks.
11121123|NCT03926871|Experimental|Experienced|They received the same ergonomic training as the newbies, and should have been hired for more than 6 months in the company. In this period they had already acquired patterns of movement and self-protection to accomplish the tasks.
11121124|NCT03926845|Active Comparator|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|The cream contains 0.2% Isobutylamido-thiazolyl-resorcinol.
11121125|NCT03926845|Placebo Comparator|Vehicle|The cream contains no active ingredients.
11121126|NCT03926832|Experimental|Patients with Sarcoidosis|Participants with Sarcoidosis. This arm will complete baseline questionnaires assessing daytime sleepiness (Epworth Sleepiness Scale - ESS) and fatigue (Fatigue Assessment Scale - FAS). All participants will perform home polygraphy and will be treated with CPAP for three months if moderate-to-severe OSA has been diagnosed and re-assessed with the same questionnaires along with a complete analysis of CPAP adherence by analyzing the compliance report of the device.
11121127|NCT03926819|Active Comparator|Single Ascending Dose|
11121128|NCT03926819|Active Comparator|Multiple Ascending Dose|
11121129|NCT03926806|Active Comparator|Plain yoghurt|2x200g plain yoghurt/day for 12 weeks
11121130|NCT03926806|Experimental|Vitamin B yoghurt|2x200g yoghurt enriched with vitamins B for 12 weeks
11121131|NCT03926793|Experimental|Cohort 1|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
11121132|NCT03926793|Experimental|Cohort 2|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
11121133|NCT03926793|Experimental|Open Label Extension|Eligible subjects may participate in the Open Label Extension (OLE) study for a period of 24 weeks.
11121134|NCT03926780|Active Comparator|Warfarin|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin by the regular starting dose with follow up of the INR to target (2-3)
11121135|NCT03926780|Experimental|Rivaroxaban|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban in a dose of 20 mg per day
11121136|NCT03926767|Experimental|Pain Neuroscience Education + orofacial and neck exercises|All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
11121137|NCT03926767|Active Comparator|Orofacial and neck exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
11121138|NCT03926754|Active Comparator|Mirabegron|Active treatment arm (mirabegron)
11121139|NCT03926754|Placebo Comparator|Placebo|Placebo
11121140|NCT03926741|Experimental|GSNOR Challenge testing|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
11121141|NCT03926728|Experimental|Cohort A - 85µg CTH522-CAF01|Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01. This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
11121142|NCT03926728|Experimental|Cohort B - 85µg CTH522-CAF01+ TO CTH522|Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional doses TO CTH522 (12µg) is administered in each eye. The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
11121220|NCT03926195|Experimental|Double-Blind Phase: Filgotinib|Filgotinib up to Week 13
11121221|NCT03926195|Placebo Comparator|Double-Blind Phase: Placebo|Placebo up to Week 13
11121626|NCT03923231||BMI >30|Adults with a BMI of >30 kg/m2 who are receiving atazanavir as part of clinical care
11121143|NCT03926728|Experimental|Cohort C - 85µg CTH522-CAF01+ID CTH522|Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140. The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID. The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
11121144|NCT03926728|Experimental|Cohort D - 15µg CTH522-CAF01|Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
11121145|NCT03926728|Experimental|Cohort E - 85µg CTH522-CAF09b|Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01. The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
11121146|NCT03926728|Placebo Comparator|Cohort F - Placebo|Cohort F will receive only placebo in form of 0.9% NaCl saline.
11121147|NCT03926702|Experimental|Radiopharmaceutical administration|All participants receive radiopharmaceutical for positron-emission tomography (PET) study.
11121148|NCT03926689|Experimental|Suaahara II Standard + SMS|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.) Suaahara II monthly SMS campaign targeting all adult household members of households in the 1000-day period between conception and a child's second birthday
11121149|NCT03926689|Active Comparator|Suaahara II Standard|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.)
11121150|NCT03926676|Experimental|Grandio blocks|Nano hybrid composite blocks
11121151|NCT03926676|Active Comparator|E max|ceramic blocks
11121152|NCT03926663|Experimental|group Bupivacaine|Group B; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) as preincisional local infiltration of the nasal mucosa of the nasal septum ,injected once before surgical intervention
11121153|NCT03926663|Active Comparator|group Bupivacaine +Dexmedetomidine|group B+D; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa of the nasal septum,injected once before surgical intervention.
11121154|NCT03926637||Study Participants|Participants with MS, including CIS will complete the MSPT at their standard of care visits.
11121155|NCT03926624|Experimental|Experimental|DFP-10917 Dose: 6 mg/m²/day administered by continuous infusion for 14 days followed by a 14-day resting period per 28-day treatment cycle. If a patient experiences a significant treatment-related AE, the patient may undergo one dose reduction of DFP-10917 to 4 mg/m²/day x 14 days for subsequent treatment cycles
11121156|NCT03926624|Active Comparator|Control|"Non-Intensive:
~LoDAC: 20 mg SC BID 10 days
~Azacitidine: 75 mg/m²/day SC 7 days(or 5+2)
~Decitabine: CIV 20 mg/m²x5 days
~Venetoclax + LoDAC/Azacitidine/Decitabine:LoDAC-Venetoclax ramp-up to 600 mgxday. Cytarabine SC 20 mg/m²xday D1-10. Azacitidine or Decitabine-Venetoclax ramp-up to 400 mgxday. Azacitidine IV or SC 75 mg/m² D1-7. Decitabine IV 20 mg/m² on D1-5 or 1-10.
~Intensive:
~High DAC: cytarabine 1-2 g/m² up to 5 days, max total dose 10 g/m²
~FLAG: D1-5: fludarabine 30 mg/m² IV for 30min, D1-5: cytarabine 1-2 g/m² for 4hr daily x 5 & G-CSF 5 mcg/kg or 300 mcg/m² until PMN recovery, with or without idarubicin D1-3 8 mg/m² IV dailyx3 (FLAG-Ida)
~MEC: D1-6: mitoxantrone 6 mg/m² IV bolus, etoposide 80 mg/m² IV 1hr & cytarabine 1g/m² IV 6hr.
~CLAG/M or Ida = cladribine 5 mg/m² D1-5, cytarabine 2 g/m² D1-5, G-CSF 300 μg D0-5, mitoxantrone 10 mg/m² D1-3 or Idarubicin 10 mg/m² D1-3.
~Intermediate DAC: cytarabine 20 mg/m² IV dailyx5"
11121157|NCT03926611|Experimental|LOU064 Arm 1|Participants will be asked to take LOU064 low dose once daily
11121158|NCT03926611|Experimental|LOU064 Arm 2|Participants will be asked to take LOU064 medium dose once daily
11121159|NCT03926611|Experimental|LOU064 Arm 3|Participants will be asked to take LOU064 high dose once daily
11121160|NCT03926611|Experimental|LOU064 Arm 4|Participants will be asked to take LOU064 low dose twice daily
11121161|NCT03926611|Experimental|LOU064 Arm 5|Participants will be asked to take LOU064 medium dose twice daily
11121162|NCT03926611|Experimental|LOU064 Arm 6|Participants will be asked to take LOU064 high dose twice daily
11121163|NCT03926611|Placebo Comparator|Placebo Arm|Participants will be asked to take matching placebo twice daily
11121164|NCT03926598||Patients/Caretakers Group|Patients with Type II Diabetes and caretakers of patients with Type II Diabetes.
11121165|NCT03926598||Certified Diabetes Educators Group|Diabetes educators who help patients manage their Type II Diabetes.
11121166|NCT03926598||Physician Group|Physicians who help patients manage their Type II Diabetes.
11121167|NCT03926598||Front Desk Staff|Front desk staff who work with physicians that treat Type II Diabetes.
11121168|NCT03926598||Nurses|Nurses who help patients manage their Type II Diabetes.
11121169|NCT03926585||Responders|Patients in combination therapy due to persistent symptoms on L-thyroxin mono-therapy who experience a longtime effect of triiodothyronine treatment.
11121170|NCT03926585||Non-responders|Patients who have tried combination therapy due to persistent symptoms on L-thyroxin mono-therapy, but did not experience a longtime effect.
11121171|NCT03926572|Other|Patients with Pulmonary arterial hypertension|Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
11121172|NCT03926559|Experimental|Duramorph (Morphine)|2mg of Neuraxial Morphine given through epidural once after the patient has delivered.
11121173|NCT03926559|No Intervention|No intervention|Patient does not get any intervention.
11121174|NCT03926546|Experimental|Individual ERP|Individual Exposure and Response Prevention for OCD
11121175|NCT03926546|Experimental|Group ERP|Group Exposure and Response Prevention for OCD
11121176|NCT03926533|Experimental|Telehealth ICU Recovery Program|Components of the ICU RC telehealth visit will be structured parallel to what is done during a typical in-person clinic visit. The telehealth intervention consists of 5 chronological components conducted during two 1.5 hour telehealth clinic visits (the same time required for an in-person visit). Upon completion of the pre-intervention baseline assessment, the study coordinator will contact patients randomized to the intervention arm to schedule the first telehealth visit. Study visits will occur at 3 weeks and 3 months following hospital discharge.
11121260|NCT03925987|Experimental|Exposure therapy|Participants complete 10 weekly sessions of a group-based exposure therapy class for anxiety disorders.
11121261|NCT03925974|Experimental|HER2 overexpression|HER2 IHC 3+ or IHC2+ and ISH+
11121177|NCT03926533|No Intervention|Standard Recovery Conditions|participants assigned to the standard of care control group will be contacted by the study coordinator to ensure the patient has a primary care and/or specialist appointment scheduled. At this time, patients will also receive an electronic PICS guide for ICU survivors created by the Society of Critical Care Medicine. Patients will be directed to use the information provided in the PICS guide for ICU survivors to connect with resources.
11121178|NCT03926520|Experimental|ECT+UC group|
11121179|NCT03926520|Sham Comparator|S-ECT+UC group|
11121180|NCT03926507|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
11121181|NCT03926481|Experimental|Obesity Only|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity who are 65 years and older.
11121182|NCT03926481|Experimental|Sarcopenia and Obesity|Assess the effect of an intensive lifestyle intervention on cognitive function in adults with obesity and sarcopenia who are 65 years and older.
11121183|NCT03926455|Experimental|Typhax 0.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
11121184|NCT03926455|Experimental|Typhax 2.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
11121185|NCT03926455|Experimental|Typhax 10 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
11121186|NCT03926455|Active Comparator|Typhim Vi 25 mcg|Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
11121187|NCT03926455|Placebo Comparator|Placebo (saline)|Placebo control was administered IM Days 0 and 28 ( n=9)
11121188|NCT03926442|Experimental|Active1|Italian Herb in active breakfast meal
11121189|NCT03926442|Experimental|Active2|Cinnamon in active breakfast meal
11121190|NCT03926442|Experimental|Active3|Pumpkin Spice Mix in active breakfast meal
11121191|NCT03926442|Placebo Comparator|Placebo Comparator|Placebo Breakfast
11121192|NCT03926429||Patient with reactive arthritis|
11121193|NCT03926416|Experimental|CodaVax-H1N1, low dose|Participants will receive a single dose of either CodaVax (5 x 10^3 PFU in 200 uL) and an intramuscular injection of placebo
11121194|NCT03926416|Active Comparator|Fluzone|Participants will receive an intranasal (IN) dose of placebo and an intramuscular (IM) dose of QuadriFlu- Tetravalent Influenza Vaccine (TIV) (Fluzone®)
11121195|NCT03926416|Experimental|CodaVax-H1N1, high dose|Participants will receive a single intranasal (IN) dose of CodaVax-H1N1 (1 x 10^5 PFU in 500 uL)
11121196|NCT03926416|Placebo Comparator|Placebo|Leibovitz's L-15 medium (IN) or saline (IM)
11121197|NCT03926403|Experimental|Hypnosis|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
11121198|NCT03926403|Active Comparator|conventional management|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
11121199|NCT03926390|No Intervention|Non bovine colostrun|Preterm received preterm formula
11121200|NCT03926390|Active Comparator|Bovine colostrum group|Preterm received bovine colostrum as trophic feeding
11121201|NCT03926377|Other|Clobetasol propionate treatment|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
11121202|NCT03926364||Patients|Referred pain
11121203|NCT03926351|Placebo Comparator|Arm 1a; Placebo|Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
11121204|NCT03926351|Experimental|Arm 2a; Omega-3 capsules|Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
11121205|NCT03926338|Experimental|PD-1 inhibitor plus COX inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab) plus COX inhibitor (Celecoxib)
11121206|NCT03926338|Experimental|PD-1 inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)
11121207|NCT03926312|Experimental|Smart device-based rehabilitation|One month after myocardial infarction, patients will receive a smart band and a cellphone in order to transmit data on physical activity to electronic health record. A study nurse will periodically check compliance with recommended physical activity and intervene in the case of non-compliance.
11121208|NCT03926312|No Intervention|Control group|Patients will receive a guideline directed recommendation to increase physical activity to 30 minutes of moderate physical activity a week.
11121209|NCT03926299|Experimental|Laser|dual Fotona laser treatment (Nd:YAG and Er:YAG)
11121210|NCT03926299|Active Comparator|Topical steroid|clobetasol propionate 0.05% cream
11121211|NCT03926286|Experimental|FMT for Sjogrens|FMT- active ingredient coming from participant's screening stool
11121212|NCT03926273||group 1|Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
11121213|NCT03926273||group 2|Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
11121214|NCT03926260|Experimental|ctDNA analysis|additional blood sample of 20 ml
11121215|NCT03926247|Other|Immigrant Well-being Project Intervention|Intervention
11121216|NCT03926234||emergency triage patients|triage Level I triage Level II triage Level III triage Level IV
11121217|NCT03926221|Experimental|PBC_I plus TranS-C|The Parent Behavior Change Intervention (PBC-I) is a behavioral intervention intended to teach parent behavior change techniques to better support their adolescents to improve sleep health behavior. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
11121218|NCT03926208|Active Comparator|Control|Subjects in this group will receive the standard chlorihexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
11121219|NCT03926208|Experimental|Soak and Scrub|In addition to the standard chlorihexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
11121222|NCT03926195|Experimental|Extension Phase: Open-Label Filgotinib|Participants who received double-blind filgotinib and did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) and were arthritis responders at Week 13 will enter the Extension Phase and receive open-label filgotinib up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
11121223|NCT03926195|Other|Extension Phase: Standard of Care|Participants who received double-blind placebo and participants who received double-blind filgotinib and were arthritis non-responders who did not meet prespecified decreases in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) at Week 13 will enter the Extension Phase and receive standard of care up to Week 156. Participants who meet the criteria of prespecified decreases in sperm parameters anytime during the Extension Phase will enter the Monitoring Phase.
11121224|NCT03926195|Other|Monitoring Phase: Standard of Care|Participants with a prespecified decrease in sperm parameters (that is, ≥ 50% decrease from baseline in sperm concentration, and/or motility, and/or morphology) anytime at/after Week 13 will receive standard-of-care therapy as per investigator discretion in the Monitoring Phase for up to 52 weeks or until reversibility in semen parameters is met, whichever occurs first.
11121225|NCT03926182|Experimental|Fasted AST2818 tablets following a period of fasting|
11121226|NCT03926182|Experimental|High-fat meal AST2818 tablets following a high-fat meal|
11121227|NCT03926169|Experimental|Risankizumab: Dose A|Participants randomized to receive risankizumab dose A in treatment period A and placebo followed by risankizumab dose B in treatment period B
11121228|NCT03926169|Experimental|Risankizumab: Dose B|Participants randomized to receive risankizumab dose B in treatment period A and placebo followed by risankizumab dose B in treatment period B
11121229|NCT03926169|Placebo Comparator|Placebo|Participants randomized to receive Placebo in treatment period A and risankizumab dose B in treatment period B
11121230|NCT03926156|Experimental|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
11121231|NCT03926156|Active Comparator|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
11121232|NCT03926143|Experimental|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
11121233|NCT03926130|Experimental|Mirikizumab|"Mirikizumab given intravenously (IV) and subcutaneously (SC).
~Participants in the open-label adolescent addendum will be given mirikizumab IV and SC."
11121234|NCT03926130|Active Comparator|Ustekinumab|Ustekinumab given IV and SC.
11121235|NCT03926130|Placebo Comparator|Placebo|Placebo given IV and SC.
11121236|NCT03926117|Placebo Comparator|Placebo|Matching placebo
11121237|NCT03926117|Experimental|Ziltivekimab 7.5 mg|
11121238|NCT03926117|Experimental|Ziltivekimab 15 mg|
11121239|NCT03926117|Experimental|Ziltivekimab 30 mg|
11121240|NCT03926091|Experimental|4 cycles of TC adjuvant chemotherapy|4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
11121241|NCT03926091|Active Comparator|6 cycles of TC adjuvant chemotherapy|6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
11121242|NCT03926078|Other|Patients under 18 years of age|Group A consists of patients that receive a chest radiography in the current work-up of PE.
11121243|NCT03926078|Other|Patients aged 18 years or older|Group B consists of patients that receive a CT scan in the current work-up of PE.
11121244|NCT03926065|Experimental|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
11121245|NCT03926065|Experimental|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
11121246|NCT03926065|Experimental|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
11121247|NCT03926065|Experimental|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
11121248|NCT03926052|Active Comparator|LDX|
11121249|NCT03926052|Placebo Comparator|Placebo|
11121250|NCT03926039|Experimental|sharing decision-making program interventions|"Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study sharing decision-making plan mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process."
11121251|NCT03926039|No Intervention|Description of traditional treatment options|Description of conventional traditional treatment options
11121252|NCT03926026|Experimental|NCX 4251 QD|NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
11121253|NCT03926026|Placebo Comparator|Placebo QD|Placebo once daily for 14 days
11121254|NCT03926026|Experimental|NCX 4251 BID|NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
11121255|NCT03926026|Placebo Comparator|Placebo BID|Placebo twice daily for 14 days
11121256|NCT03926013|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-63898081. Ascending dose levels will be sequentially tested.
11121257|NCT03926013|Experimental|Part 2: Dose Expansion|Participants with mCRPC or renal cell carcinoma (RCC) will receive JNJ-63898081 at the recommended Phase 2 dose (RP2D) determined in Part 1.
11121258|NCT03926000|Active Comparator|Pregabalin (PG)|Patients will receive 150 mg pregabalin one hour before the procedure.
11121259|NCT03926000|Placebo Comparator|Control placebo (C)|Patients will receive placebo tablet one hour before surgery.
11121262|NCT03925974|Experimental|HER2 expression|HER2 IHC 2+ISH- or IHC 1+ and ISH+
11121263|NCT03925961|No Intervention|control arm|All subjects in the control arm will receive the current preoperative and post operative instructions.
11121264|NCT03925961|Experimental|'education booklet' arm|All subjects in the 'education booklet' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery
11121265|NCT03925961|Experimental|'education booklet and preoperative' arm|All subjects in the 'education booklet and preoperative' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery. Those subjects randomized to the 'education booklet and preoperative' arm will receive a pre-operative phone call by the research study's lead nurse, Catherine Davidson, approximately 1 week after participants enroll in the study. She will review pre-operative and post-operative guidelines pertinent to participants' operative as outlined in the patient information booklet. The amount of time (in minutes) that this phone call takes will be recorded in an excel file sheet.
11121266|NCT03925948|Experimental|Intervention|This is a one arm study with all participants enrolled into this arm.
11121267|NCT03925935|Experimental|Experimental|Up to 3 sequential dose escalation cohorts of AB-205
11121268|NCT03925909|Experimental|Eriomin 200 mg|The volunteers will receive one capsule containing 200 mg eriocitrin
11121269|NCT03925909|Experimental|Eriomin 400 mg|The volunteers will receive one capsule containing 400 mg eriocitrin
11121270|NCT03925909|Experimental|Eriomin 800 mg|The volunteers will receive one capsule containing 800 mg eriocitrin
11121271|NCT03925909|No Intervention|Placebo|The volunteers will receive a capsule containing corn starch (placebo)
11121272|NCT03925896|Experimental|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
11121273|NCT03925883|Active Comparator|Patient Navigation|Patients randomized to this arm will receive patient navigation with the goal of completing a follow-up colonoscopy within 12 months of a positive FIT result.
11121274|NCT03925883|No Intervention|Usual Care|Patients will receive usual care screening opportunities
11121275|NCT03925870|Experimental|KN046 monotherapy|Eligible subjects will be enrolled and receive KN046 monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first.
11121276|NCT03925857|Experimental|Allocetra-OTS|Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
11121277|NCT03925857|Experimental|Allocetra-OTS Two doses|Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg
11121278|NCT03925818|Experimental|B.I.D. TMPPI + Lactobacillus-10|pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
11121279|NCT03925818|Active Comparator|B.I.D. Bismuth|pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days
11121280|NCT03925805||Chronic disease|Cardiovascular disease (including diabetes), mental disease, musculoskeletal disease
11121281|NCT03925792|Experimental|Treatment Group|Lifestyle Medicine Group 1
11121282|NCT03925792|Experimental|Waitlist Control Group|Lifestyle Medicine Group 2
11121283|NCT03925779|Active Comparator|(Dexmedetomidine)Dex group|The patients will be administered a loading dose of i.v. dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h, titrated according to the sedation score, till the end of the procedure
11121284|NCT03925779|Active Comparator|Propofol-Remifentanil (P-R) group|Propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute then and 0.01-0.1 μg kg/min.
11121285|NCT03925740|Experimental|MI Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
11121286|NCT03925740|Experimental|PreviDent Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
11121287|NCT03925740|Active Comparator|1.23% APF Control Group|Regular application of APF for 4 minutes with high volume suction to the whole mouth.
11121288|NCT03925727|Experimental|1% tavilermide ophthalmic solution|
11121289|NCT03925727|Experimental|5% tavilermide ophthalmic solution|
11121290|NCT03925727|Placebo Comparator|Vehicle ophthalmic solution|
11121291|NCT03925714|Other|life style|life style control only
11121292|NCT03925714|Active Comparator|Metformin|Metformin 500 mg twice daily
11121293|NCT03925714|Experimental|Nigetella salivata|NS 450 mg twice daily
11121294|NCT03925701|Experimental|vildagliptin|vildagliptin 50 mg twice daily
11121295|NCT03925701|Active Comparator|vildagliptin\metformin|vildagliptin\metformin twice daily
11121296|NCT03925688||without heterotopic ossification|There had not existed radiographic evidences of heterotopic ossification.
11121297|NCT03925688||with heterotopic ossification|There had existed radiographic evidences of heterotopic ossification or formatted ectopic lamellar bone.
11121298|NCT03925675|Experimental|Axumin (fluciclovine-F18) PET/CT scan|Axumin (fluciclovine-F18) PET/CT scan to evaluate possible glioma recurrence to help differentiate scar (fake recurrence) from true tumor recurrence
11121299|NCT03925662|Active Comparator|Folfox with avastin|Folfox with avastin only
11121300|NCT03925662|Experimental|Mebendazole|Folfox with avastin with mebendazole
11121301|NCT03925636|Experimental|Dietary therapy for C. difficile colonization|Dietary therapy intervention for this arm is the Specific Carbohydrate Diet.
11121302|NCT03925623||Commercial closure system|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with a standard two piece push and turn cap and asked to open this during 2 five minute trials.
11121303|NCT03925623||Physically based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped a novel closure that was designed using anthropometric data such that it disallows children from engaging the system and enables adults. Children will be asked to open this during 2 five minute trials.
11121304|NCT03925623||Cognitively based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with the design feature that was introduced as part of the physical intervention (above); however, this treatment is sized such that children should be able to engage it (if they understand how). In having these three treatments, we began to evaluate the paradigm which enables the design to work. (Do they fail to understand how?- Cognitive treatment fail- and or Can they not effectively manipulate the closure? --- Physical failure).
11121305|NCT03925610||Morbidly obese patients with moderate-to-severe OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.
~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.
~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).
~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
11121306|NCT03925610||Morbidly obese patients with no or mild OSA|"Morbidly obese patients recovering from general anesthesia after weight loss surgery (gastric bypass and sleeve placement) surgery.
~All patients will undergo preoperative and postoperative continuous transcutaneous and intermittent arterial blood PCO2 monitoring.
~Sedation depth and pain assessment will be performed in the post-anesthesia care unit (PACU). Fentanyl only will be administered during surgery and in PACU to provide analgesia (verbal numerical score ≤ 3).
~A total of 9, 10-mL blood samples (including a preoperative blank sample) will be obtained throughout the study period (1 preoperatively, 4 intraoperatively and 4 in the PACU) to measure fentanyl concentration in the plasma. Five 1-mL samples will be used to determine arterial PCO2."
11121307|NCT03925584|Experimental|Music Therapy|Implement standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.
11121308|NCT03925571|Experimental|music-listening group|patient will listen to music during the dental surgery (1 to 1h30 hours).
11121309|NCT03925571|No Intervention|non music-listening group|patient will receive their dental intervention without music-listening.
11121310|NCT03925558|Active Comparator|Probiotic formula|Lactobacillus strains
11121311|NCT03925558|Placebo Comparator|Placebo formula|Placebo
11121312|NCT03925532|Experimental|Supportive Care (denosumab)|Patients receive 2 doses of denosumab SC between days 70-130 and days 250-310 after allogeneic hematopoietic stem cell transplant in the absence of disease progression or unacceptable toxicity.
11121313|NCT03925519||non-obese|non-obese diabetic patients (n= 25, BMI ≤ 30 kg/m2) were subjected to supervised aerobic exercise
11121314|NCT03925519||obese group|obese diabetic group (n= 25, BMI ≥ 30 kg/m2)
11121315|NCT03925493|No Intervention|Control Group Procedures (RPE based exercise)|Patients in the control group will follow standard exercise prescription protocols in CR. Exercise intensity will be guided by the patient's reported rating of perceived exertion (RPE). The modified Borg scale will be used by the patients to determine their RPE. Therefore, a scale of 1-10 will be used. The general goal will be to exercise between intensity level 3 or 4 (i.e. moderate intensity), per current program standards. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise as appropriate. Exercise progression will be guided by RPE and clinical assessment.
11121316|NCT03925493|Experimental|Exercise Test and Heart Rate Range|Patients randomly assigned to this group will complete a graded exercise test (GXT) per standard protocols. The researchers will obtain the patients peak heart rate from this stress test. Obtaining an accurate peak heart rate will allow for the calculation of a target heart rate range (THRR) using the Karvonen formula. Based upon the Karvonen formula, the THRR will be between 60-80% of the patient's heart rate reserve. The Karvonen formula can be calculated as follows ((peak heart rate - resting heart rate) X % intensity (0.6 or 0.8) + resting heart rate)). An example would be: (155 -75) X (.6) + 75) = 123; ((155 - 75) X (.8) + 75 = 139) THRR: 123 - 139. Patients will then adjust their exercise intensity to match this target heart rate range for the duration of their time in cardiac rehabilitation. Cardiac rehabilitation staff will provide feedback about heart rate when they are able.
11121317|NCT03925493|Experimental|Exercise Test, Heart Rate Range, and Heart Rate Monitor|"Patients randomly assigned to this group will also undergo a stress test (GXT) and exercise within a target heart rate range (THRR) during cardiac rehabilitation comparable to second arm of the trial. Additionally, they will receive a personal heart rate monitor (HRM). This monitor will consist of a polar heart rate chest strap and polar watch. Patients will be asked to wear this during cardiac rehabilitation and adjust their own exercise intensity. This will provide continuous feedback to the patient about their heart rate. Cardiac rehabilitation staff will also provide feedback when available.
~The investigators are using the heart rate monitors because cardiac rehab staff are not always able to adjust exercise intensity for all patients, and telemetry is not always used."
11121318|NCT03925480|Experimental|Azithromycin|A single 2g dose of Azithromycin
11121319|NCT03925480|Placebo Comparator|Placebo|Matching Placebo
11121320|NCT03925467|Experimental|proximal acupoints|Acupuncture needles will be administered at proximal acupoints
11121321|NCT03925467|Experimental|distal acupoints|Acupuncture needles will be administered at distal acupoints
11121322|NCT03925467|Placebo Comparator|sham acupoints|Sham acupuncture needles will be administered in the abdominal sham acupoints.
11121627|NCT03923218||Smoker patients with chronic periodontitis|Smoker patients with chronic periodontitis
11121323|NCT03925454||In-Centre Haemodiafiltration (ICHDF) Group|Participants undergoing ICHDF treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
11121324|NCT03925454||Home HaemoDialysis (HHD) Group|Participants undergoing HHD treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
11121325|NCT03925441||Pediatric participants with chronic severe plaque psoriasis|Participants with chronic severe plaque psoriasis receiving adalimumab in routine clinical practice
11121326|NCT03925428|Experimental|Treatment (entinostat, molibresib)|Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11121327|NCT03925402||Ertapenem|Patients who received ertapenem as an empirical antibiotic
11121328|NCT03925402||Other carbapenems|Patients who received carbapenems other than ertapenem as an empirical antibiotic
11121329|NCT03925363|Active Comparator|Active|Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
11121330|NCT03925363|Sham Comparator|Control|Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
11121331|NCT03925350|Experimental|Niraparib|Patients receive niraparib PO daily
11121332|NCT03925337|Experimental|Arm-1 Standard Colonoscopy/AI-Assisted Combined Colonoscopy|Normal scope insertion and withdrawal first, followed by a second withdrawal with the research software running on a separate screen to catch any additional polyps missed during the first withdrawal.
11121333|NCT03925337|Experimental|Arm-2 AI-Assisted Combined Colonoscopy/Standard Colonoscopy|Normal scope insertion but first withdrawal with the research software running on a separate screen, followed by a second withdrawal without the research software running.
11121334|NCT03925324|Experimental|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.
11121335|NCT03925324|Placebo Comparator|Placebo|Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.
11121336|NCT03925298||group 1|participants with elevated serum troponin level (≥0.01μg/L)
11121337|NCT03925298||group 2|those with normal serum troponin level (<0.01μg/L)
11121338|NCT03925285|Experimental|IV fluorescent tracer bevacizumab-800CW|Patients will be administered with 10 or 25 bevacizumab-800CW.
11121339|NCT03925272|Experimental|Patients with Suppurated Hidradenitis|"Human biological samples :
~Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions.
~bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)"
11121340|NCT03925272|Experimental|Patients with Alzheimer disease|"Human biological samples :
~stool, blood (20 ml)
~bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test"
11121341|NCT03925272|Experimental|Patients with familial adenomatous polyposis|"Human biological samples :
~whole blood (30 to 100 mL), optional stool collection
~bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation"
11121342|NCT03925272|Experimental|Patients with chronic inflammatory diseases (SPA, Crohn, ...)|"Human biological samples :
~whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears
~Bio-clinical data :
~Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress."
11121343|NCT03925272|Experimental|Healthy cases|"Human biological samples :
~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions
~Bio-clinical data :
~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
11121344|NCT03925272|Experimental|Healthy cases relatives|"Human biological samples :
~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions
~Bio-clinical data :
~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
11121345|NCT03925259|Active Comparator|Full-ACT|Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of eight modules in the Full-ACT arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all eight mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; self-as-context; values; and committed action.
11121372|NCT03925077|Active Comparator|Standardised Exercise Training (SET)|All M2M sessions are delivered using videos uploaded to the SCIPE website. Participants in SET will have access to the website and attend three 60-minute SET sessions per week for a total of 8 weeks. Each session provides traditional exercises that target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
11121531|NCT03923972||heads of Nephrology departments|Medical and/or administrative directors of e nephrology department with knowledge of the healthcare system in their country
11121346|NCT03925259|Experimental|ACT-SAC|"Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of seven modules in the ACT-SAC arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; values; and committed action.
~The ACT-SAC condition removed the self-as-context module; therapists were instructed to avoid any reference to self-as-context or to support discussions regarding this process."
11121347|NCT03925246|Experimental|Nivolumab|Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 weeks for 8 doses (4 months), followed by a 60 minutes intravenous infusion at dose of 480 mg every 4 weeks for 8 doses (8 months) or until progression, death , unacceptable toxicity or end of the research.
11121348|NCT03925233||HER2+ Breast Cancer|
11121349|NCT03925233||ER+ Breast Cancer|
11121350|NCT03925233||Triple Negative Breast Cancer|
11121351|NCT03925220|Experimental|Substance Use Prevention Intervention|Parents will be given a handbook specific to the gender of their child that provides information and advice communication and substance use prevention. Parents will then participate in a one-hour session with an interventionist where the main points in the handbook will be reviewed and they will fill out an action plan on how to make changes in communication about substances with their child. The interventionist will also provide parents with a referral packet. Two weeks after the in-person session, participants will have a half-hour follow-up phone call with the same study interventionist. For the home-based component, parents will receive two messages each week with reminders and tips that reinforce the information covered in the handbook. Finally, participants will receive a magnet about the importance of family meals that they will be instructed to put on their refrigerators.
11121352|NCT03925220|Active Comparator|Nutrition, Physical Activity, and Weight Talk Comparison|"For the comparison condition, after the baseline assessment, parents will receive a handbook on nutrition and physical activity entitled: Healthy Eating & Physical Activity Across Your Lifespan: Helping your Child - Tips for Parents. This handbook, which is adapted from the handbook developed by the National Institute of Diabetes and Digestive and Kidney Diseases and the Weight Control Information Network, is approximately the same length as the intervention handbook and is available in English and Spanish. It is given with an insert on reducing weight talk and weight teasing in the family. Parents will also receive a magnet with a message about nutrition and exercise. To control for contact time, these participants will meet in person with a study staff member two weeks after receiving the handbook, complete an action plan, and have the 30-minute call, as well as receive two text messages twice per week for 13 weeks with tips and reminders from the comparison handbook and insert."
11121353|NCT03925194|Experimental|Anakinra|
11121354|NCT03925194|Placebo Comparator|Placebo|
11121355|NCT03925181|Experimental|Intervention|Recovery counselling group.
11121356|NCT03925181|No Intervention|Waitlist control|Waitlist control group. Will receive intervention after arm one is complete.
11121357|NCT03925168|Experimental|Experimental|Music therapy
11121358|NCT03925168|No Intervention|Control|No music therapy
11121359|NCT03925155|Experimental|Chlorhexidine gluconate vaginal scrub|Use of chlorhexidine 4% vaginal scrub instead of current standard of care 10% povidone iodine vaginal scrub for cesarean sections
11121360|NCT03925155|Active Comparator|Povidone-iodine vaginal scrub|Current standard of care 10% povidone iodine vaginal scrub for cesarean sections
11121361|NCT03925142|Active Comparator|Controlled healthy vegetarian diet|Subjects will be randomized and assigned to consume the controlled Healthy Vegetarian Eeating Pattern for 5 weeks.
11121362|NCT03925142|Experimental|Controlled beef diet|Subjects will be randomized and assigned to consume the beef diet for 5 weeks, which will substitute predominantly starchy vegetables and refined grains with 6 oz. of lean unprocessed beef/day.
11121363|NCT03925129|Experimental|TENS|
11121364|NCT03925129|Sham Comparator|Sham TENS|
11121365|NCT03925116|No Intervention|usual care|"women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.
~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
11121366|NCT03925116|Experimental|Contraceptive pathway|"Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:
~collect relevant medical history
~provide educational material on birth control options
~provide a link to bedsider.com for further information
~They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.
~Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation."
11121367|NCT03925103|Experimental|3D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a three-dimensional display system
11121368|NCT03925103|Active Comparator|2D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a two-dimensional display system
11121369|NCT03925090|Experimental|Neoadjuvant and Adjuvant Toripalimab+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT Other Names:anti-PD-1 antibody, JS001
11121370|NCT03925090|Placebo Comparator|Neoadjuvant and Adjuvant Placebo+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: placebo placebo 240mg every 2 weeks with a total of 2 cycles as neoadjuvant treatment; placebo 240mg every 3 weeks with a total of 8 cycles as adjuvant treatment 2 weeks after CCRT.
11121371|NCT03925077|Active Comparator|Movement to Music (M2M)|All M2M sessions are delivered using videos uploaded to a secure study website (the SCIPE website). Participants in M2M will have access to the website and attend three 60-minute M2M sessions per week for a total of 8 weeks. Each session provides rhythmic-based exercises that are choreographed to music to target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
11121402|NCT03924908|Experimental|VRH|Virtual reality hypnosis
11121373|NCT03925077|No Intervention|Attention Control (AC)|Participants in AC will not have access to any exercise videos. They will have access to the weekly educational articles on health and fitness, same as the ones received by the M2M and SET groups, through the SCIPE website.
11121374|NCT03925064||Diabetic pregnancies|Pregnant women with pregestational or gestational diabetes mellitus
11121375|NCT03925064||non-diabetic pregnancies|Pregnant women without pregestational or gestational diabetes mellitus
11121376|NCT03925051|Experimental|CMAB807|60mg by subcutaneous injection once on the first day.
11121377|NCT03925051|Active Comparator|Prolia®|60mg by subcutaneous injection once on the first day.
11121378|NCT03925038|Active Comparator|Treatment as Usual|Participants will receive psychotherapy (treatment as usual).
11121379|NCT03925038|Experimental|Augmented Care|Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
11121380|NCT03925025|No Intervention|Control|Standard therapy
11121381|NCT03925025|Active Comparator|Magnesium sulfate|Standard therapy plus magnesium sulfate
11121382|NCT03925025|Active Comparator|Nimodipine|Standard therapy plus nimodipine
11121383|NCT03925012|Experimental|Intervention|Child participants will attend the healthy lifestyle summer program for 4 weeks, five days per week. The summer intervention will include daily one-hour nutrition education, one-hour behavioral counseling, and 3 one-hour exercise sessions. These physical activities include flexibility, games, traditional fitness, and dancing. Counseling and school psychology students, registered dietitian/nutrition educators, and fitness specialists will lead the respective sessions. Parental guardians will participate in a two-hour weekly parental sessions that involve: 1)nutrition education with cooking demonstrations of healthy recipes; 2)behavioral counseling to learn effective parenting strategies on how to support their child's healthy nutrition and exercise habits and goals; and 3)exercise sessions where parents will engage in different physical activities and will receive fitness tips on how to promote an active lifestyle for the entire family.
11121384|NCT03924999|Experimental|Combined decongestive treatment & Combined exercise|"Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 5 days a week, for 6 weeks (totally, 30 sessions).
~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
11121385|NCT03924999|Experimental|Intermittent pneumatic compression & Combined exercise|"Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
11121386|NCT03924999|Active Comparator|Combined exercise|All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
11121387|NCT03924986|Experimental|Tislelizumab combined with Gemcitabine Plus Cisplatin|"Tislelizumab will be administered once every 3 weeks (Q3W)
~Gemcitabine on Day 1, Day 8 of each 3 week cycle, for 4 to 6 cycles
~Cisplatin on Day 1 of each 3 week cycle, for 4 to 6 cycles"
11121388|NCT03924986|Placebo Comparator|Placebo combined with Gemcitabine Plus Cisplatin|"Placebo will be administered once every 3 weeks (Q3W)
~Gemcitabine on Day 1, Day 8 of 3 week each cycle, for 4 to 6 cycles
~Cisplatin on Day 1 of 3 week each cycle, for 4 to 6 cycles"
11121389|NCT03924973|Experimental|Experimental group|"Children below the age of 3 in this group received 2 years of ESDM intervention for 12 hours per week, and then treatment as usual for the 3 following years.
~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.
~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.
~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community."
11121390|NCT03924973|Other|Control group|"Children in this group received treatment as usual delivered in the community for the 2 years of IDEA.
~Participants will still receive treatment as usual delivered in the community during IDEA-2, in the 3 years following IDEA."
11121391|NCT03924960|Experimental|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
11121392|NCT03924960|Active Comparator|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
11121393|NCT03924960|Other|Control|Usual care control group
11121394|NCT03924947|Experimental|Arm A|Participants will receive Pancrelipase delayed release (DR) Capsules manufactured by modernized process uniform coated pellets (MP) in treatment period 1, followed by currently marketed Pancrelipase DR Capsules in treatment period 2.
11121395|NCT03924947|Experimental|Arm B|Participants will receive currently marketed Pancrelipase delayed release (DR) Capsules in treatment period 1, followed by Pancrelipase DR Capsules manufactured by modernized process uniform coated pellets (MP) in treatment period 2.
11121396|NCT03924934||Possible CA-CRE|Patients with suspected CA-CRE, discharged home after a previous hospitalization or outpatient visit during which CA-CRE was isolated from a clinical culture (approximately 210 patients)
11121397|NCT03924934||HA-CRE|Hospitalized patients with healthcare-associated CRE, who are not discharged home (HA-CRE) (210 selected control patients)
11121398|NCT03924934||HA-CRE discharged home|Patients eventually discharged home, either directly or through another facility, after a hospitalization during which HA-CRE was isolated from a clinical culture (100)
11121399|NCT03924934||Community contacts|Contacts of patients with CRE (approximately 1,500)
11121400|NCT03924921|Experimental|autogenic training|Autogenic training
11121401|NCT03924921|Experimental|wait list|usual care for 6 months Autogenic training after 6 months
11121404|NCT03924895|Experimental|Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
11121405|NCT03924895|Active Comparator|Surgery alone|Participants receive standard of care surgery alone.
11121406|NCT03924895|Experimental|Enfortumab Vedotin + Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.
11121407|NCT03924869|Experimental|SBRT+Pembolizumab|Participants receive SBRT once every 3 days for 3-5 fractions (dependent on tumor type/location; 45-54 Gray [Gy] total) over approximately 2 weeks PLUS pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
11121408|NCT03924869|Placebo Comparator|SBRT+Placebo|Participants receive SBRT once every 3 days for 3-5 fractions (dependent on tumor type/location; 45-54 Gy total) over approximately 2 weeks PLUS placebo (normal saline solution) via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
11121409|NCT03924856|Experimental|Pembrolizumab + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.
11121410|NCT03924856|Placebo Comparator|Placebo + Gemcitabine + Cisplatin + Surgery|Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.
11121411|NCT03924830|Active Comparator|Bulk without Surface Sealant|53 teeth will receive restorations using Bulk fill restoration without surface sealant
11121412|NCT03924830|Experimental|Bulk with Biscover|53 teeth will receive restorations using Bulk fill restoration with Biscover surface sealant
11121413|NCT03924830|Experimental|Bulk with Permaseal|53 teeth will receive restorations using Bulk fill restoration with Permaseal surface sealant
11121414|NCT03924804|Experimental|Group A: 2 ml/kg group|
11121415|NCT03924804|Experimental|Group B: 8 ml/kg group|
11121416|NCT03924804|Experimental|Group C: 16 ml/kg group|
11121417|NCT03924791|Experimental|Transforaminal Epidural Injection|Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3
11121418|NCT03924791|No Intervention|Oral pain medication|Patients will receive oral pain medication according to general practitioner guidelines.
11121419|NCT03924778|Experimental|DASH diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber
11121420|NCT03924778|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber
11121421|NCT03924765|Experimental|Healthy individuals using powered exoskeleton|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
11121422|NCT03924752|Experimental|Healthy individuals using powered exoskeleton|This study will be conducted on a sample population of able-bodied subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
11121423|NCT03924739|Experimental|Intervention group|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model.
11121424|NCT03924739|No Intervention|Control group|The control group will receive the conventional care provided by the study hospital.
11121425|NCT03924726|Other|Control and experimental (4 weeks MOP)|This is a split mouth study. At the experimental site in group 1, three Micro-osteoperforation (MOP) were made directly at the buccal cortical bone of extracted first premolars sites, at equidistance from the canine and second premolar under local anaesthesia. This group received four sessions of MOPs at an interval of 4 weeks.
11121426|NCT03924726|Other|Control and experimental ( 8 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.
11121427|NCT03924726|Other|Control and experimental (12 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 12 weeks.
11121428|NCT03924713||Community Health Worker|"initial comprehensive health, behavioral, and social needs assessment;
~development of an individualized 'action plan' to address identified needs;
~linkage to necessary services and work with neighborhood-based health care and social services organization to address each individual's unique needs; and 4) provide follow-up support as needed."
11121429|NCT03924713||Usual Health Plan Services|1) receipt of other plan services besides the CHW program for which they are eligible.
11121430|NCT03924700|Experimental|Biportal endoscopic discectomy|Biportal endoscopic discectomy for lumbar herniated intervertebral disc
11121431|NCT03924700|Active Comparator|Microdiscectomy|Microdiscectomy for lumbar herniated intervertebral disc
11121432|NCT03924687|Experimental|ACT group|ACT group: participants receiving the 8-week bibliotherapy intervention based on Acceptance and Commitment Therapy
11121433|NCT03924687|No Intervention|control group|Wait-list control condition: participants placed on a wait-list (and receiving the intervention following the 9 week duration of the intervention)
11121434|NCT03924674|Active Comparator|Stepped Wedge Group 1: Sept. 2019 Launch|"Interventions will include:
~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF
~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;
~Tools to promote discussion about timing and necessity of routine lab draws
~Education and feedback for physicians regarding costs and harms of routine lab testing"
11121435|NCT03924674|Active Comparator|Stepped Wedge Group 2: Nov. 2019 Launch|"Interventions will include:
~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF
~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;
~Tools to promote discussion about timing and necessity of routine lab draws
~Education and feedback for physicians regarding costs and harms of routine lab testing"
11121532|NCT03923959|Active Comparator|Intervention|100 cc normal saline with 1g of tranexamic acid in solution
11121533|NCT03923959|Placebo Comparator|Placebo|100 cc normal saline
11121436|NCT03924674|Active Comparator|Stepped Wedge Group 3: Jan. 2020 Launch|"Interventions will include:
~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF
~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;
~Tools to promote discussion about timing and necessity of routine lab draws
~Education and feedback for physicians regarding costs and harms of routine lab testing"
11121437|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
11121438|NCT03924648||premature ovarian insufficiency|Idiopatic premature ovarian insufficiency (POI), defined as loss of ovarian function and subsequent amenorrhea before the age of 40.
11121439|NCT03924648||Control|The investigators compared patients with POI to a cohort of age matched healthy controls recruited among women who visited the gynecology clinic for routine examination or from hospital workers. All volunteers for the control group had regular menstrual cycles and no concomitant health problems.
11121440|NCT03924635|Active Comparator|Symbicort® as maintenance and reliever treatment|Patients on low dose ICS/LABA prior to study entry (per GINA 2018 guidelines) will receive Symbicort® (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on medium dose ICS/LABA prior to study entry (per GINA 2018 guidelines) will receive Symbicort® (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
11121441|NCT03924635|Active Comparator|Symbicort® as maintenance, salbutamol as reliever treatment|Patients on low dose ICS/LABA prior to study entry (per GINA 2018 guidelines) will receive Symbicort® (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on medium dose ICS/LABA prior to study entry (per GINA 2018 guidelines) will receive Symbicort® (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
11121442|NCT03924622|Experimental|Group 1: Mepilex on Litter + AE Mattress + 30 degree backrest|Intervention: Mepilex
11121443|NCT03924622|No Intervention|Group 2: Without Mepilex on Litter + AE mattress + backrest|Intervention: Control (no Mepilex)
11121444|NCT03924622|Experimental|Group 3: Mepilex on VSB on AE mattress|Intervention: Mepilex
11121445|NCT03924622|No Intervention|Group 4: Without Mepilex on VSB on AE mattress|Intervention: Control (no Mepilex)
11121446|NCT03924622|Experimental|Group 5 Prolonged Field Care (PFC) - LiquiCell on Talon litter|Intervention: LiquiCell mat
11121447|NCT03924622|No Intervention|Group 6: PFC Without LiquiCell on Talon Litter|Intervention: Control (no LiquiCell)
11121448|NCT03924609||Bone metastasis screening|The information about bone metastasis screening is retrospectively collected.
11121449|NCT03924596|Experimental|Luban Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
11121450|NCT03924596|Active Comparator|Uralyt-U Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)
11121451|NCT03924596|Experimental|Luban Uric acid|25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
11121452|NCT03924596|Active Comparator|Uralyt-U Uric acid|25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2
11121453|NCT03924570|Experimental|Intervention|This arm will receive training in the use of the IPASS package to improve communications during hands off.
11121454|NCT03924570|No Intervention|Control|Until randomization this arm will continue running hands offs per usual care.
11121455|NCT03924557|Active Comparator|Genotyping Intervention Supportive Care|For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
11121456|NCT03924557|No Intervention|Delayed Genotyping Intervention Supportive Care|For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
11121457|NCT03924544|Experimental|Decorin Group|26 patients will receive subconjunctival injection of 100 µg decorin 15 minutes before surgery, 1, 3, and 7postoperatively. A30-gauge needle was used to inject 100 µL of decorin. The needle was placed at the nasal margin of the superior rectus muscle
11121458|NCT03924544|Active Comparator|Mitomycin Group|MMC will then be applied in 26 patients to the sclera at a concentration of 0.3 mg/ml using cellulose sponges, which will be removed after 3 minutes followed by copious irrigation with balanced saline solution (BSS).
11121459|NCT03924531|Experimental|Mindful Awareness Program|The group that received mindfulness training.
11121460|NCT03924531|Active Comparator|Health Promotion Program|The group that received the health information.
11121461|NCT03924518|Experimental|granisetron group|3ml granisetron（3mg） will be diluted in 22 mL of 0.9% normal saline,and the granisetron diluted will be intravenously injected for at 10 minutes， every 8 hours for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
11121462|NCT03924518|Placebo Comparator|placebo group|Normal saline 25ml every 8h for 4 days or until leaving the ICU(death or transfer from ICU to general ward or discharge), whichever come first.
11121463|NCT03924505|Experimental|Implementation Manual and External Facilitation|This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.
11121464|NCT03924505|Active Comparator|Implementation Manual - only|This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.
11121534|NCT03923946|Experimental|Intervention|Compassionate Imagery Intervention- up to three 1:1 sessions, up to one hour each with the primary researcher
11121535|NCT03923946|No Intervention|Control|Treatment as usual arm
11121465|NCT03924479|Experimental|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
11121466|NCT03924479|Sham Comparator|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
11121467|NCT03924453||Pearl Powered by Proov|Participants are given hormone tests strips and a digital app and all instructions for use, collectively called the Pearl Power by Proov kit. The app will analyze hormonal test strip information to predict and confirm ovulation
11121468|NCT03924440||PDG Test strip Users|"Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence).
~Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered their tests and recorded their results. Test results were reported back researchers via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip."
11121469|NCT03924427|Experimental|BMS-986165|Given daily
11121470|NCT03924414|Active Comparator|Zoledronic acid (ZA)|A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes
11121471|NCT03924414|Placebo Comparator|Placebo|A single intravenous infusion of placebo infused over 45 minutes
11121472|NCT03924401|Experimental|Participants Receiving Abatacept|Pediatric participants who are undergoing 7/8 URD HSCT for serious NMHD will receive 8 doses of abatacept in addition to conventional GVHD prophylaxis.
11121473|NCT03924388|Experimental|Short-term transcutaneous spinal cord stimulation|"In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function.
~In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and ~ 70° upright (adjusted by tilt-up table)."
11121474|NCT03924388|Experimental|Long-term transcutaneous spinal cord stimulation|"In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function.
~The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and ~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly."
11121475|NCT03924388|Experimental|Project 3|For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
11121476|NCT03924362|Active Comparator|Simultaneous Bilateral PCNL|Patients undergo simultaneous bilateral PCNL.
11121477|NCT03924362|Active Comparator|Unilateral PCNL|Patients undergoing unilateral staged PCNL.
11121478|NCT03924349|Experimental|ICG clip|Three clips are fixed in three directions (120 degrees apart) at the distal of the lesion (just distal) before surgery
11121479|NCT03924336|Experimental|Advanced- platelets rich fibrin with open flap debridement|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually.Then the defects will be thoroughly debrided using curettes and ultrasonic scalers.The clinical measurements will be then recorded.After debridement and intraoperative recordings, , one PRF of the required size will be filled into the intraosseous defect, and the other will be used to prepare the membrane that will be used to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using 4-0 silk sutures
11121480|NCT03924336|Active Comparator|Open flap debridement|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually.Then the defects will be thoroughly debrided using curettes and ultrasonic scalers.The dclinical measurements will be then recorde.After debridement and intraoperative recordings, The interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
11121481|NCT03924323|Experimental|Escitalopram 10 mg/day|Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion
11121482|NCT03924323|Placebo Comparator|Placebo|Matching oral administration of placebo once daily
11121483|NCT03924310|Experimental|Arm amputees|This single arm conducts all experiments. In three out of four experiments both interventions (with feedback & without feedback) are used, the fourth experiment does not allow the intervention without feedback.
11121484|NCT03924297|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
11121485|NCT03924284||NPA positive|NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
11121486|NCT03924284||NPA negative|NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
11121487|NCT03924284||Saliva positive|Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
11121488|NCT03924284||Saliva negative|Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
11121491|NCT03924245|Experimental|Treatment (entinostat, olaparib)|Patients receive entinostat PO 1 week before starting combination therapy (day -7). Patients then receive entinostat PO on days 1, 8, 15, and 22, olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity
11121492|NCT03924219||Pediatric Solid Organ Transplant (SOT) Recipients|Pediatric patients (<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
11121493|NCT03924206||Minimally invasive surgery with smoke evacuation system (SES)|minimally invasive surgical procedures during which a smoke evacuation device is used
11121494|NCT03924206||Minimally invasive surgery without SES|minimally invasive surgical procedures during which no smoke evacuation device is used
11121495|NCT03924206||Open surgery with SES|open surgical procedures during which a smoke evacuation device is used
11121496|NCT03924206||Open surgery without SES|open surgical procedures during which no smoke evacuation device is used
11121497|NCT03924193|Active Comparator|LDX|
11121498|NCT03924193|Active Comparator|Cognitive-Behavioral Therapy|
11121499|NCT03924193|Active Comparator|LDX and Cognitive Behavioral Therapy|
11121500|NCT03924180|Experimental|GMP - Dietary Supplement for PKU patients|Glycomacropeptides -GMP Glytactin
11121501|NCT03924180|Active Comparator|Control -Amino acids mixtures|Mixtures of conventional amino acids.
11121502|NCT03924167|Experimental|Families Receiving Weaving Healthy Families Intervention|The Weaving Healthy Families curriculum is a cognitive-behavioral, support group model for high-risk families related to alcohol, tobacco, or other drugs (ATOD) and/or or domestic violence, child abuse, or neglect. This curriculum is tailored for all ages (i.e., (a) parents/caregivers; (b) early childhood (4-7); (c) children (8-10); and (d) adolescent (11-18) and is aimed at reducing alcohol and other drug (AOD) abuse, promote unity, address mental health problems, strengthen parenting skills, and bolster wellness and resilience.
11121503|NCT03924167|No Intervention|Families who have not yet receive the Weaving Healthy Families|Baseline group --data will be collected prior to receiving the intervention in this stepped-wedge trial design.
11121504|NCT03924154|Experimental|RVT-1201|RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 [Anticipated])
11121505|NCT03924154|Placebo Comparator|Placebo|Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 [Anticipated])
11121506|NCT03924141|Experimental|Third year nursing students - intervention|Third year nursing students will receive the intervention in de-escalation training
11121507|NCT03924141|No Intervention|Third year nursing students - control|Third year nursing students will receive no training in de-escalation
11121508|NCT03924115|Experimental|Group Total|This group of patients was chosen at random. They are patients who receive the full PST as intervention, that is, they receive a Smartphone with the AFAM-Health application with all the contents of the PST and data plan for 1 year.
11121509|NCT03924115|Experimental|Group Partial|This group of patients was chosen at random under the criteria of parity with group A. They are patients who receive partial PST as intervention, that is, they only receive video capsules reproduced in the CESFAM waiting room as educational content.
11121510|NCT03924115|No Intervention|Group Control|This group of patients is the control group, that is, they do not receive any type of intervention additional to the one they already receive from their CESFAM.
11121511|NCT03924102|Experimental|patients with acute decompensated systolic and diastolic heart|
11121512|NCT03924089|Experimental|Oral nutritional supplement with probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics.
~Physical activity recommendations."
11121513|NCT03924089|Experimental|Oral nutritional supplement without probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics.
~Physical activity recommendations."
11121514|NCT03924089|Active Comparator|Individualized dietary recommendations|Individualized dietary recommendations. Physical activity recommendations.
11121515|NCT03924076|Experimental|Treatment Group|Received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL) for 90 days
11121516|NCT03924076|Placebo Comparator|Placebo Group|Received UHT milk (125 mL) for 90 days
11121517|NCT03924063|Other|conservative treatment|conservative treatment with physical therapy and non steroidal anti-inflammatory drugs
11121518|NCT03924050|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
11121519|NCT03924050|Placebo Comparator|Group Placebo combined with standard chemotherapy|
11121520|NCT03924037|Active Comparator|Zero Suicide|Participants randomly assigned to the Zero Suicide arm will also participate in a weekly support group until the final follow-up time point when they will be crossed-over into the intergenerational knowledge sharing group.
11121521|NCT03924037|Experimental|Zero Suicide plus KICKS|Participants randomly assigned to the Zero Suicide plus KICKS arm will participate in a weekly intergenerational knowledge sharing group.
11121522|NCT03924024|Experimental|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
11121523|NCT03924011|Sham Comparator|Control group|Receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
11121524|NCT03924011|Experimental|Treatment group|Receives PBMT (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
11121525|NCT03923998|Experimental|Neoadjuvant chemoradiotherapy followed by surgery|Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
11121526|NCT03923985|Active Comparator|Active Arm|1 tablet / day of probiotic containing 10 Mld L. crispatus during two months
11121527|NCT03923985|No Intervention|Control Arm|No treatment
11121528|NCT03923972||Patients with chronic kidney disease|Patients with non dialysis dependent chronic kidney disease stages 4-5, patients on renal replacement therapy treated with peritoneal dialysis or hemodialysis, patients after renal transplantation
11121536|NCT03923933|Placebo Comparator|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
11121537|NCT03923933|Experimental|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
11121538|NCT03923920||Spinal Stenosis Biopsy|Biopsy of ligamentum flavum tissue during spinal stenosis surgery sent to pathology for amyloid-specific analysis
11121539|NCT03923907|Experimental|EIM group|patients with Hypertension (HT) will be recruited by a trained nurse when the patient attends the yearly to bi-yearly complication screening program called the risk assessment and management program (RAMP) program. This program is provided to all patients with HT, who are seen in the Government-funded primary care clinics in Hong Kong. The nurse will encourage the patient by motivational interviewing techniques and prescribe exercise. Combined exercise skills will be taught in the 12-week weekly exercise classes by certified physical trainers. Peer support is encouraged during and after the 12-week program. Regular feedback, prompting and problem solving will be provided by the nurse at 3m, 6m, and 12m. Exercise level will be monitored by validated wrist trackers to feedback participants, nurse and physical trainer by mobile apps and website. Resources to exercise will be made known to patients by apps, website and healthcare professionals.
11121540|NCT03923907|No Intervention|usual care|There is no extra intervention to patients allocated in this arm, except that they receive information and advice on lifestyle changes including benefits from exercise from the nurse at recruitment as stated above. Participants in both arms will have no changes in medication within the first 12-week to determine the BP difference between the two groups. In Hong Kong, patients have unlimited access to emergency department and general outpatient services. All patients with HT receive RAMP program counselling and screening every 1-2 years. These are not limited by the current trial.
11121541|NCT03923894|Experimental|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
11121542|NCT03923894|Placebo Comparator|Placebo|Placebo 2.07 g/day for 8 weeks.
11121543|NCT03923881|Experimental|Study group|Patients with oral squamous cell carcinoma that have been included in ICON-study and are scheduled for treatment of neck
11121544|NCT03923868|Experimental|dose escalation in healthy subjects|
11121545|NCT03923868|Experimental|dose escalation in hyperuricemia patients|
11121546|NCT03923855|Experimental|BTL-899 Therapy Arm|
11121547|NCT03923842|Experimental|ARM A: Denosumab Treatment|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
11121548|NCT03923842|Active Comparator|ARM B Control Arm|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for 12 months
11121549|NCT03923829|Experimental|Zinc administration with scaling and root planing|systemic administration of Zinc cap of 50 mg elemental zinc as zinc sulphate, once a day for 12 weeks in addition to scaling and root planing
11121550|NCT03923829|Active Comparator|scaling and root planing|scaling and root planing
11121551|NCT03923816|Experimental|Group (R)|Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
11121552|NCT03923816|Experimental|Group (C)|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).
11121553|NCT03923803||Chronic obstructive pulmonary disease|patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
11121554|NCT03923790|Experimental|STOP model|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet and a blue tooth enabled BP monitor with an iPad. A video telehealth visit occurs 7 days after discharge attended by a nurse practitioner (NP) or MD , social worker (SW), and pharmacist. The NP and pharmacist review the BP data to determine the need for medication adjustment. The SW assesses the need for resources. BP is reviewed via an online portal every 2 weeks until average BP is < 130/80mmHg, then monthly. Uncontrolled BP prompts a call from the pharmacist to discuss medication adherence and titration. Subsequent video telehealth visits occur 1 month, 3 months, and 5 months after enrollment.
11121555|NCT03923790|Active Comparator|Usual Care|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet.
11121556|NCT03923777|Other|Active Surveillance|Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.
11121557|NCT03923764|Experimental|Intervention group|1.3 g protein per kg bodyweight per day for 8 weeks
11121558|NCT03923764|Active Comparator|Kontrol group|habitual diet
11121559|NCT03923751||Polish Hospitals|Hospitals with anesthesia or intensive care practices
11121560|NCT03923738|Experimental|Tocilizumab|Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.
11121561|NCT03923725|Experimental|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
11121562|NCT03923725|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
11121563|NCT03923725|Experimental|Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)|Triple ACTs
11121564|NCT03923725|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs
11121592|NCT03923491|Active Comparator|Reading and Readiness|The Reading and Readiness group will receive information on school readiness promotion. Materials will be adapted and delivered by the community health worker (CHW) with a similar dose and schedule as the intervention group (three home visits and three phone calls). During the home visits, the CHW will show a video that models early childhood caregiver-child activities and demonstrates simple methods to interact with their children. They will also send a video of themselves reading with a child, receive text-messages based on these materials as well as the print materials during the last three months of the intervention.
11121565|NCT03923712|No Intervention|Control Group|Participants randomly assigned to control group will be instructed to maintain their normal life habits with respect to physical activity and diet. During the 5 months of intervention participants from this group will receive at least one call from the researchers to be interested in their health status and inform them about the next evaluation appointment, as well as, an objectively evaluation of the main behaviours in the middle of intervention. Investigators will inform about the relevance of attending the full process and respecting the condition and rule as control. Participants from the control group will be freely offered the possibility to get involve in a similar intervention protocol at the end of the study in order to benefit from the potential positive effect of exercise.
11121566|NCT03923712|Experimental|Supervised exercise programme|5 months of supervised physical exercise program. The individualized and progressive Health periodization model will be applied establishing an initial individualizing period, as well as identifying any need or adaptation to apply during the exercise program. The physical exercise program will be applied in a period of progressive increase whose initial objective will be to reach the volume and intensity established by the international recommendations of physical activity (http://www.health.gov/paguidelines/) for this population. Briefly, a volume of 150 min/week of moderate-vigorous physical activity (60% -85% reserve heart rate) spread over a maximum of 5 days and including force work 2-3 days/week. The training load will progressively increase with a wave and flexible periodization.
11121567|NCT03923699|No Intervention|Standard of care arm|Operating rooms in the standard of care group will be monitored but, the ACT clinicians will not contact the operating room unless it is clinically necessary for patient safety purposes.
11121568|NCT03923699|Experimental|Anesthesia Control Tower monitoring|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room using AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes.
11121569|NCT03923686|Experimental|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
11121570|NCT03923686|Active Comparator|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
11121571|NCT03923673|Experimental|Subjects with Heart Failure with Preserved Ejection Fraction|Subjects with Heart Failure with Preserved Ejection Fraction (HFpEF) will receive a minimally invasive treatment called a pericardiotomy.
11121572|NCT03923660|Experimental|Concentric-eccentric|Concentric-eccentric
11121573|NCT03923660|Experimental|Eccentric-concentric|Eccentric-concentric
11121574|NCT03923647||Laparoscopy and CT scan|Usage of laparoscopy after inflation of co2 infra umbilical
11121575|NCT03923634|Experimental|Princess® RICH|"Eligible subjects will be injected with Princess® RICH (this is an open-label study).
~Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids."
11121576|NCT03923621|Experimental|Experimental - EPSiT|Endoscopic Pilonidal Sinus Treatment
11121577|NCT03923621|Active Comparator|Control - excision|Excision treatment
11121578|NCT03923608||strength test|The maximum strength test of external shoulder rotators will be performed on 5 different tools with specific protocols.
11121579|NCT03923608||Endurance test|"Test designed by the Laboratory of Sports Physical Therapy (LAFIDE) of FCT / UNESP - Presidente Prudente, used in the prescription of training for gain of localized muscular endurance. Will be realized in the tools: Isokinetic dynamometer, elastic bands, pulley and halter.
~The test will consist of the maximum possible repetitions (until fatigue) with loads of 70%, 80% and 90% of the maximum force (in different sessions)."
11121580|NCT03923582|No Intervention|Ecological needs assessment|To conduct a needs assessment of sexual health care delivery in Tanzania. To determine whether midwifery, nursing, medical and allied health science students would benefit from one curriculum or separate curricula tailored by discipline. We will conduct focus groups and key informant interviews of all three groups.
11121581|NCT03923582|No Intervention|Develop a sexual health training curriculum|We will further adapt a sexual health training curriculum tailored to Tanzanian/East African/Sub-Saharan context and pilot test it and train local faculty to implement it.
11121582|NCT03923582|Placebo Comparator|To evaluate the effectiveness of the sexual health curriculum|We will conduct a randomized, controlled, single blinded trial of the curriculum against a waitlist control assessing effects on sexual health knowledge, attitudes and sexual history and counseling skills.
11121583|NCT03923569|Other|Alzheimer's Disease patients group|This group contains the 40 (anticipated) participants with a diagnosis of Alzheimer's disease
11121584|NCT03923569|Other|Healthy control group|This group contains the 40 (anticipated) age and sex -matched healthy controls
11121585|NCT03923556|Experimental|Sugammadex|Sugammadex
11121586|NCT03923556|Active Comparator|Neostigmine|Neostigmine
11121587|NCT03923530|Experimental|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
11121588|NCT03923517|Experimental|YOD caregiver|The participants will be encouraged to use RHAPSODY for four weeks. After that they will have two individual MEET sessions with experts (social worker and psychologist).
11121589|NCT03923504|Active Comparator|Physical Activity Intervention (PAI)|Tailored multi-level physical activity intervention (PAI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
11121590|NCT03923504|Active Comparator|Healthy Living Control Group|Healthy living intervention (HLI) on exercise capacity, cardiovascular and cognitive function, health-related quality of life (QOL), strength and fatigue among lymphoma and breast cancer patients undergoing active treatment with anthracycline based chemotherapy (anthra-bC).
11121591|NCT03923491|Experimental|Healthy Feeding, Healthy Eating|The experimental arm will receive three home over the first three months of the intervention.Visits will be conducted by a community health worker (CHW) trained in Motivational Interviewing. The home visits will include video-feedback on a meal; in-home cooking demonstrations; tailored text-messages, and mailed materials. During the last three months of the intervention, CHW will conduct monthly phone calls, together with mailed materials and text messages. The intervention will be tailored for families based on the child's appetitive traits and eating behaviors.
11121593|NCT03923478|Experimental|ABI-M201|"Cohort A: 1 capsule one time a day
~Cohort B: 1- 5 capsules one time a day"
11121595|NCT03923465|Active Comparator|EPP with EMD+BS|Using minimally invasive surgery, entire papilla preservation technique with the adjunctive use of amelogenins and bone substitutes
11121596|NCT03923465|Other|EPP without EMD+BS|Using minimally invasive surgery, entire papilla preservation technique without the adjunctive use of amelogenins and bone substitutes
11121597|NCT03923452|Experimental|MBSR: Mindfulness-based stress reduction|Participants will be exposed to the 9-week MBSR program, facilitated by a trained MBSR facilitator.
11121598|NCT03923452|No Intervention|WLC: Wait list Control|Participants will be asked to log their self-care activities every week.
11121599|NCT03923439|Experimental|MRI protocol|For stroke patients, the follow-up MRI (named MRI-2) after successfully recanalized thanks to thrombectomy, intravenous thrombolysis or spontaneously, will be performed between 24h and 72h after recanalization on our new Canon 3T research magnet with high gradient system. Patients will be explored for a follow-up evaluation at 3 months with a final MRI (named MRI-3) that will be performed on the Canon 3T research magnet.
11121600|NCT03923413||patients with chronic heart failure without LVAD support|patients with chronic heart failure without LVAD support
11121601|NCT03923413||patients with end-stage heart failure with LVAD support|patients with end-stage heart failure with LVAD support
11121602|NCT03923400||JI-GIST|The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
11121603|NCT03923400||G-GIST|The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
11121604|NCT03923387|Experimental|MynxGrip|MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
11121605|NCT03923387|Active Comparator|Manual compression|Manual compression hemostasis
11121606|NCT03923374||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 200 pregnant (<16weeks) mothers who have opioid use disorder and are taking buprenorphine
11121607|NCT03923374||Pregnant Mothers|Planned recruitment of 100 pregnant (>16weeks) mothers who do not have any history of opioid use disorder.
11121608|NCT03923361|Experimental|Propofol|
11121609|NCT03923348|Experimental|Leva Users|Subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.
11121610|NCT03923335||high-risk group|patients with any of the four genes hypermethylated
11121611|NCT03923335||low-risk group|patients with none of the four genes hypermethylated
11121612|NCT03923322|Experimental|Botanical Tincture|The 12-week study includes a 2-week screening, 8-week treatment, and 2-week withdrawal periods. A 2-week screening period will be used to establish the presence and persistence of trial entry criteria and train patients in the mode of data collection. Participants randomly assigned to the Botanical Tincture arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose. Participants who received Botanical Tincture during the study will be followed by a 2-week randomized withdrawal design to address the need for maintenance treatment to prevent sign or symptom recurrence. The participant will be randomly reassigned to receive either Botanical Tincture or placebo at a dosage of 2.5 ml once a day by mouth at any time during the day that they prefer.
11121613|NCT03923322|Placebo Comparator|Placebo|Participants randomly assigned to placebo arm at Week 2 will take 2.5 ml by mouth once a day at any time during the day that they choose during the 8-week treatment period.
11121614|NCT03923309||Intended rectal preservation|When rectal preservation (non-operative management or local excision) was agreed by their surgeon.
11121615|NCT03923309||Unintended rectal preservation|When rectal preservation (non-operative management or local excision) was disagreed by their surgeon.
11121616|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 13 doses
11121617|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 4 doses and 75mg intravenously of Tremelimumab every 4 weeks for up to 4 doses
11121618|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and Olaparib|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg orally of Olaparib twice a day
11121619|NCT03923257|Experimental|PRRT with 177Lu-DOTA-tyr3-OCTREOTATE|"177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.
~This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE."
11121620|NCT03923244|Experimental|cohorte 1|"Normal patient consultation schedule for cataract surgery with:
~Preoperative appointment scheduled for the patient
~Post-operative appointment 1 month before surgery No additional appointments.
~After geting consent and during the two consultations:
~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.
~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.
~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
11121621|NCT03923231||Children <5 years|Children under the age of 5 years who are receiving atazanavir as part of clinical care
11121622|NCT03923231||Children 6-11|Children aged 6-11 years who are receiving atazanavir as part of clinical care
11121623|NCT03923231||Adolescents 12-17|Adolescents aged 12-17 years who are receiving atazanavir as part of clinical care
11121624|NCT03923231||Pregnant women|Women who are at least 20 weeks gestation, who are receiving atazanavir as part of clinical care
11121628|NCT03923218||non-smoker patients with chronic periodontitis|non-smoker patients with chronic periodontitis
11121629|NCT03923218||periodontally healthy patients|periodontally healthy patients
11121630|NCT03923205|Active Comparator|Control meal|The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
11121631|NCT03923205|Active Comparator|The test meal|The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
11121632|NCT03923192||vistacam|
11121633|NCT03923192||ICDAS II|
11121634|NCT03923192||Digital radiograph|
11121635|NCT03923179|Experimental|pyrotinib+Etoposide|
11121636|NCT03923166|Experimental|pyrotinib+ capecitabine|
11121637|NCT03923153|Active Comparator|Inspiratory muscle training group|Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
11121638|NCT03923153|Sham Comparator|Sham group|Sham group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
11121639|NCT03923153|Active Comparator|High intensity Inspiratory muscle training group|High intensity Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
11121640|NCT03923140|Experimental|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
11121641|NCT03923127|Experimental|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
11121642|NCT03923114|Other|Patient group with treatment response|PET/CT imaging of patients with response to GLP-1 receptor agonist treatment
11121643|NCT03923114|Other|Patient group without treatment response|PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment
11121644|NCT03923101||Patients with Keratoconus|Aim is to include as many Keratoconus patients as possible with the intention to elucidate how the disease begins and develops during lifetime.
11121645|NCT03923088|Experimental|jacobson's progressive muscle relaxation technique|
11121646|NCT03923088|Experimental|audiovisual distraction technique|
11121647|NCT03923088|No Intervention|conventional|
11121648|NCT03923075|Active Comparator|Dexmedetomidine|"Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type body weight (Kg)/4 or body weight (Kg) X 0.25.
~THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
11121649|NCT03923075|Placebo Comparator|0.9 % saline|"Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: body weight (Kg)/4 or body weight (Kg) X 0.25 THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
11121650|NCT03923062|Experimental|G I A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
11121651|NCT03923062|Experimental|G I B(left side):will be treated by cryopeeling|left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
11121652|NCT03923062|Experimental|G II A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
11121653|NCT03923062|Experimental|G II B (left side):will be treated by tranexemic acid|left side of patient's face will be treated by tranexemic acid(cyclokapron)
11121654|NCT03923049|Other|PET/MRI|Diagnostic testing with simultaneous PET/MRI for cardiac sarcoidosis diagnosis
11121655|NCT03923036||Metastatic colorectal cancer|"The French county Calvados registry of digestive cancers will allow to identify patients with a metastatic colorectal cancer diagnosed between 2004 and 2014.
~Patients will be included if the cancer was diagnosed at the metastatic stage between 2004 and 2014 or non-metastatic before 2004 that became metastatic between 2004 and 2014 (synchronous and metachronous tumors)"
11121656|NCT03923010|Experimental|Itraconazole|Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
11121657|NCT03922997|Experimental|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
11121658|NCT03922984|Experimental|Glioblastoma Patients|Patients with histologically proven glioblastoma will undergo enhanced MRI with arterial spin labeling at weeks 0, 3, 6, 10, 18, 26, and 34 after beginning standard of care treatment.
11121659|NCT03922971|Other|National comparison|Ability to view center's rate compared with all others
11121660|NCT03922971|Other|National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1
11121661|NCT03922945|Experimental|VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-56: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily
11121662|NCT03922945|Experimental|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-12: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Weeks 13-14: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 15-56: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
11121663|NCT03922945|Placebo Comparator|Placebo|Subjects will receive placebo oral capsule, once daily for up to 56 weeks
11121664|NCT03922932||Group A: PDR|This group will consist of 25 subjects with active proliferative diabetic retinopathy (PDR) and 25 subjects with treated PDR.
11121665|NCT03922932||Group B: NPDR|This group will consist of 50 subjects with severe non-proliferative diabetic retinopathy (NPDR), 50 subjects with moderate NPDR, and 50 subjects with mild NPDR.
11121666|NCT03922932||Group ME: Macular Edema|This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.
11121667|NCT03922932||Group C: DM without Retinopathy|This group will consist of 50 subjects with diabetes mellitus (DM) who do not have retinopathy.
11121668|NCT03922932||Group D: Healthy Controls|This group will consist of 40 subjects with healthy eyes who do not have diabetes.
11121669|NCT03922919|Active Comparator|Cefotaxime or ceftriaxone group|free use of cefotaxime or ceftriaxone by the investigator
11121670|NCT03922919|Experimental|Cefotaxim group|Systematic use of cefotaxime
11121671|NCT03922906|Experimental|Motus Pure-Vu System|The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
11121672|NCT03922893||Proband|First individual in a family to consent to this protocol
11121673|NCT03922893||Family Member Participants|Family members of the proband will be approached to consent to this protocol
11121674|NCT03922880|Experimental|Advanced Uveal Melanoma|
11121675|NCT03922867|No Intervention|Control Group|Subjects with receive standard of care for management of insomnia in subjects with fibromyalgia
11121676|NCT03922867|Active Comparator|Intervention Group|Subjects will receive standard of care and additionally complete the online cognitive behavior therapy program
11121677|NCT03922854||Mobile Monitor Group|Participants are recruited to this study if they have been monitored during their labour with a monica AN 24 monitor
11121678|NCT03922841||Subjects with pleural disease|"The subject must meet all of the following inclusion criteria to participate in this study.
~Evidence of pleural disease on chest radiograph or bedside ultrasound or Computed Tomography regardless of underlying aetiology
~No age or gender restrictions
~Ability to provide informed consent"
11121679|NCT03922815|Experimental|haemodynamic parametres-guided deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to disappearance of cilliary reflex; in the case of heart rate and/or arterial blood pressure increase by 20% a rescue dose of fentanyl 0,5 mcg per kilogram of body weight will be administered
11121680|NCT03922815|Experimental|SE-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weight of fentanyl in the case of heart rate and/or arterial blood pressure increase by 20%
11121681|NCT03922815|Experimental|AoA-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weightof fentanyl in the case of increase of SPI value > delta 15
11121682|NCT03922802|Experimental|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|"May receive up to 45 minutes of AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
~Intervention: Device: AIH prior to Noninvasive spinal stimulation during gait training"
11121683|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
11121684|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with sham transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
11121685|NCT03922776|Experimental|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection
~at diagnosis, before chemotherapy (pre-CT)
~after chemotherapy (post-ct)
~Intervention : Collection of two blood samples (5mL)
~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment
~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
11121686|NCT03922763|Active Comparator|Anatomically-matched cut|
11121687|NCT03922763|Active Comparator|Cutting guide|
11121688|NCT03922750|Experimental|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
11121689|NCT03922750|Experimental|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
11121690|NCT03922750|Experimental|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
11121691|NCT03922737|Active Comparator|In-person office visit|
11121692|NCT03922737|Active Comparator|Telehealth visit with provider|
11121693|NCT03922724|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
11121694|NCT03922724|Experimental|2/IOC Arm|Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis
11121695|NCT03922724|No Intervention|3/Donor Arm|Donors for Recipients in Arm 1 or Arm 2
11121696|NCT03922711|Experimental|Pridopidine Dose 1|Dose 1 (oral capsule) for 12 weeks following 4 week dosage regimen titration period
11121697|NCT03922711|Experimental|Pridopidine Dose 2|Dose 2 for (oral capsule) for 12 weeks following 4 week dosage regimen titration period
11121698|NCT03922711|Placebo Comparator|Placebo|Matching placebo (oral capsule) for 16 weeks
11121699|NCT03922698||Case Group|Patients who undergo surgical intervention of carotid trombo-endo-arterectomy at the Department of Vascular Surgery of the IRCCS Neuromed, with specific inclusion/exclusion criteria
11121700|NCT03922685|Active Comparator|Morning sedentary arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 11:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
11121701|NCT03922685|Active Comparator|Morning exercise arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 7:20 and 11:20, 3-ml blood samples were collected at 10-min intervals.After the 11:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
11121702|NCT03922685|Active Comparator|Evening sedentary arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 23:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
11121703|NCT03922685|Active Comparator|Evening exercise arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 19:20 and 23:20, 3-ml blood samples were collected at 10-min intervals.After the 23:20 blood sample, subjects were released from MCRU.
~This arm is compared to the other three arms."
11121704|NCT03922672|Experimental|Piano group|This group will consist of the adult with Parkinson's disease and their caregiver for a total of 14 pairs.
11121705|NCT03922659|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
11121706|NCT03922659|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
11121707|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
11121708|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
11121709|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
11121710|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
11121711|NCT03922646|Experimental|NEAT Active Experimental Group|People in the active group will receive NEAT intervention
11121712|NCT03922646|Active Comparator|Control Group|People in the control group will receive non-essential regularly-scheduled programming (active control) coinciding with the same timeframe
11121713|NCT03922633|Experimental|Cohort 1 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121714|NCT03922633|Experimental|Cohort 1 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121715|NCT03922633|Experimental|Cohort 2 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121716|NCT03922633|Experimental|Cohort 2 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121717|NCT03922633|Experimental|Cohort 3 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121718|NCT03922633|Experimental|Cohort 3 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121719|NCT03922633|Experimental|Cohort 4 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121720|NCT03922633|Experimental|Cohort 4 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121721|NCT03922633|Experimental|Cohort 5 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121722|NCT03922633|Experimental|Cohort 5 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
11121723|NCT03922620|Experimental|Liposomal Bupivacaine Group|No peripheral nerve block will be given. Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area.
11121724|NCT03922620|Active Comparator|Peripheral Nerve Block Group|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block). No local analgesic agent infiltration
11121725|NCT03922607|Experimental|Substudy 1: Group 1|Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14
11121726|NCT03922607|Experimental|Substudy 1: Group 2|Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14
11121727|NCT03922607|Experimental|Substudy 1: Group 3|Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14
11121728|NCT03922607|Experimental|Substudy 2: Group 1|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28
11121729|NCT03922607|Experimental|Substudy 2: Group 2|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28
11121730|NCT03922594||Cameroon|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
11121731|NCT03922594||China|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
11121732|NCT03922594||Ivory Coast|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex and severely disproportionate length or weight according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
11121733|NCT03922594||Sri Lanka|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
11121734|NCT03922594||Vietnam|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
11121735|NCT03922581|Experimental|Mindfulness-Based Cognitive Therapy|Participants randomized to this study arm will receive Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks.
11121736|NCT03922581|No Intervention|Wait-list Control Group|Participants randomized to the wait-list control study arm will be administered the study assessments while not receiving active treatment. Participants will be given the opportunity to participate in the MBCT intervention following completion of the study assessments.
11121737|NCT03922568||Density Gradient Centrifugation (DGC)|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
11121738|NCT03922568||Physiological ICSI (PICSI)|Semen processing is done by double layer DGC method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
11121739|NCT03922568||Magnetic Activated Cell Sorting (MACS)|Semen processing is done by double layer DGC method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
11121740|NCT03922555|Experimental|ASTX727 (Cedazuridine + Cytidine Antimetabolite Decitabine)|-ASTX727 administered orally for 5 or 6 consecutive days every 28d cycle and will de-escalate to 4 consecutive days every 28 d cycle.
11121741|NCT03922555|Experimental|Expansion Cohort|"Oral ASTX727 will be administered daily for 4, 5 or 6 consecutive days
~Surgical resection will take place 12 days (+/- 1 day) after initiation of treatment"
11121742|NCT03922542|Active Comparator|Accelerated|Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
11121743|NCT03922542|Active Comparator|Standard|Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
11121744|NCT03922529|Active Comparator|Standard of Care|Care after an acute heart event will be at the discretion of the participants clinical providers.
11121745|NCT03922529|Experimental|MACRO|Research staff will provided personalized engagement, de-prescribing, and explicitly facilitate enrollment into Cardiac Rehabilitation with risk assessment placement to determined the best fit of a flexible range of options of cardiac rehab (site-, home, or hybrid).
11121746|NCT03922516|Other|Reporting order: Plain Film - ULDCT|"The plain film of half the participants (randomized) will be submitted for reporting by a radiologist as a first imaging method. After finishing this report, the same radiologist will assess the ULDCT of this participant. In this second report, the findings of both examinations will be summarized, and a second report will be filed.
~Emergency physicians will first receive the report for the plain film of the chest and will be asked for the diagnosis and its probability. Next, the report for ULDCT will be presented to them. Again, diagnosis and probabilities will be documented."
11121747|NCT03922516|Other|Reporting order: ULDCT - Plain Film|"For half the participants (randomized) radiologists will first receive the data from ULDCT of the chest and write a report. Subsequently, they will receive the data from the plain film of the chest and may expand their report (explicitly separated).
~Emergency physicians will first receive the report for the ULDCT of the chest and will be asked for probabilities of the nine most frequent diagnoses in chest-imaging plus other. Next, they will be presented with the report for the plain film and will again be asked to give an estimation of the probabilities for the same diagnoses as before."
11121748|NCT03922503|Experimental|Advanced- platelets rich fibrin with DFDBA|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
11121749|NCT03922503|Active Comparator|Collagen membrane and DFDBA|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
11121750|NCT03922490|Experimental|Knee Arthroscopy + Adipose Derived Stem Cells (ADSC)|Experimental Group: will undergo diagnostic knee arthroscopy with injection of adipose derived stem cells. Will also carry out all procedures associated with study (Physical Exam, Magnetic Resonance Imaging (MRIs), X-rays, Questionnaires).
11121751|NCT03922490|Other|Observation Cohort: Knee Arthroscopy|Observational Group: will undergo diagnostic knee arthscropy (No injection of adipose derived stem cells). Will also carry out all procedures associated with study (Physical Exam, MRIs, X-rays, Questionnaires).
11121787|NCT03922165||DS peds eligible for Adenotonsillectomy|Dyads of caregivers and children with DS aged 3-13 years diagnosed with SDB and referred for treatment with adenotonsillectomy.
11121788|NCT03922152|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
11121789|NCT03922139|Experimental|Botox|"Ultrasound guided 1 mg/1 mL injection.
~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
11121752|NCT03922477|Experimental|Atezolizumab + Hu5F9-G4|An initial safety evaluation will be performed in participants with relapsed AML. If atezolizumab in combination with Hu5F9-G4 is initially safe and tolerable in participants an additional cohort with R/R AML will be evaluated to further test the safety and anti-tumor activity. If dose-limiting toxicities (DLT) are observed in >=33% of participants in this initial cohort, a dose de-escalation cohort will be enrolled. If less than 33% of enrolled and dosed participants in any given cohort experience a DLT, an expansion cohort of 15 participants will be enrolled at the highest tolerated dose for this combination. If a dose de-escalation cohort is needed, an expansion cohort will be enrolled at the lower tolerated dose for this combination.
11121753|NCT03922451||Pediatric patients supported on ECMO|
11121754|NCT03922438|Experimental|Cleft margin flap with anterior palatal closure|Usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
11121755|NCT03922425|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
11121756|NCT03922425|No Intervention|Standard care|
11121757|NCT03922412|Active Comparator|plantar block|Short lasting sciatic nerve block (mepivacaine 1% 200mg) and long lasting plantar block (ropivacaine 0,5% 25mg + 2mg dexamethasone) with distal deep peroneal block (ropivacaine 0,5% 2ml).
11121758|NCT03922412|Active Comparator|Sciatic popliteal block|Long lasting sciatic nerve block (ropivacaine 0,5% 100mg + 2mg dexamethasone)
11121759|NCT03922399|Other|Laser and Surgery in patients with major burn scars|Evaluating patients with major burn scar after laser and surgical treatments Multiple-directions evaluation, including senior plastic resident, young resident, professional burn surgeons, senior nurse with burn scar, one non-medical patients(usually patients' family and friends)
11121760|NCT03922386|Other|JX model|Subjects implanted with an RA XFINE lead (JX model)
11121761|NCT03922386|Other|TX model|Subjects implanted with an RV XFINE lead (TX model)
11121762|NCT03922373|Experimental|Benzonatate|
11121763|NCT03922360|Active Comparator|Best Practices|
11121764|NCT03922360|Experimental|Best Practices + Financial Incentives|
11121765|NCT03922347|No Intervention|routine care|
11121766|NCT03922347|Active Comparator|Screening program including 2 consecutive tests|
11121767|NCT03922347|Active Comparator|Screening program with mobile health|
11121768|NCT03922334|Experimental|Navigation Group|Women who are randomized into NNM2 will be assigned to a patient navigator. The patient navigator will meet with the patient after delivery occurs for introductions and education. The patient navigator will offer support and resources (transportation, community referrals, support for your mental health, connection to your doctors, etc.). The navigator will also help to schedule postpartum medical appointments, and will remind the patients of these appointments via text, email, or phone calls. The navigator will continue to provide psychosocial support and continued linkage to resources through one-year postpartum.
11121769|NCT03922334|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
11121770|NCT03922321|Experimental|Open Label RVT-1401|Open Label RVT-1401 weekly 680 mg for two weeks followed by weekly 340 mg for four weeks
11121771|NCT03922308|Placebo Comparator|Standard of Care (SoC) + Placebo Twice Daily|Participants will receive SoC daily plasma exchange (PEX) immediately followed by placebo (0.9% saline) and after 12 +/- 1 hours until remission is achieved.
11121772|NCT03922308|Experimental|SoC + SHP655 Once Daily + Placebo 12 Hours Later|Participants will receive SoC daily PEX and intravenous (i.v.) injection of 40 +/- 4 International units per kilogram (IU/kg) of SHP655 once daily immediately after PEX and placebo 12 +/- 1 hours after completion of PEX until remission is achieved.
11121773|NCT03922308|Experimental|SoC + SHP655 Twice Daily|Participants will receive SoC daily plasma exchange and i.v. injection of 40 +/- 4 IU/kg of SHP655 twice daily (BID) immediately after PEX and 12 +/- 1 hours after completion of PEX until remission is achieved.
11121774|NCT03922295|Active Comparator|endoscopic double flap group|
11121775|NCT03922295|Active Comparator|endoscopic single flap group|
11121776|NCT03922282|Experimental|Gasless BABA|BABA robotic-thyroidectomy that do not using carbon dioxide but using elevation of flap.
11121777|NCT03922282|Active Comparator|Classic BABA|BABA robotic-thyroidectomy using carbon dioxide.
11121778|NCT03922269||Transgender individual with a diagnosis of HIV|The participant self-identifies as transgender and/or has a current gender identity which differs from gender assigned at birth, is 18 years old or above, has a diagnosis of HIV infection and has been prescribed antiretroviral therapy.
11121779|NCT03922230||Early esophageal cancer group|Pathological examination diagnosed as Early esophageal cancer.The ratio of male to female is 3:1, and the age is between 50 and 70 years old.
11121780|NCT03922230||Middle and advanced ES group|Pathological examination diagnosed as Middle and advanced esophageal cancer.
11121781|NCT03922230||Normal group|Confirmed as the normal by health checkups.
11121782|NCT03922217|Experimental|Mindfulness|This group will be given the Mindfulness mobile intervention, Mindful My Way (MMW)
11121783|NCT03922204|Experimental|MCLA-145|In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days
11121784|NCT03922191||Pediatric population|Infants diagnosed with cardiac post-surgery mediastinitis within the HUDERF Hospital within the last 20 years.
11121785|NCT03922191||Adult population|Adults diagnosed with cardiac post-surgery mediastinitis within the CHU Brugmann Hospital within the last 20 years.
11121786|NCT03922178|Experimental|Elective coronary surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and anesthesiology wards. Subjects referred for elective coronary surgery will be prospectively included during the length of the study.
11121790|NCT03922126|Experimental|Listos peer intervention|Listos intervention (peer counseling, PrEP information, and HIV/STI testing kits)
11121791|NCT03922126|Active Comparator|Peer only group|Peer only group (peer counseling, PrEP information)
11121792|NCT03922113||Critically ill patients|Patients who spent a minimum of 48h in ICU
11121793|NCT03922113||Surgical patients|Patients who were scheduled for elective colorectal surgery
11121794|NCT03922113||Healthy subjects|Healthy volunteers
11121795|NCT03922100|Experimental|Dose Escalation and Expansion (Phase I)|Dose escalation will be applied until one patient experiences first cycle DLT (Dose Limiting Toxicity) or 2 patients at any dose level experience non-DLT NCI CTCAE Grade ≥2 drug-related toxicity during the first cycle. Once the Maximum Tolerated Dose (MTD) is identified, a maximum of 10 additional patients will be enrolled (dose expansion).
11121796|NCT03922100|Experimental|AML FLT3 mutated (Phase II)|Cohort of AML FLT3 mutated patients. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
11121797|NCT03922100|Experimental|CMML (Phase II)|Cohort of patients with CMML. NMS-03592088 will be administered at the recommended Phase II dose (RP2D) defined in Phase I part.
11121798|NCT03922087||Control Group|The pregnancy women without any diseases.
11121799|NCT03922087||Disease Group|The pregnancy women with cardio-metabolic and endocrinic disorders such as gestational diabetes, obesity, hypertension, thyroid diseases, anemia and other cardio-metabolic diseases.
11121800|NCT03922074|Experimental|Non-anesthesiologist administered propofol|Sedation directed by an endoscopist in which the intravenous drugs are propofol and fentanyl . Target level sedation: moderate - deep.
11121801|NCT03922074|Active Comparator|Monitored anesthesia care|Sedation directed by an anesthesiologist in which the used intravenous drugs and target level sedation are chosen by the anesthesiologist.
11121802|NCT03922061|Experimental|fIPV-dmLT|fractional-dose inactivated polio vaccine (fIPV) given intradermally with double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant
11121803|NCT03922061|Active Comparator|fIPV|fractional-dose inactivated polio vaccine (fIPV) given intradermally
11121804|NCT03922048|Experimental|Cohort 1 Part A: HTX-011|Adolescents ≥12 to <17 years of age. A single dose of HTX-011 via instillation into the surgical site.
11121805|NCT03922048|Active Comparator|Cohort 1 Part A: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.
11121806|NCT03922048|Experimental|Cohort 1 Part B: HTX-011|Adolescents ≥12 to <17 years of age. Dose to be determined from Cohort 1 Part A.
11121807|NCT03922048|Active Comparator|Cohort 1 Part B: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
11121808|NCT03922048|Experimental|Cohort 2 Part A: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
11121809|NCT03922048|Active Comparator|Cohort 2 Part A: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
11121810|NCT03922048|Experimental|Cohort 2 Part B: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
11121811|NCT03922048|Active Comparator|Cohort 2 Part B: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
11121812|NCT03922048|Experimental|Cohort 3: HTX-011|Children ≥3 to <6 years of age. Dose to be determined from Cohorts 1 and 2.
11121813|NCT03922048|Active Comparator|Cohort 3: bupivacaine HCl|Children ≥3 to <6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
11121814|NCT03922035|Experimental|Arm I (CBM588)|Patients receive standard peri-/post-transplant supportive care and CBM588 PO BID from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.
11121815|NCT03922035|Active Comparator|Arm II (standard of care)|Patients receive standard peri-/post-transplant supportive care.
11121816|NCT03922022|Experimental|EIM group|patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study
11121817|NCT03922009|Experimental|Virtual Reality group|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
11121818|NCT03922009|No Intervention|control group|General routine care
11121819|NCT03921996|Experimental|arm A: ePLND|Radical prostatectomy with extended pelvic lymph node dissection
11121820|NCT03921996|Active Comparator|arm B: no PLND|Radical prostatectomy only
11121821|NCT03921983|Experimental|LTOT +|COPD patients with long term oxygenotherapy
11121822|NCT03921983|Active Comparator|LTOT -|COPD patients without chronic hypoxemia (no LTOT)
11121823|NCT03921970|Active Comparator|Group ESP = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. From superior to inferior; trapezius (upper), rhomboideus major (middle), erector spinae (lower) muscles will be visualized on the hyperechoic transverse process. The 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be inserted in a cranio caudal direction and then for correction of the needle 5 ml normal saline solution will be enjected into the erector spina muscle fascia (figure). Following confirmation of the correct position of the needle, a dose of 20 ml %0.25 bupivacaine was administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine).
11121824|NCT03921970|No Intervention|Group C = Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
11121825|NCT03921957|Experimental|stereotactic|
11121826|NCT03921944|Other|one year post total shoulder surgery|
11121827|NCT03921931|Experimental|healthy volunteers|light stimulation
11121828|NCT03921931|Experimental|primary open angle glaucoma patients|light stimulation
11121829|NCT03921931|Experimental|age-related macular degeneration patients|light stimulation
11121830|NCT03921918|Other|Evaluation of Fluid Expression Technology|This study aims to provide important insights with respect to the safety, performance, and real-life usability of pumping technology
11121831|NCT03921905||Patients with CAD|In this study will be included patients with stable CAD
11121832|NCT03921892|Other|In-person parenting education|Participants will complete two six-hour in-person parenting education sessions on two consecutive Saturdays
11121833|NCT03921892|Active Comparator|On-line parenting education|Participants will complete on-line parenting education at the times and locations of their choice over a two-week period.
11121834|NCT03921879|Experimental|Stage 1 Dose Escalation|The dose escalation arm will use a modified 3+3 design to determine the maximum tolerated dose. or maximum tested dose.
11121835|NCT03921879|Experimental|Stage 2 Dose Expansion|The dose expansion arm will use the maximum tolerated dose to determine preliminary efficacy.
11121836|NCT03921853|Active Comparator|Active comparator|Control group with obesity under Resistant Training
11121837|NCT03921853|Experimental|Experimental group with morbid obesity|Experimental group with morbid obesity under Resistant Training
11121838|NCT03921840|Experimental|Intervention|Based on the self-efficacy theory, participants in the intervention arm will receive personalized, circadian-based activity guidelines, a 2-hour in person education session, real time physical activity self-monitoring, interactive prompts, biweekly phone consultation with the research team, and financial incentives for achieving weekly physical activity goal.
11121839|NCT03921840|Placebo Comparator|Control|The control group will receive general education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
11121840|NCT03921827|Experimental|EECP therapy|Half of the study sample will be allocated to EECP therapy (35 sessions) of 1-hour each. Acetazolamide challenged HMPAO-SPECT will be performed before randomization and repeated 2-months after the completion of EECP therapy. MRI of the brain would be performed after completion of EECP therapy to document any silent stroke.
11121841|NCT03921827|No Intervention|Best Medical Therapy|This group will receive the best medical therapy according to our institutional practice and as per the recommendations of American Stroke Association.
11121842|NCT03921814|Experimental|Treatment with IPL device|This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual [5]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
11121843|NCT03921801|No Intervention|Control|14-week control period.
11121844|NCT03921801|Experimental|Intervention|14-week intervention. Intervention includes weekly gait retraining sessions with real-time electromyography biofeedback and home-based strength training session for plantarflexor muscles three times per week.
11121845|NCT03921801|No Intervention|Young adults - control|Outcome measures obtained at a single time point. The data is used to compare outcome measured between older and young adults.
11121846|NCT03921788||Group 1|Patients with venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
11121847|NCT03921788||Group 2|Patients without venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
11121848|NCT03921788||Group 3|Volunteers without pain syndromes of any location. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
11121849|NCT03921775|Experimental|Treatment group A|IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance
11121850|NCT03921775|Active Comparator|Treatment B|IV pumping of propofol at 120~150mg/kg/h for anesthesia induction and 3~12mg/kg/h for anesthesia maintenance
11121851|NCT03921762|Experimental|Artis Active IOL|Artis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
11121852|NCT03921762|Experimental|AT Lara IOL|AT Lara IOLs will be implanted in patients eyes during cataract surgery
11121853|NCT03921749|Experimental|Focused shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be focused shock wave therapy (0.20 mJ/mm 2 )
11121854|NCT03921749|Experimental|Raidal shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be radial shock wave therapy (3 bar)
11121855|NCT03921736|No Intervention|Control Group|Control group consisted of 40 postmenopausal women with normal blood pressure.
11121856|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide|Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
11121857|NCT03921736|Experimental|Hypertensive women group receiving perindopril.|Patients received perindopril 4 mg/day p.o for 1 year.
11121858|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide and EPT|Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
11121859|NCT03921736|Experimental|Hypertensive women group receiving perindopril and EPT.|Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
11121860|NCT03921736|Experimental|Hipotensive women group receiving EPT.|Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.
11121892|NCT03921515|Other|1|Blister Induction
11121893|NCT03921515|Other|2|Skin Biopsies
11121929|NCT03921281|Other|control group|The control group (n=38) will receive rehabilitation treatment for 3 times per week for 12 weeks.
11121930|NCT03921268|Experimental|Treatment A|Dose A estimated delivered single dose of AZD1402 nebuliser solution administered via a nebuliser.
11121861|NCT03921723|Experimental|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of >= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
11121862|NCT03921710|Active Comparator|CAPA-IVM|Immature oocytes are culture in the new capacitation-IVM system.
11121863|NCT03921710|Active Comparator|Standard-IVM|Immature oocytes are cultured in the standard IVM system.
11121864|NCT03921697||Parkinson Disease Patients|"Patients with PD will be recruited at Fondazione Policlinico Universitario Gemelli and Fondazione Don Gnocchi ONLUS in Rome. All included patients will be affected by idiopathic PD. Clinical data will be acquired by a trained neurologist.
~We will remotely monitor 300 patients through wearable sensors. Subjects will be instructed to wear the sensor for 14 consecutive days."
11121865|NCT03921684|Experimental|Neoadjuvant Treatment|All subjects will receive chemoradiation followed by chemotherapy and nivolumab as neoadjuvant treatment
11121866|NCT03921671|Experimental|Ramucirumab +carboplatin+ paclitaxel|All patient will receive the combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with recurrent and / or metastatic thymic carcinoma or thymoma B3 with area of carcinoma, in the first line.
11121867|NCT03921658||Cohort 1 - Cross-sectional (within 2 years of diagnosis)|Individuals diagnosed and treated for ovarian cancer in past two years, will complete 1 study measure
11121868|NCT03921658||Cohort 2- Prospective (from diagnosis)|Individuals newly diagnosed with ovarian cancer, will complete 3 study measures (baseline/diagnosis, completion of chemotherapy, one year post-diagnosis)
11121869|NCT03921645|Experimental|aerosol combined group|aerosol combined intravenous antibiotics group，amikacin 15mg/kg, qd
11121870|NCT03921645|No Intervention|No intervention group|this group follow the usual treatment without any intervention
11121871|NCT03921632|Experimental|Education Program Effectiveness|Outpatients and inpatients from UNC Center of Excellence for Eating Disorders clinic
11121872|NCT03921619|No Intervention|No Sling|Participants will perform the balance tests without any added equipment.
11121873|NCT03921619|Experimental|Sling (Dominant)|Participants will perform the balance tests with a sling on the dominant arm.
11121874|NCT03921606|Experimental|Experimental group|The experimental group will receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. However, the total time spent by the interventionist will not be more than that for a traditional MI with several long sessions. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up. The total time spent will be recorded and analysed.
11121875|NCT03921606|Other|Control group|The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
11121876|NCT03921593||Simultaneous Pancreas Kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Simultaneous Pancreas Kidney Transplant (SPK)
11121877|NCT03921593||Pancreas after kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Pancreas after kidney Transplant (PAK)
11121878|NCT03921593||Pancreas Transplant Alone Recipients|Patient affected by Insulin Dependent Diabetes Mellitus with hypoglycemia unawareness undergoing Pancreas Transplant Alone (PTA)
11121879|NCT03921580|Placebo Comparator|Control Canned Tuna|Control Canned Tuna
11121880|NCT03921580|Experimental|Enriched Canned Tuna Variety 1|Enriched Canned Tuna Variety 1: Wakame fiber
11121881|NCT03921580|Experimental|Enriched Canned Tuna Variety 2|Enriched Canned Tuna Variety 2: Polyphenols
11121882|NCT03921567|Experimental|Group I|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
11121883|NCT03921567|Active Comparator|Group II|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
11121884|NCT03921567|Placebo Comparator|The control group|will be given opioids during surgery, opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
11121885|NCT03921554|Experimental|Aicardi Goutières Syndrome patients receiving Baricitinib|Baricitinib will be taken by mouth as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
11121886|NCT03921541|Experimental|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
11121887|NCT03921541|Placebo Comparator|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
11121888|NCT03921541|Experimental|Pegzilarginase Long Term Extension|After 24 weeks, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
11121889|NCT03921528|Experimental|Cohort 1|Ambulatory Type 3 SMA
11121890|NCT03921528|Experimental|Cohort 2|Type 2 SMA / Non-Ambulatory Type 3 SMA
11121891|NCT03921528|Experimental|Cohort 3|Type 2 SMA
11121894|NCT03921502|Experimental|ERCP with sphincterotomy + gall bladder drainage with LAMS|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist. After this, transmural drainage of the gallbladder will be performed by placing a LAMS Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL will be placed on it to generate the anastomosis between the aforementioned structures.
11121895|NCT03921502|Active Comparator|ERCP with sphincterotomy|An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist.
11121896|NCT03921489|Experimental|Subchondroplasty in treating bone marrow edema|These patients will have calcium phosphate mineral compound injected into the bone marrow lesions.
11121897|NCT03921476||Subjects on spironolactone for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
11121898|NCT03921476||Subjects on oral antibiotics for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
11121899|NCT03921463||caesarean section|
11121900|NCT03921463||vaginal delivery|
11121901|NCT03921450|Experimental|Inhibitory repetitive transcranial magnetic stimulation (rTMS)|1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
11121902|NCT03921450|Active Comparator|Facilitatory intermittent theta burst stimulation (iTBS)|"Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.
~total of 15 sessions in 3 weeks"
11121903|NCT03921450|Placebo Comparator|Placebo|1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
11121904|NCT03921450|No Intervention|Waiting group|This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm
11121905|NCT03921437|Experimental|decision support intervention|The intervention measures in this study were discussed with the nephrologist and CKD health teachers. Based on theoretical considerations, the experimental group provides decision support. Measures, including CKD Guardian as a decision-maker, and the use of e-book software to develop medical decision-assist tools, and the application and decision-making mode complemented by introduction and selection, including team discussions, option discussions, and decision-making conversations. The control group is introduced with traditional care instructions for routine care. The experimental group and the control group were referred to the CKD health teacher for the introduction of renal replacement therapy by the physician. The experimental group was guided by CKD Health Education to guide the patients to participate in the discussion, discuss the advantages and disadvantages of each treatment and guide patients to explore preferences. And value, supplemented by discussion and final decision.
11121906|NCT03921437|No Intervention|routine care|According to the nursing routine provide paper education.
11121907|NCT03921424|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of Pneumovax™23 at Week 8 (Vaccination 2)
11121908|NCT03921424|Experimental|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of Pneumovax™23 at Week 8 (Vaccination 2)
11121909|NCT03921411|Experimental|Nemolizumab|Nemolizumab
11121910|NCT03921398||Patients with ESRD|Patients with history of biopsy-proven lupus nephritis (all classes of lupus nephritis)
11121911|NCT03921398||Patients with active lupus prior to treatment and no ESRD|Patients with biopsy-proven ACTIVE lupus nephritis
11121912|NCT03921398||Healthy individuals|Healthy individuals
11121913|NCT03921385||Single cohort - navigated cranial and spine surgery|
11121914|NCT03921372|Experimental|Normal Tension Glaucoma (NTG)|Patients with diagnosed NTG
11121915|NCT03921372|Experimental|Healthy Control Subjects|Subjects with no sign of glaucoma, Age and sex matched
11121916|NCT03921359|Experimental|Conventional physical training|Participants assigned to this arm will receive the conventional physical training.
11121917|NCT03921359|Experimental|SMARTfit training|Participants assigned to this arm will receive the SMARTfit training.
11121918|NCT03921346|Experimental|Arm A (mobile device app)|"Paramedics preparing drugs with the help of the mobile device app PedAMINES™.
~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of the mobile device app PedAMINES™."
11121919|NCT03921346|Active Comparator|Arm B (conventional preparation method)|"Paramedics preparing drugs with the help of conventional method.
~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of conventional method"
11121920|NCT03921333|Active Comparator|Low dose plant extract|300 mg
11121921|NCT03921333|Active Comparator|Middle dose plant extract|500 mg
11121922|NCT03921333|Active Comparator|High Dose plant extract|700 mg
11121923|NCT03921333|Placebo Comparator|Placebo control|Cellulose microcrystalline
11121924|NCT03921320|Active Comparator|Bilateral sympathectomy|Bilateral sequential (one surgical procedure) videothoracoscopic R4 sympathectomy
11121925|NCT03921320|Experimental|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the right (dominant) side
11121926|NCT03921320|Experimental|Contralateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the left (contralateral) side
11121927|NCT03921294|Experimental|Single Arm|Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.
11121928|NCT03921281|Experimental|treatment group|The treatment group (n=38) will receive scalp acupuncture combined with rehabilitation treatment for 3 times per week for 12 weeks.
11121931|NCT03921268|Experimental|Treatment B|Dose B estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
11121932|NCT03921268|Experimental|Treatment C|Dose C estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
11121933|NCT03921255|Active Comparator|TAF Incongruent (TAF-INC)|Active condition (TAF-INC) cognitive bias modification for interpretations (CBM-I), incorporates an obsessional thought meant to elicit either moral or likelihood TAF, followed by a sentence incongruent to TAF bias and meant to reduce the impact of the previous statement. Before moving on, participants must fill-in and correctly solve a key word important in the interpretation of the sentence. Participants then must correctly solve a short yes/no comprehension question to ensure understanding of the scenario.
11121934|NCT03921255|Placebo Comparator|TAF Congruent (TAF-CON)|Maintenance/Control condition (TAF-CON) CBM-I, differs in that participants are provided with a sentence congruent with TAF bias. Again, participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
11121935|NCT03921255|Placebo Comparator|Stress Management Psychoeducation|In the stress management psychoeducation (SMP) psychoeducation about stress and stress management are provided, similar in length to the obsessional thought and interpretations presented in the TAF-INC and TAF-CON. Like the other conditions there is a key word to solve, and participants were only able to move on when they correctly solved the key word and the accompanying yes/no comprehension question.
11121936|NCT03921242||Metformin Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom metformin was prescribed at baseline for this first time in each patient's medical history.
11121937|NCT03921242||Sulfonylurea Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom sulfonylurea was prescribed at baseline for this first time in each patient's medical history.
11121938|NCT03921242||DPP4 Inhibitor Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom a DPP4 Inhibitor was prescribed at baseline for this first time in each patient's medical history.
11121939|NCT03921242||SGLT2 Inhibitor Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom an SGLT2 Inhibitor was prescribed at baseline for this first time in each patient's medical history.
11121940|NCT03921242||GLP1 Receptor Agonist Cohort|Group of study participants having both Type 2 Diabetes and Chronic Kidney disease and meeting the study's inclusion criteria for whom a GLP1 receptor agonist was prescribed at baseline for this first time in each patient's medical history.
11121941|NCT03921229|Experimental|Intervention|6-months of 11 web-based intervention (tele-coaching) sessions (9 biweekly sessions and 2 monthly sessions) of approximately 30 minutes each; continued use of eTrack nebulizer and vest monitor photo capture as measures of adherence.
11121942|NCT03921216||Diabetic nephropathy, on hemodialysis|
11121943|NCT03921216||Chronic kidney disease, on hemodialysis|Chronic kidney disease of other causes than Diabetes.
11121944|NCT03921203||Type 2 diabetes patients|
11121945|NCT03921203||Healthy controls|
11121946|NCT03921190|Active Comparator|Open-mouth|Patients receiving maxillary buccal infiltration anesthesia (MBIA) with their mouth wide open
11121947|NCT03921190|Experimental|Closed-mouth|Patients receiving MBIA using a closed-mouth technique
11121948|NCT03921177|Experimental|Multiple micronutrient supplement|Daily micronutrient supplement
11121949|NCT03921177|Placebo Comparator|Placebo|Daily identifcal placebo tablet
11121950|NCT03921164||Patients scheduled for a neuroradiology procedure|Interventional neuroradiology procedure under general anesthesia requiring a continuous monitoring of mean arterial pressure and cardiac output, including electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and monitoring of neuromuscular function. In addition, for all patients, data from trans-oesophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.
11121951|NCT03921151|Other|Cocaine-dependent|Participants who use and are dependent on cocaine
11121952|NCT03921151|Other|Non-drug|Participants who are not drug users
11121953|NCT03921138||Benign laparoscopic hysterectomy|Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy
11121954|NCT03921125||Responders|
11121955|NCT03921125||Non responders|
11121956|NCT03921112|Active Comparator|lung ultrasound|
11121957|NCT03921112|Active Comparator|x-ray, ABG, RSBI, Vetilator parameters|
11121958|NCT03921099|No Intervention|Vancomycin only|Vancomycin 15-20mg/kg intravenous every 8-12 hours.
11121959|NCT03921099|Experimental|Vancomycin +Ascorbic acid|Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.
11121960|NCT03921086|Other|Hypertensive patients|Newly diagnosed or poorly controlled hypertensive patients will be initiated on appropriate therapy as per a specific algorithm.
11121961|NCT03921073|Experimental|Intralesional injection of T-VEC|Participants will undergo intralesional injections of up to 4 cc of 10^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.
11121962|NCT03921060|No Intervention|Main Study|Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan (if not completed as standard of care within 6 months prior to research visit), micro CT, and blood collection.
11121963|NCT03921060|Experimental|Denosomab Sub-study|Approximately 50 subjects with CF that have completed the main study and have results which indicate bone disease are eligible to participate in the sub study. Subjects who consent will receive treatment with denosumab (60 mg/ml via subcutaneous injection in the upper arm, upper thigh, or abdomen every 6 months) for up to 5 years. These subjects will be asked to return every 6 months for injections and annually (+/- 6 months) for up to 5 years for a DEXA scan, micro CT, and blood collection.
11121964|NCT03921047||Ancillary-correlative (next generation sequencing)|Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.
11121965|NCT03921034|Active Comparator|continuous ACB with IPACK block|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and IPACK block with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine
11121966|NCT03921034|Sham Comparator|continuous ACB with sham subcutaneous saline injection|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and a sham IPACK block with subcutaneous saline injection along the medial thigh
11121967|NCT03921021|Experimental|Telomelysin (OBP-301)|All patients will receive Telomelysin (OBP-301) at 1x1012 viral particles (VP)/ tumor injection administered every two weeks x 4 injections as well as standard dose pembrolizumab 200 mg IV every 3 weeks. The tumor will be injected with OBP-301 four times (d1, d15, d29, d43). The preference is to inject the primary tumor endoscopically. Metastatic lesions may be injected on a case-by-case basis after discussion with the PI (Shah).
11121968|NCT03921008|Experimental|Paclitaxel and Radiation|"All patients will receive standard of care induction chemotherapy with 6 weekly cycles of paclitaxel at 80 mg/m^2. They will then receive 6 weekly cycles of paclitaxel at 80 mg/m^2 concurrently with radiation therapy. Patients will be receiving paclitaxel as part of their routine care, but in order to participate in this study, their induction chemotherapy regimen must be paclitaxel. Radiation therapy is 50.4 Gy in 28 fractions delivered within 7 weeks.
~Standard of care surgery ideally within 6 weeks after completing concurrent chemotherapy and radiation therapy"
11121969|NCT03920956|Experimental|Experimental: 24-hour ABPM by Pharmacists|Patients will meet with the pharmacist to be equipped with a 24-hour ambulatory blood pressure monitor (ABPM). Patients will return the monitor for the pharmacists to download the results to send to their medical provider.
11121970|NCT03920943|Other|Core and TAT measurements|As part of the standard of care, flight paramedics will insert an esophageal or rectal temperature probe in patients meeting including criteria to enable continuous temperature monitoring. Paramedics will measure core temperature on at least two occasions, the first measurements made at least 5 minutes after insertion of the temperature probe, and also prior to departure from the sending facility.
11121971|NCT03920930|Experimental|Early-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached."
11121972|NCT03920930|Active Comparator|Late-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied after the preparation of the femur and tibia bone shortly before the prosthesis is inserted and during the retreat from the knee joint."
11121973|NCT03920917|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.
~Esophageal temperature will be monitored to prevent esophageal injury.
~A 28mm second or third cryoballoon catheter will be used.
~Esophageal temperature will be monitored to prevent esophageal injury.
~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.
~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.
~The procedure and cryoablation times will be evaluated.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11121974|NCT03920917|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.
~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.
~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.
~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.
~Evaluated the procedure and radiofrequency ablation time.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11121975|NCT03920904||Bupivacaine dosage in PIFB block|The pharmacokinetics of bupivacaine 0.25% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following a PIFB block will be determined by the collection of blood samples at predetermined time points.
11121976|NCT03920891|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.
~Esophageal temperature will be monitored to prevent esophageal injury.
~A 28mm second or third cryoballoon catheter will be used.
~Esophageal temperature will be monitored to prevent esophageal injury.
~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.
~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.
~The procedure and cryoablation times will be evaluated.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11121977|NCT03920891|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.
~Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.
~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.
~Evaluated the procedure and radiofrequency ablation time.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11121978|NCT03920878|Experimental|Aflibercept injected Pre- and Post-operatively|Pre- and Post-operative time of Aflibercept injections
11121979|NCT03920878|Active Comparator|Aflibercept injected intraoperatively|Intraoperative time of Aflibercept injection
11121980|NCT03920865|Experimental|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
11122098|NCT03920033|Active Comparator|Standard|66 Gy/ 33 fractions (fraction size 2 Gy)
11121981|NCT03920865|Experimental|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
11121982|NCT03920852|Experimental|Ruxolitinib cream|
11121983|NCT03920839|Experimental|INCMGA00012 + gemcitabine/cisplatin|
11121984|NCT03920839|Experimental|INCMGA00012 + pemetrexed/cisplatin|
11121985|NCT03920839|Experimental|INCMGA00012 + pemetrexed/carboplatin|
11121986|NCT03920839|Experimental|INCMGA00012 + paclitaxel/carboplatin|
11121987|NCT03920826|Experimental|tACS stimulation group|NEXALIN ADI transcranial alternating current stimulator
11121988|NCT03920826|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
11121989|NCT03920813|Experimental|Antitumor drugs|Mercaptopurine administered at standard dose for children with hematological neoplasms.
11121990|NCT03920800||Conservative management - progression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
11121991|NCT03920800||Conisation|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
11121992|NCT03920800||Conservative management - spontaneous regression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
11121993|NCT03920787|Experimental|Inositol|Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
11121994|NCT03920787|Placebo Comparator|Placebo|Administration of placebo. 2 capsules every day for 1 month
11121995|NCT03920774||Familial Dysautonomia|Patients diagnosed with familial dysautonomia, a genetic disorder that affects the development and survival of nerve cells in the autonomic nervous system. It primarily affects neurons that control involuntary actions like regulation of blood pressure and breathing. It also affects the sensory nervous system and the perception of pain, heat and cold.
11121996|NCT03920748||Difficult laryngoscopy (Group D)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 3-4 are classified as difficult laryngoscopy ( Group D).
11121997|NCT03920748||Easy laryngoscopy (Group E)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 1-2 are classified as easy laryngoscopy ( Group E).
11121998|NCT03920735||Opportunistic infection|Immunocompromised or frail patients with an opportunistic infection
11121999|NCT03920735||Control group|Immunocompromised or frail patients with no opportunistic infection
11122000|NCT03920722|Experimental|Rituximab|Experimental regimen: One year Glucocorticoid treatment and Rituximab IV 1 gram on Day 1 and 15
11122001|NCT03920722|Placebo Comparator|Rituximab-Placebo|Standard regimen: One-year Glucocorticoid treatment and Placebo-Rituximab IV on Day 1 and 15
11122002|NCT03920709||Chronic HIV-1 infected subjects : 50 Viremic subjects|plasma HIV RNA > 500 copies/mL, treatment-naive or treated (failing) regardless of the cause of persistent viremia
11122003|NCT03920709||Chronic HIV-1 infected subjects : 50 Treated Aviremic subjects|< 50 copies/mL under treatment for at least 12 months
11122004|NCT03920709||Chronic HIV-1 infected subjects :10 Spontaneous Controllers|from the ANRS CO21 CODEX Cohort or not (5 last viral loads < 400 copies /ml)
11122005|NCT03920683||Diabete type 1 and 2|Data collection from patients treated in the diabetes department, in Pitié-Salpêtrière hospital, and adressed for a one-day hospitalization to assess cardiovascular comorbidities.
11122006|NCT03920670|Experimental|Group 1|TetraGraph on dominant arm, ToFscan on non-dominant arm
11122007|NCT03920670|Active Comparator|Group 2|TetraGraph on non-dominant arm, ToFscan on dominant arm
11122008|NCT03920657|Experimental|Deferasirox|patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.
11122009|NCT03920644|Experimental|DPI-386 Nasal Gel|Receives Active Nasal Gel 2 times per treatment day
11122010|NCT03920644|Placebo Comparator|Placebo nasal gel|Receives Nasal Gel 2 times per treatment day
11122011|NCT03920644|Active Comparator|TDS Patch|Receives one patch per treatment.
11122012|NCT03920631|Experimental|Cohort 1: Microtransplantation (MST)|MST:Infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
11122013|NCT03920631|Experimental|Cohort 2/2b: MST + Nivolumab|"2: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day+14)
~2b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day+14)."
11122014|NCT03920631|Experimental|Cohort 3/3b: MST + Nivolumab|"3: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day-1).
~3b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day-1)."
11122015|NCT03920631|Experimental|Cohort 4: Expansion|Microtransplantation (Day 0) + nivolumab (at RP2D)
11122016|NCT03920618|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
11122017|NCT03920618|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
11122018|NCT03920618|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
11122019|NCT03920605|Active Comparator|Peginterferon alfa group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
11122020|NCT03920605|Active Comparator|Combination group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week and meanwhile oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive treatment of oral TDF 300 mg once per day from 49 to 144 weeks.
11122157|NCT03919643||SLE patients with nephritis|No intervention. Peripheral blood and urine samples will be obtained
11122021|NCT03920592|Experimental|Video watching|"All participants will watch 4 videos of potential everyday school situations, adapted for boys and girls.
~Videos contain different levels of bullying (presence/absence) and virtual reality (presence/absence).
~Every pupil will watch the 4 types of video content randomly."
11122022|NCT03920579|Experimental|Sequence 1|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: D326, D337, D013(3 tabs, once)
11122023|NCT03920579|Experimental|Sequence 2|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 2(1 tab, once)
11122024|NCT03920579|Experimental|Sequence 3|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 1(1 tab, once)
11122025|NCT03920579|Experimental|Sequence 4|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: D326, D337, D013
11122026|NCT03920579|Experimental|Sequence 5|Period 1: D326, D337, D013(3 tabs, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: CKD-386 formulation 2(1 tab, once)
11122027|NCT03920579|Experimental|Sequence 6|Period 1: D326, D337, D013 (3 tabs, once)/ Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: CKD-386 formulation 1(1 tab, once)
11122028|NCT03920553|Experimental|Test Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it. No bleeding was observed after the frenectomy performed with laser. Then, commercially available Hiyaluronic acid was topically applied to the relevant area to completely cover the surgical field to the test group. Following the frenectomy performed with laser, no application was made to the control group patients.
11122029|NCT03920553|No Intervention|Control Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it.
11122030|NCT03920540|Experimental|GC1111|All subjects should receive the GC1111 for 52 weeks.
11122031|NCT03920540|Active Comparator|Comparator|All subjects should receive the comparator for 52 weeks.
11122032|NCT03920527|Active Comparator|Six months|Six months of itraconazole
11122033|NCT03920527|Experimental|12 months|12-months of itraconazole
11122034|NCT03920514|Active Comparator|GROUP 1|IUI 24 hours after hCGadminstration
11122035|NCT03920514|Active Comparator|GROUP 2|IUI 36 hours after hCG adminstration
11122036|NCT03920514|Active Comparator|GROUP 3|IUI 48 hours after hCG adminstration
11122037|NCT03920514|Active Comparator|GROUP 4|IUI at time of hCG adminstration
11122038|NCT03920501|Experimental|Tele-Critical Care|Tele-Critical Care + Audit & Feedback.
11122039|NCT03920501|No Intervention|Usual Care|Usual Care.
11122040|NCT03920475||TAU (treatment as usual) group|Patients with depression, meeting inclusion criteria, who needed antidepressant treatment and received either sertraline or venlafaxine.
11122041|NCT03920462|Other|Programme of intelligent electric bike for health (single arm)|All volunteers will realise the programme of intelligent electric bike for health with connected vests.
11122042|NCT03920449|Active Comparator|Botulinum toxin injection|
11122043|NCT03920449|Active Comparator|Posterolateral internal sphincterotomy|
11122044|NCT03920436|Experimental|Infrared water group|This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.
11122045|NCT03920436|Sham Comparator|sham group|This group takes drinking water using a tumbler at room temperature for 8 weeks.
11122046|NCT03920423|No Intervention|shallow depth|Radial arterial deth is shallow than the cutoff point that relative to results.
11122047|NCT03920423|Experimental|improved depth|Radial arterial deth is shallow than the cutoff point that relative to results, and increased by injection of saline to more than deep cutoff point.
11122048|NCT03920410|Experimental|stimulated serotonergic activity|
11122049|NCT03920410|Experimental|unstimulated serotonergic activity|
11122050|NCT03920397|Experimental|Adipose tissue-derived stem/stromal cells|Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
11122051|NCT03920397|Experimental|Daily 2000 UI of daily oral cholecalciferol|To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.
11122052|NCT03920384|Experimental|Experimental therapy arm|16 (minimum 4, maximum 20) sessions of therapy for psychosis including new therapeutic ingredients
11122053|NCT03920384|Active Comparator|Standard Psychological Therapy for Psychosis|16 (minimum 4 maximum 20) sessions of standard psychological therapy for psychosis.
11122054|NCT03920371|Experimental|gamma camera imaging|hand held camera
11122055|NCT03920345|Experimental|Treatment: Endoscopic ET on SI joint|New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.
11122056|NCT03920319|Experimental|Bupropion|Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
11122057|NCT03920319|Placebo Comparator|Placebo|Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
11122099|NCT03920020|Other|the concentric isokinetic exercise group|the concentric isokinetic exercise group will perform quadriceps and hamstring concentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
11122158|NCT03919643||SLE patients with without nephritis|No intervention. Peripheral blood and urine samples will be obtained
11122058|NCT03920306|Experimental|Intervention|"Drug administration for the experimental arm includes:
~AgNO3 applied to the fistula tract.
~A topical adhesive of either 2-Octylcyanoacrylate glue (Dermabond), or Fibrin glue, or Histoacryl glue (Tissue Seal), will be applied over the fistula's aperture.
~Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous fistula tract closure, whichever comes first."
11122059|NCT03920293|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
11122060|NCT03920293|Placebo Comparator|Placebo|Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.
11122061|NCT03920267|Experimental|BMS-986165 Dose 1|
11122062|NCT03920267|Experimental|BMS-986165 Dose 2|
11122063|NCT03920267|Experimental|BMS-986165 Dose 3|
11122064|NCT03920254|Experimental|Active Treatment TD-1473 with Dose A|Oral daily dose of TD-1473 for up to 156 weeks
11122065|NCT03920254|Experimental|Active Treatment TD-1473 with Dose B|Oral daily dose of TD-1473 for up to 156 weeks
11122066|NCT03920254|Experimental|Active Treatment TD-1473 with Dose C|Oral daily dose of TD-1473 for up to 156 weeks
11122067|NCT03920241||MBSR group|Attendants to Mindfulness-Based Stres Reduction programs offered to the community by Complutense University
11122068|NCT03920241||CCT group|Attendants to Compassion Cultivation Training programs offered to the community by Complutense University
11122069|NCT03920241||Control group|Control group matched by age, gender, and meditation experience.
11122070|NCT03920228|Experimental|Open label period|
11122071|NCT03920228|Placebo Comparator|Randomized period - Dosing A|
11122072|NCT03920228|Experimental|Randomized period - Dosing B|
11122073|NCT03920228|Experimental|Randomized period - Dosing C|
11122074|NCT03920215|Experimental|Active Comparator: OC-01 Low Dose|
11122075|NCT03920215|Experimental|Active Comparator: OC-01 Mid Dose|
11122076|NCT03920215|Experimental|Active Comparator: OC-01 High Dose|
11122077|NCT03920215|Experimental|Placebo Comparator: Placebo|
11122078|NCT03920176|Active Comparator|Computed tomography coronary angiography|
11122079|NCT03920176|Sham Comparator|Assign Score only|
11122080|NCT03920163|Active Comparator|Control|Stable , penetrating trauma patients undergoing laparotomy who receive standard post operative care
11122081|NCT03920163|Experimental|ERATS|Stable penetrating trauma patients undergoing laparotomy who receive enhanced recovery measures post operatively .
11122082|NCT03920150|Active Comparator|Control|5 ml alcoholic solution containing 24'000 IU vitamin D for 3 months
11122083|NCT03920150|Active Comparator|IMP|Vitamin D oily capsules containing 24'000 IU vitamin D for 3 months
11122084|NCT03920150|Active Comparator|IMP + loading dose|Vitamin D oily capsules containing 24'000 IU vitamin D for an individual number of weeks calculated with the formula: 40 x (100 - actual value [nmol/l] x body weight [kg] / 24'000 IU.
11122085|NCT03920137|Active Comparator|Active- UP-ST|The intervention will be the UP-ST therapy sessions. Treatment will be delivered using the new UP-ST protocol that will be developed in Phase I by integrating components of smoking cessation treatments (e.g. using the nicotine patch) with the theoretical model and treatment components of the existing UP treatment protocol, which includes both a therapist14 and patient12 manual. The UP-ST will maintain the same focus on transdiagnostic mechanisms of change as in the original UP, but will be adapted to integrate the smoking cessation focus and concurrent use of NRT. Thus, the investigators can successfully adapt and develop the new UP-ST to be delivered in eight 90-minute sessions and will be able to incorporate content from each of the 8 modules of the UP in the new UP-ST protocol.
11122086|NCT03920137|Experimental|Control- Standard|The Intervention will be the standard therapy sessions. Participants will receive a standard smoking cessation treatment based on the most recent clinical practice guideline from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence19. The investigative team has considerable expertise in developing and evaluating behavioral and pharmacological treatments for smoking cessation. Treatment will be delivered in eight, 90-minute sessions over an eight-week period.
11122087|NCT03920124|Experimental|High intensity interval exercise|Completion of four separate step and walk-based high intensity interval exercise sessions, followed by completion of six week unsupervised (at home) high intensity interval exercise intervention
11122088|NCT03920111|Other|Group 1 - Any status|Up to 3-4 healthy adults
11122089|NCT03920111|Other|Group 2 - FlaviPrime Naive|Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
11122090|NCT03920111|Other|Group 3 - Flavivirus Exposed|Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
11122091|NCT03920098||Primipara pregnant women|Primipara pregnant women
11122092|NCT03920085|Experimental|LifeScan BGMSs|OneTouch Verio, OneTouch Select Plus and OneTouch Ultra Blood Glucose Monitoring Systems (BGMSs) tested using subject capillary blood and compared to a reference instrument (YSI 2900).
11122093|NCT03920072|Other|Open label|All subjects will be administered subcutaneously burosumab every 4 weeks at the dosage defined in study UX023-CL303 or UX023-CL304 until December 2021 or when the drug becomes commercially available.
11122094|NCT03920059|Placebo Comparator|FD arm|MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
11122095|NCT03920059|Active Comparator|CC Arm|MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48
11122096|NCT03920046||Effects of passive smoking on children|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents smoking.
11122097|NCT03920033|Experimental|Hypofractionated|65 Gy/ 26 fractions (fraction size 2.5 Gy)
11122100|NCT03920020|Other|the eccentric isokinetic exercise group|the eccentric isokinetic exercise group will perform quadriceps and hamstring eccentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
11122101|NCT03920020|Other|the control group|the control group will perform the standard exercise program predetermined by us consisting of stretching exercises and isometric strengthening (these exercises will be done at home, too) and the conventional physiotherapy program will be applied 3 times a week during 6 weeks.
11122102|NCT03920007|Experimental|SAR439483|SAR439483 single dose according to an ascending dose design (dose escalation phase) or SAR439483 single dose (dose expansion phase)
11122103|NCT03919994||ABILIFY MAINTENA®|Subjects newly initiated
11122104|NCT03919994||ARISTADA®|Subjects newly initiated
11122105|NCT03919994||INVEGA SUSTENNA®|Subjects newly initiated
11122106|NCT03919994||RISPERDAL CONSTA®|Subjects newly initiated
11122107|NCT03919981||nephropathic cystinosis patients receiving cysteamine|nephropathic cystinosis patients receiving cysteamine. The blood samples of the group will be used to evaluate the action of cysteamine on osteoclastic differentiation and resorption activity of NC patients, depending on the underlying genotype.
11122108|NCT03919968|Experimental|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
11122109|NCT03919968|Active Comparator|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
11122110|NCT03919955|Experimental|Atomoxetine and Oxybutynin|Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.
11122111|NCT03919955|Placebo Comparator|Placebo|Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.
11122112|NCT03919942|Experimental|OxyFlower gel|pericoronitis treatment with oxyflower gel.
11122113|NCT03919942|Experimental|Chlorhexidine gel|pericoronitis treatment with chlorhexidine gel.
11122114|NCT03919942|Placebo Comparator|Placebo gel|pericoronitis treatment with placebo gel.
11122115|NCT03919929|Active Comparator|Diet Intervention|Weight loss with dietary intervention
11122116|NCT03919929|Experimental|GLP-1 Intervention|Participants will take a daily oral tablet of semaglutide for 4 months.
11122117|NCT03919916|Experimental|Serratus plane block and patient controlled analgesia|"Initial local anaesthetic bolus of 0.4 ml/kg of 0.25% levobupivacaine. Subsequent continuous local anaesthetic infusion of 0.125% levobupivacaine
~Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes"
11122118|NCT03919916|Active Comparator|Patient controlled analgesia only|Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes
11122119|NCT03919890|Experimental|ONO-7684 Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
11122120|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
11122121|NCT03919890|Experimental|ONO-7684 Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
11122122|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
11122123|NCT03919890|Experimental|ONO-7684 Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
11122124|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
11122125|NCT03919877|Other|Optimizing Diet for Glycemic Control|"All individuals will go through all the phases of the study.
~Phase 1: Metabolic testing to determine insulin resistance status.
~Phase 2: Participants follow their own diet while using the CGM (continuous glucose monitor). Participants are provided with 5-10 standardized foods to test during this phase.
~Phase 3: Participants are provided with additional standardized foods and counseled to continue their own diet during this phase.
~Phase 4: Participants are counseled on reducing or limiting the foods that caused glucose spikes and they are also counseled on macronutrient composition of their diet based on lipid profile. Participants use the CGM for another cycle of 2-3 weeks to assess effectiveness of the recommendations. Blood is drawn for analyses before and after this cycle."
11122126|NCT03919864|Other|CONNECT Intervention Group|CONNECT includes a multi-component e-tool with the following: (1) a brief educational video that seeks to empower and educate caregivers about the importance of self-care and benefits of supportive care resource use; (2) an assessment of multidimensional supportive care needs (e.g., psychological, behavioral, social, financial, educational, spiritual); (3) a tailored resource list that includes local and national resources corresponding to caregivers needs (Table1); and (4) an optional automated referral to a caregiver navigator to facilitate connection to resources.
11122127|NCT03919864|Other|CONTROL Group|Control arm participants will receive a generic (i.e., not tailored) printed list of hospital, community, and national supportive care resources. Control participants will not receive the educational video, complete the E-tool Preference survey, or have an option for an automated referral to a caregiver navigator
11122128|NCT03919838|Active Comparator|Probiotics|Participants will receive two lozenges containing probiotic bacteria and cranberry.
11122129|NCT03919838|Placebo Comparator|Placebo - No probiotics|Participants will receive a control two lozenges containing no probiotic bacteria.
11122154|NCT03919669|Experimental|All Subjects|All subjects will complete PET imaging sessions evaluating the tau PET radioligand [18F]MK-6240 at baseline, as well as at 6, 12 and 24 months post-baseline.
11122155|NCT03919656|Experimental|Dapagliflozin|Dapagliflozin 10 mg daily (orally)
11122156|NCT03919656|Placebo Comparator|Placebo|Matching placebo for dapagliflozin daily (orally). Does not contain active ingredient
11122130|NCT03919812|Experimental|Vitamin D supplementation according to baseline Vitamin D|The intervention provided according to the participants' state of vitamin D sufficiency. vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance was systematically monitored using drug monitoring diary evaluated by researchers. Blood samples for the study objectives were taken at enrollment and after eight weeks of cholecalciferol supplementation during routinely scheduled visits to the clinic.
11122131|NCT03919799|Experimental|Group 1|20 subjects will be randomized to receive orally administered belumosudil 200 mg QD double-blinded for the first 28 weeks. Subjects will then will be unblinded and continue on the same belumosudil dose for the remaining 24 weeks.
11122132|NCT03919799|Experimental|Group 2|20 subjects will be randomized to receive orally administered belumosudil 200 mg BID double-blinded for the first 28 weeks. Subjects will then will be unblinded, and continue on the same belumosudil dose for the remaining 24 weeks.
11122133|NCT03919799|Placebo Comparator|Group 3|20 subjects will be randomized to receive orally administered matched placebo double-blinded for the first 28 weeks. Subjects will then will be unblinded and re-randomized to one of the belumosudil doses (200 mg QD or 200 mg BID) in a 1:1 fashion.
11122134|NCT03919786|Experimental|intervention group|"Durg：0.375% Ropivacaine and 1% lidocaine
~topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation.
~Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex"
11122135|NCT03919786|Placebo Comparator|normal saline group|Same volume of normal saline will be administrated
11122136|NCT03919773|Active Comparator|Treatment Arm|IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
11122137|NCT03919773|Placebo Comparator|Treatment Placebo Arm|albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
11122138|NCT03919760||NAVIGATE EPI|"This group of first episode psychosis patients is receiving NAVIGATE early psychosis intervention (EPI) as their regular clinical standard of care.
~The project team is implementing NAVIGATE at several early psychosis intervention (EPI) programs in different geographic regions of Ontario. The team will recruit consecutive referrals to these programs in order to determine longitudinal change in functioning and symptoms (hypothesis #3).
~Additionally, the primary data collected for these patients will be linked deterministically to data sources held at the Institute for Clinical Evaluative Sciences (ICES) via their unique health card number. Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
11122139|NCT03919760||Non-NAVIGATE EPI|"This group of first episode psychosis patients received early psychosis intervention other than NAVIGATE as their regular clinical standard of care.
~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
11122140|NCT03919760||Non-EPI|"This group of first episode psychosis patients did not receive early psychosis intervention as their regular clinical standard of care.
~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
11122141|NCT03919734||AI ACS/possible ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression equal to or above 50 nmol/l. The patients should not have clinical signs of Cushing Syndrome, such as catabolic skin and muscle changes.
11122142|NCT03919734||AI non-ACS|Patients with adrenal incidentalomas and cortisol following overnight 1-mg dexamethasone suppression below 50 nmol/l.
11122143|NCT03919734||Treatment with Inhalation Steroids|Patients treated with inhalation steroids with and without ACS/possible ACS but not operated with adrenalectomy.
11122144|NCT03919734||Adrenalectomy|Patients with unilateral AI operated with adrenalectomy
11122145|NCT03919734||Controls|"A Group of Controls matched for sex and age, achieved by the government agency Statistics Sweden (SCB)."
11122146|NCT03919721|Experimental|Learners receiving Applied Behavior Analysis therapy|All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.
11122147|NCT03919708||Enriched Population|Children between the ages of 2-8 who present to an eye clinic. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans and exam should be performed within a single visit. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
11122148|NCT03919708||Unenriched Population|Children between the ages of 2-8 who present to a general pediatric clinic, with no history of eye disorders or amblyopia. Eligible and recruited children will be scanned with a PVS device and an RBI device, and then be provided with a full, gold standard eye exam by a pediatric ophthalmologist. All scans will be performed at a single visit, but the exam may require a follow up visit, depending on the availability of a pediatric ophthalmologist at the clinic at the time of study enrollment. Scans should take no longer than 20 seconds each, and ophthalmic exam should take approximately 30 minutes.
11122149|NCT03919695|Experimental|structural and behavioral intervention|The KISOBOKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component changes the mode of work payment from cash to mobile money.
11122150|NCT03919695|Active Comparator|Screening and Referral|Brief feedback on AUDIT-C score, referral for alcohol counseling, and briefly discussion of the importance of HIV care engagement and adherence.
11122151|NCT03919682|Experimental|Training, Phase 1|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in April-May 2015
11122152|NCT03919682|Experimental|Training, Phase 2|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in November-December 2015
11122153|NCT03919682|No Intervention|Control|6 health centers served as controls and did not receive training during the study period
11122159|NCT03919643||Healthy controls (blood donors)|No intervention. Peripheral blood and urine samples will be obtained
11122160|NCT03919630|Experimental|Cervical Thrust Mobilizations|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine.
11122161|NCT03919630|Active Comparator|Cervical Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
11122162|NCT03919617|Experimental|Open-Label REMD-477|
11122163|NCT03919604||ECLS group|Patients with CF undergoing LUTX. Need for intraoperative extracorporeal life support
11122164|NCT03919604||Non-ECLS group|Patients with CF undergoing LUTX. No need for intraoperative extracorporeal life support
11122165|NCT03919591|Other|Open Label Pilot|Open Label Pilot Study. All subjects will receive the viral challenge inoculum.
11122166|NCT03919578|Experimental|Hep B Batch 1|1 dose of 1 mL Hepatitis B Batch 1
11122167|NCT03919578|Experimental|Hep B Batch 2|1 dose of 1 mL Hepatitis B Batch 2
11122168|NCT03919578|Experimental|Hep B Batch 3|1 dose of 1 mL Hepatitis B Batch 3
11122169|NCT03919578|Active Comparator|Hep B (Bio Farma)|1 dose of 1 mL Hepatitis B (Bio Farma)
11122170|NCT03919565|Active Comparator|TDF group|80 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 144 weeks.
11122171|NCT03919565|Experimental|Peginterferon alfa group|40 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
11122172|NCT03919552|Experimental|Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and carboplatin (AUC 5 on day 1) every three weeks for three cycles during radiotherapy.
11122173|NCT03919552|Active Comparator|Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during radiotherapy.
11122174|NCT03919526|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/ CD22 CAR-T cells in the MRD-positive ALL patients.
11122175|NCT03919513|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
11122176|NCT03919513|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the inspiratory pressure threshold device, combined CPAP and inspiratory pressure threshold device and continue oxygen therapy randomly.
11122177|NCT03919500|Experimental|Erythropoietin|Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
11122178|NCT03919500|Placebo Comparator|Normal saline|Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.
11122179|NCT03919487||Back-to-back colonoscopy group|As I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy.
11122180|NCT03919461|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows. Etodolac:400mg PO bid for the entire intervention period, Propranolol (slow release): 20 mg PO b.i.d. for 5 preoperative days; 80 mg PO b.i.d. on the day of surgery; 40 mg PO b.i.d. for the first post-operative week and 20 mg PO b.i.d. for the second post-operative week.
11122181|NCT03919461|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
11122182|NCT03919448|Active Comparator|Zutrab® (Bevacizumab Richmond)|a single 1 mg/kg IV dose of Bevacizumab
11122183|NCT03919448|Active Comparator|Avastin®|a single 1 mg/kg IV dose of Bevacizumab
11122184|NCT03919448|Active Comparator|Cizumab®|a single 1 mg/kg IV dose of Bevacizumab
11122185|NCT03919435|Experimental|On Drug|
11122186|NCT03919422|Active Comparator|IC group|Interscalene brachial plexus-Cervical plexus
11122187|NCT03919422|Experimental|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
11122188|NCT03919409|Experimental|Part A: Cohort 1: TS-161 15 mg|Single dose of TS-161 15 mg or placebo in a fasted condition.
11122189|NCT03919409|Experimental|Part A: Cohort 2: TS-161 50 mg|Single dose of TS-161 50 mg or placebo which will be dosed first in a fasted condition, and then in a fed condition, with a washout period in between 2 dosing. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
11122190|NCT03919409|Experimental|Part A: Cohort 3: TS-161 100 mg|Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
11122191|NCT03919409|Experimental|Part A: Cohort 4: TS-161 200 mg|Single dose of TS-161 200 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
11122192|NCT03919409|Experimental|Part A: Cohort 5: TS-161 400 mg|Single dose of TS-161 400 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
11122193|NCT03919409|Experimental|Part B: Cohort 6: TS-161 TBD|Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.
11122194|NCT03919409|Experimental|Part C: Cohort 7: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
11122195|NCT03919409|Experimental|Part C: Cohort 8: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
11122196|NCT03919409|Experimental|Part C: Cohort 9: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
11122197|NCT03919396|Experimental|OrthoK|Group wearing Breath-O corrected orthokeratology lenses for 2 years
11122198|NCT03919396|No Intervention|SV Lenses|Group wearing spectacle with single vision lenses for 2 years
11122199|NCT03919383|Experimental|Lenvatinib Plus Toripalimab|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 21-day treatment cycles, and received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11122200|NCT03919370||Cerebral ischemia|Patients undergoing planned surgery for carotid stenosis
11122201|NCT03919370||Reperfusion|Patients undergoing cerebral trombectomy.
11122202|NCT03919357||Verbal|Passing of a specialized questionnaire on verbal disorders
11122203|NCT03919357||Non-verbal|Passing of a specialized questionnaire on non verbal disorders
11122204|NCT03919357||Attention|Passing of a specialized questionnaire on attention disorders
11122205|NCT03919357||Complaint about learning|Passing of a specialized questionnaire on learning disorders
11122206|NCT03919344|Other|Central SAS cases|Patients with central apnea
11122207|NCT03919344|Other|Obstructive SAS controls|Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
11122208|NCT03919344|Other|Snorers controls|Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas <15 / h)
11122209|NCT03919331|Experimental|Experimental|Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
11122210|NCT03919318|Experimental|AH-Plus|
11122211|NCT03919318|Experimental|EndoSeal MTA|
11122212|NCT03919318|Experimental|Endosequence BC Sealer|
11122213|NCT03919292|Experimental|Neratinib + Divalproex Sodium|Neratinib by mouth (PO) once daily + Divalproex Sodium (Valproate) by mouth (PO) twice daily on days 1-28 of each course.
11122214|NCT03919279|Experimental|active arm with active tVNS for 1 month|
11122215|NCT03919266|Other|Control|usual antibiotic treatment
11122216|NCT03919266|Experimental|Intervention|targeted antibiotic treatment according to the results of PCR multiplex
11122217|NCT03919253|Experimental|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously; nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
11122218|NCT03919240|Experimental|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells
11122219|NCT03919227|Experimental|Group 1: empty bladder|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS.
11122220|NCT03919227|Active Comparator|Group 2: natural state of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS.
11122221|NCT03919214|Other|QardioArm and Messaging System|Participants will self-monitor their blood pressure using the Qardio Bluetooth device and obtain 3 separate blood pressure measurements per week (2 morning, 1 evening) for 12 weeks. An automated messaging system for blood pressure management will be triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg. This automated message will be sent to the participant's primary care provider, with copies to the participant and the primary medical oncologist.
11122222|NCT03919201|Sham Comparator|Control group|No exercise intervention
11122223|NCT03919201|Experimental|Resistance band exercise intervention|Exercise intervention group (resistance band exercise training for 12 weeks, 5x per week, for 60 minutes per day).
11122224|NCT03919188|Experimental|body heat loss (BHL) air control|Incubator control using BHL air control method
11122225|NCT03919188|Active Comparator|air temperature control (ATC)|Incubator control using air temperature control (ATC) method
11122226|NCT03919188|Active Comparator|skin servocontrol (SSC)|Incubator control using skin servocontrol method
11122227|NCT03919175|Experimental|Umbralisib+Rituximab|"A treatment cycle is defined as 28 consecutive days.
~Umbralisib will be administered at 800 mg by mouth once daily on days 1-28 of cycles 1-24.
~Rituximab will be administered at 375 mg/m2 by intravenous infusion on Cycle 1 Day 1 and may be administered at 375 mg/m2 by intravenous infusion or at 1400 mg by subcutaneous injection on days 8, 15, 22 of cycle 1, day 1 of cycles 2 to 6, then every 8 weeks starting on day 1 of cycle 7 until completion of 24 cycles of umbralisib (i.e. every other cycle for 18 cycles or 9 doses, for a total of 15 doses of rituximab), or until progression or intolerance."
11122228|NCT03919162|Experimental|600 mg|First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-16 600 mg BID
11122229|NCT03919162|Experimental|300 mg|First 4 weeks 150 mg BID, week 5-12 300 mg BID
11122230|NCT03919162|Experimental|150 mg|8 weeks on 150 mg BID
11122231|NCT03919162|Placebo Comparator|Placebo|
11122232|NCT03919136||Primary Objective|Evaluation of the devices accuracy referenced to interventional (A-line) measurement.
11122233|NCT03919110||Genetically Undiagnosed SAID Patients (guSAID)|"adults and children, with different SAID of unknown pathogenesis, for which no specific mutations is identified and whose pathogenic mechanism remains unknown:
~Still Disease,
~Recurrent pericarditis,
~Neutrophilic dermatosis,
~Schnitzler,
~Vasculitis (Kawasaki disease, Behçet disease, Takayasu arteritis),
~Inflammation of unknown origin,
~Chronic/recurrent osteitis."
11122234|NCT03919110||Parents of guSAID patients|Enrollment of parents of guSAID patients is justified by the TRIO genomic analysis (patient plus two parents) of the guSAID patients without known mutations. Indeed, the TRIO based whole-exome sequencing helps to facilitate the interpretation of genotypes and improve genetic explorations
11122235|NCT03919110||Monogenic SAID patients (mSAID)|This group of patients will serve as positive control to classify other diseases and encompass the following diseases: FMF, TRAPS, HIDS, and CAPS. Investigators aim at recruiting 50 patients per disease entity.
11123968|NCT03906981||Caries active|6-9 year-old caries active (>5 dmft/DMFT) children
11122236|NCT03919110||Patient Free of inflammatory disorders control subjects|In order to set a reference / baseline for the identification of biomarkers the study will need non-inflammatory samples.
11122237|NCT03919097||Control|No atrial arrhythmia post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
11122238|NCT03919097||Atrial fibrillation post ablation|Atrial arrhythmia (Atrial Fibrillation) post-ablation of a flutter by radiofrequency of the isthmus of the cavotricuspid valva.
11122239|NCT03919097||Flutter recidive|Recidive of the flutter after ablation.
11122240|NCT03919097||Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, with previous antecedents of atrial fibrillation.
11122241|NCT03919097||No Atrial Fibrillation antecedents|Patients with atrial fibrillation after flutter ablation, without antecedents of atrial fibrillation.
11122242|NCT03919084|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
11122243|NCT03919084|Experimental|THRIVE+|Enhanced screening-and-referral with motivational interviewing and patient navigation services
11122244|NCT03919071|Experimental|Treatment (radiation therapy, dabrafenib, trametinib)|Patients undergo standardized local RT 5 days a week (Monday-Friday) for 6-7 weeks. Four weeks after completion of RT, patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11122245|NCT03919058|Active Comparator|Regime 1: control regime|All participants start with the control regime, where baseline activity will be measured.
11122246|NCT03919058|Experimental|Regime 2: Sit regime/sit less regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
11122247|NCT03919058|Experimental|Regime 3: Sit less regime/sit regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
11122248|NCT03919058|Experimental|Regime 4: Exercise regime|The exercise regime is the final regime for all participants. This is comparable with the sit regime, but 1h of sitting is replaced with 1 exercise bout.
11122249|NCT03919045|Experimental|Sodium chloride injection|Sodium chloride 9mg/ml by injection
11122250|NCT03919045|Placebo Comparator|Needle sting|Brief needle stings without injection
11122251|NCT03919019|Experimental|Macuprev Group|patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months
11122252|NCT03919019|Placebo Comparator|Placebo Group|patients taking oral placebo 2 capsules per day for 6 months
11122253|NCT03919006|Active Comparator|Periodontitis|"GCF, saliva and serum samples were taken before and after treatment from periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
11122254|NCT03919006|Active Comparator|Gingivitis|"GCF, saliva and serum samples were taken before and after treatment from gingivitis patients.
~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
11122255|NCT03919006|Placebo Comparator|Periodontally healthy|GCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
11122256|NCT03918993||Group T|31 Patients with ED who receiving 5 mg/day of Tadalafil for 8 weeks.
11122257|NCT03918993||Group C|Thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up
11122258|NCT03918980|Experimental|Part 1 Dose A|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122259|NCT03918980|Experimental|Part 1 Dose B|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122260|NCT03918980|Experimental|Part 1 Dose C|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122261|NCT03918980|Experimental|Part 1 Dose D|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122262|NCT03918980|Experimental|Part 1 Dose E|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122263|NCT03918980|Experimental|Part 1 Dose F|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122264|NCT03918980|Experimental|Part 1 Dose G|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122265|NCT03918980|Experimental|Part 1 Dose H|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122266|NCT03918980|Experimental|Part 1 Dose I|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122267|NCT03918980|Experimental|Part 1 Dose J|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
11122268|NCT03918980|Placebo Comparator|Part 1 Placebo|(Single Ascending Dose) Healthy volunteers will receive a single dose of placebo.
11122269|NCT03918980|Experimental|Part 2 Dose K|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
11122270|NCT03918980|Experimental|Part 2 Dose L|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
11122271|NCT03918980|Experimental|Part 2 Dose M|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
11122272|NCT03918980|Experimental|Part 2 Dose N|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
11122273|NCT03918980|Experimental|Part 2 Dose O|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
11122274|NCT03918980|Experimental|Part 2 Dose P|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
11122275|NCT03918980|Placebo Comparator|Part 2 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo once daily for 12 days
11122276|NCT03918980|Experimental|Part 3 Dose Fasted|Healthy volunteers will receive a single dose of LOU064 given under fasting conditions followed by a single dose of LOU064 given after a high fat meal (cross-over design).
11122843|NCT03915067|Active Comparator|BOTOX Low Dose|BOTOX Low Dose will be injected into the platysma muscle on Day 1.
11122277|NCT03918980|Experimental|Part 3 Dose Fed|Healthy volunteers will receive a single dose of LOU064 given after a high fat meal followed by a single dose of LOU064 given under fasting conditions (cross-over design).
11122278|NCT03918980|Experimental|Part 4 Dose R|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
11122279|NCT03918980|Experimental|Part 4 Dose S|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
11122280|NCT03918980|Placebo Comparator|Part 4 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo twice daily for 12 days
11122281|NCT03918980|Experimental|Part 5 Formulation A|Healthy Volunteers will receive a single dose of LOU064 formulation A followed by a single dose of LOU064 formulation B (cross-over design).
11122282|NCT03918980|Experimental|Part 5 Formulation B|Healthy Volunteers will receive a single dose of LOU064 formulation B followed by a single dose of LOU064 formulation A (cross-over design).
11122283|NCT03918980|Experimental|Part 6 Dose T|Subjects with atopic dermatitis will receive a twice daily dose of LOU064 for 4 weeks
11122284|NCT03918980|Placebo Comparator|Part 6 Placebo|Subjects with atopic dermatitis will receive a twice daily dose of placebo for 4 weeks
11122285|NCT03918967|Experimental|CT-G11|CT-G11 Experimental Drug
11122286|NCT03918967|Experimental|CT-G20|CT-G20 Experimental Drug
11122287|NCT03918967|Placebo Comparator|CT-G11 Placebo|
11122288|NCT03918967|Placebo Comparator|CT-G20 Placebo|
11122289|NCT03918954|Active Comparator|Physical sensory room|In the inpatient ward there is a specifically designed room for calming down which a patient can request access to. In the room there is calming music, soft mats, nature themed wallpaper and calming visual lighting.
11122290|NCT03918954|Experimental|Virtual sensory room|The patients will have access to wireless virtual reality glasses during a session. The glasses will have a specially made protection that will be disinfected between each user, all users will also have the opportunity to choose a disposable cover for the glasses. The VR glasses are adjustable and adaptable to all types of head sizes and can be used with regular glasses. The application accessable in the VR glasses is called Calm Place, a virtual natural environment with day and night cycles, dynamic weather and associated soundscapes.
11122291|NCT03918941|Experimental|Carey|
11122292|NCT03918941|Active Comparator|conventional information|
11122293|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1|1 drop in each eye at bedtime.
11122294|NCT03918915|Experimental|Part 1: SYD-101 Dose 1; Part 2: Vehicle|1 drop in each eye at bedtime.
11122295|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
11122296|NCT03918915|Experimental|Part 1: SYD-101 Dose 2; Part 2: Vehicle|1 drop in each eye at bedtime.
11122297|NCT03918915|Placebo Comparator|Part 1: Vehicle; Part 2: SYD-101 Dose 2|1 drop in each eye at bedtime.
11122298|NCT03918889|Experimental|dexmedetomidine|patients receive dexmedetomidine infusion
11122299|NCT03918889|Experimental|midazolam|patients receive midazolam infusion
11122300|NCT03918876||Healty Dancers|Healthy adult dancers
11122301|NCT03918876||Injured Dancers|Injured adult dancers
11122302|NCT03918863|Experimental|Neuromuscular electrical stimulation|8-week exercise program, twice a week, with neuromuscular eletrical stimulation on vastus medialis and gluteus medius.
11122303|NCT03918863|Active Comparator|Exercise|8-week exercise program, twice a week.
11122304|NCT03918850|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.
~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
11122305|NCT03918850|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.
~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
11122306|NCT03918837|Sham Comparator|Sham rTMS|"The investigators will perform sham rTMS at 30% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days. The coil will have a 180° rotation compared to the active coil position, thus making the magnetic field ineffective on the patient's cortex.
~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment.
~All participants of this group will have the opportunity to undergo an active rTMS treatment right after the end of each one's participation in the study."
11122307|NCT03918837|Active Comparator|Active rTMS|"The investigators will perform active rTMS at 120% of the Motor Threshold, with a 1Hz frequency and 1200 pulses during one session. The target will be the right Orbito Frontal Cortex, localized using Neuronavigation. Sessions will last fifteen minutes; subjects will perform two sessions a day during five days.
~Participants will undergo a MRI with anatomical and ASL sequences one week before and four weeks after treatment"
11122308|NCT03918811|Experimental|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
11122309|NCT03918811|Active Comparator|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
11122310|NCT03918798|Experimental|Chloroprocaine 1%|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
11122311|NCT03918798|Experimental|Chloroprocaine 2%|All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
11122394|NCT03918057|Active Comparator|Treatment as Usual Group|Participants receive usual obstetric care and are placed on a wait-list until six months postpartum. All activities or efforts participants make to treat or improve their sleep on their own is recorded and coded. After the final assessment six months postpartum, participants have the option of receiving 1.5-hour sessions (for a total of 5 session) of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
11122312|NCT03918785|Experimental|Rice Germ|"The Rice Germ was supplied in vacuum jars of a weight of 130 grams. These jars once opened, were stored in the refrigerator (-3-4°C). Together with cans, small containers were provided to act as dosers and served to determine the correct dose to be taken (25 grams, twice a day). The rice germ or placebo were continually taken every day twice a day (25 grams in the morning with breakfast and 25 grams in the afternoon as snacks) for 5 weeks. The rice germ was supplied by the company Acquerello (TenutaColombara, Livorno Ferraris, Vercelli, Italy)."
11122313|NCT03918785|Active Comparator|Control group|Active comparator, which consisted of an isocaloric wheat germ-based supplement. Characteristics of supplementation are the same of experimental group.
11122314|NCT03918772||Perioperative immediate hypersensitivity|Patients having experienced perioperative immediate hypersensitivity
11122315|NCT03918746|Experimental|internet Attachment-Based Compassion Therapy (iABCT)|"The intervention will consist of an internet version of Attachment-Based Compassion Therapy (iABCT).
~The length of the intervention will depend on the pace of each participant that will be advised to carry out one module per week, taking days between sessions to complete homework assignments. It is estimated that the online intervention can be completed in eight weeks, with a maximum period of ten weeks. However, each participant will be free to advance at his/her own pace. Formal telephone support will be not systematically provided, but participants will contact for technical assistance (i.e., web accessibility problems or forgotten password) if necessary."
11122316|NCT03918733|Experimental|surgical treatment|surgical treatment of failed root canal treated teeth following secondary root canal treatment.
11122317|NCT03918733|Experimental|Non surgical retreatment|Non surgical retreatment of failed root canal treated teeth
11122318|NCT03918720|Experimental|Trekkers|
11122319|NCT03918720|No Intervention|Controls|
11122320|NCT03918707||Prospective|The prospective group will consist of approximately 15 evaluable patients who will undergo rWGS sequencing in addition to standard of care genetic testing. Subjects in this study will be drawn from children admitted to the NICU at OSF HealthCare Children's Hospital of Illinois who meet inclusion criteria.
11122321|NCT03918707||Historical Control|The historical control group will consist of patients admitted to the NICU between January 1, 2016 and December 31, 2018 who received genetic testing at less than 4 months of age and fulfil eligibility criteria.
11122322|NCT03918694|Active Comparator|Experimental|Participants will receive Vit C tablets
11122323|NCT03918694|Placebo Comparator|Placebo|Participants will receive placebo tablets
11122324|NCT03918681|Experimental|Intervention Group|The experimental group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups experimental group participants will receive gait retraining cues to transition to a NRFS running pattern.
11122325|NCT03918681|No Intervention|Control Group|The control group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups control group participants will not receive any gait retraining cues and will only be instructed on standard of care return to run metrics to include volume, load, and duration of running.
11122326|NCT03918655||Patient newly diagnosed with AML (prospectively)|Patient newly diagnosed with AML in Saint Antoine hospital or Tours University hospital in 2018 to 2020.
11122327|NCT03918655||Patient diagnosed with AML (retrospectively)|Patient diagnosed with AML in Saint Antoine hospital in 2015 to 2018
11122328|NCT03918642|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
11122329|NCT03918642|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
11122330|NCT03918629|Experimental|Clostridium difficile vaccine - 3 dose|All 3 doses are the Clostridium difficile vaccine
11122331|NCT03918629|Experimental|Clostridium difficile vaccine - 2 dose|2 of the 3 doses are the Clostridium difficile vaccine with the other being placebo
11122332|NCT03918616||PD + AD|Patients with newly-diagnosed (onset of suggestive symptoms not later than 3 months) Parkinson disease (PD) or Alzheimer disease (AD) with no previous specific treatment, no anti-inflammatory drugs assumed in the three months preceding the enrolment and no chronic inflammatory diseases or cancer.
11122333|NCT03918616||Control group|An age and gender matched control group (n=50) was formed, on a volunteer basis, by the spouse of the probands participating in the study.
11122334|NCT03918603|Experimental|ultra-protective multimodal ventilation group|Patient will be diposed on ventral decubitus: one session at least more than 12 hours between inclusion and H48
11122335|NCT03918603|No Intervention|protective ventilation group|Patient will received usual care
11122336|NCT03918590|Active Comparator|A single drop of nepafenac 0.3% suspension|A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
11122337|NCT03918590|Other|Patching|A light pressure patch applied for two hours
11122338|NCT03918590|Placebo Comparator|A single drop of preservative-free Artificial Tears|A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
11122339|NCT03918577|Experimental|right cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their right external ear canal, with before and after measures of OCRD symptom severity and insight.
11122340|NCT03918577|Experimental|left cold caloric vestibular stimulation|OCRD participants in this arm will receive an approx 60 second infusion of distilled cold(4)c water in their left external ear canal, with before and after measures of OCRD symptom severity and insight.
11122844|NCT03915067|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1.
11122341|NCT03918551|Other|Sequence AB|25 subjects assigned to the sequence AB will receive a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11122342|NCT03918551|Other|Sequence BA|25 subjects assigned to the sequence BA will receive a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11122343|NCT03918538|Experimental|The intervention group|"After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual.
~The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers."
11122344|NCT03918538|No Intervention|The control group|Participants in the control group received regular medication education.
11122345|NCT03918499|Experimental|Treatment (pembrolizumab, cyclophosphamide, and IRX-2)|Participants receive pembrolizumab IV over 30 minutes on day 1. Participants also receive cyclophosphamide IV on day 1 and IRX-2 SC for 10 days starting on day 4 during cycles 1, 5, 9, 13, 17, 21, 25, 29, and 33. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease or unacceptable toxicity.
11122346|NCT03918486||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
11122347|NCT03918473|Experimental|Mobilization with Movement|A weight- bearing mobilization directed to the talocrural joint in a standing position.
11122348|NCT03918473|Experimental|Thrust Mobilization|A high velocity, low amplitude thrust mobilization directed to the talocrural joint with the participant in a non-weight bearing position.
11122349|NCT03918460|Experimental|Intervention|All patients enrolled are intended to be treated
11122350|NCT03918447|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.
~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100.
~Patients will be assessed at an in-person follow-up visit at Week 104."
11122351|NCT03918447|Experimental|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.
~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100.
~Patients will be assessed at an in-person follow-up visit at Week 104."
11122352|NCT03918447|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.
~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive placebo during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 and will continue treatment through Week 100.
~Patients will be assessed at an in-person follow-up visit at Week 104"
11122353|NCT03918421||Immunogloblin M-anti myelin-associated-glycoprotein neuropathy|Patient group (25 subjects) presenting with an Immunogloblin M-anti myelin-associated-glycoprotein peripheral neuropathy
11122354|NCT03918408|Experimental|Pulsed, accelerated|30 mW, 5 sec, 5 sec off, 10 minutes of illumination
11122355|NCT03918408|Active Comparator|Conventional|9 mW, continuous 10 minutes of illumination
11122356|NCT03918395|Placebo Comparator|Placebo|Placebo beverage
11122357|NCT03918395|Active Comparator|Protein-Polyphenol supplement|Protein-polyphenol beverage
11122358|NCT03918382|No Intervention|Control group|First phase. 97 participants. This group will continue standard procedure regarding side effect registration and handling. When the 97 patients have been included and have finished their radiotherapy the second phase will be initiated.
11122359|NCT03918382|Experimental|PRO group|Second phase. 194 participants. This group will be assigned to the intervention which is weekly electronic Patient-Reported Outcomes. Patients report the symptoms (PRO) on a tablet before each weekly control visit. The clinician will use the patients PRO answers as part of the consultation. The PRO symptoms consist of head and neck relevant items fra PRO-CTCAE™ (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) and EORTC (European Organisation for Research and Treatment of Cancer) item library.
11122360|NCT03918369|Experimental|Laparoscopic Intracorporeal anastomosis|Laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis.
11122361|NCT03918369|Active Comparator|Laparoscopic extracorporeal anastomosis|Laparoscopic right hemicolectomy with extracorporeal anastomosis.
11122395|NCT03918031|Active Comparator|PFI for Smoking & Distress Tolerance|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking and distress tolerance.
11122396|NCT03918031|Active Comparator|PFI for Smoking Only|A brief, one-session computer-delivered personalized feedback intervention (PFI) that addresses smoking only (no distress tolerance component).
11122397|NCT03918005|Experimental|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
11122362|NCT03918356|Experimental|Inclusion Body Myositis patients|Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
11122363|NCT03918356|Experimental|Idiopathic Inflammatory Myopathies patients|Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
11122364|NCT03918356|Placebo Comparator|control|Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
11122365|NCT03918343|Other|All patients|
11122366|NCT03918317|Experimental|AirXpanders AeroFormtissue expander + Radiation therapy|AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
11122367|NCT03918291|Experimental|Addition of whole-body vibration to squat training|The addition of whole-body vibration to squat training (for 12 weeks, 3x/week). The mechanical stimulation parameters of the vibration consisted of the following: frequency of 35 to 40 Hz, amplitude of 4 mm and acceleration that ranged from 2.78 to 3.26 G
11122368|NCT03918291|Other|Squat training|Squatting exercises for 12 weeks, 3x/week
11122369|NCT03918278|Experimental|MK-0482 Monotherapy|Participants receive escalating doses of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
11122370|NCT03918278|Experimental|MK-0482 + Pembrolizumab Combination Therapy|Participants receive escalating doses of MK-0482 via IV infusion + pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 administrations (up to approximately 2 years).
11122371|NCT03918265|Experimental|Efficiency of tacrolimus on autoimmune cytopenia|"A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.
~Medication time should last at least 6 months."
11122372|NCT03918252|Experimental|Arm A Nivolumab Only|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
11122373|NCT03918252|Experimental|Arm B Nivolumab + Ipilimumab|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
11122374|NCT03918239|Experimental|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
11122375|NCT03918239|Experimental|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
11122376|NCT03918226|Other|Exploratory Laparotomy|Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis
11122377|NCT03918213|Experimental|healthy subjects examined with solid-state catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
11122378|NCT03918200||Study|Women with unexplained infertility
11122379|NCT03918200||Control|Fertile women who had normal physical and pelvic examination, regular menstrual cycles, don't use hormonal contraceptive, had one child at least.
11122380|NCT03918187|Experimental|bupivacaine|12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
11122381|NCT03918187|Active Comparator|nalbuphine|12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
11122382|NCT03918187|Active Comparator|midazolam|12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
11122383|NCT03918174|Experimental|Dart Splint orthosis|The Dart-Splint orthosis allows oblique wrist motion along the Dart Throwing Motion (DTM) plane, thus inhibiting movement of the healing structures following surgery around the distal radius. This is a hinged orthosis that permits selective midcarpal mobilization along the plane of the DTM is a novel orthotic device that was developed in order to facilitate protected midcarpal motion.
11122384|NCT03918174|Experimental|The conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions.
11122385|NCT03918161|Experimental|MRE exam|Magnetic Resonance Elastography (MRE) exam associated with standard T1-weighted and T2-weighted sequences
11122386|NCT03918148||SGLT-2i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:
~dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily"
11122387|NCT03918148||DPP-4i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:
~sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily"
11122388|NCT03918135|Experimental|Paracetamol|Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 100 patients
11122389|NCT03918135|Experimental|İbuprofen|İbuprofen 400mg of ibuprofen (intrafen 400mg/4ml solution Gen ilaç sanayi,Turkey ) intravenous (IV) was given 100 patients
11122390|NCT03918109|Experimental|OTO-313|
11122391|NCT03918109|Placebo Comparator|Placebo|
11122392|NCT03918083|Other|5-pronged wellness approach|30-day assessment of daily exercise, mindfulness, sleep, social connectedness, and nutrition
11122393|NCT03918057|Experimental|Cognitive-Behavioural Therapy Group|Participants receive 5 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
11122398|NCT03918005|Active Comparator|High glycemic load diet|Foods with high glycemic index or glycemic load (white rice, white bread, corn flakes, mashed potatoes, orange juice, banana, persimmon, grape, raisins, honey, sugar)
11122399|NCT03917979|Experimental|Individual GIM|Participants are provided with a series of individual GIM sessions.
11122400|NCT03917979|Other|Waitlist Control|Participants complete an initial wait list period, then are provided with a series of Group GIM sessions.
11122401|NCT03917966|Experimental|SHR-1210+Docetaxel+nedaplatin|SHR-1210+Docetaxel+nedaplatin
11122402|NCT03917953|Experimental|Arm I|Patients receive transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
11122403|NCT03917953|Sham Comparator|Arm II|Patients receive sham transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
11122404|NCT03917940|Experimental|Omega 3 + glimepiride|group 1: 35 patients treated with (Omega - 3 1000mg / day oral plus glimepiride 2mg or 3mg /day.
11122405|NCT03917940|Placebo Comparator|Control|group 2: 35 patients treated with glimepiride 2mg or 3mg /day.
11122406|NCT03917927|Experimental|Eztetic dental implant|Eztetic 3.1mm diameter, lengths 8, 10, 11.5, 13, 16 mm
11122407|NCT03917914|Active Comparator|Bisoprolol|1.25, 2.5 or 5mg of bisoprolol daily
11122408|NCT03917914|Placebo Comparator|Placebo|1.25, 2.5 or 5mg of matched placebo daily
11122409|NCT03917901|Experimental|Anxiety Sensitivity Training|The Anxiety Sensitivity training (AST) will provide: (1) psychoeducation on anxiety sensitivity and its consequences, (2) psychoeducation on the relationship between anxiety sensitivity and obesity-related health behavior correlates, and (3) concrete, evidenced-based strategies to reduce anxiety sensitivity.
11122410|NCT03917901|Placebo Comparator|Health Control|The Health Control (HC) will cover general health care, such as information on wearing sunscreen and regular attendance to doctor appointments. The HC will not provide any recommendations or education on mood, dietary, or physical habits.
11122411|NCT03917888|Experimental|Lung ultrasound|Patients will be monitored for ventilator associated pneumonia using lung ultrasound combined with clinical features
11122412|NCT03917888|No Intervention|Chest x-ray|Patients will be monitored for ventilator associated pneumonia using chest x-ray and clinical features.
11122413|NCT03917875|No Intervention|Control|
11122414|NCT03917875|Experimental|PFI|
11122415|NCT03917862|No Intervention|Control|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques.
11122416|NCT03917862|Active Comparator|TDM-621|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques and will receive the TDM-621 for complementary hemostasis.
11122417|NCT03917849|Experimental|Heavy slow resistance training|"The program is performed 3 times per week using resistance equipment in a fitness center. Each session consists of three 2-legged loaded quadriceps and lower limb kinetic chain exercises. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 3 exercises.
~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 times, 15-repetition maximum (15RM ), in week 1; 3 times, 12RM , in weeks 2 to 3; 4 times, 10RM , in weeks 4 to 5; 4 times, 8RM , in weeks 6 to 8; and 4 times, 6RM , in weeks 9 to 12."
11122418|NCT03917849|Experimental|Inertial flywheel resistance training|The program is performed 3 times per week using resistance equipment in a fitness center. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 12 repetition máximum (RM) with moment inertia 0.05 m² from week 1-6 and 8 repetition máximum (RM) with moment inertia = 0.10 m² from week 6-12.
11122419|NCT03917823|Experimental|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
11122420|NCT03917823|Sham Comparator|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
11122421|NCT03917810|Active Comparator|MODSUG|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
11122422|NCT03917810|Experimental|LOWSUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
11122423|NCT03917810|Experimental|LOWCHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
11122424|NCT03917797|Experimental|MSC treatment|Intervention: a previously selected dose of MSCs (Phase IIa) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
11122425|NCT03917797|Placebo Comparator|Placebo|Intervention: A Placebo (infusion vehicle) will be administered by i.v. infusion at baseline and 6 months of follow-up (total 12 months), to patients with Severe Renal SLE subject also to Standard of Care treatment with Methylprednisolone and Cyclophosphamide followed by Mycophenolate.
11122426|NCT03917784|Experimental|Curcumin and bioperine|This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months
11122427|NCT03917784|Placebo Comparator|Placebo|This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months
11122428|NCT03917771|Experimental|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery. Lower Limb measurement and care education
11122429|NCT03917771|Active Comparator|Usual follow-up|The usual follow-up will be carried out in GO consultation (0,1,6,12 months)
11122430|NCT03917758|Experimental|Diabetic patients|30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.
11122431|NCT03917745|Experimental|eHealth mindfulness intervention group|8 weeks of internet mindfulness training
11122432|NCT03917745|No Intervention|Control group|Care as usual
11122433|NCT03917732|Experimental|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.
~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
11122434|NCT03917732|Active Comparator|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.
~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
11122435|NCT03917719|Experimental|Dose 1|Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.
11122436|NCT03917706||Congenital Heart Disease|Adults suffering from congenital heart disease, followed within the CHU Brugmann hospital, operated during childhood.
11122437|NCT03917693|Active Comparator|Phytin capsules|2.4 g phytin to be consumed daily for a period of 2 weeks. Participants will consume 2 test capsules containing phytin, 3 times a day with a meal for a period of 2 weeks.
11122438|NCT03917693|Placebo Comparator|Microcrystalline cellulose (MCC) capsules|2.4 g MCC to be consumed daily for a period of 2 weeks. Participants will consume 2 placebo capsules, each containing microcrystalline cellulose, 3 times a day with a meal for a period of 2 weeks.
11122439|NCT03917680|Experimental|Type III angioedema|White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
11122440|NCT03917680|Experimental|Idiopathic angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
11122441|NCT03917680|Experimental|Type I or II angioedema|White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.
11122442|NCT03917680|Experimental|Post IEC (conversion enzyme inhibitors) angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.
11122443|NCT03917680|Experimental|Histaminic angioedema|Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
11122444|NCT03917680|Other|Control|Healthy individuals, no angioedema.
11122445|NCT03917667||Geriatric patients|Patients aged 70 years and older who are admitted to the acute care geriatric units.
11122446|NCT03917654|Experimental|Arm 1a/3c|Arm 1a (pilot) + Arm 3c (main) to receive 40 microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of artemether/lumefantrine (AL) on day -7
11122447|NCT03917654|Active Comparator|Arm 1b/3d|Arm 1b (pilot) + Arm 3d (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
11122448|NCT03917654|Experimental|Arm 2a/3a|Arm 2a (pilot) + Arm 3a (main) to receive 40 microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7 and 154
11122449|NCT03917654|Active Comparator|Arm 2b/3b|Arm 2b (pilot) + Arm 3b (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7 and 154
11122450|NCT03917654|Experimental|Arm 3e|Arm 3e (main) to receive 40 microg of Pfs230D1M-EPA/AS01 on days 0, 28, 168; receipt of AL on day -7
11122451|NCT03917654|Active Comparator|Arm 3f|Arm 3f (main) to receive HAVRIX (day 0), TYPHIM Vi (day 28), HAVRIX (day 168); receipt of AL on day -7
11122452|NCT03917654|No Intervention|Arm 4a|Receipt of AL on day 154
11122453|NCT03917654|No Intervention|Arm 4b|Receipt of AL on day 154
11122454|NCT03917641|Experimental|Patients after Oculoplastic surgery|"Each participant will use one compression with Khat leaves and another standard compression and will decide on which eye to use which compression.
~The compressions will be used for 10 minutes per every waking hour in the first 2 days post-op.
~The patient will take pictures of both his eyes in days 1,3 and 7 post operative days."
11122455|NCT03917628|Experimental|SCT630|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing SCT630
11122456|NCT03917628|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
11122457|NCT03917615|Experimental|"after women health course"|The participants will be instructed to contract the pelvic floor muscle
11122458|NCT03917615|Active Comparator|"before women health course"|The participants will be instructed to contract the pelvic floor muscle
11122459|NCT03917602|Experimental|Patients with large macular holes|Patients suffering from large macular holes as documented by spectral domain OCT will undergo pars plan vitrectomy with human amniotic membrane insertion into the macular hole.
11122460|NCT03917589||Patients with corticosteroids|Patients who have systematically been treated by high-dose corticosteroids after the delivery
11122461|NCT03917589||Patients without corticosteroids|Patients who haven't been systematically treated by high-dose corticosteroids after the delivery.
11122462|NCT03917576|Active Comparator|Normoglicamic group|Control normoglycaemic participants
11122463|NCT03917576|Active Comparator|Hyperglicaemic group|Control hyperglicaemic group
11122464|NCT03917576|Experimental|Experimental group|Experimental Type 2 Diabetes Mellitus Group
11122465|NCT03917563|Experimental|Intervention group|WATCHMAN LAA occluder treatment
11122466|NCT03917550|Experimental|Recovery (Transdiagnostic & self)|A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.
11122467|NCT03917550|Active Comparator|Transdiagnostic|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
11122468|NCT03917537||HNSCC patients have used Nivolumab|Retrospectively analyze WGS information from cancer tissues from HNSCC patients have used Nivolumab
11122877|NCT03914820|Active Comparator|Comparator|Standard surgey without HIPEC CO2
11122469|NCT03917524||no need for any adjuvant therapy|Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy
11122470|NCT03917524||with risk factors|Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status
11122471|NCT03917511|Experimental|Robotic training with mirror therapy|20 minutes mirror therapy followed by 40 minutes robotic-assisted training
11122472|NCT03917511|Sham Comparator|Robotic-assisted training|20 minutes sham mirror therapy followed by 40 minutes robotic-assisted training
11122473|NCT03917498|Experimental|Single Pre-Operative Radiation Therapy with Delayed Surgery|Single Pre-Operative Radiation Therapy with Delayed Surgery
11122474|NCT03917472|Experimental|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
11122475|NCT03917472|Active Comparator|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
11122476|NCT03917459|Experimental|LCZ696|
11122477|NCT03917459|Active Comparator|Enalapril|
11122478|NCT03917446||Euvolaemic|
11122479|NCT03917446||Hypovolaemic|
11122480|NCT03917433|Experimental|Exposure with Tactile Feedback|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
11122481|NCT03917433|Experimental|Exposure with Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. The participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
11122482|NCT03917433|Experimental|Exposure with Tactile Feedback and Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world. Also, the participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
11122483|NCT03917433|Other|Virtual Reality Exposure Therapy Alone|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
11122484|NCT03917420|Experimental|Tenofovir/Emtricitabine|Participants will take 5 once daily doses above noted combination tab at 200mg/300mg before each sampling visit
11122485|NCT03917407|Active Comparator|Arm1: DUR-928 treatment for moderate alcoholic hepatitis|Enrolled alcoholic hepatitis patients would have MELD of 11-20; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with moderate alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
11122486|NCT03917407|Active Comparator|Arm 2: DUR-928 treatment for severe alcoholic hepatitis.|Enrolled alcoholic hepatitis patients would have MELD of 21-30; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with severe alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
11122487|NCT03917394||rHuEPO monotherapy group|rHuEPO was administrated during hospitalization period.
11122488|NCT03917394||iron sucrose monotherapy group|Iron sucrose was administrated during hospitalization period.
11122489|NCT03917394||rHuEPO combined with iron sucrose group|rHuEPO combined with iron sucrose was administrated during hospitalization period.
11122490|NCT03917394||control group|Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.
11122491|NCT03917381|Experimental|Arm|GEN1046 Open label, single arm trial where GEN1046 will be administered
11122492|NCT03917368|Experimental|Ultrasound scan of the internal jugular veins|Hospitalised adult patients, requiring a scheduled central venous catheterisation and measurement of the central venous pressure as part of their usual care, will undergo a non-invasive ultrasound scan of the internal jugular veins (both side of the neck) synchronized with an ECG trace, to assess the jugular venous pulse. This procedure will be performed once throughout the study.
11122493|NCT03917342|Active Comparator|Control Group|EEG measure in 15 healthy women undergoing elective hysteroscopy under single shot spinal anesthesia. Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
11122494|NCT03917342|Active Comparator|Healthy parturients|EEG measure in 15 healthy parturients undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
11122495|NCT03917342|Active Comparator|Preeclamptic parturients|EEG measure in 15 parturients with preeclampsia undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
11122496|NCT03917329|Other|ACT and PBS group workshop|The intervention in this study is an Acceptance and Commitment Therapy (ACT) and Positive Behaviour Support (PBS) group workshop for parents and education staff of children with intellectual disabilities.
11122497|NCT03917316||ADHD|
11122498|NCT03917316||Control|
11122499|NCT03917303|Active Comparator|Adalimumab|Episodic adalimumab monotherapy as first line treatment for 6 months
11122500|NCT03917303|Active Comparator|Standard step-up care|Step-up care as first line treatment, starting with corticosteroids.
11122501|NCT03917290|Experimental|Intervention|Upon clearance to RTP after concussion, participants randomized to NMT will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency for 8 weeks.
11122502|NCT03917290|No Intervention|Usual Care|Participants cleared to RTP in the usual care arm will return to sports and not undergo any intervention.
11122503|NCT03917277|Experimental|Musculoskeletal ultrasound of the ankle|"see Intervention description"
11122504|NCT03917264|Active Comparator|Tooth-borne treatment|Titanium curettes
11122505|NCT03917264|Experimental|Implant-specific treatment|Implant brush
11122549|NCT03916978|Placebo Comparator|Control Group: Participants receiving Platelet Free Plasma|Women in menopause, 45-55 years old, treated with autologous PFP intra ovarian infusion.
11122550|NCT03916952||Healthy younger|All participants between 18 and 65 years of age that completed the test
11122506|NCT03917251|Other|Right ventricular Pacemaker|Patients with right ventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
11122507|NCT03917251|Other|Biventricular Pacemaker|Patients with Biventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
11122508|NCT03917238|Other|Patients with T1D|gallium-68-exendin followed by a PET/CT scan (twice)
11122509|NCT03917225|Active Comparator|Active|
11122510|NCT03917225|Placebo Comparator|Placebo|
11122511|NCT03917212||Patients|Patients with propionic acidemia, isovaleric acidemia, methylmalonic acidemia
11122512|NCT03917212||Controls|Healthy humans
11122513|NCT03917186|Active Comparator|Group sevoflurane|Administration under labelling conditions
11122514|NCT03917186|Experimental|Group desflurane|Administration under labelling conditions
11122515|NCT03917173|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin
11122516|NCT03917173|Active Comparator|Comparator|Standard surgery
11122517|NCT03917160|Experimental|EMS treatment|Subjects will undergo treatment with EMS and measurements
11122518|NCT03917160|No Intervention|Control|Subjects will undergo measurements only
11122519|NCT03917147||AUB in Post-Menopause|Abnormal Uterine Bleeding (AUB) in Post-Menopause
11122520|NCT03917147||Endometrial Thickening in post-menopause|Ultrasonographic detection of Thickened Endometrium in post-menopause
11122521|NCT03917147||Endometrial Thickening in pre-menopause|Ultrasonographic detection of Thickened Endometrium in pre-menopause
11122522|NCT03917147||Pharmacological history of Tamoxifen-related therapy regimens|Patients who had been treated with Tamoxifen
11122523|NCT03917134|Experimental|cephalosporin + Metronidazole|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
11122524|NCT03917134|Placebo Comparator|cephalosporin + placebo|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
11122525|NCT03917121|Experimental|Jet anesthesia|Local infiltration anesthesia delivered using Madajet XL® (MADA Medical Products, Inc., Carlstadt, NJ, USA) needle-free jet injector
11122526|NCT03917121|Active Comparator|Conventional infiltration anesthesia|Local infiltration anesthesia delivered using 25 gauged short needle attached, 1.8 ml carpule loaded standard metal dental syringe
11122527|NCT03917108|Active Comparator|retraction cord|
11122528|NCT03917108|Other|subgingival clamp|
11122529|NCT03917095|Active Comparator|Mesalazine conventional enema|Participants undergo the conventional enema of Mesalazine Enemas (4g) for one week.
11122530|NCT03917095|Experimental|Mesalazine TET enema|Participants undergo the TET enema of Mesalazine Enemas (4g) for one week.
11122531|NCT03917095|Active Comparator|Compound Glutamine conventional enema|Participants undergo the conventional enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
11122532|NCT03917095|Experimental|Compound Glutamine TET enema|Participants undergo the TET enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
11122533|NCT03917095|Experimental|Compound Glutamine and Mesalazine TET enema|Participants undergo the TET enema of Mesalazine(4g) and Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
11122534|NCT03917082|Experimental|standard of care endocrine therapy for two years|Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
11122535|NCT03917069|Experimental|nab-paclitaxel + endostatin+ carboplatin|nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d
11122536|NCT03917069|Active Comparator|paclitaxel+carboplatin|paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
11122537|NCT03917056|Experimental|Long needle group|Participants were treated with CAES using long needle.
11122538|NCT03917056|Experimental|Short needle group|Participants were treated with CAES using short needle.
11122539|NCT03917043|Experimental|APG-2449|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 15 patient at the MTD dose level.
11122540|NCT03917030|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
11122541|NCT03917030|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
11122542|NCT03917017|Experimental|Radiomics and Watson artificial intelligence|
11122543|NCT03917004|Experimental|hypotension group (group H )|particcipants in hypotension group are received controlled hypertension in the operation.
11122544|NCT03917004|No Intervention|control group (group C )|participants in cotrol group are received no controlled hypertension in the operation
11122545|NCT03916991|Experimental|Neuromuscular Exercise|Neuromuscular Exercise
11122546|NCT03916991|No Intervention|Control|No intervention
11122547|NCT03916991|Sham Comparator|Sham Exercise|Sham Exercise
11122548|NCT03916978|Experimental|Participants receiving PRP treatment|Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.
11122551|NCT03916952||Healthy older|All participants > 65 years of age that completed the test
11122554|NCT03916926|Experimental|"A simple medical strategy consisting of SDF"|The treatment will be bi-annual application (at baseline and 26 weeks) of topical 38% silver diamine fluoride (Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL) following manufacturer's instructions and guidelines published by UCSF (2016).
11122555|NCT03916926|Active Comparator|"A typical dental strategy consisting of ART + FV"|Atraumatic Restorative Treatment (ART) will be a modification of the approach used by Lo and colleagues (2006), and the cavity restored at baseline with resin reinforced glass-ionomer cement (GIC) (GC Corporation, Japan). Participants in this arm will also receive biannual topical fluoride varnish application (FluoriMax, Elevate) according to manufacturer's instructions.
11122556|NCT03916913|Experimental|Local therapy|Consolidation local radiotherapy
11122557|NCT03916900|Experimental|Pulpotomy|"Group A (Experimental group) Pulpotomy:
~The teeth will be anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain) by inferior alveolar nerve block.Under rubber dam isolation, pulpotomy will be performed with a large sterile round end bur in a high speed hand piece with copious irrigation; pulp tissue will be removed by a sharp spoon excavator to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet moistened with 2.5% NaOCL for 2 min and repeated if needed.
~After hemostasis, Biodentine (Septodont, Saint Maur des Fausses, France) will be mixed according to the manufacturer's instructions and gently placed over the pulp to thickness of 2-3 mm.Biodentine will be covered by resin modified glass-ionomer and teeth will be restored using composite resin.A postoperative radiograph will be taken by parallel technique."
11122558|NCT03916900|Active Comparator|Root canal treatment|"Group B (control group) Root canal treatment:
~The teeth were anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain).Under rubber dam isolation, root canal treatment will be performed in single visit.Working length will be determined using stainless steel k-files (Mani, Inc.) keeping 0.5 to 1.0 mm short of the apex using a RootZX apex locator (J. Morita, Irvine, CA) and confirmed radiographically. Mechanical preparation will be achieved by a crown-down technique using using the M-PRO system (IMD, Shanghai, China) and irrigation with 5 mL 2.5% NaOCl between instruments.Obturation will be done with gutta-percha (Meta Biomed Co. Ltd, Cheongwongun, Chungbuk, Korea) and resin sealer ADseal (Meta Biomed CO., LTD, Korea) using cold lateral condensation technique and restored with composite resin with a base of glass-ionomer cement. A postoperative radiograph will be taken by parallel technique."
11122559|NCT03916887|Experimental|golf training|10-week golf training program
11122560|NCT03916874||Pregnant females and her newborn.|A longitudinal study of one cohort of 250 pregnant females less than 22 weeks gestation and her newborn. Swabs and samples (low vaginal, skin, urine, blood and stool) will be requested at one time point during each trimester from the participant. In addition, there are three different questionnaires at trimester 2.
11122561|NCT03916861|Experimental|Bioelectrical Impedance|The first group will be monitored by Inbody S20 analysis to measure fluid status. The Bioimpedance will be measured each time prior to hemodialysis session . The value of BIA measurement of more than 0.4 will be considered as edema.
11122562|NCT03916861|Active Comparator|Physicain-guided group|The fluid monitoring will be managed by physician-adjustment by physical examination and fluid balance record . The fluid balance (FB) is the total fluid administered minus the total fluids eliminated over a period of time.
11122563|NCT03916848|Experimental|Combined Micro-Macro SEEG Electrodes|Implanting SEEG electrodes with combined micro-macro electrodes capable of recording clinical data and experimental micro electrode single unit data
11122564|NCT03916835|Other|Music Therapy during cleaning care 1|"This group receives music therapy during cleaning care 1 and not during the cleaning care 2.
~Each patient will act as their own control"
11122565|NCT03916835|Other|Music Therapy during cleaning care 2|"This group receives music therapy during cleaning care 2 and not during the cleaning care 1.
~Each patient will act as their own control"
11122566|NCT03916822||ABMR|Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies
11122567|NCT03916822||TCMR|Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3
11122568|NCT03916822||No Rejection|Biopsy-proven, or clinical criteria
11122569|NCT03916809|Experimental|Active EMST + Standard Care|Patients randomized to the Active EMST + Standard Care arm (ACTIVE) will use the EMST150 device as packaged, i.e. following package instructions with a device that has its valve spring maintained.
11122570|NCT03916809|Sham Comparator|Sham EMST + Standard Care|Those randomized to the Sham EMST + Standard Care arm (SHAM) will use an EMST150 device that has been modified by removing the internal spring, which allows the valve to open in response to airflow through the device regardless of the amount of pressure generated.
11122571|NCT03916796|Experimental|Dietary Counseling/Exercise/ERAS/Psychological Counsel|"Patients must be treated using daily image-guided radiotherapy
~Dietary counseling at baseline
~Exercise intervention at baseline, physical therapy visits during radiotherapy & during the post-radiotherapy period until the week of surgery
~Enhanced recovery after surgery (ERAS) - patients with extremity and trunk STC will be treated with the hip/knee protocol and patients with abdominal/retroperitoneal STS will be treated with the hepatobiliary protocol
~Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
11122572|NCT03916783|Experimental|Combination intervention|Selected families in the other 20 clinics (n=~40 families) will be assigned to the treatment condition (delivered over 9 months) to receive BSC plus a family EE intervention comprising of a matched family development account (FDA) for health-related expenses, including transport to UCI, food/nutrition, and health insurance. Combined with the Family EE will be four sessions of Financial Literacy and Management (FL&M) and two sessions of cancer education. The sessions will be conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.
11122573|NCT03916770|Active Comparator|whole body vibration|WBV(whole body vibration) will be applied to interventional group for 4 weeks, 2 days a week, a total of 8 sessions while standing upright with the WBV powerplate pro5 device.(Vibration frequency: 30Hz, amplitude: 2.2 mm and duration 1x10 seconds (starting period) + 3x30 seconds).
11122611|NCT03916523|Experimental|Group B|Infants in the group receive CPAP for respiratory support in the delivery room. No sustained lung inflation will be applied.
11122574|NCT03916770|Sham Comparator|Sham whole body vibration|The sham WBV will be applied to the Control group. A WBV device with 99.5% weakened amplitude will be used for sham WBV. (Application duration of the sham WBV will be 1x10 seconds (starting period) + 3x30 seconds).
11122575|NCT03916757|Experimental|V-Boost recipients|In this open label study all eligible participants will receive daily tablet of V-Boost
11122576|NCT03916744|Experimental|GDC-9545 Dose Level 1|
11122577|NCT03916744|Experimental|GDC-9545 Dose Level 2|
11122578|NCT03916744|Experimental|GDC-9545 Dose Level 3|
11122579|NCT03916731|Experimental|STARgraft AV|Participants will be implanted with 6mm diameter STARgraft AV grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
11122580|NCT03916731|Active Comparator|Control (ePTFE)|Participants will be implanted in the same upper arm location with standard 6mm diameter ePTFE dialysis access grafts. All other aspects of this study arm are identical to the Experimental one.
11122581|NCT03916718||Dementia|The target population includes patients seen at Ochsner Clinic Foundation, >=55 years old, diagnosed with dementia, and meeting other inclusion/exclusion criteria. this study will recruit subjects identified as high utilizers of the Ochsner System. This will be defined by >= 2 ED visits, >= 2 Hospitalizations, or some combination prior to baseline. We will co-variate by insurance plan.
11122582|NCT03916705|Other|single study arm|All enrolled participants will undergo ultrasound evaluation and chiropractic low back spinal manipulation treatment.
11122583|NCT03916692|Experimental|Standard Process - glucose balance|Standard Process - glucose balance formula (200 kcal)
11122584|NCT03916692|Experimental|Energy smart Carbohydrate blend|Energy smart carbohydrate blend (50 grams, 200 kcal)
11122585|NCT03916692|Active Comparator|Liquid Dextrose Control|Liquid dextrose solution in the form of TRUTOL ® Glucose Tolerance Test Beverage (50 grams, 200 kcal)
11122586|NCT03916679|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
11122587|NCT03916653|Experimental|Test group|Osseous resection using piezoelectric device
11122588|NCT03916653|Active Comparator|Control group|Osseous resection using conventional rotary instruments
11122589|NCT03916640|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.
11122590|NCT03916640|Active Comparator|Humulin® + Symlin®|Simultaneous, separate subcutaneous injections of human insulin and pramlintide.
11122591|NCT03916640|Active Comparator|Humalog®|Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.
11122592|NCT03916627|Experimental|Cohort A1|Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
11122593|NCT03916627|Experimental|Cohort A2|Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
11122594|NCT03916627|Experimental|Cohort A3|Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
11122595|NCT03916627|Experimental|Cohort B|Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
11122596|NCT03916627|Experimental|Cohort C|Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC)
11122597|NCT03916614|Experimental|START treatment|Participants randomized into the treatment arm will receive the START intervention as described above alongside usual care from the VPOP staff
11122598|NCT03916614|Active Comparator|standard of care|Those randomized to the control arm will receive the usual screening for PTSD and referral for outpatient services if warranted as well as usual care from VPOP staff.
11122599|NCT03916601|Experimental|Test (T)|SAR341402 Mix 70/30: single dose injection
11122600|NCT03916601|Active Comparator|Reference 1 (R1)|NovoLog Mix 70/30: single dose injection
11122601|NCT03916601|Active Comparator|Reference 2 (R2)|NovoMix30: single dose injection
11122602|NCT03916601|Experimental|Reference 3 (R3)|SAR341402 rapid-acting solution: single dose injection
11122603|NCT03916588||Memory Care Unit Residents|Residents on a locked memory care unit in southeastern Louisiana will be enrolled. Engaged family members and staff will also consent to provide qualitative information on the resident.
11122604|NCT03916562|Experimental|Healthy Participants|The investigators will determine how asymmetric walking constraints influence spatiotemporal coordination, energetic cost, and dynamic balance in healthy individuals. The investigators will manipulate spatiotemporal coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
11122605|NCT03916562|Experimental|Post-stroke Participants|The investigators will determine how different patterns of coordination during walking influence energetic cost and dynamic balance in people post-stroke. The investigators will manipulate coordination using a special treadmill. Energetic cost will be quantified using expired gas analysis and inverse dynamic approaches. Stability will be evaluated by characterizing participants' ability to recover from unexpected perturbations.
11122606|NCT03916549|Experimental|Group 1|The patients with bowel dysfunction following low anterior resection performed at least 1 year ago will undergo acupuncture. The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
11122607|NCT03916536|Active Comparator|Holmium Laser|holmium laser enucleation of the prosteate
11122608|NCT03916536|Active Comparator|Thulium Laser|Thulium laser enucleation of the prosteate
11122609|NCT03916536|Active Comparator|Bipolar Enucleation|Bipolar enucleation of the prosteate
11122610|NCT03916523|Experimental|Group A|Infants in the group receive CPAP for respiratory support in the delivery room. In addition, they receive a total of 15 sustained lung inflations in the first 96 hours of life; 6 in the first day, 3 in the second day, 3 in the third day and 3 in the forth day of life.
11122612|NCT03916523|Active Comparator|Group C|Infants in this group are intubated in the delivery room and supported with mechanical ventilation.
11122613|NCT03916510|Experimental|Dosing schedules 1 to 6|"Dosing Group 1:
~- Loading dose pre chemoradiation (CRT) - 1x10^12 viral particles (vp)
~Dosing Group 2:
~Loading dose pre CRT - 1x10^12 vp
~Maintenance dose post CRT - 1x10^12vp
~Dosing Group 3:
~Loading dose pre CRT - 1x10^12vp
~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 1x10^12vp
~Maintenance dose post CRT - 1x10^12vp
~Dosing Group 4:
~- Loading dose pre CRT - 3x10^12vp
~Dosing Group 5:
~Loading doses pre CRT - 3x10^12vp
~Maintenance dose post CRT - 3x10^12vp
~Dosing Group 6:
~Loading dose pre CRT - 3x10^12vp
~Concurrent doses on Week 1, Day 1 and Day 5 of CRT - 3x10^12vp
~Maintenance post CRT - 3x10^12vp"
11122614|NCT03916497||Group 1 : kidney transplant recipients (KTR)|
11122615|NCT03916497||Group 2 : hemodialysis patients|
11122616|NCT03916497||Group 3 : Control patients|
11122617|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention|AQ: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). The participant may or may not stay solely on AQ throughout the study.
11122618|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention + NSC|AQ+NSC: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). NSC sessions are scheduled approximately every other week (frequency) and last approximately 30 minutes per session (dose). The participant may or may not stay on AQ+NSC throughout the study.
11122619|NCT03916484|Experimental|AQ followed by AQ+NSC|At 3 months, those who were initially randomized to AQ who meet protocol defined definition for intervention non-responsiveness, are reassigned to AQ+NSC to complete months 4 - 6 of the trial.
11122620|NCT03916484|Experimental|AQ+NSC followed by AQ|At 3 months, those who were initially randomized to AQ+NSC who meet protocol defined definition for intervention responsiveness, may get re-randomized to AQ alone to complete months 4 - 6 of the trial.
11122621|NCT03916471|Experimental|S (SOLYX)|The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.
11122622|NCT03916471|Experimental|O (OBTRYX II)|The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.
11122623|NCT03916458||Subjects with reported metastatic renal cell carcinoma|The subjects have been treatment with sunitinib and they reached complete remission
11122624|NCT03916445||gynecological cancer|all patients having a consultation doctor during the recruiting time
11122625|NCT03916445||chronic gynecological disease|all patients having a consultation doctor during the recruiting time
11122626|NCT03916432|Experimental|Interventional group|HELIOS biodegradable polymer sirolimus-eluting stents
11122627|NCT03916419|Experimental|Safety lead-in: Chemoradiation + Durvalumab|"The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.
~Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every two weeks for up to 12 months."
11122628|NCT03916419|Experimental|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every two weeks for up to 12 months.
11122629|NCT03916406|Experimental|Sequence 1|midazolam alone followed by combination of PF 06835919 and midazolam
11122630|NCT03916406|Experimental|Sequence 2|PF 06835919 in combination with midazolam followed by midazolam alone
11122631|NCT03916393|Experimental|PF-06651600 Treatment A|Active pharmaceutical ingredient (API)solution in water
11122632|NCT03916393|Experimental|PF-06651600 Treatment B|API in sweetened solution
11122633|NCT03916393|Experimental|PF-06651600 Treatment C|API blend suspension in water
11122634|NCT03916393|Experimental|PF-06651600 Treatment D|API blend suspension in apple sauce
11122635|NCT03916393|Other|Bitrex (Registered) Treatment E|Positive control for bitterness
11122636|NCT03916380|No Intervention|Group A|Tacrolimus Extended Release + Midazolam
11122637|NCT03916380|Active Comparator|Group B|Tacrolimus Extended Release + Midazolam + Grapefruit Juice
11122638|NCT03916367||Early Stage Lung Cancer|The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
11122639|NCT03916354||appropriate GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is in the recommended normal range is in this group.
11122640|NCT03916354||excess GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is over the upper limit of the recommended normal range is in this group.
11122641|NCT03916354||insufficient GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is below the lower limit of the recommended normal range is in this group.
11122642|NCT03916341|Experimental|Non-user|Non- users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
11122643|NCT03916341|Experimental|Chronic EC user|Chronic EC users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
11122644|NCT03916341|Experimental|Chronic TC smoker|Chronic TC smokers will use, in a randomized, crossover fashion with a 4 week washout, a 1) TC with nicotine (own brand), 2) research TC with very low level nicotine, and 3) a straw (control)
11122645|NCT03916328|Active Comparator|DMPA+ and TDF+|HIV-infected women on DMPA, and TDF containing ART.
11122646|NCT03916328|Experimental|DMPA+ and B/F/TAF+|HIV-infected women on DMPA, and B/F/TAF.
11122647|NCT03916328|Experimental|DMPA- and B/F/TAF+|HIV-infected women on non hormonal contraception, and B/F/TAF.
11122648|NCT03916315|Experimental|Transdiagnostic Treatment|Participants in this group will receive from 11 to 17 sessions of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
11122649|NCT03916315|No Intervention|Control group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 11-12 sessions will take place in the intervention group.
11122650|NCT03916302||Complicated outcome|"The patients meet at least one of the following criteria:
~systolic blood pressure < 90 mmHg for at least 15 minutes
~need for catecholamine administration because of persistant arterial hypotension or shock
~need for mechanical ventilation
~need for cardiopulmonary resuscitation
~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
11122651|NCT03916302||Non-complicated outcome|"The patients meet none of the following criteria:
~systolic blood pressure < 90 mmHg for at least 15 minutes
~need for catecholamine administration because of persistant arterial hypotension or shock
~need for mechanical ventilation
~need for cardiopulmonary resuscitation
~bleeding classified according to the International Society on Thrombosis and Haemostasis classification (major bleeding and non-major clinically relevant bleeding)."
11122652|NCT03916276|Active Comparator|Cognitive Therapy (CT) Condition|Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain.
11122653|NCT03916276|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
11122654|NCT03916276|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
11122655|NCT03916263|Experimental|Traditional Treatment|Participant receives recommendations for caloric intake, exercise and prescription for metformin if indicated
11122656|NCT03916263|Other|One-On-One Low Starch Dietary Instruction|Participant receives One-On-One Low Starch Dietary Instruction from Study Collaborator
11122657|NCT03916263|Other|Low Starch Dietary Instruction by Video|Participant receives Low Starch Dietary Instruction by Video Link
11122658|NCT03916250|Experimental|PF-06700841 cream 0%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
11122659|NCT03916250|Experimental|PF-06700841 cream 0.1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
11122660|NCT03916250|Experimental|PF-06700841 cream 0.3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
11122661|NCT03916250|Experimental|PF-06700841 cream 1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
11122662|NCT03916250|Experimental|PF-06700841 cream 3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
11122663|NCT03916250|Experimental|White petrolatum|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
11122664|NCT03916237|No Intervention|CONTROL|Control group
11122665|NCT03916237|Experimental|GROUP A no referral|Screener does not document need for home visit or medical legal partnership referral.
11122666|NCT03916237|Experimental|GROUP B1 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener does not document need for medical legal partnership.
11122667|NCT03916237|Experimental|GROUP B2 home assessment only|Screener documents need for home assessment. Home assessment does not document need for home remediation. Screener documents need for medical legal partnership.
11122668|NCT03916237|Experimental|GROUP C1 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener does not document need for medical legal partnership.
11122669|NCT03916237|Experimental|GROUP C2 home assessment and remediation|Screener documents need for home assessment. Home assessment documents need for home remediation. Screener documents need for medical legal partnership.
11122670|NCT03916237|Experimental|D medical legal partnership only|Screener does not document need for home assessment. Screener does not document need for medical legal partnership.
11122671|NCT03916224||Intubated critically ill patients|Critically ill patients older than 18 years old, intubated in an Intensive Care Unit.
11122672|NCT03916211|No Intervention|routine treatment|Diabetic foot routine treatment without intervention
11122673|NCT03916211|Experimental|MSCs treatment|On the basis of routine treatment of diabetic foot, adipose stem cells will be added to treat diabetic foot
11122674|NCT03916198|Experimental|PDRN(polydeoxyribonucleotide)|polydeoxyribonucleotide 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
11122675|NCT03916198|Placebo Comparator|CONTROL(normal saline)|normal saline 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
11122676|NCT03916185|Experimental|RSV ΔNS2/Δ1313/I1314L Vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
11122677|NCT03916185|Experimental|RSV 6120/ΔNS2/1030s Vaccine|Participants will receive a single dose of the RSV 6120/ΔNS2/1030s vaccine at study entry (Day 0).
11122678|NCT03916185|Experimental|RSV 276 Vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
11122679|NCT03916185|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11122680|NCT03916172|Experimental|APT Treatment|Participants in this arm will receive the Open Door Approach to Parenting Teenagers (APT). It offers 6 weekly 50-minute appointments with an optional 7th review session.
11122681|NCT03916172|No Intervention|Waiting List|Participants in this group will be placed on a waiting list and will receive APT treatment after no longer than 25 weeks.
11122682|NCT03916159|Experimental|Extrauterine Placental Transfusion EPT|Intervention group
11122683|NCT03916159|Active Comparator|Delayed cord clamping DCC|Control group
11122684|NCT03916146|Experimental|Behavioral Parent Training|
11122685|NCT03916146|No Intervention|Control|
11122686|NCT03916133|Other|Intervention group|Included patients will undergo angiographic FDCT perfusion imaging.The study will be embedded in the standard procedure of pre-operative diagnostics and angiographic control after EC-IC bypass treatment of steno-occlusive disease and during pre-embolization mapping and embolization procedure. An informed consent will be acquired during consultations in the preparatory process of the different examinations and treatments
11122687|NCT03916120||Postoperative Analgesic Failure|
11122688|NCT03916120||Postoperative Analgesic Success|
11122689|NCT03916107|Experimental|Levator muscle and tarsus resection|
11122690|NCT03916107|Active Comparator|Frontal muscle flap|
11122691|NCT03916094|Experimental|HLX22 group|HLX22, at four dose levels (1, 3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
11122692|NCT03916081|Active Comparator|ARQ-151 cream 0.05%|
11122693|NCT03916081|Active Comparator|ARQ-151 cream 0.15%|
11122694|NCT03916081|Placebo Comparator|ARQ-151 cream Vehicle|
11122695|NCT03916068|Experimental|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO2) - 100% oxygen at 2.4 atmospheres ATA for 90 minutes, Monday-Friday for 30 sessions (six weeks)
11122696|NCT03916068|Active Comparator|Trental and Vitamin E|Trental (pentoxifylline), 400 milligrams three times a day in combination with Vitamin E, 400 international units orally twice daily for six months
11122697|NCT03916055|Experimental|Exposure and response prevention (ERP)|Therapist-guided and parent-guided internet-delivered exposure and response prevention (ERP)
11122698|NCT03916055|Active Comparator|Education on tics|Therapist-guided and parent-guided internet-delivered education on tics
11122699|NCT03916042|Experimental|Reproxalap (0.25% Novel Formulation) QID to BID|
11122700|NCT03916042|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
11122701|NCT03916029|Active Comparator|Facilitator|120 hours training for local community members delivered on-country face-to-face during 6 4-day weeks and over a 3-6 month period. Certificate II modules in Aboriginal Primary Health Care, ear and hearing health skills development (otoscopy, tympanometry, and hearScreen) and employment as Ear Health Facilitators to the end of the trial.
11122702|NCT03916029|No Intervention|Control|No Facilitator. Brief 6-monthly 2 to 3 hour in-service training via zoom for health professionals.
11122703|NCT03916016|Experimental|Intervention Group|The intervention group received enhanced integrated behavioral health care.
11122704|NCT03916016|Active Comparator|Control Group|The control group received care as usual only.
11122705|NCT03916003|Experimental|PQ7|high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
11122706|NCT03916003|No Intervention|standard care|As per national guidelines for P. falciparum treatment
11122707|NCT03915990|Other|control group|60 healthy pregnant women will be included
11122708|NCT03915990|Active Comparator|controlled diabetics|30 diabetic pregnant women with controlled Diabetes (i.e. HbA1C less than 6.5 %)
11122709|NCT03915990|Active Comparator|uncontrolled diabetics|30 diabetic pregnant women with uncontrolled Diabetes (i.e. HbA1C equal or more to 6.5 %)
11122710|NCT03915964|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
11122711|NCT03915964|Experimental|Baricitinib High Dose|Baricitinib administered orally.
11122712|NCT03915964|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
11122713|NCT03915951|Experimental|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.
~Patients will receive the following per 28-day (± 3 days) cycle:
~Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)
~Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
11122714|NCT03915938|Experimental|Group S-Ketamine|S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
11122715|NCT03915938|Placebo Comparator|Group Placebo|A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.
11122716|NCT03915912|Experimental|Mindfulness meditation|Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and ~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.
11122719|NCT03915886|Experimental|JNJ-0440 (Low Dose) or Placebo|Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
11122720|NCT03915886|Experimental|JNJ-0440 (Medium Dose) or Placebo|Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
11122721|NCT03915886|Experimental|JNJ-0440 (High Dose) or Placebo|Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.
11122722|NCT03915873||vWB patients|
11122723|NCT03915873||control|
11122724|NCT03915860|Experimental|Trifarotene|Open label, CD5789 (trifarotene) 50μg/g Cream
11122725|NCT03915847|Active Comparator|Single layer closure|
11122726|NCT03915847|Active Comparator|Double layer closure|
11122727|NCT03915847|Active Comparator|Doble layer closure with trimming|
11122728|NCT03915834||endovascular treatment group|
11122729|NCT03915821|Experimental|Patients diagnosed as major depression according to DSM V|"All patients presented with major depression disorder not received ECT previously within 6 monthes, admitted to the study site ( Psychiatry department, in Assiut University Hospital, Assiut, Egypt). They Fulifilled will be recruited within 6 monthes duration .
~The patients classified into group A comprised that will be treated with Unipolar ECT, and group B comprised that will be treated Biploar ECT."
11122730|NCT03915808|Experimental|Conjugated linoleic acid plus lifestyle counselling|supplementation of 3.2 g/day conjugated linoleic acid and receive education sessions regularly
11122731|NCT03915808|Placebo Comparator|Sunflower oil plus lifestyle counselling|supplementation of equivalent sunflower oil, and receive education sessions regularly
11122732|NCT03915782|Experimental|Remote Ischemic Conditioning (RIC) positive|Patients with remote ischemic conditioning
11122733|NCT03915782|Sham Comparator|Control group|The control group will receive a sham procedure (same procedure than Remote Ischemic Conditioning (RIC) with brachial cuff inflation to 30 millimeters (mm) of mercury (Hg) during 40 minutes).
11122734|NCT03915769|Experimental|0.46 mg ozanimod oral capsule once daily (QD)|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.46 mg ozanimod.
11122735|NCT03915769|Experimental|0.92 mg ozanimod oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.92 mg ozanimod.
11122736|NCT03915769|Placebo Comparator|Placebo oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with a placebo capsule, followed by 3 days of treatment with two placebo capsules, followed by two placebo capsules.
11122737|NCT03915756|Experimental|With drain|Participants who received a drain during surgery
11122738|NCT03915756|No Intervention|Without drain|Participants who did not receive a drain during surgery
11122739|NCT03915743|Experimental|Palliative care|Specialized palliative care arm in a newly formed COPD outpatient clinic
11122740|NCT03915743|No Intervention|Usual care|Usual care in a standard pulmonary out-patient clinic. Treatment as described in national standards.
11122741|NCT03915730|Experimental|Smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
11122742|NCT03915730|Experimental|Non-smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Never smoked patients were included into the nonsmoker group
11122743|NCT03915730|No Intervention|Smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
11122744|NCT03915730|No Intervention|Non-smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Never smoked patients were included into the nonsmoker group
11122745|NCT03915704|Experimental|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
11122746|NCT03915704|Experimental|Shotblocker|ShotBlocker is a small, flat, yellow horseshoe-shaped plastic tool that is non-invasive, appropriate for every age group, does not have the characteristics of medication or adverse effects. ShotBlocker has short, blunt points that provide contact with skin on one side, and a hole that exposes the injection site in the middle of the tool. It is used by being held on the skin surface during injection. The pointed surface of the tool is placed on the administration area right before the injection
11122747|NCT03915704|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
11122748|NCT03915691|Active Comparator|Ripple Mapping|Intervention: Ripple Mapping guided catheter ablation of atrial tachycardia.
11122749|NCT03915691|Active Comparator|Conventional Mapping|Intervention: conventional catheter ablation of atrial tachycardia.
11122750|NCT03915678|Experimental|Population 1: Pancreatic cancer|Participants with pancreatic cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
11122751|NCT03915678|Experimental|Population 2: Virus-associated tumors|Participants with virus-associated tumors will be treated with Atezolizumab combined with BDB001 and radiotherapy.
11122752|NCT03915678|Experimental|Population 3: anti-PD-1/L1 refractory non-small lung cancer|Participants with anti-PD-1/L1 refractory non-small lung cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
11122753|NCT03915678|Experimental|Population 4: Soft-tissue sarcoma|Participants with soft-tissue sarcoma will be treated with Atezolizumab combined with BDB001 and radiotherapy.
11122754|NCT03915678|Experimental|Population 5: anti-PD-1/L1 refractory bladder cancer|Participants with anti-PD-1/L1 refractory bladder cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
11122755|NCT03915678|Experimental|Population 6: Triple negative breast cancer|Participants with anti-PD-1/L1 refractory triple negative breast cancer will be treated with Atezolizumab combined with BDB001 and radiotherapy.
11122756|NCT03915665|Active Comparator|Standard treatment|Manual treatment One application of Chlorhexidine 1% gel
11122757|NCT03915665|Experimental|Comprehensive treatment|Supragingival biofilm removal with Erythritol air-powder Submucosal biofilm removal with Erythritol air-powder (30%-60% power)
11122758|NCT03915652|Experimental|Rheum iCMP Wave 1|20 patients enrolled immediately in Rheum iCMP
11122759|NCT03915652|Experimental|Rheum iCMP Wave 2|20 patients enrolled in Rheum iCMP after 4 months; will receive monthly lupus educational materials mailed to their home during the first 4 months
11122760|NCT03915652|Experimental|BWH iCMP to Rheum iCMP|70 lupus patients within the Partners system who are already enrolled in BWH iCMP will have their iCMP nurse trained in lupus-specific care
11122761|NCT03915639|Experimental|Cocktail|Participants in Group Cocktail are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with the multimodal cocktail.
11122762|NCT03915639|Active Comparator|Ropivacaine|Participants in Group Ropivacaine are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with ropivacaine.
11122763|NCT03915626|Experimental|RLD patch|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
11122764|NCT03915626|Experimental|generic patch|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
11122765|NCT03915626|Experimental|RLD patch with heat|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
11122766|NCT03915626|Experimental|generic patch with heat|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
11122767|NCT03915613|Experimental|Insulin|"Intranasal insulin will be made prepared from Humulin® R [insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly]. Each mL contains: 100 units of insulin injection, human biosynthetic (rDNA Origin) REGULAR. Nonmedicinal ingredients contain: glycerol, hydrochloric acid, m-cresol, sodium hydroxide and water for injection.
~Unopened vials should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials should be stored at room temperature <25°C (<77°F) and discarded after 28 days.
~To obtain a dose Humulin R 160 U / placebo
~16 sprays (0.1 mL/spray) are to be given per dose
~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.
~The sprays will be administered between alternating nostrils"
11122768|NCT03915613|Placebo Comparator|Sterile Diluent|"Intranasal placebo will be prepared from Eli Lilly's sterile diluent used with Humulin® R (10 mL/vial, manufactured by Eli Lilly). Nonmedicinal ingredients contain: dibasic sodium phosphate, glycerin, liquefied phenol, metacresol, hydrochloric acid, sodium hydroxide and water for injection.
~Unused sterile diluent should be kept at controlled room temperature until the expiration date. The USP defines controlled room temperature as (20° to 25°C [68° to 77°F]), with excursions permitted (15° to 30°C [59° to 86°F]). Once in-use, the sterile diluent vial should be used within 28 days.
~Participants will follow the same dosage, frequency, and administration as Humulin:
~16 sprays (0.1 mL/spray) are to be given per dose
~This works out to 16 sprays split between each nostril such that each nostril receives 8 sprays.
~The sprays will be administered between alternating nostrils"
11122769|NCT03915600|Experimental|Quinoa|Personalized diet added with quinoa
11122770|NCT03915600|Experimental|Flaxseed|Personalized diet added with Flaxseed
11122771|NCT03915600|Experimental|Quinoa and Flaxseed|Personalized diet added with quinoa and flaxseed
11122772|NCT03915600|No Intervention|Normal diet|Personalized diet without dietary supplement
11122773|NCT03915587|Other|Fluid Challenge|After defining fluid responders from non-responders in this single arm prospective trial, we will compare the predictive utility of non-invasive devices such as the CipherOx-CRI and IVC CI to currently employed indices (heart rate, systolic blood pressure, urine output and pulse pressure variability) to gauge the need for additional fluid and ongoing resuscitation.
11122774|NCT03915574|Experimental|Dural Puncture Epidural|Participants will receive a dural puncture epidural block with a 25 gauge spinal needle followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
11122775|NCT03915574|Active Comparator|Standard Epidural|Participants will have standard epidural infusion followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
11122776|NCT03915561|Active Comparator|Study group|This group will be received intravenous injection with 10ml transparent mixture solution with 40mg Dynastat and 0.9% saline twice
11122777|NCT03915561|Placebo Comparator|Placebo|This group will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice
11122778|NCT03915548|Experimental|The Behavioral Activation/ Problem Solving Intervention|BA/PS teaches survivors to a) systematically examine the reasons an activity is challenging, b) set achievable short-term goals that have the potential to improve participation, c) brainstorm solutions including activity adaptations and environmental modifications, d) construct and implement a detailed action plan, and e) evaluate the results and level of goal attainment. The structured process gives participants repeated practice in goal reengagement that leads them progressively closer to their long-term functional goals. The BA/PS framework integrates the cognitive-behavioral therapies of Behavioral Activation and Problem-solving Treatment and incorporates concepts from an occupational therapy theory called the Person-Environment-Occupational Performance Model.
11122836|NCT03915119|Experimental|Agility Group|"Initial Visit: Completes a soccer ball dribbling agility task in which they must dribble a soccer ball toward an artificial way-point, while avoiding artificial obstacles overlaid onto the real world via a Microsoft Hololens augmented reality display.
~Second (Training) Visit"
11122837|NCT03915106||Bracing|AIS patients undergoing bracing to control the spinal curve progression
11122838|NCT03915106||Surgical|Severe AIS patients requiring surgical intervention to correct the spinal curve
11122779|NCT03915548|Active Comparator|Attention Control Condition|"Investigators provide education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts. The control condition will match the intervention in terms of the number of sessions, the delivery by telephone, use of an occupational therapist, and the use of homework between sessions (i.e., reading the education materials for the control condition versus executing the action plan for the BA/PS condition)."
11122780|NCT03915535|Active Comparator|MaxSimil|Subjects of group A will receive a constant daily dose of 4.3g of MaxSimil, a combination of EPA + DHA in proportions of 500/200, for a period of 90 days.
11122781|NCT03915535|Experimental|MAG-EPA|Subjects of group B will receive a constant daily dose of 4.4g of MAG-EPA, a purified formulation of EPA with traces of DHA (730/050), for a period of 90 days.
11122782|NCT03915522|Experimental|Adductor Canal Block|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a single adductor canal block wiht 20cc of 0.5% Ropivacaine using ultrasound guidance .
11122783|NCT03915522|Placebo Comparator|Placebo Comparator|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a sham adductor canal block with 2ml of 1% subcutaneous lidocaine at the level of the adductor canal using ultrasound guidance.
11122784|NCT03915509|Experimental|Bioactive group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
11122785|NCT03915509|Active Comparator|Sandblasted group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
11122786|NCT03915496|Experimental|PF-04965842 200 mg|
11122787|NCT03915496|Experimental|PF-04965842 100 mg|
11122788|NCT03915496|Placebo Comparator|Placebo|
11122789|NCT03915483|Experimental|tDCS group|one session of computerized change detection attentional filter exercise (selective attention) combined with real tDCS
11122790|NCT03915483|Sham Comparator|sham group|one session of computerized change detection attentional filter exercise (selective attention) combined with sham tDCS
11122791|NCT03915470|Experimental|XF-73|0.3 mL applications in each naris of 0.2% w/w XF-73 nasal gel for a cumulative dose of 6.0 mg of XF-73.
11122792|NCT03915470|Placebo Comparator|Placebo|0.3 mL applications in each naris of placebo to match XF-73 nasal gel.
11122793|NCT03915457|Experimental|Dry immersion Control Group|5 days of dry-immersion
11122794|NCT03915457|Experimental|Thigh Cuffs intervention|5 days of dry-immersion with thigh cuffs
11122795|NCT03915444|Experimental|NabCG|nab-paclitaxel 125mg/m2 cisplatin 25 mg/m2 gemcitabine 1000 mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days
11122796|NCT03915431|Experimental|NCS-01|human bone marrow derived cells
11122797|NCT03915431|Placebo Comparator|Placebo|placebo
11122798|NCT03915418|Experimental|Connected tools|3 nights at home with connected tools only and 1 night at hospital with connected tools and PSG.
11122799|NCT03915405|Experimental|KHK2455 in Combination with Avelumab|
11122800|NCT03915379|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-67571244. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
11122801|NCT03915379|Experimental|Part 2: Dose Expansion|Participants in 2 expansion cohorts of acute myeloid leukemia (AML) or either high-risk myelodysplastic syndromes (MDS) or very high-risk MDS will receive JNJ-67571244 at the RP2D determined in Part 1.
11122802|NCT03915366|No Intervention|Standard of Care (SoC)|"Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:
~Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days"
11122803|NCT03915366|Experimental|Valganciclovir plus SoC|Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group
11122804|NCT03915366|Experimental|Tuberculosis Treatment plus SoC|"Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group
~Doses of tuberculosis treatment:
~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.
~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.
~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
11122805|NCT03915366|Experimental|Tuberculosis Treatment plus Valganciclovir plus SoC|"Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group
~Doses of tuberculosis treatment:
~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.
~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.
~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
11122806|NCT03915353||Experiment|No interventions
11122807|NCT03915353||Control|No interventions
11122839|NCT03915093|Experimental|study group|receive educational nursing protocol
11122840|NCT03915093|Active Comparator|control group|receive routine hospital care
11122841|NCT03915080|Other|Oktokog alpha (Advate)|Personalized treatment according to individual PK using intravenous injection of oktokog alpha with dose and dose interval according to MyPKFIT and phenotypic evaluation.
11122808|NCT03915340|Other|Sequence ABAB|16 subjects assigned to the sequence ABAB will receive a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in Periods 1 and 3 and a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11122809|NCT03915340|Other|Sequence BABA|16 subjects assigned to the sequence BABA will receive a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in Periods 1 and 3 and a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11122810|NCT03915327|Experimental|Intravenous iron group|Enrolled subjects would receive intravenous iron dextran within 24 hours of the subject's inclusion.
11122811|NCT03915327|No Intervention|Control group|Clinical management, including surgical procedures, anesthesia, and perioperative management, are performed in accordance with standard clinical practice.
11122812|NCT03915314||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
11122813|NCT03915314||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
11122814|NCT03915301||ESPB|Erector spinae plane block group
11122815|NCT03915301||Opioids|Opioid group
11122816|NCT03915288|Experimental|Group continuous training at moderate intensity|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity - MICT (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).
~Regarding the MICT training, this was done with fast walk or jog in endless band with the floor tilted to reach the desired intensity. Also by bicycle, rowing and elliptical. During the entire intervention the participants was monitored by a Polar Multisport RS800CX, oximetry and with the Borg scale to avoid exceeding the training intensity (60-80% FCM, 6 to 8 Borg)."
11122817|NCT03915288|Experimental|Group high Intensity Interval Training|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).
~Concerning the HIIT training, it consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group, which we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%)."
11122818|NCT03915288|Active Comparator|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities. It is highlighted that in the institutions where the patients of the 3 groups attended, there is not a physical training area supervised by a professional. Therefore, the intervention protocol was not excluded or denied to the participants of the control group, but continuity and supervision was given for investigative purposes to its process and treatment. In addition, none of the 3 groups stopped their medical treatment or that of the other professionals that make up the interdisciplinary team.
11122819|NCT03915262||Crohn's Disease|
11122820|NCT03915249||Allogeneic-HSCT candidates|Physical activity, pulmonary functions (FEV1, FVC, FEV1/FVC, FEF25-75%, PEF), exercise capacity, respiratory (maximal inspiratory and expiratory pressures (MIP, MEP)) and peripheral muscle strength were evaluated in allogeneic-HSCT candidates.
11122821|NCT03915236|Experimental|Group 1: MON4STRAT Strategy|
11122822|NCT03915236|Active Comparator|Group 2: Conventional treatment|
11122823|NCT03915223|Experimental|"Arm Injection corticosteroids"|Single dose of Solumedrol 2 mg/kg
11122824|NCT03915223|Placebo Comparator|"Arm  injection physiological serum"|Single dose of physilogical serum
11122825|NCT03915210||Candidates of HSCT|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
11122826|NCT03915210||Healthy individuals|Physical activity level using a metabolic holter device, dynamic lung volumes (FEV1, FVC, FEV1/FVC, PEF, FEF25-75%) using a spirometer and quality of life using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 version 3.0 were objectively evaluated.
11122827|NCT03915197|Experimental|group 1|cohorts of infants with acute bronchiolitis
11122828|NCT03915184|Experimental|CAR-BCMA T Cells|Phase 1b will include two parts, a dose escalation part to determine the recommended dose for the expansion part. During expansion patients will be treated with the recommended dose determined in the expansion part.
11122829|NCT03915171|Experimental|MSI-H|IHC/PCR tested as dMMR/ MSI-H
11122830|NCT03915171|Experimental|MSS|IHC/PCR tested as pMMR/ MSS
11122831|NCT03915145|Experimental|Kinesio tape group|Kinesio tape application has been applied
11122832|NCT03915145|Sham Comparator|Sham group|Sham kinesio tape application has been applied
11122833|NCT03915145|Other|Control group|No intervention has been applied
11122834|NCT03915132|Experimental|VMAT plus Nimotuzumab|Patients receive Nimotuzumab weekly during radiotherapy .
11122835|NCT03915119|Experimental|VR Obstacle group|"Initial Visit: navigates a cluttered array of fixed and moving virtual obstacles to reach a way-point (goal) as fast and efficiently (avoiding obstacles) as possible. In each block, task difficulty (i.e., complexity) will increase linearly, regardless of success or failure (≥ 1 collision before reaching the goal).
~Second (Training) Visit (randomized into two groups):"
11122842|NCT03915067|Active Comparator|BOTOX High Dose|BOTOX High Dose will be injected into the platysma muscle on Day 1.
11122845|NCT03915054|Active Comparator|AREG-IVM|"Per case (6mL) 5940 µL Basal Medium
~60 µL IVM MIX Do not need to filtrate media."
11122846|NCT03915054|Active Comparator|STD-IVM|Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
11122847|NCT03915041|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
11122848|NCT03915041|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
11122849|NCT03915028|Experimental|Treated group by thermal cure|Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
11122850|NCT03915028|No Intervention|Control group|Control group will receive a thermal cure after the end of the study
11122851|NCT03915015|Other|the study|Patients with a PPM or ICD getting a clinically indicated MRI
11122852|NCT03915002||Patients|"Steatohepatitis:
~Alcoholic Steatohepatitis and Alcoholic liver disease
~Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)"
11122853|NCT03915002||Disease control|Patients 18 years or older with a diagnosis of cholestatic liver diseases (primary biliary cholangitis or primary sclerosing cholangitis) or hepatotropic virus (hepatitis C or B virus), according to the current international guidelines.
11122854|NCT03915002||Control subjects|"Patients over 18 years old without a diagnosis of liver disease that for any other reason (i.e candidate to liver donor, patients with liver metastasis that require surgery, patients with any type of benign liver tumor or HCC in a healthy liver).
~Patient over 18 years old with a documented alcoholic used disorder in their clinical records and without any evidence of liver disease."
11122855|NCT03914989|Experimental|Experimental group|Individuals in this group receive exposure to a higher concentration of essential oil fragrances nightly.
11122856|NCT03914989|Placebo Comparator|Active control group|Individuals in this group receive exposure to a lower concentration of essential oil fragrances nightly.
11122857|NCT03914976||patient who will have a high risk digestive surgery|patient who will have a high risk digestive surgery: esophagectomy, major hepatectomy> 3 segments, duodeno cephalic pancreatectomy
11122858|NCT03914963|Experimental|Fibrin sealant treatment hemipelvis|•Drug: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis).
11122859|NCT03914963|Placebo Comparator|Control hemipelvis|Other hemipelvis
11122860|NCT03914950|Other|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen < 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x
~Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range
~1 x 500 ml water oral, 1 x
~Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
11122861|NCT03914937||Intervention Group: Virtual Reality|Patients will wear a virtual reality device in addition to standard lidocaine/novocaine numbing agent
11122862|NCT03914937||Control Group: Music|Patients will listen to music in addition to standard lidocaine/novocaine numbing agent
11122863|NCT03914924|Active Comparator|Exercise Program|Ex: The participants will be submitted to only exercise sessions for 12 weeks.
11122864|NCT03914924|Experimental|Exercise and Lifestyle Education Program|ExLE: The participants will be submitted to exercise sessions and education classes for 12 weeks.
11122865|NCT03914911|Experimental|Study Arm|The radiologist will perform a routine ultrasonic guided biopsy procedure using the Smart Biopsy Device, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
11122866|NCT03914898|Experimental|Nurse led intervention group|The nurse-led intervention is a programme to help nurses to improve professional quality of life and reduce psychological distress. The nurse-led intervention programme comprised four sessions; which lasted approximately 1.5-2 h. The Intervention group was divided into two smaller groups of 12 people. TIntervention were applied in a quiet and comfortable room in an uncrowded part of the hospital. The nurses were served food and beverage, and an intimate atmosphere was created. Interventions were applied by first author, the first author had previously managed nurse support groups, patient groups with breast cancer. The first author who was a psychiatric nurse has also been an active educator in the psychiatric and mental health nursing and coping with stress education classes offered at an urban university and was trained in cognitive behavioural therapy. The content and structure of the group sessions were based on the principles of cognitive restructuring techniques.
11122867|NCT03914898|No Intervention|Control Group|No intervention was applied to the nurses in the control group during the study. After the research process was completed, the same program was applied to the control group nurses who were willing to participate in the program.
11122868|NCT03914859|Other|Exposed|Urinary level of 1-hydroxypyrene, the most sensitive biomarker of PAH exposure greater than 0.1 μmol / mol creatinine
11122869|NCT03914859|Other|Not exposed|Urinary level of 1-hydroxypyrene, the most sensitive marker of PAH exposure below 0.1 μmol / mol creatinine
11122870|NCT03914846|Experimental|Cohort I (ultrasound)|Patients with skin lesions undergo at least 1 ultrasound during the consultation. Patients may undergo at most 2 additional scans after the standard of care approach for non-malignant lesions at the discretion of the radiation oncologist and/or dermatologist.
11122871|NCT03914846|Experimental|Cohort II (ultrasound)|Skin cancer patients who undergo surgery or radiation undergo 2-5 ultrasounds over a 1 year period (a baseline ultrasound scan may be performed prior to treatment, followed by 1 scan during and/or after radiation, and additional ultrasounds may be conducted [at the discretion of the treating physician] upon completion of radiation and/or surgery, at approximately 1, 6, and 12 month follow-up examinations).
11122872|NCT03914846|Experimental|Cohort III (ultrasound)|Participants with inflammatory skin disorders (psoriasis, eczema, alopecia, acne) undergo ultrasound at baseline and follow-up visits.
11122873|NCT03914833||Patients|Patients aged 13 to 25 years old with a concussion in sports practice less than 72 hours previously
11122874|NCT03914833||Control - High-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
11122875|NCT03914833||Control - Non-high-level athelete|healthy subjects aged 13 to 25 years students at one of the partner institutions
11122876|NCT03914820|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
11122880|NCT03914794|Experimental|Treatment: Pemigatinib|Patients will receive pemigatinib for 4 to 6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
11122881|NCT03914781|Experimental|SPIN-SELF program|Offered access to the online SPIN-SELF program in addition to usual care
11122882|NCT03914781|No Intervention|Not Offered the SPIN-SELF program|Usual care
11122883|NCT03914768|Experimental|Immunomodulatory DC vaccine to target DIPG and GBM|Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.
11122884|NCT03914755|Experimental|Cohort 1|50 mg twice daily on Days 1-13 and once daily on Day 14
11122885|NCT03914755|Experimental|Cohort 2|150 mg twice daily on Days 1-13 and once daily on Day 14
11122886|NCT03914755|Experimental|Cohort 3|300 mg twice daily on Days 1-13 and once daily on Day 14
11122887|NCT03914742|Experimental|Phase 1: Dose Finding|"Recurrent IDH1/2-mutant grade II-III glioma: BGB290: Days 1-28, 60 mg PO BID TMZ: Days 1-28, 20 QD starting dose
~TMZ de-escalated treatment schedule if necessary (days 1-21; days 1-14; days 1-7) BGG held constant at 60mg PO BID"
11122888|NCT03914742|Experimental|Phase 2: Arm A Alkylator-resistant|"Grade II-III: Recurrent IDH1/2-mutant glioma (WHO grades II/III) who have failed TMZ AND another alkylator
~BGB290 + TMZ at dose combination established in Phase 1"
11122889|NCT03914742|Experimental|Phase 2: Arm B NOT Alkylator-resistant|"Grade II-III:Recurrent IDH1/2-mutant glioma (WHO grades II/III) Failed TMZ OR another alkylator;
~>/=12 months since last treatment
~BGB290 + TMZ at dose combination established in Phase 1"
11122890|NCT03914742|Experimental|GBM Arm|Exploratory grade IV patients only BGB290 at Ph II dose for 7 days pre-surgery Progressed following RT + Chemo
11122891|NCT03914742|Experimental|Surgical Arm|Recurrent IDH1/2-mutant glioma (WHO grade II-IV) eligible for re-resection BGB-290: 60mg PO BID for 6 days AND day once day of surgery (day 7)
11122892|NCT03914729|Active Comparator|Primary Closure|After pilonidal sinus is excised, subcutaneous fat and skin are closed in midline with a running suture
11122893|NCT03914729|Active Comparator|Gluteus Maximus Plasty Flap|After pilonidal sinus is excised, gluteus maximus fascia flaps will be mobilised, approximated in the midline and fixed with a running suture. Subcutaneous fat and skin are closed in midline with a running suture.
11122894|NCT03914703||EZ Pass Suture Passer|Patients who have surgery using the EZ Pass Suture Passer Instrument either in rotator cuff or soft tissue repair
11122895|NCT03914703||Precision Flexible Reamer|Patients who have surgery using the Precision Flexible Reamer Instrument in ACL repair
11122896|NCT03914690|Experimental|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
11122897|NCT03914690|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
11122898|NCT03914677|Experimental|Mecamylamine Oral Tablet|Initial dose - mecamylamine 2.5 mg tablet po 3 hours prior to provocative testing; subsequent dose escalations as needed, to 5 mg and then 7.5 mg, using the same testing methodology.
11122899|NCT03914664||Tourette Syndrome|Adults (>18 years of age) with diagnosis of Tourette syndrome
11122900|NCT03914664||Healthy Control|Adults who are generally healthy with no known neurologic or psychiatric diagnoses
11122901|NCT03914651|Active Comparator|300IU rFSH stimulation group|300IU rFSH stimulation group is defined as patients using gonadotropin-releasing hormone（GnRH）antagonist protocol with a 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation.
11122902|NCT03914651|Experimental|150IU rFSH stimulation group|150IU rFSH Gonal-F® stimulation group is defined as patients using GnRH antagonist protocol with a 150IU rFSH starting dose during controlled ovarian stimulation.
11122903|NCT03914638|Experimental|Active|Active intervention arm. Treatment for 8 weeks per treatment period.
11122904|NCT03914638|Placebo Comparator|Placebo|Placebo arm. Treatment for 8 weeks per treatment period.
11122905|NCT03914625|Active Comparator|Arm A (SR-Avg control)|Arm A: See detailed description.
11122906|NCT03914625|Experimental|Arm B (SR-Avg experimental)|Arm B: See detailed description.
11122907|NCT03914625|Active Comparator|Arm C (SR-High Control)|Arm C: See detailed description.
11122908|NCT03914625|Experimental|Arm D (SR-High experimental)|Arm D See detailed description.
11122909|NCT03914625|Experimental|B-LLy|See detailed description.
11122910|NCT03914625|Experimental|DS B-ALL|See detailed description.
11122911|NCT03914625|Experimental|NCI SR or HR DS B-ALL|See detailed description.
11122912|NCT03914612|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity."
11122913|NCT03914612|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity."
11122983|NCT03914092|Experimental|study group|female patients with vocal fold nodules undergoing intralesional steroid injection
11122984|NCT03914092|Active Comparator|control group|female patients with vocal fold nodules undergoing Smith Accent voice therapy
11123033|NCT03913728|No Intervention|No telephone interview|All patients are randomised for a second time; 80% won't have a phone call and this will be as per standard care.
11122914|NCT03914599||Neurological Disorder|For all neurological disorder participants an electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy. For participants with a diagnosis of Charcot Marie Tooth (CMT) disease, they will have an additional Neuropathy Score to assess disease severity.
11122915|NCT03914599||Healthy Control|An electromyography (EMG) study will be done to determine nerve conduction speed, and a blood draw will be completed for genetic (DNA) testing. Motor measures, cognitive measures and surveys will be completed to assess walking and brain processing speed. Four optional assessments will be offered and only completed if the participant consents to them and include: optical coherence tomography (pictures of the back of the eye), visual evoked potential (to evaluate the nerve pathways of the eye), brain MRI, and skin biopsy.
11122916|NCT03914586||Septic patients with AKI|Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.
11122917|NCT03914547|Experimental|REDCHiP|REDCHiP uses 10- video-based telemedicine sessions to deliver T1D education, behavioral parent training, and problem-solving to enhance parents' knowledge and skills. Sessions last about 45-60 minutes each.
11122918|NCT03914547|Active Comparator|ATTN|ATTN uses 10- video-based telemedicine sessions to deliver general patient education specific to young children. Similar to REDCHiP, all ATTN sessions last 45-60 minutes.
11122919|NCT03914534|Experimental|Test Formulation of Valproic Acid|Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2
11122920|NCT03914534|Active Comparator|Reference Formulation of Valproic Acid|Valcote tablets 500 mg Single dose administered in dosing period 1 or 2
11122921|NCT03914508|Experimental|Memory + Behavioral Weight Loss (M+BWL)|The M+BWL program will integrate memory interventions to the BWL program. The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
11122922|NCT03914495|Placebo Comparator|Placebo|Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
11122923|NCT03914495|Active Comparator|Inulin|Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
11122924|NCT03914482|Other|Patients at risk of FLD|Patients who choose to participate in the study that meet the inclusion criteria
11122925|NCT03914469|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
11122926|NCT03914469|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
11122927|NCT03914456|Experimental|Body Weight Supported Treadmill Training|"The rehabilitation program consisted of five hours per day of the treatment, five times a week for two months (40 sessions). The treatment protocol included kinesiotherapy (passive and active mobilizations, muscle lengthening), BWSTT, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training. The duration of each event was approximately one hour.
~The initial time of the treatment on the BWSTT was 20 minutes, and the modification of the time depended on the endurance and capability of each patient. Training charge began at 40% body weight supported and at treadmill speeds of at least 1.5 km per hour. The treadmill speed was increased progressively to 2.5 km per hour, and the level of weight supported was adjusted within sessions to achieve knee extension."
11122928|NCT03914443|Experimental|Cohort A|"Nivolumab: 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
11122929|NCT03914443|Experimental|Cohort B|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 800 mg/m^2, every 3 week CDDP: 80 mg/m^2, every 3 week "
11122930|NCT03914443|Experimental|Cohort C|"Nivolumab: 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
11122931|NCT03914443|Experimental|Cohort D|"Nivolumab: 240 mg lead-in followed by 360 mg, every 3 week 5-FU: 750 mg/m^2, every 3 week CDDP: 70 mg/m^2, every 3 week DTX: 70mg/m^2, every 3 weeks"
11122932|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured dairy|
11122933|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured non-dairy|
11122934|NCT03914430|Experimental|Water|Energy-free control
11122935|NCT03914417|Experimental|Imiquimod 3.75% cream|applied topically
11122936|NCT03914404|Experimental|Test group|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.
~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
11122937|NCT03914404|Experimental|Control Group|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.
~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
11122938|NCT03914378||Discovery Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
11122939|NCT03914378||Discovery Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
11122940|NCT03914378||Validation Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
11122941|NCT03914378||Validation Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
11123011|NCT03913871|Experimental|Telephone (text messages) support for healthy eating|Participants will receive average of 1-2 text messages per day for 4 weeks focused on health eating with the aim increasing consumption of fruits, vegetables and water; and a reduce intake of sugar sweetened beverages.
11123340|NCT03911479|Other|Clinical Threatment|Convencional treatment in a public tertiary outpatients care unit
11122942|NCT03914365|Active Comparator|Ultrasound-guided pudendal nerve block (PNB)|"Standard circumcision under general anaesthesia with ultrasound-guided pudendal nerve block.Pudendal nerve block patients will be positioned dorsally with the legs in the  frog  position (hips in abduction, knees flexed, sole of the feet together). An ultrasound-guided technique will be used as described previously. A linear probe will be positioned horizontally between the ischiatic tuberosity and the rectum. The ischiorectal fossa is then located between these two landmarks. Using a sterile tech-nique, an echogenic 22 gauge, 50 mm block needle will be inserted out of plane on the superior edge of the probe, midline between the ischiatic tuberosity and the rectum. After feeling two distinct fascial  clics  and confirmation of correct needle posi-tioning in the ischiorectal fossa under ultrasound, 0,2 mL/kg (max 10mL) of ropiva-caine 0,25% will be injected under real-time ultrasound-guidance after negative aspiration. The same technique will be repeated on the contralateral side."
11122943|NCT03914365|Active Comparator|Ultrasound-guided penile nerve block (DPNB)|Standard circumcision under general anaes-thesia with ultrasound-guided penile nerve block.Penile nerve block patients will be positioned in the supine position. An ultrasound-guided technique will be used as described previously. A linear probe will be placed transversely at the base of the penis while an assistant applies caudal traction to the penis. The penile neurovascular sheath is then located just above the corpus cavernosum. The dorsal penile nerve, dorsal penile artery and penile deep dorsal vein are visualized deep to Buck's fascia. Using a sterile technique, a 25 gauge, 1,5 inch needle will be inserted in-plane from lateral to medial so that the needle tip is placed into the penile neurovascular sheath, 0,1 mL/kg (max 4 mL) of ropivacaine 0,25% will be injected under real-time ultrasound guidance while retracting the needle so that the local anaesthetic solution spreads bilaterally filling the neurovascular space.
11122944|NCT03914352|Experimental|PD-1 antibody group|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
11122945|NCT03914352|Active Comparator|Controlled group|In this group entrolled patients were treated with TACE in the 30 days after hepatic resection.
11122946|NCT03914339|Experimental|Test group|Eighteen periodontally compromised patients who will be given both orthodontic and periodontal treatment .
11122947|NCT03914339|Active Comparator|control group|Eighteen periodontally compromised patients will receive periodontal treatment alone .
11122948|NCT03914326|Experimental|Oral semaglutide|One tablet daily for 3.5 to 5 years
11122949|NCT03914326|Placebo Comparator|Placebo|One tablet daily for 3.5 to 5 years
11122950|NCT03914313|Experimental|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat Pro, in which the exoskeleton device is equipped with a VR screen. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Lokomat will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
11122951|NCT03914313|Active Comparator|Robotic treatment without VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Nanos, in which the exoskeleton device is equipped with a screen with a visual feedback (but not virtual reality). The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Nanos will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
11122952|NCT03914313|Active Comparator|Conventional treatment|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a conventional gait rehabilitation. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Beside conventional overground training for gait, motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
11122953|NCT03914300|Experimental|Treatment (cabozantinib S-malate, nivolumab, ipilimumab)|Patients receive cabozantinib S-malate PO QD on days -14 to -1 prior to cycle 1, days 1-42 of cycles 1-4 and days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1, 15, and 29 of cycles 1-4 and day 1 of subsequent cycles and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Treatment repeats every 42 days for cycles 1-4 and every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
11122954|NCT03914287|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
11122955|NCT03914287|No Intervention|Control|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
11122956|NCT03914274|No Intervention|"Thermometer FTN Medisana, precision 0.18º C),"|"Temperatures were taken with an infrared thermometer FTN Medisana, precision 0.18º C.
~The temperature will be taken into account to see if it will vary according to the socket used as the temperature is a favoring element of dermic injuries on the feet."
11122957|NCT03914274|No Intervention|Non-elastic tape measure|"Perimeter was measured with a flexible, non-elastic tape measure Lawton 18-0160, precision 1 mm.
~The measurement of the feet perimeters will be taken into account to see if it will vary according to the socket used and related to injuries in the feet."
11122958|NCT03914274|No Intervention|Bascule|"Weight was measured using scales (Tanita UM-076, precision 0.1kg). The scale is used to control the weight of the participants in order to find out their body mass index since the weight can influence the appearance of lesions on the feet."
11122959|NCT03914274|No Intervention|Altimeter|"Height was measured using the weight rod of different scales SECA 704, precision 1 mm) The altimeter is used to measure the participants in order to find out their body mass index."
11123403|NCT03911024|Placebo Comparator|General Health|
11123404|NCT03911011|Active Comparator|Fresh air|2 litres of fresh air
11122960|NCT03914274|Experimental|Socks|"Socks were of two types: technical socks, designed for high performance sports use Lurbel brand, models Tierra and Set, and non-technical socks for everyday use. The socks had different composition: Tierra:50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra; Set:75% cotton, 17% polyamide, 8% lycra and cotton: 98% cotton, 2% elastane.
~Different socks were given to the participants to see if the different compositions influenced the appearance of injuries in a short route route and little difficulty"
11122961|NCT03914274|No Intervention|"Geographical Position System Garmin ETREX 20"|"The height range and the pace hikers were controlled with a Garmin ETREX 20X Geographical Position System"
11122962|NCT03914248||Active large vessel vasculitis|PET/MR scan
11122963|NCT03914235|Experimental|Tumescent anesthesia|A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
11122964|NCT03914235|Active Comparator|Local anesthesia with tourniquet.|"Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
~At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery."
11122965|NCT03914222|Other|CardioSpire Device|Patients blows into Respirix device or uses BIPAP machine for a few breaths solely to obtain signal.
11122966|NCT03914209||EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
11122967|NCT03914183|Other|Control|Standard of care arm - using insulin pen needles as previously prescribed
11122968|NCT03914183|Active Comparator|mCPN intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:
~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles."
11122969|NCT03914157|Active Comparator|15 patients with ARAS randomized to SWT|We will study 15 patients with ARAS randomized to SWT twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography [MDCT]), oxygenation, and fibrosis (magnetic resonance imaging [MRI]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
11122970|NCT03914157|Sham Comparator|15 patients with ARAS sham|we will study 15 patients with ARAS randomized to or sham twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography [MDCT]), oxygenation, and fibrosis (magnetic resonance imaging [MRI]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.
11122971|NCT03914144||Normal Vaginal Delivery|The group of patients who achieved a normal delivery will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
11122972|NCT03914144||Insturmental Vaginal Delivery|The group of patients who underwent instrumental delivery (ventouse or forceps) will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
11122973|NCT03914144||Emergency Caesarean Section|Each patient will be recorded how many catheter episodes occurred during their labour and delivery.
11122974|NCT03914144||Elective Caesarean Section|We expect all patients in this group to have an indwelling catheter sited before their elective caesarean sections, however we will assess each patient individually to confirm whether they had a catheter for their delivery.
11122975|NCT03914131|Experimental|study group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.
~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.
~Dosage form:Capsule"
11122976|NCT03914131|Placebo Comparator|control group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.
~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.
~Dosage form:Capsule"
11122977|NCT03914118|Active Comparator|Preoperative modafinil + postoperative placebo|
11122978|NCT03914118|Active Comparator|Preoperative modafinil + postoperative modafinil|
11122979|NCT03914118|Placebo Comparator|Preoperative placebo + postoperative placebo|
11122980|NCT03914118|No Intervention|Control group|
11122981|NCT03914105|Active Comparator|Without music|Test without music
11122985|NCT03914066|Experimental|Group treatment in primary care|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
11122986|NCT03914040|Experimental|IPSE program|IPSE is conceptually divided in two phases: 1) pre-immersion preparation, 2) immersion.
11122987|NCT03914040|No Intervention|Traditional course|Participants in the control group will receive the current face-to-face course.
11122988|NCT03914027|No Intervention|Control|Patients allocated to the control group will follow the same procedure except for not using tele-rehabilitation.
11122989|NCT03914027|Experimental|Intervention|The intervention is the use of a tele-rehabilitation program during 12 weeks. The patient's training time will be registered automatically. The control group will receive standard treatment only.
11122990|NCT03914014|Active Comparator|intervention|connective tissue manipulation
11122991|NCT03914014|Placebo Comparator|placebo ultrasound|placebo ultrasound
11122992|NCT03914014|No Intervention|control|control group
11122993|NCT03914001|Other|NMIBC patients|eligible patients will undergo initial mpMRI before initial TURBT, then followed by second mpMRI and second resection TURBT after 4 weeks
11122994|NCT03913988|Active Comparator|LUCID DREAMING, STRESS REDUCTION, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:
~Psychoeducation regarding lucid dreaming, stress reduction, and sleep hygiene
~Practice of lucid dreaming induction techniques
~Guided visualization
~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
11122995|NCT03913988|Active Comparator|LUCID DREAMING, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:
~Psychoeducation regarding lucid dreaming and sleep hygiene
~Practice of lucid dreaming induction techniques
~Guided visualization
~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
11122996|NCT03913988|Active Comparator|SLEEP HYGIENE|"This group will meet for 2 online group sessions and 4 email communications. The 2 online group sessions will each last 1 hour and occur in weeks 1 and 12. The 4 email communications will occur in weeks 3, 5, 7, and 9 and consist of individual communication between each participant and the PI or co-investigator. Each email communication will require 10 minutes of participants' time.
~The control group will be asked to engage in Sleep Hygiene techniques in which they adhere to a recommended protocol and record their adherence in a Sleep Hygiene Tracking Log, requiring 5 minutes per day.
~Through the 2 online sessions and the individual email with the investigators, participants will have the opportunity to discuss their experience with adherence to the sleep hygiene program and tracking log. Investigators will help participants trouble shoot problems adhering to the sleep hygiene protocol."
11122997|NCT03913962|Experimental|Patient|Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
11122998|NCT03913962|Active Comparator|Control|healthy children sex- and age-matched
11122999|NCT03913949|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
11123000|NCT03913936|Experimental|NEWLY DIAGNOSED|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.
~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
11123001|NCT03913936|Experimental|SURVIVOR|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.
~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
11123002|NCT03913936|Experimental|LIVING WITH ADVANCED DISEASE|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.
~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
11123003|NCT03913923|Experimental|BCD-217 and BCD-100|Patients will receive 4 blinded infusions of BCD-217 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
11123004|NCT03913923|Active Comparator|BCD-100 monotherapy|Patients will receive 4 blinded infusions of BCD-100 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
11123005|NCT03913910||Lipogems|Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice.
11123006|NCT03913897|Experimental|virtual reality group|The children in the groups were distracted by virtual reality goggles 2 minutes before venipuncture, until the process was over.
11123007|NCT03913897|Experimental|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
11123008|NCT03913897|No Intervention|control group|No intervention was made to children in the control group
11123009|NCT03913884|Experimental|Concentrated growth factor Group|Group I (test); in which CGF fibrin matrix was applied to the extraction socket
11123010|NCT03913884|Experimental|Non-Concentrated growth factor Group|Group II (control); in which CGF was not applied to the extraction socket
11123012|NCT03913871|Active Comparator|Telephone (text messages) support for physical activity|Participants will receive an average of 1-2 text messages per day for 4 weeks that offer physical activity and general health/wellbeing advice.
11123013|NCT03913858|Other|high-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
11123014|NCT03913858|Other|low-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
11123015|NCT03913845|Experimental|0.5% lidocaine with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
11123016|NCT03913845|Active Comparator|Normal saline with epinephrine|On the day of surgery, the operating room pharmacist will prepare 20 cc of either study drug (0.5% lidocaine with epinephrine 1:200,000) or normal saline with epinephrine 1:200,000) in identical appearing 20cc syringes to be injected retropubically. Our group's routine clinical practice is to inject 20cc of 0.5% lidocaine with epinephrine 1:200,000 retropubically along the path of the midurethral sling trocars. Suburethral injection of local anesthestic will be performed at surgeon discretion. Surgical teams, anesthesia teams and patients will be blinded to allocation assignment. The investigational drug pharmacist will maintain the randomization sequence.
11123017|NCT03913832|Experimental|sirolimus drug coated balloon (SCB)|Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB)
11123018|NCT03913832|Active Comparator|paclitaxel releasing coronary balloon catheter.|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter
11123019|NCT03913819||substance abuse group|Patients with voiding dysfunction secondary to substance abuse in a special clinic
11123020|NCT03913806|Experimental|Treatment group|Bevacizumab-IRDye800CW
11123021|NCT03913793|Active Comparator|Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction with peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
11123022|NCT03913793|Active Comparator|Non-Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction without peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
11123023|NCT03913793|No Intervention|Control group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction, not enrolled into exercise program.
11123024|NCT03913780|Active Comparator|Group 1 (Medical record)|For group 1, participants do not have intervention as groups 2 and 3. This group consists of reviewing the medical history of the year 2000 to determine the variables of the study and then compare them with groups 2 and 3. This group of participants they were from the year 2000 and whose information will be strictly taken from their medical history was based on initial training with warm-up and walking, after that, aerobic training was performed from 50 to 70% of their maximum heart rate and they finished their session training with breathing exercises, coordination, balance and walking.
11123025|NCT03913780|Experimental|Group 2: Aerobic exercise + Strength training in MMSS|"For group 2, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more strength exercises for upper limbs with dumbbells, multi-strength equipment and Theraband.
~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
11123026|NCT03913780|Experimental|Group 3: Aerobic exercise + Strength training in MMII|"For group 3, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more the strength training for lower limbs with theraband, multi-strength equipment and exercises for activation of the sole-twin pump.
~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
11123027|NCT03913754||Lupus Patients with kidneys failure|Assessment of quality of life on everydays life trough questionnare
11123028|NCT03913754||Lupus Patients without kidneys failure|Assessment of quality of life on everydays life trough questionnare
11123029|NCT03913741|Experimental|Experimental tisotumab vedotin|Open label, single arm trial where tisotumab vedotin will be administered
11123030|NCT03913728|Experimental|Outcome of blood test provided|These patients are given the results of their drug level blood tests and treatment can be altered/ further advice can be provided as a result of this.
11123031|NCT03913728|No Intervention|Outcome of blood test not provided|The blood results for these people are not fed back to the patient or the clinical site.
11123032|NCT03913728|Experimental|Patients have a telephone interview|All patients are randomised for a second time; 20% (10) of them will have a semi-structured phone interview
11123034|NCT03913715|Active Comparator|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
11123035|NCT03913715|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient.
11123036|NCT03913702|Active Comparator|Ketorolac|Assigned patients will receive a subacromial injection of ketorolac 60mg (2ml + 8ml lidocaine 1%)
11123037|NCT03913702|Active Comparator|Methylprednisolone|Assigned patients will receive a subacromial injection of methylprednisolone 80mg (1ml + 9ml lidocaine 1%)
11123038|NCT03913689|Other|StimRouter Neuromodulation System|Implant of the Bioness StimRouter Neuromodulation System in subjects with chronic pain of peripheral nerve origin
11123039|NCT03913676|Experimental|Velibra|All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).
11123040|NCT03913663|Active Comparator|study group|20 patient with hemineglect, minimum 6 months post stroke
11123041|NCT03913663|Active Comparator|control group|20 patient with hemineglect, minimum 6 months post stroke
11123042|NCT03913650|Active Comparator|Nerve block(+)|patient accept nerve block for post-op pain control
11123043|NCT03913650|Sham Comparator|Morphine|patient received morphine for post-op pain control
11123044|NCT03913637|Experimental|Strategy Training|In addition to receiving everything in Enhanced Usual Care, participants will engage in 10 sessions over 5 weeks with a trained research interventionist. Participants will describe activities they do, no longer do, or have never done using the cards from the Activity Card Sort as a guide. The therapist will ask the participants to use this information to identify and prioritize activity-based goals to address in the remaining sessions. These sessions will take place in a location of the participant's choice and will last approximately 1 hour.
11123045|NCT03913637|Active Comparator|Enhanced Usual Care|Enhanced usual care will allow older adults to interact with services and support. All mental health treatment (e.g., medications that you may be taking) and psychotherapy (e.g. counseling or social services) will be documented and monitored. Furthermore, all participants assigned to Enhanced Usual Care will receive the same assessments as other participants. The close monitoring will track potential changes in symptoms (e.g., depressive symptoms), and participants will be referred to services as appropriate.
11123046|NCT03913624|Experimental|50 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 50 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
11123047|NCT03913624|Experimental|35 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
11123048|NCT03913624|No Intervention|Control group|Conventional treatment
11123049|NCT03913611|Other|Traditional Rehabilitation|In this arm, patients will undergo the standard rehabilitation protocol, with sling use for 6 weeks.
11123050|NCT03913611|Experimental|Accelerated Rehabilitation|In this arm, patients will undergo the accelerated rehabilitation protocol, with no sling use outside the immediate postoperative period.
11123051|NCT03913585|Experimental|Lifestyle intervention|The intervention group comprises ~4800 patients born 1959-1988, living in the municipalities of Haderslev or Middelfart, and affiliated to one of the participating GPs. No control group is included.
11123052|NCT03913572||REVOLVE|Patients that have agreed to be prospectively enrolled in the study and undergo Injection of adipose-derived stem cells into perianal fistula with the REVOLVE system
11123053|NCT03913572||Retrospective cohort|Patients that have undergone treatment of perianal disease without use of adipose-derived stem cell injection.
11123054|NCT03913559|Experimental|Inotuzumab ozogamicin|"Experimental:Inotuzumab Ozogamicin (InO) Patients with B cell acute lymphoblastic leukemia (B-ALL) that is showing early signs of relapsing (coming back) or is not responding to treatment (refractory).
~Interventions:methotrexate, hydrocortisone and cytarabine into the central nervous system (called triple intrathecal chemotherapy or IT chemotherapy) during this study.
~Premedication: diphenhydramine, acetaminophen and methylprednisolone"
11123055|NCT03913546|Sham Comparator|Sham spinal manipulation|Participants in the 'sham' group will receive a sham mechanical thrust (force set at level 0) instead of an actual one. In the force level 0, no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition. Therefore, the subject does not distinguish between intervention or placebo.
11123056|NCT03913546|Experimental|Actual spinal manipulation|Participants in the actual actual spinal manipulative therapy (SMT) group will be assessed through the Activator basic method. SMT will be performed with the Activator IV Adjusting Instrument (Activator Methods International, Phoenix, AZ) varying the force level depending on the adjusted segment.
11123057|NCT03913533|Active Comparator|Control group|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
11123058|NCT03913533|Experimental|Intervention group|Heart rate assessment using Tap-based smartphone application At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
11123059|NCT03913520|Other|Congenital Heart Disease|Undergoing evaluation at 30 days
11123060|NCT03913507|Experimental|one group : patients with suspicion of cystic fibrosis|
11123061|NCT03913494|Experimental|4 Week Snoozeal Use|Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
11123062|NCT03913481|Experimental|ANH|Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
11123063|NCT03913481|Other|Standard care|No ANH
11123064|NCT03913468||Received Ascorbic Acid IV|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who were treated within the first 24 hours of admission with the combination of IV ascorbic acid, IV thiamine, and IV hydrocortisone, with a duration of 4 days or until patient leaves the ICU.
11123065|NCT03913468||Control Group|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who did not receive any treatment with IV ascorbic acid.
11123066|NCT03913455|Other|Guadecitabine and Carboplatin|Each cycle = 28 days; Subjects receive 4 cycles
11123067|NCT03913442|Placebo Comparator|Placebo|Placebo in capsule identical to study drug
11123068|NCT03913442|Experimental|Colchicine|Colchicine 0.8 mg orally once daily
11123069|NCT03913429|Active Comparator|Control Group|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.
~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml."
11123070|NCT03913429|Experimental|Study Group|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.
~A total of 5ml of Ropivacaine 0.37% infiltrated on each side."
11123071|NCT03913416|Experimental|3D|Surgery with surgeon trained using a 3D printed model of the pulmonary malformation.
11123072|NCT03913416|Other|Control group|Conventional surgery without training using a 3D printed model of the pulmonary malformation.
11123073|NCT03913403||Intervention|Participants will receive 2 ECHO's and 2 Blood Draws
11123074|NCT03913377|Experimental|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
11123075|NCT03913377|Experimental|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
11123076|NCT03913364|Experimental|Experimental Obese mothers|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
11123077|NCT03913364|Placebo Comparator|Placebo Obese mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
11123078|NCT03913364|Experimental|Experimental normal weight mothers|One portion (50g) of an ice-cream containing B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
11123079|NCT03913364|Placebo Comparator|Placebo normal weight mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
11123080|NCT03913351|Experimental|Lifestyle modification program|The dietary intervention program will be scheduled for 12 months, and conducted by a dietitian.The program aims to increase energy expenditure and reduce caloric intake, with an emphasis on long-term lifestyle and behavioural change. An exercise instructor will provide advice on physical activity. A mobile tracking device to monitor calories expenditure will be provided to each participant during they study period to encourage physical activity.
11123081|NCT03913351|No Intervention|Control|standard care of treatment, as in routine clinical practice
11123082|NCT03913338|Other|Study group|LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.
11123083|NCT03913338|Other|Control group|LASIK only
11123084|NCT03913325|Experimental|PREVSAM model|
11123085|NCT03913325|Active Comparator|Treatment as usual|
11123086|NCT03913312|Experimental|DAC combined with unrelated cord blood transplantation|Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC>1.5*107/kg), d0.
11123087|NCT03913286|Experimental|Intervention|The participant will be implanted with the Blackrock Microsystems MultiPort system.
11123088|NCT03913273|Experimental|Intervention group|Intervention: AMI transtibial amputation
11123089|NCT03913273|Active Comparator|Control group|Intervention: Standard transtibial amputation
11123090|NCT03913260|Experimental|Part A: LY3375880 Formulation A|LY3375880 Formulation A administered subcutaneously (SC).
11123091|NCT03913260|Experimental|Part A: LY3375880 Formulation B|LY3375880 Formulation B administered subcutaneously SC.
11123092|NCT03913260|Experimental|Part A: LY3375880 Formulation C|LY3375880 Formulation C administered SC.
11123093|NCT03913260|Placebo Comparator|Part A: Positive Control|Positive Control (buffer matrix, only) administered SC.
11123094|NCT03913260|Experimental|Part B: LY3375880 Test 1|LY3375880 Test 1 Formulation administered SC.
11123095|NCT03913260|Experimental|Part B: LY3375880 Test 2|LY3375880 Test 2 Formulation administered SC.
11123096|NCT03913260|Experimental|Part B: LY3375880 Test 3|LY3375880 Test 3 Formulation administered SC.
11123097|NCT03913247||Group with different size measures|Each patient included in the study will have different measure of size.
11123098|NCT03913234|Experimental|Combination of Letrozole, Trastuzumab with Ribociclib|Phase IB (dose escalation of ribociclib with fixed dose of letrozole and Ribociclib) Phase II (ribociclib of RPIID with fixed dose of letrozole and ribociclib)
11123099|NCT03913221|Active Comparator|Low Dose Caffeine (5 mg/kg)|Within 24 hours of delivery, participants will receive low dose administration of Caffeine citrate.
11123100|NCT03913221|Active Comparator|High Dose Caffeine (10 mg/kg)|Within 24 hours of delivery, participants will receive high dose administration of Caffeine citrate.
11123101|NCT03913208|Experimental|Study group|Will be subjected to priority to freeze
11123102|NCT03913208|Active Comparator|Control group|Will receive fresh embryo transfere
11123103|NCT03913195|Experimental|Sentinel Group|Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
11123104|NCT03913195|Experimental|Core Group|Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
11123105|NCT03913182|Experimental|apatinib group|apatinib：500mg po Qd
11123106|NCT03913169|Other|Students in Interprofessional Education Curriculum|The interprofessional intervention for the students to be employed in this study will include five modalities in a scaffolded structure progressing from low- to high-fidelity experiences over a two-year period: (1) classroom didactic sessions; (2) simulation laboratory sessions; (3) standardized patient sessions; (4) community-based clinical case conferences; and, (5) community-based interprofessional rotations.
11123107|NCT03913169|Other|Patients Experience with Interprofessional Care|For patients and their families, those who receive care from an Interprofessional team will receive the usual health care they normally receive at the participating clinics. In many cases patients already receive this care, but are unaware of it. Most of what occurs in Interprofessional practice happens outside of the patient encounter. For patients the process is generally invisible, but its affects are felt in terms of better communications with the patient. In this study, patients will be informed as usual about the presence of students as learners and will have the opportunity to decline student involvement in their care. The only difference for the patients and their families will be a request to fill out a survey form on paper indicating their perception of the experience in terms of quality of care and its potential impact on their access to care.
11123108|NCT03913169|Other|Clinician (Preceptor) Interprofessional Education Curriculum|Clinicians will experience many of the same learning experiences as the students, but will differ in the level of education and its focus. Clinicians and faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
11123109|NCT03913169|Other|Faculty in Interprofessional Education Curriculum|Doctor of Osteopathic Medicine and Physician Assistant Faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
11123110|NCT03913156|Other|Part 1|Part 1 of the study will recruit subjects who are about to be introduced to a concentrated phe-free protein substitute (i.e. second stage protein substitute) for the first time.
11123111|NCT03913156|Other|Part 2|Part 2 of the study will recruit subjects who have already been introduced to a concentrated phe-free protein substitute (i.e. have already transferred from phe-free infant formula onto a second stage protein substitute). This group will be included to evaluate the acceptability of the study product in patients who have already moved onto a second stage protein substitute.
11123112|NCT03913143|Experimental|Group 1: Dose 1 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
11123113|NCT03913143|Active Comparator|Group 2: Dose 2 sepofarsen (QR-110)|Initial loading dose, followed by maintenance doses at month 3 and every 6 months there after, administered by intravitreal injection (24 months duration of treatment). After 12 months treatment of the contralateral eye may be initiated
11123114|NCT03913143|Sham Comparator|Group 3: Sham|Sham Intravitreal Injection (no experimental drug administered), at month 0, month 3 and every six months there after. After 12 months cross over to active study drug may be initiated
11123115|NCT03913130|Experimental|Drug QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
11123116|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 0.3mg dose|Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
11123117|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 1 mg dose|Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
11123118|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 3 mg dose|High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
11123119|NCT03913117|Experimental|PVX-6|Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.
11123120|NCT03913104|Experimental|Medication Abortion Patients|Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
11123121|NCT03913091|Experimental|20 mL 0.5% Bupivacaine HCL|
11123122|NCT03913091|Experimental|Interscalene nerve block with Liposomal + Bupivacaine 0.5%|Administered in an Interscalene block for TSA
11123123|NCT03913078|Active Comparator|Group Fitness|Subjects will be offered several sessions per week of a traditional group fitness program led by a trained group leader.
11123124|NCT03913078|Active Comparator|PlayFit|Subjects will be offered several sessions per week of a modified sports fitness program, led by a trained group leader.
11123125|NCT03913065||Included patients|Cardiac arrest patients from sites participating in the TTM-2 CT-substudy still unconscious 48 hours after cardiac arrest are routinely examined with head computed tomography as soon as possible after inclusion.
11123126|NCT03913052|Experimental|Injection|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine was performed once when the knee joint was in the supine position and the knee was in the extension.
11123127|NCT03913039||transperineal protocol|"Transperineal biopsy approach with avoidance of rectal flora
~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated
~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria
~Multi-antibiotic prophylaxis
~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
11123128|NCT03913039||Traditional biopsy|"Transrectal approach
~Standard 12-core template
~Surgeon-specific antibiotic prophylaxis
~Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
11123405|NCT03911011|No Intervention|no fresh air|no supply of fresh air
11123129|NCT03913026|Experimental|Main intervention|Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
11123130|NCT03913013|Experimental|FFT with MCC App (FFT-MCC)|Youth in this study arm will receive 12 sessions of FFT (psychoeducation, communication skills training, and problem-solving skills training) with their parents and siblings. They and their parents will make regular mobile app ratings of mood, sleep, family functioning, stress, and perceived criticism. Children and parents will call into a voice-activated phone system and be asked to speak freely for 3-5 minutes about their health and family functioning. They will be guided through 12 lesson plans in which they practice skills such as active listening or identifying prodromal signs of episodes, paralleling what they are learning in sessions. The clinician will be able to set a weekly skill training assignment and observe the family's practice of the skill between sessions. They will adapt session content accordingly.
11123131|NCT03913013|Active Comparator|FFT with App Assessments only (FFT-Assess)|Youth in this condition will receive the same 12 sessions of FFT, but the app will be limited to daily and weekly assessments of their mood, sleep, stress, and family functioning. The app will not provide the skill training offered in the FFT-MCC condition.
11123132|NCT03913000|Experimental|ID-085 single dose|Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
11123133|NCT03912987||Affected|Affected with ALS or a related disorder, including ALS-FTD, FTD, PLS, and PMA.
11123134|NCT03912987||Healthy Controls|Those never diagnosed with and not at particular risk for developing ALS or a related disorder.
11123135|NCT03912974|Active Comparator|Pretreatment with escitalopram|Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
11123136|NCT03912974|Placebo Comparator|Pretreatment with placebo oral capsule|Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
11123137|NCT03912935|No Intervention|Sniffing position|Subject will be maintained in standard intubation position which is supine position with head elevation with head rest (foam donut).
11123138|NCT03912935|Experimental|Bed up head elevation position|Subject will be maintained at bed up 20-30 degree aiming alignment between the external auditory meatus with sternal notch
11123139|NCT03912922|Experimental|Sit regime|Subjects will follow the sit regime during four days. Each day consists of 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
11123140|NCT03912922|Experimental|Sit less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
11123141|NCT03912922|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours sitting, 1 hour walking, 1 hour standing, 1 hour exercise and 8 hours sleeping. The cycle session will be at approximately 60% maximal power. Exact cycling intensity and duration will be calculated to ensure equal total energy expenditure between the sitting less and the exercise regime.
11123142|NCT03912909|Active Comparator|Phase 1|Empagliflozin 10mg daily or placebo
11123143|NCT03912909|Placebo Comparator|Phase2|Empagliflozin 10mg daily or placebo
11123144|NCT03912896|Experimental|Children with autism spectrum disorder|
11123145|NCT03912857|Experimental|test group|"Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
~Apatinib :250 mg or 375 mg, qd"
11123146|NCT03912844||Liver resection/liver transplantation after SIRT|The cohort consist of patients that have after decision of a multidisciplinary tumorboard received a SIRT tor made them later eligible for following liver resection or liver transplantation.
11123147|NCT03912831|Experimental|KITE-439|"Phase 1A (Dose Escalation): Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-439.
~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-439, at a dose selected based on Phase 1A."
11123148|NCT03912818|Experimental|Cohort II (durvalumab, cis-gem)|Patients receive durvalumab IV over 60 minutes on day 1, cisplatin IV over 60 minutes on day 1, and gemcitabine IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo cystectomy within 6 weeks.
11123149|NCT03912818|Experimental|Cohort III (Durvalumab, carbo-gem)|Patients receive durvalumab IV over 60 minutes on day 1, carboplatin IV over 60 minutes on day 1, and gemcitabine IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo cystectomy within 6 weeks.
11123150|NCT03912818|Experimental|Treatment (durvalumab, DD MVAC)|Patients receive durvalumab IV over 60 minutes on day 1, methotrexate over 3 minutes on day 1, vinblastine IV over 3 minutes on day 2, doxorubicin IV over 5 minutes on day 2, and cisplatin IV over 60 minutes on day 2. Cycles repeat every 14 days up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo cystectomy within 6 weeks.
11123151|NCT03912805|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
11123152|NCT03912805|Experimental|ET-01|botulinum toxin, Type A, topical liniment, administered once at baseline
11123153|NCT03912792||XLHED Patients|
11123154|NCT03912792||Healthy Controls|
11123155|NCT03912779|Experimental|C2Hear RLOs|C2Hear RLOs (https://www.youtube.com/C2HearOnline): nine (custom earmould) or eight (open fit hearing aid) multi-media learning clips covering practical and psychosocial components of owning a hearing aid, alongside user testimonials (n= 7). Participants asked to watch all relevant to their prospective hearing aid coupling (custom earmould or open fit), with no limit on number of views. A paper diary documented usage during the study duration.
11123156|NCT03912779|Placebo Comparator|Printed hearing aid booklet|A 32-page printed A5 colour booklet, designed and written by local Audiology staff, supplied to all prospective hearing aid owners at the study centre as standard care. Same booklet supplied irrespective of hearing aid style (custom/open fit). All content conveyed via text and supporting pictures only. Participants assigned to the placebo comparator were asked to read the booklet once. A paper diary documented usage during the study duration.
11123157|NCT03912766||Transurethral Prostatectomy|male patients undergoing transurethral prostatectomy (TURP) for benign prostatic hyperplasia, routine surgical removal using resectoscope
11123158|NCT03912753|Experimental|Comunică|Comunică is delivered over eight 60-min live chat sessions, delivered by trained psychologists, on our mHealth study platform compatible with any mobile device (laptops, smartphones).
11123159|NCT03912753|Active Comparator|Education Attention Control (EAC)|"The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.Topics include 1) GBM identity, 2) HIV 101, 3) HIV/STI testing, 4) alcohol and the body, 5) the role of alcohol in HIV risk, 6) HIV-status disclosure and sexual health communication, 7) finding social supports, and 8) summary. EAC participants will receive five quiz questions after each module, with correct answers in a following screen."
11123160|NCT03912740|Active Comparator|Remifentanil Analgesia|Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
11123161|NCT03912740|Active Comparator|Remifentanil and Dexmedetomidine Analgesia|Continuous intraoperative analgesia with remifenanil + dexmedetomidine
11123162|NCT03912727|Experimental|Alpha-lipoic acid|18 patients will receive alpha lipoic acid (thiotacidR) product with their standard therapy.
11123163|NCT03912727|Placebo Comparator|Control|18 patients will receive their standard therapy only.
11123164|NCT03912714|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy in therapy refractory ulcerative colitis patients after pre-operative endoscopic biopsies of the appendix
11123165|NCT03912714|Active Comparator|Non-active UC|Patients with non-active ulcerative colitis planned for surveillance colonoscopy will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
11123166|NCT03912714|Active Comparator|Healthy control|'Healthy control' patients (i.e. patients planned for colonoscopy for polyps) will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
11123167|NCT03912688|Experimental|single acupoint stimulation|
11123168|NCT03912688|Experimental|dual acupoints stimulation|
11123169|NCT03912688|No Intervention|no stimulation|
11123170|NCT03912675|Experimental|RigeneraTM protocol|Teatment with Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol.
11123171|NCT03912675|Experimental|Control|Treatment with Integra® dermal substitute only.
11123172|NCT03912662|Other|Hernia prevention cohort|
11123173|NCT03912649|Experimental|RemovAid arm|"RemovAid arm -
~All subjects have their implant removed by the RemovAid device"
11123174|NCT03912636|Active Comparator|Diaphragmatic breathing in healthy volunteers in study1|Healthy volunteers will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
11123175|NCT03912636|Active Comparator|Diaphragmatic breathing in rumination patients in study1|Rumination patients will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
11123176|NCT03912636|Active Comparator|Deep slow breathing in healthy volunteers in study1|Healthy volunteers will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
11123177|NCT03912636|Active Comparator|Deep slow breathing in rumination patients in study1|Rumination patients will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
11123178|NCT03912636|Placebo Comparator|Normal breathing in healthy volunteers in study1|healthy volunteers will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
11123179|NCT03912636|Placebo Comparator|Normal breathing in rumination patients in study1|rumination patients will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
11123180|NCT03912636|Active Comparator|Diaphragmatic breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
11123181|NCT03912636|Active Comparator|Deep slow breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
11123182|NCT03912623|Active Comparator|3 weeks SPA Treatment|"3-week thermal cure:
~Spa treatment harmonized in the different stations
~Therapeutic education workshops and conferences common to all stations in the form of practical workshops during supervised lunches
~Adapted physical activity, workshops are common to all spas and use an electric bike suitable for health (VELIS) with briefing and debriefing. An APA (Adapted Physical Activity) coaching consultation at the end of the cure for personalized post-cure programs and objectives is planned as well as a telephone or internet coaching during the 5 months post-cure (objectives and adaptation, motivation)
~Maintenance of the usual treatment within 6 months post randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by the software Diascope and / or HAS
~Information booklet for inclusion (French Association of Diabetics)"
11123183|NCT03912623|Sham Comparator|Discovery week end|"Maintenance of usual treatment within 6 months post-randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by Diascope and HAS software In addition, a discovery access to the baths of 2-3 days will be offered to patients. Finally, the information booklet on diabetes will be given at the inclusion (French Federation of Diabetics)."
11123184|NCT03912610||Health control group|5 health volunteer are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
11123185|NCT03912610||Knee osteoarthritis group|5 patients of knee osteoarthritis accompanied with depression or anxiety are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
11123186|NCT03912597|Experimental|Virtual Reality [A]|Participants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
11123187|NCT03912597|Active Comparator|Brochure Waitlist Control [A]|Participants read an informational brochure about depression, then answer post-intervention questionnaires. After that, they will be given a chance to watch the VR video at the end of their participation session.
11123188|NCT03912597|Active Comparator|Standard Video Control [B]|Participants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
11123440|NCT03910699|Experimental|Three-row anastomosis|Colorectal anastomosis is created with a three-row circular surgical stapler
11123189|NCT03912597|Experimental|Virtual Reality [B]|Participants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
11123190|NCT03912571|Active Comparator|Mild Cognitive Impairment (MCI)|Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
11123191|NCT03912571|Active Comparator|Normal Cognition (NL)|Clinical Dementia Rating [CDR] of 0 or Global Deterioration Scale [GDS] of 1-2
11123192|NCT03912558|Experimental|Butterfly device implantation|"Butterfly device implantation will be performed following initial cystoscopy to evaluate prostate condition and rule out other pathologies.
~Following implant size selection, the Butterfly implant will be deployed and positioned through the cystoscope over-sheath. After deployment the cystoscope (with its optics) will be re-introduced into the urethra to examine the Butterfly device position."
11123193|NCT03912545||Trauma patients|Subjects experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
11123194|NCT03912545||Obstetric hemorrhage patients|Subjects experiencing obstetric hemorrhage such that viscoelastic testing is performed as standard of care is performed to assess coagulopathy.
11123195|NCT03912532|Experimental|NGM282 Dose 1|Administered by subcutaneous injection
11123196|NCT03912532|Experimental|NGM282 Dose 2|Administered by subcutaneous injection
11123197|NCT03912532|Experimental|NGM282 Dose 3|Administered by subcutaneous injection
11123198|NCT03912532|Placebo Comparator|Placebo|Administered by subcutaneous injection
11123199|NCT03912519|Active Comparator|Parallel placement of 16 gauge electrodes|Parallel Group will undergo radiofrequency ablation via the approach described in Spine Intervention Practice Guidelines via 16 gauge electrodes. Specifically, the target nerve will be targeted with a parallel approach so as the electrode lay parallel to the nerves location within the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
11123200|NCT03912519|Active Comparator|Perpendicular placement with 22 gauge electrodes|Perpendicular Group will undergo radiofrequency ablation via the approach described in Spine Intervention Society Practice Guidelines for medial branch blocks, using a 22 gauge electrode. Specifically, the target nerve will be targeted with a perpendicular approach so as the tip of electrode contact the nerve at some point of it course along the sulcus formed by the neck of superior articular process and transverse process (or sacral ala for L5) cephalad to the point it is covered by the mamillo-accessory ligament.
11123201|NCT03912506||Patient admitted in the ICU for leptospirosis|Patient admitted in the ICU for leptospirosis None intervention was performed according to retrospective design
11123202|NCT03912493|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. The conventional program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
11123203|NCT03912493|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
11123204|NCT03912480|Experimental|Stem cells from human exfoliated teeth|"Basic treatment:
~The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).
~Stem cell therapy:
~Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .
~Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment.
~Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed."
11123205|NCT03912454|Experimental|BMAC Injection|
11123206|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 1|
11123207|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 2|
11123208|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 3|
11123209|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 4|
11123210|NCT03912428|Other|Single arm|all groups get the same studies
11123211|NCT03912415|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
11123212|NCT03912415|Placebo Comparator|Placebo|
11123213|NCT03912402|Experimental|BCD-100|BCD-100 mg/kg Q3W
11123214|NCT03912389|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
11123215|NCT03912389|Placebo Comparator|Placebo|
11123216|NCT03912376||Healthy Volunteer|Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history.
11123217|NCT03912363|Active Comparator|Rotating fluids|Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.
11123218|NCT03912363|Active Comparator|Insulin infusion|Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.
11123219|NCT03912350|Experimental|Test group|Participants with moderate hepatic impairment.
11123220|NCT03912350|Active Comparator|Reference group|Healthy pariticipants with normal hepatic function.
11123221|NCT03912337|Placebo Comparator|Placebo|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
11123222|NCT03912337|Experimental|Erenumab|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
11123244|NCT03912194|Experimental|Early Withdrawal Exposure plus NAW Regulation Training|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) across the first 4 hours of abstinence over 4 separate sessions.
11123441|NCT03910686|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
11123223|NCT03912324|Experimental|Unipolar voltage subtraction map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter
~Esophageal temperature will be monitored to prevent esophageal injury
~Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture
~the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)
~Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map
~Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map
~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection
~Evaluate time to complete isolation after additional ablation
~Evaluation of Procedure and Ablation time, and perfusion saline dose
~Rhythm follow-up after the procedure in accordance with the study design."
11123224|NCT03912324|Experimental|CT myocardial thickness map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter
~Esophageal temperature will be monitored to prevent esophageal injury.
~Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.
~Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map
~Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map
~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection
~Evaluate time to complete isolation after additional ablation
~Evaluation of Procedure time, Ablation time, and perfusion saline dose
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11123225|NCT03912324|Active Comparator|Empirical PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter
~Esophageal temperature will be monitored to prevent esophageal injury.
~The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.
~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection
~Evaluate time to complete isolation after additional ablation
~Evaluation of Procedure time, Ablation time, and perfusion saline dose
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11123226|NCT03912285|Experimental|Amlodipine, losartan, and amlodipine plus losartan|"Period 1:
~amlodipine 10mg will be administered orally once a day for 9 days.
~Period 2:
~losartan 100mg will be administered orally once a day for 9 days after 13 days of the washout period.
~Period 3:
~amlodipine 10mg once a day plus losartan 100mg once a day will be administered orally for 9 days after 6 days of the washout period."
11123227|NCT03912272|Placebo Comparator|Usual Care Control|Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend >70% of the classes.
11123228|NCT03912272|Experimental|High-intensity Interval Training Group|HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend >70% of the classes.
11123229|NCT03912259|Experimental|Dupilumab|Subcutaneously once every 2 weeks following a loading dose on Day 1
11123230|NCT03912259|Placebo Comparator|Placebo matching dupilumab|Subcutaneously once every 2 weeks (double the amount of placebo on Day 1 to match the loading dose)
11123231|NCT03912246|Experimental|Healthy volunteers|"Human biological samples:
~whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.
~Bio-clinical data :
~adjusted to the purpose of the searches will be collected"
11123232|NCT03912246|Experimental|Patients with neuro-meningeal infection|"Human biological samples:
~Whole blood (serum or plasma, PBMCs, red blood cells), urine, feces, saliva, tears, mouth and skin swabs.
~Extended collection of CSF
~Bio-clinical data :
~adjusted to the purpose of the searches will be collected"
11123233|NCT03912233|Experimental|Part 1: F/MF genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive multiple dose levels of VX-121 in TC with TEZ/VX-561.
11123234|NCT03912233|Placebo Comparator|Part 1: Placebo|
11123235|NCT03912233|Experimental|Part 2: F/F genotypes VX-121 in TC with TEZ/VX-561|Subjects will receive VX-121 in TC with TEZ/VX-561
11123236|NCT03912233|Active Comparator|Part 2: Placebo + TEZ/IVA|
11123237|NCT03912220|Experimental|Nicotinamide Riboside|Experimental group of participants will receive Nicotinamide riboside at a dose of 900 mg twice a day orally.
11123238|NCT03912220|Placebo Comparator|Placebo|Study participants in the placebo arm will receive placebo pills that are similar in size and shape to the experimental group drug.
11123239|NCT03912207|Experimental|Group 1, 2 Day Bronchoscopy|Group 1: 10 volunteers will receive 1 x 107 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 1 volunteers will have a bronchoscopy 2 days post challenge
11123240|NCT03912207|Experimental|Group 2, 7 Day Bronchoscopy|Group 2: 10 volunteers will receive 1 x 107 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 2 volunteers will have a bronchoscopy 7 days post challenge
11123241|NCT03912207|Experimental|Group 3, 14 Day Bronchoscopy|Group 3: 10 volunteers will receive 1 x 107 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 3 volunteers will have a bronchoscopy 14 days post challenge
11123242|NCT03912207|Experimental|Group 4, 28 Day Bronchoscopy|Group 4: 10 volunteers will receive 1 x 107 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 4 volunteers will have a bronchoscopy 28 days post challenge
11123243|NCT03912207|Experimental|Group 5, 56 Day Bronchoscopy|Group 5: 10 volunteers will receive 1 x 107 cfu aerosol inhaled BCG and 3 volunteers will receive aerosol inhaled normal saline placebo. All Group 5 volunteers will have a bronchoscopy 56 days post challenge
11123336|NCT03911518|Experimental|Intervention|Loop drainage.
11123337|NCT03911505|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
11123245|NCT03912194|Active Comparator|Early Withdrawal Exposure plus Relaxation Control Training|The development, application, modification, and repeated practice of relaxation strategies across the first 4 hours of abstinence over 4 separate sessions.
11123246|NCT03912194|Active Comparator|NAW Regulation Training Only|The development, application, modification, and repeated practice of individualized withdrawal regulation strategies (e.g., behavioral and cognitive strategies for allaying withdrawal symptoms) over 4 separate sessions involving smoking as usual.
11123247|NCT03912194|Active Comparator|Relaxation Control Training Only|The development, application, modification, and repeated practice of relaxation strategies over 4 separate sessions involving smoking as usual.
11123248|NCT03912181||Familial chylomicronaemia syndrome (FCS)|"Patient homozygous or compound heterozygous mutation in lipoprotein lipase (LPL) gene
~Patient homozygous or compound heterozygous mutation in any Apolipoprotein A5 (Apo A5), glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2), genes and heterozygous (het) mutation in LPL gene"
11123249|NCT03912181||Multifactorial chylomicronemia syndrome|"Patient with heterozygous mutation in lipoprotein lipase (LPL) , Apolipoprotein A5 (Apo AV), GPI HBP1, LMF1, ApoC2 genes and any additional combination of functional variant
~Patient with any additional combination of functional variant in LPL gene Apo AV, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2) genes"
11123250|NCT03912168|Experimental|Question Prompt List|
11123251|NCT03912168|Active Comparator|3 questions list|
11123252|NCT03912155||Patients|20 patients per presumed location of the epileptogenic zone (see experimental plan) for a total of 120 patients, including 30 minors. For patients, a MEG-EEG-SEEG examination during the SEEG exploration period.
11123253|NCT03912155||Controles|For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.
11123254|NCT03912142||Three dimensional transperineal ultrasound|"This is a single arm study. All women who delivered vaginally will be included in the study .
~The planned interventions are:
~Clinical vaginal and rectal examination Three dimensional transperineal ultrasound."
11123255|NCT03912129|Other|pediatric Evans Syndrome|Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
11123256|NCT03912116|Experimental|Amniotic Umbilical Cord Particulate Injection|100mg Amniotic Umbilical Cord Particulate in 8cc saline
11123257|NCT03912116|Placebo Comparator|Saline Injection|8cc saline
11123258|NCT03912103|Active Comparator|Interdiciplinary medication review intervention|The clinical pharmacist perform medication review and presents medication interventions orally and written to the physician. The physician perform the changes and inform the patient about the changes. 7 days after intervention the patient receives a follow up phone call from the pharmacist about the medication interventions. If the pharmacist during the follow up phone call identify any complications due to compliance/add on/deprescribing the pharmacist uses motivational conversation to come to a solution.14 days after the beginning of the intervention the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire and measured on a Likert scale (1-5). 30 days after the beginning of the intervention the pharmacist collect an updated medication history. Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group.
11123259|NCT03912103|No Intervention|Control group|Standard treatment without a medication review and follow up related to medication changes (standard treatment).14 days after the enrollment the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire measured on a Likert scale (1-5). 30 days after the enrollment the pharmacist collect an updated medication history.Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group
11123260|NCT03912077|Experimental|Culturally Adapted Cognitive Behavioural Therapy|"Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) is an evidence-based psychological intervention manual developed by Devon Hinton, MD from Harvard University and Baland Jalal from University of Cambridge. It is a group therapy protocol that consists of 7 sessions.
~It is a brief, feasible and culturally sensitive intervention that has a transdiagnostical approach. Detailed information about Syrian culture, idioms of stress, cultural differences, and psychological problems that Syrian refugee women have been facing and their needs, expectations and sensitivities are considered in the adaptation process. Examples, cultural metaphors and imageries that take part in the manual are adapted according to Syrian culture."
11123261|NCT03912077|No Intervention|Treatment as Usual|Control arm participants will receive routine social support and/or care according to ordinary practice of the non-governmental organization (treatment as usual). Also, they will receive baseline and post assessments according to the study schedule.
11123262|NCT03912064|Experimental|CD25/Treg-depleted DLI + Ipilimumab|"Ipilimumab is administered intravenously every 12 weeks
~Patients will receive a defined dose of CD25hi Treg depleted DLI intravenoudsly"
11123263|NCT03912051|Experimental|asymmetric balloon|Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon
11123264|NCT03912038||Null or low consumption|No-intervention. The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
11123265|NCT03912038||Moderate consumption|No-intervention. The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
11123266|NCT03912038||High consumption|No-intervention. The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
11123267|NCT03912025||Mild hemodynamic CHD|"Mild severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses, as outlined in the European Society of Cardiology Section on Sports Cardiology consensus guidelines (Budts W, Borjesson M, Chessa M, van Buuren F, Trindade PT, Corrado D, Heidbuchel H, Web G, Holm J, Papadakis M. 2013).
~They define functional parameters such as systolic function, oxygen saturation, rhythm disorders, elevated pressure or volume load, etc. to divide patients into 3 hemodynamic groups. Based on their model, we define mild CHD as ones falling into the group that can train at High Intensity exercise levels."
11123338|NCT03911492|Other|SCP Pressure Management|Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg.
11123339|NCT03911479|Experimental|Bariatric Surgery Group|
11123268|NCT03912025||Moderate hemodynamic CHD|"Moderate severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses. Based on their model, we define moderate CHD as those that can train at Moderate Intensity."
11123269|NCT03912012|Other|Children and adolescent with a history of type 1 diabetes|Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years. Glomerular hyper filtration and endothelial dysfunction will be evaluate.
11123270|NCT03911999||Non-prostate cancer subjects|No clinical evidence of prostate cancer
11123271|NCT03911999||Subjects with pathologically insignificant prostate cancer|Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score < 7.
11123272|NCT03911999||Subjects with pathologically significant prostate cancer|Significant cancers are those with either Gleason score > 7, evidences of extra-prostatic extension with positive margins, or seminal vesicles / lymph nodes involvement.
11123273|NCT03911986|Other|Immediate External Loop Recorder|Participants randomized to the Immediate External Loop Recorder group will be monitored for the duration of the first week of the study using the Novacor R-Test 4.
11123274|NCT03911986|Other|Delayed External Loop Recorder|Participants randomized to the Delayed External Loop Recorder group will be monitored for the duration of the second week of the study using the Novacor R-Test 4.
11123275|NCT03911973|Experimental|Talazoparib + Gedatolisib|"Talazoparib + Gedatolisib
~Dose Level -1: Gedatolisib 150mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 1: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 2: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 1.00 mg/orally qd, Days 1-28"
11123276|NCT03911960|Experimental|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
11123277|NCT03911960|Active Comparator|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
11123278|NCT03911947|Active Comparator|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
11123279|NCT03911947|Active Comparator|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
11123280|NCT03911947|Active Comparator|AB (actual bicarbonat level)|Measurment 4 times per day, ABA (acid-bases analyses)
11123281|NCT03911934|Active Comparator|Usual care|Usual care in the geriatric outpatient clinic.
11123282|NCT03911934|Experimental|Usual care plus polypharmacy intervention|Usual care in the geriatric outpatient clinic plus polypharmacy intervention. Polypharmacy intervention consists of a medication review by a physician from the Department of Clinical Pharmacology plus additional communication with patients' GPs before and after the visit in the outpatient clinic.
11123283|NCT03911921|Experimental|RSYYT decoction|RSYYT decoction Compound granules of traditional Chinese medicine
11123284|NCT03911921|Experimental|Astragalus membranaceus|one herb decoction Compound granules of one herb (Astragalus membranaceus)
11123285|NCT03911908|Active Comparator|ERC guided CPR (intervention/NIRS group)|CPR protocol according to current ERC guidelines (2015)
11123286|NCT03911908|No Intervention|ERC-based CPR (control group)|modified CPR protocol based on current ERC guidelines (2015), extended by evaluation of NIRS readings and interventions to optimize CPR quality
11123287|NCT03911895||patients with coronary artery diseas undergoing PCI|Effect of stent length on patients with coronary artery undergoing PCI
11123288|NCT03911882||Celergen Administration|The food supplement Celergen was administered to fibromyalgia patients following a protocol of a daily intake for the period of a total of 3 months (90 days)
11123289|NCT03911869|Experimental|Standard Dose Arm|"Patients in the standard-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.
~450 mg encorafenib orally once a day (QD)
~45 mg binimetinib orally twice a day (BID)
~Patients who are able to tolerate the standard dose during the first 4 weeks of treatment (Cycle 1) should be dose-escalated to 600 mg encorafenib QD plus 45 mg binimetinib BID provided they meet protocol-defined criteria."
11123290|NCT03911869|Experimental|High Dose Arm|"Patients in the high-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.
~300 mg encorafenib orally twice a day (BID)
~45 mg binimetinib orally twice a day (BID)"
11123291|NCT03911856|Experimental|Non-invasive assesment techniques|We hypothesize that non-invasive indices of right ventricular RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction pulmonary arterial hypertension and heart failure with preserved ejection fraction(PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
11123292|NCT03911856|Experimental|Efficacy of acute-oxygen therapy during exercise|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing pulse volume recording PVR, increasing RV functional reserve, increasing gas diffusion).
11123293|NCT03911843|Experimental|CASES|Of eligible subjects, 45/67 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
11123294|NCT03911843|Active Comparator|CONTROLS|Others 22/67 subjects joined to the study as data contributors, and were entered as controls (CONTR).
11123295|NCT03911830|Experimental|Exercise followed cold water immersion|Exercise program on cycloergometer and its submerged recovery
11123296|NCT03911817|No Intervention|IV vasopressor|Will receive IV vasopressor infusion only
11123297|NCT03911817|Active Comparator|Midodrine|Will receive midodrine in addition to IV vasopressor infusion
11123298|NCT03911804|Experimental|Bolus group|
11123299|NCT03911804|Active Comparator|Infusion group|
11123300|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
11123301|NCT03911765|Experimental|Executive Function cognitive training|20 hours of digital cognitive training targeting executive function.
11123302|NCT03911765|Active Comparator|Games|10 hours of computer games c available online which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc), followed by 10 hours of of digital cognitive training targeting executive function.
11123303|NCT03911752||People with Acquired Brain Injury|People with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=8).
11123304|NCT03911752||Partners of people with Acquired Brain Injury|Partners of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
11123305|NCT03911752||Relatives of people with Acquired Brain Injury|Relatives of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
11123306|NCT03911739|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.
~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
11123307|NCT03911739|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.
~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
11123308|NCT03911726|Other|Healthy subjects|30 healthy subjects will undergo a single PET/MR-measurement.
11123309|NCT03911726|Experimental|First-episode, drug-naive patients with schizophrenia|20 first-episode, drug-naive patients with schizophrenia will undergo a single PET/MR-measurement.
11123310|NCT03911726|Experimental|Pretreated chronically ill patients with schizophrenia|90 pretreated chronically ill patients with schizophrenia will undergo a single PET/MR-measurement.
11123311|NCT03911713|Experimental|VX-561|Subjects will be randomized to receive 1 of 4 dose levels of VX-561.
11123312|NCT03911713|Active Comparator|IVA|
11123313|NCT03911687|No Intervention|Control Group|"Control data will be collected in the CONCERN CDS system that will be live in the EHR, but in silent release mode (e.g., not providing notification to clinicians)."
11123314|NCT03911687|Experimental|Intervention Group|"Experimental data will be collected in the CONCERN CDS system that will be live in the EHR in active release mode (e.g., providing CONCERN CDS system notification to clinicians)."
11123315|NCT03911674|Experimental|Oral stimulation|Oral stimulation protocol: manual stimulation of the oral sucking
11123316|NCT03911674|No Intervention|Control|No intervention
11123317|NCT03911661|Active Comparator|Standard Management|The standard management phase will be historical and consist of warfarin management during the 12-months prior to signing informed consent.
11123318|NCT03911661|Experimental|Fearon Algorithm (FA) Anticoagulation Management Service|Once study patients have received an approved FA report, the FA AMS phase of the study will commence. An investigator will communicate the new warfarin tablet size, if necessary, and use the FA report to determine warfarin doses for the patient.
11123319|NCT03911661|Experimental|Fearon Algorithm (FA) Patient Self Management|At the conclusion of the six-month FA anticoagulation management service phase, patients will be trained to use the FA for patient self management (PSM) and after successfully demonstrating the ability to engage in PSM the FA PSM phase of the study will commence.
11123320|NCT03911648||Group B;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
11123321|NCT03911648||Group L;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44
11123322|NCT03911635|Experimental|Hypospadias in children|Distal shaft hypospadias at age of 12 years or less
11123323|NCT03911609|Experimental|Isometric (Static) Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
11123324|NCT03911609|Experimental|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
11123325|NCT03911583|Active Comparator|Control Group (CG)|Education, modifying diet and light physical activity (LPA)
11123326|NCT03911583|Active Comparator|Moderate physical activity group (MPA)|Education, modifying diet and moderate physical activity (MPA)
11123327|NCT03911583|Active Comparator|Intense physical activity group (IPA)|Education, modifying diet and intense physical activity (IPA)
11123328|NCT03911570||Glucosamine Sulfate Group (GS Group)|GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
11123329|NCT03911570||Control Group|Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).
11123330|NCT03911557|Experimental|Patients with moderate to high tumor mutational burden|Patients with recurrent or refractory disease in solid tumors naïve to anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy and have moderate to high tumor mutational burden (TMB)
11123331|NCT03911544|Active Comparator|TIVA anesthesia with BIS monitoring|The depth of anesthesia will be adjusted with the help of BIS monitoring.
11123332|NCT03911544|No Intervention|TIVA anesthesia without BIS monitoring|The depth of anesthesia will adjusted as in standard practice (clinical signs of poor anesthesia such as increase in blood pressure and/or heart rate, tearing and profuse sweating)
11123333|NCT03911531||Fetuses|DNA obtained from amniotic fluid samples
11123334|NCT03911531||Neonates|DNA obtained from neonatal blood samples
11123335|NCT03911518|Active Comparator|Control|Incision and drainage.
11123341|NCT03911466|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.
~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
11123342|NCT03911466|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.
~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
11123343|NCT03911453|Experimental|Treatment (rucaparib)|"Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of programmed cell death-1 with ligand (PD-L1) by immunohistochemistry (IHC)
~. Starting Dose 600 mg twice daily Dose Level -1 500 mg twice daily Dose Level -2 400 mg twice daily Dose Level -3 300 mg twice daily"
11123344|NCT03911440|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
11123345|NCT03911440|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
11123346|NCT03911427|Experimental|Powder Mix 1|Oat powder product, mixed with water
11123347|NCT03911427|Placebo Comparator|Powder Mix 2|Brown rice milk powder product, mixed with water
11123348|NCT03911414|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
11123349|NCT03911414|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700mg QD) based on age .
11123350|NCT03911401|Experimental|0.3% OPA-15406|Twice daily
11123351|NCT03911401|Experimental|1% OPA-15406|Twice daily
11123352|NCT03911401|Placebo Comparator|Placebo|Twice daily
11123353|NCT03911388|Experimental|HSV G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
11123354|NCT03911375|Experimental|Mindfulness Based Stress Reduction (MBSR)|Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.
11123355|NCT03911375|No Intervention|Control|Participants assigned to the control group will follow the usual treatment, according to their diagnosis.
11123356|NCT03911362|Active Comparator|Lumbopelvic Stabilisation Exercises|Starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction
11123357|NCT03911362|Active Comparator|Pelvic Floor Exercises|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres and for slowly contracting muscle fibres,slow contraction by counting to ten hold for a count of ten, then gradually relax by counting to ten.
11123358|NCT03911336|Experimental|Group A - test|Group A (Test) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
11123359|NCT03911336|Active Comparator|Group B - Control 1|Group B (Control 1) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3- day period, starting the regime at 2 PM on the day of the extraction.
11123360|NCT03911336|Active Comparator|Group C - Control 2|Group C (Control 2) - Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
11123361|NCT03911310|Experimental|PET/CT 1: [18F]PSMA-11, PET/CT 2: [68Ga]PSMA-11|Patients in this arm will first receive the experimental radiotracer [18F]PSMA-11 PET/CT followed by the [68Ga]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
11123362|NCT03911310|Active Comparator|PET/CT 1: [68Ga]PSMA-11, PET/CT 2: [18F]PSMA-11|Patients in this arm will first receive the experimental radiotracer [68Ga]PSMA-11 PET/CT followed by the [18F]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
11123363|NCT03911271|Experimental|Loading dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
11123364|NCT03911271|Experimental|Low dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
11123365|NCT03911271|Placebo Comparator|Placebo|"In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
11123366|NCT03911258|Experimental|Nasal flora in CF patient|
11123367|NCT03911245||Patients with age equal or older than 40 years|
11123368|NCT03911245||Patients with age less than 40 years|
11123369|NCT03911232|Experimental|Enhanced recovery|rocuronium 2 effective dose at anesthesia induction sugammadex after skin incision and before extubation (total 2 mg/kg iv)
11123370|NCT03911232|No Intervention|Conventional anesthesia|standard general anesthesia protocol (1 effective dose of rocuronium at anesthesia induction)
11123406|NCT03910998|Active Comparator|"Group M for Moderate muscle relaxation, low doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.
~Rocuronium IV bolus guided by TOF that must remain between 1-3 / 4 during surgery."
11123371|NCT03911219||EHealth system support (Arm A)|Patients with stage IV non-squamous non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (SCLC) with indication for first- line treatment with atezolizumab in combination with platinum-based chemotherapy induction followed by maintenance therapy with atezolizumab according to the German Summary of Product Characteristics
11123372|NCT03911219||Standard care (Arm B)|Patients with stage IV non-squamous non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (SCLC) with indication for first- line treatment with atezolizumab in combination with platinum-based chemotherapy induction followed by maintenance therapy with atezolizumab according to the German Summary of Product Characteristics
11123373|NCT03911206|Experimental|Arm 1 : Inspirtory muscle training (IMT)|IMT exercises at home will gradually ramp up.
11123374|NCT03911206|Experimental|Arm 2: Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
11123375|NCT03911206|Experimental|Arm 3: IMT and Exercise|a combination of arm 1 and arm 3
11123376|NCT03911206|No Intervention|Arm 4: Routine care|no interventions will occur in this group besides testing procedures and offering access to the study team in case asthma-related questions come up.
11123377|NCT03911193|Experimental|Cabozantinib|Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days.
11123378|NCT03911180|Experimental|PFN straight parallel blade|All patients with pertrochanteric fracture that is eligible will undergo PFNA with straight parallel blade.
11123379|NCT03911167||RG|RG: robotic group
11123380|NCT03911167||LG|LG:laparoscopic group,
11123381|NCT03911167||OG|OG：open group
11123382|NCT03911154|Experimental|SmartSleep Modality Assignment|This study uses within subject comparison. For each subject, the order of SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 4 stimulation modalities.
11123383|NCT03911141|No Intervention|Control|Participants receive a daily text message stating whether or not they achieved their step goal on the prior day during the 12 months of intervention and 6 months of follow-up.
11123384|NCT03911141|Experimental|Gamification Intervention|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.
~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.
~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.
~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
11123385|NCT03911141|Experimental|Financial Incentive Intervention|"Participants are informed that each week that money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.
~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
11123386|NCT03911141|Experimental|Gamification and Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
11123387|NCT03911128||Participants with newly diagnosed ALL|
11123388|NCT03911115||Bariatric surgery|Individuals that have undergone a gastric bypass (RYGB) or a sleeve gastrectomy (SG)
11123389|NCT03911102|Experimental|Cohort 1: DaxibotulinumtoxinA Dose A|Subjects will receive Dose A of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL
11123390|NCT03911102|Experimental|Cohort 2: DaxibotulinumtoxinA Dose B|Subjects will receive Dose B of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL
11123391|NCT03911102|Experimental|Cohort 3: DaxibotulinumtoxinA Dose C|Subjects will receive Dose C of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL
11123392|NCT03911102|Experimental|Cohort 4: DaxibotulinumtoxinA Dose D|Subjects will receive Dose D of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL
11123393|NCT03911089|Other|Open label|UCD Anamix Infant
11123394|NCT03911076|Experimental|PVX-2|Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein
11123395|NCT03911076|Placebo Comparator|Placebo|Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)
11123396|NCT03911063|Experimental|Cognitive behavioral therapy (CBT)|
11123397|NCT03911063|Active Comparator|Placebo Talking Sessions|
11123398|NCT03911050|Experimental|Apple consumption|Each subject took apple blends 600 g (made from two apples with seed removal) in a single dose, and samples (urine and blood and feces) at different timepoints were collected following administration of apple blends.
11123399|NCT03911050|Placebo Comparator|Control group|Each subject took breakfast without any apple-related products in a single dose, and samples (urine and blood and feces) at different timepoints were collected following breakfast.
11123400|NCT03911037|Active Comparator|Standard Medical Therapy + G CSF Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required). G-CSF ( prefilled syringe) at the dosage of 5 μg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
11123401|NCT03911037|Placebo Comparator|Standard Medical Therapy + Placebo|"Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required).
~Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered."
11123402|NCT03911024|Active Comparator|HIV|
11123407|NCT03910998|Experimental|"Group D for Deep muscle relaxation, high doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.
~Bolus of rocuronium 0.1 mg/kg IV will be given during surgery to keep the TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes)."
11123408|NCT03910972|Experimental|Part A, Group A (Sm-TSP-2/Alhydrogel 10 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
11123409|NCT03910972|Experimental|Part A, Group B (Sm-TSP-2/Alhydrogel 10 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
11123410|NCT03910972|Experimental|Part A, Group C (Sm-TSP-2/Alhydrogel 30 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
11123411|NCT03910972|Experimental|Part A, Group D (Sm-TSP-2/Alhydrogel 30 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
11123412|NCT03910972|Experimental|Part A, Group E (Sm-TSP-2/Alhydrogel 100 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
11123413|NCT03910972|Experimental|Part A, Group F (Sm-TSP-2/Alhydrogel 100 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
11123414|NCT03910972|Active Comparator|Part A, Group G (HBV)|Hepatitis B Vaccine
11123415|NCT03910972|Experimental|Part B, Group H (Sm-TSP-2/Alhydrogel +/- AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, with or without AP 10-701, dose and formulation determined in Part A
11123416|NCT03910972|Active Comparator|Part B, Group I (HBV)|Hepatitis B Vaccine
11123417|NCT03910959|Experimental|Animal-assisted therapy|Patients receive three weeks of two AAT sessions, each lasting ca 30 minutes.
11123418|NCT03910959|Active Comparator|treatment as usual|Patients receive three weeks of two control sessions, each lasting ca 30 minutes.
11123419|NCT03910946||diabetic and renal|all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection
11123420|NCT03910920||Cystic fibrosis patients with PA|All the children with acute or chronic Pseudomonas aeruginosa infection and followed-up in our cystic fibrosis center will be included in this study.
11123421|NCT03910907||Standard of care|Men treated for mycoplasma according to standard of care
11123422|NCT03910907||Standard of care plus|Men treated for mycoplasma according to standard of care with regimen selected based on laboratory detection of resistance markers
11123423|NCT03910881|Experimental|open-platform patient support system|Proof of concept testing of app
11123424|NCT03910855|Experimental|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
11123425|NCT03910855|Active Comparator|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
11123426|NCT03910842|Experimental|CD19-TriCAR-T/NK（SILK）|CD19-TriCAR-T/SILK cells will be administered intravenously
11123427|NCT03910829|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
11123428|NCT03910829|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
11123429|NCT03910829|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
11123430|NCT03910803|Other|Brodalumab - Open Label|"Randomized subjects will be receiving Brodalumab (210 mg) administered by subcutaneous injection at the following visits: Baseline, week 1, week 2 and every two weeks thereafter, until Week 24.
~Investigational Product not to be administer into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by Hidradenitis Suppurativa."
11123431|NCT03910790|Experimental|19 Gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle
11123432|NCT03910738|Experimental|Testosterone treatment (Nebido®)|"Treatment/Nebido® arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®).
~Treatment will be injected at baseline, week 6, 18, 30, 42 and 54"
11123433|NCT03910738|Placebo Comparator|Placebo|"Placebo arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution.
~Placebo will be injected at baseline, week 6, 18, 30, 42 and 54"
11123434|NCT03910725||Obesity|Patients with BMI >40 awaiting stapled bariatric surgery, without a history of or concomitant ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be recruited prospectively from the bariatric surgery preoperative assessment clinics.
11123435|NCT03910725||Rheumatoid arthritis|Patients with RA without diagnosed or known ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication will be recruited prospectively from rheumatology clinics, prior to initiation of biologic or diseased modifying anti-rheumatic drugs.
11123436|NCT03910725||Dilated cardiomyopathy|TTNtv-positive and -negative DCM patients from the Royal Brompton Hospital biobank have provided informed consent to be contacted for research
11123437|NCT03910712|Experimental|Pyrotinib and trastuzumab plus aromatase inhibitor|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11123438|NCT03910712|Active Comparator|Trastuzumab plus aromatase inhibitor|Participants will receive trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11123439|NCT03910699|Active Comparator|Two-row anastomosis|Colorectal anastomosis is created with a two-row circular surgical stapler
11123442|NCT03910686|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
11123443|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
11123444|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
11123445|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
11123446|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
11123447|NCT03910673|Experimental|2-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 2 hours after start of third infusion dose. n = 6
11123448|NCT03910673|Experimental|30-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 30 minutes after start of third infusion dose. n = 6
11123449|NCT03910673|Experimental|5-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 5 hours after start of third infusion dose. n = 6
11123450|NCT03910673|Experimental|75-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 75 minutes after start of third infusion dose. n = 6
11123451|NCT03910673|Experimental|8-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 8 hours after start of third infusion dose. n = 6
11123452|NCT03910660|Other|Lead-in Stage|"Patients will be observed for dose-limiting toxicity (DLT) during Cycle 1. 3 patients will be treated initially with 0.4 mg Talabostat Mesylate plus PEMBRO:
~If there are no DLTs, the dose of Talabostat Mesylate will be escalated to 0.6 mg in the next cohort.
~If ≥1/3 of patients has a DLT in Cycle 1, either 3 patients (if 1 experiences a DLT) or 6 to 9 patients (if 2 or 3 experiences a DLT) will be added at the 0.4 mg Talabostat Mesylate dose.
~For the 0.4 mg cohort:
~If <1/3 of the patients experience a DLT, consideration will be given to dose to 0.6 mg Talabostat Mesylate plus PEMBRO.
~If 1/3 of the patients experience a DLT, the Efficacy Stage can commence. If >1/3 of the patients experience a DLT, a discussion will be held as to how to proceed.
~Following dose escalation to 0.6 mg. If there are no DLTs, the Efficacy Stage can commence. If ≥1/3 patients have a DLT in Cycle 1, after a discussion, 6 to 9 patients will be added at the 0.6 mg Talabostat Mesylate dose level."
11123453|NCT03910660|Other|Efficacy Stage|After assessment of the safety and confirmation of the Talabostat Mesylate/PEMBRO dose schedule to be used in the subsequent stage, the Efficacy Stage will begin. Eligible patients will receive Talabostat Mesylate QD on Days 1 to 14 of a 21-day cycle plus PEMBRO 200 mg administered IV on Day 1 every 21 days.
11123454|NCT03910647|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
11123455|NCT03910647|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
11123456|NCT03910634|Experimental|IMRT combined with carboplatin|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
11123457|NCT03910634|Placebo Comparator|IMRT combined with carboplatin and fluorouracil|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
11123458|NCT03910621|Experimental|Miglustat|Miglustat is administered three times a day as an oral capsule
11123459|NCT03910608|Experimental|DLPFC+10 IPL|Stimulation of dorsolateral prefrontal cortex (DLPFC) 10 ms before inferior parietal lobule (IPL) presumes that the DLPFC to IPL input facilitates insula postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
11123460|NCT03910608|Experimental|IPL+10 DLPFC|Stimulation of IPL 10 ms before DLPFC presumes that the IPL to DLPFC input inhibits insula postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
11123461|NCT03910608|Experimental|IPL+4 DPLFC|Stimulation of IPL 4 ms before DLPFC is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula inhibits insula postsynaptic output by weakening the IPL to insula input, thereby impairing cognition response.
11123462|NCT03910608|Experimental|DLPFC+4 IPL|Stimulation of DLPFC 4 ms before IPL is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula potentiates insula postsynaptic output by strengthening the IPL to insula input, thereby improving cognition response.
11123463|NCT03910608|Experimental|DLPFC+4 MPFC|Stimulation of DLPFC 4 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
11123464|NCT03910608|Experimental|MPFC+4 DLPFC|Stimulation of MPFC 4 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
11123465|NCT03910608|Experimental|DLPFC+10 MPFC|Stimulation of DLPFC 10 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
11123466|NCT03910608|Experimental|MPFC+10 DLPFC|Stimulation of MPFC 10 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
11123467|NCT03910595|Experimental|Mepitel Film Arm|This is a single arm trial where all patients will receive the intervention of Mepitel Film.
11123501|NCT03910322|Placebo Comparator|Placebo|Placebo arm. Similar trial product, but without Bif195 bacteria
11123468|NCT03910582|Experimental|Experimental group|Subjects in this group will be treated with personalized frozen-thawed embryo transfer. The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
11123469|NCT03910582|Active Comparator|Control group|Subjects in this group will be treated with routine frozen-thawed embryo transfer.The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
11123470|NCT03910556||no complication|the patients who did not develop any kind of complication and no re-craniotomy
11123471|NCT03910556||with complication (s)|the patients who developed at least one of non-neurological complication or required re-craniotomy
11123472|NCT03910543|Experimental|Patients with Cutaneous Sarcoidosis|Patients with cutaneous sarcoidosis that may also have also have internal organ sarcoidosis
11123473|NCT03910543|Experimental|Patients with Granuloma Annulare|Patients with granuloma annulare that is long-standing and/or widespread
11123474|NCT03910530|Experimental|INCMGA00012|Single-agent INCMGA00012.
11123475|NCT03910530|Experimental|INCB001158 75 mg|Single-agent INCB001158.
11123476|NCT03910530|Experimental|INCB001158 100 mg|Single-agent INCB001158.
11123477|NCT03910530|Experimental|INCMGA00012 + INCB001158|Combination of INCMGA00012 and INCB001158.
11123478|NCT03910517||E-sport athletes|People aged 15-35 who engage in structured E-sport (e.g. community-based, pro team or educational setting).
11123479|NCT03910504|Active Comparator|Rocuronium 0,3 mg/kg|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.
~Patients, who have been randomized to this group, will be obtained single reduced dose of rocuronium (0,3 mg/kg) once intravenous bolus. The dose of rocuronium will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment. The drug will be diluited in a syringe with 20 ml of solution."
11123480|NCT03910504|Experimental|No rocuronium|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.
~Patients, who have been randomized to this group, will not receive rocuronium, but normal saline will be administered by the anesthesiologist in charge of the patients. The dose of normal saline (20 ml in one syringe) will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment."
11123481|NCT03910491|Experimental|Intervention|All participants who enroll in the study will be assigned to a PriCARE group program that will adhere to the approximately 9 hour PriCARE curriculum.The trainings are administered to groups of approximately 4-12 caregivers at a time and are led by 2 mental health providers trained in the PriCARE curriculum. The curriculum will be delivered in 2-6 sessions over a 2-20 week period.
11123482|NCT03910478|Experimental|Self-collected Dried Blood Spot (DBS) monitoring|N=100 Subject collected DBS CMV monitoring with mobile technology support
11123483|NCT03910478|Active Comparator|Standard Monitoring Control|N=50 Standard care with office based testing
11123484|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma
11123485|NCT03910452|Experimental|1|This is a single arm open-label pilot study.
11123486|NCT03910439|Experimental|1|Avelumab 800 mg IV every two weeks in combination with radiation therapy
11123487|NCT03910413|Other|Dual Energy CT|
11123488|NCT03910400|Experimental|MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
11123489|NCT03910400|Experimental|Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
11123490|NCT03910387|Experimental|Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl)|Patients receive gemcitabine/nab-paclitaxel combination chemotherapy on days 1, 8 and 15, and telotristat ethyl PO QD, BID, or TID on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11123491|NCT03910387|Active Comparator|Group 2 (gemcitabine/nab-paclitaxel)|Patients receive gemcitabine/nab-paclitaxel chemotherapy (at the discretion of the investigator) on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11123492|NCT03910374|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
11123493|NCT03910374|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
11123494|NCT03910361|Experimental|Evogliptin|evogliptin 5mg
11123495|NCT03910361|Active Comparator|Pioglitazone|pioglitazone 15mg
11123496|NCT03910348|Experimental|Whole body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting (2-4mm peak to peak) on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Each patient received the vibrations under supervision using five different static positions: squat, deep squat, widestep squat, lunge, and hands-front lunge. The exercise programs for each experimental groups consisted of 20 to 60-minute sessions on three days per week for 24 weeks, and they were performed under the supervision.
11123497|NCT03910348|Experimental|High-impact exercise|Depending on their individual calcium and vitamin D intakes, each patient advised to receive supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D.
11123498|NCT03910348|No Intervention|Control|Depending on their individual calcium and vitamin D intakes, each patient received supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D. The demographic characteristics of the participants were obtained at the baseline assessment.
11123499|NCT03910335||LSS patients|"Case/control study: Patients from surgical departments awaiting surgery for LSS will will out the questionnaire.
~Cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)"
11123500|NCT03910335||Non-LSS patients|Case/control study and cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)
11123667|NCT03909165|Experimental|Part B. Sugammadex 2 mg/kg|Single IV bolus of sugammadex at 2 mg/kg.
11123502|NCT03910322|Experimental|Low-dose Bif195|Active trial product with minimum 15 billion CFU daily dose
11123503|NCT03910322|Experimental|High-dose Bif195|Active trial product with minimum 50 billion CFU daily dose
11123504|NCT03910309||1 or 2 level TLIF candidates|Any subject determined to ALREADY be a candidate for 1 or 2 level transforaminal interbody fusion surgery
11123505|NCT03910296||Acceptance & Commitment Therapy|"Acceptance & Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.
~Each subject will participate for 6 sessions of Acceptance & Commitment Therapy (ACT).
~ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values."
11123506|NCT03910257|Experimental|nutrition education module|12 activities of the nutrition education module pre and post test
11123507|NCT03910257|No Intervention|control group|no intervention pre and post test
11123508|NCT03910244|Experimental|Pomalidomide|Oral Pomalidomide will be provided as a capsule at 4 mg/day dose. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
11123509|NCT03910244|Placebo Comparator|Placebo|A placebo matching the study drug will be provided as a capsule. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
11123510|NCT03910231|Placebo Comparator|Placebo|Placebo
11123511|NCT03910231|Experimental|15mg Tolvaptan|15mg Tolvaptan
11123512|NCT03910231|Experimental|30mg Tolvaptan|30mg Tolvaptan
11123513|NCT03910218|Experimental|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
11123514|NCT03910218|Placebo Comparator|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
11123515|NCT03910205||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
11123516|NCT03910205||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
11123517|NCT03910205||Healthy patients with gingivitis|Systemically healthy patients with gingivitis
11123518|NCT03910205||Healthy patients with healthy gingiva|Systemically healthy patients with healthy gingiva
11123519|NCT03910192|Experimental|Mindfulness meditation coaching|Mindfulness-based coaching - participants will receive instructions on (a) mindfulness meditation and gentle mindful movement through home-based and in-class participation at the Southlake Cardiovascular Rehabilitation Clinic and (b) personal coaching support. The health coach will further assist participants through either face-to-face or telephone-based discussions. They will meet with the health coach at mutually-agreed upon on times for designated time periods.
11123520|NCT03910192|Active Comparator|dietary cardiovascular risk reduction coaching|Cardiovascular risk reduction education - No change to standard of care where participants will receive instructions (in person or by phone call) on how to integrate exercise and dietary changes in your lifestyle to reduce your risk of future cardiovascular events. These instructions will be centered around the DASH dietary practices.
11123521|NCT03910166|Experimental|DCB group|use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
11123522|NCT03910166|Active Comparator|BMS group|use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
11123523|NCT03910153|Placebo Comparator|Placebo - (Age 30-50 years)|
11123524|NCT03910153|Experimental|MSPrebiotic - (Age 30-50 years)|
11123525|NCT03910153|Placebo Comparator|Placebo - (Aged 70 years and above)|
11123526|NCT03910153|Experimental|MSPrebiotic - (Aged 70 years and above)|
11123527|NCT03910140|Experimental|TILA-TACE group|
11123528|NCT03910127|Experimental|TQB2450 + Anlotinib (10 mg)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 10 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11123529|NCT03910127|Experimental|TQB2450 + Anlotinib (12 mg)|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11123530|NCT03910127|Placebo Comparator|TQB2450 + Placebo|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Placebo for Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11123531|NCT03910114||Dotarem Enhancement Group|
11123532|NCT03910114||Gadovist Enhancement Group|
11123533|NCT03910114||Magnevist Enhancement Group|
11123534|NCT03910101|Active Comparator|Hand surgery and intensive rehabilitation|"The surgical treatment for reducing spasticity comprises lengthening of tendons, muscle release and occasionally correction of deformities. Lengthening of a tendon or releasing a muscle from its insertion, results in relaxation of the whole muscle-tendon unit. Hence, the spasticity is not gone, but reduced in strength.
~The tendon lengthening procedures is performed by a stair-step incision technique followed by reattachment in the lengthened position using a side-to-side, cross-stich technique. The load to failure of the sutured tendon is approximately 200Newton, which gives a sufficient safety margin for early active mobilization of the tendons involved. This suture technique thus enables active training directly after surgery.
~Postoperative rehabilitation includes wrapping and a custom-made splint, for day and night use, muscle activation and passive stretching 2-4 times per day without the splint."
11123535|NCT03910101|Active Comparator|Botulinum toxin injections|Botulinum toxin injections are given in spastic muscles of the upper extremity. Dosage and number of injections per muscle vary depending on the degree and extent of spasticity. For optimal effect on hand function, botulinum toxin is accompanied by the treatment of individualized exercise and splinting when needed.
11123668|NCT03909165|Experimental|Part B. Sugammadex 4 mg/kg|Single IV bolus of sugammadex at 4 mg/kg.
11123536|NCT03910088|Placebo Comparator|control group|received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
11123537|NCT03910088|Active Comparator|Pregabalin|received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
11123538|NCT03910088|Active Comparator|Hydrocortisone|received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
11123539|NCT03910075|Experimental|I-ACQUIRE High Dose|High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)
11123540|NCT03910075|Experimental|I-ACQUIRE Moderate Dose|Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)
11123541|NCT03910075|Active Comparator|Usual & Customary Treatment|Usual & Customary Treatment
11123542|NCT03910062||VA ECMO|Patients under VA-ECMO with a femoral reperfusion cannula.
11123543|NCT03910049||Study group|The group will include all adult patients that will sign ICF and will be operated for total thyroidectomy regardless of the undelying disease
11123544|NCT03910036|Experimental|PRP group|15 patients to constitute the PRP-group was injected intra-articularly with about 5 ml of PRP in the operated knee joint
11123545|NCT03910036|No Intervention|control group|The other fifteen patients were not injected and constituted control group.
11123546|NCT03910023|Active Comparator|Control group|The control group will perform home exercises alone
11123547|NCT03910023|Experimental|Spa group|The spa group will be proposed an additional spa treatment
11123548|NCT03910010|Experimental|Experimental: placebos|Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
11123549|NCT03910010|No Intervention|Waitlist|Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
11123550|NCT03910010|No Intervention|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
11123551|NCT03909984|Other|Intervention|All participants will be monitored for 2 months.
11123552|NCT03909971|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
11123553|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|42 patients will receive both electroacupuncture（HANS100A）therapy and routine rehabilitation training.
11123554|NCT03909958|Other|Routine rehabilitation training Group|42 patients will receive simple routine rehabilitation training.
11123555|NCT03909945|Experimental|Interventional arm|The intervention consisted in the daily administration, during 60 days, of a 796 mg tablet of aqueous extracts of leaves of Annona muricata between 08:00 AM and 09:00 AM.
11123556|NCT03909932||Patients enrolled in the cross-sectional study|Patients over 18 years old, consulting in neuro-urology department.
11123557|NCT03909919|Experimental|Heart Failure|Heart Failure patients Subjects diagnosed with heart faikure, who will receive the best treatment of clinical practice, will be recruited. They must be more than 70 years old.
11123558|NCT03909919|Active Comparator|Healthy Subjects|Healthy Subjects/ Match control Healthy subjects of the same age as people with heart failure.
11123559|NCT03909906|Active Comparator|Euphytose®|Euphytose® 2 tablets 3 times per day for 14 days
11123560|NCT03909906|Placebo Comparator|Placebo|Matched placebo 2 tablets, 3 times per day for 14 days
11123561|NCT03909893|Experimental|Adaptive Radiation Therapy|
11123562|NCT03909880|No Intervention|Control|Without kinesio tape on the forearm of subjects
11123563|NCT03909880|Placebo Comparator|kinesio taping with neutral tension|Kinesio tape with neutral tension on the forearm of subjects
11123564|NCT03909880|Experimental|kinesio taping with additional 20% tension|Kinesio tape with 20% additional tension on the forearm of subjects
11123565|NCT03909854|Active Comparator|Adaptive Pressure Control|The Adaptive Pressure Control arm is the baseline mode/protocol for medical intensive care unit mechanical ventilation
11123566|NCT03909854|Active Comparator|Assist Volume Control|The assist volume control arm is the new protocol that will be implemented and tested for feasibility
11123567|NCT03909841||DM|DM without DPN (Diabetic Peripheral Neuropathy)
11123568|NCT03909841||DPN|DM with DPN (Diabetic Peripheral Neuropathy)
11123569|NCT03909841||DPN-P|DM with DPN-P (Diabetic Peripheral Neuropathic Pain)
11123570|NCT03909828||Parkinson's disease patients|patients with Idiopathic Parkinsonism
11123571|NCT03909815|Experimental|Intervention|Insertion of dual mobility cup
11123572|NCT03909815|Active Comparator|Control|Insertion of standard cup
11123573|NCT03909802|Experimental|Experimental group|This arm will receive interventions consisting of self-management combined with family management programs.
11123574|NCT03909802|Placebo Comparator|Control group|Usual care refers to incorporating wound assessment, wound irrigation using NaCl, debridement, wound dressing, evaluation, and health education unmet with the self-and-family management of DFU program criteria in this study. All of the usual care will be performed and evaluated by the wound care nurses working at the selected clinics for this study.
11123575|NCT03909789|Active Comparator|plant based bioequivalent dietary nitrate supplement|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
11123576|NCT03909789|Placebo Comparator|placebo|The Placebo does not contain any nitric oxide supplement.
11123577|NCT03909776|Active Comparator|IA group|Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
11123578|NCT03909776|Sham Comparator|IV group|Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
11123579|NCT03909763|Experimental|Berberine plus danazol|Berberine plus danazol group
11123580|NCT03909750|Experimental|Lipoaspiration Microcannula ARM 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
11123581|NCT03909750|Experimental|Isolation-Concentration Adipose cSVF ARM 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
11123582|NCT03909750|Experimental|Normal Saline IV ARM 3|Sterile Normal Saline IV with cSVF
11123583|NCT03909737|Experimental|Azithromycin to pregnant women and azithromycin to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week Expanded Programme on Immunization (EPI) visits
11123584|NCT03909737|Experimental|Azithromycin to pregnant women and placebo to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
11123585|NCT03909737|Experimental|Placebo to pregnant women and azithromycin to infants|Oral placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
11123586|NCT03909737|Placebo Comparator|Placebo to pregnant women and placebo to infants|Placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
11123587|NCT03909737|Experimental|No intervention to pregnant women and azithromycin to infants|No intervention to pregnant women and 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
11123588|NCT03909737|Placebo Comparator|No intervention to pregnant women and Placebo to infants|No intervention to pregnant women and placebo to infants at 6 and 14 week EPI visits
11123589|NCT03909724|Active Comparator|TAS-102 (Lonsurf)|35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
11123590|NCT03909724|Experimental|High Dose Intermittent Sunitinib|700 mg once every 2 weeks.
11123591|NCT03909698||Hemodialysis patients on amoxicillin-clavulanic acid|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for amoxicillin-clavulanic acid."
11123592|NCT03909698||Hemodialysis patients on ceftazidim|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for ceftazidim."
11123593|NCT03909698||Hemodialysis patients on piperacillin-tazobactam|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for piperacillin-tazobactam."
11123594|NCT03909698||Hemodialysis patients on vancomycin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for vancomycin."
11123595|NCT03909698||Hemodialysis patients on teicoplanin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.
~All blood and urine samples are analyzed for teicoplanin."
11123596|NCT03909685|Experimental|the intervention arm|During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy
11123597|NCT03909685|No Intervention|a waitlist control arm|The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm
11123598|NCT03909672|Experimental|Cupping therapy with 2 suctions|Participants in the intervention group will receive the application of cupping therapy with two acrylic type 1 cups with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally. This group will consist of the application of windsheets with 2 suctions for 10 minutes, once a week, for 10 weeks. The cups shall be secured by means of elastic bands.
11123599|NCT03909672|Placebo Comparator|Cupping Therapy sham|"The placebo group will receive the application of cupping therapy with 2 cups of acrylic type size 1 with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of applying the sham winds for 10 minutes, once a week for 10 weeks.
~However, the cups will be made with small holes <2 mm in diameter to release the negative pressure in seconds. The cups will also be fixed by means of elastic bands."
11123600|NCT03909659|No Intervention|Control|Normal salt
11123601|NCT03909659|Experimental|Reduced-sodium added-potassium salt substitute|salt substitute
11123602|NCT03909646|Active Comparator|Surgical excision|Standard surgical excision with 5 mm safety margin
11123603|NCT03909646|Active Comparator|Photodynamic therapy|PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval
11123604|NCT03909646|Active Comparator|5% 5-Fluorouracil|5FU cream, which has to be applied by the patient twice daily for 4 weeks.
11123605|NCT03909633||A: anesthesia group|Patients accepting endoscopy check under anesthesia will be included in this group as group A,will doing a series of tests
11123606|NCT03909633||B:Non-anesthesia group|patients undergoing endoscopy check without anesthesia will be included in this group as controls voluntarily,namely group B,will doing a series of tests
11123607|NCT03909620|Experimental|LDCT arm|All eligible participants will undergo screening with LDCT
11123608|NCT03909607|Active Comparator|SDK 0.75 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 0.75mg/k
11123609|NCT03909607|Active Comparator|SDK 1.0 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.0mg/k
11123610|NCT03909607|Active Comparator|SDK 1.5 mg/kg|The patients will receive sub-dissociative ketamine at a dose of 1.5mg/k
11123611|NCT03909594|Experimental|Nerve Block with Bupivacaine an|Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
11123612|NCT03909594|Active Comparator|Nerve Block with Bupivacaine al|Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
11123613|NCT03909581|Active Comparator|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization
11123614|NCT03909581|Active Comparator|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator
11123615|NCT03909568|Experimental|Third molar surgery|Split mouth comparison of effect of complete third molar removal vs coronectomy of contralateral third molar
11123616|NCT03909555||Short-term intensive insulin therapy|Patients who used to participated in short-term intensive insulin therapy for 14 days when diabetes was newly diagnosed
11123617|NCT03909555||Routine diabetic therapy|Received routine diabetic therapy
11123618|NCT03909542||Ileostomy Closure|Patients who have undergone an ileostomy closure procedure.
11123619|NCT03909529|Experimental|Digoxin 250 micrograms (MCG) Oral Tablet|Administration of 20 mL of 25 mg / 5 mL singe dose Day 1 to Day 9 randomized to digoxin and Spironolactone treatment. On day 6, after overnight fasting of at least 10.00 hours, either digoxin or spironolactone will be administered orally for drug drug interaction evaluation
11123620|NCT03909529|Experimental|Spironolactone 25 mg/ 5 mL S/F Suspension|Crossover administration of 20 mL of 25 mg / 5 mL Day 1 to Day 9 randomized to Spironolactone or digoxin treatment. On day 6, after overnight fasting of at least 10.00 hours, either spironolactone or digoxin will be administered orally for drug drug interaction evaluation
11123621|NCT03909516|No Intervention|Standard of Care|"Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded."
11123622|NCT03909516|Active Comparator|Standard of Care + iovera° Treatment|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded.
~Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events.
~Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.
~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
11123623|NCT03909503|Experimental|Porcine-derived collagen wound dressing|The dressing is a sheet of collagen composed of type I collagen derived from porcine peritoneal membrane. The dressing also contains additional components from the procine extracellular matrix. The dressing is a currently marketed, cleared device in the United States indicated for the management of full- and partial-thickness wounds, including: pressure ulcers, diabetic ulcers, venous ulcers, and several other wound types.
11123624|NCT03909490|Active Comparator|Control|
11123625|NCT03909490|Experimental|intervention- tool|
11123626|NCT03909477||Cannabis Smoker|Participants in this group will be current or former cannabis smokers
11123627|NCT03909464||Patients receiving neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving known neurotoxic agents. Common neurotoxic agents include vinca alkaloids (ie. vincristine), taxanes (ie. Taxol), platins (ie. Oxaliplatin) and some other drugs beyond these categories (ie. Bortezomib).
~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:
~EORTC-QLQ CIPN20 Questionnaire
~Michigan Neuropathy Screening Instrument Questionnaire"
11123628|NCT03909464||Patients receiving non-neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving agents with negligible or doubtful risk of neurotoxicity.
~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:
~EORTC-QLQ CIPN20 Questionnaire
~Michigan Neuropathy Screening Instrument Questionnaire"
11123629|NCT03909451|Experimental|Dose 1|Sotagliflozin dose 1, once daily for 8 days
11123630|NCT03909451|Experimental|Dose 2|Sotagliflozin dose 2, once daily for 8 days
11123631|NCT03909451|Placebo Comparator|Placebo|Placebo, once daily for 8 days
11123632|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 0|"Carfilzomib at 20mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
11123633|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 1|"Carfilzomib at 27mg/m2 over 10 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
11123634|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 2|"Carfilzomib at 36mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
11123635|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 3|"Carfilzomib at 45mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
11123636|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 4|"Carfilzomib at 56mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
11123637|NCT03909412|Experimental|Carfilzomib Mobilization - Dose Level 5|"Carfilzomib at 70mg/m2 over 30 minutes will be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone 40mg and G-CSF.
~For patients who are naïve to carfilzomib based therapy a priming dose of Carfilzomib (20mg/m2) will be administered 1 week prior to the cohort dosing."
11123638|NCT03909373||Cohort|patients with carpal tunnel syndrome
11123639|NCT03909360|Experimental|drainage|Placement of subhepatic drainage tube for laparoscopic cholecytetomy
11123640|NCT03909360|No Intervention|no drainage|no placement of subhepatic drainage tube for laparoscopic cholecytetomy
11123641|NCT03909347|Experimental|PLAN (intervention)|Group 1 will receive the study intervention during the 6 months of the study, after the first baseline questionnaire. The intervention is as follows: participants will be asked to take part in a one-time, one-hour education in participants' home or any community location that is most convenient for the participants by a trained community health worker. An educational resource that participants can read at home will be provided at the end of education session. Participants' community health worker will call the participants monthly to identify barriers to dementia care and help participants and participants' elder with making an appointment or transportation to the health care facility, when participants request for assistance.
11123642|NCT03909347|Active Comparator|Standard of care (control)|Group 2 will receive a signs and treatment of dementia pamphlet by the Alzheimer's Association and will be referred to the elder's primary physician.
11123643|NCT03909334|Active Comparator|Arm A (Osimertinib and Ramucirumab)|Osimertinib and Ramucirumab
11123644|NCT03909334|Active Comparator|Arm B (Osimertinib)|Osimertinib
11123645|NCT03909321|Active Comparator|Control group (Health Education)|Control group will perform one session per week, composed of theoretical-practical classes on fundamentals of BT and lectures on health education.
11123646|NCT03909321|Experimental|Beach tennis training group|The Beach Tennis (BT) group will perform two sessions per week of the Beach Tennis training. This intervention will last 12 weeks.
11123647|NCT03909308|No Intervention|Control session|Control session without any exercise. The participants will remain in seated rest throughout 45 min.
11123648|NCT03909308|Experimental|Beach Tennis session|The participants will perform a beach tennis training session throughout 45 min.
11123649|NCT03909295|Experimental|LCZ696|All eligible patients will receive LCZ696 b.i.d.
11123650|NCT03909282|Active Comparator|Surgery|
11123651|NCT03909282|Experimental|Neoadjuvant partial breast irradiation|Partial breast irradiation will be delivered once a day for 5 days before surgery. The planned daily dose is 6 Gy.
11123652|NCT03909269||Haemodialysis and type 2 diabetes|On chronic haemodialysis and type 2 diabetes
11123653|NCT03909269||Control group|Type 2 diabetes and with eGFR above 60ml/min
11123654|NCT03909256|Experimental|NUTRI-HAB|"The intervention group participates in a targeted rehabilitation program 'NUTRI-HAB' with a focus on eating problem after treatment for head and neck cancer. The program comprises:
~a five day residential stay with patient education
~a two day follow-up residential stay after 3 months
~two telephone consultations with clinical dietitian between the two residential stays."
11123655|NCT03909256|No Intervention|Control group|"The control group receives no intervention other than usual care in the study period.
~After 3 months, the control group will be offered participation in the same residential rehabilitation program as the intervention group parcitipated in."
11123656|NCT03909230||Day 2 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
11123657|NCT03909230||Day 4 post ovulation|Ultrasound of the endometrium, Endometrial fluid sample, Blood sample
11123658|NCT03909217|Experimental|TECAS|Patients will receive transcutaneous electrical cranial-auricular acupoint stimulation (TECAS) daily.
11123659|NCT03909217|Active Comparator|Anti-depressants|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by a clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
11123660|NCT03909204|Other|LAPEC|Patients with cecal percutaneous catheter placement.
11123661|NCT03909191||treatment-naïve|treatment-naïve patients with chronic HBV infection
11123662|NCT03909191||NAs treated CHB patients|CHB patients undergoing long-term NAs treatment
11123663|NCT03909178|Active Comparator|Hip Arthroscopy Surgery with Acetabular Labral Repair|Hip Arthroscopy Surgery with Acetabular Labral Repair
11123664|NCT03909178|Active Comparator|Physical Therapy Focused on the Hip and Hemi-pelvis|Physical Therapy focusing on the hemipelvis strengthening, including the lower back, lower abdominal core, quadriceps, hamstrings, and gluteal muscles.
11123665|NCT03909165|Experimental|Part A. Sugammadex 2 mg/kg|Single intravenous (IV) bolus of sugammadex at 2 mg/kg
11123666|NCT03909165|Experimental|Part A. Sugammadex 4 mg/kg|Single IV bolus of sugammadex at 4 mg/kg.
11123669|NCT03909165|Active Comparator|Part B. Neostigmine|Single IV bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
11123670|NCT03909152|Experimental|PR+ Granulosa cell tumor|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
11123671|NCT03909152|Experimental|PR+ Low grade serous ovarian cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
11123672|NCT03909152|Experimental|PR+ Endometrioid endometrial cancer|Enrolled patients will initiate treatment with onapristone ER 50 mg by mouth twice daily, about 12 hours apart, beginning Day 1 of Cycle 1. A Cycle is 28 days
11123673|NCT03909139||All Patients|40 patients age 18 or older with evidence consistent with a tear of the acetabular labrum and breakdown of the chondrolabral junction and consent to a arthroscopic labral tear repair.
11123674|NCT03909126|Experimental|Montreal Region of Quebec|Vaccination with Boostrix at time of gestational diabetes screening in a hospital setting
11123675|NCT03909126|No Intervention|Montérégie|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
11123676|NCT03909126|Experimental|Maurice Region|Vaccination with Boostrix of pregnant women receiving routine care at high volume clinic
11123677|NCT03909126|No Intervention|National Capital|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
11123678|NCT03909113|Experimental|amino acid based formula|amino acid based formula
11123679|NCT03909100|Experimental|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
11123680|NCT03909074|Experimental|Experimental group|36-71 months old children-experimental EV71 vaccine.
11123681|NCT03909074|Active Comparator|Vaccine-controlled group|36-71 months old children-control EV71 vaccine.
11123682|NCT03909074|Active Comparator|Age-controlled group|6-35 months old children-experimental EV71 vaccine.
11123683|NCT03909061|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent maintenance training materials. They will complete data collection measures embedded in the maintenance training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Assistive Technology Module Questionnaire (ATM-Q), and the Wheelchair Maintenance Training Questionnaire (WMT-Q).
11123684|NCT03909061|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the wheelchair maintenance training. Participants may also be asked to complete a user satisfaction survey.
11123685|NCT03909061|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the wheelchair maintenance training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent maintenance training program.
11123686|NCT03909048|Experimental|Interactive Psycho-education|Interactive psycho-education using interactive dashboard.
11123687|NCT03909048|Placebo Comparator|Psycho-education|Non-interactive psycho-education not using interactive dashboard.
11123688|NCT03909035|Experimental|Medication therapy management|Medication therapy management by the community pharmacist in collaboration with the General Practitioners to the Optimizations of Prescriptions
11123689|NCT03909035|No Intervention|Usual pharmaceutical care|Usual pharmaceutical care provided by the community pharmacist (first level pharmaceutical analysis of the prescriptions)
11123690|NCT03909009|Active Comparator|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
11123691|NCT03909009|Sham Comparator|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
11123692|NCT03908996|Experimental|Profile by Sanford|All enrolled subjects are assigned to participate in the Profile by Sanford weight management program for a period of 12 months..Subjects will follow the Profile program and will be provided a nutritional plan which includes consuming Profile nutritional supplements and other food items. Subjects will work with a Profile lifestyle coach to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior. Subjects on this research study will follow the Profile by Sanford weight loss and management plan as all Profile members. All enrolled subjects will collect and return a fecal specimen prior to beginning the Profile by Sanford weight management plan and again after 6 months of participation.
11123693|NCT03908983|Experimental|Implanted Patients|Implantation of Kalios Device
11123694|NCT03908970|Experimental|1% OPA-15406|Twice daily
11123695|NCT03908970|Placebo Comparator|Placebo|Twice daily
11123696|NCT03908957|Experimental|Ga68-Dolacga Injection|The healthy volunteer was injected with Ga68-Dolacga Injection iv and performed PET imaging for liver reserve evaluation.
11123697|NCT03908944|Active Comparator|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
11123698|NCT03908944|Experimental|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
11123699|NCT03908931|Experimental|MRI|
11123700|NCT03908918|Experimental|Active group|Mobile-app delivered mindfulness intervention. Dosage: 4 times per week for 4 weeks
11123701|NCT03908918|Other|Waitlist control|Waitlist control - receiving the app after 6 months
11123702|NCT03908905||Intervention|
11123703|NCT03908892|Experimental|Combination group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, plus local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day, till paronychia relief or progression.
11123704|NCT03908892|Active Comparator|Control group|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day, till paronychia relief or progression.
11123705|NCT03908879|Experimental|Intraosseous (IO) catheter placement confirmation methods|All patients will undergo all three confirmation methods/procedures. Method 1 is a triage test and an index test. Method 2 is an index test. Method 3 is a reference standard. None of the procedures being performed in this study are regulated by the United States Food and Drug Administration.
11123706|NCT03908866|Experimental|PICC(Peripherally inserted central catheter)|Patients randomly assigned to receive a peripherally inserted central catheter(PICC).
11123707|NCT03908866|Active Comparator|CVC(Central venous catheter )|Patients randomly assigned to receive a centrally inserted central venous catheter(CVC).
11123708|NCT03908853||Patients|Subjects with painful bone metastases caused by primary breast cancer.
11123709|NCT03908853||Controls|Gender and age matched healthy volunteers.
11123710|NCT03908840|Experimental|TBI 302 Safety, Tolerability|5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).
11123711|NCT03908827|Experimental|Active BMAC treatment|60 mL of bone marrow will be aspirated from the iliac crest of each subject in the active treatment group. The bone marrow aspirate (BMA) will be centrifuged using a single spin protocol such that the red blood cells are minimized and the total nucleated and platelet cells are concentrated into a 12 mL volume of bone marrow aspirate concentrate (BMAC).
11123712|NCT03908827|No Intervention|Wait List Control|Participants will continue with their usual treatment, inclusive of medications or conservative treatments and will continue with activity guidelines as previously provided by clinical staff whilst awaiting joint arthroplasty
11123713|NCT03908814|Experimental|Drug: LDP|"This is a dose-escalation trial, all participants will receive treatment with LDP. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.
~Cohort 1: 0.1 mg/kg Cohort 2: 0.3 mg/kg Cohort 3: 1 mg/kg Cohort 4: 3 mg/kg Cohort 5: 10 mg/kg Cohort 6: 10 mg/kg"
11123714|NCT03908801|Experimental|Intervention|Specialized water dance intervention
11123715|NCT03908801|No Intervention|Control|No intervention
11123716|NCT03908788|Experimental|Intplex test|In vitro diagnostic device
11123717|NCT03908775|Active Comparator|Group VL|C-MAC Videolaryngoscope Patients intubated with C-MAC Videolaryngoscope
11123718|NCT03908775|Active Comparator|Group DL|Direct Laryngoscope Patients intubated with Direct laryngoscope
11123719|NCT03908762|Experimental|iSage|The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose <70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
11123720|NCT03908762|Active Comparator|Conventional Management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured <70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.
11123721|NCT03908736|Other|Single-arm cohort|Baseline experimental measurements will be collected for each individual participant twice prior to zinc supplementation (0 month and 3 month time points). After zinc supplementation, experimental measurements will be collected for each individual participant at the 6 month and 9 month time points. The zinc intervention is zinc picolinate 15 mg once per day for 6 months.
11123722|NCT03908723|Experimental|all patients in the study|
11123723|NCT03908710|Other|home Home blood pressure levels in hypertensive participants|Only one arm. No control group.
11123724|NCT03908697|Experimental|Single cohort|All 20 participants will use ClearBlue and Mira monitors on first morning urine
11123725|NCT03908684||Head and Neck|
11123726|NCT03908684||Prostate|
11123727|NCT03908684||Rectum|
11123728|NCT03908684||Prostate Characterization|
11123729|NCT03908671|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers
11123730|NCT03908658|Active Comparator|Inspiratory Muscle Training and Nasal High Flow|Inspiratory Muscle Training will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Nasal High Flow will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
11123731|NCT03908658|Active Comparator|Inspiratory Muscle Training and Venturi mask|IMT will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Venturi mask will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
11123732|NCT03908645|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
11123733|NCT03908645|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
11123734|NCT03908632||Step 1|Subjects 14 years or older diagnosed with Community Acquired Pneumonia (CAP) and positive serology for primary pulmonary coccidioidomycosis (PPC) will enroll in Step 1 within 14 days of symptom onset, n=1000
11123735|NCT03908632||Step 2|Subjects with a diagnosis of primary pulmonary coccidioidomycosis (PPC) confirmed by positive serologic testing during Step 1 will enter Step 2 within 14 days of their test collection date, n=200
11123736|NCT03908619|Active Comparator|TTP (Group A)|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
11123737|NCT03908619|Active Comparator|TTP (Group B)|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
11123738|NCT03908619|Active Comparator|TTP (Group C)|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
11123739|NCT03908619|Experimental|TTP (Group D)|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
11123740|NCT03908606|Experimental|Periodontitis patients with diabetes type 2|scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment
11123741|NCT03908606|Experimental|Periodontitis patients|scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels.
11123742|NCT03908606|No Intervention|Healthy control group|We measured serum levels of hs-CRP in all healthy control subjects
11123743|NCT03908593|Active Comparator|One month of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month
11123744|NCT03908593|Experimental|Twelve months of therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months
11123745|NCT03908580|Experimental|Meditoxin®|Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.
11123746|NCT03908567|Placebo Comparator|Placebo|Nasal spray solution without active ingredient
11123747|NCT03908567|Experimental|1 mg AM-125|Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.
11123748|NCT03908567|Experimental|10 mg AM-125|Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.
11123749|NCT03908567|Experimental|20 mg AM-125|Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.
11123750|NCT03908567|Experimental|Oral 16 mg betahistine|Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.
11123751|NCT03908554|Experimental|intervention|The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home).
11123752|NCT03908554|No Intervention|Control|Participants of the control group rested in a room for 40 minutes and were told that they could read every session.
11123753|NCT03908528|Experimental|Chemotherapy|• Group one: 25 patients will receive four cycles of AC followed by weekly taxol for 12 weeks.
11123754|NCT03908528|Experimental|Chemotherapy+alpha lipoic acid|• Group two: 25 patients will receive four cycles of AC followed by weekly taxol for 12 weeks. in addition to oral 600 mg alpha lipoic acid (ALA) once daily.
11123755|NCT03908489|Experimental|intervention we want to test vital pulpotomy using garlic oil|interventional group as garlic oil pulpotomy dressed in zinc oxide powder
11123756|NCT03908489|Active Comparator|control or comparator as mta vital pulpotomy in primary molars|mta vital pulpotomy in primary molars
11123757|NCT03908476|Experimental|Subjects using BurstDR SCS systems|Spinal cord stimulation with a Burst waveform.
11123758|NCT03908476|Experimental|Subjects using DRG systems|Dorsal root ganglion stimulation.
11123759|NCT03908463||The patients who undergo percutaneous coronary intervention|The patients who undergo percutaneous coronary intervention will be enrolled.
11123760|NCT03908450|Active Comparator|Control intervention|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
11123761|NCT03908450|Experimental|Experimental intervention|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
11123762|NCT03908437|Experimental|Rapid initiation|Rapid initiation of buprenorphine/naloxone, counseling, peer support and case management
11123763|NCT03908437|Active Comparator|Treatment as usual|Seeking treatment from the BAC/CRC (treatment as usual)
11123764|NCT03908424||CONTROL|Parturients who gave birth to a normal birth and did not receive epidural anesthesia.
11123765|NCT03908424||Normal Epidural|Parturients who gave birth to a normal birth with epidural anesthesia without an unintentional dural puncture.
11123766|NCT03908424||PDPH conservative treatment|Parturients who gave birth to a normal birth with epidural anesthesia and had an unintentional dural puncture, these women were treated conservatively.
11123767|NCT03908424||PDPH treated with Blood Patch|. Parturients who had a normal birth with epidural anesthesia and had an unintentional dural puncture and were treated with a blood patch following PDPH.
11123768|NCT03908411|Active Comparator|Paratracheal pressure|Left Paratracheal pressure is applied by ultrasound transducer after confirmation of the location of the esophagus.
11123769|NCT03908411|Active Comparator|Sellick's maneuver|Conventional Sellick's maneuver is applied.
11123770|NCT03908372|Experimental|Induction chemotherapy(IC)+IMRT|Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm
11123771|NCT03908372|Active Comparator|Concurrent chemoradiotherapy(CCRT)|cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy
11123772|NCT03908359|Active Comparator|traditional cataract surgery|
11123773|NCT03908359|Experimental|minimal invasive lens surgery|
11123774|NCT03908346|Other|Decision Aid for Surrogate Decision Makers|In this pilot trial all participants will be presented with the decision aid and queried as to the feasibility, acceptability and knowledge translation that is gained by exposure to the decision aid
11123775|NCT03908333|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
11123776|NCT03908320|Experimental|Menstrual Cycle Timing|
11123777|NCT03908320|Active Comparator|Menstrual Cycle Monitoring|
11123779|NCT03908294||Chronic hepatitis C under antiviral treatment with DAA|Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.
11123780|NCT03908281|Experimental|Fasted Exercise|Exercise training will be performed in the fasted state (i.e., before breakfast).
11123781|NCT03908281|Active Comparator|Postprandial Exercise|Exercise will be performed in the postprandial period (i.e., after breakfast)
11123782|NCT03908268|Active Comparator|CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Standard Children's Learning Center Program group.
11123783|NCT03908268|Experimental|FNI plus CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Family Nurture Intervention plus Standard CLC Program group.
11123784|NCT03908255|Placebo Comparator|Control Group|The control group will receive current standard of care (transarterial chemoembolization of the liver, serial bloodwork and imaging, serial assessments in clinic), consume a maltodextrin placebo supplement beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
11123785|NCT03908255|Experimental|Intervention Group|In the intervention group, patients will receive current standard of care (transarterial chemoembolization of the liver, serial bloodwork and imaging, serial assessments in clinic) and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.
11123786|NCT03908242|Experimental|Salvianolic Acid A|2 anticipated doses are 90 mg and 180 mg.
11123787|NCT03908242|Placebo Comparator|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
11123788|NCT03908229|Experimental|Trainee colonoscopy|"In the investigation arm colonoscopy will be performed by gastroenterology fellows. The fellows will always start the case and proceed generally until they are unable to make further progress despite coaching from the staff attending.
~During the procedures with fellows, the staff attending will always actively participate in the entire procedure and assess for the presence of any lesions."
11123789|NCT03908229|Active Comparator|Experienced physician colonoscopy|In the control arm all colonoscopy will be performed by full-time board-certified gastroenterologists who have each done more than 5000 colonoscopy examinations.
11123790|NCT03908203|Other|Treatment Arm|
11123791|NCT03908190|No Intervention|Treatment As Usual|Participants will receive treatment as usual within the VHA Women's Wellness Clinic including any appropriate treatment or treatments for their medical and psychosocial concerns as determined by their primary care teams.
11123792|NCT03908190|Experimental|Treatment As Usual Plus Personalized Support for Progress|In addition to treatment as usual, women will receive the Personalized Support for Progress intervention.
11123793|NCT03908177|Experimental|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
11123794|NCT03908177|Active Comparator|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
11123795|NCT03908164|Experimental|Vaccination at <23+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW). Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
11123796|NCT03908164|Experimental|Vaccination at 24-27+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
11123797|NCT03908164|Experimental|Vaccination at 28-31+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
11123798|NCT03908138|Active Comparator|RDD group|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
11123799|NCT03908138|Active Comparator|VDD group|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
11123800|NCT03908125|Other|Continuous Glucose Monitoring Device|
11123801|NCT03908112|Active Comparator|Standard Community Concussion Care (SC)|Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.
11123802|NCT03908112|Experimental|SC plus Simple Convergence Procedures (SC+)|In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.
11123803|NCT03908112|Experimental|SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)|Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.
11123804|NCT03908099|Experimental|Fit-For-Fertility program|The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
11123805|NCT03908099|Active Comparator|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months.
11123806|NCT03908086||RA patients|Incident patients with rheumatoid arthritis as identified by the Danish National Patient Registry and the rheumatology registry, DANBIO.
11123807|NCT03908086||General population|All other adults, as Identified by the Civil Registration System. Patients who develop RA contribute person-years in the general population cohort until RA diagnosis
11123808|NCT03908073|Active Comparator|Active transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
11123809|NCT03908073|Placebo Comparator|Sham transcutaneous vagal nerve stimulation|The participant will be taught how to use the device and administer doses in our laboratory and independently at home over a period of 24 hours.
11123810|NCT03908060|Experimental|Intravenous single-dose methadone|A 10 ml syringe with 2 mg/ml of methadone will be prepared and and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
11123811|NCT03908060|Active Comparator|Intravenous single-dose morphine|A 10 ml syringe with 2 mg/ml of morphine will be prepared and study drug will be administered as intravenous bolus dose (0.2 mg/kg) corresponding to 1 ml for every 10 kg of ideal body weight (height (cm) - 105).
11123812|NCT03908047||healthy volunteers|
11123813|NCT03908034|No Intervention|Uncontrollable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
11123814|NCT03908034|Experimental|Uncontrollable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
11123815|NCT03908034|Experimental|Uncontrollable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.
~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
11123816|NCT03908034|Experimental|Uncontrollable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
11123817|NCT03908021||children with type 1 diabetes mellitus|Saliva from 50 children ages 5 to 15 years old who had been diagnosed with type 1 diabetes mellitus and are followed at the Pediatric Endocrinology Clinic, Hadassah University Hospital Mt. Scopus and Ein Kerem, Jerusalem, Isreal,
11123818|NCT03908021||Control|50 healthy children, preferably their siblings, matched in age and gender.
11123819|NCT03908008|Active Comparator|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
11123820|NCT03908008|Experimental|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
11123821|NCT03907995|Experimental|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
11123822|NCT03907982|Experimental|DCCV + PVI|"DC cardioversion (DCCV) plus Pulmonary Vein Isolation (Cryoablation)
~At end of pulmonary vein isolation, DCCV performed (if patient still in AF). An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure."
11123823|NCT03907982|Active Comparator|DC cardioversion (DCCV)|Acute treatment of heart rhythm by cardioversion. An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure.
11123824|NCT03907969|Experimental|Core Module: AZD7648 Monotherapy|AZD7648 will be administered orally on an empty stomach
11123825|NCT03907969|Experimental|Combination Module 1: AZD7648 + PLD|AZD7648 will be administered in combination with PLD
11123826|NCT03907969|Experimental|Combination Module 2: AZ7648 + Olaparib|AZD7648 will be administered in combination with olaparib
11123827|NCT03907956|Experimental|INTERVENTION|The subjects included in the intervention group will be treated with Dry Needling with Fascial Winding Technique according to the original Four-Pole Carpal Dry Needling approach, which has already been validated recently by means of a first ultrasound study.
11123828|NCT03907956|No Intervention|CONTROL|The individuals of the control group will remain within the normal course of their waiting list status for CTS surgery, without receiving any extraordinary treatment to what is normally practiced in this situation.
11123829|NCT03907943|Other|Surgical treatment of carotid endarterectomy|The change in the cognitive function will be assessed in all patient undergoing carotid endarterectomy.
11123830|NCT03907930|Active Comparator|conventional|this arm will have both nephrostomy tube and ureteric catheter after completing the operation
11123831|NCT03907930|Active Comparator|tubeless|the arm will have only ureteric catheter rafter completing the operation
11123832|NCT03907917|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
11123833|NCT03907917|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
11123969|NCT03906968|Experimental|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
11123834|NCT03907891|Experimental|Motivational social support (MSS) from a nurse alone|Participants will receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse. The nurse will apply motivational interviewing techniques to explore the patient's thoughts about making a behavior change to attain adequate physical activity (PA). Patients will be encouraged to exercise based on instructions provided by the hospital staff. The patient's ability to take their radial pulse before and after PA will be assessed, and patients will be provided written instructions on the correct manner to take a radial pulse. Patients will receive daily motivational text messages from the nurse for 6 weeks. The texts will be sent via the REDCap automated system. The automated system confirms that texts were sent. The motivational interviewer nurse will confirm by phone that the patient receives her/his first text from the REDCap system.
11123835|NCT03907891|Experimental|MSS from nurse with additional significant other support (SOS)|Participants will also receive a 60-minute session of motivational interviewing via videoconference or telephone (at participant discretion) in their home from a trained nurse and text messages from a nurse for 6 weeks, as described in arm 1. In addition, patients will receive daily text messages from their significant other for 6 weeks. Researchers developed the 42 significant other text messages. The motivational interviewing nurse will provide the text messages to the significant other in writing. The order of texts sent from the significant other will be randomized so that we can determine their effectiveness in general. The significant other will be asked to type and send the text message listed for each date to the patient. Study staff will confirm by phone that the patient received the first text from the significant other. Patients will be asked to track the number of text messages from the significant other that they read over the 6-week period using the log provided.
11123836|NCT03907891|Active Comparator|Attention control (AC)|Participants in the AC group will receive a 60-minutes session with a nurse via videoconference or telephone (at participant discretion) viewing of American Heart Association educational videos and and documents regarding IHD. The nurse will additionally provide a written copy of the hospital physical activity instructions, will assess the patient's ability to take their pulse, and provide written instructions on the correct manner to take a radial pulse.
11123837|NCT03907878|Experimental|Ligelizumab|Ligelizumab q4w
11123838|NCT03907865|Experimental|intense|Patients have been randomized to receive Softacort eye drops for 12 days 4 times daily followed by 2 days twice daily treatment resulting in a total time of 14 days
11123839|NCT03907865|Experimental|standard|Patients have been randomized to receive Softacort eye drops for 8 days 3 times daily followed by 3 days twice daily treatment resulting in a treatment time of 11 days total
11123840|NCT03907852|Experimental|TC-210 T Cells|TC-210 T Cells
11123841|NCT03907852|Experimental|Lymphodepletion followed by TC-210 T Cells|fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by TC-210 T Cells
11123842|NCT03907852|Experimental|Phase 2 Dose|MPM, cholangiocarcinoma, and ovarian cancer will receive TC-210 at the RP2D; NSCLC patients will receive TC-210 at the RP2D or TC-210 at the RP2D followed by anti-PD1
11123843|NCT03907839|Active Comparator|Endurance Training (ET)|endurance training for control group
11123844|NCT03907839|Experimental|ET+cognitive training(CT)|endurance training added to cognitive training for exprimental COPD group
11123845|NCT03907826|Experimental|PD-1 antibody plus IMRT|Patients randomized to this arm will receive PD-1 antibody (JS001) 240mg every three weeks during IMRT and as adjuvant therapy.
11123846|NCT03907826|Active Comparator|IMRT|Patients randomized to this arm will receive IMRT alone.
11123847|NCT03907813|Experimental|liposomal bupivacaine infiltration|Local infiltration of all wound layers with liposomal bupivacaine (Exparel(R)) 20 ml diluted with 70 ml of normal saline to 90 ml for patient with a BMI of 39 and under. If BMI is 40 or more the 20 ml of liposomal bupivicaine will be diluted to 150 ml by adding 130 ml of normal saline
11123848|NCT03907813|Placebo Comparator|Saline infiltration|Local infiltration of all wound layers with saline, using to match the amount. The amount of total fluid is divided into 4 and instilled with 1-2 ml at a time in between fascial layers after fascial closure. Each 1/4 will be instilled laterally (2) and on each side of the incision(2)- extra fluid is placed subcutaneously.
11123849|NCT03907800|Experimental|Nab-paclitaxel + Carboplatin ± Herceptin|
11123850|NCT03907787|Other|One-group pretest-posttest quasi-experimental design|50 subjects with moderate knee osteoarthritis were supplied for four weeks with two tablets/day, each containing 350 mg of standardized extracts of Zingiber officinale and Acmella oleracea.
11123851|NCT03907748|Experimental|Music Intervention|The music intervention will be provided to participant dyads (people with dementia and their cohabiting family caregivers) allocated to the first intervention. Caregivers will be trained to use the music intervention in three 2-hour training sessions with an intervention trainer (a music therapist). Training will take place at the dyad's home. The caregiver will then be asked to deliver the music intervention to the person with dementia at least 5x per week for 30 minutes.
11123852|NCT03907748|Active Comparator|Reading Intervention|The reading intervention will be provided to participant dyads (people with dementia and their cohabiting caregivers) allocated to the second intervention. Caregivers will be trained to use the reading intervention in three 2-hour training sessions with an intervention trainer. Training will take place at the dyad's home. The caregiver will then be asked to deliver the reading intervention to the person with dementia at least 5x per week for 30 minutes.
11123853|NCT03907748|No Intervention|Standard Care|Participant dyads (people with dementia and their cohabiting caregivers) allocated to the standard care group will not receive any training or be asked to deliver an intervention.
11123854|NCT03907735||2nd trimester|Second trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained primarily after second trimester surgical abortions or Dilation and Evacuation (D&E) procedures as well as after rare gravid hysterectomies or after late second trimester cesarean deliveries.
11123855|NCT03907735||Non-pregnant|Myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in non-pregnant women undergoing gynecologic surgery under anesthesia for laparoscopic tubal ligation.
11123856|NCT03907735||1st trimester|First trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained after first trimester surgical abortions or suction dilation and curettage (D&C).
11123857|NCT03907735||After term pregnancy (3rd trimester)|Third trimester myometrial tissue samples will be collected by core needle biopsy under ultrasound guidance in anesthetized women. Samples will be obtained at the time of cesarean delivery.
11123858|NCT03907722||Genotypic variants|AA, AG and GG genotype
11123859|NCT03907709||First Responders in In-Home Addiction Treatment Program|- First responders (individual who does or has worked as a police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer)
11123860|NCT03907696|Other|Intervention|The intervention arm participate in an educational program that aimed at reducing stigma
11123861|NCT03907696|No Intervention|control|regular curriculum with no addition educational contents
11123862|NCT03907683|Experimental|Random Messaging|Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.
11123863|NCT03907670||CML patients who will receive imatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment (imatinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
11123864|NCT03907670||CML patients who will receive nilotinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(nilotinib)measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
11123865|NCT03907670||CML patients who will receive dasatinib|Patients with chronic myeloid leukemia newly diagnosed, who will receive Tyrosine Kinase inhibitor treatment(dasatinib) measure the fluctuations in the levels of sCTLA-4, TGFβ1, and PDMPs, and to clarify the clinical significance of these biomarkers during TKI therapy in patients with CML
11123866|NCT03907657|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with Von-Hippel Lindau disease will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
11123867|NCT03907644|Experimental|Active FPS|We use Starstim AC (alternative current) -Stimulator R32. FPS protocol will be used with 20 minutes 2mAmp 6 Hz tACS to the middle frontal gyrus (DLPFC, F4 in EEG electrodes with 10-20 system measurement) and inferior parietal cortex (IPC, P4), as the main nodes of the frontoparietal network, in synchronous oscillation. The 4 return electrodes will receive 0.5 mAmp each around each active electrode (High Definition Montage). The electrodes are silver/silver chloride that are wet with conductive gel. We will use surface landmarks and EEG caps on the head to place the electrodes, which are held in place by head caps with holes indicating places for electrode positioning.
11123868|NCT03907644|Sham Comparator|Sham FPS|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
11123869|NCT03907631||Acute Severe Ulcerative Colitis|Patients hospitalised for acute severe ulcerative colitis will be invited to participate. Participants will be treated at the discretion of their treating physicians as per standard of care. We expect some participants will undergo an endoscopic assessment, some participants will be treated with standard versus accelerated infliximab dosing, permitting comparisons, in addition to other treatment strategies.
11123870|NCT03907618||Group 1 diagnosed with Diabetes Mellitus|Patients with Type 1 Diabetes Mellitus aged 18-40 years who had ovarian reserve with gynecological examination
11123871|NCT03907618||group 2 control group|Healthy volunteer patients aged 18-40 years who have no diagnosis of Type 1 Diabetes Mellitus and whose ovarian reserve is evaluated by gynecological examination
11123872|NCT03907592|Experimental|L-carnitine Group|Group participated in the training protocol and supplemented by 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout 24 weeks.
11123873|NCT03907592|Experimental|Leucine Group|Group participated in the training protocol and supplemented by 4000mg of L-leucine per day throughout 24 weeks.
11123874|NCT03907592|Experimental|Control Group|Group participated in the training protocol without any supplementation throughout 24 weeks.
11123875|NCT03907579|Experimental|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
11123876|NCT03907566||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals, and Turkish version of the Eating Assessment Tool.
11123877|NCT03907553||Health and Anemia|"individuals belonging to the Health and Anemia'' prospective population-based observational study (2003-2013) of all elderly residents (>65 years) in the municipality of Biella"
11123878|NCT03907553||Monzino|"individuals belonging to the Monzino Over 80 trial"
11123879|NCT03907540|Experimental|Part 1, Treatment A - KD025 Tablet|KD025 Tablet, 200 mg
11123880|NCT03907540|Experimental|Part 1, Treatment B - [14C]-KD025 solution for infusion|[14C]-KD025 solution for infusion, 20 μg/mL (100 μg in 5mL), containing NMT 37 kBq (1000 nCi) [14C], as a 15 min IV infusion, 100 μg
11123881|NCT03907540|Experimental|Part 2, Treatment C - [14C]-KD025 capsule|[14C]-KD025 capsule, containing NMT 9.8 MBq (215 μCi) 14C, 200 mg
11123882|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells)|Patients receive autologous PRGN-3005 UltraCAR-T cells IP or IV.
11123883|NCT03907514|Experimental|Intervention Group (IG)|"The adolescents in this group will use the FALE application through a smartphone in the waiting room before the dental appointment. When starting to answer the application, the adolescent will report his/her level of dental anxiety through the question, How do you feel about coming to see your dentist today?, and record his/her answer on a seven-point face scale. Then the participant will continue to answer the 12 other questions, and finally registers his/her anxiety level once more through the same question."
11123884|NCT03907514|No Intervention|Control Group (CG)|"Similarly to IG, the adolescents in this group will use the FALE application through a smartphone, but only to record their level of anxiety by answering the question How do you feel about coming to see your dentist today? using a seven-point face scale. Instead of continuing to answer the other questions, the application will guide him to wait for the one-minute interval (expected time to answer the questionnaire) and, once more, ask the same question regarding his/her feeling about the experience with the dentist."
11123885|NCT03907501|Experimental|Synbiotic|Two grams of organic Triphala powder (Banyan Botanicals, Inc.) with 1 capsule VSL#3® (VSL Pharmaceuticals, Inc.) probiotic taken with a few ounces of room temperature water in the morning and at bedtime for 8 weeks. Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.) and VSL#3® (VSL Pharmaceuticals, Inc.) capsules.
11123886|NCT03907501|Active Comparator|Probiotic|Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
11123887|NCT03907501|Placebo Comparator|Placebo|Subjects will be provided both written and verbal instructions and given a kit containing placebo capsules. Subjects will be instructed to take 2 (inert) capsules with room temperature water in the morning and at bedtime.
11123888|NCT03907488|Experimental|Arm I (chemotherapy, nivolumab, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 5-10 and 20-25 for adults or days 4-9 for pediatric patients. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician.
11123889|NCT03907488|Experimental|Arm II (chemotherapy, brentuximab vedotin, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 5-10 and 20-25 for adults or days 4-9 for pediatric patients. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician.
11123890|NCT03907475|Active Comparator|Arm I (durvalumab)|Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11123891|NCT03907475|Experimental|Arm II (gemcitabine hydrochloride, durvalumab)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11123892|NCT03907475|Experimental|Arm III (pegylated liposomal doxorubicin, durvalumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11123893|NCT03907475|Experimental|Arm IV (capecitabine, durvalumab)|Patients receive capecitabine PO BID on days 1-14 and 22-36 and durvalumab IV over 60 minutes on days 8, 22, and 36 of cycle 1, days 8 and 22 of cycle 2, and days 1 and 22 of subsequent cycles. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11123894|NCT03907475|Experimental|Arm V (carboplatin, durvalumab)|Patients receive carboplatin IV over 30-60 minutes on days 1 and 22 and durvalumab IV over 60 minutes on days 8, 22, and 36 of cycle 1, days 8 and 22 of cycle 2, and days 1 and 22 of subsequent cycles. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11123895|NCT03907475|Experimental|Arm VI (paclitaxel, durvalumab)|Patients receive paclitaxel IV over 60 minutes on days 1 and 22 and durvalumab IV over 60 minutes on days 8, 22, and 36 of cycle 1, days 8 and 22 of cycle 2, and days 1 and 22 of subsequent cycles. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11123896|NCT03907475|Experimental|Arm VII (nab-paclitaxel, durvalumab)|Patients receive nab-paclitaxel IV over 30 minutes on days 1 and 22 and durvalumab IV over 60 minutes on days 8, 22, and 36 of cycle 1, days 8 and 22 of cycle 2, and days 1 and 22 of subsequent cycles. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11123897|NCT03907462|Experimental|Treatment One|Participants assigned to the SMART 2.0 with technology and personal health coaching treatment group (i.e., treatment one) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total, and 4) technology-mediated, real-time individual health coaching. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; be asked to interact with their online group via social media as frequently as possible; and speak with their health coach at a predetermined session schedule.
11123898|NCT03907462|Experimental|Treatment Two|Participants assigned to the SMART 2.0 technology alone treatment group (i.e., treatment two) will receive the following: 1) consumer-level wearable and scale with a corresponding app, 2) daily text messages related to physical activity, diet, sleep and weight loss/maintenance, and 3) access to SMART 2.0 social media pages and content through an online group with 6 to 12 participants total. Participants will receive 1 to 2 text messages on a daily basis; be asked to use their wearable on a daily basis and self-weigh using the scale at least once per week; and be asked to interact with their online group via social media as frequently as possible.
11123899|NCT03907462|No Intervention|Control|Participants assigned to the control group will receive a consumer-level wearable and scale with a corresponding app to use at their discretion.
11123900|NCT03907449||Symptoms of Strep Throat|"Any patient presenting with symptoms of pharyngitis
~Fever
~Sore throat
~Swollen lymph nodes in neck
~Redness of throat/tonsils
~White/yellow patches on tonsils
~Not currently on antibiotics"
11124041|NCT03906500|No Intervention|control group|Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020
11123901|NCT03907436|Sham Comparator|USDA diet arm|Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.
11123902|NCT03907436|Experimental|Mediterranean diet arm|Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.
11123903|NCT03907423|Experimental|Rosuvastatin|DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients)
11123904|NCT03907423|Placebo Comparator|Control|DM-type 2 patient who will receive glimepiride-metformin combination (20 patients).
11123905|NCT03907410|Experimental|Arm 1: Incentives, plus reminders & feedback (IRF)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).
~During the Experiment period (Months 1-3), Arm 1 will receive the IRF intervention.
~During the Observation period (Months 4-6), all the arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
11123906|NCT03907410|Active Comparator|Arm 2: Reminders & feedback ONLY|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).
~During the Experiment period (Months 1-3), Arm 2 will receive ONLY reminders and feedback, without nominal financial incentives.
~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
11123907|NCT03907410|No Intervention|Arm 3 (Control)|"There will be a run-in period to determine eligibility for randomization and collect baseline adherence data (Month 0).
~During the Experiment period (Months 1-3), Arm 3 will not receive any component of the IRF intervention.
~During the Observation period (Months 4-6), all three arms will have continued daily ICS monitoring to assess enduring effects of each arm - no IRF."
11123908|NCT03907397|Active Comparator|Treatment|Ingests peanut - . Depending upon reaction threshold, participants may begin with different starting amounts of store bought peanut butter measured with study-supplied kitchen measuring spoons.
11123909|NCT03907397|No Intervention|Avoidance|Avoids peanut, standard care
11123910|NCT03907384|Experimental|Mat Pilates training|The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
11123911|NCT03907384|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
11123912|NCT03907371|Experimental|Donepezil|Patients receive donepezil with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
11123913|NCT03907371|Placebo Comparator|Control|Patients receive placebo with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
11123914|NCT03907358||cataract in old age|
11123915|NCT03907358||cataract in young age|
11123916|NCT03907345|Experimental|Exposure|Participants of this arm receive one 120-minute session of exposure treatment for spider fear.
11123917|NCT03907345|No Intervention|No Exposure|Participants of this arm receive no exposure or other adequate treatment.
11123918|NCT03907332|Experimental|Intervention Arm|"Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).
~Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:
~One visit during the second trimester of the pregnancy
~Two visits during the third trimester of pregnancy"
11123919|NCT03907332|No Intervention|Control Arm|Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.
11123920|NCT03907306|Experimental|Patients after open hemorrhoidectomy (study group)|Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.
11123921|NCT03907306|Active Comparator|Patients after open hemorrhoidectomy (control group)|Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.
11123922|NCT03907293||Phase-III Cardiac Rehabilitation|Eight weeks of supervised exercise sessions (one session per week).
11123923|NCT03907293||Phase-III and Phase IV Cardiac Rehabilitation|Twenty weeks of supervised exercise sessions (one session per week for first eight weeks [phase-III], session frequency determined by participant for remaining twelve weeks [phase-IV].
11123924|NCT03907293||No Cardiac Rehabilitation|Participants who declined to take part in a cardiac rehabilitation programme.
11123925|NCT03907280|Experimental|T1-T2-R-T3|
11123926|NCT03907280|Experimental|R-T1-T2-T3|
11123927|NCT03907280|Experimental|T2-R-T1-T3|
11123928|NCT03907267|Experimental|Taurine|
11123929|NCT03907267|Placebo Comparator|Saline|
11123970|NCT03906955|Experimental|Efficacy for Lifestyle PA|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for lifestyle physical activity.
11124791|NCT03901482|Experimental|STS101 Low Dose|STS101 (dihydroergotamine nasal powder), low dose
11123930|NCT03907254|Experimental|National Capital Region (NCR)|10-week longitudinal pre-post study, in which each participant will serve as their own control. Each participant will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up, and at a three-month post-training follow-up. The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
11123931|NCT03907241|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
11123932|NCT03907228|Experimental|RHT-3201|Lactobacillus rhamnosus IDCC 3201, Tyndallization (RHT-3201) (100 billion Colony Forming Units/sachet)
11123933|NCT03907228|Placebo Comparator|Placebo|Dextrose Anhydrous
11123934|NCT03907215|Other|Treatment A and B|"On Day 1 and Day 2, subjects will EITHER receive:
~a single dose of 50 mg ACT-541468 (Treatment A) on Day 1 and a single dose of ACT- 541468 placebo (Treatment B) on Day 2 OR
~a single dose of ACT-541468 placebo (Treatment B) on Day 1 and a single dose of 50 mg ACT-541468 (Treatment A) on Day 2."
11123935|NCT03907215|Other|Treatment C, D, E, and F|"From Day 3 to Day 10, subjects will on each day receive:
~• a single dose of 20 mg citalopram and EITHER a single dose of ACT-541468 placebo OR a single dose of 50 mg ACT-541468."
11123936|NCT03907202|Active Comparator|KBP-089|"Three cohorts:
~Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg
~Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg
~Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg"
11123937|NCT03907202|Placebo Comparator|Placebo|For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.
11123938|NCT03907189||Emergent Inflammation|Subjects with emergent inflammation detected by Podimetrics RTM Mat within the last week.
11123939|NCT03907189||No Inflammation|Subjects with no emergent inflammation detected by Podimetrics RTM Mat within the last week.
11123940|NCT03907176|Experimental|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (regimen 1)
11123941|NCT03907176|Experimental|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (regimen 2)
11123942|NCT03907163|Experimental|healthy subjects|
11123943|NCT03907163|Placebo Comparator|healthy volunteers|
11123944|NCT03907150||Pneumothorax|Pneumothorax
11123945|NCT03907150||Normal|Normal lung
11123946|NCT03907124|Experimental|Genetically-guided treatment arm|The active arm - where patients will receive genetically-guided treatment
11123947|NCT03907124|No Intervention|Treatment as usual (TAU) control arm|TAU is the control arm - where patients will continue to receive their usual treatment as before.
11123948|NCT03907111|Experimental|Chitosan gauze|100cm^2 Gauze made by chitosan material. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
11123949|NCT03907111|Placebo Comparator|Traditional gauze|100cm^2 Gauze made by traditional cotton yarn. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
11123950|NCT03907098|Experimental|endostar + chemotherapy|"Endostar 15 mg per square of BSA, continuous intravenous infusion 24 hours a day, continuous administration for 7 days, every three weeks.
~Chemotherapy regimens are selected by physicians based on regular clinical decision."
11123951|NCT03907085|Active Comparator|High intensity laser therapy (HILT) + exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
11123952|NCT03907085|Placebo Comparator|Placebo HILT + exercise|Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
11123953|NCT03907072|Experimental|WVE-210201 (Dose A)|
11123954|NCT03907072|Experimental|WVE-210201 (Dose B)|
11123955|NCT03907072|Placebo Comparator|Placebo|
11123956|NCT03907059|Active Comparator|Omnivorous|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (whey) + 12 weeks of resistance training
11123957|NCT03907059|Experimental|Vegan|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (soy) + 12 weeks of resistance training
11123958|NCT03907046|Active Comparator|Apixaban|Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
11123959|NCT03907046|Placebo Comparator|Aspirin|Aspirin dose will be 81 mg tablet once daily.
11123960|NCT03907033|Active Comparator|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
11123961|NCT03907033|Experimental|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
11123962|NCT03907020|Experimental|Meabolic Availabiliy of Barley|Healthy adult men
11123963|NCT03907007|No Intervention|Sole Medication|Monitoring under current prescribed medication
11123964|NCT03907007|Active Comparator|Combined stimulation & medication|Concurrent usage of stimulation with the prescribed medication
11123965|NCT03907007|Active Comparator|Sole Stimulation|Alternating usage of stimulation to the prescribed medication
11123966|NCT03906994|Experimental|Subjects with Amblyopia|Adult amblyopia subjects will play the video game Mario Kart Wii
11123971|NCT03906955|Active Comparator|Efficacy for Work-life Balance|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for work-life balance.
11123972|NCT03906942|Experimental|Fun For Wellness (FFW)|Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
11123973|NCT03906942|No Intervention|Usual Care (UC)|Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center.
11123974|NCT03906929|Experimental|Pediatric forearm fracture|
11123975|NCT03906903|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, three per weekday, with a final result of 30 sessions in this modality with a 30 minutes Cognitive Stimulation after session.
11123976|NCT03906903|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 30 sessions, three per weekday with a 30 minutes Cognitive Stimulation afterwards.
11123977|NCT03906877|Experimental|Injection laryngoplasty group (IL)|The patients in the first group will receive an IL of hyaluronic acid in the paralyzed vocal fold within a maximum of three months after the onset of symptoms. The Ear-Noise-Throat (ENT) physician will perform the injection in office, under topical anaesthesia.
11123978|NCT03906877|Experimental|Voice therapy group (VT)|Patients from the second group will be involved in 15 sessions of thirty minutes of voice therapy, twice a week, and will have to do home practice. Patients will have to record these training sessions. Initiation of this intervention should also take place within the first three months after the onset of symptoms. They will also receive an injection of physiological saline under the skin of the neck (sham of injection).
11123979|NCT03906877|Sham Comparator|Sham group|The patients of the third group will be treated following the traditional wait-and-see policy. They will receive an injection of physiological saline under the skin of the neck and will be seen during 15 sessions of 30 minutes, twice a week. Therefore, this will be a sham procedure for both IL and VT.
11123980|NCT03906864|No Intervention|Control group|Usual care consisted of 2 half hourly therapy sessions per day from Monday to Friday and medical ward rounds 3 times a week. Multidisciplinary rounds were conducted every 2 weeks. Any specific goals or interventions were at the discretion of the managing team.
11123981|NCT03906864|Experimental|Intervention group|Intervention group had structured assessments and checklists (as part of the integrated care pathway) in addition to usual care.
11123982|NCT03906851|Experimental|Activity and diet|"Multi-component, holistic model with a) physical activity, b) nutrition, and c) psychosocial work.
~A: physical activity will be provided as a pedagogical tool in subjects Mathematics, Norwegian and English B: Focus on school meals and menus in school cafeteria C: Psychosocial work with focus on the associations between physical activity, nutrition and psychosocial health. Collaboration between schools and school health services"
11123983|NCT03906851|No Intervention|Control|Schools are required to perform teaching activities, school meals and school cafeteria menus as usual
11123984|NCT03906838|Experimental|Regional Nerve Block|Subjects in the regional anesthesia cohort will have a regional anesthesia block and/or catheter placement administered according to current hospital policies and our established standard of care.
11123985|NCT03906838|No Intervention|No Regional Nerve Block|Subjects in the no regional anesthesia cohort will not get pre-operative regional anesthesia, and their surgery and anesthesia will be performed according to normal policies and standard of care in our hospital.
11123986|NCT03906825|Active Comparator|dietary supplement CEAG|The dietary supplements consists of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG).
11123987|NCT03906825|Placebo Comparator|Placebo|The Placebo does not contain any CEAG.
11123988|NCT03906812|Active Comparator|Unmonitored floor admission|Participants in this arm will be admitted to an unmonitored floor bed.
11123989|NCT03906812|Active Comparator|Floor admission with telemetry|Participants in this arm will be admitted to a telemetry bed.
11123990|NCT03906799|Experimental|Low OMT-28|Verum, low OMT-28
11123991|NCT03906799|Experimental|Middle OMT-28|Verum, middle OMT-28
11123992|NCT03906799|Experimental|High OMT-28|Verum, high OMT-28
11123993|NCT03906799|Placebo Comparator|Placebo|Placebo
11123994|NCT03906786|Experimental|motivacional interviewing group|
11123995|NCT03906786|No Intervention|control group|
11123996|NCT03906773||Intervention|The investigators seek to conduct a pragmatic trial including 2 sister clinical sites to test an innovation using a patient portal framework for Advance Care Planning. The intervention site implemented the intervention (secure patient portal delivered pre-visit planning framework for Advance Care Planning communication). The presence of ACP and the quality of documentation will be assessed through post-intervention chart review. Practice level enrollment was sought for the trial, and the framework will be delivered to all patients during a period of roll out. About 250 patients will receive the intervention.
11123997|NCT03906773||control|The control site delivered usual care during the same period of roll out.
11123998|NCT03906747||Patients|Patients at their end-of-life (EOL) phase attending the emergency department
11123999|NCT03906747||Family members and next-of-kin of (EOL) patients|Family members and next-of-kin of EOL patients in the emergency department
11124000|NCT03906747||Healthcare workers|Comprised of doctors in the emergency department, nurses and general practitioners
11124001|NCT03906734|Experimental|alfieri technique + Septal myectomy|Septal myectomy plus mitral valve repair using alfieri stich
11124002|NCT03906734|Active Comparator|Subvalvular intervention + Septal myectomy|Septal myectomy plus subvalvular mitral valve intervention
11124140|NCT03905798||Lorazepam|Patients administered Lorazepam in accordance with the indication (for Status Epilepticus, SE) and have no history of using this drug
11124003|NCT03906721|Experimental|Conditioning & Open-Label Placebo (COLP)|Days 1 to 5 will include the acquisition phase where oxycodone will be prescribed on a schedule of 3-4 times per day and paired with open-placebo and smelling the essential oil. Days 6 to 10 will be the evoked phase, and patients will receive full oxycodone dosage on alternating days with open placebo and smelling the essential oil.
11124004|NCT03906721|Other|Control|For the duration of the study, days 1 to 10, oxycodone will be prescribed on a schedule of 3-4 times per day.
11124005|NCT03906708||Premature Infants|Premature infants born between 24+0 and 36+6 weeks of gestation.
11124006|NCT03906695|Experimental|10-Day Schedule|"10-Day Schedule
~Investigational Medicinal Products (IMP) will be administered for 10 days in total per 4 weeks, i.e. a 28-day cycle."
11124007|NCT03906695|Experimental|5-Day Schedule A|"5-Day Schedule A
~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
11124008|NCT03906695|Experimental|5-Day Schedule B|"5-Day Schedule B
~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
11124009|NCT03906695|Experimental|5-Day Schedule C|"5-Day Schedule C
~IMP will be administered for 5 days in total per 4 weeks, i.e. a 28-day cycle."
11124010|NCT03906695|Experimental|7-Day Schedule|"7-Day Schedule
~IMP will be administered for 7 days in total per 4 weeks, i.e. a 28-day cycle."
11124011|NCT03906682|Experimental|RAP Club program|RAP Club is a 12-session universal prevention program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
11124012|NCT03906682|Active Comparator|Healthy Topics program|Like RAP Club, Healthy Topics is a 12-session program delivered twice per week over six weeks during the school day. The program is delivered by a trained facilitator and young adult community member.
11124013|NCT03906669|Active Comparator|Letrozole|Letrozole 2.5mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
11124014|NCT03906669|Experimental|Letrozole and Prometrium|Letrozole 2.5mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
11124015|NCT03906669|Experimental|Tamoxifen and Prometrium|Tamoxifen 20mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery
11124016|NCT03906656|Active Comparator|KAFO/SCO|Home use of 3 months with existing knee ankle foot orthosis (KAFO) or existing stance control orthosis (SCO)
11124017|NCT03906656|Experimental|C-Brace|Home use of 3 months with newly fitted C-Brace microprocessor-controlled stance and swing control orthosis.
11124018|NCT03906643|Experimental|HS-201|HS-201 will be administered intravenously as a single dose
11124019|NCT03906630||Shoulder patients|
11124020|NCT03906617|Experimental|Bupivacaine/epinephrine + dexamethasone|
11124021|NCT03906617|Active Comparator|Liposomal bupivacaine|
11124022|NCT03906604|Other|Dominant hand-open Carpal Tunnel Release|Standard mini-open carpal tunnel release (standard of care) on the dominant hand.
11124023|NCT03906604|Other|Dominant hand-Incisionless thread carpal tunnel release|Incisionless thread carpal tunnel release on the dominant hand.
11124024|NCT03906591|Experimental|allogenic bone ring|
11124025|NCT03906591|Active Comparator|autogenous bone ring|
11124026|NCT03906578|Active Comparator|Probiotic|Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10^11 CFU) in the evening for 8 weeks
11124027|NCT03906578|Placebo Comparator|Placebo|Two sachets placebo in the evening for 8 weeks
11124028|NCT03906565|Experimental|utidelone|Utidelone Injection: 40 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced or metastatic CRC
11124029|NCT03906552|Experimental|acupressure group|"2 neonates did not calm down before heel lancing; oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well.
~Acupressure was performed when the mother was holding the neonate on her arm. For two minutes, acupressure was performed in the acupressure points (Kun Lun (UB60) and Taixi (K3). Each point was applied acupressure for 60 seconds, and heel lancing was performed right after this procedure. The acupuncture points that Kun Lun (UB60) and Taixi (K3) are on the side of the ankle."
11124030|NCT03906552|Experimental|masssage group|"oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).
~Foot massage was performed when the mother was holding the neonate on her arm. Each neonate was given foot massage for two minutes, and heel lancing was performed right after the massage."
11124031|NCT03906552|No Intervention|control group|"oxygen saturation and heart rate values of 1 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).
~No application was made to theneonates in the control group before heel lancing procedure"
11124032|NCT03906539|Placebo Comparator|Control Group|The patients in control groups will receive tablet atorvastatin (10 mg/day) and a placebo capsule.
11124033|NCT03906539|Experimental|VCO Group|The VCO group will receive capsule VCO (1000mg/day) as an add-on to tablet atorvastatin (10 mg/day).
11124034|NCT03906526|Experimental|Monotherapy Arm 1: Nivolumab|Nivolumab IV every 2 weeks
11124035|NCT03906526|Experimental|Monotherapy Arm 2: Motolimod|Motolimod IT injection weekly
11124036|NCT03906526|Experimental|Combination Arm 3: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod IT injection weekly
11124037|NCT03906526|Experimental|Combination Arm 4: Nivolumab and Motolimod|Nivolumab IV every 2 weeks and Motolimod SC injection weekly
11124038|NCT03906513|Active Comparator|Active treatment|20 patients will be treated with active treatment (OMK2)
11124039|NCT03906513|Placebo Comparator|Placebo|10 patients will be treated with placebo (lubricant eye drops)
11124040|NCT03906500|Experimental|Intervention|"The intervention consist of three main components.
~School environmental component
~The component targeting the high school environment consisted of two separate elements:
~Revision of school alcohol policy
~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.
~Student components
~The Student components consisted of three main elements:
~Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee
~Pocket movie campaign
~Social norms campaign
~Parent components
~The parent component consisted of three separate elements:
~Parent Information Meeting
~Parent Information Folder
~Parent Information Website"
11124042|NCT03906487|Experimental|Intimate partner violence|The women in this arm must have suffered at least two physical aggressions. They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.
11124043|NCT03906487|Active Comparator|Control group|The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event. These women will be recruited by a call for volunteers.
11124044|NCT03906474|Experimental|Group 1|A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
11124045|NCT03906474|Experimental|Group 2|A second blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to one blood-stage challenge in the VAC063 trial. Group 2 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 3 (malaria-naïve controls).
11124046|NCT03906474|Experimental|Group 3|Malaria-naïve controls will receive a primary blood-stage controlled human P. falciparum malaria infection. Group 3 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 2 (undergoing a second challenge).
11124047|NCT03906448|Experimental|Astrocytoma Patients|Patients newly diagnosed with Grade II and III astrocytoma.
11124048|NCT03906448|No Intervention|Control Arm|Data collection from medical record only
11124049|NCT03906435|No Intervention|Control Arm|Standard of care information given by NICU staff and Follow up Clinic staff, including information about health care, diagnosis, medications, daily cares, anticipatory guidance, and discharge prep information.
11124050|NCT03906435|Experimental|Intervention CBT Arm|In addition to Standard of care information that the control arm receives, this arm will also receive 5 CBT sessions focusing on past NICU trauma, emotional coping, parental perceptions of child vulnerability, and helpful parenting and emotional coping skills.
11124051|NCT03906422|Experimental|"A: 0.016 Nitinol"|"0.016 Nitinol (3M Unitek, Monrovia, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
11124052|NCT03906422|Experimental|"B: 0.016 Ormco 27oC NiTi"|"0.016 Ormco 27oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
11124053|NCT03906422|Experimental|"C: 0.016 Ormco 35oC NiTi"|"0.016 Ormco 35oC NiTi (Ormco, Glendora, CA) archwire to be tied to the fixed orthodontic brackets at the initial bonding appointment."
11124054|NCT03906409|Active Comparator|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
11124055|NCT03906409|Experimental|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
11124056|NCT03906396|Experimental|Intervention Group|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant for 6 weeks, 3 times per week. Games use for the activity are Sports Kinect and Sports Kinect 2. The activity can be performed in solo or in pairs with another participant. The game activity will be played only at the site chosen for this study.
11124057|NCT03906396|No Intervention|Control Group|No standard activity is provided for the participants. The participants will continue with their normal daily life activities.
11124058|NCT03906383|Experimental|Remote Ischemic Conditioning|
11124059|NCT03906370||MS patients/cases|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
11124060|NCT03906370||Healthy subjects/controls|Patients admitted for diagnostic investigations to the MS clinic were offered participation if aged >18 years and no previous use of immunosuppressing or modifying drugs within 6 months. The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
11124061|NCT03906305|Experimental|Dry needling in a myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into trigger point spastic muscle of the shoulder.
11124062|NCT03906305|Active Comparator|Dry needling in a non myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into a non trigger point spastic muscle of the shoulder.
11124063|NCT03906292|Experimental|Asciminib 60mg QD|Standard therapy of Imatinib 400 mg QD and asciminib 60 mg QD
11124064|NCT03906292|Experimental|Asciminb 20 mg BID|Standard therapy of Nilotinib 300 mg BID and asciminib 20 mg BID
11124065|NCT03906292|Experimental|Asciminib 40 mg QD|Standard therapy of Nilotinib 300 mg BID and asciminib 40 mg QD
11124066|NCT03906292|Experimental|Asciminib 80 mg QD|Standard therapy of Dasatinib 100 mg QD and asciminib 80 mg QD
11124067|NCT03906279||Myopic participants|
11124068|NCT03906279||Emmetropic participants|
11124069|NCT03906279||Hyperopic participants|
11124070|NCT03906266|Active Comparator|nutric score|> 5 indicates high risk for malnutrition < 4 indicates low risk for malnutrition
11124071|NCT03906266|Placebo Comparator|adductor pollicis|< 20 mm indicates high high risk for malnutrition > 20 mm indicates low risk for malnutrition
11124072|NCT03906266|Placebo Comparator|SGA score|SGA 1 indicates no malnutrition SGA 2 indicates good diet SGA 3 indicates high risk for malnutrition
11124073|NCT03906266|Placebo Comparator|NRS 2002 score|> 3 indicates high risk for malnutrition
11124074|NCT03906253|Experimental|Factionated Laser Resurfacing - Right Arm|Right forearm treatment of fractionated laser resurfacing.
11124075|NCT03906253|Experimental|Factionated Laser Resurfacing - Left Arm|Left forearm treatment of fractionated laser resurfacing.
11124076|NCT03906240|No Intervention|No intervention|Veterans will access the online portal and complete session measures, but will not be presented with any intervention content (i.e., videos, journaling exercise, and goal setting exercise)
11124077|NCT03906240|Experimental|Moral Elevation Intervention|Moral Elevation Intervention (described in intervention section).
11124633|NCT03902574|Experimental|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
11124078|NCT03906227|Active Comparator|low CD5+ /on maintenance|Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
11124079|NCT03906227|Active Comparator|high CD5/ on maintenance|Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
11124080|NCT03906227|Experimental|high CD5 / NO maintenance|Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
11124081|NCT03906201|Experimental|Control Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment
11124082|NCT03906201|Experimental|Ecdysterone Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment
11124083|NCT03906188|Experimental|LitEmotion group|This group will play to LitEmotion video game.
11124084|NCT03906188|No Intervention|Control group|This group will no do receive any intervention with the video game
11124085|NCT03906175|Experimental|Whole-body hyperthermia|Whole-body hyperthermia will be applied 2 times during 4 weeks. At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
11124086|NCT03906175|No Intervention|Wait list|Participants will wait for 6 weeks (primary outcome assessment point). They will then receive the same treatment procedure as the experimental group. They will also be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
11124087|NCT03906162|Experimental|Motivational interviewing|Experimental content + base intervention
11124088|NCT03906162|Active Comparator|Control intervention|Base intervention
11124089|NCT03906149|Experimental|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
11124090|NCT03906149|Active Comparator|Standard medical care|Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.
11124091|NCT03906136|Experimental|TREAT-TO-TARGET (T2T)|"Participants will receive secukinumab at a dose of 150 milligrams (mg) as subcutaneous (s.c.) injection at 150 mg dose at Baseline, Week 1, 2, 3, 4 and 8. From Week 12, only responders will continue to receive 4-weekly doses until Week 32 if they maintain the response. In case these patients experience a loss of response from week 24 they will be escalated to secukinumab 300 mg s.c. every 4 weeks until Week 32.
~Patients who are non-responders at Week 12 will receive 4-weekly secukinumab 300 mg s.c. until Week 24. From Week 24, only responders will continue to receive 4-weekly secukinumab 300 mg s.c. until Week 32. Patients who are non-responders to secukinumab 300 mg at Week 24 will receive biweekly of adalimumab biosimilar 40 mg s.c. until Week 34"
11124092|NCT03906136|Active Comparator|Standard-of-care (SOC)|SOC treatment up to the maximum recommended dose at the discretion of the investigator as according to current recommendation for treatment of axSpA
11124093|NCT03906123|Experimental|NBP|DL-3-n-butylphthalide (NBP), soft capsule, 200mg Tid, po, for 48 weeks.
11124094|NCT03906123|Placebo Comparator|Placebos|Placebo, soft capsule, 200mg Tid, po, for 48 weeks.
11124095|NCT03906110||C-Cares|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) Materials and FIT kits.
11124096|NCT03906110||C-Cares Plus|Participants will be given Community Colorectal Cancer Awareness, Research, Education and Screening (C-CARES) materials, FIT kids, and personalized one-on-one education and coaching.
11124097|NCT03906097|Experimental|intervention|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
11124098|NCT03906097|No Intervention|control|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
11124099|NCT03906084|Active Comparator|Corticotomy facilitated orthodontics.|Corticotomy is carried out under local anesthesia in right side.
11124100|NCT03906084|Experimental|Corticotomy and low level laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
11124101|NCT03906071|Experimental|Nivolumab and Sitravatinib|Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.
11124102|NCT03906071|Active Comparator|Docetaxel|Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.
11124103|NCT03906058|Experimental|Anlotinib|
11124104|NCT03906045|Experimental|All patients|10 patients with moderate COPD and 10 patients with severe/very severe COPD inhale BGF followed by a breath hold of up to 10 seconds.
11124105|NCT03906032|Experimental|Intra-medullary hip Nail|Surgery
11124106|NCT03906032|Active Comparator|Sliding hip screw|Surgery
11124107|NCT03906006|Experimental|ABP-671, Cohort 1-|ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
11124108|NCT03906006|Experimental|ABP-671, Cohort 2-|ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
11124109|NCT03906006|Experimental|ABP-671, Cohort 3-|ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
11124634|NCT03902548|Experimental|Brain uptake and kinetics in Alzheimer's patients|
11124110|NCT03906006|Experimental|ABP-671, Cohort 4-|ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
11124111|NCT03905993||Experimental: unique group.|At V0: 1238 subjects were screened At V1: 1012 subjects (12 later withdrew) gave the following samples: blood, nasal swab,stool. 323 subjects among 1000 gave one additional sample (Skin Biopsy) At V2: 504 subjects came at V2 to perform blood, nasal swab and stool samples
11124112|NCT03905980||Vaginal delivery|woman who terminate their pregnancy by vaginal delivery
11124113|NCT03905980||Cesarean delivery|woman who terminate their pregnancy by cesarean delivery
11124114|NCT03905967|Experimental|Lenvatinib + TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib.
11124115|NCT03905967|Active Comparator|Lenvatinib|Lenvatinib alone
11124116|NCT03905954||Parkinson's Diagnosis|Usual care
11124117|NCT03905941|Experimental|Metformin then oral combined hormonal contraceptives|Subjects will take metformin 2000 mg/day for the first 6 months, followed by 6 months of oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg.
11124118|NCT03905941|Active Comparator|Oral combined hormonal contraceptives then metformin|Subjects will take oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg for the first 6 months, followed by 6 months of metformin 2000 mg/day.
11124119|NCT03905928|Experimental|18mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a tobacco flavor.
11124120|NCT03905928|Placebo Comparator|0mg/ml Tobacco Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a tobacco flavor.
11124121|NCT03905928|Experimental|18mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 15mg/ml nicotine concentration and a strawberry vanilla flavor.
11124122|NCT03905928|Placebo Comparator|0mg/ml Strawberry Vanilla Flavor ECIG|Participants will be provided with an ECIG containing 0mg/ml nicotine concentration and a strawberry vanilla flavor.
11124123|NCT03905915|Other|Preoperative virtual reality session|Amsterdam Anxiety score recorded before VR session is followed by a 15 min VR session and finally Amsterdam Anxiety score is recorded after VR session
11124124|NCT03905902|Experimental|DCVAC/OvCa with standard of care|"Induction period: DCVAC/OvCa with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and pegylated liposomal doxorubicin, with or without bevacizumab
~Maintenance period: DCVAC/OvCa with bevacizumab, best supportive care or a PARPi"
11124125|NCT03905902|Placebo Comparator|Placebo with standard of care|"Induction period: DCVAC Placebo with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and doxorubicin, with or without bevacizumab
~Maintenance Period:DCVAC placebo with bevacizumab, best supportive care or a PARPi carboplatin and gemcitabine or carboplatin and paclitaxel with or without bevacizumab, best supportive care or a PARPi"
11124126|NCT03905889|Experimental|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
11124127|NCT03905876|Other|assessment of psychological experience|Questionnaire
11124128|NCT03905863|No Intervention|Standard of care arm|Patients in the standard of care arm will receive the standard care for their type of wound from their wound care centre.
11124129|NCT03905863|Active Comparator|Intervention arm|Patients in the intervention arm will receive standard of care plus Natrox® Oxygen Wound Therapy as treatment for their wound.
11124130|NCT03905850|Experimental|Somapacitan 5/10/10 mg|One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.
11124131|NCT03905850|Experimental|Somapacitan 10/5/10 mg|One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
11124132|NCT03905850|Experimental|Somapacitan 10/10/5 mg|Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
11124133|NCT03905837|Experimental|Lidocaine IV|Group 1: intravenous lidocaine and paravertebral saline (SF). In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
11124134|NCT03905837|Experimental|Lidocaine PV|Group 2: intravenous SF and paravertebral lidocaine. During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
11124135|NCT03905837|Active Comparator|no lidocaine|Group 3: intravenous remifentanil and paravertebral SF. During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.
11124136|NCT03905824|Experimental|Debridement and microfracture in LOC + Cells|Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.
11124137|NCT03905824|Active Comparator|Debridement and microfracture in LOC|Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus.
11124138|NCT03905811|Experimental|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
11124139|NCT03905811|Placebo Comparator|Placebo|Placebo administered once daily p.o. for 12 weeks
11124635|NCT03902548|Experimental|Dosimetry in healthy volunteers|
11124141|NCT03905785|Experimental|Parenting Intervention Group(Samarthan)|Parenting intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
11124142|NCT03905785|No Intervention|Wait list Control group|wait list control group was given no intervention for the trial period. They were offered sam intervention after the intervention was completed in experimental group.
11124143|NCT03905772|Experimental|Voluntary exercise|The participants will perform 36 voluntary contractions of 20% of maximal voluntary isometrical contraction, 3 times per week for 8 weeks.
11124144|NCT03905772|Experimental|Wide pulse responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
~This group will classified in responder in the acute fase."
11124145|NCT03905772|Experimental|Wide pulse non responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
~This group will classified in non responder in the acute fase."
11124146|NCT03905772|Experimental|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
11124147|NCT03905759|Active Comparator|colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
11124148|NCT03905759|Active Comparator|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
11124149|NCT03905759|Active Comparator|amiodarone|amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
11124150|NCT03905746||acute decompensation group|patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis
11124151|NCT03905746||Pathological control group|patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event
11124152|NCT03905733||general anesthesia with rigid bronchoscopy|Patients 7 years or younger who undergo general anesthesia with rigid bronchoscopy
11124153|NCT03905720|No Intervention|Treatment As Usual|Participants will receive routine care consisting of usual analgesic medications for pain in adults with cancer.
11124154|NCT03905720|Active Comparator|Acupuncture|Along with routine pain medications, participants will be offered daily acupuncture treatments for up to four days.
11124155|NCT03905720|Active Comparator|Pain Counseling|Along with routine pain medications, participants will receive evidence-based psychosocial support through education and counseling provided by qualified study staff.
11124156|NCT03905720|Active Comparator|Acupuncture and Pain Counseling|Along with routine pain medications, participants will be offered daily acupuncture treatments and pain counseling for up to four days as described above.
11124157|NCT03905707|Experimental|Glepaglutide SC injections twice weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly.
~In this long term safety study, there is no placebo arm."
11124158|NCT03905707|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|"Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly.
~In this long term safety study, there is no placebo arm."
11124159|NCT03905694|Experimental|Lumasiran|Participants will receive lumasiran during the study.
11124160|NCT03905681|Active Comparator|"Active TENS Group Group A"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. While the device is off, it will be set at the following settings: The selector switch will be set to 'Milli' or milliamperes, and the frequency dial will be rotated to 100 Hertz. The participant will be instructed to rotate both dials in a clockwise direction if more intensity is desired, or counter-clockwise if less intensity is desired. The participant will wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
11124161|NCT03905681|Placebo Comparator|"Placebo TENS Group Group B"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. However, no electrical stimulation will be provided. The participant will also wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
11124162|NCT03905668||ICU Patients|Adults in admitted to an ICU at University of Florida Health Gainesville with an expected length of stay greater than 24 hours which are not on any form of contact precaution or isolation. Patients will have continuous video, accelerometer, and electromyographic monitoring for up to seven days while in the ICU.
11124163|NCT03905668||ICU Patient Friends/Family Members|Adult visitors of participating ICU patients that are willing to provide feedback to the learning algorithms.
11124164|NCT03905655|Placebo Comparator|Group 1|Three placebo tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
11124165|NCT03905655|Active Comparator|Group 2|Two 300 mg NTZ tablets and one placebo tablet administered orally in the morning and three placebo tablets in the evening in addition to continuing TDF, TAF or ETV therapy
11124166|NCT03905655|Active Comparator|Group 3|Two 300 mg NTZ tablets and one placebo tablet administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
11124167|NCT03905655|Active Comparator|Group 4|Three 300 mg NTZ tablets administered orally twice daily with food in addition to continuing TDF, TAF or ETV therapy
11124168|NCT03905642|Experimental|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
11124169|NCT03905629||Patients aged 75 years and older hospitalized as an emergency|Patients considered will be all patients aged 75 years and older (on the day of the index admission) hospitalized as an emergency (i.e. after visit to ED) between january 2017 and december 2017.
11124701|NCT03902067|Placebo Comparator|Control Group|Routine treatment
11124170|NCT03905616|Experimental|healthy subjects|25 healthy subjects with a normal/corrected vision fitting to all of the inclusion/exclusion criteria. All the subjects will be tested on the same visual stimuli, leading to intrasubject comparison analyses of functional magnetic resonance imaging (fMRI) activity between conditions.
11124171|NCT03905603|Experimental|ACTH (Cosyntropin), rhCG (Ovidrel)|ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
11124172|NCT03905590|Experimental|periapical surgery with amniotic membrane|periapical surgery will be done and amniotic membrane will be placed over the defect before closure of flap
11124173|NCT03905590|Active Comparator|periapical surgery without amniotic membrane|periapical surgery will be done without the placement of amniotic membrane over the defect before closure of flap
11124174|NCT03905577|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
11124175|NCT03905577|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
11124176|NCT03905577|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
11124177|NCT03905564|Experimental|Doxylamine succinate/pyridoxine hydrochloride|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.
11124178|NCT03905564|Active Comparator|Diclegis (Registered Trademark)|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.
11124179|NCT03905551|Placebo Comparator|Standard Dialysis|Patients participated in a 7 months exercise trials receiving standard dialysis (at 37oC)
11124180|NCT03905551|Experimental|Cold Dialysis|Patients participated in a 7 months exercise trials receiving cold dialysis (at 35oC)
11124181|NCT03905538|Experimental|[18F]FLT-PET/CT Arm|The experimental [18F]FLT-PET/CT will be completed before initiation of chemotherapy and prior to the third cycle (or month) of chemotherapy. Laboratory analysis and correlative radiology, as directed per clinical care based on the primary diagnosis, are required within 30 days of the baseline [18F]FLT PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
11124182|NCT03905525|Experimental|Cohort 1 /Arm A|CFZ533 dose 1
11124183|NCT03905525|Experimental|Cohort 1/Arm B|CFZ533 dose 2
11124184|NCT03905525|Experimental|Cohort 1/Arm C|CFZ533 dose 3
11124185|NCT03905525|Placebo Comparator|Cohort 1/Arm D|Placebo dose (up to week 24)
11124186|NCT03905525|Experimental|Cohort 1/Arm D1|CFZ533 dose 1 (from week 24)
11124187|NCT03905525|Experimental|Cohort 2/Arm E|CFZ533 dose 1
11124188|NCT03905525|Placebo Comparator|Cohort 2/Arm F|Placebo dose (up to week 24)
11124189|NCT03905525|Experimental|Cphort 2/Arm F1|CFZ533 dose 2 (from week 24)
11124190|NCT03905512|Experimental|SEL-212|IV infusion of SEL-212 every 28 days for a total of up to 6 infusions of SEL-212.
11124191|NCT03905512|Active Comparator|KRYSTEXXA|IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for a total of up to 12 infusions of KRYSTEXXA®.
11124192|NCT03905499|Experimental|Robotic mediated therapy|Robotic mediated therapy with MJS (multi joint system) Tecnobody
11124193|NCT03905486|Active Comparator|G1: patients will receive pregabalin|pregabalin as a mono-therapy will be administered in increment doses for 3 months
11124194|NCT03905486|Active Comparator|G2: patients will receive pregabalin and milnacipran|pregabalin and milancipran as a combination therapy will be administered in increment doses for 3 months
11124195|NCT03905447|Experimental|PC945|
11124196|NCT03905447|Other|Standard of Care|Standard of care anti-fungal medication
11124197|NCT03905434||Control|A total of 15 healthy controls will be enrolled and miRNA samples will be collected
11124198|NCT03905434||Stroke|A total of 30 acute stroke patients with large vessel occlusions will be enrolled.
11124199|NCT03905421||usual care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. They will not be randomized to palliative care.
11124200|NCT03905421||palliative care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. Based on the patients in Group 1 and 3 PH and a high SYMPACT score> 1.0 in any domain they will be randomized to receive standard care or a palliative care initial consult.
11124201|NCT03905408|Experimental|50 mL Dextrose|50 mL of 50% dextrose
11124202|NCT03905408|Experimental|100 mL Dextrose|100 mL of 50% dextrose
11124203|NCT03905408|Experimental|150 mL Dextrose|150 mL of 50% dextrose
11124204|NCT03905408|Experimental|200 mL Dextrose|200 mL of 50% dextrose
11124205|NCT03905395|Active Comparator|Meditation and mindfulness intervention|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
11124206|NCT03905395|No Intervention|Control group|Women in the no intervention arm will receive no introduction to meditation and mindfulness - only questionnaires at the same time as the intervention group receives questionnaires.
11124207|NCT03905382|Other|Qualitaitve|Qualitaitve
11124208|NCT03905369|Experimental|Decision aid, SDM booster and deliberation training|In the first arm, patients have COMBO, consisting of the decision aid, the SDM-booster, and the values deliberation training for physicians
11124209|NCT03905369|Active Comparator|Deliberation training|In the second arm, patients have the values deliberation training for physicians alone.
11124245|NCT03905148|Experimental|Part A: Dose Level 4|Mirdametinib at 6 or 8 mg once a day and lifirafenib at 20 or 25 mg once a day depending on the safety and tolerability observed at Levels 1, 2, and 3
11124246|NCT03905148|Experimental|Part B: Group 1|Non-small cell lung cancer with confirmed K-RAS mutations, approximately 15 participants
11124247|NCT03905148|Experimental|Part B: Group 2|Endometrial cancer with confirmed K-RAS mutations, approximately 15 participants
11124248|NCT03905148|Experimental|Part B: Group 3|Tumor type of interest based on preliminary anti-tumor clinical activities observed in Part A, approximately 15 participants
11124210|NCT03905356|Experimental|Exercise|"The exercise intervention will utilize the Moving Through Cancer: A Guide to Exercise for Cancer Survivors framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises)."
11124211|NCT03905343|Experimental|A: endocrine therapy + ribociclib|
11124212|NCT03905343|Active Comparator|B: mono-chemotherapy|
11124213|NCT03905330|Experimental|Maralixibat|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
11124214|NCT03905330|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
11124215|NCT03905317|Experimental|Bevacizumab|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
11124216|NCT03905304|Experimental|Meditoxin|Meditoxin administered 200U~300U, single-dose administration.
11124217|NCT03905304|Active Comparator|Botox|Botox administered 200-300U, single-dose administration.
11124218|NCT03905291|Experimental|MT921 60mg Group|MT921 60 mg
11124219|NCT03905291|Experimental|MT921 120mg Group|MT921 120 mg
11124220|NCT03905291|Experimental|MT921 150mg Group|MT921 150 mg
11124221|NCT03905291|Placebo Comparator|Placebo Group|Placebo
11124222|NCT03905278|Experimental|Parental guidance|"In the experimental condition, the two significant caregivers of the child or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. The intervention consists of four sessions, centered on supporting the child in the context of parental cancer principally through communication.
~Assessments are conducted at two periods : before and after the intervention."
11124223|NCT03905278|No Intervention|Waiting List group|"In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months.
~Assessments are conducted at 9 weeks of interval."
11124224|NCT03905265|Experimental|Moxidectin 2 mg|Moxidectin 2 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
11124225|NCT03905265|Experimental|Moxidectin 8 mg|Moxidectin 8 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
11124226|NCT03905265|Experimental|Moxidectin 20 mg|Moxidectin 20 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
11124227|NCT03905265|Experimental|Moxidectin 36 mg|Moxidectin 36 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
11124228|NCT03905239|Experimental|algorithm arm|Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
11124229|NCT03905239|No Intervention|no algorithm arm|Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
11124230|NCT03905226||Heart Failure|Patients whom initiated a hospital pathway for heart failure management within the Paris Saint Joseph Hospital Group (GHPSJ) between January 1, 2015 and December 31, 2018.
11124231|NCT03905213|Active Comparator|conventional gauze|Device is a conventional gauze and the change will be to the day 2 and 4 of surgery
11124232|NCT03905213|Experimental|polyurethane dressing|Device is a polyurethane dressing and the change will be to the day 7 of surgery
11124233|NCT03905213|Experimental|vacuum therapy dressing|Device is a vacuum therapy dressing and the change will be to the day 7 of surgery
11124234|NCT03905200||coronary artery disease|Patients who were diagnosed with coronary heart disease at admission and planned to undergo coronary angiography
11124235|NCT03905187|Other|Control Group|Group received education only
11124236|NCT03905187|Other|Traditional CR Group|Group received cardiac rehabilitation including education and exercise
11124237|NCT03905187|Experimental|Stress-Modified CR Group|Group received cardiac rehabilitation including education, exercise and stress management
11124238|NCT03905174|Active Comparator|Standard treatment|A porous collar for either distal or proximal femoral replacements
11124239|NCT03905174|Active Comparator|standard treatment + HA|A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements
11124240|NCT03905174|Active Comparator|standard treatment + HA + autogenic cells|A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements
11124241|NCT03905161||Myasthenia patients|Danish patients with myasthenia gravis seen at the Department of Neurology, Rigshospitalet
11124242|NCT03905148|Experimental|Part A: Dose Level 1|Mirdametinib at 2 mg once a day and lifirafenib at 15 mg once a day
11124243|NCT03905148|Experimental|Part A: Dose Level 2|Mirdametinib at 2 mg once a day and lifirafenib at 20 mg once a day
11124244|NCT03905148|Experimental|Part A: Dose Level 3|Mirdametinib at 4 mg once a day and lifirafenib at 20 mg once a day
11124249|NCT03905135|Experimental|1- Experimental Treatment: Dose Escalation|IL-15 by civ infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by IV infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine MTD
11124250|NCT03905135|Experimental|2- Experimental Treatment: Dose Expansion|IL-15 by civ infusion at the MTD on days 1- 5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 ofeach cycle
11124251|NCT03905122||continous veno-venous hemodialysis|to measure the fluid changes by using bioreactance method in continous veno-venous hemodialysis group
11124252|NCT03905122||hemodialysis|to measure the fluid changes by using bioreactance method in hemodialysis group
11124253|NCT03905109|Experimental|ABX464|50 mg
11124254|NCT03905109|Placebo Comparator|Placebo|50 mg matching placebo
11124255|NCT03905096|Experimental|Part 1|
11124256|NCT03905096|Experimental|Part 2|
11124257|NCT03905083|Experimental|Exercise rehab|Investigators aim to evaluate how exercise training may provide beneficial effects on the skeletal muscle and/or pulmonary vasculature in select subjects with pulmonary arterial hypertension, scleroderma or mixed connective tissue disease or patients with exercise pulmonary arterial hypertension
11124258|NCT03905083|No Intervention|No exercsie rehab|Some participants will not be assigned to do exercise rehab so we would be using them as a control arm to intervention group
11124259|NCT03905070||Study Group|The study group consisted of people who had undergone bariatric surgery and who had at least 6 months after the operation.
11124260|NCT03905070||Control Group|The control group will consist of asymptomatic individuals whose BMI is 18-25 kg / m2 and has not participated in any exercise program in the last one year.
11124261|NCT03905057|Sham Comparator|Sham ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), using a sham applicator which is highly similar to the active applicator except that the sham applicator does not emit shockwaves, twice a week (total of 6 weeks) without treatment interval. Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
11124262|NCT03905057|Active Comparator|Active ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks). Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
11124263|NCT03905044||CC|eyes with congenital cataracts
11124264|NCT03905031|Experimental|InfraScanner 2000|All participants entered into the study will undergo at least one cranial scanning using the InfraScanner 2000 within 4 hours before or after CT scan. Patients will know the results of the CT scan but not of the InfraScanner 2000. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative.
11124265|NCT03905018|Experimental|tadalafil|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally
11124266|NCT03905018|Placebo Comparator|calcined magnesia (placebo)|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the second will receive 20 mg of calcined magnesia (placebo),after a single administration
11124267|NCT03905005||Pre-flexed reconstruction plate|Patients who undergo mandibular reconstruction using a pre-flexed osseosynthesis reconstruction plate along with free-tissue transfer for reconstruction of a mandibular continuity defect.
11124268|NCT03905005||Printed reconstruction plate|Patients who undergo mandibular reconstruction using a 3D-printed reconstruction plate made by selective laser melting (SLM), along with free-tissue transfer for reconstruction of a mandibular continuity defect.
11124269|NCT03904992|No Intervention|Non-exposed|Subjects with access to nutritional counseling sessions every 30 days
11124270|NCT03904992|Experimental|Exposed|Subjects with access to the progressive web app in their smartphones.
11124271|NCT03904979|Experimental|Therapeutic Writing Prompts|Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
11124272|NCT03904979|Placebo Comparator|General Writing Prompts|"Participants will be given writing prompts that discuss neutral topics unrelated to their life stress, resilience, or coping."
11124273|NCT03904979|No Intervention|No Writing|Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.
11124274|NCT03904966|Experimental|ESWT+ Kinesiotaping|Low-dye Kinesio taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
11124275|NCT03904966|Sham Comparator|ESWT+Shamtaping|Sham taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
11124276|NCT03904966|Other|ESWT|Extracorporeal shock wave therapy for 5 sessions (5-week)
11124277|NCT03904953|Experimental|Study group|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
11124278|NCT03904953|Active Comparator|Control group|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
11124279|NCT03904940|Experimental|Total Contact Insole Group|Ethyl vinyl acetate insole shaped in the cast of the patient's foot, every 6 months.
11124280|NCT03904940|Sham Comparator|Flat Insole group|Flat insole made the same material ethyl vinyl acetate, every 6 months.
11124281|NCT03904927|Experimental|Experimental Arm|The arm will be treated with combined chemotherapy and local therapy such as radiation, surgery or radiofrequency ablation.
11124282|NCT03904927|Active Comparator|Control Arm|The arm will be treated with chemotherapy alone.
11124283|NCT03904914||AIS group|Patients confirmed with adolescent idiopathic scoliosis (AIS)
11124357|NCT03904446|Experimental|Methylergonovine 0.2 mg|Standard Oxytocin Infusion at the time of Cesarean Section plus 0.2 mg of Intramuscular Methergine
11124284|NCT03904901|Active Comparator|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, drink with water and drink before bed. Probiotics contain a dose of 10 9 CFU per capsule.
11124285|NCT03904901|Placebo Comparator|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
11124286|NCT03904888|Other|l-TAPP without local anesthetics|These patients will undergo a laparoscopic surgery without local anaesthetics.
11124287|NCT03904888|Other|l-TAPP with local anesthetics|These patients will undergo a laparoscopic surgery with local anaesthetics.
11124288|NCT03904888|Other|r-TAPP without local anesthetics|These patients will undergo a robot-assisted surgery without local anaesthetics.
11124289|NCT03904888|Other|r-TAPP with local anesthetics|These patients will undergo a robot-assisted surgery with local anaesthetics.
11124290|NCT03904862|Experimental|Phase I - Skeletally-immature|Skeletally-immature children with refractory or recurrent medulloblastoma of the SHH group
11124291|NCT03904862|Experimental|Phase II - Skeletally-mature|Skeletally-mature subjects with refractory or recurrent medulloblastoma of the SHH group
11124292|NCT03904862|Experimental|Surgical|Subjects who are eligible for the Phase I or Phase II arm of the trial and are candidates for surgery, may be enrolled in the surgical arm prior to initiation of the Phase I or Phase II treatment.
11124293|NCT03904849|Active Comparator|Cannabidiol|Cannabidiol 6 mL of 100 mg/mL cannabidiol oral solution per day for 8 days
11124294|NCT03904849|Placebo Comparator|Placebo|Placebo 6 mL oral solution per day for 8 days
11124295|NCT03904836|Experimental|Tobramycin|Subjects with end-stage renal disease who have been involved in an intermittent hemodialysis program and who have suspected or diagnosed Gram-negative rod-type infection
11124296|NCT03904823|Experimental|famitinib, HS-10296|
11124297|NCT03904810|No Intervention|Control|Subjects in this group do not received any intervention
11124298|NCT03904810|Active Comparator|Moderate Intensity Continuous Training ×3/wk|Subjects in this group will receive three sessions of Moderate-Intensity Continuous Training per week throughout the 8 weeks experimental period
11124299|NCT03904810|Active Comparator|High Intensity Interval Training×3/wk|Subjects in this group will receive three sessions of High-Intensity Interval Training per week throughout the 8 weeks experimental period
11124300|NCT03904810|Active Comparator|High Intensity Interval Training×2/wk|Subjects in this group will receive two session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
11124301|NCT03904810|Active Comparator|High Intensity Interval Training×1/wk|Subjects in this group will receive one session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
11124302|NCT03904797|Experimental|e-PRO|EI service coordinators participated in a 90-minute training on the study protocol, to gain clearance to recruit families when they were being contacted to schedule their annual reviews of progress. The recruitment protocol was later modified in response to low enrollment, such that a designated EI staff member was paired with research staff to recruit participants. Eligible and interested caregivers visited the project website to create an account, confirmed study eligibility, provided informed consent and HIPAA authorization for abstracting select EI service use data, and completed a demographic questionnaire and the Young Children's Participation and Environment Measure (YC-PEM) e-PRO. Caregivers received immediate access to an online report summarizing their e-PRO responses to share with their child's EI team
11124303|NCT03904784||School withdrawal teenagers|The study is based on questionnaries, interview with teenagers and/or their familly
11124304|NCT03904771|Active Comparator|Food for Mind -intervention group|Nutrition counselling + peer support
11124305|NCT03904771|Active Comparator|Befriending group -control group|Social activation + peer support
11124306|NCT03904758|Experimental|Monitoring of pH with Restech|The patients with EER randomized into this arm will undergo pH monitoring using Restech system
11124307|NCT03904758|Experimental|Monitoring of oesophageal impedance|The patients with EER randomized into this arm will undergo monitoring of oesophageal impedance
11124308|NCT03904745|Experimental|Atosiban used before embryo transfer|the patients in this group will be administered 6,75mg atosiban intravenously.
11124309|NCT03904745|No Intervention|Control group|the patients in this group will not be administered atosiban before embryo transfer.
11124310|NCT03904732||Cohort 1|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention
11124311|NCT03904732||Cohort 2|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
11124312|NCT03904732||Cohort 3|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for primary prevention
11124313|NCT03904732||Cohort 4|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for secondary prevention
11124314|NCT03904732||Cohort 5|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
11124315|NCT03904732||Cohort 6|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
11124316|NCT03904732||Cohort 7|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for primary prevention
11124317|NCT03904732||Cohort 8|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for secondary prevention
11124318|NCT03904719|Experimental|CM082 plus JS001|CM082 tablets 150mg is orally given once daily in a 28-day cycle, combinational JS001 240mg was given intravenously on day 1 once every 21 days.
11124351|NCT03904498|Experimental|Placebo then Tolcapone|Participants in this arm will receive placebo during the first medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8), and tolcapone during the second medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8).
11124352|NCT03904485||SPKT|patients with end-stage diabetic nephropathy got simultaneous pancreas-kidney transplantation
11124353|NCT03904485||RT|patients with end-stage diabetic nephropathy got single kidney transplantation
11124354|NCT03904472|Experimental|Web-based CBTI|Participants will have 8 weeks to receive 6 therapy sessions. Content is dynamically driven by an animated therapist who guides the user through the program.
11124319|NCT03904706|Experimental|Audits only|"Formalized audit teams with monthly meetings at each facility.
~Audit Intervention phases:
~Identification of facility leadership (i.e physicians or leading health care providers) to be trained on best practices in obstetric and perinatal care in the implementation of the audits.
~Training of identified audit leaders (main investigator is typically a physician)
~a. 5-day training workshop to include: i. Day 1: maternal death and near misses, perinatal, neonatal deaths and morbidity outcomes ii. Day 2: 'Three-delay' framework and identifying modifiable factors iii. Day 3: data collection and setting up the audit system iv. Days 4-5: mentoring on the identification of the audit teams and initiating audit implementation
~Creating audit team (composed of at least two obstetricians, 2 pediatricians plus the main investigator)
~Establishing and launching the audit cycle (monthly meetings)
~Annual re-certification of audit leaders"
11124320|NCT03904706|Experimental|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
11124321|NCT03904706|No Intervention|Control|Monthly outcome data will be collected from health facilities where no audits will be conducted. Data from this group will help evaluate the effectiveness of the intervention arms on perinatal and neonatal mortality.
11124322|NCT03904693|Experimental|FDC therapy + Placebo macitentan + Placebo tadalafil|Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.
11124323|NCT03904693|Active Comparator|Macitentan mono-therapy + Placebo tadalafil + Placebo FDC|Subjects to receive macitentan 10 mg plus matching placebos for the two other study treatments.
11124324|NCT03904693|Active Comparator|Tadalafil mono-therapy + Placebo macitentan + Placebo FDC|Subjects to receive tadalafil 40 mg (2 x 20 mg) plus matching placebos for the two other study treatments.
11124325|NCT03904680|Active Comparator|Methotrexate|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.
11124326|NCT03904680|Active Comparator|Methotrexate and Vitamin D|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.
11124327|NCT03904667||Watson on oncology recommends surgery|
11124328|NCT03904667||Watson on oncology does not recommend surgery|
11124329|NCT03904654|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 60-minute consecutive weekly MBCT group sessions.
11124330|NCT03904641|Experimental|aPDT + ART group|In this group, both aPDT and ART will be performed.
11124331|NCT03904641|Experimental|ART group|In this group, only ART will be performed.
11124332|NCT03904628|Experimental|150 mg, BIW in every 28d|TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
11124333|NCT03904628|Experimental|200 mg, BIW in every 28d|TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
11124334|NCT03904628|Experimental|250 mg, BIW in every 28d|TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
11124335|NCT03904615|Active Comparator|Whey Protein|30 g of whey protein twice daily during hospitalization and for 30 days after discharge
11124336|NCT03904615|Active Comparator|Collagen Protein|30 g of collagen protein twice daily during hospitalization and for 30 days after discharge
11124337|NCT03904615|Placebo Comparator|Placebo|30 g of maltodextrin twice daily during hospitalization and for 30 days after discharge
11124338|NCT03904602|Experimental|Edema Wear|Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.
11124339|NCT03904589||Coronary Heart Disease|
11124340|NCT03904576|Experimental|Treatment (T)|
11124341|NCT03904576|Placebo Comparator|Reference Treatment (R)|
11124342|NCT03904563|Experimental|Bevacizumab|All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month break.Then every patients are treated with 6 courses of Bevacizumab 1-2 months later.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for 6 courses.
11124343|NCT03904550|Active Comparator|Cisatracurium + Neostigmine|Patients in the rocuronium/sugammadex group will receive 0.6 mg/kg of rocuronium for neuromuscular paralysis during induction. Additional rocuronium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
11124344|NCT03904550|Active Comparator|Rocuronium + Sugammadex|Patients in the cisatracurium/neostigmine group will receive 0.2 mg/kg of cisatracurium for neuromuscular paralysis during induction. Additional cisatracurium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
11124345|NCT03904537|Experimental|PD1-TIL combined with chemotherapy|Participants would received anti-PD-1 antibody-activated TILs after the final adjuvant chemotherapy.
11124346|NCT03904524|Experimental|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
11124347|NCT03904511|Experimental|Low Dose Souroubea-Platanus|190 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
11124348|NCT03904511|Experimental|High Dose Souroubea-Platanus|380 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
11124349|NCT03904511|Placebo Comparator|Placebo|Inert placebo in an identical vegicap to the experimental treatment groups. Administered once daily for 14 days.
11124350|NCT03904498|Experimental|Tolcapone then Placebo|Participants in this arm will receive tolcapone during the first medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8), and placebo during the second medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8).
11124355|NCT03904459||cases|Children with juvenile idiopathic arthritis
11124356|NCT03904459||controls|healthy children
11124358|NCT03904446|Placebo Comparator|Placebo (Normal Saline)|Standard Oxytocin Infusion at the time of Cesarean Section plus 1 milliliter (mL)of normal saline given intramuscular
11124359|NCT03904433|Experimental|1. Sunflower oil|Sunflower oil (30 g)
11124360|NCT03904433|Experimental|2. Caprylic acid|Caprylic acid (20 g) + Sunflower oil (10 g)
11124361|NCT03904433|Experimental|3. Caprylic acid + Glucose|Caprylic acid (20 g) + Sunflower oil (10 g) + Glucose (50 g)
11124362|NCT03904433|Experimental|4. Coconut oil|Coconut oil (30 g)
11124363|NCT03904433|Experimental|5. Coconut oil + Glucose|Coconut oil (30 g) + Glucose (50 g)
11124364|NCT03904433|Experimental|6. Coconut oil + Caprylic acid|Coconut oil (30 g) + Caprylic acid (20 g)
11124365|NCT03904420|Experimental|Group A - New Model|Standardized programming and testing method
11124366|NCT03904420|Active Comparator|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
11124367|NCT03904407|Experimental|Probiotic|Lactobacillus probiotic capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
11124368|NCT03904407|Placebo Comparator|Placebo|Matching Lactobacillus probiotic placebo capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
11124369|NCT03904394|Placebo Comparator|Placebo Mouthwash|
11124370|NCT03904394|Active Comparator|Antibacterial Mouthwash|
11124371|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in phakic eyes|
11124372|NCT03904381|Active Comparator|stand-alone procedure of XEN implantation in pseudophakic eyes|
11124373|NCT03904381|Active Comparator|XEN implantation combined with cataract extraction|
11124374|NCT03904368|Active Comparator|Myomectomy group|women with intramural myoma not reaching endometrial cavity will undergo open myomectomy followed by ovarian stimulation for in vitro fertilization 6 months after the operation
11124375|NCT03904368|Active Comparator|Conservative group|women with intramural myoma not reaching endometrial cavity will undergo ovarian stimulation for in vitro fertilization
11124376|NCT03904355|Active Comparator|Fiboroid group|Women with intramural myoma no reaching the cavity
11124377|NCT03904355|Active Comparator|Non fibroid group|Women without myomas
11124378|NCT03904342|Active Comparator|Sophie CBT|The Sophie Cognitive Behavioral Therapy (CBT) intervention is a tablet-based computerized CBT and self-management education intervention that consists of an evidence-based cognitive behavioral therapy self-management curriculum divided into 6 discrete modules. Patients will have up to 8 weeks to work through the modules on the tablet.
11124379|NCT03904342|Active Comparator|iHope CBT|iHope CBT is a telemedically-delivered CBT package. The iHope system comprises a HIPAA-compliant platform on which real, live, licensed clinicians provide cognitive behavioral therapy via video conferencing, phone calls, and text messaging. iHope will be delivered on subjects' preferred electronic device (mobile phone, laptop, tablet).
11124380|NCT03904329||Obese Patients with non valvular AF|Obese Patients with non valvular AF using oral anti coagulants
11124381|NCT03904316|Experimental|Biodesign graft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with an acellular matrix derived from porcine small intestine submucosa, Biodesign Otologic graft
11124382|NCT03904316|Active Comparator|Autograft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with autologous temporalis fascia.
11124383|NCT03904303|Experimental|Geloprep|Novel and patented Polyethylene glycol 3350 mixture
11124384|NCT03904303|Active Comparator|Moviprep|Standard of care Polyethylene glycol 3350 mixture
11124385|NCT03904290|Other|Pre-PFO closure|Subjects evaluated at 'baseline' prior to percutaneous closure of PFO, and re-evaluated at 3 months post percutaneous closure of PFO
11124386|NCT03904277||No PFO|Research subjects who present no evidence of PFO - IE no appearance of saline contrast microbubbles within 3 cardiac cycles
11124387|NCT03904277||Small PFO|Research subjects who present evidence of having a small PFO or ASD - IE appearance of 1-11 saline contrast microbubbles within 3 cardiac cycles
11124388|NCT03904277||Large PFO|Research subjects who present evidence of having a large PFO - IE appearance of 12+ saline contrast microbubbles within 3 cardiac cycles.
11124389|NCT03904264|Experimental|Hearing Aid Study|Measure the reduction in tinnitus handicap when mild amplification through receiver-in-the-canal hearing aids is provided to adults with bothersome tinnitus and normal hearing thresholds.
11124390|NCT03904264|No Intervention|VA Clinician Interviews|Document the opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. The data for this arm of the study will be collected via telephone interview.
11124391|NCT03904251|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin 44mg/m2 - cytarabine 100mg/m2 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab ozogamicin 3 mg/m2 (max 4.5 mg) IV over 120 minutes on day 7, or days 4 and 7, or days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi receive consolidation therapy at the discretion of the treating physician and/or proceed to allogeneic HSCT."
11124392|NCT03904238|Experimental|CBT-H (Individual format)|Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
11124393|NCT03904238|Experimental|CBT-H (Group format)|Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
11124394|NCT03904225|Experimental|tegio|Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation
11124395|NCT03904225|No Intervention|control|patients was oberved
11124396|NCT03904212|Active Comparator|Adipose tissue injection|Patients will be treated with freshly harvested autologous adipose tissue
11124397|NCT03904212|Placebo Comparator|Placebo|Patients will be treated with saline
11124756|NCT03901729|Experimental|Arm 2-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
11124398|NCT03904199|Experimental|Basal-Prandial-Correctional Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.
11124399|NCT03904199|Active Comparator|Standard of Care Insulin Regimen|Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.
11124400|NCT03904186|Experimental|QUIT Treatment for Smoking Cessation and Distress Tolerance|Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
11124401|NCT03904186|Active Comparator|Time and Intensity-Match Control|Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
11124402|NCT03904186|No Intervention|Standard of Care|At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
11124403|NCT03904173||EMIT-1 - Multi-parameter tests|Patients with hormone sensitive HER2 negative primary breast cancer without lymph node metastasis. Treatment recommendations will be based on the Prosigna test result, in addition to conventional clinicopathological parameters.
11124404|NCT03904160|Sham Comparator|Nurse-lead group|Nurse-lead sessions for weight management. Ten sessions lasting 90 minutes each in three groups of 10-14 participants. Each session comprise education about healthy diet, psychoeducation and discussions.
11124405|NCT03904160|Experimental|Web-based group|Web-based weight management system with peer-based conversation possibility. Three groups of 10-14 participants who gather together for three nurse-lead sessions in the weeks 0, 5, and 12. The web-based program can be used for a year.
11124406|NCT03904160|Experimental|Web-based personal|Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
11124407|NCT03904147|Experimental|Roll-In|TriClip Device treatment for physicians requiring additional training prior to beginning randomized cohort enrollment.
11124408|NCT03904147|Active Comparator|Randomized Cohort|TriClip (Device) Group vs. Medical Therapy (Control) Group
11124409|NCT03904147|Experimental|Single Arm|Subjects in which it is believed TR is not going to be reduced to moderate or less severity will receive the TriClip device.
11124410|NCT03904134|Other|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
11124411|NCT03904134|Other|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
11124412|NCT03904134|Other|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
11124413|NCT03904108|Experimental|Ramucirumab|Ramucirumab 10 mg/kg IV day 1, every 3 weeks for 4 cycles
11124414|NCT03904095|Active Comparator|Psoas compartment block group (PCB)|Single- shot ultrasound (Esaote Mylab30) guided PCB with 15 ml 0.25% bupivacain ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the PCB group (Group I).
11124415|NCT03904095|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the ESP group (Group II).
11124416|NCT03904095|Placebo Comparator|The Control group|The Control group receive no intervention ( Group III).
11124417|NCT03904082|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).
11124418|NCT03904082|Active Comparator|Serratus Anterior Plane Block Group (SAP)|Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).
11124419|NCT03904082|Placebo Comparator|Control Group|The Control group receive no intervetion ( Group III).
11124420|NCT03904069|Experimental|Comparison of different cell doses of AMG 553|Subjects will receive IV infusion of AMG 553
11124421|NCT03904056|Active Comparator|ETDRS-PRP group|Patients with proliferative diabetic retinopathy submitted to panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
11124422|NCT03904056|Experimental|ISQ-RP group|Patients with proliferative diabetic retinopathy submitted to retinal photocoagulation targeted to ischemic retina combined with intravitreal injection of ranibizumab (IVR) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
11124423|NCT03904043|Experimental|Radiation + FOLFOX|"Pelvic radiotherapy 5GY x 5 fractions once daily
~Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily
~FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).
~Oxaliplatin day 1 every 14 days
~Leucovorin day 1 every 14 days
~5-FU bolus day 1 every 14 days
~5-FU infusion day 1 every 14 days over 46 hours
~Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.
~An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted"
11124424|NCT03904030|Experimental|Anti-Gravity Treadmill rehabilitation|Patients in the intervention group are participating to the Alter G exercises (n=27). The groups are randomized, so after patients have signed consent, an envelop will be opened and there can be seen in which groups patients will participate.
11124425|NCT03904030|Active Comparator|Traditional rehabilitation|Traditional exercises with instructions are given to the patients (n=27) (as a control group).
11124426|NCT03904017|Experimental|Hyperoxia|Will receive 15liters per minute supplemental oxygen via a partial non-rebreather facemask.
11124427|NCT03904017|Placebo Comparator|Placebo|will receive 15liters per minute medical air via a partial non-rebreather facemask.
11124428|NCT03904004||Esophageal motility disorders|Individuals with sympmtoms related to esophageal motility disorders who receive a endoscopic or surgical treatment
11124429|NCT03903991||Thoracotomy|All patients needing pulmonary surgery under thoracotomy
11124430|NCT03903978|Experimental|CORE condition|CORE is a 6-week web-based prevention programme whose main objective is to teach coping skills and strategies to cope with stressful everyday situations in order to improve resilience, promote self-efficacy and increase well-being. The intervention consists of 6 interactive modules designed for weekly sessions and organized in 6 dimensions: autonomy, self-acceptance, environmental mastery, purpose in life, positive relationships, and personal growth. Each module includes exercises to practice the proposed skills. The program includes multimedia elements: videos, audios, vignettes, images.
11124431|NCT03903978|Active Comparator|Healthy lifestyle|This program will provide information to promote a healthy lifestyle, on issues related to physical and mental health and physical activity, as well as diet and sleep management. The components of psychoeducation are based on the intervention protocol for depression (Castro, et al. 2015) based on low intensity psychological intervention models for mild or moderate depressive symptoms in primary care (Garcia-Herrera et al 2011; NICE, 2009; Nieuwsma et al 2012).
11124432|NCT03903978|No Intervention|Waiting List Control|Participants assigned to the Waiting List control group will be evaluated and monitored at the start of the study, 4 weeks, 8 weeks and follow-ups at 3 months. After the last follow-up evaluation, they will be given access to CORE training.
11124433|NCT03903965||diabetic patients after cataract surgery|diabetic patients after cataract surgery
11124434|NCT03903965||non-diabetic patients after cataract surgery|non-diabetic patients after cataract surgery
11124435|NCT03903952|Other|Papanicolaou smear result (control group)|women who did not have intraepithelial neoplasia as a result of smear
11124436|NCT03903952|Other|Papanicolaou smear result (study group)|women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear
11124437|NCT03903939|Experimental|Iloprost|Patients randomized to active treatment (n = 110 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first
11124438|NCT03903939|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n= 110 patients) will receive continuous infusion of isotonic saline (equal volume) for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
11124439|NCT03903926|Experimental|Cohort one|5000 volunteers (6-35 months)-EV71 vaccine
11124440|NCT03903926|No Intervention|Cohort two|10000 unvaccinated volunteers (6-35 months)
11124441|NCT03903926|No Intervention|Cohort three|500 unvaccinated volunteers (36-71 months)
11124442|NCT03903913|Experimental|Dose Escalation Study|"Subjects will receive up to three inhaled doses of S- 1226. Each dose will be administered over a 2-minute treatment period (with a minimum 2-minute break between treatments) with a nebulizer as follows.
~Three S-1226 formulations will be tested sequentially:
~S-1226(4%) is composed of 3 mL PFOB and 4% CO2
~S-1226(8%) is composed of 3 mL PFOB and 8% CO2
~S-1226(12%) is composed of 3 mL PFOB and 12% CO2
~Each formulation will be administered by inhalation for a period of 2 minutes.The nebulizer will be filled with 3 mL of PFOB. The nebulizer is connected to a compressed medical gas mixture consisting of either 4%, 8% or 12%, CO2. A driving pressure of 20 psi will be used, producing a gas flow rate of 9 L/min."
11124443|NCT03903913|Experimental|Daily Dosing Study|"Eligible subjects will receive S-1226 twice daily for 5 consecutive days. Subjects will receive up to three doses of S-1226 in the morning and afternoon, administered over three 2-minute periods with a Circulaire nebulizer, filled with one of the dosages outlined below, depending on the safety and tolerability data gathered from the dose escalation study for that particular subject.
~S-1226(4%) is composed of 3 mL PFOB and 4% CO2
~S-1226(8%) is composed of 3 mL PFOB and 8% CO2
~S-1226(12%) is composed of 3 mL PFOB and 12% CO2"
11124444|NCT03903900|Experimental|Intervention group|Adults with chronic pain (n=48) matching the inclusion and exclusion criteria will be included.
11124445|NCT03903887|Experimental|PD1-TIL combined with chemotherapy|Participants would receive anti-PD1 antibody-activated TILs after the final cycle of adjuvant chemotherapy.
11124446|NCT03903874|Experimental|DIAL intervention|Deep south Interactive voice response system Active Lifestyle (DIAL) intervention. Participants will receive 12 months of automated physical activity phone counseling. Participants will report their physical activity to the IVR system each day for 3 months, twice/week in months 3-6, and once/week in months 6-12 and receive progress feedback via IVR system, along with community health worker support.
11124447|NCT03903874|No Intervention|Wait List Control|The wait list control participants will be instructed to maintain their normal routine until completion of the 6-month assessments and then receive the same 12-month DIAL intervention. To maintain engagement, these participants will be involved in monthly lunch and learns, focus groups, etc on cancer topics other than PA (e.g., screening) during the wait period.
11124448|NCT03903861|Experimental|Glucose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
11124449|NCT03903861|Experimental|Galactose alone|Participants will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
11124450|NCT03903861|Experimental|Glucose and galactose|Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
11124451|NCT03903848|Experimental|Exercise session|One session of physical exercise
11124565|NCT03903081|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC110114 tablet (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study
11124452|NCT03903835|Active Comparator|Control: Standard Care|Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.
11124453|NCT03903835|Experimental|Treatment 1: Enzalutamide|Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment of Abiraterone or Enzalutamide.
11124454|NCT03903835|Experimental|Treatment 2: Abiraterone|Patients with an intact androgen receptor (AR) and without TP53 mutations will have an increased chance of being randomised to treatment of Abiraterone or Enzalutamide.
11124455|NCT03903835|Experimental|Treatment 3: Carboplatin|DNA-repair deficient patients will have an increased chance of receiving Carboplatin.
11124456|NCT03903835|Experimental|Treatment 4: Cabazitaxel|Patients with the TMPRSS2-ERG gene fusion will have increased chance of receiving chemotherapy at study onset.
11124457|NCT03903835|Experimental|Treatment 5: Docetaxel|Patients with the TMPRSS2-ERG gene fusion will have increased chance of receiving chemotherapy at study onset.
11124458|NCT03903822|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
11124459|NCT03903822|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
11124460|NCT03903822|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
11124461|NCT03903822|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
11124462|NCT03903822|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
11124463|NCT03903822|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
11124464|NCT03903822|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
11124465|NCT03903822|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
11124466|NCT03903809|Experimental|HS-20039 Pegol-Sihematide|Pegol-Sihematide's starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 13 doses
11124467|NCT03903809|Active Comparator|ReHuman Erythropoietin Injection|ESPO(Recombinant Human Erythropoietin Injection) ESPO's starting dose was 6000 IU per week
11124468|NCT03903796|Experimental|HS-10234 25mg|HS-10234 + TDF placebo for up to 96 weeks
11124469|NCT03903796|Active Comparator|TDF 300mg|TDF + HS-10234 placebo for up to 96 weeks
11124470|NCT03903796|Experimental|Open-label HS-10234|All participants who complete the double-blind period (96 weeks) will be eligible to receive open-label HS-10234 until week 144 of the study.
11124471|NCT03903783|Active Comparator|Cefotaxime|
11124472|NCT03903783|Active Comparator|Ceftriaxone|
11124473|NCT03903770|Experimental|Intervention|Upper extremity rehabilitation
11124474|NCT03903757||Obese subjects with and without T2D|
11124475|NCT03903757||control subjects|
11124476|NCT03903744|Experimental|Treatment arm|Patients treated with cardioneuroablation.
11124477|NCT03903744|Active Comparator|Control arm|Patients treated with standard non-pharmacological methods.
11124478|NCT03903718|Experimental|MEDI8852 (dose 1) - part 1|Participants will receive a single intravenous infusion (IV) of MEDI8852 (dose 1)
11124479|NCT03903718|Sham Comparator|Placebo - part 2|Participants will received a single IV infusion of placebo ( matched to MEDI8852) on day 2
11124480|NCT03903718|Active Comparator|Oseltamivir (OS) 75 mg - part 2|Participants will receive 75 mg orally twice a day for 5 days starting at day 2
11124481|NCT03903718|Experimental|MEDI8852 (dose 2) - part 2|Participants will receive a single IV dose of MEDI8852 on day 2 (dose 2)
11124482|NCT03903718|Experimental|MEDI8852 (dose 1) - part 2|Participants will receive a single IV infusion of MEDI8852 on day 2 (dose 1)
11124483|NCT03903718|Experimental|MEDI8852 (dose 2) +OS 75 mg part 2|Participants will receive a single IV infusion of MEDI8852 (dose 2) on day 2 and 75mg of Oseltamivir twice a day for 5 days starting at day 2
11124484|NCT03903705|Experimental|VEGFR cohort:|Fruquintinib
11124485|NCT03903692|Experimental|Marine polysaccharide dressing|
11124486|NCT03903692|Active Comparator|Carboxymethylcellulose dressing|
11124487|NCT03903679|Active Comparator|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway supreme during the septal surgery.
11124488|NCT03903679|Sham Comparator|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
11124489|NCT03903666|Experimental|Cohort|47 Down syndrome patients age from 4 to 16
11124490|NCT03903653|Active Comparator|Chemodenervation + Serial Casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection and weekly serial casting Intervention = Weekly Serial Casting AND Botulinum Toxin A injection (350-400 units per treated limb)
11124491|NCT03903653|Active Comparator|Chemodenervation without serial casting|in this group a total of 10 patients will undergo Botulinum Toxin A injection. Intervention = Botulinum Toxin A injection (350-400 units per treated limb) alone.
11124492|NCT03903640|Experimental|Optune + Ipilimumab + Nivolumab|"Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
~Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses
~Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.
~Treatment may continue for up to 1 year"
11124493|NCT03903627|Experimental|Verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~(1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.
~Those who will not be able to contract will be taught by the ultrasound as a biofeedback."
11124566|NCT03903081|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg HEC110114 tablet (N=8) or matching placebo (N=2)
11124494|NCT03903614|Experimental|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
11124495|NCT03903614|Active Comparator|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
11124496|NCT03903601||Ischemic changes|Patients with ischemic changes in the brain diagnosed by MRI
11124497|NCT03903601||No ischemic changes|Patients without ischemic changes in the brain diagnosed by MRI
11124498|NCT03903588||Normal|Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
11124499|NCT03903588||Glaucoma|Eyes that have been diagnoses with Glaucoma
11124500|NCT03903588||Retinal Disease|Eyes that have been diagnoses with a Retinal Disease
11124501|NCT03903575|Experimental|En Masse Retraction|Group treated by retracting the six anterior teeth simultaneously.
11124502|NCT03903575|Active Comparator|Two-Step Retraction|Group treated by retracting the canines incisors in two different steps.
11124503|NCT03903562|Experimental|V503|V503 administered as a 0.5 mL intramuscular injection at Day 1, Month 2 and Month 6.
11124504|NCT03903549|Experimental|Brain uptake and kinetics in Parkinson patients|
11124505|NCT03903549|Experimental|Brain uptake and kinetics in healthy volunteers|
11124506|NCT03903549|Experimental|Dosimetry in healthy volunteers|
11124507|NCT03903536||Thrombectomy|Patients with thrombosed external hemorrhoids undergoing thrombectomy
11124508|NCT03903536||Local excision/ Hemorrhoidectomy|Patients with thrombosed external hemorrhoids undergoing local excision/ hemorrhoidectomy
11124509|NCT03903510|Experimental|Virtual Reality|Participants will experience Virtual Reality during their cast removal
11124510|NCT03903510|No Intervention|Standard of care|Participants will receive their usual standard of care treatment during cast removal
11124511|NCT03903497|Other|NBI assessment using the WASP classification|
11124512|NCT03903484|Experimental|Deprescribing intervention|Included patient participants will meet with their clinical pharmacist to complete a survey about medication use and quality of life. Then working with the pharmacist, patients will prioritize medications that are no longer needed for discontinuing. A deprescribing plan will be created and the pharmacist will work with the patient to complete this plan. The patient will also be provided resources from the study toolbox to support the patients as they work through deprescribing the targeted drugs. Once the deprescribing plan is completed there will be a patient survey that will capture satisfaction with the deprescribing experience and patient quality of life.
11124513|NCT03903471|Experimental|22G-ProCore Group|The experimental group with 22G-ProCore needle is expected to enroll 300 patients. The 22G-ProCore needle has a 1.5mm long groove 2.5mm above the needle tip, which is expected to have the advantage of taking more biopsy tissues than the 22G-Standard needle.
11124514|NCT03903471|Active Comparator|22G-Standard Group|The control group of 22G-Standard needle is expected to include 300 patients, and there is no groove above the needle tip compared with 22G-ProCore needle.
11124515|NCT03903458|Experimental|Tinostamustine and Nivolumab|Experimental drug combination arm
11124516|NCT03903445|Experimental|MaPa Kids|"Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids) Parenting training for parents of children aged 2-9
~Program length: 8 consecutive weekly sessions
~Incentive: PHP 500 or approximately £7 per participant
~Participants: N=15 per group"
11124517|NCT03903445|Experimental|MaPa Teens|"Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens) Parenting training for parents of children aged 10-17
~Program length: 9 consecutive weekly sessions
~Adult Incentive: PHP 500 or approximately £7 per participant
~Child incentive: PHP 300 or approximately £4 per participant
~Participants: N=15 per group"
11124518|NCT03903432|Other|45 participants, in one center - Assuta|Patients with chronic sinusitis who are scheduled to undergo ESS at Assuta will be recruited and patients will sign an informed consent form for performing MRI (new protocol-without gadolinium injection) in addition to the routine CT.
11124519|NCT03903419|Experimental|68Ga-PSMA PET-CT and 18F-FDOPA PET-CT|Functional imaging: 68Ga-PSMA and 18F-FDOPA PET-CT Immunohistochemistry of initial chirurgical sample with determination of PSMA expression
11124520|NCT03903393||preeclamptic women|systolic blood pressure(BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg; hypertension diagnosed after 20 weeks gestation; new-onset hypertension with new-onset proteinuria or other signs/symptoms of preeclampsia after 20 weeks or chronic proteinuria with newonset hypertension.
11124521|NCT03903393||controls|Normal pregnant women
11124522|NCT03903380|Active Comparator|MT treatment + Usual care exercise|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where usual care exercise protocol will be introduced.
~The manual therapy protocol that will be used is the one proposed by Beltrán-Alacreu et al. (2015). The mentioned protocol consist of specific passive movements in the facet cervical joints, global mobilization of the cervical spine and high-velocity technique in the thoracic región."
11124523|NCT03903380|Experimental|MT treatment + Augmented reality (AR) exercises|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where AR will be applied as an exercise method.
~The same manual therapy protocol will be used for both groups.
~For this group, the Microsoft HoloLens Development Edition device will be used, which is a holographic device that allows us to interact with high definition holograms in its environment. The application that will be used will be the Roboraid software, this app is a shooter, which requires the cervical movement to move the pointer and be able to play."
11124524|NCT03903367|Active Comparator|control|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
11124567|NCT03903081|Experimental|1200 mg single dose|Healthy subjects, receiving a single dose of 1200 mg HEC110114 tablet (N=8) or matching placebo (N=2)
11124568|NCT03903081|Experimental|1600 mg single dose|Healthy subjects, receiving a single dose of 1600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
11124525|NCT03903367|Active Comparator|paravertebral block|Bilateral thoracic paraverteberal catheters will be inserted preoperative at level of T4 in order to block thoracic dermatomal levels from T3-T7 and 0.3ml/kg 0.25% bupivacaine bouls dose in each catheter maximum 20 ml in each catheter before induction and testing sensation bilaterally by pinprick and ice after 15-20min from injection then standard GA and after tracheal intubation continuous infusion of 0.1 ml /kg/h 0.25% bupivacaine in each catheter and stopped at the end of the operation , When HR or MBP increased ≥20% from base line readings, increamental dose of fentanyl will be given (2mcg /kg), the catheters will be removed after 24 h.
11124526|NCT03903341|Other|idiopathic blepharospasm (BSP) de novo|bold signal in visual pathway
11124527|NCT03903341|Other|Healthy subjects|bold signal in visual pathway
11124528|NCT03903315||medical treatment alone|Patients with central malignant airway obstructions undergoing medical treatment alone
11124529|NCT03903315||endoscopic + medical treatment|Patients with central malignant airway obstructions undergoing medical and endoscopic treatment
11124530|NCT03903302|Active Comparator|CS 1 I SAD|Single dose pharmacokinetics of CS1 I
11124531|NCT03903302|Active Comparator|CS 1 II SAD|Single dose pharmacokinetics of CS1 II
11124532|NCT03903302|Active Comparator|CS 1 III SAD|Single dose pharmacokinetics of CS1 III
11124533|NCT03903302|Active Comparator|CS 1 II MAD|Multiple dose pharmacokinetics of CS1 II
11124534|NCT03903289|Experimental|Automated red cell exchange|Automated red cell exchange
11124535|NCT03903289|Active Comparator|Manual red cell exchange|Manual red cell exchange
11124536|NCT03903289|Sham Comparator|Simple red cell transfusion|Simple red cell transfusion
11124537|NCT03903276|No Intervention|Control|assessment of pain scale and functional capacity
11124538|NCT03903276|Experimental|Experimental|assessment of pain scale and functional capacity, TENS 30 minutes 3 sessions
11124539|NCT03903250|Placebo Comparator|Sugar|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
11124540|NCT03903250|Experimental|A-GPC|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
11124541|NCT03903224|Active Comparator|Combined PECS II and TTP blocks (PT)|"Modified Pectoralis block (PECS II) : Using ultrasound we proceed to inject 10 ml of bupivacaine 0.25% between the pectoral muscles and 10 ml under Pmm above the serratus muscle.
~Transversus Thoracic Plane block : 10 mL bupivacaine (0.25%) is injected between the transversus thoracic muscle and the internal intercostal muscle between the third and fourth left ribs connecting at the sternum."
11124542|NCT03903224|Active Comparator|Erector Spinae Block (E)|Using ultrasound an echogenic 22-G block needle is inserted in-plane in a cranial-to-caudal direction until contact is made with the T5 transverse process. A total of 30 bupivacaine 0.25% is then injected while seeing the fluid lifting the erector spinae muscle off.
11124543|NCT03903211|Experimental|Cognitively normal individuals|Cognitively normal individualswill receive a single IV injection of [18F]PI-2620.
11124544|NCT03903211|Experimental|Subjects with Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment will receive a single IV injection of [18F]PI-2620.
11124545|NCT03903211|Experimental|Subjects with Alzheimer Disease|Alzheimer Disease Subjects with Alzheimer Disease will receive a single IV injection of [18F]PI-2620.
11124546|NCT03903185|Active Comparator|HCV-infected patients with hematological malignancy|HCV-infected patients with hematological malignancy on maintenance chemotherapy
11124547|NCT03903185|Active Comparator|Control HCV-infected patients|Control HCV-infected patients without haematological malignancy or co-morbidities.
11124548|NCT03903172|Experimental|Binder Arm|Abdominal binder + standard of care postpartum pain management
11124549|NCT03903172|No Intervention|Standard of Care|Standard of care postpartum pain managment
11124550|NCT03903159|Other|Treatment Group|Positive Peer Journaling (PPJ)
11124551|NCT03903146|Experimental|Intervention Group|This group of participants was assigned to receive the intervention by the bicultural/bilingual team of Peer counselor and Lactation Consultant. An intensive support intervention (1 prenatal visit, 1 in-hospital visit, 1 home postpartum visit, and free phone calls) were conducted individually to mothers participating until 6 months after the birth of the infant.
11124552|NCT03903146|No Intervention|Control Group|All participants in this group received traditional prenatal care in the clinic and received the usual educational material (in their proficient language) about breastfeeding during prenatal care provided by the Special Supplemental Nutritional for Women, Infants, and Children (WIC) program implemented in the clinics. Women were also able to receive one breastfeeding consultation during their hospital stay in the birthing center as part of the actual protocol established in the UK Chandler Hospital (Baby-friendly Hospital that includes support of breastfeeding during hospital stay). Women in the usual care group did not have any contact with the study IBCLC/PC.
11124553|NCT03903133|Other|vitamin E supplementation|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
11124554|NCT03903120|Experimental|ASSIST|Study 1 and 2
11124555|NCT03903120|No Intervention|Delayed Control|Study 1 and 2
11124556|NCT03903120|Experimental|Massed ASSIST|Study 3
11124557|NCT03903120|Experimental|Distributed ASSIST|Study 3
11124558|NCT03903107|Placebo Comparator|Conventional His Bundle Pacing|Patients in this arm will receive permanent his bundle pacing using conventional fluoroscopy technique
11124559|NCT03903107|Experimental|Fluoroless His Bundle Pacing|Patients in this arm will receive permanent his bundle pacing utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure
11124560|NCT03903094||Subjects With Overactive Bladder Treatment|Subjects who have dispensing records for treatment of overactive bladder will be included
11124561|NCT03903094||Subjects Without Overactive Bladder Treatment|Subjects who do not have dispensing records for treatment of overactive bladder will be included
11124562|NCT03903081|Experimental|100 mg single dose|It includes two groups, one group is pilot study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=2) . Another group is formal study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=8) or matching placebo (N=2)
11124563|NCT03903081|Experimental|300 mg single dose|Healthy subjects, receiving a single dose of 300 mg HEC110114 tablet (N=8) or matching placebo (N=2)
11124564|NCT03903081|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
11124569|NCT03903081|Experimental|600 mg multiple doses|Healthy subjects, receiving 600 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
11124570|NCT03903081|Experimental|800 mg multiple doses|Healthy subjects, receiving 800 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
11124571|NCT03903081|Experimental|1000 mg multiple doses|Healthy subjects, receiving 1000 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
11124572|NCT03903068|Experimental|NEXALIN Stimulator Group|In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.
11124573|NCT03903068|Sham Comparator|Pseudo-Stimulator Group|In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.
11124574|NCT03903042||Group 1|Center 1: Traditional camera(Canon) vs Aurora camera
11124575|NCT03903042||Group 2|Center 2: Traditional camera(Zeiss) vs Aurora camera
11124576|NCT03903042||Group 3|Center 3: Traditional camera(Topcon) vs Aurora camera
11124577|NCT03903029||Low-dose (10mg) rosuvastatin|Four statin benefit groups per 2013 ACC/AHA guideline in Korea
11124578|NCT03903016|Experimental|Test (T)|Insulin Lispro (SAR342434), 200 Units/ml, single dose on day 1 of each period
11124579|NCT03903016|Active Comparator|Reference (R)|Insulin Lispro Sanofi® ,100 Units/ml, single dose on day 1 of each period
11124580|NCT03903003|Active Comparator|preoxygenation mask applied to the cesarean|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
11124581|NCT03903003|Active Comparator|high flow nasal oxygenation applied to the ceserian|In order to protect the mother from hypoxia, preoxygenation is performed with high flow nasal oxygenation mask before induction of anesthesia.
11124582|NCT03902990|Experimental|Dual task|Treadmill training + cognitive tasks + standard exercise programme
11124583|NCT03902990|Active Comparator|Single task|Treadmill training + standard exercise programme
11124584|NCT03902990|Active Comparator|Control|Standard exercise programme
11124585|NCT03902977|Experimental|Arm A|quilting
11124586|NCT03902977|Active Comparator|Arm B|conventional suture
11124587|NCT03902964||women treated for breast cancer in 2017 (cohort A)|all patients who completed breast cancer treatment between January 1 and May 31, 2017. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
11124588|NCT03902964||women treated for breast cancer in 2015 (cohorte B)|all patients who completed breast cancer treatment between January 1 and 31 May 2015. Withdrawal of men, metastatic patients from the outset, patients with a history of breast cancer or any other location, selection of 20 patients with breast cancer in situ at random
11124589|NCT03902951|Experimental|Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)|Patients receive leuprolide SC on day 1, Patients receive a single dose of leuprolide SC on day 1 and apalutamide PO QD and abiraterone acetate PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning 2 months of initiation of ADT, patients also receive SBRT over 1, 3, or 5 fractions in the absence of disease progression or unacceptable toxicity.
11124590|NCT03902938|Experimental|Biodesign Otologic Graft|Graft following canal wall down mastoidectomy.
11124591|NCT03902938|Active Comparator|Autograft temporalis fascia|Graft following canal wall down mastoidectomy.
11124592|NCT03902925|Experimental|Group 1- Sub-tenon plus lidocaine jelly|Patients are going to be submitted to lidocaine 2% jelly topical anesthesia for 5 minutes then to sub-tenon injection of 2-4 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
11124593|NCT03902925|Active Comparator|Group 2- peribulbar|Patients are going to be submitted to peribulbar injection of 4-6 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
11124594|NCT03902912|Experimental|prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
11124595|NCT03902899|Experimental|Intervention-arm|"All endoscopists employed by 9 semi-randomly chosen hospitals in the Netherlands will be exposed to an educational intervention (oral presentation): an oral awareness training which will be delivered twice, first in 2014 and then in 2016/2017.
~In total 38 endoscopists are included from these 9 hospitals."
11124596|NCT03902899|No Intervention|Control arm|A random set of 100 endoscopists will be selected ass a reference group. These 100 endoscopists were unaware of the present study, and were thus blinded for their allocation.
11124597|NCT03902886||cerebral palsy infants|gait analysis
11124598|NCT03902886||typically developed infants|gait analysis
11124599|NCT03902873|No Intervention|usual compression|A group who get no real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
11124600|NCT03902873|Active Comparator|real-time audiovisual feedback|A group who get the real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
11124601|NCT03902847|Experimental|Motor imagery|All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but previously, a mental practice based on kinesthetic mental motor imagery was performed. To reinforce the process of motor imagery, a video with the exercises was shown to the subjects before performing the mental practice. All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
11124630|NCT03902587||Cervical Elastography|During each sonogram in which cervical lengths are measured, 5 additional cervical indices will be collected using Samsung's E-cervix technology. Each index will then be separated based on characteristics to create a nomogram for singletons, twins, and those with interventions already in place (i.e. cerclage and/or progesterone) at the time of their E-cervix assessment.
11124631|NCT03902574|Experimental|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
11124632|NCT03902574|Experimental|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
11124792|NCT03901482|Experimental|STS101 High Dose|STS101 (dihydroergotamine nasal powder), high dose
11124602|NCT03902847|Experimental|Action observation|"All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but prior to the real execution, a video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
~All the participants also received a booklet with written information about the indications and exercises to be practiced at home to ensure that the training program was performed properly. Each week, participants received messages to remind and motivate them to undertake the exercise program daily."
11124603|NCT03902847|Active Comparator|Control group|The subjects in this group received an intensive training program based on stabilization exercises of lumbo-pelvic region, which are common exercises used in rehabilitation of patients with chronic non-specific low back pain.
11124604|NCT03902834|Experimental|Intervention|
11124605|NCT03902795||Group of 62 eyes|Group of 62 eyes with rhegmatogenous retinal detachment who underwent successful vitrectomy with SF6 tamponade
11124606|NCT03902782|Experimental|ESP block|patients will receive an ultrasound guided ESP block (technique as described by Forero et al) under strict sterile conditions in the operating room area. After identifying the T5 transverse process (TP) and after infiltration of lidocaine 2% subcutaneously. A 22g 100mm block needle will be advanced under vision, in a cephalad to caudad direction, until the tip contacts the T5 TP. 20 ml of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be injected under the erector spinae muscle. A visible separation of the erector spinae muscle from the TP will be the sign of a successful block. A 20 ml syringe of Normal Saline will be given to the surgeon (unaware of the content) at the end of the surgery, for the intercostal nerve block as per standard present technique.
11124607|NCT03902782|Sham Comparator|ESP sham block|patients will receive an ultrasound guided sham ESP block under strict sterile conditions in the operating room area as described above. 20 ml of Normal Saline will be injected under the erector spinae muscle. A 20 ml syringe of 0.25% bupivacaine with 5 mcg/ml of epinephrine and 10 mg dexamethasone will be given to the surgeon (blinded to the content) at the end of the surgery for the intercostal nerve block.
11124608|NCT03902769|Experimental|No allogeneic SCT|For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan
11124609|NCT03902769|Active Comparator|Standard post induction therapy|For slow responding AML patients, post induction therapy will be provided according to treating physician discretion
11124610|NCT03902756|Experimental|Flow-Volume loop guided endotracheal cuff inflation|Endotracheal cuff will be inflated by Flow-Volume loop guided until getting proper sealing.
11124611|NCT03902756|Active Comparator|Stethoscope-guided endotracheal cuff infration|Endotracheal cuff will be inflated by Stethoscope-guided until getting proper sealing.
11124612|NCT03902743|Experimental|Intervention group|Participants will receive an Anticipatory Care Plan
11124613|NCT03902743|No Intervention|Control group|Usual care
11124614|NCT03902730|Other|Back Squat Variation One|In a randomized order, traditional back squat will be completed.
11124615|NCT03902730|Other|Back Squat Variation Two|In a randomized order, barefoot back squat will be completed.
11124616|NCT03902730|Other|Back Squat Variation Three|In a randomized order, box squat will be completed.
11124617|NCT03902730|Other|Back Squat Variation Four|In a randomized order, traditional back squat with chains will be completed.
11124618|NCT03902717||minimally invasive cardiac surgery|Group of patients that will undergo minimally invasive cardiac surgery
11124619|NCT03902704|Experimental|Cleverscope|Cleverscope is a new videolaryngoscope used for tracheal intubation. in this group we use this device to intubate participants.
11124620|NCT03902704|Active Comparator|Laryngoscope / Videolaryngoscope C-MAC® Storz|in this group we use a standart comercial device for intubation (laryngoscope or C-MAC) to intubate participants
11124621|NCT03902691|Experimental|Pegol-Sihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks.
11124622|NCT03902691|Active Comparator|ESPO (Recombinant Human Erythropoietin Injection）|ESPO administration 1 to 3 times per week.
11124623|NCT03902678|Experimental|EUS - FNA for benign PVT by imaging|Intervention: Procedure/Surgery: EUS guided fine needle aspiration of portal vein thrombus
11124624|NCT03902665|Experimental|Allogeneic hematopoietic stem cell transplantation|Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor
11124625|NCT03902652|Experimental|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.
~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.
~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.
~During CC+SI the clinical team will only use 21% oxygen."
11124626|NCT03902652|Active Comparator|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.
~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.
~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.
~During CC+SI the clinical team will only use 100% oxygen."
11124627|NCT03902626||Physiotherapy students|Degree course
11124628|NCT03902626||Medical students|Degree course
11124629|NCT03902613|Experimental|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
11124636|NCT03902535||Group I (geriatric and quality of life assessments)|Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion.
11124637|NCT03902535||Group II (quality of life assessment)|Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
11124638|NCT03902522|Experimental|Leronlimab (PRO 140)|Subjects will be on existing ART for one week followed by PRO 140 700mg weekly SC Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
11124639|NCT03902509|Experimental|Pirfenidone|pirfenidone + basic treatment
11124640|NCT03902509|Other|Controll|with basic treatment and without pirfenidone treatment
11124641|NCT03902496|Experimental|Avulux Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
11124642|NCT03902496|Sham Comparator|Sham Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
11124643|NCT03902470|Experimental|Thoracic epidural anaesthesia for vats|"Patients in thoracic epidural (TE) group will pre-medicated using midazolam 3-4 mg intravenous (IV)and fentanyl 50 mcg intravenously(i.v.). Then patients will placed in the lateral decubitus position. An epidural catheter will be inserted between T3-T4 and T4-T5 for all thoracic procedures except sympathectomy and thymectomy. A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5% and 50 mcg of fentanyl.
~The objective is to achieve sensory and motor block between C7 and T7 levels. At this level diaphragmatic respiration is maintained. The anaesthesia level will be monitored by warm-cold discrimination."
11124644|NCT03902470|Active Comparator|General anesthesia for vats|Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
11124645|NCT03902457|Experimental|test site|The sinus mucosa will be elevated and, at the test sites, a collagen membrane will be placed subjacent the sinus mucosa
11124646|NCT03902457|Experimental|control site|The sinus mucosa will be elevated and, at the control sites, a collagen membrane will not be placed subjacent the sinus mucosa
11124647|NCT03902444||Credo® Stent and NeuroSpeed® PTA balloon catheter|Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine
11124648|NCT03902431|No Intervention|Control|CVD risk prior to the patient and clinician training
11124649|NCT03902431|Experimental|Training|CVD risk after the patient and clinician training
11124650|NCT03902405|Active Comparator|Active CEASAR Intervention|"Participants will be given the active CEASAR intervention where they will be trained to avoid cues associated with stimulant use and approach healthy cues based on the orientation of the images presented. Individuals will be asked to approach (pull in) portrait images and avoid (push away) landscape images. In the active condition, pushed pictures (landscape orientation) will exclusively be stimulant-use related pictures. Conversely, healthy images will be in the portrait orientation which will be pulled in."
11124651|NCT03902405|Placebo Comparator|Placebo CEASAR|In the control condition, stimulant use-related pictures will be randomized and equally divided into push (landscape) and pull (portrait) conditions.
11124652|NCT03902392|Active Comparator|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
11124653|NCT03902392|Placebo Comparator|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
11124654|NCT03902379|Experimental|Supportive Care (CCI intervention)|Patients complete 3 modules of online CCI intervention.
11124655|NCT03902366||AUD+/HCV+|"With current Alcohol Use Disorder and with HCV
~About to initiate DAA therapy for HCV"
11124656|NCT03902366||AUD-/HCV+|"Without current Alcohol Use Disorder and with HCV
~About to initiate DAA therapy for HCV"
11124657|NCT03902366||AUD+/HCV-|-With Alcohol Use Disorder and without HCV
11124658|NCT03902366||AUD-/HCV-|-Without Alcohol Use Disorder and without HCV
11124659|NCT03902353|Other|Adults without diagnosis of PH|Adults without diagnosis of PH carrying an heterozygous EIF2AK4
11124660|NCT03902340|Experimental|TENS|Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS)
11124661|NCT03902340|Active Comparator|level 2 systemic analgesic treatments|Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity.
11124662|NCT03902327|Experimental|NAC group|NAC for 12 weeks, 1.6 mg/day, 4x400 mg; a diet based on general recommendations for people with carbohydrate metabolism disorder
11124663|NCT03902327|Active Comparator|Control group|Placebo for 12 weeks and a diet based on general recommendations for people with carbohydrate metabolism disorder
11124664|NCT03902314|Active Comparator|Lidocaine|Lidocaine infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
11124665|NCT03902314|Placebo Comparator|Saline|Saline infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
11124666|NCT03902301|Active Comparator|Dietary group|A diet based on general recommendations for people with insulin resistance for 20 weeks.
11124667|NCT03902301|Experimental|Lactobacillus rhamnosus group|Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.
11124668|NCT03902288|Experimental|Patients with type 2 diabetes|Patients with type 2 diabetes at early stages of type 2 diabetes (FSG: 7.1 15.8 mmol/L)
11124669|NCT03902288|Active Comparator|Healthy individuals|Healthy individuals match age and gender to the experimental group
11124670|NCT03902275|Experimental|Quantra|Evaluation of bloodsamples using the Quantra and Multiplate device
11124671|NCT03902275|Active Comparator|Control|Evaluation of bloodsamples using the ROTEM and Multiplate device
11124672|NCT03902249|Active Comparator|Dexamethasone group|Patients who received 0.15mg/kg of Dexamethasone in 8ml of saline
11124673|NCT03902249|Placebo Comparator|Placebo group|Patients who received the same volume of saline as the study group (8ml)
11124674|NCT03902236||Cystic fibrosis group|Children diagnosed with cystic fibrosis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
11124675|NCT03902236||Bronchiectasis group|Children diagnosed with bronchiectasis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
11124676|NCT03902236||Healthy group|Healthy children more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
11124677|NCT03902223|Experimental|Enhanced Screening Protocol For Cardiac Sarcoidosis|Arm will be randomly assigned to undergo enhanced screening methods (ambulatory ECG and echocardiogram) at month 0 and month 24, as well as a phone call/chart review at month 12.
11124678|NCT03902223|Active Comparator|Routine Screening for Suspected Cardiac Sarcoidosis|Arm will be randomly assigned for the routine standard of care/no intervention with enhanced screening methods. They will be offered the EKG and symptom check at months 0 and 24, as well as a phone call/chart review at month 12.
11124679|NCT03902210|Experimental|Online Yoga|The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety & modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.
11124680|NCT03902210|Placebo Comparator|Podcast|The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
11124681|NCT03902197|Experimental|CD19 hsCAR-T|This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR
11124682|NCT03902184|Experimental|Cohort 1: Relapsed/refractory Sezary Syndrome|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
11124683|NCT03902184|Experimental|Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
11124684|NCT03902184|Experimental|Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
11124685|NCT03902171||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
11124686|NCT03902171||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
11124687|NCT03902158|Experimental|Glasses|
11124688|NCT03902158|No Intervention|Distraction techniques|No glasses will be used
11124689|NCT03902145||Intervention Group|Children previously in the intervention group received one egg per day for 6 months beginning when the child was between 6-9 months of age.
11124690|NCT03902145||Control Group|
11124691|NCT03902132|Experimental|Core Stability exercises group|Core Stability exercises
11124692|NCT03902132|Active Comparator|Traditional low back physical therapy group|Traditional low back physical therapy management
11124693|NCT03902119|Experimental|INIBY tool|Patients will undergo a single treatment session consisting of applying a suboccipital muscle inhibition technique using the so-called INYBI tool. The treatment session will last approximately 5 minutes
11124694|NCT03902119|Active Comparator|Manual suboccipital inhibition|Patients will receive a single treatment session consisting of the use of the manual suboccipital muscles inhibition technique.The treatment session will last approximately 5 minutes
11124695|NCT03902106|Active Comparator|beta2-agonist and exercise|Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
11124696|NCT03902106|Sham Comparator|placebo and exercise|Subjects undergo exercise training with administration of sham placebo
11124697|NCT03902093|Experimental|Hearing Aid|Actual Patients in the clinic will be evaluated by their Audiologist, if they are candidates to use the Lyric Hearing aid they will be asked if they want to participate in the study which will include imaging of the ear canal with a device similar to the regular ear device used in the clinic to check if there are any changes to the morphology of the ear canal.
11124698|NCT03902080|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
11124699|NCT03902080|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 24 weeks.
11124700|NCT03902067|Experimental|UC-MSC|UC-MSC transplantation
11124702|NCT03902054|Experimental|Experimental Group - High dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV
11124703|NCT03902054|Experimental|Experimental Group - Medium dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV
11124704|NCT03902054|Experimental|Experimental Group - Low dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of low dosage investigational sIPV
11124705|NCT03902054|Active Comparator|Control Group -commercialized sIPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV
11124706|NCT03902054|Active Comparator|Control Group -commercialized IPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV
11124707|NCT03902041||Treatment Group|The patients will receive Eltrombopag treatment after transplantation at d1.
11124708|NCT03902041||Control Group|The patients will not receive Eltrombopag treatment after transplantation.
11124709|NCT03902028|Experimental|Reinforced multidisciplinary follow-up|"Entrance medication reconciliation performed by a pharmacist
~Patient compliance evaluation
~Patient quality of life evaluation
~Pharmaceutical analysis with focus on medication optimization with a specific check-list (according to ESC 2016 recommendations)
~Hospitalisation discharge medication reconciliation
~Patient pharmaceutic interview at the hospitalisation discharge
~Transmission of informations to the general practitioner and the pharmacist's patient
~Multidisciplinary consult at 1 month after hospitalisation discharge"
11124710|NCT03902028|No Intervention|Standard care|"Drug review by a paramedic or a pharmacist
~Pharmaceutical analysis
~Therapeutic optimisation based on the usual practices care of the cardiologic department
~Writing of the prescription given on leaving hospital based on the usual care of the department
~Treatments explanations and support to the patient on the usual care
~Transmission of the hospitalisation report to the patient general practitioner as the usual practice
~Medical consult in usual time frames (an average of 1 month after hospitalisation discharge) at the patient location of choice"
11124711|NCT03902015|Experimental|Nuance Phone case|"Nuance Hearing has developed a technology enabling focused hearing. The Selective Noise Cancellation (SNC) technology consists of an advanced beam-forming algorithm that tones down the ambient sound by up to 15 decibels (dB) in order to focus on a primary audio source. The device consists of a special phone case(for iPhone) containing microphone array. Controlling the direction of focus is enabled through the use of a designated app. The user can place the phone case on his/hers table and can choose the direction of preferred listening, without having to ask the talker to hold the device."
11124712|NCT03902002|Experimental|Group 1: matched healthy subjects|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
11124713|NCT03902002|Experimental|Group 2: subjects with mild hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
11124714|NCT03902002|Experimental|Group 3: subjects with moderate hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
11124715|NCT03902002|Experimental|Group 4: subjects with severe hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
11124716|NCT03901989|Active Comparator|zeolite|50 subjects receive the substance 3 times per day as powder
11124717|NCT03901989|Placebo Comparator|cellulose|50 subjects receive the substance 3 times per day as powder
11124718|NCT03901976|Other|Bed Exit Detection On|prevention of fall by a true bed exit detection
11124719|NCT03901963|Experimental|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
11124720|NCT03901963|Active Comparator|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
11124721|NCT03901950|Experimental|XNW7201|
11124722|NCT03901937|Placebo Comparator|Placebo|parenteral nutrition without ω-3 polyunsaturated fatty acid
11124723|NCT03901937|Experimental|ω-3 fatty acid|parenteral nutrition with ω-3 polyunsaturated fatty acid
11124724|NCT03901924|Active Comparator|Volume Support Mode Mechanical Ventilation|Volume support mode ventilation is a spontaneous mode where a target goal volume is set on the ventilator. This ventilatory strategy is dependent on patients spontaneously breathing and triggering (or activating) the ventilator to support the breath. The ventilator adjusts the amount of pressure support to deliver with each breath (i.e. if the patient's tidal volume is greater than the set target volume, then the ventilator will decrease the amount of pressure support in the subsequent breath to try to achieve the goal volume and vice versa). The respiratory rate is not set in this mode of ventilation and is dependent on the patient. For patients randomized to this mode, the goal tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
11124725|NCT03901924|Active Comparator|Assist Control Mode Mechanical Ventilation|In assist control mode ventilation, the machine is programmed to deliver a set tidal volume and set respiratory rate. Patients can breathe over the set respiratory rate, but the volume of breath that they receive is fixed and delivered by the ventilator. For patients randomized to this mode, the tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
11124757|NCT03901729|Active Comparator|Arm 2-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
11124793|NCT03901482|Placebo Comparator|STS101 Placebo|STS101 Placebo
11124726|NCT03901898|Experimental|Training, audit, and reminders|An investigator will deliver a 20-30-minute briefing on intervention delivery to all staff at participating practices, followed by one-on-one audit training (1 hour) with the staff member responsible for conducting the audit. Each practice conducts an audit of their patients with diabetes to identify all people who have not attended retinopathy screening with the national programme. At 6 months, practices conducts a re-audit. Practice staff add electronic alerts to the records of eligible patients, to prompt GPs and nurses to remind patients. Practices are reimbursed at study entry with further payment following intervention cessation based on number of patients audited. Face-to-face verbal reminders are delivered by GPs and practice nurses to eligible patients attending for an appointment during the study period. All eligible patients receive a reminder phone call from a practice nurse and a GP-endorsed reminder letter accompanied by an information leaflet.
11124727|NCT03901898|Other|Wait list control|In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
11124728|NCT03901885|Other|Major women operated for deep endometriosis|Major women operated for deep endometriosis at the Lyon Sud Hospital Center (CHLS) of the Hospices Civils de Lyon (HCL).
11124729|NCT03901872||Acute Iliofemoral DVT|Suitable patients would be invited to take part in this trial as part of standard of care.
11124730|NCT03901859||Patients with ADHD|drug-naive patients with ADHD, aged 7-18 year old
11124731|NCT03901859||Healthy Controls|drug-naive healthy controls, aged 7-18 year old
11124732|NCT03901846|Other|ColdZyme|"The study is intended to verify the method used to measure the duration of ColdZyme®.
~Each participant will be his own control as samples are taken before application of ColdZyme and used as an internal control."
11124733|NCT03901833|Experimental|Telemedicine Support|Weekly telemedicine breastfeeding support visits for four weeks, delivered via telemedicine
11124734|NCT03901833|Placebo Comparator|Control|Standard of care
11124735|NCT03901820|No Intervention|DrApp Without SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
11124736|NCT03901820|Experimental|DrApp With SIMDA|There are approximately 100 inpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (SIMDA).
11124737|NCT03901807|Experimental|PMX Treatment|Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)
11124738|NCT03901807|No Intervention|Control|Standard medical care alone
11124739|NCT03901794||With Clear Sight|record and observe the data including SVI, CI, SVR with clearSight during hemodialysis
11124740|NCT03901781|Experimental|Cohort One|Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
11124741|NCT03901781|Experimental|Cohort Two|Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
11124742|NCT03901781|Experimental|Cohort Three|Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
11124743|NCT03901768|Experimental|Group dexamethasone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
11124744|NCT03901768|Experimental|Group triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
11124745|NCT03901768|Experimental|Group dexamethasone with triamcinolone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
11124746|NCT03901768|Placebo Comparator|Placebo group|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
11124747|NCT03901755||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
11124748|NCT03901755||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
11124749|NCT03901742|Active Comparator|Standard Enteral Nutrition|Standard Enteral Nutrition: cow's milk based infant formula (Nidina, Nestlé, Barcelona, Spain).
11124750|NCT03901742|Active Comparator|Protein-enriched nutrition|Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain)
11124751|NCT03901742|Active Comparator|High Protein-enriched Nutrition|High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
11124752|NCT03901729|Experimental|Arm 1|BAY1753011 30mg in addition to standard of care (SoC) for part A and part B
11124753|NCT03901729|Placebo Comparator|Arm 2|Placebo of BAY1753011 in addition to SoC for part A and part B
11124754|NCT03901729|Experimental|Arm 1-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
11124755|NCT03901729|Active Comparator|Arm 1-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
11124758|NCT03901716|Experimental|Sufentanil|Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
11124759|NCT03901716|Experimental|Fentanyl|Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
11124760|NCT03901716|Experimental|Remifentanil|Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
11124761|NCT03901703|Active Comparator|Dorsiflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their dorsiflexor muscles alongside standard functional progressive strengthening exercises.
11124762|NCT03901703|Active Comparator|Plantarflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their plantarflexor muscles alongside standard functional progressive strengthening exercises.
11124763|NCT03901703|Active Comparator|Dorsiflexor and Plantarflexor Muscle strengthening Group|The children in this group will receive functional exercises aiming to strengthen both their dorsiflexor and plantarflexor muscles alongside standard functional progressive strengthening exercises.
11124764|NCT03901690|Experimental|Arm Betaglucin|It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.
11124765|NCT03901690|Active Comparator|Arm Imiquimod|51 individuals between the ages of 18 and 50 will receive 5% imiquimod.
11124766|NCT03901677|Experimental|Tai-chi training|Tai-chi training performe as a group exercise. Duration for tai chi exercise will be 60 minutes for 2 days per week for 12 weeks. Each session includes 10 min warm-up and cool-down and 40 min Tai Chi exercises. During exercises, attention paid to correct positioning of the upper and lower extremity joints, and mentally concentration achieve. Slow and controlled movements will carry out by a specialized physiotherapist.
11124767|NCT03901651|Active Comparator|Standard colonoscopy|"Patients submitted for screening, surveillance or diagnostic colonoscopy. A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.
~Each polyp and adenoma will be recorded, including the size and location. Polyps will be removed before the second procedure."
11124768|NCT03901651|Experimental|Retroview colonoscopy|"The same group of patients. A second colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the first colonoscopy findings.
~The operator will record the polyps and adenoma encountered, describing the size and location."
11124769|NCT03901638|Experimental|Tllsh2910 to placebo|Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
11124770|NCT03901638|Experimental|Placebo to Tllsh2910|Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks
11124771|NCT03901625|Active Comparator|ManualTB+Floss|Cleaning teeth with a manual toothbrush and a dental floss three times a day.
11124772|NCT03901625|Experimental|ManualTB+Waterjet|Cleaning teeth with a manual toothbrush and a waterjet three times a day.
11124773|NCT03901625|Experimental|Electric TB+Floss|Cleaning teeth with an electric toothbrush and dental floss three times a day .
11124774|NCT03901625|Experimental|Electric TB +Waterjet|Cleaning teeth with an electric toothbrush and a waterjet three times a day .
11124775|NCT03901612|Placebo Comparator|Saline solution|Post operative analgesia throw the thoracic Erector spinae catheter with saline solution and opioid rescue
11124776|NCT03901612|Experimental|Ropivacaine|Post operative analgesia throw the thoracic Erector spinae catheter with Ropivacaine 0.2% solution and opioid rescue
11124777|NCT03901599||Children between 5-10Kg|Children with a body weight between 5-10Kg
11124778|NCT03901599||Children between 10-20Kg|Children with a body weight between 10-20Kg
11124779|NCT03901599||Children between 20-40Kg|Children with a body weight between 20-40Kg
11124780|NCT03901586|Experimental|Patients who had Richter intervention|
11124781|NCT03901573|Experimental|Checkpoint Inhibitor-Naive cSCC, MCC Pts|Anti-PD-1/PD-L1 naïve patients with cSCC and MCC
11124782|NCT03901573|Experimental|Checkpoint Inhibitor-Relapsed/Refractory cSCC MCC Melanoma Pts|Anti-PD-1/PD-L1 relapsed/refractory patients with cSCC, MCC and melanoma
11124783|NCT03901547|Other|Education and Documentation (Tier 1)|Education only. Participants who do not wish to enroll in the behavioral observation group are followed in the education only. This includes participation in a two week palliative medicine elective which is a part of the medical trainees training and training in the serious illness communication guide (SICG). Participants can opt out of the pre and post training confidence surveys, and simulated patient encounters. Electronic documentation of the SICG by these trainees will be monitored prospectively. Participants will be provided reminders and profile information on their own documentation rate of the SICG via email and have the ability to opt out of receiving emails if they wish.
11124784|NCT03901547|Other|Priming and additional measures (Tier 2)|Education and behavioral observation cohort. These participants must sign an informed consent to participate in this part of the study. In addition to all of Tier 1 activities, participants also complete psychological inventories at three time points to measure emotion regulation and burnout, and participate in a semi-structured interview.
11124785|NCT03901534|Other|Moderate to Severe OSA - treated|Moderate-to-severe OSA Treated with and adherent to Auto-CPAP
11124786|NCT03901534|Experimental|Moderate to Severe OSA - withdrawal|Moderate-to-severe OSA Withdrawal of Auto-CPAP
11124787|NCT03901508|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
11124788|NCT03901508|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
11124789|NCT03901495|Experimental|Diaana|"The patient fullfill Diaana
~The resident physician takes connaissance of the Diaana summary
~The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)
~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
11124790|NCT03901495|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)
~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
11124794|NCT03901469|Experimental|Experimental: ZEN003694 in Combination with Talazoparib|ZEN003694 will be administered orally once daily with Talazoparib orally once daily in 28-day cycles, enrolling TNBC patients. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2
11124795|NCT03901456|Experimental|Treatment|Participants in the treatment arm will receive the Care to Plan (CtP) intervention.
11124796|NCT03901456|Active Comparator|Control|Usual care
11124797|NCT03901430|Experimental|Class|Group navigation model
11124798|NCT03901417|Active Comparator|Non-ablative Fractional Laser|Non-ablative fractional laser (brand name Fraxel Restore) only on one half of the face.
11124799|NCT03901417|Active Comparator|Non-ablative Fractional Laser Plus Microneedling|Non-ablative fractional laser (brand name Fraxel Restore) in combination with a microneedling device (SkinPen) on the other half of the face.
11124800|NCT03901391||Retinitis Pigmentosa|
11124801|NCT03901378|Experimental|Single Arm|Pembrolizumab 200mg IV day 1 with Carboplatin AUC 6 IV day 1 or Cisplatin 80mg/m2 day 1 with etoposide 100mg/m2 days 1-3 of 21 day cycle. Repeat 4-6 cycles to be followed by maintenance Pembrolizumab 200mg IV day 1 every 21 days until progression or intolerance for up to 2 years.
11124802|NCT03901365|Experimental|Group 1|Patient received manual therapy in addition neuroscience pain education sessions
11124803|NCT03901365|Active Comparator|Group 2|Patient received manual therapy in addition tradition education sessions
11124804|NCT03901352|Experimental|Mirogabalin|"The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
~The patients with creatinine clearance (CLcr) 30 to < 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose"
11124805|NCT03901352|Placebo Comparator|Placebo|Placebo (14-weeks)
11124806|NCT03901339|Experimental|Sacituzumab Govitecan|Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day cycle)
11124807|NCT03901339|Active Comparator|TPC Comparator|"TPC determined prior to randomization.
~Per NCCN guidelines (with dose modifications for if toxic) Eribulin; Capecitabine; Gemcitabine; Vinorelbine"
11124808|NCT03901326|Experimental|CTA/CT-FFR care group|If the subjects are randomly allocated to CTA/CT-FFR arm, they will be examined by DeepFFR for three major epicardial arteries. If CT-FFR value of one or more major coronary arteries is less than 0.75, ICA will be performed directly; if CT-FFR is 0.75-0.8 (including 0.8), physicians will decide whether to start intensive drug therapy or ICA; if CT-FFR value is more than 0.8, only drug therapy will be needed. The clinical management plan will be suggested including optimal medical therapy, ICA, PCI, CABG and other intervention according to the result of this non-invasive examination.
11124809|NCT03901326|No Intervention|routine clinically-indicated diagnostic care group|If the subjects are randomized to CID arm, attending physicians will decide next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.
11124810|NCT03901313|Experimental|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
11124811|NCT03901313|Experimental|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
11124812|NCT03901313|Experimental|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
11124813|NCT03901313|Experimental|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
11124814|NCT03901313|Experimental|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
11124815|NCT03901313|Experimental|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
11124816|NCT03901300|Experimental|Fundamental Motor Skills (FMS)|The FMS group will utilize the PLAY FMS app that provides instructional lessons, peer modeling videos, and activity breaks to deliver 720 minutes of targeted, structured FMS instruction time to the child over a 12 week period.
11124817|NCT03901300|Active Comparator|Unstructured Physical Activity|The active comparator group will use a version of the PLAY app that provides instructional lessons to promote the equivalent dosage of unstructured physical activity for the child.
11124818|NCT03901287|Experimental|dual energy CT|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
11124819|NCT03901274|Active Comparator|Clinical Services Support Condition|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework.
11124820|NCT03901274|Experimental|Patient-Centered Enhancements|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework. The clinicians in this condition will receive additional training on two Patient-Centered Enhancements (PCE).
11124821|NCT03901261|Experimental|Down syndrome patients|
11124822|NCT03901248||Normoglycemia|Participant with normal blood glucose level with No Intervention
11124823|NCT03901248||Impaired Glucose Tolerance|Participants with Impaired Glucose Tolerance blood glucose level with No Intervention
11124824|NCT03901248||Type 2 Diabetes|Newly diagnosed type 2 diabetes patients with No Intervention
11124825|NCT03901235|Experimental|Mesenchymal Stromal Cells|
11124826|NCT03901222|Active Comparator|Bi-Anodal tDCS|Subjects will receive 20 min of bi-anodal tDCS
11124827|NCT03901222|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
11124921|NCT03900611|No Intervention|healthy control|
11125455|NCT03897023||Stable patient|Stable patients who admitted to ICU for observation.
11124828|NCT03901209|Experimental|Laser osteotomy|The planned mid-face osteotomy (e.g. LeFort I) is performed using the CARLO osteotomy device, where a patient-specific intervention plan based on preoperative imaging is loaded on the system to allow the device to show and suggest a location for the osteotomy.
11124829|NCT03901196||Interstitial Lung Disease|Ex : sarcoidosis, IPF
11124830|NCT03901183|Experimental|Interventional|Participants receive a 8 week nutritional counseling with weekly group meetings to establish a plant-based diet.
11124831|NCT03901183|No Intervention|Control|Waiting list. Participants receive no intervention during study period, equal intervention is offered after the end of study.
11124832|NCT03901170|Experimental|letrozole|patients with letrozole
11124833|NCT03901170|No Intervention|control|patients without letrozole
11124834|NCT03901157|Experimental|Active yogurt|Contains 120 g yogurt + 60 g oil-gel particles (containing 6 g oil) + 24 g water
11124835|NCT03901157|Active Comparator|Control yogurt|Contains 120 g yogurt + 54 g empty gel particles + 6 g oil in 24 g water
11124836|NCT03901144|Experimental|cream 1107.57|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
11124837|NCT03901144|Active Comparator|Glycerol cream|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
11124838|NCT03901144|Active Comparator|Paraffin cream|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
11124839|NCT03901144|No Intervention|Untreated|Untreated are on the volar forearm
11124840|NCT03901131||BAY98-7040|"Female adult women in reproductive age, who want to use a contraceptive method will be enrolled after the decision for treatment with Mesigyna has been made by the investigator.
~Indications and contraindications according to the local market authorization/SmPC should be carefully considered."
11124841|NCT03901118|Experimental|chiauranib plus etoposide|Patients receive the combined treatment of chiauranib plus etoposide, 28 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Etoposide is given orally, 50mg once daily for 21 days, 7 days off, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
11124842|NCT03901118|Experimental|chiauranib plus paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
11124843|NCT03901105|Experimental|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
11124844|NCT03901092|Experimental|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
11124845|NCT03901079||CTO BridgePoint system|Crossboss catheter/Stingry balloon catheter
11124846|NCT03901053|Experimental|AB|Participants in this arm will receive the Reaktiv AFO made by FabTech Systems LLC first, then the PhatBrace AFO by Bio-Mechanical Composites Inc. second.
11124847|NCT03901053|Experimental|BA|Participants in this arm will receive the PhatBrace AFO by Bio-Mechanical Composites Inc. first, then the Reaktiv AFO made by FabTech Systems LLC second.
11124848|NCT03901040|Other|obese patient|we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
11124849|NCT03901027|Experimental|Parents of children with chronic illnesses|psycho-educational intervention for parents
11124850|NCT03901014|Active Comparator|Baseline diet|1 week baseline diet
11124851|NCT03901014|Experimental|Very low carbohydrate diet|2 week very low carbohydrate ketogenic diet
11124852|NCT03901001|Active Comparator|oseltamivir and adjunctive sirolimus|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
11124853|NCT03901001|Placebo Comparator|oseltamivir alone|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
11124854|NCT03900988|Active Comparator|intravenous N-acetylcysteine (NAC) and oseltamivir|
11124855|NCT03900988|Placebo Comparator|intravenous 5% dextrose and oseltamivir|
11124856|NCT03900975||Vulvar Paget Disease|Women with vulvar paget disease
11124857|NCT03900962|Experimental|Slow-speed strength training|The slow-speed strength training group performed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds.
11124858|NCT03900962|Experimental|High-speed power training|During the first three weeks of training, the high-speed power training group completed the concentric phase of each resistance exercise over two seconds, paused at full extension/flexion for one second, and then performed the eccentric phase for two seconds. Thereafter, this group completed the concentric phase of five resistance exercises (squat, press-up, incline chest press, seated row and push-press) as fast as possible whilst still taking two seconds to complete the eccentric phase.
11124859|NCT03900949|Experimental|Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)|INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS < 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS >= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.
11124860|NCT03900936||Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
11124861|NCT03900923|Experimental|98% pure CBD|98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.
11124862|NCT03900910|Other|Gastric cancer prevention|13C-urea breath test and anti-H. pylori treatment for those who are tested positive.
11124863|NCT03900884|Experimental|Letrozole + Palbociclib + Venetoclax|"The Letrozole dose is 2.5 mg (D1-28) for all dose levels.
~Starting dose Level 1: Palbociclib 100 mg (D1-21) and Venetoclax 100 mg (D1-21) daily."
11124864|NCT03900871|Experimental|Experimental group|
11124865|NCT03900871|Placebo Comparator|Control group|
11124866|NCT03900858|Experimental|Isoniazid/ Rifapentine 3 times a week|Intervention：Isoniazid/ Rifapentine 3 times a week given by DOT oral Rifapentine (450mg) plus Isoniazid (400mg) for 12 doses
11124867|NCT03900858|No Intervention|No Intervention|No preventive treatment Follow up without intervention. Have already done.
11124868|NCT03900845|Experimental|Environmental Chamber|All participants will wear all three study prostheses in an environmental chamber set at 35 degrees Celsius and 50% relative humidity.
11124869|NCT03900845|Experimental|Field Measurements|All participants will wear all three study prostheses in their home, work, and community environments for two weeks.
11124870|NCT03900832|Placebo Comparator|PAD without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124871|NCT03900832|Experimental|PAD warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124872|NCT03900832|Placebo Comparator|PAD neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124873|NCT03900832|Experimental|PAD heating suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124874|NCT03900832|Experimental|PAD lower limb warm water immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124875|NCT03900832|Placebo Comparator|Healthy subjects without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124876|NCT03900832|Experimental|Healthy subjects warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124877|NCT03900832|Placebo Comparator|Healthy subjects neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124878|NCT03900832|Experimental|Healthy subjects heat suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124879|NCT03900832|Experimental|Healthy subjects lower limb immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
11124880|NCT03900806|Experimental|Basic Cognitive Rehabilitation|The basic arm will consist of a brief cognitive training programme without individual guidance throughout the intervention, involving three to five sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks.
11124881|NCT03900806|Experimental|Extensive Cognitive Rehabilitation|The extensive arm will consist of a comprehensive training program, involving five to eight sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks. After the first session, each further session in the extensive group involves tailored therapy guidance . Cognitive strategy modules will be assigned by the therapist depending on the participants' cognitive profile and personal treatment goals.
11124882|NCT03900806|No Intervention|Waitlist control group|Participants in the waiting list control group will be offered the opportunity to follow the basic cognitive rehabilitation program after completion of the 26-week follow-up measurement.
11124883|NCT03900793|Experimental|Dose Escalation and Expansion|"Part 1: This is a study escalating doses (Dose level 1-3) of losartan on a continuous daily dosing schedule and sunitinib (escalating on dose level 4) on a daily dosing with 4 weeks on, 2 weeks off. A cycle of therapy is 6 weeks (42 days).Dosing will be performed based on body surface area (BSA). This portion of the study uses a 3+3 design (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level).
~Part 2: Once the Maximally Tolerated Dose (MTD) has been determined, 12 patients will enroll to the expansion cohort. These patients will receive the MTD as long as less then 33% of patients experience dose-limiting toxicities."
11124992|NCT03900052|Experimental|Haptics recall|Haptic biofeedback cane with no further instruction or practice given.
11124884|NCT03900780|Experimental|PGT-A group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
11124885|NCT03900780|Active Comparator|Control group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
11124886|NCT03900767|Experimental|Phase I Group I (AAC-Out)|"GROUP I: Clinics participate in AAC-Out intervention consisting of an EHR-based point of care alert that requires clinic staff to Advise and Connect tobacco users to the Utah Quitline, or to opt out (i.e. the default requires an action- Advise and Connect, or Opt Out)."
11124887|NCT03900767|Experimental|Phase I Group II (AAC-In)|Clinics participant in AAC-In intervention consisting of an EHR based point of care reminder that allows medical staff to choose when to perform Advise and Connect (i.e. the default does not require a connection).
11124888|NCT03900767|Experimental|Phase II Group I (Continued EHR and text messages)|Patients receive a monthly text message for 6 months following each tobacco user's clinic visit that includes a simple one-touch response to directly connect to the Quitline.
11124889|NCT03900767|Experimental|Phase II Group II (Continued EHR)|Patients receive continued clinic level EHR intervention following each tobacco user's clinic visit.
11124890|NCT03900767|Experimental|Phase III Group I (Continued EHR and text messages)|Patients receive a monthly text message for 6-12 months following each tobacco user's clinic visit that includes a simple one-touch response to directly connect to the Quitline.
11124891|NCT03900767|Experimental|Phase III Group II (Text messages, Counseling call)|Patients receive a monthly text message plus 2 brief telephone calls from patient navigators/health educators for 6-12 months following each tobacco user's clinic visit.
11124892|NCT03900754|Experimental|Intranasal Oxytocin|Dosages of oxytocin: 20IU or 40IU.
11124893|NCT03900754|Placebo Comparator|Placebo|Saline
11124894|NCT03900741|Experimental|Submerged healing|Bone regeneration of peri-implantitis defects following a submerged healing
11124895|NCT03900741|Active Comparator|Non-submerged healing|Bone regeneration of peri-implantitis defects following a non-submerged healing
11124896|NCT03900728|Active Comparator|Auriculotherapy with needles|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
11124897|NCT03900728|Active Comparator|Auriculotherapy with gold beads|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
11124898|NCT03900728|Sham Comparator|Placebo group|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
11124899|NCT03900715|Experimental|Luspatercept Administration|Luspatercept will be administered as a subcutaneous injection every 3 week (21 days; Q3W), at an initial dose level of 1.0 mg/kg. Doses may be titrated up starting at dosing visit Week 7 Day 1 (W7D1)
11124900|NCT03900702|Active Comparator|Active Intervention|Gaze-driven games, played at home on PC with eye-tracker, to train resistance to attention distraction and speed of processing.
11124901|NCT03900702|No Intervention|Wait List Control|Wait list then cross over to active intervention.
11124902|NCT03900689||Health Services Research - Part 1 Survey|Participants will be asked to complete a series of surveys. This will be preferentially completed on the same day of the visit but may be completed at a subsequent visit, over the telephone or taken home and sent back to the clinic.
11124903|NCT03900689||Health Services Research - Part 2 - Focus Group|Patients identified in Part 1 will be offered participation in the focus groups in Part 2. All patients enrolled in Part 1 will be considered for participation in Part 2. Approximately 30 total patients will be invited to participate. Patients who agree to be contacted will receive a telephone call or contacted in clinic and invited to participate in the Part 2 focus group.
11124904|NCT03900676|Experimental|VB-1953 topical gel - 2% QD|VB-1953 topical gel - 2% QD
11124905|NCT03900676|Experimental|VB-1953 topical gel - 2% BID|VB-1953 topical gel - 2% BID
11124906|NCT03900676|Placebo Comparator|VB-1953 topical gel- 0% (Vehicle) QD|VB-1953 topical gel- 0% (Vehicle) QD
11124907|NCT03900676|Placebo Comparator|VB-1953 Vehicle|VB-1953 topical gel- 0% (Vehicle) BID
11124908|NCT03900663||Breast fed infants|
11124909|NCT03900663||Formula fed infants|
11124910|NCT03900663||vaginally delivered infants|
11124911|NCT03900663||Infants delivered by caesarean section|
11124912|NCT03900650|Experimental|Alcoholic beverage|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%.
11124913|NCT03900650|Active Comparator|Non-alcoholic beverage|Participants will receive a beverage that does not contain alcohol (fruit juice only).
11124914|NCT03900650|Experimental|High provocation manipulation|Participants receive an experimental manipulation designed to evoke negative emotions such as frustration.
11124915|NCT03900650|Active Comparator|Low provocation manipulation|Participants receive an experimental manipulation that is designed to evoke neither positive or negative emotions.
11124916|NCT03900637|Experimental|Arm I|"MammaPrint high risk :
~Neoadjuvant chemotherapy : Adriamycin/Cyclophosphamide #4 followed by Docetaxel #4
~MammaPrint low risk :
~Premenopausal women : Letrozole 2.5mg PO QD + leuprorelin acetate 3.6mg SQ every 4weeks during 16 weeks (if needed, maximum for 24 weeks)
~Postmenopausal women : Letrozole 2.5mg PO QD during 16 weeks (if needed, maximum for 24 weeks)"
11124917|NCT03900624|No Intervention|Methylprednisolone Arm|Non-randomized, prospective, observational arm of children receiving standard care for status asthmaticus in the PICU with intravenous methylprednisolone.
11124918|NCT03900624|Experimental|Dexamethasone Arm|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus.
11124919|NCT03900611|Experimental|Active stimulation|
11124920|NCT03900611|Sham Comparator|Sham stimulation|
11124922|NCT03900598|Experimental|Part 1 (Dose Escalation): JNJ-67856633|Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
11124923|NCT03900598|Experimental|Part 2 (Cohort Expansion): JNJ-67856633|Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
11124924|NCT03900585|Experimental|Interval walking|Interval walking for 10 weeks, 150 minutes per week administered by an app on the patient's telephone.
11124925|NCT03900585|No Intervention|Control|Patients live as normal, though aerobe training restricted to a maximum of 30 minutes a week.
11124926|NCT03900572|Experimental|HPV vaccine|Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
11124927|NCT03900572|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
11124928|NCT03900559|Experimental|"NO-FEAR Airlines program with still images"|"Intervention group that uses NO-FEAR Airlines program with still images to carry out the exposure."
11124929|NCT03900559|Experimental|"NO-FEAR Airlines program with still and navigable images"|"Intervention group that uses NO-FEAR Airlines program with still and navigable images to carry out the exposure."
11124930|NCT03900559|No Intervention|Waiting list control group|"Participants of this group are able to access NO-FEAR Airlines program after 6 weeks of waiting period.
~After that period, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (only still images or still + navigable images)."
11124931|NCT03900533|Experimental|Adjunctive group emotion regulation skills training|Participants will receive a 7 week group emotion regulation skills training together with parents adjacent to treatment as usual provided by the child- and adolescent psychiatric clinic
11124932|NCT03900533|Active Comparator|Treatment as usual (TAU)|Participants will receive treatment as usual for 7 weeks as provided by the child- and adolescent psychiatric clinic
11124933|NCT03900520||Pneumonia group (PREVAIL-Pneumo)|Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
11124934|NCT03900520||Community group (PREVAIL-Community)|Children aged 1-35 years living in the community with no known systemic illness
11124935|NCT03900520||Economic group (PREVAIL-Econ)|PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
11124936|NCT03900494|Active Comparator|Children treated with VHC 1|In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. We only compare the efficacy of the two VHC devices.
11124937|NCT03900494|Active Comparator|Children treated with VHC 2|In this group children are receiving salbutamol with valved holding chamber number 2. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria. In this group children are receiving salbutamol with valved holding chamber number 1. Otherwise the children in both groups are treated exactly the same way. The only difference is the device used to deliver the bronchodilator. Children in both arms have the same condition and the same inclusion and exclusion criteria.
11124938|NCT03900481|Experimental|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive
11124939|NCT03900468|Experimental|Active Deep Brain Stimulation (DBS)|
11124940|NCT03900455|Experimental|Hydrocellular polyurethane foam multilayer dressing|
11124941|NCT03900455|Active Comparator|standard preventive care|
11124942|NCT03900442|Experimental|PTX-100|IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles
11124943|NCT03900429|Placebo Comparator|Matching Placebo|Placebo Daily
11124944|NCT03900429|Active Comparator|80 mg MGL-3196|80 mg daily
11124945|NCT03900429|Active Comparator|100 mg MGL-3196|100 mg daily
11124946|NCT03900416|Experimental|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
11124947|NCT03900416|No Intervention|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
11124948|NCT03900403|No Intervention|Habitual Intake|This will be the comparative arm, of 6 weeks before and after the study participant is on their habitual diet
11124949|NCT03900403|Experimental|Walnut Intake|Experimental Arm of 12 weeks of Walnut Intake, with study visits at baseline (prior to walnut intake) and after 6 and 12 weeks of 40g of Walnut Intake.
11124950|NCT03900390|Experimental|Cross Ischemic Preconditioning Group|the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions
11124951|NCT03900390|No Intervention|Control Group|The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.
11124952|NCT03900377|Experimental|Lg-B-NHL or MCL|For previously untreated patients with Lg-B-NHL or MCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 0 (the day before Day 1 only in Cycle 1), and SyB L-0501RI will be intravenously administered at 90 mg/m^2/day on Day 1 and Day 2 of each 28-day cycle with up to 6 cycles.
11124953|NCT03900377|Experimental|DLBCL|For patients with recurrent or refractory DLBCL, rituximab will be intravenously administered at 375 mg/m^2 on Day 1, and SyB L-0501RI will be intravenously administered at 120 mg/m^2/day on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles.
11124954|NCT03900364|Other|robot-assisted partial nephrectomy|partial nephrectomy performed with the da Vinci Surgical System
11124955|NCT03900364|Other|laparoscopic partial nephrectomy|partial nephrectomy performed with conventional laparoscopic surgery
11124956|NCT03900351|Active Comparator|Group A: Study group|They will receive the Wii fit protocol of virtual reality games for 40 minutes, 3 times per week, for 8 weeks, in addition to the regular exercise rehabilitation protocol according to the criterion of Adams et al. (2012).
11124957|NCT03900351|Experimental|Group B: Control group|They will receive the regular exercise rehabilitation protocol only for 40 minutes, for 3 days per week, for 8 weeks.
11124958|NCT03900338||PWV>10|Patients with PWV > 10 (SSphygmoCor) in two different measurements
11124959|NCT03900338||PWV<10|Patients with PWV < 10 (SphygmoCor) in two different measurements
11124960|NCT03900325|Experimental|Nimacimab|2.5 mg/kg
11124961|NCT03900325|Placebo Comparator|Placebo|0.9% sodium chloride
11124962|NCT03900312|Experimental|Intervention|The program consists of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices.
11124963|NCT03900299|Other|oncoplastic breast surgery|
11124964|NCT03900286|Experimental|Single Arm Study|Total Diet Replacement for 12 weeks, food reintroduction 6 weeks
11124965|NCT03900273|Experimental|Novel measures of cognition and everyday function|"No Practice Effects (NPE) cognitive battery
~Miami Computerized Functional Assessment Scale (CFAS)
~Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52."
11124966|NCT03900273|Active Comparator|Established measures of cognition and everyday function|"Preclinical Alzheimer's Cognitive Composite (PACC)
~Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
~Functional Assessment Questionnaire (FAQ).
~Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period.
~Assessments will take place at baseline, week 12, and week 52."
11124967|NCT03900260|Other|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
11124968|NCT03900234||Residents of the single rural settlement|No interventions will be administered
11124969|NCT03900221||Pregnant women with multiple sclerosis or related neurological|Children born to women with multiple sclerosis or related neurological syndromes.
11124970|NCT03900195|Experimental|Bottle PEP|Bottle PEP is a positive expiratory system that is applied via a tube of more than 5 mm of thickness and a bottle filled with water about 10 cms.
11124971|NCT03900195|No Intervention|Control|No interventions will be applied.
11124972|NCT03900182|Active Comparator|HBO treated group|Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment.
11124973|NCT03900182|Sham Comparator|crossover group|Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT
11124974|NCT03900169||Stemi patient|Stemi patient who underwent Ppci
11124975|NCT03900156|No Intervention|comparison group|The CG received no extra care.
11124976|NCT03900156|Experimental|Intervention Group|Intervention Group, goal-setting with follow-up, will have a structured goalsetting interview using the Bangor Goal-Setting Interview ; once goals are identified and clearly expressed in accordance with SMART principles (specific, measureable, achievable, realistic, and timed)
11124977|NCT03900143|Experimental|Treatment - Tightra|Treatment group with the Tightra device
11124978|NCT03900130|Experimental|Full group|"There is only one arm in this study. The group of 25 subjects all undergo a repeated measures 2 x 2 factorial design, fully crossed such that all subjects are tested under all four combinations of factors.
~The intervention Preload amounts to two factors, caloric load and protein to carbohydrate ratio of the preload, both of which can take on two levels high or low."
11124979|NCT03900117|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
11124980|NCT03900104|Experimental|Transcervical endometrial injection arm|Tracer injection performed by a transcervical catheter in endometrial cancer patients.
11124981|NCT03900104|Active Comparator|Cervical injection arm|Tracer injection was administered via the cervical route in endometrial cancer patients.
11124982|NCT03900091||Cases with clinical meningitis|Patients aged 0-12 years with suspected CNS infection, at the pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda.
11124983|NCT03900091||Control subjects|Patients aged 0-12 years, visiting the outpatient pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda, with fever clinically considered non-severe.
11124984|NCT03900078|Active Comparator|Control group|After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.
11124985|NCT03900078|Experimental|Incisional negative pressure group|After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.
11124986|NCT03900065|No Intervention|Control group|No preconditioning of the flap.
11124987|NCT03900065|Experimental|Preconditioned group|Preconditioning of the flap prior to surgery.
11124988|NCT03900052|No Intervention|Naïve|Conventional cane with no instruction given
11124989|NCT03900052|Active Comparator|Scale training|Conventional cane, scale training, and instruction on proper cane use
11124990|NCT03900052|Active Comparator|Scale recall|Conventional cane with no further instruction or practice given
11124991|NCT03900052|Experimental|Haptics training|Haptic biofeedback cane with explanation and training.
11125063|NCT03899558|Experimental|Intervention|HNHF device (intervention) + usual care
11124993|NCT03900039|Active Comparator|Conventional Polyethylene versus metal head|This is the more conventional group bearing surfaces
11124994|NCT03900039|Experimental|Conventional Polyethylene versus oxidized zirconium head|This group uses the more conventional polyethylene against the newer head
11124995|NCT03900039|Experimental|Newer Cross linked Polyethylene metal head|In this group we continued with the conventional polyethylene, but added in the new type of head (oxidized zirconium)
11124996|NCT03900039|Experimental|Newer Cross linked Polyethylene versus oxidized zirconium head|In this group, we added both the new head and the new polyethylene
11124997|NCT03900026|Placebo Comparator|Placebo Treatment|Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
11124998|NCT03900026|Experimental|Evolocumab Treatment|Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
11124999|NCT03900013|Experimental|Injectable Platelet Rich Fibrin (i-PRF) with DFDBA|"In I-PRF assigned group, 10 cc of blood per intraosseous defect will be collected right after administering the anaesthesia and will be processed according to the technique proposed by Choukroun et al., 2017 (centrifuged at 700 rpm, for 2-3 minutes). The yellow part will be collected using a syringe and added to a cup that contains the bone grafting material.
~The i-PRF consolidated bone graft will placed into the intraosseous defect."
11125000|NCT03900013|Active Comparator|Demineralized Freeze-Dried Bone Allograft (DFDBA) alone|After debridement and intraoperative recordings, in the control group, the bone graft material will be placed in the intraosseous defect without overfilling.
11125001|NCT03900000|Other|Short_Physiotherapy|one period of physiotherapy (8 weeks)
11125002|NCT03900000|Other|Long_Physiotherapy|two periods of physiotherapy (à 8 weeks)
11125003|NCT03899987|Experimental|Arm I (aspirin, interferon alpha, rintatolimod, surgery)|Patients receive aspirin PO BID on days -5 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3, 8-10 and 15-17 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 22-26.
11125004|NCT03899987|Experimental|Arm II (aspirin, rintatolimod, surgery)|Patients receive aspirin PO BID on days -5 to 7 and rintatolimod IV over 2 hours on days 1-3, 8-10 and 15-17 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 22-26.
11125005|NCT03899987|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy about 4 weeks after enrollment.
11125006|NCT03899974|Experimental|70% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 70% high-amylose flour)
11125007|NCT03899974|Experimental|85% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 85% high-amylose flour)
11125008|NCT03899974|Active Comparator|Control bread|Mixed meal with 80g of available carbohydrates coming mainly from conventional bread
11125009|NCT03899961|Active Comparator|Oxytocin|Oxytocin 2.5 U i.v.
11125010|NCT03899961|Experimental|Carbetocin|Carbetocin 100 µg i.v.
11125011|NCT03899948|Experimental|Teacher Anxiety Program for Elementary Students (TAPES)|Teachers in the experimental condition attend a 6-hour training on the TAPES program. The teachers learn to implement a brief intervention (5 meetings) with the student and his or her parent, utilize classroom anxiety-reduction strategies, and apply relationship enhancement strategies to improve the relationship with the target student and parents.
11125012|NCT03899948|Active Comparator|Teacher Anxiety Training (TAT)|Teachers in this condition receive training about childhood anxiety and classroom anxiety-reduction strategies using a 3-hour typical teacher professional development training format.
11125013|NCT03899935||Group A: obese patients|Obese patients undergoing laparoscopic surgery for endometriosis
11125014|NCT03899935||Group B: non-obese patients|Non-obese patients undergoing laparoscopy for endometriosis
11125015|NCT03899922||Uveitis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of uveitis of patient treated by a drug, with a chronology compatible with the drug toxicity
11125016|NCT03899909|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 6 dose levels in ascending order
11125017|NCT03899909|Placebo Comparator|Placebo SAD|Single doses of placebo
11125018|NCT03899909|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 4 dose levels in ascending order
11125019|NCT03899909|Placebo Comparator|Placebo MAD|Multiple doses of placebo
11125020|NCT03899883|Experimental|Pegloticase|Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)
11125021|NCT03899857|Experimental|Pembrolizumab|Temozolomide-based radiochemotherapy (TMZ/RT=>TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=>TMZ.
11125022|NCT03899844||Cognitively normal|896 of the 1120 enrolled will not exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
11125023|NCT03899844||Cognitively impaired|224 of the 1120 enrolled will exhibit subjective impairment as defined by a brief clinical test. These participants will complete an initial blood collection and cognitive testing, and a subset of participants will be asked to return for a larger blood collection, amyloid (PiB) PET imaging, and MRI.
11125024|NCT03899831|Experimental|Function-Based Elopement Treatment (FBET)|Participants in this group will receive Function-Based Elopement Treatment (FBET) for 16 weeks.
11125025|NCT03899831|Active Comparator|Parent Education Program (PEP)|Participants in this group will take part in a parent education program (PEP) for 16 weeks.
11125026|NCT03899818|Other|new generation DEB|drug-eluting balloon (DEB)
11125027|NCT03899818|Other|second generation DES|standard therapy with second generation drug-eluting stent (DES)
11125028|NCT03899805|Experimental|Liposarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8
~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
11125029|NCT03899805|Experimental|Leiomyosarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8
~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
11125030|NCT03899805|Experimental|Undifferentiated Pleomorphic sarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8
~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
11125031|NCT03899792|Experimental|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The maximum tolerated dose (MTD)/recommended dose from Phase 1
11125032|NCT03899779|Active Comparator|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
11125033|NCT03899779|Experimental|Online hypnotherapy|12 weeks treatment with online hypnotherapy
11125034|NCT03899779|Active Comparator|Online psychoeducation|12 weeks treatment with online psychoeducation
11125035|NCT03899766||Animal Assisted Intervention|children interact and play with the expert of Animal Assisted Intervention (AAI) and his/her trained dog in the waiting room and then, are accompanied by a parent (as standard care) and the AAI in the venipuncture room during and immediately after the procedure
11125036|NCT03899766||Clowns|children interact and play with hospital clowns in the waiting room and then, are accompanied by a parent (as standard care) and the clown in the venipuncture room during and immediately after the procedure
11125037|NCT03899766||Musicians|children interact and play with a musician in the waiting room and then, are accompanied by a parent (as standard care) and the musician in the venipuncture room during and immediately after the procedure
11125038|NCT03899766||Non-clinical Conversation|children are accompanied by a parent in the waiting room and then in the venipuncture room during the procedure, thus receiving standard care
11125039|NCT03899753|Experimental|2-Octyl Cyanoacrylate and mesh|The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
11125040|NCT03899753|Active Comparator|2-Octyl Cyanoacrylate|The wound will be closed with just 2-Octyl Cyanoacrylate
11125041|NCT03899740||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.
~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
11125042|NCT03899727||Pregnant group|pregnant women in the third trimester of pregnancy
11125043|NCT03899727||Non-pregnant group|middle aged women
11125044|NCT03899714|Active Comparator|Ankle evertors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the ankle evertors, the ice bag will be applied to the lateral side of the ankle encompassing the lateral malleolus.The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
11125045|NCT03899714|Active Comparator|Hip adductors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the hip adductors, the ice bag will be applied to the medial side of the thigh, covering the entire area from the groin, to just above the knee joint. The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
11125046|NCT03899701|Experimental|PEC I and PEC II block|Ultrasound guided nerve block group.
11125047|NCT03899688|Experimental|test site|The space obtained underneath the sinus mucosa will be filled with the xenograft without protecting the antrostomy with a collagen membrane in the test sites.
11125048|NCT03899688|Other|control site|The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
11125049|NCT03899675|Experimental|Caffeine|Volunteers will ingest 300mg caffeine one hour before strength training.
11125050|NCT03899675|Placebo Comparator|Placebo|Volunteers will ingest 300mg placebo one hour before strength training.
11125051|NCT03899662|Experimental|Cognitive and Physical Training|24 sessions (8 weeks, 3 times per week) of computer based 45 minute cognitive and 45 minute physical training.
11125052|NCT03899649||IRE Cohort|Patients who received SOC and received IRE
11125053|NCT03899649||SOC Cohort|Patients who received SOC and did not receive IRE
11125054|NCT03899636|Experimental|IRE|
11125055|NCT03899636|Active Comparator|Control|
11125056|NCT03899610|Experimental|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:
~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)
~Interval debulking surgery
~Adjuvant treatment:
~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
11125057|NCT03899597|Experimental|artificial contractions (ARTCON) group|All participating patients in the intervention (ARTCON) group will undergo oxytocin exposure in the form of a continuous intravenous infusion according to dosage guidelines of The Czech Society of Obstetrics and Gynaecology. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed in order for the assumed effects of physiological stress associated with labor to occur.
11125058|NCT03899597|Placebo Comparator|standard approach (SA) group|All participating patients in the control (SA) group will undergo placebo exposure in the form of a continuous intravenous infusion. The exposure will take two hours to complete and should be finished at least one hour before elective caesarean section is performed.
11125059|NCT03899584|Active Comparator|Treatment with 4-aminopyridine|The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
11125060|NCT03899584|Placebo Comparator|Placebo oral capsule|Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
11125061|NCT03899571|Active Comparator|5 days|oral oseltamivir 75 mg once daily for 5 days post-exposure
11125062|NCT03899571|Active Comparator|10 days|oral oseltamivir 75 mg once daily for 10 days post-exposure
11125065|NCT03899545|Experimental|Serratus Plane Block|Serratus plane block will be applied after induction of general anesthesia.
11125066|NCT03899545|Active Comparator|Serratus Plane Block plus Pectoral I block|Serratus plane plus pectoral I block will be applied after induction of general anesthesia.
11125067|NCT03899532|Experimental|Remote Ischemic Conditioning|"Remote ischemic conditioning will be performed using a standard manual blood pressure cuff. The pressure in the blood pressure cuff will be maintained at 30 mm of Hg higher than the patient's systolic blood pressure. 4 cycles of ischemic conditioning will be performed each day for a period of 7 days. Each cycle consists of 5 min of controlled upper limb ischemia (cuff up) followed by 5 min of reperfusion (cuff down). The total duration of the treatment cycle will be 40 min. The study protocol is based on our published literature in traumatic brain injury.
~Blood samples will be collected at 0 hours (before randomization). Then the first 4 cycles of RIC (done consecutively) will be performed, blood samples will be taken at 6 hours post randomization and then at 24 hours post randomization. RIC cycles will then be performed on a daily basis followed by taking a blood sample once daily during the patients' length of stay up to a maximum of 7 days"
11125068|NCT03899532|Placebo Comparator|No Remote Ischemic Conditioning|Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
11125069|NCT03899506||Olanzapine|Patients receiving 10 mg IM Olanzapine per the ED protocol
11125070|NCT03899506||Midazolam|Patients receiving 5 mg IM Midazolam per the ED protocol
11125071|NCT03899493||Primiparous & Multiparous|Women having borne at least one child > 20 weeks gestational age
11125072|NCT03899493||Nulliparous|Women in whom this is their first pregnancy > 20 weeks who are anticipated to deliver
11125073|NCT03899480|Experimental|Haploidentical Natural Killer Cells|Day -7 the subject will undergo inguinal lymph node biopsy & colonoscopy to obtain ileal & rectal biopsies. Blood samples will be obtained. PBMCs will be obtained to sort into CD4 subsets & measure frequencies of HIV RNA & DNA. On Day -1, the donor will undergo apheresis & donor cells will be obtained & incubated overnight. On Day 0 subjects will be infused with N-803 activated NK cells. Subjects will receive 1st dose of N-803 4 hrs after the infusion. Plasma will be obtained at 2, 4 & 12 hrs after. Subjects will return on Days 2, 4, 7, 10, & 14 for blood draw. Subjects will return Days 21 & 42 for blood work & to receive 2 additional doses of N-803, for a total of 3 doses. Subjects will be monitored for toxicity assessment by targeted physical exam & laboratory evaluations on Days 2, 4, 7, 10, 21, & 42. On day 49, we will perform lymph node biopsy & colonoscopy to obtain ileal & rectal tissues. The patient will then be followed until day 100 post infusion.
11125074|NCT03899467|Experimental|Arm 1: biological dose group|"400mg/day of proxalutamide
~Group 1: Post enzalutamide failure
~Group 2: Post abiraterone failure"
11125075|NCT03899467|Experimental|Arm 2: MTD dose group|"500mg/day of proxalutamide
~Group 1: Post enzalutamide failure
~Group 2: Post abiraterone failure"
11125076|NCT03899454|Experimental|Extract administration|administration of a mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
11125077|NCT03899454|Placebo Comparator|Control|Placebo
11125078|NCT03899441|No Intervention|Control|Patients in the control arm will have pre-operative teaching from their physician and sign consent for surgery, as is the current standard of care at the investigators' institution.
11125079|NCT03899441|Experimental|Video arm|Patients in the intervention arm will watch two short animated video about minimally-invasive endometrial cancer surgery followed by focused pre-operative teaching from their physician. They will then sign consent for surgery.
11125080|NCT03899428|Experimental|Immune Checkpoint Therapy|The subjects will receive durvalumab 1500 mg Q4W
11125081|NCT03899428|Experimental|Target Therapy|The subjects will receive tyrosine kinase inhibitors, including sorafenib, lenvatinib, regorafenib, or cabozantinib, daily
11125082|NCT03899415|Experimental|TCR-Redirected T Cells|HBV antigen specific TCR redirected T cells
11125083|NCT03899402|Active Comparator|Control|Standard of care insulin will be used as an active comparator arm for 1/3 of patients (38 patients) for the entire duration of the study.
11125084|NCT03899402|Experimental|Dual Therapy|Once a week injection of Semaglutide (a GLP-1 receptor agonist) in addition to standard of care insulin for the first six months in 2/3 of patients (76 patients). Semaglutide is a clear, colorless solution that contains 2 mg of semaglutide in a 1.5 mL (1.34 mg/mL) pre-filled, disposable, single-patient-use pen injector. Semaglutide will be started at the 0.25 mg dose for the first two weeks, then increased to 0.5 mg at week 2, and then yet again increased to 1.0 mg at week 4.
11125085|NCT03899402|Experimental|Triple therapy|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of Dapagliflozin (an SGLT-2 inhibitor) added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)). Dapagliflozin will be started at 5 mg for one week, and then increased to 10 mg for the remainder of the study
11125086|NCT03899402|Placebo Comparator|Triple therapy control|Once a day oral pill (green, plain, diamond shaped film coated 5 mg tablet) of the Placebo form of Dapagliflozin added to once a week injection of semaglutide and standard of care insulin in the second 6 months of 1/2 of the dual therapy arm (1/3 of total patients (38 patients)).
11125087|NCT03899389||Acute Coronary Syndrome (ACS)|Patients with STEMI or NSTEMI infarction, who were admitted to the hospital with chest pain.
11125088|NCT03899389||Stable Angina (SA)|Patients with stable angina who were scheduled for conventional coronary angiography.
11125089|NCT03899389||Control Group (CON)|Healthy control group responding by age and gender to examined groups.
11125090|NCT03899376|Active Comparator|Conventional radiotherapy|patients with gynecological cancer treated with adjuvant conventional radiotherapy
11125091|NCT03899376|Experimental|Volumetric modulated arc therapy|Patients with gynecological cancer treated with adjuvant VMAT radiotherapy
11125092|NCT03899363|Experimental|surgery|
11125093|NCT03899363|Active Comparator|custom thermoplastic orthosis|
11125150|NCT03899064|Experimental|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
11125151|NCT03899064|Experimental|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
11125094|NCT03899337|Active Comparator|Standard of Care Arm (CHOP-R)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:
~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5"
11125095|NCT03899337|Experimental|Experimental Arm (CHOP-R + Acalabrutinib)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:
~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5
~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
11125096|NCT03899337|Experimental|Cohort 1 - Acalabrutinib Monotherapy - Platform Trial|Registration arm in platform study. Patients registered to Cohort 1 will receive 100 mg acalabrutinib monotherapy, twice daily, continuously from day 1 until disease progression, toxicity, patient choice or death.
11125097|NCT03899337|Experimental|Cohort 2 - CHOP-R + Acalabrutinib - Platform Trial|"Registration arm in platform study. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:
~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5
~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
11125098|NCT03899324|Experimental|Group 1: Experimental Bumetanide|bumetanide with a titration period
11125099|NCT03899324|Placebo Comparator|Group 2: Placebo comparator|placebo intake identically to group 1
11125100|NCT03899311||PSMF cohort|The cohort is instructed to follow a protein-sparing modified fast diet and is given standard health care in the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital.
11125101|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Autoimmune Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125102|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Orthopedic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125103|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Neurologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125104|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Urologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125105|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Cardiac Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125106|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Renal Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125107|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Pulmonary Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
11125108|NCT03899285|Experimental|Citalopram increase (group A)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of citalopram 20 mg for a length of 14 days. The total dose of citalopram will be 40 mg once daily.
~Follow up will last 8 weeks in total."
11125109|NCT03899285|Placebo Comparator|Placebo (group B)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of placebo (a capsule without medication) for a length of 14 days. The total dose of citalopram will be 20 mg once daily.
~Follow up will last 8 weeks in total."
11125110|NCT03899285|No Intervention|Observational arm (group c)|"Eligible patients to this arm are responders to citalopram. A diminution of at least 30% of the symptoms from baseline with the MADRS is required to enter this arm. At the end of the first phase, these patients will pursue their citalopram 20 mg for the rest of the study (=6 weeks). It's possible that in this group, the treatment approach may vary depending the physician.
~Follow up will last 8 weeks in total."
11125111|NCT03899272||Osteoarthritis|All new patient present to clinic referred for osteoarthritis for considering joint replacement Present with knee pain (unilateral or bilateral) contributed by osteoarthritis
11125112|NCT03899259|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11125113|NCT03899259|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11125114|NCT03899259|Placebo Comparator|Placebo|Placebo administered orally.
11125115|NCT03899246|Experimental|Capsaicin Arm|Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
11125152|NCT03899064|Experimental|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
11125153|NCT03899064|Experimental|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
11125154|NCT03899064|Experimental|Challenge: Control, irradiation|No application, but irradiation
11125116|NCT03899233|Active Comparator|Fractional CO2 laser combined with Tranexamic acid|one side of the face of all participants will be subjected to low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond for 3 sessions every 6 weeks. In addition to Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, on the 2nd and the 4th week of each laser session. With total treatment time for each patient of 4 months and another month free of sessions for followup.
11125117|NCT03899233|Active Comparator|Tranexamic acid alone|the other side of the face of all participants will be subjected Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, every 2 weeks for 4 months then another month free of sessions for followup.
11125118|NCT03899220|Experimental|Intervention|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence.
11125119|NCT03899220|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Enhanced treatment as usual includes a one session behavioral engagement in care intervention as well as substance use treatment counseling.
11125120|NCT03899207|Experimental|training +acupressure|In the training+acupressure group, 10 women were excluded from the study since they could not participate in acupressure application at different times, 2 women were excluded since they had menstrual irregularities and 4 women were excluded since they could not be contacted.
11125121|NCT03899207|Experimental|training|In the training group, 4 women were excluded since they did not participate in the reminder training, 1 woman was excluded since she had menstrual irregularities, 3 women were excluded since they wanted to withdraw from the study and 3 women were excluded from the study since they could not be contacted.
11125122|NCT03899207|No Intervention|control|In the control group, 4 women were excluded from the study since they could not be reached and 5 women were excluded since they did not agree to participate in the posttest.
11125123|NCT03899194|Active Comparator|escitalopram|Patients will only be treated with escitalopram from the minimum dosage.
11125124|NCT03899194|Experimental|escitalopram+ fish oil capsules|Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.
11125125|NCT03899181|Active Comparator|1 Hz 2400 TNT Treatment|Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..
11125126|NCT03899181|Active Comparator|1 Hz 3600 TNT Treatment|Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.
11125127|NCT03899181|Sham Comparator|Sham TNT Treatment|This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar & 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.
11125128|NCT03899168|Experimental|Social Tag Popularity|Popularity of Social Tags (antidepressants more popular vs. psychotherapy more popular)
11125129|NCT03899168|Experimental|Confidence in Prior Attitudes|Confidence in prior attitudes (high vs. low: recalling situations in which participants were confident or uncertain about their thoughts)
11125130|NCT03899168|Experimental|Source Credibility|Credibility of the source (tagging community: experts - many years of professional experience vs. novices - students in the first semester)
11125131|NCT03899155|Experimental|Nivolumab Dose 1|Specified Dose on Specified Days
11125132|NCT03899155|Experimental|Nivolumab Dose 2|Specified Dose on Specified Days
11125133|NCT03899142|Experimental|human hepatitis B immunoglobulin|once, i.m.
11125134|NCT03899129|Experimental|simultaneous working length control|• Using simultaneous working length control during root canal preparation using E-CONNECT S endomotor with integrated apex locator.
11125135|NCT03899129|Active Comparator|Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
11125136|NCT03899116||G50|The tourniquet cuff pressure will be deflated gradually by 50 mm Hg every 2 minutes till complete deflation.
11125137|NCT03899116||G100|The tourniquet cuff pressure will be deflated gradually by 100 mm Hg every 2 minutes till complete deflation.
11125138|NCT03899116||G0|The tourniquet cuff will be released till complete deflation.
11125139|NCT03899103|Experimental|Repeated Courses of Rituximab Only|First course Course Rituximab at Randomization. Prophylactic 2nd and 3rd course rituximab re-administration will be done at 8 months and 16 months of follow-up if B cell count normalize.
11125140|NCT03899103|Active Comparator|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
11125141|NCT03899090|Experimental|Float Pool|Floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
11125142|NCT03899090|Active Comparator|Float Chair|Floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
11125143|NCT03899090|Experimental|Float Pool Preferred|Floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)
11125144|NCT03899077|Active Comparator|Arm A|The standard hormonal treatment in combination with salvage radiotherapy is ADT by a LHRH agonist or antagonist for 24 weeks. LHRH agonists and antagonists include leuprolide, goserelin, triptorelin, and degarelix.
11125145|NCT03899077|Experimental|Arm B|Patients will receive 6 cycles (each cycle is 30 days) of the study drug (4x 60mg tablets daily in a single intake).
11125146|NCT03899064|Experimental|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
11125147|NCT03899064|Experimental|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
11125148|NCT03899064|Experimental|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
11125149|NCT03899064|Experimental|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
11125155|NCT03899051|Experimental|Test group|Papilla reconstruction would be done with platelet rich fibrin
11125156|NCT03899051|Active Comparator|Control group|Papilla reconstruction would be done with subepithelial connective tissue graft
11125157|NCT03899038|Experimental|Deceasing|Spinal anesthesia with decreasing dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
11125158|NCT03899038|Active Comparator|Similar|Spinal anesthesia with similar dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
11125159|NCT03899025|Other|Suspected scaphoid fracture|Patients with a suspected scaphoid fracture
11125160|NCT03898999||Older adult|Individuals belonging to the population group of the elderly (60 years or more)
11125161|NCT03898986|Experimental|MZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11125162|NCT03898986|Experimental|DZ twins (IIV or LAIV4)|Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11125163|NCT03898973|Other|Study Phase|Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
11125164|NCT03898960||Mechanical Thrombectomy|NIMBUS Device
11125165|NCT03898947||Tamoxifen users|Women undergoing therapy with Tamoxifen after surgery for breast cancer.
11125166|NCT03898947||Aromatase inhibitors|Women undergoing therapy with Aromatase Inhibitors after surgery for breast cancer.
11125167|NCT03898947||No treatment|Women who did not undergo any hormonal therapy after surgery for breast cancer.
11125168|NCT03898934|Experimental|Vitamin D group|These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study
11125169|NCT03898934|Placebo Comparator|Placebo group|These group will receive placebo for the same periods of study group
11125170|NCT03898921|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
11125171|NCT03898921|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
11125172|NCT03898908|Experimental|COMBO450|"Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets
~In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death."
11125173|NCT03898895|Experimental|Radiotherapy+anti-PD-1|The total radiation dose is over 40Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
11125174|NCT03898895|Active Comparator|Gemcitabine+cisplatin|Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
11125175|NCT03898882||BMI 20 - 29.9 kg/m2|
11125176|NCT03898882||BMI > 30 kg/m2|
11125177|NCT03898856|Experimental|Crofelemer and Diagnostic tests for cause of chronic diarrhea|125 mg tablets taken by mouth twice daily for 28 days
11125178|NCT03898843|Experimental|Animal assisted therapy group|Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
11125179|NCT03898843|Active Comparator|Control Group|"Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires"
11125180|NCT03898830|Experimental|eon™ FR 1064 nm device|Patient will be treated with the eon™ FR 1064 nm device
11125181|NCT03898817||Taking of cutaneous cells by biopsy|Taking of cutaneous cells by biopsy and a sample of blood
11125182|NCT03898804|Experimental|BCI and FES|Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
11125183|NCT03898791|Experimental|LY3295668 Erbumine Cohort A|LY3295668 erbumine administered orally.
11125184|NCT03898791|Experimental|LY3295668 Erbumine Cohort B|LY3295668 erbumine administered orally.
11125185|NCT03898791|Experimental|LY3295668 Part JP|LY3295668 erbumine administered orally.
11125186|NCT03898765|Experimental|Experimental：Dry blood spot screening|
11125187|NCT03898752|Experimental|Lifestyle intervention|Diet, omega-3 fish oil (1g daily), CoQ10 (100 mg/day) and a normal Multi-vitamin, Smoking cessation, weight loss, exercise,
11125219|NCT03898531||hip prosthesis ceramic/polyethylene in simple mobility|
11125188|NCT03898739|Active Comparator|traction therapy from neutral position|Patients in this group will receive traction decompression from neutral neck position with rope angle (0°)
11125189|NCT03898739|Active Comparator|traction therapy from lateral bending|patients will undergo traction decompression from (30°) lateral bending of the neck toward the non-affected side
11125190|NCT03898739|Active Comparator|traction from flexion with lateral bending and rotation|patients will be treated with traction decompression from (15°) neck flexion, (30°) lateral bending toward non- affected side and (15°) rotation to the affected side.
11125191|NCT03898726|Active Comparator|laparoscopical l cuff closure|needle holder laparoscopic vaginal cuff closure
11125192|NCT03898726|Active Comparator|transvaginal cuff closure|transvaginal cuff closure
11125193|NCT03898700|Active Comparator|coaching face to face|10, 1 hour sessions of face to face strength based coaching sessions
11125194|NCT03898700|Active Comparator|phone coaching|10, 1 hour sessions of strength based coaching via phone.
11125195|NCT03898687|Other|MAGMEN arm|Patients with melanoma of the extremities included in the protocol. SLNB will be performed with the addition of magtrace (SPIO) injection, 0.2 ml around previous scar. The patients will undergo MRI of the involved basin (Axilla-groin)and receive the SpIO injection the day before SLN biopsy. A separate SPIO MRI will be performed before the operation. All patients will receive all 3 methods for SLN identification as described in the protocol.
11125196|NCT03898674|Experimental|GDT feasibility|Patients undergoing microcirculatory goal directed therapy
11125197|NCT03898661|Experimental|local collagenase|Patients receiving local injection of collagenase into the esophageals stricture
11125198|NCT03898648|Experimental|Depressed patients with history of suicide attempt|Depressed patients with a lifetime history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
11125199|NCT03898648|Experimental|Depressed patients without any history of suicide attempt|Depressed patients without history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
11125200|NCT03898635||Background group|The treatment regimen does not include linezolid throughout the treatment course.
11125201|NCT03898635||Background-linezolid group|Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.
11125202|NCT03898635||Linezolid initial group|Linezolid was in initial treatment regimen.
11125203|NCT03898622|Active Comparator|Group with levothyroxine|Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5u / L ) to complete three months of intervention.
11125204|NCT03898622|Placebo Comparator|Group Placebo|"atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria.
~Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5 / month) to complete three months of intervention."
11125205|NCT03898609|Experimental|Low-fat diet|20% fat 20% protein 60% carbohydrate
11125206|NCT03898609|Experimental|Low-carbohydrate diet|45% fat 20% protein 35% carbohydrate
11125207|NCT03898596|Other|ECG Monitoring|ECG readings will be collected for neonatal patients who require or currently have UVC
11125208|NCT03898583|Experimental|Microarray patch A|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
11125209|NCT03898583|Experimental|Microarray patch B|21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
11125210|NCT03898583|Placebo Comparator|Vehicle|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
11125211|NCT03898583|Active Comparator|Daivobet|21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
11125212|NCT03898570||Patients undergoing vascular surgery procedures|Patients will report outcomes via their smartphone.
11125213|NCT03898557|Experimental|Usual Care|"Participants randomized to this arm will receive a card with information to report results via WhatsApp, similar to the existing card used in the STAR program. This card will have a dedicated Usual Care WhatsApp number (different from the existing STAR program numbers).
~Potential self-test recipients will be shown the WhatsApp card and instructed on how to anonymously report use of self-test to the WhatsApp number. Recipients will be instructed to message the WhatsApp number for the following reasons:
~1. So study staff know the self-test recipients used the test and it went ok. 2. So study staff can help the self-test recipients understand the results of the test. 3. If the self-test recipients need support from study staff to access care and services."
11125214|NCT03898557|Experimental|Plan and Pledge|"Participants randomized to this arm will revive the Usual Care WhatsApp card and and a brief template to make a plan and make a pledge for test completion and results reporting, to take the HIV self-test. The card will include a dedicated Plan and Pledge WhatsApp number.
~Potential self-tester recipients will be shown the WhatsApp card, including Plan and Pledge statements, and will be encouraged by STAR field staff to use the card in their own time to make a plan and sign the pledge as part of receiving the test kit and instructions for how to complete the card. Importantly, testers will be able to keep the card for themselves. There is no expectation to share the plan or the pledge signature with the STAR field staff who distribute self-tests. Field staff will clarify for self-tests recipients that the Plan and Pledge process and card do not change the confidentiality of testing in any way."
11125215|NCT03898544||Group primary TKA|Patients operated of primary TKA Stryker for knee osteoarthritis.
11125216|NCT03898544||Group TKA revision|Patients operated of a first revision of TKA for a mechanical failure, with the revision Stryker TKA
11125217|NCT03898531||hip prosthesis metal/polyethylene in simple mobility|
11125218|NCT03898531||hip prosthesis metal/polyethylene in double mobility|
11125224|NCT03898518|No Intervention|Control Group|The control group was in the facility for all jump rope exercise sessions but did not participate in the exercise intervention.
11125225|NCT03898518|Experimental|Experimental Group|The experimental group performed the jump rope exercise intervention.
11125226|NCT03898505|Placebo Comparator|Placebo|Placebo powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour. Participants in the placebo group will ingest 1 scoop of the placebo material per day (30-35g). Placebo powder is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Placebo will be consumed once per day for 60 days.
11125227|NCT03898505|Experimental|Low Dose|All Participants randomized to the low dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 50 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the low dose group will ingest 1 scoop of this test product per day (30-35g). Low dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Low dose test product will be consumed once per day for 60 days.
11125228|NCT03898505|Experimental|High Dose|All Participants randomized to the high dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 200 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the high dose group will ingest 1 scoop of this test product per day (30-35g). High dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. High dose test product will be consumed once per day for 60 days.
11125229|NCT03898492|Other|Intervention|The participants in this group participated in exercise two times/week for 8 weeks
11125230|NCT03898492|No Intervention|Control|The participants in the control group were instructed to maintain their daily routines.
11125231|NCT03898479|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
11125232|NCT03898466|Experimental|Fluticasone Furoate|"Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.
~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
11125233|NCT03898466|Placebo Comparator|Matching Placebo|"Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.
~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
11125234|NCT03898453|Experimental|Group EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
11125235|NCT03898453|Other|Group Control : support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.
~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
11125236|NCT03898427||Individuals with atopic dermatitis|Sensor technology and digital measures will be used to evaluate scratch and sleep in individuals with atopic dermatitis receiving standard of care treatments (SOC) who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
11125237|NCT03898401|Experimental|1 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125238|NCT03898401|Experimental|2 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125239|NCT03898401|Experimental|3 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125240|NCT03898401|Experimental|4 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125241|NCT03898401|Experimental|5 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125284|NCT03898258||neurogenic bladder|individuals with chronic (≥12 months) neurogenic lower urinary tract dysfunction due to spinal cord injury (SCI)
11125285|NCT03898245|Active Comparator|active tDCS|intervention : Intensity 2mA, 30minues, 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS
11125242|NCT03898401|Experimental|6 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125243|NCT03898401|Experimental|7 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125244|NCT03898401|Experimental|8 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125245|NCT03898401|Experimental|9 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125246|NCT03898401|Experimental|10 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125247|NCT03898401|Experimental|11 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125248|NCT03898401|Experimental|12 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125249|NCT03898401|Experimental|13 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125250|NCT03898401|Experimental|14 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125251|NCT03898401|Experimental|15 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125252|NCT03898401|Experimental|16 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125253|NCT03898401|Experimental|17 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125254|NCT03898401|Experimental|18 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125255|NCT03898401|Experimental|19 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125256|NCT03898401|Experimental|20 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125257|NCT03898401|Experimental|21 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125286|NCT03898245|Sham Comparator|sham tDCS|Intensity 2mA, 8 seconds (but looks same as an intervention 30mins), 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS (sham mode)
11125258|NCT03898401|Experimental|22 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125259|NCT03898401|Experimental|23 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125260|NCT03898401|Experimental|24 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125261|NCT03898401|Experimental|25 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125262|NCT03898401|Experimental|26 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125263|NCT03898401|Experimental|27PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125264|NCT03898401|Experimental|28 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125265|NCT03898401|Experimental|29 PRP|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125266|NCT03898401|Experimental|30 PRp|"Inclusion criteria:
~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.
~Exclusion criteria:
~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
11125267|NCT03898388|Experimental|Knee Synovial Fluid collection before Regenexx-SD|Measure components of knee synovial fluid 2-4 days before the Regenexx-SD treatment.
11125268|NCT03898375|Experimental|VR-enhanced treadmill walking|Participants will be tested during 4 sessions of 20 minutes treadmill walking.
11125269|NCT03898362|Active Comparator|pneumatically powered wheelchair or scooter|participants will use pneumatic powered wheelchair or scooter
11125270|NCT03898362|Active Comparator|battery powered wheelchair or scooter|participants will use battery powered wheelchair or scooter
11125271|NCT03898349|No Intervention|Non-Texters|"Patients did not receive the automated text messaging system Annie"
11125272|NCT03898349|Active Comparator|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
11125273|NCT03898336|Experimental|broad-spectrum micronutrients|broad-spectrum micronutrients description: capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
11125274|NCT03898336|Placebo Comparator|placebo|capsules containing placebo
11125275|NCT03898323|Experimental|AABM Training|Alcohol Approach Bias Modification (AABM) training is a computer training program that participants interact with by pushing and pulling a joystick. Participants are asked to respond to the format of a presented picture, irrespective of the pictures' content. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. AABM training consists of 3 sessions per week over 2 weeks, for a total of 6 sessions.
11125276|NCT03898310|Experimental|Cranberry Extract Capsules|36mg of proanthocyanidins in cranberry capsules
11125277|NCT03898310|Placebo Comparator|Placebo Capsules|
11125278|NCT03898297||Healthy control|30 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
11125279|NCT03898297||MDD|30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
11125280|NCT03898297||Bipolar|30 subjects with bipolar disorder may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
11125281|NCT03898284||Impulse Oscillometry|Patients with Idiopathic Pulmonary Fibrosis. The objective is to determine whether another lung function technique, impulse oscillometry, is of interest to identify disease progression before changes in forced vital capacity can be ascertained.
11125282|NCT03898271|Experimental|Virtual World Training|Synchronous PTSD training in a virtual world environment
11125283|NCT03898271|Active Comparator|Web-based Video Training|Asynchronous web-based PTSD training
11125287|NCT03898206|Experimental|Prolonged sitting|Participants will remain seated for 5 h and instructed to reduce excessive movement, only rising from the chair to void.
11125288|NCT03898206|Experimental|Breaking up sitting with walking breaks|Participants will rise from the seated position every 30 min throughout the experimental period to walk on a motorised treadmill at a light intensity walking (as determined during the preliminary test) for 3 min. Participants will start walk on a treadmill at 30 min (so physical activity would be at 30-33 min), 60 min (physical activity will be at 60-63 min), 90 min (physical activity will be at 90-93 min), 120 min (physical activity will be 120-123 min), 150 min (physical activity will be at 150-153 min ), and 180 min (physical activity will be at 180-183 min) in the breakfast postprandial period and 30 min (physical activity will be 30-33 min), 60 min (physical activity will be at 60-63 min), and 90 min (physical activity will be at 90-93 min) in the lunch postprandial period. After performing walking activity, they will return to the seated position.
11125289|NCT03898193|Other|Sequence Test-Reference (TR)|17 participants (total number of enrolled volunteers - 34) assigned to sequence TR will receive a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 1 and a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11125290|NCT03898193|Other|Sequence Reference-Test (RT)|17 participants (total number of enrolled volunteers - 34) assigned to sequence RT will receive a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 1 and a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11125291|NCT03898180|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) until progressive disease or discontinuation. Lenvatinib may be continued past 35 cycles until a discontinuation criterion is met.
11125292|NCT03898180|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD until progressive disease or discontinuation. Placebo may be continued past 35 cycles until a discontinuation criterion is met.
11125293|NCT03898167|Active Comparator|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator on behalf of Harris Health System.
11125294|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit|Participants receive a scripted telephone recall from a patient navigator on behalf of Harris Health System and receive a mailed HPV self-sampling kit with a pre-paid return envelope.
11125295|NCT03898167|Experimental|Mailed HPV Self-Sampling Kit + Patient Navigation|Participants receive a scripted telephone recall and mailed self-sampling kit with a pre-paid return envelope. Within 3-5 days of the kit's mail-out, participants will receive a telephone call from a patient navigator to provide one-on-one education.
11125296|NCT03898154|Experimental|Glucocorticoid (GC) group|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
11125297|NCT03898154|No Intervention|Control (non-GC) group|No GC administration
11125298|NCT03898141|Experimental|Animal-assisted placebo condition (AAPL)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream.
~Additionally, they will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high de-gree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Therefore, the distance between participant and dog will always be the same. However, partici-pants will still be able to see the dog."
11125299|NCT03898141|Placebo Comparator|Placebo only (PO)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
11125300|NCT03898141|Experimental|Dog only (DO)|"Participants will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. During the experiment the dog will be lying in the room with some distance to avoid further physical interaction.
~After the introduction of the dog, participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements"
11125301|NCT03898141|No Intervention|No dog, no placebo (ND)|Participants will participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements.
11125302|NCT03898115|Experimental|CHG Bathing Implementation|In a step-wedged design, ICUs and BMT units will be enrolled into a educational program to improve knowledge/compliance with daily CHG bathing
11125303|NCT03898115|No Intervention|Control|In a step-wedged design, ICUs and BMT units will be enrolled over a rolling 4 month time frame; when not enrolled, this data will serve as control data
11125304|NCT03898102|Experimental|Regorafenib treatment with Zn supplement|Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
11125305|NCT03898102|Active Comparator|Regorafenib treatment only|Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.
11125306|NCT03898089|Other|Core Exercise Group|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks.
11125307|NCT03898089|Experimental|Core Exercise plus Myofascial Relaxation Group|In addition to the core stabilization exercises myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks.
11125308|NCT03898063|Active Comparator|Control|participants will receive a standard-of-care brochure detailing HIV status disclosure.
11125309|NCT03898063|Experimental|intervention 1: 90 DAYS film|participants will watch the film, 90 DAYS
11125310|NCT03898063|Experimental|intervention 2: 90 DAYS film plus epilogue|participants will watch the film, 90 DAYS and also a brief epilogue created by the research team that connects key messages in the narrative and steps to enact safe disclosure
11125311|NCT03898050|Experimental|A-P|Anterior - Posterior pad placement
11125312|NCT03898050|Experimental|A-L|Anterior - Lateral pad placement
11125313|NCT03898037|Experimental|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.
~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
11125314|NCT03898037|Experimental|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.
~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
11125315|NCT03898037|Experimental|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.
~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
11125316|NCT03898037|No Intervention|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
11125317|NCT03898024|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
11125318|NCT03898024|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
11125319|NCT03898024|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
11125320|NCT03898024|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
11125321|NCT03898024|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
11125322|NCT03898011|Other|Sequence Test-Reference (TR)|14 participants (total number of enrolled volunteers - 28) assigned to sequence TR will receive a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 1 and a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11125323|NCT03898011|Other|Sequence Reference-Test (RT)|14 participants (total number of enrolled volunteers - 28) assigned to sequence RT will receive a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 1 and a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11125324|NCT03897998|Active Comparator|Naloxone|NARCAN® Naloxone Nasal Spray will be used to block placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
11125325|NCT03897998|Sham Comparator|Saline|Saline will be used as a sham comparator for blocking placebo effects during the fMRI experiment. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
11125326|NCT03897972|Active Comparator|Non-personalised general diet advice|Control group to receive non-personalised dietary advice based on general public health dietary recommendations for Northern Europe. Advice will be delivered to the participant via the eNutri web application.
11125327|NCT03897972|Experimental|Personalised diet advice|Intervention group to receive personalised dietary advice generated by the eNutri app from their actual dietary intakes and tailored according to their body mass index and food preferences. Advice will be delivered to the participant via the eNutri app web application and will be generated based on their adherence to an 11-item diet quality score suitable for Northern European populations.
11125328|NCT03897959|Other|Kohli vs Foley Study|Compare various performance characteristics of two urinary catheters.
11125329|NCT03897946|Experimental|Group A: Hepatitis B exposed, with birth dose|"The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study."
11125330|NCT03897946|No Intervention|Group B: Hepatitis B unexposed, no birth dose|"For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B)."
11125331|NCT03897946|Experimental|Group C: Hepatitis B unexposed, with birth dose|"Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule."
11125332|NCT03897933||Erector spinae plane block group (ESP)|Single- shot ultrasound guided ESP block with 30 ml 0.25% bupivacain at the T10 vertebral level will performed preoperatively to patients in the ESP group (Group I).
11125333|NCT03897933||non- blocked Group|consists of the patient group without any procedure
11125334|NCT03897907|Experimental|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
11125335|NCT03897907|Placebo Comparator|Control Education|This arm will provide education of basic knee anatomy and will not address maladaptive psychological behaviors.
11125336|NCT03897894|Experimental|Enhanced Service Package|"The enhanced service package provides 40 sequential sessions selected by CFS program staff in advance and implemented over a twelve-week period. Activities are meant to build upon and reinforce one another and are organized into seven psychosocial themes: 1) Building community: Our space together, 2) Emotional learning: My feelings, 3) Wellbeing and coping: Feeling good, 4) Social support: My friends and family, 5) Relating to others: Being a good friend, 6) Protection and boundaries: My safety, and 7) Building on strengths: All my supports. Each session takes approximately 1.5 - 2 hours to facilitate and will conclude with 1-1.5 hours unstructured free play time."
11125337|NCT03897894|Experimental|Basic Service Package|The basic service package offers a mixture of recreational and non-formal education activities over a twelve-week period. Each session lasts around 1.5 - 3 hours. Structured activities offered include basic literacy and numeracy lessons, life skills exercises, health and hygiene sessions, and traditional song and dance. Many activities are centered around various forms of play that enable expression and age-appropriate skill development. Unstructured free play and playground time is allocated throughout the daily session.
11125338|NCT03897894|No Intervention|Control|Waitlist control will receive delayed treatment of intervention after the primary assessment period.
11125339|NCT03897881|Experimental|Combination treatment arm|mRNA-4157 and pembrolizumab
11125340|NCT03897881|Active Comparator|Control treatment arm|Pembrolizumab only
11125341|NCT03897868|Experimental|Experimental 1|HCP1803 High
11125342|NCT03897868|Experimental|Experimental 2|HCP1803 Middle
11125343|NCT03897868|Experimental|Experimental 3|HCP1803 Low
11125344|NCT03897868|Active Comparator|Active Comparator 1|HGP0904 High
11125345|NCT03897868|Active Comparator|Active Comparator 2|HGP0904 Low
11125346|NCT03897868|Active Comparator|Active Comparator 3|HGP0608
11125347|NCT03897868|Placebo Comparator|Placebo Comparator|Placebo
11125348|NCT03897855|Other|Patient (TSPT-R)|Post Traumatic Stress Disorder
11125349|NCT03897855|Experimental|control|No Post Traumatic Stress Disorder
11125350|NCT03897842|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
11125351|NCT03897816||"PERINATAL"|Pregnant women consecutively referred and admitted to the Perinatal Psychiatric Outpatient Department
11125352|NCT03897816||"OUTPTS"|Pregnant women belonging to the Outpatients Psychiatric Department who did not have psychiatric issues linked to their pregnancy or in the relationship with their children
11125353|NCT03897816||Healthy controls|Pregnant women the general population, with no history of mental health issues
11125354|NCT03897803||Group (I):juvenile dermatomyositis (JDM)|"Group (I): twenty children diagnosed to have juvenile dermatomyositis (JDM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.
~."
11125355|NCT03897803||Group (II):idiopathic inflammatory myopathies(IIM)|"Group (II): twenty adults diagnosed to have idiopathic inflammatory myopathies(IIM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.
~•"
11125356|NCT03897803||Group (III): juvenile control group|"20 healthy children matching age and sex as first control group to children with JDM .Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
~."
11125357|NCT03897803||Group (VI):adult control group|20 healthy adults matching age and sex as second control group to adults with IIM. Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
11125358|NCT03897790||Patients under vasoconstrictor|Patients older than 65 years old and hypertensive, requiring vasoconstrictor (phenylephrine or Neosynephrine) during general anesthesia.
11125381|NCT03897569||patellofemoral pain syndrome|twenty subjects with anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
11125359|NCT03897777|Experimental|Hypertension (Exercise Intervention)|Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
11125360|NCT03897764|Experimental|Superior Hypogastric Block group|The group which superior hypogastric block performed intraoperatively
11125361|NCT03897764|Placebo Comparator|placebo controlled group|The group which placebo used
11125362|NCT03897738|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
11125363|NCT03897738|Placebo Comparator|Placebo|"Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
~Placebo capsules are identical to Amberen and Smart B capsules."
11125364|NCT03897725|Experimental|Telehealth Intervention|Study participants will be randomized into either the control or experimental group. Participants in the intervention group will receive routine care which will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP. This group will also receive SMS texting every 4 weeks between in-person visits (weeks 16, 20, 28,32, 40, 44) reminding them to pick up their medication. The experimental group will also be seen in follow up every month for the first 3 months and then spaced out to visits every 3 months. The SMS texting will occur every 4 weeks between in-person visits, the experimental group will also have 2 tele-health visits (which will be conducted within a participant's home using an app) that will occur every 4 weeks between each of the traditional in-person visits to provide more frequent monitoring and counseling regarding adherence.
11125365|NCT03897725|No Intervention|Routine Care|The control group will follow the schedule from previous adolescent PrEP studies where participants are recommended to follow up at 4, 8, and 12 weeks and then every 3 months following initiation of PrEP.
11125366|NCT03897699|Experimental|active tDCS + Mindful Breathing Training|20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training
11125367|NCT03897699|Sham Comparator|sham tDCS + Mindful Breathing Training|The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session
11125368|NCT03897686|Experimental|NOLTREX™, II-III grade OA|72 patients with II-III grade of gonarthrosis will randomised to receive PAHG
11125369|NCT03897686|Placebo Comparator|Placebo, II-III grade ОА|72 patients with II-III grade of gonarthrosis will randomised to receive saline solution
11125370|NCT03897673|Experimental|Early Iron|Children in the immediate iron group will receive iron syrup for the first three months (84 days) and placebo syrup for the fourth month.
11125371|NCT03897673|Experimental|Delayed Iron|Children in the delayed iron group will receive placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months.
11125372|NCT03897673|No Intervention|Community Control Children|Healthy, non-anemic community children will be enrolled from the same households and villages as the children with malaria. They will not have ZPP tested or receive iron, but they will also be under the same illness surveillance as the children with malaria.
11125373|NCT03897660|Active Comparator|TG form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acidsesterified in a reconstitute triglyceride form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
11125374|NCT03897660|Active Comparator|EE form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in ethyl esters form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
11125375|NCT03897660|Experimental|MaxSimil (MAG form of omega-3)|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
11125376|NCT03897647|Experimental|POCUS Patients|A bedside echocardiogram will be taken using a point-of-care pocket ultrasound (General Electric (GE) Vscan). Central venous pressure (right atrial pressure) and pulmonary capillary wedge pressure (left atrial pressure) will be collected from pulmonary artery catheters.
11125377|NCT03897634|Experimental|Experiences Hearing Aid user|Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
11125378|NCT03897621|Experimental|tranexamic acid|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
11125379|NCT03897621|Placebo Comparator|Normal saline|Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language
11125380|NCT03897595|Other|Mpact cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
11125382|NCT03897569||control|twenty-six asymptomatic subject will be recruited for this study and should have no pain or other relevant clinical symptoms in the lower quadrant
11125383|NCT03897556|Active Comparator|High-dose|This arm consists of cancer survivors who receive two guarana energy bars to take per day for six weeks; one in the morning and one around lunch time.
11125384|NCT03897556|Active Comparator|Low-Dose|This arm consists of cancer survivors who receive one guarana energy bar to take per day for six weeks; one in the morning only.
11125385|NCT03897556|Other|Usual Care|This arm receives usual-care only as cancer survivors.
11125386|NCT03897543|Experimental|ABX196|IM injection of 0.1, 0.2, and 0.4 µg of ABX196
11125387|NCT03897530|Experimental|Prevention|During the session, participants are presented with randomly ordered conditions: menthol cigarettes and five flavored e-cigarettes (menthol/mint, fruits, sweets, alcohol, snacks/meals), menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes, non-menthol cigarettes and five flavored e-cigarettes, and non-menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes. Participants' visual attention is evaluated by eye-tracking equipment.
11125388|NCT03897517|Experimental|Proprietary Botanical Blend|Proprietary Botanical Blend - Dietary supplement with alpha amylase and sucrase inhibitory activity. 2 capsules
11125389|NCT03897517|Placebo Comparator|Placebo|Non/minimally nutritive nonactive material: rice flour. 2 capsules
11125390|NCT03897504|Experimental|feminizing genitoplasty using inner surface of the prepuce|Feminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
11125391|NCT03897491|Experimental|Interstitial photodynamic therapy|20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
11125392|NCT03897478||Ischemic Stroke|"Ischemic stroke subjects presenting within 30 hours from symptom onset will have al PAX Gene Blood RNA tubes drawn upon arrival to the Emergency Department (if available) or hospital.
~Biomarker blood draw"
11125393|NCT03897478||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn. Control group matched with ischemic stroke subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.
~Biomarker blood draw"
11125394|NCT03897465|Experimental|Lomatuell Pro|Lomatuell Pro® is a wound contact layer consisting of wide-meshed tulle, impregnated with a polymer matrix, which form a gel on contact with wound exudate to facilitate moist wound healing.
11125395|NCT03897465|Active Comparator|UrgoTul|UrgoTul® is a flexible contact layer with TLC healing matrix comprised of a conformable polyester mesh impregnated with hydrocolloid and petroleum jelly particles.
11125396|NCT03897452|Experimental|Fentanyl for procedural pain|"A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.
~This is not an RCT with several arms."
11125397|NCT03897439|Active Comparator|Usual Care (UC)|196 African American smokers will receive 12 weeks of smoking cessation counseling and 18 weeks of nicotine patch.
11125398|NCT03897439|Experimental|Optimized Care (OPT)|196 African American smokers will receive 12 weeks of smoking cessation counseling. They will receive the nicotine patch and up to two pharmacotherapy adaptations (VAR, BUP+NP) based on verified smoking status at Weeks 2 and 6 for a total of 18 weeks of pharmacotherapy.
11125399|NCT03897426|No Intervention|Standard-of-care arm|Patients randomized to the Standard-of-care-arm were provided 60 minutes of RD time for consultation through in person visits.
11125400|NCT03897426|Experimental|Intervention arm|"Mediterranean Diet - Remote Coaching using a Mobile App.
~Patients randomized to the intervention arm were allotted 60 minutes of RD time through a Mobile App (for remote consultation), given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD. Remote coaching by RD was the intervention."
11125401|NCT03897413|Experimental|Sequence 1|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fed state in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
11125402|NCT03897413|Experimental|Sequence 2|Participants received a single oral dose of 0.75 mg S-888711 in the fed state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
11125403|NCT03897413|Experimental|Sequence 3|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state in period 2, and a single oral dose of 0.75 mg S-888711 in the fed state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
11125404|NCT03897400||study group|women in reproductive age with crohn's disease
11125405|NCT03897400||control group|women in reproductive age without crohn's disease,
11125406|NCT03897361|Experimental|CTNS-RD-04 Gene Therapy|This is a single arm study without randomization. Eligible subjects will receive the final product: CTNS-RD-04.
11125407|NCT03897348|Experimental|Lacosamide 100 mg|100 mg capsule of lacosamide, an FDA-approved anticonvulsant. A single dose is given at the beginning of 1 of the 3 ADP sessions.
11125408|NCT03897348|Experimental|Lacosamide 200 mg|200 mg capsule of lacosamide, an FDA-approved anticonvulsant. A single dose is given at the beginning of 1 of the 3 ADP sessions.
11125409|NCT03897348|Placebo Comparator|Placebo|A matching capsule of placebo. A single dose is given at the beginning of 1 of the 3 ADP sessions.
11125410|NCT03897335|Active Comparator|Aminophylline pre CPB & immediately post CPB|
11125411|NCT03897335|Placebo Comparator|Placebo|
11125412|NCT03897309|Experimental|Monovalent GI.1|Monovalent GI.1 tableted vaccine group
11125413|NCT03897309|Experimental|Monovalent GII.4|Monovalent GII.4 tableted vaccine group
11125414|NCT03897309|Experimental|Bivalent GI.1 and GII.4 vaccine group|Bivalent vaccine group consisting of co-administration of GI.1 and GII.4 vaccine
11125416|NCT03897296|Experimental|healthy subjects examined with water-perfused catheter|healthy subjects - subjects without signs of functional and organic anorectal pathology
11125417|NCT03897283|Experimental|Anlotinib + TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11125418|NCT03897270|Experimental|Diagnostic (photoacoustic imaging of the breast)|Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.
11125419|NCT03897257|Experimental|UHE-103A1 cream|Topical cream applied twice daily for 2 weeks.
11125420|NCT03897257|Experimental|UHE-103A2 cream|Topical cream applied twice daily for 2 weeks.
11125421|NCT03897257|Experimental|UHE-103B cream|Topical cream applied twice daily for 2 weeks.
11125422|NCT03897257|Experimental|UHE-103A1B cream|Topical cream applied twice daily for 2 weeks.
11125423|NCT03897257|Experimental|UHE-103A2B cream|Topical cream applied twice daily for 2 weeks.
11125424|NCT03897244|Experimental|High-dose dual therapy|group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
11125425|NCT03897244|Experimental|Bismuth High-dose dual therapy|group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
11125426|NCT03897244|Active Comparator|Amoxicillin-Metronidazole Bismuth quadruple therapy|group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
11125427|NCT03897218|Placebo Comparator|Group 1|Patients consuming placebo (millet flakes) each day
11125428|NCT03897218|Experimental|Group 2|Patients consuming oatmeal flakes with a low dosage of prebiotic food supplements
11125429|NCT03897218|Experimental|Group 3|Patients consuming oatmeal flakes with a high dosage of prebiotic food supplements
11125430|NCT03897205|Experimental|Imlifidase|Subjects randomized to imlifidase treatment will receive one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
11125431|NCT03897205|Active Comparator|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment will receive 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) may replace PE, at the discretion of the investigator.
11125432|NCT03897179|Experimental|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
11125433|NCT03897166|Experimental|Trimodality Imaging|Positron Emission Tomography coupled with Computed Tomography computed coupled with Magnetic Resonance Imaging and whole-body Biphoton Absorptiometry
11125434|NCT03897153|Experimental|Experimental:Diagnostic|Diagnostic Test: SONAS® Ultrasound Device
11125435|NCT03897140|Experimental|Patients scheduled for an echocardiogram|Patients ≥18 years scheduled for an echocardiographic examination. This is a non-randomized, un-blinded, study in patients with an indication for an echocardiographic examination. Enrolled patients will be stratified into two groups based on known cardiac abnormalities to ensure a sufficient number of patients with cardiac abnormalities and into 3 strata of BMI: normal, overweight and obese.
11125436|NCT03897127|Active Comparator|Standard arm|
11125437|NCT03897127|Experimental|Investigational arm|
11125438|NCT03897114|Experimental|Cocoa group|The cocoa will be provided in sachets. The intervention will be carried out for 10 weeks. Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
11125439|NCT03897114|Placebo Comparator|Placebo group|Maltodextrin will be supplied as a placebo, which will be provided in sachets. Athletes will take 5g of product per day.
11125440|NCT03897101||MILD NE|"gestational age > 35 weeks and weight > 1800 gr
~Apgar score < 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes or evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses
~evidence of mild encephalopathy graded according to Sarnat&Sarnat neurological evaluation
~normal amplitude integrated electroencephalography
~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
11125441|NCT03897101||ISOLATED METABOLIC ACIDOSIS|"gestational age > 35 weeks and weight > 1800 gr
~evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses
~Normal Sarnat&Sarnat neurological evaluation
~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
11125442|NCT03897101||HEALTY CONTROLS|"gestational age > 35 weeks and weight > 1800 gr Normal blood pH or base excess
~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokiness will be evaluated"
11125443|NCT03897088|Experimental|Arm A:|
11125444|NCT03897088|Placebo Comparator|Arm B|
11125445|NCT03897075|Experimental|Arm A|
11125446|NCT03897075|Placebo Comparator|Arm B|
11125447|NCT03897062|Active Comparator|Treatment group|Patients (n=64): 20mg tablets of suvorexant nocte daily for six months
11125448|NCT03897062|Placebo Comparator|Placebo group|Placebo control group: Patients (n=64): 1 placebo tablet nocte daily for six months in addition to treatment as usual
11125449|NCT03897049|Experimental|TWC App|The intervention is a mobile app delivered sexual health promotion program designed specifically for transgender women. The mobile app will include more than 30 interactive activities including resource maps, PrEP and PEP content, and communication forums for connecting with other transgender women. The intervention/app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
11125450|NCT03897049|Active Comparator|General Health App|Participants will download a general health mobile app that contains sexual health information. The control mobile app is intended to be used regularly, approximately two times per week during the 90 day active participation period.
11125451|NCT03897036|Experimental|CX-4945 28 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 28 of each treatment cycle
11125452|NCT03897036|Experimental|CX-4945 21 Day Dose Duration|CX-4945 capsules at 1000mg BID, on Days 1 through 21 of each treatment cycle
11125453|NCT03897036|Experimental|Expansion CX-4945 Locally Advanced BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
11125454|NCT03897036|Experimental|Expansion CX-4945 Metastatic BCC|CX-4945 capsules at 1000mg BID, on the dosing schedule identified during the Phase I treatment duration increment part of the study
11125456|NCT03897010|Active Comparator|Silica-calcium phosphate composite Group|Participants underwent socket augmentation procedures and dental implant placement in a staged approach. Atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. Free gingival gingival graft (1.5 to 2 mm thick) was taken from the area between the first and second premolar, 5 mm from gingival margin. Bioactive porous SCPC dental bone graft granules in the size range 90-710 micron were mixed with saline and loosely packed in the extraction sockets as per the manufacturer. The grafted SCPC granules were covered with free gingival graft obtained from the palatal tissues and sutured to stabilize the grafting material in place.
11125457|NCT03897010|Placebo Comparator|Control Group|Participants underwent atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. The socket left to heal.
11125458|NCT03896984||Cohort_2LX|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as first liine (1L) after diagnosis of mCRPC who then received Ra-223 monotherapy as second line (2L) treatment
11125459|NCT03896984||Cohort_2LH|Patients with mCRPC who received NAH monotherapy (Abiraterone or Enzalutamide) as 1L after diagnosis of mCRPC who then received another NAH monotherapy (i.e., Abiraterone to Enzalutamide or Enzalutamide to Abiraterone) as 2L treatment. None of the patients had ever received Radium-223 dichloride
11125460|NCT03896971|Experimental|Thrombopoietin mimetic plus immunosuppressive therapy|The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
11125461|NCT03896971|No Intervention|Immunosuppressive therapy|A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
11125462|NCT03896945|Placebo Comparator|Placebo|Placebo capsules will be administered orally twice a day over a 15-week period.
11125463|NCT03896945|Experimental|AVP-786|AVP-786 capsules will be administered orally twice a day over a 15-week period.
11125464|NCT03896932|Experimental|minipooled- Intravenous immunoglobulin(MP-IVIG)|• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
11125465|NCT03896919||cases|HLA-DQ mismatched recipient-donor pairs
11125466|NCT03896919||control|HLA-DQ matched recipient- donor pairs
11125467|NCT03896906|Experimental|Group N|pre-oxygenation with High-flow nasal cannula
11125468|NCT03896906|Active Comparator|Group M|pre-oxygenation with simple mask
11125469|NCT03896893|No Intervention|Standard of Care|Routine bathing and skin care as per hospital practice
11125470|NCT03896893|Experimental|1% chlorhexidine gluconate (CHG)|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays (total of 8 days CHG application)
11125471|NCT03896893|Experimental|Emollient therapy|Aquaphor skin cream applied from the neck down daily on weekdays (total of 8 days emollient application)
11125472|NCT03896893|Experimental|1% CHG plus emollient therapy|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays followed immediately by Aquaphor skin cream (total of 8 days CHG application plus emollient application)
11125473|NCT03896880||blood culture positive|hematological malignancy patients with positive blood culture
11125474|NCT03896867|Experimental|Anapod™ Humi-Therm Heated Humidification System|Patient warming will be provided via the Anapod™ Humi-Therm Heated Humidification System Breathing Circuit.
11125475|NCT03896867|Active Comparator|Bair Hugger™ Warming Blanket|Patient warming will be provided via the Bair Hugger™ Warming Blanket.
11125476|NCT03896854|Experimental|CD19 positive relapsed or refractory acute myeloid leukemia|MICM typing confirmed CD19 positive relapsed and refractory acute myeloid leukemia
11125477|NCT03896841||PCOS|premenopausal patients with PCOS
11125478|NCT03896841||control subjects|non-pregnant healthy control subjects
11125479|NCT03896828|Experimental|Sedentary|Sedentary (SED): Participants will remain seated in the lab all-day (7.5 hr).
11125480|NCT03896828|Experimental|Walking Breaks|Walking breaks (WALK): Participants will perform 2-minute walking breaks at 3.1 mph on a treadmill every 30 minutes (7.5 hr).
11125481|NCT03896828|Experimental|Resistance-exercise breaks|"Resistance exercise breaks (RE): Participants will perform 15 squats (1-minute) every 30 minutes. To reduce the risk of injury, standardize squat-depth, and recruit similar muscle groups as walking, the squats performed will be a chair-stand with calf-raise (7.5 hr)."
11125482|NCT03896802|Experimental|Low PEEP|PEEP 5 cmH2O
11125483|NCT03896802|Experimental|High PEEP|PEEP 15 cmH2O
11125484|NCT03896789|No Intervention|Baseline|All sites will collect usual care data from 9 months to 21 months.
11125485|NCT03896789|Experimental|PEGASUS Program (Intervention)|This arm (half of the sites) will receive the PEGASUS program (intervention) from 21 months to 57 months.
11125486|NCT03896789|No Intervention|Usual Care (Control)|This arm (half of the sites) will maintain usual care. They will receive the opportunity for the PEGASUS program training (intervention) at the end of study data collection (57 months) period.
11125487|NCT03896776|Experimental|Community Based Organization (CBO) Delivery|"CBOs will be selected through a Request for Proposal (RFP) process. The RFP will describe research and KIU! delivery activities to be conducted as part of the study and allowable budget to carry out the activities. The RFP will ask CBOs to describe past experience providing HIV services for YMSM. Selected CBOs will recruit participants into the intervention and encourage participants to complete each session of intervention content at baseline, 3 Month Follow-up, and 6 Month Follow-up.
~Participants in the CBO delivery arm will receive baseline HIV and STI testing at a CBO. Participants will receive an at-home STI test kit at 12 Month Follow-up."
11125513|NCT03896659|Experimental|Depressed: Hydrocortisone, then Placebo|"Participants in the depressed' arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
11125514|NCT03896659|Experimental|Depressed: Placebo, then Hydrocortisone|"Participants in the depressed' arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
11125488|NCT03896776|Experimental|Direct to Consumer (DTC) Delivery|"In the DTC arm, participants will be recruited online via paid social media advertising (e.g., Facebook, Instagram). Advertisements will target placements by age, gender, sexual orientation, racial background, likes that are relevant to YMSM (e.g., local LGBT organizations, out celebrities), and location (i.e., target county). Dating/sex-seeking apps (e.g., Grindr) will also be used to recruit YMSM, using a similar advertising approach as social media. These online recruitment strategies will be supplemented by referrals from local organizations and participant registries, and snowball recruitment. Study staff at Northwestern University will manage this recruitment process and encourage participants to complete each session of intervention content at baseline, 3 Month Follow-up, and 6 Month Follow-up.
~Participants in the DTC delivery arm will receive at-home HIV and STI test kits at baseline. Participants will receive an at-home STI test kit at 12 Month Follow-up."
11125489|NCT03896763|Experimental|Supine / CMV|Supine positioning and conventional mechanical ventilation
11125490|NCT03896763|Experimental|Prone / CMV|Prone positioning and conventional mechanical ventilation
11125491|NCT03896763|Experimental|Supine / HVOF|Supine positioning and high-frequency oscillatory ventilation
11125492|NCT03896763|Experimental|Prone / HFOV|Prone positioning and high-frequency oscillatory ventilation
11125493|NCT03896750|Active Comparator|Part A Group 1A|6 healthy participants with normal estimated Glomerular Filtration Rate (eGFR > / = 90 mL/min/1.73 m^2) matched to Group 2 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and BMI at dosing (+/- 20% of BMI, but between 18 and 35 kg/m^2) will receive a single oral dose of 200 mg pretomanid
11125494|NCT03896750|Experimental|Part A Group 2|6 participants with End Stage Renal Disease (ESRD) not on dialysis: Stage 5, Modification of Diet in Renal Disease (MDRD) with estimated Glomerular Filtration Rate (eGFR < 15 mL/min/1.73 m^2) matched to Group 1A will receive a single oral dose of 200 mg pretomanid
11125495|NCT03896750|Active Comparator|Part B Group 1B|6 healthy participants with normal eGFR of > / = 90 mL/min/1.73 m^2 matched to Group 3 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and BMI at dosing (+/- 20% of BMI, but between 18 and 35 kg/m^2) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
11125496|NCT03896750|Active Comparator|Part B Group 1C|6 healthy participants with normal eGFR > / = 90 mL/min/1.73 m^2 matched to Group 4 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and BMI at dosing (+/- 20% of BMI, but between 18 and 35 kg/m^2) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
11125497|NCT03896750|Active Comparator|Part B Group 1D|6 healthy participants with normal eGFR > / = 90 mL/min/1.73 m^2 matched to Group 5 by race, gender, age (+/- 10 years, but between 18 to 70 years of age) and BMI at dosing (+/- 20% of BMI, but between 18 and 35 kg/m^2) will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
11125498|NCT03896750|Experimental|Part B Group 3|6 participants with mild renal impairment: Stage 2, MDRD (eGFR 60-89 mL/min/1.73 m^2) matched to Group 1B will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
11125499|NCT03896750|Experimental|Part B Group 4|6 participants with moderate renal impairment: Stage 3, MDRD (eGFR = 30-59 mL/min/1.73 m^2) matched to Group 1C will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
11125500|NCT03896750|Experimental|Part B Group 5|6 participants with severe renal impairment: Stage 4, MDRD (eGFR = 15-29 mL/min/1.73 m^2) matched to Group 1D will receive a single oral dose of 200 mg pretomanid after the PK and safety of subjects enrolled in Part A have been reviewed
11125501|NCT03896737|Experimental|Dara-VCd|"treatment period includes administration of four 28-day cycles of induction with Dara- VCd; then patients will undergo transplant and finally they will receive two 28-day cycles of Dara-VCd consolidation treatment.
~The response will be assessed after each cycle. Patients in the first randomization will be stratified according to FISH (standard/missing vs high risk,defined as del17, t 4;14, t 14;16) and ISS (I vs II and III).
~TREATMENT SCHEMA - INDUCTION Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4.
~Bortezomib: 1.3 mg/m2 given SC injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or IV infusion on days 1, 8, 15, 22; Dexamethasone: 40 mg given orally or by IV infusion on days 1, 8, 15,22 Repeat for four 4-week induction cycles."
11125502|NCT03896737|Active Comparator|VTd|"treatment period includes administration of four 28-day cycles of induction with VTd; then patients will undergo transplant and finally they will receive two 28-day cycles of VTd consolidation treatment.
~TREATMENT SCHEMA INDUCTION
~ARM VTd:
~Bortezomib: 1.3 mg/m2 given by SC injection on days 1, 4, 8, 11 of 28-day cycle; Thalidomide: 100 mg given orally on days 1-28. Dexamethasone: 20 mg given orally or by IV injection on days 1, 2, 3, 4, 8, 9, 10 and 11 of every 28-day cycle.
~Repeat for four 4-week induction cycles."
11125503|NCT03896724|Experimental|Group 1|n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M.
11125504|NCT03896724|Experimental|Group 2|n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M.
11125505|NCT03896724|Placebo Comparator|Group 3 (control group)|n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial.
11125506|NCT03896711|Experimental|Active Intervention|Intervention arm with MEMORI Corps program
11125507|NCT03896711|Other|Control|Augmented waitlist control.
11125508|NCT03896698|Experimental|TUS treatment|AD patients with TUS treatment
11125509|NCT03896698|No Intervention|Non-TUS treatment|AD patients with Non-TUS treatment
11125510|NCT03896685|Experimental|endTB-Q: BeDeCLi 24 or 39 weeks|endTB-Q regimen: bedaquiline-delamanid-linezolid-clofazimine (BeDeCLi). Subjects who are randomized to this arm will be assigned to duration of 24 or 39 weeks , according to the participant's extent-of-TB-disease phenotype. Participants may take as long as 32 weeks to complete all doses of a 24-week treatment regimen, and up to 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of the experimental regimens will be oral and weight based.
11125511|NCT03896685|Active Comparator|endTB-Q: Control arm|endTB-Q is the control regimen, designed according to latest World Health Organization guidelines.
11125512|NCT03896672|Experimental|Treatment with Continuous Positive Airway Pressure|All patients will undergo to physiotherapeutic treatment based on the previous training of the physiotherapist
11125589|NCT03896178||Controls|Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
11125515|NCT03896659|Experimental|Healthy Controls: Hydrocortisone, then Placebo|"Participants in the healthy control arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
11125516|NCT03896659|Experimental|Healthy Controls: Placebo, then Hydrocortisone|"Participants in the healthy control arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
11125517|NCT03896646|Experimental|Treatment (personalized radioembolization, SPECT/CT HIDA)|Patients undergo yttrium-90 microsphere radioembolization with yttrium Y 90 glass microspheres using personalized dose measurements. Patients also undergo SPECT/CT HIDA scan before radioembolization and 2-4 months after radioembolization.
11125518|NCT03896633|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
11125519|NCT03896633|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
11125520|NCT03896620||Stage II-III Sarcomas undergoing preoperative RT|
11125521|NCT03896620||Stage II-III Sarcomas undergoing postoperative RT|
11125522|NCT03896620||Stage IV Sarcomas|
11125523|NCT03896594|Experimental|HL237 200mg|HL237 100mg 1 tablet twice a day
11125524|NCT03896594|Experimental|HL237 400mg|HL237 100mg 2 tablets twice a day
11125525|NCT03896594|Experimental|HL237 800mg|HL237 400mg 1 tablet twice a day
11125526|NCT03896581|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen.
11125527|NCT03896581|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo.
11125528|NCT03896568|Experimental|Part I (oncolytic adenovirus Ad5-DNX-2401)|Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.
11125529|NCT03896568|Experimental|Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)|Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.
11125530|NCT03896542|Experimental|Commercial video game|the group commercial video game received 30 minutes of conventional therapy plus 30 minutes of rehab training using Xbox Kinect-based games.
11125531|NCT03896542|Experimental|Rehabilitation video game|the group rehabilitation video game received 30 minutes of conventional therapy plus 30 minutes of rehab games.
11125532|NCT03896542|No Intervention|The control group|The control group received 30 minutes of conventional therapy
11125533|NCT03896529|No Intervention|No-stress control group|Participants in this group will perform the psychology tasks (virtual navigation) without any manipulation of psychological stress
11125534|NCT03896529|Experimental|Stress group|Participants in this group will perform the psychology tasks (virtual navigation) under manipulated psychological stress (anticipatory threat of shock)
11125535|NCT03896516|Experimental|Active Drug|GOAT Inhibitor
11125536|NCT03896516|Placebo Comparator|Placebo|Placebo Participants will take GLWL-01 450 mg b.i.d. or matched placebo for up to 16 days
11125537|NCT03896503|Active Comparator|Arm I (topotecan hydrochloride )|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II at disease progression.
11125538|NCT03896503|Experimental|Arm II (topotecan hydrochloride, M6620)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and M6620 IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11125539|NCT03896490|Experimental|ACT|
11125540|NCT03896490|Placebo Comparator|Control|
11125541|NCT03896477|Experimental|Pneumosil|PCV-10
11125542|NCT03896477|Active Comparator|Prevenar 13|PCV-13
11125543|NCT03896477|Active Comparator|Synflorix|PCV-10
11125544|NCT03896464|Active Comparator|Soft-tissue hamstring|All patients in the study will undergo arthroscopic-assisted, single-bundle, complete transphyseal, anatomic primary ACL reconstruction at the discretion of the surgeon, considering the individual patient's age, physeal status, and anticipated years of growth remaining to skeletal maturity. Patients in this arm will undergo soft-tissue autograft reconstruction using hamstrings (i.e. semitendinosus and/or gracilis) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
11125545|NCT03896464|Active Comparator|Quadriceps tendon|Patients in this arm will undergo soft-tissue autograft reconstruction using all-soft-tissue quadriceps (i.e. full or partial thickness) grafts. Grafts will be secured on the femur and tibia according to surgeon preference, given literature demonstrating no clear superior method for graft fixation.
11125546|NCT03896451|Other|GMK Sphere|"Patients receiving total knee replacement surgery with the device Medacta GMK Sphere"
11125547|NCT03896451|Other|GMK PS|"Patients receiving total knee replacement surgery with the device Medacta GMK PS"
11125548|NCT03896438|Experimental|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
11125549|NCT03896438|Experimental|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
11125550|NCT03896438|Sham Comparator|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
11125551|NCT03896425|Experimental|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
11125552|NCT03896425|Experimental|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
11125553|NCT03896425|Sham Comparator|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
11125554|NCT03896412|Experimental|Detection of circulating tumor DNA|sampling of 20 ml of blood the day before surgery, the day after , 6 months after diagnosis and every 3 months thereafter until 18 months of follow up
11125555|NCT03896399|Experimental|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
11125622|NCT03895957|Experimental|Group 2: VR Mind|Virtual Reality Exposure Therapy VR Mind
11125556|NCT03896386|Other|Use of seizure diary|People diagnosed with epilepsy that lives with a dog that is able to anticipate the onset of a seizure. They will be ask to use a diary (bespoke smartphone app) to register the occurrence of seizures and the alerting behaviour of the dogs.
11125557|NCT03896373||Lupus erythematosus|Patients with inactive lupus erythematosus, active lupus erythematosus or newly diagnosed
11125558|NCT03896360|Experimental|Food order behavioral intervention plus standard care|Subjects will receive standard nutrition counseling and additional carbohydrate-last food order behavioral counseling.
11125559|NCT03896360|Other|Standard care|Subjects will receive standard nutrition counseling.
11125560|NCT03896347||ViBone®|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
11125561|NCT03896347||Demineralized Bone Matrix|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
11125562|NCT03896347||Bone Morphogenetic Protein|One product will be used on each level. At the time of surgery, implantation of ViBone®, DBM, and BMP will be randomized between the three treated levels.
11125563|NCT03896334|Experimental|Isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training will train three times per week, during 24 weeks. They will perform a bout of isometric handgrip exercise: four sets of 2-min of isometric contractions (using alternate hands) at 30% of maximal voluntary contraction.
11125564|NCT03896334|Sham Comparator|Control group|All participants randomized to control group will realize stretching and relaxation exercises, three times per week, during 24 weeks.
11125565|NCT03896321|Active Comparator|Asprin|Patient will receive dual anti platelet asprin And clopidogrel
11125566|NCT03896321|Active Comparator|Clopidogrel|Patient will receive dual anti platelet asprin And clopidogrel
11125567|NCT03896321|Active Comparator|Warfarin|Patient will receive oral anticoagulation
11125568|NCT03896321|Active Comparator|Novel oral anticoagulant|Patient will receive oral anticoagulation
11125569|NCT03896295|Experimental|M281|
11125570|NCT03896282|Active Comparator|daycare facility|After surgery patient stay at daycare facility for mobilisation and stay until discharge or transfer to standard patient ward if nor discharged by 20.000
11125571|NCT03896282|Active Comparator|standard patient ward|After surgery patients are transferred to standard patient ward for mobilisation and stay until discharge.
11125572|NCT03896269|Experimental|Treatment (liposome-encapsulated daunorubicin-cytarabine)|"INDUCTION THERAPY: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. After 2-5 weeks, patients who do not achieve a CR/CRi/CRp, have acceptable or no toxicity, and have stable disease and no disease progression may receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Patients who achieve at least a HI response, receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 5-8 weeks, patients who do not show clinically significant disease progression or unacceptable toxicity may receive liposome-encapsulated daunorubicin-cytarabine for up to 12 additional cycles."
11125573|NCT03896256|Experimental|Treatment Arm|Patients will be admitted to the hospital for a total of 5 full days from the time of admission until discharge. Ketamine infusion will be started on day 1. Adjustments to ketamine infusion will be made according to standard acute pain service protocol.
11125574|NCT03896243||Uterine artery ligation (UAL)|"We would like toinvite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.
~They would be evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
11125575|NCT03896243||Control Group:|"We would like to invite the patients to the hospital at least 6 months after C-section who delivered baby without any complication.
~They would be also evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
11125576|NCT03896230|Active Comparator|Arm 1: 0.1 mg/kg ketamine|0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
11125577|NCT03896230|Active Comparator|Arm 1: 0.2 mg/kg ketamine|0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
11125578|NCT03896230|Active Comparator|Arm 1: 0.3 mg/kg ketamine|0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
11125579|NCT03896217|Active Comparator|Simvastatin|Simvastatin is part of the pharmacotherapeutic group of HMG-CoA reductase inhibitors (ATC-Code: C10A A01). Simvastatin is licensed within the EU for hypercholesterolemia and cardiovascular prevention but for this trial its use will be outside its licensed indication. Oral Simvastatin will be taken 40mg daily (one tablet in the evening) for 4 weeks and then at week 4 up titrated to 80mg daily (two tablets in the evening.
11125580|NCT03896217|Placebo Comparator|Placebo|Matched Placebo (one tablet in the evening) for 4 weeks and then at week 4 up titrated to two tablets daily in the evening.
11125581|NCT03896204|Experimental|telephone-supported group|
11125582|NCT03896204|Experimental|Other group|
11125583|NCT03896191||Stable, satisfied primary TKR|Participants who have a stable TKR (as assessed by the surgical team) and are satisfied with their knee replacement (as assessed by a questionnaire).
11125584|NCT03896191||Unstable, dissatisfied primary TKR|Participants who are dissatisfied with their TKR, with instability (including instability due to aseptic loosening) and consequently awaiting revision TKR.
11125585|NCT03896178||Firefighters|
11125586|NCT03896178||Pilots|
11125587|NCT03896178||Police|
11125588|NCT03896178||Military personnel|
11125590|NCT03896165|Experimental|Teaching Reiki|Parent-adolescent pairs will be in the study for a total of nine weeks from enrollment to the follow up visit. During Week 1, the parent will receive Reiki training, a poster with suggested hand positions and a commercially-available book about Reiki in the home. During Week 2 the parent will receive a Reiki booster session with a repeat of the training and may ask questions in the home. At the end of Week 4, measures will be repeated either in person or by phone. During Week 8, measures will be repeated, another hair sample obtained and the parent will participate in a qualitative interview. The qualitative interview will be administered in person by trained Ohio State University College of Nursing study staff as part of the interview session. Interviews will be audio recorded using a hand-held audio recording device. Audio recording is voluntary and participants can choose to not have their interview recorded and still be a part of the study.
11125591|NCT03896152|Experimental|Arm 1|approximately 2 year Treatment with low LNP023 dose
11125592|NCT03896152|Experimental|Arm 2|approximately 2 year Treatment with higher LNP023 dose
11125593|NCT03896139||VUMC EHR cohort|De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).
11125594|NCT03896139||Toxicity induced by kinase inhibitors in Vigibase database|Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity
11125595|NCT03896126||Gastroparesis Patients|20 gastroparesis patient ages 20-49
11125596|NCT03896126||Healthy Controls|40 healthy controls ages 20-49
11125597|NCT03896113|Experimental|Celecoxib|Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery will receive celecoxib 400 mg twice a day, for 15 days before the curative surgery for their endometrial cancer. The patients will undergo an endometrial biopsy at the inclusion and during the surgery.
11125598|NCT03896100||Element 2|Four clinical samples will be taken from each eligible subject and used to assess two clinical removal methods and two in vitro removal methods.
11125599|NCT03896100||Element 3|Four clinical samples will be taken from each eligible subject and used to assess three different storage methods.
11125600|NCT03896100||Element 4|Four clinical samples will be taken from each eligible subject and used to assess different ocular regions.
11125601|NCT03896087|Experimental|clinical performance of the HCV DBS assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the for assays (medical devices) used for the qualitative and quantitative detection of Hepatitis C RNA.
11125602|NCT03896087|Active Comparator|comparison PQ marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
11125603|NCT03896074|Experimental|Atezolizumab|Patients allocated to Arm A will be treated with atezolizumab administered intravenously at 1200 mg every 3 weeks given until disease progression, toxicity or patient refusal
11125604|NCT03896074|Experimental|Atezolizumab plus bevacizumab|Patients in the Arm B will receive atezolizumab administered intravenously at 1200 mg every 3 weeks plus bevacizumab intravenously at 15 mg/kg every 3 weeks given until disease progression, toxicity or patient refusal
11125605|NCT03896048||Successful extubation|
11125606|NCT03896048||Failed extubation|Failed extubation will be defined as a patient who in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.
11125607|NCT03896035|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
11125608|NCT03896035|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
11125609|NCT03896022|Active Comparator|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
11125610|NCT03896022|Active Comparator|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
11125611|NCT03896022|Sham Comparator|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
11125612|NCT03896009|Experimental|AXS-07|Taken once upon a qualifying migraine
11125613|NCT03896009|Active Comparator|Meloxicam|Taken once upon a qualifying migraine
11125614|NCT03896009|Active Comparator|Rizatriptan|Taken once upon a qualifying migraine
11125615|NCT03896009|Placebo Comparator|Placebo|Taken once upon a qualifying migraine
11125616|NCT03895996|Experimental|AVT001 (Treatment)|Infusion of AVT001 (treatment) in monthly doses x 3, 7x10^6-10x10^6 cells/dose
11125617|NCT03895996|Placebo Comparator|Matched placebo|Infusion of AVT001-matched placebo in monthly doses x 3
11125618|NCT03895983||Thrombus aspiration group|Will include 135 patients who will have PPCI with thrombus aspiration
11125619|NCT03895983||Standard PPCI group|Will include 135 patients who will have PPCI without thrombus aspiration
11125620|NCT03895970|Experimental|Lenvatinib plus Pembrolizumab|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
~Pembrolizumab is a recombinant anti-human PD-1 monoclonal antibody."
11125621|NCT03895957|Experimental|Group 1: VR Mind+|Virtual Reality Exposure Therapy VR Mind+
11125623|NCT03895957|Active Comparator|Control group: CBT|Cognitive Behavioral Therapy
11125624|NCT03895944|Experimental|iv low dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10^6) in Leukemia or Lymphoma patients
11125625|NCT03895944|Experimental|iv middle dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10^6) in Leukemia or Lymphoma patients
11125626|NCT03895944|Experimental|iv high dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10^6) in Leukemia or Lymphoma patients
11125627|NCT03895918|Experimental|Delayed Group (delayed parental skills)|Participants continue medication adherence monitoring over 2 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
11125628|NCT03895918|Experimental|Early Group (early parental skills)|Participants continue medication adherence monitoring over 1 week and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
11125629|NCT03895918|Experimental|Late Group (late parental skills)|Participants continue medication adherence monitoring over 3 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
11125630|NCT03895905||Genotype of HR-HPV 16/18|Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy
11125631|NCT03895905||Genotype of HR-HPV Non-16/18|Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy
11125632|NCT03895892|Placebo Comparator|Water Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
11125633|NCT03895892|Experimental|Experimental 1|Ketone salts supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
11125634|NCT03895892|Experimental|Experimental 2|Ketone salts/caffeine supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
11125635|NCT03895879|Experimental|Intervention|Tocilizumab administered every 2 weeks
11125636|NCT03895879|Active Comparator|Control|Tocilizumab administered every week
11125637|NCT03895879|Active Comparator|Standard dose (screening < 15 mg/L)|Tocilizumab administered every week
11125638|NCT03895866||Group A|High-risk HPV persistent infection more than half a year and reversion
11125639|NCT03895866||Group B|High-risk HPV non-infection
11125640|NCT03895853|Active Comparator|Group I (standard of care)|Patients receive standard of care for septic shock.
11125641|NCT03895853|Experimental|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
11125642|NCT03895840|Experimental|Intra-articular Zilretta injection|32 mg Zilretta in a 5ml diluent for each knee, per manufacturer guidelines
11125643|NCT03895827|Active Comparator|Passive Referral Control|Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.
11125644|NCT03895827|Experimental|Recovery Initiation and Management after Overdose (RIMO)|Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.
11125645|NCT03895814|Experimental|Multi-baseline Step Training|"Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week protective step training period. Participants will also be assessed 2 months later at a follow-up visit."
11125646|NCT03895801|Experimental|Group A Experimental + active comparator|IFX-1 + reduced dose GC
11125647|NCT03895801|Active Comparator|Group B Placebo + active comparator|Placebo-IFX-1 + standard dose GC
11125648|NCT03895801|Placebo Comparator|Group C Experimental + placebo comparator|IFX-1 + Placebo-GC
11125649|NCT03895788|Experimental|niraparib and brivanib|Subjects will be assigned into niraparib 100mg+brivanib 200mg, niraparib 200mg+brivanib 200mg, niraparib 200mg+brivanib 400mg, niraparib 200mg+brivanib 600mg dose group at the first day of the first cycle.
11125650|NCT03895749|Active Comparator|Neo40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
11125651|NCT03895749|Placebo Comparator|Placebo|Per Capsule: Beet Juice concentrate, Carmine, Croscarmellose Sodium, D-Mannitol, Magnesium Stearate, Orange flavour, Silicon dioxide, Stevia rebaudiana leaf, Xylitol.
11125652|NCT03895723|Experimental|Minimally Invasive surgery|the intevention of Minimally Invasive procedure contains laparoscopic and robotic liver resection
11125653|NCT03895723|Other|Open surgery|the open surgery means traditional open surgery for liver resection
11125654|NCT03895710||Sleep-deprived group|i. Self-reported time in bed (period from bedtime to get-up time) during school days of <8 hours per day ii. Self-perceived insufficient sleep during school days
11125655|NCT03895710||Normal sleep group|i. Self-reported time in bed during school days of >=8 hours per day ii. Self-perceived sufficient sleep during school days
11125656|NCT03895697|Experimental|Sequence 1|V2: Single fixed dose (sc injection) of dasiglucagon batch B then at V3: Single fixed dose (sc injection) of dasiglucagon batch A
11125657|NCT03895697|Experimental|Sequence 2|V2: Single fixed dose (sc injection) of dasiglucagon batch A then at V3: Single fixed dose (sc injection) of dasiglucagon batch B
11125658|NCT03895684|Experimental|Sp-2577|Twice-daily administration of oral SP-2577
11125659|NCT03895671|Experimental|AP-CML|Patient with Philadelphia chromosome positive CML in accelerated phase is defined by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), ≥ 20% basophils in PB or BM, ≥ 30% blasts plus promyelocytes (with blasts <30%) in PB or BM, <100 x109/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome);
11125660|NCT03895671|Experimental|MBC-CML|Patient with Philadelphia chromosome positive CML in myeloid blast crisis is defined by the presence of ≥ 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease.
11125661|NCT03895658|Experimental|ECT|ECT treatment, within subject crossover
11125662|NCT03895658|Experimental|MRI|Structural and functional neuroimaging pre and post ECT treatment
11125663|NCT03895658|Experimental|TMS|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
11125664|NCT03895645||Study Participants|Participants on the studies' samples that are transferred to this protocol
11125665|NCT03895619|Experimental|Men living with HIV|Uptake of safer conception strategies among men living with HIV and/or their female partners
11125666|NCT03895606||HIPEC|patients undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy due to carcinomatosis.
11125667|NCT03895580|No Intervention|Group 1|Medical nutrition therapy session with no further dietary counseling throughout the study.
11125668|NCT03895580|Experimental|Group 2|Medical nutrition therapy session plus in-store point-of-purchase (POP) education.
11125669|NCT03895580|Experimental|Group 3|Medical nutrition therapy session plus combined in-store/online point-of-purchase (POP) education.
11125670|NCT03895567|Experimental|ABC|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
11125671|NCT03895567|Experimental|ACB|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
11125672|NCT03895567|Experimental|BAC|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
11125673|NCT03895567|Experimental|BCA|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
11125674|NCT03895567|Experimental|CAB|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
11125675|NCT03895567|Experimental|CBA|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
11125676|NCT03895554||Normal volunteers|Normal, healthy volunteers with undergo cardiac PET stress testing.
11125677|NCT03895541|Other|Stratification|All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity.
11125678|NCT03895515||Fiasp®|Participants with type 1 diabetes who have switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin.
11125679|NCT03895502|Experimental|12-month Edoxaban|Edoxaban for 12 months
11125680|NCT03895502|Active Comparator|3-month Edoxaban|Edoxaban for 3 months
11125681|NCT03895489|Experimental|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
11125682|NCT03895489|Active Comparator|Stryker|Stryker Triathlon Total Knee prosthesis
11125683|NCT03895489|Active Comparator|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
11125684|NCT03895476|Active Comparator|control group|palatal wound will not be protected with any material
11125685|NCT03895476|Active Comparator|group 1|palatal wound will be protected with Platelet rich Fibrin
11125686|NCT03895476|Active Comparator|group 2|wound will consist of collagen protection with the additional layer of cyanoacrylate surgical glue.
11125687|NCT03895476|Active Comparator|group 3|wound will consist of collagen protection with the application
11125688|NCT03895450|Experimental|Aerobic Exercise Protocol (AEP)|Symptom threshold will be determined at baseline and repeated every 3 weeks using the Buffalo Concussion Treadmill Test. Briefly, there will be an initial 4min warm up at 1.7mph. The protocol will start with treadmill speed se to 3.3 mph and 0.0% incline. Each subsequent minute, the incline will increase by 1.0% to a max of 15%. At 15% grade, if the participant is still able to continue, treadmill speed will increase by 0.4mph each minute. Heart rate (HR) and rating of perceived excretion (RPE Borg scale) will be measured every minute. The test will be terminated upon symptom exacerbation at which time HR and RPE will be recorded. Every 3 weeks the symptom threshold test will be repeated for all participants and exercise prescription will be adjusted accordingly.
11125689|NCT03895450|Placebo Comparator|Stretching Protocol (SP)|The exercise testing for the stretching protocol to determine exercise prescription will be the same as described above.
11125690|NCT03895437|Experimental|TOL-3021|TOL-3021 2 mg/mL
11125691|NCT03895437|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
11125692|NCT03895424|Experimental|Iron Fatty Acid Complex (IFAC)|The iron fatty acid complex encapsulated and administered to the participants
11125693|NCT03895424|Experimental|Micellarized iron fatty acid complex (MIFAC)|Micellarized form of the iron fatty acid complex which is enscapsulated and administered to the participants
11125694|NCT03895424|Active Comparator|Control Ferrous Sulfate|Ferrous sulfate that is provided in the form of a solution along with a capsule that contains the same amount of fat that is present in the other two arms.
11125695|NCT03895411|Experimental|Sotalol|Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc
11125696|NCT03895411|Active Comparator|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc
11125728|NCT03895190|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
11125729|NCT03895190|Experimental|Experimental: Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
11125697|NCT03895398|Experimental|nutrition and psychosocial intervention arm|"12 selected ECE centers will be selected to be the intervention group. ECE teachers will be trained on psychosocial and nutrition care for children and expected to deliver the information and parenting class to mother.
~Community health officers will be trained on how to monitored the activities regularly and providing technical assistance to ECE teachers if needed.
~mothers will received weekly parenting class. in the parenting class mothers will be informed on how to provide appropriate feeding and psychosocial stimulus to their children. nutrient dense food supplementation in the form of liver and fish floss will be prepared together and distributed.
~underfive children will received nutrient dense food supplementation in the form of liver and fish floss and expected to be eaten everyday for 6 months"
11125698|NCT03895398|No Intervention|control arm|no intervention is given to this arm
11125699|NCT03895385|Experimental|Bimekizumab|Subjects randomized to this arm will receive a single dose bimekizumab followed by inactivated influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
11125700|NCT03895385|No Intervention|No Treatment|Subjects randomized to this arm will receive the influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
11125701|NCT03895372|Experimental|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
11125702|NCT03895372|Experimental|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
11125703|NCT03895372|Experimental|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
11125704|NCT03895372|Experimental|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
11125705|NCT03895372|Experimental|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
11125706|NCT03895359|Active Comparator|Transarterial Chemoembolization (TACE)|
11125707|NCT03895359|Active Comparator|TACE Plus Stereotactic Body Radiation Therapy (SBRT)|
11125708|NCT03895346|Experimental|Mindfulness|Class meeting three times a week for six months, led by a certified mindfulness meditation instructor. Includes instruction and practice on techniques such as breathing, body scan, physical sensations, and yoga.
11125709|NCT03895346|Active Comparator|Brain Games and Puzzles|Class meeting three times a week for six months, led by a qualified instructor. Includes teaching and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
11125710|NCT03895333||study group|women with hearing loss and osteoporosis will develop the study group.
11125711|NCT03895333||control group|women who have hearing loss but have no osteoporosis will constitute the control group.
11125712|NCT03895320|Experimental|Intervention Program|The intervention and control programs will consist of similar, but not identical components. The intervention will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the intervention program, the self-assessment ('Sexual Health Quiz'), score ('Sexual Health Score') and messaging ('Sexual Health Messaging') will pertain to sexual and reproductive health. For the intervention program, the self-assessment, will include a valid clinical prediction tool, established to predict STI positivity. Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen after the risk score. The program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
11125713|NCT03895320|Other|Control Program|The intervention and control programs will consist of similar, but not identical components. The Control Program will include a) a brief self-assessment (also called 'quiz'), b) score, and c) personalized messaging. For the Control Program, the self-assessment ('Water Sugar Sweetened Beverages (SSB) Quiz'), score ('Water SSB Score') and messaging ('Water SSB Messaging') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment. However, based on the answers given on the control quiz, steps the control participant can take to meet the recommended daily intake of water and sugar sweetened beverages will be displayed on the screen after they complete the quiz. The control program will be delivered via tablet. All participants regardless of randomization group, will be offered a STI screening kit immediately after receipt of their respective program.
11125714|NCT03895307|Experimental|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
11125715|NCT03895307|Placebo Comparator|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
11125716|NCT03895307|Experimental|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
11125717|NCT03895307|Placebo Comparator|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
11125718|NCT03895294|Experimental|Health care under the strategic purchase-Clinical pathway|Health care under the strategic purchase and the Clinical pathway for the treatment of chronic Hepatitis C
11125719|NCT03895294|Active Comparator|Usual care process prior strategic purchase-clinical pathway|Usual care process prior to the establishment of the strategic purchase and the Clinical Pathway
11125720|NCT03895255|Active Comparator|IMA high ligation with routine SFM|Inferior mesenteric artery is ligated close to its origin. Splenic flexure is always mobilized.
11125721|NCT03895255|Experimental|IMA skeletonization and low ligation with selective SFM|Inferior mesenteric artery is ligated below the origin of left colic artery. Splenic flexure is mobilized only if needed.
11125722|NCT03895242|Experimental|Group 1:First supine position,then prone position|First group was supine position then prone position.
11125723|NCT03895242|Experimental|Group 2:First prone position, then supine position|Second group was first prone position, then supine position.
11125724|NCT03895229|Experimental|Experimental Arm|Subjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet [Jardiance]
11125725|NCT03895203|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
11125726|NCT03895203|Active Comparator|Adalimumab dosage regimen|Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
11125727|NCT03895203|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
11125730|NCT03895177|Experimental|low kVp high mAs CT group|doing pancreatic CT with 80 kVp tube current with more than 500 mA tube current for the evaluation of pancreatic cancer resectability
11125731|NCT03895164|Placebo Comparator|Standard NE|Control Group will receive standard nutrition education package from primary health care.
11125732|NCT03895164|Experimental|Enhanced NE|Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
11125733|NCT03895151|Experimental|Milk supplementation|"Children will receive 130 ml fresh milk, 6 days/week for 20 weeks (January-June 2019).
~Milk will be provided and delivered by appointed supplier directly to school. Milk will be distributed with name of the student on the bottle - during break time.
~Subjects must be consumed with supervision of the teacher at school during the break.
~If they can not finish the milk at once, they can store it in the provided cool box. Student then can consume it again before they go home. Teacher have to record the remaining milk in each bottle that corresponds to every child name and record it in the provided form.
~Prior to holiday, student will be given the milk according to school leave days.
~Enumerators should collect the form every 3 days and make a recap in the provided form."
11125734|NCT03895151|Experimental|Food Based Recommendation (FBR) nutrition education|FBR group will received nutrition education delivered by trained teacher under the supervision of researcher/research assistant once a week. Those who received nutrition education is not only the recruited subjects but also includes their classmates.
11125735|NCT03895151|No Intervention|Control|Control group will receive standard nutrition education
11125736|NCT03895138|Active Comparator|Standard Glucommander Protocol (SGP)|CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
11125737|NCT03895138|Experimental|Optimized Glucommander (OGM)|CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
11125738|NCT03895125|Experimental|[year1] PD group|
11125739|NCT03895125|Active Comparator|[year1] healthy control group|
11125740|NCT03895125|Experimental|[year2-3] freezer|
11125741|NCT03895125|Experimental|[year2-3] non-freezer|
11125742|NCT03895112|Experimental|AVID200|intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
11125743|NCT03895099|Experimental|A - Early follicular phase|Treatment by desogestrel at day 1 to day 3
11125744|NCT03895099|Experimental|B - Medium follicular phase|Treatment by desogestrel at day 4 to day 7
11125745|NCT03895099|Experimental|C - Late follicular phase|Treatment by desogestrel at day 7 to day 11
11125746|NCT03895099|Experimental|D - Ovulatory Phase|Treatment by desogestrel at day 12 to day 15
11125747|NCT03895099|Experimental|E - Luteal phase|Treatment by desogestrel at day 16 to day 30
11125748|NCT03895086|Experimental|Specific Physical Activity|Specific patient care in telephone coaching of fibromyalgia patients.
11125749|NCT03895086|Other|Classic Physical Activity|Classic patient care in common group of multipathological patients.
11125750|NCT03895073||healthy|healthy volunteers' replies to questionnaire
11125751|NCT03895073||heart failure|heart failure patients' replies the questionnaire
11125752|NCT03895060|Experimental|autogenous ring blockls with GBR covered by collagen membrane|Vertical and horizontal ridge augmentation using autogenous onlay ring blocks combined with simultaneous guided bone regeneration using native collagen membrane in atrophic anterior maxilla.
11125753|NCT03895047|Active Comparator|dACC,I,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
11125754|NCT03895047|Active Comparator|dACC,AC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week.12 sessions of Neurofeedback Training, 1-2 times per week."
11125755|NCT03895047|Active Comparator|I,dACC,AC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
11125756|NCT03895047|Active Comparator|I,AC,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
11125757|NCT03895047|Active Comparator|AC,dACC,I|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
11125788|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and microwave application|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
11125758|NCT03895047|Active Comparator|AC,I,dACC|"Within each training session, participants will receive 7 minutes training for each of the three brain areas Insula (I), dorsal anterior cingulate cortex (dACC) & the auditory cortex (AC) resulting in 21Minutes of training for each session. The arm Title describes the order in which participants within this Arm will receive the three trainings. (E.g. dACC,I,AC: each participant in this group receives the training of the dACC first and the AC last.) This sequence order is kept stable during all training sessions.
~12 sessions of Neurofeedback Training, 1-2 times per week."
11125759|NCT03895021|Experimental|Intervention|This multifaceted, adapted program focuses preventing falls through balance and strength exercises, teachings from guest experts (e.g., PT, Pharmacist, vision) and at-home safety education. Participants attended weekly 2-hour group sessions (8 -12 persons) over the course of 8 weeks delivered in Spanish by trained Hispanic/Latino personnel in two communities in Wisconsin.
11125760|NCT03895008||Cardia gastric cancer|Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
11125761|NCT03895008||Non-cardia gastric cancer|Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
11125762|NCT03894995|No Intervention|Part 1. Focus group discussions on ventilation preferences|Participant's perceived benefits/detriments of having ventilation options in the household and their opinions on the behavior change material developed to encourage increased household ventilation will be explored using 6-9 focus group discussions with 10-12 participants each.
11125763|NCT03894995|No Intervention|Part 2. PM 2.5 pilot|Indoor, outdoor, and personal particulate matter concentrations among ten mother-child pairs and their homes will be monitored.
11125764|NCT03894995|Experimental|Part 3. Intervention|Households will participate in a baseline survey and a Beck-DeGroot-Marshak auction to establish willingness-to-pay for ventilation. If the household wins, or if it is decided to install ventilation in all intervention households, the household will receive installation of a ventilating mechanism.
11125765|NCT03894995|No Intervention|Part 3. Control|For 12 month after intervention, the air exchange rate will be measured in all control households.
11125766|NCT03894995|No Intervention|Part 4. Spillover|Households that neighbor enrolled study households will be surveyed and asked whether they, on their own, chose to install a window. If they did install a window, they will be asked how much they paid.
11125767|NCT03894982||What is Asthma|"Reviewing asthma is a lung disease. There is no cure, but asthma can be well controlled so that your child can be healthy and join in all their favorite activities.
~Asthma causes the airways (breathing tubes in the lungs) to get smaller, making it hard to breathe.Common symptoms of asthma are coughing, wheezing, chest tightness and trouble breathing.
~These symptoms are ongoing and get better with asthma medicines."
11125768|NCT03894982||Triggers|Reviewing specifics around children with asthma have extra sensitive airways and many things around them can make their asthma worse. The things around your child that cause an asthma attack are called triggers. Triggers are different for each child. Your doctor can help you figure out your child's triggers. Try to keep your child away from their triggers, especially at home and at school where your child spends most of their time.
11125769|NCT03894982||Medications and Asthma Action Plan|Review what is an asthma action plan, how to use an asthma action and the medications listed on each individuals plan.
11125770|NCT03894969|Experimental|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group will receive 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects will receive 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
11125771|NCT03894969|Experimental|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group will receive 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects will receive 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211
11125772|NCT03894969|Experimental|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group will receive 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects will receive 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301
11125773|NCT03894969|Active Comparator|NTHi-Mcat Group|Subjects enrolled in this group will receive 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
11125774|NCT03894956||Participants with Hidradenitis Suppurativa (HS)|Participants who along with their treating physician have elected for treatment with Humira as per routine clinical practice for the treatment of HS
11125775|NCT03894943|Experimental|General|All subjects will undergo ordinary surgical treatment for their lumbar disc herniation. Experimentally, all subjects participating in the study will receive PET/CT scans and sensory testing as specified below.
11125776|NCT03894930|Experimental|Metta meditation|Eight-week, guided metta meditation training that is administered online
11125777|NCT03894930|No Intervention|Wait-list|Eight-week wait-list control with no training
11125778|NCT03894917||Group 1|Participants 65 years or older
11125779|NCT03894917||Group 2|Participants less than 65 years
11125780|NCT03894904|Experimental|Premixed Papaverine|2mL of the 50mL premixed syringe of papaverine as dispensed from pharmacy ( NaCl 0.9% inj 48.8 mL + papaverine 6mg+ heparin 100 units).
11125781|NCT03894904|Active Comparator|Heparin|2 ml of the 10 mL of 2 units/mL of heparin from the pressurized fast flush bag from the operating room.
11125782|NCT03894891|Experimental|Docetaxel+Cisplatin+Nivolumab+Radioimmunotherapy|Docetaxel will be administered per standard institutional every 3 weeks Nivolumab will be administered intravenously every 3 weeks Cisplatin will be administered intravenously every 3 weeks Radioimmunotherapy will be conducted 3 weeks after the last cycle of TPN (docetaxel, cisplatin and nivolumab)
11125783|NCT03894865|Experimental|urban school|Male students from selected urban schools undergo screening for idiopathic scoliosis
11125784|NCT03894865|Experimental|countryside schools|Male students from selected countryside schools undergo screening for idiopathic scoliosis
11125785|NCT03894852||AML|cases with denovo AML and t-AML
11125786|NCT03894852||MDS|cases with denovo MDS and t-MDS
11125787|NCT03894839|Active Comparator|glutaraldehyde disinfection and microwave application|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
11126117|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
11125789|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and microwave application|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
11125790|NCT03894839|Active Comparator|glutaraldehyde disinfection and ozone therapy|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
11125791|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and ozone therapy|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
11125792|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and ozone therapy|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
11125793|NCT03894826|Experimental|TREATMENT|Participants will be administered 230 mg/m2/day of oral Vorinostat [100 mg tablets] in addition to standard of care anti-seizure medication for a duration of 6 weeks.
11125794|NCT03894813|Experimental|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
11125795|NCT03894813|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
11125796|NCT03894800|Active Comparator|Methoxyflurane (M)|"A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
11125797|NCT03894800|Active Comparator|Fentanyl (F1)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
11125798|NCT03894800|Active Comparator|Fentanyl (F2)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
11125799|NCT03894800|Placebo Comparator|NaCl (C)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.
~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.
~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
11125800|NCT03894774|Experimental|Intensive InPatient Psychotherapy Treatment Group (IG)|Intensive non-pharmaceutical inpatient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic frame where patients live over the whole treatment (approximately a 1:1-ratio caregiver per patient is given) of 6 to 8 month treatment duration.
11125801|NCT03894774|Active Comparator|Waiting Control Group (WCG)|"Treatment as usual (mostly combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy).
~Duration: At least 3 month to a maximum of 6 month."
11125802|NCT03894774|No Intervention|Healthy Control Group (HCG)|"Matched Pairs design to control for gender, age and handedness. HCG measurements are planned and conducted according to the exact durations of their matched inpatient pair of the IG.
~Mandatory to control for effects of factors such as brain maturation."
11125803|NCT03894761|Other|Patients with Rotator Cuff Syndrome|The patients diagnosed with rotator cuff syndrome by clinical and magnetic resonance imaging.
11125804|NCT03894748|Experimental|MT10109L(Botulinum toxin type A)|
11125805|NCT03894748|Active Comparator|BOTOX® 50U(Botulinum toxin type A)|
11125806|NCT03894722|Placebo Comparator|Group I (control; saline only)|Control Group: Intraoperative irrigation with saline solution only.
11125807|NCT03894722|Experimental|Group II (0.5% concentration of PVP-I )|Experimental Group: Intraoperative irrigation with 0.5% concentration of PVP-I solution.
11125808|NCT03894722|Experimental|Group III (1% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 1% concentration of PVP-I solution.
11125809|NCT03894722|Experimental|Group IV (3% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 3% concentration of PVP-I solution.
11125832|NCT03894501|Other|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
11125833|NCT03894475|Active Comparator|Sequence A|Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
11125810|NCT03894709|Experimental|The family-centered care model|Interventions include a family-centered approach to interdisciplinary care and a family caregiving-training component to enhance family caregivers' competence in providing post-operative care and handling behavioral problems of adults with cognitive impairment. The interdisciplinary care model consists of geriatric consultation, continuous rehabilitation, and discharge planning. The family-centered approach involves family caregivers using a structured guide to assess the condition of the hip-fractured patient with cognitive impairment. Habits, daily routines, preferences, behavioral problems and environmental safety and stimuli are explored. The strengths, weakness, and resources of the family are assessed. The behavioral problems and symptoms to target are identified. Both the research nurse and the caregiver will then collaborate on a tentative plan to minimize the behavioral problems.
11125811|NCT03894709|No Intervention|Usual care|During hospitalization, patients receive health teaching for exercise while still in bed. Physical therapy usually starts only for those who received arthroplasty of hip replacement. Physical therapists train patients to use a walker and get in/out of bed through consultation. Usually, patients are discharged from the hospital without home assessment, nor are in-home programs provided for rehabilitation or nursing care. The usual care does not involve interdisciplinary care protocols, continuity of care, or specific care for hip-fractured patients with cognitive impairment.
11125812|NCT03894683|Experimental|Melatonin|Melatonin (10 mg tablets) by oral root, ingested at bedtime for 6 months
11125813|NCT03894683|Placebo Comparator|Placebo|Placebo tablets in the same shape as melatonin tablets, ingested the same as the melatonin tablets.
11125814|NCT03894670|Active Comparator|SmartBar™|The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
11125815|NCT03894670|Experimental|Standard mixed breakfast meal|The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
11125816|NCT03894644|Experimental|Group A: simulation training before instruments|Group A performed simulation training before the recognition of real surgical instruments.
11125817|NCT03894644|Active Comparator|Group B:instruments before simulation training|Group B performed the recognition of real surgical instruments without prior simulation training.
11125818|NCT03894631|Active Comparator|Phaco/KDB|Eyes needing glaucoma and cataract extraction will receive combined KDB and phacoemulsification in one eye of a patient
11125819|NCT03894631|Active Comparator|Phaco/Trabectome|Contralateral eyes needing glaucoma and cataract extraction will receive combined Trabectome and phacoemulsification in contralateral eye of the same patient
11125820|NCT03894618|Experimental|SL-279252|Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
11125821|NCT03894592|Active Comparator|Virtual Reality analgesia|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format
11125822|NCT03894592|No Intervention|Control|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention
11125823|NCT03894579|Experimental|SNK01|SNK01 infused weekly for 4 consecutive weeks
11125824|NCT03894553|Experimental|FUS Mesencephalotomy|Subjects will receive unilateral stereotactic focused ultrasound mesencephalotomy using the ExAblate Neuro device for severe, opioid-resistant pain associated with head and neck cancer.
11125825|NCT03894540|Experimental|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion
~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
11125826|NCT03894540|Experimental|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion
~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
11125827|NCT03894540|Experimental|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion
~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
11125828|NCT03894540|Experimental|IPN60090 food effect|"Part 1: Food Effect of IPN60090
~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
11125829|NCT03894527|Active Comparator|Control|"Subjects with simple obesity will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.
~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
11125830|NCT03894527|Active Comparator|Metabolic Syndrome|"Subjects with metabolic syndrome will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.
~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
11125831|NCT03894501|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
11125834|NCT03894475|Active Comparator|Sequence B|Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
11125835|NCT03894462|Active Comparator|Zero Suicide Usual Care|"In Onondaga County, NYS aims to implement a countywide Zero Suicide Safety Net of providers who share enhanced protocols for clinical care, staff training, and data collection (improved EMR coding of suicidal behavior). Participating behavioral health systems have agreed to common protocols for clinical care, training, and data collection. Participating providers receive robust training in suicide prevention best practices. Because of the wide participation of mental health facilities in the NYS-OMH Zero Suicide project, most subjects who engage in outpatient treatment will receive that treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged."
11125836|NCT03894462|Experimental|Zero Suicide Usual Care + ASSIP|"Patients in this treatment arm will receive ASSIP brief therapy in addition to being able to access any usual care as recommended by their provider.
~ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan."
11125837|NCT03894449|Placebo Comparator|Placebo only|
11125838|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt FeSO4|
11125839|NCT03894449|Experimental|Prebiotic GOS & Iron Salt FeSO4|
11125840|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt NaFeEDTA|
11125841|NCT03894449|Experimental|Prebiotic GOS & Iron Salt NaFeEDTA|
11125842|NCT03894410||Continuing Lapatinib|Patients continued using treatment containing Lapatinib after progression on Lapatinib.
11125843|NCT03894410||Change HER-2 treatment|Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).
11125844|NCT03894410||Lapatinib plus capetabine|Patients used lapatinib plus capetabine.
11125845|NCT03894410||Lapatinib plus Trastuzumab and one chemotherapy|Patients used lapatinib plus trastuzumab and one chemo regimen.
11125846|NCT03894397|Experimental|Stimulation of left BNST|
11125847|NCT03894397|Experimental|Stimulation of right BNST|
11125848|NCT03894397|Experimental|Stimulation of bilateral BNST|
11125849|NCT03894397|Placebo Comparator|Stimulation OFF|
11125850|NCT03894384||Group:1|Gastric cancer patients
11125851|NCT03894384||Group:2|Patients with benign gastric diseases
11125852|NCT03894371|Other|Thermage|Subjects will undergo treatment with the Thermage FLX system using a 900 pulse, 4cm2 Total Tip to treat the face and neck and a 450 pulse, 0.25cm2 tip to treat the upper and lower eyelids.
11125853|NCT03894358|Active Comparator|FeFum and 7.5 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
11125854|NCT03894358|Active Comparator|FeFum and 3 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
11125855|NCT03894358|Active Comparator|FeFum and no prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate
11125856|NCT03894345|Experimental|Open-label treatment with Prazosin|"Week 1 Day 1-3: 0.5 mg at bedtime Day 4-7: 1.0 mg at bedtime Week 2 Day 8-10: 2.0 mg at bedtime Day 11-14: 4.0 mg at bedtime Week 3 2 mg in the morning, 4 mg at bedtime Week 4 4 mg in the morning, 4 mg at bedtime Week 5 4 mg in the morning, 6 mg at bedtime Week 6 4 mg in the morning, 8 mg at bedtime
~Dosage of Prazosin will be titrated at the discretion of the study physician."
11125857|NCT03894332||SBT Success|Patients took part of this cohort when succeeding the Spontaneous Breathing Trial (SBT).
11125858|NCT03894332||SBT Failure|"Patients took part of this cohort when failing the Spontaneous Breathing Trial (SBT).
~SBT Failure is defined by one or more of the following criteria occurring during the SBT:
~loss of ≥ 2 points of Glasgow Coma Scale
~respiratory rate/ tidal volume ≥105 breaths/min/L
~arterial partial pressure of oxygen ≤60 mmHg on inspired oxygen fraction (FiO2) ≥0.5 and/or pH <7.32 or a decrease in pH ≥0.07 units at the end of the SBT
~systolic Blood Pressure <90 mmHg or ≥180 mmHg or increased by ≥20%
~Heart Rate >140 beats/min or increased by 20%
~onset of major heart arrhythmias, or electrocardiographic signs of cardiac ischemia
~Respiratory Rate ≥35 breaths/min or increased by ≥50%
~increased effort, respiratory distress (as indicated by diaphoresis, accessory respiratory muscles recruitment, facial signs of distress and/or paradoxical breath)"
11125859|NCT03894332||Extubation Success|Patients took part of this cohort when, after extubation, did not need continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours.
11125860|NCT03894332||Extubation Failure|"Need for continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours from extubation, as defined by:
~Respiratory Rate >25 breaths/min for 2 hours
~Heart Rate >140 beats/min or sustained increase or decrease >20%
~clinical signs of respiratory muscle failure
~arterial partial pressure of oxygen (PaO2) <80 mmHg on inspired oxygen fraction (FiO2) ≥50%
~Arterial partial pressure of carbon dioxide >45 mmHg with pH <7.33"
11125861|NCT03894306||medication lock box + brief counseling|
11125862|NCT03894306||medication lock bag + brief counseling|
11125863|NCT03894306||brief counseling alone|
11125864|NCT03894293||ventilator group|It's a observational study. Participants entry the Respiratory Care Center and are evaluated. If the participant meet the inclusion criteria, the first assessments will be collected. After the weaning training, the second assessment will be collected before the the endotracheal tube is removed.
11125865|NCT03894280|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
11125866|NCT03894280|Active Comparator|Reference Product|SERETIDE DISKUS 250/50
11125867|NCT03894267|Experimental|Experimental Arm|"Self-adhesive silicone bordered foam dressing will be secured to the heels and sacrum.
~Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.
~Follow up 20 days"
11125868|NCT03894267|No Intervention|Control Arm|"Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.
~Follow up for 20 days."
11125910|NCT03893955|Experimental|Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors|Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.
11125869|NCT03894254|Experimental|Patients with subjective cognitive complaint or neurocognitive|: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study
11125870|NCT03894241|Experimental|Sedentary condition|
11125871|NCT03894241|Experimental|Moderate-intensity continuous training|
11125872|NCT03894241|Experimental|Cooperative-high-intensity interval training|
11125873|NCT03894228||Biologics exposed cohort|Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.
11125874|NCT03894228||Immunomodulators exposed cohort|Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.
11125875|NCT03894228||Non-exposed cohort|Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.
11125876|NCT03894215|Experimental|AGEN2034 + Placebo|AGEN2034 administered with placebo monotherapy: approximately 100 patients.
11125877|NCT03894215|Experimental|AGEN2034 + AGEN1884|AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.
11125878|NCT03894202||Ultra-early aneurysm treatment|Ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping within the initial twenty-four hours.
11125879|NCT03894202||Non-ultra-early aneurysm treatment|Non-ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping after the initial twenty-four hours.
11125880|NCT03894189|Active Comparator|doxapram group (GROUP D)|The patients in this group will receive loading dose of (1 mg/kg) followed by an infusion of (1mg/kg/h)
11125881|NCT03894189|Active Comparator|theophylline group (GROUP T)|the therapeutic loading dose (5mg/kg) followed by an infusion of (0.5 mg/kg/h)
11125882|NCT03894176||PTX3 concentration|First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
11125883|NCT03894150|Experimental|F0002-ADC|
11125884|NCT03894137|Experimental|Grains of Paradise|
11125885|NCT03894137|Placebo Comparator|Placebo|
11125886|NCT03894124|Other|Study intervention|Pifeltro® (doravirine 100mg) daily dose for 7 days
11125887|NCT03894111||living patients|living patients in intersivecare unit about 28 days
11125888|NCT03894111||deceased patients|deceased patients in intersivecare unit about 28 days
11125889|NCT03894098|Active Comparator|Single shot regional popliteal and saphenous block|Standard of care traditional single shot popliteal / saphenous regional block for acute pain control after elective ankle surgery
11125890|NCT03894098|Experimental|High ankle block|High ankle block for acute pain control after elective ankle surgery
11125891|NCT03894085|Experimental|GAD group|"General anxiety disorder(GAD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine (20-40mg) treatment for 4 weeks"
11125892|NCT03894085|Experimental|PD group|"Panic disorder(PD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine (20-40mg)treatment for 4 weeks"
11125893|NCT03894085|Experimental|SAD group|"Social anxiety disorder(SAD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine (20-40mg)treatment for 4 weeks"
11125894|NCT03894085|Experimental|OCD group|"Obsessive-compulsive disorder (OCD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)
~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks
~Paroxetine(40-80mg) treatment for 4 weeks"
11125895|NCT03894085|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
11125896|NCT03894072|Active Comparator|HFHO-CPAP|This group will have HFHO before CPAP
11125897|NCT03894072|Active Comparator|CPAP-HFHO|This group will have CPAP and then HFHO
11125898|NCT03894059||Retrospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period preceding the implementation of the educational intervention for ambulance telecommunicators.
11125899|NCT03894059||Prospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period following the implementation of the educational intervention for ambulance telecommunicators.
11125900|NCT03894046|Experimental|Part A|
11125901|NCT03894046|Experimental|Part B|
11125902|NCT03894007|Experimental|A: Experimental|"Four courses of docetaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide + atezolizumab. In total seven courses of preoperative treatment. Response evaluations after course four.
~Postoperatively, if pathologic complete response, patients receive 14 courses of adjuvant trastuzumab every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
11125903|NCT03894007|Active Comparator|B: Standard|"Four courses of docetaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide. In total seven courses of preoperative treatment. Response evaluations after course four.
~Postoperatively, if pathologic complete response patients receive 14 courses of adjuvant trastuzumab (combined with pertuzumab in case of high-risk disease features) every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
11125904|NCT03893994|Experimental|Stretching group|Posterior shoulder stretching exercises
11125905|NCT03893994|No Intervention|Control Group|No exercise will be applied
11125906|NCT03893981|Experimental|Proprioception and Balance Training|Proprioception and Balance Program
11125907|NCT03893981|Experimental|Strengthening Training|Strengthening Program
11125908|NCT03893968|Experimental|Informed by a doctor|Information by a doctor
11125909|NCT03893968|Experimental|Informed by an assistant nurse|Information by an assistant nurse
11125911|NCT03893955|Experimental|Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
11125912|NCT03893955|Experimental|Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
11125913|NCT03893955|Experimental|Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
11125914|NCT03893955|Experimental|Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
11125915|NCT03893955|Experimental|Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
11125916|NCT03893955|Experimental|Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
11125917|NCT03893929||Chinese patients with clinical suspicious of prostate cancer|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
11125918|NCT03893916|Experimental|cohort|MEG - EEG HR
11125919|NCT03893903|Experimental|IDH1 peptide vaccine|IDH1R132H peptide vaccine alone
11125920|NCT03893903|Experimental|combination|IDH1R132H peptide vaccine and Avelumab
11125921|NCT03893903|Experimental|Avelumab|Avelumab alone
11125922|NCT03893890||No Treatment|Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
11125923|NCT03893877|Experimental|nasal cannula|device:nasal cannula will be applied to patients for oxygenation under deep sedation
11125924|NCT03893877|Active Comparator|nasal mask|device:nasal mask will be applied to patients for oxygenation under deep sedation
11125925|NCT03893864|Experimental|Intervention Group (CoQ10)|Runner athletes > 50 years old, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions
11125926|NCT03893864|Active Comparator|Control Group|Runner athletes > 50 years old with the same characteristics as the Experimental arm, served as control group, maintaining the training sessions Both groups were evaluated before and after the month of intervention or no intervention.
11125927|NCT03893851|Experimental|ICC-T|Interactions Competencies with Children - for Teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
11125928|NCT03893851|No Intervention|Control|The control schools do not receive any intervention
11125929|NCT03893838||Post refractive surgery without HOA|Patients post refractive surgery that do not complain on the high order aberrations such as glare, halo and starburst.
11125930|NCT03893838||Post refractive surgery with HOA|Patients post refractive surgery that do complain on the high order aberrations such as glare, halo and starburst.
11125931|NCT03893838||Post refractive surgery with rainbow HOA|"Patients post refractive surgery that do complain on:
~the high order aberrations such as glare, halo and starburst but with the chromatic aureola
~difficulties working with LCD projectors, monitors, cell phones and tablets"
11125932|NCT03893825|Experimental|TV-46000 - A|Dose regimen A
11125933|NCT03893825|Experimental|TV-46000 - B|Dose regimen B
11125934|NCT03893799|Other|Administer 240mg FeS/9mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 240 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and be followed for 28 days.
11125935|NCT03893799|Other|Administer 240mg FeS/27mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 240 mg Iron Sucrose and 27 mg of Stannous Protoporphyrin and be followed for 28 days.
11125936|NCT03893799|Other|Administer 240mg FeS/90mg SnPP dose in healthy subjects|6 healthy subjects will be administered a single dose of 240 mg Iron Sucrose and 90 mg of Stannous Protoporphyrin and be followed for 28 days.
11125937|NCT03893799|Other|Administer 240mgFeS/27mgSnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 240 mg Iron Sucrose and 27 mg of Stannous Protoporphyrin and be followed for 28 days.
11125938|NCT03893799|Other|Administer 240 FeS/90mg SnPP dose in subjects with stage 3 CKD|6 subjects with stage 3 CKD will be administered a single dose of 240 mg Iron Sucrose and 90mg of Stannous Protoporphyrin and be followed for 28 days.
11125939|NCT03893799|Other|Administer 240mgFeS/27mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 240 mg Iron Sucrose and 27 mg of Stannous Protoporphyrin and be followed for 28 days.
11125940|NCT03893799|Other|Administer 240mgFeS/90mgSnPP dose in subjects with stage 4 CKD|6 subjects with stage 4 CKD will be administered a single dose of 240 mg Iron Sucrose and 90mg of Stannous Protoporphyrin and be followed for 28 days.
11125941|NCT03893786|Experimental|Robotic Treatment|"Fifteen patients with Parkinson's Disease will perform ten 45-minutes training sessions of the upper limb using the Armeo®Spring applied bilaterally, an electromedical device aimed at improving force and coordination in neurologically affected patients.
~The device was built to sustain the forearm during the upper limb training and it is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
11125942|NCT03893786|Active Comparator|Conventional Treatment|Fifteen patients with Parkinson's Disease will undergo ten 45-minutes training sessions of the upper limb with a traditional approach, performing the same excercises of the experimental group, i.e. flexo-extension of the wrist, prono-supination of the forearm, etcc.
11125943|NCT03893760||No Pulonary Hypertension|the presence of mean pulmonary pressures (PAPm) at the right heart catheterization < 25 mmHg
11125944|NCT03893760||Postcapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg and postcapillary wedge pressure (PCWP) >15 mmHg
11126254|NCT03891641|No Intervention|Control Group|Control Subjects continue their normal daily activities.
11125945|NCT03893760||combined postcapillary/precapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg, PAWP >15 mmHg and diastolic peak gradient (DPG - diastolic pulmonary pressure - PCWP) ≥7 mmHg and/or pulmonary vascular resistence (PVR) >3 WU, where available.
11125946|NCT03893747|Experimental|the first batch vaccine producted by 40 L reactor|500 subjects will be randomly received the first batch vaccine producted by 40 L reactor
11125947|NCT03893747|Experimental|the second batch vaccine producted by 40 L reactor|500 subjects will be randomly received the second batch vaccine producted by 40 L reactor
11125948|NCT03893747|Experimental|the third batch vaccine producted by 40 L reactor|500 subjects will be randomly received the third batch vaccine producted by 40 L reactor
11125949|NCT03893747|Experimental|the first batch vaccine producted by 150 L reactor|500 subjects will be randomly received the first batch vaccine producted by 150 L reactor
11125950|NCT03893747|Experimental|the second batch vaccine producted by 150 L reactor|500 subjects will be randomly received the second batch vaccine producted by 150 L reactor
11125951|NCT03893747|Experimental|the third batch vaccine proudected by 150 L reactor|500 subjects will be randomly received the third batch vaccine producted by 150 L reactor
11125952|NCT03893734|Active Comparator|methadone group|Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
11125953|NCT03893734|Placebo Comparator|hydromorphone group|Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
11125954|NCT03893721||malnourished under five children|children from 2 to 5 years with malnutrition
11125955|NCT03893721||well nourished under five children|children from 2 to 5 years without malnutrition
11125956|NCT03893708|Experimental|Prenatal yoga|Each class will be outlined as follows: 1) opening greeting/intention setting, 2) pranayama (i.e., breathing exercises), 3) warm-up/sun salutations (i.e., flowing sequence), 4) yoga sequence (e.g., combination of sun salutations, vinyasa, and standing, seated, and/or balancing poses), 5) cool-down 6) Savasana (i.e., final resting pose), and 7) class closing. Meditation and breath awareness (e.g., linking each movement with breath) will be emphasized throughout each class. All classes will focus on safety and alignment and be appropriate for women during pregnancy by incorporating modifications to poses/exercises as necessary (e.g., yoga block, strap). Certified yoga instructors with a bachelors degree in a health related field and experience teaching pregnant women will instruct all yoga classes. Participants will be provided with a 'yoga during pregnancy' safety packet that includes a list of prenatal yoga poses that women may do at their own leisure at home.
11125957|NCT03893708|Active Comparator|Pregnancy education|Participants will be asked to attend a group-based pregnancy education group (similar to a birth education class). The class format will include a didactic portion followed by group discussion (N=12). The following evidence-based topics (based on the American College of Obstetrics and Gynecologists) to be discussed may include (but not limited to): financial management in preparation for baby, preparing for labor and delivery, transitioning into motherhood, sleep hygiene, and baby bonding. A labor and delivery nurse and certified Dula will instruct all classes.
11125958|NCT03893695|Experimental|metastatic HCC|"Stage one - Dose de-escalation:
~Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001.
~Stage two- the expansion cohort:
~14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort."
11125959|NCT03893682|Experimental|Dose Escalation and Expansion|CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
11125960|NCT03893669|Experimental|Group 1|NBP607 0.5ml
11125961|NCT03893669|Active Comparator|Group 2|Agrippal 0.5ml
11125962|NCT03893643||pediatric population|Pediatric population aged 0 to 15 years with neurofibromatosis type 2
11125963|NCT03893630|Active Comparator|Control Group|Patients will receive standard of care.
11125964|NCT03893630|Experimental|Acetylsalicylic Acid 81mg|Patients will receive low dose (81mg) acetylsalicylic acid (Aspirin).
11125965|NCT03893630|Experimental|Acetylsalicylic Acid 162mg|Patients will receive low dose (162mg) acetylsalicylic acid (Aspirin).
11125966|NCT03893617|Active Comparator|Propranolol group|This group will receive a single oral dose (80mg) of propranolol in a blinded capsule during their acute stress study visit.
11125967|NCT03893617|Placebo Comparator|Placebo group|This group will receive a single blinded capsule containing no active medication during their acute stress study visit.
11125968|NCT03893604|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
11125969|NCT03893604|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
11125970|NCT03893591||Body mass index below 35|
11125971|NCT03893591||Body mass index 35 and above|
11125972|NCT03893578|Experimental|Interventional Arm|Access, delivery, and retrieval of the Conveyor system with correct positioning of the valve delivery system to facilitate correct positioning of the implant at the mitral location in patients with a failing bioprosthetic valve.
11125973|NCT03893565|Experimental|GSK2831781 dose 1|Eligible participants will receive GSK2831781 IV in the double blind induction phase at Week 0, 2, 6, and 10. Participants identified as Responders at Week 10 will then receive GSK2831781 SC q4w during the double-blind ETP from Week 14 until Week 26. Participants identified as Non-Responders at Week 10 will be allocated to open label induction phase to receive GSK2831781 IV from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 SC q4w from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
11125974|NCT03893565|Experimental|GSK2831781 dose 2|Eligible participants will receive GSK2831781 IV in the double blind induction phase at Week 0, 2, 6, and 10. Participants identified as Responders at Week 10 will then receive GSK2831781 SC q4w during the double-blind ETP from Week 14 until Week 26. Participants identified as Non-Responders at Week 10 will be allocated to open label induction phase to receive GSK2831781 IV from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 SC q4w from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
11126007|NCT03893292||Preoperative cooled radiofrequency ablation|Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
11125975|NCT03893565|Experimental|GSK2831781 dose 3|Eligible participants will receive GSK2831781 IV in the double blind induction phase at Week 0, 2, 6, and 10. Participants identified as Responders at Week 10 will then receive GSK2831781 SC q4w during the double-blind ETP from Week 14 until Week 26. Participants identified as Non-Responders at Week 10 will be allocated to open label induction phase to receive GSK2831781 IV from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 SC q4w from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
11125976|NCT03893565|Experimental|GSK2831781 dose 4|Eligible participants will receive GSK2831781 IV in the double blind induction phase at Week 0, 2, 6, and 10. Participants identified as Responders during induction phase will then receive GSK2831781 SC q4w during the double-blind ETP until Week 26. Non-Responders to GSK2831781 IV at Week 10 will be allocated to open label induction phase to receive GSK2831781 IV until Week 22 and responders will enter open label ETP to receive GSK2831781 SC q4w until Week 38. Open label ETP non-responders will discontinue treatment.
11125977|NCT03893565|Placebo Comparator|Placebo matching GSK2831781|Eligible participants will receive Placebo in the double blind induction phase at Week 0, 2, 6, and 10. Participants identified as Responders at Week 10 will continue to receive Placebo SC q4w during the double-blind ETP from Week 14 until Week 26. Participants identified as Non-Responders at Week 10 will be allocated to open label induction phase to receive GSK2831781 IV from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 SC q4w from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
11125978|NCT03893552|Experimental|Patient with sleep disordered breathing symptoms|Patients referring to the clinic of sleep disorders will be asked to participate in this study. A negative expiratory pressure will be applied via a cough-assist attached to a facial mask.
11125979|NCT03893539|Other|Robotic Bronchoscopy|The Ion™ Endoluminal System assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion™ Endoluminal System enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.
11125980|NCT03893526|Placebo Comparator|Placebo|Participants are subjected to a standardized meal
11125981|NCT03893526|Active Comparator|Entrestro|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
11125982|NCT03893526|Active Comparator|Sitagliptin|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
11125983|NCT03893526|Active Comparator|Entrestro + sitagliptin|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
11125984|NCT03893526|Active Comparator|Valsartan|206mg valsartan as one single dose followed by a standardized meal
11125985|NCT03893500|Experimental|Initiating a new PAH medication|Participants will start a new PAH medication
11125986|NCT03893500|Active Comparator|Continuing previous PAH medication regimen|Participants will continue the medication regimen that they were on prior to enrollment
11125987|NCT03893487|Experimental|Treatment (fimepinostat, tumor resection)|"Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.
~MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor."
11125988|NCT03893474|Other|Control Arm|All investigations are the same in both arms, but patients within this arm will be seen in the hospital as per standard practice.
11125989|NCT03893474|Other|Study Arm|All investigations are the same in both arms, but patients within this arm will be seen in a community optometrist practice.
11125990|NCT03893448|Experimental|V114|Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
11125991|NCT03893448|Active Comparator|Prevnar 13™|Participants receive 4 total 0.5 mL IM vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
11125992|NCT03893435|Experimental|Sacubitril/Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
11125993|NCT03893435|Active Comparator|Valsartan|In successfully revascularized post-AMI patients with LVEF ≤40% Valsartan with an initial dose of 40 mg PO BID, with subsequent titrations to target maintenance dose of 160 mg BID as tolerated.
11125994|NCT03893422|Experimental|WB-010|3 capsules administered twice daily with morning and evening meal for 12 weeks
11125995|NCT03893422|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 12 weeks
11125996|NCT03893422|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 12 weeks
11125997|NCT03893409||pulmonary function|
11125998|NCT03893409||biological sample detection outcome|
11125999|NCT03893370|Active Comparator|Treatment|RJA MCS
11126000|NCT03893370|Sham Comparator|Sham Control|Sham
11126001|NCT03893357||Positive for antiphospholipid antibodies|Patients tested positive for antiphospholipid antibodies
11126002|NCT03893357||Negative for antiphospholipid antibodies|Patients tested negative for antiphospholipid antibodies
11126003|NCT03893344||Cases|patients with Multiple Sclerosis in different stages diagnosed clinically according to revised McDonald's criteria 2010
11126004|NCT03893344||Control|Healthy peaple
11126005|NCT03893318|Experimental|Study Group|will receive intravenous lidocaine during and after posterior spinal fusion for AIS
11126006|NCT03893318|Placebo Comparator|Control Group|will receive saline placebo during and after surgery.
11126008|NCT03893253|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
11126009|NCT03893253|Active Comparator|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
11126010|NCT03893253|No Intervention|Control group|The control group will receive no booster teaching at all.
11126011|NCT03893240|Other|Participants with Late Onset Pompe disease|This is a multi-center, low-interventional study with a retrospective component in participants with LOPD. During a single study visit, assessments including but not limited to, liver health, neutralizing antibodies to SPK-3006 capsid and GAA, anti-GAA binding antibodies, GAA activity and GAA antigen levels will be performed. Additional information will be collected to provide retrospective evaluations relating to muscle and liver inflammation and/or injury. Historic data relating to Pompe disease will be collected from medical records. The retrospective and laboratory data collected may assist in providing baseline information for a future investigational gene therapy study.
11126012|NCT03893227||Patients|Patients with chronic upper airway inflammation
11126013|NCT03893227||Healthy control|Healthy controls without chronic upper airway inflammation
11126014|NCT03893214|Experimental|intervention group|Virtual reality exposure for acrophobia - this arm receives the virtual reality exposure intervention in the initial phase and has a four-week follow-up assessment.
11126015|NCT03893214|Placebo Comparator|waitlist control group|This arm watches a movie in the initial phase in order to control for effects of behavioral approach test that is done before and after the intervention and for time effects. In the second phase after four weeks, this arm receives the virtual reality exposure after collection of outcome measures.
11126016|NCT03893201||Venaseal|Patients that have undergone venaseal
11126017|NCT03893188||People asking for PrEP|All individuals aged >18 years asking for PrEP prescription at one of the participating centers will be asked to participate to the SwissPrEPared Study(consecutive ongoing recruitment). Only HIV negative individuals will be deemed eligible.
11126018|NCT03893175|Experimental|Ibuprofen|"During the double-blind stage, subjects will receive blinded ibuprofen (400 mg by mouth) when pain is at least 4/10 following third molar extraction.
~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.
~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
11126019|NCT03893175|Placebo Comparator|Placebo|"During the double-blind stage, subjects will receive blinded placebo when pain is at least 4/10 following third molar extraction.
~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.
~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
11126020|NCT03893162|Experimental|"Multi-strain probiotic BioKult"|4 capsules daily for 8 weeks
11126021|NCT03893162|Placebo Comparator|Placebo|4 capsules daily for 8 weeks
11126022|NCT03893149|Experimental|Active-Start intervention|Supervised exercise training
11126023|NCT03893149|No Intervention|Control group|No-exercise
11126024|NCT03893136||Control group|The control group mainly consists of healthy volunteers. The whole blood is obtained and frozen to detect the corresponding biochemical markers in the futures. The vascular tissues are obtained from the deserted and free abdominal aorta conjugated to the renal artery in the kidney transplantation.
11126025|NCT03893136||sham TA group|In the TA cohort, patients are divided into two groups mainly, sham TA group and scramble TA group. The sham TA group is the TA group who is given the traditional and classical intervention or treatment and so on.
11126026|NCT03893136||scramble TA group|Compared to sham TA group in the cohort, scramble TA group refers to TA patients who are given novel drugs or new drugs which are safe to treat other autoimmune diseases but have not been used to treat TA yet, or some new interventions and so on.
11126027|NCT03893123||Firefighters|
11126028|NCT03893110|Experimental|Instrumentation with Carbon/PEEK pedicle screw system|Posterior instrumentation using a Carbon/PEEK pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
11126029|NCT03893110|Active Comparator|Instrumentation with titanium pedicle screw system|Posterior instrumentation using a titanium pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
11126030|NCT03893097|Active Comparator|Praziquantel|Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
11126031|NCT03893097|Experimental|Artesunate-Mefloquine|Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.
11126032|NCT03893084|Experimental|Intervention|Preconception guidance prepared by reference to the guidelines published in the literature, women were given pre-pregnancy training.
11126033|NCT03893084|No Intervention|Control|The women in the control group were not given training, and routine practice was performed.
11126034|NCT03893071|Experimental|Hydroxypropyl-β-cyclodextrin IV|Hydroxypropyl-β-cyclodextrin will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
11126035|NCT03893045|Experimental|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
11126036|NCT03893045|Active Comparator|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL)
11126037|NCT03893032|Experimental|Modafinil 200mg|single, 200 mg dose of modafinil
11126038|NCT03893032|Experimental|mixed amphetamine salts|single 10 mg dose of mixed amphetamine salts
11126039|NCT03893032|Placebo Comparator|placebo|placebo
11126068|NCT03892876|Sham Comparator|Control TS-ve|Healthy controls who receive sham comparator
11126040|NCT03893019|Experimental|Dose Level 1: 1x10e5 MB-CART20.1 cells|3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously
11126041|NCT03893019|Experimental|Dose Level 2: 1x10e6 MB-CART20.1 cells|3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously
11126042|NCT03893019|Experimental|Dose Level 3: 1x10e7 MB-CART20.1 cells|3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously
11126043|NCT03893006|Experimental|UnAssisted (UA)|This term refers to driving a vehicle manually without any vehicle automation technology. It will serve as a baseline concerning behaviors, representations and neural results associated with unassisted automobile driving.
11126044|NCT03893006|Experimental|Assisted (A)|This term refers to driving with warning technology which upon activation sounds an a warning when the vehicle is too close to the edge of the road (off-road warning , Navarro, Mars, & Hoc, 2007; Suzuki & Jansson, 2003) or too close to the vehicle in front of it (anti-collision warning; Lee, McGehee, Brown, & Reyes, 2002).
11126045|NCT03893006|Experimental|Shared Control (SC)|This term refers to shared tactical control between the driver and the automated assistive technology, both working simultaneously on the physical trajectory of the vehicle, laterally (Griffiths & Gillespie, 2005; Mulder, Abbink, & Boer, 2012) as well as longitudinal (Adell, Várhelyi, & Hjälmdahl, 2008).
11126046|NCT03893006|Experimental|Partly Autonomous (PA)|"This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name Highly Automated Driving (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology."
11126047|NCT03893006|Experimental|Fully Autonomous (FA)|This term refers to a completely automated driving experience. The on-board technologies take over all the driving tasks for any driving situation.
11126048|NCT03893006|Experimental|Any Automation (AA)|This term refers to a situation where the drivers can choose the automation device of their choice among the five types presented above and can change it whenever they think it is good to do so.
11126049|NCT03892993|Experimental|Supportive care (decision aid)|Participants use decision aid and complete questionnaires.
11126050|NCT03892980|Experimental|Nipple Sparing Mastectomy|
11126051|NCT03892967|Experimental|E2C2 Collaborative Care|A guideline-informed intervention that combines low touch automated provision of symptom self-management education, coupled with EHR clinical decision support, for moderate symptoms with conventional, high-touch, collaborative care provided by a nurse-physician team for more intense symptoms. Additionally, the E2C2 intervention will increase the frequency of symptom and function screening. Prior to E2C2 intervention initiation, patients will only be assessed in association with a physician or allied health provider encounter. They will not be assessed when seen for nurse-only visits, or for systemic treatments. Following E2C2 intervention activation, they will be assessed every other week which will require remote, portal-based assessment for patients who lack clinic appointments.
11126052|NCT03892954||adolescents with CFS ( n= 100)|Participants with CFS who had constant or persisting fatigue lasting 3 months with the severe functional disability to such extent that prevents normal school attendance and also had no drug prescriptions (including hormone contraceptives), any medical or psychiatric disorder that might explain the fatigue were included in this study
11126053|NCT03892954||health control ( n=50).|healthy control subjects with no CFS
11126054|NCT03892941|Experimental|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
11126055|NCT03892941|No Intervention|Clinical routine|Mapping of the electrical input of the cochlear implant will be based on a one-size-fits-all, as is part of clinical routine.
11126056|NCT03892928|Placebo Comparator|Propofol group|2-5 mg/kg.h propofol during the whole colonoscopy
11126057|NCT03892928|Other|Dexmedetomidine group|0.1mcg/kg continuous infusion for 15min, 0.7-1mcg/kg.h during the whole colonoscopy
11126058|NCT03892915|Experimental|Depression Care|Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.
11126059|NCT03892915|No Intervention|Usual care|Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).
11126060|NCT03892902|Experimental|Treatment A (50 mg ACT-541468)|1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.
11126061|NCT03892902|Experimental|Treatment B (100 mg ACT-541468)|2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.
11126062|NCT03892902|Experimental|Treatment C (7.5 mg zopiclone)|2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).
11126063|NCT03892902|Experimental|Treatment D (placebo)|2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.
11126064|NCT03892889|Experimental|ABILIFY MYCITE|Subjects will receive Abilify MyCite for 3 months (Months 1 to 3) and at the Month 3 visit, the investigator should decide if subjects will continue on Abilify MyCite for an additional 3 months (Months 4 to 6) or switch to a standard-of-care treatment (eg, oral atypical antipsychotics or a long acting injectable [LAI]) for the duration of treatment.
11126065|NCT03892876|Experimental|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
11126066|NCT03892876|Sham Comparator|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
11126067|NCT03892876|Experimental|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
11126114|NCT03892603|Experimental|Strengthening exercises program|
11126069|NCT03892863|Active Comparator|active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
11126070|NCT03892863|Sham Comparator|sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
11126071|NCT03892850|Experimental|nurse prescription|experimental group receiving pharmacological nurse prescription
11126072|NCT03892850|Active Comparator|medical prescription|control group receiving medical prescription
11126073|NCT03892837|Active Comparator|Control group|Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
11126074|NCT03892837|Experimental|PRP group|Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis. Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
11126075|NCT03892824|Experimental|Vine™ Filter + OAC|Vine™ Filter in each common carotid artery (CCA) with oral anticoagulant treatment (either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC)) for the duration of the study
11126076|NCT03892811||Infants referred for swallow study|"This is a within-subjects intervention study where each infant in the study will receive all three conditions.
~The three study conditions are bottle-feeding with 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple."
11126077|NCT03892785|Experimental|Tocilizumab group|
11126078|NCT03892785|Active Comparator|Methotrexate group|
11126079|NCT03892772|Experimental|SAS0421a, SAS0421b and SAS0421c|Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.
11126080|NCT03892772|Active Comparator|SAS0421a and SAS0421b|Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
11126081|NCT03892772|Active Comparator|SAS0421c|Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
11126082|NCT03892772|Placebo Comparator|Placebo|Participants will take placebos for 3 days.
11126083|NCT03892759|Other|Evaluation and Treatment|Subjects will be evaluated through inspection and palpation of the thoracic and lumbar spine, and other body regions as necessary. The provider will make a diagnosis of somatic dysfunction based off the TART (tissue texture change, asymmetry, restriction of motion, tenderness/pain) findings.
11126084|NCT03892746|Active Comparator|Active tDCS + task oriented practice|
11126085|NCT03892746|Sham Comparator|Sham tDCS + task oriented practice|
11126086|NCT03892733|Experimental|Intervention|CHEKS (calorie health, education, knowledge and skills) intervention will educate participants about calories in fast-food and teach skills to select lower calorie fast-food items.
11126087|NCT03892733|No Intervention|Control|Participants will receive a brochure about healthier choices in fast-food restaurants.
11126088|NCT03892720|Experimental|Treatment (SBRT)|Patients undergo stereotactic body radiation therapy with either standard radiation treatment software or HyperArc software technology for 2-3 fractions per week over a 2-week period for 5 fractions.
11126089|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
11126090|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
11126091|NCT03892694|Active Comparator|Treatment|MCS
11126092|NCT03892694|Sham Comparator|Sham Control|Sham
11126093|NCT03892681|Other|contrast agents for liver MRI|
11126094|NCT03892668|Experimental|tranexamic acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
11126095|NCT03892668|Active Comparator|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
11126096|NCT03892668|Placebo Comparator|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
11126097|NCT03892642|Experimental|BCG + Avelumab|Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
11126098|NCT03892629|Experimental|Baduanjin exercise group|Participants in this group received Baduanjin exercise
11126099|NCT03892629|Active Comparator|Instrument rehabilitation group|Participants in this group received rehabilitation by using tri-ball respiratory trainer
11126100|NCT03892629|Active Comparator|Baduanjin Exercise and Instrument Rehabilitation|Participants in this group received both instrument rehabilitation and Baduanjin exercise
11126101|NCT03892629|No Intervention|No Intervention|Participants in this group only received routine drug-treatment
11126102|NCT03892616|Experimental|A - B - C|
11126103|NCT03892616|Experimental|D - A - B|
11126104|NCT03892616|Experimental|E - B - A|
11126105|NCT03892616|Experimental|C - A - D|
11126106|NCT03892616|Experimental|A - E - C|
11126107|NCT03892616|Experimental|E - D - A|
11126108|NCT03892616|Experimental|B - C - D|
11126109|NCT03892616|Experimental|C - E - B|
11126110|NCT03892616|Experimental|B - D - E|
11126111|NCT03892616|Experimental|D - C - E|
11126112|NCT03892616|Experimental|C - B - A|
11126113|NCT03892616|Experimental|A - E - D|
11126118|NCT03892577||Patients with advanced hepatobiliary tumors|2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program: 1. Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject; 2. Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc; 3. Immunotherapy or immunotherapy combined with targeted therapy.
11126119|NCT03892564|Experimental|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
11126120|NCT03892564|Experimental|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
11126121|NCT03892564|Experimental|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
11126122|NCT03892564|Experimental|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
11126123|NCT03892564|Experimental|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
11126124|NCT03892551||patients admitted to emergency ward|all patients admitted to the emergency ward and awaiting triage are observed
11126125|NCT03892525|Experimental|treatment|
11126126|NCT03892512|Active Comparator|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
11126127|NCT03892512|Active Comparator|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
11126128|NCT03892499|Experimental|Healthy Volunteers|Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.
11126129|NCT03892486|Experimental|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
11126130|NCT03892486|No Intervention|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
11126131|NCT03892473|Experimental|Flexible Assertive Community Treatment (FACT)|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
11126132|NCT03892473|Active Comparator|Care as usual (CAU)|Active Comparator: CAU (Care as usual) Patients with SMI receiving usual care, meaning mostly medical treatment
11126133|NCT03892460|Experimental|Treatment|Neuromuscular electrical stimulation
11126134|NCT03892460|No Intervention|Control|No treatment control
11126135|NCT03892447|Experimental|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
11126136|NCT03892447|Active Comparator|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
11126137|NCT03892434|Active Comparator|Bevacizumab|
11126138|NCT03892434|Active Comparator|Dexamethasone|
11126139|NCT03892421|Experimental|Modified DHAP|Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.
11126140|NCT03892408|Experimental|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
11126141|NCT03892408|No Intervention|Standard|standard anesthesia
11126142|NCT03892395|Active Comparator|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:
~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
11126143|NCT03892395|Placebo Comparator|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:
~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
11126144|NCT03892382|Active Comparator|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
11126145|NCT03892382|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
11126146|NCT03892369|Experimental|Alcohol|The participant receive 0.5 g ethanol per kg body weight over 10 minutes. Subsequently blood samples are taken frequently the next ten hours.
11126147|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
11126148|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
11126149|NCT03892343||Transplant recipients|Patients undergoing live donor kidney transplant.
11126150|NCT03892343||Non-transplanted|Patients on the deceased donor waiting list without prospect of a live donor transplant.
11126151|NCT03892330|Experimental|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
11126152|NCT03892330|Active Comparator|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
11126153|NCT03892330|Active Comparator|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
11126154|NCT03892330|Active Comparator|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
11126155|NCT03892317|Other|Medication adherence interventions|Pharmacist led medication adherence interventions which will be tailored to individual patient need
11126388|NCT03890705||postpartum women|Women aged (15-49) and had given birth in the past 12 months
11126156|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
11126157|NCT03892291||Civilian mTBI|Civilians with persistent symptoms from mTBI
11126158|NCT03892291||Civilian Control|Civilian healthy controls
11126159|NCT03892291||Active Duty Control|Active duty service member healthy controls
11126160|NCT03892291||Active Duty mTBI|Active duty service members with persistent symptoms from mTBI who are referred for physical therapy due to their symptoms
11126161|NCT03892278|Experimental|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
11126162|NCT03892278|Experimental|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
11126163|NCT03892278|Active Comparator|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
11126164|NCT03892252||before surgery|no intervention(s)
11126165|NCT03892252||after surgery|no intervention(s)
11126166|NCT03892239|Experimental|Intervention|Monitoring and suggestion of training progress. Behaviour change strategy based on increasing knowledge.
11126167|NCT03892239|Active Comparator|Control|Monitoring and suggestion of training progress.
11126168|NCT03892226||1, no myocardial injury|normal troponin level (hs-troponin T ≤ 99. percentile, i.e. 14ng/ml)
11126169|NCT03892226||2, chronic myocardial injury|elevated, but stable troponin level; (hs-troponin T> 99. percentile and rise/fall ≤ 20% in the control)
11126170|NCT03892226||3, acute myocardial injury|dynamic troponin elevation; (hs-troponin T> 99. percentile and rise/fall >20% in the control)
11126171|NCT03892213|Other|Benznidazole and E1224|Benznidazole and E1224
11126172|NCT03892200|Experimental|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
11126173|NCT03892200|No Intervention|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
11126174|NCT03892187|Experimental|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
11126175|NCT03892187|No Intervention|Control Group|Participants receive usual care prior to surgery.
11126176|NCT03892174|No Intervention|Treatment protocol without adsorption|
11126177|NCT03892174|Active Comparator|Treatment protocol with adsorption|
11126178|NCT03892161|Experimental|Standard dose DRV/r|Standard dose DRV/r 800/100mg without Rifampicin
11126179|NCT03892161|Experimental|Standard DRV/r with Rifampicin|Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
11126180|NCT03892161|Experimental|Boosed ritonavir 200mg|Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
11126181|NCT03892161|Experimental|Double dose DRV/r 1600/200mg QD|Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
11126182|NCT03892161|Experimental|Double dose DRV/r 800/100mg BD|Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
11126183|NCT03892148|Active Comparator|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
11126184|NCT03892148|Experimental|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
11126185|NCT03892135||Physicians|3 paediatricians and 3 rheumatologists
11126186|NCT03892135||Parents|Parents
11126187|NCT03892135||Children|Children
11126219|NCT03891901|Experimental|Cohort 1d: Imatinib (400 mg) + Rifabutin + Isoniazid|Participants will receive 400 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
11126188|NCT03892122|Other|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient
~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
11126189|NCT03892122|Other|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
11126190|NCT03892109|Active Comparator|Gingitrac|The gingitrac cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the selected abutment. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
11126191|NCT03892109|Active Comparator|traxodent|The traxodent cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the tooth. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
11126192|NCT03892109|Experimental|Ultrapk cord|the cord packed into the gingival sulcus around the tooth
11126193|NCT03892109|Placebo Comparator|nocord|used directly in the tray
11126194|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
11126195|NCT03892083|Active Comparator|Anodal tDCS (M1)|tDCS applied over primary motor cortex. Dose: 1mA, 20 minutes
11126196|NCT03892083|Experimental|Anodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
11126197|NCT03892083|Experimental|Cathodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
11126198|NCT03892083|Sham Comparator|Sham tDCS|tDCS applied over the cerebellum Dose: 1mA, 20 minutes (30s ON)
11126199|NCT03892070|Experimental|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
11126200|NCT03892070|Placebo Comparator|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
11126201|NCT03892057|Experimental|Internet-based Positive Psychological Intervention|The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
11126202|NCT03892057|No Intervention|Attention Control Group|Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
11126203|NCT03892044|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11126204|NCT03892018|Active Comparator|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.
~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.
~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
11126205|NCT03892018|Active Comparator|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.
~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.
~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
11126206|NCT03892005||MOTIVATION HIP Total Hip System|All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MOTIVATION HIPTM Total Hip System in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.
11126207|NCT03891979|Experimental|Pembrolizumab + Antibiotics|Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.
11126208|NCT03891966|Active Comparator|Splint|
11126209|NCT03891966|Active Comparator|Soft Dressing|
11126210|NCT03891953|Experimental|DKY709|DKY709 monotherapy
11126211|NCT03891953|Experimental|DKY709 + PDR001|Combination therapy with DKY709 and PDR001
11126212|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia
~Aged from 20-80 years old"
11126213|NCT03891927|Experimental|olive group|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO ( high polypheol Extra virgin olive oil)
11126214|NCT03891927|No Intervention|non olive group|No intervention
11126215|NCT03891914|Experimental|Symptomatic Multiple Myeloma on first-line treatment|
11126216|NCT03891901|Experimental|Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid|Participants will receive 50 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
11126217|NCT03891901|Experimental|Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid|Participants will receive 100 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
11126218|NCT03891901|Experimental|Cohort 1c: Imatinib (200 mg) + Rifabutin + Isoniazid|Participants will receive 200 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
11126220|NCT03891901|Experimental|Cohort 2a: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
11126221|NCT03891901|Experimental|Cohort 2b: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
11126222|NCT03891888|No Intervention|Control|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
11126223|NCT03891888|Experimental|Intervention|Patients in this group will receive a bone graft in addition to the undergoing standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
11126224|NCT03891875|Experimental|Elamipretide|40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
11126225|NCT03891875|Placebo Comparator|Placebo|subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
11126226|NCT03891862|Experimental|Valbenazine|Valbenazine oral capsules administered once daily for 8 weeks. Randomization into this arm occurs after open-label treatment with valbenazine once daily for 8 weeks. Total treatment up to 16 weeks.
11126227|NCT03891862|Placebo Comparator|Placebo|Placebo oral capsules administered once daily for 8 weeks. Randomization into this arm occurs after open-label treatment with valbenazine once daily for 8 weeks. Total treatment up to 16 weeks.
11126228|NCT03891849|Experimental|octreotide (25 µg/hour) perfusion|octreotide (25 µg/hour) plus norepinephrine will be administered for patient with haemorrhagic shock after variceal bleeding during 2 to 5 days according recommendations and regular protocol in the medical unit
11126229|NCT03891836||medical students|All students from the chosen classes in each study year will be invited to complete self-administered questionnaire
11126230|NCT03891823|Experimental|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.
~Subjects will be followed for 12 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 12-month follow-up."
11126231|NCT03891823|Active Comparator|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.
~Subjects will be followed for 12 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 12-month follow-up."
11126232|NCT03891810|Experimental|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
11126233|NCT03891810|No Intervention|Control|This group was a wait list control group who received the treatment following the intervention period.
11126234|NCT03891797|Experimental|Cognitive Processing Therapy|12 sessions of group-based Cognitive Processing Therapy administered 1x/week for 90 minutes each session.
11126235|NCT03891797|No Intervention|Control|No treatment/treatment as usual. Participants will complete questionnaires at three time points with no intervention.
11126236|NCT03891784|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11126237|NCT03891771|No Intervention|Usual Care|Patients allocated to usual care will receive standard follow-up procedures at their primary care facility.
11126238|NCT03891771|Experimental|Telemonitoring sensors|Patients allocated to this arm will receive a complex sensor platform aimed at detecting falls at home, nocturia and several environmental variables, including carbon monoxide concentrations, humidity and temperature. The system also includes a panic button that can be used to request assistance in emergencies.
11126239|NCT03891758|Experimental|BK1310|
11126240|NCT03891758|Active Comparator|ActHIB® and Tetrabik|
11126241|NCT03891745||prone group|prone extubation
11126242|NCT03891745||supine group|supine extubation
11126243|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
11126244|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
11126245|NCT03891719|Experimental|Changes in nose symmetry|- Direct anthropometric assessment (frontal, oblique, lateral and basal views) and three- dimensional observations of the nose preoperatively and postoperatively in order to evaluate the nostril symmetry, the angles, ratios of the nose and its relation to the face.
11126246|NCT03891706|Experimental|TCR-T cell infusion|Patient will exposed to Individualized Tumor-t Cell Receptor (TCR) -Mediated T Cells therapy
11126247|NCT03891693|Experimental|Passeo-18 Lux and SUPERA® stent|Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty
11126248|NCT03891680|Experimental|Botox injection|
11126249|NCT03891680|Active Comparator|Genicular Radio frequency|
11126250|NCT03891667|Experimental|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing starts at 250 mg on day 1, none on day 2, 250 mg on day 3, none on day 4, and then 250 mg x 3 days. If tolerated, the dose is then increased to 500 mg/day.
11126251|NCT03891667|Active Comparator|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing of disulfiram starts at 250 mg on day 1, none on day 2, 250 mg on day 3, none on day 4, and then 250 mg x 3 days. If tolerated, the dose is then increased to 500 mg/day.
11126252|NCT03891654|Experimental|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
11126253|NCT03891641|Experimental|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
11126255|NCT03891628|Experimental|Modified ABC and SEEK|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
11126256|NCT03891628|Active Comparator|Modified DEF and SEEK|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
11126257|NCT03891615|Experimental|Niraparib + Osimertinib|"Niraparib will be administered orally once daily
~Osimertinib will be administered by mouth once daily"
11126258|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
11126259|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
11126260|NCT03891589|Experimental|Optimized CF with Taburia|The intervention groups consisted of promotion of optimized complementary feeding with home fortification (taburia) one sachet per week
11126261|NCT03891589|Experimental|Optimized CF only|The intervention groups consisted of promotion of optimized complementary feeding without home fortification (taburia)
11126262|NCT03891589|Experimental|Taburia|The intervention groups consisted of provision taburia home fortification three sachet per week
11126263|NCT03891589|No Intervention|Control|No intervention but gave a standard education from primary health center
11126264|NCT03891576|Experimental|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
11126265|NCT03891576|Active Comparator|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
11126266|NCT03891576|Other|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
11126267|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:
~Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)
~Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)
~Involving prepubertal (seventh grade or roughly age 12 years) children.
~AND
~Activity Tracker Criteria:
~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking
~- Meets these criteria within either one or both years of follow-up"
11126268|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:
~Participation in more than 1 sport at any physical activity level OR
~Participation in none or low training and/or competition in organized sports for any period of time.
~Involving prepubertal children.
~AND
~Activity Tracker Criteria:
~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking
~- Meets these criteria during both years of follow-up"
11126269|NCT03891550|Experimental|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
11126270|NCT03891524|Experimental|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
11126271|NCT03891524|Experimental|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
11126272|NCT03891524|Experimental|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
11126273|NCT03891524|Experimental|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID orally for 10 to 14 postoperative days.
11126274|NCT03891524|Experimental|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
11126275|NCT03891524|Experimental|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
11126276|NCT03891524|Experimental|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
11126277|NCT03891524|Active Comparator|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
11126278|NCT03891498|Experimental|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
11126279|NCT03891472|Experimental|Arm 1|
11126280|NCT03891459|Experimental|spray+ group|"In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as oxytocin). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks."
11126281|NCT03891459|Placebo Comparator|control group|"In control condition, the materials and procedure were same with the spray+ condition except the nasal spray was told as saline instead. Oxytocin materials used in current experiments were adopted from previous study"
11126282|NCT03891446|Experimental|Bimatoprost SR 10mcg; Lead-in study 192024-093|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
11126283|NCT03891446|Experimental|Bimatoprost SR 15mcg; Lead-in studies 192024-093/-095|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
11126342|NCT03891043|Experimental|Group B, Selenium group|Selenium consisted in a pill of 100 micrograms, to be taken twice a day.
11126284|NCT03891446|Experimental|Bimatoprost SR 10mcg; Lead-in studies 192024-091/-092|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
11126285|NCT03891446|Experimental|Bimatoprost SR 15mcg; Lead-in studies 192024-091/-092|"Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye
~Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment."
11126286|NCT03891433|Active Comparator|Carbapenems group|Meropenem (1g intravenously every 8 hours or adjusted to renal function) or Ertapenem (1g intravenously every 24 hours or adjusted to renal function) by 10 days.
11126287|NCT03891433|Active Comparator|Piperacillin/tazobactam.|Piperacillin / Tazobactam (4.5gr intravenously every 6 hours or adjusted to renal function) by 10 days.
11126288|NCT03891420|Experimental|Galidesivir|Galidesivir IV infusion
11126289|NCT03891420|Placebo Comparator|Placebo|Placebo IV infusion
11126290|NCT03891407|Experimental|HIV Self-testing Group|Camp members will receive information about HIV self-testing from peer educators who will be nominated by you and other camp members in your camp. Camp members in the STEP project will receive pretest counseling and a 10 minute demonstration. They will receive 1 oral fluid HIV self-test kit to conduct the self-test at home or in a private location during the next 1 month and a phone number to call in case you need assistance when performing the self-test at home. They will also receive information about the nearest HIV Care and Treatment Center where they can seek a confirmatory HIV test and start HIV treatment in the event of a positive self-test result.
11126291|NCT03891407|No Intervention|Non-intervention Group|Camp members will be encouraged to seek HIV testing at the clinics.
11126292|NCT03891381|Experimental|Tetragraph|Patients will be randomized to receive quantitative monitoring in the operating room. Neuromuscular management will be guided by information provided by the monitor
11126293|NCT03891381|Active Comparator|Qualitative monitoring|The screen of the Tetragraph will be covered so that information is not provided to the clinician. The monitor will therefore function as a standard peripheral nerve monitor (clinicians will only observe the response to nerve stimulation)
11126294|NCT03891368|Experimental|Virtual Learning Collaborative|The virtual learning collaborative (VLC) is an 18-month intensive training, skill building, and structured implementation process focused on reinforcing fidelity to the InSHAPE model.
11126295|NCT03891368|Active Comparator|Technical Assistance|"The technical assistance (TA) condition includes four scheduled conference calls between an InSHAPE expert TA coach and the agency's InSHAPE team, with the option for sites to request additional calls as needed through 18-months post-randomization."
11126296|NCT03891355|Experimental|Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D)|"Carfilzomib (K) (maximum period of treatment= 24 cycles)
~K on days 1-2, 8-9, 15-16 during cycles 1-12. The dosage of K will be 20 mg/m2 10' iv infusion on day 1 and 2 during cycle 1 and then 27 mg/m2 10' iv infusion thereafter;
~K: on days 1-2, 15-16 during cycles 13-24. The dosage of K will be 27 mg/m2 10' iv infusion. Lenalidomide (R) (maximum period of treatment= 24 cycles)
~R: 25 mg/daily on day 1 to 21 of a 28 days course; for patients with creatinine clearance ≥ 30 mL/min but < 50 mL/min the dosage of R will be 10 mg/daily on day 1 to 21 of a 28 days course.
~Dexamethasone (D) (maximum period of treatment= 24 cycles) PO or IV D on days 1-2, 8-9, 15-16, 22-23. The dosage will be 20 mg between 30 minutes and 4 hours prior to K. For patients older than 75 years the dosage may be reduced at 10 mg."
11126297|NCT03891342|Experimental|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
11126298|NCT03891342|Experimental|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
11126299|NCT03891329|Other|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family ICDs and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
11126300|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
11126301|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
11126302|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
11126303|NCT03891316||Anaesthesiologists PACU|Anaestesiologists working in the postoperative care unit.
11126304|NCT03891316||Anaesthesiologists not exposed|Anaesthesiologists working outside of the operating theatre.
11126305|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
11126306|NCT03891303||Transfused group (TR)|Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
11126307|NCT03891303||Non-transfused (non-TR)|Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
11126308|NCT03891277|Active Comparator|Ferrous succinate|Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
11126309|NCT03891277|Placebo Comparator|placebo|placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
11126310|NCT03891264|Experimental|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
11126311|NCT03891238|Experimental|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
11126312|NCT03891225|Experimental|Amniotic Membrane implantation Arm|All consecutive patients undergone pancreaticoduodenectomy with high FRS will be treated with implantation of AM, by overlapping it over the pancreo-jejunal anastomosis.
11126386|NCT03890731|Other|Adult patients|Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.
11126313|NCT03891212|Experimental|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
11126314|NCT03891212|No Intervention|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
11126315|NCT03891199|No Intervention|Control|Traditional THA.
11126316|NCT03891199|Active Comparator|Intervention|Robotic-arm assisted THA.
11126317|NCT03891186|Experimental|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
11126318|NCT03891186|Active Comparator|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
11126319|NCT03891173|Experimental|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
11126320|NCT03891173|Active Comparator|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
11126321|NCT03891160|Experimental|Group A - 3D models|Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
11126322|NCT03891160|No Intervention|Group B - Control|Group B will be the controls and will not receive a 3D model.
11126323|NCT03891147|Experimental|Electro-acupunture (EA) group|"Patients will receive the treatment of electro-acupuncture with acupoints (i) Riyue (GB-24) ; (2) Danshu (B19) ; (3) Ganshu (B18) ; (4) Qimen (LR14) ; (5) Yanglingquan (GB34)
~The EA will be conducted by using disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length). The needles are inserted at a depth of 10-30 mm vertically or obliquely into acupoints, on which electrical stimulation with continuous waves with 2 Hz and 100 Hz are delivered for 15 min for each frequency through an electrical acupuncture treatment instrument (Hwarto, SDZ-II). The intensities of stimulation are adjusted to a level at which patients feel most comfortable. Each session lasts for 30 minutes."
11126324|NCT03891147|No Intervention|Usual care group|Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
11126325|NCT03891134|Experimental|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
11126326|NCT03891121|Experimental|Occlusal splint|Patients were treated with occlusal splint.
11126327|NCT03891121|Experimental|Botulinum toxin|Patients were treated with botulinum toxin injection.
11126328|NCT03891121|Experimental|Both|Patients were treated with occlusal splint and botulinum toxin injection together.
11126329|NCT03891108|Active Comparator|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
11126330|NCT03891108|Experimental|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
11126331|NCT03891108|Experimental|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
11126332|NCT03891108|Experimental|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
11126333|NCT03891095|Experimental|Intranasal oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)
11126334|NCT03891095|Experimental|L-DOPA|L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)
11126335|NCT03891095|Placebo Comparator|Placebo|Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)
11126336|NCT03891082|Active Comparator|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
11126337|NCT03891082|Active Comparator|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
11126338|NCT03891069|Experimental|Interventional arm|Participants will be invited to play the five different Exergames, for a total of 5 minutes.
11126339|NCT03891056|Active Comparator|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
11126340|NCT03891056|Active Comparator|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
11126341|NCT03891043|Placebo Comparator|Group A, Placebo group|Placebo consisted in a pill of 100 micrograms of starch, to be taken twice a day.
11126387|NCT03890718|Experimental|Donat lenticul|
11126343|NCT03891030|Experimental|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
11126344|NCT03891030|No Intervention|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
11126345|NCT03891017|Experimental|vacuum casting|Vacuum casting will be performed using the Ottobock vacuum casting system. For our vacuum casting procedures, we will be following the protocols outlined in the Harmony Fabrication Quick Guide
11126346|NCT03891017|Active Comparator|hydrostatic casting|For the aqua casting system, we will be using an in-house manufactured device. This device will be created following guidelines from the PCAST Technical Manual
11126347|NCT03891004|Experimental|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
11126348|NCT03891004|Active Comparator|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
11126349|NCT03890991|Experimental|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
11126350|NCT03890991|Active Comparator|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
11126351|NCT03890991|Active Comparator|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
11126352|NCT03890991|No Intervention|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
11126353|NCT03890978|Experimental|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
11126354|NCT03890978|Other|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
11126355|NCT03890965|Experimental|Experimental|Adult patients with chronic sequelae in the upper limb after neurological damage
11126356|NCT03890952|Experimental|Arm B Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients not undergoing salvage surgery
11126357|NCT03890952|Experimental|Arm A Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients undergoing salvage surgery
11126358|NCT03890939|Experimental|BiPAP AutoSV Advanced System One|
11126359|NCT03890939|Experimental|Dreamstation BiPAP AutoSV|
11126360|NCT03890939|Active Comparator|ResMed S7 VPAP Adapt device|
11126361|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
11126362|NCT03890913||Observation|All childcare centers enrolled to Aim 1 will be observed. The physical activity environment will be examined before and after the implementation of playground stencils.
11126363|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
11126364|NCT03890887|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1291583 alone. Test - BI 1291583 + Itraconazole
11126365|NCT03890874||First year medical students|First year medical students of jubilee mission medical college and research institute
11126366|NCT03890861|Experimental|Physical activity intervention|The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
11126367|NCT03890861|Active Comparator|Active control|The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
11126368|NCT03890848|Experimental|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
11126369|NCT03890848|Active Comparator|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
11126370|NCT03890835|Active Comparator|Mineral Trioxide Aggregate (MTA)|
11126371|NCT03890835|Experimental|Biodentine|
11126372|NCT03890809|Experimental|Normal liver function|Single dose
11126373|NCT03890809|Experimental|Mild liver impairment|Single dose
11126374|NCT03890809|Experimental|Moderate liver impairment|Single dose
11126375|NCT03890809|Experimental|Severe liver impairment|Single dose
11126376|NCT03890796|Experimental|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
11126377|NCT03890796|Sham Comparator|Dementia Care Education Group (DE)|Will received dementia care education
11126378|NCT03890783||Patients after surgery of oropharyngeal cancers|Patients after surgery of oropharyngeal cancers with soft palate with free flap reconstruction and adjuvant radiotherapy
11126379|NCT03890770|Experimental|Normal renal function|Single dose
11126380|NCT03890770|Experimental|Mild renal disease|Single dose
11126381|NCT03890770|Experimental|Moderate renal failure|Single dose
11126382|NCT03890770|Experimental|Severe renal failure|Single dose
11126383|NCT03890770|Experimental|End-stage renal disease requiring dialysis|Two single doses administered with washout
11126384|NCT03890757||serratus anteriorblock|Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe
11126385|NCT03890744|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
11126389|NCT03890692|Experimental|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
11126390|NCT03890666|Experimental|Digital System (DS) Group|DS group patients utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard
11126391|NCT03890666|Active Comparator|Concurrent Control (CC) Group|CC group patients will be treated with their standard of care albuterol-administering rescue inhalers
11126392|NCT03890653|Experimental|Performance-Based Financing|At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
11126393|NCT03890653|Experimental|Decentralized Facility Financing|In the other half of the LGA's in each treated state, at least one facility per ward will receive Decentralized Facility Financing (DFF) or equivalent financing that is not be linked to any service delivery targets. These payments would be made on a quarterly basis.
11126394|NCT03890653|No Intervention|Control|This is a pure control arm with no additional interventions.
11126395|NCT03890640|Experimental|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
11126396|NCT03890627||Thoracic bio-reactance measurement of cardiac output|
11126397|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
11126398|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
11126399|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
11126400|NCT03890588|Experimental|CKD enhanced clinical decision support (CKD-CDS Intervention)|Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm.
11126401|NCT03890588|No Intervention|Usual Care|A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
11126402|NCT03890575|Experimental|Airway Stent for Malignant Stricture|Patients with malignant stricture were implanted with covered metallic segmented stent modified with 3D printing.
11126403|NCT03890562|Experimental|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
11126404|NCT03890549||obstructive sleep apnea group|The patients were diagnosed by thoracic and ENT (Eye-Nose-Throat) specialist through polysomnography.
11126405|NCT03890536||Biliary atresia|Biliary atresia is an obstructive cholangiopathy of infancy. It is the most common cause of neonatal cholestasis and the most frequent indication for liver transplantation in children. Patients with biliary atresia have conjugated hyperbilirubinemia (serum direct bilirubin > 1mg/dL) AND are scheduled for/undergo exploratory laparotomy for diagnosis and Kasai portoenterostomy for surgical treatment of BA.
11126406|NCT03890536||Non-BA=disease controls|All infants with other cholestatic syndromes (except biliary atresia) will be eligible for study enrollment in disease controls/non-biliary atresia. This involves the diagnosis of liver diseases caused by syndromes of intrahepatic cholestasis with or without hyperbilirubinemia.
11126407|NCT03890536||Normal|All healthy infants with no acute or chronic liver related illness.
11126408|NCT03890523|Experimental|Segmented Airway Stent for Gastro-Respiratory fistula|Segmented covered metallic airway stent modified with 3D printing was used for gastro-respiratory fistula.
11126409|NCT03890510|Active Comparator|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
11126410|NCT03890510|Active Comparator|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
11126411|NCT03890497|Active Comparator|Full dose of IPV|IPV first dose between 9 -13 months with second dose administered 2 months later.
11126412|NCT03890497|Active Comparator|Fractional Dose of IPV|fIPV first dose between 9 -13 months with second dose administered 2 months later
11126413|NCT03890484|Experimental|New Peers|Participants will drink with two new peers (i.e. strangers), who they did not know prior to the study and their Peer Type.
11126414|NCT03890484|Experimental|Close Friends|Participants will recruit and drink with two of their close friends and their Peer Type
11126415|NCT03890471|Experimental|Preoperative telephone call|Patients will receive routine preoperative counseling in the clinic plus a provider initiated telephone call 3 days before surgery.
11126416|NCT03890471|No Intervention|No preoperative telephone call|Patients will receive routine preoperative counseling in the clinic.
11126417|NCT03890458|Experimental|Experimental|
11126418|NCT03890458|No Intervention|Control|
11126419|NCT03890445||Adalimumab Biosimilar (Hyrimoz)|Patients with moderate-to-severe CD receiving Hyrimoz™ treatment according to the Hyrimoz™ label at the discretion of the investigator
11126420|NCT03890445||Infliximab Biosimilar (Zessly)|Patients with moderate-to-severe CD receiving Zessly™ treatment according to the Zessly™ label at the discretion of the investigator
11126421|NCT03890432|Experimental|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
11126422|NCT03890432|Active Comparator|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
11126423|NCT03890432|Other|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
11126424|NCT03890419|Active Comparator|Control Group|Control Group participants will be exposed to full spectrum light during the study.
11126425|NCT03890419|Experimental|Green light Group|Green light Group participants will be exposed to green light during the study.
11126426|NCT03890419|Experimental|Blue light Group|Blue light Group participants will be exposed to green light during the study.
11126427|NCT03890406|Experimental|Group D|Deep neuromuscular blockade
11126428|NCT03890406|Active Comparator|Group M|Moderate neuromuscular blockade
11126429|NCT03890393||patients with episodic headache|
11126430|NCT03890393||patients with chronic headache|
11126431|NCT03890393||healthy controls|
11126432|NCT03890380|Experimental|Magneto Wire|Patients treated with Magneto Wire
11126433|NCT03890367|Experimental|Group 1: MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection at Day 0 (n=235)
11126434|NCT03890367|Active Comparator|Group 2: Nimenrix® vaccine|Nimenrix® vaccine single injection at Day 0 (n=235)
11126435|NCT03890367|Active Comparator|Group 3: NeisVac-C® vaccine|NeisVac-C® vaccine single injection at Day 0 (n=235)
11126436|NCT03890341|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-64530440|Participants will receive single oral dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and midazolam 2 mg with under fed conditions (high fat meal) on Day 1 followed by JNJ-64530440 2,000 mg on Days 6 under fasted conditions ; JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg under fed conditions on Day 13; JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) from Days 14 to 18; single oral dose of JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg on Day 19 under fed conditions (high fat meal); and JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) on Days 20 to 22.
11126437|NCT03890328|Experimental|RF group|radiofrequency-assisted spleen-preserving therapy group.
11126438|NCT03890328|No Intervention|CT group|Conventional Treatment of Blunt Splenic Injury group.
11126439|NCT03890315||Neuropathic pain|Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of >1 month Unilateral extremity pain will be recruited
11126440|NCT03890315||Control|Age and gender matched control patients will also be recruited to show whether differences exist in outcome measures.
11126441|NCT03890302|Experimental|Cohort A|0.5 mg/kg study drug, or placebo, administered once
11126442|NCT03890302|Experimental|Cohort B|2 mg/kg study drug, or placebo, administered once
11126443|NCT03890302|Experimental|Cohort C|4 mg/kg study drug, or placebo, administered once
11126444|NCT03890302|Experimental|Cohort D|8 mg/kg study drug, or placebo, administered once
11126445|NCT03890302|Experimental|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
11126446|NCT03890289|Experimental|Idelalisib Plus Obinutuzumab|"Single arm: Regimen: GAUDEALIS q28 days
~Obinutuzumab Dose: 1000 mg IV Day 1, 8, 15 (1st cycle)
~Obinutuzumab Dose: 1000 mg IV Day 1 (2nd cycle onward)
~Idelalisib Dose: 150 mg BID oral Daily (24 weeks)"
11126447|NCT03890276|Active Comparator|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
11126448|NCT03890276|Experimental|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
11126449|NCT03890263|Experimental|Opioid deprescribing and self-management|
11126450|NCT03890250|Sham Comparator|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
11126451|NCT03890250|Experimental|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.
~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
11126452|NCT03890237|No Intervention|Control|Business as usual, no intervention
11126453|NCT03890237|Experimental|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
11126454|NCT03890237|Experimental|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
11126455|NCT03890237|Experimental|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
11126456|NCT03890237|Experimental|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
11126457|NCT03890224|No Intervention|Control group|no home non-invasive ventilation (NIV), only hospital NIV
11126458|NCT03890224|Active Comparator|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
11126459|NCT03890224|Active Comparator|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
11126460|NCT03890224|Active Comparator|Rescue home NIV|home non-invasive ventilation (NIV) on demand
11126461|NCT03890211|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, the mother will be encouraged to provide KMC whenever possible. For hypothermic infants, if the temperature is not rising by ½°C per hour with KMC alone, the Infant Warmer will be offered as an addition. In these cases, the heat will be provided by placing the Infant Warmer over the infant's back while the mother provides KMC. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the Infant Warmer by being placed directly on the warmer as it lies flat. Use of hat and socks will be encouraged by additional clothes will only be added in addition to the warmer per caregiver request, as it reduces heat transfer.
11126462|NCT03890211|No Intervention|Control|Data such as infant temperature, date of birth, etc. will be collected from those who enroll in the control group. No experimental intervention will be administered.
11126463|NCT03890198|Experimental|chimeric Antigen Receptor T cell|LCAR-C182A Cells
11126464|NCT03890185|Experimental|A: Chemo+RT low dose|Chemo + Low dose RT: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin (CDDP) 75mg/m2 IV D1 and radiation therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for a total of 2 cycles every 21 days.
11126465|NCT03890185|Active Comparator|B: Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
11126466|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
11126467|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
11126468|NCT03890159|Experimental|Computer Assisted Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours, and patients will progress to the difficulty level automatically. Their performance during this process (response time etc.) will be recorded.
11126469|NCT03890159|Experimental|Conventional Cognitive Rehabilitation|The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests.
11126470|NCT03890159|No Intervention|Waiting list controls|These patients will get no intervention as means of cognitive rehabilitation, but will get their usual treatments.
11126471|NCT03890146||intensive care patients|patient hospitalised in intensive care unit veinous and capillary ponction
11126472|NCT03890133|Experimental|Ba-Duan-Jin group|The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital; Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks.
11126473|NCT03890133|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.
~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
11126474|NCT03890133|No Intervention|Healthy control group|
11126475|NCT03890120|Experimental|Cilofexor|Cilofexor for 96 weeks
11126476|NCT03890120|Placebo Comparator|Placebo|Placebo for 96 weeks
11126477|NCT03890107||Pediatric tympanostomy tube patients|Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the PhotoniCare TOMi Scope
11126478|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
11126479|NCT03890068|Experimental|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
11126480|NCT03890055|Experimental|Clinical trial group|（Carboplatin/cisplatin + etoposide）+ （Anlotinib Hydrochloride 12 mg/day ，Each cycle was defined as 2 weeks on-treatment fol- lowed by 1 week off-treatment）, after 4-6 cycles of treatment, the treatment was continued with anlotinib until disease progression.
11126481|NCT03890042|Active Comparator|Dienogest group|
11126482|NCT03890042|Active Comparator|Gynera group|
11126483|NCT03890029|Other|Intervention|"Once potential participants have given consent and determined eligible, they will undergo an initial assessment.Pre, post- and follow-up testing. This consists of verbal scales including emotional well-being scales and mental health symptom scales. They will be administered in a group 30-60 minute session. Neuropsychological testing and psychophysiological tests given will require 90 minutes. Neuropsychological testing will be completed at pre and post testing only. In order to ensure unbiased assessment, pre- and post- and follow-up testing will be conducted by individuals blinded to study condition.
~Randomization. After pre-testing, all individuals will be randomly assigned to either the active treatment group or minimal attention control condition. After this, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. After five weeks, all participants will be post-tested."
11126927|NCT03886935||Fontan patients|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
11126484|NCT03890029|Other|Control|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training
11126485|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
11126486|NCT03890003|Experimental|AID System Containing Insulin Lispro|The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.
11126487|NCT03889990|Other|healthy smokers|"Healthy smokers males, aged >18years, with >10 pack/years,receiving no medications
~Intervention: the use of an IQOS"
11126488|NCT03889977|Experimental|Exercise|Resistance exercise 45 min following breakfast
11126489|NCT03889977|No Intervention|Control|No exercise (resting) following breakfast
11126490|NCT03889964||patients with stable COPD|
11126491|NCT03889951||group 1|group of ALL patients with IKZF1 deletion mutation.
11126492|NCT03889951||group 2|group of ALL patients with no detected mutation
11126493|NCT03889925|Experimental|Autologous conditioned plasma group|Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.
11126494|NCT03889925|Experimental|Autologous conditioned plasma with hyaluronic acid group|Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.
11126495|NCT03889912|Experimental|Cemiplimab|Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion
11126496|NCT03889899|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11126497|NCT03889886|Placebo Comparator|Vehicle|Vehicle
11126498|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
11126499|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
11126500|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
11126501|NCT03889873|Experimental|Drinking; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
11126502|NCT03889873|Experimental|Drinking; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
11126503|NCT03889873|Experimental|Drinking; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
11126504|NCT03889873|Experimental|Drinking; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
11126505|NCT03889873|Experimental|Smartphone; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
11126506|NCT03889873|Experimental|Smartphone; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
11126507|NCT03889873|Experimental|Smartphone; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
11126508|NCT03889873|Experimental|Smartphone; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
11126509|NCT03889860||Uveitis group|
11126510|NCT03889860||Control group|age and sex matched group to the uveitis group
11126511|NCT03889847|Experimental|silicone DLT|Fibreoptic intubation with silicone double lumen tube
11126512|NCT03889847|Experimental|PVC DLT|Fibreoptic intubation with PVC double lumen tube
11126513|NCT03889834|Experimental|Autotransfusion: blood stored at 4 ° C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days
11126514|NCT03889834|Experimental|Autotransfusion: blood stored at -80°C|Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days
11126515|NCT03889834|Other|Controls not transfused|no transfusion
11126516|NCT03889821|Active Comparator|Child-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM).
11126517|NCT03889821|Experimental|Child- and Parent-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM). Parents also participate in 6 separate, individual sessions of Mindfulness Based Stress Reduction (MBSR).
11126518|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
11126519|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
11126520|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
11126521|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
11126522|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
11126523|NCT03889795|Experimental|Dose Escalation|C3 (Metformin, Simvastatin and Digoxin) will be dosed each day of a 28 calendar day cycle. The starting dose level will be increased with each cohort. There are 3 cohorts. Upon reaching maximum tolerated dose, an expansion cohort will be opened. Cohort 1 - Metformin 850mg po/day, Simvastatin 5mg po/day, Digoxin 0.0625 mg po/day. Cohort 2 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 20 mg po/day, Digoxin 0.25 mg po/day. Cohort 3 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 40 mg po/day, Digoxin 0.25 mg po/day for two weeks, 0.375 mg po/day for the next two weeks for cycle 1. Subjects will receive 0.50 mg po/day in Cohort 3, Cycle 2 and beyond. Metformin to be taken at Breakfast and Dinner time (as applicable), Simvastatin at Bed time and Digoxin in the Morning.
11126524|NCT03889756|Experimental|Ketamine|Ketamine is an FDA-approved anesthetic agent that is commonly used to induce surgical anesthesia due to its low incidence of significant respiratory depression and hypotension. It as a N-methyl-D-aspartate (NMDA) receptor antagonist and glutamatergic modulator, and has been demonstrated in multiple controlled clinical trials to have rapidly acting antidepressant and anti-suicidal effects in adults.
11126525|NCT03889756|Placebo Comparator|Midazolam|Midazolam, the active control in this study, is a medication that is approved by the Food and Drug Administration as a sedative for both children and adults.It is a benzodiazepine with a short half-life that was chosen so as to blind the psychotomimetic effects of Ketamine.
11126526|NCT03889743|Experimental|Dexamethasone|
11126527|NCT03889743|Placebo Comparator|controls|
11126528|NCT03889717|Experimental|400 iu|neonates who will receive vitamin d dose at 400 iu per day
11126529|NCT03889717|Active Comparator|1000 iu|neonates who will receive vitamin d dose 1000 iu per day
11126530|NCT03889704|Experimental|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
11126531|NCT03889691||Control group|The control group consisted of patients who verbal explanation of the surgical procedure and the potential postoperative complications was given with a written informed consent document
11126532|NCT03889691||Study group|Participants in the study group asked to watch impacted lower third molar extraction video which was previously uploaded to the internet with their own device. This video includes only visual components of the surgery such as anesthesia, incision, extraction and suturing. Patients in the second group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document.
11126533|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
11126534|NCT03889665|Experimental|Suspension training group|
11126535|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.
~OCT (investigation) before and after cataract extraction"
11126536|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
11126537|NCT03889639|Experimental|Arm 1|12 weeks of SAR442168 dose 1 followed by 4 weeks of Placebo
11126538|NCT03889639|Experimental|Arm 2|12 weeks of SAR442168 dose 2 followed by 4 weeks of Placebo
11126539|NCT03889639|Experimental|Arm 3|12 weeks of SAR442168 dose 3 followed by 4 weeks of Placebo
11126540|NCT03889639|Experimental|Arm 4|12 weeks of SAR442168 dose 4 followed by 4 weeks of Placebo
11126541|NCT03889639|Experimental|Arm 5|4 weeks of Placebo followed by 12 weeks of SAR442168 dose 1
11126542|NCT03889639|Experimental|Arm 6|4 weeks of Placebo followed by 12 weeks of SAR442168 dose 2
11126543|NCT03889639|Experimental|Arm 7|4 weeks of Placebo followed by 12 weeks of SAR442168 dose 3
11126544|NCT03889639|Experimental|Arm 8|4 weeks of Placebo followed by 12 weeks of SAR442168 dose 4
11126545|NCT03889626|Experimental|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
11126546|NCT03889626|Experimental|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
11126547|NCT03889626|No Intervention|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
11126548|NCT03889613|Experimental|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
11126549|NCT03889600|Experimental|REDD-CAT Recipient|The nurse care manager will incorporate the administration of the REDD-CAT to the patient as part of the standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
11126550|NCT03889587|Experimental|Innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibula bone flaps. In simultaneous innervated group, neurorrhaphy between the ilioinguinal nerve or fibula flap nerve with inferior alveolar nerve or great auricular nerve will be performed.
~Intervention: Procedure: Innervation"
11126551|NCT03889587|Active Comparator|Non-innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibular bone flaps. In traditional noninnervated group, neurorrhaphy will not be performed.
~Intervention: Procedure: Non-innervation"
11126552|NCT03889574||combination of aspirin, P2Y12 Inhibitor with a NOAC|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
11126553|NCT03889574||combination of aspirin, P2Y12 Inhibitor with warfarin|As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible
11126554|NCT03889561|Experimental|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
11126555|NCT03889561|No Intervention|Control|SSB taxes
11126556|NCT03889548|Experimental|Mental Imagery|
11126557|NCT03889548|No Intervention|Control|
11126558|NCT03889535|Active Comparator|Resin strip crowns|Current standard full coverage restoration provided for primary incisors. Please see intervention section for detailed description of technique.
11126559|NCT03889535|Experimental|Zirconia crowns|Experimental treatment under study. Zirconia crowns are an alternative restorative option. Please see intervention section for detailed description of technique.
11126560|NCT03889496|Other|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
11126561|NCT03889483|Other|NeuroCatch™ Platform Assessment|All participants will undergo two NeuroCatch™ Platform Assessments.
11126562|NCT03889470|Active Comparator|200 microgram NTG|200 microgram NTG through the radial sheath
11126563|NCT03889470|Placebo Comparator|Saline|Saline infusion through the radial sheath
11126564|NCT03889457||Patients with venous thromboembolic disease|Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.
11126565|NCT03889444||OZURDEX®|Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.
11126566|NCT03889431|Experimental|Capsule group|Group one received iodine capsule
11126567|NCT03889431|Experimental|Iodized salt group|Group two received iodized salt
11126568|NCT03889418|Active Comparator|Electronic medical recorded clinical decision support|Usual care only
11126569|NCT03889418|Active Comparator|stepped opioid collaborative care model|Usual care AND collaborative care with behavioral health integration
11126570|NCT03889405|Experimental|Study group|Healthy 32 weeks or more pregnant women, at early stage of labor.
11126571|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
11126572|NCT03889379|Experimental|Effects of Albuterol on Immune Cell Composition|This is a single subject repeated measure experimental design with each participant acting as his/her own control.
11126573|NCT03889366|Experimental|NXP001 Oral Capsule|
11126574|NCT03889366|Experimental|NXP001 Oral Suspension|
11126575|NCT03889366|Active Comparator|Emend®|
11126576|NCT03889353|Experimental|BCI sessions|up to 3 test sessions (Day-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (Day 1-Day 5 and Day 8-Day 12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
11126577|NCT03889340||Phase 1 cohort|Subjects resuscitated from cardiac arrest will undergo cooling per standard of care with the IQool device.
11126578|NCT03889327|Experimental|Cognitive Feedback and Psychoeducation (CFP)|Participants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
11126579|NCT03889327|Active Comparator|Healthy Eating Habits (HEH)|The control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
11126580|NCT03889314|Experimental|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
11126581|NCT03889314|Placebo Comparator|Placebo|
11126582|NCT03889314|No Intervention|No Treatment|7 day wash-out period between months
11126583|NCT03889301|Experimental|E-E Video|Watch E-E video that incorporates health and educational messages
11126584|NCT03889301|Active Comparator|Discussion|Structured discussion about depression and anxiety
11126585|NCT03889288|No Intervention|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
11126586|NCT03889288|Experimental|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
11126587|NCT03889275|Experimental|Sequential|MEDI5395 and durvalumab administered sequentially
11126588|NCT03889275|Experimental|Concurrent|MEDI5395 and durvalumab administered concurrently
11126716|NCT03888313||Patients participating in the pretreatment group consultation|Patients who chosse to participate in a group consultation (with other patients also in the process of undergoing surgery for colorectal cancer).
11126589|NCT03889262|Active Comparator|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
11126590|NCT03889262|Active Comparator|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
11126591|NCT03889249|Active Comparator|Tenecteplase (tNK-TPA)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
11126592|NCT03889249|Active Comparator|Alteplase ( tPA)|The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).
11126593|NCT03889236|Experimental|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
11126594|NCT03889236|Experimental|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
11126595|NCT03889236|Placebo Comparator|Placebo|4 capsules a day of the placebo for 3 months.
11126596|NCT03889223|Active Comparator|The LDF neuraxial positioning technique|In the LDF neuraxial positioning technique, fifty participants were planned to lay down the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist. Volunteers jaw touch to chest and legs in abdominal flexion with hands are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
11126597|NCT03889223|Experimental|The SCF neuraxial positioning technique|In the SCF neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
11126598|NCT03889210|Active Comparator|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
11126599|NCT03889210|Placebo Comparator|Placebo|Placebo will be given in a total volume of 100 ml.
11126600|NCT03889197|No Intervention|Control|Standard care
11126601|NCT03889197|Active Comparator|Sodium supplementation algorithm|Beginning on the 14th postnatal day and continuing until 36 weeks postmenstrual age, infants randomized to the algorithm will have a spot urine sodium concentration determined every two weeks and sodium supplementation provided according to the algorithm.
11126602|NCT03889184|Experimental|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
11126603|NCT03889184|No Intervention|Usual care|the control group will receive usual care
11126604|NCT03889158|Experimental|Acute Inflammation/Antioxidant|"All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
~All participants will receive ascorbic acid (Vit C) on two occasions [oral pill, 2g, 2x (baseline, during acute inflammation)]."
11126605|NCT03889145|Active Comparator|Telmisartan, Amlodipine|
11126606|NCT03889145|Active Comparator|Hydrochlorothiazide|
11126607|NCT03889145|Experimental|Telmisartan, Amlodipine, Hydrochlorothiazide|
11126608|NCT03889132||Premenopausal women with obesity|
11126609|NCT03889132||Postmenopausal women with obesity|
11126610|NCT03889132||Men with obesity|
11126611|NCT03889132||Premenopausal women without obesity|
11126612|NCT03889132||Postmenopausal women without obesity|
11126613|NCT03889132||Men without obesity|
11126614|NCT03889119|Active Comparator|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
11126615|NCT03889119|Other|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
11126616|NCT03889106||Lassa fever|
11126617|NCT03889093|Other|Yttrium-90|This single arm study is to evaluate immunologic changes following the treatment of primary or secondary malignancies of the liver utilizing beta-emitting, Yttrium-90.
11126618|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
11126619|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
11126620|NCT03889080||Control|Age- and gender-matched healthy controls
11126621|NCT03889067|Experimental|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10^4CFU
~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
11126622|NCT03889054|No Intervention|Control|Current clinical management
11126623|NCT03889054|Active Comparator|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
11126624|NCT03889041||Caregivers of children with EA-TEF|Caregivers of children with esophageal atresia and tracheoesophageal fistula will be included in the study.
11126625|NCT03889015|Active Comparator|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
11128158|NCT03878355|Experimental|radical endoscopic sinus surgery plus Draf 3 surgery|
11126626|NCT03889015|Experimental|probiotic yogurt|Probiotics are live microorganisms that confer oral health benefits by adhering to the oral mucosa and surface of teeth as a part of the biofilm thus preventing the adhesion, colonization, and proliferation of cariogenic bacteria inhibiting the formation of pathogenic plaque
11126627|NCT03888989|Other|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
11126628|NCT03888963|Experimental|PRF|
11126629|NCT03888963|Sham Comparator|SHAM|
11126630|NCT03888950|Experimental|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
11126631|NCT03888924|Experimental|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
11126632|NCT03888924|Placebo Comparator|Placebo treated patients|a single dose of placebo.
11126633|NCT03888911|Experimental|High dose IQP-LU-104 (5120mg)|High dose treatment group
11126634|NCT03888911|Experimental|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
11126635|NCT03888911|Placebo Comparator|Placebo|Placebo group
11126636|NCT03888898|Active Comparator|N95 Filtering Facepiece Respirator|control fit testing
11126637|NCT03888898|Experimental|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
11126638|NCT03888885|Experimental|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
11126639|NCT03888885|No Intervention|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
11126640|NCT03888872|Experimental|Group I|Group I (Study): will consist of 20 patients with diabetic neuropathy and will receive High tone power therapy in addition to selected physical therapy program (Wobble board training, AROM exercises for both UL & LL, gentle manual stretching exercises for both UL & LL and graduated gait training). for 10 sessions every other day, each session for 1.45 hours (60 minutes for HiTop and 45 minutes for selected physical therapy program).
11126641|NCT03888872|Experimental|Group II|Group II (Control): will consist of 20 patients with diabetic neuropathy and will receive selected physical therapy program only same as group I. For 10 sessions every other day, each session for 45 minutes.
11126642|NCT03888859|Experimental|Intravenous (i.v.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intravenous (IV) infusion
11126643|NCT03888859|Experimental|Intra-hepatic artery (i.a.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intra-hepatic artery (IA) infusion
11126644|NCT03888859|Experimental|Intratumoral Injections (i.t.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intratumoral injections (i.t.) infusion
11126645|NCT03888846|Other|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
11126646|NCT03888846|Experimental|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
11126647|NCT03888833||Veno arterial extracorporeal membrane oxygenation|
11126648|NCT03888820|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
11126649|NCT03888820|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
11126650|NCT03888807|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
11126651|NCT03888807|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees
11126652|NCT03888781||With Left Ventricular Remodeling|By Echocardiography
11126653|NCT03888781||Without Left Ventricular Remodeling|By Echocardiography
11126654|NCT03888768|Active Comparator|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss >1L and subsequent post operative follow up till 6month
11126655|NCT03888768|No Intervention|Standard Care|patient will received standard hospital practise
11126717|NCT03888300|Experimental|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
11126656|NCT03888755|Experimental|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
11126657|NCT03888742||ADT Group|Participants received continue ADT treatment for at least more than 6 months
11126658|NCT03888742||RRP Group|Participants have radical prostatectomy performed more than 6 months ago.
11126659|NCT03888729|Experimental|HCV treatment-naïve participants|HCV-infected individuals naïve to DAA therapy regimen; in this group we consider also HCV-infected individuals who have failed interferon-based therapy. Sofosbubir/velpatasvir (SOF/VEL) will be administered once daily for 12 weeks to eligible HCV treatment-naïve participants.
11126660|NCT03888729|Experimental|HCV treatment-experienced participants|HCV treatment-experienced participants, i.e.HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen. Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants
11126661|NCT03888716|Experimental|KL1333|25 and 100 mg KL1333 encapsulated tablets for daily oral dosing
11126662|NCT03888716|Placebo Comparator|Matching placebo|25 and 100 mg KL placebo encapsulated tablets for daily oral dosing
11126663|NCT03888703|Experimental|Treatment|
11126664|NCT03888703|No Intervention|Control|
11126665|NCT03888690|Active Comparator|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
11126666|NCT03888690|Active Comparator|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
11126667|NCT03888677|Active Comparator|Standard|Standard FEC (F600, E60, C600) every 3rd week.
11126668|NCT03888677|Experimental|Tailored|Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
11126669|NCT03888677|Active Comparator|Registered|Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
11126670|NCT03888664|Experimental|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
11126671|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
11126672|NCT03888625|Active Comparator|Group A: Conventional ILM peeling|peeling with complete removal of the internal limiting membrane (ILM)
11126673|NCT03888625|Active Comparator|GroupB: Inverted ILM Peeling|the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
11126674|NCT03888612|Experimental|ARV-110|"Part A: Oral tablet(s), once or twice daily in 28 day cycles
~Part B: Oral tablet(s), once or twice daily in 28 day cycles"
11126675|NCT03888586|Experimental|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
11126676|NCT03888586|Experimental|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
11126677|NCT03888573|Active Comparator|Stretch|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms.
11126678|NCT03888573|Active Comparator|Traction|Patients within Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
11126679|NCT03888560|Experimental|Micro-osteoperforations|"Lower arch, 2 MOPs vertically at interdental area bilaterally mesial to lower 6's ; mesial to lower 1st premolar; mesial to lower 2's and between the lower 1's.The 7 locations for perforations will be repeated 4 weekly until the completion of treatment.
~Upper arch , 2 MOPs vertically,bilaterally at the buccal aspect on the cortical bone between the 1's and distal to the 2's during levelling and alignment, repeated every 4 weekly until completion of treatment. MOPs at the extraction site of the upper arch will be started one month post extraction of upper 4's until completion of treatment.
~The exact location for MOPs insertion as following: the first point will be placed 6mm from the free gingival margin, and the second point will be placed 5mm from the first point."
11126680|NCT03888560|No Intervention|control|Conventional orthodontic treatment without any aid in tooth acceleration method / device
11126681|NCT03888547|Experimental|OT-HAWP|"The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules:
~Week 1: Sleep Hygiene Week 2: Fatigue Management Week 3: Cancer-related cognitive impairments Week 4: Stress Management Each session will last 1.5 hours (45 minutes of group education and 45 minutes of individual modifications and strategy recommendations."
11126682|NCT03888534|Experimental|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants >= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m^2) and <1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
11126683|NCT03888521|Experimental|Resound Relief|All participants are in the same group, and receive the same intervention - use of the Resound Relief smartphone app for 6 months
11126718|NCT03888287|Experimental|Retrospective Phase|150 patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
11126719|NCT03888287|Experimental|Prospective Phase-Watch Rx system|150 patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
11126928|NCT03886935||Healthy biventricular controls|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
11128159|NCT03878355|Experimental|radical endoscopic sinus surgery|
11126684|NCT03888508|Experimental|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
11126685|NCT03888508|No Intervention|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
11126686|NCT03888495|Experimental|Gender socialization (GS)|Gender socialization workshops raised awareness on gender, its social construction and inequality, notions of masculinity and femininity, division of labor, access and control over resources. The workshop also included skill-building sessions on effective communication and negotiation and relationship building.
11126687|NCT03888495|Experimental|GS + Financial literacy (FL)|Financial literacy workshops promoted knowledge and skills in budgeting, financial planning and accessing and using financial services and income generating activities.
11126688|NCT03888495|Experimental|GS + FL + Family planning|Family planning counseling was provided to couples by family planning providers from nearby facilities. Couples were encouraged to seek services in facilities of their choice. A voucher system provided financial support for the poorest couples.
11126689|NCT03888495|No Intervention|Control|Couples were interviewed at baseline, and will be interviewed at endline.
11126690|NCT03888482|Other|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
11126691|NCT03888482|Other|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
11126692|NCT03888469|Other|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
11126693|NCT03888469|Other|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
11126694|NCT03888456|Experimental|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
11126695|NCT03888456|Sham Comparator|Control|participants will receive a single touch sham intervention mimicking the intervention
11126696|NCT03888443||uCP children|15 Children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol twice separated from 2 to 4 weeks
11126697|NCT03888443||uCP children with botulinum toxin injections|5 children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol three times
11126698|NCT03888443||healthy volunteers (TDC children)|20 children aged from 6 to 17 (healthy volunteers) will realize the bimanual protocol once
11126699|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
11126700|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
11126701|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
11126702|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
11126703|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
11126704|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
11126705|NCT03888391|Experimental|Active TNS|Participants will receive trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for up to 12 months of this open-extension trial.
11126706|NCT03888378|Active Comparator|0.3% Topical Minocycline Ointment|Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID, morning and evening to eyelid margin
11126707|NCT03888378|Active Comparator|1% Topical Minocycline Ointment|Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID, morning and evening to eyelid margin
11126708|NCT03888378|Placebo Comparator|Topical Vehicle Ointment|Topical administration of Topical Vehicle Ointment. Regimen: Apply BID, morning and evening to eyelid margin
11126709|NCT03888365||Cohort A|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH. This is an observational study; Treprostinil is not used as an intervention in this study.
11126710|NCT03888365||Cohort B|Participants who are taking other PAH medications (instead of inhaled treprostinil). This is an observational study; Treprostinil is not used as an intervention in this study.
11126711|NCT03888339|Active Comparator|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
11126712|NCT03888339|Experimental|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
11126713|NCT03888326|Experimental|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
11126714|NCT03888326|Sham Comparator|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
11126715|NCT03888326|No Intervention|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
11126720|NCT03888287|Experimental|Retrospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
11126721|NCT03888287|Experimental|Prospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
11126722|NCT03888274|Experimental|Active|
11126723|NCT03888261|Active Comparator|Active Intervention:|Mind-body intervention (incl. Relaxation Response Resiliency Program & the Open and Calm Program)
11126724|NCT03888261|No Intervention|No Intervention|No intervention (Study participants will receive routine clinical practice)
11126725|NCT03888248|Active Comparator|Exercises|Daily muscle-strengthening exercises
11126726|NCT03888248|Experimental|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
11126727|NCT03888235|Experimental|Immediate corrective exercises|"At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.
~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that."
11126728|NCT03888235|Experimental|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.
~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that."
11126729|NCT03888235|Active Comparator|Delayed treatment|"These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.
~The concurrent use of both treatments will be assessed at their last visit one month after that."
11126730|NCT03888222|Placebo Comparator|Placebo|"Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) capsule orally once daily for 3 months (90 days)."
11126731|NCT03888222|Active Comparator|100 mg of Bosutinib|Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 2 will receive the 100 mg of Bosutinib one (1) capsule orally once daily for 3 months (90 days).
11126732|NCT03888209|Experimental|Anodal tDCS|Patients will receive 20min anodal tDCS
11126733|NCT03888209|Sham Comparator|Sham tDCS|Patients will receive 20 minutes of Sham anodal tDCS
11126734|NCT03888196|Experimental|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
11126735|NCT03888196|Placebo Comparator|Control Group|500 mg/day of Celulose. 2 weeks treatment
11126736|NCT03888183|Placebo Comparator|salt solution without 0.15% HA|
11126737|NCT03888183|Active Comparator|preservative-free 0.15% HA|
11126738|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
11126739|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
11126740|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
11126741|NCT03888157||Liraglutide|Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
11126742|NCT03888144|Active Comparator|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
11126743|NCT03888144|Experimental|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
11126744|NCT03888131|Experimental|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
11126745|NCT03888131|Active Comparator|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
11126746|NCT03888118|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
11126747|NCT03888118|No Intervention|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
11126748|NCT03888105|Experimental|FL|Follicular lymphoma grade 1-3a cohort
11126749|NCT03888105|Experimental|DLBCL|Diffuse large B-cell lymphoma cohort
11126750|NCT03888105|Experimental|MCL|Mantle Cell Lymphoma cohort
11126751|NCT03888105|Experimental|MZL|Marginal Zone Lymphoma cohort
11126752|NCT03888105|Experimental|Other B-NHL|Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM])
11126753|NCT03888092|Experimental|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
11126754|NCT03888079||Local anesthetic|Patients who chose local anesthesia for their surgery
11126755|NCT03888079||General anesthetic|Patients who chose general anesthesia for their surgery
11126756|NCT03888066|Experimental|Group 1: Patiromer|Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.
11126757|NCT03888066|Placebo Comparator|Group 2: Placebo|Subjects will be randomized to receive a daily dose of placebo with possible dose adjustments based on subsequent local serum potassium levels.
11126758|NCT03888053|Active Comparator|BB-101 Treatment Arm|BB-101 liquid formulation concentration of 2 µg/mL or 20 µg/mL will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
11126759|NCT03888053|Placebo Comparator|Placebo Arm|Placebo will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
11126855|NCT03887390|Experimental|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
11126760|NCT03888040|Experimental|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
11126761|NCT03888040|Experimental|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
11126762|NCT03888027|No Intervention|Control|Patients receive no intervention
11126763|NCT03888027|Active Comparator|WalkMORE group|"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:
~Standard of care; or
~WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE volunteer two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the Research Coordinator to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team."
11126764|NCT03888014||Treatment group|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
11126765|NCT03887988||Orbital Fracture|Patients with dislocated fracture of the inferior and/or medial orbital wall
11126766|NCT03887975|Active Comparator|Percentage of force in monoplane occlusion|Different occlusal scheme evaluation using tscan
11126767|NCT03887975|Active Comparator|Percentage of force in lingualized occlusion|Different occlusal scheme evaluation using tscan
11126768|NCT03887962|Experimental|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
11126769|NCT03887962|Active Comparator|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
11126770|NCT03887949|Active Comparator|VCV|Volume controlled ventilation
11126771|NCT03887949|Active Comparator|PCV|Pressure controlled ventilation
11126772|NCT03887949|Experimental|PCV-VG|Pressure controlled ventilation with volume guarantee
11126773|NCT03887936|Experimental|Testosterone arm|Testosterone gel 1.62%
11126774|NCT03887936|Placebo Comparator|Placebo arm|Matching placebo will be prepared by the Michael DeBakey VA Medical Center Pharmacy.
11126775|NCT03887923|Experimental|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
11126776|NCT03887910|Experimental|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
11126777|NCT03887910|Experimental|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
11126778|NCT03887910|No Intervention|Control|Usual care with developmental toys.
11126779|NCT03887897|Active Comparator|Airtraq|Airtraq laryngoscope
11126780|NCT03887897|Active Comparator|Macintosh|Macintosh laryngoscope
11126781|NCT03887884|Experimental|CVT-301|Single inhaled dose of CVT-301 84 mg
11126782|NCT03887884|Active Comparator|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
11126783|NCT03887871|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T
~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
11126784|NCT03887871|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T
~Period 2: Harnal-D Tab. 1T"
11126785|NCT03887858|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T
~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
11126786|NCT03887858|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T
~Period 2: Harnal-D Tab. 1T"
11126787|NCT03887845||Open gastrointestinal surgery|All patients enrolled in this group would undergo open gastric and colorectal resection surgery.
11126788|NCT03887845||Laparoscopic gastrointestinal surgery|All patients enrolled in this group would undergo laparoscopic gastric and colorectal resection surgery.
11126789|NCT03887832|Experimental|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
11126790|NCT03887832|Active Comparator|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
11126791|NCT03887793|Experimental|VACs intervention|Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI. Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
11126792|NCT03887793|No Intervention|Wait list control|Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
11126793|NCT03887780||Treatment|Rivaroxaban treatment-naïve patients, at least 18 years of age and presenting with NVAF will be considered eligible for participation in this study only after the decision to treat with rivaroxaban has been made by the treating physician.
11126794|NCT03887754|Active Comparator|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
11128160|NCT03878355|Experimental|functional endoscopic sinus surgery|
11126795|NCT03887754|Active Comparator|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.
~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
11126796|NCT03887754|Active Comparator|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
11126797|NCT03887754|Placebo Comparator|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
11126798|NCT03887741|Experimental|Plasmapheresis|3 patients will have monthly plasmapheresis for 6 months and followed for a total of 12 months
11126799|NCT03887741|Experimental|Plasma infusion|3 patients will have biweekly plasma infusion for 6 months and followed for 12 months
11126800|NCT03887741|No Intervention|Control group|3 patients will be followed for 12 months
11126801|NCT03887728||Artificial (HRT) Cycles|"Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days
~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.
~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.
~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.
~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.
~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone"
11126802|NCT03887728||Spontaneous natural cycles|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.
~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.
~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).
~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
11126803|NCT03887715|Active Comparator|Active|Group will have VNS activated 2 weeks post implant.
11126804|NCT03887715|Sham Comparator|Control|Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.
11126805|NCT03887702|Experimental|Group A (tenofovir alafenamide)|Participants receive TAF orally (PO) once daily (QD) immediately or within 28 days after initial dose of chemotherapy. Courses repeat for a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
11126806|NCT03887702|Experimental|Group B (tenofovir alafenamide)|Participants receive TAF PO QD after HBV reactivation during chemotherapy. Courses repeat for a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
11126807|NCT03887702|Experimental|Group C (tenofovir alafenamide, usual care)|Participants receive TAF PO QD at the discretion of the physician per usual care. Courses for a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
11126808|NCT03887689|Experimental|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
11126809|NCT03887676|Active Comparator|Arbaclofen|
11126810|NCT03887676|Placebo Comparator|Placebo|
11126811|NCT03887650|Experimental|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
11126812|NCT03887650|Active Comparator|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
11126813|NCT03887637||Danoprevir Sodium triple therapy|"DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg.
~Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours."
11126814|NCT03887637||Sofosbuvir/ Velpatasvir therapy|Sofosbuvir/ Velpatasvir :500mg (two drugs in one tablet) orally once daily for 12 weeks.
11126815|NCT03887637||Ombitasvir/Paritaprevir therapy|Ombitasvir/Paritaprevir: Ombitasvir two tablets orally once daily for 12 weeks; Paritaprevir one tablet orally twice daily for 12 weeks.
11126816|NCT03887637||Grazoprevir/elbasvir therapy|Grazoprevir/elbasvir: 150mg (two drugs in one tablet) orally once daily for 12 weeks.
11126817|NCT03887637||Daclatasvir/Asunaprevir therapy|Daclatasvir (60mg)one tablet once daily and Asunaprevir (100mg)one tablet twice daily for 24weeks
11126818|NCT03887637||Danoprevir Sodium/Sofosbuvir therapy|Danoprevir Sodium: 100mg (one tablet) orally twice daily for 12 weeks;Sofosbuvir:400mg (one tablet) orally once daily for 12 weeks.
11126819|NCT03887624|Experimental|Experimental group|Ethosuximide(2 weeks) + Escitalopram (4 weeks)
11126820|NCT03887624|Placebo Comparator|Control group|Placebo(2 weeks)+Escitalopram(4 weeks)
11126856|NCT03887377|Experimental|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.
~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
11126821|NCT03887611||thyroid nodules|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of thyroid surgery or thyroid biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
11126822|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
11126823|NCT03887585|Experimental|Achilles tendon lengthening|Surgery of percutaneous Achilles tendon lengthening by triple hemisection
11126824|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
11126825|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
11126826|NCT03887559|Experimental|Intervention group|Group-based stabilization and skill-training combined with individual treatment.
11126827|NCT03887559|Active Comparator|controls|Individual treatment as usual only.
11126828|NCT03887546|Experimental|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.
~12 weeks, 5 days/week, 15 minutes/day."
11126829|NCT03887546|Active Comparator|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
11126830|NCT03887533|Experimental|1000 mg/kg|VTS-270 1000 mg/kg
11126831|NCT03887533|Experimental|1500 mg/kg|VTS-270 1500 mg/kg
11126832|NCT03887533|Experimental|500 mg/kg|VTS-270 500 mg/kg
11126833|NCT03887520|Other|Cardiovascular disease|Patients with established Cardiovascular disease
11126834|NCT03887507|Experimental|Experimental|There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
11126835|NCT03887507|Active Comparator|Standard Therapy|The standard group shall perform 4 sessions of physiotherapy in the same period for two consecutive weeks, with one hour per session in its specialized MS association, on 1st, 3rd, 8th, 10th and 15th days. This will be applied by experienced physiotherapists during the treatment of people with MS. The program will consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept. Patients in this group will walk at least for 20 minutes per day during the study period.
11126836|NCT03887494|Experimental|Y-Strut Implant|Single interventional arm
11126837|NCT03887481|Experimental|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
11126838|NCT03887481|Experimental|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
11126839|NCT03887468|Active Comparator|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
11126840|NCT03887468|Active Comparator|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
11126841|NCT03887455|Experimental|Core Study: Lecanemab 10 mg/kg biweekly|
11126842|NCT03887455|Placebo Comparator|Core Study: Placebo|
11126843|NCT03887455|Experimental|Extension Phase: Lecanemab 10 mg/kg biweekly|
11126844|NCT03887442|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
11126845|NCT03887442|Experimental|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
11126846|NCT03887429|Experimental|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
11126847|NCT03887429|Experimental|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
11126848|NCT03887429|Experimental|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
11126849|NCT03887429|Experimental|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
11126850|NCT03887416|Active Comparator|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).
~Dapagliflozin 10 MG Oral Tablet [Farxiga] will be administered through out the planned intervention period of the study (12 weeks).
~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
11126851|NCT03887416|Placebo Comparator|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).
~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
11126852|NCT03887403|Experimental|Multimodal Intervention|Multimodal Intervention Based on Person-centered Communication
11126853|NCT03887403|Active Comparator|Usual Care|Patients receive usual advices in primary health care centers
11126854|NCT03887390|No Intervention|Usual Care|Participants in this arm will receive care as usual.
11126857|NCT03887377|Placebo Comparator|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
11126858|NCT03887364|Active Comparator|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
11126859|NCT03887364|Experimental|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
11126860|NCT03887351||JGH Cohort|This cohort will not be subjected to any intervention.
11126861|NCT03887351||RVH Cohort|This cohort will not be subjected to any intervention.
11126862|NCT03887338|Other|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
11126863|NCT03887325|Active Comparator|Maxipost|
11126864|NCT03887325|Placebo Comparator|Saline|
11126865|NCT03887312|Experimental|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
11126866|NCT03887312|Active Comparator|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
11126867|NCT03887299|Placebo Comparator|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
11126868|NCT03887299|Active Comparator|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
11126869|NCT03887286|Experimental|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
11126870|NCT03887273|Experimental|Q-Cells dose level 1|One time surgical transplantation of Q-Cells dose level 1 unilaterally into spinal cord demyelinated lesion
11126871|NCT03887273|Experimental|Q-Cells dose level 2|One time surgical transplantation of Q-Cells dose level 2 unilaterally into spinal cord demyelinated lesion
11126872|NCT03887273|Experimental|Q-Cells dose level 3|One time surgical transplantation of Q-Cells dose level 3 unilaterally into spinal cord demyelinated lesion
11126873|NCT03887260|Active Comparator|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
11126874|NCT03887260|Experimental|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
11126875|NCT03887247|Active Comparator|E-Mail Alert|Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
11126876|NCT03887247|No Intervention|As-Usual|As-usual (no email) approach.
11126877|NCT03887234|Active Comparator|Through the coracoid|The semitendinosus tendon graft goes through the 4.5 mm coracoid drill hole.
11126878|NCT03887234|Experimental|Around the coracoid|The semitendinosus tendon graft goes around the coracoid.
11126879|NCT03887221|Experimental|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
11126880|NCT03887221|Experimental|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
11126881|NCT03887208|Experimental|Autologous adipose derived stem cells|Autologous ADSC injection combined with laser therapy of the skin.
11126882|NCT03887208|Placebo Comparator|Placebo - Normal saline injection|Normal sline injection combined with laser therapy of the skin.
11126883|NCT03887195||students|The clinical sample is made up of 501 students (male and female) in the 4th year of medicine at Paris Descartes University, participating at the obligatory training module during the 2018-2019 academic year : this constitutes the entire population concerned by the intervention.
11126884|NCT03887182|Experimental|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
11126885|NCT03887182|Experimental|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
11126886|NCT03887182|Active Comparator|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
11126887|NCT03887169|Experimental|Methionine|
11126888|NCT03887156|Other|Arm 1|One arm
11126889|NCT03887143||Arterial ischemic stroke in patients less than 18 years old|"Patients < 18 years old
~Suspected or confirmed cerebral infarction
~With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy
~Patients treated between January 2015, 1st and May 2018, 31st"
11126890|NCT03887130|Experimental|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
11126891|NCT03887130|Active Comparator|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
11126892|NCT03887130|Active Comparator|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
11126893|NCT03887117|Active Comparator|IQOS-1|"IQOS + Exercise Training Program
~Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program."
11126894|NCT03887117|Active Comparator|IQOS-2|"No Training
~Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program."
11126895|NCT03887117|Active Comparator|Cigarette Smoking|"Cigarette Smoking + Exercise Training Program
~Subjects randomized to continued cigarette smoking and participation in an exercise training program."
11126896|NCT03887117|Active Comparator|Smoking Abstinence|"Smoking Abstinence + Exercise Training Program
~Subjects randomized to smoking abstinence and participation in an exercise training program."
11126925|NCT03886948|Experimental|Prefilled Syringe (PFS) with LY3074828|PFSs containing LY3074828
11126926|NCT03886948|Experimental|AutoInjector (AI) with LY3074828|AI containing LY3074828
11126897|NCT03887091|Experimental|Postwire© Virtual Education Cohort|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility.
~In randomized into the Virtual Education Cohort:A video based, personalized web page will be created that has information related to the participants therapeutic clinical trial.
~This web page will have videos of a research nurse explaining how to take study medication(s), how to fill out the study drug diary, and a description of the main side effects associated with the study drugs.
~Clinic Visit Video Recording Cycle 1-4/Day 1
~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7"
11126898|NCT03887091|No Intervention|No Video Intervention|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility
~Participants randomized to the control cohort will follow standard of care procedures involving clinic visits that do not include the use of video or access to a personalized web page.
~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7."
11126899|NCT03887078|Experimental|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
11126900|NCT03887078|Experimental|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
11126901|NCT03887078|Experimental|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
11126902|NCT03887078|Experimental|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
11126903|NCT03887078|Experimental|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
11126904|NCT03887078|No Intervention|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
11126905|NCT03887078|Experimental|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
11126906|NCT03887078|No Intervention|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
11126907|NCT03887065|Experimental|Starting dose|Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
11126908|NCT03887065|Experimental|Intermediate dose of JM-4|Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
11126909|NCT03887065|Experimental|High dose of JM-4|Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
11126910|NCT03887052|Experimental|Study Arm|Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)
11126911|NCT03887039||ADHD group|clinical examination
11126912|NCT03887039||normal group|clinical examination
11126913|NCT03887026|Experimental|NKT Low Dose|NKT single dose - Low
11126914|NCT03887026|Experimental|NKT High Dose|NKT single dose - High
11126915|NCT03887026|Placebo Comparator|Placebo|Placebo single dose
11126916|NCT03887013|No Intervention|CHD routine therapy|Patients with CHD will be treated with evidence-based therapy including antiplatelet drugs,beta-blockers,statins,angiotensin-converting enzyme inhibitor (ACEI),nitrates,etc. Percutaneous coronary intervention (PCI) could be performed if needed.
11126917|NCT03887013|Experimental|CHD routine therapy+Trimetazidine|Apart from the drug and PCI therapy mentioned above,patients will be given treatment of trimetazidine.
11126918|NCT03887000|Experimental|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
11126919|NCT03887000|Experimental|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
11126920|NCT03886987|Experimental|Device and Control|"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml
~Negative control: Blank patch Dose: Not applicable"
11126921|NCT03886974||Adults with type 1 diabetes|People with T1D who are 18 years or older.
11126922|NCT03886974||Parents of adults with type 1 diabetes|Parents who have adult children with type 1 diabetes.
11126923|NCT03886974||Healthcare providers managing patients with type 1 diabetes|Licensed healthcare providers who are managing patients with T1D (whether in adult or pediatric practice).
11126924|NCT03886961|Experimental|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
11126929|NCT03886922|Active Comparator|Glibenclamide and Levcromakalim|Participants will recieve levcromakalim/placebo infusion after glibenclamide administration
11126930|NCT03886922|Active Comparator|Glibenclamide and Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
11126931|NCT03886922|Sham Comparator|Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
11126932|NCT03886909|Active Comparator|Home-Based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant.
11126933|NCT03886909|Active Comparator|Prehabilitation Education|Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute.
11126934|NCT03886896|Experimental|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
11126935|NCT03886896|No Intervention|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
11126936|NCT03886883|Experimental|Exercise-induced hypoalgesia (EIH)|Exercise-induced hypoalgesia - isometric muscle contractions of the hand flexors
11126937|NCT03886883|Active Comparator|Static stretch (SS)|A static stretch of the knee flexors
11126938|NCT03886883|Sham Comparator|Rest|No intervention
11126939|NCT03886883|Experimental|Conditioning painful stimulus (CPM)|Conditioned pain modulation - cold pressure test
11126940|NCT03886870|Experimental|Lifestyle and work intervention|Lifestyle intervention with work focus.
11126941|NCT03886870|Experimental|Lifestyle intervention|Lifestyle intervention without work focus.
11126942|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
11126943|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
11126944|NCT03886831|Experimental|PRT543|PRT543 will be administered orally
11126945|NCT03886818|Experimental|PICO strategy|"Use of PICO™ device from the ankle surgery to the post-surgery day 7.
~Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
11126946|NCT03886818|Active Comparator|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
11126947|NCT03886805|Experimental|Dual task with variable- and fixed-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks. From the 1st to 12th week the participants will be trained under variable-priority instructions (half the session will be focused on balance motor task and the half the session focused on cognitive task performance). From the 13th to 24th week) the participants will perform dual tasks under fixed-priority instructions (simultaneous focus attention on balance and cognitive tasks). The motor tasks will be performed in a circuit compose of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, working memory, among other cognitive tasks.
11126948|NCT03886805|Active Comparator|Dual-task with variable-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks (48 sessions). From the 1st to 24th week, the participants will be trained under variable-priority instructions, in which they will be asked to spend half the session focused on balance (motor task) and the half the session focused on cognitive task performance. The motor tasks (gait and postural balance) of this protocol will be performed in a circuit compose of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, rescue working memory, among other cognitive tasks.
11126949|NCT03886792|Experimental|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
11126950|NCT03886792|Sham Comparator|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
11126951|NCT03886779|Active Comparator|Prolensa (Bromfenac Ophthalmic Solution) 0.07%|Bausch and Lomb, Rochester, NJ Dose: Subjects will instill one drop into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1 hour before surgery and for 14 days after surgery.
11126952|NCT03886779|Active Comparator|Ilevro® (nepafenac ophthalmic suspension ) 0.3%|Alcon Laboratories, Inc., Fort Worth, TX Dose: Subjects will instill one drop of test article into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one day prior to surgery (Day 1), continue on the day of surgery plus1 hour before surgery and for 14 days after surgery.
11128737|NCT03874156|Placebo Comparator|Placebo group|Matched placebo tablet once daily
11126953|NCT03886766|Experimental|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
11126954|NCT03886766|Experimental|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
11126955|NCT03886766|Experimental|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
11126956|NCT03886753||Ease|Subjects using Ease as standard treatment. Registry and PK sampling
11126957|NCT03886753||Dream|Subjects using Dream as standard treatment. Registry and PK sampling
11126958|NCT03886753||Soothe|Subjects using Soothe as standard treatment. Registry and PK sampling
11126959|NCT03886753||Shine|Those subjects using Shine as standard treatment. Registry and PK sampling
11126960|NCT03886740|Experimental|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
11126961|NCT03886740|Experimental|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
11126962|NCT03886727|Active Comparator|Rubber Dam|Isolation of single tooth using rubber dam
11126963|NCT03886727|Active Comparator|Cotton Roll|Isolation of quadrant using cotton rolls
11126964|NCT03886701|Experimental|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
11126965|NCT03886688|Experimental|single ascending|Drug or placebo, oral, fast, single dose ascending
11126966|NCT03886688|Experimental|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
11126967|NCT03886688|Experimental|Food Effect|Drug or placebo, oral, fed or fast, single dose
11126968|NCT03886675|Experimental|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
11126969|NCT03886675|Active Comparator|Saline|Flushing of stent-grafts with saline
11126970|NCT03886662|Experimental|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
11126971|NCT03886649|Experimental|Copanlisib + Venetoclax|Phase Ib -> dose escalation with 2 expansion cohorts
11126972|NCT03886636|Experimental|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
11126973|NCT03886636|Experimental|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
11126974|NCT03886636|Active Comparator|Control group|in Group 3, participants received home exercise program only.
11126975|NCT03886623|Experimental|4-day systematic oral hygiene|The intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
11126976|NCT03886623|Other|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
11126977|NCT03886610||Healthy controls|Individuals without spinal cord injury
11126978|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration >2 weeks)
11126979|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
11126980|NCT03886597|Experimental|60 Arbequina Table Olives|Pharmacokinetics Study
11126981|NCT03886597|Experimental|120 Arbequina Table Olives|Pharmacokinetics Study
11126982|NCT03886597|Experimental|60 Table Olives|Table Olives Nutritional Intervention
11126983|NCT03886597|No Intervention|Control|Control of Table Olives Nutritional Intervention
11126984|NCT03886584|Experimental|Patients with with neuropsychiatric conditions|"In this arm, five groups :
~Patients with DFT, diagnosed according Racovsky criteria
~Patients with Lewi Body dementia, diagnosed according McKeith criteria
~Patients with pre-demential Alzheimer, diagnosed according Dubois criteria
~Patients with Alzheimer, diagnosed according MMSE
~Patients with bipolar disorder, diagnosed according DSM 5"
11126985|NCT03886584|Active Comparator|Healthy subjects|Healthy controls appaired in age, sex and educational level
11126986|NCT03886558|Experimental|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
11127024|NCT03886259|Active Comparator|Pain neuroscience education|Subjects with chronic pain after total knee replacement will receive two sessions of pain neuroscience education, conducted by a physiotherapist
11127025|NCT03886246|Experimental|Spesolimab (every 6 weeks)|
11126987|NCT03886558|Experimental|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
11126988|NCT03886545||caregivers with shoulder pain|
11126989|NCT03886545||Healthy subjects|
11126990|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
11126991|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
11126992|NCT03886519|Active Comparator|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
11126993|NCT03886519|Active Comparator|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
11126994|NCT03886493|Experimental|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
11126995|NCT03886480|Experimental|SaeboVR|Use of the SaeboVR for task specific upper extremity training
11126996|NCT03886467|Active Comparator|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
11126997|NCT03886467|No Intervention|Control|community development activities only.
11126998|NCT03886441|Experimental|Prevention group|Participants inhaled beclomethasone propionate aerosol daily during chest radical radiotherapy (total dose 60GY).
11126999|NCT03886441|No Intervention|Traditional therapy group|Participants were not given daily inhalation of beclomethasone propionate when undergoing radical chest radiotherapy (total dose 60GY).
11127000|NCT03886428|Experimental|100% Portion Size|Test meal with portion size 100% of baseline
11127001|NCT03886428|Experimental|125% Portion Size|Test meal with portion size 125% of baseline
11127002|NCT03886428|Experimental|150% Portion Size|Test meal with portion size 150% of baseline
11127003|NCT03886428|Experimental|175% Portion Size|Test meal with portion size 175% of baseline
11127004|NCT03886415|Experimental|Jaktinib hydrochloride tablets 1|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 200mg qd dose group
11127005|NCT03886415|Experimental|Jaktinib hydrochloride tablets 2|This is the dose group was given twice a day. Jaktinib hydrochloride tablets 2 100mg bid dose group
11127006|NCT03886402|Experimental|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
11127007|NCT03886389|Experimental|Carbohydrate/intervention group|Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
11127008|NCT03886389|No Intervention|Control group|Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.
11127009|NCT03886376|Experimental|Massage|The massage will be performed three times during a training week, after a physical training and before the swimming training
11127010|NCT03886376|Placebo Comparator|Superficial Massage|The placebo will be performed three times during a training week, after a physical training and before the swimming training
11127011|NCT03886376|No Intervention|Control|The control groups will maintain their normal routine of training. Immediately after the physical training the athletes will be instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
11127012|NCT03886363|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
11127013|NCT03886363|No Intervention|Wait-list control|Usual practice
11127014|NCT03886350||Patients with cystic fibrosis|Patients with CF whom follow-up is undertaken at University Hospital of Tours, France
11127015|NCT03886337|No Intervention|Control|The control arm will be surgical care according to usual practice with usual ambient lighting
11127016|NCT03886337|Experimental|Treatment Arm|The treatment arm will include surgical care according to usual practice with germicidal ambient lighting
11127017|NCT03886324|Experimental|DCB Treatment|Stricture patients treated by DCB
11127018|NCT03886311|Experimental|Talimogene laherparepvec, Nivolumab and Trabectedin|"This is an open label phase 2 study using known doses of TALIMOGENE LAHERPAREPVEC injected intratumorally, and NIVOLUMAB AND TRABECTEDIN given intravenously.
~A total of 40 previously untreated and treated patients will receive TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks, NIVOLUMAB 240 mg IV over 30 min q 2 weeks and TALIMOGENE LAHERPAREPVEC intratumorally q 2 weeks according to tumor size (see Schematic of Study Design and Imlygic product information; www.accessdata.fda.gov). Patients in this study may continue treatment until significant disease progression (see below for criteria for discontinuation of therapy) or unacceptable toxicity occurs up to one year of therapy."
11127019|NCT03886298|Experimental|radiofrequency splanchnic denervation|
11127020|NCT03886298|Active Comparator|retrocrural celiac denervation|
11127021|NCT03886272|Experimental|BI 730357 (Test)|
11127022|NCT03886272|Experimental|BI 730357 (Reference)|
11127023|NCT03886259|Experimental|Exercise and pain neuroscience education|Subjects with chronic pain after total knee replacement will receive 24 sessions of neuromuscular exercise therapy, supervised by a physiotherapist, and two sessions of pain neuroscience education, conducted by a physiotherapist
11127026|NCT03886246|Experimental|Spesolimab (every 12 weeks)|
11127027|NCT03886233||Traditional Treatment for Autoimmune uveitis|Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
11127028|NCT03886233||Biological Treatment for Autoimmune uveitis|Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
11127029|NCT03886220|Experimental|Participants receiving elagolix|Participants will be administered with elagolix
11127030|NCT03886220|Experimental|Participants receiving placebo|Participants will be administered with placebo
11127031|NCT03886207|Experimental|Warm water with ginger powder footbath|Participants who receive a warm water with added ginger powder footbath four times a week over a six-week period.
11127032|NCT03886207|Active Comparator|Warm water only footbath|Participants who receive a warm water only footbath four times a week over a six-week period.
11127033|NCT03886194|Active Comparator|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
11127034|NCT03886194|Experimental|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
11127035|NCT03886181|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11127036|NCT03886168|Experimental|Immediate IGCIP|Immediate signal processing intervention of a biomedical device
11127037|NCT03886168|Active Comparator|Deferred IGCIP|Delayed signal processing intervention of a biomedical device
11127038|NCT03886155||Trigger Finger Biopsy|Biopsy of trigger finger tenosynovial tissue during trigger finger release surgery sent to pathology for amyloid-specific analysis
11127039|NCT03886142|Active Comparator|radiofrequency|genicular nerves pulsed radiofrequency
11127040|NCT03886142|Active Comparator|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
11127041|NCT03886129||Participants with Transient Ischaemic Attack|"Inclusion Criteria:
~Willing to participate
~Capacity to consent
~Aged >18 years
~Able (in the Investigator's opinion) and willing to comply with all study requirements
~A diagnosis of acute (≤7 days) TIA, made by a specialist that fulfils the 2009 American Heart Association definition of TIA
~Good understanding of written and verbal English
~Exclusion Criteria:
~Unwilling to take part
~Unable to consent
~Aged <18 years
~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements
~Female participants who are pregnant, lactating or planning pregnancy during the course of the study
~Atrial fibrillation
~Severe heart failure (Ejection Fraction <30%)
~Severe respiratory disease
~Inadequate bilateral transcranial Doppler windows
~Carotid stenosis ≥70% (unilateral or bilateral)
~Participant enrolled in an interventional research study.
~Poor understanding of written and verbal English"
11127042|NCT03886129||Healthy Control Participants|"Inclusion Criteria:
~Willing to participate
~Capacity to consent to the study
~Aged >18 years
~Able (in the Investigator's opinion) and willing to comply with all study requirements
~Good understanding of written and verbal English
~Exclusion Criteria:
~Unwilling to take part
~Unable to consent
~Aged <18 years
~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements
~Female participants who are pregnant, lactating or planning pregnancy during the course of the study
~Atrial fibrillation
~Severe heart failure (Ejection Fraction <30%)
~Severe respiratory disease
~Inadequate bilateral transcranial Doppler windows
~Carotid stenosis ≥70% (unilateral or bilateral)
~Participant enrolled in an interventional research study.
~Poor understanding of written and verbal English"
11127043|NCT03886116|Active Comparator|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.
~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
11127044|NCT03886116|No Intervention|No Exercise|Patient is not required to do any exercise.
11127045|NCT03886103|Experimental|Healthy volunteer|Single of 14C-PXL770
11127046|NCT03886090|Experimental|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
11127047|NCT03886090|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
11127048|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
11127049|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
11127050|NCT03886064|No Intervention|Control group|Only measurement of clinical endpoints at time zero, then at 6, 12 and 24 months and minimal counseling.
11127051|NCT03886064|Other|Interventional group|Measurement of clinical endpoints at time zero, then at 6, 12 and 24 months and minimal counseling followed by multi-behavioral intervention adapted to local resources.
11127052|NCT03886051|Experimental|test group|Connective Tissue Graft before Orthodontic treatment
11127053|NCT03886051|Active Comparator|control group|Orthodontic treatment only
11127054|NCT03886038|Active Comparator|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDS/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
11127055|NCT03886038|Active Comparator|RA on synthetic or biological DMARDs|RA patients tretad with syntetic or bioloogial DMARDs for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
11127056|NCT03886038|Active Comparator|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
11127083|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
11127057|NCT03886025|Experimental|Combined anodal tDCS and cognitive training|Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
11127058|NCT03886025|Sham Comparator|Combined sham tDCS and cognitive training|Combined sham tDCS and cognitive training. Sham tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). For sham tDCS, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each tDCS session will be 20 minutes.
11127059|NCT03886012|Experimental|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.
~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
11127060|NCT03886012|Sham Comparator|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.
~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
11127061|NCT03885999|Experimental|Fecobionics studies|
11127062|NCT03885973|Experimental|Lactobacillus plantarum|1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10^8 CFU will be given daily for three weeks.
11127063|NCT03885973|Placebo Comparator|Placebo|1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.
11127064|NCT03885947|Experimental|VPA expanded cord blood stem cells|"CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.
~VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation"
11127065|NCT03885934|Experimental|V114|Each dose consists of 0.5 mL Intramuscular (IM) injection. Schedule A, 7 to 11 months of age, 3 doses: Dose 1 at randomization, Dose 2 at 1-2 months after Dose 1, and Dose 3 at 2-3 months after Dose 2 and at ≥12 months of age. Schedule B, 12 to 23 months of age, 2 doses: Dose 1 at randomization, and Dose 2 at 2-3 months after Dose 1. Schedule C, 2 to 17 years of age, 1 dose: Single dose at randomization.
11127066|NCT03885934|Active Comparator|Prevnar 13|Each dose consists of 0.5 mL IM injection. Schedule A, 7 to 11 months of age, 3 doses: Dose 1 at randomization, Dose 2 at 1-2 months after Dose 1, and Dose 3 at 2-3 months after Dose 2 and at ≥12 months of age. Schedule B, 12 to 23 months of age, 2 doses: Dose 1 at randomization, and Dose 2 at 2-3 months after Dose 1. Schedule C, 2 to 17 years of age, 1 dose: Single dose at randomization.
11127067|NCT03885921|Experimental|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
11127068|NCT03885921|Experimental|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
11127069|NCT03885908|Active Comparator|In-person geriatric co-management group|
11127070|NCT03885908|Experimental|Automated geriatric co-management program group|
11127071|NCT03885895|Active Comparator|Participants with freckles (one side of the face)|one randomized side of the face will be treated by Intradermal Tranexamic acid
11127072|NCT03885895|Active Comparator|Participants with freckles (other side of the face)|other side will be treated by Q switched KTP laser
11127073|NCT03885882|Experimental|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
11127074|NCT03885882|Experimental|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
11127075|NCT03885882|Experimental|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
11127076|NCT03885882|Experimental|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
11127077|NCT03885869||Type 2 Diabetics|Type 2 diabetic individuals aged 30-65 years
11127078|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
11127079|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
11127080|NCT03885843|Experimental|RDN Group|renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
11127081|NCT03885843|Sham Comparator|Sham Group|renal artery angiography group, without any renal nerve stimulation, mapping or denervation
11127082|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
11127225|NCT03884738|Active Comparator|Concentric|Leg Curl Training
11127084|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
11127085|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
11127086|NCT03885817|Experimental|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
11127087|NCT03885817|Active Comparator|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
11127088|NCT03885804|Sham Comparator|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
11127089|NCT03885804|Active Comparator|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
11127090|NCT03885791|Experimental|Vaginal cryotherapy - intervention|"The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a slushy consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer."
11127091|NCT03885791|Placebo Comparator|Vaginal cryotherapy - control|The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
11127092|NCT03885778|Experimental|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
11127093|NCT03885778|Experimental|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
11127094|NCT03885765||Test group|The first 60 patients recruited.
11127095|NCT03885765||Validation group|The last 100 patients recruited.
11127096|NCT03885752|Active Comparator|the control group|
11127097|NCT03885752|Placebo Comparator|the gum group|
11127098|NCT03885739|Other|Patients with hip fracture|15 consecutive HF patients who were admitted to a single level 3 center and who report severe pain despite a standardized analgesia protocol. Patients were assessed by the Pain Service as part of a multidisciplinary care pathway and a Continuous Pericapsular Nerve Group blocks was offered as a component of a multimodal analgesic regimen.
11127099|NCT03885726|Active Comparator|Treatment as Usual|
11127100|NCT03885726|Experimental|High Velocity Nasal Insufflation|
11127101|NCT03885713|Active Comparator|Patients with treatment|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice, or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)-subcutaneus) per clinical practice
11127102|NCT03885713|No Intervention|healthy control|
11127103|NCT03885700|Experimental|intervention group|
11127104|NCT03885700|No Intervention|control group|
11127105|NCT03885687|Experimental|Exercise with Music Intervention|The Exercise with Music intervention is a recorded exercise playlist, which is tailored to a patient's individual physical abilities and music choices.
11127106|NCT03885687|Active Comparator|Active Control Group|The active control group will receive exercise brochure and will be advised to exercise at least twice daily.
11127107|NCT03885674|Experimental|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
11127108|NCT03885674|No Intervention|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
11127109|NCT03885661|Experimental|Icosapent ethyl|Icosapent ethyl with a total daily dose of 4 grams, as 2 x 1 gram capsules by mouth twice daily, against a statin background
11127110|NCT03885661|No Intervention|Usual Care|Statin background
11127111|NCT03885648||Cases|Women's age will range 25-70 years. Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II.
11127112|NCT03885648||Controls|Controls will be women surgically intervened of breast augmentation or reduction.
11127113|NCT03885635|Active Comparator|Hemiarch repair|Standard hemiarch repair with open distal anastomosis in the proximal arch without replacement of the head vessels.
11127114|NCT03885635|Active Comparator|Extended arch repair|Ascending aortic and arch replacement with or without head vessel re-implantation and single TEVAR device placement within 1 week.
11127115|NCT03885609|Experimental|Treatment - toothwave brush|Subjects using the Silk'n ToothWave RF utilizing toothbrush
11127116|NCT03885609|Sham Comparator|Control - powered toothbrush|Subject using a regular powered toothbrush with no RF.
11127117|NCT03885596|Experimental|Open-Label CA-008|CA-008 4.2 mg reconstituted in saline
11127118|NCT03885583|Active Comparator|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
11127226|NCT03884738|Active Comparator|Eccentric|Nordic Hamstring Training
11127119|NCT03885583|Active Comparator|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
11127120|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
11127121|NCT03885557|Experimental|Group I Experimental Dynamic oscillatory stretch(DOS)|Dynamic oscillatory stretch technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group.
11127122|NCT03885557|Active Comparator|Group II Static Stretching(SS) Group|Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group.
11127123|NCT03885544|Active Comparator|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
11127124|NCT03885544|Experimental|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
11127125|NCT03885544|Experimental|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
11127126|NCT03885518|Active Comparator|Intervention|Participants attending the childcare centers randomized to this arm will receive the stencil activities after baseline assessments have been completed. We will follow-up with assessments after 6-8 weeks
11127127|NCT03885518|Placebo Comparator|Wait-List|Participants attending the childcare centers randomized to this arm will receive the stencil activities approximately 8 weeks after enrolling, after baseline and follow-up assessments have been completed.
11127128|NCT03885479||IBD patients|"Full history taking and examination
~Colonoscopy, biopsy and histopathology to determine the extent of the lesion
~An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
~Patients will be categorized into 3 groups (UC patients, Crohn disease patients and controls)
~All of the following factors will be taken into consideration; type and duration of the treatment, age of diagnosis, BMI, smoking status and activity of the disease at the time of the study"
11127129|NCT03885479||Controls|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
11127130|NCT03885466|Experimental|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
11127131|NCT03885466|No Intervention|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
11127132|NCT03885453||Panic Disorder / Agoraphobia|Patients with Panic Disorder / Agoraphobia as major diagnosis
11127133|NCT03885453||Depression|Patients with Depression as major diagnosis
11127134|NCT03885440||Young adult, without OSAS|20<=Age<40 years old, apnea-hypopnea index(AHI)<5
11127135|NCT03885440||Young adult, with OSAS|20<=Age<40 years old, AHI>=5
11127136|NCT03885440||older adult, without OSAS|Age>=40 years old, AHI<5
11127137|NCT03885440||older adult, with OSAS|Age>=40 years old, AHI>=5
11127138|NCT03885427|Experimental|oral ketamine|evaluate sedative,and analgesic effects
11127139|NCT03885427|Active Comparator|nebulized ketamine|evaluate sedative, and analgesic effects
11127140|NCT03885414|Experimental|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
11127141|NCT03885401|Experimental|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
11127142|NCT03885401|No Intervention|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
11127143|NCT03885388|Active Comparator|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
11127144|NCT03885388|Experimental|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
11127145|NCT03885362|Experimental|Dexcom G6 and Abbott Freestyle Libre|"Participants will have a Dexcom G6 sensor and Abbott FreeStyle Libre sensor inserted in the abdomen and upper arm respectively. Participants will be asked to swipe the FreeStyle Libre reader across the sensor a minimum of every 8 hours. Participants will be asked to continue their usual regimen of self-monitoring capillary blood glucose (SMBG).
~During haemodialysis, a dialysis circuit blood sample will be drawn at 0 (pre-dialysis) 30, 60, 90, 120, 150, 180, 210 and 240 minutes and immediately after dialysis. Samples from the circuit will be analysed on the YSI glucose analyser. Participants will be asked to change the FreeStyle Libre sensors at day 14. The blinded CGM data will be uploaded at the time of each sensor change by the research team."
11127227|NCT03884738|Active Comparator|Neuromuscular Electrical Stimulation|Stimulation Training
11128738|NCT03874143|Experimental|RCom equipped with a smartphone|
11127146|NCT03885349|Experimental|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
11127147|NCT03885349|Active Comparator|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
11127148|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
11127149|NCT03885323|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
11127150|NCT03885323|Placebo Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
11127151|NCT03885310|Experimental|DCB Treatment|Stricture patients treated by DCB
11127152|NCT03885297||Overweight/obese participants|Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
11127153|NCT03885284|Experimental|Dose Level 1|"mFOLFIRINOX + Proton beam radiation
~Radiation given on days 8-12 of cycle 6"
11127154|NCT03885284|Experimental|Dose Level 2|"mFOLFIRINOX + Proton beam radiation
~Radiation given on days 15-19 of cycle 6"
11127155|NCT03885271|Experimental|Group A (Experimental group) Hall Technique|Clinical examination to assess the clinical inclusion criteria. Radiographic examination.The child will be positioned upright in the dental chair . The correct size of PMC for the tooth will be selected. The tooth will be rinsed and dried, and the PMC dried. The PMC will be filled with glass ionomer luting cement. The PMC will be placed evenly over the tooth and the child instructed to bite down firmly until the crown was pushed down over the tooth;If the child was unable or unwilling to bite down on the PMC, finger pressure will be used to seat the crown Extruded cement will be removed, and the child will be asked to keep biting on the Hall PMC until the cement sets and once cement sets, excess cement is removed, floss will be used to clear the aproximal contacts, and post-fitting instructions will be given (Innes et al. 2007).
11127156|NCT03885271|Active Comparator|Group B (control group) Formecresol Pulpotomy|Clinical examination to assess the clinical inclusion criteria. Radiographic examination. The teeth anesthetized, rubber dam isolation, Complete caries removal achieved with a sterile round steel bur in a slow- speed handpiece. Access to the pulp chamber performed using a sterile slow-speed round steel bur. The pulp amputation with a sterile diamond bur in a high-speed handpiece and pulpal debris removed with a sterile saline solution on a sterile cotton pledget. After pulp amputation haemostasis achieved using a sterile cotton pledget. Formocresol (FC) applied using a sterile cotton pledget for 5 minutes. After removal of the formocresol soaked cotton pledget, the pulp chamber rinsed with water using an air-water syringe. The pulp chamber dried with a sterile cotton pledget, followed by application of Zinc Oxide & Eugenol and zinc phosphate. Tooth preparation done to receive stainless steel crown.
11127157|NCT03885258|Experimental|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
11127158|NCT03885245|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 8 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 6 weeks and then enter crossover phase of an additional 8 weeks. Drug will be dispensed at Visit 4.
11127159|NCT03885245|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 8 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 6 weeks and then enter crossover phase of an additional 8 weeks. Drug will be dispensed at Visit 4.
11127160|NCT03885232|Experimental|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
11127161|NCT03885232|Active Comparator|Control|Control-Care as usual
11127162|NCT03885219|Experimental|nab-paclitaxel and S-1|chemotherapy of Nab-Paclitaxel and S-1, repeat 21 days for up to 8 cycles. The following treatment including pancreatectomy, continuing same chemotherapy, S-1 maintenance therapy, or radiotherapy will be decided after discussion between physicians and patients.
11127163|NCT03885206|Experimental|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
11127164|NCT03885206|No Intervention|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
11127165|NCT03885193||HMS plus group|HMS plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
11127166|NCT03885193||ACT plus group|ACT plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
11127167|NCT03885180|Experimental|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
11127168|NCT03885180|No Intervention|Stop anticoagulation group|Just stop oral anticoagulation like routine
11127169|NCT03885167||Affected Individuals with Known SCA3|In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
11127170|NCT03885167||Healthy Individual Control Subjects|In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
11127228|NCT03884725|Active Comparator|fibrinogen concentrate|patients randomized to fibrinogen group receive intravenous infusion of drug prepared based on ROTEM measurement of maximum clot firmness (MCF)
11127171|NCT03885154|Active Comparator|Valproic Acid|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
11127172|NCT03885154|Active Comparator|Dihydroergotamine|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
11127173|NCT03885154|Active Comparator|Cross-Over to Dihydroergotamine|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
11127174|NCT03885154|Active Comparator|Cross-Over to Valproic Acid|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
11127175|NCT03885141|Placebo Comparator|Men - Placebo|Men - Placebo, 1 tablet if a wake up occurs
11127176|NCT03885141|Experimental|Men - Zolpidem 1.75 mg|Men - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
11127177|NCT03885141|Experimental|Men - Zolpidem 3.5 mg|Men - Zolpidem 3.5 mg, 1 tablet if a wake up occurs
11127178|NCT03885141|Placebo Comparator|Women - Placebo|Women - Placebo, 1 tablet if a wake up occurs
11127179|NCT03885141|Experimental|Women - Zolpidem 1.0 mg|Women - Zolpidem 1.0 mg, 1 tablet if a wake up occurs
11127180|NCT03885141|Experimental|Women - Zolpidem 1.75 mg|Women - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
11127181|NCT03885128|Experimental|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
11127182|NCT03885128|Experimental|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
11127183|NCT03885115|Experimental|Intervention|Participants randomly assigned to the experiential group (EG) will receive a 12-week structured exercise that will consist of two group fitness sessions (i.e. kickboxing, Zumba, fitness yoga, and other aerobic exercises) every week. Certified fitness instructors will lead each session and participants will learn strategies how to be more active during the daily routines at home. Parents or other relatives in the EG will participate in one 2-hour session every four weeks (total of 3 sessions) designed to help them support their children and entire family in being active and eat healthy at home. Parents will meet with a fitness instructor who will provide specific tips on how to increase physical activity at home as well as providing community resources to be active. A basic nutrition education and cooking demonstrations, and healthy recipes will be also provided to parents at these workshops. Data/assessments are collected, pre and post the 12 weeks intervention.
11127184|NCT03885115|No Intervention|Control|Participants randomly assigned to the control group (CG) will receive once a week recreational structured group play/game sessions led by trained BOUNCE interns/staff. The control group will receive 60 minute of structured free play sessions (i.e. recreational games) once a week for 12 weeks. Every 4 weeks, parents will be given (either sent home with their child or via email or mail) basic nutrition information, healthy recipes, and tips to promote physical activity at home as well as community resources to be active. Data/assessments are collected, pre and post the 12 weeks intervention.
11127185|NCT03885102|Experimental|Intervention|12 months intradialytic exercise intervention
11127186|NCT03885102|Active Comparator|Usual care|Usual care according to current guidelines
11127187|NCT03885089||Infliximab [infliximab biosimilar 3]|Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS
11127188|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
11127189|NCT03885063|Experimental|Benjamin Rose Institute Care Consultation (BRI-CC)|
11127190|NCT03885063|No Intervention|No intervention|
11127191|NCT03885037||Infliximab [infliximab biosimilar 3]|Patients with Rheumatoid Arthritis treated by Infliximab BS
11127192|NCT03885024|Active Comparator|Retention Video|"Participants the peer-driven retention arm will receive video-based and in-person training from Retention Specialists on how to encourage study retention. Participants will watch a 7 minute video that standardizes retention messages. A brief face-to-face conversation with the Retention Specialist follows the video viewing to answer questions and reinforce video messages. At the end of the training, participants receive information about their recruit(s) who consented to release their information to their recruiters. Peers remind their enrolled study buddy to attend their scheduled follow up assessments. Participants meet with a study Retention Specialist by phone or in person, at 3 and 9 months after enrollment to answer questions about peer retention strategies and remind participants of their peers' contact information and follow-up schedules."
11127193|NCT03885024|No Intervention|Standard Retention Strategy|Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
11127194|NCT03885011|Experimental|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
11127300|NCT03884218|Other|Thermal Comfort|Infra red thermal image
11127301|NCT03884205||test group|patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
11127195|NCT03885011|Active Comparator|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.
~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
11127196|NCT03885011|Active Comparator|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
11127197|NCT03884998|Experimental|Treatment (copanlisib and nivolumab)|Participants receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11127198|NCT03884985|Experimental|Normal Vision|This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
11127199|NCT03884972|Experimental|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11127200|NCT03884972|Experimental|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
11127201|NCT03884959|Experimental|HepaStem Infusion|A calculated dose based on patient's body weight will be administered via Permanent mesenteric Portal Access and Catheter for four times or a Transient Percutaneous Transhepatic Catheter for three times.
11127202|NCT03884946|Active Comparator|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
11127203|NCT03884946|Placebo Comparator|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
11127204|NCT03884933|Experimental|Mobile team community mental health services|
11127205|NCT03884933|No Intervention|Current clinical services|
11127206|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
11127207|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
11127208|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
11127209|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
11127210|NCT03884881|Other|metagenomic next generation sequencing|Adjust medication for patients with severe pneumonia based on mNGS results
11127211|NCT03884881|Other|Conventional pathogen detection|Blood, bronchoalveolar lavage fluid (BALF), bronchial secretions samples will be collected and microbiologically tested prior to initial empirical antibiotic use.
11127212|NCT03884868|No Intervention|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
11127213|NCT03884868|Experimental|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
11127214|NCT03884855|Active Comparator|Classical Cardiac Rehabilitation|Patients benefit from a classic cardiac rehabilitation cycle during 3 months.
11127215|NCT03884855|Experimental|Karate Rehabilitation|Patients benefit from cardiac rehabilitation cycle with traditional karate during 3 months.
11127216|NCT03884842|Active Comparator|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.
~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
11127217|NCT03884842|Placebo Comparator|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
11127218|NCT03884829|Experimental|CYC140 single agent|CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle
11127219|NCT03884803|Other|HealthyMoms web-based program|An on-line self-help psychoeducational website for new moms that includes educational learning modules and tools to prevent/reduce depression. .
11127220|NCT03884803|Other|Control group|No access to the intervention but to continue with standard care. Will complete the same questionnaires as the HealthyMoms group.
11127221|NCT03884790|Experimental|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
11127222|NCT03884764|Experimental|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
11127223|NCT03884764|Active Comparator|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
11127224|NCT03884751|Experimental|CAR-GPC3 T Cells|The subjects are enrolled into 2 dose levels cohorts in sequence
11127229|NCT03884725|Placebo Comparator|control|patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF)
11127230|NCT03884712|Experimental|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
11127231|NCT03884699|Other|Segmental maxillary lefort I re-positioning|Accuracy of the planned virtually re-positioned segmental Lefort I maxilla using a specifically designed patient implant, comparing the virtual plan to the actual postoperative position.
11127232|NCT03884686|Experimental|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
11127233|NCT03884686|No Intervention|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
11127234|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
11127235|NCT03884634||Dabir Microsurface Overlay Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned ON (in addition to standard operating room table mattress and heating/cooling gel pad).
11127236|NCT03884634||Control Group|Patients undergoing cardiac surgery with the Dabir Micropressure Overlay in place and turned OFF (in addition to standard operating room table mattress and heating/cooling gel pad).
11127237|NCT03884621|Experimental|EHP Group|The Enhanced post-discharge home-based care program (EHP) offers one coaching session upon hospital discharge and 12-week home follow-up (including 6 home visits, 6 telephone calls and 24-hour hotline) post hospital discharge to participants by an especially trained nurse case manager with the support of a clinical team. The five intervention protocols integrate with an individualized home-based rehabilitation training and self-care plan.
11127238|NCT03884621|No Intervention|Control Group|Usual discharge care and post-discharge care provided to all stroke patients discharged home.
11127239|NCT03884595||No SIRS|Children without clinical signs of SIRS, according to Goldstein criteria.
11127240|NCT03884595||SIRS|Children with clinical signs of SIRS, according to Goldstein criteria.
11127241|NCT03884595||Sepsis|Children with clinical signs of sepsis, according to Goldstein criteria.
11127242|NCT03884595||Severe sepsis|Children with clinical signs of severe sepsis, according to Goldstein criteria.
11127243|NCT03884595||Septic Shock|Children with clinical signs of septic shock, according to Goldstein criteria.
11127244|NCT03884582||HealthyVolunteers|
11127245|NCT03884569||Patients treated with CLET|"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through drugs-in-special-situation request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account."
11127246|NCT03884556|Experimental|Arm 1, Single Agent|TTX-030
11127247|NCT03884556|Experimental|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
11127248|NCT03884556|Experimental|Arm 3, Chemotherapy Combination|TTX-030 plus docetaxel
11127249|NCT03884556|Experimental|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
11127250|NCT03884543|Experimental|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
11127251|NCT03884543|No Intervention|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
11127252|NCT03884530|Active Comparator|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
11127253|NCT03884530|Active Comparator|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
11127254|NCT03884517|Experimental|BAT8003 0.2mg/kg|BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3
11127255|NCT03884517|Experimental|BAT8003 0.5mg/kg|BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3
11127256|NCT03884517|Experimental|BAT8003 1mg/kg|BAT8003，1mg/kg，intravenous infusion, sample size 3
11127257|NCT03884517|Experimental|BAT8003 2mg/kg|BAT8003，2mg/kg，intravenous infusion, sample size 3
11127258|NCT03884517|Experimental|BAT8003 4mg/kg|BAT8003，4mg/kg，intravenous infusion, sample size 3
11127259|NCT03884517|Experimental|BAT8003 6mg/kg|BAT8003，6mg/kg，intravenous infusion, sample size 3
11127260|NCT03884517|Experimental|BAT8003 8mg/kg|BAT8003，8mg/kg，intravenous infusion, sample size 3
11127261|NCT03884517|Experimental|BAT8003 10mg/kg|BAT8003，10mg/kg，intravenous infusion, sample size 3
11127262|NCT03884517|Experimental|Amplification group|BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg
11127263|NCT03884491|Experimental|Vortioxetine|
11127264|NCT03884478|Experimental|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
11127302|NCT03884205||control group|patients with PTCL who receive CEOPE as the first-line therapy strategy
11127303|NCT03884192|Experimental|Sintilimab Arm|Sintilimab consolidation therapy
11127304|NCT03884192|No Intervention|Observation Arm|Observation
11127305|NCT03884166||stroke|
11127265|NCT03884478|Experimental|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
11127266|NCT03884478|Other|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use & Control) and Round 4 (Stigma-Coping & Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
11127267|NCT03884465|Experimental|Inhaled dry powder treprostinil (LIQ861)|Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.
11127268|NCT03884452|Experimental|Atorvastatin 80 mg|80 mg atorvastatin taken orally, once daily for 12 weeks
11127269|NCT03884452|Experimental|Ezetimibe + Atorvastatin 40 mg|10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
11127270|NCT03884452|Experimental|Ezetimibe + Atorvastatin 80 mg|10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
11127271|NCT03884452|Experimental|Simvastatin 80 mg|80 mg simvastatin taken orally, once daily for 12 weeks
11127272|NCT03884452|Experimental|Ezetimibe + Simvastatin 40 mg|10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
11127273|NCT03884452|Experimental|Ezetimibe + Simvastatin 80 mg|10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
11127274|NCT03884439||Infliximab [infliximab biosimilar 3]|Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
11127275|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
11127276|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
11127277|NCT03884413||Breast cancer survivors|Study of spontaneous fertility outcomes following breast cancer history
11127278|NCT03884413||Control group|Study of spontaneous fertility outcomes in healthy volonteers population
11127279|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
11127280|NCT03884387|Experimental|Use of a Patient Decision Aid|A Patient Decision Aid is used in this arm in the clinical encounter. A tool designed to facilitate shared decision making when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
11127281|NCT03884387|No Intervention|Usual counceling|Usual counseling in the clinical encounter, when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
11127282|NCT03884374|Experimental|African American Group|African Americans with knee osteoarthritis (OA).
11127283|NCT03884374|Experimental|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
11127284|NCT03884361|Experimental|Vaginal Microbiome as result of aminocentesis|aginal Microbiome as result of aminocentesis by a blood and a vaginal samples that will taken before and after the aminocentesis
11127285|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
11127286|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
11127287|NCT03884335|Active Comparator|epidural group|An epidural catheter was placed at L1-L2 level, and tested, prior to induction. Induction was performed intravenously with fentanyl (1.5mcg•Kg-1), propofol (1.5-2 mg•Kg-1), and rocuronium (0.6 mg•Kg-1). Orotracheal intubation was performed. Prior to skin incision 8 mL of 0.25% levo-bupivacaine were administered epidurally, and a continuous perfusion of 0.125% levo-bupivacaine at 5 mL was started.
11127288|NCT03884335|Experimental|TAP group|Bilateral Transversus abdominis plane blockade (TAP) was performed following induction of anaesthesia ( the same of epidural group) and prior to skin incision, the high-frequency lineal probe (Sonosite MicroMAXXTM) was placed midway between the costal margin and iliac crest, and transversus abdominis muscle located behind the rectus abdominis and below the IOM. 20 mL of LA (bupivacaine 0.375%) was administered via a 22 gauge Quincke spinal needle inserted in-plane on each side of the abdomen. A successful block was recorded if the plane was seen to expand with fluid under ultrasound vision.
11127289|NCT03884322|Experimental|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
11127290|NCT03884322|Active Comparator|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
11127291|NCT03884309|Experimental|Experimental Hydrolyzed Protein Infant Formula|hydrolyzed protein infant formula powder in cans
11127292|NCT03884296|Other|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
11127293|NCT03884270|Experimental|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
11127294|NCT03884257|Experimental|Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).
11127295|NCT03884257|Active Comparator|IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).
11127296|NCT03884244|Active Comparator|taking chewing gum patients|
11127297|NCT03884244|No Intervention|no chewing gum|
11127298|NCT03884231||Leads-only configuration|The leads-only configuration consists of at least one implanted lead protected with a lead protection boot, as well as an optional cranial burr hole cover. Any leads must be completely implanted with the surgical incision closed.
11127299|NCT03884231||Full system configuration|The full system configuration consists of at least one IPG, one lead, one extension, and an optional cranial burr hole cover. All devices must be completely implanted with the surgical incision closed.
11127307|NCT03884153|Experimental|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
11127308|NCT03884127||hyperlipidaemia|On the basis of the intervention of therapeutic sexual life style, a case control study was conducted on the intervention of oral ezetimibe tablet and orlistat capsule for 12 weeks and hyperlipidemia patients who persisted in the use of basic treatment.
11127309|NCT03884114|Other|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
11127310|NCT03884101|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
11127311|NCT03884101|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
11127312|NCT03884088|Experimental|Experimental Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
11127313|NCT03884075|Experimental|Arm A: Steatosis|Participants with steatosis on baseline biopsy
11127314|NCT03884075|Experimental|Arm B: NASH|Participants with NASH on baseline biopsy
11127315|NCT03884075|No Intervention|Arm C: Healthy|Healthy Volunteers
11127316|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
11127317|NCT03884049|Experimental|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
11127318|NCT03884049|Sham Comparator|Sham Embolization Group|Group undergoes sham embolization
11127319|NCT03884036|Active Comparator|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
11127320|NCT03884036|Placebo Comparator|Control group|Normal saline 1 cc IM
11127321|NCT03884023||AD group|Alzheimer's disease
11127322|NCT03884023||aMCI group|Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
11127323|NCT03884023||NC group|Normal Control
11127324|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
11127325|NCT03883997||Participants|Professional male soccer players from the second professional Mexican division.
11127326|NCT03883984|Experimental|Cysteamine|Cysteamine Bitartrate plus standard asthma care
11127327|NCT03883984|Placebo Comparator|Placebo Oral Tablet|Placebo plus standard asthma care
11127328|NCT03883971|Experimental|3D model|patient is given 3D printed model of her fetus's face
11127329|NCT03883971|Placebo Comparator|picture|patient is given a fetal picture only.
11127330|NCT03883958|Active Comparator|TPVB|
11127331|NCT03883958|Experimental|ESPB|
11127332|NCT03883945|Placebo Comparator|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
11127333|NCT03883945|Active Comparator|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
11127334|NCT03883945|Placebo Comparator|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
11127335|NCT03883945|Active Comparator|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
11127336|NCT03883945|Placebo Comparator|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
11127337|NCT03883945|Active Comparator|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
11127338|NCT03883945|Placebo Comparator|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
11127339|NCT03883945|Active Comparator|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
11127340|NCT03883932|Experimental|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
11127341|NCT03883932|Active Comparator|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
11127342|NCT03883919|Experimental|Group 1: Paricalcitol 75 mcg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.
~Paricalcitol 75 mcg on Days 1 and 8
~treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
11127343|NCT03883919|Experimental|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.
~Paricalcitol 7 mcg/kg on Days 1 and 8
~treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
11127344|NCT03883906|Experimental|Viral Specific T-cells (VSTs)|
11127345|NCT03883893|Active Comparator|IV Tylenol|Participants will receive IV acetaminophen 15mg/kg in the OR.
11127346|NCT03883893|Placebo Comparator|Normal Saline|Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
11127347|NCT03883880|Experimental|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
11127452|NCT03883204|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
11128739|NCT03874143|No Intervention|RCom with paper-based system|
11127348|NCT03883880|Experimental|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
11127349|NCT03883880|Experimental|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
11127350|NCT03883867||Normal|The subject population will involve 10 non-pregnant women. The tactile imaging reprifucibility sub-group will include 5 non-pregnant subjects with 2 tactile imaging examinations completed in one session. All other subjects will have a single tactile imaging examination.
11127351|NCT03883867||Pregnant|The subject population will involve 10 pregnant women without known complications at 36-37 weeks of pregnancy scheduled for a regular examination. All pregnant subjects should be examined weekly after completing 36th week of an uncomplicated pregnancy. Routine gynecologic examination includes external and internal obstetrical examination.
11127352|NCT03883854||1 group|"Complete iron profile
~serum iron
~serum ferritin
~total iron binding capacity
~transferrin saturation (TSAT)"
11127353|NCT03883841||Study group|patients with iron deficiency anemia
11127354|NCT03883841||control group|normal pregnant patients
11127355|NCT03883828|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
11127356|NCT03883828|No Intervention|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
11127357|NCT03883815||Assesment treatment intensity|Assesment treatment intensity during neurodevelopmental therapy session and active video games therapy session
11127358|NCT03883802|Experimental|Foxy-5|Arm will receive Foxy-5 as neo-adjuvant therapy prior to surgical removal of tumour and afterwards until initiation of FOLFOX 6 months regimen
11127359|NCT03883802|Active Comparator|Standard therapy|Surgical removal of tumour followed by 6 months FOLFOX regimen
11127360|NCT03883789||Normal pregnancies|Participants who have normal uncomplicated pregnancies
11127361|NCT03883789||Pregnancies with complications|Participants who undergo pregnancy with liver disease or develop liver disease or other conditions
11127362|NCT03883776|Experimental|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.
~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
11127363|NCT03883763|Experimental|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
11127364|NCT03883763|Active Comparator|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
11127365|NCT03883737|Experimental|Group 1: PNM in pain knee|participants in whom PNM will be applied to the femoral nerve of the pain knee
11127366|NCT03883737|Experimental|Group 2: PNM in non-pain knee|participants in whom PNM will be applied to the femoral nerve of the non-pain knee
11127367|NCT03883724|Experimental|Brief behavioral treatment for insomnia|This group will undergo behavioral intervention proven to improve sleep among older adults: brief behavioral treatment for insomnia
11127368|NCT03883724|Other|Information-only control|This group is called information-only control. They will be provided sleep-related information. They will also view a video content of which overlap substantially with BBTI but without individualized behavioral instructions.
11127369|NCT03883711||Patients with acute coronary syndrome or myocardial injury|Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
11127370|NCT03883698|Experimental|ESRD, alternate day dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
11127371|NCT03883698|Experimental|ESRD, daily dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
11127372|NCT03883698|Active Comparator|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
11127373|NCT03883685|Experimental|experimental group|40 subjects will be randomly allocated to receive probiotics pills for consecutive 8 weeks.
11127374|NCT03883685|Placebo Comparator|Control group|40 subjects will be randomly allocated to receive placebo pills for consecutive 8 weeks.
11127375|NCT03883672|Experimental|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
11127376|NCT03883659|Active Comparator|traditional paper hangouts group|patients use the traditional paper hangouts to conduct the home exercise program at home
11127377|NCT03883659|Experimental|smartphone group|patients use the smartphone to conduct the home exercise program at home
11127378|NCT03883646|Experimental|Mindfulness|Mindfulness
11127379|NCT03883646|Experimental|Relapse Prevention|
11127380|NCT03883646|No Intervention|Waitlist Control|
11127381|NCT03883646|No Intervention|Treatment as Usual|
11127382|NCT03883633||Enrolled Participants|All participants enrolled will be tracked from initial assessment to study completion.
11127383|NCT03883620|Experimental|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
11127453|NCT03883204|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
11127384|NCT03883620|Experimental|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
11127385|NCT03883620|Placebo Comparator|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
11127386|NCT03883620|Experimental|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
11127387|NCT03883620|Placebo Comparator|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
11127388|NCT03883620|Experimental|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
11127389|NCT03883620|Placebo Comparator|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
11127390|NCT03883607|Experimental|80mg|elafibranor 80mg
11127391|NCT03883607|Experimental|120mg|elafibranor 120mg
11127392|NCT03883594|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
11127393|NCT03883581|Experimental|ALS individuals with bulbar dysfunction|Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.
11127394|NCT03883555||Optiflow tm|High flow nasal therapy (HFNT)
11127395|NCT03883555||Non invasive ventilation (NIV)|Non invasive ventilation (NIV)
11127396|NCT03883542||serous BOT|simple serous BOT ovarian tissue
11127397|NCT03883542||serous BOT with non-invasive implants|BOT ovarian tissue presenting with non-invasive implants
11127398|NCT03883542||sBOT with micropapillary grow pattern|BOT ovarian tissue presenting with micropapillary grow pattern
11127399|NCT03883542||serous BOT with invasive implants|sBOT ovarian tissue presenting with invasive implants at the time of diagnosis
11127400|NCT03883529|Experimental|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
11127401|NCT03883516|Placebo Comparator|No pre-briefing prior to the simulation training|No pre-briefing prior to the simulation training
11127402|NCT03883516|Active Comparator|Pre-briefing with the current SE treatment guidelines|pre-briefing with the current SE treatment Guidelines published by the American Epilepsy Society
11127403|NCT03883516|Active Comparator|pre- briefing with consolidated SE treatment guideline|"pre-briefing with the consolidated one page SE treatment guideline"
11127404|NCT03883503|Experimental|Beer alone|Consumption of beer (correlated for weight to reach a blood alcohol concentration of 0.8) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
11127405|NCT03883503|Active Comparator|Beer and water|Consumption of beer and additional water (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of water, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
11127406|NCT03883503|Active Comparator|Beer and stock|Consumption of beer and additional stock(correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
11127407|NCT03883503|Placebo Comparator|Water alone|Consumption of water alone (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
11127408|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
11127409|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
11127410|NCT03883477|Experimental|Endoscopic Release|12 out of 24 patients recommended for surgical treatment of trigger finger will be randomized to undergo endoscopic release.
11127411|NCT03883477|Active Comparator|Standard Open Release|12 out of 24 patients recommended for surgical treatment of trigger finger will be randomized to undergo standard open surgical release.
11127412|NCT03883464|Experimental|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
11127413|NCT03883464|No Intervention|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
11127414|NCT03883451|Experimental|Helmet type|football player helmet model
11127454|NCT03883191|Experimental|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
11127455|NCT03883191|Placebo Comparator|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
11127456|NCT03883178|Experimental|Neurolysis|
11127457|NCT03883165|Experimental|high-intensity neck strengthening group|
11127458|NCT03883165|Experimental|low-intensity neck strengthening group|
11127459|NCT03883165|Other|Control group|
11127493|NCT03882905|Experimental|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
11127415|NCT03883438|Active Comparator|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
11127416|NCT03883438|Experimental|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
11127417|NCT03883425||Case 1: formal home service recipients|Adults aged 65 or older living at home who receive formal home service (household, meal delivery, transportation, shopping) at least one a week
11127418|NCT03883425||Case 2: formal home care recipients|Adults aged 65 or older living at home who receive formal home care (shower/bath nursing assistance, nursing care) at least once a week
11127419|NCT03883425||Control: free of formal home care or home service|Adults aged 65 or older living at home who do not receive formal home care or home service.
11127420|NCT03883412|Experimental|Exercise Alone|16 weeks of treatment
11127421|NCT03883412|Experimental|Liraglutide alone|16 weeks of treatment
11127422|NCT03883412|Experimental|Exercise + Liraglutide|16 weeks of treatment
11127423|NCT03883399||Colorectal surgeons|Survey among Spanish colorectal surgeons
11127424|NCT03883386|Experimental|Loratadine first|Take treatment daily for 7 days.
11127425|NCT03883386|Placebo Comparator|Placebo first|Take placebo daily for 7 days.
11127426|NCT03883373||Cortical group|Group of patient who had an alveolar bone graft with cancellous bone and a cortical block
11127427|NCT03883373||Cancellous group|Group of patient who had an alveolar bone graft with cancellous bone only
11127428|NCT03883360|Experimental|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
11127429|NCT03883360|Placebo Comparator|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
11127430|NCT03883347|Active Comparator|Group DEX|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.
11127431|NCT03883347|Active Comparator|Group REMI|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.
11127432|NCT03883334|Experimental|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
11127433|NCT03883334|No Intervention|Control group|combine antiretroviral therapy only
11127434|NCT03883321||CBSM|Patients included in this group participate in the CBSM program. They attend 10 sessions of stress management according to the CBSM program, 9 take place over 3 months and the tenth session takes place 3 months after the 9th session. The session is composed of relaxation and cognitive and behavioral therapy, which is carried out in groups of 8 to 10 patients
11127435|NCT03883321||Waiting list|"The CBSM group is compared to the waiting list group that does not benefit from the CBSM program. After completing their assessment in the waiting list group, patients in this group will be integrated into the CBSM group but will not be evaluated as such."
11127436|NCT03883308|Experimental|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
11127437|NCT03883308|Active Comparator|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
11127438|NCT03883295|Experimental|Control|root canal treatment will be initiated
11127439|NCT03883295|Experimental|NeoMTA Plus|vital pulp treatment using neomta plus will be used.
11127440|NCT03883282||study group|Patients who have been participated in RCT in the period from 2011 to 2018 (study group)
11127441|NCT03883282||control group|- Patients who have never participated in RCT
11127442|NCT03883269|Experimental|Erythromycin 4%|Erythromycin 4% topical gel formulation, BID, 4 weeks
11127443|NCT03883269|Experimental|Clindamycin 1%|Clindamycin 1% topical lotion formulation, BID, 4 weeks
11127444|NCT03883269|Placebo Comparator|ethanol solution|70% topical ethanol solution, BID, 4 weeks
11127445|NCT03883256|Active Comparator|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
11127446|NCT03883256|Active Comparator|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
11127447|NCT03883243|No Intervention|Control|Patients will only receive a brochure explaining the importance of physical activity with recommendations to improve it.
11127448|NCT03883243|Experimental|Telecoaching|Patients will receive a brochure explaining the importance of physical activity with recommendations to improve it. Next to this patients will receive the telecoaching intervention in which a coaching application linked to a step counter is installed on the patients smartphone, which will weekly give a new physical activity goal to improve the amount of steps per day for 8 weeks.
11127449|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
11127450|NCT03883217|Experimental|Vibration|PDVibe2 with vibration turned on
11127451|NCT03883217|No Intervention|No vibration|PDVibe2 with vibration turned off
11127460|NCT03883152||Head and neck cancer|Eating difficulty is one of the most common problems for head and neck cancer (HNC), in particular, who are in advanced disease stage and receive surgery, radiation (RT) or concurrent radio-chemotherapy (CCRT) (Vissink, Burlage, Spijkervet, Jansma, & Coppes, 2003; Lazarus et al., 2014). The consequences of multi-treatment bring structural and functional changes in oral, pharynx, or larynx and influence the normal eating process (Logemann et al., 2006; Lazarus et al., 2013; Patterson, McColl, Wilson, Carding, Rapley, 2015; McLaughlin, 2014).
11127461|NCT03883139|Active Comparator|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.
~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 3 hours a week (3 days, 1 hour per day)."
11127462|NCT03883139|Active Comparator|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.
~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 3 hours a week (3 days, 1 hour per day)."
11127463|NCT03883126|Active Comparator|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
11127464|NCT03883126|Active Comparator|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
11127465|NCT03883126|Sham Comparator|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
11127466|NCT03883126|Sham Comparator|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
11127467|NCT03883126|No Intervention|Group E|Group E will have no intervention, they will only complete assessment sessions.
11127468|NCT03883113|Experimental|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
11127469|NCT03883113|Placebo Comparator|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
11127470|NCT03883100|Experimental|HQP1351|
11127471|NCT03883087|Experimental|HQP1351|
11127472|NCT03883074|Experimental|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
11127473|NCT03883074|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
11127474|NCT03883061||mortality of sepsis|the study sample would be extracted from electronic health records in emergence departments. risk factor analysis and mathematical modeling would be performed to evaluate the significant and independent risk factors and predictive models.
11127475|NCT03883035|Experimental|EAS-aided group|esophagogastroduodenoscopy examination with the assistance of automatic quality-control system
11127476|NCT03883035|No Intervention|control group|conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system
11127477|NCT03883022|Experimental|Vancomycin (V Group)|
11127478|NCT03883022|Active Comparator|Without Vancomycin (NV Group)|
11127479|NCT03882996|Experimental|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
11127480|NCT03882983|Experimental|Antria Cell Preparation Process|Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments
11127481|NCT03882970|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11127482|NCT03882970|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11127483|NCT03882970|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11127484|NCT03882970|Active Comparator|Insulin Degludec|Insulin degludec administered SC once a day.
11127485|NCT03882957|Active Comparator|Video|videos of media tasks being completed
11127486|NCT03882957|Experimental|media multi-task|media tasks
11127487|NCT03882957|Experimental|sustained attention task|a cognitive task that trains sustained attention
11127488|NCT03882931|Experimental|TMS to left DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the left DLPFC and complete a visuomotor rotation task.
11127489|NCT03882931|Experimental|TMS to right DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the right DLPFC and complete a visuomotor rotation task.
11127490|NCT03882931|Sham Comparator|TMS Control|A Sham Theta Burst Transcranial Magnetic Stimulation will be delivered to the right/left DLPFC and complete a visuomotor rotation task.
11127491|NCT03882931|Experimental|FUS to right/left DLPFC|Low intensity Focused Ultrasound stimulation will be delivered to either the left or right DLPFC depending on the subject's DLPFC response during their functional MRI flanker task.
11127494|NCT03882905|Placebo Comparator|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
11127495|NCT03882905|Experimental|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
11127496|NCT03882905|Placebo Comparator|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
11127497|NCT03882892|Placebo Comparator|Placebo + Atorvastatin|Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
11127498|NCT03882892|Experimental|Ezetimibe + Atorvastatin|Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.
11127499|NCT03882879|Experimental|Arm 1|Participants in Arm 1 will begin participation in 6 months of karate classes immediately after the pre-intervention study visits.
11127500|NCT03882879|Experimental|Arm 2|Participants in Arm 2 will continue their usual exercise routine for six months followed by karate classes for six months
11127501|NCT03882866|Experimental|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
11127502|NCT03882866|Active Comparator|3D-printed coplanar template|3D-printed coplanar template is used in this group.
11127503|NCT03882853|Active Comparator|Conservative exercise group (CEG)|Conservative exercise group
11127504|NCT03882853|Experimental|Tree pose added exercise group (TPAEG)|Tree pose added exercise group
11127505|NCT03882840|Experimental|itNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
11127506|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
11127507|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
11127508|NCT03882801|Experimental|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
11127509|NCT03882801|Experimental|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
11127510|NCT03882788|Active Comparator|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.
~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
11127511|NCT03882788|Active Comparator|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.
~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
~The anesthetic may be supplemented with dexmedetomidine 0.05 mcg/kg/hr but not to exceed 1.0 mcg/kg/hr. Narcotic-based anesthetic will be used by the cardiac anesthesia team and the CPB technician throughout the operative case."
11127512|NCT03882775|Experimental|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
11127513|NCT03882775|Active Comparator|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
11127514|NCT03882762|Experimental|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:
~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
11127515|NCT03882762|Experimental|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:
~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
11127516|NCT03882762|Experimental|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:
~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
11127517|NCT03882762|Experimental|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:
~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
11127518|NCT03882723|Active Comparator|BiTrac MaxShield™ with standard elbow (FFM)|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
11127519|NCT03882723|Active Comparator|BiTrac™ Full Face with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
11127520|NCT03882723|Active Comparator|Respironics PerforMax with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
11127521|NCT03882723|Active Comparator|Philips Respironics AF531 with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
11127522|NCT03882710|Experimental|metoprolol XR capsule|
11127523|NCT03882710|Placebo Comparator|placebo capsule|
11127524|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
11127525|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
11127526|NCT03882671|Experimental|Monitoring Device|Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv
11127527|NCT03882645|Experimental|CHH-diet arm|"During the 4-week intervention period, free meals conformed to CHH-diet will be provided 3 times per daily (breakfast, lunch, dinner). Different center offers different meals of different cuisines but all conformed to CHH-diet. The main nutrientional healthy goal of different cuisines will be achieved through specific nutrient targets, including fat, carbohydrate, protein, dietary fiber, sodium, potassium, magnesium and calcium."
11127528|NCT03882645|Other|local usual diet arm|During the 4-week intervention period, three meals per day (breakfast, lunch, dinner) will be provided free of charge in line with local dietary characteristics. The energy,protein, carbohydrate, as week as dietary fiber, sodium, calcium, magnesium and potassium will be kept the same as that in the run-in phase.
11127529|NCT03882632|Experimental|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
11127530|NCT03882619|Experimental|Calligraphy group|
11127531|NCT03882619|No Intervention|Treatment-as-usual group|
11127532|NCT03882606|Other|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
11127533|NCT03882593||Analysis of arterial filters during CPB|This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams
11127534|NCT03882567|Experimental|Electro Neuro adaptative Regulator|8 SCENAR sessions (twice a week) (30 min of duration) following the protocols for treatment several points in the body
11127535|NCT03882567|Sham Comparator|Sham Electro Neuro adaptative Regulator|8 Sham SCENAR sessions (twice a week) (30 min of duration), following the same protocol tan experimental group but the machine will be turn off 30 seconds after starting on the treatment.
11127536|NCT03882554|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
11127537|NCT03882541|No Intervention|Control group|headphones without music, without sedation
11127538|NCT03882541|Active Comparator|sedative group|headphones without music, with sedation
11127539|NCT03882541|Experimental|experimental group|headphones with music, without sedation
11127540|NCT03882528|Experimental|Infective controls|
11127541|NCT03882515|Experimental|Experimental group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after myofascial release
11127542|NCT03882515|Sham Comparator|Sham group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after continuous surface slip technique
11127543|NCT03882515|Active Comparator|Control group|Evaluation and reassessment of asymptomatic individuals
11127544|NCT03882502|Experimental|stimulation group|
11127545|NCT03882502|Sham Comparator|sham stimulation|
11127546|NCT03882489||Cohort 1 : Height 150-165 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 1 includes patients whose the height is between 150 and 165 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 40 mg in the cohort 1 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 25 to 50 mg for cohort 1.
11127547|NCT03882489||Cohort 2 : Height 166-180 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 2 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 45 mg in the cohort 2 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 30 to 55 mg for cohort 2.
11127575|NCT03882294|Placebo Comparator|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
11127576|NCT03882281|Experimental|A group|Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
11128740|NCT03874130|Active Comparator|Scopolamine|0.2 mg scopolamine HBr per dose
11127548|NCT03882489||Cohort 3 : Height 181-195 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 3 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 50 mg in the cohort 3 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 35 to 60 mg for cohort 3.
11127549|NCT03882476|Experimental|Experimental|The experimental arm will involve patients monitored by InSight.
11127550|NCT03882476|No Intervention|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
11127551|NCT03882463|Experimental|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
11127552|NCT03882450|No Intervention|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
11127553|NCT03882450|Active Comparator|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
11127554|NCT03882437|Experimental|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of two dose levels depending on the cohort.
11127555|NCT03882424|Experimental|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
11127556|NCT03882424|Active Comparator|China-approved Bevacizumab|Intravenous administration
11127557|NCT03882424|Active Comparator|US-licensed Avastin|Intravenous administration
11127558|NCT03882411|Experimental|Electronic shared decision making (eSDM) Tool|When a clinic's randomly allotted intervention period arrives, coronary heart disease patients in a given cluster of clinics will complete a web application, which delivers screening, behavioral activation and shared decision making (eSDM), and providers will receive a patient preference report generated from the application.
11127559|NCT03882411|No Intervention|Usual Care|In the year prior to the allocated intervention period, coronary heart disease patients will receive usual care from their providers.
11127560|NCT03882398|Experimental|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
11127561|NCT03882398|Active Comparator|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
11127562|NCT03882372|Experimental|Nasal high flow|"Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.
~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow."
11127563|NCT03882372|No Intervention|Usual care|"Patient randomized to the control group will have no other specific intervention than their usual care.
~Patients under long-term oxygen will preserve their usual flow."
11127564|NCT03882359|Active Comparator|Definity|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of DEFINITY® 100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run forinclude 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
11127565|NCT03882359|Experimental|MVT-100|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of MVT-100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run forinclude 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
11127566|NCT03882346|No Intervention|Control Group|Patients in Control Group will receive best supportive care for the disease.
11127567|NCT03882346|Experimental|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
11127568|NCT03882333|Experimental|Acute exercise|Acute exercise (bicycle at stationary cycle).
11127569|NCT03882333|No Intervention|Rest|Rest (lying down or sitting in a chair) for 30 minutes, i.e. same time duration as in experimental arm.
11127570|NCT03882320|Experimental|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
11127571|NCT03882320|Active Comparator|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
11127572|NCT03882307|No Intervention|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
11127573|NCT03882307|Active Comparator|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
11127574|NCT03882294|Experimental|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10^10 CFU/bottle (80 ml)
11127577|NCT03882281|Experimental|B group|Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
11127578|NCT03882268|Experimental|MIYCN interventions|10 facilities run by 2 NGOs that will be randomly selected to receive intensified MIYCN interventions.
11127579|NCT03882268|No Intervention|Comparison facilities|10 facilities run by same 2 NGOs that run the intervention facilities, which will not receive any standardized MIYCN interventions.
11127580|NCT03882255|Experimental|Treatment Period 1: Ponesimod (2 mg)|Participants will receive a single dose ponesimod 2 milligram (mg) oral tablet under fed conditions on Day 1. Participants not fulfilling discontinuation criteria can continue to Treatment Period 2 after a washout period of at least 7 days and a maximum of 14 days.
11127581|NCT03882255|Experimental|Treatment Period 2:Ponesimod, Propranolol, Placebo Propranolol|Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.
11127582|NCT03882242|Experimental|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
11127583|NCT03882216|Experimental|test group pouch technique|free connective tissue graft augmentation using pouch technique
11127584|NCT03882216|Experimental|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
11127585|NCT03882203|Experimental|treatment|Patients receive the study protocol: CLAME sequential with FLu-Bu as conditioning regimen followed by low-dose decitabine maintenance
11127586|NCT03882190|No Intervention|group 1|
11127587|NCT03882190|Experimental|group 2|
11127588|NCT03882177|Experimental|Arm 1: Pravastatin (40 mg) and Rifafour|"Participants will receive pravastatin (40 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens."
11127589|NCT03882177|Experimental|Arm 2: Pravastatin (80 mg) and Rifafour|"Participants will receive pravastatin (80 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens."
11127590|NCT03882177|Experimental|Arm 3: Pravastatin (120 mg) and Rifafour|"Participants will receive pravastatin (120 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens.
~(Arm 3 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
11127591|NCT03882177|Experimental|Arm 4: Pravastatin (160 mg) and Rifafour|"Participants will receive pravastatin (160 mg) and Rifafour daily for 14 days. Pravastatin will be given alone on Day 1, and pravastatin + Rifafour will be given on Days 2-15.
~Vitamin B6 will be added to each of the regimens.
~(Arm 4 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.)"
11127592|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
11127593|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
11127594|NCT03882151|Experimental|Epilog Preop|patients receive Epilog preop analysis
11127595|NCT03882138|Active Comparator|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
11127596|NCT03882138|Active Comparator|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
11127597|NCT03882125|Experimental|Mindfulness|Assigned to a 6-week mindfulness-based relapse prevention course
11127598|NCT03882112|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
11127599|NCT03882112|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
11127600|NCT03882099||Pregnant women with pre-eclampsia|
11127601|NCT03882099||Pregnant women with eclampsia|
11127602|NCT03882099||Normotensive pregnant women|
11127603|NCT03882086|Experimental|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
11127604|NCT03882086|No Intervention|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
11127605|NCT03882073|Experimental|Intervention group|Modified amputation procedure
11127606|NCT03882073|Active Comparator|Control group|Standard amputation procedure
11127607|NCT03882060|Experimental|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
11127608|NCT03882060|Placebo Comparator|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
11127609|NCT03882047|Experimental|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
11127610|NCT03882047|Active Comparator|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
11127611|NCT03882047|Placebo Comparator|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
11127612|NCT03882034|Experimental|1|Intervention arm, Patient received pegvisomant
11127613|NCT03882021|Other|Mapping protocol with GRID catheter|All patient will undergo a protocol required mapping protocol using the GRID catheter.
11127614|NCT03882008|Experimental|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
11127615|NCT03881995|Active Comparator|iGlarLixi|Subjects will receive premixed Insulin glargine + lixisenatide once daily for 12 weeks
11127616|NCT03881995|Active Comparator|Insulin glargine|Subjects will receive Insulin glargine once daily for 12 weeks
11127617|NCT03881982|Experimental|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.
~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
11127618|NCT03881982|Other|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.
~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
11127619|NCT03881969|Experimental|Financial incentive offered|Patient offered £100 incentive payment in initial trial invitation letter.
11127620|NCT03881969|Experimental|No incentive. Payment not offered|Patient sent standard trial invitation letter with no offer of incentive payment.
11127621|NCT03881956|Other|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
11127622|NCT03881943|Active Comparator|Ticagrelor|Ticagrelor 60mg BD for 3 months
11127623|NCT03881943|Active Comparator|Aspirin|Aspirin 100mg daily for 3 months
11127624|NCT03881930|Experimental|Experimental group|"Balance rehabilitation with modified visual input:
~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.
~They will perform balance training with modified visual input."
11127625|NCT03881930|Active Comparator|control group|"Balance rehabilitation with no modified visual input:
~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.
~They will perform balance training with no modified visual input."
11127626|NCT03881904|Active Comparator|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
11127627|NCT03881904|No Intervention|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
11127628|NCT03881891|Experimental|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
11127629|NCT03881891|No Intervention|Standard care arm|This arm will comprise of patients who receive the usual care.
11127630|NCT03881878|Experimental|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks
~Docetaxel (75mg/m2, IV)
~Atezolizumab (1200mg, IV)
~Trastuzumab (600mg, SC)
~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)
~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks
~Atezolizumab (1200mg, IV)
~Trastuzumab (600mg, SC)
~Pertuzumab (420mg, IV)"
11127631|NCT03881878|Experimental|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks
~Docetaxel (75mg/m2, IV)
~Atezolizumab (1200mg, IV)
~Trastuzumab (600mg, SC)
~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)
~(B, Adjuvant setting) :
~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by
~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
11127632|NCT03881852|Experimental|AXS-12 (reboxetine)|
11127633|NCT03881852|Placebo Comparator|Placebo|
11127634|NCT03881839||patient in emergency department|
11127635|NCT03881826||Haematological patients|
11127636|NCT03881826||Healthy volunteers|
11127637|NCT03881813|Experimental|Fiber reinforced composite retainers|Fiber reinforced composite retainers were inserted in group 1 and were evaluated after every 3 months for a follow up period of 3 months.
11127638|NCT03881813|Experimental|Multistranded stainless steel retainers|Multistranded stainless steel retainers were inserted in group 2 and were evaluated after every 3 months for a follow up period of 3 months.
11127639|NCT03881787|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
11127640|NCT03881787|Active Comparator|Cetuximab|Cetuximab,Erbitux 250mg/m2 single administration
11127641|NCT03881774|Experimental|experimental arm|cord blood derived CAR T cells group
11127642|NCT03881761|Experimental|experimental arm|CAR-T cell group
11127643|NCT03881748|Experimental|Manual acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points.
11127644|NCT03881748|Experimental|Electro-acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points with additional application of weak electrical stimulation
11127645|NCT03881735|Experimental|Cohort A (enasidenib, hematopoietic cell transplantation)|Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
11127646|NCT03881735|Active Comparator|Cohort B (enasidenib)|Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11127647|NCT03881722|Active Comparator|thickened formula|
11127648|NCT03881722|Experimental|Mg alginate|
11127649|NCT03881709|Experimental|The intervention group|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
11127650|NCT03881709|No Intervention|The control group|The control group will receive a health education about prostate biopsy.
11128741|NCT03874130|Active Comparator|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
11127651|NCT03881696|Experimental|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.
~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.
~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
11127652|NCT03881696|Experimental|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.
~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
11127653|NCT03881696|Placebo Comparator|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.
~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.
~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
11127654|NCT03881696|Experimental|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:
~Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR
~Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.
~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
11127655|NCT03881696|Experimental|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy
~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.
~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
11127656|NCT03881696|Experimental|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.
~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
11127657|NCT03881696|Other|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.
~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:
~Long-term follow-up with dietary consumption of a food;
~Long-term follow-up with avoidance of a food; or
~Rescue OIT for a food.
~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will remain in Stage 3 until December 2023.
~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
11127658|NCT03881683|Experimental|HRD and BRCA mutations|
11127659|NCT03881670|Placebo Comparator|Lotrafilcon B|
11127660|NCT03881670|Active Comparator|Lotrafilcon B Hydraluxe|
11127661|NCT03881657|Experimental|Intervention Group|The intervention group received a reverse colocated integrated behavioral health intervention or usual care
11127662|NCT03881657|Active Comparator|Control Group|The control group received behavioral health services only (usual care)
11127663|NCT03881644|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Imigran infusion (0.4 mg/min) for 10 mins"
11127664|NCT03881644|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Isotonic saline for 10 mins (placebo)"
11127665|NCT03881631|Experimental|Mindfulness Based Stress Reduction (MBSR) Program|The MBSR program is an eight-week-long course designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
11127666|NCT03881631|Active Comparator|Living Well (LW) Program|LW is an eight-week course of group presentations and discussions on topics related to the promotion of health and well-being in the context of dementia caregiving. LW is designed to teach participants how to improve their physical and emotional health as a complement to traditional medical treatments.
11127667|NCT03881631|No Intervention|Usual Care|The usual care arm is a no intervention group wherein participants experience their usual circumstances.
11127668|NCT03881618|Experimental|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
11127669|NCT03881618|Active Comparator|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
11127670|NCT03881605|Experimental|MRI screening|Contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain at baseline, 4 months, 8 months and 12 months.
11127671|NCT03881605|No Intervention|Symptom-directed surveillance|Imaging of the brain will take place only if patients develop symptoms that are suggestive of brain metastases (e.g. headaches, vision changes, gait instability).
11127672|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
11127673|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
11127674|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
11127675|NCT03881579|Other|Usual care|one random half of patients will receive usual care
11127676|NCT03881579|Experimental|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
11127677|NCT03881566||Immunocompetent sepsis patients|Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
11127678|NCT03881566||Immunocompromised sepsis patients|Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
11127679|NCT03881566||Patients without sepsis|Patients who admitted intensive care unit without sepsis
11127680|NCT03881553|Experimental|Premature Infants (NICU)|Premature infants receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
11127681|NCT03881553|Experimental|Opioid-Exposed Newborns (NICU)|Opioid-exposed newborns receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
11127682|NCT03881553|Experimental|Hospitalized Infants (PICU)|Infants receiving treatment in the Pediatric Intensive Care or Inpatient Unit will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
11127683|NCT03881540|Active Comparator|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
11127684|NCT03881540|Active Comparator|tDNA-CC group|Follow tDNA intervention and conventional counselling
11127685|NCT03881540|Other|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
11127686|NCT03881527|Experimental|Resection of the aortic valve leaflets with device|Patients in which the aortic valve has been resected using the nitinol blade
11127687|NCT03881527|Other|Resection of the aortic valve leaflets in standard fashion|Patients in which the aortic valve has been resected using a conventional blade or scissor
11127688|NCT03881488|Experimental|Part 1 Dose Escalation|Escalating doses of CTX-471 depending on cohort at enrollment.
11127689|NCT03881488|Experimental|Part 2 Dose Expansion|Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
11127690|NCT03881475||healthcare workers|Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
11127691|NCT03881462|Experimental|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
11127692|NCT03881449|Experimental|ABILIFY MYCITE Group|"If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.
~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
11127693|NCT03881449|No Intervention|Treatment as Usual (TAU) Group|"TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.
~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
11127694|NCT03881436|Experimental|Pelvic MRI|"This arm involves patients undergoing a pelvic MRI.
~At the end of the planned sequence, but before any contrast agent injection:
~Acquisition of a an additional anatomical T2 SPACE sequence
~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
11127695|NCT03881436|Experimental|Pelvic surgery|"This arm involves patients undergoing a pelvic surgery and coming for a postoperative MRI. An additional MRI is performed before the surgery and additional sequences are added to the planned postoperative MRI, at the end of the planned sequence, but before any contrast agent injection:
~Acquisition of a an additional anatomical T2 SPACE sequence
~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
11127696|NCT03881423|Active Comparator|Deep block|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
11127697|NCT03881423|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
11127698|NCT03881410|Experimental|Shear-wave elastography-guided|
11127699|NCT03881410|Active Comparator|Convention ultrasound-guided|
11127700|NCT03881397|No Intervention|Control (Track B assessed at Time 2)|A survey regarding tech use, health behaviors and well-being including physical activity, anxiety, and sleep
11127701|NCT03881397|Experimental|Online Family Media Use Plan (Track A)|The Online Family Media Use Plan group will receive a link to American Academy of Pediatrics Family Media Use plan at the end of the survey, which describes internet safety ideas for teens and parents to review and create together.
11127702|NCT03881397|Experimental|Media Use Resources Awareness (Track B assessed at Time 3)|Resources offered to parents and teens that include tools and data for safe technology use among teens
11127703|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
11127704|NCT03881371|Experimental|Safinamide|Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
11127705|NCT03881371|Placebo Comparator|Placebo|Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
11127706|NCT03881358|Active Comparator|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
11127707|NCT03881358|Experimental|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
11127708|NCT03881319|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
11127709|NCT03881319|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
11127710|NCT03881319|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
11127711|NCT03881306|Experimental|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
11127712|NCT03881293|Placebo Comparator|Placebo Lubricant Gel|5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
11127713|NCT03881293|Active Comparator|Lidocaine 2% Gel|5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
11127714|NCT03881280|No Intervention|Control group|Treatment as usual for 4 weeks
11127715|NCT03881280|Experimental|Intervention group|Education through the app for 4 weeks
11127716|NCT03881267|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a venous leg wound in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing and compression
11127717|NCT03881267|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on venous leg wounds in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing and compression
11127718|NCT03881254|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
11127719|NCT03881254|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
11127720|NCT03881241||Study Treatment|EVOS SMALL PLating System
11127721|NCT03881228|Experimental|Intervention|"at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given
~at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive
~weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
11127722|NCT03881228|No Intervention|Standard of care|Routine care at the health facility
11127723|NCT03881215|Experimental|Platelet Rich Plasma|PRP
11127724|NCT03881215|Active Comparator|intra-uterine balloon|
11127725|NCT03881202|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
11127726|NCT03881189|Experimental|SUNEKOS ® 200|"The 1st intradermal treatment (T1i) with Sunekos ® 200 was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)"
11127727|NCT03881176|Experimental|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.
~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
11127728|NCT03881163|Experimental|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
11127729|NCT03881163|Experimental|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
11127730|NCT03881150|Experimental|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.
~Counseling is considered about physical activity, diet, smoking, and medication compliance."
11127763|NCT03880916|Placebo Comparator|Placebo group|"Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)
~Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
11127731|NCT03881150|Active Comparator|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
11127732|NCT03881137|Experimental|Intervention|Geriatric assessment with management
11127733|NCT03881137|No Intervention|Control|Patients receiving supportive care and follow up according to routine practice
11127734|NCT03881111|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
11127735|NCT03881111|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
11127736|NCT03881098|Other|Squamous Cell Carcinoma Pre-Malignant Lesions|The prospective SCC-PML cohort is envisioned to provide a well-matched group of high-risk subjects that will provide clinically comparable subjects with lesional sites representing progressive and non-progressive disease.
11127737|NCT03881072|Other|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
11127738|NCT03881059|Placebo Comparator|Part A: Placebo|
11127739|NCT03881059|Experimental|Part A: BMS-986165 Dose A|
11127740|NCT03881059|Experimental|Part A: BMS-986165 Dose B|
11127741|NCT03881059|Experimental|Part B: Ustekinumab + BMS-986165 Placebo|
11127742|NCT03881059|Experimental|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
11127743|NCT03881059|Experimental|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
11127744|NCT03881046||lung cancer|
11127745|NCT03881046||healthy control group|
11127746|NCT03881033|Placebo Comparator|P12|
11127747|NCT03881033|Active Comparator|P7+5|
11127748|NCT03881020|Experimental|SMART|Silver modified atraumatic restorative treatment group in which advantage Arrest Silver diamine Fluoride 38% (Elevate oral Care, USA ) will be applied to carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
11127749|NCT03881020|Active Comparator|Conventional ART|Conventional atraumatic restorative treatment group in which a sharp excavator will be used to remove caries from carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
11127750|NCT03881007|Experimental|LCM|Mouthwash with LCM
11127751|NCT03881007|Placebo Comparator|Placebo|Mouthwash with placebo
11127752|NCT03880981|Active Comparator|Acetaminophen|Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain
11127753|NCT03880981|Active Comparator|Ibuprofen|Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain
11127754|NCT03880968|Active Comparator|inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
11127755|NCT03880968|Sham Comparator|inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
11127756|NCT03880968|Active Comparator|low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to sequential tapering group (B1).
11127757|NCT03880968|Active Comparator|low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
11127758|NCT03880968|Sham Comparator|low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to discontinuation group (B3).
11127759|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:
~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis
~Failed previous shoulder joint replacement"
11127760|NCT03880942|Active Comparator|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
11127761|NCT03880942|Placebo Comparator|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
11127762|NCT03880916|Experimental|Duloxetine group|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)
~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
11127764|NCT03880903|Experimental|normal saline with bronchdilator|will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
11127765|NCT03880903|Experimental|hypertonic saline with bronchodilator|will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
11127766|NCT03880903|Experimental|hypertonic saline only|will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
11127767|NCT03880890|Active Comparator|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
11127768|NCT03880890|Active Comparator|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
11127769|NCT03880877|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).
~Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle."
11127770|NCT03880877|Active Comparator|Regorafenib|Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.
11127771|NCT03880851|Other|Hypofractionated image-guided radiotherapy|"Hypofractionated image-guided radiotherapy IGRT to a total dose of 60 Gy (20 fractions) is performed.
~Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.
~Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy."
11127772|NCT03880838|No Intervention|No contact control|Participants are not contacted.
11127773|NCT03880838|Experimental|Letter|Participants are only contacted through a letter with a personal testimonial.
11127774|NCT03880838|Experimental|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
11127775|NCT03880838|Experimental|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
11127776|NCT03880838|Experimental|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
11127777|NCT03880838|Experimental|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
11127778|NCT03880838|Experimental|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
11127779|NCT03880838|Experimental|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
11127780|NCT03880838|Experimental|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
11127781|NCT03880838|Experimental|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
11127782|NCT03880838|Experimental|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
11127783|NCT03880838|Experimental|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
11127784|NCT03880838|Experimental|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
11127785|NCT03880838|Experimental|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
11127786|NCT03880825|Other|Metformin Only|
11127787|NCT03880825|Other|Levoketoconazole Only|
11127788|NCT03880825|Other|Levoketoconazole + Metformin|
11127789|NCT03880812|Experimental|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
11127790|NCT03880812|No Intervention|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
11127791|NCT03880799|Experimental|Mindfulness Intervention|Newly diagnosed breast cancer patients who undergo a mindfulness session before their surgical appointment.
11127792|NCT03880786|Experimental|PNE test lead|
11127793|NCT03880773|Experimental|Stapler|
11127794|NCT03880773|Active Comparator|ultrasonic shears|
11127795|NCT03880760|Experimental|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
11127796|NCT03880760|Placebo Comparator|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
11127797|NCT03880747||Vagus nerve preserving group|Patients who underwent vagus nerve-preserving distal gastrectomy for early gastric cancer
11127798|NCT03880734|Experimental|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
11127799|NCT03880734|Experimental|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
11127800|NCT03880721||Good prognosis|
11127801|NCT03880721||Poor prognosis|
11127802|NCT03880721||Recurrence|
11127803|NCT03880721||Not Recurrence|
11127804|NCT03880721||Survival|
11127805|NCT03880721||Death|
11127836|NCT03880448|Experimental|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
11127837|NCT03880448|Placebo Comparator|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
11127806|NCT03880695|Experimental|Anlotinib+ Liposomal Doxorubicin|Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
11127807|NCT03880682||Study Group|Kidney transplant recipients with chronic HCV infection who were treated using direct acting antivirals.
11127808|NCT03880656|Experimental|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
11127809|NCT03880656|No Intervention|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
11127810|NCT03880656|Experimental|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
11127811|NCT03880643||Study Group|Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.
11127812|NCT03880630|Experimental|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
11127813|NCT03880617||Chronic Myeloid Leukemia (CML)|For CML, the first-line targeted drug is imatinib, and then second line as nilotinib and dasatinib. In the past, the median survival of CML is around 4 to 6 years (NCI, 2008). Fortunately, the launch of the targeted therapy, the median survival is expected to approach normal life expectancy for most patients. However, limited to the less than 20 years of advent of TKI, the exact effects on survival time is not yet determined.
11127814|NCT03880617||Gastrointestinal Stromal Tumor (GIST)|For patients with GIST, the imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) (Heinrich et al, 2003) is the first line drug and sunitinib as the second line drug. Sunitinib is an anti-angiogenesis agent by virtue of targeting multiple tyrosine kinases, including the vascular endothelial growth factor receptors (VEGFR). With these target drugs, the survival of advanced GIST patients is prominently prolonged (Lamba, Ambrale, Lee, Gupta, Rafiyath, & Liu D, 2012). The median overall survival (OS) of advanced GIST patients increased from 18 to 57 months with imatinib therapy (Blanke et al, 2008).
11127815|NCT03880604|Active Comparator|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
11127816|NCT03880604|Active Comparator|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
11127817|NCT03880578||surgery (withdrawn, not continuing recruiting)|thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
11127818|NCT03880578||radioiodine|thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
11127819|NCT03880578||control|thyroid patients followed without surgery or radioiodine treatment
11127820|NCT03880565|Experimental|ECMO Facilitated Resuscitation|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation: ECMO is initiated expeditiously, regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
11127821|NCT03880565|Other|Standard ACLS Resuscitation|Standard Advanced Cardiac Life Support (ACLS) Resuscitation: Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
11127822|NCT03880539|Other|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
11127823|NCT03880526||Semi-Structured Interview|Participants will choose to participant in an individual in-depth interview to be conducted by investigators to gain information about the participant's background, cancer status and treatment.
11127824|NCT03880526||Focus Groups|Participants may choose to participate in one of three focus groups of no more than 10 participants in each group to to gain information about the participant's background, cancer status and treatment.
11127825|NCT03880513||Longitudinal study|Patients during overt and after cure of endogenous Cushing's syndrome.
11127826|NCT03880513||Cross-sectional study|Patients with proven endogenous Cushing's syndrome (overt or subclinical).
11127827|NCT03880500|Sham Comparator|Patient|25 Patients will receive a spinal manipulative therapy Intervention, the other 25 Patients receive a sham Intervention.
11127828|NCT03880500|No Intervention|Control|No intervention
11127829|NCT03880487|Experimental|KP-1199|
11127830|NCT03880487|Placebo Comparator|Placebo oral capsules|
11127831|NCT03880487|Active Comparator|Oxycodone oral capsules|
11127832|NCT03880474|Experimental|MVA-NP+M1|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.)
11127833|NCT03880474|Placebo Comparator|Saline Placebo|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
11127834|NCT03880461|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines.
11127835|NCT03880461|No Intervention|Usual Care - Control|Usual Medical Care
11127838|NCT03880435|Experimental|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
11127839|NCT03880435|No Intervention|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
11127840|NCT03880422|Experimental|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
11127841|NCT03880409|Active Comparator|2% lidocaine with 1:000,000 epinephrine|supplemental intraseptal injections using 0.8 mL 2% lidocaine with 1:000,000 epinephrine
11127842|NCT03880409|Active Comparator|4% articaine with 1:000,000 epinephrine|buccal infiltration of 1.8 ml 4% articaine with 1:000,000 epinephrine
11127843|NCT03880396|Other|hypofractionated Rth with weekly cisplatin 40mg/m2|hypofractionated radioyherapy with weekly cisplatin 40mg/m2
11127844|NCT03880383|Experimental|Group 1 - Coaching|"Upon enrollment to the study, parents in this group will have immediate access to the full intervention:
~Coaching: Telephone contact with coaches, who will provide information, education and support about the child's development. Coaching will be adapted to family needs, situation, preferences and child's condition.
~Online parent education: Parents will be provided access to empowering online tools, such as educational resources, chosen or developed by other parents and researchers.
~Peer support tools: Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge."
11127845|NCT03880383|Other|Group 2- Partial and delayed coaching|"Parents in this group will have delayed and partial access to coaching, at the end of the 18-month period. Parents in this group will have a one-time session with a developmental coach who can give them guidance about their child's development. Parents in this group will also then get access to online parent education and peer support tools, indefinitely, until the online platform is de-activated.
~* Both arms/groups* will obtain usual care for their child, in addition and independent of full or partial coaching."
11127846|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
11127847|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
11127848|NCT03880357|Experimental|Test Product|Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)
11127849|NCT03880357|Active Comparator|Reference Product|Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)
11127850|NCT03880357|Placebo Comparator|Placebo|Vehicle of the test product (Taro Pharmaceuticals Inc.)
11127851|NCT03880344|Experimental|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
11127852|NCT03880344|Active Comparator|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
11127853|NCT03880331|Active Comparator|Aggressive Debridement|Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
11127854|NCT03880331|Active Comparator|Minimal Debridement|No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
11127855|NCT03880318|Other|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
11127856|NCT03880292|Other|Intraoperative Maneuvers|To document intraoperative maneuvers performed in repsonse to alerts
11127857|NCT03880279|Experimental|TAC01-CD19|TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
11127858|NCT03880266|Experimental|Group 1|Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 1)
11127859|NCT03880266|Experimental|Group 2|Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 2)
11127860|NCT03880266|Experimental|Group 3|Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 3)
11127861|NCT03880266|Experimental|Group 4|Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 4)
11127862|NCT03880253|Experimental|CTP-692 Low Dose or Matching Placebo|Once daily dosing
11127863|NCT03880253|Experimental|CTP-692 Mid Dose or Matching Placebo|Once daily dosing
11127864|NCT03880253|Experimental|CTP-692 High Dose or Matching Placebo|Once daily dosing
11127865|NCT03880240|Experimental|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
11127866|NCT03880240|Experimental|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
11127867|NCT03880240|Experimental|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
11127868|NCT03880240|Sham Comparator|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
11127869|NCT03880227|Experimental|anodal stimulation tDCS to rTPJ|anodal tDCS to the rTPJ followed by behavioral testing
11127870|NCT03880227|Sham Comparator|sham tDCS to rTPJ|sham tDCS to the rTPJ followed by behavioral testing
11127871|NCT03880227|Experimental|anodal stimulation tDCS to dmPFC|anodal tDCS to the dmPFC followed by behavioral testing
11127872|NCT03880227|Sham Comparator|sham tDCS to dmPFC|sham tDCS to the dmPFC followed by behavioral testing
11127873|NCT03880214||stem cells transplanted pediatric patients|screen pediatric patients at least 3 months after they undergo allogeneic hematopoietic stem cells transplantation to detect any risk factors for developing oral manifestations of chronic graft -versus-host disease during this period
11127874|NCT03880201||patient undergoing upper limb orthopaedic surgery|The study will be performed on patient undergoing upper limb orthopaedic surgery which will be performed under ultrasound guided supraclavicular block.
11127875|NCT03880175|Experimental|FCC DEB and Anti-stigma|
11127876|NCT03880175|Experimental|FCC DEB and HIV info|
11127877|NCT03880175|Experimental|FCC DEB and ART info|
11127878|NCT03880175|Experimental|FCC DEB and HIV-ART info|
11127879|NCT03880175|Experimental|FCC DEB and high coupon value|
11127880|NCT03880175|Experimental|FCC DEB and no info|
11127881|NCT03880175|Experimental|FCC non-DEB and Anti-stigma|
11127882|NCT03880175|Experimental|FCC non-DEB and HIV info|
11127883|NCT03880175|Experimental|FCC non-DEB and ART info|
11127884|NCT03880175|Experimental|FCC non-DEB and HIV-ART info|
11127885|NCT03880175|Experimental|FCC non-DEB and high coupon value|
11127886|NCT03880175|Experimental|FCC non-DEB and no info|
11127887|NCT03880175|Experimental|FCC control and Anti-stigma|
11127888|NCT03880175|Experimental|FCC control and HIV info|
11127889|NCT03880175|Experimental|FCC control and ART info|
11127890|NCT03880175|Experimental|FCC control and HIV-ART info|
11127891|NCT03880175|Experimental|FCC control and High coupon value|
11127892|NCT03880175|No Intervention|FCC control and no info|
11127893|NCT03880162|Experimental|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
11127894|NCT03880162|Active Comparator|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
11127895|NCT03880149|Experimental|Omega-3 supplementation|Omega-3 fatty supplementation and vitamin E. Each 1 g omega-3 capsule contain 600 mg omega-3 including 400 mg EPA + 200 mg DHA. Individual omega-3 dose will be determined according to the athlete's body mass, 1 g omega-3 / 15 kg body mass per day and vitamin E: 1 capsule of vitamin E (400 IU) for every five omega-3 capsules
11127896|NCT03880149|Placebo Comparator|Placebo|Medium-chain triglyceride (MCT) and vitamin E. Each MCT capsule contain 1 g, the dose will be 115 mg per kg body mass per day, and vitamin E: 1 capsule of vitamin E (400 IU) for every five MCT capsules
11127897|NCT03880136|Experimental|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
11127898|NCT03880136|Experimental|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
11127899|NCT03880123|Experimental|Selinexor/Ixazomib|Patients will receive combination treatment with selinexor and ixazomib. The dose of ixazomib is fixed at 4 mg, whereas several different dose levels of selinexor may be evaluated. No patients will receive a placebo.
11127900|NCT03880097||Research Biopsy|"The research biopsy is the same procedure as a standard of care percutaneous biopsy. A core (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes."
11127901|NCT03880071|Experimental|DBT + ACT group|- The experimental group (DBT+ ACT) led in Montpellier during 6 months.
11127902|NCT03880071|Other|DBT group|The control group (DBT) led in Geneva during 12 months.
11127903|NCT03880058|Active Comparator|SLI-F06|
11127904|NCT03880058|Placebo Comparator|Formulation Buffer|
11127905|NCT03880045|Active Comparator|Topical TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
11127906|NCT03880045|Active Comparator|placebo to TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid
11127907|NCT03880032|Experimental|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
11127908|NCT03880032|No Intervention|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Transportation will be facilitated to assist participants in attending appointments and medically indicated ultrasounds will be paid for (as in the intervention group).
11128197|NCT03878121|Experimental|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
11127909|NCT03880019|Experimental|Treatment (olaparib, temozolomide)|Patients receive olaparib PO BID and temozolomide PO QD on days 1-7. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11127910|NCT03880006|No Intervention|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
11127911|NCT03880006|Experimental|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
11127912|NCT03879993|Experimental|Exercise group|Exercise group was resistance training three times per week, during 45 to 60 minutes per day. Training program was composed by bench press, leg press 45°, lat pulldown, knee extension, dumbbell lateral raise, horizontal leg curl, triceps pulldown, seated calf raise, biceps curls and abdominal. Participants should complete 3 series with 8-12 repetitions of each exercise, which was supervised by trained research personnel. There were 60 seconds of interval between series and exercises were separated by a 120 seconds recovery period.
11127913|NCT03879993|No Intervention|Control group|Control group was not do any exercise during intervention period. Participants was asked to keep their habitual routine until finish the final evaluations.
11127914|NCT03879980|Placebo Comparator|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
11127915|NCT03879980|Experimental|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
11127916|NCT03879967|Experimental|Allograft block graft|For lateral alveolar ridge augmentation, all patients will be treated with allograft block with guided bone regeneration. After a minimal healing phase of six months, implants would be placed in the augmented site. After a healing phase of about 4months, the implants would be loaded and then followed until the control appointment approximately 3 years later.
11127917|NCT03879954|Other|OOP-IJV|Out of plane inetrnal jugular vein catetherization
11127918|NCT03879954|Other|IP-SSV|in plane supraclavicular subclavian vein catetherization
11127919|NCT03879928|Placebo Comparator|Placebo for SAD|Placebo comparator for SAD
11127920|NCT03879928|Experimental|FM101 75 mg for SAD|Single ascending doses of FM101
11127921|NCT03879928|Experimental|FM101 150 mg for SAD|Single ascending doses of FM101
11127922|NCT03879928|Experimental|FM101 300 mg for SAD|Single ascending doses of FM101
11127923|NCT03879928|Experimental|FM101 600 mg for SAD|Single ascending doses of FM101
11127924|NCT03879928|Experimental|FM101 1200 mg for SAD|Single ascending doses of FM101
11127925|NCT03879928|Experimental|FM101 2400 mg for SAD|Single ascending doses of FM101
11127926|NCT03879928|Placebo Comparator|Placebo for MAD|Placebo comparator for MAD
11127927|NCT03879928|Experimental|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
11127928|NCT03879928|Experimental|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
11127929|NCT03879928|Experimental|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
11127930|NCT03879928|Experimental|FM101 300 mg under fasted condition for FE|Food Effect of FM101
11127931|NCT03879928|Experimental|FM101 300 mg under fed condition for FE|Food Effect of FM101
11127932|NCT03879915||Prospective Dental Implant placement|Patients prospectively included and treated following current recommendations
11127933|NCT03879915||Retrospective Dental Implant placement|Patients retrospectively included, that did not benefit from current recommendations
11127934|NCT03879889|Experimental|Intervention|Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
11127935|NCT03879889|No Intervention|Control|Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.
11127936|NCT03879876|Experimental|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
11127937|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID|
11127938|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID|
11127939|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
11127940|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
11127941|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
11127942|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
11127943|NCT03879837|Experimental|Investigational Test Product|Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation
11127944|NCT03879837|Active Comparator|Reference Listed Drug|Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation
11127945|NCT03879837|Placebo Comparator|Placebo|Placebo pressurized metered dose inhaler, no active content
11127946|NCT03879824|Experimental|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)
~The active intervention in this arm of the study is secondary radial artery access during TAVI"
11127947|NCT03879824|Active Comparator|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)
~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
11127948|NCT03879811|Experimental|MMR-Proficient Colorectal Cancer|"The first 3 subjects will receive oral TMZ at 150mg/m2 day 1 to 5 during cycle
~1, followed by nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1 (i.e. Cycle 2 day 1). Nivolumab will continue for up for 2 years maximum. If confirmed that TMB increased in at least 2 of 3 subjects following 1 cycle of TMZ, then subsequent patients will continue to receive TMZ during cycle 1 only, and the original three participants will not be replaced. If it is determined that TMB did not increase following 1 cycle of TMZ, then subsequent patients will receive TMZ up to cycle 3, those first 3 patients will discontinue further Nivolumab and be replaced and an additional 6 patients will initially be enrolled. If confirmed that TMB increased in at least 1 of 6 subjects following 3 cycles of TMZ, then 12 more patients will be allowed to enroll for a total of 18 in stage I."
11127949|NCT03879798|Experimental|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan.
11127950|NCT03879785|Active Comparator|Self-Administration followed by Interviewer-Administered|
11127951|NCT03879785|Active Comparator|Interviewer-Administered followed by Self-Administration|
11127952|NCT03879772|Experimental|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
11127953|NCT03879772|Experimental|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
11127954|NCT03879772|Experimental|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
11127955|NCT03879772|Active Comparator|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
11127956|NCT03879772|Placebo Comparator|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
11127957|NCT03879759|Experimental|Arm 1|NAC - Relapse Prevention (4 wks)
11127958|NCT03879759|Placebo Comparator|Arm 2|NAC - Relapse Prevention (4 wks)
11127959|NCT03879746|Active Comparator|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
11127960|NCT03879746|Active Comparator|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
11127961|NCT03879746|Active Comparator|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
11127962|NCT03879746|Placebo Comparator|placrbo group|the fourth group will include 40 patients will be given placebo
11127963|NCT03879733|Experimental|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
11127964|NCT03879733|Other|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.
~Will receive the intervention from Sept. 2019 - June 2020."
11127965|NCT03879720|Active Comparator|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
11127966|NCT03879720|Experimental|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
11127967|NCT03879707|Experimental|Experimental|Melatonin and magnesium for 14 days
11127968|NCT03879707|Placebo Comparator|Control|Placebo for 14 days
11127969|NCT03879694|Experimental|Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)|Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
11127970|NCT03879681|No Intervention|No Intervention|
11127971|NCT03879681|Experimental|Jelly Snakes|
11128742|NCT03874117|Other|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
11127972|NCT03879668||eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
11127973|NCT03879668||Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
11127974|NCT03879655|Experimental|VTS-270|Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the subject, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.
11127975|NCT03879642|Experimental|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
11127976|NCT03879642|No Intervention|Waitlist|10 week no intervention to provide waitlist control condition
11127977|NCT03879629|Experimental|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
11127978|NCT03879629|Experimental|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
11127979|NCT03879629|Active Comparator|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by >10% to a value less than 53% and continued until end of therapy
11127980|NCT03879616|Experimental|An Enhanced Reminder|"Members randomized to this arm of the study will receive an enhanced reminder protocol, which will include multiple reminders, multiple modalities, and motivational messages. The timing of reminders will depend on the wait time between the date the appointment is made and the date of the appointment.
~An email reminder will be sent to all members who have provided their personal email information.
~Members will receive up to two text messages that roll over to an IVR automated phone call if the text cannot be delivered.
~Members scheduled for colonoscopy will also receive a single IVR-T reminder to begin their bowel prep the morning of the calendar day prior to the procedure."
11127981|NCT03879616|Other|Control|"Members randomized to this arm of the study will receive a single text message that rolls over to an IVR automated phone call if the text cannot be delivered. This message will be delivered 7 business days prior to the appointment. This replicates the current protocol for GI procedures. Of note, members who schedule appointments within 7 days of the procedure currently receive no reminders."
11127982|NCT03879603|Experimental|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
11127983|NCT03879603|Experimental|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
11127984|NCT03879603|Experimental|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
11127985|NCT03879603|Experimental|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
11127986|NCT03879603|Experimental|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
11127987|NCT03879603|Experimental|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
11127988|NCT03879590|Experimental|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
11127989|NCT03879590|Active Comparator|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
11127990|NCT03879577|Experimental|Docetaxel|Investigators will give patients docetaxel through drip every 3 weeks for four doses for 12 weeks before a repeat breast ultrasound. After breast ultrasound, if the investigator feels the injection is good, surgery will be done.
11127991|NCT03879577|Other|Herceptin|Herceptin will be given to patients under the skin of the thigh every 3 weeks for 18 times if they are HER2-positive
11127992|NCT03879577|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with a poor response to docetaxal will receive FEC injection by drip every 3 weeks.
11127993|NCT03879577|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years every 3 months for contraception and fertility preservation.
11127994|NCT03879577|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
11127995|NCT03879564|Placebo Comparator|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
11127996|NCT03879564|Experimental|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
11127997|NCT03879551|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere on the hand motor area for 10 consecutive sessions totally over period of 10 days.
11127998|NCT03879551|Sham Comparator|Sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere with coil perpendicular on scalp for 10 consecutive sessions totally over period of 10 days.
11127999|NCT03879538|Active Comparator|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
11128000|NCT03879538|Placebo Comparator|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
11128001|NCT03879525|Experimental|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
11128002|NCT03879525|Active Comparator|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
11128003|NCT03879512|Experimental|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
11128004|NCT03879486|Experimental|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
11128005|NCT03879486|No Intervention|Control arm|controls at transrectal ultrasound guided prostate biopsy
11128006|NCT03879460|Experimental|Open Label|Open label
11128007|NCT03879447||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
11128008|NCT03879447||Lumbar spondylolisthesis group|Lumbar spondylolisthesis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
11128009|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
11128010|NCT03879421|Active Comparator|Group 1 (Epithelium-off accelerated CXL)|patients with corneal thickness > 400 µm (thinnest location) were assigned into Epi-off accelerated CXL procedure
11128011|NCT03879421|Active Comparator|Group 2 (Epithelium-on accelerated CXL)|patients with corneal thickness > 380 µm and < 400 µm thinnest location) were assigned into Epi-on Trans-epithelial accelerated CXL procedure
11128012|NCT03879408|Experimental|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
11128013|NCT03879408|Experimental|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
11128014|NCT03879408|Active Comparator|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
11128015|NCT03879408|Active Comparator|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
11128016|NCT03879408|Placebo Comparator|Placebo tablet|Single dose of four placebo tablets
11128017|NCT03879395||Cohort|Patients with stage IV malignant melanoma with abdominal metastasis (M1c) that underwent abdominal surgery with metastasectomy during the study period.
11128018|NCT03879382|Experimental|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
11128019|NCT03879356|Other|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
11128020|NCT03879343||Clinical group|Children aged six to eleven with clinical diagnosis of attention deficit / hyperactivity disorder were recruited for interview and completion of questionnaires
11128021|NCT03879343||Control group|Normally developing children aged six to eleven studying in local mainstream primary schools were recruited for completion of questionnaires
11128022|NCT03879304|Experimental|Multimodal physiotherapy program with RV|The RV intervention group receives a multimodal physiotherapy program with tradicional exercises of physiotherapy and also a training with virtual reality glasses to complete de 6-MWT also with the glasses on.
11128023|NCT03879304|Active Comparator|Multimodal physiotherapy program|Traditional intervention group receives assistance of a multimodal program of physiotherapy without virtual reality glasses.
11128024|NCT03879278|Other|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
11128025|NCT03879278|Other|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
11128026|NCT03879278|Other|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
11128027|NCT03879265||Study group|No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).
11128028|NCT03879252|Experimental|Tooth brushing|
11128029|NCT03879252|Active Comparator|Mouthwash|
11128030|NCT03879239|Active Comparator|Vibrant Capsule mode A|Vibrant Capsule mode A administered 5 times per week
11128031|NCT03879239|Active Comparator|Vibrant Capsule mode B|Vibrant Capsule mode B administered 5 times per week
11128032|NCT03879239|Placebo Comparator|Placebo Capsule|Placebo Capsule administered 5 times per week
11128033|NCT03879226|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
11128034|NCT03879226|Experimental|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
11128035|NCT03879226|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
11128036|NCT03879226|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
11128037|NCT03879213|Experimental|Active|freeze-dried red raspberry powder (25 g) in active breakfast meal
11128038|NCT03879213|Placebo Comparator|Placebo|Placebo breakfast
11128039|NCT03879200|No Intervention|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
11128774|NCT03873883|Experimental|Dose Escalation- Monotherapy|Specified dose on specified days
11128040|NCT03879200|Experimental|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
11128041|NCT03879187|Experimental|High-fat diet|Participants underwent a 7 day high-fat, high-energy diet intervention with metabolic measurements before and after
11128042|NCT03879174|Experimental|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
11128043|NCT03879161|Experimental|Device Arm|Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.
11128044|NCT03879148|Active Comparator|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
11128045|NCT03879148|No Intervention|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
11128046|NCT03879135|Experimental|On-Demand|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
11128047|NCT03879135|Experimental|Prophylaxis|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
11128048|NCT03879122|Active Comparator|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
11128049|NCT03879122|Experimental|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
11128050|NCT03879122|Experimental|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
11128051|NCT03879109|Experimental|Arm A: Induction Chemotherapy followed by Pelvic reirradiation|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
~oxaliplatin: 85 mg/m2
~irinotecan: 180 mg/m²
~folinic acid: 400 mg/m2
~5FU : 400 mg/m2 (bolus)
~5FU : 2400 mg/m2 (continuous infusion)
~Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week."
11128052|NCT03879109|Active Comparator|Arm B: Chemotherapy alone|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
~oxaliplatin: 85 mg/m2
~irinotecan: 180 mg/m²
~folinic acid: 400 mg/m2
~5FU : 400 mg/m2 (bolus)
~5FU : 2400 mg/m2 (continuous infusion)"
11128053|NCT03879096|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
11128054|NCT03879083|Experimental|With reproduction of palatal rugae|Participants will receive maxillary complete dentures with a reproduction of the patients's own palatal rugae to the palatal surface.
11128055|NCT03879083|Active Comparator|Without reproduction of palatal rugae (smooth surface)|Participants will receive maxillary complete dentures with smooth palatal surfaces without a reproduction of the patients's own palatal rugae to the palatal surface.
11128056|NCT03879070|Experimental|Intervention group|
11128057|NCT03879070|No Intervention|Control group|
11128058|NCT03879057|Experimental|Surufatinib 200mg/JS001 240mg|Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
11128059|NCT03879057|Experimental|Surufatinib 300mg/JS001 240mg|Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
11128060|NCT03879044|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.
11128061|NCT03879031||Outpatients with low back pain|"All outpatients with non-specific subacute or chronic low back pain will be submitted to a physical therapy program including:
~information on pain mechanisms and the favorable nature of non-specific low back pain;
~advice on positions, movements and activities recommended or advised against in people with low back pain, both at work and during leisure time;
~active postural correction exercises, overactive muscles lengthening and weak musculature strengthening;
~passive manual techniques, aimed at muscle relaxation and recovery of lumbar joint mobility.
~A cluster of Clinical tests to measure lumbar stability will be administrated before the starting of the first session and at the ending of the last session of the physical therapy program."
11128062|NCT03879018|Experimental|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
11128063|NCT03879018|Experimental|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
11128064|NCT03879005|Other|Renal scintigraphy|5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.
11128567|NCT03875352|Experimental|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
11128065|NCT03878992|Other|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
11128066|NCT03878979|Experimental|Newly diagnosed SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN.
11128067|NCT03878979|Experimental|Reccurence of SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred.
11128068|NCT03878966|Experimental|Invasive Strategy group|Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
11128069|NCT03878953|Experimental|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
11128070|NCT03878940|Other|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
11128071|NCT03878927|Experimental|Cohort A|"CPX-351 : Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2/day on Days 1,3 and 5 (90 minute IV infusion)
~Gemtuzumab ozogamicin: 3mg/m^2/day on Day 1 (2 hour IV infusion)"
11128072|NCT03878927|Experimental|Cohort B|"CPX-351: Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2 on Days 1, 3 and 5 (90 minute IV infusion)
~Gemtuzumab ozogamicin: 3mg/m^2 on Days 1, 4 (2 hour IV infusion)"
11128073|NCT03878927|Experimental|Cohort C|"CPX-351: Daunorubicin 44mg/m^2 and cytarabine 100mg/m^2 on Days 1, 3, and 5 (90 minute IV infusion)
~Gemtuzumab ozogamicin: 3mg/m^2 on Days 1, 4 and 7 (2 hour IV infusion)"
11128074|NCT03878914|Experimental|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)
~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks
~40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.
~Wean off in 4 weeks
~CORTICOSTEROID THERAPY FOR A RELAPSE
~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission
~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
11128075|NCT03878914|Active Comparator|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)
~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks
~40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.
~Wean off in 4-6 weeks
~CORTICOSTEROID THERAPY FOR A RELAPSE
~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission
~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
11128076|NCT03878901|Sham Comparator|control group|Cotton Blanket Warming (CBW) starts 30 min preoperatively and then continues throughout the entire operation.
11128077|NCT03878901|Experimental|warm group|"Warm according to different hypothermia risk for low risk ---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) continues throughout the entire operation.
~moderate risk---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) and fluid warming continues throughout the entire operation.
~high risk ----Forced-air warming(FAW) starts at least 30 min preoperatively, FAW and fluid warming continues throughout the entire operation."
11128078|NCT03878888|Experimental|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
11128079|NCT03878888|No Intervention|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
11128080|NCT03878875||High Noise Exposure|One group (20, 10f:10m) with previous exposure i.e. nightclubs ++
11128081|NCT03878875||Low Noise Exposure|Group (20, 10f:10m) with less exposure measured through NESI
11128082|NCT03878849|Experimental|2X-121|Oral administration of 2X-121 once daily as 600 mg hard gelatin capsules in a 28 days cycle.
11128083|NCT03878823|Experimental|ODM-209 Part 1 Dose escalation|
11128084|NCT03878823|Experimental|ODM-209 Part 2 Dose expansion|
11128085|NCT03878810|Experimental|Exergaming, restless legs syndrome (+)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
11128086|NCT03878810|Experimental|Exergaming, restless legs syndrome (-)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
11128087|NCT03878810|No Intervention|Control, restless legs syndrome (+)|No specific intervention.
11128088|NCT03878810|No Intervention|Control, restless legs syndrome (-)|No specific intervention.
11128089|NCT03878784|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Imigrane infusion (0.4 mg/min) for 10 mins"
11128090|NCT03878784|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins
~AND
~Isotonic saline for 10 mins (placebo)"
11128091|NCT03878771|Experimental|autologous Platelet rich fibrin in Orabase (PRF)|applied to oral ulcer and/or mucositis 3 times per day
11128092|NCT03878771|Active Comparator|Clobetasol propionate 0.05%(Dermovate cream) in orabase|applied to oral ulcer and/or mucositis 3 times per day
11128093|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
11128094|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
11128095|NCT03878758|Experimental|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
11128096|NCT03878745|Experimental|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
11128097|NCT03878745|Active Comparator|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
11128098|NCT03878732||Caucasian female|
11128099|NCT03878732||Hispanic female|
11128100|NCT03878719|Experimental|Safety Run-in Phase|"binimetinib taken twice daily (BID) and
~encorafenib taken once daily (QD)
~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol."
11128101|NCT03878719|Experimental|Expansion Phase|"binimetinib taken twice daily (BID) and
~encorafenib taken once daily (QD)
~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol."
11128102|NCT03878706||GLP1 and SGLT2i group|40 patients treated with a combination of liraglutide and empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
11128103|NCT03878706||GLP1 group|40 patients treated with liraglutide.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
11128104|NCT03878706||SGLT2i group|40 patients treated with empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
11128105|NCT03878706||Control group|40 patients treated with insulin and metformin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
11128106|NCT03878693|Experimental|A|Oral APAP and IV Fomepizole.
11128107|NCT03878693|Active Comparator|B|Oral APAP.
11128108|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
11128109|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
11128110|NCT03878667|Placebo Comparator|No Diet|No diet or exercise or calcium intervention
11128111|NCT03878667|Experimental|High Calorie Diet|High calorie (2,600 calorie) diet and exercise and calcium
11128112|NCT03878667|Experimental|Low Carbohydrate/High Protein Diet|Low carbohydrate (63% protein, 7% carbohydrate, 30% fat) diet and exercise and calcium
11128113|NCT03878667|Experimental|High Carbohydrate/Low Protein|High carbohydrate (15% protein, 55% carbohydrate, 30% fat) diet and exercise and calcium
11128114|NCT03878654|Experimental|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
11128115|NCT03878641|Experimental|Children in Grade 1 to 5 with literacy and language needs|The investigators intend to identify children in Grade 1 to 5 who demonstrate language-based learning difficulties. Using the two-stage screening, the investigators will identify children who produce substantial number of reading miscues and/or self-correct more less 25% of their miscues, and/or who present weaknesses in expressive language skills with a total CUBED score lower than grade-specific cut scores.
11128116|NCT03878628|Experimental|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
11128117|NCT03878615||Elective Hepatic Surgery|Patientes undergoing elective hepatic resection, managed according to departement routine.
11128118|NCT03878602|Active Comparator|Control Group|Newborns will be subjected to umbilical cord immediate clamping
11128119|NCT03878602|Experimental|Study Group|Newborns will be subjected to umbilical cord delayed clamping
11128120|NCT03878589|Active Comparator|Oxytocin Crossover Placebo Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of oxytocin (OT) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of placebo (P) twice a day will be self-administered.
11128121|NCT03878589|Active Comparator|Placebo Crossover Oxytocin Group|During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of placebo (P) twice a day at home, at 8-9AM and again at 5-6PM. After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of oxytocin (OT) twice a day will be self-administered.
11128157|NCT03878368|Active Comparator|Control|32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
11128122|NCT03878576|Active Comparator|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
11128123|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
11128124|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
11128125|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
11128126|NCT03878563||ascites with/without SBP|Cirrhosis with ascites and existing SBP or prior SBP
11128127|NCT03878563||ascites and decreased protein concentrati|Cirrhosis with ascites and decreased protein concentration <1,5 g/d
11128128|NCT03878563||ascites and normal protein concentration|Liver cirrhosis witha scites and protein concentration >1,5 g/d
11128129|NCT03878563||Liver cirrhosis without ascites|Patients with liver corrhosis without ascites
11128130|NCT03878563||Healthy controls without liver cirrhosis or other pathology|Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy
11128131|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
11128132|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
11128133|NCT03878524|Experimental|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.
~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health & Science University (OHSU).
~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
11128134|NCT03878511|Experimental|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
11128135|NCT03878511|Placebo Comparator|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
11128136|NCT03878485|Experimental|Stereotactic MRI-guided Adaptive Radiotherapy|-Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
11128137|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1|
11128138|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib|
11128139|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
11128140|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
11128141|NCT03878459|Experimental|Intervention|pioglitazone treatment
11128142|NCT03878459|Placebo Comparator|control|subjects will receive placebo
11128143|NCT03878446|Experimental|0.24 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
11128144|NCT03878446|Experimental|0.20 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
11128145|NCT03878446|Experimental|0.16 mg/kg somapacitan|Same treatment in main period (13 weeks) and extension period (39 weeks)
11128146|NCT03878446|Active Comparator|0.035 mg/kg Norditropin®|Same treatment in main period (13 weeks) and extension period (39 weeks)
11128147|NCT03878446|Active Comparator|0.067 mg/kg Norditropin®|Same treatment in main period (13 weeks) and extension period (39 weeks)
11128148|NCT03878433|Active Comparator|Drug|Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
11128149|NCT03878433|Placebo Comparator|No Drug|2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
11128150|NCT03878420|Experimental|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
11128151|NCT03878420|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
11128152|NCT03878394|Experimental|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
11128153|NCT03878394|Experimental|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
11128154|NCT03878381|Experimental|Compounded Skin Care Cream|One side of the face will be randomly chosen as the treatment side
11128155|NCT03878381|Placebo Comparator|Placebo|The other side of the face will be randomly chosen as the control
11128156|NCT03878368|Experimental|Intervention|32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
11128838|NCT03873402|Experimental|Nivolumab + ipilimumab placebo|
11128161|NCT03878342|Active Comparator|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
11128162|NCT03878342|Experimental|No Radiotherapy|No Irradiation- Active surveillance
11128163|NCT03878329|No Intervention|standard of care|standard of care treatment
11128164|NCT03878329|Experimental|remote home monitoring|use of telemedicine based remote home monitoring
11128165|NCT03878316|Active Comparator|Intranasal Oxytocin|Oxytocin, 40 U per dose, intranasally twice-daily. One dose is defined as intranasal administration of 0.05 mL per each nostril for a total dose of 0.1 mL. The total daily dose of oxytocin will be 80 U or 0.2 mL.
11128166|NCT03878316|Placebo Comparator|Instrasal Placebo|Identically matched placebo administered intranasally twice-daily. One dose is defined as intranasal administration of 0.05 mL per each nostril for a total single dose of 0.1 mL or 0.2 mL total per day.
11128167|NCT03878303|Experimental|AC0058TA|AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
11128168|NCT03878303|Placebo Comparator|Placebo AC0058TA|Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
11128169|NCT03878290|Experimental|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
11128170|NCT03878290|No Intervention|Control|Treatment as usual
11128171|NCT03878277|Experimental|Cold Brew Coffee|6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.
11128172|NCT03878264|Experimental|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
11128173|NCT03878264|Experimental|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
11128174|NCT03878251|Other|X fragile syndrome patients|
11128175|NCT03878251|Other|Angelman syndrome patients|
11128176|NCT03878251|Other|Rett syndrome patients|
11128177|NCT03878251|Other|Patients with other genetic rare syndromes with intellectual d|
11128178|NCT03878238|Placebo Comparator|Placebo|
11128179|NCT03878238|Experimental|Probiotic|
11128180|NCT03878225|Active Comparator|Ketone Mono Ester|"The ketone mono ester is commercially available dietary supplement beverage named H.V.M.N. Ketone Ester, marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study."
11128181|NCT03878225|Placebo Comparator|Placebo|The placebo beverage will consist of water added with a colorless, bitter flavor enhancer and a sweetening agent (Stevia) to approximate the taste of the KME beverage as closely as possible. The bitter flavor enhancer used is denatonium benzoate (Bitrex®). The placebo beverage will be delivered to patients in bottles identical to those used in the active arm. Patients, investigators and other caregivers will be blinded to treatment allocation until time of database unlock.
11128182|NCT03878212|Experimental|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
11128183|NCT03878212|Active Comparator|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
11128184|NCT03878212|No Intervention|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
11128185|NCT03878199|Experimental|Treatment (CPX-351, ruxolitinib, allogeneic SCT)|See Detailed Description.
11128186|NCT03878186|Experimental|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
11128187|NCT03878186|Other|Usual Care (UC)|Participants will receive Usual Care only
11128188|NCT03878160|Other|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
11128189|NCT03878160|Other|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
11128190|NCT03878160|Other|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
11128191|NCT03878147|Other|HIV infected|HIV infected children
11128192|NCT03878147|Other|HIV exposed uninfected|HIV exposed, uninfected children
11128193|NCT03878147|Active Comparator|HIV unexposed uninfected|HIV unexposed uninfected children (community controls)
11128194|NCT03878134|Active Comparator|Patients|750 male or female, 18 and older patients
11128195|NCT03878121|Experimental|A1|Ad4-Env150KN at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
11128196|NCT03878121|Experimental|A2|Ad4-Env145NFL at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
11128198|NCT03878121|Experimental|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
11128199|NCT03878108|Active Comparator|HCLF diet|high-carbohydrate, low-fat (HCLF) diet.
11128200|NCT03878108|Active Comparator|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
11128201|NCT03878095|Experimental|Treatment (olaparib, ceralasertib)|Patients receive olaparib PO BID on days 1-28 and ceralasertib PO QD on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11128202|NCT03878082|Active Comparator|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
11128203|NCT03878082|Active Comparator|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
11128204|NCT03878082|Placebo Comparator|IVPCA|pain control with IVPCA
11128205|NCT03878069||ERT with ADA|Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
11128206|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
11128207|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
11128208|NCT03878043||Patients without Readmissions|Patients with TSDH who were not readmitted within a 6-month time period following their initial visit.
11128209|NCT03878043||Patients with Readmissions|Patients with TSDH who were readmitted within a 6-month time period following their initial visit.
11128210|NCT03878030||Subjects with spinal muscular atrophy types 2 and 3|Intrathecal nusinersen will be administered to all subjects per FDA approved label.
11128211|NCT03878017|Experimental|skin marking of clipped axillary LN|all eligible patients underwent skin marking of their clipped axillary LN post neoadjuvant chemotherapy to determine the retrieval rate of the clipped nodes
11128212|NCT03878004|Experimental|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
11128213|NCT03878004|Placebo Comparator|Placebo Group|45 people who will receive placebo in the therapeutic scheme
11128214|NCT03877991|Experimental|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
11128215|NCT03877991|Experimental|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
11128216|NCT03877991|Experimental|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
11128217|NCT03877978||Severe traumatized patients|Severe traumatized patients with an Index Severity Score (ISS) ≥ 15 admitted to the trauma center of Edouard Herriot Hospital.
11128218|NCT03877965||Children with single ventricle congenital heart disease|Receiving digoxin per standard of care during the interstage period
11128219|NCT03877952|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
11128220|NCT03877939||Non-pregnant patients|Patients with β-hCG test < 10 UI/L.
11128221|NCT03877939||Patients with viable pregnancy|Patients with β-hCG test > 10 UI/L whose pregnancy is confirmed between gestational weeks 6 and 8.
11128222|NCT03877939||Patients with biochemical pregnancy|Patients with β-hCG test > 10 UI/L and without sac observed.
11128223|NCT03877939||Patients with ectopic pregnancy|Patients with β-hCG test > 10 UI/L whose sac is implantated outside the uterine cavity.
11128224|NCT03877939||Patients with clinical miscarriage|Patients with β-hCG test > 10 UI/L whose sac is implanted inside the uterine cavity, but non-viable pregnancy is confirmed before gestational week 8.
11128225|NCT03877926|Experimental|AV7909 Lot 1|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
11128226|NCT03877926|Experimental|AV7909 Lot 2|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
11128227|NCT03877926|Experimental|AV7909 Lot 3|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. Groups 1 to 3 will each receive one of the three consecutively manufactured lots of AV7909, per the study visit schedule.
11128228|NCT03877926|Active Comparator|BioThrax|Participants meeting the entry criteria will be randomized 2:2:2:1 to one of four study groups. In Group 4, one lot of BioThrax will be administered, per the study visit schedule.
11128229|NCT03877874||Asthmatic children|"Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily
~Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
11128230|NCT03877874||Non-Asthmatic children|no intervention
11128231|NCT03877861||Readiband Sleep Tracking - Patient|This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits.
11128232|NCT03877861||Readiband Sleep Tracking - Control|Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes.
11128233|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.
~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
11128234|NCT03877835|Other|Ropivacaine|SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml
11128734|NCT03874195|Experimental|Intervention|Intervention Arm subjects will receive access to PCforMe.
11128235|NCT03877822|Experimental|Habitual activity and 2 days bed rest|Participants will undergo 2 days of habitual activity and 2 days bed rest
11128236|NCT03877809|Experimental|Open label trial|Sirolimus 0.5 mg tablets
11128237|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
11128238|NCT03877783|Experimental|group of intervention|"participants receive
~personalized advice of a dietician about mediterranean diet
~individualized training program,
~recommendation about optimized pharmacological treatment as in high risk groups for cardiovascular diseases"
11128239|NCT03877783|No Intervention|group of control|"participants receive
~written information about the advantages of a healthy diet
~written information about the advantages of physical activity,
~medical treatment according to the latest version of the national guidelines issued by the Swedish Medical Product Agency"
11128240|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
11128241|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
11128242|NCT03877744|Experimental|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
11128243|NCT03877744|Active Comparator|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
11128244|NCT03877731|Active Comparator|hypertrophic cariomyopathy, isolated septal myectomy|Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy
11128245|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + edge-to-edge|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)
11128246|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + sliding plasty|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)
11128247|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + chordae|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection
11128248|NCT03877731|No Intervention|Arterial hypertension + left ventricular hypertrophy|Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
11128249|NCT03877731|No Intervention|Control|Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
11128250|NCT03877718|Experimental|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
11128251|NCT03877718|Experimental|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
11128252|NCT03877718|Experimental|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
11128253|NCT03877718|Experimental|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
11128254|NCT03877718|Experimental|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
11128255|NCT03877718|Experimental|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
11128256|NCT03877705|Experimental|Dissolving xylitol chewable tablets|Listerine ready tabs 3 times/day
11128257|NCT03877705|Active Comparator|Xylitol chewing gum|Trident original 3 times/day
11128258|NCT03877692|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
11128259|NCT03877692|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
11128260|NCT03877679|Experimental|turmeric paste|Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).
11128261|NCT03877679|Active Comparator|Triamcenolone in orabase|Triamcenolone + na ploycarboxylate
11128262|NCT03877653|Experimental|Interventional|Single arm, active stimulation
11128263|NCT03877653|Placebo Comparator|Placebo|"When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.
~Sites will not have access to WaveCrest programmer. Study devices can only be programmed by Stimwave representatives."
11128264|NCT03877640|Active Comparator|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
11128265|NCT03877640|Sham Comparator|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
11128266|NCT03877627|No Intervention|Negative 1|Patients in this arm will not undergo Pelvic and Peritoneal Lymphadenectomy.
11128267|NCT03877627|Experimental|Negative 2|Patients in this arm will undergo Pelvic and Peritoneal Lymphadenectomy.
11128268|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
11128269|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score<10% will be recognized as the comparison group
11128270|NCT03877601|Experimental|Topical administration of bevacizumab-800CW|The tracer will be topically administered 5 minutes prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform).
11128271|NCT03877588|Other|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
11128272|NCT03877562|Experimental|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
11128273|NCT03877562|Placebo Comparator|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
11128274|NCT03877549|Placebo Comparator|Placebo|10cc 0.0625% bupivacaine
11128275|NCT03877549|Experimental|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
11128276|NCT03877549|Experimental|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
11128277|NCT03877536|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
11128278|NCT03877523|Experimental|Cocarnit|disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg
11128279|NCT03877510|Experimental|Open Label IPX203|Subjects will receive IPX203 140 mg, IPX203 210 mg, IPX203 280 mg, or IPX203 350 mg for approximately 9 months. The dose and dosing frequency will be determined by the investigator.
11128280|NCT03877497|Experimental|SBIRT-A|The screening, brief intervention and referral to treatment (SBIRT) will be adapted and used as the intervention in the experimental arm
11128281|NCT03877497|Active Comparator|INFO-C|The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material
11128282|NCT03877471|Experimental|Low dosage|The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.
11128283|NCT03877471|Experimental|Medium dosage|The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.
11128284|NCT03877471|Experimental|High dosage|The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.
11128285|NCT03877458|Experimental|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
11128286|NCT03877458|Experimental|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
11128287|NCT03877458|Placebo Comparator|Placebo group|Taking 1 Placebo capsule at bed time everyday for three months.
11128288|NCT03877445|Other|Melasma Group exposed left half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
11128289|NCT03877445|Other|Melasma Group exposed right half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
11128290|NCT03877432|Experimental|Dermatome stimulation|Check the effect of improving the function of bladder storage and bladder capacity before and after dermatome stimulation.
11128291|NCT03877406|Active Comparator|Control group|up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor
11128292|NCT03877406|Experimental|Study group|addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents
11128293|NCT03877393|Experimental|PRO-GFD|Probiotic supplementation + gluten-free diet
11128294|NCT03877393|Placebo Comparator|PLA-GFD|Placebo supplementation + gluten-free diet
11128295|NCT03877393|Experimental|PRO-GD|Probiotic supplementation + gluten-containing diet
11128296|NCT03877393|Placebo Comparator|PLA-GD|Placebo supplementation + gluten-containing diet
11128297|NCT03877367|Experimental|Upper Extremity Group, Day 1|"Day 1: This group will receive a pre-test, upper extremity intervention, and post-test.
~Day 2: This group will receive a pre-test, lower extremity intervention, and post-test."
11128298|NCT03877367|Experimental|Lower Extremity Group, Day 2|"Day 1: This group will receive a pre-test, lower extremity intervention, and post-test.
~Day 2: This group will receive a pre-test, upper extremity intervention, and post-test."
11128299|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
11128300|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
11128301|NCT03877328|Experimental|Virtual Coach|BiotechCoachForAll
11128302|NCT03877315|Active Comparator|Stemmed|Subjects operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
11128303|NCT03877315|Active Comparator|Non-Stemmed|Subjects operated with stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
11128304|NCT03877302|Experimental|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
11128368|NCT03876860|Active Comparator|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
11128305|NCT03877302|No Intervention|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
11128306|NCT03877289|Experimental|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
11128307|NCT03877289|Placebo Comparator|Placebo|Orasweet liquid placebo
11128308|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
11128309|NCT03877276|Experimental|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
11128310|NCT03877276|Experimental|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
11128311|NCT03877276|Experimental|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
11128312|NCT03877276|Experimental|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
11128313|NCT03877276|Experimental|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
11128314|NCT03877276|Experimental|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
11128315|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
11128316|NCT03877263|Other|OB/GYN physician-collected vaginal swab|"Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.
~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
11128317|NCT03877263|Other|Patient-collected vaginal swab|"Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.
~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
11128318|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
11128319|NCT03877237|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
11128320|NCT03877237|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
11128321|NCT03877224|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
11128322|NCT03877224|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
11128323|NCT03877211|Experimental|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
11128324|NCT03877211|Active Comparator|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
11128325|NCT03877198|Experimental|CLiO2|Automated oxygen control by the CLiO2 algorithm
11128326|NCT03877198|Experimental|Oxygenie|Automated oxygen control by the Oxygenie algorithm
11128327|NCT03877185||3-Injection-Protocol Group|Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).
11128328|NCT03877185||Multiple-Injection- Protocol Group|Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.
11128329|NCT03877172|No Intervention|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
11128330|NCT03877172|Active Comparator|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
11128331|NCT03877146|No Intervention|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
11128332|NCT03877146|Experimental|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
11128333|NCT03877133|Other|Regional oxygen saturation group|Near-infrared spectroscopy application to the skin near the kidney
11128434|NCT03876327|No Intervention|PD patients that will not receive FMT|do not receive treatment-35 patients.
11128334|NCT03877120|Sham Comparator|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.
~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
11128335|NCT03877120|Active Comparator|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
11128336|NCT03877107|Other|single cohort|Participants presenting at least 2/3 of symptom triad : gait disturbance, urinary symptoms and cognitive disturbance Ventricular enlargement non explained by cortical atrophy Cognitive capacity to understand the study and give informed consent (mini mental state > 13), speaking and reading french.
11128337|NCT03877094|Active Comparator|Nature Virtual Reality Video|After signing the Informed Consent Form, the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy. In the end of the procedure, the patient you will receive a Ipad (specific to the study and blocked for other functions) to respond a demographic questionnaire to characterize the sample and the likerts questionnaire to measure their pain, comfort, well-being, stress and anxiety during the procedure.
11128338|NCT03877094|No Intervention|Control group|This control group will not receive an intervention.
11128339|NCT03877081|Experimental|Probiotics. Intervention patients|This patients will receive 2 doses of oral probiotics a day, for seven days
11128340|NCT03877081|Placebo Comparator|Placebo group|This patients will receive 2 doses of oral placebo a day, for seven days
11128341|NCT03877068|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
11128342|NCT03877068|Active Comparator|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, PCP or research teams).
11128343|NCT03877055|Experimental|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
11128344|NCT03877042|Experimental|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
11128345|NCT03877029||Study II|"Women with a screen-detected breast cancer after attending BreastScreen Norway
~Women who have never attended BreastScreen Norway despite of several invitation, and who are diagnosed with symtomatic breast cancer.
~Both groups of women will receive the questionnaire."
11128346|NCT03877029||Study III|"Women with a screen-detected breast cancer after attending BreastScreen Norway
~Women with interval breast cancer after attending BreastScreen Norway
~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway
~Women free from breast cancer"
11128347|NCT03877029||Study IV|"Women with a screen-detected breast cancer after attending BreastScreen Norway
~Women with interval breast cancer after attending BreastScreen Norway
~Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway"
11128348|NCT03877016|Active Comparator|TENS Eco2|TENS Eco2 is the classical device in patients with chronic neuropathic pain
11128349|NCT03877016|Experimental|actiTENS|ActiTENS is a new TENS device, that seems less cotraining.
11128350|NCT03877003|Experimental|Egg Intake|Consumption of 3 eggs per day for breakfast during 4 weeks
11128351|NCT03877003|Experimental|Choline Supplement Intake|Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks
11128352|NCT03876990|Experimental|Multiplex PCR + Current strategy|Results of the multiplex PCR will be send as soon as possible to the infectious disease phycian for quick adaptation of antibiotic treatment. Positive blood cultures will also undergo current diagnosis strategy for bacteremia and fungemia.
11128353|NCT03876990|Active Comparator|Current strategy alone|Current diagnostic strategy based on the identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
11128354|NCT03876977|No Intervention|Non-invasive|Neuropathic drugs Pudendal infiltration
11128355|NCT03876977|Experimental|Robotic laparoscopic decompression|Robotic laparoscopic decompression of pudendal nerve entrapment.
11128356|NCT03876951|Experimental|vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery
11128357|NCT03876938|Active Comparator|aprepitant|aprepitant / dexamethasone/ ondansetron
11128358|NCT03876938|Experimental|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
11128359|NCT03876938|Experimental|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
11128360|NCT03876925|Experimental|CT053PTSA|60-100mg
11128361|NCT03876912|Experimental|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 2-3 weeks after ADT and at development of CRPC
11128362|NCT03876899|Active Comparator|Evening Primrose Oil|
11128363|NCT03876899|Placebo Comparator|Placebo|
11128364|NCT03876886|Active Comparator|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
11128365|NCT03876886|Experimental|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
11128366|NCT03876873|Experimental|Group A|Head Rotation During Face Mask Ventilation. Step 1: Neutral Position (1 minute), Step 2: Head Rotation (1 minute), Step 3: Neutral Position (1 minute)
11128367|NCT03876873|Experimental|Group B|Head Rotation During Face Mask Ventilation. Step 1: Head Rotation (1 Minute), Step 2: Neutral Position (1 minute), Step 3, Head Rotation (1 Minute)
11128369|NCT03876860|Experimental|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
11128370|NCT03876847||Spontaneous Coronary Artery Disection|The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
11128371|NCT03876847||Control|A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.
11128372|NCT03876834|Experimental|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
11128373|NCT03876834|No Intervention|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
11128374|NCT03876808|Experimental|Convective pre-warming|Undergo convective warming during the preoperative preparations, completed for a minimum of 60 minutes prior to entering the operating room
11128375|NCT03876808|No Intervention|Standard of care|Undergo standard of care, which includes providing each patient with blankets and sheets, as well as more blankets on patient request.
11128376|NCT03876795|Active Comparator|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
11128377|NCT03876795|Experimental|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
11128378|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
11128379|NCT03876769|Experimental|Single dose of CTL019|"Based on the subject's weight one of two possible dose ranges will be prepared for the subject:
~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight
~OR
~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
11128380|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
11128381|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
11128382|NCT03876743|Experimental|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
11128383|NCT03876743|Experimental|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
11128384|NCT03876743|Experimental|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
11128385|NCT03876743|Experimental|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
11128386|NCT03876730||Study group|3-18 aged children with cerebral palsy
11128387|NCT03876717|Experimental|Colesevelam, active arm|"Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.
~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days"
11128388|NCT03876717|Placebo Comparator|Placebo|Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam
11128389|NCT03876704|Experimental|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
11128390|NCT03876704|Active Comparator|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
11128391|NCT03876691||Do not resuscitate|Patients who are suggested to family about a do-not-resuscitate order treatment by physicians.
11128392|NCT03876678|Experimental|Light therapy and oral L. salivarius AP-32|Light therapy and taking 1 L. salivarius AP-32 probiotic capsule two times everyday for 7 days.
11128393|NCT03876678|Experimental|Light therapy and oral B. Animalis subsp. Lactis CP-9|Light therapy and taking 1 B. Animalis subsp. Lactis CP-9 probiotic capsule two times everyday for 7 days.
11128394|NCT03876678|Placebo Comparator|Light therapy and oral placebo|Light therapy and taking 1 placebo capsule two times everyday for 7 days.
11128395|NCT03876665||Focus Group|"Active Duty Air Force, Army and Navy women diagnosed with PCOS.
~Up to three focus groups per service branch will be conducted. Considering attrition for those who may volunteer and not show up for the FG session, the investigators will recruit up to 20 participants per site, with the goal of including a maximum of six participants per FG to maximize individual participation."
11128396|NCT03876652|Experimental|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
11128397|NCT03876652|Active Comparator|DDD-R|Patients with a pacemaker programmed in DDD-R mode
11128398|NCT03876639|Active Comparator|IPM_2/18|Application of formulation IPM_2/18
11128399|NCT03876639|Active Comparator|PAR_2/18|Application of formulation PAR_2/18
11128400|NCT03876626|Other|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
11128435|NCT03876327|No Intervention|healthy people live with PD patients|do not receive treatment-50 participants.
11128436|NCT03876314|Experimental|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
11128401|NCT03876626|Other|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
11128402|NCT03876613|Active Comparator|Turkish music group|Rast makam
11128403|NCT03876613|Active Comparator|classical western music|Vivaldi
11128404|NCT03876613|Active Comparator|soft rock music|Elvis presley
11128405|NCT03876613|Placebo Comparator|control group|No music
11128406|NCT03876600|Experimental|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.
~In this management patient come to hospital one day before this surgical operation and he is operated next day"
11128407|NCT03876600|Active Comparator|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.
~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
11128408|NCT03876587|Experimental|Pyrotinib Maleate combine with Docetaxel|"Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects.
~Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection."
11128409|NCT03876574|Experimental|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
11128410|NCT03876561|Experimental|Prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 sessions per week before stoma closure and 1 sessions per week during 6 weeks following stoma closure. Complementary sessions are allowed if necessary.
11128411|NCT03876561|No Intervention|No intervention|No pelvic floor prehabilitation will be proposed before stoma closure. The pelvic floor prehabilitation will be proposed to patients suffering from LARS
11128412|NCT03876548|Experimental|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
11128413|NCT03876522||Lafora Disease Patients|Documented genetic diagnosis of Lafora disease; clinical diagnosis of Lafora disease and a sibling with a known mutation in EPM2A or EPM2B; clinical diagnosis of Lafora disease and a previously undescribed mutation in EPM2A or EPM2B; asymptomatic siblings if mutation positive prior to enrollment.
11128414|NCT03876509||Impedance Cardiography|Impedance Cardiography
11128415|NCT03876496|Experimental|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
11128416|NCT03876483|No Intervention|Standard of Care|Youth enrolled in care at control facilities will receive current standard of care related to HIV care and transition to adult care.
11128417|NCT03876483|Experimental|Virtual peer support group|Youth enrolled in care at intervention facilities will be invited to participate in a virtual peer support program
11128418|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
11128419|NCT03876457|Experimental|Endovascular Thrombectomy plus Medical Management|
11128420|NCT03876457|Active Comparator|Medical Management|
11128421|NCT03876444|Experimental|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
11128422|NCT03876444|Active Comparator|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
11128423|NCT03876431|Active Comparator|Traditional Exercise Group|Only traditional exercises will be performed in the early post-op period.
11128424|NCT03876431|Experimental|Easy-Flex Group|Easy-Flex group will be treated with the Easy-Flex device in addition to the traditional exercise program.
11128425|NCT03876418|No Intervention|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
11128426|NCT03876418|Active Comparator|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
11128427|NCT03876405|Experimental|sensory feedback|"A non-invasive air-mediated sensory feedback system embedded in the prosthesis socket.
~Group description: Individuals with acquired forearm amputation."
11128428|NCT03876392|Experimental|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
11128429|NCT03876353|Other|Left Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
11128430|NCT03876353|Other|Right Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
11128431|NCT03876340|Active Comparator|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
11128432|NCT03876340|Experimental|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
11128433|NCT03876327|Experimental|PD patients that will receive FMT|fecal microbial transplantation once at the beginning of the study-15 patients.
11128437|NCT03876314|No Intervention|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
11128438|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
11128439|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
11128440|NCT03876262|Experimental|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
11128441|NCT03876262|Experimental|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
11128442|NCT03876262|Active Comparator|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
11128443|NCT03876262|Experimental|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
11128444|NCT03876249||RSV positive group|Children who had RSV infection within the first 60 days of life
11128445|NCT03876249||RSV negative group|Children without known RSV infection within the first 60 days of life
11128446|NCT03876236||Rest|Quiet rest in supine position, 2 hrs.
11128447|NCT03876210|Other|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101
~Number of subject: 23
~Wash out Period: over 7 days (between each period)
~Dosage: Once daily, at 2D each period"
11128448|NCT03876210|Other|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002
~Number of subject: 23
~Wash out Period: over 7 days (between each period)
~Dosage: Once daily, at 2D each period"
11128449|NCT03876197|Experimental|Autologous Adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
11128450|NCT03876197|Placebo Comparator|Placebo|2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
11128451|NCT03876184|Experimental|RMO|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
11128452|NCT03876184|Experimental|G&H|"This group has been allocated with upper and lower round 0.014 G&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
11128453|NCT03876184|Experimental|Orthocare|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
11128454|NCT03876184|Active Comparator|Conventional|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
11128455|NCT03876171|Experimental|CIFFTA|Family Therapy, Individual Therapy, and Psycho-educational Modules
11128456|NCT03876171|Active Comparator|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
11128457|NCT03876158|Active Comparator|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
11128458|NCT03876158|Other|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
11128459|NCT03876145|Experimental|Minimal ovarian stimulation with rec-FSH|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 International Unit (IU) Gonal-f (Follitropin alfa, Merck Serono, Germany) after the seventh day.
11128460|NCT03876145|Experimental|Minimal ovarian stimulation with HMG|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) after the seventh day.
11128461|NCT03876145|No Intervention|Mild ovarian stimulation with rec-FSH|The group of mild ovarian stimulation that will receive 150 IU Gonal-f (Follitropin alfa, Merck Serono, Germany) daily from Day 3 of the menstrual cycle.
11128462|NCT03876145|No Intervention|Mild ovarian stimulation with HMG|The group of mild ovarian stimulation that will receive 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) daily from Day 3 of the menstrual cycle.
11128463|NCT03876119|Experimental|Intraarterial alteplase|Patients within this arm will be given a 30 minutes intraarterial (IA) infusion of alteplase (Actylise®) at a drug concentration of 0.5mg/ml. At 20 minutes of IA treatment onset, the infusion will be temporarily stopped and restarted until completion of the 30 minutes infusion only if the mTICI 2b score has not improved on control angiography. Study drug will be prepared according to the following steps: 1. Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml; 2. Dilute this solution in 30 cc of normal saline, to attain a 60 cc solution at a concentration of 0.5mg/ml; 3. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225) multiplied by 2).
11128464|NCT03876119|Placebo Comparator|Placebo|The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution. Study drug will be prepared according to the following steps: 1. Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml; 2. Dilute this solution in 30 cc of normal saline, to attain a 60 cc solution at a concentration of 0.5mg/ml; 3. Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225) multiplied by 2).
11128465|NCT03876106|Experimental|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
11128466|NCT03876106|Experimental|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
11128467|NCT03876106|Experimental|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
11128468|NCT03876080|Experimental|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
11128469|NCT03876080|Sham Comparator|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
11128470|NCT03876067|Experimental|Ozone Group|in which Ozone will be added to cold blood cardioplegia
11128471|NCT03876067|Placebo Comparator|Control Group|: in which in which only cold blood cardioplegia
11128472|NCT03876054||Spinal cord stimulation (SCS)|Subjects using Abbott SCS systems
11128473|NCT03876054||Dorsal root ganglion stimulation (DRG)|Subjects using Abbott DRG system
11128474|NCT03876041|Active Comparator|dexamethasone group|this group will receive Dexamethasone: 0.1 to 0.3 mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
11128475|NCT03876041|Active Comparator|methylprednisolone group|this group will receive Methylprednisolone: 5-10mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
11128476|NCT03876028|Experimental|Ibrutinib (before leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment before leukapheresis
11128477|NCT03876028|Experimental|Ibrutinib (after leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment after leukapheresis.
11128478|NCT03876015||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
11128479|NCT03876002|Experimental|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of [18F]PBR06 PET to measure microglial activation in brain.
11128480|NCT03875989|Active Comparator|Arm A|
11128481|NCT03875989|Experimental|Arm B|
11128482|NCT03875976|Active Comparator|Fast Track Protocol|Patients treated using Fast Track Care Protocol
11128483|NCT03875976|Active Comparator|Standard Protocol|Patients treated using Standard Care Protocol
11128484|NCT03875963|Experimental|Antibiotic loaded bone filler|Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin]. The concurrent use of antibiotics is at the discretion of the treating physician.
11128485|NCT03875963|No Intervention|Standard of care|Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.
11128486|NCT03875950|Experimental|Training intervention|In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
11128487|NCT03875950|No Intervention|Standard of care control|In this randomized cluster randomized control trial design, the no intervention arm refers to the 12 study sites that are randomly assigned not to receive the clinician training intervention. Instead, these study sites will receive the standard of care, which is no standardized patient actor training, for health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
11128488|NCT03875937|Experimental|Tranexamic acid 1 gram intramuscularly|Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.
11128489|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
11128490|NCT03875911|Active Comparator|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
11128491|NCT03875911|Active Comparator|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
11128492|NCT03875911|Active Comparator|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
11128493|NCT03875898|Experimental|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
11128494|NCT03875898|Placebo Comparator|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
11128495|NCT03875885|Other|CONNECT Intervention Group - Group A|A web-based intervention (CONNECT) to empower and connect caregivers of newly diagnosed cancer patients to supportive care resources A randomized pilot study will be conducted to assess feasibility and acceptability and obtain data on caregiver and patient outcomes. CONNECT e-tool, re-education and optional referral (2 weeks post CONNECT e-tool). Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
11128496|NCT03875885|Other|CONNECT Comparison Group - Group B|Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
11128497|NCT03875872||Group propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
11128498|NCT03875872||Group inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
11128499|NCT03875859|Experimental|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
11128500|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
11128501|NCT03875833|Experimental|Collagen Nerve Wrap Conduit|
11128502|NCT03875833|No Intervention|Control|
11128503|NCT03875820|Experimental|Dose Escalation Phase|"Escalating doses of RO5126766 and VS-6063 will be evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation will follow a 3+3 design with a maximum of four patient cohorts.
~This arm is now complete."
11128504|NCT03875820|Experimental|Dose Expansion KRAS mutant NSCLC Cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).
11128505|NCT03875820|Experimental|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).
~This arm is now complete."
11128506|NCT03875820|Experimental|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with LGSOC (20 patients).
11128507|NCT03875820|Experimental|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with CRC (10 patients).
~This arm is now complete."
11128508|NCT03875807|Active Comparator|0 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 0 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
11128509|NCT03875807|Active Comparator|30 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 30 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
11128510|NCT03875794|Experimental|Osteopathic Manipulation|"This research will be carried out as a prospective, non-randomized pilot study in women aged 18-40 who are 2 weeks to 28 weeks postpartum.
~The intervention investigated in this study is osteopathic manipulation."
11128511|NCT03875781|Experimental|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:
~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
11128512|NCT03875781|Active Comparator|B: Radiochemotherapy|"Active comparator: preoperative radiochemotherapy:
~Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor"
11128513|NCT03875768|Experimental|Intervention|Participants will track their daily dietary intake for six months using an app and will receive automated feedback daily via text message based on DASH nutrients. Participants in-need of coaching based on their adherence to the key nutrients in the DASH dietary pattern or engagement in the intervention will receive responsive digital coaching from Nourish registered dietitians.
11128514|NCT03875768|No Intervention|Control|Participants will receive information about the DASH dietary pattern and will track their daily dietary intake using an app for six months.
11128515|NCT03875755|Experimental|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
11128516|NCT03875755|Placebo Comparator|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
11128517|NCT03875742|Other|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
11128518|NCT03875742|Other|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
11128519|NCT03875729|Experimental|teplizumab|Sterile solution for injection.
11128520|NCT03875729|Placebo Comparator|Placebo|Sterile solution for injection
11128521|NCT03875716|No Intervention|Low Risk|"Pathologic T1-2, N0-1
~Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck
~-≤2 positive lymph nodes confined to level II and/or level III
~No extranodal extension
~Clear margins"
11128522|NCT03875716|Experimental|Intermediate Risk|"Pathologic T1-2N0-2 and any one of the following features:
~->2 positive lymph nodes
~<15 lymph nodes retrieved on neck dissection for each side of the neck
~Positive lymph nodes in level IB, IV, or V
~-≤1mm extranodal extension
~Positive lymph node(s) contralateral to the primary tumor
~Close margins
~Reduced-dose adjuvant radiation therapy"
11128523|NCT03875716|Experimental|High Risk|"Pathologic T1-4N0-2 and any one of the following features:
~->1mm extranodal extension
~Microscopic positive margins
~Adjuvant radiation therapy without chemotherapy"
11128524|NCT03875690|Experimental|Experimental group|
11128525|NCT03875690|Placebo Comparator|Control group|
11128526|NCT03875677|Experimental|HD-tDCS group|Constant current (2mA) will be applied for 20min and the anode will be placed over the defined target area
11128527|NCT03875677|Experimental|Conventional tDCS group|Constant current (2mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
11128528|NCT03875677|Sham Comparator|Sham HD-tDCS group|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
11128529|NCT03875664|Active Comparator|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
11128530|NCT03875664|Placebo Comparator|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
11128531|NCT03875638|Experimental|Early Alzheimer's Disease Group Low Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of low-dose levetiracetam (125 mg twice daily)
11128532|NCT03875638|Experimental|Early Alzheimer's Disease Group High Dose|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of high-dose levetiracetam (500mg twice daily).
11128533|NCT03875638|Placebo Comparator|Early Alzheimer's Disease Group Placebo|Subjects with Alzheimer's Disease will undergo a four-week treatment period consisting of placebo twice daily.
11128534|NCT03875638|No Intervention|Healthy Control Group|A group of demographically similar subjects without Alzheimer's Disease will undergo baseline testing only, without any intervention
11128535|NCT03875625|Experimental|Morbid obesity- Bariatric surgery group|Morbid obese subjects who will consent to bariatric surgery
11128536|NCT03875625|Experimental|Morbid obesity-Dietitian led life style intervention group|Morbid obese subjects who will not consent to bariatric surgery but instead opt for dietitian led life style intervention
11128537|NCT03875625|Experimental|Mild obesity-Dietitian led life style intervention group|Mild- Moderate subjects assigned through a randomized controlled trial to the dietitian led life style intervention
11128538|NCT03875625|Experimental|Mild obesity-Conventional care group (control)|Mild- Moderate subjects assigned through a randomized controlled trial to conventional care
11128539|NCT03875573|Experimental|Chemotherapy and radiotherapy|The combination of weekly paclitaxel 80 mg/m² IV followed by every 2 week dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative Stereotactic Body Radiotherapy on the primary tumour (3x8 Gy or 3x lower dose if recommended after safety run-in).
11128540|NCT03875573|Experimental|Chemotherapy and pre-operative radiotherapy plus durvalumab|The combination of weekly paclitaxel 80 mg/m² IV followed by every 2 week dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy or 3x lower dose if recommended after safety run-in) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg every 4 weeks.
11128541|NCT03875573|Experimental|Chemotherapy & pre-op radiotherapy + durvalumab + oleclumab|The combination of weekly paclitaxel 80 mg/m² IV followed by every 2 week dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy or 3x lower dose if recommended after safety run-in) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg every 4 weeks and the addition of the anti-CD73 antibody oleclumab IV 3000 mg every 2 weeks for 5 cycles, followed by every 4 for 2 cycles.
11128542|NCT03875560|Experimental|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
11128543|NCT03875560|Experimental|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
11128544|NCT03875560|Experimental|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
11128545|NCT03875560|Experimental|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
11128546|NCT03875560|Experimental|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
11128547|NCT03875547||Patients with haemophilia B|Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
11128548|NCT03875521||12 hours|
11128549|NCT03875521||< 12hours|
11128550|NCT03875508|Experimental|Risankizumab autoinjector|Participants will be self-administering risankizumab using a pre-filled autoinjector
11128551|NCT03875495|Experimental|Temferon|"Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene.
~Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny."
11128552|NCT03875482|Experimental|Risankizumab|Participants randomized to receive risankizumab
11128553|NCT03875482|Experimental|Placebo|Participants randomized to receive placebo for risankizumab
11128554|NCT03875469|Experimental|CT patients_Centargo_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
11128555|NCT03875469|Experimental|CT-patients_Stellant_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
11128556|NCT03875469|Experimental|CT-patients_Centargo_2|Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
11128557|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
11128558|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
11128559|NCT03875417||Group A|Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.
11128560|NCT03875417||Group B|Patients who did not develop recurrences after surgery.
11128561|NCT03875404|Experimental|Deep Brain Stimulation subjects|
11128562|NCT03875391|Experimental|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
11128563|NCT03875391|Placebo Comparator|Placebo and trauma film paradigm|Intervention: Drug: Placebos
11128564|NCT03875378|Experimental|Transdermal estrogen/progesterone|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) patch applied weekly for 18 months
11128565|NCT03875378|Placebo Comparator|Placebo|Placebo patch applied weekly for 18 months
11128566|NCT03875365||POPE Patients|Patients who underwent POPE for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus.
11129041|NCT03872128|Placebo Comparator|placebo|30 patients randomly assigned to receive a placebo daily.
11128568|NCT03875352|Experimental|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
11128569|NCT03875339|Active Comparator|Navigator Arm|Examination of adherence to follow-up with a navigator.
11128570|NCT03875339|No Intervention|Non-Intervention Arm|Examination of adherence to follow-up without a navigator.
11128571|NCT03875326|Sham Comparator|Sham Stimulation|Sham (placebo) dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
11128572|NCT03875326|Experimental|1 mA Dosage Stimulation|1 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
11128573|NCT03875326|Experimental|2 mA Dosage Stimulation|2 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
11128574|NCT03875326|Experimental|3 mA Dosage Stimulation|3 milliAmp dose of HD-tDCS treatment for 30 minutes, for between 5-30 sessions.
11128575|NCT03875313|Experimental|Cohort 1: CB-839 and Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken daily
11128576|NCT03875313|Experimental|Cohort 2: CB-839 and Talazoparib|800 mg CB-839 taken twice daily and 1 mg talazoparib taken daily
11128577|NCT03875300|Experimental|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
11128578|NCT03875300|No Intervention|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
11128579|NCT03875287|Experimental|Decitabine and Cedazuridine|Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.
11128580|NCT03875274|Placebo Comparator|Ropivacaine group|Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB
11128581|NCT03875274|Experimental|Ropivacaine and morphine group|Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
11128582|NCT03875261|Experimental|Study arm|Participants are treated with the investigational medical product
11128583|NCT03875248|Other|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
11128584|NCT03875248|Other|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
11128585|NCT03875248|Other|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
11128586|NCT03875235|Experimental|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
11128587|NCT03875235|Placebo Comparator|Placebo Arm|Placebo + Gemcitabine + Cisplatin
11128588|NCT03875209|Experimental|Arm 1: 10E8.4/iMab IV or SC HIV-|Arm 1; Groups A-C; 3 dosing groups: HIV-uninfected individuals
11128589|NCT03875209|Experimental|Arm 2: 10E8.4/iMab IV HIV-|Arm 2; Groups D-F; 3 dosing groups: HIV-uninfected individuals
11128590|NCT03875209|Experimental|Arm 3: 10E8.4/iMab IV HIV+|Arm 3; Groups G-I; 3 dosing groups: HIV-infected individuals with HIV-1 RNA levels between 2,000 and 100,000 copies/mL and cluster of differentiation 4 (CD4)>350 cells/mm3
11128591|NCT03875209|Experimental|Arm 4: 10E8.4/iMab SC HIV-|Arm 4; Groups J and K: HIV-uninfected individuals
11128592|NCT03875196|Experimental|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
11128593|NCT03875196|Experimental|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
11128594|NCT03875183|Experimental|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
11128595|NCT03875183|Experimental|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
11128596|NCT03875183|Experimental|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
11128597|NCT03875183|Placebo Comparator|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
11128598|NCT03875170|Experimental|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
11128599|NCT03875170|Active Comparator|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
11128600|NCT03875157|Experimental|IBI318 DL1|
11128601|NCT03875157|Experimental|IBI318 DL2|
11128602|NCT03875157|Experimental|IBI318 DL3|
11128603|NCT03875157|Experimental|IBI318 DL4|
11128604|NCT03875157|Experimental|IBI318 DL5|
11128605|NCT03875157|Experimental|IBI318 DL6|
11128606|NCT03875157|Experimental|IBI318 DL7|
11128607|NCT03875157|Experimental|IBI318 DL8|
11128608|NCT03875157|Experimental|IBI318 DL7b|
11128609|NCT03875157|Experimental|IBI318 DL8b|
11128610|NCT03875157|Experimental|IBI318 RP2D|
11128611|NCT03875144|Experimental|association of PIPAC and systemic chemotherapy|4 PIPAC of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks alternating with standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
11128612|NCT03875144|Active Comparator|systemic chemotherapy alone|6 cycles of Cisplatin 75mg/m² + Pemetrexed 500mg/m²
11128613|NCT03875118|Experimental|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
11128614|NCT03875118|Active Comparator|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
11128615|NCT03875092|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
11128616|NCT03875092|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
11128617|NCT03875079|Experimental|Part I Safety Run in: RO6874281 + Pembrolizumab|"Cohort 1.1 (CPI naive and experienced melanoma participants):
~Participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.
~Cohort 1.2 (CPI experienced melanoma participants only):
~Participants will receive RO6874281 in combination with Pembrolizumab via an induction and maintenance schedule for RO6874281: QW three times (D1, D8, D15) followed by Q3W dosing (D22 and subsequent). Pembrolizumab is to be administered Q3W, starting on Day 1. Participants will be observed for 2 pembrolizumab cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part III of this study."
11128618|NCT03875079|Experimental|Part II Expansion: RO6874281 + Pembrolizumab|Part II will start once all participants in Part I Cohort 1.1 have completed the observation period. Approximately 34 participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks).
11128619|NCT03875079|Experimental|Part III Expansion: RO6874281 + Pembrolizumab|Part III will start once all participants in Part I Cohorts 1.1 and 1.2 have completed the observation period. Approximately 80 participants will be randomised to receive RO6874281 in combination with Pembrolizumab in either a Q3W or QW/Q3W schedule.
11128620|NCT03875066|Other|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
11128621|NCT03875066|Other|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
11128622|NCT03875053|Experimental|Monitoring device, Quality of Life Assessment, Questionnaire|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
11128623|NCT03875014||group 1|Bipolar hemiarthroplasty grop
11128624|NCT03875014||group 2|Total hip replacement dual mobility group
11128625|NCT03875001|Experimental|BI 1358894|
11128626|NCT03875001|Placebo Comparator|Placebo|
11128627|NCT03874988|Experimental|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
11128628|NCT03874988|Experimental|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
11128629|NCT03874988|Experimental|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
11128630|NCT03874988|Experimental|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
11128631|NCT03874962|Experimental|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
11128632|NCT03874962|No Intervention|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
11128633|NCT03874949|Active Comparator|SEALITE Regular|zinc oxide eugenol sealer
11128634|NCT03874949|Experimental|SEALITE Ultra|zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)
11128635|NCT03874936|Experimental|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
11128636|NCT03874936|Experimental|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
11129042|NCT03872115|Experimental|Setting 1|PDVibe2 set to high frequency and low amplitude
11128637|NCT03874936|Placebo Comparator|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
11128638|NCT03874923|Active Comparator|250 mL of fluid challenge|
11128639|NCT03874923|Experimental|500 mL of fluid challenge|
11128640|NCT03874897|Experimental|CAR-CLDN18.2 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
11128641|NCT03874884|Experimental|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 4 cycles of treatment. An additional 2 cycles of treatment can be given based on clinical benefit achieved and toxicity experienced.
11128642|NCT03874871||Function preserving gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
11128643|NCT03874871||Standard gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
11128644|NCT03874858|Experimental|Nilotinib|Oral 300 mg hard capsules taken once a day
11128645|NCT03874845|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
11128646|NCT03874845|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
11128647|NCT03874832|Experimental|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
11128648|NCT03874832|Experimental|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
11128649|NCT03874832|Experimental|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
11128650|NCT03874832|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
11128651|NCT03874832|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
11128652|NCT03874819|Active Comparator|Control group|Conventional Hemodialysis using a high-flux dialyzer
11128653|NCT03874819|Experimental|Experimental group|Conventional Hemodialysis using a medium cut-of dialyzer
11128654|NCT03874806|Experimental|single|local anesthetic is delivered as a single bolus
11128655|NCT03874806|Active Comparator|continuous|local anesthetic is delivered as a continuous infusion
11128656|NCT03874793|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
11128657|NCT03874793|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
11128658|NCT03874780|Experimental|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
11128659|NCT03874767|Active Comparator|10th floor south|"The unit in this arm will be assigned physical therapists plus mobility technicians in the first month and only physical therapists in the following month.
~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:
~On evaluation, a PT will assign a JH-HLM scale rating to the patient
~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list
~The mobility technician will then see that patient daily, unless the score is <4
~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate
~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
11128660|NCT03874767|Active Comparator|6th floor Round Wing|"The unit in this arm will be assigned only physical therapists in the first month and physical therapists plus mobility technicians in the following month.
~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:
~On evaluation, a PT will assign a JH-HLM scale rating to the patient
~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list
~The mobility technician will then see that patient daily, unless the score is <4
~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate
~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
11128661|NCT03874754|Experimental|The iHBE program group|an intervention group
11128662|NCT03874754|No Intervention|Usual Care (Control group)|A control group
11128663|NCT03874741|Experimental|Arm - Experimental|Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11128664|NCT03874728||Older people at risk of falls|Older people at risk of falls
11128665|NCT03874715|Experimental|Switching arm: Alternative use of SAR341402 and NovoLog|Alternating use of SAR341402 and NovoLog, self-administered by subcutaneous injection at mealtime, starting with NovoLog for the first 4 weeks, then SAR341402 for 4 weeks, followed by NovoLog for 4 weeks and then SAR341402 for the last 4 weeks on top of Lantus as basal insulin.
11128666|NCT03874715|Active Comparator|Non-Switching arm: NovoLog|Continuous use of NovoLog, self-administrated by subcutaneous injection at mealtime, during the 16-week Treatment Period on top of Lantus as basal insulin.
11128667|NCT03874702||Ischemic stroke patients with <4.5 hours of onset .|analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base.
11128668|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
11128669|NCT03874663||Oral HIV Self-testing|Evaluate the acceptability and performance of a directly assisted oral HIV self-testing (HIVST) in a youth population aged 14-24 in Nigeria
11128670|NCT03874650|Experimental|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.
~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:
~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
11128671|NCT03874650|Experimental|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
11128672|NCT03874650|Placebo Comparator|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
11128673|NCT03874637|Experimental|Treatment|Active therapy
11128674|NCT03874637|Sham Comparator|Sham Control|Sham Control
11128675|NCT03874611|Experimental|electrophysiological data from DBS|
11128676|NCT03874598|Experimental|Ear acupuncture|
11128677|NCT03874598|Active Comparator|Psychoeducation|
11128678|NCT03874585|Active Comparator|Standard Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange) and free nicotine replacement.
11128679|NCT03874585|Experimental|Enhanced Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange), free nicotine replacement, and the 6-week text messaging intervention.
11128680|NCT03874572|Experimental|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
11128681|NCT03874559||Arm A|All patients enrolled will be placed in Arm A. Serum blood draw samples will be collected as well as additional data from medical records will be collected. This data includes demographic data, clinical information from notes, radiology images and reports, diagnostic test results, and procedure and pathology reports.
11128682|NCT03874546|Experimental|Prognostic evaluation|Questionnaire at Day1, Day7 and 6 months.
11128683|NCT03874533|Experimental|self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.
~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
11128684|NCT03874520|Experimental|Video triage|The sick child will be assessed on video by the operator at the call-center.
11128685|NCT03874520|No Intervention|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
11128686|NCT03874507|Experimental|Technology-based therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive either virtual reality (VR) or augmented reality (AR) to improve clinical outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step.
11128687|NCT03874507|No Intervention|Standard of Care therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive physical therapy based on his/her providers recommendations to improve outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step
11128688|NCT03874494|Experimental|Brexpiprazole|2-4 mg/day, once daily for 6 weeks, oral administration
11128689|NCT03874494|Active Comparator|Aripiprazole|10-20 mg/day, once daily for 6 weeks, oral administration
11128690|NCT03874481||PCI|Patients who had stent
11128691|NCT03874442|No Intervention|Controls|
11128692|NCT03874442|Experimental|CliniPup|
11128693|NCT03874429|Experimental|T2259|1 drop in each eye 2 to 4 times daily
11128694|NCT03874429|Active Comparator|Vismed Multi|1 drop in each eye 2 to 4 times daily
11128695|NCT03874416|Experimental|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
11128696|NCT03874416|Active Comparator|Control group|Non-specific rehabilitation of working memory, usual therapy.
11128697|NCT03874403|Experimental|NIVATS|Patients receiving Non-intubated VATS with DSA changes
11128698|NCT03874403|Other|Intubated VATS|Patients receiving intubated VATS with DSA changes
11128699|NCT03874390|Experimental|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
11128700|NCT03874390|Active Comparator|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
11128735|NCT03874169||High-Risk of GI Bleed|Patients that have a high risk of having a gastrointestinal bleed upon admission into the ICU based on their medical history and symptoms. These patients will have a biosensor watch, the E4 wristband, placed on them to monitor their vital signs.
11128736|NCT03874156|Active Comparator|Intervention group|Atorvastatin 40 mg once daily
11128701|NCT03874377|Experimental|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
11128702|NCT03874377|Active Comparator|Usual Care|In this arm participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
11128703|NCT03874364|Active Comparator|Lidocaine gel, counselling, monitor|
11128704|NCT03874364|Active Comparator|Lidocaine gel, counselling, no monitor|
11128705|NCT03874364|Active Comparator|Lidocaine gel, no counselling, monitor|
11128706|NCT03874364|Active Comparator|Lidocaine gel, no counselling, no monitor|
11128707|NCT03874364|Placebo Comparator|Lubricating gel, counselling, monitor|
11128708|NCT03874364|Placebo Comparator|Lubricating gel, counselling, no monitor|
11128709|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, monitor|
11128710|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, no monitor|
11128711|NCT03874351|Experimental|Active tDCS|The active tDCS will involve 20-minutes of direct current at intensity of 1.5 milliamperes (mA).
11128712|NCT03874351|Sham Comparator|Sham tDCS|Sham will include 30 seconds of stimulation at 1.5 mA, followed by 0 mA for the remaining time.
11128713|NCT03874338||Colchicine|
11128714|NCT03874338||Placebo|
11128715|NCT03874325|Experimental|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
11128716|NCT03874325|Experimental|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
11128717|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
11128718|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
11128719|NCT03874299||Kidney Transplant Receipients|
11128720|NCT03874286|Experimental|Liver Transplant|Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.
11128721|NCT03874273|Experimental|crizotinib +|Patients with unresectable, relapsed or refractory inflammatory myofibroblastic tumor, receiving crizotinib
11128722|NCT03874260|Experimental|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
11128723|NCT03874260|Placebo Comparator|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
11128724|NCT03874247|Experimental|Pelubiprofen|
11128725|NCT03874247|Placebo Comparator|Pelubiprofen placebo|
11128726|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 1|Subjects will receive 3 single ascending oral doses (SAD) of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 1 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
11128727|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 + placebo in Cohort 2|Subjects will receive 3 SAD of GSK3186899 and 1 dose of placebo as spray dried powder, under fasted conditions on Day 1 of cohort 2 in each of the four treatment periods. In each treatment period GSK3186899 and placebo will be administered in a 3:1 ratio. A wash out period of at least 10 days will be maintained between each treatment period.
11128728|NCT03874234|Experimental|Part A: Subjects receiving GSK3186899 in Cohort 3|Subjects will receive GSK3186899 orally, under fasted condition and fed conditions on Day 1 of cohort 3 in each of the two treatment periods. There will be a wash out period of at least 10 days between each treatment period. A dose level will be determined based on the effect of food on the safety, tolerability and PK of a single dose of GSK3186899, with dose level selected from Cohorts 1 and 2.
11128729|NCT03874234|Experimental|Part B: Subjects receiving GSK3186899|Subjects will receive GSK3186899, orally, twice daily (BID) on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
11128730|NCT03874234|Placebo Comparator|Part B: Subjects receiving placebo|Subjects will receive placebo, orally, BID on Days 1 to 10. Subjects will receive each dose after either fed or fasted conditions. Part B will be initiated based on the review of all safety, tolerability and PK data from Part A.
11128731|NCT03874208|Other|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
11128732|NCT03874208|Other|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
11128733|NCT03874195|Active Comparator|Control|"Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative care)."
11128743|NCT03874117|Other|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
11128744|NCT03874104|Experimental|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
11128745|NCT03874091|Active Comparator|GA group|Patients will receive general anaesthesia for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
11128746|NCT03874091|Experimental|ESP group|Patients will receive general anaesthesia with bilateral ESP block for laparoscopic nephrectomy/NSS/ Hynes Anderson procedures. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
11128747|NCT03874052|Experimental|Treatment (ruxolitinib, venetoclax)|Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
11128748|NCT03874039||Healthy Adults|Healthy adults with no prior diagnosis of atopic dermatitis
11128749|NCT03874039||Atopic Dermatitis|Adults with prior diagnosis of Atopic Dermatitis from board certified dermatologist
11128750|NCT03874026|Experimental|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
11128751|NCT03874013|Experimental|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
11128752|NCT03874013|Active Comparator|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
11128753|NCT03874000|Experimental|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
11128754|NCT03873987|Active Comparator|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
11128755|NCT03873987|Experimental|New Formulation of Oritavancin|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
11128756|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:
~DualDur dark-field microscopic test
~DualDur dark-field automatic microscopic test
~Western blot IgM and IgG
~Bózsik Western blot IgM and IgG
~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG
~DualDur Polymerase chain reaction"
11128757|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:
~DualDur dark-field microscopic test
~DualDur dark-field automatic microscopic test
~Western blot IgM and IgG
~Bózsik Western blot IgM and IgG
~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG
~DualDur Polymerase chain reaction"
11128758|NCT03873961|Experimental|High-intensity laser therapy|The participants received stretching and exercise guidance and underwent the BTL-6000 High Intensity Laser 12 W with 10 mm pen applicator high intensity laser procedures (mode = continuous, power = 7 W, dose = 120 J/cm2, total time= 7 min. 8 sec.) 3 times per week (total of 8 procedures).
11128759|NCT03873961|Active Comparator|Low-level laser therapy|The participants received stretching and exercise guidance underwent the LAS-Expert with laser shower applicator Low-level Laser therapy procedures (785 nm wavelength, 4,0 J/cm2, 35cm2, 6:40 min) 3 times per week (total of 8 procedures).
11128760|NCT03873948||Control|Healthy patients
11128761|NCT03873948||Periodontitis|Patients with periodontal disease
11128762|NCT03873948||Cardiovascular|Patients with cardiovascular disease
11128763|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
11128764|NCT03873935||Control|Healthy subjects
11128765|NCT03873935||Periodontitis|Patients with periodontal disease
11128766|NCT03873935||Cardiovascular|Patients with cardiovascular disease
11128767|NCT03873935||Periodontitis+Cardiovascular|People with both cardiovascular and periodontitis
11128768|NCT03873922|Experimental|Ketogenic diet intervention|Ketogenic meals will be offered for the participants during the trial.
11128769|NCT03873922|No Intervention|Control group|Conventional hospital meals as usual will be offered during the trial.
11128770|NCT03873909|Active Comparator|Fruit Smoothie|Post-prandial study feeding 155-200 g mamey sapote mesocarp, 6 g of soybean oil , crushed ice and 150-200 g of water to reach a total volume of 450 mL. (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin).
11128771|NCT03873909|Active Comparator|Matrix-Free Shake|Post-prandial study feeding 2 g of carotenoid powder formula (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin), 37.5 g of sugar, 75 µg of citric acid, 6 g of soybean oil emulsified into 300 g of water using 3 g of soy lecithin as well as ca. 100 g of crushed ice, yielding a shake volume of 450 mL.
11128772|NCT03873896|Experimental|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
11128773|NCT03873896|Active Comparator|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
11128775|NCT03873883|Experimental|EOS100850 and Pembrolizumab Combination Therapy|Specified dose on specified days
11128776|NCT03873883|Experimental|EOS100850 and SOC Combination Chemotherapy|Specified EOS100850 dose on specified days
11128777|NCT03873870|Experimental|68Ga -DOTATATE PET scan|
11128778|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
11128779|NCT03873844|Experimental|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
11128780|NCT03873831|Active Comparator|Social Skills Control (A-A)|"The children in the A-A condition, a true control, will remain without a dog for the full 10 weeks."
11128781|NCT03873831|Experimental|Social Skills Dog (A-B)|"The A-B condition will involve standard instruction for 5 weeks (A), followed by 5 weeks of group instruction while a therapy dog is present in the room (B)."
11128782|NCT03873831|Experimental|Social Skills Dog (B-A)|"The B-A condition will be identical, except the first 5 weeks of instruction will include the dog, followed by 5 weeks of standard instruction with no dog."
11128783|NCT03873818|Experimental|Treatment (ipilimumab, pembrolizumab)|Patients receive ipilimumab IV over 90 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles for ipilimumab and up to 35 cycles for pembrolizumab in the absence of disease progression or unacceptable toxicity.
11128784|NCT03873805|Experimental|Treatment (PSCA CAR T cells)|Patients may receive lymphodepleting regimen including fludarabine IV on days -5 to -3 and cyclophosphamide IV on days -5 to -3 or on days -4 and/or -3. Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.
11128785|NCT03873792|Other|Allergy pregnant women|
11128786|NCT03873792|Other|Health pregnant women|
11128787|NCT03873779|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
11128788|NCT03873766|Active Comparator|Intrapleural fibrinolytic therapy (IPFT)|"Procedure/Surgery: Pleural Sampling
~Procedure/Surgery: Pleural fluid drainage
~Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.
~Other: Surgical Consultation
~Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.
~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained
~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
11128789|NCT03873766|Active Comparator|Surgery|"Procedure/Surgery: Pleural Sampling
~Procedure/Surgery: Pleural fluid drainage: Chest tube placement
~Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.
~Other: Surgical Consultation
~Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon
~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained
~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
11128790|NCT03873753|Experimental|Oral cleaning|The oral cavity will be clean with gauze and mineral water three times a day.
11128791|NCT03873753|Active Comparator|No oral cleaning|The oral cavity will not be cleaned.
11128792|NCT03873740|Experimental|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
11128793|NCT03873740|Experimental|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
11128794|NCT03873740|Experimental|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
11128795|NCT03873740|Experimental|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
11128796|NCT03873727|Experimental|Prevenar13/ Pneumovax|Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).
11128797|NCT03873727|Placebo Comparator|Placebo / Pneumovax|Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)
11128798|NCT03873714|Experimental|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
11128799|NCT03873688|Experimental|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
11128800|NCT03873688|Sham Comparator|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
11128936|NCT03872778|Experimental|Phase I Cohort II|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 60% ECD for 3 cycles (q6w)"
11128801|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
11128802|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
11128803|NCT03873649||Patients with subacute or chronic hypersensitivity pneumonitis|"Procedures that each subject will undergo include:
~Chest CT scan to determine extent of disease.
~Pulmonary function testing to determine severity of disease.
~Bronchoscopy with lavage.
~Venipuncture."
11128804|NCT03873636|Experimental|Active Stimulation|Active stimulation of targeted brain regions involved in task-switching and dual-tasking.
11128805|NCT03873636|Sham Comparator|Sham Stimulation|Sham stimulation of targeted brain regions involved in task-switching and dual-tasking.
11128806|NCT03873623||Kidney Transplant Recipients|
11128807|NCT03873610|Experimental|Stress and Symptom Management Program 1|
11128808|NCT03873610|Experimental|Stress and Symptom Management 2|
11128809|NCT03873597|Experimental|Tele-coaching + Usual Care|This group will undergo a 12 week physical activity tele-coaching intervention consisting of a step-counter and smartphone application, in addition to usual care. Usual care will also include sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
11128810|NCT03873597|No Intervention|Usual Care|This group will receive sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
11128811|NCT03873532|Experimental|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
11128812|NCT03873532|Active Comparator|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
11128813|NCT03873519|Experimental|Cold North|Group A: Cold color scheme, room facing North
11128814|NCT03873519|Experimental|Cold South|Group B:Cold color scheme, room facing South
11128815|NCT03873519|Experimental|Warm North|Group C: Warm color scheme, room facing North
11128816|NCT03873519|Experimental|Warm South|Group D: Warm color scheme, room facing South
11128817|NCT03873506|Experimental|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
11128818|NCT03873493|Experimental|Venetoclax + Ibrutinib|Venetoclax 400 mg, potentially up to 600 mg, orally once daily (QD) plus Ibrutinib 420 mg dosed orally QD.
11128819|NCT03873480|Active Comparator|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
11128820|NCT03873480|No Intervention|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
11128821|NCT03873467|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
11128822|NCT03873467|Other|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
11128823|NCT03873454|Active Comparator|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
11128824|NCT03873454|Other|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
11128825|NCT03873454|Other|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
11128826|NCT03873441|Experimental|Computer Games-Aided Balance Training Group|The participants in CGR group will be asked to sit or stand (as per the screening result) on fixed & compliant surfaces; to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects using bi-manual grip gradually progressing to head rotations (mouse mounted on a cap worn by participant); finally using trunk movements as a part of experimental therapy protocol. While performing CGR; children will be standing on a thin pressure mat (placed over fixed or compliant surface). This will allow us to record the information of COP displacement [body sway] while CGR intervention implementation. This information will be used to quantify therapy dosage. The CGR Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
11128827|NCT03873441|Active Comparator|Conventional Balance Training Group|The control group will be receiving the conventional balance training for static and dynamic balance function improvement. The therapy will be provided in sitting or standing (as per the screening result) in a graded manner progressing from fixed surfaces to movable compliant surfaces. The Conventional Balance Training Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
11128828|NCT03873428|Other|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
11128829|NCT03873415|Experimental|Formulation A|Dosage formulation and area of release varies between arms
11128830|NCT03873415|Experimental|Formulation B|Dosage formulation and area of release varies between arms
11128831|NCT03873415|Experimental|Formulation C|Dosage formulation and area of release varies between arms
11128832|NCT03873415|Experimental|Formulation D|Dosage formulation and area of release varies between arms
11128833|NCT03873415|Experimental|Formulation E|Dosage formulation and area of release varies between arms
11128834|NCT03873415|Experimental|Formulation F|Dosage formulation and area of release varies between arms
11128835|NCT03873415|Experimental|Formulation G|Dosage formulation and area of release varies between arms
11128836|NCT03873415|Experimental|Formulation H|Dosage formulation and area of release varies between arms
11128837|NCT03873402|Experimental|Nivolumab + ipilimumab|
11128839|NCT03873389||Ocrelizumab|All participants enrolled in the study. All participants will be receiving the treatment of interest (Ocrelizumab)
11128840|NCT03873376|Experimental|Opt-in|Receive offer to order self-sampling kit
11128841|NCT03873376|Experimental|Opt-out|Receive self-sampling kit unsolicited
11128842|NCT03873376|Experimental|Control|Receive open reminder to be screened by physician
11128843|NCT03873363|Experimental|PS|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
11128844|NCT03873363|Active Comparator|CR|Implantation of a cruciate retaining Total Knee Arthroplasty.
11128845|NCT03873350|Experimental|Living kombucha|
11128846|NCT03873350|Placebo Comparator|Heat-sterilized kombucha|
11128847|NCT03873350|No Intervention|Water|
11128848|NCT03873337|Experimental|NRT + Persistence Targeted Smoking Cessation in Schizophrenia|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling with a focus on task persistence.
11128849|NCT03873337|Active Comparator|NRT + Modified Clearing the Air|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling that does not focus on task persistence.
11128850|NCT03873324|Experimental|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.
~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
11128851|NCT03873324|Placebo Comparator|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
11128852|NCT03873311|Experimental|Azacytidine + HAG Regimen|Azacytidine（75mg/m2 ）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) , Cytarabine 10mg/(m2.d), G-CSF 200ug/(m2.d) )
11128853|NCT03873311|Active Comparator|Azacytidine|75mg/m2
11128854|NCT03873298|Experimental|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
11128855|NCT03873298|Experimental|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
11128856|NCT03873285|Experimental|Genodermatosis patients|Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
11128857|NCT03873272|Active Comparator|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
11128858|NCT03873272|Active Comparator|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
11128859|NCT03873272|Placebo Comparator|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
11128860|NCT03873259|Experimental|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
11128861|NCT03873246|Placebo Comparator|Placebo|
11128862|NCT03873246|Active Comparator|OC-01 0.1%|
11128863|NCT03873246|Active Comparator|OC-01 0.2%|
11128864|NCT03873233|Active Comparator|Volume Controlled Ventilation|Volume Controlled Ventilation with Aisys Carestation ventilator and normal endotracheal tube'
11128865|NCT03873233|Active Comparator|Flow Controlled Ventilation|Flow Controlled Ventilation with Evone ventilator and Tritube
11128866|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
11128867|NCT03873207|Experimental|Intervention|Pedal fat grafting followed by PopSole™ offloading device
11128868|NCT03873207|Other|Standard of care|Pedal fat grafting followed by standard post-operative care with padding of the insoles
11128869|NCT03873194|Experimental|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
11128870|NCT03873194|Other|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
11128871|NCT03873155|Experimental|Mindfulness-based cognitive therapy|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
11128872|NCT03873142|Experimental|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
11128873|NCT03873129|Experimental|A-CHESS|participant will be using the A-CHESS mobile app for 12 months
11128874|NCT03873116|Experimental|BCX7353 110mg once daily|BCX7353 capsules administered orally once daily
11128875|NCT03873116|Experimental|BCX7353 150mg once daily|BCX7353 capsules administered orally once daily
11128876|NCT03873116|Placebo Comparator|Placebo|Matching placebo oral capsules administered orally once daily
11128877|NCT03873090|Experimental|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
11128878|NCT03873077|No Intervention|intravenous analgesia|Patient receives intravenous analgesia: paracetamol 30 mg/kg, diclofenac 75 mg, clonidine 1 µg/kg and morfine 0,05 mg/kg
11128879|NCT03873077|Other|intravenous analgesia + LIA|Patient receives intravenous analgesia and a local infiltration analgesia in the knee
11128937|NCT03872778|Experimental|Phase I Cohort III|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 80% ECD for 3 cycles (q6w)"
11128880|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
11128881|NCT03873051|Experimental|Challenge-Focused Program|This group will receive the challenge-focused group program
11128882|NCT03873051|Experimental|Rewards-Focused Program|This group will receive the rewards-focused group program
11128883|NCT03873038|Experimental|Part 1, Panel A: MK-2060 (8 mg)|Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.
11128884|NCT03873038|Experimental|Part 1, Panel B: MK-2060 (20 mg)|Participants will receive a single 20-mg dose of MK-2060 via IV infusion.
11128885|NCT03873038|Experimental|Part 1, Panel C: MK-2060 (40 mg)|Participants will receive a single 40-mg dose of MK-2060 via IV infusion.
11128886|NCT03873038|Experimental|Part 2: MK-2060 (25 mg)|Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 4 weeks (Weeks 2-4).
11128887|NCT03873038|Placebo Comparator|Part 1 (Panels A, B, C) and Part 2: Placebo|Part 1: Participants will receive a single dose of placebo via IV infusion. Part 2: Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via infusion weekly for 4 weeks.
11128888|NCT03873025|Experimental|Pembrolizumab and CXD101|"Initial dose ('dose level 0'):-
~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 20mg twice daily PO (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity.
~Reduced dose level ('Dose level -1'; if >1 DLT observed at dose level 0):
~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 given twice daily, 20mg in the morning and 10mg in the evening (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity."
11128889|NCT03873012||OCT-guided group|OCT-guided PCI with EES or BES
11128890|NCT03873012||Angiography-guidance group|Angio-guided PCI with EES or BES
11128891|NCT03872999|Experimental|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
11128892|NCT03872986|Experimental|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
11128893|NCT03872986|Experimental|Giomer only|Beautifil II dental restorative material
11128894|NCT03872986|Experimental|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
11128895|NCT03872986|Experimental|GIC only|Equia forte dental restorative material
11128896|NCT03872973|Experimental|Training Group|Neuromuscular training will be performed in this group for 6 weeks.
11128897|NCT03872973|Experimental|Strobe Group|This group will perform neuromuscular training for 6 weeks with a strobe glasses.
11128898|NCT03872973|No Intervention|Control Group|This group will not perform any neuromuscular training program.
11128899|NCT03872960|Experimental|Intervention Arm: Expedited transfer to a CAC|The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-arrest STE patients. This involves pre-alert of the CAC and strategic delivery of the patient to the catheter laboratory (24 hours a day, 7 days a week). Patients will receive definitive post-resuscitation care: intubation and ventilation, where necessary, targeted temperature management, and goal directed therapies including evaluation and identification of underlying cause of arrest with access to immediate reperfusion if necessary. Prognostication will occur no earlier than 72 hours post-cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest to the designated centre.
11128900|NCT03872960|No Intervention|Control Arm: Current standard of care|The control arm comprises the current standard of pre-hospital advanced life support (ALS) care management for patients with ROSC following cardiac arrest of suspected cardiac aetiology. The patient is conveyed to the geographically closest emergency department. Management thereafter will be as per standard hospital protocols however as in the intervention arm, prognostication is to be delayed in trial patients until at least 72 hours post arrest.
11128901|NCT03872947|Experimental|Arm A: TRK-950 + FOLFIRI|"Colorectal Cancer
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
11128902|NCT03872947|Experimental|Arm B: TRK-950 + Gemcitabine/Cisplatin|"Cholangiocarcinoma or Bladder Cancer
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Cisplatin will be administered by infusion. Then, Gemcitabine will be administered as an intravenous infusion."
11128903|NCT03872947|Experimental|Arm C: TRK-950 + Gemcitabine/Carboplatin|"Ovarian Cancer
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on days 1 and 8, Gemcitabine will be administered as an intravenous infusion. On day 1, following the administration of TRK-950 and Gemcitabine, Carboplatin will be administered intravenously."
11128904|NCT03872947|Experimental|Arm D: TRK-950 + Ramucirumab/Paclitaxel|"Gastric Cancer
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Ramucirumab will be administered as an IV infusion. Paclitaxel will be dosed on days 1, 8 and 15, after the Ramucirumab on days 1 and 15 and after the TRK-950 on day 8."
11128905|NCT03872947|Experimental|Arm E: TRK-950 + PD1 inhibitors|"•Solid Tumors
~E-1: TRK-950 + Nivolumab
~•TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.
~E-2: TRK-950 + Pembrolizumab
~•TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
11128906|NCT03872947|Experimental|Arm F: TRK-950 + Imiquimod Cream|"Palpable subcutaneous malignant lesions
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. Imiquimod cream is to be applied 5 of 7 days in a row with 2 days rest for a maximum of 2 cycles (total 6 weeks)."
11128938|NCT03872778|Experimental|Phase I Cohort IV|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 100% ECD for 3 cycles (q6w)"
11128907|NCT03872947|Experimental|Arm G: TRK-950 + Bevacizumab|"Renal Cell Carcinoma
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Bevacizumab will be administered as an IV infusion."
11128908|NCT03872947|Experimental|Arm H: TRK-950 + PD1 inhibitors|"•Melanoma
~H-1: TRK-950 + Nivolumab
~•TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion.
~H-2: TRK-950 + Pembrolizumab
~•TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Pembrolizumab will be administered as an IV infusion."
11128909|NCT03872947|Experimental|Arm I: TRK-950 + Nivolumab/Ipilimumab|"Melanoma
~TRK-950 will be administered intravenously on days 1, 8 and 15 of a 21-day cycle. After the administration of TRK-950 on day 1, Nivolumab will be administered as an IV infusion. In cycles 1 through 4 only, after the infusion of Nivolumab, Ipilimumab will be administered intravenously. This cycle will be repeated for four (4) cycles. Beginning with cycle 5, TRK-950 will be administered on days 1, 8, 15, and 22 of a 28 day cycle. After the administration of TRK-950 on days 1 and 15, Nivolumab will be administered as an IV infusion."
11128910|NCT03872947|Experimental|Arm J: TRK-950 + FOLFIRI|"Colorectal Cancer
~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. On days 1 and 15 Irinotecan will be administered IV. Leucovorin will be infused to match the duration of the irinotecan infusion. 5-FU will be administered as IV bolus, followed by TRK-950 administration. After the TRK-950, 5-FU will be administered by a continuous infusion."
11128911|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
11128912|NCT03872934||classical western music|classical western music (vivaldi)
11128913|NCT03872934||soft rock music|soft rock music (elvis)
11128914|NCT03872934||control group (group not listening music)|control
11128915|NCT03872921|Experimental|norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years
11128916|NCT03872921|Placebo Comparator|Placebo to norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years
11128917|NCT03872908||Cohort 1|Evaluation of patient's satisfaction when wearing surgical gloves (dominant hand) versus chilled gloves (non-dominant hand) at the end of paclitaxel administration.
11128918|NCT03872908||Cohort 2|Evaluation of the efficacy of the compression induced by surgical gloves against peripheral neuropathies in patients treated by oxaliplatine after a 595 mg/m2 cumulated dose.
11128919|NCT03872869|Active Comparator|Hip School|The participants in the Hip School were required to attend three 1.5 hour classes which were conducted by specially trained physiotherapists in premise at Lund University.
11128920|NCT03872869|Active Comparator|Tai Chi for arthritis (TCA)|The treatment intervention with TCA was scheduled in a group setting. Class size for Tai Chi groups was 8- 10 individuals. The group was led by a physiotherapist, specially trained in the concept, in premise at Lund University. The participants in the Tai Chi group were required to attend classes for 12-16 one- hour sessions, twice a week for the first four weeks and then once a week.
11128921|NCT03872869|No Intervention|Control group|
11128922|NCT03872856|Active Comparator|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
11128923|NCT03872856|No Intervention|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
11128924|NCT03872843|Active Comparator|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
11128925|NCT03872843|Active Comparator|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
11128926|NCT03872830|Experimental|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
11128927|NCT03872830|Experimental|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
11128928|NCT03872830|Experimental|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
11128929|NCT03872830|Placebo Comparator|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
11128930|NCT03872817|Experimental|Intervention ProLiSMentAl|"Experimental Group receive mental health literacy psychoeducational intervention called ProLiSMentAl that consist of 4 sessions of 90 minutes."
11128931|NCT03872817|No Intervention|Control Group|Control Group receive usual approach.
11128932|NCT03872804|Experimental|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
11128933|NCT03872791|Experimental|KN046|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment
11128934|NCT03872791|Experimental|KN046 plus nab-paclitaxel|Subjects will receive KN046 at a dose of 3 mg/kg or 5 mg/kg via intravenous infusion on Days 1 and 15 of every 28-day cycle until disease progression, unacceptable toxicity or completion of 2 years of treatment Subjects will receive nab-paclitaxel at a dose of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity
11128935|NCT03872778|Experimental|Phase I Cohort I|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
11128939|NCT03872778|Experimental|Phase I Cohort V|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 120% ECD for 3 cycles (q6w)"
11128940|NCT03872778|Experimental|Phase I Cohort VI|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: 100% ECD for 2 cycles (q6w)"
11128941|NCT03872778|Experimental|Phase IIa|"[68 Ga]-NeoB: 50 micrograms/dose at screening
~[177Lu]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
11128942|NCT03872765|Other|Patients with chronic anal fissure|Use of laser in surgery of chronic anal fissure instead of the conventional surgical techniques.
11128943|NCT03872752|Experimental|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
11128944|NCT03872739|Experimental|distilled water|Oral distilled water at the rate of 3 mL/kg/h rate during undergoing enhanced computed tomography examination before 1-2 and after 4-6 hours
11128945|NCT03872739|Placebo Comparator|Saline|intravenous saline hydration at the rate of 1 mL/kg/h rate during undergoing enhanced computed tomography examination before and after 12 hours
11128946|NCT03872700|Experimental|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
11128947|NCT03872700|Experimental|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
11128948|NCT03872687|Experimental|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size for 6 months.
11128949|NCT03872687|Active Comparator|interdental brushes|Subjects in this group will only receive interdental brushes 6 months.
11128950|NCT03872674|No Intervention|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
11128951|NCT03872674|Experimental|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
11128952|NCT03872661|Experimental|Drug and surgery|Neoadjuvant therapy followed by surgery. Neoadjuvant therapy included four drugs. IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles; bevacizumab was administered at a dose of 15 mg/kg; pemetrexed was given 500 mg/m^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles; carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles. Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
11128953|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
11128954|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
11128955|NCT03872635|Experimental|CHO Drinking Grope|receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
11128956|NCT03872635|No Intervention|Traditional fast Grope|fast on standard hospital protocol (8 hour fasting for solid and 4 hour fasting for clear liquid
11128957|NCT03872622|Other|CD patients|New onset Crohn's disease patients
11128958|NCT03872622|Other|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
11128959|NCT03872596|Experimental|Part A: Sequence 1|"Titration Period:
~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.
~Treatment Period:
~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
11128960|NCT03872596|Experimental|Part A: Sequence 2|"Titration Period:
~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.
~Treatment Period:
~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
11128961|NCT03872596|Experimental|Part A: Sequence 3|"Titration Period:
~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.
~Treatment Period:
~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
11128962|NCT03872596|Experimental|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
11128963|NCT03872596|Experimental|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
11128964|NCT03872583|Experimental|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
11128965|NCT03872583|Active Comparator|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
11128966|NCT03872570|Active Comparator|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
11128967|NCT03872570|Active Comparator|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
11129006|NCT03872349|Experimental|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 7.1% from saturated fat; 20.7% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
11129043|NCT03872115|Experimental|Setting 2|PDVibe2 set to high frequency and medium amplitude
11129044|NCT03872115|Experimental|Setting 3|PDVibe2 set to high frequency and high amplitude
11128968|NCT03872557|Active Comparator|Tyrosine (TYR) depletion, then oral TYR|"TYR supplementation: Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before oral glucose tolerance test (OGTT). On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.
~Visit 2. Placement of intravenous catheter for the collection of serial blood samples and an OGTT with supplementation with oral tyrosine supplement. To supplement the OGTT with Tyrosine, the contents of four (4) L-Tyrosine 500 mg capsule are given 45 minutes before the oral glucose solution is administered. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity."
11128969|NCT03872557|No Intervention|TYR depletion, then no oral TYR|"Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before OGTT. On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.
~Subsequent Visit 3. This visit will consist of placement of intravenous catheter for the collection of serial blood samples and an OGTT without supplementation with oral tyrosine supplement."
11128970|NCT03872531||Cohort 1|Includes age group 3-5 with a cap at 20 subjects. This is a retrospective, observational study
11128971|NCT03872531||Cohort 2|Includes age group 6-10 with a cap at 30 subjects. This is a retrospective, observational study
11128972|NCT03872531||Cohort 3|Includes age group 11-15 with a cap of 30 subjects. This is a retrospective, observational study
11128973|NCT03872531||Cohort 4|Includes age group 16-20 with a cap of 20 subjects. This is a retrospective, observational study
11128974|NCT03872531||Cohort 5|Includes age group 21-30 with a cap at 20 subjects. This is a retrospective, observational study
11128975|NCT03872531||Cohort 6|Includes age group 31-40 with a cap at 20 subjects. This is a retrospective, observational study
11128976|NCT03872531||Cohort 7|Includes age group 41 and over with a cap at 35 subjects. This is a retrospective, observational study
11128977|NCT03872505|Active Comparator|Chemotherapy + Durvalumab|Arm A: Carboplatin, Paclitaxel and Durvalumab
11128978|NCT03872505|Experimental|Chemo + Durvalumab + Radiation Therapy|Arm B: Carboplatin, Paclitaxel and Durvalumab + Radiation Therapy
11128979|NCT03872492|Experimental|Patients with Major Depressive Disorder|"Patients will be followed for 12 weeks. Hospital visits will be made at week 2 and week 6 (Phase1) as well as week 8 and week 12 (Phase 2).
~At the end of phase 1 if the patient is considered as an responder he will make more than one visit at week 12.
~If the patient is considered as non-responder, he will make 2 other visits: at week 8 and week 12.
~Between each visit, the patient will perform REDRESS application assessments every day for My daily survey and every 3 days for the other assessments."
11128980|NCT03872479|Experimental|Adults Low Dose|Single dose of AGN-151587 administered by subretinal injection surgery
11128981|NCT03872479|Experimental|Adults Middle Dose|Single dose of AGN-151587 administered by subretinal injection surgery
11128982|NCT03872479|Experimental|Adults High Dose|Single dose of AGN-151587 administered by subretinal injection surgery
11128983|NCT03872479|Experimental|Pediatric Middle Dose|Single dose of AGN-151587 administered by subretinal injection surgery
11128984|NCT03872479|Experimental|Pediatric High Dose|Single dose of AGN-151587 administered by subretinal injection surgery
11128985|NCT03872453|Active Comparator|Arm 1 - BHV-3500 (zavegepant) 5 mg|One dose of 5 mg
11128986|NCT03872453|Active Comparator|Arm 2 - BHV-3500 (zavegepant) 10mg|One dose of 10 mg
11128987|NCT03872453|Active Comparator|Arm 3 - BHV-3500 (zavegepant) 20mg|One dose of 20mg
11128988|NCT03872453|Placebo Comparator|Arm 4 - Matching BHV-3500 (zavegepant) Placebo|One dose of placebo
11128989|NCT03872440||EGFR T790M patients|EGFR T790M patients who have progressed on osimertinib or other third generation (mutant selective) EGFR TKI therapy
11128990|NCT03872440||EGFR exon 19 del or L858R patients|EGFR exon 19 del or L858R patients who have progressed on first line osimertinib
11128991|NCT03872440||Exon 20 insertion mutations patients|Patients with Exon 20 insertion mutations (n=10; regardless of drug therapy). Includes EGFR Exon 20 and up to two HER2 Exon20 patients
11128992|NCT03872427|Experimental|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11128993|NCT03872414|Experimental|Healthy Younger Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
11128994|NCT03872414|Experimental|Healthy Older Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
11128995|NCT03872414|Experimental|Parkinson Disease Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
11128996|NCT03872414|Active Comparator|Control Group|Participants will receive rt-fMRI training to increase primary auditory cortex activation.
11128997|NCT03872401|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W) for a minimum of 4 years.
11128998|NCT03872401|Experimental|Evolocumab 140 mg Q2W|Participants will receive 140 mg evolocumab by subcutaneous injection once every 2 weeks for a minimum of 4 years.
11128999|NCT03872388|Experimental|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
11129000|NCT03872388|Active Comparator|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
11129001|NCT03872375|Experimental|Intermittent Calorie Restriction + Dietary Counseling|"Participants will be asked to consume a single 530 kilocalorie shake (i.e., High Calorie Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.
~Subjects are also asked to follow RDN dietary recommendations."
11129002|NCT03872375|Active Comparator|Dietary Counseling|A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
11129003|NCT03872362||Training dataset|No interventions
11129004|NCT03872362||External validation1|No interventions
11129005|NCT03872362||External validation2|No interventions
11129007|NCT03872349|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 14.4% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
11129008|NCT03872336|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
11129009|NCT03872336|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
11129010|NCT03872323|Active Comparator|Endovascular treatment|
11129011|NCT03872323|Active Comparator|Open surgery|
11129012|NCT03872310|Active Comparator|Active comparator|Within group
11129013|NCT03872310|Sham Comparator|Sham comparator|Within group
11129014|NCT03872297|Placebo Comparator|Placebo supplement|Consumption of a non active food complement during 3 months.
11129015|NCT03872297|Active Comparator|Naticol supplement|Consumption of the active food complement during 3 months containing Naticol.
11129016|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
11129017|NCT03872271|Experimental|Experimental|ileal pouch-anal anastomosis without diverting loop ileostomy
11129018|NCT03872271|Active Comparator|Control|ileal pouch-anal anastomosis with diverting loop ileostomy
11129019|NCT03872258|Active Comparator|Control|Counseling on physical activity
11129020|NCT03872258|Experimental|Intervention|Add an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle
11129021|NCT03872245|Experimental|PENS T6 + Probiotics|The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
11129022|NCT03872245|Active Comparator|PENS T6|The patients will undergo PENS T6 during 10 weeks.
11129023|NCT03872232|Experimental|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
11129024|NCT03872232|Active Comparator|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
11129025|NCT03872232|Active Comparator|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
11129026|NCT03872219|Placebo Comparator|Placebo|The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.
11129027|NCT03872219|Experimental|intervention arm|The children will receive and they are exposed daily to materials of high microbiological biodiversity.
11129028|NCT03872206|Experimental|HPN536-2001 - Fix Dosing Arm|"Part 1 (Dose Escalation): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion with a fix dose. Dose escalation per cohort until an estimated therapeutic dose level has been reached.
~Part 2 (Dose Expansion):
~Group 1: Eligible patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
~Group 2: Eligible patients with pancreatic adenocarcinoma.
~Group 3: Eligible patients with mesothelioma."
11129029|NCT03872206|Experimental|HPN536-2001 - Step Dosing Arm|Part 1 (Dose Escalation): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion with one or two increasing step dose(s) initially until a target dose as been given. Dose escalation per cohort until an estimated therapeutic dose level has been reached.
11129030|NCT03872206|Experimental|HPN536-2001 - Part 2|Part 2 (Dose Expansion): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant mesothelioma, pancreatic adenocarcinoma or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion.
11129031|NCT03872193|Experimental|Physio Therapy|We intervention this group some routine exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees.
11129032|NCT03872193|Experimental|Virtual Reality|This group had physical therapy program plus virtual reality exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees. And virtual reality exercises were done for this group. Skiing,kayak, football,rafting and jumping activities were done in this exerciese.
11129033|NCT03872180|Experimental|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
11129034|NCT03872167|Active Comparator|MANUAL|Manual titration of non-invasive mechanical ventilation using polysomnography and randomized
11129035|NCT03872167|Active Comparator|AUTOMATIC|Automatic titration of the non-invasive mechanical ventilation using the same device in an automatic mode with assured volume and pressure support.
11129036|NCT03872154|Experimental|Intervention|"In this group (intervention), physicians will conduct checklist-guided shared decision making to determine the patient's code status. Additionally, physicians will be given a decision aid, which they are told to use to illustrate impact and outcome of in-hospital cardiac arrests.
~Ancillary project (patients considered as futile): In this group (intervention), physicians will conduct checklist-guided communication."
11129037|NCT03872154|No Intervention|Usual Care|In this group (control), physicians will conduct code status discussions as usually.
11129038|NCT03872141||patients with stage I-III breast cancer|Patients with Stage I-III breast cancer who will receive paclitaxel or docetaxel treatments as part of their standard of care adjuvant or neoadjuvant therapy are eligible for this study.
11129039|NCT03872128|Active Comparator|patients receiving 300mg PREG|30 patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
11129040|NCT03872128|Active Comparator|patients receiving 500mg PREG|30 patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
11129045|NCT03872115|Experimental|Setting 4|PDVibe2 set to medium frequency and low amplitude
11129046|NCT03872115|Experimental|Setting 5|PDVibe2 set to medium frequency and medium amplitude
11129047|NCT03872115|Experimental|Setting 6|PDVibe2 set to medium frequency and high amplitude
11129048|NCT03872115|Experimental|Setting 7|PDVibe2 set to low frequency and low amplitude
11129049|NCT03872115|Experimental|Setting 8|PDVibe2 set to low frequency and medium amplitude
11129050|NCT03872115|Experimental|Setting 9|PDVibe2 set to low frequency and high amplitude
11129051|NCT03872102||Aim 1: Develop a biomarker of PD disease progression rate|"For Aim 1, we will enroll PD subjects spanning a range of progression rates that have been tracked at UT Southwestern Medical Center.
~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data and known data on clinical progression using statistical techniques to determine a biomarker that associates with progression rate."
11129052|NCT03872102||Aim 2: Develop a biomarker to distinguish between PD, PSP, MSA|"For Aim 2, we will recruit subjects with PD, MSA, and PSP. We will also recruit healthy age/sex-matched controls. All subjects will complete a series of clinical assessments at three different time points, roughly 6-8 months apart:
~Levodopa Equivalent Daily Dose
~Parkinson disease questionnaire
~Schwab and England ADL Scale
~MDS-UPDRS (PD and healthy controls only)
~UMSARS (MSA subjects only)
~PSPRS (PSP subjects only)
~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data from the participants along with prospectively collected information on clinical progression using statistical techniques to determine a biomarker that associates with the differentiation of PD, MSA, and PSP."
11129053|NCT03872089|Experimental|Study participants|Measurements of the temperature of the plantar arch by thermal imaging. Result analysis regarding podologic grade ( 0-1-2-3)
11129054|NCT03872076|Experimental|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
11129055|NCT03872076|Active Comparator|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
11129056|NCT03872063|Experimental|Myofascial|Each session will last 17 minutes, taking place for 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the technique of myofascial induction and eccentric exercises will be performed.
11129057|NCT03872063|Active Comparator|Eccentric|Each session will have a duration of 9 minutes, taking place during 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the eccentric exercises will be performed.
11129058|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
11129059|NCT03872050||Migraine|Patients who have been diagnosed with migraine
11129060|NCT03872037|Active Comparator|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
11129061|NCT03872037|Experimental|Selective removal of caries and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
11129062|NCT03872024|Experimental|Morbidly obese adult patients|Only one group of patients in the study: morbidly obese adult patients who will have an examination with the XXL probe prototype of the FibroScan 630 Research Model
11129063|NCT03872011|Experimental|Vitamin C,thiamine,hydrocortisone|"The combination of vitamin C, thiamine, hydrocortisone :
~Vitamin C 2g every 6 hours x 5-days Thiamine 200mg every 12 hours x 5-days Hydrocortisone 200mg as a continuous infusion x 5-days"
11129064|NCT03872011|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
11129065|NCT03871998|Experimental|Interventional arm|Skin barrier protection in the first 2 months of life.
11129066|NCT03871998|No Intervention|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
11129067|NCT03871985|Experimental|Lavage combined with aspiration|Intermittent subglottic secretions lavage combined with aspiration
11129068|NCT03871985|Active Comparator|Pure aspiration|Intermittent subglottic secretions aspiration
11129069|NCT03871972|Experimental|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
11129070|NCT03871959|Experimental|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
11129071|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels > 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
11129072|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was <100 mg/dL and who agreed to participate in the study.
11129073|NCT03871933||AECOPD|acute exacerbation of COPD
11129074|NCT03871933||stable COPD|
11129075|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
11129076|NCT03871907|Active Comparator|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
11129077|NCT03871907|No Intervention|Control|standard cardiac rehabilitation program
11129078|NCT03871894|Active Comparator|Control arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy as per the standard enteral nutritional practice in a critical care setting in cirrhotics till the period admitted in ICU(Intensive care unit) 35-40 Kcal/Kg IBW/day; 1.5-2g protein per kg per day.
11129079|NCT03871894|Experimental|Intervention arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy based on indirect calorimetry measurements till the period admitted in ICU(Intensive care unit)
11129080|NCT03871881||Atrial septal defect|Patients with an open atrial septal defect, diagnosed in childhood
11129081|NCT03871881||Ventricular septal defect|Patients who had surgical closure of a ventricular septal defect in childhood
11129082|NCT03871881||Healthy control|Healthy, young adults matched on age, gender and education
11129083|NCT03871868||study group|In Woman With Myoma Uteri
11129084|NCT03871868||control group|In Woman Without Myoma Uteri
11129085|NCT03871855|Experimental|A:SHR-1702 Dose Escalation|SHR-1702 given intravenously (IV).
11129086|NCT03871855|Experimental|B:SHR-1702 Dose Expansion|SHR-1702 given intravenously (IV).
11129087|NCT03871855|Experimental|C:SHR-1702 and Camrelizumab Dose Escalation|SHR-1702 and Camrelizumab given intravenously (IV).
11129088|NCT03871855|Experimental|D:SHR-1702 and Camrelizumab Dose Expansion|SHR-1702 and Camrelizumab given intravenously (IV).
11129089|NCT03871842|Active Comparator|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
11129090|NCT03871842|Sham Comparator|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
11129091|NCT03871829|Active Comparator|Arm A: Carfilzomib+Dexamethasone (Kd)|Participants will receive carfilzomib 20 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1 and then 70 mg/m^2 on Days 8 and 15 of Cycle 1 and thereafter on Days 1, 8, 15 of Cycle 2 onwards. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
11129092|NCT03871829|Experimental|Arm B: Dara-SC in combination with Kd (DKd)|Participants will receive daratumumab subcutaneous (Dara-SC) 1800 mg by SC injection on Days 1, 8, 15, 22 for Cycle 1 and 2, Days 1 and 15 for Cycle 3-6, Day 1 for Cycle 7 onwards. Participants will receive carfilzomib 20 mg/m^2 IV on Cycle 1 Day 1 and then 70 mg/m^2 on Day 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
11129093|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
11129094|NCT03871803|Active Comparator|Arm A|"Controlled Withdrawal of Beta-blockers and Cardiopulmonary Exercise Testing (CPET) Patient will be assessed for chronotr0pic incompetence by CPET. If the patient exhibits chronotropic incompetence, we will reduce half dose of previous beta-blocker.
~A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day.
~After second CPET, the patient will introduce the half-dose of beta-blocker and will be evaluated in 3 days. If clinical stability, the patient will introduce the previous dose of beta-blocker A third CPET will be performed at 15-day"
11129095|NCT03871803|Active Comparator|Arm B|"Cardiopulmonary Exercise Testing (CPET) and Controlled Withdrawal of Beta-blockers Patient will be assessed for chronotropic incompetence by CPET.If the patient exhibits chronotropic incompetence, a cardiologist will evaluate clinically the patient and the heart rate in 3 days and will be assessed by CPET at 15-day.
~After second CPET, the patient will reduce half dose of previous beta-blocker. A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day."
11129096|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
11129097|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
11129098|NCT03871777|Active Comparator|Vegetarians|Healthy vegetarians (vegans and lacto-ovo vegetarians) 18 and 50 years formed this arm.
11129099|NCT03871777|Sham Comparator|Omnivores|Healthy omnivores with similar characteristics of vegetarians (age, body mass index, gender and physical activity levels) formed this arm
11129100|NCT03871751|Experimental|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
11129101|NCT03871738|Experimental|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
11129102|NCT03871738|No Intervention|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
11129103|NCT03871725|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
11129104|NCT03871712|Experimental|Motivational Interview (MI)|In the MI arm, a NAV case worker will meet the participants after the baseline assessment (electronic questionnaires) and randomisation and conduct the MI. The NAV case-worker will either meet (or call) again after a few weeks (anticipated 2-4 weeks) and conduct another MI.
11129146|NCT03871491|Placebo Comparator|Placebo|By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.
11129147|NCT03871478|Active Comparator|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
11129148|NCT03871478|Active Comparator|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
11129149|NCT03871478|Active Comparator|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.
~Injected at the start of every Mohs excision stage"
11129105|NCT03871712|Active Comparator|Stratified vocational advice intervention (SVAI)|A trained physiotherapist will call the participants after the baseline assessment and randomisation. The SVAI intervention will be stratified due to the participants risk of long term sick leave estimated by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. The low/moderate risk group will receive 1-2 phone calls, and the high risk group will be followed up 2-4 times. The follow-up can include face to face Meetings bewteen the Physical therapist and the participant, and also the employer and general practitioner when needed. The intervention will include an assessment of the participants obstacles for returning to work and help to develop and implement an action plan to overcome obstacles. The physical therapists' will cooperate with other health care providers and employer when needed.
11129106|NCT03871712|No Intervention|Usual follow-up|This arm will be the control group receiving usual NAV follow-up. The other two groups will also receive usual NAV follow-up additionally to the interventions.
11129107|NCT03871699|Experimental|Iron Reposition|The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.
11129108|NCT03871686|Experimental|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
11129109|NCT03871686|No Intervention|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
11129110|NCT03871673|Active Comparator|Cornstarch|Ingestion of cornstarch, the standard treatment for hepatic GSD.
11129111|NCT03871673|Experimental|Sweet Polvilho|Ingestion of sweet polvilho, the starch in study.
11129112|NCT03871660|Other|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
11129113|NCT03871660|Other|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
11129114|NCT03871647||POAF group|Patients who will experience AF at any time during the first six days after the operation.
11129115|NCT03871647||Non POAF group|Patients with a sinus rhythm during the first six days after the operation.
11129116|NCT03871621|Experimental|Previous diabetic medical treatment & Dapagliflozin|Previous diabetic medication add on SGLT2 inhibitor (Dapagliflozin 10 mg) daily for 6 months
11129117|NCT03871621|Active Comparator|Previous diabetic medical treatment & standard care|Previous diabetic medication with drug adjustment by standard diabetes care except SGLT2 inhibitors for 6 months
11129118|NCT03871608||DTM Disorders|Patient with DTM Disorders with Examination of functional etiologies on DTM Disorders and Assessment of symptoms on DTM Disorders
11129119|NCT03871595|Experimental|Test Treatment|Non-fasting state
11129120|NCT03871595|Experimental|Reference Treatment|Fasting state
11129121|NCT03871582||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
11129122|NCT03871569|Active Comparator|telemedecine nursing home|One buccodental teleexpertise at the completion day and a second buccodental teleexpertise at the end of study
11129123|NCT03871569|No Intervention|control nursing home|Only one buccodental teleexpertise at the end of study
11129124|NCT03871556|Experimental|Experimental Group|
11129125|NCT03871543|Other|Part 1|All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1
11129126|NCT03871543|Other|Part 2|All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.
11129127|NCT03871530|Experimental|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
11129128|NCT03871530|Experimental|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
11129129|NCT03871530|Experimental|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
11129130|NCT03871530|Experimental|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
11129131|NCT03871530|Experimental|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
11129132|NCT03871530|Experimental|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
11129133|NCT03871530|Experimental|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
11129134|NCT03871530|Experimental|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
11129135|NCT03871530|Experimental|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
11129136|NCT03871530|Experimental|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
11129137|NCT03871530|Experimental|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
11129138|NCT03871530|Experimental|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
11129139|NCT03871530|Experimental|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
11129140|NCT03871530|Experimental|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
11129141|NCT03871517|Experimental|Indobufen|Drug: Indobufen and aspirin mimetic Day 1: The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg
11129142|NCT03871517|Active Comparator|Aspirin|Drug: Aspirin and Indobufen mimetic Day 1:The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.
11129143|NCT03871504|Experimental|submaximal isometric exercise.|submaximal isometric exercise will be performed.
11129144|NCT03871504|No Intervention|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
11129145|NCT03871491|Experimental|Intervention|The study intervention is a single 2 g dose of directly observed oral azithromycin.
11129215|NCT03871023|Active Comparator|PREVENA Dressing|Negative wound presure applied to third cohort
11129150|NCT03871465|Experimental|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
11129151|NCT03871465|Experimental|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
11129152|NCT03871465|Experimental|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
11129153|NCT03871452|Active Comparator|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
11129154|NCT03871452|Active Comparator|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
11129155|NCT03871439|Experimental|PF-05221304 Formulation A|
11129156|NCT03871439|Experimental|PF-05221304 Formulation B|
11129157|NCT03871413|Active Comparator|Manual repositioning maneuver|Diagnostics and treatment of BPPV with manual repositioning maneuvers. In case of posterior canal involvement, Epley's maneuver will be used. In case of horizontal canal involvement, the log roll maneuver will be used.
11129158|NCT03871413|Experimental|Treatment in mechanical rotational chair (TRV-chair)|"Diagnostics and treatment of BPPV with the use of a TRV chair. In case of posterior canal involvement, Epley's maneuver will be used with the addition of 10 kinetic impulses in each position.
~In case of horizontal canal involvement, the log roll maneuver will be used with the addition of 10 kinetic impulses in each position."
11129159|NCT03871400|Other|NanoMetalene/PEEK|
11129160|NCT03871400|Other|NanoMetalene/Allograft|
11129161|NCT03871387|Experimental|Deep Block Group|"Continuous Rocuronium infusion during surgery
~Maintain TOF = 0 & PTC= 1~2
~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
11129162|NCT03871387|Active Comparator|Moderate Block Group|"Continuous Rocuronium infusion during surgery
~Maintain TOF 1~2
~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
11129163|NCT03871361|Experimental|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.
~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.
~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
11129164|NCT03871348|Experimental|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
11129165|NCT03871348|Experimental|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
11129166|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
11129167|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
11129168|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
11129169|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
11129170|NCT03871322|Active Comparator|Vitamin D group|vitamin D supplementation - time to fracture healing
11129171|NCT03871322|Active Comparator|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
11129172|NCT03871322|Placebo Comparator|Placebo group|Placebo - time to fracture healing
11129173|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
11129174|NCT03871270||Participants|Those with severe chronic illnesses, which included but were not limited to various forms of advanced cancer, blood dyscrasias, graft vs. host disease, and rare genetic conditions.
11129175|NCT03871257|Active Comparator|Arm I (carboplatin, vincristine)|"INDUCTION: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 and vincristine IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive carboplatin IV over 60 minutes on days 1, 8, 15, and 22 and vincristine IV on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity."
11129176|NCT03871257|Experimental|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment is continuous and repeats every 28 days for 27 cycles in the absence of disease progression or unacceptable toxicity.
11129177|NCT03871244|Experimental|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
11129178|NCT03871244|Active Comparator|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
11129243|NCT03870815||CABG|Patients with CAD who undergoing CABG
11129179|NCT03871231|Experimental|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
11129180|NCT03871218|Active Comparator|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
11129181|NCT03871218|No Intervention|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
11129182|NCT03871205|Experimental|Vaccinated group|Neoantigen loaded-DC vaccination will be performed with 6 doses in total, once per week, adjacent lymph-node injection.
11129183|NCT03871192|Experimental|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
11129184|NCT03871192|Active Comparator|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
11129185|NCT03871192|Experimental|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
11129186|NCT03871192|Active Comparator|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
11129187|NCT03871192|Experimental|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
11129188|NCT03871192|Active Comparator|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
11129189|NCT03871153|Other|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
11129190|NCT03871127||Left main coronary disease|
11129191|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
11129192|NCT03871114||Control group|
11129193|NCT03871101|Active Comparator|Scalpel|Soft tissue incision with scalpel in second- stage implant surgery.
11129194|NCT03871101|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz H mode, 10% water and 10% air) in second-stage implant surgery.
11129195|NCT03871088|Active Comparator|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
11129196|NCT03871088|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
11129197|NCT03871088|Active Comparator|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
11129198|NCT03871075|Experimental|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
11129199|NCT03871075|Experimental|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
11129200|NCT03871075|Active Comparator|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
11129201|NCT03871075|Active Comparator|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
11129202|NCT03871062|Active Comparator|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
11129203|NCT03871062|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
11129204|NCT03871049|Placebo Comparator|group 1|intathecal bupivacaine
11129205|NCT03871049|Active Comparator|group 2|intrathecal bupivacaine with dexamethasone
11129206|NCT03871036|Experimental|Tremelimumab 75 (R1)|"Run-in phase-1 (R1): n=3 patients will be treated with:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 75 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
11129207|NCT03871036|Experimental|Tremelimumab 225 (R2)|"Run-in phase-2 (R2): n=3 patients will be treated with:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 225 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
11129208|NCT03871036|Experimental|Tremelimumab vs Tremelimumab+Durvalumab (R3)|"Run-in phase-3 (R3): n=2 x 3 patients will be randomized over 2 arms:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45
~OR
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 75 mg on day 1 of cycles 2-5
~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
11129209|NCT03871036|Experimental|Tremelimumab 300 (R4)|"Run-in phase-4 (R4): n=3 patients will be treated with:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 300 mg once on day 1 of cycle 2
~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
11129210|NCT03871036|Experimental|Tremelimumab 750 (A)|"Arm A:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
11129211|NCT03871036|Experimental|Tremelimumab+Durvalumab (B)|"Arm B:
~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6
~tremelimumab 300 mg once on day 1 of cycle 2
~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
11129212|NCT03871036|Experimental|Tremelimumab without paclitaxel (C)|"Arm C (control arm):
~• tremelimumab 750 mg on day 1 of cycles 1-5 and then every 12 weeks until week 41"
11129213|NCT03871023|Active Comparator|Simple dressing|Standard, waterproof dressing applied to wound
11129214|NCT03871023|Active Comparator|PICO Dressing|Negative Wound pressure applied second cohort
11129216|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
11129217|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
11129218|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
11129219|NCT03870997|Experimental|Diabetes Digital Intervention|
11129220|NCT03870997|Experimental|Generic Digital Intervention|
11129221|NCT03870997|No Intervention|No Influenza Vaccination Intervention|
11129222|NCT03870984|Experimental|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
11129223|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
11129224|NCT03870958|Experimental|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
11129225|NCT03870958|Active Comparator|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
11129226|NCT03870945|Experimental|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
11129227|NCT03870945|Experimental|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
11129228|NCT03870932|Experimental|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
11129229|NCT03870932|Active Comparator|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
11129230|NCT03870919|Other|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks. After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
11129231|NCT03870906|Experimental|WhatsApp interaction|Individual and group chat interactions.
11129232|NCT03870906|Placebo Comparator|Text message|Regular text messages with similar frequency to those in the Intervention group.
11129233|NCT03870893|Experimental|Intervention group|Intervention is administered to patients in this Arm.
11129234|NCT03870893|No Intervention|control group|No intervention
11129235|NCT03870880|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during the open label extension.
11129236|NCT03870880|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during the open label extension.
11129237|NCT03870867||Seniors who have fallen|Emergency department patients over the age of 65 who present to the emergency department after a fall.
11129238|NCT03870854|Experimental|PEFA targeted substrate ablation|Use of PEFA strategy to identify and target VT isthmuses.
11129239|NCT03870841|Experimental|PC945|PC945 5mg once daily
11129240|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.
~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
11129241|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
11129242|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
11129244|NCT03870815||PCI|Patients with CAD who undergoing PCI with second-generation DES
11129245|NCT03870789||Retrospective|The Investigators will examine data from 1-year prior to paramedic implementation of the Hamilton Early Warning Score tool.
11129246|NCT03870789||Prospective|The Investigators will examine data from 1-year after paramedic implementation of the Hamilton Early Warning Score tool.
11129247|NCT03870776|Placebo Comparator|Placebo|Patients will receive the placebo during 42 days.
11129248|NCT03870776|Experimental|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
11129249|NCT03870776|Experimental|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
11129250|NCT03870763|Experimental|Dimethyl Fumarate 240 mg|Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
11129251|NCT03870763|Experimental|Peginterferon Beta-1a 125 µg|Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
11129252|NCT03870763|Placebo Comparator|Placebo|Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
11129253|NCT03870750|Experimental|Arm I (SPC)|Patients undergo SPC on days -15 before to +56 after transplant. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
11129254|NCT03870750|Experimental|Arm II (CMC)|Patients undergo a CMC program on days -15 to 56. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT..
11129255|NCT03870750|Experimental|Arm III (SPC and CMC)|Patients undergo interventions as outlined in Arm I and Arm II. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
11129256|NCT03870750|Active Comparator|Arm IV (standard of care)|Patients receive standard of care. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT.
11129257|NCT03870737|Experimental|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
11129258|NCT03870711|Experimental|group A|10% lidocaine spray
11129259|NCT03870711|Placebo Comparator|group B|sterile water
11129260|NCT03870698|Experimental|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
11129261|NCT03870698|No Intervention|Open group|The patients who underwent open procedures for periampullary tumors
11129262|NCT03870685|Active Comparator|TAP block with Exparel|Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.
11129263|NCT03870685|Active Comparator|Surgical Site Infiltration of Exparel|Patients will receive surgical site infiltration of Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by surgeon.
11129264|NCT03870672|Active Comparator|CCFES + rTMS facilitating cHMC|"This rTMS paradigm is the New Approach. Facilitation of the intact hemisphere target (cHMC) will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
11129265|NCT03870672|Active Comparator|CCFES + rTMS facilitating iM1|"This rTMS paradigm is the Conventional Approach.Facilitation of M1 will be achieved using 5Hz rTMS. After rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
11129266|NCT03870672|Sham Comparator|CCFES + Sham rTMS|"This rTMS paradigm is the Sham Approach. Immediately after sham rTMS, the participant will participate in one hour of CCFES-mediated functional task practice. The therapist will instruct and guide the participants in practicing functional tasks with their paretic hand with the assistance of CCFES. Tasks will involve using the paretic hand to pick up, manipulate, and release objects commonly used in daily life. Early sessions will focus on simpler tasks, such as practicing opening the hand adequately to acquire an object."
11129267|NCT03870646|Experimental|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
11129268|NCT03870646|Placebo Comparator|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
11129269|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
11129270|NCT03870607|Experimental|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
11129271|NCT03870607|No Intervention|Control group|This group will lead nutritionally based just before starting Ch-RT.
11129272|NCT03870594||diabetic|patients suffer from diabetes mellitus
11129273|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
11129274|NCT03870581|Experimental|AI-SMART group|Participants' warfarin therapy were guided by an AI-based miniprogram embedded in the Wechat social software.
11129275|NCT03870581|Active Comparator|Human-SMART group|Participants' warfarin therapy were guided by an human-based miniprogram embedded in the Wechat social software.
11129276|NCT03870555|Experimental|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.
~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.
~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.
~A washout period of at least 16 days will be maintained between each Treatment Period."
11129277|NCT03870555|Experimental|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.
~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.
~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.
~A washout period of at least 16 days will be maintained between each Treatment Period."
11129278|NCT03870555|Experimental|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.
~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.
~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
11129279|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
11129280|NCT03870529|Experimental|Vitamin A compound|Participants receive vitamin A compound PO for 7 consecutive days in the absence of disease progression or unacceptable toxicity. Within 21 days of completing treatment, participants then undergo surgical resection.
11129281|NCT03870529|Active Comparator|Therapeutic Conventional Surgery|Description Participants undergo surgical resection.
11129282|NCT03870516|Placebo Comparator|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
11129283|NCT03870516|Active Comparator|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
11129284|NCT03870503|Active Comparator|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
11129285|NCT03870503|Active Comparator|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol
11129286|NCT03870503|Active Comparator|Carbetocin|The patient will be received Carbetocin 100 mic gm IV
11129287|NCT03870490|Experimental|Healthy Subjects|VNRX-5133 + cefepime
11129288|NCT03870477|Other|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
11129289|NCT03870464||Prospective arm|Quality of Life questionnaires EORTC-QoL30 and Euro EQ-5D-5L questionnaires are distributed. Blood samples are collected consecutively during ICI and at a follow-up period of one year. CT-scans extended of thorax, abdomen and the lower extremities are performed at baseline and at 6 months. MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.Prospective registration of irAEs are registered during ICI and for one year of follow-up.Enrolment period 1th of April 2018- 31th of January 2020.
11129290|NCT03870451|Experimental|Cohort 1 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
11129291|NCT03870451|Experimental|Cohort 2 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
11129292|NCT03870438|Experimental|Intervention|"Children infected with HIV-1 will be referred to the National Programme for confirmed HIV diagnosis and immediate ART.
~For children that are not HIV-1 infected, the results on the mother's viral load will guide the next steps:
~Mothers with a detectable plasma viral load (≥ 1000 copies/mL): their children will be initiated on lamivudine oral solution.
~Mothers with an undetectable viral loads (<1000 copies/mL): their children will not be initiated on lamivudine oral solution at 6-8 weeks of age. However, additional monitoring on the viral load of the mother and the diagnosis of the child will take place at 6 months: If the maternal plasmatic viral load is ≥ 1000 copies/mL, the child will be initiated on lamivudine oral solution."
11129293|NCT03870438|No Intervention|Control|Routine Option B+ national guidelines including HIV-1 plasmatic viral load testing will be adhered to. Visits will take place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred to the National Programme for confirmed diagnosis and immediate ART.
11129294|NCT03870425|Placebo Comparator|MINCED-SKEWED|Minced meat administered with a skewed protein distribution pattern
11129295|NCT03870425|Experimental|MINCED-EVEN|Minced meat administered with an even protein distribution pattern
11129354|NCT03870230|Experimental|controls|healthy, age and sex matched, control subjects
11129296|NCT03870412|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle.
11129297|NCT03870399|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
11129298|NCT03870386|Experimental|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts < 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts > 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
11129299|NCT03870386|Active Comparator|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
11129300|NCT03870373||Test Subject|neonatal patients undergoing complex cardiac surgical procedures
11129301|NCT03870360|Experimental|HOLA: A Culturally-Tailored Health Promotion Intervention|16 week, multicomponent, health promotion intervention
11129302|NCT03870360|Active Comparator|Healthy lifestyles education program|Educational material on mental health, physical activity, and information on community resources
11129303|NCT03870347||Biliary Dilation Cohort|Patients referred for endoscopic evaluation of biliary dilation
11129304|NCT03870334|Experimental|BT-11 1,000 mg|
11129305|NCT03870334|Placebo Comparator|Placebo|
11129306|NCT03870321|Experimental|Core training|The subjects who are in the experimental group will carry out the Core training routine
11129307|NCT03870321|No Intervention|Control|The subjects who are in the control group will not receive intervention and will continue with their daily routine and training
11129308|NCT03870308|Experimental|Deep Brain Stimulation subjects|
11129309|NCT03870295|Experimental|Patients suffering from polyneuropathies|Type C fibre conduction velocity determination in patients suffering from polyneuropathy
11129310|NCT03870295|Active Comparator|Control patients|Type C fibre conduction velocity determination in control patients
11129311|NCT03870282|Experimental|9h 15m Goal|
11129312|NCT03870282|Experimental|"9h 15m Goal | Texts B"|
11129313|NCT03870282|Experimental|"9h 15m Goal | Texts A"|
11129314|NCT03870282|Experimental|"9h 15m Goal | Texts A&B"|
11129315|NCT03870282|Experimental|"9h 15m Goal | Incentive B"|
11129316|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts B"|
11129317|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A"|
11129318|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A&B"|
11129319|NCT03870282|Experimental|"9h 15m Goal | Incentive A"|
11129320|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts B"|
11129321|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A"|
11129322|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A&B"|
11129323|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B"|
11129324|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts B"|
11129325|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts A"|
11129326|NCT03870282|Experimental|"9h 15m Goal | Incentives A&B | Texts A&B"|
11129327|NCT03870282|Experimental|Personal Goal|
11129328|NCT03870282|Experimental|"Personal Goal | Texts B"|
11129329|NCT03870282|Experimental|"Personal Goal | Texts A"|
11129330|NCT03870282|Experimental|"Personal Goal | Texts A&B"|
11129331|NCT03870282|Experimental|"Personal Goal | Incentive B"|
11129332|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts B"|
11129333|NCT03870282|Experimental|"Personal Goal | Incentive B | Text A"|
11129334|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts A&B"|
11129335|NCT03870282|Experimental|"Personal Goal | Incentive A"|
11129336|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts B"|
11129337|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A"|
11129338|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A&B"|
11129339|NCT03870282|Experimental|"Personal Goal | Incentive A&B"|
11129340|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts B"|
11129341|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts A"|
11129342|NCT03870282|Experimental|"Personal Goal | Incentives A&B | Texts A&B"|
11129343|NCT03870269|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11129344|NCT03870269|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11129345|NCT03870256|Active Comparator|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
11129346|NCT03870256|Active Comparator|Carbetocin|Patient receives 100 mic gm carbetocin IV
11129347|NCT03870243|Active Comparator|Bubble CPAP|10 hospitals will be selected randomly for this arm
11129348|NCT03870243|Active Comparator|Low flow oxygen|10 hospitals will be selected for low flow oxygen therapy
11129349|NCT03870230|Experimental|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
11129350|NCT03870230|Experimental|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
11129351|NCT03870230|Experimental|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
11129352|NCT03870230|Experimental|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
11129353|NCT03870230|Experimental|OHT|patients with ocular hypertension
11129355|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
11129356|NCT03870191|Active Comparator|Twin Block Group|This group will receive twin block injections.
11129357|NCT03870191|Active Comparator|Trigger Point Injection Group|This group will receive trigger point injections.
11129358|NCT03870178|Active Comparator|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
11129359|NCT03870178|Sham Comparator|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
11129360|NCT03870165|Active Comparator|Salmon|After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
11129361|NCT03870165|Experimental|Isolated mixture|After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
11129362|NCT03870152|Experimental|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: an AFB surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further AFB surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
11129363|NCT03870152|No Intervention|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB surveillance at 6, 12, 24, and at 36 months post-randomisation; with further AFB surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
11129364|NCT03870139|Active Comparator|Cerebral stimulation|"Active transcranial direct current stimulation
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the dominant lower limb) and supraorbital cathode (ipsilateral to the dominant lower limb)."
11129365|NCT03870139|Experimental|Combined stimulation 1|"Active peripheral electrical stimulation (PES_sensorial) combined with active transcranial direct current stimulation
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
11129366|NCT03870139|Active Comparator|Peripheral stimulation|"Active peripheral electrical stimulation (PES_motor).
~PES: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
11129367|NCT03870139|Experimental|Combined stimulation 2|"Active sensorial peripheral electrical stimulation (PES_sensorial) combined with active motor peripheral electrical stimulation (PES_motor)
~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level
~PES_motor: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
11129368|NCT03870126|Placebo Comparator|Flavored Beverage Mix 1|Flavored still beverage
11129369|NCT03870126|Experimental|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
11129370|NCT03870126|Experimental|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
11129371|NCT03870126|Experimental|Flavored Beverage Mix 4|Flavored still beverage with caffeine
11129372|NCT03870113|Experimental|Vaccinated group|Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
11129373|NCT03870100|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
11129374|NCT03870100|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
11129375|NCT03870100|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
11129376|NCT03870100|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
11129377|NCT03870100|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
11129378|NCT03870087||Robotic PCI|All subjects treated with CorPath GRX during the PCI procedure.
11129379|NCT03870074||Responders|Patients with improvement of at least one NYHA class after one year from CRT.
11129380|NCT03870074||Non-responders|Patients with no improvement of at least one NYHA class after one year from CRT.
11129381|NCT03870061|No Intervention|Control|
11129382|NCT03870061|Experimental|Treatment|This arm receives the full New Incentives' conditional cash transfer program (All Babies Are Equal Initiative).
11129383|NCT03870048|Active Comparator|tDCS effects on pain and fatigue|tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
11129384|NCT03870048|Placebo Comparator|Sham effects on pain and fatigue|Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
11129385|NCT03870022|Other|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
11129386|NCT03870009|Experimental|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
11129387|NCT03869996|Active Comparator|fast track total knee arthroplasties|patients treated using fast track care protocol
11129388|NCT03869996|Active Comparator|standard care total knee arthroplasties|patients treated using standard care protocol
11129389|NCT03869983|Active Comparator|Active Comparator|Omnipaque™ (iohexol) Injection, 755 mg/mL iohexol (350 mgI/mL)
11129390|NCT03869983|Experimental|Experimental|CE-Iohexol Injection, 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL
11129391|NCT03869970|Active Comparator|Rest|Discharge instructions focused on 24 - 48 hours of rest then symptom guided activity, Fitbit monitored.
11129392|NCT03869970|Active Comparator|mHealth|"Use of the resilience application on a smart phone to assess daily symptoms over 14 days and follow a self directed, symptom guided return to physical activity. Also Fitbit monitored."
11129393|NCT03869970|Active Comparator|Activity|Low intensity activity regardless of symptoms using their Fitbit to measure said activity with goals (eg. 10,000 steps/ day.
11129394|NCT03869970|Active Comparator|Both Activity and mHealth|"This group will receive both interventions and utilize the SuperBetter app. Interventions will be integrated by having research assistants support the subject to set and physical activity goals and milestones to the subject's pre-programmed general resilience goals in the SuperBetter© app (e.g. take a 30 min walk, march in place for 5 minutes, increase my step count by 2000 today, achieve 10,000 steps today)."
11129395|NCT03869957|Experimental|Intervention group|We will use ~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day [Omegaven® ](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
11129396|NCT03869957|No Intervention|Control group|Will be administering ~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
11129397|NCT03869944|Experimental|Intervention|Lamivudine Oral Solution
11129398|NCT03869931|Experimental|Fenofibrate|(Refer to intervention)
11129399|NCT03869918|No Intervention|Usual Care|Participant is assigned to undergo standard of care.
11129400|NCT03869918|Experimental|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
11129401|NCT03869918|No Intervention|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
11129402|NCT03869905|Experimental|Aquamin®|To be taken for 180 days
11129403|NCT03869905|Placebo Comparator|Placebo first then Aquamin®|Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)
11129404|NCT03869892|Experimental|S95005 + Bevacizumab|
11129405|NCT03869892|Active Comparator|Capecitabine + Bevacizumab|
11129406|NCT03869879|Active Comparator|Feedback-assisted physical therapy|During a visual feedback session, therapists will spend 30min per session using the Mobility Rehab system for gait training with patients. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
11129407|NCT03869879|Placebo Comparator|Traditional physical therapy|During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
11129408|NCT03869866|Experimental|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
11129409|NCT03869853|Experimental|intervention|Entrepreneurial stimulation and integrated education
11129410|NCT03869853|Experimental|control|no intervention
11129411|NCT03869827||IUGR|All birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea with isolated intrauterine growth restriction at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2016.
11129412|NCT03869827||Control|To each of these children with intrauterine growth restriction is matched a control child: the child without intrauterine growth restriction of the same gestational age whose date of birth is consecutive to that of the case.
11129413|NCT03869814||Non-cancer|900 asymptomatic individuals without prior history of cancer
11129414|NCT03869814||Cancer|900 individuals with confirmed malignancy
11129415|NCT03869801|Active Comparator|ESP Block|
11129416|NCT03869801|Active Comparator|QLB block|
11129417|NCT03869775||control group|no additional disease
11129418|NCT03869775||working group-1|additional disease only DM and no cardıovascular autonomous neuropathıa
11129419|NCT03869775||working group-2|additional disease only DM and pozitif cardıovascular autonomous neuropathıa
11129420|NCT03869762|Experimental|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.
~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
11129421|NCT03869749|Experimental|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
11129422|NCT03869749|Active Comparator|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
11129423|NCT03869736|Experimental|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
11129424|NCT03869736|Sham Comparator|Placebo|Oxygen-air mixture
11129425|NCT03869723||Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
11129426|NCT03869723||Virtual planning|Fibula free flap in mandibular reconstruction using preoperative virtual planning, cutting guides and osteosynthesis plates. Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
11129427|NCT03869710|Experimental|Dry-Needling|Ultrasound-Guided Dry-Needling Therapy focused on the active and latent myofascial trigger points.
11129428|NCT03869697|Experimental|SCB-313|Cohorts in SAD phase: 5 mg, 10mg, 20mg, 40mg, 80 mg. Cohort in MAD phase: biological effective dose determined from SAD phase. 1 intrapleural injection of SCB-313 on Day 1 for the SAD cohorts, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
11129429|NCT03869684|Experimental|MT-0814 High dose|
11129432|NCT03869671|Experimental|PrEP uptake/adherence intervention|A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
11129433|NCT03869671|Active Comparator|Harm reduction standard of care|Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
11129434|NCT03869632|Experimental|YL-13027|YL-13027 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
11129435|NCT03869619||All enrolled patients|All patient who signed the consent form for participation to the study
11129436|NCT03869593||Patients presenting E. coli and S. aureus bacteremia|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
11129437|NCT03869580||Stent infection|Patients diagnosed with urinary tract infection associated with double J stent
11129438|NCT03869580||No stent infection|Patients with double J stent without infection during the study period
11129439|NCT03869567|Experimental|Cone beam CT|A cone beam CT wll be performed just after thrombectomy on patients with acute ischemic stroke
11129440|NCT03869554|Experimental|Renal disease|detection of Fabry disease
11129441|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
11129442|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
11129443|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
11129444|NCT03869528|Active Comparator|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
11129445|NCT03869528|Experimental|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
11129446|NCT03869515||chILD|The chILD syndrome exists when a child with DLD has had the common causes of DLD excluded as the primary diagnosis and has at least three of the following four criteria: (1) respiratory symptoms (e.g., cough, rapid and/or difficult breathing, or exercise intolerance); (2) respiratory signs (e.g., resting tachypnea, adventitious sounds, retractions, digital clubbing, failure to thrive, or respiratory fail- ure); (3) hypoxemia; and (4) diffuse abnormalities on CXR or a CT scan.
11129447|NCT03869515||Control|Healthy subjects were recruited from participants of an ongoing prospective birth cohort study: 'The Pulmonary Function Assessment for Bronchopulmonary Dysplasia (BPD) and Recurrent Lower Respiratory Tract Infections (LRTI) in Chinese Children'. Exclusion criteria were major birth defects, upper airway pathology, cardiac or neurological diseases, failure to thrive, a history of severe respiratory disease with intensive care unit admission, previous physician-diagnosed LRTI, gestational age (GA) <37 weeks or birthweight (BW) <2.5 kg.
11129448|NCT03869489|Experimental|Anodal left dorsolateral prefrontal cortex tDCS stimulation|
11129449|NCT03869489|Experimental|Anodal right dorsolateral prefrontal cortex tDCS stimulation|
11129450|NCT03869489|Sham Comparator|Sham tDCS stimulation|
11129451|NCT03869476|Experimental|BioscoreSMP cohort|
11129452|NCT03869463|Experimental|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function & processing speed.
11129453|NCT03869463|Active Comparator|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
11129454|NCT03869463|Placebo Comparator|Waitlist Control|This group will not receive cognitive training during study participation.
11129455|NCT03869450|Experimental|Restylane Volyme|According to the treatment algorithm, treated with Restylane Volyme
11129456|NCT03869450|Experimental|Restylane Defyne|According to the treatment algorithm, treated with Restylane Defyne
11129457|NCT03869450|Experimental|Restylane Lyft Lidocaine|According to the treatment algorithm, treated with Restylane Lyft Lidocaine
11129458|NCT03869437|Experimental|Cefiderocol|Participants will receive Cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for up to 14 days
11129459|NCT03869437|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and intravenously administered per country-specific guidelines
11129460|NCT03869424|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
11129461|NCT03869424|No Intervention|No-treatment control group|Participants do not receive the nasal spray.
11129462|NCT03869411|Experimental|aerobic exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
11129463|NCT03869411|Experimental|home exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness.The home exercise group will give the exercise recommendation based on ACSM's guideline, and it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
11129464|NCT03869411|Active Comparator|health control group|This study will recruit subjects without type 2 diabetes and the age matched to the diabetes groups.
11129465|NCT03869398|No Intervention|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
11129466|NCT03869398|Experimental|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
11129467|NCT03869385|Experimental|Albumin group|Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
11130846|NCT03859882|Placebo Comparator|placebo|in 2 administration (08:00 and 14:00) per day
11129468|NCT03869385|No Intervention|Control group without albumin:|The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.
11129469|NCT03869372|Experimental|Healthy subjects|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.
~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
11129470|NCT03869372|Experimental|Subjects with IBS|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.
~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
11129471|NCT03869372|Experimental|Subjects with FD|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.
~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
11129472|NCT03869359|Experimental|Group A|Gluten-free diet with placebo powder vs Gluten-free diet with gluten powder
11129473|NCT03869359|Experimental|Group B|Gluten-free diet with gluten powder vs Gluten-free diet with placebo powder
11129474|NCT03869346||GG|wild-type homozygote (CYP3A4*1/*1, GG)
11129475|NCT03869346||GA|mutant heterozygote (CYP3A4*1/*1G, GA),
11129476|NCT03869346||AA|mutant homozygote (CYP3A4*1G/*1G, AA)
11129477|NCT03869333|Experimental|Group A: 2.5ug InvaplexAR-Detox or Placebo|3 intramuscular injections of 2.5ug InvaplexAR-DETOX (16 participants) or placebo (4 participants)
11129478|NCT03869333|Experimental|Group B: 10ug InvaplexAR-Detox or Placebo|3 intramuscular injections of 10ug InvaplexAR-DETOX (16 participants) or placebo (4 participants)
11129479|NCT03869333|Experimental|Group C: 25ug InvaplexAR-Detox or Placebo|3 intramuscular injections of 25ug InvaplexAR-DETOX (16 participants) or placebo (4 participants)
11129480|NCT03869320|Experimental|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
11129481|NCT03869320|Placebo Comparator|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
11129482|NCT03869320|Experimental|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
11129483|NCT03869320|Placebo Comparator|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
11129484|NCT03869307|Experimental|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
11129485|NCT03869307|Active Comparator|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
11129486|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
11129487|NCT03869281||PTA|patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
11129488|NCT03869281||Controls|outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
11129489|NCT03869268|Active Comparator|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).
~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
11129490|NCT03869268|Active Comparator|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).
~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
11129491|NCT03869268|Active Comparator|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).
~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
11129492|NCT03869268|Active Comparator|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).
~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
11129493|NCT03869268|Active Comparator|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).
~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
11129494|NCT03869268|Active Comparator|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.
~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
11131823|NCT03853304|Active Comparator|Double-fortified salt (DFS)|Salt fortified with iron and iodine
11129495|NCT03869268|Active Comparator|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).
~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
11129496|NCT03869268|Active Comparator|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.
~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
11129497|NCT03869255||Hospitalized patients|Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
11129498|NCT03869255||Community patients|"People coming to donate blood in Etablissement Français du Sang will be included and a nasal swab will be performed"
11129499|NCT03869242|Experimental|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
11129500|NCT03869242|Active Comparator|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
11129501|NCT03869229|Active Comparator|osteoarthritis of the knee|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
11129502|NCT03869229|Active Comparator|osteoarthritis of the hip|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
11129503|NCT03869229|Active Comparator|osteoarthritis of the glenohumeral joint|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
11129504|NCT03869216|Experimental|Intervention|Patients in the intervention will receive the educational intervention
11129505|NCT03869216|No Intervention|Usual Care|Patients in the control arm will receive usual care
11129506|NCT03869203|Experimental|Enhanced recovery after surgery (ERAS) patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the ERAS perioperative care.
11129507|NCT03869203|No Intervention|Control patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the traditional perioperative care.
11129508|NCT03869190|Active Comparator|Atezolizumab (Stage 1)|Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129509|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin (Stage 1)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129510|NCT03869190|Experimental|Atezolizumab + Niraparib (Stage 1)|Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129511|NCT03869190|Experimental|Atezolizumab + Hu5F9-G4 (Stage 1)|Participants will receive atezolizumab and Hu5F9-G4 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129512|NCT03869190|Experimental|Atezolizumab + Tiragolumab (Stage 1)|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129513|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan (Stage 1)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129514|NCT03869190|Experimental|Atezolizumab + Tocilizumab (Stage 1)|Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129515|NCT03869190|Experimental|Atezolizumab + RO7122290 (Stage 1)|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129516|NCT03869190|Experimental|RO7121661 (Stage 1)|Participants will receive RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129517|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin (Stage 2)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129518|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan (Stage 2)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
11129519|NCT03869177|Other|Intervention arm|Clusters (psychiatric outpatient clinics) in the intervention arm receives a comprehensive implementation support program during the trial period.
11129520|NCT03869177|No Intervention|Control arm|Clusters (psychiatric outpatient clinics) in the control arm receives no implementation support during the trial period.
11129521|NCT03869164|Experimental|ValmpClamp Arm|
11129554|NCT03868917|No Intervention|ultrasound group|The participants have continuous thoracic paravertebral block performed using only the ultrasound approach.
11129555|NCT03868917|Experimental|pressure measurement group|The participants have continuous thoracic paravertebral block performed using the ultrasound-guided approach combined with pressure measurement techniqueduring needle advancement.
11129556|NCT03868904||OCS Lung INSPIRE Trial|
11129522|NCT03869138|Experimental|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
11129523|NCT03869125||Obstructive sleep apnoea group|Blood pressure measurement
11129524|NCT03869112|Experimental|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
11129525|NCT03869112|Experimental|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
11129526|NCT03869112|No Intervention|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
11129527|NCT03869099||Sindh|
11129528|NCT03869099||KPK|
11129529|NCT03869099||Punjab|
11129530|NCT03869099||Balochistan|
11129531|NCT03869086|Experimental|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
11129532|NCT03869086|Experimental|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
11129533|NCT03869073|Experimental|Low Dose|This treatment arm will receive the highest dose of evolocumab currently marketed and approved: 420mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
11129534|NCT03869073|Experimental|High Dose|This treatment arm will receive double the highest dose of evolocumab currently marketed and approved: 840mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
11129535|NCT03869073|Placebo Comparator|Placebo|This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
11129536|NCT03869060|Experimental|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose [0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL)] inoculated subcutaneously.
11129537|NCT03869047|Active Comparator|quadratus lumborum block(dexmedetomidine+bupivacaine)|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine ,total volume 20 ml.
11129538|NCT03869047|Active Comparator|quadratus lumborum block(bupivacaine)|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20%.
11129539|NCT03869034|Experimental|Combined group (TAI+PD-1)|Patients receive PD-1 inhibitor of Sintilimab on the first day of TAI+PD1 treatment. On the day 2-3 during the same hospitalization, the FOLFOX chemotherapy regimen of TAI is perform for 48 hours. The TAI+PD1 treatment will repeat every 3 weeks until patients receive surgical resection or detect disease progression.
11129540|NCT03869034|Active Comparator|Control group (TAI only)|Patients only receive TAI treatment without PD-1. The FOLFOX chemotherapy regimen of TAI is same as the experimental group and repeat every 3 weeks until patients receive surgical resection or detect disease progression.
11129541|NCT03869021|Active Comparator|Computer guided surgery|A surgical guide is 3d printed to guide through the surgery, the patients of this group will have the distraction surgery by a guide designed by Mimics 19.0, Materialise NV,Belgium
11129542|NCT03869021|Other|No surgical guide (free hand surgery)|control group added to investigate the effect of surgical guide
11129543|NCT03869008|Sham Comparator|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.
~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
11129544|NCT03869008|Experimental|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
11129545|NCT03868995|Sham Comparator|Sham injection|Dextrose water injection to subcutaneous layer at tender point
11129546|NCT03868995|Experimental|Tendon injection|Dextrose water injection to injured tendon
11129547|NCT03868982|Experimental|NAVA group|Participent in this group will received NAVA for two days
11129548|NCT03868982|No Intervention|Control group|Participent in this group will received standard care
11129549|NCT03868969|Experimental|Fosfomycin|Fosomycin tromethamine, one sachet for 21 days
11129550|NCT03868956|Experimental|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
11129551|NCT03868943|Experimental|Solriamfetol|Given orally daily
11129552|NCT03868930|Experimental|STEP-Home|The STEP-Home Arm involves a skills-based intervention focused on Emotional Regulation, Problem Solving, and Attention Training strategies.
11129553|NCT03868930|Active Comparator|PCGT|The Present Center Group Therapy (PCGT) Arm involves a nonspecific, supportive intervention, focused on identifying and discussing current life stressors.
11129557|NCT03868891|Active Comparator|Eustachi|Subjects with or without cleft palate will use the Eustachi 2 times a day for 8 weeks.
11129558|NCT03868891|Active Comparator|EMST150|Subjects with or without cleft palate will use the EMST150 2 times a day for 8 weeks.
11129559|NCT03868891|Active Comparator|EMST150 + Esutachi|Subjects with or without cleft palate will use the EMST150 and Eustachi 2 times a day for 8 weeks.
11129560|NCT03868878|Experimental|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
11129561|NCT03868878|Sham Comparator|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
11129562|NCT03868865|Experimental|Integrative mind-body-medicine group program|The 66 hour program encompasses mindfulness training, yoga, moderate exercise, nutrition, naturopathic self-help strategies, cognitive restructuring and acupuncture for the management of side effects caused by chemotherapy.
11129563|NCT03868852|Experimental|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
11129564|NCT03868839|Experimental|Telmisartan Pill|Subjects will start telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
11129565|NCT03868813||Interview with People with Diabetes|One-on-One interview with people with diabetes
11129566|NCT03868813||Interview with Health Coaches|One-on-One interview with health coaches
11129567|NCT03868800|Other|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
11129568|NCT03868787|Experimental|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
11129569|NCT03868787|Sham Comparator|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
11129570|NCT03868774|Active Comparator|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
11129571|NCT03868774|Active Comparator|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
11129572|NCT03868761|Other|Single Arm|21 male and female teenage participants will be randomized to one of three varying baseline assessment periods of two, four, or six weeks. Multiple baseline is a type of single-case experimental design (SCED) that is a time- and cost-effective method for evaluating efficacy of a new treatment, Sonoma Rises. The randomization of participants to baseline periods of varying lengths enables assessment of whether symptom changes occur when, and only when, the intervention is applied.
11129573|NCT03868748|Placebo Comparator|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
11129574|NCT03868748|Experimental|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
11129575|NCT03868748|Experimental|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
11129576|NCT03868735|Experimental|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
11129577|NCT03868735|No Intervention|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
11129578|NCT03868722|Experimental|Treatment arm|Treatment with Acalabrutinib and Venetoclax is initiated within 14 days after randomization.
11129579|NCT03868722|No Intervention|Observation arm|Observation period is initiated within 14 days after randomization.
11129580|NCT03868709|Experimental|Penehyclidine group|Penehyclidine inhalation is administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
11129581|NCT03868709|Placebo Comparator|Placebo group|Placebo inhalation is administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
11129582|NCT03868696|Sham Comparator|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
11129583|NCT03868696|Experimental|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
11129584|NCT03868683|Other|Glucose Reference 1|Glucose solution containing 30 g of glucose
11129585|NCT03868683|Other|Glucose Reference 2|Glucose solution 2 containing 30 g of glucose
11129586|NCT03868683|Other|Glucose Reference 3|Glucose solution 3 containing 30 g of glucose
11129587|NCT03868683|Experimental|Sucrose|Sucrose solution containing 30 g of sucrose
11129588|NCT03868683|Experimental|Regular Bake beans in tomato sauce|Bake bean in tomato sauce with high levels of sucrose (37%)
11129589|NCT03868683|Experimental|Bake beans in tomato sauce, reduced sugar|Bake bean in tomato sauce with medium levels of sucrose (29.9%)
11129590|NCT03868683|Experimental|Bake beans in tomato sauce, low GI|Bake bean in tomato sauce with low levels of sucrose (18.5%)
11129591|NCT03868670|Experimental|Responsive Neurostimulation|Surgical arm. Patients expected to receive treatment.
11129592|NCT03868657|Active Comparator|Moxifloxacin|Per os, 800 mg, once daily for 4 days
11129593|NCT03868657|Placebo Comparator|Placebo|Per os, 800 mg, once daily for 4 days
11129594|NCT03868644|Experimental|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
11129595|NCT03868644|Experimental|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
11129596|NCT03868644|Experimental|VCT and Condoms|Youth are offered both VCT and condoms.
11129597|NCT03868644|No Intervention|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
11129598|NCT03868631|Active Comparator|Soy protein group|
11129599|NCT03868631|Active Comparator|Whey protein group|
11129600|NCT03868618|Experimental|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
11129601|NCT03868605|Experimental|EMR/ESD|Standard EMR or ESD technique
11129602|NCT03868605|Experimental|Over- the- scope full- thickness resection device|Endoscopic full thickness resection
11129603|NCT03868592|Experimental|Gastric sleeve surgery|before and after weight loss from bariatric surgery
11129604|NCT03868579|Experimental|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
11129605|NCT03868566|Experimental|SNP-612 dose1|dose1 once a day orally for 12 weeks
11129606|NCT03868566|Experimental|SNP-612 dose2|dose2 once a day orally for 12 weeks
11129607|NCT03868566|Experimental|SNP-612 dose3|dose3 once a day orally for 12 weeks
11129608|NCT03868566|Placebo Comparator|SNP-612 placebo|placebo once a day orally for 12 weeks
11129609|NCT03868553||Under-10|
11129610|NCT03868553||Under-12|
11129611|NCT03868553||Under-16 female|
11129612|NCT03868553||Under-16 male|
11129613|NCT03868540|Experimental|BI 1291583|
11129614|NCT03868540|Placebo Comparator|Placebo|
11129615|NCT03868527||Hematological diseases|Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital
11129616|NCT03868514||TiLOOP Bra Pocket|Medical Device
11129617|NCT03868501|Experimental|High Working memory load: n-back task|During the intervention, each participant of this group will finish the 3-back task.
11129618|NCT03868501|Experimental|Low Working memory load: n-back task|During the intervention, each participant of this group will finish the 1-back task.
11129619|NCT03868488|Experimental|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
11129620|NCT03868488|Experimental|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
11129621|NCT03868475|Experimental|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.
~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.
~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
11129622|NCT03868475|Active Comparator|Open surgical excision|"Patients will undergo standard open surgical excision.
~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.
~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
11129623|NCT03868462|Other|Optical Coherence Tomography (OCT)|
11129624|NCT03868449|Experimental|Question Prompt List|Participants will be given a Question Prompt list that has been developed by the research team
11129625|NCT03868449|Active Comparator|3 questions list|Participants will be given 3 questions from the AskShareKnow method
11129626|NCT03868436|Other|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
11129627|NCT03868423|Experimental|Treatment (brigatinib)|Patients receive brigatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11129628|NCT03868410|Active Comparator|cPMD rTMS + Training|New Approach
11129629|NCT03868410|Active Comparator|iM1 rTMS + Training|Conventional Approach
11129630|NCT03868397|Experimental|Liver MRI|In this study, MRI refers to phase-contrast 4D flow sequence.
11129631|NCT03868371|Active Comparator|1. high - 2. low|These are the patients receiving a high phosphorous containing meal in the first trial day, and a low phosphorous containing meal in the second trial day.
11129777|NCT03867305|No Intervention|Control group|
11129632|NCT03868371|Active Comparator|1. low - 2. high|These are the patients receiving a low phosphorous containing meal in the first trial day, and a high phosphorous containing meal in the second trial day.
11129633|NCT03868358|Active Comparator|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
11129634|NCT03868358|Placebo Comparator|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
11129635|NCT03868332||inflammatory bowel diease patients|
11129636|NCT03868332||normal indivuals|
11129637|NCT03868319|Experimental|control group|nonprotective ventilation with a tidal volume of 9 ml kg-1 PBW with ZEEP
11129638|NCT03868319|Experimental|LPV group|a tidal volume of 6 ml kg-1 PBW with a 7 cmH2O level PEEP
11129639|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
11129640|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
11129641|NCT03868293|Experimental|Drug-Resistant Epilepsy (temporal lobe)|Pulsed low intensity focused ultrasound
11129642|NCT03868280|Active Comparator|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
11129643|NCT03868280|Active Comparator|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
11129644|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
11129645|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
11129646|NCT03868241|Experimental|Bactiguard-coated Devices|Patients will receive endotracheal tube, central venous catheter and urinary cather coated with gold, silver and palladium (Bactiguard coating)
11129647|NCT03868241|Placebo Comparator|Control|Shelf endotracheal tube, central venous catheter and urinary cather available at each intensive care unit without any type of coating designed to prevent infection
11129648|NCT03868228|Experimental|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
11129649|NCT03868215||Patients with endoscopically removed malignant polyps|Patients with endoscopically removed malignant polyps
11129650|NCT03868202|No Intervention|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
11129651|NCT03868202|Active Comparator|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
11129652|NCT03868189|Experimental|electroneuromyography|
11129653|NCT03868189|Placebo Comparator|control|
11129654|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
11129655|NCT03868176||Active comparator: standard of care|
11129656|NCT03868163||Glecaprevir plus Pibrentasvir|"Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
11129657|NCT03868150|Active Comparator|Inducible Atrial Fibrillation|Treatment with Amiodarone
11129658|NCT03868150|Other|Inducible Atrial Fibrillation - Standard Care|No initial Amiodarone Treatment unless POAF seen on post operative care unit.
11129659|NCT03868150|Other|Non-Inducible Atrial Fibrillation|Amiodarone treatment if POAF seen on post-operative care unit
11129660|NCT03868137|Placebo Comparator|Placebo|3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion
11129661|NCT03868137|Experimental|Ibuprofen|3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.
11130086|NCT03865160|Placebo Comparator|Placebo (NaCl 0.9%) eye drops|Placebo (NaCl 0.9%) eye drops, both eyes at bedtime
11129662|NCT03868124|Experimental|Implant Group 1|G2TR intraocular implant containing Travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
11129663|NCT03868124|Experimental|Implant Group 2|G2TR intraocular implant containing Travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
11129664|NCT03868124|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
11129665|NCT03868111|Experimental|Sufentanil|Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
11129666|NCT03868111|Experimental|Remifentanil|Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.
11129667|NCT03868098|Active Comparator|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
11129668|NCT03868098|Placebo Comparator|Placebo ointment (vehicle)|Placebo
11129669|NCT03868072|Experimental|Reference/Test|"Period 1: XELJANZ 5Mg Tablet 1T
~Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
11129670|NCT03868072|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tofacitinib Tablet 1T
~Period 2: XELJANZ 5Mg Tablet 1T"
11129671|NCT03868059|Experimental|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
11129672|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
11129673|NCT03868033|Experimental|Continuous Denosumab|Continuous anti-resorptive therapy by Denosumab for 2 years
11129674|NCT03868033|Experimental|Zoledronic acid to Denosumab|treat with Zoledronic acid for one year and then shift to Denosumab for another one year
11129675|NCT03868033|Experimental|Continuous Zoledronic acid|Continuous anti-resorptive therapy by Zoledronic acid for 2 years
11129676|NCT03868033|Experimental|Zoledronic acid to observation|"treat with Zoledronic acid for one year and then close follow up by bone turn over marker.
~resume another dose of Zoledronic acid if elevated CTX level above normal range"
11129677|NCT03868020|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
11129678|NCT03868007|Experimental|RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent RIC twice daily for 14 days.And the RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
11129679|NCT03868007|Sham Comparator|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
11129680|NCT03867994|Experimental|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
11129681|NCT03867994|Experimental|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
11129682|NCT03867994|Experimental|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
11129683|NCT03867981|Experimental|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
11129684|NCT03867981|Experimental|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
11129685|NCT03867981|Active Comparator|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
11129686|NCT03867968|Experimental|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
11129687|NCT03867968|Active Comparator|Control|An existing website related to traumatic brain injury.
11130121|NCT03864939|Placebo Comparator|Standard|A standard RRP is performed.
11129688|NCT03867955||Patients who have a neurosurgical intervention|Patients who have a neurosurgical intervention will be included. They will have a collection of datas.
11129689|NCT03867942|Active Comparator|monolayer group|monolayer of Gemigliptin/Rosuvastatin
11129690|NCT03867942|Experimental|bilayer group|bilayer of Gemigliptin/Rosuvastatin
11129691|NCT03867929||STUDY|Patient with serum 25-Hydroxy vitamin D level <27.32
11129692|NCT03867929||CONTROL|Patient with serum 25-Hydroxy vitamin D level >27.32
11129693|NCT03867916|Experimental|Health services research (Patient COUNTS)|Patients attend focus groups to help develop patient portal and navigation program. Patients use in-person navigation program. Patients also complete data collection and surveys over 15 minutes via web portal at baseline, 3 months, and 6 months and user experience survey at end of program participation.
11129694|NCT03867877|Experimental|Periodized Training with Motor Practice|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
11129695|NCT03867877|Experimental|Simple Periodized Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and 60-75% of subjects' maximum strength for the hypertrophy day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down
11129696|NCT03867864|Experimental|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
11129697|NCT03867864|Other|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
11129698|NCT03867851|Experimental|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
11129699|NCT03867851|Active Comparator|Heparin|Heparin treatment according to clinical praxis.
11129700|NCT03867812|No Intervention|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
11129701|NCT03867812|Experimental|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
11129702|NCT03867812|Active Comparator|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
11129703|NCT03867812|Active Comparator|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
11129704|NCT03867799|Experimental|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
11129705|NCT03867786|Experimental|Exercise Condition|Participants will undergo a 40 minute exercise protocol
11129706|NCT03867786|Active Comparator|Video Control Condition|Participants will view a 40 minute nature video
11129707|NCT03867773|Experimental|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
11129708|NCT03867773|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
11129709|NCT03867773|Experimental|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
11129710|NCT03867760|Experimental|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
11129711|NCT03867760|Active Comparator|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
11129712|NCT03867747|Experimental|Cardiac Radiosurgery|25 Gy in a single fraction
11129713|NCT03867734|Experimental|2g Aztreonam|Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea
11129714|NCT03867721|Experimental|Ventilator PB560 (Covidien)|The non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
11129715|NCT03867721|Experimental|Ventilator Trilogy (Philips Respironics)|The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
11129716|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
11129717|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
11129718|NCT03867695|Experimental|Serratus Block|"At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
~Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle.
~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product."
11129719|NCT03867695|Placebo Comparator|Placebo Block - Control Group|"Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle.
~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product."
11129720|NCT03867682|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 1 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).
~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.
~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
11129721|NCT03867669|Experimental|Single Patient Room|Patients randomized to this arm will be admitted to a NICU single patient room.
11129722|NCT03867669|Placebo Comparator|Open Bay|Patients randomized to this arm will be admitted to the open bay NICU Unit.
11129723|NCT03867656|Experimental|GLP-2|Glucagon-like peptide 2
11129724|NCT03867656|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
11129725|NCT03867656|Placebo Comparator|Placebo|Saline
11129726|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
11129727|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
11129728|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
11129729|NCT03867617|Experimental|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
11129730|NCT03867617|Active Comparator|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
11129731|NCT03867604|Sham Comparator|Sham injection|Subcutaneous injection at upper trapezium muscle level
11129732|NCT03867604|Experimental|Fascia injection|Fascia injection, below upper trapezium muscle
11129733|NCT03867591|Experimental|Gastro-AD® Group|The participants randomized to this group 1 g of Gastro-AD® powder per sachet + flavoring agents.
11129734|NCT03867591|Placebo Comparator|Placebo Group|Participants in this arm will take a sachet containing maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
11129735|NCT03867578|Other|Exploratory Phase - Standard CT Imaging and HR-MRI|The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
11129736|NCT03867578|Other|Testing Phase- Conventional and HR-MRI and Ultrasound|Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
11129737|NCT03867565|No Intervention|No nutritional diagnosis|Patients without nutritional diagnosis get SOC
11129738|NCT03867565|Experimental|Nutritional diagnosis|Patients with nutritional diagnosis get nutritional intervention by dietitian.
11129739|NCT03867552|Experimental|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
11129740|NCT03867552|Active Comparator|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
11129741|NCT03867539|Active Comparator|Control Group; Bupivacaine + opioids|"This is the standard of care arm. This group will receive pre-operative opioid education and standard of care, which consists of an injection of 10cc bupivacaine (plus ~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies."
11129742|NCT03867539|Experimental|Experimental Group: Exparel, no opioids|This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel (liposomal bupivacaine), ~5cc of bupivacaine, and ~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
11129743|NCT03867513||mTBI cases|Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
11129744|NCT03867513||Acute trauma controls|Non-head trauma controls matched for age and sex with the mTBI group
11129745|NCT03867500|Experimental|Niacin|Intravenous niacin infusion
11129746|NCT03867500|Placebo Comparator|Saline|Intravenous saline infusion
11129747|NCT03867487|Experimental|Study intervention|Empagliflozin 10 mg will be taken daily
11129748|NCT03867487|Placebo Comparator|Control arm|Placebo oral tablet will be taken daily
11129749|NCT03867474|Experimental|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
11129750|NCT03867474|No Intervention|Control - Usual Care|Control
11129778|NCT03867292|Experimental|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
11129751|NCT03867461|Active Comparator|Group A|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group A: Initial Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-80 mmHg, End tidal CO2 38-40 mmHg."
11129752|NCT03867461|Active Comparator|Group B|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group B: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg,"
11129753|NCT03867461|Active Comparator|Group C|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group C: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 24-26 mmHg, Subsequent Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg,"
11129754|NCT03867461|Active Comparator|Group D|"Adult patients determined to be candidates for venous sinus stenting.
~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:
~For Group D: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-100 mmHg, End tidal CO2 24-24 mmHg,"
11129755|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with posssible endocrine conditions.
11129756|NCT03867435||Individuals with DM1|Individuals with myotonic dystrophy type 1 (DM1)
11129757|NCT03867435||Individuals with DM2|Individuals with myotonic dystrophy type 2 (DM2)
11129758|NCT03867409|Experimental|Concordant virtual human|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
11129759|NCT03867409|Experimental|Dis-concordant virtual human|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
11129760|NCT03867409|Experimental|Concordant text|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
11129761|NCT03867409|Experimental|Dis-concordant text|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
11129762|NCT03867396|Active Comparator|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
11129763|NCT03867396|Active Comparator|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
11129764|NCT03867396|Experimental|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
11129765|NCT03867383|Experimental|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).
~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
11129766|NCT03867383|Placebo Comparator|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.
~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
11129767|NCT03867370|Experimental|Group A|Group A:TORIPALIMAB 240mg ,Q3W, up to 48 Weeks;
11129768|NCT03867344|Active Comparator|Hypoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute hypoglycemic hyperinsulinemic clamp procedure (50mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
11129769|NCT03867344|Placebo Comparator|Normoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute normoglycemic hyperinsulinemic clamp procedure (90mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
11129770|NCT03867331|Experimental|5 microgram VLPM01|5 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
11129771|NCT03867331|Experimental|15 microgram VLPM01|15 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
11129772|NCT03867331|Experimental|30 microgram VLPM01|30 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
11129773|NCT03867331|Experimental|Controlled Human Malaria Infection (CHMI) Phase|Infectivity Control Participants, n=6
11129774|NCT03867318|Experimental|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
11129775|NCT03867318|Experimental|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
11129776|NCT03867305|Experimental|MOBIDERM group|
11129779|NCT03867292|Active Comparator|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
11129780|NCT03867279|Experimental|Flossing|The subjects included in this group will perform a protocol of reeducation exercises plus the application of the Flossing technique. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
11129781|NCT03867279|Active Comparator|Reeducation exercises|The subjects included in this group will carry out a protocol of reeducation exercises. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
11129782|NCT03867253|Active Comparator|ORY-2001 Low dose|0.6mg ORY-2001 capsule
11129783|NCT03867253|Active Comparator|ORY-2001 High dose|1.2mg ORY-2001 capsule
11129784|NCT03867253|Placebo Comparator|Placebo|Placebo capsule
11129785|NCT03867240|Experimental|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
11129786|NCT03867240|Placebo Comparator|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
11129787|NCT03867214|Experimental|Experimental|"Receiving TXA, Study group
~Tranexamic acid, Study group tranexamic acid 1g,
~intravenous injection, pre-operationally"
11129788|NCT03867214|Placebo Comparator|Placebo Comparator|"Normal saline, Control group
~Not receiving tranexamic acid, Control group Normal
~saline 100mL, intravenous injection, pre-operationally"
11129789|NCT03867201|Experimental|Erenumab|Administered by pre-filled syringe
11129790|NCT03867201|Placebo Comparator|Placebo|Administered by pre-filled syringe
11129791|NCT03867188|Experimental|Liiposomal Bupivacaine Group|Qualified participants with a soft tissue sarcoma of the thigh will be given the alternative protocol utilizing liposomal bupivacaine (Exparel®). The alternative protocol will utilize general or spinal anesthesia, but will also include the use of intraoperative liposomal bupivacaine instead of a regional nerve block.
11129792|NCT03867188|No Intervention|Control Group|A retrospective control group will be assembled from electronic medical records of 3 patients who underwent resection of a soft tissue sarcoma of the thigh and will be accessed and analyzed for the variable of interest.
11129793|NCT03867175|Experimental|Arm 1 Stereotactic Body Radiation Therapy/Pembrolizumab|3-10 treatments of SBRT/ pembrolizumab IV for 30 minutes every 3-4 weeks for 1 year at doctor's discretion.
11129794|NCT03867175|Experimental|Arm 2 Pembrolizumab|Patients receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
11129795|NCT03867162|Experimental|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
11129796|NCT03867149|Other|patient with first thalamic infarct|Patient with first thalamic infarct, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
11129797|NCT03867149|Other|healthy subject matched with control|Healthy subject matched with control, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
11129798|NCT03867136|Experimental|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
11129799|NCT03867136|Active Comparator|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
11129800|NCT03867123|Experimental|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + 2-OHOA (during Concurrent phase - duration 6 weeks)*:
~2-OHOA will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).
~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.
~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.
~* One extra week may be allowed."
11129801|NCT03867123|Experimental|Arm 2 (maintenance phase)|"TMZ + 2-OHOA (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):
~2-OHOA will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. 2-OHOA will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).
~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.
~Both arms will be followed by a 4-week safety follow-up"
11129802|NCT03867110|Placebo Comparator|Placebo|Placebo is to be taken orally once a day (QD) in the morning for 12 consecutive weeks.
11129803|NCT03867110|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) is to be taken orally QD in the morning for 12 consecutive weeks.
11129804|NCT03867110|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129805|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11130122|NCT03864926|Active Comparator|Standard of Care|Standard of Care Tacrolimus
11129806|NCT03867110|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129807|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129808|NCT03867110|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129809|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 40 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129810|NCT03867110|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129811|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 80 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
11129812|NCT03867097|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
11129813|NCT03867097|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
11129814|NCT03867084|Experimental|Pembrolizumab|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.
11129815|NCT03867084|Placebo Comparator|Placebo|Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.
11129816|NCT03867071|Experimental|erythropoietin (EPO) group|
11129817|NCT03867071|Placebo Comparator|Placebo (PLA) group|
11129818|NCT03867058||Cochlear implant users with Nucleus and AB devices|"Temporal processing acuity will be compared using electrodes or electrode configurations that create broad versus sharp spatial excitation.
~Speech recognition will be compared in the same group of subjects using electrode-dependent focused versus monopolar stimulation."
11129819|NCT03867045|Experimental|mRCC treated with cabozantinib|Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
11129820|NCT03867032|Experimental|Cochlear implant users|The group will receive auditory training (psychophysical), and will be evaluated for speech recognition to determine the effect of training.
11129821|NCT03867019||Subjects with BPPV|"Patients diagnosed with BPPV, who meet the following criteria:
~Main complain of spinning sensation (Vertigo) when changes are made in head position relative to gravity.
~Positive Dix-Hallpike / Supine Roll Test, confirmed by presence of nystagmus."
11129822|NCT03867019||Subjects without BPPV (Control group)|Patients who do not suffer from dizziness / spinning sensation (Vertigo), and do not meet the exclusion criteria in the study.
11129823|NCT03867006|No Intervention|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
11129824|NCT03867006|Experimental|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
11129825|NCT03867006|Experimental|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
11129826|NCT03866993|Experimental|AK105 plus Carboplatin and Paclitaxel|Subjects receive AK105 200 mg intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
11129827|NCT03866993|Placebo Comparator|placebo plus Carboplatin and Paclitaxel|Subjects receive placebo intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
11129828|NCT03866980|Experimental|AK105 plus Carboplatin and Pemetrexed|Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
11129829|NCT03866980|Placebo Comparator|Placebo plus Carboplatin and Pemetrexed|Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
11129830|NCT03866967|Experimental|AK105|Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
11129831|NCT03866954|Experimental|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
11129832|NCT03866941||synthetic cannibinoids users|
11129833|NCT03866928|Experimental|Stiripentol|
11129834|NCT03866915||Patients undergoing elective surgery|All patients older than 18 years undergoing elective surgery that receive a preoperative visit by anesthesiologists in which Aortic pulse wave velocity measurement and the 6 minutes walking test (6MWT) is carried out
11129835|NCT03866902|Experimental|Nutrition and Physical Activity Intervention|"Classes for the intervention mothers will be run by a bilingual interventionist and will last 105 minutes weekly for 12 weeks and then monthly for 6 months.
~Classes for intervention group children will be 105 minutes weekly for 12 weeks and then monthly for 6 months."
11130123|NCT03864926|Experimental|Experimental|Envarsus XR
11129836|NCT03866902|Active Comparator|English for Second Language Intervention|"Mothers in the control group will receive English as a Second Language (ESL) classes taught by professional ESL teachers; they will receive the same number of contacts and time as the intervention group mothers for 105 minutes weekly for 12 weeks and 105 minutes monthly for 6 months.
~Children in the control group will be read to and color with crayons 105 minutes weekly for 12 weeks and then 105 minutes monthly for 6 months."
11129837|NCT03866889|Experimental|Strength|Maximum strength protocol based on a Maximum Repetition (1RM). The aim of the application of the training is to produce an increase in strength based on training with high loads (80% 1RM), individually and covering the muscles of the lower extremity (quadriceps, hamstrings, gluteus maximus).
11129838|NCT03866889|Active Comparator|Normal activity|The subjects included in the control group will perform the same physical activity to improve the strenght until the beginning of the study. The exercises will be done in the same conditions and with the same period (4 days / week)
11129839|NCT03866876||Hôpital Femme Mère Enfants births|
11129840|NCT03866863||HFME births.|All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.
11129841|NCT03866850||Cochlear implant users with late-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration).
~Examine neural spatial excitation patterns with long and short phase duration. Measure speech recognition using long and short phase duration stimulation patterns."
11129842|NCT03866850||Cochlear implant users with early-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration) and compare that with the late-onset group.
~Examine neural spatial excitation patterns with long and short phase duration within the non-leaky phase duration range.
~Measure speech recognition using long and short phase duration stimulation patterns."
11129843|NCT03866837|Active Comparator|Study group A: GOS|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and galacto-oligosaccharides (GOS), 7.5 mg.
11129844|NCT03866837|Active Comparator|Study group B: bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), bovine lactoferrin (bLF), 1.0 g.
11129845|NCT03866837|Active Comparator|Study group C: GOS + bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.
11129846|NCT03866837|Placebo Comparator|Study group D|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).
11129847|NCT03866824|Experimental|PRP group|
11129848|NCT03866824|Active Comparator|reference treatment|
11129849|NCT03866811|Experimental|Intervention arm|The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
11129850|NCT03866811|No Intervention|Control arm|Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
11129851|NCT03866798|Experimental|Panzyga|Panzyga
11129852|NCT03866785|Other|STEP 1: Patient with prostate cancer|First, patients with prostate cancer will be included during step 1. They will have an interview.
11129853|NCT03866785|Other|STEP 2: Patient with prostate cancer and a physical activity|"Secondly, patient with prostate cancer and a physical activity will be included during step 2. They are called peer.
~They will have a questionnaire Adult Physical Activity Questionnaire (APAQ), an activity actigraph and a peer training. The peer will help patients to realize the Physical Activity Program during step 3."
11129854|NCT03866785|Other|STEP 3: Physical Activity Program|"Finally, patients with prostate cancer (different from step 1) and who agrees to participate at the Physical Activity Program will be included during step 3.
~They will have an activity actigraph and a questionnaire Adult Physical Activity Questionnaire (APAQ) at inclusion and 3 months later.
~They will receive the Physical Activity Program."
11129855|NCT03866772|Active Comparator|MISOPROSTOL|"oral misoprostol, 50 microgram, every 4 hours
~Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm
~maximal number of doses: 6
~Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.
~Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.
~Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
11129856|NCT03866772|Active Comparator|DOUBLE BALLOON|"Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.
~Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration
~If AROM cannot be performed- oxytocin infusion will be initiated at first.
~If Bishop <3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
11129857|NCT03866772|Active Comparator|MISOPROSTOL+DOUBLE BALLOON|
11129858|NCT03866746|Active Comparator|Group A|received aflibercept injections alone
11129859|NCT03866746|Experimental|Group B|received 3 aflibercept injections followed by micropulsed laser
11129860|NCT03866733|Active Comparator|Narcotics group (group N)|intervention: injection of boluses of intra venous Narcotics (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
11129861|NCT03866733|Experimental|Erector spinea block group (group B)|intervention: after induction our intervention will be the performance of ultrasound guided bilateral continous Erector spinea block with insertion of catheters then 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
11129862|NCT03866720|Active Comparator|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
11129863|NCT03866720|Experimental|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
11129864|NCT03866720|No Intervention|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
11129865|NCT03866694|Experimental|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
11129866|NCT03866694|Active Comparator|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
11129867|NCT03866681|Experimental|Patients cohort|A total of 40 patients with refractory classic PNH will be included and will be intervened by a combined therapy including sirolimus and low-dose warfarin
11129868|NCT03866668|Experimental|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
11129869|NCT03866655|Experimental|Intervention|
11129870|NCT03866655|No Intervention|Control|
11129871|NCT03866629||Lifitegrast 5%|Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.
11129872|NCT03866616|Active Comparator|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
11129873|NCT03866616|Experimental|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
11129874|NCT03866603||Parkinson´s disease individuals|The participants that are clinically diagnosed with Parkinson's disease
11129875|NCT03866603||Family member of a participant with LRRK2 parkinsonism|The first and second degree family members of the ROPAD Study participants with LRRK2 parkinsonism
11129876|NCT03866603||High risk population|Populations at high risk such as Ashkenazi Jewish and Arab Berber
11129877|NCT03866590||Patients being at risk for Pyruvate Kinase Deficiency|Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology
11129878|NCT03866577|Experimental|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
11129879|NCT03866577|Experimental|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
11129880|NCT03866577|Experimental|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
11129881|NCT03866577|Experimental|Part D|ITP patients will receive repeated doses of M254
11129882|NCT03866564||Multi-Afflicted|Participants with multiple self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
11129883|NCT03866564||Un-Afflicted|Participants who report no afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
11129884|NCT03866564||Single Afflicted|Participants with one self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
11129885|NCT03866551|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
11129886|NCT03866538|No Intervention|Continued Budesonide|Patients in this arm continue budesonide at the dose they were taking at the time of enrollment in the trial
11129887|NCT03866538|Experimental|Withdrawal of Budesonide|Patients are weaned off of budesonide over 2 weeks and continued off of the medication for the duration of the trial
11129888|NCT03866525|Experimental|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.
~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
11129889|NCT03866512|Experimental|Acipimox ingestion during immobilization|Oral ingestion of Acipimox during 2 days of forearm immobilization
11129890|NCT03866512|Experimental|B-agonist during immobilization|Oral ingestion of salbutamol during 2 days of forearm immobilization
11129891|NCT03866512|Placebo Comparator|Placebo ingestion during immobilization|Oral ingestion of a placebo 2 days of forearm immobilization
11129892|NCT03866499|Experimental|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
11129893|NCT03866499|Active Comparator|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
11129894|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
11129895|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
11129896|NCT03866473|Experimental|Retilux Photobiomodulation|670nm wavelength device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device).
11129923|NCT03866291||Non ESBL-carrier|No further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
11129897|NCT03866473|Sham Comparator|Sham Light Device|Broad spectrum light device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device)
11129898|NCT03866460||Hearing evaluation DPOAE|Post IA hearing evaluation will be allowed up until 9 months after IA completion (or roughly one year from initiation of treatment). After completion of standard treatment for RB that included IA carboplatin.
11129899|NCT03866447|Active Comparator|vitamin D versus placebo|This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
11129900|NCT03866447|Active Comparator|Adapalene versus placebo|this group will be treated by topical Adapalene (0.1%) versus versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
11129901|NCT03866434|Experimental|SPD422 + Omeprazole|Participants will receive 1 milligram (mg) of SPD422 (Anagrelide hydrochloride) (2*0.5 mg) capsule orally on Day 1 in fasted state (10 hours prior to and until 4 hours following administration of anagrelide), followed by 40 mg of Omeprazole capsule orally once daily (prior to breakfast) on Days 2 to Day 7, followed by 1 mg of Anagrelide in fasted state in combination with Omeprazole 40 mg on Day 8.
11129902|NCT03866421||Kidney transplanted patients|"Number of patients: 16
~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.
~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).
~Same interventions as in the control Group.
~Including/ Exclusion criteria are listed under the section Eligibility"
11129903|NCT03866421||Control group|"Number of patients: 16
~Participants in this group are matched on age and BMI according to the kidney transplanted patients.
~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.
~Furthermore, participants have to have normal kidney function.
~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
11129904|NCT03866408|Active Comparator|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
11129905|NCT03866408|Placebo Comparator|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
11129906|NCT03866408|Active Comparator|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
11129907|NCT03866408|Active Comparator|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.
~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
11129908|NCT03866395|No Intervention|Control Group|drug therapy according to the guidelines
11129909|NCT03866395|Experimental|Ivabradine Group|drug therapy according to the guidelines + Ivabradine 5 mg twice a day
11129910|NCT03866382|Experimental|Treatment (cabozantinib, nivolumab, ipilimumab)|Patients receive cabozantinib PO QD on days 1-21 of cycles 1-4 and on days 1-28 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4. Patients then receive nivolumab IV over 30 minutes on day 1 of subsequent cycles. Treatment repeats every 21 days for cycles 1-4 and every 28 days for subsequent cycles for 2 years in the absence of disease progression or unacceptable toxicity.
11129911|NCT03866369|Experimental|Experimental|IMP Under investigation
11129912|NCT03866369|Placebo Comparator|Placebo to Match|
11129913|NCT03866356|Experimental|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
11129914|NCT03866356|No Intervention|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
11129915|NCT03866343|Active Comparator|Low AGE diet|Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
11129916|NCT03866343|Other|High AGE diet|Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
11129917|NCT03866330|Active Comparator|osteoarthritis of the knee|Intraarticular injection of WJMSC
11129918|NCT03866330|Active Comparator|osteoarthritis of the hip|Intraarticular injection of WJMSC
11129919|NCT03866330|Active Comparator|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
11129920|NCT03866317|Experimental|Secukinumab|Secukinumab 300 mg injection at week 0, 1, 2, 3, 4, then every 4 weeks until week 12
11129921|NCT03866304|Experimental|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
11129922|NCT03866291||ESBL carrier|"This cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group.
~Sera is donated after 4-6 weeks and in year."
11129924|NCT03866265|Active Comparator|Supplement Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a food supplement capsule (containing 0.125 g of FGE-Salmon-PLs) per day for a period of 28 days.
~After the period of 28 days, each participant will provide blood samples at the 29th day.
~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.
~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the food supplement will now be administered the placebo capsules for 28 days (a placebo capsule per day)"
11129925|NCT03866265|Placebo Comparator|Placebo Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a placebo capsule (containing 0.125 g of glycerin) per day for a period of 28 days.
~After the period of 28 days, each participant will provide blood samples at the 29th day.
~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.
~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the placebo capsules will now be administered the food supplement capsules for 28 days (a food supplement capsule per day)"
11129926|NCT03866252|Experimental|Treatment Arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
11129927|NCT03866252|Active Comparator|Control Arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
11129928|NCT03866239|Experimental|Obinutuzumab Pretreatment (OpT) + Cibisatamab + Atezolizumab|Participants will receive obinutuzumab approximately 2 weeks before receiving atezolizumab and cibisatamab on Day 1 of each treatment cycle (cycle = 21 days).
11129929|NCT03866213|Experimental|Quantitative Measurement of Bilirubin|Bilirubin content of the neonate will be measured by the following: BiliSpec, laboratory spectophotometric bilirubinometer (Reichert UNISTAT), and transcutaneous bilirubinometer. The infant may or may not be receiving phototherapy treatment at the time of sample measurement.
11129930|NCT03866200|Experimental|resveratrol|
11129931|NCT03866200|Placebo Comparator|Placebo|
11129932|NCT03866187|Experimental|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
11129933|NCT03866187|Active Comparator|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
11129934|NCT03866187|Placebo Comparator|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
11129935|NCT03866187|Experimental|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
11129936|NCT03866187|Active Comparator|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
11129937|NCT03866187|Active Comparator|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
11129938|NCT03866187|Experimental|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
11129939|NCT03866187|Active Comparator|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
11129940|NCT03866174|Experimental|Psilocybin|Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water.
11129941|NCT03866174|Active Comparator|Niacin|Participants will receive a single 100 mg dose of niacin along with the Set and Setting protocol. Niacin is administered orally as a capsule and taken with water.
11129942|NCT03866161||CPAP group|Obstructive sleep apnea patients treated with continuous positive airway pressure
11129943|NCT03866148|Active Comparator|ILR|Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
11129944|NCT03866148|No Intervention|No ILR|Participants who will not get the Implantable Loop Recorder (Reveal-LINQ).
11129945|NCT03866135||patients with osteoporosis|Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) assessment. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD)
11129946|NCT03866135||patients without osteoporosis|Bone mineral densities of patients were based on the World Health Organization (WHO) classification of a T score between -1 and -2.5 for osteopenia
11129947|NCT03866122|Experimental|Neonates (NICU or KMC Ward)|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
11129948|NCT03866109|Experimental|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
11130082|NCT03865199|No Intervention|Control Group|The control group will receive care as usual at the abortion clinic. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
11129949|NCT03866096|Experimental|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
11129950|NCT03866096|Active Comparator|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
11129951|NCT03866083|Experimental|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
11129952|NCT03866083|Active Comparator|Stadard Medical treatment|Stadard Medical treatment
11129953|NCT03866070|Experimental|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
11129954|NCT03866070|Active Comparator|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
11129955|NCT03866057||1 study group|All patients hospitalized in 4 intensive rehabilitation Structures of Don Gnocchi Foundation during the enrollment period, suffering from acute (within 30 days) ischemic or emorragic stroke
11129956|NCT03866044||Parkinson's Disease (PD)|"Patients with Parkinson's Disease meeting the following criteria:
~Inclusion criteria:
~Aged 18 or more.
~Clinically established or probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease
~Signed informed consent
~Exclusion criteria:
~Pregnancy or breastfeeding
~History of other neurologic or psychiatric disease
~Pacemaker or other implanted electronic devices
~Claustrophobia"
11129957|NCT03866044||Healthy participants|"Healthy participants age- and sex-matched to the PD group.
~Inclusion criteria:
~Age- and sex-matched to PD group (aged 18 or more)
~Signed informed consent
~Exclusion criteria:
~Pregnancy or breastfeeding
~History of neurologic or psychiatric disease
~Pacemaker or other implanted electronic devices
~Claustrophobia"
11129958|NCT03866031|Experimental|M:2.75|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 2.75 mm
11129959|NCT03866031|Experimental|M3.25|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 3.25 mm
11129960|NCT03866031|Experimental|S3.75|12 Patients will be provided with 2 standard sized implant-supported mandibular overdentures d: 3.75 mm
11129961|NCT03866018|Experimental|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
11129962|NCT03866005|Placebo Comparator|Placebo Arm - Standard Treatment|50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration
11129963|NCT03866005|Experimental|Experimental Arm - 2 DiVFuSS formula softgel capsules|50 subjects receiving two DiVFuSS softgels per day
11129964|NCT03866005|Experimental|Experimental Arm - 4 DiVFuSS formula softgel capsules|50 subjects receiving 4 DiVFuss softgels per day
11129965|NCT03865992|Experimental|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
11129966|NCT03865992|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
11129967|NCT03865979|Active Comparator|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.
~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
11129968|NCT03865979|No Intervention|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
11129969|NCT03865953|Active Comparator|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
11129970|NCT03865953|Placebo Comparator|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
11129971|NCT03865940|Experimental|Lidocaine then Lidocaine + Guanfacine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1).
~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine."
11129972|NCT03865940|Experimental|Lidocaine + Guanfacine then Lidocaine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1).
~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine."
11129973|NCT03865927|Experimental|GKT137831|GKT137831 will be administered orally, at a dose of 400 mg twice daily, for a total of 24 weeks.
11129974|NCT03865927|Placebo Comparator|Placebo Oral Tablet|Identically-appearing placebo oral tablets will be administered orally, twice daily, for a total of 24 weeks.
11129975|NCT03865914||Type 2 diabetic nephropathy|The cohort will be followed for at least two years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
11129976|NCT03865901||Non-diabetic pregnant women|Non-diabetic women with singleton pregnancy undergoing screening for gestational diabetes who provide plasma samples for testing with the Mellitus GCD59 Test
11129977|NCT03865888|Active Comparator|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
11129978|NCT03865888|Active Comparator|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
11129979|NCT03865875|Experimental|Multimodal Prehabilitation Program|"Pretreatment exercise program and nutrition program
~-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation"
11130083|NCT03865186|Experimental|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
11129980|NCT03865862|Experimental|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
11129981|NCT03865862|Active Comparator|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
11129982|NCT03865849|Active Comparator|Conventional radiofrequent treatment|The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15°. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip
11129983|NCT03865849|Active Comparator|Cooled radiofrequent treatment|The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief).
11129984|NCT03865823||anal Fistula|patient with anal fistula with indication to surgical treatment
11129985|NCT03865810||Gastric Surgery|Adult patients undergoing elective gastric surgery for cancer
11129986|NCT03865797|Experimental|Experimental|Before carrying out each session of the intervention, each subject included in the experimental group will have a sports bandage on both ankles. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
11129987|NCT03865797|Active Comparator|Control|The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
11129988|NCT03865784|Experimental|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
11129989|NCT03865784|Active Comparator|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
11129990|NCT03865771|Experimental|EPILEPSY GROUP|"Patients with typical BECTS (benign group) or atypical BECTS or ECSWS (severe group)
~Medical visit
~Neuropsychological testing
~Neuropsychological procedure
~Video EEG and polysomnography (standard of care procedure): 2h wake and whole night
~Sleep diary"
11129991|NCT03865771|Other|CONTROL GROUP|"Patients hospitalized for non neurologic illness (diabetes, nephropathy, chronic intestinal disease)
~Medical visit
~Neuropsychological testing
~Neuropsychological procedure
~Video EEG and polysomnography : 2h wake and whole night
~Sleep diary"
11129992|NCT03865758|Experimental|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
11129993|NCT03865758|No Intervention|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
11129994|NCT03865745|Experimental|Korean Red Ginseng|Product: Red ginseng Everytime 1 pack(3g/day)
11129995|NCT03865732|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
11129996|NCT03865732|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
11129997|NCT03865719|Other|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
11129998|NCT03865706|Experimental|Inulin 32 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.
11129999|NCT03865706|Experimental|Inulin 16 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.
11130000|NCT03865706|Placebo Comparator|Placebo|Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.
11130001|NCT03865693|Experimental|scarmbler treatment group|Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
11130002|NCT03865693|Sham Comparator|sham treatment group|conservative management without scarmbler therapy
11130003|NCT03865680|Experimental|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
11130048|NCT03865394|Experimental|Autologous ADSC cells in fibrin solution|"Application of autologous ADSC stem cells in fibrin gel, to cover wound surface with thin cells layer.
~Therapy is based on standard procedure of diabetic foot ulcer treatment combined with application onto the wound surface autologous ADSC stem cell in fibrin solution."
11130004|NCT03865680|Active Comparator|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
11130005|NCT03865667||Primary Total Hip Arthroplasty|Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
11130006|NCT03865654|Experimental|Surveillance Mammography Communication Tool|"Conduct 30 telephone-based patient interviews
~4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography
~Perform cognitive testing of the communication tool"
11130007|NCT03865641|Experimental|Virtual reality intervention|Experimental group : virtual reality intervention
11130008|NCT03865641|No Intervention|Control group|conventional rehabilitation without virtual reality intervention
11130009|NCT03865615|Experimental|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
11130010|NCT03865615|Experimental|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
11130011|NCT03865602|Experimental|Sepsis Transition And Recovery (STAR)|Virtual sepsis navigation delivered across the peri-hospital discharge interval
11130012|NCT03865602|Active Comparator|Usual Care|Patients and their providers will have no access to the STAR program. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
11130013|NCT03865589|Experimental|Patients Undergoing HCT|All patients enrolled will undergo US SWE at specific time points as outlined in the protocol based on disease course.
11130014|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
11130015|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
11130016|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
11130017|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.
~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .
~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
11130018|NCT03865563|Experimental|Pancreatic adenocarcinoma|Participants with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma will receive pancreatic retrograde venous infusion of gemcitabine/lipiodol
11130019|NCT03865550|Placebo Comparator|Placebo|
11130020|NCT03865550|Active Comparator|Ketamine|
11130021|NCT03865537|Experimental|Cold snare & Eleview injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview
11130022|NCT03865537|Experimental|Cold Snare & Placebo injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo
11130023|NCT03865537|Active Comparator|Hot snare & Eleview injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview
11130024|NCT03865537|Active Comparator|Hot snare & Placebo injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo
11130025|NCT03865524|Experimental|Experimental|Total knee arthroplasty implanted with GPS navigation system.
11130026|NCT03865524|Active Comparator|Control|Total knee arthroplasty implanted with standard guides.
11130027|NCT03865511|Experimental|TAGRISSO® 80mg (Osimertinib)|"Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
~Tumor biopsies performed at baseline and clinical progression. ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial."
11130028|NCT03865498|Experimental|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
11130029|NCT03865498|Experimental|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
11130030|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
11130049|NCT03865394|Active Comparator|Standard care in diabetic foot ulcer|Retrospective analysis of treatment outome in patients who underwent standard care procedure in diabetic foot ulcer treatment
11130050|NCT03865381|Other|Virtual Diabetes Clinic|The Onduo Virtual Diabetes Clinic (VDC) is the suite of diabetes management services including remote monitoring, diet/lifestyle coaching, medication management accessed via Onduo App and partner apps. Subjects will engage with a Care Lead through the App and will have a medical consultation via telemedicine with an Onduo VDC Physician.
11130031|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
11130032|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
11130033|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters;
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
11130034|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster:high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
11130035|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
11130036|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters
~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
11130037|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)
~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);
~Engagement booster - low: No Engagement Boosters
~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
11130038|NCT03865472|Experimental|Arm I (rTMS)|Patients undergo rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
11130039|NCT03865472|Sham Comparator|Arm II (sham rTMS)|Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
11130040|NCT03865459|Experimental|Video group|The video group watched relaxing video with a ceiling mounted television during the whole cystoscopy.
11130041|NCT03865459|No Intervention|Control group|The control group received the standard treatment from a surgical technician who works in the cystoscopy during the whole procedure.The control group didn't watch relaxing video during the procedure.
11130042|NCT03865446|Experimental|Cohort 1 (Dacomitinib)|severe hepatic impairment group
11130043|NCT03865446|Experimental|Cohort 2 (Dacomitinib)|normal hepatic function
11130044|NCT03865433|Experimental|Exercise Group|Intervention: aerobic exercise Subjects in the exercise group will be prescribed exercise at a target heart rate (THR) of approximately 80% of the achieved heart rate during the Buffalo Concussion Treadmill Test (BCTT). They will be given this prescription in writing to provide to their athletic trainer. Subjects will complete 30 minutes of daily exercise (including 5 minutes of warm up and 5 minutes of cool down) on an exercise bike or walking and supervised by an athletic trainer. This program may be modified by increasing heart rate threshold 5-10 beats per minute per week by the athletic trainer as the heart rate for symptom exacerbation increases.
11130045|NCT03865433|Placebo Comparator|Placebo/Stretching|Intrvention: stretching program Subjects assigned to the Stretching/Placebo group will be given a stretching protocol and instructions to report to their athletic trainer on a daily basis as soon as possible. . Subjects will then complete a 15-25 minute stretching program under supervision by the athletic trainer or other designated research personnel. The stretching protocol will be progressive and will change weekly as subjects continue their recovery.
11130046|NCT03865407|Active Comparator|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
11130047|NCT03865407|No Intervention|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
11130084|NCT03865186|Experimental|control group|no intervention was applied to the control group
11130051|NCT03865368|Experimental|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
11130052|NCT03865368|Active Comparator|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
11130053|NCT03865355||Cohort 1 / High grade Glioma|"Cohort 1:
~Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))
~Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
11130054|NCT03865355||Cohort 2 / Low grade Glioma|"Cohort 2:
~Histologically confirmed low-grade (grade I/II) glioma
~Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy"
11130055|NCT03865355||Cohort 3 / Conditionally healthy volunteers|"Cohort 3:
~No oncological disease was diagnosed
~Planned treatment (reconstructive surgery after craniofacial trauma)"
11130056|NCT03865342|Experimental|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
11130057|NCT03865342|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
11130058|NCT03865329|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
11130059|NCT03865316|Experimental|SedLine Vs Comparator Test Group|
11130060|NCT03865290|Experimental|Healthy Control Ondansetron 8 mg|Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
11130061|NCT03865290|Experimental|Diabetic (DM) gastroenteropathy Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
11130062|NCT03865290|Experimental|Non-ulcer dyspepsia (NUD) Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
11130063|NCT03865290|Placebo Comparator|Healthy Control Placebo|Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
11130064|NCT03865290|Placebo Comparator|Diabetic (DM) gastroenteropathy Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
~Oral matched placebo administered three times a day for weeks 3-6"
11130065|NCT03865290|Placebo Comparator|Non-ulcer dyspepsia (NUD) Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
~Oral matched placebo administered three times a day for weeks 3-6"
11130066|NCT03865277|Other|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
11130067|NCT03865277|Experimental|dose-escalated radiochemotherapy|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
11130068|NCT03865277|Experimental|escalated radiochemoth., carbon boost|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
11130069|NCT03865277|Other|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
11130070|NCT03865277|Other|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
11130071|NCT03865264|Active Comparator|Living Liver donor|"Recovery enhancement program:
~At least 6 weeks of physical and relaxation skills training pre-transplant.
~Taking nutritional drink for 5 days before and after the surgery.
~Opioid sparing pain management."
11130072|NCT03865264|Active Comparator|Living Kidney donor|"Recovery Enhancement Program
~At least 4 weeks of physical and relaxation skills training pre-transplant.
~Taking nutritional drink for 5 days before and after the surgery.
~Opioid sparing pain management."
11130073|NCT03865264|No Intervention|Living Kidney donor (Control)|"Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.
~To control post-op pain, subject will use medication per standard of care, including PCA pump."
11130074|NCT03865251|Experimental|experimental group|Kinesiology tape application to dominant leg during lying and standing positions
11130075|NCT03865238|Experimental|EV71vac|
11130076|NCT03865238|Placebo Comparator|Placebo|
11130077|NCT03865225|Sham Comparator|Control group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes sham-biofeedback over a period of three days
11130078|NCT03865225|Active Comparator|Treatment group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes biofeedback sessions over period of three days
11130079|NCT03865212|Experimental|Group A (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1.
11130080|NCT03865212|Experimental|Group B (VSV-IFNbetaTYRP1)|Patients receive recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1 IT and IV over 30-60 minutes 2-4 hours later on day 1. Cycle 1 continues for 28 days, with subsequent cycles repeating every 21 days in the absence of disease progression or unacceptable toxicity.
11130081|NCT03865199|Experimental|Intervention Group|The intervention arm will view a digital story on a tablet created by the research team, then respond to a writing prompt. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
11130085|NCT03865160|Active Comparator|Atropine eye drops, 0.01%|Atropine eye drops, 0.01%, both eyes at bedtime
11130087|NCT03865147|Experimental|Phase 1 open, pilot phase|A pilot group of 10 patients who will receive Tri-Solfen only (non-randomised) once, prior to debridement
11130088|NCT03865147|Experimental|Phase 2 - Tri-Solfen|A group of 20 patients who will receive EMLA cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by a single application of Tri-Solfen.
11130089|NCT03865147|Active Comparator|Phase 2 - Standard Care|A group of 20 patients who will receive EMLA Cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by standard of care post-operative analgesia.
11130090|NCT03865147|Experimental|Phase 3 - Tri-Solfen|A group of 20 patients who will receive two applications of Tri-Solfen (2mL/10cm2), once prior to debridement and once on completion of the procedure.
11130091|NCT03865147|Active Comparator|Phase 3 - EMLA|A group of 20 patients who will receive EMLA Cream (60-minute application) prior to surgical debridement
11130092|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
11130093|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
11130094|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
11130095|NCT03865121|Experimental|Nicotine Nasal Spray 10 MG/ML|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
11130096|NCT03865108|Experimental|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
11130097|NCT03865108|Placebo Comparator|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
11130098|NCT03865082|Experimental|IO Naive Subjects MSS CRC|8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
11130099|NCT03865069|Active Comparator|automated oxygen control with VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) with automated pressure control (Volume Guarantee®).
11130100|NCT03865069|Active Comparator|automated oxygen control without VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) without automated pressure control (Volume Guarantee®).
11130101|NCT03865056|Experimental|High-Flow Nasal Cannula|
11130102|NCT03865056|Experimental|Noninvasive ventilation|
11130103|NCT03865030|Active Comparator|psoriatic patients|psoriatic patients that are recruited from the dermatology clinic. This arm will undergo audiovestibular evaluation.
11130104|NCT03865030|Active Comparator|healthy volunteers|Healthy volunteers that are members of the hospital staff and will be recruited from the hospital. This arm will undergo audiovestibular evaluation.
11130105|NCT03865017|Experimental|Regulatory T cells|Biologicals: Autologous Regulatory T cells (1.7*10^5 cells/kg, i.v) other name: GB301
11130106|NCT03865017|Placebo Comparator|Placebo|Saline+cell suspension solution infusion
11130107|NCT03865004|Placebo Comparator|Placebo|
11130108|NCT03865004|Active Comparator|Paracetamol|
11130109|NCT03865004|Active Comparator|Dexketoprofene|
11130110|NCT03864991|No Intervention|Routine Care|This group will be followed up for routine care, maintaining a standard log book for documenting blood sugar and insulin dosages per advice and explanation by doctors, nurses and nutritionists.
11130111|NCT03864991|Active Comparator|e-device for step count (fit-bit)|This group will receive e-device for step count (fit-bit) in addition to routine care.
11130112|NCT03864991|Active Comparator|e-messages for log book|This group will receive daily e-messages for maintaining log book in addition to routine care.
11130113|NCT03864991|Active Comparator|e-messages for log book & fit-bit|This group will receive e-device for step count (fit-bit), daily e-messages for maintaining log book for blood sugar, insulin dosages and step count in addition to routine care.
11130114|NCT03864978|Experimental|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
11130115|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
11130116|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
11130117|NCT03864978|Placebo Comparator|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
11130118|NCT03864965|Experimental|Intervention Group|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will receive the guided advance care planning conversations with the PI
11130119|NCT03864965|No Intervention|Control Patients|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will not receive the guided advance care planning conversations with the PI
11130120|NCT03864939|Experimental|dHAM|dHAM wrap is placed during RRP.
11130124|NCT03864913|Experimental|Randomized SQ vs IM|Subjects randomized to either SQ or IM testosterone injections follow study protocol.
11130125|NCT03864913|Experimental|Non-randomized SQ|Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.
11130126|NCT03864913|Experimental|Non-randomized IM|Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.
11130127|NCT03864900|Experimental|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
11130128|NCT03864900|No Intervention|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
11130129|NCT03864887||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
11130130|NCT03864887||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
11130131|NCT03864887||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
11130132|NCT03864887||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
11130133|NCT03864861||Elective Bariatric Surgery|Patients older than 18 undergoing elective bariatric surgery
11130134|NCT03864835|Experimental|Moderate intensity aerobic exercise|All subjects will undergo DXA and CRF measurement (relative VO2max) under the supervision of an American College of Sports Medicine (ACSM)-certified fitness professional and study physician at the Penn State PM&R Research Laboratories. Subjects selected for the interventional pilot trial will receive a FitBit Charge2 HR and be instructed on how to use a FitBit Hear Rate monitor, Fitbit application, Fitbit website, and Fitabase (secure data management platform utilized by >400 clinical trials). Participants will record their daily food and beverage intake through the Fitbit app. Individualized feedback will be provided by a registered dietician (RD). Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist.
11130135|NCT03864822|Experimental|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
11130136|NCT03864822|Placebo Comparator|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
11130137|NCT03864809||psoriasis patients|sleep disturbance
11130138|NCT03864809||atopic dermatites patients|sleep disturbance
11130139|NCT03864809||control|sleep disturbance
11130140|NCT03864796||cases of newly diagnosed ITP|no intervention
11130141|NCT03864796||cases of ITP after responding to treatment|no intervention
11130142|NCT03864796||healthy subjects|no intervention
11130143|NCT03864783|Experimental|Curcumin (Meriva®)|Meriva® 500 mg tablet (contains 100 mg curcumin) Dosage: 2 tablets twice daily for 42 days (+/- 3 days)
11130144|NCT03864783|Placebo Comparator|Placebo|Placebo. Dosage: 2 tablets twice daily to mimic Meriva® tablets.
11130145|NCT03864770|Experimental|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
11130146|NCT03864770|Active Comparator|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
11130147|NCT03864757|Experimental|UVFP correction surgery|Short-term implantation of VOIS and evaluation of voice quality and glottal closure.
11130148|NCT03864731|Other|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
11130149|NCT03864718||complex anal fistula|
11130150|NCT03864692||Hypotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure drop below 80 mmHg or have symptoms of hypotension such as dizziness, nausea and vomiting during the procedure.
11130151|NCT03864692||Normotension group|Parturients undergoing elective C/S under spinal anesthesia whose systolic arterial pressure does not drop below 80 mmHg or have any symptoms of hypotension during the procedure.
11130152|NCT03864679|Experimental|Exercise|Subjects will perform a cycling tests
11130153|NCT03864666|Other|Sequence 1|Treatment RTRT
11130154|NCT03864666|Other|Sequence 2|Treatment TRTR
11130155|NCT03864653|Other|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
11130156|NCT03864640||Colorectal cancer|Patients with colorectal cancer
11130157|NCT03864627|Experimental|MOR106 and TCS|Repeated s.c. doses of MOR106, administered concomitantly with TCS (medium potency). On Day 1 a loading dose (LD) will be administered.
11130158|NCT03864627|Placebo Comparator|Placebo and TCS|Repeated s.c. doses of placebo, administered concomitantly with TCS (medium potency). On Day 1 a loading dose (LD) will be administered (placebo).
11130159|NCT03864614|Experimental|SAGE-217|
11130160|NCT03864601|Experimental|14C-JNJ-56136379|Participants will receive a single oral 25 milligram (mg) dose of 14C-JNJ-56136379 on Day 1 under fed conditions.
11130161|NCT03864588|Placebo Comparator|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
11130162|NCT03864588|Experimental|Intervention|Surgeon preforms inter-operative adductor canal block
11130163|NCT03864575|Experimental|Combination Group|Celecoxib 400 mg/d Nivolumab 240 mg q2w
11130164|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
11130165|NCT03864562||White European|Healthy individuals of white European descent
11130166|NCT03864549|Experimental|probiotic femina II|research group will receive the probiotic formula Femina II (2 capsules/day) until delivery.
11130167|NCT03864549|Placebo Comparator|Placebo|control group will receive a placebo (2 capsules/day) until delivery.
11130168|NCT03864536|No Intervention|No-contact control|No-contact control
11130169|NCT03864536|Active Comparator|Psychoeducation control|Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
11130170|NCT03864536|Experimental|Psychoeducation + CogRx|Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
11130171|NCT03864523|Experimental|XAMNPIO|Pioglitazone 15 mg tablets 2/day during 2 years
11130172|NCT03864497||Orthotopic liver transplantation candidates|No intervention, imaging test and risk stratification as part of routine clinical care.
11130173|NCT03864484|Experimental|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
11130174|NCT03864484|Active Comparator|Usual rehabilitation|The control group receives usual rehabilitation.
11130175|NCT03864471|Experimental|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
11130176|NCT03864471|Active Comparator|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
11130177|NCT03864458|Experimental|KHK7791 A|Patients take KHK7791 low dose BID.
11130178|NCT03864458|Experimental|KHK7791 B|Patients take KHK7791 middle dose BID.
11130179|NCT03864458|Experimental|KHK7791 C|Patients take KHK7791 high dose BID.
11130180|NCT03864458|Experimental|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
11130181|NCT03864458|Placebo Comparator|Placebo|Patients take Placebo BID.
11130182|NCT03864445|Experimental|KHK7791|Patients take KHK7791 BID and can down titrate, based on a GI tolerability question.
11130183|NCT03864445|Placebo Comparator|Placebo|Patients take Placebo BID.
11130184|NCT03864432|Experimental|25mg SAD|
11130185|NCT03864432|Experimental|50mg SAD|
11130186|NCT03864432|Experimental|100mg SAD|
11130187|NCT03864432|Experimental|50mg Multiple dosing|
11130188|NCT03864419|Experimental|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
11130189|NCT03864419|Experimental|Cohort II (DLBCL)|Patients receive rituximab and hyaluronidase human IV or SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
11130190|NCT03864419|Experimental|Cohort III (Adult BL)|Patients receive rituximab and hyaluronidase human IV or SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
11130191|NCT03864419|Experimental|Cohort IV (MCD)|Patients receive rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
11130192|NCT03864406|Experimental|A|Phase 1: a single dose of rivaroxaban on day 1 followed by serial PK/PD blood sampling Phase 2: cobicistat once daily (Days 2 7), followed by single dose of rivaroxaban and serial PK/PD blood sampling on day 7 Phase 3: darunavir /cobicistat once daily (days 8-13) followed by single dose of rivaroxaban and serial PK /PD blood sampling on day 13.
11130193|NCT03864406|Experimental|B|Phase 1: a single dose of apixaban on day 1 followed by serial PK/PD blood sampling Phase 2: cobicistat once daily (Days 2-7), followed by single dose of apixaban and serial PK /PD blood sampling on day 7 Phase 3: darunavir /cobicistat once daily (days 8-13) followed bysingle dose of apixaban and serial PK/PD blood sampling on day 13.
11130194|NCT03864393|Experimental|Multimodal overground locomotor training|Individuals with Parkinson's Disease that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 12-week multimodal exercise training intervention performed twice per week.
11130195|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :
~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
11130196|NCT03864367||Device|This group will use the MWeST lift device along with regular physical therapy. The lift device is the Prism Medical FGA-700 Bariatric Floor Lift including a sling to assist in walking.
11130197|NCT03864367||Control|This group will only receive regular physical therapy.
11130198|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
11130199|NCT03864341|Experimental|Homelessness Prevention Services|
11130200|NCT03864328|Experimental|RVT-1601 Low Dose|
11130201|NCT03864328|Experimental|RVT-1601 Mid Dose|
11130202|NCT03864328|Experimental|RVT-1601 High Dose|
11130203|NCT03864328|Placebo Comparator|Placebo|
11130204|NCT03864315|Experimental|Vitiligo|30 Patients with Vitiligo
11130335|NCT03863444|Experimental|Intervention Group|Routine Care + Prenatal Preparation Education
11132587|NCT03847844|Placebo Comparator|Group B|Placebo (normal saline) and standard treatment
11130205|NCT03864302|Experimental|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.
~Table 1: PEELP framework:
~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I…"
11130206|NCT03864302|No Intervention|Control|The control group proceeds directly to standard VR-simulator training.
11130207|NCT03864289|Experimental|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours.
11130208|NCT03864276|Experimental|inhalation anesthesia (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
11130209|NCT03864276|Experimental|Total intravenous anesthesia (propofol) group|Anesthesia is induced and maintained with propofol and sufentanil
11130210|NCT03864263||Children with HBsAg-positive patients|Children from a father or mother who are infected with HBV
11130211|NCT03864263||Children without a family history of HBV|Children without a family history of HBV infection
11130212|NCT03864250|Experimental|Tacrolimus monotherapy|
11130213|NCT03864250|Active Comparator|Tacrolimus combined with hormone therapy|
11130214|NCT03864237|Experimental|Alcohol texts|Participants assigned to this arm will receive a text message each day for 10 weeks, containing factual information about campus drinking norms.
11130215|NCT03864237|Placebo Comparator|Attention control|"Participants assigned to this arm will receive a text message each day for 10 weeks, containing this day in history facts."
11130216|NCT03864211|Active Comparator|Toriplimab monotherapy|Toriplimab is administrated 3 mg/kg intravenously every 3 weeks continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
11130217|NCT03864211|Experimental|Thermal ablation plus toriplimab|One to three target lesions will be ablated completely. Toriplimab therapy will be initiated on day 3 or day 14 after ablation (3 mg/kg intravenously every 3 weeks). Toriplimab is administraed continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
11130218|NCT03864198|Other|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
11130219|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody positive)|
11130220|NCT03864185|Placebo Comparator|Placebo group (IgG4 autoantibody positive)|
11130221|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody negative)|
11130222|NCT03864172|Placebo Comparator|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
11130223|NCT03864172|Active Comparator|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
11130224|NCT03864172|Active Comparator|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
11130225|NCT03864172|Active Comparator|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
11130226|NCT03864159|Experimental|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time.The intervention through the suction cups will consist of its application and produce increased flexibility of the hamstring musculature. The technique will be performed with the subject in prone position, on the stretcher, while the physiotherapist will be placed next to the member to be treated. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
11130227|NCT03864159|Active Comparator|Foam roller|The intervention will be carried out before starting the training session. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
11130228|NCT03864146|Experimental|Pioglitazone|Pioglitazone titrated to 45mg by mouth each day
11130229|NCT03864146|Placebo Comparator|Placebo|placebo, identical 45mg pill
11130230|NCT03864133|Other|Omidria|Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.
11130231|NCT03864094|Active Comparator|Ephedrine Propofol Remifentanil|Prophylactic Ephedrine
11130232|NCT03864094|Active Comparator|Phenylephrine Propofol Remifentanil|Prophylactic Phenylephrine
11130233|NCT03864094|Active Comparator|Norepinephrine Propofol Remifentanil|Prophylactic Norepinephrine
11130234|NCT03864094|Sham Comparator|Sodium chloride Propofol Remifentanil|NaCl Placebo
11130235|NCT03864068|Placebo Comparator|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
11130236|NCT03864068|Experimental|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
11130237|NCT03864068|Experimental|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
11130238|NCT03864068|Experimental|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
11130239|NCT03864055||Pediatric Otogenic CSVT|Children with Otogenic Cerebral Sinus Vein Thrombosis (CSVT)
11130428|NCT03862768|Experimental|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
11130240|NCT03864042|Experimental|Arm 1 - CYP Probe Cocktail|"Patients will receive a single oral dose of the CYP Probe Cocktail on Day -7, Day 1, and Day 14:
~25 mg losartan oral tablet
~30 mg dextromethorphan oral capsule
~50 mg caffeine oral liquid
~20 mg omeprazole oral capsule
~2 mg midazolam oral syrup
~encorafenib/binimetinib continuous daily dosing starting Day 1:
~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
~All drugs will be taken within 10 minutes."
11130241|NCT03864042|Experimental|Arm 2 - Rosuvastatin and Bupropion|"Patients will receive a single oral dose of rosuvastatin and bupropion once on Day -7, Day 1 and Day 14:
~10 mg rosuvastatin oral tablet
~75 mg bupropion immediate release (IR) oral tablet
~encorafenib/binimetinib continuous daily dosing starting Day 1:
~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
~All drugs will be taken within 10 minutes."
11130242|NCT03864042|Experimental|Arm 3 - Modafinil|"Patients will begin encorafenib/binimetinib continuous daily dosing starting Day 1:
~450 mg (6 x 75 mg) encorafenib oral capsules once daily (QD)
~45 mg (3 x 15 mg) binimetinib oral tablet twice daily (BID)
~then receive continuous treatment of modafinil on Day 15 through Day 21:
~- 400 mg modafinil tablet once daily (QD)"
11130243|NCT03864016|Other|Standard group|
11130244|NCT03864016|Experimental|Pupillometry group|
11130245|NCT03864003|Experimental|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
11130246|NCT03864003|Active Comparator|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
11130247|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
11130248|NCT03863977|Active Comparator|Dex4 group|After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
11130249|NCT03863977|Active Comparator|Dex8 group|After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
11130250|NCT03863977|Active Comparator|control group|After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.
11130251|NCT03863964|Placebo Comparator|plasma TXA and ROTEM test at baseline|Blood test
11130252|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 15 minutes|Blood test
11130253|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 30 minutes|Blood test
11130254|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1 hour|Blood test
11130255|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1.5 hours|Blood test
11130256|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2 hours|Blood test
11130257|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2.5 hours|Blood test
11130258|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 hours|Blood test
11130259|NCT03863951||Patients with poststroke depression|No intervention
11130260|NCT03863951||Patients without poststroke depression|No intervention
11130261|NCT03863938|Experimental|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
11130262|NCT03863938|Experimental|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
11130263|NCT03863938|Experimental|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
11130264|NCT03863925|Experimental|Propofol Target Controlled Infusion Group (Group T)|Patients in group T underwent anesthesia with Propofol (dosage form: 10mg/mL) target controlled infusion by Schnider model, starting at concentration of effect site (Ce) of 1.5 mcg/mL and titrating to achieve Observer's Assessment of Alertness/Sedation (OAA/S) Scale level 3 (responds only after name called loudly or repeatedly). Patients were paralyzed with suxamethonium (dosage form: 20mg/mL; dosage: 1mg/kg) once adequate sedation level achieved. TCI was stopped once the psychiatrist applied electroconvulsive stimulation to patients' bilateral frontal regions. Assisted ventilation with bag-valve-mask device by experienced anesthesiologists was began since patients were sedated until adequate spontaneous respiration was regained after each single electroconvulsive therapy (ECT) session. Every patient receive total six to twelve ECT sessions, and each ECT session was conducted one day apart.
11130265|NCT03863925|Active Comparator|Propofol Bolus Group (Group B)|Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
11130266|NCT03863912|Active Comparator|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
11130267|NCT03863912|Other|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
11130268|NCT03863899|Experimental|Nerve block|ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)
11130269|NCT03863899|Active Comparator|Local infiltration|local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)
11130270|NCT03863886|Experimental|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
11130271|NCT03863886|Experimental|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
11130336|NCT03863431|Active Comparator|High-fat diet|"Participants will consume a diet rich in fat (approximately 65% of total energy) and low in carbohydrate for 14 days.
~Measurements will be made at 0, 7 and 14 days."
11130272|NCT03863886|Experimental|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
11130273|NCT03863873|Active Comparator|PRP Injection Group|PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
11130274|NCT03863873|Active Comparator|Steroid injection Group|A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection
11130275|NCT03863860|Experimental|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
11130276|NCT03863860|Placebo Comparator|Placebo capsules, 50mg per capsule|Placebo capsules, PO
11130277|NCT03863847|Active Comparator|Online Neurofeedback|This intervention entails online feedback of pain-related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
11130278|NCT03863847|Sham Comparator|Online Sham Neurofeedback|This intervention entails online sham feedback of non-pain related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
11130279|NCT03863834|Experimental|Treatment arm|Subjects receive the RFAL treatment
11130280|NCT03863821|Experimental|HHHFNC group|Practice 6 MWT with HHHFNC
11130281|NCT03863821|No Intervention|non-HHHFNC group|Practice 6 MWT without HHHFNC
11130282|NCT03863808|Experimental|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.
~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.
~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
11130283|NCT03863808|Active Comparator|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).
~Exercises will be graduated according to the patient pain tolerance."
11130284|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
11130285|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
11130286|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
11130287|NCT03863743|Other|Control|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. Patient will undergo treating physician's standard of care for total hip or knee replacement. Patient will receive bladder scans in PACU, upon admission to the nursing unit, and prior to discharge (post-void).
11130288|NCT03863743|Experimental|Experimental|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. If considered high risk (determined by IPSS), then patient Patient will undergo integrated care pathway that avoids narcotics. Bladder volume will be measured in PACU, after admission to the nursing unit, and prior to discharge from the hospital (post-void).
11130289|NCT03863730|Experimental|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
11130290|NCT03863730|Active Comparator|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
11130291|NCT03863717|Experimental|Arm Endurance Exercise Training Group|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
11130292|NCT03863717|Active Comparator|Control Group|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
11130293|NCT03863704|Sham Comparator|nerve stimulation ear then leg|Subjects in this arm will be randomized to receive nerve stimulation with TENS of the ear followed by leg stimulation
11130294|NCT03863704|Sham Comparator|nerve stimulation leg then ear|Subjects in this arm will be randomized to receive leg nerve stimulation with TENS followed by ear nerve stimulation
11130295|NCT03863704|Other|Subjects receiving Infliximab|Subjects on Infliximab as part of their clinical care will not be randomized as the study treatment for these subjects will be the same. The sham arm is not included for patients on infliximab.
11130296|NCT03863691|Active Comparator|amisulpride group|300 mg of the atypical antipsychotic drug amisulpride
11130297|NCT03863691|Placebo Comparator|placebo group|Similar looking capsules for placebo control
11130298|NCT03863678|Experimental|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
11130299|NCT03863678|Experimental|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
11130426|NCT03862781|Other|Intra-corporeal|Right Hemicolectomy
11130300|NCT03863665|Experimental|Telemetric Bluetooth home BP monitors|Telemetric Bluetooth home BP monitors will be provided to participants during their inpatient stay or clinic visit, and will commence 3- times-daily readings immediately. The BP monitoring team will assess BP readings daily and advise medication adjustments to achieve a target BP of <120/80 mm Hg
11130301|NCT03863665|No Intervention|Standard clinical care|Standard clinical care including usual BP treatment, without home monitoring, undertaken in the clinical care setting
11130302|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
11130303|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
11130304|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
11130305|NCT03863626|Active Comparator|Frusemide IV shots = group A|Frusemide as IV shots
11130306|NCT03863626|Active Comparator|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
11130307|NCT03863613|Active Comparator|Pessary group|A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
11130308|NCT03863613|Active Comparator|Cerclage group|Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
11130309|NCT03863613|Active Comparator|Pessary plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
11130310|NCT03863613|Active Comparator|Cerclage plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
11130311|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
11130312|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
11130313|NCT03863587|Experimental|HLX12 group|HLX12 are given intravenous infusion 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
11130314|NCT03863587|Active Comparator|Cyramza (Ramucirumab) group|Ramucirumab are given intravenous infusion of Cyramza 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
11130315|NCT03863574|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
11130316|NCT03863574|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
11130317|NCT03863574|Placebo Comparator|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
11130318|NCT03863561||Waiting room sample|Patients with type 1 or type 2 diabetes attending an LMC Diabetes & Endocrinology specialist clinic in Ontario completed the SCPI in the waiting room while attending their usual appointment with their healthcare provider.
11130319|NCT03863561||DSME Intervention|Patients with poor glycemic control (A1C >8.0%) were enrolled into a diabetes self-management education (DSME) program. The SCPI was completed at their first and last visit and and their individual results were incorporated into the care paths that were then customized for that participant. The patient met with a diabetes educator five to seven times over the course of three to four months.
11130320|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
11130321|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
11130322|NCT03863535|Experimental|Intravitreal conbercept+Panretinal coagulation|
11130323|NCT03863535|Active Comparator|Panretinal coagulation|
11130324|NCT03863522|Other|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
11130325|NCT03863509||Exclusive Smokers|Smokes Daily; >/= 5 cigarettes/day for last 6 months
11130326|NCT03863509||Exclusive E-Cig users|E-cig usage >/= 5 days/week for last 3 months
11130327|NCT03863509||Dual users|>/= 5 cigarettes/day for last 6 months AND E-cig usage >/= 5 days/week for last 3 months
11130328|NCT03863509||Never users|< 100 cigarettes in lifetime, none for > 5 years; < 3 E-cig usage in lifetime
11130329|NCT03863496|Other|Neuromuscular scoliosis|
11130330|NCT03863483|Experimental|Sintilimab plus chemotherapy|Sintilimab (200 mg) plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
11130331|NCT03863483|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice between docetaxel and pemetrexed) every 3 weeks.
11130332|NCT03863470|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 12 weeks of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the ICU. The length of the control phase will differ for each ICU cluster, depending on the sequence in which ICU-clusters are assigned to switch to the intervention phase.
11130333|NCT03863470|Active Comparator|Early mobilization intervention|The clinical team will set a standardized mobility goal for each patient during morning rounds and display the goal on the patient's door. A facilitator will be established in the ICU to communicate mobility goals and activities across clinical personnel shifts. Patient mobility scores will be displayed to clinical and administrative staff in the ICU via the ICU board.
11130334|NCT03863444|Active Comparator|Control Group|Routine Care
11130337|NCT03863431|Active Comparator|High-carbohydrate diet|"Participants will consume a diet rich in carbohydrate (approximately 70% of total energy) and low in fat for 14 days.
~Measurements will be made at 0, 7 and 14 days."
11130338|NCT03863418|Experimental|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
11130339|NCT03863418|Placebo Comparator|placebo|maltodextrin
11130340|NCT03863405|Experimental|Metformin Group|850 mg metformin twice daily for six months in addition to standard therapy
11130341|NCT03863405|Active Comparator|Control Group|placebo in addition to standard therapy for rheumatoid arthritis
11130342|NCT03863392|Experimental|oral|patients undergoing induction of labour using misoprostol oral solution
11130343|NCT03863392|Experimental|vaginal|patients undergoing induction of labour using vaginal misoprostol
11130344|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
11130345|NCT03863379||Control group|Able bodied persons
11130346|NCT03863366|Experimental|Prucalopride|1mg prucalopride capsule
11130347|NCT03863366|Placebo Comparator|Placebo|Lactose placebo capsule
11130348|NCT03863353|Experimental|Education Intervention|This group will receive the scenario-tailored STOMP educational feedback
11130349|NCT03863353|No Intervention|Control|This group will receive only standard of care information.
11130350|NCT03863340|Experimental|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
11130351|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-1)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-1 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
11130352|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-2)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-2 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
11130353|NCT03863327||Acute severe 3-vessel disease or critical left main stenosis|"Severe 3-vessel disease: >/=75% stenosis in all three major coronary vessels (or equivalents in the case of anatomic variants or preexisting bypass) with an acute culprit lesion (TIMI<3) or
~Left main stenosis > 50% (see Smith review paper for reference): acute left main culprit of any TIMI score, or any lesion of the left main with TIMI<3 or
~Any other cardiac catheterization findings prompting initiation of emergent coronary artery bypass grafting within the next 120 hours"
11130354|NCT03863327||No evidence of acute coronary occlusion|"At least three sequential negative cardiac biomarkers within 24 hours of presentation
~cardiac catheterization showing no culprit lesion.
~Angiogram showing an acute culprit lesion but both no occlusion (TIMI 2 or greater) and troponins not exceeding the cutoff above
~If positive troponin values present but no angiography, then the patient must have echocardiography showing no wall motion abnormality and troponin values less than the above cutoff
~If the patient has insufficient data to classify into one of these categories, the patient must be excluded from the study as they cannot be classified as ACO or non-ACO. For example, patients with extremely high troponin but no culprit seen on cath may have acute occlusion with complete autolysis of thrombus, myocarditis, spasm, etc. Thus the investigators cannot classify them as NO ACO when the possibility of ACO remains and cannot be disproven."
11130355|NCT03863314|Active Comparator|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
11130356|NCT03863314|Experimental|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
11130357|NCT03863301|Experimental|MR-guided single dose preoperative PBI|
11130358|NCT03863288|Placebo Comparator|Intranasal Spray Placebo|Nasal spray of placebo liquid solution as a single dose. fMRI scan pre and post administration.
11130359|NCT03863288|Active Comparator|Oxytrocin Intranasal Spray 8IU|Nasal spray of Oxytocin8IU liquid solution as a single dose. fMRI scan pre and post administration.
11130360|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 24IU|Nasal spray of Oxytocin 24IU liquid solution as a single dose. fMRI scan pre and post administration.
11130361|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 48IU|Nasal spray of Oxytocin 48IU liquid solution as a single dose. fMRI scan pre and post administration.
11130362|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 80IU|Nasal spray of Oxytocin 80U liquid solution as a single dose. fMRI scan pre and post administration.
11130363|NCT03863275|Other|No intervation|Children between the ages of 7 and 12 diagnosed with class II dental classification, who attend the Leonardo Da Vinci School after carrying out an intraoral and extraoral photography study and diagnostic impressions with study models accepting participation in the study, Children over the age of 12 who have an agreement according to the results of medical care. Patients with Pierre Robin syndrome or any form of cleft.
11130364|NCT03863275|Experimental|Myofunctional apparatus|Boys and girls between 7 and 12 years skeletal class II, for the study group the individuals will be selected from the UNICIEO postgraduate clinic of orthopedic clinic orthodontics after conducting a full clinical case study exposed to a board of specialist teachers in orthodontics, where by means of several diagnostic methods a skeletal class II is confirmed that involves a treatment with myofunctional apparatus SN1; patients presenting syndromes that generate craniofacial alterations, patients with previous orthopedic treatment, patients with signs of condyle lesions, patients with Pierre Robin syndrome or any form of slit will be excluded.
11130427|NCT03862781|Other|Extra-corporeal|Right Hemicolectomy
11130365|NCT03863249|Active Comparator|The exCELLigence system|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.
~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.
~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.
~The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit."
11130366|NCT03863249|Active Comparator|Origen|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.
~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.
~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.
~The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit."
11130367|NCT03863249|Active Comparator|Echevarne|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.
~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.
~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.
~The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit."
11130368|NCT03863236|Active Comparator|regular diet|The control group (group 1) will continue their regular diet.
11130369|NCT03863236|Active Comparator|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support two weeks before the operation and the nutritional support will continue 10 days after the operation.
11130370|NCT03863223|Experimental|A|Pyrotinib Plus trastuzumab and docetaxel
11130371|NCT03863223|Placebo Comparator|B|Placebo plus trastuzumab and docetaxel
11130372|NCT03863210|Experimental|Participants who received informations about lifestyle change|
11130373|NCT03863197|Experimental|Intervention group|During a 12-week period children receive 3-4 sessions of progressive strength training per week on top of the usual care. All children will be provided with an individualized training program and supporting equipment. One or 2 session per week will be performed under supervision of the physical therapist, whilst the remaining sessions will be performed at home. Progression is closely monitored by the principal investigator and training programs are adjusted if necessary.
11130374|NCT03863197|No Intervention|Waitlist-control group|The waitlist-control group will continue their usual care without additional treatment for 12-weeks, followed by a 12-week period of progressive supervised home-based strength training.
11130375|NCT03863184|Experimental|ALR in Combination|Acalabrutinib, lenalidomide, and rituximab in combination
11130376|NCT03863171||Ocular ischemia syndrome|Patients with ocular ischemia syndrome
11130377|NCT03863171||Control|Patients with age-related macular degeneration
11130378|NCT03863145|Experimental|1|Part 1 (Dose Escalation): 100 mg daily.
11130379|NCT03863132|Active Comparator|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
11130380|NCT03863132|No Intervention|Medical Treatment Group|Patients will receive optimal medical treatment alone.
11130381|NCT03863093|Experimental|An erythritol powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
11130382|NCT03863093|Active Comparator|ultrasonic instrumentation|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
11130383|NCT03863080|Experimental|Regimen A|RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
11130384|NCT03863080|Experimental|Regimen B|RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
11130385|NCT03863080|Placebo Comparator|Placebo|Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
11130386|NCT03863067|Experimental|Lumbar spinal stenosis patients|Epiduroscopy in patients with lumbar spinal stenosis
11130387|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
11130388|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
11130389|NCT03863041|Other|Additional MRI SCAN sequence|Additional sequence performed during MRI scan
11130390|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
11130391|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
11130392|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
11130393|NCT03863015|Active Comparator|Tocilizumab|A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
11130394|NCT03863015|Placebo Comparator|Isotonic saline|A one hour infusion of isotonic saline
11130395|NCT03863002|No Intervention|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).
11130490|NCT03862326|Other|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
11130396|NCT03863002|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
11130397|NCT03862976|Experimental|computerized cardiotocography|computerized cardiotocography
11130398|NCT03862976|Active Comparator|standard cardiotocography|standard cardiotocography non stresstest
11130399|NCT03862963|Active Comparator|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
11130400|NCT03862963|Experimental|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
11130401|NCT03862950|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
11130402|NCT03862950|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
11130403|NCT03862937|Experimental|Experimental|The experimental group will perform 12 weeks of strength training twice a week associated with whey protein supplementation.
11130404|NCT03862937|Placebo Comparator|Placebo|The placebo group will perform 12 weeks of strength training twice a week associated with maltodextrin supplementation.
11130405|NCT03862924|Experimental|Active condition|Participants in the active condition will be provided with the Standardized Research Electronic Cigarette (SREC) and will be encouraged to use the SREC whenever they would normally smoke a cigarette.
11130406|NCT03862924|No Intervention|Standard Condition|Participants in this condition will be asked to continue to smoke their usual brand of cigarettes.
11130407|NCT03862911|Active Comparator|Standard of Care Treatment (Arm 1)|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
11130408|NCT03862911|Experimental|Stereotactic Arm (Arm 2)|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
11130409|NCT03862898|Experimental|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
11130410|NCT03862898|Active Comparator|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
11130411|NCT03862872|Experimental|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
11130412|NCT03862872|Active Comparator|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
11130413|NCT03862872|Placebo Comparator|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
11130414|NCT03862859|Active Comparator|Treatment with Warfarin|Warfarin with dosing targeting an international normalized ratio of 2-3.
11130415|NCT03862859|No Intervention|No treatment|No treatment
11130416|NCT03862846|Experimental|Group|REN001 Low Dose
11130417|NCT03862833|Experimental|experimental group|"Zoledronic acid and IL-2 Zoledronic acid: 4 mg
~Three IL2 levels will be tested:
~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion"
11130418|NCT03862833|No Intervention|control group|no experimental treatment
11130419|NCT03862807|Experimental|Patisiran|Participants will receive patisiran during the Treatment Period.
11130420|NCT03862794|Experimental|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
11130421|NCT03862794|Active Comparator|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
11130422|NCT03862794|Experimental|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
11130423|NCT03862794|Active Comparator|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
11130424|NCT03862794|Experimental|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
11130425|NCT03862794|No Intervention|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
11130429|NCT03862768|Active Comparator|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
11130430|NCT03862755|Experimental|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
11130431|NCT03862742||Patients admitted to the hospital|We will recruit patient volunteers from the Scripps Green Hospital and Scripps Memorial Hospital inpatient teaching services.
11130432|NCT03862729||Early minimally invasive surgery group|For patients in minimally invasive surgery group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
11130433|NCT03862729||conventional treatment group|Eligible patients not accepting early minimally invasive surgery are classified as the conventional treatment group. Conventional treatment includes medical treatment and conventional craniotomy. According to the intention-to-treat principle, patients treated by minimally invasive surgery beyond the 24 hours interval after ICH onset are also classified as conventional treatment group.
11130434|NCT03862716|Experimental|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
11130435|NCT03862716|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
11130436|NCT03862703|Experimental|Experimental group|PTSD Help intervention combined with care as usual.
11130437|NCT03862703|No Intervention|Control group|Care as usual.
11130438|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
11130439|NCT03862677||Patients with (suspicion of) primary EOC|
11130440|NCT03862677||Patients with recurrent EOC|
11130441|NCT03862651|Experimental|Cangrelor|Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period
11130442|NCT03862651|No Intervention|placebo|patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered
11130443|NCT03862638|Experimental|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
11130444|NCT03862625|Experimental|a modular adaptive seating system|In the first group, there is home exercises program for scoliosis and a modular adaptive seating system.
11130445|NCT03862625|Active Comparator|home exercises for scoliosis|In the second group there is only home exercise program for scoliosis.
11130446|NCT03862612|Active Comparator|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
11130447|NCT03862612|Experimental|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
11130448|NCT03862599|Sham Comparator|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
11130449|NCT03862599|Active Comparator|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
11130450|NCT03862586|Experimental|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
11130451|NCT03862586|Placebo Comparator|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
11130452|NCT03862573|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during the dental procedure
11130453|NCT03862573|No Intervention|Control (Standard of Care)|Participants are distracted with Standard-of-Care by dentists and/or parents.
11130454|NCT03862560|Experimental|Experimental group|Female soccers that perform a strength training
11130455|NCT03862560|No Intervention|Control group|Female soccers that do not perform a strength training
11130456|NCT03862547|Experimental|Men with ED and diabetes|"A peripheral blood sample from the cubital vein
~A collection of peripheral blood from the routinary cubital vein for hormone dosage and metabolic evaluation
~An introverted cavernous infiltration of Prostaglandin E1 to achieve erection (Aprostadil);
~A blood sample from both the corpus cavernosum and the cubital vein, once the erection is achieved Baseline interaction of prostaglandin E1 on the concentration of NGF released in the medium and on the expression of its receptors Evaluation of NGF and Cytokine levels Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs"
11130457|NCT03862534|Experimental|CAF|After the restoration of the enamel patients were treated with a CAF
11130458|NCT03862534|Experimental|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
11130459|NCT03862521|Experimental|Low carbohydrate diet group|Low carb diet, carbohydrates make up 30-40% of total daily calories.
11130460|NCT03862521|Experimental|Very low carbohydrate diet|Very low carb diet, carbohydrates make up 20-29% of total daily calories.
11130461|NCT03862508|Experimental|Experimental|Five Plyometric exercises
11130462|NCT03862508|No Intervention|Control|Subjects included in the control group will not receive any intervention
11130491|NCT03862326|Experimental|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
11130492|NCT03862326|Experimental|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
11130463|NCT03862495|Experimental|Chlamydia Screening and Treatment|At the time of recruitment and prior to delivery, this group will have immediate testing for C. trachomatis and N. gonorrhoeae. Physicians will notify C. trachomatis positive results to pregnant women and suggest them and their spouses to get treated according to the national standard treatment plan for Chlamydia (Azithromycin 1g, single oral administration). Patients will be followed up to confirm cure of C. trachomatis in one month. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
11130464|NCT03862495|Experimental|Control|This group will have testing after delivery (immediately following childbirth) or in the event of an adverse pregnancy outcome for C. trachomatis and N. gonorrhoeae. In the event of a positive test, patients will be informed of the positive test results the same way as the intervention group. Specific treatment options will be the same as the intervention group. Physicians will ask patients to return to Nanhai Hospital one month after treatment for test of cure. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
11130465|NCT03862482|Active Comparator|Brånemark 2, Swede-Vent 2, Screw-Vent 1.|Device placement: B (Brånemark dental implant) placed at two sites, SW (Swede-Vent dental implant) placed at two sites, SC (Screw-Vent dental implant) placed at one site.
11130466|NCT03862482|Experimental|Brånemark 1, Swede-Vent 2, Screw-Vent 2.|Device placement: B (Brånemark dental implant) placed at one site, SW (Swede-Vent dental implant) placed at two sites, SC (Screw-Vent dental implant) placed at two sites.
11130467|NCT03862482|Experimental|Brånemark 2, Swede-Vent 1, Screw-Vent 2.|Device placement: B (Brånemark dental implant) placed at two sites, SW (Swede-Vent dental implant) placed at one site, SC (Screw-Vent dental implant) placed at two sites.
11130468|NCT03862469|Other|Study Procedure (all participants)|"Diagnostic Phase (2 months): at-home urine hormone testing and completion of daily online surveys.
~Individualized Task (-6 to -2 days from the subsequent menstrual cycle)"
11130469|NCT03862456|Experimental|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
11130470|NCT03862456|Active Comparator|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
11130471|NCT03862443|Experimental|Fixed Incentive|Eligible to earn a weekly payment during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will win $5; high adherence threshold (brushing twice per day for 14 days in a week) will win $10.
11130472|NCT03862443|Experimental|Drawing Incentive|Eligible to earn a weekly drawing entry with different winning probabilities during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
11130473|NCT03862443|No Intervention|Control - Delayed Incentive|No rewards during the first 2-months, but information on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app. After the Month 2 follow-up visit, may opt to participate in a delayed 2-month open label extension to earn the same monetary rewards the fixed incentive intervention group could earn Baseline through Month 2. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
11130474|NCT03862430|Experimental|NVX 108|NVX-108 infusion in conjunction with Radiation Treatment and temozolimide
11130475|NCT03862430|Placebo Comparator|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolimide
11130476|NCT03862417|Experimental|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
11130477|NCT03862417|No Intervention|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
11130478|NCT03862404|Placebo Comparator|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
11130479|NCT03862404|Experimental|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
11130480|NCT03862391|Active Comparator|Postsurgical Pain|pain is defined as unpleasant sensation that can range from mild, localized discomfort to agony.
11130481|NCT03862391|Active Comparator|Postanesthesia nausea and vomiting|nausea defined as feeling of sickness or discomfort in the stomach that may come with an urge to vomit.
11130482|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
11130483|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
11130484|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
11130485|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
11130486|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
11130487|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
11130488|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
11130489|NCT03862352||Coronary artery perforation (iatrogenic)|Any coronary artery perforation defined according to the Ellis criteria.
11130493|NCT03862313|Experimental|active-rtACS arm|Active rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
11130494|NCT03862313|Sham Comparator|sham-rtACS arm|Sham rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
11130495|NCT03862287|Active Comparator|Intrathecal Lidocaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
11130496|NCT03862287|Active Comparator|Intrathecal Bupivacaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
11130497|NCT03862274||CLN2 Natural History Control Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
11130498|NCT03862274||CLN2 Treatment Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
11130499|NCT03862261|No Intervention|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
11130500|NCT03862261|Experimental|Intervention|Integrated pediatric TB services
11130501|NCT03862248|Experimental|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
11130502|NCT03862248|Experimental|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
11130503|NCT03862248|Active Comparator|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
11130504|NCT03862235||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.
~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
11130505|NCT03862235||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.
~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
11130506|NCT03862235||Sedentary control|"This group were sedentary men without cardiovascular disease.
~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
11130507|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
11130508|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
11130509|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
11130510|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
11130511|NCT03862209|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
11130512|NCT03862209|No Intervention|Standard care|Health care settings and their providers randomised to the control condition receive usual care: participant will gain standard care; ambulatory care, day hospitals or hospital admission.
11130513|NCT03862196|Experimental|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
11130514|NCT03862196|No Intervention|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
11130515|NCT03862183||dyslipidemia in hypertension|
11130516|NCT03862183||hypertension|
11130517|NCT03862170|Active Comparator|Ciprofloxacin|Patients in this arm will receive Ciprofloxacin 400mg IV 120mn (prophylactic antibiotic) before their HDR brachytherapy
11130518|NCT03862170|Experimental|Cefazolin|Patients in this arm will receive Cefazolin 2000mg IV 60mn (prophylactic antibiotic) before their HDR brachytherapy
11130519|NCT03862170|No Intervention|No prophylactic antibiotics|Patients in this arm will not receive any prophylactic antibiotics before their HDR brachytherapy
11130520|NCT03862157|Experimental|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11130521|NCT03862144|Experimental|Netupitant/Palonosetron & Dexamethasone|"Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.
~Dexamethasone 12 mg will be added on day 1 only of each cycle."
11130554|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
11130555|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
11130522|NCT03862131|Experimental|MyoStrain® unblinded treatment arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk Group
~The unblinded treatment arm will enhance patient management by augmenting standard of care with serial MyoStrain® monitoring of the impact of cancer therapy on myocardial function.
~Higher Risk unblinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.
~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
11130523|NCT03862131|Active Comparator|MyoStrain® blinded control arm|"After consenting to the PROACT study, patients will undergo a baseline MRI to determine their risk stratification for the study. This baseline MyoStrain® MRI must demonstrate 2 or more segments measuring >-10% or 9 or more segments >-17% for entrance into the study as the Higher Risk group
~The blinded control arm will provide investigators with LVEF and LVEDV/LVESV measurements, which are clinical, in conjunction with standard of care
~Higher Risk blinded patients will continue to undergo MyoStrain® MRI testing, regardless of study arm, at 1 month (+1 week), 3 months (+ 1 week), 6 months (+1 week), 12 months (+ 30 days), 24 months (+30 days), and 36 months (+30 days) after the baseline visit.
~In addition to the MyoStrain® testing, patients will also be asked to complete a brief patient satisfaction questionnaire at each PROACT time point."
11130524|NCT03862105|Experimental|Health App with Provider Monitoring/Care|30 patients enrolled by the study team will receive notifications through a mobile health app (Twistle) before and after surgery. Patient Reported Outcome data will be collected through patient responses in this app and timely clinician feedback will be provided to patients to prevent complications and readmission.
11130525|NCT03862092|Experimental|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
11130526|NCT03862079|Experimental|Arm I (TGD + FMT)|Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
11130527|NCT03862079|Experimental|Arm II (FMT)|Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
11130528|NCT03862079|Active Comparator|Arm III (standard therapy)|Patients receive standard of care.
11130529|NCT03862066||Received Nivolumab|
11130530|NCT03862066||Nivolumab Naive|
11130531|NCT03862053|Active Comparator|Manuka honey eyedrops|optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study
11130532|NCT03862053|Placebo Comparator|Normal saline 0.9% eyedrops|sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study
11130533|NCT03862040|Experimental|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
11130534|NCT03862027|Experimental|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed > 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
11130535|NCT03862014|Experimental|SDF only|SDF will be applied on molars with MIH
11130536|NCT03862014|Active Comparator|SDF+ARR|SDT+ARR will be applied on molars with MIH
11130537|NCT03862001|Experimental|LungCARE Group|The intervention group will receive the LungCARE intervention
11130538|NCT03862001|No Intervention|Comparison Group|The comparison group will receive usual care.
11130539|NCT03861988|Experimental|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
11130540|NCT03861988|Experimental|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
11130541|NCT03861988|Placebo Comparator|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
11130542|NCT03861975|Experimental|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
11130543|NCT03861949|No Intervention|Conventional|preoxygenation done with 100% oxygen in supine position
11130544|NCT03861949|Experimental|Positive-pressure|preoxygenation done with 5 cmH2O CPAP (continuous positive airway pressure) in supine position with 100% oxygen
11130545|NCT03861949|Experimental|Head-up|preoxygenation done in 25 degree head-up position with 5 cmH2O CPAP with 100% oxygen
11130546|NCT03861936|Experimental|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
11130547|NCT03861936|Experimental|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
11130548|NCT03861936|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
11130549|NCT03861923|Experimental|Dry needling and exercise|
11130550|NCT03861923|Sham Comparator|Sham dry needling and exercise|
11130551|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
11130552|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
11130553|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
11130642|NCT03861364|Active Comparator|High Propofol|High Propofol induction dose
11130556|NCT03861897|Experimental|Intervention KRP-NI + KM|Realization of Non instrumental pleural chest physiotherapy and Mobilization physiotherapy sessions (KRP-NI)
11130557|NCT03861897|Active Comparator|Control KM|Realization of mobilization physiotherapy sessions (KM)
11130558|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
11130559|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
11130560|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
11130561|NCT03861871|Experimental|Fenfluramine Hydrochloride|
11130562|NCT03861858|Experimental|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, & Linehan, 2007; Rathus & Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
11130563|NCT03861845|Active Comparator|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
11130564|NCT03861845|Experimental|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
11130565|NCT03861845|Experimental|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education & training on how to use the pillbox.
11130566|NCT03861832|Experimental|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
11130567|NCT03861832|Placebo Comparator|Placebo|A placebo that looks the same and is in a similar bottle
11130568|NCT03861819|Experimental|VIIT Intervention|This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.
11130569|NCT03861806|Experimental|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
11130570|NCT03861806|Sham Comparator|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
11130571|NCT03861793|Experimental|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
11130572|NCT03861793|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 21 days at escalating doses or at the recommended phase 2 dose; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label
11130573|NCT03861780|Experimental|Project X 26ml|3.15% w/v CHG / 70% v/v IPA contained within a saturated at use applicator. 26ml volume. Single use.
11130574|NCT03861780|Experimental|Project X 5.1ml|3.15% w/v CHG / 70% v/v IPA contained within a saturated at use applicator. 5.1ml volume. Single use.
11130575|NCT03861780|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG / 70% v/v IPA. Swabstick. Single use.
11130576|NCT03861767|Experimental|SPRY: Metformin LD-SC|"LD-SC (low-dose, short course)
~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130577|NCT03861767|Experimental|SPRY: Metformin LD-IC|"LD-IC (low-dose, intermediate course)
~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130578|NCT03861767|Experimental|SPRY: Metformin LD-LC|"LD-LC (low-dose, long course)
~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130579|NCT03861767|Experimental|SPRY: Metformin ID-SC|"ID-SC (intermediate-dose, short course)
~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130580|NCT03861767|Experimental|SPRY: Metformin ID-IC|"ID-IC (intermediate-dose, intermediate course)
~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130581|NCT03861767|Experimental|SPRY: Metformin ID-LC|"ID-LC (intermediate-dose, long course)
~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130582|NCT03861767|Experimental|SPRY: Metformin HD-SC|"HD-SC (high-dose, short course)
~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130583|NCT03861767|Experimental|SPRY: Metformin HD-IC|"HD-IC (high-dose, intermediate course)
~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130584|NCT03861767|Experimental|SPRY: Metformin HD-LC|"HD-LC (high-dose, long course)
~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
11130585|NCT03861767|Placebo Comparator|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
11130586|NCT03861754|Experimental|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
11130587|NCT03861754|Experimental|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:
~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
11130588|NCT03861754|Experimental|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:
~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
11130589|NCT03861754|No Intervention|Control Group|Control group, no intervention, only measurements and questionnaires
11130590|NCT03861741|Experimental|Participants|All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases. Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records. Data on imaging investigations will be obtained from TTE and MRI. Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci. Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
11130591|NCT03861728|Experimental|Viral Conjunctivitis Treatment|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with 0.01% Hypochlorous acid
11130592|NCT03861728|Placebo Comparator|Viral Conjunctivitis Placebo|Patients with viral conjunctivitis as defined by a + AdenoPlus test and clinical symptoms and signs of viral conjunctivitis who will be treated with Basic Sterile Saline
11130593|NCT03861715||Single Dose antagonist Degarelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.
11130594|NCT03861715||Multidose antagonist Ganirelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.
11130595|NCT03861702|Experimental|FOLFOX + Irinotecan|"Oxaliplatin 60 mg/m2 Intravenously (IV) over 2 hours Leucovorin400 mg/m2 IV over 2 hours after completion of oxaliplatin nal-Irinotecan (free base) 50 mg/m2 IV over 90 minutes after completion of leucovorin 5-Fluorouracil 2,400 mg/m2 IV over 46 hours via infusion pump at home
~All drugs administered on day 1 of each 14 day cycle."
11130596|NCT03861689|Active Comparator|Tight control arm|Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
11130597|NCT03861689|No Intervention|Control arm|Patients in the control arm will have management according to physician own decision.
11130598|NCT03861676|Experimental|Focal brachytherapy|"Drug: 18F-DCFPyl Other names: PET, PSMA
~Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy"
11130599|NCT03861663|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
11130600|NCT03861650|Experimental|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
11130601|NCT03861650|Sham Comparator|Saline|Sham or placebo drug in the control group
11130602|NCT03861637|Active Comparator|drug : ESA for p correction of PTA|ESA (Aranesp or mir-CERA) injection 1 mg per kg sc every week for 1 year to correct PTA to level between 12-13g/dl.
11130603|NCT03861637|Active Comparator|ara or cera|ESA (Aranesp) 1mg/ kg (or equivalent doses) of MIR-CERA injection for 1 year to correct PTA to level between 13-15g/dl.
11130604|NCT03861624|Experimental|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
11130605|NCT03861624|Active Comparator|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
11130606|NCT03861611|Experimental|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
11130607|NCT03861611|Experimental|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
11130608|NCT03861611|Experimental|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
11130609|NCT03861598|Experimental|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
11130610|NCT03861585|Experimental|semantic group|"Half of the participants (named the semantic group) perform a semantic categorisation task."
11130611|NCT03861585|Experimental|emotional group|"Half of the participants (named the emotional group) perform an emotional evaluation task."
11130612|NCT03861572|Experimental|Isokinetic eccentric group|The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
11130643|NCT03861364|Active Comparator|Low Propofol|Low Propofol induction dose
11130644|NCT03861351|Experimental|Mini WELL Toric Ready intraocular lens|
11130645|NCT03861338|Experimental|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
11130646|NCT03861312|Experimental|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
11130613|NCT03861572|Active Comparator|Traditional eccentric training|Participants will be engaged in an intervention program consisting of 12 weeks of traditional eccentric training. The training will be carried out with the volunteers at gym in stand position. Concentric phase will be realized with both legs and the eccentric one only with one of them. Training progression will be the same from de isokinetic eccentric group. The same periodization from eccentric group will be used to permit us a posteriori comparison between groups. Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions. Each training session will comprise the same specific warming protocol for the ankle joint from the eccentric training.
11130614|NCT03861559|Experimental|mometasone furoate nasal spray|Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
11130615|NCT03861559|Placebo Comparator|placebo nasal spray|Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.
11130616|NCT03861546|Experimental|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
11130617|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
11130618|NCT03861507|Other|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
11130619|NCT03861494|Other|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
11130620|NCT03861494|Other|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
11130621|NCT03861481|Experimental|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
11130622|NCT03861481|Placebo Comparator|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
11130623|NCT03861468|No Intervention|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
11130624|NCT03861468|Active Comparator|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
11130625|NCT03861455|Experimental|dupilumab group|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
11130626|NCT03861455|Placebo Comparator|placebo group|patient receive placebo
11130627|NCT03861429|Experimental|Me & My Wishes Intervention/Group 1|In Group 1 (early intervention group) NHs, video recording, editing, and viewing will occur within three months of baseline.
11130628|NCT03861429|Other|Me & My Wishes Wait-list control/Group 2|In Group 2 (delayed sharing) NHs, residents will be on a wait-list; after the delayed start, their video will be produced and viewed within three months.
11130629|NCT03861416|Experimental|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
11130630|NCT03861416|Experimental|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
11130631|NCT03861416|Placebo Comparator|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
11130632|NCT03861403|Experimental|All Solid Tumors|"Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle
~Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle"
11130633|NCT03861403|Experimental|Advanced Triple Negative Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
11130634|NCT03861403|Experimental|Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
11130635|NCT03861403|Experimental|Advanced Metastatic Castration-Resistant Prostate Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
11130636|NCT03861403|Experimental|Advanced Platinum-Resistant Ovarian Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):
~Subjects receive the following treatment:
~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle
~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle
~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
11130637|NCT03861390|Active Comparator|Prednisone, then Placebo|
11130638|NCT03861390|Placebo Comparator|Placebo, then Prednisone|
11130639|NCT03861377|Active Comparator|Remifentanil R2|Low dose Remifentanil induction dose (R2)
11130640|NCT03861377|Active Comparator|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
11130641|NCT03861377|Active Comparator|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
11130647|NCT03861312|Experimental|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
11130648|NCT03861299|Experimental|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
11130649|NCT03861299|Active Comparator|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
11130650|NCT03861273|Experimental|PF-06838435/ fidanacogene elaparvovec|
11130651|NCT03861260|Other|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
11130652|NCT03861260|Other|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
11130653|NCT03861247|Active Comparator|Control group|
11130654|NCT03861247|Experimental|Intervention group|
11130655|NCT03861234|Experimental|BI 836880|Single Rising Dose part followed by a Multiple Rising Dose part
11130656|NCT03861221|Experimental|Conebeam Breast Computed Tomography|
11130657|NCT03861208|Experimental|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
11130658|NCT03861208|Other|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
11130659|NCT03861195||Da Vinci Robotic Surgical System|
11130660|NCT03861195||conventional laparoscopic surgery|
11130661|NCT03861182|Other|Adult Healthy Volunteers|
11130662|NCT03861182|Other|Neonates|
11130663|NCT03861169|Experimental|Viscoeleastic delivery & trabeculotomy|Patients with open angle glaucoma and cataract
11130664|NCT03861156|Experimental|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
11130665|NCT03861143|Experimental|BT-11 low-dose (500 mg)|Oral
11130666|NCT03861143|Experimental|BT-11 high-dose (1,000 mg)|Oral
11130667|NCT03861143|Placebo Comparator|Placebo|Oral
11130668|NCT03861130||Kawasaki disease|Kawasaki disease affected childrens
11130669|NCT03861117|Experimental|Assisted strategy|Ability to be weaned is determined with pressure support and positive end-expiratory pressure.
11130670|NCT03861117|Active Comparator|Non assisted strategy|Ability to be weaned is determined with T-piece.
11130671|NCT03861104|Active Comparator|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.
~intervention is watching informative video."
11130672|NCT03861104|No Intervention|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
11130673|NCT03861091|Experimental|Risedronate|Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
11130674|NCT03861091|Placebo Comparator|Matching Placebo|Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
11130675|NCT03861078|Active Comparator|Own brand cigarette use|During each session, participants will complete a 10-puff, directed product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
11130676|NCT03861078|Experimental|ECIG 15 mg nicotine, sweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
11130677|NCT03861078|Experimental|ECIG 15 mg nicotine, unsweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
11130678|NCT03861078|Experimental|ECIG 0 mg nicotine, sweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
11130679|NCT03861078|Experimental|ECIG 0 mg nicotine, unsweetened|During each session, participants will complete a 10-puff product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.
11130680|NCT03861065|Experimental|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
11130681|NCT03861065|Active Comparator|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
11130682|NCT03861052|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11130683|NCT03861052|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11130684|NCT03861052|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11130685|NCT03861052|Active Comparator|0.75 mg Dulaglutide|0.75 mg dulaglutide administered SC once a week.
11130686|NCT03861039|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11130687|NCT03861039|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11130688|NCT03861039|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11130723|NCT03860805|Active Comparator|Laparoscopic bilateral salpingectomy|Patients who seek for surgical permanent contraception and randomized to laparoscopic bilateral salpingectomy
11132826|NCT03846206|No Intervention|Usual diet|Patients do usual diet for three months
11130689|NCT03861026|Experimental|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.
~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
11130690|NCT03861026|No Intervention|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.
~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
11130691|NCT03861013|Experimental|Intervention group|Participation in a multidimensional stress prevention program (GeDStress).
11130692|NCT03861013|No Intervention|Wait-list control group|Participants on the wait-list control group will not receive any treatment between the baseline and last follow-up. After the study has ended, they have the option to participate in the program.
11130693|NCT03861000|Experimental|1|Healthy Controls
11130694|NCT03860987|Experimental|1|Treatment
11130695|NCT03860974|Experimental|Serratus Plane (single injection)|
11130696|NCT03860974|Active Comparator|Paravertebral (single injection)|
11130697|NCT03860961|Active Comparator|Standard Survivorship Care Plan (SCP)|Practices review a SCP with patients and send it to the PCP during the last week of RT.
11130698|NCT03860961|Experimental|Enhanced Survivorship Care Plan (SCP)|Practices review a treatment plan with patient and send it to the PCP at the beginning of RT. Practices also review a SCP with patients and send it to the PCP during the last week of RT.
11130699|NCT03860948|Experimental|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
11130700|NCT03860948|Experimental|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
11130701|NCT03860935|Experimental|AG10 800 mg|Subjects will receive AG10 800 mg twice daily. 6 Minute Walk Test (6MWT) primary outcome will be assessed at the end of 12 months, followed by all-cause mortality and cardiovascular-related hospitalization assessed at the end of 30 months.
11130702|NCT03860935|Placebo Comparator|Placebo|Subjects will receive placebo to match twice daily. 6 Minute Walk Test (6MWT) primary outcome will be assessed at the end of 12 months, followed by all-cause mortality and cardiovascular-related hospitalization assessed at the end of 30 months.
11130703|NCT03860896|Experimental|GB004|GB004 for oral administration daily
11130704|NCT03860896|Placebo Comparator|Placebo|Placebo for oral administration daily
11130705|NCT03860883|Experimental|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
11130706|NCT03860883|Active Comparator|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
11130707|NCT03860870|Experimental|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
11130708|NCT03860857|Experimental|Age 60-65 ApoE e4+|Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130709|NCT03860857|Experimental|Age 66-70 ApoE e4-|Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130710|NCT03860857|Experimental|Age 66-70 ApoE e4+|Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130711|NCT03860857|Experimental|Age 71-75 ApoE e4-|Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130712|NCT03860857|Experimental|Age 71-75 ApoE e4+|Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130713|NCT03860857|Experimental|Age 76-80 ApoE e4-|Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130714|NCT03860857|Experimental|Age 76-80 ApoE e4+|Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130715|NCT03860857|Experimental|Age 81-85 ApoE e4-|Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130716|NCT03860857|Experimental|Age 81-85 ApoE e4+|Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
11130717|NCT03860844|Experimental|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
11130718|NCT03860831|Experimental|intranasal (IN)|"Group IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg).
~the calculated dose will be equally divided into the two nostrils by the parents"
11130719|NCT03860831|Active Comparator|intramuscular (IM)|"Group IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
~Mild to moderate restraint was done with the help of the parents during drug administration."
11130720|NCT03860818|No Intervention|Control Arm|Usual Care
11130721|NCT03860818|Experimental|Intervention Arm|Technology-enabled pharmacist intervention
11130722|NCT03860805|Active Comparator|Laparoscopic tubal ligation|Patients who seek for surgical permanent contraception and randomized to laparoscopic tubal ligation
11130724|NCT03860792|Experimental|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
11130725|NCT03860792|Active Comparator|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy. Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
11130726|NCT03860766|Sham Comparator|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
11130727|NCT03860766|Experimental|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
11130728|NCT03860766|Experimental|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
11130729|NCT03860766|Experimental|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
11130730|NCT03860753|Experimental|Pioglitazone|
11130731|NCT03860753|Placebo Comparator|Placebo|
11130732|NCT03860740||High intensity physical exercise|Supervised Exercise Group: Customized and supervised exercise high intensity training program during 2-3 weeks previous surgery.
11130733|NCT03860740||Control|Supervised Stretching Group: a stretching and body balance classes will be developed to control the possible confounders and to control the exercise level of participants.
11130734|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
11130735|NCT03860688|Experimental|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
11130736|NCT03860675|Active Comparator|persons with Multiple Sclerosis (MS)|
11130737|NCT03860675|Placebo Comparator|Healthy controls|
11130738|NCT03860662|Active Comparator|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
11130739|NCT03860662|Other|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
11130740|NCT03860649|Experimental|Nordic Walking|The patient walk program consists of 3 moments: warm up, walk and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.
11130741|NCT03860649|Experimental|Jogging|This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.
11130742|NCT03860649|Experimental|Dance|This group will undergo 24 Dance sessions inspired by Forró dance rhythm and Samba dance rhythm. Classes will be divided into four stages: Joint warm up and stretching on the chairs; strengthening, balance and rhythm exercises with the support of the barre; exercises inspired by the Samba and Forró dance (Brazilian ballroom dance) basic steps; and Final cool down. The intensity of the classes will be measured according to the beats per minute (BPMs) of the songs used in each moment and by the Borg Scale of Perceived Exertion.
11130743|NCT03860649|Experimental|Pilates Training|"Classes composed of three phases: Warming up, main part and back to calm. Warming up will begin with pre-Pilates training exercises for 5 minutes (eg. breathing exercises, hip joint mobilization, shoulder girdle, etc.), the main part of the lesson will be the Pilates training drill sequence for the beginner level that will be conducted for 50 minutes in which all exercises will be performed on the floor.
~The sequence of the eighteen exercises of the main part of the lesson is described in the table below. Back to Calm: will be carried out for 5 final minutes with standing exercises with the subject reclining on the wall to reconnect the subject with orthostatic posture.
~In the each of the phases of the lesson will be shown to the subject the table of BORG with the objective of measuring the intensity of perceived exertion, using the Borg Scale of Perceived Exertion."
11130744|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.
~The day they receive their HCG trigger,
~The day of transvaginal oocyte retrieval (TVOR) and
~The day of embryo transfer (ET)."
11130844|NCT03859895||Observational (with bone scan)|Former Interventional Arm participants of the ZiPP trial.
11133333|NCT03842644|Experimental|Tension Reduction|Tension reduction device for 3 months post surgery
11130745|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.
~The day we coordinate with embryologist (day of progesterone +/-1)
~The day of embryo transfer (ET)."
11130746|NCT03860623||Overweight|Otherwise healthy overweight and obese men (BMI 30-40kg/m2) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
11130747|NCT03860623||Normal Weight|Healthy normal weight men (BMI 18-25kg/m2, but including those with BMI up to 28kg/m2 if waist circumference <96cm) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
11130748|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
11130749|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
11130750|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
11130751|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
11130752|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
11130753|NCT03860597|Active Comparator|Memantine|
11130754|NCT03860597|Placebo Comparator|Placebo|
11130755|NCT03860584|Experimental|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.
11130756|NCT03860584|Placebo Comparator|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
11130757|NCT03860571|Placebo Comparator|Placebo|
11130758|NCT03860571|Experimental|BT-11|
11130759|NCT03860558|Experimental|Lifestyle Intervention|20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.
11130760|NCT03860558|Active Comparator|No-Intervention Controls|10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
11130761|NCT03860558|Active Comparator|Healthy Controls|10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
11130762|NCT03860545||non-AKI|patient without acute kidney injury (AKI) during perioperative observation period
11130763|NCT03860545||AKI|patient with diagnosis acute kidney injury (AKI) established during perioperative observation period
11130764|NCT03860532|Active Comparator|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
11130765|NCT03860532|Active Comparator|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
11130766|NCT03860519|Experimental|Intervention Group|"The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has poor adherence ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR at risk alerts if a patient transitions to a not well controlled or poorly controlled status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard)."
11130767|NCT03860519|Experimental|Control Group|The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
11130768|NCT03860506|Experimental|PSI-697|
11130769|NCT03860506|Placebo Comparator|Placebo|
11130770|NCT03860493||Study group|Only patients who might benefit from intraoperative fluorescent tissue perfusion assessment according to the primary surgeon will be enrolled in the study. The patients will be screened and consent during their office visit with their surgeon at the Cleveland Clinic Foundation. Each surgeon will follow the standard Open surgical protocol of his/her subspecialty, and will comply with the following additional steps according to the type of surgery:
11130771|NCT03860480|Active Comparator|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.
~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.
~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
11130845|NCT03859882|Experimental|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
11130772|NCT03860480|Sham Comparator|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.
~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.
~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
11130773|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
11130774|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
11130775|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
11130776|NCT03860441|Experimental|Intervention group|Participants in the intervention group received 24 sessions of computerized cognitive training, with a total time of 960 min.
11130777|NCT03860441|Active Comparator|Active control group|Participants in the control group attended activities separate activities, such as learning about healthy lifestyle, had cooking and other social lessons for the same amount as the intervention group performed cognitive training.
11130778|NCT03860428|Active Comparator|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
11130779|NCT03860428|Active Comparator|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
11130780|NCT03860428|Sham Comparator|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
11130781|NCT03860415|Experimental|Probiotic|Vivomixx
11130782|NCT03860415|Placebo Comparator|Placebo|
11130783|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
11130784|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
11130785|NCT03860389|Experimental|Exercise effects on anxiety|An exercise programme will be administered 3 times a week for up to an 16 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will involve aspects of fundamental movement skills and will be fun for the students to participate in.
11130786|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
11130787|NCT03860363||Treatment Group|Patients selected to participate.
11130788|NCT03860350|Active Comparator|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
11130789|NCT03860350|Placebo Comparator|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
11130790|NCT03860337|Experimental|Alginate then Control|This group will be given the alginate then the control sausages
11130791|NCT03860337|Experimental|Control then Alginate|This group will be given the control then alginate sausages
11130792|NCT03860324|No Intervention|Control-group|No peripheral nerve block
11130793|NCT03860324|Experimental|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
11130794|NCT03860324|Active Comparator|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
11130795|NCT03860311|Experimental|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
11130796|NCT03860311|Active Comparator|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
11130797|NCT03860298|Experimental|NaviFUS System|FUS treatment for 10 minutes
11130798|NCT03860272|Experimental|3-Week Monotherapy|Experimental: Open Label 3+3 Dose escalation of AGEN1181, every 3 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg administered by IV.
11130799|NCT03860272|Experimental|6-Week Monotherapy|3+3 Dose escalation of AGEN1181, every 6 weeks, starting at dose level 1 mg/kg up to 4 mg/kg administered by IV.
11130800|NCT03860272|Experimental|6-Week Combination Therapy|3+3 Dose escalation of AGEN2034, every 3 weeks, at dose level 3 mg/kg in combination with AGEN1181, every 6 weeks, starting at dose level 0.1 mg/kg up to 4 mg/kg administered by IV.
11130801|NCT03860259|Placebo Comparator|Control|Auriculotherapy will be performed by PI using a cryopuncture device in the pre-operative setting with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
11130802|NCT03860259|Active Comparator|Intervention|Auriculotherapy will be performed by PI using a cryopuncture device in the pre-operative setting with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
11130803|NCT03860233|Experimental|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
11130804|NCT03860233|Experimental|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
11130805|NCT03860220|Active Comparator|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
11130806|NCT03860220|Placebo Comparator|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
11130807|NCT03860207|Experimental|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
11130808|NCT03860194|Experimental|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.
~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
11130809|NCT03860194|No Intervention|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.
~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
11130810|NCT03860181|Active Comparator|Traditional Dermabond + subcuticular sutures|Subcuticular sutures with traditional Dermabond applied to incision.
11130811|NCT03860181|Active Comparator|Metal staples|Metal staples
11130812|NCT03860181|Experimental|Dermabond PRINEO|Dermabond PRINEO System
11130813|NCT03860168|Other|PICU Up! pre- and post-implementation|Each unit will begin in the baseline, usual care phase and then be randomized to implement the PICU Up! program during a set time period, followed by the post-implementation phase.
11130814|NCT03860155|Experimental|allo-APZ2-ACLF|Application of IMP into peripheral vein (arm) by use of a perfusor.
11130815|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
11130816|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
11130817|NCT03860129|Other|ISO|Drug name: Isoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (0.5 Vol%)
11130818|NCT03860129|Other|SEVO|Drug name: Sevoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (1.0 Vol%)
11130819|NCT03860129|Other|DES|Drug name: Desflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (3.0 Vol%)
11130820|NCT03860116|Experimental|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
11130821|NCT03860116|Active Comparator|control group|participants in the control arm receive standard-of-care followup service
11130822|NCT03860090|Active Comparator|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
11130823|NCT03860090|Active Comparator|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
11130824|NCT03860077|Experimental|Very Low Nicotine Content Cigarettes|
11130825|NCT03860077|Active Comparator|Normal Nicotine Content Cigarettes|
11130826|NCT03860038|Experimental|TJ202|
11130827|NCT03860025||Single dislocation.|Patients with a single postoperative hip dislocation without subsequent revision surgery.
11130828|NCT03860025||Recurrent dislocation.|Patients with two or more postoperative hip dislocations without subsequent revision surgery.
11130829|NCT03860025||Revision due to dislocation.|Patients with one or more postoperative hip dislocations with subsequent revision surgery due to recurrent instability.
11130830|NCT03860025||Controls.|Matched patients without postoperative hip dislocation or revision of any reason.
11130831|NCT03860012|Experimental|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
11130832|NCT03859986|Experimental|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
11130833|NCT03859986|Placebo Comparator|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
11130834|NCT03859973|Experimental|BI 425809|Active drug treatment arm
11130835|NCT03859973|Experimental|Placebo|Placebo drug arm
11130836|NCT03859947||Patients with acute bronchiolitis|
11130837|NCT03859934|Active Comparator|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
11130838|NCT03859934|Placebo Comparator|Placebo|Placebo each day 1 hour before bedtime for 3 months
11130839|NCT03859921|Experimental|Dydrogesterone group|Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.
11130840|NCT03859921|Placebo Comparator|Placebo group|Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.
11130841|NCT03859908|Experimental|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
11130842|NCT03859908|Active Comparator|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
11130843|NCT03859895||Observational (without bone scan)|Former Observational Arm participants of the ZiPP trial.
11133334|NCT03842644|No Intervention|Control|No tension reduction
11130847|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose A|Resected participants are administered with Pancrelipase dose A. At week 1,5, or 9, participants who meet dose modification criteria will be administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
11130848|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose B|Resected participants are administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
11130849|NCT03859869|Experimental|Non-Resected Participants Receiving Pancrelipase Dose B|Non-resected participants are administered with Pancrelipase dose B.
11130850|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
11130851|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
11130852|NCT03859843|Active Comparator|PRP|
11130853|NCT03859843|Active Comparator|Chemical peeling (Salycilic acid)|
11130854|NCT03859843|Active Comparator|Chemical peeling (Jessenr's solution)|
11130855|NCT03859830|Experimental|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
11130856|NCT03859830|Active Comparator|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
11130857|NCT03859817||Patients with albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
11130858|NCT03859817||patients with normo albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
11130859|NCT03859804|Experimental|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
11130860|NCT03859804|Active Comparator|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
11130861|NCT03859778||pharmacy students|
11130862|NCT03859765|Experimental|HCT Symptoms and Steps|HCT Symptoms and Steps participants will complete in-person (3) and video-conferencing (4) coping skills training and activity coaching sessions teaching cognitive behavioral coping skills to manage pain, fatigue, and distress and increase activity. Participants will be given a wireless activity tracker and a smartphone for accessing the study mobile app.
11130863|NCT03859765|No Intervention|HCT Education|HCT Education participants will receive 1 brief in clinic session prior to discharge home providing education related to symptom management and physical activity, and a wireless activity tracker. HCT Education participants will also receive 6 brief phone calls upon return home.
11130864|NCT03859752|Experimental|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
11130865|NCT03859739|Experimental|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg.
11130866|NCT03859739|Experimental|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
11130867|NCT03859739|Experimental|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
11130868|NCT03859739|Experimental|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
11130869|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
11130870|NCT03859726||Non compliance group|6hLC<10%
11130871|NCT03859713|Experimental|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
11130872|NCT03859713|Experimental|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
11130873|NCT03859713|Experimental|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
11130874|NCT03859713|Experimental|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
11130875|NCT03859700|Experimental|DBV712 250mcg|
11130876|NCT03859687|Experimental|Intervention group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) plus a liquid oral vitamin A supplementation
11130877|NCT03859687|Experimental|Control group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) only, 'No vitamin A supplementation'
11130878|NCT03859648|Experimental|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
11130879|NCT03859635|Active Comparator|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
11130910|NCT03859375||2 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint two of a predefined area of the skin.
11130880|NCT03859635|Active Comparator|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
11130881|NCT03859635|Active Comparator|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
11130882|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
11130883|NCT03859583|Experimental|Capsaicin|4 tsp of cayenne pepper in a 60g omelette
11130884|NCT03859583|Placebo Comparator|Control|60 g omelette
11130885|NCT03859570|Experimental|Pentoxifylline|Pentoxifylline and standard of care therapy
11130886|NCT03859570|Placebo Comparator|Placebo|Placebo and standard of care therapy
11130887|NCT03859557||4-Quadrant Random Forceps Biopsy|Random sampling within a quadrant of esophageal tissue using forceps.
11130888|NCT03859557||WATS biopsies|Wide area transepithelial sampling with computer aided pathologic interpretation of tissue.
11130889|NCT03859531||CF patients planned to receive Orkambi|CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
11130890|NCT03859518||patients with Vitiligo|
11130891|NCT03859518||control|
11130892|NCT03859505|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
11130893|NCT03859505|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) active.
11130894|NCT03859492||Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
11130895|NCT03859479|Experimental|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
11130896|NCT03859479|Active Comparator|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
11130897|NCT03859466|Experimental|Intervention Arm|For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information: This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
11130898|NCT03859466|No Intervention|Control Arm|For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
11130899|NCT03859440|Experimental|DSiHy (test lens)|
11130900|NCT03859440|Active Comparator|Silicone hydrogel soft contact lens CE-marked for daily use|
11130901|NCT03859427|Active Comparator|Carfilzomib once-weekly|Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using once-weekly carfilzomib 56 mg/m2
11130902|NCT03859427|Active Comparator|Carfilzomib twice-weekly|Carfilzomib, lenalidomide, dexamethasone (KRd) regimen using twice-weekly carfilzomib 27 mg/m2
11130903|NCT03859414|Active Comparator|Therapeutic Dose 1|Single dose administration of CHF 5993 100/6/12.5 µg pMDI 2 inhalations. Total dose of CHF 5993 pMDI = 200/12/25 µg
11130904|NCT03859414|Active Comparator|Therapeutic Dose 2|Single dose administration of CHF 5993 200/6/12.5 µg pMDI 2 inhalations. Total dose of CHF 5993 pMDI = 400/12/25 µg
11130905|NCT03859414|Active Comparator|Supra-therapeutic Dose|Single dose administration of CHF 5993 100/6/12.5 µg pMDI 8 inhalations Total dose of CHF 5993 pMDI = 800/48/100 µg
11130906|NCT03859414|Placebo Comparator|Placebo|Single dose administration of CHF 5993 pMDI placebo
11130907|NCT03859401|Experimental|Control - Experimental Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
11130908|NCT03859401|Experimental|Experimental - Control Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Experimental-Control Arm will undergo the Experimental Admission first, utilizing an artificial pancreas (AP) controller that has the ability to anticipate exercise (EnMPC), followed by the Control Admission, which will utilize an AP controller that does not have the ability to anticipate exercise (rMPC). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
11130909|NCT03859388||Chronic ABMR|Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
11130911|NCT03859375||3 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint three of a predefined area of the skin.
11130912|NCT03859362|Experimental|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
11130913|NCT03859349|Active Comparator|Systematic Sampling|Patients will undergo systematic sampling of lymph node stations in the mediastinum with a minimum sampling of 3 stations: 4R, 4L and 7, as is the standard of care. Other stations may be included at the endoscopist's discretion. CLNS is not used for this arm.
11130914|NCT03859349|Experimental|Selective Targeted Sampling|"Patients will first undergo endosonographic assessment of 3 mediastinal lymph node stations (i.e. 4R, 4L, and 7) using the four criteria of the CLNS. Lymph node stations that exhibit a CLNS >1/4 will be biopsied as is standard of care. Lymph node stations with CLNS ≤ 1/4 will be marked as not requiring biopsy but will be biopsied nevertheless, so that there is no deviation from the standard of care. Other stations may be included at the endoscopist's discretion."
11130915|NCT03859336|Experimental|Transdermal Neuromodulation Stimulation|"Day 1 of Transdermal Neuromodulation Stimulation (TENS) is a one-day sham stimulation, consisting of: 30 seconds of sensation in which amplitude is increased up to the threshold of salient sensation, followed by 19 minutes of no stimulation (device is turned off), followed by 30 more seconds of salient stimulation. Day 1 is used to exclude those who cannot tolerate study procedures and placebo responders; it will also serve as baseline for anxiety measures. TENS treatment begins one day after sham, and lasts 3 days with 20 minutes of stimulation per day. One day following open label treatment all participants will once again receive sham stimulation following the same procedures utilized at Day 1.
~Treatment amplitude is adjusted for each participant, in which the stimulation will be administered just below the participant's sensation threshold. Amplitude from the TENS device does not exceed 20mA. Frequency will be at 300hz."
11130916|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
11130917|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
11130918|NCT03859323|Experimental|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
11130919|NCT03859323|Experimental|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
11130920|NCT03859323|Experimental|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
11130921|NCT03859323|Placebo Comparator|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
11130922|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
11130923|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
11130924|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
11130925|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
11130926|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
11130927|NCT03859323|Placebo Comparator|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
11130928|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
11130929|NCT03859310||Glaucoma|diagnosis of glaucoma
11130930|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
11130931|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
11130932|NCT03859297|Experimental|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
11130933|NCT03859297|No Intervention|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
11130934|NCT03859297|Active Comparator|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
11130935|NCT03859284|Active Comparator|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.
~other names: ''flowable composite ''"
11130936|NCT03859284|Experimental|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
11130937|NCT03859284|Experimental|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
11130938|NCT03859271|Experimental|brief motivational interviewing|Participants will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
11130974|NCT03859115|Experimental|sevoflurane-TENS|Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.
11133395|NCT03842215||silver hair people|Exam subject's physical function by a smart physical exam
11130939|NCT03859271|Placebo Comparator|Placebo Control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
11130940|NCT03859258||Patient having Cesarean section|Transvaginal sonography for patients having ceserean section to assess uterine Niche development and parameters
11130941|NCT03859258||Patient delivered vaginally|Transvaginal sonography for patients having vaginal delivery to confirm absence of uterine Niche development
11130942|NCT03859245|Experimental|Experimental group|Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
11130943|NCT03859245|Active Comparator|Control group|Subjects in the control group will follow current dietary protocol (Standard American Diet- SAD). Photobiomodulation therapy,via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
11130944|NCT03859232|Experimental|Delta Dry® Pantaloon Group|
11130945|NCT03859232|Active Comparator|Cotton Padding Group|
11130946|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130947|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130948|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130949|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130950|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130951|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130952|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130953|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
11130954|NCT03859219|Placebo Comparator|Placebo in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
11130955|NCT03859219|Placebo Comparator|Placebo in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
11130956|NCT03859219|Placebo Comparator|Placebo in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
11130957|NCT03859206|Experimental|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :
~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.
~the intervention : is breaking the septation within the loculated empyema"
11130958|NCT03859206|No Intervention|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
11130959|NCT03859193|No Intervention|Standard care|
11130960|NCT03859193|Experimental|Video|Participants will watch an Nutritional video at their second high risk visit
11130961|NCT03859180|Experimental|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
11130962|NCT03859180|No Intervention|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
11130963|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
11130964|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
11130965|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.
~AND consenting to be part of the study"
11130966|NCT03859141|Experimental|Experimental group-phase Ⅰ|Quadrivalent influenza vaccine
11130967|NCT03859141|Experimental|Experimental group-phase Ⅲ|Quadrivalent influenza vaccine
11130968|NCT03859141|Active Comparator|Control group 1-phase Ⅲ|Trivalent influenza vaccine (contains B/Victoria strain)
11130969|NCT03859141|Active Comparator|Control group 2-phase Ⅲ|Trivalent influenza vaccine (contains B/Yamagata strain)
11130970|NCT03859128|Active Comparator|Group A|TORIPALIMAB 240mg ,Q3W, up to 48 Weeks
11130971|NCT03859128|Placebo Comparator|Group B|Placebo 240mg Q3W, up to 48 Weeks
11130972|NCT03859115|Active Comparator|preanesthesia-TENS|Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.
11130973|NCT03859115|Sham Comparator|preanesthesia-sham|Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.
11130975|NCT03859115|Active Comparator|sevoflurane-sham|Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.
11130976|NCT03859115|Experimental|propofol-TENS|Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.
11130977|NCT03859115|Active Comparator|propofol-sham|Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.
11130978|NCT03859102|No Intervention|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
11130979|NCT03859102|Experimental|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.
~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.
~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
11130980|NCT03859076|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
11130981|NCT03859076|Active Comparator|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
11130982|NCT03859063|Experimental|Intervention|Regular follow up by a community based stroke coordinator
11130983|NCT03859063|Active Comparator|Control|Usual care
11130984|NCT03859050|Experimental|LPS arm|
11130985|NCT03859037|Experimental|Umbilical cord milking|One group will have umbilical cord milking and will ba assessed for blood pressure,oxygen saturation and heart rate by monitor
11130986|NCT03859037|Placebo Comparator|Immediate cord clamping|One group will have immediate cord clamping and will be assessed for bloob pressure,heart rate,oxygen saturation by monitor
11130987|NCT03859024|Active Comparator|Standard Protocol|Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
11130988|NCT03859024|Experimental|Enhanced Recovery Protocol|A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
11130989|NCT03859011|Experimental|Acupuncture|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
11130990|NCT03859011|Placebo Comparator|"Usual care"|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments) for 6 months. Questionnaires will be readministered at 2.5 and 6 months. After the control phase the participants will continue usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks, 8.5 months), then no acupuncture between 8.5 months and 12 months.
11130991|NCT03858998|Experimental|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
11130992|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
11130993|NCT03858985|Active Comparator|Transcutaneous Vagus Nerve Stimulation|Cervical Transcutaneous vagus nerve stimulation. Participants will undergo once daily cervical transcutaneous vagus nerve stimulation.
11130994|NCT03858985|Sham Comparator|Sham Vagus Nerve Stimulation|Sham Cervical Transcutaneous Vagus Nerve Stimulation. Participants will undergo once daily sham cervical transcutaneous vagus nerve stimulation.
11130995|NCT03858972|Experimental|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.
~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
11130996|NCT03858959|Experimental|HYBENX® Oral Tissue decontaminantTM (HBX)|HYBENX® Oral Tissue decontaminantTM is a concentrated aqueous solution of sulfonated aromatics and free sulphates. Once placed onto susceptible organic material, the product instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution by virtue of its porous structure and high water content.
11130997|NCT03858959|Active Comparator|Chlorhexidine Digluconate CorsodylTM (CHX)|Chlorhexidine Digluconate CorsodylTM Dental Gel 1% is an antiseptic gel with cationic nature, effective against a wide range of Gram positive and negative bacteria, favourable to the plaque control and oral inflammation prevention.
11130998|NCT03858946|Sham Comparator|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
11130999|NCT03858946|Experimental|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
11131000|NCT03858933|Experimental|Limbic Modulation Index Neurofeedback|"This arm of the study will undergo a novel neurofeedback treatment, targeting downregulation of deep limbic structures, specifically the amygdalae.
~Participants in this arm will complete 15 neurofeedback sessions."
11131001|NCT03858933|Active Comparator|Alpha/Theta Neurofeedback|"This arm of the study will undergo a proven PTSD neurofeedback treatment, alpha/theta regulation, during which participants will try various mental strategies to increase the presence of theta waves.
~Participants in this arm will complete 15 neurofeedback sessions."
11131002|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
11131003|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
11131004|NCT03858894|Experimental|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
11131005|NCT03858894|Experimental|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
11131006|NCT03858881|Active Comparator|PROJECT PERSONALITY|
11131007|NCT03858881|Experimental|VR PERSONALITY PROJECT|
11131008|NCT03858881|Placebo Comparator|SHARING FEELINGS PROGRAM|
11131009|NCT03858868|Experimental|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
11131010|NCT03858868|Other|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
11131011|NCT03858855|Experimental|Group I (bergamot essential oil)|Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
11131012|NCT03858855|Experimental|Group II (chamomile essential oil)|Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
11131013|NCT03858855|Experimental|Group III (ginger essential oil)|Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
11131014|NCT03858855|Active Comparator|Group IV (almond essential oil)|Patients inhale 7 drops of almond essential oil and complete journal as in group I.
11131015|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
11131016|NCT03858829|Experimental|fear of movement scale|
11131017|NCT03858816|Experimental|Mixture probiotics|The probiotic contain 1 ×10^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
11131018|NCT03858816|Placebo Comparator|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
11131019|NCT03858803|Active Comparator|FM2 first, LAST delayed|Parent intervention, Families Matter 2 (FM2), immediate, adolescent intervention, Living as a Safer Teen (LAST), delayed six months
11131020|NCT03858803|Active Comparator|FM2 and LAST simultaneous|Parents participate in Families Matter 2 (FM2) and adolescents in Living as a Safer Teen (LAST) intervention immediately following the baseline assessment.
11131021|NCT03858803|Active Comparator|Comparison arm|Comparison arm in which both parents and adolescents will be offered their respective interventions following the final assessment. Following the final assessment parents will be offered the Families Matter (FM2) intervention and youth the Living as a Safer Teen (LAST) intervention as an ethically justified service.
11131022|NCT03858790|Experimental|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
11131023|NCT03858790|Sham Comparator|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
11131024|NCT03858777|Active Comparator|Sarcoidosis patients without evidence of active myocarditis|A single blood draw.
11131025|NCT03858777|Experimental|Sarcoidosis patients with evidence of active myocarditis|Two blood draws 2 months apart.
11131026|NCT03858777|Active Comparator|Acute ST elevation myocardial infarction (STEMI)|Three blood draws, baseline, 6 hours and 24 hours.
11131027|NCT03858777|Placebo Comparator|Healthy controls|A single blood draw
11131028|NCT03858751|Placebo Comparator|Placebo|Placebo capsule before bedtime
11131029|NCT03858751|Experimental|LTM1201AZ|LTM1201AZ capsule before bedtime
11131030|NCT03858751|Experimental|LTM1201AT|LTM1201AT capsule before bedtime
11131031|NCT03858751|Experimental|LTM1201AG|LTM1201AG capsule before bedtime
11131032|NCT03858751|Experimental|LTM1201AD|LTM1201AD capsule before bedtime
11131033|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.
~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
11131034|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
11131035|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
11131036|NCT03858725|Experimental|D569/CKD-374 5mg|"Period 1: D569 Tab. 1T
~Period 2: CKD-374 5mg Tab. 1T"
11131037|NCT03858725|Experimental|CKD-374 5mg/D569|"Period 1: CKD-374 5mg Tab. 1T
~Period 2: D569 Tab. 1T"
11131038|NCT03858712|Other|Passive Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.
~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice
~ePRO Home: -- ePRO oral between visits at home.
~Passive care team alert -- EHR inBasket notification"
11131039|NCT03858712|Other|Active Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.
~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice
~ePRO Home: -- ePRO oral between visits at home.
~Active care team alert -- practice nurse monitoring of ePRO home responses score = 3 indicating a moderate-severe toxicity (grade 3 or higher"
11131040|NCT03858699||Individuals with stroke|Participants in sub-acute and chronic phases post-stroke (>1 month post-stroke) will be recruited for participation in this study.
11131041|NCT03858699||Adult control participants|Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.
11131042|NCT03858686|Active Comparator|400 mg FP-025 capsules|Based on a double-blind randomized schedule, 16 subjects will receive FP-025 capsules in Period 1 and matching placebo FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
11131043|NCT03858686|Placebo Comparator|FP-025 Placebo Capsules|Based on a double-blind randomized schedule, 16 subjects will receive matching placebo FP-025 capsules in Period 1 and FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
11131044|NCT03858673||Ligations group|VTH via the Tsuzi method with residual uterine ligament ligation (ligations group)
11131045|NCT03858673||Without ligations group|Traditional VTH without residual uterine ligament ligation (without ligations group)
11131046|NCT03858660||Elderly|Healthy elderly No intervention.
11131047|NCT03858647||Sensorineural hearing loss patients post cochlear implant|Patients who have documented sensorineural hearing loss and have received cochlear implantation (per standard of care).
11131048|NCT03858634|Experimental|KPL-716|Weekly for 8 weeks
11131049|NCT03858634|Placebo Comparator|Placebo|Weekly for 8 weeks
11131050|NCT03858621|Experimental|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
11131051|NCT03858621|No Intervention|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
11131052|NCT03858608|Experimental|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.
~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.
~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention [target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%]"
11131053|NCT03858608|Active Comparator|Usual asthma care|Usual asthma management
11131054|NCT03858595|Experimental|Intervention|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. Investigators will train our study participants (high-risk pregnant women) on how to use Salu Health Gauge to measure BP as well as how to charge them. Trained FFWs will visit the households weekly and synchronize the device with a tablet computer to collect the stored data. The FFWs will measure the weight of the participants using a digital weighing scale at enrollment and on a monthly bases thereafter. Investigators will keep monitoring up to termination of pregnancy. in any health issue arises, our health worker will ensure that an appropriate referral is made to a tertiary care facility. This intervention will be in addition to the conventional antenatal and postnatal care."
11131055|NCT03858595|No Intervention|Control group|All those women randomized to the control arm will receive conventional antenatal and postnatal care only. Investigators will collect the outcome data from the households and/or the health centers by follow-up visits or over phone. Investigators will consell participants, women both in the control group, to make at least four antenatal visits. In addition, Investigators will provide counselling about eating healty and keeping physically active during pregnancy. Investigators will provide general nutrition education on taking balanced energy and protein diet.
11131056|NCT03858582|Experimental|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
11131057|NCT03858582|Experimental|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
11131058|NCT03858582|Experimental|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
11131059|NCT03858569|Active Comparator|Oxytocin|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus
11131060|NCT03858569|Active Comparator|Oxytocin plus uterine massage|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus and transabdominal uterine massage will be performed.
11131061|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.
~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
11131062|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.
~-No treatment"
11131063|NCT03858543|Experimental|Fractional laser treatment & Poly-L Lactic Acid (Sculptra)|One Fractional laser treatment on half of the body with Sciton Laser and Scluptra
11131064|NCT03858543|Active Comparator|Fractional laser treatment|One Fractional laser treatment on half of the body with Sciton Laser
11131065|NCT03858530|Experimental|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
11131066|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:
~Aseptic necrosis of the humeral head
~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis
~Failed previous total shoulder replacement, resurfacing or other procedure"
11131067|NCT03858504|Experimental|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
11131068|NCT03858504|Active Comparator|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
11131069|NCT03858491|Experimental|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
11131070|NCT03858478|Experimental|Biktarvy arm|one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks
11131071|NCT03858465|Active Comparator|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
11131072|NCT03858465|Active Comparator|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
11131073|NCT03858452|Active Comparator|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
11131074|NCT03858452|Active Comparator|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
11131075|NCT03858452|Active Comparator|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
11131076|NCT03858439|Experimental|Intervention|Single arm study. All participants will receive dietary intervention.
11131077|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:
~Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)
~And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids
~Exclusion criteria:
~Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)
~Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
11131078|NCT03858413||Chronic kidney disease stage V|No intervention
11131079|NCT03858413||Chronic kidney disease stage III|No intervention
11131080|NCT03858387||Meropenem|Critically ill patients who require meropenem therapy
11131081|NCT03858387||Imipenem|Critically ill patients who require imipenem therapy
11131082|NCT03858374|Experimental|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
11131083|NCT03858374|Active Comparator|control group 1|Patients in control group 1 were transferred by slide board.
11131084|NCT03858374|Active Comparator|control group 2|Patients in control group 2 were transferred by bedsheet.
11131085|NCT03858348||fluticasone / salmeterol treatment|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol (Group A)
11131086|NCT03858348||fluticasone / salmeterol and extra LAMA|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol and extra a long-acting muscarinic receptor antagonist (anticholinergic, LAMA) (Group B).
11131087|NCT03858335|Experimental|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
11131088|NCT03858335|No Intervention|Control|Children in control group will receive only traditional rehab therapies without wearing splint
11131089|NCT03858322|Experimental|Carboplatin + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle
~Carboplatin will be administered intravenously 3 times per cycle"
11131090|NCT03858322|Experimental|Cyclophosphamide + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle
~Cyclophosphamide will be administered once per cycle"
11131091|NCT03858309|Experimental|Breathing Group 1|Arm 1 will receive an 8-week intervention that consists of a set of breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
11131092|NCT03858309|Active Comparator|Breathing Group 2|Arm 2 will receive an 8-week intervention that consists of slow breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
11131093|NCT03858296|Experimental|Emotional awareness|4 modules of emotional awareness training
11131094|NCT03858296|Experimental|Cognitive reappraisal|4 modules cognitive reappraisal training
11131095|NCT03858296|Experimental|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
11131096|NCT03858283|Experimental|Mindfulness Based Health Care Program|
11131097|NCT03858283|No Intervention|Control|
11131098|NCT03858270|Experimental|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
11131099|NCT03858270|Placebo Comparator|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
11131171|NCT03857776|Other|Standard care|Standard care including referral to a homepage about complementary alternative medicine
11131100|NCT03858257|Experimental|High flow nasal oxygen|The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation. The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered. The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e. increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy). Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
11131101|NCT03858257|Other|Standard oxygenation|Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice. The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
11131102|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
11131103|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
11131104|NCT03858231|Active Comparator|Opioid|
11131105|NCT03858231|Active Comparator|Non-opioid|
11131106|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
11131107|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
11131108|NCT03858205|Experimental|Treatment (low-dose radiation therapy)|Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the absence of disease progression or unacceptable toxicity. Patients with no pain relief may receive additional radiotherapy at 4 weeks following initial radiotherapy.
11131109|NCT03858192|Experimental|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
11131110|NCT03858192|Experimental|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
11131111|NCT03858192|Experimental|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
11131112|NCT03858179|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
11131113|NCT03858179|Experimental|PBMT + training/ placebo + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
11131114|NCT03858179|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
11131115|NCT03858179|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
11131116|NCT03858166|Active Comparator|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
11131117|NCT03858166|Experimental|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy.
11131118|NCT03858153|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
11131119|NCT03858153|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
11131120|NCT03858127||Male infants born <32 weeks gestation|
11131121|NCT03858114|Experimental|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
11131122|NCT03858114|Active Comparator|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
11131123|NCT03858101||PKU subjects|
11131124|NCT03858101||Age and sex-matched non-PKU comparison subjects|
11131125|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
11131126|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
11131127|NCT03858075|Experimental|Single ascending doses with BLU-782|
11131128|NCT03858075|Placebo Comparator|Single ascending doses with placebo|
11131129|NCT03858075|Experimental|Multiple ascending doses with BLU-782|
11131130|NCT03858075|Placebo Comparator|Multiple ascending doses with placebo|
11131131|NCT03858075|Experimental|Food effect of BLU-782 taken with food|
11131132|NCT03858075|Experimental|Food effect of BLU-782 taken without food|
11131133|NCT03858062|Active Comparator|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
11131134|NCT03858062|Experimental|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
11131135|NCT03858049|Experimental|Crinone|
11131136|NCT03858049|Experimental|Crinone plus Duphaston|
11131137|NCT03858036|Active Comparator|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
11131234|NCT03857360|Active Comparator|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
11131138|NCT03858036|Active Comparator|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
11131139|NCT03858023|Experimental|Hippotherapy|Children in hippotherapy arm will participate in hippotherapy (30 min/sessions, twice a week, 15 weeks)
11131140|NCT03858023|No Intervention|Control|Children in control group will not receive hippotherapy
11131141|NCT03857997||Patients|
11131142|NCT03857997||Parents|
11131143|NCT03857984|Experimental|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
11131144|NCT03857971|Other|Coronary OCT imaging of non flow-limiting lesion|Coronary OCT imaging will be performed of fractional flow reserve (FFR) negative lesions to assess plaque morphology.
11131145|NCT03857958|Experimental|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
11131146|NCT03857958|Active Comparator|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
11131147|NCT03857945|Active Comparator|Mobility Device Training Group|Patients receiving preoperative mobility device(s) training before surgery
11131148|NCT03857945|No Intervention|No Mobility Device Training Group|Patients not receiving preoperative mobility device(s) training before surgery
11131149|NCT03857932|Experimental|SLNB and non-slns resection|"Participants only receive SLNB
~preoperative CT lymphography
~SLNB with stained non-SLN resection
~SLNB with ARM dissection"
11131150|NCT03857932|Experimental|SLNB group|Participants only receive SLNB
11131151|NCT03857919|Experimental|TearCare|Subjects will have heat applied to the eyelids for 15 minutes followed by manual expression of the meibomian glands.
11131152|NCT03857919|Active Comparator|LipiFlow|Subjects will have heat and pressure applied to the eyelids for 12 minutes.
11131153|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
11131154|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
11131155|NCT03857893|Active Comparator|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
11131156|NCT03857893|Experimental|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.
~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
11131157|NCT03857867|Experimental|Tactile Stimulation Glove|Patients will receive actual tactile stimulation. They will be blinded to this randomization until month 3.
11131158|NCT03857867|Sham Comparator|Sham Stimulation Glove|"Patients will receive sham tactile stimulation. They will be blinded to this randomization until month 3 and will be able to receive the real stimulation glove at month 3."
11131159|NCT03857854|Experimental|treatment group|pirfenidone group
11131160|NCT03857854|Placebo Comparator|placebo group|control group
11131161|NCT03857841|Experimental|20 pmol phospholid/kg body weight|UNEX-42 administered at 20 pmol phospholid/kg body weight
11131162|NCT03857841|Experimental|60 pmol phospholid/kg body weight|UNEX-42 administered at 60 pmol phospholid/kg body weight
11131163|NCT03857841|Experimental|200 pmol phospholid/kg body weight|UNEX-42 administered at 200 pmol phospholid/kg body weight
11131164|NCT03857841|Placebo Comparator|Placebo|Phosphate-buffered saline
11131165|NCT03857815|Experimental|SBRT in combined with anti-PD-1 antibody|HCC Patients will be received stereotactic body radiation therapy (SBRT) to primary lesions or metastatic lesions, such as liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
11131166|NCT03857802|Experimental|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
11131167|NCT03857802|No Intervention|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
11131168|NCT03857789|Other|Regular care|Participant will be received by Healthcare professional (HCP). The HCP will administer a questionnaire. The HCP will discuss the results.
11131169|NCT03857789|Experimental|New care|Participant will be received by Healthcare professional (HCP). The social robot will administer a questionnaire. The HCP will discuss the results.
11131170|NCT03857776|Other|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.
~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
11131172|NCT03857763|Experimental|Apatinib+Paclitaxel+Cisplatin+RT|Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w
11131173|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
11131174|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
11131175|NCT03857737|Experimental|ESD group|This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
11131176|NCT03857737|Active Comparator|Surgery group|This group include patients who are going to undergo surgery for early gastric cancer.
11131177|NCT03857724|Experimental|prolapse surgery|
11131178|NCT03857711|Active Comparator|Conventional CABG|Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
11131179|NCT03857711|Active Comparator|CABG+ PVI|CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
11131180|NCT03857711|Active Comparator|CABG+ PVI+amiodarone|CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
11131181|NCT03857711|Active Comparator|CABG+amiodarone|CABG+class III antiarrhythmic drug- amiodarone, group, n=70
11131182|NCT03857698|Experimental|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
11131183|NCT03857698|Experimental|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
11131184|NCT03857698|Experimental|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
11131185|NCT03857698|Experimental|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
11131186|NCT03857698|Experimental|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
11131187|NCT03857698|Experimental|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
11131188|NCT03857698|Experimental|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
11131189|NCT03857685||Proliferation in an in-vitro model|An in-vitro model is used to study lens epithelial cell proliferation
11131190|NCT03857672|Experimental|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
11131191|NCT03857672|No Intervention|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
11131192|NCT03857659|Experimental|Point of care ultrasound (POC-US)|Point of care ultrasound (POC-US) to measure abdominal circumference and amniotic fluid every 4 weeks from 28-36 weeks
11131193|NCT03857659|Active Comparator|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
11131194|NCT03857646|Other|Intralipid|
11131195|NCT03857646|Other|SMOF lipid|
11131232|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
11131233|NCT03857373||Renal Cancer|Patients identified with RCC
11131196|NCT03857633||Pre Dialysis (CKD Stage 4/5)|Patients recruited from low clearance clinic with advanced CKD (stage 4/5). Patients will undergo Cardiac MRI 1 - With Gadolinium Contrast at the time of recruitment and Cardiac MRI 2 - With Gadolinium Contrast at time of commencement on renal replacement therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
11131197|NCT03857633||Haemodialysis Dialysis (CDK Stage 5d)|Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
11131198|NCT03857633||Peritoneal Dialysis (CDK Stage 5d)|Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
11131199|NCT03857620|Active Comparator|Arm I (usual care)|Healthcare providers/institutions perform usual care.
11131200|NCT03857620|Experimental|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
11131201|NCT03857620|Experimental|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
11131202|NCT03857594||Individuals at risk of hereditary cancer syndrome|All individuals at risk of a hereditary cancer syndrome with or without a known germline mutation from clinical genetic testing.
11131203|NCT03857581|Experimental|Clozapine Arm|
11131204|NCT03857581|Active Comparator|Olanzapine Arm|
11131205|NCT03857568|Experimental|SHR0410 group|SHR0410 will be dosed
11131206|NCT03857568|Experimental|Placebo|Placebo will be dosed
11131207|NCT03857542|Experimental|AGN-190584|Ophthalmic solution, one drop, dosed bilaterally, once daily for 30 days
11131208|NCT03857542|Placebo Comparator|Vehicle|Matching ophthalmic solution, one drop, dosed bilaterally, once daily for 30 days
11131209|NCT03857529|Experimental|conventional tDCS concurrent with CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
11131210|NCT03857529|Experimental|unconventional tDCS concurrent with CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
11131211|NCT03857529|Experimental|conventional tDCS preceding CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
11131212|NCT03857529|Experimental|unconventional tDCS preceding CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
11131213|NCT03857529|Sham Comparator|sham tDCS with CCFES|sham tDCS preceding and concurrent with CCFES
11131214|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
11131215|NCT03857503||Coronary Lesion Assessment with iFR|Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.
11131216|NCT03857490|Experimental|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
11131217|NCT03857490|Placebo Comparator|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
11131218|NCT03857477||Stage 1|Caucasian men aged 55-69 to undergo genetic SNP profiling.
11131219|NCT03857477||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer will be offered an MRI scan, prostate biopsy and prostate cancer screening.
11131220|NCT03857464|Other|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C difficile infections using the centralized testing facilities.
11131221|NCT03857464|Other|Crossover Arm Two|Hospital wards in this arm will utilize testing for C difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
11131222|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
11131223|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
11131224|NCT03857425|Experimental|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks
11131225|NCT03857425|Experimental|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
11131226|NCT03857425|Experimental|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
11131227|NCT03857412|Sham Comparator|Non capsular polishing|No capsular polishing taking place during cataract surgery
11131228|NCT03857412|Active Comparator|Capsular polishing|Capsular polishing taking place during cataract surgery
11131229|NCT03857399|Experimental|Arm-1|Patients will be assigned to receive intravenous local caspofungin (70 mg on day 1 and 50 mg once daily),If the study therapy was well tolerated but fever persisted for four or more days and the patient's clinical condition deteriorated, the dosage could be increased to 70 mg once daily.For patients who have no evidence of baseline or breakthrough fungal infection, study therapy was administered until the absolute neutrophil count was at least 500 per cubic millimeter and for up to 72 hours thereafter. The onsite investigator determined the duration of therapy for patients with baseline or breakthrough fungal infections; however,it was recommended that treatment be given for at least 14 days and for at least 7 days after neutropenia and symptoms resolved.
11131230|NCT03857399|Active Comparator|Arm-2|Patients will be assigned to receive intravenous original caspofungin (70 mg on day 1 and 50 mg once daily),the therapeutical duration is 4 Days.
11131231|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
11131235|NCT03857360|Placebo Comparator|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
11131236|NCT03857347|Experimental|Brief Psychoeducation Intervention|2 group session psychoeducation intervention feasibility study
11131237|NCT03857334|Experimental|Arm A|
11131238|NCT03857334|Active Comparator|Arm B|
11131239|NCT03857321|Experimental|Insulin first, then placebo|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive placebo at visit 3 during second intervention period.
11131240|NCT03857321|Experimental|Placebo first, then insulin|Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
11131241|NCT03857308|Experimental|Mindfulness Training|
11131242|NCT03857308|Active Comparator|Reappraisal Training|
11131243|NCT03857282|Active Comparator|Aerobic Exercises|Bicycling Exercise (lower Limb)
11131244|NCT03857282|Experimental|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
11131245|NCT03857269|Experimental|Acupoint Massage group|Choose Chinese medicine acupuncture points： Shenting, Baihui, Sishencong, Diwei, Chengling, Fengchi, Fengfu，Zusanli and Sanyinjiao，32 points per acupressure.32 times per acupoint.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
11131246|NCT03857269|Experimental|Aromatherapy group|Make a 5x5cm bag and put a cotton ball in the bag and the bag is clipped to the patient's collar.Dispense 10% lavender essential oil, 2-3 drops a day in cotton balls.Cotton ball replacement daily. Intervention frequency will be monday to saturday per week for 6 months.（n=30）
11131247|NCT03857269|Experimental|Acupoint Massage and Aromatherapy group|At the same time as the acupressure, the essential oil is applied to the collar and begins to sniff.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
11131248|NCT03857269|No Intervention|Blank control group|The group selects elderly people with MCI who do not receive intervention after informed.Participate in routine activities of Nursing homes.
11131249|NCT03857256|Experimental|Active Treatment|CP105F (Oat beta-glucan), 0.5g TID (3, 6 or 12 tablets per day for a dose of either 1.5g, 3g or 6gr) for 12 weeks.
11131250|NCT03857256|Placebo Comparator|Placebo|matching placebo 3, 6 or 12 tablets per day for 12 weeks.
11131251|NCT03857243|Experimental|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
11131252|NCT03857243|Placebo Comparator|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
11131253|NCT03857230|Experimental|Sequence A: Primapur - Gonal-F|Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
11131254|NCT03857230|Active Comparator|Sequence B: Gonal-F - Primapur|Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
11131255|NCT03857217||Post-cardiotomy patients|Patients submitted to cardiac surgery
11131256|NCT03857204|Experimental|performing US scans for fetal weight assessment.|
11131257|NCT03857191||Patients already treated for OSA|The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation
11131258|NCT03857191||Patients with a high OSA risk|This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
11131259|NCT03857191||Patients with a low OSA risk|This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
11131260|NCT03857165|Experimental|Low dose SAP-001|SAP-001 (Experimental drug) low dose versus placebo
11131261|NCT03857165|Experimental|Mid dose SAP-001|SAP-001 (Experimental drug) mid dose versus placebo
11131262|NCT03857165|Experimental|High dose SAP-001|SAP-001 (Experimental drug) high dose versus placebo
11131263|NCT03857152|Other|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
11131264|NCT03857139|Experimental|NRT smoking Cessation Intervention|All participants will be provided with the Nicotine Patch as an intervention
11131265|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.
~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
11131266|NCT03857113||PSMA-radioguided surgery|Tc-99m-PSMA combined with a gamma probe, guidance of the surgical resection of recurrent PC lymph node metastases
11131267|NCT03857100|Active Comparator|Intervention|Receives letter and report
11131268|NCT03857100|No Intervention|Control|Does not receive letter and report
11131269|NCT03857087||Diagnostic 68Ga PSMA PET/MRI|Patients receive gallium Ga 68-labeled PSMA-11 IV over 1-2 minutes. After about 60 minutes, patients undergo PET/MRI for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.
11131270|NCT03857074|Experimental|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
11131271|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
11131353|NCT03856476||Dyslipidemia group|Children and adolescents with dyslipidemia
11131272|NCT03857048|Active Comparator|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
11131273|NCT03857048|Experimental|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
11131274|NCT03857048|Active Comparator|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
11131275|NCT03857035|Experimental|Piezosurgery group|"One side of the patients will be randomly selected and labeled as experimental group. In experimental group, impacted third molar will be extracted using piezosurgery."
11131276|NCT03857035|Placebo Comparator|Rotary Instruments Group|"The other side will be accepted as control group. In the control group, impacted third molar will be extracted using conventional rotary instruments."
11131277|NCT03857022|Experimental|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
11131278|NCT03857022|No Intervention|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
11131279|NCT03857009||Symptomatic|No intervention.
11131280|NCT03857009||Asymptomatic|No intervention.
11131281|NCT03856996|Experimental|Group 1: Stable CH505TF gp120 + GLA-SE|Participants in Group 1 will receive 100 mcg of Stable CH505TF gp120 admixed with 10 mcg of GLA-SE by intramuscular (IM) injection at Months 0, 2, and 6.
11131282|NCT03856996|Experimental|Group 2: Transient CH505TF gp120 + GLA-SE|Participants in Group 2 will receive 100 mcg of Transient CH505TF gp120 admixed with 10 mcg of GLA-SE by IM injection at Months 0, 2, and 6.
11131283|NCT03856983|No Intervention|Control group|Control group who will do usual rehabilitation.
11131284|NCT03856983|Experimental|Experimental group|Experimental group who will do usual rehabilitation and visualization of point-light human actions
11131285|NCT03856970|Experimental|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
11131286|NCT03856970|Experimental|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
11131287|NCT03856970|Experimental|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).
~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
11131288|NCT03856957|Experimental|Endocuff colonoscopy|Colonoscopy performed with Endocuff
11131289|NCT03856957|Placebo Comparator|Conventional colonoscopy|Colonoscopy performed without any device
11131290|NCT03856944|Experimental|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
11131291|NCT03856918|Experimental|PEEP 3 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 3 cm of water during thoracic surgery.
11131292|NCT03856918|Experimental|PEEP 6 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 6 cm of water during thoracic surgery.
11131293|NCT03856918|Experimental|PEEP 9 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 9 cm of water during thoracic surgery.
11131294|NCT03856905|Active Comparator|Physical therapy group|The children in this group will receive the conventional physical therapy program (CPTP). It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neuro-developmental techniques, and gait training. The total program will be conducted for 1 h, three sessions/week for 12 weeks.
11131295|NCT03856905|Experimental|Extra-corporeal shock wave therapy group|The children in this group only will receive the extra-corporeal shock wave therapy (ESWT). An electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG) will be used. The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode, one session/week for 12 weeks. The treatment is painless and does not require any kind of anesthesia or the use of analgesic drugs
11131296|NCT03856905|Experimental|Functional electrical stimulation group|"The children in this group will receive the functional electrical stimulation (FES). The FES will be applied by using the WalkAide system (Innovative Neurotronics, Austin, TX, USA).
~The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait."
11131297|NCT03856892|Experimental|Active intervention|Intensive breath-based Hatha yoga program (more breath, more hours of practice)
11131298|NCT03856892|Active Comparator|Active Control|Less intensive practice on body (not breath) based yoga practices
11131299|NCT03856892|No Intervention|Passive control|No intervention is followed other than daily duties while in the same environment as both of the active groups.
11131300|NCT03856879|No Intervention|Usual care|Providers in this arm will provide usual care to their HIV+ patients with COPD.
11131354|NCT03856476||Control group|Children and adolescents without dyslipidemia
11131301|NCT03856879|Experimental|Proactive E-consult|Providers in this arm will receive proactive E-consults with expert recommendations for COPD care prior to appointments with HIV+ patients with COPD.
11131302|NCT03856866|Experimental|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
11131303|NCT03856866|Placebo Comparator|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
11131304|NCT03856853|Experimental|treatment group|pirfenidone group
11131305|NCT03856853|Placebo Comparator|placebo group|placebo group
11131306|NCT03856840||Bullous Pemphigoid Patients|Bullae and blood serum, which are obtained before and under treatment, will be compared in each other regardless of any condition.
11131307|NCT03856827|Experimental|IW-6463|IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food
11131308|NCT03856827|Placebo Comparator|Placebo|Matching placebo tablets administered orally
11131309|NCT03856814||Patients with varicose veins|Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators.
11131310|NCT03856801|Experimental|Whole-body vibration in normoxia condition|Training session in normoxia condition
11131311|NCT03856801|Experimental|Whole-body vibration in hypoxia condition|Training session in hypoxia condition
11131312|NCT03856788|Placebo Comparator|Saline|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with normal saline on the ipsilateral side as the extraction site.
11131313|NCT03856788|Active Comparator|Bupivacaine|Patients will undergo general anesthesia with a post-induction, post-intubation, pre-procedural subcostal TAP block with bupivacaine on the ipsilateral side as the extraction site.
11131314|NCT03856762|Experimental|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
11131315|NCT03856762|Experimental|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
11131316|NCT03856762|Experimental|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
11131317|NCT03856749|Experimental|Early Treatment|The wheelchair user and caregiver will be trained together on wheelchair skills. Training will be individualized dependent on initial results of wheelchair skills test and identified individual goals and will occur about a week after the initial data collection session.
11131318|NCT03856749|Other|Delayed Treatment|"The wheelchair user and caregiver will receive usual care, which may include wheelchair skills training for both wheelchair users and caregivers( but which often does not do so to an adequate extent) for 5 weeks. At the end of 5 weeks, the wheelchair user and caregiver will be trained together on wheelchairs skills similar to the protocol for the experimental group."
11131319|NCT03856736|Experimental|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
11131320|NCT03856736|Experimental|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
11131321|NCT03856710|Active Comparator|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
11131322|NCT03856710|Active Comparator|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
11131323|NCT03856697|Experimental|Abivertinib Maleate Capsules+ Placebo Gefitinib Tablets|Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Placebo Gefitinib Tablets (250 mg orally, once daily), in accordance with the randomization schedule.
11131324|NCT03856697|Active Comparator|Gefitinib Tablets+ Placebo Abivertinib Maleate Capsules|Placebo Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Gefitinib Tablets(250 mg orally, once daily), in accordance with the randomization schedule.
11131325|NCT03856684|Active Comparator|Self-sampling kit sent at home|Sending of a vaginal self-sampling kit at home
11131326|NCT03856684|Experimental|Self-sampling kit sent at home + SMS reminder|"Sending of a vaginal self-sampling kit at home + a SMS reminder is sent if the woman do not (in 2 months) :
~perform a pap smear
~or send her vaginal self-sample to the laboratory
~or contact the screening center to inform to an exclusion reason"
11131327|NCT03856684|Experimental|"Letter offering a self-sampling kit on request+ SMS reminder"|"Sending of letter offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us.
~If they do ask for the kit, one kit is sending to their home.
~For these women, a SMS reminder is sent if the woman do not (in 2 months) :
~perform a pap smear
~or send her vaginal self-sample to the laboratory
~or contact the screening center to inform to an exclusion reason"
11131328|NCT03856684|Experimental|"SMS offering a self-sampling kit on request+ SMS reminder"|"Sending of SMS offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us.
~If they do ask for the kit, one kit is sending to their home.
~For these women, a SMS reminder is sent if the woman do not (in 2 months) :
~perform a pap smear
~or send her vaginal self-sample to the laboratory
~or contact the screening center to inform to an exclusion reason"
11131329|NCT03856671|Experimental|oral antibiotics+mechanical bowel preparation|Liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. A combination of neomycin 1g and metronidazole 0.2g every 6 hours was also administrated. Enteroclysis was conduted for patients on surgical morning.
11131330|NCT03856671|No Intervention|simple mechanical bowel preparation|Only liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. Enteroclysis was conduted for patients on surgical morning.
11131355|NCT03856463|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay patient navigator who will provide information regarding early advance care planning, documentation of goals of care, and coordinating home-based care. The intervention arm will also receive usual care as provided by their local oncologists.
11131356|NCT03856463|Active Comparator|Control Group Arm|The control group will receive usual care as provided by their local oncologists.
11131331|NCT03856658|Experimental|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
11131332|NCT03856645|Experimental|OKG-0301 0.012% w/v|
11131333|NCT03856645|Experimental|OKG-0301 0.03% w/v|
11131334|NCT03856645|Placebo Comparator|Vehicle Control|
11131335|NCT03856632|Active Comparator|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
11131336|NCT03856632|Experimental|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
11131337|NCT03856619|Experimental|Aubagio®/Teriflunomide|Single dose of Aubagio® to be taken orally, once daily in the morning
11131338|NCT03856606|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will not be asked to perform interval exercise.
11131339|NCT03856606|Experimental|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
11131340|NCT03856593|Experimental|Letter A Intervention|The intervention arm will involve letter A sent to prescribers in Los Angeles County.
11131341|NCT03856593|Experimental|Letter B Intervention|The intervention arm will involve letter B sent to prescribers in Los Angeles County.
11131342|NCT03856580|Experimental|Self-injection|Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
11131343|NCT03856580|Experimental|"Injection by HCP at drop-in clinics"|"Participants will report to a drop-in clinic, where a healthcare provider will inject them with an inert version of injectable cabotegravir. Visits will take <10 minutes, and participants will be able to come whenever they want (when their injection is due) during clinic drop-in hours, which will be staggered in 2-hour windows during each week day. The inert substance that will be injected is intended to mimic injectable cabotegravir as closely as possible (described above). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as drop-in clinic hours, directions to the drop-in clinic site, study contact information, etc..."
11131344|NCT03856580|No Intervention|Control group|Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
11131345|NCT03856554|Experimental|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
11131346|NCT03856541|Experimental|SHR-A1403 Dose Escalation|SHR-A1403 given intravenously (IV).
11131347|NCT03856515|Experimental|E-cigarettes with Nicotine|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
11131348|NCT03856515|Placebo Comparator|E-cigarettes without Nicotine|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
11131349|NCT03856502|Experimental|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
11131350|NCT03856502|Active Comparator|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
11131351|NCT03856489||Patients|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 10 am.
11131352|NCT03856489||Nurses|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 7:30 am.
11131357|NCT03856450|Active Comparator|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
11131358|NCT03856450|Experimental|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
11131359|NCT03856437|Experimental|Gain-framed messages|Participants in this arm receive gain-framed HPV vaccination messages.
11131360|NCT03856437|Experimental|Loss-framed messages|Participants in this arm receive loss-framed HPV vaccination messages.
11131361|NCT03856424|Other|Modality 1 - Washout - Modality 2 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
11131362|NCT03856424|Other|Modality 1 - Washout - Modality 3 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
11131363|NCT03856424|Other|Modality 2 - Washout - Modality 1 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
11131364|NCT03856424|Other|Modality 2 - Washout - Modality 3 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
11131365|NCT03856424|Other|Modality 3 - Washout - Modality 2 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
11131366|NCT03856424|Other|Modality 3 - Washout - Modality 1 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
11131367|NCT03856411|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
11131368|NCT03856411|Placebo Comparator|Group Placebo combined with standard chemotherapy|
11131369|NCT03856385|Experimental|Mindful Walking|Four weekly 60 minute sessions of mindful walking.
11131370|NCT03856385|No Intervention|Control|Weekly email messages encouraging physical activity.
11131371|NCT03856372|Experimental|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
11131372|NCT03856372|Active Comparator|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
11131373|NCT03856359|Experimental|Rifaximin|rifaximin 550 milligrams (mg) orally twice daily for 3 months
11131374|NCT03856346||Phaco-vitrectomy|
11131375|NCT03856333|Other|traditional treatment|30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
11131376|NCT03856320|No Intervention|Usual Care|Patient attends a MOVE! visit (weight management visit).
11131377|NCT03856320|Experimental|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
11131378|NCT03856294|Experimental|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
11131379|NCT03856294|Placebo Comparator|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
11131380|NCT03856281|Experimental|Intervention Group A|LymphAssist IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
11131381|NCT03856281|Experimental|Intervention Group B|Sequential IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
11131382|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
11131383|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
11131384|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
11131385|NCT03856255|Experimental|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
11131386|NCT03856242|No Intervention|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
11131387|NCT03856242|Active Comparator|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
11131388|NCT03856242|Active Comparator|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
11131389|NCT03856229|Active Comparator|Group A conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
11131390|NCT03856229|Experimental|Group B shortened steroid regimen|"Subjects will receive the shortened steroid regimen for the severity of pneumonia with prednisone or equivalent with methylprednisolone, depending the severity of pneumonia:
~Moderate PCP. 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).
~Severe PCP. 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
11131391|NCT03856216|Experimental|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
11131392|NCT03856216|Experimental|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
11131393|NCT03856190|Active Comparator|"Fasting and best practice nutrition"|Initial fasting followed by 11 weeks plant-based diet
11131394|NCT03856190|Active Comparator|Standard Nutrition Counselling|12 weeks standard antiinflammatory diet
11131395|NCT03856177|Experimental|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
11131396|NCT03856177|Experimental|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
11131397|NCT03856164|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
11131398|NCT03856164|Placebo Comparator|Placebo|Normal saline for intravenous administration.
11131399|NCT03856151|Active Comparator|Early heating Group|"For Early heating Group, each subject will receive Treatment 1# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and do Treatment 2#.
~Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks."
11131400|NCT03856151|Active Comparator|Late heating Group|"For Late heating Group, each subject will receive Treatment 2# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and do Treatment 1#.
~Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks.
~Treatment 1# will be regular dialysis 3 times per week for 4 weeks."
11131401|NCT03856138||diarrhea with probiotics supplement|The children suffered from diarrhea, gastroenteritis oral probiotics during the clinical course
11131402|NCT03856138||diarrhea without probiotics supplement|The children suffered from diarrhea, gastroenteritis no oral probiotics during the clinical course
11131403|NCT03856138||healthy control|The children without diarrhea/ gastroenteritis
11131404|NCT03856125|Experimental|PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
11131405|NCT03856125|Sham Comparator|Sham PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of sham percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
11131406|NCT03856112|Experimental|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11131407|NCT03856112|Active Comparator|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11131408|NCT03856112|Experimental|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
11131409|NCT03856099|Experimental|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
11131410|NCT03856086|Active Comparator|Enhanced usual care (EUC)|"ICs randomized to EUC following baseline questionnaire completion will be given instructions (Appendix I) on how to access or create an account to access the myMSK online portal IC Resources page (https://my.mskcc.org/login). If the caregiver does not wish to enroll in MyMSK, the research study staff will send them an email with sample referral material ( Appendix D. The IC Resources page includes links to extant MSK educational materials for ICs (e.g., A Guide for Caregivers [47]), contact information for psychosocial services (e.g., Caregivers Clinic in the MSK Counseling Center), and external resources (e.g., educational materials and services through the CSC, American Cancer Society, and others) (Appendix D,)."
11131411|NCT03856086|Experimental|CancerSupportSource-CG screening plus consultation (S+C)|"ICs randomized to S+C will complete the web-based CSS-CG (Appendix C) using a tablet immediately following baseline study measures. In case of technical issues, ICs may complete Appendix C with the guidance of a member of the research study team. The CSS-CG asks ICs to rate their level of concern for 33 different possible problems: if a need is rated as low (i.e., A little or less concern), after each problem is rated ICs will be prompted to request pertinent educational materials if they are interested. If a need is endorsed (i.e., Moderate or greater concern), ICs are asked through the web-based electronic platform (https://mskcc.mycarereport.com) whether they would like educational materials and/or to speak with someone about that need (i.e., receive a referral)."
11131412|NCT03856073|Experimental|Novice|Anesthesiologists without experiment of manufacturing bronchoscopy.
11131413|NCT03856060|Experimental|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
11131414|NCT03856060|Experimental|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
11131415|NCT03856047|Experimental|NNC0174-0833, 4.5 mg|Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
11131416|NCT03856047|Experimental|NNC0174-0833, 2.4 mg|Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
11131417|NCT03856047|Experimental|NNC0174-0833, 1.2 mg|Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
11131418|NCT03856047|Experimental|NNC0174-0833, 0.6 mg|Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
11131419|NCT03856047|Experimental|NNC0174-0833 0.3 mg|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
11131420|NCT03856047|Placebo Comparator|Placebo 2.4 mg (NNC0174-0833)|Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
11131421|NCT03856047|Placebo Comparator|Placebo 4.5 mg (NNC0174-0833)|Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
11131422|NCT03856047|Placebo Comparator|Placebo 1.2 mg (NNC0174-0833)|Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
11131423|NCT03856047|Placebo Comparator|Placebo 0.6 mg (NNC0174-0833)|Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
11131424|NCT03856047|Placebo Comparator|Placebo 0.3 mg (NNC0174-0833)|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
11131425|NCT03856047|Active Comparator|Liraglutide 3.0 mg|Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
11131426|NCT03856047|Placebo Comparator|Placebo 3.0 mg (Liraglutide)|Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
11131427|NCT03856034|Experimental|Fetoscopic repair|
11131428|NCT03856021|Active Comparator|Microfracture|
11131429|NCT03856021|Active Comparator|Microfracture with Bone Marrow Aspirate Concentrate|
11131430|NCT03856008|Experimental|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
11131431|NCT03856008|Experimental|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
11131432|NCT03856008|No Intervention|Control.|No intervention will be applied.
11131433|NCT03855995||Active Surveillance Group|Children less than (<) 18 months of age who were identified at any administration of DTP/HepB/Hib (usually given at 6, 10 and 14 weeks of age) or at hospitalisation before administration of 3rd dose of DTP/HepB/Hib and vaccinated with at least one dose of DTP/HepB/Hib; including both RTS,S/AS01E vaccinated and unvaccinated children (from exposed or unexposed clusters) and living in the HDSS area will be enrolled into the active surveillance group.
11131434|NCT03855995||Enhanced Hospitalisation Surveillance Group|Children <5 years of age and hospitalised at any time during the study, living in the health and demographic surveillance system (HDSS) area will be enrolled into the enhanced hospital surveillance group.
11131435|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
11131436|NCT03855956|Experimental|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
11131437|NCT03855956|Other|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
11131438|NCT03855943|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
11131439|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.
~All patients will go through functional MRI study"
11131440|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
11131441|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
11131442|NCT03855917|Experimental|Sof plus G/P|Four weeks of sofosbuvir (400mg) plus glecaprevir-pibrentasvir (300mg/120mg) will be administered, followed by immediate retreatment of virological relapse with glecepravir/pibrentasvir (300mg/120mg) for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
11131443|NCT03855904|Experimental|TC-325|The intervention (experimental) arm patients are treated initially with TC-325 alone. Treatment failure for TC-325 is defined as endoscopists cannot achieve hemostasis with 1 syringe (20gm) of TC-325.
11131444|NCT03855904|Active Comparator|Traditional treatment (Control group)|Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
11131445|NCT03855891|Experimental|Study group|A group of patients with blood tests
11131446|NCT03855865|Experimental|Rapastinel|Rapastinel (450 mg prefilled syringe, weekly intravenous IV administration).
11131447|NCT03855865|Active Comparator|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
11131448|NCT03855865|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
11131449|NCT03855852|Active Comparator|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
11131450|NCT03855852|Experimental|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
11131451|NCT03855839||Healthy participants|Participants will be ask to perform a repetitive upper limb task while posture is being monitored.This will be done while wearing a posture shirt, compression shirt or no shirt.
11131452|NCT03855826|Experimental|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
11131453|NCT03855826|Active Comparator|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
11131454|NCT03855813|Other|Test-retest reliability|Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.
11131483|NCT03855527|Active Comparator|Chlorhexidine group|Atraumatic restorative treatment will be performed. Then, the cavities will be disinfected by placing a cotton pellet soaked in chlorhexidine solution (Consepsis®2% Chlorhexidine Antibacterial Solution) for 1 minute, air dried and restored using glass ionomer cement.
11131604|NCT03854708|Experimental|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg*min of pancreatic polypeptide was intravenously infused.
11131455|NCT03855800|Experimental|Clinical Follow-up|"Participants not undergoing surgery will be assigned to the Clinical Follow-up study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, or for 3 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted"
11131456|NCT03855800|Other|Surgical|"Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the Immediate Surgery study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known."
11131457|NCT03855787|Active Comparator|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
11131458|NCT03855787|Active Comparator|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
11131459|NCT03855774|Other|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
11131460|NCT03855761|Experimental|Intervention group|Experimental Occupational Therapy services
11131461|NCT03855761|Active Comparator|Comparison group|Treatment as usual
11131462|NCT03855735|Experimental|Intervention Group (IG)|Those who give birth and relatives who have been arbitrarily assigned to the control group receive online training on different communication models competencies and will gain access to the digital app.
11131463|NCT03855735|No Intervention|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app. The control group will receive a paper-pencil version.
11131464|NCT03855722|Experimental|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
11131465|NCT03855722|Sham Comparator|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
11131466|NCT03855696|Experimental|MG1113|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody
~Each vial contains 1mL of study drug
~The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg and 6.6 mg/kg by IV injection. The highest dose will be 13.3 mg/kg administered to hemophilia patients. In hemophilia patients, 3.3 mg/kg will be administered by SC injection, and 6.6 mg/kg and 13.3 mg/kg (highest dose) will be administered by IV injection."
11131467|NCT03855696|Placebo Comparator|Placebo of MG1113|"Placebo of MG1113
~Each vial contains 1mL of study drug"
11131468|NCT03855683|Experimental|Group therapy (Unified Protocol)|Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.
11131469|NCT03855657||Inflammatory Bowel Disease Patient|Patient with confirmed diagnosis of Inflammatory Bowel Disease
11131470|NCT03855657||Healthy control|Controls (non-IBD) will comprise individuals undergoing colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms, and friends and spouses or partners of patients at Prince of Wales Hospital or Alice Ho Miu Ling Nethersole Hospital, or any individuals who are interested to participate in this study.
11131471|NCT03855657||Healthy relatives of Inflammatory Bowel Disease patient|Relatives or household members of both patients with IBD or other diseases and controls will be recruited.
11131472|NCT03855644||Pelvic fracture patients|(1) 1<Age<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
11131473|NCT03855631||Kabuki syndrome/ unaffected parents|Intervention on primary cultured cells from 4 patients with KS and sex match parents
11131474|NCT03855618||1 case group|Consecutive 10 post-stroke patients in intensive rehabilitation treatment with an acute event occurring no later than 15 days from admission to the SOR Neurological Foundation don Gnocchi ONLUS IRCCS; age 18-90. It is required to sign an informed consent to the patient's participation in the study or if unable to sign, of the proxy.
11131475|NCT03855579|Experimental|Levosimendan|Intraoperative infusion of Levosimendan
11131476|NCT03855579|Active Comparator|Milrinone|Intraoperative infusion of Milrinone
11131477|NCT03855566|Other|Intervention|Enrolled participants will receive the intervention.
11131478|NCT03855553|Experimental|FBT|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
11131479|NCT03855553|Experimental|CBT-E|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
11131480|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score > 2 (for females > 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
11131481|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.
~Propensity matching according to the:
~CHA2DS2-VASc parameters
~LVEF: preserved (<40%), mid-range (40-49%) and reduced (>50%)
~Presence of diastolic dysfunction
~Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)
~Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone
~BMI: (<30kg/m2), (30-39kg/m2) and (≥40kg/m2)
~Smoking (>5 cigarettes per day)"
11131482|NCT03855527|Experimental|Silver Diamine Fluoride (SDF) group|Atraumatic restorative technique will be performed. Then the cavities will be dried with a gentle flow of compressed air. One drop of silver diamine fluoride (Advantage Arrest Silver Diamine Fluoride 38% - Bottle) will be dispensed into a dappen dish. A micro brush will be bent, dipped into SDF and dabbed on the side of the dappen dish to remove excess liquid before application. SDF will be applied directly to affected tooth surface and dried with gentle flow of compressed air for 1 minute. Excess SDF will be removed with cotton roll. Teeth will be restored with glass ionomer cement (GC Fuji IX).
11131484|NCT03855527|Sham Comparator|Atraumatic Restorative Treatment without Disinfection|Cavities will be cleaned according to the ART approach.The cavity will be enlarged if needed using sterile hatchet.The carious dentin will be removed with excavators starting at the enamel-dentine junction. The unsupported thin enamel will be fractured off with the hatchet. The caries will be removed carefully until firm dentin is reached (physically resistant to hand excavation). The cavity will be cleaned with wet cotton pellets. Cavities will be restored immediately using conventional glass ionomer cement. All the cavities in the 3 groups will be temporary restored with glass ionomer cement handled according to manufacturer's instructions, however acid etching will not be carried out in order to make sample collection easier following the experimental period.
11131485|NCT03855514|Active Comparator|NuShield|NuShield® is a sterile, dehydrated placental allograft
11131486|NCT03855514|No Intervention|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
11131487|NCT03855501|Active Comparator|Mineral trioxide aggregate|The root canals were gently instrumented with K-files and copious irrigation was done with 2.5% sodium hypochlorite(NaOCI) by means of a 30 gauge endodontic irrigating needle . After drying with large sterile paper points, calcium hydroxide(CH) paste was mixed with saline and applied to the root canal with a lentulo spiral filler at low speed. A cotton pellet was used to gently compress CH into the root canal and its placement was examined radiographically before placing ZOE as temporary restoration into the access cavity. After one week, CH was removed from the canal by using both the files and the irrigation with 2.5% NaOCI and 17% ethylenediaminetetraacetic acid (EDTA). A final irrigation was made with 2% chlorhexidine (CHX) before obturation. Following drying the root canal with sterile paper points, MTA was placed with a MTA Endo Gun into the apical portion of canals with a minimum 4-mm thickness and adapted to the canal walls with an endodontic hand plugger.
11131488|NCT03855501|Active Comparator|Calcium hydroxide|After using the same biomechanical root canal preparation protocol, the root canal was filled to working length with CH paste. Both clinical and radiographical examinations were performed to evaluate the barrier formation and periapical healing. When a continuous hard tissue barrier was observed apically on radiographs that was verified by clinical probing and complete or significant periapical healing was noticed, the root canal was obturated and coronary restorations were completed as done in MTA group
11131489|NCT03855488|Experimental|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
11131490|NCT03855488|Experimental|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
11131491|NCT03855488|Placebo Comparator|Neutral Control Condition|Listen to descriptions of neutral scenarios
11131492|NCT03855475|Experimental|Aerobic exercise|Exercise training
11131493|NCT03855475|Active Comparator|Stretching|Control
11131494|NCT03855462|Experimental|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :
~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.
~MCT ablation after 4 to 6 weeks (after effective retinopexy)"
11131495|NCT03855449|Other|Task Analysis Intervention Group|DECIDE problem-solving curriculum will be delivered in a group setting.
11131496|NCT03855423|Experimental|Tocotrienol-rich Fraction (TRF)|Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.
11131497|NCT03855410|Experimental|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
11131498|NCT03855410|Experimental|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
11131499|NCT03855397|Experimental|Microneedles|Application of microneedle patch, 30G hypodermic needle (positive control) and flat patch (negative control) in the lip, buccal, tongue, palatal and gingival mucosa for pain and safety assessment
11131500|NCT03855384|Experimental|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
11131501|NCT03855384|Placebo Comparator|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
11131502|NCT03855371|Experimental|Decitabine plus arsenic trioxide|decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
11131503|NCT03855358|Experimental|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
11131504|NCT03855345|Experimental|Control group|In this group, the participants will be submitted to the conventional treatment. The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
11131538|NCT03855176|Active Comparator|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
11131505|NCT03855345|Experimental|aPDT group|In this group, besides the conventional treatments, patients will also receive aPDT. aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F & A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
11131506|NCT03855332|Placebo Comparator|Placebo|"All participants will undergo three phases in random order:
~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
11131507|NCT03855332|Experimental|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
11131508|NCT03855332|Active Comparator|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
11131509|NCT03855319|Experimental|SMR neurofeedback training to MCI|"A sensorimotor/theta neurofeedback training consisted of 20 individuals sessions, twice a week during 11 weeks maximum. For each subject, NF was planned and conducted by a neuropsychologist experienced in neurophysiology an neurofeedback. Each session lasted 1h10 minutes and was conducted as follows:
~Preparation and installation of the electrodes, verification of the impedance, adjustement of the calibration.
~NF training (tasks and video described below)(45minutes)
~Feedback and debriefing about the session (15 minutes)"
11131510|NCT03855306|Experimental|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
11131511|NCT03855306|Active Comparator|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
11131512|NCT03855293|Other|Study group|rhexis protection shield
11131513|NCT03855293|No Intervention|Control group|regular surgery
11131514|NCT03855280|Experimental|APVO101|
11131515|NCT03855267|Placebo Comparator|Group A|Propofol 20 mg/ml, recommended anesthesia induction dose of 0.1~0.125 ml/kg, anesthesia maintenance pump speed of 0.2~0.5ml/kg/h. keep bispectral index within 40 # 60
11131516|NCT03855267|Active Comparator|GroupB|EP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
11131517|NCT03855267|Active Comparator|Group C|EP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
11131518|NCT03855267|Active Comparator|Group D|EP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
11131519|NCT03855254|Experimental|Positive communication|
11131520|NCT03855254|No Intervention|Control (neutral communication)|
11131521|NCT03855254|Experimental|Negative communication|
11131522|NCT03855241|Active Comparator|Informational Sheet|Persons picking up an opioid prescription will receive an informational sheet that describes how to properly dispose of leftover opioid medications
11131523|NCT03855241|Active Comparator|Drug Disposal Kit|Persons picking up an opioid prescription will receive a drug disposal kit (DisposeRx Drug Disposal kit) and instructions on how to use it
11131524|NCT03855241|No Intervention|No intervention|Persons picking up an opioid prescription will receive no additional information or materials on disposal.
11131525|NCT03855228|Experimental|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
11131526|NCT03855228|Active Comparator|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
11131527|NCT03855228|Active Comparator|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
11131528|NCT03855228|Placebo Comparator|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
11131529|NCT03855215|Experimental|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.
~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.
~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:
~CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended."
11131530|NCT03855215|No Intervention|Control|Working as routine
11131531|NCT03855202|Experimental|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
11131532|NCT03855202|Experimental|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
11131533|NCT03855202|Experimental|infusion group 3|PS,dose is 70mg/kg
11131534|NCT03855202|Placebo Comparator|Placebol|0.9% sodium chloride installation after 24 hours
11131535|NCT03855189|Experimental|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
11131536|NCT03855189|Active Comparator|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
11131537|NCT03855189|Placebo Comparator|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
11131539|NCT03855176|Experimental|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
11131540|NCT03855163|Experimental|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
11131541|NCT03855163|Experimental|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
11131542|NCT03855163|Experimental|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
11131543|NCT03855163|No Intervention|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
11131544|NCT03855137|Active Comparator|Atogepant 30 mg BID|Taken twice daily
11131545|NCT03855137|Active Comparator|Atogepant 60 mg|Taken once daily
11131546|NCT03855137|Placebo Comparator|Placebo|Taken twice daily
11131547|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
11131548|NCT03855111|Experimental|Standard (fixed) protocol Acu/Moxa - Active|"Standard (Fixed) Acupuncture / Moxibustion Active Protocol
~Subjects receive active standard Acu/Moxa protocol aimed at reducing neuropathic pain/discomfort."
11131549|NCT03855111|Experimental|Individualized (tailored) protocol Acu/Moxa - Active|"Individualized (Tailored) Active Acupuncture / Moxibustion Protocol
~Subjects receive active individualized Acu/Moxa protocol based on traditional Chinese medicine assessment aimed reducing neuropathic pain/discomfort."
11131550|NCT03855111|No Intervention|Sham Acu/Placebo Moxa (Control)|"Sham Acu/Placebo Moxa (Control)
~Note. All subjects randomized to the Control will be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
11131551|NCT03855111|No Intervention|WaitList (Control)|"WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Acupuncture / Moxibustion.
~Note. All subjects randomized to the Control will then be offered 12 active protocol acupuncture/ moxibustion treatments, at no cost, at the end of their study participation."
11131552|NCT03855098|Other|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
11131553|NCT03855072|Experimental|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback
~- intervention:
~All cases will undergo one surgery under general anesthesia.
~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region
~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.
~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS
~The customized fixation plate is positioned to fix the proximal and distal segment together"
11131554|NCT03855072|Active Comparator|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation
~- intervention:
~All cases will undergo one surgery under general anesthesia
~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .
~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.
~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
11131555|NCT03855059|Placebo Comparator|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
11131556|NCT03855059|Active Comparator|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
11131557|NCT03855046|Experimental|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
11131558|NCT03855046|Active Comparator|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
11131559|NCT03855033|Experimental|Media Aware Sexual Health - High School|Students received the web-based Media Aware Sexual Health - High School program.
11131560|NCT03855033|No Intervention|Typical Health Education Programming|Students received their regular health education programming not related to sexual health education.
11131561|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
11131562|NCT03855007|Experimental|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
11131563|NCT03854994|Experimental|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
11131564|NCT03854981|Placebo Comparator|Standard Care|If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.
11131565|NCT03854981|Active Comparator|Exercise + Standard Care|Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.
11131566|NCT03854968|Experimental|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
11131567|NCT03854955|Experimental|iScribes|Device-based scribing service used for dictation and documentation.
11131568|NCT03854955|No Intervention|Traditional Dictation|Standard dictation and documentation methods used.
11131569|NCT03854942|Other|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
11131642|NCT03854487|Sham Comparator|Sham mirror|
11131570|NCT03854942|Other|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
11131571|NCT03854942|Other|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
11131572|NCT03854929|Active Comparator|Ciprofloxacin|Each sachet CIPROFLOXACIN of 3g powder contains: 250mg Ciprofloxacin HCl, dissolved in water, dosed to 15mg/kg body weight /twice daily (apart 12 hours)/ 3 days.
11131573|NCT03854929|Experimental|Azithromycin|Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days
11131574|NCT03854916|Experimental|Caminemos Juntas App|Participants use the Caminemos app.
11131575|NCT03854916|Active Comparator|World Walking App|Participants use the World of Walking App.
11131576|NCT03854903|Experimental|Dose Level A1|"Palbociclib: 75mg daily for 21 days of each 28 day cycle
~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle
~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
11131577|NCT03854903|Experimental|Dose Level A2|"Palbociclib: 75mg daily for the first 21 days of each 28 day cycle
~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
11131578|NCT03854903|Experimental|Dose Level B1|"Palbociclib: 100mg daily for 21 days of each 28 day cycle
~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle
~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
11131579|NCT03854903|Experimental|Dose Level B2|"Palbociclib: 100mg daily for 21 days of each 28 day cycle
~Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle
~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
11131580|NCT03854890|No Intervention|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
11131581|NCT03854890|Experimental|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
11131582|NCT03854877|Experimental|Health behaviour intervention|Personalised health behaviour e-health intervention. The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to promote health habits. Based on personal needs participants can choose tasks for physical activity, relaxation, healthy eating, sleep etc. They get regular feedback, tasks and support from their personal trainer via phone and computer.
11131583|NCT03854877|No Intervention|Control group|Only before and after measurements
11131584|NCT03854864||Oncologists|French oncologists
11131585|NCT03854851|Experimental|NALDEBAIN|In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.
11131586|NCT03854851|Active Comparator|MORPHINE|In group MORPHINE, subjects will receive morphine as needed after surgery.
11131587|NCT03854838|Experimental|Toripalimab +Radiotherapy|Radiotherapy, intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks ) will be administered as an intravenous infusion over 60 minutes.
11131588|NCT03854825||AKI|patients with postoperative AKI defined by KDIGO
11131589|NCT03854825||no AKI|patients without postoperative AKI defined by KDIGO
11131590|NCT03854812|Active Comparator|Group M|magnesium sulphate as adjuvant to propofol
11131591|NCT03854812|Active Comparator|Group F|fentanyl as adjuvant to propofol
11131592|NCT03854799|Experimental|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:
~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
11131593|NCT03854786|Active Comparator|Oxyjun|Oxyjun- 400 mg OD after breakfast
11131594|NCT03854786|Placebo Comparator|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
11131595|NCT03854773|Active Comparator|Erector spinae block (Group ESPB)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
11131596|NCT03854773|Active Comparator|Thoracal paravertebral block group (Group TPVB)|In group B, TPVB will be performed. US probe will be placed 2-3 cm laterally following the visualization T5 spinous process in sagittal orientation. The ribs and transverse processes will be visualized as hyperechoic structures. The costotransverse ligament will be visualized in the superior, and the pleura in the anterior region. Using in plane technique, the block needle will be inserted in the cranio-caudal direction until the costotransverse ligament will be passed. For confirmation of correct position of the needle, 5 ml saline will be injected. After the negative aspiration of cerebrospinal fluid, blood and air; 20 ml of 0.25% bupivacaine will be performed and it will be seen of moving downwards of the pleura during the injection
11131597|NCT03854773|Other|Control group (Group C)|Patients in control group will be only received fentanyl via a patient controlled analgesia (PCA) device.
11131598|NCT03854760|Experimental|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
11131599|NCT03854747|No Intervention|control group|
11131600|NCT03854747|Experimental|working group|
11131601|NCT03854734|No Intervention|Usual Care|Educational emails about broad health topics to keep control group engaged
11131602|NCT03854734|Active Comparator|Multi-Component Intervention|(1) a community event to raise parental awareness of the importance of vaccination; (2) social marketing to target parents' attitudes and knowledge around vaccinations in the form of educational material
11131603|NCT03854721|Experimental|VAX014|Intravesical VAX014 (dose: 3.33x10^10 - 9.0x10^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
11131643|NCT03854487|Active Comparator|Covered mirror|
11131605|NCT03854708|Experimental|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg*min of pancreatic polypeptide was intravenously infused.
11131606|NCT03854708|Placebo Comparator|Placebo|0.9 % saline solution was intravenously infused.
11131607|NCT03854695||Cohort 1|Cohort 1: clinically uninfected (1A and 1C) ulcers.
11131608|NCT03854695||Cohort 2|Cohort 2: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) with no recent antibiotic therapy (within 28 days)
11131609|NCT03854695||Cohort 3|Cohort 3: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) on antibiotic therapy
11131610|NCT03854682|Experimental|Surgical|Radiofrequency microtenotomy (RF): A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
11131611|NCT03854682|Active Comparator|Non-surgical|Strength training: Consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
11131612|NCT03854669|Experimental|Assessing pain reporting accuracy|Subjects will undergo pre-operative evaluation of their pain reporting accuracy ability in order to assess its relation to post-operative acute pain and analgesic consumption
11131613|NCT03854656|No Intervention|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
11131614|NCT03854656|Experimental|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
11131615|NCT03854643|Experimental|Pilates group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
11131616|NCT03854643|Experimental|Control group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
11131617|NCT03854630|Active Comparator|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
11131618|NCT03854630|Experimental|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
11131619|NCT03854617|Experimental|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
11131620|NCT03854617|Active Comparator|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period.
11131621|NCT03854591||Gunshot related injury|Patients admitted to orthopaedic trauma service with gunshot related injury
11131622|NCT03854578|Experimental|BI 1358894|
11131623|NCT03854578|Experimental|Citalopram|
11131624|NCT03854578|Experimental|Placebo matching BI 1358894|
11131625|NCT03854565||Mild ARDS|patients have mild ARDS according to Berlin definition
11131626|NCT03854565||Moderate ARDS|patients have moderate ARDS according to Berlin definition
11131627|NCT03854565||Severe ARDS|patients have severe ARDS according to Berlin definition
11131628|NCT03854552|Experimental|BI 764198|Single rising oral doses
11131629|NCT03854552|Placebo Comparator|Placebo|Single rising oral doses
11131630|NCT03854539|Experimental|Active Stimulation 0.5|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
11131631|NCT03854539|Sham Comparator|Sham Stimulation|0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles
11131632|NCT03854539|No Intervention|No Stimulation|0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles
11131633|NCT03854539|Experimental|Active Stimulation 1.0|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.
11131634|NCT03854539|Experimental|Active Stimulation 0.25|0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
11131635|NCT03854526||Patients without Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months and with at least one tooth with coronal dental restoration
11131636|NCT03854526||Patients with Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months, with at least one tooth with coronal dental restoration and presenting a Gougerot Sjogren disease
11131637|NCT03854513||-Group 1 (anuric)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output less than 100ml / day
11131638|NCT03854513||Group 2 (good UOP)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output 400ml / day or more
11131639|NCT03854500|Active Comparator|Tenecteplase|Tenecteplase
11131640|NCT03854500|Active Comparator|Alteplase|Alteplase
11131641|NCT03854487|Experimental|Mirror therapy|
11131644|NCT03854474|Experimental|Treatment (tazemetostat, pembrolizumab)|Patients receive tazemetostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11131645|NCT03854461|Active Comparator|Educational material|Participants will be given written educational material to encourage dietary change towards a better quality diet. Educational material will be adapted from resources used in previous dietary intervention studies.
11131646|NCT03854461|Experimental|Personalised dietary advice and educational material|Participants will also be given the educational material, but will be encouraged to make dietary change using individualized recommendations incorporating food markers of specific components of a high quality diet. Food markers of diet quality will be used to develop an algorithm to deliver personalized dietary advice. Based on biomarker data, a system of categorization of biomarker status will be developed, alongside dietary advice related to this biomarker categorization, and decision trees created, as previously described in the Food4Me study, to ensure standardized delivery of advice within this intervention arm.
11131647|NCT03854435|Experimental|Heart rate assessed by using a stethoscope (auscultation)|Heart rate will be assessed by using a stethoscope (auscultation) in newborn infants immediately after birth
11131648|NCT03854435|Active Comparator|Heart rate assessed by palpation of the umbilical cord|Heart rate will be assessed by palpation of the umbilical in newborn infants immediately after birth
11131649|NCT03854422|Active Comparator|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
11131650|NCT03854422|Active Comparator|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
11131651|NCT03854422|Active Comparator|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
11131652|NCT03854409|Experimental|Part A - Deltoid Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
11131653|NCT03854409|Experimental|Part A - Gluteal Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
11131654|NCT03854409|Experimental|Part A - Deltoid Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
11131655|NCT03854409|Experimental|Part A - Gluteal Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
11131656|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (X)|Participants will receive a single dose of aripiprazole LAI.
11131657|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (Y)|Participants will receive a single dose of aripiprazole LAI.
11131658|NCT03854409|Experimental|Part B - Gluteal Site: Group 2|Participants will receive a single dose of aripiprazole LAI.
11131659|NCT03854396|Active Comparator|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
11131660|NCT03854396|Placebo Comparator|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
11131661|NCT03854383|Sham Comparator|Misoprostol alone|Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses
11131662|NCT03854383|Active Comparator|Isosorbide mononitrate with misoprostol|Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses
11131663|NCT03854370|Experimental|Baby shampoo|Baby shampoo used for surgical site prep
11131664|NCT03854370|Active Comparator|Peridex (Chlorhexidine)|Peridex used for surgical site prep
11131665|NCT03854370|Active Comparator|TechniCare (chloroxynel)|TechniCare used for surgical site prep
11131666|NCT03854370|Active Comparator|Betadine (Povidone- iodine)|Betadine used for surgical site prep
11131667|NCT03854357|Experimental|Additional Isolated Subscapularis Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
11131668|NCT03854357|Active Comparator|Standard Post-Operative TSA Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
11131669|NCT03854344|Experimental|Group 1|Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
11131670|NCT03854344|Active Comparator|Group 2|Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
11131698|NCT03854175|Active Comparator|Sildenafil group|40 women are give sildenafil citrate 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle, in addition to oral 2mg of estradiol valerat 6-8 hourly from the day 2-14 of the menstrual cycle
11133465|NCT03841760|Experimental|PSMA PET/CT|One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL
11131671|NCT03854331|Experimental|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
11131672|NCT03854331|No Intervention|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
11131673|NCT03854318||Family|Direct family members of enrolled patients will be asked to enroll in the study to providespecimens for genetic testing, next-generation sequencing, and other related studies.
11131674|NCT03854318||RUNX1|Patients enrolled in this protocol will have been referred with a known or suspected RUNX1mutation.
11131675|NCT03854305|Experimental|PRV-6527|Oral administration, 2X daily for 12 weeks
11131676|NCT03854305|Placebo Comparator|Placebo|Oral administration, 2X daily for 12 weeks
11131677|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
11131678|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
11131679|NCT03854279|Experimental|Bizact|Tonsillectomy will be done With the Bizact device
11131680|NCT03854279|Active Comparator|Electro-scissor|Tonsillectomy will be done With electro-scissors
11131681|NCT03854266|Experimental|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
11131682|NCT03854266|Active Comparator|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
11131683|NCT03854253|Experimental|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
11131684|NCT03854253|Active Comparator|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
11131685|NCT03854240|Active Comparator|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
11131686|NCT03854240|Active Comparator|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
11131687|NCT03854227|Experimental|Dose Escalation|Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
11131688|NCT03854227|Experimental|Non small cell lung cancer monotherapy|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
11131689|NCT03854227|Experimental|Urothelial carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
11131690|NCT03854227|Experimental|Head and neck squamous cell carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
11131691|NCT03854227|Experimental|Non small cell lung cancer PF-06939999 plus docetaxel|Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
11131692|NCT03854227|Experimental|Non small cell lung cancer dose finding|Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
11131693|NCT03854214|Active Comparator|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
11131694|NCT03854214|Sham Comparator|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
11131695|NCT03854201|Experimental|Personalized Exercise Counseling (PEC)|The Personalized Exercise Counselling intervention includes 3 face-face counseling sessions and 4-6 phone calls during six months. In addition, the participants are provided with the ExSed® interactive accelerometer to record their physical activity 24/7 from which they will receive personal daily feedback on their smart phone, which is provided to each person not having a suitable one of their own to be used during the 6-month intervention period.
11131696|NCT03854201|No Intervention|Control-arm|The participants only take part in the study measurements at baseline and the three follow-up time points. They will be provided personal written information by the UKK Institute on their blood sugar and lipid profiles, objectively measured physical activity (light, moderate, vigorous), standing, sedentary behaviour and sleep, and the three fitness tests measuring flexibility, muscular strength and cardiorespiratory fitness.
11131697|NCT03854188|Experimental|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
11131699|NCT03854175|Active Comparator|estradiol group|40 women are given oral estradiol valerate tablets 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium in addition to placebo in the same way as sildenafil
11131700|NCT03854162|Active Comparator|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
11131701|NCT03854162|Active Comparator|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
11131702|NCT03854162|Active Comparator|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
11131703|NCT03854162|Active Comparator|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
11131704|NCT03854149||Adults with CHD & non-valvular atrial arrhythmias|Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)
11131705|NCT03854123||Old MS patients|"75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP)."
11131706|NCT03854110|Experimental|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 of a 28 day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
11131707|NCT03854097|Experimental|Active PAD group|-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
11131708|NCT03854097|Experimental|Placebo PAD group|-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
11131709|NCT03854097|Experimental|Healthy Volunteers|-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
11131710|NCT03854084|Experimental|Intervention group|The cranial osteopathic techniques
11131711|NCT03854084|Sham Comparator|control group|Control group
11131712|NCT03854071|Other|Group 1|Heart failure patients with preserved ejection fraction
11131713|NCT03854071|Other|Group 2|Heart failure patients with reserved ejection fraction
11131714|NCT03854071|Other|Group 3|Patients with pulmonary hypertension
11131715|NCT03854071|Other|Group 4|Patients with acute myocardial infarction
11131716|NCT03854071|Other|Group 5|Patients with suspected but not treated coronary artery disease
11131717|NCT03854071|Other|Group 6|Healthy Volunteers
11131718|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)
~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning ~ evening), bicarbonate < 27 mmol/L awake)
~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning > evening, bicarbonate ≥ 27 mmol/L awake)
~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) > 45 mmHg awake)
~stage IV: OHS with end organ damage (hypercapnia , PCO2 > 45 mmHg awake, cardiometabolic comorbidities)
~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
11131719|NCT03854045|Experimental|Home-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the home with 2 clinicians present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR but are not eligible for Medicaid reimbursement.
11131720|NCT03854045|Active Comparator|Clinic-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the clinic with 1 clinican present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR and eligible for Medicaid reimbursement.
11131721|NCT03854032|Experimental|Arm I (BMS986205, nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.
11131722|NCT03854032|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.
11131723|NCT03854019|Experimental|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
11131724|NCT03854019|Placebo Comparator|Placebo|Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
11131725|NCT03854006|Active Comparator|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is < 75 s. In case of TTI>75s a 240s bonus freeze is applied.
~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
11131789|NCT03853551|Experimental|Single|Single arm
11131726|NCT03854006|Active Comparator|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
11131727|NCT03853993|Experimental|Experimental group-phase I|Quadrivalent influenza vaccine
11131728|NCT03853993|Experimental|Experimental group-phase III|Quadrivalent influenza vaccine
11131729|NCT03853993|Active Comparator|Control group-1-phase III|Trivalent influenza vaccine (contains B/Victoria strain)
11131730|NCT03853993|Active Comparator|Control group-2-phase III|Trivalent influenza vaccine (contains B/Yamagata strain)
11131731|NCT03853980|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
11131732|NCT03853967|Experimental|screening|participants performed lung cancer screening by Low Dose CT scan
11131733|NCT03853954|Experimental|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: <15 minutes
11131734|NCT03853941|No Intervention|Control|Patients in the control group will receive treatment as usual.
11131735|NCT03853941|Experimental|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
11131736|NCT03853928|Experimental|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
11131737|NCT03853928|Placebo Comparator|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
11131738|NCT03853915|Experimental|FDG PET Scan|[F-18] - FDG PET Scan and blood sample to measure HPV DNA
11131739|NCT03853902|Experimental|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
11131740|NCT03853902|Active Comparator|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
11131741|NCT03853889|Active Comparator|preepidural ONSD|The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
11131742|NCT03853889|Experimental|post epidural ONSD|The diameter of the optic nerve sheath to be measured with the help of ultrasonography Immediately after epidural anesthesia(post epidural ONSD) (T1), 15 minutes (T2), 30 min (T3), 60. min (T4) epidural anesthesia. The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
11131743|NCT03853863|Experimental|minimalist shoes walking group (MSW)|Subjects in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., in-school walking training with minimalist shoes).
11131744|NCT03853863|Active Comparator|traditional shoes walking group (TSW)|Subjects in the TSW group will be given a pair of protective shoes with arch support while following the same wearing pattern as the MSW group (i.e., in-school walking training with protective shoes).
11131745|NCT03853850|Experimental|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
11131746|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
11131747|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
11131748|NCT03853824|Other|Intervention arm|Patients randomised to increased postoperative surveillance.
11131749|NCT03853824|Other|Control arm|Patients randomised to usual postoperative care.
11131750|NCT03853811|Experimental|Mitchell Shoe + AFO|Group will receive standard Mitchell shoes along with the custom orthotic insert.
11131751|NCT03853811|No Intervention|Standard Mitchell Shoe (Control - Standard Treatment)|Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.
11131752|NCT03853798|Experimental|Cohort 1|"Participants who received placebo in Study AG348-C-006 will enroll in Cohort 1.
~Part 1 (Dose Optimization Period, 12 weeks): Participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day and then to 50 mg twice a day depending on their response to AG-348 and tolerability.
~Part 2 (Fixed Dose Period, 12 weeks): Last dose received in Part 1, twice a day.
~After completion of Part 2, participants who, in the opinion of the Investigator, have demonstrated clinical benefit from AG-348 treatment will continue AG-348 treatment in the Continued Treatment Period."
11131753|NCT03853798|Experimental|Cohort 2|"Participants who received AG-348 in Study AG348-C-006 will enroll in Cohort 2.
~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-006."
11131754|NCT03853798|Experimental|Cohort 3|"Participants who received AG-348 in Study AG348-C-007 will enroll in Cohort 3.
~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-007."
11131755|NCT03853785|Active Comparator|Intralesional MMR vaccine|Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
11131756|NCT03853785|Active Comparator|intralesional candida antigen|intralesional candida antigen in genital warts
11131757|NCT03853785|Active Comparator|Topical Podophyllin|Topical Podophyllin in genital warts
11131758|NCT03853759||Patients with Heart Failure|
11131759|NCT03853759||Healthy İndividuals|
11131760|NCT03853746|Experimental|Ocrelizumab|All participants will receive Ocrelizumab
11131761|NCT03853720|Experimental|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
11131762|NCT03853707|Experimental|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11131763|NCT03853707|Active Comparator|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11131764|NCT03853707|Experimental|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11131765|NCT03853694|Active Comparator|Group 1 (Standard of Care Group)|150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
11131766|NCT03853694|Experimental|Group 2 (Duramorph + EXPAREL TAP)|50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
11131767|NCT03853694|Experimental|Group 3 (EXPAREL TAP)|EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
11131768|NCT03853681|Other|additional blood sampling|
11131769|NCT03853668|Active Comparator|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.
~Exercise intensity is 50-65%of maximal heart rate (MHR)"
11131770|NCT03853668|Experimental|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
11131771|NCT03853655|No Intervention|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
11131772|NCT03853655|Experimental|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
11131773|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
11131774|NCT03853629||CF|"Age 1-17
~Diagnosis of Cystic Fibrosis
~Living in or around London"
11131775|NCT03853629||Controls|"Age 1-17
~Healthy
~Living in or around London"
11131776|NCT03853616|Experimental|Phase I: DL 0: 1x10e5 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
11131777|NCT03853616|Experimental|Phase I: DL 1: 5x10e5 MB-CART19.1 cells|Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
11131778|NCT03853616|Experimental|Phase I: DL 2: 1x10e6 MB-CART19.1 cells|Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.
11131779|NCT03853616|Experimental|Phase I: DL 3: 3x10e6 MB-CART19.1 cells|In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.
11131780|NCT03853616|Experimental|Phase II - Recommended dose MB-CART19.1|Phase II will evaluate the efficacy and safety in patients treated with the recommended dose in Cohorts 1 to 3, respectively.
11131781|NCT03853603|Placebo Comparator|Placebo|Maltodextrin
11131782|NCT03853603|Active Comparator|Santa herba extract|Santa herba extract
11131783|NCT03853590|Active Comparator|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
11131784|NCT03853590|Experimental|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
11131785|NCT03853577|Active Comparator|Psilocybin|
11131786|NCT03853577|Placebo Comparator|Placebo|
11131787|NCT03853564|Experimental|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
11131788|NCT03853564|Sham Comparator|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
11131790|NCT03853538|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
11131791|NCT03853538|Active Comparator|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
11131792|NCT03853525|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with BAY207543 is investigated.
11131793|NCT03853525|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with vaseline is investigated.
11131794|NCT03853512|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
11131795|NCT03853512|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
11131796|NCT03853499||Successful vacuum extraction|Patients for whom vacuum extraction was successful
11131797|NCT03853499||Failed vacuum extraction|Patients who had an emergency caesarean section after failed vacuum extraction
11131798|NCT03853473|No Intervention|Standard of Care|Study participants will receive standard of care.
11131799|NCT03853473|Experimental|Remote Ischemic Preconditioning|Study participants will perform remote ischemic preconditioning daily, at home, from study enrollment to their date of surgery.
11131800|NCT03853460|Active Comparator|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
11131801|NCT03853460|Active Comparator|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
11131802|NCT03853447||Diagnostic imaging|"The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including
~Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.
~Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.
~Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria."
11131803|NCT03853434|Experimental|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
11131804|NCT03853434|No Intervention|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
11131805|NCT03853421|Experimental|Dose cohort 3 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
11131806|NCT03853421|Experimental|Dose cohort 6 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
11131807|NCT03853421|Experimental|Dose cohort 9 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
11131808|NCT03853408||First Admission|Cholecystectomy during first admission
11131809|NCT03853408||Second Admission|Cholecystectomy during second admission
11131810|NCT03853395|Active Comparator|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
11131811|NCT03853395|Experimental|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
11131812|NCT03853382|Experimental|Cognitive Analytic Informed Brief Therapy|
11131813|NCT03853382|No Intervention|Treatment As Usual|
11131814|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|
11131815|NCT03853343|Placebo Comparator|Placebo|3 capsules per day (1 before each meal) of cellulose
11131816|NCT03853343|Active Comparator|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
11131817|NCT03853330|Active Comparator|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
11131818|NCT03853330|Active Comparator|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
11131819|NCT03853317|Experimental|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on Blinded Independent Central Review (BICR).
11131820|NCT03853304|Experimental|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
11131821|NCT03853304|Experimental|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
11131822|NCT03853304|Experimental|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
11131824|NCT03853291|Experimental|PICT Workbook|PICT Workbook components will include: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set.
11131825|NCT03853291|Active Comparator|Information Pamphlet|Informational pamphlet about pain in dementia and a link to the Alzheimer's Association website.
11131826|NCT03853278|Experimental|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
11131827|NCT03853278|No Intervention|No intervention control group|The control group will receive health education leaflets.
11131828|NCT03853265|No Intervention|Control|
11131829|NCT03853265|Experimental|Virtual Reality|Simulated dental office visit
11131830|NCT03853252|Other|Skin biopsy|
11131831|NCT03853239|Active Comparator|face mask crossover nasal ventilation|
11131832|NCT03853239|Active Comparator|nasal ventilation crossover face mask|
11131833|NCT03853213|Experimental|Cognitive Bias Modification Training|"Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., death, chest pain) and toward neutral stimuli (e.g., curve, barn doors). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign."
11131834|NCT03853213|Sham Comparator|Attention Control Training|Participants in this placebo control group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is the placebo version of Cognitive Bias Modification Training for Attention. It is designed NOT to train attention toward or away from threatening or neutral information. The second task is the placebo version of Cognitive Bias Modification Training for Interpretation. It is designed NOT to train the interpretation of information as either threatening or benign.
11131835|NCT03853200|Experimental|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
11131836|NCT03853200|Active Comparator|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
11131837|NCT03853200|Active Comparator|Group III|17% EDTA with no antibacterial activity . the control group
11131838|NCT03853187|Experimental|Durvalumab (MEDI4736) neo-adjuvant|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC. Patients are amendable to adjuvant chemo and/or radiation treatment, per standard-of-care. Additionally, patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and ex vivo In-111-oxine labelled CD8+ T-cells after two courses of treatment, prior to surgery.
11131839|NCT03853174|Active Comparator|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
11131840|NCT03853174|Other|RT|Resistance training were prformed. Intensity was gradually increased.
11131841|NCT03853161|Experimental|Vapotherm arm|Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA
11131842|NCT03853161|Experimental|NIPPV arm|Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator
11131843|NCT03853148|Active Comparator|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
11131844|NCT03853148|Active Comparator|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
11131845|NCT03853148|Active Comparator|Otago + GYYB + Behavioral activation|This condition will incorporate OEP and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
11131846|NCT03853135||Behçet group|Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed.
11131847|NCT03853135||control group|including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed.
11131848|NCT03853122|Active Comparator|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:
~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).
~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).
~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
11133568|NCT03840928||Crohn's-related Arthritis|
11131849|NCT03853122|Experimental|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):
~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
11131850|NCT03853109|Experimental|Cohort 1|Cohort 1
11131851|NCT03853109|Experimental|Cohort 2|Cohort 2
11131852|NCT03853109|Experimental|Cohort 3|Cohort 3
11131853|NCT03853109|Experimental|Cohort 4|Cohort 4
11131854|NCT03853109|Experimental|Cohort 5|Cohort 5
11131855|NCT03853109|Experimental|Cohort 6|Cohort 6
11131856|NCT03853109|Experimental|Cohort 7|Cohort 7
11131857|NCT03853109|Experimental|Cohort 8|Cohort 8
11131858|NCT03853109|Experimental|Cohort 9|Cohort 9
11131859|NCT03853096|Experimental|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.
~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
11131860|NCT03853083|Experimental|Hypoxi Equipment|
11131861|NCT03853083|Active Comparator|Recumbent Bicycle|
11131862|NCT03853057|Experimental|non-invasive ventilation|Non-invasive positive pressure at different body positions: sitting - supine - prone - right lateral and left lateral.
11131863|NCT03853044|Experimental|Chidamide plus CHOP|Participants received six 21-day cycles of chidamide, combined with six cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (21-day cycles).
11131864|NCT03853031|Active Comparator|LVEDA guided intraoperative fluid therapy|Patients in TEE group will be given crystalloid fluids during surgery guided by LVEDA cm2 to be maintained between 10 -18 cm2 , if LVEDA < 10 cm2 then 200ml colloid bolus will be given and increase in LVEDA noted.
11131865|NCT03853031|Active Comparator|CVP guided intraoperative fluid therapy|Patients in CVP group will be given crystalloid fluids during surgery guided by CVP values to be maintained between 10 -16 cms of water H2O ,if CVP value < 10 cms H2O then 200 ml colloid bolus will be given and increase in CVP value noted.
11131866|NCT03853018|No Intervention|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
11131867|NCT03853018|Experimental|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
11131868|NCT03853018|Experimental|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
11131869|NCT03853005|Placebo Comparator|Group A (controlled group)|They will not receive HVHDF treatment
11131870|NCT03853005|Active Comparator|Group B (HVHDF group)|They will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.
11131871|NCT03852992|Experimental|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:
~Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)
~Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)
~Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
11131872|NCT03852992|Placebo Comparator|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage
~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
11131873|NCT03852992|Experimental|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage
~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
11131874|NCT03852992|Experimental|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage
~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure
~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
11131875|NCT03852979|Experimental|neo-adjuvant chemotherapy|The patients are given weekly paclitaxel 80 mg/m2 + carboplatin AUC=2 (or AUC=6 per three weeks) during 12 weeks/4 courses followed by conization if tumor size is reduced to <2 cm
11131876|NCT03852966|Experimental|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
11131877|NCT03852953||Study 1: Under- and overdiagnosed group|Non-proportional stratified sample of women diagnosed with interval or screen-detected breast cancers after participation in BreastScreen Norway. This sample will include under- or overdiagnosed cancers, as well as cancers that were not under- or overdiagnosed.
11131878|NCT03852953||Study 2: Rate of overdiagnosis group|Women residing in Norway, born between 1927 and 1934 (inclusive). This cohort will include women who have attended screening and who have not attended screening.
11131879|NCT03852953||Study 3: Awareness and knowledge group|Women aged 50-69, and practising family doctors aged 25-75, currently living in Norway.
11131880|NCT03852940|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
11131881|NCT03852940|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
11131882|NCT03852914|Experimental|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
11131883|NCT03852901|Experimental|Single Arm|Single group
11131884|NCT03852888|Experimental|mtugroup|All patients managed for rheumatoid arthritis (according to the ACR / EULAR 2010 criteria) in the Rheumatology Department of the University Hospital of Reims and treated with methotrexate monotherapy.
11131885|NCT03852875|Experimental|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
11131886|NCT03852875|Sham Comparator|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
11131887|NCT03852862|Experimental|Serratus plane block with paravertebral block|Association of Serratus plane block and paravertebral block for anesthesia
11131888|NCT03852862|Active Comparator|paravertebral block alone|Paravertebral block for anesthesia
11131889|NCT03852849|No Intervention|routine care group|Medical institutions will provide patients routine care according to the national program standard.
11131890|NCT03852849|Experimental|medicine intervention group|The dosage of 400 mg EFV will be used in the antiviral therapy.
11131891|NCT03852849|Experimental|consolidated intervention group|Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
11131892|NCT03852836|Other|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
11131893|NCT03852836|Other|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
11131894|NCT03852823|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
11131895|NCT03852810||Receiving surgical intervention via XEN Gel Stent (XEN)|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
11131896|NCT03852810||Receiving surgical intervention via trabeculectomy|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
11131897|NCT03852797|Active Comparator|Ketamine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
11131898|NCT03852797|Active Comparator|Ketamine + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
11131899|NCT03852797|Active Comparator|Propofol|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
11131900|NCT03852797|Active Comparator|Propofol + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
11131901|NCT03852797|Active Comparator|Etomidate|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
11131902|NCT03852797|Active Comparator|Etomidate + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
11131903|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
11131904|NCT03852771|Experimental|Treatment|All participants will receive the intervention
11131905|NCT03852758|Experimental|Outdoor Exercise|2 sessions of outdoor exercise per week
11131906|NCT03852758|Experimental|Indoor Exercise|2 sessions of indoor exercise per week
11131907|NCT03852745|Other|Cognitive Behavioral Therapy|Online cognitive behavioral therapy intervention for 2 hours a week for 12 weeks.
11131908|NCT03852732|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
11131909|NCT03852719|Experimental|Arm A - Bulevirtide 10 mg/day|Observation for 48 weeks followed by Bulevirtide 10 mg/day for 96 weeks and further follow-up period for 96 weeks
11131910|NCT03852719|Experimental|Arm B - Bulevirtide 2 mg/day|Bulevirtide 2 mg/day for 144 weeks with a further follow-up period of 96 weeks
11131911|NCT03852719|Experimental|Arm C - Bulevirtide 10 mg/day|Bulevirtide 10 mg/day for 144 weeks with a further follow-up period of 96 weeks
11131912|NCT03852706|Experimental|LORETA|In the first session, Low Resolution Brain Electromagnetic Tomography (LORETA) will be used in combination with Z-scores to identify participants' resting state EEG differences relative to a database of norms of their demographic. EEG abnormalities which are consistent with the research literature on neural changes associated with AVH will then be targeted for normalization using neurofeedback training using LORETA in combination with Z-scores.
11131913|NCT03852706|Other|Treatment as usual|Maintenance use of an atypical antipsychotic (e.g., clozapine) with support, when needed, of a community nurse.
11131914|NCT03852693||Retrospective Group|
11131915|NCT03852693||Prospective Group|
11131916|NCT03852667|No Intervention|Control|No intervention between the two test sessions
11131917|NCT03852667|Active Comparator|Pain Neuroscience Education|Two sessions (30 min) of Pain Neuroscience Education
11131918|NCT03852667|Experimental|Pain neuroscience education - exercise|2 sessions of PNE and 5 sessions of exercise therapy.
11131919|NCT03852654|Experimental|treatment|
11131920|NCT03852641|Experimental|Bolus gavage feeds|Bolus gavage feeds over 15-30 minutes
11131921|NCT03852641|Experimental|Continuous feeds|Continuous feeds over 2.0 hrs
11131922|NCT03852628|Active Comparator|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol
~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
11131923|NCT03852628|Placebo Comparator|Placebo|"Placebo (SL pill qd, IM injection q4weeks)
~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
11133569|NCT03840928||Juvenile Idiopathic Arthritis|
11133570|NCT03840928||Lupus|
11131924|NCT03852615|Experimental|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
11131925|NCT03852615|Other|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
11131926|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
11131927|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
11131928|NCT03852589|Active Comparator|C-MAC Videolaryngoscope|C-MAC Videolaryngoscope: An intubating device that is used for endotracheal intubation. Proseal laryngeal mask airway will be inserted with C-MAC Videolaryngoscope
11131929|NCT03852589|Active Comparator|Blind|Proseal laryngeal mask airway will be inserted with digital finger
11131930|NCT03852576|Experimental|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
11131931|NCT03852563|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
11131932|NCT03852563|Active Comparator|Women_Hemiface Vaseline|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
11131933|NCT03852550|Experimental|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition[TM] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
11131934|NCT03852550|No Intervention|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
11131935|NCT03852537|Active Comparator|Usual Care|Usual care as determined by the patient's primary team.
11131936|NCT03852537|Experimental|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP < 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level > 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
11131937|NCT03852524|Experimental|Study Arm|The study arm will receive subcutaneous methylnaltrexone (0.15mg/kg rounded to 8 or 12 mg) before surgery and then daily, for the following three days after surgery (four doses).
11131938|NCT03852524|Placebo Comparator|Placebo Arm|The placebo arm will receive subcutaneous placebo before surgery and then daily, for the following three days after surgery (four doses).
11131939|NCT03852511|Experimental|Intratumoural (Cohort 1)|Patients will receive a single dose of NG-350A by IT injection.
11131940|NCT03852511|Experimental|Intratumoural (Cohort 2)|Patients will receive one cycle of multiple doses of NG-350A by IT injection.
11131941|NCT03852511|Experimental|Intravenous|Patients will receive three single doses of NG-350A by IV infusion.
11131942|NCT03852498|Experimental|Lenti-D Drug Product|
11131943|NCT03852485||Normal|no glaucoma or retinal pathology or corneal conditions
11131944|NCT03852485||Glaucoma|diagnosis of glaucoma
11131945|NCT03852485||Retina|diagnosis of AMD, DR or other retinal pathology
11131946|NCT03852485||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
11131947|NCT03852472|Placebo Comparator|Group A|Placebo b.i.d
11131948|NCT03852472|Active Comparator|Group B|Avacopan 10 mg b.i.d
11131949|NCT03852472|Active Comparator|Group C|Avacopan 30 mg b.i.d
11131950|NCT03852459|Experimental|Active Arm|S-Ibuprofen Topical Gel 5%
11131951|NCT03852459|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
11131952|NCT03852446|Experimental|Part 1: Single Ascending Dose|
11131953|NCT03852446|Experimental|Part 2: Bioavailability and Food Effect|"Single dose of Indoximod HCL (F2) formulation under fasting conditions
~Single dose of Indoximod HCL (F2) formulation under fed conditions
~Single dose of Indoximod base formulation under fasting conditions"
11131954|NCT03852433|Active Comparator|Arm A - Peginterferon alfa-2a|Peginterferon alfa-2a for 48 weeks with additional 48 weeks follow up
11131955|NCT03852433|Experimental|Arm B - Bulevirtide 2 mg/day|Bulevirtide 2 mg/day in combination with peginterferon alfa-2a for 48 weeks followed by Bulevirtide 2 mg/day for 48 weeks and additional 48 weeks follow up
11131956|NCT03852433|Experimental|Arm C - Bulevirtide 10 mg/day|Bulevirtide 10 mg/day in combination with peginterferon alfa-2a for 48 weeks followed by Bulevirtide 10 mg/day for 48 weeks and additional 48 weeks follow up
11131957|NCT03852433|Experimental|Arm D - Bulevirtide 10 mg/day|Bulevirtide 10 mg/day for 96 weeks with additional 48 weeks follow up
11131958|NCT03852420|Experimental|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
11131959|NCT03852407|Experimental|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
11132019|NCT03851874|Active Comparator|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
11133571|NCT03840928||Myositis|
11131960|NCT03852407|Experimental|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
11131961|NCT03852381|Experimental|Spinal Cord Stimulation|"At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.
~The trial will proceed as follows:
~Day 1-4: Paresthesia-based SCS (PB-SCS)
~Day 5-8: No SCS (placebo)
~Day 9-12: PF-SCS
~Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.
~Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density)."
11131962|NCT03852368|Experimental|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
11131963|NCT03852368|Experimental|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
11131964|NCT03852368|Experimental|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
11131965|NCT03852355|Active Comparator|Radiofrequency|bilateral 3rd occipital nerve RF under fluoroscopic guidance
11131966|NCT03852355|Active Comparator|Systemic steroid|received systemic steroids oral prednisolone tablet, 10 mg/day.
11131967|NCT03852329|Experimental|Navigated|Lateral skull base navigation intervention is applied
11131968|NCT03852316|Experimental|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
11131969|NCT03852303|Active Comparator|ivermectin once a year|Ivermectin one dose per year and anti-epileptic treatment
11131970|NCT03852303|Experimental|ivermectin 2 times a year|Ivermectin one dose 2 times a year and anti-epileptic treatment
11131971|NCT03852303|Experimental|ivermectin 3 times a year|vermectin one dose 3 times a year and anti-epileptic treatment
11131972|NCT03852251|Experimental|AK104|AK104 IV every 2 weeks (q2w)
11131973|NCT03852251|Experimental|AK104 and chemotherapy|"AK104 IV every 2 weeks (q2w)
~oxaliplatin IV 85 mg/m2 q2w
~capecitabine 1000 mg/m2，twice a day (bid) for day 1 to day 10 per cycle"
11131974|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
11131975|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
11131976|NCT03852225||OHCA patients|Patients resuscitated for out-of-hospital cardiac arrest of non-traumatic origin and investigated by intra-arrest echocardiography.
11131977|NCT03852212|No Intervention|Control Group|The control group did not received any treatment
11131978|NCT03852212|Experimental|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
11131979|NCT03852199||Case Group|Our study was performed with 30 healthy individuals at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. The FS of the knee joint was measured with a Pressure Biofeedback Device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN), a device similar to a sphygmomanometer. To correlate the outcomes of biofeedback device, simultaneously, a surface electromyography (EMG) data of M. Quadriceps femoris muscle activation levels from the individuals were recorded.
11131980|NCT03852186|Active Comparator|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
11131981|NCT03852186|Experimental|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
11131982|NCT03852173|Experimental|"Intervention group Wasserschulen"|Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
11131983|NCT03852173|No Intervention|Control group|No intervention (usual education). Schools do not receive any project material. Schools got the information that they are part of a study on drinking and eating habits of third grade elementary school children.
11131984|NCT03852160|Experimental|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram [mg] [initial dose for elderly participants 65-74 years of age] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg [initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study] or 84 mg [maximum uptitrated esketamine dose]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
11132020|NCT03851874|Active Comparator|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
11132045|NCT03851692|Active Comparator|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
11132046|NCT03851679||pregnancy woman|woman who are submitted to elective Cesarean Section in spinal anesthesia
11133572|NCT03840928||Osteoarthritis|
11131985|NCT03852160|Active Comparator|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
11131986|NCT03852147|Active Comparator|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
11131987|NCT03852147|Experimental|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
11131988|NCT03852134|Experimental|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
11131989|NCT03852134|Active Comparator|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.
~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
11131990|NCT03852121|Experimental|Intervention group|Participants will receive bibliotherapy without withdrawing from the usual care. They will be asked to read the designated manual (consists of eight chapters) within a recommended period of time (over 8 weeks). Weekly telephone coaching will also be provided to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves. An orientation will be organized before the first session. Two booster sessions will be organized during the study.
11131991|NCT03852121|No Intervention|Control group|The participants in the control group will only receive usual care provided by the community health professionals.
11131992|NCT03852108|Experimental|Group comfort care|Socio-aesthetic care
11131993|NCT03852108|No Intervention|Group control|Conventional care
11131994|NCT03852095||minor trauma|Child from 1 to 18 years old suffering an isolated minor trauma presenting at the hospital emergency services.
11131995|NCT03852069|Placebo Comparator|Placebo|16 g maltodextrin/day + recipes based on vegetables poor in inulin-type fructans
11131996|NCT03852069|Experimental|Inulin|16 g inulin/day + recipes based on vegetables rich in inulin-type fructans
11131997|NCT03852056|Placebo Comparator|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
11131998|NCT03852056|Experimental|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
11131999|NCT03852043|Experimental|High-intensity interval training|
11132000|NCT03852043|Active Comparator|Moderate-intensity continuous training|
11132001|NCT03852030|Experimental|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.
~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
11132002|NCT03852030|Placebo Comparator|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
11132003|NCT03852030|No Intervention|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
11132004|NCT03852017|Experimental|Mindfulness Audio Program|Mindfulness Audio Program is a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life
11132005|NCT03852017|Active Comparator|Music Audio Program|Music Audio Program is a daily audio session of peaceful and relaxing music
11132006|NCT03852004|Experimental|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
11132007|NCT03852004|Placebo Comparator|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
11132008|NCT03851991|Active Comparator|arbidol|200mg, three times per day, for 2-5 Days.
11132009|NCT03851991|Placebo Comparator|Placebos|two capsules, three times per day, for 2-5 Days.
11132010|NCT03851978|Experimental|Pharmacist Vaccine Education|
11132011|NCT03851952|Other|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
11132012|NCT03851939|Experimental|treatment group|Transarterial Chemoinfusion (TAI) Combine Toripalimab
11132013|NCT03851913|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
11132014|NCT03851913|No Intervention|control group|no neo-adjuvant treatment before operation
11132015|NCT03851900|Experimental|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
11132016|NCT03851900|Active Comparator|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
11132017|NCT03851900|Placebo Comparator|Distilled water|Distilled water with no desensitizing components.
11132018|NCT03851887|Experimental|treatment group|TAI combine SBRT
11133573|NCT03840928||Osteoporosis|
11132021|NCT03851861|Experimental|Mediterranean Diet|Participants will be given individualized diet education on the Mediterranean diet and instructed to follow the diet for the 5-week intervention period. Individualized diet education will be administered by a licensed, registered dietitian nutritionist (RDN) followed by weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
11132022|NCT03851848|Experimental|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
11132023|NCT03851848|Experimental|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
11132024|NCT03851835|Experimental|Ondansetron Oral Solution|Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg. One dose every 8 hours (q8h). Six doses over 48 hours.
11132025|NCT03851835|Placebo Comparator|Placebo Oral Solution|Compounded Placebo Oral Solution to match experimental arm
11132026|NCT03851809|Experimental|neurologic intensive care in acute brain injury|With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
11132027|NCT03851796|Active Comparator|TEENS+Parents as Coaches|"Parents are taught strategies to support and facilitate child weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on strategies to facilitate healthy weight management in their child(ren). Topics include role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen. They receive personalized feedback throughout the program.
~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents will receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
11132028|NCT03851796|Active Comparator|TEENS+Parent Weight Loss|"Parents are given a weight loss goal of 1-2 lbs/week, and specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program.
~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
11132029|NCT03851783|Experimental|Solar-powered oxygen|Solar panels used to drive an oxygen concentrator will deliver medical grade oxygen at a rate of 1-5L/min, for the treatment of children with hypoxemia.
11132030|NCT03851783|No Intervention|Standard of care|Patients presenting with hypoxemia and pneumonia will be treated by standard of care prior to the implementation of solar-powered oxygen at a chosen site. This may include some allocation of oxygen via cylinders, but will likely be minimal or not available.
11132031|NCT03851770|Other|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
11132032|NCT03851757|Active Comparator|waist-shaped interdental brush|waist-shaped interdental brush, use four times per interdental space
11132033|NCT03851757|Active Comparator|cylindric interdental brush|cylindric interdental brush, use four times per interdental space
11132034|NCT03851744|Active Comparator|Sea Level|Carbohydrate metabolism measured at SL
11132035|NCT03851744|Experimental|High Altitude|Carbohydrate metabolism measured at HA
11132036|NCT03851731|Experimental|Naltrexone|Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
11132037|NCT03851731|Experimental|Naloxone|Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
11132038|NCT03851731|Experimental|Naltrexol|Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
11132039|NCT03851718|Experimental|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
11132040|NCT03851718|Active Comparator|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
11132041|NCT03851705|Experimental|Part 1 - Inclisiran|Participants will receive a dose of 300 milligram (mg) Inclisiran for injection administered by SC injection on Day 1 and Day 90.
11132042|NCT03851705|Placebo Comparator|Part 1 - Placebo|Participants will receive a dose of placebos administered by SC injection on Day 1 and Day 90.
11132043|NCT03851705|Experimental|Part 2 - Inclisiran|All participants will receive a dose of 300 mg inclisiran for injection administered by SC injection on Day 270, Day 450 and Day 630.
11132044|NCT03851692|Active Comparator|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
11132047|NCT03851666|Placebo Comparator|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
11132048|NCT03851666|Experimental|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).
~The daily dose administrated is 15 grams."
11132049|NCT03851666|Active Comparator|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).
~The daily dose administrated is 15 grams."
11132050|NCT03851653|Experimental|Lifestyle Intervention Group (LIG)|Participants from this group will receive a cognitive-behavioral intervention addressing weight loss and lifestyle habits such as hypocaloric diet, moderate exercise, smoking and alcohol avoidance, and sleep hygiene. This behavioral intervention will be combined with the usual treatment for OSA, i.e. CPAP.
11132051|NCT03851653|No Intervention|Control group|Participants from the control group will not receive any type of intervention apart from the usual care (CPAP).
11132052|NCT03851640|Experimental|HC-1119|80mg;
11132053|NCT03851640|Placebo Comparator|placebo|80mg;
11132054|NCT03851627|Active Comparator|Testosterone undecanoate|intramuscular Testosterone undecanoate 1000mg/4ml
11132055|NCT03851627|Placebo Comparator|Testosterone like Placebo|intramuscular Testosterone undecanoate like Placebo
11132056|NCT03851614|Experimental|Cohort A|Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
11132057|NCT03851614|Experimental|Cohort B|Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
11132058|NCT03851601||ECP|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
11132059|NCT03851588|Active Comparator|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
11132060|NCT03851588|Placebo Comparator|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
11132061|NCT03851575|Active Comparator|Control arm|Usual guideline therapy
11132062|NCT03851575|Experimental|Accelerated arm|Accelerated treatment of endocarditis
11132063|NCT03851562|Experimental|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
11132064|NCT03851562|Placebo Comparator|Placebo (physiological saline solution)|Placebo (physiological saline solution)
11132065|NCT03851549|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)
11132066|NCT03851536|Experimental|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
11132067|NCT03851536|Experimental|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
11132068|NCT03851471|Experimental|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
11132069|NCT03851458||Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
11132070|NCT03851458||SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and 24-hour dietary surveys can be done over phone . Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
11132071|NCT03851445|Other|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
11132072|NCT03851432|Experimental|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
11132073|NCT03851432|Experimental|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
11132074|NCT03851432|Placebo Comparator|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
11132075|NCT03851419||People living with HIV|People living with HIV (ART naive or on ART)
11132076|NCT03851419||People not infected with HIV|HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
11132077|NCT03851406|Active Comparator|5% Hypertonic Saline|Subjects will inhale 5% hypertonic saline
11132078|NCT03851406|No Intervention|No Treatment|No inhaled treatment
11132079|NCT03851393|Experimental|Peptest™ analysis of saliva pepsin|Induction of cough with inhaled citric acid and measurement of saliva pepsin following citric acid cough challenge using the peptest lateral device
11132080|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
11132212|NCT03850483|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
11132081|NCT03851367|Experimental|Sling suspension therapy|3-week duration of exercises using red cord and consisting of 15 sessions for 30 minutes each.
11132082|NCT03851367|Active Comparator|Swiss ball therapy|3-week duration exercise for trunk muscles strengthening and posture improvement consisting of 15 sessions for 30 minutes each.
11132083|NCT03851354|Other|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
11132084|NCT03851341|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
11132085|NCT03851341|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
11132086|NCT03851315||LBBAP group|patients received left bundle branch area pacing
11132087|NCT03851315||traditional RVP group|Age and sex-matched patients received traditional right ventricular pacing
11132088|NCT03851302|Experimental|Active RIC + isometric hand exercise|Subjects will receive an active remote ischemic conditioning (200mmHg cuff pressure) before an active isometric hand exercise.
11132089|NCT03851302|Sham Comparator|Sham RIC + isometric hand exercise|Subjects will receive an sham remote ischemic conditioning (10 mmHg below the subjects' diastolic blood pressure) before an active isometric hand exercise.
11132090|NCT03851289|Experimental|test (PRF-CS)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and calcium sulfate was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
11132091|NCT03851289|Active Comparator|control (PRF-X)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and xenograft (MinerOss® X) was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
11132092|NCT03851276|Other|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
11132093|NCT03851263|Experimental|Evolocumab|All subjects are treated with evolocumab 140mg every 2 weeks (q2w) starting on day 1 and ending on day 1071 (week 153).
11132094|NCT03851250|Experimental|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10^9 to 10^10 Colony Forming Units.
~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
11132095|NCT03851250|Placebo Comparator|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.
~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
11132096|NCT03851237|Experimental|Cohort 1a: Any Treatment Group|"Early-staged localized pancreatic cancer
~Standard of care diagnostic biopsy
~64Cu-DOTA-ECL1i-PET/CT imaging - immediately after the dynamic study
~Receive treatment with upfront surgery such as whipple procedure"
11132097|NCT03851237|Experimental|Cohort 1b: Standard of Care Treatment Chemotherapy|"Borderline resectable, locally advanced/metastatic or recurrent pancreatic cancer
~Standard of care diagnostic biopsy (if available tissue to be used for CCR2 expression)
~64Cu-DOTA-ECL1i-PET/CT imaging pretherapy
~Treatment with any standard of care (SOC) chemotherapy
~Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with positive scan at baseline/early therapy at the time of standard of care follow-up imaging appointment --Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with negative scan at baseline/early therapy at time recurrence is diagnosed by any standard imaging modality"
11132098|NCT03851237|Experimental|Cohort 2: CCR2-Targeted Therapy|"Locally advanced or borderline resectable pancreatic cancer
~Biopsy per therapeutic protocol (if available tissue to be used for CCR2 expression)
~64Cu-DOTA-ECL1i-PET/CT imaging pretherapy
~2 cycles of CCR2-targeted therapy
~Biopsy per therapeutic protocol (tissue to be used for CCR2 expression) --Additional 64Cu-DOTA-ECL1i-PET/CT imaging after 2 cycles of therapy"
11132099|NCT03851224|Active Comparator|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
11132100|NCT03851224|Active Comparator|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
11132101|NCT03851224|Active Comparator|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
11132102|NCT03851198|Experimental|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
11132103|NCT03851198|Active Comparator|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
11132104|NCT03851172|Experimental|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
11132105|NCT03851172|Experimental|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
11132106|NCT03851172|Placebo Comparator|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
11132107|NCT03851159|Placebo Comparator|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
11132108|NCT03851159|Experimental|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
11132109|NCT03851159|Placebo Comparator|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
11132110|NCT03851159|Experimental|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
11133574|NCT03840928||Psoriasis|
11132111|NCT03851146|Experimental|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.
~Dose level : Target Number LeY CART cells infused *
~-1 (if needed): 1 x 10e8
~2 x 10e8
~5 x 10e8
~1 x 10e9
~5 x 10e9
~Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols
~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
11132112|NCT03851133||All Participants|Blood samples, tumor samples and data will be collected from all participants as applicable.
11132113|NCT03851120|Experimental|Intervention|200 pregnant women will be given Probiotic and LC-PUFA, psychosocial stimulation, and healthy eating education
11132114|NCT03851120|Placebo Comparator|Control|200 pregnant women will be given placebo, psychosocial stimulation, and healthy eating education
11132115|NCT03851107|Experimental|Community-based activity program|Engagement in 6-week community-based activity program
11132116|NCT03851094|No Intervention|Group A|
11132117|NCT03851094|Experimental|Group B|Wellth app
11132118|NCT03851081|Experimental|Treatment (inotuzumab ozogamicin, liposomal vincristine)|See Detailed Description.
11132119|NCT03851068|Experimental|Tria Aortic Valve|Patients receiving the Foldax Tria Aortic Valve
11132120|NCT03851055|Active Comparator|intervention group|will receive zinc supplementation
11132121|NCT03851055|No Intervention|Control group|Patients will receive placebo only
11132122|NCT03851042|Experimental|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
11132123|NCT03851042|Active Comparator|No intervention|Routine PACU care post hysterectomy for up to 4 hours
11132124|NCT03851029|Experimental|Tai chi|(Yang 24 postures) Moderate intensity HRR (40%-60%)
11132125|NCT03851029|Active Comparator|Aerobic Training|Elliptical Moderate intensity HRR (40%-60%)
11132126|NCT03851016|Experimental|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
11132127|NCT03851016|Experimental|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
11132128|NCT03851003|Experimental|Endometrial suturing|Uterine incision repair including suturing of the endometrium
11132129|NCT03851003|Experimental|Non - Endometrial suturing|Uterine incision repair without suturing of the endometrium
11132130|NCT03850990|Experimental|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
11132131|NCT03850990|Experimental|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
11132132|NCT03850977||Patients and controls|Patients diagnosed with chronic pancreatitis or cirrhosis and healthy controls
11132133|NCT03850964|Active Comparator|Pazopanib|Pazopanib 50mg oral daily dosing [two 25mg capsules]. If after 3mths primary endpoint not achieved, and safety is maintained, consideration for advance in dose to up to 100mg daily
11132134|NCT03850964|Placebo Comparator|Placebo oral capsule|Placebo
11132135|NCT03850951|Experimental|"Lingual appliances AO®"|Patients with moderate crowding will be treated without extraction using lingual fixed appliances from American Orthodontics company.
11132136|NCT03850951|Experimental|"Labial appliances AO®"|Patients with moderate crowding will be treated without extraction using labial fixed appliances from American Orthodontics company.
11132137|NCT03850938|Experimental|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
11132138|NCT03850938|Active Comparator|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
11132139|NCT03850925|Experimental|Picosecond laser|Intervention: four consecutive sessions of 1,064-nm picosecond laser at 3-week intervals
11132140|NCT03850925|Active Comparator|Fractional laser|Intervention: four consecutive sessions of nonablative fractional laser at 3-week intervals
11132141|NCT03850912|No Intervention|Activity 1: Stakeholder Feedback|"Obtain stakeholder feedback to inform eSyM finalization and implementation from:
~patient advisory councils
~health system leaders
~clinicians
~clinic support staff/administration
~IT/Informatics"
11132142|NCT03850912|No Intervention|Activity 2: eSym Build|"Build and deploy eSyM
~Finalize training materials based on findings from stakeholder engagement"
11132143|NCT03850912|Experimental|Activity 3: Pilot Test eSyM App|"Pilot testing of the eSyM app will include:
~Activity 3a (eSyM app usage by patients)
~Activity 3b (User acceptability testing)
~Activity 3c (Medical record abstraction)"
11132144|NCT03850912|Experimental|Activity 4: eSyM+ Participants|"These patients (and/or proxy) will report their symptoms in eSyM
~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM+ version)
~A medical record abstraction will be completed for ALL eSyM+ patients"
11132145|NCT03850912|Experimental|Activity 4: eSyM- Participants|"These patients (and/or proxy) will NOT report their symptoms in eSyM
~A subset of these patients will be asked to complete a research questionnaire called the SASS Questionnaire (eSyM- version)
~A medical record abstraction will be completed for ALL eSyM- patients"
11132146|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
11132147|NCT03850899||Controls|Heavy drinkers without significant liver disease
11132148|NCT03850899||Donor|Healthy non-drinkers
11132149|NCT03850886|Experimental|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
11133575|NCT03840928||Psoriatic Arthritis|
11132150|NCT03850886|Active Comparator|Control group|diabetes management including metformin or Sulphonylurea
11132151|NCT03850873|Experimental|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily
11132152|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
11132153|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
11132154|NCT03850847||Multi-Methods Study|"Step 1: Semi-structured Interviews
~Step 2: National Telephone Survey"
11132155|NCT03850834|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|
11132156|NCT03850834|Placebo Comparator|Placebo Enteric-coated Tablets|
11132157|NCT03850821|Experimental|Connect Social Mechanisms Intervention|"The primary components of the intervention included: Get-to-know-you sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging."
11132158|NCT03850821|No Intervention|Typical ASP curriculum wait-list control|No intervention was implemented within the active wait-list control condition, which served as the typical ASP curriculum control/comparison. After completion of the 8-week intervention (12 weeks including baseline and post-intervention data collection), the control condition received the social mechanisms curriculum as a token of appreciation for participating in measurement.
11132159|NCT03850808||decline in left ventricular function|This group will be patients in whom a decline in left ventricular systolic function was found.
11132160|NCT03850808||preserved left ventricular function|This group will consist of patients in whom left ventricular systolic function is preserved.
11132161|NCT03850795|Experimental|HC-1119|Oral dose of 80 mg/day
11132162|NCT03850795|Active Comparator|enzalutamide|Oral dose of 160 mg/day
11132163|NCT03850782|Experimental|Bimatoprost SR - Dose A|"Study Eye: Participants will receive 1 - 3 Cycles of Bimatoprost SR administrations of Dose A
~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
11132164|NCT03850782|Experimental|Bimatoprost SR - Dose B|"Study Eye: Participants received 1-3 Cycles of Bimatoprost SR administrations of Dose B
~Fellow Eye: The eye that does not receive Bimatoprost SR treatment will receive standard of care or up to one administration of Bimatoprost SR."
11132165|NCT03850769|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
11132166|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
11132167|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers"
11132168|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers Predisposition to kidney injury biomarkers
~Also tobacco consumption will be measured"
11132169|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).
~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)
~In these patients kidney function will be evaluated by:
~Early kidney damage biomarkers
~Also Tobacco consumption will be measured"
11132170|NCT03850730|Experimental|Pazopanib|Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
11132171|NCT03850717||Traditional Chinese Acupuncture|"Use traditional acupuncture, stronger, deeper, harder-acupuncture"
11132172|NCT03850717||Japanese Acupuncture|"Use traditional shallow, lighter acupuncture, softer-acupuncture"
11132173|NCT03850691|Experimental|Cohort 1: Nivolumab|
11132174|NCT03850691|Experimental|Cohort 2: Nivolumab & Ipilimumab|
11132175|NCT03850678|Experimental|Hearing Aid|Group of participants with hearing loss. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels, while manipulating different hearing aid parameters and also without the provision of amplification, will be assessed.
11132213|NCT03850483|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
11132214|NCT03850483|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
11133576|NCT03840928||Rheumatoid Arthritis|
11132176|NCT03850678|No Intervention|Normal Hearing|Group of participants with normal hearing that serve as a reference group. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels will be assessed.
11132177|NCT03850665|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
11132178|NCT03850665|Active Comparator|Anterolateral approach|Anterolateral Approach surgery to replace the hip.
11132179|NCT03850652|Active Comparator|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
11132180|NCT03850652|Placebo Comparator|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
11132181|NCT03850639|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
11132182|NCT03850639|No Intervention|Wait list control|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.
11132183|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
11132184|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
11132185|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
11132186|NCT03850613|Experimental|Intervention arm|Participants in the intervention arm download the E-painting mobile app and use this app to make their own painting.
11132187|NCT03850600|Experimental|Diet-CD|dietary intervention: 8-10 weeks of diet intervention
11132188|NCT03850600|No Intervention|No-Diet-CD|Usual diet with no intervention
11132189|NCT03850600|No Intervention|No-Diet-Control|Unaffected controls at the same gestational stage will follow usual diet and no intervention
11132190|NCT03850587|Experimental|YYC301-1 & Celocoxib placebo|"YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.
~*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex)."
11132191|NCT03850587|Experimental|YYC301-2 & Celocoxib placebo|"YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.
~*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)"
11132192|NCT03850587|Experimental|YYC301-3 & Celocoxib placebo|"YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.
~*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)"
11132193|NCT03850587|Active Comparator|YYC301 placebo & Celecoxib|Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
11132194|NCT03850574|Experimental|HM43239|This phase 1/2 study consists of dose escalation and expansion. Dose escalation cohort is planned up to 10 dose levels. If subject in the dose escalation cohort at any dose level achieves clinical response then the dose level will continue to enroll.
11132195|NCT03850561|Active Comparator|Coenzyme Q10 200|Coenzyme Q10 200mg/day for 3 months
11132196|NCT03850561|Active Comparator|Coenzyme Q10 400|Coenzyme Q10 400mg/day for 3 months
11132197|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
11132198|NCT03850535|Experimental|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
11132199|NCT03850535|Experimental|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
11132200|NCT03850535|Experimental|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
11132201|NCT03850535|Experimental|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
11132202|NCT03850522|Experimental|Vaccination|Vaccination with PD-L1 peptide
11132203|NCT03850509|Experimental|OPS-2071 150 mg|150 mg BID Oral for 12 weeks
11132204|NCT03850509|Experimental|OPS-2071 300 mg|300mg BID Oral for 12 weeks
11132205|NCT03850509|Experimental|OPS-2071 600 mg|600 mg BID Oral for 12 weeks
11132206|NCT03850509|Experimental|Matching placebo|Matching placebo BID Oral for 12 weeks
11132207|NCT03850496|No Intervention|Group A|No device utilised for 6 weeks.
11132208|NCT03850496|Experimental|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
11132209|NCT03850496|Experimental|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
11132210|NCT03850483|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
11132211|NCT03850483|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
11132215|NCT03850483|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
11132216|NCT03850483|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
11132217|NCT03850483|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
11132218|NCT03850483|Experimental|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
11132219|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
11132220|NCT03850444|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
11132221|NCT03850444|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
11132222|NCT03850431|Experimental|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
11132223|NCT03850431|Experimental|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
11132224|NCT03850431|Experimental|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
11132225|NCT03850431|Experimental|Combination of all Nudges|A letter with all four types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
11132226|NCT03850431|No Intervention|Usual Care|An appointment reminder that includes basic appointment information on date, location, and phone number(s) for scheduling changes.
11132227|NCT03850418|Experimental|AZA|azacitidine
11132228|NCT03850405|Experimental|Chocolate|20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day
11132229|NCT03850405|No Intervention|Control|20 patients (matched per gender) undergoing a low-fat dietary regimen
11132230|NCT03850392|Active Comparator|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).
~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
11132231|NCT03850392|Active Comparator|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
11132232|NCT03850392|No Intervention|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
11132233|NCT03850379|Experimental|Levo|Levofloxacin 500 mg once daily
11132234|NCT03850379|Active Comparator|Cipro|Ciprofloxacin 500 mg BID
11132235|NCT03850366|Experimental|Bortezomib|
11132236|NCT03850353||OSAS|Patients with Obstructive Sleep Apnea (AHI>15 in a sleep study)
11132237|NCT03850353||Dizziness|Patients with Dizziness (defined as a non-spinning sensation, without illusion of movement)
11132238|NCT03850353||No OSAS No Dizziness|Patients without dizziness and no evidence for OSAS (subjects referred for the ENT or the Sleep clinic with no dizziness and no evidence of OSAS )
11132239|NCT03850327|Experimental|BIOMONITOR III|
11132240|NCT03850314|Experimental|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
11132241|NCT03850301|Experimental|Etifoxine then XBD173|
11132242|NCT03850301|Experimental|XBD173 then Etifoxine|
11132367|NCT03849287|Experimental|Group 1|"Period 1: CKD-333, formula I
~Period 2: CKD-333, formula II
~Period 3: CKD-330, D090"
11132243|NCT03850288||Anorexia Nervosa|"Patients with a diagnosis of anorexia nervosa (According to the DSM-V criteria). These patients are characterized by a restriction of food intake leading to weight loss or a failure to gain weight resulting in a significantly low body weight of what would be expected for someone's age, sex and height. Moreover, there is a fear of becoming fat or of gaining weight.Then, these patients have a distorted view of themselves and of their condition."
11132244|NCT03850288||Bulimia Nervosa|"Patients with a diagnosis of bulimia nervosa. According to the DSM-V criteria, these patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time, an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode, recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise.
~The binge eating and inappropriate compensatory behaviours both occur, on average, at least once a week for three months. Moreover, there is a self-evaluation influenced by body shape and weight."
11132245|NCT03850288||Binge Eating Disorder|Patients with a diagnosis of Binge Eating Disorder. These patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time (e.g. within any 2-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode. The binge eating episodes are associated with three or more of the following: eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts of food when not feeling physically hungry, eating alone because of feeling embarrassed by how much one is eating, feeling disgusted with oneself, depressed or very guilty afterward,marked distress regarding binge eating is present. Moreover, binge eating occurs, on average, at least once a week for three months
11132246|NCT03850275|Sham Comparator|Placebo|<3mg of caffeine
11132247|NCT03850275|Active Comparator|Caffeinated placebo|~100mg caffeine
11132248|NCT03850275|Experimental|E+shots|~100mg caffeine + adaptogens
11132249|NCT03850262||patients with posterolateral corner trauma of the knee|
11132250|NCT03850210|Experimental|Short Splint|
11132251|NCT03850210|Active Comparator|Traditional, Long Splint|
11132252|NCT03850197||TMM followed by EarPopper + Tympanometry|"Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
11132253|NCT03850197||EarPopper + Tympanometry followed by TMM|"Participants will be asked to complete the EarPopper plus tympanometry then TMM tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize ET pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
11132254|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
11132255|NCT03850171|Experimental|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
11132256|NCT03850171|No Intervention|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
11132257|NCT03850158|Experimental|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
11132258|NCT03850132|Experimental|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
11132259|NCT03850119|Experimental|Intradermal Nanofat|This side of the scar received intradermal injection of nanofat during the closure of the donor site.
11132260|NCT03850119|No Intervention|Control|This side of the scar received no injection.
11132261|NCT03850106|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose)
11132262|NCT03850106|Active Comparator|Indus810|Indus810 ( 500mg/d)
11132263|NCT03850093|Active Comparator|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
11132264|NCT03850093|Active Comparator|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
11132265|NCT03850093|Placebo Comparator|control|placebo was given to patients of control group 2 hours preoperative
11132266|NCT03850080|Experimental|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
11132267|NCT03850067|Experimental|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
11132296|NCT03849781|Active Comparator|Intervention|NeoBeat will be placed on all newborns immediately after birth to assess the heartrate for at least 5 minutes, or longer if the newborn needs resuscitation. Intervention subjects will have a visible display of the heart rate on the NeoBeat, to guide healthcare providers in further management of the newborn.
11132325|NCT03849547|Experimental|App training group|Subjects in App training group will receive App Balance training via smartphone application.
11133577|NCT03840928||Scleroderma|
11132268|NCT03850067|Experimental|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
11132269|NCT03850067|Experimental|Nivolumab combination|When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab (Nivo) IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and Nivo, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy. For subjects responding to the initial combination of CC-90011 and chemotherapy, as per RECIST 1.1, CC-90011 single agent will be given as maintenance therapy. These subjects will receive 60 mg of CC-90011 orally once weekly, Days 1, 8, 15, and 22, during cycles of 28 days each. For subjects responding to the initial combination of CC-90011 and chemotherapy with Nivo, CC-90011 with Nivo will be given as maintenance therapy. These subjects will receive 60 mg of CC-90011 orally once weekly, Days 1, 8, 15, and 22, and Nivo IV 240 mg Days 1 and 15 during cycles of 28 days each
11132270|NCT03850028|Other|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
11132271|NCT03849989|Experimental|Hailey Hailey|"Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.
~Skin biopsy specimens will be taken before and after lasertherapy at three time points.
~Before treatment:
~Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction
~Immediately after treatment of the treated area:
~2 mm punch for histopathology
~Six weeks after treatment:
~Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy"
11132272|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
11132273|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
11132274|NCT03849963|Experimental|Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection ([13C]pyruvate) during magnetic resonance spectroscopic imaging
11132275|NCT03849950|Experimental|SMARTCare|"Training in self-management support (SMS) strategies for ambulatory nursing staff
~A web-based self-management education (I-Can-Manage Cancer) for patients
~Telephone-based, nurse-led health coaching
~Optional end of study patient interview (sub-study)"
11132276|NCT03849950|Active Comparator|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
11132277|NCT03849937|Experimental|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
11132278|NCT03849937|Active Comparator|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
11132279|NCT03849924|Experimental|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
11132280|NCT03849924|Experimental|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
11132281|NCT03849924|No Intervention|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
11132282|NCT03849898||Mandibular Fracture|"Elderly patients of > 60 years who present a mandibular fracture
~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
11132283|NCT03849885|Experimental|Propionibacterium Dermal Colonization|Two 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 4 biopsies taken per subject.
11132284|NCT03849872|Experimental|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) [14C]-ONO-5788 in 6 healthy male subjects.
11132285|NCT03849872|Experimental|Part 2 Mass Balance|Single oral dose of 10 mg [14C]-ONO-5788 capsule containing 4.1 MBq (111 μCi) [14C]-radioactivity in 6 healthy male subjects.
11132286|NCT03849859|Active Comparator|Single plastic stent|Deployment of single plastic stent
11132287|NCT03849859|Active Comparator|Multiple plastic stents|Deployment of multiple plastic stent
11132288|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
11132289|NCT03849833|Other|Vitamin D3 supplementation|All participants will be selected for treatment with cholecalciferol, vitamin D3 supplementation and included in this single arm
11132290|NCT03849820|Active Comparator|Robotic-assisted partial nephrectomy|da Vinci surgical robotic assisted partial nephrectomy
11132291|NCT03849820|Active Comparator|Open partial nephrectomy|Open partial nephrectomy surgery
11132292|NCT03849807|Experimental|Experimental group|Chiropractic care
11132293|NCT03849807|Active Comparator|Control group|Usual health care
11132294|NCT03849794|Experimental|Experimental group|Chiropractic Care Plus Physiotherapy
11132295|NCT03849794|Active Comparator|Control group|Physiotherapy
11132297|NCT03849781|No Intervention|Standard Care|NeoBeat will be placed on the newborn to collect information on heart rate, but heart rate is not displayed to the healthcare providers. If the newborn is in need of resuscitation to initiate spontaneous respiration, the baby will be transferred to the resuscitation bay. According to recommendations the heart rate should be assessed and positive pressure ventilation initiated within one minute of life. Standard care is to assess heart rate by conventional ECG and/or pulse oximetry, alternatively auscultation of the heart.
11132298|NCT03849768|Experimental|HS-10296|110mg PO once daily
11132299|NCT03849768|Active Comparator|Gefitinib|250mg PO once daily
11132300|NCT03849755|Other|PEPPER/Control|Group with intervention applied (PEPPER system) during the first three months and then, after wash -out period, swap to control group (using standard bolus calculator) for the next 3 months.
11132301|NCT03849755|Other|Control/PEPPER|Group without intervention applied (using standard bolus calculator) during the first three months and then, after wash -out period, swap to intervention group (using PEPPER system) for the next 3 months.
11132302|NCT03849742|Experimental|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
11132303|NCT03849729|Active Comparator|Phentermine|Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.
11132304|NCT03849729|Placebo Comparator|Placebo|Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.
11132305|NCT03849716||Participants with atopic dermatitis (AD)|Participants included in observational study OBS15333 (atopic dermatitis pediatric registry) who consent to enter this companion study LPS15496. Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enter either protocol, and neither protocol OBS15333 nor LPS15496 specifies assignment of any drug intervention
11132306|NCT03849703|Experimental|Full Intervention #1|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the coparenting curriculum before the romantic relationships curriculum.
11132307|NCT03849703|Experimental|Full Intervention #2|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the romantic relationships curriculum before the coparenting curriculum.
11132308|NCT03849703|Other|Partial Intervention #1|Participants will receive the romantic relationships curriculum along with the control curriculum.
11132309|NCT03849703|Other|Partial Intervention #2|Participants will receive the coparenting curriculum along with the control curriculum.
11132310|NCT03849690|Experimental|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
11132311|NCT03849677||Omnivore|
11132312|NCT03849677||Vegan|
11132313|NCT03849664|Experimental|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
11132314|NCT03849664|Placebo Comparator|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
11132315|NCT03849651|Experimental|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.
~Cells for infusion are prepared using the CliniMACS system."
11132316|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
11132317|NCT03849612|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
11132318|NCT03849599|Experimental|PRV-300|Subjects in this arm will receive the study drug, PRV-300, via IV infusion, followed by an 8-week follow-up period.
11132319|NCT03849599|Placebo Comparator|Placebo|Subjects in this arm will receive placebo via IV infusion, followed by an 8-week follow-up period.
11132320|NCT03849573|Experimental|Mindfulness-based stress reduction + Hormone Therapy Education|
11132321|NCT03849573|Active Comparator|Hormone Therapy Education + Overall Health Education|
11132322|NCT03849560|Experimental|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)
~Active ingredients:
~type A (H1N1) influenza virus antigen 5 µg;
~type A (H3N2) influenza virus antigen 5 µg;
~type B (Yamagata lineage) influenza virus antigen 5 µg;
~type B (Victoria lineage) influenza virus antigen 5 µg;
~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
11132323|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.
~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)
~Active ingredients:
~type A (H1N1) influenza virus antigen 5 µg;
~type A (H3N2) influenza virus antigen 5 µg;
~type B (Yamagata lineage) influenza virus antigen 5 µg;
~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
11132324|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.
~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)
~Active ingredients:
~type A (H1N1) influenza virus antigen 5 µg;
~type A (H3N2) influenza virus antigen 5 µg;
~type B (Victoria lineage) influenza virus antigen 5 µg;
~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
11132326|NCT03849547|Active Comparator|Home training group|Subjects in Home training group will receive Home Balance training advised by physical therapist.
11132327|NCT03849547|No Intervention|Control group|Control group will receive only education of ankle injury prevention related information.
11132328|NCT03849534|Active Comparator|Soft occlusal appliance|Individually casted appliances
11132329|NCT03849534|Active Comparator|Jaw exercises|Resistance exercises to do twice a day
11132330|NCT03849534|Active Comparator|Counseling|Just information at the first visit
11132331|NCT03849521||Asymptomatic group|Group with asymptomatic patients with carotid atherosclerosis.
11132332|NCT03849521||Symptomatic group|Group with symptomatic patients with carotid atherosclerosis.
11132333|NCT03849508|Active Comparator|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
11132334|NCT03849508|Experimental|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
11132335|NCT03849495|Experimental|Group A|"Period 1: D745
~Period 2: CKD-370"
11132336|NCT03849495|Experimental|Group B|"Period 1: CKD-370
~Period 2: D745"
11132337|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:
~Clinical Evaluation;
~Fine Needle Aspiration Cytology;
~Multiparametric Magnetic Resonance Imaging.
~Postoperative Collection of Final Histopathological Diagnosis"
11132338|NCT03849469|Experimental|Arm 1|Arm 1: XmAb®22841 Monotherapy
11132339|NCT03849469|Experimental|Arm 2|Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
11132340|NCT03849456|Experimental|GWP42006|Oral solution taken twice daily with food for 52 weeks.
11132341|NCT03849443|Placebo Comparator|Group 1 PLACEBO|
11132342|NCT03849443|Experimental|Group 2 IV TXA|
11132343|NCT03849443|Experimental|Group 3 Pre-Oral TXA|
11132344|NCT03849443|Experimental|Group 4 Full Oral TXA|
11132345|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
11132346|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
11132347|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
11132348|NCT03849404|Experimental|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
11132349|NCT03849404|Experimental|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
11132350|NCT03849391|Experimental|Skate group|This group takes Skate Skin extract for 12 weeks
11132351|NCT03849391|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
11132352|NCT03849378|Experimental|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
11132353|NCT03849378|Placebo Comparator|Placebo group|This group takes Placebo Extract for 12 weeks.
11132354|NCT03849365|Experimental|TOOKAD VTP|TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
11132355|NCT03849352|Other|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
11132356|NCT03849339|Experimental|Group 1|"Period 1: D635
~Period 2: CKD-387"
11132357|NCT03849339|Experimental|Group 2|"Period 1: CKD-387
~Period 2: D635"
11132358|NCT03849326|Experimental|"Non-fatigued patients"|
11132359|NCT03849326|Experimental|"Fatigued patients"|
11132360|NCT03849313|Experimental|AVT02 100mg/mL|Biosimilar Adalimumab AVT02
11132361|NCT03849313|Active Comparator|EU-Humira 100mg/mL|EU Approved Adalimumab originator Humira
11132362|NCT03849313|Active Comparator|US-Humira 100mg/mL|US licensed Adalimumab originator Humira
11132363|NCT03849300|No Intervention|Control Group|No exercise intervention
11132364|NCT03849300|Experimental|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.
~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).
~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
11132365|NCT03849300|Experimental|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.
~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).
~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
11132366|NCT03849300|Active Comparator|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.
~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.
~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
11132368|NCT03849287|Experimental|Group 2|"Period 1: CKD-333, formula I
~Period 2: CKD-330, D090
~Period 3: CKD-333, formula II"
11132369|NCT03849287|Experimental|Group 3|"Period 1: CKD-333, formula II
~Period 2: CKD-330, D090
~Period 3: CKD-333, formula I"
11132370|NCT03849287|Experimental|Group 4|"Period 1: CKD-333, formula II
~Period 2: CKD-333, formula I
~Period 3: CKD-330, D090"
11132371|NCT03849287|Experimental|Group 5|"Period 1: CKD-330, D090
~Period 2: CKD-333, formula I
~Period 3: CKD-333, formula II"
11132372|NCT03849287|Experimental|Group 6|"Period 1: CKD-330, D090
~Period 2: CKD-333, formula II
~Period 3: CKD-333, formula I"
11132373|NCT03849274|Experimental|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
11132374|NCT03849274|Active Comparator|Pressure Garment|For control group, subject will be intervened by conventional PG only
11132375|NCT03849274|No Intervention|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
11132376|NCT03849261|Experimental|Group 1|"Period 1: D635
~Period 2: CKD-387"
11132377|NCT03849261|Experimental|Group 2|"Period 1: CKD-387
~Period 2: D635"
11132378|NCT03849248|Experimental|Intervention|This group of babies will have a maternal scented cloth placed under their heads
11132379|NCT03849248|No Intervention|Control|This group of babies will have a clean non- maternal scented cloth placed under their head
11132380|NCT03849222|Active Comparator|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
11132381|NCT03849222|Experimental|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
11132382|NCT03849222|Active Comparator|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
11132383|NCT03849222|Experimental|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
11132384|NCT03849209|Experimental|Stylet Slow-Pull Technique group|In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
11132385|NCT03849209|Active Comparator|Standard Suction Technique group|In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
11132386|NCT03849196|Experimental|2L PEG-Asc|2L PEG-Asc for bowel preparation
11132387|NCT03849196|Active Comparator|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
11132388|NCT03849183|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (0.5cc) is subcutaneously injected before radial artery cannulation.
11132389|NCT03849183|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation.
11132390|NCT03849170|Experimental|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
11132391|NCT03849170|Placebo Comparator|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration & performance.
11132392|NCT03849157|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
11132393|NCT03849157|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
11132394|NCT03849144|Experimental|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
11132395|NCT03849144|Active Comparator|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
11132396|NCT03849118|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
11132586|NCT03847844|Experimental|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
11132397|NCT03849105|Experimental|Single administration of 131I-IPA (1f group)|Study participants with GBM receive a single administration of 4-L-[131I]iodo-phenylalanine (131I-IPA), followed by 18 cycles of external radiotherapy, each cycle being of 2 Gy.
11132398|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-parallel group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above, 1- 3 days prior to 1st XRT. The 2nd and 3rd 131I-IPA fractions will be administered after 5-9 XRT fractions (subject to investigator's discretion and day of IMP administration) following the previous 131I-IPA fraction. The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.
11132399|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-sequential group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above 1- 3 days prior to 1st XRT. The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.
11132400|NCT03849105|Experimental|Dose escalation of fractionated dosing|Dose escalation will be made in steps of 2.0 GBq, i.e. 4.0 (3*1.33 GBq), 6.0 GBq (3*2.0 GBq), up to 8.0 GBq (3*2.67 GBq) until the maximum tolerated dose (MTD) is reached, using cohorts of N=3 patients.
11132401|NCT03849092|Experimental|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
11132402|NCT03849092|Experimental|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
11132403|NCT03849092|No Intervention|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
11132404|NCT03849079|Experimental|Hyponut|
11132405|NCT03849066||Part 1: Cross-Sectional PRSA|This will be a cross-sectional analysis of 300 children with neurological impairment and polypharmacy.
11132406|NCT03849066||Part 2: Longitudinal PRSA|This will be a 12-month prospective cohort study of 50 children with neurological impairment and polypharmacy.
11132407|NCT03849053|Experimental|Mézières method|
11132408|NCT03849053|Active Comparator|Control Group|
11132409|NCT03849027|Experimental|Methoxyflurane|"Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .
~Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®)."
11132410|NCT03849027|Sham Comparator|Sham Methoxyflurane|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test
11132411|NCT03849014|Active Comparator|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
11132412|NCT03849014|Active Comparator|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
11132413|NCT03849001|Experimental|Exercise Conditions|"Participants will undergo four Exercise Conditions (i.e., light intensity leg cycling, moderate intensity leg cycling, vigorous intensity leg cycling, and a seated, quiet rest) in a randomized, counterbalanced order."
11132414|NCT03848975|Experimental|Simulation training for ECV|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the Control group for VE : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
11132415|NCT03848975|Experimental|Simulation training for VE|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the the control group for for ECV : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
11132416|NCT03848962||Subjects for observational study|Various conditions & healthy subjects
11132417|NCT03848949|Experimental|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
11132418|NCT03848949|No Intervention|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
11132419|NCT03848936||adult cerebral palsy patients|>18 age cerebral palsy diagnosed patients evaluated with a survey.
11132420|NCT03848910|Experimental|Investigational device - Sound Processor|
11132421|NCT03848897|Experimental|Non falling elderly|
11132422|NCT03848897|Experimental|Falling elderly|
11132423|NCT03848897|Experimental|Non falling patients with Parkinson's disease|
11132424|NCT03848884|Experimental|Adherence monitoring and education|
11132425|NCT03848871|Experimental|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
11132426|NCT03848858|Experimental|EMDR plus TAU|20 individual weekly sessions of 60 minutes each of Eye Movement Desensitization and Reprocessing Therapy (EMDR), plus Treatment as Usual (TAU), applying first the standard EMDR protocol (Shapiro, 2005), and then a specific protocol for the sequelae of somatic illness and medical trauma (Hase, 2018).
11132489|NCT03848403|Experimental|Ixekizumab (Reference)|Reference formulation 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection in a prefilled syringe in one of three study periods.
11132427|NCT03848858|No Intervention|TAU only|The patients in this condition are newly diagnosed and will be introduced to the study in their first appointment with the Infectious Diseases Unit, in which analyses of HIV-related biological markers are taken. In a follow up appointment between 1 and 2 weeks later, antiretroviral treatment is initiated. There is a further check-up 1-2 months after initiating antiretroviral treatment, and then 6-monthly check-ups. In these checkups, measures of CD4 and the CD4/CD8 ratio are taken and treatment adherence is reviewed. The patients receiving EMDR therapy will also participate in these activities.
11132428|NCT03848845|Experimental|Part 1: Dose escalation|Subjects will receive belantamab mafodotin at escalating doses of 2.5 milligrams per kilograms (mg/kg) and 3.4 mg/kg along with 200 mg pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day cycle to establish RP2D. There will be maximum of 35 cycles of combination treatment.
11132429|NCT03848845|Experimental|Part 2: Expansion cohort|Subjects will receive belantamab mafodotin at RP2D along with 200 mg pembrolizumab via IV infusion on Day 1 of each 21-day cycle. There will be maximum of 35 cycles of combination treatment.
11132430|NCT03848832|Experimental|5 milligrams per kilogram per day (mg/kg/day) GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
11132431|NCT03848832|Experimental|15 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
11132432|NCT03848832|Placebo Comparator|Placebo|Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
11132433|NCT03848819|Other|Control pursed lip breathing|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe adopting the pursed lip breathing technique. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
11132434|NCT03848819|Experimental|pNIV|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe via the VitaBreath device. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
11132435|NCT03848806|Experimental|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
11132436|NCT03848806|Active Comparator|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
11132437|NCT03848793|Other|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
11132438|NCT03848793|Other|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
11132439|NCT03848793|Other|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
11132440|NCT03848793|Other|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
11132441|NCT03848780|Experimental|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
11132442|NCT03848780|No Intervention|Control Group|No pharmacological preconditioning was implemented
11132443|NCT03848767|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
11132444|NCT03848754|Experimental|Pracinostat with Gemtuzumab Ozogamicin|
11132445|NCT03848741|Placebo Comparator|Non-exercise control with placebo|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
11132446|NCT03848741|Experimental|Non-exercise control with HMB+VitD|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
11132447|NCT03848741|Active Comparator|Resistance exercise training with placebo|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
11132448|NCT03848741|Experimental|Resistance exercise training with HMB+VitD|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
11132449|NCT03848728|Experimental|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
11132450|NCT03848728|No Intervention|Control Clinics|Optimized country standard of care
11132451|NCT03848715|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight; 1 infusion
11132452|NCT03848715|Placebo Comparator|Placebo|same volume of 0.9% saline
11132453|NCT03848702|Experimental|Healthy volunteers|All volunteers wore the DRFB
11132454|NCT03848702|Experimental|Patients with DRF|All patients wore the DRFB
11132455|NCT03848689||FQ PPA Group|Fluoroquinolone Preprescription Authorization from Infection Control consult, once, prior to prescribing fluoroquinolone
11132456|NCT03848689||Control Group|No preprescription authorization needed from Infection control prior to prescribing fluoroquinolone
11132457|NCT03848663|Experimental|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
11132458|NCT03848663|Active Comparator|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
11132459|NCT03848650|Experimental|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
11132460|NCT03848637|Experimental|Group 1|"Period 1: D387 (reference drug)
~Period 2: CKD-387 (test drug)"
11132461|NCT03848637|Experimental|Group 2|"Period 1: CKD-387 (test drug)
~Period 2: D387 (reference drug)"
11132462|NCT03848624|Experimental|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
11132463|NCT03848611|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
11132464|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
11132465|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
11132466|NCT03848585|Experimental|Pilloxa Pillbox|
11132467|NCT03848585|Sham Comparator|Non active Pilloxa Pillbox|
11132468|NCT03848572|No Intervention|Usual care|Patients will enter standard 12-month clinical follow-up
11132469|NCT03848572|Experimental|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
11132470|NCT03848559|Experimental|Airway device placement|airway device is placed during the dive
11132471|NCT03848546|Experimental|PDA|Intervention group: receives the personalized dietary advice
11132472|NCT03848546|Active Comparator|Control|Receives the general advice (two flyers containing information about fiber intake)
11132473|NCT03848533|Experimental|melatonin plus metformin|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.
~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days."
11132474|NCT03848533|Active Comparator|metformin plus placebo|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.
~Will administrate homologated placebo once a day in the night (before bedtime) per 90 days."
11132475|NCT03848533|Experimental|melatonin plus placebo|"It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.
~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days."
11132476|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (>=9) activity-scale score at anytime between preoperatively and now.
11132477|NCT03848507|Experimental|20% Albumin|Administration of 3ml per kg bodyweight of 20% albumin within 30 min during cystectomy.
11132478|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
11132479|NCT03848481|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
11132480|NCT03848481|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
11132481|NCT03848468|Active Comparator|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
11132482|NCT03848468|Experimental|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
11132483|NCT03848455||Parkinson's disease group|"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;
~Newly diagnosed primary PD patients, diagnosed within 3-6 months;
~informed consent to the study;
~age > 18 older."
11132484|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.
11132485|NCT03848442|Experimental|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
11132486|NCT03848416|Experimental|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
11132487|NCT03848416|Experimental|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
11132488|NCT03848416|Experimental|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
11132490|NCT03848403|Experimental|Ixekizumab (Test 1)|Test 1 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
11132491|NCT03848403|Experimental|Ixekizumab (Test 2)|Test 2 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
11132492|NCT03848390|Experimental|Modified Time-restricted Feeding|
11132493|NCT03848390|Active Comparator|Conventional diet|
11132494|NCT03848377||Automated EMG/SSEP monitored|"In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored.
~As this is an observational study, no intervention is planned."
11132495|NCT03848364|Experimental|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
11132496|NCT03848351|No Intervention|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
11132497|NCT03848351|Active Comparator|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.
~Oral Hygiene Instruction (OHI)
~Professional supragingival scaling and polishing"
11132498|NCT03848338|Other|Pilot Group|Intra and Post-operative Electrocochleography
11132499|NCT03848325|Experimental|Sleep deprivation|All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2).
11132500|NCT03848312|Experimental|Computerized Cognitive Training|Participants will complete computerized cognitive training.
11132501|NCT03848312|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities.
11132502|NCT03848299|Experimental|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
11132503|NCT03848286|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
11132504|NCT03848273||Ischemic|questionnaire, physical-neurological examination, labor investigations, EEG
11132505|NCT03848273||Hemorrhagic|questionnaire, physical-neurological examination, labor investigations, EEG
11132506|NCT03848273||Control|questionnaire, physical-neurological examination, labor investigations, EEG
11132507|NCT03848260|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time (duration: 30-120 mins/each time) and 3 times within 3 months.
~Intervention: using the magnetic device prototype"
11132508|NCT03848247|Experimental|Control group|Participants will be injected with 0.5ml Isotonic saline into a neck muscle
11132509|NCT03848247|Experimental|Neck pain|Participants will be injected with 0.5ml NGF into the a neck muscle
11132510|NCT03848234|Experimental|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
11132511|NCT03848234|Placebo Comparator|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
11132512|NCT03848221|Experimental|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
11132513|NCT03848221|Active Comparator|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
11132514|NCT03848221|No Intervention|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
11132515|NCT03848208|Experimental|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132516|NCT03848208|Placebo Comparator|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132517|NCT03848208|Experimental|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132518|NCT03848208|Placebo Comparator|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132519|NCT03848208|Experimental|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132520|NCT03848208|Placebo Comparator|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132521|NCT03848208|Experimental|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132522|NCT03848208|Placebo Comparator|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132523|NCT03848208|Experimental|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132524|NCT03848208|Placebo Comparator|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132525|NCT03848208|Experimental|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132526|NCT03848208|Placebo Comparator|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132527|NCT03848208|Experimental|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132528|NCT03848208|Placebo Comparator|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132529|NCT03848208|Experimental|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132530|NCT03848208|Placebo Comparator|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132531|NCT03848208|Experimental|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132532|NCT03848208|Placebo Comparator|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
11132533|NCT03848182|Experimental|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
11132534|NCT03848169|Experimental|Experimental group|Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
11132535|NCT03848169|Sham Comparator|Control Group|Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.
11132536|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
11132537|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
11132538|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
11132539|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
11132540|NCT03848143|Experimental|BOTOX|"Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
~1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
~Each patient will receive 50 U of onabotulinum toxin A."
11132541|NCT03848130|Active Comparator|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
11132542|NCT03848130|Active Comparator|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
11132543|NCT03848130|Active Comparator|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
11132544|NCT03848117|Active Comparator|(DTF massage & Mill's manipulation)(Group 1)|For any given subject in group 1, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in 1st group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
11132545|NCT03848117|Active Comparator|( Taping & MWM) (Group 2).|For any given subject in group 2, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
11132546|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
11132547|NCT03848091||Antibiotic pretreatment|patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
11132548|NCT03848078|Other|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
11132549|NCT03848078|No Intervention|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
11132550|NCT03848065|Experimental|V114-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of V114 on Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
11132551|NCT03848065|Experimental|V114-IM|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
11132552|NCT03848065|Active Comparator|PCV13-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13) at Visit 1, 2, 3 and 5(approximately 3, 4, 5, and 12 to 15 months of age).
11132553|NCT03848039|Experimental|Gardasil-9|Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
11132554|NCT03848039|Placebo Comparator|Placebo|Placebo injection at 0, 2 and 6 months
11132555|NCT03848026||Group 1|middle ear fluid viscosity <439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
11132556|NCT03848026||Group 2|middle ear fluid viscosity >439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
11132557|NCT03848013|Active Comparator|Treatment|Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
11132558|NCT03848013|No Intervention|Follow -up period|follow up of the treated cases for 2 months
11132559|NCT03848000|Experimental|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
11132560|NCT03848000|Active Comparator|NHS Standard Care only|Alcohol addiction counselling.
11132561|NCT03847987|Experimental|Part 1|Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses.
11132562|NCT03847987|Experimental|Part 2|Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses.
11132563|NCT03847974|Experimental|LIB003|LIB003
11132564|NCT03847961|No Intervention|Control Group|The control group receive routine treatment of sepsis only. All sites agree, when feasible, to follow the tenets of the Surviving Sepsis Campaign clinical practice guidelines for management of sepsis.
11132565|NCT03847961|Experimental|Experimental Group|The experimental group receive routine treatment of sepsis combined with hemoperfusion with cytokine adsorption column (CA330).
11132566|NCT03847935||Surgery|Patients who underwent surgical release of A1 pulley
11132567|NCT03847935||corticosteroid injections only|Patients who underwent local corticosteroid injections only, and no other treatment
11132568|NCT03847935||hand therapy only occupational/physical|1 visit: orthosis fabrication, range of motion, nodule and ice massage.
11132569|NCT03847935||Injection and Hand therapy|This group of participants received a combination of corticosteroid injection in the affected finger and one visit of hand therapy.
11132570|NCT03847935||Modality Hand Therapy|Ongoing hand therapy treatment, which included the above plus modalities such as ultrasound or iontophoresis.
11132571|NCT03847935||Injection and Modality Hand Therapy|Ccombination of local cortiscosteroid injection to the affected digit and ongoing hand therapy with modalities.
11132572|NCT03847922|Placebo Comparator|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
11132573|NCT03847922|Experimental|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
11132574|NCT03847909|Experimental|DCR-PHXC|Intervention, drug, DCR-PHXC
11132575|NCT03847909|Placebo Comparator|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
11132576|NCT03847896|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
11132577|NCT03847896|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
11132578|NCT03847896|Active Comparator|BD MDI (PT008) 160 µg|
11132579|NCT03847896|Active Comparator|AS MDI (PT007) 180 µg|
11132580|NCT03847896|Placebo Comparator|Placebo MDI|
11132581|NCT03847883|Active Comparator|0.6 mg/kg Ateplase|Low dose 0.6 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke (n = 26 in cohort A)
11132582|NCT03847883|Active Comparator|0.75 mg/kg Ateplase|Low dose 0.75 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A)
11132583|NCT03847883|Active Comparator|0.9 mg/kg Ateplase|Low dose 0.9 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A and n= 330 in Cohort B)
11132584|NCT03847857|Experimental|Surgery+PFS|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during McKeown esophagectomy.
11132585|NCT03847857|Placebo Comparator|Surgery|Arm B underwent conventional anastomosis during McKeown esophagectomy.
11132588|NCT03847831|Experimental|PPASF Group|"Schools enrolled in the postprimary active school flag program. All 17 elements are included. Feasibility is measured of the 17 elements.
~Student representatives are selected to have accelerometer, physical health measures and perceived health collected for feasibility purposes."
11132589|NCT03847818|Experimental|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
11132590|NCT03847805|Experimental|Experimental|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
11132591|NCT03847805|Active Comparator|Control|The control group followed a program of glenohumeral stabilization exercises,
11132592|NCT03847792|Active Comparator|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
11132593|NCT03847792|Active Comparator|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
11132594|NCT03847792|Placebo Comparator|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
11132595|NCT03847779|Experimental|Non-neuropathy|"Type 2 diabetic without neuropathy:
~Negative findings on Semmes-Weinstein monofilament
~Neuropathy symptom score (NSS) <3
~Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.
~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
~rest cutaneous microcirculation (perfusion and vasomotion)
~Exercise cutaneous microcirculation (perfusion and vasomotion)
~Foot lowering cutaneous microcirculation (perfusion and vasomotion)
~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)
~blood sampling
~heart rate variability at rest
~pedometer during 4 days
~international Physical Activity Questionary
~Qualify of Life questionary (EQVOD)"
11132596|NCT03847779|Experimental|Neuropathy|"Type 2 diabetic with neuropathy
~Positive findings on Semmes-Weinstein monofilament
~Neuropathy symptom score (NSS) >3
~Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.
~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
~rest cutaneous microcirculation (perfusion and vasomotion)
~Exercise cutaneous microcirculation (perfusion and vasomotion)
~Foot lowering cutaneous microcirculation (perfusion and vasomotion)
~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)
~blood sampling
~heart rate variability at rest
~pedometer during 4 days
~international Physical Activity Questionary
~Qualify of Life questionary (EQVOD)"
11132597|NCT03847779|Experimental|Controls|"matched for age, sexe and BMI with diabetic patients.
~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
~rest cutaneous microcirculation (perfusion and vasomotion)
~Exercise cutaneous microcirculation (perfusion and vasomotion)
~Foot lowering cutaneous microcirculation (perfusion and vasomotion)
~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)
~blood sampling
~heart rate variability at rest
~international Physical Activity Questionary
~Qualify of Life questionary (EQVOD)"
11132598|NCT03847766|Experimental|PRO-based follow-up|Patients will receive a questionnaire every 3 months. The PRO questionnaire is used as decision aid together with other available clinical data to decide whether the patient needs a visit or not. Hence, patients only visit the outpatient clinic if there is a clinical need or a patient's wish. The actual response for each questionnaire automatically results in a colour code (green, yellow or red). A red or yellow response indicates that the patient needs to be contacted. A green colour indicates no need for a visit. Based on an overview of the questionnaire and the patient's blood samples a physician decides whether this patient should have a telephone consultation or the patient needs to be seen in the clinic.
11132599|NCT03847766|Experimental|PRO-based telephone consultations|Patients receive an electronic questionnaire every 3 months prior to a scheduled telephone consultation.The PRO questionnaire is used as dialogue support during the telephone consultation. The actual response for each item automatically results in a colour code (green, yellow or red). A red response indicates that the patient has a problem; a yellow colour indicates a potential problem, while a green colour indicates no problems.
11132600|NCT03847766|No Intervention|Usual outpatient follow-up visits|Patients in the control group will continue to have usual scheduled outpatient follow-up visits at the hospital initiated by the physician every 3 months. These patients do not use the clinical PRO questionnaire, but complete the research questionnaires.
11132601|NCT03847753||Danish population|The cohort includes all those born in Denmark between 1900-2015, and who resided there in the period of 2000-2016.Whether they received a diagnosis of one of the following mental disorders will be ascertained: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Eating Disorders, Neurotic Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders The risk of receiving a later diagnosis of one of the following types of general medical conditions will then be estimated: Circulatory, Endocrine, Pulmonary and Allergy, Gastrointestinal, Urogenital, Musculoskeletal, Hematological, Cancer, Neurological
11132602|NCT03847740|Experimental|Right Isometric Thumb Force (ITF) handle|
11132603|NCT03847740|Experimental|Left Isometric Thumb Force (ITF) handle|
11132604|NCT03847727||Experimental: 6 cycles BR -> 4 x BR|Induction plus BR as maintenance (N=56)
11132605|NCT03847727||Proper historical control: 6 cycles BR|Induction only (N=56)
11132606|NCT03847714|Active Comparator|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
11132607|NCT03847714|Placebo Comparator|Placebo|3g of a similar looking and tasting powder, twice daily
11132608|NCT03847701|Active Comparator|High in SDS|Balanced diet high in Slowly Digestible Starch
11132609|NCT03847701|Placebo Comparator|Low in SDS|Balanced diet low in Slowly Digestible Starch
11132610|NCT03847688||Treatment resistant Major Depressive Disorder|
11132640|NCT03847467|Placebo Comparator|Placebo|"Phase I: 20 young adult participants age 18-25 years dosed at 2 gm placebo per day. (10UC/10CD)
~Phase II (post Phase I interim safety analysis): 40 participants age 11-25 years dosed at 2 gm placebo per day. (20UC/20CD)"
11132680|NCT03847181||NVAF-patients_1|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
11132611|NCT03847675|Experimental|Intervention|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age. A 4:50 minutes video clip would be shown during the initial visit. This video discusses the benefits of reading displaying practical tips for parents; it includes tips on how to read, pointing at the words.
~A schematic pamphlet highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents.
~After each visit participants will receive an age appropriate book for their child.
~Focus groups will be conducted by a qualitative researcher"
11132612|NCT03847675|No Intervention|Control|The research assistant gives routine advice on child development including importance of reading and advice on nutrition and safety and gives parents a leaflet about early child development and complementary feeding
11132613|NCT03847662||Community Based Production and Access of Complimentary Foods|"Nine communes were randomly selected with the cluster inclusion criteria as having high levels of; agricultural production, childhood under-nutrition and food security. This was carried out in the three rural mountainous provinces of Lao Cai, Lai Chau, and Ha Giang. In each of these provinces, one district and three subsequent communes were selected, for a total of 9 communes. The districts of Bat Xat, Tam Duong, and Vi Xuyen were selected in Lao Cai, Lai Chau and Ha Giang province respectively. This second stage district sampling selected sites with similar characteristic of population density, area, number of women of reproductive age(15-35y), percentage of children(<2y), income primarily from agricultural production, poverty and climate data.
~Changes were observed on food security and nutritional status with exposure to community based self reported purchasing local agricultural products and access to locally produced fortified complimentary foods."
11132614|NCT03847649|Active Comparator|Cohort 1: High Risk|
11132615|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm A|
11132616|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm B|
11132617|NCT03847636|Active Comparator|Familial Adenomatous Polyposis (FAP)|Individuals with duodenal adenomas (DAs) and FAP with Spigelman class 2,3 or 4, treated with cryoballoon ablation (intervention)
11132618|NCT03847636|Active Comparator|Sporadic duodenal adenomas|Individuals with at least 1 sporadic duodenal adenoma (DA) between 1-5 cm in maximum diameter, treated with cryoballoon ablation (intervention)
11132619|NCT03847623|Experimental|Curcumin|Capsules, taken orally, 8g per day (Bi-daily dosing)
11132620|NCT03847623|Placebo Comparator|Placebo|Capsules, taken orally, bi-daily dosing
11132621|NCT03847610|Experimental|Healthy volunteer|
11132622|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
11132623|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
11132624|NCT03847571||Acetazolamide|Oral administration of acetazolamide 5 mg/kg/day for 4 weeks
11132625|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
11132626|NCT03847545|Experimental|Intervention|The participants who have an effect of 20% or more after 14 days of Fampridine treatment, measured using 6 Spot Step Test (SSST) or Timed 25 Footwalk (F25-FW), will continue as cases and will receive Fampridine throughout the trial.
11132627|NCT03847545|No Intervention|Non-treated controls|Participants who do not have an effect of 20% or more after 14 days of Fampridine treatment, measured using 6 Spot Step Test (SSST) or Timed 25 Footwalk (F25-FW), will continue as untreated controls. They will not receive Fampridine in the remainder of the trial.
11132628|NCT03847532|Other|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
11132629|NCT03847532|Other|Patients with multiple colon polyps|Number of polyps from 4+
11132630|NCT03847532|Other|Control sample|Patients who did not have colon polyps
11132631|NCT03847519|Experimental|Safety Phase Part A|"Enroll subjects with metastatic squamous or non-squamous NSCLC who have become refractory or intolerant to standard therapy. ADXS-503 monotherapy will be evaluated at 2 planned escalating dose levels:
~Dose level 1: 1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.
~Dose level 2: 5e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
11132632|NCT03847519|Experimental|Safety Phase Part B|"Enroll subjects with metastatic squamous or non-squamous NSCLC. ADXS-503 will be evaluated at 2 planned escalating dose levels in combination with a fixed dose of pembrolizumab:
~Dose level 1: 1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.
~Dose level 2: 5e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
11132633|NCT03847519|Experimental|Efficacy Phase Part C|"Enroll subjects with metastatic squamous or non-squamous NSCLC.
~1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
11132634|NCT03847506|Experimental|EZE/ROS+CAN/AML|Ezetimibe/Rosuvastatin 10 mg/10 mg and Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
11132635|NCT03847506|Active Comparator|CAN/AML|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
11132636|NCT03847506|Active Comparator|EZE/ROS+CAN|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg, once a day for 6 weeks
11132637|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
11132638|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
11132639|NCT03847467|Experimental|2'-Fucosyllactose|"Phase I: 36 young adult participants aged 18-25 years. Group 1: 1 gm per day n=12 (6UC/6CD) Group 2: 5 gm per day n=12 (6UC/6CD) Group 3: 10 gm per day n=12 (6UC/6CD)
~Phase II (post Phase I interim safety analysis): 120 participants aged 11-25 years Group 1: 1 gm per day n=40 (20UC/20CD) Group 2: 5 gm per day n=40 (20UC/20CD) Group 3: 10 gm per day n=40 (20UC/20CD)"
11132717|NCT03846869|Experimental|major cations|bood sample
11133578|NCT03840915|Experimental|Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824|
11132641|NCT03847454|Experimental|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
11132642|NCT03847454|Active Comparator|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
11132643|NCT03847441|Active Comparator|Group I|
11132644|NCT03847441|Active Comparator|Group II|
11132645|NCT03847441|Active Comparator|Group III|
11132646|NCT03847441|Placebo Comparator|Group IV|
11132647|NCT03847428|Experimental|Arm A|Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)
11132648|NCT03847428|Experimental|Arm B|Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)
11132649|NCT03847428|Placebo Comparator|Arm C|Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)
11132650|NCT03847402|Experimental|GDD intervention|The early integrated intervention for GDD
11132651|NCT03847402|Active Comparator|GDD non-intervention|Community intervention for GDD
11132652|NCT03847402|Experimental|ASD intervention|The early integrated intervention for ASD
11132653|NCT03847402|Active Comparator|ASD non-intervention|Community intervention for ASD
11132654|NCT03847402|Experimental|ADHD intervention|The early integrated intervention for ADHD
11132655|NCT03847402|Active Comparator|ADHD non-intervention|Community intervention for ADHD
11132656|NCT03847389|Other|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
11132657|NCT03847363||general anesthesia|patients underwent general anesthesia
11132658|NCT03847363||general and epidural anesthesia|patients underwent general and epidural anesthesia
11132659|NCT03847363||general anesthesia combined with nerve block|patients underwent general anesthesia combined with nerve block
11132660|NCT03847337|Experimental|New to diagnosis|We will test two telemedicine tools with children who have not been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
11132661|NCT03847337|Experimental|Previously diagnosed|We will test two telemedicine tools with children who have been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
11132662|NCT03847324|Active Comparator|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
11132663|NCT03847324|Experimental|PNE|Usual care + Preoperative Pain Neuroscience Education
11132664|NCT03847324|Experimental|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
11132665|NCT03847311|Placebo Comparator|Placebos|Subjects will receive sugar pill.
11132666|NCT03847311|Active Comparator|Sulfasalazine|Subjects will receive the active drug.
11132667|NCT03847298||Pacemaker|
11132668|NCT03847298||Control|
11132669|NCT03847272|Experimental|Patients|
11132670|NCT03847259||A(public school)|"it will be consists of 200 adolescent female from public schools, their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire.
~pain will be evaluated by VISUAL ANALOG SCALE(VAS) .stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21)."
11132671|NCT03847259||B(international school)|it will be consists of 200 adolescent female from international schools their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire .pain will be evaluated by VISUAL ANALOG SCALE (VAS).stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21).
11132672|NCT03847246|Active Comparator|Baraclude® tablets，1.0 mg|
11132673|NCT03847246|Experimental|Entecavir tablets，1.0 mg|
11132674|NCT03847233|Experimental|Jetstream Atherectomy System|
11132675|NCT03847207|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
11132676|NCT03847207|Experimental|Part 2 Pasireotide PD Assessment|Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
11132677|NCT03847207|Experimental|Part 3 Proof of Pharmacological Effect|Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
11132678|NCT03847194|Experimental|PRISM Intervention Arm|"The goal of the intervention is to teach resilience resource skills for use in current or future stressful situations. The total intervention consists of two, 45-60 minute, one-on-one sessions approximately 2-4 weeks apart followed by a family meeting discussing the skills learned. Following the family session through week 12, participants receive bi-weekly booster contacts (1:1 check-in sessions with the interventionist) to practice/refresh skills and check-ins on how skills have been utilized. These boosters will then be delivered monthly in months 4-6. In addition, all PRISM participants have access to the digital PRISM app, which offers an interactive practice and tracking interface to continue enhancing skills."
11132679|NCT03847194|No Intervention|Usual Care|Families in both randomization arms will receive usual medical care for diabetes, including psychosocial care provided by the mental health professionals affiliated with the diabetes clinic if needed. At both sites, every diabetes patient is cared for by a team of diabetes specialists which includes a provider (MD, Physician Assistant and/or Nurse Practitioner), dietician, and social worker. Subspecialty referrals for additional mental health or other support are made at the discretion of the primary diabetes provider.
11132718|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
11132681|NCT03847181||NVAF-patients_2|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
11132682|NCT03847181||NVAF-patients_3|Adult patients with non-valvular atrial fibrillation (NVAF) and one year health records in the British THIN-database, who have not yet used rivaroxaban, apixaban and warfarin.
11132683|NCT03847168|Experimental|KN026|Patient will be intravenously administrated with one dose of KN026. Dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
11132684|NCT03847155|Experimental|Nicotine|The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.
11132685|NCT03847155|Placebo Comparator|Placebo|The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.
11132686|NCT03847142|Experimental|ASTHMAXcel arm|The ASTHMAXcel arm represents the study intervention, which is a patient-facing mobile application for adult patients with asthma.
11132687|NCT03847142|Active Comparator|Usual care arm|This arm represents usual care delivered in the outpatient primary care setting at the study sites.
11132688|NCT03847129|Experimental|Biofeedback training group|The participants in the biofeedback training group attend a 30 minute biofeedback protocol per session, two times a week for six to eight weeks that is also combined with the regular diabetic care treatment in the Occupational Therapy Room.
11132689|NCT03847129|Active Comparator|Home-based training group|The participants in this group receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment.
11132690|NCT03847129|No Intervention|Control group|The participants in the control group receive only diabetes disease prevention consultation once and outcome assessments twice.
11132691|NCT03847103|Experimental|Robotic-aided rehabilitation with bilateral practice|In addition to a 10-minutes sensorimotor stimulation programs, the experimental group received 40-minutes Robotic-assisted Therapy with Bilateral Practice programs.
11132692|NCT03847103|Active Comparator|Unilateral task-specific training|In addition to a 10-minutes sensorimotor stimulation programs, the control subjects received 40-minute unilateral task-specific training.
11132693|NCT03847090|Experimental|Reloxaliase|Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
11132694|NCT03847090|Placebo Comparator|placebo|placebo capsule
11132695|NCT03847077|Experimental|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application
11132696|NCT03847077|Active Comparator|Standard counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
11132697|NCT03847038|Experimental|Intervention|Multimodal lifestyle-interventional. Participants are disclosed their 5-year dementia risk estimate
11132698|NCT03847025||Lead extraction|Patients undergoing clinically indicated lead extraction procedures.
11132699|NCT03847012|Experimental|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
11132700|NCT03846999||Long-term breast cancer survivors|"Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
~Analyze comorbidities and patterns of use of health services by tumor characteristics."
11132701|NCT03846999||Women without history of cancer|Analyze comorbidities and patterns of use of health services. Describe the specific use of health services in primary care vs. specialized care.
11132702|NCT03846986|Active Comparator|Apple Juice1|100% Apple Juice
11132703|NCT03846986|Experimental|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
11132704|NCT03846986|Placebo Comparator|Raw Apple|Raw Apple
11132705|NCT03846973|Experimental|Tranexamic acid|group-I will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes followed by an intravenous infusion of 1 g TXA to be given and completed over 8 h in the hospital
11132706|NCT03846973|Placebo Comparator|Placebo|group-II will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes but will receive placebo (normal saline) infusion to be given and completed over 8 h in the hospital
11132707|NCT03846960|Experimental|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
11132708|NCT03846947|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
11132709|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
11132710|NCT03846921||Viral infection|Patients with proven viral infections will have laboratory blood test taken
11132711|NCT03846921||Bacterial Infection|Patients with proven bacterial infections will have laboratory blood test taken
11132712|NCT03846908|Experimental|MCT|subjects start with MCT fat load
11132713|NCT03846908|Experimental|SFA|subjects start with SFA fat load
11132714|NCT03846908|Experimental|MUFA|subjects start with MUFA fat load
11132715|NCT03846895|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.
~The laser parameters that will be used are the following:
~Power: 40 watts,
~Dwell time:1000μs,
~Spacing 1000 μm,
~Depth: SmartStak parameter 3
~D-pulse mode."
11132716|NCT03846895|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.
~The laser parameters that will be used are the following:
~Power: 0.5 watts,
~Dwell time:1000μs,
~Spacing 1000 μm,
~Depth: SmartStak parameter 1,
~Smart-pulse mode."
11132719|NCT03846843|Experimental|OCR-002 - Treatment A|• OCR-002 - Treatment A: A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions
11132720|NCT03846843|Experimental|OCR-002 - Treatment B|• OCR-002 - Treatment B: A single 5 g oral dose of OCR-002 oral solution administered under fed conditions
11132721|NCT03846843|Experimental|OCR-002 - Treatment C|• OCR-002 - Treatment C: A single 5 g intravenous dose of OCR-002 solution infused over 1 hour under fasting conditions
11132722|NCT03846843|Experimental|Treatment D|• OCR-002 - Treatment D: A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions following discontinuation of lactulose
11132723|NCT03846843|Experimental|OCR-002 - Treatment E|• OCR-002 - Treatment E: 6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
11132724|NCT03846843|Experimental|OCR-002 - Treatment F|• OCR-002 - Treatment F: 12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
11132725|NCT03846843|Experimental|OCR-002 - Treatment G|• OCR-002 - Treatment G: 21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
11132726|NCT03846830|Active Comparator|IVE/VPT 6 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 6 weeks, 6 weeks washout, and then crossover into the other group for a final 6 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout the 6 weeks of exercise.
11132727|NCT03846830|Experimental|IVE/VPT 3 week Crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving daily exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training will not start until the washout period.
11132728|NCT03846830|Active Comparator|IVE/VPT 3 week crossover|Subjects will randomly be placed in one of two groups (IVE or VPT) involving every other day exercise for 3 weeks, 3 weeks washout, and then crossover into the other group for a final 3 weeks. The Incremental Velocity Error (IVE) group uses a device worn on the head that delivers a moving target during head motion; while Traditional Vestibular Rehabilitation (VPT) uses the traditional eye and head turning rehabilitation exercises. Gait and balance training offered throughout the 3 weeks of exercise.
11132729|NCT03846817|Experimental|FAIS with intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.
~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).
~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
11132730|NCT03846817|Experimental|FAIS without intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.
~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).
~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
11132731|NCT03846765|Experimental|Phenylephrine continuous infusion|
11132732|NCT03846765|Experimental|Dobutamine continuous infusion|
11132733|NCT03846752|Active Comparator|7 Fr. radial access|radial artery access for complex PCI
11132734|NCT03846752|Active Comparator|7 Fr. femoral access|femoral artery access for complex PCI
11132735|NCT03846739|Active Comparator|Oxytocin & Placebo, 6 IU|Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
11132736|NCT03846739|Active Comparator|Oxytocin & Placebo, 12 IU|Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
11132737|NCT03846739|Active Comparator|Oxytocin & Placebo, 24 IU|Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
11132738|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
11132739|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
11132740|NCT03846713|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
11132741|NCT03846713|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
11132742|NCT03846700|Experimental|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume > 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
11132743|NCT03846700|Active Comparator|holep|patients with prostatic volume > 65 ml will be treated with holmium laser technique (Holep)
11132744|NCT03846700|Active Comparator|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
11132745|NCT03846661|Active Comparator|Physiomesh|Patients undergoing laparoscopic incisional hernia repair reinforced with a Physiomesh.
11132746|NCT03846661|No Intervention|other mesh|Patients undergoing laparoscopic incisional hernia repair reinforced with other meshes than Physiomesh.
11132789|NCT03846453|Experimental|0.25% HL036 Ophthalmic Solution|HL036 ophthalmic solution
11132790|NCT03846453|Placebo Comparator|Placebo|Placebo vehicle solution
11132791|NCT03846440||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
11132792|NCT03846427|Experimental|Zanubrutinib|
11132747|NCT03846648|Active Comparator|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.
~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.
~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
11132748|NCT03846648|Placebo Comparator|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
11132749|NCT03846635||Patients with Suspected Cellulitis|"Patients who undergo an infectious diseases consultation for suspected cellulitis of the upper or lower limbs are eligible to be enrolled. Patients who consent to participation will have chart data extracted and undergo a skin surface temperature measurement of the affected area and surrounding skin using a commercially available infrared thermometer. The dimensions of suspected cellulitis are also measured.
~Patients with cellulitis admitted to hospital undergo daily measurements of temperature and dimensions. These patients are also asked standardized questions about their symptoms based on the patient global impression of improvement scale."
11132750|NCT03846609|Experimental|double balloon platform|Device: double balloon interventional platform (DiLumen)
11132751|NCT03846609|Active Comparator|no double balloon platform|Device: no double balloon interventional platform (DiLumen)
11132752|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
11132753|NCT03846583|Experimental|Dose Escalation|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
11132754|NCT03846583|Experimental|Arm A: Active Brain Metastases|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
11132755|NCT03846583|Experimental|Arm B: Surgical Resection Needed|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
11132756|NCT03846583|Experimental|Arm C: Progressive Extracranial Disease|"Tucatinib is administered orally twice daily
~Abemaciclib is administered orally twice daily
~Trastuzumab is adminidtered intravenously once every three weeks
~Aromatase Inhibitor is administered orally once daily"
11132757|NCT03846570|Active Comparator|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
11132758|NCT03846570|Placebo Comparator|Placebo|Matching placebo (identically package) administered BID
11132759|NCT03846557||Treatment|Transcatheter Aortic Valve Implantation (TAVI)
11132760|NCT03846544|No Intervention|control group|
11132761|NCT03846544|Experimental|double pick up group|
11132762|NCT03846531|Active Comparator|Nano-Pulse Stimulation (NPS) Lesion|Three of four selected SK lesions receive Nano-Pulse Stimulation treatment.
11132763|NCT03846531|No Intervention|Non-Treated Lesion|One of four SK lesions is randomized to not receiving Nano-Pulse Stimulation treatment.
11132764|NCT03846518|Active Comparator|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
11132765|NCT03846518|Experimental|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
11132766|NCT03846505|Experimental|Oxytocin|"A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
11132767|NCT03846505|Placebo Comparator|Placebo|"A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
11132768|NCT03846492|Experimental|Active tDCS|The direct current will be delivered at 2 mA intensity via rubber electrodes in saline- soaked sponges for 30 min per day for 2 weeks, 5 days/week. Inhibitory stimulation will be delivered to the frontal lobes.
11132769|NCT03846492|Sham Comparator|sham tDCS|Sham tDCS will use the same parameters except that the device will automatically turn off after a certain duration.
11132770|NCT03846479|Experimental|Itacitinib|Itacitinib 200 mg administered orally daily
11132771|NCT03846466|Experimental|Part1 Dose 1A|Single administration
11132772|NCT03846466|Placebo Comparator|Part1 Dose 1P|Single administration
11132773|NCT03846466|Experimental|Part1 Dose 2A|Single administration
11132774|NCT03846466|Placebo Comparator|Part1 Dose 2P|Single administration
11132775|NCT03846466|Experimental|Part1 Dose 3A|Single administration
11132776|NCT03846466|Placebo Comparator|Part1 Dose 3P|Single administration
11132777|NCT03846466|Experimental|Part1 Dose 4A|Single administration
11132778|NCT03846466|Placebo Comparator|Part1 Dose 4P|Single administration
11132779|NCT03846466|Experimental|Part1 Dose 5A|Single administration
11132780|NCT03846466|Placebo Comparator|Part1 Dose 5P|Single administration
11132781|NCT03846466|Experimental|Part1 Dose 6A|Single administration
11132782|NCT03846466|Placebo Comparator|Part1 Dose 6P|Single administration
11132783|NCT03846466|Experimental|Part1 Dose 7A|Single administration
11132784|NCT03846466|Placebo Comparator|Part1 Dose 7P|Single administration
11132785|NCT03846466|Experimental|Part2 Dose 1A|Multiple administration
11132786|NCT03846466|Placebo Comparator|Part2 Dose 1P|Multiple administration
11132787|NCT03846466|Experimental|Part2 Dose 2A|Multiple administration
11132788|NCT03846466|Placebo Comparator|Part2 Dose 2P|Multiple administration
11132793|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
11132794|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
11132795|NCT03846388|Other|Patients with unexplained infertility|
11132796|NCT03846388|Other|patients with tubal, male factor or polycystic ovary syndrome|
11132797|NCT03846375|Experimental|Participants in DBT|Psychotherapy: The participants will be given standard DBT treatment.
11132798|NCT03846375|Other|Control Group|Control Group at preintervention.
11132799|NCT03846362|Experimental|intermediate risk MRD2>0,1%|MRD2>0,1% - FLA - MRD3 - HSCT
11132800|NCT03846349|Experimental|Study Group|Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week
11132801|NCT03846349|Sham Comparator|Control group|"Participants from the control group will perform a sham reeducation protocol using an EMT threshold at minimal resistance. The expiratory pressure will remain unchanged over the weeks."
11132802|NCT03846336|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
11132803|NCT03846336|Other|Healthy individuals|20 healthy volunteers with matching ages and genders.
11132804|NCT03846323|Experimental|Visiting policies: open 24h/24|Visiting policies: 24 hours a day, 7 days a week
11132805|NCT03846323|Other|Restriction of visiting policies|Restriction of visiting policies < 6 hours
11132806|NCT03846310|Experimental|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
11132807|NCT03846310|Experimental|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
11132808|NCT03846310|Experimental|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
11132809|NCT03846310|Experimental|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
11132810|NCT03846284|Placebo Comparator|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
11132811|NCT03846284|Experimental|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.
~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
11132812|NCT03846284|Experimental|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
11132813|NCT03846271|Experimental|Oxytocin then placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
11132814|NCT03846271|Experimental|Placebo then oxytocin|Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
11132815|NCT03846258|Active Comparator|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
11132816|NCT03846258|Active Comparator|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
11132817|NCT03846245||Young adults group|Cognitively unimpaired 18-25 years old
11132818|NCT03846245||Old adults group|Cognitively unimpaired >= 70 years old
11132819|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
11132820|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
11132821|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
11132822|NCT03846219|Experimental|IMU-838 (30 mg/day)|"Tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets.
~Duration: until the end of the main treatment period (24 weeks) and, optionally, during the extended treatment period (up to 9.5 years)."
11132823|NCT03846219|Experimental|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.
~Duration: until the end of the main treatment period (24 weeks) and, optionally, during the extended treatment period (up to 9.5 years)."
11132824|NCT03846219|Placebo Comparator|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.
~Duration: until the end of the main treatment period (24 weeks). For the optional extended treatment period, patients receiving placebo during the main treatment period will be randomized to 30 or 45 mg/day IMU-838."
11132825|NCT03846206|Experimental|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
11132827|NCT03846193|Experimental|GT005 Dose 1|A single dose of GT005 will be administered via subretinal injection
11132828|NCT03846193|Experimental|GT005 Dose 2|A single dose of GT005 will be administered via subretinal injection
11132829|NCT03846193|Experimental|GT005 Dose 3|A single dose of GT005 will be administered via subretinal injection
11132830|NCT03846193|Experimental|GT005 Dose 1, 2 or 3|A single dose of GT005 will be administered via subretinal injection. This dose will be determined by dose levels determined to be tolerable in Arms 1,2 and 3
11132831|NCT03846193|Experimental|GT005 Dose 2 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
11132832|NCT03846193|Experimental|GT005 Dose 3 with Orbit Subretinal Delivery System|A single dose of GT005 will be administered with subretinal injection via suprachoroidal cannulation approach
11132833|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
11132834|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
11132835|NCT03846167||FTT PET/CT|"The imaging procedure may include one or both of the following imaging sessions; 1) a 45- 60 minute dynamic scan, starting at approximately the same time as the injection and/or 2) a skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT.
~Participants will be asked to complete the following research procedures: [18F]FTT PET/CT scan before surgery or treatment [18F]FTT PET/CT scan after you start treatment (optional)"
11132836|NCT03846154|Experimental|Intervention group|"Children and adolescents in the intervention group received:
~A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.
~Access to schools and school material
~Family visits
~Their parents received training regarding agriculture and microcredit projects, and financial assistance
~FORNET if affected by trauma-related symptoms, and/or acting aggressive
~If needed medical assistance is provided
~If needed legal assistance is provided"
11132837|NCT03846154|No Intervention|Control group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
11132838|NCT03846141|Placebo Comparator|Placebo|Room air for inhalation
11132839|NCT03846141|Experimental|Hydrogen|Hydrogen (4%) for inhalation
11132840|NCT03846115|Experimental|Peer-Led Seeking Safety app|This app is designed for Peer-Led Seeking Safety and includes enhanced app features.
11132841|NCT03846115|Active Comparator|Control app|This is a basic app that controls for time and attention. The basic app serves as the intervention in this trial.
11132842|NCT03846102|Experimental|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)
~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)
~[<64 kg : 100 mg : 2.0 mg/kg : 40 ml]
~[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml]
~[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml]
~Acetaminophen 1 gram (tablets) 4 times daily.
~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
11132843|NCT03846102|Placebo Comparator|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.
~Ideal Body Weight : Total volume (ml)
~[<64 kg : 40 ml]
~[65-74 kg : 45 ml]
~[≥ 75 kg : 50 ml]
~Acetaminophen 1 gram (tablets) 4 times daily.
~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
11132844|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
11132845|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
11132846|NCT03846076|Experimental|Internet-delivered CBT|10 weeks of CBT delivered via the Internet.
11132847|NCT03846063|Experimental|Intervention: Home-based rehabilitation program|"A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.
~The intervention group will be compared with existing patientdata who received usual care in the Netherlands"
11132848|NCT03846050|Experimental|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.
~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
11132849|NCT03846050|Experimental|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.
~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
11132850|NCT03846050|Placebo Comparator|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.
~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
11132851|NCT03846037|Placebo Comparator|Ground|Participants in this group perform protocol exercises on a stable surface.
11132852|NCT03846037|Experimental|vibrating platform|Participants in this group perform protocol exercises on a vibrating platform.
11132980|NCT03845153|Placebo Comparator|Placebo|20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.
11132853|NCT03846024|Experimental|RibFx belt arm|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
11132854|NCT03846024|No Intervention|Control|"Patients in the control arm receive normal standard of care for rib fractures at the participating institution.
~The current standard of care for rib fractures at the University of Vermont (participating institution) is as follows: includes oral and IV analgesia and other multimodal pain control as appropriate, including muscle relaxants such as methocarbamol (robaxin) unless there is a contraindication, pulmonary hygiene/toilet and respiratory care (including frequent evaluations by physicians, respiratory therapists, and nursing staff, early mobilization, and monitoring for pulmonary complication (via vital signs, pulse oximetry, oxygen requirement, chest imaging if appropriate)."
11132855|NCT03846011||Experiment group|All eligible patients administered for active stone removal.
11132856|NCT03845998|Experimental|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.
~The intervention is to use the three-finger method."
11132857|NCT03845998|Active Comparator|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.
~The intervention is to use the weight-related method."
11132858|NCT03845985|Experimental|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
11132859|NCT03845985|No Intervention|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
11132860|NCT03845972|No Intervention|before SSFTB|
11132861|NCT03845972|Experimental|after SSFTB|
11132862|NCT03845959|Experimental|TD0019.6cap|estimated dose, 2 oral capsules/time x 3 times/day
11132863|NCT03845959|Experimental|TD0019.9cap|1.5 times of estimated dose 2 oral capsules/time x 3 times/day
11132864|NCT03845959|Placebo Comparator|Placebo|Placebo 2 placebo oral capsules /time x 3 times/day
11132865|NCT03845946||Hereditary angioedema type I/II|Hereditary angioedema with C1Inh deficiency
11132866|NCT03845946||Acquired angioedema|Angioedema with acquired C1Inh deficiency
11132867|NCT03845946||Drug induced angioedema|Angioedema associated with ACEi used
11132868|NCT03845946||Mast cell induced angioedema|Spontaneous mast cell induced isolated angioedema
11132869|NCT03845946||Hereditary angioedema with nC1Inh|Hereditary angioedema with normal C1Inh and with F12, PLG, ANGPT2 mutations
11132870|NCT03845933|Active Comparator|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
11132871|NCT03845933|Active Comparator|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
11132872|NCT03845920|Other|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])
11132873|NCT03845920|Experimental|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
11132874|NCT03845920|Experimental|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])
11132875|NCT03845920|Experimental|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
11132876|NCT03845907|Active Comparator|Imagio Gen 1B|Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe
11132877|NCT03845907|Active Comparator|Imagio Gen 1|Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System
11132878|NCT03845894|Active Comparator|Liposomal Bupivacaine ISB|
11132879|NCT03845894|Active Comparator|Bupivacaine with adjuvants ISB|
11132880|NCT03845881|Active Comparator|Opioid|Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
11132881|NCT03845881|Placebo Comparator|Non Opioid|Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
11132882|NCT03845868||Egang hospital physical examination center|
11132883|NCT03845868||Ezhou CDC physical examination center|
11132884|NCT03845855|Experimental|Virtual reality with robotic gait|virtual reality treatment with robotic gait therapy 2 times for week by 6 weeks.
11132885|NCT03845855|Active Comparator|Robotic gait therapy only|only robotic gait therapy 2 times for week by 6 weeks
11132886|NCT03845842|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour and are asked to tick critical situations/appropriate responses that might be useful to them."
11132887|NCT03845842|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to reduce their cannabis use (We want you to plan to reduce your cannabis use). Participants are presented with a table with two columns and twenty rows. Twenty 'high risk' situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to use cannabis and identifying ways to overcome those temptations had been shown to help people change their behaviour. Implementation intentions are formed by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
11132888|NCT03845829|Experimental|Patients with TBAD treated with TEVAR|In situ laser assisted fenestration for the left subclavian artery during the TEVAR procedure for TBAD.
11132889|NCT03845777||Surgical Staff|The surgical staff group is the only group of the study. Blood samples of the surgical staff before and after the using antiseptics solution that include iodine were analyzed.
11132890|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
11132891|NCT03845751|Experimental|ADT protocol|ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). Additionally, oral antiandrogen bicalutamide 50 mg once per day is given for 3 months, starting the same day of LHRH agonist injection. ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
11132892|NCT03845712|Experimental|MT1621, dC/dT|This is an open label study with all participants in a single arm. Patients will take MT1621 up to a maximum of 400 mg/kg/day. MT1621 is deoxycytidine (dC) and deoxythymidine (dT) powders for solution for reconstitution in water. Study drug will be supplied as powder in packets containing 0.5 or 2.0 g of dC or dT, and is typically dosed three times/day.
11132893|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, < 4 weeks post stroke, age >18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, <4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
11132894|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (>3 months post-stroke)
11132895|NCT03845673|Experimental|Psyllium|This group of patients was given psyllium for 6 weeks
11132896|NCT03845673|Experimental|Bowel recipe|This group was administered a specialized bowel recipe for 6 weeks
11132897|NCT03845660|No Intervention|Usual Care|Providers taking care of patients randomized to this arm will have no alert related to the patients prognosis.
11132898|NCT03845660|Experimental|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
11132899|NCT03845647|Experimental|Tumor diameter<=2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
11132900|NCT03845647|Experimental|Tumor diameter>2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
11132901|NCT03845621|Active Comparator|CM-OA-OA-CM Sequence|Use of a conventional custom-made mouthguard (CM) while playing water polo for first and fourth weeks and the occlusal-adjusted custom-made mouthguard (OA) for the second and third weeks.
11132902|NCT03845621|Active Comparator|OA-CM-CM-OA Sequence|Use of an occlusal-adjusted custom-made mouthguard (OA) for the first and fourth weeks and a conventional custom-made mouthguard (CM) while playing water polo for the second and third weeks.
11132903|NCT03845608|Experimental|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
11132904|NCT03845608|Other|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
11132905|NCT03845608|No Intervention|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
11132906|NCT03845595|Experimental|(LF-rTMS) group|Patients in the study group were treated with the contralesional (LF-rTMS) once per day for 20 minutes, Daily, 5 sessions per week (Sunday to Thursday), for 2 consecutive weeks in addition to the conventional upper limb physical therapy interventions.
11132907|NCT03845595|Active Comparator|Control group|Patients in the control group were treated with the conventional upper limb physical therapy interventions (40 minutes to 1 hour, daily, 5 times per week for two consecutive weeks )
11132908|NCT03845582|Experimental|ALK-001|Capsule
11132909|NCT03845582|Placebo Comparator|Placebo|Capsule
11133025|NCT03844906|Placebo Comparator|Placebo|
11133579|NCT03840915|Experimental|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824|
11132910|NCT03845569|Other|Habitual Protein phase|A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
11132911|NCT03845569|Experimental|Moderate Protein Phase|A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
11132912|NCT03845543|Experimental|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
11132913|NCT03845530|Active Comparator|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
11132914|NCT03845530|Active Comparator|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
11132915|NCT03845517|Placebo Comparator|Placebo|Placebo
11132916|NCT03845517|Experimental|PF-06700841 15 mg|PF-06700841 15 mg
11132917|NCT03845517|Experimental|PF-06700841 30 mg|PF-06700841 30 mg
11132918|NCT03845517|Experimental|PF-06700841 45 mg|PF-06700841 45 mg
11132919|NCT03845504|Experimental|Open Label|Open-label rTMS sessions will occur within ~2 days after the baseline session with daily sessions delivered to left DLPFC over 2-6 weeks. Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
11132920|NCT03845491||SR Classic|SR (Trevo®]) + BGC (FlowGate2] or Merci)
11132921|NCT03845491||SR Combination|"SR (Trevo) + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump
~+ LS (AXS Infinity LS, AXS Infinity LS Plus)
~or
~SR (Trevo) + Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2 or Merci)"
11132922|NCT03845491||Direct Aspiration|"Asp Cath (AXS Catalyst DAC, Vecta) ± Pump + LS (AXS Infinity LS, AXS Infinity LS Plus)
~or
~Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2, Merci)"
11132923|NCT03845478|Active Comparator|Control Group (CG)|Education, modifying diet and physical activity
11132924|NCT03845478|Experimental|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
11132925|NCT03845465|Active Comparator|Education|Participants in the Education group will complete a behavioral health contract and will receive an educational packet.
11132926|NCT03845465|Experimental|PA + Education|Participants in the Positive Affect + Education group will complete a behavioral health contract and receive an educational packet. In addition, they will receive intervention components aimed at inducing positive affect.
11132927|NCT03845413|Active Comparator|Intervention|The intervention arm consisted of 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
11132928|NCT03845413|Active Comparator|Control|The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
11132929|NCT03845400||Type I or Type II HAE Participants|Participants will be followed for 36 months after the enrollment date up to the time of withdrawal, lost to follow-up, death or end of follow-up (36 months) whichever comes first.
11132930|NCT03845387|Experimental|KDT-3594|
11132931|NCT03845387|Other|Pramipexole|Reference drug
11132932|NCT03845374|Experimental|Conventional Antibiotics+ Hyper-CL™ lens|Conventional treatment with topical Antibiotics+ Hyper-CL™ lens
11132933|NCT03845374|No Intervention|Conventional Antibiotics|Conventional treatment with topical Antibiotics
11132934|NCT03845361|Experimental|C. hand|Radial artery cannulation
11132935|NCT03845361|No Intervention|N.C. hand|No cannulation of the radial artery
11132936|NCT03845348|Experimental|TD3|TD3, bi-daily x 4 weeks
11132937|NCT03845348|Experimental|TD7|TD7, bi-daily x 4 weeks
11132938|NCT03845348|Active Comparator|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
11132939|NCT03845335|Experimental|HA-coated hybrid implant|Patient allocated to this group will receive an iMAX® Hyaluronic Acid-coated hybrid dental implant for their dental implant-supported restoration.
11132940|NCT03845335|Active Comparator|Moderately rough implant|Patient allocated in this group will receive an iMAX® non-coated moderately rough dental implant with a machined neck their dental implant-supported restoration.
11132941|NCT03845322|Experimental|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
11132942|NCT03845322|Placebo Comparator|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
11132943|NCT03845309|Experimental|Nutritional intervention for CHF|
11132944|NCT03845296|Experimental|Treatment (rucaparib)|Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11132945|NCT03845283|Experimental|Physical Activity|Participants will receive the core 6-month weight loss program and the tailored intervention to promote structured physical activity.
11132946|NCT03845283|Experimental|Core Program|Participants will receive the core 6-month weight loss program alone. This program includes weekly lessons for the first 12 weeks and monthly lessons for the remaining 12 weeks. Participants will track their intake, physical activity, and weight, input these data into the system, and received tailored feedback.
11132947|NCT03845283|Experimental|Physical Activity & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the virtual meetings to support weight loss.
11132948|NCT03845283|Experimental|Virtual Meetings|Participants will receive the core 6-month weight loss program and the virtual meetings to support weight loss.
11132949|NCT03845283|Experimental|Physical Activity & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and access to the virtual reality platform for behavioral weight loss skills training.
11132950|NCT03845283|Experimental|Virtual Reality|Participants will receive the core 6-month weight loss program and access to the virtual reality platform for behavioral weight loss skills training.
11132951|NCT03845283|Experimental|Physical Activity, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the virtual meetings to support weight loss, and access to the virtual reality platform for behavioral weight loss skills training.
11132952|NCT03845283|Experimental|Virtual Reality & Virtual Meetings|Participants will receive the core 6-month weight loss program, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
11132953|NCT03845283|Experimental|Physical Activity & Bite Counter|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the Bite Counter device to reduce dietary intake.
11132954|NCT03845283|Experimental|Bite Counter|Participants will receive the core 6-month weight loss program and the Bite Counter device to reduce dietary intake.
11132955|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
11132956|NCT03845283|Experimental|Bite Counter & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
11132957|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
11132958|NCT03845283|Experimental|Bite Counter & Virtual Reality|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
11132959|NCT03845283|Experimental|Physical Activity, Bite Counter, Virtual Reality & Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
11132960|NCT03845283|Experimental|Bite Counter, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
11132961|NCT03845270|Experimental|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
11132962|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:
~Blood eosinophils
~FeNO
~Eosinophils in bronchoalveolar lavage
~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
11132963|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:
~Blood eosinophils
~FeNO
~Eosinophils in bronchoalveolar lavage
~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
11132964|NCT03845244|Active Comparator|Flow reduction first group|Flow reduction first -> FiO2 reduction -> conventional oxygen therapy
11132965|NCT03845244|Active Comparator|FiO2 reduction first group|FiO2 reduction first -> flow reduction -> conventional oxygen therapy
11132966|NCT03845244|Active Comparator|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -> conventional oxygen therapy
11132967|NCT03845231|Other|unvaccinated|will receive no Flucelvax vaccination and will receive human challenge virus
11132968|NCT03845231|Experimental|Vaccinated|will receive Flucelvax vaccination and human challenge virus
11132969|NCT03845218|Active Comparator|single arm|participants with and without RP
11132970|NCT03845205|Experimental|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
11132971|NCT03845205|No Intervention|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
11132972|NCT03845192|Other|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
11132973|NCT03845179|Placebo Comparator|Placebo|Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
11132974|NCT03845179|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
11132975|NCT03845166|Experimental|XL092 Single-Agent Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 3-6 subjects in a standard 3 plus 3 design."
11132976|NCT03845166|Experimental|XL092 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
11132977|NCT03845166|Experimental|XL092 + Atezolizumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
11132978|NCT03845166|Experimental|XL092 + Atezolizumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
11132979|NCT03845153|Active Comparator|Metformin|20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.
11132981|NCT03845140|Experimental|Cohort 1, Treatment 1a: L-PZQ ODT|Participants aged 4 to 6 years infected with Schistosoma (S.) mansoni will receive single oral dose of L-PZQ ODT 50 milligram/Kilogram (mg/Kg) after food-intake.
11132982|NCT03845140|Active Comparator|Cohort 1, Treatment 1b: Biltricide®|Participants aged 4 to 6 years infected with S. mansoni will receive single oral dose of Biltricide® 40 mg/Kg crushed tablet after food intake.
11132983|NCT03845140|Experimental|Cohort 2: L-PZQ ODT|Participants aged 2 to 3 years infected with S. mansoni will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake.
11132984|NCT03845140|Experimental|Cohort 3: L-PZQ ODT|Participants aged 3 to less than 24 months infected with S. mansoni will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake.
11132985|NCT03845140|Experimental|Cohort 4: L-PZQ ODT|Participants aged 3 months to 6 years infected with S. haematobium will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake. Additional participants will receive 60 mg/Kg of L-PZQ ODT as decided by the Independent data monitoring committee (IDMC).
11132986|NCT03845127|Experimental|Revivent TC Ventricular Enhancement System plus GDMT|Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
11132987|NCT03845127|Active Comparator|GDMT Only|Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
11132988|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 40%|
11132989|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 80%|
11132990|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 40%|
11132991|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 80%|
11132992|NCT03845101|Experimental|CBT In VR|Receives CBT in group format augmented with Virtual Reality Exposure Therapy
11132993|NCT03845101|Active Comparator|CBT in vivo|Active comparator, receives CBT in group format, TAU
11132994|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: <12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
11132995|NCT03845075|Experimental|active arm|The active medication arm will be given co-administration of 0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks.
11132996|NCT03845075|Placebo Comparator|placebo arm|The placebo arm will receive matching placebo tablets.
11132997|NCT03845049|Experimental|group aflibercept|
11132998|NCT03845049|Placebo Comparator|control group|
11132999|NCT03845036|Experimental|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
11133000|NCT03845036|Active Comparator|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
11133001|NCT03845023|Placebo Comparator|Placebo|Placebo
11133002|NCT03845023|Active Comparator|Dose 1|AD036 Dose 1
11133003|NCT03845023|Active Comparator|Dose 2|AD036 Dose 2
11133004|NCT03845023|Active Comparator|Dose 3|AD036 Dose 3
11133005|NCT03845010|Active Comparator|Sotalol|
11133006|NCT03845010|Active Comparator|Flecainide and verapamil|
11133007|NCT03845010|Active Comparator|Catheter ablation|
11133008|NCT03844997|Experimental|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).
~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
11133009|NCT03844984|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
11133010|NCT03844984|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
11133011|NCT03844971|Experimental|Computer assisted surgery|Intervention will be fabrication of patient specific surgical guide for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction using patient computed tomography with the aid of computer aided surgical simulation software
11133012|NCT03844958|Experimental|Red Furu|Volunteer was randomized into group red furu
11133013|NCT03844958|Experimental|Fresh Tofu|Volunteer was randomized into group tofu
11133014|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
11133015|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
11133016|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
11133017|NCT03844945|Placebo Comparator|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
11133018|NCT03844932|Experimental|ST-0529 18.75 mg|ST-0529: 18.75 mg orally twice daily (BID)
11133019|NCT03844932|Experimental|ST-0529 37.5 mg|ST-0529: 37.5 mg orally twice daily (BID)
11133020|NCT03844932|Experimental|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
11133021|NCT03844932|Placebo Comparator|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
11133022|NCT03844919|Experimental|rTMS + CBIT|Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
11133023|NCT03844919|Active Comparator|Sham rTMS + CBIT|Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
11133024|NCT03844906|Experimental|SAGE-718|
11133026|NCT03844880|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
11133027|NCT03844880|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
11133028|NCT03844867|Experimental|Filippo Cea and Carmel|Subjects <65 years.
11133029|NCT03844854|No Intervention|Control Group|Without intervention.
11133030|NCT03844854|Experimental|Research Group|With providing stabilization occlusal splint and manual therapy.
11133031|NCT03844841|Active Comparator|Propofol|Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous
11133032|NCT03844841|Active Comparator|Dexmedetomidine|Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous
11133033|NCT03844828|Experimental|POD FT IOL Implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT and POD F.
11133034|NCT03844815|Experimental|Treatment|"Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21
~Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21
~During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21"
11133035|NCT03844802|Experimental|Dry needling and exercise|Dry needling and neck exercises. Patients will receive 2 dry needling sessions a week during 2 weeks (4 sessions in total). They will also undergo neck exercises in treatment days and in between sessions days at home.
11133036|NCT03844802|Sham Comparator|Sham dry needling and exercise|"Sham dry needling and neck exercises. Patients will receive 2 sham dry needling sessions a week during 2 weeks (4 sessions in total). As formerly described, patients in this group will receive dry needling in those neck muscles with active or latent myofascial trigger points, but without evoking local twitch responses. They will also do neck exercises in treatment days and in between sessions days at home."
11133037|NCT03844789|Experimental|Closed Loop Control (CLC)|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology & Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
11133038|NCT03844789|Active Comparator|Control Group|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.
11133039|NCT03844776|Active Comparator|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
11133040|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
11133041|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
11133042|NCT03844763|Experimental|Phase I - II trial of CTX, RT, Avelumab|CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.
11133043|NCT03844750|Experimental|Treatment (FOLFOX, pembrolizumab, surgery)|Patients receive between 4 and 8 FOLFOX treatments, based on the treating physician's opinion. Approximately 2 weeks after the last dose of FOLFOX, patients receive pembrolizumab IV over 30 minutes on day 1. About 2 weeks later, patients undergo hepatic resection.
11133044|NCT03844737|Experimental|VisuXL® Treatment|
11133045|NCT03844724|Experimental|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
11133046|NCT03844724|Active Comparator|Group B|subjects using the peripheral balloon dilatation catheter
11133047|NCT03844711|Experimental|Electrical diaphragmatic stimulation|For transcutaneous electrical diaphragmatic stimulation, surface electrodes will be used that will be positioned at the transcutaneous motor points of the diaphragm.
11133048|NCT03844711|Experimental|Inspiratory muscle training|The training will start with a minimum load of 30% and will be progressed until reaching 60% of the PImax.
11133049|NCT03844711|Active Comparator|Conventional physiotherapy|The protocol of physiotherapy by the physiotherapists of HCPA will be twice a day and consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
11133050|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
11133051|NCT03844685|Experimental|Treatment group|1 tablet /day of MCE-11 (Promensil) taken orally for 24 months
11133052|NCT03844685|Placebo Comparator|Placebo group|Placebo tablet (without active principle) given once a day for 24 months
11133053|NCT03844672|Experimental|Low Concentration / Low Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a low power for three weeks.
11133054|NCT03844672|Experimental|Low Concentration / High Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a high power for three weeks.
11133055|NCT03844672|Experimental|High Concentration / Low Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a low power for three weeks.
11133056|NCT03844672|Experimental|High Concentration / High Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a high power for three weeks.
11133057|NCT03844659|Experimental|Intervention Group|"The song Weightless by Marconi Union will be playing during subjects labor epidural placement."
11133058|NCT03844659|Other|Non Intervention Group|No song will be played during subjects labor epidural placement.
11133059|NCT03844646|Experimental|CGM plus dietitian|Intermittent use of a continuous glucose monitor (CGM) plus dietitian support
11133060|NCT03844646|Other|Dietitian only|Dietitian support only
11133061|NCT03844633|Experimental|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
11133062|NCT03844633|Placebo Comparator|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
11133063|NCT03844633|No Intervention|Open arm|No intervention provided
11133064|NCT03844620|Experimental|Arm I (ctDNA testing, regorafenib, TAS-102)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.
11133065|NCT03844620|Active Comparator|Arm II (SOC)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle as per standard of care. Patients in this arm will continue treatment in the absence of disease progression or unacceptable toxicity.
11133066|NCT03844607|Experimental|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
11133067|NCT03844607|Sham Comparator|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
11133068|NCT03844594|Experimental|Eptifibatide Drug: Eptifibatide Injection|
11133069|NCT03844581|Active Comparator|interferential current|interferential current with a constant frequency of 100Hz for pain relief, then using rhythmic frequency of 1-100 Hz that help to disperse infiltration and adhesions for 8 successive weeks
11133070|NCT03844581|Active Comparator|anticholinergics|anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks
11133071|NCT03844568|Experimental|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
11133072|NCT03844568|No Intervention|Control group|Usual pneumonia treatment
11133073|NCT03844555|Experimental|End Stage Renal Disease|Single oral dose of elafibranor 120mg
11133074|NCT03844555|Experimental|Healthy|Single oral dose of elafibranor 120mg
11133075|NCT03844542|Experimental|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
11133076|NCT03844542|No Intervention|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
11133077|NCT03844529|Experimental|Sunmax FULLSGEN with Lidocaine|A subject would only receive single injection treatment(day 1) using Sunmax FULLSGEN , and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
11133078|NCT03844529|Active Comparator|Sumax FACIALGAIN collagen Implant with Lidocaine|A subject would only receive single injection treatment(day 1) using Sumax FACIALGAIN collagen Implant with Lidocaine, and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
11133079|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
11133080|NCT03844516|Sham Comparator|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
11133081|NCT03844503|Placebo Comparator|Cereal Bar no fiber|Cereal bar without fiber
11133082|NCT03844503|Active Comparator|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
11133083|NCT03844503|Active Comparator|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
11133084|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
11133085|NCT03844490|Experimental|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.
~At this time, cord clamping will be made."
11133086|NCT03844477|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
11133087|NCT03844477|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
11133088|NCT03844451|Experimental|Liposomal bupivicaine with nerve block|The treatment group will receive an intraoperative V2 trigeminal nerve block using liposomal bupivacaine in addition to a standard bupivacaine nerve block.
11133089|NCT03844451|Placebo Comparator|Nerve block only|The control group will undergo conventional perioperative management without an ERAS protocol and standard bupivacaine intraoperative nerve block.
11133090|NCT03844438|Experimental|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
11133091|NCT03844425|Active Comparator|Conventional Vacuum-Formed Retainers|Vacuum-formed retainers constructed on conventional stone models.
11133092|NCT03844425|Experimental|Vacuum-Formed Retainers From DLP|Vacuum-formed retainers constructed on 3D reconstructed models using digital light processing technique (DLP).
11133093|NCT03844425|Experimental|Vacuum-Formed Retainers From FDM|Vacuum-formed retainers constructed on 3D reconstructed models using fused deposition modeling technique (FDM).
11133094|NCT03844412|Active Comparator|peripheral treatment|5% lidocaine/5 mg/ml 0.02% estradiol compound cream
11133095|NCT03844412|Active Comparator|central treatment|tricyclic antidepressant nortriptyline pill
11133096|NCT03844412|Active Comparator|combined peripheral and central treatments|5% lidocaine/5 mg/ml 0.02% estradiol compound cream and tricyclic antidepressant nortriptyline pill
11133097|NCT03844412|Placebo Comparator|placebo|placebo cream and placebo pill
11133098|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
11133099|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
11133100|NCT03844386|Experimental|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
11133101|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
11133102|NCT03844386|Placebo Comparator|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
11133103|NCT03844373|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.
11133104|NCT03844360|Experimental|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
11133105|NCT03844347|Experimental|C-Bien|
11133106|NCT03844347|No Intervention|Control|
11133107|NCT03844321|Experimental|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
11133108|NCT03844321|Experimental|Mindfulness Light|3 sessions of online mindfulness therapy
11133109|NCT03844308|Experimental|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
11133110|NCT03844308|Active Comparator|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
11133111|NCT03844295|Experimental|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
11133112|NCT03844295|Placebo Comparator|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
11133113|NCT03844282||CArBON (baseline)|The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
11133114|NCT03844282||CARS (exposure to a potentially concussive event)|The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
11133115|NCT03844269|Experimental|AKL-T01|
11133116|NCT03844256|Experimental|Regimen A|"Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.
~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
11133117|NCT03844256|Experimental|Regimen B|"Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.
~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
11133118|NCT03844256|Experimental|Regimen C|"Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.
~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
11133119|NCT03844243|Experimental|NGF condition + Control condition|"All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.
~After 4 weeks:
~All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
11133120|NCT03844243|Experimental|Control condition + NGF condition|"All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.
~After 4 weeks:
~All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
11133121|NCT03844230|Other|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
11133122|NCT03844230|Other|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
11133123|NCT03844217|Experimental|Macimorelin 0.5mg/kg body weight|"Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.
~Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.
~Macimorelin 0.75mg/kg body weight"
11133124|NCT03844204|Experimental|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
11133125|NCT03844204|Active Comparator|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
11133126|NCT03844191|Experimental|Part 1 Cohort 1|Cohort 1: 0.05 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
11133127|NCT03844191|Experimental|Part 1 Cohort 2|Cohort 2: 0.075 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
11133128|NCT03844191|Experimental|Part 2 Cohort 1|Cohort 1: initial dose to be selected by the Safety Review Committee (SRC) after completion of Part 1 (the same initial dose used in Part 1 or one of the previously studied higher doses that is lower than the overall RUC-4 BED) 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
11133129|NCT03844191|Experimental|Part 2 Cohorts 2-3|7 subjects (6 receiving RUC-4, 1 receiving placebo) will be enrolled in each dose cohort, with a safety evaluation performed after 2 subjects in a dose cohort receive RUC 4 and at the completion of dosing for all subjects in the dose cohort. Dose escalation to be determined by the SRC charter and will continue until identification of the overall RUC-4 BED or MTD
11133130|NCT03844191|Experimental|Part 2 Dose Expansion Cohort 1|"14 subjects will receive a selected dose of RUC-4 based on SRC review of dose escalation data.
~In the expansion cohort, 7 subjects weighing 55 to 65 kg and 7 subjects weighing 100 to 120 kg will be enrolled; 12 subjects will receive a single subcutaneous dose of RUC-4 and 2 will receive matched placebo"
11133131|NCT03844178|Active Comparator|The right eyes with compensation for Pupil centroid shift|
11133132|NCT03844178|Active Comparator|The left eyes without compensation for Pupil centroid shift|
11133133|NCT03844165|Experimental|Diet change (red rice) with yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
11133134|NCT03844165|Active Comparator|Yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
11133135|NCT03844152|Experimental|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
11133136|NCT03844139||Feeding pump group(continous)|Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours
11133137|NCT03844139||Glycerin syringe group(intermittent)|Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times
11133138|NCT03844126|Experimental|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
11133139|NCT03844113|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
11133140|NCT03844113|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo for 6 months
11133141|NCT03844100|Experimental|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia
~Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week
~Person with above symptoms that started at least 6 months before and continused for minimum 3 months
~Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease
~Person who do not respond to at least 2 general treatments for FD
~Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =>5)"
11133142|NCT03844087|Experimental|multiplanar neuromuscular training arm|The intervention arm will be involved in the training intervention outlined. Briefly, each participant will be asked to train on the TopSpin360 3 times per week for 3-5 sets for the duration of the study. Each set will take roughly 15-30 seconds to perform and training will take part during regularly scheduled training sessions.
11133143|NCT03844074|Experimental|bevacizumab|ONS-5010
11133144|NCT03844074|Active Comparator|ranibizumab|
11133145|NCT03844061|Experimental|MMF + Rituximab + Belimumab|Two infusions of 1000 mg of Rituximab, two weeks apart, weekly subcutaneous injections of 200 mg of Belimumab, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
11133146|NCT03844061|Placebo Comparator|MMF + Placebo + Placebo|Two placebo infusions of normal saline, two weeks apart, weekly saline placebo subcutaneous injections, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
11133147|NCT03844048|Experimental|Venetoclax|Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.
11133148|NCT03844035|Experimental|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator(oxytet oral irrigatör).All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual).PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites.Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
11133149|NCT03844035|Experimental|Interdental brush group|Fifteen patients using toothbrush and interdental brush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
11133222|NCT03843541|Placebo Comparator|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
11133150|NCT03844035|Active Comparator|Control group|Fifteen patients using only toothbrush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
11133151|NCT03844022||McArdle disease|Glycogen storage disease
11133152|NCT03844022||Healty controls|Age and gender matched
11133153|NCT03844009|Experimental|Debriefing|Participant's of the debriefing group had a computer integrated debriefing at the end of each scenario of the computer-based simulator
11133154|NCT03844009|No Intervention|No debriefing|Participant's of the debriefing group had no computer integrated debriefing at the end of each scenario of the computer-based simulator
11133155|NCT03843996|Experimental|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
11133156|NCT03843996|Experimental|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
11133157|NCT03843983|Other|Lipiflow treatment|Lipiflow® application: Treated with Lipiflow. All patients in this study are treated with Lipiflow once.
11133158|NCT03843970|Experimental|Levobupivacaine Hydrochloride 0,5%|The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.
11133159|NCT03843970|Active Comparator|isobaric bupivacaine 0,5%|The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.
11133160|NCT03843957|Experimental|"Clinic Patients on high touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
11133161|NCT03843957|Experimental|"Clinic Patients on low touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
11133162|NCT03843957|Experimental|"Clinic personnel on high touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
11133163|NCT03843957|Experimental|"Clinic personnel on low touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
11133164|NCT03843944|Experimental|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
11133165|NCT03843931|Active Comparator|GLA:D|8 weeks of education (1 session/week for 2 weeks) and exercise therapy (2 sessions/week for 6 week)
11133166|NCT03843931|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injection (5 ml of 0.9% sodium chloride) every 2 weeks over an 8-week period
11133167|NCT03843918|Experimental|Group A (Phase II only)|LAE001+ADT
11133168|NCT03843918|Placebo Comparator|Group B (Phase II only)|Placebo+ADT
11133169|NCT03843879|Active Comparator|TAP Block|Single-injection transversus abdominis plane block
11133170|NCT03843879|Active Comparator|IV Lidocaine|Continuous intravenous lidocaine infusion
11133171|NCT03843866|Active Comparator|Suture & steri-strips|
11133172|NCT03843866|Active Comparator|Adhesive Glue|
11133173|NCT03843853|Experimental|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
11133174|NCT03843840||Diseased Retina|
11133175|NCT03843827|Active Comparator|Group A (LMA Group)|Active Comparator: Group A (LMA Group) LMA-Classic™ laryngeal mask airway (Classic™LMA) by Dr. Archie Brain into clinical practice in 1988 brought about a revolution in anesthesia. In the literature, there are over 2,500 studies supporting Classic™ LMA usage. Following the success and popularity of Classic™ LMA, many different variants of this device have been designed and marketed,trying to offer a simple and effective alternative to the endotracheal intubation.
11133176|NCT03843827|Active Comparator|Group B (I gel Group)|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature,thus minimising air leakage
11133177|NCT03843814|Experimental|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.
~Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.
~An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.
~Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
11133178|NCT03843801|Active Comparator|Volume reduction|Intragastric sutures are done to reduce the volume of the stomach
11133179|NCT03843801|Active Comparator|Gastric emptying reduction|Intragastric sutures are done to slower the gastric emptying
11133180|NCT03843801|Active Comparator|Increasing distension|Intragastric sutures are done to maximalize the gastric distension
11133181|NCT03843788|Experimental|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
11133219|NCT03843554|Experimental|Oral Mucosal Deterging and Dental Prophylaxis (OMDP)|Oral Mucosal Deterging & Dental Prophylaxis (OMDP) protocol: Subjects assigned to OMDP will attend weekly intervention visits during which they will have their teeth cleaned and will receive the OMDP intervention as follows: subjects will receive a professional dental prophylaxis including periodontal surface debridement and deterging of the oral mucosal surfaces. Subjects will be asked to follow OMDP oral hygiene instructions at home.
11133182|NCT03843788|Experimental|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
11133183|NCT03843788|No Intervention|Post-CS Routine Care|Routine pharmacologic care will be provided.
11133184|NCT03843788|No Intervention|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
11133185|NCT03843775|Experimental|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
11133186|NCT03843762||Adolescents|Adolescents, male or female, ages 11 - 17. Participants will complete 7 days/nights of actigraphy and sleep-based EEG and questionnaires.
11133187|NCT03843749|Experimental|HER2-positive Metastatic Colorectal Cancar|
11133188|NCT03843736|No Intervention|Health control group|Participants are healthy women and there are no interventions.
11133189|NCT03843736|Experimental|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
11133190|NCT03843736|Experimental|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
11133191|NCT03843736|Experimental|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
11133192|NCT03843710|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11133193|NCT03843710|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11133194|NCT03843710|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11133195|NCT03843710|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11133196|NCT03843697|Experimental|Patients with IBD who develop resistance to anti TNF|Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs
11133197|NCT03843684|Experimental|Knee osteoarthritis patients|
11133198|NCT03843671|Experimental|Group 1|Hyperbaric oxygen Hyperbaric chamber
11133199|NCT03843671|Sham Comparator|Group 2|Sham for hyperbaric oxygen Hyperbaric chamber
11133200|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
11133201|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
11133202|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
11133203|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
11133204|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
11133205|NCT03843645|Active Comparator|general anesthesia group|patients allocated to the general anesthesia group will be subjected to general anesthesia with sevoflurane (inhalational agent) used for maintenance
11133206|NCT03843645|Active Comparator|regional anesthesia group|patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with ropivacaine and fentanyl
11133207|NCT03843632|Experimental|VARIVAX™|All participants will receive one dose subcutaneous (sc) VARIVAX™ on Day 1. Participants 13 years and older will also receive a second dose sc VARIVAX™ on Day 43.
11133208|NCT03843619||Non-E-referral|Patients who are referred in the traditional manner between two separate organizations.
11133209|NCT03843619||E-referral|Patients who are referred in an automated manner between two separate organizations.
11133210|NCT03843606|Experimental|diet 1|60% fat, 15% protein, 25% carbohydrates
11133211|NCT03843606|Experimental|diet 2|70% fat, 15% protein, 15% carbohydrates
11133212|NCT03843606|Experimental|diet 3|80% fat, 15% protein, 5% carbohydrates
11133213|NCT03843593||Melanoma patients|This is a pilot prospective study to identify the factors patients consider in deciding whether or not to undergo adjuvant therapy. Patients are eligible regardless of whether they decide to accept adjuvant therapy. If the researcher plans to treat the participant with pembrolizumab instead of nivolumab, it should be known that although the video discusses nivolumab, the risks and benefits are the same.
11133214|NCT03843580|No Intervention|Standard Allocation|apnea without oxygenation like usual traitement
11133215|NCT03843580|Experimental|oxygenation optiflow|optiflow oxygenation during apnea
11133216|NCT03843567|Placebo Comparator|Didactic Training|Training will be conducted in a classroom for those participants randomised to receive didactic training, with training provided via a PowerPoint (Microsoft Inc., Redmond, Washington, USA) presentation by an expert endoscopist. An endoscopist with extensive experience in optical characterisation using virtual chromoendoscopy reviewed all teaching material.
11133217|NCT03843567|Active Comparator|Computer-based self-training|Participants randomised to the computer-based self-learning group will be given the same PowerPoint presentation as the didactic group and completed the training in a separate room. Participants completed training without feedback interaction.
11133218|NCT03843554|Placebo Comparator|Standard of Care Oral Hygiene|Standard of Care Oral Hygiene group (SOC-OH): Subjects assigned to SOC-OH will attend weekly oral care visits where they will have their teeth brushed with a soft bristled toothbrush by the interventionist. No treatment to the oral mucosa will be provided to this group as part of the intervention. Subjects will receive oral care instructions and will be asked to follow SOC oral hygiene instructions at home.
11133220|NCT03843541|Experimental|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
11133221|NCT03843541|Active Comparator|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
11133223|NCT03843528|Experimental|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.
~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
11133224|NCT03843515|Experimental|Neoadjuvant nivolumab|All subject will receive 400mg flat dose nivolumab in the neoadjuvant setting
11133225|NCT03843502|Experimental|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
11133226|NCT03843489|Experimental|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
11133227|NCT03843489|Sham Comparator|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
11133228|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
11133229|NCT03843463|Experimental|Naming Treatment + Escitalopram|10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)
11133230|NCT03843463|Placebo Comparator|Naming Treatment + Placebo|10 mg placebo daily for three months
11133231|NCT03843437|Experimental|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
11133232|NCT03843437|Placebo Comparator|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
11133233|NCT03843424|Active Comparator|Enhanced Standard of Care (eSOC)|This group will receive the eSOC program. A minimum of 6 visits to the primary care provider (PCP) and includes assessment of weight status, patient/family motivation and readiness to change, promotion of healthy eating and activity habits, and use of health behavior change strategies.
11133234|NCT03843424|Active Comparator|Family-Based Behavioral Treatment (FBT + eSOC)|This group will receive eSOC plus the FBT program. Family-based behavioral treatment (FBT), an effective treatment that targets both child and parents meeting regularly with a health coach for healthy eating, activity, positive parenting strategies, and managing environmental cues.
11133235|NCT03843398|Experimental|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
11133236|NCT03843398|Active Comparator|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
11133237|NCT03843385|Experimental|faecal microbiota filtrate|Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
11133238|NCT03843385|Active Comparator|faecal microbiota|Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
11133239|NCT03843385|Sham Comparator|Placebo|Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
11133240|NCT03843372|Experimental|First night TNHF group|The first night will receive transnasal high flow (TNHF) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
11133241|NCT03843372|Active Comparator|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept transnasal high flow therapy.
11133242|NCT03843359|Experimental|Part 1A: GSK3745417 Monotherapy, Dose-escalation Cohort|Subjects will receive GSK3745417 IV at every one week intervals (Q1W). Escalating doses of GSK3745417 will be evaluated using NCRM approach.
11133243|NCT03843359|Experimental|Part 1B: GSK3745417 Monotherapy Dose Expansion Cohort|Subjects will be administered the recommended Phase 2 dose of GSK3745417 IV Q1W established in Part 1A of the study.
11133244|NCT03843359|Experimental|Part 2A: GSK3745417 + pembrolizumab, Dose escalation Cohort|Subjects will receive GSK3745417 IV Q1W for 2 weeks followed by GSK3745417 along with pembrolizumab 200 mg IV once every 3 weeks (Q3W). Escalating doses of GSK3745417 in combination with 200 mg pembrolizumab will be evaluated.
11133245|NCT03843359|Experimental|Part 2B: GSK3745417 combination Expansion Cohort|Subjects will receive GSK3745417 IV Q1W for 2 weeks then once every 3 week (Q3W) in combination with pembrolizumab 200 mg IV Q3W.
11133246|NCT03843346||Cohort 1: Postoperative group|"Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.
~Tumours of any size will be eligible
~Between 1 and 3 lymph nodes involved by tumour as assessed by Consultant Pathologist
~Micro metastases (<=0.2mm) will be eligibile
~Isolated tumour cells only (node negative i+/i-) are excluded"
11133247|NCT03843346||Cohort 2: Preoperative group|"Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.
~Min tumour size 2.1mm (T2)
~Histological proof of involvement of at 1 lymph node, including micrometastases (<=0.2mm)"
11133248|NCT03843333|Experimental|CHW Intervention|CHWs will deliver three intervention components (Tai Ji Quan: Moving for Better Balance, Behavioral Activation, and Resource Navigation) to all participants at intervention sites over a 6-month period.
11133249|NCT03843333|Active Comparator|Enhanced Usual Care|Comparison participants will receive a guide on community resources for older adults, and assistance from the research team in making initial connections to resources if desired.
11133250|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.
~Patients will be enrolled in this group only if the device is one of the following:
~INSPIRIS RESILIA;
~EDWARDS INTUITY;
~Carpentier-Edwards PERIMOUNT Magna-Ease."
11133251|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.
~Patients will be enrolled in this group only if the device is one of the following:
~SAPIEN 3;
~SAPIEN XT."
11133252|NCT03843307|Experimental|Electrical stimulation|
11133301|NCT03842930|Other|MVP® Vascular Plug|Embolization using MVP®-Plug (Medtronic Inc., Minneapolis, MI, USA).
11133302|NCT03842917||Patient starting bevacizumab treatment for cancer|Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
11133253|NCT03843294|Experimental|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
11133254|NCT03843281|Experimental|Paracetamol|Paracetamol 1 g (100 mL) IV + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
11133255|NCT03843281|Placebo Comparator|Placebo|Placebo (NaCl 0.9% 100 mL IV) + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
11133256|NCT03843268|Active Comparator|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
11133257|NCT03843268|Placebo Comparator|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
11133258|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
11133259|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
11133260|NCT03843242|Experimental|Pacemaker with Fixed long AV delay|"Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible.
~The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months.
~Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As ~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap ~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec"
11133261|NCT03843242|Experimental|Pacemaker with VpS® algorithm on|Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.
11133262|NCT03843242|Experimental|Pacemaker with IRSplus algorithm on|IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.
11133263|NCT03843229|Experimental|treatment group|The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
11133264|NCT03843229|Other|control group|The control group only receives Transarterial Chemoembolization (TACE).
11133265|NCT03843203|Sham Comparator|s-tDCS|- Intervention: 'Transcranial Direct Current Stimulation - tDCS The patients will receive tDCS sham treatment. The patients will receive sham tDCS treatment over primary motor cortex. According to 10-20 EEG system, anode will be placed at left C3 and cathode at o contralateral F3. In sham stimulation the device only release flow current, in the first 30 s of session and in the remaining 30s in the end of the session, during 20 minutes.
11133266|NCT03843203|Active Comparator|M1 a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS
~The patients will receive tDCS active treatment over primary motor cortex.
~According to 10-20 EEG system, anode will be placed at left C3 and cathode at contralateral supraorbital Fp2.
~Active stimulation uses a 2 milliamperes current during 20 minutes."
11133267|NCT03843203|Active Comparator|DLPFC a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS
~The patients will receive tDCS active treatment over dorsolateral prefrontal cortex.
~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.
~Active stimulation uses a 2 milliamperes current during 20 minutes."
11133268|NCT03843190|Experimental|Take Off Pounds Sensibly (TOPS)|This group will receive TOPS intervention at the start of the study.
11133269|NCT03843190|Other|Waitlist control|This group will be the control group for the initial year of the study. Then at the completion of the study they will receive the TOPS intervention.
11133270|NCT03843177||Ingrown toenails|
11133271|NCT03843177||Control|
11133272|NCT03843151|Experimental|All subjects: Reference followed by Test treatments|Reference - BI 1358894 alone. Test - BI 1358894 + Itraconazole
11133273|NCT03843125|Experimental|Baricitinib High Dose|Baricitinib administered orally.
11133274|NCT03843125|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
11133275|NCT03843112|Active Comparator|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
11133276|NCT03843112|Placebo Comparator|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
11133277|NCT03843099|Active Comparator|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
11133278|NCT03843099|Experimental|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
11133279|NCT03843086|Active Comparator|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
11133280|NCT03843086|Active Comparator|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
11133281|NCT03843073|Experimental|Connected Catheter Users|
11133282|NCT03843060|Experimental|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
11133283|NCT03843060|Experimental|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
11133284|NCT03843047|Other|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
11133285|NCT03843047|Other|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
11133286|NCT03843034||Study group|Infertile women with autoimmune disease
11133287|NCT03843034||Control group|Women from couples with severe male infertility
11133288|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
11133289|NCT03843008|Experimental|Melatonin Group|Participants will receive 3mg of melatonin at 18:00 (+/- one hour) each evening up to seven days or for the duration of his or her hospital stay.
11133290|NCT03843008|No Intervention|No Melatonin Group|Participants will receive no melatonin for the length of their hospital stay.
11133291|NCT03842995|Placebo Comparator|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
11133292|NCT03842995|Experimental|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
11133293|NCT03842982|Experimental|Arm A (PDS or IDS + HIPEC)|"Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy)
~Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).
~Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care."
11133294|NCT03842982|No Intervention|Arm B (PDS or IDS)|"Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC)
~Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).
~Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care."
11133295|NCT03842969|Experimental|RO7234292 (RG6042) Q8W|Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.
11133296|NCT03842969|Experimental|RO7234292 (RG6042) Q16W|Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
11133297|NCT03842956|Active Comparator|Primary wound healing|Primary woundclosure in Allgöwer suture technique
11133298|NCT03842956|No Intervention|Secondary wound healing|no closure, open wound healing
11133299|NCT03842943|Experimental|Combination T-VEC/Pembrolizumab|"Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab
~T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.
~Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection."
11133300|NCT03842930|Other|Platinum-fibered Microcoils (FPC)|Embolization using platinum fibred Coils (Cook Incorporated, Bloomington, IN, USA)
11133303|NCT03842904|Experimental|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
11133304|NCT03842904|Active Comparator|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
11133305|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
11133306|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
11133307|NCT03842839|Experimental|COPD in Grade A|Patient with Grade A COPD (according to GOLD 2019), will start to use Tiotropium once daily.
11133308|NCT03842839|Active Comparator|COPD in Grade C|Patient with Grade C COPD (according to GOLD 2019), will start to use Olodaterol + Tiotropium once daily.
11133309|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
11133310|NCT03842800|Other|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
11133311|NCT03842800|Other|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
11133312|NCT03842800|Other|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
11133313|NCT03842800|Experimental|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
11133314|NCT03842787||SLE patients with lupus Nephritis|"14 SLE patients with lupus Nephritis
~Biological analysis and biopsy were (routinely) performed
~Ethics The protocol will be submitted to a randomly chosen Institutional Review Board (Comité de Protection des Personnes), in compliance to French regulation.
~Investigators will include patients followed for routine care. Patients will be informed that samples (serum and kidney biopsy) that are performed for routine patient care will subsequently be used for research purposes, with no additional blood draw/biopsy. They will sign informed consent."
11133315|NCT03842774|Experimental|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
11133316|NCT03842774|Placebo Comparator|Control group|taken 3 tablets of placebo once a day for 12 weeks
11133317|NCT03842761|Experimental|Dose group 1|Low Dose
11133318|NCT03842761|Experimental|Dose group 2|Medium Dose
11133319|NCT03842761|Experimental|Dose group 3|High Dose
11133320|NCT03842761|Experimental|Dose Group 4|Dose for healthy volunteers dependent on results from prior dose groups with patients
11133321|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
11133322|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
11133323|NCT03842735|Experimental|exercise and rehabilitation counselling|Subjects enrolled in exercise group make physical exercises and receive rehabilitative counselling indications
11133324|NCT03842735|Other|rehabilitation counselling|Subjects enrolled in exercise group only receive rehabilitative counseling indications.
11133325|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
11133326|NCT03842709|Placebo Comparator|Standard Treatment + Placebo|Patients reporting sub-optimal results of pain therapy, assigned to placebo in addition to routine care.
11133327|NCT03842709|Experimental|Standard Treatment + Pramipexole|Patients reporting sub-optimal results of pain therapy, assigned to receive pramipexole in addition to routine care.
11133328|NCT03842696|Experimental|Vorinostat|
11133329|NCT03842670|Active Comparator|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
11133330|NCT03842670|Active Comparator|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
11133331|NCT03842657|Other|calcium-free citrate-containing dialysate|Dialysis session will be performed with a non-heparin grafted membrane, a dialysate without calcium (0 mmol/L) and citrate 0.8 mmol/L, a reinjection of a calcium solution (300 mM) according to the ionic dialysance, and no heparin addition
11133332|NCT03842657|Other|heparin-grafted membrane|dialysis session will be performed with a heparin-grafted membrane, a dialysate with calcium (1.65 mmol/L) and citrate 0.8 mmol/L, and no heparin addition
11133335|NCT03842631||Superficial Group|Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
11133336|NCT03842631||Deep Group|Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
11133337|NCT03842605|Experimental|Strength training|
11133338|NCT03842579|Experimental|Exercise and Protein (EXEPROT)|Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
11133339|NCT03842579|Active Comparator|Protein-only (PROT)|"Participants in PROT-group receive the nutritional intervention: The high-protein diet.
~The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.
~Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake."
11133340|NCT03842579|Active Comparator|Recommendations (REC)|"Participants in the REC-Group receive the comparative intervention: Recommendations.
~The official national dietary recommendations for adults >65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.
~During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition)."
11133341|NCT03842566||20-29 Years Old|
11133342|NCT03842566||30-39 Years Old|
11133343|NCT03842566||40-49 Years Old|
11133344|NCT03842566||50-59 Years Old|
11133345|NCT03842566||60-69 Years Old|
11133346|NCT03842566||70-79 Years Old|
11133347|NCT03842553||Police officers|Police officers from the cantonal police forces in Bern, Switzerland
11133348|NCT03842553||Firefighters|Firefighters from the professional fire service of the Canton Bern, Switzerland
11133349|NCT03842553||Ambulance personnel|Ambulance personnel of the Canton Bern, Switzerland
11133350|NCT03842553||Emergency nurses|Emergency nurses of the Emergency Unit of the University Hospital of Bern, Switzerland
11133351|NCT03842553||Psychiatric nurses|Psychiatric nurses of the University Hospital of Psychiatry, University of Bern, Switzerland
11133352|NCT03842540|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
11133353|NCT03842540|Active Comparator|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
11133354|NCT03842527|Active Comparator|Standard Fasting Group|Ultrasound scan of gastric antrum 1 hour prior to procedure. Patients assigned to this group will follow standard fasting procedures of no eating or drinking 8 hours prior to C-section.
11133355|NCT03842527|Experimental|Carbohydrate Loading Group|"Ultrasound scan of gastric antrum 1 hour prior to procedure.
~Patients assigned to this group must stop eating 8 hours prior to their scheduled C-section time.
~The night before their C-section they must drink 800mL of 100% apple juice (not from concentrate) OR 800mL of cranberry juice cocktail, not both
~The day of their C-section, starting 3 hours before surgery and to be finished 2 hours before surgery time, patients must drink 400mL of 100% apple juice OR 400mL of cranberry juice cocktail, not both
~Please note:
~The apple juice must be 100% juice, not from concentrate
~The cranberry juice cocktail must not be plain cranberry juice"
11133356|NCT03842514|Experimental|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)
~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate
~Phase 3: No intervention - 7 days washout with usual diet
~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
11133357|NCT03842514|Experimental|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)
~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate
~Phase 3: No intervention - 7 days washout with usual diet
~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
11133358|NCT03842501|Placebo Comparator|Placebo|
11133359|NCT03842501|Experimental|Release supplement|
11133360|NCT03842488|Experimental|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
11133361|NCT03842488|Active Comparator|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
11133362|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
11133363|NCT03842475||Control|Healthy volunteers with normal body mass index
11133364|NCT03842462|Active Comparator|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
11133365|NCT03842462|Active Comparator|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
11133366|NCT03842462|Experimental|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:
~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
11133367|NCT03842449|Experimental|Smoking pregnant woman withCO measurement|
11133368|NCT03842449|Other|Smoking pregnant woman without CO measurement|
11133369|NCT03842449|Other|Non Smoking pregnant woman|
11133370|NCT03842436|Experimental|Digital Pills|Digital Pills containing Truvada ingested once daily as PrEP
11133371|NCT03842423||Study Group|All patients under the age of 18 who were treated for upper extremity injuries between 2002 and 2018 and receiving brachial plexus anaesthesia.
11133372|NCT03842410|Other|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
11133373|NCT03842397|Experimental|Implanted Patients|Implantation of Kephalios Device 1
11133374|NCT03842384|Experimental|distress tolerance training|computer- and text- message delivered intervention that enhances motivation through personalized feedback and increases tolerance of distress through skills training.
11133375|NCT03842384|Other|treatment as usual|standard outpatient buprenorphine treatment
11133376|NCT03842371||Sepsis with type 2 diabetes|Sepsis patients with type 2 diabetes
11133377|NCT03842371||Sepsis without type 2 diabetes|Sepsis patients without type 2 diabetes
11133378|NCT03842371||Volunteers|Healthy volunteers
11133379|NCT03842358|Experimental|Phase I - Training Set|"20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data
~A hand-held hybrid probe will be used for the scans"
11133380|NCT03842358|Experimental|Phase 2: Prospective Trial|"US-DOT (US/NIR) Imaging Exam
~Breast biopsy or FNA performed (standard of care)
~A hand-held hybrid probe will be used for the scans"
11133381|NCT03842345||Psychiatric patients|Major depression, Bi-polar, schizophrenia, ADHD, OCD, PTSD
11133382|NCT03842345||healthy controls|young healthy controls to serve as norm.
11133383|NCT03842332|Experimental|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
11133384|NCT03842332|No Intervention|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
11133385|NCT03842319|Experimental|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
11133386|NCT03842319|Experimental|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
11133387|NCT03842306||Study Cohort|Patients undergoing rapid sequence intubation in the emergency department for which end tidal oxygen was monitored.
11133388|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
11133389|NCT03842267|Active Comparator|Gemigliptin 50mg|
11133390|NCT03842267|Placebo Comparator|Gemigliptin Placebo|
11133391|NCT03842254|Experimental|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
11133392|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
11133393|NCT03842241||Without foot orthoses|Other: without foot orthoses
11133394|NCT03842228|Experimental|Treatment (copanlisib hydrochloride, olaparib, and durvalumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 and olaparib PO BID. Beginning cycle 2, patients receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days for 24 months in the absence of disease progression or unacceptable toxicity.
11133396|NCT03842202|Experimental|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
11133397|NCT03842202|Placebo Comparator|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
11133398|NCT03842189|Experimental|M281|
11133399|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
11133400|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
11133401|NCT03842163||Patients with LVH of unknown etiology|
11133402|NCT03842150||derivation cohort|
11133403|NCT03842150||validation cohort|
11133404|NCT03842137|Active Comparator|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
11133405|NCT03842137|Sham Comparator|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
11133406|NCT03842124|Active Comparator|Intervention|Use of bidirectional rail (superior and inferior approaches) and force sensing using a force gauge to optimize Force application to less than 8 lbs during the extraction procedure.
11133407|NCT03842124|No Intervention|Control|Conventional lead extraction procedures using a superior approach is performed by experienced operators. Although force information is available the operators are blinded to the information. Inferior rail is left to the discretion of the operator.
11133408|NCT03842111||Region XI Head Start children and families|children (1049) parents (1049) classrooms/teachers (73) program directors (21) center directors (36)
11133409|NCT03842098||Musculoskeletal Disorders patients|Enroll the post operative musculoskeletal disorders patients and follow up their clinic visits and treatment regimen to analyze their utility in healthcare
11133410|NCT03842085|Experimental|MBS301|Drug: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
11133411|NCT03842072|No Intervention|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
11133412|NCT03842072|Active Comparator|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
11133413|NCT03842059|Experimental|Computer-aided detection|
11133414|NCT03842059|Placebo Comparator|Standard colonoscopy|
11133415|NCT03842046|Active Comparator|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
11133416|NCT03842046|Active Comparator|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
11133417|NCT03842033|Other|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
11133418|NCT03842033|Other|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
11133419|NCT03842033|Other|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
11133420|NCT03842020|Experimental|Amiodarone dosage|Blood pharmacokinetics samples
11133421|NCT03842007|Active Comparator|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
11133422|NCT03842007|Active Comparator|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
11133423|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
11133424|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
11133425|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
11133426|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
11133427|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
11133428|NCT03841968|Active Comparator|Dynamic needle tip positioning|Dynamic needle tip positioning
11133429|NCT03841968|Active Comparator|Conventional long-axis|Conventional long-axis
11133430|NCT03841955|Experimental|Experimental group|Peripheral implantation of central venous catheters and accessories with high pressure tolerance
11133431|NCT03841955|Experimental|Control group|Peripheral intubation of central venous catheter
11133432|NCT03841942|Other|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
11133464|NCT03841773|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
11133433|NCT03841942|Other|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
11133434|NCT03841929|Experimental|Study Arm|ELGANs recruited to the study group in addition to standard of care will have continuous cerebral NIRS monitoring for the initial 72 hours and TNE studies at definitive time frames and a hemodynamic report will be provided to the clinical team using the results of the multimodal monitoring and clinical data. The report will be a description of the hemodynamic status without any suggestions for management.
11133435|NCT03841929|No Intervention|Standard Arm|ELGANs recruited into Standard arm will have the standard monitoring including cardiorespiratory monitoring. The invasive blood pressure monitoring, NIRS and TNE monitoring as per the clinical team's discretion - consistent with the current standard of care. No hemodynamic report will be provided routinely.
11133436|NCT03841903||relapsing-remitting MS undergoing spinal cord MRI|
11133437|NCT03841903||secondary progressive MS undergoing spinal cord MRI|
11133438|NCT03841903||primary progressive MS undergoing spinal cord MRI|
11133439|NCT03841903||healthy control (HC) undergoing spinal cord MRI|
11133440|NCT03841890|Experimental|Intubation with the Clarus Video System as a video stylet|
11133441|NCT03841890|Experimental|Intubation with the Clarus Video System as a lightwand|
11133442|NCT03841890|Active Comparator|Intubation with direct laryngoscope|
11133443|NCT03841877|Experimental|AH Plus-Cervical|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned at the cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
11133444|NCT03841877|Experimental|MTA Fillapex-Cervical|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned at the cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
11133445|NCT03841877|Experimental|AH Plus-2mm|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned 2 mm below cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
11133446|NCT03841877|Experimental|MTA Fillapex-2mm|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned 2 mm below cervical level.
~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
11133447|NCT03841864|Other|Grade 1 Vein Visualization|Visual vein classification grade described as excellent Visualization. Objective vein criteria to be included in this group are vein raised above skin and wider than 1mm. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
11133448|NCT03841864|Other|Grade 2A Vein Visualization|Veins that don't fit grade 1 or 2b classification (see respective group descriptions). This groups visual vein classification is described as fair visualization. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
11133449|NCT03841864|Other|Grade 2b Vein Visualization|Only faint vein shadow appearance described as poor visualization. Initial IV placement attempt will be ultrasound guided
11133450|NCT03841864|Other|Grade 3 Vein Visualization|No vein visualization. Initial IV placement attempt will be ultrasound guided
11133451|NCT03841851|No Intervention|temporization without soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.
~Atraumatic extraction of badley decayed teeth in the aesthetic area
~traditional drilling for immediate implant placement .
~immediate temporization ."
11133452|NCT03841851|Active Comparator|temporization with soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.
~Atraumatic extraction of badley decayed teeth in the aesthetic area
~traditional drilling for immediate implant placement .
~immediate temporization .
~subepithelial connective tissue graft from the palate ."
11133453|NCT03841838|Experimental|Energy drink|Two 12 oz bottles of energy drink
11133454|NCT03841838|Placebo Comparator|Placebo|Two 12 oz bottles of placebo drink
11133455|NCT03841825|No Intervention|Control|No messages or oral hygiene instructions
11133456|NCT03841825|Experimental|Text message reminders|Standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays
11133457|NCT03841825|Active Comparator|In-person oral hygiene instructions|Oral hygiene instructions and motivation during visit
11133458|NCT03841825|Experimental|Text messages and in-person instructions|standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays and oral hygiene instructions and motivation during visit
11133459|NCT03841812|Experimental|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
11133460|NCT03841812|Experimental|Propofol & Sevoflurane|2mg/kg/h Propofol & 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
11133461|NCT03841786|Placebo Comparator|Control diet|Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.
11133462|NCT03841786|Experimental|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.
11133463|NCT03841773|Experimental|TNX-102 SL Tablet 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
11133466|NCT03841747|Experimental|Pembrolizumab + Paclitaxel|200 mg Pembrolizumab intravenously (IV) every 3 weeks (Q3W) plus 80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
11133467|NCT03841747|Active Comparator|Paclitaxel|80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
11133468|NCT03841734|Experimental|Treatment bosentan|
11133469|NCT03841721|Experimental|linezolid 300 mg|
11133470|NCT03841708|Active Comparator|Pleth Variability Index|In the experimental group patients will be hemodynamically resuscitated in the early phases after ROSC based on the pleth variability index on top of standard non invasive monitoring
11133471|NCT03841708|Placebo Comparator|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG.
11133472|NCT03841695|Experimental|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
11133473|NCT03841695|Active Comparator|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
11133474|NCT03841682|Experimental|I-CARE2 Intervention|"Participants should continue with their usual medical care. Additionally, participant receive the I-CARE2 intervention.
~Trained health coaches deliver the I-CARE2 intervention over 6 months. The intervention provides 9 individual counseling sessions on problem solving treatment and behavior counselling to manage mood and lose weight (4 weekly, 2 biweekly, and then 3 monthly; 1 hour each), 11 home-viewed GLB videos (weekly; 20-30 minutes each), and self-study and self-monitoring activities. Throughout the intervention, participants are asked to wear and sync a study-provided Fitbit pedometer, and to log their weight, minutes of physical activity, and dietary intake using the Fitbit website or mobile app."
11133475|NCT03841682|No Intervention|Usual Care|Participants should continue with their Usual Medical Care. Additionally, participants receive information on wellness and behavioral health promotion at UI Health and a Fitbit pedometer.
11133476|NCT03841669|Experimental|Aerobic Exercise Group|This is the experimental group. Supervised exercise will be held 2 times a week for 60 minutes and 1 time a week for 30 minutes at home.
11133477|NCT03841669|Active Comparator|Physical Activity & Health Information Group|This is the control group. Participants will engage in daily life monitoring every 6 weeks.
11133478|NCT03841643|Active Comparator|C group|In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department.
11133479|NCT03841643|Experimental|P group|In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany).
11133480|NCT03841630|Experimental|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
11133481|NCT03841630|Placebo Comparator|Placebo|Matching placebo administered as an injection under the skin in healthy participants
11133482|NCT03841617|Active Comparator|124I PET/CT scan after rhTSH|124I PET/CT scan after preparation with human recombinant TSH
11133483|NCT03841617|Active Comparator|124I PET/CT scan after thyroid hormone withdrawal|124I PET/CT scan after preparation with thyroid hormone withdrawal
11133484|NCT03841604|Experimental|Experimental|Safinamide methanesulfonate film coated tablets once daily
11133485|NCT03841604|Placebo Comparator|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily
11133486|NCT03841591|Active Comparator|Insulin Group|This includes women with GDM allocated to receive insulin treatment. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
11133487|NCT03841591|Active Comparator|Metformin Group|This includes women with GDM allocated to receive metformin treatment. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
11133488|NCT03841578|Experimental|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
11133489|NCT03841565|Experimental|Treatment (pomalidomide, daratumumab, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable toxicity.
11133490|NCT03841552|Experimental|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
11133491|NCT03841552|Active Comparator|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
11133492|NCT03841539|Experimental|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
11133493|NCT03841539|Active Comparator|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
11133494|NCT03841526|Experimental|Glucagon RTU, 50% insulin pump reduction|
11133495|NCT03841526|Placebo Comparator|Placebo, 50% insulin pump reduction|
11133496|NCT03841526|Experimental|Glucagon RTU, no basal rate reduction|
11133580|NCT03840915|Experimental|Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824|
11133497|NCT03841513|No Intervention|Control|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
11133498|NCT03841513|Active Comparator|Laparoscopic Burch Colposuspension|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
11133499|NCT03841500|Active Comparator|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).
~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
11133500|NCT03841500|Active Comparator|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).
~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
11133501|NCT03841487||Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI).
11133502|NCT03841487||PCI alone|In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
11133503|NCT03841474|Experimental|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
11133504|NCT03841474|No Intervention|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
11133505|NCT03841474|Experimental|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
11133506|NCT03841461||Academicians|The academicians working in any program of any higher education institution
11133507|NCT03841448|Experimental|Cemdisiran|Participants will receive cemdisiran during the Treatment and optional Open-Label Extension (OLE) Periods in combination with standard of care.
11133508|NCT03841448|Placebo Comparator|Placebo|Participants will receive matching placebo during the Treatment Period in combination with standard of care. During the optional OLE Period participants will receive cemdisiran in combination with standard of care.
11133509|NCT03841435|Experimental|Hypofractionated Radiotherapy|15 Gy given in 3 fractions over 2 weeks
11133510|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
11133511|NCT03841396|Active Comparator|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
11133512|NCT03841396|Active Comparator|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
11133513|NCT03841383||Healthy controls|
11133514|NCT03841383||Hypertensive patients|
11133515|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.
~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.
~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
11133516|NCT03841357|Experimental|Abatacept and Usual Care|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
11133517|NCT03841357|Active Comparator|Usual Care|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
11133518|NCT03841344|Active Comparator|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
11133519|NCT03841344|Active Comparator|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
~Patients diagnosed with PAH initiating PAH therapy for the first time"
11133520|NCT03841344|Active Comparator|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
11133521|NCT03841344|Active Comparator|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
~Patients with PAH who are NOT undergoing changes in their treatment regime"
11133522|NCT03841331|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
11133523|NCT03841331|Placebo Comparator|5 mg Placebo Tablets|Placebo Tablets
11133524|NCT03841318|Experimental|Sjogren's Syndrome|
11133525|NCT03841305|Active Comparator|portal vein embolization|Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
11133526|NCT03841305|Experimental|liver venous deprivation|Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.
11133527|NCT03841292|Active Comparator|Active tDCS+Varenicline|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
11133528|NCT03841292|Sham Comparator|Sham tDCS+Varenicline|Sham tDCS (Nuraleve, Canada)(30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
11133529|NCT03841253|Experimental|Observation Phase|A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
11133581|NCT03840915|Experimental|Cohort D: Docetaxel + M7824|
11133530|NCT03841253|Experimental|Treatment Phase|If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
11133531|NCT03841227|Active Comparator|Active-tDCS|10 patients will receive Active-tDCS intervention (2mA, 20 min) at home.
11133532|NCT03841227|Sham Comparator|Sham-tDCS|10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.
11133533|NCT03841201|Experimental|Treatment|"Lenvatinib peroral qd (8 mg for patients with body weight <60kg and 12 mg for patients with body weight ≥ 60kg)
~Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
11133534|NCT03841188|Other|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
11133535|NCT03841162||Patients with suspected sepsis|Patients for whom blood cultures are drawn at the Emergency Department or the department of Infectious Diseases/Nephrology
11133536|NCT03841149||VolUS3D patients|Patients with renal tumour
11133537|NCT03841136|Experimental|anlotinib combined with EP|anlotinib combined with etoposide and platinum
11133538|NCT03841123|Experimental|Intervention|At the maternity wards mothers will receive dietary counseling and leaflets as a reminder to prevent the early introduction of added sugar and ultra-processed foods.
11133539|NCT03841123|No Intervention|Control|At the maternity wards mothers assigned to control groups will have all the health assistance related to the maternity routine without any interference from the study protocol.
11133540|NCT03841110|Experimental|FT500 Monotherapy|FT500 administered once weekly for 3 weeks as a monotherapy
11133541|NCT03841110|Experimental|FT500 in Combination with Immune Checkpoint Inhibitor|FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
11133542|NCT03841110|Experimental|FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor|FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
11133543|NCT03841097|Active Comparator|Extended Release Tacrolimus Tablets|Dosed once daily in the morning and started at a dose of 0.14 mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
11133544|NCT03841097|Active Comparator|Immediate Release Tacrolimus Capsules|Dosed twice daily 12 hours apart and started at a dose of 0.1mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
11133545|NCT03841084|Active Comparator|Conservative Oxygen Management Strategy|Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
11133546|NCT03841084|Active Comparator|Liberal Oxygen Management Strategy|Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
11133547|NCT03841071||ROM/CFS intervention|The ROM/CFS group (N>100), consists of patients who have undergone urostomy, colostomy, or ileostomy operations, and who are included in the routine follow-up program of the outpatient ostomy clinic at the Department of Surgery, Førde Central Hospital from April 2018 to June 2021.
11133548|NCT03841058|Active Comparator|Abaloparatide|Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
11133549|NCT03841058|Placebo Comparator|Placebo|Placebo administered subcutaneously with a pen once daily for 6 months
11133550|NCT03841045||ulcerative colitis patient|people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
11133551|NCT03841045||CD patient|people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
11133552|NCT03841045||Health people|control group. no IBD patients can be included. patients with other diseases can be included.
11133553|NCT03841032|Experimental|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
11133554|NCT03841019|Experimental|magnetic seizure therapy|12 treatment sessions of MST, three times per week.
11133555|NCT03841019|Active Comparator|electroconvulsive therapy|12 treatment sessions of ECT, three times per week.
11133556|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
11133557|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
11133558|NCT03840993|Experimental|MT-2990|MT-2990, IV, over 16 weeks
11133559|NCT03840993|Placebo Comparator|Placebo|Placebo, IV, over 16 weeks
11133560|NCT03840967|Other|Niraparib|
11133561|NCT03840954|Experimental|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
11133562|NCT03840954|No Intervention|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
11133563|NCT03840941||Frail patients with COPD|No intervention
11133564|NCT03840941||Non-frail patients with COPD|No intervention
11133565|NCT03840928||Ankylosing Spondylitis|
11133566|NCT03840928||Fibromyalgia|
11133567|NCT03840928||Gout|
11133582|NCT03840902|Experimental|Arm 1: cCRT plus M7824 followed by M7824|Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with M7824 followed by M7824.
11133583|NCT03840902|Active Comparator|Arm 2: cCRT plus placebo followed by durvalumab|Participants will receive cCRT: Cisplatin/Etoposide or Carboplatin/Paclitaxel or Cisplatin/Pemetrexed concomitant with Intensity Modulated Radiation Therapy (IMRT) along with placebo matched to M7824 followed by durvalumab.
11133584|NCT03840889||Women with a severe late PPH|Women with a severe late PPH will be recruited prospectively after verification of the inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who will provide the patients information about the study and include them unless they object
11133585|NCT03840876|Experimental|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
11133586|NCT03840876|No Intervention|Group I|Patients were ventilated with a small size endotracheal tube.
11133587|NCT03840863|Experimental|Commercially-Available Energy drink|Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks
11133588|NCT03840850|Experimental|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
11133589|NCT03840850|No Intervention|Usual care only|Usual care including personalized lifestyle advice
11133590|NCT03840837|No Intervention|Arm 1: baseline only (cross-sectional)|At baseline, all participants will undergo instrumented gait/balance testing, using a wearable sensor (Dynaport MT), and cognitive testing, using a computerized cognitive test battery (NeuroTrax Mild Cognitive Impairment & Early Dementia Battery by MindStreams). In other words, all participants will be part of arm 1.
11133591|NCT03840837|Experimental|Arm 2: rivastigmine (longitudinal)|As study intervention, a subgroup of participants will then be treated with transdermal rivastigmine patch for 12 weeks, with dose increases every 4 weeks and titration up to 13.3 mg/24h, if tolerated. For the arm 2 subgroup of participants, the same assessment that was performed at baseline (quantitative gait testing and NeuroTrax computerized cognitive test battery) will be repeated after 12 weeks, with the patient on a stable dose of transdermal rivastigmine.
11133592|NCT03840824||Cancer Survivor|Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
11133593|NCT03840824||Similar aged healthy controls|Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
11133594|NCT03840824||Late Reproductive Age|Pre-menopausal, healthy women of late reproductive age
11133595|NCT03840811|Experimental|Group 1|Subjects (n = up to 8) will receive a bacterial inoculum containing only the isogenic mutant N. gonorrhoeae strain
11133596|NCT03840811|Experimental|Group 2|Subjects (n = up to 8) will receive a bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain.
11133597|NCT03840811|Experimental|Group 3|Subjects (n= up to 16) will receive a bacterial inoculum containing a mixture of equivalent numbers the isogenic mutant and WT strain
11133598|NCT03840798||Pretest/Baseline period|
11133599|NCT03840798||Posttest/go-live period|
11133600|NCT03840785|Experimental|interventional group A|2 tango session per week during 6 month (M0 to M6)
11133601|NCT03840785|Placebo Comparator|Control group B|2 tango session per week during 3 month (M3 to M6)
11133602|NCT03840772|Experimental|Eribulin|"Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.
~Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision."
11133603|NCT03840759|Experimental|usual care|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant and inpatient geriatric consultation team after a complete geriatric assessment (CGA). The CGA includes the assessment of depression, dementia, physical performance of Activity of Daily Living (ADL) and nutrition using Geriatric Depression Scale (GDC-15), Mini-Mental State Examination (MMSE), Barthel Index (BI), and Mini Nutritional Assessment-Short Form (MNA®-SF) respectively. Besides the geriatric physician, our multidisciplinary team included a social worker, nutritionist and physical therapist. In the control group, the participants only received routine hospital care and no geriatric physician was consulted.
11133604|NCT03840746|No Intervention|Habitual diet|participants remain on their habitual diet
11133605|NCT03840746|Experimental|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
11133606|NCT03840746|Experimental|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
11133607|NCT03840733||Participants from NCT01985568|All subjects who previously enrolled in the Parent Study's behavioral weight loss intervention (NCT01985568).
11133608|NCT03840707|Experimental|Experimental group|"LIFEwithIBD Programme is a manualized acceptance, mindfulness and compassionate-based group intervention for inflammatory bowel disease patients. It included 9 weekly group sessions, 1.30h hours each, run in small groups (ranging from 10 to 15 participants).
~Participants in this group also receive inflammatory bowel disease treatment as usually performed at the Coimbra University Hospital."
11133609|NCT03840707|No Intervention|Control group|Treatment as Usual (TAU) Standard personalized treatment of inflammatory bowel disease
11133610|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
11133611|NCT03840694|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
11133612|NCT03840681|Experimental|Ridge augmentation by collagen membrane|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~Flap will be done.
~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at defected area then covered at the defected area by a collagen membrane which will be stabilized by tacks.
~The site will then be copiously irrigated with saline in preparation for closure.
~The flap will then be closed using interrupted 4/0 resorbable sutures."
11133760|NCT03839641|Experimental|High Fat Meal Second|Arm 2 participants randomized to receive low fat meal first, and high fat meal second
11133613|NCT03840681|Active Comparator|augmentation by titanium reinforced PTFE|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~Flap will be done.
~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.
~The site will then be copiously irrigated with saline in preparation for closure.
~The flap will then be closed using interrupted 4/0 resorbable sutures."
11133614|NCT03840655||palmar hyperhidrosis|VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions.
11133615|NCT03840642|Active Comparator|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
11133616|NCT03840642|Experimental|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
11133617|NCT03840629||Hypotonic fluid maintenance|exclusive administration of 0.33% saline mixed with potassium and dextrose 5%
11133618|NCT03840629||Isotonic fluid maintenance|exclusive administration of 0.9% saline
11133619|NCT03840616|Experimental|VT-1161 150 mg capsule|
11133620|NCT03840616|Active Comparator|Fluconazole 150 mg|
11133621|NCT03840603|No Intervention|Control|Usual care of patients with suspected Low RespiratoryTract Infection at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.
11133622|NCT03840603|Experimental|Film Array RP2 Assay guided|In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected Low RespiratoryTract Infection for the Film Array RP2 Assay guided plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.
11133623|NCT03840590|Experimental|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
11133624|NCT03840590|Active Comparator|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
11133625|NCT03840577|Placebo Comparator|Clinical monitoring group|In the clinical monitoring group, the doses of sedative drugs will be regulated according to the patient's RASS. The RASS of the patient will be evaluated twice per nursing shift (every 4 hours). The BIS monitor will be placed on the patient, but blind to the nursing team, with the objective to measure the BIS values.
11133626|NCT03840577|Experimental|BIS group|"In the group Sedation guided by BIS, the sedation will be guided by the value of BIS. The BIS value of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The objective of BIS will be between 40 and 60.
~According to the BIS value of the patient at the time of the evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target BIS, with 20% modifications of the current dose at the time of evaluation."
11133627|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
11133628|NCT03840564||control group|the analyzes will be done at the central laboratory
11133629|NCT03840551|Other|Subjects|Subjects involved are required to do some specific motor tasks, commonly found in all main sports. Evaluated with inertial sensors (XSENS) and marker-based motion capture (BTS)
11133630|NCT03840538|Experimental|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
11133631|NCT03840538|Placebo Comparator|Placebo group|Placebo capsule taken twice daily for 5 weeks
11133632|NCT03840525|Experimental|Qigong Intervention|The qigong intervention consists of 1 hour/week qigong classes for 12 weeks at our community partner site. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
11133633|NCT03840525|Sham Comparator|Sham Qigong|This group will also have 1 hour/weekly classes that include movements that are similar to qigong but will not include the meditation or breathwork that will be included in the actual qigong intervention arm.
11133634|NCT03840525|No Intervention|Treatment-as-usual|This group will receive no classes.
11133635|NCT03840512|Experimental|Oral CBD 75 BID|
11133636|NCT03840512|Experimental|Oral CBD 150 BID|
11133637|NCT03840512|Experimental|Oral CBD 300 BID|
11133638|NCT03840499||Willing to participate in clinical study|
11133639|NCT03840499||Not-willing to participate in clinical study|
11133640|NCT03840486|Active Comparator|Non-rebreather mask (NRBM)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 LPM for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
11133668|NCT03840278|Experimental|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).
~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
11133641|NCT03840486|Active Comparator|Non-invasive ventilator mask (NIV)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-invasive ventilator mask (NIV) overlying the sensor. Participants will be randomized to the order of their treatment sequence as follows: NIV at 50% FiO2 for 3 minutes, NIV at 75% FiO2 for 3 minutes, NIV at 100% FiO2 for 3 minutes, the maximal reading at the end of this trial will be recorded. The study subjects will be allowed to rest until their EtO2 returns to their baseline, then they will be placed back on NIV at 100% FiO2, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
11133642|NCT03840473|Experimental|MET+ICT+Conventional intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by ICT (90-second hold-time) and MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
11133643|NCT03840473|Experimental|MET+Conventional Intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
11133644|NCT03840473|Active Comparator|Conventional Intervention|Received hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) only.
11133645|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
11133646|NCT03840447|Experimental|Chronic Disease Self-Management programme|
11133647|NCT03840434|Other|CCS group|Measurements by intramuscular punction and non invasive tool
11133648|NCT03840421|Experimental|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
11133649|NCT03840421|Active Comparator|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
11133650|NCT03840408|Experimental|Mitochondrial therapy with radiofrequency ablation|
11133651|NCT03840408|Active Comparator|Surgery|
11133652|NCT03840395|Active Comparator|Active PES|Patients randomized to receive active Pharyngeal Electrical Stimulation (PES) via a Phagenyx Catheter.
11133653|NCT03840395|Sham Comparator|Sham PES|Patients randomized to sham will not receive any Pharyngeal Electrical Stimulation (PES) but will still have the Phagenyx Catheter inserted.
11133654|NCT03840382|Experimental|Tele-PrEP Intervention|The telemedicine intervention will allow participants to discuss HIV prevention and PrEP with PrEP specialists at an academic medical center via videoconference from their local community based organization (CBO). During the intervention, participants will gain information related to HIV and PrEP, view a video to improve motivation for engagement in PrEP related care, and receive resources to address barriers to care.
11133655|NCT03840369|Experimental|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
11133656|NCT03840369|Experimental|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
11133657|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
11133658|NCT03840343|Experimental|Lower Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
11133659|NCT03840343|Experimental|Higher Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
11133660|NCT03840330|Experimental|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
11133661|NCT03840330|Experimental|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
11133662|NCT03840330|No Intervention|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
11133663|NCT03840317|Experimental|Senl_1904A CD19 CAR-T|Autologous CD19-targeting CAR T cells, dosage 3*10^5/kg, intravenous injection once
11133664|NCT03840317|Experimental|Senl_1904B CD19 CAR-T|Autologous CD19-targeting CAR T cells,dosage 3*10^5/kg, intravenous injection once
11133665|NCT03840304|Experimental|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
11133666|NCT03840304|No Intervention|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
11133667|NCT03840291|Experimental|Edoxaban treatment|"Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.
~Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi
~Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:
~Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)
~Low body weight ≤ 60 kg
~Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
11133757|NCT03839654|Experimental|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
11134740|NCT03832816|Experimental|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
11133669|NCT03840278|Experimental|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).
~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
11133670|NCT03840265|Other|Carotid endarterectomy|All patients in this study will undergo carotid endarterectomy procedure
11133671|NCT03840252|Active Comparator|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.
~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
11133672|NCT03840252|Active Comparator|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.
~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
11133673|NCT03840252|Active Comparator|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.
~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
11133674|NCT03840239|Experimental|TNT arm|"Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.
~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
11133675|NCT03840239|Active Comparator|CRT arm|"Drug: Neoadjuvant chemotherapy, Capecitabine, 5 weeks; adjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles.
~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
11133676|NCT03840226|Active Comparator|Magnesium|oral magnesium oxide tablets [Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel]
11133677|NCT03840226|Placebo Comparator|Placebo|Placebo tablets
11133678|NCT03840213||Patients undergoing chemotherapy treatment|Patients over 18 years of age, followed at the ICLN day hospital or hospitalized and undergoing chemotherapy treatment
11133679|NCT03840200|Experimental|Ipatasertib + Rucaparib|A Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer. There will be a 7-day run-in period with ipatasertib alone prior to Cycle 1, Day 1. After the completion of the ipatasertib run-in period, participants will begin Cycle 1, Day 1 of the ipatasertib and rucaparib combination treatment. Each cycle has 28 days. Participants will be split into 4 cohorts: Dose Level 1 group - 300 mg ipatasertib once daily (QD) + 400 mg rucaparib twice daily (BID), Dose Level 2a: 300 mg ipatasertib QD + 600 mg rucaparib BID, Dose Level 2b: 400 mg ipatasertib QD + 400 mg rucaparib BID, Dose Level 3: 400 mg ipatasertib QD + 600 mg rucaparib BID
11133680|NCT03840200|Experimental|Part 2: Ipatasertib + Rucaparib|A Dose-Expansion Phase (Part 2) - The recommended dose identified in Part 1 (highest dose level of ipatasertib and rucaparib with an acceptable safety profile and less than one-third of participants experience a dose limiting toxicity) will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
11133681|NCT03840174|Experimental|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2 and Month 6
11133682|NCT03840174|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2 and Month 6
11133683|NCT03840148|Experimental|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
11133684|NCT03840148|Active Comparator|Meropenem|Meropenem will be administered q8h IV over 30 minutes.
11133685|NCT03840135|Experimental|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
11133686|NCT03840135|Placebo Comparator|Placebo|Placebo, nasal and sublingual spray - 7 days.
11133687|NCT03840122|Experimental|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
11133688|NCT03840122|Active Comparator|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
11133689|NCT03840109||All Participants|All participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. The participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
11133690|NCT03840096|Experimental|Quadriceps NMES using Breg Flex|
11133691|NCT03840096|No Intervention|Control|
11133692|NCT03840083|Experimental|Sleep|Individuals will either nap (Exps 1, 4) or have overnight sleep (Exps 2, 3, 5, 6)
11133693|NCT03840083|No Intervention|Wake|Individuals will stay awake for the same amount of time as they slept in the sleep condition
11133694|NCT03840070|Experimental|Potenfill|
11133695|NCT03840057|Experimental|Azithromycin|Participants randomized to the azithromycin arm would receive 250mL of reconstituted solution containing 500mg of generic azithromycin to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic or renal impairment. No dose adjustment is made for geriatric population.
11133758|NCT03839654|No Intervention|non-continuous positive airway pressure|The non-CPAP treatment group received baseline medicine treatment without CPAP treatment.
11133759|NCT03839641|Experimental|High Fat Meal First|Arm 1 participants randomized to receive high fat meal first, and low fat meal second
11133696|NCT03840057|Experimental|Metoclopramide|Participants randomized to the metoclopramide arm would receive 2mL of solution containing 10mg of generic metoclopramide to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic impairment. A 50% dose reduction is made for those with creatinine clearance of less than 40mL/minute. No dose adjustment is made for geriatric population.
11133697|NCT03840057|Placebo Comparator|Placebo|Participants randomized to the placebo arm during Part 1 (azithromycin) of the study would receive 250mL of 0.9% sodium chloride solution to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. Participants randomized to the placebo arm during Part 2 (metoclopramide) of the current study would receive 2mL of 0.9% sodium chloride solution to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy.
11133698|NCT03840044|Other|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
11133699|NCT03840044|Other|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
11133700|NCT03840031|Experimental|Orange Fleshed Sweet Potato High Iron|Meal sequence B, OFSP High Fe
11133701|NCT03840031|Active Comparator|Orange Fleshed Sweet Potato Control|Meal sequence A, OFSP control
11133702|NCT03840018|No Intervention|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
11133703|NCT03840018|Other|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
11133704|NCT03840005|Placebo Comparator|Placebo|2:1 in favour of UDCA
11133705|NCT03840005|Experimental|Ursonorm (Ursodeoxycholic acid)|UDCA 30 mg/kg daily, tablet form taking orally , administered 3 monthly for 12 months, dose titration during the 1st month will occur.
11133706|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
11133707|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
11133708|NCT03839966|Experimental|Active Treatment|Interpretation Bias Modification for Loneliness
11133709|NCT03839966|Active Comparator|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
11133710|NCT03839953|Active Comparator|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
11133711|NCT03839953|Experimental|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
11133712|NCT03839940|Experimental|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
11133713|NCT03839940|Placebo Comparator|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
11133714|NCT03839927||Evaluation Group|Survey Application
11133715|NCT03839914|Active Comparator|Intervention - Vancomycin|Intervention: 1g vancomycin powder locally applied to the deep wound and subcutaneous layer prior to closure.
11133716|NCT03839914|No Intervention|Control - No vancomycin application|No intervention, control group All other wound closure procedure and wound care and monitoring are the same
11133717|NCT03839901|Experimental|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
11133718|NCT03839901|Experimental|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
11133719|NCT03839888|Experimental|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
11133720|NCT03839875|Experimental|Active Treatment|
11133721|NCT03839862||Responder|Patient responding to TNF-inhibition
11133722|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
11133723|NCT03839849|Experimental|i-PRF (Test)|injected subgingivally i-PRF after scaling and root planing
11133724|NCT03839849|Active Comparator|saline (Control)|injected subgingivally saline after scaling and root planing
11133725|NCT03839836|No Intervention|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
11133726|NCT03839836|Experimental|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
11133727|NCT03839836|Experimental|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
11133728|NCT03839836|Experimental|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
11133729|NCT03839836|Experimental|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
11133730|NCT03839823|Active Comparator|Comparator arm|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine will be administer to patients enrolled in the control group. The chemotherapy regimen will be decided by the treating physician.
11133731|NCT03839823|Experimental|Ribociclib arm|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.
~Ribociclib (600 mg) is dosed orally for the first 21 days out of a 28 day cycle.
~Letrozole (2.5 mg) or anastrozole (1 mg) are dosed orally daily (28 days out of the 28 day cycle).
~Goserelin (3.6 mg) is continuously released via a subcutaneous implant injected on Day 1 of each 28 day cycle."
11133732|NCT03839810|Experimental|stochastic resonance|stochastic resonance electrical stimulation is applied to the upper extremity during the subjects perform upper extremity motor function.
11133733|NCT03839810|Sham Comparator|sham stimulation|sham electrical stimulation (same electrode location, but no electrical current is applied) is applied to the upper extremity during the subjects perform upper extremity motor function.
11133734|NCT03839797|Experimental|Cadet Healthy Personal Skills|Cadet Healthy Personal Skills
11133735|NCT03839797|Active Comparator|Standard Health Education|Standard Health Education
11133736|NCT03839784||Neurocognitive Assessment Arm|
11133737|NCT03839771|Placebo Comparator|Arm A: Placebo|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |
~The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day
~The dosage for Placebo for AG-221 (IDH2): 100mg dose/day"
11133738|NCT03839771|Experimental|Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |
~The dosage for AG-120 (IDH1): 500 mg dose/day
~The dosage for AG-221 (IDH2): 100mg dose/day"
11133739|NCT03839758|Active Comparator|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
11133740|NCT03839758|Active Comparator|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
11133741|NCT03839758|Experimental|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
11133742|NCT03839758|Experimental|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
11133743|NCT03839745|Other|Power level 10, 35, or 70 watts|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
11133744|NCT03839745|Other|1 of the other 2 remaining power levels|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
11133745|NCT03839745|Other|Remaining power level|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level
11133746|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
11133747|NCT03839719|Experimental|Group OC|"Ocimum sanctum (OC) is a natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is also listed by the U.S. FDA as an herb Generally Recognized As Safe (GRAS) for its intended use as a therapeutic herb. Pharmacological constitutes present in the extract are eugenol, Urosolic acid, Carvacrol, linalool , limatrol, caryophyllene, and methyl carvicol. The literature showed that Ocimum sanctum extract has significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
~Other Names:
~Tulsi Holy Basil"
11133748|NCT03839719|Active Comparator|Group CHX|"Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in a variety of oral disorders in various formulations.
~As an antimicrobial agent, chlorhexidine is effective in vitro against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes and yeasts and fungi. The digluconate of chlorhexidine (1:6Di 4' chlorophenyl-diguani-dohexane) is a synthetic antimicrobial drug which has been widely used as a broad spectrum antiseptic.
~Other Names:
~Chlorhexidine"
11133749|NCT03839719|Placebo Comparator|Group PI|"Group PI: Placebo (Distilled water) as the mouthrinse.
~Placebo (Distilled water) 10 ml is used as mouthrinse. Distilled water is commonly used as an excipient in a variety of drugs and it is also widely used as a placebo.
~Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
~Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria."
11133750|NCT03839706|Experimental|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
11133751|NCT03839693|Placebo Comparator|Vehicle|Vehicle
11133752|NCT03839693|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
11133753|NCT03839693|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
11133754|NCT03839667|Experimental|intensive diet intervention group|The participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
11133755|NCT03839667|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
11133756|NCT03839667|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
11133761|NCT03839628|Experimental|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
11133762|NCT03839615|Active Comparator|guided bone regeneration using ptfe|"Augmented anterior maxillary bone ridge using ptfe with 1:1 autogenous bone and xenograft mixture
~Patients of both groups will be subjected to CBCT (diagnostic for upper arch).
~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~intervention:
~Flap will be done.
~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a ptfe membrane which will be stabilized by tacks."
11133763|NCT03839615|Experimental|collagen membrane|"Local anesthesia will be given to the patient. intervention:
~Flap will be done.
~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks."
11133764|NCT03839602|Experimental|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
11133765|NCT03839589|Experimental|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
11133766|NCT03839589|Placebo Comparator|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
11133767|NCT03839576|Experimental|Computerized cognitive training|The computerized cognitive training will take place at each participant's residence. Participants will be asked to practice at least 1 session a day for 6 months, and a session lasts for 60 minutes.
11133768|NCT03839576|Experimental|Lower extremity strengthening|"This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months.
~Each session will last 60 min."
11133769|NCT03839576|Experimental|Tai chi chuan|The 8-form Yang-style tai chi intervention will take place at a subject's residence or the neighborhood once a week for 6 months, and each session will last for 60 minutes.
11133770|NCT03839576|No Intervention|Social interaction|Immediately after the baseline assessment, the care manager will visit the subject in this group once for comparability with the other two intervention groups.
11133771|NCT03839563|Experimental|Conventional exercise|This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months. Each session will last 60 min.
11133772|NCT03839563|Experimental|Tai chi chuan|The 8-form Yang-style tai chi chuan intervention will take place at a subject's residence or in the neighborhood once a week for 6 months, and each session will last 60 min.
11133773|NCT03839563|No Intervention|Health education/usual physical activity|After the baseline, the case manager will visit subjects in this group once for comparability with the other two intervention groups and instruct them to maintain their usual physical activity.
11133774|NCT03839550|Experimental|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
11133775|NCT03839550|Active Comparator|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
11133776|NCT03839524|Experimental|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
11133777|NCT03839498|Experimental|Axitinib (AG-013736)|Subjects with Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma will receive 16 weeks of therapy (Axitinib), and be seen in clinic every 4 weeks to monitor therapy.
11133778|NCT03839485|Active Comparator|Pasta Guedes-Pinto|Endodontic treatment using Guedes-Pinto Paste
11133779|NCT03839485|Experimental|Pasta Guedes-Pinto without antibiotic|Endodontic using Guedes-Pinto paste without antibiotic
11133780|NCT03839472|Experimental|Continuous Bladder Irrigation (CBI)|"Each subject will have a TURBT procedure performed per standard of care procedure, which will be followed by the study intervention - Continuous Bladder Irrigation (CBI) for up to two hours after procedure.
~Six samples of discarded bladder irrigation will be collected from each participant (N=20) immediately after TURBT and after the completion of each liter of normal saline 0.9% irrigation (1 to 5 L) for a total of 120 samples."
11133781|NCT03839459|Experimental|Denosumab|
11133782|NCT03839446|Experimental|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
11133783|NCT03839433|Active Comparator|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
11133784|NCT03839433|Placebo Comparator|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
11133785|NCT03839420|Experimental|CZM IOL|
11133786|NCT03839420|Active Comparator|Competitor IOL|
11133787|NCT03839407|Experimental|MUSE device Class 21|Participants will utilize the MUSE device for 12 weeks during the intervention period.
11133788|NCT03839407|No Intervention|No MUSE device Class 21|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
11133789|NCT03839407|Experimental|MUSE device Class 22|Participants will utilize the MUSE device for 12 weeks during the intervention period.
11134039|NCT03837691|No Intervention|Diet and Exercise|A moderate intensity diet & exercise program to treat primary obesity
11133790|NCT03839407|No Intervention|No MUSE device Class 22|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
11133791|NCT03839394|Experimental|Educational pamphlets + telephone|
11133792|NCT03839394|Active Comparator|Educational pamphlets|
11133793|NCT03839368|Experimental|K plate|fixation of angle fracture using K plate versus two miniplates
11133794|NCT03839368|Active Comparator|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
11133795|NCT03839355|Active Comparator|Eliquis|
11133796|NCT03839355|Active Comparator|Warfarin|
11133797|NCT03839342|Experimental|Binimetinib + Encorafenib|Binimetinib and encorafenib are administered orally on a twice daily or once daily schedule, respectively in 28-day cycles. Treatment will continue until it is discontinued due to unacceptable toxicity, clinical or radiological disease progression as per RECIST 1.1, investigator decision, and/or withdrawal of consent.
11133798|NCT03839329|Experimental|ACT Group Condition|The ACT group condition will receive two 90-minute group Acceptance and Commitment Training (ACT) workshops (scheduled approximately one week apart) and will complete assessments.
11133799|NCT03839329|No Intervention|Assessment-Only Condition|The Assessment-only condition will not receive any intervention and will only complete assessments.
11133800|NCT03839316|Active Comparator|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).
~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.
~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
11133801|NCT03839316|Sham Comparator|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
11133802|NCT03839303|Experimental|Mini Implant Supported Appliance|this group will receive an Infra-zygomatic Mini Implant Supported Appliance after leveling and alignment of the four upper incisors for 8 months or till class I canine or incisors realation is reached with follow up every month
11133803|NCT03839303|Active Comparator|Headgear|this group will receive a high pull headgear appliance attached to a removable acrylic maxillary splint for 8 months or till class I canine or incisors realation is reached with follow up every month
11133804|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
11133805|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
11133806|NCT03839277|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
11133807|NCT03839277|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
11133808|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
11133809|NCT03839251|Other|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
11133810|NCT03839238|Experimental|Meniscus Injured patients|hESC Derived MSC Like Cell
11133811|NCT03839225|Other|Children, Adolescents and Adults|children, adolescents and adults who have been victims of the armed conflict in the municipalities of Soacha-Cundimanarca (Colombia)
11133812|NCT03839212|Experimental|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
11133813|NCT03839173|No Intervention|Retrospective Chart Review|Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
11133814|NCT03839173|Experimental|Prospective|"All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent.
~Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data."
11133815|NCT03839160|Active Comparator|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
11133816|NCT03839160|Placebo Comparator|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
11133817|NCT03839147|Experimental|Education and Counseling|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. This education consisted of the definition and the purpose of hysterosalpingography, when and how it was applied, in what cases it was applied, whether it was a painful procedure, possible side effects and additional benefits of infertility treatment
11133818|NCT03839147|No Intervention|Control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography. Within 5 minutes of completing the hysterosalpingography procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale .
11133819|NCT03839134|Experimental|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
11133820|NCT03839134|Active Comparator|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
11133821|NCT03839134|Experimental|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
11133822|NCT03839134|Active Comparator|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
11133823|NCT03839134|Experimental|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
11133824|NCT03839134|Active Comparator|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
11133825|NCT03839121||single arm: CRT-DX|
11133826|NCT03839108|Active Comparator|Paraffin wax group|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
11133827|NCT03839108|Experimental|Prolotherapy group|"Drug = prolotherapy (%15 dextrose solution) into hand joints
~%15 dextrose solution will be injected into medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period."
11133828|NCT03839082|Active Comparator|Usual Care then FitBit|This is the waitlist control arm.
11133829|NCT03839082|Experimental|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
11133830|NCT03839069|Experimental|Minor Salivary Gland Transplantation|Cicatrizing conjunctivitis patients that received minor salivary gland transplantation for dry eye treatment.
11133831|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
11133832|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
11133833|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
11133834|NCT03839043|Experimental|"Quit for a bit"|"Brief behavioral intervention (~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
11133835|NCT03839043|Active Comparator|"Quit for good"|"Brief behavioral intervention (~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
11133836|NCT03839030|Experimental|MBHP-Educa|Mindfulness-based intervention
11133837|NCT03839030|Active Comparator|Cognitive stimulation|Talking about education
11133838|NCT03839030|Active Comparator|Long-term meditation|Long-term meditators (up 5 years)
11133839|NCT03839017|Experimental|Digital cognitive aid|The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
11133840|NCT03839017|Experimental|Without digital cognitive aid|The leader practices advanced combat casualty care without the digital cognitive aid designed as a smartphone app. Intervention: Device: SIMMAXMARCHERYAN2 Without digital cognitive aid during the management of simulated war wounded.
11133841|NCT03839004|Experimental|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
11133842|NCT03839004|No Intervention|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
11133843|NCT03838991|Experimental|Monostotic fibrous dysplasia|Patients with monostotic Fibrous dysplasia.
11133844|NCT03838991|Experimental|Polyostotic fibrous dysplasia|Patients with polyostotic Fibrous dysplasia.
11133845|NCT03838991|Active Comparator|Controls|Control patients having a scheduled surgery for osteoarthritis.
11133846|NCT03838978|Experimental|Calypso Knee System|Calypso Knee System
11133847|NCT03838965|Experimental|biobeat sensor|
11133848|NCT03838952|Experimental|Chinese herbal medicine group|drug for the subjects
11133849|NCT03838939|Experimental|interventional group|"M3 (group with 3 to 10 patients) Intensification Biotherapy Education Workshops : Subcutaneous injection education and biotherapy management"
11133850|NCT03838939|Placebo Comparator|Control group|"M3 (individual) Intensification Biotherapy Education: Subcutaneous injection education and biotherapy management."
11133851|NCT03838926|Experimental|Trichostatin A|
11133852|NCT03838913||IPNB|intraductal papillary neoplasm of the bile duct
11133853|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
11133854|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
11133855|NCT03838887||control group|"Pregnant women:
~Age between 18-35 years
~Parity: primigravidas and multiparas.
~Have no history of preeclampsia or eclampsia.
~Have no history of chronic hypertension.
~Not diabetic.
~Not have antiphospholipid syndrome.
~Not have autoimmune disease such as SLE"
11133856|NCT03838887||High risk group|"Pregnant women with:
~History of preeclampsia -Eclapmsia
~Chronic hypertension
~Diabetic
~Antiphospholipid syndrome.
~Autoimmune syndrome such as SLE."
11133857|NCT03838874|Active Comparator|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA. A standardized study card will be used to track patients throughout their various phases of care.
11133858|NCT03838874|Active Comparator|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA. A standardized study card will be used to track patients throughout their various phases of care.
11133859|NCT03838861|Active Comparator|Control|Standard follow-up in doctors setting
11133860|NCT03838861|Experimental|Intervention|Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
11133861|NCT03838848|Experimental|Safety cohort KN046 3mg|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
11133862|NCT03838848|Experimental|Safety cohort KN046 5mg|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
11133863|NCT03838848|Experimental|Efficacy cohort KN046|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
11133864|NCT03838835|Experimental|Equine-facilitated group therapy|
11133865|NCT03838835|Experimental|Augmented equine-facilitated CBT group program|
11133866|NCT03838835|Other|Wait List Control (WLC)|
11133867|NCT03838822|Experimental|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
11133868|NCT03838809|Experimental|INTERVENTION|A group that underwent a neurological physiotherapy program with electromyography-biofeedback on the hand and the foot
11133869|NCT03838809|Active Comparator|CONTROL|A group that underwent a conventional physiotheraphy intervention
11133870|NCT03838796|Active Comparator|lenvatinib|use lenvatinib after liver resection in HCC patients
11133871|NCT03838796|Active Comparator|lenvatinib and TACE|use lenvatinib and TACE after liver resection in HCC patients
11133872|NCT03838783|No Intervention|Usual CSII|Continue to use the established CSII insulin therapy
11133873|NCT03838783|Experimental|Untethered CSII|Basal dosing - total CSII basal dose will be delivered by 50% through continuing CSII therapy used prior to study enrollment and 50% through the addition of once daily insulin degludec injected in the morning; Bolus dosing - continue the established bolus insulin dose
11133874|NCT03838770|Experimental|Active|
11133875|NCT03838770|Placebo Comparator|Sham|
11133876|NCT03838757||Patients|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
11133877|NCT03838757||Healthy controls|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
11133878|NCT03838744|Active Comparator|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy at the dose 1.5 or 1.3 mg/m2 (according institutional practice) given as intravenous infusion at day 1 every 3 weeks (21 days cycle)
11133879|NCT03838744|Experimental|Experimental arm: Trabectedin + Olaparib|Trabectedin at the dose 1.1mg/m2 given as intravenous infusion at day 1 every 3 weeks (21 days cycle) plus Olaparib per os at the dose of 150 mg twice a day
11133880|NCT03838731|Experimental|REGN1908-1909|
11133881|NCT03838731|Placebo Comparator|Placebo|
11133882|NCT03838705|Other|bariatric surgery patients|patients aged 18-65 years with ASA status II-III, BMI>40 who were undergoing bariatric surgery operation
11133883|NCT03838692|Experimental|Ponatinib Arm|Ponatinib tablets will be taken by mouth, continuously, once daily at a dose of 45 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment can be taken with water, with or without food, at approximately the same time each day.
11133884|NCT03838679||Cohort 1|80 participants with neovascular AMD and a minimum history of 12 months of anti- VEGF therapy will be included in cohort 1 and examined only once (1 study visit).
11133885|NCT03838679||Cohort 2|40 participants with treatment-naive neovascular AMD receiving standardized anti- VEGF therapy will be included in cohort 2 and followed for 12 months (6 study visits).
11133886|NCT03838666|Experimental|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
11133887|NCT03838653||Left main bronchus (LMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the left main bronchus (correct placement).
11133888|NCT03838653||Right main bronchus (RMB) intubation|Thoracic surgery patient is intubated with left side double lumen tube (L-DLT) and a fiberoptic bronchoscope is used to verify optimal positioning. The patient is designated as this group when the endobronchial lumen is observed to be in the right main bronchus (incorrect placement).
11133889|NCT03838640|Experimental|Study group|Consecutive eligible patients requiring endoscopic surgery for sinonasal pathology Transnasal localization of internal carotid artery with TEE ECHO device will be performed
11133890|NCT03838614|Experimental|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
11133891|NCT03838614|Experimental|RAS group|Rhythmical auditory stimulation gait training group
11133892|NCT03838614|Experimental|MPT group|Muscle power training group
11133893|NCT03838614|Other|Control group|Usual care group
11133894|NCT03838601|Experimental|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
11133895|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:
~st: 10 Days after patients received radical resection.
~nd: When patients finished the chemotherapy or target drug delivery two cycles.
~rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.
~th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
11133896|NCT03838575|Active Comparator|A - NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.
~No drapes or sponges of any kind may be used."
11133897|NCT03838575|Active Comparator|B - SKIN PREP|"Mechanism: A broad-spectrum antiseptic to clean and prepare the skin prior to surgery.
~Supplier: BD"
11133898|NCT03838575|Active Comparator|C - DRAPE|"Mechanism: A thin impregnated plastic sheet applied to the prepared skin prior to incision to maintain sterility.
~Supplier: 3M Infection Prevention"
11133899|NCT03838575|Active Comparator|D - SPONGE|"Mechanism: Small absorbable sponges placed into the wound at the time of closure which deliver high concentrations of antibiotic locally to kill pathogens present that may go on to cause SSI.
~Supplier: SERB"
11133900|NCT03838575|Active Comparator|E - SKIN PREP and DRAPE|See descriptions in single arms (B & C)
11133901|NCT03838575|Active Comparator|F - SKIN PREP and SPONGE|See descriptions in single arms (B & D)
11133902|NCT03838575|Active Comparator|G - DRAPE and SPONGE|See descriptions in single arms (C & D)
11133903|NCT03838575|Active Comparator|H - SKIN PREP and DRAPE and SPONGE|See descriptions in single arms (B, C & D)
11133904|NCT03838562|Experimental|Virtual Reality Arm|
11133905|NCT03838562|Active Comparator|Control Arm|
11133906|NCT03838549|Experimental|implant for breast reconstruction|20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy. They will have a prophylactic mastectomy with immediate breast reconstruction
11133907|NCT03838536|Experimental|Whole egg powder|Participants are given whole egg powder which contains high levels of the nutrients choline, lutein, and docosahexaenoic acid.
11133908|NCT03838536|Placebo Comparator|Egg white powder|The participants are given an egg white powder that does not contain the target nutrients (choline, lutein, and docosahexaenoic acid).
11133909|NCT03838523|Experimental|OLP group|"At baseline, patients are given an explanation about why placebos without deception might be effective.
~Women allocated to this group receive an 4-week Open Label Placebo treatment. After 4 weeks, they are randomized again to either continue or discontinue the OLP treatment for another 4 weeks."
11133910|NCT03838523|No Intervention|No-treatment group|"At baseline, patients are given an explanation about why placebos without deception might be effective.
~Women assigned to the no-treatment group do not receive any treatment as part of the study."
11133911|NCT03838510|Experimental|Brief Counseling Intervention|
11133912|NCT03838510|No Intervention|Control Group|
11133913|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
11133914|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
11133915|NCT03838484|Experimental|Healthy: placebo first, nicotine last|Healthy controls will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
11133916|NCT03838484|Experimental|Healthy: nicotine first, placebo last|Healthy controls will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
11133917|NCT03838484|Experimental|SCZ: placebo first, nicotine last|Subjects with schizophrenia (SCZ) will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
11133918|NCT03838484|Experimental|SCZ: nicotine first, placebo last|Subjects with schizophrenia (SCZ) will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
11133919|NCT03838471||Central sensitization symptoms|This group will contain persons with a clinically relevant degree of symptoms of CS (CSI score ≥40).
11133920|NCT03838471||No Central sensitization symptoms|This group will contain persons with a lower degree of symptoms of CS (CSI score < 40).
11133921|NCT03838458||Study|Children with isolated hypospadias
11133922|NCT03838458||Control|Children with planned circumcision
11133923|NCT03838445|Experimental|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
11133924|NCT03838432|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
11133925|NCT03838419|Active Comparator|BCS + WBI|breast conserving surgery followed by whole breast irradiation
11133926|NCT03838419|Experimental|BCS + IORT|Breast conserving surgery incl intraoperative radiotherapy
11133927|NCT03838406|Experimental|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy
~FOLFOX :
~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.
~CAPOX:
~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
11133928|NCT03838406|Active Comparator|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy
~FOLFOX :
~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.
~CAPOX:
~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
11133929|NCT03838380|No Intervention|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
11133930|NCT03838380|Experimental|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
11133931|NCT03838367|Experimental|Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
11133932|NCT03838367|Experimental|Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
11133933|NCT03838367|Experimental|Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
11133934|NCT03838367|Experimental|Phase II- MTD to be established for the combination treatment|MTD PRO 140 SC + AUC 5 Carboplatin in 30 subjects
11133935|NCT03838354|Experimental|A|Chidamide 2.5 mg po tiw
11133936|NCT03838354|Experimental|B|Chidamide 5 mg po tiw
11133937|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
11133938|NCT03838328|Experimental|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
11133939|NCT03838328|Experimental|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
11133940|NCT03838328|Active Comparator|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
11133941|NCT03838315|Experimental|Neural Mobilization with Soft Tissue Mobilization|"Neural Mobilization with Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization and Post Isometric Relaxation Techniques.
~Frequency for Neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 40mints each session)"
11133942|NCT03838315|Active Comparator|Neural mobilization without Soft Tissue Mobilization|Neural Mobilization without Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural Mobilization Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 30mints each session)
11133943|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
11133944|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
11133945|NCT03838289||Individuals with absent filling of CVs|Individuals with absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
11133946|NCT03838289||individuals without any absent filling of CVs|Individuals without any absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
11133947|NCT03838276|Active Comparator|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
11133948|NCT03838276|Experimental|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
11133949|NCT03838263|Experimental|Experimental arm|Experimental arm with nivolumab 2 infusions (2 weeks apart) before Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
11133950|NCT03838263|Active Comparator|Control arm|Control arm: Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
11133951|NCT03838250|Experimental|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
11133952|NCT03838237||Fabry Disease patients|Patients with genetic diagnosis of Fabry Disease, clinical indication to Migalastat and signs of cardiac involvement (early or advanced) will undergo cardiological evaluation before and 18 months after therapy with Migalastat (123 mg every other day)
11133953|NCT03838224|Experimental|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
11134165|NCT03836781|Active Comparator|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
11133954|NCT03838224|Sham Comparator|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
11133955|NCT03838211|Experimental|stimulation group|Anodal tDCS + intensive cognitive Training
11133956|NCT03838211|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
11133957|NCT03838198|Other|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
11133958|NCT03838198|Other|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
11133959|NCT03838198|Other|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
11133960|NCT03838198|Other|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
11133961|NCT03838185|Experimental|Study Drug|Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
11133962|NCT03838185|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
11133963|NCT03838172||Parents|Parents who have a burned child
11133964|NCT03838159|Experimental|Experimental: Neo-Adjuvant Immunotherapy|"Neoadjuvant treatment (paclitaxel+carboplatin+nivolumab) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)
~Adjuvant treatment (Nivolumab): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months."
11133965|NCT03838159|Active Comparator|Control: Neo-Adjuvant chemotherapy|"Neoadjuvant treatment (paclitaxel+carboplatin) will start within 1-3 days from enrollment/ randomisation. 3 cycleswill be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)"
11133966|NCT03838146|No Intervention|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
11133967|NCT03838146|Experimental|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
11133968|NCT03838146|Experimental|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts[17-19]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
11133969|NCT03838146|Experimental|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
11133970|NCT03838133|Experimental|TLC590 dose 1 (152 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
11133971|NCT03838133|Experimental|TLC590 dose 2 (190 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
11133972|NCT03838133|Experimental|TLC590 dose 3 (228 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
11133973|NCT03838133|Active Comparator|Naropin®|Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)
11133974|NCT03838133|Placebo Comparator|Placebo|Normal Saline (0.9% sodium chloride, 10 mL)
11133975|NCT03838133|Active Comparator|Bupivacaine|Bupivacaine HCl 50 mg (0.5%, 10 mL)
11133976|NCT03838120|Other|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
11133977|NCT03838107||Inpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the inpatient FIRST clinic at CCHMC and one of their parents or legal guardian.
11133978|NCT03838107||Outpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the outpatient Pain Management Center at CCHMC and one of their parents or legal guardian.
11133979|NCT03838107||Healthy Controls|For comparison purposes, healthy controls and one of their parents or legal guardian will be enrolled in this study as well.
11133980|NCT03838094|Active Comparator|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
11133981|NCT03838094|Experimental|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
11133982|NCT03838081|Experimental|Group 1|Group 1: Patients who were given only basic information verbally
11133983|NCT03838081|Experimental|Group 2|Group 2: Patients with detailed written information about preoperative, intraoperative, and postoperative periods
11133984|NCT03838081|Experimental|Group 3|Group 3: Patients with previous experience and knowledge about third molar extraction
11133985|NCT03838068|Active Comparator|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
11133986|NCT03838068|Experimental|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
11133987|NCT03838055|Experimental|SLN only|Pelvic SLN's defined by ICG injected cervically
11133988|NCT03838042|Experimental|Nivolumab and Entinostat|Combination Study of Nivolumab and Entinostat
11133989|NCT03838029|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.
11133990|NCT03838029|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
11133991|NCT03838016|Experimental|Treatment cohort with classic galactosemia|These children and their parents receive the Babble Boot Camp intervention and also participate in the close monitoring activities (progress reports that the speech-language pathologist generates during the online meeting with the family; monthly daylong audio recording; questionnaires that are sent out every three to six months; formal speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years).
11133992|NCT03838016|Experimental|Treatment cohort with classic galactosemia, delayed start|The children in the control cohort enter the study when they are younger than 5 months old and participate in the close monitoring until they are 24 months old. They start getting the same treatment type and intensity as the treatment cohort but at a delayed age, when they turn 15 months.
11133993|NCT03838016|No Intervention|Older control cohort with classic galactosemia|The children in the older control cohort are 2 to 4 1/2 years old and provide standardized test results in the area of speech and language development. They receive no treatment and no close monitoring.
11133994|NCT03838016|No Intervention|Typical controls|These children are free of any medical or developmental diagnosis. They enter the study at ages 2 to 5 months and provide close monitoring data until they are 24 months old, then they receive standardized speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years, just like the treatment cohort, but the typical controls receive no treatment under this study.
11133995|NCT03838003|Experimental|Experimental: Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
11133996|NCT03838003|No Intervention|No Intervention: Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
11133997|NCT03837977|Active Comparator|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
11133998|NCT03837977|Active Comparator|docetaxel|75mg/m*2 intravenously over 60 minutes) every 21 days]
11133999|NCT03837964|Experimental|Treatment T|Fed
11134000|NCT03837964|Experimental|Treatment R|Fasted
11134001|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
11134002|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
11134003|NCT03837938|Experimental|Levopront® syrup 30 mg/5 ml|Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml t.i.d. for 7 days The study drugs will be taken t.i.d. (with the interval of not less than 6 hours, between meals) during 7 days.
11134004|NCT03837938|Active Comparator|Libexin® 100 mg tablets|"Libexin® (prenoxdiazine) 100 mg tablets
~1 tablet t.i.d. for 7 days."
11134005|NCT03837925|Experimental|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
11134006|NCT03837925|Placebo Comparator|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
11134007|NCT03837912|Experimental|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
11134008|NCT03837912|No Intervention|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
11134040|NCT03837665|Experimental|PRP Treatment|Participants receive platelet rich plasma treatment. Participants will be asked to make up to 5 trips to the clinic (one for eligibility, one for the PRP, three follow-up visits). Participation is expected to last up to about 6 weeks. After the second visit and application of PRP, patients will be monitored closely for any complications or concerns. This will include a follow up phone call 3-5 days after the initial application of PRP. Patients will also be followed closely in 2 week intervals or sooner should any problems or concerns arise.
11134009|NCT03837899|Experimental|Durvalumab / Tremelimumab Combination Therapy|"Part 1 (dose finding) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are initially administered at dose level 1 and dose escalated based on results from PK modeling and tolerance to determine the RP2D. Both drugs are administered every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvavalumab for 4 doses, from cycles 2-5. (sarcoma, NB and NHL)
~Part 2 (dose expansion phase) Durvalumab + tremelimumab Combination Treatment. Durvalumab and tremelimumab are administered at the RP2D, every 4 weeks as intravenous infusions. Tremelimumab is only administered with durvalumab for 4 doses, from cycles 2-5. (solid tumors, hematological malignancies and HL)
~* Patients in the Hodgkin lymphoma cohort will receive durvalumab as monotherapy, administered every 4 weeks as an intravenous infusion. Tremelimumab may be added for 4 doses at time of progression."
11134010|NCT03837886|Experimental|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
11134011|NCT03837886|Placebo Comparator|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
11134012|NCT03837873|Experimental|DLCL002 protocol|Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.
11134013|NCT03837860|Active Comparator|Oxycodone/Placebo|Each study participant will receive all three study interventions in random order.In this arm, the participant receives oxycodone or placebo
11134014|NCT03837860|Active Comparator|Oxycodone/Risperidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or risperidone
11134015|NCT03837860|Active Comparator|Oxycodone/Ziprasidone|Each study participant will receive all three study interventions in random order. In this arm the participant receives a combination of oxycodone or ziprasidone
11134016|NCT03837847|Experimental|Intervention|Participants in this group will receive 12 weekly health coaching calls followed by 12 weeks of living a normal life.
11134017|NCT03837847|Active Comparator|Attention Control|Participants in this group will receive 6 educational guides and 6 calls to remind them to read the educational guides (over a 12 week period). The participants will then move to 12 weeks of weekly health coaching calls.
11134018|NCT03837834|Experimental|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
11134019|NCT03837834|Experimental|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
11134020|NCT03837821|Experimental|All Subjects|Abemaciclib 200 mg oral, every 12 hours
11134021|NCT03837808|Experimental|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
11134022|NCT03837808|Active Comparator|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
11134023|NCT03837795|Experimental|Neurofeedback therapy group|
11134024|NCT03837782|Experimental|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.
~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
11134025|NCT03837782|No Intervention|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.
~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).
~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
11134026|NCT03837769|Experimental|Aktiia SA PulseWatch|Aktiia OBPM PulseWatch wrist device
11134027|NCT03837756|Placebo Comparator|Arm A: Placebo/Placebo|This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
11134028|NCT03837756|Active Comparator|Arm B: Lefitolimod/Placebo|This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
11134029|NCT03837756|Active Comparator|Arm C: Placebo/3BNC117 + 10-1074|This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
11134030|NCT03837756|Active Comparator|Arm D: Lefitolimod/3BNC117 + 10-1074|This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
11134031|NCT03837743|Experimental|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
11134032|NCT03837743|Placebo Comparator|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
11134033|NCT03837717|Experimental|Holding First|Holding will occur on the second day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
11134034|NCT03837717|Experimental|No Holding First|Holding will occur on the third day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
11134035|NCT03837704|Active Comparator|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
11134036|NCT03837704|Active Comparator|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
11134037|NCT03837704|Active Comparator|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
11134038|NCT03837691|Experimental|g-Cath EZ|Placement of Snowshoe suture anchors from g-Cath EZ Delivery Catheters, in a defined pattern in the mid and distal portions of the stomach, along with a moderate intensity diet & exercise program, to treat primary obesity.
11134041|NCT03837639|Experimental|Arm crank ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
11134042|NCT03837639|Experimental|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
11134043|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
11134044|NCT03837626|Placebo Comparator|Placebo|6 months of daily placebo
11134045|NCT03837626|Experimental|Amiloride|6 months of amiloride (max dose 5 mg) treatment
11134046|NCT03837613||Group 1 (TT<4mm)|Patients with a preoperative tumor thickness less than 4 mm. Intervention: tumor resection and neck dissection
11134047|NCT03837613||Group 2 (TT >= 4mm)|Patients with a preoperative tumor thickness equal to or more than 4 mm Intervention: tumor resection and neck dissection
11134048|NCT03837600||Healthy Cohort|Participants who have smoked less than 5 pack-years, have quit smoking for more than 15 years and have no known lung diseases.
11134049|NCT03837600||High-risk Cohort|Participants who are at high risk for lung cancer including current smokers who have smoked for more than 30 pack-years and have not quit within 15 years.
11134050|NCT03837600||Cancer Cohort|Participants who have been diagnosed with lung cancer.
11134051|NCT03837587||Patients group|Patients with temporomandibular disorders
11134052|NCT03837561|Experimental|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
11134053|NCT03837561|Active Comparator|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
11134054|NCT03837548|Experimental|Training with Neurofeedback|
11134055|NCT03837548|Experimental|The other Training with Neurofeedback|
11134056|NCT03837535||Patients undergoing surgery|Swedish patients, >18 years undergoing surgery 2007-2014
11134057|NCT03837522|Active Comparator|Procurement Biopsy: Frozen section|In the routine care condition, biopsies will be processed immediately as a frozen section.
11134058|NCT03837522|Active Comparator|Procurement Biopsy: Permanent section|In the intervention group, the biopsy processing will be delayed to permanent section, and therefore not available until allocation is complete.
11134059|NCT03837509|Experimental|INCB001158 + daratumumab SC|
11134060|NCT03837509|Active Comparator|Daratumumab monotherapy|
11134061|NCT03837509|Experimental|INCB001158 monotherapy cross over INCB001158 + daratumumab SC|INCB001158 monotherapy, then cross over to INCB001158 + daratumumab SC
11134062|NCT03837496|Experimental|STRIDE Run-In|"Stride is delivered as a Five weekly one-hour virtual (videophone) or in-person sessions in small groups with a trained clinician
~Two 15-minute check-in phone calls later in the study
~Participants will store hormonal therapy medication in a bottle provided by the study team.
~Participants will complete questionnaires at enrollment and 3-months post- enrollment"
11134063|NCT03837496|Experimental|STRIDE|"Stride is delivered as six weekly one-hour virtual (videophone) sessions in small groups with a trained clinician (or individually, in the rare instance in which scheduling doesn't allow for groups and the participant is approaching the 12-week assessment window)
~Two 15-minute check-in phone calls later in the study
~Participants will store hormonal therapy medication in a bottle provided by the study team.
~Participants will complete questionnaires at enrollment, 12-weeks, and 24-weeks post-enrollment"
11134064|NCT03837496|Active Comparator|Medication Monitoring Control|"Medication monitoring plus standard care
~Participants will store hormonal therapy medication in a bottle provided by the study team.
~Participants will complete questionnaires at enrollment, 12-weeks and 24-weeks post-enrollment"
11134065|NCT03837483|Experimental|Gene Therapy|OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene
11134066|NCT03837470|Experimental|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
11134067|NCT03837457|Experimental|Cobomarsen|
11134068|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
11134069|NCT03837405|Active Comparator|Diet Education|All participants will receive instruction in the Carbohydrate-Restricted (CR) diet and basic behavioral strategies in weekly, in-person, group sessions for 3 months. The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat.
11134070|NCT03837405|Experimental|Diet Education + Mindfulness|In addition to the diet components described above, participants randomized to the Education + Mindfulness (Ed+MBI) group will receive MBI components using the Eat Right Now (ERN) platform. This will consist of two integrated components: 1) use of the ERN app at home, during the week, to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based discussions of how the mindful eating practices are going, trouble-shooting obstacles/pain points, and doing group exercises and reflecting on them.
11134071|NCT03837392|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) - participants in this arm take part in a 3-hour group (3-8 participants) ACT intervention. This group will focus on developing psychological flexibility, which is defined as behaviorally pursuing one's values even in the presence of barriers (e.g., thoughts, emotions).
11134072|NCT03837392|Active Comparator|Psychoeducation Control|Control group: Psychoeducation - participants in this group will partake in a 3-hour group session with other perinatal women. Participants will be presented with information about depression and anxiety symptoms that may occur during the perinatal and postpartum periods. The symptoms will be discussed as a group with the goal being increased support between group members. There will not be a discussion of optimal coping strategies.
11134073|NCT03837379|Other|Treatment As Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
11134074|NCT03837379|Experimental|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
11134075|NCT03837366|Experimental|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
11134076|NCT03837366|Active Comparator|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
11134077|NCT03837353|Experimental|Cohort 1A|"Cohort 1A Dose Level 1: DKN-01 300 mg intravenously (IV) on Days 1 and 15, docetaxel 75 mg/m2 on Day 1 every 3 weeks (21- day cycles).
~Dose Level 2: DKN-01 600 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles).
~Dose Level -1: DKN-01 150 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles)."
11134078|NCT03837353|Experimental|Cohort 1B|Cohort 1B: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)
11134079|NCT03837353|Experimental|Cohort 1C|Cohort 1C: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)
11134080|NCT03837353|Experimental|Cohort 2A|"Dose Level 1: DKN-01 300 mg IV on Days 1 and 15 of a 28-day cycle. Dose Level 2: DKN-01 600 mg IV on Days 1 and 15 of a 28-day cycle.
~Dose Level -1: DKN-01 150 mg IV on Days 1 and 15 of a 28-day cycle."
11134081|NCT03837353|Experimental|Cohort 2B|Cohort 2B: DKN-01 at MTD or highest dose tested: Days 1 and 15 (28-day cycles)
11134082|NCT03837340|Experimental|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
11134083|NCT03837340|Active Comparator|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
11134084|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
11134085|NCT03837314|Experimental|Deep Brain Stimulation|"Deep Brain stimulation using a novel device. Bioinduction Picostim Deep Brain Stimulation system"
11134086|NCT03837301|Experimental|NESS-EFTR|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation (basin dissection)
11134087|NCT03837288|No Intervention|Vaginal progesterone only|continue on vaginal progesterone only
11134088|NCT03837288|Experimental|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
11134089|NCT03837275|Experimental|humsfe|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique)
11134090|NCT03837275|Active Comparator|closed sinus lift|transcrestal maxilllary sinus floor elevation
11134091|NCT03837262|Experimental|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
11134092|NCT03837249|Placebo Comparator|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
11134093|NCT03837249|Active Comparator|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
11134094|NCT03837249|Active Comparator|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
11134095|NCT03837236|Experimental|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
11134096|NCT03837223||"patients underwent rescue protocols and fresh embryotransfer"|they were patients with good prognosis with a mean age of 34.13 ± 4.42 years, with a good ovarian reserve
11134097|NCT03837210|Experimental|Test Drug|This group is treated with Herbal formulation.
11134098|NCT03837210|Active Comparator|Control Drug|This group is treated with Quintuple therapy
11134099|NCT03837197|Experimental|Kidney-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
11134100|NCT03837197|No Intervention|Kidney-Static Cold Storage|Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
11134101|NCT03837197|Experimental|Liver-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
11134102|NCT03837197|No Intervention|Liver-Static Cold Storage|Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
11134103|NCT03837184|Experimental|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
11134104|NCT03837171|Active Comparator|Liberal strategy|Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
11134105|NCT03837171|Experimental|Restrictive strategy|Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
11134106|NCT03837158|Experimental|Control-group|Two Tissue Level TiZr Sand blasted long grit acid-etched (SLA) implants placed in positions 33 and 43 (diameter 3.3mm, length ≥10mm), early loading
11134107|NCT03837158|Experimental|Experimental-group|Four narrow-diameter implants (NDI) TiZr SLA implants in positions 34, 32, 42, and 44 (diameter 2.4mm, length ≥10mm), immediate loading
11134108|NCT03837145||Liver transplant recipients|Adult patients requiring elective post-operative ventilation after a living donor liver transplant receiving intravenous propofol infusion for sedation titrated to Bi-Spectral Index (BIS) score of 60-80,as per our institutional protocol.
11134109|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
11134110|NCT03837119||Heterozygous Hemoglobinopathy|pregnancy outcome in women with heterozygous hemoglobinopathy
11134111|NCT03837119||No Heterozygous Hemoglobinopathy|pregnancy outcome in women without heterozygous hemoglobinopathy
11134112|NCT03837106|Experimental|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
11134113|NCT03837106|No Intervention|No intervention|Control group, no intervention
11134114|NCT03837093|Experimental|dose A|ILT-101
11134115|NCT03837093|Experimental|dose B|ILT-101
11134116|NCT03837093|Experimental|dose C|ILT-101
11134117|NCT03837093|Experimental|dose D|ILT-101
11134118|NCT03837093|Experimental|dose E|ILT-101
11134119|NCT03837093|Experimental|Placebo|
11134120|NCT03837080|Experimental|Nutrition Education|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care will go through a series of individual and group nutrition educations. Educations are specifically tailored for chronic pain patients, based on our preliminary findings on this group of patients.
11134121|NCT03837080|No Intervention|Control|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
11134122|NCT03837054|Other|Breast cancer patients with external polychemotherapy|
11134123|NCT03837041|Active Comparator|Reconditioning Proprioception group|Training Proprioception 1 hour for 2 day a week
11134124|NCT03837041|No Intervention|Control group|
11134125|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.
~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
11134126|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
11134127|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
11134128|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
11134129|NCT03837015|Active Comparator|Estring alone|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
11134130|NCT03837015|Active Comparator|Estring and vaginal RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30
11134131|NCT03837015|Active Comparator|Estring and oral RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.
11134132|NCT03837015|Active Comparator|Vaginal RepHresh Pro-B|Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.
11134133|NCT03837002|Experimental|foot care protocol|foot examination at the first interview, foot care and training once a month and weekly follow-up for 3 months, foot examination at the last interview (six month)
11134134|NCT03837002|No Intervention|Control|foot examination at the first interview, foot examination at the last interview (six month)
11134163|NCT03836807|Experimental|Ketoprofen|Single oral administration of Ketoprofen lysine salt 40 mg granules
11134164|NCT03836807|Placebo Comparator|Placebo|Single oral administration of placebo granules
11134135|NCT03836989|Experimental|Sensory|"Plan to use a monophasic waveform having 100µmsec pulse duration, 300msec interpulse interval, and at a pulse rate 20 Hz and using tolerated voltage for a total of 20 minutes. Electrical stimulation will be produced with the Orthostim 3 device. The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral arm.
~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated."
11134136|NCT03836989|Experimental|Subsensory|"Plan to use a monophasic waveform having 100µmsec pulse duration, 300msec interpulse interval, and at a pulse rate 20 Hz and using tolerated voltage for a total of 20 minutes. Electrical stimulation will be produced with the Orthostim 3 device. The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral arm.
~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
11134137|NCT03836976|Experimental|All participants|All participants receive auditory gamma sensory stimulation.
11134138|NCT03836963|Experimental|cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
11134139|NCT03836963|Active Comparator|cognitive and memory strategy control training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
11134140|NCT03836963|Active Comparator|active control for cognitive and memory strategy training|The cognitive training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours. For the active control of memory strategy training, strategies will be performed daily; this will take only a few minutes a day to accomplish.
11134141|NCT03836950|Experimental|active rTMS|For active rTMS, a butterfly coil and MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark) will be used. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
11134142|NCT03836950|Sham Comparator|sham rTMS|For sham rTMS, the procedure will be carried out at the left DLPFC but a sham coil will be used. The MagVenture coil has an active side and a placebo side allowing a double-blind study to be conducted. The sham system looks, sounds and feels like active rTMS.
11134143|NCT03836937|Experimental|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
11134144|NCT03836937|No Intervention|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
11134145|NCT03836924||Perampanel|Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
11134146|NCT03836911|Active Comparator|serious game|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a serious game
11134147|NCT03836911|Other|Classic program|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a classical exercise program in older subjects living in a nursing home
11134148|NCT03836898|Experimental|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
11134149|NCT03836885|Experimental|Apremilast|Oral tablet
11134150|NCT03836885|Placebo Comparator|Placebo|Oral tablet
11134151|NCT03836872|Experimental|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
11134152|NCT03836872|Sham Comparator|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
11134153|NCT03836872|No Intervention|Standard Control Group|The third arm will be a standard care control arm.
11134154|NCT03836859|Experimental|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
11134155|NCT03836859|Placebo Comparator|Placebo|Vehicle: formulation containing L-methionine as excipient.
11134156|NCT03836846|Placebo Comparator|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
11134157|NCT03836846|Active Comparator|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
11134158|NCT03836833|Experimental|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
11134159|NCT03836833|Experimental|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
11134160|NCT03836820|Experimental|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
11134161|NCT03836820|Experimental|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
11134162|NCT03836820|Experimental|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
11134166|NCT03836781|Other|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
11134167|NCT03836768|Experimental|Experimental Treatment|DTRMWXHS-12, oral capsule, daily, 28 days as a cycle
11134168|NCT03836755|Other|METACOS|Required to do some motor tasks during static and dynamic RSA
11134169|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
11134170|NCT03836729|Experimental|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
11134171|NCT03836716|Experimental|Arimoclomol|Arimoclomol, capsule
11134172|NCT03836703|Active Comparator|Single Dose Daily Iron|single dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
11134173|NCT03836703|Experimental|Double dose Daily iron|Double dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
11134174|NCT03836690|Experimental|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
11134175|NCT03836677|Experimental|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
11134176|NCT03836677|Experimental|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
11134177|NCT03836664|Experimental|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
11134178|NCT03836664|Placebo Comparator|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
11134179|NCT03836651|Active Comparator|Control Group|Following completion of baseline data collection, participants will be randomized to one of two groups. The research assistant will open a pre-assigned envelope in which group assignment was determined by a random number/block generator. The intervention is designed to complement guideline directed medical management. Therefore, both the intervention and control group will continue to be medically managed by their health care provider as usual. In order to avoid introducing the confound of extra attention paid to the intervention group, the control group will have the same visit and call schedule as the intervention group.
11134180|NCT03836651|Experimental|Intervention Group|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
11134181|NCT03836638|Experimental|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
11134182|NCT03836638|Experimental|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
11134183|NCT03836638|Active Comparator|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
11134184|NCT03836625|No Intervention|Control|The control arm will receive standard CareConekta, which will track their mobility with no additional features.
11134185|NCT03836625|Experimental|Intervention|The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >100 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
11134186|NCT03836612||People with inflammatory bowel disease|Adults (18+) with inflammatory bowel disease registered with a contributing GP practice during the study period
11134187|NCT03836612||Controls|Adults (18+) without inflammatory bowel disease registered with a contributing GP practice during the study period
11134188|NCT03836599|Experimental|24 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
11134189|NCT03836599|Experimental|12 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.
11134190|NCT03836599|Placebo Comparator|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
11134191|NCT03836586|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
11134192|NCT03836586|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
11134193|NCT03836573|Experimental|E-cigarette only decision aid|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of information on e-cigarettes only. Patients will only be enrolled in this group in phase II if they self-identify as 'uninterested in quitting cigarettes'. During the physician encounter will be given harm-reduction guidance.
11134194|NCT03836573|Experimental|E-cigarette and Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. Patients will only be enrolled in this group in phase II if they self identify as 'interested in quitting and using e-cigarettes'. During the physician encounter will be given e-cigarette cessation guidance.
11134195|NCT03836573|Experimental|Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. All patients in phase I will be enrolled in this group. In addition, patients in phase II who self-identify as 'interested in quitting but do not use e-cigarettes' will also be enrolled in this group. During the physician encounter will be given standard smoking cessation guidance.
11134196|NCT03836560|Active Comparator|Usual group|"Usual group with nicotine patch only:
~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
11134197|NCT03836560|Active Comparator|Intervention group|"Nicotine patch and nicotine gum:
~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
11134198|NCT03836547|Experimental|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
11134199|NCT03836547|Active Comparator|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
11134200|NCT03836534||patient coming to the emergency department|the group studied only concern adult adults consulting in the emergency departments and leaving after their consultations, during the permanence of care
11134201|NCT03836508|Active Comparator|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
11134202|NCT03836508|Active Comparator|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
11134203|NCT03836495|Experimental|White bread unfortified (WB)|bread with no lysine no phosphorus
11134204|NCT03836495|Experimental|White bread fortified with lysine (WB-L)|Bread with lysine
11134205|NCT03836495|Experimental|White bread fortified with phosphorus (WB-P)|bread with phosphorus
11134206|NCT03836495|Experimental|White bread fortified with lysine and phosphorus (WB-LP)|Bread with phosphorus and lysine
11134207|NCT03836482|Experimental|Selective Cytopheretic Device|
11134208|NCT03836456|Experimental|Experimental Intervention|Mindfulness Based Stress Resilience Training: This approach will be conducted with study participants for 4 weeks. One evening per week.
11134209|NCT03836456|Active Comparator|Active Control Intervention|Health Enhancement Program: This is a validated active comparator used in Mindfulness-based training studies. It will be conducted with the participants one evening per week for 4 weeks.
11134210|NCT03836443|Active Comparator|NAFL patients (group 1)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
11134211|NCT03836443|Active Comparator|NASH patients (group 2)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
11134212|NCT03836430|Experimental|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
11134213|NCT03836430|No Intervention|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
11134214|NCT03836417||Idiopathic interstitial pneumonias|Patients with idiopathic interstitial pneumonias undergoing surgical lung biopsy
11134215|NCT03836404|Experimental|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
11134216|NCT03836391|Experimental|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).
~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
11134217|NCT03836378|Experimental|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
11134218|NCT03836378|No Intervention|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
11134219|NCT03836365|Active Comparator|Preoperative counseling office visit|Participants will present for an in-person preoperative counseling office visit (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
11134220|NCT03836365|Active Comparator|Preoperative counseling phone call|Participants will receive a preoperative counseling phone call (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
11134221|NCT03836352|Experimental|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
11134222|NCT03836352|Experimental|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
11134291|NCT03835845|Experimental|PICO7Y|PICO 7Y is a single-use NPWT System consisting of a small portable pump & pump clip, 2 AA batteries, 2 large multisite dressings, 2 extension tubes and secondary fixation strips.
11134223|NCT03836326|Experimental|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
11134224|NCT03836326|Other|Control|Infants in the control group will receive standard care only.
11134225|NCT03836313|Experimental|cryoneurolysis treatment|TKA patients randomized to receive preoperative rehabilitation and cryoneurolysis treatment with the iovera° device (n=70)
11134226|NCT03836313|No Intervention|no cryoneurolysis treatment (standard of care)|TKA patients randomized to receive preoperative rehabilitation only (no cryoneurolysis treatment) (n=70)
11134227|NCT03836300|Experimental|Infants with FXS and their parent/primary caregiver|Implement intervention in two phases
11134228|NCT03836287|Experimental|Active|Sofpironium bromide, 15% gel, once per day
11134229|NCT03836287|Placebo Comparator|Vehicle|Vehicle gel, once per day
11134230|NCT03836274|Experimental|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
11134231|NCT03836261|Experimental|Acalabrutinib, Venetoclax|Acalabrutinib in combination with Venetoclax
11134232|NCT03836261|Experimental|Acalabrutinib, Venetoclax, Obinutuzumab|Acalabrutinib in combination with Venetoclax with or without Obinutuzumab
11134233|NCT03836261|Active Comparator|Chemoimmunotherapy|"Chemoimmunotherapy
~FCR: Fludarabine, Cyclophosphamide and Rituximab"
11134234|NCT03836248|Other|1-Current practice Medication treatment|Medication treatment according to current practice.
11134235|NCT03836248|Sham Comparator|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
11134236|NCT03836248|Experimental|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
11134237|NCT03836222|Experimental|PCS499 MR Tablet Prototype 2|600 mg single dose
11134238|NCT03836222|Active Comparator|Trental MR tablet 400mg|single dose
11134239|NCT03836222|Experimental|PCS499 MR Tablet Prototype 4|600mg single dose
11134240|NCT03836222|Experimental|PCS499 MR Tablet Prototype 1|600mg single dose
11134241|NCT03836222|Active Comparator|Trental MR Tablet|400 mg multiple dose
11134242|NCT03836222|Experimental|PCS499 MR Tablet 900mg|multiple dose
11134243|NCT03836222|Experimental|PCS499 MR Tablet 600mg|multiple dose
11134244|NCT03836209|Experimental|Arm A|"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.
~Consolidation: High-dose cytarabine for up to 4 cycles."
11134245|NCT03836209|Active Comparator|Arm B|"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.
~Consolidation: High-dose cytarabine for up to 4 cycles."
11134246|NCT03836196|Experimental|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
11134247|NCT03836183|Other|ultrasound|"ultrasound is the only study group for all the patients
~pleuropulmonary ultrasound
~clinical examination
~fibroscopy."
11134248|NCT03836170|Experimental|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
11134249|NCT03836157|Experimental|Mirvetuximab and Bevacizumab|"Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.
~Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
11134250|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
11134251|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
11134252|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).
~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
11134253|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
11134254|NCT03836079|Experimental|ADHF Patients|Treatment with preCARDIA System
11134255|NCT03836066|Experimental|Experimental: Atezolizumab plus Bevacizumab arm|1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
11134256|NCT03836053|Experimental|AMG 420|Single Arm Design
11134257|NCT03836040|Experimental|Dose level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
11134258|NCT03836040|Experimental|Dose level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
11134259|NCT03836040|Placebo Comparator|Placebo|
11134260|NCT03836014|Experimental|Fixed duration therapy for 24 months.|Daratumumab, Lenalidomide, Dexamethasone
11134261|NCT03836014|Active Comparator|Continuous therapy|Daratumumab, Lenalidomide, Dexamethasone
11134262|NCT03836001|Placebo Comparator|Placebo Oral Tablet|We aim to recruit at least 20 patients who will undergo two months of dosing with placebo (inactive drug or sugar pill), followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant at 5 mg (taken by mouth) daily for continued safety monitoring.
11134362|NCT03835416|Experimental|WL-Control|0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability.
11134263|NCT03836001|Active Comparator|Serlopitant Tablet|We aim to recruit at least 20 patients who will undergo two months of Serlopitant dosing, followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant 5 mg (taken by mouth) daily for continued safety monitoring.
11134264|NCT03835988|Experimental|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
11134265|NCT03835975|Active Comparator|13vPnC|Pneumococcal conjugate vaccine
11134266|NCT03835975|Active Comparator|PPSV23|Pneumococcal polysaccharide vaccine
11134267|NCT03835975|Experimental|20vPnC|Pneumococcal conjugate vaccine
11134268|NCT03835962|Experimental|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
11134269|NCT03835949|Experimental|TJ004309 plus Atezolizumab|TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
11134270|NCT03835936|Active Comparator|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
11134271|NCT03835936|Experimental|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
11134272|NCT03835923|Experimental|lifestyle intervention|Telemedicine-supported lifestyle intervention trough individual structured exercise training (endurance and strength training), increase in daily physical activity, and individual nutritional recommendations
11134273|NCT03835923|Active Comparator|usual care|general exercise and nutritional recommendations according to current guidelines
11134274|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
11134275|NCT03835910|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.
~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
11134276|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.
~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
11134277|NCT03835910|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.
~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
11134278|NCT03835884|Experimental|AR-13503 Implant Low Dose|Single dose of AR-13503 Implant Low Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
11134279|NCT03835884|Experimental|AR-13503 Implant High Dose|Single dose of AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
11134280|NCT03835884|Experimental|AR-13503 Implant High Dose + Aflibercept|Single dose of AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant plus intravitreal injections of aflibercept into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks
11134281|NCT03835884|Experimental|AR-13503 Implant Maximum Dose + Aflibercept|Single dose of AR-13503 Implant High Dose (42.4 µg) administered as an intravitreal implant plus intravitreal injections of aflibercept into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks
11134282|NCT03835884|Experimental|AR-13503 Implant High Dose + sham|Single dose of AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant plus sham injections (touch eye only; no injection) into a single eye of up to 18 subjects (9 nAMD and 9 DME)who will be followed for 24 weeks
11134283|NCT03835884|Experimental|AR-13503 Implant Maximum Dose + sham|Single dose of AR-13503 Implant Maximum Dose (42.4 µg) administered as an intravitreal implant plus sham injections (touch eye only; no injection) into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks
11134284|NCT03835884|Experimental|Sham + Aflibercept|Sham injection (touch eye only; no injection) plus intravitreal injections of Aflibercept into a single eye of up to 18 subjects (9 nAMD and 9 DME) who will be followed for 24 weeks
11134285|NCT03835884|Experimental|AR-13503 Implant Maximum Dose|Single dose of AR-13503 Implant Maximum Dose (42.4 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
11134286|NCT03835871|Experimental|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 12 weeks
11134287|NCT03835871|Experimental|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg per day Daily dose of Beclomethasone 200 µg 1 inhalation 100 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
11134288|NCT03835871|Experimental|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg per day Daily dose of Beclomethasone 100 µg 1 inhalation 50 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
11134289|NCT03835871|Placebo Comparator|placebo|Intervention: Drug: placebo 2 inhalations 2 times a day for 12 weeks
11134290|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
11134741|NCT03832816|Experimental|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
11134292|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
11134293|NCT03835819|Experimental|IMGN853 + Pembrolizumab|"Pembrolizumab is administered intravenously once every 3 weeks
~IMGN853 is administered intravenously once every 3 weeks"
11134294|NCT03835806|Active Comparator|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
11134295|NCT03835806|Experimental|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
11134296|NCT03835793||Early-RRSO|"RRSO before the age of 45 years
~RRSO was done 10 or more years ago"
11134297|NCT03835793||Late-/non-RRSO group|"Natural menopause ≥ 50 years of age
~No RRSO ≤ age of 55
~No treatment-induced menopause ≤ 50 years of age"
11134298|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
11134299|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
11134300|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
11134301|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
11134302|NCT03835767|Experimental|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: -All participants who eat baked milk less than once per month. -Participants who never eat baked milk or straight milk. .On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
11134303|NCT03835767|Experimental|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
11134304|NCT03835767|Experimental|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: -All participants who eat peanut less than once per month -Participants who never eat peanut. never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
11134305|NCT03835767|Experimental|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
11134306|NCT03835754|Experimental|OCS Preservation|
11134307|NCT03835741|Experimental|Automated Oxygen titration|In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
11134308|NCT03835741|Other|Manual Oxygen titration|In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff
11134309|NCT03835728|Active Comparator|Treatment Arm|Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
11134310|NCT03835728|Placebo Comparator|Treatment Placebo Arm|Saline will be used as the matching placebo
11134311|NCT03835715|Experimental|Vortioxetine|
11134312|NCT03835702|No Intervention|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
11134313|NCT03835702|Experimental|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
11134314|NCT03835689|Experimental|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
11134315|NCT03835689|Experimental|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
11134316|NCT03835689|No Intervention|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
11134317|NCT03835676|Experimental|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
11134318|NCT03835663||Patients with non erosive reflux|Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
11134319|NCT03835663||Patients with erosive reflux|Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
11134320|NCT03835663||Patients with no reflux|Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
11134321|NCT03835650||Severe PGP|Patients with severe PGP (VAS over 75mm, PGP confirmed with dedicated functional tests)
11134322|NCT03835650||mild and moderate PGP|Patients with mild and moderate PGP (VAS below 75mm, PGP confirmed with dedicated functional tests)
11134323|NCT03835650||no PGP|Patients in early postpartum period, with no symptoms and signs of PGP
11134324|NCT03835637|Experimental|Regimen A|
11134325|NCT03835637|Experimental|Regimen B|
11134326|NCT03835637|Experimental|Regimen C|
11134327|NCT03835637|Experimental|Regimen D|
11134328|NCT03835637|Experimental|Regimen F|
11134329|NCT03835637|Experimental|Regimen H|
11134330|NCT03835637|Experimental|Regimen I|
11134331|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
11134332|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.
~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
11134333|NCT03835611|Experimental|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
11134334|NCT03835611|Active Comparator|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
11134335|NCT03835598||Patients with cardiac biological prosthesis|
11134336|NCT03835585|Experimental|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
11134337|NCT03835585|Active Comparator|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
11134338|NCT03835572|Experimental|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
11134339|NCT03835572|Active Comparator|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
11134340|NCT03835559|Active Comparator|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure for treatment of incompetent Saphenous Veins is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
11134341|NCT03835559|Active Comparator|Surgical stripping|For treatment of incompetent Saphenous Veins, surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries under all types of anesthesia (general, spinal, regional block, or local anesthesia). The saphenous vein is then removed using a stripper. Compression stocking is apply.
11134342|NCT03835546||Early treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy presenting recent HIV-1 infection. Recent HIV-1 infection was defined as having a positive plasma viral load and/or p24 antigen with a negative ELISA or having a positive ELISA and undetermined Western-Blot, or having a positive ELISA and absence of p31 antigen in a positive Western-Blot, or seroconversion ELISA in less than 3 months.
11134343|NCT03835546||Regularly treated patients|Patients with confirmed HIV-1 infection attended in the HIV Unit of the Hospital Universitari Germans Trias i Pujol who initiated therapy, did not fulfil the criteria for recent HIV-1 infection, and had an estimated time >6 months reported by the patient and/or by the responsible physician since HIV transmission.
11134344|NCT03835546||Seronegative volunteers|HIV-uninfected volunteers, matched to age, sex, and educational level with groups A and B.
11134345|NCT03835533|Experimental|Cohort A: NKTR-214 + Nivolumab|
11134346|NCT03835533|Experimental|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
11134347|NCT03835533|Experimental|Cohort C: CDX-301 + INO-5151 + Nivolumab|
11134348|NCT03835520|Experimental|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
11134349|NCT03835520|Experimental|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
11134350|NCT03835507|Placebo Comparator|Control group|Inject Normal saline 100ml * 12 times (1month apart)
11134351|NCT03835507|Experimental|Low dose group|Inject 500IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
11134352|NCT03835507|Experimental|High dose group|Inject 750IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
11134353|NCT03835494|Experimental|Fallot patients|Fallot patients
11134354|NCT03835494|Experimental|healthy controls|healthy volunteers
11134355|NCT03835481|Placebo Comparator|Placebo|Blinded period of Placebo until Week 12
11134356|NCT03835481|Experimental|BI 730357|Blinded period of BI 730357 until Week 12 (4 dose levels or placebo as continued from trial 1407-0030). Open label period of BI30357 from Week 12 to end of trial (2 dose levels).
11134357|NCT03835468|Experimental|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
11134358|NCT03835468|Placebo Comparator|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
11134359|NCT03835442|Active Comparator|baclofen arm|baclofen 10mg tid for 4 weeks
11134360|NCT03835442|Placebo Comparator|placebos arm|placebo tid for 4 weeks
11134361|NCT03835429|Experimental|MyTAP oral appliance plus mouth shield|MyTAP plus mouth shield
11134742|NCT03832816|Experimental|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
11134363|NCT03835416|Experimental|WL-Protein|>30 g of high quality protein per meal, 1.2 g protein/kg body weight/day. Fourteen servings of high quality (30 g/serving) protein (lean meats, low fat dairy products) provided to participants each week to increase compliance.
11134364|NCT03835403|No Intervention|Usual Care (control arm)|These cardiac arrests will receive standard EMS response.
11134365|NCT03835403|Experimental|HeartRunner Activation|For these cardiac arrests, HeartRunners will be activated in addition to standard EMS response.
11134366|NCT03835390|Experimental|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
11134367|NCT03835377|Experimental|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
11134368|NCT03835377|Active Comparator|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety)
11134369|NCT03835351|Other|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
11134370|NCT03835351|No Intervention|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
11134371|NCT03835338|Experimental|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
11134372|NCT03835338|Active Comparator|Control Group|The control group will receive Pulmonary Vein Isolation
11134373|NCT03835325|Experimental|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
11134374|NCT03835312|Experimental|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
11134375|NCT03835299|No Intervention|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
11134376|NCT03835299|Experimental|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
11134377|NCT03835299|No Intervention|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
11134378|NCT03835286|Experimental|Vitamin C|Vitamin C experimental group
11134379|NCT03835286|Placebo Comparator|Control|Placebos Controlled group
11134380|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
11134381|NCT03835273||Minimally invasive surgery|Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.
11134382|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
11134383|NCT03835260|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
11134384|NCT03835221|Experimental|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
11134385|NCT03835208|Experimental|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:
~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
11134386|NCT03835208|Experimental|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.
~This means a distribution of carbohydrate as follows:
~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
11134387|NCT03835195|Experimental|Diabetes Disease Management Program|Diabetes Disease Management Program
11134388|NCT03835195|Active Comparator|Usual Care Process|Usual care process
11134389|NCT03835182|Active Comparator|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
11134390|NCT03835182|Active Comparator|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
11134391|NCT03835182|Other|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
11134392|NCT03835117|Experimental|Wide-spectrum nutritional supplement|The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.
11134422|NCT03834896|Experimental|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
11134393|NCT03835117|Placebo Comparator|Placebo control|Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.
11134394|NCT03835104|Active Comparator|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).
~There will be only 1 test at study entry"
11134395|NCT03835104|Experimental|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).
~There will be only 1 test at study entry"
11134396|NCT03835091||Patient with mechanical ventilation and sedation|All patient hospitalized in intensive care under sedation and mechanical ventilation without neurologic disorder
11134397|NCT03835078|Experimental|methalfilcon A contact lenses / fanfilcon A contact lenses|All subjects will first wear methafilcon A contact lenses for four (4) weeks of daily wear, then be refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
11134398|NCT03835065|Active Comparator|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
11134399|NCT03835065|Experimental|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
11134400|NCT03835039||HIE|Infants with a diagnosis of HIE
11134401|NCT03835013|Placebo Comparator|Infusion A|"60 minute intravenous infusion of 0.9% saline
~Followed by:
~60 minute intravenous infusion of 0.9% saline"
11134402|NCT03835013|Active Comparator|Infusion B|"60 minute intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min and 0.9% saline.
~Followed by:
~60 minute infusion of GLP-1 7-36 amide 1.2pmol/kg/min and 0.9% saline"
11134403|NCT03835013|Active Comparator|Infusion C|"60 minute intravenous infusion of glucagon 25ng/kg/min and 0.9% saline.
~Followed by:
~60 minute infusion of glucagon 50ng/kg/min and 0.9% saline"
11134404|NCT03835013|Active Comparator|Infusion D|"60 minute intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min and glucagon 25ng/kg/min.
~Followed by:
~60 minute infusion of GLP-1 7-36 amide 0.6pmol/kg/min and glucagon 50ng/kg/min"
11134405|NCT03835013|Active Comparator|Infusion E|"60 minute intravenous infusion of GLP-1 7-36 amide 1.2pmol/kg/min and glucagon 25ng/kg/min.
~Followed by:
~60 minute infusion of GLP-1 7-36 amide 1.2pmol/kg/min and glucagon 50ng/kg/min."
11134406|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
11134407|NCT03834974|Experimental|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
11134408|NCT03834974|Active Comparator|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
11134409|NCT03834961|Experimental|Treatment (larotrectinib)|Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.
11134410|NCT03834948|Experimental|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
11134411|NCT03834948|Experimental|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
11134412|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
11134413|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
11134414|NCT03834935|Experimental|Pim|20 patients receiving topical Elidel (pimecrolimus 1%) bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
11134415|NCT03834935|Placebo Comparator|Pl|20 patients receiving placebo (control group), cold cream bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
11134416|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
11134417|NCT03834922||Sternotomy|Patients undergoing sternotomy
11134418|NCT03834922||Breast|Patients undergoing breast surgery
11134419|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
11134420|NCT03834909|Active Comparator|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
11134421|NCT03834909|Experimental|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
11134423|NCT03834883|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
11134424|NCT03834883|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
11134425|NCT03834883|Experimental|Premenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
11134426|NCT03834883|Placebo Comparator|Premenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
11134427|NCT03834870|Experimental|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
11134428|NCT03834857|Other|single|Implantation of Stentrode TM device
11134429|NCT03834844|No Intervention|Usual Care|patient receives same care as patients not enrolled in study intervention
11134430|NCT03834844|Experimental|AF education|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week.
11134431|NCT03834844|Experimental|Mindfulness Meditation Practice|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
11134432|NCT03834844|Experimental|Weekly Phone Calls|Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
11134433|NCT03834844|Experimental|AF Education and Mindfulness Meditation|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
11134434|NCT03834844|Experimental|AF Education and Weekly Phone Calls|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
11134435|NCT03834844|Experimental|Mindfulness Meditation and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
11134436|NCT03834844|Experimental|Meditation and Education and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
11134437|NCT03834831|Active Comparator|Coenzyme Q10|Coenzyme Q10 200mg/day for 3 months
11134438|NCT03834831|Active Comparator|Selenium|Selenium mcg/day for 3 months
11134439|NCT03834818|Experimental|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
11134440|NCT03834805|Experimental|Pregnant women with a normal pregnancy|Assesment of fetal lung and liver stiffness with 2D Ultrasounds Shear Wave Elastography
11134441|NCT03834779|Other|DOORS-CHW Intervention|"The type of intervention is behavioral.
~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
11134442|NCT03834779|No Intervention|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
11134443|NCT03834766|Active Comparator|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
11134444|NCT03834766|Placebo Comparator|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
11134445|NCT03834753|Experimental|bevacizumab|ONS-5010
11134446|NCT03834753|Active Comparator|ranibizumab|
11134447|NCT03834740|Experimental|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:
~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
11134448|NCT03834740|Experimental|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:
~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
11134449|NCT03834740|Experimental|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:
~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
11134450|NCT03834714|Active Comparator|Noise Stimulus and Infrared Light|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive infrared light therapy for 2 out of the 4 visits and sham infrared light therapy for the other 2 visits.
11134531|NCT03834129|Placebo Comparator|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
11134451|NCT03834714|Sham Comparator|Noise Stimulus and Sham|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive sham infrared light therapy for 2 out of the 4 visits and infrared light therapy for the other 2 visits.
11134452|NCT03834701|Experimental|EUS guided radiofrequency ablation|Radiofrequency ablation will be performed using a system that consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure.
11134453|NCT03834688|Experimental|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
11134454|NCT03834662|Experimental|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
11134455|NCT03834662|Experimental|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
11134456|NCT03834662|Experimental|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
11134457|NCT03834649|Active Comparator|Mucograft|Soft tissue augmentation of the defective alveolar ridge using Mucograft inside the prepared vestibular pouch leaving part of the mucograft exposed at the crestal area and will be sutured using 5/0 suture material around the defect margin and secured in the vestibular pouch.
11134458|NCT03834649|Experimental|Partially de-epithelialized connective tissue graft|Soft tissue augmentation of the defective alveolar ridge using Partially de-epithelialized connective tissue graft by preparing vestibular pouch at the defect site and place the de-epithelialized part inside the pouch leaving the epithelialized part sutured and exposed at the crestal area
11134459|NCT03834636|Active Comparator|Nanoparticulated composite - self-etch|
11134460|NCT03834636|Active Comparator|Nanoparticulated composite - total-etch|
11134461|NCT03834636|Active Comparator|Nanohybrid composite - self-etch|
11134462|NCT03834636|Active Comparator|Nanohybrid composite - total-etch|
11134463|NCT03834623|Experimental|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
11134464|NCT03834610|Active Comparator|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
11134465|NCT03834610|Active Comparator|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
11134466|NCT03834610|Active Comparator|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
11134467|NCT03834610|Placebo Comparator|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
11134468|NCT03834584|Experimental|AG-636|AG-636 dosed orally.
11134469|NCT03834571|Experimental|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.
~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11134470|NCT03834571|Active Comparator|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.
~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
11134471|NCT03834558|No Intervention|Control Group|They will follow their daily routine without added exercise
11134472|NCT03834558|Experimental|Intervention Group|They will perform the mixed exercise program
11134473|NCT03834545||cycling group|They attended three sessions of exercise on three different conditions : a classic ergometric bicycle without chairback, an ergometric bicycle with chairback with virtual environment and the other session without virtual environment
11134474|NCT03834532|Experimental|Intervention|Participants randomized to the intervention group will receive a breast reconstruction decision aid. Participants will be provided instructions on how to access and navigate the decision aid. Participants will access the decision aid through a website link that is emailed to them or on a tablet at the study site.
11134475|NCT03834532|Active Comparator|Control|Participants randomized to the control group will receive two website pages on healthy living with breast cancer from an educational website. Participants will be provided instructions on how to access and navigate the website pages. Participants will access the website pages through a link that is emailed to them or on a tablet at the study site.
11134476|NCT03834519|Experimental|Pembrolizumab + Olaparib|Participants receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).
11134477|NCT03834519|Active Comparator|Abiraterone + Prednisone or Enzalutamide|Participants receive abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone 10 mg as one 5 mg tablet BID until progression OR Participants receive enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules QD until progression.
11134478|NCT03834506|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
11134532|NCT03834116|Experimental|Inspiratory muscle training group|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
11134533|NCT03834116|No Intervention|Control group|The control group will receive standard treatment in a fast-track design.
11134534|NCT03834103|Other|Arm 1: Self-rehabilitation arm|Self-rehabilitation arm
11134479|NCT03834506|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).
~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
11134480|NCT03834493|Experimental|Pembrolizumab + Enzalutamide|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.
11134481|NCT03834493|Placebo Comparator|Placebo + Enzalutamide|Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.
11134482|NCT03834480|Experimental|• Steroid Group (S)|
11134483|NCT03834480|Experimental|• Platelet rich plasma Group (PRP)|
11134484|NCT03834467|Experimental|Arm 1 - Elevation Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 1 then presents the Moral Elevation stimulus video after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
11134485|NCT03834467|Sham Comparator|Arm 2 - Control Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 2 then presents the control stimulus (nature video) after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
11134486|NCT03834454|Active Comparator|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
11134487|NCT03834454|Active Comparator|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
11134488|NCT03834441|Other|Oral screening|
11134489|NCT03834441|Other|Written screening|
11134490|NCT03834428|Active Comparator|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
11134491|NCT03834428|Experimental|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
11134492|NCT03834415|Experimental|Lactobacillus reuteri DSM17038|Lactobacillus reuteri DSM17038, 1x108 CFU once a day for 30 days
11134493|NCT03834415|Placebo Comparator|Placebo probiotics|Placebo for probiotics, pols drops similar in consistency and flavor as experimental product
11134494|NCT03834389|Experimental|Experimental Group|Experimental group: case-based teaching method applied
11134495|NCT03834389|No Intervention|Control Group|Control group: classical teaching method applied
11134496|NCT03834363|Active Comparator|Morphine capsules and Placebo patch|Morphine retard 10 mg twice daily Placebo patch, change every three days.
11134497|NCT03834363|Experimental|Placebo capsules and Fentanyl patch|Placebo capsules twice daily Fentanyl patch 12 mcg/hr, change every three days
11134498|NCT03834363|Placebo Comparator|Placebo capsules and Placebo patch|Placebo capsules twice daily Placebo patch, change every three days
11134499|NCT03834350|Other|At-Home Breathes Program|Participants will participate in the at-home BREATHES program which will consist of a video education module and using a hand-held spirometry device, SpiroPD.
11134500|NCT03834324|Experimental|intervention|FES
11134501|NCT03834311|Experimental|isokinetic|
11134502|NCT03834311|Active Comparator|exercise band|
11134503|NCT03834298|Experimental|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
11134504|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
11134505|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
11134506|NCT03834272|Experimental|1st Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
11134507|NCT03834272|Experimental|2nd Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.5 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
11134508|NCT03834272|Experimental|3rd Tier Dose Level- LUM Imaging System|12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
11134509|NCT03834259|Active Comparator|Group 1|12.5 mg 0.5% hyperbaric bupivacaine
11134510|NCT03834259|Active Comparator|Group 2|10 mg 0.5% hyperbaric bupivacaine
11134511|NCT03834259|Active Comparator|Group 3|12.5 mg 0.5% hyperbaric bupivacaine
11134512|NCT03834233|Experimental|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
11134513|NCT03834220|Experimental|Debio 1347|Participants will receive Debio 1347 once daily from Day 1 to Day 28 in 28-Day cycles.
11134514|NCT03834207|Experimental|Intervention Group|Use of the C3-Cloud IT system
11134535|NCT03834090|Experimental|rESWT|the group receiving rESWT
11134536|NCT03834090|Active Comparator|supervised exercises|the group receiving supervised exercises
11134537|NCT03834077|Experimental|Tissue flossing|Conventional physiotherapy consisted in electrotherapy and stretching in addition to tissue flossing.
11134538|NCT03834077|Placebo Comparator|Placebo comparator|Conventional physiotherapy consisted in electrotherapy and stretching in addition with tissue flossing without tension.
11134743|NCT03832803|Experimental|Empty Bladder|Empty bladder prior to treatment.
11134515|NCT03834194|Experimental|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
11134516|NCT03834194|Experimental|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
11134517|NCT03834194|Experimental|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
11134518|NCT03834194|Experimental|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
11134519|NCT03834194|Experimental|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
11134520|NCT03834194|Experimental|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
11134521|NCT03834194|Experimental|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
11134522|NCT03834194|Experimental|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
11134523|NCT03834181|Experimental|Monitoring evaluation|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"
11134524|NCT03834168|Other|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
11134525|NCT03834155|Experimental|Hospital-based CR + Movn Application|Hospital-based CR +mobile application
11134526|NCT03834155|Experimental|Choice CR + mobile application|Choice of hospital or home-based CR + Movn Application
11134527|NCT03834155|Experimental|Hospital-based CR + Movn Application +Nudge|Hospital-based CR + mobile application and nudges
11134528|NCT03834155|Experimental|Choice CR + mobile application and nudges|Choice of Hospital or home-based CR + Movn Application + Nudge
11134529|NCT03834142|Experimental|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
11134530|NCT03834129|Experimental|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
11134539|NCT03834064|Experimental|Intervention|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the intervention arm. Caregivers working in that home will receive the oral health promotion strategy/intervention over the course of a year.
11134540|NCT03834064|No Intervention|Control|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the control arm. Caregivers in that home will not receive the oral health promotion strategy/intervention over the course of a year but will be offered a compressed intervention after a year.
11134541|NCT03834051|Experimental|Open Label|Fecal Microbiota Transplantation
11134542|NCT03834038|Experimental|Open Label Lyophilized Fecal Microbiota Transplantation|Eligible participants with history of recurrent or refractory CDI
11134543|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of practice supports available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
11134544|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of practice supports available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
11134545|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of practice supports available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
11134546|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of practice support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
11134547|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of practice support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
11134548|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of practice support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
11134549|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of practice support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
11134550|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of practice support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
11134551|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of practice support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
11134552|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of practice support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
11134553|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of practice support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
11134554|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of practice support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
11134555|NCT03834012|Experimental|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
11134556|NCT03834012|Active Comparator|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
11134557|NCT03834012|Placebo Comparator|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
11134558|NCT03834012|Experimental|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
11134559|NCT03833999|Experimental|Ondansetron and lactulose|Ondansetron 8mg three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
11134560|NCT03833999|Placebo Comparator|Placebo and lactulose|placebo oral capsule, one three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
11134561|NCT03833986|Experimental|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
11134562|NCT03833986|No Intervention|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
11134563|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
11134564|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
11134565|NCT03833960||1-cN0/pN0|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was ypN0.
11134566|NCT03833960||2-cN+/pN0|Patients with initially clinically involved axilla (cN1-2), submitted to neoadjuvant treatment, followed by surgical procedure within ALND or SLNB was done, and the final pathological report was complete axillary remission (ypN0).
11134567|NCT03833960||3-cN0/pN+|Patients with initially clinically negative axilla (cN0), submitted to neoadjuvant treatment, followed by surgical procedure within SLNB was done, followed by ALND because of positive pathological report of sentinel node(s).
11134568|NCT03833960||4-cN+/pN+|Patients with initially clinically positive axilla (cN1-3) submitted to neoadjuvant treatment, followed by surgical procedure within ALND was done and the final pathological report was ypN1-3.
11134569|NCT03833947|Experimental|lignocaine with bicarbonate|Endotracheal tube cuff was filled with mixture of 7.5% sodium bicarbonate with 2% lignocaine in a ratio of 0.5:9.5 ml
11134570|NCT03833947|Active Comparator|lignocaine with dexamethasone|Endotracheal tube cuff was filled with mixture of dexamethasone with 2% lignocaine in a ratio of 0.5:9.5 ml
11134571|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
11134572|NCT03833921|Other|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
11134573|NCT03833908|Experimental|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
11134574|NCT03833908|No Intervention|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
11134575|NCT03833895|Experimental|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
11134576|NCT03833895|Experimental|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
11134577|NCT03833895|Placebo Comparator|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
11134578|NCT03833882|Experimental|MAF1217/Cationorm|
11134579|NCT03833882|Experimental|Cationorm/MAF1217|
11134580|NCT03833869|Experimental|Assisted hatching|Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
11134581|NCT03833869|No Intervention|Control|Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
11134582|NCT03833843||TGA|
11134583|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) >20 injections
11134584|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) < 5 injections
11134585|NCT03833817|Experimental|Intervention arm|This study is a single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
11134586|NCT03833804|Experimental|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
11134587|NCT03833791|Active Comparator|Control Group (CON)|education and modifying diet
11134588|NCT03833791|Experimental|Moderate physical activity Group (PAM)|education, modifying diet and physical activity prescription
11134589|NCT03833791|Experimental|Intensity physical activity Group (PAI)|education, modifying diet and physical activity prescription
11134590|NCT03833778|Other|Intervention group|Answering disease related questions during playing a tablet game
11134591|NCT03833778|No Intervention|control group|
11134592|NCT03833765|Experimental|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
11134593|NCT03833765|Active Comparator|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
11134594|NCT03833752|Experimental|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
11134595|NCT03833752|Active Comparator|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
11134615|NCT03833596|Active Comparator|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
11134744|NCT03832803|Other|Full Bladder|Conventional drinking protocol - 200ml water prior to treatment.
11134596|NCT03833739|Experimental|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.
~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
11134597|NCT03833739|Experimental|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.
~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
11134598|NCT03833726|Experimental|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
11134599|NCT03833726|Sham Comparator|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
11134600|NCT03833713|Experimental|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
11134601|NCT03833713|Active Comparator|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
11134602|NCT03833700|Experimental|Dose Escalation Part: E7386|Participants will receive E7386 10, 15, 20 mg (milligram) or more, tablets, orally, twice daily, in 28-days treatment cycle until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
11134603|NCT03833700|Experimental|Expansion Part|Participants will receive E7386, tablets, orally, twice daily in 28-days treatment cycle until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. The highest dose of E7386 which is deemed tolerable or the optimal dose based on PK or PD analysis in dose escalation part will be used.
11134604|NCT03833687|Experimental|Profhilo®|"The 1st treatment was performed during the basal visit and repeated after 1 month.
~3 mL of Profhilo® for each brachial zone, 1.5 mL for hemiabdomen was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 horizontal-levels for each tested areas (3-4-3 injection points respectively for the 1st, the 2nd and the 3rd horizontal-level). The amount of product to be injected was of 0.3 ml for each point."
11134605|NCT03833674|Experimental|Adults with incomplete SCI|Adults with chronic, incomplete SCI who have >20% impairment in respiratory function, who will complete a battery of clinical assessments and 4 randomly ordered intervention and testing blocks (Daily AIH Block, Sham dAIH Block, Respiratory Strength Training Block and AIH + Strength Training Block).
11134606|NCT03833661|Experimental|M7824|
11134607|NCT03833648|No Intervention|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
11134608|NCT03833648|Experimental|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
11134609|NCT03833635|Experimental|OMT|
11134610|NCT03833635|Placebo Comparator|Control|
11134611|NCT03833622|Experimental|Shared decision aid assessment|Patients will be selected to have a goals of care discussion with an emergency physician utilizing a pilot decision aid and will be asked for feedback to assist with refinement of the decision aid.
11134612|NCT03833609|Experimental|Online yoga training (Group A)|Participants will receive an e-pamphlet on physical exercise developed by The Arthritis Society, and will be invited to complete a yoga training program. The yoga training program is a structured low-intensity Vishwas-Raj. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
11134613|NCT03833609|Experimental|Online aerobic dance training (Group B)|Participants will receive the e-pamphlet on physical exercise and will be invited to complete an aerobic dance program. The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
11134614|NCT03833609|No Intervention|Wait list control (Group C)|Participants will receive the e-pamphlet on physical exercise and will be instructed to continue with their current medical care while they are on the wait list (12 weeks). After the completion of the study, the yoga and aerobic dance training videos will be available to all participants including those in the control group. In recruitment documents, this group will be termed the e-pamphlet group.
11134745|NCT03832790||adolescents with type 1 diabetes|Adolescents ages 14-19 with type 1 diabetes
11134616|NCT03833596|Experimental|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
11134617|NCT03833596|Experimental|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
11134618|NCT03833583|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
11134619|NCT03833583|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
11134620|NCT03833570|Experimental|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment
~Symptomatic treatment which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks
~Symptomatic treatment dose: Three times a day for six weeks"
11134621|NCT03833570|Active Comparator|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:
~Miconaz oral gel
~BBC oral spray
~Oracure gel
~Alkamisr sachets
~Dose: Three times a day for six weeks"
11134622|NCT03833557|Active Comparator|Nanohydroxyapatite Pulpotomy|"Biphasic calcium phosphate. Straumann BoneCeramic Regenerative Pulpotomy of 24 mandibular second primary molars using Nanohydroxyapatite
~In Group 1: 24 mandibular second primary molars Caries removal and deroofing of pulp chamber Following the manufacturer's instructions, Nanohydroxyapatite was mixed with distilled water to homogeneous consistency then introduced into the pulp chamber and condensed properly against the pulp orifices.
~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.
~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy"
11134623|NCT03833557|Active Comparator|MTA Pulpotomy|"Angelus Grey MTA , Regenerative Pulpotomy Pulpotomy of 24 mandibular second primary molars using MTA Caries removal and deroofing of pulp chamber The MTA powder was mixed with sterile water in a 3:1 powder/water ratio according to the manufacturer's instructions to obtain a thick creamy paste, then placed on the floor of the pulp chamber using a messing gun and compacted against the pulp orifices with a condenser over a moist cotton pellet.
~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.
~Clinical and radiographic evaluation at one, three ,six & 12 months after pulpotomy."
11134624|NCT03833557|Active Comparator|Formocresl Pulpotomy|"Buckley' s Formocresol , Fixation pulpotomy Pulpotomy of 24 mandibular second primary molars using Formocresol Caries removal and deroofing of pulp chamber
~A cotton pellet with formocresol was placed on the pulp stumps then removed and ZO/E dressing was condensed against the pulp stumps.
~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.
~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy for clinical and radiographic evaluation. Independently, two examiners evaluated the teeth clinically and radiographically."
11134625|NCT03833544|Experimental|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
11134626|NCT03833531|Active Comparator|PTSD-ImRS|PTSD treatment
11134627|NCT03833531|Experimental|Integrated SFT-ImRS|Integrated PTSD-PD treatment
11134628|NCT03833518|Experimental|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
11134629|NCT03833505||Group 1,|E. vermicularis-positive
11134630|NCT03833505||Group 2|E. vermicularis-negative
11134631|NCT03833492|Experimental|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
11134632|NCT03833492|No Intervention|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
11134633|NCT03833479|Experimental|No further treatment|No further treatment
11134634|NCT03833479|Experimental|TSR-042|TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted).
11134635|NCT03833466|Experimental|metformin and chemotherapy|
11134636|NCT03833453|Active Comparator|PTSD-EMDR|PTSD treatment
11134637|NCT03833453|Experimental|Integrated DBT-EMDR|Integrated PTSD-PD-treatment
11134638|NCT03833440|Experimental|Durvalumab + Monalizumab|
11134639|NCT03833440|Experimental|Durvalumab + MEDI9447|
11134640|NCT03833440|Experimental|Durvalumab + AZD6738|
11134641|NCT03833440|Active Comparator|Docetaxel|
11134642|NCT03833427|Experimental|Selumetinib at Dose Level 1 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; every three weeks [Q3W]) in combination with selumetinib at dose level 1 (dosed orally; twice daily [BID]) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134643|NCT03833427|Experimental|Selumetinib at Dose Level 2 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 2 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134644|NCT03833427|Experimental|Selumetinib at Dose Level 3 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 3 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134645|NCT03833427|Experimental|Selumetinib at Dose Level 4 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 4 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134646|NCT03833427|Experimental|Selumetinib at Dose Level 5 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 5 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134879|NCT03831958||Family member|Family member of survivor of pediatric Cushing disease
11134647|NCT03833427|Experimental|Selumetinib at Dose Level 6 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 6 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134648|NCT03833427|Experimental|Selumetinib at Dose Level 7 + Pembrolizumab|Participants receive 200 mg pembrolizumab (IV infusion; Q3W) in combination with selumetinib at dose level 7 (dosed orally; BID) for up to 35 treatment cycles (cycle length: 3 weeks). During each 3-week cycle, selumetinib will be administered only for the first two weeks.
11134649|NCT03833414||(Group1)|Triceps lifting approach .
11134650|NCT03833414||(Group 2)|olecranon osteotomy approach
11134651|NCT03833401|Sham Comparator|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation. This will serve as control group.
11134652|NCT03833401|Experimental|Autologous tissue transplantation|Root canal disinfection will be performed and revascularization will be induced with autologous tissue transplantation.
11134653|NCT03833388|Experimental|TOP1630 Ophthalmic Solution|
11134654|NCT03833388|Placebo Comparator|Placebo to TOP1630 Ophthalmic Solution|
11134655|NCT03833375|No Intervention|Usual Care (n=20)|Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
11134656|NCT03833375|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
11134657|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally
~Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
11134658|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally
~Placebo Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
11134659|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally
~Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
11134660|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally
~Placebo Ritonavir - 1 capsule once a day orally
~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.
~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
11134661|NCT03833349|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11134662|NCT03833349|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11134663|NCT03833349|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11134664|NCT03833336|Placebo Comparator|Placebo|normal saline solution plus oral lactose capsules
11134665|NCT03833336|Active Comparator|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
11134666|NCT03833336|Active Comparator|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
11134667|NCT03833336|Active Comparator|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
11134668|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
11134669|NCT03833284|Experimental|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
11134702|NCT03833089|No Intervention|Control|ICD recipients in optimal Medical treatment as per guidelines according to their comorbidity
11134880|NCT03831958||Subjects|survivor of pediatric Cushing disease
11134670|NCT03833284|Experimental|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
11134671|NCT03833271|Active Comparator|TNF-alpha inhibitor|
11134672|NCT03833271|Active Comparator|Methotrexate|
11134673|NCT03833271|Active Comparator|Healthy|
11134674|NCT03833258|No Intervention|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
11134675|NCT03833258|Experimental|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
11134676|NCT03833245|No Intervention|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
11134677|NCT03833245|Experimental|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
11134678|NCT03833232|Experimental|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
11134679|NCT03833232|No Intervention|gastrectomy without omentopexy|Gastric section without omentopexy
11134680|NCT03833219|No Intervention|Control (monitor only)|Continue in monitoring only mode
11134681|NCT03833219|Experimental|Social comparison feedback|Report user's handheld phone use/ hour of driving for week. Compare this week's performance to distribution for driver cohort.
11134682|NCT03833219|Experimental|End of rating period incentive|Monitor throughout intervention period and compare overall use to distribution for cohort. Notify participant at end of intervention period regarding the amount they have earned.
11134683|NCT03833219|Experimental|End of rating period incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant at end of intervention period regarding the amount they have earned.
11134684|NCT03833219|Experimental|Weekly loss-framed incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned.
11134685|NCT03833219|Experimental|Larger weekly loss-framed incentive+social comparison feedback|"Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned. Incentive amount is higher than Weekly loss-framed incentive + social comparison feedback Arm."
11134686|NCT03833206|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
11134687|NCT03833206|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
11134688|NCT03833193|Experimental|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
11134689|NCT03833180|Experimental|VLS-101 Schedule 1|Open label VLS-101 at 0.5,1.0, 1.5, 2.25, 2.5, 2.75, or 3.0 mg/kg given IV on Day 1 of repeated 21-day cycles.
11134690|NCT03833180|Experimental|VLS-101 Schedule 2|Open label VLS-101 at 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, or 2.25 mg/kg given IV on Days 1 and 8 of repeated 21-day cycles.
11134691|NCT03833180|Experimental|VLS-101 Schedule 3|Open label VLS-101 at 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, or 2.25 mg/kg given IV on Days 1, 8, and 15 of repeated 28-day cycles.
11134692|NCT03833167|Experimental|Pembrolizumab|Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
11134693|NCT03833167|Placebo Comparator|Placebo|Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
11134694|NCT03833154|Experimental|SoC SBRT + Durvalumab Therapy|"SBRT - delivered in 3, 4, 5 or 8 fractions.
~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met."
11134695|NCT03833154|Placebo Comparator|SoC SBRT + Placebo Therapy|"SBRT - delivered in 3, 4, 5 or 8 fractions.
~Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met."
11134696|NCT03833128|Experimental|Group 1 - Part A|REN001 Low Dose oral once daily x 12 weeks
11134697|NCT03833128|Experimental|Group 2 - Part A|REN001 High Dose oral once daily x 12 weeks
11134698|NCT03833128|Experimental|Group 3 - Part B|REN001 High Dose oral once daily x 12 weeks
11134699|NCT03833115|Experimental|vaginal gel containing sodium lauryl sulfate|
11134700|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
11134701|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:
~Severe patients
~Non-severe patients"
11134736|NCT03832816|Experimental|Vaporized THC alone|5mg pure THC
11134703|NCT03833089|Experimental|Targeted serum potassium levels|ICD recipients recipients in optimal Medical treatment as per guidelines according to their comorbidity. In addition to guideline recommended treatment, this cohort will be treated to increase serum potassium levels to 4.5-5.0 mEq/L.
11134704|NCT03833076|Experimental|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.
~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
11134705|NCT03833076|Placebo Comparator|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.
~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
11134706|NCT03833063|Placebo Comparator|placebo|injections with sodium chloride
11134707|NCT03833063|Active Comparator|botulinum toxin A|injections with botulinum toxin A
11134708|NCT03833050||Heart Transplant Recipients|"Heart Transplant Recipients meeting the criteria for enrollment and consented will be followed post transplant for 1 year after enrollment into the study.
~Blood samples will be obtained at their 1, 3, 6, 12 months and any for cause heart biopsy's obtained. There will be no active intervention for recipients that are enrolled. Results from the samples will not be obtained in real time."
11134709|NCT03833024|Active Comparator|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
11134710|NCT03833024|Placebo Comparator|Placebo|"Placebo for 6 months
~1 Tablet, BID (morning and evening) for 6 months"
11134711|NCT03833011|No Intervention|no intervention|
11134712|NCT03833011|Experimental|Osteopathic manipulation|
11134713|NCT03832998|Experimental|Dose Level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
11134714|NCT03832998|Experimental|Dose Level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
11134715|NCT03832998|Placebo Comparator|Placebo|
11134716|NCT03832985|Experimental|Receive an adult-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
11134717|NCT03832985|Experimental|Receive a pediatric-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
11134718|NCT03832985|Active Comparator|Control - No result|Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
11134719|NCT03832972||Women using birth control|
11134720|NCT03832972||Women not using birthcontrol|
11134721|NCT03832959|No Intervention|Non esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.
11134722|NCT03832959|Experimental|Esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM
11134723|NCT03832946|Experimental|A. TD139 10 mg once a day|Inhalation of TD139
11134724|NCT03832946|Experimental|B. TD139 3 mg once a day|Inhalation of TD139
11134725|NCT03832946|Placebo Comparator|C. TD139 Placebo once a day|Inhalation of TD139 Placebo
11134726|NCT03832933|Experimental|High Protein Diet|
11134727|NCT03832933|Active Comparator|Standard Protein Diet|
11134728|NCT03832907|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.
~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
11134729|NCT03832894|Active Comparator|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.
~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
11134730|NCT03832894|Placebo Comparator|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
11134731|NCT03832868|Experimental|Pre-visit decision aid|Patients receiving the decision aid pre-visit will be given a paper copy of the decision aid in the waiting room and will have a minimum of 15 minutes to review it - either in the waiting room or in the exam room while waiting for the electrophysiologist.
11134732|NCT03832868|Experimental|Post-visit decision aid|Patients receiving the decision aid after the encounter will meet with the electrophysiologist first and receive the aid afterward.
11134733|NCT03832855|Experimental|Treatment|4 mg pING-hHER3FL ID or IM
11134734|NCT03832829|Experimental|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
11134735|NCT03832816|Placebo Comparator|Placebo|Distilled Water
11134919|NCT03831633|Experimental|AKYNZEO|
11134746|NCT03832777|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
11134747|NCT03832777|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
11134748|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
11134749|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
11134750|NCT03832751|Experimental|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
11134751|NCT03832751|Active Comparator|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
11134752|NCT03832738|Experimental|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
11134753|NCT03832738|Experimental|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
11134754|NCT03832738|Placebo Comparator|Placebo|Placebo Tablets daily for 16 weeks.
11134755|NCT03832725|Active Comparator|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
11134756|NCT03832725|Active Comparator|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
11134757|NCT03832712|Active Comparator|Surgical|Participants randomized to surgery
11134758|NCT03832712|Active Comparator|Medical|Participants randomized to best medical treatment
11134759|NCT03832699|Experimental|Oral progesterone|
11134760|NCT03832699|Active Comparator|Vaginal progesterone|
11134761|NCT03832686|Experimental|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
11134762|NCT03832686|No Intervention|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
11134763|NCT03832673|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
11134764|NCT03832660|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
11134765|NCT03832660|Active Comparator|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
11134766|NCT03832660|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
11134767|NCT03832647|Experimental|Salicylic acid & Epiduo 0.1%-2.5% Topical Gel|"Salicylic acid: Once-a-day, on the morning, during 12 weeks.
~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
11134768|NCT03832647|Placebo Comparator|Hydréane légère & Epiduo 0.1%-2.5% Topical Gel|"Hydréane légère: Once-a-day, on the morning, during 12 weeks.
~Epiduo gel: Once-a-day, on the evening (before bedtime) during 12 weeks."
11134769|NCT03832634|Other|Fetal Genome Profiling|Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.
11134770|NCT03832621|Experimental|temozolomide + nivolumab + ipilimumab|Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
11134771|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
11134772|NCT03832595|Active Comparator|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
11134773|NCT03832595|Experimental|Intervention Arm|Patients will receive a care bundle
11134774|NCT03832582|Experimental|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
11134775|NCT03832569|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
11134776|NCT03832556|Experimental|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.
~CT scan with biphasic injection of contrast product;
~MRI with injection of contrast."
11134777|NCT03832530|Experimental|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
11134778|NCT03832517|Active Comparator|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
11134779|NCT03832517|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
11134780|NCT03832517|Active Comparator|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
11134781|NCT03832517|Placebo Comparator|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
11134782|NCT03832504|Experimental|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
11134783|NCT03832504|Experimental|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
11134784|NCT03832504|Experimental|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
11134785|NCT03832504|Experimental|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
11134786|NCT03832504|Experimental|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
11134787|NCT03832504|Experimental|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
11134788|NCT03832491|Other|Control Group|"Home Based Therapy: 13 patients with PCD
~Airway clearence techniques, everday of the week, during eight weeks"
11134789|NCT03832491|Experimental|Game and home based therapy group|"Game based approach programme: 13 patients with PCD
~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.
~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.
~Airway clearence techniques, everday of the week, during eight weeks"
11134790|NCT03832478|Experimental|Virtual Reality Headset Given|Virtual Reality headset (Samsung Gear VR) with mindfulness meditation app is given for patient use prior to surgery date and for duration of postoperative stay.
11134791|NCT03832465|Experimental|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
11134792|NCT03832465|Active Comparator|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
11134793|NCT03832452|Experimental|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
11134794|NCT03832452|Placebo Comparator|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
11134795|NCT03832452|Active Comparator|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
11134796|NCT03832452|Experimental|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
11134797|NCT03832452|Experimental|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
11134798|NCT03832452|Placebo Comparator|Part B: Treatment D|A single oral dose of placebo
11134799|NCT03832439|Active Comparator|Probiotic|This arm will be receiving probiotic supplements.
11134800|NCT03832439|Placebo Comparator|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
11134801|NCT03832426|Experimental|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
11134802|NCT03832426|Experimental|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
11134803|NCT03832426|Experimental|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
11134804|NCT03832426|Experimental|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
11134805|NCT03832413||Stroke|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134806|NCT03832413||TBI|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134807|NCT03832413||ABD|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134808|NCT03832413||Fibromyalgia|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134809|NCT03832413||PDD|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134810|NCT03832413||ADHD|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134811|NCT03832413||MCI|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134812|NCT03832413||Dementia|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134813|NCT03832413||Healthy|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134814|NCT03832413||Cognitive impairment|Diagnostic Test: DELPhI (TMS-EEG analysis)
11134815|NCT03832400|Experimental|MET-2 20 g|Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily
11134816|NCT03832400|Experimental|MET-2 40 g|Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily
11134817|NCT03832400|Placebo Comparator|Placebo oral capsule|Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules
11134818|NCT03832387|Experimental|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.
~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
11134920|NCT03831633|Active Comparator|Standard of Care|
11134819|NCT03832387|Active Comparator|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.
~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
11134820|NCT03832361|Experimental|IMGN853|IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
11134821|NCT03832348|Experimental|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
11134822|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
11134823|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
11134824|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
11134825|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
11134826|NCT03832309|Active Comparator|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
11134827|NCT03832309|Other|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
11134828|NCT03832296|Experimental|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
11134829|NCT03832296|Active Comparator|Health Education (Attention Control)|Health Education Intervention
11134830|NCT03832283|Other|Usual Care Depression Screening|Patients randomized to this intervention arm will receive usual care annual depression screening when they come in for a clinic visit and are due for screening. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression screening. The CAD-MDD/CAT-DI screening during clinic visit will occur in a patient room, prior to their appointment with a primary care provider.
11134831|NCT03832283|Experimental|Population MyChart Depression Screening|Patients randomized to this intervention arm will continue to receive usual care annual depression screening when they come in for a clinic visit and are due for screening. In addition, they will receive email invitations to complete the CAD-MDD/CAT-DI screening via MyChart. Email invitations will be sent at preset intervals until depression screening is completed, or the end of the 1-year follow-up period, whichever comes first.
11134832|NCT03832283|Other|Usual Care Depression Monitoring|Patients who have depression and are randomized to this intervention arm will receive usual care PHQ-9 monitoring during clinic visits. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression assessment.
11134833|NCT03832283|Experimental|Population MyChart Depression Monitoring|Patients who have depression and are randomized to this intervention arm will continue to receive usual care depression monitoring when they come for clinic visits. In addition, they will receive email invitations at preset intervals to complete the CAT-DI monitoring via MyChart. Invitations will be sent until major depressive disorder (MDD) remission is achieved, or the 1-year follow-up period ends, whichever comes first.
11134834|NCT03832270|Experimental|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
11134835|NCT03832270|Active Comparator|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
11134836|NCT03832257|Experimental|ECHO CT Intervention|Weekly video conference between hospitalist at Beth Israel and skilled nursing facilities.
11134837|NCT03832257|Other|Matched Non- Participating Facilities|Matched non-participating facilities
11134838|NCT03832244||Simple snoring|Patients undergoing to Sub-mental ultrasonography with Normal sleep: Fewer than 5 events per hour measured in over-night polysomnography
11134839|NCT03832244||Mild OSA|Patients undergoing to Sub-mental ultrasonography with Mild sleep apnea: 5 to 14 events per hour measured in over-night polysomnography
11134840|NCT03832244||Moderate OSA|Patients undergoing to Sub-mental ultrasonography with Moderate sleep apnea: 15 to 29 events per hour measured in over-night polysomnography
11134975|NCT03831165|Experimental|melatonin 3mg + Acyclovir 400mg|GI - melatonin 3mg + Acyclovir 400mg
11134841|NCT03832244||Severe OSA|Patients undergoing to Sub-mental ultrasonography with Severe sleep apnea: 30 or more events per hour measured in over-night polysomnography
11134842|NCT03832231|Experimental|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
11134843|NCT03832218|Other|Mitochondrial disease|Psychiatric assessment
11134844|NCT03832205||Capaciflector monitoring group|Patients undergoing their pre-planned, routine cardiopulmonary exercise test (CPET). Additional, non-invasive capaciflector monitoring only - no therapeutic intervention.
11134845|NCT03832192|Experimental|care.coach Avatar|
11134846|NCT03832192|No Intervention|Control|
11134847|NCT03832179|Active Comparator|Anti-vascular endothelial growth factor|Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
11134848|NCT03832179|Experimental|Ozurdex|Intravitreal Ozurdex
11134849|NCT03832166|Experimental|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F & V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 18 weeks with minimal contact
11134850|NCT03832166|Experimental|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
11134851|NCT03832153||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
11134852|NCT03832153||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
11134853|NCT03832140||Patients with monoclonal gammopathy|
11134854|NCT03832140||patients with a normal plasma protein electrophoresis|
11134855|NCT03832127|Experimental|Fludatep|PET with 18F-Fludarabine
11134856|NCT03832114|Experimental|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
11134857|NCT03832114|Experimental|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
11134858|NCT03832101|Experimental|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
11134859|NCT03832101|Experimental|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
11134860|NCT03832101|Active Comparator|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
11134861|NCT03832088|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated for sarcopenia and balance disorders
11134862|NCT03832075|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
11134863|NCT03832049|Active Comparator|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
11134864|NCT03832049|Experimental|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
11134865|NCT03832049|Experimental|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
11134866|NCT03832049|Experimental|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
11134867|NCT03832049|Experimental|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
11134868|NCT03832036|Experimental|Patients with lumbar disc herniation|
11134869|NCT03832023|No Intervention|Facility-based model|Standard of care of each country
11134870|NCT03832023|Experimental|Community-based model|Screening and initiating preventive therapy in communities
11134871|NCT03832010|Active Comparator|Crisaborole|Participants will be instructed to apply emollient, topical steroid, and or crisaborole (blinded) to affected areas with eczema.
11134872|NCT03832010|Placebo Comparator|Vehicle|Participants will be instructed to apply emollient, topical steroid, and or vehicle (blinded) to affected areas with eczema.
11134873|NCT03832010|Sham Comparator|Control|Participants will be instructed to apply emollient, topical steroid, and or emollient (blinded) to affected areas with eczema.
11134874|NCT03831997||Historical Controls|The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
11134875|NCT03831997||Prospective Arm|The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
11134876|NCT03831984|Active Comparator|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
11134877|NCT03831984|Placebo Comparator|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
11134878|NCT03831971|Experimental|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
11134881|NCT03831945|Placebo Comparator|Group 1|25 HIV-infected Adults (age 18-65 years) on cART with suppressed viremia will be randomized to normal saline placebo
11134882|NCT03831945|Active Comparator|Group 2|25 HIV-infected Adults (age 18-65 years) on cART with suppressed viremia will be randomized to receive VRC01 plus 10-1074
11134883|NCT03831932|Experimental|Treatment (telaglenastat HCl, osimertinib)|Patients receive telaglenastat hydrochloride PO BID and osimertinib PO QD (starting cycle 1 day 16 of phase I). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11134884|NCT03831919|Experimental|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
11134885|NCT03831919|Placebo Comparator|control|Wear single vision spectacles (no add)
11134886|NCT03831906|No Intervention|Control|"All children admitted in the hospital and presenting with WHO-defined severe pneumonia will be immediately managed as part of routine care per the WHO Standard of Care (SOC), including broad spectrum antibiotics, oxygen therapy if required, additional supportive care and specific therapies for comorbidities such as HIV infection.
~For research purposes, children will benefit from HIV testing, malaria testing, and complete blood count (CBC) if not systematically performed as routine care in the country/hospital, as well as from a digitalized chest X-ray (CXR). Additionally, samples will be collected for future biomarkers studies (biobank)."
11134887|NCT03831906|Experimental|Interventional|Children will benefit from the WHO SOC and additional strategies for research purposes (HIV and malaria testing, CBC, CXR, and biobank) as described in the control arm, plus the study intervention.
11134888|NCT03831893|Sham Comparator|Control|A food product similar to the test products but without nopal
11134889|NCT03831893|Experimental|Nopal food product 1|Food product with Nopal
11134890|NCT03831893|Experimental|Nopal food product 2|Food product with Nopal
11134891|NCT03831880|Other|Daily to Weekly|Genotropin to somatrogon
11134892|NCT03831880|Other|Weekly to Daily|somatrogon to Genotropin
11134893|NCT03831867|Experimental|Pilates|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
11134894|NCT03831867|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
11134895|NCT03831854|Active Comparator|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
11134896|NCT03831854|Placebo Comparator|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
11134897|NCT03831841|Experimental|Intervention|Multicomponent exercise programe involving all physical fitness paramenters and consisting on sesions of 1 hour, 3 days a week.
11134898|NCT03831841|No Intervention|Control|Control group with no intervention programe
11134899|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
11134900|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
11134901|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
11134902|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
11134903|NCT03831802|Experimental|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
11134904|NCT03831802|Active Comparator|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
11134905|NCT03831789|Active Comparator|Unilateral cerebellar rTMS|
11134906|NCT03831789|Experimental|Bilateral cerebellar rTMS|
11134907|NCT03831776|Experimental|Bosutinib-Ropeginterferon combination|
11134908|NCT03831776|Active Comparator|Bosutinib monotherapy|
11134909|NCT03831763|Active Comparator|ColdZyme|
11134910|NCT03831763|No Intervention|Optional care only|
11134911|NCT03831750|Experimental|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
11134912|NCT03831750|No Intervention|Control|Participants will receive the standard of care for IBD.
11134913|NCT03831737|Experimental|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.
~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
11134914|NCT03831737|Experimental|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.
~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
11134915|NCT03831724|Experimental|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
11134916|NCT03831711|Experimental|Diagnostic (68-Ga RM2, PET/MRI)|Patients receive 68-Ga RM2 IV and after 45 minutes undergo PET/MRI over 30-60 minutes.
11134917|NCT03831698|Experimental|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
11134918|NCT03831646||dermatological patients|atopic dermatitis and psoriasis patients with mild and moderate severity of dermatoses in the stage of exacerbation
11134921|NCT03831607|Experimental|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
11134922|NCT03831594|Experimental|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
11134923|NCT03831594|Active Comparator|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
11134924|NCT03831581|Experimental|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
11134925|NCT03831568||Children with given device for mechanical cough|
11134926|NCT03831555|Active Comparator|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
11134927|NCT03831555|No Intervention|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
11134928|NCT03831542||direct aspiration group|Transvaginal ultrasound-guided oocyte retrieval was performed 36 hours after ovulation trigger. A 17-gauge double lumen needle will be used to aspirate a single follicle without flushing. If an oocyte is obtained, the subject will be assigned to group 1. If not, operator will proceed with follicular flushing.
11134929|NCT03831542||flushing group|If an oocyte is not obtained with direct aspiration, operator will proceed to follicular flushing and the subject will be assigned to group 2 if an oocyte is obtained following follicular flushing.
11134930|NCT03831529||ICU older patient|Older patient (> 65 years old) admitted to ICU with severe acute cholangitis
11134931|NCT03831516||Non Invasive Electroanatomical Mapping|Patients will undergo non invasive electroanatomical mapping (CardioInsight by Medtronic) prior and during an invasive electrophysiology study and ablation of ventricular Arrhythmias.
11134932|NCT03831503|Experimental|Cohort A|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 0.5 mg DNA/dose. Inoculation will be administered as 0.5 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
11134933|NCT03831503|Experimental|Cohort B|Participants (n=6 per cohort) will be administered 1 injection (Day 0) of INO-A002 at 1 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
11134934|NCT03831503|Experimental|Cohort C|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 2 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
11134935|NCT03831503|Experimental|Cohort D|Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 4 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
11134936|NCT03831464|Experimental|Metformin treatment group|
11134937|NCT03831464|Placebo Comparator|Placebo control group|
11134938|NCT03831451|Experimental|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
11134939|NCT03831451|Active Comparator|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
11134940|NCT03831438|Other|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).
~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
11134941|NCT03831425|Experimental|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
11134942|NCT03831425|Placebo Comparator|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
11134943|NCT03831412|Active Comparator|CBT-I|5 sessions of treating insomnia
11134944|NCT03831412|Active Comparator|ERRT|5 sessions of treating post-trauma nightmares
11134945|NCT03831399|Placebo Comparator|Control Group|"Subjects in control group will receive placebo (lactose) 6g/day in two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.
~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
11134946|NCT03831399|Active Comparator|Intervention Group|"Subjects in intervention group will receive leucine 6g/day, in tin two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.
~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
11134976|NCT03831165|Active Comparator|Acyclovir 400mg|GII - Acyclovir 400mg twice a day
11134977|NCT03831165|Placebo Comparator|placebo + melatonin 3mg|GIII - placebo + melatonin 3mg
11134947|NCT03831386|Active Comparator|Vacuum|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.
11134948|NCT03831386|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
11134949|NCT03831373|Experimental|Upper-limb-focused resistance training|
11134950|NCT03831373|Experimental|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
11134951|NCT03831373|Active Comparator|Stretching exercise|Stretching exercise program in a sitting position.
11134952|NCT03831360|Experimental|Hatha Yoga|12 weeks of hatha yoga
11134953|NCT03831360|Experimental|Group CBT|12 weeks of group CBT
11134954|NCT03831347|Experimental|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
11134955|NCT03831334|Experimental|Minoxidil Treatment|Low dose oral minoxidil
11134956|NCT03831321|Active Comparator|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
11134957|NCT03831321|Placebo Comparator|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
11134958|NCT03831308||Breast cancer new diagnosis|group will include volunteer women, diagnosed with breast cancer, in any stage, aged 18y or more; at least 100 patients will be recruited in medical oncology appointments; all subjects should be periodically submitted to non-invasive evaluation tests - that is, clinical test/clinical and physical assessment to collect information on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
11134959|NCT03831295|Experimental|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.
~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
11134960|NCT03831282|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
11134961|NCT03831269|Active Comparator|Azithromycin|The dose of azithromycin will be 10mg/kg/day oral suspension for 3 consecutive days for pediatric patients (<12 years old) and 500mg/day in three consecutive days for adults. The cycle will be repeated every seven days (3 cycles/month) and will be repeated if required according to patient's response up to 6 cycles. Side effects of therapy will be recorded. This protocol is based on previous case reports.
11134962|NCT03831269|Active Comparator|Nb UVB|Patients recruited for nbUVB phototherapy will have an initial dose of 0.3J-0.5J according to Fitzpatrick's skin type. The dosage will be increased by 0.3J in every other treatment session. The sessions will be given 3 times weekly until improvement is noted or reaching 8 weeks at the EOS. We arrived at this initial dose based on our previous experience with Egyptian patients in Kasr Alainy phototherapy unit in Dermatology Department, Cairo University.
11134963|NCT03831256|Active Comparator|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
11134964|NCT03831256|Experimental|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
11134965|NCT03831243|Active Comparator|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
11134966|NCT03831243|Experimental|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy & Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
11134967|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
11134968|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
11134969|NCT03831191|Experimental|LY3375880 Dose 1|LY3375880 administered subcutaneously (SC).
11134970|NCT03831191|Experimental|LY3375880 Dose 2|LY3375880 administered SC.
11134971|NCT03831191|Experimental|LY3375880 Dose 3|LY3375880 administered SC.
11134972|NCT03831191|Placebo Comparator|Placebo|Placebo administered SC.
11134973|NCT03831178|Experimental|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
11134974|NCT03831178|Placebo Comparator|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
11134978|NCT03831152|Experimental|Experimental ADV7103|All patients receive ADV7103 at their individualized dose
11134979|NCT03831139|Experimental|Prevention|TIM&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
11134980|NCT03831139|No Intervention|Control|The youth participate in school as usual.
11134981|NCT03831126||betamethasone treatment|
11134982|NCT03831113|Experimental|Buprenorphine Magnitude Group|Subjects will receive alternating reductions of 1 mg and then 2 mg weekly. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
11134983|NCT03831113|Experimental|Buprenorphine Frequency Group|Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
11134984|NCT03831113|Experimental|Buprenorphine Dosing Group|Subjects will receive dose reductions identical to either the Magnitude (alternating 1 and 2 mg reductions) or Frequency (2 mg reductions on alternating 1 and 2 week intervals) groups. Subjects on BID dosing, as prescribed by their MAT provider, will be assigned to the Dosing group (n=10).
11134985|NCT03831100|Experimental|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
11134986|NCT03831100|Placebo Comparator|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. Participants in the AC arm will thus undergo 5 weekly, 60-minute, tablet-based video sessions in which they undergo non-manualized discussions with a non-trained member of the study team.
11134987|NCT03831087|Other|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
11134988|NCT03831087|Other|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
11134989|NCT03831061|Experimental|Cognitive stimulation|"10 sessions of 45 minutes/week during 10 weeks. Each session included : (a) temporo-spatial orientation , (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.
~There are 54 participants subdivided into two groups of 27 participants that perform the same intervention in different days of the week."
11134990|NCT03831061|No Intervention|Control group (No intervention)|There are 68 participants in total. These participants did not receive intervention.
11134991|NCT03831048|Experimental|DCD Heart Possible|
11134992|NCT03831048|Active Comparator|Standard of Care Heart Only|
11134993|NCT03831035||15 patients and both parents.|The patients are aged 12 months or under hospitalized in the ICU suffering from multiple congenital malformations and/or neurologic symptoms.
11134994|NCT03831009|Active Comparator|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
11134995|NCT03831009|Active Comparator|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
11134996|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
11134997|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
11134998|NCT03830983||Stroke of likely cardioembolic cause or undetected mechanism|Lesions in at least one territory on MRI & absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% in arteries supplying the ischemic area(s) & absence of severe small vessel disease including micro-bleeds on Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% & absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
11134999|NCT03830983||Atherosclerotic stroke|Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% leading to the infarcted territory & absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% and presence of severe small vessel disease possibly including micro bleeds.
11135000|NCT03830983||Controls|Age and sex matched healthy controls with no history of stroke or AF.
11135001|NCT03830970|Experimental|1/2 cup canned mixed beans|Consumption of 1/2 cup of canned mixed beans everyday for 4 weeks
11135002|NCT03830970|Experimental|1 cup canned mixed beans|Consumption of 1 cup of canned mixed beans everyday for 4 weeks
11135003|NCT03830970|Other|Control: White Rice|Consumption of 1 cup of white rice everyday for 4 weeks
11135004|NCT03830957|Active Comparator|Ivabradine|
11135005|NCT03830957|Active Comparator|metoprolol|
11135006|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI
~Interventions:
~Blood sampling
~transthoracic echocardiography
~Late Gadolinium-Enhancement Cardiac Magnetic Resonance
~Coronary Angio Computed Tomography"
11135007|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI
~Interventions:
~Blood sampling
~transthoracic echocardiography
~Late Gadolinium-Enhancement Cardiac Magnetic Resonance
~Coronary Angio Computed Tomography"
11135008|NCT03830931||Primary knee arthroplasty patients|Fasting Plasma Glucose test will be obtained the morning after surgery and the frequency of hyperglycemia in non diabetic and diabetic patients will be evaluated
11135009|NCT03830918|Experimental|Arm A (temozolomide, niraparib)|Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11135010|NCT03830918|Active Comparator|Arm B (best supportive care)|Patients receive best supportive care.
11135011|NCT03830905|Experimental|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
11135012|NCT03830905|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
11135013|NCT03830892|Active Comparator|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
11135014|NCT03830892|Active Comparator|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
11135015|NCT03830879||No treatment|This cohort study have any no treatment.
11135016|NCT03830866|Experimental|Durvalumab (intravenous infusion)|durvalumab + standard of care concurrent chemoradiation therapy(SoC CCRT) followed by durvalumab monotherapy up to 24 months or until PD from the date of randomization
11135017|NCT03830866|Placebo Comparator|Placebo (matching placebo for intravenous infusion)|placebo + standard of care concurrent chemoradiation therapy(SoC CCRT)
11135018|NCT03830853||Successful CTO PCI achieved|Patients will have successful CTO PCI (chronic total occlusion percutaneous coronary intervention) followed by physiological and intracoronary imaging. These measurements will be repeated at a 3 month follow up angiogram procedure.
11135019|NCT03830840||Adult Individuals with Type 2 diabetes|Individuals ≥18 years of Hispanic/Latino heritage with an established diagnosis of type 2 diabetes
11135020|NCT03830840||Adult Family member|Adult family members, ≥18 years, of the individual with type 2 diabetes
11135021|NCT03830840||Child family member with diabetes|Child, ≥7 years but <18 years, family member with diabetes
11135022|NCT03830840||Child family member without diabetes|Child, ≥7 years but <18 years, family member without diabetes
11135023|NCT03830827|Experimental|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.
~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
11135024|NCT03830827|Experimental|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.
~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
11135025|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
11135026|NCT03830801|Experimental|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
11135027|NCT03830788|Active Comparator|Brachytherapy|radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate
11135028|NCT03830788|Experimental|stereotactic body radiotherapy (SBRT)|radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.
11135029|NCT03830775|Experimental|Experimental - PRP injection|2cc of PRP is injected into the ulnocarpal joint
11135030|NCT03830775|Placebo Comparator|control - Saline injection|2cc of 0.9% sterile saline is injected into the ulnocarpal joint
11135031|NCT03830762|Experimental|Cohort 1 / Cohort 2 (Active)|20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.
11135032|NCT03830762|Placebo Comparator|Cohort 1 / Cohort 2 (Placebo)|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
11135033|NCT03830749|Experimental|Single Arm|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
11135034|NCT03830736|Placebo Comparator|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
11135035|NCT03830736|Experimental|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
11135448|NCT03827772|Other|Control Arm|Nutritional supplementation, supportive management
11135036|NCT03830736|Experimental|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
11135037|NCT03830736|Experimental|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
11135038|NCT03830736|Experimental|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
11135039|NCT03830723|Other|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
11135040|NCT03830710||Group A|30 patients diagnosed with oral leukoplakia
11135041|NCT03830710||Group B|30 patients diagnosed with oral lichen planus
11135042|NCT03830710||Group C|30 patients having oral squamous cell carcinoma with the tongue being the most commonly affected site
11135043|NCT03830710||Group D|30 age and gender matched individuals having no oral mucosal lesions acting as a control group
11135044|NCT03830697|Experimental|Menstruation situation TCM symptom score standard|
11135045|NCT03830697|Placebo Comparator|Sham intervention|
11135046|NCT03830684|Experimental|low-dose group|Baicalein Tablets group
11135047|NCT03830684|Experimental|high-dose group|Baicalein Tablets group
11135048|NCT03830684|Placebo Comparator|placebo group|control group
11135049|NCT03830671|Experimental|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
11135050|NCT03830658|Experimental|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
11135051|NCT03830658|Active Comparator|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
11135052|NCT03830645|Experimental|Platelet rich plasma group|
11135053|NCT03830632|Experimental|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
11135054|NCT03830632|Active Comparator|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .
~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
11135055|NCT03830619||lung cancer patients|
11135056|NCT03830619||normol volunteers|
11135057|NCT03830606|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
11135058|NCT03830593||Group 1|laparoscopic adrenalectomy group 1: tumor size as < 6 (group1)
11135059|NCT03830593||Group 2|Laparoscopic adrenalectomy group2: tumor size ≥ 6 cm (group2)
11135060|NCT03830593||Learning Curve|The patients, underwent laparoscopic adrenalectomy, were also classified into group A (1-25), B (26-50), C (51-75), and D (76-102) according to the chronological order of their surgery in order to evaluate the learning curve.
11135061|NCT03830580|Experimental|Sung voice|
11135062|NCT03830580|No Intervention|Control|
11135063|NCT03830567||Pharmacist prescription|
11135064|NCT03830567||Clinician prescription|
11135065|NCT03830554|Experimental|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
11135066|NCT03830554|No Intervention|control group|participants of this group received no intervention.
11135067|NCT03830528|Experimental|Part A-1|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
11135068|NCT03830528|Experimental|Part A-2|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
11135069|NCT03830528|Experimental|Part A-3|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
11135070|NCT03830528|Experimental|Part B|There will be one cohort of Japanese healthy men dosed with multiple doses of KW-6356 or placebo and one potential additional cohort (KW-6356 dose as determined in Part A or placebo)
11135071|NCT03830528|Experimental|Part C-1|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
11135072|NCT03830528|Experimental|Part C-2|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
11135073|NCT03830528|Placebo Comparator|Placebo|
11135074|NCT03830515|Experimental|Closure of lacerations with microMend|Laceration closure with microMend
11135075|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
11135076|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
11135077|NCT03830489|Experimental|Large volume based preparation|This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.
11135078|NCT03830489|Active Comparator|Low volume based preparation|This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet
11135079|NCT03830476|Experimental|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
11135080|NCT03830476|Active Comparator|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
11135081|NCT03830463|Experimental|CTP-692|
11135082|NCT03830463|Placebo Comparator|Placebo|
11135083|NCT03830437||Case group|The group will be subjected to double weighing, before and after the next 6 breastfeeding. Breastfeeding will be carried out each 4 hr.
11135084|NCT03830437||Control group|The group will be subjected to monitoring of body weight only at 24, 36 hr and 48 hr of life.
11135085|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
11135086|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
11135087|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
11135088|NCT03830411|Experimental|Arm A: Sintilimab|Participants will receive Sintilimab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
11135089|NCT03830411|Active Comparator|Arm B: Chemotherapy (Docetaxel or Pemetrexed)|Participants randomized to the chemotherapy arm will receive docetaxel or pemetrexed until disease progression per standard RECIST v1.1 or unacceptable toxicity.
11135090|NCT03830398|Active Comparator|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
11135091|NCT03830398|Active Comparator|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
11135092|NCT03830398|Placebo Comparator|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
11135093|NCT03830385|Experimental|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
11135094|NCT03830372|Experimental|VR Tier One|"Patients will receive:
~10 sessions of 20 minutes of VR Tire One therapeutic game,
~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,
~30 minutes individual aerobic training,
~30 minutes balance exercises."
11135095|NCT03830372|Active Comparator|Control|"Patients will receive:
~10 sessions of 20 minutes of Schultz Autogenic Training,
~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,
~30 minutes individual aerobic training,
~30 minutes balance exercises."
11135096|NCT03830359|Other|T2769|T2769 Ophthalmic solution One drop in each eye 3 to 6 times daily
11135097|NCT03830346|Experimental|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
11135098|NCT03830346|Experimental|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
11135099|NCT03830333|Experimental|Ceftolozane/Tazobactam + Metronidazole|Ceftolozane 1000 mg / Tazobactam 500 mg; plus Metronidazole 500 mg by intravenous (IV) infusion every 8 hours for 4 to 14 days. Participants with creatinine clearance (CrCL) of 30 to ≤ 50 mL/min will receive Ceftolozane 500 mg / Tazobactam 250 mg.
11135100|NCT03830333|Active Comparator|Meropenem + Placebo|Meropenem 1000 mg; plus saline by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive meropenem by IV infusion every 12 hours.
11135101|NCT03830320|Active Comparator|Healthy Volunteers|In the first stage, twenty (20) healthy adult subjects will be injected with [64Cu]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
11135102|NCT03830320|Experimental|Atrial Fibrillation Patients|In the second stage, forty (40) patients with LAA thrombus documented by TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care.
11135103|NCT03830307|Experimental|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
11135104|NCT03830294|Experimental|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
11135105|NCT03830294|Active Comparator|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
11135106|NCT03830281|Experimental|LY900014|LY900014 administered via continuous subcutaneous (SC) insulin infusion (CSII).
11135107|NCT03830281|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) administered via CSII.
11135108|NCT03830268|Experimental|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.
~Interventions:
~No MCT intake with breakfast, no lunch (i.e. CTL)
~No MCT intake with lunch, no breakfast (i.e CTL inverted)
~10g of Betaquik with breakfast, no lunch (i.e BQ10)
~20g of Betaquik with breakfast, no lunch (i.e BQ20)
~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
11135109|NCT03830268|Experimental|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.
~Interventions:
~No MCT intake with breakfast, no lunch (i.e. CTL)
~No MCT intake with lunch, no breakfast (i.e CTL inverted)
~10g of Betaquik with breakfast, no lunch (i.e BQ10)
~20g of Betaquik with breakfast, no lunch (i.e BQ20)
~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)
~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
11135110|NCT03830255||Renal Transplant patients treated with cyclosporin|
11135111|NCT03830255||Renal Transplant patients treated with tacrolimus|
11135112|NCT03830242|Experimental|<Sup>18<Sup>F-FDG PET/CT study group|<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
11135113|NCT03830242|Other|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
11135114|NCT03830229||1/Germline positive mesothelioma|Individuals with mesothelioma who have a BAPl or other DNA repair/cancer predispositionmutation regardless of CLIA confirmation
11135115|NCT03830229||2/CLIA confirmed germline mutation without mesothelioma|Individuals with a CLIA confirmed BAP1 or other DNA repair/cancer predisposition mutation who do not have a diagnosis of mesothelioma
11135116|NCT03830216|Experimental|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
11135117|NCT03830216|Sham Comparator|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
11135118|NCT03830203|Experimental|BAT1806|BAT1806 injection: 8 mg/kg, intravenous infusion by 60 min
11135119|NCT03830203|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 8 mg/kg, intravenous infusion by 60 min
11135120|NCT03830190|Experimental|Intervention group|Parkinson's disease nurse specialist care
11135121|NCT03830190|No Intervention|Control group|No intervention
11135122|NCT03830177|Experimental|Adults|All adults in the study will receive the treatment for dry scalp.
11135123|NCT03830177|Experimental|Children|All children in the study will receive the treatment for dry scalp.
11135124|NCT03830164|Experimental|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
11135125|NCT03830151|Experimental|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
11135126|NCT03830138||Acute coronary syndrome patients:|One hundred patients with acute coronary syndrome.
11135127|NCT03830138||Controls:|Fifty healthy control
11135128|NCT03830125|Experimental|Single Ascending Doses|
11135129|NCT03830125|Experimental|Multiple Ascending Doses|
11135130|NCT03830112|Experimental|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).
~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).
~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.
~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).
~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
11135131|NCT03830112|Active Comparator|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).
~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).
~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).
~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
11135132|NCT03830086|Other|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
11135133|NCT03830086|Other|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
11135134|NCT03830073||Group I:|Seventy patients with pancreatitis
11135135|NCT03830073||Group II:|Thirty healthy controls
11135136|NCT03830060||Group I:|Fifty AP patients on admission
11135137|NCT03830060||Group II:|The previous AP patients after 72 hours
11135138|NCT03830047|Active Comparator|nd yag laser|Applying nd yag laser to vulva
11135139|NCT03830047|Sham Comparator|Co2 laser|Applying CO2 laser to vulva
11135491|NCT03827551|Experimental|Parkinson's Patients|
11135140|NCT03830034|Experimental|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
11135141|NCT03830034|Active Comparator|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.
11135142|NCT03830021|Experimental|Salt reduction program|Salt reduction program.
11135143|NCT03830021|Active Comparator|Healthy lifestyle program|Healthy lifestyle program.
11135144|NCT03830008|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
11135145|NCT03830008|Experimental|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
11135146|NCT03829995|No Intervention|Control group|Participants in the control group received the normal care following the Danish standard procedure.
11135147|NCT03829995|Active Comparator|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
11135148|NCT03829982|Experimental|bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
11135149|NCT03829982|Experimental|dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
11135150|NCT03829969|Experimental|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
11135151|NCT03829969|Placebo Comparator|placebo|Placebo combine with paclitaxel and cisplatin
11135152|NCT03829956|Other|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
11135153|NCT03829943||Vitamin D deficiency|The study group will be males discovered to have Vitamin D deficiency.
11135154|NCT03829943||Control group|The control group will be males with normal Vitamin D status
11135155|NCT03829930|Experimental|Entinostat and Enzalutamide|Entinostat and Enzalutamide
11135156|NCT03829917|Experimental|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day [50 mg tid] for 28 days.
11135157|NCT03829917|Active Comparator|Miltefosine|Miltefosine pills alone [2.5 mg/day [50 mg tid] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
11135158|NCT03829917|Active Comparator|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
11135159|NCT03829904|Experimental|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
11135160|NCT03829904|Placebo Comparator|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
11135161|NCT03829891|Experimental|Beinaglutide|"Beinaglutide for 8 weeks,
~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
11135162|NCT03829891|Active Comparator|glargine|"Glargine for 8 weeks,
~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
11135163|NCT03829878|Experimental|CP101|CP101 (Full Spectrum Microbiota) Capsule
11135164|NCT03829878|Placebo Comparator|Placebo|Placebo for CP101
11135165|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
11135166|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
11135167|NCT03829839|Active Comparator|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
11135168|NCT03829839|Active Comparator|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
11135169|NCT03829826||Patients receiving IVIg|Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.
11135170|NCT03829826||de novo SCIg patients/IVIg-Naive Group|This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
11135196|NCT03829670||Patients without delirium|"Cytochrome P450 testing
~Delirium Status: Admission, Hospital Discharge, Outpatient Visit
~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
11135171|NCT03829813|Experimental|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
11135172|NCT03829813|Experimental|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
11135173|NCT03829813|Experimental|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
11135174|NCT03829800|Experimental|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
11135175|NCT03829800|Experimental|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
11135176|NCT03829800|Experimental|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
11135177|NCT03829800|Active Comparator|Glicolab®|Glucose solution
11135178|NCT03829787||Bipolar without Anxiety or Substance Use Disorder|Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
11135179|NCT03829787||Bipolar disorder with a current anxiety disorder only|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
11135180|NCT03829787||Bipolar disorder with a current anxiety disorder and a current|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
11135181|NCT03829787||Bipolar disorder with a current substance use disorder only|Subjects who are diagnosed with bipolar disorder & a substance use disorders but not a current anxiety disorder
11135182|NCT03829787||Healthy Volunteers|
11135183|NCT03829774|Experimental|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
11135184|NCT03829774|Placebo Comparator|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
11135185|NCT03829761|Experimental|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
11135186|NCT03829761|Sham Comparator|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
11135187|NCT03829748|Experimental|Intermittent aspiration|Empty syringe of 10cc and intermittent aspiration during puncture
11135188|NCT03829748|No Intervention|Continous/standard aspiration|Empty syringe of 10cc and continous aspiration during puncture
11135189|NCT03829735|Experimental|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
11135190|NCT03829722|Experimental|Nivolumab, Carboplatin/Paclitaxel, Radiotherapy|Therapy will continue for 21 weeks total. This includes 4 doses of of nivolumab (240mg/m2) before and concurrent with RT/carboplatin/paclitaxel and 4 adjuvant nivolumab doses (480mg/m2) after the end of RT.
11135191|NCT03829709|Experimental|Intervention Group|The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
11135192|NCT03829696|Experimental|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.
~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
11135193|NCT03829683|Active Comparator|Vitamin C infusion (ascorbic acid)|Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)
11135194|NCT03829683|Placebo Comparator|Placebo|Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours
11135195|NCT03829670||Delirium Group|"UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.
~The participant may decline participation after this UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) assessment and will be removed from the study.
~The Short IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) is administered to the legally authorized representative or caregiver by Dr. Schmidt. If the potential participant scores 3.3 or lower, the participant will continue in the delirium group. If higher, patient likely with pre-existing dementia. These patients are not eligible for study participation.
~Delirium Rating Scale 98 will be performed on the ALGH (Advocate Lutheran General Hospital) rehabilitation unit
~Cytochrome P450 testing
~Delirium Status: Admission, Hospital Discharge, Outpatient Visit
~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
11136025|NCT03823677|Experimental|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
11135197|NCT03829657|Experimental|ampreloxetine (Open Label (OL))|Participants will receive ampreloxetine as a single, oral, daily dose of active drug for 16 weeks.
11135198|NCT03829657|Experimental|ampreloxetine|After completing the OL, participants randomized to ampreloxetine will receive single, oral, daily dose of active drug for a further 6 weeks.
11135199|NCT03829657|Placebo Comparator|Placebo|After completing the OL, participants randomized to Placebo will receive single, oral, daily dose of placebo for 6 weeks.
11135200|NCT03829644|Experimental|Intervention|Participants in the intervention arm will be fitted with a semi-rigid prefabricated lumbar brace (Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618) in addition to their current back pain management program.
11135201|NCT03829644|No Intervention|Control|Participants in this arm will be instructed to follow their current back pain management program.
11135202|NCT03829631|Experimental|Intervention|Participants will be instructed to follow their current low back pain management program, in addition, they will be instructed to wear a lumbar brace (Horizon 627 Lumbar Brace) during the day for four weeks only when they are in pain in addition to their current management program.
11135203|NCT03829631|No Intervention|Control|Participants will be instructed to follow their current low back pain management program.
11135204|NCT03829618|Active Comparator|Topical Lidocaine|16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.
11135205|NCT03829618|Active Comparator|Nebuliser Solution|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.
11135206|NCT03829618|Active Comparator|Nebuliser Suspension|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.
11135207|NCT03829605||Group I:|Fifty AMI patients on admission
11135208|NCT03829605||Group II:|The previous AMI patients after 12 hours
11135209|NCT03829592|Placebo Comparator|misoprostol in neutral media|Intervention : misoprostol in a neutral media will be given to women to induce labour
11135210|NCT03829592|Active Comparator|Misoprostol in acidic media|Intervention : misoprostol in acidic media will be given to induce labour
11135211|NCT03829592|Sham Comparator|Misoprostol in alkaline media|Intervention : misoprostol in alkaline media will be given to induce labour
11135212|NCT03829566|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
11135213|NCT03829553|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
11135214|NCT03829553|Active Comparator|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
11135215|NCT03829540|Experimental|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
11135216|NCT03829527|Experimental|Psychotherapy|
11135217|NCT03829514|Experimental|Fenofibrate|Single arm. Participants will take study medication
11135218|NCT03829501|Experimental|KY1044 monotherapy phase 1|KY1044 monotherapy dose escalation
11135219|NCT03829501|Experimental|KY1044 and atezolizumab phase 1|KY1044 and atezolizumab combination dose escalation
11135220|NCT03829501|Experimental|KY1044 monotherapy phase 2|KY1044 monotherapy
11135221|NCT03829501|Experimental|KY1044 and atezolizumab phase 2|KY1044 and atezolizumab combination
11135222|NCT03829488|Experimental|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
11135223|NCT03829488|Active Comparator|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
11135224|NCT03829475|Experimental|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
11135225|NCT03829475|Placebo Comparator|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
11135226|NCT03829462|Experimental|Irinotecan + regorafenib (REGIRI)|irinotecan (180 mg/m2) at day1 of each cycle + regorafenib (160 mg/day) from day 2 to day 8
11135227|NCT03829462|Active Comparator|regorafenib|Regorafenib (160 mg/day) for 3 weeks followed by 1 week off
11135228|NCT03829449|Experimental|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
11135229|NCT03829436|Experimental|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
11135230|NCT03829436|Experimental|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression.
11135231|NCT03829436|Experimental|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
11135232|NCT03829436|Experimental|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
11135257|NCT03829202|Experimental|A-B-A Group|Daily use of own mechanical knee for 4 weeks (A), followed by RheoKnee microprocessor prosthetic knee for 4 weeks (B), and concluding with own mechanical knee for 4 weeks (A).
11135233|NCT03829410|Experimental|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m2 orally Day 1 through 5 every 14-days over two treatment courses (1 cycle) in combination with FOLFIRI (180 mg/m2 irinotecan, 400 g/m2 leucovorin, 400 mg/m2 bolus 5-fluorouracil (5-FU), and 2400 mg/m2 continuous intravenous infusion 5-FU) + 5 mg/kg bevacizumab.
~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) orally Day 1 through 5 every 14-days over two treatment courses (1 cycle) in combination with FOLFIRI (180 mg/m2 irinotecan, 400 g/m2 leucovorin, 400 mg/m2 bolus 5-fluorouracil (5-FU), and 2400 mg/m2 continuous intravenous infusion 5-FU) + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
11135234|NCT03829384|Experimental|mRNA-1944|Escalating dose levels
11135235|NCT03829384|Placebo Comparator|Placebo|Saline
11135236|NCT03829371|Experimental|ARM A|"ARM A
~Velcade (V):
~1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;
~1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.
~Melphalan (M):
~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.
~Prednisone (P):
~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
11135237|NCT03829371|Experimental|ARM B|"ARM B:
~Lenalidomide (R):
~-25 mg orally on days 1-21 of each cycle.
~Dexamethasone (d):
~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
11135238|NCT03829358|Experimental|Probiotic|Lactobacillus plantarum IS-10506
11135239|NCT03829358|Placebo Comparator|Placebo|Placebo
11135240|NCT03829345|Experimental|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
11135241|NCT03829332|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
11135242|NCT03829332|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
11135243|NCT03829319|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
11135244|NCT03829319|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
11135245|NCT03829293|Experimental|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
11135246|NCT03829293|No Intervention|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
11135247|NCT03829280|Experimental|Cognitive Adaptation Training|Psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery.
11135248|NCT03829280|Active Comparator|Community Treatment|Medication follow-up and case management as provided by the community mental health center according to usual care.
11135249|NCT03829267|Experimental|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
11135250|NCT03829267|Active Comparator|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
11135251|NCT03829254|Experimental|NUC-7738|NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
11135252|NCT03829241|Experimental|Arm 1: BHV-4157- Experimental|
11135253|NCT03829241|Placebo Comparator|Arm 2: Placebo Comparator Drug|
11135254|NCT03829228|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.
11135255|NCT03829215|Experimental|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.
~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.
~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
11135256|NCT03829215|No Intervention|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.
~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.
~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
11135258|NCT03829202|Experimental|B-A-B Group|Daily use of RheoKnee microprocessor prosthetic knee for 4 weeks (B), followed by own mechanical knee for 4 weeks (A), and concluding with RheoKnee microprocessor prosthetic knee for 4 weeks (B).
11135259|NCT03829189|Active Comparator|inulin|
11135260|NCT03829189|Placebo Comparator|maltodextrin|
11135261|NCT03829176|No Intervention|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
11135262|NCT03829176|Experimental|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
11135263|NCT03829163|Active Comparator|Conventional Walker Group|
11135264|NCT03829163|Experimental|HAW Group|
11135265|NCT03829150|Experimental|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
11135266|NCT03829150|Experimental|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
11135267|NCT03829137|Experimental|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
11135268|NCT03829137|Sham Comparator|Sham laser acupuncture|sham laser acupuncture (no laser output)
11135269|NCT03829124|Experimental|ketamine + propofol group|use ketamine + propofol for ECT induction
11135270|NCT03829124|Active Comparator|propofol group|use propofol only for ECT induction
11135271|NCT03829111|Active Comparator|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11135272|NCT03829111|Experimental|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11135273|NCT03829085|Active Comparator|Early oral refeeding|"The patients will be started the oral refeeding from the first day of admission in the hospital.
~Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day"
11135274|NCT03829085|No Intervention|FASTING|The oral diet will be reintroduced in a traditional stepwise manner until the symptoms, signs, inflammatory parameters of AP have resolved
11135275|NCT03829072|Experimental|cooking Education and adapted physical activity|
11135276|NCT03829046|Placebo Comparator|Placebo|Placebo SC QM
11135277|NCT03829046|Active Comparator|Evolocumab|Evolocumab SC 420mg/dL QM
11135278|NCT03829033|Active Comparator|Radiotherapy delivered with photons|
11135279|NCT03829033|Experimental|Radiotherapy delivered with protons|
11135280|NCT03829020|Experimental|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-21 of cycle 1 and days 1-14 of cycles 2-6. Patients also receive nelfinavir mesylate PO on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with PD at any time within 5 cycles or no uMR or MR after 2 cycles or no uPR or PR after 4 cycles also receive bortezomib SC once weekly every 21 days in the absence of disease progression or unacceptable toxicity.
11135281|NCT03829007|Experimental|PD-L1 imaging|89Zr-durvalumab iv injection followed by a PET/CT scan at day 5 after injection.
11135282|NCT03828994|Experimental|TECH-PN|Participants receive community health nurse visits, text-messaging support, additional testing and field based visits with a nurse practitioner.
11135283|NCT03828994|No Intervention|TECH-N|Participants receive enhanced standard of care with community health nurse visits and text-messaging support.
11135284|NCT03828981|Active Comparator|fast-track recovery program|"Pre-operative Verbal and video information Tobacco cessation Daily physical activity Light meal 6 hours and clear liquids up to 2 hours before surgery No bowel preparation A warm blanket Premedication paracetamol 1g and tematsepam 20mg
~Intraoperatively For nausea and voimiting dexamethasone 10mg, dehydrobensperidol 1mg and ondancetron 4mg before emergence Analgesia: ropivacain at port sites before incision and at vaginal vault Opioids intravenously at discretion of anesthesiologist supplemented with Dexketoprofen 50mg Urinary catheter early removal Postoperative Pain: tramadol 50mg and ketoprofen100mg i.v., oral opioid if needed; patients with normal pain control receive oral pregabalin 25mg every 8 hours, paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours until discharge Out of bed after 2 hours from the end of surgery A liquid diet, if tolerated regular normal diet. For emesis ondansetron 4mg"
11135285|NCT03828981|No Intervention|conventional recovery program|"Preoperative preparation Verbal and written information Cessation of oral intake after previous midnight. Premedication paracetamol 1g+ diatsepam 5mg.
~Intraoperative A warm blanket at the start of procedure. Prophylaxis for nausea and vomiting: Dexamethasone 5mg at induction, and Dehydrobenzperidol 1mg, ondancetron 4mg before emergence. Analgesia: injection of ropivacain 5% 20ml at port sites at the end of surgery, Opioids i.v. (oxycodone)
~Postoperative Pain medication:Opioids i.v. (oxycodone), paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours Urinary catheter removal on next morning. Prolonged bowel and bed rest and gradual reintroduction of feeding."
11135286|NCT03828968|Other|Bladder scan|Bladder scan performed on resident in homes for aged
11135287|NCT03828955|Experimental|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage.
11135288|NCT03828955|Placebo Comparator|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.
11135289|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
11135290|NCT03828929|Experimental|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
11135291|NCT03828929|Placebo Comparator|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
11135292|NCT03828916|Other|NuShield|
11135293|NCT03828903|Experimental|pleural effusion patients|medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained
11135294|NCT03828890|Other|Single Arm Trial|Intervention includes screening eye exam using Optos technology
11135295|NCT03828877|No Intervention|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
11135296|NCT03828877|Active Comparator|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
11135297|NCT03828864|Active Comparator|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
11135298|NCT03828864|Placebo Comparator|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
11135299|NCT03828851|Experimental|Experimental group|ADL training program.
11135300|NCT03828851|No Intervention|Control group|Receive rehabilitation program in the hospital.
11135301|NCT03828838|Experimental|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
11135302|NCT03828825|Experimental|Patent Foramen Ovale Closure|The percutaneous closure of Patent Foramen Ovale is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis.
11135303|NCT03828812|Active Comparator|Breakfast promotion|Receiving the recommendation of daily breakfast
11135304|NCT03828812|Active Comparator|Nighttime snack reduction|Receiving the recommendation of reducing nighttime snack frequency
11135305|NCT03828812|Experimental|Breakfast promotion + nighttime snack reduction|Receiving the recommendation of daily breakfast + reducing nighttime snack frequency
11135306|NCT03828799|Experimental|Folfirinox-R|Folfirinox + regorafenib
11135307|NCT03828786|Active Comparator|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
11135308|NCT03828786|No Intervention|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
11135309|NCT03828773|Other|high-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): homozygous for rs230561 and/or rs381652
11135310|NCT03828773|Other|low-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): other than homozygous for rs230561 and/or rs381652
11135311|NCT03828760|Experimental|Music Listening|Patients will receive music of choice to listen to using a music-playing device in the waiting room prior to IUD insertion, as well as during the procedure.
11135312|NCT03828760|No Intervention|Standard Care|Patients will receive standard care (excluding the use of music) from providers at the clinic to minimize pain and anxiety during the procedure.
11135313|NCT03828747|Experimental|Semorinemab|Semorinemab will be administered intravenously in the double-blind treatment period, and semorinemab will be administered in the optional open-label extension period.
11135314|NCT03828747|Placebo Comparator|Placebo|Placebo will be administered intravenously in the double-blind treatment period.
11135315|NCT03828734|Experimental|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
11135316|NCT03828734|Experimental|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
11135317|NCT03828721|Active Comparator|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
11135318|NCT03828721|Experimental|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
11135319|NCT03828708|Experimental|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
11135320|NCT03828708|Experimental|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
11135321|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
11135346|NCT03828513|Active Comparator|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2> 90%.
11135347|NCT03828500|Experimental|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
11135348|NCT03828500|No Intervention|Control Arm|
11135349|NCT03828487|Experimental|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
11135322|NCT03828682|Experimental|Prospective Arm|"De novo kidney transplant recipients receiving:
~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
11135323|NCT03828682|Active Comparator|Comparator arm|"Historical control arm consisting of the following
~De novo kidney transplant recipients receiving:
~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
11135324|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
11135325|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
11135326|NCT03828656|Experimental|Open Label Treatment Arm|Open-label Intervention with the NightWare Therapeutic System every night.
11135327|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
11135328|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
11135329|NCT03828617|Experimental|20vPnC Lot 1|20vPnC Lot 1
11135330|NCT03828617|Experimental|20vPnC Lot 2|20vPnC Lot 2
11135331|NCT03828617|Experimental|20vPnC Lot 3|20vPnC Lot 3
11135332|NCT03828617|Active Comparator|13vPnC|13vPnC
11135333|NCT03828604|Experimental|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
11135334|NCT03828604|Active Comparator|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
11135335|NCT03828591|Other|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
11135336|NCT03828591|Other|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
11135337|NCT03828578|Experimental|High flow oxygen therapy|"Patients allocated to the intervention group will receive high flow oxygen therapy via the tracheostomy tube from cessation of mechanical ventilation. The HFOT will provide oxygen therapy at a flow rate of 50-60 litres per minute at a FiO2 titrated by the bedside clinician to maintain a peripheral oxygen saturation of 95% of more (unless otherwise clinically indicated and documented by an appropriate consultant).
~Once transferred to the ward patients will continue to receive HFOT 24 hours per day at a rate of 50-60 litres per minute at a maximum oxygen concentration of 40% to achieve oxygen saturations 95% and above (unless otherwise documented).
~Patients may be disconnected from the HFOT for short periods for toileting, mobilising etc. Tracheostomy weaning will continue as per standard practice with an aim of cuff deflation followed by decannulation once clinically appropriate. systems. Following decannulation patients will resort to standard oxygen therapy as needed."
11135338|NCT03828578|No Intervention|Standard Care|Patients randomised to the standard care study arm will receive routine post-operative care as currently performed within the host organisation. Following cessation of mechanical ventilation, oxygen therapy will be delivered using equipment and rates appropriate to the clinical picture. On transfer to the ward patients will continue with existing methods of oxygen therapy and will be weaned from these accordingly. Patients will continue to use heat moisture exchanges (e.g. Swedish nose or Buchannan protectors) as clinically indicated, as well as having saline nebulisers prescribed and administered as per standard. Tracheostomy weaning will continue in accordance with current practice. Data on all of the applied procedures will be recorded.
11135339|NCT03828565|Active Comparator|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
11135340|NCT03828565|No Intervention|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
11135341|NCT03828539|Experimental|Erenumab|70 mg and 140 mg Erenumab
11135342|NCT03828539|Active Comparator|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
11135343|NCT03828526|Experimental|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.
~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.
~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
11135344|NCT03828526|Active Comparator|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
11135345|NCT03828513|Active Comparator|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
11135380|NCT03828240|Other|Enhanced rehabilitation|
11135350|NCT03828474|Experimental|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
11135351|NCT03828474|Experimental|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
11135352|NCT03828461|Experimental|BITS + VR|Facilitated group therapy with behavioral practice; 16 weeks
11135353|NCT03828448|Experimental|ublituximab + umbralisib|"Ublituximab: 900 mg administered through Cycle 12, via IV infusion
~Umbralisib: 800 mg administered through Cycle 24, via daily oral tablet"
11135354|NCT03828435|Experimental|healthy control|This group does not undergo any treatment . Intervention : rTMS
11135355|NCT03828435|Experimental|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.
~Intervention : rTMS"
11135356|NCT03828422||patients with essential thrombocythemia|"essential thrombocythemia with JAK2 V617F positive mutation
~patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014
~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
~all signed the informed consent
~examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019
~blood for laboratory tests
~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
11135357|NCT03828422||control group|"the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives
~they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease
~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)
~all signed the informed consent
~blood for laboratory tests
~examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019
~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
11135358|NCT03828409|Active Comparator|Short stitch|short stitch used as one arm
11135359|NCT03828409|Active Comparator|Long stitch|Long stitch as conventional mass-closure technique
11135360|NCT03828396||High risk (positive)|Colorectal cancer and advanced adenoma
11135361|NCT03828396||Low risk (Negative)|Healthy people and other colorectal diseases
11135362|NCT03828383|Experimental|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
11135363|NCT03828383|Sham Comparator|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
11135364|NCT03828370|Active Comparator|Usual & Customary Information Group|"Study Cohort Assessment:
~Baseline 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
11135365|NCT03828370|Experimental|B-SMART Intervention Group|"Study Cohort Assessment:
~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
11135366|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
11135367|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
11135368|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
11135369|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
11135370|NCT03828344|Experimental|hUC-MSC treatment|BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.
11135371|NCT03828344|Placebo Comparator|Placebo control|The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit.
11135372|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
11135373|NCT03828318|Experimental|Patient Activation Arm|
11135374|NCT03828318|No Intervention|Standard Care Arm|
11135375|NCT03828305|Experimental|Training and creation of the Network-CPR|Training in CPR
11135376|NCT03828305|Active Comparator|Control Group|Primary Care Center Emergency Personnel
11135377|NCT03828292|Experimental|Japanese subjects with relapsed/refractory multiple myeloma|Subjects will be administered escalating doses of GSK2857916 (2.5 mg/kg or 3.4 mg/kg) as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Subjects will be treated until disease progression, withdrawal of consent or until acceptable toxicity.
11135378|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
11135379|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
11135381|NCT03828227|Active Comparator|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :
~Serum albumin level ≥ 30g/L,
~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).
~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
11135382|NCT03828227|Active Comparator|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :
~Serum albumin level ≥ 30g/L,
~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).
~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
11135383|NCT03828227|Active Comparator|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:
~Serum albumin level < 30g/L.
~And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).
~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
11135384|NCT03828201|Experimental|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
11135385|NCT03828201|Experimental|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
11135386|NCT03828201|Experimental|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
11135387|NCT03828201|Experimental|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
11135388|NCT03828188|Experimental|group A|"Red Ginseng Concentrated Powder in 12 weeks → rest in 4 weeks → Placebo 12 weeks.
~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)
~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
11135389|NCT03828188|Experimental|group B|"Placebo 12 weeks→ rest in 4 weeks → Red Ginseng Concentrated Powder in 12 weeks.
~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)
~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
11135390|NCT03828175|Other|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
11135391|NCT03828149|Active Comparator|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
11135392|NCT03828149|Placebo Comparator|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
11135393|NCT03828136|Experimental|ACDF with Bio2 Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
11135394|NCT03828136|Active Comparator|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
11135395|NCT03828123|Experimental|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
11135396|NCT03828110||Children with neurological impairment|
11135397|NCT03828097|Experimental|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
11135398|NCT03828097|Placebo Comparator|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
11135399|NCT03828084|Experimental|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
11135400|NCT03828084|Experimental|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
11135401|NCT03828084|Experimental|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
11135402|NCT03828084|Active Comparator|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
11135403|NCT03828071|Other|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
11135404|NCT03828058|Experimental|Envarsus XR|Envarsus XR orally administered Daily
11135405|NCT03828058|Active Comparator|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus
~Dosage of prograf will be determined by trough levels and adjusted accordingly"
11135406|NCT03828045||Psoriatic Arthritis patients on Apremilast|Patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration.
11135407|NCT03828032|Experimental|Mannitol injection|The participant receive mannitol injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
11135408|NCT03828032|Experimental|Hypertonic saline injection|The participant receive hypertonic saline of specific concentration injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
11135409|NCT03828019|Active Comparator|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.
~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
11135446|NCT03827785|Sham Comparator|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
11135447|NCT03827772|Experimental|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
11135410|NCT03828019|Active Comparator|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.
~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
11135411|NCT03828006|Experimental|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
11135412|NCT03828006|Placebo Comparator|Placebo Group|One tablet per day of placebo.
11135413|NCT03827993|No Intervention|Routine surveillance|"Routine surveillance consists of attending gynecologic oncology office visits and being provided with an educational pamphlet discussing common sexual health concerns in gynecologic cancer patients, describing vaginal dilators, moisturizers, and lubrication. Resources for psychosocial counseling, physical therapy, and the sexual health clinic will be provided as well.
~Participants will have follow up at baseline, 3, 6, 9, and 12 months. Baseline visit consists of the initial visit where the Female Sexual Function Index (FSFI) screen was performed. Subsequent follow up visits will consist of FSFI, Female Sexual Distress Scale (FSDS), Kessler 10 surveys, and clinical assessment with Vaginal Assessment Scale and Vulvar Assessment Scale (VAS and VuAS)."
11135414|NCT03827993|Experimental|Dedicated sexual health clinic appointment|"Dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This will consist of the provider performing a focused history and physical, who will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
~The participants will follow up at 3, 6, 9, and 12 months after initial visit, either with the sexual health focused provider or their primary gynecologic oncologist, as determined by the needs of the participant per the provider."
11135415|NCT03827967|Experimental|1x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
11135416|NCT03827967|Experimental|2x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
11135417|NCT03827967|Experimental|4x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
11135418|NCT03827967|Experimental|8x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
11135419|NCT03827954|Experimental|Experimental Treatment|HeartMapp+CT
11135420|NCT03827941|Active Comparator|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
11135421|NCT03827941|Active Comparator|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
11135422|NCT03827928|Experimental|Yoga/meditation|A 6-week yoga/meditation intervention.
11135423|NCT03827928|No Intervention|Wait list|A wait list control period.
11135424|NCT03827915|No Intervention|Third trial of DC cardioversion|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive a third trial of DC cardioversion (Standard of care)
11135425|NCT03827915|Experimental|Double sequential external defibrillation|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive DSED
11135426|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
11135427|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
11135428|NCT03827889|Experimental|WMP of fluoride varnish|Whole mouth protocol group
11135429|NCT03827889|Experimental|TWLP of fluoride varnish|Tooth with lesion Protocol
11135430|NCT03827889|Active Comparator|DHP (educational intervention)|Diet and Hygiene guidance Protocol
11135431|NCT03827876|Experimental|Open Label Enstilar|once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
11135432|NCT03827863||ARDS WITH ACP|"Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg < PaO2/FIO2≤300 mmHg), moderate (100 mmHg < PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.
~Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR>2.8m/s; RVEDA/LVEDA>0.6 or Right ventricle/left ventricle basal diameter ratio>1.0 or systolic D sign; IVC >2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity >2.2m/s."
11135433|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
11135434|NCT03827850|Active Comparator|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
11135435|NCT03827850|Active Comparator|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
11135436|NCT03827850|Active Comparator|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
11135437|NCT03827837|Experimental|SHR-1210 combined with Famitinb|SHR-1210 + Famitinib
11135438|NCT03827824|Experimental|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
11135439|NCT03827824|Active Comparator|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
11135440|NCT03827811||PandrTB cohort|endTB participants on experimental regimen
11135441|NCT03827798|Experimental|CFZ533|s.c.
11135442|NCT03827798|Experimental|LYS006|p.o.
11135443|NCT03827798|Placebo Comparator|Placebo to CFZ533|Matching placebo (s.c.)
11135444|NCT03827798|Placebo Comparator|Placebo to LYS006|Matching placebo (p.o.)
11135445|NCT03827785|Experimental|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
11135449|NCT03827759||septic arthritis (group A)|Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;
11135450|NCT03827759||inflammatory arthritis (group B)|Patients with idiopathic juvenile arthritis
11135451|NCT03827759||control (group C)|10 healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.
11135452|NCT03827733||AD patients|Participants who are diagnosed with AD.
11135453|NCT03827733||Spouse of the AD patients|Spouse of AD patients, and live together with AD patients.
11135454|NCT03827733||Elderly participants with normal congition|Community dwelling elderly with normal cognition .
11135455|NCT03827720|Experimental|Control|Healthy volunteers monitored with Sense Device
11135456|NCT03827720|Experimental|Intracranial Hemorrhage|Intracranial hemorrhage patients monitored with Sense Device
11135457|NCT03827720|Experimental|Acute Ischemic Stroke with LOV|Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
11135458|NCT03827720|Experimental|AIS without LOV|Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
11135459|NCT03827707|Experimental|Noise|
11135460|NCT03827707|Sham Comparator|Silence|
11135461|NCT03827694||Patients with possible PIMI|
11135462|NCT03827681|Experimental|TIPS + Vasoactive Drug|
11135463|NCT03827681|Active Comparator|SEMS + Vasoactive Drug|
11135464|NCT03827668|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
11135465|NCT03827655|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
11135466|NCT03827655|Experimental|TAK-954 0.1 mg/100 mL|TAK-954 0.1 milligram per 100 milliliter (mg/100 mL), 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
11135467|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
11135468|NCT03827655|Experimental|TAK-954 0.1 mg/100 mL + Placebo|TAK-954 0.1 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily placebo infusions postsurgery from Days 2 to 10 or until resolution of upper and lower GI function.
11135469|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily placebo infusions postsurgery from Days 2 to 10 or until resolution of upper and lower GI function.
11135470|NCT03827642|Experimental|Cohort 1: Treatment Sequence A-D-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
11135471|NCT03827642|Experimental|Cohort 2: Treatment Sequence B-C-D-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
11135472|NCT03827642|Experimental|Cohort 3: Treatment Sequence C-A-B-D|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
11135473|NCT03827642|Experimental|Cohort 4: Treatment Sequence D-B-A-C|Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
11135474|NCT03827629|Experimental|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
11135475|NCT03827629|Experimental|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
11135476|NCT03827629|Experimental|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
11135477|NCT03827629|Experimental|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
11135478|NCT03827629|Experimental|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
11135479|NCT03827629|Experimental|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
11135480|NCT03827616|Active Comparator|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
11135481|NCT03827616|Active Comparator|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
11135482|NCT03827603|Experimental|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
11135483|NCT03827590|Experimental|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
11135484|NCT03827590|Active Comparator|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
11135485|NCT03827590|Active Comparator|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
11135486|NCT03827590|Placebo Comparator|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
11135487|NCT03827577|Experimental|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.
~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
11135488|NCT03827577|Active Comparator|Control Arm|"Standard medical treatment
~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
11135489|NCT03827564|Experimental|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
11135490|NCT03827564|Experimental|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
11135492|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
11135493|NCT03827499|Experimental|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
11135494|NCT03827499|Experimental|NoEx-HMB|HMB Dietary supplementation
11135495|NCT03827499|Placebo Comparator|Ex-Plac|Multicomponent physical exercise program
11135496|NCT03827499|No Intervention|Controls|No intervention
11135497|NCT03827486|Active Comparator|Standard of care|
11135498|NCT03827486|Experimental|Domicilary exercise program|
11135499|NCT03827473|Experimental|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11135500|NCT03827473|Experimental|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11135501|NCT03827460|Experimental|Free access alcohol self-administration|During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking
11135502|NCT03827460|Experimental|Clamped alcohol exposure|A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.
11135503|NCT03827460|Experimental|2 year followup|Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
11135504|NCT03827447|Active Comparator|Drug: Vancomycin Group|Subjects will receive oral vancomycin capsules by mouth, 125 mg every 6 hours for 14 days.
11135505|NCT03827447|Placebo Comparator|Drug: Placebo Group|Subjects will receive a placebo oral capsule by mouth every 6 hours for 14 days. The placebo oral capsule is manufactured by Study Site's pharmacy to be identical in size, shape, color, appearance and taste as the drug comparator
11135506|NCT03827434|Active Comparator|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
11135507|NCT03827434|Placebo Comparator|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
11135508|NCT03827408|Active Comparator|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
11135509|NCT03827408|Experimental|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
11135510|NCT03827408|Experimental|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
11135511|NCT03827395|Experimental|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
11135512|NCT03827395|Placebo Comparator|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
11135513|NCT03827382|Active Comparator|Intervention|Patients with intensive Lifestyle intervention
11135514|NCT03827382|No Intervention|Control|Patients with Standard Diabetes care
11135515|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
11135516|NCT03827356|Experimental|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
11135517|NCT03827356|Active Comparator|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
11135518|NCT03827343||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
11135519|NCT03827330||Patients|Patients who had Candida species growth from blood cultures drawn at the National Institutes of Health
11135520|NCT03827317|Other|HER2 positive metastatic breast cancer|8 HER2 positive patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
11135521|NCT03827317|Other|HER2 negative metastatic breast cancer|8 HER2 negative patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
11135522|NCT03827304|Experimental|Burns dressings patients|Virtual Reality pain distraction games scenarios
11135523|NCT03827291|Experimental|Quadratus lumborum block|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
11135524|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia.
11135525|NCT03827278|Experimental|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
11136026|NCT03823677|Experimental|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
11135526|NCT03827278|Experimental|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
11135527|NCT03827265|Experimental|TMS on SMA|"Device: repetitive transcranial magnetic stimulation (real)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the Supplementary Motor Area (SMA).
~Other Name: rTMS (active stimulation)"
11135528|NCT03827265|Experimental|TMS on PPC|"Device: repetitive transcranial magnetic stimulation (rTMS)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will target the posterior parietal cortex (PPC).
~Other Name: rTMS (active stimulation)"
11135529|NCT03827265|Experimental|TMS on dlPFC|"Device: repetitive transcranial magnetic stimulation (rTMS)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain.This arm will target the dorsolateral prefrontal cortex (dlPFC).
~Other Name: rTMS (active stimulation)"
11135530|NCT03827265|Sham Comparator|TMS (Sham Stimulation)|"Device: repetitive transcranial magnetic stimulation (rTMS)
~Transcranial magnetic stimulation (TMS) uses magnetic stimulation to change patterns of activity in your brain. This arm will be a sham stimulation.
~Other Name: rTMS (sham stimulation)"
11135531|NCT03827239|No Intervention|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
11135532|NCT03827239|Experimental|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
11135533|NCT03827213|Experimental|Exparel|an injection of the drug Exparel, a form of the anesthetic bupivacaine
11135534|NCT03827213|Active Comparator|Indwelling Catheter|ropivacaine, given through a catheter inserted between the shoulders
11135535|NCT03827200|Experimental|Ambrisentan|Ambrisentan
11135536|NCT03827187|Experimental|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
11135537|NCT03827174|Active Comparator|Comparison intervention|Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee.
11135538|NCT03827174|Experimental|Experimental intervention|"Return To Work Coordination + Behaviour Change Ability Programme
~Behaviour Change Ability Programme:
~Return to work coordination
~Education for employers and employees in pain neuroscience, validation, and problem-solving
~Patient specific goal setting for return to work
~Exercise and behavioural skills training related to return to work"
11135539|NCT03827161|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
11135540|NCT03827161|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
11135541|NCT03827148|Experimental|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
11135542|NCT03827148|No Intervention|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
11135543|NCT03827135|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
11135544|NCT03827135|Experimental|Cyriax manipulation|Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle stretching.
11135545|NCT03827122|Experimental|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
11135546|NCT03827109|Experimental|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics.
11135547|NCT03827109|Active Comparator|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community.
11135548|NCT03827096|Experimental|Human AMSC (passage 3) 3P in 1.5 mL|Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
11135549|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
11135550|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
11135551|NCT03827070|Experimental|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
11135593|NCT03826732|No Intervention|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
11135594|NCT03826719|Experimental|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
11135595|NCT03826719|Active Comparator|Agrippal|1 dose of 0.5mL by Intramuscular injection
11135552|NCT03827057|Experimental|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
11135553|NCT03827057|Active Comparator|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
11135554|NCT03827044|Experimental|Avelumab|6 months of 2 weekly Avelumab
11135555|NCT03827044|No Intervention|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
11135556|NCT03827031|No Intervention|Control group|
11135557|NCT03827031|Experimental|B1 interventional group|
11135558|NCT03827031|Experimental|B2 interventional group|
11135559|NCT03827018|Active Comparator|mavrilimumab|Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
11135560|NCT03827018|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
11135561|NCT03827005|Placebo Comparator|placebo|3 grams cornstarch once per day for one day.
11135562|NCT03827005|Experimental|L-arginine|3 g L-arginine once per day for one day.
11135563|NCT03826992|Experimental|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days 1-21 per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 21 doses of venetoclax will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.
~Venetoclax is given daily by mouth per assigned dose level."
11135564|NCT03826979|Experimental|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
11135565|NCT03826953|Other|Nurse led allergy clinic|nurse led allergy clinic
11135566|NCT03826940|Experimental|NF1 - experimental|
11135567|NCT03826940|Placebo Comparator|NF1 - control|
11135568|NCT03826940|Experimental|ASD - experimental|
11135569|NCT03826940|Placebo Comparator|ASD - control|
11135570|NCT03826927||AF and cerebrovascular event|patients with AF and recent (< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events
11135571|NCT03826914|Experimental|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
11135572|NCT03826914|Placebo Comparator|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
11135573|NCT03826901|Experimental|Part 1: adults and adolescents (12 years and above)|Delgocitinib cream (dosage: A mg/g).
11135574|NCT03826901|Experimental|Part 2: children (2-11 years)|Delgocitinib cream (dosage: B mg/g).
11135575|NCT03826875|Experimental|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
11135576|NCT03826875|Placebo Comparator|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
11135577|NCT03826862|Experimental|intervention group|All patients receive CT three-dimensional reconstruction before surgery.
11135578|NCT03826862|No Intervention|control group|All patients did not receive CT three-dimensional before surgery
11135579|NCT03826849|No Intervention|Waitlist Control|Assessment only condition for all 12 weeks of participation.
11135580|NCT03826849|Experimental|Insomnia Coach|Intervention condition that involves use of the Insomnia Coach app for 6 weeks.
11135581|NCT03826836|No Intervention|Control Group|Treatment as usual (i.e. best medical treatment).
11135582|NCT03826836|Experimental|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
11135583|NCT03826823|Experimental|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
11135584|NCT03826810|Experimental|aPDT + ART group|In this group, both aPDT and ART were performed.
11135585|NCT03826810|Experimental|ART group|In this group, only ART was performed.
11135586|NCT03826784|Experimental|BHA|Subjects treated with BHA + standard of care
11135587|NCT03826784|No Intervention|Control|Subjects treated as per standard of care
11135588|NCT03826771|Experimental|POWER training|high velocity strength training
11135589|NCT03826771|Active Comparator|Stretching|Upper and lower body range of motion exercises
11135590|NCT03826758|Other|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
11135591|NCT03826758|No Intervention|Standard care|No change in their clinical practice.
11135592|NCT03826732|Experimental|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
11135596|NCT03826706|Active Comparator|C-MAC Videolaryngoscope D blade|Patients was intubated with C-MAC videolaryngoscope D blade.
11135597|NCT03826706|Active Comparator|McGrath MAC Videolaryngoscope X3 blade|Patients was intubated with McGrath MAC Videolaryngoscope X3 blade
11135598|NCT03826693|Experimental|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
11135599|NCT03826693|Placebo Comparator|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
11135600|NCT03826680|Active Comparator|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
11135601|NCT03826680|Active Comparator|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
11135602|NCT03826654|Experimental|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
11135603|NCT03826654|Placebo Comparator|control|daily intake of plain oil
11135604|NCT03826641|Experimental|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
11135605|NCT03826641|Experimental|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
11135606|NCT03826641|Experimental|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
11135607|NCT03826641|Experimental|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
11135608|NCT03826628|Experimental|0.5% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
11135609|NCT03826628|Experimental|1.0% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
11135610|NCT03826628|Placebo Comparator|Placebo|Placebo cream topical, applied once daily before bed on affected area for 26 weeks
11135611|NCT03826615|Experimental|Gabapentin|Gabapentin premedication group
11135612|NCT03826615|No Intervention|No medication|Control group
11135613|NCT03826602|Experimental|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
11135614|NCT03826589|Experimental|Avelumab and Axitinib|"Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)
~Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
11135615|NCT03826576|Experimental|Intervention Group|Intervention group will receive a Multicomponent Intervention.
11135616|NCT03826576|No Intervention|Control Group|Control group will not receive any kind of intervention, only it will receive information about AMED criteria and allergens of food.
11135617|NCT03826563|Placebo Comparator|Placebo|Subjects will receive pill placebo nightly
11135618|NCT03826563|Experimental|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
11135619|NCT03826550|Experimental|Diclofenac Sodium Gel3%|Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.
11135620|NCT03826550|Active Comparator|Solaraze|Solaraze Gel dosed twice daily for 60 days.
11135621|NCT03826550|Placebo Comparator|Placebo|Placebo Gel dosed twice daily for 60 days.
11135622|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
11135623|NCT03826524|Active Comparator|Low Dose Epinephrine|Epinephrine up to 2mg total
11135624|NCT03826524|Active Comparator|Standard Dose Epinephrine|Epinephrine up to 8mg total
11135625|NCT03826511|Active Comparator|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
11135626|NCT03826511|Active Comparator|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
11135627|NCT03826498|Experimental|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
11135628|NCT03826498|Other|Standard therapy|Patients with standard therapy as control group
11135629|NCT03826485|Experimental|A group|Period 1: PRIC Period 2: Pranlukast hydrate
11135630|NCT03826485|Experimental|B group|Period 1: Pranlukast hydrate Period 2: PRIC
11135631|NCT03826472|Experimental|Almond Butter|Participants will consume one ounce per day (~32 g) of almond butter as an evening snack (i.e., after dinner and before sleep).
11135632|NCT03826472|No Intervention|No-snack Control|Participants will consume nothing besides water after dinner/bed sleep.
11135633|NCT03826459|Active Comparator|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
11135634|NCT03826459|Experimental|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
11135635|NCT03826446|Other|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
11135636|NCT03826446|Other|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
11135637|NCT03826433|Experimental|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)
11135638|NCT03826433|No Intervention|Control Group|Control Group: Using basic contrast .
11135639|NCT03826420|Experimental|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
11135640|NCT03826420|Experimental|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
11135641|NCT03826420|Experimental|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
11135642|NCT03826420|No Intervention|Control Group|
11135643|NCT03826407||Coma patients|Patients in coma with Glasgow Coma Scale (GCS) score ≤ 8 (No intervention)
11135644|NCT03826407||Control|Matched healthy controls without current neurological diagnoses
11135645|NCT03826394|Experimental|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
11135646|NCT03826394|Experimental|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
11135647|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54
~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is > 60, absence of clinical proteinuria.
~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.
~The patients are examined once."
11135648|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54
~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR <60).
~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.
~The patients are examined once."
11135649|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
11135650|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
11135651|NCT03826355|Active Comparator|Stripping technique|The endometrioma is removed according to standard surgery.
11135652|NCT03826355|Experimental|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
11135653|NCT03826342|Experimental|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
11135654|NCT03826342|Active Comparator|Time, attention, and information-matched control|Well-validated
11135655|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
11135656|NCT03826316|Experimental|Mutonpain Injection 10 mg/ml|
11135657|NCT03826303|Experimental|E-cigarette with ethanol, 1 puff|
11135658|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 1 puff|
11135659|NCT03826303|Experimental|E-cigarette with ethanol, 10 puffs|
11135660|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 10 puffs|
11135661|NCT03826290|Experimental|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
11135662|NCT03826290|No Intervention|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
11135663|NCT03826277|Experimental|Melanostop peel treatment group|"Adult women aged between 20-50 years old.
~Melasma on the face
~Fitzpatrick phototypes I-IV
~Presenting facial melasma
~In good health condition"
11135664|NCT03826264||Korea Centers|Seoul, Korea All Patients undergoing TAVR
11135665|NCT03826264||Stanford University|California, USA All Patients undergoing TAVR
11135666|NCT03826264||Northwestern University|Evanston, Illinois, USA All Patients undergoing TAVR
11135667|NCT03826264||Cheng-Hsin Hospital|Taipei, Taiwan All Patients undergoing TAVR
11135668|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
11135669|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
11135670|NCT03826238||ARBD and depression|10 patients with ARBD and at least moderate depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale ≥ 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
11135671|NCT03826238||ARBD and no depression|10 patients with ARBD and no clinically relevant depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale < 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
11135672|NCT03826238||Healthy|10 healthy controls (no ARDB, no depression, no cognitive deficit). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
11135673|NCT03826225||Study Cohort|All participants are considered to be in the study cohort and will have the study device placed externally on their skin in order to collect human ECG data.
11135674|NCT03826212|Experimental|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
11135675|NCT03826212|Placebo Comparator|Placebo|Placebo 1,600 mg/day for 12 weeks.
11135676|NCT03826186|Active Comparator|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
11135677|NCT03826186|Experimental|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
11135735|NCT03825796|Experimental|Treatment (CPX-351, enasidenib mesylate)|See detailed description
11135678|NCT03826173|Experimental|Positive Psychology|On a weekly basis, participants will engage in group-based intervention sessions that focus on personal strengths and the value of positive emotions and cognitions. Participants will receive daily text-messages addressing the content introduced during group sessions.
11135679|NCT03826173|Active Comparator|Physical Activity Promotion|On a weekly basis, participants will engage in group-based intervention sessions that focus on the standard physical activity promotion components of the PPPA condition. Participants will receive daily text-messages addressing the content introduced during group sessions.
11135680|NCT03826160||Tesamorelin|Individuals who plan to initiate tesamorelin clinically
11135681|NCT03826160||No Treatment|Individuals who decline to initiate tesamorelin despite a clinical indication
11135682|NCT03826147|Active Comparator|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
11135683|NCT03826147|Placebo Comparator|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
11135684|NCT03826134|Experimental|[11C]-PXT012253|
11135685|NCT03826121|Experimental|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
11135686|NCT03826121|Placebo Comparator|Placebo|placebo for 12 weeks
11135687|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
11135688|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
11135689|NCT03826095||Multiple Sclerosis|Patients with a clinically definitive diagnosis of MS, 0-5.5 Extended Disability Status Scale range.
11135690|NCT03826095||Healthy individuals|Voluntary healthy individuals with similar age and gender
11135691|NCT03826069|Active Comparator|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
11135692|NCT03826069|Experimental|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
11135693|NCT03826056|Active Comparator|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
11135694|NCT03826056|Experimental|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
11135695|NCT03826043|Experimental|Experimental arm|Hospitalized patient
11135696|NCT03826030|Sham Comparator|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
11135697|NCT03826030|Active Comparator|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
11135698|NCT03826030|Active Comparator|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
11135699|NCT03826017|Experimental|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
11135700|NCT03826017|Placebo Comparator|Placebo|Placebo for 12 weeks.
11135701|NCT03826004|Placebo Comparator|Placebo|Saline solution 2ml before anesthetic induction
11135702|NCT03826004|Experimental|Clemastine|Clemastine fumarate 2mg/2ml before anesthetic induction
11135703|NCT03825991||Control group|Cohort 1 is a a control group matched 1:5 to the exposed group on sex and age. This group i randomly assigned via Statistics Denmark and does not have a diagnosis of back pain in the time period 2008-2013. They do however have another diseases registered in the Danish Patient Registry, which only contains information on patients having had contacts with the hospital sector i Denmark. Used for study 1.
11135704|NCT03825991||Specific back pain (unexposed)|Cohort 2 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Spinal Disc Herniation DM51.1 and Spinal stenosis DM48.0 (ICD-10 classification).
11135705|NCT03825991||Unspecific back pain (exposed)|Cohort 3 consists of patients registered with one of the following diagnosis in the time period 2008-2013 in Denmark: Other intervertebral disc disorders DM51*-51.1, Dorsalgia DM54, Other disorders of muscle DM62, Postprocedural musculoskeletal disorders not elsewhere classified DM96 and Segmental and somatic dysfunction DM99 (ICD-10 classification)
11135706|NCT03825991||Total population (DM*)|Cohort 4 is the total population including all BPD diagnosis in the time period 2008-2013 in Denmark. This cohort will be used as basis for study 2 and 3, although de definitions of the groups specific back pain (unexposed) and unspecific back pain (exposed) will used in sub-analysis.
11135813|NCT03825185|Experimental|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
11135707|NCT03825978|Active Comparator|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
11135708|NCT03825978|No Intervention|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
11135709|NCT03825965|Experimental|Cannabidiol (CBD)|Oral medicinal cannabis (125 mg cannabidiol daily suspended in oil)
11135710|NCT03825965|Placebo Comparator|Placebo|Visually identical placebo (medium chain triglyceride oil)
11135711|NCT03825952|Experimental|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
11135712|NCT03825939|Experimental|Intravenous Tranexamic Acid|"1g TXA administered intravenous piggyback at start of surgery OR
~1g TXA administered intravenous piggyback at start and at time of closure of surgery"
11135713|NCT03825939|Experimental|Topical Tranexamic Acid|"Experimental
~- Single dose topical TXA (1g/50 mL in 0.9% sterile saline) administered during surgery"
11135714|NCT03825939|Placebo Comparator|Intravenous Placebo|- IV 0.9% sterile saline
11135715|NCT03825939|Placebo Comparator|Topical Placebo|- Topical 0.9% sterile saline
11135716|NCT03825926||Gestational Diabetes Mellitus|The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
11135717|NCT03825926||Non-Gestational Diabetes Mellitus|normal group
11135718|NCT03825913|Active Comparator|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.
~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.
~Participants in the exercise intervention will complete 24 sessions."
11135719|NCT03825913|Sham Comparator|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
11135720|NCT03825900|Active Comparator|Active tDCS|Active transcranial direct current stimulation
11135721|NCT03825900|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
11135722|NCT03825887|Active Comparator|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
11135723|NCT03825887|Experimental|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
11135724|NCT03825874||amikacin IV|Febrile urinary tract infection treated with amikacin IV
11135725|NCT03825874||Other antibiotics|Febrile urinary tract infection treated with other antibiotic, according to the recommendations: ceftriaxone or cefixime
11135726|NCT03825861|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
11135727|NCT03825848|Experimental|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
11135728|NCT03825848|Experimental|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
11135729|NCT03825835|Active Comparator|30% group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
11135730|NCT03825835|Experimental|60% group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
11135731|NCT03825822|Experimental|ImPaC Resource Intervention (INT)|The INT arm will receive the 7-step web-based ImPaC intervention to use over 6 months. The intervention is divided into the Plan Stage and the Change Stage. The Plan Stage (steps 1-4) is expected to be completed in 1 month. The Change Stage (steps 5-7) is expected to be completed in 1-2 months. We anticipate that Change Teams will be able to complete 2 cycles of change over the 6-month intervention period.
11135732|NCT03825822|Other|Standard Practice (SP)|The SP arm will continue as usual with their unit or institutional standard pain practices and any strategies that they would normally use to improve them (e.g. new staff orientation).
11135733|NCT03825809|Experimental|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:
~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
11135734|NCT03825809|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
11135736|NCT03825783|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single infusion in subjects with severe LAD-I
11135737|NCT03825770|Experimental|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
11135738|NCT03825770|Active Comparator|General Education|General Education about Kidney Disease
11135739|NCT03825757|Experimental|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
11135740|NCT03825757|Placebo Comparator|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
11135741|NCT03825744|Experimental|Hetrombopag Olamine+Standard Therapy|
11135742|NCT03825744|Placebo Comparator|Placebo+Standard Therapy|
11135743|NCT03825731|Experimental|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
11135744|NCT03825718|Experimental|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
11135745|NCT03825705|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
11135746|NCT03825692|Experimental|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule Arm is Zhizhu Kuanzhong Capsule, Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd. ; Approval number: NMPA approval number: GUOYAOZHUNZI Z20020003; Dosage and administration: 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals
11135747|NCT03825692|Placebo Comparator|Zhizhu Kuanzhong Placebo Capsule|Zhizhu Kuanzhong Placebo Capsule Arm is Zhizhu Kuanzhong Capsule Mimics composed of microcrystalline cellulose, mannitol and magnesium stearate, which used for filling agent and lubricant respectively; Specification: 0.43 g/granule; Manufacturer: Lonch Group, Shuangren Pharmaceutical Co., Ltd.; Dosage and administration: Be identical with the investigational drug.
11135748|NCT03825666|Experimental|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
11135749|NCT03825666|No Intervention|Control|control group following standard guidelines
11135750|NCT03825653||one group|"This study will be carried out on three hundred postmenopausal.They will be selected from gynecological outpatient clinic of (Oum El Masryn Hospital).
~their age will range from 60-70 years.Their BMI will not exceed 30 kg/m2. They are complaining from stress urinary incontinence."
11135751|NCT03825640|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.
~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
11135752|NCT03825627|Active Comparator|Antisaccade Task (active tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
11135753|NCT03825627|Sham Comparator|Antisaccade Task (sham tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm sham Transcranial Direct Current Stimulation will be used during the task.
11135754|NCT03825627|Active Comparator|Approach Avoidance Task (active tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
11135755|NCT03825627|Sham Comparator|Approach Avoidance Task (sham tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
11135814|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
11135815|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
11135756|NCT03825614|Experimental|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
11135757|NCT03825614|Active Comparator|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
11135758|NCT03825614|No Intervention|Control group|Participants in the control group have no exercise in this study.
11135759|NCT03825601|Other|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
11135760|NCT03825601|Other|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
11135761|NCT03825588|Experimental|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
11135762|NCT03825588|Experimental|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
11135763|NCT03825588|Experimental|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
11135764|NCT03825588|Active Comparator|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
11135765|NCT03825575|Experimental|Incontinence and low level laser therapy|Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
11135766|NCT03825562|Experimental|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
11135767|NCT03825562|Active Comparator|control group|Control group is offered to attend the intervention afterwards
11135768|NCT03825549|No Intervention|Control|No intervention
11135769|NCT03825549|Experimental|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
11135770|NCT03825549|Experimental|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
11135771|NCT03825549|Experimental|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
11135772|NCT03825536|Experimental|Oral methamphetamine|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the experimental treatment arm, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
11135773|NCT03825536|Placebo Comparator|Placebo oral capsule|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the placebo treatment arm, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
11135774|NCT03825523|Experimental|Group A Immediate treatment (iART)|Other: time to start the ART within 48 hours of admission to hospitalization
11135775|NCT03825523|Active Comparator|Group B Conventional treatment (cART)|Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.
11135776|NCT03825510|Experimental|Treatment Arm|
11135777|NCT03825497|Experimental|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
11135778|NCT03825497|No Intervention|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
11135779|NCT03825471|Experimental|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
11135780|NCT03825471|Placebo Comparator|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
11135816|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
11135781|NCT03825445|Experimental|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
11135782|NCT03825445|Experimental|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
11135783|NCT03825393||Fibromyalgia|Non-anemic FMS patients who were diagnosed based on 2011 FMS diagnostic criteria of the American Rheumatology College
11135784|NCT03825393||Control|Non-anemic women without a FMS diagnosis
11135785|NCT03825380|Experimental|T4032|
11135786|NCT03825380|Active Comparator|Lumigan®|
11135787|NCT03825367|Other|Open label design|Nivolumab and 5-azacytidine,
11135788|NCT03825354|Experimental|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
11135789|NCT03825354|No Intervention|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
11135790|NCT03825341|Active Comparator|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.
11135791|NCT03825341|Active Comparator|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
11135792|NCT03825328|Experimental|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
11135793|NCT03825315|Experimental|DAXI for Injection: LOW Dose|LOW Dose Group
11135794|NCT03825315|Experimental|DAXI for Injection: HIGH Dose|HIGH Dose Group
11135795|NCT03825315|Placebo Comparator|Placebo|Placebo Group.
11135796|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
11135797|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
11135798|NCT03825289|Experimental|Treatment (trametinib, hydroxychloroquine)|Patients receive trametinib PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11135799|NCT03825276|Experimental|Mango consumption|
11135800|NCT03825263|No Intervention|Control|Participants receive normal treatment
11135801|NCT03825263|Experimental|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
11135802|NCT03825250|No Intervention|Group A: Control|Standard of care
11135803|NCT03825250|Experimental|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
11135804|NCT03825250|Experimental|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
11135805|NCT03825250|Experimental|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
11135806|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
11135807|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
11135808|NCT03825211|Experimental|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
11135809|NCT03825211|Active Comparator|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
11135810|NCT03825198|Active Comparator|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.
~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
11135811|NCT03825198|Sham Comparator|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
11135812|NCT03825185|Experimental|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
11136027|NCT03823677|Experimental|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
11135817|NCT03825159|Experimental|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
11135818|NCT03825159|Active Comparator|brace group|Using spinal orthosis BRACE
11135819|NCT03825146|Experimental|Treatment Arm (AMPC)|AMPC will be intravenously infused.
11135820|NCT03825133|Experimental|Bone Marrow Aspirate Concentrate|Patients treated with single injection of BMAC in the knee
11135821|NCT03825133|Experimental|Leukocyte Rich Platelet Rich Plasma|Patients treated with single injection of LR-PRP in the knee
11135822|NCT03825133|Experimental|Hyaluronic Acid|Patients treated with 3 single injection of high molecular HA in the knee ( one injection weekly)
11135823|NCT03825120||Women from original OVA cohort|
11135824|NCT03825107|Active Comparator|Patching|2 hours per day 7 days per week patching of the fellow eye
11135825|NCT03825107|Experimental|Dichoptic Videos|watching 6 dichoptic videos during each 2 week period
11135826|NCT03825081|Experimental|Intervention|"Interventions will be the drugs:
~pilocarpine - 0.5%
~brimonidine - 0.2%
~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
11135827|NCT03825068|Active Comparator|ESP block group|patients receive ESP Bock with local anaesthetics
11135828|NCT03825068|Placebo Comparator|control group|general anaestesia
11135829|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
11135830|NCT03825042|Experimental|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
11135831|NCT03825042|Placebo Comparator|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
11135832|NCT03825029|Experimental|Pillow Group|There will be a pillow placed between the patients legs during their operation.
11135833|NCT03825029|No Intervention|Control Group|They will receive a normal total hip arthroplasty.
11135834|NCT03825016|Experimental|Lidocaine|Lidocaine Hydrochloride
11135835|NCT03825016|Experimental|Diclofenac|Oral Diclofenac
11135836|NCT03825003||Basketball Players|Outcome assessments were done.
11135837|NCT03825003||Sedentary Peers|Outcome assessments were done.
11135838|NCT03824990|No Intervention|Before-intervention phase|All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
11135839|NCT03824990|Experimental|Intervention phase|All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
11135840|NCT03824990|Experimental|Sustainability intervention phase|All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
11135841|NCT03824951|Experimental|Anti-CD19 iCAR NK Cells|
11135842|NCT03824938|Experimental|Aspirin|Aspirin 650 mg capsule by mouth, single dose
11135843|NCT03824938|Active Comparator|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
11135844|NCT03824938|Placebo Comparator|Placebo|Placebo 650 mg capsule by mouth, single dose
11135845|NCT03824925|Placebo Comparator|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
11135846|NCT03824925|Experimental|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
11135847|NCT03824912|Experimental|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
11135848|NCT03824912|Active Comparator|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
11135849|NCT03824912|Placebo Comparator|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
11135850|NCT03824899|Experimental|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
11135851|NCT03824886|Experimental|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
11135852|NCT03824886|No Intervention|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
11135853|NCT03824873|Active Comparator|internal iliac artery ligation + cesarean hysterectomy|
11135854|NCT03824873|Active Comparator|cesarean hysterectomy|
11135855|NCT03824860|Experimental|Yoga Program|Eight-weeks, therapist and self-guided yoga
11135856|NCT03824860|No Intervention|Treatment as usual|Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
11135857|NCT03824847|Active Comparator|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
11135858|NCT03824847|Placebo Comparator|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
11135859|NCT03824834|Experimental|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) with supervised exercise training.
11135860|NCT03824834|Placebo Comparator|Exercise training with placebo|Placebo treatment with supervised exercise training.
11135861|NCT03824821||IBS|
11135862|NCT03824808|Active Comparator|Treatment group|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
11135863|NCT03824808|Placebo Comparator|Control group|0.9% Sodium Chloride Injection
11135864|NCT03824795|Active Comparator|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
11135865|NCT03824795|Active Comparator|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
11135866|NCT03824795|Active Comparator|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
11135867|NCT03824782|No Intervention|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
11135868|NCT03824782|Experimental|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
11135869|NCT03824769|Active Comparator|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
11135870|NCT03824769|Experimental|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
11135871|NCT03824756|Experimental|NGO supported GMP program|Intervention: NGO supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
11135872|NCT03824756|Active Comparator|Non-supported GMP program|Comparison: Non-supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
11135873|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
11135874|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
11135875|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
11135876|NCT03824717|Other|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
11135877|NCT03824704|Experimental|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)
~Cohort A1
~Cohort A2"
11135878|NCT03824691|Experimental|Cabozantinib + Durvalumab|Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily
11135879|NCT03824678|Experimental|Administration of CC-220|All subjects will receive one 1-mg CC-220 capsule administered orally with approximately 240 mL of non-carbonated, room temperature water, and administered by trained clinical staff.
11135880|NCT03824665|Active Comparator|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
11135881|NCT03824665|Active Comparator|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
11135882|NCT03824665|Active Comparator|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
11135883|NCT03824652|Experimental|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
11135884|NCT03824652|Active Comparator|Usual Diet|Usual diet for 4-10 weeks
11135885|NCT03824639|Experimental|Exercise group|Structured exercise
11135886|NCT03824639|Active Comparator|Control group|Health education
11135887|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
11135888|NCT03824613||Endometrial cancer patients|
11135889|NCT03824613||Control group|Patients without cancer
11135890|NCT03824587|Experimental|Tenapanor 30 mg BID|"During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).
~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period."
11135891|NCT03824587|Placebo Comparator|Placebo|same size, weight and appearance of experimental drug
11135892|NCT03824574|Experimental|Treatment arm|Subjects receiving the clear mandibular advancement appliance
11135893|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
11135894|NCT03824535|Experimental|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
11135895|NCT03824522||All Study Participants|All participants enrolled will be treated with ADYNOVATE for hemophilia A at the time of enrollment according to a regimen determined by the study site treating physician/investigator.
11135896|NCT03824509||Patients with an echocardiagram who suffered a stroke or TIA|"Medical record number
~Sex
~Age
~BMI
~Body surface area
~Smoking status
~Congestive heart failure
~Hypertension
~Diabetes,
~Previous history of heart attack or vascular disease
~Previous history of stroke
~Date of stroke
~Type of stroke
~CHA2DS2-VASc scores
~On an anticoagulant yes/no at time of stroke
~Date of atrial fibrillation diagnosis
~Date of echocardiogram
~Echocardiographic features:
~a. Left atrial volume, indexed to body surface area (BSA) b. Left ventricular hypertrophy 4. Stroke outcome:
~Mortality
~NIH Stroke Scale
~Modified Rankin Scale
~Discharge placement:
~i. Home ii. Long term care iii. Skilled nursing facility e. 6-month survival"
11135897|NCT03824509||Control Group - matched CHA2DS2-VASc score, age, and gender|"Controls from both PBMC and MMC will be obtained. Controls are patients from 2014-2017 with matched age (+/- 5 years), gender, and CHA2DS2-VASc score who had atrial fibrillation and had not had a documented stroke or TIA in EPIC or the Get with the Guidelines registry maintained at PBMC. Controls must have an echocardiogram on record and have a diagnosis of atrial fibrillation at the time of the echocardiogram."
11135898|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
11135899|NCT03824483|Experimental|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
11135900|NCT03824470||Group E(rocuronium)|E, after the administration of 1 mg / kg lidocaine, 2 mg / kg propofol, 1 mcg / kg remifentanil and 0.6 mg / kg rocuronium intravenously, patients will be intubated and general anesthesia will be performed when the Tof value is 0.
11135901|NCT03824470||Group R (remifentanil)|1 mg / kg lidocaine, 4 mcg / kg remifentanil and 2 mg / kg propofol intravenously.patients will be intubated and general anesthesia will be performed when the Tof value is 0
11135902|NCT03824457|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
11135903|NCT03824457|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
11135904|NCT03824444|Experimental|Treatment|Implant and followup
11135905|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):
~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .
~."
11135906|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
11135907|NCT03824418||Chromoendoscopy follow-up|
11135908|NCT03824418||Autofluorescence follow-up|
11135909|NCT03824405|Active Comparator|BTX 1204|BTX 1204 twice daily
11135910|NCT03824405|Placebo Comparator|Vehicle|Vehicle twice daily
11135911|NCT03824392|Experimental|Cohort 1|ATYR1923 1.0 mg/kg or placebo
11135912|NCT03824392|Experimental|Cohort 2|ATYR1923 3.0 mg/kg or placebo
11135913|NCT03824392|Experimental|Cohort 3|ATYR1923 5.0 mg/kg or placebo
11135914|NCT03824379|Experimental|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
11135915|NCT03824379|Active Comparator|Control|30 patients will receive the standard therapy (anti-diabetic)
11135916|NCT03824366|Experimental|Volumetric MR imaging planning|"All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.
~Patients will receive standard of care palliative radiation therapy"
11135917|NCT03824353|Experimental|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
11135918|NCT03824353|Placebo Comparator|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
11135919|NCT03824340|Active Comparator|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
11135920|NCT03824340|No Intervention|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
11135921|NCT03824327|Experimental|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
11135922|NCT03824314|Experimental|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
11135923|NCT03824314|Experimental|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.
~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
11135924|NCT03824301|Active Comparator|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
11135925|NCT03824301|Active Comparator|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
11135926|NCT03824301|No Intervention|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
11135927|NCT03824288|Active Comparator|The landmark technique|PTA a needle aspiration attempted according to the landmark technique is conducted. If the initial aspiration is unsuccessful, two additional attempts are made in the middle and lower pole of the tonsil.
11135928|NCT03824288|Experimental|Ultrasound-guided aspiration|An intraoral ultrasound is conducted with a Burr-Hole N11C5s transducer (BK Ultrasound) and if an abscess cavity is suspected, an ultrasound-guided aspiration is performed with an in-plane needle guide attached to guide the needle.
11136020|NCT03823677|No Intervention|control group 60|"60 minutes normoxia
~Interventions:
~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels
~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
11136021|NCT03823677|Experimental|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
11135929|NCT03824275|Experimental|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
11135930|NCT03824262|Experimental|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
11135931|NCT03824262|Active Comparator|Group II|Mistral-Air Plus forced-air warming device
11135932|NCT03824249|Experimental|Spontaneous breathing|Performance of indirect calorimetry in spontaneously breathing children through the use of indirect calorimetry.
11135933|NCT03824249|Experimental|NIV-CPAP|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 centimeters of water (cmH2O). CPAP will be applied via single-limb circuit with intentional leak.
11135934|NCT03824249|Experimental|NIV-PS|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 cmH2O and Pressure support (PS) of 8 cmH2O. Non-invasive ventilation will be applied via single-limb circuit with intentional leak.
11135935|NCT03824236|Experimental|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
11135936|NCT03824236|Experimental|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
11135937|NCT03824236|No Intervention|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
11135938|NCT03824223|Other|new/old HCT component order|"new/old hypoxic challenge test (HCT) component order
~Where the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen and the old test uses pulse oximetry to titrate supplementary oxygen."
11135939|NCT03824223|Other|old/new HCT component order|"old/new hypoxic challenge test (HCT) component order
~Where the old test uses pulse oximetry to titrate supplementary oxygen and the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen."
11135940|NCT03824210||Stage 1|School children age 11-18 (from two nominated schools) and young carers 11-18
11135941|NCT03824210||Stage 2|Young carers from Young Carers in Herts 11-18
11135942|NCT03824197|Other|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
11135943|NCT03824197|Other|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
11135944|NCT03824184|Active Comparator|manipulation of endometrium|Manipulation of endometrium with saline
11135945|NCT03824184|No Intervention|control group|Control group : No intervention
11135946|NCT03824171|Experimental|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
11135947|NCT03824171|Experimental|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
11135948|NCT03824158|Active Comparator|Facilitated advance care planning (in-person or telephonic)|Patients randomized to this arm will participate in in-person or telephonic facilitated advance care planning (ACP) discussions using the Respecting Choices model.
11135949|NCT03824158|Active Comparator|Web-based advance care planning|Patients randomized to this arm will participate in web-based ACP via the PREPARE website.
11135950|NCT03824145|Experimental|Immediate Intervention|"The experimental arm will receive a 12-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 12-week intervention includes:
~1) a curriculum binder covering 12-weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 12-weeks, with four in-person supervised exercise sessions and eight telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to three cooking classes emphasizing plant-based eating."
11135951|NCT03824145|No Intervention|Wait List Control|The Wait List Control group receives no intervention for 12-weeks. Following the 12-week waitlist period, the wait list control group participants receive the experimental intervention.
11135952|NCT03824132|Experimental|Intervention Group|
11135953|NCT03824132|Active Comparator|Waitlist Control Group|
11135954|NCT03824119|Active Comparator|Standard Postpartum Care|Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.
11135955|NCT03824119|Active Comparator|Standard Postpartum Care without NSAIDs|Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.
11135956|NCT03824106|Experimental|Arm1.Socialization|Participants will attend twice-weekly classes (one-hour each) at the YMCA led by an experienced instructor and volunteers who will help facilitate social interactions. Sessions will include structured social activities (such as icebreakers and cards) and guest speakers with topics relevant to seniors. Light refreshments will be served at each session.
11135957|NCT03824106|Experimental|Arm2.Group Exercise|"Participants will attend the exercise program, twice-weekly, classes at one of three YMCA sites in Hamilton/Brantford/Burlington for 6-months. In the first 15-minutes, participants will check-in and report any injuries/concerns. The exercise component will be an hour followed by time allotted for participants to socialize.
~Supplemental Home Exercise: In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults."
11135958|NCT03824106|Experimental|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2. However, participants in each arm of the trial will attend separate exercise classes at the YMCA to avoid possible contamination.
~Protein Supplementation: the protein supplement (each serving) contains 350 kcal, 20-gram protein, 1.5 g β-Hydroxy β-Methylbutyrate (HMB), and participants are advised to take this with a meal or within 3 hours of exercise on activity days."
11135959|NCT03824093|Active Comparator|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
11135960|NCT03824093|Active Comparator|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
11135961|NCT03824080|Experimental|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles without a treatment-free period in between.
~Responding patients (as per criteria of European LeukaemiaNet and International MDS working Group (2006)) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
11135962|NCT03824067|Active Comparator|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
11135963|NCT03824067|Experimental|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
11135964|NCT03824054||colorectal resection arm|Patients affected by symptomatic deep infiltrating endometriosis involving the bowel and submitted to colo-rectal resection
11135965|NCT03824041|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
11135966|NCT03824041|Experimental|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
11135967|NCT03824041|Experimental|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
11135968|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
11135969|NCT03824015|Experimental|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
11135970|NCT03824015|Other|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
11135971|NCT03824002|Experimental|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
11135972|NCT03824002|Active Comparator|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
11135973|NCT03823989|Experimental|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
11135974|NCT03823989|Experimental|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
11135975|NCT03823989|Experimental|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
11135976|NCT03823963|Other|Standard care|pressure ulcer prevention standard care
11135977|NCT03823963|Experimental|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
11135978|NCT03823950|Experimental|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.
~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
11135979|NCT03823950|No Intervention|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
11135980|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
11135981|NCT03823937||Control|18-70 years healthy subjects
11135982|NCT03823924||Psoriatic arthritis|
11135983|NCT03823924||Healthy volunteers|
11135984|NCT03823911|Active Comparator|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
11135985|NCT03823911|Experimental|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
11135986|NCT03823911|Experimental|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
11136022|NCT03823677|Experimental|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
11136023|NCT03823677|Experimental|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
11135987|NCT03823898|Experimental|Supervised exercise|"Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants were involved in two supervised exercise sessions per week plus healthy lifestyle interactive sessions.
~The experimental intervention consisted of: a) monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study; b) The supervised exercise sessions were prescribed using an aerobic mode performed at a moderate-to-vigorous intensity during 45 minutes, twice a week, preferably during the weekends."
11135988|NCT03823898|Active Comparator|Control Group|Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants received no intervention
11135989|NCT03823898|Experimental|Monthly behavioral sessions|"Participants in this group received a lifestyle intervention from baseline to 4 months and then from 4 to 16 months participants were involved in non-supervised exercise group sessions with monthly behavioral sessions.
~The experimental intervention consisted of monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study"
11135990|NCT03823885|Experimental|E-cig|One time exposure to e-cig
11135991|NCT03823885|Experimental|sham|One time exposure to empty e-cig
11135992|NCT03823872|Experimental|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
11135993|NCT03823872|Experimental|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
11135994|NCT03823859||Healthy volunteers|"Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)
~Indirect calorimetry
~Dual energy X-ray Absorptiometry (DXA)"
11135995|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism
~Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)
~Indirect calorimetry
~Dual energy X-ray Absorptiometry (DXA)"
11135996|NCT03823846|Experimental|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
11135997|NCT03823846|Active Comparator|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
11135998|NCT03823820||Cesarean section|Women attending for elective CS.
11135999|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
11136000|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:
~Pre-eclampsia requiring hospital admission.
~Hyperemesis gravidarum.
~Major postpartum haemorrhage."
11136001|NCT03823820||control|Gestational age matched controls.
11136002|NCT03823807|Experimental|SH-1028|QD,Oral
11136003|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
11136004|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
11136005|NCT03823781|Experimental|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
11136006|NCT03823781|Placebo Comparator|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
11136007|NCT03823768|Active Comparator|Arm 1: Control|Tacrolimus immediate release twice daily for 6 months
11136008|NCT03823768|Experimental|Arm 2: Intervention|Envarsus daily for 6 months.
11136009|NCT03823742|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
11136010|NCT03823742|Experimental|Low FODMAP diet|Low FODMAP diet
11136011|NCT03823729|Experimental|Elosan Cabin|Treatment with Elosan cabin
11136012|NCT03823729|No Intervention|No Treatment|Continuation of taking pain medication as prescribed before study start.
11136013|NCT03823703|Experimental|Miricorilant- 900 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 900 mg miricorilant once daily for 12 weeks.
11136014|NCT03823703|Experimental|Miricorilant- 600 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg miricorilant plus placebo once daily for 12 weeks.
11136015|NCT03823703|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive placebo once daily for 12 weeks.
11136016|NCT03823690|Active Comparator|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.
~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
11136017|NCT03823690|Active Comparator|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
11136018|NCT03823677|No Intervention|control group 15|"Protein expression and emotional test
~15 minutes normoxia
~Interventions:
~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels
~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
11136019|NCT03823677|No Intervention|control group 30|"30 minutes normoxia
~Interventions:
~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels
~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
11136024|NCT03823677|Experimental|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
11136028|NCT03823677|Experimental|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
11136029|NCT03823677|Experimental|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
11136030|NCT03823677|Experimental|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
11136031|NCT03823677|Experimental|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
11136032|NCT03823677|Experimental|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
11136033|NCT03823664||Type 2 Diabetic|"Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L). OR * A1C ≥6.5% (48 mmol/mol). OR * Patients with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).OR* 2-h Plasma Glucose ≥200 mg/dL (11.1 mmol/L) during oral glucose tolerance test*
~* American Diabetes As. (ADA) type 2 diabetes diagnosis criteria"
11136034|NCT03823664||Prediabetic|"Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (Impaired Fasting Glucose)* OR A1C 5.7-6.4% (39-47 mmol/mol)* OR 2-h Plasma Glucose during 75-g Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (Impaired Glucose Tolerance)*
~* ADA prediabetes criteria"
11136035|NCT03823664||Healthy|Healthy glucose metabolism and according to endocrinology visit no health problems related or affect cardiorespiratory fitness and other parameters examined in this study.
11136036|NCT03823651|Experimental|Patient|These are patients undergoing hematopoetic stem cell transplant. Patients will complete Interval training, undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
11136037|NCT03823651|Experimental|Caregiver|These are the assigned caregivers for transplant patients. Caregivers will undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
11136038|NCT03823638|Experimental|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
11136039|NCT03823638|Placebo Comparator|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
11136040|NCT03823625|Experimental|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
11136041|NCT03823625|Experimental|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
11136042|NCT03823612|Experimental|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
11136043|NCT03823612|Active Comparator|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient
~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
11136044|NCT03823599|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
11136045|NCT03823599|Active Comparator|control group|Alcohol brief intervention
11136046|NCT03823586||Children|
11136047|NCT03823586||Adolescents|
11136048|NCT03823573|Experimental|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
11136049|NCT03823573|Active Comparator|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
11136050|NCT03823560|Experimental|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.
~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:
~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;
~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
11136051|NCT03823560|Placebo Comparator|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.
~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:
~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;
~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
11136052|NCT03823534|Experimental|Experimental Arm|For the first 24 hours following surgery, patients younger than 65 years old will be administered a maximum of 120 mg/day bolus IV ketorolac (30 mg every 6 hours). Patients older than 65 years old or with history of advanced renal impairment will receive a maximum of 60 mg/day bolus IV ketorolac (15 mg every 6 hours). All patients may also be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate- severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. At discharge, they will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours, quantity 50. Those with preexisting liver disease will be prescribed the equivalent in oxycodone and will not receive acetaminophen for mild pain.
11136053|NCT03823534|Placebo Comparator|Control|Following surgery, patients will be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate-severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. They will also be given a placebo injection of normal saline every 6 hours for the first 24 hours following surgery. At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours PRN quantity 50, unless they have preexisting liver disease, in which case they will be prescribed the equivalent in oxycodone. They will not receive a nerve block.
11136054|NCT03823521|Experimental|Cardioplexol™- Cardioplegia Solution|Cardioplexol™ will be used as cardioplegic solution in cardiac surgery
11136055|NCT03823508|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (left dorsolateral prefrontal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
11136262|NCT03822182|Active Comparator|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
11136056|NCT03823508|Placebo Comparator|sham tDCS|Patients will receive sham tDCS (15 secondes of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
11136057|NCT03823495|Experimental|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
11136058|NCT03823495|No Intervention|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
11136059|NCT03823482|Experimental|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
11136060|NCT03823482|No Intervention|Control group|Participants in control group will have general anesthesia without lidocaine administration.
11136061|NCT03823469|Active Comparator|Intervention: Nutritional counseling + CCTP|Nutritional counseling + Culinary Coaching Telemedicine Program (CCTP)
11136062|NCT03823469|Active Comparator|Control: Nutritional counseling only|Two 30-minute nutritional counseling sessions
11136063|NCT03823456|Experimental|True self-acupressure group|"True self-acupressure group [Enhanced standard care + True self-acupressure intervention protocol]:
~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
11136064|NCT03823456|Placebo Comparator|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
11136065|NCT03823456|No Intervention|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
11136066|NCT03823417|Placebo Comparator|Normal saline placebo|the participant will get saline 0.9% intravenous infusion for the duration of the surgery
11136067|NCT03823417|Experimental|Intravenous Tranexamic acid|Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
11136068|NCT03823404|Experimental|COR388 80 mg bid|
11136069|NCT03823404|Experimental|COR388 40 mg bid|
11136070|NCT03823404|Placebo Comparator|Placebo bid|
11136071|NCT03823391|Experimental|ABBV-3373 Followed by Placebo|Participants will be administered with ABBV-3373 and placebo for adalimumab every other week for 12 weeks. After 12 weeks, participants will receive placebo for adalimumab every other week until Week 22.
11136072|NCT03823391|Experimental|Adalimumab|Participants will be administered with placebo for ABBV-3373 and adalimumab every other week for 12 weeks. After 12 weeks, participants will receive adalimumab every other week until Week 22.
11136073|NCT03823378|Experimental|Participants receiving ABBV-599|Participants will be administered with ABBV-599 (ABBV-105 dose A and upadacitinib dose A)
11136074|NCT03823378|Experimental|Participants receiving ABBV-105 dose A and placebo|Participants will be administered with ABBV-105 dose A and placebo for upadacitinib
11136075|NCT03823378|Experimental|Participants receiving ABBV-105 dose B and placebo|Participants will be administered with ABBV-105 dose B and placebo for upadacitinib
11136076|NCT03823378|Experimental|Participants receiving ABBV-105 dose C and placebo|Participants will be administered with ABBV-105 dose C and placebo for upadacitinib
11136077|NCT03823378|Experimental|Participants receiving Upadacitinib Dose A and placebo|Participants will be administered with upadacitinib dose A and placebo for ABBV-105
11136078|NCT03823365|Experimental|Indolent NHL or CLL patients|Adults diagnosed with indolent non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL) in need of first line treatment consisting of either FCR or BR as per investigator assessment
11136079|NCT03823352|Experimental|Antroquinonol|Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
11136080|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
11136081|NCT03823313|Experimental|Spiritual Care Assessment and Intervention|
11136082|NCT03823300|Experimental|Faricimab|
11136083|NCT03823300|Active Comparator|Aflibercept|
11136084|NCT03823287|Experimental|Faricimab|
11136085|NCT03823287|Active Comparator|Aflibercept|
11136086|NCT03823261|Experimental|CBT|
11136087|NCT03823248|Experimental|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
11136088|NCT03823248|Active Comparator|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
11136089|NCT03823235|Experimental|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
11136090|NCT03823235|No Intervention|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
11136091|NCT03823222|Experimental|Duckweed protein|20 gram of isolated protein
11136092|NCT03823222|Experimental|Whey protein|20 gram of isolated protein
11136093|NCT03823209|Experimental|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.
~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.
~All social network members will be asked about intervention exposure at 6- and 15-month followups."
11136094|NCT03823209|Active Comparator|Comparison|Participants will receive brief HIV counseling at baseline visit.
11136095|NCT03823196|Experimental|Verum900|The arm will receive 900 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
11136096|NCT03823196|Experimental|Verum1800|The arm will receive 1800 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
11136097|NCT03823183|Experimental|Multi-domain training|Group that receives cognitive training and physical training
11136098|NCT03823183|Experimental|Cognitive training|Group that receives cognitive training and physical control activity
11136099|NCT03823183|Experimental|Physical activity|Group that receives control cognitive activity and physical training
11136100|NCT03823183|Active Comparator|Active control|Group that receives cognitive control activity and physical control activity
11136101|NCT03823170|Experimental|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
11136102|NCT03823170|Active Comparator|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
11136103|NCT03823170|Experimental|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
11136104|NCT03823157|Experimental|Tai Chi|Tai Chi exercise
11136105|NCT03823144|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.
11136106|NCT03823131|Experimental|Arm A: Tavo-EP, pembrolizumab, epacadostat|tavo-EP:pUMVC3-hIL-12-NGVL33 (tavo-EP) will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks. Epacadostat will be administered at the dose level determined in the dose escalation safety lead-in.
11136107|NCT03823131|Experimental|Arm B: Tavo-EP, pembrolizumab|tavo-EP:pUMVC3-hIL-12-NGVL33 (tavo-EP) will be injected intratumorally on Days 1, 5 and 8 every 6 weeks to up to 7 accessible lesions without exceeding 20 mL per day. Injected lesions will then be electroporated using the ImmunoPulse electroporation device. Pembrolizumab will be administered by a 30 minute IV infusion at a dose of 200 mg every 3 weeks.
11136108|NCT03823118|Experimental|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
11136109|NCT03823105|Experimental|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
11136110|NCT03823092||Normal|phakic participants with no evidence of eye disorders
11136111|NCT03823092||Cataract|participants with cataract
11136112|NCT03823092||AMD|participants with age related macular degeneration
11136113|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
11136114|NCT03823092||other macula|participants with macular ddisorders other than AMD
11136115|NCT03823092||DR|participants with diabetic retinopathy
11136116|NCT03823079|Experimental|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)
~Concurrent Chemoradiotherapy:
~Radiation: judged according to the tumor site and radiotherapy purpose.
~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)
~Raltitrexed: 3 mg/m2 q3w"
11136117|NCT03823079|Active Comparator|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)
~Concurrent Chemoradiotherapy:
~Radiation: judged according to the tumor site and radiotherapy purpose.
~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)
~Raltitrexed: 3 mg/m2 q3w"
11136118|NCT03823066|Experimental|Coach Pepper|Pepper is a humanoid socially assistive robot
11136119|NCT03823053|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
11136151|NCT03822793|Experimental|Group 1: perfusion of 500 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive a perfusion of 500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
11136120|NCT03823053|Experimental|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
11136121|NCT03823040|Active Comparator|Tinox® group|Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
11136122|NCT03823040|Experimental|Oxiconazole nitrate SLNs loaded gel group|13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
11136123|NCT03823027|Experimental|Single-arm|The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
11136124|NCT03823014|Experimental|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
11136125|NCT03823001|Experimental|Virtual prostate biopsy (VB) monitoring|"Prostate-specific antigen (PSA) and digital rectal exam (DRE) are standard of care for monitoring patients on active surveillance or at risk of having low-risk prostate cancer. A novel virtual biopsy (VB) monitoring protocol will be implemented:
~PSA bi-annually or more often according to the discretion of the urologist.
~Annual DRE.
~Visit with the urologist bi-annually.
~Multi-parametric MRI (mpMRI) every year for 3 years.
~Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
11136126|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
11136127|NCT03822975|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
11136128|NCT03822975|Active Comparator|Heparin|Heparin alone during primary PCI
11136129|NCT03822962|Other|Standard Tylenol Regimen|"Patient will be given a standard regimen:
~Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed."
11136130|NCT03822962|Active Comparator|Ibuprofen 600mg|Tylenol 1000 mg by mouth every 6 hours scheduled and ibuprofen 600 mg tablet by mouth every 8 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
11136131|NCT03822949|Experimental|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
11136132|NCT03822949|Sham Comparator|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
11136133|NCT03822936|Experimental|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
11136134|NCT03822923|Experimental|Experimental group|Neurodynamics (Dynamic Neural Mobilization) with conventional treatment (stretching, AROM) will be applied.
11136135|NCT03822923|Active Comparator|control group|Conventional treatment (stretching, AROM) will be applied
11136136|NCT03822910||Healthy Controls|Matched Healthy Controls
11136137|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
11136138|NCT03822897|Other|Two Treatment Options|"Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks
~Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy"
11136139|NCT03822884|Experimental|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
11136140|NCT03822884|Experimental|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
11136141|NCT03822884|Active Comparator|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
11136142|NCT03822871|Experimental|Cohort A-E|Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled.
11136143|NCT03822871|Experimental|Cohort F - at Recommended Phase 2 Dose|Cohort F: Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled at the recommended phase 2 dose.
11136144|NCT03822845|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
11136145|NCT03822832|Experimental|Spesolimab|i.v.
11136146|NCT03822832|Placebo Comparator|Placebo|i.v.
11136147|NCT03822819|Experimental|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
11136148|NCT03822819|Placebo Comparator|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
11136149|NCT03822806|Experimental|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise (using the videogame JustDance) for the first 30 minutes of those 2 hours using the video game (continuing to wear the patch for 90 minutes after exercise).
11136150|NCT03822793|Placebo Comparator|Placebo|Patient will be included in this group by randomization and they will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.
11136152|NCT03822793|Experimental|Group 2: perfusion of 1000 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive a perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
11136153|NCT03822793|Experimental|Group 3: perfusion of 1500 mg Exacyl|Patient will be included in the group 3 by randomization and they will receive a perfusion of 1500 mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
11136154|NCT03822793|Experimental|Group 4: perfusion of 3000 mg Exacyl|Patient will be included in the group 4 by randomization and they will receive a perfusion of 3000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
11136155|NCT03822780|Experimental|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.
~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
11136156|NCT03822767|Experimental|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
11136157|NCT03822767|Active Comparator|Control Group|wIPV-wIPV-bOPV vaccination schedule
11136158|NCT03822754|Experimental|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
11136159|NCT03822754|Active Comparator|Control Group|wIPV-bOPV-bOPV vaccination schedule
11136160|NCT03822728|No Intervention|Without 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
11136161|NCT03822728|Experimental|With 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
11136162|NCT03822715|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
11136163|NCT03822702|No Intervention|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.
~The same tasks will be ask to do again three days later."
11136164|NCT03822702|No Intervention|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.
~The same tasks will be ask to do again three days later."
11136165|NCT03822702|No Intervention|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
11136166|NCT03822702|Experimental|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.
~For post-test, the same procedure will be ask to do again about one and a half month later .
~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
11136167|NCT03822702|Experimental|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.
~For post-test, the same procedure will be ask to do again about one and a half month later .
~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
11136168|NCT03822702|No Intervention|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.
~The same procedure will be ask to do again about one and a half month later."
11136169|NCT03822689|Active Comparator|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
11136170|NCT03822689|Active Comparator|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
11136171|NCT03822676|Experimental|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
11136172|NCT03822676|No Intervention|No stent|No prophylactic stent before surgery
11136173|NCT03822663|Experimental|Caffeine supplementation|Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
11136174|NCT03822663|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo.
11136175|NCT03822637|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
11136176|NCT03822637|Placebo Comparator|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
11136177|NCT03822624|Experimental|Probiotic group|
11136178|NCT03822624|Placebo Comparator|Placebo group|
11136179|NCT03822611|Experimental|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
11136180|NCT03822611|No Intervention|No subsidy|In these communities, no household receives a voucher.
11136181|NCT03822598|Experimental|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
11136182|NCT03822598|Active Comparator|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
11136183|NCT03822585|Other|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters & Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
11136184|NCT03822572|Experimental|A - endurance exercise|All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
11136185|NCT03822572|Other|B - control arm|Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
11136186|NCT03822559|Experimental|DE-111A eye drops|
11136187|NCT03822559|Active Comparator|0.0015% tafluprost eye drops|
11136188|NCT03822546|Experimental|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
11136189|NCT03822546|Active Comparator|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
11136190|NCT03822546|Active Comparator|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
11136191|NCT03822546|Active Comparator|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
11136192|NCT03822546|Active Comparator|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
11136193|NCT03822546|Active Comparator|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
11136194|NCT03822533|Other|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.
~Patients can seek a physician anytime after the first assessment with the physiotherapist."
11136195|NCT03822533|Other|Physician as primary assessor|"The Healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.
~Patients can seek a physiotherapist anytime after the first assessment with the physician."
11136196|NCT03822520|Experimental|Celecoxib, Moxifloxacin, Water in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days
~Wash-out period (3~6 days)
~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day
~Wash-out period (3~6 days)
~Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
11136197|NCT03822520|Experimental|Celecoxib, Water, Moxifloxacin in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days
~Wash-out period (3~6 days)
~Intervention Pure water: Water 150ml by mouth without any drug, once for one day
~Wash-out period (3~6 days)
~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
11136198|NCT03822520|Experimental|Moxifloxacin, Water, Celecoxib in order|"Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day
~Wash-out period (3~6 days)
~Intervention Pure water: Water 150ml by mouth without any drug, once for one day
~Wash-out period (3~6 days)
~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
11136199|NCT03822520|Experimental|Water, Moxifloxacin, Celecoxib in order|"Intervention Pure water: Water 150ml by mouth without any drug, once for one day
~Wash-out period (3~6 days)
~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day
~Wash-out period (3~6 days)
~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
11136200|NCT03822507|Experimental|KHK7580 1mg-12mg|
11136201|NCT03822507|Active Comparator|Cinacalcet 25mg-100mg|
11136202|NCT03822494|Experimental|Dose Escalated CyberKnife SBRT|
11136203|NCT03822481|Experimental|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
11136204|NCT03822481|No Intervention|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
11136205|NCT03822468|Experimental|Ribociclib 400 mg|Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
11136206|NCT03822468|Active Comparator|Ribociclib 600 mg|Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
11136207|NCT03822455|Active Comparator|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
11136208|NCT03822455|Placebo Comparator|Placebo DPI|Placebo DPI containing lactose and excipients
11136209|NCT03822429||women < 35 years old|
11136210|NCT03822429||women between 36 and 38 years old|
11136211|NCT03822429||women between 39 and 40 years|
11136212|NCT03822429||women > 41 years old|
11136213|NCT03822416|Experimental|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
11136214|NCT03822416|Other|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
11136215|NCT03822403|Active Comparator|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
11136261|NCT03822182|Other|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
11136216|NCT03822403|Active Comparator|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
11136217|NCT03822390||Patients|Patients older than 18 years undergoing colonoscopy in one the participating centres.
11136218|NCT03822377|Experimental|Experimental arm|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.
~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
11136219|NCT03822377|Active Comparator|Control arm|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.
~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
11136220|NCT03822364|Experimental|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
11136221|NCT03822364|Experimental|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
11136222|NCT03822364|Experimental|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
11136223|NCT03822364|Placebo Comparator|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
11136224|NCT03822364|Active Comparator|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
11136225|NCT03822364|Placebo Comparator|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
11136226|NCT03822364|Experimental|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
11136227|NCT03822364|Placebo Comparator|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
11136228|NCT03822364|Experimental|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
11136229|NCT03822364|Placebo Comparator|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
11136230|NCT03822364|Experimental|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
11136231|NCT03822364|Placebo Comparator|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
11136232|NCT03822364|Experimental|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
11136233|NCT03822364|Placebo Comparator|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
11136234|NCT03822351|Experimental|Control Arm (Durvalumab monotherapy)|durvalumab IV
11136235|NCT03822351|Experimental|Arm A (durvalumab + oleclumab):|durvalumab IV and oleclumab IV
11136236|NCT03822351|Experimental|Arm B (durvalumab + monalizumab)|durvalumab IV and monalizumab IV
11136237|NCT03822338|Experimental|Pneumoperitoneum preconditioning group|Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.
11136238|NCT03822338|Sham Comparator|Control group|Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation.
11136239|NCT03822312|Experimental|DBT-TOBI|"Subjects will be imaged using DBT-TOBI at the time points indicated in the Study Calendar (Baseline, before cycle 2, and additional optional time points).
~Both breasts will be measured in turn.
~Each breast is symmetrically centered on the x-ray detector/optical illuminator and is first compressed according to standard mammography procedures to determine the amount of force needed for each given patient
~An optional Magnetic Resonance Imaging TOBI (MRI-TOBI) scan will also be performed."
11136240|NCT03822299|No Intervention|Placebo|Patients receive suspension of their own feces.
11136241|NCT03822299|Active Comparator|30 g donor dose|Patients receiving 30 g of a healthy donor feces.
11136242|NCT03822299|Active Comparator|60 g donor dose|Patients receiving 60 g of a healthy donor feces.
11136243|NCT03822286|Experimental|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
11136244|NCT03822286|Active Comparator|Control|Traditional classroom teaching course programs.
11136245|NCT03822273|Experimental|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
11136246|NCT03822273|Active Comparator|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
11136247|NCT03822273|Placebo Comparator|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
11136248|NCT03822260||Sur1/ Trpm 4 acitivities at SAH|only after collecting sample,
11136249|NCT03822247|Experimental|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.
~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
11136250|NCT03822247|No Intervention|Conventional Perioperative Care|Patients undergoing conventional care
11136251|NCT03822234|Experimental|Modified ileal conduit|With our modified ileal conduit technique
11136252|NCT03822234|No Intervention|Conventional ileal conduit|Conventional ileal conduit
11136253|NCT03822221|Experimental|SK20º|MVIC and NMES with hip at 85º and knee at 20º
11136254|NCT03822221|Experimental|SK60º|MVIC and NMES with hip at 85º and knee at 60º
11136255|NCT03822221|Experimental|LK20º|MVIC and NMES with hip at 0º and knee at 20º
11136256|NCT03822221|Experimental|LK60º|MVIC and NMES with hip at 0º and knee at 60º
11136257|NCT03822208|Active Comparator|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
11136258|NCT03822208|Placebo Comparator|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
11136259|NCT03822195||asymptomatic|asymptomatic patients undergoing carotid endoarterectomy for stenosis >70% (velocimetric criteria at echodoppler)
11136260|NCT03822195||symptomatic|symptomatic (TIA, crescendo TIA, minor stroke) patients undergoing carotid endoarterectomy, independently from stenosis evaluated by echodoppler
11136332|NCT03821675|Active Comparator|Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
11136263|NCT03822182|Active Comparator|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
11136264|NCT03822169|Experimental|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
11136265|NCT03822169|Active Comparator|Choline added as a salt|control shake with choline added as a salt and added DHA.
11136266|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
11136267|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
11136268|NCT03822143|Experimental|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
11136269|NCT03822130|Placebo Comparator|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
11136270|NCT03822130|Experimental|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
11136271|NCT03822130|Experimental|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
11136272|NCT03822117|Experimental|Pemigatinib|Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions). Cohort B (Solid tumor malignancies with activating point mutations in FGFR1-3) Cohort C (Solid tumor malignancies with any other FGFR1-3 point mutations and variants of unknown significance).
11136273|NCT03822104|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
11136274|NCT03822104|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
11136275|NCT03822091|Active Comparator|TERLIPRESSIN GROUP|
11136276|NCT03822091|Experimental|TERLIPRESSIN WITH NORADRENALINE GROUP|
11136277|NCT03822078|Placebo Comparator|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
11136278|NCT03822078|Experimental|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
11136279|NCT03822065|Experimental|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
11136280|NCT03822065|Experimental|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
11136281|NCT03822052|Active Comparator|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
11136282|NCT03822052|Active Comparator|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
11136283|NCT03822052|Active Comparator|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
11136284|NCT03822052|Active Comparator|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
11136285|NCT03822026|Other|patients with severe TBI|Patients with severe TBI enrolled in the study undergo an hyperventilation test, in which the alveolar ventilation is increased by a stepwise increase in tidal volumes and respiratory rate until a reduction of etCO2 of 0.7 kPa is achieved.
11136286|NCT03822013|Experimental|Miglustat|"Miglustat is administered, dose is adjusted according to Body Surface Area as below:
~>1.25 : 200 mg TDS 0.88-1.25 : 200mg BID 0.73-0.88 :100mg TDS 0.47-0.73 : 100mg BID <0.47 :100mg daily"
11136287|NCT03822013|No Intervention|No Miglustat|
11136288|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
11136289|NCT03821987|Experimental|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.
~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
11136290|NCT03821974|Experimental|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
11136291|NCT03821974|Experimental|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
11136292|NCT03821961|Experimental|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
11136293|NCT03821948||Average CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with average CRC risk undergoing a standard of care colonoscopy procedure
11136294|NCT03821948||Increased CRC Risk Group|Stool sample collection and blood draw in men and women aged 40 and older with increased CRC risk undergoing a standard of care colonoscopy procedure
11136295|NCT03821935|Experimental|ABBV-151 Monotherapy|Various doses of ABBV-151 administered during dose escalation, followed by dose expansion of ABBV-151 administered at the Recommended Phase 2 Dose (RP2D).
11136296|NCT03821935|Experimental|ABBV-151 + ABBV-181 Combination Therapy|Various doses of ABBV-151 plus ABBV-181 Dose A administered every 4 weeks (Q4W) during dose escalation, followed by dose expansion of ABBV-151 administered at the RP2D plus ABBV-181 Dose A administered Q4W.
11136297|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
11136298|NCT03821922||Control|Those healthy pregnant women
11136299|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
11136300|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
11136328|NCT03821701|Active Comparator|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
11136397|NCT03821233|Experimental|ZW49|
11136301|NCT03821896|Experimental|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
11136302|NCT03821896|Active Comparator|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
11136303|NCT03821883|Experimental|Aspirin group|Study patients assigned to Aspirin group will receive enteric coated aspirin (100 mg/day).
11136304|NCT03821883|Placebo Comparator|Control group|Study patients assigned to control group will receive placebo.
11136305|NCT03821870||Standard treatment|Standard first line treatment
11136306|NCT03821857|Experimental|Women|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
11136307|NCT03821844|Experimental|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
11136308|NCT03821844|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
11136309|NCT03821831||Continuous Positive Airway Pressure|This group consists of consenting patients and their parents who choose Continuous Positive Airway Pressure (CPAP). The CPAP is a type of therapy that applies mild air pressure to a person's upper airway to keep their airway open so that they can breathe normally while they sleep.
11136310|NCT03821831||Orthodontic Intervention|This group consists of consenting patients and their parents who choose orthodontic intervention will be seen by participating orthodontists who will determine types of orthodontic intervention; mandibular advancement devices or rapid maxillary expansion devices. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
11136311|NCT03821831||Control|This group consists of consenting patients and their parents who choose to remain untreated. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
11136312|NCT03821818||Control|Food Allergen Elimination only
11136313|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise > 75% max HR), five times/day.
11136314|NCT03821805|Experimental|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
11136315|NCT03821805|No Intervention|Control group|Rest for 30 min
11136316|NCT03821792|Experimental|Treatment (abiraterone acetate, prednisone, apalutamide)|Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
11136317|NCT03821779|Experimental|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.
~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).
~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
11136318|NCT03821779|Experimental|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:
~real exposure: oral presentation to a panel of examiners
~virtual reality : oral presentation to virtual examiners
~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.
~Psychometric evaluation will be performed prior to experimental sessions."
11136319|NCT03821779|Experimental|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:
~virtual reality : oral presentation to virtual examiners
~real exposure: oral presentation to a panel of examiners
~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.
~Psychometric evaluation will be performed prior to experimental sessions."
11136320|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
11136321|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)> 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
11136322|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
11136323|NCT03821714|Experimental|Glucocorticoid combination therapy Group|The patients of the experimental group are treated with intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (200 mg continuous intravenous injection in 24h for 3-5 days or until ICU discharge), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
11136324|NCT03821714|Active Comparator|Glucocorticoid Group|The patients of the Glucocorticoid Group are treated with hydrocortisone (200 mg continuous intravenous injections in 24h for 3-5 days or until ICU discharge)
11136325|NCT03821701|Experimental|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
11136326|NCT03821701|Active Comparator|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
11136327|NCT03821701|Experimental|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
11136329|NCT03821688|Experimental|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
11136333|NCT03821675|Sham Comparator|Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
11136334|NCT03821662|Experimental|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
11136335|NCT03821649|Experimental|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
11136336|NCT03821649|Active Comparator|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
11136337|NCT03821636|Sham Comparator|Standard Roux-en-Y|
11136338|NCT03821636|Active Comparator|Long alimentary limb Roux-en-Y|
11136339|NCT03821623|Experimental|Nicotinamide riboside|Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.
11136340|NCT03821623|Placebo Comparator|Placebo|Subjects will take placebo pills twice a day for 3 months.
11136341|NCT03821610|Active Comparator|Fludarabine / Melphalan / Alemtuzumab|Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells
11136342|NCT03821610|Experimental|Cyclophosphamide / TBI (8Gy)|Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow
11136343|NCT03821597|Experimental|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
11136344|NCT03821597|Active Comparator|No sequential compression devices|No sequential compression devices are applied.
11136345|NCT03821571|Experimental|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
11136346|NCT03821571|Active Comparator|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
11136347|NCT03821558|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak exercise performance) and low-intensity intervals (60-70% of peak exercise performance).
11136348|NCT03821558|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo moderate continuous exercise training at 75% of peak exercise performance.
11136349|NCT03821545|Active Comparator|Lidocaine Group|
11136350|NCT03821545|Active Comparator|Ketamine Group|
11136351|NCT03821545|Active Comparator|Lidocaine and Ketamine Group|
11136352|NCT03821545|Placebo Comparator|Placebo (0.9% NaCl) Group|
11136353|NCT03821532|No Intervention|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
11136354|NCT03821532|Experimental|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
11136355|NCT03821519|Experimental|Relapsed after Haplo transplant|
11136356|NCT03821506|Experimental|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
11136357|NCT03821506|Placebo Comparator|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
11136358|NCT03821493|Experimental|PF-06651600 treatment arm|This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
11136359|NCT03821480|Experimental|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
11136360|NCT03821480|Active Comparator|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
11136361|NCT03821467|Experimental|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
11136362|NCT03821454|Experimental|Capecitabine|The experimental group received oral capecitabine for eight cycles.
11136363|NCT03821454|Placebo Comparator|Placebo|The placebo group received oral placebo for eight cycles.
11136364|NCT03821441|Experimental|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.
~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
11136365|NCT03821441|Experimental|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.
~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
11136366|NCT03821441|Experimental|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
11136367|NCT03821428|Experimental|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
11136368|NCT03821428|Placebo Comparator|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
11136369|NCT03821415|Experimental|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
11136370|NCT03821415|Experimental|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
11136371|NCT03821415|Experimental|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
11136372|NCT03821415|Placebo Comparator|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
11136373|NCT03821402|Experimental|DAXI for injection dose LOW DOSE|LOW dose group
11136374|NCT03821402|Experimental|DAXI for injection dose MEDIUM DOSE|MEDIUM dose group
11136375|NCT03821402|Experimental|DAXI for injection Dose HIGH DOSE|HIGH dose group
11136376|NCT03821402|Placebo Comparator|Placebo|Placebo group
11136377|NCT03821389|Experimental|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
11136378|NCT03821389|Active Comparator|NIOD Frequencer of 60Hz|
11136379|NCT03821376|Experimental|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
11136380|NCT03821363|Experimental|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
11136381|NCT03821363|Experimental|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
11136382|NCT03821363|Experimental|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
11136383|NCT03821350|No Intervention|Control Group|The control group was given verbal information
11136384|NCT03821350|Experimental|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
11136385|NCT03821337|Experimental|rTMS|Participants will receive 18 sessions of active rTMS delivered at 120% rMT.
11136386|NCT03821337|Placebo Comparator|Sham TMS|Participants will receive 18 sessions of sham rTMS delivered through an inactive coil.
11136387|NCT03821324|Other|Intervention|Device: Venus Viva
11136388|NCT03821311|Experimental|Computed tomography examination|Each patient will undergo a low-dose supine position chest CT scan including end-inspiratory and expiratory acquisitions, corresponding to the routine protocol for COPD patients, except that this end-inspiratory/end-expiratory CT is repeated 3 times for total of 6 CT acquisitions.
11136389|NCT03821298|Experimental|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
11136390|NCT03821285|Experimental|pulmonary rehabilitation|Pulmonary rehabilitation program
11136391|NCT03821272|Experimental|PepCan|Vaccine regimen consisting of seven injections of PepCan (50 μg per peptide dose)
11136392|NCT03821272|Placebo Comparator|Placebo|Vaccine regimen consisting of seven injections of placebo (saline) to mimic PepCan
11136393|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
11136394|NCT03821246|Experimental|Cohort A (atezolizumab)|Patients receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
11136395|NCT03821246|Experimental|Cohort B (atezolizumab, tocilizumab)|Patients will receive one (1) cycle of neoadjuvant atezolizumab and one (1) cycle of tocilizumab, 6mg/kg will be administered IV on day 1 of a 14 day IV prior to RP; atezolizumab will be administered in an identical fashion as Cohort A. RP will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
11136396|NCT03821246|Experimental|Cohort C (atezolizumab, etrumadenant)|Patients will receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle and etrumadenant will be taken at a dose of 150mg PO, once daily, until 48 hours prior to RP, for at least 12 days. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
11136398|NCT03821220|Active Comparator|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
11136399|NCT03821220|Active Comparator|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
11136400|NCT03821220|Active Comparator|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
11136401|NCT03821207|Active Comparator|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
11136402|NCT03821207|Active Comparator|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
11136403|NCT03821207|Placebo Comparator|The control group|The control group will perform no exercise or massage.
11136404|NCT03821194|Experimental|Gua sha group|do gua sha for the subjects
11136405|NCT03821194|Active Comparator|control group|give hot pack for the subjects
11136406|NCT03821181|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
11136407|NCT03821181|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
11136408|NCT03821168|Active Comparator|intravitreal injection of bevacizumab and erythropoietin|erythropoietin:
11136409|NCT03821168|Active Comparator|intravitreal injection of bevacizumab|bevacizumab:1.25 mg
11136410|NCT03821155|Active Comparator|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
11136411|NCT03821155|Experimental|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
11136412|NCT03821142|Experimental|Calistar S for transvaginal pelvic organ prolapse repair|Single arm, prospective cohort trial evaluating Calistar S for transvaginal mesh repair for pelvic organ prolapse
11136413|NCT03821129|Other|GORE® CARDIOFORM Septal Occluder|Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
11136414|NCT03821116|Experimental|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
11136415|NCT03821116|Experimental|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
11136416|NCT03821103|Experimental|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
11136417|NCT03821103|Experimental|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
11136418|NCT03821090||cases|"Eighty rheumatoid arthritis patients fulfilling American College of Rheumatology (ACR) 2010 classification criteria, all of them will be subjected to
~History including disease duration , course and associated diseases
~Clinical examination with specific joint examination
~RA disease activity will be evaluated by a 28- joint DAS (DAS28).
~The Framingham 10 year risk of general cardiovascular disease score will be calculated 5-12-lead ECG
~6-Echocardiography 7-Carotid intima media thickness (cIMT)using carotid doppler 8-Venous blood will be withdrawn to do the following laboratory tests
~CBC
~ESR &CRP
~RF& Anti-ccp
~Urine analysis , Urea and creatinine , and GFR
~Uric acid level
~Homocystine
~Lipogram
~HA1C
~TNF α
~High sensitive cardiac troponin I (hs-cTnI)"
11136419|NCT03821090||control|"fifty healthy subjects age and sex matched will be included , all of them will be subjected to
~History
~Clinical examination .
~The Framingham 10 year risk of general cardiovascular disease score will be calculated 4-12-lead ECG
~5-Echocardiography 6-Carotid intima media thickness (cIMT)using carotid doppler 8-Venous blood will be withdrawn to do the following laboratory tests
~Complete Blood Count (CBC)
~Erythrocyte Sedimentation Rate (ESR) &C Reactive Protein(CRP)
~Rheumatoid Factor (RF)& Anti-ccp
~Urine analysis , Urea and creatinine , and Glomerular Filtration Rate(GFR)
~Uric acid level
~Homocystine
~Lipogram
~HA1C
~TNF α
~High sensitive cardiac troponin I (hs-cTnI)"
11136420|NCT03821064|Experimental|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
11136421|NCT03821038|Experimental|CYT107|Intravenous (IV) administration of CYT107 at 10 μg/kg twice a week for 3 weeks
11136422|NCT03821038|Placebo Comparator|Placebo|Intravenous (IV) administration of the same volume of NaCl 0.9% twice a week for 3 weeks
11136423|NCT03821025|Active Comparator|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
11136424|NCT03821025|Active Comparator|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
11136425|NCT03821012||CSCAP-1|STEMI with symptom onset within 12 h regardless of whether receiving reperfusion or symptom onset within 12-24 h of needing PPCI
11136426|NCT03821012||CSCAP-2|STEMI patients with symptom onset within 30 days
11136427|NCT03821012||CSCAP-3|STEMI patients with symptom onset within 30 days
11136428|NCT03820999|Experimental|Teaching arm|The Primary Health Care physicians getting oral and written information on tick-bites and Lyme disease with focus on Lyme neuroborreliosis.
11136429|NCT03820999|No Intervention|Passive arm|The Primary Health Care physicians that does not get contacted with an offer to receive oral and written information.
11136430|NCT03820986|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
11136431|NCT03820986|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
11136432|NCT03820973|Experimental|Brief CBT for Anxiety|Participants will receive Brief Cognitive Behavioral Therapy for Anxiety (bCBT). Sessions with clinicians will be provided via VA Video Connect to Home (VVC-H). Participants will have the option to select from a list of skills to tailor to his/her preferences. Participants will be able to receive up to 9 total sessions and generally last 30 to 40 minutes. For the purpose of this study, treatment duration will be limited to 3 months to ensure standardization of study outcome measures.
11136433|NCT03820947|Experimental|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
11136434|NCT03820947|Active Comparator|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
11136435|NCT03820947|Active Comparator|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
11136436|NCT03820947|Other|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
11136437|NCT03820934|Other|Patients undergoing Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these test. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
11136438|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.
~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
11136439|NCT03820908|Experimental|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
11136440|NCT03820882|Experimental|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
11136441|NCT03820882|Active Comparator|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
11136442|NCT03820869|Active Comparator|Control|Children with ASD
11136443|NCT03820869|Experimental|Intervention|Children with ASD
11136444|NCT03820856|Experimental|acupuncture plus fire needle group|
11136445|NCT03820856|Active Comparator|acupuncture group|
11136446|NCT03820843|Experimental|Art therapy|Art therapy and standard orthophonic rehabilitation
11136447|NCT03820843|No Intervention|Control group|Only standard orthophonic rehabilitation
11136448|NCT03820830|Experimental|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
11136449|NCT03820830|Active Comparator|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
11136450|NCT03820817|Experimental|Treatment (rifaximin)|Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.
11136451|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
11136452|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
11136453|NCT03820791|Experimental|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
11136454|NCT03820791|No Intervention|No poster|No poster is placed in patients' room.
11136455|NCT03820778|Experimental|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
11136456|NCT03820752||Pediatric chronically ill patients|"Through a questionnaire parents of chronically ill patients will be asked about the vaccination status of all recommended vaccines of their child. Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.
~A blood sample to determine antibodies against measles, mumps, rubella and pertussis will be drawn from children who consent to sampling.
~The following groups of patients will be questioned: diabetes, allergy, congenital heart disease, cystic fibrosis, immunodeficiency and transplant patients, cancer patients."
11136457|NCT03820752||Adult chronically ill patients|"Through a questionnaire chronically ill patients will be asked about their vaccination status of diphtheria, tetanus,pertussis, flu, pneumococcal and hepatitis B vaccine(s). Also questions on disease, therapy and sociodemographic factors that can influence vaccination coverage will be asked.
~A blood sample to determine antibodies against diphtheria, tetanus and pertussis will be drawn.
~The following groups of patients will be questioned: diabetes, chronic kidney disease, heart failure, COPD, immunodeficiency and transplant patients, HSCT patients."
11136458|NCT03820739||Cohort 1|Subjects who received an Ebola vaccine prime vaccination in EBOVAC-Salone are eligible for enrolment in this study. Adults are defined as participants 18 years of age or older at the time of prime vaccination, and children are defined as participants aged 1 to 17 years at the time of prime vaccination in EBOVAC-Salone.
11136459|NCT03820739||Cohort 2 (offspring)|Infants conceived by a female participant in EBOVAC-Salone during the 3 months following vaccination with Ad26.ZEBOV or during the 28 days following vaccination with MVA-BN®-Filo.
11136460|NCT03820726|Experimental|All subjects|
11136656|NCT03819465|Experimental|B2|Durvalumab + Investigator's choice of chemotherapy + danvatirsen
11136461|NCT03820713|Experimental|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
11136462|NCT03820713|Placebo Comparator|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
11136463|NCT03820700|No Intervention|Control group|[Randomized] Patients in control group will receive regular nursing care but no behavioral therapy intervention.
11136464|NCT03820700|Experimental|Hypnosis (Hypn)|[Randomized] Patients will receive a hypnosis recorded audiotape.
11136465|NCT03820700|Experimental|Virtual reality (VR)|[Randomized] Patients will see a 3D movie with a beautiful landscape.
11136466|NCT03820700|Experimental|Virtual reality hypnosis (VRH)|[Randomized] Patients will see the same 3D film combined with a hypnotic voice.
11136467|NCT03820687|Active Comparator|Intervention Group|Participants in the intervention group will receive 3 components: 1) a culturally tailored clinical trial educational video, 2) a brochure and 3) support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trials by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option for cancer.
11136468|NCT03820687|Active Comparator|Usual Care Control Group|Participants in the usual care control group will receive a general clinical trial fact sheet.
11136469|NCT03820674|Experimental|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
11136470|NCT03820674|Active Comparator|Health Education Intervention|Receiving control intervention
11136471|NCT03820661|Other|High Resolution Ultasound|Diagnostic high resolution ultrasound pre-operatively and intraoperatively
11136472|NCT03820648|Experimental|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
11136473|NCT03820648|Active Comparator|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
11136474|NCT03820635||Calcified|those with evidence of vascular calcification
11136475|NCT03820635||Non-calcified|those with no evidence of vascular calcification
11136476|NCT03820622|Experimental|DIOR group|in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
11136477|NCT03820622|Active Comparator|Bingo group|in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)
11136478|NCT03820609|Experimental|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
11136479|NCT03820596|Experimental|Sintilimab+Chidamide|"Sintilimab：200mg(fixed dosage), ivd, qd, q21d
~Chidamide:
~Phase I: 20mg-30mg,biw,continued oral，to evaluate RP2D. Phase II：RP2D，continued oral"
11136480|NCT03820570|Experimental|lichtenstein|hernia repair
11136481|NCT03820557|Experimental|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
11136482|NCT03820544|Experimental|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
11136483|NCT03820544|Active Comparator|Standard of care surgical resection|Patients undergo standard of care surgical resection.
11136484|NCT03820531|Experimental|Suspected mucinous pancreas cyst|In all pancreas cysts > 15mm and/or pancreas duct dilatation > 5mm in patients who are fit for surgery EUS-guided pancreas cyst fluid aspiration is conducted. In cyst fluid CEA and lipase examination, cytology and Next Generation Sequencing is performed. After that, the pancreas cyst will be resected and histopathologically analysed.
11136485|NCT03820518|Experimental|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
11136486|NCT03820518|Experimental|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
11136487|NCT03820492|Other|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
11136488|NCT03820479||Apfel score 1|Female
11136489|NCT03820479||Apfel score 2|Female, non smoker
11136490|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
11136491|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
11136492|NCT03820466|Active Comparator|Aspirin|Aspirin 100 mg once daily and Placebo Atorvastatin once daily
11136493|NCT03820466|Active Comparator|Atorvastatin|Atorvastatin 20 mg once daily and Placebo Aspirin once daily
11136494|NCT03820466|Experimental|Aspirin-Atorvastatin|Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
11136495|NCT03820466|Placebo Comparator|Placebo|Placebo Aspirin once daily and Placebo Atorvastatin once daily
11136496|NCT03820453|Experimental|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
11136497|NCT03820453|Placebo Comparator|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
11136498|NCT03820440|Experimental|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:
~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
11136499|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
11136500|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
11136501|NCT03820414|Experimental|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
11136502|NCT03820414|Experimental|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
11136503|NCT03820414|Experimental|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
11136504|NCT03820414|Experimental|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
11136505|NCT03820414|Placebo Comparator|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
11136506|NCT03820401|Experimental|Solacea_postHDF_1/1anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro, Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136507|NCT03820401|Experimental|Solacea_postHDF_1/2anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136508|NCT03820401|Experimental|FX800_postHDF_1/1anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136509|NCT03820401|Experimental|FX800_postHDF_1/2anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~blood & dialysate sampling at 60min after dialysis start
~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136510|NCT03820401|Experimental|Solacea_HD_1/1anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro, Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: standard anticoagulation dose
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136511|NCT03820401|Experimental|Solacea_HD_1/2anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro, Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136512|NCT03820401|Experimental|FX800_HD_1/1anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136513|NCT03820401|Experimental|FX800_HD_1/2anticoagulation|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136514|NCT03820401|Experimental|FX800_HD_1/2anticoagulation_albuprime|"intervention:
~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose
~preparation of dialyzer: the dialyzer was preprimed with albumin solution
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136515|NCT03820401|Experimental|Evodial_HD_no anticoagulation|"intervention:
~choice of dialyzer: Evodial 1.3 (Baxter, USA)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: no anticoagulation is administered
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136516|NCT03820401|Experimental|Evodial_HD_no anticoagulation_albuprime|"intervention:
~choice of dialyzer: Evodial 1.3 (Baxter, USA)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: no anticoagulation is administered
~preparation of dialyzer: the dialyzer was preprimed with albumin solution
~measurement:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136517|NCT03820401|Experimental|Solacea_preHDF_1/4anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: pre dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136518|NCT03820401|Experimental|Solacea_postHDF_1/4anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136519|NCT03820401|Experimental|Solacea_HD_1/4anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose
~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136520|NCT03820401|Experimental|Solacea_preHDF_no anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: pre dilution hemodiafiltration
~choice of anticoagulation strategy: no anticoagulation is administered
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136521|NCT03820401|Experimental|Solacea_postHDF_no anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: post dilution hemodiafiltration
~choice of anticoagulation strategy: no anticoagulation is administered
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136522|NCT03820401|Experimental|Solacea_HD_no anticoagulation|"intervention:
~choice of dialyzer: Solacea dialyzer (Nipro Japan)
~choice of dialysis mode: hemodialysis
~choice of anticoagulation strategy: no anticoagulation is administered
~measurements:
~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
11136523|NCT03820388|Experimental|Propofol Group|Propofol 2 mg/kg
11136524|NCT03820388|Experimental|Etomidate Group|Etomidate 0.3 mg/kg
11136525|NCT03820388|Experimental|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
11136526|NCT03820349||Cystic Fibrosis|Subjects with cystic fibrosis
11136527|NCT03820349||controls|matched healthy controls
11136528|NCT03820336|Experimental|Extra Virgin Olive Oil|
11136529|NCT03820336|Placebo Comparator|Control Oil|
11136530|NCT03820323|No Intervention|Standard of Care|Participants in the Standard-of-Care control arm will receive laboratory based VL testing based on the existing Kenyan national guidelines. DRM testing will be done if there is a failing 2nd line ART regimen based on the current Kenyan guideline.
11136531|NCT03820323|Experimental|Intervention|POC VL and targeted DRM testing.
11136532|NCT03820310|Experimental|Experimental group|traditional therapy plus autologous Tcm cellular immunotherapy.
11136533|NCT03820310|No Intervention|control group|traditional therapy alone, such as radiotherapy or chemotherapy.
11136534|NCT03820297|Other|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
11136535|NCT03820284||Group A|Group A inflammatory bowel disease with helicobacter pylori infection
11136536|NCT03820284||Group B|Inflammatory bowel disease without helicobacter pylori infection
11136537|NCT03820271|Other|SuperMELD|
11136538|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks|Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
11136539|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
11136540|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
11136541|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
11136542|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 3 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
11136543|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to < 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
11136544|NCT03820245|Experimental|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
11136545|NCT03820245|Experimental|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
11136546|NCT03820245|Active Comparator|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
11136547|NCT03820245|Placebo Comparator|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
11136548|NCT03820232||Surgical patients|Patients who were candidates for major or urological surgery under general anaesthesia will be observed. In particular, the core body temperature will be measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
11136549|NCT03820219|Placebo Comparator|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
11136550|NCT03820219|Active Comparator|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
11136551|NCT03820206|Active Comparator|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
11136552|NCT03820206|Placebo Comparator|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
11136553|NCT03820193|Experimental|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
11136554|NCT03820193|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
11136555|NCT03820180|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11136556|NCT03820180|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
11136557|NCT03820167||Fresh sample|"Morphologically good embryos will be cultured in a culture dish and the supernatants will be collected freshly from culture system at day 3 and stored at -20 ̊ c until being tested.
~Quantification of mtDNA in fresh and frozen culture media using qPCR technique."
11136558|NCT03820167||Frozen embryos|Morphologically good embryos scheduled for freezing will be cryopreserved for less than one year and thawed, the supernatant will be collected and stored at -20 ̊ c until being tested. Quantification of mtDNA in fresh and frozen culture media using qPCR technique.
11136559|NCT03820154|Active Comparator|Skin Prick Test TAPE|"The Skin Prick Test Tape is an innovative sterile all-in drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names."
11136657|NCT03819465|Experimental|B3|Durvalumab + investigator's choice of chemotherapy + oleclumab
11136658|NCT03819465|Experimental|B4|MEDI5752
11136560|NCT03820154|Active Comparator|Skin Prick Test|The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.
11136561|NCT03820141|Experimental|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
11136562|NCT03820128|Active Comparator|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.
~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
11136563|NCT03820128|Active Comparator|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .
~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
11136564|NCT03820115|Experimental|Elastic abdominal binder|
11136565|NCT03820115|No Intervention|No binder|
11136566|NCT03820102||Vit D deficiency|Chronic HCV patients with vitamin D deficiency Sustained virological response after treatment
11136567|NCT03820102||Normal Vit D|Chronic HCV patients with normal vitamin D level Sustained virological response after treatment
11136568|NCT03820076|Experimental|dose 1|AZT-04
11136569|NCT03820076|Experimental|dose 2|AZT-04
11136570|NCT03820076|Experimental|dose 3|AZT-04
11136571|NCT03820063|Experimental|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8
~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1
~Carboplatin AUC 6mg•ml/min administered intravenously on day 1
~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)
~Treatment cycles are repeated on day 22
~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
11136572|NCT03820037|Active Comparator|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
11136573|NCT03820037|Experimental|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
11136574|NCT03820024|Experimental|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
11136575|NCT03820024|No Intervention|No Messages|No feedback messages
11136576|NCT03820011|Experimental|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 26 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
11136577|NCT03819998||PCOS group|women who have PCOS
11136578|NCT03819998||control group|women who donnot have PCOS
11136579|NCT03819985|Experimental|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
11136580|NCT03819972|Placebo Comparator|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
11136581|NCT03819972|Active Comparator|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
11136582|NCT03819972|Active Comparator|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
11136583|NCT03819972|Active Comparator|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
11136584|NCT03819959||Intensive Care Patients|Polytrauma patients who have been admitted to intensive care
11136585|NCT03819946|Experimental|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
11136586|NCT03819946|Active Comparator|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
11136587|NCT03819933|Other|Pregnant women and their partners|"For the qualitative arm of this mixed method study, using an exploratory sequential design, investigators will enroll ~ 30 adult pregnant women admitted estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners to participate in a post-counseling semi-structured interview to explore preferred language and approaches, and better inform questionnaire development. Sample size will be up to 30 families, or until thematic saturation is achieved (total up to 60 if all partners agree to participate).
~For the quantitative arm of this study, investigators will enroll ~100 adult pregnant women admitted between estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners (up to total ~200 if all partners present and agree to participate)."
11136788|NCT03818542|Experimental|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
11136588|NCT03819933|Other|Counseling MFM and Neonatology providers|Investigators will enroll ~100 counseling Maternal-Fetal Medicine (MFM) specialists and 100 counseling Neonatologists (total ~200 providers), who provided counseling to the enrolled pregnant women between 22 0/7-25 6/7 weeks' estimated gestation for anticipated extremely preterm delivery. This assumes 1 counseling provider from MFM and 1 from Neonatology per pregnant woman, although there could be more if a consult is performed by both an attending physician and a training fellow or practitioner, or less, if a counseling provider declines to participate in the study. There will be anticipated repetition of counseling providers, accounted for in the statistical analysis. Providers will be asked to complete educational interventions to improve counseling at extreme prematurity.
11136589|NCT03819920|Placebo Comparator|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
11136590|NCT03819920|Active Comparator|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
11136591|NCT03819907|No Intervention|Control|"15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).
~Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer"
11136592|NCT03819907|Active Comparator|Audiovisual (AV) Guided Relaxation|Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
11136593|NCT03819907|Experimental|Virtual Reality (VR) Guided Relaxation|"Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
~Other Names:
~• Samsung Galaxy 7s/Samsung adaptable VR headset"
11136594|NCT03819894|Experimental|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
11136595|NCT03819894|No Intervention|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
11136596|NCT03819881|Experimental|STMC-103H|"Oral administration of STMC-103H twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:
~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
11136597|NCT03819881|Placebo Comparator|Placebo|"Oral administration of placebo twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:
~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
11136598|NCT03819868|Active Comparator|High Cost|Restoration using a high-cost sealant
11136599|NCT03819868|Experimental|Low Cost|Restoration using a low-cost sealant
11136600|NCT03819842|No Intervention|Aphakic Measure only|Eye measured in aphakic state only
11136601|NCT03819842|Active Comparator|Pseudophakic measure|Eye measured in aphakic state then again in pseudophakic state with toric IOL using the ORA System. Pseudophakic measurement obtained will provide data about placement of toric iol and the surgeon will use that data to rotate the iol if necessary.
11136602|NCT03819829|Other|Blood sample|Blood sample
11136603|NCT03819816|Experimental|DEA-App|The intervention (DEA) group will receive the newly developed app.
11136604|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
11136605|NCT03819803|Experimental|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.
~Intervention: Fecal microbiota transplantation"
11136606|NCT03819790|Experimental|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
11136607|NCT03819790|Active Comparator|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
11136608|NCT03819777||Idiopathic PAH|
11136609|NCT03819777||CTD-PAH|
11136610|NCT03819777||CTD without PAH|
11136611|NCT03819764|Active Comparator|Aerobic Exercise & Repetitive Task Practice|"Participants will perform the following:
~45 minutes of cycling
~45 minutes of upper extremity repetitive arm exercises"
11136612|NCT03819764|Active Comparator|Upper Extremity Repetitive Task Practice Only|"Participants will perform the following:
~1. 90 minutes of upper extremity repetitive arm exercises"
11136613|NCT03819751|Other|MRI-targeted prostate biopsy|Participants receive both type of MRI-targeted biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.
11136614|NCT03819738|Experimental|fMRI intervention|
11136615|NCT03819725|Other|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla® ) and glucose measurements will be monitored during 2-5 days. Oral food intake will be recorded.
11136616|NCT03819712|Experimental|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
11136617|NCT03819712|Experimental|Recurrent UTI|
11136618|NCT03819699|Experimental|Cohort 1 - dose regimen 1|Cohort 1: encompasses patients enrolled prior to the PA1
11136619|NCT03819699|Experimental|Cohort 2 - dose regimen 2|Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
11136620|NCT03819699|Experimental|Cohort 2 - dose regimen 3|Cohort 2: 10 patients who will not receive a booster vaccine
11136621|NCT03819686|Experimental|Living ACTS website|In addition to the provision of standard transplant education procedures, a patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching the 20-minute video).
11136818|NCT03818269|Other|Control|
11136622|NCT03819686|Other|Standard transplant education procedures|Usual Care, which involves the provision of standard transplant education procedures at each transplant center, which entail reviewing a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two 10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
11136623|NCT03819673|Experimental|Intervention Group (IG)|Care based on the computerised decision-support tool
11136624|NCT03819673|No Intervention|Control Group (CG)|Usual care advice by primary care provider or dietitian of participating hospital
11136625|NCT03819660|Experimental|amifampridine phosphate|Oral tablets, 15 to 80 mg per day in divided doses 3 to 4 times a day for up to 18 months.
11136626|NCT03819647|Experimental|stiripentol (Diacomit)|
11136627|NCT03819634|Experimental|Lantern infusion set|Multi-slitted lantern infusion set
11136628|NCT03819621|Experimental|OCULAR PROSTHESIS MOTILITY|All participants ocular prosthesis motility will be measured using the mediGrid app, Image J software in comparison to the ruler as a gold standard.
11136629|NCT03819608|Experimental|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
11136630|NCT03819608|Active Comparator|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
11136631|NCT03819608|Active Comparator|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
11136632|NCT03819608|Active Comparator|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
11136633|NCT03819595|Experimental|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
11136634|NCT03819595|Active Comparator|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
~After 3 months, it become supervised arm"
11136635|NCT03819582|Experimental|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
11136636|NCT03819569|Active Comparator|Biopsy|Subjects receive a renal cell biopsy prior to making a decision about treatment
11136637|NCT03819569|Sham Comparator|No Biopsy|Subjects do not receive a renal cell biopsy prior to making a decision about treatment
11136638|NCT03819556|Active Comparator|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
11136639|NCT03819556|No Intervention|Control|Diet free from milk protein
11136640|NCT03819543|Experimental|Transcranial Direct Current Stimulation|
11136641|NCT03819530|Experimental|Supplementation Group|Receives baseline deworming medication. Intervention: receive daily micronutrient supplementation packets- 6 month supply, to be taken every day. Blood iron and anthropometric measurements taken at 0 and 6 months.
11136642|NCT03819530|No Intervention|Control Group|Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 6 months.
11136643|NCT03819517|Active Comparator|Resveratrol|500 mg of time released micronized trans-Resveratrol
11136644|NCT03819517|Placebo Comparator|Placebo|Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented
11136645|NCT03819504|Experimental|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
11136646|NCT03819491|Experimental|Group A|100 mg OD
11136647|NCT03819491|Experimental|Group B|100 mg BID
11136648|NCT03819478|Placebo Comparator|RecProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
11136649|NCT03819478|Active Comparator|6-mo HiProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
11136650|NCT03819478|Active Comparator|18-mo HiProt|"Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643):
~Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.
~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
11136651|NCT03819465|Experimental|A1|Durvalumab
11136652|NCT03819465|Experimental|A2|Durvalumab + danvatirsen
11136653|NCT03819465|Experimental|A3|Durvalumab + oleclumab
11136654|NCT03819465|Experimental|A4|MEDI5752
11136655|NCT03819465|Experimental|B1|Durvalumab + Investigator's choice of chemotherapy
11136659|NCT03819426|Experimental|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
11136660|NCT03819426|Experimental|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
11136661|NCT03819387|Experimental|NBF-006|
11136662|NCT03819361||Suspected OSA|
11136663|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
11136664|NCT03819335|Active Comparator|Standard care|Usual follow-up of diabetes type 1 with face-to-face visits
11136665|NCT03819335|Experimental|mySugr app|Telemedical assistance with mySugr app
11136666|NCT03819322|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.
~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
11136667|NCT03819322|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
11136668|NCT03819309|Experimental|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
11136669|NCT03819309|Active Comparator|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
11136670|NCT03819296|Experimental|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.
~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.
~PROJECT 3: Patients undergo FMT."
11136671|NCT03819283|Other|Hepatic evaluation|
11136672|NCT03819270|Experimental|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
11136673|NCT03819270|Placebo Comparator|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
11136674|NCT03819257||Patients with perianal Crohn's disease.|
11136675|NCT03819244|Experimental|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
11136676|NCT03819244|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
11136677|NCT03819231|Experimental|Mindfulness and intranasal oxytocin|Given oxytocin through intranasal administration and self-directed mindfulness training.
11136678|NCT03819231|Active Comparator|Mindfulness and placebo|Given sterile saline through intranasal adminstration and self-directed mindfulness training.
11136679|NCT03819231|Sham Comparator|Sham mindfulness and placebo|Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.
11136680|NCT03819218|Experimental|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
11136681|NCT03819205|Experimental|kinesiotaping group(before/after)|"Hemiplegic CP:Kinesiotaping on the affected side
~Diplegic, tetraplegic CP: side of upper extremity which children have been used to but have obstacles in daily life
~intervention Duration: For 1 week at least 2-3 hours a day, renewing if it's necessary.
~Note:Patients will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day.
~Evaluation: In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion"
11136682|NCT03819192||neonates with signs of EONS|
11136683|NCT03819192||neonates without signs of EONS|
11136684|NCT03819192||pregnant women with PPROM|
11136685|NCT03819179|Experimental|Serum|Burt's Bees Serum
11136686|NCT03819179|Experimental|Serum with Biulin|Burt's Bees Serum with Biulin
11136687|NCT03819179|Experimental|Serum with Berenew Complex|Burt's Bees Serum with Berenew Complex
11136688|NCT03819179|Experimental|Serum with Ecoskin|Burt's Bees Serum with Ecoskin
11136689|NCT03819179|Experimental|Serum with Bonicell|Burt's Bees Serum with Bonicell
11136690|NCT03819166|Experimental|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
11136691|NCT03819166|Sham Comparator|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
11136692|NCT03819153|Experimental|Semaglutide|Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
11136693|NCT03819153|Placebo Comparator|Placebo|Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
11136728|NCT03818971|Other|alcohol consumption without alcohol use disorder|subjects with regular alcohol consumption without AUD according to the DSM 5 without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
11136694|NCT03819140|Active Comparator|Continuous OCP Therapy|Participants randomly assigned to this arm will receive 8 packs of a 21 day oral contraceptive pills (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which comes in a formulation of 21 days of active hormone and 7 days of sugar pills. In this arm, participants will only be expected to take active hormone pills (colored pills) for the 6 months straight without stopping or taking the sugar pills in each pack.
11136695|NCT03819140|Active Comparator|Cyclical OCP Therapy|Participants randomly assigned to this arm will receive 6 packs of a 21 day oral contraceptive pill (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which has 21 days of active hormone and 7 days of sugar pills. Participants will take one pill daily for 6 months and be expected to take the sugar pills at the end of each monthly pack prior to starting a new pack.
11136696|NCT03819127|Active Comparator|Metformin|metformin 1 g twice a day for 24 weeks
11136697|NCT03819127|Experimental|Metformin plus vildagliptin|metformin 1 g plus vildagliptin 50 mg twice a day for 24 weeks
11136698|NCT03819114|Experimental|A: LNG EC 1.5 mg among women on EFV-based ART (randomized)|Participants will receive one 1.5 mg tablet of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
11136699|NCT03819114|Experimental|B: LNG EC 3.0 mg among women on EFV-based ART (randomized)|Participants will receive two 1.5 mg tablets (3 mg) of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
11136700|NCT03819114|Experimental|C: LNG EC 1.5 mg among women on DTG-based ART (assigned)|Participants will receive one 1.5 mg tablet of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
11136701|NCT03819114|Experimental|D: LNG EC 3.0 mg among women on RIF-INH TB Therapy (assigned)|Participants will receive two 1.5 mg tablets (3 mg) of LNG EC on Day 0 and will be followed post-treatment for 4 weeks.
11136702|NCT03819101|No Intervention|Arm A|Standard of Care (SOC) for CRPC
11136703|NCT03819101|Experimental|Arm B|SOC + acetylsalicylic acid 100 mg daily
11136704|NCT03819101|Experimental|Arm C|SOC + atorvastatin 80 mg daily
11136705|NCT03819101|Experimental|Arm D|SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8
11136706|NCT03819088|Experimental|Group I (zinc months 1 and 2)|Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
11136707|NCT03819088|Experimental|Group II (zinc months 3 and 4)|Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
11136708|NCT03819075|Experimental|Laser|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units.
11136709|NCT03819075|Active Comparator|Control|Standard periimplantitis treatment will be conducted in the control group.
11136710|NCT03819062|Experimental|Refractory Constipation with LLLT|Low level laser therapy (LLLT) will be administered to patients with severe refractory chronic constipation
11136711|NCT03819049|Experimental|Cohort 1: ExPEC10V (Low Dose)|Participants will be randomized to receive a single intramuscular (IM) injection of low dose ExPEC10V on Day 1.
11136712|NCT03819049|Experimental|Cohort 1: ExPEC10V (Medium dose)|Participants will be randomized to receive a single IM injection of medium dose ExPEC10V on Day 1.
11136713|NCT03819049|Experimental|Cohort 1: ExPEC10V (High dose)|Participants will be randomized to receive a single IM injection of high dose ExPEC10V on Day 1.
11136714|NCT03819049|Experimental|Cohort 1: ExPEC4V|Participants will be randomized to receive a single IM injection of ExPEC4V on Day 1.
11136715|NCT03819049|Experimental|Cohort 1: Prevnar 13|Participants will be randomized to receive a single IM injection of Prevnar 13 on Day 1.
11136716|NCT03819049|Experimental|Cohort 2: ExPEC10V|Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
11136717|NCT03819049|Placebo Comparator|Cohort 2: Placebo|Participants will be randomized to receive a single IM injection of matching placebo on Day 1.
11136718|NCT03819036|Experimental|Patients|Questionnaires for patients requiring dental emergencies care
11136719|NCT03819023|No Intervention|Normal subjects|
11136720|NCT03819023|Active Comparator|respiratory suppressing drugs|
11136721|NCT03819010|Active Comparator|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
11136722|NCT03819010|Active Comparator|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
11136723|NCT03818997|Experimental|BTC Cohort|Patient in BTC cohort will receive immune therapy and DKN-01 IV until PD
11136724|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab + paclitaxel (Arm 1)|Patient randomized in the EGC Arm 1 will receive immune therapy, DKN-01 and chemotherapy intravenously (IV) until PD.
11136725|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab without paclitaxel (Arm 2)|Patient randomized in the EGC Arm 2 will receive immune therapy and DKN-01 IV until PD
11136726|NCT03818984|Experimental|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
11136727|NCT03818971|Experimental|alcohol consumption with alcohol use disorder (AUD)|subjects with regular alcohol consumption with AUD according to the DSM 5 without any other substance use disorder (except alcohol) without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
11136758|NCT03818789|Placebo Comparator|Control|A study skills video is shown intended to have no effect on exercise but to match for time.
11136729|NCT03818971|Other|no alcohol consumption|subjects without alcohol consumption without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
11136730|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
11136731|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
11136732|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
11136733|NCT03818958||fibromyalgia|subjects with fibromyalgia
11136734|NCT03818945|Other|Sodium Fluoride Varnish|
11136735|NCT03818945|Active Comparator|PRG barrier Giomer|
11136736|NCT03818932|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
11136737|NCT03818932|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
11136738|NCT03818919|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
11136739|NCT03818919|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
11136740|NCT03818906|Active Comparator|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
11136741|NCT03818906|Experimental|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
11136742|NCT03818906|Experimental|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
11136743|NCT03818906|Experimental|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
11136744|NCT03818893|Experimental|New Combination Immunotherapy|"Patients will receive Pembrolizumab once every 3 weeks and a maximum of 35 doses over 105 weeks .
~The patients should be inpatient during treatment with GEN0101 in each treatment cycle and may be outpatient during off-treatment period with GEN0101, observation period, follow-up period with Pembrolizumab.
~GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously (including skin tumor site). Nonetheless, it will not be deemed as deviation if an injection has been given subcutaneously unintentionally, e.g., leakage around the peri-injection sites.
~A dose will be 60,000 mNAU in total, and 1 mL per injection site should be administered to 6 injection sites in total. For a patient, the total dose in a treatment cycle will be 360,000 mNAU (360 NAU), and the total dose over 2 treatment cycles will be 720,000 mNAU (720 NAU)."
11136745|NCT03818880|Experimental|Treatment|Subjects wearing novel spectacle lenses will be assessed
11136746|NCT03818867|Experimental|Cerclage arm|Pregnancies which had cervical cerclage inserted.
11136747|NCT03818867|No Intervention|No-cerclage arm|Pregnancies which did not have cervical cerclage inserted.
11136748|NCT03818854|Experimental|Human Mesenchymal Stromal Cells|A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.
11136749|NCT03818854|Experimental|Cell Reconstitution Media|A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes.
11136750|NCT03818841|Experimental|High-flow nasal cannula group|Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
11136751|NCT03818841|Other|Non-rebreathing oxygen mask group|In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
11136752|NCT03818828|Experimental|TTAX01|TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
11136753|NCT03818815|Active Comparator|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
11136754|NCT03818815|Placebo Comparator|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
11136755|NCT03818802|Active Comparator|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
11136756|NCT03818802|Placebo Comparator|Placebo|Correspondent placebo, a pill not containing the active component.
11136757|NCT03818789|Experimental|Mindfulness|A mindfulness training is applied to see if it supports exercise endurance in-lab and during follow-up
11136759|NCT03818776|Experimental|Arm 1 - 60 CGyE in 20 fractions|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.
~Radiation will follow dose escalation scheme:
~60 CGyE in 20 fractions (3+3 participants, 3-6 total)"
11136760|NCT03818776|Experimental|Arm 2 - 69 CGyE in 23 fractions followed by expansion cohort a|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.
~Radiation will follow dose escalation scheme:
~69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)"
11136761|NCT03818763|Experimental|Autologous CD34+PBSC transduced with a lentiviral vector|Patients will receive a patient specific (autologous) cytokine mobilized CD34+Peripheral Blood Stem Cells (PBSC) transduced ex vivo with a lentiviral vector containing cDNA encoding the human B-domain deleted FVIII protein.
11136762|NCT03818750|Experimental|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :
~light drinkers (score between 1 to 3)
~heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
11136763|NCT03818737|Experimental|Autologous BMAC versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either bone marrow derived mesenchymal stem cells (MSCs) or corticosteroid (CS) injection (30:10). All subjects randomized to this arm will undergo bone marrow aspiration, but will only receive one of the injections. At each site, 30 subjects in this arm will receive a standard Orthobiologic injection of Bone Marrow Concentrate (BMAC) and 10 will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
11136764|NCT03818737|Experimental|Adipose-derived SVF versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either an injection of Adipose-derived Stromal Vascular Fraction (SVF) or corticosteroid (CS) (30:10). All subjects randomized to this arm will undergo small volume lipoplasty, but will only receive one of the injections. At each site, 30 subjects in this arm will receive the Adipose-derived Stromal Vascular Fraction (SVF) and 10 subjects will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
11136765|NCT03818737|Experimental|Umbilical Cord Tissue (UCT) versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either an injection of cryopreserved doses of cord tissue MSCs or corticosteroid (30:10) injected into the knee. At each site, 30 subjects in this arm will receive the umbilical cord tissue MSCs and 10 subjects will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
11136766|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
11136767|NCT03818711|Experimental|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
11136768|NCT03818711|Active Comparator|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
11136769|NCT03818685|Experimental|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
11136770|NCT03818685|Active Comparator|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
11136771|NCT03818672|Experimental|Rifaximin|Rifaximin 550 mg BID
11136772|NCT03818659|Active Comparator|Self-Guided|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
11136773|NCT03818659|Experimental|Full Support|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
11136774|NCT03818659|No Intervention|Usual Care|"The investigators will also conduct non-randomized comparisons of BP control in the Full Support and Self-Guided intervention arms to BP control in non-participating Usual Care institutions in PCORnet."
11136775|NCT03818633|Experimental|Elastic abdominal binder|
11136776|NCT03818633|No Intervention|No binder|
11136777|NCT03818607|Other|T (ABP 959) / R (eculizumab)|ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
11136778|NCT03818607|Other|R (eculizumab) / T (ABP 959)|Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2
11136779|NCT03818581|Active Comparator|Treatment Group|
11136780|NCT03818581|Placebo Comparator|Placebo Responders|
11136781|NCT03818581|Active Comparator|Placebo Non-responders Re-randomized to Treatment|
11136782|NCT03818581|Placebo Comparator|Placebo Non-responders Re-randomized to Placebo|
11136783|NCT03818568|Experimental|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
11136784|NCT03818568|Active Comparator|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
11136785|NCT03818555|Other|Sebacia Microparticles Treatment|
11136786|NCT03818542|Experimental|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
11136787|NCT03818542|Experimental|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
11136789|NCT03818542|Experimental|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
11136790|NCT03818516|Experimental|Treatment Arm (Infliximab Arm)|Participants in this arm will receive one time intravenous infusion of infliximab (5 mg/kg body weight) over a 2 to 2½ hour period while participants rest in an infusion chair.
11136791|NCT03818516|Placebo Comparator|Placebo Arm (Saline Arm)|Participants in this arm will receive one time intravenous infusion of Saline (0.9% Sodium Chloride) over a 2 to 2½ hour period while participants rest in an infusion chair.
11136792|NCT03818503||OligoCare|Patients with oligometastatic disease treated with radical radiotherapy
11136793|NCT03818503||ParticleCare|Patients with cancer treated with particle therapy
11136794|NCT03818490|Experimental|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
11136795|NCT03818490|No Intervention|Control|Patients in this group did not experience an intervention.
11136796|NCT03818451|No Intervention|Control Group|"All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:
~Surgical evacuation of hemorrhagic masses and brain contusion
~Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures
~Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage"
11136797|NCT03818451|Experimental|Study Group|Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
11136798|NCT03818438||Case subjects adult patients with chronic ankle instability|"Male or female subjects aged 18-45, presenting :
~at least one acute lateral ankle sprain (i.e. initial ankle sprain more than 12 months before inclusion),
~at least one residual symptom (giving way OR sensation of instability OR recurrent ankle sprain), confirmed by a score < 24 on the Chronic Ankle Instability Tool (CAIT)
~Impact on activities of daily living and sport, score < 90% on Foot and Ankle Ability Measure (FAAM) and < 80% on FAAM-sport Case subjects are free of any other lower extremity pathologies or pain Subjects presenting bilateral chronic ankle instability are excluded"
11136799|NCT03818438||Healthy subjects|Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
11136800|NCT03818425||Clinical Population|In- and Out-Patients diagnosed with depression (F32, F33), anxiety disorder (F40, F41; ICD-10) or posttraumatic stress disorder (F43.1; ICD-10)
11136801|NCT03818425||Healthy Controls|Subjects with no previous or actual mental disorder
11136802|NCT03818412|Experimental|Soft Tissue Sarcoma|"A sample of archival tumor tissue will be collected.
~Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken:
~Prior to planned radiation treatment
~2-4 weeks after cancer surgery
~Every 12 weeks after surgery for up to 2 years"
11136803|NCT03818399|Experimental|overdose patients|subjects that receive acute administration of SUBOXONE sublingual film in the ED followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, and receive monthly SUBLOCADE injections for 6 months in the context of outpatient treatment.
11136804|NCT03818386|Experimental|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT
~Other Names:
~Gadolinium-chelated polysiloxane based nanoparticles
~3 intravenous injections at 100mg/kg
~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)
~Fr1: AGuIX® injection before the first radiation session
~Fr6: AGuIX® injection before the sixth radiation session
~30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
11136805|NCT03818386|Active Comparator|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
11136806|NCT03818373|Other|Patients with univentricular congenital heart disease|Patients 8 years old or more with functionally univentricular congenital heart disease
11136807|NCT03818360|Experimental|Smokers attending A&E|Receive an evidence-based smoking cessation intervention comprising brief advice plus active referrals for smokers attending emergency departments in Hong Kong.
11136808|NCT03818347|Experimental|oxyhydrogen generator (AMS-H-03)|Model: AMS-H-03 Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively In this group, the patients will inhale hydrogen and oxygen with oxyhydrogen generator. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11136809|NCT03818347|Placebo Comparator|Control|In this group, the patients will inhale normal air with analogue machine. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11136810|NCT03818334|Experimental|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
11136811|NCT03818334|Active Comparator|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
11136812|NCT03818321|Experimental|Methenamine Hippurate with Cranberry|Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
11136813|NCT03818321|Placebo Comparator|Placebo with Cranberry|"Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016."
11136814|NCT03818308|Experimental|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
11136815|NCT03818295|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-praliciguat
11136816|NCT03818282|Experimental|Paclitaxel for injection (albumin-bound)|
11136817|NCT03818269|Other|Septic shock|
11136819|NCT03818256|Experimental|CORT118335- 600 mg|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
11136820|NCT03818256|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
11136821|NCT03818243|Experimental|RLS-|patients with Parkinson disease without RLS
11136822|NCT03818243|Experimental|RLS+|patients with Parkinson disease with RLS
11136823|NCT03818217|Experimental|Coach Pepper group|Pepper is a humanoid socially assistive robot.
11136824|NCT03818217|Other|Tablet group|Tablet training
11136825|NCT03818204|Experimental|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl & NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.
~-Intervention - Magnetic Levator Prosthesis (MLP)"
11136826|NCT03818204|Other|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.
~-Intervention - Magnetic Levator Prosthesis (MLP)"
11136827|NCT03818191|Active Comparator|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
11136828|NCT03818191|Placebo Comparator|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
11136829|NCT03818178|Experimental|Intralipid|
11136830|NCT03818178|Experimental|Palm Oil|
11136831|NCT03818178|Placebo Comparator|Saline|
11136832|NCT03818165|Experimental|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
11136833|NCT03818152|Other|study group|Reliability study isokinetic strength assessment of the lower limbs.
11136834|NCT03818126|Experimental|del Nido cardioplegia|
11136835|NCT03818126|Active Comparator|cold blood cardioplegia|
11136836|NCT03818113||HTK-Bretschneider cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with HTK-Bretschneider cardioplegic solution
11136837|NCT03818113||St. Thomas cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with St. Thomas cardioplegic solution
11136838|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
11136839|NCT03818074|Experimental|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
11136840|NCT03818061|Experimental|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
11136841|NCT03818061|Experimental|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
11136842|NCT03818048|Experimental|Group Propofol|propofol infusion
11136843|NCT03818048|Experimental|Group Sevoflurane|inhalation with sevoflurane
11136844|NCT03818035|Experimental|Part 1: Guselkumab|Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
11136845|NCT03818035|Experimental|Part 2: Guselkumab q8w and Guselkumab q16w|Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder [SRe]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score >5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
11136846|NCT03818035|Experimental|Part 2: Guselkumab q8w|Participants (Non SRe) in group 2c with a PASI score greater than (>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
11136847|NCT03818035|Experimental|Part 3: Guselkumab Withdrawal|Participants from groups 2a and 2b with a PASI score <3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 116 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to [>=] 3) at week 68 or PASI >5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
11136848|NCT03818022|Experimental|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
11136849|NCT03818022|No Intervention|Control|
11136850|NCT03818009||women undergoing elective CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
11136851|NCT03818009||women undergoing emergency CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
11136852|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.
~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure <90 mm Hg or the need for norepinephrine), oliguria (urine output <0.5 mL/kg/hr), and cool, mottled extremities.
~Their CO increases >15% after passive leg raising."
11136853|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase >15% after passive leg raising maneuver.
11136854|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
11137148|NCT03816059||Hospitalized - chronic lung disease|Hospitalized patients with exacerbation of chronic lung disease
11136855|NCT03817970|Experimental|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
11136856|NCT03817970|Experimental|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
11136857|NCT03817970|Experimental|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
11136858|NCT03817957|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
11136859|NCT03817957|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
11136860|NCT03817957|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
11136861|NCT03817931|Placebo Comparator|Placebo|Placebo pill identical will be identical to tablets in the other 2 arms.
11136862|NCT03817931|Active Comparator|Anticholinergic|Solifenacin 5 mg tablet orally once daily for 30 days
11136863|NCT03817931|Active Comparator|Beta-3 agonists, adrenergic|Mirabegron 25 mg tablet orally once daily for 30 days
11136864|NCT03817918|Experimental|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
11136865|NCT03817905|Experimental|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
11136866|NCT03817892|No Intervention|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).
~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
11136867|NCT03817892|Experimental|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).
~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
11136868|NCT03817892|Experimental|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
11136869|NCT03817892|Experimental|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
11136870|NCT03817879|Experimental|VivaSight double-lumen tube|
11136871|NCT03817879|Active Comparator|Conventional double-lumen tube|
11136872|NCT03817866||BRAHMS CgA II KRYPTOR|Adult patients with well defined grade 1 and grade 2 GEP-NETs. Serial serum samples from all patients will be analyzed using the BRAHMS CgA II KRYPTOR Assay.
11136873|NCT03817853|Experimental|Obinutuzumab+Chemotherapy|Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone [CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone [CVP - 21-day cycle]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.
11136874|NCT03817827|Experimental|Acupuncture|this group will receive Acupuncture therapy for 30 minutes three times per week
11136875|NCT03817827|Experimental|diet modification|this group will receive diet using soy products a
11136876|NCT03817827|Experimental|combined group|will receive both acupuncture therapy and soy products
11136877|NCT03817814||Women with Breast Cancer|This is a cross-sectional survey of young women with breast cancer (YWBC) who received a consultation with an MSK Fertility Nurse Specialist before starting cancer treatment.
11136878|NCT03817801|Experimental|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
11136879|NCT03817801|Active Comparator|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
11136880|NCT03817788|Active Comparator|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
11136881|NCT03817788|Experimental|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
11136882|NCT03817775|No Intervention|Control|The control group will undergo coronary angiography without music intervention.
11136883|NCT03817775|Experimental|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
11136884|NCT03817749|Experimental|Experimental|"Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.
~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.
~All meals will be provided throughout the supplementation period
~Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period."
11136885|NCT03817749|Placebo Comparator|Placebo|Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm
11136997|NCT03817021|Experimental|NAP SACC on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned off
11137149|NCT03816059||Outpatient|Outpatients
11136886|NCT03817736|Experimental|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.
~Procedure of TACE will be standardized.
~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
11136887|NCT03817723||Specialist surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy. C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
11136888|NCT03817723||Resident surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy.C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
11136889|NCT03817697||Drug users|The cohort will be constituted of adult patients drug users, substituted/weaned or not, consulting at the Croix-Rousse CSAPA
11136890|NCT03817684|Experimental|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
11136891|NCT03817684|Experimental|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
11136892|NCT03817684|Placebo Comparator|Placebo|
11136893|NCT03817671|Other|Control arm (5% O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 5% O2, and 89.3% N2 till embryo transfer
11136894|NCT03817671|Experimental|Experimental arm (2%O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 2% O2, and 92.3% N2 till embryo transfer
11136895|NCT03817658|Experimental|SHR-1210|SHR-1210
11136896|NCT03817658|Placebo Comparator|placebo|placebo
11136897|NCT03817645|Experimental|Panaceo MED|Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.
11136898|NCT03817645|Placebo Comparator|Control|Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.
11136899|NCT03817632||A Standard|Computer assisted primary total knee replacement with OrthoPilot FS 101 navigation system and Software 5.1
11136900|NCT03817632||B Elite|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0
11136901|NCT03817619|Active Comparator|Treatment R (reference)|Single-dose ELB/GZR as a whole tablet in a fasted state.
11136902|NCT03817619|Experimental|Treatment T (test)|Single-dose crushed ELB/GZR in a fasted state.
11136903|NCT03817606|Experimental|Tritanium Posterior Lumbar Cage|Surgical placement of the Tritanium Posterior Lumbar Cage
11136904|NCT03817606|Active Comparator|AVS PEEK UniLIF|Surgical placement of the AVS PEEK UniLIF Posterior Lumbar Cage
11136905|NCT03817593||Transcendental Meditation (TM)|"Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
~To ensure the quality of practice, a group follow-up will be performed 10 days after a completion of the course, and then each participant will receive personal meetings with TM instructor on a weekly basis during the first month, and twice a month for the second and third months.
~After additional 3 months participants in this group will be examined again, to assess sustainability of the effect"
11136906|NCT03817593||controls|Control group - Treatment as usual (TAU)
11136907|NCT03817580|Experimental|Project X 26ml|3.15 % w/v CHG / 70% v/v IPA contained within a saturated at use swabstick. 26ml volume. Single use.
11136908|NCT03817580|Experimental|Project X 5.1ml|3.15 % w/v CHG / 70% v/v IPA contained within a saturated at use swabstick. 5.1ml volume. Single use.
11136909|NCT03817580|Active Comparator|Prevantics Maxi Swabstick|3.15 % w/v CHG / 70% v/v IPA. Swabstick. 5.1ml volume. Single use.
11136910|NCT03817567|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W
11136911|NCT03817554|Experimental|Treatment group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
11136912|NCT03817554|Placebo Comparator|Control group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.
11136913|NCT03817541|Experimental|Bariatric surgery|Patients due for bariatric surgery, BMI > 30
11136914|NCT03817541|Experimental|Cholecystectomy|Normal weight patients due for cholecystectomies
11136915|NCT03817528|Experimental|ITI-007|Open-Label ITI-007 40-60 mg
11136916|NCT03817502|Experimental|Cariprazine 1.5 mg/d|Cariprazine capsules, oral administration, once daily.
11136917|NCT03817502|Experimental|Cariprazine 4.5 mg/d|Cariprazine capsules, oral administration, once daily.
11136918|NCT03817502|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
11136919|NCT03817489|Experimental|Intervention: Baduanjin qigong|This arm of participants will be receiving the Baduajin qigong intervention.
11136920|NCT03817489|Experimental|Intervention: Mindfulness meditation|This arm of participants will be receiving the Mindfulness meditation intervention.
11136921|NCT03817489|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a Wait-list Control group.
11136922|NCT03817476|Experimental|T1-T2-R|
11136923|NCT03817476|Experimental|T1-R-T2|
11136924|NCT03817476|Experimental|T2-T1-R|
11136925|NCT03817476|Experimental|T2-R-T1|
11136926|NCT03817476|Experimental|R-T1-T2|
11136927|NCT03817476|Experimental|R-T2-T1|
11136928|NCT03817463||Patients with T2DM|
11136998|NCT03816995|Active Comparator|Alexis O Wound Protector|Participants will undergo standard surgical procedure using the Alexis O wound protector.
11136929|NCT03817450|Experimental|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
11136930|NCT03817450|No Intervention|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
11136931|NCT03817424|Experimental|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
11136932|NCT03817424|Experimental|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
11136933|NCT03817424|Experimental|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
11136934|NCT03817424|Placebo Comparator|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
11136935|NCT03817411|Active Comparator|Telatinib+Capecitabine+Oxaliplatin|Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
11136936|NCT03817411|Placebo Comparator|Placebos+Capecitabine+Oxaliplatin|Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
11136937|NCT03817398|Experimental|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
11136938|NCT03817385|Experimental|repetitive TMS (Transcranial Magnetic Stimulation)|rTMS and physical / occupational therapy
11136939|NCT03817385|Experimental|robotic GT (Gait Training)|robotic gait training for 20 times and physical / occupational therapy
11136940|NCT03817385|No Intervention|traditional rehabilitation|patient only received traditional rehabilitation program
11136941|NCT03817372|Active Comparator|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
11136942|NCT03817372|Active Comparator|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
11136943|NCT03817359|Experimental|Mix infusion using single TCI pump|participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump infusion
11136944|NCT03817359|No Intervention|Separate infusion using two TCI pumps|participants receive total intravenous anesthesia with remifentanil and propofol separately by two TCI pumps infusion
11136945|NCT03817346|Active Comparator|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
11136946|NCT03817346|Placebo Comparator|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
11136947|NCT03817333||ACOS smoking history >20 pack-years|Subjects with asthma-COPD overlap syndrome
11136948|NCT03817333||IRAO smoking history <5 pack-years|Subjects with an incomplete reversibility of airway obstruction
11136949|NCT03817320|Other|Open label design|Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin
11136950|NCT03817307|Experimental|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2* weighted MRI scan (prior to surgery).
11136951|NCT03817294|Active Comparator|Eccentric cycling|
11136952|NCT03817294|Active Comparator|Concentric cycling|
11136953|NCT03817294|Active Comparator|Single leg cycling|
11136954|NCT03817294|Active Comparator|Lower limb resistance training|
11136955|NCT03817281||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
11136956|NCT03817268|Experimental|Capecitabine monotherapy group|
11136957|NCT03817268|No Intervention|Control group|
11136958|NCT03817255|Experimental|Substance use|In this screening intervention, participants complete a substance use questionnaire (=intervention).
11136959|NCT03817255|Active Comparator|Physical activity|In this screening control condition, participants complete a physical activity questionnaire (=control).
11136960|NCT03817242|Active Comparator|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
11136961|NCT03817242|Active Comparator|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
11136962|NCT03817229|Active Comparator|Control Group|mHealth education module and automated digital reminders
11136999|NCT03816995|Experimental|CleanCision Wound Protector|Participants will undergo standard surgical procedure using the CleanCision Wound Retraction and Protection System
11137000|NCT03816982|Active Comparator|Bupivacaine HCl/Bupivacaine CISB|23 patients will be enrolled to receive a single-injection bupivacaine HCL interscalene block with bupivacaine CISB added.
11137696|NCT03812367||Group 4|The chronic zoledronic acid (≥2 years with at least 2 annual injections)
11136963|NCT03817229|Experimental|Treatment Group|mHealth education module, automated digital reminders, and individualized adherence feedback (stage 1 SMART). After three months of intervention, the treatment group will be evaluated for responsiveness (> 95%) based on the 30-day adherence outcome (stage 2 SMART). If participants in the treatment group demonstrate adherence > 95%, they will continue with the treatment arm of receiving automated digital reminders and individualized adherence feedback. If they are deemed to be non-responsive (adherence < 95%), they will be re-randomized to either: 1) continued automated digital reminders and individualized adherence feedback or 2) a mHealth problem solving module with three therapist-guided problem-solving sessions.
11136964|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
11136965|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
11136966|NCT03817216|Active Comparator|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
11136967|NCT03817203|Experimental|Kinesio tape group|Kinesio tape application and pelvic floor exercise have been applied
11136968|NCT03817203|Sham Comparator|Control group|Sham kinesio tape application and pelvic floor exercise have been applied
11136969|NCT03817190|Experimental|2g Oral DS107|2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
11136970|NCT03817190|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 16 weeks
11136971|NCT03817177|Placebo Comparator|nasal prong|conventional nasal prong application after the surgery in postanesthetic care unit (PACU)
11136972|NCT03817177|Experimental|high flow nasal cannula oxygenation|high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)
11136973|NCT03817164|Active Comparator|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
11136974|NCT03817164|Sham Comparator|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
11136975|NCT03817125|Placebo Comparator|SER-401 Matching Placebo/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.
11136976|NCT03817125|Experimental|SER-401/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.
11136977|NCT03817112|Active Comparator|Dexmedetomidine|Infusion of dexmedetomidine
11136978|NCT03817112|Active Comparator|Propofol|Propofol infusion
11136979|NCT03817099|Experimental|My Dia-RNP|In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
11136980|NCT03817099|Active Comparator|Usual Care|Participant in this group will continue in a usual care (UC) group. They will receive dietary advice based on the Practical Guide to Diabetes Management in Ramadan produced by Ministry of Health (2015).
11136981|NCT03817086|Experimental|Hand coordination and mental practice|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to mentally imagine doing the task with an action observation of perfect performance.
11136982|NCT03817086|Active Comparator|Hand coordination and action observation|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to observe a visual feedback of performance.
11136983|NCT03817073|Experimental|Iowa Oral Performance Instrument (IOPI)|All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).
11136984|NCT03817060|Active Comparator|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
11136985|NCT03817060|Active Comparator|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
11136986|NCT03817047|Experimental|Physical active learning (PAL)|"Three components:
~Physical education (60 minutes)
~Physical active learning (30 minutes)
~Physical activity (30 minutes)"
11136987|NCT03817047|Experimental|Don't worry - be happy|"Two components:
~Physical education (60 minutes) - don't worry class
~Physical activity (60 minutes) - be happy class"
11136988|NCT03817047|No Intervention|Control group|Current practice
11136989|NCT03817034|Experimental|Multimodal Analgesia|
11136990|NCT03817021|Experimental|All Factors On|Nutrition and Physical Activity Self-Assessment of Childcare (Core NAP SACC) will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned on
11136991|NCT03817021|Experimental|NAP SACC on/ECE on/Parent RF on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned off
11136992|NCT03817021|Experimental|NAP SACC on/ECE on/Child Regulation on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned on
11136993|NCT03817021|Experimental|NAP SACC on/ECE on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned off
11136994|NCT03817021|Experimental|NAP SACCon/Parent RF on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned on
11136995|NCT03817021|Experimental|NAP SACC on/Parent RF on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned off
11136996|NCT03817021|Experimental|NAP SACC on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned on
11137767|NCT03811912|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
11137001|NCT03816982|Experimental|Liposomal Bupivacaine Added to Interscalene Block|23 patients will be enrolled to receive a single-injection bupivacaine HCl interscalene block with liposomal bupivacaine added to same injection.
11137002|NCT03816969|Active Comparator|Self-pressurized air-Q with blocker|Self-pressurized air-Q with blocker has a greater seal pressure compared to Air-Q blocker, easier and faster in insertion and has less morbidity and complications while and after insertion
11137003|NCT03816969|Active Comparator|Air-Q ILA blocker|It has a drain tube through which a suction tube is passed
11137004|NCT03816956|Experimental|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
11137005|NCT03816956|Placebo Comparator|Placebo treatment|Control group: Placebo administered intravenously the day of enrolment.
11137006|NCT03816943|No Intervention|Control|control group with no intervention
11137007|NCT03816943|Experimental|Whatsapp|intervention group receiving a Whatsapp instant text message with encouraging words after bond up of fixed appliances
11137008|NCT03816943|Experimental|Call|intervention group receiving a phone cal with encouraging words after bond up of fixed appliances
11137009|NCT03816930|Active Comparator|Mechanical cord usage|Mechanical retraction
11137010|NCT03816930|Active Comparator|Chemical contained retraction usage|Chemical retraction
11137011|NCT03816930|Active Comparator|MZ-6 laser tip used throughing|Laser retraction
11137012|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
11137013|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
11137014|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
11137015|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
11137016|NCT03816891|Experimental|KPL-716|Weekly for 8 weeks
11137017|NCT03816891|Placebo Comparator|Placebo|Weekly for 8 weeks
11137018|NCT03816878|Experimental|Cohort 1: pLAIV Recipients|Participants who have received the pandemic live attenuated influenza vaccines (pLAIVs) H2N2, H6N1, or H9N2 during a previous CIR study will receive a single dose of 0.5 mL H5N1 pISV vaccine at Day 0.
11137019|NCT03816878|Experimental|Cohort 2: pLAIV Naive|Participants who have never previously received a pLAIV will receive one dose of 0.5 mL H5N1 pISV vaccine at Day 0.
11137020|NCT03816852|Experimental|High dose group|Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml
11137021|NCT03816852|Experimental|Medium dose group|Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml
11137022|NCT03816852|Experimental|Low dose group|Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml
11137023|NCT03816839|Experimental|SAR439859|administered orally once daily or twice daily as monotherapy in fasted or fed state
11137024|NCT03816826|Experimental|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
11137025|NCT03816826|Experimental|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
11137026|NCT03816826|Experimental|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
11137027|NCT03816800|Placebo Comparator|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
11137028|NCT03816800|Active Comparator|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
11137029|NCT03816800|Active Comparator|Active Non-Allergic|Over the course of 6 months non-allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
11137030|NCT03816787|Experimental|dry cupping for patients of low back pain|Patients will receive four consecutive dry cupping therapy application in one month.
11137031|NCT03816787|Active Comparator|dry cupping for health people|Health people will receive four consecutive dry cupping therapy application in one month.
11137032|NCT03816774|No Intervention|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
11137033|NCT03816774|Active Comparator|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
11137034|NCT03816761|Experimental|Fast-acting insulin aspart, default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
11137035|NCT03816761|Experimental|Fast-acting insulin aspart, non-default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
11137036|NCT03816748|Experimental|intervention|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept HFNC treatment
11137037|NCT03816748|No Intervention|control|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept usual care
11137038|NCT03816735|Active Comparator|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
11137076|NCT03816540|Active Comparator|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
11137077|NCT03816527||AUD patients|Individuals with alcohol use disorder
11137039|NCT03816735|Active Comparator|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
11137040|NCT03816722|Experimental|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
11137041|NCT03816722|Experimental|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
11137042|NCT03816709|Other|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
11137043|NCT03816696|Experimental|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
11137044|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 3 months and treatment is ongoing at the time of enrollment.
11137045|NCT03816670|Experimental|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
11137046|NCT03816670|Experimental|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
11137047|NCT03816670|Experimental|normal responders day 2|"normal responders women stimulated with CF from day 2"
11137048|NCT03816670|Experimental|normal responders day 4|"normal responders women stimulated with CF from day 4"
11137049|NCT03816670|Experimental|high responders day 2|"high responders women stimulated with CF from day 2"
11137050|NCT03816670|Experimental|high responders day 4|"high responders women stimulated with CF from day 4"
11137051|NCT03816657||Cohort1|Cohort1 (PD-L1+/low NLR)
11137052|NCT03816657||Cohort2|Cohort 2 (PD-L1-/High NLR)
11137053|NCT03816644|Experimental|5-Cog|The 5-Cog coupled with a decision tree is a simple, 5-minute procedure that will identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. The 5-Cog includes the Picture Memory Impairment Screen (PMIS), Motoric Cognitive Risk syndrome (MCR), and the Symbol Match test. The 5-Cog will be given after randomization and before the patients sees the physician. The 5-Cog will sort patients with 'cognitive impairment' from those with 'no cognitive impairment'. After completing the 5-Cog, the non-physician tester will send a message through the Electronic medical record (EMR) system to provide the physician with the 5-Cog results and guide the them through the follow-up based on the results.
11137054|NCT03816644|Active Comparator|Health Literacy & Grip Assessment|The 5 minute assessment includes the Short Assessment of Health Literacy (SAHL) and a grip assessment measured using a handgrip dynamometer. After completing the SAHL and grip assessment, the non-physician tester will send a message through the EMR to provide the physician with the results from the assessments and guide the them through the follow-up based on the results.
11137055|NCT03816631|Experimental|Part A: Group 1: Severe hepatic function|Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2*300 mg tablet) under fasted condition on Day 1.
11137056|NCT03816631|Experimental|Part A and B: Group 2: Normal hepatic function|Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
11137057|NCT03816631|Experimental|Part B: Group 3: Moderate hepatic function|Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
11137058|NCT03816631|Experimental|Part B: Group 4: Mild hepatic function|Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
11137059|NCT03816618|Experimental|CONTROL|CONTROL GROUP
11137060|NCT03816618|Experimental|TREATMENT1|TREATMENT GROUP 1
11137061|NCT03816618|Experimental|TREATMENT2|TREATMENT GROUP 2
11137062|NCT03816618|Experimental|TREATMENT3|TREATMENT GROUP 3
11137063|NCT03816605||control|Cells were cultured in the basic medium containing 2× penicillin and streptomycin antibody.
11137064|NCT03816605||Recombinant FGF19|Cells were cultured in the basic medium with recombinant FGF19 at concentration of 100ng/ml.
11137065|NCT03816605||High-glucose|Cells were cultured in the high-glucose medium at concentration of 25mM.
11137066|NCT03816605||FGF19 and HG|Cells were cultured in the medium with both recombinant FGF19 and high-glucose.
11137067|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
11137068|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
11137069|NCT03816579|Experimental|PRO-A|Beef protein
11137070|NCT03816579|Experimental|PRO-B|Complementary proteins at each meal
11137071|NCT03816579|Experimental|PRO-C|Complementary proteins over 24 hours
11137072|NCT03816579|No Intervention|CON|Low protein (<5 g) meal
11137073|NCT03816566|Experimental|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
11137074|NCT03816553|Experimental|SHR-1210 + Apatinib|Participants receive SHR-1210 200mg (3mg/kg for underweight patients) intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
11137075|NCT03816540|Experimental|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
11137078|NCT03816527||Healthy controls|Healthy controls
11137079|NCT03816514|Experimental|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
11137080|NCT03816514|Active Comparator|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
11137081|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones.
11137082|NCT03816501|Other|no music|preoperative music will not be listened
11137083|NCT03816488|Experimental|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
11137084|NCT03816488|Experimental|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
11137085|NCT03816488|No Intervention|Placebo|Self-administered placebo taken 2 hours prior to surgery
11137086|NCT03816475|Experimental|Hypofractionated radiotherapy|5x5 Gy radiotherapy and delayed surgery (after 6-8 weeks)
11137087|NCT03816449|Active Comparator|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
11137088|NCT03816449|Placebo Comparator|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
11137089|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
11137090|NCT03816423|No Intervention|Traditional counseling|Patients will undergo routine prenatal care visit with clinical practicioner only
11137091|NCT03816423|Experimental|video group|"Participants randomized to the intervention group (video education) will view the prenatal screening video How to Decide About Prenatal Genetic Testing, followed by a routine prenatal appointment."
11137092|NCT03816410|Experimental|LAA amputation group|
11137093|NCT03816410|No Intervention|No LAA amputation group|
11137094|NCT03816397|Active Comparator|Continue adalimumab|Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.
11137095|NCT03816397|Placebo Comparator|Stop adalimumab|Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.
11137096|NCT03816384|Active Comparator|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
11137097|NCT03816384|Experimental|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
11137098|NCT03816384|Experimental|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
11137099|NCT03816371|Active Comparator|supine 0 degree head-of-bed elevation|0 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
11137100|NCT03816371|Experimental|30 degree head-of-bed elevation|30 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
11137101|NCT03816371|Experimental|45 degree head-of-bed elevation|45 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
11137102|NCT03816358|Experimental|Arm I (anetumab ravtansine, nivolumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
11137103|NCT03816358|Experimental|Arm II (anetumab ravtansine, nivolumab, ipilimumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive ipilimumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of cycles 2-4. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
11137104|NCT03816358|Experimental|Arm III (anetumab ravtansine, nivolumab, gemcitabine)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive gemcitabine hydrochloride over 30-40 minutes on days 1 and 8. Treatment repeats every 21 or 28 days (cycle 1) in the absence of disease progression or unacceptable toxicity.
11137105|NCT03816345|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11137106|NCT03816332|Experimental|Treatment (tacrolimus, prednisone, nivolumab, ipilimumab)|"Patients receive tacrolimus PO BID and prednisone PO QD. Within 28 days, patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 24 cycles (96 weeks) in the absence of disease progression or unacceptable toxicity.
~Patients who experience PD or patients who have experienced allograft loss at 16 weeks receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Patients also receive tacrolimus PO BID and prednisone PO QD. Cycles repeat every 3 weeks for 4 cycles (12 weeks) in the absence of disease progression or unacceptable toxicity. Starting 6 weeks later, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 21 cycles (84 weeks) in the absence of disease progression or unacceptable toxicity."
11137147|NCT03816059||Hospitalized - stroke|Hospitalized patients with stroke
11137107|NCT03816319|Experimental|Group I (twice weekly UAE inhibitor TAK-243)|Patients receive UAE inhibitor TAK-243 IV over 10 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
11137108|NCT03816319|Experimental|Group II (once weekly UAE inhibitor TAK-243)|Patients receive UAE inhibitor TAK-243 IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
11137109|NCT03816306||Single group study|
11137110|NCT03816293|Active Comparator|Negative Pressure Wound Therapy|NPWT use on closed incision for 7 days after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
11137111|NCT03816293|No Intervention|Control Dressing|Standard dressing on closed incisions after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
11137112|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
11137113|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
11137114|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
11137115|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
11137116|NCT03816267|Active Comparator|Nebulizer|Containing salbutamol
11137117|NCT03816267|Experimental|Metered Dose Inhaler and spacer|Containing Salbutamol
11137118|NCT03816241|No Intervention|Control|Vignette contains no extra information.
11137119|NCT03816241|Experimental|Frame|Vignette is framed in a particular manner
11137120|NCT03816241|Experimental|Norms|Vignette contains extra information about norms
11137121|NCT03816241|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
11137122|NCT03816228|Experimental|Experimental Flortaucipir|
11137123|NCT03816215|Experimental|Adolescent Participants|Participants will be assigned to participate in community service (from a menu of options) for 30 hours.
11137124|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
11137125|NCT03816189||Diffuse SSc|Recruitment of 20 patients with diffuse SSc
11137126|NCT03816189||Limited SSc|Recruitment of 20 patients with limited SSc
11137127|NCT03816189||Healthy subjects|Recruitment of 20 healthy subjects (control)
11137128|NCT03816176|Experimental|Isavuconazonium sulfate|Participants will receive a loading dose of isavuconazonium sulfate (via intravenous or oral administration at the investigator's discretion) every 8 hours (± 2 hours) on Days 1 and 2 followed by once-daily maintenance dosing
11137129|NCT03816163|Experimental|zolbetuximab +nab-paclitaxel + gemcitabine|Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
11137130|NCT03816163|Active Comparator|nab-paclitaxel + gemcitabine|Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
11137131|NCT03816137|Active Comparator|ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
11137132|NCT03816137|Active Comparator|EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100G Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
11137133|NCT03816137|Active Comparator|ConS UFO and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
11137134|NCT03816137|Active Comparator|EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
11137135|NCT03816137|Active Comparator|ConS UFO and ConM SOSIPs and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0 and 3 months
~ConM SOSIP Administered at 12 months
~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
11137136|NCT03816124|Experimental|Genicular RF|Patients who will receive genicular radiofrequency ablation
11137137|NCT03816111|Experimental|TEACH-PD Training Curriculum|All patients at sites randomized to this arm will receive the TEACH-PD Training Curriculum
11137138|NCT03816111|Active Comparator|Current Standard PD Training|All patients at sites randomized to this arm will receive the unit's current PD training materials and plan
11137139|NCT03816098||elderly patients with dysphagia|
11137140|NCT03816098||elderly patients without dysphagia|
11137141|NCT03816085|Experimental|Shoe with 4 cm heel|Shoes with 4 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
11137142|NCT03816085|Experimental|Shoe with 10 cm heel|Shoes with 10 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
11137143|NCT03816085|No Intervention|Without shoes|Women will be included in the tests to measure balance, muscular endurance and function without shoes.
11137144|NCT03816072|Active Comparator|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
11137145|NCT03816072|Active Comparator|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
11137146|NCT03816059||Hospitalized - ACS|Hospitalized patients with acute coronary syndrome
11137150|NCT03816046|Experimental|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
11137151|NCT03816046|Experimental|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
11137152|NCT03816033|Active Comparator|Cryotherapy|Cryotherapy ablation energy will be utilised in the catheter ablation procedure
11137153|NCT03816033|Active Comparator|Radiofrequency|Radiofrequency ablation energy will be utilised in the catheter ablation procedure
11137154|NCT03816020|Active Comparator|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
11137155|NCT03816020|Placebo Comparator|Placebo Group|Participant receiving Placebo BIDfor 30 days
11137156|NCT03816007|Experimental|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
11137157|NCT03816007|Active Comparator|Relaxation/Health Education|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator.
11137158|NCT03815994|Experimental|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
11137159|NCT03815994|Sham Comparator|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
11137160|NCT03815981||Allergic|Collection of blood, stool, urin samples
11137161|NCT03815981||Sensitized|Collection of blood, stool, urin samples
11137162|NCT03815981||Non-Allergic|Collection of blood, stool, urin samples
11137163|NCT03815968|Experimental|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
11137164|NCT03815968|No Intervention|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
11137165|NCT03815955|Experimental|Non-Sedentary Behaviour Group|Participants in this arm will model the primary care team as they engage in minimal sedentary behaviour and replace sitting with standing and light, incidental movements.
11137166|NCT03815955|No Intervention|Standard Care Control Group|Participants that are limited to standing, due to amputations, diabetic foot pain and ulcers, or sensory diabetic neuropathy, will follow standard care and attend the DIGMA in a seated position.
11137167|NCT03815942|Experimental|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
11137168|NCT03815942|Experimental|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
11137169|NCT03815929|Active Comparator|Standard replacement therapy regimen|100 mcg transdermal estradiol patch (or equivalent oral dose)
11137170|NCT03815929|Active Comparator|Titrated replacement therapy regimen|Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level
11137171|NCT03815929|No Intervention|Timed Control Group|Healthy age-matched subjects not on hormone therapy
11137172|NCT03815916|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11137173|NCT03815916|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11137174|NCT03815916|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11137175|NCT03815916|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
11137176|NCT03815903|Active Comparator|A - induction chemotherapy|
11137177|NCT03815903|Experimental|B - chemoradiotherapy|
11137178|NCT03815890|Experimental|1A; LumB|Nivolumab
11137179|NCT03815890|Experimental|1B; TNBC|Nivolumab
11137180|NCT03815890|Experimental|2A; LUMB|Nivolumab and ipilimumab
11137181|NCT03815890|Experimental|2B; TNBC|Nivolumab and ipilimumab
11137182|NCT03815877|Active Comparator|The intervention group (C group receiving caffeinated coffee)|100cc coffee at 3, 6 and 9 hours after the Cesarean section
11137183|NCT03815877|Placebo Comparator|The control group (N group receiving decaffeinated coffee)|100cc decaf coffee at 3, 6, 9 hours after the Cesarean section
11137184|NCT03815864||D2SA+|Median fluoresce intensity > or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
11137185|NCT03815864||D2SA-|Median fluoresce intensity < 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
11137186|NCT03815851|Experimental|experimental：prophylactic drainage|leave prophylactic drainage after surgery
11137187|NCT03815851|No Intervention|control|not leave prophylactic drainage after surgery
11137188|NCT03815838|Experimental|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
11137189|NCT03815825|Experimental|IONIS-FB-LRx|Stage 1 participants will receive IONIS-FB-LRx randomized to 1 of 3 dose levels, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 will expand 2 of the dosing cohorts in a new randomized group of participants based on the Stage 1 interim analysis. Participants will be randomized to 1 of 2 of the expanded cohorts, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
11137190|NCT03815825|Experimental|Placebo|Stage 1 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
11137191|NCT03815812|Experimental|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
11137192|NCT03815812|Placebo Comparator|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
11137193|NCT03815799|Experimental|Erector Spinae Plane Block Group|"Procedure:
~In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve erector spinae block under ultrasound guidence after the strict aseptic precautions."
11137194|NCT03815799|Sham Comparator|Control|Routine standard perioperative and postoperative analgesic protocol will be given.
11137195|NCT03815786|Experimental|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
11137196|NCT03815786|Other|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
11137197|NCT03815760|Experimental|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.
~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.
~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
11137198|NCT03815760|Active Comparator|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.
~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
11137199|NCT03815747|Experimental|Treatment Group|Treatment with the investigational device - High- Intensity Focused Electromagnetic (HIFEM) Field Device
11137200|NCT03815734|No Intervention|control group|Non intervention group
11137201|NCT03815734|Experimental|intervention group|motor imagery group
11137202|NCT03815721|Experimental|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
11137203|NCT03815721|Experimental|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
11137204|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
11137205|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
11137206|NCT03815695|Experimental|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of FT-4202 or placebo. The first cohort will receive 200 mg of FT-4202 or placebo. Dose escalation will occur if FT-4202 or placebo is tolerated. The maximum dose of FT-4202 or placebo will be 1500 mg.
11137207|NCT03815695|Experimental|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The first cohort will receive 100 mg of FT-4202 or placebo daily X 14 days. The maximum dose of FT-4202/placebo will be 600 mg FT-4202/placebo daily for 14 days.
11137208|NCT03815695|Experimental|Food Effect Cohort in healthy subjects|Health Volunteer subject cohort of 10 subjects who will receive a single dose of FT-4202 with food and without food. Dose will be administered per the protocol defined dose.
11137209|NCT03815695|Experimental|Single ascending dose cohorts in SCD subjects|Sickle cell disease subject cohort randomized 6:2 receiving a single dose of FT-4202 or placebo. The dose of FT-4202/placebo administered will be a dose that was found to be safe in healthy subjects.
11137210|NCT03815695|Experimental|Multiple ascending dose cohorts in SCD subjects|Sickle cell disease subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The dose of FT-4202/placebo administered will be a dose less than the maximum tolerable dose evaluated in MAD healthy volunteers.
11137211|NCT03815695|Experimental|12-week dosing cohort in SCD subjects|Sickle cell disease subjects cohort to receive up to 84 consecutive daily doses of open-label FT-4202. The dose of FT-4202 administered will not exceed the highest dose evaluated in the MAD SCD subject cohorts
11137212|NCT03815682|Experimental|TRQ15-01|Dose escalating TRQ15-01
11137213|NCT03815669||Arthroscopic subacromial decompression|Patients referred to arthroscopic subacromial decompression
11137214|NCT03815656|Experimental|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
11137215|NCT03815643|Experimental|Avelumab|
11137216|NCT03815630|Experimental|PD-1 and dc-cik treatment group|
11137217|NCT03815617|Active Comparator|Probiotic|The study design is a crossover randomized double-blind two-block placebo-controlled single center trial with an allocation ratio of 1:1 conducted between February 2017 and May 2018. Subjects are randomized at baseline visit to receive Block 1 (Zircombi 3 g, containing Bifidobacterium longum BB536 four billion CFU, Lactobacillus rhamnosus HN001 one billion CFU with B6 vitamin 1.4 mg) and Block 2 (placebo: maltodextrins, corn starch, silicon dioxide) depending on the randomization sequence. Subjects received one sachet pack daily containing placebo or probiotic. The active treatment was undistinguishable from placebo by physical and organoleptic characteristics. Participants in the study followed a free diet.
11137218|NCT03815617|Placebo Comparator|Placebo|Same appearance of probiotic.
11137219|NCT03815604|Experimental|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
11137220|NCT03815604|Active Comparator|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
11137221|NCT03815604|Experimental|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
11137222|NCT03815604|Active Comparator|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
11137223|NCT03815591|Experimental|adolescents between ages of 10-16|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, attitudes, intentions, social norms, and behaviors around tobacco use, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
11137224|NCT03815578|Experimental|Rheumatoid Arthritis (RA) patients|RA according to the ACR/EULAR 2010 classification criteria
11137225|NCT03815565|Experimental|levobupivacaine 0.125%|continuous femoral block with levobupivacaine 0.125%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
11137226|NCT03815565|Active Comparator|ropivacaine 0.2%|continuous femoral block with ropivacaine 0.2%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
11137768|NCT03811912|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
11137227|NCT03815552|Experimental|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
11137228|NCT03815539|Experimental|dry eye group|Part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
11137229|NCT03815526|Experimental|Dynamic tape|
11137230|NCT03815526|Experimental|Kinesio tape|
11137231|NCT03815526|Experimental|Sport tape|
11137232|NCT03815513|Experimental|cases|Patient with spontaneous intracerebral hemorrhage
11137233|NCT03815513|Experimental|controls|Healthy control without history of symptomatic cerebrovascular diseases
11137234|NCT03815500|Experimental|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
11137235|NCT03815487|Experimental|Therapy with Hybrid Closed Loop (HCL)|"The Intervention is the specific function of the Insulin Pump from Medtronic® with the name MiniMed® 670G (MMT-1780) to deliver Insulin as medication.
~This Medtronic MiniMed 670G Insulin Pump in Auto Mode is an Hybrid closed loop (HCL) system including an Auto Mode function. It provides as intervention several additional effects concerning automatically insulin delivery by pump: e.g. in case of high values (or predicted) - more insulin will be administered automatically, in case of low values (or predicted) - the insulin infusion will be decreased a suspended and resumed again. The patients will wear the pump continuously."
11137236|NCT03815487|Active Comparator|Sensor Augmented Pump (SAP) therapy|"The Intervention is the specific therapy of the Sensor Augmented Insulin Pump MiniMed® 670G (MMT-1780) without Auto Mode.
~This Medtronic MiniMed 670G Insulin Pump without Auto Mode' is a Sensor Augmented Pump (SAP) therapy and means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. The patients will wear the pump also continuously, but have to respond manually after the alarm. There are no automatically steps from the pump."
11137237|NCT03815474|Experimental|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
11137238|NCT03815461|Experimental|experiment group|Nab-paclitaxel+S-1
11137239|NCT03815448|Experimental|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
11137240|NCT03815448|Placebo Comparator|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
11137241|NCT03815435|Experimental|Balanced anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/ kg) + Propofol (2-3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: Desflurane 0.8-1.2 MAC + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60
11137242|NCT03815435|Experimental|Total intravenous anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/kg) + Propofol (2 -3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: continuous administration of Propofol 6-12 mg /kg/h + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60 Hypotensives: Nitro Pohl 1mg/ml 0-10 ml/h
11137243|NCT03815409|Experimental|BWSTT group|The sessions were conducted on a treadmill with partial weight unload.
11137244|NCT03815409|Other|Control group|The traditional PT rehabilitation treatment included passive, active and active-assisted exercises, according to the methods commonly used (Kabat, Bobath).
11137245|NCT03815396|Experimental|Part 1 Single Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
11137246|NCT03815396|Experimental|Part 2 Multiple Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
11137247|NCT03815383|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
11137248|NCT03815370|Placebo Comparator|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
11137249|NCT03815370|Experimental|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
11137250|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. >2 years in some, >6 months in others.
11137251|NCT03815344|Active Comparator|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
11137252|NCT03815344|Experimental|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
11137253|NCT03815331|Experimental|PD treatment with Xiaflex® plus Aveed|Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
11137254|NCT03815318|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
11137255|NCT03815305|Active Comparator|Topical CA and Placebo Oral Drug|Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
11137256|NCT03815305|Placebo Comparator|Petroleum Jelly and placebo oral drug|Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
11137257|NCT03815305|Experimental|Centella asiatica extract and Topical CA|Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
11137258|NCT03815292|Experimental|MMH-MAP|Oral administration. 2 tablets twice daily. Tablets should be held in the mouth until completely dissolved, then swallowed. The duration of treatment will be 24 weeks.
11137259|NCT03815292|Placebo Comparator|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
11137355|NCT03814694|Active Comparator|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
11137260|NCT03815279|Experimental|High-risk SMM and MM|"Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.
~Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.
~Maintenance (1 year):
~Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks."
11137261|NCT03815279|Experimental|Intermediate-risk SMM|"Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.
~Maintenance (1 year):
~Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks."
11137262|NCT03815266|Experimental|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).
~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
11137263|NCT03815253|Experimental|Acupuncture group|"Body electro-acupuncture will be conducted for 2 sessions per week over 8 consecutive weeks.
~Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.
~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
11137264|NCT03815253|Placebo Comparator|sham-acupuncture group|"As to the participants allocated to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to act as sham control at the same acupoints with same stimulation modality. However, the needles will be only adhered to the skin instead of insertion. The validity and credibility of this model has been well demonstrated."
11137265|NCT03815240|Other|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
11137266|NCT03815240|Active Comparator|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
11137267|NCT03815240|Active Comparator|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
11137268|NCT03815240|Active Comparator|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
11137269|NCT03815227|Experimental|Outpatient birth|Maternity out the same date or the next day of the birth
11137270|NCT03815214|Experimental|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4&2&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
11137271|NCT03815214|Placebo Comparator|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
11137272|NCT03815201|Placebo Comparator|Group 1|exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
11137273|NCT03815201|Active Comparator|Group 2|exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
11137274|NCT03815188||Heart Valve Surgery|Pre-operative patients undergoing heart valve surgery will be selected and data recorded from each patient on the day of their surgery. This patient cohort is required in order to be able to accurately measure their JVP upon physical examination. Patients must have a central line inserted as part of their ongoing clinical management.
11137275|NCT03815175|Experimental|XIENCE|XIENCE + 1 month DAPT
11137276|NCT03815162|Experimental|High Flavanol Cocoa extract|278mg total flavanols (38.3mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (836 mg total flavanols; 115mg epicatechin) for 3 months
11137277|NCT03815162|Placebo Comparator|Alkalised cocoa|0mg total flavanols (0mg epicatechin) per opaque cellulose capsule 3 capsules consumed once per day (0mg total flavanols; 0mg epicatechin) for 3 months
11137278|NCT03815149||patients with intracranial aneurysm(s)|Standard of care elective, unscheduled or emergency procedures for the treatment of an unruptured or ruptured intracranial aneurysm(s) using a Pipeline™ Flex Embolization Device(s) with Shield Technology™
11137279|NCT03815136|Active Comparator|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
11137280|NCT03815136|Placebo Comparator|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
11137281|NCT03815097|Experimental|Intervention|Monitored anesthesia care with a mapleson circuit and nasal trumpet
11137282|NCT03815097|No Intervention|Standard of care|Standard monitored anesthesia care
11137283|NCT03815084|Experimental|PD-1 and DC-NK treatment group|
11137284|NCT03815071|Experimental|ips-nsc treatment group|
11137285|NCT03815058|Experimental|Safety Run-in Period: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of RO7198457.
11137286|NCT03815058|Active Comparator|Randomized Period: Arm A: Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with RO7198457 plus pembrolizumab (Arm B) after confirmed disease progression.
11137287|NCT03815058|Experimental|Randomized Period: Arm B: RO7198457 + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of RO7198457.
11137288|NCT03815045|Active Comparator|Landmark-based lumbar puncture|Landmark-based LP
11137289|NCT03815045|Active Comparator|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
11137290|NCT03815032|Experimental|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:
~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
11137291|NCT03815032|Experimental|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
11137292|NCT03815019|Experimental|Megestrol|"Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is off label to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect.
~The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable."
11137293|NCT03815019|Placebo Comparator|Placebo|Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
11137294|NCT03815006|Experimental|Free Style Libre device|At the start, a blood sample will be taken for the measurement of HbA1c. Training and education on the use of FSL will be provided by the research team. Participants will be advised to use flash glucose monitoring continuously for the next 24 weeks.
11137295|NCT03815006|No Intervention|Self-monitoring of blood glucose|At the start, a blood sample will be taken for the measurement of HbA1c. Masked FSL will be applied for two weeks, during the last two weeks of control period. Education will focus on using fingerstick measurement for treatment optimisation.
11137296|NCT03814980|Experimental|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
11137297|NCT03814967|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
11137298|NCT03814967|Active Comparator|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
11137299|NCT03814967|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
11137300|NCT03814954|Active Comparator|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
11137301|NCT03814954|Experimental|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
11137302|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.
~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
11137303|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.
~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
11137304|NCT03814928|Experimental|Caregivers e-Learning Intervention|
11137305|NCT03814915||Study 1 - Prediabetes|"The primary objective of Study 1 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in non-diabetic high-risk participants.
~Participants in Study 1 were recruited from existing prospective cohort studies in or around each of the following European cities: Malmö, Sweden (Malmö Diet and Cancer Study); Amsterdam, The Netherlands (Hoorn Study); Copenhagen, Denmark (Inter99); and Kuopio, Finland (METSIM). A clinically practicable screening tool (DIRECT-DETECT) was used to identify at-risk participants from existing cohort studies, who were then recruited into this new prospective cohort study (Study 1)."
11137306|NCT03814915||Study 2- Diabetic|The primary objective of Study 2 is to collect biosamples and information that might yield novel, predictive biomarkers for glycaemic deterioration in people who have recently been diagnosed with type 2 diabetes. Participants in Study 2 of DIRECT are recruited from or nearby each of the following European cities: Malmö, Sweden; Amsterdam, the Netherlands; Copenhagen, Denmark; Exeter, UK; Newcastle, UK; Dundee, UK. Potential participants are recruited through targeted searches of existing databases and research registers combined with person-to-person contact at educational clinics and through routine retinal screening programmes.
11137307|NCT03814902|Experimental|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
11137308|NCT03814889|Active Comparator|Vibration pattern 1|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137309|NCT03814889|Active Comparator|Vibration pattern 2|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137310|NCT03814889|Active Comparator|Vibration pattern 3|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137311|NCT03814889|Active Comparator|Vibration pattern 4|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137312|NCT03814889|Active Comparator|Vibration pattern 5|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137313|NCT03814889|Active Comparator|Vibration pattern 6|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137314|NCT03814889|Active Comparator|Vibration pattern 7|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137315|NCT03814889|Active Comparator|Vibration pattern 8|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137408|NCT03814395||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
11137316|NCT03814889|Active Comparator|Vibration pattern 9|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137317|NCT03814889|Active Comparator|Vibration pattern 10|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
11137318|NCT03814889|Placebo Comparator|No vibration|A light will blink instead of a vibration pattern being displayed.
11137319|NCT03814876|Experimental|SCI intervention|Spinal cord injury intervention group
11137320|NCT03814876|Active Comparator|SCI control|Spinal cord injury control
11137321|NCT03814876|Experimental|TBI intervention|Traumatic brain injury intervention group
11137322|NCT03814876|Active Comparator|TBI control|Traumatic brain injury control group
11137323|NCT03814850|Experimental|Treatment group: standard blood pressure cuff|A standard blood pressure cuff inflated on the participants arm for 4 cycles; each cycle will include 5 minutes of inflation followed by 5 minutes of deflection. RIPC will be applied via a standard blood pressure cuff. The ischemic cycle will involve cuff inflating to 30mmHg above resting systolic blood pressure and demonstration of loss of radial pulse.
11137324|NCT03814850|Sham Comparator|Sham group: standard blood pressure cuff|The blood pressure cuff will be inflated to 30mmHg during the first 5 minutes of each cycle and deflated for the following 5 minutes, with re-demonstration of radial pulse. This will be repeated for 4 cycles.
11137325|NCT03814824|Active Comparator|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
11137326|NCT03814824|Active Comparator|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
11137327|NCT03814811||Bone metastasis(+) with low cOC|Patients who have bone metastasis with low number of circulating osteocalcin-positive (cOC) cells
11137328|NCT03814811||Bone metastasis(+) with high cOC|Patients who have bone metastasis with high number of circulating osteocalcin-positive (cOC) cells
11137329|NCT03814811||Bone metastasis(-) with low cOC|Patients who have metastasis only in extraskeletal sites with low number of circulating osteocalcin-positive (cOC) cells
11137330|NCT03814811||Bone metastasis(-) with high cOC|Patients who have metastasis only in extraskeletal sites with high number of circulating osteocalcin-positive (cOC) cells
11137331|NCT03814798|Experimental|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
11137332|NCT03814798|Experimental|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
11137333|NCT03814798|Experimental|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
11137334|NCT03814798|Experimental|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
11137335|NCT03814772||Liver transplant|"18 years to 65
~48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
11137336|NCT03814759|Experimental|SP+CCRT|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks
11137337|NCT03814746|Experimental|Crizanlizumab (SEG101) at 5.0 mg/kg|Participants will receive Crizanlizumab (SEG101) at 5.0 mg/kg
11137338|NCT03814746|Experimental|Crizanlizumab (SEG101) at 7.5 mg/kg|Participants will receive Crizanlizumab (SEG101) at 7.5 mg/kg
11137339|NCT03814746|Placebo Comparator|Placebo|Participants will receive the placebo drug.
11137340|NCT03814733|Experimental|Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137341|NCT03814733|Experimental|Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137342|NCT03814733|Active Comparator|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137343|NCT03814733|Active Comparator|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137344|NCT03814733|Placebo Comparator|Placebo for Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137345|NCT03814733|Placebo Comparator|Placebo for Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137346|NCT03814733|Placebo Comparator|Placebo for Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
11137347|NCT03814720|Experimental|Group 1|5 subjects, ages 18-40 will be administred 20 mcg IM of H1ssF 3928 on Day 0.
11137348|NCT03814720|Experimental|Group 2A|12 subjects, ages 18-40 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
11137349|NCT03814720|Experimental|Group 2B|12 subjects, ages 41-49 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
11137350|NCT03814720|Experimental|Group 2C|12 subjects, ages 50-59 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
11137351|NCT03814720|Experimental|Group 2D|12 subjects, ages 60-70 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
11137352|NCT03814707|Active Comparator|Topical application 0.2%Hyaluronic Acid|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting and covered by periodontal pack
11137353|NCT03814707|Experimental|Platelet Rich Fibrin|Palatal donor site will receive a platelet rich fibrin and then will be sutured by criss cross suture then covered by periodontal pack.
11137354|NCT03814694|Experimental|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
11137356|NCT03814668|Experimental|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
11137357|NCT03814668|Active Comparator|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
11137358|NCT03814668|Placebo Comparator|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
11137359|NCT03814655|Experimental|Full digital workflow|"Intraoral scan of the partially edentulous site, antagonists and occlusion registration. Radiopaque tray customization over the partially edentulous arch.
~CBCT with customized radiopaque tray.
~Merging files in R2 Gate software and implant planning.
~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.
~Digital impression for final screw-retained crown/bridge.
~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
11137360|NCT03814655|Active Comparator|Partially digital workflow|"Impression of the edentulous arch and antagonist, occlusion registration. Radiopaque tray customization over the edentulous arch.
~CBCT with customized radiopaque tray.
~Stone models alone, maximum intercuspal position and customized radiopaque tray will be scanned using a desktop scanner.
~Merging files (CBCT and model stl) in R2 Gate software and implant planning.
~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.
~Classic impression in customized tray with Impregum.
~Functional models will be scanned using the same desktop scanner.
~Final screw-retained crown/bridge manufacturing.
~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
11137361|NCT03814642|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
11137362|NCT03814642|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
11137363|NCT03814642|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
11137364|NCT03814629|Other|precancerous lesions of gastric cancer|120 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia,It was randomly divided into 60 cases of treatment group and 60 cases of control group,treatment group was given Weifuchun tablets,The control group was given vitamin tablets.
11137365|NCT03814616|Experimental|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
11137366|NCT03814616|Experimental|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
11137367|NCT03814616|Experimental|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
11137368|NCT03814603||African Americans|
11137369|NCT03814603||Non-Hispanic Whites|
11137370|NCT03814590|Experimental|Group Low Dose_PLAIN_A|Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137371|NCT03814590|Experimental|Group Medium Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137372|NCT03814590|Experimental|Group High Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137373|NCT03814590|Placebo Comparator|Group Placebo_A|Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137374|NCT03814590|Experimental|Group Low Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137375|NCT03814590|Experimental|Group Low Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137376|NCT03814590|Experimental|Group Low Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137377|NCT03814590|Experimental|Group Medium Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137378|NCT03814590|Experimental|Group Medium Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137379|NCT03814590|Experimental|Group Medium Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137380|NCT03814590|Experimental|Group High Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137381|NCT03814590|Experimental|Group High Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137382|NCT03814590|Experimental|Group High Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137383|NCT03814590|Placebo Comparator|Group Placebo_B|Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
11137409|NCT03814382|Experimental|Acupuncture|All subjects will receive up to 10 needles for 20 minutes for 1 treatment using acupuncture needles.
11137410|NCT03814369|Experimental|AmplifEYE colonoscopy|Colonoscopy performed with AmplifEYE equipped
11137411|NCT03814369|No Intervention|Standard colonoscopy|Standard colonoscopy performed
11137384|NCT03814577|Active Comparator|Desflurane|Anesthesia will be maintained with Desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture.Total Intravenous Anesthesia will not be used in this group. While target desflurane minimum alveolar concentration (MAC) will be 1-1.5 and Bispectral Index values will be between 40-60, the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
11137385|NCT03814577|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia: Anesthesia will be maintained with inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture. Desflurane will not be used in this group. Total Intravenous Anesthesia (propofol and remifentanyl infusion) will be performed to the patients while target Bispectral Index values were between 40-60. Also the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
11137386|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
11137387|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
11137388|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.
~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
11137389|NCT03814551||Comparison|Cohort of participants who regularly eat in cafeteria without health signage.
11137390|NCT03814551||Signage|Cohort of participants who regularly eat in cafeteria in which health signage is placed.
11137391|NCT03814525|Active Comparator|Photobiomodulation group|PBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
11137392|NCT03814525|Placebo Comparator|Control group|Participants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
11137393|NCT03814512|Experimental|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
11137394|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
11137395|NCT03814473|Experimental|Dietary intervention|All participants will follow an ad libitum self-administered Paleo diet for 8-weeks
11137396|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
11137397|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
11137398|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
11137399|NCT03814447|Experimental|anti- MESO CAR-T cells|The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).
11137400|NCT03814434|Experimental|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
11137401|NCT03814434|Experimental|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
11137402|NCT03814434|Experimental|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
11137403|NCT03814434|Experimental|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
11137404|NCT03814421|Experimental|Low dose intermittent|Pantoprazole 40mg as a bolus injection daily for 72hours
11137405|NCT03814421|Active Comparator|High dose continous|Pantoprazole 40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours
11137406|NCT03814408|Experimental|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
11137407|NCT03814395||Exposure group|Group with environmental, nutritional or lifestyle exposures
11137412|NCT03814356|Experimental|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
11137413|NCT03814343|Active Comparator|Active comparator|10 patients with NDMs onychomycosis treated with amphotericin B in 30% DMSO.
11137414|NCT03814343|Placebo Comparator|control comparator|10 patients with NDMs onychomycosis treated with 30% DMSO.
11137415|NCT03814330|Placebo Comparator|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
11137416|NCT03814330|Active Comparator|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
11137417|NCT03814317|Experimental|Study Group|"Sarcoidosis patients with interstitial lung disease and precapillary pulmonary hypertension based on right heart catheterization (RHC).
~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
11137418|NCT03814304|Experimental|Personalized tDCS|Personalized tDCS: Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
11137419|NCT03814304|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
11137420|NCT03814291|Experimental|cohort 1 IBI302 treated with first dose level of IBI302|
11137421|NCT03814291|Experimental|cohort 2 IBI302 treated with second dose level of IBI302|
11137422|NCT03814291|Experimental|cohort 3 IBI302 treated with third dose level of IBI302|
11137423|NCT03814291|Experimental|cohort 4 IBI302 treated with fourth dose level of IBI302|
11137424|NCT03814291|Experimental|cohort 5 IBI302 treated with fifth dose level of IBI302|
11137425|NCT03814291|Experimental|cohort 6 IBI302 treated with sixth dose level of IBI302|
11137426|NCT03814278|Experimental|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
11137427|NCT03814278|Experimental|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
11137428|NCT03814265|Experimental|Intervention|Laughter yoga group
11137429|NCT03814265|No Intervention|Control|No intervention
11137430|NCT03814252|Experimental|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
11137431|NCT03814239||no protocol|liberal fluid therapy
11137432|NCT03814239||protocol|fluid therapy according to stroke volume variation (SVV) monitor, tranexamic acid administration, use of cell saver
11137433|NCT03814226|Experimental|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
11137434|NCT03814226|Active Comparator|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
11137435|NCT03814213||No-CGA|Patients were not initially offered CGA due to no booking for CGA
11137436|NCT03814213||CGA alone|Patients had CGA, but no tailored follow-up upon identified problems
11137437|NCT03814213||CGA with tailored care|CGA and a tailored follow-up and care for 90 days following the CGA
11137438|NCT03814200|Experimental|Treatment period A|"Treatment A1: saline 0.9%
~followed by
~Treatment A2: ACT-246475"
11137439|NCT03814200|Experimental|Treatment period B|"Treatment B1: rifampicin
~followed by
~Treatment B2: ACT-246475"
11137440|NCT03814187|Experimental|Inclisiran|"Inclisiran sodium 300 milligrams (mg) will be administered as a single SC injection on Day 1*, 90, then every 180 days to Day 990.
~*Subjects who received blinded placebo in the feeder study will receive blinded inclisiran and subjects who received blinded inclisiran in the feeder study will receive blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-5 study will not receive any injection of study drug/placebo on Day 1."
11137441|NCT03814148|Experimental|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
11137442|NCT03814148|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
11137443|NCT03814135|Experimental|HIPNOS 3|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Hipnos 3 and 1 placebo tablet, oral, once a day."
11137444|NCT03814135|Experimental|HIPNOS 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Hipnos 5 and 1 placebo tablet, oral, once a day."
11137445|NCT03814135|Placebo Comparator|HIPNOS Placebo|The study is double-dummy. Thus, the patient will take 2 tablet of placebo, oral, once a day.
11137446|NCT03814122|Experimental|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
11137566|NCT03813251|Experimental|Assigned Interventions|ForConti Contix Fecal Incontinence Management System (FIMS)
11137447|NCT03814122|Active Comparator|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
11137448|NCT03814109|Experimental|LENINGRADO|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Leningrado association and 1 tablet Natrilix® SR placebo, oral, once a day."
11137449|NCT03814109|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:
~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado association placebo, oral, once a day."
11137450|NCT03814096|Experimental|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test [GTT]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
11137451|NCT03814083|Experimental|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
11137452|NCT03814083|Active Comparator|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
11137453|NCT03814083|Sham Comparator|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
11137454|NCT03814070|Active Comparator|Non-reinforced full arch acrylic restorations|
11137455|NCT03814070|Experimental|full arch acrylic restorations with fiber-reinforced framework|
11137456|NCT03814057||Elderly Medical Patients at hospital admission|
11137457|NCT03814031||EAD|Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST > 2,000 IU/L within the first 7 days.
11137458|NCT03814031||Non EAD|No EAD
11137459|NCT03814005|Experimental|Control Arm (Normal Renal and Hepatic Function)|Pevonedistat 20 milligram per square meter (mg/m^2), infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously, once on Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
11137460|NCT03814005|Experimental|Renal Arm (Severe Renal Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously, once on Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 15 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies and docetaxel 75 mg/m^2 OR carboplatin AUC4, infusion, intravenously, once along with paclitaxel 135 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 15 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
11137461|NCT03814005|Experimental|Mild Hepatic Arm (Mild Hepatic Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously, once on Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies, and carboplatin AUC4, infusion, intravenously, once along with paclitaxel 135 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
11137462|NCT03814005|Experimental|Moderate Hepatic Arm (Moderate Hepatic Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously, once on Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 10 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies, and carboplatin AUC4, infusion, intravenously, once along with paclitaxel 90 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 10 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
11137463|NCT03813992|Active Comparator|MED2005 0.2%|MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt
11137464|NCT03813992|Active Comparator|MED2005 0.4%|MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt
11137465|NCT03813992|Active Comparator|MED2005 0.6%|MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt
11137466|NCT03813992|Placebo Comparator|Placebo vehicle|Placebo vehicle applied topically prior to a sexual intercourse attempt
11137467|NCT03813979|Experimental|Hepatic impairment group|Dolutegravir in HIV-seronegative subjects with severe hepatic impairment (child-Pugh score 10 or greater)
11137468|NCT03813979|Active Comparator|Matched controls|Dolutegravir in control group matched for gender, age and BMI with subjects in hepatic impairment group
11137469|NCT03813953|Experimental|Local Anaesthetic Wound Infiltration|Wound catheter delivering local anaesthetic for 48 hours post-operatively following liver resection
11137470|NCT03813953|Active Comparator|Epidural|Conventional practice following liver resection
11137471|NCT03813940|Experimental|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
11137472|NCT03813940|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
11137473|NCT03813927|Experimental|Vitamin D|supplementation with tablet 170 μg Vitamin D each day.
11137474|NCT03813927|Placebo Comparator|Placebo|Placebo, tablet with 20 μg Vitamin D each day.
11137475|NCT03813914|Experimental|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
11137476|NCT03813914|Placebo Comparator|Placebo comparator|placebo 2 pills/day for 3 months
11137477|NCT03813901|Experimental|Samalochana Counselling group|Arsha Vidya advaita vedanta based counselling were given to the women
11137478|NCT03813901|Other|Wait-list control group|Wait list group were not given any supportive care during the period. After that, they were offered the similar program as Counselling group.
11137479|NCT03813888|Experimental|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
11137480|NCT03813888|Other|Usual Activity Group|After school, control group were asked to conitue their usual routine.
11137481|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.
~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1~5mg per patient), alfentanil (200~1000mcg per patient) and propofol (small boluses of 10~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
11137482|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.
~LMA group: routine induction medications include propofol (50~200mg per patient), fentanyl (50~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
11137483|NCT03813836|Experimental|pembrolizumab + best supportive care|Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
11137484|NCT03813823||Phobic|Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders
11137485|NCT03813823||Nonphobic|Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders
11137486|NCT03813810||Normal|People without any chronic pulmonary diseases.
11137487|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
11137488|NCT03813810||Asthma|Patients with asthma
11137489|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
11137490|NCT03813797|Experimental|Arm A: Low Pressure (5-7 mmHg)|Laparoscopic colectomy surgery with low pressure (5-7mmHg)
11137491|NCT03813797|Active Comparator|Arm B: Standard pressure (12-15 mmHg)|Laparoscopic colectomy surgery with standard pressure (12-15mmHg)
11137492|NCT03813784|Experimental|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
11137493|NCT03813784|Active Comparator|B|Capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m^2, IV q3w
11137494|NCT03813784|Experimental|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210
11137495|NCT03813771|Experimental|Abnormal T-cells: Benepali + T2T Care|"Treatment Arm C will receive Benepali and methotrexate combination therapy and followed as per T2T care over a total duration of 24 weeks. Sulfasalazine or Hydroxychloroquine may be added to therapy at follow up visits in-line with T2T care.
~Benepali will be administered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
~Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks."
11137496|NCT03813771|Active Comparator|Abnormal T-cells: Methotrexate + T2T Care|"Treatment Arm B will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination synthetic DMARD (Including sulfasalazine and/or hydroxychloroquine).
~therapy if not achieving low disease activity (LDA) at, or after, 8 weeks)."
11137497|NCT03813771|Other|Normal T-cells: Methotrexate + T2T Care|Treatment Arm A will receive standard T2T care as per Arm B.
11137498|NCT03813758||finger after digital nerve cut|
11137499|NCT03813758||healthy finger|
11137500|NCT03813745||early denudation|Cumulus-oocyte complexes will be denudated in 30 min after oocyte retrieval
11137501|NCT03813745||late denudation|Denudation will be done 2 hr after oocyte retrieval
11137502|NCT03813732|Other|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
11137503|NCT03813719||All patients attending Rapid access Gynaecology Clinic|All patients attending Rapid access Gynaecology Clinic for the first time.
11137504|NCT03813706|Active Comparator|LN-prRLN dissection|
11137505|NCT03813706|Experimental|no LN-prRLN dissection|
11137506|NCT03813693|Experimental|towels with chlorhexidine gluconate 2%|Composed of 25 patients, who received 2 towels with chlorhexidine gluconate 2% packages each containing six towels and detailed instructions on the form and sequence of application of the towels; the time of application, that is, the night before surgery, between 20 and 22h, and, on the morning of surgery, between 5 and 6h; besides other general orientations.
11137507|NCT03813693|Active Comparator|chlorhexidine gluconate 2% liquid|Composed of 23 patients, two 100 ml flasks of chlorhexidine gluconate 2% liquid were supplied, and detailed instruction manual for the product, containing form and application sequence; time of application (the night before surgery, between 20 and 22h, and on the morning of surgery, between 5 and 6h); and general guidelines.
11137508|NCT03813680|Active Comparator|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
11137509|NCT03813680|Active Comparator|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
11137510|NCT03813680|Active Comparator|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
11137511|NCT03813667|No Intervention|Control|The control patients have standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist and recorded in the medical record
11137512|NCT03813667|Experimental|Intervention|The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in end-of-life palliative care.
11137513|NCT03813654|No Intervention|Control (Group A)|During the intervention block of the Field Trial, at the end of the first night shift, the participant will be told about their randomization group. In the control group (Group A), participants will not be given any instructions about the timing or duration of their sleep, but will be instructed to follow their usual night shift sleep routine.
11137514|NCT03813654|Experimental|8-h Afternoon-Evening Sleep (Group B)|In the 8-h afternoon-evening sleep intervention group (Group B), participants will be instructed to go to bed between 13:00 and 14:00 (depending on their individual commute time) and to remain in bed attempting to sleep for 8 hours (until 21:00-22:00) before the next two night shifts.
11137515|NCT03813654|Experimental|8-h Free Sleep (Group C)|In the 8-h free sleep group (Group C), participants will be instructed to remain in bed for 8 continuous hours before the next two night shifts, but will not be given any instruction regarding which 8 hours they should sleep.
11137516|NCT03813641|Experimental|RALOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
11137517|NCT03813641|Active Comparator|CAPOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
11137518|NCT03813628|Experimental|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
11137519|NCT03813628|Experimental|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
11137520|NCT03813628|Active Comparator|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
11137521|NCT03813615|Experimental|"Pilot Proof-of-Concept"|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear (breast, prostate, and endometrial) or non-linear (lung) dosing schedule for a minimum of 2 weeks.
11137522|NCT03813615|Experimental|Phase 1a: Dose-Finding / Escalation|Individualized, progressive aerobic training consisting of treadmill walking ranging from a total of 150 mins/wk to 300 mins/wk delivered over 5 sessions/wk following a linear or non-linear dosing schedule for a minimum of 2 weeks.
11137523|NCT03813615|Experimental|Phase 1b: Dose-Expansion|Individualized, progressive aerobic training consisting of treadmill walking delivered to achieve the RP2D identified in the phase 1a trial for a minimum of 2 weeks.
11137524|NCT03813602|Experimental|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
11137525|NCT03813589||PMK patients|Patients already implanted with double chamber pacemaker able to detect automatically congestive heart failure and collect atrial events.
11137526|NCT03813576|Other|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
11137527|NCT03813563||Mix group|Patients who used two balanced salt solutions during icu stay
11137528|NCT03813563||RL group|Patients who have only used lactated Ringer's during icu stay
11137529|NCT03813563||PLA group|Patients who have only used PlasmaLyte during icu stay
11137530|NCT03813550|Other|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
11137531|NCT03813537|No Intervention|Standard of Care|The control will be discharged with standard of care follow-up instructions and scheduled for a standard follow-up clinic visit within 2-3 weeks post-op.
11137532|NCT03813537|Experimental|Phone Call|The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
11137533|NCT03813524|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
11137534|NCT03813498|Experimental|intervention group|
11137535|NCT03813498|Other|control group|
11137567|NCT03813238|Experimental|Deutetrabenazine|administered as oral tablets at a starting dose of 6 mg once daily
11137568|NCT03813238|Placebo Comparator|Placebo|Matching placebo
11137536|NCT03813485|Active Comparator|Dry needling in upper trapezius|"Patients receive dry needling in latent myofascial trigger point in upper trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
11137537|NCT03813485|Experimental|Dry needling in lower trapezius|"Patients receive dry needling in latent myofascial trigger point in lower trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
11137538|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
11137539|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
11137540|NCT03813459||Subsyndromal delirium positive|Presence of Subsyndromal delirium in Intensive Care patients
11137541|NCT03813459||Delirium positive|Presence of Delirium in Intensive Care patients
11137542|NCT03813459||No delirium|Non subsyndromal delirium or delirium in Intensive Care patients
11137543|NCT03813433|Experimental|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
11137544|NCT03813433|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
11137545|NCT03813420||Physiotherapy students|"Pittsburgh Sleep Quality Index-PSQI:The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month
~International Physical Activity Questionnaire-IPAQ: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as the intensity of physical activity in the last seven days.
~Short Form-36-SF-36: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts."
11137546|NCT03813407|Experimental|Active Arm ( Sodium Zirconium Cyclosilicate SZC)|"This study will enrol males and females aged birth to <18 years with hyperkalaemia, except neonates with a gestational age less than 30 weeks or a birth weight less than 1500 g.
~All subjects are eligible for open-label treatment with SZC during the Correction Phase, and subjects aged 2 to <18 years who are eligible to participate in the Maintenance Phase will be randomised in a 1:1 ratio to double-blinded treatment with SZC or matching placebo comparator."
11137547|NCT03813407|Placebo Comparator|Placebo Arm|To compare the effect of SZC vs placebo on maintaining normokalaemia during the MP.28-day maintenance phase (MP) primary endpoint (primary analysis endpoint): The proportion of subjects in whom normokalaemia can be maintained throughout the MP.
11137548|NCT03813394|Experimental|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
11137549|NCT03813394|Experimental|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
11137550|NCT03813381|Experimental|Intervention Arm (IA)|Patients randomized in the Intervention Arm (IA) will be given personalized diet based on calorie and protein restriction. Calorie restriction will be up to 600 kcal below patients' energy requirements and the amount of protein will be 0.8g of protein/Kg body weight mostly form plant-origin food.
11137551|NCT03813381|No Intervention|Control Arm (CA)|Participants in the CA will be given information about the importance of a healthy lifestyle in reducing the risk of cancer and will receive a leaflet based on WCRF/AICR recommendations.
11137552|NCT03813355|Experimental|Active stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
11137553|NCT03813355|Sham Comparator|Sham stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations
11137554|NCT03813342|Experimental|Multichannel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 4 channels of visual information, each of which represents a joint angle (right and left hips, right and left knees).
11137555|NCT03813342|Experimental|Single Channel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 1 channel of visual information that encompasses information from 4 lower limb joint angles (right and left hips, right and left knees).
11137556|NCT03813329|Placebo Comparator|Placebo|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of Calcium carbonate
11137557|NCT03813329|Active Comparator|Acute Sodium Bicarbonate|3 doses of calcium carbonate (110 mg·kg-1, 130 mg·kg-1, 160 mg·kg-1), followed by one acute does (300 mg·kg-1) of sodium bicarbonate.
11137558|NCT03813329|Experimental|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
11137559|NCT03813316|Experimental|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
11137560|NCT03813316|Experimental|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
11137561|NCT03813303|Active Comparator|Midazolam group|Midazolam and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist . Complications and procedure and recovery times were recorded for comparison with the Fentanyl group.
11137562|NCT03813303|Active Comparator|Fentanyl group|Fentanyl and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist .Complications and procedure and recovery times have were recorded for comparison with the Midazolam group.
11137563|NCT03813290|Experimental|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.
~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
11137564|NCT03813277|Experimental|Dexmedetomidine|Dexmedetomidine 100microg/ml
11137565|NCT03813264|Experimental|preliminary arm|pairs of patients and their therapists
11137569|NCT03813225|No Intervention|Conventional Analgesia|"These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation for handling an analgesic in cardiovascular surgery, this start in surgery with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.
~and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus."
11137570|NCT03813225|Experimental|Serrato intercostal plane Block|These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.In this Arm the patient will give a bilateral serratus intercostal plane block, will be performed echo-guided puncture in the line anterior axillar with fifth costal arch, whit 21 ml of anesthetic mass, 20 ml of Levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone. and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus
11137571|NCT03813199|Experimental|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks
~+ methotrexate"
11137572|NCT03813199|Experimental|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks
~+ methotrexate"
11137573|NCT03813199|Placebo Comparator|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks
~+ methotrexate"
11137574|NCT03813186|Experimental|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
11137575|NCT03813186|Experimental|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
11137576|NCT03813173|Active Comparator|central cervical dissection|
11137577|NCT03813173|Experimental|non central cervical dissection|
11137578|NCT03813160|Experimental|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
11137579|NCT03813160|Experimental|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
11137580|NCT03813160|Placebo Comparator|Placebo|Subjects will receive placebo twice daily
11137581|NCT03813147|Experimental|Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)|Patients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of each cycle. Patients then receive azacitidine IV over 15 minutes QD on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients with CNS2 or CNS3 receive cytarabine intrathecally or methotrexate intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and 11-34. Cycles continue for 35 days in the absence of disease progression or unacceptable toxicity. Patients with stable or greater with non-hematologic toxicities probably or definitely related to pevonedistat may receive an additional cycle of treatment.
11137582|NCT03813134|Active Comparator|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg).
~No mechanical support device allowed."
11137583|NCT03813134|Experimental|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
11137584|NCT03813121|Experimental|midazolam intravenous infusion|single midazolam infusion (0.02 mg/kg over 20 minutes)
11137585|NCT03813121|Placebo Comparator|placebo intravenous infusion|single placebo infusion (saline over 20 minutes)
11137586|NCT03813121|Experimental|ketamine intravenous infusion|single ketamine infusion (0.5 mg/kg over 20 minutes)
11137587|NCT03813108|Experimental|1: 3: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
11137588|NCT03813108|Experimental|2: 3: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
11137589|NCT03813108|Experimental|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
11137590|NCT03813108|Experimental|4: 3: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
11137591|NCT03813108|Other|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
11137592|NCT03813108|Other|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
11137593|NCT03813108|Other|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
11137594|NCT03813095|Experimental|APH-1501 400mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
11137595|NCT03813095|Experimental|APH-1501 600mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 600mg BID ( twice daily) for 28 days.
11137596|NCT03813095|Experimental|APH-1501 800mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 800mg BID ( twice daily) for 28 days.
11137638|NCT03812744|Experimental|WCCE|
11137597|NCT03813095|Placebo Comparator|Placebo Comparator: Placebo|Nano-encapsulated for oral delivery. The study is planned for patients to receive a placebo dose BID ( twice daily) for 28 days.
11137598|NCT03813082|Experimental|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
11137599|NCT03813082|Experimental|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
11137600|NCT03813069|Other|Laboratory study|
11137601|NCT03813069|Other|Field study: IR3535|
11137602|NCT03813069|Other|Field study: Permethrin lower dose|
11137603|NCT03813069|Other|Field study: Permethrin higher dose|
11137604|NCT03813069|No Intervention|Field study: control arm|
11137605|NCT03813056|Experimental|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
11137606|NCT03813056|Placebo Comparator|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
11137607|NCT03813043|Other|Midazolam|Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly
11137608|NCT03813030|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
11137609|NCT03813030|Experimental|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
11137610|NCT03813004|Experimental|Young healthy adults|
11137611|NCT03812991|No Intervention|Non-Treatment Group|This is the Non-Treatment Arm of the study. No intervention is to be administered.
11137612|NCT03812991|Experimental|Miacalcin Calcitonin Salmon Nasal Spray|1 spray (200 IU) qDay, alternate nostrils daily
11137613|NCT03812978|No Intervention|Control|Standard treatment
11137614|NCT03812978|Experimental|Intervention|Standard treatment and intervention (Smart phone application)
11137615|NCT03812965|Experimental|Group 1 - Botulinum Toxin type A (4 points of application)|4 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle and Levators labii superioris muscle (n=10 Patients)
11137616|NCT03812965|Experimental|Group 2 - - Botulinum Toxin type A (2 points of application)|2 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle (n=10 Patients)
11137617|NCT03812913||Turner Syndrome|"35 girls with Turner syndrome (except patients with part of a Y chromosome in their karyotype and r(X) cases).
~age : 7 years -16 years and 11 months.
~Psychological evaluation of cognition, social cognition and affective cognition"
11137618|NCT03812913||isolated GHD|"35 girls with isolated Growth Hormone Deficiency (GHD).
~age : 7 years -16 years and 11 months.
~Psychological evaluation of cognition, social cognition and affective cognition"
11137619|NCT03812900|Experimental|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
11137620|NCT03812900|Experimental|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
11137621|NCT03812900|Active Comparator|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
11137622|NCT03812900|Active Comparator|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
11137623|NCT03812874|Experimental|PTX-9908 Injection group|IV injection.
11137624|NCT03812874|Placebo Comparator|Placebo/Vehicle group|IV injection
11137625|NCT03812861|Experimental|CAMDS bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients with the help of a cognitive aid bundle
11137626|NCT03812861|No Intervention|No bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients without the help of a cognitive aid bundle
11137627|NCT03812848|No Intervention|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
11137628|NCT03812848|Experimental|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
11137629|NCT03812822|Experimental|Insole Group|Gait and foot posture analysis with and without the insole.
11137630|NCT03812822|No Intervention|Control Group|Gait and foot posture analysis.
11137631|NCT03812809|Experimental|BPI-7711|BPI-7711: 180mg, QD, oral
11137632|NCT03812796|Experimental|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
11137633|NCT03812783|Experimental|HAIC of FOLFIRINOX plus sorafenib|
11137634|NCT03812783|Active Comparator|HAIC of FOLFOX plus sorafenib|
11137635|NCT03812770|Experimental|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
11137636|NCT03812770|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
11137637|NCT03812757||Supraclavicular fossa US scanning|Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
11137640|NCT03812731|Active Comparator|Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2 mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.
~Children in will then receive CEB with 0.2 % ropivacaine 1-ml/kg for maintaining analgesia"
11137641|NCT03812731|Active Comparator|Non- Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2-mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.
~Children in will then receive fentanyl citrate 1-mcg/kg/hr for maintaining analgesia"
11137642|NCT03812718|Active Comparator|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
11137643|NCT03812718|Active Comparator|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
11137644|NCT03812705|Experimental|fecal microbiome transplantation|"Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;
~If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;
~If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
11137645|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
11137646|NCT03812666||Severe stroke|Patients with severe (defined as NIHSS score of > 10) acute stroke, either ischemic or hemorrhagic. (n= 150)
11137647|NCT03812666||Moderately stroke|Patients with moderately severe (defined as NIHSS score of > 5 but < 11) acute stroke, either ischemic or hemorrhagic. (n= 25)
11137648|NCT03812666||Mild stroke|Patients with mild (defined as NIHSS score of <6) acute stroke, either ischemic or hemorrhagic. (n= 25)
11137649|NCT03812653|Experimental|Intervention Arm: CPAP with Usual Care.|6 months of CPAP plus usual medical therapy.
11137650|NCT03812653|No Intervention|Control Arm: Usual Care.|6 months of usual medical therapy alone.
11137651|NCT03812640|Experimental|Vicryl|Vicryl suture
11137652|NCT03812640|Active Comparator|Nylon|Nylon suture
11137653|NCT03812627|Experimental|Re-intervention of hip prosthesis made of ceramic or metal|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
~50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal
~(25 patients by group)"
11137654|NCT03812627|Experimental|Re-intervention of hip prosthesis of stainless steel ball|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
~50 patients for re-intervention of hip prosthesis of stainless steel ball."
11137655|NCT03812627|Experimental|Re-intervention of knee prosthesis|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.
~50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal."
11137656|NCT03812627|Experimental|Dead patients IMD holders autopsied|Autopsy: 80 dead patients IMD holders will be autopsied.
11137657|NCT03812627|Active Comparator|Dead patients non-IMD holders autopsied|Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.
11137658|NCT03812627|Active Comparator|patients before first prosthesis surgery|Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done
11137659|NCT03812614|Experimental|FAM ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:
~Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.
~Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting approximately 2 ½ hours each.
~Receive case management contacts with a Community Health Worker (CHW) every 2-4 weeks for approximately 20 minutes each time for the remainder of the 12-month enrollment period."
11137660|NCT03812614|Active Comparator|I-DSME + CM|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:
~Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.
~Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting approximately 2 hours each.
~Receive case management contacts with a Community Health Worker (CHW) every 2-4 weeks for approximately 20 minutes each time for the remainder of the 12-month enrollment period."
11137661|NCT03812588|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
11137662|NCT03812588|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
11137663|NCT03812588|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
11137664|NCT03812588|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
11137665|NCT03812575||Active eosinophilic esophagitis|
11137666|NCT03812575||Eosinophilic esophagitis in remission|
11137667|NCT03812575||No eosinophilic esophagitis|
11137668|NCT03812562|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
11137669|NCT03812549|Experimental|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.
~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
11137670|NCT03812536|No Intervention|Void|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
11137671|NCT03812536|Experimental|No Void|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
11137672|NCT03812523|Active Comparator|Control|Duloxetine 60 mg qd
11137673|NCT03812523|Experimental|Intervention|Lorcaserin 10 mg bid
11137674|NCT03812510|Experimental|A-101|Topical Solution
11137675|NCT03812497|Experimental|Obese Children Group|To reduce the weight, every obese children will receive individualized education program about a way of dietary control and exercise in their usual life. This individualized education program, developed by investigators, specialized dietitian and exercise teacher, is scheduled once a month.
11137676|NCT03812497|No Intervention|Normal Weight Children Group|Normal weight children
11137677|NCT03812484|Experimental|SCF Parole|Parolee supervised under the SCF Supervision model
11137678|NCT03812484|Active Comparator|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
11137679|NCT03812471|Experimental|Main study: 3D volumes acquisitions|3D volume acquisitions
11137680|NCT03812471|Experimental|Ancillary study: 2D and 3D acquisitions|2D standard measurements and 3D volumes acquisitions
11137681|NCT03812458|Experimental|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
11137682|NCT03812458|No Intervention|Control|The families who will not receive the brochure and are not encouraged to visit the website.
11137683|NCT03812445|No Intervention|No Intervention|the patients in this arm will not receive probiotics.
11137684|NCT03812445|Experimental|Experimental|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus for 3 months.
11137685|NCT03812432|Experimental|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
11137686|NCT03812419|Active Comparator|group I|Esomeprazole 40 mg capsules once daily for 6 months
11137687|NCT03812419|Active Comparator|group II|Pantoprazole 40 mg tablets once daily for 6 months
11137688|NCT03812406|Experimental|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
11137689|NCT03812406|Active Comparator|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
11137690|NCT03812393|Experimental|Treatment|TNBC patients with HER2 signal positive are treated with neratinib for 3 weeks followed by 12 weeks of neratinib in combination with weekly paclitaxel and carboplatin
11137691|NCT03812380|Experimental|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
11137692|NCT03812380|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
11137693|NCT03812367||Group 1|The denosumab naïve group
11137694|NCT03812367||Group 2|The zoledronic acid naïve group
11137695|NCT03812367||Group 3|The chronic denosumab (> 1 year with at least 3 biannual injections)
11137697|NCT03812354|Active Comparator|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
11137698|NCT03812354|Experimental|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.
~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand."
11137699|NCT03812328|Experimental|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
11137700|NCT03812328|Active Comparator|Enoxaparin|SC, QD for up to 10 ± 2 days
11137701|NCT03812328|Experimental|SelK2|I.V., single-dose
11137702|NCT03812315|Experimental|Propolis chewing gum|2 % pure raw propolis, 20-35% gum base, 2.5% flavors, 0.3% sorbitol and 0.3% coloring substance. Children will be instructed to chew the specially prepared propolis chewing gum for at least 20 minutes, twice daily, after breakfast and before bedtime.
11137703|NCT03812315|Active Comparator|Propolis mouthwash|The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
11137704|NCT03812302|Experimental|DOTATATE|All 15 GCA patients will undergo 68-Ga HA-DOTATATE PET/CT imaging at baseline, in addition to FDG PET/CTA (as part of standard of care). DOTATATE PET/CT imaging will be repeated at 6 months follow-up.
11137705|NCT03812289|Experimental|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
11137706|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
11137707|NCT03812263|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
11137708|NCT03812250|Active Comparator|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
11137709|NCT03812250|Active Comparator|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
11137710|NCT03812237|Experimental|(EWB) Early Weight Bearing (2 Weeks Post-op)|Subjects in the EWB group were allowed to begin bearing 50 pounds (lbs) through their hindfoot in either the boot or the short leg cast at the two-week visit. They were allowed to advance their weightbearing as tolerated by 25 lbs every four days until full weightbearing through the hindfoot was achieved.
11137711|NCT03812237|No Intervention|(SOC) Standard of Care Weight Bearing (6-8 Weeks Post-op)|Subjects in the SOC group were allowed to heel touch weightbear for balance only on the operative foot until the six to eight week visit. At this visit all subjects were placed into a short leg walking boot. Non-weightbearing patients were permitted to begin the progressive weightbearing protocol, without hindfoot restriction.
11137712|NCT03812224|Active Comparator|Erenumab|Dose 1 erenumab
11137713|NCT03812224|Placebo Comparator|Placebo|Placebo
11137714|NCT03812211|Active Comparator|Active Supplement|Participants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
11137715|NCT03812211|Placebo Comparator|Placebo|Participants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
11137716|NCT03812198|Active Comparator|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
11137717|NCT03812198|Active Comparator|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
11137718|NCT03812198|Experimental|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.
~The formulation depends on the outcome of Part 1."
11137719|NCT03812198|Experimental|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.
~The formulation depends on the outcome of Part 1."
11137720|NCT03812198|Experimental|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.
~The formulation depends on the outcome of Part 1."
11137721|NCT03812198|Placebo Comparator|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
11137722|NCT03812198|Placebo Comparator|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
11137723|NCT03812185|No Intervention|TEE image before suctioning orogastric tube|for intraoperative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. This Arm is TEE image BEFORE suctioning.
11137724|NCT03812185|Experimental|TEE image after suctioning orogastric tube|This Arm is TEE image AFTER suctioning
11137725|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
11137726|NCT03812159|Experimental|Presurgical planning|Undergo crania-vault reconstruction following the presurgical planning (iCSPlan)
11137727|NCT03812146|Experimental|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
11137872|NCT03811236|Experimental|Cold exposure|
11137728|NCT03812146|Active Comparator|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
11137729|NCT03812133||Surgical patients|Patients who were electively scheduled for surgery.
11137730|NCT03812120|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
11137731|NCT03812120|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
11137732|NCT03812107|Experimental|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
11137733|NCT03812107|Active Comparator|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
11137734|NCT03812094|Active Comparator|Basic Bladder advice|Basic bladder advice as given from a pre-specified document, study nurse
11137735|NCT03812094|Active Comparator|Alarm|Alarm Enurad 400
11137736|NCT03812094|No Intervention|No treatment|No treatment during study period.
11137737|NCT03812081|Active Comparator|Group A Baska Mask|In which Baska Mask Airway (size 3,4,5) will used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
11137738|NCT03812081|Active Comparator|Group B Proseal Mask|In which Laryngeal Mask Airway- Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
11137739|NCT03812068|Experimental|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
11137740|NCT03812068|Active Comparator|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
11137741|NCT03812055||LSD|Subjects diagnosed or suspected to have any of the following lysosomal storage diseases: Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidoses.
11137742|NCT03812055||Control|Subjects with no known lysosomal storage disorder
11137743|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
11137744|NCT03812029|Experimental|EYP001a Dose 1|Oral dose twice daily for 12 weeks (84 days)
11137745|NCT03812029|Experimental|EYP001a Dose 2|Oral dose once daily for 12 weeks (84 days)
11137746|NCT03812029|Experimental|EYP001a Dose 3|Oral dose once daily for 12 weeks (84 days)
11137747|NCT03812029|Placebo Comparator|Placebo|Oral dose twice daily for 12 weeks (84 days)
11137748|NCT03812016|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time ( duration: 30-120 mins/each time) and 3 times within 3 months.
~Intervention: using the magnetic device prototype"
11137749|NCT03812003|Experimental|remifentanil|After emergence and extubation of endotracheal tube, remifentanil 1mcg/kg were diluted with 0.9% saline to 50 ml, added in IV bag, and drip for 30 minutes.
11137750|NCT03812003|No Intervention|no intervention|After emergence and extubation of endotracheal tube, 0.9% saline 50ml were added in IV bag and drip for 30 minutes.
11137751|NCT03811990|No Intervention|Control|
11137752|NCT03811990|Active Comparator|Intervention|
11137753|NCT03811977|Experimental|Test group|Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.
11137754|NCT03811977|Placebo Comparator|Placebo group|Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.
11137755|NCT03811964|Other|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
11137756|NCT03811964|Other|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
11137757|NCT03811964|Other|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
11137758|NCT03811964|Other|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
11137759|NCT03811964|Other|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
11137760|NCT03811964|Other|group control|healthy subject
11137761|NCT03811951|Experimental|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
11137762|NCT03811951|Experimental|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
11137763|NCT03811938|Active Comparator|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
11137764|NCT03811938|Experimental|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
11137765|NCT03811925|Other|DCB|
11137766|NCT03811925|Other|Stenting|
11137769|NCT03811899|Experimental|18F-DCFPyL PET/CT imaging|We will use technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
11137770|NCT03811886|Experimental|Phase I: Natalizumab|"Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg
~Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study."
11137771|NCT03811873|Other|Intervention|Single-Arm trial
11137772|NCT03811860|Active Comparator|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
11137773|NCT03811860|Active Comparator|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
11137774|NCT03811847|Experimental|Methylphenidate|During this study, participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order.
11137775|NCT03811847|Placebo Comparator|Placebo|During this study the participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order. Placebo is being used in this study to compare to see if any improvements in cognition other areas are due to the study drug or due to other reasons.
11137776|NCT03811834|Experimental|TAK-788 160 mg + [14C]-TAK-788 50 mcg|[14C]-TAK-788 160 mg TAK-788 160 mg, unlabeled capsule, orally, once under fasted state, followed by [14C]-TAK-788 50 mcg (approximately 2 mcCi), infusion, intravenously over 15 minutes, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by [14C]-TAK-788 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
11137777|NCT03811821|Active Comparator|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
11137778|NCT03811821|Active Comparator|Sacral Nerve Stimulation (SNS)|Wire electrode inserted to S3 or S4, connected to stimulator. This involves two surgical procedures and a clinic visit of 45 minutes duration at weeks 0, 2 and 6 weeks respectively.
11137779|NCT03811821|Active Comparator|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
11137780|NCT03811808||MSA patients|patients diagnosed with possible or probable multiple system atrophy
11137781|NCT03811795|Other|Arm 1-Repeat Cryoballoon Ablation|Subjects will be randomized to repeat cryoballoon ablation.
11137782|NCT03811795|Other|Arm 2-Radiofrequency Ablation|Participants will have radiofrequency ablation guided by high-fidelity mapping (Rhythmia) following an initial cryoballoon ablation.
11137783|NCT03811782|Experimental|Single-task Training Group|Single-task walking group
11137784|NCT03811782|Experimental|Dual-task Training Group|Dual-task walking group
11137785|NCT03811782|Experimental|Analogy Training Group|Analogy walking group
11137786|NCT03811769|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
11137787|NCT03811769|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best medical treatment
11137788|NCT03811756|Active Comparator|Test group|Participants will receive investigational product - Test syrup containing CoQ10 and collagen (daily dose 10 mL: fish collagen (Peptan®): 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg).
11137789|NCT03811756|Placebo Comparator|Placebo group|Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
11137790|NCT03811743|Experimental|Adolescents Participants|Adolescents will participate in the Dyad Plus program along with their caregivers. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
11137791|NCT03811743|Experimental|Caregivers of adolescents participants|Adult caregivers will participate in the Dyad Plus program along with their youth participants. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
11137792|NCT03811730|Experimental|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
11137793|NCT03811730|Active Comparator|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
11137794|NCT03811717|Experimental|FAST+EX - FAST|FAST+EX then FAST alone
11137795|NCT03811717|Experimental|FAST - FAST+EX|FAST alone then FAST+EX
11137796|NCT03811704|Experimental|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
11137797|NCT03811691|Other|1.5 Tesla MRI Scan|Subjects will undergo 1.5T MRI exam
11137798|NCT03811691|Other|3 Tesla MRI Scan|Subjects will undergo 3T MRI exam
11137799|NCT03811678|Experimental|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
11137800|NCT03811678|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
11137801|NCT03811678|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
11137802|NCT03811678|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
11137803|NCT03811678|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
11137804|NCT03811678|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
11137805|NCT03811678|Experimental|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
11137806|NCT03811678|Experimental|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
11137807|NCT03811678|Experimental|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
11137808|NCT03811665|Experimental|Stereotactic body radiation therapy (SBRT)|
11137809|NCT03811665|Active Comparator|Radiofrequency Ablation (RFA)|
11137810|NCT03811652|Experimental|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
11137811|NCT03811652|Experimental|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
11137812|NCT03811652|Experimental|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
11137813|NCT03811652|Experimental|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
11137814|NCT03811652|Experimental|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
11137815|NCT03811652|Experimental|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
11137816|NCT03811639|Active Comparator|RF ablation|Patients treated with point-by-point radio-frequency ablation
11137817|NCT03811639|Experimental|Cryoballoon ablation|Patients treated with cryoballoon ablation
11137818|NCT03811626|Experimental|Intervention|Patient who underwent cognitive-behavioral rehabilitation
11137819|NCT03811626|No Intervention|Comparator|Patient with no specific management
11137820|NCT03811613|Experimental|Photobiomodulation group|"17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).
~Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks."
11137821|NCT03811613|Sham Comparator|Sham group|"18 Parkinson´s disease patients were randomly assigned to the sham group.
~Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group)."
11137822|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
11137823|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
11137824|NCT03811587|Experimental|Treatment group|Diabetes type 2 patients will take a fasting mimicking diet of 5 consecutive days a month, for a duration of 12 months. Besides this, they will receive usual diabetes care from the general practitioner.
11137825|NCT03811587|No Intervention|Control group|Diabetes type 2 Patients will have no intervention, they will receive usual diabetes care from the general practitioner.
11137826|NCT03811574|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue semaglutide 2.4 mg until week 68.
11137827|NCT03811574|Placebo Comparator|Placebo (semaglutide 2.4 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg/week), until the target dose (2.4 mg) is reached after 16 weeks. Participants will continue placebo (semaglutide 2.4 mg) until week 68.
11137828|NCT03811574|Experimental|Semaglutide 1.7 mg|Participants will receive semaglutide injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue semaglutide 1.7 mg until week 68.
11137829|NCT03811574|Placebo Comparator|Placebo (semaglutide 1.7 mg)|Participants will receive placebo (semaglutide) injections once-weekly for 68 weeks. Participants will be initiated at a once-weekly dose of 0.25 mg and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0 and 1.7 mg/week), until the target dose (1.7 mg) is reached after 12 weeks. Participants will continue placebo (semaglutide 1.7) until week 68.
11137830|NCT03811561|Experimental|Semaglutide|Participants will receive semaglutide once weekly as subcutaneous (s.c., under the skin) injection added to standard of care.
11137831|NCT03811561|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) once weekly as subcutaneous subcutaneous (s.c., under the skin) injection added to standard of care.
11137832|NCT03811548|Experimental|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
11137833|NCT03811548|Experimental|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
11137834|NCT03811548|Experimental|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
11137835|NCT03811535|Experimental|Somapacitan weekly|Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
11137836|NCT03811535|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks (main trial period).
11137837|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
11137838|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
11137839|NCT03811509|Active Comparator|AI with osteoporosis|Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
11137840|NCT03811509|No Intervention|AI without osteoporosis|All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
11137841|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
11137842|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
11137843|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
11137844|NCT03811483||Female gender|
11137845|NCT03811483||Male gender|
11137846|NCT03811470||1|Patients with diabetes mellitus including: type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
11137847|NCT03811457|Experimental|Welgenaleucel (UWC19)|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage: 100mL in total Frequency:the first day, the second day, the third day Duration:total three times
11137848|NCT03811444|Experimental|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
11137849|NCT03811444|Experimental|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
11137850|NCT03811444|Experimental|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
11137851|NCT03811431|Experimental|CEUS guidance|SonoVue 2, 4 ml
11137852|NCT03811431|Experimental|Conventional US guidance|No drugs
11137853|NCT03811418|Experimental|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
11137854|NCT03811418|Active Comparator|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
11137855|NCT03811405|Experimental|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
11137856|NCT03811392|Active Comparator|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
11137857|NCT03811392|Active Comparator|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
11137858|NCT03811379|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
11137859|NCT03811353||Children with cerebral palsy|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
11137860|NCT03811353||Healthy children|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
11137861|NCT03811327|Experimental|Treatment group|Zero-time Exercise group
11137862|NCT03811327|No Intervention|Waitlist group|
11137863|NCT03811314|Experimental|Strength training|Muscle strength training programs
11137864|NCT03811314|Experimental|Aerobic training|Aerobic training programs
11137865|NCT03811301|Experimental|Interventional|Wireless Implantable Neurodevice Microsystem
11137866|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
11137867|NCT03811275|Experimental|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
11137868|NCT03811275|Experimental|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
11137869|NCT03811262|Active Comparator|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
11137870|NCT03811262|Active Comparator|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
11137871|NCT03811249|Experimental|Implantation-Non-randomized|Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively for an additional 36 month period to measure long term safety and effectiveness outcomes.
11137874|NCT03811223|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
11137875|NCT03811223|Placebo Comparator|Placebo|Placebo injection once every 2 weeks for 12 weeks
11137876|NCT03811197|Experimental|individual MNT|Dietary counseling via face to face meeting
11137877|NCT03811197|Experimental|Individual MNT and T|Dietary counseling via face to face meeting and Telemedicine
11137878|NCT03811197|Experimental|Individual MNT and HS|Dietary counseling via face to face meeting and Hypnotic Suggestions
11137879|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
11137880|NCT03811158|Experimental|HHHFNC group|On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
11137881|NCT03811158|Sham Comparator|UHFOM group|On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min
11137882|NCT03811145|Experimental|Tendoncel|Topically applied experimental gel - Tendoncel. 80ul applied once a day for 21 consecutive days.
11137883|NCT03811145|Placebo Comparator|Placebo control gel|Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
11137884|NCT03811132||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
11137885|NCT03811132||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
11137886|NCT03811132||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
11137887|NCT03811132||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
11137888|NCT03811119|Active Comparator|MANTA vascular closure device|Arteriotomy closure with a collagen-based vascular closure device (MANTA™)
11137889|NCT03811119|Active Comparator|Suture based vascular closure device|Arteriotomy closure with 2 or more suture-based vascular closure devices (ProGlide)
11137890|NCT03811106|Active Comparator|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
11137891|NCT03811106|Other|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
11137892|NCT03811093|Experimental|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
11137893|NCT03811093|Placebo Comparator|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
11137894|NCT03811080|Experimental|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
11137895|NCT03811080|Experimental|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
11137896|NCT03811080|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
11137897|NCT03811067|No Intervention|Control group|
11137898|NCT03811067|Active Comparator|TAP group|Transversus abdominis plane block administered group
11137899|NCT03811067|Active Comparator|RS group|Rectus sheath block administered group
11137900|NCT03811054|Experimental|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
11137901|NCT03811041|Experimental|PC articulated with MDA|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.
11137902|NCT03811041|Active Comparator|Routine cares|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.
11137903|NCT03811041|Experimental|Parental depression|Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.
11137904|NCT03811028|Experimental|SOBI003|"SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.
~SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined."
11137933|NCT03810872|Other|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
11137934|NCT03810859|Experimental|All patients|Blood sample
11137905|NCT03811015|Experimental|Arm A (cisplatin, IMRT, nivolumab)|Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions. Within 4 weeks after completion of concurrent therapy, patients receive nivolumab IV once weekly over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
11137906|NCT03811015|Active Comparator|Arm B (cisplatin, IMRT, observation)|"Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions, and then go on observation.
~Patients will be offered the option to cross-over to Arm C if they have clearly documented progression within 12 months from the end of cisplatin/radiation therapy."
11137907|NCT03811015|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
11137908|NCT03811002|Experimental|Arm I (etoposide, cisplatin, carboplatin, radiation therapy)|Patients receive etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D-CRT or IMRT BID for approximately 3 weeks or QD for approximately 6-7 weeks in the absence of disease progression or unacceptable toxicity.
11137909|NCT03811002|Active Comparator|Arm II (etoposide, cisplatin, carboplatin, radiation therapy)|Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
11137910|NCT03810989|Experimental|infra-red sauna|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
11137911|NCT03810989|Experimental|argometer and treadmill|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
11137912|NCT03810989|Experimental|combination of sauna and hot bath|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
11137913|NCT03810989|Experimental|combination of sauna and hot bath in CKD|During the ﬁrst month (control phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be calculated. During the next two months (intervention phase) the patient will be subjected to three session of sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the patients will be immersed up to neck for one hour in water at 37 -43 C .
11137914|NCT03810976|Experimental|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
11137915|NCT03810963|Experimental|FES Cycling and Nutrition Counseling|"Device:
~HIIT-FES cycling will be performed 30 minutes per session, 3 times per week for 3 weeks combined with
~Behavior:
~Nutrition counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
11137916|NCT03810963|Other|Nutritional Counseling Only|"Behavior:
~Nutritional counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
11137917|NCT03810950|Experimental|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
11137918|NCT03810950|Active Comparator|Control Condition|Participants reads newspaper before Barlab-Exposure
11137919|NCT03810937|Active Comparator|Group sniffing (S)|intervention: Head position changes : we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.
11137920|NCT03810937|Active Comparator|Group Flat (F)|intervention: Head position changes same procedure will be done but starting from sniffing position and the patient will be intubated in flat position.
11137921|NCT03810924|Active Comparator|Control|Participants reads newspaper before Barlab-Exposure
11137922|NCT03810924|Experimental|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
11137923|NCT03810924|Experimental|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
11137924|NCT03810911|Active Comparator|Early start|Participants given study drug immediately at randomization
11137925|NCT03810911|No Intervention|Delayed start|Participants given study drugs 12 weeks after randomization
11137926|NCT03810898|Experimental|Phase 1 (a & b)|"Radioligand [¹¹C]CHDI-00485180-R and/or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 young (< 35) HCs/ Imaging- MRI and PET/
~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
11137927|NCT03810898|Experimental|Phase 2a|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/
~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs
~1 Radioligand administered 1x- HCs/"
11137928|NCT03810898|Experimental|Phase 2b|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/
~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs
~1 Radioligand administered 1x -HCs/"
11137929|NCT03810898|Experimental|Phase 2c|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/
~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs
~1 Radioligand administered 1x- HCs/"
11137930|NCT03810885|Experimental|Salt reduced bread|Bread with reduced salt content
11137931|NCT03810885|Experimental|Dietary advice and Salt reduced bread|bread with reduced salt content, dietary advice
11137932|NCT03810885|Placebo Comparator|Normal bread|Bread with standard salt content
11137936|NCT03810833|Experimental|Participants with Brilliance sensor placement|Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
11137937|NCT03810820|Other|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
11137938|NCT03810807|Experimental|Dacomitinib and Osimertinib|"Patients will begin on combination dacomitinib and osimertinib at the prescribed doses.
~A cycle will be 28 days in duration. The study will use a standard 3+3 dose escalation design."
11137939|NCT03810794|Experimental|Acupuncture Treatment Group|Participants in this group will be given acupuncture treatment in combination with donepezil for 12 weeks.
11137940|NCT03810794|Active Comparator|Donepezil Group|Participants in this group will be given only donepezil for 12 weeks.
11137941|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
11137942|NCT03810768||Intensive Care Patients|Postoperative high-risk patients who have been admitted to intensive care after surgery
11137943|NCT03810755|Other|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
11137944|NCT03810755|Other|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
11137945|NCT03810742|Experimental|Nanoliposomal Irinotecan + TAS-102|different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
11137946|NCT03810729|Active Comparator|Modified Allen's Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on the participant's hand. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
11137947|NCT03810729|Active Comparator|Smartphone assessment|The smartphone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's index finger and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
11137948|NCT03810716|Experimental|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
11137949|NCT03810716|No Intervention|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
11137950|NCT03810703|Placebo Comparator|placebo arm|Participant will receive placebo oral capsule during this four hour session.
11137951|NCT03810703|Experimental|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
11137952|NCT03810703|Experimental|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
11137953|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3704
11137954|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3704
11137955|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3704
11137956|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
11137957|NCT03810690|Experimental|Dose Expansion Phase: mRNA-3704|
11137958|NCT03810677||Patients with varicose veins, eligible for EVLA|
11137959|NCT03810664|Experimental|Somatrogon pre-filled PEN|
11137960|NCT03810664|Active Comparator|Somatrogon frozen liquid formulation|
11137961|NCT03810651|Other|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
11137962|NCT03810638||Heart Failure Patients|All Heart Failure Patients seen at 3 major academic medical centers.
11137963|NCT03810625|Experimental|Sequence AB|D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
11137964|NCT03810625|Experimental|Sequence BA|D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
11137965|NCT03810599|Other|Early cardiac rehabilitation|Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.
11137966|NCT03810586|Experimental|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
11137967|NCT03810573|Experimental|NB1-1.5|NB1 low dose
11137968|NCT03810573|Experimental|NB1-2.0|NB1 high dose
11137969|NCT03810573|No Intervention|Autograft|Autograft
11137970|NCT03810560|No Intervention|open flap debridement|surgical treatment of periodontal pocket without any intervention
11137971|NCT03810560|Active Comparator|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
11137972|NCT03810547|Active Comparator|Spinal anesthesia|Patients undergoing abdominoplasty under spinal anesthesia may need to drug administration like propofol or ketamine or change anesthesia to general anesthesia.
11137973|NCT03810547|No Intervention|General anesthesia|General anesthesia for abdominoplasty
11137974|NCT03810534|Experimental|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
11137975|NCT03810534|No Intervention|Control|Standard discharge planning at the skilled nursing facility only.
11138523|NCT03806933|Experimental|NT 201 Dose group 5|Open Label Extension Period. Intramuscular injection into the glabellar area.
11137976|NCT03810521|Experimental|CLT low-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
11137977|NCT03810521|Experimental|CLT medium-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
11137978|NCT03810521|Experimental|CLT high-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
11137979|NCT03810495|Experimental|OLANI (naltrexone implant)|2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
11137980|NCT03810482|Experimental|The study population|"The study population as described by eligibility criteria.
~Intervention: 6 minute walking test Intervention: pedometer"
11137981|NCT03810456|Active Comparator|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
11137982|NCT03810456|Active Comparator|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
11137983|NCT03810456|No Intervention|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
11137984|NCT03810443|Experimental|pulmonary arterial hypertension|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
11137985|NCT03810430|Active Comparator|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
11137986|NCT03810430|No Intervention|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
11137987|NCT03810417|Active Comparator|Digifab|Digifab intravenous
11137988|NCT03810417|Placebo Comparator|Placebo|saline intravenous
11137989|NCT03810404|Experimental|Sodium bicarbonate supplementation|Group taking oral SB supplementation in a different-dose regimen.
11137990|NCT03810404|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (NaCl).
11137991|NCT03810391|Experimental|preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group A were >11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
11137992|NCT03810391|Placebo Comparator|preoperative anxiety and saline|preoperative anxiety scores of patients in Group B were >11 and received an infusion of the same volume of physiological saline
11137993|NCT03810391|Experimental|non-preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group C were ≤ 11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
11137994|NCT03810391|Placebo Comparator|non-preoperative anxiety and saline|preoperative anxiety scores of patients in Group D were ≤11 and received an infusion of the same volume of physiological saline
11137995|NCT03810378|Experimental|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
11137996|NCT03810378|Experimental|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
11137997|NCT03810365|Experimental|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
11137998|NCT03810365|Active Comparator|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
11137999|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
11138000|NCT03810339|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
11138001|NCT03810326|Experimental|Intervention|
11138002|NCT03810313|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
11138003|NCT03810313|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
11138004|NCT03810300|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
11138005|NCT03810300|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
11138006|NCT03810300|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
11138007|NCT03810300|Experimental|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
11138008|NCT03810300|Experimental|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
11138009|NCT03810300|Experimental|Control|No transfer, no behavior change communication
11138010|NCT03810287|Experimental|Patients receiving Domperidone|Patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.
11138011|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
11138012|NCT03810261|Experimental|Oil-based vitamin D group|Oil-based vitamin D, 1000 IU/day for 8 weeks
11138013|NCT03810261|Experimental|Water-based vitamin D group|Water-based vitamin D, 1000 IU/day for 8 weeks
11138014|NCT03810261|Experimental|Vitamin D capsules group|Vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks
11138015|NCT03810261|No Intervention|Control group|This group will receive no intervention.
11138016|NCT03810235|Active Comparator|Transdermal Lidocaine Patch|Drug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
11138017|NCT03810235|Placebo Comparator|Transdermal Hydrocolloid Placebo Patch|Drug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
11138018|NCT03810209|Active Comparator|magnesium sulphate group|The investigator injected 28.5 mL of bupivacaine 0.5% and 1.5 ml MgSo4 (150 mg), a total volume of 30 ml, it was confirmed visually by the ultrasound.
11138019|NCT03810209|Placebo Comparator|control group|The investigator injected 28.5 mL of Bupivacaine 0.5% and 1.5 mL of normal saline, a total volume of 30 ml, it was confirmed visually by the ultrasound.
11138020|NCT03810196|Other|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
11138021|NCT03810196|Other|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
11138022|NCT03810183|Experimental|QAW039|QAW039 450 mg
11138023|NCT03810183|Placebo Comparator|Placebo|Placebo
11138024|NCT03810170|Active Comparator|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
11138025|NCT03810170|Experimental|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
11138026|NCT03810157|Experimental|Laser-assisted hatching system|Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.
11138027|NCT03810157|No Intervention|Control group|Nothing is done.
11138028|NCT03810144||Vectra Guided|For patients in the guided care arm, treating physicians will receive the Vectra DA MBDA Test score prior to the patient visit and will have a set of guidance for decision-making based on these scores. Treating physicians will be strongly encouraged to follow the guidance but will not be required to do so. For test results to be available at the time of each visit in the MBDA guided treatment arm, blood testing will be performed 7-10 days before the visit.
11138029|NCT03810144||Usual Care|For patients in the UC arm, treating physicians will not have access to MBDA scores until the end of the study.
11138030|NCT03810131|No Intervention|Waitlist control|This is a group who are waiting for treatment (the control group)
11138031|NCT03810131|Experimental|BOA online intervention|The is the group who are receiving the BOA online intervention.
11138032|NCT03810118|Experimental|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
11138033|NCT03810105|Experimental|Castration Sensitive Biochemically Recurrent Prostate Cancer|Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer
11138034|NCT03810079|Active Comparator|Anodal tDCS High Vigilance|Patients will undergo continuous 8 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined high level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
11138035|NCT03810079|Active Comparator|Anodal tDCS Low Vigilance|Patients will undergo continuous 8 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined low level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
11138036|NCT03810079|Sham Comparator|Sham tDCS Random Vigilance|Patients will undergo continuous 8 channels EEG and receive sham tDCS (bilateral prefrontal stimulation) at a random level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
11138037|NCT03810066|Experimental|Osimertinib|
11138038|NCT03810053|Experimental|Mobile App/Online Module|Subjects will watch a short video containing information about cancers and benefits of uptake cancer prevention and early detection measures. Information regarding gender, age, smoking status, BMI and positive cancer history in family will be captured. Subjects will be provided with a list of cancer prevention and early detection measures based on the responses provided.
11138039|NCT03810040|Active Comparator|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
11138040|NCT03810040|Experimental|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
11138041|NCT03810027||OAB with nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Precence of nocturnal polyuria will be classified in this group.
11138071|NCT03809871|No Intervention|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
11138301|NCT03808311|Experimental|Intensive BP treatment arm|Participants in the intensive BP treatment arm will be treated to a systolic BP target of <120 mmHg.
11138042|NCT03810027||OAB without nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Absence of nocturnal polyuria will be classified in this group.
11138043|NCT03810014|Experimental|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
11138044|NCT03810014|Experimental|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
11138045|NCT03810014|Experimental|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
11138046|NCT03810014|Experimental|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
11138047|NCT03810001|No Intervention|standard ICSI procedure|a single spermatozoon was injected into the ooplasm
11138048|NCT03810001|Experimental|modified ICSI procedure|slight mechanical stimulation before standard ICSI procedure
11138049|NCT03809988|Experimental|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
11138050|NCT03809988|Active Comparator|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
11138051|NCT03809975|Active Comparator|Control Arm|"Current model of care
~Patients will undergo the current standard of care in the Orthopaedic Outpatient Clinic in Tan Tock Seng Hospital. Patients will undergo routine consultation with an orthopaedic surgeon and will be provided with standard treatment as necessitated based on the assessment of the orthopaedic surgeon. Subsequent follow up appointments will be scheduled at the discretion of the orthopaedic surgeon. Patients will be referred to the physiotherapists, dietitian and psychologists as necessary for regular or adhoc sessions at the discretion of the allied health professional."
11138052|NCT03809975|Experimental|Intervention Arm|"Multidisciplinary Community Program
~Community based, personalized, structured, 12-week multidisciplinary program that includes Orthopaedics, Physiotherapy, Dietitics, Psychology interventions. This intervention involves the use of formal assessment such as BMI and psychological questionnaires to determine the need for dietetics or psychological intervention. In addition, there are educational sessions to improve patient's understanding of osteoarthritis and improve their activation level. An optional support group session will be arranged at approx. 3-4 months after completion of the 12-week intervention program to improve sustainability of treatment effect."
11138053|NCT03809962||Ostenil® Plus|1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
11138054|NCT03809949|Active Comparator|Fentanyl Opioid Anesthesia|Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
11138055|NCT03809949|Placebo Comparator|Saline Nonopioid Anesthesia|Opioid free anesthesia (syringe of saline is given instead of fentanyl) and the same general anesthesia is given as group A(muscle relaxant ,propofol, inhalation for maintance).
11138056|NCT03809936|Active Comparator|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
11138057|NCT03809936|Sham Comparator|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
11138058|NCT03809923|Experimental|Dexmedetomidine Combined With Lidocaine Infusion Affect PONV|
11138059|NCT03809923|Experimental|Effect of infusion saline on PONV|
11138060|NCT03809923|Experimental|Effect of infusion lidocaine on PONV|
11138061|NCT03809923|Experimental|Effect of infusion dexmedetomidine on PONV|
11138062|NCT03809910|Experimental|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
11138063|NCT03809910|Experimental|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
11138064|NCT03809910|Sham Comparator|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
11138065|NCT03809910|Active Comparator|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
11138066|NCT03809897|Experimental|Varenicline|Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
11138067|NCT03809897|Active Comparator|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21 mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
11138068|NCT03809884|Experimental|Dietary Counselling|All enrolled patients will undergo a 1:1 counselling with a registered dietitian (with possible inclusion of family members, as appropriate). The dietitian will undertake an assessment of the comorbidities (e.g. diabetes), dietary intake, dietary habits (e.g. eating out, food preparation, socio-cultural aspects) and provide an individually tailored strategy to increase potassium in the diet. Secondly, on a weekly basis, the dietitian will contact the patient by telephone, or electronically (as preferred by the patient) to reinforce the advice and provide support/advice as necessary.
11138069|NCT03809884|Active Comparator|Potassium Citrate Supplement|Patients who are not able to successfully increase their potassium intake at 4 weeks with dietary counselling will receive potassium citrate supplements. They will receive oral potassium supplementation in the form of 50 to 100 mmol of potassium citrate (as 25 to 50 ml of the liquid solution).
11138070|NCT03809871|Experimental|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
11138514|NCT03806946||group1|ADHD with normal EEG
11138515|NCT03806946||group 2|ADHD with abnormal EEG
11138072|NCT03809858|Experimental|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
11138073|NCT03809858|Experimental|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
11138074|NCT03809845|Active Comparator|Motor neuron disease|
11138075|NCT03809845|Active Comparator|Benign fasciculation syndrome|
11138076|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
11138077|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
11138078|NCT03809819||Patients with MRKHS|Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
11138079|NCT03809819||Control group|A control group of 13 age-matched, childless, sexually active women
11138080|NCT03809806|Other|patients after hysterectomy|modified anterior transvaginal mesh surgery
11138081|NCT03809793|Active Comparator|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
11138082|NCT03809793|Placebo Comparator|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
11138083|NCT03809780|Experimental|Lenalidomide,dexamethasone|"high dose: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly
~low dose: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly Schedule"
11138084|NCT03809767|Experimental|CS1003 monoclonal antibody|
11138085|NCT03809754|Experimental|OCT-guided PCI|
11138086|NCT03809754|Sham Comparator|Angiography-guided PCI|
11138087|NCT03809741|Experimental|Preventing L&D Infections|Low-cost bundled L&D infection prevention interventions will be implemented, including education, visual reminders, feedback, and alcoholic hand rub supply. Infection control practices and child delivery outcomes will be assessed after implementation of these interventions.
11138088|NCT03809728|Other|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
11138089|NCT03809702|Active Comparator|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
11138090|NCT03809702|Placebo Comparator|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
11138091|NCT03809689|Other|acute infarction|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
11138092|NCT03809689|Other|acute infarction requiring reperfusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
11138093|NCT03809689|Other|chronic ischemic occlusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment
11138094|NCT03809676||heaart transplant recipients|
11138095|NCT03809676||healthy controls|
11138096|NCT03809663|Experimental|Tezepelumab high dose|subcutaneous injection every 2 weeks
11138097|NCT03809663|Experimental|Tezepelumab low dose|subcutaneous injection every 4 weeks
11138098|NCT03809663|Experimental|Tezepelumab medium dose|subcutaneous injection every 2 weeks
11138099|NCT03809663|Placebo Comparator|Placebo|subcutaneous injection every 2 weeks or every 4 weeks
11138100|NCT03809650|Experimental|Open-label treatment period|oral administration of macitentan 10 mg once daily
11138101|NCT03809637|Experimental|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
11138102|NCT03809624|Experimental|Part 1 Escalation|INBRX-105 will be escalated in subjects with locally advanced or metastatic solid tumors.
11138103|NCT03809624|Experimental|Expansion Cohort Non-small Cell Lung Cancer|Subjects will be treated with single-agent INBRX-105 at either the MTD or RP2D.
11138104|NCT03809624|Experimental|Expansion Cohort Melanoma|Subjects will be treated with single-agent INBRX-105 at either the MTD or RP2D.
11138105|NCT03809624|Experimental|Expansion Cohort PD-L1 Basket|Subjects with head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
11138106|NCT03809611|Experimental|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
11138107|NCT03809611|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
11138108|NCT03809598|Experimental|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
11138516|NCT03806946||group 3|Epilepsy
11138109|NCT03809598|No Intervention|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
11138110|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
11138111|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
11138112|NCT03809572|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support.
11138113|NCT03809572|No Intervention|Treatment as usual (TAU)|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
11138114|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
11138115|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
11138116|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
11138117|NCT03809546|Placebo Comparator|Placebo|
11138118|NCT03809546|Active Comparator|7.5 mg THC|
11138119|NCT03809546|Active Comparator|15 mg THC|
11138120|NCT03809533|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Kidney recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.
~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
11138121|NCT03809533|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Starting post-operative day 1, kidney recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
11138122|NCT03809520|Experimental|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
11138123|NCT03809507||NC Clinicians|Qualtrics Survey of NC Clinicians with DEA registration
11138124|NCT03809494|Experimental|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
11138125|NCT03809494|Placebo Comparator|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
11138126|NCT03809481|Experimental|Danaparoid Sodium|Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.
11138127|NCT03809481|Active Comparator|Argatroban|Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.
11138128|NCT03809468|No Intervention|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
11138129|NCT03809468|Experimental|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
11138130|NCT03809455|Experimental|FAR Arm|
11138131|NCT03809455|Placebo Comparator|Placebo Arm|
11138132|NCT03809442|Experimental|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.
~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
11138133|NCT03809442|Experimental|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.
~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.
~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
11138225|NCT03808896|No Intervention|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
11138134|NCT03809442|Experimental|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
11138135|NCT03809442|Experimental|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
11138136|NCT03809442|Experimental|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.
~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.
~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
11138137|NCT03809442|Placebo Comparator|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.
~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
11138138|NCT03809429|Experimental|FE 999049 + GnRH agonist (GONAPEPTYL)|
11138139|NCT03809429|Experimental|FE 999049 + GnRH antagonist (CETROTIDE)|
11138140|NCT03809416|No Intervention|Control|32 biopsy specimens from acne scars will be excised without any treatment.
11138141|NCT03809416|Sham Comparator|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
11138142|NCT03809416|Active Comparator|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
11138143|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
11138144|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
11138145|NCT03809390|Experimental|Vaginal seeding group|Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
11138146|NCT03809390|No Intervention|Control group|Managed based on the standard practice in the study site
11138147|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
11138148|NCT03809364|Experimental|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is anticipated to be 4 sessions in length and conducted weekly.
11138149|NCT03809364|No Intervention|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
11138150|NCT03809351|Experimental|[F-18]AV-1451-PET/MRI|All participants in this study will undergo a tau-PET imaging using the tracer [F-18]AV-1451 with a simultaneous PET/MRI system. The [F-18]AV-1451 dosage is 740MBq (10 mCi) given intravenously, and the PET/MRI imaging will occur 75-105 min after tracer injection.
11138151|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
11138152|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
11138153|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
11138154|NCT03809312|Active Comparator|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
11138155|NCT03809312|Placebo Comparator|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
11138156|NCT03809312|Active Comparator|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
11138157|NCT03809312|Placebo Comparator|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
11138158|NCT03809299|Other|Ad libitum meal timing first|This arm will receive the ad libitum meal timing intervention first, followed by the twice a day feeding intervention.
11138159|NCT03809299|Other|Twice a day meals first|This arm will receive the twice a day feeding intervention first, followed by the ad libitum meal timing intervention.
11138160|NCT03809286|Experimental|Active Stimulation|Participants will be receiving active rTMS.
11138161|NCT03809286|Sham Comparator|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
11138162|NCT03809273|Experimental|Yangxinshi|
11138163|NCT03809273|Active Comparator|Trimetazidine|
11138164|NCT03809260|Experimental|Part 1|Metformin/Vancomycin
11138165|NCT03809260|Experimental|Part 2|Metformin
11138226|NCT03808870|Experimental|NBM-BMX|
11138517|NCT03806946||group 4|Healthy control group
11138166|NCT03809234|Experimental|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
11138167|NCT03809234|Placebo Comparator|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
11138168|NCT03809221|Experimental|early follicular phase down-regulation|Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle. If complete pituitary down-regulation is achieved after 28-42 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours after pre-ovulatory hCG injection transvaginally under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
11138169|NCT03809221|Active Comparator|luteal phase down-regulation|Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle. If complete pituitary down-regulation is achieved after 14-21 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and the serum hormone level and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours later under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
11138170|NCT03809195|Experimental|Hypnosis Intervention|The intervention is clinical hypnosis--a single in-person session followed by instructions to listen to audio recordings at home. The sessions consist of the provider's voice guiding the participant into a relaxed and focused state and providing therapeutic suggestions--for example, to replace discomfort with a more pleasant sensation, to ease anxiety, and to increase energy.
11138171|NCT03809195|No Intervention|Waitlist Control|This group will serve as a control comparison and be offered the intervention after control data collection is complete.
11138172|NCT03809182|Experimental|Dexmedetomidine|After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
11138173|NCT03809182|Placebo Comparator|0.9% Sodium-chloride|After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
11138174|NCT03809169|Experimental|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
11138175|NCT03809169|Experimental|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
11138176|NCT03809169|Experimental|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
11138177|NCT03809169|Experimental|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
11138178|NCT03809156|Experimental|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
11138179|NCT03809143|Experimental|Depot buprenorphine arm|All participants will receive monthly injections of depot buprenorphine (RBP-6000, Sublocade)
11138180|NCT03809130|Experimental|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
11138181|NCT03809130|Active Comparator|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
11138182|NCT03809117|Experimental|Experimental|Gastrointestinal Polymerase Chain Reaction test performed and results communicated to treatment provider. Followed by usual care per treating physician.
11138183|NCT03809117|Active Comparator|Control|Gastrointestinal Polymerase Chain Reaction test performed at the conclusion of the study. Clinician will not be informed of results. Usual Care performed per treating physician.
11138184|NCT03809104|Experimental|elderly with sarcopenia|Virtual reality-based rehabilitation programs
11138185|NCT03809091||Bronchiectasis|The patient with bronchiectasis who has no apparent bronchiectasis-causing etiology will be enrolled. The patient's family who has no bronchiectasis will be also enrolled to identify the patient-specific variants.
11138186|NCT03809078|Experimental|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
11138187|NCT03809078|Experimental|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
11138188|NCT03809065|Experimental|group N|Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
11138189|NCT03809065|Active Comparator|group L|Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .
11138190|NCT03809052|Experimental|A1 - 5 mg GB1211 single dose|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
11138191|NCT03809052|Experimental|A2 - 20 mg GB1211 single dose|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
11138227|NCT03808857|Experimental|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
11138192|NCT03809052|Experimental|A3 - 50 mg GB1211 single dose|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
11138193|NCT03809052|Experimental|A4 - 100 mg GB1211 single dose|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
11138194|NCT03809052|Experimental|A5 - 200 mg GB1211 single dose|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
11138195|NCT03809052|Experimental|B1 - GB1211 multiple ascending doses, dose level 1|GB1211 administered orally twice daily over 10 days. The dosing frequency/interval is to be determined based on data from Part A. Dosing will start following review of safety, tolerability, and PK data from a single dose with exposure higher than the predicted steady-state exposure. The predicted total daily exposure will not exceed the highest exposure observed in Part A. 8 healthy subjects will receive GB1211 and 3 subjects will receive placebo.
11138196|NCT03809052|Experimental|B2 - GB1211 multiple ascending doses, dose level 2|GB1211 administered orally twice daily over 10 days. The dosing frequency/interval is to be determined based on data from Part A and B1. The predicted total daily exposure will not exceed the highest exposure observed in Part A. 8 healthy subjects will receive GB1211 and 3 subjects will receive placebo.
11138197|NCT03809052|Experimental|C1 - Multiple doses of GB1211 in patients|GB1211 administered orally twice daily over 42 days. The dose level of Part C is to be determined following completion of Part A and at least 1 cohort of Part B. The total daily dose administered, dose interval/frequency, and dosing duration will be based on review of data from Parts A and B. 15 subjects will receive GB1211 and 10 subjects will receive placebo.
11138198|NCT03809039|Experimental|Single Ascending Dose: MT-6345 & Placebo|
11138199|NCT03809039|Experimental|Multiple Ascending Dose: MT-6345 & Placebo|
11138200|NCT03809026||Study group|Couples where the men have Klinefelter's syndrome, maturation stop in the spermatogenesis or failed retrieval of testicular sperm by conventional techniques with needle or TruCut, and where testicular sperm could be obtained by micro-TESE.
11138201|NCT03809026||Control group|Couples as in the study group, but where testicular sperm could not be obtained by micro-TESE. The oocytes therefore must be fertilized using donor sperm.
11138202|NCT03809013|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
11138203|NCT03809000|Active Comparator|Salvage Radiation Therapy + Standard ADT|Salvage RT will be given up to 66.60 Gy along with 24 months of a GnRH analog with or without 1-4 months of bicalutamide.
11138204|NCT03809000|Experimental|Salvage Radiation Therapy + Enhanced ADT|Salvage RT will be given up to 66.60 Gy along with 24 months of a GnRH analog + 24 months of enzalutamide.
11138205|NCT03808987|Experimental|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
11138206|NCT03808987|Experimental|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
11138207|NCT03808987|Experimental|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
11138208|NCT03808987|Experimental|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
11138209|NCT03808974|Experimental|Intervention|The intervention group will be shown an educational video
11138210|NCT03808974|Active Comparator|Control|The control group will be given an educational leaflet
11138211|NCT03808961|Active Comparator|Group 1 ? Niacin Arm|Oral 100 mg fixed dose twice daily x 18-months (200 mg total / day) with assessments @ baseline, 6 month, 12 month and 18 months
11138212|NCT03808961|Active Comparator|Group 2 ? Niacinamide Arm|Oral 100 mg fixed dose twice daily (200 mg total / day) x 18-months with assessments @ baseline, 6 month, 12 month and 18 months
11138213|NCT03808961|Placebo Comparator|Group 3 ? Placebo Wait-listed Arm|Oral placebo twice daily x 18- months with assessments @ baseline, 6 month, 12 month and 18 months
11138214|NCT03808948|Experimental|All Patients|VFI dose: 47 mg / 3 mL Number of doses: 2 Route of administration: intravenous
11138215|NCT03808935|Experimental|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
11138216|NCT03808935|Placebo Comparator|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.
~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
11138217|NCT03808922|Experimental|DAS181|DAS181 4.5mg qd x 7 OR 10 days
11138218|NCT03808922|Placebo Comparator|Placebo|Placebo qd x 7 OR 10 days
11138219|NCT03808922|Experimental|DAS181 OL|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (< 40kg)
11138220|NCT03808922|Experimental|DAS181 COVID-19|DAS181 4.5mg q12h x 7 OR 10 days
11138221|NCT03808909|Experimental|Doula|Participants will be assigned a doula.
11138222|NCT03808909|No Intervention|Control|Participants will not be assigned a doula.
11138223|NCT03808896|Active Comparator|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
11138224|NCT03808896|Active Comparator|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
11138230|NCT03808831|Experimental|Experimental groups|Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
11138231|NCT03808831|Sham Comparator|Sham group|In the sham group, subjects wear a sham system with record but no alert function.
11138232|NCT03808818|Active Comparator|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
11138233|NCT03808818|Experimental|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
11138234|NCT03808805|Experimental|studied group|Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days
11138235|NCT03808805|Active Comparator|comparative group|Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days
11138236|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
11138237|NCT03808779|Experimental|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
11138238|NCT03808779|Active Comparator|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
11138239|NCT03808766|Other|Tumor <=3cm|Embolization with particulate or liquid embolic agent
11138240|NCT03808766|Other|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
11138241|NCT03808766|Other|Tumor > 7cm|Embolization with particulate or liquid embolic agent
11138242|NCT03808753|Experimental|Treatment - hemodynamic tests: EEOT and mFC|Interventions: all the enrolled patients will be tested using the EEOT and the mFC.
11138243|NCT03808740|Experimental|Roux-en-Y gastric bypass (RYGB)/Atomoxetine|Participants with standard of care RYGB will receive atomoxetine, 0.5 mg/kg/day for 3 days
11138244|NCT03808740|Experimental|Vertical sleeve gastrectomy (VSG) /Atomoxetine|Participants with standard of care VSG will receive atomoxetine 0.5 mg/kg/day for 3 days
11138245|NCT03808740|Placebo Comparator|Roux-en-Y gastric bypass (RYGB)/Placebo|Participants with standard of care RYGB will receive placebo 0.5 mg/kg/day for 3 days
11138246|NCT03808740|Placebo Comparator|Vertical sleeve gastrectomy (VSG)/ Placebo|Participants with standard of care VSG will receive placebo 0.5 mg/kg/day for 3 days
11138247|NCT03808727|Experimental|Massed Cognitive Processing Therapy (MCPT)|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. MCPT will be delivered in an intensive outpatient setting (12 sessions in 5 days) composed of both group and individual sessions.
11138248|NCT03808727|Active Comparator|Standard Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Standard CPT will be delivered in 12 one-hour sessions over 6 weeks and involves only individual sessions.
11138249|NCT03808714|Active Comparator|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
11138250|NCT03808714|Active Comparator|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
11138251|NCT03808701|Experimental|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11138252|NCT03808701|Experimental|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11138253|NCT03808688|Other|Netarsudil Ophthalmic Solution 0.02%|
11138254|NCT03808675|Experimental|Aerobic|Participants randomized to aerobic exercise
11138255|NCT03808675|Other|Control|Participants randomized to usual care with PD specific health education
11138256|NCT03808662|Experimental|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
11138257|NCT03808662|Active Comparator|Arm 2:Standard of Care|
11138258|NCT03808649|Active Comparator|Individualized group|Participants are given different volume of a preparation of mannitol based on BMI as oral contrast agent over an hour prior to the examination.
11138259|NCT03808649|Experimental|conventional group|Participants are given 1500ml of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
11138260|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
11138261|NCT03808610|Experimental|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
11138262|NCT03808597|Experimental|Intervention group|The participants in this group will be exposed to digital health promotion. Please note that the participants are not randomly chosen, but stratified after the project villages. The participants in this group belong to the villages: Izazi and Migoli.
11138263|NCT03808597|No Intervention|Control group|"The participants in this group will be not be exposed to digital health promotion, but the villages will receive the intervention after one year. Please note that the participants are not randomly chosen, but stratified after the project villages.
~The participants in this group belong to the villages: Kimande and Idodi."
11138264|NCT03808584|No Intervention|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
11138265|NCT03808584|Experimental|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
11138266|NCT03808571||Study group|Pregnancies complicated with intrauterine growth restricted fetuses
11138267|NCT03808571||Control group|Healthy pregnancies
11138268|NCT03808558|Experimental|TVB-2640|Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
11138269|NCT03808545|Active Comparator|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
11138270|NCT03808545|Experimental|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
11138271|NCT03808532|Experimental|High-Risk with Moisturizer|
11138272|NCT03808532|No Intervention|High-Risk without Moisturizer|
11138273|NCT03808519|Experimental|n3 PUFA|n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
11138274|NCT03808519|Placebo Comparator|Placebo|Organic Sunflower Oil 5000mg per day
11138275|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
11138276|NCT03808493|Experimental|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
11138277|NCT03808493|Experimental|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
11138278|NCT03808493|Experimental|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
11138279|NCT03808493|Experimental|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
11138280|NCT03808480|Experimental|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.
~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
11138281|NCT03808467|Experimental|CRT + TAU|Cognitive Remediation Therapy + Treatment As Usual
11138282|NCT03808467|Other|TAU only|Treatment As Usual
11138283|NCT03808454|Experimental|Platelet rich plasma (PRP)|PRP injection only
11138284|NCT03808454|Experimental|PRP+Rehabilitation|PRP injection combined with rehabilitation
11138285|NCT03808454|Active Comparator|Rehabilitation|Rehabilitation treatment only
11138286|NCT03808441|No Intervention|Standard Arm|"Dabrafenib + Trametinib
~Switch to N+I at first progression"
11138287|NCT03808441|Active Comparator|ctDNA Guided Switch|"Dabrafenib + Trametinib
~Switch to N+I when ctDNA levels in the blood have dropped by ≥80%."
11138288|NCT03808428|Experimental|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
11138289|NCT03808415|Experimental|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
11138290|NCT03808402||High dose surfactant|Infants who receive a first dose of surfactant between 170 and 200 mg/kg
11138291|NCT03808402||Low dose surfactant|Infants who receive a first dose of surfactant between 100 and 130 mg/kg
11138292|NCT03808389|Experimental|Treatment group: Donor FMT|Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
11138293|NCT03808389|Sham Comparator|Control group: Autologous FMT|Fecal microbiota transplantation using the patient's own fecal matter.
11138294|NCT03808376|Experimental|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
11138295|NCT03808363|Experimental|High Intensity Interval Training Group|Approximately eight individuals with spinal cord injuries will participate in high intensity interval training for 6 weeks
11138296|NCT03808350|Placebo Comparator|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
11138297|NCT03808350|Active Comparator|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
11138298|NCT03808337|Active Comparator|Standare of Care|Patients with newly diagnosed metastatic non-small cell lung cancer or triple negative breast cancer may be enrolled on protocol prior to receiving any systemic therapy. If these patients are randomized to the standard of care arm (Arm 1), they will initiate appropriate therapy as determined by their oncologist. Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist.
11138299|NCT03808337|Experimental|Stereotactic Body Radiotherapy (SBRT) + Standard of Care|Patients enrolled on Arm 2 of the study will undergo Stereotactic Body Radiotherapy/SBRT to all known metastases seen on imaging studies performed prior to enrollment. Radiotherapy will be given concurrently to all metastatic sites. Minimum BED for ablative SBRT is more than or equal to 48 Gy10. Patients can undergo systemic therapy concurrently with SBRT at the discretion of treating radiation oncologist and medical oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
11138302|NCT03808311|Other|Standard BP treatment arm|Participants in the standard BP treatment arm will be treated to a systolic BP target of <140 mmHg.
11138303|NCT03808298|Experimental|Treatment Sequence 1: A, B, C|
11138304|NCT03808298|Experimental|Treatment Sequence 2: A, C, B|
11138305|NCT03808298|Experimental|Treatment Sequence 3: B, A, C|
11138306|NCT03808298|Experimental|Treatment Sequence 4: B, C, A|
11138307|NCT03808298|Experimental|Treatment Sequence 5: C, A, B|
11138308|NCT03808298|Experimental|Treatment Sequence 6: C, B, A|
11138309|NCT03808298|Experimental|Treatment Sequence 7: A, B, D|
11138310|NCT03808298|Experimental|Treatment Sequence 8: A, D, B|
11138311|NCT03808298|Experimental|Treatment Sequence 9: B, A, D|
11138312|NCT03808298|Experimental|Treatment Sequence 10: B, D, A|
11138313|NCT03808298|Experimental|Treatment Sequence 11: D, A, B|
11138314|NCT03808298|Experimental|Treatment Sequence 12: D, B, A|
11138315|NCT03808285||mandibular osteomylitis|description of mandibular osteomylitis due to denosumab
11138316|NCT03808272|Experimental|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
11138317|NCT03808259|Experimental|Part 1: OTF Sublingual and IV|Participants will receive (S)-ketamine oral thin film (OTF) at a dose of 7 milligram (mg) [cohort 1], 14 mg [cohort 2], and 28 mg [cohort 3] via sublingual route or 14 mg (S)-ketamine intravenous (IV) infusion for 40 minutes or matching placebo in 1 of 3 serial cohorts. Dose escalation decisions to further cohorts of Part 1 will be made based on safety and tolerability profile of the preceding lower dose level.
11138318|NCT03808259|Experimental|Part 2: IV Different Infusion Duration|Participants will receive single dose (S)-ketamine less than or equal to (<=)14 mg IV at a different infusion duration or matching placebo at a different infusion duration. The infusion duration and dose will be chosen after completion of Part 1.
11138319|NCT03808246|Experimental|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
11138320|NCT03808246|Experimental|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
11138321|NCT03808246|Experimental|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
11138322|NCT03808246|Experimental|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.
~The intervention is using the demo version of a self-injector pen."
11138323|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
11138324|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
11138325|NCT03808220||post-surgical patients|post-surgical patients > 18 years
11138326|NCT03808220||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
11138327|NCT03808207|Experimental|Intervention group|Increase of the average intake of dietary DHA: dietary advices concerning the concentration of docosahexaenoic acid (DHA) in several foods; the recommended daily or weekly intake of different food options (animal, vegetal) in order to reach the average intake of 300-350 mg DHA/day
11138328|NCT03808207|No Intervention|Control group|No specific dietary advice; Only endorsement and promotion of breastfeeding.
11138329|NCT03808194|Active Comparator|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
11138330|NCT03808194|Experimental|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
11138331|NCT03808181|Other|Active treatment with ChloraSolv|Single arm
11138332|NCT03808168|Active Comparator|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
11138333|NCT03808168|Active Comparator|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
11138334|NCT03808155|Active Comparator|Tamsulosin|The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.
11138335|NCT03808155|Placebo Comparator|Placebo Oral Tablet|The placebo is taken once a day per os five days prior to the operation and two days after the operation.
11138336|NCT03808142||Treatment|During a 3-month period all patients with an active myBETAapp account will be invited to participate in the study (3-month invitation period=enrolment period).Patients seeking more information about the study will be able to access a detailed informed consent form via their app providing step-by-step background information. Those patients wishing to participate in the study will be able to provide (electronic) informed consent (ICF).
11138337|NCT03808129|Active Comparator|ESP Group: Bupivacaine and lidocaine|ESP Group: Bupivacaine and lidocaine: Erector Spinae Plane Block : (1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine) was administered.
11138338|NCT03808129|No Intervention|control group|Control Group:
11138339|NCT03808116|Experimental|SmartBx biopsy collection|"Biopsy cores will be collected from the breast during US guided biopsy procedure.
~The number of cores taken will be decided per the physician discretion according to the clinical demand.
~Additional two biopsy core will be taken the SmartBx cassette"
11138340|NCT03808103|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
11138341|NCT03808103|Experimental|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
11138342|NCT03808090|Experimental|Normal Individuals|Normal individuals: no prior history of KS, no obesity, no diabetes
11138343|NCT03808090|Experimental|Calcium Oxalate Kidney Stone Formers|Those individuals that have a high propensity to form calcium oxalate kidney stones
11138344|NCT03808090|Experimental|Type 2 Diabetes|Those individuals that have been diagnosed with type 2 diabetes
11138345|NCT03808090|Experimental|Type 2 diabetic kidney stone formers|Those individuals that have been diagnosed with type 2 diabetes and kidney stones.
11138346|NCT03808077|Experimental|Interventional Group: Deep Neuromuscular Blockade|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
11138347|NCT03808077|Active Comparator|Control Group: Moderate Neuromuscular Blockade|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
11138348|NCT03808064|Experimental|FCHV home visit|
11138349|NCT03808064|No Intervention|FCHV no visit|
11138350|NCT03808051|Experimental|Physiological-based cord clamping|Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
11138351|NCT03808051|Active Comparator|Time-based cord clamping|Infants are clamped first and then moved to the standard resuscitation table for further treatment and intervention needed for cardiopulmonary stabilisation. Clamping is time based and performed immediately or delayed at 30-60 seconds, depending on the clinical condition of the infant. Uterotonic drugs are administered immediately after cord clamping.
11138352|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
11138353|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
11138354|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
11138355|NCT03808025|Experimental|education|The teaching arm would consist of a standardized dialogue the surgeon will complete with the patient in order to familiarize the patient with the risks of over-prescribing opioid medication and set patient expectations regarding the clinic's opioid prescribing pattern protocol, in an effort to minimize the number of opioid pills prescribed or refills required, the amount actually used, and the untoward side effects of opioid use (e.g. respiratory depression, nausea, sedation, restriction from driving, and access to and use by those the medication was not intended).
11138356|NCT03808025|No Intervention|no education|Standard preoperative care without dedicated teaching regarding opioid use and risks
11138357|NCT03808012|Experimental|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
11138358|NCT03807999|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
11138359|NCT03807999|Experimental|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
11138360|NCT03807986|Experimental|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
11138361|NCT03807986|Experimental|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
11138362|NCT03807973|Experimental|Fibromyalgia|
11138363|NCT03807973|Experimental|Chronic Fatigue Syndrome|
11138364|NCT03807973|Experimental|Multiple Sclerosis|
11138365|NCT03807973|Experimental|Healthy Controls|
11138366|NCT03807960|Experimental|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
11138367|NCT03807960|Experimental|written|The written form which include the same knowledge will give to the patient for reading.
11138368|NCT03807960|Other|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
11138369|NCT03807947|Experimental|Radial access|
11138370|NCT03807947|Active Comparator|Transfemoral Access|
11138371|NCT03807934|Experimental|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
11138372|NCT03807934|Sham Comparator|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
11138373|NCT03807921|Experimental|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.
~Aspirin will be administered 100 mg daily."
11138374|NCT03807921|Active Comparator|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
11138375|NCT03807908|Experimental|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.
~Subjects will wear the tape for as long as possible up to 5-7 days."
11138376|NCT03807908|Sham Comparator|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.
~Subjects will wear the tape for as long as possible up to 5-7 days."
11138377|NCT03807895|Experimental|REBT Career Intervention|High-school students in the experiment group attend to eight modules of career intervention with rational emotive behavioral therapy (REBT) techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive Restructuring, Exposure/behavior activation and problem solving, Planning, Goal Setting.
11138518|NCT03806946||group 5|ADHD and epilepsy
11138378|NCT03807895|Active Comparator|Regular Career Intervention|High-school students in the treatment as usual group attend to eight modules of career intervention with regular career intervention techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Problem solving, Planning, Goal Setting.
11138379|NCT03807882|Experimental|Test group|Bilateral Maintenance ECT (B/L M-ECT)
11138380|NCT03807882|Active Comparator|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
11138381|NCT03807869|Experimental|coexisting glaucoma and cataract|Patients with coexisting glaucoma and cataract qualified to combined glaucoma surgery
11138382|NCT03807856|Active Comparator|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
11138383|NCT03807856|Active Comparator|Standard of Care|Standard treatment for acute pancreatitis
11138384|NCT03807843|Experimental|Treatment Arm|Subjects randomized to the treatment arm will receive two vaccinations with MV-CHIK, a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. The vaccinations will be provided on days 0 and 28 after enrollment.
11138385|NCT03807843|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive two injections of sterile physiological saline. The injections will be provided on days 0 and 28 after enrollment.
11138386|NCT03807830|Other|One arm feasbility study|
11138387|NCT03807817|Experimental|Moderate Alcohol|
11138388|NCT03807817|Experimental|Low Alcohol|
11138389|NCT03807817|Active Comparator|Placebo Alcohol|
11138390|NCT03807817|Active Comparator|No Alcohol|
11138391|NCT03807804|Experimental|HLCM051 group【ARDS caused by pneumonia cohort】|"Patients will receive the standard therapy
~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
11138392|NCT03807804|No Intervention|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
11138393|NCT03807804|Experimental|HLCM051 group【ARDS caused by COVID-19 cohort 】|"Patients will receive the standard therapy
~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
11138394|NCT03807791|Experimental|Patient living in the Unit of Long Term Care|Patient living in the Unit of Long Term Care without any limit time
11138395|NCT03807778|Experimental|TAK-788, Phase 1 Part|TAK-788 40 milligrams (mg) (as the starting dose), capsules, orally, once daily on Days 1-28 of each 28-day treatment cycle for up to disease progression or intolerable toxicity, or another discontinuation criterion, and increasing until 160 mg, once daily (for up to approximately 10-12 cycles).
11138396|NCT03807778|Experimental|TAK-788, Phase 2 Part|TAK-788 160 mg, once daily, for up to approximately 10-12 cycles.
11138397|NCT03807765|Experimental|Nivolumab followed by stereotactic radiosurgery (SRS)|480 mg Nivolumab will be given intravenously every 4 weeks, followed by SRS the week after the initial dose of Nivolumab.
11138398|NCT03807752|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
11138399|NCT03807752|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
11138400|NCT03807739|Experimental|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
11138401|NCT03807739|Experimental|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
11138402|NCT03807726|Experimental|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
11138403|NCT03807726|No Intervention|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
11138404|NCT03807713|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
11138405|NCT03807700|Experimental|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
11138406|NCT03807700|No Intervention|No adhesive|In this arm, participants will not use any denture adhesive.
11138407|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
11138408|NCT03807674|Other|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
11138519|NCT03806933|Experimental|NT 201 Dose group 1|Stage 1 and 2. Intramuscular injection into the glabellar area.
11138409|NCT03807674|Experimental|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
11138410|NCT03807661|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
11138411|NCT03807635|Experimental|simulation of skin pricking type 450|The evaluator simulated the capillary blood sampling with the safety lancet type 450
11138412|NCT03807635|Experimental|simulation of skin pricking type 610|The evaluator simulated the capillary blood sampling with the safety lancet type 610
11138413|NCT03807609|Experimental|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
11138414|NCT03807609|Experimental|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
11138415|NCT03807609|Experimental|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
11138416|NCT03807596|Active Comparator|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling & root planing (SRP) alone.
11138417|NCT03807596|Experimental|Hyaluronic acid & SRP group|Chronic periodontitis & type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling & root planing (SRP) with the adjunctive use of hyaluronic acid.
11138418|NCT03807583|No Intervention|Control group|
11138419|NCT03807583|Active Comparator|AMINOVEN® 10%|"The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.
~The product is administered per os during the first hour of dialysis sessions for the duration of the study."
11138420|NCT03807583|Experimental|RENORAL®|"The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.
~The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins."
11138421|NCT03807570|Experimental|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
11138422|NCT03807570|Placebo Comparator|Placebo|Placebo 30 ml/day for 12 weeks
11138423|NCT03807557|Experimental|Robotic mCIMT group|1 hour unilateral robotic therapy, followed by 30 minutes of functional practice of affected UE using shaping technique, 3/week for 8 weeks and restraint of the unaffected limb at home for 2 hrs per day
11138424|NCT03807557|Active Comparator|Control group|conventional upper extremity rehabilitation training 1.5 hours per session, 3/week for 8 weeks and home exercise 2 hrs per day
11138425|NCT03807544|Experimental|TENS treatment arm|This study is a usability study, where all subjects will receive the same experimental treatment for their single visit.
11138426|NCT03807531|Other|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
11138427|NCT03807518|Experimental|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
11138428|NCT03807518|No Intervention|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
11138429|NCT03807505|Active Comparator|Interscalene nerve block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot interscalene brachial plexus nerve block or an interscalene brachial plexus nerve catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
11138430|NCT03807505|Active Comparator|Erector Spinae Plane block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot erector spinae plane block or receive erector spinae plane catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
11138431|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
11138432|NCT03807479|Experimental|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
11138433|NCT03807466|Active Comparator|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
11138434|NCT03807466|No Intervention|Static/Paginated Report|LTC physician receives static/paginated report only
11138435|NCT03807466|Active Comparator|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report
~[note: this is not part of randomization assignment, but a quasi-experimental study]"
11138520|NCT03806933|Experimental|NT 201 Dose group 2|Stage 1. Intramuscular injection into the glabellar area.
11138436|NCT03807466|No Intervention|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report
~[note: this is not part of randomization assignment, but a quasi-experimental study]"
11138437|NCT03807453||Psoriasis Vulgaris patients-Lesion|
11138438|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
11138439|NCT03807453||Seborrheic Dermatitis-Lesion|
11138440|NCT03807453||Seborrheic Dermatitis-Lesion free|
11138441|NCT03807453||Control Group|
11138442|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
11138443|NCT03807427|Experimental|READY-Nepal|Skills groups based on dialectical behavior therapy principles delivered over 10-12 weeks in a classroom format.
11138444|NCT03807427|No Intervention|Waitlist Control|Adolescent participants assigned to the control condition will be placed on a waitlist for future enrollment in READY-Nepal. After primary data collection has ceased, those assigned to the control arm will receive the identical READY-Nepal intervention delivered in the experimental condition.
11138445|NCT03807414||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing treatment with oXiris will be prospectively observed.
11138446|NCT03807401|Active Comparator|Classical prismatic adaptation|Classical prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
11138447|NCT03807401|Experimental|Virtual prismatic adaptation|virtual prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
11138448|NCT03807401|Experimental|Imaged prismatic adaptation|Imaged prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
11138449|NCT03807388|Experimental|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.
~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
11138450|NCT03807388|Other|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
11138451|NCT03807375|Other|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
11138452|NCT03807375|No Intervention|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
11138453|NCT03807362|Experimental|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
11138454|NCT03807349|Other|N-Force Screws|N-Force Screws augmented with N-Force Blue in Intracapsular Femur Fractures.
11138455|NCT03807336|Experimental|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
11138456|NCT03807336|Active Comparator|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
11138457|NCT03807323|Experimental|'Lifestyle counselling and exercise' .|The study is a single-arm study where all participants undergo the same intervention 'Lifestyle counselling and exercise' .
11138458|NCT03807310|Experimental|Group Long-drink|"83 advanced COPD patients will receive:
~Targeted nutrient supplementation (Long-drink) once daily
~Counselling once monthly"
11138459|NCT03807310|Placebo Comparator|Group Placebo|"83 advanced COPD patients will receive:
~Isocaloric placebo supplement once daily
~Counselling once monthly"
11138460|NCT03807297|Other|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
11138461|NCT03807297|Other|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
11138462|NCT03807284|Experimental|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
11138463|NCT03807284|No Intervention|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
11138464|NCT03807271|Experimental|Smart Pilot(R) View|Anesthesia provided by standard procedure, additionally guided by Smart Pilot(R) View, a device with calculated and graphically produced depth of anesthesia.
11138465|NCT03807271|No Intervention|Standard|Anesthesia provided by standard procedure.
11138466|NCT03807258|Experimental|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
11138467|NCT03807258|Active Comparator|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
11138468|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
11138469|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
11138470|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
11138471|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
11138472|NCT03807232||pbARDS|Burn patients who developed post-burn ARDS
11138473|NCT03807232||No pbARDS|Burn patients without development of post-burn ARDS
11138474|NCT03807219|Active Comparator|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
11138475|NCT03807219|Placebo Comparator|Placebo|80 subjects will be on the Placebo arm.
11138521|NCT03806933|Experimental|NT 201 Dose group 3|Stage 1. Intramuscular injection into the glabellar area.
11138522|NCT03806933|Experimental|NT 201 Dose group 4|Stage 2. Intramuscular injection into the glabellar area.
11138476|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
11138477|NCT03807193|Experimental|Fixed treatment, weekly support|Receives a predetermined treatment program and have weekly support.
11138478|NCT03807193|Experimental|Fixed treatment, support on demand|Receives a predetermined treatment program and have access to support on demand.
11138479|NCT03807193|Experimental|Selected treatment, weekly support|Select their own treatment material and have weekly support.
11138480|NCT03807193|Experimental|Selected treatment, support on demand|Select their own treatment material and have access to support on demand.
11138481|NCT03807180|Other|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
11138482|NCT03807180|No Intervention|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
11138483|NCT03807167|Experimental|Patients|
11138484|NCT03807167|Active Comparator|healthy controls|
11138485|NCT03807154|Experimental|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
11138486|NCT03807154|Experimental|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
11138487|NCT03807154|No Intervention|Wait-list|Wait-list control group
11138488|NCT03807141|Experimental|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.
~The ongoing antiepileptic medication will be continued unchanged"
11138489|NCT03807141|No Intervention|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
11138490|NCT03807115|Other|Intervention|Arm: Intervention: Implementation of stroke mobility guidelines
11138491|NCT03807115|No Intervention|Control|Arm: Control: Usual care
11138492|NCT03807102|Experimental|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
11138493|NCT03807089|Experimental|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
11138494|NCT03807089|Active Comparator|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
11138495|NCT03807076|Other|GIP-A|Infusion of GIP-A alone as a study tool.
11138496|NCT03807076|Placebo Comparator|Placebo|Saline
11138497|NCT03807063|Experimental|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
11138498|NCT03807050|Experimental|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
11138499|NCT03807037|Experimental|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
11138500|NCT03807037|Placebo Comparator|Control|Matching Placebo (Placebo oral capsule)
11138501|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
11138502|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
11138503|NCT03807011|Active Comparator|fentanyl|A bolus dose of fentanyl 2 μg/kg was administered intravenously at anesthetic induction
11138504|NCT03807011|Active Comparator|remifentanil|Remifentanil was continuously infused at a rate of 0.2 μg/kg/min from anesthetic induction to the end of surgery
11138505|NCT03806998|Experimental|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
11138506|NCT03806998|Placebo Comparator|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
11138507|NCT03806985|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
11138508|NCT03806985|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
11138509|NCT03806985|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
11138510|NCT03806985|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
11138511|NCT03806985|Experimental|High Dose Psilocybin/Low Dose Psilocybin|Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
11138512|NCT03806985|Experimental|Low Dose Psilocybin/High Dose Psilocybin|Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.
11138513|NCT03806959|Other|Pan Capsule and colonoscopy|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only
11138524|NCT03806920|Active Comparator|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:
~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
11138525|NCT03806920|Active Comparator|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:
~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
11138526|NCT03806920|Active Comparator|Intervention C|"Nutritional intervention in healthy subjects:
~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
11138527|NCT03806920|Active Comparator|Intervention D|"Nutritional intervention in healthy subjects:
~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
11138528|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
11138529|NCT03806894||Arab populations|Muslim, Christian, Druze
11138530|NCT03806881||Treatment group|Patients treated with a Glenius Glenoid Reconstruction System
11138531|NCT03806868|Active Comparator|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
11138532|NCT03806868|Sham Comparator|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
11138533|NCT03806855||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
11138534|NCT03806855||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
11138535|NCT03806842|Experimental|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
11138536|NCT03806829|Active Comparator|Water + Meal|250 ml Water and a high calorie, high fat meal (>900 kcal, 50g fat)
11138537|NCT03806829|Experimental|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (>900 kcal, 50g fat)
11138538|NCT03806829|Experimental|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (>900 kcal, 50g fat)
11138539|NCT03806829|Experimental|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (>900 kcal, 50g fat)
11138540|NCT03806816|Experimental|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
11138541|NCT03806816|Experimental|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
11138542|NCT03806803|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
11138543|NCT03806803|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
11138544|NCT03806790|Experimental|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
11138545|NCT03806790|Active Comparator|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
11138546|NCT03806777|Experimental|Intra-nasal dexmedetomidine|A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.
11138547|NCT03806764|No Intervention|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
11138548|NCT03806764|Other|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.
~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
11138549|NCT03806751|Experimental|[O-15]water PET/MRI|Volunteers will have two brain PET/MRI scans; first scan after injection of [O-15]water; second scan after injection of 1 gram of acetazolamide followed by injection of [O-15]water.
11138550|NCT03806738|Experimental|Shared Decision Making Questionnaire|"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.
~One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
11138551|NCT03806738|Other|Standard of Care Questionnaire|"Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.
~One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
11138552|NCT03806725||Liver transplant (LTx) candidates with eGFR>=60|Liver transplant candidates with renal function defined by eGFR above or equal to 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement.
11138553|NCT03806725||LTx candidates with eGFR<60|"Liver transplant candidates with decreased renal function.
~Defined by eGFR less than 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement."
11138554|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
11138555|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
11138556|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
11138557|NCT03806699|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
11138558|NCT03806699|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
11138559|NCT03806699|Placebo Comparator|Control group|Participants will receive 0.5 mL (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
11138560|NCT03806686|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
11138561|NCT03806686|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
11138562|NCT03806686|Placebo Comparator|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
11138563|NCT03806673|Active Comparator|primipara|primipara subjected to their first epidural block
11138564|NCT03806673|Active Comparator|multipara|multipara subjected to their repeated epidural block.
11138565|NCT03806621||Rotational Atherectomy|
11138566|NCT03806608|Experimental|Crestal|Implants were placed with the implant-abutment interface(IAI) at the level of the the alveolar ridge
11138567|NCT03806608|Experimental|Subcrestal|Implants were placed with the implant-abutment interface(IAI) 1 mm below the level of the alveolar ridge
11138568|NCT03806595|Experimental|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
11138569|NCT03806595|Placebo Comparator|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
11138570|NCT03806582|Active Comparator|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
11138571|NCT03806582|No Intervention|control|control group; treatment according to current standards, observation of the effect on right ventricular function
11138572|NCT03806569|Active Comparator|MAC-cbt group treatment for adult ADHD|"The patients will be treated with psychological group treatment for 8 sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process. This will be called Mindfulness, Acceptance and Commitment-Therapy for adult Patients with ADHD"
11138573|NCT03806569|Sham Comparator|Relaxation-group for adult ADHD|"The patients will be treated with a relaxation-treatment, long-time established as Jacobson muscle relaxing technique."
11138574|NCT03806556|Experimental|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
11138575|NCT03806556|Placebo Comparator|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
11138576|NCT03806530|Active Comparator|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
11138577|NCT03806530|Placebo Comparator|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
11138578|NCT03806530|Placebo Comparator|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
11138579|NCT03806530|Placebo Comparator|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
11138580|NCT03806517||Tremor dominant type group|Tremor dominant type (TDT) group will consist of the patients with tremor premotor symptoms.
11138581|NCT03806517||PIGD dominant type group|Postural instability and gait difficulty dominant type (PIGDT) group will consist of the patients with axial premotor symptoms.
11138582|NCT03806517||Healthy control group|Healthy control group will consist of the subjects with same age and sex matched individuals in PD group.
11138583|NCT03806504|Active Comparator|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
11138584|NCT03806504|Active Comparator|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
11138585|NCT03806491|Experimental|CBT-I + AUD-TAU|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
11138586|NCT03806491|Active Comparator|Sleep Hygiene + AUD-TAU|Sleep hygiene education delivered once to all participants
11138587|NCT03806478|Experimental|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
11138588|NCT03806478|Experimental|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
11138589|NCT03806478|Experimental|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
11138590|NCT03806478|Placebo Comparator|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
11138591|NCT03806465||Feasibility survey|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age. For the midline household survey, this would be restricted to children aged 12-23 months of age.
11138592|NCT03806465||Sentinel hospital surveillance|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age who are hospitalized in the 18 sentinel hospitals.
11138593|NCT03806465||Community mortality surveillance|These will be children whose deaths are reported in the vaccinating and in non-vaccinating areas aged less than 5 years of age .
11138594|NCT03806452|Experimental|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.
~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
11138595|NCT03806452|Placebo Comparator|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.
~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
11138596|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
11138597|NCT03806426|Experimental|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
11138598|NCT03806426|Placebo Comparator|Treatment Group B|Placebo 500mg
11138599|NCT03806413||Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
11138600|NCT03806374|Active Comparator|Fentanyl|Administered propofol and fentanyl for induction.
11138601|NCT03806374|Active Comparator|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
11138602|NCT03806361|Experimental|With ADRC|Supplementation of fat grafts with ADRC
11138603|NCT03806361|Active Comparator|Structural|Structural fat grafting
11138604|NCT03806348|Experimental|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
11138605|NCT03806348|No Intervention|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
11138606|NCT03806335|Experimental|Infiltration|Patients will receive pre-incision infiltration of 2.5 ml local anesthesia mixture in each tonsil.
11138607|NCT03806335|Placebo Comparator|Placebo|Patients will receive pre-incision infiltration of 2.5 ml saline in each tonsil.
11138608|NCT03806322|Experimental|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
11138609|NCT03806322|Experimental|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
11138610|NCT03806309|Active Comparator|Arm A : maintenance with FOLFIRI|FOLFIRI (IV; folinic acid 400 mg/m2, irinotecan 180 mg/m2, 5-FU bolus 400 mg/m2 and continuous infusion 2,400 mg/m2; in case of previous reduction in the dose of 5FU or irinotecan, dose adjustment will be accepted).
11138611|NCT03806309|Experimental|Arm B : maintenance with OSE2101 monotherapy|"OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 6 doses then every 8 weeks for the remainder of year one and then every 3 months during year 2, for a maximum treatment duration of 24 months, and reintroduction of FOLFIRI at disease progression or unacceptable toxicity.
~OSE2101 vaccine is a preservative-free, sterile suspension of 10 synthetically manufactured peptides, an aqueous/DMSO (dimethylsulfoxide) buffer system, and emulsified before use with Montanide® ISA 51 adjuvant. When extemporaneously reconstituted, the product is formulated with 0.5 mg/mL of each peptide (5.0 mg/mL total peptide)."
11138612|NCT03806309|Experimental|Arm C: maintenance with OSE2101 plus nivolumab|OSE2101 (subcutaneous injection on day 2, every 3 weeks for 6 doses then every 8 weeks for the remainder of year one and then every 3 months during year 2) plus nivolumab (360 mg IV infusion on day 1 every 3 weeks for 6 doses, then 480 mg every 4 weeks), for a maximum treatment duration of 24 months, and reintroduction of FOLFIRI at disease progression or unacceptable toxicity
11138613|NCT03806296|Experimental|Manipulation|"For ~2 weeks, participants will be asked to adhere to the following:
~Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)
~Decrease evening blue light exposure via blue blocker goggles (2 h before bed)
~Increase morning bright light exposure via bright light goggles (30 m after rise)
~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
11138614|NCT03806296|Active Comparator|Control|"For ~2 weeks, participants will asked to adhere to the following:
~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
11138615|NCT03806283||Cohort 1 no Preeclampsia|Cohort 1: 16 mothers with no diagnosis of preeclampsia during pregnancy (8 male, 8 female neonate) Omental Biopsy and placental collection will be performed
11138616|NCT03806283||Cohort 2 mild or severe Preeclampsia|Cohort 2: 16 mothers with diagnosis of mild or severe preeclampsia during pregnancy (8 male, 8 female neonate) Omental Biopsy and placental collection will be performed
11138617|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.
~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
11138618|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.
~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
11138650|NCT03806062|Active Comparator|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
11138651|NCT03806049|Experimental|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + TSR042
11138652|NCT03806049|Experimental|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
11138619|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.
~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
11138620|NCT03806257|No Intervention|Control|Subjects in the control arm will receive standard of care, which consists of mobilization to a bedside chair at least once, and ambulate one-half ICU circumference on postoperative day one. On postoperative days two through five, the subject will be mobilized to the bedside chair at least once, and ambulated at least once with target of one full ICU circumference. These subjects will receive gait training and safe ambulation education, and wear a FitBit Charge 2 watch for five days after surgery.
11138621|NCT03806257|Experimental|Enhanced Physical Therapy Protocol|Subjects in the experimental arm will recieve a FitBit Charge 2 watch, and will be mobilized to the bedside chair on postoperative day zero. On postoperative day two subjects will be mobilized to the bedside chair twice, ambulate one-half of the ICU circumference, and receive gait and safe ambulation training. On postoperative days two through five, subjects will mobilize to the bedside chair three times, and will be encouraged to ambulate three times, each time with a target of one full ICU circumference.
11138622|NCT03806244|No Intervention|PREOP|Navigation without intraoperative acquisition of images: Use of conventional preoperative images (CT-MRI) to establish intraoperative navigation.
11138623|NCT03806244|Experimental|PEROP|Navigation with intraoperative acquisition of images: Intraoperative acquisition (robotic c-Arm) of images to establish intraoperative navigation.
11138624|NCT03806231|Experimental|Outpatient Cervical Ripening|Patients randomized to the outpatient cervical ripening arm will come in for a scheduled visit in Labor and Delivery prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be monitored for 2 hours and sent home after a the following are present: (1) reactive non-stress test (NST) (2) category 1 tracing x 2 hours (3) no vaginal bleeding (4) normal maternal vital signes (5) intact bag of water (BOW) and (6) less than 1 contraction every 10 minutes at the time of discharge. The patient will remove the insert the following morning prior to her scheduled induction.
11138625|NCT03806231|Active Comparator|Inpatient Cervical Ripening|The patient will be admitted into the Labor and Delivery unit prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be watched with continuous fetal monitoring for 2 hours. The patient remains hospitalized and the following morning the induction will be started per Intermountain Healthcare protocol.
11138626|NCT03806218|Active Comparator|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
11138627|NCT03806218|Active Comparator|SC-RFA|Switching monopolar RFA using separable clustered electrodes
11138628|NCT03806192|Experimental|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
11138629|NCT03806192|Experimental|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
11138630|NCT03806179|Experimental|Betalutin with rituximab treatment|Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
11138631|NCT03806166|Experimental|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
11138632|NCT03806166|Active Comparator|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
11138633|NCT03806153|Active Comparator|Conventional morphology arm (reference method)|
11138634|NCT03806153|Experimental|Morphokinetic arm|
11138635|NCT03806140|Active Comparator|Intervention group|Receive daily text messages
11138636|NCT03806140|No Intervention|Control group|No text messages, only written educational materials
11138637|NCT03806127|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
11138638|NCT03806127|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
11138639|NCT03806114|Other|Anterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
11138640|NCT03806114|Other|Posterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
11138641|NCT03806114|Other|Anterior Approach No Precautions|This group receives does not precautions and have a total hip arthroplasty with an anterior approach.
11138642|NCT03806114|Other|Posterior Approach No Precautions|This group receives does not receive precautions and have a total hip arthroplasty with a posterior approach.
11138643|NCT03806101|Experimental|Arm 1|Single dose of rosuvastatin on Day 1 of Period 1 and Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 2.
11138644|NCT03806101|Experimental|Arm 2|Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 1 and single dose of rosuvastatin on Day 1 of Period 2.
11138645|NCT03806088||patients of chronic kidney disease|no interventions
11138646|NCT03806075|Experimental|Peutz-Jeghers patients|All Peutz-Jeghers patients meet the clinical criteria
11138647|NCT03806075|Placebo Comparator|Health persons|Those without Peutz-Jeghers syndrome
11138648|NCT03806062|Active Comparator|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
11138649|NCT03806062|Active Comparator|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.
~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
11138653|NCT03806049|Active Comparator|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
11138654|NCT03806036|Active Comparator|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
11138655|NCT03806036|Placebo Comparator|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
11138656|NCT03806023|Experimental|All subjects|All subjects undergo same full protocol, including PNS and TMS at rest and active hand movements (signals from thumb muscle) triggered PNS and TMS.
11138657|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
11138658|NCT03805997|Experimental|Experimental Group|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
11138659|NCT03805997|Placebo Comparator|Control Group|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
11138660|NCT03805984|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
11138661|NCT03805984|Placebo Comparator|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
11138662|NCT03805984|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
11138663|NCT03805984|Placebo Comparator|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
11138664|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
11138665|NCT03805958|Experimental|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
11138666|NCT03805958|Active Comparator|Real time|Confirmed landmark by ultrasound scan during procedure
11138667|NCT03805945|Experimental|dexmedetomidine group|After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
11138668|NCT03805945|Placebo Comparator|control group|Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
11138669|NCT03805932|Experimental|1|Moxetumomab Pasudotox-tdfk + Rituximab
11138670|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-relatedrisk genes
11138671|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
11138672|NCT03805854|Experimental|Transcranial alternating current stimulation (tACS)|
11138673|NCT03805841|Experimental|Active|tarloxotinib bromide
11138674|NCT03805828|Experimental|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
11138675|NCT03805828|Active Comparator|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis[a whooping cough]),(3) communicable diseases of childhood (Measles,Mumps,rubella[German Measles]and Poliomyelitis(,and (4) infection control.
11138676|NCT03805802|Experimental|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
11138677|NCT03805802|Placebo Comparator|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
11138678|NCT03805789|Experimental|AAT (low dose)|Open label. Alpha-1 antitrypsin (AAT) is a lyophilized product for intravenous administration
11138679|NCT03805789|Experimental|AAT (medium dose)|Open label. AAT is a lyophilized product for intravenous administration
11138680|NCT03805789|Experimental|AAT (high dose)|Open label. AAT is a lyophilized product for intravenous administration
11138681|NCT03805789|Experimental|AAT (selected dose from open-label)|Double-blind. AAT is a lyophilized product for intravenous administration
11138682|NCT03805789|Placebo Comparator|Placebo|Albumin solution administered intravenously
11138683|NCT03805776|Experimental|Interventional|Will observe intermittent fasting
11138684|NCT03805776|No Intervention|Control|
11138685|NCT03805763|Experimental|Large extent of ILM Peeling|Extent of ILM peeling is 4DD and the ILM flap is inserted
11138686|NCT03805763|Experimental|Small extent of ILM Peeling|Extent of ILM peeling is 2DD and the ILM flap is inserted
11138687|NCT03805750|Experimental|CBD/THC|Treatment arm
11138688|NCT03805750|Placebo Comparator|Placebo|
11138689|NCT03805737|Experimental|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
11138690|NCT03805737|Active Comparator|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
11138691|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level & probing depth ≤ 3 mm. Plaque samples will be collected.
11138725|NCT03805477|Experimental|Nintedanib|Nintedanib 150 mg Kps bid (oral)
11138692|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
11138693|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
11138694|NCT03805711|Experimental|Aortic Valve Replacement with HLT® Transcatheter System|Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
11138695|NCT03805698|Experimental|Platelet-rich Plasma (PRP) group|"Forty-eight (48) subjects undergoing arthroscopic debridement for TFCC tears will be randomized intraoperatively to treatment with PRP (24 subjects).
~Intervention: use of Cascade device; Autologous Fibrin & Platelet System; once processed, the PRP is injected into the debrided wrist"
11138696|NCT03805698|Placebo Comparator|Placebo - normal saline group|"Forty-eight (48) subjects undergoing arthroscopic debridement for TFCC tears will be randomized intraoperatively to treatment with normal saline (24 subjects).
~Intervention: normal saline injected into debrided wrist"
11138697|NCT03805672|Active Comparator|Low Dose Enoxaparin|Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
11138698|NCT03805672|Active Comparator|High Dose Enoxaparin|Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.
11138699|NCT03805659|Experimental|HD-tDCS, then Sham|Subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
11138700|NCT03805659|Experimental|Sham, then HD-tDCS|Subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).
11138701|NCT03805646|No Intervention|No Mobile Phone-administered Triage Tool|For each hospital site: Baseline data will be collected for six months.
11138702|NCT03805646|Experimental|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year."
11138703|NCT03805633||Sarcoidosis Patients|Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.
11138704|NCT03805633||Diabetes Patients|Patients followed by UAB Endocrinology with diabetes mellitus.
11138705|NCT03805633||Sarcoidosis and Diabetes patients|Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.
11138706|NCT03805620|Active Comparator|Phys Group|physical training group
11138707|NCT03805620|Active Comparator|Cog Group|cognitive training group
11138708|NCT03805620|Experimental|Phys-Cog Group|combined physical-cognitive training group
11138709|NCT03805620|No Intervention|Con Group|educational control group
11138710|NCT03805607|Placebo Comparator|Placebo|1 ml of normal saline
11138711|NCT03805607|Experimental|Ketorolac|30 mg of ketorolac in 1 ml
11138712|NCT03805594|Experimental|Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
11138713|NCT03805594|Experimental|Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
11138714|NCT03805594|Experimental|Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)|Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
11138715|NCT03805581|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
11138716|NCT03805568|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
11138717|NCT03805568|Active Comparator|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5~2.5 ng/ml) during the surgery
11138718|NCT03805555|Active Comparator|Radiofrequency ablation|Best radiofrequency ablation
11138719|NCT03805555|Experimental|Cryoballoon ablation|Best cryoballoon ablation
11138720|NCT03805542|No Intervention|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
11138721|NCT03805542|Experimental|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
11138722|NCT03805516|Experimental|Intervention|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.
~12 weekly SCOPP-CW educational modules delivered via WeChat.
~6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
11138723|NCT03805516|Active Comparator|Control|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.
~12 weekly non-tailored educational modules on general health topics delivered via WeChat."
11138724|NCT03805503|Experimental|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.
~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.
~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
11138726|NCT03805464|Experimental|Knee Joint Effusion|Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.
11138727|NCT03805451|Experimental|Life Steps for PrEP for Youth|Life Steps for PrEP for Youth was derived from our prior PrEP work supported by the National Institute of Mental Health and will be tailored for YMSM/TWSM based on the findings from 20 qualitative interviews with YMSM and TWSM and 10 qualitative interviews with key informants. It will likely consist of four weekly sessions at the time of PrEP initiation and two booster sessions, which occur two and three months after PrEP initiation. Overall, the core components of the intervention will focus on medication adherence, sexual behavior, and problem solving barriers to adherence, using motivational interviewing when needed.
11138728|NCT03805451|No Intervention|Standard of Care|After being prescribed PrEP, participants will receive standard-of-care adherence support for PrEP. They will have blood collected for medication adherence measures and will complete computer assisted behavioral surveys during study visits. Participants in this arm will also be followed for 6 months.
11138729|NCT03805438|Experimental|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).
~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
11138730|NCT03805425|Experimental|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
11138731|NCT03805412|Active Comparator|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
11138732|NCT03805412|No Intervention|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
11138733|NCT03805399|Experimental|pyrotinib with capecitabine|If patients were LAR subtype with HER2 gene activated mutation
11138734|NCT03805399|Experimental|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype without HER2 gene activated mutation, but had PIK3CA mutation, enter into arm B1; If patients were LAR subtype without HER2 gene activated mutation or PIK3CA mutation, enter into arm B2
11138735|NCT03805399|Experimental|anti PD-1 with nab-paclitaxel|If patients were IM subtype(CD8 positive T cell more than 20%)
11138736|NCT03805399|Experimental|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation
11138737|NCT03805399|Experimental|BLIS with anti-VEGFR included therapy|If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation
11138738|NCT03805399|Experimental|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation
11138739|NCT03805399|Experimental|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation
11138740|NCT03805386|Active Comparator|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
11138741|NCT03805386|Experimental|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
11138742|NCT03805360|Sham Comparator|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
11138743|NCT03805360|Experimental|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
11138744|NCT03805347|Experimental|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
11138745|NCT03805347|Placebo Comparator|Starch|Starch in capsule，1gm/time, 3 times daily
11138746|NCT03805334|Experimental|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn ~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
11138747|NCT03805308|No Intervention|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
11138748|NCT03805308|Experimental|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
11138749|NCT03805295|Experimental|Spring 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Winter-Spring 2018. They will serve as the control group in Fall 2018.
11138750|NCT03805295|Experimental|Fall 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Fall 2018.
11138751|NCT03805282|Experimental|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
11138808|NCT03804905|No Intervention|Usual care|Eligible patients of physicians allocated to the usual care arm will continue to access their medications through self-pay or other mechanisms.
11138752|NCT03805282|Active Comparator|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
11138753|NCT03805282|Active Comparator|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
11138754|NCT03805282|Active Comparator|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
11138755|NCT03805269|Experimental|TAP block|USG guided TAP block
11138756|NCT03805269|Active Comparator|wound infiltration|local anesthetics infiltration at surgical incision site
11138757|NCT03805243|Experimental|test of sensors for somnonaute device|monitoring with sensors
11138758|NCT03805243|Experimental|test of sensors for uronaute device|monitoring with sensors
11138759|NCT03805243|Experimental|test of sensors for toconaute device|monitoring with sensors
11138760|NCT03805243|Experimental|test of sensors for cardioskin device|monitoring with sensors
11138761|NCT03805243|Experimental|test of sensors for neuronaute device|monitoring with sensors
11138762|NCT03805230||Cohort A|all patients admitted to participating hospitals during 7 consecutive days
11138763|NCT03805230||Cohort B|30 sequential patients with a single additional inclusion criterion
11138764|NCT03805178|Experimental|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
11138765|NCT03805178|Experimental|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
11138766|NCT03805152|Active Comparator|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
11138767|NCT03805152|Active Comparator|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
11138768|NCT03805139|Experimental|Ajwa Dates group|55-65gms Ajwa dates 7 days a week for 6 weeks
11138769|NCT03805139|No Intervention|Control|No intervention
11138770|NCT03805126|Experimental|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
11138771|NCT03805126|Active Comparator|Usual Care|Usual care includes consultation with a social worker and a community health worker.
11138772|NCT03805113|Experimental|Intervention group|Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.
11138773|NCT03805113|Placebo Comparator|Control group placebo|Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.
11138774|NCT03805100|Experimental|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
11138775|NCT03805100|Active Comparator|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
11138776|NCT03805087|Experimental|Coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
11138777|NCT03805061|Active Comparator|Aerobic exercise group|Group 1 was 'aerobic exercise group'. Patients in this group were included in an aerobic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise.
11138778|NCT03805061|Active Comparator|Isokinetic exercise group|Group 2 was 'isokinetic exercise group'. Patients in this group were included in an isokinetic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study.
11138779|NCT03805048|Other|Native Vessel PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
11138780|NCT03805048|Other|Graft PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
11138781|NCT03805035|Sham Comparator|sham EA group|Minimal needling at ST36 and GB34 (n=10)
11138782|NCT03805035|Experimental|true EA group|EA at ST36 and GB34 (n=10)
11138783|NCT03805035|Active Comparator|EA+antihistamine(low dose) group|EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
11138784|NCT03805035|Active Comparator|EA+antihistamine(high dose) group|EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)
11138785|NCT03805022|Experimental|Arm A|"Control-Arm phase III high-risk CINSARC:
~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 3 cycles in neoadjuvant setting.
~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
11138786|NCT03805022|Experimental|Arm B|"Experimental-Arm phase III high-risk CINSARC:
~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 6 cycles in neoadjuvant setting.
~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
11138787|NCT03805022|Experimental|Prospective cohort|Patients will be treated at the discretion of the investigator
11138788|NCT03805009|Experimental|Robotic Group (RG)|Robotic Group (RG) will perform, in addition to conventional therapy, gait training using an end-effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 20 sessions. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
11138789|NCT03805009|No Intervention|Conventional Group (CG)|Conventional Group (CG) will perform conventional gait rehabilitation program. The treatment will include: muscle strengthening exercises and stretching of the lower limb, and static and dynamic exercises for the recovery of balance in the supine and standing positions using assistive devices; training gait exercises with parallel bars or in open spaces performed both with and without assistive devices; training to climb up and down stairs; exercises to improve proprioception in the supine, sitting and standing positions, using a proprioceptive footboard; exercises to improve trunk control.
11138790|NCT03804996|Experimental|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
11138791|NCT03804996|Experimental|TG-1101|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy.
11138792|NCT03804983|Active Comparator|Hybrid Closed Loop (HCL)|Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ with Hybrid Closed Loop (HCL) or the Control-IQ with MyTDI. Participants randomized to Control-IQ, participants will continue using their home insulin parameters during the ski admission and then 5 additional days at home.
11138793|NCT03804983|Experimental|Control-IQ with MyTDI|"Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ or the Control-IQ with MyTDI. Participants randomized to Control-IQ with MyTDI, participants will be adjusted as noted below during the ski admission and will then continue these parameters for 5 additional days at home:
~A single basal rate equal to total daily insulin (TDI)/48 will be implemented across the whole day
~A single correction factor (CF) of 1650/TDI will be implemented across the whole day
~Carbohydrate ratios (CR) will be set at:
~00:00-04:00 CR=450/TDI
~04:00-11:00 CR=360/TDI
~11:00-00:00 CR=450/TDI TDI will be set at the internal Control-IQ estimation total daily dose; if not available, total daily dose over the last 5 days will be used."
11138794|NCT03804970|Experimental|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
11138795|NCT03804970|Experimental|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
11138796|NCT03804970|Active Comparator|Control group|Watching brief video and basic explanation for disease
11138797|NCT03804957|Active Comparator|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
11138798|NCT03804957|Experimental|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
11138799|NCT03804944|Active Comparator|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
11138800|NCT03804944|Active Comparator|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
11138801|NCT03804944|Active Comparator|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
11138802|NCT03804944|Active Comparator|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
11138803|NCT03804931|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation
11138804|NCT03804931|Sham Comparator|placebo fecal microbiota transplantation|Infusion of Saline
11138805|NCT03804931|Other|Traditional treatments|Drug:5-Aminosalicylic acid(5-ASA) and/or Prednisone
11138806|NCT03804918|Experimental|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
11138807|NCT03804905|Experimental|Drug cards|Eligible patients of physicians allocated to the drug cards arm will receive drug cards from their physician.
11138809|NCT03804892|Experimental|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
11138810|NCT03804892|Other|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
11138811|NCT03804879|Experimental|LMB763|LMB763 capsules
11138812|NCT03804879|Placebo Comparator|Placebo|Placebo comparator
11138813|NCT03804866|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
11138814|NCT03804866|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
11138815|NCT03804853|Experimental|Immediate Active Shoulder Rehabilitation|
11138816|NCT03804853|Active Comparator|Traditional Should Rehabilitation|
11138817|NCT03804840|Placebo Comparator|Placebo|
11138818|NCT03804840|Active Comparator|7.5 mg THC|
11138819|NCT03804840|Active Comparator|15 mg THC|
11138820|NCT03804827||Heart Failure With Sleep Disordered Breathing|AHI3% >/= 5 events per hour of sleep.
11138821|NCT03804827||Heart Failure without Sleep Disordered Breathing|AHI3% < 5 events per hour of sleep.
11138822|NCT03804814|Active Comparator|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
11138823|NCT03804814|No Intervention|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
11138824|NCT03804801|Experimental|Intervention Arm (or Group)|This arm will receive the intervention (Hibiscus Sabdariffa extract supplement)
11138825|NCT03804801|No Intervention|Control Arm (or Group)|This arm will receive no intervention whatsoever, not even placebo
11138826|NCT03804788|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
11138827|NCT03804788|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
11138828|NCT03804775||case group|patients presenting with gallstone disease
11138829|NCT03804775||control group|inpatients with no history of gallstones
11138830|NCT03804762|Experimental|patients received treatment of TS-RECS|
11138831|NCT03804749|Experimental|Group 1-1|The dose of suramin sodium is 10 mg/kg
11138832|NCT03804749|Placebo Comparator|Group 1-2|The placebo is 0.9% sodium chloride injection
11138833|NCT03804749|Experimental|Group 2-1|The dose of suramin sodium is 15mg/kg
11138834|NCT03804749|Placebo Comparator|Group 2-2|The placebo is 0.9% sodium chloride injection
11138835|NCT03804749|Experimental|Group 3-1|The dose of suramin sodium is 20mg/kg
11138836|NCT03804749|Placebo Comparator|Group 3-2|The placebo is 0.9% sodium chloride injection
11138837|NCT03804736|Active Comparator|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
11138838|NCT03804736|Experimental|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
11138839|NCT03804723|Experimental|GC withdrawal|
11138840|NCT03804723|Placebo Comparator|non GC withdrawal|
11138841|NCT03804710|Experimental|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
11138842|NCT03804710|Experimental|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
11138843|NCT03804710|Placebo Comparator|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
11138844|NCT03804697|Experimental|selective anticoagulation group|"Selective anticoagulation group used anticoagulant when thromboelastogram（TEG） indicated hypercoagulability.
~TEG was performed 1 day before the surgery, 1 day after the surgery, 3 days after the surgery, and 5 days after the surgery.
~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
11138845|NCT03804697|Active Comparator|conventional anticoagulation group|"The Intervention for conventional anticoagulation group was using anticoagulant until one month after surgery routinely.
~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
11138846|NCT03804684|Experimental|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases. Eyes will have normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal, reliable standard automatic perimetry and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
11138847|NCT03804684|Experimental|Mild Glaucoma|Subjects between 21 and 80 years of age with Mild Glaucoma. Eyes will have reliable standard automatic perimetry with no more than -6 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
11138905|NCT03804203|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11138906|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
11138848|NCT03804684|Experimental|Moderate Glaucoma|Subjects between 21 and 80 years of age with Moderate Glaucoma. Eyes will have reliable standard automatic perimetry with between -6 mean and -12 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
11138849|NCT03804671|Experimental|All Subjects|Test treatment T followed by Reference treatment R
11138850|NCT03804645|Experimental|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
11138851|NCT03804645|Experimental|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
11138852|NCT03804645|Experimental|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
11138853|NCT03804645|Experimental|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
11138854|NCT03804645|Experimental|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
11138855|NCT03804632||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from October to December 2017 with age 18 and above
11138856|NCT03804619|Experimental|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
11138857|NCT03804619|Experimental|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
11138858|NCT03804606|Experimental|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
11138859|NCT03804606|No Intervention|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
11138860|NCT03804606|Active Comparator|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
11138861|NCT03804593||Group 1|Diagnosis of cirrhosis and no HCC confirmed by medical imaging including MRI or CT performed within 6 months of study enrollment. If lesions are present, a Liver Imaging Reporting and Data System (LI-RADS) score of LR-1 or LR-2.
11138862|NCT03804593||Group 2|Diagnosis of HCC confirmed by medical imaging (MRI or CT performed within 6 months of study enrollment with LI-RADS score of LR-5) and/or biopsy with histopathology.
11138863|NCT03804567|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
11138864|NCT03804567|Active Comparator|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
11138865|NCT03804554||Patients taking nivolumab|
11138866|NCT03804541|Experimental|[14C]Ensartinib|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。
11138867|NCT03804528|Experimental|Exercise group|Each participant will engage in 60 minute daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions).
11138868|NCT03804515|Experimental|14C-labeled Poziotinib|
11138869|NCT03804502|Experimental|TearCare|Subjects will receive one TearCare treatment at the baseline visit
11138870|NCT03804489|Experimental|Decision aids group|Shared decision making using decision aids,
11138871|NCT03804489|No Intervention|Control group|Standard oral explanation with booklet.
11138872|NCT03804476|Experimental|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
11138873|NCT03804476|Placebo Comparator|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
11138874|NCT03804463|Experimental|radical surgery group|Endometrial cancer radical surgery to be administered in this arm.
11138875|NCT03804463|Experimental|fertility preservation group|Fertility-sparing surgery to be administered in this arm.
11138876|NCT03804463|Experimental|ovarian preservation group|Ovarian preservation surgery to be administered in this arm.
11138877|NCT03804450|Experimental|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
11138878|NCT03804450|Experimental|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
11138907|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
11138908|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
11138879|NCT03804424|Experimental|Cohort 1: Pilot 64Cu-LLP2A Imaging|"12 adult individuals (6 patients with known MM; 6 healthy volunteers)
~All subjects who enter the study in Cohort 1 will be injected with 11 mCi (RANGE 8.8-13.2 mCi) of 64Cu-LLP2A and undergo body imaging twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry Body imaging will be performed approximately at the following time points:
~Immediately after 64Cu-LLP2A administration (2 subjects 1 healthy volunteer and 1 subject with MM)
~1 to 3 hours after 64Cu-LLP2A administration (4 subjects)
~3 to 8 hours after 64Cu-LLP2A administration (4 subjects)
~18 to 30 hours after 64Cu-LLP2A administration (2 subjects: 1 healthy volunteer and 1 subject with MM)
~10 of the subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
11138880|NCT03804424|Experimental|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"20 patients with MM will be recruited
~Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic image over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI scan for attenuation correction, subjects will be injected with a dose of 11 mCi of 64Cu-LLP2A (RANGE 8.8 - 13.2 mCi) and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
11138881|NCT03804411|Experimental|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
11138882|NCT03804411|Experimental|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
11138883|NCT03804398|Experimental|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
11138884|NCT03804398|Active Comparator|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
11138885|NCT03804385|Other|intercostal tube|insertion of intercostal tube is surgical operation used in pneumothorax
11138886|NCT03804372|Experimental|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
11138887|NCT03804359|No Intervention|GEMRITUX protocol|6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
11138888|NCT03804359|Experimental|Personalized treatment|"restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)
~restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;
~Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6."
11138889|NCT03804333|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
11138890|NCT03804333|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11138891|NCT03804320|Other|Patients with small renal masses|Active surveillance
11138892|NCT03804307|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
11138893|NCT03804307|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11138894|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
11138895|NCT03804281|Experimental|Test group|esthetic crown lengthening with microsurgical approach
11138896|NCT03804281|Active Comparator|Control group|esthetic crown lengthening with conventional approach.
11138897|NCT03804268|Experimental|AGN-190584|One drop bilaterally, once daily for 30 days
11138898|NCT03804268|Placebo Comparator|Vehicle|One drop bilaterally, once daily for 30 days
11138899|NCT03804255||Observational (survey)|Participants complete a self-administered web-based Biomarker Survey and may also complete an Outcome Validation Survey.
11138900|NCT03804242|Experimental|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
11138901|NCT03804242|No Intervention|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
11138902|NCT03804229|Experimental|active group|Take two pills (100 mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
11138903|NCT03804229|Placebo Comparator|control group|Take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
11138904|NCT03804203|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
11138909|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
11138910|NCT03804177|Experimental|implant with hyaluronic melatonin vit c|implant placement with topical application of hyaluronic and melatonin and systemic administration of vitamin C
11138911|NCT03804177|Active Comparator|immediate implant|immediate implant placement alone without melatonin or hyauronic acid nor vitamin c
11138912|NCT03804164|Experimental|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
11138913|NCT03804151|Experimental|FitSpirit Intervention|FitSpirit physical activities and events are organized by participants' schools during the school year. Girl-only activities such as physical activity sessions, speaking engagements, turnkey running program and special events can be offered. The number, type and frequency of activities are decided by each school.
11138914|NCT03804138||Patient|patient with COPD
11138915|NCT03804138||control group|patient without COPD
11138916|NCT03804086|Experimental|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
11138917|NCT03804086|Active Comparator|Control Group|Open flap debridement alone.
11138918|NCT03804073|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
11138919|NCT03804073|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11138920|NCT03804060|Experimental|Cooling + Recanalization|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after recanalization.
11138921|NCT03804060|Active Comparator|Recanalization only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.
11138922|NCT03804047|Experimental|Kinesio Tape (KTG)|Participants allocated into the KTG will receive a single time application of the kinesio tape flexible tape (Kinesio® Tex, Albuquerque, NM, USA) in the upper-body (i.e., back part of the trunk) and in the lower-body (i.e., legs and ankle) according to standardized procedures (https://kinesiotaping.com/how-to/). The tape is latex-free and wearable for weeks without causing skin irritation (i.e., hypoallergenic); and safe for populations ranging from pediatric to geriatric. The tape will be applied by a Physical Therapist with experience in tape application. Tape application will be conducted in a private room with a complete structure for the procedure.
11138923|NCT03804047|Sham Comparator|Sham Tape (STG)|Participants allocated into the STG will receive a single time application of an inflexible tape (i.e., sham tape) in the same body segments as the intervention condition. Tape application will be conducted in a private room with a complete structure for the procedure.
11138924|NCT03804034|Experimental|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
11138925|NCT03804034|Experimental|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
11138926|NCT03804034|Experimental|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
11138927|NCT03804034|No Intervention|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
11138928|NCT03804021||1|Subjects who received a dose of ADVM-043 in a prior clinical study
11138929|NCT03804008|Active Comparator|Fundamental advice and a heel cup|
11138930|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise|
11138931|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise and injection|
11138932|NCT03803995|Other|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
11138933|NCT03803982|Experimental|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
11138934|NCT03803982|No Intervention|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
11138935|NCT03803969|Other|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
11138936|NCT03803956|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
11138937|NCT03803956|Placebo Comparator|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
11138938|NCT03803943|Experimental|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
11138939|NCT03803943|Placebo Comparator|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
11138940|NCT03803930|Other|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
11138941|NCT03803930|Other|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
11138942|NCT03803930|Other|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
11138943|NCT03803930|Other|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
11138944|NCT03803917|Other|Treatment|Injection with freshly collected autologous adipose tissue
11138945|NCT03803904|Experimental|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
11138946|NCT03803904|Active Comparator|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
11138947|NCT03803891||Endoscopic full-thickness resection|Patients with neoplastic lesions less than 30mm unresectable en bloc by other less invasive endoscopic techniques, including lesions suggestive of T1 colorectal cancer, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting sign (recurrent, incomplete prior resection or untreated lesions).
11138948|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
11138949|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
11138950|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
11138951|NCT03803865|Active Comparator|Headspace|30-day smartphone based mindfulness training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
11138952|NCT03803865|Active Comparator|Recharge|30-day smartphone based reflection and problem solving training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
11138953|NCT03803852|Experimental|0°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 0°
11138954|NCT03803852|Experimental|45°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 45°
11138955|NCT03803852|Experimental|90°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 90°
11138956|NCT03803852|Experimental|135°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 135°
11138957|NCT03803839|Active Comparator|Clodronate|1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
11138958|NCT03803839|Placebo Comparator|Saline|1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
11138959|NCT03803826|Experimental|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:
~adjust the atrioventricular interval so that E and A waves do not overlap
~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.
~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
11138960|NCT03803826|No Intervention|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
11138961|NCT03803813||sepsis group|Patients have developed sepsis at ICU admission or during their ICU stay.
11138962|NCT03803813||non-sepsis group|Patients do not develope sepsis at ICU admission or during their ICU stay.
11138963|NCT03803800|Experimental|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
11138964|NCT03803800|Placebo Comparator|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
11138965|NCT03803800|Experimental|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
11139099|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
11138966|NCT03803800|Placebo Comparator|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
11138967|NCT03803787|Experimental|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
11138968|NCT03803787|No Intervention|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
11138969|NCT03803787|Experimental|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
11138970|NCT03803787|No Intervention|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
11138971|NCT03803774|Experimental|Treatment (IMRRT, birinapant)|Beginning on day 1, patients undergo IMRRT 5 days a week (Monday-Friday). Patients also receive birinapant IV over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
11138972|NCT03803761|Experimental|Treatment (copanlisib, fulvestrant)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and fulvestrant IM over 1-2 minutes on days 1 and 15 of cycle 1 and on day 1 beginning cycle 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11138973|NCT03803748|Experimental|Eyestil Plus®|"It's a clinical comparative performance study. Eyestil Plus® eyedrops multidose to be not inferior to Vismed multidose eye drops. Eyestil Plus is an ophthalmic aqueous formulation, multidose sterile preservative free, medical device, class IIB and CE marked. It contains 0.4% sodium hyaluronate. It is not available yet in the French Market.
~The dosage per medical device will be 6 drops a day per dry eye during the three months study period,"
11138974|NCT03803748|No Intervention|Vismed|"Vismed Multi® is also a sterile multidose preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate.
~The dosage per medical device will be 6 drops a day per dry eye during the three months study period.
~The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes."
11138975|NCT03803722|Experimental|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.
~dosage: 6 drops a day for three months period."
11138976|NCT03803722|No Intervention|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.
~dosage: 6 drops a day for three months period."
11138977|NCT03803709|Placebo Comparator|placebo|"maltodextrin received at 4g/day on day 3 and 4
~maltodextrin received at 8g/day from day 5 to 14
~maltodextrin received at 16g/day from day 15 to 20"
11138978|NCT03803709|Experimental|inulin|"inulin received at 4g/day on day 3 and 4
~inulin received at 8g/day from day 5 to 14
~inulin received at 16g/day from day 15 to 20"
11138979|NCT03803696|Active Comparator|Enhanced Standard Care|"Baseline data collection, registration and randomization
~Inform primary transplant clinician of sexual dysfunction causing distress
~Receive American Cancer Society sexual educational material"
11138980|NCT03803696|Active Comparator|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization
~3 Monthly visits with trained study nurse practitioners
~Referral to specialist if
~Psychological etiology
~Sexual Trauma
~Relationship Discord
~Concern for Malignancy or anatomic scarring requiring surgery"
11138981|NCT03803683|Experimental|mLab App Intervention|Youth randomized to the intervention arm (arm 1) will be provided with the mLab App, 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at their 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
11138982|NCT03803683|Active Comparator|Standard of Care HIV Information Control Arm|Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
11138983|NCT03803683|Active Comparator|HIV Home Tests|Youth randomized to the HIV home testing arm (arm 3) will be provided with the 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at the 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
11138984|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
11138985|NCT03803657||Neonates|Neonates 0-28 days
11138986|NCT03803657||Infant|29 days to 1 year
11138987|NCT03803657||Child|>1 year and <10 kg
11138988|NCT03803644|Experimental|Administration of CC-92480 - Part 1|dose escalation
11138989|NCT03803644|Experimental|Administration of CC-92480 under fasted conditions - Part 2|Food effect
11138990|NCT03803644|Experimental|Administration of CC-92480 under fed conditions - Part 2|food effect
11139100|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
11138991|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with <5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
11138992|NCT03803618||Control|Age and sex matched neighborhood controls
11138993|NCT03803605|Experimental|VRC07-523LS + Vorinostat (VOR)|Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours.
11138994|NCT03803592|Experimental|Dyadic MCS program|"Participants from the experimental group will receive a dyadic multisensory and cognitive stimulation (MCS) programme.
~The MCS program is a 15- week program. In the first 4 weeks, participants will attend the center-based Face-to-face (FTF) session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers with the PWD at home and was suggested to deliver the intervention 3 times/week at home. The home-based sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions over the intervention period."
11138995|NCT03803592|No Intervention|Control group|Participants from the control group will receive usual care and no intervention will be received.
11138996|NCT03803566|Experimental|Faster|This group will comprise participants who complete the grooved pegboard test at baseline with a time of less than 71 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
11138997|NCT03803566|Experimental|Slower|This group will comprise participants who complete the grooved pegboard test at baseline with a time of greater than 70 seconds. One half of the members in this group will perform the two interventions in the order of pegboard practice and then force control practice, whereas the other half of the group will perform the two practice interventions in the opposite order.
11138998|NCT03803553|Experimental|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance
~- ctDNA-POSITIVE: FOLFIRI Protocol
~FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).
~infusions will consist of the drugs
~5-Fluorouracil
~Irinotecan
~Leucovorin"
11138999|NCT03803553|Active Comparator|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance
~-- Active surveillance.
~Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.
~After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.
~Additional scans and tumor markers will be at the discretion of the clinician. ."
11139000|NCT03803553|Active Comparator|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance
~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.
~Additional scans and tumor markers will be at the discretion of the clinician"
11139001|NCT03803553|Experimental|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.
~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab
~-ctDNA-Positive, MSI-H: Nivolumab Protocol
~Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).
~infusions will consist of the drug Nivolumab"
11139002|NCT03803553|Experimental|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.
~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab
~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol
~Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).
~infusions will consist of the drug Cetuximab"
11139003|NCT03803540|Experimental|Fecal Microbiota Transplantation|Lean healthy donor frozen fecal microbiota will be administered via duodenal infusion in an upper gastrointestinal endoscopy
11139004|NCT03803527|Experimental|EST|"All subjects enrolled into the study will:
~Complete a clinical history
~Have vitals obtained
~Complete Patient-reported outcomes
~Have Esophageal mucosal biopsies collected as part of standard of care at the time of the most recent endoscopy to report the peak eosinophilia per hpf.
~Complete the Esophageal String test"
11139005|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb < 10 g/dL). Ambulatory hemodialysis 3 times per week.
~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.
~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
11139006|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb > 10 g/dL). Ambulatory hemodialysis 3 times per week.
~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.
~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
11139007|NCT03803488|Experimental|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
11139041|NCT03803202|Experimental|Stage 1, Group 1 ASP3772 in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
11139008|NCT03803475|Experimental|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 mCi +/- 10% of 68Ga-PSMA-11.
11139009|NCT03803449|Active Comparator|Control group|Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam
11139010|NCT03803449|Experimental|Fentanyl group|Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.
11139011|NCT03803436|Experimental|Study arm|Liver transplant
11139012|NCT03803436|Active Comparator|Parallel arm|Chemotherapy
11139013|NCT03803423|Experimental|The Donor App|Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
11139014|NCT03803397|Experimental|PV-001-DC alone|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells
11139015|NCT03803384|Experimental|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
11139016|NCT03803384|Experimental|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
11139017|NCT03803371|Experimental|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets by mouth on Day 1 of period 1 or 2
11139018|NCT03803371|Active Comparator|Ultracet tablet|Ultracet tablet (Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg) by mouth on Day 1 of period 1 or 2
11139019|NCT03803358|Experimental|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
11139020|NCT03803358|Active Comparator|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
11139021|NCT03803332|Active Comparator|Exposure Therapy|Participants receive 10 90-minute exposure therapy sessions for PTSD following the treatment procedures as outlined in the standard Prolonged Exposure therapy manual.
11139022|NCT03803332|Active Comparator|Interpersonal Psychotherapy|Participants receive 14 weekly 50-minute Interpersonal Psychotherapy sessions focused on the interpersonal sequelae of trauma in current daily life.
11139023|NCT03803319|Active Comparator|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
11139024|NCT03803319|Active Comparator|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
11139025|NCT03803319|Placebo Comparator|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
11139026|NCT03803306|Experimental|Vedic Medical Astrology Group (VMA)|
11139027|NCT03803306|Sham Comparator|Placebo vedic medical astrology (PMA)|
11139028|NCT03803293|Other|Primary cohort|All eligible Biobank participants that receive the majority of their care at Mayo Clinic based on EHR length and depth had pharmacogenomic testing done.
11139029|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
11139030|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
11139031|NCT03803267|Active Comparator|Erector spinae plane block|Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique
11139032|NCT03803267|Active Comparator|Quadratus lumborum block|Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique
11139033|NCT03803254|Experimental|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
11139034|NCT03803254|Active Comparator|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
11139035|NCT03803241|Experimental|PVE + CD133|preop portal vein embolization + stem cells infusion
11139036|NCT03803241|Sham Comparator|PVE|only preop portal vein embolization
11139037|NCT03803228|Experimental|DUOSTIM|(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted.
11139038|NCT03803228|Active Comparator|Conventional stimuli|"(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted.
~(stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1"
11139039|NCT03803215||Theophylline group|Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
11139040|NCT03803215||Control untreated group|A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder
11139187|NCT03802201|Experimental|PTG-300|PTG-300 Active
11139042|NCT03803202|Active Comparator|Stage 1, Group 1 PCV13 in Adults|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
11139043|NCT03803202|Experimental|Stage 2, Group 2 ASP3772 in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
11139044|NCT03803202|Active Comparator|Stage 2, Group 2 PCV13 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
11139045|NCT03803202|Active Comparator|Stage 2, Group 3 PPSV23 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
11139046|NCT03803189|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports each time they complete a survey, and their PCP will receive supports in the EMR to facilitate postpartum mental healthcare.
11139047|NCT03803189|No Intervention|Usual care|The control arm will not receive intervention materials, unless they express suicidality, in which case they will receive a message with supports for suicidality including local emergency departments and crisis lines and an urgent message via EMR and fax will be sent to their PCP. Control arm participants will be asked to complete a baseline e-survey in their third trimester, and a follow-up e-survey 24-weeks after their baby is born.
11139048|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
11139049|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling & root planing.
11139050|NCT03803163|Experimental|TransCon Treprostinil|
11139051|NCT03803150|Experimental|PRA approach|PRA extends downward in curvilinear fashion in cervicomastoid skin crease
11139052|NCT03803150|Active Comparator|RT approach|RT begins 5mm below the ear lobe and continues 3 to 3.5cm inferiorly.
11139053|NCT03803137|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
11139054|NCT03803124|Active Comparator|Tolvaptan|"Drug: Tolvaptan
~1 tablet before renography"
11139055|NCT03803124|Placebo Comparator|Placebo|"Placebo
~1 tablet before renography"
11139056|NCT03803111|Experimental|Initial FCM|Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program
11139057|NCT03803111|Experimental|Initial exercise|Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM
11139058|NCT03803085|Experimental|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
11139059|NCT03803085|Experimental|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
11139060|NCT03803072|Experimental|Time restricted eating (TRE)|prolonging the duration of fasting between the last evening meal and the first meal of the next day
11139061|NCT03803072|No Intervention|control|Standard care. Will receive a booklet about physical activity recommendations and healthy eating in pregnancy
11139062|NCT03803059|Experimental|Fine lines and wrinkles|Microneedle treatment to face and neck areas.
11139063|NCT03803033|Experimental|Intervention|The objective of the group was to introduce an experimental clinical pharmacy-based home medication review service in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan. The intervention under evaluation in the study is the pharmacy-based home medication review service.
11139064|NCT03803033|No Intervention|Control|The objective of the control group was to identify changes in treatment and associated costs that take place in patients as part of the usual practice, as compared to the intervention arm, regardless of the clinical pharmacist service intervention.
11139065|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.
~fractional flow reserve and SPECT detection before and after intervention."
11139066|NCT03803007|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
11139067|NCT03803007|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
11139068|NCT03802994|Experimental|Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
11139069|NCT03802994|Active Comparator|Elderly DM II and/or HTN, normal renal function|Persons with DMII or hypertension but normal renal function between ages 65-75 years of age
11139070|NCT03802994|Active Comparator|Healthy elderly|Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
11139071|NCT03802994|Active Comparator|Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
11139072|NCT03802994|Experimental|Healthy young|Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
11139073|NCT03802955|Experimental|ADG106 Dose escalation|
11139074|NCT03802942|Experimental|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
11139075|NCT03802942|No Intervention|Control|Regular meal plan supplied by the hospital
11139094|NCT03802812|Active Comparator|Investigational arm|"Perform bronchial washing using investigational methods.
~virtual bronchoscopic navigation (VBN)-guided thin bronchoscope (4.0mm of outer diameter)"
11139095|NCT03802799|Experimental|ZYN002|ZYN002 - CBD Transdermal Gel
11139096|NCT03802786|Experimental|Moderate hepatic impairment|Single dose of Imeglimin
11139097|NCT03802786|Experimental|Normal hepatic function|Single dose of Imeglimin
11139076|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:
~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.
~Derivation Cohort of Prognostic Prediction Model:
~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
11139077|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:
~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.
~Validation Cohort of Prognostic Prediction Model:
~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
11139078|NCT03802916|Experimental|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
11139079|NCT03802916|Experimental|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
11139080|NCT03802903|Experimental|Remo-Wax|Test product will be applied into ear canal for 20-60 minutes.
11139081|NCT03802877|Active Comparator|Resource bank|The web-based resource bank includes information and perspectives about GDM, nutrition, and physical activity. The information is presented through video capsules, on-line text, printable pdfs, and podcasts. It is presented by health care professionals and patients.
11139082|NCT03802877|Experimental|Resource bank and ePlatform|In addition to resource bank access, participants will receive a digital scale, physical activity monitor (pedometer), and ePlatform log-in information. They will track daily weights and step counts. They will receive prompts to access educational and motivational tools based on the data that they enter and whether or not they enter data. The investigators will use the ePlatform developed by StepsCount, a Canadian pedometer company with a well-developed ePlatform for pedometer data upload, tracking, and automated messaging. The company is permitting us further customization for study purposes. Data will be uploaded onto a secure cloud-based platform controlled by the pedometer and digital scale companies.
11139083|NCT03802877|Experimental|Resource bank and health coach|"In addition to resource bank access, the coach will contact the participant weekly (telephone, text, email) to discuss progress and challenges in terms of achieving physical activity goals, rate of GWG, and maintaining health eating patterns, as well as any concerns.Participants not randomized to a coaching strategy will be advised to consult with their treating healthcare team directly if they develop symptoms of concern.
~The coach will encourage participants to track their weight gain and physical activity (e.g., walks, classes, activity lists, etc.) and to share this information. However, they will not have access to the study ePlatform and will not be provided with pedometers or digital scales."
11139084|NCT03802877|Experimental|Resource bank with ePlatform and coach|Participants will have resource bank access as well as ePlatform and coaching interventions.The health coach will have access to the data on the ePlatform. They will receive telephone calls from the research assistant/health coach if they are off target despite the platform tools and support. They will be encouraged to consult the resource bank and will brainstorm with the health coach to decide how to achieve their GWG and step count targets.
11139085|NCT03802864|Experimental|Liposomal Bupivacaine|Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
11139086|NCT03802864|Active Comparator|Standard Bupivacaine|Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
11139087|NCT03802851|Experimental|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
11139088|NCT03802851|No Intervention|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
11139089|NCT03802838|Active Comparator|Acupuncture|Acupuncture+Amisulpride
11139090|NCT03802838|Other|Amisulpride|Amisulpride only.
11139091|NCT03802825|Active Comparator|Patient Navigation|Participants randomized to the patient navigation only arm will be referred to a KPNW patient navigator using a standard electronic health record-based referral process. Once the participant has completed the Your Current Life Situation (YCLS) assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 month period by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention. Participant will also receive monthly mailing of American Diabetes Association educational materials.
11139092|NCT03802825|Experimental|Patient Navigation+Diabetes Self-Management Training|"In addition to receiving patient navigation as described above, participants in this arm will also be referred to Project Access NOW by study staff using REDCap. As part of the partnership with KPNW, Project Access NOW will be provided with participants' contact information via REDCap to facilitate the referral to a certified CHW within a community-based organization. Project Access NOW will connect participants to a community-based organization based on their preference, previous experience with an agency, geography, and capacity.
~The CHW will follow-up with the participant to conduct a home visit and follow-up on community-based referrals already placed by the KPNW patient navigator and assess for additional needs. The timing of the diabetes self-management training will be based on the needs of the participant."
11139093|NCT03802812|No Intervention|Conventional arm|"Perform bronchial washing using conventional methods.
~CT-guided thick bronchoscope"
11139098|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
11139101|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab Alone|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab.
11139102|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab + Tremelimumab|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab + Tremelimumab.
11139103|NCT03802734|Experimental|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
11139104|NCT03802734|No Intervention|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
11139105|NCT03802721|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
11139106|NCT03802721|Experimental|Brussels sprouts before 50 ng dose|Subjects will consume 50 g (about 1/2 cup) of lightly steamed Brussels sprouts each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
11139107|NCT03802721|Experimental|DIM supplement before 50 ng dose|Subjects will consume 300 mg DIM supplement ( 2 capsules of BioResponse DIM® 150) each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP). A 300 mg DIM dose will be co-administrated with the 50 ng BaP dose
11139108|NCT03802708|Other|control|control
11139109|NCT03802682|Experimental|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A [reference]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B [test]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
11139110|NCT03802682|Experimental|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B [test]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A [reference]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
11139111|NCT03802669||caries free children aged between 3-6|
11139112|NCT03802669||caries active children aged between 3-6|
11139113|NCT03802669||caries free children aged between 6-12|
11139114|NCT03802669||caries active children aged between 6-12|
11139115|NCT03802669||caries free adult aged between 18-25|
11139116|NCT03802669||caries active adult aged between 18-25|
11139117|NCT03802656|Experimental|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
11139118|NCT03802630|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
11139119|NCT03802630|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
11139120|NCT03802617|Experimental|MR13A9 low dose|
11139121|NCT03802617|Experimental|MR13A9 medium dose|
11139122|NCT03802617|Experimental|MR13A9 high dose|
11139123|NCT03802617|Placebo Comparator|Placebo|
11139124|NCT03802604|Experimental|Talimogene laherparepvec + Atezolizumab|"Talimogene laherparepvec: Cycle 1 - 10^6 PFU/mL. Cycle 2, 3, 4 & 5 - 10^8 PFU/mL.
~Atezolizumab 840 mg"
11139125|NCT03802591|Experimental|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
11139126|NCT03802591|Placebo Comparator|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
11139127|NCT03802578|Experimental|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
11139128|NCT03802578|No Intervention|CONTROL GROUP|Patients in the control group continued their usual medical care.
11139129|NCT03802565|Experimental|Tolperisone 50 mg|TID (150 mg/day)
11139130|NCT03802565|Experimental|Tolperisone 100 mg|TID (300 mg/day)
11139131|NCT03802565|Experimental|Tolperisone 150 mg|TID (450 mg/day)
11139132|NCT03802565|Experimental|Tolperisone 200 mg|TID (600 mg/day)
11139133|NCT03802565|Placebo Comparator|Placebo|TID
11139134|NCT03802552|Experimental|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
11139135|NCT03802552|Experimental|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
11139136|NCT03802539|Experimental|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
11139137|NCT03802539|No Intervention|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
11139138|NCT03802526|Experimental|NVP-1805-R1|"Drug: NVP-1805-R1
~1 tablet, oral dosing"
11139139|NCT03802526|Experimental|NVP-1805-R2|"Drug: NVP-1805-R2
~1 tablet, oral dosing"
11139140|NCT03802526|Experimental|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
11139141|NCT03802513|Other|Single arm|This study has 1 health-related intervention. Veterans with somatosensory tinnitus will receive individualized physiotherapy.
11139142|NCT03802487|Experimental|Sotagliflozin|One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.
11139143|NCT03802474||Group A|girls with primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
11139144|NCT03802474||Group B|girls with normal painless menstruation without primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
11139145|NCT03802461|Active Comparator|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
11139146|NCT03802461|No Intervention|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
11139147|NCT03802448|Active Comparator|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.
~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
11139148|NCT03802448|Experimental|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.
~Myofascial wrist retinaculum (Transverse carpal ligament) release.
~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
11139149|NCT03802435|Experimental|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
11139150|NCT03802435|Active Comparator|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
11139151|NCT03802435|Placebo Comparator|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
11139152|NCT03802422|Experimental|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
11139153|NCT03802422|Placebo Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
11139154|NCT03802396|Experimental|CN-105|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
11139155|NCT03802396|Placebo Comparator|Placebo|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17
~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
11139156|NCT03802370|Other|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
11139157|NCT03802357|Experimental|High training intensity|Exercise Training with high intensities consists of a cycling Interval Training at 100% of the individual Peak work rate, resistance Training for 3 sets à 8 repetitions and squats on a Vibration plate.
11139158|NCT03802357|Active Comparator|moderate training intensity|Exercise Training with moderate intensities consists of a cycling endurance Training at 60% of the individual Peak work rate, resistance Training for 3 sets à 20 repetitions and squats on the floor.
11139159|NCT03802344|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
11139160|NCT03802344|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
11139161|NCT03802344|Placebo Comparator|Vehicle|One application daily for 8 weeks
11139162|NCT03802331|Experimental|Test Treatment|fed
11139163|NCT03802331|Experimental|Reference Treatment|fasted
11139164|NCT03802318|Experimental|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
11139165|NCT03802318|Placebo Comparator|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
11139166|NCT03802318|Experimental|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
11139167|NCT03802318|Placebo Comparator|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
11139168|NCT03802305|Experimental|Computerized intraosseous technique (Quicksleeper™)|patients will receive the anesthetic solution with computerized intraosseous technique anesthesia near the tooth roots involved.
11139169|NCT03802305|Active Comparator|loco-regional anesthesia (IANB technique)|patients will receive the anesthetic solution with the loco-regional anesthesia technique: near the place where the nerve goes into the jaw, based on osteo muscular markers.
11139170|NCT03802292|Active Comparator|Single Ascending Dose YQ23|
11139171|NCT03802292|Placebo Comparator|Single Dose Placebo|
11139172|NCT03802279||Rhabdomyolysis with myoblasts back up|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited from a diagnostically muscle biopsy and whose myoblasts are available.
~Patients benefit from an effort test as part of their care."
11139173|NCT03802279||Rhabdomyolysis|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited or not from a diagnostically muscle biopsy but whose myoblasts are not available.
~Patients benefit from an effort test as part of their care."
11139174|NCT03802279||Witness patients : effort test|10 patient-matched healthy controls for age and sex having performed an effort test and cardiac exploration as part of their care.
11139175|NCT03802279||Witness patients : myoblasts|6 healthy controls matched by age and sex having performed a muscle biopsy as part of their care and whose myoblasts are kept.
11139176|NCT03802266|Experimental|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
11139177|NCT03802266|Active Comparator|CT group|CT-guided Transthoracic Needle Aspiration
11139178|NCT03802253|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
11139179|NCT03802253|Active Comparator|RCD|Participants in this group will focus on standard care with daily reduced calorie diet (RCD)
11139180|NCT03802240|Experimental|Sintilimab +IBI305+Pemetrexed+Cisplatin|
11139181|NCT03802240|Experimental|Sintilimab +Placebo2+Pemetrexed+Cisplatin|
11139182|NCT03802240|Active Comparator|Placebo1+Placebo2+Pemetrexed+Cisplatin|
11139183|NCT03802227|Experimental|Group 1|NKTR-181 400 mg and oxycodone IR placebo
11139184|NCT03802227|Experimental|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
11139185|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
11139186|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
11139188|NCT03802188||SLE Cohort|Investigators will use existing data collected on adult SLE patients enrolled into respective study cohorts from participating centers.
11139189|NCT03802188||Qualitative group|For the interviews, patients with SLE who are currently or have taken Hydroxychloroquine will be recruited from rheumatology clinics in Calgary and Montreal to participate in an interview and/or participate in a brief survey.
11139190|NCT03802162|Experimental|CKD-355A|
11139191|NCT03802162|Experimental|CKD-355B|
11139192|NCT03802162|Active Comparator|D797, D324|
11139193|NCT03802149|Experimental|Ulipristal Acetate|Participants will be administered a one time dose of 90mg ulipristal acetate 18-24-hours prior to dilation and evacuation (surgical abortion) for cervical preparation.
11139194|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
11139195|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
11139196|NCT03802123|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
11139197|NCT03802110|Experimental|Single Arm|Defibrillation threshold (DFT) testing Arm
11139198|NCT03802097|Experimental|Treatment group|No antimicrobial prophylaxis
11139199|NCT03802097|No Intervention|Control group|Antimicrobial prophylaxis
11139200|NCT03802084|Experimental|vactosertib/imatinib combination|
11139201|NCT03802071|Experimental|Durvalumab+doxorubicin combination|
11139202|NCT03802058|Experimental|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
11139203|NCT03802045|Experimental|Low frequency EA|"25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 2Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm)."
11139204|NCT03802045|Experimental|High frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
11139205|NCT03802045|Experimental|Alternating frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz and 2Hz for 3 seconds each; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
11139206|NCT03802045|Active Comparator|Control Group|"25 participants will follow exactly the same protocol as the experimental groups, however they will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient.
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
11139207|NCT03802045|Placebo Comparator|Placebo Group|"25 participants will will follow exactly the same protocol as the experimental groups, however an adhesive moxa (Dong Yang®) will be placed on each acupoint and the needle will be inserted over it, so that the participant only feels the needle prick, but without perforation of the skin and the deQi sensation. In addition, as in the control group, the electrodes will be connected to the needles, however, no electrical current will be applied.
~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
11139208|NCT03802032|Experimental|Study Group|15g of Topical Xylocaine gel
11139209|NCT03802032|Placebo Comparator|Control group|15g of KY Jelly
11139210|NCT03802019|Experimental|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
11139211|NCT03802019|Experimental|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
11139212|NCT03802019|Experimental|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
11139213|NCT03802019|Experimental|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
11139214|NCT03802019|Experimental|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
11139215|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
11139216|NCT03801993||All Subjects|Subjects with a diagnosis of Cystic Fibrosis (CF) who meet all the inclusion and none of the exclusion criteria will be eligible for participation in this study.
11139217|NCT03801980|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
11139218|NCT03801980|Placebo Comparator|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
11139219|NCT03801967|Experimental|AZD9977|Each participant will receive AZD9977 at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
11139220|NCT03801967|Placebo Comparator|Placebo|Each participant will receive placebo at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
11139221|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
11139222|NCT03801941|Experimental|Group A|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with the ATLAS Device at the 4th day and without the device at the 5th day of a 4 weeks rehabilitation program.
11139223|NCT03801941|Experimental|Group B|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without the ATLAS Device at the 4th day and with the device at the 5th day of a 4 weeks rehabilitation program.
11139224|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
11139225|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
11139226|NCT03801915|Experimental|1/Arm 1|Pre-operative escalation doses of MVT-5873,pancreatectomy or hepatectomy and post-operative MVT-5873 treatment
11139227|NCT03801915|Experimental|2/Arm 2|Pre-operative RD of MVT-5873, pancreatectomy orhepatectomy and post-operative MVT-5873 treatment
11139228|NCT03801902|Experimental|Arm I (durvalumab, ACRT)|Patients receive durvalumab IV over 60 minutes on day 1 starting 2 weeks prior to radiation therapy. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ACRT 1 fraction per day, 5 days per week for 15 fractions.
11139229|NCT03801902|Active Comparator|Arm II (durvalumab, standard RT)|Patients receive durvalumab as in Arm I. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions.
11139230|NCT03801889|Experimental|Cohort 1|SP-420 initially at 28 mg/kg
11139231|NCT03801889|Experimental|Cohort 2|SP -20 initially at 56 mg/kg
11139232|NCT03801889|Experimental|Cohort 3|SP-420 initially at 84 mg/kg
11139233|NCT03801876|Experimental|Group I (PBT, paclitaxel, carboplatin, esophagectomy)|Patients undergo PBT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive paclitaxel (50 mg/m^2) IV and carboplatin (AUC=2 [maximum 300 mg]) IV on days 1, 8, 15, 22, 29, and 36 while undergoing PBT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
11139234|NCT03801876|Active Comparator|Group II (IMRT, paclitaxel, carboplatin, esophagectomy)|Patients undergo IMRT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive paclitaxel (50 mg/m^2) IV and carboplatin (AUC=2 [maximum 300 mg]) IV on days 1, 8, 15, 22, 29, and 36 while undergoing IMRT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
11139235|NCT03801863||Ultrasound-guided Erector Spinae Block|Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
11139236|NCT03801863||No Ultrasound-guided Erector Spinae Block|Patients with no peripheral nerve block to serve as the control.
11139237|NCT03801850|Experimental|observational cohort|
11139238|NCT03801837|Active Comparator|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
11139239|NCT03801837|Placebo Comparator|Control Diet|This group will continue with their Habitual Diet
11139240|NCT03801824|Active Comparator|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
11139241|NCT03801824|Experimental|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
11139242|NCT03801798|Experimental|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.
~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL
~V2 to V17 : IV bolus injection twice a week
~V18 to V33 : IV bolus injection once a week"
11139243|NCT03801798|Placebo Comparator|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.
~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL
~V2 to V17: IV bolus injection twice a week
~V18 to V33: IV bolus injection once a week"
11139244|NCT03801785|Experimental|Children induced to suck pacifiers.|Children will suck a pacifier of identical shape and type and will be allowed other NNS habits.
11139245|NCT03801785|No Intervention|Children induced to stop sucking.|Children will be induced by DDSs to stop sucking and their parents will be advised how to stop their children's NNS habits.
11139246|NCT03801772|Active Comparator|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
11139449|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
11139450|NCT03800381||Active TB only|Children with clinical diagnosis or acid-fast bacilli (AFB) smear positive TB disease
11139247|NCT03801772|No Intervention|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
11139248|NCT03801759|Experimental|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
11139249|NCT03801759|Experimental|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
11139250|NCT03801759|Experimental|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
11139251|NCT03801746|Experimental|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
11139252|NCT03801746|Experimental|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
11139253|NCT03801746|Experimental|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
11139254|NCT03801733|Experimental|Rosuvastatin, Vadadustat|Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.
11139255|NCT03801733|Experimental|Sulfasalazine. Pravastatin, Vadadustat|"Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.
~Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
11139256|NCT03801733|Experimental|Atorvastatin, Simvastatin, Vadadustat|"Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.
~Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
11139257|NCT03801720|No Intervention|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
11139258|NCT03801720|Experimental|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
11139259|NCT03801707|Experimental|Sofosbuvir/Velpatasvir (Epclusa)|
11139260|NCT03801681||myocarditis|patients with clinically suspected myocarditis
11139261|NCT03801668|Experimental|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
11139262|NCT03801668|Active Comparator|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
11139263|NCT03801655|Experimental|Bio-Kult|4 capsules/day
11139264|NCT03801655|Placebo Comparator|Placebo|4 capsules/day
11139265|NCT03801642|Experimental|Dapagliflozin|10 mg dapagliflozin oral tablet taken once daily for 12 weeks
11139266|NCT03801642|Placebo Comparator|Matching placebo|Placebo oral tablet taken once daily for 12 weeks
11139267|NCT03801629|Experimental|Acute morphine challenge|All subjects will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.07 mg/kg).
11139268|NCT03801616|Experimental|Virtual Reality|Every participant is provided with a VR headset
11139269|NCT03801603|Experimental|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
11139270|NCT03801590|Experimental|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
11139271|NCT03801577|Experimental|Hepaxa|Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)
11139272|NCT03801564|Experimental|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
11139273|NCT03801564|Experimental|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
11139274|NCT03801551|Experimental|Patient|
11139308|NCT03801252|Experimental|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
11139309|NCT03801252|Placebo Comparator|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
11139275|NCT03801538|Experimental|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.
~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.
~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
11139276|NCT03801538|Other|NAs group|CHB patients do not need to change their NAs treatment.
11139277|NCT03801525|Experimental|ublituximab + umbralisib + venetoclax|"ublituximab: 900 mg; to be administered through cycle 6 only
~umbralisib: 800 mg; to be administered daily
~venetoclax: to begin at cycle 4 (dose ramp-up schedule) and continue through cycle 24"
11139278|NCT03801512|Experimental|Steroid Injections|Inject steroid at neuritis nerve root.
11139279|NCT03801512|Experimental|Acupuncture|Acupuncture at acupoints BL23 to BL26.
11139280|NCT03801512|Experimental|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
11139281|NCT03801499|Experimental|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11139282|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
11139283|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
11139284|NCT03801473|Experimental|robot assisted gait|
11139285|NCT03801473|Active Comparator|conventional rehabilitation|
11139286|NCT03801460|No Intervention|SOC|Standard of Care
11139287|NCT03801460|Experimental|RAPR|Remotely administered physiological reconditioning program
11139288|NCT03801434|Experimental|Treatment (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11139289|NCT03801421|Experimental|Continous suture group|The surgical incision will be treated by mass continous suture with PDS.
11139290|NCT03801421|Active Comparator|Control group|The surgical incision will be treated by interrupted suture with thread.
11139291|NCT03801382|Other|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
11139292|NCT03801382|Other|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
11139293|NCT03801382|Other|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
11139294|NCT03801382|Other|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
11139295|NCT03801382|Other|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
11139296|NCT03801369|Experimental|Treatment (Olaparib and Durvalumab)|Patients with biopsy proven TNBC will undergo a pre-treatment biopsy, after which they will receive a 28 days induction treatment of olaparib (oral, twice a day). At the 2 week mark, patients will then undergo a repeat on-treatment biopsy. Beginning cycle 2, durvalumab will be administered (IV over 1 hr) every 4 weeks, in addition to olaparib. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, may continue on therapy beyond the planned 13 cycles.
11139297|NCT03801356|Other|Selective Nerve Root Block|Patient will receive a Selective Nerve Root Block injection at the target level prior to surgical intervention.
11139298|NCT03801343|Experimental|Nutrakos®|12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement
11139299|NCT03801330|Active Comparator|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
11139300|NCT03801330|Experimental|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
11139301|NCT03801317|Experimental|BC/ egg|4.3 grams egg powder + 5.7 grams bovine colostrum
11139302|NCT03801317|Placebo Comparator|Control|15 grams corn-soya blend
11139303|NCT03801304|Experimental|Atezolizumab associated with vinorelbine|"Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.
~Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
11139304|NCT03801291|Active Comparator|Transvaginal repair|Repair of anterior rectocele via the vagina
11139305|NCT03801291|Active Comparator|Transperineal repair|Repair of anterior rectocele via the perineum
11139306|NCT03801265|Active Comparator|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
11139307|NCT03801265|Experimental|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
11139310|NCT03801239||patients with Overactive Bladder (OAB)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
11139311|NCT03801239||patients with Mixed Urinary incontinence (MUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
11139312|NCT03801239||patients with Stress Urinary Incontinence (SUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
11139313|NCT03801226|Experimental|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
11139314|NCT03801226|Active Comparator|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
11139315|NCT03801213|Active Comparator|Urinary catheterization|
11139316|NCT03801213|Experimental|manual bladder stimulation Technique|
11139317|NCT03801200|Experimental|Apatinib combined with Radiotherapy|"Drugs: Apatinib Apatinib (500 mg/d) was given orally for one week before the brain radiotherapy, and then, continued to be administered at the same way during the brain radiotherapy period (3 weeks). It was given for another one week after the end of the brain radiotherapy.
~Radiotherapy: Intensity-modulated radiotherapy (IMRT).
~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:
~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;
~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy/15 to patients with 1-5 metastatic lesions."
11139318|NCT03801200|No Intervention|Radiotherapy alone|"Radiotherapy: Intensity-modulated radiotherapy (IMRT).
~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:
~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;
~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy /15 to patients with 1-5 metastatic lesions."
11139319|NCT03801187|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
11139320|NCT03801187|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
11139321|NCT03801187|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
11139322|NCT03801174|Experimental|Partner-assisted intervention|Patients and partners will receive intervention
11139323|NCT03801174|Active Comparator|Patient-only intervention|Patients will receive intervention
11139324|NCT03801161|No Intervention|Healthy infants|
11139325|NCT03801161|Experimental|Infants with an inflammatory condition|Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
11139326|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
11139327|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
11139328|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
11139329|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
11139330|NCT03801135|No Intervention|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
11139331|NCT03801135|Experimental|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
11139332|NCT03801135|Active Comparator|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
11139333|NCT03801122|Experimental|Tranexamic acid 3g/day|Administration of tranexamic acid 3g/day, with 3 injections/8 hours.
11139334|NCT03801122|Experimental|Tranexamic acid 1.5g/day|Administration of tranexamic acid 1.5g/day, with 3 injections/8 hours.
11139335|NCT03801122|No Intervention|No treatment|No treatment (no administration of tranexamic acid)
11139336|NCT03801109|Experimental|Hyperbaric group|
11139337|NCT03801109|Experimental|Magnetic group|
11139338|NCT03801109|Active Comparator|Physical group|
11139339|NCT03801109|No Intervention|Baseline group|
11139340|NCT03801096|Experimental|Narrative Based Therapuetic Assessment|
11139341|NCT03801096|Active Comparator|Health Education (HE)|
11139447|NCT03800407||Concurrent EFV-based ART plus anti-TB therapy|ART-naïve HIV-infected children aged 3 - 14 years with TB coinfection who initiate EFV-based ART while receiving first-line anti-TB therapy
11139448|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
11139342|NCT03801083|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic biliary tract cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
11139343|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
11139344|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
11139345|NCT03801057|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
11139346|NCT03801057|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
11139347|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
11139348|NCT03801031|Active Comparator|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
11139349|NCT03801031|Placebo Comparator|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
11139350|NCT03801018||Parents who have used the donation of gametes|
11139351|NCT03801018||Children born of gametes donation|
11139352|NCT03800979|Experimental|Tofacitinib|All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
11139353|NCT03800966|Experimental|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
11139354|NCT03800966|Placebo Comparator|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
11139355|NCT03800953|Experimental|Avelumab (Bavencio)|This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
11139356|NCT03800940|Experimental|Fistulography and trans-drain occlusion|Fistulography is performed to assess the condition of the fistula, and trans-drain occlusion is performed by injecting glue (NBCA and Lipiodol) through the drain to occlude the tract.
11139357|NCT03800940|Sham Comparator|Fistulography|Fistulography is performed to assess the condition of the fistula, without trains-drain occlusion.
11139358|NCT03800927|Placebo Comparator|Sham Ultrasound Device|No ultrasound treatment
11139359|NCT03800927|Active Comparator|Active Ultrasound Device|Active treatment
11139360|NCT03800914|Experimental|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
11139361|NCT03800914|Active Comparator|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
11139362|NCT03800901|Active Comparator|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
11139363|NCT03800901|Experimental|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
11139364|NCT03800888|Experimental|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
11139365|NCT03800888|Experimental|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
11139366|NCT03800888|No Intervention|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
11139367|NCT03800875|Experimental|Insulin-Pramlintide Closed-Loop Strategy|Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
11139368|NCT03800875|Active Comparator|Insulin-alone Closed Loop Strategy|"Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal.
~Drug(s): Insulin (FiAsp)"
11139381|NCT03800836|Experimental|Arm F2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
11139369|NCT03800862||CTP and CT-FFR|"This will be a prospective, observational study designed to include a convenience sample of all qualifying patients undergoing myocardial CTP and CT-FFR.
~The study will enroll patients who have chest discomfort and will require further evaluation for the presence of coronary artery disease. Patients in the study will include those who have had a clinically indicated CCTA for suspicion of coronary artery disease and are determined to have a coronary stenosis ≥50% and ≤99%. However, patients with Left main disease greater than 50% and occluded vessels Coronary Artery Disease Reporting and Data System (CAD RADS 5) will be excluded from the study. CCTA is a clinically indicated and standard of care procedure at Lancaster General Hospital.
~."
11139370|NCT03800836|Experimental|Arm A1: Ipat + Atezo + Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139371|NCT03800836|Experimental|Arm A2: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139372|NCT03800836|Experimental|Arm A3: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139373|NCT03800836|Experimental|Arm B1: Ipat + Atezo + Nab-Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139374|NCT03800836|Experimental|Arm B2: Ipat + Atezo + Nab-Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139375|NCT03800836|Experimental|Arm C1: (Ipat + Pacl) (2 weeks) + Atezo|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139376|NCT03800836|Experimental|Arm C2 (Ipat + Pacl) (2 weeks) + Atezo|Expansion (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139377|NCT03800836|Experimental|Arm D1: (Atezo + Pacl) (2 weeks) + Ipat|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139378|NCT03800836|Experimental|Arm D2: (Atezo + Pacl) (2 weeks) + Ipat|Expansion (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139379|NCT03800836|Experimental|Arm E: Ipat + Atezo|Participants (Cohort 2) will receive Ipatasertib orally daily on Days 1-28 of Cycle 1 (35-day cycle) and on Days 1-21 of subsequent cycles (28-day cycles). Atezolizumab will be administered by IV infusion on Days 8 and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139380|NCT03800836|Experimental|Arm F1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
11139382|NCT03800836|Experimental|Arm G1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
11139383|NCT03800836|Experimental|Arm G2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
11139384|NCT03800836|Experimental|Arm H: Ipat + Atezo + Pacl|Participants (Cohort 4) will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
11139385|NCT03800823|Experimental|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
11139386|NCT03800823|Active Comparator|Standard care|Standard care for overweight and obesity
11139387|NCT03800810|Experimental|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
11139388|NCT03800810|Experimental|Intervention 1|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
11139389|NCT03800810|Experimental|Intervention 2|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
11139390|NCT03800810|Experimental|Intervention 3|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
11139391|NCT03800797|Experimental|LX-P group|loxoprofen sodium hydrogel patch (LX-P) 100 mg per day for 4 weeks
11139392|NCT03800797|Active Comparator|LX-T group|loxoprofen sodium tablet (LX-T) 60 mg t.i.d. for 4 weeks
11139393|NCT03800784|Experimental|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
11139394|NCT03800771|Experimental|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
11139395|NCT03800758|Experimental|Expressive Helping writing|"Writing sessions 1-3: Participants complete one 20-minute expressive writing session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.
~Writing session 4: One 20-40 minute peer support writing session about 1 week after completion of writing session 3."
11139396|NCT03800758|Active Comparator|Factual Writing|"Writing sessions 1-3: Participants complete one 20-minute factual session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.
~Writing session 4: One 20-40 minute factual writing session about 1 week after completion of writing session 3."
11139397|NCT03800745|No Intervention|No Medication|No intervention is assigned in Arm A.
11139398|NCT03800745|Experimental|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
11139399|NCT03800745|Experimental|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
11139400|NCT03800732|Experimental|Night workers.|Night workers of the military police of Minas Gerais, Uberlândia, who will participate in the three interventions of the study.
11139401|NCT03800719|Experimental|Intervention Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, regular messages through Instant Messaging (IM), psychosocial support and referral to SC services through IM
11139402|NCT03800719|Active Comparator|Control Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, SMS message on general health
11139403|NCT03800706|Experimental|TQB2450|
11139446|NCT03800407||EFV-based ART|ART-naïve HIV-infected children aged 3 - 14 years who initiate EFV-based ART
11139404|NCT03800693|Active Comparator|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11139405|NCT03800693|Experimental|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11139406|NCT03800680|No Intervention|Usual Care (Arm 1)|Participants will receive usual care by their diabetes clinics.
11139407|NCT03800680|Experimental|DMP (Arm 2)|Participants will receive usual care by their diabetes clinics and the Diabetes Management Package (DMP).
11139408|NCT03800680|Experimental|DMP + M-POWER Rewards (Arm 3)|Participants will receive usual care by their diabetes clinics, the Diabetes Management Package (DMP), and the financial incentive program, M-POWER Rewards.
11139409|NCT03800667|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1000 mg of vitamin C for one month,
11139410|NCT03800667|No Intervention|Women not taking vitamin C|Women who are undergoing elective gynecological surgeries and who are randomized not to take any vitamin C for one month.
11139411|NCT03800654|Other|Mindful Action for Pain (MAP) Development|In the first arm, MAP will be fully developed.
11139412|NCT03800654|Active Comparator|MAP vs. CBT-CP|In the second arm, MAP will be compared to CBT-CP to establish feasibility of a larger, future trial.
11139413|NCT03800641|Experimental|oral administration|oral administration of dexmedetomidine 4μg/kg
11139414|NCT03800641|Active Comparator|intravenous administration|intravenous administration of dexmedetomidine 0.8μg/kg
11139415|NCT03800641|Experimental|nasal administration|nasal administration of dexmedetomidine 1μg/kg
11139416|NCT03800602|Experimental|Treatment (nivolumab, metformin)|Patients receive metformin PO BID starting on day 1. After 14 days of metformin only period patients also receive nivolumab IV every 4 weeks starting on day 15. Courses repeat every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity or consent withdrawal.
11139417|NCT03800589|Active Comparator|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
11139418|NCT03800589|Active Comparator|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
11139419|NCT03800563|Experimental|Laser assisted liposuction|Laser Assisted Liposuction with the LipoLife system.
11139420|NCT03800550|Experimental|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
11139421|NCT03800550|Experimental|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
11139422|NCT03800537|Experimental|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
11139423|NCT03800524|Experimental|Tauroursodeoxycholic acid (TUDCA)|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules
~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
~Mode of administration: orally
~Duration: 18 months"
11139424|NCT03800524|Placebo Comparator|Reference therapy|"Placebo capsules identical to active compound
~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal
~Mode of administration: orally
~Duration: 18 months"
11139425|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
11139426|NCT03800498|Experimental|Intervention|For twelve weeks, only intervention group were given DASH education
11139427|NCT03800498|No Intervention|Controlled|Controlled group not received DASH education
11139428|NCT03800485|Experimental|IMT-GE|the participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will increase from the 15% of the maximal inspiratory preassure until the 60% of the maximal inspiratory preassure.
11139429|NCT03800485|Placebo Comparator|IMT-GP|The participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will be the 10% of the maximal inspiratory preassure during all the 8 weeks
11139430|NCT03800472|Experimental|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
11139431|NCT03800472|Placebo Comparator|Placebo SAD IR (Part 1)|Single doses of Placebo IR
11139432|NCT03800472|Experimental|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
11139433|NCT03800472|Placebo Comparator|Placebo SAD MR (Part 2)|Single doses of Placebo MR
11139434|NCT03800472|Experimental|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
11139435|NCT03800472|Experimental|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
11139436|NCT03800472|Placebo Comparator|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
11139437|NCT03800472|Experimental|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
11139438|NCT03800472|Placebo Comparator|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
11139439|NCT03800459|Experimental|Experimental: Intervention group|Experimental: Intervention group
11139440|NCT03800459|No Intervention|Control:no intervation group|Control:no intervation group
11139441|NCT03800446|Other|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
11139442|NCT03800433|No Intervention|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
11139443|NCT03800433|Experimental|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
11139444|NCT03800420|Experimental|BBT-401-1S|BBT-401-1S, Oral capsule, QD
11139445|NCT03800420|Placebo Comparator|Placebo|Placebo, Oral capsule, QD
11139451|NCT03800381||Active TB with HIV Co-infection|Children with clinical diagnosis or AFB smear positive TB disease who test positive for HIV infection
11139452|NCT03800368|Experimental|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
11139453|NCT03800368|Experimental|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
11139454|NCT03800368|Active Comparator|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
11139455|NCT03800355||Male breast cancer|The study target population is all cases of male breast cancer (MBC), diagnosed with invasive breast cancer between the years 2000 and 2017, and treated in the Medical Oncology Departments of participating sites.
11139456|NCT03800342|Experimental|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
11139457|NCT03800329|Active Comparator|Snap40 Monitor|Patients randomly assigned to wear the Snap40 monitor will wear the device for 48 hours following discharge from the hospital.
11139458|NCT03800329|Placebo Comparator|No Monitor|Patients randomly assigned to not wear the Snap40 monitor will continue with their follow-up surgical care in the ordinary fashion.
11139459|NCT03800316|Experimental|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
11139460|NCT03800303|Experimental|two-week family-based treatment|Active treatment includes a two-week family-based partial hospitalization treatment utilizing and integrated therapeutic design.
11139461|NCT03800290|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.
~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
11139462|NCT03800290|Placebo Comparator|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.
~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
11139463|NCT03800277|Experimental|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
11139464|NCT03800277|Experimental|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
11139465|NCT03800277|Experimental|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
11139466|NCT03800277|Placebo Comparator|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
11139467|NCT03800264|Active Comparator|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
11139468|NCT03800264|Active Comparator|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
11139469|NCT03800251|Other|Fasting parturients at term|Fasting parturients at term, admitted for elective cesarean section, who consent to partake in the study
11139470|NCT03800238|Experimental|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
11139471|NCT03800238|Active Comparator|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
11139472|NCT03800225|Experimental|Repair|Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
11139473|NCT03800225|Active Comparator|Patella tendon graft|The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.
11139474|NCT03800199|Experimental|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
11139475|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
11139476|NCT03800173|Experimental|Galidesivir|Galidesivir IV infusion
11139477|NCT03800173|Placebo Comparator|placebo|Placebo IV infusion
11139478|NCT03800147|Active Comparator|High-fat diet|"Participants will follow a high-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).
~Blood samples, stool samples and clinical information will be collected during the study."
11139479|NCT03800147|Active Comparator|Low-fat diet|"Participants will follow a low-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).
~Blood samples, stool samples and clinical information will be collected during the study."
11139480|NCT03800134|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemotherapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:
~carboplatin/paclitaxel
~cisplatin/gemcitabine
~pemetrexed/cisplatin
~pemetrexed/carboplatin"
11139511|NCT03799926|Experimental|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
11139481|NCT03800134|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy|"Placebo in concurrence with platinum-based chemotherapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on tumour histology and Investigator discretion:
~carboplatin/paclitaxel
~cisplatin/gemcitabine
~pemetrexed/cisplatin
~pemetrexed/carboplatin"
11139482|NCT03800121||localized and metastatic sarcomas|"In total, several blood tests specific to the EXOSARC study will be necessary:
~A first blood test of 7 mL during the initial assessment (inclusion)
~Then four blood samples of 32mL distributed over 6 months (localized sarcoma group) or three blood samples of 32mL performed during chemotherapy treatments (metastatic sarcoma group)."
11139483|NCT03800108|Other|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
11139484|NCT03800095|Experimental|Conventional haematological care|Patients with haematological malignancy Conventional haematological care
11139485|NCT03800095|Experimental|Conventional care associated with a monthly consultation|Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
11139486|NCT03800082|No Intervention|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
11139487|NCT03800082|Experimental|Treatment|Participants allocated to the treatment group will also learn how to use the HEARTPA♀N intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in to the pain diary app daily (via automated alerts) over the 3-month period to complete pain diary entries and develop and track their goals related to their pain, activities, sleep, emotions and medications. Participants will be directed to the PC for technical problems.
11139488|NCT03800069||Arm 1|A finger stick sample is collected and tested on the study device.
11139489|NCT03800056||Group 1 APS 1|Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.
11139490|NCT03800056||Group 2 APS2|Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
11139491|NCT03800043||Children with own caries experience|Children with own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
11139492|NCT03800043||Children without own caries experience|Children without own caries experience (visible on a photo; teeth clearly visible), sufficient compliance
11139493|NCT03800030|Experimental|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
11139494|NCT03800030|Experimental|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
11139495|NCT03800030|Experimental|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
11139496|NCT03800030|Experimental|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
11139497|NCT03800030|Experimental|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
11139498|NCT03800030|Experimental|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.
~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
11139499|NCT03800017|Experimental|Hyperoxia|During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
11139500|NCT03800017|Placebo Comparator|Healthy Controls|During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
11139501|NCT03799991|Experimental|Vestibular therapy|Vestibular therapy (Vestibular physical therapy) entails an 8-week course of exercises delivered by a physical therapist designed to improve vestibular function.
11139502|NCT03799991|Active Comparator|Active control|"The active control regimen consists of eye movement exercises (e.g. smooth pursuit eye movements) and also general conditioning exercises (e.g. range of motion exercises, lifting light weights with the arms and legs). This regimen is vestibular neutral in that head movements which specifically challenge the vestibular system are avoided."
11139503|NCT03799978|Experimental|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
11139504|NCT03799978|Experimental|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
11139505|NCT03799965|Active Comparator|ERAS protocol are evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital
~It is to compare the incidences of complications of the groups"
11139506|NCT03799965|Active Comparator|ERAS protocol are not evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital
~It is to compare the incidences of complications of the groups"
11139507|NCT03799952|Experimental|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
11139508|NCT03799952|No Intervention|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
11139509|NCT03799939|Active Comparator|Intervention group|Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.
11139510|NCT03799939|No Intervention|Control group|Participants in control group are operated with no preventive mesh.
11139512|NCT03799926|Experimental|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
11139513|NCT03799926|Experimental|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
11139514|NCT03799926|Experimental|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
11139515|NCT03799926|Experimental|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
11139516|NCT03799926|Experimental|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
11139517|NCT03799926|Experimental|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
11139518|NCT03799926|Experimental|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
11139519|NCT03799913|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
11139520|NCT03799900|Experimental|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
11139521|NCT03799900|Placebo Comparator|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
11139522|NCT03799900|Experimental|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
11139523|NCT03799900|Placebo Comparator|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
11139524|NCT03799900|Experimental|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
11139525|NCT03799900|Placebo Comparator|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
11139526|NCT03799900|Experimental|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
11139527|NCT03799900|Placebo Comparator|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
11139528|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
11139529|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
11139530|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
11139531|NCT03799900|Active Comparator|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
11139532|NCT03799900|Placebo Comparator|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
11139533|NCT03799887|Active Comparator|0% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
11139534|NCT03799887|Experimental|10% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
11139535|NCT03799887|Experimental|20% unweighed BWSTT|20% unweighed Body Weight Supported Treadmill Training
11139536|NCT03799874|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days.
11139537|NCT03799874|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 5 days.
11139538|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
11139539|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
11139540|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
11139541|NCT03799848|Experimental|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
11139542|NCT03799835|Active Comparator|Arm A : control arm|"BCG therapy only
~BCG therapy will be administered in two phases:
~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)
~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
11139543|NCT03799835|Experimental|Arm B: experimental arm|"BCG therapy + administration of atezolizumab
~BCG therapy will be administered in two phases:
~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)
~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).
~atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum)."
11139544|NCT03799822|Active Comparator|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
11139545|NCT03799822|Experimental|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
11139546|NCT03799822|Experimental|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
11139547|NCT03799809|Active Comparator|Voriconazole|Will receive 400 mg of Intrabronchial Voriconazole every week for 4 weeks along with standard medical therapy.
11139924|NCT03797001|Placebo Comparator|placebo|Placebo subcutaneous injection, daily for 24 weeks
11139548|NCT03799809|No Intervention|Control|Will receive standard medical therapy alone (hemostatics, anti-tussive and others as deemed appropriate by treating physician)
11139549|NCT03799796|Experimental|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
11139550|NCT03799783|Experimental|dex|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
11139551|NCT03799757|Active Comparator|Bupivacaine|The wound was installed by 40ml of 0.25% bupivacaine through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes.
11139552|NCT03799757|Placebo Comparator|Placebo|The wound was installed by 40ml of 0.9% normal saline through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes. (placebo group)
11139553|NCT03799744|Experimental|VCN-01 and Durvalumab; concomitant.|Combination VCN-01 (single iv dose) with Durvalumab, Concomitant schedule; Dose Escalation of VCN-01
11139554|NCT03799744|Experimental|VCN-01 and Durvalumab; sequential|Combination VCN-01 (single iv dose) with Durvalumab, Delayed schedule (14 days); Dose Escalation of VCN-01
11139555|NCT03799731|Experimental|Cohort I: GM102 single agent|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22 of each 28-day cycle
11139556|NCT03799731|Experimental|Cohort II: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
11139557|NCT03799718|Experimental|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
11139558|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
11139559|NCT03799692|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
11139560|NCT03799679|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1* 12 cycles ( weekly), followed by epirubicin 90mg/m2, iv, d1 + cyclophosphamide 600mg/m2, iv, d1 * 4 cycles (14 days per cycle)
11139561|NCT03799666|Experimental|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
11139562|NCT03799666|Active Comparator|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
11139563|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
11139564|NCT03799640|Experimental|Standard Yoga|Yoga will be performed using linear forward and backward movements.
11139565|NCT03799640|Experimental|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
11139566|NCT03799640|Experimental|Educational Control|Lectures on Health and Wellness
11139567|NCT03799627|Experimental|Vadadustat|The initial dose of vadadustat (300, 450, or 600 milligrams [mg]) will be based upon the dose of epoetin alfa dose participants had received prior to vadadustat treatment
11139568|NCT03799627|Experimental|Vadadustat TIW|Participants randomized to vadadustat (Main and erythropoiesis-stimulating agent [ESA] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
11139569|NCT03799627|Active Comparator|Epoetin alfa|Epoetin alfa
11139570|NCT03799614|Experimental|Lower dose vibration|RMBand lower dose vibration
11139571|NCT03799614|Experimental|Higher dose vibration|RMBand higher dose vibration
11139572|NCT03799601|Experimental|combination of docetaxel, carboplatin and anlotinib|
11139573|NCT03799588|Experimental|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
11139574|NCT03799575||A|Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
11139575|NCT03799575||B|Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
11139576|NCT03799562|Experimental|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
11139577|NCT03799562|Placebo Comparator|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
11139578|NCT03799536|Experimental|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11139579|NCT03799536|Active Comparator|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11139580|NCT03799523|Experimental|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
11141002|NCT03789461|Experimental|Fecal Microbiota Transplantation|FMT infusion
11139581|NCT03799510|Experimental|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
11139582|NCT03799510|Experimental|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
11139583|NCT03799510|No Intervention|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
11139584|NCT03799497||Patients suffering from Anorexia Nervosa|Subjects with a diagnostic of anorexia nervosa disorder
11139585|NCT03799497||Control group|Healthy subjects with no psychiatric disorder
11139586|NCT03799484|Other|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
11139587|NCT03799484|Other|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
11139588|NCT03799471||IBD with MSK pain|IBD patients with self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, MSK pain features, co-morbidity, and IBD features
11139589|NCT03799471||IBD without MSK pain|IBD patients without self-reported MSK pain. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, co-morbidity, and IBD features
11139590|NCT03799471||Healthy Controls|Healthy controls. No intervention. Participants will be assessed once regarding: somatosensory functioning, psychological features, and co-morbidity.
11139591|NCT03799458|Active Comparator|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
11139592|NCT03799458|Sham Comparator|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
11139593|NCT03799458|No Intervention|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
11139594|NCT03799445|Experimental|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
11139595|NCT03799432|Experimental|TF-CBT Learning collaborative + COAST-IS|In addition to participating in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls, organizations will receive additional training and tailored implementation support.
11139596|NCT03799432|Active Comparator|TF-CBT Learning collaborative|Organizations will participate in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls.
11139597|NCT03799419|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
11139598|NCT03799419|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
11139599|NCT03799419|Experimental|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
11139600|NCT03799419|Sham Comparator|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
11139601|NCT03799406|Active Comparator|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
11139602|NCT03799406|Placebo Comparator|Placebo group|placebo
11139603|NCT03799393|Active Comparator|Control Group|"The control group will receive a brief tablet-based questionnaire followed by standard, paper discharge instructions on car safety. Children ≥13 years old and above will answer questions themselves. They will complete a questionnaire on the usefulness of their discharge education.
~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
11139604|NCT03799393|Experimental|Experimental/CIAS Group|"The Experimental/CIAS Group will receive a brief tablet-based questionnaire followed by the intervention - CIAS, an interactive tablet computer program that gives educational information customized to the patient's age and size. Children ≥13 years old will answer questions and interact with the program themselves. They will complete a questionnaire on the usefulness of their discharge education.
~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
11139605|NCT03799380|Active Comparator|Control - Standard of Care|Standard of care nutritional support
11139606|NCT03799380|Experimental|Experimental - Gatorade|Standard of care nutritional support with the addition of daily Gatorade G2
11139607|NCT03799354|Experimental|Treatment Group|Maximal strenght training (MST) plus endurance training (ET)
11139608|NCT03799354|Active Comparator|Control group|Endurance training (ET)
11139625|NCT03799224|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.
~Details:
~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
11139626|NCT03799211|Experimental|Motivational Interviewing|
11139627|NCT03799211|Active Comparator|Usual Care|
11139609|NCT03799341|Experimental|Tangible Prize-Based Contingency Management (TangiblePBCM)|For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
11139610|NCT03799341|Experimental|Voucher Prize-Based Contingency Management (VoucherPBCM)|For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
11139611|NCT03799341|Active Comparator|Treatment As Usual (TAU)|Participants in all arms will be engaged with TAU outpatient substance use services and will be recommended to participate in at least two outpatient group and/or individual psychotherapy encounters per week. Participants assigned to the TAU only arm will be asked to engage with recommended outpatient treatment services for 12-weeks (as described above) but will not receive adjunctive PBCM during this time period. Participants in the TAU arm will additionally be asked to provide urine specimens on a twice-weekly basis for lab-based urinalysis. However, these participants will not interact with a CM provider or receive contingent reinforcement based on urinalysis results.
11139612|NCT03799328|Experimental|multi-OIT|Low dose OIT with multiple allergens
11139613|NCT03799315|Experimental|Jail-Based Use of Smoking Cessation Treatment (JUST)|Participants will receive guidline-based smoking cessation counseling while in jail and phone-based smoking cessation counseling sessions and nicotine lozenges after release from jail.
11139614|NCT03799315|No Intervention|Enhanced Treatment As Usual (TAU)|Participants will receive the usual, limited smoking cessation treatment while in jail, plus an additional health and wellness education session in jail. Nicotine lozenges will be offered at the end of the study to those who did not quit smoking.
11139615|NCT03799302|No Intervention|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
11139616|NCT03799302|Experimental|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
11139617|NCT03799289|Experimental|Yoga|Participants randomized to the yoga intervention arm will receive 12 weeks of group-based yoga instruction, following a 12-week standard behavioral weight loss program. Group-based yoga instruction will occur twice per week and classes will be 60 minutes in duration. The yoga program will consist of breathing, postural, and meditation practices and home-based yoga practice will also be prescribed.
11139618|NCT03799289|Active Comparator|Cooking/dietary education|Participants randomized to the cooking/dietary education intervention arm will receive 12 weeks of group-based, cooking/dietary education instruction, following a 12-week standard behavioral weight loss program. This group-based instruction will occur twice per week and classes will be 60 minutes in duration. Classes will focus on providing basic nutrition knowledge and culinary skills, and will include cooking demonstrations.
11139619|NCT03799276|Experimental|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients
~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
11139620|NCT03799250|Experimental|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.
~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.
~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.
~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.
~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
11139621|NCT03799250|Active Comparator|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
11139622|NCT03799237|Experimental|GOS trap and dengue NS1 antigen kit|Gravid Oviposition Sticky (GOS) traps will be placed to trap adult Aedes mosquitoes and changed weekly. NS1 will be used to detect dengue in trapped Aedes mosquitoes. When dengue NS1 positive mosquitoes are found, community will be alerted via flyers, banners and other means. Routine Aedes/dengue control and surveillance will be carried out as usual as per the current Ministry of Health guidelines.
11139623|NCT03799237|No Intervention|Control|The GOS traps will be placed randomly in the control arm once per month for entomological survey. Routine Aedes control and surveillance will be carried out as per the current Ministry of Health guidelines. Dengue control measure will be initiated by the health authorities when human cases are reported from this arm.
11139624|NCT03799224|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT
~Details:
~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
11139628|NCT03799198|Experimental|WMP + Rx|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately one year. After discussing with the study doctor, participants will receive one of the following listed 5 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) lorcaserin or lorcaserin extended-release, 3) phentermine/topiramate extended-release, 4) naltrexone/bupropion extended-release and 5) liraglutide 3.0 mg.
11139629|NCT03799198|Active Comparator|WMP alone|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately one year.
11139630|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
11139631|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
11139632|NCT03799146|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
11139633|NCT03799146|Experimental|Waiting List control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
11139634|NCT03799133|Experimental|Patients with Florence device|Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.
11139635|NCT03799120|Placebo Comparator|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
11139636|NCT03799120|Experimental|tamsulosin BID|0.4 mg tamsulosin BID
11139637|NCT03799107||Retrospective|Children born with assistance
11139638|NCT03799107||Prospective|People who have sought evaluation/treatment for infertility
11139639|NCT03799094|Experimental|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
11139640|NCT03799094|Experimental|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
11139641|NCT03799081|Other|Fetoscopy in missed abortion|Women who have decided to undergo fetoscopy in missed abortion
11139642|NCT03799068|Active Comparator|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
11139643|NCT03799068|Active Comparator|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
11139644|NCT03799055||easy intubation|Cormack _Lehane : 1&2
11139645|NCT03799055||difficult intubation|Cormack _Lehane : 3&4
11139646|NCT03799042|Experimental|Vitural Reality|Virtual Reality 3D glass
11139647|NCT03799042|Active Comparator|Inter-generation interaction|Elders-teenager interaction
11139648|NCT03799029|Active Comparator|active control group low-intensity|Low intensity version of the same cognitive training program Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
11139649|NCT03799029|Experimental|experimental training group cognitive training|a multifactorial cognitive program that tackles working memory, attention, inhibition, planification and reasoning Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
11139650|NCT03799029|No Intervention|control healthy participants|Just a control group including healthy participants No intervention
11139651|NCT03799003|Experimental|ASP1951 Monotherapy Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1951.Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
11139652|NCT03799003|Experimental|ASP1951 Monotherapy Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in a monotherapy or combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
11139653|NCT03799003|Experimental|ASP1951 Optional Monotherapy Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
11139654|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Escalation|The combination escalation cohort will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
11139655|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in the combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
11139656|NCT03799003|Experimental|ASP1951 plus pembrolizumab Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
11139657|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
11139658|NCT03798964||Elective term cesarean|Low-risk women undergoing elective term cesarean section
11139659|NCT03798964||Term vaginal delivery|Low-risk women undergoing term vaginal delivery
11139660|NCT03798964||Preterm vaginal delivery|Women undergoing preterm vaginal delivery
11139661|NCT03798951|Experimental|Prehabilitation program|The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient. The program will have a duration of, at least, 4 weeks.
11139662|NCT03798951|No Intervention|Control|The patients included in this group will, also, receive a basal evaluation by a physiotherapist, a nutritionist and a psychologist. These patients will not receive a tailored prehabilitation program and will be revaluated the day before surgery.
11139663|NCT03798912|Active Comparator|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
11139664|NCT03798912|Experimental|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
11139665|NCT03798912|Experimental|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
11139666|NCT03798912|Experimental|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
11141622|NCT03785080|Experimental|restart NOAC very early|restart NOAC within 24 hours
11139667|NCT03798899|Experimental|Penthrox® (Methoxyflurane)|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.
~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).
~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
11139668|NCT03798899|Placebo Comparator|Normal Saline|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.
~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).
~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
11139669|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
11139670|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
11139671|NCT03798873|Experimental|FeelWell™ Compression garment use with increase mobility|"Subjects are randomized to wear custom-fitted FeelWell™ Compression garment daily during regular and exercise activities.
~Subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity."
11139672|NCT03798873|Other|Increase mobility|For the control group, subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity. The control group will not be assigned a compression garment during the trial.
11139673|NCT03798834|Experimental|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
11139674|NCT03798834|Placebo Comparator|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
11139675|NCT03798821|Experimental|Experimental|One capsule a day will be consumed. At breakfast for the six weeks.
11139676|NCT03798821|Placebo Comparator|Comparator|One capsule a day will be consumed. At breakfast for the six weeks.
11139677|NCT03798808|Experimental|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
11139678|NCT03798808|No Intervention|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
11139679|NCT03798782|Experimental|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
11139680|NCT03798782|Active Comparator|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
11139681|NCT03798769|Experimental|Supportive Oncology Care at Home|"The Supportive Oncology Care at Home intervention entails the following:
~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers for phone calls and home visits by Medically Home based on a clinician-derived algorithm
~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;
~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
11139682|NCT03798743|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
11139683|NCT03798730|Experimental|Solid Model|"Cake
~-Control Vanilla Cake and Protein Fortified Vanilla Cake
~Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
11139684|NCT03798730|Experimental|Liquid Model|"Whey Protein Beverages
~Native sample (protein unheated)
~Denatured whey protein (protein heated to denature)"
11139685|NCT03798717|No Intervention|Control|Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
11139686|NCT03798717|Experimental|Pre OGTT|Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
11139687|NCT03798717|Experimental|Post OGTT|Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
11139688|NCT03798691|Active Comparator|Anti-TNF monotherapy|Patients with IBD on Anti-TNF monotherapy will be given the shingrix vaccine. Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
11139689|NCT03798691|Active Comparator|Vedolizumab|"Patients with IBD on vedolizumab monotherapy will be given the shingrix vaccine.
~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
11139690|NCT03798678|Experimental|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
11139691|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
11139723|NCT03798418|Experimental|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
11139692|NCT03798639|Experimental|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
11139693|NCT03798639|Active Comparator|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
11139694|NCT03798626|Experimental|1st line colorectal cancer|Treatment for 1st line metastatic colorectal cancer (mCRC) with Gevokizumab, modified FOLFOX6, bevacizumab
11139695|NCT03798626|Experimental|2nd line colorectal cancer|Treatment for 2nd line mCRC with Gevokizumab, FOLFIRI, bevacizumab
11139696|NCT03798626|Experimental|2nd line gastroesophageal cancer|Treatment for 2nd line metastatic gastroesophageal cancer (mGEC) with Gevokizumab, paclitaxel, ramucirumab
11139697|NCT03798626|Experimental|2nd or 3rd line renal cell carcinoma|Treatment for 2nd or 3rd line metastatic renal cell carcinoma (mRCC) with Gevokizumab, cabozantinib
11139698|NCT03798613|Active Comparator|Apple Watch 4 Series Device|Apple watch 4 series heart rate monitoring device
11139699|NCT03798613|Active Comparator|Continuous Telemetry|Standard continuous telemetry monitoring device
11139700|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.
~Inclusion Criteria:
~Adult ICU patients (>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).
~Exclusion criteria:
~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score > 6)"
11139701|NCT03798587||OS patients|"Patients with age ≥18 years that were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).
~Patients with age <18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.
~The target group corresponds to patients hospitalized at Istituto Ortopedico Galeazzi, undergoing surgical eradication of primary osteosarcoma.
~Patients will be considered eligible for enrollment in the study if able to sign the consent to the procedure after appropriate information from the reference surgeon or signed by parents or legal guardian after appropriate information from the reference surgeon (if age <18).
~Inclusion Criteria:
~Indication for primary OS eradication surgery
~Patients hospitalized in Istituto Ortopedico Galeazzi
~Exclusion criteria:
~-Patients not able to sign the Informed Consent."
11139702|NCT03798574||IMD Case|No intervention
11139703|NCT03798574||Control|No intervention
11139704|NCT03798561|Experimental|82 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 82 µg/cm2 single application in 7 days or Placebo TG (6 subjects ASN008: 2 subjects placebo) (6:2)
11139705|NCT03798561|Experimental|164 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 164 µg/cm2 single application in 7 days or Placebo (6:2)
11139706|NCT03798561|Experimental|328 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 328 µg/cm2 single application in 7 days or Placebo (6:2)
11139707|NCT03798561|Experimental|492 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 492 µg/cm2 single application in 7 days or Placebo (6:2)
11139708|NCT03798561|Experimental|ASN008 TG TBD Cohort 1 or Placebo|Part B: ASN008 TG Cohort 1 daily application for 15 days or Placebo (9 subjects ASN008: 3 subjects Placebo) (9:3)
11139709|NCT03798561|Experimental|ASN008 TG TBD Cohort 2 or Placebo|Part B: ASN008 TG Cohort 2 daily application for 15 days or Placebo (9:3)
11139710|NCT03798561|Experimental|ASN008 TG TBD Cohort 3 or Placebo|Part B: Placebo TG Cohort 3 daily application for 15 days or Placebo (9:3)
11139711|NCT03798548|Experimental|Brief Bedside CBT|
11139712|NCT03798548|No Intervention|Treatment As Usual|
11139713|NCT03798522|Experimental|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
11139714|NCT03798522|Active Comparator|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
11139715|NCT03798509|Experimental|Human CD19 targeted T Cells Injection|
11139716|NCT03798483|Experimental|Individualized exercise|Participants after a lateral kneecap dislocation will be enrolled into an individualized exercise intervention supervised by a physiotherapist
11139717|NCT03798470|Experimental|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
11139718|NCT03798457||Patients with CAP hospitalized in IM|Data of Patients with Community-acquired pneumonia (CAP) hospitalized in Internal Medicine Units will be collected for this study; no intervention is planned for this study
11139719|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score>-2.5.
11139720|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
11139721|NCT03798431|Experimental|M-ROCC|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
11139722|NCT03798418|Active Comparator|exercise group|elastic band strengthening exercise
11141623|NCT03785080|Active Comparator|restart NOAC early|restart NOAC at 72 - 84 hours
11139724|NCT03798405|Experimental|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:
~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
11139725|NCT03798405|No Intervention|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
11139726|NCT03798392|Active Comparator|SP group|
11139727|NCT03798392|Active Comparator|Baska group|
11139728|NCT03798379|Active Comparator|Exercise group|Eligible patients who were planned to receive neurotoxic chemotherapy
11139729|NCT03798379|No Intervention|Control group|Patients eligible for the study and received the 3rd cycle of chemotherapy
11139730|NCT03798366|Experimental|GLPG1690|
11139731|NCT03798366|Placebo Comparator|Placebo|
11139732|NCT03798353|Experimental|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.
~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
11139733|NCT03798353|Active Comparator|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
11139734|NCT03798340|Experimental|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
11139735|NCT03798340|Active Comparator|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
11139736|NCT03798327|Experimental|Home Palliative Care|Randomized to Intervention Arm
11139737|NCT03798327|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their dementia and other illnesses.
11139738|NCT03798314|Experimental|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
11139739|NCT03798301|Experimental|Treatment Arm|Suspension of CMV-specific T-cells in 10 mL of 0.9% NaCl with 2% HSA. Single dose max. 25,000 T cells/kg body weight (BW) of the recipient delivered via IV bolus injection.
11139740|NCT03798288|Experimental|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.
~The weekly plan includes three categories of content;
~information/education
~recommended daily number of steps
~recommended strength and flexibility exercises"
11139741|NCT03798288|Active Comparator|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
11139742|NCT03798275|Active Comparator|the study group|healthy pregnant women with borderline oligohydramnios who accept to drink a cup of coffee
11139743|NCT03798275|No Intervention|the control group|healthy pregnant women with normal amniotic volume
11139744|NCT03798262|Active Comparator|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
11139745|NCT03798262|Placebo Comparator|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
11139746|NCT03798249|Active Comparator|Gluten|Patients will receive acutely 16 g of gluten and 2 muffins glutenfree with 8 g of gluten, twice a day, during 5 days
11139747|NCT03798249|Placebo Comparator|Placebo|Patients will receive acutely 16 g of whey protein and 2 glutenfree muffins, twice a day, during 5 days
11139748|NCT03798236|Experimental|PBF-1650 40mg|
11139749|NCT03798236|Experimental|PBF-1650 80mg|
11139750|NCT03798236|Experimental|PBF-1650 120mg|
11139751|NCT03798236|Experimental|PBF-1650 240mg|
11139752|NCT03798236|Placebo Comparator|Placebo|
11139753|NCT03798223|Experimental|180/low|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
11139754|NCT03798223|Experimental|180/high|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
11139755|NCT03798223|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
11139756|NCT03798223|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
11139757|NCT03798210|Placebo Comparator|Placebo|Look and taste-alike placebo tablets in white plastic vials.
11139758|NCT03798210|Experimental|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
11139759|NCT03798197|Active Comparator|30 mg estetrol (E4) without food (fasted)|Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.
11139846|NCT03797638|Other|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
11139760|NCT03798197|Experimental|30 mg estetrol (E4) with food (fed)|Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.
11139761|NCT03798184|Experimental|Selective-etch with bioglass surface roughening|
11139762|NCT03798184|Active Comparator|Selective-etch without bioglass surface roughening|
11139763|NCT03798184|Experimental|Self-etch with bioglass surface roughening|
11139764|NCT03798184|Active Comparator|Self-etch without bioglass surface roughening|
11139765|NCT03798145|Experimental|Surgical Retinotomy|Surgical retinotomy will be constructed in the area of the scotoma.
11139766|NCT03798119|Experimental|Switch to TAF|Subjects who meet the inclusion and exclusion criteria will switch prior NUCs to TAF 25 mg/day for 96 weeks
11139767|NCT03798106|Experimental|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
11139768|NCT03798093|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
11139769|NCT03798093|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
11139770|NCT03798080|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning with or without metformin for 30 weeks
11139771|NCT03798080|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day with or without metformin for 30 weeks
11139772|NCT03798054|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
11139773|NCT03798054|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
11139774|NCT03798054|Active Comparator|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
11139775|NCT03798041|Experimental|Debridement group|The subjects in this group will be debrided within 24 hours after surgery.
11139776|NCT03798041|No Intervention|Control group|The subjects in this group will experience wound dressing change regularly 24 hours after surgery.
11139777|NCT03798028|Experimental|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.
11139778|NCT03798028|No Intervention|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
11139779|NCT03798015||mitral valve surgery|outcome of mitral valve surgery (stroke yes or no)
11139780|NCT03798002|Experimental|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
11139781|NCT03798002|Active Comparator|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
11139782|NCT03797989|Experimental|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
11139783|NCT03797989|Experimental|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
11139784|NCT03797989|Experimental|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
11139785|NCT03797989|Experimental|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
11139786|NCT03797989|Experimental|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
11139787|NCT03797989|Experimental|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately six months (and up to nine months) later after their secondary challenge.
11139788|NCT03797989|Experimental|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
11139789|NCT03797989|Experimental|Phase C: Group 9|Twelve new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
11139790|NCT03797989|Experimental|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately six months (and up to nine months) after their secondary challenge.
11139791|NCT03797989|Experimental|Phase D: Group 10|The twelve volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
11139792|NCT03797989|Experimental|Phase D: Group 12|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
11139793|NCT03797989|Experimental|Phase E: Group 11|The twelve volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to nine months) after their secondary challenge.
11139794|NCT03797989|Experimental|Phase E: Group 13|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 11
11139795|NCT03797976|Experimental|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
11139796|NCT03797963|Active Comparator|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
11139797|NCT03797963|Experimental|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
11139798|NCT03797950|No Intervention|Control|No active intervention
11139799|NCT03797950|Experimental|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
11139800|NCT03797950|Experimental|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
11139801|NCT03797937|Experimental|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI).
11139802|NCT03797937|No Intervention|Matched healthy controls|
11139803|NCT03797924|Active Comparator|ICBN with ropivacaine|Participants will receive ICBN with ropivacaine. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
11139804|NCT03797924|Placebo Comparator|No ICBN block|Participants will have the site prepped, but no ICBN block given. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
11139805|NCT03797911|Experimental|active resistive capacitive monopolar radiofrequency|"Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): The intervention group will receive the treatment with activated resistive capacitive monopolar radiofrequency system, with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.
~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
11139806|NCT03797911|Placebo Comparator|Inactive resistive capacitive monopolar radiofrequency|"Application of the technique in the control group (inactivated resistive capacitive monopolar radiofrequency therapy): The control group will receive the treatment with inactivated resistive capacitive monopolar radiofrequency system (placebo), with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.
~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
11139807|NCT03797898|Experimental|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
11139808|NCT03797898|No Intervention|Control|usual care well child care
11139809|NCT03797885||Patients with type 2 diabetes mellitus (T2DM)|Patients with type 2 diabetes, at the hospital setting.
11139810|NCT03797885||Patients with T2DM and established cardiovascular disease|Subgroup of patients with type 2 diabetes and established cardiovascular disease
11139811|NCT03797872|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice. Commonly Initial therapy will be with methotrexate alone unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (sulfasalazine or leflunomide). In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
11139847|NCT03797625|Experimental|Endostar Combined With IP|Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1
11139848|NCT03797612|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
11139921|NCT03797027|Other|10 cm cushion|Patients in 10 cm cushion group undergo prone percutaneous nephrolithotomy with an 10 cm abdominal cushion
11139812|NCT03797872|Experimental|Local/IM steroid injections|Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local injections of methylprednisolone or triamcinolone to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication. All active joints will be treated with injections. Injections can be either be given as an intra-articular injection or as an intra-muscular injection. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy).
11139813|NCT03797846|Active Comparator|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
11139814|NCT03797846|Active Comparator|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
11139815|NCT03797833|No Intervention|Standard treatment|ECV according to standard practice.
11139816|NCT03797833|Active Comparator|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
11139817|NCT03797807|Experimental|MINST|Minimally invasive non surgical treatment
11139818|NCT03797807|Active Comparator|MIST|Minimally invasive surgical treatment
11139819|NCT03797807|Active Comparator|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
11139820|NCT03797807|Active Comparator|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
11139821|NCT03797794|Experimental|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
11139822|NCT03797794|Sham Comparator|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
11139823|NCT03797781|Experimental|High protein|
11139824|NCT03797781|Experimental|Low protein|
11139825|NCT03797781|Experimental|Minimum protein|
11139826|NCT03797768|Experimental|Intervention|
11139827|NCT03797768|No Intervention|Control|
11139828|NCT03797755||Palliative Cancer Patients|Stage IV cancer patients evaluated for palliative radiotherapy.
11139829|NCT03797742||NC|Patients without heart failure.
11139830|NCT03797742||DCM|Dilated cardiomyopathy patients.
11139831|NCT03797742||ICM|Ischemic cardiomyopathy patients.
11139832|NCT03797729|Placebo Comparator|Normal saline|
11139833|NCT03797729|Experimental|Tirofiban|
11139834|NCT03797716|No Intervention|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.
~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.
~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
11139835|NCT03797716|Experimental|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
11139836|NCT03797703|Experimental|Treatment|Patients will be randomly allocated into the treatment group. The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
11139837|NCT03797703|No Intervention|Control|Patients will be randomly allocated into the control group. The control group will not receive a rectal enema.
11139838|NCT03797690|Experimental|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure. End of treatment will be considered as the last session of needle aponeurotomy.
11139839|NCT03797690|Active Comparator|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy). End of surgical treatment will be considered as the removal of the stitches (two weeks after the surgical treatment).
11139840|NCT03797677|Experimental|Home based airway clearance with Metaneb|"Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
~The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment."
11139841|NCT03797664|Experimental|Experimental: CDX-6114|7.5, 15.0 and 22.5g
11139842|NCT03797664|Placebo Comparator|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
11139843|NCT03797651|Active Comparator|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
11139844|NCT03797651|Experimental|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
11139845|NCT03797638|Experimental|Patients with writer's cramp|Patients with writer's cramp
11139922|NCT03797014|Experimental|B/F/TAF|Treatment group (1-arm study)
11139849|NCT03797612|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
11139850|NCT03797599|Experimental|20 minutes of mindfulness practice|Two sessions a week for two weeks of: 5 minutes listening to audio book excerpts followed by 20 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
11139851|NCT03797599|Active Comparator|5 minutes of mindfulness practice|Two sessions a week for two weeks of: 20 minutes listening to audio book excerpts followed by 5 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
11139852|NCT03797599|Placebo Comparator|Audio book control|Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
11139853|NCT03797586|Experimental|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal . For ST37, 0.30×40mm needles will be vertically inserted approximately 15 mm. For all the acupuncture points, needle insertion will be followed by manipulation with an even lifting and twisting method three times to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
11139854|NCT03797586|Sham Comparator|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes.
11139855|NCT03797573|Active Comparator|active tDCS|Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
11139856|NCT03797573|Sham Comparator|sham tDCS|Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
11139857|NCT03797560|Experimental|Ba-Duan-Jin group|"Ba-Duan-Jin therapy: The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital.
~Placebo pregabalin capsules: Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks."
11139858|NCT03797560|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.
~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
11139859|NCT03797534|No Intervention|Standard anticoagulant group|
11139860|NCT03797534|Experimental|Bayesian model group|
11139861|NCT03797521|Experimental|SXC-2023 50mg QD|SXC-2023 50mg dosed once daily for 6 weeks
11139862|NCT03797521|Experimental|SXC-2023 200mg QD|SXC-2023 200mg dosed once daily for 6 weeks
11139863|NCT03797521|Experimental|SXC-2023 800mg QD|SXC-2023 800mg dosed once daily for 6 weeks
11139864|NCT03797521|Placebo Comparator|Matching Placebo QD|Matching Placebo dosed once daily for 6 weeks
11139865|NCT03797508|Other|threatened miscarriage|ultrasound ,CA125,progesterone
11139866|NCT03797482||Intra-operative tumour tissue biopsies|Intra-operative tumour tissue biopsies will be collected for all patients
11139867|NCT03797469|Active Comparator|Nicotinamide and Pyruvate (N&P)|This group will receive two separate sets of tablets containing 3 x 1000 mg of Vitamin B3 (nicotinamide) and 2 x 1500 mg of Pyruvate.
11139868|NCT03797469|Placebo Comparator|Placebo|This group will receive an equal number of tablets as the N&P group.
11139869|NCT03797456|Experimental|ICP-022|
11139870|NCT03797443|Experimental|AA NABPLAGEM|Ascorbic Acid Paclitaxel protein-bound cisplatin gemcitabine
11139871|NCT03797417||Disease|patients with vitiligo
11139872|NCT03797417||Healthy Control|healthy control
11139873|NCT03797404||Mepolizumab|Patients receiving mepolizumab
11139874|NCT03797404||Patients w/o mepolizumab (retrospective)|Retrospective control group of patients not exposed to mepolizumab, included in the COBRA cohort and the ASMATHERM protocol, who had 2 sets of biopsies and BAL within a 6 to 12 month-interval, without change in their treatment. Clinical data for this patients are available at inclusion and after 12 months.
11139875|NCT03797391|Experimental|Dose Escalation-Part 1, Expansion-Part 2|"In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Participants may continue to receive study drug until discontinuation criteria are met. Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.
~In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks)."
11139876|NCT03797378|Experimental|eM2M|Participants in the eM2M arm will participate in an intervention that involves three 60-minute M2M sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. At the beginning and end of each session, vital signs (heart rate, blood pressure and peripheral capillary oxygen saturation) are obtained from participants. Participants rate perceived exertion, pain, and fatigue level on a log. Participants set weekly exercise goals and expectations at first session of each week. Participants also record daily activities using a provided log.
11139877|NCT03797378|No Intervention|Waitlist Control|Participants in the waitlist control arm are instructed to maintain their usual activities during the 12-week intervention period and are asked to record their activities on a provided log.
11139878|NCT03797365|Active Comparator|Classical rehabilitation|Twenty women will benefit from two-phases perineal rehabilitation: first phase pelvic floor muscles (PFM)'s analytic rehabilitation, then a functional rehabilitation.
11139879|NCT03797365|Experimental|Classical and cognitive associated rehabilitation|Twenty women will receive, added to the classic perineal rehabilitation, the cognitive rehabilitation and will have to execute twice a day the rehabilitation protocol.
11139880|NCT03797352|No Intervention|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
11139881|NCT03797352|Experimental|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
11139882|NCT03797339||Discovery cohort|1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
11139883|NCT03797339||Validation corhort|3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort. During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
11139884|NCT03797326|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
11139885|NCT03797313||Patient's expectations met at Hospital discharge|ARF survivors whose expectations for recovery at hospital discharge are fully met 6 months later.
11139886|NCT03797313||Patient's with unmet expectations at Hospital Discharge|ARF survivors whose expectations for recovery at hospital discharge are not fully met 6 months later.
11139887|NCT03797300|Experimental|Primary|
11139888|NCT03797287|Experimental|Tensor Tunnler|The Tensor Tunneler (Chattanooga, TN) will be used to create the bone tunnels during the arthroscopic procedure. This is an FDA approved device and is used currently in routine clinical practice.
11139889|NCT03797287|Active Comparator|Smith and Nephew PEEK Helicoil Anchor|The anchors used in this trial are FDA approved and are used currently in routine clinical practice (Anchor Rotator Cuff Repair).
11139890|NCT03797261|Experimental|Venetoclax + AMG 176|Venetoclax and AMG 176 will be administered in combination. Different combinations of dose levels for venetoclax and AMG 176 will be explored.
11139891|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
11139892|NCT03797248||Cohort 2|adjuvant chemotherapy only
11139893|NCT03797235|Experimental|Dominant Arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the dominant forearm
11139894|NCT03797235|Active Comparator|Non-dominant arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the non-dominant forearm.
11139895|NCT03797222|Experimental|Vitamin E Supplementation|Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.
11139896|NCT03797209|Experimental|AXIOS Patient|
11139897|NCT03797196|Active Comparator|group 1|standard tacrolimus with mycophenolate mofetil
11139898|NCT03797196|Experimental|group 2|low dose tacrolimus with everolimus
11139899|NCT03797183||Premature Infants|Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
11139900|NCT03797183||Chronic Respiratory Disease|Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
11139901|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
11139902|NCT03797183||Healthy Controls|Age and height matched healthy controls
11139903|NCT03797157|Experimental|H2MF|Human milk-based breast milk fortifier
11139904|NCT03797157|Active Comparator|Standard fortifier|Standard care: bovine milk-based breast milk fortifier
11139905|NCT03797144|Experimental|Fenestrated Screw System|
11139906|NCT03797131|Experimental|KB195 Arm|
11139907|NCT03797118|Experimental|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
11139908|NCT03797105|No Intervention|Control, 0 days|control group, no intervention
11139909|NCT03797105|Experimental|1 day|received the intervention 1 day/week
11139910|NCT03797105|Experimental|3 days|received the intervention 3 days/week
11139911|NCT03797105|Experimental|5 days|received the intervention 5 days/week
11139912|NCT03797092|Active Comparator|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
11139913|NCT03797092|No Intervention|Control group|No treatment
11139914|NCT03797079|Active Comparator|Group A (ESP block)|Ultrasound-guided ESP block will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
11139915|NCT03797079|Active Comparator|Group B (TEA)|TEA will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
11139916|NCT03797053||Cohort 1 : metastatic cohort|Cohort1: Cohort of patients with stage III inoperable or IV metastatic melanoma This cohort will enable the achievement of objectives 1 (proof of concept) and 2 (establishment of prognostic and predictive value).
11139917|NCT03797053||Cohort 2 : adjuvant cohort|"Cohort 2: Cohort of patients with melanoma who are candidates for sentinel lymph node analysis.
~This group includes patients with melanoma in whom sentinel lymph node testing is performed. According to current French recommendations, these are patients whose primary melanoma has a Breslow index (thickness) of more than 1 mm or ulcerated primary melanoma (loss of the epidermis)."
11139918|NCT03797040|Experimental|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
11139919|NCT03797027|Other|No cushion|Patients in no cushion group undergo prone percutaneous nephrolithotomy without an abdominal cushion
11139920|NCT03797027|Other|5 cm cushion|Patients in 5 cm cushion group undergo prone percutaneous nephrolithotomy with an 5 cm abdominal cushion
11139923|NCT03797001|Experimental|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
11139925|NCT03796988|Experimental|Intervention arm|The donor area will be anesthetized with injected local anesthesia, harvested with the ART device, and bandaged with an occlusive dressing. The skin harvested will be placed on the recipient wound area. The area will be bandaged will a non-stick silicone dressing (covered by appropriate primary and secondary dressings) and left intact for 1-7 days.
11139926|NCT03796975|Experimental|Combination of Pioglitazone and Metformin Tablets|dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
11139927|NCT03796975|Active Comparator|Metformin Hydrochloride Tablets|dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
11139928|NCT03796962|Experimental|25 mg XEN1101|Capsule filled with 25 mg XEN1101
11139929|NCT03796962|Experimental|20 mg XEN1101|Capsule filled with 20 mg XEN1101
11139930|NCT03796962|Experimental|10 mg XEN1101|Capsule filled with 10 mg XEN1101
11139931|NCT03796962|Placebo Comparator|Placebo|Placebo capsule
11139932|NCT03796949||threatened preterm birth|Women with either preterm labor or preterm prelabor rupture of the membranes. Blood samples taken at time of inclusion in the study.
11139933|NCT03796949||Controls|Women with normal pregnancies. Blood samples taken at time of inclusion in the study, either prelabor (during pregnancy) or during active phase of labor.
11139934|NCT03796936|Experimental|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
11139935|NCT03796936|Active Comparator|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
11139936|NCT03796923|Active Comparator|Intervention I|Intervention (I): early follow-up visit from the community nurse within 24 hours after discharge
11139937|NCT03796923|Experimental|Intervention II|Intervention (II): early follow-up by the geriatric team within 24 hours after discharge
11139938|NCT03796923|Other|Control|Usual care: individualized follow-up performed by the GP and municipality services
11139939|NCT03796910|Experimental|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
11139940|NCT03796910|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
11139941|NCT03796910|Experimental|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
11139942|NCT03796910|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
11139943|NCT03796897|Experimental|Leucine-enriched protein + exercise|whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
11139944|NCT03796897|Sham Comparator|Habitual diet + exercise|habitual diet only
11139945|NCT03796884|Experimental|Arm I (linaclotide)|Patients receive linaclotide PO daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 8.
11139946|NCT03796884|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 8.
11139947|NCT03796871|Experimental|Dermapol|Use of the experimental medical device
11139948|NCT03796858|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).
11139949|NCT03796858|Experimental|Group 2: Placebo followed by Guselkumab|Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.
11139950|NCT03796845|Experimental|No-limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
11139951|NCT03796845|Active Comparator|Limited movement after surgery|Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
11139952|NCT03796832|Experimental|Flat Flexible Shoes+Exercise Therapy|This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
11139953|NCT03796832|Active Comparator|Stable Supportive Shoes+Exercise Therapy|This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
11139954|NCT03796819|Experimental|lymphadenectomy|This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
11139955|NCT03796819|No Intervention|No lymphadenectomy|This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
11139988|NCT03796598|Active Comparator|Group 2: Oral FMT and rectal placebo|Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
11139989|NCT03796598|Experimental|Group 1: Dual Oral and rectal FMT|Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
11141901|NCT03783273|Active Comparator|D3 + milk|200 microgram vitamin D3 added to 500 mL of skimmed-milk.
11139956|NCT03796793|Experimental|Intervention arm|The intervention arm will include tissue collection and wound debridement. Wound debridement will be performed using a sharp circular disposable dermal 5mm curette (Integra Miltex, New Jersey) with the patient in a reclining or supine position to remove the slough, nonviable tissue, and any fibrous tissue down to the vascular base. Local anesthetics will be applied to the wound 30-45 minutes prior to debridement. Tissue collection (2 3mm punch biopsies) will be performed at the wound edge before debridement and after debridement, using standard sterile punch biopsy technique. In addition, an optional 3mm punch biopsy of normal, healthy skin will be obtained from the upper inner thigh. After tissue sample collection, patients in the intervention arm will then receive standard of care bandaging and compression.
11139957|NCT03796793|No Intervention|Standard of care arm|Standard of care will include foam dressing (e.g. Mepilex) and a four-layer compression system (e.g. Profore), which will be changed weekly by the study team. This dressing and compression system will be used in all participants.
11139958|NCT03796780|Active Comparator|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
11139959|NCT03796780|Placebo Comparator|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
11139960|NCT03796767|Experimental|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
11139961|NCT03796767|Experimental|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
11139962|NCT03796767|Experimental|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
11139963|NCT03796754|Active Comparator|YoBEKA Intervention|
11139964|NCT03796754|No Intervention|Control group|
11139965|NCT03796728|Other|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
11139966|NCT03796715||Red Cell Distribution Width (RDW)|RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
11139967|NCT03796715||Presepsin (sCD14-ST)|Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
11139968|NCT03796702|Experimental|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
11139969|NCT03796702|Experimental|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
11139970|NCT03796689|Experimental|Smartphone-linked|
11139971|NCT03796689|Active Comparator|Standard|
11139972|NCT03796676|Placebo Comparator|Placebo|Placebo
11139973|NCT03796676|Experimental|PF-04965842 100 mg QD|active
11139974|NCT03796676|Experimental|PF-04965842 200 mg QD|active
11139975|NCT03796663|Active Comparator|Mindful Parenting Only|"Participants in this arm will receive only the Mindful Parenting Program at the start of the study. Bögels and Restifo's (2014) Mindful Parenting Program is an adaptation for parents of MBCT, and MBSR; the program will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.
~Following the completion of the Mindful Parenting Sessions, participants in this arm will be asked continue to participate in data collection for the post-intervention assessment time point (i.e. 8 weeks after the completion of the Mindful Parenting group sessions) and for the 2-month follow up assessment time point (i.e. 16 weeks after the completion of the Mindful Parenting group sessions). After they have completed both assessments, they will be offered the opportunity to participate in the MATCH BPT program if they so choose (no data will be collected)."
11139976|NCT03796663|Experimental|Mindful Parenting and BPT Combined|"Participants in this arm will receive the Mindful Parenting Program at the start of the study, which will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.
~Following the completion of the Mindful Parenting Sessions, participants in this arm will receive receive individually-implemented MATCH BPT sessions, which will consist of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 1 hour sessions. The MATCH manual is comprised of 33 modules (i.e. coping, giving effective instructions, learning to relax, etc.). For the purpose of this study we will be utilizing the section on BPT, which consists of 12 modules with corresponding handouts and worksheets."
11139977|NCT03796650|Experimental|Fecal microbiota transplantation|Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
11139978|NCT03796650|Active Comparator|Antibiotic treatment|Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.
11139979|NCT03796637|Experimental|nmDMD Participants|Participants who have been receiving ataluren, dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for >=9 months from ongoing PTC-sponsored nmDMD clinical trials.
11139980|NCT03796624|Experimental|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
11139981|NCT03796624|Active Comparator|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
11139982|NCT03796611||multiple sclerosis patient|MS is defined according to McDonald criteria 2017. MS patients included have a disease duration of less than 1 year
11139983|NCT03796611||other neurological inflammatory disease|autoimmune encephalitis, myasthenia gravis, chronic inflammatory demyelinating polyradiculitis
11139984|NCT03796611||neurological non inflammatory disease|benign intracranial hypertension, degenerative disorder
11139985|NCT03796611||healthy controls|transfusion volunteers from transfusion center
11139986|NCT03796598|Placebo Comparator|Placebo|Oral and rectal placebo at visit 2 Oral placebo at day 30
11139987|NCT03796598|Active Comparator|Group 3: Oral placebo and rectal FMT|Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
11139990|NCT03796585|Experimental|Intervention|Pharmacists assigned to this group will receive an immunization registry training program and informational flyer.
11139991|NCT03796585|Active Comparator|Control|Pharmacists assigned to this group will receive an informational flyer. They will not receive training.
11139992|NCT03796572|Experimental|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
11139993|NCT03796572|Sham Comparator|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
11139994|NCT03796559|Experimental|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
11139995|NCT03796533|Other|Posaconazole pharmacokinetics|Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
11139996|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
11139997|NCT03796507|Experimental|Temozolomide Arm|This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.
11139998|NCT03796494|Active Comparator|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
11139999|NCT03796494|Experimental|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
11140000|NCT03796481||Cases|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) with comorbid insomnia
11140001|NCT03796481||Controls|People with chronic spinal pain (i.e. chronic low back pain or chronic neck pain) without comorbid insomnia
11140002|NCT03796468|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
11140003|NCT03796468|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best treatment medical
11140004|NCT03796455|Experimental|Fish Oil|2.0 g EPA + DHA / day + placebo powder
11140005|NCT03796455|Experimental|Fish Oil and HMB|2.0 g EPA + DHA + 3.0 g HMB / day
11140006|NCT03796455|Placebo Comparator|Placebo|3 g/d soy oil: corn oil (50:50 ratio) + placebo powder
11140007|NCT03796442|Experimental|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
11140008|NCT03796442|Active Comparator|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
11140009|NCT03796429|Experimental|GS+Toripalimab|
11140010|NCT03796416|Active Comparator|misoprostol|"Induction using misoprostol:
~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
11140011|NCT03796416|Experimental|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:
~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.
~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
11140012|NCT03796403|Experimental|diclofenac and bupivacaine group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
11140013|NCT03796403|Placebo Comparator|bupivacaine only group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.
11140014|NCT03796390|Experimental|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
11140015|NCT03796377|Other|Rivaroxaban|Single oral dose of 20 mg rivaroxaban
11140016|NCT03796377|Other|Rivaroxaban after CYP- and P-gp induction|Single oral dose of 20 mg rivaroxaban after pretreatment with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
11140017|NCT03796364|Active Comparator|control group|standard SRILI treatment
11140018|NCT03796364|Experimental|observation group|Endostar® plus standard treatment
11140019|NCT03796351|Experimental|MT10107(botulinum toxin type A)|Subjects will be administered a single equivalent dose of MT10107 by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
11140020|NCT03796351|Active Comparator|BOTOX® 50U(botulinum toxin type A)|Subjects will be administered a single equivalent dose of BOTOX® 50U by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
11140021|NCT03796338||Critically ill patients|age > 18 years
11140022|NCT03796325||Depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities and depression
11140023|NCT03796325||No-depression|patients characterize with morbid obesity or obesity type 2 with co-morbidities without depression
11140024|NCT03796312|Experimental|Tub Bathing|In this group, preterm infants were given tub bathing.
11140025|NCT03796312|Active Comparator|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
11140026|NCT03796299||1|Patients with bladder cancer
11140027|NCT03796299||2|Patients with upper urinary tract cancer
11140028|NCT03796299||3 (control)|Controls
11140029|NCT03796286|Placebo Comparator|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
11140030|NCT03796286|Experimental|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
11140031|NCT03796286|Experimental|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
11140032|NCT03796273|Experimental|Arm I (ketoconazole)|Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
11140033|NCT03796273|Active Comparator|Arm II (standard surgery)|Patients undergo standard surgery.
11140034|NCT03796260|Experimental|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
11140035|NCT03796260|Experimental|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
11140036|NCT03796247||multiple sclerosis|
11140037|NCT03796247||healthy control|
11140038|NCT03796234|Experimental|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
11140039|NCT03796234|Experimental|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
11140040|NCT03796221|Active Comparator|Control Group|Will receive standard pediatric obesity treatment
11140041|NCT03796221|Experimental|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
11140042|NCT03796208|Experimental|Tobacco Intervention|Participants in this group will be randomized to the Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC) intervention.
11140043|NCT03796208|Active Comparator|Treatment As Usual|Participants in this group will be randomized to tobacco treatment as usual.
11140044|NCT03796195|Experimental|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
11140045|NCT03796182|Experimental|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
11140046|NCT03796182|Experimental|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
11140047|NCT03796169|Experimental|Endoscopist|Intervention for personal notification, open notification and colonoscopy quality education by a GI faculty
11140048|NCT03796156|Experimental|Aspirin|75mg of non enteric coated aspirin once daily added to usual medications
11140049|NCT03796156|No Intervention|Usual care|Usual medications only
11140050|NCT03796143|Experimental|ACT self-help book condition|Participants in this condition will be asked to read The Mindfulness and Acceptance Workbook for Depression by Strosahl and Robinson (2008), a self-help book based on acceptance and commitment therapy.
11140051|NCT03796143|Active Comparator|CBT self-help book condition|Participants in this condition will be asked to read Cognitive Behavioral Workbook for Depression by Knaus (2006), a self-help book based on acceptance and commitment therapy.
11140052|NCT03796143|Other|Choice of two self-help books|Participants in this condition will have the option of receiving either the self-help book by Strosahl and Robinson (2008) or the book by Knaus (2006).
11140053|NCT03796130|Experimental|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm
~The participants will be randomlyallocated intotwo groups.
~In group (A): myomectomy will be performed before ART
~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
11140054|NCT03796130|No Intervention|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm
~The participants will be randomly allocated into two groups.
~In group (B):women will have their trial of ART without myomectomy"
11140055|NCT03796117|Experimental|Experimental Group 1: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
11140056|NCT03796117|Experimental|Experimental Group 2: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
11140057|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
11140058|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
11140059|NCT03796091|Active Comparator|Educational Brochure|Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.
11140060|NCT03796091|Active Comparator|Body Project Traditional|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice & Shaw, 2001).
11140061|NCT03796091|Active Comparator|Body Project Expanded|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).
11140062|NCT03796078|Active Comparator|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
11140063|NCT03796078|Active Comparator|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
11140064|NCT03796078|Active Comparator|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
11140095|NCT03795870|Active Comparator|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
11140065|NCT03796065|Experimental|FSI-R Treatment|Families randomized into the FSI-R Treatment arm will receive the 10-module Family Strengthening Intervention in addition to any outside services or programs they are participating in.
11140066|NCT03796065|No Intervention|FSI-R Control|Families randomized into the FSI-R Control arm will not receive the FSI-R treatment. Instead, they will continue with their usual care, referred to as Treatment as Usual (TAU).
11140067|NCT03796052|Experimental|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
11140068|NCT03796039|Experimental|Standing and Social Intervention|Participants be exposed to an additional 100 minutes of standing per week. Participants will do this by standing for 20 minutes Monday through Friday.
11140069|NCT03796039|No Intervention|Control Group|Control group will receive social visits, but no exposure to standing
11140070|NCT03796026|Experimental|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram [mg] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
11140071|NCT03796026|Experimental|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
11140072|NCT03796013|Experimental|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
11140073|NCT03796013|Experimental|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
11140074|NCT03796000||colonoscopy: obese and smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
11140075|NCT03796000||colonoscopy: obese and non-smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
11140076|NCT03796000||colonoscopy: lean and smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
11140077|NCT03796000||colonoscopy: lean and non-smoker|"10 small tissue samples of the Colon transversum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
11140078|NCT03796000||gastroscopy: obese and non-smoker undergoing bariatric surgery|"6 small tissue samples of the gastric corpus and 6 of the Duodenum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample
~1cm long piece of the jejunum, which is usually disposed during bariatric surgery."
11140079|NCT03796000||gastroscopy: lean and non-smoker|"6 small tissue samples of the gastric corpus and 6 of the Duodenum
~3 EDTA blood samples and 1 Serum blood sample
~in some cases 1 single stool sample"
11140080|NCT03795987|Experimental|Open Label Treatment Arm|Intervention with NightWare Therapeutic System
11140081|NCT03795974|Active Comparator|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
11140082|NCT03795974|Experimental|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
11140083|NCT03795961|Experimental|Active tDCS group|This group will include 42 patients with CTS Intervention (active transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
11140084|NCT03795961|Sham Comparator|Sham tDCS group|This group will include 42 patients with CTS Intervention (sham or inactive transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
11140085|NCT03795948|Other|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
11140086|NCT03795935|Experimental|Treatment|Patients who were previously implanted with a traditional DBS lead and have subsequently developed stimulation induced side effects will gain significantly more tremor control without side effects when re-implanted with a directional DBS lead. We expect these patients' quality of life will improve. These patients typically will have had significant tremor relief (greater than 75% reduction from preoperative tremor rating scale) without side effects at their one year post operative follow-up. With the expected disease progression they will have had to increase their DBS stimulation to the degree that their DBS now causes side effects in order to block their tremor
11140087|NCT03795922|Experimental|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
11140088|NCT03795922|Placebo Comparator|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
11140089|NCT03795909|Experimental|Ruxolitinib and Placebo|Ruxolitinib 2.5 mg twice daily by oral
11140090|NCT03795909|Placebo Comparator|Placebo and Ruxolitinib|Sugar pill 2.5 mg twice daily by oral
11140091|NCT03795896|Experimental|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
11140092|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
11140093|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
11140094|NCT03795870|Active Comparator|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
11140096|NCT03795844|Active Comparator|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
11140097|NCT03795844|Active Comparator|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
11140098|NCT03795844|Active Comparator|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
11140099|NCT03795844|Active Comparator|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
11140100|NCT03795831||Cohort|Adult patients, undergoing surgery requiring general anesthesia, planned to be monitored with a system that accurately measures and stores the intra-arterial waveform.
11140101|NCT03795818|Other|IPT-A|Interpersonal psychotherapy for adolescents (IPT-A) is a psychosocial treatment for adolescents. It has been shown to be effective for adolescents with depression. It is now being studied as to its benefit for adolescents who meet criteria for PTSD or have subthreshold PTSD symptoms.
11140102|NCT03795805|Other|TKA and Tourniquet|Total knee arthroplasty and use of tourniquet limb cuff at 270 mmHg
11140103|NCT03795805|Experimental|Intraarticular lidocain|Total knee arthroplasty with Intaarticular lidocain
11140104|NCT03795792|Experimental|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
11140105|NCT03795792|Placebo Comparator|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
11140106|NCT03795779|Experimental|CLL1-CD33 cCAR T cells|CLL1-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs
11140107|NCT03795753|Experimental|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
11140108|NCT03795753|Sham Comparator|Non-functioning Communicator|Non-functioning study communication device is used.
11140109|NCT03795740|Experimental|Precise|precise PEA therapy with the guide of 3-D imaging techniques
11140110|NCT03795740|Placebo Comparator|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
11140111|NCT03795727|Experimental|Sectional matrix|precontoured sectional matrix band
11140112|NCT03795727|Active Comparator|Circumferential matrix|Circumferential matrix band applied by tofflemire retainer
11140113|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
11140114|NCT03795701|Placebo Comparator|Placebo|Subjects in placebo group will receive placebo plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will also be asked to maintain physical activity.
11140115|NCT03795701|Experimental|Liraglutide 3.0|Subjects in Liraglutide 3.0 group will receive Saxenda® plus behavioral weight loss counselling to portion control to achieve 500 kcal daily deficit based on MedGem required maintenance calories (not to be reduced below 1000 kcal per day for any subject). Subjects will be asked to maintain physical activity. The dose of Saxenda® will be increased weekly in the first 4 weeks (.6; 1.2; 1.8; 2.4 mg) and maintained on 3 mg for 12 weeks.
11140116|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.
~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
11140117|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
11140118|NCT03795675|Experimental|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
11140119|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
11140120|NCT03795649|No Intervention|The control group (Group K)|The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
11140121|NCT03795649|Active Comparator|Group A, Tranexamic acid|The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
11140122|NCT03795649|Other|Group B, autologous transfusion|The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
11140123|NCT03795649|Other|Group C, alogenous transfusion|The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
11140124|NCT03795636|Experimental|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract
~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
11140651|NCT03791944|Active Comparator|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
11140125|NCT03795636|Active Comparator|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
11140126|NCT03795623|Sham Comparator|Conventional arm|Muted audio recordings of the patients relatives.
11140127|NCT03795623|Experimental|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
11140128|NCT03795610|Experimental|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 21 days
11140129|NCT03795597|Experimental|Carfilzomib IV at dose: 20 mg/m2|The participants will receive Carfilzomib IV at dose: 20 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and Granulocyte-Colony stimulating factor (G-CSF) given daily until engraftment occurs.
11140130|NCT03795597|Experimental|Carfilzomib IV at dose: 27 mg/m2|The participants will receive Carfilzomib IV at dose: 27 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
11140131|NCT03795597|Experimental|Carfilzomib IV at dose: 36 mg/m2|The participants will receive Carfilzomib IV at dose: 36 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
11140132|NCT03795597|Experimental|Carfilzomib IV at dose: 45 mg/m2|The participants will receive Carfilzomib IV at dose: 45 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
11140133|NCT03795597|Experimental|Carfilzomib IV at dose: 56 mg/m2|The participants will receive Carfilzomib IV at dose: 56 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
11140134|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
11140135|NCT03795571|Experimental|R2-GOD|
11140136|NCT03795558|Experimental|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
11140137|NCT03795558|Experimental|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
11140138|NCT03795558|Experimental|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
11140139|NCT03795558|Experimental|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
11140140|NCT03795558|Experimental|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
11140141|NCT03795558|Experimental|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
11140142|NCT03795545|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.
~The rest of the session at 22kv (full power)."
11140143|NCT03795545|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
11140144|NCT03795532|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
11140145|NCT03795532|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
11140146|NCT03795519|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-olinciguat
11140147|NCT03795506|Experimental|Active TLA Device|12 week overnight treatment with the active Temperature Controlled Laminar Airflow device.
11140148|NCT03795506|Placebo Comparator|Placebo TLA Device|12 week overnight treatment with the placebo Temperature Controlled Laminar Airflow device.
11140149|NCT03795493|Experimental|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
11140150|NCT03795493|No Intervention|Control Group|Standard chemotherapy treatment and oncology care.
11140151|NCT03795480|Experimental|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
11140652|NCT03791931|Other|Patients|Oxidative stress measurement in cleavage state embryos
11140152|NCT03795480|No Intervention|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
11140153|NCT03795454|Experimental|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
11140154|NCT03795454|No Intervention|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
11140155|NCT03795441|Experimental|Ad26.RSV.preF|Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
11140156|NCT03795428|Experimental|Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose|Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.
11140157|NCT03795415||Immediate Arm (G1)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G1 will receive the intervention Gundo-So immediately. (From month 3 to month 6).
~112 women will be in immediate arm in 14 groups of 8 women."
11140158|NCT03795415||Delayed Arm (G2)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G2 will receive the intervention Gundo-So 3 months after. (From month 6 to month 9).
~112 women will be in delayed arm in 14 groups of 8 women."
11140159|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
11140160|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
11140161|NCT03795389|Experimental|3.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).
11140162|NCT03795389|Experimental|5.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
11140163|NCT03795389|Experimental|8.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
11140164|NCT03795350|Experimental|TRIMBOW|"Experimental: BDP/FF/GB
~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
11140165|NCT03795337|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
11140166|NCT03795324|Experimental|Redlove Apple|"Redlove Apple intervention
~This product is a biofortified cultivar apple with anthocyanins."
11140167|NCT03795324|Experimental|Green Apple|"Green Apple intervention
~This product is a common cultivar apple without anthocyanins."
11140168|NCT03795324|Experimental|Aronia Drink|"Aronia drink intervention
~This product is an infusion of aronia fruit extract rich in anthocyanin."
11140169|NCT03795311|Experimental|Administration of chemotherapy molecules|"The treatment period is divided into 15-day periods.
~Schema of the administration to the treatments which will proceed in the same way with each cycle:
~Bevacizumab (5 mg/kg; during 30 min) + Oxaliplatine (85 mg/m2, during 2 hours) + Acide folinique (400 mg/m2) or Levofolinate de calcium (200 mg/m2) AND Irinotecan (during 2 hours) + 5-fluorouracile (2400 mg/m2 ; 46 hours) + Irinotecan (1 hour)"
11140170|NCT03795298|Experimental|WATCHMAN FLX|WATCHMAN FLX implant including modified post-implant drug regimen.
11140171|NCT03795298|Active Comparator|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
11140172|NCT03795285||Septic neonates:|fifty neonates with sepsis.
11140173|NCT03795285||Controls:|twenty healthy neonates.
11140174|NCT03795272|Experimental|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
11140175|NCT03795272|Placebo Comparator|Placebo|Patients will be treated with oral placebo twice daily for 24 months
11140176|NCT03795259|Active Comparator|Sevoflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 2% sevoflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
11140177|NCT03795259|Active Comparator|Desflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 6% desflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
11140178|NCT03795246|Experimental|Study Process|Consultation, Biological Test, Pelvic Ultrasound
11140179|NCT03795233|Experimental|Fecal microbiota transplantation|Fecal microbiota transplant G3 capsules will be administered after standard of care with oral vancomycin therapy in participants with primary Clostridium difficile infection.
11140180|NCT03795233|Active Comparator|Oral vancomycin alone (Control)|Oral vancomycin therapy will be administered as per standard of care in participants with primary clostridium difficile infection.
11140181|NCT03795220|Active Comparator|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
11140182|NCT03795220|Active Comparator|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
11140183|NCT03795220|Active Comparator|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
11140184|NCT03795220|Active Comparator|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
11140205|NCT03795064|Active Comparator|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
11141902|NCT03783273|Active Comparator|D3 droplets|200 microgram vitamin D3 as droplets + 500 mL of water.
11140185|NCT03795207|Experimental|Arm SBRT + DURVALUMAB|"Radiation (SBRT) + Immunotherapy treatment (Durvalumab)
~64 patients will be enrolled in this arm
~Durvalumab, will be started one month prior to SBRT and then given for a total of 12 months.
~Patient will receive one injection per months (1500 mg/cycle)
~SBRT will be started one month after Durvalumab and patients will receive 3 fractions of radiation"
11140186|NCT03795207|Active Comparator|Arm SBRT|"Radiation (SBRT)
~32 patients will be enrolled in this arm
~Patients will receive only 3 fractions of radiation"
11140187|NCT03795194|Other|8-day|8-day course of ampicillin clavulanate antibiotic
11140188|NCT03795194|Other|4-day|4--day course of ampicillin clavulanate antibiotic
11140189|NCT03795168|Experimental|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.
~Outcomes measured:
~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise
~at the first and last visit: force plate system assessment (balance)"
11140190|NCT03795168|Sham Comparator|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.
~Outcomes measured:
~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise
~at the first and last visit: force plate system assessment (balance)"
11140191|NCT03795142|Experimental|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
11140192|NCT03795142|Placebo Comparator|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
11140193|NCT03795129|Experimental|SleepLife Application w/FitBit|"Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.
~Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application."
11140194|NCT03795129|Active Comparator|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it).
~Subjects will receive no training with regard to how to access SleepLife Application.
~Subjects' physicians will receive no subject sleep data."
11140195|NCT03795116|Experimental|LED-RL phototherapy|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
11140196|NCT03795116|Sham Comparator|Mock irradiation|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
11140197|NCT03795103|Experimental|Patients achieving neuromuscular electrical stimulation|LEPAD patients achieving a 12-week program of neuromuscular electrical stimulation. Group of arteriopathic patients who will perform electrostimulation sessions at home and independently. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
11140198|NCT03795103|Other|Control|Group of artriopathic patients who will maintain their usual drug management. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
11140199|NCT03795103|Other|Healthy volunteers|Ancillary study. Participants will perform a precise program of walking sessions performed outdoors and independently and the same biological parameters as those assessed in arteriopathic patients will be assessed
11140200|NCT03795090|Active Comparator|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
11140201|NCT03795090|Experimental|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
11140202|NCT03795077|No Intervention|control group|Control group followed traditional lectures about professional ethics during 3 months as usual.
11140203|NCT03795077|Experimental|experimental group|Experimental group followed the programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used. Techniques used: concept maps, glossaries, brainstorming, four corners activity, aquarium, philip 6-6, kahoot, Realm Individual-Process Situation, reduced groups, guided debates, and discussion groups.
11140204|NCT03795064|Experimental|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
11140206|NCT03795051|Experimental|Navigated TMS|Each participant will receive 30 sessions of 10 Hz or 20 Hz navigated transcranial magnetic stimulation over the left DLPFC.
11140207|NCT03795038|Other|Lipoprotein Apheresis MONET and DALI|"Patients routinely treated with MONET:
~The first subgroup will be treated first with the MONET adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber System.
~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the MONET adsorber system"
11140208|NCT03795038|Other|Lipoprotein Apheresis DIAMED and DALI|"Patients routinely treated with DIAMED:
~The first subgroup will be treated first with the DIAMED adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber system.
~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DIAMED adsorber System."
11140209|NCT03795025|Experimental|3x10RM + no training|
11140210|NCT03795025|Experimental|6x10RM + no training|
11140211|NCT03795025|Experimental|3x10RM + 6x10RM|
11140212|NCT03795025|No Intervention|Control|This arm includes 3 weeks of testing and 7 weeks of no intervention and post tests, followed by 7 weeks of progressive unilateral strength training 3 times per week for 7 weeks. Both legs exercises individually with 3 sets of 10 maximal repetitions.
11140213|NCT03795012|Active Comparator|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
11140214|NCT03795012|Active Comparator|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
11140215|NCT03794999||Benralizumab-exposed group|Pregnant women with asthma exposed to benralizumab anytime during pregnancy or within 8 weeks prior to last menstrual period
11140216|NCT03794999||Asthmatic comparison group|Pregnant women currently treated for asthma not exposed to benralizumab during pregnancy or within 8 weeks prior to last menstrual period
11140217|NCT03794999||Non-asthmatic comparison group|Pregnant women who are not diagnosed with asthma, have not had exposure to a known human teratogen, and have not taken benralizumab during pregnancy.
11140218|NCT03794986|Experimental|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
11140219|NCT03794986|Active Comparator|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
11140220|NCT03794973|Experimental|TOL-3021|TOL-3021 2 mg/mL
11140221|NCT03794973|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
11140222|NCT03794960|Experimental|TOL-3021|
11140223|NCT03794960|Placebo Comparator|TOL-3021 Placebo|
11140224|NCT03794947|Experimental|Remote Ischaemic Conditioning|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg (arm) and 220 mmHg (leg). RIC will be completed 3 times weekly for 4 weeks.
11140225|NCT03794947|Sham Comparator|Sham Intervention|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The arm and leg blood pressure cuffs in the sham intervention will inflate to 20mmHg. Sham will be completed 3 times weekly for 4 weeks.
11140226|NCT03794934|Placebo Comparator|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
11140227|NCT03794934|Active Comparator|Intervention|provide structured education when applying CGM for 3 months
11140228|NCT03794921|No Intervention|Usual Care|Patients referred to conventional PR or eligible for PR but declined. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
11140229|NCT03794921|Experimental|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website as often as they wish, but at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be prominently displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
11140230|NCT03794908|Experimental|Light therapy A via the Re-Timer®|"60 minutes/day
~For the first hour after waking"
11140231|NCT03794908|Active Comparator|Light therapy B via the Re-Timer®|"60 minutes/day
~For the first hour after waking"
11140232|NCT03794895|Experimental|Single arm clinical trial|
11140233|NCT03794882|Experimental|QLB + Medical Management|Subjects will undergo Intervention: Procedure/Surgery: Quadratus Lumborum Block and receive Intervention: Procedure: Standard Medical Management as needed.
11140234|NCT03794882|Active Comparator|Standard Medical Management|Subjects will receive Intervention: Procedure: Standard Medical Management as needed.
11140258|NCT03794713|Experimental|Patient support tool group|Subjects were managed the HR by using the Patient Support Tool through a smart phone application and a wristband and be guided by physicians
11140235|NCT03794869|Experimental|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of the core: awareness of breathing, front and side plate abdominal, glute bridge/hip elevations, lift extended leg, pelvic tilt, hamstring stretch, strengthening lower abdominals, cat-camel posture, trunk rotations with flexed knees, rolling in sitting and lumbar extension with hip extensión in prone
11140236|NCT03794869|Active Comparator|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
11140237|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
11140238|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
11140239|NCT03794843|Experimental|Nimodipine Injection (II)|The specification of this injection is 5 ml: 4 mg , which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:16 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
11140240|NCT03794843|Experimental|Nimodipine Injection|The specification of this injection is 50 ml: 10 mg ,which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:4 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
11140241|NCT03794830|Experimental|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
11140242|NCT03794830|Active Comparator|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
11140243|NCT03794804|Active Comparator|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.
~The IP use should start when following conditions have been fulfilled:
~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND
~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache
~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
11140244|NCT03794804|Placebo Comparator|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.
~The IP use should start when following conditions have been fulfilled:
~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND
~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache
~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
11140245|NCT03794791||education|Education will be used to see whether or not improve the HCV screening and diagnosis in HBsAg(+) patients. Blood test ,HCV-RNA quantification test and HCV genotyping will be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
11140246|NCT03794791||no education|There is no education at all.Screening and diagnosis of HCV infection in HBsAg(+) patients are based on voluntary. Blood test ,HCV-RNA quantification test and HCV genotyping will still be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
11140247|NCT03794778|Experimental|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
11140248|NCT03794778|Active Comparator|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
11140249|NCT03794765|Experimental|Antibiotic|Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
11140250|NCT03794765|Placebo Comparator|Placebo|Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
11140251|NCT03794752|Other|Head Mounted Device|Head-Mounted Visual Enhancement Device developed by Evergaze Technology LLC has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation.
11140252|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
11140253|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
11140254|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
11140255|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.
~No intervention. No age limit."
11140256|NCT03794726|Active Comparator|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
11140257|NCT03794726|Experimental|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
11140259|NCT03794713|No Intervention|Control group|Subjects were received a usual patient care at baseline, which left to the discretion of physicians, without any specific intervention at follow-up period
11140260|NCT03794700|No Intervention|Control|
11140261|NCT03794700|Other|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
11140262|NCT03794687||Distal Radial Artery|Left heart catheterization via the distal radial artery (dorsal aspect of the hand at the base of the thumb).
11140263|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
11140264|NCT03794661|Experimental|Single Arm|Clinician programmer electrode screening mode tool
11140265|NCT03794648|Experimental|Intervention Group|
11140266|NCT03794648|No Intervention|Control Group|
11140267|NCT03794635|Experimental|Patients|Latino/a advanced cancer patients
11140268|NCT03794635|Experimental|Caregivers|Caregivers of Latino/a advanced cancer patients
11140269|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
11140270|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
11140271|NCT03794596|Experimental|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
11140272|NCT03794596|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
11140273|NCT03794583|Experimental|Inhaled treprostinil solution|Inhaled treprostinil solution (6mcg/breath), 4 times daily (QID) during waking hours.
11140274|NCT03794570|Sham Comparator|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
11140275|NCT03794570|Experimental|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
11140276|NCT03794557|Experimental|PUL-042|PUL-042 Inhalation Solution
11140277|NCT03794557|Placebo Comparator|Placebo|Sterile Water for injection
11140278|NCT03794544|Experimental|Arm A: Durvalumab monotherapy|durvalumab IV
11140279|NCT03794544|Experimental|Arm B: Durvalumab + Oleclumab|durvalumab IV and oleclumab IV
11140280|NCT03794544|Experimental|Arm C: Durvalumab + Monalizumab|durvalumab IV and monalizumab IV
11140281|NCT03794544|Experimental|Arm D: Durvalumab + Danvatirsen|danvatirsen IV and durvalumab IV
11140282|NCT03794518|Experimental|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
11140283|NCT03794518|Placebo Comparator|Placebo|Beta blockers, ACEI, ARB, and aldosterone
11140284|NCT03794505|Active Comparator|Shoulder infiltration|Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg
11140285|NCT03794505|Experimental|Suprascapular nerve block|Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg
11140286|NCT03794492|Experimental|Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.|Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.
11140287|NCT03794479||Travellers|Adults planning for travel
11140288|NCT03794453||Stroke patients|
11140289|NCT03794440|Experimental|Sintilimab +IBI305|
11140290|NCT03794440|Active Comparator|Sorafenib|
11140291|NCT03794427|Experimental|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
11140292|NCT03794427|Active Comparator|Spinal anesthesia|spinal anesthesia will be performed
11140293|NCT03794414|Experimental|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
11140294|NCT03794414|Experimental|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
11140295|NCT03794388|Experimental|Arm CAPSAICINE topical|"Application of capsaicin patches at 8% on the painful area
~1 to 2 patches will be administered during the consultation. If necessary, a second application will be realized 3 months later."
11140296|NCT03794388|Active Comparator|Arm PREGABALINE|"Pregabalin tablets will be initiated at a dose of 50 mg / day taken in 2 doses Depending on the tolerance, the dose will be increased to 100 mg / day and then to 150 mg / day to reach a maximum dose of 600 mg / day.
~An interval of 3 to 7 days must be observed between each dose increase."
11140297|NCT03794375|Active Comparator|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
11140298|NCT03794375|Experimental|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.
~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
11140299|NCT03794362||Local Anesthetics|Lidocaine
11140300|NCT03794362||N-methyl-D-aspartate Antagonists|Ketamine
11140301|NCT03794362||SNRIs|Duloxetine
11140302|NCT03794362||Alpha-2 adrenergic agonists|Dexmedetomidine
11140303|NCT03794362||Oral Analgesics|NSAIDs, acetaminophen
11140304|NCT03794362||Non-pharmacologic interventions|Acupuncture
11140305|NCT03794349|Active Comparator|Regimen A (chemotherapy, dinutuximab, sargramostim)|Patients receive temozolomide PO, via NG, or G tube on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12 of a 21-day cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
11141903|NCT03783273|Placebo Comparator|No vitamin D|500 mL of Water.
11140306|NCT03794349|Experimental|Regimen B (eflornithine, chemotherapy, dinutuximab)|Patients receive eflornithine PO, via NG, or G tube on days -6 to 7 and days 15-21 of cycle 1 and days 1-7 and 15-21 of subsequent cycles, temozolomide PO, via NG, or G tube on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12. Treatment duration is 28 days for cycle 1 and then every 21 days in subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
11140307|NCT03794336|Experimental|Alogliptin|Single dose of alogliptin once daily for 16 weeks
11140308|NCT03794336|Active Comparator|Acarbose|Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2
11140309|NCT03794323|Experimental|BI 764122|
11140310|NCT03794323|Placebo Comparator|Placebo|
11140311|NCT03794310|Experimental|NPF-08 （1-day treatment）|
11140312|NCT03794310|Experimental|NPF-08 （2-day split dose）|
11140313|NCT03794310|Active Comparator|Moviprep（1-day treatment）|
11140314|NCT03794297|Experimental|Treatment (dabrafenib mesylate, trametinib dimethyl sulfoxide)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11140315|NCT03794271|Experimental|Pupilometer group|In this group, intraoperative analgesia is performed using pupilometer guided anesthesia.
11140316|NCT03794271|Active Comparator|SPI group|In this group, intraoperative analgesia is performed using SPI guided anesthesia
11140317|NCT03794258|Experimental|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
11140318|NCT03794258|Experimental|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
11140319|NCT03794245|Experimental|Men-Centered HIV Testing|Mobile HIV testing is conducted at sites in the community where men gather.
11140320|NCT03794245|Active Comparator|Clinic-based HIV Testing|Men are referred to the nearest clinic for HIV counseling and testing
11140321|NCT03794245|Experimental|Linkage to Care for HIV+ Men|The patient coordinator arranges an appointment time at the clinic and accompanies the patient to the initial visit
11140322|NCT03794245|Active Comparator|Clinic Referral for HIV+ Men|Men diagnosed with HIV are referred to the nearest clinic for treatment of HIV
11140323|NCT03794232|Experimental|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
11140324|NCT03794232|Placebo Comparator|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
11140325|NCT03794219|Experimental|Kinesio tape plus NSAID|Kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions in addition to 750 mg/day oral naproxen.
11140326|NCT03794219|Active Comparator|NSAID|750 mg/day oral naproxen is administered for 10 days.
11140327|NCT03794206|Experimental|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
11140328|NCT03794180|Experimental|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
11140329|NCT03794180|Placebo Comparator|Placebo|0 mg/kg via single IV infusion
11140330|NCT03794167|Experimental|busulfan cyclophosphamide etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
11140331|NCT03794167|Active Comparator|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
11140332|NCT03794154|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
11140333|NCT03794154|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
11140334|NCT03794141|Experimental|Tervas|Follow up group from an earlier study. Information on risk gene status. All test persons were given information on healthy diet and life style.
11140335|NCT03794141|Experimental|Informed|Information on risk gene status was given before intervention. All test persons were given information on healthy diet and life style.
11140336|NCT03794141|Active Comparator|non informed|Information on risk gene status was not given before intervention. All test persons were given information on healthy diet and life style.
11140337|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
11140338|NCT03794128||2 - shared neoantigen cancer vaccine screening|
11140339|NCT03794102|Active Comparator|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
11140340|NCT03794102|Active Comparator|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
11140341|NCT03794089|Experimental|Brief anxiety intervention|Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
11140342|NCT03794089|Active Comparator|Usual PC-MHI care|Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care
11140343|NCT03794076|Active Comparator|Cromoglycate|Cromoglycate nasal spray
11140344|NCT03794076|Placebo Comparator|Placebo|Saline nasal spray
11140345|NCT03794063||Robson group 1|Nulliparous women, single cephalic, more than or equal to 37 weeks, in spontaneous labour
11140346|NCT03794063||Robson Group 2|Nulliparous women, single cephalic, more than or equal to 37 weeks, induced or Caesarean section before labour
11140347|NCT03794063||Robson Group 3|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more than or equal 37 weeks gestation in spontaneous labour
11142110|NCT03781804|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
11140348|NCT03794063||Robson Group 4|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more or equal 37 weeks gestation who had labour induced or were delivered by Caesarean section before labour
11140349|NCT03794063||Robson Group 5|All Multiparous women with at least one CS with a single cephalic pregnancy, more or equal to 37 weeks gestation
11140350|NCT03794063||Robson Group 6|All nulliparous women with a single breech pregnancy
11140351|NCT03794063||Robson Group 7|Multiparous women with a single breech pregnancy including women with previous Caesarean section
11140352|NCT03794063||Robson Group 8|All women with multiple pregnancies including women with previous Caesarean sections
11140353|NCT03794063||Robson Group 9|All women with a single pregnancy with a transverse or oblique lie, including women with previous Caesarean Section (s)
11140354|NCT03794063||Robson Group 10|All women with a single cephalic pregnancy less than 37 weeks gestation, including women with previous Caesarean section (s)
11140355|NCT03794050|Experimental|resistance training exercise|All participants complete one session of resistance training exercise
11140356|NCT03794050|Experimental|aerobic training exercise|All participants complete one session of aerobic training exercise
11140357|NCT03794037|Active Comparator|control|dydrgesterone 10 mg( tab)/12hs/14 days
11140358|NCT03794037|Experimental|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
11140359|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
11140360|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
11140361|NCT03794011|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
11140362|NCT03793985|Experimental|A (R+T+R+T)|Period 1 : R Period 2 : T Period 3 : R Period 4 : T
11140363|NCT03793985|Active Comparator|B (T+R+T+R)|Period 1 : T Period 2 : R Period 3 : T Period 4 : R
11140364|NCT03793972|Experimental|Triage with referral to primary care|Triage and referral according to eMTS.
11140365|NCT03793972|Active Comparator|Triage without referral to primary care|Weekends with usual care
11140366|NCT03793959|Experimental|Synbiotic Supplement|Daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis, identical to Placebo-- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
11140367|NCT03793959|Placebo Comparator|Placebo Supplement|Daily placebo supplement (5g maltodextrin, identical to Experimental -- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
11140368|NCT03793946|Experimental|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
11140369|NCT03793946|No Intervention|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
11140370|NCT03793920|Experimental|PEA patients without alcohol disorder|A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.
11140371|NCT03793920|Sham Comparator|PEA patients with alcohol disorder|A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.
11140372|NCT03793920|Sham Comparator|Healthy controls with AD father|A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
11140373|NCT03793920|Sham Comparator|Healthy controls without AD father|A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
11140374|NCT03793907|Active Comparator|Cohort 2 (walking program)|Patients receive a Fitbit to track their physical activity, and complete an unsupervised walking program daily at home, increasing physical activity stepwise weekly, for 6 months.
11140375|NCT03793907|Experimental|Cohory 1 (strength training)|Patients receive a Fitbit to track their physical activity, and complete an in-person personalized and supervised full-body strength training program over 1 hour BID up to 52 sessions for 6 months.
11140376|NCT03793894|Active Comparator|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
11140377|NCT03793894|Experimental|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
11140378|NCT03793881|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
11140379|NCT03793881|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
11140380|NCT03793868|Experimental|Low dose|Perampanel 4mg PO x1
11140381|NCT03793868|Placebo Comparator|Placebo|Receiving placebo
11140382|NCT03793868|Experimental|High dose|Perampanel 8 mg PO x1
11140383|NCT03793855|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
11140384|NCT03793855|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
11140385|NCT03793842|Experimental|Usual care then PEEP titration by EIT|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan ARDS protocol high-PEEP arm
11140386|NCT03793842|Experimental|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
11140387|NCT03793829|Experimental|GM-CSF and H2NVAC vaccine|GM-CSF Dose and route: 125 mcg admixed with vaccine; intradermal injection Every 14 days ± 2 days for a maximum of 4 cycles H2NVAC vaccine 4 peptides, at dose level as shown below, admixed with GM-CSF; intradermal injection. Every 14 days ± 2 days for a maximum of 4 cycles
11140466|NCT03793231||Control patients|Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.
11140388|NCT03793816|Active Comparator|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:
~Incision of the anterior palatal arch
~Locating of the cranial pole of the tonsil
~Dissection of the tonsil capsule
~Localized coagulation of bleeding vessels
~Detaching of the inferior pole from the pharynx tissue"
11140389|NCT03793816|Active Comparator|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
11140390|NCT03793803|Experimental|Home Palliative Care|Randomized to Intervention Arm
11140391|NCT03793803|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their primary illness(es).
11140392|NCT03793790|Experimental|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
11140393|NCT03793790|Experimental|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
11140394|NCT03793790|Experimental|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
11140395|NCT03793790|Experimental|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
11140396|NCT03793790|Sham Comparator|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
11140397|NCT03793777|Placebo Comparator|placebo|microcrystalline cellulose supplementation
11140398|NCT03793777|Experimental|Aronia|aronia melanocarpa supplementation
11140399|NCT03793764|Active Comparator|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
11140400|NCT03793764|Active Comparator|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
11140401|NCT03793764|No Intervention|Group C|In this group no intervention will be performed after the end of operation.
11140402|NCT03793751|Experimental|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
11140403|NCT03793751|Placebo Comparator|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
11140404|NCT03793738|Active Comparator|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
11140405|NCT03793738|Active Comparator|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
11140406|NCT03793725|Experimental|SHR-1210 + Apatinib|Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd
11140407|NCT03793712|Experimental|Lu AF11167 low dose|
11140408|NCT03793712|Experimental|Lu AF11167 high dose|
11140409|NCT03793712|Placebo Comparator|Placebo|
11140410|NCT03793699||case group : realized a suicide attempt|adults having realized a suicide attempt and without histories of suicide attempt.
11140411|NCT03793699||control group : only suicidal ideas|adults having suicidal ideas without suicidal acting out and without histories of suicide attempt.
11140412|NCT03793686|Experimental|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
11140413|NCT03793686|Placebo Comparator|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
11140414|NCT03793673|Other|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.
~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
11140415|NCT03793673|Other|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
11140416|NCT03793673|Other|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.
~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
11140417|NCT03793673|Other|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
11140418|NCT03793647|Active Comparator|Low Intensity EMS|Conventional Stimulation
11140419|NCT03793647|Experimental|High Intensity EMS|Russian Stimulation
11140420|NCT03793647|Placebo Comparator|Placebo|no Stimulation, supported by phone contact
11140421|NCT03793634|Experimental|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
11140422|NCT03793634|Active Comparator|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
11140423|NCT03793621|Experimental|BI 730357|
11140424|NCT03793621|Placebo Comparator|Placebo|
11140425|NCT03793608|Experimental|Dupilumab|Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
11140426|NCT03793595|Experimental|Seated Battle Ropes Protocol|
11140427|NCT03793595|Active Comparator|Seated Upper Extremity Arm Bike|
11140428|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
11140429|NCT03793569|No Intervention|Control group|Participants will be recruited and asked to complete Edinburgh Postnatal Depression Scale (EPDS) at specific timepoints postpartum.
11140430|NCT03793569|Experimental|Intervention group|Participants will be recruited, asked to complete Edinburgh Postnatal Depression Scale at specific timepoints postpartum, and attend a peer discussion group.
11140465|NCT03793231||Fungal Cases|Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.
11140431|NCT03793556|Experimental|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
11140432|NCT03793556|Active Comparator|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
11140433|NCT03793543|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
11140434|NCT03793530|Experimental|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
11140435|NCT03793530|Active Comparator|Control group|Transforaminal lumbar interbody fusion with local bone graft
11140436|NCT03793517|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT.
~Details:
~The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2."
11140437|NCT03793517|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant.
~Details:
~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3."
11140438|NCT03793491||Patients having Parkinson's disease|Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
11140439|NCT03793478|Experimental|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
11140440|NCT03793465|Experimental|Tart Cherry Concentrate|Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Servings (1 ounce or 2 tablespoon/serving) per day for three days
11140441|NCT03793439|Experimental|Open-label treatment|All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.
11140442|NCT03793439|Experimental|Open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
11140443|NCT03793426||Fibryga|Fibryga (human plasma-derived fibrinogen concentrate)
11140444|NCT03793413|Experimental|Surgical group|
11140445|NCT03793413|No Intervention|Observation group|
11140446|NCT03793387|Experimental|Pre-op|
11140447|NCT03793387|Active Comparator|Intra-op|
11140448|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
11140449|NCT03793361|Experimental|Arm A|Regorafenib
11140450|NCT03793361|Placebo Comparator|Arm B|Placebo
11140451|NCT03793348|Experimental|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
11140452|NCT03793335||Gastric cancer prevention|This prospective study consists of 40,000 participants; after randomization, each arm has 20,000 participants. Arm 1: participants receive H. pylori stool antigen test; Arm 2: participants receive the combination of H. pylori stool antigen test and serum pepsinogen test.
11140453|NCT03793335||Colorectal cancer prevention|This prospective study consists of 40,000 participants; after randomization; each arm has 20,000 participants. Arm 1: participants with positive fecal immunochemical test (FIT) receive routine referral confirmatory diagnosis approach; Arm 2: participants with positive FIT receive routine referral confirmatory diagnosis approach and participants with high FIT results receive additional aggressive referral confirmatory diagnosis approach.
11140454|NCT03793322|Experimental|Indocyanine-Green(ICG) injection group|
11140455|NCT03793309|Experimental|Low dose|Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
11140456|NCT03793309|Experimental|High dose|Subjects in this group receive 800 IU vitamin D daily for 4 weeks.
11140457|NCT03793296|Experimental|Paravalvular leak|After transcatheter- or surgical valve replacement
11140458|NCT03793283||Continous Subcutaneous Insulin Infusion|"All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII.
~Forty-five patients are actually treated with CSII in our hospital."
11140459|NCT03793283||Multiple dose insulin injections (MDI):|"Forty-five T1DM adult patients attended in Ciudad Real General University Hospital and treated with MDI.
~MDI patients will be selected through simple random sampling (1:1) from our T1DM patient database."
11140460|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).
~drugs described in the clinic."
11140461|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
11140462|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
11140463|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
11140464|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
11140467|NCT03793218|Experimental|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
11140468|NCT03793218|Active Comparator|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
11140469|NCT03793205|Experimental|Long-acting G-CSF group|Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
11140470|NCT03793205|Experimental|Short-acting G-CSF group|Patients in long-acting G-CSF group only accept short-acting G-CSF.
11140471|NCT03793192|Experimental|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
11140472|NCT03793192|No Intervention|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
11140473|NCT03793179|Experimental|Arm A (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 6 weeks of disease progression, patients receive pemetrexed IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then may receive pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11140474|NCT03793179|Experimental|Arm B (pembrolizumab, pemetrexed, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 6 weeks of disease progression, patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease progression or unacceptable toxicity and until to disease progression for pemetrexed.
11140475|NCT03793179|Active Comparator|Arm C (pembrolizumab, pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes, pemetrexed IV over 10 minutes, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive pembrolizumab IV over 30 minutes and pemetrexed IV over 10 minutes on day 1. Cycles repeat every 21 days for up to 2 years for pembrolizumab in the absence of disease progression or unacceptable toxicity and until to disease progression for pemetrexed.
11140476|NCT03793166|Active Comparator|Arm A (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 or 60 minutes and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~TREATMENT:
~Patients with PD receive cabozantinib PO daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity.
~Patients with CR receive nivolumab IV over 30 or 60 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients with non-CR/non-PD receive nivolumab IV over 30 or 60 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
11140477|NCT03793166|Experimental|Arm B (nivolumab, cabozantinib)|"INDUCTION: Patients receive nivolumab IV over 30 or 60 minutes and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~TREATMENT:
~Patients with PD receive cabozantinib PO daily on days 1-28. Treatment repeats every 28 days until further disease progression or unacceptable toxicity.
~Patients with CR receive nivolumab IV over 30 or 60 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients with non-CR/non-PD receive nivolumab IV over 30 or 60 minutes on day 1 and cabozantinib PO daily on days 1-28. Treatment repeats every 28 days in the absence of"
11140478|NCT03793153|No Intervention|Control|Standard Lower Segment Cesarean Section (LSCS) will be done.
11140479|NCT03793153|Active Comparator|Study|Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
11140480|NCT03793140|Experimental|CPI-613|CPI-613 IV induction (Days 1-5 for first 2 Cycles [14-day cycles]), followed by CPI-613 IV maintenance (Days 1-5 for all Cycles thereafter [21-day cycles].
11140481|NCT03793127|Other|Young group|20-40 years of age
11140482|NCT03793127|Other|Old group|60-80 years of age
11140483|NCT03793114|Experimental|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
11140484|NCT03793114|Active Comparator|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
11140485|NCT03793114|No Intervention|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
11142111|NCT03781791|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
11140486|NCT03793114|Other|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
11140487|NCT03793114|Other|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
11140488|NCT03793114|Experimental|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
11140489|NCT03793114|Experimental|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
11140490|NCT03793101||BiMICS 1.4|Group 1.4 - Patients operated with 1.4 mm BiMICS technique
11140491|NCT03793101||BiMICS 1.8|Group 1.8 - Patients operated with 1.8 mm BiMICS technique
11140492|NCT03793075|Placebo Comparator|Propofol group (P)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
11140493|NCT03793075|Active Comparator|Ketamine group ((K)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
11140494|NCT03793036|No Intervention|FAST group|preoperative fasting
11140495|NCT03793036|Experimental|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
11140496|NCT03793010|Experimental|FX006|FX006 32mg
11140497|NCT03793010|Placebo Comparator|Normal Saline|Normal Saline
11140498|NCT03792997|Active Comparator|control|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid
11140499|NCT03792997|Experimental|study|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid but the investigators add in this arm lipid emulsion & prednisolone & LMWH
11140500|NCT03792984|Placebo Comparator|Metformin + Placebo|
11140501|NCT03792984|Experimental|Calcium carbonate + Vitamin D3 + Metformin|
11140502|NCT03792971|Experimental|Fixed Sequence|
11140503|NCT03792958|Experimental|CM082|CM082 tablet
11140504|NCT03792945|Active Comparator|extracorporeal shock wave therapy|ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
11140505|NCT03792945|Active Comparator|local injection|40 mg of local Depomedrol (methylprednisolone) injection will be applied to group 2 once. Injection will be made from wrist with carpal tunnel syndrome.Patients will be given a splint at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
11140506|NCT03792945|No Intervention|carpal tunnel wrist brace|"Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day.
~Participants will use the carpal tunnel wrist brace 3 months."
11140507|NCT03792932|Active Comparator|Laparoscopic distal pancreatectomy|
11140508|NCT03792932|Active Comparator|Open distal pancreatectomy|
11140509|NCT03792919|Experimental|Cessation of NAs treatment|Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
11140510|NCT03792919|Active Comparator|Keep on current NAs treatment|Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
11140511|NCT03792906|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
11140512|NCT03792906|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
11140513|NCT03792893|Experimental|Higher Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
11140514|NCT03792893|Experimental|Lower Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
11140515|NCT03792880|Active Comparator|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
11140516|NCT03792880|Experimental|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
11140517|NCT03792867|Experimental|Radical Resection and HIPEC|
11140518|NCT03792841|Experimental|AMG 160 Treatment|Part 1: AMG 160 is administered intravenously at different dose levels.
11140519|NCT03792841|Experimental|AMG 160 + Pembrolizumab|Part 2: AMG 160 is administered intravenously at different dose levels. Pembrolizumab will be administered intravenously at a dose of 200 mg.
11140520|NCT03792841|Experimental|AMG 160 + Etanercept Prophylaxis|Part 3: AMG 160 is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously at a dose of 50 mg in cycle 1 only.
11140521|NCT03792841|Experimental|AMG 160 Outpatient Center|Part 4: AMG 160 is administered intravenously at RP2D/MTD in an oncology outpatient center up to 48 hours.
11140522|NCT03792828|Active Comparator|Control|Duloxetine HCl 30mg is not used.
11140523|NCT03792828|Experimental|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
11140524|NCT03792815|Experimental|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2
11140525|NCT03792802|Active Comparator|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
11140526|NCT03792802|Active Comparator|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
11140527|NCT03792789|Experimental|mCIMT with real rTMS|Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
11140528|NCT03792789|Sham Comparator|mCIMT with sham rTMS|Modified Constraint Induced Movement Therapy with sham Repetitive Transcranial Magnetic Stimulation (using sham coil). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with sham rTMS over contralateral primary motor cortex using sham coil which simulated sound and touch of real coil but has no electro-magnetic waves.
11140529|NCT03792776|Active Comparator|Air|Endotracheal tube cuff inflation with air
11140530|NCT03792776|Experimental|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
11140531|NCT03792776|Experimental|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
11140532|NCT03792763|Experimental|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
11140533|NCT03792763|Placebo Comparator|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution
~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
11140534|NCT03792750|Experimental|Experimental Arm A|2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
11140535|NCT03792737|Experimental|Investigational group 1|Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.
11140536|NCT03792737|Experimental|Investigational group 2|Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.
11140537|NCT03792737|Active Comparator|Control group|Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.
11140538|NCT03792724|Experimental|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
11140539|NCT03792724|Experimental|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
11140540|NCT03792711|Experimental|HMB group|2 servings (440 mL)/day Ensure® Plus Advance for use as a supplement with or between meals
11140541|NCT03792711|No Intervention|Control group|Standard of care includes mainly dietary consultation for healthy aging by dietitians to reach sufficient dietary protein intake.
11140542|NCT03792698|Experimental|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
11140543|NCT03792685|Experimental|Normal weight|Normal weight men. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
11140544|NCT03792685|Experimental|Overweight/obesity|Men with overweight or obesity. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
11140545|NCT03792685|Experimental|Diabetes|Men with prediabetes or type 2 diabetes mellitus. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
11140546|NCT03792672|Experimental|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
11140547|NCT03792672|Experimental|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
11140548|NCT03792672|Experimental|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
11140612|NCT03792178|Active Comparator|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
11142112|NCT03781791|Placebo Comparator|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
11140549|NCT03792672|Experimental|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
11140550|NCT03792672|Experimental|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
11140551|NCT03792672|Experimental|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
11140552|NCT03792659||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
11140553|NCT03792646|Experimental|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
11140554|NCT03792646|Placebo Comparator|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
11140555|NCT03792633|Experimental|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
11140556|NCT03792633|Experimental|Poor Response to Prior B Cell Directed Engineered cell therapy|
11140557|NCT03792620|Experimental|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).
~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
11140558|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
11140559|NCT03792594||Historical control group|The patients receive arthroscopic repair only
11140560|NCT03792581|Active Comparator|EV1000 monitor|MAP management will be done as usual ( adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
11140561|NCT03792581|Experimental|EV1000 monitor + closed-loop system|fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
11140562|NCT03792568|Experimental|ALK mutation|
11140563|NCT03792555|Experimental|Paltusotine|
11140564|NCT03792555|Placebo Comparator|Placebo|
11140565|NCT03792542|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
11140566|NCT03792529||breast cancer with HER2 overexpression|
11140567|NCT03792529||hormone receptor-positive breast cancer|
11140568|NCT03792529||triple negative breast cancer|
11140569|NCT03792516|Experimental|Artesunate ointment 40%, 1 cycle|Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.
11140570|NCT03792516|Experimental|Artesunate ointment 40%, 2 cycles|Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.
11140571|NCT03792516|Experimental|Artesunate ointment 40%, 3 cycles|Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.
11140572|NCT03792503|Experimental|Apatinib，Pemetrexe|Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
11140573|NCT03792490|Experimental|Fasudil 30 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days
11140574|NCT03792490|Experimental|Fasudil 60 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days
11140575|NCT03792490|Placebo Comparator|Placebo|Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%
11140576|NCT03792477|Experimental|Part 1: Treatment A|Single 200mg IM testosterone cypionate solution (Test formulation)
11140577|NCT03792477|Active Comparator|Part 1: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
11140578|NCT03792477|Experimental|Part 2: Treatment A|Single 200 mg IM testosterone cypionate solution (Test formulation)
11140579|NCT03792477|Active Comparator|Part 2: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
11140580|NCT03792425|Other|implant with immediate temporization|Immediate nonfunctional loading
11140581|NCT03792425|Other|Delayed implant without temporization|Conventional loading protocol
11140582|NCT03792412|Experimental|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
11140613|NCT03792178|Experimental|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
11140583|NCT03792412|Other|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
11140584|NCT03792399|Experimental|Immediate feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to immediate feedback after data downloaded into computer.
11140585|NCT03792399|Other|Delayed feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to delayed feedback (standard care, i.e., CGM graphs interpretation at scheduled 3 months outpatient visit).
11140586|NCT03792386|Active Comparator|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
11140587|NCT03792386|Active Comparator|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
11140588|NCT03792373||frailty|
11140589|NCT03792373||nonfrailty|
11140590|NCT03792360|Experimental|Single Arm|
11140591|NCT03792347|Experimental|Arm 1|Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 15 and 29. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
11140592|NCT03792321|Active Comparator|Testosterone|Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
11140593|NCT03792321|Placebo Comparator|Placebo|Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.
11140594|NCT03792308|Experimental|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.
~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.
~."
11140595|NCT03792308|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).
~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.
~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
11140596|NCT03792295|Experimental|Multimodal Therapy|Patients will receive scheduled ibuprofen 400mg po q 4 hours and acetominophen 1gram po q 8 hours during the post operative phase and oxycodone 5mg po q 4 to 6 hours as needed for pain control.
11140597|NCT03792295|Active Comparator|Classic/standard opiod Therapy|Patients will receive oxycodone 5mg po q 4 to 6 hours as needed during their post operative phase for pain control.
11140598|NCT03792282|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
11140599|NCT03792282|Active Comparator|RCD|Participants in this group will focus on daily reduced calorie diet (RCD).
11140600|NCT03792269|Experimental|Multi-channel chemotherapy|Patients will receive intraperitoneal irinotecan (50mg, d1, q2w).
11140601|NCT03792269|Active Comparator|Control Group|Patients will receive intravenous oxaliplatin (130mg/m^2, d1, q3w), and oral capecitabine (1.0g, d1-14, q3w).
11140602|NCT03792256|Experimental|Treatment (Palbociclib)|Patients receive Palbociclib 50 mg/m^2 (starting dose with maximum dose of 100 mg) PO (or via NG-tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.
11140603|NCT03792243||Parastomal hernia|Patients undergoing parastomal hernia repair in Denmark between 2007 and 2017
11140604|NCT03792230|Experimental|Video|This group received educatıon via video material
11140605|NCT03792230|Experimental|Brochure|This group received education via written material (brochure)
11140606|NCT03792230|No Intervention|Control|This group received standart clinical education
11140607|NCT03792217|Experimental|1.3% NaOCl|Root canal irrigation done using 1.3% NaOCl.
11140608|NCT03792217|Active Comparator|5.25% NaOCl|Root canal irrigation done using 5.25% NaOCl.
11140609|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.
~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
11140610|NCT03792191|Experimental|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
11140611|NCT03792191|Active Comparator|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
11140614|NCT03792165|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
11140615|NCT03792165|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
11140616|NCT03792152|Experimental|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
11140617|NCT03792152|Active Comparator|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
11140618|NCT03792139|Experimental|LY3200882|LY3200882 administered orally.
11140619|NCT03792139|Experimental|Itraconazole + LY3200882|Itraconazole + LY3200882 administered orally.
11140620|NCT03792126|No Intervention|Standard Care|
11140621|NCT03792126|Experimental|Implicit Learning Approach|
11140622|NCT03792113|Experimental|Autologous fibrin glue|The periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to 2 mm from the coronal margin and repositioned back on to the root surface. Thereafter, the tissues will be kept in position with a gentle pressure using a wet gauze for 30 - 60 seconds.
11140623|NCT03792113|Active Comparator|4-0 silk suture|The periodontal flap will be approximated using 4-0 black silk suture.
11140624|NCT03792100|Experimental|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
11140625|NCT03792100|Active Comparator|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
11140626|NCT03792087|Experimental|SmofKabiven Peripheral|Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
11140627|NCT03792087|Active Comparator|Hospital compounded emulsion|Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
11140628|NCT03792074|Experimental|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
11140629|NCT03792074|Active Comparator|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
11140630|NCT03792061|Experimental|Strategy Training|Strategy training is an activity intervention training approach developed based on the theoretical tenets of metacognitive training. The purpose of strategy training is to guide individuals to generate problem-solving skills to address challenges that they identify in daily activities.
11140631|NCT03792061|No Intervention|Reflective listening|
11140632|NCT03792048|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
11140633|NCT03792048|No Intervention|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
11140634|NCT03792035|Experimental|Experimental group|First time given 8 capsules of Tongxinluo, then given 4 capsules of Tongxinluo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
11140635|NCT03792035|Placebo Comparator|Control group|First time given 8 capsules of placebo, then given 4 capsules of placebo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
11140636|NCT03792022||Group 1|Adherence to timely vaccine uptake
11140637|NCT03792009|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
11140638|NCT03792009|Placebo Comparator|Paracervical block with normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
11140639|NCT03791996|No Intervention|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
11140640|NCT03791996|Experimental|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
11140641|NCT03791983|Experimental|Therapy Group|
11140642|NCT03791983|Other|Control Group|
11140643|NCT03791970|Experimental|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
11140644|NCT03791970|Active Comparator|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
11140645|NCT03791957||Group A - Healthy Periodontium|Absence of clinical signs of inflammation like bleeding on probing, erythema, edema, attachment loss, bone loss, patient symptoms, (bone levels at 1-3mm apical to CEJ) n=20
11140646|NCT03791957||Group B - Gingivitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla, n=20
11140647|NCT03791957||Group C - Periodontitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla,periodontal pocketing, clinical attachment loss, radiographically assessed bone loss n=20
11140648|NCT03791944|Experimental|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
11140649|NCT03791944|Active Comparator|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
11140650|NCT03791944|Experimental|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
11140653|NCT03791918|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11140654|NCT03791918|Active Comparator|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
11140655|NCT03791905|Experimental|TP Arm|Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
11140656|NCT03791905|Experimental|FOLFOX Arm|Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
11140657|NCT03791892|Experimental|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
11140658|NCT03791892|Active Comparator|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
11140659|NCT03791879|Active Comparator|• Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k|
11140660|NCT03791879|Active Comparator|• Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.|
11140661|NCT03791879|Active Comparator|• Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/|
11140662|NCT03791879|Active Comparator|• Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.|
11140663|NCT03791866|Experimental|30% target total enteral nutrition|
11140664|NCT03791866|Experimental|60% target total enteral nutrition|
11140665|NCT03791866|Active Comparator|100% target total enteral nutrition|
11140666|NCT03791853||Light-CT|All specimens are detected using Light-CT
11140667|NCT03791840||Ultrasound evaluation|Eligible patients undergo lymph node biopsy or lymph node dissection. Before surgery, the status of axillary lymph node status was evaluated using ultrasound. After surgery, all lymph node specimens would be collected and be assessed using ultrasound in a special evaluation system in vitro.
11140668|NCT03791827||Corticosteroid|Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
11140669|NCT03791827||Corticosteroid and cyclophosphamide|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
11140670|NCT03791827||Corticosteroid and mycophenolate mofetil|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
11140671|NCT03791827||Corticosteroid and azathioprine|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
11140672|NCT03791827||Corticosteroid and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
11140673|NCT03791827||Corticosteroid and cyclosporine A|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
11140674|NCT03791827||Corticosteroid, mycophenolate mofetil and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
11140675|NCT03791827||Retuximab|An option for refractory lupus nephritis
11140676|NCT03791814|Experimental|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
11140677|NCT03791801|Active Comparator|Neostigmine|Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1
11140678|NCT03791801|Active Comparator|Sugammadex|Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).
11140679|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
11140680|NCT03791775|Experimental|Polidocanol 3% Foam|Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany).
11140681|NCT03791762|Experimental|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
11140682|NCT03791762|Experimental|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
11140683|NCT03791762|Experimental|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
11140684|NCT03791749|Experimental|Breastfeeding Support|Home visits will be conducted at 1-2 and 5-6 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
11140685|NCT03791749|No Intervention|Standard Care|Home visits will be conducted at 1-2 and 5-6 weeks post-delivery. No intervention will be administered.
11140686|NCT03791736|Experimental|Sandostatine|Injection of Sandostatine
11140687|NCT03791723|Experimental|Sacubitril/valsartan|After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
11140863|NCT03790462|Experimental|Music intervention group 3|"Raga C will be played for 10 minutes & data collected."
11140688|NCT03791723|Active Comparator|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
11140689|NCT03791710|Placebo Comparator|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
11140690|NCT03791710|Active Comparator|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
11140691|NCT03791697|Active Comparator|Telephone Group|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.
~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.
~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes."
11140692|NCT03791697|No Intervention|In Person Clinic Visit Group|For the patient randomized into the clinic group, the clinic visit will entail questions about common postoperative complications (including fever, nausea/vomiting, pain, urinary symptoms, constipation, etc.). As per usual, vital signs and a focused physical examination will be completed at the clinic visit. All clinic visits will be performed by an FPRMS fellow and/or attending physician
11140693|NCT03791684|Active Comparator|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
11140694|NCT03791684|Active Comparator|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
11140695|NCT03791671|Experimental|individual balance training|"After the initial assessments, the three week intervention time begins, which is completed with the reassessments.
~The patients receive 2x weekly individual balance training for 25 minutes each. This runs in addition to the normal, prescribed rehabilitation program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period."
11140696|NCT03791671|Active Comparator|group balance training|"The patients receive 2x weekly group balance training for 25 minutes each. This runs in addition to the normal, prescribed rehab program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period.
~In group therapy are 3 to 6 patients with different neurological diagnoses. As it is usual in rehabilitation everyday life."
11140697|NCT03791658|Other|Asthmatics|"From the patients file the following information will be collected by the investigators:
~Age
~Sex
~FEV1 derived from the last spirometry (including spirometry performed on day of study visit).
~GINA step (Global Initiative for Asthma).
~Number of exacerbations in the year prior to the study.
~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.
~FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).
~Patients will fill out:
~The 12-question TAI-questionnaire (test for the adherence to inhalers)
~The Asthma Control Test (ACT)"
11140698|NCT03791658|Other|COPD-patients|"From the patients file the following information will be collected by the investigators:
~Age
~Sex
~Pack Years
~GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)
~Number of exacerbations in the year prior to the study.
~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.
~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.
~Patients will fill out:
~The 12-question TAI-questionnaire (test for the adherence to inhalers)
~The COPD Assessment Test (CAT)"
11140699|NCT03791645|Experimental|SKY Intervention|Participants in the intervention group will get to participate in the SKY program, for 5 days with each day session taking 3 hours/day. SKY program involves a) specific breathing exercises and social interaction with other participants in the program. Following completion of the program, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use. After completion of the 5 day SKY program, participants will practice SKY every day at home for 30 days. They will also need to attend 4 weekly group sessions during this period and each session is expected to last 1 hour. At the end of the 30 day period, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use.
11140700|NCT03791645|No Intervention|Usual treatment|Participants assigned to the control group will not have access to the SKY program but will continue with usual care. They will also complete questions after 5 days and again after 30 days.
11140701|NCT03791632|No Intervention|witness|2 control CE2 classes without oral sensitization actions
11140702|NCT03791632|Experimental|group intervention 1|2 CE2 classes with a classical lecture style presentation
11140703|NCT03791632|Experimental|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
11140704|NCT03791632|Experimental|group intervention 3|2 CE2 classes with digital media intervention
11140705|NCT03791619|Active Comparator|Higher Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
11140731|NCT03791437|Active Comparator|Control groups|Post chest operative use traditional drainage system until Patient's discharge day Not use Digital chest drainage system
11140706|NCT03791619|Active Comparator|Lower Cylinder Toric IOL|Consented subjects that are eligible will have both eyes implanted with a TECNIS Symfony IOL. Each eye may have a different TECNIS Symfony IOL implanted, as determined by the surgeon and the TECNIS Symfony Toric IOL calculator; however, at least one eye must be implanted with either a Symfony Toric IOL Model ZXT150 (lower-cylinder group) or a Model ZXT300 or ZXT375 (higher-cylinder group) and the fellow eye must have the same or a lower toric power. The eye with the highest toric power IOL will determine the model group.
11140707|NCT03791593|Experimental|Experimental group|The patient will receive evolocumab 420 mg/month on top of guideline-driven medical treatment
11140708|NCT03791593|No Intervention|Control group|The patient will continue guideline-driven medical treatment
11140709|NCT03791580|Experimental|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
11140710|NCT03791580|Experimental|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
11140711|NCT03791580|Experimental|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
11140712|NCT03791580|No Intervention|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
11140713|NCT03791554|Active Comparator|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.
~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
11140714|NCT03791554|Active Comparator|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:
~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.
~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
11140715|NCT03791541|No Intervention|No Intervention|Only surveys will be done and re admissions tracked. No additional interventions based on survey results will be done.
11140716|NCT03791541|Experimental|Intervention|"Pharmacist Services
~Surveys plus increased outpatient pharmacist/pharmacy student services including but not limited to pre and post clinic visit phone calls, prescription counseling, and helping with adherence and compliance with medications. Increased services will be given based on survey results."
11140717|NCT03791528|Active Comparator|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
11140718|NCT03791528|No Intervention|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
11140719|NCT03791515|Active Comparator|Calcitonin Gene-Related Peptide (CGRP)|"30 patients with PPTH will be allocated to receive intravenous infusion of 1.5 µg/min calcitonin-gene related peptide over 20 minutes
~Other Name: CGRP"
11140720|NCT03791515|Placebo Comparator|Placebo|"30 patients with PPTH wil be allocated to receive 40 mL Placebo (isotonic saline) over 20 minutes.
~Other Name: Isotonic Saline"
11140721|NCT03791502|Experimental|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
11140722|NCT03791502|Experimental|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
11140723|NCT03791502|No Intervention|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
11140724|NCT03791489|Experimental|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
11140725|NCT03791476|Placebo Comparator|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
11140726|NCT03791476|Experimental|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
11140727|NCT03791463|Experimental|After meal|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
11140728|NCT03791463|Experimental|Fasting|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered at the end of a 10-hour fast.
11140729|NCT03791450||pancreaticoduodenectomy|patients underwent pancreaticoduodenectomy in recent ten years.
11140730|NCT03791437|Experimental|Experiment groups|Post chest operative use Digital chest drainage system until Patient's discharge day
11140839|NCT03790618|Experimental|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
11140732|NCT03791424|Experimental|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
11140733|NCT03791424|Placebo Comparator|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
11140734|NCT03791398|Experimental|ONC201 Level 1 (Starting Dose Level)|625mg ONC201 Cycle 1 Day -7 dose then once week
11140735|NCT03791398|Experimental|ONC201 Level 2|500 mg ONC201 Cycle 1 Day -7 dose then once week
11140736|NCT03791398|Experimental|ONC201 Level 3|375 mg ONC201 Cycle 1 Day -7 dose then once week
11140737|NCT03791398|Experimental|Nivolumab|240mg IV flat dose q 2 weeks
11140738|NCT03791385|Experimental|Study subjects|Children with ASD and their parents/caregivers were trained on tooth-brushing twice, two weeks apart using Picture Exchange Communication System (PECS) PECS as a pictures/cards series showing a structured tooth-brushing method.
11140739|NCT03791372|Placebo Comparator|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
11140740|NCT03791372|Experimental|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells>1*10^7/kg). The infusion speed is 1ml/min.
11140741|NCT03791333||multi trauma patients group|
11140742|NCT03791307|Experimental|Traditional Pilates group|This group will perform only exercises based on the traditional Pilates method
11140743|NCT03791307|Experimental|Modified Pilates group|This group will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer
11140744|NCT03791307|No Intervention|Control group|This group will not perform any physical exercise during the trial period.
11140745|NCT03791294|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
11140746|NCT03791294|No Intervention|Control|No treatment
11140747|NCT03791281|Experimental|BASIS|Received a 3-hour BASIS implementation strategy.
11140748|NCT03791281|Active Comparator|Attention Control|Received a 3-hour session designed to control for dose, information provided, and presenter effects.
11140749|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
11140750|NCT03791255|Experimental|Resin Modified Calcium Silicate|light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
11140751|NCT03791255|Active Comparator|Light Cured Calcium Hydroxide|gold standard for pulp capping, It allows for the formation of a reparative dentine bridge through cellular differentiation, extracellular matrix secretion and subsequent mineralization.
11140752|NCT03791242|Active Comparator|Group 1|72 morbidly obese patients (12 patients per participating site) with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
11140753|NCT03791242|Active Comparator|Group 2|72 morbidly obese patients (12 patients per participating site) with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
11140754|NCT03791216||Psoriasis patients to be treated only topically|
11140755|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
11140756|NCT03791216||Age-, sex- and BMI percentile-matched controls|
11140757|NCT03791216||Patients being treated with isotretinoin for acne|
11140758|NCT03791203|Experimental|Calorie restriction (MACR)|Participants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
11140759|NCT03791203|No Intervention|Control group|Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
11140760|NCT03791190|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
11140761|NCT03791190|Experimental|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.
~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
11140762|NCT03791177|Experimental|Study Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
11140763|NCT03791177|Sham Comparator|Control Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
11140764|NCT03791164|Experimental|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
11140840|NCT03790618|Experimental|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
11140765|NCT03791164|Active Comparator|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
11140766|NCT03791138|Experimental|intervention group|Care as usual and an online patient decision aid
11140767|NCT03791138|No Intervention|control group|Care as usual with a standard information leaflet
11140768|NCT03791125|Experimental|Experimental|
11140769|NCT03791125|Placebo Comparator|Placebo|
11140770|NCT03791112|Experimental|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
11140771|NCT03791112|Experimental|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
11140772|NCT03791112|Experimental|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
11140773|NCT03791112|Experimental|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
11140774|NCT03791112|Experimental|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
11140775|NCT03791112|Experimental|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
11140776|NCT03791099|Experimental|Metronidazole|19,8 mg of metronidazole in one polymer matrix
11140777|NCT03791099|No Intervention|Only SRP|standard non-surgical treatment- scaling/root planing
11140778|NCT03791086||Patients with bronchiectasis|Adult patients with bronchiectasis meeting the inclusion criteria.
11140779|NCT03791060|Experimental|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.
~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
11140780|NCT03791047|Experimental|Experimental Group: Balance analysis|Sixty older subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
11140781|NCT03791047|Active Comparator|Control Group:Balance Analysis|Sixty young subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
11140782|NCT03791021||third trimester pregnant women|the group of participants in this research would include approximately 100 subjects in the third trimester of their pregnancy. the participants would be collected in the central area of Israel from various socioeconomic groups. each participant would be asked to make draw a person (DAP) test, and answer a number of questionnaires including Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory II (BDI-II), and Traumatic Events Questionnaire (TEQ).
11140783|NCT03790995||High risk prostate cancer|"Patients with initial cT2c-3-4, cN +, Gleason score (GS) more than 7 or PSA > 20ng/mL were labelled as high-risk prostate cancer.
~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
11140784|NCT03790995||Low - intermediate risk prostate cancer|"Initial PSA levels less or equal than 20 ng/mL with GS of 7 or less and cT1-2a-2b, 2 were labelled as low and intermediate risk prostate cancer and served as a control group.
~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
11140785|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
11140786|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
11140787|NCT03790982|Experimental|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
11140788|NCT03790982|Experimental|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
11140789|NCT03790969|Experimental|26 gauge needle|intervention group
11140790|NCT03790969|Active Comparator|23 gauge needle|control group
11140791|NCT03790956|Experimental|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
11140792|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
11140793|NCT03790904|Active Comparator|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
11140794|NCT03790904|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
11140795|NCT03790904|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
11140796|NCT03790891|Experimental|CD19-TriCAR-T/SILK|CD19-TriCAR-T/SILK cells will be administered intravenously
11140797|NCT03790878|Experimental|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
11140798|NCT03790878|Active Comparator|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
11140799|NCT03790878|Placebo Comparator|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
11140800|NCT03790865|Experimental|Low-Dose Livoletide|Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
11140801|NCT03790865|Experimental|High-Dose Livoletide|Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
11140802|NCT03790865|Placebo Comparator|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
11140803|NCT03790852|Experimental|KSI-301 2.5 mg|KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
11140804|NCT03790852|Experimental|KSI-301 5 mg|KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
11140805|NCT03790839|Experimental|Sequential arm ABC|A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
11140806|NCT03790826|Experimental|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.
~Interventions: cystoscopy"
11140807|NCT03790813|Experimental|Eligible patients|
11140808|NCT03790800|Experimental|Intervention group|If systolic blood pressure>180:IV Urapidil 25mg If systolic blood pressure>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
11140809|NCT03790800|No Intervention|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is >220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
11140810|NCT03790787|Experimental|Sequential arm ABC|A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
11140811|NCT03790774|Experimental|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
11140812|NCT03790761|Experimental|PREP 8.0 Curriculum|All participants enrolled in the program will be given the PREP 8.0 curriculum - there will be no comparison group.
11140813|NCT03790748|Other|spinal needle(27 g) within touhy needle(17 g)|
11140814|NCT03790748|Other|spinal needle (25 g) within touhy needle (17g)|
11140815|NCT03790748|Other|Touhy epidural needle 17 guage|
11140816|NCT03790735||Diagnostic test|Targeted chromosomal aberrations detection by FISH (MDA TEST).
11140817|NCT03790722|Experimental|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
11140818|NCT03790722|Experimental|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
11140819|NCT03790709|Experimental|High dose ANAVEX2-73|High dose active once daily orally
11140820|NCT03790709|Experimental|Mid dose ANAVEX2-73|Mid dose active once daily orally
11140821|NCT03790709|Placebo Comparator|Placebo oral capsule|Placebo dose once daily orally
11140822|NCT03790696|Experimental|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
11140823|NCT03790696|Sham Comparator|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
11140824|NCT03790683|Experimental|EnsoETM + Standard of Care|Participants receive esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU.
11140825|NCT03790683|Active Comparator|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
11140826|NCT03790670|Experimental|Leukine Treatment|24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
11140827|NCT03790657|Experimental|tDCS Dosage A|"mild electrical stimulation (Dosage level A) delivered to the frontal region of the brain during practice of a complex walking task"
11140828|NCT03790657|Experimental|tDCS Dosage B|"mild electrical stimulation (Dosage level B) delivered to the frontal region of the brain during practice of a complex walking task"
11140829|NCT03790644|Experimental|exoskeleton assist|walking with assist of a powered exoskeleton
11140830|NCT03790631||imipenem TDM|Adult patients receiving imipenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140831|NCT03790631||meropenem TDM|Adult patients receiving meropenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140832|NCT03790631||piperacillin TDM|Adult patients receiving piperacillin (with or without tazobactam) for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140833|NCT03790631||flucloxacillin TDM|Adult patients receiving flucloxacillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140834|NCT03790631||amoxicillin TDM|Adult patients receiving amoxicillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140835|NCT03790631||ceftazidime TDM|Adult patients receiving ceftazidime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140836|NCT03790631||cefepime TDM|Adult patients receiving cefepime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
11140837|NCT03790618|Placebo Comparator|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
11140838|NCT03790618|Experimental|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
11140841|NCT03790605|Experimental|1% curcumin chip|Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
11140842|NCT03790605|Placebo Comparator|Placebo chip|Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
11140843|NCT03790592|Experimental|trifocal IOL|patients implanted with a trifocal intraocular lens
11140844|NCT03790579||Women with gestational diabetes|We randomly selected the 40 pregnant women diagnosed GDM by two-step procedure based on Carpenter-Coustan criteria at this hospital. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
11140845|NCT03790579||Healthy women|We also randomly selected 40 healthy pregnant with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
11140846|NCT03790566|Experimental|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
11140847|NCT03790566|Active Comparator|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
11140848|NCT03790553|Active Comparator|50.4Gy|Total radiotherapy dose of 50.4Gy.
11140849|NCT03790553|Experimental|61.2Gy|Total radiotherapy dose of 61.2Gy.
11140850|NCT03790540|Experimental|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.
~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
11140851|NCT03790540|Active Comparator|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
11140852|NCT03790527|Experimental|CBM training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.
~Half of the participants will be random-assigned into the CBM training group; Each participant will do these task twice( e.g. Before training and after training)"
11140853|NCT03790527|Sham Comparator|Sham training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.
~Half of the participants will be random-assigned into the sham training group; Each participant will do these task twice( e.g. Before training and after training)"
11140854|NCT03790514|Experimental|Heat Wrap Group|
11140855|NCT03790514|Placebo Comparator|Control Group|
11140856|NCT03790501||People living with HIV (PLHIV).|We will recruit and enroll 850 people living with HIV (PLHIV) to participate in this longitudinal observational study.
11140857|NCT03790488|Experimental|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
11140858|NCT03790475|No Intervention|Current screening practice.|Subjects randomized into this group will receive named invitations for colonoscopy with pre-specified date, contact details of dedicated screening center. Invitations will be sent 6 weeks prior to suggested date of screening test. All subjects not responding to the invitation will receive a reminder letter 3 weeks prior to proposed appointment date. Additionally, a re-invitation for colonoscopy (screening test in 6 weeks) will be sent to participants not responding to the first invitation and the reminding letter.
11140859|NCT03790475|Experimental|Sequential screening strategy.|"Subjects randomized into this group will be initially invited to participate in a screening colonoscopy as per group 1. All subjects who will refuse colonoscopy or do not respond to invitation within 6 weeks since the first letter, will receive another invitation letter with FIT test enclosed.
~The screening office will contact persons with a positive test result in order to determine the date of the colonoscopy appointment.
~A negative test result will be sent together with a recommendation to have another screening test performed 2 years later and information about the possible delivery of the test in two years."
11140860|NCT03790475|Experimental|Multiple options screening strategy.|"Subjects in this group will receive a letter with an offer to choose between colonoscopy or FIT screening.
~The first letter will include an invitation with a scheduled date of colonoscopy (in 6 weeks) and a FIT kit.
~Three weeks before a scheduled date of colonoscopy subjects randomized into this group will receive a reminder letter with an information about proposed screening methods. After the scheduled date of the colonoscopy examination, subjects who will not respond to the invitation for colonoscopy and will not send the FIT test back to the laboratory will receive another invitation for colonoscopy (in 6 weeks) and a FIT kit."
11140861|NCT03790462|Experimental|Music intervention group 1|"Raga A will be played for 10 minutes & data collected."
11140862|NCT03790462|Experimental|Music intervention group 2|"Raga B will be played for 10 minutes & data collected."
11140864|NCT03790462|No Intervention|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
11140865|NCT03790449|Experimental|PreLiFe-programme|A Mobile Preconception Lifestyle programme
11140866|NCT03790449|Other|Attention Control|Attention Control Programme
11140867|NCT03790436|Experimental|Betaquik|
11140868|NCT03790423|Experimental|18F-ASIS PET|One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection
11140869|NCT03790410|Active Comparator|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:
~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
11140870|NCT03790410|Active Comparator|Inspiratory muscle training group|"Complex pulmonary rehabilitation:
~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
~Inspiratory muscle training
~The training program contains strengthening exercises on the diaphragm muscle."
11140871|NCT03790384|No Intervention|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
11140872|NCT03790384|Experimental|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
11140873|NCT03790371|Active Comparator|misoprostol group|misoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
11140874|NCT03790371|Placebo Comparator|placebo|while the control group received a placebo tablet in the same regimen as the study group.
11140875|NCT03790358|Placebo Comparator|Placebo|Placebo
11140876|NCT03790358|Experimental|low dose MDMA|6.5ug dose of serotonin agonist
11140877|NCT03790358|Experimental|medium dose|13ug dose of serotonin agonist
11140878|NCT03790358|Experimental|high dose|26ug dose of serotonin agonist
11140879|NCT03790345|Experimental|Experimental group 1|15 subjects will be randomly assigned to adjuvant treatment with 200mg of vitamin B6 (pyridoxine).
11140880|NCT03790345|Experimental|Experimental group 2|15 subjects will be randomly assigned to adjuvant treatment with 2mg of vitamin B12 (cobalamin).
11140881|NCT03790345|Sham Comparator|Placebo oral tablet|15 subjects will be randomly assigned to adjuvant treatment with placebo.
11140882|NCT03790332|Experimental|Phase 1/2|"Part A: Subjects ≥1 to <12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED).
~Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED.
~Part B: Subjects ≥1 to <12 years of age( upper age limit is < 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily."
11140883|NCT03790319||Single Workshop 'The Emotional Backpack'|Subjects of this group are participating in one single workshop over three days.
11140884|NCT03790319||Year Program 'The Power of Feelings'|Subjects of this group are participating in three workshops of over 3 days each in a continuing group over nine months. They are animated to deal with the content inbetween the workshops through biweekly e-mails and to exchange in couples.
11140885|NCT03790293|Experimental|Rituximab|Rituximab in combination with reduced corticosteroids is administrated
11140886|NCT03790293|Active Comparator|Standard corticosteroid|Standard corticosteroid is administrated
11140887|NCT03790280|Experimental|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
11140888|NCT03790280|No Intervention|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
11140889|NCT03790267||Hip arthroplasty|
11140890|NCT03790267||Knee arthroplasty|
11140891|NCT03790267||Shoulder arthroplasty|
11140892|NCT03790241|Experimental|Young males of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
11140893|NCT03790241|Experimental|Young females of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
11140894|NCT03790241|Experimental|Aged males of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
11140895|NCT03790241|Experimental|Aged females of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
11140896|NCT03790241|Experimental|Obese young males|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
11140897|NCT03790241|Experimental|Obese young females|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
11140898|NCT03790241|Experimental|Obese aged males|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
11140899|NCT03790241|Experimental|Obese aged females|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
11140900|NCT03790228|Experimental|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
11140901|NCT03790215|Experimental|cohort for treatment|Participants enrolled are given dydrogesterone tablet of 10mg twice a day, from day 15 to day 24 of the menstrual cycle over a period of 3 months.
11140902|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
11140903|NCT03790189|Experimental|Bone Marrow Concentrate|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
11140904|NCT03790176|Other|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
11140905|NCT03790176|Other|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
11140906|NCT03790163|Placebo Comparator|levobupivacaine at ( 23˚C)|Levobupivacine hydrochloride at ( 23˚C) will be received 3.5 ml levobupivacaine at the operating room temperature 23˚C will be administered
11140907|NCT03790163|Active Comparator|Warm levobupivacaine at (30˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (30˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
11140908|NCT03790163|Active Comparator|Warm levobupivacaine at (37˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (37˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
11140909|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
11140910|NCT03790137|Experimental|Treatment group|The treatment group will include approximately 10 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for up to 6 months.
11140911|NCT03790111|Experimental|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg plus 1L therapy for the duration of the study
11140912|NCT03790098|Experimental|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
11140913|NCT03790098|No Intervention|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
11140914|NCT03790085|Experimental|Risperidone|It can be used after schizophrenia is diagnosed. Risperidone affects prolactin and may affect menstruation in young women, so we will try not to use it in such patients. Patients were randomized to a single Risperidone control trial for 8 weeks to evaluate the clinical efficacy of the patients. Risperidone routine daily 2-6 mg, up to 8 mg, can be taken orally twice a day.
11140915|NCT03790085|Experimental|Olanzapine|It can be used after schizophrenia is diagnosed. Olanzapine is not generally used in patients with diabetes and hyperlipidemia. Patients were randomized to a single Olanzapine control trial for 8 weeks to evaluate the clinical efficacy of the patients. Olanzapine is available once or twice a day, starting at 5 mg daily and up to 20 mg daily.
11140916|NCT03790085|Experimental|Aripiprazole|It can be used after schizophrenia is diagnosed. Aripiprazole has no specific contraindications. Patients were randomized to a single Aripiprazole control trial for 8 weeks to evaluate the clinical efficacy of the patients. Aripiprazole is taken orally once a day, starting at 10 mg daily and up to 30 mg daily.
11140917|NCT03790072|Experimental|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.
~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
11140918|NCT03790059|Experimental|RFA combined with H101 group|The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
11140919|NCT03790059|Other|Conventional RFA group|The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
11140920|NCT03790033|Experimental|UCHA group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Shinhwa Pharmaceutical company
11140921|NCT03790033|Placebo Comparator|Placebo group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Tsumura Co., Tokyo, Japan
11140922|NCT03790020|Active Comparator|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
11140923|NCT03790020|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
11140924|NCT03790020|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
11140925|NCT03790020|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
11140926|NCT03790007|Active Comparator|Transversus Abdominis Plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
11140927|NCT03790007|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
11140928|NCT03790007|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the gallbladder excision area-periportal area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periportal area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
11140929|NCT03790007|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
11140957|NCT03789773|Experimental|Diagnostic (holographic mm-wave imaging)|Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.
11140958|NCT03789760|Experimental|active group|take two pills (120 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
11142143|NCT03781557|Experimental|High-concentrated DHA|High-concentrated DHA fish oil softgels
11140930|NCT03789994|Experimental|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.
~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
11140931|NCT03789994|Other|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
11140932|NCT03789981||At diagnosis|Immunogenic profile in patients affected by primary or secondary AML at diagnosis
11140933|NCT03789981||At relapse|Immunogenic profile in patients affected by primary or secondary AML at relapse
11140934|NCT03789955|Experimental|Fluoroscopic-guided TEB|After assessment of the epidural space using the loss of resistance technique with air under fluoroscopic guidance, six fluoroscopic views will be obtained: true anteroposterior, contralateral oblique (CLO) at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral for comparison CLO view with lateral view.
11140935|NCT03789942|Active Comparator|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
11140936|NCT03789942|Active Comparator|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.
~Oral surgery procedures Suturing End of procedure"
11140937|NCT03789942|Active Comparator|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.
~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
11140938|NCT03789929||The Emotional Backpack|Healthy adults participating in the offered online-course on their own initiative.
11140939|NCT03789929||Feelings as Powers|Healthy adults participating in the offered online-course on their own initiative.
11140940|NCT03789916|Experimental|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
11140941|NCT03789916|Active Comparator|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
11140942|NCT03789890|Experimental|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
11140943|NCT03789877|Experimental|Group I (home-based walking program, rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
11140944|NCT03789877|Active Comparator|Group II (home-based exercise program, sham rTMS)|Patients participate in a home-based exercise program of at least 10,000 steps per day (about 30 minutes of daily exercise) for 5 days weekly (150 minutes per week) for 12 weeks. Patients also undergo sham repetitive transcranial magnetic stimulation over 1 hour for 8 sessions during the first 2 weeks of the walking program.
11140945|NCT03789864||single-arm, non-randomized Biodynamic imaging (BDI)|Single-arm, non-randomized, Biodynamic phenotypic profiling of cancer (specifically, mycosis fungoides) therapy, gemcitabine . Standard of Care treatment with gemcitabine in this setting is 1200 mg/m2 as a 30 minute infusion given intravenously on days 1, 8, and 15 of every 28-day treatment cycle. Standard dose reductions are expected in patients experiencing unacceptable toxic effects of treatment. All subjects will undergo standardized staging tests, with tumor stage defined according to established guidelines. For this study, three 6-mm x 4-mm dermal punch biopsies from one or more target lesions will be collected prior to treatment initiation and submitted for Biodynamic imaging (BDI). All patients will be considered off-study after completing cycle 2.
11140946|NCT03789851|Experimental|core needle biopsy|All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
11140947|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
11140948|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
11140949|NCT03789812|Active Comparator|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
11140950|NCT03789812|Experimental|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
11140951|NCT03789812|Experimental|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
11140952|NCT03789812|Experimental|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
11140953|NCT03789799|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
11140954|NCT03789799|Placebo Comparator|Placebo|From the first postoperative day for ten days, single vaginal capsule per day of sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
11140955|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
11140956|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
11140959|NCT03789760|Placebo Comparator|control group|take two pills (120 mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
11140960|NCT03789734|Experimental|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
11140961|NCT03789734|Experimental|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
11140962|NCT03789734|Experimental|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
11140963|NCT03789734|Experimental|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
11140964|NCT03789721||Adrenoleukodystrophy|All patients living in the United States diagnosed with adrenoleukodystrophy, either by newborn screen, based on family history or otherwise, are eligible to participate in this study.
11140965|NCT03789708|Experimental|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
11140966|NCT03789708|Placebo Comparator|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
11140967|NCT03789708|Experimental|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
11140968|NCT03789708|Experimental|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
11140969|NCT03789695|Active Comparator|Dabigatran|
11140970|NCT03789695|Active Comparator|Warfarin|
11140971|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
11140972|NCT03789656|Experimental|Paltusotine|
11140973|NCT03789643|Experimental|JTT-251 Dose 1|One dose of study drug by mouth daily for 24 weeks
11140974|NCT03789643|Experimental|JTT-251 Dose 2|One dose of study drug by mouth daily for 24 weeks
11140975|NCT03789643|Experimental|JTT-251 Dose 3|One dose of study drug by mouth daily for 24 weeks
11140976|NCT03789643|Placebo Comparator|Placebo|One dose of study drug by mouth daily for 24 weeks
11140977|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
11140978|NCT03789617|Experimental|EBViNT Cell|
11140979|NCT03789604|Experimental|CS1001 monoclonal antibody|
11140980|NCT03789604|Placebo Comparator|CS1001 placebo|
11140981|NCT03789591|Active Comparator|Standard Arm|Participants randomized to the standard arm will receive a starting dose of hydroxyurea of 20 mg/kg/day.
11140982|NCT03789591|Experimental|Alternative Arm|Participants randomized to the alternative arm will receive a pharmacokinetic guided starting dose of hydroxyurea based on PK labs drawn at a baseline visit to target an area under the curve (AUC) of 115 mg*h/L in an attempt to approximate maximum tolerated dose (MTD). This dose will not exceed the maximum tolerated dose of 35 mg/kg/day.
11140983|NCT03789578|Experimental|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
11140984|NCT03789578|Experimental|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
11140985|NCT03789578|Experimental|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
11140986|NCT03789565||Group 1. Healthy individuals from periodontal perspective:|GI < 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
11140987|NCT03789565||Group 2. Individuals diagnosed with Gingivitis|GI > 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
11140988|NCT03789565||Group 3. Individuals diagnosed with CP|GI > 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography.
11140989|NCT03789552|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.
~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
11140990|NCT03789552|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.
~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
11140991|NCT03789552|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
11140992|NCT03789539|Active Comparator|LD Universal Influenza Vaccine Uniflu|low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
11140993|NCT03789539|Active Comparator|HD Universal Influenza Vaccine Uniflu|high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
11140994|NCT03789539|Placebo Comparator|Placebo|saline 0.5 ml
11140995|NCT03789526|Experimental|Group 1|Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
11140996|NCT03789526|No Intervention|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
11140997|NCT03789513|Other|Triage with different options|"All women will have an HPV test, partial genotyping (16/18/45 versus other high-risk HPV [hr-HPV]) and VIA. The different options for triage that will be compared are:
~Participants hr-HVP+ and VIA+ participants selected for treatment;
~Participants HPV 16/18/45+ selected for treatment;
~Participant HPV 16/18/45+ and/or VIA+ selected for treatment;"
11140998|NCT03789500|Experimental|study arm|
11140999|NCT03789487|Experimental|Non-responders to CRT|Non-responders to CRT who will undergo an electrical optimization of the settings of their device
11141000|NCT03789474|No Intervention|Group A|No intervention was done ,served as a control group.
11141001|NCT03789474|Experimental|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
11141003|NCT03789448|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
11141004|NCT03789448|Experimental|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
11141005|NCT03789435||Amputees|Patients underwent trans-tibial and trans-femoral amputation of any etiology at the Rizzoli Orthopedic Institute from 2015 to 2017 with the presence of analgesia data for surgery in a computerized record (SIR, Rizzoli information system). A questionnaire for the detection of residual limb pain will be administrate to all the survivors.
11141006|NCT03789422|Active Comparator|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
11141007|NCT03789422|Active Comparator|one drug|Levocetirizine 20 mg/day for a month
11141008|NCT03789409|Experimental|Intermittent Fasting|Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
11141009|NCT03789409|No Intervention|Ad libitium|Participants will be allowed to have hospital meals and all the desired intake without time limit.
11141010|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
11141011|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
11141012|NCT03789370|Active Comparator|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
11141013|NCT03789370|Active Comparator|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
11141014|NCT03789357||Single Arm|All patients admitted to the Acute Stroke Unit
11141015|NCT03789344|Experimental|Acupuncture treatment|
11141016|NCT03789344|Active Comparator|Psychotherapy|
11141017|NCT03789344|Placebo Comparator|blank control|
11141018|NCT03789331||Transgender Male individuals|"Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery.
~Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
11141019|NCT03789331||Normal healthy female individuals|"Group Description: Healthy women with normal sexual orientation.
~Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
11141020|NCT03789318|Active Comparator|CA-008|
11141021|NCT03789318|Placebo Comparator|Placebo|
11141022|NCT03789305||Critically ill patients|Critically ill patients admitted to intensive care for more than 48 hours
11141023|NCT03789292|Experimental|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
11141024|NCT03789292|Active Comparator|Humira SC (adalimumab)|Humira SC (adalimumab)
11141025|NCT03789279||Distal transradial arterial access|Patients undergoing invasive coronary angiography via the distal radial approach (anatomical snuffbox)
11141026|NCT03789266|Experimental|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
11141027|NCT03789266|Other|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
11141028|NCT03789253||AS cohort with progression|AS cohort with tumor progression
11141029|NCT03789253||AS cohort without progression|AS cohort without tumor progression
11141030|NCT03789240|Experimental|1|Window of treatment with Copanlisib 60mg via IV for a single 28 day cycle, once weekly for the first 3 weeks and then a 1- week break followed by induction therapy with copanlisib and rituximab. Induction therapy will be 6 cycles (28 days) of: copanlisib dose and administration same as window, rituximab 375mg/m2 via IV, once weekly for the first 4 weeks during cycle 1, subsequent cycles (cycles 2-6), rituximab will be dosed only once on day 1 of the cycle.
11141031|NCT03789227|Placebo Comparator|Group C|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 4 ml saline in a total volume 12 ml.
11141032|NCT03789227|Active Comparator|Group D|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 8 mg dexamethasone with 4 ml saline in a total volume 12 ml.
11141033|NCT03789227|Active Comparator|Group K|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 15 mg ketorolac with 4 ml saline in total volume 12 ml.
11141034|NCT03789214|Placebo Comparator|Placebo|Placebo sleep medication (Placebo oral capsule)
11141035|NCT03789214|Active Comparator|Low Dose Suvorexant|Low dose sleep medication
11141036|NCT03789214|Active Comparator|High Dose Suvorexant|High dose sleep medication
11141037|NCT03789201|Experimental|Healthy Volunteers|thematic permission to use non-invasive techniques regarded as having minimal risk in healthy individuals, such as, MRI, EEG, EMG, lowfrequency stimulation(= 1 Hz), electrical stimulation of the skin to mimic thesomatosensory artifact of TMS, and behavioral tests
11141038|NCT03789188||Healthy Volunteers|CC Registered Nurses
11141039|NCT03789175|Other|Subjects receiving supplement|Subjects with Li-Fraumeni syndrome with TP53 mutations will receive NR
11141040|NCT03789162||Confirmed CRC with Residual Lesion|A diagnosis of CRC confirmed with a tissue biopsy or a colorectal lesion at least 1 cm in size suspicious for adenoma (including sessile serrated adenoma) or CRC on a pre-enrollment colonoscopy.
11141041|NCT03789149|Experimental|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
11141042|NCT03789136||Primary colon cancer|
11141043|NCT03789136||Liver metastases|
11141044|NCT03789136||Inguinal hernia (control)|
11141045|NCT03789136||Abdominal hysterectomy (control)|
11141046|NCT03789123|Experimental|Study Group (patients with OMA)|"I) Untreated patients (n=142)
~II) Dienogest (n=142)
~III) Dienogest/Estradiol valerate+Dienogest (n=142)"
11141047|NCT03789123|Sham Comparator|Control Group(patients without OMA)|"I) Untreated patients (n=142)
~II) Dienogest/Estradiol valerate+Dienogest (n=142)"
11141048|NCT03789110|Experimental|Nivolumab+Ipilimumab|"Ipilimumab is administered intravenously every 6 weeks
~Nivolumab is administered intravenously every 2 weeks"
11141049|NCT03789097|Experimental|Combination therapy|Vaccination with Flt3L, Radiation, and Poly ICLC combined with Pembrolizumab
11141050|NCT03789084|Experimental|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
11141051|NCT03789084|Other|Referral to mental health provider|Provider makes referral to a mental health provider
11141052|NCT03789071||Patient scheduled for general anesthesia with intubation|Patients in this group (only group) will have clinical airway assessment and external ultrasound assessment of the airway
11141053|NCT03789058|Active Comparator|Control Group|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
11141054|NCT03789058|Experimental|Treatment Group|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
11141055|NCT03789045||Obese men|Metabolic thresholds and fat oxidation points relationship in Obese males, age 18-60y, body fat > 30%
11141056|NCT03789045||Male athletes cyclists|Metabolic thresholds and fat oxidation points relationship in Athletic males, cyclist, age 18-60y, >12h of training weekly
11141057|NCT03789045||Sedentary females|Metabolic thresholds and fat oxidation points relationship in Sedentary nonactive females, age 40-60y,
11141058|NCT03789045||Moderately trained males|Metabolic thresholds and fat oxidation points relationship in moderately trained males, different sports, age 18-60y, < 3h of training weekly
11141059|NCT03789045||Male athletes runners|Metabolic thresholds and fat oxidation points relationship in Athletic males, different sports, age 18-60y, >12h of training weekly
11141060|NCT03789032|Experimental|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
11141061|NCT03789019|Experimental|BP-C1|"Dose-response part: patients who have completed the first 32-day treatment period with BP-C1 under Protocol BMC2011-1/Protocol MBC-BPC1/IIB or Protocol BMC2012-4, and having a maximum of moderate toxicity at the end of treatment are offered to continue in the second 32-day treatment period with BP-C1 under the protocol BMC2011-02. Patients completing 64-day treatment period with BP-C1 will be followed up for 28 days.
~Follow-up study: the patients will be given BP-C1 as long as they obtain benefit from the treatment (i.e. until disease progression or increase in toxicity not above moderate grade)."
11141062|NCT03789006|Active Comparator|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
11141063|NCT03789006|Active Comparator|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
11141064|NCT03788993|Experimental|Blue-depleted evening light condition|
11141065|NCT03788993|Active Comparator|Normal light condition|
11141066|NCT03788980||carotid endarterectomy group|patients undergoing carotid endarterectomy
11141067|NCT03788967|Experimental|TBPM-PI-HBr 300 mg film-coated tablets|TBPM-PI-HBr 600 mg administered orally three times per day for 7 to 10 days.
11141068|NCT03788967|Active Comparator|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 10 days.
11141069|NCT03788954|Active Comparator|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
11141070|NCT03788954|Active Comparator|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
11141071|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
11141072|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
11141073|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
11141074|NCT03788941||Catheter ablation|Patients will only receive catheter ablation of atrial fibrillation for treatment.
11141075|NCT03788915|Active Comparator|Online dietician lifestyle counseling|Online dietetic lifestyle counseling
11141076|NCT03788915|Placebo Comparator|Usual care|Usual care
11141077|NCT03788902|Experimental|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
11141078|NCT03788902|No Intervention|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
11141079|NCT03788889|Active Comparator|Lorazepam + Ketamine + Placebo A|"Ketamine - infusion (0.15 - 0.4 mg/kg/hr) and placebo injections titrated by increases of 0.075 mg/kg/hr every 30 minutes for Clinical Institute Withdrawal Assessment for Alcohol (revised version) (CIWA-Ar) greater than or equal to 10 in addition to lorazepam symptom-triggered therapy
~Ketamine dosing will be based on ideal body weight
~Ketamine infusion will be discontinued once CIWA-Ar less than 10 for 4 hours"
11141080|NCT03788889|Active Comparator|Lorazepam + Phenobarbital + Placebo B|"Phenobarbital - IV push (260 mg loading followed by 130 mg q1 hour) with placebo infusion until CIWA-Ar less than 10 with a maximum daily dose of 10mg/kg in addition to lorazepam symptom-triggered dosing for recurrent symptoms (Gold 2007)
~Maximum daily dose will be used in order to prevent over sedation as well as provide adequate storage in pharmacy monitored refrigerators for study drugs"
11141081|NCT03788889|Placebo Comparator|Lorazepam + Placebo A + Placebo B|Lorazepam will be administered every 30 minutes as indicated based on CIWA-Ar protocol for Cottage Health in addition to placebo injections and placebo infusion
11141082|NCT03788876|Active Comparator|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
11141366|NCT03786913||control group|20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
11141367|NCT03786887|Experimental|Nalbuphine|
11141083|NCT03788876|Sham Comparator|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
11141084|NCT03788863||Pregnant women exposed to glucocorticoids|Pregnant women exposed to any glucocorticoid or corticosteroid or steroids in early pregnancy or first trimester of pregnancy
11141085|NCT03788863||Non-exposed pregnant women|Women not using any glucocorticoid or corticosteroid or steroids during pregnancy
11141086|NCT03788837|Experimental|intravenous Ilomedin|a first dose of Ilomedin of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
11141087|NCT03788837|Placebo Comparator|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
11141088|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
11141089|NCT03788811||Control subjects|Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.
11141090|NCT03788811||Patients with schizophrenia (SZ)|Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
11141091|NCT03788811||Patients with bipolar disorder Type I (BP1)|Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
11141092|NCT03788798|No Intervention|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
11141093|NCT03788798|Experimental|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
11141094|NCT03788785|Experimental|Experimental arm|The specific tobacco cessation intervention of the treatment group will begin during the diagnostic phase of the HNSCC by three ½ hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days top. The most important point is that this intervention will be provided by trained nurses of the health care team within the ENT department, rather than in an external smoking cessation center.
11141095|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
11141096|NCT03788772|Experimental|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
11141097|NCT03788759|Experimental|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
11141098|NCT03788759|Placebo Comparator|Placebo group|25 subjects will be randomized to placebo.
11141099|NCT03788746||Patients diagnosed with advanced urothelial carcinoma|Patients with a confirmed diagnosis of advanced urothelial carcinoma, prior to or during first line therapy, who have available tumor tissue samples collected as part of standard of care
11141100|NCT03788733|Experimental|Melatonin|Melatonin ORAL FILM 3mg will be taken by the subject once a day for 8 weeks
11141101|NCT03788733|Placebo Comparator|placebo|ORAL FILM 3mg placebo will be taken by the subject once a day for 8 weeks
11141102|NCT03788720|Experimental|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
11141103|NCT03788720|Sham Comparator|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
11141104|NCT03788707|Experimental|Passive leg raising|Passive leg raising for 3 minutes after 20 seconds of lying flat
11141105|NCT03788694|Experimental|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
11141106|NCT03788681|Active Comparator|"oral estradiol  estradiol valerate"|"this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI .This group will receive oral estradiol  estradiol valerate  (Cyclo-Progynova® , 2mg , Bayer Schering Pharma Ag , Germany ) from within 24 hours ovum pickup of the cycle."
11141107|NCT03788681|Placebo Comparator|placebo|this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI . This group will receive oral placebo (tablets) from within 24 hours ovum pickup of the cycle
11141108|NCT03788668|Active Comparator|Hyoid suspension with barbed reposition pharyngoplasty|
11141109|NCT03788668|No Intervention|barbed reposition pharyngoplasty|
11141110|NCT03788642|Active Comparator|Control LED Shoe arm|Patients with DFU will wear LED shoe 30 minutes per day
11141111|NCT03788642|Active Comparator|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes per day
11141112|NCT03788629|Experimental|Study Group 1|Bobath Concept+ Talocrural joint Mulligan MWM techniques were applied to this group.
11141113|NCT03788629|Active Comparator|Study Group 2|Subtalar joint Mulligan MWM techniques were applied to this group in addition to Bobath Concept+ Talocrural joint Mulligan MWM techniques
11141114|NCT03788616|Active Comparator|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
11141115|NCT03788616|Active Comparator|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
11141368|NCT03786874|Active Comparator|20 teams the first year (G1)|control group
11141116|NCT03788603|Experimental|Rogaratinib (BAY1163877)|Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
11141117|NCT03788590|Experimental|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
11141118|NCT03788577|Experimental|Oligonol intake group|This experimental arm will be applied for Oligonol 200mg/tab 1 tab per day. The program will last for 12 weeks.
11141119|NCT03788577|Placebo Comparator|Placebo group|This Placebo arm will be given capsules made of starch 1 tab per day. The program will last for 12 weeks.
11141120|NCT03788538|No Intervention|group 1 with no dexmedetomidine|
11141121|NCT03788538|Experimental|group 2 with dexmedetomidine 0.25μg/kg/h|
11141122|NCT03788538|Experimental|group 2 with dexmedetomidine 0.5μg/kg/h|
11141123|NCT03788538|Experimental|group 3 with dexmedetomidine 1μg/kg/h|
11141124|NCT03788525|Experimental|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
11141125|NCT03788525|Experimental|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
11141126|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
11141127|NCT03788499|No Intervention|Control arm|routine oral care and functional exercise.
11141128|NCT03788499|Experimental|Massage arm|Massage of Maxillofacial and oral cavity plus routine oral care and functional exercise
11141129|NCT03788486|Experimental|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
11141130|NCT03788473||Control.|Healthy Pregnant
11141131|NCT03788473||Case.|Pregnant with Periodontal Disease
11141132|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.
~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
11141133|NCT03788447|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
11141134|NCT03788447|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
11141135|NCT03788434|Experimental|VE303 High Dose|Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.
11141136|NCT03788434|Experimental|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.
11141137|NCT03788434|Placebo Comparator|Placebo|Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.
11141138|NCT03788421|Active Comparator|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
11141139|NCT03788421|Active Comparator|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
11141140|NCT03788408|Experimental|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
11141141|NCT03788408|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
11141142|NCT03788395|Experimental|Symbicort Turbohaler plus Turbo+|10 asthmatic children
11141143|NCT03788395|Active Comparator|Symbicort Turbohaler without Turbo+|10 asthmatic children
11141144|NCT03788369||Multivessel coronary artery disease|must include left anterior descending artery
11141145|NCT03788356|Experimental|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
11141146|NCT03788356|Experimental|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
11141147|NCT03788356|Experimental|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
11141148|NCT03788356|Experimental|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
11141149|NCT03788343|Experimental|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.
~Female
~<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0
~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0
~Male
~<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0
~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0
~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.
~Patients will take Phe for 4 weeks."
11141150|NCT03788343|Placebo Comparator|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.
~Patients will take the Placebo for 4 weeks."
11141151|NCT03788330|Experimental|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
11141152|NCT03788330|Placebo Comparator|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
11141153|NCT03788330|No Intervention|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
11141181|NCT03788096|Placebo Comparator|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
11141182|NCT03788083|Placebo Comparator|placebo|
11141183|NCT03788083|Active Comparator|TriMix|
11141154|NCT03788304|Active Comparator|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -
~Positive End Expiratory Pressure (PEEP): 5 cmH2O.
~Pressure support (PS): 12-20 cmH2O.
~FiO2 will be adjusted to achieve a SpO2 at least 95%"
11141155|NCT03788304|Experimental|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .
~will be set with: -
~Temperature at 37°C or 34°C
~Flow rate 30: 50 L/min.
~FiO2 will be adjusted to achieve a SpO2 at least 95%"
11141156|NCT03788291|Experimental|Acalabrutinib and Rituximab treatment|"Rituximab: administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, Then 50 mg SQ thereafter.
~Acalabrutinib: 100 mg po BID starting on day 8 of cycle 1.
~Patients who have attained a complete response who are also MRD negative at cycle 12 will undergo a BM biopsy to confirm CR and MRD negatively. If confirmed, the patient will stop therapy and be followed until disease progression.
~Patients not in a MRD negative CR, will continue acalabrutinib.
~Repeat response assessments (CTs, MRD testing in blood) will be performed at 24 cycles of therapy for those continuing on acalabrutinib. If both negative the patient will undergo a BM biopsy to confirm CR and MRD negativity. If confirmed, the patient will stop therapy and be followed until disease progression. In the absence of a CR or if MRD +, acalabrutinib may be continued until disease progression, unacceptable toxicity or physician/patient discretion."
11141157|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.
~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.
~Participants will be required to answer digital questionnaires twice a day via smartphone."
11141158|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.
~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.
~Participants will be required to answer digital questionnaires twice a day via smartphone."
11141159|NCT03788265|Experimental|injection|
11141160|NCT03788252|Active Comparator|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
11141161|NCT03788252|No Intervention|Non-Renamezin|no use of Renamezin
11141162|NCT03788239|Experimental|Arm 1|Right knee wound closure by staples and Left Knee wound closure by sutures
11141163|NCT03788239|Experimental|Arm 2|Right knee wound closure by sutures and Left Knee wound closure by staples
11141164|NCT03788226|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
11141165|NCT03788226|Active Comparator|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.
~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.
~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
11141166|NCT03788213|Active Comparator|3 week RT|Adjuvant Radiotherapy delivered over 3 weeks
11141167|NCT03788213|Experimental|1 Week RT|Adjuvant Radiotherapy delivered over 1 week
11141168|NCT03788200|Active Comparator|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
11141169|NCT03788200|Active Comparator|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
11141170|NCT03788174|Experimental|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
11141171|NCT03788161|Experimental|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
11141172|NCT03788161|Placebo Comparator|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
11141173|NCT03788135|Experimental|Quadriceps cooling|Participants in this group will receive a cold pack on anterior thigh muscles for 20 minutes.
11141174|NCT03788135|Experimental|Hamstring cooling|Participants in this group will receive a cold pack on posterior thigh muscles for 20 minutes.
11141175|NCT03788135|Experimental|Calf cooling|Participants in this group will receive a cold pack on posterior leg muscles for 20 minutes.
11141176|NCT03788135|Experimental|Back cooling|Participants in this group will receive a cold pack on posterior low back muscles for 20 minutes.
11141177|NCT03788135|No Intervention|Control|The participants in the control group will be rested for 20 minutes without any intervention.
11141178|NCT03788122|Other|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
11141179|NCT03788109|Other|device: combined solid state HRiM|combined solid state high resolution esophageal impedance and manometry (HRiM)
11141180|NCT03788096|Experimental|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
11141369|NCT03786874|Experimental|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
11141184|NCT03788057|Other|stable asthma|"In patients with previously stable course of the asthma, every 3 months the symptoms are evaluated and the dose of ICS is customized - in accordance with the GINA guidelines. This decision is based solely on clinical data (control of symptoms) and is the same as in patients not participating in the study.
~In patients participating in the study, inflammatory parameters are also measured (sputum eosinophilia, eNO, EBT, bronchial reactivity), but results are not known to clinician taking decision about possible ICS dose reduction."
11141185|NCT03788044|Experimental|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
11141186|NCT03788044|Experimental|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
11141187|NCT03788044|Experimental|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
11141188|NCT03788044|No Intervention|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
11141189|NCT03788031|Experimental|Perceptual learning group - Amblyopia|Visual training
11141190|NCT03788031|Active Comparator|Perceptual learning group - Control|Visual training
11141191|NCT03788031|Placebo Comparator|Occlusion therapy - Amblyopia|Patching
11141192|NCT03788018|Experimental|Effect of IV lidocaine and dexmedetomidine on PONV|
11141193|NCT03788018|Experimental|Effect of IV saline on PONV|
11141194|NCT03788005|Active Comparator|Intervention group|"Early mobilization as soon as possible, within a maximum of 12 hours post-surgery.
~Subdural drains will be closed when the patient is allowed to mobilize and will be open during a nocturnal period of 8 hours. Subdural drains will be removed past 48 hours of surgery."
11141195|NCT03788005|No Intervention|Control Group|Bed rest with head of bed at 0 degrees for 48h. Subdural drains will be removed past 48 hours of surgery.
11141196|NCT03787992|Experimental|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
11141197|NCT03787992|Active Comparator|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
11141198|NCT03787979|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
11141199|NCT03787979|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
11141200|NCT03787966|Experimental|ATOPE-B|An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
11141201|NCT03787966|Active Comparator|ATOPE-I|An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
11141202|NCT03787953||Anti-PD-1/PD-L1 antibodies|Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
11141203|NCT03787940|Active Comparator|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
11141204|NCT03787940|Active Comparator|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
11141205|NCT03787940|Experimental|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
11141206|NCT03787927|Other|5 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
11141207|NCT03787927|Other|5 day RTP, then 5 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
11141231|NCT03787745|Active Comparator|Ischemic postconditioning|In addition to state of the art primary PCI in patients with TIMI0-1 ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed, however thrombectomy will not be allowed
11141232|NCT03787745|Placebo Comparator|Conventional|State of the art primary PCI in patients with TIMI0-1 will be performed, however thrombectomy will not be allowed
11141404|NCT03786601||Group A,|High-risk HPV infection in postmenopausal women
11141405|NCT03786601||Group B|High-risk HPV negative in postmenopausal women
11141208|NCT03787927|Other|5 day RTP, then 10 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
11141209|NCT03787927|Other|5 day RTP, then 15 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
11141210|NCT03787927|Other|10 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
11141211|NCT03787927|Other|15 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.
~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'
~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
11141212|NCT03787914|Experimental|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
11141213|NCT03787914|Active Comparator|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
11141214|NCT03787901|Experimental|Morula Vitrification Arm|
11141215|NCT03787901|Active Comparator|Blastocyst Vitrification Arm|
11141216|NCT03787875||Control|The control group included 10 periodontally healthy subjects without signs or symptoms of periodontal disease.
11141217|NCT03787875||Study|"The study group included 15 subjects diagnosed with mild or advanced chronic periodontitis. Each periodontal patient had one non-affected single-rooted tooth (healthy site) and another single-rooted tooth with periodontitis (periodontitis site) with the following features:
~Healthy site: a single-rooted tooth with probing depths below or equal to 3 mm without recession and without bleeding on probing.
~Periodontitis site: another single-rooted tooth from the same patient with clinical attachment loss equal to or greater than 6 mm and bleeding upon probing."
11141218|NCT03787862||Hyperspectral Imaging (HSI)|Patients scheduled for foot surgery will be imaged using the HSI device. Data will be gathered from the electronic medical record for one year to determines the outcomes of the surgery, any complications, re-hosptializations, re-ulcerations or amputation.
11141219|NCT03787849|Active Comparator|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction . After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
11141220|NCT03787849|Active Comparator|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
11141221|NCT03787836|No Intervention|Controls|The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
11141222|NCT03787836|Experimental|Exercisers (Maintained)|The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
11141223|NCT03787836|Experimental|Exercisers (Increased Intensity)|The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
11141224|NCT03787823|Other|Retzius-sparing RARP|Arm B randomizes men with an indication for radical robotic Prostatectomy (RARP) to retzius-sparing transdouglas RARP
11141225|NCT03787823|Other|anterior transperitoneal RARP|Arm A randomizes men with an indication for radical robotic Prostatectomy (RARP) to anterior transperitoneal RARP
11141226|NCT03787784|Experimental|AI visible group|
11141227|NCT03787784|No Intervention|AI invisible group|
11141228|NCT03787771||FMT recipents|Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research
11141229|NCT03787771||FMT donors|Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research.
11141230|NCT03787758|Experimental|SAGE-718|
11141263|NCT03787511|Other|Diabetic patients with chronic cough|Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
11141233|NCT03787732|Active Comparator|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
11141234|NCT03787732|Active Comparator|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
11141235|NCT03787719|Experimental|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
11141236|NCT03787719|No Intervention|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
11141237|NCT03787706|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
11141238|NCT03787706|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
11141239|NCT03787693|No Intervention|Stroke Symmetric Non-VR|In this control arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
11141240|NCT03787693|Experimental|Stroke Symmetric VR|In this experimental arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
11141241|NCT03787693|No Intervention|Stroke Asymmetric Non-VR|In this control arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
11141242|NCT03787693|Experimental|Stroke Asymmetric VR|In this experimental arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
11141243|NCT03787680|Experimental|Cohort 1 (DRPro)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
11141244|NCT03787680|Experimental|Cohort 2 (DRDef)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
11141245|NCT03787667||Patients with pathologically diagnosed colorectal cancer|Patients with pathologically diagnosed colorectal cancer
11141246|NCT03787654|Experimental|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
11141247|NCT03787654|Sham Comparator|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
11141248|NCT03787654|Active Comparator|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
11141249|NCT03787641|Other|Protamine doze|Protamine Sulfate will be administered through an infusion pump in aliquots at a predefined rate (25 mg/min). Blood samples will be withdrawn after each aliquot and quantified for anti-Xa, IIa and ACT.
11141250|NCT03787628|Experimental|Cannabidiol Oral Solution (CBD)|Sixty participants who meet all eligibility criteria will be randomized to receive CBD or placebo in each of three dose cohorts (30 participants per cohort): CBD 700 and 1400 mg/day. The cohorts will be studied sequentially according to ascending dose order to ensure safety.
11141251|NCT03787628|Placebo Comparator|Placebo|Within each cohort, participants will be randomized by baseline buprenorphine plasma level (either below or ≥ 2 ng/ml) so that 20 participants will receive active study medication and 10 will receive placebo. Thus, there will be 3 groups of 20 participants per treatment, including a group with 20 participants who receive placebo.
11141252|NCT03787615|Other|The sipIT tools|The wrist-worn sensors used to detect a drinking event (FitBit Versa with custom algorithm), an H2OPal connected water bottle and fluid consumption monitoring mobile applications.
11141253|NCT03787602|Experimental|Experimental: Stage 1, Arm 1b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
11141254|NCT03787602|Experimental|Experimental: Stage 1, Arm 2b|KRT-232 180mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
11141255|NCT03787589|Experimental|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
11141256|NCT03787589|No Intervention|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
11141257|NCT03787563|Active Comparator|Active Herbal tea|One tea bag infusion three times a day each before breakfast, lunch and dinner.
11141258|NCT03787563|Placebo Comparator|Placebo Tea|Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.
11141259|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
11141260|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
11141261|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
11141262|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
11141406|NCT03786601||Group C|High-risk HPV infection in gestational women
11141264|NCT03787511|Other|Diabetic patients without chronic cough|Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
11141265|NCT03787498|Experimental|PLX2853|Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.
11141266|NCT03787485||LINKS Participants|Study participants who took part in the LINKS intervention.
11141267|NCT03787485||Electronic Medical Record Controls|The principal analytical strategy is propensity score matching, which will lead to the generation of a natural control group from the health centers existing electronic medical records. Propensity matching is highly effective in addressing selection bias of known confounders and enables causal inferences when randomization is not possible, feasible or appropriate, by creating matched groups with similar covariate distributions. Matched controls will be extracted from the electronic medical record from the participating clinics.
11141268|NCT03787472|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
11141269|NCT03787472|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
11141270|NCT03787459|Active Comparator|oseltamivir plus placebo|
11141271|NCT03787459|Experimental|oseltamivir plus arbidol|
11141272|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
11141273|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
11141274|NCT03787433||ARC - Assisted Rehabilitation Care|All study participants will be asked to use ARC during for their post-stroke home based rehabilitation for up to 6 months.
11141275|NCT03787420|Active Comparator|traditional communication system|
11141276|NCT03787420|Experimental|intelligent communication system|
11141277|NCT03787407|Experimental|Mindfulness training with neurofeedback|mindfulness training with neurofeedback using mobile application instruction and review of the application will be provided
11141278|NCT03787407|Active Comparator|Mindfulness training|mindfulness training using mobile application instruction and review of the application will be provided
11141279|NCT03787407|No Intervention|Self-care|
11141280|NCT03787394|Experimental|FAAA-enriched|food products enriched with FAAA-conjugates
11141281|NCT03787394|Placebo Comparator|Plain|Food products without FAAA-conjugates
11141282|NCT03787381|Other|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
11141283|NCT03787368|Experimental|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
11141284|NCT03787368|Experimental|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
11141285|NCT03787368|Placebo Comparator|Placebo|Single intravenous infusion placebo
11141286|NCT03787355|Experimental|Cone Morse Connection Implants|2 neighboring Morse connection Implants
11141287|NCT03787355|Active Comparator|platform matched implants|2 neighboring platform matched implants.
11141288|NCT03787342|Experimental|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
11141289|NCT03787342|Experimental|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
11141290|NCT03787342|Experimental|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
11141291|NCT03787342|Active Comparator|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
11141292|NCT03787329||Bone marrow concentration group|The patients receive core decompression surgery with bone marrow concentration.
11141293|NCT03787329||Historical control group|The previous age-, gender-, and stage-matched patients who received core decompression surgery only.
11141294|NCT03787316|Experimental|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
11141324|NCT03787095|Placebo Comparator|Cohort 1: Placebo|"Participants will receive placebo, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
11141407|NCT03786601||Group D|High-risk HPV negative in gestational women
11141408|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
11141295|NCT03787303|Experimental|Triiodothyronine (T3)|Following discontinuation of L-thyroxine (T4), triiodothyronine (T3) will be initiated at a 3:1 ratio. The dose will be titrated by the investigator to maintain levels of free T4 < 50% of normal range while maintaining a euthyroid state. Triiodothyronine (T3) tablets for oral administration will be prescribed once or twice daily depending on the total dose. Treatment duration will be approximately 9 months during which time the subjects will continue to be treated and monitored as usual for their metastatic breast cancer. During the study period and at the conclusion of the study period, there will be continuous evaluations of the disease status and thyroid status with the option of resuming the original thyroid replacement or continuation of the triiodothyronine (T3).
11141296|NCT03787290|Experimental|Tocilizumab|Participants will receive tocilizumab followed by whole-body hyperthermia
11141297|NCT03787290|Active Comparator|Placebo|Participants will receive a placebo followed by whole-body hyperthermia
11141298|NCT03787264|Experimental|BAAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated
~Induction: 6 cycles (q 28d) of Obinutuzumab + Acalabrutinib + Venetoclax
~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Acalabrutinib + Venetoclax
~Maintenance treatment will be continued until (whichever occurs first):
~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity
~maintenance cycle 8
~progression of CLL or start of a subsequent therapy
~unacceptable toxicity"
11141299|NCT03787251|Experimental|experimental group|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
11141300|NCT03787251|Active Comparator|Control group|"The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected).
~The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.
~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice."
11141301|NCT03787238|Experimental|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
11141302|NCT03787238|No Intervention|Standard of Care|Standard of Care treatment
11141303|NCT03787225|Experimental|NNC0174-0833 (0.3 mg)|Participants will receive single dose of NNC0174-0833
11141304|NCT03787225|Experimental|NNC0174-0833 (0.9 mg)|Participants will receive single dose of NNC0174-0833
11141305|NCT03787225|Experimental|NNC0174-0833 (1.8 mg)|Participants will receive single dose of NNC0174-0833
11141306|NCT03787225|Placebo Comparator|Placebo (NNC0174-0833)|Participants will receive placebo (NNC0174-0833)
11141307|NCT03787212|Experimental|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
11141308|NCT03787212|Experimental|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
11141309|NCT03787199|Experimental|Andago|Application of walking over-ground with body-weight support in the Andago
11141310|NCT03787199|Active Comparator|Treadmill|Application of walking on a treadmill with body-weight support
11141311|NCT03787186|Experimental|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by [14C]-GLPG1690 solution for infusion
11141312|NCT03787186|Experimental|[14C]-GLPG1690 capsules|[14C]-GLPG1690 capsules
11141313|NCT03787173|No Intervention|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
11141314|NCT03787173|Active Comparator|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
11141315|NCT03787173|Experimental|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
11141316|NCT03787160|Active Comparator|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
11141317|NCT03787160|Other|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
11141318|NCT03787147|Other|Spinal Injection|Adults receiving Spinal Injection(SI) without Virtual Reality(VR).
11141319|NCT03787147|Active Comparator|Google Cardboard|Adults receiving SI while using Google Cardboard Virtual reality head mounted display powered by a iPod touch
11141320|NCT03787147|Active Comparator|Oculus|Adults receiving SI while using VR with Oculus Rift.
11141321|NCT03787134|Experimental|2016-0500-Healthy YoungAdults|working memory and attention
11141322|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
11141323|NCT03787095|Experimental|Cohort 1: Cemiplimab|"Participants will receive 0.3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
11141409|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
11141325|NCT03787095|Experimental|Cohort 2: Cemiplimab|"Participants will receive 1 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
11141326|NCT03787095|Placebo Comparator|Cohort 2: Placebo|"Participants will receive placebo, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
11141327|NCT03787095|Experimental|Cohort 3: Cemiplimab|"Participants will receive 3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
11141328|NCT03787095|Placebo Comparator|Cohort 3: Placebo|"Participants will receive placebo, administered at Day 0 and Week 6 for a total of two infusions.
~Participants will also continue their current non-study provided ART regimen."
11141329|NCT03787082|Experimental|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
11141330|NCT03787082|Placebo Comparator|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
11141331|NCT03787069|Experimental|Lignocaine group|This group will be given 1.5 mg/kg I/V lignocaine before intubation
11141332|NCT03787069|Placebo Comparator|Placebo|This group will be given 6 ml normal saline before intubation
11141333|NCT03787056|Other|Cancer patients|ONCOPRO will enroll 410 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 16 cohorts will be open, including: breast cancer, gastric carcinoma, renal cell carcinoma, prostate carcinoma, melanoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, head and neck carcinoma, pancreatic adenocarcinoma, ovarian carcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma and B-cell lymphoma. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies.
11141334|NCT03787043|Experimental|Sequence Group A|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted
~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed"
11141335|NCT03787043|Experimental|Sequence Group B|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed
~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted"
11141336|NCT03787030|Experimental|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
11141337|NCT03787030|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
11141338|NCT03787017|Experimental|Sequence Group A|"1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted
~2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted"
11141339|NCT03787017|Experimental|Sequence Group B|"1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted
~2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted"
11141340|NCT03787004|Experimental|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
11141341|NCT03787004|Experimental|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
11141342|NCT03787004|Experimental|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
11141343|NCT03787004|Placebo Comparator|Part 2 Placebo|Placebo oral tablet
11141344|NCT03786991||Organ donors|Organ donors after neurologic death (NDD) of 18 years old and older for whom consent to organ donation has been obtained.
11141345|NCT03786991||Liver and kidney Recipients|Liver and kidney recipients of 18 years old and older.
11141346|NCT03786978|Experimental|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
11141347|NCT03786978|Active Comparator|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
11141348|NCT03786965|Other|On-pump CABG.|On-pump CABG.
11141349|NCT03786965|Other|Off-pump CABG.|Off-pump CABG.
11141350|NCT03786965|Other|Pump-assisted CABG.|Pump-assisted CABG.
11141351|NCT03786965|Other|Heart Valve Procedure without CABG.|Heart Valve Procedure without CABG.
11141352|NCT03786965|Other|Heart Valve Procedure with CABG.|Heart Valve Procedure with CABG.
11141353|NCT03786952|Experimental|Stress, immediate, males|Stress immediately before learning in males
11141354|NCT03786952|Experimental|Stress, delayed, males|Stress 30 minutes before learning in males
11141355|NCT03786952|Sham Comparator|Sham control, immediate, males|Sham control immediately before learning in males
11141356|NCT03786952|Sham Comparator|Sham control, delayed, males|Sham control 30 minutes before learning in males
11141357|NCT03786952|Experimental|Stress, immediate, females|Stress immediately before learning in females
11141358|NCT03786952|Experimental|Stress, delayed, females|Stress 30 minutes before learning in females
11141359|NCT03786952|Sham Comparator|Sham control, immediate, females|Sham control immediately before learning in females
11141360|NCT03786952|Sham Comparator|Sham control, delayed, females|Sham control 30 minutes before learning in females
11141361|NCT03786939|Other|On-pump CABG.|On-pump CABG.
11141362|NCT03786939|Other|Off-pump CABG.|Off-pump CABG.
11141363|NCT03786939|Other|Pump-assisted CABG.|Pump-assisted CABG.
11141364|NCT03786926|Experimental|Treatment|All patients take HMPL-689 taken daily
11141365|NCT03786913||children with muscle disease|fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
11141370|NCT03786861|Active Comparator|42 eyes in aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free in aberration free group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
11141371|NCT03786861|Active Comparator|24 eyes in corneal WFG group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing corneal WFG patterns in corneal WFG group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
11141372|NCT03786848|Experimental|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
11141373|NCT03786835|No Intervention|Control (No intervention)|Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
11141374|NCT03786835|Experimental|Nutrition group|Participants will receive protein enriched food to supplement the diet for 6 months.
11141375|NCT03786835|Experimental|Exercise group|Participants will exercise 3 times a week for 60 minutes each time over 6 months.
11141376|NCT03786835|Experimental|Nutrition + Exercise group|Participants will receive protein enriched food to supplement the diet and exercise 3 times a week for 60 minutes each time over 6 months.
11141377|NCT03786822|Experimental|Non-fluoroscopic Cryoballoon PVI|"Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.
~Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.
~Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
11141378|NCT03786822|Active Comparator|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
11141379|NCT03786809|Experimental|Experimental|Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
11141380|NCT03786809|Placebo Comparator|Placebo|Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
11141381|NCT03786796|Experimental|Olaparib|Participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L that have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy with measureable disease on CT imaging according to RECIST 1.1 criteria. Participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily provided there are no grade 3 or greater adverse events experienced. Reassessment will occur at least monthly for toxicity. Radiological scans will be performed every 3 months to assess disease response. Treatment will be continued until clinical and/or radiographic progression according to RECIST 1.1 criteria or unmanageable toxicity requiring cessation.
11141382|NCT03786783|Experimental|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
11141383|NCT03786770|Experimental|Cohort 1: Dose A|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.
11141384|NCT03786770|Experimental|Cohort 2: Dose B|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.
11141385|NCT03786770|Experimental|Cohort 3: Dose C|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.
11141386|NCT03786770|Experimental|Cohort 4: Dose D|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of FHL and GL.
11141387|NCT03786757|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy.
11141388|NCT03786757|No Intervention|dual antiplatelet therapy (DAPT)|Conventional dual antiplatelet therapy will be adopted.
11141389|NCT03786744|Experimental|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
11141390|NCT03786744|Other|Standard therapy.|Patients with standard therapy as control group.
11141391|NCT03786731|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
11141392|NCT03786731|No Intervention|CAU group|Care-As-Usual group
11141393|NCT03786718|Experimental|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
11141394|NCT03786705||Trauma patients' SBP ≥ 90 mm Hg with EMS|Only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm Hg at the ER were included in this study. The enrolled trauma patients divided into 2 groups, those who had received blood transfusion ≥ 10 U (massive transfusion) and those who had not (non-massive transfusion).
11141395|NCT03786692|Experimental|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
11141396|NCT03786692|Active Comparator|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
11141397|NCT03786679|Active Comparator|Orthosis group|An orthosis with the broken arm in neutral position fixed for four weeks. After these four weeks the patient is instructed to start rehabilitation.
11141398|NCT03786679|Active Comparator|Early rehabilitation group|The patient is instructed to start early rehabilitation about one week after the trauma.
11141399|NCT03786640||Single Arm|Patients implanted with an SJM Tendril STS 2088 or Isoflex 1944/1948 lead, together with an Assurity MRI or Endurity MRI pacemaker, and who will undergo a 3T MRI scan are eligible to participate in this study.
11141400|NCT03786627|Experimental|Combined NMES and motor control|This group will receive combined 15-minute neuromuscular electrical stimulation and 30-minute motor control training based on movement system impairment concept.
11141401|NCT03786627|Placebo Comparator|Motor control and placebo NMES|This group will receive placebo NMES for 15 minutes followed by 30 minutes motor control training based on movement system impairment concept.
11141402|NCT03786614|Active Comparator|Discontinuation arm|This group will be discontinued from serotonergic antidepressants and shifting them to other categories of antidepressants, i.e., medications that work through dopamine or nor-epinephrine, or by reducing the serotonin signal rather than increasing synaptic serotonin, as might be accomplished with low dose, sub-anti-psychotic doses of some second-generation anti-psychotics.
11141403|NCT03786614|Active Comparator|Continuation arm|This group will continue taking serotonergic antidepressants which is the standard care of treatment.
11141410|NCT03786575|Experimental|NGS detection group|Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
11141411|NCT03786562|Placebo Comparator|Placebo group|
11141412|NCT03786562|Active Comparator|Nalbuphine group|
11141413|NCT03786549|No Intervention|Control|Patients included in this arm wil have usual follow-up.
11141414|NCT03786549|Experimental|Care transitional program|"Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent
~Three axes are :
~Educative, family (patient and parent), at home
~Psychological, with the patient individually
~Medico-social orientation, group of patients"
11141415|NCT03786536|Experimental|Treatment|All volunteers will receive the same treatment
11141416|NCT03786523|Experimental|TRF|Time Restricted Feeding
11141417|NCT03786523|Active Comparator|CER|Continuous Energy Restriction
11141418|NCT03786510|Active Comparator|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
11141419|NCT03786510|Experimental|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
11141420|NCT03786510|Experimental|Intensive program only|The INT only group participated in a 4-week intensive program
11141421|NCT03786484|Experimental|PBF-999 20 mg|
11141422|NCT03786484|Experimental|PBF-999 40 mg|
11141423|NCT03786484|Experimental|PBF-999 80 mg|
11141424|NCT03786484|Experimental|PBF-999 120 mg|
11141425|NCT03786484|Experimental|recommended phase 2 dose (RP2D)|
11141426|NCT03786471|Active Comparator|Health Systems-Based Dementia Care|Dementia care that is based in the health care system, which partners with community-based organizations to provide comprehensive, coordinated, patient-centered care. The health system-based dementia care arm uses a Dementia Care Specialist (Nurse Practitioner or Physician Assistant) supervised by a physician to tailor and facilitate dementia care delivery in collaboration with the primary care physician (co-management). The Health Systems-Based Dementia Care arm is based on UCLA's Alzheimer's and Dementia Care Program.
11141427|NCT03786471|Active Comparator|Community-Based Dementia Care|Dementia care that is based in community organizations, which gives equal attention to patients and their primary family or friend caregivers. The community-based dementia care arm uses Care Consultants (Social Workers or Nurses). Patients with dementia are engaged in the program whenever possible. Caregivers can be the sole program participant, when patients are too impaired. The program establishes a long-term relationship between Care Consultants and families. The exact content of assistance provided is tailored to the preferences of individual patients and caregivers, and is holistic in the range of potential concerns of problems addressed. The Community-Based Dementia Care arm is based on the Benjamin Rose Institute on Aging's Care Consultation Program.
11141428|NCT03786471|Other|Enhanced Usual Care|Dementia care that most closely corresponds to traditional care. This arm will also receive standardized educational materials (hard copies and internet-based resources), referral to the Alzheimer's Association 1-800 national hotline to speak to a master's level consultant for decision-making support, crisis assistance, and caregiver education, as well as referral to local programs and services.
11141429|NCT03786458|Experimental|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
11141430|NCT03786432|Experimental|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
11141431|NCT03786419|Experimental|Atezolizumab|Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
11141432|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
11141433|NCT03786393||Fibromyalgia|100 participants diagnosed with fibromyalgia according to ACR 1990 criteria.
11141434|NCT03786393||Control|
11141435|NCT03786380|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
11141436|NCT03786367||CTEPH|Clinically stable patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) recruited from the Pulmonary Hypertension outpatient clinics at Hotel Dieu Hospital, Kingston, Ontario.
11141437|NCT03786367||Control|Age and sex-matched healthy control data collected as part of previous studies will be used as historic controls for this study.
11141438|NCT03786354|Experimental|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
11141439|NCT03786354|Experimental|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
11141440|NCT03786341|Experimental|with auxiliary illuminator|the walking training was by conventional strategy with lase quad-cane.
11141441|NCT03786341|Placebo Comparator|control group|Ambulation training WITHOUT laser quad-cane.
11141442|NCT03786328|Other|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
11141443|NCT03786328|Other|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
11141444|NCT03786315|Experimental|Intervention|VOLITION: Two intervention components; one targeted at patients and one at GPs.
11141445|NCT03786315|No Intervention|Usual care|Usual care: GP consults with patient as per usual care.
11141446|NCT03786302|Experimental|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
11141447|NCT03786302|Active Comparator|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
11141448|NCT03786289|Experimental|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection
11141449|NCT03786289|Active Comparator|Recombinant human erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection
11141450|NCT03786276|Experimental|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
11141451|NCT03786276|Experimental|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
11141452|NCT03786276|Experimental|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
11141453|NCT03786263||Prospective Treatments for NS|"Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.
~Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.
~Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome."
11141454|NCT03786237|Experimental|Treatment Oral Capsules / Intravenous|
11141455|NCT03786224|Experimental|Abstinent|
11141456|NCT03786211|Active Comparator|IANB without panoramic|They will get Ianb without using panoramic
11141457|NCT03786211|Experimental|IANB with panoramic|They will get IANB by the guide of panoramic
11141458|NCT03786198|Experimental|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
11141459|NCT03786198|Active Comparator|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
11141460|NCT03786185|Experimental|Adolescents with dyslexia|MusicPlast training
11141461|NCT03786185|Active Comparator|Adolescents without dyslexia|MusicPlast training
11141462|NCT03786185|Experimental|Young Adults|MusicPlast training
11141463|NCT03786185|Active Comparator|Young Adults Control|MusicPlast Control, in a similar design as MusicPlast
11141464|NCT03786185|Experimental|Seniors|MusicPlast training
11141465|NCT03786172|Experimental|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
11141466|NCT03786172|Active Comparator|Usual care|A 10-second brief advice to quit smoking
11141467|NCT03786133||type 2 diabetics|Analysis of microbiological tests in chronic periodontitis patients with type 2 diabetes mellitus
11141468|NCT03786133||non-diabetics|Analysis of microbiological tests in chronic periodontitis patients without type 2 diabetes mellitus
11141469|NCT03786120||1|First 25 subjects
11141470|NCT03786120||2|Second cohort of 25 subjects
11141471|NCT03786094|Active Comparator|Eribulin|
11141472|NCT03786094|Experimental|Balixafortide + eribulin|
11141473|NCT03786081|Experimental|A: Tisotumab Vedotin + bevacizumab|Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
11141474|NCT03786081|Experimental|B: Tisotumab vedotin + pembrolizumab|Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
11141475|NCT03786081|Experimental|C: Tisotumab vedotin + carboplatin|Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
11141476|NCT03786081|Experimental|D: Tisotumab vedotin + carboplatin|Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
11141477|NCT03786081|Experimental|E: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
11141478|NCT03786081|Experimental|F: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
11141479|NCT03786081|Experimental|G: Tisotumab vedotin monotherapy|Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
11141480|NCT03786055|Experimental|Somatic Yoga and Meditation (SYM)|Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
11141481|NCT03786042|Active Comparator|E-cigarette ad exposure|
11141482|NCT03786042|Sham Comparator|non e-cigarette ad exposure|
11141483|NCT03786029|Experimental|A (Acetaminophen)|22 children will receive 320mg (10ml) 30 minutes before the local anesthesia injection.
11141484|NCT03786029|Placebo Comparator|B (Placebo)|22 children will receive 10ml 30 minutes before the local anesthesia injection.
11141485|NCT03786029|Experimental|C (Ibuprofen)|22 children will receive 200mg (10ml) 30 minutes before the local anesthesia injection.
11141486|NCT03786016|Experimental|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
11141487|NCT03786003|Experimental|VATS|Video-assisted thoracoscopic surgery
11141488|NCT03786003|Active Comparator|Thoracotomy|Open surgery
11141489|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
11141490|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.
~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
11141491|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).
~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
11141492|NCT03785977||Air-Q 5-9kg|Participants weighing 5-9kg may be chosen to wear the Air-Q device.
11141493|NCT03785977||Air-Q 10-14kg|Participants weighing 10-14kg may be chosen to wear the Air-Q device.
11141494|NCT03785977||Air-Q 15-20kg|Participants weighing 15-20kg may be chosen to wear the Air-Q device.
11141495|NCT03785977||ETT 5-9kg|Participants weighing 5-9kg may be chosen to wear the ETT device.
11141496|NCT03785977||ETT 10-14kg|Participants weighing 10-14kg may be chosen to wear the ETT device.
11141497|NCT03785977||ETT 15-20kg|Participants weighing 15-20kg may be chosen to wear the ETT device.
11141498|NCT03785964|Experimental|Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
11141499|NCT03785964|Placebo Comparator|Placebo|Placebo 150 mg by mouth, twice daily
11141500|NCT03785951|Experimental|Whey Protein Isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
11141501|NCT03785951|Experimental|Wheat Protein|Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
11141502|NCT03785951|Experimental|Wheat protein with leucine|Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
11141503|NCT03785938|Experimental|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:
~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
11141504|NCT03785938|Placebo Comparator|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:
~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day
~Placebo will be delivered in similar, packaging, appearance and taste."
11141505|NCT03785925|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Participants will receive bempegaldesleukin (NKTR-214) in combination with nivolumab.
11141506|NCT03785912|Experimental|Internet-based self-help|The self-help program consists of eight text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
11141507|NCT03785912|No Intervention|Waiting control group|Access to internet-based intervention after 12 weeks.
11141508|NCT03785899|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
11141509|NCT03785899|Experimental|SPOCnew and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 2s."
11141510|NCT03785899|Experimental|SPOCnew and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 8s."
11141511|NCT03785899|Active Comparator|SPOCold and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 2s."
11141512|NCT03785899|Active Comparator|SPOCold and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).
~The SpO2 signal averaging time is 8s."
11141513|NCT03785886|Experimental|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.
~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
11141514|NCT03785886|Experimental|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.
~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
11141515|NCT03785886|Experimental|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.
~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
11141516|NCT03785873|Experimental|Nal-Irinotecan and Nivolumab|
11141517|NCT03785860|Placebo Comparator|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
11141518|NCT03785860|Active Comparator|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
11141519|NCT03785821|Experimental|BMSO|Bitter melon seed oil supplementation
11141520|NCT03785821|Placebo Comparator|OO|Olive oil supplementation
11141548|NCT03785613|Experimental|Test Product T1: Buprenorphine patch (9 mg)|"Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.
~Matching placebo patch to T1: simultaneous application for 96 hours on the upper back."
11141624|NCT03785067|Experimental|Triple Pill (Active Treatment)|"Main Study: Fixed low-dose combination BP-lowering pill (Triple Pill) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg
~Sub-Study: single-arm"
11141521|NCT03785808|Experimental|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
11141522|NCT03785808|Experimental|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
11141523|NCT03785808|Active Comparator|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which ~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
11141524|NCT03785795||Uncertain diagnosis of true labor|Patients who cannot be accurately classified as experiencing true labor or false labor based on standard clinical assessments.
11141525|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
11141526|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
11141527|NCT03785769|Active Comparator|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by HVGIC restoration.
11141528|NCT03785769|Experimental|HVGIC restoration with non pre-etching|HVGIC restoration without the pre-etching of the surface.
11141529|NCT03785756|Experimental|Prolonged Release Group|Ibuprofen 300 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
11141530|NCT03785756|Active Comparator|Immediate Release Group|Ibuprofen 200 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
11141531|NCT03785756|Placebo Comparator|Placebo Group|Placebo of IR tablet Placebo of PR tablet
11141532|NCT03785743|Experimental|TLPD|Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
11141533|NCT03785743|Experimental|OPD|Open pancreaticoduodenectomy for pancreatic cancer
11141534|NCT03785730|Experimental|NRCC|Enlargement of the wells with metal sandpaper.
11141535|NCT03785730|Active Comparator|Restoration with resin composite|Selective caries removal and restoration with resin composite
11141536|NCT03785717|Active Comparator|ROG only|cancellous (1-2 mm) & cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
11141537|NCT03785717|Active Comparator|ROG & ESWT|cancellous 1-2mm & cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
11141538|NCT03785704|Experimental|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
11141539|NCT03785704|No Intervention|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
11141540|NCT03785691|Experimental|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).
~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
11141541|NCT03785691|Experimental|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.
~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
11141542|NCT03785691|Placebo Comparator|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.
~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
11141543|NCT03785678|Experimental|Tenecteplase|Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
11141544|NCT03785678|Placebo Comparator|Placebo|Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
11141545|NCT03785665|Experimental|Participants|All study participants will be examined by the MD1 capsules, 2-5 capsules per person, one capsule at a time. Efforts will be made to maintain balanced numbers between men and women and even distribution of ages
11141546|NCT03785652|Experimental|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
11141547|NCT03785652|Placebo Comparator|Placebo|Placebo tablet
11141549|NCT03785613|Experimental|Test Product T2: Buprenorphine patch (3.8 mg)|"Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters. Single application of patch during 96 hours, on skin in the midclavicular line directly under the clavicle.
~Matching placebo patch to T2: simultaneous application for 96 hours on the upper back."
11141550|NCT03785613|Active Comparator|Reference Product R: Transtec patch (20 mg)|"Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.
~Matching placebo patch to R: simultaneous application for 96 hours on the upper back."
11141551|NCT03785600|Experimental|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
11141552|NCT03785600|Sham Comparator|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
11141553|NCT03785587|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 24 weeks
11141554|NCT03785574|Active Comparator|A:chemotherapy immediately|Treated with chemotherapy immediately. First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
11141555|NCT03785574|Experimental|B:follow up|"B1: follow up until hCG level met FIGO diagnostic criteria of GTN, then chemotherapy.
~B2: follow up until hCG level declined to normal spontaneously."
11141556|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
11141557|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
11141558|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
11141559|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
11141560|NCT03785535|Experimental|Actual treatment|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (2-90 Hz), low intensity and long daily duration (3h).
11141561|NCT03785535|Sham Comparator|Sham|Sham treatment will be applied using identical instruments and with power and duration programmed identically. However, in this case, the output will not be the signal activating the vibration motors, but rather an electrical signal turning on an incorporated pilot light indicating that the (simulated) treatment was operating
11141562|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
11141563|NCT03785496|Experimental|PDR001+MCS110 Arm|MCS110 and PDR001 will be administered once every 3 weeks via i.v. infusions over 1 hour and30 minutes, respectively. The drugs will be administered separately with at least a 30 min break between the two antibodies. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. Both study drugs may be infused using the same i.v. access site. The same administration sequence must be followed for all patients, i.e. PDR001 should be infused first. If an infusion reaction occurs after administration of PDR001, the subsequent MCS110 infusion must be delayed until it is safe for the patient to receive MCS110 based on the clinical discretion of the investigator. The delay between PDR001 and MCS110 infusions can be up to 4 hours if clinically indicated.
11141564|NCT03785483|Experimental|Motivation|Using implementation intention techniques such as action planning. Every week, participants state when, where, and what kind of prescribed exercises they will do.
11141565|NCT03785483|Active Comparator|Mindfulness|10 minutes of audio recordings daily. Recordings contain: awareness of the breath, acceptation of thoughts and emotions, awareness of postures, awareness during stretching, awareness of a single movement (moving legs up while standing).
11141566|NCT03785483|No Intervention|Treatment as usual|Physical activity prescribe 120 minutes per week.
11141567|NCT03785470|Experimental|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
11141568|NCT03785457|Experimental|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
11141569|NCT03785457|Experimental|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
11141570|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
11141571|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
11141572|NCT03785431|Experimental|Intervention|Patient diagnosed with ST elevation myocardial infarction will undergo bioresorbable stent deployment in culprit lesion.
11141573|NCT03785418|Experimental|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
11141574|NCT03785418|No Intervention|Control Arm|Standard Clinical Practice
11141575|NCT03785405|Experimental|sacubitril/valsartan|single arm, open label sacubitril/valsartan
11141576|NCT03785392|Active Comparator|Group 1 Inplane|Study with the technique Inplane group
11141577|NCT03785392|Active Comparator|Group 2 out of plane|Study with the technique out of plane
11141578|NCT03785379|Active Comparator|Caloric restriction and early SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
11141619|NCT03785106|Experimental|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
11141620|NCT03785106|Active Comparator|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
11141579|NCT03785379|Active Comparator|Caloric restriction and late SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
11141580|NCT03785366|Experimental|VeraCept|VeraCept subjects will be inserted with VeraCept on Day 1. At Day 57 subjects will be informed that they received VeraCept and may continue in the study for up to 5 years
11141581|NCT03785366|Active Comparator|ParaGard|ParaGard subjects will be inserted with ParaGard on Day 1. At Day 57 subjects will be informed that they received ParaGard and may choose to have the ParaGard removed or continue use per standard of clinical care.
11141582|NCT03785353|Experimental|PNE Group|A group of Spanish-speaking individuals will listen to a translated lecture related to PNE (PNE lecture). They will fill out the R-NPQ pre and post the lecture.
11141583|NCT03785340|Experimental|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
11141584|NCT03785340|Placebo Comparator|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
11141585|NCT03785327|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
11141586|NCT03785327|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
11141587|NCT03785327|Experimental|Autism Training Program|Training program designed to increase autism understanding followed by behavioral testing Intervention:Training program
11141588|NCT03785327|No Intervention|Social interaction without intervention|Control condition: Behavioral testing without an intervention component
11141589|NCT03785314|Active Comparator|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
11141590|NCT03785314|Active Comparator|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
11141591|NCT03785301|Experimental|FGM group|Diabetic patients will use FreeStyle Libre Flash Glucose Monitoring (FGM) system(unmasked) to monitor glucose level once a month for 3 months.
11141592|NCT03785301|No Intervention|SMBG group|Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
11141593|NCT03785288|Active Comparator|HDR VBT 3 fxs of 7Gy|Arm 1: HDR vaginal brachytherapy 3 fractions of 7Gy
11141594|NCT03785288|Active Comparator|HDR VBT 6 fxs of 4Gy|Arm 2: HDR vaginal brachytherapy 6 fractions of 4Gy
11141595|NCT03785275||Subjects with stable near-normal T1D|"Mixed-meal tolerance test
~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
11141596|NCT03785275||Subjects with unstable T1D|"Mixed-meal tolerance test
~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
11141597|NCT03785262|Sham Comparator|Sham|Inactive uroshield device
11141598|NCT03785262|Experimental|Active Uroshield|Active uroshield device
11141599|NCT03785249|Experimental|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
11141600|NCT03785249|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
11141601|NCT03785249|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity of MRTX849
11141602|NCT03785249|Experimental|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
11141603|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
11141604|NCT03785249|Experimental|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
11141605|NCT03785236||Tx-group|T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
11141606|NCT03785236||Control group|T1D patients that await islet of Langerhans transplantation
11141607|NCT03785223|Experimental|Methylphenidate Hydrochloride Controlled-Release Capsules|Flexibly dosed at 25-100 mg per day
11141608|NCT03785223|Placebo Comparator|Placebo Capsules|1-4 capsules daily
11141609|NCT03785210|Experimental|1/ Arm 1|Nivolumab, tadalafil and oral vancomycin
11141610|NCT03785184|Experimental|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
11141611|NCT03785171||Moyamoya disease|The cohort includes patients with Moyamoya disease diagnosed by DSA examination who are treated by surgical revascularization.
11141612|NCT03785158|Active Comparator|Melatonin|3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
11141613|NCT03785158|Placebo Comparator|Placebo Group|Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
11141614|NCT03785145|Experimental|MT10109L|MT10109L will be injected into the LCL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
11141615|NCT03785145|Placebo Comparator|Placebo|Placebo will be injected into the LCL: initial double-blind treatment on Day 1.
11141616|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
11141617|NCT03785119||Standard strategy|According to embryo quality (morphologic criteria)
11141618|NCT03785119||Experimental strategy|Association of embryo quality and sCD146 rate
11141625|NCT03785067|Placebo Comparator|Placebo|"Main Study: Matched placebo, received via blinded study capsules
~Sub-Study: single-arm"
11141626|NCT03785054|Experimental|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
11141627|NCT03785054|Experimental|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141628|NCT03785054|Experimental|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141629|NCT03785054|Experimental|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141630|NCT03785054|Experimental|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141631|NCT03785054|Experimental|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141632|NCT03785054|Experimental|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141633|NCT03785054|Experimental|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141634|NCT03785054|Experimental|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
11141635|NCT03785054|Experimental|Food Effect|6 subjects receiving single dose of HTL0014242 on two occasions (fed and fasted) and separated by 14 days. The dose of HTL0014242 selected following review of safety and tolerability data from previous lower dose levels.
11141636|NCT03785041|Active Comparator|Levobupivacaine and tramadol Preemptive|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
11141637|NCT03785041|Active Comparator|Tramadol and levobupivacaine postoperative|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
11141638|NCT03785041|Active Comparator|Tramadol and levobupivacaine preemptive and postoperative|20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
11141639|NCT03785041|Active Comparator|Levobupivacaine|20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
11141640|NCT03785028|Experimental|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
11141641|NCT03785015|Experimental|Withold aspirin till after endoscopic haemostasis|Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.
11141642|NCT03785015|Active Comparator|Withold aspirin till 72 hours|Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.
11141643|NCT03785002|Experimental|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
11141644|NCT03785002|Active Comparator|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
11141645|NCT03784976|Experimental|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
11141646|NCT03784976|No Intervention|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
11141647|NCT03784963|Experimental|Primary Prevention Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
11141648|NCT03784963|Placebo Comparator|Primary Prevention Non-Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
11141649|NCT03784963|Experimental|Secondary Prevention Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
11141650|NCT03784963|Placebo Comparator|Secondary Prevention Non-Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
11141651|NCT03784950|Experimental|Rating tool only|Rating eConsults from peer specialists in first phase
11141652|NCT03784950|Experimental|Feedback only|Receiving feedback from peer specialists in first phase
11141653|NCT03784950|Experimental|Rating Tool plus Feedback|Both rating and feedback in second phase.
11141654|NCT03784924||Initial prostate biopsy|Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.
11141655|NCT03784911||During Cancer Treatment Group|Participants' body composition will be estimated using a SOZO device at 5 different time points across their cancer treatment. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, cancer distress assessment, ECOG performance status, hand grip strength test, and 24-hour food recall. DEXA scans will be performed before treatment and after completion of treatment.
11142144|NCT03781557|Experimental|High-concentrated EPA|High-concentrated EPA fish oil softgels
11141656|NCT03784898|Other|Participants Diagnosed With ITP|Participants with RMS who developed ITP after Lemtrada treatment were included in this study and provided blood samples for future genetic testing and biomarker analysis.
11141657|NCT03784885|Experimental|30 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 30 μg of AD07010
11141658|NCT03784885|Experimental|45 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 45 μg of AD07010
11141659|NCT03784885|Active Comparator|AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine
11141660|NCT03784859||All patients in study|5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.
11141661|NCT03784846|Experimental|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
11141662|NCT03784846|Active Comparator|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
11141663|NCT03784846|No Intervention|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
11141664|NCT03784820|Experimental|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
11141665|NCT03784820|Active Comparator|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
11141666|NCT03784807||Infected|Patients with prosthetic joint or osteoarticular infection
11141667|NCT03784807||Not infected|Patients with implant failure not due to infection
11141668|NCT03784794|Experimental|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
11141669|NCT03784794|Active Comparator|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
11141670|NCT03784781||Asthmatic children|Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
11141671|NCT03784781||Controls|Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
11141672|NCT03784768|Experimental|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition after 45-minute conventional physiotherapy session for 3-days in 5-days, while each patient in plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 7.5-minute.
11141673|NCT03784768|Active Comparator|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
11141674|NCT03784755|Active Comparator|Arm 1 (standard of care)|"Standard systemic therapy
~+ Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden"
11141675|NCT03784755|Experimental|Arm 2 (standard systemic therapy + ablative therapy))|"Local Ablative therapy to all sites of disease (including untreated prostate primary)
~+ Standard systemic therapy"
11141676|NCT03784742|Active Comparator|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
11141677|NCT03784742|Placebo Comparator|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
11141678|NCT03784729|Experimental|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted."
11141679|NCT03784729|Sham Comparator|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm.
11141680|NCT03784716|Experimental|Ketogenic Diet|Ketogenic Diet for 28 Days
11141681|NCT03784716|Active Comparator|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
11141682|NCT03784703|Experimental|Atrovastatin|atorvastatin (40 mg per day) for 12 months
11141683|NCT03784703|Experimental|Rosuvastatin|Rosuvastatin (10 mg per day) for 12 months
11141684|NCT03784690|Experimental|Individualized BP group|Individualized intraoperative BP management
11141685|NCT03784690|Placebo Comparator|Standard treatment group|Standard intraoperative BP management
11141686|NCT03784677|Experimental|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11141687|NCT03784664|Active Comparator|Arterial blood gas|
11141688|NCT03784664|Experimental|Veinous blood gas|
11141757|NCT03784183|Experimental|mild AD-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
11141689|NCT03784638|Experimental|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
11141690|NCT03784638|Placebo Comparator|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
11141691|NCT03784625|Experimental|therapeutic dose activity (level 1)|[131]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
11141692|NCT03784625|Experimental|therapeutic dose activity (level 2)|[131]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
11141693|NCT03784625|Experimental|therapeutic dose activity (level 3)|[131]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
11141694|NCT03784625|Experimental|therapeutic dose activity (level 4)|[131]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
11141695|NCT03784612|Experimental|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.
~Intervention: App-technology for healthy eating habits."
11141696|NCT03784612|No Intervention|Control group|The control group will receive standard care.
11141697|NCT03784599|Experimental|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks
~Osimertinib 80 mg once daily, orally, continuous
~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
11141698|NCT03784586||Positive EPS - ICD|Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
11141699|NCT03784586||Negative EPS - PMK|All non inducible patients underwent PMK implantation
11141700|NCT03784573|Active Comparator|Dog + handler|
11141701|NCT03784573|Placebo Comparator|No dog|
11141702|NCT03784560||study group|anesthesia residents with 24 hours working shift
11141703|NCT03784547||multiple sclerosis patients|multiple sclerosis patients receiving ocrelizumab 600 mg endovenous every 6 months
11141704|NCT03784534|Experimental|Healthy volunteers|"Subjects will be asked to perform:
~high= density (64 sensors) EEG
~clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
~anatomical MRI (T1 and tensor imaging) scan)"
11141705|NCT03784534|Experimental|Patients|"Patients will be asked to perform:
~high= density (64 sensors) EEG
~clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth
~anatomical MRI (T1 and tensor imaging) scan)"
11141706|NCT03784521|Experimental|In-line filtration|For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).
11141707|NCT03784521|Active Comparator|Control|For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.
11141708|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
11141709|NCT03784495|Placebo Comparator|Placebo (P)|Placebo.
11141710|NCT03784495|Experimental|Melatonin (M)|1 mg/day of melatonin.
11141711|NCT03784495|Experimental|Essential Aminoacids (eAA)|4 g/day of essential aminoacids
11141712|NCT03784495|Experimental|Essential Aminoacids + Melatonin (eAAM)|4 g/day of essential aminoacids and 1 mg/day of melatonin
11141713|NCT03784469|Experimental|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
11141714|NCT03784469|No Intervention|Control group|No changing body position in bed,remaining supine position in complete bed rest and immobilized for four hours.
11141715|NCT03784456|Experimental|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
11141716|NCT03784456|Active Comparator|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
11141717|NCT03784443|Active Comparator|Iluvien Arm|Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
11141718|NCT03784443|Sham Comparator|Control Arm|To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
11141719|NCT03784430|Active Comparator|Implant|Immediate dental implant placement
11141720|NCT03784430|Experimental|Implant+CTG|Immediate dental implant placement with CTG.
11141721|NCT03784417|Experimental|EUS-guided laser ablation|Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
11141722|NCT03784404|Active Comparator|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
11141723|NCT03784404|Active Comparator|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
11141724|NCT03784391||Treatment|Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
11141725|NCT03784391||Reference|Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment
11141726|NCT03784378|Experimental|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
11141727|NCT03784365|Active Comparator|First group|This group will receive an intravenous antibiotic for three days. The first dose will be given within half hour before the POEM procedure.
11141728|NCT03784365|Experimental|Second group|This group will receive only one dose of intravenous antibiotic within half hour before the POEM procedure
11141729|NCT03784352|Experimental|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
11141730|NCT03784352|No Intervention|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
11141731|NCT03784339|Placebo Comparator|Physiotherapy|Participants will receive standard physiotherapy care, which will involve strength exercises and taping.
11141732|NCT03784339|Experimental|Physiotherapy + education|Physiotherapy + education Standard physiotherapy care plus 30 minute education session addressing fear of movement and catastrophizing thoughts.
11141733|NCT03784326|Experimental|Treatment (oxaliplatin, fluorouracil, atezolizumab, surgery)|Patients receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 4-6 weeks of treatment completion, patients undergo surgical resection. Beginning 6 weeks after surgery, patients continue to receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive atezolizumab monotherapy IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11141734|NCT03784313|Experimental|Perforators flaps (PF group)|
11141735|NCT03784313|Sham Comparator|Secondary intention wound healing|
11141736|NCT03784300|Active Comparator|50 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.
11141737|NCT03784300|Placebo Comparator|50 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.
11141738|NCT03784300|Active Comparator|100 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.
11141739|NCT03784300|Placebo Comparator|100 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.
11141740|NCT03784300|Active Comparator|200 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.
11141741|NCT03784300|Placebo Comparator|200 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.
11141742|NCT03784287|Experimental|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
11141743|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
11141744|NCT03784261|Active Comparator|SAR, usually subucutaneous injection every 2 weeks|
11141745|NCT03784261|Active Comparator|TCZ, usually subucutaneous injection every 2 weeks|
11141746|NCT03784261|Active Comparator|ABT, usually subucutaneous injection every week|
11141747|NCT03784248||asymptomatic carrier|
11141748|NCT03784248||uninfected subjects|
11141749|NCT03784235|Experimental|Knee exercises|12 weeks of strength training focusing on the knee mobilising muscles including squat, lunge and knee extension exercises.
11141750|NCT03784235|Experimental|Hip exercises|12 weeks of strength training focusing on the hip stabilising muscles including sidelying and standing hip abduction, clam and hip extension exercises.
11141751|NCT03784222|Experimental|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
11141752|NCT03784222|Other|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
11141753|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
11141754|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
11141755|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
11141756|NCT03784183|Experimental|moderate AD-experimental|Experimental Intervention: The CS shall be carried out in groups (5-7 participants), twice a week. Each session lasts 90 minutes. CS sessions begin with a training for temporal and spatial orientation in which participants are asked to recognize and recall the date and the place with the help of some environmental aids (calendars, clocks, pictures and maps). Then the participants complete an array of cognitive tasks for memory, attention, language, visuo-spatial functions and executive functions. These tasks range from individual paper-and-pencil exercises to verbal-learning exercises that have to be solved by the group.
11141816|NCT03783793|Active Comparator|Cognitive Training With 2048|
11141758|NCT03784183|Experimental|MCI-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
11141759|NCT03784183|No Intervention|moderate AD-placebo|
11141760|NCT03784183|No Intervention|mild AD-placebo|
11141761|NCT03784183|No Intervention|MCI-placebo|
11141762|NCT03784170|Experimental|Treatment|FemPulse System at one device setting
11141763|NCT03784170|Sham Comparator|Control|FemPulse System at a different device setting
11141764|NCT03784144|Experimental|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
11141765|NCT03784144|Active Comparator|Control|The patients will perform both tests without any cognitive condition
11141766|NCT03784131|Experimental|Personalized Tissue Engineered Vein|P-TEV
11141767|NCT03784118|Experimental|Children|Children who are followed up after arterial catheterization for evaluation of complications, using ultrasonography
11141768|NCT03784105|Experimental|Codeine|
11141769|NCT03784105|Placebo Comparator|Siripus simplex|
11141770|NCT03784092|No Intervention|control|
11141771|NCT03784092|Experimental|feedback|
11141772|NCT03784079|Experimental|Part 1 (Cohort 1): Subjects receiving GSK3640254 200 mg|Eligible subjects from Cohort 1 of Part 1 will be randomized to receive GSK3640254 two 100 mg oral capsules along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141773|NCT03784079|Experimental|Part 1 (Cohort 2): Subjects receiving GSK3640254 10 mg|Eligible subjects from Cohort 2 of Part 1 will be randomized to receive GSK3640254 two 5 mg oral capsules along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141774|NCT03784079|Placebo Comparator|Part 1: Subjects receiving placebo|Eligible subjects from Part 1 will be randomized to receive two oral capsules of placebo to match GSK3640254 Mesylate salt along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141775|NCT03784079|Experimental|Part 2 (Cohort 1): Subjects receiving GSK3640254 5 mg|Eligible subjects from Cohort 1 of Part 2 will be randomized to receive GSK3640254, 5 mg oral capsule to provide approximately 30 percent of maximum effect, along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141776|NCT03784079|Experimental|Part 2 (Cohort 2): Subjects receiving GSK3640254 40 mg|Eligible subjects from Cohort 2 of Part 2 will be randomized to receive GSK3640254, two 20 mg oral capsules to provide approximately 75 percent of maximum effect, along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141777|NCT03784079|Experimental|Part 2 (Cohort 3): Subjects receiving GSK3640254 100 mg|Eligible subjects from Cohort 3 of Part 2 will be randomized to receive GSK3640254, 100 mg oral capsule to provide approximately 90 percent of maximum effect, along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141778|NCT03784079|Placebo Comparator|Part 2: Subjects receiving placebo|Eligible subjects from Part 2 will be randomized to receive oral capsule of placebo to match GSK3640254 Mesylate salt along with approximately 240 mL of water following ingestion of a moderate calorie and fat meal.
11141779|NCT03784066|Active Comparator|A|Durvalumab
11141780|NCT03784066|Active Comparator|B|Durvalumab + Tremelimumab
11141781|NCT03784053||Immersive virtual reality|Participants will receive eight 30-minute sessions of immersive virtual reality.
11141782|NCT03784040|Experimental|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
11141783|NCT03784040|Experimental|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.
11141784|NCT03784027|Experimental|Automated closed loop insulin delivery (intervention arm)|"Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 4 months.
~Intervention: Device: CamAPS FX"
11141785|NCT03784027|Active Comparator|Sensor augmented pump therapy (control arm)|Sensor augmented pump therapy over 4 months
11141786|NCT03784014|No Intervention|Arm No NGS|"Patients will be treated by standard first-line chemotherapy regimen and tumor assessment will be performed every 2 cycles (ie. 6 weeks) during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.
~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
11141787|NCT03784014|Experimental|Arm NGS|"Patients will be treated by standard first-line chemotherapy regimen and tumor assessment will be performed every 2 cycles (ie. 6 weeks) during treatment. After tumor assessment at the end of first-line chemotherapy (for a maximum of 6 cycles) and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.
~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
11141788|NCT03784014|Experimental|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
11141789|NCT03784001|Active Comparator|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
11141867|NCT03783442|Experimental|Tislelizumab + chemotherapy|Tislelizumab administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
11141790|NCT03784001|Experimental|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
11141791|NCT03784001|Active Comparator|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
11141792|NCT03783988|Other|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
11141793|NCT03783975|Experimental|Simplified Cascade Screening|Free, mail-in, saliva-based screening for the KCNQ1 Thr224Met variant.
11141794|NCT03783962|Experimental|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the NFS foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
11141795|NCT03783962|Active Comparator|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
11141796|NCT03783949|Active Comparator|Standard arm (arm A)|Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w)
11141797|NCT03783949|Experimental|First experimental arm (arm B)|Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w)
11141798|NCT03783949|Experimental|Second experimental arm (arm C)|Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)
11141799|NCT03783936|Other|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days
~mFOLFOX6
~oxaliplatin 85 mg/m2 IV Day 1 and
~leucovorin 400 mg/m2 IV Day 1 and
~5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and
~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and
~Avelumab 800 mg IV Day 1
~Cycles 10 and subsequent; Maintenance; Cycle = 14 days
~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
11141800|NCT03783923|Experimental|Deflazacort|Participants will receive deflazacort 0.6 milligrams per kilograms per day (mg/kg/day) orally. The dose could be reduced in case of tolerability issues. Any participant assigned to placebo prior to the Version 4.0 amendment (prior to or after 01 February 2020) will have the option to be consented under Version 4.0 and will be switched to deflazacort for 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (prior to 01 February 2020) will have the option to re-consent under Protocol Version 4.0 and continue for an additional 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (after 01 February 2020) will have the option to re-consent under Protocol Version 4.0 at their Week 13 Visit and continue treatment until Week 26. Any new participant enrolled until 31 May 2020 will receive deflazacort for 26 weeks.
11141801|NCT03783910|Experimental|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).
~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
11141802|NCT03783910|Placebo Comparator|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
11141803|NCT03783897|Experimental|EDP-305 and Oral Contraceptive|
11141804|NCT03783884|Active Comparator|Treatment|Subject receives Lungpacer LIVE Catheter insertion for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.
11141805|NCT03783884|No Intervention|Control|Subject does not receive Lungpacer LIVE Catheter or DPTS. Subject receives only Standard of care for weaning from mechanical ventilation.
11141806|NCT03783871|Experimental|Single-arm|Subjects will be treated with microwave ablation.
11141807|NCT03783858|Other|Single|
11141808|NCT03783845|Experimental|test group|"Metronidazole 400mg,three times daily for two weeks
~Amoxicillin 500mg,three times daily for two weeks."
11141809|NCT03783845|No Intervention|control group|no intervention during study period
11141810|NCT03783819|Active Comparator|Active treatment|One forearm will be treated with ointment containing Hypericum perforatum oil. Forearm (left or right) will be chosen according to randomization protocol.
11141811|NCT03783819|Placebo Comparator|Placebo treatment|Other forearm will be treated with placebo ointment. Forearm (left or right) will be chosen according to randomization protocol.
11141812|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
11141813|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
11141814|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
11141815|NCT03783793|Experimental|Mindfulness Training App|
11141817|NCT03783780|Experimental|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
11141818|NCT03783767|Experimental|Leadership Intervention Group|Teachers in the intervention group will receive a half day workshop from a member of the research team. These teachers will then provide a four week training program to Grade 6/7 students, who will then deliver a 10-week fundamental movement skill (FMS) training program to Grade 3/4 students.
11141819|NCT03783767|No Intervention|Waitlist Control|This group of students and teachers will act as a waitlist control group. Therefore, during the same time that the other group is receiving the intervention, this group will proceed with their normal practices.
11141820|NCT03783754|Experimental|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
11141821|NCT03783754|Placebo Comparator|Placebo|received via blinded study oral capsules
11141822|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
11141823|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
11141824|NCT03783702|Experimental|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
11141825|NCT03783702|Active Comparator|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
11141826|NCT03783689|Active Comparator|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
11141827|NCT03783689|Sham Comparator|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
11141828|NCT03783676|Experimental|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
11141829|NCT03783676|Placebo Comparator|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
11141830|NCT03783663|Experimental|Sleep education plus Misfit Shine 2|This arm receives sleep education from the study nurse and also receives a Misfit Shine 2 to wear for 12 weeks to self-monitor sleep.
11141831|NCT03783663|No Intervention|sleep education only|This arm receives only sleep education from the study nurse.
11141832|NCT03783650|Experimental|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry & BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
11141833|NCT03783650|Active Comparator|Cohort 2|0-6 months: Control condition Usual Care and Registry & BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
11141834|NCT03783637|Other|Whole Grain Oat|Volunteers will consume a breakfast meal containing whole grain oats after 7 days of a whole grain free diet.
11141835|NCT03783637|Other|Whole Grain Wheat|Volunteers will consume a breakfast meal containing whole grain wheat after 7 days of a whole grain free diet.
11141836|NCT03783624|Experimental|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic… a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again…."
11141837|NCT03783624|Placebo Comparator|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
11141838|NCT03783624|No Intervention|Usual care|Patients continue with their usual treatments
11141839|NCT03783611|Experimental|Intervention group|The intervention group has access to the MyPlan 2.0. eHealth intervention. MyPlan is a eHealth intervention designed to increase physical activity. The intervention is based on the self-regulation theory and focuses on pre- and post-intentional processes to increase physical activity.
11141840|NCT03783611|No Intervention|control group|The control group receives no intervention
11141841|NCT03783598|Experimental|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
11141842|NCT03783598|No Intervention|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
11141843|NCT03783585|Experimental|cognitive behavioral therapy for insomnia (CBT-I)|Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
11141844|NCT03783585|Experimental|CBT-I + biweekly support|Participants randomized to this arm will participate in a 6-week web-based CBT-I program. In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
11141845|NCT03783572|Experimental|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
11141846|NCT03783572|Active Comparator|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
11141847|NCT03783559|Experimental|Arm A|TACE plus chemotherapy ± target therapy
11141848|NCT03783559|Active Comparator|Arm B|chemotherapy ± target therapy
11141849|NCT03783546|Experimental|Immediate Acupuncture|"Will receive a standardized acupuncture protocol for a 10-week period
~20 sessions: twice a week for 10 weeks
~After the completion of the 10 weeks main study period, participants will cross over to the usual care as a follow-up without acupuncture for additional 10 weeks."
11141850|NCT03783546|Active Comparator|Delayed acupuncture|"Will receive standard usual care without acupuncture for 10 weeks
~Participants will cross over to receive the same acupuncture protocol for 10 weeks --10 sessions: once a week for 10 weeks before exiting the study"
11141851|NCT03783533|Experimental|Adolescents|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
11141852|NCT03783520|Experimental|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
11141853|NCT03783520|Active Comparator|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
11141854|NCT03783507|Experimental|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
11141855|NCT03783507|Experimental|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
11141856|NCT03783507|Experimental|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
11141857|NCT03783507|Experimental|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
11141858|NCT03783494|Experimental|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
11141859|NCT03783481|Experimental|Mobile community group|join the mobile community via the smartphone application
11141860|NCT03783481|Active Comparator|No community group|
11141861|NCT03783468|Experimental|light sedation pressure support ventilation|
11141862|NCT03783455|Active Comparator|Non arthroscopic joint lavage (NAJL)|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper.
11141863|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the NAJL plus corticosteroid group was given an intra-articular injection containing 40 mg of triamcinolone acetonide.
11141864|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the patients were given an intra-articular injection containing 4 ml of a bioengineered hyaluronic acid.
11141865|NCT03783455|Active Comparator|Intraarticular injection of hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
11141866|NCT03783455|Active Comparator|Intraarticular injection of corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 40 mg of triamcinolone acetonide.
11141900|NCT03783273|Active Comparator|D3 + juice|200 microgram vitamin D3 added to 500 mL of juice.
11141868|NCT03783442|Active Comparator|Placebo + chemotherapy|Placebo administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
11141869|NCT03783429|Active Comparator|Intervention group|The intervention group will receive low-dose digoxin
11141870|NCT03783429|Placebo Comparator|Placebo group|The placebo group will receive a matching placebo
11141871|NCT03783416|Experimental|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
11141872|NCT03783416|Placebo Comparator|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
11141873|NCT03783403|Experimental|CC-95251 alone|CC-95251 administered by IV (intravenous) infusion
11141874|NCT03783403|Experimental|CC-95251 in combination with rituximab|CC-95251 administered by IV (intravenous) infusion; Rituximab administered by IV (intravenous) infusion.
11141875|NCT03783403|Experimental|CC-95251 in combination with cetuximab|CC-95251 administered by IV (intravenous) infusion; Cetuximab administered by IV (intravenous) infusion.
11141876|NCT03783390|No Intervention|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
11141877|NCT03783390|No Intervention|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
11141878|NCT03783390|No Intervention|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
11141879|NCT03783390|No Intervention|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
11141880|NCT03783390|No Intervention|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
11141881|NCT03783390|Experimental|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
11141882|NCT03783377|Experimental|ARO-APOC3|
11141883|NCT03783377|Placebo Comparator|Placebo|
11141884|NCT03783364|Experimental|preoperative|preoperative radiotherapy
11141885|NCT03783364|Active Comparator|postoperative|postoperative radiotherapy
11141886|NCT03783351|No Intervention|Conventional Therapy|Patients randomized to the Conventional Therapy arm will receive either clopidogrel or ticagrelor, according to the clinical and procedural characteristics of patients. CYP2C19 genotyping will be performed at the end of study.
11141887|NCT03783351|Active Comparator|CYP2C19 Genotyping|CYP2C19 genotyping will be performed within 48 hours after randomization. CYP2C19 *2 or *3 reduced function allele patients will receive ticagrelor 90 mg bid, whereas non-*2 or -*3 CYP2C19 patients will receive clopidogrel 75 mg once daily.
11141888|NCT03783338|Active Comparator|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
11141889|NCT03783338|Experimental|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
11141890|NCT03783338|Experimental|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
11141891|NCT03783325|Other|UV Counseling|Evaluate the effectiveness of dosimetry feedback on sun exposure behaviors, attitudes, and awareness in patients diagnosed with melanoma.
11141892|NCT03783325|Experimental|Visual Analysis - UV Photo|Assess the relationships between UV camera score, silicone mold of a skin patch, phenotypic evaluation and sun-exposure behaviors. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
11141893|NCT03783325|Experimental|Biological Sample|Determine the relationship between measures of sun exposure and genomic characteristics of tumors in melanoma patients. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
11141894|NCT03783312|Placebo Comparator|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
11141895|NCT03783312|Active Comparator|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
11141896|NCT03783312|Active Comparator|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
11141897|NCT03783299|Experimental|Village-based MTAT|"Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older.
~The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
11141898|NCT03783299|Experimental|Peer navigator-led FTAT|"Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals.
~The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
11141899|NCT03783273|Experimental|Whey protein complex-bound D3 + juice|200 microgram vitamin D3 in a whey protein-complex added to 500 mL of juice.
11141904|NCT03783260|Experimental|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
11141905|NCT03783247|Experimental|FIB|hip fracture with fascia Iliaca block
11141906|NCT03783247|Experimental|PENG|Hip fracture with Pericapsular nerve group block
11141907|NCT03783234||Older Adult Patients|ED patients age of ≥ 75 who have nurse assessed Clinical Frailty Scale ≥ 4.
11141908|NCT03783221|Experimental|High-fat diet|
11141909|NCT03783221|Active Comparator|High-residue diet|
11141910|NCT03783208|Experimental|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
11141911|NCT03783208|Placebo Comparator|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
11141912|NCT03783195|Experimental|High GRS group|This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
11141913|NCT03783195|Experimental|Low GRS group|This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
11141914|NCT03783182|Active Comparator|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
11141915|NCT03783182|Placebo Comparator|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
11141916|NCT03783169||Symptomatic patients|All pregnant women (under the care of the Maternal-Fetal Medicine physicians or Faculty Medical Center physicians with MFM involvement) experiencing a hypertensive emergency (sustained systolic blood pressure > 160 mmHg or sustained diastolic blood pressure > 110 mmHg {or both} on at least two consecutive occasions 15 minutes apart). All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
11141917|NCT03783169||Asymptomatic patients|All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
11141918|NCT03783156|Other|hot snare|polypectomy with hot snare
11141919|NCT03783156|Other|cold snare|polypectomy with cold snare
11141920|NCT03783143||Clinical Cohort|This study population will consist of patient volunteers that visit one of our clinical sites withan undiagnosed febrile illness.
11141921|NCT03783143||Cross-sectional Cohort|Cross sectional study participants are volunteers from the general population selected from census lists.
11141922|NCT03783130|Experimental|Group 1|Subj will receive Trimer 4571, 100 mcg IV on Day 0, Week 8, Week 20
11141923|NCT03783130|Experimental|Group 2|Subj will receive Trimer 4571, 100 mcg SC on Day 0,Week 8, Week 20
11141924|NCT03783130|Experimental|Group 3|Subj will receive Trimer 4571, 500 mcg IM on Day 0,Week 8, Week 20
11141925|NCT03783130|Experimental|Group 4|Subj will receive Trimer 4571, 500 mcg SC on Day 0,Week 8, Week 20
11141926|NCT03783117|Experimental|Magnetic field treatment|Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
11141927|NCT03783104|Experimental|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
11141928|NCT03783104|Active Comparator|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
11141929|NCT03783091|Experimental|Hydroxocobalamin|Single IV infusion administered over a 10-15 minute period
11141930|NCT03783091|Placebo Comparator|Saline Placebo|Single IV saline administered over a 10-15 minute period.
11141931|NCT03783078|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
11141932|NCT03783065|Experimental|Experimental group|Procedure: Laparoscopic splenectomy and pericardial devascularization Drug: Propranolol
11141933|NCT03783065|Active Comparator|Control group|Procedure: Endoscopic therapy Drug: Propranolol
11141934|NCT03783052|Other|Healthy volunteers|10 Healthy volunteers
11141935|NCT03783052|Other|Obese volunteers|10 Obese Volunteers
11141936|NCT03783052|Other|Roux-en-Y Gastric Bypass patients|10 volunteers with a Roux-en-Y Gastric Bypass
11141937|NCT03783052|Other|Sleeve Gastrectomy patients|10 volunteers with a Sleeve Gastrectomy
11141938|NCT03783039|Experimental|SURGICEL Powder|SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
11141939|NCT03783039|Active Comparator|SURGICEL Original|SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form
11141940|NCT03783026|Experimental|Administration of CC-10004|Apremilast 30 mg BID in monotherapy or in combination with Methotrexate
11141941|NCT03783013|Other|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
11141942|NCT03783013|Other|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
11141943|NCT03783000|Experimental|All subjects|Treatment T followed by Treatment R
11141944|NCT03782987|Experimental|Treatment T|BI 730357 plus Itraconazole
11141945|NCT03782987|Experimental|Treatment R|BI 730357 alone
11142145|NCT03781557|Placebo Comparator|Olive Oil|Olive Oil softgels
11141946|NCT03782974|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
11141947|NCT03782974|Placebo Comparator|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
11141948|NCT03782961|Experimental|Stand up|After application of the product (sodium lactate and combination of polymers) will remain standing for 30 minutes
11141949|NCT03782961|Experimental|Lying down|After application of the product (sodium lactate and combination of polymers) remained lying down with the legs stretched for 30 minutes;
11141950|NCT03782948|Active Comparator|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,
~walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;
~practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
11141951|NCT03782948|Experimental|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,
~walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;
~practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;
~practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
11141952|NCT03782935|Experimental|prenatal multivitamin mineral supplement|received prenatal multivitamin mineral supplement at time of enrollment TheraVit multivitamin/mineral prenatal supplement with instructions to take 1 per day through the remainder of pregnancy
11141953|NCT03782935|Experimental|prenatal multivitamin mineral supplement plus choline|received prenatal multivitamin mineral supplement plus additional choline supplemental vitamin TheraVit multivitamin mineral supplement plus 750 mg. choline with instructions to take1 multivitamin mineral supplement and 750 mg. per day of choline through the remainder of pregnancy
11141954|NCT03782935|No Intervention|Comparison|Advised to follow obstetrics standard of care which is to take a prenatal vitamin/mineral supplement
11141955|NCT03782922|Experimental|Exercise Training Program|
11141956|NCT03782922|No Intervention|Control|
11141957|NCT03782909|Experimental|Behaviour change intervention|Intensive behaviour change for 6 weeks, followed by a maintenance phase for 6 weeks
11141958|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
11141959|NCT03782857|Experimental|Intervention group|Initiation/stepwise escalation of antihypertensive medication in case of blood pressure above individual target Initiation/stepwise escalation of cholesterol lowering medication in case of LDL-cholesterol above individual target Advice on healthy lifestyle and life long adherence to preventive medication
11141960|NCT03782857|No Intervention|Control group|Participants had the usual treatment: all patients were invited to one visit in the outpatient clinic three months after discharge with a diagnosis of stroke/TIA
11141961|NCT03782844|Experimental|Arm 1|Simple CPAP + Traditional CPAP
11141962|NCT03782844|Experimental|Arm 2|Traditional CPAP + Simple CPAP
11141963|NCT03782831|Experimental|TACE plus PD-1 antibody|Patients received hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11141964|NCT03782831|Active Comparator|TACE alone|Patients received hepatic intra-arterial infusion with lipiodol mixed with hemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received placebos intravenously every 2 weeks
11141965|NCT03782818|Experimental|Olaparib|After a 4-week pre-treatment phase to ensure that patients are on stable doses of PAH medication, patients will be given progressive doses of olaparib up to 300 mg BID for 24 weeks.
11141966|NCT03782805|Experimental|treatment group|Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.
11141967|NCT03782805|Placebo Comparator|Placebo group|Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months
11141968|NCT03782792|Experimental|Spesolimab|
11141969|NCT03782792|Experimental|Placebo|
11141970|NCT03782779|Experimental|Breathing program and regular exercise|Diaphragmatic Breathing Program plus regular upper and lower limb exercises
11141971|NCT03782779|Active Comparator|Regular Exercise|Regular upper and lower limb exercises
11141972|NCT03782766|Experimental|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
11141973|NCT03782766|No Intervention|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
11141974|NCT03782766|Other|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
11141975|NCT03782753||Group A|25 LRRK2-PD patients
11141976|NCT03782753||Group B|25 idiopathic PD patients
11141977|NCT03782753||Group C|25 HC subjects
11141978|NCT03782740|Experimental|Dysmenorrhea Melatonin 10 mg|In the dysmenorrhea group: 2 capsules with 5 mg melatonin will be given in the evening for seven days consecutively during menstruation for two mentrual cycles. Compared with placebo.
11141979|NCT03782740|Experimental|Endometriosis Melatonin 20 mg|In the endometriosis group: 4 capsules with 5 mg melatonin will be given every evening during eight weeks. Compared with placebo.
11141980|NCT03782714|Experimental|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
11141981|NCT03782714|No Intervention|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
11142113|NCT03781778|Experimental|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
11141982|NCT03782701|Active Comparator|Experimental|For each patient, each eye will be randomized to receive a single drop of either brimonidine tartrate ophthalmic solution 0.025% or a sterile balanced saline solution.
11141983|NCT03782701|Sham Comparator|Control|For each patient, each eye will be randomized to receive a single drop of either brimonidine tartrate ophthalmic solution 0.025% or a sterile balanced saline solution.
11141984|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
11141985|NCT03782675|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device the device is turned on or not.
11141986|NCT03782675|Experimental|Air Barrier System|In the experimental (interventional) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
11141987|NCT03782662|Experimental|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
11141988|NCT03782662|Experimental|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
11141989|NCT03782662|Experimental|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
11141990|NCT03782662|Experimental|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
11141991|NCT03782662|Placebo Comparator|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
11141992|NCT03782649|Experimental|RSP-08|All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.
11141993|NCT03782636|Experimental|Aldesleukin|Ultra-low dose aldesleukin injected subcutaneously, at a dose of 0.2 x 106 IU/m2 twice-weekly , three days apart, for 6 months.
11141994|NCT03782636|Placebo Comparator|Placebo|Placebo sc, at a similar dose (expressed in ml) to the active drug
11141995|NCT03782623||Intensive care patients after elective open aortic surgery|
11141996|NCT03782623||Intensive care patients after bilateral lung transplantation|
11141997|NCT03782623||Anesthetic intensive care patients, unplanned admission|
11141998|NCT03782610||Primary Study Cohort|450 Infants
11141999|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
11142000|NCT03782584|Experimental|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
11142001|NCT03782584|Other|Control Group|they will be given daily life advises to prevent neck pain
11142002|NCT03782571|Experimental|Test1/Test2/Control/Test3|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
11142003|NCT03782571|Experimental|Test2/Test3/Test1/Control|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
11142004|NCT03782571|Experimental|Test3/Control/Test2/Test1|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
11142005|NCT03782571|Experimental|Control/Test1/Test3/Test2|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
11142006|NCT03782558||Patients with CTS|Surgical transection of transverse ligament
11142007|NCT03782532|Experimental|Dupilumab|For patients without oral corticosteroids (OCS) maintenance therapy, dose 1 of dupilumab administered once in 2 weeks (q2w) with loading dose of dupilumab, two times dose 1; for patients on OCS maintenance therapy, the dose will be dupilumab dose 2 q2w with loading dose 2 times dose 2
11142008|NCT03782532|Placebo Comparator|Placebo for dupilumab|For patients without OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 1 q2w with loading dose; for patients on OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 2 q2w with loading dose
11142009|NCT03782519|Experimental|Incremental hemodialysis|Patients who will begin HD with two treatment sessions per week
11142010|NCT03782519|Active Comparator|Conventional hemodialysis|Patients who will begin HD three times a week
11142011|NCT03782506|Experimental|Interactive Music Therapy|Ten 45-minute individual interactive music therapy sessions.
11142012|NCT03782506|Active Comparator|Verbal-based Support|Ten 45-minute individual verbal support sessions.
11142013|NCT03782493|Experimental|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
11142046|NCT03782207||Cohort 1 (UC LOT2+later lines[LOT2+] & platinum eligible LOT1)|Participants diagnosed with locally advanced or metastatic Urothelial Cancer previously treated with platinum-containing chemotherapy.
11142014|NCT03782493|No Intervention|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
11142015|NCT03782480|Active Comparator|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
11142016|NCT03782480|Placebo Comparator|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
11142017|NCT03782467|Experimental|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
11142018|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
11142019|NCT03782441|Experimental|RSP-19|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 42 days.
11142020|NCT03782428|Active Comparator|Probiotic group|27 participants received probiotics twice daily for six months
11142021|NCT03782428|Placebo Comparator|Placebo group|25 participants received placebo twice daily for six months
11142022|NCT03782415|Experimental|MN-166 (ibudilast) and temozolomide|Part 1: Combination treatment of MN-166 (ibudilast) 60 mg/day (30 mg twice a day) for 28 days and temozolomide 150 mg/m² on Days 1-5 of 28-day cycle. Part 2: Open-label, fixed-dose MN-166 (ibudilast) and temozolomide combination treatment for 6 cycles until disease progression, unacceptable tolerability and/or toxicity or loss of life.
11142023|NCT03782402|Experimental|Cannabinoids of varied strength|Strengths of cannabinoids will vary across groups
11142024|NCT03782402|Active Comparator|Cannabinoids of various strengths|Strengths of cannabinoids will vary across groups
11142025|NCT03782389||Elite football players aged 16-40 years|
11142026|NCT03782376|Experimental|Group 1: Ustekinumab (IV re-induction)|Participants who experience a secondary loss of response (LoR) to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg and matching placebo subcutaneously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
11142027|NCT03782376|Active Comparator|Group 2: Ustekinumab (Continuous q8w SC maintenance)|Participants who experience a secondary LoR to 90 mg ustekinumab maintenance treatment, administered subcutaneously q8w will receive ustekinumab 90 mg subcutaneously and matching placebo intravenously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
11142028|NCT03782363|Experimental|Autologous CIK Dose level 1|autologous CIK at dose level 1
11142029|NCT03782363|Experimental|Autologous CIK Dose level 2|autologous CIK at dose level 2
11142030|NCT03782363|Experimental|Autologous CIK Dose level 3|autologous CIK at dose level 3
11142031|NCT03782363|Experimental|Autologous CIK Dose level 4|autologous CIK at dose level 4
11142032|NCT03782350|Experimental|Tranexamic Acid Dosage 1|A bolus of 30 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 16 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 2 mg/kg.
11142033|NCT03782350|Active Comparator|Tranexamic Acid Dosage 2|A bolus of 10 mg/kg Tranexamic Acid for 20 min followed by a maintenance dose of 2 mg/kg/h Tranexamic Acid until the end of surgery, and a pump prime dose 1 mg/kg.
11142034|NCT03782311||2 groups: OHSE-high and OHSE-low|"OHSE-high: Group with ≥ 50 OHSE scores received motivation and oral hygiene instructions .
~OHSE-low: Group with < 30 OHSE scores received motivation and oral hygiene instructions ."
11142035|NCT03782272|Experimental|AA-ORS|Those receiving enterade oral re-hydration solution with amino acids
11142036|NCT03782272|Placebo Comparator|Placebo|Those receiving placebo solution without amino acids or rehydration salts
11142037|NCT03782259|Placebo Comparator|Placebo|10mg tabs placebo matching dapagliflozin.
11142038|NCT03782259|Active Comparator|Active|10mg tabs of dapagliflozin
11142039|NCT03782246|No Intervention|Usual Care|No intervention, participant will continue their usual care for pain and MS. We will collect information about what treatments are used by the usual care participants. They will be offered the opportunity to participate in one of the two active study treatments (MBCT or CBT) after completion of the 6-month followup.
11142040|NCT03782246|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Participants will attend eight, 2-hour group treatment MBCT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. MBCT integrates mindfulness meditation practices within a CBT-oriented framework to address not only unhelpful pain cognitions and behaviors but also attentional control, decoupling of attention from emotion, mindful cognitions, and meditative behavior.
11142041|NCT03782246|Experimental|Cognitive Behavioral Therapy (CBT)|Participants will attend eight, 2-hour group treatment CBT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. CBT focuses on increasing adaptive pain coping strategies and reducing unhelpful thoughts and behaviors related to pain. Strategies include relaxation techniques, goal-setting, activity pacing, and changing unhelpful thinking patterns.
11142042|NCT03782233|Experimental|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
11142043|NCT03782233|Other|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
11142044|NCT03782220|Experimental|Kinesio taping group|"Kinesio taping group
~Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.
~Once a week , for 4 weeks"
11142045|NCT03782220|Placebo Comparator|Shame taping group|"Shame taping group
~Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.
~Once a week , for 4 weeks"
11142107|NCT03781817|Experimental|Intranasal ketamine|Participants randomized to Intranasal Ketamine group will receive Intranasal ketamine and IV normal saline.
11142047|NCT03782207||Cohort 2 (NSCLC LOT2 plus later lines [LOT2+])|Participants diagnosed with Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after prior chemotherapy. Participants with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumor mutations should also have received targeted therapy.
11142048|NCT03782207||Cohort 3 (NSCLC LOT1 plus EGFR+/ALK+ LOT2+)|"EMA: Participants diagnosed with locally advanced/metastatic non-squamous NSCLC not previously treated. Participants with EGFR-activating mutations or ALK-positive tumor mutations should have received at least one line of targeted therapy.
~FDA: for the treatment of adult participants with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Participants with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ."
11142049|NCT03782207||Cohort 4 (ES-SCLC LOT1)|Participants diagnosed with extensive stage (ES) small cell lung cancer (SCLC) not previously treated.
11142050|NCT03782194|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MRI data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
11142051|NCT03782194|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
11142052|NCT03782181|Active Comparator|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
11142053|NCT03782181|No Intervention|Control group|No intervention arm
11142054|NCT03782168||Placental Abruption|Mother-infant dyads with suspected or confirmed diagnosis of placental abruption
11142055|NCT03782168||Phenotypically-matched controlled group|Healthy mother-infant dyads admitted for delivery
11142056|NCT03782155|Experimental|HMB and glutamine supplementation|Patients with type 2 diabetes with supplementation HMB 3g, powder once a day and glutamine powder 14g once a day supplementation during 15 days.
11142057|NCT03782155|Placebo Comparator|placebo patients|Patients with type 2 diabetes with placebo( calcium caseinate) supplementation during 15 days 17g of powder once a day
11142058|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
11142059|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- [darunavir+cobicistat combination]
11142060|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
11142061|NCT03782129||Diabetic patients with DFU|Diabetic patients with DFU diagnosed in 2010
11142062|NCT03782103|Experimental|Zurex Prep (70% IPA)|Isopropyl alcohol (IPA) 70%
11142063|NCT03782103|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
11142064|NCT03782103|Placebo Comparator|Zurex Prep Vehicle|Zurex Prep without IPA
11142065|NCT03782090|Active Comparator|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
11142066|NCT03782090|Experimental|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
11142067|NCT03782064|Experimental|Nivolumab+DC/myeloma fusions/GM-CSF|"Nivolumab will be given every two weeks
~The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
11142068|NCT03782051|Active Comparator|Phacovisco group|group had combined phacoemulsification and viscocanalostomy
11142069|NCT03782051|Active Comparator|OloPhacovisco group|group had combined phacoemulsification and viscocanalostomy and Ologen
11142070|NCT03782038|Experimental|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
11142071|NCT03782025||Patients with increased PK-INR|Critically ill patients with spontaneously increased prothrombin complex (PK-INR) who are given phytomenadione intravenously at the discretion of the treating physician
11142072|NCT03782012|Experimental|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
11142073|NCT03782012|Experimental|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
11142074|NCT03781999|Experimental|Actiful|a supplement containing 500 mg orange extract and 200 mg pomegranate actives
11142075|NCT03781999|Placebo Comparator|Placebo|Maltodextrin
11142076|NCT03781986|Experimental|APG115 mono-therapy|APG115 at 150mg is taken orally every other day within one hour after food. Cycle length 21 days
11142077|NCT03781986|Experimental|APG115 + Carboplatin|APG115 at 150mg is taken orally every other day within one hour after food. Carboplatin is given IV at AUC=4.5, Cycle length 21 days
11142078|NCT03781973|No Intervention|Pre-intervention|"Those whose last pediatric visit was in the year before the intervention (2018).
~Medical record data abstracted from patient charts at the time of the final pediatric visit."
11142079|NCT03781973|Other|Early Intervention|"Those whose last pediatric visit was in the year immediately after the start of the intervention (2019).
~The intervention will begin on Jan 1, 2019 and includes the following :
~Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .
~Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.
~Patient transition experience surveys at the final pediatric visit and 12 months later.
~Diabetes teams may direct patients and families to online transition resources."
11142108|NCT03781804|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
11142109|NCT03781804|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
11142080|NCT03781973|Other|Post-Intervention|"Those whose last pediatric visit was in the second year after the intervention (2020).
~The intervention includes the following :
~Data Platform: Medical record data abstracted from patient charts at the time of the final pediatric visit. .
~Quality performance feedback reports: We will generate centre-level performance reports. Centres will be able to compare their performance to that of all other centres and to achievable benchmarks.
~Patient transition experience surveys at the final pediatric visit and 12 months later.
~Diabetes teams may direct patients and families to online transition resources."
11142081|NCT03781960|Experimental|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
11142082|NCT03781947|Experimental|90 mg s.c.|A single s.c. injection of 90 mg teverelix TFA administered on Day 1
11142083|NCT03781947|Experimental|60 mg s.c.|A single s.c. injection of 60 mg teverelix TFA administered on Day 1
11142084|NCT03781947|Experimental|90 mg i.m.|A single i.m. injection of 90 mg teverelix TFA administered on Day 1
11142085|NCT03781947|Experimental|120 mg s.c.|A single s.c. injection of 120 mg teverelix TFA administered on Day 1
11142086|NCT03781934|Experimental|HCC|Phase 2a expansion cohort HCC
11142087|NCT03781934|Experimental|iCCA|Phase 2a expansion cohort iCCA
11142088|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
11142089|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
11142090|NCT03781908|Experimental|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
11142091|NCT03781908|Active Comparator|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
11142092|NCT03781895|Placebo Comparator|A0|"A0- On day 0,before intervention placebo,
~Microcrystalline Cellulose (303.8gm)
~Butylated Hydroxy Toluene (0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~weekly,orally,for 90days"
11142093|NCT03781895|Placebo Comparator|A90|"A90- On day 90,after intervention placebo,
~Microcrystalline Cellulose (303.8gm)
~Butylated Hydroxy Toluene (0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~weekly,orally,for 90days"
11142094|NCT03781895|Active Comparator|B0|"B0- On day 0,before intervention cholecalciferol,
~Cholecalciferol (40,000IU)
~Microcrystalline Cellulose (58.1 gm)
~Butylated Hydroxy Toluene ( 0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~80.000IU/week,orally,for 90 days"
11142095|NCT03781895|Active Comparator|B90|"B90- On day 90,after intervention cholecalciferol,
~Cholecalciferol (40,000IU)
~Microcrystalline Cellulose (58.1 gm)
~Butylated Hydroxy Toluene ( 0.2mg)
~Magnesium Stearate (3mg)
~Gelatin Capsule Shell (1mg)
~80.000IU/week,orally,for 90 days"
11142096|NCT03781882|Active Comparator|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
11142097|NCT03781882|Active Comparator|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
11142098|NCT03781869|Experimental|Anlotinib + Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, and Anlotinib 12mg/d on day 1 to day 14 , repeated every 21 days, a total of 4-6 cycles, and then continue to take Anlotinib 12mg/d on day 1 to day 14, repeated every 21 days until progressive Disease(PD).
11142099|NCT03781869|Placebo Comparator|Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, repeated every 21 days, a total of 4-6 cycles, and then follow up observation until PD.
11142100|NCT03781856|Experimental|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
11142101|NCT03781856|Active Comparator|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
11142102|NCT03781843|Active Comparator|Genicular nerve block with lidocaine|The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 6 mL of a solution containing 6 mL of 2% lidocaine or 6 mL dextrose or 6 mL saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves Interventions: Drug: 6 mL 2% lidocaine Procedure: Genicular nerve block
11142103|NCT03781843|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.
~Interventions:Drug: Saline Procedure: Genicular nerve block"
11142104|NCT03781843|Placebo Comparator|Genicular nerve block with dextrose|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a dextrose was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.
~Interventions:Drug: Dextrose Procedure: Genicular nerve block"
11142105|NCT03781830|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
11142106|NCT03781817|Active Comparator|Intravenous ketamine|Participants randomized to IV ketamine will be receive IV ketamine and Intranasal normal saline.
11142114|NCT03781778|Active Comparator|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
11142115|NCT03781765|Active Comparator|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
11142116|NCT03781765|Active Comparator|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
11142117|NCT03781752|Experimental|Methylphenidate|Youth with ADHD
11142118|NCT03781739|Experimental|MANP|subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
11142119|NCT03781739|Placebo Comparator|Placebo|subjects receiving placebo (saline solution, single subcutaneous injection)
11142120|NCT03781726|Experimental|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
11142121|NCT03781713|Active Comparator|STUDY GROUP|patients who triggered triggers and had interventions. Kdigo: interventions to prevent renal replacement therapy Delta SOFA: interventions to improve SOFA score Hypoglycemia: Interventions to prevent new episodes of hypoglycemia in the next 24 hours Drug interaction risk D or X - Intervention in the therapeutic plan in order to avoid adverse drug reactions. Antimicrobial stewardship: optimization of antimicrobial therapy based on Gram stain, MALDI TOF, MIC, antimicrobial susceptibility
11142122|NCT03781713|No Intervention|CONTROL GROUP|patients who did not triggered triggers
11142123|NCT03781700|Experimental|Prednisolone|Prednisolone
11142124|NCT03781700|Placebo Comparator|Placebo|Placebo oral tablet
11142125|NCT03781687|Active Comparator|Bilateral|Bilateral ESP block will be performed
11142126|NCT03781687|Active Comparator|Unilateral|Unilateral ESP block will be performed
11142127|NCT03781674|Active Comparator|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
11142128|NCT03781674|Active Comparator|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
11142129|NCT03781674|Placebo Comparator|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
11142130|NCT03781661|Experimental|Intervention Group|The participants in the intervention group will be provided with extended information of the advantages of the CT examination of the heart's arteries. This will be given to the participants both orally and written in form of a leaflet. In addition will they be given the opportunity for a visual go-through of their own calcium score images. After this they will be informed of the normal examination result.
11142131|NCT03781661|No Intervention|Control group|Control Group receives standard care.
11142132|NCT03781648|Other|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
11142133|NCT03781648|Experimental|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
11142134|NCT03781635|Active Comparator|bolus of intravenous ketamine|A bolus of 0.25mg.kg-1 of ketamine will be first administered at the time of incision (T0) then every single hour for the rest of the surgery. Study starts at incision (T0) for ketamine administration and ends when the surgical team starts closing the deep layers of the abdominal incision.
11142135|NCT03781635|Experimental|continuous infusion of intravenous ketamine|An infusion of 0.25 mg.kg-1.h-1 is started at T0 (incision) with an infusion pump and is kept at the same rate until the surgical team starts closing the deep layers of the abdominal incision. Consumption of the infusion pump is noted at T0 (incision) and at each hour during the surgery until the infusion is discontinued.
11142136|NCT03781622|Experimental|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
11142137|NCT03781609|Active Comparator|Roller system group (RG)|A group performing motor learning manual wheelchair propulsion repetitions on a roller system.
11142138|NCT03781609|Active Comparator|Overground group (OG)|A group performing motor learning manual wheelchair propulsion repetitions overground.
11142139|NCT03781609|Placebo Comparator|Placebo - Wheelchair skills group (WSG)|A group receiving conventional manual wheelchair skills training.
11142140|NCT03781596|Experimental|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
11142141|NCT03781596|Placebo Comparator|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
11142142|NCT03781583|Experimental|HMD|"We have several versions (listed below) of a headworn smartHMD. Each can provide verbal and/or tactile feedback to the user. Feedback is controlled by either the experimenter or by computer vision algorithms.
~1. The ODG Smartglasses is commercially available. This system uses computer vision to guide a user to the destination using audio and/ or vibration feedback.
~2) Tactile stimulator array. This device uses an Arduino Micro, HC-05 Bluetooth Module, L293D Motor Driver and coin vibration motors attached to a head-worn headband or glasses frame. The motors can be controlled directly by an experimenter or by computer vision algorithms.
~3) Computer Vision Navigation prototyping system consists of two components: Intel RealSense camera and Alienware M15 laptop.
~All participants will receive the same 3 interventions: no HMD used, HMD worn but not active, and HMD worn and active. Participants may be tested with any or all of the systems described above."
11142146|NCT03781544|Experimental|Diclofenac|Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
11142147|NCT03781544|Active Comparator|Paracetamol|"Paracetamol (Paracetamol Sintetica):
~A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm)."
11142148|NCT03781544|Experimental|Tramadol|"Tramadol (Tramadol-Mepha):
~A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm)."
11142149|NCT03781531||Venous thromboembolism|Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
11142150|NCT03781518|Experimental|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
11142151|NCT03781518|Active Comparator|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
11142152|NCT03781505|Experimental|Intravenous paracetamol with Caudal Ropivacaine|"Paracetamol is widely accepted and most commonly used as an adjuvant for postoperative analgesia. It also improves the quality of recovery by attenuating the pain associated with the surgical position. Adverse effects associated with the paracetamol are rare <1/10000, which includes malaise, increased level of hepatic transaminases and hypersensitivity reaction. It has been studied in combination with caudal analgesia with bupivacaine through the rectal route 7,8 with variable results.
~Caudal anaesthesia is effective in alleviating pain below the umbilicus. Also if the caudal block is administered at the beginning of surgery, the effect will start wearing off 2 to 3 hours post surgery. Administration of paracetamol towards end of surgery may help with both these issues. In this study we aim to investigate the effect of adding intravenous paracetamol in combination with caudal analgesia with ropivacaine, hoping that it may improve quality of postoperative analgesia and recovery."
11142153|NCT03781505|Placebo Comparator|Placebo|Intravenous Normal Saline with Caudal Ropivacaine
11142154|NCT03781479|Experimental|amifampridine phophate - placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
11142155|NCT03781479|Experimental|placebo - amifampridine phophate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
11142156|NCT03781466|Active Comparator|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
11142157|NCT03781466|Active Comparator|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
11142158|NCT03781466|Active Comparator|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
11142159|NCT03781440|Experimental|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
11142160|NCT03781440|Placebo Comparator|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
11142161|NCT03781427|Active Comparator|Standard care|Cardiac resynchronization therapy: Usual output programming
11142162|NCT03781427|Experimental|High output|Cardiac resynchronization therapy: High output programming
11142163|NCT03781414|Active Comparator|Arm 1|Control/Standard of Care: TAC + MMF + Corticosteroids
11142164|NCT03781414|Experimental|Arm 2|CFZ533 dose A + MMF + Corticosteroids
11142165|NCT03781414|Experimental|Arm 3|CFZ533 dose B + MMF + Corticosteroids
11142166|NCT03781388|Experimental|Starting dose of Bupivacaine (9 mg)|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
11142167|NCT03781388|Experimental|Subsequent dose|
11142168|NCT03781375|Placebo Comparator|Methotrexate + Placebo|Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
11142169|NCT03781375|Experimental|Methotrexate + Etanercept|Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
11142170|NCT03781362|Experimental|CPI-100 Monotherapy|"Dose Escalation Groups:
~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study
~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
11142171|NCT03781362|Experimental|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
11142172|NCT03781349|Active Comparator|MENS|MENS are applied through placement of six electrodes (size of 4x4cm), of which four were placed exactly like the TENS electrodes and the other two, one in the palm and the other at the height of the asteroid ganglion. Duration of the intervention was 24 min for a total of 15 sessions. The frequency was 50 Hz and the intensity was 100 μA.
11142173|NCT03781349|Active Comparator|TENS|TENS are applied through the placement of four electrodes on either side of the deltoid muscle, on the front and back surfaces of the shoulder joint for 20 min and each patient received 15 sessions (five per week). A constant current of high frequency was used (100 HZ) and its intensity was initiated at 10mA and was then gradually increased to 15mA
11142174|NCT03781336|Experimental|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
11142175|NCT03781336|No Intervention|Wait list control|Wait list control (5 weeks)
11142176|NCT03781323|Experimental|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.
~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
11142177|NCT03781310|Experimental|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
11142178|NCT03781310|Active Comparator|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
11142179|NCT03781297|Active Comparator|Intervention: NET+G|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks plus the option to receive genealogical services.
11142180|NCT03781297|Active Comparator|Intervention: NET|In addition to usual care, participants will receive six sessions of Narrative Exposure Therapy over six weeks.
11142181|NCT03781284|Experimental|PET/MRI with bowel purgation|
11142182|NCT03781284|Experimental|PET/MRI without bowel purgation|
11142183|NCT03781271|Experimental|Fraction 1-Addition of EMN|During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
11142184|NCT03781271|Experimental|Fraction 3-Addition of EMN|For the second group of patients in the trial the same protocol will be followed as in the first group, the only difference will be that the electromagnetic navigation is used during the second implantation procedure immediately preceding fraction 3 as opposed to fraction 1, the time at which it was used for the first group of patients.
11142185|NCT03781258|Other|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
11142186|NCT03781245|Experimental|Early|Intervention is administered for cycle 1 and 2 with researchers and following this the company continues intervention independently.
11142187|NCT03781245|Active Comparator|Lagged|Intervention is not administered for cycle 1; researchers administer intervention in cycle 2 and following this the company continues intervention independently.
11142188|NCT03781232|Experimental|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
11142189|NCT03781232|Experimental|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
11142190|NCT03781219|Experimental|HL-085 plus Vemurafenib|HL-085 will be administered as BID with specified dose. And the Vemurafenib will be taken as the instruction in the label ( 960 mg, BID)
11142191|NCT03781206|No Intervention|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
11142192|NCT03781206|Experimental|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
11142193|NCT03781167|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 52 weeks.
11142194|NCT03781154|Experimental|Individually Supervised exercise|Virtually supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components.
11142195|NCT03781154|Experimental|Group-based exercise|Virtually supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components. Group size will be 5-15 participants to optimize social interaction, and activities will be structured so that participants come in close proximal distance of each other at least once per session (e.g. circuit training, squat with ball toss to a partner). There will be scheduled opportunities for social interaction (e.g. water breaks at least 3 times during class, partner 'get to know you' questions during aerobic exercise, etc.), and group roles will be assigned for class participants (e.g. leading warm up or stretching).
11142196|NCT03781141|Experimental|Absorbable suture|Wound closure with absorbable suture.
11142197|NCT03781141|Active Comparator|Non-absorbable suture|Wound closure with non-absorbable suture.
11142198|NCT03781128|Other|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
11142199|NCT03781128|Other|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
11142200|NCT03781115|Experimental|Ziprasidone|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug ziprasidone (Geodon). The investigators will start with a single 20mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 40 and 60mg tablets). If Ziprasidone causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG) taken.
11142201|NCT03781115|Experimental|Olanzapine|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug olanzapine (Zyprexa). The investigators will start with a single 2.5 mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 5, 7.5, and 10 mg tablets).If olanzapine causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG).
11142276|NCT03780686|Active Comparator|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
11142202|NCT03781115|Placebo Comparator|Placebo Comparator|The investigators have prepared a placebo which duplicates the exact color and size of the study drug capsule to use as a non-drug control.
11142203|NCT03781102|Experimental|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
11142204|NCT03781102|Other|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
11142205|NCT03781089|Experimental|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L.
11142206|NCT03781089|No Intervention|Usual care arm|Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
11142207|NCT03781076|Experimental|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
11142208|NCT03781076|No Intervention|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
11142209|NCT03781063|Experimental|Lasofoxifene|5 mg/d of oral lasofoxifene
11142210|NCT03781063|Active Comparator|Fulvestrant|500 mg fulvestrant intramuscular (IM)
11142211|NCT03781050|Experimental|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months
~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
11142212|NCT03781037|Experimental|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
11142213|NCT03781011|Experimental|TMAO high producer|Low carnitine/choline diet intervention
11142214|NCT03781011|Active Comparator|TMAO low producer|Low carnitine/choline diet intervention
11142215|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
11142216|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
11142217|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
11142218|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
11142219|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
11142220|NCT03780985|Active Comparator|intrauterine device insertion with a suture fixation|IUD through hysterotomy incision during cesarean section with a suture fixation
11142221|NCT03780985|Active Comparator|intrauterine device insertion without a suture fixation|IUD through hysterotomy incision during cesarean section without a suture fixation
11142222|NCT03780972|Active Comparator|Cohort 1, 25 μg ONL1204|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver 25 μg of ONL1204 (0.5 mg/ml ONL1204 formulation)
11142223|NCT03780972|Active Comparator|Cohort 2, 50 μg ONL1204|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver 50 μg of ONL1204 (0.5 mg/ml ONL1204 formulation)
11142224|NCT03780972|Active Comparator|Cohort 3, 100 μg ONL1204|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver 100 μg of ONL1204 (2.0 mg/ml ONL1204 formulation)
11142225|NCT03780972|Active Comparator|Cohort 4, 200 μg ONL1204|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver 200 μg of ONL1204 (2.0 mg/ml ONL1204 formulation)
11142226|NCT03780959|Placebo Comparator|Etanercept/Placebo|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
11142227|NCT03780959|Experimental|Etanercept/Etanercept|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.
11142228|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
11142229|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
11142230|NCT03780933|No Intervention|control group|conventional treatment (corticosteroids, mechanical ventilation)
11142231|NCT03780933|Experimental|test group (vitamin C)|high dose vitamin c iv infusion
11142232|NCT03780920|Active Comparator|Osteopathic treatment|
11142233|NCT03780920|No Intervention|Control group|
11142234|NCT03780907|Experimental|E2007 1 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
11142235|NCT03780907|Experimental|E2007 2 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
11142236|NCT03780907|Placebo Comparator|Placebo|Tablet, once daily to be taken in the morning, one hour before breakfast, with a glass of water.
11142237|NCT03780894|Experimental|Experimental treatment|The active treatment consists of intravenous injection of 2g of fibrinogen concentrate, 1g of tranexamic acid, 2 red bood cells concentrate O Rh(D) negative (Banc de Sang i Teixits, Barcelona, Spain), and crystalloids at pre-hospital phase of care.
11142238|NCT03780894|Active Comparator|Standard treatment|Patients in the control arm will be treated according the existing protocols based on crystalloids and tranexamic acid administration.
11142239|NCT03780881|Experimental|Expectation confirmation|The participants in this group receive manipulated feedback indicating that their performance was very good in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
11142240|NCT03780881|Experimental|Expectation disconfirmation|The participants in this group receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
11142241|NCT03780868|Active Comparator|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .
~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
11142242|NCT03780868|Active Comparator|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.
~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
11142243|NCT03780855|Experimental|nerve scaffold group|the experimental group of cases with peripheral sensory nerve injuries will be treated with nerve scaffold.
11142244|NCT03780855|No Intervention|non-nerve scaffold group|the control group of cases will be treated without nerve scaffold.
11142245|NCT03780842|Experimental|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
11142246|NCT03780842|Experimental|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
11142247|NCT03780829|Experimental|hypoxia plus training|combined hypoxia treatment with exercise training
11142248|NCT03780829|Sham Comparator|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
11142249|NCT03780829|Experimental|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
11142250|NCT03780829|Placebo Comparator|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
11142251|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
11142252|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
11142253|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
11142254|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
11142255|NCT03780816||UChicago Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
11142256|NCT03780816||Cancer Center 5|Pending theoretical sampling
11142257|NCT03780816||Cancer Center 6|Pending theoretical sampling
11142258|NCT03780803|Experimental|Patients with PAH|home cardiac rehabilitation and respiratory rehabilitation
11142259|NCT03780803|Experimental|Patients with HFREF|home cardiac rehabilitation and respiratory rehabilitation
11142260|NCT03780803|Experimental|Patients with IHD|home cardiac rehabilitation and respiratory rehabilitation
11142261|NCT03780803|No Intervention|Control group|No rehabilitation
11142262|NCT03780790|Active Comparator|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the middle layer of the thoracolumbar fascia close to the lateral interfascial triangle
11142263|NCT03780790|Active Comparator|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
11142264|NCT03780790|Active Comparator|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
11142265|NCT03780777|Experimental|Home Hazard Removal Group|A tailored home-modification (home-hazard removal) intervention for residents with a high fall risk, delivered in the home by occupational therapists over one to two visits and with a booster session at three months.
11142266|NCT03780764|Active Comparator|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
11142267|NCT03780764|Experimental|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
11142268|NCT03780751|Experimental|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
11142269|NCT03780751|Experimental|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
11142270|NCT03780751|No Intervention|Waitlist|Participants will receive no immediate treatment but will be able to choose either MIND or COPE after a six months waiting period.
11142271|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
11142272|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
11142273|NCT03780725|Experimental|All Subjects|Part 1 followed by Part 2
11142274|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
11142275|NCT03780686|Active Comparator|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
11142277|NCT03780686|No Intervention|Standard fluid management|Standard fluid managements.
11142278|NCT03780673|Experimental|Simvastatin 20 mg + Rifaximin 400 mg|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 months
11142279|NCT03780673|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin|Placebo of simvastatin and placebo of rifaximin orally for 12 months
11142280|NCT03780647||Patients with suspicion of thoracic outlet syndrome|
11142281|NCT03780634|Experimental|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11142282|NCT03780634|Active Comparator|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11142283|NCT03780621|Experimental|Andrographis and Withania|Active ingredient: 550 mg of Andrographis paniculata (standardized to 40 mg andrographolides) and Withania somnifera (standardized to 10 mg withanolides) taken twice daily, once in the morning and once in the evening
11142284|NCT03780621|Placebo Comparator|Placebo|550 mg capsule visually identical to the active dietary supplement, containing brown sugar, microcrystalline cellulose, corn starch, and magnesium stearate
11142285|NCT03780608|Experimental|GC|Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.
11142286|NCT03780608|Experimental|Melanoma|Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
11142287|NCT03780595|Experimental|Passiflora|
11142288|NCT03780595|Placebo Comparator|Control|
11142289|NCT03780582|Experimental|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
11142290|NCT03780582|Experimental|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
11142291|NCT03780582|Experimental|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
11142292|NCT03780569|Experimental|NovoTTF-200A/Radiotherapy/Temozolomide|Patients will receive multiple 1 month courses of continuous NovoTTF-200A treatment together with standard Radiotherapy/Temozolomide followed by maintenance Temozolomide.
11142293|NCT03780556|Active Comparator|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
11142294|NCT03780556|Active Comparator|Pethidine|Patients received pethidine 50mg intravenous to control pain
11142295|NCT03780543|Active Comparator|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care nucleos(t)ide (SOC NrtI)-suppressed and HBeAg-negative will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years.
11142296|NCT03780543|Active Comparator|HBeAg-positive Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated. Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years. Subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.
11142297|NCT03780543|Active Comparator|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.
~Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 48 weeks, after which time their viral response will be evaluated at Week 100. Subjects who meet the virologic response criteria at Week 100 will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years, while those subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.
~Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks."
11142298|NCT03780530|Active Comparator|subcuticular suturing|
11142299|NCT03780530|Active Comparator|surgical glue|
11142300|NCT03780530|Active Comparator|adhesive steri-strip tape|
11142301|NCT03780517|Experimental|BOS172738|In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.
11142302|NCT03780491|No Intervention|Control|The first 50 patients will have usual care with providers conducting the visit in their typical manner.
11142340|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
11142341|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
11142303|NCT03780491|Experimental|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
11142304|NCT03780478|Experimental|SPG Block|Sphenopalatine ganglion block
11142305|NCT03780478|Placebo Comparator|Placebo Control|Saline injection
11142306|NCT03780465|Active Comparator|Oral idronoxil|10 male and female subjects randomised to 400 mg active Oral idronoxil suspension or oral placebo suspension (n=8 active; n= 2 placebo).
11142307|NCT03780465|Experimental|NOX66 400 mg|10 male and female subjects randomised to 400 mg active NOX66 (A) suppository or 400 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
11142308|NCT03780465|Experimental|NOX66 600 mg|10 male and female subjects randomised to 600 mg active NOX66 (A) suppository or 600 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
11142309|NCT03780452||Tibiotalocalcaneal arthrodesis with DynaNail|Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
11142310|NCT03780439||infection group and non-infection group|patients were divided into 2 sub-groups according to the presence of infection or not after radical gastrectomy for gastric cancer.
11142311|NCT03780426|Experimental|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
11142312|NCT03780426|Experimental|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
11142313|NCT03780413|Active Comparator|PR-ESSENCE treatment|The treatment group receives PR-ESSENCE for 10 weeks. Outcome measures are collected pre- and post-treatment, and after 6 months and one year.
11142314|NCT03780413|Active Comparator|Control (TAU)|"The control group receives 10 weeks of treatment as usual (TAU) (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year."
11142315|NCT03780400|Experimental|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
11142316|NCT03780387|Experimental|Inhaled Allergen Challenge|Felis Catus sensitive, mild asthmatics will undergo inhaled allergen challenge.
11142317|NCT03780374|Active Comparator|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
11142318|NCT03780374|Experimental|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
11142319|NCT03780374|Experimental|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
11142320|NCT03780361|Experimental|Aflibercept injection group|"drug: Eylea (aflibercept) (11.12mg/0.278ml) dose: 2mg (0.05ml) usage: With topical anesthesia and intravitreal injection of aflibercpt in aseptic condition.
~frequency and duration: monthly intravitreal aflibercept injections."
11142321|NCT03780348|Experimental|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
11142322|NCT03780348|Active Comparator|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
11142323|NCT03780348|Experimental|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
11142324|NCT03780335||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
11142325|NCT03780335||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
11142326|NCT03780322|Experimental|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
11142327|NCT03780322|Active Comparator|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
11142328|NCT03780309|Active Comparator|EXERCISE|Participants participated in a the exercise training program and engaged in exercise self-monitoring.
11142329|NCT03780309|Experimental|EXERCISE+PEH|Participants participated in the exercise training program and engaged in exercise self-monitoring and blood pressure self-monitoring (daily and before and after exercise).
11142330|NCT03780296|Experimental|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
11142331|NCT03780283|Experimental|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
11142332|NCT03780283|No Intervention|placebo|observation
11142333|NCT03780270|Active Comparator|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.
~=> Group: Fluoride Varnish"
11142334|NCT03780270|Experimental|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.
~=> Group: Curodont Repair + Fluoride Varnish"
11142335|NCT03780270|Experimental|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).
~=> Group: Curodont Repair + Curodont Protect"
11142336|NCT03780257|Experimental|QR-421a|Single dose administration
11142337|NCT03780257|Sham Comparator|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
11142338|NCT03780244|Experimental|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
11142339|NCT03780244|Active Comparator|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
11142342|NCT03780205||Bilateral Group|Patients have bilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 each eye.
11142343|NCT03780205||Unilateral Group|Patients have unilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
11142344|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
11142345|NCT03780179|Experimental|MMRvaxpro|
11142346|NCT03780179|Placebo Comparator|Placebo|
11142347|NCT03780166|Experimental|Parsaclisib|
11142348|NCT03780114||interns|intern pediatric dentists
11142349|NCT03780088|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
11142350|NCT03780075|Experimental|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
11142351|NCT03780075|Experimental|1.85GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
11142352|NCT03780075|Experimental|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
11142353|NCT03780062|Experimental|S100B protein dosing|
11142354|NCT03780049|Experimental|HAIC plus H101|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery
11142355|NCT03780049|Active Comparator|HAIC|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery
11142356|NCT03780036|Experimental|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
11142357|NCT03780036|Experimental|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
11142358|NCT03780010|Experimental|TRC105 + B + P + C|TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
11142359|NCT03779997|Experimental|Video-based DOT Application|
11142360|NCT03779997|No Intervention|Treatment as Usual (TAU)|
11142361|NCT03779971|Placebo Comparator|Control|The placebo comparator will be a fully controlled diet made from typical American foods and containing no beans or pulses.
11142362|NCT03779971|Experimental|Lentil|The lentil arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain lentils.
11142363|NCT03779971|Experimental|Chickpeas|The chickpea arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain chickpeas.
11142364|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
11142365|NCT03779945|Active Comparator|posteriolateral lumbar fusion +bone graft+ PRP|the addition of autologous platelet rich plasma to the bone graft
11142366|NCT03779945|Active Comparator|posteriolateral lumbar fusion+bone graft only|posteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
11142367|NCT03779919|Experimental|High Energy|Extracorporeal shock wave therapy with 0.3 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
11142368|NCT03779919|Experimental|Low Energy|Extracorporeal shock wave therapy with 0.05 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
11142369|NCT03779919|Placebo Comparator|Sham|Extracorporeal shock wave therapy with 0 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
11142370|NCT03779906|Experimental|ISOVUE|Isovue will be given to all subjects per the standard of clinical care.The specific iodine concentration and volume of ISOVUE used during the radiologic procedure will depend on the type of procedure and the standards in place at the site where the procedure is performed.
11142371|NCT03779893|Active Comparator|conventional group|Conventional resin based Pits & fissures sealant 3M™ Clinpro™ Sealant is administrated
11142372|NCT03779893|Experimental|bioactive group|Bioactive Pits & fissures sealant BioCoat® by Premier®.
11142373|NCT03779867|Experimental|Arm I (acute exercise)|Participants undergo a moderate-intensity acute exercise bout over 45 minutes.
11142374|NCT03779867|Active Comparator|Arm II (rest)|Participants rest by sitting for 45 minutes.
11142375|NCT03779854|Experimental|Arm I (chemotherapy, naive T-cell depleted PBSC)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.
~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.
~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.
~TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0.
~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
11142376|NCT03779854|Active Comparator|Arm II (chemotherapy, unmanipulated T cell replete BM)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.
~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.
~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.
~TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0.
~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
11142377|NCT03779841|Experimental|AGN-151607 (250 U)|Injections of 50 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
11142378|NCT03779841|Experimental|AGN-151607 (125 U)|Injections of 25 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
11142379|NCT03779841|Placebo Comparator|Placebo|Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
11142380|NCT03779815|Experimental|[18F]Florbetaben PET/CT imaging|"Maximally 18 subjects with multiple myeloma (up to 6 subjects in whom amyloidosis in suspected and up to 12 subjects in whom amyloidosis is not suspected)
~Intravenous injection of [18F]Florbetaben and PET/CT scanning
~Intervention: Drug ([18F]Florbetaben)"
11142381|NCT03779802|Experimental|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
11142382|NCT03779789|Experimental|vortioxetine|
11142383|NCT03779789|Active Comparator|SSRIs|
11142384|NCT03779776|Experimental|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
11142385|NCT03779776|Placebo Comparator|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
11142386|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
11142387|NCT03779737|Active Comparator|Habitual training|The control group will be monitored passively for the detection of adverse or secondary events.
11142388|NCT03779737|Experimental|Muscular resistance training|This phase includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week.
11142389|NCT03779737|Experimental|Cardiorespiratory training|In stage, a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.
11142390|NCT03779724|Experimental|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
11142391|NCT03779724|Active Comparator|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
11142392|NCT03779711|Experimental|Treatment|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
11142393|NCT03779711|Active Comparator|Control|Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
11142394|NCT03779698|Experimental|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
11142395|NCT03779698|Active Comparator|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
11142396|NCT03779685|Active Comparator|General anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
11142397|NCT03779685|Experimental|Regional anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
11142398|NCT03779672|Active Comparator|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.
~Dose regimen:
~Memantine Hydrochloride
~Week #1: 5 mg id (am), 1 caps
~Week #2: 5 mg bid (am and pm), 2 caps
~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps
~Washout (Weeks #7-8)
~Placebo
~Week #9: id (am), 1 caps
~Week #10: bid (am and pm), 2 caps
~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps"
11142399|NCT03779672|Placebo Comparator|Placebo Memantine Hydrochloride 10 mg|"Placebo
~Week #1: id (am), 1 caps
~Week #2: bid (am and pm), 2 caps
~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps
~Washout (Weeks #7-8) Memantine Hydrochloride
~Week #9: 5 mg id (am), 1 caps
~Week #10: 5 mg bid (am and pm), 2 caps
~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
11142400|NCT03779659|Experimental|Synapse TENS device|SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
11142401|NCT03779659|Active Comparator|Topical anesthetic gel|Topical anesthetic Gel is the active comparator in this study. The topical anesthesia (anesthetic gel) Centrix LolliCaine with 20% benzocaine in single package of 0.3 ml will be used. The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure. This will be done based American Association of Pediatric Dentistry guidelines for the use of local anesthesia.
11142402|NCT03779646|Experimental|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
11142403|NCT03779646|No Intervention|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
11142404|NCT03779633|Experimental|Linoladiol Estradiol|Linoladiol Estradiol cream 6 weeks before surgery of pelvic organ prolapse
11142405|NCT03779633|Placebo Comparator|Placebo|Placebo cream 6 weeks before surgery of pelvic organ prolapse
11142406|NCT03779620|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
11142407|NCT03779607|Active Comparator|IPS e.max Press(lithium di silicate)|Lithium disilicate reinforced glass ceramics are available in the market in two forms according to the technique of manufacturing, either heat pressed ingots or CAD/CAM blocks for milling. The heat pressed lithium disilicate glass ceramic consists of approximately 70% lithium disilicatecrystals(the main crystal phase) having a needle like shape that are embedded in a glassy matrix. The crystals length is about 3 to 6 μm. The heat pressed ingots are fully crystallized and the restoration is fabricated by the lost wax technique where the lithium disilicate ingots are pressed into the investment mold at high temperature. The pressed lithium disilicate has strong flexural strength values(range 400 ± 40 MPa)
11142408|NCT03779607|Experimental|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.
~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
11142409|NCT03779594|Experimental|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
11142410|NCT03779581|Experimental|Exercise Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting. In addition, 7 of the randomly selected patients received De-rotation Breathing Exercises.
11142411|NCT03779581|Active Comparator|Control Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting.
11142412|NCT03779581|Active Comparator|Age Matched Normal Group|The Group consisted of age-matched normal subjects. Following exercises were performed, Postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting.
11142413|NCT03779568|Experimental|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
11142414|NCT03779555||Patients taking lenalidomide for multiple myeloma|-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
11142415|NCT03779542||open-angle group|ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope
11142416|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
11142417|NCT03779529|Active Comparator|Arm label extra-vergin olive oil (EVOO)|Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be >10mg.
11142418|NCT03779529|Active Comparator|Arm label refined olive oil (ROO)|Participants will ingest two tablespoons of refined olive oil during the day: one spoon containing 10 g of refined olive oil at lunch and one at dinner.
11142419|NCT03779516|Active Comparator|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
11142420|NCT03779516|Active Comparator|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
11142421|NCT03779503|Active Comparator|midafilcon A|Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.
11142422|NCT03779503|Active Comparator|somofilcon A|Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.
11142423|NCT03779477|Experimental|Coping with Stress Course|The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
11142424|NCT03779477|No Intervention|Control|There will be no intervention in the control group. If the program will be effective, this group will also undergo the Coping with Stress Program after the termination of the study.
11142425|NCT03779464|Experimental|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
11142426|NCT03779464|Active Comparator|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
11142427|NCT03779451|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery
11142428|NCT03779451|Active Comparator|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily at bedtime starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
11142429|NCT03779451|No Intervention|control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
11142430|NCT03779438|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
11142431|NCT03779438|Placebo Comparator|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
11142432|NCT03779425|Experimental|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
11142433|NCT03779412|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
11142434|NCT03779412|Active Comparator|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
11142435|NCT03779399||Patient with benign ovarian tumor|25 patients with benign ovarian tumor (cystadenoma) were admitted to IInd Department of Gynecology, Lublin Medical University, Lublin, Poland.
11142436|NCT03779399||Patient with borderline tumor|11 women with borderline ovarian tumor were admitted to IInd Department of Gynecology
11142437|NCT03779399||Patient with ovarian cancer|24 women with ovarian cancer were admitted to IInd Department of Gynecology
11142438|NCT03779399||Patient without ovarian pathology|20 patient with unexpleined infertility were admitted to IInd Department of Gynecology
11142439|NCT03779386|Experimental|Music during labor and delivery|Music during labor and delivery
11142440|NCT03779386|No Intervention|No music during labor and delivery|No music during labor and delivery
11142441|NCT03779373|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
11142442|NCT03779373|Experimental|EV1000 monioring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
11142443|NCT03779360|Active Comparator|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
11142444|NCT03779360|Experimental|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
11142445|NCT03779360|Active Comparator|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
11142446|NCT03779347|Experimental|Schistosomiasis treated during pregnancy|Praziquantel 40mg/kg once will be given during pregnancy at second to third trimester
11142447|NCT03779347|Active Comparator|Schistosomiasis treated after pregnancy|Praziquantel 40mg/kg once will be given to parturient after delivery during lactation
11142448|NCT03779347|Experimental|All study participants|UCP-LF CAA and composite diagnostic reference test based on extensive egg microscopy, plus serology, plus qPCR on egg DNA, and plus POC-CC will be used to detect schistosomiasis infection in pregnant women
11142449|NCT03779334|Experimental|Open-label Arm|Participants will be enrolled to receive risdiplam orally once daily at a dose selected to achieve the targeted exposure range
11142450|NCT03779321|Other|Lean panelists|Lean panelists or normal weight panelists with a BMI between 18.5 and 24.9 Acceptability was assessed
11142451|NCT03779321|Other|Obese panelists|Obese panelists with a BMI between 25 and 29.9 Acceptability was assessed
11142452|NCT03779308|Experimental|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
11142453|NCT03779295|Experimental|Pulse laser therapy applied to right side of face|
11142454|NCT03779295|Experimental|Pulse laser therapy applied to left side of face|
11142455|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
11142456|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
11142457|NCT03779269|Experimental|color meditation|only color meditation
11142458|NCT03779269|Experimental|Sound meditation|Only sound mediation
11142459|NCT03779269|Experimental|Color and sound combined meditation|Combined group
11142460|NCT03779269|No Intervention|Control group|Only control group
11142461|NCT03779256||Women with bowel endometriosis.|Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D and 3D transvaginal ultrasound before surgery.
11142462|NCT03779243|Experimental|5mg Melatonin and Sleep Education|Participants will take 5mg Melatonin nightly, 1 hour before bedtime and be provided educational materials to improve sleep hygiene. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits.
11142463|NCT03779243|Placebo Comparator|Placebo Control|"Participants will be given placebo pills to be taken daily 1 hour before bedtime and are a sleep aid. Participants will not receive any sleep education materials. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits."
11142464|NCT03779230|Experimental|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
11142465|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
11142466|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
11143209|NCT03774095|No Intervention|No oil|6-hour oral glucose tolerance test
11142467|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
11142468|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
11142469|NCT03779204|Experimental|Rent subsidies + Mentorship|Participants in this arm (n = 12) will receive rent subsidies (ranging from $400 - $500/month) for 24 months as part of the intervention and be matched with an adult mentor recruited by one of the community partners.
11142470|NCT03779204|Active Comparator|Rent subsidies only|Participants in this arm (n = 12) will receive rent subsidies only (ranging from $400 - $500/month) for 24 months as part of the comparator group intervention. This group will not receive mentorship.
11142471|NCT03779191|Experimental|Intervention|Patients in this intervention arm will receive the therapeutic combination of Alectinib dosed PO 600 mg bis in die (BID) with meals and Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
11142472|NCT03779178|Experimental|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
11142473|NCT03779178|Placebo Comparator|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
11142474|NCT03779152||non asthmatic subjects|
11142475|NCT03779152||intermittent asthmatics|
11142476|NCT03779152||severe asthmatics sensitive to corticosteroids|
11142477|NCT03779152||severe asthmatics resistant to corticosteroids|
11142478|NCT03779152||moderate asthmatics|
11142479|NCT03779139|Active Comparator|Intrahepatic islets alone|
11142480|NCT03779139|Experimental|Intrahepatic and omental pouch islets|
11142481|NCT03779139|Sham Comparator|Normal Volunteers|
11142482|NCT03779126|Experimental|Active comparator|Low frequency electrical stimulation for 60 minutes, three times a week during 60 days.
11142483|NCT03779126|Experimental|Other|High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
11142484|NCT03779126|Experimental|Experimental group|Low and High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
11142485|NCT03779126|Placebo Comparator|Placebo|Placebo electrical stimulation for 60 minutes, three times a week during 60 days. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current
11142486|NCT03779113|Experimental|Treatment|All patients to received study drug (HMPL-523)
11142487|NCT03779100|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11142488|NCT03779087|Experimental|10d TL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
11142489|NCT03779087|Active Comparator|10d AL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, amoxicillin 500 mg and metronidazole 250 mg q.i.d. for 10 days
11142490|NCT03779074|Active Comparator|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
11142491|NCT03779074|Experimental|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
11142492|NCT03779074|Experimental|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
11142493|NCT03779061|Experimental|Remimazolam Tosilate|
11142494|NCT03779061|Active Comparator|Propofol|
11142495|NCT03779048|Active Comparator|Behavioral Treatment + Placebo|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.
~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
11142496|NCT03779048|Active Comparator|Behavioral Treatment + Medication|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.
~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
11142497|NCT03779035|Experimental|Gemcitabine plus Capecitabine|Gemcitabine (1000 mg per square meter) on days 1 and 8 Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
11142498|NCT03779035|Active Comparator|Capecitabine|Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
11142499|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
11142500|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
11142501|NCT03779009|Experimental|Tracer injection|
11142502|NCT03778996|Experimental|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
11142503|NCT03778996|Experimental|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
11142504|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
11142505|NCT03778983||Control group|The reference group included same age- and gender-matched children without a chronic health condition.
11142506|NCT03778970|Experimental|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
11142507|NCT03778970|Active Comparator|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
11142508|NCT03778957|Experimental|Arm A|Transarterial Chemoembolization (TACE) in combination with Durvalumab
11142509|NCT03778957|Experimental|Arm B|Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab
11142510|NCT03778957|Placebo Comparator|Arm C|Transarterial Chemoembolization (TACE) in combination with Placebos
11142511|NCT03778944|Active Comparator|M group|Mannitol infusion
11142512|NCT03778944|Active Comparator|D group|Dopamine infusion
11142513|NCT03778944|Active Comparator|C group|Adequate hydration
11142514|NCT03778931|Experimental|Elacestrant|Subjects in Arm 1 will receive elacestrant
11142515|NCT03778931|Active Comparator|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
11142516|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
11142517|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
11142518|NCT03778905||stroke patient with complete post-acute care hospitalization|This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.
11142519|NCT03778892|Experimental|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
11142520|NCT03778892|No Intervention|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
11142521|NCT03778879|Experimental|Group 1:With CCX872-B|Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
11142522|NCT03778879|No Intervention|Group 2:Without CCX872-B|SBRT Alone: 25 Gy in 5 fractions over 5-7 days
11142523|NCT03778866|Experimental|Bicarbonate-buffered Medium|
11142524|NCT03778866|No Intervention|HEPES-MOPS-buffered Medium|
11142525|NCT03778853|Experimental|Anlotinib Hydrochloride|Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
11142526|NCT03778827|Experimental|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of one weekly 60-minute individual parent training session and 12 weekly hours ( 3 hours per day for 4 days per week) with the child in center-based therapy environment for a total of 13 weekly treatment hours.
11142527|NCT03778827|No Intervention|Delayed Treatment Group (DTG)|Delayed Treatment Group will consist of treatment as usual. At the end of controlled phase, participants in the DTG will be offered PRT-C in a preschool setting in an open-label fashion with a design similar to the double-blind phase.
11142528|NCT03778814|Experimental|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
11142529|NCT03778801||fibromyalgia syndrome|Thirty patients with a diagnosis of fibromyalgia syndrome according to the 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria and a disease duration of longer than three months
11142530|NCT03778801||chronic neck pain|30 patients with chronic neck pain lasting for more than three months and didn't meet 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria.
11142531|NCT03778801||healthy controls|30 healthy controls without pain or additional disease
11142532|NCT03778788|Active Comparator|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
11142533|NCT03778788|Active Comparator|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
11142568|NCT03778489|Experimental|Hypertensive|Men and women in age-group 35-65 years Resting blood pressure of >140/90 mmHg non or only anti-hypertensive medication
11142569|NCT03778489|Active Comparator|Control|Men and women in age-group 35-65 years Resting blood pressure of <140/90 mmHg no medication
11142534|NCT03778788|Active Comparator|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
11142535|NCT03778775||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and liver stiffness measurement by FibroTouch.
11142536|NCT03778762|Active Comparator|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
11142537|NCT03778762|Placebo Comparator|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
11142538|NCT03778749|Experimental|electromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
11142539|NCT03778749|Experimental|acceleromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
11142540|NCT03778749|Experimental|acceleromyographic NMT monitoring at the eyebrow|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
11142541|NCT03778736|Experimental|Cumulase denudation|
11142542|NCT03778736|No Intervention|Hyaluronidase denudation|
11142543|NCT03778723|Experimental|Total intravenous anesthesia (TIVA)|Patients will receive total intravenous anesthesia using Propofol and Midazolam
11142544|NCT03778723|Active Comparator|Inhalation Anesthesia|Patients will receive Inhalation anesthesia using Sevoflurane
11142545|NCT03778697|Experimental|Adolescent Endosleeve|Patients who will undergo endoscopic sleeve gastroplasty
11142546|NCT03778684|Experimental|Normal Body mass index without central obesity|
11142547|NCT03778684|Experimental|High Body mass index with central obesity|
11142548|NCT03778671|Experimental|Group B|Patients will receive bupivacaine 0.25%
11142549|NCT03778671|Active Comparator|Group D|Patients will receive bupivacaine 0.25% + 1 µg/kg dexmedetomedine .
11142550|NCT03778671|Active Comparator|Group F|Patients will receive bupivacaine 0.25% + 1µg/kg fentanyl
11142551|NCT03778658|Experimental|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
11142552|NCT03778632|Experimental|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
11142553|NCT03778632|Active Comparator|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
11142554|NCT03778619|Experimental|single arm|"Phase 1
~MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly
~Group 1: 1 x 10^7 cells/㎏
~Group 2: 3 x 10^7 cells/㎏
~Group 3: 9 x 10^7 cells/㎏
~Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.
~Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)
~Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle
~Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1."
11142555|NCT03778606|Experimental|Potato starch supplementation|Twelve patients found to be colonized with C. difficile will undergo twice a day potato starch supplementation.
11142556|NCT03778593|Experimental|mFOLFIRINOX|D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks
11142557|NCT03778580|Experimental|pyridoxamine|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
11142558|NCT03778580|Placebo Comparator|identical placebo|identical placebo po bid for one year
11142559|NCT03778567|Other|lamivudine + nucleotide analogue|At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued
11142560|NCT03778554|Experimental|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice
~Bisoprolol up to a total dose of 10 mg daily
~Carvedilol up to a total dose of 50 mg daily
~Metoprolol succinate up to a total dose of 200 mg daily
~Nebivolol up to a total dose of 10 mg daily"
11142561|NCT03778554|No Intervention|No beta blocker treatment|Standard care without beta blocker treatment
11142562|NCT03778541|Experimental|CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
11142563|NCT03778541|Active Comparator|RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
11142564|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
11142565|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
11142566|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
11142567|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
11142612|NCT03778203|Experimental|Cohort 3A|Birth date between 2006 and 2009 receiving seasonal inactivated influenza vaccine (IIV)
11142570|NCT03778476|Experimental|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
11142571|NCT03778476|No Intervention|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
11142572|NCT03778463|Experimental|Synovectomy|
11142573|NCT03778463|No Intervention|No synovectomy|
11142574|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
11142575|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
11142576|NCT03778437|Active Comparator|landmark techniques|Subclavian vein catheterization is performed without the guidance of ultrasound. The needle was inserted 1 cm inferior and 1 cm lateral to the junction of the middle and medial thirds of the clavicle (infraclavicular approach)
11142577|NCT03778437|Experimental|ultrasound-guided with aiming method|Subclavian vein catheterization is performed with our newly proposed aiming method with the guidance of ultrasound.
11142578|NCT03778437|Experimental|ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique.
11142579|NCT03778411||cACLD|200 people with compensated advanced chronic liver disease who have not undergone liver transplant
11142580|NCT03778411||cACLD-post transplant|100 people with compensated advanced chronic liver disease who have previously undergone liver transplant
11142581|NCT03778398|Experimental|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
11142582|NCT03778385|Experimental|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
11142583|NCT03778385|Experimental|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
11142584|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
11142585|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
11142586|NCT03778359||Gonadotropin-releasing hormone agonist treatment|Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment
11142587|NCT03778359||Intrauterine device treatment|Endometriosis post-operative intrauterine device treatment
11142588|NCT03778359||Hormone therapy|Endometriosis post-operative hormone therapy
11142589|NCT03778359||Oral contraceptive|Endometriosis post-operative oral contraceptive
11142590|NCT03778346|Experimental|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.
11142591|NCT03778333|Experimental|Open label single arm study|All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.
11142592|NCT03778320|Experimental|CTP-692|
11142593|NCT03778320|Active Comparator|D-Serine|
11142594|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
11142595|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
11142596|NCT03778294|Experimental|Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)|Patients receive 18F-DOPA IV and undergo PET/MRI or PET/CT imaging scan. Patients then receive proton beam radiotherapy over 5 or 10 consecutive days excluding weekend and standard of care temozolomide on days 1-7 or 1-14. Beginning course 2, patients receive standard of care temozolomide on days 1-5. Courses with temozolomide repeat every 28 days for up to 7 courses in the in the absence of disease progression or unacceptable toxicity.
11142597|NCT03778281|Experimental|Baclofen group|Treatment of Chemotherapy-related Hiccups With Baclofen
11142598|NCT03778281|Other|Methoxyclopramide group|Treatment of Chemotherapy-related Hiccups With Methoxyclopramide
11142599|NCT03778281|Experimental|Baclofen group 2|After 3 days, if the metoclopramide treatment is ineffective, it will cross into the baclofen group 2.
11142600|NCT03778281|Other|Methoxyclopramide group 2|After 3 days, if the baclofen treatment is ineffective, it will cross into the metoclopramide group 2.
11142601|NCT03778268|Experimental|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
11142602|NCT03778255|Experimental|Undergoing sentinel lymph node biopsy|
11142603|NCT03778242|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1 gm tranexamic acid ( 2 ampoules) in 100 ml saline by slow infusion
11142604|NCT03778242|Active Comparator|oxytocin plus placebo to TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus2 placebo ampoules to tranexamic acid(TA) in 100 ml saline by slow infusion
11142605|NCT03778229|Experimental|osimertinib + savolitinib|osimertinib + savolitinib
11142606|NCT03778216|Experimental|FBT-ARFID|Family Based Treatment of child ARFID
11142607|NCT03778216|No Intervention|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
11142608|NCT03778203|Experimental|Cohort 1A|6-12 months old receiving seasonal inactivated influenza vaccine (IIV)
11142609|NCT03778203|Experimental|Cohort 1B|3-12 months old with natural influenza infection
11142610|NCT03778203|Experimental|Cohort 2A|Greater than 12 months of age with birth date after 2009 receiving seasonal inactivated influenza vaccine (IIV)
11142611|NCT03778203|Experimental|Cohort 2B|Greater than 12 months of age, birth date after 2009 with natural influenza infection
11142613|NCT03778203|Experimental|Cohort 3B|Birth date between 2006 and 2009 with natural influenza infection
11142614|NCT03778203|Experimental|Cohort 4A|Birth date between 2003 and 2006 receiving seasonal inactivated influenza vaccine (IIV)
11142615|NCT03778203|Experimental|Cohort 4B|Birth date between 2003 and 2006 with natural influenza infection
11142616|NCT03778190|Experimental|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
11142617|NCT03778177|Experimental|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
11142618|NCT03778164|Experimental|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
11142619|NCT03778164|Active Comparator|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
11142620|NCT03778151|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus to modulate DMN activity. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
11142621|NCT03778151|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The SHAM protocol will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
11142622|NCT03778138|Experimental|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
11142623|NCT03778112|Experimental|Negative mpMRI Prostate Scan|SBRT to the whole prostate
11142624|NCT03778112|Experimental|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
11142625|NCT03778099|Experimental|Cinnamon Group|Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
11142626|NCT03778099|Placebo Comparator|Placebo Group|"Placebo capsules will contain 450 mg of starch and 50 mg of cinnamon powder (to improve blindness regarding taste and odor). Color, shape, and size of placebo capsules will be exactly the same as the cinnamon capsules.
~2g/day along with clomiphene citrate"
11142627|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
11142628|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
11142629|NCT03778073|Experimental|TG-1501|TG-1501 will be administered as a 60-minute intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle.
11142630|NCT03778060|Experimental|Transcutaneous stimulation|Participants in the clinical study will consist of subjects with essential tremor who are scheduled more than 3 months in advance to undergo deep brain stimulation surgery for treatment of essential tremor at Mayo Clinic. Subjects will wear a Cala TWO stimulator to reduce hand tremors.
11142631|NCT03778047|Experimental|enzalutamide|160mg
11142632|NCT03778047|Experimental|HC-1119|To be determined
11142633|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
11142634|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
11142635|NCT03778021|Experimental|Intervention Group|Students in the intervention group will receive the curriculum and school garden during the second academic school year (Year 2)
11142636|NCT03778021|Active Comparator|Delayed Intervention Group|For the delayed intervention group schools, students will receive the intervention at the beginning of Year 3
11142637|NCT03778008|Experimental|Recombinant bovine basic fibroblast growth factor|
11142638|NCT03778008|Active Comparator|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
11142639|NCT03777982|Experimental|LHRH Agonist or Antagonist|-LHRH agonist or antagonist should be prescribed per standard of care
11142640|NCT03777982|Experimental|Prednisone+Apalutamide+Abiraterone Acetate +LHRH Agonist|"LHRH agonist or antagonist should be prescribed per standard of care
~Abiraterone acetate will be taken once daily
~Prednisone will be taken twice daily
~Apalutamide will be taken once daily"
11142641|NCT03777956|Active Comparator|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
11142642|NCT03777956|Placebo Comparator|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
11142643|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
11142644|NCT03777930|Experimental|chemotherapy group|the patients were recepted chemotherapy alone
11142645|NCT03777930|Experimental|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
11142646|NCT03777930|Experimental|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
11142647|NCT03777930|Experimental|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
11142648|NCT03777917|Experimental|Belotero Balance®|
11142649|NCT03777917|No Intervention|No treatment|
11142711|NCT03777488|Experimental|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:
~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
11142650|NCT03777904||Children with high serum ferritin|Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.
11142651|NCT03777891|Experimental|group A|received Silicone gel phonophoresis: Silicone gel (strataderm) was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes. The Ultrasound Device is Sonopulse 590: Nonius, sonopuls 590, S.NO.03-202 type 14663.900 was a therapeutic ultrasound device manufactured by Enraf Holland.
11142652|NCT03777891|Experimental|group B|received Contractubex phonophoresis: Contractubex (Merz Pharma, Frankfurt, Germany was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes.
11142653|NCT03777891|Experimental|group C|received Corticosteroid phonophoresis: A thin film of coupling medium (gel) was put on the hypertrophic scar and sufficient quantity of Triamcinolone was put by a syringe over the whole scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes
11142654|NCT03777878|Active Comparator|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
11142655|NCT03777878|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
11142656|NCT03777878|Active Comparator|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
11142657|NCT03777865|Experimental|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
11142658|NCT03777852|Experimental|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
11142659|NCT03777852|Active Comparator|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
11142660|NCT03777826|Other|Open label (1 arm)|Open label use of study product (post-marketing): PKU Synergy
11142661|NCT03777813|Experimental|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):
~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)
~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:
~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)
~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node
~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):
~IV oxaliplatin 85 mg/m² in 2 h on D1
~IV Leucovorin 200 mg/m² in 2 h on D1, followed by
~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by
~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
11142662|NCT03777813|Active Comparator|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:
~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)
~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node
~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):
~IV oxaliplatin 85 mg/m² in 2 h on D1
~IV Leucovorin 200 mg/m² in 2 h on D1, followed by
~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by
~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
11142663|NCT03777800|Experimental|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
11142664|NCT03777800|Active Comparator|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
11142665|NCT03777787|Experimental|Bitter|A single intragastric administration of denatonium benzoate (1 µmol/kg)
11142666|NCT03777787|Placebo Comparator|Placebo|A single intragastric administration of placebo (water)
11142667|NCT03777774|Active Comparator|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
11142668|NCT03777774|Active Comparator|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
11142669|NCT03777774|Active Comparator|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
11142670|NCT03777761|Experimental|Treatment Sequence ABC|tucatinib + placebo + moxifloxacin (administered in sequential treatment periods)
11142671|NCT03777761|Experimental|Treatment Sequence CAB|moxifloxacin + tucatinib + placebo (administered in sequential treatment periods)
11142672|NCT03777761|Experimental|Treatment Sequence BCA|placebo + moxifloxacin + tucatinib (administered in sequential treatment periods)
11142673|NCT03777761|Experimental|Treatment Sequence CBA|moxifloxacin + placebo + tucatinib (administered in sequential treatment periods)
11142674|NCT03777761|Experimental|Treatment Sequence ACB|tucatinib + moxifloxacin + placebo (administered in sequential treatment periods)
11142675|NCT03777761|Experimental|Treatment Sequence BAC|placebo + tucatinib + moxifloxacin (administered in sequential treatment periods)
11142676|NCT03777748|Experimental|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
11142677|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
11142678|NCT03777722|Experimental|Aim 1: Active Intervention then Placebo|Tailored Lighting intervention (TLI). The active TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The active lighting intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the placebo control intervention for 8 weeks.
11142679|NCT03777722|Experimental|Aim 1: Placebo Intervention then Active|The placebo lighting intervention is designed to have no effect on the circadian system. The control intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the active tailored lighting intervention for 8 weeks.
11142680|NCT03777709|Experimental|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
11142681|NCT03777709|No Intervention|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
11142682|NCT03777696|Active Comparator|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
11142683|NCT03777696|Active Comparator|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
11142684|NCT03777696|Placebo Comparator|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
11142685|NCT03777683|Experimental|Dietary Supplement (OLIGOPIN)|Intervention group will receive French maritime pine bark extract supplement (OLIGOPIN) in the form oral capsules containing 50 mg French maritime pine bark extract plus 130 mg Microcrystalline Cellulose. OLIGOPIN powder of each capsule are dissolved in 10 ml deionized water and given to patients via gavage (3 capsule per day) for 10 days
11142686|NCT03777683|Placebo Comparator|Placebo|Control group will receive oral capsules containing 130 mg Microcrystalline Cellulose with 10 ml of deionized water via gavage (3 capsule per day) for 10 days.
11142687|NCT03777670||Cases|Infants with suspected sepsis
11142688|NCT03777670||Controls|Infants with no suspicion of sepsis
11142689|NCT03777657|Experimental|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
11142690|NCT03777657|Placebo Comparator|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
11142691|NCT03777644|Experimental|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
11142692|NCT03777644|Placebo Comparator|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
11142693|NCT03777631|No Intervention|Standard medical therapy group|The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
11142694|NCT03777631|Active Comparator|Catheter ablation group|Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed >100 CA annually were participated in the present study in principle.
11142695|NCT03777605|Experimental|"NTG1523, rapid absorbable capsule"|"Nitroglycerine 0.4 milligram taken as ordinary tablets or NTG1523 rapid absorbable capsule once in the morning, and subsequently blood samples and observations for 2 hours are performed"
11142696|NCT03777592|Active Comparator|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
11142697|NCT03777592|Sham Comparator|ESPB with saline|ESPB will be performed using 20ml of saline.
11142698|NCT03777579|Experimental|JS001 Plus Nab-Paclitaxel|Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
11142699|NCT03777579|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
11142700|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
11142701|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
11142702|NCT03777553|Experimental|VETNET|Narrative Exposure Therapy for Justice-Involved Veterans
11142703|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients > 85 years; Elective and urgent surgery.
11142704|NCT03777514|Active Comparator|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.
~Participants in this group will also receive oral vitamin C as a placebo."
11142705|NCT03777514|Active Comparator|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
11142706|NCT03777501|Experimental|non-random whole body vibration group|Each participant will receive the non-random type whole body vibration treatment about one hour after the administration of medicine.
11142707|NCT03777501|Active Comparator|conventional therapy group|For the conventional therapy group, participants will receive the occupational therapy including dynamic balance training and functional ambulatory training. Each session is 10 minutes.
11142708|NCT03777488|Experimental|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:
~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
11142709|NCT03777488|Experimental|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:
~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
11142710|NCT03777488|Experimental|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:
~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
11142795|NCT03776903||non-endemic|Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.
11142712|NCT03777488|Experimental|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:
~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
11142713|NCT03777488|Experimental|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:
~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
11142714|NCT03777475|Experimental|low dose|low oxaliplatin (85mg/m2)
11142715|NCT03777475|Active Comparator|high dose|high oxaliplatin (135mg/m2)
11142716|NCT03777462|Active Comparator|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
11142717|NCT03777462|Experimental|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
11142718|NCT03777462|Experimental|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
11142719|NCT03777449||Vertical bone loss|Infra-osseous defects
11142720|NCT03777449||Horizontal bone loss|Supra-osseous defects
11142721|NCT03777449||Combined bone loss|Combined supra-osseous and infra-osseous defects
11142722|NCT03777436|Experimental|Arm A- Apremilast with Placebo|Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
11142723|NCT03777436|Experimental|Arm B - Apremilast 30 mg|All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
11142724|NCT03777423|Experimental|PEEK framework partial dentures|High performance ketone polymers introduced lately.These polymer-based frameworks provide better esthetics, higher elasticity, lighter in weight, have low water sorption and solubility, and are easily repaired and reproduced.
11142725|NCT03777423|Active Comparator|Cobalt-chromium framework partial dentures|it is considered the gold standard framework. These frameworks are less bulky with high strength, conduct heat and electricity well, and have good durability. some disadvantages include hypersensitivity, adverse tissue reactions and bad aesthetics.
11142726|NCT03777410||Vanguard|Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
11142727|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
11142728|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
11142729|NCT03777345|Active Comparator|cobalt-chromium framework partial dentures|It's the gold standard biocompatible metal alloy used in thin sections, provide high strength and stiffness ,conduct heat and cold for a more natural experience, and is resistant to corrosion but their disadvantages include esthetic issues with metal display, oral galvanism, adverse tissue reactions,and osteolysis of abutment teeth.
11142730|NCT03777345|Experimental|PEEK framework partial dentures|It's a promising polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
11142731|NCT03777332|Experimental|APL-2 15 mg/0.1 mL Monthly for 24 months|
11142732|NCT03777319|Experimental|Spironolactone|Twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
11142733|NCT03777319|Active Comparator|Prednisolone|Twelve subjects will be prescribed a standard clinical dose of prednisolone of 0.75 mg/kg/day or weekend dosing of 5 mg/kg/day as per sites standard of care. The prednisolone will be provided will be provided as suspension.
11142734|NCT03777306|Experimental|ARM A EARLY INTERVENTION GROUP|In Arm A, the intervention group, the participants will start on the program immediately. The participants will receive MPI educational program, implemented in parallel with standard of care treatment. The MPI is implemented at the time of enrollment x 12 weeks
11142735|NCT03777306|Experimental|ARM B DELAYED INTERVENTION GROUP|Arm B, is a wait-list control group that will serve as the control. The wait-list control group will be observed for an initial 12 week period while receiving usual care and then have the educational intervention implemented from week 12-24 in parallel with standard of care
11142736|NCT03777293|Experimental|training cohort|ultrasound viscoelasticity
11142737|NCT03777293|Other|testing cohort|ultrasound viscoelasticity
11142738|NCT03777280|Experimental|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
11142796|NCT03776890|Experimental|DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=30) will be recruited to participate.
11142739|NCT03777280|Active Comparator|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
11142740|NCT03777267|Experimental|Experimental: Active CR|For this single arm, open label, exploratory trial this will be the intervention arm using active CR.
11142741|NCT03777254|Experimental|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E
~Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E
~Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E
~Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
11142742|NCT03777241|Active Comparator|Behavioral Intervention Team|The participants in this arm will receive the Behavioral Intervention Team.
11142743|NCT03777241|Active Comparator|Standard of Care|The participants in this arm will receive the standard of care.
11142744|NCT03777228||Control|Individuals without traumatic brain injury
11142745|NCT03777228||Mild TBI|Individuals with mild traumatic brain injury
11142746|NCT03777228||Moderate to Severe TBI|Individual with moderate to severe traumatic brain injury
11142747|NCT03777215|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of angiotensin-(1-7). The doses are: 2, 4, and 8 ng/kg/min. Each dose will be maintained for 10 minutes, with the highest dose maintained for an additional 90 minutes. The total infusion period is 120 minutes.
11142748|NCT03777215|Placebo Comparator|Placebo|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7). The total infusion period is 120 minutes.
11142749|NCT03777202|Experimental|High-flow nasal oxygen during sleep endoscopy|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
11142750|NCT03777202|Active Comparator|Low-flow nasal oxygen during sleep endoscopy|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
11142751|NCT03777189|Experimental|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
11142752|NCT03777176|Experimental|Standard of Care + dasiglucagon|8 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
11142753|NCT03777176|Other|Standard of Care|4 weeks of standard of care + 4 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
11142754|NCT03777163|Other|Butantan Trivalent Influenza Vaccine|"Butantan Institute Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen
~Patients will receive one dose (0,5 ml) via intramuscular injection."
11142755|NCT03777163|Other|Sanofi Trivalent Influenza Vaccine|"Sanofi Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen
~Patients will receive one dose (0,5 ml) via intramuscular injection."
11142756|NCT03777150|Experimental|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
11142757|NCT03777150|Experimental|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
11142758|NCT03777137||TMS during heat pain stimuli|This is a single institution, single-blinded, long-term exploratory study using participant as his/her own control to evaluate and compare the analgesic effect of experimental heat pain of TMS during early versus late times on a vigilance behaviors toward pain (CPT, Continuous Performance Task). Vigilance behaviors include errors, reaction times and activation.
11142759|NCT03777124|Experimental|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
11142760|NCT03777124|Active Comparator|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
11142761|NCT03777111|Active Comparator|Single Task Training Group|"Gait and balance exercises will be applied in single task training group.
~Semi-tandem, tandem stand with eyes open and close
~One leg stance with eyes open and close
~Gait exercises; walking forwards, backwards, sidewards, semi-tandem and tandem walking
~Reaching forward and sidewards with eyes open and close"
11142762|NCT03777111|Experimental|Dual Task Training Group|"The exercises given in the single task training group will be combined with the cognitive tasks.
~Semi-tandem, tandem stand with recall a sequence of numbers
~One leg stance with writing pre-defined letters or words with other foot
~Semi-tandem or tandem walking with saying previous number (one or two previous) from number that researcher has given before
~Walking sidewards with collecting numbers that researcher has given
~Walking backwards with counting forward by one (then two or three)
~Reaching forward with counting backward one (then two or three)
~Reaching sidewards with saying next number (one or two next) from number that researcher has given before"
11142763|NCT03777085|Experimental|TQB2303|
11142764|NCT03777085|Active Comparator|Rituximab|
11142765|NCT03777059|Active Comparator|Atogepant 30 mg|Taken once daily
11142766|NCT03777059|Active Comparator|Atogepant 60 mg|Taken once daily
11142767|NCT03777059|Placebo Comparator|Placebo|Taken once daily
11142768|NCT03777059|Active Comparator|Atogepant 10 mg|Taken once daily
11142769|NCT03777046|No Intervention|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
11142770|NCT03777046|Active Comparator|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
11142831|NCT03776747|Active Comparator|Group Two: Supine MRI scans|Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
11142832|NCT03776734|Experimental|cryotherapy application|effect of cold application
11142771|NCT03777046|Experimental|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
11142772|NCT03777033|No Intervention|Control Group|Patients after thyroidectomy will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.
11142773|NCT03777033|Experimental|Study group|Intervention: the patients will be given prophylactically ca and vit D. Patients after thyroidectomy will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb Intervention: The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days)
11142774|NCT03777020|Experimental|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
11142775|NCT03777020|Other|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
11142776|NCT03777007|Experimental|Experimental|The application used is build upon the company's category-defining, SPARTA Platform and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
11142777|NCT03776994|Experimental|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate
~Vaccinations on Day 0, Day 28, and Day 140"
11142778|NCT03776994|Experimental|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone
~Vaccinations on Day 0, Day 28, and Day 140"
11142779|NCT03776994|Experimental|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone
~Vaccinations on Day 0, Day 28, and Day 140"
11142780|NCT03776994|Experimental|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)
~Vaccinations on Day 0, Day 28, and Day 140"
11142781|NCT03776994|Experimental|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)
~Vaccinations on Day 0, Day 28, and Day 140"
11142782|NCT03776994|Experimental|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)
~Vaccinations on Day 0, Day 28, and Day 140"
11142783|NCT03776981|No Intervention|Baseline Gait Comparisons of Groups|Determine if kinetic (time to first peak ground reaction force [T1] and second peak ground reaction force [F2], both in the sagittal plane) and kinematic (peak stance knee flexion angle [KFA] and external knee adduction moment [KAM]) gait variables, and speed, differ between patients with KOA and age and gender matched controls during self-selected paced ambulation, and determine which ones have predictive relationships with Knee Injury and Osteoarthritis Outcome Score (KOOS) scores in the patients with KOA.
11142784|NCT03776981|Experimental|Gait with core activation|Determine if volitional core activation alters gait kinetics (T1 and F2), kinematics (KFA and KAM), and speed in patients with and without KOA during self-selected paced ambulation when compared to ambulating without volitional core activation, and whether the subjective pain complaints are significantly changed in the group with KOA. Determine whether there are baseline differences in core activation between those with and without KOA.
11142785|NCT03776981|Experimental|Knee OA Gait After core stabilization|Determine if a six-week core stabilization program alters KOOS score, and the kinetics (T1 and F2), kinematics (KFA and KAM), and speed of gait in patients with KOA during self-selected paced ambulation as compared to their pre-intervention baselines. Determine if there is a predictive relationship between the number of completed intervention sessions performed and these observed changes.
11142786|NCT03776968|Experimental|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
11142787|NCT03776955|Experimental|Oral Carvedilol|6.25 mg or 12.5 mg if tolerated
11142788|NCT03776955|Placebo Comparator|Oral Placebo|
11142789|NCT03776929|No Intervention|Standard Care|No intervention - Standard care only. Group of 32 subjects
11142790|NCT03776929|Experimental|Dialectical Behavioral Therapy|Dialectical Behavioral Therapy in addition to standard care. Four hour and a half group sessions (or one-on-one sessions, if not enough for a group session) commencing after surgery while still inpatient. Each session is designed to stand-alone, allowing for enrolling patients on a rolling basis.
11142791|NCT03776916|Experimental|Group 1|"Simethicone administration 20-30 min before the procedure:
~Patients intake simethicone solution 20-30 min before the procedure."
11142792|NCT03776916|Experimental|Group 2|"Simethicone administration 31-60 min before the procedure:
~Patients intake simethicone solution 31-60 min before the procedure."
11142793|NCT03776916|Experimental|Group 3|Simethicone administration >60 min before the procedure; Patients intake simethicone solution >60 min before the procedure.
11142794|NCT03776903||endemic|Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.
11142797|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.
~The participation in the study will consist in:
~Plasmatic collection at the time of AIS, for study of plasma biomarkers
~Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
11142798|NCT03776864|Experimental|Treatment (pembrolizumab, umbralisib)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib PO daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11142799|NCT03776851|Experimental|Erythropoietin|Erythropoietin plus standard of care (RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability)
11142800|NCT03776851|No Intervention|No Intervention|Standard of care: RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability
11142801|NCT03776838|Experimental|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
11142802|NCT03776838|Active Comparator|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
11142803|NCT03776825||Perianal Crohn's Disease|Permacol Paste injection
11142804|NCT03776812|Experimental|Continuous Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
11142805|NCT03776812|Experimental|Intermittent Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
11142806|NCT03776812|Active Comparator|Nab-paclitaxel Comparator|Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
11142807|NCT03776799|Other|Stent-avoiding approach|using clinically proven drug coated balloons
11142808|NCT03776799|Other|Stent-based approach|using drug eluting nitinol stents. Interwoven nitinol stents in heavily calcified lesions at the operator's discretion.
11142809|NCT03776786|Experimental|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
11142810|NCT03776786|Placebo Comparator|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11142811|NCT03776786|Experimental|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
11142812|NCT03776786|Experimental|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
11142813|NCT03776786|Experimental|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
11142814|NCT03776786|Experimental|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
11142815|NCT03776786|Experimental|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142816|NCT03776786|Placebo Comparator|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142817|NCT03776786|Experimental|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142818|NCT03776786|Placebo Comparator|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142819|NCT03776786|Experimental|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142820|NCT03776786|Placebo Comparator|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142821|NCT03776786|Experimental|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142822|NCT03776786|Placebo Comparator|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
11142823|NCT03776773|Active Comparator|patients AR (+) and sleep apnea (+)|Patients with AR and obstructive sleep apnea (OSA) will have sleep and pollution exposure recordings
11142824|NCT03776773|Active Comparator|AR (-) and sleep apnea (+)|Patients without allergic rhinitis (+ sleep apnea) will have sleep and pollution exposure recordings
11142825|NCT03776773|Active Comparator|AR (+) and sleep apnea (-)|Patients with allergic rhinitis but no sleep apnea will have sleep and pollution exposure recordings
11142826|NCT03776773|Sham Comparator|AR (-) and sleep apnea (-)|Volunteers without allergic rhinitis and no sleep apnea will have sleep and pollution exposure recordings
11142827|NCT03776760||Fingerstick Point of Care GeneXpert HCV Test|Participants will have HCV testing using the finger-stick point of care GeneXpert quantitative HCV RNA assay.
11142828|NCT03776760||Treat - SOF/VEL|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - sofosbuvir/velpatesvir
11142829|NCT03776760||Treat - G/P|Participants with active HCV infection will be offered treatment with one of two pan-genoptyic regimens available in Australia - glecaprevir/pibrentasvir
11142830|NCT03776747|Experimental|Group One: Prone MRI Scans|Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
11142835|NCT03776708|Experimental|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
11142836|NCT03776708|Sham Comparator|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
11142837|NCT03776695|Experimental|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11142838|NCT03776695|Placebo Comparator|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11142839|NCT03776695|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11142840|NCT03776695|Placebo Comparator|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11142841|NCT03776695|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11142842|NCT03776695|Placebo Comparator|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11142843|NCT03776695|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11142844|NCT03776695|Placebo Comparator|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
11142845|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
11142846|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
11142847|NCT03776669|Active Comparator|LSG alone|"Intervention: laparoscopic sleeve gastrectomy alone.
~LSG will be performed laparoscopically via a 5-port technique. The greater omentum is dissected by using the 5-mm laparoscopic LigaSure or Harmonic from 4 cm proximal to the pyloric ring to the angle of His. Sleeve calibration is done by a 36-French bougie inserted along the lesser curvature. Then the stomach is transected with sequential firings of linear green, gold, and blue 60 mm staplers starting about 4 cm proximal to the pylorus and ending approximately 2 cm distal to the left of the esophagus. The staple-line of the remnant gastric tube is oversewn with 3-0 V-Loc to prevent leakage and hemorrhage."
11142848|NCT03776669|Experimental|LSG + HHR|"Intervention: concomitant laparoscopic sleeve gastrectomy + hiatal hernia repair.
~The surgical detail of LSG is the same as described in LSG alone arm, and the surgical detail of HHR is described as below.
~The hiatus is approached from the right side of the EGJ, through the lesser omentum. The hiatal defect is repaired by 1-0 Surgilon interruptedly, and then a commercialized U-shaped Biodesign Hiatal Hernia Graft is placed to the EGJ to cover the posterior side but spare the anterior side of the hiatus. Care must be taken to avoid direct contact of mesh to the esophagus to avoid any unnecessary complication. After the mesh is appropriately placed and oriented, 2 ml of TISSEEL solution for sealant is applied all over the mesh for fixation."
11142849|NCT03776656|Experimental|Allopurinol|Oral administration of Allopurinol (Zyloric®) for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure
11142850|NCT03776643|Experimental|ILT-101 (ld-IL2)|Subcutaneous injections of ILT-101
11142851|NCT03776643|Placebo Comparator|placebo|Subcutaneous injections of placebo
11142852|NCT03776630|Other|Control|Patients undergoing surgery for benign pelvic lesions
11142853|NCT03776630|Other|Ovarian Cancer|
11142854|NCT03776630|Other|Endometrial Cancer|
11142855|NCT03776617|Experimental|Group Ropivacaine|general anesthesia + scalp block with 20 ml xylocaine 1% and 20ml ropivacaine 0.5%
11142856|NCT03776617|Experimental|Group Ropivacaine-Dexmedetomidine|general anesthesia + scalp block with 20 ml xylocaine 1%, 20ml ropivacaine 0.5% and 1mcg/kg dexmedetomidine
11142857|NCT03776617|No Intervention|Group control|general anesthesia
11142858|NCT03776617|Sham Comparator|Group sham|general anesthesia + Scalp block with 40ml Normal Saline
11142859|NCT03776604|Experimental|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.
~Dosing time: 48 h after chemotherapy."
11142860|NCT03776591|Experimental|Open D3|Right colectomy Open surgery Central lymphadenectomy and vascular ligation
11142861|NCT03776591|Active Comparator|Laparoscopic CME with CVL|Right colectomy Laparoscopic surgery Central lymphadenectomy and vascular ligation
11142862|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
11142863|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
11142864|NCT03776565||Operative hysteroscopy|women with an operative hysteroscopy planned
11142865|NCT03776565||Planned caesarean section|Pregnant women with a planned caesarean section
11142866|NCT03776552|Active Comparator|Low energy diet (LED)|8-week LED (<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks <1300 kcal/day and 4 weeks <1500 kcal/day)
11142867|NCT03776552|Active Comparator|Gradual weight loss (GWL)|16-week standard GWL-course (controls)
11142869|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
11142870|NCT03776513|Experimental|experimental group|Thirty obese boys (12-17 years old) undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
11142871|NCT03776513|Other|control group|Thirty healthy boys (12-17 years old) paired for pubertal stage, level of education and socio-economic level undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
11142872|NCT03776500|Experimental|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
11142873|NCT03776500|Placebo Comparator|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
11142874|NCT03776500|Experimental|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
11142875|NCT03776500|Placebo Comparator|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
11142876|NCT03776500|Experimental|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
11142877|NCT03776500|Placebo Comparator|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
11142878|NCT03776500|Experimental|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
11142879|NCT03776500|Placebo Comparator|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
11142880|NCT03776487|Experimental|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.
~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
11142881|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
11142882|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
11142883|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
11142884|NCT03776461|Experimental|80 pin applicator|
11142885|NCT03776461|Active Comparator|160 pin applicator|
11142886|NCT03776448|Experimental|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by [Bioextract Ltd, Sri Lanka] and is available commercially.
11142887|NCT03776448|Placebo Comparator|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially.
11142888|NCT03776435||CT-exposed group|
11142889|NCT03776435||CT-unexposed group|
11142890|NCT03776422|Experimental|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
11142891|NCT03776409||vancomycin plus piperacillin/tazobactam|Critically ill patients who received the combination of VAN (vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and PTZ were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
11142892|NCT03776409||vancomycin plus other beta-lactams|Critically ill patients who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
11142893|NCT03776396||Experimental cohort|"33 patient undergoing to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania, in which an innovative Perioperative Goal Directed Therapy (PGDT) protocol will be used."
11142894|NCT03776396||Historical control group|"33 patients underwent to kidney transplantation from cadaver at University Hospital G. Rodolico of Catania in 2015, in which a PGDT protocol was not used, but a common hemodynamic monitoring, based on parameters such as central venous pressure and / or invasive arterial pressure, was performed."
11142895|NCT03776383|Active Comparator|Antibiotic use feedback letter 1|Antibiotic use feedback letter 1 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic prescribing for acute respiratory conditions
11142896|NCT03776383|Active Comparator|Antibiotic use feedback letter 2|Antibiotic use feedback letter 2 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic durations for common infections
11142897|NCT03776383|No Intervention|Control|Controls will not receive a letter
11142898|NCT03776370|Experimental|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
11142899|NCT03776370|Active Comparator|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery
11142900|NCT03776357|Experimental|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
11142901|NCT03776344|Experimental|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
11143386|NCT03772756|Active Comparator|control group|the control group will receive chemoradiotherapy only
11142902|NCT03776344|No Intervention|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
11142903|NCT03776331||Myeloma Patients|
11142904|NCT03776331||Controll group|
11142905|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
11142906|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
11142907|NCT03776305|Experimental|Imipenem ECMO|1-h infusion of 0.5 g of imipenem, q6h
11142908|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
11142909|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
11142910|NCT03776279|Experimental|Mitoxantrone Hydrochloride Liposome Injection|4 weeks is a treatment cycle, and the first day of each cycle is administered.
11142911|NCT03776253|Experimental|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.
~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
11142912|NCT03776240|Experimental|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
11142913|NCT03776240|Active Comparator|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
11142914|NCT03776240|Active Comparator|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
11142915|NCT03776227|Experimental|Sotagliflozin Test|One tablet of sotagliflozin administered orally under fasting conditions
11142916|NCT03776227|Active Comparator|Sotagliflozin Reference|Two tablets of sotagliflozin administered orally under fasting conditions
11142917|NCT03776201|Experimental|Internal Focus|"The internal focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The Internal Focus group will be reminded to focus their attention internally via the prompt keep your feet as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
11142918|NCT03776201|Experimental|External Focus|"The external focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30 wobble board with five bases ranging from 1 (easy) to 3 (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The external focus group will be reminded to focus their attention externally via the prompt please keep the board as level as possible prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used."
11142919|NCT03776201|No Intervention|Control|The control group will not receive any balance training
11142920|NCT03776188||no groups - observational study|no groups - observational study
11142921|NCT03776175|Placebo Comparator|Placebo|Placebo (PF 05221304) BID Placebo (PF 06865571) BID
11142922|NCT03776175|Experimental|PF-05221304 Monotherapy|15 mg PF-05221304 BID Placebo (PF-06865571) BID
11142923|NCT03776175|Experimental|PF-06865571 Monotherapy|Placebo (PF-05221304) BID 300 mg PF-06865571 BID
11142924|NCT03776175|Experimental|PF-05221304 and PF-06865571 Combination|15 mg PF-05221304 BID 300 mg PF-06865571 BID
11142925|NCT03776162|Active Comparator|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
11142926|NCT03776162|Experimental|Bridge Enhanced ACL Repair|Procedure/Surgery Bridge Enhanced ACL Repair (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to group into.
11142927|NCT03776149|Experimental|Beetroot juice (dietary nitrate)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of beetroot juice (Beet It (HeartBeet Ltd.), Ipswich, UK). During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
11142928|NCT03776149|Placebo Comparator|Black currant juice (placebo control)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of a nitrate-depleted placebo. During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
11142929|NCT03776136|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
11142930|NCT03776110|Experimental|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.
~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
11142931|NCT03776110|Experimental|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.
~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
11142932|NCT03776110|Experimental|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.
~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
11142933|NCT03776110|Experimental|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.
~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
11142934|NCT03776097||Defect Fill.|Observational study of the patients that were treated with biomaterials at the surgery in the previous study
11142935|NCT03776097||No defect Fill.observational|Observational study of the patients that were not treated with biomaterials at the surgery of te previous study
11142936|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
11142937|NCT03776071|Active Comparator|RT plus TMZ and ENZ; ENZ alone; TMZ and ENZ|Radiotherapy (RT) plus temozolomide (TMZ) and enzastaurin (ENZ) (Concurrent Phase) followed by enzastaurin alone (Single-Agent Phase), then temozolomide and enzastaurin (Adjuvant Phase)
11142938|NCT03776071|Placebo Comparator|RT plus TMZ and placebo; placebo; TMZ and placebo|Radiotherapy (RT) plus temozolomide (TMZ) and placebo followed placebo then by temozolomide and placebo
11142939|NCT03776058|Experimental|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
11142940|NCT03776058|Placebo Comparator|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
11142941|NCT03776045|No Intervention|Standard care|This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study.
11142942|NCT03776045|Experimental|Standard care plus exercise|This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy.
11142943|NCT03776032|Experimental|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
11142944|NCT03776032|Placebo Comparator|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
11142945|NCT03776019|Experimental|Modulated|modulated music
11142946|NCT03776019|Sham Comparator|Typical|typical music
11142947|NCT03776006||TPLA|
11142948|NCT03775993|Active Comparator|GHD|
11142949|NCT03775993|Placebo Comparator|Placebo|
11142950|NCT03775954||1) Fetal Congenital Heart Disease|Pregnancy with major fetal congenital heart disease, after 20 weeks gestation, and as neonate following delivery. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
11142951|NCT03775954||2) History of fetal demise (Stillbirth)|Pregnancy with a history of an unexplained fetal demise (stillbirth at 20 -40 weeks gestation) during any prior pregnancy. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
11142952|NCT03775954||3) Fetal hydrops, immune or non-immune|Pregnancy with fetal hydrops, immune or non-immune, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
11142953|NCT03775954||4) Fetal gastroschisis|Pregnancy with fetal gastroschisis, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
11142954|NCT03775954||5) Twin pregnancy, monochorionic|Twin pregnancy, monochorionic, with or without twin-twin transfusion syndrome, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (fMCG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
11142955|NCT03775941||Cross-Sectional Lifespan Connectomics Study|
11142956|NCT03775928|Experimental|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
11142957|NCT03775928|Active Comparator|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
11142958|NCT03775915|Experimental|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
11142959|NCT03775915|Sham Comparator|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
11142960|NCT03775902|Experimental|Healthy subjects|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
11142961|NCT03775902|Experimental|Pre and/or type 2 diabetics|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
11142962|NCT03775889|Experimental|Behavioral|Behavioral Gardening Exposure
11143111|NCT03774797||Pre-Implementation Patients|Enrolled patients will take online surveys following a prenatal or a postpartum visit.
11142963|NCT03775876|Active Comparator|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
11142964|NCT03775876|Active Comparator|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
11142965|NCT03775863||Latin American multicenter Cohort|Transplanted patients with HCC in LATAM from 2005-2011
11142966|NCT03775863||French mutlicenter Cohort|Transplanted patients with HCC in France from 2003-2005
11142967|NCT03775863||Italian multicenter Cohort|Transplanted patients with HCC in Italy from 2005-2011
11142968|NCT03775850|Experimental|Cohort A|Cohort A includes patients with microsatellite stable (MSS) colorectal cancer (CRC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
11142969|NCT03775850|Experimental|Cohort B|Cohort B includes patients with Triple Negative Breast Cancer (TNBC). Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
11142970|NCT03775850|Experimental|Cohort C|Cohort C includes patients with non-small-cell lung cancer (NSCLC), bladder cancer; gastroesophageal (GE) cancer, any microsatellite unstable, or renal cell carcinoma (RCC) who are relapsed to prior PD-1/L1 therapy. Patients will receive a 14 day run-in of EDP1503 alone, following which they will be treated with a combination of EDP1503 and pembrolizumab.
11142971|NCT03775837|Experimental|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
11142972|NCT03775837|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
11142973|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
11142974|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
11142975|NCT03775785|Experimental|tailored enteral nutrition|Tailored Human milk fortification procedure Tailored milk fortification will be done twice a day (8 am and 8 pm) for each following 12 hour nursing shift. Standard fortification will be added first. The remainder amount of protein, lipids and carbohydrates required to meet the recommended by ESPGHAN doses will be acheived by adding single ingrediant nutrients.
11142976|NCT03775785|No Intervention|standard enteral nutrition|Standard fortification will be added according to the unit protocol.
11142977|NCT03775772|Other|Oral Health - Test Group|- study population is randomly assigned to control and test group
11142978|NCT03775772|Other|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
11142979|NCT03775759|Experimental|Study arm|Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy
11142980|NCT03775759|Active Comparator|Control arm|LVAD implantation plus medical therapy
11142981|NCT03775746|Experimental|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
11142982|NCT03775746|Active Comparator|Clopidogrel|Clopidogrel 75mg o.d.
11142983|NCT03775746|Active Comparator|Ticagrelor|Ticagrelor 90mg b.i.d.
11142984|NCT03775733|Experimental|Hydrolysed red ginseng extract|Hydrolysed red ginseng extract 2.4g/day for 12 weeks
11142985|NCT03775733|Placebo Comparator|Placebo|Placebo for 12 weeks
11142986|NCT03775720|Experimental|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
11142987|NCT03775720|Experimental|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
11142988|NCT03775707|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11142989|NCT03775681|Experimental|Device feasibility (Laryngeal Mask Airway, ERCP)|Patients wear Laryngeal Mask Airway after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.
11142990|NCT03775668|Experimental|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
11142991|NCT03775655|Active Comparator|LD-DEX|This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).
11142992|NCT03775655|No Intervention|Control group|This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).
11142993|NCT03775642|Experimental|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
11142994|NCT03775642|Placebo Comparator|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
11142995|NCT03775629|Experimental|Polmacoxib and Tramadol combination|Tramadol HCl 300mg once/day + 2 mg Polmacoxib capsule once/day for 14 days
11142996|NCT03775629|Active Comparator|Polmacoxib|Polmacoxib 2mg 14days
11142997|NCT03775629|Active Comparator|Tramadol|Tramadol hydrochloride (HCl) 150mg 5days
11143032|NCT03775369|Active Comparator|Resistance training|"Resistance Training (warm-up; resistance training units; cooling down; group sessions; supervised; moderate and individualized exercising load):
~6 weeks, 2 sessions/week, 40-60min/session"
11142998|NCT03775616|Experimental|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
11142999|NCT03775590|Active Comparator|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
11143000|NCT03775590|Active Comparator|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
11143001|NCT03775590|Active Comparator|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
11143002|NCT03775577||HFpEF|Participants with Heart Failure with Preserved Ejection Fraction
11143003|NCT03775577||HFrEF|Participants with Heart Failure with Reduced Ejection Fraction
11143004|NCT03775577||Hypertensive Subjects|Participants with Hypertension
11143005|NCT03775577||Healthy Subjects|Participants without heart failure and without commodities
11143006|NCT03775564|Experimental|REMEDRUGBY|TAU + RemedRugby Program
11143007|NCT03775564|Active Comparator|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
11143008|NCT03775551|No Intervention|Control|The participants belonging to the hospitals assigned to the control group the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC following usual practice.
11143009|NCT03775551|Experimental|Improvement cycle|In participants belonging to the hospitals assigned to the intervention group,the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC using innovative intervention to assure continuity of care and assistant level approach. This innovations will be crafted from the rapid improvement cycles considering the environment and key aspects of the every day care at the participating centers.
11143010|NCT03775538|Experimental|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
11143011|NCT03775538|Experimental|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
11143012|NCT03775525|Experimental|Experimental: monotherapy|GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
11143013|NCT03775512|Experimental|Main Arm|Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation with nMARQ RF Generator
11143014|NCT03775512|Experimental|Second Arm (variable flow)|subjects will be treated with QDOT Micro catheter with variable flow nMARQ RF generator
11143015|NCT03775499|Other|Period 1: Placebo - Period 2: BL NCC 2705|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
11143016|NCT03775499|Other|Period 1: BL NCC 2705 - Period 2: Placebo|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
11143017|NCT03775486|Experimental|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:
~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
11143018|NCT03775486|Experimental|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
11143019|NCT03775473|Other|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
11143020|NCT03775460|Placebo Comparator|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
11143021|NCT03775460|Experimental|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
11143022|NCT03775447||Parkinson's Disease Patients|"A diagnosis of Parkinson's disease in the opinion of the enrolling investigator
~Disease duration: any
~Male or female age 18 years or older at time of PD diagnosis."
11143023|NCT03775447||Healthy Control (HC) Subjects|• Male or female age 18 years or older at Screening.
11143024|NCT03775434|Experimental|B244|B244 suspension in 30ml/bottle
11143025|NCT03775421|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
11143026|NCT03775408||FAST Patients|Patients at Sunnybrook Health Sciences Centre with femur fractures that will undergo a femoral antegrade intramedullary nailing procedure.
11143027|NCT03775395|Experimental|HAIC plus Lenvatinib|
11143028|NCT03775395|Active Comparator|HAIC plus Sorafenib|
11143029|NCT03775382|Placebo Comparator|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
11143030|NCT03775382|Active Comparator|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
11143031|NCT03775369|Active Comparator|Endurance training|"Endurance Training (warm-up; endurance on bike; brisk walking; cooling down; group sessions; supervised; moderate and individualized exercising load):
~6 weeks, 2 sessions/week, 40-60min/session"
11143109|NCT03774810|Experimental|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
11143033|NCT03775369|Active Comparator|Control condition|"Control condition (individualized counselling, but not intended as a bona fide intervention, that is to say: not intended to actively improve participants' well-being):
~6 weeks, social support and counseling,1-2 sessions/week; 30 min/session"
11143034|NCT03775356|No Intervention|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
11143035|NCT03775356|Active Comparator|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
11143036|NCT03775343||General Anesthesia|"General anesthesia:
~25 patients older than 65 years, undergoing elective eye surgery under general anesthesia.
~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative.
~Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
11143037|NCT03775343||Local anesthesia with sedoanalgesia|"25 patients older than 65 years, undergoing elective eye surgery under local anesthesia in combination with sedoanalgesia.
~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
11143038|NCT03775343||Control Group|"25 patients, not undergoing any operative intervention. To determine a normal reference value of cognitive functions, a group of 25 individuals without an operative intervention will be recruited as a control group.
~Intervention: neurocognitive testing (Neurocognitive Test Battery) at 3 determined time points (0, 6 and 24 hours)"
11143039|NCT03775330|Experimental|SRS|Stereotactic radiosurgery
11143040|NCT03775330|Experimental|SRS plus WBRT|Stereotactic radiosurgery plus whole brain radiation
11143041|NCT03775317|Experimental|Video Laryngoscopy|
11143042|NCT03775317|Active Comparator|Direct Laryngoscopy|
11143043|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
11143044|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
11143045|NCT03775278|Experimental|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
11143046|NCT03775278|Placebo Comparator|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
11143047|NCT03775265|Active Comparator|Arm I (RT, chemotherapy)|Patients undergo RT (3D CRT or IMRT) Monday-Friday for up to 7 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy, and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.
11143048|NCT03775265|Experimental|Arm II (RT, chemotherapy, atezolizumab)|Patients undergo RT (3DCRT or IMRT) Monday-Friday for up to 7 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 60 minutes on day 1 of chemotherapy. Treatment repeats every 21 days for a total of 6 months (9 doses total) in the absence of disease progression or unacceptable toxicity.
11143049|NCT03775252|Experimental|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
11143050|NCT03775239|Other|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
11143051|NCT03775239|Other|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
11143052|NCT03775226|Experimental|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
11143053|NCT03775213|Experimental|Standard Materials + Decision Aid|Participants receive standard materials used to communicate DCIS management choices, plus a decision aid.
11143054|NCT03775213|No Intervention|Standard Materials|Participants receive standard materials used to communicate DCIS management choices.
11143055|NCT03775200|Experimental|Low dose|Low dose Psilocybin
11143056|NCT03775200|Experimental|Medium dose|Medium dose Psilocybin
11143057|NCT03775200|Experimental|High dose|High dose Psilocybin
11143058|NCT03775161|Experimental|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
11143059|NCT03775148|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
11143060|NCT03775148|No Intervention|CAU Group|Care-As-Usual group
11143061|NCT03775135||Children with neuromuscular diseases|Questionnaires will be administered by children with neuromuscular disease between 12 and 25 years and their parents
11143062|NCT03775122|Placebo Comparator|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)
~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
11143063|NCT03775122|Experimental|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.
~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
11143064|NCT03775109|Active Comparator|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
11143065|NCT03775109|Placebo Comparator|Dextrose|
11143110|NCT03774810|Experimental|Low Frequency Intermittent Dosing|1 to 3 active doses per week PRN. The intervention is zolpidem tartrate 5 mg or 10 mg.
11143066|NCT03775096|Experimental|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
11143067|NCT03775070|Experimental|Simvastatin|Simvastatin, 0.5mg/kg/d(maximum 20mg), once daily
11143068|NCT03775057|Experimental|MyDose Coach app intervention|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
11143069|NCT03775044|Experimental|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
11143070|NCT03775031|Active Comparator|Fraxel 1927nm|Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
11143071|NCT03775031|Active Comparator|Fraxel 1550nm|Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
11143072|NCT03775031|Active Comparator|25% TCA Peel|25% TCA on 5 x 5 cm of sun exposed back
11143073|NCT03775031|Placebo Comparator|Control|Patient serves as their own control
11143074|NCT03775018|Experimental|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
11143075|NCT03775018|Active Comparator|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
11143076|NCT03775005|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
11143077|NCT03775005|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11143078|NCT03774992|Experimental|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
11143079|NCT03774992|Experimental|Cross over|Subjects randomized to SVS in the CONTROL-study
11143080|NCT03774979|Experimental|SHR-1701|intravenous infusion
11143081|NCT03774966|Active Comparator|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
11143082|NCT03774966|Experimental|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
11143083|NCT03774953|Experimental|Intervention group|protein and vitamin supplementation
11143084|NCT03774953|No Intervention|Control group|No supplementations
11143085|NCT03774940|Experimental|fever|patients that have fever after PNL
11143086|NCT03774940|Active Comparator|No fever|Patients without fever after PNL
11143087|NCT03774927|Experimental|10 Hz treatment group|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
11143088|NCT03774927|Experimental|20 Hz treatment group|In active rTMS, 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
11143089|NCT03774927|Sham Comparator|Control Group|In sham rTMS, all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
11143090|NCT03774914||Lemtrada|Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
11143091|NCT03774901|Experimental|avelumab maintenance|Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
11143092|NCT03774888|Experimental|connective tissue graft|Connective tissue grafting (CTG) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
11143093|NCT03774888|Experimental|Acellular Dermal Matrix|Acellular Dermal matrix (ADM) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
11143094|NCT03774888|Active Comparator|No soft tissue graft|Control group where no soft tissue graft is added to the lateral ridge augmentation.Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
11143095|NCT03774875|Experimental|Apremilast 30 mg twice daily|Subjects will take oral tablets of apremilast for up to 52 weeks (30 mg twice daily).
11143096|NCT03774875|Placebo Comparator|Placebo followed by Apremilast 30mg twice daily|Subjects will take placebo for 16 weeks. After Week 16, subjects will be switched to receive apremilast (30 mg twice daily) until Week 52.
11143097|NCT03774862||Medullary carcinoma of colorectal cancers|
11143098|NCT03774862||non-medullary carcinomas of the colorectal cancers|
11143099|NCT03774849|Experimental|Picoway™ 532nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
11143100|NCT03774849|Experimental|PicoWay™ 730nm wavelength|PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
11143101|NCT03774849|Experimental|PicoWay ™1064nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
11143102|NCT03774836|Active Comparator|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
11143103|NCT03774836|Active Comparator|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
11143104|NCT03774836|Placebo Comparator|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
11143105|NCT03774823|Experimental|Freeze Plus|Subjects in this arm will receive treatment using RF and PEMF
11143106|NCT03774823|Experimental|Ultrasound|Subjects in this arm will receive treatment using ultrasound
11143107|NCT03774810|Experimental|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
11143108|NCT03774810|Experimental|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
11143112|NCT03774797||Post-Implementation Patients|All enrolled patients will take online surveys following a prenatal or a postpartum visit. A subset will be interviewed after the postpartum survey.
11143113|NCT03774797||Post-Implementation Providers|All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
11143114|NCT03774784||ALECT2 Disease|
11143115|NCT03774771|Placebo Comparator|Placebo|In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
11143116|NCT03774771|Experimental|Cinacalcet 50 mg QD|In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
11143117|NCT03774771|Experimental|Cinacalcet 75 mg QD|In Part 1 participants received 75 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 40 mg cinacalcet capsules twice a day for 15 days.
11143118|NCT03774771|Experimental|Cinacelcet 100 mg QD|In Part 1 participants received 100 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 50 mg cinacalcet capsules twice a day for 15 days.
11143119|NCT03774758||Cohort 1A: Benign nodule on screening CT|"High-risk patients eligible for lung cancer screening but with negative radiographic findings on CT screening (Lung RADS ≤2).
~≥30 pack-year history of cigarette smoking
~≥55 years of age
~Current smoker or quit within the past 15 years"
11143120|NCT03774758||Cohort 1B: Incidental benign nodule|"Patients with lung nodules ≥ 6 mm on routine (non-lung cancer screening) CT evaluation deemed suspicious for malignancy by initial physician judgment but not malignant by ≥2 years of radiographic stability and consensus clinical opinion.
~1- Age ≥40 years."
11143121|NCT03774758||Cohort IC: Presumed lung cancer|"Patients with lung cancer (histologically proven or presumed by consensus opinion of tumor board); prior to definitive therapy.
~1- Age ≥40 years."
11143122|NCT03774758||Cohort 2A: Suspicious nodule|"High-risk patients with newly diagnosed suspicious nodule of Lung RADS ≥3 on CT screening.
~≥30 pack-year history of cigarette smoking
~≥55 years of age
~Current smoker or quit within the past 15 years"
11143123|NCT03774758||Cohort 2B: Suspicious incidental nodule|"Patients with newly diagnosed incidentally-found lung nodules ≥ 6 mm on routine CT evaluation deemed suspicious for malignancy by physician judgment.
~1- Age ≥40 years."
11143124|NCT03774758||Cohort 2C: Post-treatment lung cancer|"Patients with previously treated lung cancer (histologically proven or by consensus opinion); status-post completion of definitive therapy (resection +/- chemotherapy or SBRT with curative intent) within the previous year with no current evidence of disease.
~1- Age ≥40 years."
11143125|NCT03774745|Experimental|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).
~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
11143126|NCT03774745|Placebo Comparator|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
11143127|NCT03774732|Experimental|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.
~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.
~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).
~Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
11143128|NCT03774732|Active Comparator|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:
~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )
~Non squamous-cell lung carcinoma:
~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)
~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
11143129|NCT03774719|Experimental|Hand-carried ultrasound arm|This is the only arm of the study. It will be comprised of 154 inpatients who had a renal ultrasound ordered or performed within the past 4 hours. The intervention will be performing hand-carried ultrasound to evaluate for presence and degree of hydronephrosis.
11143130|NCT03774706|Active Comparator|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
11143131|NCT03774706|Active Comparator|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
11143132|NCT03774693|Active Comparator|GS [General anesthesia]|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
11143133|NCT03774693|Active Comparator|GR [General anesthesia + regional block]|"Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
~Also patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block. Fentanyl boluses of 0.5 mcg.Kg-1 will be given when needed to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1."
11143134|NCT03774680|Active Comparator|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
11143135|NCT03774680|Placebo Comparator|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
11143136|NCT03774667||Placenta Previa|Pregnant women is diagnosed with placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
11143137|NCT03774667||None-Placenta Previa|Pregnant women is diagnosed without placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
11143138|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Four dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
11143139|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Four dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
11143140|NCT03774641||Taking Lamotrigine|Lamotrigine (Lamictal), dosage will be based on a reference concentration of blood-serum levels
11143141|NCT03774628|Experimental|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
11143142|NCT03774628|Experimental|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
11143143|NCT03774615|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
11143144|NCT03774602|Experimental|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
11143145|NCT03774589|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
11143146|NCT03774589|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
11143147|NCT03774576|Experimental|RO7017773|Single dose of RO7017773
11143148|NCT03774576|Experimental|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
11143149|NCT03774537|Experimental|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.
11143150|NCT03774537|Other|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
11143151|NCT03774524|Active Comparator|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
11143152|NCT03774524|Active Comparator|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
11143153|NCT03774524|Placebo Comparator|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
11143154|NCT03774511|Active Comparator|Study group 1|High Intensity Interval Excercise
11143155|NCT03774511|Active Comparator|Study group 2|Moderate Intensity Interval Exercise
11143156|NCT03774511|No Intervention|Control group|No Intervention
11143157|NCT03774498|Active Comparator|Sensodyne repair and protect|NovaMin & fluoride toothpaste
11143158|NCT03774498|No Intervention|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
11143159|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
11143160|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
11143161|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
11143162|NCT03774472|Experimental|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Participants with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
~PHASE II: Participants with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of course 1 and on days 1-28 of subsequent courses. Participants also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, courses may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
11143163|NCT03774459|Experimental|High dose ANAVEX2-73|High dose ANAVEX2-73
11143164|NCT03774459|Experimental|Mid dose ANAVEX2-73|Mid dose ANAVEX2-73
11143165|NCT03774459|Placebo Comparator|Placebo oral capsule|Placebo oral capsule
11143166|NCT03774446|Experimental|Seliciclib|Up to 800 mg/day oral seliciclib for 4 days each week for 4 weeks
11143167|NCT03774433|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
11143168|NCT03774407|Other|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
11143169|NCT03774407|Experimental|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
11143170|NCT03774394|Experimental|Diabetes Mellitus patients with Chronic Kidney Disease|"Patients with CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.
~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
11143171|NCT03774394|Active Comparator|Diabetes Mellitus patients without Chronic Kidney Disease|"Patients without CKD will be administered a 600-mg LD of Clopidogrel followed by a single 75-mg MD administered after 24 hours.
~Blood samples collected at baseline will be incubated with clopidogrel active metabolite."
11143172|NCT03774381|Experimental|Bifidobacterium breve B-3 group|160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
11143173|NCT03774381|Placebo Comparator|Control group|160 mg of placebo was orally administered per day for 12 weeks.
11143207|NCT03774108|Experimental|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
11143208|NCT03774108|Placebo Comparator|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
11143174|NCT03774368|Other|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
11143175|NCT03774368|Other|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
11143176|NCT03774355|Experimental|CG1801|Dosing 'CG1801' followed by dosing 'CGL1802'
11143177|NCT03774355|Experimental|CGL 1802|Dosing 'CGL1802' followed by dosing 'CG1801'
11143178|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
11143179|NCT03774329|Experimental|physical activity program|Child with an adapted physical activity program
11143180|NCT03774329|Other|Usual care|
11143181|NCT03774303|Experimental|mobile intervention|families to be prepared for day surgery with a mobile application
11143182|NCT03774303|Active Comparator|control group|families to be prepared for day surgery with current practice
11143183|NCT03774290|Experimental|PBF-680 10 mg|10 mg of PBF-680 once a day
11143184|NCT03774290|Placebo Comparator|Placebo oral capsules|Placebo once a day
11143185|NCT03774277|Experimental|Intervention Communities|Packed Promise for a Healthy Heart intervention, free Tribal Wellness Center membership, a Fitbit, and the AYA culturally based mobile walking app.
11143186|NCT03774277|No Intervention|Control Communities|Free Tribal Wellness Center membership, Fitbit, and the AYA culturally based mobile walking app
11143187|NCT03774264||Xiaflex group|"Patients will be evaluated in our urology clinic at baseline for possible inclusion in our study. All patients at baseline evaluation will be evaluated for duration of symptoms, relationship stability, IIEF and PDQ. All patients will obtain a penile Doppler ultrasound with the aid of a vasoactive substance by a specially trained technician. During this visit, plaque measurements will be taken: location of plaque, distance of plaque from the tip of the penis, degree of curvature measured by goniometer.
~Ultrasound characteristics will be documented: Type (Type 1: The plaque appears as a thickening of the tunica albuginea without acoustic shadowing. Type 2: A moderately calcified plaque with a typical ultrasound shadow. Type 3: A severely calcified plaque with typical ultrasound shadowing) and Grade of calcification (grade 1 (<0.3 cm), grade 2 (>0.3 cm, <1.5 cm), grade 3 (>1.5 cm; or ≥ 2 plaques >1.0 cm). Sample data sheet attached as appendix 2."
11143188|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - PRP Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to undergo platelet rich plasma injection
11143189|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - ESWT Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to extracorporeal shock wave therapy
11143190|NCT03774238|Other|COPD patients|FMD analysis
11143191|NCT03774225|Experimental|Manual and verbal guidance (MVG)|The MVG Group will be done by experimental group with the manual and verbal guidance of a physiotherapist using four games of X-Box Kinect system®
11143192|NCT03774225|Experimental|No manual and verbal guidance (NMVG)|The NMVG Group will be done by experimental group using four games of X-Box Kinect system® in the presence of a physiotherapist that will care about the safety of the participants without interfere in their moviment pattern.
11143193|NCT03774225|Active Comparator|Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
11143194|NCT03774212|Experimental|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
11143195|NCT03774212|Experimental|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
11143196|NCT03774199|Other|Pulse oximeter calibration population|
11143197|NCT03774186|Active Comparator|Sensor-augmented pump therapy (SAPT)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor but there will be no automated insulin adjustments made by the system.
11143198|NCT03774186|Experimental|Hybrid closed-loop therapy (HCL)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor with automated insulin adjustments made by the system, but continued meal boluses from the women.
11143199|NCT03774173|Experimental|Aramchol 300 mg|Aramchol 300 mg twice daily (every 12 hours)
11143200|NCT03774173|Experimental|Aramchol 600 mg|Aramchol 600 mg once daily (every 24 hours)
11143201|NCT03774160|Experimental|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
11143202|NCT03774160|No Intervention|Comparison|No intervention is implemented in the comparison arm.
11143203|NCT03774134||CME group|The CME group consisted of patients, who underwent elective CME for sigmoid colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2014.
11143204|NCT03774134||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for sigmoid adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
11143205|NCT03774121|Experimental|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
11143206|NCT03774121|Sham Comparator|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
11143210|NCT03774095|Active Comparator|Hydrolyzed pine nut oil|6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
11143211|NCT03774095|Active Comparator|Hydrolyzed pine nut oil and olive oil|3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
11143212|NCT03774082|Experimental|INC424 (ruxolitinib)|Subjects who will be administered 5mg ruxolitinib tablet or ruxolitinib oral pediatric formulation twice a day.
11143213|NCT03774069|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
11143214|NCT03774069|Active Comparator|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
11143215|NCT03774056|Experimental|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
11143216|NCT03774043|Experimental|Single session of Acute Intermittent Hypoxia (AIH)|
11143217|NCT03774043|Placebo Comparator|Single session of Sham Acute Intermittent Hypoxia (Sham AIH)|
11143218|NCT03774043|Experimental|Two successive sessions of AIH|
11143219|NCT03774043|Placebo Comparator|Two successive sessions of Sham AIH|
11143220|NCT03774030|Experimental|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
11143221|NCT03774017|Other|Traditional microsurgery group|Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
11143222|NCT03774017|Experimental|Hybrid operation group|Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
11143223|NCT03773991||Maintenance Hemodialysis Patients|"Patients on chronic hemodialysis therapy due to end-stage renal disease.
~Proton Lung MRI
~Sodium MRI of the leg
~Chest CT
~Transthoracic Echocardiography
~Fractional Exhaled Nitric Oxide
~Six-Minute Walk Test
~Pulmonary Function Tests
~Blood sampling
~Self-administered dyspnea questionnaires"
11143224|NCT03773978|Experimental|Baricitinib Open-Label|Baricitinib given orally.
11143225|NCT03773978|Experimental|Baricitinib Double Blind|Baricitinib given orally.
11143226|NCT03773978|Placebo Comparator|Placebo Double Blind|Placebo given orally.
11143227|NCT03773965|Experimental|Baricitinib|Baricitinib given orally.
11143228|NCT03773952|Experimental|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
11143229|NCT03773952|Placebo Comparator|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
11143230|NCT03773939||Derivation cohort|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624, NCT03577405, and NCT03553069)
11143231|NCT03773939||External validation cohort|We will create a multicenter cohort based on prospectively collected data derived from the Dutch National Intensive Care Evaluation (NICE) registry
11143232|NCT03773926|Experimental|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.
~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
11143233|NCT03773913||Four facilities in Kozah District|Baseline estimated population of 33,412 served by four public sector facilities in Kozah District.
11143234|NCT03773900|Experimental|Chitin-Glucan supplementation|
11143235|NCT03773900|Placebo Comparator|Placebo supplementation|
11143236|NCT03773887|Other|acute alcoholic hepatitis|collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
11143237|NCT03773887|Other|Alcoholic cirrhosis|collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
11143238|NCT03773887|Other|Without chronic liver disease|collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
11143239|NCT03773861|Other|Participants|Active BLS- Instructors at the Bern Simulation and CPR- Center (BeSiC), at the Bern University Hospital, Bern, Switzerland. Participants have to oversee a BLS instructional session, where standardized errors are performed by trained volunteers.
11143240|NCT03773848|Experimental|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
11143241|NCT03773848|Experimental|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
11143242|NCT03773835|Experimental|HSK3486|0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
11143243|NCT03773822|Placebo Comparator|Placebo of hydrocortisone and placebo of fludrocortisone|Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
11143244|NCT03773822|Experimental|Combination of hydrocortisone + fludrocortisone|Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
11143245|NCT03773809|Placebo Comparator|Group A0|Vitamin D3 deficient ACO patients with placebo at day 0.
11143246|NCT03773809|Placebo Comparator|Group A90|Vitamin D3 deficient ACO patients with placebo at day 90.
11143247|NCT03773809|Active Comparator|Group B0|Vitamin D3 deficient ACO patients with vitamin D3 at day 0.
11143248|NCT03773809|Active Comparator|Group B90|Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
11143249|NCT03773796|Other|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
11143250|NCT03773783|Active Comparator|Twin Block|Twin Block appliance
11143251|NCT03773783|Experimental|Button and Bead|Button and Bead appliance
11143252|NCT03773757|Experimental|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
11143253|NCT03773757|No Intervention|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
11143254|NCT03773744|Experimental|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
11143255|NCT03773744|Experimental|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
11143256|NCT03773731|Experimental|High intensity interval training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:
~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test
~30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.
~10 minutes with 30% of maximal power output."
11143257|NCT03773731|Active Comparator|Moderate intensity continuous training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:
~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test
~30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output
~10 minutes with 30% of maximal power output."
11143258|NCT03773718||Russkoe pole|400 patients
11143259|NCT03773705|Active Comparator|Electrocautery group|Electrocautery used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
11143260|NCT03773705|Active Comparator|Scalpel group|Scalpel used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
11143261|NCT03773692|Experimental|Passive feedback and JITAI|"Passive feedback and JITAI
~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
11143262|NCT03773679|Experimental|Exercise Group|"Daily exercise program involved Range of Motion (ROM) exercises against extremity resistances and extension and flexion in upper and lower extremities. Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes."
11143263|NCT03773679|No Intervention|Control Group|The preterm infants in the control group did not receive the daily exercise program, only the standard clinical routine.
11143264|NCT03773666|Experimental|Durvalumab|-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
11143265|NCT03773666|Experimental|Durvalumab + Oleclumab|"Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
~Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle"
11143266|NCT03773653|Experimental|BMT to be combined with BAT|Participants in this group will receive bilateral robotic priming and bilateral arm training or mirror therapy within the 90-minute training sessions.
11143267|NCT03773653|Experimental|BMT to be combined with MT|Participants in this group will receive bilateral robotic priming and mirror therapy within the 90-minute training sessions.
11143268|NCT03773653|Active Comparator|BMT to be combined with IOT|Participants in this group will receive bilateral robotic priming and impairment-oriented training within one 90-minute training session.
11143269|NCT03773640|Experimental|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
11143270|NCT03773640|Active Comparator|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
11143271|NCT03773601|Experimental|Athletes|Athletes will undergo a 4-days sleep monitoring with the use of the Sleep Profler. At the same time, they will fill the Total Quality of Recovery (TQR) scale and the Pittsburgh Sleep Quality Index (PSQI).
11143272|NCT03773588|Active Comparator|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
11143273|NCT03773588|Active Comparator|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
11143274|NCT03773575|Experimental|Prevena|PREVENA™ PEEL & PLACE™ Dressing Kit
11143275|NCT03773575|No Intervention|Standard Care|sterile gauze dressing supplemented with an Ace wrap
11143276|NCT03773562|Other|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
11143277|NCT03773549||Body dysmorphic disorder|Meet DSM-5 criteria for principal body dysmorphic disorder, assessed via the Structured Clinical Interview for the DSM-V Axis I Disorders (SCID)
11143278|NCT03773549||Healthy control|Individuals who do not have a current psychiatric diagnosis, assessed via the Mini-International Neuropsychiatric Interview (MINI)
11143279|NCT03773536|Experimental|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
11143280|NCT03773523|Experimental|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
11143281|NCT03773523|Sham Comparator|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
11143282|NCT03773510|Active Comparator|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
11143283|NCT03773510|Experimental|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.
~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
11143284|NCT03773497|Other|Common snack combination|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of a combination of common snack foods (pretzels, potato chips, and popcorn).
11143285|NCT03773497|Other|Cheese broccoli|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli.
11143286|NCT03773497|Other|Cheese broccoli with Daikon radish powder|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder.
11143287|NCT03773497|Other|Uncooked broccoli with ranch-type dip|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of uncooked, freeze-dried broccoli with ranch-type dip.
11143288|NCT03773484|Experimental|Clinical Decision Support/Audit & Feedback|Clinical decision support nudges (Accountable Justification and Active Choice (SmartSet)) within the electronic health record and Audit and Feedback on performance. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart.
11143289|NCT03773471|No Intervention|Control Arm|Standard of care
11143290|NCT03773471|Experimental|Intervention Arm|Mobile Health App
11143291|NCT03773458|Other|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
11143292|NCT03773432|Other|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
11143293|NCT03773432|Other|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
11143294|NCT03773419|Experimental|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
11143295|NCT03773419|Active Comparator|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
11143296|NCT03773406|Active Comparator|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
11143297|NCT03773406|Active Comparator|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
11143298|NCT03773406|Active Comparator|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
11143299|NCT03773406|Sham Comparator|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
11143300|NCT03773393|Experimental|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
11143301|NCT03773380|Experimental|Feasibility|50 patients will be recruited to take part in this feasibility study. They will all undergo this Breathe Anew Program post-surgery. Breathe Anew consists of radiological surveillance, physical rehabilitation using a Fitbit, mindfulness therapy, and referral for symptom management specialists when needed.
11143302|NCT03773367|Experimental|Treatment with chemotherapy pre- and postoperative.|
11143303|NCT03773354|Experimental|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
11143304|NCT03773328|Experimental|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.
~Cohort dosing will be as follows:
~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
11143305|NCT03773315|Experimental|UMH group|This group takes UMH extract for 12 weeks
11143306|NCT03773315|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
11143307|NCT03773302|Experimental|Infigratinib (BGJ398) 125 mg|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
11143308|NCT03773302|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
11143309|NCT03773276|Experimental|Norepinephrine boluses|Single arm study
11143310|NCT03773263|Experimental|sequential oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. COCs were removed from aspirated follicular fluid and transferred into HEPES-buffered collection medium. The immature oocytes will be cultured in sequential IVM medium 1 for 6 hours (37℃, 5% CO2), and removed into sequential IVM medium 2 for further cultivation. After 24 and 40 hours cultivation, the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle.
11143311|NCT03773263|Active Comparator|traditional oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
11143312|NCT03773250|Experimental|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
11143313|NCT03773250|No Intervention|Control|No intervention will be provided.
11143314|NCT03773237|Active Comparator|SMOFLipid|SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
11143315|NCT03773237|Active Comparator|IntraLipid|Intralipid is a lipid emulsion that contains soybean oil
11143316|NCT03773224|Active Comparator|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
11143317|NCT03773224|No Intervention|Control|The surgical wound is closed layer by layer without irrigation
11143318|NCT03773211|Experimental|Renaparin|Solution administered once to kidney ex-vivo
11143319|NCT03773211|Placebo Comparator|Placebo|Placebo administered once to kidney ex-vivo
11143320|NCT03773198|Experimental|ERCS Group|
11143321|NCT03773198|Placebo Comparator|Control Group|
11143322|NCT03773172|Placebo Comparator|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
11143323|NCT03773172|Active Comparator|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
11143324|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
11143325|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
11143326|NCT03773146|No Intervention|Control|No airtime incentive was given for completing the survey
11143327|NCT03773146|Experimental|1X Incentive|1X Airtime Incentive
11143328|NCT03773146|Experimental|Lottery|Lottery Airtime Incentive
11143329|NCT03773133|Experimental|Treatment|i.v. administrations of up to three radioactivity levels of Satoreotide tetraxetan.
11143330|NCT03773120|Experimental|Using Neuromonitoring to find EBSLN|With Neuromonitoring of the EBSLN using nerve monitoring system
11143331|NCT03773120|No Intervention|No Using Neuromonitoring to find EBSLN|Without Neuromonitoring of the EBSLN using nerve monitoring system
11143332|NCT03773107|Experimental|Phase I|Cohort 1) 5mg ruxolitinib, Cohort 2) 10mg ruxolitinib, Cohort 3) 15mg ruxolitinib
11143333|NCT03773107|Other|Phase II|Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen
11143334|NCT03773094|Experimental|Guava leaves extract|A natural product that is prepared as a mouthwash
11143335|NCT03773094|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
11143336|NCT03773081|Other|Magmaris implantation|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice.
11143337|NCT03773068|Experimental|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
11143338|NCT03773068|Experimental|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg [13C715N]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
11143339|NCT03773068|Experimental|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
11143340|NCT03773055|Active Comparator|NPC-06 (High dosage)|18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
11143341|NCT03773055|Active Comparator|NPC-06 (Low dosage)|15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
11143342|NCT03773055|Placebo Comparator|Placebo|Saline will be administered intravenously
11143343|NCT03773042|Experimental|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
11143344|NCT03773042|Active Comparator|Propofol|1.0mg/kg, 2.0mg/kg
11143345|NCT03773029|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 capsules)
11143346|NCT03773029|Placebo Comparator|control|2 capsules of placebo
11143347|NCT03773016|Experimental|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
11143348|NCT03773016|Experimental|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
11143349|NCT03773003|Active Comparator|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
11143350|NCT03773003|Placebo Comparator|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
11143351|NCT03773003|Active Comparator|Arm 3: Healthy control group|Group receiving probiotics
11143352|NCT03773003|Placebo Comparator|Arm 4: Healthy control group|Group receiving placebo (corn starch)
11143353|NCT03772990|Experimental|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
11143354|NCT03772990|Placebo Comparator|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
11143355|NCT03772977|Experimental|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
11143356|NCT03772977|No Intervention|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
11143357|NCT03772964|Experimental|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
11143358|NCT03772964|Experimental|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
11143359|NCT03772964|Experimental|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
11143360|NCT03772951|Active Comparator|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
11143361|NCT03772951|Placebo Comparator|Clozapine|Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
11143362|NCT03772938|Active Comparator|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
11143363|NCT03772938|Sham Comparator|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
11143364|NCT03772925|Experimental|Treatment (belinostat, pevonedistat)|Patients receive belinostat IV QD over 30 minutes on days 1-5 and pevonedistat IV QD over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11143365|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
11143366|NCT03772899|Experimental|Study Intervention|Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.
11143367|NCT03772886|Experimental|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during the active phase of labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
11143368|NCT03772886|No Intervention|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
11143369|NCT03772873||MIPE|Patients undergoing minimally invasive pilonidal excision with trephination.
11143370|NCT03772873||Other|Patients undergoing a different procedure for pilonidal disease.
11143371|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
11143372|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
11143373|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
11143374|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
11143375|NCT03772847|Experimental|ginkgolide group|ginkgolide plus alteplase
11143376|NCT03772847|No Intervention|control|alteplase
11143377|NCT03772834|Experimental|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
11143378|NCT03772834|Active Comparator|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
11143379|NCT03772834|Active Comparator|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
11143380|NCT03772834|Active Comparator|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
11143381|NCT03772808|Experimental|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
11143382|NCT03772795|Active Comparator|Group 1- Alignment with fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Uniteks, 0.022 Roth prescription brackets.Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
11143383|NCT03772795|Experimental|Group 2- Alignment with clear aligners|Clear aligner orthodontic appliance (EON, Eon Dental NV, Belgium). Teeth alignment with clear aligners.
11143384|NCT03772769|Experimental|Subjects with advanced deep space odontogenic infection|Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
11143385|NCT03772756|Experimental|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
11143387|NCT03772743|Other|Culprit-only revascularization|All patients randomized to culprit only revascularization must not undergo percutaneous coronary intervention (PCI) any lesion except from the culprit lesion already treated at the moment of the randomization. Staged procedures are considered protocol violation.
11143388|NCT03772743|Other|Complete functionally-guided revascularization|Patients who are randomized to this strategy will receive revascularization of the culprit lesion and guided by functional assessment on all non-culprit lesions. Functional evaluation is mandatory for all stenosis with diameter stenosis % between 50 and 90% at visual estimation. Revascularization must be guided by functional assessment on all vessels. The system utilized to obtain functional evaluation is left to Operator's discretion. PCI is allowed only if functional evaluation is positive according to the threshold of the chosen functional system. It is suggested to achieve functional complete revascularization within the index procedure, while it is mandatory to obtain it within the index hospitalization.
11143389|NCT03772730||Group 1|Multiply injured patients having at least one operative orthopaedic injury to the pelvis, acetabulum, femur, or diaphyseal tibia with planned definitive fixation to occur prior to discharge.
11143390|NCT03772717|Experimental|Vital EMS+|Participants will receive electrical neuromuscular stimulation via a Vital EMS+ device, along with the standard of care treatment.
11143391|NCT03772717|Sham Comparator|Sham device|Participants will receive a sham device that does not deliver electrical neuromuscular stimulation, along with the standard of care treatment.
11143392|NCT03772691|Experimental|lateral suspension|All operations will be performed with patient in loyd davies position, sterilization of the perineum then sterilization of the vagina
11143393|NCT03772691|Active Comparator|sacropexy|Our ﬁrst passage is the peritoneum incision overlying the sacral promontory (L5-S1) to expose the anterior longitudinal ligament, which is the anchorage point of the mesh on the sacrum. We create a tunnel under the peritoneum on the right side through the cul-de-sac of Douglas till reach the cervix or vaginal cuff (after hysterectomy).
11143394|NCT03772678|Placebo Comparator|Placebo|0.9% Saline For SAD and MAD arms.
11143395|NCT03772678|Experimental|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
11143396|NCT03772678|Experimental|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
11143397|NCT03772678|Experimental|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
11143398|NCT03772665|Experimental|Emixustat|10 mg
11143399|NCT03772665|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
11143400|NCT03772652||Peri-implantitis|Subjects who were diagnosed with peri-implantitis and received treatment at least five years ago at the Graduate Periodontics Clinic at University of Michigan with sufficient baseline data. Soft tissue measurements (observation) of the implant will be completed.
11143401|NCT03772639|Experimental|Experimental group|The experimental group received a standard medical and pharmacological care in a daily format and shared decision making (SDM). The general framework of SDM was developed focusing on self-management goals which include education that addresses continuous use of medication, behavioral change, breathing training, learning to interpret changes in the disease and its consequences, and use of medical and community resources.
11143402|NCT03772639|No Intervention|Control Group|The control group received standard care and pharmacological care including systemic steroids, antibiotics, inhaled bronchodilators, and oxygen therapy.
11143403|NCT03772626|Experimental|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
11143404|NCT03772613|Active Comparator|Low ACT Target|ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
11143405|NCT03772613|Active Comparator|Medium ACT Target|ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
11143406|NCT03772613|Active Comparator|High ACT Target|ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
11143407|NCT03772600|Experimental|Dexcom G6|Use a Dexcom G6 CGM for 24 months
11143408|NCT03772600|No Intervention|FreeStyle Libre|"Keep using their FreeStyle Libre for 6 months. Before the 6 month time point is reached, patients will wear a blinded Dexcom G6 for 28 days, together with their FreeStyle Libre.
~Cross-over to Dexcom G6 for 18 months."
11143409|NCT03772587|Placebo Comparator|Group 1|
11143410|NCT03772587|Experimental|Group 2|
11143411|NCT03772587|Experimental|Group 3|
11143412|NCT03772587|Experimental|Group 4|
11143413|NCT03772587|Experimental|Group 5|
11143414|NCT03772574|Experimental|THRIVE|THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).
11143415|NCT03772574|Active Comparator|Facemask|Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).
11143416|NCT03772561|Experimental|AZD5363+Olaparib+Durvalumab|"A traditional 3+3 design will be used during the dose escalation part of the study.
~Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities."
11143417|NCT03772548||Patients with spinal cord injury|
11143418|NCT03772548||Healthy subjects|
11143419|NCT03772535|No Intervention|Control Group|Subjects in this arm will receive the standard postoperative pain prescription protocol.
11143420|NCT03772535|Active Comparator|Pharmacogenomics Guided Group|Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.
11143421|NCT03772522|Experimental|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.
~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.
~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
11143422|NCT03772522|Placebo Comparator|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.
~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
11143423|NCT03772509|Experimental|CATI|Introduction and consent via computer assisted telephone interview
11143424|NCT03772509|No Intervention|IVR|Introduction and consent via interactive voice response
11143425|NCT03772496|Experimental|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
11143426|NCT03772483|Active Comparator|Control group|Local anesthesia with conventional syringe
11143427|NCT03772483|Active Comparator|Virtual reality group|Local anesthesia with conventional syringe + VR device
11143428|NCT03772470|No Intervention|Control|No airtime incentive was given for completing the survey
11143429|NCT03772470|Experimental|1X Incentive|1X airtime incentive
11143430|NCT03772470|Experimental|2X incentive|2X airtime incentive
11143431|NCT03772470|Experimental|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
11143432|NCT03772444|Active Comparator|Beetroot juice|
11143433|NCT03772444|Placebo Comparator|Control group 1|
11143434|NCT03772444|Sham Comparator|Control group 2|
11143435|NCT03772431|Experimental|Male Informational|Male voice, informational introduction
11143436|NCT03772431|Experimental|Male Motivational|Male voice, motivational introduction
11143437|NCT03772431|Experimental|Female Informational|Female voice, informational introduction
11143438|NCT03772431|Experimental|Female Motivational|Female voice, motivational introduction
11143439|NCT03772418|Placebo Comparator|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
11143440|NCT03772418|Active Comparator|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
11143441|NCT03772405|Experimental|Nascum Plus and ACC|In a cross-over design, patients are exposed to pollen in the ACC twice for 4 hours each 3 weeks apart. Subjects will receive treatment with Nascum Plus either 5 minutes before the first or the second 4 hour pollen challenge.
11143442|NCT03772379|Experimental|tooth borne hyrax expander group|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars .
11143443|NCT03772379|Experimental|tooth borne hyrax expander with microosteoperforation|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars and microosteoperforation .
11143444|NCT03772366||Warfarine|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Warfarine
11143445|NCT03772366||Fluindione|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
11143446|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
11143447|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
11143448|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
11143449|NCT03772353|Experimental|Letrozole Combined with Pyrotinib and SHR6390|During phase 1b part of this trial, treatment will be administered in cycles of 28 days and consist of letrozole 2.5 mg and pyrotinib 400 mg orally once daily in combination with SHR6390 (at protocol defined dose levels) po daily for 21 days followed by 7 days off. Once the recommended phase II dose (RP2D) has been determined, testing of this drug combination will be expanded in the phase II part to determine the progression-free survival (PFS) rate.
11143450|NCT03772340|Experimental|Tradipitant|
11143451|NCT03772340|Placebo Comparator|Placebo|
11143452|NCT03772327|Experimental|Routine counseling + AdhereTech bottle|"Participants will receive routine medication adherence counseling and be given the AdhereTech smart bottle with reminders."
11143453|NCT03772327|Active Comparator|Routine counseling|Participants will receive routine medication adherence counseling.
11143454|NCT03772314|Active Comparator|Modafinil|Participants in this study arm will take modafinil.
11143455|NCT03772314|Experimental|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
11143456|NCT03772301||Group 1|At least 200 Jewish Holocaust survivors of the first generation living in Germany and Israel - an equal number in each country
11143457|NCT03772301||Group 2|The second generation, whose parents lived in Europe during the Second World War, now live in Germany (originating from Western and Eastern Europe) - at least 200 participants.
11143458|NCT03772301||Group 3|Third generation of Jewish Holocaust survivors who participated in the first phase, currently living in Germany and Israel - at least 200 participants including at least 100 subjects in each country. These are adults only. The research program does not include children and adolescents
11143459|NCT03772288|Experimental|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
11143460|NCT03772288|Experimental|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
11143461|NCT03772275|Active Comparator|New york Heart Association Class II-IV|New york Heart Association Class II-IV heart failure
11143462|NCT03772275|Active Comparator|New york Heart Association Class I|New york Heart Association Class I with no heart failure
11143463|NCT03772262|Experimental|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
11143464|NCT03772262|Experimental|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
11143465|NCT03772249|Experimental|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
11143466|NCT03772249|Placebo Comparator|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
11143467|NCT03772249|Experimental|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
11143468|NCT03772249|Placebo Comparator|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
11143469|NCT03772249|Experimental|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
11143470|NCT03772249|Placebo Comparator|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
11143471|NCT03772249|Experimental|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
11143472|NCT03772249|Placebo Comparator|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
11143473|NCT03772249|Experimental|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
11143474|NCT03772249|Placebo Comparator|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
11143475|NCT03772249|Experimental|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
11143476|NCT03772249|Placebo Comparator|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
11143477|NCT03772249|Experimental|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
11143478|NCT03772249|Placebo Comparator|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
11143479|NCT03772249|Experimental|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
11143480|NCT03772249|Placebo Comparator|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
11143481|NCT03772249|Experimental|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
11143482|NCT03772249|Placebo Comparator|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
11143483|NCT03772249|Experimental|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)
~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)
~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
11143484|NCT03772249|Experimental|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
11143485|NCT03772249|Experimental|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
11143486|NCT03772249|Experimental|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
11143487|NCT03772223|Experimental|Treatment sequence 1 (ABC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027) , Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
11143488|NCT03772223|Experimental|Treatment sequence 2 (BCA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
11143489|NCT03772223|Experimental|Treatment sequence 3 (CBA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
11143490|NCT03772223|Experimental|Treatment sequence 4 (ACB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
11143491|NCT03772223|Experimental|Treatment sequence 5 (BAC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
11143492|NCT03772223|Experimental|Treatment sequence 6 (CAB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
11143493|NCT03772210|Active Comparator|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
11143494|NCT03772210|Sham Comparator|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
11143529|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
11143495|NCT03772210|Active Comparator|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
11143496|NCT03772210|Sham Comparator|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
11143497|NCT03772210|Active Comparator|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
11143498|NCT03772210|Sham Comparator|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
11143499|NCT03772210|Experimental|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.
~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
11143500|NCT03772184|Active Comparator|cervical inversion|
11143501|NCT03772184|No Intervention|no cervical inversion|
11143502|NCT03772158|Experimental|Treatment A|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
11143503|NCT03772158|Experimental|Treatment B|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.
11143504|NCT03772158|Experimental|Treatment C|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
11143505|NCT03772158|Active Comparator|Treatment D|Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
11143506|NCT03772158|Active Comparator|Treatment E|Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
11143507|NCT03772145||Tofacitinib|Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy
11143508|NCT03772132|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
11143509|NCT03772119||Surgical treatment of hemivertebra|cohort of children with a vertebral malformation treated by surgical resection
11143510|NCT03772106|Experimental|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
11143511|NCT03772106|Experimental|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
11143512|NCT03772093|Active Comparator|Patients with manual massage therapy|30 patients were randomly assigned to massage therapy. The procedures were performed for ten days, with weekend break. Manual massage of lumbar area was performed by certified massage therapist with the typical course of the procedure. The technique was consisted of stroking, kneading, grinding, patting and shaking. The procedure lasted twenty minutes.
11143513|NCT03772093|Active Comparator|Patients with Trabert current therapy|30 patients were randomly assigned to Trabert current therapy. The Trabert current was administered by 143 frequency, time of 2 ms impulse, time of break 5 ms. The current was generated by Pulsotronic ST-6D device (ZAMED©). The electric pads were placed on the lumbar area, in the middle part of spine. The anode in the lower part, near to buttocks. The intensity of current was regulated between 15-25 mA. The time of procedure lasted fifteen minutes.
11143514|NCT03772080|Experimental|Early counseling of prematurity in high-risk pregnancies|
11143515|NCT03772080|No Intervention|Standard counseling of prematurity in high-risk pregnancies|
11143516|NCT03772067|Experimental|MBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will contain 38 g protein mostly from milk and dairy products.
11143517|NCT03772067|Active Comparator|OBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will 38 g protein without milk or dairy products mostly from other proteins, i.e. eggs, tuna, soy, oatmeal. Milk product will be avoided in this diet also in other meals along the day.
11143518|NCT03772054|Active Comparator|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
11143519|NCT03772054|Experimental|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
11143520|NCT03772041|Experimental|OPC-61815 injection 16 mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
11143521|NCT03772041|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
11143522|NCT03772028|No Intervention|conventional surgery|Primary cytoreductive surgery without HIPEC
11143523|NCT03772028|Experimental|HIPEC|Primary cytoreductive surgery with HIPEC with cisplatin
11143524|NCT03772015||Study|"Patients who had the operation of laparoscopic lateral mesh suspension for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month"
11143525|NCT03772015||Control|Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
11143526|NCT03772002|Experimental|HCV screening|
11143527|NCT03771989|Active Comparator|Intervention|Patients are treated with an intra articular injection with autologous, micro-fragmented adipose tissue.
11143528|NCT03771989|Placebo Comparator|Control|Patients are treated with an intra articular injection with saline (placebo).
11143530|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
11143531|NCT03771963|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 ml, injection, subcutaneously (SC), once on Day 1 (Month 0) (dose 1) followed by TDV 0.5 ml, injection, SC once on Day 90 (Month 3) (dose 2).
11143532|NCT03771950|Experimental|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
11143533|NCT03771950|No Intervention|Control group|Treatment as usual.
11143534|NCT03771937|Experimental|Intervention|Intervention group received a telephone follow-up intervention, which consisted of a pre-discharge education program and three telephone follow-up sessions based on the RAM.
11143535|NCT03771937|No Intervention|Control group|the control group received routine care.
11143536|NCT03771924|Experimental|inorganic phosphate|"Experimental intervention:
~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
11143537|NCT03771924|Placebo Comparator|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
11143538|NCT03771911|Other|AED guided|"Laypeople will be guided by an Automatic External Defibrillator's (AED) voice instructions during the cardiopulmonary resuscitation.
~No other help is available."
11143539|NCT03771911|Other|Telephone guided|"Laypeople will be guided by telephone assistance (from an Emergency Call Center) during the cardiopulmonary resuscitation.
~AED voice instructions are also available."
11143540|NCT03771898|Experimental|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 210 weeks.
11143541|NCT03771885|Experimental|Group A|4 weeks place followed by 4 weeks IMP
11143542|NCT03771885|Experimental|Group B|4 weeks IMP followed by 4 weeks placebo
11143543|NCT03771872|Experimental|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
11143544|NCT03771872|Sham Comparator|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
11143545|NCT03771859||Participants who initiate adjuvant treatment with nivolumab|
11143546|NCT03771846|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
11143547|NCT03771846|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
11143548|NCT03771833|Other|Main MARIA scan visit|For Arm 1, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 1 participants will receive study information that they will be sent home with and informed that they will be approached via a telephone call in 2-3 days (or the closest working day to that date) to enquire if they would like to schedule an appointment for the study visit. If so, this will be scheduled to occur around 7 days from the date of the phone call.
11143549|NCT03771833|Other|Same-day MARIA scan visit|"For Arm 2, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 2 participants will receive study information and as much time as possible to consider their involvement with the study (at least 1 hour). If the patient agrees to participate, they will be scheduled to have their MARIA scans at a time that suits their commitments that day.
~This arm also includes the 2b group, who can optionally consent to a dielectric constant reading of their routinely-aspirated cyst fluid before this is disposed of as per usual site process."
11143550|NCT03771820|Experimental|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
11143551|NCT03771820|Active Comparator|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
11143552|NCT03771807|Placebo Comparator|Placebo & facial cleansing|"Maltodextrin and food coloring
~Subjects will clean the right side of their face with a cosmetic instrument daily"
11143553|NCT03771807|Active Comparator|Beauty From Within & facial cleansing|"Study Product contains collagen hydrolysate, ceramide wheat extract oil and lutein
~Subjects will clean the right side of their face with a cosmetic instrument daily"
11143554|NCT03771794|Active Comparator|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
11143555|NCT03771794|Sham Comparator|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
11143556|NCT03771781|Other|Empagliflozin Tablets|The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
11143557|NCT03771781|Other|Empagliflozin Tab 25 MG|The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
11143558|NCT03771768|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
11143559|NCT03771768|Experimental|Diode laser|Diode laser 980 nm & 100mWatt.
11143560|NCT03771755|Active Comparator|Ibuprofen group|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
11143561|NCT03771755|Placebo Comparator|Acetaminophen group|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
11143562|NCT03771742|Active Comparator|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
11143601|NCT03771430|Active Comparator|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
11143563|NCT03771742|Experimental|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
11143564|NCT03771729|Experimental|LCZ696 treatment|LCZ696 200mg twice daily
11143565|NCT03771716|Experimental|African Dance|This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
11143566|NCT03771716|Active Comparator|African Cultural Immersion|This is the active control group. Participants will participate in a variety of educational activities related to African Culture, including traditional cooking, lectures, crafts, music and films. They will meet 3 times per week for the same duration as the Dance group. However, they will not participate in aerobic activity during the classes, and most activities will be conducted in a seated position.
11143567|NCT03771690|No Intervention|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
11143568|NCT03771690|No Intervention|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
11143569|NCT03771690|Experimental|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
11143570|NCT03771690|Experimental|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
11143571|NCT03771677|Active Comparator|Active Comparator:NAs group|"Active Comparator:nucleotide analogues(NAs)
~patients continue to use NAs"
11143572|NCT03771677|Experimental|Experimental:PEG-IFN group|"Experimental: peg-interferon alfa-2a
~patients switch to sequential peg-interferon α-2a"
11143573|NCT03771664|Experimental|SAGE-217|
11143574|NCT03771664|Placebo Comparator|Placebo|
11143575|NCT03771651|Experimental|Aspirin|Subjects will take 81mg tablets of aspirin daily for 14 days prior to surgery for removal of fallopian tubes.
11143576|NCT03771638|Experimental|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
11143577|NCT03771638|Other|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
11143578|NCT03771625||single-group studies|All the patients received chemotherapy and radiotherapy.
11143579|NCT03771612|Active Comparator|Naproxen|
11143580|NCT03771612|Placebo Comparator|Placebo|
11143581|NCT03771599|Active Comparator|Control group|"Routine physical therapy
~[Time Frame: Twelve weeks]"
11143582|NCT03771599|Experimental|Intervention group|"Traditional massage + Routine physical therapy
~[Time Frame: Twelve weeks]"
11143583|NCT03771586|Experimental|SAGE-718|
11143584|NCT03771586|Placebo Comparator|Placebo|
11143585|NCT03771573|Experimental|Home based intervention|will be submitted to a total of 24 sessions of an unsupervised Cardiovascular Physical Therapy protocol, composed of the following steps: warm up, proper training (aerobic training + muscle training for upper and lower limbs with theraband in 5 series with 10 repetitions) often three times a week for eight weeks.
11143586|NCT03771573|Placebo Comparator|Control group|Will not be submitted to the Cardiovascular Physiotherapy Rehabilitation protocol for unsupervised domiciliary, only monitorization of cardiovascular variables.
11143587|NCT03771573|Active Comparator|Professional seupervision based|eight weeks of supervised activities by professional. Each day and for 20 days (20 sessions), volunteers will undergo exercises on cycle ergometer during 30 minutes for upper and lower limbs
11143588|NCT03771560|Experimental|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
11143589|NCT03771547||More 80|The first group included ERCP patients aged 80 and above.
11143590|NCT03771547||Less 80|The second group included those ERCP patients younger than 80.
11143591|NCT03771534|Experimental|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
11143592|NCT03771508||PillCam SB3 procedure|Subjects with normal/abnormal PillCam SB3 procedure
11143593|NCT03771495|Experimental|Hip Joint Mobilization|passive accessory movement on femur in anterior/posterior direction, grade III for four minutes and passive physiological movement of the most restricted hip joint movement, grade III for one minute (without pain), and a verbal education of hypothesized underlying effect mechanisms.
11143594|NCT03771495|Sham Comparator|Laying on of Hands|grade I, very small amplitude without encountering any tissue resistance for five minutes, thus effectively a Laying on of Hands, with a verbal education of hypothesized underlying effect mechanisms.
11143595|NCT03771482|Active Comparator|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
11143596|NCT03771482|Active Comparator|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
11143597|NCT03771469|Experimental|Questionnaires and sleep studies|Caregivers of patients meeting eligibility criteria will be invited to participate. If they agree to participate, baseline SRBD-PSQ, OSA-18, and PedsQL questionnaires along with written informed consent forms will be mailed to them along with their standard scheduling paperwork. Caregivers will be asked to review the consent form and complete the questionnaires and bring the paperwork to clinic on the day of their visit. Sleep study testing will also be ordered prior to their visit so that it can be scheduled within a month of the initial clinic visit and again three months later.
11143598|NCT03771443|Experimental|gluten free toothpaste|experimental gluten free toothpaste with natural ingredients prepared for the study to be used 3 times per day for six months
11143599|NCT03771430|Experimental|Non-surgical group|Osteoarthritis education, exercise and eCBT
11143600|NCT03771430|Experimental|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
11143602|NCT03771417|Experimental|Resistance Exercise|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week.
11143603|NCT03771417|Experimental|RE plus Low Intensity Physical Activity|Exercise Intervention: Participants will be asked to complete supervised resistance exercise 2 days per week and regular unsupervised low intensity physical activity breaks in sedentary time 5 days per week [6x10 min breaks/d at 2 metabolic equivalents (METS) or ~30-40% peak oxygen consumption (VO2 peak), ~500 kcal/wk above resting metabolism].
11143604|NCT03771417|Active Comparator|RE plus Moderate IntensityExercise|Exercise Intervention: Participants will be asked to complete supervised RE 2 days per week and supervised calorically matched moderate intensity physical activity 3 days per week (50 min/session at 4 METS (~60-75% VO2 peak), ~500 kcal/week above resting metabolism).
11143605|NCT03771404|Other|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
11143606|NCT03771391|Experimental|4 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 4 weeks.
11143607|NCT03771391|Experimental|8 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 8 weeks.
11143608|NCT03771391|Experimental|12 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 12 weeks.
11143609|NCT03771378|Experimental|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
11143610|NCT03771378|Active Comparator|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
11143611|NCT03771365||Standard-PCNL|Perform PCNL with ≥24 Fr access tract for the treatment of ≥2 renal stones
11143612|NCT03771365||Mini-PCNL|Perform PCNL with 12-20 Fr access tract for the treatment of ≥2 renal stones
11143613|NCT03771365||Super-mini PCNL|Perform SMP for the treatment of ≥2 renal stones
11143614|NCT03771339|Active Comparator|Continuous Epidural Analgesia|Continuous epidural analgesia using ropivacaine 0.375% 3 mL boluses followed by ropivacaine 0.2% with rate 6 mL per hour for 24 hours
11143615|NCT03771339|Experimental|Bilateral Quadratus Lumborum Block|Bilateral Quadratus lumborum block using ropivacaine 0.2% 20 mL each injection after surgery
11143616|NCT03771326|Experimental|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
11143617|NCT03771326|Experimental|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
11143618|NCT03771313|Other|PK/PD|Open-label prospective study with participants receiving treating physician-approved intravenous ceftaroline, dosed according to current recommendations. Blood samples collected at baseline, 1 hour, 1.5 hours, 3 hours, and 6 hours after infusion.
11143619|NCT03771300|Experimental|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
11143620|NCT03771300|Experimental|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
11143621|NCT03771300|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
11143622|NCT03771287|Experimental|OpenSound Navigator (OSN) Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
11143623|NCT03771287|Active Comparator|omni-directional Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the Omni-directional microphone system enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
11143624|NCT03771274|Experimental|Tecnis ZLB00 & Symfony IOL|The Tecnis multifocal ZLB00 and the Symfony IOLs are presbyopia correcting lenses designed to improve the vision at distance, intermediate and near reducing the need for glasses in patients undergoing cataract surgery.
11143625|NCT03771261|Placebo Comparator|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d.
11143626|NCT03771261|Active Comparator|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of > 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
11143627|NCT03771248|Active Comparator|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
11143628|NCT03771248|Experimental|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
11143629|NCT03771235|Experimental|Mindfulness-based Intervention for Tics|8-week group-based mindfulness-based program
11143630|NCT03771235|Active Comparator|Tic Information and Coping Strategies|8-week group-based educational and supportive therapy program
11143631|NCT03771222|Experimental|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 ~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 ~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
11143632|NCT03771222|No Intervention|No prophylactic DLI|
11143633|NCT03771209|Experimental|ultrasound assessment|The aim of this study is the creation of a five-step ultrasound examination to evaluate and monitor HF patients during hospitalization and short follow-up.
11143634|NCT03771196|Experimental|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
11143635|NCT03771196|Active Comparator|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
11143636|NCT03771170|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
11143637|NCT03771170|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
11143638|NCT03771157|Experimental|Shingrix shingles vaccine treatment|On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
11143639|NCT03771144|Experimental|Experimental|
11143640|NCT03771131|Experimental|Experimental group|Group receiving the multi-domain cognitive training
11143641|NCT03771131|No Intervention|Control group|Passive control group
11143642|NCT03771105|Experimental|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
11143643|NCT03771105|Active Comparator|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
11143644|NCT03771105|Active Comparator|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
11143645|NCT03771105|Active Comparator|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
11143646|NCT03771092|Experimental|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
11143647|NCT03771092|Experimental|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
11143648|NCT03771092|Experimental|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
11143649|NCT03771092|Experimental|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
11143650|NCT03771092|Experimental|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
11143651|NCT03771066|Experimental|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
11143652|NCT03771066|Placebo Comparator|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
11143653|NCT03771053|Experimental|Ezetimibe with simvastatin group|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
11143654|NCT03771053|Active Comparator|Simvastatin group|simvastatin 40mg everyday for 12 months after PCI
11143655|NCT03771040|Experimental|Masitinib (titration to 6.0 mg/kg/day)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
11143656|NCT03771040|Placebo Comparator|Placebo|Participants receive matched placebo
11143657|NCT03771027|Experimental|Low FODMAP diet group|four weeks of the low FODMAP diet based on Monash University low FODMAP diet App.
11143658|NCT03771027|Active Comparator|Control group|four weeks of the diet based on NICE guidelines and contained products with different FODMAP content
11143659|NCT03771014|Experimental|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
11143660|NCT03771014|No Intervention|Standard care|Patients will receive standard physiotherapy regimen
11143661|NCT03771001|Other|Convenience sample participants|In this feasibility study all participants will receive the intervention.
11143662|NCT03770988|Experimental|poziotinib single arm study|Single Arm study
11143663|NCT03770975|Active Comparator|Delayed implant placement with immediate provisionalization|Single delayed implant placement in the esthetic zone with placing an immediate temporary crown placed within 48 hours after the surgery
11143664|NCT03770975|Experimental|Implant with immediate temporization and soft tissue graft|Single delayed implant placement in the esthetic zone with placing a subepithelial connective tissue graft buccal to the implant and immediate temporary crown within 48 hours after the surgery
11143665|NCT03770962|Experimental|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
11143666|NCT03770962|No Intervention|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
11143667|NCT03770936|No Intervention|Control group|No intervention
11143668|NCT03770936|Active Comparator|Candesartan|Candesartan 8 mg/day
11143669|NCT03770936|Active Comparator|Ramipril|Ramipril 1.25 mg/day
11143671|NCT03770923|Active Comparator|Rupatadine|Rupatadine 10 mg once daily.
11143672|NCT03770923|Active Comparator|Montelukast|Montelukast 10 mg daily
11143673|NCT03770910|Placebo Comparator|Placebo+placebo|Saline infusions
11143674|NCT03770910|Active Comparator|GIP+placebo|GIP(1-42), receptor agonist
11143675|NCT03770910|Experimental|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
11143676|NCT03770910|Experimental|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
11143677|NCT03770910|Experimental|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
11143678|NCT03770910|Experimental|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
11143679|NCT03770897|Experimental|3D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed with 3d technology device by young surgeons, tutored by an expert assistant.
11143680|NCT03770897|Active Comparator|2D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed by young surgeons (tutored by an expert assistant) with the standard 2D viewing method.
11143681|NCT03770884||Rheumatoid arthritis|EULAR-ACR criteria Whatever the treatment and the disease activity
11143682|NCT03770884||Axial spondyloarthritis|ASAS criteria for axial disease Whatever the treatment and the disease activity
11143683|NCT03770884||digital osteoarthritis|According to ACR criteria Whatever the treatment and the disease activity
11143684|NCT03770871|Active Comparator|IPT using Dycal (TM )|Indirect pulp treatment; IPT using Dycal (TM ); (2 paste system) by partial caries removal
11143685|NCT03770871|Experimental|IPT using Vitrebond (TM )|Indirect pulp treatment; IPT using Vitrebond (TM );(powder and liquid) by partial caries removal
11143686|NCT03770858||Crisaborole and wearable sensor|Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
11143687|NCT03770832||Infants at Risk for Atypical Motor Development (high-risk)|
11143688|NCT03770832||Infants Expected to Have Typical Motor Development (low-risk)|
11143689|NCT03770819|Placebo Comparator|Placebo group|Application of placebo gel followed by sham Photodynamic therapy
11143690|NCT03770819|Active Comparator|Zinc oxide gel group|Application of Zinc oxide gel followed by sham Photodynamic therapy.
11143691|NCT03770819|Experimental|PDT group|Application of placebo gel followed by Photodynamic therapy.
11143692|NCT03770819|Experimental|Zinc oxide and PDT group|Application of Zinc oxide gel followed by Photodynamic therapy.
11143693|NCT03770806|Experimental|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
11143694|NCT03770806|Experimental|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
11143695|NCT03770806|Experimental|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
11143696|NCT03770793|Experimental|Lung-sono guided|Before starting one-lung ventilation, alveolar recruitment is performed under the examination with ultrasound. Find the minimal airway pressure that actually starts to resolve the observed atelectasis. Repeat alveolar recruitment with the minimal pressure untill the atlelectasis is not visible.
11143697|NCT03770793|No Intervention|Conventional|Before starting one-lung ventilation, alveolar recruitment is performed with the pressure of 30mmHg for 10 seconds which is a conventional method.
11143698|NCT03770780|Experimental|SAGE-718|
11143699|NCT03770780|Placebo Comparator|Placebo|
11143700|NCT03770767|Experimental|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
11143701|NCT03770767|Active Comparator|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
11143702|NCT03770754|Experimental|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
11143703|NCT03770754|Experimental|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
11143704|NCT03770754|Experimental|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
11143705|NCT03770741|Experimental|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
11143706|NCT03770741|Other|Treatment as usual|Treatment according local guidelines and practices.
11143707|NCT03770728|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (prefilled syringe) administered once weekly for 30 weeks
11143708|NCT03770728|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (prefilled syringe) administered once weekly for 30 weeks
11143709|NCT03770728|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (prefilled syringe) administered once weekly for 30 weeks
11143710|NCT03770728|Placebo Comparator|Placebo|Matching placebo (prefilled syringe) administered once weekly for 30 weeks
11143711|NCT03770702|No Intervention|Control group|No intervention
11143712|NCT03770702|Active Comparator|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
11143713|NCT03770702|Active Comparator|Statins|Statin + Traditional therapy.
11143714|NCT03770689|Experimental|Phase Ib: M3814 + Capecitabine + RT|
11143715|NCT03770689|Experimental|Phase II: M3814 + capecitabine + RT|
11143716|NCT03770689|Placebo Comparator|Phase II: Placebo + capecitabine + RT|
11143717|NCT03770676|Experimental|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
11143907|NCT03769350|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
11143718|NCT03770676|Experimental|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
11143719|NCT03770676|Experimental|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
11143720|NCT03770663|Experimental|European strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12
~In association with:
~6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day"
11143721|NCT03770663|Experimental|American strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12
~In association with:
~Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL."
11143722|NCT03770650|Experimental|IVUS-guided DK crush stenting|"In the IVUS-guided DK crush stenting group, IVUS will be before side branch stenting, after rewiring side branch, after 1st kissing balloon inflation, after rewiring side branch, after 2nd kissing balloon inflation.
~For LM bifurcation lesions involving ostial LAD and LCX: minimum stent are (MSA) should be ≥10mm2 (LM), 7 mm2 (LAD), and 6 mm2 (LCX), with stent expansion index ≥90% (CSA≥90% of distal reference lumen area in LCX) and symmetry index >0.8.
~For non-LM bifurcation lesion involving the MSA should be ≥6 mm2 in the main vessel; and the MSA in the ostial side branch should be ≥5 mm2 and ≥90% of distal reference lumen area; and symmetry index should be >0.8."
11143723|NCT03770650|Active Comparator|Angiography-guided DK crush stenting|In the Angiography-guided DK crush stenting group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of ≥Type B dissection.
11143724|NCT03770637|Experimental|Glucagon RTU (glucagon injection)|Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
11143725|NCT03770637|Placebo Comparator|Placebo|Non-active vehicle for Glucagon RTU; 60 μL injection
11143726|NCT03770624|Experimental|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
11143727|NCT03770624|Experimental|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
11143728|NCT03770624|Experimental|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
11143729|NCT03770624|Experimental|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
11143730|NCT03770624|Experimental|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
11143731|NCT03770624|Active Comparator|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
11143732|NCT03770611|Active Comparator|Probiotic|Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
11143733|NCT03770611|Active Comparator|Prebiotic|Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
11143734|NCT03770611|Experimental|Symbiotic|Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
11143735|NCT03770611|Placebo Comparator|Placebo|Subjects receiving placebo of probiotic and prebiotic per day during 3 months
11143736|NCT03770598|Active Comparator|Distressed|Study participants who do indicate distress or who do meet criteria for depression or anxiety will be randomized to receive either treatment as usual (referral to Psychiatry or Psychology for evaluation and further treatment) or team based care model.
11143737|NCT03770598|Active Comparator|Non-Distressed|Study participants who do not indicate distress or who do not meet criteria for depression or anxiety will be randomize to monitoring only or to receive psycho-education regarding subjects that when used can promote wellness.
11143738|NCT03770585|Active Comparator|Group 1(Fluoroscopy guided group)|IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
11143739|NCT03770585|Active Comparator|Group2 (Ultrasound guided group)|In Ultrasound guided group, with Ultrasound guidance, , a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml(20mg) methylprednisolone acetate is administered intra-articular (until resistance was encountered) and injected around the posterior facet joint capsule.
11143740|NCT03770572|Experimental|Open-label, single-dose, dose-escalation study of AT-GTX-502|"Cohort 1: AT-GTX-502 Low-Dose
~Cohort 2: AT-GTX-502 High-Dose"
11143741|NCT03770559|Active Comparator|Open-RAMPS|Patients with pancreatic cancer treated by traditional open surgery
11143742|NCT03770559|Experimental|MI-RAMPS|Patients with pancreatic cancer treated by laparoscopic surgery
11143743|NCT03770546|Experimental|Osteoarthritis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
11143744|NCT03770546|Active Comparator|Osteoarthritis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
11143745|NCT03770546|Experimental|Adhesive Capsulitis - Amnion Injection|BioDRestore Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from human amniotic tissues.
11144408|NCT03766100|Experimental|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
11143746|NCT03770546|Active Comparator|Adhesive Capsulitis - Betamethasone Injection|Betamethasone Sodium Phosphate and Betamethasone Acetate injection (To clarify, this is one formulation/injected solution, not separate solutions/interventions)
11143747|NCT03770533|Other|MR-proADM guided|
11143748|NCT03770533|No Intervention|Standard Care|
11143749|NCT03770520|Experimental|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
11143750|NCT03770520|Active Comparator|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
11143751|NCT03770507|Experimental|Treadmill Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
11143752|NCT03770507|Experimental|Cyclo Ergometer Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
11143753|NCT03770494|Experimental|LY3405105|LY3405105 administered orally.
11143754|NCT03770481|Experimental|Assess the NLCS' feasibility|"Hypothesis: No significant differences will be observed in recruitment and attrition between NLCS intervention and control groups.
~Approach: Determine rates of enrollment and drop-outs between groups."
11143755|NCT03770481|Experimental|Assess the NLCS' acceptability|"Hypothesis: More surrogates agree that the NLCS is suitable, appropriate, effective and willing to adhere versus treatment as usual (TAU) communication.
~Approach: Assess outcome using the validated instrument, Client Satisfaction Questionnaire (CSQ-8)."
11143756|NCT03770481|Experimental|Assess the NLCS' preliminary effects|Hypothesis: NLCS improves communication and decreases surrogates' psychological distress (e.g., anxiety and depression) Approach: Compare pre- and post-intervention scores of the Quality of Communication (QOC) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Decisional Conflict Scale (DCS) between intervention and control groups.
11143757|NCT03770455|Experimental|Avelumab + 2nd generation ADT|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
11143758|NCT03770442|Experimental|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.
~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.
~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
11143759|NCT03770442|Active Comparator|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
11143760|NCT03770429|Experimental|AZD6738|Patients will receive AZD6738 orally on a 28-day cycle
11143761|NCT03770416|Experimental|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
11143762|NCT03770416|Experimental|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
11143763|NCT03770403|Experimental|ARGX-113|
11143764|NCT03770390|Other|The study population|"Patients included in this study have pectus excavatum. The have either already undergone corrective surgery during the four years prior to the inclusion period, or are scheduled for surgery during the inclusion period.
~Intervention: Surgical correction of pectus excavatum"
11143765|NCT03770377|Experimental|Stroke without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
11143766|NCT03770377|Experimental|Stroke with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
11143767|NCT03770377|Experimental|SCA6 without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
11143768|NCT03770377|Experimental|SCA6 with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
11143769|NCT03770377|Active Comparator|Age-Matched Controls|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
11143770|NCT03770338|No Intervention|Control|Recruitment for fusion surgery as usual
11143771|NCT03770338|Experimental|Teriparatide|Preoperative 1 month use of teriparatide, before lumbar fusion surgery
11143772|NCT03770325|Experimental|Berberine|berberine (500 mg orally twice a day)
11143773|NCT03770325|Placebo Comparator|Placebo|placebo (500 mg orally twice a day)
11143774|NCT03770312|Active Comparator|Low intensity statin group|Taking low intensity statin
11143775|NCT03770312|Active Comparator|Moderate intensity statin group|Taking moderate intensity statin
11143776|NCT03770299|Experimental|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
11143777|NCT03770299|Active Comparator|Arm B|SOC (chemotherapy in eligible participants or observation)
11143778|NCT03770286|Active Comparator|Fluoride Varnish alone|5% sodium fluoride varnish will be applied to all teeth the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
11143779|NCT03770286|Experimental|SDF with Super Floss|SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
11144409|NCT03766100|No Intervention|Control group|Insomnia is untreated.
11143780|NCT03770286|Experimental|SDF without Super Floss|SDF will be applied to around the (buccal, lingual, and occlusal) embrasures of the target interproximal lesions with the use of a microbrush for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
11143781|NCT03770273|Active Comparator|placebo|8 SC injections of placebo
11143782|NCT03770273|Active Comparator|sarilumab|8 (SC) injections of 200 mg/1.14 mL of sarilumab over 16 weeks
11143783|NCT03770260|Experimental|Treatment (ixazomib citrate, pevonedistat)|Patients receive ixazomib citrate PO QD on days 1, 8, and 15, and pevonedistat IV over 60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11143784|NCT03770247|Experimental|intraoperative group (IOCPN group)|Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.
11143785|NCT03770247|Active Comparator|CT group (CTCPN group)|CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection
11143786|NCT03770234|Experimental|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
11143787|NCT03770234|Experimental|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
11143788|NCT03770221|Experimental|Financial Incentive|"Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
~Additionally, participants in this arm will receive $20 for every week they maintain contact with CATCH service providers, as required by their care plan. Contact can be by phone, text, email, or in person with CATCH service providers over 6 months of follow up, or until they are successfully transitioned to longer-term supports (for up to $80/month per participant)."
11143789|NCT03770221|Active Comparator|Usual Care|Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
11143790|NCT03770208|Placebo Comparator|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
11143791|NCT03770208|Experimental|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
11143792|NCT03770195||Abdominoplasty Patients|Patients undergoing full abdominoplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
11143793|NCT03770182|Experimental|Group A|"NEUROLITH
~Cycle 1: Active treatment
~Cycle 2: Sham treatment"
11143794|NCT03770182|Experimental|Group B|"NEUROLITH
~Cycle 1: Sham treatment
~Cycle 2: Active treatment"
11143795|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
11143796|NCT03770143||Group 1|Infants feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life
11143797|NCT03770143||Group 2|Infants feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life
11143798|NCT03770143||Group 3|Having similar demographical properties with infants feeding with breast milk (gender, age, weight, height)
11143799|NCT03770130|Experimental|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
11143800|NCT03770130|Placebo Comparator|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
11145528|NCT03758365|Active Comparator|Desonide 0.05% cream|Single application of Desonide 0.05%
11143801|NCT03770117||Prehabilitation|"In this arm of the study, participants will undergo prehabilitation prior to surgery. This is intended to increase the participants overall health prior to surgery to try and increase their general well-being during and after surgery.
~Prehabilitation is multimodal therapy comprising:
~Assessment for malnutrition and nutritional support dependent on the outcome
~Optimisation of management of pancreatic exocrine insufficiency
~Assessment of muscle mass and strength
~Individually tailored, goal directed exercise regimen under the care of physiotherapy"
11143802|NCT03770117||Standard Procedure|In this arm, participants will not receive any Rehabilitation prior to the surgery. This is the current standard care and will act as the control data for this study.
11143803|NCT03770104|Experimental|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
11143804|NCT03770104|Experimental|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
11143805|NCT03770091|Experimental|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
11143806|NCT03770091|Placebo Comparator|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
11143807|NCT03770091|Experimental|Foam alone|Patients will use Theraworx foam without compression wrap
11143808|NCT03770078|Experimental|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
11143809|NCT03770065||Group A|
11143810|NCT03770065||Group B|
11143811|NCT03770052|Experimental|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
11143812|NCT03770052|Active Comparator|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
11143813|NCT03770039|Experimental|2-period, fixed sequence|fixed sequence with 2 treatment period
11143814|NCT03770026|Active Comparator|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
11143815|NCT03770026|Experimental|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
11143816|NCT03770013|Active Comparator|bupivacaine 0.25% and Dexmedetomidine|bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)
11143817|NCT03770013|Active Comparator|bupivacaine and clonidine|20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP
11143818|NCT03770013|Placebo Comparator|bupivacaine and placebo|bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP
11143819|NCT03770000|Experimental|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
11143820|NCT03769974|Experimental|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
11143821|NCT03769974|Experimental|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
11143822|NCT03769974|Placebo Comparator|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
11143823|NCT03769961||ET (DBS-, Ataxia+)|Essential Tremor without DBS with Ataxia on examination
11143824|NCT03769961||ET (DBS-, Ataxia-)|Essential Tremor without DBS and without Ataxia on examination
11143825|NCT03769961||ET (DBS+, Ataxia+)|Essential Tremor with DBS with Ataxia on examination
11143826|NCT03769961||ET (DBS+, Ataxia-)|Essential Tremor with DBS without Ataxia
11143827|NCT03769935|Experimental|experimental arm|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
~S1 25 mg/m2 oral, everyday until progression disease"
11143828|NCT03769935|Active Comparator|active comparator|cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
11143829|NCT03769922|Experimental|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
11143830|NCT03769922|Active Comparator|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
11143831|NCT03769896|Active Comparator|Treatment Group|Nabilone 0.25 mg
11143832|NCT03769896|Placebo Comparator|Placebo Group|Placebo (corn starch)
11143833|NCT03769883|Experimental|Dietary control (DCON)|The macro-nutrient distributions are in line with the current guidelines from the national Diabetes Association and Canadian guidelines, where individualization in macronutrient distribution should lie within the range of 45-60E% carbohydrate, 15-20E% protein and 20-35E% fat. The dietary plan will aim at reducing saturated fat intake <7E% aiming at a caloric deficit of 500 kilo calories/day
11145529|NCT03758365|Placebo Comparator|Vehicle cream|Single application of Vehicle
11143834|NCT03769883|Experimental|Moderate Exercise Dose (MED)|Two aerobic training sessions per week of 45-60 min duration and one session per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
11143835|NCT03769883|Experimental|High Exercise Dose (HED)|Four aerobic training sessions per week of 45-60 min duration and two sessions per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
11143836|NCT03769883|No Intervention|Control|No intervention
11143837|NCT03769870|Other|Teneligliptin|
11143838|NCT03769870|Other|Atorvastatin|
11143839|NCT03769870|Other|Teneligliptin + Atorvastatin|
11143840|NCT03769857|Experimental|NEM® + BIOCURC®|"NEM® + BIOCURC®
~NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks"
11143841|NCT03769857|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
11143842|NCT03769844|Experimental|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
11143843|NCT03769844|Experimental|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
11143844|NCT03769844|Experimental|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
11143845|NCT03769844|Experimental|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
11143846|NCT03769831|Experimental|SHR2285|Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
11143847|NCT03769831|Experimental|Placebo|Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.
11143848|NCT03769818|Active Comparator|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
11143849|NCT03769818|Active Comparator|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
11143850|NCT03769818|Placebo Comparator|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
11143851|NCT03769805|Experimental|Anlotinib Arm|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
11143852|NCT03769792|Experimental|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.
~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.
~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.
~The planned interventions are:
~Blood and faeces tests
~Impedance spectroscopy test
~Full gynecological and proctological examination
~Transanal ultrasonography
~Anorectal manometry"
11143853|NCT03769779|Experimental|Treatment|Lutein (FloraGLO™) in safflower oil
11143854|NCT03769779|Placebo Comparator|Placebo|safflower oil
11143855|NCT03769766|Active Comparator|Curcumin|"Other names for the supplement: BCM-95 CG (Biocurcumax),Tumeric
~Manufacture- DolCas Biotech, LLC.
~Classification - type of agent: Supplement
~Protocol dose: 500 mg twice"
11143856|NCT03769766|Placebo Comparator|Placebo|"Drug: placebo
~placebo orally twice a day Other Names: •sugar pill"
11143857|NCT03769753|Experimental|intraoperative use of IRE|Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
11143858|NCT03769740||CPR Group|
11143859|NCT03769727|Active Comparator|Traditional|Procedure: Tube thoracostomy Traditional chest tube placement
11143860|NCT03769727|Experimental|Reactor Device|Device: Reactor Device The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
11143861|NCT03769714|Active Comparator|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
11143862|NCT03769714|Experimental|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
11143863|NCT03769701|Active Comparator|Group 1, SMGC four times/day|Women with GDM and SMGC 4 times/day; fasting and 1-hour post-prandial of breakfast, lunch and dinner
11143864|NCT03769701|Experimental|SMGC two times/day|Women with GDM and SMGC 2 times/day; pre-prandial and 1-hour post-prandial of breakfast, lunch or dinner alternating the meal each day.
11143865|NCT03769688|Experimental|Cervicovaginal secretions|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of cervicovaginal secretions (10 mg in 1 ml total volume, 0.9 ml normal saline).
11143866|NCT03769688|Placebo Comparator|Saline placebo|Participants will receive standard of care antibiotics (vaginal Metronidazole gel). After standard antibiotic treatment, participants will receive a single intravaginal dose of sterile saline placebo (1 ml total volume).
11143867|NCT03769675|Experimental|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
11143868|NCT03769662|Experimental|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
11143869|NCT03769649|Experimental|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
11143870|NCT03769623|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter
11143871|NCT03769623|Active Comparator|Powerline|Balloon dilated catheter
11145603|NCT03757858|Active Comparator|HT+CT|
11143872|NCT03769610|Active Comparator|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
11143873|NCT03769610|Experimental|Outpatient Foley catheter|Subjects are asked to return to the hospital ~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
11143874|NCT03769597|Experimental|Iohexol administration|After injecting a loading dose of 5ml of Iohexol Inj 300 MG/ML bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
11143875|NCT03769571|Other|parental coaching program at ESDM (P-ESDM)|
11143876|NCT03769571|No Intervention|CONTROL|
11143877|NCT03769558||JIA patients prescribed abatacept|
11143878|NCT03769532|Experimental|Pembrolizumab + Azacitidine|"Pembrolizumab (IMP): 200 mg i.v. (fixed dose) / Azacitidine (SOC): 75 mg/m2 s.c.
~maximum duration of treatment: up to 24 weeks"
11143879|NCT03769519|No Intervention|Control (Group 1)|This group is considered the control group. This group will have scheduled texts and emails for the monthly surveys after the participant completes the baseline questionnaires.
11143880|NCT03769519|Experimental|ARICA Intervention (Group 2)|This group is considered the intervention group. Participants in this group will receive weekly texts and emails containing asthma facts and myths. They will also complete monthly surveys and participate in asthma education sessions.
11143881|NCT03769506|Active Comparator|ASP-1929 Photoimmunotherapy|Use of ASP-PIT therapy
11143882|NCT03769506|Active Comparator|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
11143883|NCT03769493|Experimental|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
11143884|NCT03769480||Study Group|Study Group=Athletes with Disability
11143885|NCT03769480||Control Group|Control Group=Healthy Athletes
11143886|NCT03769467|Experimental|tabelecleucel in combination with pembrolizumab|Tabelecleucel will be administered initially to 12 subjects at a dose of 2 x 10^6 cells/kg intravenously (IV) on Day 1, Day 8, and 15 of a 21-day cycle. Pembrolizumab will be administered to adult subjects at 200 mg or to pediatric subjects (12 to < 18 years of age) at 2 mg/kg IV every 3 weeks.
11143887|NCT03769454|Experimental|PP-001 low dose group|
11143888|NCT03769454|Placebo Comparator|Placebo low dose group|
11143889|NCT03769454|Experimental|PP-001 mid dose group|
11143890|NCT03769454|Placebo Comparator|Placebo mid dose group|
11143891|NCT03769454|Experimental|PP-001 high dose group|
11143892|NCT03769454|Placebo Comparator|Placebo high dose group|
11143893|NCT03769441|Active Comparator|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
11143894|NCT03769441|Placebo Comparator|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
11143895|NCT03769428|Active Comparator|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)
~An intravenous patient controlled analgesia device will be given to the patients postoperatively"
11143896|NCT03769428|Placebo Comparator|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected
~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
11143897|NCT03769415|Experimental|Intrinsic subtyping of Primary Breast Cancer|Intrinsic subtype of primary breast tissue from metastatic breast cancer subject will be determined
11143898|NCT03769402|Active Comparator|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
11143899|NCT03769402|Placebo Comparator|Control|Control test
11143900|NCT03769389|Experimental|assessing the GI + GL of Birhi + YEO 0% fat yoghurt|47g of total carbohydrate in which contains 43.6g of Freeze-dried of Birhi powder+ 150g of 0% fat yoghurt
11143901|NCT03769389|Experimental|assessing the GI + GL of Khassab + YEO 0% fat yoghurt|47g of total carbohydrate in which contains34.6g of freeze-dried Khassab powder+ 150g of 0% fat yoghurt
11143902|NCT03769389|Experimental|assessing the GI + GL of 50g of Glucose in 100 ml of water|50g of pure glucose dissolved in 100ml of water
11143903|NCT03769376|Active Comparator|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
11143904|NCT03769376|Active Comparator|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
11143905|NCT03769363|Experimental|Smartphone-delivered CBT for SAD|12-week Smartphone delivered CBT for SAD.
11143906|NCT03769363|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for SAD following the 12-week waitlist control).
11143908|NCT03769350|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
11143909|NCT03769337||Infected|Serum biomarkers in patients with diagnosis of prosthetic joint infection
11143910|NCT03769337||Not Infected|Serum biomarkers in patients with implant failure not caused by infection
11143911|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
11143912|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
11143913|NCT03769311|Experimental|Pre-Operative Cetuximab Therapy|Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
11143914|NCT03769298|Experimental|Envarsus XR|Envarsus XR (extended release) will be administered orally, once-daily, for 6 months.
11143915|NCT03769285|Experimental|Nicotinamide|
11143916|NCT03769285|Placebo Comparator|Placebo|
11143917|NCT03769272||Echocardiographic targeting|
11143918|NCT03769272||Electrogram targeting|
11143919|NCT03769259|Experimental|Brief Cognitive Behavioral Therapy|
11143920|NCT03769259|Active Comparator|Present-Centered Therapy|
11143921|NCT03769246|Experimental|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.
~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
11143922|NCT03769246|Active Comparator|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
11143923|NCT03769233|Experimental|Mindfulness-based Intervention|5 week, manual-based group MBI treatment for depressive and anxious symptoms
11143924|NCT03769220||inpatient rehabilitation ward|"The first 20 participants will be recruited from the inpatient rehabilitation ward at Robert-Bosch-Hospital (RBK). The treating medical doctor will inform potentially eligible participants about the possibility of being involved in this study. Should participants confirm their interest a research assistant will complete a detailed information session and obtain written informed consent prior enrolment.
~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
11143925|NCT03769220||outpatient rehabilitation clinic|"Further 20 participants will be recruited through the outpatient rehabilitation clinic at Robert-Bosch-Hospital (RBK). The treating doctor will again inform the potential participant about the study and invite them to participate. A research assistant will complete a detailed information session and written informed consent will be obtained prior enrolment.
~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
11143926|NCT03769220||community dwelling older adults|"Lastly 20 community dwelling older adults will be invited to participate. Recruitment will occur through advertisement at a locally run seniors fitness group, conducted every Thursday at RBK. Older adults who are interested in being involved will be invited to receive additional information about the study and the involved procedures before providing written informed consent and being enrolled.
~Participants in the study don't receive any interventions, just a baseline measurement (only health outcomes are assessed)."
11143927|NCT03769207|Other|Ambulatory ECG|
11143928|NCT03769194|Active Comparator|VLA15 low dose|VLA15 low dose with Alum.
11143929|NCT03769194|Active Comparator|VLA15 medium dose|VLA15 medium dose with Alum.
11143930|NCT03769194|Active Comparator|VLA15 high dose|VLA15 high dose with Alum.
11143931|NCT03769194|Placebo Comparator|Placebo|
11143932|NCT03769181|Experimental|Phase 1: cHl/DLBCL/PTCL|Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose
11143933|NCT03769181|Experimental|Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
11143934|NCT03769181|Experimental|Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
11143935|NCT03769181|Experimental|Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
11143936|NCT03769181|Experimental|Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
11143937|NCT03769168|Experimental|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
11143938|NCT03769168|Experimental|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
11143939|NCT03769155|Experimental|A (VX15/2503, nivolumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and nivolumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
11143940|NCT03769155|Experimental|B (VX15/2503, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and ipilimumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
11143941|NCT03769155|Experimental|C (VX15/2503, nivolumab, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes, nivolumab IV over 30 minutes, and ipilimumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
11143942|NCT03769155|Experimental|D (nivolumab, surgery)|Participants receive nivolumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
11143943|NCT03769155|Active Comparator|E (surgery)|Participants undergo surgery.
11143944|NCT03769129|Experimental|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
11144056|NCT03768336|Experimental|3RP Group Sessions|"The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions
~Mini relaxation practice
~Weekly goal check-ins
~RR-practice"
11143945|NCT03769129|Other|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
11143946|NCT03769116|Experimental|SRP-9001 in Part 1 Followed by Placebo in Part 2|Patient will receive SRP-9001 at Part 1 followed by matching Placebo at Part 2 followed by an open-label extension at Part 3.
11143947|NCT03769116|Experimental|Placebo in Part 1 Followed by SRP-9001 in Part 2|Patient will receive matching Placebo at Part 1 followed by SRP-9001 at Part 2 followed by an open-label extension at Part 3.
11143948|NCT03769103|Active Comparator|SRS + Osimertinib|Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
11143949|NCT03769103|Experimental|Osimertinib alone|Osimertinib 80mg PO daily
11143950|NCT03769090|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
11143951|NCT03769090|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
11143952|NCT03769090|Active Comparator|AS MDI (PT007) 90 µg|
11143953|NCT03769077|Experimental|Exergaming (Case) Group|"Participants assigned to the exergame condition will play the exergames for 30 minutes, 5 days a week for 3 weeks (15 exergame sessions). Outcomes will be acquired at baseline (before intervention), and at the end of every week during the 3 week intervention phase. Participants will also receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital.
~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
11143954|NCT03769077|No Intervention|Comparison Group|"Participants will receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital and will complete questionnaires and assessments at the same time points during study participation.
~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
11143955|NCT03769064|Experimental|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
11143956|NCT03769064|Experimental|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
11143957|NCT03769064|Experimental|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
11143958|NCT03769064|Experimental|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
11143959|NCT03769064|Experimental|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
11143960|NCT03769064|Experimental|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
11143961|NCT03769038|Other|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
11143962|NCT03769025|Experimental|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
11143963|NCT03769025|Active Comparator|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
11143964|NCT03769012|Experimental|Treatment|Beta-Glucan
11143965|NCT03769012|Placebo Comparator|Placebo|Placebo
11143966|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
11143967|NCT03768986|Active Comparator|Treatment Group A|Standard referral for HIV testing and online HIV risk reduction training
11143968|NCT03768986|Experimental|Treatment Group B|Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
11143969|NCT03768973||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
11143970|NCT03768973||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
11143971|NCT03768960|Experimental|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
11143972|NCT03768947|Experimental|Heat Therapy Arm|Participants in this open-label pilot study will undergo heat therapy via hot water immersion (hot-tub).
11143973|NCT03768934|No Intervention|Control|No airtime incentive for completing the survey
11143974|NCT03768934|Experimental|1X Incentive|1X airtime incentive
11143975|NCT03768934|Experimental|2X incentive|2X airtime incentive
11143976|NCT03768934|Experimental|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
11143977|NCT03768921|Experimental|PEEP Titriation|patients with respiratory distress syndrome will undergo alveolar recruitment in the mechanical ventilator and will have their final positive mechanical ventilator pressure determined by ventilator evaluation by the electrical impedance tomograph. The increase of the peep in the mechanical ventilator to perform the alveolar recruitment will be of 2 in 2 cmH2O every 2 minutes until the pressure reaches 25 cmH20, after the pressure was reduced in the same way being evaluated in the tomograph what will be the point with greater alveolar recruitment, having greater ventilation, without alveolar hyperdistension or alveolar collapse.
11143978|NCT03768908|Active Comparator|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
11143979|NCT03768908|Active Comparator|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose.
11143980|NCT03768895||MRI group|The criteria for patient inclusion were: Age > 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age < 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
11143981|NCT03768882|Experimental|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
11143982|NCT03768882|Experimental|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
11143983|NCT03768869|Experimental|Low Risk: Oupatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
11143984|NCT03768869|Active Comparator|Low Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
11143985|NCT03768869|Active Comparator|High Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
11143986|NCT03768856|Experimental|Temporally Feathered Radiation Therapy (TFRT)|"Temporally feathered radiation therapy is designed for targets within close proximity to multiple organs at risk. The foundation of this planning technique is the rotation of radiation dose to the nearby organs at risk on a daily basis, and hence the term feathering."
11143987|NCT03768843|Other|traumatic odontoid fracture|C1 C2 fusion screws
11143988|NCT03768830|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
11143989|NCT03768830|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
11143990|NCT03768830|Experimental|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
11143991|NCT03768830|No Intervention|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
11143992|NCT03768817||Patients treated with triheptanoin|Patients with LC-FAOD treated with triheptanoin before 01 September 2018 under eIND
11143993|NCT03768804|Other|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
11143994|NCT03768804|Other|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
11143995|NCT03768791|Experimental|SCS off|
11143996|NCT03768791|Experimental|SCS on|
11143997|NCT03768778|Other|Debridement|
11143998|NCT03768765||Long Term Medication Usage|Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
11143999|NCT03768765||Short Term Medication Usage|Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)
11144000|NCT03768752||Diastolic Dysfunction|Patients with pre-existing or new diastolic dysfunction.
11144001|NCT03768752||Normal Diastolic Function|Patients with normal diastolic function.
11144002|NCT03768739||CICU extubated patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
11144003|NCT03768726|Experimental|Ziprasidone|"All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period.
~During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules.
~During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication."
11144004|NCT03768713|Experimental|Drug (Suvorexant)|20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)
11144005|NCT03768713|Placebo Comparator|Placebo|20 mg of Placebo daily (taken orally ~1 hour before bedtime)
11144006|NCT03768700||Cohort|Hospitalization in a Post-Resuscitation Rehabilitation Care Units (SRPR)
11144007|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration > 4 weeks and/or > five admissions last year.
~Assessment of diagnoses, functioning and health services"
11144008|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.
~Assessment of diagnoses, functioning and health services"
11144009|NCT03768661||SILC Group|patients with symptomatic cholelithiasis submitted to a single-incision laparoscopic cholecystectomy
11144010|NCT03768661||Laparoscopy Group|patients with symptomatic cholelithiasis submitted to a standard three trocar laparoscopic cholecystectomy
11144011|NCT03768648|Experimental|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
11144012|NCT03768648|Active Comparator|Control|40 Healthy controls (HC)
11144013|NCT03768635||Necrotizing external otitis|description of necrotizing external otitis
11144014|NCT03768622||surgery for femoral neck fracture|patients with proximal femoral fracture (type: femoral neck fracture) with surgical procedure: partial hip arthroplasty
11144015|NCT03768622||surgery for pertrochanteric femoral fractures|patients with proximal femoral fracture (type:pertrochanteric femoral fractures) with surgical procedure: intramedullary nail type Gamma® Nail or similar
11145604|NCT03757845|No Intervention|Control diet|
11144016|NCT03768609|Experimental|Group 1: Sequence AB|Participants will receive Treatment A (pimodivir 600 milligram [mg] orally as two tablets of 300 mg each) on Day 1 in Period 1 followed by Treatment B (pimodivir 600 mg as two tablets of 300 mg each plus cyclosporine 400 mg orally as four capsules of 100 mg each) on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
11144017|NCT03768609|Experimental|Group 2: Sequence BA|Participants will receive Treatment B on Day 1 in Period 1 followed by Treatment A on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
11144018|NCT03768596|Experimental|Nudge|receiving nudge and form
11144019|NCT03768596|Active Comparator|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
11144020|NCT03768596|No Intervention|No intervention|receiving no nudge nor form
11144021|NCT03768583|Experimental|Group TSM ICT sneakers|"ICT with sneaker
~five weeks
~twice a week
~half hour."
11144022|NCT03768583|Experimental|Group TSM ICT barefoot|"ICT barefoot
~five weeks
~twice a week
~half hour."
11144023|NCT03768583|Experimental|Group TSM health barefoot|"Health with sneaker
~five weeks
~twice a week
~half hour."
11144024|NCT03768583|Experimental|Group TSM health sneakers|"Health barefoot
~five weeks
~twice a week
~half hour."
11144025|NCT03768570|No Intervention|Surveillance|
11144026|NCT03768570|Active Comparator|Durvalumab|
11144027|NCT03768557|Experimental|Minocycline|single dose of minocycline (200mg)
11144028|NCT03768557|Placebo Comparator|Placebo|lactose pills (400mg)
11144029|NCT03768544|Experimental|Self-help guided by a lay provider|
11144030|NCT03768544|Other|Waiting list where participants wait for delayed treatment|
11144031|NCT03768531|Experimental|Arm A: Nivolumab|
11144032|NCT03768531|Experimental|Arm B: Nivolumab and Cabrilizumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
11144033|NCT03768505|Experimental|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
11144034|NCT03768492|Experimental|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
11144035|NCT03768492|Placebo Comparator|Placebo|placebo cream during and for 4 weeks following radiation
11144036|NCT03768479|Experimental|FES-Fulvestrant|Patients with ER positive breast cancer receive Fulvestrant as the first line treatment enrolled in the study would receive 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant.
11144037|NCT03768466|Experimental|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
11144038|NCT03768440|Experimental|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
11144039|NCT03768440|Active Comparator|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
11144040|NCT03768427|Experimental|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
11144041|NCT03768427|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
11144042|NCT03768427|Experimental|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
11144043|NCT03768427|Active Comparator|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
11144044|NCT03768414|Experimental|Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride)|Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11144045|NCT03768414|Experimental|Arm II (cisplatin, gemcitabine hydrochloride)|Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11144046|NCT03768401|Experimental|Educational Seminars and Wellness Clinics|"I. Community outreach educational seminars about wellness and exercise while living with a neurological physical disability and measurement of the effects of these seminars for training individuals with neurological physical disabilities and their care givers (family, therapists, community personal trainers and community funders such as Lions or Rotary Clubs) about how to create a safe cost-effective exercise program .
~II. Creation and measurement of the effects of a wellness clinic for those with a neurological physical disability."
11144047|NCT03768388|Other|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
11144048|NCT03768388|Other|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
11144049|NCT03768375|Experimental|target therap|The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
11144050|NCT03768375|Experimental|FORFIRINOX|The patients wil receive conventional chemotherapy(FORFIRINOX)
11144051|NCT03768362|Experimental|Undergoing plication strabismus surgery|
11144052|NCT03768362|Active Comparator|Undergoing resection strabismus surgery|
11144053|NCT03768349|Experimental|PET/CT Ga-68 PSMA|Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT
11144054|NCT03768349|Experimental|PET/CT F-18 Labeled PSMA 1007|F-18 Labeled PSMA 1007 PET/CT
11144055|NCT03768336|Active Comparator|Waitlist Control|"The 3RP-AYA will be delivered in weekly sessions over the course of approximately 8 weeks, for a total of 8 sessions
~Mini relaxation practice
~Weekly goal check-ins
~RR-practice"
11144057|NCT03768323|No Intervention|Control|No airtime incentive was given for completing the survey
11144058|NCT03768323|Experimental|1X incentive|1X airtime incentive
11144060|NCT03768310|Experimental|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.
~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
11144061|NCT03768310|Experimental|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.
~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
11144062|NCT03768297|Experimental|immediate implant with dual zone therapeutic concept|
11144063|NCT03768297|Active Comparator|immediate implant with buccal bone fill|
11144064|NCT03768284||Psoriasis patients|Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
11144065|NCT03768284||Parents of psoriasis patients|Parents of patients who developed psoriasis before 12 years of age
11144066|NCT03768284||Up to third-degree family members with or without psoriasis|Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
11144067|NCT03768245|Experimental|Behaviour|Physical activity and the Health Education programs are applied.
11144068|NCT03768245|Active Comparator|Nutrition|In this Arm, the the Physical activity, the Health education and Nutrition program are applied.
11144069|NCT03768219|Experimental|Stage 1 (SAD) Cohort 1|6 subjects will receive 2 mcg/kg of APVO210 2 subjects will receive placebo
11144070|NCT03768219|Experimental|Stage 1 (SAD) Cohort 2|6 subjects will receive 5 mcg/kg of APVO210 2 subjects will receive placebo
11144071|NCT03768219|Experimental|Stage 1 (SAD) Cohort 3|6 subjects will receive 10 mcg/kg of APVO210 2 subjects will receive placebo
11144072|NCT03768219|Experimental|Stage 1 (SAD) Cohort 4|6 subjects will receive 20 mcg/kg of APVO210 2 subjects will receive placebo
11144073|NCT03768219|Experimental|Stage 1 (SAD) Cohort 5|6 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
11144074|NCT03768219|Experimental|Stage 1 (SAD) Cohort 6|6 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
11144075|NCT03768219|Experimental|Stage 1 (SAD) Cohort 7|6 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
11144076|NCT03768219|Experimental|Stage 1 (SAD) Cohort 8|6 subjects will receive 320 mcg/kg of APVO210 2 subjects will receive placebo
11144077|NCT03768219|Experimental|Stage 2 (MAD) Cohort 9|8 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
11144078|NCT03768219|Experimental|Stage 2 (MAD) Cohort 10|8 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
11144079|NCT03768219|Experimental|Stage 2 (MAD) Cohort 11|8 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
11144080|NCT03768219|Experimental|Stage 2 (MAD) Cohort 12|8 subjects will receive 360 mcg/kg of APVO210 2 subjects will receive placebo
11144081|NCT03768219|Experimental|Expansion Cohort (Psoriasis)|"12 subjects will receive the starting dose for the Psoriasis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.
~8 subjects will receive placebo"
11144082|NCT03768219|Experimental|Expansion Cohort (Ulcerative Colitis)|"12 Subjects will receive the starting dose for the Ulcerative Colitis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.
~8 subjects will receive placebo"
11144083|NCT03768206|Experimental|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity & assist with goal setting during therapy sessions.
11144084|NCT03768206|Active Comparator|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
11144085|NCT03768193|Experimental|Deep serratus anterior plane block|Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
11144086|NCT03768193|Active Comparator|Surgically-placed paravertebral block|Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
11144087|NCT03768180||Patient with infective endocarditis|All patients diagnosed with infective endocarditis after TAVR
11144088|NCT03768167|Other|patients with metastatic spinal lesions|corpectomy
11144089|NCT03768154|Experimental|study arm|all patients will receive all four intervention in the same sequential method
11144090|NCT03768141||Liver surgery|Any type of liver surgery
11144091|NCT03768089|Experimental|Part A: VX-121 in Healthy Subjects (HS)|Single dose escalation.
11144092|NCT03768089|Placebo Comparator|Part A: Placebo|
11144093|NCT03768089|Experimental|Part B: VX-121 in HS|Multiple-dose escalation.
11144094|NCT03768089|Placebo Comparator|Part B: Placebo|
11144095|NCT03768089|Experimental|Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-121 in TC with TEZ/IVA.
11144096|NCT03768089|Placebo Comparator|Part C: Placebo|
11144097|NCT03768089|Experimental|Part D: VX-121 in TC with TEZ/IVA in subjects with CF|VX-121 in TC with TEZ/IVA in subjects with CF.
11144098|NCT03768089|Placebo Comparator|Part D: Placebo|
11144099|NCT03768063|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawl of study consent, unacceptable toxicity, pregnancy, patient non-compliance, or study termination by the Sponsor, whichever occurs first.
11144100|NCT03768050|Active Comparator|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
11144101|NCT03768050|No Intervention|Standard care|Usual care at the community and geriatric residences by primary care physicians
11144102|NCT03768037|Experimental|Anlotinib plus Pemetrexed|Anlotinib plus Pemetrexed
11144103|NCT03768037|Other|Pemetrexed|Pemetrexed
11144104|NCT03768024|Experimental|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144105|NCT03768024|Experimental|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144106|NCT03768024|Experimental|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144107|NCT03768024|Experimental|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144108|NCT03768024|Experimental|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144109|NCT03768024|Experimental|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144110|NCT03768024|Experimental|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
11144111|NCT03767998|Experimental|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
11144112|NCT03767998|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
11144113|NCT03767998|Experimental|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
11144114|NCT03767985|Active Comparator|Occlusion therapy|Participants are prescribed 2 hours of occlusion therapy per day, 7 days a week.
11144115|NCT03767985|Experimental|Dichoptic video game therapy|Participants receive dichoptic video game therapy: 1 hour per week at the out-patient clinic under direct supervision.
11144116|NCT03767972|Experimental|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
11144117|NCT03767959|Experimental|Chen's U-Suture|Patients in this group will treated by Chen's U-suture technique in pancreaticojejunostomy.
11144118|NCT03767959|Active Comparator|Classic pancreatic duct to mucosa|Patients in this group will treated by classic pancreatic duct to mucosa technique in pancreaticojejunostomy.
11144119|NCT03767946||Group 1|"Children both genders according to age:
~*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
11144120|NCT03767946||Group 2|"Children both genders according to age:
~*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
11144121|NCT03767946||Group 3|"Children both genders according to age:
~*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
11144122|NCT03767946||Group 4|"Children both genders according to age:
~*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
11144123|NCT03767933|Active Comparator|Non-Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo, both administered once during the study at the time of recruitment.
11144124|NCT03767933|Experimental|Non-Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg), both administered once during the study at the time of recruitment.
11144125|NCT03767933|Active Comparator|Opioid Trial: Arm 1|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
11144126|NCT03767933|Experimental|Opioid Trial: Arm 2|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg) + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.
11144127|NCT03767933|Experimental|Opioid Trial: Arm 3|Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone (0.05mg/kg, maximum 5 mg), all administered once during the study at the time of recruitment.
11144128|NCT03767920|Active Comparator|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
11144129|NCT03767920|Active Comparator|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
11144196|NCT03767413|Active Comparator|PNF group|It will be consisted of 15 -25 healthy subjects receiving only proprioceptive nueromuscular facilitation training for 5 weeks with 17 days follow up after completion of program.
11144130|NCT03767907|Experimental|Online Cognitive Behavioural Therapy|Computer-based training for cognitive behavioural therapy (CBT4CBT) consists of seven modules, and includes a series of interactive videos presenting characters portrayed by professional actors struggling with real-life situations. These characters first experience a common risky situation or problem and then demonstrate the application of a targeted skill. The program further comprises games and interactive exercises to teach and model effective use of skills and strategies.
11144131|NCT03767907|Active Comparator|Treatment as Usual|Treatment as usual consists of weekly group and/or individual psychotherapy as determined by the clinical team. Psychotherapy will include structured relapse prevention, include cognitive and behavioural techniques, motivational enhancement, mindfulness, and specialized topics (e.g., vocational training, rainbow services) as appropriate.
11144132|NCT03767894|Experimental|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
11144133|NCT03767881|Experimental|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
11144134|NCT03767855|Experimental|CK-3773274 for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274
11144135|NCT03767855|Placebo Comparator|Placebo for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo
11144136|NCT03767855|Experimental|CK-3773274 for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274
11144137|NCT03767855|Placebo Comparator|Placebo for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo
11144138|NCT03767855|Experimental|CK-3773274 for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274
11144139|NCT03767855|Placebo Comparator|Placebo for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo
11144140|NCT03767855|Experimental|Food Effect|Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion
11144141|NCT03767855|Experimental|Relative Bioavailability|Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.
11144142|NCT03767829|Experimental|Part A: SAD: ALN-AAT02|Participants will be administered a single dose of ALN-AAT02.
11144143|NCT03767829|Placebo Comparator|Part A: SAD: Placebo|Participants will be administered a single dose of matching placebo.
11144144|NCT03767829|Experimental|Part B: MAD: ALN-AAT02|Participants will be administered multiple doses of ALN-AAT02.
11144145|NCT03767829|Placebo Comparator|Part B: MAD: Placebo|Participants will be administered multiple doses of matching placebo.
11144146|NCT03767816|Experimental|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
11144147|NCT03767816|Active Comparator|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
11144148|NCT03767803||Positive Preeclampsia group|A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery
11144149|NCT03767803||Study Cohort|A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.
11144150|NCT03767790|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
11144151|NCT03767790|No Intervention|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
11144152|NCT03767777|Experimental|Intervention arm|Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
11144153|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
11144154|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
11144155|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
11144156|NCT03767764||Control|Normal human serum from donors without liver disease
11144157|NCT03767738|Experimental|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
11144158|NCT03767725|Experimental|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART19 cells.
11144159|NCT03767673|Experimental|Patients after esophageal atresia|Patients older than 12 years following surgical repair of congenital esophageal atresia will be included after written informed consent. Patients will be subjected to spirometry to determine their age, weight (determined by Kilogram (kg) on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
11144197|NCT03767413|Experimental|PNFMP|It will be consisted of 15 -25 healthy subjects receiving proprioceptive nueromuscular facilitation training and mental practice technique for 5 weeks with 17 days follow up after completion of program.
11144160|NCT03767673|Active Comparator|Control group|Age and sex matched adolescents will be recruited as control group and will be included after written informed consent. Adolescents will be subjected to spirometry to determine their age, weight (determined by Kilogram on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
11144161|NCT03767660|Experimental|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
11144162|NCT03767647|Experimental|Intervention group|Receives 6 lessons in 6 different weeks on Emotional Intelligence
11144163|NCT03767647|No Intervention|Control group|Receives no intervention.
11144164|NCT03767634||Neonatal population (Project A)|Neonates born between 1st January 2012 and 31st December 2017 and admitted to a neonatal unit in England, Scotland and Wales).
11144165|NCT03767634||No PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who did not receive any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
11144166|NCT03767634||PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who received any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
11144167|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
11144168|NCT03767608||Patients with type 2 diabetes mellitus|Patients diagnosed with T2DM according to the ADA
11144169|NCT03767608||Lean healthy controls|Lean healthy controls
11144170|NCT03767595|Experimental|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
11144171|NCT03767582|Experimental|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
11144172|NCT03767582|Experimental|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
11144173|NCT03767582|Experimental|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
11144174|NCT03767569|Experimental|Myo-inositol|Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology)
11144175|NCT03767569|Other|Folic acid|Folic acid 0.4 mg daily during 12 weeks before start of ART
11144176|NCT03767556|No Intervention|Control|This group will not receive intervention
11144177|NCT03767556|Experimental|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
11144178|NCT03767543|Experimental|iGlarlixi DAILY|Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
11144179|NCT03767543|Active Comparator|iGlarlixi WEEKLY|Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
11144180|NCT03767530|Experimental|Mibo Thermoflo (thermal device)|3 sessions at 2 weeks interval (basal, week 2, week 4)of 11 minutes per eye of thermal therapy with Mibo Thermoflo.
11144181|NCT03767530|Active Comparator|Warm compresses and eyelid massage|2 times per day, 11 minutes per eye.
11144182|NCT03767517|Experimental|Active Intervention|Usual Care + Tele-consult Intervention
11144183|NCT03767517|Active Comparator|Usual Care|Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
11144184|NCT03767504|Experimental|Musclin|Thymol based dietary supplement
11144185|NCT03767491|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
11144186|NCT03767491|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
11144187|NCT03767478|Sham Comparator|Group A - Sham Comparator|12 Months of Sham Comparator (Sham Revitive Medic Neuromuscular Stimulation Device).
11144188|NCT03767478|Active Comparator|Group B1 - Active Comparator & Active Comparator|Active Comparator for 6 months (Revitive Medic Neuromuscular Stimulation Device). Then randomisation into active comparator (Revitive Medic Neuromuscular Stimulation Device) for further 6 months.
11144189|NCT03767478|Active Comparator|Group B2 - Active Comparator & Sham Comparator|Active Comparator for 6 months (Revitive Medic Neuromuscular Stimulation Device). Then randomisation into sham comparator (Sham Revitive Medic Neuromuscular Stimulation Device) for further 6 months.
11144190|NCT03767465||PembroHIV|HIV-infected subjects with advanced melanoma or other oncological conditions in which the use of immunological checkpoint inhibitors is clinically indicated
11144191|NCT03767452|Experimental|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
11144192|NCT03767439|Experimental|Nivolumab, Vismodegib, Ipilimumab|"Patients will receive a two week run-in of Vismodegib 150 mg PO daily followed by concurrent Nivolumab 480 mg IV every 4 weeks and Vismodegib 150 mg PO daily.
~In an exploratory fashion, patients will have the option to receive combination Ipilimumab 1 mg/kg IV every 6 weeks and Nivolumab 360 mg IV every 3 weeks at the time of disease progression."
11144193|NCT03767426|No Intervention|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
11144194|NCT03767426|Active Comparator|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
11144195|NCT03767426|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
11144410|NCT03766087|Experimental|surgery group|Decompressive craniectomy associated with optimal medical management of intracranial pressure.
11144198|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
11144199|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
11144200|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
11144201|NCT03767387|Active Comparator|Prehabilitation + standard care|Trimodal Prehabilitation consisting on motivation, personalisation and supervision of physical activity before major surgery
11144202|NCT03767387|No Intervention|Standard care|Standard care before major surgery
11144203|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital
~Inguinal swab sample
~Anal swab sample
~Fecal sample
~Risk factor assessment"
11144204|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).
~Inguinal swab sample
~Anal swab sample
~Fecal sample
~Risk factor assessment"
11144205|NCT03767361|Active Comparator|Fresh PRBCs|Neonates will receive fresh packed red blood cells transfusion within 7 days of donation
11144206|NCT03767361|Active Comparator|Old PRBCs|Neonates will receive fresh packed red blood cells transfusion older than 7 days yet within the standard range accepted universally will be transfused to this group.
11144207|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection|Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
11144208|NCT03767348|Experimental|Dose escalation of RP1 by IT injection|Dose escalation of RP1 alone in 3 cohorts with intratumoral injections in deep/visceral tumors
11144209|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab intravenously (IV)|Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
11144210|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV)|Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
11144211|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
11144212|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in bladder cancer|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with bladder cancer
11144213|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
11144214|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with NMSC
11144215|NCT03767348|Experimental|RP1(IT) and nivo(IV) in anti-PD1 Refractory Cutaneous Melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy for at least 12 weeks and have confirmed disease progression
11144216|NCT03767335|Experimental|MEN1611|MEN1611 + Trastuzumab +/- Fulvestrant
11144217|NCT03767322|Active Comparator|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
11144218|NCT03767322|Placebo Comparator|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
11144219|NCT03767322|Active Comparator|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
11144220|NCT03767309|Experimental|Test group|SCTG will be harvested from the palate in the intervention group (coronally advanced flap and abrasively de-epithelialized free gingival graft)
11144221|NCT03767309|Active Comparator|Control group|SCTG will be harvested from the palate using Zucchilli's technique (zucchelli, 2010) in the control group (coronally advanced flap and conventionally de-epithelialized free gingival graft)
11144222|NCT03767296|Experimental|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
11144223|NCT03767296|Experimental|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
11144224|NCT03767296|Experimental|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
11144225|NCT03767296|Experimental|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
11144226|NCT03767270|Experimental|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
11144227|NCT03767270|Placebo Comparator|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
11144228|NCT03767257|Experimental|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
11144229|NCT03767244|Experimental|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy, followed by an additional six cycles of treatment.
11144230|NCT03767244|Experimental|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by radical prostatectomy, followed by an additional six cycles of placebo treatment.
11144231|NCT03767231|Experimental|HCV POC VL Group|This group will receive the POC HCV viral load testing via fingerstick using the novel Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
11144232|NCT03767231|No Intervention|Reference Group|This group will receive the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing only. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
11144233|NCT03767218|Experimental|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 12 of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
11144234|NCT03767218|Active Comparator|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
11144235|NCT03767205|Experimental|stroke patients|All participants perform overground walking and treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot).
11144236|NCT03767192|Experimental|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
11144237|NCT03767192|Sham Comparator|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
11144238|NCT03767179||Study Group|The study group consisted of 30 fertile, under 35 years old women who were included in the study for the first time missed abortus diagnosis.
11144239|NCT03767179||Control Group|30 cases with the same trimester, fertile, and under 35 years old who were referred to Obstetrics clinic, who had no systemic disease, were included in the study.
11144240|NCT03767153|Experimental|80 pin applicator|
11144241|NCT03767153|Active Comparator|160 pin applicator|
11144242|NCT03767140|Experimental|Verum acupucnture|Real acupuncture treatment
11144243|NCT03767140|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
11144244|NCT03767127||Appropriate transfusion policy|Patients transfused with high arterial-venous oxygen difference (≥3.7 ml/dl) or non-transfused with low arterial-venous oxygen difference (<3.7 ml/dl)
11144245|NCT03767127||Non-Appropriate transfusion policy|Patients transfused despite low arterial-venous oxygen difference or non-transfused with high arterial-venous oxygen difference
11144246|NCT03767114|Experimental|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
11144247|NCT03767114|Experimental|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
11144248|NCT03767101|Experimental|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All of this sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
11144249|NCT03767101|Active Comparator|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All of this sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
11144250|NCT03767101|Other|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
11144251|NCT03767088|Active Comparator|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
11144252|NCT03767088|Active Comparator|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
11144253|NCT03767088|Sham Comparator|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
11144254|NCT03767075|Experimental|Module 1 Arm 1 - atezolizumab|"Genomically selected populations will all receive the same drug (6 groups of mutation will be evaluated)
~Arm 1A: BRCA1 or BRCA2 mutations
~Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations
~Arm 1C: tumors with POLE mutation, POLD1 mutation.
~Arm 1D: hypermutated tumors
~Arm 1E: tumors with other mutations in DNA-repair genes.
~Arm 1F: tumors with amplified PDL1
~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 100 patients in part B of module 1."
11144255|NCT03767062|Active Comparator|Topiramate|Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
11144290|NCT03766815|Placebo Comparator|Placebo|Fiber supplement mixed with jelly will be ingested for 18 days with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
11144407|NCT03766113|Other|Patients at the chronic stage after stroke|"36 subjects
~Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
11144256|NCT03767062|Active Comparator|Greater Occipital +Supratrochlear Nerve Block|"Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼ (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood."
11144257|NCT03767049||Lung transplant patients readmitted in ICU|
11144258|NCT03767036|Active Comparator|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
11144259|NCT03767036|Active Comparator|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
11144260|NCT03767036|Experimental|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
11144261|NCT03767023||Stable AAA|"= patients with a small abdominal aortic aneursym diameter < 55 mm "
11144262|NCT03767023||instable AAA|"=patients with a large abdominal aortic aneursym diameter > 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair EVAR"
11144263|NCT03767010|Experimental|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
11144264|NCT03767010|Experimental|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
11144265|NCT03766997|Experimental|local injection|Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.
11144266|NCT03766997|Active Comparator|topical|Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.
11144267|NCT03766984|Experimental|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
11144268|NCT03766984|Experimental|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
11144269|NCT03766984|Experimental|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
11144270|NCT03766971|Experimental|Early-onset Cigarette Smokers|Participants who began smoking cigarettes earlier in life (<16 years old) will be randomized to 7 or 21 days of tobacco cessation.
11144271|NCT03766971|Experimental|Late-onset Cigarette Smokers|Participants who began smoking cigarettes later in life (>16 years old) will be randomized to 7 or 21 days of tobacco cessation.
11144272|NCT03766958||Registry Patients With BDX-XL2 Results|Patients providing consent to have data collected to observe how BDX-XL2 results were used in the clinical management of their lung nodules.
11144273|NCT03766958||Contemporaneous Group Without BDX-XL2|Contemporaneous group who did not have BDX-XL2 test results for use in the clinical management of their lung nodules.
11144274|NCT03766932||Blood culture candida positive group|
11144275|NCT03766932||Tracheal aspiration candida culture positive group|
11144276|NCT03766932||Urine candida culture positive group|
11144277|NCT03766932||Other aseptic humoral candida positive group|
11144278|NCT03766919|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead)
11144279|NCT03766906|Experimental|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
11144280|NCT03766893|Experimental|Pharmacy based opioid use disorder care|A single-arm pilot study to test the collaborative pharmacy practice agreement for MAT (using the medications buprenorphine or injectable naltrexone) care model with up to 12 patients with opioid use disorder, assessing feasibility of medication dispensing, administration, and monitoring in the pharmacy, and determining patient acceptability of this model.
11144281|NCT03766880|Experimental|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
11144282|NCT03766867|Experimental|Vortioxetine|
11144283|NCT03766867|Placebo Comparator|Placebo|
11144284|NCT03766854|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.
~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
11144285|NCT03766854|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.
~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
11144286|NCT03766841|Experimental|Facilitated Enrollment|Patients will be aided in the account creation and usage of a consumer informatics tool to collect and report patient-contextual data within the electronic health record
11144287|NCT03766841|No Intervention|Usual Care|Patients will be invited to use the patient contextual data tool as per usual care, but will not receive additional assistance in account creation and usage.
11144288|NCT03766828||inside-out-access technique with inside-out access device|
11144289|NCT03766828||access technique including Sharp recanalization|
11144291|NCT03766815|Experimental|BCAA 200mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (200mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
11144292|NCT03766815|Experimental|BCAA 400mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (400mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
11144293|NCT03766802|Active Comparator|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.
~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
11144294|NCT03766802|Active Comparator|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises
~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
11144295|NCT03766802|Sham Comparator|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
11144296|NCT03766789|Active Comparator|Intervention|They will receive the cell phone application, as reminder of medications time and dose.
11144297|NCT03766789|No Intervention|Control|Patients will receive standard of care recommendations.
11144298|NCT03766776|Experimental|Anlotinib Arm|
11144299|NCT03766763|Experimental|ARM A VENETOCLAX|VENETOCLAX
11144300|NCT03766750|Experimental|LIMA|
11144301|NCT03766750|Active Comparator|Tradjenta®|
11144302|NCT03766750|Active Comparator|Forxiga®|
11144303|NCT03766737|Other|Eligible patients for AI test.|Device: An intelligent visual acuity diagnostic system for children. An artificial intelligence to evaluate children's vision.
11144304|NCT03766724|Experimental|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
11144305|NCT03766724|Experimental|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
11144306|NCT03766724|Experimental|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
11144307|NCT03766724|Experimental|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
11144308|NCT03766711|Experimental|Actual - Augmented|Reaching task as a physical therapy intervention. First with 1:1 visual feedback, then with augmented forward symmetry.
11144309|NCT03766711|Experimental|Augmented - Actual|Reaching task as a physical therapy intervention. First with augmented forward symmetry, then with 1:1 visual feedback.
11144310|NCT03766685|Experimental|Bimekzumab-SS|Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
11144311|NCT03766685|Experimental|Bimekizumab-AI|Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
11144312|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
11144313|NCT03766659|Other|MOSE|EUS-FNB with MOSE
11144314|NCT03766659|Other|ROSE|EUS-FNA with ROSE
11144315|NCT03766646|Experimental|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
11144316|NCT03766646|Active Comparator|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
11144317|NCT03766633||Living liver donors|This is a group of living liver donors that underwent a CT prior to donating their partial liver to a recipient.
11144318|NCT03766620||Tube Fed Participants|Individuals with diabetes and malnutrition receiving tube feed as sole source nutrition.
11144319|NCT03766607|Experimental|Trastuzumab with Ramucirumab and Paclitaxel|Single arm study of trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) every 21 days + ramucirumab (8 mg/kg) on days 1 & 15 every 28 days + paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days
11144320|NCT03766594|Active Comparator|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
11144321|NCT03766594|Active Comparator|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
11144322|NCT03766581|Placebo Comparator|BMS-986177 Placebo|Specified Dose on Specified Days
11144323|NCT03766581|Experimental|Dose 1: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144324|NCT03766581|Experimental|Dose 2: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144325|NCT03766581|Experimental|Dose 3: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144326|NCT03766581|Experimental|Dose 4: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144327|NCT03766581|Experimental|Dose 5: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144328|NCT03766581|Experimental|Dose 6: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144329|NCT03766581|Experimental|Dose 7: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
11144330|NCT03766568|Experimental|Diagnostic with JGG endoscope|
11144331|NCT03766555|Experimental|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
11144332|NCT03766555|Active Comparator|Liver Resection|Liver resection will be performed in patients randomized to this arm.
11144333|NCT03766542|Active Comparator|CPAP|Oronasal CPAP therapy applied as per current international guidelines
11144334|NCT03766542|Experimental|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
11144406|NCT03766113|Other|Patients at the early stage after stroke|"30 subjects
~Effectiveness of an electroencephalogram-neurofeedback"
11144335|NCT03766516||Cohort|"Any patient planning to administer BrentuximabVedotin to treat the target disease.
~Any patient administering BrentuximabVedotin to treat the target disease.
~Any patient tracing BrentuximabVedotin after treating the target disease.
~Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin."
11144336|NCT03766503|Other|Intervention|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
11144337|NCT03766490|Experimental|Anlotinib Hydrochloride plus gefitinib or icotinib|
11144338|NCT03766477||Individuals with sleep bruxism|"Individuals with sleep bruxism evaluated in three different methods regarding their sleep quality:
~Pittsburgh Sleep Quality Index (IQSP) and Johansson
~Smartphone APP
~Polysomnography"
11144339|NCT03766464||with sleep bruxism, apnea and DTM|"Patients who will undergo analysis of:
~Evaluation of TMD and pain sensitivity Evaluation of SB Evaluation of AB"
11144340|NCT03766438|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
11144341|NCT03766438|No Intervention|Control|The comparison group will receive usual clinical care.
11144342|NCT03766425|Experimental|Aflibercept|Aflibercept applied intraoperatively as a subconjunctival injection at a dose of 0.05 ml (40 mg / ml) and one week after the operation at the same dose, also subconjunctival.
11144343|NCT03766425|Active Comparator|Mitomycin|Mitomycin applied during a surgery at a concentration of 0.3mg / ml for 3 min. on a soaked sponge.
11144344|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
11144345|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
11144346|NCT03766399|Experimental|Part 1a (SAD) Cohort 1|6 participants will receive inhaled dose 1 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
11144347|NCT03766399|Experimental|Part 1a (SAD) Cohort 2|6 participants will receive inhaled dose 2 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
11144348|NCT03766399|Experimental|Part 1a (SAD) Cohort 3|6 participants will receive inhaled dose 3 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
11144349|NCT03766399|Experimental|Part 1a (SAD) Cohort 4|6 participants will receive inhaled dose 4 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
11144350|NCT03766399|Placebo Comparator|Part 1a (SAD) Cohort 5|6 participants will receive inhaled dose 5 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
11144351|NCT03766399|Experimental|Part 1a (SAD) Cohort 6|6 participants will receive inhaled dose 6 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
11144352|NCT03766399|Experimental|Part 1b (IV cohort 1)|All 6 participants will receive single IV dose of AZD0449 solution.
11144353|NCT03766399|Experimental|Part 2a (MAD) Cohort 1|6 participants will receive inhaled dose 7 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
11144354|NCT03766399|Experimental|Part 2a (MAD) Cohort 2|6 participants will receive inhaled dose 8 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
11144355|NCT03766399|Experimental|Part 2b (MAD/healthy volunteers) Cohort 3|18 healthy volunteers will receive inhaled dose 9 of AZD0449 nebulized suspension and 12 healthy volunteers will receive inhaled placebo.
11144356|NCT03766399|Experimental|Part 3a (DPI/PoM)|18 participants will receive inhaled dose 10 of AZD0449 DPI and 6 participants will receive inhaled placebo.
11144357|NCT03766399|Experimental|Part 1b (IV cohort 2)|6 healthy volunteers will receive single IV dose of AZD0449 solution.
11144358|NCT03766399|Experimental|Part 3b (DPI/healthy volunteers)|Part 3b is optional. 8 healthy volunteers; 6 volunteers will receive AZD0449 DPI and 2 volunteers will recieve placebo.
11144359|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
11144360|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
11144361|NCT03766373|Active Comparator|Drug: OP0201|
11144362|NCT03766373|Placebo Comparator|Drug: Placebo|
11144363|NCT03766360|Experimental|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
11144364|NCT03766360|No Intervention|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
11144365|NCT03766347||Pediatric Neuromyelitis Optica|Participants under the age of 18 that are positive for Aquaporin-4 antibody.
11144366|NCT03766334|Experimental|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
11144367|NCT03766334|No Intervention|Diabetes Diet|only Diabetes Diet
11144368|NCT03766321|Active Comparator|Fecal microbiota transplantation (FMT)|"Fecal microbiota transplantation will be performed during two endoscopic procedures (at baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum. Fecal microbiota will be diluted in saline solution 200 ml and infused at 30 ml/minute speed. Every endoscopic procedure will be performed with sedation of the patient.
~Feces for FMT will be obtained by known healthy donors for C. difficile infection according to standard selection procedures."
11144369|NCT03766321|Placebo Comparator|Placebo|"ALS patients will undergo upper GI endoscopy with small-intestine biopsies at baseline and after 6 months. Patients in the placebo arm will not receive any treatment during these procedures, but will undergo intestinal biopsy.
~Every endoscopic procedure will be performed with sedation of the patient."
11144370|NCT03766308|Experimental|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
11144371|NCT03766308|Active Comparator|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
11144372|NCT03766295|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
11144373|NCT03766295|Active Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
11144374|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
11144375|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
11144376|NCT03766269|Other|Baseline Opioid|One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
11144377|NCT03766256|Experimental|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
11144378|NCT03766243|Experimental|Brochure and DVD plus nursing training|"In addition to the control intervention, see below, the experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. The nurse provided theoretical explanations on the exercises, watched the explanatory DVD with the patients, answering questions and commenting relevant points, and then had the patients repeat the exercises in front of a mirror under direct observation, so that any errors could be pointed out and corrected."
11144379|NCT03766243|Active Comparator|Brochure and DVD only|"After recruitment, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use. At the same time, she contacted the research nurse to obtain the random allocation to one of the study groups for that patient.
~These exercises had to be done every day for the entire duration of the program (12 months) and registered in the diary with any comments."
11144380|NCT03766230||peribulbar anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using peribulbar anesthesia
11144381|NCT03766230||topical anesthesia1|Time interval between two eyes' cataract surgery is or less than 14 days and using topical anesthesia
11144382|NCT03766230||peribulbar anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using peribulbar anesthesia
11144383|NCT03766230||topical anesthesia2|Time interval between two eyes' cataract surgery is from 15 to 21 days and using topical anesthesia
11144384|NCT03766230||peribulbar anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using peribulbar anesthesia
11144385|NCT03766230||topical anesthesia3|Time interval between two eyes' cataract surgery is from 22 to 28 days and using topical anesthesia
11144386|NCT03766230||peribulbar anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using peribulbar anesthesia
11144387|NCT03766230||topical anesthesia4|Time interval between two eyes' cataract surgery is from 29 to 60 days and using topical anesthesia
11144388|NCT03766230||peribulbar anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using peribulbar anesthesia
11144389|NCT03766230||topical anesthesia5|Time interval between two eyes' cataract surgery is from 61 to 90 days and using topical anesthesia
11144390|NCT03766217|Experimental|Mesenchymal stem cells associated with biomaterials|Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).
11144391|NCT03766217|Active Comparator|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations.
11144392|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
11144393|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
11144394|NCT03766191|Active Comparator|Food Ads and fMRI|
11144395|NCT03766191|Sham Comparator|Non-Food Ads and fMRI|
11144396|NCT03766191|Active Comparator|Food Ads and TV show|
11144397|NCT03766191|Sham Comparator|Non-Food Ads and TV show|
11144398|NCT03766178|Experimental|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
11144399|NCT03766165|Experimental|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
11144400|NCT03766165|Other|Control|Job announcements only
11144401|NCT03766152|Other|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
11144402|NCT03766139|Experimental|SUPERCELL GLUE(STEM CELLS AND PRFM)|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .
11144403|NCT03766139|Active Comparator|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites
11144404|NCT03766126|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
11144405|NCT03766113|Other|Healthy volunteer|"50 subjects
~A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
11144411|NCT03766087|No Intervention|conservative group|Optimal medical management of intracranial pressure only.
11144412|NCT03766074|Experimental|Intervention|vitamin D supplement every other week
11144413|NCT03766074|Placebo Comparator|control|Placebo every other week
11144414|NCT03766061|Active Comparator|Onlay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with onlay mesh hernioplasty in which we placed mesh on the anterior rectus sheath
11144415|NCT03766061|Active Comparator|Sublay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with sublay mesh hernioplasty in which we placed mesh in the retromuscular space
11144416|NCT03766048|Experimental|Single-Anterior-Mesh, SAM|
11144417|NCT03766048|Sham Comparator|Double-Mesh, DM|
11144418|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
11144419|NCT03766022|Experimental|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
11144420|NCT03766022|Active Comparator|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
11144421|NCT03766009|Active Comparator|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
11144422|NCT03766009|Experimental|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
11144423|NCT03765996|Active Comparator|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
11144424|NCT03765996|Experimental|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
11144425|NCT03765983|Experimental|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
11144426|NCT03765983|Experimental|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
11144427|NCT03765957|Experimental|Mesenchymal Stem Cells|The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
11144428|NCT03765944|Active Comparator|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
11144429|NCT03765944|Active Comparator|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
11144430|NCT03765931|Active Comparator|subjects treated with doxycycline|The participants treated by doxycycline 100 mg will have one dose but followed 5 days
11144431|NCT03765931|Placebo Comparator|subjects treated with amoxycilline|The participants treated with amoxycilline 500 mg will have 2 doses per days during 5 days treatement and follwed during these 5 days
11144432|NCT03765918|Experimental|Pembro Neoadjuvant+Pembro SOC Adjuvant|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles as a neoadjuvant prior to surgery. Following surgical resection, high risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 every 3 weeks (Q3W) for fifteen 21-day cycles plus standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive 200 mg pembrolizumab by IV infusion administered on Day 1 Q3W for fifteen 21-day cycles plus standard of care radiotherapy as adjuvant therapy.
11144433|NCT03765918|Active Comparator|No Neoadjuvant+SOC Adjuvant|Participants receive no neoadjuvant prior to surgery. Following surgical resection, high risk participants receive standard of care radiotherapy plus cisplatin 100 mg/m^2 by IV infusion on Day 1 Q3W for three 21-day cycles as adjuvant therapy. Following surgical resection, low risk participants receive standard of care radiotherapy as adjuvant therapy.
11144434|NCT03765905||PCOS diagnosis area|The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)
11144435|NCT03765905||PCOS is not diagnosed|Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study
11144436|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
11144437|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
11144438|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
11144439|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
11144440|NCT03765879|Experimental|Verum VGAIT Group|Participants in this group will receive verum (real) acupuncture and verum video-guided acupuncture imagery treatment (VGAIT).
11144441|NCT03765879|Placebo Comparator|Sham VGAIT Group|Participants in this group will receive sham acupuncture and sham VGAIT.
11144442|NCT03765866|No Intervention|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
11144443|NCT03765866|Experimental|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
11144444|NCT03765853|Other|Stretching Postural®|
11144445|NCT03765853|No Intervention|Control|
11144577|NCT03764891||Perigee|Patients who underwent Perigee procedure
11144446|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
11144447|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
11144448|NCT03765827|Experimental|Vitamin E acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
11144449|NCT03765827|Sham Comparator|Control group|No ointment will be applied
11144450|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fed)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
11144451|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fasting)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
11144452|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fed)|Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
11144453|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fasting)|Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
11144454|NCT03765788|Experimental|Secukinumab|Participants will receive secukinumab at a dose of 300 milligrams (mg) as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
11144455|NCT03765788|Placebo Comparator|Placebo|Participants will receive placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
11144456|NCT03765775|Experimental|Anlotinib Hydrochloride+Sintilimab|Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
11144457|NCT03765762|Experimental|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
11144458|NCT03765762|Placebo Comparator|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
11144459|NCT03765749||Community onset 3rd generation cephalosporin resistant entero|Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic
11144460|NCT03765749||Nosocomial onset 3rd generation cephalosporin resistant ente|Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic
11144461|NCT03765736||Screening (genetic testing)|Patients submit blood samples for genetic testing.
11144462|NCT03765710|Experimental|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
11144463|NCT03765710|Experimental|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
11144464|NCT03765697|Experimental|Lidocaine 5% medicated plaster|Up to 3 plasters were applied per day.
11144465|NCT03765671|Experimental|Mild Child-Pugh A|Single oral dose of elafibranor 120mg
11144466|NCT03765671|Experimental|Moderate Child-Pugh B|Single oral dose of elafibranor 120mg
11144467|NCT03765671|Experimental|Severe Child-Pugh C|Single oral dose of elafibranor 120mg
11144468|NCT03765671|Experimental|Healthy|Single oral dose of elafibranor 120mg
11144469|NCT03765658|Experimental|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
11144470|NCT03765645|Active Comparator|3 doses on intra venous antibiotics|Patients will receive 3 doses of intra venous antibiotics. (1 dose preoperative, 1 intra operative and 1 post-operative)
11144471|NCT03765645|Active Comparator|9 doses of intra venous antibiotics|Patients will receive 9 doses of intra venous antibiotics. (1 dose preoperative, rest 8 doses at equal intervals)
11144472|NCT03765632|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
11144473|NCT03765619|Experimental|Aspirin|250 patients will be randomized to receive Aspirin postoperatively.
11144474|NCT03765619|No Intervention|Non-Aspirin|250 patients will be randomized to not receive Aspirin postoperatively.
11144475|NCT03765606|Placebo Comparator|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg & theobromine, 93mg)
11144476|NCT03765606|Experimental|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg & theobromine, 0.2mg)
11144477|NCT03765593||Study group 1|Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
11144478|NCT03765593||Study group 2|Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
11144479|NCT03765593||Study group 3|Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
11144480|NCT03765593||Control group|Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
11144481|NCT03765580|Placebo Comparator|Control group|No fish
11144482|NCT03765580|Experimental|1 portion of fish per week|140g fish/week
11144483|NCT03765580|Experimental|2 portions of fish per week|280g fish/week
11144484|NCT03765567|Experimental|Intervention Arm|Subjects randomized to the Intervention Arm will receive usual care plus two (2) grams of Vancomycin powder administered topically. In the emergency room prior to surgical intervention, a qualified member of the study team or clinical team member will apply 2 grams of vancomycin powder directly to the open fracture site such that all visible surfaces of the wound are completely and uniformly covered, including bone edges.
11144485|NCT03765567|No Intervention|Control Arm|Subjects randomized to the Control Arm will receive usual care for open long bone fracture as determined by the treating physician.
11144486|NCT03765567|No Intervention|Observational Arm|Subjects who otherwise meet the criteria to be included in the study but are not able to provide consent, either themselves or through a Legally Authorized Representative, will be placed in the Observational Arm and receive usual care with no experimental intervention.
11144487|NCT03765554|Experimental|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
11144488|NCT03765554|Experimental|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
11144489|NCT03765541|Experimental|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
11144490|NCT03765541|Active Comparator|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
11144491|NCT03765515|Experimental|Q-Fix|"Q-Fix has the advantages of all-suture implant and has the same or better performance than the traditional anchor.
~Consistent activation effect
~Excellent performance
~Streamlined technique Q-fix is an experimental Arm."
11144492|NCT03765515|Active Comparator|Twinfix Ti|The Smith & Nephew's marketed Twinfix Suture Anchor is selected as the control product. This product is composed of anchor, suture, suture needle and inserter. The anchor is made of Ti6Al4V titanium alloy conforming to ISO5832-3. The Durabraid suture is made of polyester (Polyethylene terephthalate) conforming to YY 0167. Ultrabraid suture is made of two materials of UHMWPE and polypropylene monofilaments conforming to GB/T 19701.1. The suture needle is made of Type 420B stainless steel conforming to YY/T 0726. The stem portion of inserter that comes into contact with the body is made of Type 630B stainless steel conforming to YY/T 0726.
11144493|NCT03765502|Experimental|Nasal Glucagon Device (NG)|Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
11144494|NCT03765502|Active Comparator|Glucagon Emergency Kit (GEK)|Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
11144495|NCT03765489|Experimental|electrical muscle stimulation|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al. plus electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction"
11144496|NCT03765489|Active Comparator|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
11144497|NCT03765476|Active Comparator|TAU|treatment as usual
11144498|NCT03765476|Experimental|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
11144499|NCT03765463|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
11144500|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
11144501|NCT03765437|Experimental|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine (split-virion, inactivated) Northern hemisphere seasonal formulation 2018-2019
11144502|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).
~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:
~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.
~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
11144503|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
11144504|NCT03765411||Open Proctectomy Patients|Patients who underwent Proctectomy through an open approach
11144505|NCT03765411||Laparoscopic Proctectomy Patients|Patients who underwent Proctectomy through a Laparoscopic approach
11144506|NCT03765411||Robotic Proctectomy Patients|Patients who underwent Proctectomy through a Robotic approach
11144507|NCT03765398|Experimental|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
11144508|NCT03765385|Experimental|High-intensity training|Each high-intensity training (HIT) session will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIT is 20 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
11144509|NCT03765385|Active Comparator|Moderate-intensity continuous training|Each moderate-intensity continuous training (MICT) session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is 40 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
11144510|NCT03765359|Active Comparator|metforminhydrochloride|Metformin medication starts on 12-14 weeks of gestation. The starting dosage is 1 tablet (500 mg) x1 and it is increased gradually 1 tablet a week up to 2+2 tablets (2000mg) daily. Duration of the treatment is approximately until one week before delivery. Otherwise metformin treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
11144511|NCT03765359|Placebo Comparator|Placebo Oral Tablet|Placebo tablets starts on 12-14 weeks of gestation. The starting dosage is 1 tablet x1 and it is increased gradually 1 tablet a week up to 2+2 tablets daily. Duration of the treatment is approximately until one week before delivery. Otherwise placebo treatment combined with regular insulin and follow-up during pregnancy follows the national guidelines.
11144512|NCT03765346|Experimental|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
11144513|NCT03765346|Active Comparator|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
11144514|NCT03765346|Placebo Comparator|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
11144515|NCT03765307|Experimental|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
11144516|NCT03765307|Active Comparator|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
11144517|NCT03765294|Experimental|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
11144518|NCT03765294|Placebo Comparator|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
11144519|NCT03765281|Experimental|Navigation|Navigation intervention plus Resource List
11144520|NCT03765281|Active Comparator|Self-Navigation|Resource List intervention
11144521|NCT03765268|Active Comparator|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
11144522|NCT03765268|Active Comparator|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
11144523|NCT03765255|Experimental|In the Know: sexual health education|Cohorts/participants in the experimental (treatment) arm receive an intervention that combines 6 hours of in-person sexual health and adolescent development education with an app that includes a resource locator, text message reminders (for one month), goal setting, and other resources.
11144524|NCT03765255|No Intervention|Control: do not receive ITK intervention|Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
11144525|NCT03765242||Patient initiating warfarin|
11144526|NCT03765242||Patient initiating apixaban|
11144527|NCT03765229|Experimental|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
11144528|NCT03765216|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
11144529|NCT03765216|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).
~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
11144530|NCT03765203|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to Natera's dd-cfDNA test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
11144531|NCT03765203|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to Natera's dd-cfDNA test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
11144532|NCT03765190|Experimental|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
11144533|NCT03765177|Experimental|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
11144534|NCT03765164|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
11144535|NCT03765164|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
11144536|NCT03765151|Experimental|LLLT group|Low-level laser therapy and orthodontic retention
11144537|NCT03765151|Placebo Comparator|control group|orthodontic retention and no laser treatment.
11144538|NCT03765138|Experimental|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
11144539|NCT03765125|Experimental|collagen peptide test|1 x daily consumption of 1 blister package of the collagen-peptide test powder dissolved in water over a period of 90 days
11144578|NCT03764878||Normal weight|BMI 18.5-24.9 kg/m^2 low risk pregnancy
11144540|NCT03765125|Placebo Comparator|collagen peptide placebo|1y daily consumption of 1 blister package of the placebo powder dissolved in water over a period of 90 days
11144541|NCT03765112|Experimental|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
11144542|NCT03765099|Experimental|Animal-Assisted Interactions|Children and their caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
11144543|NCT03765099|Active Comparator|Usual Care|Children and their caregivers randomly assigned to the usual care group will receive usual care which may include play therapy, music therapy or visits with a social worker during their visits to the hospital.
11144544|NCT03765086|Active Comparator|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
11144545|NCT03765086|Active Comparator|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
11144546|NCT03765073|Experimental|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
11144547|NCT03765073|Experimental|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
11144548|NCT03765073|Experimental|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
11144549|NCT03765073|Experimental|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
11144550|NCT03765073|Experimental|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
11144551|NCT03765073|Experimental|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
11144552|NCT03765073|Experimental|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
11144553|NCT03765073|Experimental|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
11144554|NCT03765073|Experimental|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
11144555|NCT03765073|Placebo Comparator|Stage 1 Placebo|Saline control
11144556|NCT03765073|Placebo Comparator|Stage 2 Placebo|Saline control
11144557|NCT03765073|Placebo Comparator|Stage 3 Placebo|Saline control
11144558|NCT03765060|Experimental|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):
~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).
~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
11144559|NCT03765060|Active Comparator|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).
~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).
~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
11144560|NCT03765047|Experimental|Intervention Arm|"This study arm includes the schools where the School Team (school teachers, coordinator) receives the physical activity intervention. The intervention consists of four parts:
~School Engagement and Assessment
~Training
~Physical Activity Equipment and Resources
~Ongoing Assessment and Technical Assistance"
11144561|NCT03765047|No Intervention|Control Arm|The control arm includes the schools where the School Team does not receive any intervention but all the necessary data will be collected.
11144562|NCT03765034|Experimental|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
11144563|NCT03765034|Active Comparator|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
11144564|NCT03765021|Experimental|Tranexamic acid injection (Kapron)|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
11144565|NCT03765021|Active Comparator|Fractional CO2 laser resurfacing|The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
11144566|NCT03765008|Active Comparator|High Water intake|5-days of High water intake according to IOM guidelines
11144567|NCT03765008|Experimental|Low Water Intake|5-days of Low water intake of 500 mL/day
11144568|NCT03764995|Experimental|Abdominal Massage|
11144569|NCT03764995|Placebo Comparator|Placebo Ultrasound|
11144570|NCT03764969|Active Comparator|standard smoking cessation program (SCP)|standard smoking cessation program
11144571|NCT03764969|Experimental|SCP + CRT|SCP plus cognitive remediation treatment (CRT)
11144572|NCT03764969|Experimental|SCP + ICHT|SCP plus an implicit computer-based habit-modifying training (ICHT)
11144573|NCT03764956|Experimental|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
11144574|NCT03764956|Active Comparator|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
11144575|NCT03764943|Experimental|Immunonutrition Intervention|Participants will consume 3 'Impact Advanced Recovery' shakes daily for 5 days prior to surgery 2 hours prior to surgery.
11144576|NCT03764891||Uphold|Patients who underwent Uphold procedure
11144579|NCT03764878||Pregestational diabetes mellitus|Type 1 or Type 2 diabetes mellitus diagnosed prior to the pregnancy or in the first trimester
11144580|NCT03764878||Obese|Pre-pregnancy BMI ≥ 30.0 kg/m^2
11144581|NCT03764865|Experimental|day 3 embryo transfer|
11144582|NCT03764865|Experimental|day 5 embryo transfer|
11144583|NCT03764852|Experimental|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
11144584|NCT03764839|No Intervention|Active Control Group (Digital Health Education)|"Demographics survey
~Baseline surveys
~Participants receive a digital information sheet on nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery
~Post-surgery:
~Pain check-ins (2 times per week) (detailed above)
~Patients receive 30 second booster videos at 7, 14, and 21 days after surgery
~Follow-up surveys (4, 8, and 12 weeks after surgery)"
11144585|NCT03764839|Experimental|"My Surgical Success Treatment Group"|"Demographics survey
~Baseline surveys
~Intervention:
~45-minute digital behavioral pain medicine intervention My Surgical Success that emphasized cognitive and emotional regulation of pain and downregulation of physiologic arousal.
~downloadable app with an audio file
~personalized plan that allows learners to incorporate the treatment information
~Post-video survey (detailed above)
~Post-surgery:
~Pain check-ins (2 times per week) (detailed above)
~Follow-up surveys (4, 8, and 12 weeks after surgery) Intervention: Behavioral: Perioperative Digital Behavioral Pain Medicine My Surgical Success"
11144586|NCT03764826|Experimental|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
11144587|NCT03764826|Active Comparator|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
11144588|NCT03764787|Experimental|Radiation+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
11144589|NCT03764774|Experimental|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
11144590|NCT03764774|Placebo Comparator|Placebo Single dose|Single dose of placebo administered SC
11144591|NCT03764774|Experimental|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
11144592|NCT03764774|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered SC
11144593|NCT03764761|Experimental|AAC Intervention|Participants will use AAC technology of different designs delivered on iMacs or Surface tablets
11144594|NCT03764748|Experimental|mini-FMT|Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
11144595|NCT03764735|Placebo Comparator|SkQ1 Vehicle|SkQ1 (Vehicle)
11144596|NCT03764735|Active Comparator|Low Dose - SkQ1|Low-dose ophthalmic solution
11144597|NCT03764735|Active Comparator|High Dose - SkQ1|High-dose ophthalmic solution
11144598|NCT03764722|Experimental|Levosimendan|
11144599|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.
~The experimental arm will wear wireless monitoring for 5 days after transfer in subacute care unit"
11144600|NCT03764709|Active Comparator|Control arm GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.
~The active comparator arm will be monitored by nursing staff."
11144601|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.
~The experimental arm will wear wireless monitoring for 5 days after discharge at home"
11144602|NCT03764709|Active Comparator|Control Arm GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.
~The active comparator arm will perform usual checks by caregivers at home."
11144603|NCT03764696|Placebo Comparator|air, second stage of labor|"Patients randomized to the group will receive sham administered by facemask.
~The therapy will continue until after delivery"
11144604|NCT03764696|Experimental|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by high flow facemask oxygen at 50% oxygen.
~The therapy will continue until after delivery"
11144605|NCT03764683|Experimental|Drug-Drug|This arm will receive the active drug in the first and second phase of the study.
11144606|NCT03764683|Other|Placebo-Drug|This arm will receive placebo in the first phase of the study and the active drug in the second phase.
11144607|NCT03764683|Placebo Comparator|Placebo-Placebo|This arm will receive placebo in the first phase and second phase of the study.
11144608|NCT03764657||"16 patients, named Hot group"|"We considered 16 sinus excision by diathermy as a case group (named Hot group)"
11144609|NCT03764657||"13 patients, named Cold group"|"13 procedures performed by knife as control group (named Cold group)."
11144610|NCT03764644|Experimental|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
11144611|NCT03764644|Sham Comparator|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
11144612|NCT03764631||subjects with Type 2 Diabetes mellitus|
11144613|NCT03764618|Experimental|Fostamatinib|Initial dose is 100 mg PO bid. At week 4 dose will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
11144614|NCT03764618|Placebo Comparator|Placebo|Initial dose is 100 mg PO bid. At week 4 dose will be increased to placebo 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.
11144719|NCT03763864|Other|Inherited disorders|
11144615|NCT03764605|Experimental|Metformin|"Patients will take metformin starting from 500 mg a day. They will up-titrate every week, if tolerating IMP, adding one 500 mg dose 8 hours after the former, till reaching 500 mg thrice a day.
~The minimum tolerated dose requested in order to be admitted to the study is 500 mg twice a day.
~Those reaching eGFR<45 ml/min will reduce the dose by one third. Those reaching eGFR<30 will drop out the study."
11144616|NCT03764605|Active Comparator|Tolvaptan|Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
11144617|NCT03764592||VF BrS/ERS patients|Only patients that diagnosed with BrS or ERS based on ECG criteria
11144618|NCT03764579|Active Comparator|sleep and diet intervention|
11144619|NCT03764579|Active Comparator|diet intervention|
11144620|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
11144621|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
11144622|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
11144623|NCT03764553|Experimental|Liposomal irinotecan, leucovorin and 5FU|IV Nal-IRI 80 mg/m² (expressed as irinotecan hydrochloride (HCl) salt), folinic acid 400 mg/m², fluorouracil 2400 mg/m² over 46 h, every 2 weeks.
11144624|NCT03764553|Experimental|Carboplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and carboplatin area under the curve (AUC5), every three weeks.
11144625|NCT03764553|Experimental|oxaliplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2, every three weeks.
11144626|NCT03764540|Experimental|Cabazitaxel plus prednisone|"Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).
~Prednisone will be administered by oral route"
11144627|NCT03764540|Active Comparator|Docetaxel plus prednisone|"Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.
~Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).
~Prednisone will be administered by oral route"
11144628|NCT03764527|Active Comparator|Artemether-lumefantrine (AL)|One tablet of artemether-lumefantrine (Coartem®) was administered twice daily for 3 days to children with a body weight of 9 to <15 kg, and 2 tablets were administered twice daily for 3 days to children with a body weight of >15 to 25 kg. All doses were taken under direct observation.
11144629|NCT03764527|Active Comparator|Artesunate + Amodiaquine (AA)|Artesunate + amodiaquine (ASAQ) was administered as follows: 4 mg/kg body weight of artesunate plus 10 mg/kg body weight of amodiaquine once daily for 3 days under direct observation.
11144630|NCT03764514||Spinal Cord Stimulator - Permanent Implantation|
11144631|NCT03764501|Active Comparator|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
11144632|NCT03764501|No Intervention|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
11144633|NCT03764488|Experimental|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
11144634|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
11144635|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
11144636|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
11144637|NCT03764475|Other|Long-term Safety of ARQ-151|Open Label Long-term Safety of ARQ-151
11144638|NCT03764462|Experimental|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
11144639|NCT03764462|Experimental|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
11144640|NCT03764449|Experimental|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
11144641|NCT03764449|Experimental|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
11144642|NCT03764436|Experimental|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
11144643|NCT03764436|Experimental|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
11144644|NCT03764436|Experimental|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
11144645|NCT03764423|Experimental|Salmon fishmeal|7,5 g fishmeal and 7,5 g microcrytalline cellulose per day in capsules by mounth for 8 weeks
11144646|NCT03764423|Placebo Comparator|Microcrystalline cellulose|7,5 g microcrystalline cellulose per day in capsules by mounth for 8 weeks
11144647|NCT03764410|Experimental|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
11144648|NCT03764410|Active Comparator|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
11144649|NCT03764397|Experimental|Prehabilitation group|A 4-week prehabilitation educational programme (i.e., a behavioral change intervention) and to pilot that prehabilitation in combination with a 6-week gentle self-paced walking programme (with weekly telephone support) in people with FM.
11144650|NCT03764384||Hospital Monitoring Group - ALSFRS-R cohort|All patients will be first recruited to this cohort unless at their first visit the investigator deems them eligible for the Home Monitoring Device Group. At the initial screening visit, all patients recruited into the study will undergo routine assessments according to the existing MND protocol, and additionally complete the ALSFRS-R symptom-based assessment questionnaire by interview with the study researchers (with assistance from spouse, family member or carer if required). Patients will continue to complete the ALSFRS-R symptom-based questionnaire at each clinic attendance.
11144651|NCT03764384||Home Monitoring Cohort|"If eligible patients will use the N Tidal CTM, up to 3 times a day (morning, midday and evening) throughout the home monitoring period until the final outpatient clinic visit.
~In addition subjects will complete a weekly diary symptom monitoring diary which asks them about their respiratory symptoms, GP attendances, respiratory infections. Patients routine standard of care assessments will also be documented according to the protocol as well as completing the ALSFRS-R at each visit."
11144652|NCT03764371||sMPLC|Lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules).
11144653|NCT03764358|Active Comparator|Arteriovenous fistula|
11144654|NCT03764358|Experimental|Tunneled Cuffed Catheter|
11144655|NCT03764345|Experimental|Sofosbovir/Ledipasvir Daily|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
11144656|NCT03764332|Other|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
11144657|NCT03764319|Active Comparator|Intervention group|Ultra-protective ventilator settings in patients with ARDS and VV-ECMO.
11144658|NCT03764319|Active Comparator|Control group|Standard ventilator settings in patients with ARDS and VV-ECMO.
11144659|NCT03764306|Active Comparator|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
11144660|NCT03764306|Active Comparator|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
11144661|NCT03764293|Experimental|SHR-1210|SHR-1210+Apatinib
11144662|NCT03764293|Active Comparator|Control|Sorafenib
11144663|NCT03764280|No Intervention|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
11144664|NCT03764280|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
11144665|NCT03764267|Active Comparator|remifentanil|MAC group
11144666|NCT03764267|Active Comparator|general anesthetic|TIVA group
11144667|NCT03764241|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy
11144668|NCT03764241|Active Comparator|Vitamin K Antagonist|warfarin will be added in addition to dual antiplatelet therapy
11144669|NCT03764228|Experimental|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10^6, 2×10^6, 5×10^6 cell/kg, successively.
11144670|NCT03764215|Experimental|Group 1|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
11144671|NCT03764202|Other|CSEA，1μg/kg•d|"The puerpera received combined spinal epidural anesthesia
~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
11144672|NCT03764202|Other|CSEA，1.5μg/kg•d|"The puerpera received combined spinal epidural anesthesia
~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
11144673|NCT03764202|Other|GA，1μg/kg•d|"The puerpera received general anesthesia
~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
11144674|NCT03764202|Other|GA，1.5μg/kg•d|"The puerpera received general anesthesia
~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
11144675|NCT03764202|Other|CSEA，Epidural analgesia|"The puerpera received combined spinal epidural anesthesia
~Postoperative analgesia was performed with epidural analgesia
~Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
11144676|NCT03764189|No Intervention|en masse retraction only|anterior segment retraction on miniscrews without microosteoperforation
11144677|NCT03764189|Active Comparator|en masse retraction with alveocentesis|anterior segment retraction on miniscrews with microosteoperforation
11144678|NCT03764176|Active Comparator|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
11144679|NCT03764176|Experimental|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
11144680|NCT03764163|Experimental|Study Participants|Pulmonary Function Test, Questionnaires, CT scans, perfusion scan, ventilation scan, Xenon gas ventilation CT scan with hyperpolarized 3-Helium MRI Scan.
11144681|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2> 45 mmHg
11144682|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 <45 mmHg)
11144683|NCT03764137|Experimental|[89Zr]Panitumumab-PET/MRI patients|All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
11144756|NCT03763578|Active Comparator|Chlorhexidine|"The gold standard of oral therapeutics is Chlorhexidine due to its prolonged broad- spectrum antimicrobial effect."
11144890|NCT03762629|No Intervention|Normal weight control group|Normal weight children were recruited as a control group without any intervention.
11144684|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
11144685|NCT03764111|Active Comparator|large mobile ultrasound system|the ultrasound transducer is based on piezoelectric technology.
11144686|NCT03764111|Experimental|handheld ultrasound machine|The handheld device utilizes Capacitive micro-machined ultrasound transducers (CMUTs) instead of piezoelectric technology
11144687|NCT03764098|Experimental|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
11144688|NCT03764098|Placebo Comparator|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
11144689|NCT03764085|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
11144690|NCT03764085|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
11144691|NCT03764072|Experimental|VX-150|
11144692|NCT03764072|Placebo Comparator|Placebo|
11144693|NCT03764059|Experimental|Interventional|The experimental group (Filtek Bulk fill posterior restoration) .After restoration,subjects will return to site for follow up visit at 1 week and 1 year postoperative for further clinical assessments.
11144694|NCT03764059|Active Comparator|observational|The control group (Filtek™ Z350XT Universal Restorative which was approved by CFDA in 2010 and has been in the market for 5 years with some validated clinical data).After restoration,subjects will return to the site for follow up visits at 1 week and 1 year postoperative for for further clinical assessments.
11144695|NCT03764033|Experimental|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
11144696|NCT03764033|Active Comparator|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
11144697|NCT03764020|Experimental|Melatonin|"Intervention group1:
~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
11144698|NCT03764020|Placebo Comparator|Placebo|"Intervention group2 :
~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
11144699|NCT03764007|Experimental|Fluorocholine PET arm|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
11144700|NCT03763994||Control group 1|Never low back pain in the last 3 months
11144701|NCT03763994||Control group 2|occasionally (1-30days) low back pain in the last 3 months
11144702|NCT03763994||Low back pain group 3|frequently (31-60days) low back pain in the last 3 months
11144703|NCT03763994||Low back pain group 4|daily (61-90days) low back pain in the last 3 months
11144704|NCT03763981|Active Comparator|prolene seton|Prolene thread will be used as seton treatment for perianal fistulas
11144705|NCT03763981|Active Comparator|silk seton|Silk thread will be used as seton treatment for perianal fistulas
11144706|NCT03763955||PD patients|PD patients at 1-5 H&Y stage undergoes 4week Multidisciplinary Intensive Rehabilitation Treatment
11144707|NCT03763942|Experimental|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
11144708|NCT03763942|Placebo Comparator|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
11144709|NCT03763929|Experimental|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
11144710|NCT03763929|Placebo Comparator|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
11144711|NCT03763916|Active Comparator|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus [above the site of placental insertion], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus [in presence of the placenta] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
11144712|NCT03763916|Active Comparator|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter.
11144713|NCT03763903|Other|3D training|Basic laparoscopic skills (FLS tasks) training using 3D visualization
11144714|NCT03763903|Other|2D training|Basic laparoscopic skills (FLS tasks) training using 2D visualization
11144715|NCT03763877|Experimental|Group 1|PXL770 Dose 1
11144716|NCT03763877|Experimental|Group 2|PXL770 Dose 2
11144717|NCT03763877|Experimental|Group 3|PXL770 Dose 3
11144718|NCT03763877|Placebo Comparator|Group 4|Placebo oral capsule
11144720|NCT03763851|Experimental|Cannabis group|"Delta-9 Tetrahydrocannabidiol (THC) /Cannabidiol (CBD) ratio 1:1 capsule
~These capsules contain different cannabis formulations with low-dose and high-dose preparations according to the treatment group:
~Cannabis group low-dose capsule contains THC 1mg CBD 1mg
~Cannabis group high-dose capsule contains THC 2.5mg CBD 2.5mg"
11144721|NCT03763851|Placebo Comparator|Placebo group|"The placebo capsule will have no cannabis, it will look identical to the active treatment capsule, and it will also be prepared in low-dose and high-dose presentations."
11144722|NCT03763838|Experimental|Acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are known to affect physiology. Participants will also receive standard of care.
11144723|NCT03763838|Sham Comparator|Sham acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are not known to affect physiology. Participants will also receive standard of care.
11144724|NCT03763838|Other|Standard of care|Participants will receive standard of care only.
11144725|NCT03763825|Experimental|Intervention group|Patient will receive the Mini-AFTERc intervention after completion of primary breast cancer treatment.
11144726|NCT03763825|No Intervention|Control group|Patients will receive usual care after completion of primary breast cancer treatment.
11144727|NCT03763812|Other|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
11144728|NCT03763812|Other|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
11144729|NCT03763799|Experimental|multiplex PCR strategy|FilmArray® Pneumonia Panel plus
11144730|NCT03763799|Active Comparator|standard strategy|
11144731|NCT03763786|Experimental|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
11144732|NCT03763786|Active Comparator|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
11144733|NCT03763760|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
11144734|NCT03763760|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
11144735|NCT03763747|Experimental|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
11144736|NCT03763734|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
11144737|NCT03763734|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
11144738|NCT03763721|Experimental|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
11144739|NCT03763721|Active Comparator|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
11144740|NCT03763708|Experimental|Spinal Cord Stimulation|Each subject will be programmed to different settings.
11144741|NCT03763695||Retrospective control group|Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
11144742|NCT03763695||Prospective group|Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
11144743|NCT03763682|Experimental|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
11144744|NCT03763669|Experimental|Intervention|Pregnant women randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) and myo-inositol supplementation
11144745|NCT03763669|Placebo Comparator|Control|Pregnant women randomly assigned to receive (n. 40) only diet and folic acid (400 mcg per day)
11144746|NCT03763656|Experimental|Open Label|Novel oral solution formulation of hydroxyurea
11144747|NCT03763643|Experimental|Rituximab + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day 0 or -1 prior to kidney transplantation in addition to standard plasmapheresis.
11144748|NCT03763643|Placebo Comparator|Placebo + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day 0 or -1 prior to kidney transplantation in addition to standard plasmapheresis.
11144749|NCT03763630|Active Comparator|Intervention arm|House dust-mite SLIT
11144750|NCT03763630|Placebo Comparator|Control arm|Normal saline
11144751|NCT03763630|No Intervention|Observation cohort|ITEC observational cohort, no intervention administered
11144752|NCT03763617|Active Comparator|Test group|A d-ptfe membrane will be placed between the buccal bone and periosteum of an extraction socket during a 4 months healing time before it is surgically removed.
11144753|NCT03763617|No Intervention|Control group|The extraction socket will be left to heal naturally without a socket preservation intervention.
11144754|NCT03763591|Experimental|Psychological Skills Group (e.g., Active Intervention)|10-week Psychological Skills Group.
11144755|NCT03763578|Experimental|Licorice|licorice is one of the natural products that is listed by the Food and Drug Administration (FDA) as GRAS (generally regarded as safe) when used as food flavoring and sweetening agent which has an antimicrobial, anti-inflammatory and antiviral activity.
11144757|NCT03763578|No Intervention|Control Group|Participants in this group will follow only the standard preventive measures which is brushing twice a day after breakfast and before bed time and daily flossing interdentally before bed time. (No Mouthwash is used)
11144758|NCT03763565||Vaccinated group|Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
11144759|NCT03763565||Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
11144760|NCT03763539|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.
~The rest of the session at 22kv (full power)."
11144761|NCT03763539|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
11144762|NCT03763513|Active Comparator|ESWT|the first group:The group that will receive Extra corporeal shock wave therapy
11144763|NCT03763513|Experimental|ESWT+KT|the second group:The group that will receive Extra corporeal shock wave therapy + Kinesiotaping application
11144764|NCT03763500|No Intervention|Care as usual|"Regular care at participating hospitals:
~Extended written information and education of patients with atrial fibrillation."
11144765|NCT03763500|Active Comparator|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
11144766|NCT03763487|Experimental|Patients|Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling
11144767|NCT03763487|No Intervention|healthy blood donors|No intervention in this group.
11144768|NCT03763474|Experimental|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
11144769|NCT03763474|No Intervention|Control|
11144770|NCT03763461|Experimental|HFNC|HFNC will be started at flow of 40 L/min and FiO2 of 40%.
11144771|NCT03763461|Other|Oxygen Mask|Standard non-humidified oxygen therapy via an oxygen mask at 6 l/min will be performed.
11144772|NCT03763448|Experimental|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
11144773|NCT03763448|Active Comparator|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
11144774|NCT03763435||Antenatal Classes Received|Women who are involved into at least 3 comprehensive session of Antenatal pregnancy classes (educational) during the prenatal period.
11144775|NCT03763435||Without education|Groups are not randomized for not to give rise to ethical problems in order to maximize the community health care. Only women who are not involved into the educational classes due to their inaccessibility related to their own conditions or wishes.
11144776|NCT03763422|Experimental|Early Treatment arm|Radiotherapy + Temozolomide
11144777|NCT03763422|Active Comparator|Active surveillance arm|Treatment as per local practice
11144778|NCT03763409|Experimental|losartan|50 mg single-dose oral losartan
11144779|NCT03763409|Placebo Comparator|placebo|microcellulose placebo in identical capsule
11144780|NCT03763396|Experimental|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
11144781|NCT03763396|Experimental|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
11144782|NCT03763396|Experimental|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
11144783|NCT03763396|Experimental|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
11144784|NCT03763383||Free lateral arm flap|included patients who had free lateral Arm flap
11144785|NCT03763383||pedicled lateral arm flap|included patients who had pedicled lateral arm flap
11144786|NCT03763357|Experimental|Heat Therapy|Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.
11144787|NCT03763344|Experimental|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:
~the first cognitive assessment (Baseline),
~intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,
~a post-treatment cognitive assessment (Week 7), and
~a follow up cognitive assessment (Week 11)"
11144788|NCT03763344|No Intervention|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:
~the first cognitive assessment (baseline),
~seven weeks of no intervention,
~a post-treatment cognitive assessment (week 7), and
~a follow up cognitive assessment (week 11)"
11144789|NCT03763331|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks..
11144790|NCT03763331|Active Comparator|Heat Therapy|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
11144791|NCT03763318|Experimental|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
11144792|NCT03763318|Experimental|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
11144793|NCT03763318|Placebo Comparator|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
11144891|NCT03762616|Experimental|Micro-ultrasound Targeted Biopsy|
11144794|NCT03763305|Experimental|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3~5mcg/mL Propofol Fresenius and 3~5ng/mL and Remifentanil [Ultiva] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
11144795|NCT03763305|Experimental|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution [Sojourn] is used to maintain 1 age-related minimum alveolar concentration (MAC).
11144796|NCT03763305|Experimental|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane [Suprane] is used to maintain 1 age-related minimum alveolar concentration (MAC).
11144797|NCT03763292|Experimental|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
11144798|NCT03763292|No Intervention|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
11144799|NCT03763279|Experimental|Triclosan-coated barbed suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone barbed suture
11144800|NCT03763279|Experimental|Triclosan-coated monofilament suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone monofilament suture
11144801|NCT03763279|Sham Comparator|Monofilament suture|Abdominal wall closure will be performed using a monofilament suture
11144802|NCT03763266|Experimental|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
11144803|NCT03763266|Active Comparator|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
11144804|NCT03763253|Active Comparator|Control Arm: Standard of Care (SOC)|"Standard of Care (SOC) treatment as determined by treating physician (positive control) (androgen deprivation with or without docetaxel chemotherapy or other systemic standard of care treatment including but not limited to Abiraterone or Enzalutamide).
~Radiotherapy to the prostate in this arm is defined as cytoreductive (for symptom control) in high volume (>/=4) metastases or to mirror current accepted local radiotherapy dose regimens for men with low volume metastases (<4 metastases).
~Metastases directed therapy will not be permitted in the control arm. Palliative radiotherapy for symptom control or for prevention of fracture will be permitted as standard clinical practice."
11144805|NCT03763253|Active Comparator|Intervention Arm 1: Minimally Invasive Ablative Therapy (MIAT)|"MIAT to prostate in form of cryotherapy or high intensity focused ultrasound (HIFU), in addition to SOC systemic treatment. No local prostate radiotherapy will be given as part of this intervention. Radiotherapy can be given subsequently for palliative reasons.
~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
11144806|NCT03763253|Active Comparator|Intervention Arm 2: Radical Therapy|"Radical therapy in form of prostatectomy (any approach) or external beam radiotherapy (radical dose) in addition to SOC systemic treatment. Modality based on physician and patient preference and patient co-morbidities.
~For patients undergoing radical prostatectomy no local prostate radiotherapy will be given as part of the intervention. Radiotherapy can be given subsequently for palliative reasons.
~Radical radiotherapy doses in this arm will be higher than SOC.
~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
11144807|NCT03763240|Active Comparator|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
11144808|NCT03763240|Placebo Comparator|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
11144809|NCT03763227|Active Comparator|Carbonic Anhydrase Inhibitor (CAI) Arm|Patients who have received carbonic anhydrase inhibitor (CAI) therapy namely oral acetazolamide or topical brinzolamide
11144810|NCT03763227|Experimental|Intravitreal ranibizumab (IVR) arm|"Intravitreal ranibizumab (IVR) injection administered to patients who have not shown adequate response or who have not tolerated CAI therapy
~IVR therapy = Three 0.5mg IVR injection at monthly intervals"
11144811|NCT03763214|Experimental|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
11144812|NCT03763214|Active Comparator|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
11144813|NCT03763201||rheumatoid arthritis|recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
11144814|NCT03763201||control group|age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
11144815|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
11144816|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
11144817|NCT03763175|Active Comparator|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
11144818|NCT03763175|Active Comparator|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
11144853|NCT03762889|Experimental|Eyeprotx™ Group|This group of participants will use the Eyeprotx™ General Anesthesia Protective Goggles when intubated perioperatively under general anesthesia.
11144892|NCT03762616|Experimental|MRI Targeted Biopsy|
11144819|NCT03763175|Placebo Comparator|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
11144820|NCT03763162|Experimental|Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)|Patients receive daratumumab IV over 3.5-6.5 hours on days 1, 8, and 15, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and PO on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11144821|NCT03763149|Experimental|IBI188|"Part 1: Accelerated Titration Phase 0.1 mg/kg IV; QW 0.3 mg/kg IV QW; 1 mg/kg IV QW
~Part 2 : Dose Escalation Phase with initial fixed priming dose Priming dose of 1mg/kg on C1D1 followed by 3 mg/kg IV QW; 10 mg/kg IV QW; 20 mg/kg IV QW; 30 mg/kg IV QW."
11144822|NCT03763136|Experimental|hPSC-CM therapy|Procedure: Injection of allogenic human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) at time of coronary artery bypass grafting surgery, 100 million hiPSC-CMs in 2.5-5mL medium suspension will be injected into the myocardium.
11144823|NCT03763123|Experimental|Sevacizumab +Chemotherapy Combined chemotherapy drug including|Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.
11144824|NCT03763110|Experimental|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
11144825|NCT03763110|Active Comparator|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
11144826|NCT03763097||participants|Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
11144827|NCT03763084|Experimental|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
11144828|NCT03763084|Active Comparator|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
11144829|NCT03763071||Participants|Pregnant women in the 2nd or 3th trimester Patient-reported scales to measure sleep disorders
11144830|NCT03763058|Other|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
11144831|NCT03763045|Experimental|Sildenafil 25|Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.
11144832|NCT03763045|Experimental|Sildenafil 50|Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.
11144833|NCT03763045|Placebo Comparator|Placebo|Twenty hemodialysis patients will receive a placebo tablet daily for 3 months.
11144834|NCT03763032|Experimental|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
11144835|NCT03763019|Active Comparator|Respiratory rehabilitation|"Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
~Respiratory exercises 30 minutes, once daily, (incentive spirometric trainer, forced expiration, percussion, postural drainage etc.)"
11144836|NCT03763019|Placebo Comparator|Conventional rehabilitation|Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
11144837|NCT03763006|Experimental|Ocudox lid wiped|
11144838|NCT03763006|Active Comparator|Povidone Iodine|
11144839|NCT03762993|Experimental|Healthy Adults|Participants will complete vocal rest and controlled phonation
11144840|NCT03762993|Experimental|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
11144841|NCT03762980|Experimental|Right hemiplegic patients|
11144842|NCT03762980|Experimental|Left hemiplegic patients|
11144843|NCT03762967|Experimental|Lipoaspiration and SVF introduction I.|Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
11144844|NCT03762967|Active Comparator|Standard therapy I.|Patients with azoospermia that introduce with Standard therapy only.
11144845|NCT03762967|Experimental|Lipoaspiration and SVF introduction II|Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
11144846|NCT03762967|Active Comparator|Standard therapy II.|Patients with oligospermia that introduce with Standard therapy only.
11144847|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
11144848|NCT03762941||Elderly patients acutely admitted|Elderly patients (aged ≥ 65 year) admitted to emergency departments at the Hospital of Southern Jutland or Odense University
11144849|NCT03762928|Experimental|midazolam/efavirenz|
11144850|NCT03762928|Experimental|PF-06651600/midazolam/efavirenz|
11144851|NCT03762915|Experimental|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
11144852|NCT03762915|No Intervention|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
11144854|NCT03762889|Active Comparator|Eyelid Tape Group|This group of participants will be receiving the eyelid tape as the preventative measure when intubated perioperatively under general anesthesia.
11144855|NCT03762889|Active Comparator|Eye Ointment Group|This group of participants will be receiving the ointment application when intubated perioperatively under general anesthesia.
11144856|NCT03762863|Experimental|Appropriate application of a CAT tourniquet|All study subjects attended an American College of Surgeons Stop the Bleed Basic course with live training by approved instructors. 6 months after participation in the Stop the Bleed class volunteers study subjects are randomly solicited to return for a refresher session. During this refresher session the volunteer study subjects are observed to determine if they have retained tourniquet application skills and to what degree they have retained them. A 10 point check list will be used to evaluated tourniquet application skill retention.
11144857|NCT03762850|Experimental|sparsentan|Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg and continue treatment to Week 110.
11144858|NCT03762850|Active Comparator|irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
11144859|NCT03762837||Exposure group：Benign gallbladder disease|Patients with benign gallbladder diseases, such as gallbladder polyps, gallstones, etc.
11144860|NCT03762837||Non-exposed group: healthy people|Patients without benign gallbladder diseases
11144861|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
11144862|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
11144863|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
11144864|NCT03762824|Active Comparator|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
11144865|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
11144866|NCT03762811|Other|NanoFUSE® PMCF|NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.
11144867|NCT03762798|Experimental|Treatment|All participants will receive the Bridge device.
11144868|NCT03762785|Active Comparator|nebulized dexmedetomidine 2ug/kg|inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
11144869|NCT03762785|Active Comparator|nebulized dexmedetomidine 3ug/kg|inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
11144870|NCT03762772|Experimental|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
11144871|NCT03762759|Experimental|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
11144872|NCT03762759|Active Comparator|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
11144873|NCT03762746|Active Comparator|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
11144874|NCT03762746|Sham Comparator|Control|Control group is received treatment as usual
11144875|NCT03762733||Patient Relatives|Biological relatives (1st-3rd degree) of patients with histologically confirmed malignancy
11144876|NCT03762733||Patients|Patients with histologically confirmed malignancy
11144877|NCT03762720|Experimental|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
11144878|NCT03762694|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
11144879|NCT03762694|No Intervention|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
11144880|NCT03762681|Experimental|Part 1: Single Ascending Dose, HV|Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).
11144881|NCT03762681|Experimental|Part 2a: Multi-dose, CHB|Participants with CHB will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.
11144882|NCT03762681|Experimental|Part 2b: Multi-dose, CHB (Optional)|Additional study arm to open based on data collected from Part 2a. Participants with CHB will be administered different doses and frequencies of RO7239958 or placebo SC.
11144883|NCT03762668|Other|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
11144884|NCT03762668|Other|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
11144885|NCT03762655|Experimental|Neuro-Spinal Scaffold Arm|Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery.
11144886|NCT03762655|No Intervention|Comparator Arm|Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold.
11144887|NCT03762642||Mastectomy|
11144888|NCT03762642||Breast-Conserving Surgery|
11144889|NCT03762629|Experimental|Obese intervention group|Obese children were received exercise and diet intervention for 6 weeks.
11144893|NCT03762603|Experimental|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
11144894|NCT03762590|Experimental|Doxy.me plus Color Genomics Arm (Arm 1)|"Participants in this arm will receive genetic education through an online platform called Doxy.me
~The Doxy.me session will consist of two parts: 1) a pre-recorded genetic education video 2) a live interactive video conferencing session with a GENERATE genetic counselor
~After completing the Doxy.me session and post intervention questionnaires, participants will be directed to the Color Genomics study portal where they may elect to review Color Genomics' genetic education content or proceed directly to order genetic testing
~Intervention is Doxy.me genetic education +/- genetic education via Color Genomics website"
11144895|NCT03762590|Experimental|Color Genomics Only Arm (Arm 2)|"Participants in this arm will access genetic education on the Color Genomics website which includes both written information and an educational video
~After accessing the Color Genomics website, participants may elect to review educational content or proceed directly to order genetic testing
~Intervention is genetic education via Color Genomics website"
11144896|NCT03762577|Experimental|Training Group|Training group will attend ground-based walking training under the supervision of a physiotherapist for 2 days and 30 minutes a week. Patients will walk for 1-2 days in a week without supervision.
11144897|NCT03762577|No Intervention|Control Group|Patient education will be given and no intervention will be made.
11144898|NCT03762564|Experimental|Arm A (Paclitaxel + Ramucirumab)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 plus Ramucirumab 8 mg/kg as 1 hour intravenous infusion on day 1 and 15 qd 28
11144899|NCT03762564|Active Comparator|Arm B (control arm)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 qd 28
11144900|NCT03762551|Experimental|vitiligo|assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
11144901|NCT03762551|Active Comparator|psoriasis|assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
11144902|NCT03762551|Other|controls|assess the level of JAK1 in controls
11144903|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
11144904|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
11144905|NCT03762525|Other|ECG gated CTA pre and post operative at Gore IBE|To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component. Each patient will have an ECG gated CTA scan before the operation and 6-8 weeks after operation, in stead of a regular CT scan.
11144906|NCT03762525|Other|ECG gated CTA post operative at Gore IBE and Cook IBD|To compare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device. Each patient will have an ECG gated CTA after the operation, at the first doctor's appointment, in stead of a regular CT scan.
11144907|NCT03762499|Active Comparator|Prospective participants|250 participants will be recruited prospectively during the hypertension clinic, where a full set of data will be collected from each participant as part of their standard hypertension clinical service. An additional echocardiography scan will be performed for this cohort by the study team, if the scan has not been performed as a part of the clinical care service
11144908|NCT03762499|No Intervention|Retrospective participants|500 participants will be recruited retrospectively, and no additional echocardiography scan will be required for them.
11144909|NCT03762486|Active Comparator|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
11144910|NCT03762486|Active Comparator|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
11144911|NCT03762486|No Intervention|No stimulation|No stimulation was performed to the patients in the control group.
11144912|NCT03762473|Experimental|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of < 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
11144913|NCT03762473|Active Comparator|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
11144914|NCT03762460||Enhanced Measurement-Based Care (eMBC)|Participants randomized to this group will use a personally-owned smartphone, tablet, or laptop computer to access the online eMBC platform.
11144915|NCT03762460||Information website (control)|Participants randomized to this group will receive information about online resources for mental health
11144916|NCT03762447|Experimental|INCB086550|
11144917|NCT03762434|Active Comparator|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
11144918|NCT03762434|Active Comparator|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
11145082|NCT03761329|Experimental|Mini-Bier's block|Forearm intravenous regional anesthesia (mini-Bier's block) with lidocaine 0.5% 25ml
11145083|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
11144919|NCT03762421|Experimental|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
11144920|NCT03762421|Active Comparator|Control Arm|The control group will receive 5 routine training induction sessions.
11144921|NCT03762408|Experimental|ENKO 1|ENKO 1 administered by single intra-articular injection.
11144922|NCT03762408|Active Comparator|Durolane|Durolane administered by single intra-articular injection.
11144923|NCT03762395|Experimental|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
11144924|NCT03762395|Placebo Comparator|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
11144925|NCT03762382|Experimental|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
11144926|NCT03762382|Experimental|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
11144927|NCT03762382|Placebo Comparator|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
11144928|NCT03762369|Experimental|CKD-351|Latanoprost+D930
11144929|NCT03762369|Active Comparator|Latanoprost|
11144930|NCT03762369|Active Comparator|D930|
11144931|NCT03762343|Experimental|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
11144932|NCT03762343|Placebo Comparator|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
11144933|NCT03762330|Active Comparator|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
11144934|NCT03762330|No Intervention|Usual care|COPD participants receiving only usual care
11144935|NCT03762317|Active Comparator|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
11144936|NCT03762317|Placebo Comparator|Placebo|Placebo solution will be given for the duration of the study period
11144937|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
11144938|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
11144939|NCT03762291|Experimental|CVD908ssb-TXSVN|"3 different dosing schedules will be studied (3+3 design). At the beginning, patients will start on the lowest dose (1 of 3 different levels) of TXSVN. Once that dose schedule proves safe, the next group of patients will be started at a higher dose. This process will continue until all 3 dose levels are studied. If the side-effects are too severe, the dose will be lowered or the TXSVN administrations will be stopped. Each patient will receive 2 vaccinations at the same dose, 2 weeks apart, according to the following dosing schedules: The administration will be oral.
~Dose Level One:
~Day 0 2.5 x 10^5 cfu/m^2 Day 14 2.5 x 10^5 cfu/m^2
~Dose Level Two:
~Day 0 2.5 x 10^6 cfu/m^2 Day 14 2.5 x 10^6 cfu/m^2
~Dose Level Three:
~Day 0 2.5 x 10^7 cfu/m^2 Day 14 2.5 x 10^7 cfu/m^2"
11144940|NCT03762278|Experimental|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
11144941|NCT03762278|Active Comparator|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
11144942|NCT03762278|Placebo Comparator|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
11144943|NCT03762278|Placebo Comparator|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
11144944|NCT03762265|Experimental|Experimental|
11144945|NCT03762265|Placebo Comparator|Placebo|
11144946|NCT03762252|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
11144947|NCT03762252|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
11144948|NCT03762239|Active Comparator|Purified air|Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
11144949|NCT03762239|Sham Comparator|Normal air|Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
11144950|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
11145040|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).
~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.
~The Serum selenium concentrations are 18-40μg/L."
11144951|NCT03762213|Experimental|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.
~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.
~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.
~The entire duration of the experience will be kept at 10 minutes."
11144952|NCT03762213|Placebo Comparator|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
11144953|NCT03762200|Other|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
11144954|NCT03762187|Experimental|Self-affirmation|Participants completed a written self-affirmation manipulation before completing the standard counseling provided by the clinic.
11144955|NCT03762187|Active Comparator|Positive living counseling|Participants completed the standard counseling provided by the clinic (treatment as usual control condition).
11144956|NCT03762161|Experimental|Intervention TAS-102|
11144957|NCT03762148|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
11144958|NCT03762148|Experimental|ferrous sulphate|labelled iron as ferrous sulphate
11144959|NCT03762148|Experimental|ferric pyrophosphate|labelled iron as ferric pyrophosphate
11144960|NCT03762148|Experimental|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
11144961|NCT03762148|Experimental|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
11144962|NCT03762148|Experimental|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
11144963|NCT03762148|Experimental|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
11144964|NCT03762148|Experimental|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
11144965|NCT03762148|Experimental|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
11144966|NCT03762135|Experimental|Full version of the LIITah App.|Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
11144967|NCT03762135|Active Comparator|Partial App. (ELI and SNAP only)|Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.
11144968|NCT03762122|Experimental|Rogaratinib|Rogaratinib is given at a dose of 600 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.
11144969|NCT03762109|Experimental|Dantrolene Group|Patients will receive 25 mg of Dantrolene orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
11144970|NCT03762109|Placebo Comparator|Placebo Oral Tablet Group|Patients will receive a 25 mg of a placebo pill orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
11144971|NCT03762096|Experimental|Resveratrol|
11144972|NCT03762096|Placebo Comparator|Placebo|
11144973|NCT03762083|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of BV.
11144974|NCT03762057||Surgical patients|All postoperative patients admitted to surgical ICU with foley catheter in place
11144975|NCT03762044|Experimental|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
11144976|NCT03762044|Active Comparator|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
11144977|NCT03762031|Experimental|GC4711 30mg|
11144978|NCT03762031|Experimental|GC4711 60mg|
11144979|NCT03762031|Experimental|GC4711 90mg|
11144980|NCT03762031|Experimental|GC4711 120mg|
11144981|NCT03762031|Placebo Comparator|Placebo|
11144982|NCT03762031|Experimental|GC4711 75mg|
11144983|NCT03762031|Experimental|GC4711 105mg|
11144984|NCT03762018|Active Comparator|Bevacizumab plus chemotherapy|Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
11144985|NCT03762018|Experimental|Atezolizumab plus bevacizumab plus chemotherapy|Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
11144986|NCT03762005|Experimental|CRT guided resuscitation|Fluid resuscitation will be aimed at normalizing capillary refill time (CRT) during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of CRT until achieving normal values, or the patient becomes fluid unresponsive, or a safety issue develops.
11145041|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.
~The Serum selenium concentrations are more than 40μg/L."
11145605|NCT03757845|Experimental|Mediterranean diet|
11144987|NCT03762005|Active Comparator|Lactate guided resuscitation|Fluid resuscitation will be aimed at normalizing or decreasing lactate levels by more than 20% every 2 hours during the intervention during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of lactate every 2 hours until reaching target, or the patient becomes fluid unresponsive, or a safety issue develops.
11144988|NCT03761992|Active Comparator|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
11144989|NCT03761992|Placebo Comparator|Placebo|Placebo Pill
11144990|NCT03761979|Active Comparator|Strontium dose of 170 mg|The Sponsor provided each 170 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
11144991|NCT03761979|Active Comparator|strontium dose of 340 mg|The Sponsor provided each 340 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
11144992|NCT03761979|Active Comparator|Strontium dose of 680 mg|The Sponsor provided each 680 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
11144993|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
11144994|NCT03761953|Experimental|Oritavancin|Single IV infusion of 1200mg of oritavancin
11144995|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
11144996|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
11144997|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
11144998|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
11144999|NCT03761927|Active Comparator|Hearing Aid without NR enabled.|Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
11145000|NCT03761927|Experimental|Hearing Aid with NR(1)|Hearing Aid with Noise Reduction I (NR) enabled.
11145001|NCT03761927|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
11145002|NCT03761914|Experimental|Colorectal Cancer (CRC)|"N=20;
~Metastatic CRC priorly Rxed with ≥2 lines of ChemoRx (3rd/4th line); must have documented disease progression post last administration of or intolerance to standard therapies, which must have included a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS wild-type, cetuximab or panitumumab. Prior regorafenib or trifluridine/tipiracil is allowed, but not mandated;
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
11145003|NCT03761914|Experimental|Ovarian Cancer (OvC)|"N=20;
~Metastatic OvC priorly Rxed with ≥1 line of platinum-containing ChemoRx (2nd/3rd line) with either relapse or disease refractoriness; interval surgery permitted, as long as subjects have measurable disease by imaging and concomitant CA-125 increase, and/or biopsy showing OvC; must have either received (or been offered) bevacizumab therapy; those with BRCA germline mutations (gBRCA mut) must have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors.
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
11145004|NCT03761914|Experimental|Small Cell Lung Cancer (SCLC)|"N=20;
~Advanced SCLC priorly Rxed with 1 line of ChemoRx (2nd line); must have measurable disease by imaging after they progressed or were resistant to 1 prior systemic therapy; asymptomatic or treated brain metastases are allowed;
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
11145042|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.
~The Serum selenium concentrations are less than 18μg/L."
11145284|NCT03759964|Active Comparator|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
11145005|NCT03761914|Experimental|Triple Negative Breast Cancer (TNBC)|"N=15;
~TNBC priorly Rxed with 1 line of ChemoRx with residual or recurrent disease (2nd line); estrogen (ER) and progesterone receptor (PgR) negative, and HER2(-) by IHC AND HER2 non-amplified by fluorescence in situ hybridization; weak IHC positivity for ER or PgR (i.e., < 5%) eligible; must have undergone 2nd line therapy after 1st line Rx could include: neoadjuvant Rx if macroscopic disease still present after surgery OR adjuvant Rx but only if relapse occurred > 6 months from the start of pembrolizumab (P);
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
11145006|NCT03761914|Experimental|Acute Myelogenous Leukemia (AML)|"N=15;
~Pts with AML who are not eligible for allogeneic stem cell transplant and have been able to achieve morphological partial remission (PR) as their best ever response at the time of completion of their 4th cycle of upfront Rx with HMA; prior initial upfront hydroxyurea or leukapheresis Rx or history of induction early failure after up to 2 cycles of ChemoRx (7+3 or similar regimen) with seamless immediate transitioning to HMA Rx eligible; must remain on HMA therapy throughout the trial.
~PFS and OS to be assessed in all;
~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
11145007|NCT03761901||Patients with EGFR mutation positive NSCLC|
11145008|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
11145009|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
11145010|NCT03761875|Other|CHB patients|a blood sample is done during a follow-up visit
11145011|NCT03761875|Other|Control group|a blood sample
11145012|NCT03761862||Control|The control group with bilateral tubal ligation
11145013|NCT03761862||Neural Therapy|The treatment group
11145014|NCT03761849|Experimental|RO7234292 Q8W|RO4234292 is administered intrathecally every 8 weeks.
11145015|NCT03761849|Experimental|RO7234292 Q16W|RO7234292 is administered intrathecally every 16 weeks. Participants in this arm will also receive placebo at alternate weeks to keep the blind.
11145016|NCT03761849|Placebo Comparator|Placebo|Placebo will be administered every 8 weeks by IT injection.
11145017|NCT03761836|Experimental|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
11145018|NCT03761823||Healthy subjects|Healthy subjects
11145019|NCT03761823||Patients|Patients extubated after > 5 days of mechanical ventilation.
11145020|NCT03761810|Experimental|S6G5T-3|topical cream
11145021|NCT03761810|Placebo Comparator|S6G5T-8|topical cream
11145022|NCT03761797||Subjects with type 2 Diabetes Mellitus|
11145023|NCT03761784|Experimental|S6G5T-3|topical cream
11145024|NCT03761784|Placebo Comparator|S6G5T-8|topical cream
11145025|NCT03761771||colonoscopy withdrawal with the ADS monitoring|The ADS automatically initiated once the ileocecal valve was pictured by the colonoscopist or the colonoscopist recorded any image of colon during the insertion. When colonoscopists withdrew the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the ADS, which made it feasible to identify and classify lesions in real time.
11145026|NCT03761758|Experimental|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
11145027|NCT03761758|Experimental|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
11145028|NCT03761758|Experimental|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
11145029|NCT03761732|Experimental|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
11145030|NCT03761706|Experimental|Intervention Cohort|This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
11145031|NCT03761693|Experimental|Severe/classical MCADD|"Severe MCADD will be defined by ACADM mutations associated with clinical ascertainment or residual MCAD enzyme activity < 10 %, as defined previously (Touw et al., 2012).
~Interventions include fasting challenges at two and six months of age."
11145032|NCT03761693|Experimental|Mild MCADD|"Mild MCADD will be defined by the remaining ACADM genotype variants and residual MCAD enzyme activity ≥ 10%.
~Interventions include fasting challenges at two and six months of age."
11145033|NCT03761680|Experimental|MEDPass Group|Allocation of ONS in the MEDPass mode
11145034|NCT03761680|Active Comparator|Control Group|Patients receive ONS between meals or at their request as usual
11145035|NCT03761667|Experimental|NBI|The group of NBI inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
11145036|NCT03761667|No Intervention|White light endoscopy (WLE)|The group of WLE inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
11145037|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
11145038|NCT03761628|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
11145039|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
11145043|NCT03761589|Experimental|AFL Intervention Group|The AFL intervention consisted of twice a week physical activity and nutrition sessions for children and twice a week educational and physical activity sessions for parents. Each session lasted 90 minutes and all sessions were conducted in a municipal recreation center. The child program was delivered in English while the parent program was delivered in separate English-only or Spanish-only classes.
11145044|NCT03761589|Other|Wait-List Control Group|The wait-list control group received the 12-week AFL intervention after all follow-up data had been completed.
11145045|NCT03761550||Stage 2|The Process Implementation Stage
11145046|NCT03761537|Experimental|Tralokinumab|Tralokinumab loading SC injection on Day 0 followed by multiple tralokinumab injections
11145047|NCT03761537|Placebo Comparator|Placebo|Placebo loading SC injection on Day 0 followed by multiple placebo injections
11145048|NCT03761524|Experimental|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
11145049|NCT03761524|Active Comparator|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
11145050|NCT03761511|Active Comparator|Treatment arm|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
11145051|NCT03761511|Placebo Comparator|Placebo arm|Matching Placebo (capsules) once daily
11145052|NCT03761498||Normal Growth|Require less than or equal to 110 kcal/kg/day to maintain growth curve
11145053|NCT03761498||Slow Growth|Require more than 110 kcal/kg/day to maintain growth curve
11145054|NCT03761485|Experimental|Dentifrice 750 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
11145055|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF neutral|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
11145056|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
11145057|NCT03761472|Active Comparator|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
11145058|NCT03761472|Active Comparator|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
11145059|NCT03761472|No Intervention|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
11145060|NCT03761472|No Intervention|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
11145061|NCT03761446|Experimental|Older adults with Type 2 Diabetes|Male and female older adults between the ages 65-80 with type 2 diabetes
11145062|NCT03761446|Experimental|Older adults without Type 2 Diabetes|Male and female older adults between the ages 65-80 without type 2 diabetes
11145063|NCT03761433||SPI group|All patients who received the liver resection surgery will receive surgical pleth index
11145064|NCT03761420||breast cancer postoperative|got surgery for breast cancer in St Olavs Hospital, Trondheim, during 2004-2013
11145065|NCT03761407|Experimental|Group 1 (100 mg GRT0151Y)|"The dose of 100 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 100 mg. On Day 5 the last dose of 100 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group."
11145066|NCT03761407|Experimental|Group 2 (125 mg GRT0151Y)|"The dose of 125 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 125 mg. On Day 5 the last dose of 125 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group"
11145067|NCT03761407|Experimental|Group 3 (150 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 150 mg. On Day 5 the last dose of 150 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group"
11145068|NCT03761407|Experimental|Group 4 (225 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the dose of 225 mg will be administered twice (b.i.d.). On Day 5 the last dose of 225 mg will be administered in the morning.
~Matching placebo using the same dosing regimen as defined in the treatment group"
11145069|NCT03761394|Experimental|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
11145070|NCT03761394|Active Comparator|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
11145071|NCT03761394|Experimental|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
11145072|NCT03761394|No Intervention|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
11145073|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
11145074|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
11145075|NCT03761368|Experimental|RIPC group|The RIPC group underwent Remote Ischemic Preconditioning.
11145076|NCT03761368|Sham Comparator|Control group|Patients from control group had sham Remote Ischemic Preconditioning.
11145077|NCT03761355||medical student of 6th Year|Students of medical faculty of 6th Year in Medical University of Bialystok, Poland.
11145078|NCT03761342|No Intervention|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
11145079|NCT03761342|Experimental|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
11145080|NCT03761342|Experimental|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
11145081|NCT03761329|Active Comparator|Bier's block|Upperarm intravenous regional anesthesia (Bier's block) with lidocaine 0.5% 40ml
11145084|NCT03761303|Active Comparator|active rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
11145085|NCT03761303|Sham Comparator|sham rTMS|Patients in the control group receive sham rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
11145086|NCT03761290||Pseudphypoparathyroidism type 1A (PHP1A)|Case
11145087|NCT03761290||Pseudopseudohypoparathyroidism (PPHP)|Case
11145088|NCT03761290||Controls|Matched control group
11145089|NCT03761277|Other|Intrathecal Therapy|Enrolled subjects who successfully wean from all systemic opioids and have a successful intrathecal trial, proceed to the intervention phase. This includes implantation with a SynchroMed™ II infusion system in the intrathecal space for targeted drug delivery of preservative-free morphine sulfate (PFMS).
11145090|NCT03761264|Experimental|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
11145091|NCT03761264|Active Comparator|Intra-canal Pulpdent|Single visit placement of Pulpdent
11145092|NCT03761264|Active Comparator|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
11145093|NCT03761251|Experimental|Pet Fish|Participants will be instructed to partner thrice daily and once weekly fish care activities with diabetes care activities for 3 months
11145094|NCT03761238|Experimental|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
11145095|NCT03761238|Active Comparator|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
11145096|NCT03761225|Experimental|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
11145097|NCT03761225|Placebo Comparator|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
11145098|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
11145099|NCT03761212||Healthy controls|Age and sex matched healthy controls
11145100|NCT03761199|Experimental|a group of patients with AD|15 people with clinically diagnosed atopic dermatitis (AD), established on the basis of criteria Hanifin and Rajka
11145101|NCT03761199|Other|control group|15 healthy persons which will form the control group
11145102|NCT03761186|Active Comparator|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
11145103|NCT03761186|Experimental|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
11145104|NCT03761186|Experimental|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
11145105|NCT03761160|Experimental|Mobile Health App|"The developed mobile health app will include the following facets:
~Physical activities
~Dietary regimen.
~The physical activities facet will encourage patients to engage in physical activities, with daily prompts, encouragement, and tips.
~Users will be asked to record the type of physical activity they engaged in during the week, and for how long.
~The dietary aspect will ask patients to log what they ate during the day and to rate how 'healthy' it is"
11145106|NCT03761160|Active Comparator|Usual Care|Usual care per hospital guideline
11145107|NCT03761147|Experimental|Paula Method|
11145108|NCT03761147|No Intervention|Standard of Care|
11145109|NCT03761134|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
11145110|NCT03761134|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
11145111|NCT03761134|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
11145112|NCT03761121|Experimental|Primary Testing Group|"This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes
~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution
~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
11145113|NCT03761121|Experimental|Software Testing Group|"Participants will receive hour research-only scan
~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution
~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
11145114|NCT03761108|Experimental|REGN5458|Phase 1: Cohorts of multiple REGN5458 dose levels Phase 2: Until disease progression or other discontinuation criterion is met
11145115|NCT03761095|Experimental|PTC596 and Dacarbazine|Participants will receive PTC596 orally twice weekly in combination with dacarbazine IV once every 21 days. First participant will receive dacarbazine 1000 mg/m^2 IV every 21 days in combination with PTC596 200 mg tablet orally twice weekly. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose DLT information from all participants previously treated. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason (study intervention discontinuation and participant discontinuation/withdrawal).
11145116|NCT03761069|Experimental|PTC299|PTC299 will be administered orally once daily (QD) for each 28-day cycle.
11145117|NCT03761056|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, axicabtagene ciloleucel
11145118|NCT03761043|No Intervention|Pre-Intervention Arm|The nurses will have not been exposed to the behavior change intervention.
11145119|NCT03761043|Experimental|Post-Intervention Arm|The nurses will have been exposed to the behavior change intervention.
11145120|NCT03761030|Experimental|L-DOPA Arm|Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose
11145121|NCT03761030|Placebo Comparator|Placebo Arm|Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.
11145122|NCT03761017|Experimental|MGD019|Bispecific DART protein binding PD-1 and CTLA-4
11145123|NCT03761004|Experimental|WD-1603 single dose|"WD-1603 single dose:
~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
11145124|NCT03761004|Experimental|WD-1603 BID dose|"WD-1603 BID dose:
~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.
~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
11145125|NCT03761004|Active Comparator|Sinemet single dose|"Sinemet single dose:
~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
11145126|NCT03760991|Experimental|Insulin glargine (U300)|Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin
11145127|NCT03760978||dex group|Critically ill patients <18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
11145128|NCT03760965|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
11145129|NCT03760965|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
11145130|NCT03760965|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
11145131|NCT03760939|Experimental|Ambulatory care|Colorectal surgery in ambulatory care
11145132|NCT03760939|Other|Standard hospitalization|Colorectal surgery with standard hospitalization for retrospective patients who benefit from the ERAS program, selected by statistical matching.
11145133|NCT03760926|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
11145134|NCT03760913|Experimental|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
11145135|NCT03760913|Experimental|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
11145136|NCT03760913|Placebo Comparator|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
11145137|NCT03760913|Placebo Comparator|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
11145138|NCT03760900|Experimental|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
11145139|NCT03760887|Sham Comparator|No Home Sensory training|Patients who perform a home exercise program only
11145140|NCT03760887|Experimental|Home sensory training|Patients who perform home exercise and home sensory training
11145141|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
11145142|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
11145143|NCT03760861|Experimental|Prototype Microcapsule Treatment Arm|Intervention by placement of prototype weight-loss microcapsule in the stomach. Subjects will have a weight-loss microcapsule deployed endoscpically in the stomach. The intragastric balloon in the capsule will be inflated using an external magnet..
11145144|NCT03760848|Other|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
11145145|NCT03760835|Experimental|Dual-release hydrocortisone|
11145146|NCT03760835|Active Comparator|Conventional glucocorticoids|
11145147|NCT03760822|Experimental|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
11145148|NCT03760822|Active Comparator|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
11145149|NCT03760809|Experimental|Dexmedetomidine(0.5 μg／kg)|Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
11145150|NCT03760809|Experimental|group B|Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia
11145151|NCT03760796|Experimental|Corrie Digital Health Platform group|Receives the Corrie Digital Health intervention plus the standard of care
11145152|NCT03760783|Other|Effect of microgravity on human sperm|Simulated microgravity flight
11145153|NCT03760770|Experimental|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
11145154|NCT03760770|Experimental|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
11145155|NCT03760757|Experimental|PCSO-524® (no krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. Amounts per day equal to 800 mg olive oil, 400 mg lipid extract (~58 mg EPA and 44 mg DHA) and 1.8 mg vitamin E (d-alpha-tocopherol).
11145156|NCT03760757|Experimental|ESPO-572® (75% PCSO-524®, 25% krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
11145157|NCT03760744|Experimental|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
11145158|NCT03760744|Active Comparator|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
11146313|NCT03753022|Sham Comparator|Group G5|Patients submitted to CABG and peep 5
11145159|NCT03760731|Experimental|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
11145160|NCT03760731|Active Comparator|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
11145161|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 1|40 ml of preservative-free 1% chloroprocaine
11145162|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 2|40 ml of preservative-free 2% chloroprocaine
11145163|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 3|40 ml of preservative-free 3% chloroprocaine
11145164|NCT03760705||Coronary Artery Disease|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)
~Clinical, administrative, pharmacy, financial data collected by each participating hospital
~Administrative data collected by the Ministry of Health"
11145165|NCT03760705||Heart Failure|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)
~Clinical, administrative, pharmacy, financial data collected by each participating hospital
~Administrative data collected by the Ministry of Health"
11145166|NCT03760705||Atrial Fibrillation|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)
~Clinical, administrative, pharmacy, financial data collected by each participating hospital
~Administrative data collected by the Ministry of Health"
11145167|NCT03760692|Active Comparator|Group i-gel|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
11145168|NCT03760692|Experimental|Group Ambu Auragain|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
11145169|NCT03760679|Active Comparator|Laryngeal mask Supreme|Device: Laryngeal mask Supreme
11145170|NCT03760679|Experimental|i-gel|Device: i-gel
11145171|NCT03760666|Experimental|Brequinar|Brequinar dosed orally. Multiple doses.
11145172|NCT03760666|Other|Brequinar + Ribavirin|Subjects in Cohort 2 may roll over to add ribavirin dosing; subjects in Cohort 3 will start with brequinar alone then add ribavirin dosing.
11145173|NCT03760653|Experimental|Physical Exercise and probiotic group|The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
11145174|NCT03760653|Experimental|Probiotic group|Participants will follow their usual sedentary lifestyle (i.e to practice less than 3 days a week of physical exercise, as is specified in the inclusion criteria). They will take the probiotic supplementation at the established dose. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum
11145175|NCT03760653|Placebo Comparator|Placebo group|They will follow their sedentary lifestyle. Placebo probiotic will consist of a maltodextrin capsule.
11145176|NCT03760640|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
11145177|NCT03760640|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
11145178|NCT03760627|Experimental|Refugees Mindfulness Resiliency Training|The Collateral Repair Project (CRP) will conduct a Mindfulness Resiliency Training Program (MRTP) for refugees residing in Amman, Jordan. A small support group will demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
11145179|NCT03760627|Placebo Comparator|Control arm|The control group will receive the training after the study group at 2 months and the control group will then become the study group for the new session. A new group of 20 participants will be recruited who will act as a control for that session. The surveys from the control group will be compared with the study group at 0 and 2 months. Each session will last for two months. The control group will receive the training at the end of the two months. This process will be repeated for a total of nine sessions over a total period of 12 months.
11145180|NCT03760614|Experimental|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
11145181|NCT03760601|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
11145182|NCT03760601|Experimental|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
11145285|NCT03759964|Placebo Comparator|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
11145183|NCT03760588|Experimental|LCZ696|LCZ696 (target dose 200 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: LCZ696 50 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by LCZ696 100 mg b.i.d. for 2 - 4 weeks. Provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to LCZ696 200 mg b.i.d. will be performed.
11145184|NCT03760588|Placebo Comparator|Placebo|Matched to the comparator.
11145185|NCT03760575|Experimental|Pembrolizumab with image-guided surgery and chemotherapy|
11145186|NCT03760549||Extension of NasoVAX high dose|A serum sample will be collected from each eligible subject who received NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201 for evaluation of influenza hemagglutination assay against influenza A/California/07/2009(H1N1), a strain homologous to the one used for NasoVAX (monovalent AdcoCA09.HA). Ad5 antibody neutralization assay may also be performed.
11145187|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
11145188|NCT03760523|Experimental|Minnelide Dose Escalation|A 3+3 design will be used. The first 3 patients will be treated at dose level 1. If none experience a Dose Limiting Toxicity (DLT), the next 3 patients will be treated at dose level 2. If a DLT is observed in 1 out of 3 patients at dose level 1, up to an 3 more patients will be enrolled and treated at that dose level. If 2 patients at dose level have DLTs, dosing will be lowered to dose level -1 (.5 mg daily, taken orally). If 2 or more of the up to 6 patients at any dose level have DLTs, the preceding dose will be declared the Maximum Tolerated Dose (MTD). If more than 1 DLT occurs at Dose Level -1, the investigators will consider stopping the study. Once the MTD has been established, an additional 10 patients will be enrolled at this level to better characterize safety and tolerability.
11145189|NCT03760510|Experimental|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
11145190|NCT03760510|Experimental|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
11145191|NCT03760497|Experimental|CIV Group|Temporary Restoration with Glass Ionomer (Equia Forte® - GC Corporation, Tokyo, Japan) for 30 days + Restoration in Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA).
11145192|NCT03760497|Experimental|Composite Resin Group|Restoration with Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, United States).
11145193|NCT03760497|Experimental|Composite Resin Group + Laser|Composite Resin Restoration (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA) + Application of Diode Laser.
11145194|NCT03760484|Experimental|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
11145195|NCT03760471|Experimental|Collaborative palliative and oncology care|
11145196|NCT03760458|Experimental|Weight Band #1 (6 to less than 10 kg)|Children weighing 6 to less than 10 kg will receive 3 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
11145197|NCT03760458|Experimental|Weight Band #2 (10 to less than 14 kg)|Children weighing 10 to less than 14 kg will receive 4 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
11145198|NCT03760458|Experimental|Weight Band #3 (14 to less than 20 kg)|Children weighing 14 to less than 20 kg will receive 5 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
11145199|NCT03760458|Experimental|Weight Band #4 (20 to less than 25 kg)|Children weighing 20 to less than 25 kg will receive 6 dispersible tablets of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
11145200|NCT03760458|Experimental|Weight Band #5 (25 kg or greater)|Children weighing 25 kg or greater will receive 1 immediate release tablet of ABC/DTG/3TC, beginning at study entry, for at least 48 weeks and up to 144 weeks.
11145201|NCT03760445|Experimental|Part 1 - first line (1L) AML|1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
11145202|NCT03760445|Experimental|Part 1 - relapsed/refractory (R/R) AML|R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
11145203|NCT03760445|Experimental|Part 2 - Expansion Cohort 1|1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
11145204|NCT03760445|Experimental|Part 2 - Expansion Cohort 2|1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
11145205|NCT03760445|Experimental|Part 2 - Expansion Cohort 3|1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
11145206|NCT03760445|Experimental|Part 2 - Expansion Cohort 4|R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
11145207|NCT03760445|Experimental|Part 3 - DDI Cohort 1|R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
11145208|NCT03760445|Experimental|Part 3 - DDI Cohort 2|R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
11145209|NCT03760432|Experimental|Surgery|OCT-guided custom laser CXL
11145210|NCT03760419|Active Comparator|Intervention Arm|Effectiveness of the EHR-based antibiotic decision support application for promoting guideline-concordant antibiotic prescribing in children presenting for emergency care will be evaluated in a pragmatic, cluster randomized crossover study conducted over a period of 18 months that includes two respiratory seasons. The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive standard of care management. All treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
11145211|NCT03760419|No Intervention|Control Arm|The investigator will conduct a randomized controlled trial comparing a prognostic tool (intervention arm) to usual care (control arm) over a period of 24 months. Randomization will occur at the patient level. Allocation to intervention or control will be based on medical record number (even vs. odd) and will be assigned automatically once a provider confirms the diagnosis of pneumonia via the radiology alert tool. All standard of care treatment options will be available and decision-making will not be restricted in any way in either group.
11145212|NCT03760406|Experimental|Severe essential tremor treated by DBS|
11145213|NCT03760393|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
11145214|NCT03760393|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
11145215|NCT03760380|Experimental|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
11145216|NCT03760380|Experimental|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
11145217|NCT03760367|Experimental|Blue Covarine Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste containing blue covarine (Pepsodent White Now Gold, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
11145218|NCT03760367|Active Comparator|Control Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
11145219|NCT03760354|Experimental|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
11145220|NCT03760354|Placebo Comparator|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
11145221|NCT03760341|Active Comparator|cold adenoidectomy group|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - cold method
11145222|NCT03760341|Active Comparator|hot method adenoidectomy|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - hot method
11145223|NCT03760328|Active Comparator|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
11145224|NCT03760328|Sham Comparator|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
11145225|NCT03760315||targeted treatment by mNGS|In the mNGS targeted treatment group，Clinicians figure out sepsis patients' microbe by mNGS and alter or confirm targeted treatment.
11145226|NCT03760315||targeted treatment by Culture|In the Culture targeted treatment group，Clinicians figure out sepsis patients' microbe by Culture and alter or confirm targeted treatment.
11145227|NCT03760315||Experience treatment|In the experience treatment group，Clinicians didn't figure out sepsis patients' microbe even with Culture and mNGS of the plasm and other secretion to alter or confirm targeted treatment.
11145228|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
11145229|NCT03760276|Experimental|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
11145230|NCT03760263|Active Comparator|Envarsus|Once-daily extended-release tacrolimus
11145231|NCT03760263|Active Comparator|Prograf|twice-daily tacrolimus
11145232|NCT03760250|Experimental|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
11145233|NCT03760237||Acute Leukemia|Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
11145234|NCT03760224|Experimental|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
11145235|NCT03760224|Active Comparator|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
11145236|NCT03760211|Experimental|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Battle Viro on their mobile phones, an electronic pill monitoring device, and, for 24 weeks, game-related text messages guided by medication adherence data (collected from an electronic pill monitoring device).
11145237|NCT03760211|Active Comparator|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game and an electronic pill monitoring device.
11145238|NCT03760198|Experimental|botulinum toxin type A|
11145239|NCT03760198|Placebo Comparator|Placebo|
11145240|NCT03760185|Experimental|All patients|All patients in this arm will receive eye drops to be applied to one eye only. The alternative eye will not receive any eye drops and as such will serve as the control.
11145241|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
11145242|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
11145243|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
11145244|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
11145245|NCT03760159||Group RESPIRATORY SIMUL (Study A)|In 46 healthy subjects, a computer program will generate random instructions of periods of normal breathing, voluntary end-expiratory breathing cessation periods (as surrogate of central apnoea) and Muller's manœuvre (as surrogate of obstructive apnoea). Meanwhile, the KCG will record the parameters of biological interest. ECG, heart rate, beat to beat non-invasive blood pressure (Finometer), ventilation, end-tidal CO2 (AD instruments), O2 saturation (Nellcor), cardiac output (CO) (Philips) will also be recorded.
11145246|NCT03760159||Group SDB (Study B)|In patients suspected of sleep apnoea and admitted to the sleep unit of the Erasme hospital to perform sleep test as required by their medical condition, the investigators will simultaneously record KCG and PSG and qualitatively compare the data (Bland-Altman plots).
11145247|NCT03760159||Group nCPAP (Study C)|In patients with a diagnosis of sleep apnea, the investigators will determine if KCG is capable to reliably assess the efficacy of the nCPAP therapy in comparison to simultaneous PSG recording. Ongoing adjustment in the CPAP therapy pressure during the night, and its effect on cardiovascular haemodynamic assessed by the KCG, will be taken into account as well.
11145248|NCT03760159||Group UNSELECTED (Study D)|After validation of the three previous steps, the investigators plan to extend the recordings on 100 unselected consecutive patients, without recruitment restrictions, which will undergo PSG recordings because of complains of sleep apnoea.
11145249|NCT03760146|Experimental|60 years and above 20vPnC/Saline|20vPnC and saline
11145250|NCT03760146|Active Comparator|60 years and above 13vPnC/PPSV23|13vPnC and PPSV23
11145251|NCT03760146|Experimental|50 through 59 years of age 20vPnC|20vPnC
11145252|NCT03760146|Experimental|18 through 49 years of age 20vPnC|20vPnC
11145253|NCT03760146|Active Comparator|50 through 59 years of age 13vPnC|13vPnC
11145254|NCT03760146|Active Comparator|18 through 49 years of age 13vPnC|13vPnC
11145255|NCT03760133|Active Comparator|with Probiotics|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
11145256|NCT03760133|No Intervention|without Probiotics|Participants included in this group will not be taken probiotics for 1 month after bowel preparation for colonoscopy.
11145257|NCT03760120|Active Comparator|PEP standard|
11145258|NCT03760120|Sham Comparator|PEP sham|
11145259|NCT03760107|Experimental|Incentive Level High, Call|
11145260|NCT03760107|Experimental|Incentive Level High, No Call|
11145261|NCT03760107|Experimental|Incentive Level Medium, Call|
11145262|NCT03760107|Experimental|Incentive Level Medium, No Call|
11145263|NCT03760107|Experimental|No Incentive, Call|
11145264|NCT03760107|Experimental|No Incentive, No Call|
11145265|NCT03760094|Experimental|Study group|patients with lymphadenopathy
11145266|NCT03760081|Experimental|ASP1650 Escalation|An initial dose level of ASP1650 (Safety Lead-In Phase) will be evaluated in a 3-participant cohort (cohort 1) and if well tolerated, a new participant cohort (cohort 2) (minimum 3 and up to 4 participants) will be opened at the next dose level according to the Bayesian Optimal Interval (BOIN) design. Based on tolerability observed in cohort 2, an additional participant cohort (cohort 3) (minimum 3 and up to 4 participants) will be opened at the same dose level of cohort 2 or de-escalation will occur if cohort 2 is not tolerable.
11145267|NCT03760068|Active Comparator|MYL-1601D Product (100 U/mL)|
11145268|NCT03760068|Active Comparator|FlexPen NovoLog® (100 U/mL)|
11145269|NCT03760055||Glaucoma and glaucoma suspects|Patients with at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits. Patients considered suspects for glaucoma must have an intraocular pressure (IOP) greater than 21 millimeters of mercury (mmHg) or suspicious appearance of the optic nerve head but with reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
11145270|NCT03760055||Age-related macular degeneration|"Patients will be considered as having AMD if one or more of the following are present on posterior biomicroscopy (fundoscopy), indirect ophthalmoscopy or Optical Coherence Tomography (OCT) exams:
~Presence of at least intermediate-size drusen (63µm or larger in diameter)
~Retinal pigment epithelium (RPE) abnormalities such as hypopigmentation or hyperpigmentation
~Reticular pseudodrusen (also called sub retinal drusenoid deposit)
~Presence of any of the following features: geographic atrophy of the RPE, choroidal neovascularization (exudative, wet), polypoidal choroidal vasculopathy, or retinal angiomatous proliferation."
11145271|NCT03760055||Other eye diseases|Patients with other retinal degenerations such as retinitis pigmentosa or with other diseases affecting the visual pathways such as tumors, ischemic neuropathy or optic neuritis may also be included. Their diagnosis will be extracted from their clinical visits.
11145272|NCT03760055||Healthy subjects|To be considered healthy, subjects have to have IOP < 22 mmHg with no history of elevated IOP and with at least two reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
11145273|NCT03760042|Other|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
11145274|NCT03760042|Other|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.
~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
11145275|NCT03760029|Other|Study arm|All subjects in this study will be observed for 24-30 months.
11145276|NCT03760016|Active Comparator|Moderate-Intensity Aerobic Training|
11145277|NCT03760016|Experimental|High-Intensity Interval Training|
11145278|NCT03760003|Experimental|ABX464|ABX464 will be administrated orally (Capsules) and daily for 16 weeks
11145279|NCT03760003|Placebo Comparator|Matching Placebo|Matching placebo will be adminstrated orally (Capsules) and daily for 16 weeks
11145280|NCT03759990|Active Comparator|insertion time|
11145281|NCT03759990|Active Comparator|intubation time|
11145282|NCT03759977|Experimental|Adapted Physical Activity group|This group will receive 3 sessions per week of specific physical activity.
11145283|NCT03759977|No Intervention|Usual accompaniment group|This group will continue to follow the usual accompaniment of the nursing home.
11145286|NCT03759951|Experimental|Control|No intervention. Participated only in measurements at baseline, at 6 months and at 12 months.
11145287|NCT03759951|Experimental|DoIT-1|Participated in a supervised 1-year workout exercise training program once per week and in measurements at baseline, at 6 months and at 12 months.
11145288|NCT03759951|Experimental|DoIT-2|Participated in a supervised 1-year workout exercise training program twice per week and in measurements at baseline, at 6 months and at 12 months.
11145289|NCT03759951|Experimental|DoIT-3|Participated in a supervised 1-year workout exercise training program thrice per week and in measurements at baseline, at 6 months and at 12 months.
11145290|NCT03759938|Experimental|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
11145291|NCT03759938|Active Comparator|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
11145292|NCT03759925|Experimental|Nutritional Support|The intervention consists of home delivery of medically-appropriate food support (DASH and diabetic diet compliant) in the form of prepared meals and/or groceries and monthly individual nutritional counseling with a Registered Dietician.
11145293|NCT03759925|No Intervention|Standard of Care|The control group will receive standard of care follow up care after their hospitalization for acute decompensated heart failure.
11145294|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
11145295|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
11145296|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
11145297|NCT03759873|Experimental|Incentives|Patient earns incentives for completing cardiac rehabilitation sessions.
11145298|NCT03759873|Experimental|Case Management|Patient is assigned a case manager while in hospital.
11145299|NCT03759873|Experimental|Incentives and Case Management|Patient receives both the Incentives and Case Management interventions.
11145300|NCT03759873|No Intervention|Usual care|This control condition does not receive either intervention.
11145301|NCT03759860|Experimental|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.
~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.
~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
11145302|NCT03759860|Sham Comparator|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.
~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
11145303|NCT03759847|Experimental|Vanguard|Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
11145304|NCT03759834|Experimental|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
11145305|NCT03759821|Experimental|Nutrition, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Between 12 and 18 months, there will be booster sessions to reinforce key messages.
11145306|NCT03759821|Experimental|Nutrition, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and the groups will meet biweekly for a period of 12 months. Between 12 and 18 months, there will be booster sessions to reinforce key messages.
11145307|NCT03759821|Experimental|Nutrition+parenting, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months.
11145308|NCT03759821|Experimental|Nutrition+parenting, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months.
11145309|NCT03759821|No Intervention|Standard of care control|Local standard of care
11145310|NCT03759808|Experimental|Persistent Post-Concussion Symptoms|Concussed participants with persistent post-concussion symptoms (PPCS) who receive the psychological intervention.
11145311|NCT03759795|Experimental|Intervention Group|Acceptance and Commitment Training (ACTr)
11145312|NCT03759795|No Intervention|Wait-list control|No intervention during trial. Participants in this group will be offered the training once the study is complete.
11145313|NCT03759782|Experimental|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
11145314|NCT03759782|Active Comparator|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if <70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
11145315|NCT03759769|Experimental|simulator|Practice at home all activities of the wheelchair simulator, at least 20 minute per session, at least one session every second day
11145316|NCT03759769|Active Comparator|control|Practice on a computer video game, at least 20 minute per session, at least one session every second day
11145317|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
11145318|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
11145319|NCT03759743|Experimental|Probiotics|
11145320|NCT03759743|Placebo Comparator|Placebo|
11145321|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
11145322|NCT03759691||Stroke patients|Structured interviews of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
11145323|NCT03759691||Bystander|Structured interviews of bystanders of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
11145324|NCT03759678|Experimental|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.
~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).
~Patients 6-12 years old will receive weight-tiered doses:
~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)
~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
11145325|NCT03759678|No Intervention|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
11145326|NCT03759665|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.
~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).
~Patients 6-12 years old will receive weight-tiered doses:
~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
11145327|NCT03759665|No Intervention|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
11145328|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
11145329|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
11145330|NCT03759639|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.
~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).
~Patients 6-12 years old will receive weight-tiered doses:
~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
11145331|NCT03759639|No Intervention|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
11145332|NCT03759626|Active Comparator|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
11145333|NCT03759626|Active Comparator|pupils benefiting from the reflective intervention|Second year students from general high schools.
11145334|NCT03759613|Experimental|Experimental Group|Thirty subjects with unilateral upper burn injury will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. Their evaluations will be made within 5 days following burn injury.
11145335|NCT03759613|Active Comparator|Control Group|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, they will be asked to walk their natural walking.
11145336|NCT03759613|Sham Comparator|Control Grup (Restricted arm swing)|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, their arms will be fixed with a bandage on their bodies. Their arm swing will be restricted.
11145337|NCT03759600|Experimental|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 - 28 of each 28-day treatment cycle up to 6 cycles till data cut-off: 01 July 2019.
11145338|NCT03759587|Experimental|Niraparib 300 mg|Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment Cycle (Up to 3 Cycles till data cut-off 17 March 2019).
11145339|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
11145340|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
11145341|NCT03759561|Active Comparator|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscop under cervical collar application.
11145342|NCT03759561|Active Comparator|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
11146314|NCT03753022|Experimental|Group G10|Patients submitted to CABG and peep 10
11145343|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
11145344|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
11145345|NCT03759535||Control group and Case group|"Control group:
~The allograft kidneys function normally. The rejection of allograft kidneys are excluded. The patients have no infectious complications.
~Case group:
~There is obvious evidence for acute rejection of the allograft kidneys. The patients have no infectious complications."
11145346|NCT03759522|Experimental|Healthy Controls|
11145347|NCT03759522|Experimental|Fibromyalgia Subjects|
11145348|NCT03759522|Experimental|Chronic Fatigue Syndrome Subjets|
11145349|NCT03759522|Experimental|Multiple Sclerosis Subjects|
11145350|NCT03759509|Experimental|aerobic exercise training|three times a week, a total of twenty-four times in eight weeks
11145351|NCT03759509|No Intervention|control|routine activity
11145352|NCT03759496|Experimental|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
11145353|NCT03759483||AI group|The visual field reports in this group will be evaluated by the convolutional neural network.
11145354|NCT03759483||Human group|The visual field reports in this group will be evaluated by 3 ophthalmologists independently.
11145355|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .
~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
11145356|NCT03759457|Experimental|High Flow Nasal Cannula|High Flow Nasal Cannula is a relatively new technique able to deliver both oxygen and high flow in order to improve oxygenation and waking out CO2 from the upper airways
11145357|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)
~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
11145358|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)
~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
11145359|NCT03759431|Experimental|Vocal-cord Radiotherapy|
11145360|NCT03759431|Active Comparator|Complete Larynx Radiotherapy|
11145361|NCT03759405|Experimental|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
11145362|NCT03759392|Experimental|Omecamtiv Mecarbil|
11145363|NCT03759392|Placebo Comparator|Placebo|
11145364|NCT03759379|Experimental|Vutrisiran (ALN-TTRSC02)|Participants will receive vutrisiran during the Treatment and Treatment Extension Periods.
11145365|NCT03759379|Active Comparator|Patisiran|Participants will receive patisiran during the Treatment Period and will switch to vutrisiran during the Treatment Extension Period.
11145366|NCT03759366|Experimental|Eculizumab Intravenous (IV) Infusion|"In the Primary Evaluation Treatment Period (26 weeks), eculizumab will be administered weekly during the initial induction phase and every 2 weeks during the maintenance phase.
~In the Extension Period (up to 208 weeks), participants will continue to receive eculizumab every 2 weeks.
~Eculizumab will be administered at doses of 300, 600, 900, or 1200 milligrams (mg), based on the participant's current body weight."
11145367|NCT03759353|Active Comparator|Lactoferrin Group|Includes 49 pregnant women receiving lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin (R) , Hygint pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
11145368|NCT03759353|Active Comparator|Ferrous Sulfate Group|Includes 49 pregnant women receiving 200 mg of dried ferrous sulfate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset (Feosol (R) , Meda pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
11145369|NCT03759340|Experimental|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
11145370|NCT03759301|Active Comparator|Growth Hormones Somatropin Recombinant|Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup for the treatment group which consists of 70 women.
11145371|NCT03759301|Placebo Comparator|Placebo saline solution|Control group consisting of 70 women who will receive subcutaneous placebo injection in the same dosing as the treatment group
11145372|NCT03759288|Experimental|(Stage 1) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
11145373|NCT03759288|Experimental|(Stage 1) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous brazikumab on Day 85 and every 4 weeks through Week 48
11145374|NCT03759288|Active Comparator|(Stage 1) Humira®|Subcutaneous Humira® on Day 1, Day 15, Day 29 and every 2 weeks through Week 50
11145375|NCT03759288|Placebo Comparator|(Stage 1) Placebo|Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 2 weeks through Week 50
11145376|NCT03759288|Experimental|(Stage 2) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
11145407|NCT03759067|Active Comparator|LD group|clopidogrel 600 mg once loading, usually 2-24 h before the procedure
11145377|NCT03759288|Experimental|(Stage 2) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab 240 on Day 85 and every 4 weeks through Week 48
11145378|NCT03759288|Active Comparator|(Stage 2) Humira®|Subcutaneous Humira® on Day 1, Day 15, Day 29 and every 2 weeks through Week 50
11145379|NCT03759275||Stage 1|For the Baseline Investigation and Technical Preparation Stage
11145380|NCT03759262|Experimental|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
11145381|NCT03759249|Experimental|Treatment group|Standard Treatment of Sleep disorder according to applicable guideline
11145382|NCT03759249|No Intervention|Waiting list|Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines
11145383|NCT03759236|Experimental|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
11145384|NCT03759236|Active Comparator|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
11145385|NCT03759223|Experimental|E-PST|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
11145386|NCT03759223|Active Comparator|Control|Healthy Living Messages (Control) arm. Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
11145387|NCT03759197|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
11145388|NCT03759197|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
11145389|NCT03759184|Experimental|1|DOSE ESCALATION: IL-15 by civ infusion at escalating doses of 0.5, 1, and 2 mcg/kg /day on days 1-5 of each 4-week cycle (max 6 cycles), with obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the MTD
11145390|NCT03759184|Experimental|2|DOSE EXPANSION: 3 to 6 patients to receive IL-15 by civ infusion at the MTD on days 1-5 of cycles 1-6 with obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
11145391|NCT03759171|Experimental|Immediate Entry Group|Following the baseline interview, veterans randomized to the immediate entry group directly engaged in the Guitars for Vets Intervention and were interviewed at the end of the intervention period, roughly 6 weeks later. The intervention content and duration (6 weeks) was the same across both groups.
11145392|NCT03759171|Experimental|Delayed Entry Group|Those randomized to the delayed entry group had their baseline interview repeated at the end of the delayed entry period (4 weeks) prior to receiving the 6-week Guitars for Vets Intervention as well as after intervention completion. The intervention content and duration (6 weeks) was the same across both groups.
11145393|NCT03759158|Experimental|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
11145394|NCT03759158|Placebo Comparator|Placebo|
11145395|NCT03759145|Experimental|Intervention arm, usual rehabilitation + Jintronix exergame|On top of the usual out-patient rehabilitation sessions planned for the participant, participants attend sessions to use the Jintronix system for up 30 minutes up to 3 times per week
11145396|NCT03759145|Other|Control group|Participants continue their prescribed rehabilitation sessions
11145397|NCT03759132|Experimental|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.
~Dose: 2mA, 20 minutes"
11145398|NCT03759132|Sham Comparator|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.
~Dose: 2mA, 20 minutes (30s ON)"
11145399|NCT03759119|Experimental|Tummy Time and Parent Education|This group will receive tummy time and parent education and be encouraged to perform tummy time on their own. They will utilize the PT Pal application to record their tummy time adherence. The primary investigator performs the intervention to the participants two times a day for 10 minutes for 4 weeks.
11145400|NCT03759119|No Intervention|Parent education|This group will receive parent education only and utilize the PT Pal application to record their adherence. The primary caregiver will be encouraged to perform the same dosage of tummy time (2x/day, 10 minutes each, 4 weeks) and record their adherence on the PT Pal application.
11145401|NCT03759106|Other|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
11145402|NCT03759106|Experimental|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
11145403|NCT03759093|Active Comparator|Standard of Care|Dosing of VCD(bortezomib, cyclophosphamide, dexamethasone) or VTD (bortezomib, thalidomide, dexamethasone) combinations according to standard of care
11145404|NCT03759093|Experimental|CURATE.AI-guided dosing|CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone) or bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) combinations
11145405|NCT03759080|Active Comparator|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
11145406|NCT03759080|Experimental|MP|PNFMP group:30 individuals, these subjects received mental practice.
11145408|NCT03759067|Experimental|MD group|After randomization, the routine therapy using daily clopidogrel 75mg
11145409|NCT03759067|Active Comparator|RL group|After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.
11145410|NCT03759041|Placebo Comparator|Placebo (after placebo pre-treat.)|Once-daily dosing of Placebo (after placebo pre-treatment)
11145411|NCT03759041|Experimental|SER-287 Induction Dosing (after vanco. pre-treat.)|Once-daily dosing of SER-287 (Induction Dose, after vancomycin pre-treatment)
11145412|NCT03759041|Experimental|SER-287 Step-Down Induction Dosing (after vanco. pre-treat.)|Once-daily dosing of SER-287 (Step-Down Induction Dose, after vancomycin pre-treatment)
11145413|NCT03759028|Experimental|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
11145414|NCT03759028|Active Comparator|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
11145415|NCT03759015|Other|Health education|This arm's subjects are tasked to create an original 10-minute theater that is required to use the guidelines about physical activity and diet/nutrition.
11145416|NCT03759002||Patients|Children with end stage renal disease
11145417|NCT03759002||Controls|Healthy sex- and age adjusted children
11145418|NCT03758989|Experimental|Baseline PET|R-CHOP
11145419|NCT03758963|Experimental|Active Laser|"Once the energy to be applied for the treatment is determined through the laser irradiation testing, conduct laser therapy after selecting T corresponding to treatment laser on GUI.
~At irradiation, excluding the circle area with a 100 μm radius (200 μm diameter) from the center of the fovea, irradiate laser in the form of surrounding the leakage site with an interval of 0.5-1 spot diameter (fovea = 1 spot size). As for the test spots, the serial number needs to be given for each treatment spot with the order of irradiation, as described above.
~If pigment epithelial detachment (PED) occurs at the leakage site, irradiate laser around the PED (excluding the circle area with a 100 μm radius (200 μm diameter) from the center), not to the leakage site.
~Within 2 hours after therapy, perform tests for efficacy evaluation (color fundus photography and fluorescein angiography)."
11145420|NCT03758963|Sham Comparator|Sham Laser procedure|"Select C corresponding to Sham Therapy on GUI of the laser device, and then perform Sham therapy.
~During Sham therapy, for patient's blinding, both light from the slit lamp and sound from laser oscillation are same as laser irradiation, and no laser oscillation will occur for treatment.
~Perform subsequent procedures in the same manner as the procedure of study group."
11145421|NCT03758950|Placebo Comparator|Placebo|Once daily inhaled placebo
11145422|NCT03758950|Active Comparator|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
11145423|NCT03758937|Active Comparator|volume-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
11145424|NCT03758937|Active Comparator|pressure-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
11145425|NCT03758924|Experimental|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
11145426|NCT03758924|Placebo Comparator|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
11145427|NCT03758911||bone marrow/blood stem cell donors|Participants underwent a one time semi-structured telephone interview to understand the perspectives of bone marrow/stem cell donors experience, including how family dynamics impacted participants' decision to donate and identifying unique supportive care needs of bone marrow/stem cell donors.
11145428|NCT03758898|Experimental|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
11145429|NCT03758898|Placebo Comparator|Group 2|only mobilisation was applied to the patients in the second group
11145430|NCT03758885|Experimental|Nolasiban 900 mg|Nolasiban dispersible tablets for single oral administration
11145431|NCT03758885|Placebo Comparator|Placebo|Placebo dispersible tablets for single oral administration
11145432|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
11145433|NCT03758859|Experimental|sodium hyaluronate eye drops|the randomly allocated eye will receive sodium hyaluronate drops, followed by a repeat OCT scan; images are then evaluated for clarity by the masked assessor.
11145434|NCT03758846|Experimental|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
11145435|NCT03758846|Active Comparator|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
11145465|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
11145979|NCT03755401|Active Comparator|TAU|TAU in this study is treatment for PTSD as currently delivered at the VA
11145436|NCT03758846|Experimental|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
11145437|NCT03758846|Experimental|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
11145438|NCT03758846|Active Comparator|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
11145439|NCT03758833|Active Comparator|SET|patients receiving the elective single embryo transfer
11145440|NCT03758833|Experimental|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
11145441|NCT03758833|Active Comparator|DET|patients receiving the elective double embryo transfer
11145442|NCT03758833|Experimental|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
11145443|NCT03758820|Experimental|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.
~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
11145444|NCT03758820|No Intervention|Control group|Usual local practice
11145445|NCT03758807|Sham Comparator|Passive treatment|Passive treatment will consist of Manual Therapy with biomechanical explanation of the technique.
11145446|NCT03758807|Experimental|Active Treatment|Active treatment will consist of Manual Therapy with a neuroplasticity explanation of the technique.
11145447|NCT03758794|Active Comparator|interactive lecture module|interactive lecture
11145448|NCT03758794|Active Comparator|online educational module|online educational using a special link
11145449|NCT03758781|Experimental|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
11145450|NCT03758768|Experimental|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
11145451|NCT03758768|Active Comparator|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.
~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
11145452|NCT03758755|Experimental|BFR Therapy|This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff.. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
11145453|NCT03758755|Active Comparator|No BFR|This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR
11145454|NCT03758742|Experimental|High-Fruit Diet|
11145455|NCT03758729|Experimental|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
11145456|NCT03758716|Experimental|FB825|Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.
11145457|NCT03758703|Experimental|Pre-recorded music intervention group|The experimental group will be receiving the pre-recorded music care intervention. The intervention is to be delivered once a day for 30 minutes, over one week, on a portable Bluetooth speaker system. Participants will select their own music from the list of pre-recorded songs playlist and are free to switch to another playlist within their treatment arm should they desire. This music was specifically designed for use in palliative care. Specifically, all songs are played at 60 beats per minute to mimic resting heart rate. Instrumentation was specifically chosen to be soothing and calming
11145458|NCT03758703|Active Comparator|Pre-recorded soothing poetry group|The control group will be provided pre-recorded soothing poetry which they will self-select. Participants are allowed to switch playlists within their treatment arm each day should they desire. This control group is designed to control time, attention, and placebo effect. Thus, the soothing poetry will be offered the identical time duration of listening to recorded soothing poetry readings and played at the same time the intervention group receives the pre-recorded music.
11145459|NCT03758690|Experimental|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
11145460|NCT03758677|Experimental|Patients who progressed after EGFR-TKI without T790M mutation|Single arm; Plan to enroll 30 cases; Patients who progressed after EGFR-TKI treatment without T790M mutation
11145461|NCT03758664|Experimental|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
11145462|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
11145463|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
11145464|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
11145466|NCT03758638|Experimental|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).
~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
11145467|NCT03758638|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual
11145468|NCT03758625|Experimental|ARM A|a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
11145469|NCT03758625|Experimental|ARM B|a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
11145470|NCT03758625|Active Comparator|ARM C|a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
11145471|NCT03758625|Experimental|ARM D|pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
11145472|NCT03758625|Experimental|ARM E|pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
11145473|NCT03758625|Active Comparator|ARM F|pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
11145474|NCT03758612|Active Comparator|Cohort 1 (sentinel group) - Active|Single dose of TBI-223 50 mg (n=2) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
11145475|NCT03758612|Placebo Comparator|Cohort 1 (sentinel group) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
11145476|NCT03758612|Active Comparator|Cohort 1 (remainder of cohort) - Active|Single dose of TBI-223 50 mg (n=4).
11145477|NCT03758612|Placebo Comparator|Cohort 1 (remainder of cohort) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1).
11145478|NCT03758612|Active Comparator|Cohort 2 - Cohort 7 - Active|Single dose of TBI-223 100, 300, 600, 1200, 2000, 2600 mg; n=3 per dosing group.
11145479|NCT03758612|Placebo Comparator|Cohort 2 - Cohort 7 - Placebo|Single dose of matching Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg, n=1 per dosing group.
11145480|NCT03758612|Active Comparator|Cohort 3b - Active - Oral Capsule|Single dose of 300 mg in oral enteric capsule, n=4 per dosing group.
11145481|NCT03758612|Placebo Comparator|Cohort 3b - Placebo - Oral Capsule|Single dose of placebo for 300 mg in oral enteric capsule, n=1 per dosing group.
11145482|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 1|Single dose of TBI-223 sustained-release (SR) tablet prototype 1, 3 x 600 mg, n=6 per cohort.
11145483|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 2|Single dose of TBI-223 SR tablet prototype 2, 3 x 600 mg, n=6 per cohort.
11145484|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 3|Single dose of TBI-223 SR tablet prototype 3, 2 x 900 mg, n=6 per cohort.
11145485|NCT03758612|Active Comparator|Cohort 8 - IR Tablet fasted|Single dose of TBI-223 immediate-release (IR) tablet prototype 4, 2 x 1000 mg, n=6 per cohort; fasted prior to dose.
11145486|NCT03758612|Active Comparator|Cohort 9 - IR Tablet with meal|Single dose of TBI-223 immediate-release (IR) tablet, 2 x 1000 mg, n=6 per cohort; fed prior to dose.
11145487|NCT03758599|Experimental|Climbing Exercise Group|At the beginning of each session, a standardized body-centered, mind-setting warmup of ten minutes will take place. The general warm-up will be followed by climbing specific warm-up, which will consist of bouldering (20-30 minutes). Afterwards the rope climbing session will start. Climbing sessions also contain several sport-specific skill-development training sessions to familiarize the participants with gear and rope management, to acquire footwork and route finding, and to locate good belay spots and resting positions while climbing. At the end of the climbing session a short cool-down of five minutes will be executed.
11145488|NCT03758599|Experimental|Aerobic Exercise Group|As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
11145489|NCT03758599|Active Comparator|Social Contact Control Group|Patients allocated to the social contact control group will receive the same amount of social interaction as the exercise groups. A physiotherapist or sport scientist will be present while participants watch movies with relevant content to disease followed by interactive group discussions. This group is required to control for the impact of social contact/support on AD/PTSD and secondary outcomes.
11145490|NCT03758586|Active Comparator|Study group|Surgical residents undergoing spatial skill training.
11145491|NCT03758586|Sham Comparator|Control group|Surgical residents not undergoing spatial skill training.
11145492|NCT03758573|Experimental|Inspiratory Muscle Training (IMT)|IMT by means of the Powerbreath equipment (Classic, London, UK), according to the following parameters: initial loading of 40% of MIP, 3 sets of 10 repetitions with interval of 1 minute between each sets, 7 days a week, 2 times a day , with the patients in the bed with the angulation of 45 °. The IMT load settings will be adjusted according to the values evaluated weekly. If there is need for addition of supplemental oxygen will be performed to perform the IMT.
11145493|NCT03758573|Active Comparator|Intensive Physiotherapy (IPT)|IPT will be to individualized and supervised intervention program consisting of any of the following procedures: passive, assisted, active or resisted mobilization, sedation and orthostasis depending on the functional level of the patient, as well as bronchial hygiene therapy and pulmonary expansion therapy.
11145494|NCT03758547|Experimental|in-exufflator and percussion technique|"assess the physiological effects, of a common daily practice of secretion removal in intubated patients, that are: in-exufflator technique and percussion technique"
11145495|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging [MRI/MRS/DTI], Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]), and yearly bio-specimen collection.
11145526|NCT03758365|Active Comparator|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
11145527|NCT03758365|Active Comparator|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
11145496|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
11145497|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
11145498|NCT03758508|Active Comparator|HFO|Continuous high flow oxygen through nasal cannula for 45 hours; longer if the clinical need persists
11145499|NCT03758508|Active Comparator|NIV/HFO|Alternating noninvasive ventilation (3 hours) and high flow oxygen through nasal cannula (3 hours) for 45 hours; longer if the clinical need persists
11145500|NCT03758495||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
11145501|NCT03758495||Patients with Major Depressive Disorder|Individuals who have been previously diagnosed with major depressive disorder and meet our research criteria for symptoms indicative of major depressive disorder within their lifetime.
11145502|NCT03758495||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
11145503|NCT03758482|Other|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
11145504|NCT03758482|Other|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
11145505|NCT03758469|Experimental|HSK3486|0.4 mg/kg
11145506|NCT03758469|Experimental|rifampin , HSK3486|600 mg;0.4 mg/kg
11145507|NCT03758456|Placebo Comparator|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
11145508|NCT03758456|Experimental|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
11145509|NCT03758456|Experimental|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
11145510|NCT03758456|Experimental|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
11145511|NCT03758443|Experimental|Active Treatment TD-1473 Dose A|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
11145512|NCT03758443|Experimental|Active Treatment TD-1473 Dose B|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
11145513|NCT03758443|Experimental|Active Treatment TD-1473 Dose C|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
11145514|NCT03758443|Placebo Comparator|Placebo|Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose).
11145515|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
11145516|NCT03758417|Experimental|LCAR-B38M Chimeric Antigen Receptor T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
11145517|NCT03758404|Experimental|Low dose AAV - CNGA3|Subretinal administration of a single low dose of range AAV - CNGA3
11145518|NCT03758404|Experimental|Intermediate dose AAV - CNGA3|Subretinal administration of a single intermediate dose of range AAV - CNGA3
11145519|NCT03758404|Experimental|High dose AAV - CNGA3|Subretinal administration of a single high dose of range AAV - CNGA3
11145520|NCT03758391|No Intervention|Traditional Didactic Education|Education will be provided to fellows using the traditional didactic approach (lecture-based).
11145521|NCT03758391|Experimental|Flipped Classroom Education|Education will be provided to fellows using the flipped classroom approach.
11145522|NCT03758378|Experimental|Dietary intervention|
11145523|NCT03758365|Experimental|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
11145524|NCT03758365|Active Comparator|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
11145525|NCT03758365|Active Comparator|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
11145530|NCT03758352|Experimental|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
11145531|NCT03758352|Other|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
11145532|NCT03758339|Experimental|Tucatinib|
11145533|NCT03758326|Other|Eating disorder|Measurement of body image via Body App and relationship to body measurement
11145534|NCT03758326|Other|Healthy comparison|Measurement of body image via Body App and relationship to body measurement
11145535|NCT03758300|Experimental|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
11145536|NCT03758300|Sham Comparator|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
11145537|NCT03758287|Experimental|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.
~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .
~Gefitinib will be administered daily, at a dose of 250 mg orally ."
11145538|NCT03758274|Experimental|CBT Phone Intervention|
11145539|NCT03758274|Active Comparator|Being Read A Pamphlet on Alcohol Treatment|
11145540|NCT03758261|Other|Erector Spinae Nerve Block|Erector Spinae nerve block
11145541|NCT03758261|Other|Paravertebral Nerve Block|Paravertebral nerve block
11145542|NCT03758235|Experimental|Incobot/A 100 U|Incobot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
11145543|NCT03758235|Experimental|Incobot/A 200 U|Incobot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered in patients performin intermittent catheterization.
11145544|NCT03758235|Active Comparator|Onabot/A 100 U|Onabot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
11145545|NCT03758235|Active Comparator|Onabot/A 200 U|Onabot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered to patients performing intermittent catheterization
11145546|NCT03758222|Experimental|Arm-1: Device implantation for 1 month|Treatment group receives intervention with the Mercury Expander System implantation for 1 month, and then retrieved.
11145547|NCT03758222|Experimental|Arm-2: Device implantation for 6 months|Treatment group receives intervention with the Mercury Expander System implantation for 6 months, and then retrieved.
11145548|NCT03758209|Experimental|Prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:
~Physical status (walking, respiratory training)
~Nutrition (nutritional supplements)
~Mental status (weekly groups led by clinical psychologist on anxiety and depression management).
~Each patient will be treated in an ERAS program preoperatively."
11145549|NCT03758209|Active Comparator|ERAS|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
11145550|NCT03758196|Experimental|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
11145551|NCT03758196|No Intervention|optimized medication regimen|optimized medication regimen
11145552|NCT03758183||two-stage algorithm|Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)
11145553|NCT03758183||one-stage algorithm|total knee arthroplasty (TKA)
11145554|NCT03758170|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
11145555|NCT03758170|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
11145556|NCT03758157|Experimental|welloStationX Automated Non-Contact Thermometer|
11145557|NCT03758157|Active Comparator|Welch Allyn SureTemp Oral Thermometer|
11145558|NCT03758144|Active Comparator|study|
11145559|NCT03758144|No Intervention|CONTROL GROUP|
11145560|NCT03758131|Experimental|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
11145561|NCT03758131|Active Comparator|Motivational Interviewing|In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
11145562|NCT03758131|Placebo Comparator|Waitlist Control|Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
11145563|NCT03758118|Active Comparator|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
11145564|NCT03758118|No Intervention|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
11145565|NCT03758105|Experimental|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
11145566|NCT03758105|Active Comparator|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
11145567|NCT03758092||SGA vs AGA infants|infants, born at term (37+0/41+3 week gestation), aged 24 months, with a birth weight <10th percentile or between 10th and 90th percentile for sex, gestational age, and birth order, according to Italian neonatal anthropometric charts
11145568|NCT03758079|Active Comparator|Doxepin|10 mg Doxepin daily for 4 weeks
11145569|NCT03758079|Active Comparator|Gabapentin|Gabapentin 100mg after each dialysis session
11145570|NCT03758066|Other|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
11145571|NCT03758053||Individuals with alcohol use disorder + ACE|Individuals with AUD and varying levels of adverse childhood experiences (ACE)
11145572|NCT03758053||Healthy controls|Healthy individuals without AUD
11145573|NCT03758053||Individuals with alcohol use disorder, no ACE|Individuals with AUD and no adverse childhood experiences (ACE)
11145574|NCT03758040|Experimental|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
11145575|NCT03758040|Experimental|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
11145576|NCT03758027|Experimental|CARESS|"The proposed intervention for this study has three stages: communicate alternatively (CA), release endorphins (RE), and self-soothe (SS) (CARESS)
~CARESS is a combined skill of three activities. Each section is timed and has specific activities:
~CA - will last eight (8) minutes, and will be expression of emotion with drawing with crayons.
~RE - will last six (6) minutes, and will be a butterfly hug with a blanket. SS - will last six (6) minutes, and will be a pre-recorded music selection."
11145577|NCT03758027|Active Comparator|ISOMETRIC|This is a one time five-minute isometric circuit involving contracting muscles in different parts of the body. In order to be equivalent in time spent with the experimental intervention, this circuit will be performed three times with a five-minute break between each instance
11145578|NCT03758014|Experimental|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
11145579|NCT03758014|Active Comparator|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
11145580|NCT03758001|Experimental|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
11145581|NCT03758001|Experimental|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.
~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
11145582|NCT03757988|Experimental|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
11145583|NCT03757975||TAH|patients before and after total abdominal hysterectomy (TAH)
11145584|NCT03757975||TLH|patients before and after total laparoscopic hysterectomy (TLH)
11145585|NCT03757975||TVH|patients before and after total vaginal hysterectomy (TVH)
11145586|NCT03757975||SAH|patients before and after abdominal supracervical hysterectomy (SAH)
11145587|NCT03757975||SLH|patients before and after supracervical laparoscopic hysterectomy (SLH)
11145588|NCT03757962|Experimental|Dietary intervention|
11145589|NCT03757949|Experimental|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
11145590|NCT03757949|Placebo Comparator|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
11145591|NCT03757936|Experimental|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
11145592|NCT03757923|Experimental|metformin|TAB METFORMIN 500mg TDS
11145593|NCT03757923|Experimental|pioglitazone|TAB PIOGLITAZONE 30 mg OD
11145594|NCT03757910|Experimental|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
11145595|NCT03757910|Active Comparator|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
11145596|NCT03757897|Experimental|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
11145597|NCT03757884|Experimental|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
11145598|NCT03757871|Experimental|Laser Stimulation|laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.
11145599|NCT03757871|Placebo Comparator|Placebo|The placebo group will have an application of the pen according to the same extinguished laser criteria.
11145600|NCT03757858|Experimental|HT+ACT|
11145601|NCT03757858|Experimental|HT+ACT+PD-1|
11145602|NCT03757858|Experimental|HT+ACT+CT|
11145606|NCT03757819|Experimental|Before Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
11145607|NCT03757819|Experimental|During Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
11145608|NCT03757806|Experimental|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
11145609|NCT03757806|No Intervention|Control group|The control group will receive usual care only.
11145610|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
11145611|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
11145612|NCT03757767|Experimental|Intervention arm|Fasting for 26-hours.
11145613|NCT03757754|Experimental|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
11145614|NCT03757754|Experimental|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
11145615|NCT03757754|Experimental|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
11145616|NCT03757754|Experimental|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
11145617|NCT03757754|Experimental|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
11145618|NCT03757754|Experimental|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
11145619|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
11145620|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
11145621|NCT03757728|Other|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
11145622|NCT03757728|Other|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
11145623|NCT03757728|Other|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit [Biolitec Co]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
11145624|NCT03757715|Experimental|Treatment Group|20 mL of 1.3% bupivacaine with 2 mg dexamethasone injected locally in the location for sensory nerves of the sinus cavities and face during the functional endoscopic sinus surgery (FESS) procedure
11145625|NCT03757715|No Intervention|Control Group|No regional anesthetic of any kind during the functional endoscopic sinus surgery (FESS) procedure
11145626|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
11145627|NCT03757702||Healthy group|healthy women and being volunteereed
11145628|NCT03757689|Experimental|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
11145629|NCT03757676|Experimental|No Play|This 'no play' group functioned as the control group.
11145630|NCT03757676|Experimental|At Will Play|This group functioned as 1 of the 2 play groups.
11145631|NCT03757676|Experimental|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
11145632|NCT03757663|Experimental|UV Dosimeter|UV Dosimeter will measure participants' UV exposure for two separate 3-week periods.
11145633|NCT03757650|Active Comparator|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
11145634|NCT03757650|Active Comparator|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
11145635|NCT03757650|No Intervention|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
11145636|NCT03757637|No Intervention|General module|"Control group will be case manager care only group. Eligible patients will also invite and receive their first time assessment as baseline during hospitalization. The usual cancer care group will receive routine cancer care in the inpatient wards through OPD visits."
11145637|NCT03757637|Experimental|NLSCP|NLSCP group will receive 5 section of NLSCP. Contents of scheduled intervention will be developed baed on the literature mentioned above. Ex 1 group, patients will receive at least 3 times face-to-face NLSCP, and two times by telephone calls for following up.
11145659|NCT03757520|Active Comparator|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
11145660|NCT03757507|Experimental|Optoacoustic imaging|Optoacoustic Imaging before and after tracer administration
11145661|NCT03757494|Experimental|Use of Alpha Stim|Use of Alpha Stim Device
11145999|NCT03755258|Placebo Comparator|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
11145638|NCT03757637|Experimental|ICT supported HAP|The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For this group, patients will receive two face to face interventions in the first two sections (pre-discharge from hospital and 5th week post-op). It will be delivered by research nurse to intervene patients and help them to build up the App system. Research nurse will also help patients to be familiar with the operation system. The rest parts of the intervention will all through Apps in the scheduled time. Patients can raise their questions and concerns through APPs. Patients in the HAP can raise their concerns or questions through APP and receive interventions or answers through App interactively.
11145639|NCT03757624|Active Comparator|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
11145640|NCT03757624|Active Comparator|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
11145641|NCT03757611|Experimental|tabetri|Tabetri capsule will be administered orally twice daily for 12 weeks
11145642|NCT03757611|Placebo Comparator|Placebo|Placebo capsule will be administered orally twice daily for 12 weeks
11145643|NCT03757598|No Intervention|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
11145644|NCT03757598|Experimental|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
11145645|NCT03757585|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
11145646|NCT03757585|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
11145647|NCT03757572|Experimental|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.
~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.
~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
11145648|NCT03757572|Active Comparator|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.
~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
11145649|NCT03757559|Experimental|Cebranopadol 200 micrograms (Treatment A)|"Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
11145650|NCT03757559|Experimental|Cebranopadol 400 micrograms (Treatment B)|"Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
11145651|NCT03757559|Experimental|Cebranopadol 800 micrograms (Treatment C)|"Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
11145652|NCT03757559|Active Comparator|Hydromorphone IR 8 milligrams (Treatment D)|"Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.
~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
11145653|NCT03757559|Active Comparator|Hydromorphone IR 16 milligrams (Treatment E)|"Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.
~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
11145654|NCT03757559|Placebo Comparator|Placebo (Treatment F)|"Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.
~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
11145655|NCT03757559|Placebo Comparator|Placebo (Treatment G)|"Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.
~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
11145656|NCT03757533|Experimental|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
11145657|NCT03757533|Other|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
11145658|NCT03757520|Active Comparator|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
11145662|NCT03757481|Other|no intervention|patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin
11145663|NCT03757468|Active Comparator|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
11145664|NCT03757468|Experimental|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
11145665|NCT03757455|Experimental|Enchanced recovery after surgery protocol|ERAS-protocol as described in low risk patients after pancreaticoduodenectomy or total pancreatectomy
11145666|NCT03757455|No Intervention|Standard protocol|Standard recovery protocol after pancreaticoduodenectomy or total pancreatectomy
11145667|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
11145668|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
11145669|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
11145670|NCT03757403|Experimental|RDD1609 followed by Placebo|Application on the perianal area BID
11145671|NCT03757403|Experimental|Placebo followed by RDD1609|Application on the perianal area BID
11145672|NCT03757390|Experimental|Sequence 1|"period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg
~period 2: receive CJ-30060 5/160/10mg"
11145673|NCT03757390|Experimental|Sequence 2|"period 1: receive CJ-30060 5/160/10mg
~period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
11145674|NCT03757377|Active Comparator|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
11145675|NCT03757377|Placebo Comparator|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
11145676|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
11145677|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
11145678|NCT03757351|Experimental|DNL747 First, Placebo Second|
11145679|NCT03757351|Experimental|Placebo First, DNL747 Second|
11145680|NCT03757351|Experimental|Open-Label Extension|Conducted in the Netherlands only.
11145681|NCT03757338|Active Comparator|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
11145682|NCT03757338|Experimental|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
11145683|NCT03757325|Experimental|DNL747 First, Placebo Second|Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
11145684|NCT03757325|Experimental|Placebo First, DNL747 Second|Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
11145685|NCT03757312|Experimental|Optic nerve ultrasound|Patients requiring cardiopulmonary bypass during heart surgery and undergoing optic nerve ultrasounds.
11145686|NCT03757299|Experimental|Self HPV|
11145687|NCT03757286|Experimental|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
11145688|NCT03757286|Active Comparator|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
11145689|NCT03757273|Experimental|FFF with CAD/CAM customized cutting guide|Mandibular reconstruction using free fibular flap with CAD/CAM customized osteotomy guide.
11145690|NCT03757273|Active Comparator|FFF without customized cutting guide|Mandibular reconstruction using free fibular flap without customized osteotomy guide. CAD/CAM 3D model for mandible will be used.
11145691|NCT03757260|Experimental|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
11145692|NCT03757260|Placebo Comparator|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
11145693|NCT03757234|Experimental|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
11145694|NCT03757234|Experimental|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
11145785|NCT03756688|No Intervention|Group 1: Control|No treatment will be administered for the entirety of the study (6 months)
11145786|NCT03756688|Experimental|Group 2: Treatment|PTT for 30 min 2x/ day x 3 months, followed by no treatment x 3 months
11145787|NCT03756688|Experimental|Group 3: Treatment|PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months
11145695|NCT03757234|Experimental|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
11145696|NCT03757234|Experimental|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
11145697|NCT03757234|Active Comparator|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
11145698|NCT03757221|Experimental|Combination ixazomib + daratumumab without dexamethasone|Elderly Relapse Refractory Multiple Myeloma Patients treated by Combination ixazomib + daratumumab without dexamethasone
11145699|NCT03757208|No Intervention|Fasting group|
11145700|NCT03757208|Active Comparator|Carbohydrate rich drink (CHD) group|
11145701|NCT03757195|Experimental|augmentation by xenograft|xenograft mixed with plasma extracted from blood
11145702|NCT03757182||Wearable activity monitor|Continuous activity monitoring with Fitbit Charge HR from baseline to up to 1 year from end-of-study.
11145703|NCT03757169|Active Comparator|Control group|Verbal informations about the disease, and exercise behavior, and nutrition.
11145704|NCT03757169|Active Comparator|Hand grip group|Three supervised sessions por week: 4 series (2 at each arm) of two minutes of isometric hand grip contraction at 30% of maximal voluntary contraction. Between series there will be two minutes to rest.
11145705|NCT03757156|No Intervention|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
11145706|NCT03757156|Experimental|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
11145707|NCT03757143|Active Comparator|PVI et Insyte|Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
11145708|NCT03757143|Experimental|CHG et Insyte|Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
11145709|NCT03757143|Experimental|PVI et Nexiva|Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
11145710|NCT03757143|Experimental|CHG et Nexiva|Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
11145711|NCT03757130|Experimental|AMG 598|Multiple ascending dose cohorts
11145712|NCT03757130|Placebo Comparator|Placebo-controlled|Multiple ascending dose cohorts
11145713|NCT03757130|Experimental|AMG 598, liraglutide|"Multiple ascending dose cohorts
~Additionally liraglutide is escalated to a dose of 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day."
11145714|NCT03757130|Placebo Comparator|Placebo controlled, liraglutide|"Multiple ascending dose cohorts
~Additionally liraglutide is escalated to a dose of 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day."
11145715|NCT03757130|Experimental|AMG 598, stable liraglutide|AMG 598 at a to be determined (TBD) dose in addition to liraglutide 3.0 mg/day
11145716|NCT03757130|Placebo Comparator|Placebo controlled, stable liraglutide|Placebo at a to be determined (TBD) volume in addition to liraglutide 3.0 mg/day
11145717|NCT03757117|Experimental|Intervention|Feminizing hormone therapy and peer navigation
11145718|NCT03757104|Experimental|micro-incentives|micro-incentives only (8 communities)
11145719|NCT03757104|Experimental|EPIC-HIV|Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities)
11145720|NCT03757104|Experimental|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities)
11145721|NCT03757104|No Intervention|control|standard of care
11145722|NCT03757091|Active Comparator|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
11145723|NCT03757091|Experimental|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
11145724|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
11145725|NCT03757065||Systemic Lupus Erythematosus|
11145726|NCT03757065||Sjogren's Syndrome|
11145727|NCT03757065||Multiple Sclerosis|
11145728|NCT03757065||Systemic Sclerosis|
11145729|NCT03757065||Crohn's Disease|
11145730|NCT03757065||Ulcerative Colitis|
11145731|NCT03757065||Inflammatory Myositis|
11145732|NCT03757052|Experimental|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
11145733|NCT03757039|Experimental|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
11145734|NCT03757039|Active Comparator|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
11145735|NCT03757026|Active Comparator|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
11145736|NCT03757026|Experimental|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
11145737|NCT03757026|Experimental|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
11145738|NCT03757013||Patients treated with Apremilast|Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
11145739|NCT03757000|Experimental|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).
~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
11145740|NCT03756987|Experimental|ESPB group|Patient will receive a single shot of Ropivacaine injection 0.5% 25 mL injected at the erector spinae plane.
11145741|NCT03756987|Placebo Comparator|Control Group|Patient will receive a single shot of normal saline 25 mL injected at the erector spinae plane.
11145742|NCT03756974|Experimental|BX-1 (dronabinol)|BX-1
11145743|NCT03756974|Placebo Comparator|Placebo|Placebo of BX-1
11145744|NCT03756961|Active Comparator|Control|"Control group: The patients receive the routine based anesthesiological treatment during bariatric surgery (Gastric By-Pass or Sleeve Gastrectomy). It consists of:
~General anesthesia induction: TCI Remifentanil Cpt 6 ng/ml/ Cp 3.2 ng/m, Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).
~Maintained by Desflurane MAC (0.6-0.8) adjusted via BIS (40-60) and Remifentanil Cp 4-10 ng/ml.
~Post-operative pain management: Oxycodone 2.5 mg iv if the pain is rated by patient NRS ≧3. Paracetamol 1 g/6 h and Diclofenac 80 mg/24 h."
11145745|NCT03756961|Experimental|Intervention|"Induction: Dexmedetomidine 0.2 micrograms/kg/h iv 5 min, Esketamine 0.1mg/kg + Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).
~Maintained by Desflurane MAC (0.6-0.8) BIS (40-60), Dexmedetomidine 0.2 micrograms/kg/h, Esketamine 0.1-0.3mg/kg/h och 0.1 mg/kg in case of hypertension. At the end of surgery, Lidocaine 1 mg/kg iv (max 4 mg/kg /4 h)
~Post-operative: Dexmedetomidine (0.1-0.2 micrograms/kg/h up to 4 h post-operative). If the pain is rated NRS ≧3: Transcutaneous Nerve Stimulation (TENS) with high intensive 40-50 mA for 1 minute, if the patient still NRS ≧3, the TENS treatment is repeated one more time. If pain NRS ≧3 after two treatments with TENS: Esketamine 0.1mg/kg iv + Lidocaine 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS still ≧3 within 30 minutes after both TENS and Esketamine/Lidocaine, 2.5 mg Oxycodone iv, with a 10 minutes intervals until NRS < 3. Perioperative and at discharge, PCC will be used for the second half of the intervention."
11145746|NCT03756948|Active Comparator|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
11145747|NCT03756948|Experimental|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
11145748|NCT03756922|Experimental|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
11145749|NCT03756922|Experimental|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
11145750|NCT03756922|Experimental|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
11145751|NCT03756922|Experimental|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
11145752|NCT03756909||adenoidectomy group|Operations of adenoidectomy
11145753|NCT03756909||adenotonsillectomy group|Operations of adenotonsillectomy
11145754|NCT03756896|Experimental|Carfilzomib, pomalidomide, dexamethasone|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11145755|NCT03756883|Experimental|Test|Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
11145756|NCT03756883|Active Comparator|Reference|ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
11145757|NCT03756883|Placebo Comparator|Placebo|Placebo
11145758|NCT03756870|Experimental|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
11145759|NCT03756870|No Intervention|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
11145788|NCT03756688|Experimental|Group 4: Treatment|PTT for 30 min 2x day x 6 months
11145789|NCT03756675||haplotype PBSCT group|"Subjects in this group will receive haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system in the treatment of acute leukemia."
11145790|NCT03756649|Placebo Comparator|Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
11145760|NCT03756857|Experimental|Afterload transfer|First, an empty catheter passes to the level of the lower uterine segment under ultrasound guidance to a point where the inner catheter enters the endometrial cavity. The inner sheath is removed slowly, leaving the outer sheath just beyond the internal os. After verifying the catheter's position on the TA ultrasound scan, the physician gives the signal to the embryologist to start the embryo loading. The embryologist brings the loaded inner catheter and inserts it into the outer sheath, which is maintained in its position by the physician.
11145761|NCT03756857|Experimental|Trial Followed by Transfer|First a trial transfer is performed using both the inner catheter and outer sheath connected together in standard configuration, just before the actual embryo transfer. It is passed up to and just through the the internal os. When it appears that the actual transfer will be possible without great difficulty ,the trial catheter is withdrawn. An embryo transfer catheter is loaded and the actual transfer is performed
11145762|NCT03756844|Experimental|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
11145763|NCT03756831|Active Comparator|Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
11145764|NCT03756831|Active Comparator|Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
11145765|NCT03756831|Active Comparator|Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
11145766|NCT03756818|Experimental|Treatment (TAK-659 and paclitaxel)|Patients receive spleen tyrosine kinase inhibitor TAK-659 PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11145767|NCT03756805|Active Comparator|Group 1 (CPAP)|Patient, who are receiving a CPAP
11145768|NCT03756805|Experimental|Group 2 (UAS)|Patient, who are receiving a device for upper airway stimulation
11145769|NCT03756792|Active Comparator|First Time Control|Patients with no prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
11145770|NCT03756792|Experimental|First Time Intervention|Patients with no prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
11145771|NCT03756792|Active Comparator|Previous Experience Control|Patients with prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
11145772|NCT03756792|Experimental|Previous Experience Intervention|Patients with prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
11145773|NCT03756779|Experimental|Low Saturated Fat Diet|Goal will be to attain <7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
11145774|NCT03756779|Active Comparator|High Saturated Fat Diet|Goal will be to attain 15% of daily calories from saturated fat. Decrease intake of monounsaturated fat.
11145775|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).
~Group 1 participants are categorised into 4 groups as follows:
~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.
~Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
11145776|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.
~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
11145777|NCT03756753|Experimental|Intervention group- results known|Providers of patients enrolled in this arm of the study will be notified of the point of care respiratory testing results
11145778|NCT03756753|No Intervention|Control group- results not known|Providers of patients enrolled in the study will not be notified of the point of care respiratory testing results
11145779|NCT03756740|Experimental|Telerehabilitation|After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home. The exercises will be sent as a video to his/her mobile or e-mail according to the subject's preference. The exercises will be previously recorded and accompanied with a verbal explanation and instructions on how to correctly perform the exercises, paying close attention to specific points. In total, there will be 10 videos of exercises found effective for LBP patients.. After each face to face meeting, the physical therapist will choose from these 10 videos suitable exercises for the patients.
11145780|NCT03756740|Active Comparator|Control|"After each face to face session the patient will receive the exercises ordered by the physical therapist to perform at home.
~subjects will receive the same exercises given to experimental group according to the results of the face to face meeting. The exercises will be shown as printed pictures on paper"
11145781|NCT03756727|Experimental|Ascorbic acid group|the patients received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery.
11145782|NCT03756727|Placebo Comparator|Control comparator group|the patients received 10ml saline at the night before surgery, during the surgery and five days after surgery.
11145783|NCT03756701|Experimental|Group 1|Initial participants in the 10 mind body sessions
11145784|NCT03756701|Active Comparator|Group 2|10 week no intervention groups - receives the mind body interventions after group 1 has completed.
11145791|NCT03756649|Active Comparator|Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
11145792|NCT03756636|Other|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
11145793|NCT03756623|Experimental|Drug: Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
11145794|NCT03756623|Experimental|Drug: Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
11145795|NCT03756623|Placebo Comparator|Drug: Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
11145796|NCT03756610|Active Comparator|Active tACS & active boosting group|The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
11145797|NCT03756610|Other|Active tACS & sham boosting group|The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
11145798|NCT03756610|Sham Comparator|Sham tACS & sham boosting group|The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
11145799|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population
~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.
~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
11145800|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:
~Are suspected of the same cancer or part of an at risk-group
~Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)
~Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
11145801|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
11145802|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
11145803|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population
~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
11145804|NCT03756584|Experimental|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
11145805|NCT03756584|Active Comparator|Control stimulation|iTBS will be performed on the vertex
11145806|NCT03756571|Experimental|Ankle Foot Orthoses-Footwear Combination|The intervention is a Ankle Foot Orthoses Footwear Combination (AFO-FC). This is some form of solid ankle AFO combined with modified footwear individually designed per algorithm.
11145807|NCT03756571|Active Comparator|Traditional Solid Ankle AFO (TSAFO)|"The intervention is a solid AFO (SAFO) aligned with the ankle at 90 degrees and worn with regular footwear. We'll refer to this as the traditional SAFO (TSAFO)..."
11145808|NCT03756558|Experimental|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
11145809|NCT03756519|Experimental|Exercise|Participants in the exercise intervention arm will receive the usual care protocol plus a standardized, evidence informed exercise intervention provided by trained physiotherapy students. The exercise intervention will begin with a brief assessment to rule out contraindications to exercise and to identify any directional preferences (e.g. pain with lumbar flexion and relief with extension). The PT will then be taught four standardized exercises: the pelvic tilt exercise, a rotational exercise, a tailored graded walking program taking into account the current abilities of the patient, and an exercise based on the directional preference of the individual. These will be re-enforced with a handout including the rationale, instructions and dosage recommendations for the exercises.
11145810|NCT03756519|Active Comparator|Usual care|Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
11145811|NCT03756506|Active Comparator|DuraDerm® Group|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.
~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply DuraDerm® with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. DuraDerm® will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
11145812|NCT03756506|No Intervention|Control group: no DuraDerm|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.
~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.
~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
11145878|NCT03756090|Placebo Comparator|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
11146315|NCT03753022|Experimental|Group G15|Patients submitted to CABG and peep 15
11145813|NCT03756493|Experimental|PRF+ABG treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autologous bone graft mixed with cutted PRF will be applied to the furcation defects; then, a PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures.
11145814|NCT03756493|Active Comparator|ABG treated patients|Periodontal surgery with Autologous Bone Graft is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autologous bone graft will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
11145815|NCT03756493|Active Comparator|OFD treated patients|Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
11145816|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management
~100 participants"
11145817|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation
~35 participants"
11145818|NCT03756467|No Intervention|Arm 1|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff
11145819|NCT03756467|Experimental|Arm 2|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up
11145820|NCT03756467|Active Comparator|Arm 3|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up.
11145821|NCT03756454|Experimental|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
11145822|NCT03756454|Placebo Comparator|Normal Saline|Patients receiving normal saline as a placebo post-operatively.
11145823|NCT03756441|Experimental|Experimental: Mindfulness group|This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion protocol. They will group with have eight meetings, one per week, during a half hour and will learn the techiques to practice everyday during the week.
11145824|NCT03756441|Active Comparator|Psychotherapy group|This group will learn group problem solving techniques during eight weeks
11145825|NCT03756428|Experimental|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
11145826|NCT03756428|Placebo Comparator|Sham technique in tibialis posterior|Placebo tibialis dry needling
11145827|NCT03756415|Experimental|mask plus CO2 removal device|"a traditional mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask R,"
11145828|NCT03756415|Active Comparator|traditional face mask|Traditional mask without a CO2 clearance device inserted
11145829|NCT03756402||Healthy Subjects|All subjects underwent protein loading test and IRRIV test on the same day. The renal resistive index (RRI) measurements were performed by one trained sonographer using a multi-frequency convex probe through a manual RRI calculations. The RRIs were measured on three interlobular arteries (superior, middle and inferior) in each kidney, and expressed as a mean value. RFR was measured using an oral protein loading test and was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Urinary creatinine and sCr were measured by the enzymatic method (IL testTM Instrumentation(R), Laboratory SpA, Milano, Italy) and by ILab650 (Instrumentation Laboratory, Werfen Group, Barcelona, Spain).
11145830|NCT03756389|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
11145831|NCT03756389|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
11145832|NCT03756376||IRRIV and RFR|Enrolled patients will receive IRRIV test and RFR assessment. RFR will be evaluated through a protein loading test. (1.2 g of protein/Kg of body weight) performed with cooked beef. The RFR was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Concerning the IRRIV test, a weight of 10% of the patient's body weight is applied on the abdominal wall. RRIs is recorded in a middle interlobular artery, every minute for 10 minutes during the echo-renal stress test. The lowest RRI reached is taken as reference (stress RRI). The IRRIV is defined as the percentage difference between baseline RRI and stress RRI
11145833|NCT03756363|Experimental|Non-solvent|Non-solvent use of a rotary retreatment system
11145834|NCT03756363|Experimental|Solvent|Solvent use in combination with a rotary retreatment system
11145835|NCT03756350|Experimental|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
11145836|NCT03756337|Experimental|Neuro 2 Upgrade|Participant wears Neuro 1 sound processor and is tested, then is upgraded with the new sound processor Neuro 2 and tested.
11145837|NCT03756337|Experimental|Neuro 1 Downgrade|Participant wears Neuro 2 sound processor and is tested, then is downgraded with the sound processor Neuro 1 and tested.
11145838|NCT03756324|Experimental|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.
~Education, basic medical order."
11145839|NCT03756324|Experimental|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.
~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.
~Education, basic medical order."
11145840|NCT03756324|Active Comparator|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.
~Education, basic medical order."
11145841|NCT03756298|Experimental|Combination|Atezolizumab + capecitabine combination arm
11145842|NCT03756298|Active Comparator|Control|Capecitabine alone arm
11145843|NCT03756285|Experimental|AZD4831|AZD4831 tablets taken orally for for 90 days.
11145844|NCT03756285|Placebo Comparator|Placebo|Placebo tablets taken orally for 90 days.
11145845|NCT03756272|Experimental|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
11145846|NCT03756272|Placebo Comparator|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
11145847|NCT03756259|Other|Pneumonia perception arm|Caregivers of children under five will be interviewed qualitatively to understand in depth on perception of pneumonia. These will be mothers, fathers and grandmothers of these children. Once the formative research is done, it will inform design of an intervention whereby the caregivers will be recruited to be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject. The LHWs will also be trained on pneumonia case finding which they will manage at their end and refer if required while doing daily field visits.
11145848|NCT03756246|Experimental|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
11145849|NCT03756246|Active Comparator|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
11145850|NCT03756233|Active Comparator|Remifentanil gradually withdrawal group|20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes.
11145851|NCT03756233|Active Comparator|Remifentanil immediately stop group|The control group stopped remifentanil 10 minutes before the end of the operation.
11145852|NCT03756220|Experimental|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
11145853|NCT03756220|Placebo Comparator|Control|Normal Saline Solution
11145854|NCT03756207|Experimental|Multidisciplinary Therapy|Multidisciplinary bladder-preservation therapy: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
11145855|NCT03756194|Experimental|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.
~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
11145856|NCT03756194|Other|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.
~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
11145857|NCT03756194|No Intervention|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.
~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
11145858|NCT03756181|Experimental|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of compassion: self-kindness, mindfulness, and common humanity, and will work on soothing the processes of self-criticism, self-neglect and perfectionism that are believed to withhold upon experiencing psychological distress. There will also be sessions dedicated to incorporating self-compassion in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
11145859|NCT03756181|Active Comparator|Five-week Mindfulness-based Stress Reduction program (MBSR5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator will perform a brief check-in and may discuss the student's experience within the course of the session. These discussions will reinforce the guiding principles of meditation: awareness, non-judgment and acceptance and will work on automatic mental processes that are believed to be at the root of experiencing psychological distress. There will also be sessions dedicated to incorporating mindfulness into daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
11145860|NCT03756168|Experimental|Treatment subjects|Single group of subjects with will have the treatment of a 1060 nm diode laser administered to them
11145861|NCT03756155|Experimental|Group 1|Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30%-40% value.
11145862|NCT03756155|Experimental|Group 2|Group 2 will complete a protocol with 5 sets of 20 second isometric holds followed by 20 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30% value.
11145863|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
11145864|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
11145865|NCT03756129|Experimental|MIJ821 low dose weekly|Infusion
11145866|NCT03756129|Experimental|MIJ821 low dose bi-weekly|Infusion
11145867|NCT03756129|Experimental|MIJ821 high dose weekly|Infusion
11145868|NCT03756129|Experimental|MIJ821 high dose bi-weekly|Infusion
11145869|NCT03756129|Placebo Comparator|Placebo weekly|Infusion
11145870|NCT03756129|Active Comparator|Ketamine 0.5 mg/kg weekly|Infusion
11145871|NCT03756116|Experimental|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
11145872|NCT03756116|Active Comparator|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
11145873|NCT03756103|Experimental|SPH3127 tablet Dose 1|Low-dose group
11145874|NCT03756103|Experimental|SPH3127 tablet Dose 2|Mid-dose group
11145875|NCT03756103|Experimental|SPH3127 tablet Dose 3|High-dose group
11145876|NCT03756103|Placebo Comparator|SPH3127 tablet Placebo|Placebo Control group
11145877|NCT03756090|Experimental|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
11145879|NCT03756077||Primary diagnosis and staging|Patients suspected of or diagnosed with prostate cancer who want a differential diagnosis and staging by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT before treatment
11145880|NCT03756077||Evaluation of recurrence|Patients with a history of prostate cancer and elevated PSA level after treatment, who need to determining whether or not there are recurrences/metastatic lesions and its locations by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
11145881|NCT03756064|Experimental|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
11145882|NCT03756064|Placebo Comparator|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
11145883|NCT03756051||Cohort|This study will collect prospective longitudinal data to characterize rates and identify correlates of a) physical harms due to follow-up tests, b) financial harms, and c) inappropriate screening using electronic medical record data and manual chart review. The study will also use surveys and semi-structured interviews to characterize rates and identify correlates of screening-related psychological harms, e.g. cancer specific worry, situational anxiety, mood disturbances, and decisional regret. Lastly, investigators will create and disseminate a balance sheet of benefits and harms to inform patients, providers, healthcare organizations, payers, and policymakers about the role of hepatocellular carcinoma screening in patients with cirrhosis.
11145884|NCT03756038|Experimental|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
11145885|NCT03756038|Placebo Comparator|Drug: Oral Placebo|
11145886|NCT03756025|Experimental|Vitro Molar® (DFL, Rio de Janeiro, Brazil)|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Vitro Molar® (DFL, Rio de Janeiro, Brazil).
11145887|NCT03756025|Active Comparator|Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).
11145888|NCT03756012|Active Comparator|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths <500 μsec.
11145889|NCT03756012|Active Comparator|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths >1000 μsec
11145890|NCT03755999|Experimental|PIOMI treat group|Preterm infant receive oral massage using the premature infant oral motor intervention (PIOMI)
11145891|NCT03755999|No Intervention|Routine care group|Preterm infant receive routine care of neonatal intensive care unit(NICU)
11145892|NCT03755986|Other|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
11145893|NCT03755973|Experimental|CFA plus step-down rFSH (1A)|"A single dose of 150 IU of CFA followed by daily rFSH will be administered. The initial rFSH administration will be dosed between 100 IU and 200 IU according to the following criteria:
~200 IU: <3 follicles above 13 mm visible on transvaginal ultrasound;
~150 IU, >2 follicles above 13 mm and circulating day-8 follicle-stimulating hormone (FSH) levels ≤20 IU/mL.
~100 IU, >2 follicles above 13 mm and circulating day-8 FSH levels >20 IU/mL;
~Subjects will perform a step-down daily rFSH dose (fixed decreases in the dosing of 25 IU/day) until the triggering criteria are met or a minimum of 50 IU/day is reached. Subjects with <3 follicles above 13 mm visible will maintain 200 IU/day of rFSH until this criterion is met, initiating a fixed 25 IU/day stepdown protocol only from then onwards."
11145894|NCT03755973|Experimental|CFA plus fixed daily dose rFSH (1B)|A single dose of 150 IU of CFA followed by a fixed daily rFSH dosing protocol of 200 IU will be administered as ovarian stimulation
11145895|NCT03755973|Active Comparator|Fixed daily dose rFSH only|A fixed daily rFSH dosing protocol of 200 IU will be administered as ovarian stimulation
11145896|NCT03755960|Experimental|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
11145897|NCT03755960|Active Comparator|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
11145898|NCT03755947|Experimental|IGV|"Cytoreduction 3 cycles (I) Ibrutinib, [Imbruvica, Janssen]
~Induction 6 cycles (G) Obinutuzumab, [Gazyva, Roche]
~Consolidation 12 cycles (V) Venetoclax, [Venclexta, Abbvie]."
11145899|NCT03755934|Experimental|Dose Level 1|MEDI7352
11145900|NCT03755934|Experimental|Dose Level 2|MEDI7352
11145901|NCT03755934|Experimental|Dose Level 3|MEDI7352
11145902|NCT03755934|Placebo Comparator|Placebo|Placebo
11145903|NCT03755934|Experimental|Dose Level 4|MEDI7352
11145904|NCT03755921|Experimental|Brief and intensive therapy|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, daily
11145905|NCT03755921|Active Comparator|Therapy Weekly|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, weekly
11145906|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
11145907|NCT03755895|Experimental|experimental|patients to benefit from brachytherapy detachment under KALINOX and formal hypnosis
11145908|NCT03755895|Active Comparator|active comparator|patients to benefit from brachytherapy detachment under KALINOX
11145909|NCT03755882|Experimental|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
11145910|NCT03755882|Experimental|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
11145911|NCT03755869|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
11145912|NCT03755830|Active Comparator|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
11145913|NCT03755830|Experimental|healthy controls|A skin biopsy will be taken from each control subject.
11145914|NCT03755817|Experimental|Scenar application|Application of SCENAR device on
11145915|NCT03755817|Placebo Comparator|Scenar application with the device off|Application of SCENAR device off
11145978|NCT03755401|Experimental|TFPP|TFPP is a manualized 16-24 session psychodynamic psychotherapy targeted on trauma symptoms of PTSD
11145916|NCT03755804|Experimental|Low-Risk|Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
11145917|NCT03755804|Experimental|Intermediate-Risk|Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
11145918|NCT03755804|Experimental|High-Risk|Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
11145919|NCT03755791|Experimental|Experimental arm|Subjects with advanced HCC will receive cabozantinib 40 mg oral, qd + atezolizumab 1200 mg infusion, q3w
11145920|NCT03755791|Active Comparator|Control arm|Subjects with advanced HCC will receive sorafenib 400 mg bid (twice a day)
11145921|NCT03755791|Other|Single-Agent Cabozantinib arm|Subjects with advanced HCC will receive cabozantinib 60 mg qd
11145922|NCT03755778|Experimental|EDP-938 and itraconazole interaction (Part 1)|
11145923|NCT03755778|Experimental|EDP-938 and rifampin interaction (Part 2)|
11145924|NCT03755778|Experimental|EDP-938 and quinidine interaction (Part 3)|
11145925|NCT03755765|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
11145926|NCT03755765|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
11145927|NCT03755752|Experimental|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
11145928|NCT03755752|Experimental|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
11145929|NCT03755739|Experimental|Pembrolizumab via localized infusion|"This group dividied into two subgroups:
~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.
~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a total dose of 150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
11145930|NCT03755739|Active Comparator|Checkpoint inhibitor (CPI) Pembrolizumab via vein infusion|Checkpoint inhibitor (CPI) such as Pembrolizumab is administrated with a total dose of 2mg/kg via vein infusion (30 min), every 3 weeks.
11145931|NCT03755713|Experimental|ASP0892 Low Dose (Cohort A)|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
11145932|NCT03755713|Experimental|ASP0892 High Dose (Cohort B)|After all participants in cohort A complete study procedures, the DMC will review the safety and tolerability data and provide recommendations depending on the nature, frequency and severity of the safety profile reviewed. Recommendations will be to proceed with escalation to the next higher dose or stop dose escalation (i.e., no further dosing with study drug).
11145933|NCT03755713|Placebo Comparator|Placebo|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
11145934|NCT03755700|Placebo Comparator|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
11145935|NCT03755700|Active Comparator|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
11145936|NCT03755700|Active Comparator|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
11145937|NCT03755687|Experimental|Art Therapy Intervention|Standardized mixed media art therapy directives (e.g. drawing/painting/collaging within a circle)
11145938|NCT03755674|Experimental|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
11145939|NCT03755674|No Intervention|CONTROL|Patients following a traditional or conventional hypocaloric diet
11145940|NCT03755661|Experimental|Intervention|This intervention arm is a combined in-person text messaging intervention
11145941|NCT03755661|No Intervention|Assessment Only Control|The is the assessment only comparison condition
11145942|NCT03755648|Experimental|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
11145943|NCT03755648|Other|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
11145944|NCT03755648|Experimental|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
11145945|NCT03755635|No Intervention|Standard of care|Continuously monitoring of neonatal sepsis under standard of care at one site
11145946|NCT03755635|Experimental|Hand hygiene|The WHO multimodal hand hygiene strategy is implemented at one site
11145947|NCT03755622|Active Comparator|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
11145948|NCT03755622|Experimental|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
11145949|NCT03755609|Active Comparator|patients with oxycodone|
11145950|NCT03755609|Sham Comparator|patients with fentanyl|
11145951|NCT03755596|Experimental|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
11145952|NCT03755583|Other|EEN group|Received exclusive enteral nutrition after enrollment.
11145953|NCT03755570||CRT: Main Arm|"Cardiac Resynchronisation Therapy (CRT): Main Arm ~98 participants
~Prior to CRT Implantation & Post-Implant 6-Month Device Follow-Up Clinic:
~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning, Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B
~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
11145954|NCT03755570||ICD and PPM: Control Arm|"Implantable Cardioverter-Defibrillator (ICD) and Permanent Pacemaker (PPM): Control Arm ~98 participants
~Prior to ICD or PPM Implantation & Post-Implant 6-Month Device Follow-Up Clinic:
~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B
~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
11145955|NCT03755557|Placebo Comparator|Placebo|Application of a placebo nasal spray once daily for 8 days Nasal Sprays
11145956|NCT03755557|Active Comparator|Rhinocort|"Nasal Sprays Application of Rhinocort Aqua 64 micrograms, nasal spray once daily for 8 days. Daily dosage 256 µg/d"
11145957|NCT03755557|Experimental|Budesolv|Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays
11145958|NCT03755544||Asthma patients|"Male or female patients with diagnosed asthma who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.
~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
11145959|NCT03755544||COPD patients|"Male or female patients with diagnosed COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler.
~During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC)."
11145960|NCT03755531|Experimental|Carbetocin|One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection after labor of the baby at once.
11145961|NCT03755531|Active Comparator|Oxytocin|One ml of Oxytocin (10 IU), was given as a bolus intravenous injection after labor of the baby at once.
11145962|NCT03755518|Experimental|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
11145963|NCT03755518|Experimental|Administration of Luspatercept 1.33 mg/kg|Administered as a subcutaneous injection concomitantly with Fedratinib at 3-week (21 day) cycles
11145964|NCT03755505||Healthy Smoker|Healthy smoker with normal spirometry value
11145965|NCT03755505||COPD|Patients with smoking history at least 10 pack-year Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
11145966|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
11145967|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
11145968|NCT03755479||Single Arm Group|Patient on multiple daily injections will start Hybrid Closed Loop System Insulin Pump Minimed 670G
11145969|NCT03755466|Active Comparator|BARI|
11145970|NCT03755466|Active Comparator|Bio|
11145971|NCT03755466|Active Comparator|Tofa|
11145972|NCT03755453|Active Comparator|Audéo B-Direct fitted with fitting method A|Traditional standard fitting method which do not include adjustments from the participants.
11145973|NCT03755453|Experimental|Audéo B-Direct fitted with fitting method B|Alternative fitting method which includes additional adjustments from the participants.
11145974|NCT03755440|Experimental|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
11145975|NCT03755427|Experimental|15μg H7N9 Vaccine|Participants will be inoculated with 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
11145976|NCT03755427|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will be first inoculated with one dose of seasonal influenza vaccine and followed with one dose of aluminum hydroxide adjuvant at 21-day intervals.
11145977|NCT03755414|Experimental|Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy
~Stem cell transplantation on Day 0
~Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently
~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
11145980|NCT03755388|Experimental|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
11145981|NCT03755375|Active Comparator|E-stim Group|The E-stim Group will start treatment after the assessment. Interventions:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
11145982|NCT03755375|Active Comparator|Postural Group|The Postural Group will star treatment after the assessment. The interventions will be: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
11145983|NCT03755375|Placebo Comparator|E-stim Control Group|The E-stim Control Group will start treatment 3 months after the assessment: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
11145984|NCT03755375|Placebo Comparator|Postural Control Group|The Postural Control Group will start treatment 3 months after the assessment:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
11145985|NCT03755362|Active Comparator|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
11145986|NCT03755362|Experimental|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
11145987|NCT03755349|Experimental|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
11145988|NCT03755349|Active Comparator|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
11145989|NCT03755310|Experimental|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
11145990|NCT03755310|Placebo Comparator|Placebo|Equivalent dosage, route of administration and dose regimen.
11145991|NCT03755297|Other|Rheumatoid arthritis|Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
11145992|NCT03755297|Other|Osteoarthritis|Control patients and Blood sample analysis of patients treated as standard care
11145993|NCT03755297|Other|Rheumatoid arthritis with JAK/STAT inhibitors|Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care
11145994|NCT03755284|Experimental|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.
~For the pregnant women included in the experimental group:
~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
11145995|NCT03755284|No Intervention|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.
~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.
~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.
~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.
~Birth action follow-up form and postpartum interview forms were applied"
11145996|NCT03755258|Experimental|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
11145997|NCT03755258|Experimental|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
11145998|NCT03755258|Experimental|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
11146000|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical
11146001|NCT03755232|Experimental|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
11146002|NCT03755232|Experimental|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
11146003|NCT03755232|Active Comparator|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
11146004|NCT03755232|Active Comparator|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
11146005|NCT03755219||Swedish TEP/TAPP during 13 years|All laparoscopic repairs in the Swedish Hernia Registry 2005-2017
11146006|NCT03755206|Other|Intervention|Interrupted time series design
11146007|NCT03755193|Active Comparator|SERM plus ELD|To examine the effects of SERM plus ELD in osteoporosis patients
11146008|NCT03755193|Active Comparator|BP plus ELD|To examine the effects of BP plus ELD in osteoporosis patients
11146009|NCT03755193|Active Comparator|ELD alone|To examine the effects of ELD alone in osteoporosis patients
11146010|NCT03755180|Experimental|Group 1|Exercise Group
11146011|NCT03755180|Active Comparator|Group 2|Compression Group
11146012|NCT03755167|Experimental|IPL344|IV IPL344 administered once a day
11146013|NCT03755154|Experimental|S65487|
11146014|NCT03755141|Experimental|Herzuma|Herzuma + TPC
11146015|NCT03755128||Pregnant women and their offspring from current pregnancy|
11146016|NCT03755115|Experimental|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, D1,30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
11146017|NCT03755102|Experimental|Metastatic EGFR-Mutant Lung Cancer with evidence of C797S|
11146018|NCT03755102|Experimental|Metastatic EGFR-Mutant Lung Cancer with no evidence of C797S|
11146019|NCT03755089|Active Comparator|Oral Phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200mg phenazopyridine to take by mouth 1-2 hours before their scheduled procedure.
11146020|NCT03755089|Active Comparator|Intravesical Lidocaine|Patients randomized to the intravesical lidocaine arm will have the bladder back-filled with 30mL 2% lidocaine for the 20 minutes immediately preceding their procedure.
11146021|NCT03755076|Experimental|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
11146022|NCT03755063|Experimental|Treatment arm|Tablet with speech therapy apps
11146023|NCT03755063|No Intervention|Standard of Care|The standard care provided by speech language therapists.
11146024|NCT03755050||Sleigh Accident|Accident while using a sleigh
11146025|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
11146026|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
11146027|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
11146028|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
11146029|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
11146030|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
11146031|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
11146032|NCT03755037|Active Comparator|Estradiol and cc|"Group 1 received estradiol, cc and placebo simillar to sildenafil for induction of ovulation.
~CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient then ethinyl estradiol 0.05mg orally twice daily on the 8th day of same cycle till 11th day."
11146033|NCT03755037|Active Comparator|Sildenafil and cc|Group 2 received CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient, sildenafil citrate (Respatio) 20 mg tab orally 3 times daily from8th day of same cycle till 11th day and placebo simillar to estradiol.
11146034|NCT03755037|Placebo Comparator|Placebo and cc|Group 3 received cc and placebo similar to sildenafil and placebo similar to estradiol with the same doses.
11146035|NCT03755024||normal group|fetuses with normal growth
11146036|NCT03755024||Growth retardation group|fetuses with retarded growth
11146037|NCT03755011|Experimental|patients exposed to white noise|Six patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined; pausing will be at nurse, provider, and patient discretion during routine care and conversations with the patients.
11146038|NCT03755011|Placebo Comparator|usual care|Six patients exposed to normal ICU activity noise.
11146039|NCT03754998|Experimental|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
11146040|NCT03754985||Hyperbaric Oxygen Therapy|The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.
11146078|NCT03754660|Experimental|Untreated patients (Part B)|The highest safe, well tolerated and effective dose of Part A will be chosen for Part B.
11146041|NCT03754972|Experimental|Lumbar spinal stenosis surgery candidate|Patients with lumbar spinal stenosis and spondylolisthesis that have previously consented to surgical treatment. After recording the initial surgical plan, the Sagittal plane shear index (SPSI) will be provided to the surgeon. The surgeon may change the initial surgical plan based on the stability metric.
11146042|NCT03754959|Experimental|Dose Group 1|
11146043|NCT03754959|Experimental|Dose Group 2|
11146044|NCT03754959|Experimental|Dose Group 3|
11146045|NCT03754959|Experimental|Dose Group 4|
11146046|NCT03754959|Experimental|Dose Group 5|
11146047|NCT03754933|Experimental|Ad/PNP + fludarabine phosphate, 5 cycles|
11146048|NCT03754920|Experimental|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
11146049|NCT03754907|Experimental|stapled anastomosis group|Following the first side-to-side anastomosis at the antimesenteric border in both intestinal limbs, the staple lines are oversewn to reinforce the crotch. Thereafter, the stapler is again fired across the joined intestinal limbs to close the enterotomies. The suture line of the side-to-side anastomosis should not overlap, and the staple lines are oversewn to reinforce the double-stapled areas.
11146050|NCT03754907|Active Comparator|hand-sewn anastomosis group|Patients chose HA group will performed in an end-to-end manner using absorbable suture material.
11146051|NCT03754894|Experimental|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
11146052|NCT03754894|Experimental|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
11146053|NCT03754855||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria
11146054|NCT03754842|Placebo Comparator|Placebo|
11146055|NCT03754842|Experimental|Nicotinamide Riboside + Pterostilbene|
11146056|NCT03754829|Experimental|HSKA - Web Group|The first experimental group will receive direct access to the web version of HSKA.
11146057|NCT03754829|Experimental|HSKA - Mobile Group|The second experimental group will receive direct access to the mobile app of HSKA as well as automated supportive text messages based on PST.
11146058|NCT03754829|No Intervention|Control Group|The control group consists of a wait-list and for ethical reasons, participants in this group will gain access to the intervention (either web or mobile application) four months after the baseline.
11146059|NCT03754816|Experimental|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
11146060|NCT03754803||Treatment naïve subjects with HIV infection|Treatment naïve HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included
11146061|NCT03754803||Pre-treated subjects with HIV infection|Pre-treated HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included.
11146062|NCT03754790|Experimental|Fitusiran|Fitusiran fixed dose, once-monthly subcutaneous injection for 48 months
11146063|NCT03754777|Experimental|Modified ERAS protocol group|"Laparoscopic appendectomy with modified ERAS protocol group Preadmission. Not available due to the emergency setting. Preoperative care.
~1) Patient brochure with a detailed description of the type of pathology, surgery procedure, rehabilitation process, possible complications, and other.
~Surgery.
~Low pressure (8-9 mmHg) pneumoperitoneum.
~Routinely remove of appendix mesentery in presence of any signs of its inflammation.
~Additional local anesthesia with 0.25% ropivacaine.
~Abdominal cavity draining only in patients with perforated appendicitis and diffuse peritonitis (Gomes 5).
~Postoperative care.
~Early mobilization (2 h after surgery)
~Early fluid intake (2 h after surgery)
~Early liquid food (6 h after surgery)"
11146064|NCT03754777|Placebo Comparator|Standard care group|"Standard care laparoscopic appendectomy. Preadmission. Not available due to emergency setting. Preoperative care. 1) Patient oral informing about the type of pathology, surgery procedure and possible complications. No brochure.
~Surgery.
~Standard pressure (12-14 mmHg) pneumoperitoneum
~Abdominal draining for patients with perforated and not perforated appendicitis complicated by abscess, local or diffuse peritonitis (Gomez ≥ 3A).
~Appendix mesentery removing in the appearance of its necrotic changes.
~No intraabdominal anesthesia. Postoperative care.
~1) Mobilization in 4-6 h after surgery 2) Fluid intake in 6 hours 3) Liquid food intake in 12 hours"
11146065|NCT03754751|Experimental|Modified ERAS program group|Laparoscopic cholecystectomy with the implementation of modified ERAS program
11146066|NCT03754751|Active Comparator|Conventional care group|Laparoscopic cholecystectomy with standard perioperative treatment
11146067|NCT03754738|Experimental|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
11146068|NCT03754738|Active Comparator|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
11146069|NCT03754725|Experimental|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
11146070|NCT03754725|Placebo Comparator|Control|this group will only receive the placebo (sugar pill)
11146071|NCT03754712|Active Comparator|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
11146072|NCT03754712|No Intervention|SSRIs|Patients treated with SSRIs
11146073|NCT03754699|Experimental|Patients with a therapeutic educational intervention|Arm 1 : Interventional group: A therapeutic educational intervention is performed following pre-anesthesia assessment
11146074|NCT03754699|Active Comparator|Patients without therapeutic educational intervention|Arm 2 : Control group: standard information on pain is performed following pre anesthesia assessment
11146075|NCT03754686|Active Comparator|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
11146076|NCT03754686|Active Comparator|Paracetamol|best medical care and oral paracetamol twice daily for five days.
11146077|NCT03754660|Experimental|Untreated patients (Part A)|Untreated PAH and CTEPH patients will be enrolled to test 3 ascending doses of BAY1237592 with 4 patients per dose group up to a maximum dose of 1000 µg.
11146079|NCT03754660|Experimental|Monotherapy (Part B)|The highest safe, well tolerated and effective dose chosen from Part A will be tested in patients pretreated with PH specific monotherapy.
11146080|NCT03754660|Experimental|Combined therapy (Part B)|The highest safe, well tolerated and effective dose from Part A will be tested in patients dually pretreated with PH specific therapy.
11146081|NCT03754647|No Intervention|Patients receiving SSRIs|This group will be receive SSRIs only
11146082|NCT03754647|Active Comparator|Patients receiving Vitamin C with SSRIs|This group will be receive vitamin C (500mg) twice daily with SSRIs for 8 weeks
11146083|NCT03754634|Experimental|drugs|Eltrombopag and Diacerein
11146084|NCT03754621||Pregnants|400 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment and are TPOAb negative. Serum thyroid functions tests will be obtained on the first visit.
11146085|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
11146086|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
11146087|NCT03754595|Active Comparator|2D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 2D Laparoscopic pancreatoduodenectomy
11146088|NCT03754595|Experimental|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
11146089|NCT03754582|Experimental|Perampanel|Participants will receive 8 to12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4.
11146090|NCT03754569|Experimental|Peritoneal biopsies|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
11146091|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
11146092|NCT03754543|Active Comparator|Testmeal A|A new, whole-grain infant cereal fortified with ferrous fumarate
11146093|NCT03754543|Active Comparator|Testmeal B|An alternative new whole-grain infant cereal recipe fortified with ferrous fumarate
11146094|NCT03754543|Placebo Comparator|Testmeal C|An existing, refined grain infant cereal fortified with ferrous fumarate
11146095|NCT03754543|Active Comparator|Testmeal D|An existing, whole-grain infant cereal fortified with ferrous fumarate
11146096|NCT03754543|Active Comparator|Testmeal E|An existing, whole-grain infant cereal fortified with ferrous bisglycinate
11146097|NCT03754530|Experimental|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(>3 with WBRT or <=3 with SRS) after PD
11146098|NCT03754530|Experimental|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(>3), or SRS(<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
11146099|NCT03754517||Serofast status|The syphilitic patients who remain in a serologically positive state after therapy
11146100|NCT03754517||Untreated|untreated syphilis cases
11146101|NCT03754517||Serological cure|"In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.
~In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer."
11146102|NCT03754504|Experimental|Cranberry|Whole Cranberry Powder Supplements
11146103|NCT03754504|Placebo Comparator|Placebo|Placebo
11146104|NCT03754491|Experimental|One stage stone removal in mild cholangitis|one-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
11146105|NCT03754491|Experimental|One stage stone removal in moderate cholangitis|one-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
11146106|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
11146107|NCT03754465|Experimental|ALLO-ASC-DFU|Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
11146108|NCT03754465|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
11146109|NCT03754439||Inborn|"Infants born within Nottingham University hospitals
~< 32 weeks gestational age
~< 72 hours old"
11146110|NCT03754439||Transported|- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 < 32 weeks gestational age and <72 hours old Phase 2 any gestation and age
11146111|NCT03754413|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
11146112|NCT03754413|Other|Comparator device|No-treatment
11146113|NCT03754400|Experimental|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
11146114|NCT03754400|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
11146115|NCT03754387|Active Comparator|Antibiotic therapy group|Ceftazidime will chosen as the antibiotic for this study because of its efficacy as a monotherapy for serious intraabdominal infections, requiring only a single, daily dose. Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) is administered for 3 days to patients in the AT group, with the first dose given in the emergency department. The clinical status of patients in the AT group is reevaluated within 12 to 24 hours after admission by the surgeon on call. If the surgeon suspected progressive infection, perforated appendicitis, or peritonitis, the patient will underwent appendectomy. Intravenous antibiotic treatment will followed by 7 days of oral cefuroxime (250mg twice daily).
11146687|NCT03750552|Experimental|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
11146116|NCT03754387|Experimental|Laparoscopic Appendectomy group|Laparoscopic appendectomy will performed using. Prophylactic antibiotics (ceftazidime sodium 50mg/kg/dose ) will administered approximately 30 minutes before the incision was made. No further antibiotics will given to patients in the surgical group unless a wound infection was suspected postoperatively.
11146117|NCT03754361|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment
11146118|NCT03754361|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis treatment 3-4 times per week,2-4 hours each time.
11146119|NCT03754348|Experimental|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
11146120|NCT03754348|Other|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
11146121|NCT03754348|Experimental|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
11146122|NCT03754335|Experimental|Lumbar puncture|Lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
11146123|NCT03754335|Active Comparator|Sham lumbar puncture|Sham lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
11146124|NCT03754322|Active Comparator|Standard of care|One quarter of individuals get allocated to the standard of care arm. If the pregnant mothers are symptomatic, they receive microscopy and then are treated with anti-malarial therapy if microscopy is positive. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment.
11146125|NCT03754322|Experimental|Intervention arm microscopy|The remaining three quarters of participants either get randomized to intervention arm 1 or 2. In intervention arm 1, if the pregnant mothers are asymptomatic, they receive microscopy and then are treated with anti-malarial therapy if positive. If it is negative then they receive no treatment. If they are asymptomatic, they also receive microscopy only and then are treated with anti-malarial therapy if is positive. If it is negative then they receive no treatment.
11146126|NCT03754322|Experimental|Intervention arm LAMP and microscopy|The remaining three quarters of participants either get randomized to intervention arm 1 or 2. In intervention arm 2, if the pregnant mothers are symptomatic, they receive LAMP and microscopy and then are treated with anti-malarial therapy if either is positive. If both are negative then they receive no treatment. If they are asymptomatic, they receive LAMP and microscopy and then are treated with anti-malarial therapy if either is positive. If both are negative then they receive no treatment.
11146127|NCT03754309|Experimental|KY1005 lower dose|Low dose KY1005
11146128|NCT03754309|Experimental|KY1005 higher dose|High dose KY1005
11146129|NCT03754309|Placebo Comparator|Placebo|Matched placebo
11146130|NCT03754296||CATCHVIEW stent retriever|
11146131|NCT03754283|Experimental|Silicone|Indirect bonding performed with the silicone trays
11146132|NCT03754283|Active Comparator|Vacuum formed|Indirect bonding performed with the vacuum formed trays
11146133|NCT03754270|Active Comparator|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
11146134|NCT03754270|Experimental|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
11146135|NCT03754257|Experimental|High-frequency Electrical Stimulation|High-frequency Electrical Stimulation for 40 minutos + conventional physiotherapy, during seven days.
11146136|NCT03754257|Sham Comparator|Sham Electrical Stimulation|Sham Electrical Stimulation for 40 minutes + conventional physiotherapy, during seven days.
11146137|NCT03754244|Experimental|TQB3456|p.o. qd
11146138|NCT03754231|Experimental|Aingeal|All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.
11146139|NCT03754218|Experimental|Amnion membrane product treatment area|The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.
11146140|NCT03754218|Active Comparator|SOC Wound Covering treatment area|The donor wound site (Site B) will be covered per SOC (Standard of care).
11146141|NCT03754205|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.
~The laser parameters that will be used are the following: (1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode."
11146142|NCT03754205|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.
~The laser parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode."
11146143|NCT03754192|Other|perfusion computed tomography|Will be realsed before liver surgery
11146144|NCT03754179|Experimental|Arm A phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.
~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
11146174|NCT03753984|Experimental|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
11146145|NCT03754179|Active Comparator|Arm B phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.
~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily until disease progression. At disease progression, add-on of hydroxychloroquine 200 mg twice daily. Treatment until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment"
11146146|NCT03754179|Experimental|Phase 1|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.
~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
11146147|NCT03754166|Experimental|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).
~Visual spatial cueing is displayed in the bedroom and the bathroom."
11146148|NCT03754166|No Intervention|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
11146149|NCT03754153|Experimental|Balanced Binocular Viewing (BBV)|The experimental intervention will be BBV treatment, i.e. viewing movies for one hour or 2x30min/day on a Nintendo 3DSXL console. With this technology, the Investigators will show blurred images to the better-seeing eye and normal images to the amblyopic eye, encouraging the use of the amblyopic eye and improving acuity.
11146150|NCT03754153|Active Comparator|Standard Therapy - Occlusion (patching) or blurring (atropine)|The control intervention will be either atropine eyedrops twice a week or daily occlusion (patching) therapy of the better-seeing eye (which are the current standards). As per clinical standard, parents will be offered the choice of occlusion or eyedrop treatment.
11146151|NCT03754140|Experimental|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
11146152|NCT03754127|Experimental|Active group|tDCS
11146153|NCT03754127|Sham Comparator|Sham group|Sham tDCS
11146154|NCT03754114|Active Comparator|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
11146155|NCT03754114|Active Comparator|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
11146156|NCT03754088||Cystic fibrosis|Three cystic fibrosis patients who are homozygous for the p.Phe508del mutation.
11146157|NCT03754088||Healthy subjects|Three healthy subjects.
11146158|NCT03754075||CME group|The CME group consisted of patients, who underwent elective CME for right-sided colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2013.
11146159|NCT03754075||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for right-sided adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
11146160|NCT03754062|Placebo Comparator|Placebo|Placebo control
11146161|NCT03754062|Experimental|Haloperidol 3mg|Haloperidol
11146162|NCT03754062|Experimental|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
11146163|NCT03754049|Experimental|TLC599 12 mg|12 mg DSP with 100 μmol phospholipid via IA injection;
11146164|NCT03754049|Experimental|TLC599 6 mg|6 mg DSP with 50 μmol phospholipid via IA injection.
11146165|NCT03754049|Active Comparator|DSP 4mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.
11146166|NCT03754036|Experimental|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
11146167|NCT03754036|Experimental|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
11146168|NCT03754010|Placebo Comparator|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
11146169|NCT03754010|Experimental|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
11146170|NCT03754010|Experimental|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
11146171|NCT03754010|Experimental|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
11146172|NCT03753997|No Intervention|Conventional therapy|Patiens´s will come to the clinic for regular contact with a diabetes nurse.
11146173|NCT03753997|Experimental|Treatment by a Psychologist|Patients will meet with a diabetes educated psychologist over 9 months and will come to the clinic for regular contact with a diabetes nurse
11146240|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
11146175|NCT03753984|Experimental|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
11146176|NCT03753971|Experimental|Apneas with and without intervention|Each patient will be his own control.
11146177|NCT03753958|Experimental|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
11146178|NCT03753958|Experimental|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
11146179|NCT03753945|Experimental|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.
~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
11146180|NCT03753932|Experimental|Intervention|Dentures (fixed oral prosthesis) compared with standard treatment (removable oral prosthesis).
11146181|NCT03753919|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.
11146182|NCT03753906|Experimental|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
11146183|NCT03753880|Experimental|Hemopatch|Hemopatch used to cover the resection surface after LR
11146184|NCT03753867|Experimental|Acitretin treatment|
11146185|NCT03753854|Active Comparator|SS patients|"Homozygous sickle cell patients
~Each patient will undergo the following:
~polysomnography and oxygen saturation exam
~calculation of VOC rate within the two previous years
~Blood samples
~Physiological measurements"
11146186|NCT03753854|Experimental|SS patients apneic|"Homozygous sickle cell patients after one year of continuous positive airway pressure treatment
~Each patient will undergo the following:
~polysomnography and oxygen saturation exam
~calculation of VOC rate within the two previous years
~Blood samples
~Physiological measurements"
11146187|NCT03753841|Active Comparator|Adjustment of oral diet|Patients who need a change in their diet regime, in whom FEES shows that they have not the adequat diet.
11146188|NCT03753841|No Intervention|No adjustment of oral diet|Patients who have the adequat diet based on FEES findings.
11146189|NCT03753828||patients de novo colonized by fungi|Patients in Cystic Fibrosis de novo colonized by fungi during their follow-up
11146190|NCT03753815|Active Comparator|19G FNA needle|Patients referred for EUS-guided tissue acquisition of AIP
11146191|NCT03753815|Active Comparator|20G FNB needle|Patients referred for EUS-guided tissue acquisition of AIP
11146192|NCT03753802|Experimental|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
11146193|NCT03753802|Placebo Comparator|Control|The control group will not receive physiotherapy treatment.
11146194|NCT03753789|Experimental|Microwave Ablation|NEUWAVE Microwave Ablation System with AC software for patients undergoing a percutaneous ablation of a soft tissue liver lesion by an interventional radiologist.
11146195|NCT03753776|Placebo Comparator|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
11146196|NCT03753776|Experimental|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
11146197|NCT03753776|Placebo Comparator|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
11146198|NCT03753776|Experimental|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
11146199|NCT03753763|Experimental|Active|Safinamide methanesulfonate film-coated tablets once daily
11146200|NCT03753763|Placebo Comparator|Placebo|Safinamide Methanesulfonate matching placebo film-coated tablets once daily
11146201|NCT03753750|Experimental|Actual stimulation|Subjects enrolled in the
11146202|NCT03753750|Sham Comparator|Sham stimulation|
11146203|NCT03753737||Chemsex|Men who have Sex with Men (MSM) attending an addiction care center for past or present mild, moderate or severe substance-related disorder(s) according to DSM-V criteria, occurring in a sexual context and concerning cathinones, GHB/GBL, methamphetamine, cocaine and/or ketamine.
11146204|NCT03753737||Control|Men who have Sex with Men (MSM) consulting for a PrEP (HIV Pre-Exposure Prophylaxis) prescription who have never used cathinones, GHB/GBL, methamphetamine, cocaine or ketamine before or during sex.
11146205|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
11146206|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
11146207|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
11146208|NCT03753711|Experimental|LDH (lumbar disc hernia)|
11146209|NCT03753698|Experimental|eCoin|Neuromodulation of posterior tibial nerve
11146210|NCT03753685|Experimental|X-396(Ensartinib) Capsule|
11146211|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
11146212|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
11146213|NCT03753659|Experimental|Pembrolizumab with local ablation|"Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2
~Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3
~Pembrolizumab 200mg IV administration 2 days after local ablation
~Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
11146214|NCT03753646|Experimental|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
11146215|NCT03753646|No Intervention|Only lactating allowance|Mothers will receive only lactating allowance
11146216|NCT03753633|Experimental|Speech therapy Group|25 patients will be treated with speech therapy, once a week, during 40 minutes for 12 weeks. Oropharyngeal exercises will be performed under the supervision of a speech therapist. Patients will perform the oropharyngeal exercises at home every day.
11146217|NCT03753633|Sham Comparator|Control Group|25 patients will perform inspiratory and expiratory exercises recruiting diaphragmatic muscle.
11146218|NCT03753620|Experimental|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
11146219|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
11146220|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
11146221|NCT03753581|Experimental|Care protocol plus microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.
~Intervention with microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer."
11146222|NCT03753581|Placebo Comparator|Care protocol plus placebo microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.
~Placebo microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer previously handled that do not emit current."
11146223|NCT03753568|Experimental|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
11146224|NCT03753555|Active Comparator|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
11146225|NCT03753555|Experimental|high-dose statin group|high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.
11146226|NCT03753542|Experimental|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
11146227|NCT03753542|No Intervention|Control|The Control group will receive routine care
11146228|NCT03753529|Experimental|deep friction massage group|
11146229|NCT03753529|Experimental|pressure release group|
11146230|NCT03753529|Experimental|control group|
11146231|NCT03753516|Active Comparator|Laparoscopic - Vaginal Cuff Closure|
11146232|NCT03753516|Active Comparator|Vaginal - Vaginal Cuff Closure|
11146233|NCT03753503|Experimental|PD-TR|"Intervention:
~exercise, dose: 8-week HIIT program (three times a week) & conventional physical therapy"
11146234|NCT03753503|Active Comparator|PD-NTR|conventional physical therapy
11146235|NCT03753503|No Intervention|Healthy controls|healthy controls without any kind of therapy
11146236|NCT03753490|Other|ABC score guided therapy|Individual treatment recommendations based on the ABC-scores for stroke and bleeding.
11146237|NCT03753490|Other|Standard care|Management according to local practice, national and international guidelines.
11146238|NCT03753477|Experimental|Test Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
11146239|NCT03753477|Active Comparator|Reference Drug|Sevikar and Crestor
11146241|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
11146242|NCT03753451|No Intervention|Group 1|20 patients without periodontal disease and coronary artery disease
11146243|NCT03753451|No Intervention|Group 2|20 patients without periodontal disease and with coronary artery disease
11146244|NCT03753451|Active Comparator|Group 3|20 patients with periodontal disease and with coronary artery disease received treatment of periodontal disease
11146245|NCT03753451|Active Comparator|Group 4|20 patients with periodontal disease and without coronary artery disease received treatment of periodontal disease
11146246|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
11146247|NCT03753438||Standard of Care|Patients in this group will be standard of care
11146248|NCT03753425||PEG4L, four liters polyethylene glycol|PEG4L, four liters polyethylene glycol
11146249|NCT03753425||PEG2L, two liters polyethylene glycol with ascorbic acid|PEG2L, two liters polyethylene glycol with ascorbic acid
11146250|NCT03753425||Pico, sodium picosulfate|Pico, sodium picosulfate
11146251|NCT03753425||NaP, sodium phosphate|NaP, sodium phosphate
11146252|NCT03753425||MPS, sodium, magnesium and potassium sulphates|MPS, sodium, magnesium and potassium sulphates
11146253|NCT03753412||ICUAW ECMO group|The physical and psychological effects of ICUAW on patients receiving extracorporeal membrane oxygenation for severe cardiorespiratory failure will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
11146254|NCT03753399|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
11146255|NCT03753399|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
11146256|NCT03753399|No Intervention|Usual care|Chemotherapy without acupuncture
11146257|NCT03753386|Experimental|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
11146258|NCT03753373|Experimental|Acupuncture and Home Exercise|Acupuncture plus the prescribed home exercise program
11146259|NCT03753373|Active Comparator|Home Exercise Only|The prescribed home exercise program alone
11146260|NCT03753360|Other|Intervention Group|internet-based mindfulness meditation program
11146261|NCT03753360|Other|Active Control Group|relaxing music
11146262|NCT03753347|Experimental|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
11146263|NCT03753334|Experimental|MAG-EPA group|5g/day of omega-3-rich fish oil capsules, which include 4g of purified EPA, to be taken once a day, for 12 months.
11146264|NCT03753334|Placebo Comparator|Placebo group|5g/day of high-oleic sunflower oil capsules, to be taken once a day, for 12 months.
11146265|NCT03753321|Experimental|Whey protein|Whey protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
11146266|NCT03753321|Experimental|Soy protein|Soy protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
11146267|NCT03753321|Placebo Comparator|Placebo (maltodextrin)|Isoenergetic, maltodextrin (7 day pre-loading phase and 3 day training phase)
11146268|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling
~Eligibility criteria :
~Male or female, Age of 18 or older, Weight over 40kg
~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA
~Patients who signed a non-opposition
~Patient affiliated to social security insurance
~HBsAg positive for more than 6 months
~known status of HBeAg (positive or negative)
~Treated or not with an antiviral"
11146269|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy
~Eligibility criteria :
~Male or female, Age of 18 or older, Weight over 40kg
~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA
~Patients who signed a non-opposition
~Patient affiliated to social security insurance
~HBsAg positive for more than 6 months
~known status of HBeAg (positive or negative)
~Treated or not with an antiviral
~Patient with a liver biopsy indication as part of the treatment within 3 months."
11146270|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy
~Eligibility criteria :
~Male or female, Age of 18 or older, Weight over 40kg
~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA
~Patients who signed a non-opposition
~Patient affiliated to social security insurance
~The existence of at least one element of metabolic syndrome
~Steatosis detected by non-invasive tests (echo, CAP, MRI)"
11146271|NCT03753308||3, Blood samples from healthy donors|"No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.
~The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
11146272|NCT03753295||Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
11146273|NCT03753295||Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
11146274|NCT03753295||Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
11146275|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
11146276|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
11146277|NCT03753269|Experimental|Fasudil Hydrochloride|Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
11146278|NCT03753269|Placebo Comparator|Placebo saline|Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
11146279|NCT03753256|Active Comparator|Transbond XT|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm
~the development of demineralization
~its adverse effects after application"
11146280|NCT03753256|Experimental|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).
~The investigators will evaluate in this arm
~its abrasion behavior and the development of demineralization
~its adverse effects after the application"
11146281|NCT03753256|Experimental|Pro Seal®|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).
~The investigators will evaluate in this arm
~its abrasion behavior and the development of demineralization
~its adverse effects after the application"
11146282|NCT03753256|Experimental|Opal® Seal|"Application of different orthodontic surface sealants to participants:
~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).
~The investigators will evaluate in this arm
~its abrasion behavior and the development of demineralization
~its adverse effects after the application"
11146283|NCT03753243|Experimental|Intervention|Treatment will be planned for a total of 14 to 16 weeks. Pembrolizumab will be administered every 3 weeks via IV infusion with a dose of 200 mg per infusion. Enzalutamide will be given orally and dispensed to the patient on the date of their first infusion. The dosage of Enzalutamide will be 160 mg, administered once daily for approx. 16 weeks. GNRH agonist therapy will be administered as a standard of care therapy and will follow a standard dosage to maintain castrate levels.
11146284|NCT03753230|Experimental|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
11146285|NCT03753230|Experimental|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
11146286|NCT03753230|Active Comparator|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
11146287|NCT03753217|Experimental|qCON Monitor|Simultaneous measurement of BIS and qCON
11146288|NCT03753204|Experimental|Weinberger protocol|During the Weinberger protocol, salt loading will be achieved by the combination of a high-salt diet (isocaloric, 160 mEq Na and 70 mEq K), and an infusion of 2L of saline (300 mEq Na+). Patients will have free access to water but their food will be limited to that provided by the protocol. Salt depletion will be accomplished by administering an isocaloric diet containing 10 mEq Na and 70 mEq K and continued unlimited water intake. At 8 am, 12 noon and 4 pm, subjects will be given 40 mg of furosemide or lasix orally.
11146289|NCT03753191|Experimental|People with Dementia|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. A 2mA direct current for active tDCS (current density : .057 mA/cm2) with a 20 mins stimulation period
11146290|NCT03753191|Sham Comparator|Health Control|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. After a fade in period of 10s to mimic initial tDCS peripheral skin sensations, the stimulator will be turned off in order to prevent the induction of any neuromodulatory effect.
11146291|NCT03753178||patients|70 participants presented with clinical and motor electrophysiological evidence of common peroneal neuropathy at the fibular neck
11146292|NCT03753178||controls|70 controls
11146293|NCT03753165|Experimental|High Intensity Interval Exercise group|Patients suffering from chronic low back pain perform 12 sessions of high intensity interval exercise (HIIE) over a period of 6 weeks at an intensity of 80% of their maximal Heart rate. In addition they also receive conventional physiotherapy in the form of hot pack or TENS
11146294|NCT03753165|No Intervention|Conventional physiotherapy|Patients suffering from chronic low back pain will receive conventional physiotherapy such as TENS and hot packs applied over appropriate areas over a period of 6 weeks
11146295|NCT03753152|Experimental|Investigational medical device|Neuramis® Deep Lidocaine
11146296|NCT03753152|Active Comparator|Comparator device|YVOIRE® Volume Plus
11146297|NCT03753139||Atrial fibrillation|Patients with atrial fibrillation as recorded by Holter
11146298|NCT03753139||Sinus rhythm|Patients with sinus rhythm as recorded by Holter
11146299|NCT03753126|Other|Cardiac CT imaging|
11146300|NCT03753113|Experimental|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
11146301|NCT03753113|Active Comparator|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
11146302|NCT03753100|Active Comparator|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
11146303|NCT03753100|Active Comparator|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
11146304|NCT03753087|Experimental|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
11146305|NCT03753087|Active Comparator|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
11146306|NCT03753074|Experimental|Treatment Arm A (TAF)|390 subjects administered Tenofovir Alafenamide 25 mg once daily
11146307|NCT03753074|No Intervention|Treatment Arm B (Best supportive care)|"390 subjects received best supportive care
~During treatment period, among treatment arm B, subjects who are indicated for antiviral treatment by AASLD 2018 Guidelines of CHB (ALT 70≥ for male, 50≥ for female) will be treated with Tenofovir Alafenamide ."
11146308|NCT03753061|Experimental|Aspiration Catheter|Mechanical thrombectomy with Aspiration Catheter.
11146309|NCT03753061|Active Comparator|Stent Retriever (Solitaire FR)|Mechanical thrombectomy with Solitaire FR.
11146310|NCT03753048|Active Comparator|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
11146311|NCT03753048|Active Comparator|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
11146312|NCT03753035||epileptic children|Completion of questionnaire, during medical consultation, on compliance and quality of life
11146316|NCT03753009||iontophoretic transepithelial corneal cross-linking (I-ON CXL)|Twenty eyes of 15 patients with keratoconus (mean age 13±3.5 [SD] years, range 9 to 18) underwent Iontophoresis epi-on CXL
11146317|NCT03753009||epithelium-off collagen cross-linking (epi-off CXL)|Twenty eyes of 13 patients with keratoconus (14±4 [SD] years, range 10 to 18) underwent standard epi-off CXL
11146318|NCT03752996|Experimental|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
11146319|NCT03752983||cases|patients with SLE
11146320|NCT03752983||controls|Healthy people
11146321|NCT03752970|Experimental|Spesolimab|
11146322|NCT03752970|Placebo Comparator|Placebo|
11146323|NCT03752944|Experimental|prebent plate|fixation of le fort I osteotomy using prebent plate
11146324|NCT03752944|Active Comparator|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
11146325|NCT03752931|Active Comparator|Celiprolol|receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
11146326|NCT03752931|Active Comparator|Diltiazem|receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
11146327|NCT03752918|Experimental|MDMA|MDMA (1.5mg/kg)
11146328|NCT03752918|Placebo Comparator|Niacin|Niacin (250mg)
11146329|NCT03752905|Experimental|PTR-01 0.1 mg/kg|Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
11146330|NCT03752905|Experimental|PTR-01 0.3 mg/kg|Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
11146331|NCT03752905|Experimental|PTR-01 1.0 mg/kg|Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
11146332|NCT03752905|Placebo Comparator|Normal Saline|Saline control to mimic PTR-01.
11146333|NCT03752905|Experimental|PTR-01 3.0 mg/kg|Three intravenous infusions of PTR-01 at 3.0 mg/kg with doses 2 weeks apart.
11146334|NCT03752892|Experimental|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
11146335|NCT03752892|Active Comparator|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
11146336|NCT03752879||Case (Kristaller Group)|Group of kristeller maneuver applied in the second stage of labor due to clinical necessity.
11146337|NCT03752879||Control (no Kristaller Group)|The control group not required to kristeller maneuver
11146338|NCT03752866|Experimental|Portico™ Valve, Delivery System(s) and Loading Systems(s)|
11146339|NCT03752853|Experimental|iCBT for depression - behavioral activation first (BAF)|internet-based intervention for mild to moderate depression: patients receive behavioral activation first, followed by cognitive restructuring
11146340|NCT03752853|Experimental|iCBT for depression - cognitive restructuring first (CRF)|internet-based intervention for mild to moderate depression: patients receive cognitive restructuring first, followed by behavioral activation
11146341|NCT03752840|Experimental|Screening|
11146342|NCT03752840|Active Comparator|Case detection|
11146343|NCT03752827|Experimental|Adipose Derived Regenerative Cells|Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear
11146344|NCT03752827|Active Comparator|Corticosteroid|Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
11146345|NCT03752814|Experimental|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
11146346|NCT03752801||Script Review Parents/Caregivers|will have script reviewed and evaluated by parents/caregivers in groups of 5 up to 40 participants until 4/5 parents/caregivers demonstrate that script is understandable and acceptable.
11146347|NCT03752801||Video Review Parents/Caregivers|review and evaluation of the developed educational videos by parents/caregivers up to 20 parents who have not participated in the script review
11146348|NCT03752788|Experimental|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.
~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
11146349|NCT03752788|Active Comparator|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.
~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
11146350|NCT03752775|Experimental|subacute device assisted group|
11146351|NCT03752775|Active Comparator|subacute conventional group|
11146352|NCT03752775|Other|chronic device assisted group|
11146353|NCT03752762|No Intervention|Standard Care|Participants will receive standard health care services provided by the Health Secretary
11146390|NCT03752502|Experimental|Cerebral stimulation|"Active transcranial direct current stimulation
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
11146423|NCT03752294|Active Comparator|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
11146354|NCT03752762|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
11146355|NCT03752749|Experimental|Prednisolone + Acute Intermittent Hypoxia|
11146356|NCT03752749|Placebo Comparator|Placebo + Acute Intermittent Hypoxia|
11146357|NCT03752736|Active Comparator|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
11146358|NCT03752736|No Intervention|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.
~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
11146359|NCT03752723|Experimental|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination
~Assigned interventions: CPA, GX-I7 and pembrolizumab"
11146360|NCT03752723|Experimental|combination with GX-I7, and pembrolizumab|"Experimental: combination
~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
11146361|NCT03752710||Acute primary angle closure|
11146362|NCT03752710||Acute secondary angle closure induced by LS|
11146363|NCT03752710||Cataract|
11146364|NCT03752710||Primary chronic angle closed glaucoma|
11146365|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
11146366|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
11146367|NCT03752684|Experimental|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine and plasma.
~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
11146368|NCT03752684|Experimental|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.
~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
11146369|NCT03752684|Experimental|Oxalobacter formigenes|Subjects will ingest a liver preparation of O.formigenes
11146370|NCT03752671|Experimental|the IntraSPINE® device associated with discectomy|
11146371|NCT03752671|Active Comparator|discectomy alone|
11146372|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
11146373|NCT03752645|Experimental|intervention|Transverse Many Channels Laser Instrument
11146374|NCT03752645|No Intervention|control|
11146375|NCT03752632|Experimental|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
11146376|NCT03752632|Active Comparator|Tourniquet (control)|Control: Tourniquet
11146377|NCT03752619|Experimental|Contraction Producing Peripheral Nerve Stimulation|This group will receive: 1) muscle contraction producing peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
11146378|NCT03752619|Active Comparator|Non Contracting Producing Peripheral Nerve Stimulation|This group will receive: 1) non contraction producing peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
11146379|NCT03752606|Active Comparator|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
11146380|NCT03752606|No Intervention|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
11146381|NCT03752593||Obese|Patients with a BMI of greater than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
11146382|NCT03752593||Non-Obese|Patients with a BMI of less than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
11146383|NCT03752580|Experimental|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
11146384|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
11146385|NCT03752541|Experimental|BCMA-UCART|Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1*10~6/KgBW, 1-2*10~6/KgBW,2-3*10~6/KgBW.
11146386|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
11146387|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
11146388|NCT03752515||case|
11146389|NCT03752515||control|
11146521|NCT03751670|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician.
11146391|NCT03752502|Experimental|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
11146392|NCT03752502|Sham Comparator|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)
~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
11146393|NCT03752502|Experimental|Peripheral stimulation|"Active peripheral electrical stimulation (PES).
~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
11146394|NCT03752489|Experimental|Fluid treatment-specific algorithm|The experimental arm will involve patients monitored by the fluid treatment-customized version of InSight.
11146395|NCT03752489|Active Comparator|Standard InSight|The control arm will involve patients monitored with the standard, non-treatment specific version of InSight.
11146396|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
11146397|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
11146398|NCT03752463|Experimental|DAOI-A group|
11146399|NCT03752463|Experimental|DAOI-B group|
11146400|NCT03752463|Experimental|DAOI-C group|
11146401|NCT03752463|Placebo Comparator|Placebo group|
11146402|NCT03752450||ICU patients|All patients admitted to ICU >48 hours will be included. Eventually, a number of these patients will develop hypernatremia and form the cases. The patients who will not develop hypernatremia will be assigned as the controls.
11146403|NCT03752437|Experimental|Real Weight|Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
11146404|NCT03752437|Experimental|Ideal Weight|Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
11146405|NCT03752424|Active Comparator|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
11146406|NCT03752424|Placebo Comparator|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
11146407|NCT03752411|Experimental|Research Bottle|This group will have medication dispensed in a research bottle.
11146408|NCT03752411|Placebo Comparator|Regular prescription Bottle|This group will have medication dispensed in a regular prescription bottle
11146409|NCT03752398|Experimental|XmAb®23104|XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles
11146410|NCT03752385|No Intervention|Control Group|No intervention
11146411|NCT03752385|Experimental|Intervention Group|"Will cut their smartphone screen time in half, sleep without phone in bedroom, and have a bedtime for their phone use."
11146412|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
11146413|NCT03752359|Experimental|whey protein group|Participants received a dose of 35 grams of whey protein after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
11146414|NCT03752359|Placebo Comparator|placebo group|Participants received a dose of 35 grams of maltodextrin after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
11146415|NCT03752346|No Intervention|control group|Control group maintained their regular lifestyle and received the routine care
11146416|NCT03752346|Experimental|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
11146417|NCT03752333|Experimental|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
11146418|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
11146419|NCT03752307|Experimental|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
11146420|NCT03752307|Placebo Comparator|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
11146421|NCT03752294|Active Comparator|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
11146422|NCT03752294|Placebo Comparator|Placebo|Participants will receive placebo daily for a total of 9-months.
11146424|NCT03752281||Health and activity|The cohort consists of long-term social assistance recipients where there is need to investigate the health status and working ability.
11146425|NCT03752268|No Intervention|Enhancing Cancer Pain Management Part 1|"Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline
~Will then use MEMS to monitor LA opioid intake over approximately 8 weeks
~A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
11146426|NCT03752268|Experimental|Enhancing Cancer Pain Management Part 2|"Enhancing Cancer Pain Management will consist of 3 individual manualized sessions
~The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.
~Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.
~Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
11146427|NCT03752255|Experimental|Anxiety measurement method|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). Then patients will watch a video about impacted tooth. This video will include the complications that patients may face and what should be done after the procedure. After the watching the video, patients will fill the both DAS and STAI.
11146428|NCT03752255|Placebo Comparator|Control|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). The verbal information in detail will be given to the patients by the surgeon.This verbal information will include the complications that patients may face and what should be done after the procedure.
11146429|NCT03752242|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
11146430|NCT03752242|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Acne of the face.
11146431|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 610|
11146432|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
11146433|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 430|
11146434|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 420|
11146435|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 520|
11146436|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 450|
11146437|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 545-549|
11146438|NCT03752229|Experimental|Owem Mumford lancet|
11146439|NCT03752229|Experimental|Medicore lancet|
11146440|NCT03752229|Experimental|Arkray lancet|
11146441|NCT03752229|Experimental|Medipurpose lancet|
11146442|NCT03752229|Experimental|Sterilance lancet|
11146443|NCT03752229|Experimental|Dynarex lancet|
11146444|NCT03752229|Experimental|Ypsomed lancet|
11146445|NCT03752229|Experimental|Promismed lancet|
11146446|NCT03752229|Experimental|Cambridge Sensors lancet|
11146447|NCT03752216|Experimental|NIRAPARIB|Oral Niraparib Daily
11146448|NCT03752203|Experimental|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
11146449|NCT03752190|Experimental|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
11146450|NCT03752177|Experimental|LY3415244 Dose Escalation|LY3415244 administered intravenously (IV).
11146451|NCT03752177|Experimental|LY3415244 Dose Expansion|LY3415244 administered IV.
11146452|NCT03752164|Experimental|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
11146453|NCT03752151|Experimental|MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode|Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.
11146454|NCT03752138|Experimental|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
11146455|NCT03752138|Experimental|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
11146456|NCT03752138|Experimental|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
11146457|NCT03752138|Experimental|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
11146458|NCT03752138|Experimental|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
11146459|NCT03752125|Experimental|Flavonoid, caffeine|Flavonoid, caffeine capsules
11146460|NCT03752125|Placebo Comparator|Placebo|Placebo capsules
11146461|NCT03752112|Experimental|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
11146462|NCT03752112|Other|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
11146463|NCT03752099|Experimental|VERU-111 4.5mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
11146464|NCT03752099|Experimental|VERU-111 9mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
11146465|NCT03752099|Experimental|VERU-111 18mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
11146466|NCT03752099|Experimental|VERU-111 27mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
11146467|NCT03752099|Experimental|VERU-111 36mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
11146468|NCT03752099|Experimental|VERU-111 45mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
11146469|NCT03752086|Experimental|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
11146470|NCT03752086|Experimental|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
11146471|NCT03752073|Experimental|Trans-cervical cervical balloon|17 F non-latex Foley catheter will be placed and balloon filled with 30 cc of sterile normal saline.
11146472|NCT03752073|Experimental|Hygroscopic cervical dilators|Dilapan-S hygroscopic dilators will be placed into the cervix at the level of the internal os.
11146473|NCT03752060|Experimental|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
11146474|NCT03752060|Active Comparator|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
11146475|NCT03752060|No Intervention|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
11146476|NCT03752047||Suspicion of Sepsis|Patients who are admitted and are diagnosed with sepsis will be recruited for this investigation.
11146477|NCT03752034|Experimental|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
11146478|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
11146479|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
11146480|NCT03752008|Experimental|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
11146481|NCT03752008|Experimental|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
11146482|NCT03751995|No Intervention|Control|Participants from medical centers assigned to the control arm will receive usual care.
11146483|NCT03751995|Experimental|Intervention|Participants from medical centers assigned to the intervention arm will receive access to their choice of a mindfulness app or a webinar-based mindfulness course for 6 weeks.
11146484|NCT03751982|Active Comparator|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
11146485|NCT03751982|Experimental|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
11146486|NCT03751969|Experimental|HSK3486|"0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg)
~."
11146487|NCT03751956|Experimental|HSK3486|0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection
11146488|NCT03751943|Other|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
11146489|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
11146490|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
11146491|NCT03751917||APL patients|The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
11146492|NCT03751904|Other|AcoustiCare|Single Arm
11146493|NCT03751891|Experimental|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
11146494|NCT03751891|Active Comparator|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_A which will be fitted to the participants individual Hearing loss.
11146495|NCT03751891|Active Comparator|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_B which will be fitted to the participants individual Hearing loss.
11146496|NCT03751878|Experimental|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
11146497|NCT03751878|Other|Control arm|Standard peer review process.
11146498|NCT03751865|Experimental|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
11146499|NCT03751865|Active Comparator|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
11146500|NCT03751852|Experimental|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
11146501|NCT03751852|Active Comparator|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
11146502|NCT03751839|Experimental|Diagnostic|The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
11146503|NCT03751826|Experimental|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
11146504|NCT03751826|Experimental|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
11146505|NCT03751826|Active Comparator|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
11146506|NCT03751813|Placebo Comparator|Placebo|placebo supplement
11146507|NCT03751813|Experimental|Supplement|actual supplement
11146508|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
11146509|NCT03751787|Experimental|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
11146510|NCT03751787|Placebo Comparator|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
11146511|NCT03751774|Experimental|MAMAACT|Training of midwives in intercultural communication. A 6 hours course and 2 one hour booster sessions. Distribution of health education materials on warnings signs of pregnancy and health system navigation to pregnant women during antenatal care visits.
11146512|NCT03751774|No Intervention|Control|Care as usual
11146513|NCT03751761|Experimental|durvalumab, tremelimumab, paclitaxel|
11146514|NCT03751748|Sham Comparator|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
11146515|NCT03751748|Experimental|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
11146516|NCT03751735|Experimental|Dose 1|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up
11146517|NCT03751709|Experimental|Subjects|Blinatumomab+Haplo-Mismatched Cell Therapy (HMCT)
11146518|NCT03751696|Experimental|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 2.5 hours. The sessions will be conducted by experienced social workers.
11146519|NCT03751696|Active Comparator|'General wellbeing' class (GMWP)|The participants in the control group will receive four group sessions in a group of 6. Each session will also last for approximately 2.5 hours. The content of the classes includes workshop related to on self-compassion, body-mind-spirit, social relationship, career, family and peer support groups. The classes will be executed by the non-governmental organizations which the project can identify for collaboration.
11146520|NCT03751670|Experimental|PR+conventional treatment|Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
11146522|NCT03751657|Experimental|Insulin 287|Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.
11146523|NCT03751657|Active Comparator|Insulin glargine|Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.
11146524|NCT03751644|Experimental|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
11146525|NCT03751644|No Intervention|Placebo|Patients will not submitted to electrical stimulation.
11146526|NCT03751631|Experimental|Phenylephrine-tropicamide|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser
11146527|NCT03751631|Active Comparator|Phenylephrine|Phenylephrine 2.5% ophthalmic solution administered using a microdose dispenser
11146528|NCT03751631|Active Comparator|Tropicamide|Tropicamide 1% ophthalmic solution administered using a microdose dispenser
11146529|NCT03751618|Experimental|Capsular suture|Capsular suture at the end of hip arthroscopy
11146530|NCT03751618|Active Comparator|No capsular suture|No capsular suture at the end of hip arthroscopy
11146531|NCT03751592|Experimental|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
11146532|NCT03751566|Active Comparator|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
11146533|NCT03751566|Experimental|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
11146534|NCT03751553|Experimental|obstetric gel group|they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel.
11146535|NCT03751553|No Intervention|no intervention group|they will receive the standard care during labor and delivery without the use of the obstetrical gel
11146536|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
11146537|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
11146538|NCT03751527|Experimental|ZENFLEX stent Group|subjects applying ZENFLEX peripheral stent system
11146539|NCT03751514|Experimental|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.
~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.
~Intervention to be administered: Bordetella Pertussis B1917"
11146540|NCT03751514|Experimental|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.
~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.
~Intervention to be administered: Bordetella Pertussis B1917"
11146541|NCT03751514|Experimental|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.
~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
11146542|NCT03751501|Experimental|Experimental Group|Indocyanine green-Guided Targeted Laser photocoagulation combines routine procedures, that are, the detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT. Indocyanine green-Guided Targeted Laser photocoagulation is administered in combination with anti VEGF treatment
11146543|NCT03751501|Sham Comparator|Control Group|Sham laser is administered at randomization visit and repeated if needed 3 month later in combination with anti VEGF treatment
11146544|NCT03751488|Experimental|LY03010 351mg|LY03010 at 351 mg
11146545|NCT03751488|Experimental|LY03010 156 mg|LY03010 at 156 mg
11146546|NCT03751488|Experimental|LY03010 117mg|LY03010 at 117mg
11146547|NCT03751488|Active Comparator|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
11146548|NCT03751475|Experimental|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
11146549|NCT03751475|Active Comparator|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
11146550|NCT03751462|Experimental|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
11146551|NCT03751449|Experimental|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
11146552|NCT03751449|Active Comparator|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
11146585|NCT03751150|No Intervention|Control|Normal training, no intervention
11146553|NCT03751436|Experimental|Treatment (venetoclax, enzalutamide)|Patients receive venetoclax PO QD and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11146554|NCT03751423|Active Comparator|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
11146555|NCT03751423|Active Comparator|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
11146556|NCT03751423|Experimental|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
11146557|NCT03751384|Experimental|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
11146558|NCT03751384|Active Comparator|Drink|Dietary Supplement: Nutrifriend Cachexia
11146559|NCT03751371|Experimental|Walking Training with the HWA Device|Training with HWA device
11146560|NCT03751371|Other|Usual Care|Usual Care
11146561|NCT03751358|Experimental|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
11146562|NCT03751345|No Intervention|Treatment As Usual (TAU)|The TAU condition consists of the standard treatment elements offered to all Gateway (study site) patients, and will be received by patients in both the PW and the TAU-only condition. TAU services during the adolescent's treatment are typically eclectic and mainly entail meeting with the adolescent alone to provide support and psychoeducation, with occasional family therapy sessions. Medication management is offered as needed.
11146563|NCT03751345|Experimental|Parenting Wisely (PW)|In addition to TAU services, the PW arm includes in-person sessions where parents complete computer-administered PW sessions, in-person session including therapist coaching to reinforce PW material and personalize treatment by applying PW skills to individual issues, and access to PW material remotely so parents can access information and skills from home as needed.
11146564|NCT03751332|Other|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
11146565|NCT03751319|Active Comparator|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
11146566|NCT03751319|No Intervention|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
11146567|NCT03751306|Active Comparator|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
11146568|NCT03751306|Placebo Comparator|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
11146569|NCT03751306|Experimental|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
11146570|NCT03751293|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
11146571|NCT03751280|Experimental|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
11146572|NCT03751280|Sham Comparator|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
11146573|NCT03751267|Experimental|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
11146574|NCT03751267|No Intervention|Wait-list control|This group of patients will receive Tuina (massage) 4 weeks after baseline assessments.
11146575|NCT03751254|Experimental|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
11146576|NCT03751241|Experimental|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
11146577|NCT03751228|Experimental|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
11146578|NCT03751215|Experimental|Monofocal IOL|Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery
11146579|NCT03751202|Experimental|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
11146580|NCT03751202|Active Comparator|Reference product|ADVAIR DISKUS® 500/50
11146581|NCT03751176|Experimental|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
~FOLFIRI:
~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
11146582|NCT03751176|Active Comparator|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
11146583|NCT03751163|Active Comparator|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
11146584|NCT03751163|Placebo Comparator|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
11146586|NCT03751150|Experimental|Intervention INT-ALL|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recently performed prospective study in Gothenburg, Sweden. The exercises included cover strength training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
11146587|NCT03751137||Breast Feeding|Infants who, when enrolled, are exclusively breast feeding.
11146588|NCT03751137||Formula Feeding|Infants who, when enrolled, are exclusively formula feeding.
11146589|NCT03751124|Experimental|Relugolix plus E2/NETA|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
11146590|NCT03751124|Placebo Comparator|Placebo tablets and capsules|"Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.
~Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns."
11146591|NCT03751111|Experimental|Naloxone|Naloxone at an sublingual dose of 40 mg daily will be given to each subject.
11146592|NCT03751111|Placebo Comparator|Placebo|Sublingual placebo will be given to each subject.
11146593|NCT03751098|Experimental|Phenylephrine-tropicamide|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser
11146594|NCT03751098|Placebo Comparator|Placebo|Eyewash solution administered using a microdose dispenser
11146595|NCT03751085|Experimental|AW frame|AW frame biopsy
11146596|NCT03751072||Relapse/Refractory|
11146597|NCT03751072||MRD positive|
11146598|NCT03751059|Active Comparator|NSAID|Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op
11146599|NCT03751059|Active Comparator|Steroid|Dexamethasone: used from one week post-op to three months post-op
11146600|NCT03751046|Experimental|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
11146601|NCT03751046|Experimental|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
11146602|NCT03751033|Experimental|BSS and DisCoVisc|Following lens removal and removal of all OVD from the anterior chamber during cataract surgery, the chamber will be filled with BSS and the main incision hydrated with BSS. Intraoperative aberrometry, using the Optiwave® Refractive Analysis with VerifEye+ (ORA), will be performed, and the results of aphakic refraction and suggested IOL power will be recorded in triplicate. Immediately following, the BSS will be replaced with DisCoVisc; and, triplicate readings will be measured under the same conditions.
11146603|NCT03751020|Experimental|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
11146604|NCT03751020|Experimental|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
11146605|NCT03751020|Placebo Comparator|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
11146606|NCT03751007|Experimental|AG019 Cohort 1 - Low Dose/Adults|
11146607|NCT03751007|Experimental|AG019 Cohort 2 - High Dose/Adults|
11146608|NCT03751007|Experimental|AG019 Cohort 3 - Low Dose/Adolescents|
11146609|NCT03751007|Experimental|AG019 Cohort 4 - High Dose/Adolescents|
11146610|NCT03751007|Experimental|Combination Cohort 1 - Adults|
11146611|NCT03751007|Experimental|Combination Cohort 2 - Adolescents|
11146612|NCT03750981|Other|A 13-week pilot intervention study introducing a high-intensi|
11146613|NCT03750968|Experimental|Carotenoid group|The Carotenoid group will receive a commercially available prenatal vitamin/mineral tablet plus a softgel containing lutein/zeaxanthin, vitamin E and docosahexaenoic acid (DHA).
11146614|NCT03750968|Active Comparator|Control group|The Control group will receive the same prenatal vitamin/mineral tablet plus a softgel containing only vitamin E and DHA.
11146615|NCT03750955|Experimental|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where plaque induced gingivitis results from a cessation of oral hygiene in a sextant using a stent-induced biofilm overgrowth model.
11146616|NCT03750955|Active Comparator|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene (tooth brushing with fluoride toothpaste and flossing twice daily) is maintained.
11146617|NCT03750942|Experimental|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
11146618|NCT03750942|No Intervention|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
11146619|NCT03750929|No Intervention|Non physical exercises|Patients will not be submmitted to combined acute physical exercises (strength and aerobic)
11146620|NCT03750929|Experimental|Physical exercises|Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
11146621|NCT03750916|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
11146622|NCT03750903|Experimental|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
11146623|NCT03750903|Active Comparator|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
11146624|NCT03750877|Active Comparator|median approach|Spinal anesthesia will be performed with a conventional median approach
11146625|NCT03750877|Active Comparator|paramedian approach|Spinal anesthesia will be applied with a paramedian approach.
11146626|NCT03750864|Experimental|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
11146627|NCT03750851|Placebo Comparator|GPlacebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
11146628|NCT03750851|Experimental|GCPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
11146629|NCT03750851|Experimental|GLaser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
11146630|NCT03750851|Experimental|GLaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
11146631|NCT03750838|Experimental|Text Messaging Intervention Group|Participants in the TM Intervention condition will be provided a predetermined number of messages per week (based partially on responses from Phase 2 focus group) for 6 weeks delivered on Thursdays, Fridays, and Saturdays, which are the most common days of the week that heavy drinking occurs as well as other days and times that focus group participants indicated would be the most helpful.
11146632|NCT03750838|Active Comparator|Active Control|Participants in the attention only control condition will receive a series of TM based on nutritional data on the same schedule as those in the TM intervention and will complete a 6 week post-intervention assessment as well as all follow-ups.
11146633|NCT03750825|Experimental|Vapers|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
11146634|NCT03750825|No Intervention|Smokers|Smokers will continue to smoke.
11146635|NCT03750825|No Intervention|Nonsmokers non-vapers|Control nonsmokers non-vapers will continue to refrain from smoking or vaping.
11146636|NCT03750812|Active Comparator|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
11146637|NCT03750812|Active Comparator|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
11146638|NCT03750812|Active Comparator|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
11146639|NCT03750812|Active Comparator|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
11146640|NCT03750812|Active Comparator|Highly fit older adults - TV|This arm will sit at rest and watch television
11146641|NCT03750812|Active Comparator|Poorly fit older adults - TV|This arm will sit at rest and watch television
11146642|NCT03750812|Active Comparator|Highly fit young adults - TV|This arm will sit at rest and watch television
11146643|NCT03750812|Active Comparator|Poorly fit young adults - TV|This arm will sit at rest and watch television
11146644|NCT03750799|Experimental|Experimental group|Whole body vibration was applied on the right lower extremity.
11146645|NCT03750799|Sham Comparator|Sham group|Unlike the experimental group, sham vibration was applied to the control group.
11146646|NCT03750786|Experimental|Group A|ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
11146647|NCT03750786|Active Comparator|Group B|mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
11146648|NCT03750773|Active Comparator|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
11146649|NCT03750773|Placebo Comparator|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
11146650|NCT03750760|Active Comparator|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.
~Atorvastatin (80 mg), oral administration daily."
11146651|NCT03750760|Active Comparator|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
11146652|NCT03750747|Experimental|Intervention (Pulse Oximeter)|The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
11146686|NCT03750565|Experimental|Cohort 4|Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
11146653|NCT03750747|No Intervention|Comparison|The comparison facilities will continue providing routine IMCI services as per the existing guidelines. In routine IMCI services, IMCI service providers classify and treat children presenting with cough and difficult breathing based on history and clinical signs only. In routine IMCI services in Bangladesh, PO has not been introduced. Therefore, in the comparison facilities all children clinically classified as 'Pneumonia' will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day)
11146654|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
11146655|NCT03750734||COPD|Chronic obstructive pulmonary disease participants
11146656|NCT03750734||Cystic fibrosis|Cystic fibrosis participants
11146657|NCT03750734||Healthy volunteers|Healthy volunteers
11146658|NCT03750721||Role of rifampin in staphylococcal PJI|retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period
11146659|NCT03750708|Other|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
11146660|NCT03750708|No Intervention|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
11146661|NCT03750695|Experimental|Acute Resistance Exercise|One acute exercise session of 40 minutes of resistance exercise
11146662|NCT03750695|Experimental|Acute Aerobic Exercise|One acute session of 40 minutes of aerobic exercise
11146663|NCT03750695|Placebo Comparator|Acute Resting Session|One session of 40 minutes of quiet rest
11146664|NCT03750682|Active Comparator|Physical Activity Intervention (PA)|The PA intervention will consist of a twice per week group-based moderate-intensity program that includes aerobic, strength, flexibility, and balance training.
11146665|NCT03750682|Placebo Comparator|Health Education Intervention (HE)|The HE intervention will consist of bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics including relevance to older adults, including nutrition, understanding the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services, information on resources, etc.
11146666|NCT03750669|Experimental|Neoadjuvant Chemotherapy|Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.
11146667|NCT03750669|No Intervention|control|Patients receive surgical treatment without any neoadjuvant treatments.
11146668|NCT03750656|Active Comparator|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
11146669|NCT03750656|Active Comparator|Tamsulosin|0.4 mg tab orally daily
11146670|NCT03750643|Experimental|LY3454738 - Part A|Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants
11146671|NCT03750643|Placebo Comparator|Placebo - Part A|Placebo administered IV to healthy participants
11146672|NCT03750643|Experimental|LY3454738 - Part B|LY3454738 administered IV to healthy participants
11146673|NCT03750643|Placebo Comparator|Placebo - Part B|Placebo administered IV to healthy participants
11146674|NCT03750643|Experimental|LY3454738 - Part C|LY3454738 administered IV to participants with atopic dermatitis (AD)
11146675|NCT03750643|Placebo Comparator|Placebo - Part C|Placebo administered IV to participants with AD
11146676|NCT03750617|Experimental|pre-endoscopic screening risk assessment|
11146677|NCT03750617|No Intervention|routine screening|
11146678|NCT03750604|Active Comparator|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.
~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.
~And in males:
~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
11146679|NCT03750604|Placebo Comparator|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.
~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
11146680|NCT03750591||Integrative Korean medicine treatment group|"Observation of pain, function, quality of life, satisfaction, and adverse events in inpatients with lumbar intervertebral disc herniation hospitalized at 4 Korean medicine hospitals
~Interventions:
~Drug: Herbal medicine Procedure/Surgery: Chuna manual therapy Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s)"
11146681|NCT03750578|Experimental|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
11146682|NCT03750578|No Intervention|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
11146683|NCT03750565|Experimental|Cohort 1|Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
11146684|NCT03750565|Experimental|Cohort 2|Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
11146685|NCT03750565|Experimental|Cohort 3|Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
11146964|NCT03748602|No Intervention|Conservative therapy|Physiotherapy and pain relief
11146688|NCT03750552|Placebo Comparator|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
11146689|NCT03750539|Active Comparator|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
11146690|NCT03750539|Experimental|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
11146691|NCT03750526|Experimental|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
11146692|NCT03750526|Active Comparator|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
11146693|NCT03750526|Active Comparator|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
11146694|NCT03750526|Active Comparator|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
11146695|NCT03750513|Experimental|Treatment (LET optimized IMPT)|Patients receive LET optimized IMPT for up to 6 weeks.
11146696|NCT03750500|Experimental|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
11146697|NCT03750500|Placebo Comparator|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
11146698|NCT03750487|Experimental|e-screening & brief intervention (e-SBI)|A two-session (20 minutes each) computer-delivered screening and brief motivational intervention targeting alcohol and drug use. Computerized screening is conducted using the ASSIST. Session 1 of the BI includes personalized feedback, readiness to change interventions, and goal setting. Session 2 will contain motivational content reinforcing engagement in home visiting and promoting consideration of substance use treatment when relevant.
11146699|NCT03750487|No Intervention|Control|The control group will receive routine home visiting.
11146700|NCT03750474|Experimental|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
11146701|NCT03750474|Other|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
11146702|NCT03750461|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
11146703|NCT03750448|Active Comparator|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
11146704|NCT03750448|Active Comparator|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
11146705|NCT03750448|Active Comparator|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
11146706|NCT03750435|Experimental|Ablation for AF or left-sided AT|The patient will be admitted in hospital as for a standard ablation procedure and discharged the next day. The procedure will be carried out without using fluoroscopy and relying on the visualization of the electroanatomical mapping system.
11146707|NCT03750422|Active Comparator|Stratacel|medical grade silicone gel following Picoway Laser treatment
11146708|NCT03750422|Sham Comparator|Vehicle|Clear ultrasound gel following Picoway Laser treatment
11146709|NCT03750409|Active Comparator|Helmet Active Device|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
11146710|NCT03750409|Sham Comparator|Helmet Sham|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
11146711|NCT03750396|Experimental|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.
~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.
~Local treatments for metastatic lesions will be added in this group.
~Local treatments include modalities described below:
~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
11146712|NCT03750383|Experimental|EDP-938 and cyclosporine interaction (Part 1)|
11146713|NCT03750383|Experimental|EDP-938 and prednisone interaction (Part 2)|
11146714|NCT03750357|Experimental|Primary Relief v 2.0 with Paracetamol|Group A will be treated with Primary Relief v 2.0(1 - 100Hz) sweep stimulation with increase in power of the stimulation for fixed interval of time.
11146715|NCT03750357|No Intervention|Only Paracetamol|Group B will be treated with paracetamol drug.
11146716|NCT03750344|Experimental|ChroniSense Polso Respiratory Rate|
11146717|NCT03750331|Active Comparator|traditional patient follow-up|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule (every other week up to 6 months post-transplant, once a month up to year 1, every three months up to year 2 and every 6 months thereafter)
11146718|NCT03750331|Experimental|medically-tailored follow-up with Ap'Telecare|a group of patients assisted by Ap'Telecare and consulting their Transplant Centre following a less stringent schedule of consultations (every month up to 6 months, every other month up to year 1, every six months up to year 2 and once a year thereafter).
11146719|NCT03750318|Experimental|Aingeal|All patients will wear the Aingeal device as part of the vital sign monitoring with opioid delivery system at ward setting.
11146720|NCT03750305|Active Comparator|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
11146721|NCT03750305|Experimental|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
11146722|NCT03750292|Experimental|HEPAirX air filter|
11146723|NCT03750292|Placebo Comparator|Control air filter|
11146724|NCT03750279|Active Comparator|Exercise therapy + LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.
~LLLT applied to the knee 3 times per week for 3 weeks from baseline."
11146725|NCT03750279|Placebo Comparator|Exercise therapy + sham LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.
~Sham LLLT applied to the knee 3 times per week for 3 weeks from baseline."
11146726|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
11146727|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy to relieve pain after arthroscopy for osteochondral lesions of talus
11146728|NCT03750240|Experimental|12 Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
11146729|NCT03750227|Active Comparator|Arm A (Pre-operative SRS)|Within 2 weeks, patients undergo surgery on day 1.
11146730|NCT03750227|Experimental|Arm B (Post-operative SRS)|Within 4 weeks, patients undergo stereostatic radiosurgery on day 1.
11146731|NCT03750214|Experimental|Biop Coplposcopy System|Biop Colposcopy system procedure
11146732|NCT03750201|Experimental|Direct Selective Trabeculoplasty|Treatment by the investigational device.
11146733|NCT03750201|Active Comparator|Selective Trabeculoplasty|Treatment by the comparator device.
11146734|NCT03750175||Colorectal cancer patients|"Clinical utility of ctDNA analysis for treatment decision
~Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer"
11146735|NCT03750162|Experimental|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
11146736|NCT03750162|Experimental|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
11146737|NCT03750162|Experimental|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
11146738|NCT03750149|Experimental|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
11146739|NCT03750136|Experimental|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
11146740|NCT03750136|Active Comparator|high-dose furosemide|furosemide i.v.
11146741|NCT03750123||Kawasaki Disease (KD)|Children 5 years after Kawasaki Disease
11146742|NCT03750123||Healthy controls (HC)|Age- and sexmatched healthy siblings of children after Kawasaki Disease
11146743|NCT03750110|Active Comparator|Usual Care|Smoking Cessation NICE PH48 Guidelines
11146744|NCT03750110|Active Comparator|Intervention|Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
11146745|NCT03750097|Experimental|Walking protocol|Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.
11146746|NCT03750071|Experimental|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
11146747|NCT03750058|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
11146748|NCT03750045|Experimental|Experimental group|For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
11146749|NCT03750032|Experimental|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
11146750|NCT03750032|Experimental|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
11146751|NCT03750032|Experimental|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
11146752|NCT03750019|Experimental|Satisfying rehearsal|Participants completed the satisfying rehearsal task where they rehearsed the satisfying aspects of the lunchtime meal.
11146753|NCT03750019|Experimental|Dissatisfying rehearsal|Participants completed the dissatisfying rehearsal task where they rehearsed the dissatisfying aspects of the lunchtime meal.
11146754|NCT03750019|Active Comparator|Neutral rehearsal|Participants completed the neutral rehearsal task where they rehearsed their journey to campus that day.
11146755|NCT03750006|Experimental|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
11146756|NCT03749993|Other|Screening Arm|Screening
11146757|NCT03749967|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146758|NCT03749967|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146759|NCT03749967|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146760|NCT03749967|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146761|NCT03749967|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146762|NCT03749967|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146763|NCT03749967|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146764|NCT03749967|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146765|NCT03749967|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146766|NCT03749967|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
11146767|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
11146768|NCT03749928|Experimental|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
11146769|NCT03749928|Placebo Comparator|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
11146770|NCT03749915|Active Comparator|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
11146771|NCT03749915|Experimental|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
11146772|NCT03749902|Other|Oxytocin infusion|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.
~The oxytocin group will not receive misoprostol after the membranes have ruptured."
11146803|NCT03749642|Experimental|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
11146804|NCT03749642|Placebo Comparator|placebo|Two capsules, three times a day, for 8 weeks.
11146965|NCT03748589|Experimental|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
11146773|NCT03749902|Other|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).
~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)
~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted
~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
11146774|NCT03749889|Experimental|100 g carbs|100 grams of carbohydrate allowance for the day
11146775|NCT03749889|Active Comparator|MyPlate|Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.
11146776|NCT03749876|Active Comparator|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
11146777|NCT03749876|Experimental|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
11146778|NCT03749863|Experimental|Serial PRP injections|This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to an unilateral vocal fold for a total of 4 injections.
11146779|NCT03749850|Experimental|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide
~Single arm study"
11146780|NCT03749837|Experimental|C- MAC VS|Intubation with C- MAC VS
11146781|NCT03749837|Active Comparator|Video Endoscope|Intubation with standard fiberoptic scope
11146782|NCT03749824|Experimental|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
11146783|NCT03749824|Placebo Comparator|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
11146784|NCT03749811|Experimental|Pupillometry group|A group of participants who receive remifentanil infusion under pupillometry monitoring.
11146785|NCT03749811|No Intervention|Conventional group|A group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.
11146786|NCT03749798|Experimental|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
11146787|NCT03749785|Active Comparator|Regular carbohydrate feeding|Ingestion of 75 g sucrose, given in regular doses for the first 75 minutes of exercise during a time to exhaustion run
11146788|NCT03749785|Active Comparator|Single carbohydrate bolus|Ingestion of 75 g sucrose, given in a single bolus after 75 minutes of exercise, during a time to exhaustion run
11146789|NCT03749772|Experimental|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
11146790|NCT03749772|No Intervention|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
11146791|NCT03749759|Experimental|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
11146792|NCT03749746|Active Comparator|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
11146793|NCT03749746|Experimental|Home Blood Pressure Monitoring|In addition to usual care outlined above, each participant will receive a Bluetooth-enabled blood pressure cuff along with a checklist of proper technique and instructions on use. Women will be prompted to measure their BP across the first week of each month during the intervention. Based on guidelines, participants will take their blood pressure in the morning and evening, each time taking two readings separated by one minute.
11146794|NCT03749746|Experimental|Heart Health 4 New Moms|Participants randomized to this group will receive instruction on the use of Heart Health 4 New Moms internet-based lifestyle intervention and home blood pressure monitoring. The internet-based intervention is comprised of four key components: an online curriculum with modules on healthy eating and physical activity, a self-monitoring and tracking program, a registered dietitian will act as a lifestyle coach for participants and a customized online toolbox.
11146795|NCT03749733|Experimental|Test Product|"Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.
~The tablet will be taken with water and in a fasting condition."
11146796|NCT03749733|Active Comparator|Reference Product|"Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.
~The tablet will be taken with water and in a fasting condition."
11146797|NCT03749720|Other|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
11146798|NCT03749707|Other|SLNs from early-stage cervical cancer patients|Tissue from SLNs removed from early-stage cervical cancer patients are analyzed for HPV.
11146799|NCT03749655|No Intervention|PR+CBT|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy
11146800|NCT03749655|Experimental|PR+CBT+PA Promotion.|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy and physical activity promotion.
11146801|NCT03749642|Experimental|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
11146802|NCT03749642|Experimental|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
11146805|NCT03749642|Active Comparator|Gabapentin|"according to the following scheduling dosage regimen:
~100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);
~300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);
~400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);
~300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
11146806|NCT03749629|Active Comparator|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
11146807|NCT03749629|Placebo Comparator|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
11146808|NCT03749616|Active Comparator|Non-operative Acetaminophen|Acetaminophen will be given to participants for pain control following their injury.
11146809|NCT03749616|Active Comparator|Operative Acetaminophen|Acetaminophen will be given to participants for pain control following their surgery for arm fracture.
11146810|NCT03749616|Experimental|Non-operative NSAID|Ibuprofen will be given to participants for pain control following their injury.
11146811|NCT03749616|Experimental|Operative NSAID|Ibuprofen will be given to participants following their surgery for arm fracture.
11146812|NCT03749603|Experimental|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
11146813|NCT03749590|Experimental|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.
~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
11146814|NCT03749590|Placebo Comparator|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.
~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
11146815|NCT03749577|Experimental|L-citrulline|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
11146816|NCT03749577|Experimental|Beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
11146817|NCT03749577|Placebo Comparator|L-citrulline placebo|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
11146818|NCT03749577|Placebo Comparator|Denitrated beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.
~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
11146819|NCT03749564|Experimental|SMT Only|All patients receive 2 SMT sessions in the first week.
11146820|NCT03749564|Experimental|SMT extended|All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
11146821|NCT03749564|Experimental|SMT with Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm receives 6 additional sessions of activation exercises."
11146822|NCT03749564|Experimental|SMT with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm involves 6 additional sessions of mobilizing exercise."
11146823|NCT03749564|Experimental|SMT with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm involves 6 additions sessions including both activation and mobilizing exercises."
11146824|NCT03749564|Experimental|SMT extended with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm includes 6 additional sessions including both SMT and mobilizing exercises."
11146825|NCT03749564|Experimental|SMT extended with Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm includes 6 additional sessions including both SMT and activation exercises."
11146826|NCT03749564|Experimental|SMT extended with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.
~This arm includes 6 additional sessions including SMT, activation and mobilizing exercises."
11146827|NCT03749551||Participants|diagnostic test - patients serving as their own controls
11146828|NCT03749538|Experimental|Transcranial current stimulation|Transcranial current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated.
11146829|NCT03749538|Placebo Comparator|Placebo|This group will not receive a transcranial current stimulation session.
11146830|NCT03749525|Placebo Comparator|placebo group|5% GS solution
11146831|NCT03749525|Active Comparator|control group|shenfu injection
11146832|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
11146833|NCT03749499|No Intervention|Usual Care|Participants randomized to usual care will receive preprinted discharge instructions on HTN and a 48-72-hour referral to our FQHC (or other community health center if pre-assigned though Illinois Medicaid) to schedule their follow-up appointment (current standard of care)
11146856|NCT03749317|Experimental|Treatment|IVIEW-1201; four times per day (QID) for 7 days
11146857|NCT03749317|Placebo Comparator|Placebo|Placebo; four times per day (QID) for 7 days
11146858|NCT03749304|Experimental|ANI monitor|
11146859|NCT03749291|Experimental|Obemat2.0 Intervention Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
11146834|NCT03749499|Active Comparator|Educational and Empowerment Intervention|"Participants receive:
~HTN Educational Video about high BP, how it is diagnosed, and importance of treatment to prevent secondary complications.
~Visual Echocardiogram Image Clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change behavior and improve their BP.
~Mobile Health and Remote BP monitoring- participants receive an FDA-approved home blood pressure monitoring (HBPM) kit that includes the Nokia wireless BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
~A Post-Acute Care HTN Transition consultation (PACHT-c) with a clinical pharmacist or advanced practice nurse (APN)."
11146835|NCT03749486|Experimental|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
11146836|NCT03749473|Active Comparator|Control|Participants receive a daily message with their step count on the prior day to serve as an active control for 24 weeks (daily performance feedback). No other interventions during the 24-week study
11146837|NCT03749473|Experimental|Choice + Immediate|Participants choose a step goal between 1000-3000 steps greater than their baseline (choice). They are asked to reach their full step goal upon intervention start (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
11146838|NCT03749473|Experimental|Choice + Gradual|Participants are asked to choose a step goal between 1000-3000 steps greater than their baseline (choice). They will be asked to increase their step goal by even increments of 12.5% each week for the 8 weeks of the ramp-up period (gradual). After the 8-week ramp-up period, they will be asked to maintain the step goal for the study. They may change their goal within the range at anytime. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
11146839|NCT03749473|Experimental|Assigned + Immediate|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to reach their full step goal as soon as the intervention begins (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
11146840|NCT03749473|Experimental|Assigned + Gradual|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to achieve their step goal of 2000 steps incrementally over the 8 weeks of the ramp-up period (gradual). After the first 8 weeks, they will be asked to maintain their full step goal of 2000 for the the study. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
11146841|NCT03749460|Experimental|Treatment (nivolumab, ipilimumab, SBRT)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.
11146842|NCT03749447|Experimental|Bardoxolone methyl|"The maximum dosage is determined by proteinuria status from the last on-treatment visit in the prior qualifying study or a screening visit, if necessary. Initial daily dose of bardoxolone methyl will dose-escalate at Week 2, Week 4, and Week 6.
~Patients under the age of 18 will start dosing with bardoxolone methyl capsules every other day during Week 1 and daily at Week 2.
~Patients will receive doses of bardoxolone methyl capsules in an escalating scheme from 5 mg up to no more than 30 mg."
11146843|NCT03749434||Adults with HAIs after VAD therapy|Adult patients who have received a ventricular assist device implant.
11146844|NCT03749421||Prosigna Assay|"Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay
~The results of Prosigna assay will be provided to the study team in a standardized report.
~This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
11146845|NCT03749408|Active Comparator|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
11146846|NCT03749408|Experimental|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
11146847|NCT03749395|Active Comparator|Erector Spinae Plane Block group|"The Erector Spinae Plane block will be done as follow,the patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
~All patients will receive general anesthesia as described in conventional group"
11146848|NCT03749395|No Intervention|Conventional group|"Nothing will be injected
~All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCo2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperative when either heart rate or Non Invasive Blood Pressure report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria."
11146849|NCT03749382|Experimental|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
11146850|NCT03749382|Experimental|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
11146851|NCT03749382|No Intervention|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
11146852|NCT03749369|Active Comparator|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
11146853|NCT03749369|Placebo Comparator|SRP only|Subjects receiving scaling and root planing only
11146854|NCT03749356|Experimental|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
11146855|NCT03749330|Other|CHOP CICU|CICU Team And Loved Ones Communicating (CICU TALC)
11146860|NCT03749291|Active Comparator|Control Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
11146861|NCT03749278|Experimental|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
11146862|NCT03749278|Active Comparator|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
11146863|NCT03749252|Experimental|P03277|
11146864|NCT03749239|Experimental|Effects of collagen protein.|Non-hydrolized collagen protein
11146865|NCT03749226|Active Comparator|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
11146866|NCT03749226|No Intervention|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
11146867|NCT03749213|Experimental|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
11146868|NCT03749200|Experimental|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
11146869|NCT03749200|Active Comparator|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
11146870|NCT03749187|Experimental|Arm A (BGB-290, temozolomide)|Patients with grades III-IV newly diagnosed IDH1/2 mutant glioma receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11146871|NCT03749187|Experimental|Arm B (BGB-290, temozolomide)|"Patients with grades I-IV recurrent IDH1/2 mutant glioma receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
~Cohort B0: Patients who are surgical candidates with grades I-IV recurrent IDH1/2 mutant glioma receive PARP inhibitor BGB-290 PO BID for 7 days, pre-surgery. After recovery from surgery, patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO daily on days 1-21. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
11146872|NCT03749174|Active Comparator|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
11146873|NCT03749174|Active Comparator|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
11146874|NCT03749174|Active Comparator|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthotic postoperatively
11146875|NCT03749174|Active Comparator|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
11146876|NCT03749161|Experimental|Lentis comfort|Patient will receive the low-add multifocal IOL during cataract surgery
11146877|NCT03749161|Experimental|Lentis L-313|Patient will receive the monofocal IOL Lentis L-313 during cataract surgery
11146878|NCT03749148|Active Comparator|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
11146879|NCT03749148|Placebo Comparator|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
11146880|NCT03749135|Active Comparator|Dupilumab|Dupilumab (anti-IL4Ra), s.c. administration
11146881|NCT03749135|Placebo Comparator|Placebo Comparator|matching Placebo, s.c. administration
11146882|NCT03749109|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.
11146883|NCT03749109|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
11146884|NCT03749096|Active Comparator|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
11146885|NCT03749096|Placebo Comparator|Placebo|
11146886|NCT03749083||Tumor Sequencing|"Quality of life assessments will be collected using The Functional Assessment of Cancer Therapy- Colorectal
~Blood for circulating tumor DNA will be collected"
11146887|NCT03749070|Active Comparator|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
11146888|NCT03749070|Placebo Comparator|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
11146890|NCT03749044|Experimental|Patient Educational Tool|At the baseline visit, after having responded to the questionnaire, participants in the education arm will be given the patient educational tool.
11146891|NCT03749044|No Intervention|Standard of Care|Subjects in the standard of care arm will not receive the patient educational tool. If participants ask specific questions on pregnancy complications and/or preeclampsia, the clinicians will provide relevant information as they judge appropriate, but without handing out the patient educational tool.
11146892|NCT03749031|Placebo Comparator|Orange juice only|16 oz. orange juice per day for 4 weeks
11146893|NCT03749031|Experimental|orange juice + orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
11146894|NCT03749031|Placebo Comparator|Apple juice only|16 oz. apple juice per day for 4 weeks
11146895|NCT03749031|Experimental|Apple Juice + Apple Pomace|16 oz. apple juice + apple Pomace per day for 4 weeks
11146896|NCT03749018|Experimental|Treatment (nivolumab, DA-REPOCH)|Patients receive rituximab IV and nivolumab IV over 60 minutes on day 1. Patients also receive etoposide, vincristine sulfate and doxorubicin hydrochloride IV continuously over 96 hours, cyclophosphamide IV bolus, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After course 6, patients receive nivolumab IV over 60 minutes on day 1 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11146897|NCT03748992|Experimental|gNO|evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease
11146898|NCT03748979|Experimental|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
11146899|NCT03748979|Experimental|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146900|NCT03748979|Experimental|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146901|NCT03748979|Experimental|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146902|NCT03748979|Experimental|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146903|NCT03748979|Experimental|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146904|NCT03748979|Placebo Comparator|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
11146905|NCT03748979|Experimental|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in patients with narcolepsy.
11146906|NCT03748979|Experimental|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in patients with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146907|NCT03748979|Experimental|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in patients with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146908|NCT03748979|Experimental|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in patients with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146909|NCT03748979|Placebo Comparator|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in patients with narcolepsy.
11146910|NCT03748979|Experimental|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in patients with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146911|NCT03748979|Experimental|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in patients with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146912|NCT03748979|Placebo Comparator|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in patients with narcolepsy.
11146913|NCT03748979|Experimental|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
11146914|NCT03748979|Experimental|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
11146915|NCT03748966|Experimental|Adults with XLH|Adults with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
11146916|NCT03748966|Experimental|Children with XLH|Children (age 6-17) with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
11146917|NCT03748953|Experimental|Ixazomib|Ixazomib 3 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 1 through Cycle 4, during which period if the participants have been tolerated, the dose may be escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 5 through Cycle 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.
11146960|NCT03748641|Experimental|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
11146961|NCT03748628|Experimental|Single arm EDP-305|
11146962|NCT03748615|Experimental|Computer Guided ridge splitting in posterior mandible|fabrication of a computer aided surgical guide and performing ridge splitting in posterior mandible using piezosurgery
11146918|NCT03748953|Placebo Comparator|Placebo|Ixazomib 3 mg placebo-matching capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 1 through Cycle 4, during which period if the participants have been tolerated , the dose may be escalated to ixazomib 4 mg placebo-matching capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 5 through Cycle 26. Participants experiencing adverse events (AEs) attributed to study drug during any cycle may continue in the study but may have doses of study drug held or reduced by at least 1 dose level. Reduced doses are: 3 mg, 2.3 mg, 1.5 mg and discontinuation of study drug.
11146919|NCT03748940|Placebo Comparator|Part A: Placebo|Placebo administered subcutaneously (SC)
11146920|NCT03748940|Experimental|Part A: LY3074828|LY3074828 administered SC
11146921|NCT03748940|Placebo Comparator|Part B: Placebo|Placebo administered SC
11146922|NCT03748940|Experimental|Part B: LY3074828|LY3074828 administered SC
11146923|NCT03748940|Experimental|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
11146924|NCT03748927||1/ Cohort 1|Subjects with FL-HCC.
11146925|NCT03748914|Experimental|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
11146926|NCT03748914|Active Comparator|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
11146927|NCT03748901||Full analysis set|Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
11146928|NCT03748888|Experimental|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
11146929|NCT03748888|No Intervention|Control Group|Sedentary participants.
11146930|NCT03748875|Experimental|Intervention group|an 8-session mindfulness-based relapse prevention program
11146931|NCT03748875|No Intervention|Control group|treatment as usual
11146932|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.
~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
11146933|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
11146934|NCT03748849||Low back pain group|Males and females who have had low back pain lasting between 12 weeks - 5 years without any other health problems (physical or psychological). Following baseline measurements, all subjects are offered individualized physiotherapy. The interventions mainly consist of exercises targeting their functional limitations. These are supplemented by a thorough explanation of their pain condition. This is done within the boundaries of the current understanding of musculoskeletal pain. This is supplemented with encouragement to do regular exercise and with manual therapy if needed/indicated.
11146935|NCT03748849||Control group|"Healthy males and females who have no current musculoskeletal pain problem (specific to the low back and/or in general). Likewise, they cannot have a previous history of on-going musculoskeletal pain. On-going pain is defined as a condition that limited their function for 3 months or more.
~Participants in the control group take part in the baseline measurement and then another measurement after 6-8 weeks"
11146936|NCT03748836|Active Comparator|Single Ascending Dose ALPN-101|
11146937|NCT03748836|Placebo Comparator|Single Dose Placebo|
11146938|NCT03748836|Active Comparator|Multiple Ascending Dose ALPN-101|
11146939|NCT03748836|Placebo Comparator|Multiple Dose Placebo|
11146940|NCT03748810||Triple OADs failure|Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.
11146941|NCT03748797|Experimental|Exercise group|8-week moderate intensity exercise training under supervision
11146942|NCT03748797|No Intervention|Control group|No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have
11146943|NCT03748784|Experimental|Dose 1|6E11 vg of ADVM-022
11146944|NCT03748784|Experimental|Dose 2|2E11 vg of ADVM-022
11146945|NCT03748758|Active Comparator|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
11146946|NCT03748758|Placebo Comparator|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
11146947|NCT03748758|Active Comparator|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
11146948|NCT03748745|Experimental|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
11146949|NCT03748745|Experimental|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
11146950|NCT03748719|Experimental|Stereotactic Body Radiation Therapy, followed by Prostatectomy|Patients will receive 6 Gy per day of Stereotactic Body Radiation Therapy (SBRT) per day for 5 days, followed by prostatectomy in 3 weeks.
11146951|NCT03748706|Experimental|PTI-125|PTI-125 100 mg oral tablets administered twice daily (BID)
11146952|NCT03748693||POP Group|Women with POP undergoing surgery in our OB/GYN department.
11146953|NCT03748693||Non-POP Group|Women undergoing hysterectomy for other indications.
11146954|NCT03748680|Active Comparator|A|Intensified follow-up schedule
11146955|NCT03748680|Experimental|B|Adjuvant chemotherapy + intensified follow-up schedule
11146956|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
11146957|NCT03748654|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
11146958|NCT03748641|Experimental|Cohort 1: Participants with mCRPC and HRR gene alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg.
11146959|NCT03748641|Experimental|Cohort 2: Participants with mCRPC and No HRR Gene alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg.
11146963|NCT03748602|Experimental|TOD|Thoracic Outlet Decompression (TOD)
11146966|NCT03748589|Experimental|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
11146967|NCT03748589|Experimental|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
11146968|NCT03748589|Experimental|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
11146969|NCT03748576|Experimental|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
11146970|NCT03748576|No Intervention|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
11146971|NCT03748563|Experimental|DS-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (DS-MCE) first, followed by EGD within 48 hours.
11146972|NCT03748550|No Intervention|Control|Participants will receive standard of care treatment for their breast cancer.
11146973|NCT03748550|Experimental|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
11146974|NCT03748537|Experimental|Hydrocortisone|Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped.
11146975|NCT03748537|No Intervention|No Hydrocortisone|In control group, patient will not receive any corticosteroids for seven day after inclusion.
11146976|NCT03748524|Experimental|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
11146977|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
11146978|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
11146979|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
11146980|NCT03748498|Experimental|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
11146981|NCT03748498|Placebo Comparator|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
11146982|NCT03748485|Experimental|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
11146983|NCT03748485|Active Comparator|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
11146984|NCT03489018|Active Comparator|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
11146985|NCT03489018|Experimental|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
11146986|NCT03489018|Experimental|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
11146987|NCT03489018|Active Comparator|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
11146988|NCT03489018|Experimental|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
11146989|NCT03489018|Experimental|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
11146990|NCT03489018|Active Comparator|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
11146991|NCT03748472|Experimental|Bolus feeding|
11146992|NCT03748472|Experimental|continuous gavage feeding|
11146993|NCT03748459||Permanent suture|Subjects will have skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
11146994|NCT03748459||Resorbable suture|Subjects will have skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty
11146995|NCT03748446|Active Comparator|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.
~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
11146996|NCT03748446|Placebo Comparator|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
11146997|NCT03748433|Experimental|Continuous Glucose Monitoring (CGM)|The RT CGM group will receive a Dexcom G6 transmitter and sensors, as well as a structured education refresher focusing on hypoglycaemia avoidance, recognition, and management.
11146998|NCT03748433|No Intervention|Self Monitoring Blood Glucose (SMBG)|The SMBG group will additionally undergo blinded CGM at weeks 1 and 2, weeks 4 to 6 and weeks 9 to 12 using the Dexcom G6 system. Participants in this group will be shown how to insert the Dexcom G6 at the first clinic visit and sensors provided so they can do this at home.
11146999|NCT03748433|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
11147000|NCT03748420|No Intervention|Usual Care|Basic clinical decision support alone
11147001|NCT03748420|Experimental|ReachOut Adherence intervention|Adherence-enhanced clinical decision support plus pharmacist-based adherence outreach
11147002|NCT03748407|Other|dosages in Healthy volunteers|"Only one arm : healthy volunteer blood donors. Performing a blood test for the determination of parameters that explore thyroid status : only once.
~Absence of other healthy volunteers group all healthy volunteers have a blood test performed in the same way."
11147003|NCT03748394|Experimental|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
11147004|NCT03748394|Active Comparator|Physical activity|Physical activity according to national health recommendations
11147005|NCT03748381|Experimental|Trifocal IOL|The patients will receive two different diffractive trifocal IOLs in each eye (AT Lisa tri vs. Rayner trifocal) during cataract surgery
11147006|NCT03748368|Active Comparator|Cataract presentation|Cataract presentation prior to surgery
11147007|NCT03748368|Placebo Comparator|Placebo presentation|Placebo presentation prior to surgery
11147008|NCT03748355|Other|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
11147009|NCT03748342|No Intervention|Standard Endotracheal Tube|
11147010|NCT03748342|Active Comparator|Second-Generation LMA|
11147011|NCT03748303|Experimental|Allo IM cohort|Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
11147012|NCT03748290|Experimental|People with a SCI who will receive Lyrica 75mg for 12 weeks|
11147013|NCT03748290|Placebo Comparator|People with a SCI who will receive Placebo for 12 weeks|
11147014|NCT03748277|Experimental|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
11147015|NCT03748277|Active Comparator|Open Fusion|Bilateral decompression, open fusion + screw fixation
11147016|NCT03748251|Experimental|Short fermented pizza|the patients ate a pizza that fermented for 8 hours
11147017|NCT03748251|Experimental|Long fermented pizza|the patients ate a pizza that fermented for 24 hours
11147018|NCT03748238|Experimental|Injury group|Endometrial injury with hysteroscopy
11147019|NCT03748238|No Intervention|Control group|No hysteroscopy
11147020|NCT03748212|Active Comparator|Group 1|D935 Cap. 1T
11147021|NCT03748212|Experimental|Group 2|CKD-385 Tab. 1T
11147022|NCT03748199|Experimental|POL6014|multiple ascending doses: 80, 160 and 320 mg once or twice daily
11147023|NCT03748199|Placebo Comparator|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
11147024|NCT03748186|Experimental|STRO-002 treatment|STRO-002 at increasing dose levels
11147025|NCT03748173|Experimental|Treatment|Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is > 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at > 4 but < 24 hours if the initial response was positive and there has been subsequent deterioration.
11147026|NCT03748173|No Intervention|Usual Care|The only difference in care between treatment and usual care will be treatment with up to two doses of aerosolized Infasurf®.
11147027|NCT03748160|No Intervention|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
11147028|NCT03748160|Active Comparator|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
11147029|NCT03748160|Active Comparator|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
11147030|NCT03748147|Active Comparator|Control|Standard of care, misoprostol 25 mcg po every four hours
11147031|NCT03748147|Experimental|Intervention|Misoprostol 50 mcg po every four hours
11147032|NCT03748134|Experimental|Sintilimab + chemotherapy|"Sintilimab in combination with investigator's choice of chemotherapy
~TP regimen: Cisplatin + paclitaxel
~or
~CP regimen: Cisplatin + fluorourcil"
11147033|NCT03748134|Active Comparator|Placebo + chemotherapy|"Placebo in combination with investigator's choice of chemotherapy
~TP regimen: Cisplatin + paclitaxel
~or
~CP regimen: Cisplatin + fluorourcil"
11147034|NCT03748121|Experimental|Pranayama + Cognitive Behavioral Therapy (CBT)|To prepare patients for the CBT, they received 5-10 minutes of pranayama befor each of the 10 CBT units.
11147035|NCT03748121|Active Comparator|Cognitive Behavioral Therapy (CBT) + Pranayama|Patients wait for 10 CBT units and then received the pranayama intervention.
11147036|NCT03748108|Experimental|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
11147037|NCT03748108|Placebo Comparator|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
11147038|NCT03748082|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
11147039|NCT03748082|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
11147040|NCT03748069||Influenza positive CAPIV|All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
11147041|NCT03748069||Influenza negative CAPIV|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
11147042|NCT03748056|Experimental|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
11147043|NCT03748056|Active Comparator|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
11147044|NCT03748043|Experimental|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
11147045|NCT03748043|Experimental|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
11147046|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
11147047|NCT03748017|Placebo Comparator|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
11147048|NCT03748017|Active Comparator|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
11147049|NCT03748004|Experimental|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.
~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
11147050|NCT03748004|Placebo Comparator|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.
~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
11147051|NCT03747991||Control Infants|Infants ages 2 months to 12 months who are not on H2RA medication.
11147052|NCT03747991||Treated Infants|Infants ages 2 months to 12 months who are taking H2RA medication.
11147053|NCT03747978|Experimental|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
11147054|NCT03747978|Active Comparator|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
11147055|NCT03747965|Experimental|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
11147056|NCT03747939|Experimental|Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD|Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
11147057|NCT03747939|Placebo Comparator|Placebo|Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.
11147058|NCT03747926|Experimental|BI 705564|
11147059|NCT03747926|Placebo Comparator|Placebo|
11147060|NCT03747913|Experimental|Antioxidative Supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
11147061|NCT03747900|Experimental|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
11147062|NCT03747900|Active Comparator|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
11147063|NCT03747887|Active Comparator|School as Usual|School as usual comparison condition.
11147064|NCT03747887|Experimental|Daily Report Card|A coach will establish a Daily Report Card based on IEP goals and objectives with the parents/teachers of the child in this arm.
11147065|NCT03747874|Other|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
11147066|NCT03747861|Other|Arm for HRV monitoring|For monitoring HRV each subject will put Wristband for registration of ECG RR intervals for one hand, SenceBand in the left wrist and Holter monitor electrodes will be placed in standard configurations places.
11147067|NCT03747848|Experimental|CBT group|Subjects will participate in group treatment sessions (once a week for six weeks).
11147068|NCT03747835|Active Comparator|Exposure and Response Prevention|Inpatients will be provided three 90-minute sessions of Exposure and Response Prevention therapy each week.
11147069|NCT03747835|Active Comparator|Motivational Interviewing|Inpatients will be provided two 60-minute sessions of Motivational Interviewing each week.
11147070|NCT03747822|Active Comparator|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
11147071|NCT03747822|Active Comparator|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
11147072|NCT03747822|Other|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
11147073|NCT03747809||Patients with CIEDs having Remote Monitoring|
11147074|NCT03747809||Patients with CIEDs having no Remote Monitoring|
11147075|NCT03747796|Active Comparator|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
11147076|NCT03747796|Experimental|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
11147077|NCT03747783||Survival Group|status from radical operation to follow-up
11147078|NCT03747783||Non-Survival Group|status from radical operation to follow-up
11147573|NCT03744221|Experimental|Bovine plasma protein|Bovine plasma protein powder
11147079|NCT03747770|No Intervention|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
11147080|NCT03747770|Active Comparator|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
11147081|NCT03747770|Active Comparator|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
11147082|NCT03747770|No Intervention|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
11147083|NCT03747770|No Intervention|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
11147084|NCT03747757|Experimental|Supportive Care (CBT)|Patients undergo CBT consisting of 7 counseling sessions, up to 45 minutes each over the phone.
11147085|NCT03747744|Experimental|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
11147086|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.
~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.
~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
11147087|NCT03747718|Experimental|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
11147088|NCT03747718|Placebo Comparator|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
11147089|NCT03747692|Experimental|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
11147090|NCT03747692|Placebo Comparator|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
11147091|NCT03747679|Experimental|A- Bosutinib in water|200 Mg of bosutinib (50 mg capsule x4) in Water solution
11147092|NCT03747679|Experimental|B- bosutinib in sorbitol|200 Mg of bosutinib sorbitol base in water solution
11147093|NCT03747679|Experimental|C- - bosutinib mannitol|200 Mg of bosutinib powder mannitol base in water solution
11147094|NCT03747679|Experimental|D - bosutinib in mannitol low sweet|200 Mg of bosutinib mannitol low sweet solution
11147095|NCT03747679|Experimental|E- - bosutinib in mannitol high sweet|200 Mg of bosutinib High % sweet mannitol solution
11147096|NCT03747679|Experimental|F- - bosutinib low flavour|Taste assessment of 200 Mg of bosutinib low % Flavour
11147097|NCT03747679|Experimental|G- bosutinib high flavour|Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
11147098|NCT03747679|Experimental|H- - bosutinib capsules in low sweet|Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
11147099|NCT03747679|Experimental|I - bosutinib capsules high sweet|200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
11147100|NCT03747679|Experimental|J- - bosutinib capsules low flavour|Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
11147101|NCT03747679|Experimental|K - bosutinib capsules high flavour|Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
11147102|NCT03747679|Experimental|L - bosutinib capsules applesauce|200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
11147103|NCT03747679|Experimental|M - bosutinib capsules full fat yougurt|200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
11147104|NCT03747679|Experimental|N - bosutinib capsules in water (retest)|200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
11147105|NCT03747666|Experimental|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
11147106|NCT03747666|Experimental|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
11147107|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
11147108|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
11147109|NCT03747640|Experimental|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
11147110|NCT03747640|Sham Comparator|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
11147111|NCT03747614|Experimental|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
11147574|NCT03744221|Active Comparator|control benchmark protein Whey|Whey protein powder
11147112|NCT03747614|Experimental|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
11147113|NCT03747601|Experimental|Temporal Interference (TI) Stimulation|Temporal Interference stimulation applied to the head via standard electrodes
11147114|NCT03747588|Experimental|Laparoscopic Pancreaticoduodenectomy|LPD
11147115|NCT03747588|Placebo Comparator|Open Pancreaticoduodenectomy|OPD
11147116|NCT03747575|Experimental|Treatment|Participants will receive MSTT1041A
11147117|NCT03747575|Placebo Comparator|Placebo|Participants will receive placebo matched to MSTT1041A
11147118|NCT03747562|Experimental|Experimental group|"Patients randomised to the experimental group will receive a prescription for a gabapentin starting dose of 100 mg three times a day (ter in die, t.i.d) /day per orally, additional to the analgesics according to standard local practices.
~Gabapentin dosage may be gradually increased based on individual patient response and tolerability, and as per standard practice in accordance with the drug label. The dose can be further increased in 300 mg/day increments (dose increments of 50% - 100%) every two to three days, up to a maximum dose of 3600 mg/day. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of two weeks, and to reach 3600 mg/day is a total of three weeks."
11147119|NCT03747562|Placebo Comparator|Control group|Patients randomised to the control group will receive a prescription for a matching placebo. The starting dose will be the same as in the experimental group (100 mg three times a day per orally), additional to the analgesics according to standard local practices. Placebo can optionally follow the same dose scheme as described in the experimental arm.
11147120|NCT03747549|Experimental|Acupuncture and Home Exercise|Acupuncture and home exercise.
11147121|NCT03747549|Active Comparator|Home Exercise Alone|The prescribed home exercise program alone.
11147122|NCT03747536|Experimental|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
11147123|NCT03747536|Placebo Comparator|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
11147124|NCT03747523|Experimental|Healthy Group|40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)
11147125|NCT03747523|Experimental|ADTKD-MUC1 Group|40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)
11147126|NCT03747510|Experimental|CarpX Device|Transverse carpal ligament release with CarpX Device
11147127|NCT03747497|Experimental|contezolid acefosamil|contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days
11147128|NCT03747497|Active Comparator|linezolid|linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days
11147129|NCT03747484|Experimental|Treatment (TCR-T cells, avelumab or pembrolizumab)|"LYMPHODEPLETING CHEMOTHERAPY: Between 2-7 days prior to receiving FH-MCVA2TCR T-cells, patients receive fludarabine IV over 30 minutes and cyclophosphamide for 3 days.
~Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells."
11147130|NCT03747484|Experimental|Treatment 2 (TCR-T cells, avelumab or pembrolizumab)|"LYMPHODEPLETING CHEMOTHERAPY: Between 2-7 days prior to receiving FH-MCVA2TCR T-cells, patients receive fludarabine IV over 30 minutes and cyclophosphamide for 3 days.
~Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells."
11147131|NCT03747471|Experimental|Experimental Arm|Intervention: Diabetic Conversation Map x 4 Sessions
11147132|NCT03747471|No Intervention|Control Arm|No intervention
11147133|NCT03747458|Active Comparator|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks
~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
11147134|NCT03747458|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
11147135|NCT03747445||Roux-en-Y gastric bypass patients|severely obese non-diabetic adult female patients scheduled for RYGB
11147136|NCT03747445||Normal weight controls|normal weight healthy non-diabetic adult females
11147137|NCT03747432|Experimental|Propofol|Conscious sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
11147138|NCT03747432|Experimental|Dexmedetomidine|Conscious sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
11147139|NCT03747419|Experimental|Avelumab and Bladder-Directed Radiation|"Avelumab will be administered every 2 weeks intravenously for 6 doses unless there is unacceptable toxicity
~Two radiation dose regimens are allowed, and the regimen selected is at the discretion of the treating radiation oncologist"
11147140|NCT03747406|Experimental|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
11147196|NCT03747055|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
11147197|NCT03747042|Experimental|Treatment|"Drug: letrozole Take by mouth at a dose of 2.5 mg on days 7-56
~Other: Blood Collection Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
~Procedure: biopsy/lumpectomy/mastectomy Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis"
11147141|NCT03747406|Experimental|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
11147142|NCT03747406|No Intervention|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
11147143|NCT03747393|Active Comparator|DoD/VA CPG Core Set|The standard core set of interventions recommended by the DoD/VA clinical practice guidelines for non-surgical management of knee OA.
11147144|NCT03747393|Experimental|DoD/VA CPG Core Set + PT|In addition to DoD/VA clinical practice guidelines, patients will be referred to physical therapy (PT). Physical therapy will consist of evidence-based interventions that can be provided by a PT (exercise, manual therapy, education).
11147145|NCT03747380|Experimental|inspiratory muscle program|Inspiratory muscle training preoperative with standard of care
11147146|NCT03747380|Other|no inspiratory muscle program|standard of care: postoperative spirometry with enhanced recovery program in thoracic surgery
11147147|NCT03747367|No Intervention|Baseline|8 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab. Repeated for visit 1 and visit 2.
11147148|NCT03747367|Experimental|Insufficient Sleep|3 days with 3 hour sleep opportunities in lab, immediately following baseline on both visit 1 and visit 2.
11147149|NCT03747354|Active Comparator|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
11147150|NCT03747354|Active Comparator|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
11147151|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment
~1=placebo + fentanyl,
~2=low dose buprenorphine + fentanyl,
~3 (optional)=low dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
11147152|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment
~1=placebo + fentanyl,
~2=high dose buprenorphine + fentanyl,
~3 (optional)=high dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
11147153|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment
~1=low dose buprenorphine + fentanyl,
~2=placebo + fentanyl,
~3 (optional)=low dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
11147154|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment
~1=high dose buprenorphine + fentanyl,
~2=placebo + fentanyl,
~3 (optional)=high dose buprenorphine only
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.
~Each dosing period was followed by 10-17 days of washout."
11147155|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.
~Two treatment periods:
~1=placebo (Day 1),
~2=low dose buprenorphine + fentanyl (Day 3)
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
11147156|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.
~Two treatment periods:
~1=placebo (Day 1),
~2=mid dose buprenorphine + fentanyl (Day 3)
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
11147157|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.
~Two treatment periods:
~1=placebo (Day 1),
~2=high dose buprenorphine + fentanyl (Day 3)
~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
11147158|NCT03747328|Experimental|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
11147159|NCT03747315||Familial Mediterranean Fever (patients)|Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)
11147160|NCT03747315||Control group (patients)|Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.
11147161|NCT03747315||Healthy donors|Patients without symptoms (anonymous blood donors)
11147162|NCT03747302|Experimental|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
11147163|NCT03747302|Other|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
11147164|NCT03747289|Experimental|weight bearing group|performing exercises in a weight bearing posture
11147165|NCT03747289|Active Comparator|non-weight bearing group|performing exercises in a non- weight bearing posture
11147166|NCT03747276|Other|Clinical Trial Kiosk|
11147198|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
11147199|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.
~."
11147615|NCT03743909||patients with aberrant CD markers|by flowcytometry from hospital information system
11147167|NCT03747263|Experimental|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
11147168|NCT03747263|Active Comparator|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
11147169|NCT03747250|Experimental|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
11147170|NCT03747250|Active Comparator|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
11147171|NCT03747237|Experimental|1. method, Edema measurement methods|"The surgeon will measure from three different places on the patient's face with the help of a paper ruler to measure the edema.
~Tragus-Pogonion Tragus-Labial Comissura Angulus Mandible-Latheral Cantus Measurements will be made preoperative, postoperative 2. and 7. days and saved as milimetre."
11147172|NCT03747237|No Intervention|2. method, Edema measurement methods|Patients will be given edema scale.With the help of the edema scale, the patients will be evaluated the edema by themselves. When the patient stand in front of the mirror, they will be assessed the edema on their face. And a value between 0 and 5 will be pointed on the scale postoperative 2. and 7. days.
11147173|NCT03747224|Experimental|ARO-ANG3|
11147174|NCT03747224|Placebo Comparator|Placebo|
11147175|NCT03747211|Experimental|Aerobic exercise intervention|Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
11147176|NCT03747211|No Intervention|Control group|No intervention for 12 weeks
11147177|NCT03747198|Experimental|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
11147178|NCT03747198|Placebo Comparator|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
11147179|NCT03747185|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
11147180|NCT03747185|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
11147181|NCT03747159|Experimental|BLM+RTX treatment arm|"Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.
~Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.
~Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L."
11147182|NCT03747159|No Intervention|Standard of Care treatment arm|"Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.
~Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab."
11147183|NCT03747146|Active Comparator|Continuous Adductor Canal Catheter (ACC)|Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
11147184|NCT03747146|Sham Comparator|Adductor Canal block with sham catheter|Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.
11147185|NCT03747133|Experimental|Stereotactic Ablative Radiotherapy|Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
11147186|NCT03747120|Active Comparator|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab
~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
11147187|NCT03747120|Experimental|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab
~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
11147188|NCT03747120|Experimental|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab
~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
11147189|NCT03747094|Active Comparator|Fentanyl group|
11147190|NCT03747094|Experimental|Ketamine group|
11147191|NCT03747081|Experimental|Rivoroxaban|Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
11147192|NCT03747081|Active Comparator|warfarin|Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
11147193|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
11147194|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
11147195|NCT03747055|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
11147616|NCT03743909||patients without aberrant CD markers|by flowcytometry from hospital information system
11147200|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.
~No intervention is provided."
11147201|NCT03747016|Experimental|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
11147202|NCT03747016|Active Comparator|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
11147203|NCT03747016|Placebo Comparator|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
11147204|NCT03747016|No Intervention|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
11147205|NCT03747016|Experimental|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
11147206|NCT03747016|Active Comparator|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
11147207|NCT03747016|Placebo Comparator|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
11147208|NCT03747003||HIV-infected male patients|Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
11147209|NCT03746990||observational|Total of 2015 Libyan school children aged 7 to 16 years, from urban (Tobruk) and rural (Kufra) areas were included in the main study. The children were of almost equal number of both sexes from each age group (table-I) .The total of 1935 children were examined for enamel fluorosis
11147210|NCT03746977|Active Comparator|energy restriction and protein supplementation|Energy restriction of 500 kcal/d and total Protein Uptake (including Supplementation) of 1.2 g/kg body mass/d
11147211|NCT03746977|Active Comparator|Energy restriction, walking and protein|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d) and total protein uptake (including supplementation) of 1.5 g/kg body mass/d
11147212|NCT03746977|Active Comparator|Energy restriction, walking, protein and WB-EMS|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d), total protein uptake (including supplementation) of 1.5 g/kg body mass/d and WB-EMS application 1,5x 20 min/week
11147213|NCT03746951|Active Comparator|Fascia iliaca compartment block (FICB)|FICB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the groin.
11147214|NCT03746951|Active Comparator|Lumbar plexus block (LPB)|LPB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the back.
11147215|NCT03746938|Experimental|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
11147216|NCT03746925|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
11147217|NCT03746925|Experimental|SuperPATH|SuperPATH approach surgery to replace the hip.
11147218|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
11147219|NCT03746873|Experimental|COPD Web|Participants randomised to experimental group will be introduced to the COPD Web by a letter containing written information. All participants will receive a pedometer and written information about the importance of physical activity.
11147220|NCT03746873|No Intervention|Control|Other than receiving a pedometer and written information about the importance of physical activity the patients in the control group will not receive any intervention.
11147221|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
11147222|NCT03746834|Experimental|Treatment arm|Patients are given NASHA/Dx as a perianal injection
11147223|NCT03746821|Other|Biotin|Volunteers to take biotin suppliment
11147224|NCT03746808|Placebo Comparator|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
11147225|NCT03746808|Active Comparator|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
11147226|NCT03746795|No Intervention|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
11147227|NCT03746795|Experimental|EIT alone|Spirometric examinations realized using the EIT
11147228|NCT03746795|Experimental|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
11147229|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
11147230|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
11147231|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
11147232|NCT03746769|Experimental|Single Arm Study|
11147266|NCT03746535|Active Comparator|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
11147617|NCT03743896|No Intervention|Control group|No intervention
11147233|NCT03746756|Experimental|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
11147234|NCT03746756|Experimental|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
11147235|NCT03746743||Preterm neonates|Neonates born between 32 and 37 weeks gestation
11147236|NCT03746743||Fullterm neonates|Neonates born at or after 37 weeks gestation
11147237|NCT03746717|Experimental|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
11147238|NCT03746717|Active Comparator|Staples|Skin closure with staples
11147239|NCT03746704|Experimental|Part A: Cohort 1|Part A: Cohort 1 will receive a single IV dose of 89Zr˗DFO˗REGN3504
11147240|NCT03746704|Experimental|Part A: Cohort 2|Part A: Cohort 2 will receive a single IV dose of 89Zr˗DFO˗REGN3504. Doses in Part A are sequentially ascending.
11147241|NCT03746704|Experimental|Part A: Cohort 3|Part A: Cohort 3 will receive a single IV dose of 89Zr˗DFO˗REGN3504. Doses in Part A are sequentially ascending.
11147242|NCT03746704|Experimental|Part B|Part B will receive IV doses of 89Zr˗DFO˗REGN3504
11147243|NCT03746691|Experimental|Citalopram, 20 mg, IV|After placement of a high resolution impedance manometry catheter (transnasally), citalopram will be administered IV over 30 minutes (20 mg in 100ml saline). Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
11147244|NCT03746691|Placebo Comparator|Placebo, IV|After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
11147245|NCT03746678||C-Care Mobile Application|
11147246|NCT03746665|Experimental|meningococcal serogroup A conjugate|mothers will be vaccinated with meningococcal serogroup A conjugate vaccine between 28 - 34 weeks gestation
11147247|NCT03746665|No Intervention|control|serological samples from 100 control mother-infant pairs already recruited as part of the PROPEL trial, (SCC1433), NCT02628886
11147248|NCT03746652|Experimental|DId|Daratumumab, Ixazomib, Dexamethasone
11147249|NCT03746639|Active Comparator|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
11147250|NCT03746639|Other|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
11147251|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
11147252|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
11147253|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
11147254|NCT03746613|Experimental|Minimally invasive robotic cochlear implantation with HEARO|
11147255|NCT03746600|Experimental|Immediate Intervention Group|"Receives the eight-week intervention, Project TRAC: Tracking and Reducing Alcohol Consumption, immediately upon enrollment. This intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
11147256|NCT03746600|Other|Waitlist Control Group|"Receives the Project TRAC: Tracking and Reducing Alcohol Consumption alcohol reduction intervention after an 8-week, assessment-only period. This 8-wek intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
11147257|NCT03746587|Experimental|Arimoclomol I|Arimoclomol, oral capsule
11147258|NCT03746587|Experimental|Arimoclomol II|Arimoclomol, oral capsule
11147259|NCT03746587|Experimental|Arimoclomol III|Arimoclomol, oral capsule
11147260|NCT03746587|Placebo Comparator|Placebo|Placebo oral capsule matching experimental arm
11147261|NCT03746574|Experimental|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
11147262|NCT03746574|No Intervention|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
11147263|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
11147264|NCT03746548|Other|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
11147265|NCT03746548|Other|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
11147267|NCT03746535|Experimental|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
11147268|NCT03746522|Experimental|Setmelanotide|Dosage form: Subcutaneous injection Dosage: 3 mg Frequency: daily
11147269|NCT03746522|Placebo Comparator|Placebo|Dosage form: Subcutaneous injection Dosage: 3 mg equivalent volume Frequency: daily
11147270|NCT03746509|Experimental|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
11147271|NCT03746509|Experimental|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
11147272|NCT03746509|Active Comparator|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
11147273|NCT03746509|Active Comparator|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
11147274|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
11147275|NCT03746470|Experimental|insertion preserving|ACL reconstruction preserving insertion
11147276|NCT03746470|Active Comparator|insertion detaching|ACL reconstruction detaching insertion
11147277|NCT03746457|No Intervention|Control ART Center|Control arm with no intervention throughout the course of the study
11147278|NCT03746457|Active Comparator|Control and Cycle 3 integrated package|Control arm in Cycles 1 and 2 and in Cycle three converts to experimental
11147279|NCT03746457|Experimental|GI + CA + IC|Receives one alternative sequence of three interventions
11147280|NCT03746457|Experimental|IC + GI + CA|Receives a second alternative sequence of three interventions
11147281|NCT03746457|Experimental|CA + IC + GI|Receives a third alternative sequence of three interventions
11147282|NCT03746444|Active Comparator|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).
~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
11147283|NCT03746444|Active Comparator|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
11147284|NCT03746431|Experimental|[225Ac]-FPI-1434 Single-Dose Escalation|
11147285|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose Escalation|
11147286|NCT03746431|Experimental|FPI-1175 Cold Antibody|
11147287|NCT03746418|Placebo Comparator|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
11147288|NCT03746418|Active Comparator|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
11147289|NCT03746405|Active Comparator|Repetitive TMS (rTMS)|excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
11147290|NCT03746405|Sham Comparator|Sham repetitive TMS (rTMS)|electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)
11147291|NCT03746392|Experimental|Jumpstart Intervention|
11147292|NCT03746392|No Intervention|Usual Care|
11147293|NCT03746366|Experimental|Alcohol use disorders|[C-11]Pittsburgh Compound B (PiB) PET scan
11147294|NCT03746366|Experimental|Healthy controls|[C-11]Pittsburgh Compound B (PiB) PET scan
11147295|NCT03746353|Experimental|Early closure of ileostomy|Early clousure of ileostomy before 30 days
11147296|NCT03746353|Active Comparator|Conventional closure of ileostomy|Conventional closure of ileostomy after 30 days
11147297|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
11147298|NCT03746327|Experimental|Sivextro arm|200 mg milligram per day during 4 weeks
11147299|NCT03746314||Supportive Care Leader|A staff member who is knowledgeable about supportive care services for adult oncology patients.
11147300|NCT03746314||Oncology Providers|Physicians, nurses, physicians assistants, nurse practitioners who routinely provide cancer care to adult oncology patients.
11147301|NCT03746301||Treatment|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.
11147302|NCT03746288|Experimental|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
11147303|NCT03746288|Active Comparator|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
11147304|NCT03746275||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events
11147353|NCT03745885|Experimental|1.5mg Supaglutide or placebo|1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
11147354|NCT03745885|Experimental|3.0mg Supaglutide or placebo|3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
11147305|NCT03746262||Patients - Stage I treated with surgery|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations, and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
11147306|NCT03746262||Patients - Stage I treated with radiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
11147307|NCT03746262||Patients - Stage II treated with surgery & chemotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
11147308|NCT03746262||Patients - Stage III treated with chemoradiotherapy|ctDNA measures will be taken and descriptive statistics will be estimated. These include means, standard deviations and 95% confidence intervals. Next, within group changes in ctDNA levels will be measured for each of the four groups. These change values will be estimated with 95% confidence intervals. In addition, paired t-tests will be performed to determine whether there were statistically significant changes in ctDNA levels at time points post-treatment or follow-up. After these paired analyses are performed, an exploratory longitudinal mixed model will be fit to examine the change in ctDNA levels.
11147309|NCT03746249|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11147310|NCT03746223|Experimental|R2-R/IV-MTX（methotrexate）|experimental arm will be treated rituximab plus lenalidomide (R2) regimen for 6 cycles and followed by lenalidomide maintenance for 2 years, meanwhile intravitreal methotrexate will be given as protocol
11147311|NCT03746197|Experimental|Project EVO Multi- Treatment|Treatment group receives video game device treatment. Participant plays the game for 30 minutes a day, at least five days a week for four weeks.
11147312|NCT03746197|No Intervention|Control|No contact control
11147313|NCT03746184||Knee osteoarthritis|Treatment course
11147314|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
11147315|NCT03746158|Experimental|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
11147316|NCT03746145|Experimental|Bifidobacterium longum 1714|Participants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
11147317|NCT03746145|Experimental|Placebo|Participants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
11147318|NCT03746132|Active Comparator|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
11147319|NCT03746132|No Intervention|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
11147320|NCT03746119|Active Comparator|Nicotine-free e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine-free vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
11147321|NCT03746119|Active Comparator|Nicotine e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine containing vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
11147322|NCT03746106|Active Comparator|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
11147323|NCT03746106|Experimental|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
11147324|NCT03746106|Experimental|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
11147325|NCT03746093|Placebo Comparator|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
11147326|NCT03746093|Experimental|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
11147327|NCT03746080|Experimental|Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy|After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
11147355|NCT03745872|Experimental|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
11147328|NCT03746067|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
11147329|NCT03746067|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
11147330|NCT03746054|Experimental|active prevention|optimal medical treatment
11147331|NCT03746054|Sham Comparator|usual clinical practice|usual clinical practice in each center
11147332|NCT03746041|Experimental|abaloparatide and bevacizumab treatment|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
11147333|NCT03746015|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in flavivirus-naïve participants (Group 1) and dengue-immune participants (Group 2). TDV comprised of 1 molecularly characterized, attenuated dengue virus strain and 3 chimeric dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) respectively.
11147334|NCT03746002|Active Comparator|Metolazone Pre-dosing|Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
11147335|NCT03746002|Active Comparator|Metolazone Concurrent Dosing|Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
11147336|NCT03745989|Experimental|MK-8353 and Selumetinib Dose Escalation|Starting Dose (Dose Level [DL] 1): MK-8353 + selumetinib
11147337|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
11147338|NCT03745963|Experimental|Skin-to-skin contact|"Infants will be placed in full ventral skin-to-skin with their mother at least fifteen minutes prior to heel lance to allow time to settle and recover following transfer. Positioning will be determined based on individual maternal preference in order to optimize comfort as well as facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Skin to skin contact will continue until the procedure is completed.
~In addition, infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) during SSC. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
11147339|NCT03745963|Active Comparator|24% Oral sucrose|"Infants will be placed in a cot or in an incubator, depending on their gestational age, for the duration of the blood collection. Administration of 0.12mls (0.04mls per drop) of 24 percent oral sucrose will occur two minutes prior to the heel lance.
~The infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
11147340|NCT03745950|Experimental|Olaparib|"The Olaparib arm :
~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
11147341|NCT03745950|Placebo Comparator|Placebo|"The placebo arm :
~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
11147342|NCT03745937|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous (SC) dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week treatment extension period (TEP).
11147343|NCT03745937|Placebo Comparator|Placebo Cohort 1|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the uptitration period and thereafter once daily through 3 week TEP.
11147344|NCT03745937|Experimental|MEDI0382 Cohort 2|Participants will receive SC dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week TEP.
11147345|NCT03745937|Placebo Comparator|Placebo Cohort 2|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
11147346|NCT03745924||Patients with haemophilia B|Patients with haemophilia B without current inhibitors
11147347|NCT03745911|Experimental|Paclitaxel plus TAK-228|"Paclitaxel will be given on days 1, 8, and 15 of each 28 day cycle intravenously (every Monday or first day of business week if holiday), the day before the first TAK-228 dose. It should be given over approximately one hour.
~TAK-228 will be given orally on Days 2-4, 9-11, 16-18 and 23-25 of each 28-day cycle."
11147348|NCT03745898|Active Comparator|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
11147349|NCT03745898|Sham Comparator|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
11147350|NCT03745885|Experimental|0.15mg Supaglutide or placebo|0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
11147351|NCT03745885|Experimental|0.375mg Supaglutide or placebo|0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
11147352|NCT03745885|Experimental|0.75mg Supaglutide or placebo|0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
11147356|NCT03745846|Experimental|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
11147357|NCT03745846|Placebo Comparator|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
11147358|NCT03745833|Experimental|Intervention|Participants will be shown a brief VR-based mindfulness intervention after meals.
11147359|NCT03745820|Experimental|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
11147360|NCT03745820|Experimental|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
11147361|NCT03745820|Placebo Comparator|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
11147362|NCT03745807|Experimental|Combination|NKTR-214 + nivolumab
11147363|NCT03745794|Active Comparator|Arm I (QL block, standard of care)|Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.
11147364|NCT03745794|Experimental|Arm II (second QL block)|Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.
11147365|NCT03745781|Experimental|open-label placebo|open-label placebo
11147366|NCT03745781|No Intervention|treatment as usual|
11147367|NCT03745768|Experimental|Active iTBS Treatment|Intermittent theta burst stimulation to the dorsolateral prefrontal cortex
11147368|NCT03745768|Sham Comparator|Sham Stimulation|Sham stimulation to the dorsolateral prefrontal cortex.
11147369|NCT03745742|Other|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
11147370|NCT03745742|Experimental|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
11147371|NCT03745729|Experimental|Treatment group|
11147372|NCT03745729|Placebo Comparator|Control group|
11147373|NCT03745716|Experimental|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
11147374|NCT03745716|Experimental|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
11147375|NCT03745703|Experimental|MOCHA|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
11147376|NCT03745703|Experimental|"MOCHA+, Stories Matter"|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
11147377|NCT03745703|No Intervention|Wait-list control|There is no intervention to be administered during the 12-week wait-list control period
11147378|NCT03745690|Experimental|Treatment (near-infrared image guided surgical resection)|Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
11147379|NCT03745677|Experimental|Phase I|Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
11147380|NCT03745677|Experimental|Phase II|During Implementation Phase II, Advanced and Integrated MicroSystems (AIMS) interventions are being implemented on additional, phase II implementation units, leveraging lessons learned during phase I.
11147381|NCT03745664|Active Comparator|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).
~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
11147382|NCT03745664|Placebo Comparator|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
11147383|NCT03745651|Experimental|Ruxolitinib cream|
11147384|NCT03745651|Placebo Comparator|Vehicle cream|
11147385|NCT03745638|Experimental|Ruxolitinib cream|
11147386|NCT03745638|Placebo Comparator|Vehicle cream|
11147387|NCT03745625|Experimental|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
11147388|NCT03745625|Active Comparator|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
11147389|NCT03745612|Experimental|TRF|Time restricted feeding
11147390|NCT03745612|Active Comparator|CER|continuous energy restriction
11147391|NCT03745599|Experimental|Diclofenac|Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
11147392|NCT03745599|Experimental|Flurbiprofen|Flurbiprofen group, which received flurbiprofen 100 mg capsules and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
11147393|NCT03745599|Experimental|Benzydamine|Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules. Placebo capsules contained starch.
11147394|NCT03745586|Experimental|All study participants|
11147419|NCT03745365|Experimental|sleeve gastrectomy|"The greater omentum is divided 5 cm from the pylorus with an energy device. The antral pouch is measured 2-6cm from the pylorus along greater curve as risk benefit ratio is best within these limits.
~Devascularization is continued up the greater curve of the stomach to the short gastric vessels with the help of the assistant who maintains traction and exposure during this process. Eventually, one reaches the left crus which is an important landmark of dissection. We selectively explore the hiatus of the symptomatic and endoscopically proven hiatus hernia , and the hernia should be reduced and repaired."
11147618|NCT03743896|Experimental|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
11147395|NCT03745573|Experimental|Empateach Intervention|All teachers in intervention schools will be invited to participate. Participants in the intervention condition will receive Empateach, a 10-week group intervention. Groups meet 14 times for 1-1.5 hour length sessions, which are led by peers. The aim of the Empateach intervention is to improve 'student and teacher well-being; self-regulation; teacher classroom management and teacher's use of positive discipline techniques. The intervention uses cognitive behavioural therapy techniques to change negative thought and behaviour patterns related to corporal punishment. The teachers receive information on alternatives to corporal punishment, planning exercises and reinforcement SMS, and because the intervention is in a group setting, social support to change their behaviours. They discuss their experiences and challenges in group sessions.
11147396|NCT03745573|No Intervention|Wait-list control|Teachers in wait-list control schools will receive no specific interventions related to violence prevention during the study, but will receive the intervention after the study is over if it is shown to be effective (pending donor funding).
11147397|NCT03745521||X-linked Hypophosphatemia (XLH)|Hypophosphatemic Rickets/osteomalacia
11147398|NCT03745508|Active Comparator|Caffeinated Coffee (200 mg caffeine)|~200 mg of caffeine from instant coffee
11147399|NCT03745508|Active Comparator|Caffeinated Coffee (400 mg caffeine)|~400 mg of caffeine from instant coffee
11147400|NCT03745508|Placebo Comparator|Decaffeinated Coffee|Decaffeinated instant coffee
11147401|NCT03745495||Group 1|300 To determine the effect of HIVST on PrEP uptake among older adolescent MSM and TGW
11147402|NCT03745495||Group 2|300 To determine the effect of HIVST on retention of older adolescent MSM and TGW in HIV service
11147403|NCT03745482|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
11147404|NCT03745482|No Intervention|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.
~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
11147405|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
11147406|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
11147407|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
11147408|NCT03745443|Experimental|Intervention group|Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
11147409|NCT03745443|No Intervention|Control|Ventilation with PEEP 3 during anesthesia and surgery
11147410|NCT03745430|Experimental|Ramucirumab+Nab-paclitaxel+Gemcitabine|Nab-paclitaxel and Gemcitabine will be administered on days 1, 8 and 15 every 4 weeks for a maximum of 8 cycles.
11147411|NCT03745417|Experimental|UCMSCs group|Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks.
11147412|NCT03745404|Experimental|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
11147413|NCT03745404|Experimental|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
11147414|NCT03745404|Placebo Comparator|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
11147415|NCT03745391|Active Comparator|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
11147416|NCT03745391|Active Comparator|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
11147417|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
11147418|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
11147696|NCT03743441|Active Comparator|Exercise + Cryotherapy + LLLT|
11147420|NCT03745365|Experimental|sleeve gastrectomy with loop bipartition|Sleeve gastrectomy is performed first, then a loop gastro-ileostomy 200-250 cm from doudeno-jejunal junction was created at the dependent part of the antrum with 2 layers of with stapler but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastro-ileostomy. The staple line and anastomosis was tested with methylene blue. A drain is inserted.
11147421|NCT03745352|Experimental|Arm A (pevonedistat, azacitidine)|Patients receive pevonedistat intravenously (IV) over 60 minutes on days 1, 3, and 5 and azacitidine IV over 10-40 minutes or subcutaneously (SC) on either days 1-7, or days 1-5 and 8-9, or days 1-6 and 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11147422|NCT03745352|Active Comparator|Arm B (azacitidine)|Patients receive azacitidine IV or SC as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11147423|NCT03745339||Abstinent OUD|Men and women with history of OUD, but abstinent for at least 3 weeks and not in agonist treatment
11147424|NCT03745339||Controls|Men and women with no history of a substanceuse disorder (except nicotine, for matching purposes) and not using any drug for nonmedical purposes
11147425|NCT03745339||In-treatment OUD|Men and women with opioid use disorder (OUD) being treated with an agonist (buprenorphine or methadone)
11147426|NCT03745326|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
11147427|NCT03745326|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
11147428|NCT03745313|Experimental|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
11147429|NCT03745300|Active Comparator|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
11147430|NCT03745300|Active Comparator|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
11147431|NCT03745300|Placebo Comparator|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
11147432|NCT03745287|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
11147433|NCT03745274|Experimental|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
11147434|NCT03745274|Placebo Comparator|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
11147435|NCT03745261|Experimental|YCC capsule+conventional medicine|Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
11147436|NCT03745261|Experimental|BL capsule + conventional medicine|Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
11147437|NCT03745248|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
11147438|NCT03745248|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
11147439|NCT03745235|Experimental|"Mindfulness group"|
11147440|NCT03745235|Other|Control group|Treatment as Usual
11147441|NCT03745222|Experimental|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
11147442|NCT03745222|Experimental|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
11147443|NCT03745222|Placebo Comparator|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
11147444|NCT03745209|Experimental|Ultrasound-guided peripheral IV.|Ultrasound-guided peripheral IV cannulation
11147445|NCT03745209|No Intervention|Traditional landmark technique|Traditional landmark technique
11147446|NCT03745196|Experimental|PC945|PC945 5mg once-daily, nebulized
11147447|NCT03745196|Placebo Comparator|Placebo|Placebo, nebulized
11147508|NCT03744780|Experimental|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
11147448|NCT03745183|Experimental|Senna alata leaf decoction|The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
11147449|NCT03745170|Experimental|Sintilimab+ Oxaliplatin +capecitabine|
11147450|NCT03745170|Active Comparator|placebo +Oxaliplatin + Capecitabine|
11147451|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
11147452|NCT03745144|Experimental|First Cladribine, Then Placebo|Participants will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.
11147453|NCT03745144|Experimental|First Placebo, Then Cladribine|Participants 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.
11147454|NCT03745131||Pre-exposure prophylaxis recipients|40 healthcare workers who provide specialist medical care to patients with monkeypox and who received vaccine as pre-exposure prophylaxis.
11147455|NCT03745131||Post-exposure prophylaxis recipients|40 healthcare workers who received vaccine as post-exposure prophylaxis following monkeypox-exposure risk assessments.
11147456|NCT03745131||Control Group 1|20 healthcare workers who provided specialist medical care to patients with monkeypox but declined the offer of vaccine as pre-exposure prophylaxis.
11147457|NCT03745131||Control Group 2|Healthcare workers not involved in the care of, and have not had known exposure to, patients with monkeypox and, therefore, were not offered vaccine.
11147458|NCT03745118|Other|Monitoring Device|Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
11147459|NCT03745105|Experimental|dexamethasone|Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)
11147460|NCT03745105|Experimental|piroxicam|Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)
11147461|NCT03745105|Active Comparator|Mepivacaine HCL|Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)
11147462|NCT03745092|Experimental|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
11147463|NCT03745092|Placebo Comparator|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
11147464|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time
~Esophagus
~Skin near to temporal artery
~Skin near to carotid artery"
11147465|NCT03745053|Experimental|XLIMUS DES|Xlimus DES Implantation during coronary angioplasty
11147466|NCT03745053|Active Comparator|Synergy DES|Synergy DES Implantation during coronary angioplasty
11147467|NCT03745040|Experimental|Group A: Exparel|"Standard of Care plus Liposomal bupivacaine (Exparel®). Dosage: Exparel® 20 mL single use vial, 1.3% (13.3 mg/mL), Maximum dose of 266 mg (20 mL).
~Frequency: Single intraoperative administration"
11147468|NCT03745040|No Intervention|Group B: No Exparel|Standard of Care
11147469|NCT03745027|Experimental|In vitro fertilization|Paients undergoing in vitro fertilization with Gonadotropin-releasing Hormone agonist. Follicular fluid sialic acid levels will be measured.
11147470|NCT03745014|Active Comparator|Pheno|
11147471|NCT03745014|Active Comparator|Standard of Care|
11147472|NCT03745001|Experimental|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
11147473|NCT03745001|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
11147474|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
11147475|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
11147476|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
11147477|NCT03744975|Placebo Comparator|Placebos|Control Intervention will be 1 Placebo Capsule given orally, one time
11147478|NCT03744975|Active Comparator|LCZ 696|1st Experimental Arm will be 1 capsule of LCZ 696 given orally, one time
11147479|NCT03744949|Experimental|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
11147480|NCT03744949|Experimental|Remifentnil dose 1 ug/kg|Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
11147507|NCT03744793|Experimental|Treatment (pemetrexed, avelumab)|Patients receive pemetrexed IV over 10 minutes on day 1. Starting cycle 2, patients also receive avelumab IV over 60 minutes. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11147481|NCT03744949|Experimental|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
11147482|NCT03744949|Experimental|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
11147483|NCT03744936|Experimental|DA4Afib|Developing a tool to use during the encounter
11147484|NCT03744923|Active Comparator|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
11147485|NCT03744923|Active Comparator|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.
~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
11147486|NCT03744923|No Intervention|control group|the patients will not receive any blocks
11147487|NCT03744910|Active Comparator|Clazakizumab|350 subjects will have a 50/50 chance of being randomly assigned to receive a 12.5 mg subcutaneous (SC) injection once every 4 weeks (Q4W). 175 subjects will be treated with clazakizumab for up to 260 weeks.
11147488|NCT03744910|Placebo Comparator|Placebo|350 subjects will have a 50/50 chance of being randomly assigned to receive a SC injection of normal saline once every 4 weeks (Q4W). 175 subjects will be treated with normal saline for up to 260 weeks.
11147489|NCT03744897|Experimental|Hypnotic analgesia|"Intervention:
~- Subjects will receive hypnotic analgesia"
11147490|NCT03744897|Experimental|a-tDCS|"Intervention: transcranial direct current stimulation - tDCS
~active tDCS stimulation
~montage: bilateral DLPFC anodal/left and cathodal/right
~current:2 milliamps
~time: 20 minutes"
11147491|NCT03744897|Sham Comparator|s-tDCS|"Sham comparator: transcranial direct current stimulation - tDCS
~sham tDCS stimulation
~montage: bilateral DLPFC anodal/left and cathodal/right
~current: 0 milliamps
~time: 20 minutes"
11147492|NCT03744897|Experimental|Hypnotic analgesia + a-tDCS|"Intervention:
~hypnotic analgesia
~active tDCS stimulation
~montage: bilateral DLPFC anodal/left and cathodal/right
~current:2 milliamps
~time: 20 minutes"
11147493|NCT03744884|Experimental|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
11147494|NCT03744884|No Intervention|CP control group|Regular activity control group, for participants with CP.
11147495|NCT03744884|Experimental|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
11147496|NCT03744884|No Intervention|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
11147497|NCT03744871|Active Comparator|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
11147498|NCT03744871|No Intervention|No intervention|No respirators will be worn by the control group (control limb, n=100)
11147499|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
11147500|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
11147501|NCT03744845|No Intervention|Control group|Usual anesthetic care.
11147502|NCT03744845|Experimental|Virtual Reality Intervention Group|Virtual Reality Distraction
11147503|NCT03744832|Experimental|Point of Care Testing|"Point of care testing using the Alere i™ Strep A assay for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. If test is positive, patients will be started on antibiotics prior to discharge from the ED. If test is negative, patients will not be started on antibiotics.
~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
11147504|NCT03744832|Active Comparator|Standard Care|"Conventional testing using a standard bacterial throat culture for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. Patients will be discharged with a post-dated prescription and will be contacted in approximately 3 days if their culture results are positive to fill/take the antibiotics.
~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
11147505|NCT03744806||treated with intravitreal bevacizumab.|
11147506|NCT03744806||control group|
11147509|NCT03744767|Experimental|Single treatment arm|
11147510|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
11147511|NCT03744728|Active Comparator|Accelerate Pheno|Fast ID and AST of positive blood culture bottles using the Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System
11147512|NCT03744728|Active Comparator|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
11147513|NCT03744715|Experimental|Poziotinib|Poziotinib
11147514|NCT03744702|Experimental|Treatment|All patients will receive ascorbic acid as this is a pilot study.
11147515|NCT03744689|Active Comparator|Erector Spinae Plane Block|"Erector Spinae Plane Block Group
~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
11147516|NCT03744689|Sham Comparator|Control Group|Sham block will be done with serum physiologic.
11147517|NCT03744676|Experimental|Lisocabtagene maraleucel|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
11147518|NCT03744663|Active Comparator|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
11147519|NCT03744663|Experimental|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
11147520|NCT03744650|Experimental|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
11147521|NCT03744637|Experimental|Panel A (Parts 1 and 2)|Participants will receive a single inhaled dose of MK-5475 120 µg or a matching placebo in Period 1, MK-5475 165 µg or a matching placebo in Period 2 and MK-5475 240 µg or a matching placebo in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2, participants will receive a single inhaled dose of MK-5475 240 µg and undergo an right heart catheterization (RHC) and will receive a single inhaled dose of MK-5475 240 µg and undergo an functional respiratory imaging (FRI).
11147522|NCT03744637|Experimental|Panel B (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 300 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 360 µg and have an FRI. In Period 3, participants receive a single inhaled dose of MK-5475 360 µg and have an RHC.
11147523|NCT03744637|Experimental|Panel C (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 300 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 360 µg and have an FRI. In Period 3, participants will receive a single inhaled dose of MK-5475 360 µg and have an RHC.
11147524|NCT03744637|Experimental|Panel D (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 480 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 120 µg and have an FRI. In Period 3, participants will receive a single inhaled dose of MK-5475 120 µg and have an RHC.
11147525|NCT03744624|Experimental|With 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing both 3D printed model and computed tomography (or/and magnetic resonance imaging)
11147526|NCT03744624|Active Comparator|Without 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing only standard medical imaging computed tomography (or/and magnetic resonance imaging) without development of 3D printed model
11147527|NCT03744611|Experimental|CE|CE capsule administered orally twice daily for 12 weeks.
11147528|NCT03744611|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
11147529|NCT03744585||Cohort 1|Subjects who received at least one dose of cabozantinib during the Authorization for Use (ATU) period (12/09/2016 to 09/12/2016) for the treatment of advanced Renal Cell Carcinoma (RCC).
11147530|NCT03744585||Cohort 2|Subjects who received at least one dose of cabozantinib during the first six months after the ATU period (10/12/2016 to 16/02/2018).
11147531|NCT03744559|Experimental|R-E (Retrieval Extinction) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a lab-based smoking-related cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the R-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
11147532|NCT03744559|Experimental|R-E (Retrieval Extinction) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a smoking-related cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
11147533|NCT03744559|Other|NR-E (No R-E) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a lab-based non-smoking or neutral cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the NR-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
11147570|NCT03744234|Experimental|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
11147571|NCT03744234|Active Comparator|Steroid Injection|Steroid injection in the sacroiliac joint
11147534|NCT03744559|Other|NR-E (No R-E) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a non-smoking or neutral cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
11147535|NCT03744533|Experimental|head-down position treatment|
11147536|NCT03744533|Active Comparator|guideline-based treatment|
11147537|NCT03744520|Experimental|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
11147538|NCT03744507||Uterine Fibroids|Premenopausal women with uterine fibroids confirmed by an ultrasound.
11147539|NCT03744507||Endometriosis|Premenopausal women with endometriosis diagnosed or confirmed by surgical or direct visualization, or histopathology within 10 years of the Screening visit.
11147540|NCT03744494|Experimental|Bilateral simple orchidectomy (BSO)|The patients would have the testis, epididymis and distal cord structures excised
11147541|NCT03744494|Experimental|Subcapsular orchidectomy (BSCO)|The tunica albuginea was incised longitudinally and the testicular parenchyma scraped off it. The hilar region was secured with a haemostat and the parenchyma excised off it. A haemostatic suture was applied at the hilum. A running interlocking water-tight capsular suture was inserted
11147542|NCT03744494|Experimental|Epididymal-sparing orchidectomy (BESO)|The epididymal sinus was developed. The epididymal vessels were sequentially clamped and divided, removing the testicle from the epididymis. The caput was looped to meet the head and the adjoining surfaces of the body sutured together (epididymoplasty) Vasectomy done to reduce future risk of epididymitis
11147543|NCT03744468|Experimental|Phase 1 Dose Escalation|Dose escalation of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors
11147544|NCT03744468|Experimental|Phase 2 Dose Expansion|Further explore the safety and clinical activity of BGB-A425 in combination with tislelizumab in participants with select advanced solid tumors
11147545|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
11147546|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
11147547|NCT03744442|Active Comparator|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
11147548|NCT03744442|Active Comparator|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
11147549|NCT03744442|Active Comparator|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
11147550|NCT03744429|Experimental|Mediterranean Meal Plan|This is a single arm study in which participants will receive meals that follow a Mediterranean diet plan for 4 weeks. Breast milk samples will be collected before, during, and after the intervention period.
11147551|NCT03744416|Experimental|Intervention group|Counseling based on Epstein's active decision making on birth plan
11147552|NCT03744416|No Intervention|Control group|The standard midwife's advice on birth plan during prenatal care.
11147553|NCT03744403|Experimental|CS1001 monoclonal antibody|
11147554|NCT03744390|Experimental|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
11147555|NCT03744364|Active Comparator|Misoprostol|Group of women allocated to misoprostol induction.
11147556|NCT03744364|Active Comparator|Dinoprostone|Group of women allocated to dinoprostone induction.
11147557|NCT03744351|Other|Healthy volunteer|"45 subjects
~A single visit"
11147558|NCT03744351|Other|Clinically Isolated Syndrome|• 30 subjects
11147559|NCT03744351|Other|Non-MS patients with neurological inflammatory disease|• 20 subjects
11147560|NCT03744351|Other|MS patients (remitting or progressive untreated)|"30 untreated remittent patients
~30 progressive untreated patients"
11147561|NCT03744338||Group 1|
11147562|NCT03744325|Active Comparator|Hen's egg OIT|Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
11147563|NCT03744325|No Intervention|Hen's egg avoidance|Hen's egg is avoidance diet is continued.
11147564|NCT03744312|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
11147565|NCT03744312|Active Comparator|No cognitive impairment|Healthy Controls
11147566|NCT03744299|Other|Intervention|Patients and caregivers are asked to complete a questionnaire
11147567|NCT03744286|Experimental|Balance Slip|"Perform standard clinical balance assessments
~Determine the optimal slip distance by 10 passes each with plank movement of 2, 4, 6 and 8 on visit 1"
11147568|NCT03744247|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11147569|NCT03744247|Active Comparator|Lenvatinib alone|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received placebo intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11147575|NCT03744208|Experimental|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11147576|NCT03744195|Experimental|Group I Experimental Kinesotaping|Application of kinesotaping along with conventional treatment
11147577|NCT03744195|Active Comparator|Group II conventional training group|Application of conventional treatment
11147578|NCT03744182|Experimental|HM15211|
11147579|NCT03744182|Placebo Comparator|Placebo|
11147580|NCT03744169||Children with acute respiratory failure|Point-of-care lung ultrasound on admission to the PICU to determine the cause of respiratory failure.
11147581|NCT03744156|Experimental|Cognitive Behavioral Treatment-Insomnia|Cognitive Behavioral Treatment-Insomnia. 8 Session treatment focusing on behavior and cognitions related to sleep and pain.
11147582|NCT03744156|Experimental|Sleep Hygiene Education|Sleep Hygiene Education. 8 Session treatment focusing on sleep hygiene education.
11147583|NCT03744143|Other|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
11147584|NCT03744143|Other|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
11147585|NCT03744130|Experimental|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.
~Diagnostic Test: Contrast-enhanced Ultrasound"
11147586|NCT03744130|Experimental|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
11147587|NCT03744117|Experimental|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
11147588|NCT03744104|Experimental|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
11147589|NCT03744104|Active Comparator|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
11147590|NCT03744104|Active Comparator|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
11147591|NCT03744091|Active Comparator|10 mg P1|10 mg of P1 will be administered and compared with an active dose of 20 mg P1 on crossover
11147592|NCT03744091|Active Comparator|20 mg P1|20 mg of P1 will be administered and compared with an active dose of 10 mg P1 on crossover
11147593|NCT03744078|Active Comparator|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
11147594|NCT03744078|No Intervention|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
11147595|NCT03744065|Active Comparator|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
11147596|NCT03744065|Experimental|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
11147597|NCT03744052|Experimental|Adult Participants|Messages regarding physical activity will be texted to participants.
11147598|NCT03744026|Experimental|SonoCloud-9 Ultrasound + Carboplatin|SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)
11147599|NCT03744013|Active Comparator|Perforated|Fortiva® 1mm perforated ADM
11147600|NCT03744013|Active Comparator|Non-perforated|Fortiva® 1mm non-perforated ADM
11147601|NCT03744000|Placebo Comparator|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
11147602|NCT03744000|Active Comparator|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
11147603|NCT03743987|Sham Comparator|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
11147604|NCT03743987|Experimental|MTA group|Root resection was applied and MTA was inserted through the apical foramen
11147605|NCT03743987|Experimental|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
11147606|NCT03743987|Experimental|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
11147607|NCT03743974|Active Comparator|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
11147608|NCT03743974|Experimental|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
11147609|NCT03743961||Group A : control group|"Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions) and QoL EORTC Q30 (Quality Qf Life with 30 Questions)
~for patients with G8 score > 14/17"
11147610|NCT03743961||Group B : geriatric intervention group|Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))
11147611|NCT03743948|Experimental|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
11147612|NCT03743935|Experimental|Early cardiac MRI post-STEMI|Early stages post-STEMI (within the first 5 days)
11147613|NCT03743922|Experimental|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
11147614|NCT03743922|Placebo Comparator|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
11147697|NCT03743441|Sham Comparator|Exercise + Cryotherapy + Sham LLLT|
11147619|NCT03743883||Low-dose ASA cohort|A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
11147620|NCT03743883||Comparison unexposed cohort|When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
11147621|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
11147622|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
11147623|NCT03743857|Experimental|Manual Therapy|6 sessions of ankle manual therapy
11147624|NCT03743857|No Intervention|Control|No intervention
11147625|NCT03743844|Experimental|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
11147626|NCT03743844|No Intervention|Control group|Weight management treatment as usual
11147627|NCT03743831|Other|orotracheal intubation direct|
11147628|NCT03743831|Other|orotracheal intubation indirect|
11147629|NCT03743818|Experimental|dry needling|dry needling in trigger point in vastus medialis of quadriceps
11147630|NCT03743818|Active Comparator|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
11147631|NCT03743818|Active Comparator|hialuronic acid|infiltration of hyaluronic acid in the affected knee
11147632|NCT03743805|Experimental|Reversal drugs|Flumazenil and naloxone
11147633|NCT03743792|Experimental|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
11147634|NCT03743792|Placebo Comparator|Placebo|Placebo breakfast
11147635|NCT03743779||Intervention|Participants enrolled in Mastering Diabetes.
11147636|NCT03743766|Experimental|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).
~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
11147637|NCT03743766|Experimental|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.
~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
11147638|NCT03743766|Experimental|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
11147639|NCT03743753|No Intervention|Control|The control group will receive the current standard educational information from the surgeon along with an information package.
11147640|NCT03743753|Experimental|Experimental|The experimental group will receive an additional educational session before their operation about what to expect during their reconstructive journey, in addition to the current standard educational information from the surgeon along with an information package.
11147641|NCT03743740|Experimental|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
11147642|NCT03743740|Experimental|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
11147643|NCT03743727|Experimental|Combined Therapy LDV and SOF|
11147644|NCT03743714|Experimental|males|healthy, sedentary males
11147645|NCT03743714|Experimental|females|healthy, sedentary females
11147646|NCT03743701|Active Comparator|Transrectal ultrasound in В-mode|
11147647|NCT03743701|Experimental|Transrectal ultrasound examination using three-di|
11147648|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
11147649|NCT03743675|Experimental|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
11147650|NCT03743675|Experimental|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
11147651|NCT03743675|Experimental|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
11147652|NCT03743675|No Intervention|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
11147653|NCT03743662|Experimental|Recurrent Glioblastoma, No Surgery|One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan
11147654|NCT03743662|Experimental|Recurrent Glioblastoma, Surgery|The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.
11147655|NCT03743649|Experimental|Group I (haloperidol, placebo)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
11147656|NCT03743649|Experimental|Group II (lorazepam, placebo)|Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
11147657|NCT03743649|Experimental|Group III (haloperidol, lorazepam)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
11147658|NCT03743649|Experimental|Group IV (placebo, lorazepam)|Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
11147659|NCT03743636|Active Comparator|Nicotinamide riboside + resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 1,000 mg of NR and 125 mg of reservatrol daily for six months.
11147660|NCT03743636|Active Comparator|Nicotinamide riboside + placebo|Participants randomized to the NR + placebo arm of the study will receive 1,000 mg of NR and a placebo daily for six months.
11147661|NCT03743636|Placebo Comparator|Placebo + placebo|Participants randomized to the placebo + placebo arm of study will receive placebo pills.
11147662|NCT03743623|Experimental|Study Treatment with Neurocytotron|
11147663|NCT03743623|Placebo Comparator|Study Treatment without Neurocytotron|
11147664|NCT03743610|Experimental|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work.
11147665|NCT03743610|Experimental|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
11147666|NCT03743610|Active Comparator|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
11147667|NCT03743610|Placebo Comparator|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
11147668|NCT03743597|Experimental|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.
~All examinations will be conducted in all participants and with both stockings one after the other."
11147669|NCT03743597|Active Comparator|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.
~All examinations will be conducted in all participants and with both stockings one after the other."
11147670|NCT03743584|Experimental|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
11147671|NCT03743584|Active Comparator|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
11147672|NCT03743571|Active Comparator|anodal tDCS during exposure|anodal transcranial direct current stimulation (2mA) will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
11147673|NCT03743571|Sham Comparator|sham tDCS during exposure|sham transcranial direct current stimulation will be applied over EEG coordinate FpZ during exposure therapy at a level that provides the physical sensations of tDCS but which is non-therapeutic
11147674|NCT03743558|Experimental|children with adenoamygdala hypertrophy|
11147675|NCT03743545|Active Comparator|conventional drilling with irrigation|
11147676|NCT03743545|Experimental|low speed without irrigation|
11147677|NCT03743532|Active Comparator|Financial Incentives + NRT|Participants will receive combination nicotine replacement therapy (lozenges + patches), along with weekly financial incentives for biochemically-verified abstinence during the first 4 weeks following a scheduled quit attempt.
11147678|NCT03743532|Experimental|JUUL/e-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes. They will receive a JUUL e-cigarette device and JUULpods during the first 4 weeks following a scheduled switch date.
11147679|NCT03743532|Experimental|Financial Incentives + JUUL/e-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes, and they will receive a JUUL e-cigarette device and JUULpods during the first 4 weeks following a scheduled switch date. Participants will also receive weekly financial incentives for biochemically-verified cigarette abstinence during the first 4 weeks following the switch date.
11147680|NCT03743519|Placebo Comparator|Placebo|
11147681|NCT03743519|Experimental|Cherry juice|
11147682|NCT03743506|Experimental|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
11147683|NCT03743493||Prevalence numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017)
11147684|NCT03743493||Prevalence denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017)
11147685|NCT03743493||Guideline A numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
11147686|NCT03743493||Guideline A denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO cancer diagnosis in the year prior to the index event
11147687|NCT03743493||Guideline B numerator|An opioid prescribed or dispensed in the query period (1/1/2010-12/31/2017) AND NO inpatient cancer diagnosis OR cancer procedure in the year prior to the index event
11147688|NCT03743493||Guideline B denominator|Any diagnosis on record in the query period (1/1/2010-12/31/2017) AND NO in-patient cancer diagnosis OR cancer procedure in the year prior to the index event
11147689|NCT03743480|No Intervention|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
11147690|NCT03743480|Experimental|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
11147691|NCT03743467||Control group|Health subjects
11147692|NCT03743467||PD patients Hoehn Yahr 1|Patients with Hoehn Yahr stage 1
11147693|NCT03743467||PD patients Hoehn Yahr 2-3|Patients with Hoehn Yahr stage 2 and 3
11147694|NCT03743454||Men|
11147695|NCT03743454||Women|
11147698|NCT03743428|Experimental|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
11147699|NCT03743428|Active Comparator|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
11147700|NCT03743415|Experimental|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
11147701|NCT03743415|Experimental|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
11147702|NCT03743402|Experimental|Pain self-management|"This intervention will have 4 components:
~telephone-delivered evidence-based pain self-management training,
~web-based video of successfully tapered patients with motivational interviewing debriefing,
~a voluntary, self-paced opioid taper
~opioid and non-opioid prescribing guidance for the patient's primary care provider."
11147703|NCT03743402|Active Comparator|usual care|Patients randomized to usual care will continue to receive care as usual from their Kaiser primary care provider.
11147704|NCT03743389|Experimental|12G pigtail catheter|
11147705|NCT03743389|Active Comparator|16F chest tube|
11147706|NCT03743376|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
11147707|NCT03743376|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
11147708|NCT03743376|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
11147709|NCT03743363|Experimental|Exergame 3/week|The group does active training for 8 weeks after not training.
11147710|NCT03743363|Experimental|Exergame 2/week|The group does active training for 8 weeks after not training.
11147711|NCT03743363|Experimental|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
11147712|NCT03743324||BR group|Breast reconstruction without radiation therapy
11147713|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
11147714|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
11147715|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
11147716|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
11147717|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
11147718|NCT03743298|Experimental|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
11147719|NCT03743285|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
11147720|NCT03743272||Liver condition|Participants who have a history of of liver disease
11147721|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
11147722|NCT03743259|Experimental|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
11147723|NCT03743259|Experimental|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
11147724|NCT03743259|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
11147725|NCT03743246|Experimental|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
11147726|NCT03743233|Active Comparator|Hand file instrumentation|
11147727|NCT03743233|Active Comparator|Reciprocating instrumentation|
11147728|NCT03743207|Experimental|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
11147729|NCT03743207|Experimental|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
11147730|NCT03743194|Active Comparator|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.
~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
11147731|NCT03743194|Placebo Comparator|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
11147732|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
11147733|NCT03743181||control|will received standard care by physician in attendance
11147734|NCT03743168|Experimental|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
11147735|NCT03743168|Experimental|Continuous stretch|2 minutes continuous stretch
11147736|NCT03743155|Experimental|treatment with mesenchymal stem cells|xerostomy using mesenchymal stem cells adult autologous bone marrow
11147737|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
11147738|NCT03743129|Experimental|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
11147739|NCT03743129|No Intervention|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
11147740|NCT03743116||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
11147741|NCT03743116||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
11147742|NCT03743103|Experimental|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
11147743|NCT03743103|Active Comparator|Nitroprusside, Sodium|0.5 mcg / kg / min every 3 minutes until reaching the pressure target
11147744|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
11147745|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
11147746|NCT03743077|Experimental|Individuals with spinal cord injury|Volunteers will participate in the the spinal mobility fitness training program which includes exercise training with inspiratory muscle training.
11147747|NCT03743064|Experimental|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
11147748|NCT03743064|Placebo Comparator|Placebo|Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
11147749|NCT03743051|Experimental|100mg Anamorelin HCl|
11147750|NCT03743051|Placebo Comparator|placebo|
11147751|NCT03743038|Experimental|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
11147752|NCT03743038|Experimental|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
11147753|NCT03743025|Experimental|Dulaglutide Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
11147754|NCT03743025|Placebo Comparator|Placebo Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
11147755|NCT03743012|Experimental|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
11147756|NCT03743012|Active Comparator|Usual Care|Participants receiving usual care only
11147757|NCT03742999|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
11147758|NCT03742999|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
11147759|NCT03742999|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
11147760|NCT03742986|Experimental|HER2-negative, including TNBC or HR-positive|
11147761|NCT03742986|Experimental|HER2-positive, independent of HR status|
11147762|NCT03742973|Experimental|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
11147763|NCT03742973|Placebo Comparator|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
11147764|NCT03742973|Experimental|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
11147765|NCT03742973|Placebo Comparator|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
11147766|NCT03742960|Experimental|Behavioral Sleep Restriction|Participants will be required to go to sleep half an hour later than their usual bedtime. Wake up time will be determined via their usual wake time.
11147767|NCT03742947|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
11147768|NCT03742947|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
11147769|NCT03742934|Experimental|Formula group|short peptide formula prior to capsule endoscopy
11147770|NCT03742934|Other|Control group|regular liquid diet
11147771|NCT03742921||Relapsed or Refractory T-Cell Lymphoma patients with Istodax|Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
11147772|NCT03742908|No Intervention|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
11147773|NCT03742908|Experimental|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
11147774|NCT03742908|Experimental|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
11147775|NCT03742895|Experimental|Olaparib|Participants with HRRm or HRD-positive advanced cancer will receive oral olaparib, 300 mg twice daily (BID).
11147776|NCT03742882|Experimental|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
11147777|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
11147778|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
11147779|NCT03742843||Group of adenomyosis|Patients with adenomyosis with or without endometriosis
11147780|NCT03742843||Group of endometriosis|Patients with endometriosis without adenomyosis
11147781|NCT03742843||Group of control|Patients without adenomyosis or endometriosis
11147782|NCT03742817|Experimental|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
11147783|NCT03742817|Placebo Comparator|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
11147784|NCT03742817|Experimental|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
11147785|NCT03742817|Active Comparator|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
11147786|NCT03742804|Experimental|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
11147787|NCT03742791|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
11147788|NCT03742791|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
11147789|NCT03742778|Experimental|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
11147790|NCT03742778|Experimental|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
11147791|NCT03742765|Experimental|Incentivizing Planning|Participants will receive three texts each week asking a question to help plan for the next workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout).
11147792|NCT03742765|Experimental|Incentivizing Exercise|Participants will receive three texts each week asking a question about their workout. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout).
11147793|NCT03742752|Experimental|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).
~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
11147794|NCT03742752|Active Comparator|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
11147795|NCT03742726|Experimental|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
11147796|NCT03742713|Experimental|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
11147797|NCT03742700|Experimental|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
11147798|NCT03742700|Experimental|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
11147799|NCT03742700|Experimental|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
11147800|NCT03742700|Placebo Comparator|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
11147801|NCT03742687|Experimental|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
11147802|NCT03742687|Experimental|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
11147803|NCT03742674||Cohort patients post stroke|
11147804|NCT03742661|Experimental|Treatment Group|SPEAC System
11147805|NCT03742661|No Intervention|Standard of Care|Standard of Care
11147806|NCT03742648|Active Comparator|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
11147807|NCT03742648|Experimental|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
11147808|NCT03742635|Experimental|GMA Assessment|"Conduct General Movements Assessment (GMA) in-person/via-telemedicne (real-time) and recorded (standard of care)"
11147809|NCT03742622|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
11147810|NCT03742609|No Intervention|Information only|provision of written information regarding consequences of using a hearing aid and not using a hearing. For example using a hearing aid will improve ability to hear others.
11147811|NCT03742609|Active Comparator|Physical reminder only|provision of written information regarding consequences of using a hearing aid and not using a hearing and physical reminder to use a hearing aid. For example, a hearing aid box as a physical reminder to use the hearing aids.
11147812|NCT03742609|Active Comparator|Behaviour Plan only|provision of written information regarding consequences of using a hearing aid and not using a hearing and creation of behaviour plan to use a hearing aid. For example, when and where to use the hearing aids.
11147813|NCT03742609|Experimental|Info, Reminder and Plan|provision of written information regarding consequences of using a hearing aid and not using a hearing, physical reminder and creation of behaviour plan to use a hearing aid
11147814|NCT03742596|Experimental|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
11147815|NCT03742596|Other|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
11147816|NCT03742583|Active Comparator|Square Knot|
11147817|NCT03742583|Active Comparator|Reversing Half-Hitch Alternating Post Knot|
11147818|NCT03742570||CBBDQ|A Questionnaire
11147819|NCT03742557|Active Comparator|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.
~The intervention will be done twice weekly for 8 weeks."
11147820|NCT03742557|Placebo Comparator|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
11147821|NCT03742531|Active Comparator|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
11147822|NCT03742531|Active Comparator|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
11147823|NCT03742518|Experimental|Topical SM04554 0.15% solution|Topical SM04554 0.15% solution, once daily for up to 48 weeks
11147824|NCT03742518|Experimental|Topical SM04554 0.25% solution|Topical SM04554 0.25% solution, once daily for up to 48 weeks
11147825|NCT03742518|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for up to 48 weeks
11147826|NCT03742505|Experimental|Vitamin D|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Vitamin D Group and will receive a single dose of cholecalciferol at enrolment.
~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
11147827|NCT03742505|Placebo Comparator|Placebo|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Placebo Group and will receive a single dose of placebo at enrolment.
~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
11147828|NCT03742492|Experimental|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
11147829|NCT03742492|Placebo Comparator|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
11147830|NCT03742479|Experimental|Hyaluronic Acid Microinjection|
11147831|NCT03742466|Active Comparator|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
11147832|NCT03742466|Active Comparator|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
11147833|NCT03742453|Experimental|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
11147834|NCT03742440|Other|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
11147835|NCT03742427|Experimental|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
11147836|NCT03742414|Active Comparator|Control arm (Standard of care)|The study doctors will supply standard written information for the management of eczema with a list of non-tri-lipid creams and ointments.
11147866|NCT03742167|Experimental|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
11147867|NCT03742167|No Intervention|Control|The control arm will receive pediatric medical control physician consultation via telephone.
11147837|NCT03742414|Experimental|Active Intervention arm (proactive sequential skin care)|Participants will receive proactive sequential skin care with the twice-daily use of a tri-lipid skin barrier cream (SBC). Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream to the body and/or hydrocortisone to the face).
11147838|NCT03742401|Active Comparator|Surgery|Surgery
11147839|NCT03742401|Active Comparator|HIFU (Echopulse)|HIFU (Echopulse)
11147840|NCT03742375|Experimental|HPV genotyping|
11147841|NCT03742362|Experimental|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
11147842|NCT03742349|Experimental|1: spartalizumab + LAG525 + NIR178|phase Ib (escalation and expansion)
11147843|NCT03742349|Experimental|2: spartalizumab +LAG525 +capmatinib|phase Ib (escalation and expansion)
11147844|NCT03742349|Experimental|3: spartalizumab + LAG525 + MCS110|phase Ib (escalation and expansion)
11147845|NCT03742349|Experimental|4: spartalizumab +LAG525 +canakinumab|phase Ib (escalation and expansion)
11147846|NCT03742336|Experimental|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
11147847|NCT03742336|Experimental|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
11147848|NCT03742323|Experimental|Idelalisib|
11147849|NCT03742310|Experimental|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
11147850|NCT03742310|No Intervention|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
11147851|NCT03742297|Active Comparator|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
11147852|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
11147853|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22 Daratumumab 16 mg/Kg IV Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
11147854|NCT03742284|Other|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
11147855|NCT03742271|Experimental|senofilcon A|Subjects that are habitual spectacle wearers that have never worn contact lenses and have had an eye exam and an updated spectacle prescription in the last 6 months will be enrolled and fitted into the senofilcon A TEST Lens for a total period of 4 weeks.
11147856|NCT03742258|Experimental|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
11147857|NCT03742245|Experimental|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.
~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
11147858|NCT03742232|Experimental|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
11147859|NCT03742232|Active Comparator|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
11147860|NCT03742219|Experimental|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
11147861|NCT03742206|Experimental|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
11147862|NCT03742206|Active Comparator|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
11147863|NCT03742193|Experimental|Apatinib + GD group|Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
11147864|NCT03742180|Experimental|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
11147865|NCT03742180|Active Comparator|sublingual ketorolac|this group is planned for sublingual ketorolac
11147868|NCT03742154|Experimental|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
11147869|NCT03742154|No Intervention|Control Group|49 participants will be enrolled in this group.
11147870|NCT03742141|Experimental|Intraoperative Video Laryngoscopy|Participants undergoing neck procedures
11147871|NCT03742115|Experimental|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
11147872|NCT03742115|Experimental|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
11147873|NCT03742115|Active Comparator|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
11147874|NCT03742102|Experimental|Arm 1|durvalumab + paclitaxel
11147875|NCT03742102|Experimental|Arm 2|durvalumab + paclitaxel + capivasertib
11147876|NCT03742102|Experimental|Arm 5|durvalumab + paclitaxel + oleclumab
11147877|NCT03742102|Experimental|Arm 6|durvalumab + trastuzumab deruxtecan
11147878|NCT03742089||Treatment|Bone Anchored Hearing Surgery using a BHX implant manufactured by Oticon Medical
11147879|NCT03742076|Active Comparator|High-dose prebiotic|10 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
11147880|NCT03742076|Active Comparator|Low-dose prebiotic|5 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
11147881|NCT03742076|Placebo Comparator|Placebo|2 gm powdered fiber daily for at least 6 weeks
11147882|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
11147883|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
11147884|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
11147885|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
11147886|NCT03742050|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
11147887|NCT03742050|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
11147888|NCT03742037|Experimental|Cenerimod 0.5 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
11147889|NCT03742037|Experimental|Cenerimod 1 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
11147890|NCT03742037|Experimental|Cenerimod 2 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
11147891|NCT03742037|Experimental|Cenerimod 4 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will will be re-randomized in a double-blinded fashion in TP2 in a 1:1 ratio to placebo or cenerimod 2 mg."
11147892|NCT03742037|Placebo Comparator|Placebo|"Subjects will receive matching placebo once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).
~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
11147893|NCT03742024||Children and adolescents|Children and adolescents between the ages of 4 and 17 years old (inclusive)
11147894|NCT03741998|No Intervention|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
11147895|NCT03741998|Active Comparator|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
11147896|NCT03741985|Placebo Comparator|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
11147897|NCT03741985|Experimental|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
11147898|NCT03741972||Treatment|Patients with diabetes and heart failure that are treated with iSGLT2
11147931|NCT03741738||Normal control|A. Subjects aged 19 or older who do not have not only vitiligo but also other skin and systemic diseases
11147899|NCT03741959|Experimental|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
11147900|NCT03741959|Active Comparator|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
11147901|NCT03741946|Other|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
11147902|NCT03741933|Experimental|Apremilast|30 mg twice daily to be administered for a period of 6 months
11147903|NCT03741920|Experimental|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
11147904|NCT03741920|Active Comparator|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
11147905|NCT03741907|Experimental|FAUCS|French Ambulatory C-section
11147906|NCT03741907|Active Comparator|MLC|Gold Standard
11147907|NCT03741894|Placebo Comparator|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
11147908|NCT03741894|Experimental|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
11147909|NCT03741894|Experimental|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
11147910|NCT03741881||Patients with haemophilia|Patients with haemophilia A or B and with or without inhibitors
11147911|NCT03741868||Stage IV non-small cell lung cancer|60 - stage IV non-small cell lung cancer patients will be recruited through the Wake Forest Baptist Comprehensive Cancer Center to complete the quantitative portion of the study. We will use purposive sampling to assure representation of patients at different stages in immunotherapy (i.e., initiating treatment, anticipating scan results, after onset of immune-related side effects).12-15 of the 60 patients who complete the survey and who express interest in providing feedback on programs and participating in future research will be recruited to complete the qualitative portion of the study
11147912|NCT03741855|Experimental|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
11147913|NCT03741855|Experimental|Self-Monitoring Program|Cloud Dx kit with self-monitoring
11147914|NCT03741855|No Intervention|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
11147915|NCT03741842|Experimental|COMBO-KEY group|"The participants in the intervention group will receive a home visiting and phone coaching self-management programme (Coaching Ongoing Momentum Building On stroKe rEcovery journeY COMBO-KEY) which is underpinned by Bandura's constructs of self-efficacy and outcome expectation."
11147916|NCT03741842|No Intervention|Usual care group|The participants in the usual care group will receive usual rehabilitation services offered, including services by a community rehabilitation network such as exercise training, physical rehabilitation, or activities organised by stroke support groups.
11147917|NCT03741829||Samples from transbronchial Biopsy|Samples from participants with SCLC.
11147918|NCT03741816|Active Comparator|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
11147919|NCT03741816|Experimental|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
11147920|NCT03741803|Active Comparator|Delayed cord clamping|
11147921|NCT03741803|Active Comparator|Early cord clamping|
11147922|NCT03741777|Active Comparator|3 ml/kg of clear oral fluid|This group of patient will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
11147923|NCT03741777|Active Comparator|5 ml/kg of clear oral fluid|This group of patient will consume 5 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
11147924|NCT03741777|Active Comparator|7 ml/kg of clear oral fluid|This group of patient will consume 7 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
11147925|NCT03741777|Active Comparator|10 ml/kg of clear oral fluid|This group of patient will consume 10 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
11147926|NCT03741764|Other|Vivosorb|Only arm in study
11147927|NCT03741751|Experimental|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
11147928|NCT03741751|Sham Comparator|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
11147929|NCT03741738||Non-segmental vitiligo :|"A. Patients aged 19 years or older who were clinically diagnosed with non-segmented leukopenia at Severance Hospital.
~B. Patients (36 patients) who experienced worsening symptoms within the last 3 months and 10 patients whose symptoms were stable within 3 months C. Patients with vitiligo lesion at least 3% of the skin"
11147930|NCT03741738||Segmental VT or Focal VT|A. The investigators evaluated patients who were diagnosed as segmental vitiligo clinically on Severance hospital and who were 19 years old or older.
11147932|NCT03741725|Experimental|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
11147933|NCT03741725|Experimental|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
11147934|NCT03741725|No Intervention|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
11147935|NCT03741712|Experimental|SHR2554|Participants will receive SHR2554 orally
11147936|NCT03741712|Experimental|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
11147937|NCT03741699|Experimental|Arm 1 - experimental group|Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
11147938|NCT03741699|No Intervention|Arm 2 - control (no pre-treatment) group|The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
11147939|NCT03741686|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
11147940|NCT03741686|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
11147941|NCT03741673|Experimental|Group I (pre-operative SRS)|Patients undergo SRS within 15 days of randomization followed by surgery within 15 days. Patients may undergo additional SRS if disease returns after treatment.
11147942|NCT03741673|Active Comparator|Group II (post-operative SRS)|Patients undergo surgery within 15 days of randomization followed by standard of care SRS within 30 days. Patients may undergo additional SRS if disease returns after treatment.
11147943|NCT03741660|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
11147944|NCT03741660|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
11147945|NCT03741634|Experimental|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
11147946|NCT03741634|No Intervention|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
11147947|NCT03741621|Experimental|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
11147948|NCT03741621|Experimental|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
11147949|NCT03741621|Experimental|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
11147950|NCT03741608|Active Comparator|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
11147951|NCT03741608|Active Comparator|Education only|High blood pressure management education
11147952|NCT03741595|Experimental|Single Arm|
11147953|NCT03741582||Control - San Cristobal|"1000 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
11147954|NCT03741582||Intervention - Ciudad Bolviar|1000 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
11147955|NCT03741569|Other|parturients (gestational age ≥37 weeks).|
11147956|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
11147957|NCT03741530|Experimental|Glibenclamide group|Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
11147958|NCT03741530|Placebo Comparator|Control group|Giving standard management for ICH
11147959|NCT03741504|No Intervention|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
11147960|NCT03741504|Experimental|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
11147961|NCT03741491||Birkebeiner with AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) with AF.
11147962|NCT03741491||Birkebeiner without AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) without AF
11147963|NCT03741491||Control with AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier with AF
11147964|NCT03741491||Control without AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier without AF
11148055|NCT03740919|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) administered SC.
11148056|NCT03740919|Experimental|LY900014 Open Label|LY900014 administered SC.
11147965|NCT03741478|Experimental|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.
~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).
~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.
~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.
~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
11147966|NCT03741478|Experimental|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).
~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
11147967|NCT03741465|Active Comparator|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
11147968|NCT03741465|Experimental|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
11147969|NCT03741452|Experimental|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
11147970|NCT03741452|No Intervention|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
11147971|NCT03741439|Experimental|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
11147972|NCT03741439|Sham Comparator|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
11147973|NCT03741426|Experimental|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
11147974|NCT03741426|Experimental|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
11147975|NCT03741426|Active Comparator|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
11147976|NCT03741426|Experimental|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
11147977|NCT03741426|Active Comparator|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
11147978|NCT03741413|Experimental|Gain-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to save their lives. Thank you for your support. were send to donors in this group."
11147979|NCT03741413|Experimental|Loss-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to prevent them from death. Thank you for your support. were send to donors in this group."
11147980|NCT03741413|Experimental|Control SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can donate blood again. Thank you for your support. were send to donors in this group."
11147981|NCT03741413|No Intervention|Control group|Donors in this group were not received SMS reminders.
11147982|NCT03741400|Experimental|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
11147983|NCT03741400|No Intervention|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
11147984|NCT03741387|Experimental|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
11147985|NCT03741387|Experimental|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
11147986|NCT03741374|Experimental|Minimally-invasive non-surgical therapy|Intrabony defects treated with Minimally-invasive non-surgical therapy (MINST)
11147987|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
11147988|NCT03741348|Active Comparator|ES|Erector Spinae Plane Block
11147989|NCT03741348|Placebo Comparator|control|the control group will not receive block
11147990|NCT03741335|Experimental|Tai Ji Quan Training|An integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements.
11148057|NCT03740893|No Intervention|Cohort A (standard care reference cohort)|
11147991|NCT03741335|Experimental|Strength Training|Participants wear a weighted vest while performing exercises using functional movement patterns used in everyday activities (chair rises, 90°squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step ups).
11147992|NCT03741335|Active Comparator|Stretching Control|Participants attend a supervised flexibility program where they will perform a series of whole body stretching exercises with a focus on developing and maintaining a healthy back.
11147993|NCT03741322||Infants ages 3-24 months with respiratory infections|
11147994|NCT03741309|Active Comparator|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
11147995|NCT03741309|Sham Comparator|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
11147996|NCT03741309|Placebo Comparator|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
11147997|NCT03741296|Active Comparator|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
11147998|NCT03741296|Active Comparator|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).
~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.
~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
11147999|NCT03741283|Experimental|Optimisation of nutrition and medication|"N=approx.
~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
11148000|NCT03741283|No Intervention|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
11148001|NCT03741270|Experimental|Vaccine|
11148002|NCT03741257|Active Comparator|Group A|Received Hypertonic saline 3% as resuscitation fluid.
11148003|NCT03741257|Active Comparator|Group B|Received Hypertonic saline 1.8% as resuscitation
11148004|NCT03741244|Experimental|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).
~After 6 cycles,apatinib single drug maintained until progress."
11148005|NCT03741244|Active Comparator|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
11148006|NCT03741218|Experimental|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
11148007|NCT03741218|Experimental|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
11148008|NCT03741205|Experimental|Treatment Group|SPEAC System
11148009|NCT03741205|No Intervention|Standard of Care|Standard of Care
11148010|NCT03741192|Experimental|Treatment Group|SPEAC System
11148011|NCT03741192|No Intervention|Standard of Care|
11148012|NCT03741179|Experimental|ASA-withdrawn group|ASA treatment will be withdrawn if patients present an sFlt/PlGF < 38 at 24+0-27+6 weeks of gestation.
11148013|NCT03741179|No Intervention|ASA group|ASA treatment will continue until 36 weeks of gestation if patients present an sFlt/PlGF ratio < 38 at 24+0-27+6 weeks of gestation.
11148014|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
11148015|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
11148016|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
11148017|NCT03741140|Other|medial frontal stroke|20 patients with a recent stroke (<1 month) in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
11148018|NCT03741140|Other|lateral frontal stroke|20 patients with a recent stroke (<1 month) in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
11148019|NCT03741140|Other|Healthy participants|20 patients Healthy participants will be included in this arm, and will undergo motivation phenotyping.
11148020|NCT03741127|Other|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
11148021|NCT03741114|Active Comparator|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
11148022|NCT03741114|Active Comparator|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
11148023|NCT03741101|Experimental|single arm study|children treated with trametinib
11148024|NCT03741088|Experimental|VORTX Rx treatment|Focused ultrasound ablation of liver tumors.
11148025|NCT03741075|Active Comparator|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
11148026|NCT03741075|Experimental|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
11148058|NCT03740893|Experimental|Cohort B (AZD6738 monotherapy)|
11148059|NCT03740893|Experimental|Cohort C (olaparib monotherapy)|
11148060|NCT03740893|Experimental|Cohort D (durvalumab monotherapy)|
11148800|NCT03735758|Active Comparator|Chemotherapy|Guideline-conform chemotherapy
11148027|NCT03741062|Experimental|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
11148028|NCT03741062|Sham Comparator|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
11148029|NCT03741049||Consultants|
11148030|NCT03741049||Trainee anaesthetists|
11148031|NCT03741049||Paramedics|
11148032|NCT03741049||Students|
11148033|NCT03741036|Active Comparator|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
11148034|NCT03741036|Active Comparator|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was > 3 mm.
11148035|NCT03741036|Active Comparator|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
11148036|NCT03741023|Other|Trauma Patients|"During Hospitalization:
~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.
~Follow-Up Visits During routine care visits, we would like to obtain blood via one finger stick. A maximum of one blood draw via finger stick would be collected per month by research personnel, for up to two years."
11148037|NCT03741023|Other|Invasive Elective Surgery Patients|"During Hospitalization:
~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL (~3% total blood volume).
~Follow-Up Visits During routine care visits, we would like to obtain blood via one finger stick. A maximum of one blood draw via finger stick would be collected per month, for up to two years."
11148038|NCT03741023|Other|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
11148039|NCT03740997|Experimental|Patients with body weight ≥20 to ≤28 kg|In children weighing ≥20 to ≤28 kg, 0.1 or 0.2 mL of OPTISON per injection will be given in ascending order. The cumulative dose will not exceed 1.0 mL.
11148040|NCT03740997|Experimental|Patients with body weight >28 to ≤40 kg|If children weigh >28-≤40 kg, 0.2 or 0.3 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.5 mL.
11148041|NCT03740997|Experimental|Patients with body weight >40 kg|For children whose weight is >40 kg, 0.2 or 0.4 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.8 mL.
11148042|NCT03740984|Experimental|Hypnosis / Hypnotherapy|Hypnosis intervention has been created by a certified hypnosis therapist (Prof. Reinhard) has been audio-recorded. The hypnosis intervention is based on the patient's happy place as well as many other interventions which all focus on support and wellbeing (total recording time ca. 4 ½ hours). All patients are advice to start with the beginning, however during the course of chemotherapy they are allowed to skip mp3 files, if they prefer to listen to a new intervention.
11148043|NCT03740984|Experimental|Music therapy|"For the music therapy the following music recordings have been used. All patients were allowed to skip tracks if they did not like to listen to that particular track.
~Purple Waves - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Black Garden View - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Sunset Destination - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Crystal Tree - Berlin Symphonic Film orchestra / Christopher Franke - Pacific Coast Highway Best nature sounds / Ocean Volume 2 - Best Relaxation Music - Deep Sleep Top 10 Serse: Aria Ombra mai Fu - Andreas Scholl, Akademie für Alte music Berlin - Händel Johann Sebastian Bach: Jesus Bleibet Meine Freude (Studio) - Eduard Stan - Piano Recital Mozart: Concerto pour violon no 4 en re majeur, KV (Köchel listing) 218 - Christian Ferras; Pietro Argento; Orchestra Scarlatti di Nap - La fete a Stradivarius
~... etc."
11148044|NCT03740984|Placebo Comparator|Standard therapy|In this standard therapy the patient listens to a short explanation that they were randomized into the control arm and that they are allowed to listen to silence (tracks with no music or intervention).
11148045|NCT03740971|Experimental|Guideline-based therapy+RIC|RIC is given twice a day with 200mmHg pressure.
11148046|NCT03740971|Active Comparator|Guideline-based therapy|
11148047|NCT03740958|Experimental|Argatroban combined with rt-PA|Drug: Argatroban combined with rt-PA Argatroban as a 100 ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
11148048|NCT03740958|Active Comparator|rt-PA|Drug: rt-PA Intravenous throbolysis with 0.9mg/kg rtPA.
11148049|NCT03740945|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
11148050|NCT03740945|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
11148051|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
11148052|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
11148053|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
11148054|NCT03740919|Experimental|LY900014|LY900014 administered subcutaneously (SC).
11148061|NCT03740880|Active Comparator|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
11148062|NCT03740880|Experimental|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
11148063|NCT03740867|Experimental|Group1|"Those with poor cognition (MOCA score<23)
~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
11148064|NCT03740867|Experimental|Group2|"Those with good cognition (MOCA score≥23)
~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
11148065|NCT03740854|Active Comparator|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
11148066|NCT03740854|Active Comparator|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
11148067|NCT03740841|Other|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
11148068|NCT03740841|No Intervention|Without LUNII|Usual pre-operative visit.
11148069|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
11148070|NCT03740815|Experimental|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
11148071|NCT03740789||HBeAg positive|HBeAg positive：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
11148072|NCT03740789||HBeAg negative|HBeAg negative：group A(ALT≤ULN),group B(ALT 1-2ULN),group C(ALT≥2ULN) and treated subgroup (A1,B1,C1) and untreated subgroup (A2,B2,C2).
11148073|NCT03740763|Active Comparator|Spinal Cord Stimulation (SCS)|"Spinal Cord Stimulation (SCS)
~Pharmacological analgetic treatment and treatment with SCS for 3 months
~Add-on physiotherapy for 6 months to SCS and pharmacological analgetic treatment
~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
11148074|NCT03740763|Active Comparator|Physiotherapy|"Physiotherapy
~Pharmacological analgetic treatment for 3 months
~Physiotherapy for 3 months and pharmacological analgetic treatment
~Add-on SCS in combination with physiotherapy and pharmacological analgetic treatment for 3 months
~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
11148075|NCT03740750|Placebo Comparator|control|sham heat and sham TENS
11148076|NCT03740750|Experimental|heat only|heat applied to the back for 4 hours with sham TENS
11148077|NCT03740750|Experimental|Tens only|Tens applied for 4 hours with sham heat
11148078|NCT03740750|Experimental|Heat and Tens continuous|Heat and Tens applied together for 4 hours
11148079|NCT03740750|Experimental|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
11148080|NCT03740750|Experimental|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
11148081|NCT03740737|Experimental|Follitropin delta|
11148082|NCT03740737|Placebo Comparator|Placebo|
11148083|NCT03740724|Experimental|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
11148084|NCT03740711|Experimental|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
11148085|NCT03740711|Active Comparator|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
11148086|NCT03740698|No Intervention|SAP, open-loop|Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)
11148087|NCT03740698|Experimental|BiAP, fixed bolus calculator|Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator
11148088|NCT03740698|Experimental|BiAP, ABC4D|Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)
11148089|NCT03740685||Patients with acute pancreatitis|All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
11148090|NCT03740659|Experimental|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).
~Limbal paracentesis will be performed prior to cataract surgery."
11148091|NCT03740659|Active Comparator|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).
~Limbal paracentesis will be performed prior to cataract surgery."
11148092|NCT03740659|Active Comparator|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).
~Limbal paracentesis will be performed prior to cataract surgery."
11148093|NCT03740633|Experimental|Study group|Patients in the study group accept functional training and regular care.
11148094|NCT03740633|Active Comparator|Control group|Patients in the control group only accept regular care.
11148095|NCT03740620|Active Comparator|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
11148096|NCT03740620|Active Comparator|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
11148097|NCT03740607|Experimental|Virtual reality during PIV placement|Randomized consented adult subjects will participate in a six-minute healthcare virtual reality software program via Samsung Gear virtual reality headsets while receiving 18 or 20-gauge peripheral intravenous catheter placement in peri-operative suite in preparation for surgery. They will be asked to rate their pain and discomfort afterwards using a graphic rating scale. They will be asked several questions about satisfaction, in order to elicit clinical significance of this intervention. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
11148141|NCT03740373|Experimental|Treatment Sequence 1|Subjects will receive BGF MDI with 10 s breath hold during Treatment Period 1 and BGF MDI with 3 s breath hold during Treatment Period 2
11148232|NCT03739749|Active Comparator|Fascia lata allograft|Arthroscopic superior capsular reconstruction using a fascia lata allograft
11148098|NCT03740607|Placebo Comparator|Standard PIV placement|Adult control arm subjects will receive 18 or 20-gauge peripheral intravenous catheter placement according to current standard protocol, without virtual reality distraction .They will be asked to rate pain and discomfort afterwards using a graphic rating scale. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
11148099|NCT03740594|Active Comparator|KMC 60 min group|
11148100|NCT03740594|Active Comparator|KMC 120 min group|
11148101|NCT03740594|Active Comparator|control group|
11148102|NCT03740581|Active Comparator|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin >= 3 times per day
11148103|NCT03740581|No Intervention|Conventional|Old anti-diabetic drug regimen with or without Insulin (<3 times per day) to be continued as before
11148104|NCT03740568|Other|Normal Progesterone group|Progesterone level >10.64 ng/mL on day 4 of progesterone supplementation
11148105|NCT03740568|Experimental|Low Progesterone group|Progesterone level <10.64 ng/mL on day 4 of progesterone supplementation
11148106|NCT03740555|Experimental|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose,
11148107|NCT03740555|Placebo Comparator|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose
11148108|NCT03740555|Experimental|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route
11148109|NCT03740555|Placebo Comparator|Placebo, multiple ascending doses|Placebo, multiple ascending doses, Intravenous route,
11148110|NCT03740542|Active Comparator|Esophagectomy with Pyloroplasty|Esophagectomy with Pyloroplasty
11148111|NCT03740542|Experimental|Esophagectomy without Pyloroplasty|Esophagectomy without Pyloroplasty
11148112|NCT03740529|Experimental|Phase I Dose Escalation (LOXO-305) Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of LOXO-305 to be evaluated
11148113|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
11148114|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
11148115|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
11148116|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
11148117|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
11148118|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
11148119|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 7|(Not otherwise specified) Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late Phase studies of LOXO-305 would remain eligible to enroll in this cohort.
11148120|NCT03740529|Experimental|Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax
11148121|NCT03740529|Experimental|Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax and Rituximab
11148122|NCT03740529|Experimental|Phase 1 Dose Expansion (LOXO-305 Monotherapy)|Patients to receive the recommended Phase 2 dose of LOXO-305.
11148123|NCT03740490|Experimental|Smart-T + NRT|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT).
11148124|NCT03740490|Active Comparator|NCI QuitGuide + NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT).
11148125|NCT03740477|Experimental|Intrevention|Eligible participants will receive a 30-second smartphone-based ECG
11148126|NCT03740464|Experimental|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
11148127|NCT03740464|Active Comparator|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
11148128|NCT03740451|Experimental|Experimental group 1|Active mobilization of soft tissues
11148129|NCT03740451|Experimental|Experimental group 2|Passive mobilization
11148130|NCT03740451|No Intervention|Control group|No intervention
11148131|NCT03740425||Transfusion|Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
11148132|NCT03740425||No Transfusion|Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
11148133|NCT03740412|Experimental|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
11148134|NCT03740412|No Intervention|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
11148135|NCT03740399|Active Comparator|Group sitting|we are performing spinal anesthesia in sitting position pregnant patients
11148136|NCT03740399|Active Comparator|Group lateral decubitus position|we are performing spinal anesthesia in lateral decubitus position pregnant patients
11148137|NCT03740399|Active Comparator|Group Modified 45-degree head-up tilt|we are performing spinal anesthesia in Modified 45-degree head-up tilt position pregnant patients
11148138|NCT03740386|Experimental|lidocaine|lidocaine 2% 1:80000
11148139|NCT03740386|Experimental|articaine|articaine 4% 1:200000
11148140|NCT03740386|Experimental|bupivacaine|bupivacaine 0,5% 1:200000
11148142|NCT03740373|Experimental|Treatment Sequence 2|Subjects will receive BGF MDI with 3 s breath hold during Treatment Period 1 and BGF MDI with 10 s breath hold during Treatment Period 2
11148143|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
11148144|NCT03740334|Experimental|Ribociclib (RIBO) + Dexamethasone (DEX)|"Ribociclib administered daily for 21 consecutive days
~Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
11148145|NCT03740334|Experimental|RIBO + Everolimus (EVE) + DEX|"Ribociclib administered daily for 21 consecutive days
~Dexamethasone administered intravenously on days 1-5 and again on days 11-15
~Everolimus administered daily for 21 consecutive days"
11148146|NCT03740334|Experimental|RIBO + EVE+ DEX (dose expansion)|"Ribociclib administered daily for 21 consecutive days. Dosing at RDE
~Dexamethasone administered intravenously on days 1-5 and again on days 11-15
~Everolimus administered daily for 21 consecutive days. Dosing at RDE"
11148147|NCT03740321|Experimental|Embospheres 500-700 microns|Intervention.Embolization with 500-700 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
11148148|NCT03740321|Experimental|Embospheres 700-900 microns|Intervention.Embolization with 700-900 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
11148149|NCT03740308|Active Comparator|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
11148150|NCT03740308|Experimental|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
11148151|NCT03740295|Placebo Comparator|Control Multiple Sclerosis|
11148152|NCT03740295|Experimental|Intervention Multiple Sclerosis|
11148153|NCT03740282|Experimental|Lapiplasty|All study participants receiving Lapiplasty procedure
11148154|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
11148155|NCT03740256|Experimental|Treatment Phase|"Six dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.
~Dose Level 1 CAdVEC = 1.00E+10 HER2-specific-CAR- T = 0
~Dose Level 2 CAdVEC = 1.00E+10 HER2-specific-CAR- T = 1.00E+06
~Dose Level 3 CAdVEC = 1.00E+11 HER2-specific-CAR- T = 1.00E+06
~Dose Level 4 CAdVEC = 1.00E+11 HER2-specific-CAR- T= 1.00E+07
~Dose Level 5 CAdVEC = 1.00E+12 HER2-specific-CAR- T = 1.00E+07
~Dose Level 6 CAdVEC = 1.00E+12 HER2-specific-CAR- T = 1.00E+08"
11148156|NCT03740243|Active Comparator|buprenorphine|"Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24
~Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
11148157|NCT03740243|Experimental|buprenorphine/naloxone|"Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24
~Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
11148158|NCT03740230||Hepatitis C|Participants with Hepatitis C Genotypes 1 to 6 receiving Maviret (glecaprevir/pibrentasvir) for 8, 12, or 16 weeks.
11148159|NCT03740217|Other|Treatment A|Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.
11148160|NCT03740217|Other|Treatment B:|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.
11148161|NCT03740217|Other|Treatment C|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.
11148162|NCT03740204|Experimental|17-β estradiol with cyclic progesterone|
11148163|NCT03740204|Placebo Comparator|Placebo|
11148164|NCT03740191|Other|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:
~'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire
~kV x-ray images
~Conebeam CT"
11148165|NCT03740178|Experimental|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
11148166|NCT03740178|Placebo Comparator|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
11148167|NCT03740165|Experimental|Pembrolizumab+Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
11148168|NCT03740165|Experimental|Pembrolizumab+Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
11148210|NCT03739879|Experimental|Inspiratory muscle training (IMT)|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
11148169|NCT03740165|Active Comparator|Placebo for Pembrolizumab+Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
11148170|NCT03740152|Experimental|Transcranial Light Therapy|All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
11148171|NCT03740139|Experimental|Intervention|"The Police-Mental Health Linkage System
~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
11148172|NCT03740139|No Intervention|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
11148173|NCT03740126|Experimental|Arm A, PET/CT|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) replacing computed tomography (CT) at months 6, 12, 18 and 24, otherwise as B with CT scan months 9, 15 and 21. Quality of life assessment and liquid biopsy every 3 months for later analysis.
11148174|NCT03740126|No Intervention|Control arm B|CT-scan and clinical evaluation every 3 months. Quality of life assessment and liquid biopsy at every 3 months for later analysis.
11148175|NCT03740113|Experimental|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
11148176|NCT03740113|No Intervention|Control|Control arm receives no intervention
11148177|NCT03740100|Other|Open single arm|Bimiralisib capsules orally
11148178|NCT03740087|Experimental|Omnivorous diet|This group was assigned a meal containing beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice.
11148179|NCT03740087|Active Comparator|Vegan diet|This group was assigned a control meal consisted of salad (lettuce, tomato, lentils) and a cup of rice.
11148180|NCT03740074|Experimental|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
11148181|NCT03740061||Antwerp|
11148182|NCT03740061||Barcelona|
11148183|NCT03740061||Istanbul|
11148184|NCT03740061||Oldenburg|
11148185|NCT03740061||Krakow|
11148186|NCT03740061||Bialystok|
11148187|NCT03740061||Rome|
11148188|NCT03740061||Madrid|
11148189|NCT03740061||Leuven|
11148190|NCT03740048|Experimental|Hemodialysis and Pharmacologic Therapy|Hemodialysis regimen at the initiation of dialysis treatment: Twice-weekly hemodialysis plus adjunctive pharmacologic therapy (loop diuretic, potassium-binding agent, and sodium bicarbonate) for six consecutive weeks, continued by thrice-weekly hemodialysis (intervention group)
11148191|NCT03740048|Active Comparator|Conventional Hemodialysis Regimen|Hemodialysis regimen at the initiation of dialysis treatment: thrice-weekly hemodialysis
11148192|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
11148193|NCT03740022|Active Comparator|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
11148194|NCT03740022|Experimental|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
11148195|NCT03740009|Experimental|Perimenopausal women, depressed|Participants will take Bazedoxifene/Conjugated Estrogen orally for 3 weeks
11148196|NCT03739996|Experimental|CAB LA + VRC07-523LS|"Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.
~Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.
~VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.
~Step 3: SOC oral ART regimen for approximately 48 weeks."
11148197|NCT03739983|Experimental|VRP Therapy|All subjects on this study will receive the Vaginal Renewal Program intervention. Enrolled subjects will receive inperson instruction on how to perform the VRP. Subjects will be encouraged to use the device for 3-4 days per week for 5 minutes at a time.
11148198|NCT03739970|Experimental|Investigational Group- Silk Peptide|"Ingredient: Silk Peptide
~Type: Yellow granule stick
~Weight: Silk Peptide 9g/day
~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)
~Duration of use: 8 weeks"
11148199|NCT03739970|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose
~Type: Yellow granule stick
~Weight: Silk Peptide 0g/day
~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)
~Duration of use: 8 weeks"
11148200|NCT03739957|Experimental|BPCO Media Kit|The kit is composed of a Bluetooth pulse oximeter and an APP for Android system downloadable from Google Play and installed on the Android smartphone of the patient from version 4.1 on.
11148201|NCT03739944|Active Comparator|Laparotomic radical hysterectomy|
11148202|NCT03739944|Active Comparator|Laparotomic radical trachelectomy|
11148203|NCT03739944|Active Comparator|Laparoscopic radical hysterectomy|
11148204|NCT03739944|Active Comparator|Laparoscopic radical trachelectomy|
11148205|NCT03739931|Experimental|Arm A: mRNA-2752|
11148206|NCT03739931|Experimental|Arm B: mRNA-2752 + duvalumab|
11148207|NCT03739918||patients with adrenal masses|patients with adrenal mass managed by adrenalectomy
11148208|NCT03739905|Experimental|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
11148209|NCT03739892|Other|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
11148211|NCT03739866|Experimental|Lenacapavir (Part A)|"Participants in Cohort 1 will receive a single dose of lenacapavir 150 mg on Day 1. Following review of preliminary safety and pharmacokinetic (PK) data, participants will be enrolled in Cohorts 2-3 to receive a single dose of lenacapavir up to 450 mg on Day 1 or Cohorts 4-5 to receive a single dose of lenacapavir up to 900 mg on Day 1.
~After completion of all assessments, at Day 10, participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the remainder of the study."
11148212|NCT03739866|Placebo Comparator|Placebo|"Participants will receive a single dose of placebo on Day 1.
~After completion of all assessments, at Day 10, participants will receive B/F/TAF for the remainder of the study."
11148213|NCT03739866|Experimental|TAF (Part B)|"Participants will receive a single dose of TAF 200 mg on Day 1. Following review of preliminary safety and PK data, participants will be enrolled in Cohorts 7-8 to receive a single dose of TAF up to 600 mg on Day 1.
~After completion of all assessments, at Day 10, participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the remainder of the study."
11148214|NCT03739853|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy[19-22]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
11148215|NCT03739853|Experimental|Combination csDMARD|Arm 2 - Combination DMARD arm. All participants will be prescribed methotrexate with an additional DMARD (either sulfasalazine or leflunomide) at baseline. Response will be assessed after 12 weeks of therapy using the Minimal Disease Activity (MDA) criteria. Participants who achieve the MDA criteria by week 12 on this combination therapy will continue . Participants who show a significant response by in week 12 (a reduction in tender and swollen joint counts of at least 20%) but do not yet meet the MDA criteria should continue on this therapy for an additional 12 weeks before review. Participants failing to show significant response (reduction in joint counts by less than 20%) by week 12 on this combination therapy or those failing to meet MDA criteria by week 24 will be eligible for rescue therapy
11148216|NCT03739853|Experimental|Early TNF inhibition|Early biologic arm. All participants will be prescribed methotrexate (given weekly) with a TNF inhibitor (adalimumab given every two weeks) at baseline. Treatment with TNF inhibitor will be continued until week 24 at which time the TNF inhibitor will be tapered to week 32. The TNF inhibitor will be stopped completely after week 32 and participants will continue on methotrexate. In case of flare of disease, participants will be eligible for rescue therapy
11148217|NCT03739840|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
11148218|NCT03739840|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
11148219|NCT03739840|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
11148220|NCT03739840|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.
11148221|NCT03739827||1/Cohort 1|Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)
11148222|NCT03739827||2/Cohort 2|Relatives of subjects with a diagnosis of rare tumor; familial carriers of germline genetic variants that predispose to rare solid tumor and their relatives
11148223|NCT03739827||3/Cohort 3|Parents/guardians of children with a diagnosis of rare tumor completing PROs and participating in focus groups (if not enrolled in Cohorts 1 or 2)
11148224|NCT03739814|Experimental|Cohort 1 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description
11148225|NCT03739814|Experimental|Cohort 2 (inotuzumab ozogamicin, blinatumomab)|See Detailed Description.
11148226|NCT03739801|Experimental|Treatment (ramucirumab, liposomal irinotecan[MM-398])|Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11148227|NCT03739788|Experimental|BMS-986165|Oral and intravenous administration
11148228|NCT03739775|Other|Blood sampling|
11148229|NCT03739762|Experimental|i-STAND|i-STAND participants have a Baseline visit followed by their first Coaching visit. They are offered wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, a workbook and 10 phone-based coaching sessions focused on sitting less and standing more. At 3 months they will participate in a measurement visit. The program ends at 6 months where they wear an activPAL and participate in a measurement. Their coach will provide feedback on their sitting time from the activPAL after all activPAL wears (Baseline, 3, 6 and 12 month). They may also opt in to wear an activPAL at 6 weeks and receive feedback. They will be re-randomized at 6 months, where half will be assigned to intervention boosters (5 more phone coaching sessions / one 9-month optional activPAL wear) before the 12 month time point for a final activPAL wear and final measurement visit. Those not randomized to receive boosters will have no further contact with the study team until the 12 month time point.
11148230|NCT03739762|Active Comparator|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by their first phone-based Coaching visit. They are not offered any prompting devices or desks, and their coaching sessions focus on a variety of topics related to healthy living, but without a focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants are given a workbook. All content is from Kaiser Permanente Washington and is available to all members. Participants will select topics of interest and review them with their health coach. At 3 months, participants will participate in a measurement visit. The program ends at 6 months where participants will wear an activPAL and participate in a measurement visit. After that, they will not have contact with the study team until 12 months when they will again wear an activPAL and participate in their final measurement visit.
11148231|NCT03739749|Active Comparator|Fascia lata autograft|Arthroscopic superior capsular reconstruction using a fascia lata autograft
11148233|NCT03739749|Active Comparator|Achilles tendon allograft|Arthroscopic superior capsular reconstruction using an achilles tendon allograft
11148234|NCT03739749|Active Comparator|Bovine pericardium allograft|Arthroscopic superior capsular reconstruction using a bovine pericardium allograft
11148235|NCT03739749|Active Comparator|Swine dermal xenograft|Arthroscopic superior capsular reconstruction using a swine dermal xenograft
11148236|NCT03739749|Active Comparator|Collagen allograft|Arthroscopic superior capsular reconstruction using a collagen allograft
11148237|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
11148238|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
11148239|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
11148240|NCT03739723|No Intervention|Usual Care Arm|Programs will continue to conduct normal quality improvement activities.
11148241|NCT03739723|Experimental|Intervention Arm|The intent of the intervention arm is to provide programs with resources to inform and improve surgical residency culture.
11148242|NCT03739710|Experimental|Subjects receiving GSK3359609 (ICOS Agonist) + Docetaxel|Subjects will receive the combination once every 3 weeks as an IV infusion. Subjects receiving docetaxel will be premedicated according to approved product label or standard practice.
11148243|NCT03739710|Active Comparator|Subjects receiving Docetaxel|Subjects will receive docetaxel once in every 3 weeks as an intravenous infusion.
11148244|NCT03739697|Active Comparator|spontaneous breathing|spontaneous breathing after adminitration of anesthetics
11148245|NCT03739697|No Intervention|mechanical ventilation|mechanical ventilation after adminitration of anesthetics and neuromuscula blockade
11148246|NCT03739684|Experimental|18F-DCFPyL Injection|9 mCi (333 MBq) IV injection of 18F-DCFPyL
11148247|NCT03739671|Placebo Comparator|Non-vitamin D supplementation|Group not receiving vitamin D supplementation
11148248|NCT03739671|Experimental|Vitamin D supplementation|Group receiving vitamin D supplementation
11148249|NCT03739658|Experimental|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
11148250|NCT03739658|Experimental|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
11148251|NCT03739658|No Intervention|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
11148252|NCT03739645|Experimental|1 group. patients with intracranial electrodes for epilepsy.|Exploratory study with 1 intervention.which is painful (laser) stimulation conditioned fear with patient as his/her own control. EEG activity will be recorded from the brain during this behavioral state, an opportunity afforded by implantation of electrodes in the brain for treatment of epilepsy. Electrical activation of parts of the brain will be measured by event related spectral perturbations (ERSP).
11148253|NCT03739632|Experimental|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
11148254|NCT03739632|Experimental|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
11148255|NCT03739632|Experimental|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
11148256|NCT03739632|Placebo Comparator|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
11148257|NCT03739619|Experimental|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11148258|NCT03739606|Experimental|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11148259|NCT03739593|Experimental|AR-1105-CF1|Single dose of AR-1105-CF1 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
11148260|NCT03739593|Experimental|AR-1105-CF2|Single dose of AR-1105-CF2 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
11148261|NCT03739580|Experimental|drug-coating balloon|drug-coating balloon (Orchid) intervention
11148262|NCT03739580|Active Comparator|stent deployment|metal bare stent intervention
11148263|NCT03739554|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15 after the venetoclax ramp-up schedule is completed. Venetoclax will be taken daily at a dose that is deemed safe and tolerable after the ramp-up schedule. One cycle will be 28 days or 4 weeks.
11148264|NCT03739541|Experimental|[14C]-Benznidazole|A single dose of 100 mg [14C]-BNZ, orally administered on Day 1 following an overnight fast.
11148338|NCT03739047|Placebo Comparator|flipped spoon|Children in this study will receive behavioral feeding treatment.
11148265|NCT03739528|Experimental|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
11148266|NCT03739528|Active Comparator|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
11148267|NCT03739515|Experimental|HSCP team|Patients in this arm will receive comprehensive assessment and/or pre-discharge services by an ED-based HSCP team
11148268|NCT03739515|Active Comparator|Routine care|Patients in this arm will receive routine ED care
11148269|NCT03739502|Experimental|HBO arm|
11148270|NCT03739502|No Intervention|non-HBO arm|
11148271|NCT03739489|Active Comparator|rTMS-PSI|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the posterior superior insula right.
11148272|NCT03739489|Active Comparator|rTMS-M1|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the right primary motor cortex.
11148273|NCT03739489|Active Comparator|rTMS-F3|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the left pre frontal dorsolateral cortex.
11148274|NCT03739476|Experimental|Interventional|Quetiapine 25 miligrames 1 hour after surgery and each 12 hours for 3 days
11148275|NCT03739476|Placebo Comparator|control|Placebo 1 hour after surgery and each 12 hours for 3 days
11148276|NCT03739463|Experimental|MAG-DHA|1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks
11148277|NCT03739463|Placebo Comparator|Placebo|1500 MG of oleic acid per day until childbirth or for up to 2 weeks
11148278|NCT03739450|Experimental|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
11148279|NCT03739450|Active Comparator|Education|Participants in this arm will only receive the TBI-specific education intervention.
11148280|NCT03739437|Experimental|Mobile Contingency Management|
11148281|NCT03739437|Active Comparator|Standard Care|
11148282|NCT03739424|Experimental|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
11148283|NCT03739424|Active Comparator|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
11148284|NCT03739424|Placebo Comparator|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
11148285|NCT03739411|Experimental|Cohort I (hyperpolarized C13, MRI)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
11148286|NCT03739411|Experimental|Cohort II (hyperpolarized C13, MRI, radiation, temozolomide)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before standard treatment with radiation therapy and temozolomide and 4 weeks after completion of radiation therapy.
11148287|NCT03739398|Experimental|LUTRONIC GENUS laser with LASEMD laser|
11148288|NCT03739398|Active Comparator|LUTRONIC GENUS laser without LASEMD laser|
11148289|NCT03739385|Experimental|Intergenerational Group|Pre-school children and residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
11148290|NCT03739385|Active Comparator|Peer Group Children|Pre-school children will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
11148291|NCT03739385|Active Comparator|Peer Group Seniors|Residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
11148292|NCT03739385|No Intervention|Control Group Children|Pre-School children will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
11148293|NCT03739385|No Intervention|Control Group Seniors|Residential seniors will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
11148294|NCT03739372|Experimental|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
11148295|NCT03739372|Experimental|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
11148296|NCT03739359|Active Comparator|Gas flow 50 L/min|In this group, nasal cannula gas flow will be set at 50 L/min.
11148297|NCT03739359|Experimental|GF:IF=1|In this group, nasal cannula gas flow will be set at each individual patient's own inspiratory flow (GF:IF=1)
11148298|NCT03739359|Experimental|GF:IF=0.5|In this group, nasal cannula gas flow will be set at 50% of each individual patient's own inspiratory flow (GF:IF=0.5)
11148299|NCT03739346|Experimental|Control|Tell, show, do technique
11148300|NCT03739346|Experimental|Intervention|Hypnosis.
11148301|NCT03739333|Experimental|patients with glioblastoma|implementation of 11C-Methionine PET-MRI
11148302|NCT03739294|Experimental|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
11148303|NCT03739294|Experimental|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
11148304|NCT03739294|Experimental|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
11148305|NCT03739294|Experimental|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
11148306|NCT03739294|Experimental|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
11148307|NCT03739294|Experimental|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
11148308|NCT03739281|Other|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
11148309|NCT03739268|Active Comparator|sevelamer|Patients with type 2 diabetes treated with sevelamer
11148310|NCT03739268|Placebo Comparator|placebo|Patients with type 2 diabetes treated with placebo
11148311|NCT03739255|Experimental|Cacicol20|One drop of Cacicol20 will be applied 4-6 hours after the surgery, in one of the randomly chosen eye, and thereafter one drop daily until the reepithelialization is completed.
11148312|NCT03739255|Placebo Comparator|Placebo|One drop of conservative free artificial tear (Oculac, Thea Laboratories) will be applied to one eye at the same time when Cacicol20 is instilled to the other eye.
11148313|NCT03739242|Experimental|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
11148314|NCT03739242|Placebo Comparator|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
11148315|NCT03739229|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
11148316|NCT03739229|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
11148317|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
11148318|NCT03739203|Experimental|Cariprazine 1.5 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline.)
11148319|NCT03739203|Experimental|Cariprazine 3 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2)
11148320|NCT03739203|Placebo Comparator|Placebo|During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline.)
11148321|NCT03739190|Experimental|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
11148322|NCT03739190|Active Comparator|Reference condom A: Medium Thickness NRL Condom|
11148323|NCT03739190|Active Comparator|Reference condom B: Thick NRL Condom|
11148324|NCT03739151|Other|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
11148325|NCT03739138|Experimental|MK-4621/JetPEI™ Monotherapy (Arm 1)|Participants receive MK-4621/JetPEI™ once a week (Q1W) during each 21-day cycle for a maximum duration of 6 cycles.
11148326|NCT03739138|Experimental|MK-4621/JetPEI™ + Pembrolizumab (Arm 2)|Participants receive escalating doses of MK-4621/JetPEI™ Q1W during each 21-day cycle for a maximum duration of 6 cycles in combination with pembrolizumab at a fixed dose 200 mg every 3 weeks (Q3W) for a maximum duration of 6 cycles. Participants may continue on treatment with pembrolizumab after Cycle 6 for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621/JetPEI™ will be based on safety and tolerability.
11148327|NCT03739138|Experimental|Intrahepatic MK-4621/JetPEI™ + Pembrolizumab (Arm 3)|Participants receive MK-4621/JetPEI™ as monotherapy on Day 1 only of the first 21-day cycle (run-in phase). After the run-in phase, participants receive escalating doses of MK-4621/JetPEI™ Q3W in combination with pembrolizumab at a fixed dose 200 mg Q3W for a maximum duration of 5 cycles (Cycles 2-6). Participants may continue on treatment with pembrolizumab for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621/JetPEI™ will be based on safety and tolerability.
11148328|NCT03739125|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
11148329|NCT03739125|Placebo Comparator|Placebo|Placebo
11148330|NCT03739112|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
11148331|NCT03739112|Active Comparator|Quadrivalent Comparator Vaccine|Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine
11148332|NCT03739099|Active Comparator|Closed-loop insulin delivery 24/7, day and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
11148333|NCT03739099|Other|Closed-loop insulin delivery 7/7, dinner and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
11148334|NCT03739073|Experimental|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
11148335|NCT03739060|Active Comparator|Active TENS group|Conventional transcutaneous electric nerve stimulation
11148336|NCT03739060|Placebo Comparator|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
11148337|NCT03739047|Experimental|Desensitization with flipped spoon|Children in this study will receive behavioral feeding treatment. This arm will include desensitization.
11148438|NCT03738319||Control group|This group includes patients of benign gynecologic diseases as control.
11148339|NCT03739034|Experimental|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
11148340|NCT03739021|Experimental|Group 1 (30 participants)|
11148341|NCT03739021|Experimental|Group 2 (30 participants)|
11148342|NCT03738982|Experimental|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
11148343|NCT03738969||Laparotomy group|Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.
11148344|NCT03738969||Laparoscopy group|Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.
11148345|NCT03738956|Experimental|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
11148346|NCT03738943|Experimental|ATP, Ach, SNP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.
~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Acetylcholine: 1, 4, 8, and 16 μg/dl forearm volume/min for 3 minutes each.
~Sodium Nitroprusside: 0.25, 0.5, 1, and 2 μg/dl forearm volume/min for 3 minutes each.
~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.
~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
11148347|NCT03738943|Experimental|ATP, ADP, AMP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.
~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Adenosine Diphosphate: 20, 40, 80, and 160 μg/dl forearm volume/min for 3 minutes each.
~Adenosine Monophosphate: 25, 50, 100, and 200 μg/dl forearm volume/min for 3 minutes each.
~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.
~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
11148348|NCT03738943|Experimental|ATP, UTP, Adenosine|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.
~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Uridine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.
~Adenosine: 3.125, 6.25, 12.5, and 25 μg/dl forearm volume/min for 3 minutes each.
~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.
~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
11148349|NCT03738930|No Intervention|normal follow-up group|normal follow-up in ACS patients after PCI
11148350|NCT03738930|Experimental|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
11148351|NCT03738917|Active Comparator|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
11148352|NCT03738917|Active Comparator|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
11148353|NCT03738917|Active Comparator|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
11148354|NCT03738917|Placebo Comparator|Usual clinical practice|Usual care.
11148355|NCT03738904|Experimental|Arm 1 (multimodal ERAS)|"Arm1 (Multimodal ERAS):
~Preoperative:
~oral gabapentin 600mg and oral acetaminophen 1,000mg
~Postoperative pain control:
~Gabapentin oral 300 mg TID (#42, refill #1)
~Acetaminophen oral 1000mg TID (#42, refill #1)
~Ketorolac oral 10 mg TID (#15, refill #0)
~Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)
~Postoperative laxative regimen:
~Daily MiraLAX 1 scoop in 1 glass of water for 15 days
~Daily milk of magnesia 1 tablespoon if no bowel movement by POD2 until regular bowel movements
~Daily mineral oil 1 table spoon if no bowel movement by POD2 until regular bowel movements"
11148356|NCT03738904|Active Comparator|Arm 2 (control)|"Postoperative pain control:
~Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)
~Patients will be allowed to take oral acetaminophen and ibuprofen over the counter if needed but active narcotic-sparing pain management regimen will not be implemented
~Postoperative laxative regimen:
~Daily MiraLAX 1 scoop in 1 glass of water for 15 days
~Daily milk of magnesia 1 tablespoon if no bowel movement by POD2 until regular bowel movements Daily mineral oil 1 table spoon if no bowel movement by POD2 until regu-lar bowel movements"
11148357|NCT03738891|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen.
11148358|NCT03738878|Active Comparator|valsartan then LCZ696|"After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.
~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
11148359|NCT03738878|Active Comparator|LCZ696 then valsartan|"After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.
~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
11148360|NCT03738865|Experimental|G-Pen followed by Novo Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit
11148361|NCT03738865|Active Comparator|Novo Glucagon followed by G-Pen|1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
11148362|NCT03738852|Experimental|type 1 diabetes mellitus user aware subjects 3 months|MiniMed 670G Insulin Pump in Closed Loop/Auto Mode for 3 months duration
11148363|NCT03738852|Active Comparator|type 1 diabetes mellitus user aware subjects 4 weeks|MiniMed 670G Insulin Pump in Closed Loop/Auto Mode for 4 weeks duration
11148364|NCT03738852|Placebo Comparator|type 1 diabetes mellitus user aware subject standard insulin|Continue with subject's standard insulin regimen.
11148365|NCT03738839|Experimental|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
11148366|NCT03738839|Experimental|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
11148367|NCT03738839|Active Comparator|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
11148368|NCT03738826|Experimental|Intervention arm|Lupus clinic providers will use Surescript refill information to assess adherence level and address adherence barriers. We will assess the feasibility and acceptability of the intervention.
11148369|NCT03738813|Experimental|Treatment Group|"The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.
~In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen."
11148370|NCT03738813|Active Comparator|Participants Usual Care (PUC)|The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.
11148371|NCT03738800|Experimental|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
11148372|NCT03738800|Experimental|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
11148373|NCT03738800|Placebo Comparator|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
11148374|NCT03738787|Experimental|Pancreatic duct occlusion|Patients considered at high risk for pancreatic fistula or oncological relapse due to introperative evaluation submitted to pancreatic duct occlusion with Neoprene-based glue.
11148375|NCT03738787|Active Comparator|Pancreato-Jejunal anastomosi|Patients considered at low risk for pancreatic fistula submitted to pancreato-jejunal anastomosis.
11148376|NCT03738761|Experimental|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
11148377|NCT03738761|Experimental|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
11148378|NCT03738748|Experimental|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
11148379|NCT03738748|Active Comparator|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
11148380|NCT03738735|No Intervention|Control|Patients will receive standard of care lactated ringer's solution for the arthroscopic irrigation during surgery.
11148381|NCT03738735|Experimental|Intervention|Patients will receive hyperosmolar saline for the arthroscopic irrigation during surgery.
11148382|NCT03738722|Experimental|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
11148383|NCT03738709|Experimental|Occupational therapy group sessions|In the collective experimental group, the care includes 6 group sessions of one hour each, programmed over 2 weeks and progressive courses.
11148384|NCT03738709|Active Comparator|Individual Occupational therapy sessions|In the individual control group, care consists of 6 individual sessions of 45 minutes each, not programmed over 2 weeks and progressive courses.
11148385|NCT03738696|Experimental|Liposomal bupivacaine Interscalene Block|"Interscalene block:
~10cc (133mg) liposomal bupivacaine;PLUS
~10cc 0.25% bupivacaine"
11148386|NCT03738696|Active Comparator|Ropivacaine Interscalene Catheter|"20cc 0.25% bupivacaine interscalene block; PLUS
~Ropivacaine 0.25% interscalene catheter (6ml/hr for 48hrs)"
11148387|NCT03738670|Experimental|RFA|Single-arm prospective observational study
11148388|NCT03738657||Screening|Olfactory screening
11148389|NCT03738657||On Study|Taste testing
11148390|NCT03738631||Under 35 years|
11148391|NCT03738631||Over 44 years|
11148392|NCT03738618|Experimental|Follitropin delta|
11148393|NCT03738618|Placebo Comparator|Placebo|
11148394|NCT03738605|Experimental|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
11148395|NCT03738605|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
11148396|NCT03738592|Experimental|cochlear implant children|18 cochlear implant children wil include in this study
11148397|NCT03738592|Other|normal hearing children|18 normal hearing children wil include in this study
11148398|NCT03738579|Active Comparator|Control Group|After standard of care debridement and irrigation (using normal saline), Mepilex foam dressing will be used. Foam dressing will be used throughout the study, including for mid-week dressing changes.
11148464|NCT03738124|Experimental|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
11148399|NCT03738579|Active Comparator|Antibacterial Control|After standard of care debridement and irrigation (using normal saline), Mepilex AG foam dressing will be used. This dressing will be used throughout the study, including for mid-week dressing changes.
11148400|NCT03738579|Experimental|Next Science Group|Standard of care debridement will be performed as well as irrigation using TorrentX Wound Wash,then BlastX Wound gel will be applied to the wound before covering treatment site with Mepilex foam dressing (no AG component). BlastX will re-applied again mid-week during mid-week dressing change.
11148401|NCT03738566|Other|Endoscopic Dilation|Patients randomized to the observation group will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
11148402|NCT03738566|Active Comparator|Esophageal Self Dilation|Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.
11148403|NCT03738540|Experimental|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
11148404|NCT03738540|Active Comparator|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
11148405|NCT03738527|Experimental|TXA arm|
11148406|NCT03738527|Placebo Comparator|Placebo arm|
11148407|NCT03738514|Active Comparator|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
11148408|NCT03738514|Sham Comparator|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
11148409|NCT03738514|Placebo Comparator|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
11148410|NCT03738501|Experimental|Chest physiotherapy with SET|Chest physiotherapy will be provided by a single physiotherapist not involved in outcomes assessment. Airway clearance technique will be Slow Expiratory Technique (SET). SET is a slow modulation of airflow in order to remove bronchial secretions within infants lungs. Experimental group will also benefit for standard medical and non-pharmacological care (e.g Standard Treatment)
11148411|NCT03738501|Active Comparator|Standard treatment|Medical treatment, health education for parents, rhinopharyngeal clearance using isotonic saline solution, advices.
11148412|NCT03738488|Experimental|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
11148413|NCT03738488|Active Comparator|Images|Surgery planification with all the images available
11148414|NCT03738475|Experimental|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
11148415|NCT03738475|Placebo Comparator|Placebo|Normal saline administered intravenously on days 1 and 8.
11148416|NCT03738449|Experimental|Group 1|"Period 1: D484
~Period 2: CKD-387"
11148417|NCT03738449|Experimental|Group 2|"Period 1: CKD-387
~Period 2: D484"
11148418|NCT03738436|Active Comparator|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
11148419|NCT03738436|Experimental|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
11148420|NCT03738423|Experimental|Treatment 1|
11148421|NCT03738423|Experimental|Treatment 2|
11148422|NCT03738423|Experimental|Treatment 3|
11148423|NCT03738423|Experimental|Treatment 4|
11148424|NCT03738423|Experimental|Treatment 5|Matching placebo
11148425|NCT03738410|Active Comparator|Control Arm|The control arm will receive standard of care.
11148426|NCT03738410|Experimental|Mobile Health Messaging Arm|The Mobile Health Messaging Arm will receive standard of care, as well as the mobile health intervention. The mHealth intervention includes psycho-educational messaging as well.
11148427|NCT03738410|No Intervention|Focus Group Arm|The results of the focus groups will contribute to the wording and design of the intervention.
11148428|NCT03738397|Experimental|Participants administered with upadacitinib|Participants are administered with upadacitinib from baseline to week 24 and placebo pre-filled syringe at baseline visit (2 injections) followed by an injection every other week until week 22
11148429|NCT03738397|Experimental|Participants administered with dupilumab|Participants are administered with dupilumab (2 injections) at baseline followed by one every other week until week 22 and placebo tablets daily from baseline to week 24
11148430|NCT03738384|Experimental|TKR Patients|Any patient 3-6 weeks post-op from a TKR
11148431|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
11148432|NCT03738358|Experimental|Trehalose|
11148433|NCT03738358|Placebo Comparator|Placebo|
11148434|NCT03738345|Experimental|Oxygenation on hypoxemia patients|Adult patients with hypoxemia will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then patients will be placed on high flow nasal cannula (HFNC), HFNC flow will be titrated based on the hospital's policy or protocol and patient's comfort, patient's clinical effects on oxygenation will be monitored and recorded during the titration process.
11148435|NCT03738345|Experimental|Lung expansion on healthy volunteer|Adult healthy volunteers will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then they will be placed on HFNC, HFNC flow will be increased sequentially by research protocol and their comfort, subjects' lung expansion effects in different flow will be quantified by Electrical impedance tomography (EIT), a noninvasive assessment tool. Their comfort will also be assessed using a visual scale.
11148436|NCT03738332|Other|Low-level laser therapy|Single arm
11148437|NCT03738319||HGSOC group|This group includes patients of high grade serous ovarian cancer (HGSOC).
11148439|NCT03738306|Experimental|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
11148440|NCT03738306|Active Comparator|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
11148441|NCT03738254|Active Comparator|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
11148442|NCT03738254|Active Comparator|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
11148443|NCT03738254|Experimental|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
11148444|NCT03738241|Experimental|Arm 1|Participants will have prior administration of 2013 A/H7N9 IIV with MF59. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
11148445|NCT03738241|Experimental|Arm 2|Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
11148446|NCT03738241|Experimental|Arm 3|Participants will have prior administration of 2013 A/H7N9 IIV 15 mcg or 45 mcg unadjuvanted. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
11148447|NCT03738241|Experimental|Arm 4|Participants will have prior administration of 2013 A/H7N9 IIV + MF59 or AS03 (1st) then 2013 A/H7N9 IIV 15 mcg (2nd). Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
11148448|NCT03738241|Experimental|Arm 5|Participants who are A/H7 IIV-Naïve. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
11148449|NCT03738228|Experimental|Arm A (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.
11148450|NCT03738228|Experimental|Arm B (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.
11148451|NCT03738215|Experimental|Cariprazine 1.5 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline.)
11148452|NCT03738215|Experimental|Cariprazine 3 mg|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2)
11148453|NCT03738215|Placebo Comparator|Placebo|During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline.)
11148454|NCT03738202|Experimental|Intervention|Multifaceted intervention package will be implemented at textile mills in the intervention arm.
11148455|NCT03738202|No Intervention|Control|No intervention will be provided to mills in the control arm.
11148456|NCT03738176|Experimental|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
11148457|NCT03738176|Active Comparator|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
11148458|NCT03738163|Other|Epaderm Cream|This is an open, non randomised single arm study.
11148459|NCT03738150|Experimental|Sotatercept|Each participant will receive standard of care (SOC) plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. Dose will escalate to 0.7 mg/kg SC at Cycle 2 through the remainder of the treatment period. Dosing will be every three weeks for 24 weeks.
11148460|NCT03738137|Experimental|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
11148461|NCT03738137|Experimental|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
11148462|NCT03738137|Experimental|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
11148463|NCT03738137|Experimental|Lidocaine|Only topical anesthesia was applied.
11148465|NCT03738111|Experimental|TG02 Citrate|TG02 citrate capsules given orally.
11148466|NCT03738098|Active Comparator|Traditional Genetic Counseling|Standard of care genetic counseling session
11148467|NCT03738098|Experimental|GUÍA|Standard of care genetic counseling session with Genomic Understanding, Information and Awareness (GUÍA).
11148468|NCT03738085||Previous abdominal surgery group|Previous abdominal surgery group underwent total laparoscopic hysterectomy
11148469|NCT03738085||No previous abdominal surgery group|No Previous abdominal surgery group underwent total laparoscopic hysterectomy
11148470|NCT03738085||Obese patients underwent TAH|BMI≥30 kg/m2
11148471|NCT03738085||Obese patients underwent TLH|BMI≥30 kg/m2
11148472|NCT03738072|Experimental|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
11148473|NCT03738059|Placebo Comparator|group I (placebo)|will receive intravenous normal saline (NS)
11148474|NCT03738059|Experimental|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
11148475|NCT03738059|Experimental|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
11148476|NCT03738059|Experimental|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
11148477|NCT03738046|Experimental|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
11148478|NCT03738033||use of the educational platform|Before the hand-on practice and assessements, the participants use the platform for learning.
11148479|NCT03738033||without use of the educational platform|Before the hand-on practice and assessements, the participants did not use the platform for learning.
11148480|NCT03738020|Experimental|HA IDF|
11148481|NCT03738020|Active Comparator|Restylane|
11148482|NCT03738007|Experimental|HA IDF II|
11148483|NCT03738007|Active Comparator|Perlane|
11148484|NCT03737994|Experimental|ALK L1198F mutation (alone or combination with ALK inhibitor)|Patients with ALK L1198F mutation (alone or in combination with another ALK mutation) receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148485|NCT03737994|Experimental|C1156Y|Patients with Cy1156Y mutation receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148486|NCT03737994|Experimental|Compound mutation|Patients with a compound mutation receive lorlatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148487|NCT03737994|Experimental|F1174|Patients with F1174 receive either lorlatinib PO QD, alectinib PO BID, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148488|NCT03737994|Experimental|G1202 (including G1202del and G1202R)|Patients with G1202 (including G1202del and G1202R) receive either lorlatinib PO QD or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148489|NCT03737994|Experimental|I1171|Patients with I1171 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148490|NCT03737994|Experimental|L1196 (including L1196M)|Patients with L1196 (including L1196M) mutation receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, or ensartinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148491|NCT03737994|Experimental|MET amplification|Patients with MET amplification receive crizotinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148492|NCT03737994|Experimental|No ALK-resistance mutations|Patients with no ALK-resistant mutations receive either lorlatinib PO QD, ceritinib PO QD, alectinib PO BID, brigatinib PO QD, ensartinib PO QD, or pemetrexed IV over 10 minutes on day 1 with or without either cisplatin IV or carboplatin IV on day 1. ALK inhibitor cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Pemetrexed-based treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance treatment of pemetrexed may continue until disease progression or unacceptable toxicity.
11148493|NCT03737994|Experimental|V1180|Patients with V1180 mutation receive either lorlatinib PO QD, ceritinib PO QD, or brigatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11148494|NCT03737981|Active Comparator|Arm I (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Treatment repeats every 28 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 15, patients receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity.
11148495|NCT03737981|Experimental|Arm II (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Beginning cycle 3, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity. All patients will then receive a 15th cycle of ibrutinib. Beginning cycle 16, patients who do not achieve a BM MRD negative CR, receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a BM MRD negative CR undergo observation every 3 cycles for 6 years, then every 6 cycles thereafter.
11148525|NCT03737773|Placebo Comparator|group placebo lenses|Patients that receive non-active prismatic lenses
11148526|NCT03737760||Older Adults|Community-dwelling men and women age 70+ years
11148527|NCT03737760||Younger Adults|Healthy young adults, age 20-40 years for baseline assessments only
11148528|NCT03737734|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
11148529|NCT03737721|Experimental|Avelumab and Radical radiotherapy|Single-arm combining Avelumab with radical radiotherapy.
11148631|NCT03737006||3-Healthy Controls (UC)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
11148496|NCT03737968|Experimental|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
11148497|NCT03737968|Active Comparator|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
11148498|NCT03737955|Experimental|Treatment (gemtuzumab ozogamicin)|Patients receive gemtuzumab ozogamicin IV on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Responders and non-responders, without significant adverse events during the first course, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.
11148499|NCT03737942||control group|"Motor nerve conduction studies:
~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
11148500|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:
~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
11148501|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:
~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
11148502|NCT03737929|Experimental|Hybrid ablation procedure|In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.
11148503|NCT03737929|Active Comparator|Percutaneous endocardial catheter ablation procedure|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).
11148504|NCT03737916|Experimental|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
11148505|NCT03737916|Placebo Comparator|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
~Drug: Normal Saline Normal saline is safe for perineural injection."
11148506|NCT03737890|Experimental|Inspiratory muscle Training|4 weeks of inspiratory muscle training
11148507|NCT03737890|Active Comparator|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
11148508|NCT03737877|Experimental|Diet modification|
11148509|NCT03737864|Active Comparator|Motivational Interview|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
11148510|NCT03737864|Experimental|Patient navigation and MI|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification plus patient navigation for 30 days, or until the patient is successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
11148511|NCT03737851|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
11148512|NCT03737851|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
11148513|NCT03737851|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
11148514|NCT03737825|Active Comparator|Program 1|Computerized gaming rehabilitation Program 1.
11148515|NCT03737825|Placebo Comparator|Program 2|Computerized gaming rehabilitation Program 2.
11148516|NCT03737812|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
11148517|NCT03737812|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
11148518|NCT03737812|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
11148519|NCT03737799||Group 1 Age 18-50 at diagnosis|Diagnosed with diabetes within the previous 1 year. Aged between 18 and 50 years at the time of diabetes diagnosis
11148520|NCT03737799||Group 2 Late Onset (insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated with insulin therapy
11148521|NCT03737799||Group 3 Late Onset (no insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated without insulin
11148522|NCT03737786|Active Comparator|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
11148523|NCT03737786|Active Comparator|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
11148524|NCT03737773|Active Comparator|group prisms|Patients that receive active prismatic lenses
11148530|NCT03737708|Experimental|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
11148531|NCT03737708|Active Comparator|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
11148532|NCT03737695||Ancillary-Correlative (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
11148533|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
11148534|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
11148535|NCT03737669|Experimental|Mirasol-treated Fresh Whole Blood|Standard Fresh Whole Blood, treated with Mirasol Pathogen Reduction Technology
11148536|NCT03737669|Placebo Comparator|Standard Fresh Whole Blood|Standard-issue fresh whole blood
11148537|NCT03737656|Experimental|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
11148538|NCT03737656|Experimental|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
11148539|NCT03737656|Experimental|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
11148540|NCT03737643|Active Comparator|Arm 1|Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).
11148541|NCT03737643|Experimental|Arm 2|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.
11148542|NCT03737643|Experimental|Arm 3|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.
11148543|NCT03737643|Experimental|tBRCAm cohort|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.
11148544|NCT03737630|Experimental|GExp|This group will perform the inspiratory muscle training with moderate load
11148545|NCT03737630|Active Comparator|GCon|This group will initiate inspiratory muscle training with low load
11148546|NCT03737617|Experimental|Active arm|Weekly subcutaneous immunoglobulin therapy (0.1g/Kg) Cuvitru 20% Injectable Solution for 1 Year
11148547|NCT03737617|No Intervention|Control|Standard Care arm without immunoglobulin replacement therapy
11148548|NCT03737604|Active Comparator|Ropivacaine Continuous Infusion Catheter|Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.
11148549|NCT03737604|Active Comparator|Single dose liposomal bupivicaine|Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.
11148550|NCT03737591||Healthy individuals|Healthy individuals
11148551|NCT03737591||Patients with Colorectal cancer|Stage I-IV colorectal cancer patients
11148552|NCT03737591||Patients with Colorectal Adenomas|Patients with Colorectal Adenomas
11148553|NCT03737578|Experimental|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.
~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
11148554|NCT03737578|Active Comparator|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.
~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
11148555|NCT03737565||Coronary Artery Disease|
11148556|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
11148557|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
11148558|NCT03737539||Stage II colorectal cancer|Patients diagnosed with stage II colorectal cancer
11148559|NCT03737539||Stage III colorectal cancer|Patients diagnosed with stage III colorectal cancer
11148560|NCT03737500|Active Comparator|Standard silicone-based breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)
11148561|NCT03737500|Experimental|B-Lite® light weight breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant
11148562|NCT03737474|Experimental|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
11148563|NCT03737461|Experimental|Allogenic BM-MSCs Injection|Injection of a dose of 20.106 allogenic BM-MSCs via imaging control into the disk affected by DDD where they are expected to exert their therapeutic effects.
11148564|NCT03737461|Sham Comparator|Sham Procedure|anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment
11148632|NCT03736993|Other|Additional blood sampling|non-small cell lung cancer (NSCLC)
11148565|NCT03737448|Experimental|Group 1|"AD with serum creatinine ≥ 1 and < 2 mg/dL, OR
~ACLF 1 with
~liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
~liver failure and West Haven grade 1-2 hepatic encephalopathy, or
~coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or
~coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR
~ACLF 2 with
~liver failure and coagulation failure, or
~liver failure and West Haven grade 3-4 hepatic encephalopathy."
11148566|NCT03737448|Experimental|Group 2|"ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR
~ACLF 2 with
~liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or
~coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL)."
11148567|NCT03737422|Active Comparator|hesperidin and flaxseed|
11148568|NCT03737422|Placebo Comparator|control|
11148569|NCT03737409|Experimental|Oxygen therapy with POC (AOT group)|Patients will receive ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
11148570|NCT03737409|Sham Comparator|Sham oxygen therapy with POC (air group)|Patients will receive sham ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
11148571|NCT03737396|Active Comparator|Electronic health screening|Self-administered electronic health screening on tablet
11148572|NCT03737396|No Intervention|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
11148573|NCT03737383|Experimental|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
11148574|NCT03737370|Experimental|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m^2 [level 1] and 50mg/m^2 [level 2]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).
~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
11148575|NCT03737370|Experimental|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
11148576|NCT03737357|Experimental|SLActive® implant|
11148577|NCT03737357|Active Comparator|SLA® implant|
11148578|NCT03737344|Active Comparator|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
11148579|NCT03737344|Placebo Comparator|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
11148580|NCT03737331|Experimental|Fractal visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be fractal (i.e., pink noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
11148581|NCT03737331|Active Comparator|Periodic visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be periodic (i.e., invariant). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
11148582|NCT03737331|Sham Comparator|Random visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be random (i.e., white noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
11148583|NCT03737331|No Intervention|Control|Natural walking.
11148584|NCT03737318|Experimental|Group 1|Traditional articulation treatment
11148585|NCT03737318|Experimental|Group 2|Biofeedback--visual-acoustic
11148586|NCT03737318|Experimental|Group 3|Biofeedback-ultrasound
11148587|NCT03737305|Active Comparator|Control Group|Control group of conventional therapy with manual distraction performed by the physiotherapist in the office (active comparator)
11148588|NCT03737305|Experimental|Distractor Test Group|Test group with manual distraction performed by the physiotherapist in the office and the condylar distraction performed by the patient with the condylar distraction device in an ambulatory basis.
11148589|NCT03737292|Experimental|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
11148590|NCT03737292|Active Comparator|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
11148591|NCT03737279|Experimental|Meditation|"Intervention Group:
~Routine care plus twice daily mindful meditation"
11148592|NCT03737279|Active Comparator|Routine care|"Control Group:
~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
11148593|NCT03737266|Experimental|Sonographically assisted breast surgery|Sonography assisted breast surgery
11148594|NCT03737266|Active Comparator|Conventional breast surgery|Conventional breast surgery
11148595|NCT03737253|Active Comparator|Follitropin alpha|Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
11148596|NCT03737253|Active Comparator|Menotropin|Menotropin (Menopur, Ferring GmbH, Kiel, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
11148597|NCT03737240|Experimental|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
11148598|NCT03737240|Active Comparator|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
11148630|NCT03737006||2-Other Congenital Heart Defect (OCHD)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
11148599|NCT03737227|Other|Cinematographic recording|Cinematographic recordings of the asymptomatic participants during flexion and extension of the lumbar spine.Cinematographic recordings will be performed twice with an interval of two weeks.
11148600|NCT03737214|Experimental|Lucerastat|Dose will be based on subject's eGFR.
11148601|NCT03737201|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
11148602|NCT03737201|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
11148603|NCT03737201|Active Comparator|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
11148604|NCT03737175|Experimental|Carotid Artery Stenting group|Carotid Artery Stenting
11148605|NCT03737175|Active Comparator|Carotid Endarterectomy group|Carotid Endarterectomy
11148606|NCT03737162|Experimental|Covered stent group|Covered stent
11148607|NCT03737162|Active Comparator|Bare-metal stent group|Bare-metal stent
11148608|NCT03737149|Experimental|mymobility with Apple Watch|Post-operative mobile application-guided education and exercise paired with accurate and sensitive activity monitoring.
11148609|NCT03737149|No Intervention|Standard of Care Physical Therapy|Standard of care patient education and post-operative physical therapy, as determined by local site guidelines and care pathways.
11148610|NCT03737136|No Intervention|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
11148611|NCT03737136|Active Comparator|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
11148612|NCT03737123|Experimental|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
11148613|NCT03737110|Active Comparator|Rilonacept|Rilonacept SC injections once weekly
11148614|NCT03737110|Placebo Comparator|Placebo|Placebo SC injections once weekly
11148615|NCT03737097|Experimental|Online Spaced Education|The intervention cohort will participate in an online spaced education on fall prevention education developed for patients with multiple sclerosis.
11148616|NCT03737097|Active Comparator|Brochure Education|The control cohort will receive the fall prevention education in bolus through a Brochure developed by the National Multiple Sclerosis Society. The brochure was translated to portuguese and will be used in the study with authorization of the Society.
11148617|NCT03737084|Experimental|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
11148618|NCT03737084|No Intervention|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
11148619|NCT03737071|Experimental|Low Carbohydrate Diet|Low Carbohydrate Diet
11148620|NCT03737045|Other|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
11148621|NCT03737032|Experimental|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
11148622|NCT03737032|Experimental|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
11148623|NCT03737032|Experimental|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
11148624|NCT03737032|Experimental|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
11148625|NCT03737032|Experimental|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
11148626|NCT03737032|Experimental|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
11148627|NCT03737019|Experimental|ACT in County Council of Kalmar|Group education with ACT in six primary health care centers in County Council of Kalmar
11148628|NCT03737019|Placebo Comparator|Control health care centers of County Council of Jönköping|Five primary health care centers of County Council of Jönköping that do not get education.
11148629|NCT03737006||1-(HLHS) effected pregnancies|Consent,blood draw, nose swab, stool collection,questionnaire and review of medical records.
11148633|NCT03736980|Experimental|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
11148634|NCT03736980|Experimental|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
11148635|NCT03736980|Experimental|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
11148636|NCT03736980|Experimental|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
11148637|NCT03736967|Experimental|REGN3500|
11148638|NCT03736967|Experimental|Dupilumab|
11148639|NCT03736967|Experimental|Combo|
11148640|NCT03736967|Experimental|Placebo|
11148641|NCT03736954|Experimental|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
11148642|NCT03736941|Experimental|Patients with venous leg|"After inclusion, the medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. Follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
~During the various visits, clinical data will be collected in the patient's medical file as well as the answers to the questionnaires."
11148643|NCT03736928|Placebo Comparator|50U or placebo|Subjects randomized (4:1) to 50U AbobotulinumtoxinA or placebo
11148644|NCT03736928|Placebo Comparator|75U or placebo|Subjects randomized (4:1) to 75U AbobotulinumtoxinA or placebo
11148645|NCT03736928|Experimental|dose level 3|Subjects randomized (4:1) to dose group 3 AbobotulinumtoxinA or placebo
11148646|NCT03736928|Experimental|dose level 4|Subjects randomized (4:1) to dose group 4 AbobotulinumtoxinA or placebo
11148647|NCT03736915|Active Comparator|1 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
11148648|NCT03736915|Active Comparator|3 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
11148649|NCT03736915|Active Comparator|5 cc needle with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
11148650|NCT03736889|Experimental|Tislelizumab (BGB-A317) Injection|
11148651|NCT03736876|Experimental|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
11148652|NCT03736876|No Intervention|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
11148653|NCT03736863|Experimental|Apatinib+SHR-1210|Apatinib+SHR-1210
11148654|NCT03736850|Experimental|CS3006|
11148655|NCT03736837|Experimental|Anlotinib Plus Icotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
11148656|NCT03736811|Active Comparator|Absorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 [Vicryl] or polydioxanone [PDS II] sutures.
11148657|NCT03736811|Experimental|Nonabsorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester [Ethibond Excel] or polypropylene [Prolene] sutures.
11148658|NCT03736785|Experimental|LY3209590 Algorithm 1|LY3209590 administered subcutaneously (SC).
11148659|NCT03736785|Experimental|LY3209590 Algorithm 2|LY3209590 administered SC.
11148660|NCT03736785|Experimental|Insulin Degludec|Insulin degludec administered SC.
11148661|NCT03736772|Experimental|LY3090106|LY3090106 administered subcutaneously (SC)
11148662|NCT03736772|Placebo Comparator|Placebo|Placebo administered SC
11148663|NCT03736759|Experimental|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
11148664|NCT03736759|Active Comparator|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
11148665|NCT03736759|No Intervention|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
11148666|NCT03736746|Experimental|Motivational Interviewing|"Will entail two-to-four Motivational Interviewing sessions per participant
~Will include a battery of questionnaires
~Investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs).
~The investigator will elicit questions and goals that participants will be encouraged to discuss with their palliative care providers"
11148667|NCT03736733|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
11148668|NCT03736733|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
11148724|NCT03736330|Experimental|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
11148861|NCT03735303|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
11148669|NCT03736720|Experimental|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
11148670|NCT03736707|Experimental|Selective HFOV|Selective HFOV will be provided
11148671|NCT03736707|Active Comparator|CMV|CMV will be provided
11148672|NCT03736694|Experimental|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, & Swanson, et al, 2014; Morin, Savard, Ouellet, & Daley, 2003). One workshop has the capacity of 30 participants.
11148673|NCT03736694|Experimental|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
11148674|NCT03736694|Active Comparator|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
11148675|NCT03736681|Experimental|40cc|40c buffered 0.5% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
11148676|NCT03736681|Active Comparator|20cc|20cc 1% lidocaine with 2 units of vasopressin paracervical block with dilation and curettage under minimal sedation
11148677|NCT03736668|Experimental|Patients with Type 2 diabetes|"One year after patient's inclusion, during the additional cardiology consultation, an echocardiography will be performed by the investigator to evaluate any changes.
~Two years after the patient's inclusion, an investigator will contact by phone the general practitioner, cardiologist and / or diabetologist treating the patient to find out if any cardiovascular events occurred."
11148678|NCT03736655|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
11148679|NCT03736642||restrictive anorexia nervosa with hunger|
11148680|NCT03736642||restrictive anorexia nervosa without hunger|
11148681|NCT03736642||constitutional thinness|
11148682|NCT03736642||control subjects without eating disorders|
11148683|NCT03736629|Placebo Comparator|Placebo|8 weeks of placebo capsule once daily by mouth
11148684|NCT03736629|Active Comparator|Azithromycin|8 weeks of Azithromycin (250 mg) capsule once daily by mouth
11148685|NCT03736616|Experimental|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 & Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.
~BEAM chemotherapy & autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT
~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
11148686|NCT03736616|Experimental|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.
~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
11148687|NCT03736603|Experimental|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
11148688|NCT03736603|Experimental|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
11148689|NCT03736603|No Intervention|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
11148690|NCT03736590|Experimental|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
11148691|NCT03736590|Active Comparator|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
11148692|NCT03736577|Experimental|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.
~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
11148693|NCT03736577|No Intervention|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
11148694|NCT03736564|Experimental|68Ga-DOTATATE PET/CT|Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
11148695|NCT03736551|Experimental|Intervention|The intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing ~600 kcal/day and 100% of the RNI for vitamins and minerals.
11148896|NCT03735121|Experimental|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
11148696|NCT03736551|Active Comparator|Standard Care|Renal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
11148697|NCT03736538|Experimental|Nitrous Oxide|"Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive inhaled nitrous oxide."
11148698|NCT03736538|Placebo Comparator|Placebo Gas|"Placebo gas given at 50% nitrogen [inert]/50% oxygen.
~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive placebo gas."
11148699|NCT03736525|Experimental|Design For Wellness (DWELL)|Intervention participants will: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
11148700|NCT03736525|Other|Wait list control group|After the close of the study, we will open the Facebook group to all, and wait list control group participants can receive a delayed form of the intervention, which includes: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
11148701|NCT03736486||Type 2 Diabetes|Male and female adults of Hispanic and/or Latino heritage with an established diagnosis of Type 2 diabetes.
11148702|NCT03736473|Other|MEDI9447 monotherapy|Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies
11148703|NCT03736460|Experimental|Mindfulness-based intervention|
11148704|NCT03736460|Active Comparator|Physical training|
11148705|NCT03736460|No Intervention|Wait-list|
11148706|NCT03736447|Active Comparator|AR101 powder (Peanut allergen formulation)|Subjects will be randomized to active arm of ARC005 and will be administered IP (AR101) in escalating doses for approximately 6 months.
11148707|NCT03736447|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC005 and will be administered escalating doses of IP (placebo) for approximately 6 months.
11148708|NCT03736434|Experimental|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
11148709|NCT03736434|Active Comparator|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
11148710|NCT03736434|No Intervention|Control Group|Continue care as usual without intervention.
11148711|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
11148712|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
11148713|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
11148714|NCT03736408||1. Group without Pain - TMJ disorders symptoms|1. The symptoms concerning joints were: the type of sound symptoms (clicking or popping), their frequency and the phase of the movement of lowering and lifting the jaw during which they occurred, occurrence of the tension type headache or back pain. Hypertension of the mastication muscles is frequently connected with a parafunction activity like grinding or clenching the teeth, which cause abnormal pressure on the joints
11148715|NCT03736408||2. Group with Pain and symptoms TMJ disorder|The pain form of the disease is manifested by spontaneous pain in the preaural region, accompanied by pain or tenderness of the mastication muscle. Pain that appears during palpation examination of temporomandibular joints is frequently not related to inflammation of the soft tissue around the temporomandibular joints, as it is claimed by several authors of the paper. The cause of this problem is a long-term overload of soft tissue causally associated with excessive muscle tension, that sometimes even persists for years
11148716|NCT03736395|Active Comparator|Control|Schools in this condition will be provided a four-day training about Schoolwide Positive Behavioral Interventions and Supports, and bi-yearly feedback about progress monitoring and action planning.
11148717|NCT03736395|Experimental|I-RIM Intervention|Schools in this condition will be provided the same basic training as the control condition, plus the elements of the Idaho Rural Implementation Model (I-RIM).
11148718|NCT03736382|Experimental|Hypoxia Group|The hypoxia group is comprised of participants with OSA and hypertension that will be treated with IH and CPAP. In the present proposal, the IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2) = 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
11148719|NCT03736382|Sham Comparator|Sham Group|The sham group will be comprised of hypertensive OSA participants that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for a minimum of 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the IH protocol.
11148720|NCT03736369|Experimental|DWP14012 40mg|Orally, once daily
11148721|NCT03736369|Active Comparator|Esomeprazole 40mg|Orally, once daily
11148722|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 1|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
11148723|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 2|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
11148725|NCT03736317|Sham Comparator|control group|Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.
11148726|NCT03736317|Experimental|real mPFC cTBS group|The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.
11148727|NCT03736317|Experimental|real dlPFC iTBS group|The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.
11148728|NCT03736317|Experimental|real dlPFC iTBS + real mPFC cTBS group|Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.
11148729|NCT03736304|Placebo Comparator|Usual care|Patients will receive standard clinical care by the doctor in charge.
11148730|NCT03736304|Experimental|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
11148731|NCT03736291|Active Comparator|active rTMS|"The Active rTMS: The magnetic head uses the Magro X100's 8-shaped coil, and the intervention site is the cerebellar vermis (1 cm below the occipital carina). The stimulation intensity is gradually increased by the 80%-100% exercise threshold according to the patient's tolerance. The total number of stimulation pulses per day is 600, the basic frequency is 5 Hz, and one short burst stimulus is given every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and every 10 short bursts are stimulated for 8 s. A total of 200 short bursts of stimulation. Intervention once a day, 5 times a week, intervention for 2 weeks, a total of 10 times."
11148732|NCT03736291|Sham Comparator|sham rTMS|"The sham rTMS: The sham stimulation method was to invert the 8 shaped coil, which was 180° to the scalp, and other intervention parameters were consistent with the study group."
11148733|NCT03736265|Experimental|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55/min.
11148734|NCT03736265|No Intervention|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
11148735|NCT03736213|Experimental|Condition 1: Visual-acoustic biofeedback|Behavioral: Biofeedback--visual-acoustic
11148736|NCT03736213|Experimental|Condition 2: Ultrasound biofeedback|Behavioral: Biofeedback-ultrasound
11148737|NCT03736200|Active Comparator|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
11148738|NCT03736200|Active Comparator|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
11148739|NCT03736200|Active Comparator|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
11148740|NCT03736187|Experimental|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
11148741|NCT03736187|Experimental|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
11148742|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
11148743|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
11148744|NCT03736161|Experimental|Group A- Tofacitinib|Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
11148745|NCT03736161|Placebo Comparator|Group B- Methotrexate|Methotrexate in increasing dose starting from 15 mg weekly to a maximum dose of 25 mg weekly from the end of 1st month. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD.
11148746|NCT03736148|Experimental|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
11148747|NCT03736148|Active Comparator|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
11148748|NCT03736148|Placebo Comparator|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
11148749|NCT03736148|No Intervention|Control|No contact was given to the subject.
11148750|NCT03736122|Experimental|BSG-001|Inhalation route, daily
11148751|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
11148752|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
11148753|NCT03736083|Active Comparator|Freestyle Libre Group|Freestyle Libre Group: Participants will use the Freestyle Libre flash glucose monitoring system throughout the study for 2-3 months.
11148754|NCT03736083|No Intervention|Control Group (standard diabetes care)|This group will receive standard care. At the around 1 week and 2 month visits, control group subjects will use a blinded Freestyle Libre Pro to provide data that can be used to compare glucose variability between groups. The Libre sensor will allow the study team to measure glucose values but the subjects will not have access to this information for management/treatment decisions and usual diabetes care will be unaffected. The Freestyle Libre Pro last 14 days, can be activated in clinic, and the sensor can be returned in person or via mail where the investigators will download the data.
11148755|NCT03736044|Experimental|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
11148756|NCT03736044|No Intervention|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
11148798|NCT03735771|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
11148757|NCT03736031|Experimental|Intervention (Promotora)|The intervention group will have three face-to-face meetings with the promotora. Participant will continue to receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
11148758|NCT03736031|No Intervention|Self-Education (Control)|Participant will receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
11148759|NCT03736018|Active Comparator|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
11148760|NCT03736018|No Intervention|ICA only|Invasive coronary angiogram (ICA) performed only.
11148761|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
11148762|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
11148763|NCT03735992|Experimental|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
11148764|NCT03735992|No Intervention|Wait list|Treatment as usual.
11148765|NCT03735979|Experimental|Argatroban|100µg/kg bolus followed by 3µg/kg per minute for 12 hours
11148766|NCT03735979|Experimental|Eptifibatide|135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours
11148767|NCT03735979|Placebo Comparator|Placebo|
11148768|NCT03735966|Experimental|Pyrotinib plus trastuzumab and docetaxel and carboplatin|Pyrotinib + trastuzumab + docetaxel+carboplatin
11148769|NCT03735953|Experimental|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
11148770|NCT03735953|No Intervention|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
11148771|NCT03735940|No Intervention|Control phase|no intervention, i.e. care as usual
11148772|NCT03735940|Experimental|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
11148773|NCT03735927|No Intervention|Control phase|no intervention, i.e. care as usual
11148774|NCT03735927|Experimental|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
11148775|NCT03735914|Experimental|neuralgic patients|MRI experimentation
11148776|NCT03735901|Active Comparator|Experimental Intervention|White Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg.
11148777|NCT03735901|Placebo Comparator|Control Intervention|Matching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group.
11148778|NCT03735875|Experimental|Treatment (venetoclax, quizartinib)|Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
11148779|NCT03735862||Observations Group|Patients who have undergone a hiatal hernia repair with MIROMESH.
11148780|NCT03735849|Experimental|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
11148781|NCT03735849|Experimental|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
11148782|NCT03735836|Experimental|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
11148783|NCT03735836|Experimental|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
11148784|NCT03735810|Experimental|SAD - Cohort 1|50 mg LBS-008 or placebo
11148785|NCT03735810|Experimental|SAD - Cohort 2|100 mg LBS-008 or placebo
11148786|NCT03735810|Experimental|SAD - Cohort 3|200 mg LBS-008 or placebo
11148787|NCT03735810|Experimental|SAD - Cohort 4|400 mg LBS-008 or placebo
11148788|NCT03735810|Experimental|SAD - Cohort 5|25 mg LBS-008 or placebo
11148789|NCT03735810|Experimental|MAD - Cohort 1|10 mg LBS-008 or placebo
11148790|NCT03735810|Experimental|MAD - Cohort 2|25 mg LBS-008 or placebo
11148791|NCT03735810|Experimental|MAD - Cohort 3|5 mg LBS-008 or placebo
11148792|NCT03735810|Experimental|MAD - Cohort 4|12 mg LBS-008 or placebo
11148793|NCT03735784|Experimental|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
11148794|NCT03735784|No Intervention|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
11148795|NCT03735771|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
11148796|NCT03735771|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
11148797|NCT03735771|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
11148801|NCT03735745|Experimental|Caucasian, HPV positive, Non Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
11148802|NCT03735745|Experimental|Caucasian, HPV positive, Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
11148803|NCT03735745|Experimental|Newly diagnosed, African American/Black, HPV negative, Smoking|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
11148804|NCT03735745|Experimental|Young (<40 years old), Oral Cavity (Tongue) patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
11148805|NCT03735745|Experimental|Neoadjuvant PD-1 Blockade patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
11148806|NCT03735732||weight status|
11148807|NCT03735732||mindset|
11148808|NCT03735719||STEMI patients|Patients with first STEMI treated with primary PCI are recruited in this study.
11148809|NCT03735719||Control group|The control group will consist of patients with risk factors for cardiovascular diseases, but without history of coronary artery disease or heart failure.
11148810|NCT03735706|Active Comparator|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.
~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
11148811|NCT03735706|Experimental|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.
~A radiation dose reduction from 120 to 90 kV.
~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
11148812|NCT03735706|Experimental|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.
~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
11148813|NCT03735706|Experimental|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.
~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.
~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
11148814|NCT03735680|Experimental|Patients receiving ONM-100|All patients in this arm will receive ONM-100 for injection and undergo intraoperative imaging.
11148815|NCT03735667|Experimental|ACURATE Valve - Randomized|"Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
~*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
11148816|NCT03735667|Experimental|ACURATE Valve - Single-arm Roll-in|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
11148817|NCT03735667|Active Comparator|Commercial Valve - Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System
~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.
~*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
11148818|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
11148819|NCT03735628|Experimental|Dose escalation|"Copanlisib:
~45 mg (dose level -1) or 60 mg (dose level 1) on Day 1, Day 8 and Day 15 (28 day cycle)
~Nivolumab:
~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
11148820|NCT03735628|Experimental|Dose expansion|"Copanlisib:
~Recommended phase 2 dose established in the phase 1b part on Day 1, Day 8 and Day 15 (28 day cycle)
~Nivolumab:
~240 mg on Day 15 of Cycle 1 and on Day 1 and Day 15 of subsequent cycles (28 day cycle)."
11148821|NCT03735615|Experimental|chronic obstructive lung disease|
11148822|NCT03735615|Experimental|healthy control|
11148823|NCT03735602|Experimental|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
11148824|NCT03735589|Experimental|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
11148825|NCT03735576|Experimental|LLD-adapted cognitive behavioural therapy (CBT)|manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
11148826|NCT03735576|Active Comparator|supportive unspecific intervention (SUI)|manualized 15-session individually-delivered supportive unspecific intervention (SUI)
11148827|NCT03735563|Experimental|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
11148828|NCT03735563|Experimental|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
11148829|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
11148830|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
11148831|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.
~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).
~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
11148832|NCT03735537|Active Comparator|Teriparatide and zoledronic acid|Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector, given subcutaneously using a self-administered injection device for two years (24 months) followed by a single intravenous 5mg infusion of zoledronic acid.
11148833|NCT03735537|No Intervention|Standard Care|Continuation of existing bone modifying treatment (i.e. bisphosphonate treatment) or no active bone modifying treatment according to the clinical judgement of the local investigator.
11148834|NCT03735524|Experimental|Exercise|Conventional rehabilitation
11148835|NCT03735498|Experimental|Psychological Intervention|"Qualitative interview will be conducted
~7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online
~A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills
~A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty
~A self-care component to promote caregiver health and well-being"
11148836|NCT03735485|Experimental|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
11148837|NCT03735485|Experimental|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
11148838|NCT03735485|Experimental|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
11148839|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
11148840|NCT03735459|Experimental|Patient reminder|"Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema.
~Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider.
~Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life.
~Enrollment: Participants will complete FDLQI and PO-SCORAD.
~Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ.
~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
11148841|NCT03735459|No Intervention|No patient reminder/control|"Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment.
~Enrollment: Participants will complete FDLQI and PO-SCORAD.
~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
11148842|NCT03735446|Experimental|Prexasertib+MEC|"Cytarabine is administered intravenously on days 1-5.
~Etoposide is administered intravenously on days 1-5.
~Mitoxantrone is administered intravenously on days 1-5.
~Prexasertib is administered intravenously on days 1, 3, and 5."
11148843|NCT03735433|No Intervention|81 mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
11148844|NCT03735433|Active Comparator|162mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
11148845|NCT03735420|Experimental|Xanthohumol|Participants will receive 24 mg of 98% pure xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
11148846|NCT03735420|Placebo Comparator|Placebo oral capsule|Participants will receive vehicle (rice protein) by mouth once daily with the first daily meal.
11148847|NCT03735407|Experimental|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
11148848|NCT03735394|Experimental|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller & Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
11148849|NCT03735381|Active Comparator|Intervention 1: pedometer|"Minimum intervention:
~Use of pedometer watch from 12 to 32 GW
~Recommendations of physical activity"
11148850|NCT03735381|Experimental|Intervention 2: pedometer+goal+reminds|"Maximum intervention:
~Use of pedometer from 12 to 32 GW
~Recommendations of physical activity
~Information about get a goal of 11000 steps/day
~Reminds the goal every two weeks."
11148851|NCT03735381|No Intervention|Control: without pedometer|Women receive some recommendations of physical activity during pregnancy. They do not use the pedometer during pregnancy
11148852|NCT03735368|Placebo Comparator|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
11148853|NCT03735368|Active Comparator|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
11148854|NCT03735355|Experimental|Balloon dilation|TTS balloon dilation
11148855|NCT03735355|Active Comparator|Surgery|Resection of the fibrostenotic area
11148856|NCT03735342|Experimental|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
11148857|NCT03735342|No Intervention|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
11148858|NCT03735329|Experimental|Pulse oximetry monitoring|
11148859|NCT03735316|Experimental|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
11148860|NCT03735316|Placebo Comparator|Placebo|Subjects will receive placebo
11148862|NCT03735303|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
11148863|NCT03735303|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
11148864|NCT03735303|Experimental|control group|no intervention was given
11148865|NCT03735290|Experimental|Phase 1b: Cohort 1, ilixadencel + pembrolizumab|3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab q3w
11148866|NCT03735290|Experimental|Phase 1b: Cohort 2, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w
11148867|NCT03735290|Experimental|Phase 1b: Cohort 3, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w
11148868|NCT03735290|Experimental|Phase 1b: Cohort 4, ilixadencel + pembrolizumab|Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w
11148869|NCT03735290|Experimental|Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.
11148870|NCT03735290|Active Comparator|Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.
11148871|NCT03735277|Experimental|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters.
11148872|NCT03735264|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
11148873|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A>1，DT 160~220 ms，S/D >1，AR 0.22-0.32m/sec，E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A< 1，DT > 220 ms，S/D > 1，AR 0.21-0.28 m/sec，E/e'<10 Pseudo-normalization pattern：E/A> 1，DT 150~210 ms，S/D < 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT < 150 ms，S/D <1，AR ≥0.25m/sec，E/e'≥10
11148874|NCT03735238||Lupus Patients|All lupus patients, regardless of if they are having an active flare
11148875|NCT03735225|Experimental|IV Dasiglucagon|Dasiglucagon 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
11148876|NCT03735225|Experimental|SC 0.6 mg Dasiglucagon|Dasiglucagon 0.6 mg administered SC as a single dose
11148877|NCT03735225|Placebo Comparator|IV Placebo|Placebo 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
11148878|NCT03735212|Experimental|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
11148879|NCT03735212|No Intervention|Control Group|Participants in this group receive services as usual.
11148880|NCT03735199|Experimental|PCL-TCP scaffold|During the surgery, the PCL-TCP scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A Geistlich Bio-Gide collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
11148881|NCT03735199|Active Comparator|Geistlich Bio-Gide collagen membrane|"No space filler will be inserted in the extraction socket but similar to the test group, a Geistlich Bio-Gide collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
~denture overlying the extraction site will be completely relieved."
11148882|NCT03735186|No Intervention|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
11148883|NCT03735186|Experimental|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
11148884|NCT03735173|Active Comparator|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
11148885|NCT03735173|Active Comparator|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
11148886|NCT03735173|Active Comparator|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
11148887|NCT03735173|Active Comparator|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
11148888|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
11148889|NCT03735147|Experimental|All children|Administration of live attenuated influenza vaccine (LAIV)
11148890|NCT03735134|Active Comparator|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
11148891|NCT03735134|Active Comparator|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
11148892|NCT03735134|Active Comparator|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
11148893|NCT03735121|Experimental|Atezolizumab (Part 2)|Atezolizumab
11148894|NCT03735121|Experimental|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
11148895|NCT03735121|Experimental|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
11148897|NCT03735121|Experimental|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
11148898|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
11148899|NCT03735108||normal control group|no history of pregnancy loss
11148900|NCT03735095|Experimental|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
11148901|NCT03735082|Experimental|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
11148902|NCT03735069|Experimental|IPT (Indirect pulp treatment) group|In this group, complete caries excavation from the dentin-enamel junction will be done. Caries near the pulp will be removed with caution until the remaining dentin shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material will be placed (Vitrebond; St.Paul, MN), followed by resin-modified glass ionomer (RMGI) build-up material (Vitremer; St. Paul, MN), and the final restoration of choice for MIH involved teeth; a preformed Stainless Steel Crown (SSC).
11148903|NCT03735069|Experimental|Cvek/partial pulpotomy group|"In this group, partial pulpotomy will be attempted first, inflamed pulp tissue will be removed until healthy pulp tissue is reached (2-4mm depth), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated twice if required; otherwise, cervical pulpotomy will be done.
~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be placed in the pulp chamber (2-3mm thickness), a moist cotton pellet will be placed and Intermediate Restorative Material (IRM) to ensure setting. Patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
11148904|NCT03735069|Experimental|Cervical pulpotomy group|"In this group, a cervical pulpotomy procedure will be done where all pulp chamber tissue shall be removed until healthy pulp tissue is reached, as indicated by bleeding from all canals and arrest of hemorrhage upon pressure (for maximum 6 minutes).
~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be mixed according to manufacturer instructions and will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with Intermediate Restorative Material (IRM), the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
11148905|NCT03735056|No Intervention|Group 1 (Usual care)|Receives usual care only.
11148906|NCT03735056|Experimental|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl & Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
11148907|NCT03735056|Experimental|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
11148908|NCT03735043|Experimental|ccNexfin ©|
11148909|NCT03735030|Experimental|human hCG|
11148910|NCT03735030|Active Comparator|recombinant hCG|
11148911|NCT03735017|Active Comparator|Non-Interactive|Participants will receive non-interactive virtual reality walking sessions.
11148912|NCT03735017|Experimental|Interactive|Participants will receive interactive virtual reality walking sessions.
11148913|NCT03735004|Experimental|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
11148914|NCT03735004|Active Comparator|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
11148915|NCT03735004|Sham Comparator|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
11148916|NCT03734991|Experimental|Ibrexafungerp (SCY-078)|300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
11148917|NCT03734991|Placebo Comparator|Placebo|Matching Placebo
11148918|NCT03734978||A blood group|prematurity with sepsis
11148919|NCT03734978||O blood group|prematurity with sepsis
11148920|NCT03734978||B blood group|prematurity with sepsis
11148921|NCT03734978||AB blood group|prematurity with sepsis
11148922|NCT03734965|Active Comparator|AWAKEN INTUBATION FIBEROPTIC|awaken intubation
11148923|NCT03734965|Experimental|AWAKEN INTUBATION VIDEOLARYNGOSCOPY|awaken intubation
11148924|NCT03734952|Experimental|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
11148925|NCT03734952|Other|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
11148926|NCT03734926|Experimental|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
11148927|NCT03734926|Experimental|Part 2 Cohort A|Participants with hepatocellular carcinoma.
11148928|NCT03734926|Experimental|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
11148929|NCT03734913|Experimental|Part 1|Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.
11148930|NCT03734913|Experimental|Part 2 Cohort A|Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.
11148931|NCT03734913|Experimental|Part 2 Cohort B|Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.
11148932|NCT03734900|Placebo Comparator|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
11148933|NCT03734900|Experimental|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
11148934|NCT03734900|Experimental|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
11148935|NCT03734887|Active Comparator|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
11148936|NCT03734887|Experimental|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
11148937|NCT03734874|Active Comparator|hesperidin|
11148938|NCT03734874|Placebo Comparator|control|
11148939|NCT03734861|Experimental|BreatheSmart System|"BreatheSmart mobile application that tracks medication usage and sends real time reminders
~HeroTracker sensor that counts dosage and monitors real-time medication adherence
~CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
11148940|NCT03734861|Active Comparator|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
11148941|NCT03734848|No Intervention|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
11148942|NCT03734848|Active Comparator|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
11148943|NCT03734835|Active Comparator|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
11148944|NCT03734835|Placebo Comparator|control|no supplementation
11148945|NCT03734835|Active Comparator|flaxseed|30 grams flaxseed
11148946|NCT03734835|Active Comparator|hesperidin|1000 mg hesperidin as two capsules
11148947|NCT03734822|Other|CF|Cystic fibrosis patients undergoing general anesthesia.
11148948|NCT03734809|Experimental|pembrolizumab|"Total 51 weeks for 17 doses of pembrolizumab:
~Neoadjuvant pembrolizumab-chemotherapy: 6 weeks (2 doses of pembrolizumab)
~Concurrent pembrolizumab-chemoradiation: 9 weeks (3 doses of pembrolizumab
~Maintenance pembrolizumab: 36 weeks (12 doses of pembrolizumab)"
11148949|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
11148950|NCT03734783||Patients|HBsAg positive more than 6 months
11148951|NCT03734783||health control|
11148952|NCT03734770|Active Comparator|Subcutaneous progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
11148953|NCT03734770|Active Comparator|Vaginal progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
11148954|NCT03734757|Experimental|Trimodality|PET-CT with fluorocholine and MRI
11148955|NCT03734744|Experimental|Adults with Cystic Fibrosis|CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
11148956|NCT03734744|Experimental|Non-CF Controls with Low vitamin D|Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
11148957|NCT03734731|Other|Objective Nerve Conduction testing|Therapy of chronic pain and swelling with Monochromatic Infrared Photo Energy (MIRE) in combination with Transcutaneous Electrical Nerve Stimulation (TENS) and Cannabis or Opioids, to determine which treatment is deemed as the most successful, through objective nerve conduction testing with Neural Scan or AXON-II testing systems. Other types of therapies may be introduced during comparison reviews.
11148958|NCT03734718|Active Comparator|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
11148959|NCT03734718|Placebo Comparator|Placebo|Saline
11148960|NCT03734705|Experimental|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
11148961|NCT03734705|Sham Comparator|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
11148962|NCT03734692|Experimental|cisplatin + rintatolimod + pembrolizumab|Intraperitoneal (IP) cisplatin 50mg/m^2 solution with IP rintatolimod 200 mg solution and IV pembrolizumab 200 mg solution.
11148963|NCT03734679|Experimental|Surveil drug coated balloon|
11148964|NCT03734666|Experimental|Mindfulness Based Relapse Prevention|Participants will receive Mindfulness Based Relapse Prevention (MBRP), an existing substance use treatment, which has been modified to focus explicitly on smoking cessation and reduced alcohol use, creating Mindfulness Based Relapse Prevention - Smoking and Alcohol (MBRP-SA).
11148965|NCT03734666|Active Comparator|Cognitive Behavioral Therapy|Participants will receive Cognitive Behavioral Therapy (CBT) a well-established and commonly used treatment for substance abuse behaviors that utilizes problem solving and coping skills.
11148966|NCT03734653|Experimental|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
11148967|NCT03734640|Placebo Comparator|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
11148968|NCT03734640|Active Comparator|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
11148969|NCT03734627||Upper Gastrointestinal Surgery - Transit|
11148970|NCT03734627||Control - Transit|
11148971|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
11148972|NCT03734627||Control - Gut Function|
11148973|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
11148974|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
11148975|NCT03734601|Experimental|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
11148976|NCT03734588|Experimental|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
11148977|NCT03734575|Experimental|ClariCore System|Biopsy tissue, correlative spectral data, T2-weighted MR scans and ultrasound images acquired with the ClariCore System will be collected and recorded during standard practice transperineal biopsy.
11148978|NCT03734562|Experimental|Ablation|Substrate-based radiofrequency catheter ablation
11148979|NCT03734562|Active Comparator|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
11148980|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
11148981|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
11148982|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
11148983|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
11148984|NCT03734536|Other|REGENETEN™ Bioinductive Implant|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
11148985|NCT03734536|Other|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
11148986|NCT03734523||Pilot Group|Subjects will return at 1-week after starting the system. They will be screened for BV using the wet mount, vaginal pH and Nugent scoring. The wet mount and vaginal pH will be done in the office, the Nugent scoring will be sent to Dr. Deirdre O'Hanlon. If a superinfection with yeast has occurred, they will be treated via standard of care treatments. If BV is confirmed at the one week visit, they will be treated with a 7 day course of oral metronidazole (standard of care). Those that are diagnosed and those that are not diagnosed with BV, will continue to use Balance every day, Restore every other day, and BiopHresh every third day until the completion of the study.
11148987|NCT03734510|Active Comparator|hesperidin and flaxseed|
11148988|NCT03734510|Placebo Comparator|control|
11148989|NCT03734510|Active Comparator|flaxseed|
11148990|NCT03734510|Active Comparator|hesperidin|
11148991|NCT03734497|Active Comparator|Group Control|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
11148992|NCT03734497|Experimental|Group Preloading|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
11148993|NCT03734497|Experimental|Group Carotis FTc|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
11148994|NCT03734484|Experimental|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
11148995|NCT03734484|No Intervention|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
11148996|NCT03734471|Active Comparator|Traditional|
11148997|NCT03734471|Experimental|Reactor Device|
11148998|NCT03734458|Experimental|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
11148999|NCT03734458|Experimental|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
11149000|NCT03734458|Active Comparator|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
11149001|NCT03734445|Experimental|Vitamin supplement|Effervescent tablets containing Vitamin C, Vitamin D and zinc
11149002|NCT03734445|Placebo Comparator|Placebo|Effervescent tablets not containing Vitamin C, Vitamin D and zinc
11149004|NCT03734406|Experimental|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.
~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.
~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
11149005|NCT03734406|No Intervention|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.
~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
11149006|NCT03734393|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
11149007|NCT03734393|No Intervention|HIVD-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
11149008|NCT03734393|No Intervention|HIVD-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120
11149009|NCT03734380|Experimental|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
11149010|NCT03734380|Experimental|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
11149011|NCT03734380|Experimental|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
11149012|NCT03734367|Active Comparator|Emotional abilities training program|Intervention program on emotional abilities that will be carried out for 10 hours distributed over 5 weeks, in two and a half hour session. The work methodology will be eminently practical, working in groups including real case analysis and interactive simulation
11149013|NCT03734367|No Intervention|Control group|Control group that will not receive the training program on emotional abilities but usual care.
11149014|NCT03734354|Experimental|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
11149015|NCT03734354|Experimental|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
11149016|NCT03734354|Experimental|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
11149017|NCT03734341|Experimental|EZ START Titration|"CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.
~Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period)."
11149018|NCT03734341|Active Comparator|APAP Titration|"CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.
~Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period)."
11149019|NCT03734328|Active Comparator|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)
~Other names:
~5/0 silk suture"
11149020|NCT03734328|Experimental|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)
~Other names:
~-5/0 silk suture"
11149021|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
11149022|NCT03734302|Experimental|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
11149023|NCT03734289|Active Comparator|Immediate Coaching|Immediately following randomization, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
11149024|NCT03734289|Active Comparator|Delayed Coaching|6 weeks following the initial visit, online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
11149025|NCT03734276|Experimental|High intensity exercise|
11149026|NCT03734276|Active Comparator|Control|
11149027|NCT03734263|Experimental|open label|sodium phenylbutyrate
11149028|NCT03734250||Group Sugammadex HD|Sugammadex used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30ng/ml
11149588|NCT03730532|Experimental|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
11149029|NCT03734250||Group neostigmine HD|Neostigmine used as neuromuscular blocker reverse agent with Vitamin D status equal or above 30 ng/ml
11149030|NCT03734250||Group Sugammadex LD|Sugammadex used as neuromuscular reverse agent with Vitamin D status under 30 ng/ml
11149031|NCT03734250||Group Neostigmine LD|Neostigmine used as neuromuscular reverse agent with Vitamin D status under 30ng/ml
11149032|NCT03734237|Active Comparator|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
11149033|NCT03734237|Active Comparator|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
11149034|NCT03734237|Active Comparator|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
11149035|NCT03734224|Active Comparator|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
11149036|NCT03734224|Active Comparator|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
11149037|NCT03734211|Experimental|Evolocumab|
11149038|NCT03734211|Placebo Comparator|Placebo|
11149039|NCT03734198|Experimental|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day
~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.
~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.
~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.
~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
11149040|NCT03734185|Experimental|Learning and Coping|A health pedagogical strategy that builds on inductive teaching with high involvement of the participants. Characteristics of Learning and Coping are that 'experienced patients' plan, teach and evaluate, in cooperation with health professionals.
11149041|NCT03734185|Active Comparator|Usual Cardiac Rehabilitation|The theoretical frameworks used in some of these local healthcare services are empowerment, self-efficacy and self-management
11149042|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
11149043|NCT03734159|Experimental|parasternal block|preoperative parasternal block by ropivacaine injection
11149044|NCT03734159|Placebo Comparator|physiological serum|sodium chloride injection
11149045|NCT03734146|Experimental|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
11149046|NCT03734146|Experimental|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
11149047|NCT03734146|Experimental|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
11149048|NCT03734146|No Intervention|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
11149049|NCT03734133|Experimental|Foot orthoses|Different foot orthoses
11149050|NCT03734120||men|men undergoing routine semen analysis for infertility
11149051|NCT03734107|Experimental|PREP-DC Intervention|50 participants will be randomized to the Plan, Reflect, and Engage with Providers for Diabetes Care (PREP-DC) intervention. Participants will complete 3 intervention sessions with study interventionists and will receive text messages and other study resources during the active intervention period (3 months).
11149052|NCT03734107|No Intervention|Standard Care Comparison|50 participants will be randomized to standard care and will participate in regular diabetes clinic visits and receive standard materials on the transition to adult diabetes care, as they would have done without participation in this study.
11149053|NCT03734094|Experimental|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
11149054|NCT03734094|Active Comparator|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
11149055|NCT03734081|Experimental|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
11149056|NCT03734081|Experimental|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
11149057|NCT03734081|Experimental|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
11149058|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
11149059|NCT03734055|Experimental|Peer Mentoring|The program will consist of 12 sessions of peer mentoring that will include one standard educational session by telephone or video for approximately 60 minutes every 2 weeks. Additional interaction will be discouraged, but mentees and mentors will be asked to report any additional social interaction should it occur. The bi-weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. 60-minute calls are necessary for the delivery of educational content and mentors and mentees to be able to discuss their own experiences and potential solutions.
11149060|NCT03734055|Active Comparator|Social Support Group|Mentees randomized to the social support control group will be enrolled in a lupus support group designed specifically for this project.
11149061|NCT03734042|Experimental|PRP group|These patients will receive platelet rich plasma intrauterine infusion at day 11
11149062|NCT03734042|Placebo Comparator|Control group|These patients will receive intrauterine normal saline infusion at day 11
11149168|NCT03733405|Experimental|Postpartum Visit 2 and 6 Weeks|Participants will have postpartum visits scheduled 2 and 6 weeks after birth
11149063|NCT03734029|Experimental|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
11149064|NCT03734029|Active Comparator|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:
~Capecitabine
~Eribulin
~Gemcitabine
~Paclitaxel
~Nab-paclitaxel"
11149065|NCT03734016|Experimental|Zanubrutinib|Zanubrutinib will be orally administered until disease progression or unacceptable toxicity.
11149066|NCT03734016|Active Comparator|Ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
11149067|NCT03734003|Experimental|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.
~Common warts, plantar warts, and condyloma acuminata"
11149068|NCT03734003|Active Comparator|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
11149069|NCT03733990|Experimental|FP-1305 0.3 mg/kg|Part I/ Dose-escalation FP-1305 0.3 mg/kg is administered in three-week intervals
11149070|NCT03733990|Experimental|FP-1305 1 mg/kg|Part I, Dose-escalation FP-1305 1 mg/kg is administered in three-week intervals
11149071|NCT03733990|Experimental|FP-1305 3 mg/kg|Part I, Dose-escalation FP-1305 3 mg/kg is administered in three-week intervals
11149072|NCT03733990|Experimental|FP-1305 10 mg/kg|Part I, Dose-escalation FP-1305 10 mg/kg is administered in three-week intervals
11149073|NCT03733990|Experimental|FP-1305 0.1 mg/kg|Part I/ Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals
11149074|NCT03733964|Experimental|Manual therapy|A group of 50 people using manual therapy as a treatment method.
11149075|NCT03733964|Experimental|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
11149076|NCT03733964|Experimental|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
11149077|NCT03733964|Experimental|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
11149078|NCT03733951|Experimental|KN046|
11149079|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
11149080|NCT03733925|Experimental|Golimumab|Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
11149081|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
11149082|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
11149083|NCT03733899|Experimental|Upper lid margin/Lower lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences of an ocular surface region. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
11149084|NCT03733899|Experimental|Lower lid margin/Cornea/ Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
11149085|NCT03733899|Experimental|Cornea/Upper lid margin/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
11149086|NCT03733899|Experimental|Cornea/Lower lid margin/Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
11149087|NCT03733899|Experimental|Upper lid margin/Cornea/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
11149088|NCT03733899|Experimental|Lower lid margin/Upper lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
11149089|NCT03733886|Active Comparator|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.
~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
11149090|NCT03733886|Sham Comparator|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
11149091|NCT03733873|Experimental|desmopressin plus Suoquan|Drug1. name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months Drug2 name:Suoquan mixture form:liquid dosage:10ml/time frequence:bid duration:3 months
11149092|NCT03733873|Active Comparator|desmopressin|name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months
11149093|NCT03733860|Active Comparator|Cavernous sparing group|
11149094|NCT03733860|Other|Conventional technique group|
11149095|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
11149096|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
11149097|NCT03733821||CUD patients on HF-rTMS treatment|Patients fulfilling the Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM 5) criteria for Cocaine Use Disorder undergoing a High Frequency rTMS protocol stimulating over the left dorsolateral prefrontal cortex (DLPFC).
11149098|NCT03733808|Active Comparator|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
11149099|NCT03733808|Sham Comparator|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
11149100|NCT03733795||Control|'Healthy babies' to establish 'normal' blood flow in neonates.
11149101|NCT03733795||ECMO|Children undergoing extracorporeal membrane oxygenation for acute respiratory failure.
11149102|NCT03733795||Conventional|Neonates undergoing conventional treatment for acute respiratory failure.
11149103|NCT03733782|Active Comparator|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine < 2.0 mg/dl.
11149104|NCT03733782|No Intervention|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
11149105|NCT03733769|Experimental|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
11149106|NCT03733756|Experimental|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
11149107|NCT03733756|Active Comparator|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
11149108|NCT03733743|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
11149109|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled prior to July 2020 (Cohort 1)|ACRYSOF IQ RESTOR Multifocal Toric IOL (+3.0 D or +2.5 D) implanted in at least one eye during cataract surgery
11149110|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled after July 2020 (Cohort 2)|ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL or ACRYSOF IQ RESTOR +2.5 D Multifocal IOL implanted in at least one eye during cataract surgery
11149111|NCT03733717|Experimental|Isatuximab|Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.
11149112|NCT03733704|Experimental|Healthy volunteers|Healthy volunteers
11149113|NCT03733691|Experimental|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
11149114|NCT03733691|Experimental|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
11149115|NCT03733678|Experimental|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
11149116|NCT03733678|Experimental|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
11149117|NCT03733678|Experimental|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
11149118|NCT03733678|Experimental|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
11149119|NCT03733678|Experimental|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
11149120|NCT03733678|Experimental|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
11149121|NCT03733678|Experimental|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
11149122|NCT03733678|Experimental|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
11149123|NCT03733678|Experimental|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
11149124|NCT03733678|No Intervention|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
11149125|NCT03733678|Experimental|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
11149126|NCT03733678|Experimental|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
11149127|NCT03733678|Experimental|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
11149128|NCT03733678|Experimental|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
11149129|NCT03733678|Experimental|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
11149130|NCT03733678|Experimental|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
11149131|NCT03733678|Experimental|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
11149132|NCT03733678|Experimental|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
11149133|NCT03733678|Experimental|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
11149134|NCT03733678|Experimental|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
11149135|NCT03733665||Heart failure patients|All patients in NICOR's National Heart Failure Audit will be matched to those in NHS Digital's HES database who have a 4-character primary diagnosis of I50.0-I50.9.
11149136|NCT03733652|No Intervention|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
11149137|NCT03733652|Active Comparator|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
11149138|NCT03733639|Active Comparator|Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm Tisseel® surgeon dispenses the product all over the anastomosis. The rest of the surgical procedure is as usual."
11149139|NCT03733639|Other|no Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm  noTisseel® surgeon performs the surgical procedure as usual."
11149140|NCT03733626|Active Comparator|ViviGen® Cellular Bone Matrix|20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system
11149141|NCT03733626|Placebo Comparator|Local Bone Autograft|20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system.
11149142|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
11149143|NCT03733600||Glaucoma|All patients followed for either early or moderate forms of primary or secondary open-angle glaucoma who had undergone surgery for Xen alone or in combination with cataract surgery for phacoemulisation of the lens.
11149144|NCT03733587|Experimental|Cyclophosphamide and GX-I7|Cyclophosphamide and determined dose of GX-I7 of each cycle
11149145|NCT03733574|Experimental|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
11149146|NCT03733574|Experimental|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
11149147|NCT03733561|Experimental|LY03003|LY03003
11149148|NCT03733561|Active Comparator|Neupro transdermal patch|Neupro transdermal 4 mg patch
11149149|NCT03733548|Experimental|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
11149150|NCT03733535|Experimental|Treatment|Benralizumab 30mg subcutaneous injection on study days 0, 28 and 56 and 1.0 L 129-Xenon/4-Helium mixture, twice per visit, on days 0, 14, 28 and 112.
11149151|NCT03733522|Active Comparator|Rubber dam isolation|"Absolute isolation
~local anesthesia
~use of dental clamp and rubber dam
~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
11149152|NCT03733522|Experimental|Relative isolation|"Relative isolation
~no local anesthesia
~use of cotton roll and saliva ejector
~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
11149153|NCT03733509|Experimental|Intraoperative Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of Bupivacaine 0.25%.
~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml of saline solution (NaCl 0.9%)."
11149154|NCT03733509|Active Comparator|Ultrasound Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of of saline solution (NaCl 0.9%).
~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml Bupivacaine 0.25%."
11149155|NCT03733496||Participants from VY-AADC01 clinical studies:|Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study
11149156|NCT03733483|Experimental|Sleep Deprivation|
11149157|NCT03733470|Experimental|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
11149158|NCT03733470|Experimental|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
11149159|NCT03733457|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
11149160|NCT03733444|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
11149161|NCT03733444|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
11149162|NCT03733444|Experimental|Placebo|Placebo to match will be administered as matching film-coated tablets for oral use once daily.
11149163|NCT03733431|Active Comparator|Standard dose vagal stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
11149164|NCT03733431|Active Comparator|High dose vagal stimulation|A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
11149165|NCT03733431|Sham Comparator|Sham stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
11149166|NCT03733418||VIOLET participants|Neuropsychological evaluations will be conducted 12 (+/-4) months after randomization among a subset of 140 survivors enrolled in the VIOLET parent study at 7 (out of 42) PETAL sites.
11149167|NCT03733405|Experimental|Postpartum Visit 6 Weeks|Participants will have a postpartum visit scheduled 6 weeks after birth
11149349|NCT03732157||outpatient management of parathyroidectomy|
11149169|NCT03733379|Placebo Comparator|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
11149170|NCT03733379|Experimental|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
11149171|NCT03733379|Experimental|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
11149172|NCT03733379|Experimental|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
11149173|NCT03733353|Other|Cohort 1|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose=55 mg, capsule, once daily, 15 days
11149174|NCT03733353|Other|Cohort 2|12 healthy volunteers; 8 on EDP1815, 4 on placebo. Dose= 550 mg, capsule, once daily, 15 days
11149175|NCT03733353|Other|Cohort 3|12 subjects with mild to moderate psoriasis; 8 on EDP1815, 4 on placebo. Dose= 550 mg, capsule, once daily, 29 days
11149176|NCT03733353|Other|Cohort 4|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose= 2.76 g, capsule, once daily, 29 days
11149177|NCT03733353|Other|Cohort 5|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 2.76 g, capsule, once daily, 29 days
11149178|NCT03733353|Other|Cohort 6|24 subjects with mild to moderate psoriasis; 16 on EDP1815, 8 on placebo. Dose=550 mg, capsule, once daily, 28 days.
11149179|NCT03733353|Other|Cohort 7|24 subjects with mild to moderate atopic dermatitis; 16 on EDP1815, 8 on placebo. Dose= 550 mg, capsule, once daily, 28 days
11149180|NCT03733340|Experimental|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
11149181|NCT03733340|No Intervention|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
11149182|NCT03733327|Experimental|BUCYE|For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2.
11149183|NCT03733314|Experimental|E6011|
11149184|NCT03733314|Placebo Comparator|Placebo|
11149185|NCT03733301|Experimental|4 Milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
11149186|NCT03733301|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
11149187|NCT03733301|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with TCS.
11149188|NCT03733288|Experimental|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
11149189|NCT03733288|Experimental|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
11149190|NCT03733275|Experimental|local anesthetic group|local aensthetic group receive preopetaive lidocaine spray and lidocaine-bupivacine mixture-soaked nasal pacing after nasal reduction surgery
11149191|NCT03733275|Placebo Comparator|control group|control group receive preoperative normal saline spray and normal saline-soaked nasal packing after nasal reduction surgery
11149192|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
11149193|NCT03733249|Experimental|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)
~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
11149194|NCT03733236|Experimental|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
11149195|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
11149196|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
11149197|NCT03733210|Experimental|Lymph Node-positive Tumor|Participants whose lymph nodes are positive for cancer
11149198|NCT03733210|Experimental|Lymph Node-negative Tumor|Participants whose lymph nodes are negative for cancer
11149199|NCT03733197|Experimental|Culture specific|"The culture-specific arm may entail FIT kits plus barbers as motivational interviewers."
11149200|NCT03733197|Experimental|Control|Distribution of CRC screening brochures & FIT (Fecal Immunochemical Test) kits by barbers
11149201|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
11149202|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
11149203|NCT03733171|Active Comparator|Platelet rich plasma|endoscopic injection of PRP
11149204|NCT03733171|Placebo Comparator|CONTROL GROUP|diluted epinephrine
11149205|NCT03733158|Experimental|Normal airway|intubation in normal aurway condition
11149206|NCT03733158|Experimental|Tongue edema|intubation in Tongue edema condition
11149207|NCT03733158|Experimental|Pharyngeal obstruction|intubation in Tongue edema condition
11149208|NCT03733158|Experimental|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
11149209|NCT03733158|Experimental|Cervical collar stabilization|intubation in Cervical collar stabilization condition
11149210|NCT03733158|Experimental|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
11149211|NCT03733145|Experimental|Participants on ACE inhibitors|Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
11149212|NCT03733145|Experimental|Participants on ARBs|Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
11149213|NCT03733145|Experimental|Other Classes of Antihypertensive Agents|Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.
11149214|NCT03733132|Placebo Comparator|Placebo|Participants in placebo group will receive Placebo Oral Tablets identical to the metformin tablets for 10 months.
11149215|NCT03733132|Active Comparator|Metformin|Participants in placebo group will receive an escalating dose of Metformin hydrochloride tablets up to a dose of 2500mg for 10 months.
11149216|NCT03733119|Experimental|Arm A (Akt/ERK inhibitor ONC201)|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11149217|NCT03733119|Experimental|Arm B (Akt/ERK inhibitor ONC201, methionine-restricted diet)|Participants receive Akt/ERK inhibitor ONC201 PO on days 3, 10, and 17. Participants also receive methionine-restricted diet PO on days 1-5, 8-12, and 15-19. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11149218|NCT03733106|Experimental|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
11149219|NCT03733106|Active Comparator|control|standard two dimension digital mammography
11149220|NCT03733093||1|HIV Positive
11149221|NCT03733080||1|ages 18 and older
11149222|NCT03733067|Experimental|abatacept|Patients will be randomly allocated 1: 1 to receive either abatacept or placebo
11149223|NCT03733067|Placebo Comparator|placebo|Patients will be randomly allocated 1: 1 to receive either abatacept or placebo
11149224|NCT03733054||Men|Men with lower limb amputation
11149225|NCT03733054||Women|Women with lower limb amputation
11149226|NCT03733041|Active Comparator|rTMS|This group will be randomized to receive rTMS
11149227|NCT03733041|Sham Comparator|Sham|This group will be randomized to receive sham treatment
11149228|NCT03733041|Other|No intervention|This group will receive no intervention
11149229|NCT03733028|Experimental|Mobile Intervention for Reducing Anger (MIRA)|Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.
11149230|NCT03733028|Active Comparator|Mindfulness Intervention|Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.
11149231|NCT03733015|Active Comparator|cTBS group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. TBS refers to a rTMS protocol where pulses are applied in bursts of three, delivered at a frequency of 50 Hz and an inter-burst interval of 200 ms (5 Hz)."
11149232|NCT03733015|Active Comparator|High frequenct rTMS group|High frequency refers to a rTMS protocol where pulses are applied in at 10Hz frequency
11149233|NCT03733002|Experimental|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
11149234|NCT03733002|Placebo Comparator|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
11149235|NCT03732989|Active Comparator|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
11149236|NCT03732989|Experimental|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
11149237|NCT03732976|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
11149238|NCT03732976|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
11149239|NCT03732963|Placebo Comparator|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
11149240|NCT03732963|Active Comparator|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
11149241|NCT03732950|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab intravenously IV on day 1. Courses repeat every 3 weeks for up to 35 courses (2 years) in the absence of disease progression or unacceptable toxicity.
11149242|NCT03732937||Control group|Pregnant ladies with no medical disorders from 16 weeks till term
11149243|NCT03732937||case group|Pregnant ladies with medical disorders from 16 weeks till term
11149244|NCT03732924|Experimental|Five minute rest|
11149245|NCT03732924|Active Comparator|Zero minute rest|
11149246|NCT03732911|Experimental|Intervention|Intervention arm
11149247|NCT03732898|Experimental|New Programming Paradigm|This arm will include patients receiving stimulation with a new programming paradigm
11149248|NCT03732885|Experimental|densah burs drilling group|maxillary sinus floor elevation during implant placement using Densah burs
11149249|NCT03732885|Experimental|Summers osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
11149250|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
11149251|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
11149252|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
11149253|NCT03732846|Experimental|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
11149350|NCT03732157||conventional management of parathyroidectomy|
11149254|NCT03732833|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
11149255|NCT03732833|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
11149256|NCT03732833|Placebo Comparator|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
11149257|NCT03732820|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.
~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
11149258|NCT03732820|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.
~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
11149259|NCT03732807|Experimental|Sequence A|Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
11149260|NCT03732807|Experimental|Sequence B|Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
11149261|NCT03732807|Experimental|Sequence C|Maintenance dose #1 given QD for 48 weeks
11149262|NCT03732807|Experimental|Sequence D|Maintenance dose #2 given QD for 48 weeks
11149263|NCT03732807|Experimental|Sequence E|Maintenance dose #3 given QD for 48 weeks
11149264|NCT03732807|Experimental|Sequence F|Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
11149265|NCT03732807|Experimental|Sequence G|Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
11149266|NCT03732794|Experimental|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
11149267|NCT03732781|Experimental|Radspherin|
11149268|NCT03732768|Experimental|Radspherin|
11149269|NCT03732755|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
11149270|NCT03732742|Experimental|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
11149271|NCT03732742|Experimental|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
11149272|NCT03732729|Experimental|Massage chair|lifestyle modification education(once)+ Using massage chair
11149273|NCT03732729|No Intervention|Control|lifestyle modification education(once)
11149274|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
11149275|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
11149276|NCT03732703|Experimental|Sub-Protocol A1|Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
11149277|NCT03732703|Experimental|Sub-Protocol B1|Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
11149278|NCT03732703|Experimental|Sub-Protocol C1|Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
11149279|NCT03732703|Experimental|Sub-Protocol D1|Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
11149280|NCT03732703|Experimental|Sub-Protocol E1|Patients with Plasma cell Fluorescence In Situ Hybridization (FISH) test demonstrating presence of t(11;14) receive Venetoclax in combination with ixazomib, pomalidomide and dexamethasone (IPd)
11149281|NCT03732703|Experimental|Sub-Protocol Y1|Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)
11149282|NCT03732690|Other|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
11149283|NCT03732690|Other|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
11149284|NCT03732677|Experimental|Arm 1|Chemotherapy + Durvalumab
11149285|NCT03732677|Active Comparator|Arm 2|Chemotherapy alone
11149286|NCT03732664|Other|Single arm|
11149287|NCT03732651|Experimental|non-pulsatile blood flow|
11149288|NCT03732651|Experimental|pulsatile blood flow|
11149289|NCT03732638|Active Comparator|BHV-3000 (Rimegepant)|
11149290|NCT03732638|Placebo Comparator|Placebo Comparator|
11149291|NCT03732625|Experimental|Raltegravir|Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)
11149385|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
11149292|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
11149293|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
11149294|NCT03732599|Active Comparator|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
11149295|NCT03732599|Active Comparator|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
11149296|NCT03732586|Experimental|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
11149297|NCT03732586|Placebo Comparator|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
11149298|NCT03732573|Experimental|Intervention Group|This group will receive 9 text messages over 3 weeks. Messages will be based on goal-setting in the first week, goal-operating in the second week, and self-monitoring in the third week.
11149299|NCT03732573|No Intervention|Control Group|Participants in this group will receive no messages during the intervention period.
11149300|NCT03732560||Patients undergoing treatment with nivolumab and ipilimumab|
11149301|NCT03732560||Patients undergoing treatment with nivolumab|
11149302|NCT03732547|Experimental|'PolyIC plus PD-1 mAb' and 'PD-1 mAb'|"'PolyIC plus PD-1 mAb' group: PolyIC, 2mg, i.m., every other day, for three weeks. PD-1 mAb, 200mg, i.v., every three weeks.
~'PD-1 mAb' group: PD-1 mAb, 200mg, i.v., every three weeks."
11149303|NCT03732534|Experimental|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
11149304|NCT03732521|Experimental|Intervention group|educational therapy
11149305|NCT03732521|No Intervention|Control group|usual clinical practice
11149306|NCT03732508|Experimental|Irinotecan liposome plus SHR1316 plus fluorouracil|
11149307|NCT03732495|Experimental|Trial arm|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.
~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.
~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.
~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.
~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.
~Study drugs will be continued until a treatment discontinuation criterion is met."
11149308|NCT03732482|Placebo Comparator|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
11149309|NCT03732482|Experimental|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
11149310|NCT03732469|Experimental|Fentanyl/propofol + acetaminophen|In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
11149311|NCT03732469|Active Comparator|Fentanyl/propofol only|Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.
11149312|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
11149313|NCT03732430|Experimental|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
11149314|NCT03732417||Stroke patients|Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
11149315|NCT03732417||Telematic model treatment of patients with Stroke|The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
11149316|NCT03732404|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
11149317|NCT03732404|Placebo Comparator|Placebo|The control group will receive plain water with the same volume and timing of treatment
11149318|NCT03732391|Experimental|single arm|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will come continued with the same schedule until unacceptable toxicity or disease progression
11149319|NCT03732378|Experimental|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
11149320|NCT03732378|Placebo Comparator|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
11149321|NCT03732365|Experimental|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
11149386|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
11149322|NCT03732365|Active Comparator|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
11149323|NCT03732352|Experimental|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11149324|NCT03732339|Experimental|GILUPI CellCollector®|
11149325|NCT03732313|Active Comparator|Central toenail resection|Under local ring anaesthesua using xylocaine injection in base of big toe ,Surgical resection of the central part of toenail with underlying germinal matrix.the defect is sutures by prolene.
11149326|NCT03732313|Active Comparator|wedge toenail resection|Under local ring anaesthesiausing xylocaine injection around the base of big toe. Resect lateral wedge of toenail with removal of ingrown toenail and periungual skin. The wound is then sutured.
11149327|NCT03732300|Experimental|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
11149328|NCT03732300|No Intervention|TAU|Treatment as usual
11149329|NCT03732287|Experimental|-5 degrees Celsius for 10 seconds|
11149330|NCT03732287|Experimental|-5 degrees Celsius for 20 seconds|
11149331|NCT03732287|Experimental|-10 degrees Celsius for 10 seconds|
11149332|NCT03732287|Experimental|-10 degrees Celsius for 20 seconds|
11149333|NCT03732274|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
11149334|NCT03732261|Experimental|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
11149335|NCT03732261|No Intervention|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
11149336|NCT03732248|Active Comparator|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
11149337|NCT03732248|Placebo Comparator|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
11149338|NCT03732235||TACE+ systemic Bevacizumab|"TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
~Bevacizumab (5 mg/kg) therapy was initiated 15 days after first round of TACE and was repeated every two weeks, for a total of 8 cycles."
11149339|NCT03732235||FOLFIRI+Bevacizumab|FOLFIRI consists of 5-FU administered as a 48-hour continuous infusion to a total dose of 3,200 mg/m2 without a bolus, leucovorin 200 mg/m2, irinotecan 165 mg/m2 Bevacizumab (5 mg/kg) therapy was repeated every two weeks, for a total of 8 cycles.
11149340|NCT03732235||TACE|TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
11149341|NCT03732222|Experimental|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
11149342|NCT03732222|Experimental|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
11149343|NCT03732222|Experimental|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
11149344|NCT03732209|Experimental|Episodic future thinking|Participants will generate positive future events and related text cues that will be accessed via an electronic app to engage in episodic future thinking.
11149345|NCT03732209|Sham Comparator|Control thinking|Participants will generate non-future-oriented information and related text cues that will be accessed via an electronic app to engage in control thinking..
11149346|NCT03732183|Experimental|Podcast SMART-3RP|"The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new podcast session will be delivered every day."
11149347|NCT03732170|Experimental|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
11149348|NCT03732170|Active Comparator|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
11149387|NCT03731845|Experimental|patient|
11149351|NCT03732144|Experimental|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
11149352|NCT03732144|Other|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
11149353|NCT03732118||Minimal hepatic encephalopathy|
11149354|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
11149355|NCT03732105|Experimental|Radiotherapy|Patients in radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization. After radiotherapy, patients on the control arm will be actively monitored.
11149356|NCT03732105|Experimental|Apatinib|Patients in apatinib group will receive oral apatinib at an initial dose of 500mg daily until recurrence,death, patient withdrawal or unacceptable toxic effects.
11149357|NCT03732105|Experimental|Radiotherapy and apatinib|Patients in radiotherapy+apatinib group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50 Gy/25 fraction after randomization and after radiotherapy they will receive oral apatinib at an initial dose of 500mg/qd until recurrence,death,patient withdrawal or unacceptable toxic effects.
11149358|NCT03732105|No Intervention|Control group|Patients on the control arm will be actively monitored after randomization.
11149359|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
11149360|NCT03732079||Research group|Women with early postpartum hemorrhage.
11149361|NCT03732079||Control group|Postpartum women without abnormal bleeding.
11149362|NCT03732066|Experimental|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
11149363|NCT03732066|Other|Control Group|The control group will receive usual text messages only.
11149364|NCT03732053|Experimental|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
11149365|NCT03732053|No Intervention|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
11149366|NCT03732040|Sham Comparator|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
11149367|NCT03732040|Experimental|miswak stick|use of miswak stick twice daily
11149368|NCT03732040|Experimental|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
11149369|NCT03732027|Active Comparator|Transversus Abdominis Block [TB] group|Patients will receive Surgical Transversus Abdominis Plane Block
11149370|NCT03732027|Active Comparator|Rectus Sheath Block [RB] group|Patients will receive Surgical Rectus Sheath Block
11149371|NCT03732001|Experimental|Anlotinib combined Docetaxel|patients treated with Anlotinib and Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
11149372|NCT03732001|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
11149373|NCT03731988|Experimental|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
11149374|NCT03731988|Experimental|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
11149375|NCT03731988|Experimental|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
11149376|NCT03731975|Active Comparator|CTZ Paste|Endodontic treatment with CTZ paste.
11149377|NCT03731975|Experimental|GP Paste|Endodontic treatment with Guedes-Pinto paste.
11149378|NCT03731962|Active Comparator|Developed Contrast Induced Nephropathy|Coronary Angiography
11149379|NCT03731962|Other|Without CIN|Coronary Angiography
11149380|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
11149381|NCT03731923|Experimental|High risk group of HCC|High risk group of HCC with chronic hepatitis or liver cirrhosis. Participants undergo biannual ultrasonography and annual abbreviated liver MRI.
11149382|NCT03731910|Experimental|HCC group|Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.
11149383|NCT03731897|Experimental|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.
~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
11149384|NCT03731897|Placebo Comparator|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.
~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.
~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
11149388|NCT03731832|Experimental|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
11149389|NCT03731832|Experimental|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
11149390|NCT03731819|Experimental|Follow-up participants|Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI.
11149391|NCT03731793|Placebo Comparator|Placebo Group|Placebo. For 90 days one capsule/day.
11149392|NCT03731793|Experimental|Intervention Group|600 mg/day of non-animal Chondroitin Sulphate. One capsule/day for 90 days.
11149393|NCT03731780|Experimental|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
11149394|NCT03731780|Experimental|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
11149395|NCT03731780|Active Comparator|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
11149396|NCT03731767|Other|Subject group|Distraction thrust manipulation of the talocural joint in supine position
11149397|NCT03731754|Active Comparator|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
11149398|NCT03731754|Experimental|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
11149399|NCT03731741|Experimental|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
11149400|NCT03731741|No Intervention|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
11149401|NCT03731728|Experimental|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
11149402|NCT03731728|Experimental|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
11149403|NCT03731728|No Intervention|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
11149404|NCT03731715|Experimental|Cohort I|Subjects ≥18 years of age. Carisbamate, 200 mg, will be administered on Day 1 and 2 of the single-dose period. Carisbamate will be administered at 100 mg twice daily (BID) during the multiple-dose period.
11149405|NCT03731715|Experimental|Cohort II|Subjects 12 to <18 years of age. Carisbamate, 140 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 70 mg twice daily (BID) during the multiple-dose period.
11149406|NCT03731715|Experimental|Cohort III|Subjects 6 to <12 years of age. Carisbamate, 60 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 30 mg twice daily (BID) during the multiple-dose period.
11149407|NCT03731715|Experimental|Cohort IV|Subjects 2 to <6 years of age. The starting doses for the single dose and multiple-dose periods will be based on the PK and safety results of the first 3 cohorts.
11149408|NCT03731702||General Individuals|Any adult working at the NCI who has not used antibiotics in the past 3 months.
11149409|NCT03731689|No Intervention|Control group|Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.
11149410|NCT03731689|Experimental|Intrauterine lavage therapy group|Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.
11149411|NCT03731689|Experimental|Intrauterine gel-injection therapy group|Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.
11149412|NCT03731689|No Intervention|Healthy control group|Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.
11149413|NCT03731676|Active Comparator|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
11149414|NCT03731676|Active Comparator|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
11149415|NCT03731663|Experimental|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
11149416|NCT03731663|Sham Comparator|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
11149417|NCT03731650|Experimental|active comparator|
11149418|NCT03731650|Experimental|placebo|
11149419|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
11149420|NCT03731624||SLK|
11149421|NCT03731624||GVHD|
11149422|NCT03731624||Dry eye|
11149423|NCT03731624||Control|
11149424|NCT03731611|Active Comparator|Group A|umbilical cord milking will be done for preterm infants <34 gestational age without placental insufficiency
11149425|NCT03731611|Active Comparator|Group B|umbilical cord milking will be done for preterm infant <34 gestational age with placental insufficiency
11149426|NCT03731611|No Intervention|Group C|Immediate cord clamping for preterm infants <34 gestational age with placental insufficiency
11149427|NCT03731585|Experimental|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
11149428|NCT03731585|Experimental|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
11149429|NCT03731572|Experimental|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
11149430|NCT03731572|Active Comparator|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
11149431|NCT03731559|Active Comparator|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
11149432|NCT03731559|Active Comparator|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
11149433|NCT03731546|No Intervention|Group A|Placental insufficiency and ICC : Immediate cord clamping after delivery of the fetus in preterm infants with placental insufficiency
11149434|NCT03731546|Active Comparator|Group B|Placental insufficiency and DCC: Cord clamping 60 seconds after delivery of fetus in preterm infants with placental insufficiency
11149435|NCT03731546|Active Comparator|Group C|Normal placenta with DCC:Cord clamping 60 seconds after delivery of fetus in preterm infants without placental insufficiency
11149436|NCT03731533|Experimental|WellStart|WellStart is a 12-week virtual intensive therapeutic lifestyle program utilizing web-based encounters with physicians, dietitians, health coaches and additional resources.
11149437|NCT03731533|No Intervention|Usual Care|The control group will continue with usual care.
11149438|NCT03731520|Experimental|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
11149439|NCT03731507|Experimental|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
11149440|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
11149441|NCT03731481|Experimental|CHIP - Urban|Participants randomized by urban location of residence to receive CHIP Lifestyle Medicine program intervention.
11149442|NCT03731481|Experimental|CHIP - Rural|Participants randomized by rural location of residence to receive CHIP Lifestyle Medicine program intervention.
11149443|NCT03731481|Experimental|FPD2- Urban|Participants randomized by urban location of residence to receive FPD2 Lifestyle Medicine program intervention.
11149444|NCT03731481|Experimental|FPD2 - Rural|Participants randomized by rural location of residence to receive FPD2 Lifestyle Medicine program intervention.
11149445|NCT03731468|Active Comparator|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
11149446|NCT03731468|Sham Comparator|control group|isobaric bupivacaine will be given on each side
11149447|NCT03731455|Experimental|Investigational and Comparator devices|"Investigational (Wise Cortical Strip, WCS) and comparator (Subdural Strip Electrode, Ad-Tech Medical Instruments Corporation) devices will be used together during the baseline phase. The duration of the baseline phase is estimated to be within 10 minutes, considering simultaneous recordings from the WCS and the comparator device. During IONM phase, the WCS and (if applicable) the comparator device will remain on the brain surface for performing intraoperative neurophysiological monitoring. The duration of the IONM phase depends on patient's brain lesion type and localization and will not be affected by the WIN Study."
11149448|NCT03731442|Experimental|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
11149449|NCT03731442|Experimental|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
11149450|NCT03731429|Experimental|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
11149451|NCT03731429|Placebo Comparator|Placebo|group that receives 0.9% saline solution
11149549|NCT03730792|Experimental|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
11149550|NCT03730792|No Intervention|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
11149551|NCT03730779|Experimental|O2 recieving|Patients who receive hyperoxia
11149452|NCT03731416|Placebo Comparator|GBR by xenograft|"Patients of both groups will be subjected to CBCT (diagnostic for upper arch).
~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.
~Local anesthesia will be given to the patient.
~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.
~Flap will be done.
~In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.
~• The site will then be copiously irrigated with saline in preparation for closure.
~The flap will then be closed using interrupted 4/0 resorbable sutures."
11149453|NCT03731416|Active Comparator|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
11149454|NCT03731403|Experimental|MI Varnish|
11149455|NCT03731403|Active Comparator|Profluorid Varnish|
11149456|NCT03731390|Experimental|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
11149457|NCT03731390|Experimental|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
11149458|NCT03731390|Experimental|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
11149459|NCT03731390|Experimental|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
11149460|NCT03731377|Experimental|Intubated group|Patient in this group will receive general anesthesia with endotracheal tube intubation to perform one lung ventilation. Patient will be paralyzed and controlled ventilation will be implied.
11149461|NCT03731377|Experimental|Non-intubated group|Patient in this group will receive general anesthesia with laryngeal mask insertion. Patients in this group will not be paralyzed and keep spontaneous breathing to maintain one lung ventilation.
11149462|NCT03731364|Active Comparator|CA-008 - Pilot Stage|
11149463|NCT03731364|Placebo Comparator|Placebo - Pilot Stage|
11149464|NCT03731338||Reassured and discharged|patients who are reassured and discharged after first attendance
11149465|NCT03731338||Further diagnostic testing|Patients who went on to have further diagnostic testing
11149466|NCT03731325|Experimental|Episodic Future Thinking Group|The experimental group (N=20 families; N=40 total) will receive the Episodic Future Thinking (EFT) intervention. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now [Atance].
11149467|NCT03731325|Placebo Comparator|Healthy Thinking Group|The placebo group (N=20 families; N=40 total) will receive the Healthy Thinking (HT) intervention. HT encourages individuals to focus on the nutritional characteristics of food and the healthy benefits of physical activity.
11149468|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
11149469|NCT03731299||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
11149470|NCT03731299||Healthy adults|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
11149471|NCT03731286|Active Comparator|EnXtra|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
11149472|NCT03731286|Active Comparator|Composite (EnXtra + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
11149473|NCT03731286|Placebo Comparator|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
11149474|NCT03731260|Experimental|(Part 1) Avapritinib Dose 1 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
11149475|NCT03731260|Experimental|(Part 1) Avapritinib Dose 2 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
11149476|NCT03731260|Experimental|(Part 1) Avapritinib Dose 3 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
11149477|NCT03731260|Placebo Comparator|(Part 1) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
11149478|NCT03731260|Experimental|(Part 2) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
11149479|NCT03731260|Placebo Comparator|(Part 2) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
11149480|NCT03731260|Experimental|(Part 3) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
11149481|NCT03731247|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
11149482|NCT03731247|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
11149483|NCT03731234|Experimental|Ibrutinib+R-CHOP|Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)
11149484|NCT03731221|Experimental|Bupi HCl plus liposomal bupi|PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine
11149485|NCT03731221|Active Comparator|Bupi HCl plus saline|PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline
11149486|NCT03731208|Experimental|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
11149487|NCT03731182|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1
11149488|NCT03731182|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1
11149489|NCT03731169|Active Comparator|TDM Only|This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
11149490|NCT03731169|Experimental|Genotyping + TDM|After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
11149491|NCT03731143|Experimental|study arm|surgical opening the lower punctum using the pig tail probe and a scalpel followed by insertion of self retaining bicanalicular stent (FCI®; Paris, France).
11149492|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
11149493|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
11149494|NCT03731117|Experimental|FST|FUROSEMIDE STRESS TEST
11149495|NCT03731091|Experimental|Calcipotriene/ betamethasone dipropionate topical foam|Topical foam once daily for 4 weeks (28 days)
11149496|NCT03731091|Active Comparator|Enstilar®|Topical foam once daily for 4 weeks (28 days)
11149497|NCT03731091|Placebo Comparator|Placebo|Topical foam once daily for 4 weeks (28 days)
11149498|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
11149499|NCT03731065|Active Comparator|Fructose-maltodextrin ingestion|Ingestion of fructose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
11149500|NCT03731065|Experimental|Fructose-maltodextrin hydrogel ingestion|Ingestion of fructose and maltodextrin (glucose polymers) encapsulated in alginate-pectin hydrogel, drinks at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
11149501|NCT03731065|Active Comparator|Glucose-maltodextrin ingestion|Ingestion of glucose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
11149502|NCT03731052|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
11149503|NCT03731052|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
11149504|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
11149505|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
11149506|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
11149507|NCT03731026|Other|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
11149508|NCT03731026|Experimental|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
11149509|NCT03731026|Experimental|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
11149510|NCT03731013|Experimental|Mediterranean diet (MedDiet)|
11149511|NCT03731013|Experimental|Physical activity (PA)|
11149512|NCT03731013|Experimental|Mediterranean diet and physical activity|
11149513|NCT03731013|No Intervention|Control|
11149514|NCT03731000|Experimental|PHIL® device|Using device
11149515|NCT03730987|Experimental|HoMBRES Intervention|Four sessions (2 sessions per week, approximately 1.5 hours each) with the fathers, in which facilitators conduct educational sessions with groups of 6-8 men per group. One of the sessions includes an intervention of families talking together.
11149516|NCT03730987|Active Comparator|Diabetes Prevention Intervention|One session of 1.5 hours held once per week. Session content will focus on the importance of physical activity, healthy eating, and maintaining a healthy weight.
11149517|NCT03730974|Experimental|Experimental arm AB (Ball blanket + TAU)|"Participants will be randomized into either sequence AB or BA each lasting four weeks.
~Patients that are randomized to the AB sequence receive intervention A (Protac Ball BlanketTM 7 kg Flexible) in the first two weeks and treatment B treatment as usual (TAU) in the second period."
11149518|NCT03730974|Experimental|Experimental arm BA (TAU + Ball blanket)|Patients that are randomized to the BA sequence receive treatment B (TAU) in the first period and intervention A in the second period (Protac Ball BlanketTM 7kg Flexible).
11149519|NCT03730961|Experimental|Placebo+Diuretic to BMS-986231+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
11149520|NCT03730961|Experimental|BMS-986231+Diuretic to Placebo+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
11149521|NCT03730948|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
11149522|NCT03730935|Experimental|Intervention|Respiratory muscle endurance training (30 minutes of volitional hyperpnoea at a target ventilation of 60-70% of the individual maximal voluntary ventilation for 5 days per week for 4 weeks).
11149523|NCT03730935|Sham Comparator|Sham|Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
11149586|NCT03730532|Experimental|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
11149524|NCT03730922|Experimental|A: Delayed-immediate reconstruction|"Primary Surgery: Skin sparing mastectomy (nipple sparing if appropriate) and axillary surgery according to guidelines or protocol. Reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix.
~Delayed reconstruction: Final reconstruction with any reconstructive procedure - being it autologous or implant-based (one- or two-stage, +/- acellular dermal matrix (ADM)) - is performed 6-12 months after completion of chemotherapy and PMRT. Any contralateral procedure is allowed when doing the delayed surgery, but not in relation to the initial cancer surgery."
11149525|NCT03730922|Active Comparator|B: Delayed reconstruction|"Primary surgery: Total mastectomy and axillary surgery according to guidelines or protocol.
~Delayed reconstruction: 6-12 months after completion of PMRT: final recon-struction with any reconstructive procedure - being it autologous or implant-based (one-or two-stage, +/- ADM). Any contralateral procedure is allowed at any time point after PMRT has been delivered"
11149526|NCT03730909|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
11149527|NCT03730909|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
11149528|NCT03730896|No Intervention|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
11149529|NCT03730896|Experimental|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
11149530|NCT03730883|Experimental|Central line removal at 100ml/kg/day.|"In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.
~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in this group may continue to receive parenteral nutrition via peripheral venous access, depending on the decision of the physician taking care for the infant.
~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
11149531|NCT03730883|Active Comparator|Central line removal at 140 ml/kg/day.|"In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake (full enteral intake). In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.
~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant.
~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
11149532|NCT03730870|Experimental|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
11149533|NCT03730870|No Intervention|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
11149534|NCT03730857|Active Comparator|olanzapine|olanzapine has a dose of 10 to 20 mg daily for 12 weeks
11149535|NCT03730857|Active Comparator|risperidone|risperidone at a dose of 4 to 6 mg daily for 12 weeks
11149536|NCT03730857|Active Comparator|paliperidone|paliperidone at a dose of 6 to 12 mg daily for 12 weeks.
11149537|NCT03730844||Critically ill children|Children admitted to the PICU.
11149538|NCT03730844||Healthy controls|Healthy controls, not admitted to the PICU, without pre-existing medical conditions.
11149539|NCT03730831|Experimental|Intervention|Narrative Exposure Therapy The Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed treatment and will be performed according to the manual of Schauer et al., 2011. In the NET the experiences experienced as traumatic are worked on and placed in the context of the entire life story.
11149540|NCT03730831|No Intervention|Control|Waiting List
11149541|NCT03730818|Experimental|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.
~Each session will consist of:
~10 minutes of warm-up: general mobilisation, walking, active stretching
~40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands
~10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
11149542|NCT03730818|Active Comparator|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.
~Each session will consist of the same structure as the Water-based Exercise Group including:
~10 minutes warm up
~40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)
~10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
11149543|NCT03730805|Experimental|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
11149544|NCT03730805|Experimental|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
11149545|NCT03730805|Experimental|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
11149546|NCT03730805|Experimental|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
11149547|NCT03730805|Experimental|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
11149548|NCT03730805|No Intervention|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
11149587|NCT03730532|Experimental|Preference CAT|Cognitive Analytic Therapy Guided Self Help
11149552|NCT03730766|Experimental|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
11149553|NCT03730753|Active Comparator|Control group|Continuous infusion + patient controlled epidural analgesia
11149554|NCT03730753|Experimental|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
11149555|NCT03730740|Experimental|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
11149556|NCT03730727|Active Comparator|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
11149557|NCT03730727|Experimental|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
11149558|NCT03730727|Experimental|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
11149559|NCT03730727|Experimental|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
11149560|NCT03730714|Active Comparator|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
11149561|NCT03730714|Active Comparator|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
11149562|NCT03730714|Active Comparator|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
11149563|NCT03730701|Experimental|Prevention treatment group|
11149564|NCT03730701|No Intervention|Standard treatment group|
11149565|NCT03730688|Experimental|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
11149566|NCT03730675|Experimental|irradiation stent plus TACE|Portal irradiation stent placement will be performed before TACE procedures.
11149567|NCT03730675|Active Comparator|Sorafenib plus TACE|TACE will be performed in patients randomized to Arm B, with sequential sorafenib.
11149568|NCT03730662|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
11149569|NCT03730662|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
11149570|NCT03730662|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
11149571|NCT03730662|Active Comparator|Insulin Glargine|Insulin glargine administered SC once a day.
11149572|NCT03730649|Active Comparator|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
11149573|NCT03730649|Active Comparator|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
11149574|NCT03730636|Experimental|PCT-guided strategy|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
11149575|NCT03730636|No Intervention|Usual practice (control group)|Management of LOS and treatment is based on the attending clinician's practice and according to the usual practice.
11149576|NCT03730623|No Intervention|Control group|Usual care. Conservative management of IC
11149577|NCT03730623|Experimental|Intervention|Supervised exercise
11149578|NCT03730610|Experimental|Exercise intervention|Six months of exercise training
11149579|NCT03730597|Active Comparator|glenosphere 42|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 42. reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
11149580|NCT03730597|Active Comparator|glenosphere 38 ECC|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 38 ECC reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
11149581|NCT03730584|Experimental|Patient with Hereditary Epidermolysis Bullosa|
11149582|NCT03730571|Experimental|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
11149583|NCT03730545|Experimental|EIN group|Enteral formula including not only basic energy components, but also immune components such as omega-3 fatty acids, glutamine (Gln), arginine (Arg), and nucleotide.
11149584|NCT03730545|Active Comparator|SEN group|Enteral formula including only basic energy components.
11149585|NCT03730532|Experimental|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
11149589|NCT03730519|Active Comparator|Patients with refractory hypertension|Patients with refractory hypertension which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
11149590|NCT03730519|Active Comparator|Patients with highly variable BP|Patients with symptomatic highly variable blood pressure due to afferent baroreceptor failure which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
11149591|NCT03730506|Experimental|CBCT|
11149592|NCT03730506|Experimental|IOS|
11149593|NCT03730506|Active Comparator|desktop scanner|
11149594|NCT03730493|Experimental|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
11149595|NCT03730493|No Intervention|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
11149596|NCT03730454|Experimental|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
11149597|NCT03730454|Experimental|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
11149598|NCT03730428||pneumonitis group|Patients who developed drug-related pneumonitis after treated with everolims
11149599|NCT03730428||non-pneumonitis group|Patients who didn't develop drug-related pneumonitis after treated with everolims
11149600|NCT03730415|Experimental|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
11149601|NCT03730415|No Intervention|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
11149602|NCT03730402|Active Comparator|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
11149603|NCT03730402|Active Comparator|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
11149604|NCT03730402|Placebo Comparator|saline block|laparoscopic assisted plane block with placebo saline injection
11149605|NCT03730389|Experimental|EPVL Group|In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.
11149606|NCT03730389|No Intervention|Traditional Group|patients with 4-10mm ureteral stone, were treated by traditional treatment methods, including drinking a minimum of 2500 ml water daily and taking more exercise.
11149607|NCT03730376|No Intervention|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
11149608|NCT03730376|Experimental|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
11149609|NCT03730363|Experimental|Pentamidine + ICE|Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
11149610|NCT03730350|Experimental|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
11149611|NCT03730350|No Intervention|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
11149612|NCT03730337|Experimental|ONO-7475 monotherapy|
11149613|NCT03730337|Experimental|ONO-7475 in combination with ONO-4538|
11149614|NCT03730324|Active Comparator|Standard care|Study subject will undergo sampling of plasma and urine biomarkers.
11149615|NCT03730324|Experimental|Magnetic Resonance Imaging.|Prior to biopsies a magnetic resonance imaging scan will be performed.
11149616|NCT03730311|Experimental|Elpida 120 mg once weekly|elsulfavirine 120mg or placebo orally once weekly for 4 weeks
11149617|NCT03730311|Experimental|Elpida 200 mg once weekly|elsulfavirine 200mg or placebo orally once weekly for 4 weeks
11149618|NCT03730311|Experimental|Elpida 280 mg once weekly|elsulfavirine 280mg or placebo orally once weekly for 4 weeks
11149619|NCT03730298|Experimental|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
11149620|NCT03730298|Placebo Comparator|Placebo|Placebo: 1 cpr twice a day orally for 3 months
11149621|NCT03730285|Active Comparator|Telemedicine|Discharge with telemedicine contact to emergency nurse, doctor, and municipality
11149622|NCT03730285|No Intervention|Control|Standard care with 24-48 h observation at emergency unit
11149650|NCT03730025|Active Comparator|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
11149681|NCT03729804|Experimental|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
11149623|NCT03730259|Experimental|WebTIPS|A Tailored Program for Perioperative Anxiety and Pain (WebTIPS) aims at reducing perioperative anxiety and pain in children via an internet and mobile platform with short message service (SMS) two-way communication between a healthcare provider and patient/parent. The Web-based Tailored Intervention Preparation for Surgery (WebTIPS) program is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent surgical experience, and reduced resource utilization during the surgical episode.
11149624|NCT03730259|No Intervention|Control|Subjects in this attention control group, the Web-based Information (WebINFO) group will not be provided tailored content or access to two-way communication. Instead, this group will only receive basic information regarding the management of perioperative anxiety and postoperative pain via the internet and/or mobile platform.
11149625|NCT03730233|Active Comparator|Tension-free|Hiatal hernia repair by tension-free mesh closure
11149626|NCT03730233|Active Comparator|Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
11149627|NCT03730220||Induction of labour|
11149628|NCT03730207|Experimental|Xpede™ Bone Cement|The subjects in this group will be injected the Xpede™ Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
11149629|NCT03730207|Active Comparator|Mendec Spine Bone Cement|The subjects in this group will be injected the Mendec Spine Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
11149630|NCT03730194|Experimental|Melatonin Only|Participants in this arm will take 3 mg of melatonin 30 minutes before bedtime.
11149631|NCT03730194|Experimental|Bedtime Bank Only|Participants in this arm will utilize the Bedtime Bank, a behavioral sleep intervention.
11149632|NCT03730194|Experimental|Combination (Melatonin+Bedtime Bank)|Participants in this arm will take 3 mg melatonin 30 minutes before bedtime and utilize the Bedtime Bank, a behavioral sleep intervention.
11149633|NCT03730181|Experimental|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
11149634|NCT03730168|Experimental|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .
~The control group were on there prescribed medications only ."
11149635|NCT03730155|Experimental|CCT intervention|CCT intervention. 8 weeks with 2 hours session every week. Homework approx. 25 min. of meditation daily.
11149636|NCT03730155|No Intervention|Control waitlist|No treatment given. Participants only answer questionnaire packages.
11149637|NCT03730142|Experimental|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)
~WXFL10030390 continuous oral dosing (0.2 mg once a day)
~WXFL10030390 continuous oral dosing (0.4 mg once a day)
~WXFL10030390 continuous oral dosing (0.7 mg once a day)
~WXFL10030390 continuous oral dosing (1.1 mg once a day)
~WXFL10030390 continuous oral dosing (1.4 mg once a day)
~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
11149638|NCT03730129|Experimental|Ig replacement|Subjects will receive Hizentra 0.4 mg/kg subq once weekly.
11149639|NCT03730116||the patients with HT and concomitant stable CAD|
11149640|NCT03730103|No Intervention|Historical control group|The investigators will use data from a historical control group discharged on POD 1 after minimally invasive sacrocolpopexy to examine Aim 1 and Aim 2. This is a cohort of 60 women matching our eligibility criteria from a prospective randomized trial of two different types of lightweight polypropylene mesh (IRB #14-354). This study completed recruitment 2017. It consists of a group of women who underwent minimally invasive sacrocolpopexy using the same surgical approaches, at the same institutions
11149641|NCT03730103|Experimental|Same day discharge group|47 women will be recruited for same day discharge after laparoscopic sacrocolpopexy. We will compare aim 1 and 2 (serious adverse events and procedure-related costs) between the two groups
11149642|NCT03730077|Experimental|18F-MISO PET/CT Test Retest|Up to 5 of the 30 intended subjects will participate in a test-retest group that will undergo a second 18F-FMISO scan. Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
11149643|NCT03730077|Experimental|18F-MISO PET/CT|The investigators anticipate enrolling up to 30 subjects who will undergo 18F-FMISO PET/CT.Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
11149644|NCT03730064|Experimental|Bipolar depressed|
11149645|NCT03730051|Active Comparator|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
11149646|NCT03730051|Experimental|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
11149647|NCT03730038|Experimental|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
11149648|NCT03730038|Active Comparator|Life-style modification|
11149649|NCT03730025|Experimental|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
11149651|NCT03730012|Experimental|Gilteritinib plus Atezolizumab|Participants will be treated with gilteritinib once daily for the phase 1 portion of the study to establish the recommended dose for the phase 2 portion. In the phase 2 portion, the participants will be treated with gilteritinib once daily at dose determined by the phase 1 portion of the study. Atezolizumab will be administered once every 2 weeks for the phase 1 and 2 portions of the study. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria; whichever occurs first.
11149652|NCT03729999|Experimental|Ultrasonography|Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation.
11149653|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
11149654|NCT03729973|Active Comparator|Group (K)|"Group (K) (n=25): patients nebulized ketamine 50 mg(milgram) (1ml) plus 4ml normal saline.So total volume (5ml).
~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized 1ml ketamine (Ketalar 50mg/VI Solution for Injection) by compressor nebulizing for 15 minutes."
11149655|NCT03729973|Active Comparator|Group (M)|"Group M(n=25) : patients nebulized isotonic magnesium sulfate 250mg (3ml)( 50% Magnesium Sulfate Injection)plus 1ml normal saline.
~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized by compressor nebulizing for 15 minutes."
11149656|NCT03729973|Active Comparator|Group (L)|"Group (L) (n=25): patients nebulized lidocaine 2% 100mg .So total volume (5ml). In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized by compressor nebulizing for 15 minutes."
11149657|NCT03729973|Active Comparator|Group (C)|"Group (C) (n=25): patients nebulized normal saline(0.9%). 5ml .In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.
~Patients nebulized by compressor nebulizing for 15 minutes."
11149658|NCT03729960|Other|LENA|Lena device with Fitbit and Cocooncam being optional
11149659|NCT03729947|Active Comparator|Drain placed|Subfascial drain at end of procedure
11149660|NCT03729947|Placebo Comparator|No drain placed|No drain left at the end of study
11149661|NCT03729934|No Intervention|Control|This arm receives no treatment control.
11149662|NCT03729934|Experimental|Ketone Ester|This arm receives 25 g ketone ester.
11149663|NCT03729934|Experimental|Ketone Salt|This arm receives 25 g ketone salt.
11149664|NCT03729921|Active Comparator|gastric variceal obturation|gastric variceal obturation
11149665|NCT03729921|Experimental|gastric variceal ligation|gastric variceal ligation
11149666|NCT03729908|Experimental|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
11149667|NCT03729908|Active Comparator|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
11149668|NCT03729895|Experimental|patients with OSAS in different degrees|OSAS patients will be treated with an adjustable oral appliance and evaluated with cone-beam computed tomography and polysomnography.
11149669|NCT03729882|Other|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).
~All procedures will be performed under general anesthesia."
11149670|NCT03729882|Other|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.
~All procedures will be performed under general anesthesia."
11149671|NCT03729869|Experimental|Progesterone Males|35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
11149672|NCT03729869|Placebo Comparator|Placebo Males|35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
11149673|NCT03729869|Experimental|Progesterone Female|35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
11149674|NCT03729869|Placebo Comparator|Placebo Females|35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
11149675|NCT03729856|Experimental|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
11149676|NCT03729856|Experimental|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
11149677|NCT03729856|Experimental|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
11149678|NCT03729843||CBCT and intraoral digital radiography|simulated bone defects will be detected and measured by 2 techniques using CBCT and using intraoral digital radiography and the all measurements will be compared with the gold standard real measurements on the dry jaws
11149679|NCT03729817|Experimental|Submaximal balloon angioplasty|Endovascular intervention with submaximal balloon angioplasty
11149680|NCT03729804|Experimental|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
11149682|NCT03729791|Experimental|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
11149683|NCT03729791|Active Comparator|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
11149684|NCT03729778|Active Comparator|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
11149685|NCT03729778|Active Comparator|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
11149686|NCT03729765|Experimental|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
11149687|NCT03729765|No Intervention|standard care|The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.
11149688|NCT03729752|Active Comparator|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
11149689|NCT03729752|Experimental|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
11149690|NCT03729752|Experimental|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
11149691|NCT03729739|Experimental|QFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR).
~Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice."
11149692|NCT03729739|Active Comparator|FFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR).
~Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice."
11149693|NCT03729726|Experimental|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction & homework support), 30 hours of health (social emotional learning & sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
11149694|NCT03729726|No Intervention|Control|
11149695|NCT03729713|Experimental|Intervention|Computerized Cognitive Rehabilitation
11149696|NCT03729713|Sham Comparator|Placebo|Video game
11149697|NCT03729700|Experimental|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
11149698|NCT03729700|No Intervention|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
11149699|NCT03729687|Experimental|LARCT-US|Short Course Radiation Therapy (5 x 5 Gy in 1 week, scRT) followed by 4 cycles of Pre-operative Chemotherapy using capecitabine and oxaliplatin (CAPOX) and Surgery in High-risk Rectal Cancer
11149700|NCT03729674||Biosimilar|Exposed group
11149701|NCT03729674||Originator (legacy) drug|Reference group
11149702|NCT03729661|Experimental|Breath hold|Patients who receive a breathhold CT- and treatment
11149703|NCT03729648|Experimental|Intervention|This arm of participants will be receiving Expressive Arts Therapy as intervention
11149704|NCT03729648|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a wait-list control group
11149705|NCT03729635|Experimental|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
11149706|NCT03729622|Active Comparator|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
11149707|NCT03729622|Placebo Comparator|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
11149708|NCT03729609||Brentuximab vedotin 1.2 mg/kg (body weight)|Brentuximab vedotin 1.2 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every two weeks (up to 12 times). The dose should be adjusted depend on the participant's condition. Participants received interventions as part of routine medical care.
11149709|NCT03729596|Experimental|MGC018 Monotherapy|MGC018: Anti-B7-H3 antibody drug conjugate
11149710|NCT03729596|Experimental|MGC018 plus MGA012|MGC018: Anti-B7-H3 antibody drug conjugate; MGA012: Anti-PD-1 antibody
11149711|NCT03729583|Active Comparator|Control group|The control group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining All patients were medically stable and referred by their caring respiratory consultant
11149712|NCT03729583|Experimental|Active group|The active group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme with breathing retraining exercises. All patients were medically stable and referred by their caring respiratory consultant
11149713|NCT03729570|Experimental|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to & from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
11149911|NCT03728179|Experimental|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
11149714|NCT03729570|No Intervention|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
11149715|NCT03729557||Kidney Donors|
11149716|NCT03729557||Control group|
11149717|NCT03729544|Experimental|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
11149718|NCT03729544|No Intervention|No Alert|No provider notification
11149719|NCT03729531|Active Comparator|Conventional|The perivascular tissue is stripped off when harvesting the vein, and saline will be used to distend the vein to check for leakage.
11149720|NCT03729531|Experimental|No-touch|The vein will be harvested by frequency electrotome and the perivascular tissue will be preserved, the vein will not be distended.
11149721|NCT03729518|Experimental|Arm 1|All patients will have the volume treated and radiation dose delivered to the regional lymphatics decreased according to the characteristics of the primary site and involved lymph nodes. The high risk neck will receive 50 Gy instead of 60 Gy, and the treated volume of the contralateral low risk neck will be reduced and receive only 45 Gy.
11149722|NCT03729505|Active Comparator|Pyloric injection of magnesium sulfate and lidocaine mixture|After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine
11149723|NCT03729505|Active Comparator|Pyloric injection of saline|After sleeve gastrectomy, the pylorus is injected with normal saline
11149724|NCT03729492|Other|CTEPH/CTED work-up|
11149725|NCT03729479|Experimental|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
11149726|NCT03729479|Experimental|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
11149727|NCT03729479|Experimental|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
11149728|NCT03729479|Experimental|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
11149729|NCT03729466|No Intervention|Control group|There will be no intervention for 8 weeks
11149730|NCT03729466|Experimental|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
11149731|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
11149732|NCT03729440||corrosive patients|
11149733|NCT03729427|Experimental|Treatment Arm|ESP Block
11149734|NCT03729427|No Intervention|Control Arm|Standard of Care
11149735|NCT03729414|Active Comparator|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
11149736|NCT03729414|Experimental|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
11149737|NCT03729401|Active Comparator|DAPT - Aspirin and Ticagrelor|As per results of the PEGASUS trial, patients will be treated with aspirin 81mg daily and ticagrelor 60mg twice daily
11149738|NCT03729401|Experimental|Ticagrelor Monotherapy|Patients will only receive ticagrelor 60mg twice daily.
11149739|NCT03729401|Experimental|Personalized Therapy Arm|Patients allocated to the personalized arm (PA) will have a DAPT score calculated. For those with a score of < 2, only aspirin at 81 mg daily will be prescribed. For those with a score of ≥ 2, P2Y12 inhibitor choice will be dependent on carrier status of CYP2C19 LOF alleles. Heterozygous or homozygous carriers will receive be prescribed ticagrelor 60mg twice daily and non-carriers with will be prescribed clopidogrel 75mg daily.
11149740|NCT03729375|Experimental|10cc Patients|Intervention: Group 1 will receive 10cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
11149741|NCT03729375|Active Comparator|20cc Patients|Intervention: Group 2 will receive 20cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
11149742|NCT03729362|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
11149743|NCT03729362|Active Comparator|alglucosidase alfa/placebo|Participants received alglucosidase alfa co-administered with placebo capsules.
11149744|NCT03729349||Participants with Diagnosis of Rheumatoid Arthritis|Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
11149745|NCT03729336|Experimental|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
11149746|NCT03729336|Placebo Comparator|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
11149747|NCT03729323|Experimental|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
11149748|NCT03729323|Active Comparator|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
11149749|NCT03729310|Other|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
11149750|NCT03729310|Other|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
11149751|NCT03729297|Experimental|cabozantinib|cabozantinib 60 mg tablets OD
11149752|NCT03729284|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
11149753|NCT03729284|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
11149754|NCT03729271|Experimental|Rifaximin and breath tests|Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
11149755|NCT03729258|Experimental|Cefpodoxime 200 (b.i.d)|
11149756|NCT03729258|Active Comparator|Cefpodoxime 400 (q.d)|
11149757|NCT03729245|Experimental|Combination of bempegaldesleukin + nivolumab|Patients in Arm A will receive bempegaldesleukin in combination with nivolumab.
11149758|NCT03729245|Active Comparator|sunitinib or cabozantinib|Patients in Arm B will receive the Investigator's choice of either one of two treatment options.
11149759|NCT03729219|Experimental|ETVAX|Contains inactivated Tetravalent ETEC vaccine, 10 ug Double-mutant heat-labile toxin (dmLT) and effervescent power for oral solution administered twice 14 (plus minus 7) days intervals.
11149760|NCT03729219|Placebo Comparator|Placebo|Effervescent power for oral solution administered wice 14 (plus-minus 7) days intervals
11149761|NCT03729206|Experimental|Sublingual microscopy|
11149762|NCT03729193||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 soccer players.
11149763|NCT03729193||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 basketball players.
11149764|NCT03729193||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 volleyball players.
11149765|NCT03729193||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 archers.
11149766|NCT03729193||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 kickboxers.
11149767|NCT03729193||table tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 table tennis athletes.
11149768|NCT03729193||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 runners.
11149769|NCT03729193||field tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 field tennis athletes.
11149770|NCT03729180|Other|Pain Cohort|Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
11149771|NCT03729180|Experimental|Pharmacogenomic (PGx) Arm [Randomization Arm 1]|All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
11149772|NCT03729180|Other|Control Arm [Randomization Arm 2]|All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
11149773|NCT03729167|Experimental|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
11149774|NCT03729154|Experimental|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
11149775|NCT03729154|No Intervention|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
11149776|NCT03729141|Experimental|Added Cholesterol|
11149777|NCT03729141|Active Comparator|No Added Cholesterol|
11149778|NCT03729128|Experimental|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
11149779|NCT03729128|Placebo Comparator|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
11149780|NCT03729115|Other|Screening Arm|Enrolled patients will undergo Magnetic Resonance Imaging (MRI) every 6 months (2x/year) in addition to an annual screening mammogram.
11149781|NCT03729102|Active Comparator|Control group|Persons who had received primary immunization
11149782|NCT03729102|Experimental|Study group|Persons who had received primary immunization and later received booster vaccination for at least 3 times
11149783|NCT03729089|Experimental|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
11149784|NCT03729089|No Intervention|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
11149785|NCT03729076|Experimental|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
11149786|NCT03729076|Active Comparator|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
11149787|NCT03729063|Experimental|Twice daily expired CO measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
11149788|NCT03729063|Active Comparator|Control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
11149789|NCT03729050|Experimental|Intervention with rehabilitation coordinator|
11149790|NCT03729050|No Intervention|Control|
11149791|NCT03729037|Experimental|Serious game|Intervention: CPR self-training with serious game.
11149792|NCT03729037|Active Comparator|Training video|Intervention: CPR self-training with Keynote presentation with the addition of voice-over narration.
11149793|NCT03729011|Active Comparator|Volatile anesthesia group|
11149794|NCT03729011|Active Comparator|TIVA group|
11149795|NCT03728998|Other|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
11149796|NCT03728985|Active Comparator|Primary Study Arm|TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)
11149797|NCT03728985|Experimental|Secondary Study Arm|TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)
11149798|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)|
11149799|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)|
11149800|NCT03728959|Experimental|Liquid meal (Nutridrink)|Liquid meal (Nutridrink)
11149801|NCT03728959|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
11149802|NCT03728959|Experimental|GLP-2|Glucagon-like peptide-2
11149803|NCT03728959|Experimental|Placebo (saline)|Placebo (saline)
11149804|NCT03728946|Experimental|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
11149805|NCT03728946|No Intervention|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
11149806|NCT03728933|Experimental|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
11149807|NCT03728933|Experimental|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
11149808|NCT03728933|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
11149809|NCT03728907|Active Comparator|Audiologist-adjusted first|This arm will complete the field trial with the audiologist-adjusted fitting first, followed by the user-adjustment fitting.
11149810|NCT03728907|Experimental|User-adjusted first|This arm will complete the trial with the user-adjusted fitting first followed by the audiologist-adjusted fitting.
11149811|NCT03728894|Active Comparator|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
11149812|NCT03728894|Experimental|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
11149813|NCT03728881|Experimental|Group I (Cervarix)|Participants 9-14 years old receive Cervarix IM at baseline.
11149814|NCT03728881|Active Comparator|Group II (Gardasil)|Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
11149815|NCT03728868|Placebo Comparator|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
11149816|NCT03728868|Active Comparator|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
11149817|NCT03728868|Active Comparator|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
11149818|NCT03728855|No Intervention|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
11149819|NCT03728855|Experimental|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
11149820|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
11149821|NCT03728829||Trastuzumab+TP neoadjuvant chemotherapy|100 cases of patients with stage II-III HER2+ breast cancer will be assigned participants to neoadjuvant treatment regimen, including Trastuzumab combined with Docetaxel and Carboplatin. 5-10 ml peripheral blood will be collected from each patient and formalin fixed paraffin embedded (FFPE) blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals before and after neoadjuvant therapy. The genomic characteristics between patients achieved pCR and non-pCR will be analyzed. The clinically actionable mutations for future therapy instructions will be identified.
11149822|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
11149823|NCT03728803|Sham Comparator|Sham inspiratory muscle training|"Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance.
~The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks."
11149824|NCT03728803|Active Comparator|Active inspiratory muscle training|Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
11149825|NCT03728790|No Intervention|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
11149826|NCT03728790|Experimental|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
11149827|NCT03728777|Placebo Comparator|Placebo|
11149828|NCT03728777|Experimental|Resveratrol|Over the counter supplement
11149829|NCT03728764|Other|single arm|
11149830|NCT03728751|Experimental|study group|Study group receiving dry needling and pupil diameter will be studied up to 23 minutes after needle placement.
11149831|NCT03728738|Experimental|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
11149832|NCT03728738|Active Comparator|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
11149833|NCT03728725||TB case detection Group|Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.
11149834|NCT03728725||RIF-resistance MTB Group|"An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.
~/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations."
11149835|NCT03728712||Never smokers|Participants with no history of cigarette smoking
11149836|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
11149837|NCT03728686|Experimental|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
11149838|NCT03728686|Active Comparator|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
11149839|NCT03728686|No Intervention|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
11149840|NCT03728673|Experimental|escitalopram|
11149841|NCT03728660|Experimental|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
11149842|NCT03728660|Active Comparator|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
11149843|NCT03728647|Experimental|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
11149942|NCT03727945|Experimental|abdominopelvic exercise and posture|N=21 received supervised physiotherapy abdominopelvic exercise previous postural correction.
11149844|NCT03728647|Active Comparator|regular health education|The regular (traditional) education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
11149845|NCT03728634|Experimental|AKCEA-TTR-LRx|Single and multiple doses of AKCEA-TTR-LRx administered subcutaneously
11149846|NCT03728634|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator administered subcutaneously
11149847|NCT03728621|Experimental|Individual-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
11149848|NCT03728621|Experimental|Group-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
11149849|NCT03728608|Active Comparator|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
11149850|NCT03728608|Active Comparator|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
11149851|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:
~venepuncture
~spirometry."
11149852|NCT03728582|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be verb naming therapy in a sentence context. This will be followed by sham tDCS plus speech-language therapy after a 2 month washout period.
11149853|NCT03728582|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. Language therapy will be verb naming therapy in a sentence context. This will be followed by active tDCS plus speech-language therapy after a 2 month washout period.
11149854|NCT03728569|Other|Subjects over the age of 70 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
11149855|NCT03728569|Other|Subjects between 18 and 30 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
11149856|NCT03728556|Experimental|CS1001monoclonal antibody|
11149857|NCT03728556|Placebo Comparator|CS1001 Placebo|
11149858|NCT03728543|Experimental|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
11149859|NCT03728543|Active Comparator|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
11149860|NCT03728530|Experimental|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
11149861|NCT03728530|No Intervention|Control Group|The participants from control group did not perform any exercise.
11149862|NCT03728517||Subjects who undergo gynecologic surgery|Subjects who will undergo gynecologic surgery via vaginally, laparoscopic , or robotic who require observation or inpatient stay overnight. This group will receive pain medication in the hospital and will also be discharged home with pain medication.
11149863|NCT03728504|Experimental|ASN002 40 mg|40 mg ASN002
11149864|NCT03728504|Experimental|ASN002 80 mg|80 mg ASN002
11149865|NCT03728504|Placebo Comparator|Placebo oral tablet|Matching placebo for ASN002 doses
11149866|NCT03728491|Experimental|Healthy Figurant|Hands-on training on healthy figurants for gaining competence in TUS
11149867|NCT03728491|Experimental|Simulator|Hands-on training on US Mentor simulator for gaining competence in TUS
11149868|NCT03728491|No Intervention|Controls|Controls with no hands-on training
11149869|NCT03728478|No Intervention|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
11149870|NCT03728478|Experimental|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
11149871|NCT03728465|Experimental|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
11149872|NCT03728439|Experimental|LED therapy before exercise|The pre-exercise LED therapy applications, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
11149873|NCT03728439|Experimental|LED therapy applied on exercise interval|The LED therapy applied in the exercise interval will be performed after the first block of tests, with a maximum duration of 10 minutes and dose of 8 J/cm2. Then the second block of maximum tests will be performed.
11149874|NCT03728439|Experimental|LED therapy after exercise|The post-exercise LED therapy will be performed 10 minutes after the second battery of tests, also with 8 J/cm2 and in the same muscles irradiated in the other moments of application.
11149875|NCT03728439|No Intervention|Baseline|On that day the participants performed the exercise without receiving any intervention.
11149876|NCT03728426|Experimental|Letermovir|Open label letermovir will be administered daily for up to 12 weeks. The study allows an optional additional 12 weeks of treatment for secondary prophylaxis if clinically indicated.
11149877|NCT03728413|Other|Elderly Non-smoking|RSV A Memphis 37 will be given as intra-nasal drops.
11149878|NCT03728413|Other|Elderly ex and current smokers|RSV A Memphis 37 will be given as intra-nasal drops.
11149879|NCT03728413|Other|Young non-smokers|RSV A Memphis 37 will be given as intra-nasal drops.
11149943|NCT03727945|Experimental|abdominopelvic exercise|N=21 received supervised physiotherapy abdominopelvic exercise.
11149880|NCT03728400||Patients in neurovascular intensive care|During the patient's hospitalization in neurovascular intensive care unit, the doctor will propose to the patient to take part in this study. If the patient agree, this search will not change the patient's usual support and will not involve any further review.
11149881|NCT03728387|Experimental|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
11149882|NCT03728374|Experimental|Anlotinib|
11149883|NCT03728361|Experimental|Treatment (nivolumab, temozolomide)|Patients receive nivolumab IV on day 1 of a 28 day cycle. Patients also receive temozolomide PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11149884|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
11149885|NCT03728335|Experimental|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11149886|NCT03728322|Experimental|iHSCs treatment group|
11149887|NCT03728296|Experimental|islet body treatment group|
11149888|NCT03728283|Active Comparator|Conventional Implant placement|conventional implant placement following the manufacturer's instructions
11149889|NCT03728283|Experimental|Implant and Connective tissue grafting|implant placement in combination with connective tissue grafting
11149890|NCT03728270|Experimental|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.
~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.
~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.
~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.
~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.
~A multilayer closure of the incisions will be accomplished using Vicryl sutures."
11149891|NCT03728270|Active Comparator|Inlay Autogenous Bone Graft|"A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.
~One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.
~After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.
~The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
11149892|NCT03728257|Experimental|LTGO-Home Based Exercise|The lung transplant recipient will receive LTGO- Home Based Exercise, a behavioral exercise intervention that consists of in-home exercise training integrated with behavioral coaching using tele-rehabilitation.
11149893|NCT03728257|Active Comparator|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
11149894|NCT03728244|Experimental|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
11149895|NCT03728244|Experimental|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
11149896|NCT03728244|No Intervention|negative control group|Patients scheduled for free gingival graft harvesting
11149897|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).
~Functional Performance Tests:(12)
~Fatigue severity scale (13).
~Short-Form Health Survey 36 (SF-36) (14).
~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).
~frequency intensity time (FIT) index of kasari (16). :* Disease activity Score(DAS)(17)"
11149898|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).
~Functional Performance Tests:(12)
~Fatigue severity scale (13).
~Short-Form Health Survey 36 (SF-36) (14).
~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).
~frequency intensity time (FIT) index of kasari (16). :* SLE Disease activity Index(SLEDAI)(18)"
11149899|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).
~Functional Performance Tests:(12)
~Fatigue severity scale (13).
~Short-Form Health Survey 36 (SF-36) (14).
~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).
~frequency intensity time (FIT) index of kasari (16)."
11149900|NCT03728218|Experimental|Orthokeratology Contact lenses|
11149901|NCT03728218|Experimental|Soft Multifocal Contact lenses|
11149902|NCT03728205|Experimental|Observational|All 10 pilot subjects will be taking yoga
11149903|NCT03728192|Experimental|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:
~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
11149904|NCT03728192|No Intervention|Untreated group|H357 and HeLa cell line without any drug intervention.
11149905|NCT03728179|Experimental|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
11149906|NCT03728179|Experimental|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
11149907|NCT03728179|Experimental|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
11149908|NCT03728179|Experimental|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
11149909|NCT03728179|Experimental|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
11149910|NCT03728179|Experimental|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
11149912|NCT03728166|Experimental|Alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
11149913|NCT03728166|No Intervention|No Alert|No notification to the provider.
11149914|NCT03728153|Experimental|20mg dose|Fluoxetine 20 MG Oral Tablet
11149915|NCT03728140|Experimental|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
11149916|NCT03728140|No Intervention|New Culture Medium|embryo transfer with new culture medium in IVF-ET
11149917|NCT03728127|Experimental|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
11149918|NCT03728127|Active Comparator|DicaBr group (DCB)|Brazilian cardioprotective diet
11149919|NCT03728114|Experimental|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
11149920|NCT03728114|Sham Comparator|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
11149921|NCT03728114|Experimental|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
11149922|NCT03728114|Sham Comparator|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
11149923|NCT03728101|Experimental|Single arm|"Dabigatran etexilate
~Simvastatin + Dabigatran etexilate"
11149924|NCT03728088||Surgical Candidates|"Under- and postgraduate candidates applying for surgical training in general surgery, orthopedics, urology or plastic surgery at Ghent University Hospital.
~All candidates will complete the rating scales concerning non-technical attributes in the period prior to the surgical selections."
11149925|NCT03728088||Surgical trainees|"Surgical trainees active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital or an affiliated non-academic training hospital.
~All trainees will be invited to participate in the study. Trainees who agree to participate will complete the rating scales concerning non-technical attributes."
11149926|NCT03728088||Surgical staff|"Surgical staff members active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital.
~All surgical staff members will be invited to participate in the study. Surgical staff members who agree to participate will complete the rating scales concerning non-technical attributes."
11149927|NCT03728075|No Intervention|Control group|standard protocol for cardiac rehabilitation
11149928|NCT03728075|Experimental|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
11149929|NCT03728062|Experimental|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
11149930|NCT03728062|Experimental|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
11149931|NCT03728062|No Intervention|Control group|Participants continue their normal lunch routine.
11149932|NCT03728049|Experimental|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
11149933|NCT03728049|Other|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
11149934|NCT03728023|Experimental|AZD4205|Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days
11149935|NCT03728023|Placebo Comparator|Placebo|placebo single dose in SAD and once daily for 14 days
11149936|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
11149937|NCT03727997||AKI patients stage 3|
11149938|NCT03727971|Active Comparator|omalizumab arm|The treatment is initiated with one injection with weight and serum-Immunoglobulin E balanced omalizumab one time per cyclus
11149939|NCT03727971|Placebo Comparator|placebo arm|Participants will be administered placebo (NaCl), one time per cyclus
11149940|NCT03727958|Active Comparator|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
11149941|NCT03727958|Active Comparator|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
11150051|NCT03727100|Active Comparator|Clonidine Micropellets|single dose injection into the lumbar epidural space
11149944|NCT03727932|Other|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
11149945|NCT03727919|Experimental|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
11149946|NCT03727919|Experimental|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
11149947|NCT03727919|No Intervention|Control Group|N = 20 Intervention = standard care including conventional physiotherapy
11149948|NCT03727906|Other|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.
~Interventions (order is randomly assigned):
~no pre-sleep arousal manipulation night;
~pre-sleep arousal down-regulation night
~pre-sleep arousal up-regulation night."
11149949|NCT03727906|Other|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.
~Interventions (order is randomly assigned):
~no pre-sleep arousal manipulation night;
~pre-sleep arousal down-regulation night
~pre-sleep arousal up-regulation night."
11149950|NCT03727893|Active Comparator|Roller-based intervention Group (IG)|A group participating in a high-intensity exercise on a roller-based system.
11149951|NCT03727893|Placebo Comparator|Control Group (CG)|A group participating in an independent workout program at an accessible community-based fitness facility.
11149952|NCT03727880|Experimental|Arm A - Pembrolizumab and Defactinib|
11149953|NCT03727880|Experimental|Arm B - Pembrolizumab|
11149954|NCT03727867|Placebo Comparator|Drug group|Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
11149955|NCT03727867|Experimental|Drug plus SBRT group|After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
11149956|NCT03727854|Experimental|Premeal protein group|Premeal protein enriched bar with dietary modification
11149957|NCT03727854|Other|Dietary modofication only group|Dietary modification only
11149958|NCT03727841|Experimental|1/Arm 1|Marizomib at days 1, 8, and 15 of each 28-day cycle
11149959|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
11149960|NCT03727828||healthy control|
11149961|NCT03727815|Experimental|Mindfulness Pain Management Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target pain management through mindfulness.
11149962|NCT03727815|Experimental|Mindfulness Self Esteem Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target self esteem through mindfulness.
11149963|NCT03727815|No Intervention|Non-intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
11149964|NCT03727802|Experimental|TRK-250|
11149965|NCT03727802|Placebo Comparator|Placebo|
11149966|NCT03727789|Experimental|Treatment (CBL0137)|Patients receive FACT complex-targeting curaxin CBL0137 IA over 15 minutes.
11149967|NCT03727776|Experimental|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
11149968|NCT03727776|No Intervention|Controls|Subjects will be managed per the standard of care.
11149969|NCT03727763|Experimental|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
11149970|NCT03727750|Experimental|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
11149971|NCT03727737|No Intervention|Sham|Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
11149972|NCT03727737|Active Comparator|ACTIVE|Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
11149973|NCT03727724|Experimental|Afatinib plus cetuximab|"Afatinib, 40 mg once daily, orally.
~Cetuximab, 500 mg/m² intravenously, every 2 weeks.
~Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
11149974|NCT03727711|Experimental|Home Treatment|Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
11149975|NCT03727711|Active Comparator|Hospital Treatment|Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
11149976|NCT03727698|Experimental|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
11149977|NCT03727685|No Intervention|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
11149978|NCT03727685|Active Comparator|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
11149979|NCT03727672||Tension type headache patients|30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
11150052|NCT03727100|Sham Comparator|Sham Control|non-epidural needle placement
11149980|NCT03727672||Migraine patients|30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
11149981|NCT03727672||age matched controls|30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
11149982|NCT03727659|Experimental|SHADE therapy + CONNECT FaceBook support|SHADE is a 10-week, 10-session, computerized CBT/MET intervention for Cannabis Use Disorder and depression. At each visit, a study clinician meets with participants for a 'check-in' session, which includes: review of homework; plans for completing homework; suicide risk and mood assessment. The CONNECT FB intervention component will facilitate social support for between-session homework and CBT skills practice for managing depression and preventing relapse, and bolstering motivation to change. Daily posts will be delivered. Only those participating in the study will know about the existence of this group and will be able to access it. A weekly real-time, Facebook chat session will be held to provide feedback concerning homework practice or answer questions.
11149983|NCT03727646|Experimental|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:
~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)
~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily
~Washout Day of LVAD Surgery and/or Day 15: None"
11149984|NCT03727646|No Intervention|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
11149985|NCT03727633|Experimental|Treatment arm|hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol
11149986|NCT03727620|Experimental|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
11149987|NCT03727620|Active Comparator|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
11149988|NCT03727607|Active Comparator|Gass|DESFLURANE ANESTHESIA
11149989|NCT03727607|Active Comparator|TIVA|TOTAL INTRAVENOUS ANESTHESIA
11149990|NCT03727568|Experimental|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
11149991|NCT03727568|Experimental|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from <5 seconds for the following biopsies.
11149992|NCT03727555|Experimental|Lentivirus-mediated delivery of ABCD1 to the CNS.|Intracerebral injection with lentiviral TYF-ABCD1 vector carrying the functional gene
11149993|NCT03727542|Experimental|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
11149994|NCT03727529|Experimental|Intervention group|
11149995|NCT03727529|Active Comparator|Control group|
11149996|NCT03727516||patients undergone elbow surgery|Patients undergone elbow surgery at routine follow up at 2 or 6 months
11149997|NCT03727503|Other|group/cohort|operated patients from cardiac surgery. Once they arrived in the ICU, we will measure PPV with the capstesia and the PICCO device at baseline, and after a volume expansion of 500 ml of crystalloid.
11149998|NCT03727490|Active Comparator|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
11149999|NCT03727490|Experimental|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
11150000|NCT03727464|Experimental|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
11150001|NCT03727464|Experimental|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
11150002|NCT03727464|Active Comparator|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
11150003|NCT03727464|Experimental|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
11150004|NCT03727464|Experimental|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
11150005|NCT03727464|Active Comparator|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
11150006|NCT03727451|Experimental|PH-Pulmonary Fibrosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
~Part 2: Optional open label long term extension at the optimal dose as identified in Part 1"
11150007|NCT03727451|Experimental|PH-Sarcoidosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr
~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr
~Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1"
11150008|NCT03727438|Experimental|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
11150009|NCT03727438|Active Comparator|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
11150010|NCT03727425|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
11150011|NCT03727412|Active Comparator|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
11150012|NCT03727412|Placebo Comparator|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
11150086|NCT03726866|Experimental|Sequence 1|Sequence 1
11150087|NCT03726866|Experimental|Sequence 2|Sequence 2
11150013|NCT03727386|Experimental|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
11150014|NCT03727386|Placebo Comparator|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
11150015|NCT03727360|Experimental|Exercise Training|Group exercise and treadmill walking
11150016|NCT03727360|Active Comparator|Flexibility Control|Group exercise and flexibility exercise
11150017|NCT03727347|Experimental|InSeca Stylus|Low power radiofrequency treatment of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
11150018|NCT03727334|Experimental|Treatment|For the treatment arm, the participants will complete the intervention protocol following the first in-person study visit 6 months post-injury. The intervention involves 16 weeks of online, in-home spatial navigation training. During the 16 weeks, the participant will complete exercises for 1 hour/day, every other day.
11150019|NCT03727334|No Intervention|Control|The control arm participants will receive their typical standard of care; they will not complete the intervention but will complete all of the in-person visits at the same post-injury time-points as the treatment group.
11150020|NCT03727321|Placebo Comparator|Placebo|Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
11150021|NCT03727321|Experimental|Fecal Microbial Transplant and cellulose|"Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
~Cellulose x 6weeks"
11150022|NCT03727321|Experimental|Fiber|Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
11150023|NCT03727321|Experimental|Fecal Microbial Transplant and Fiber|"Fecal Microbial Transplant
~Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS)."
11150024|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.
~- Medical abortion pills sourced from pharmacies"
11150025|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.
~- Medical abortion pills sourced from health clinics"
11150026|NCT03727295|Experimental|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
11150027|NCT03727295|Experimental|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
11150028|NCT03727295|Placebo Comparator|The placebo group|60 cases, placebo, 3 times / day, oral
11150029|NCT03727282|Other|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
11150030|NCT03727282|Experimental|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
11150031|NCT03727269|Experimental|Wii Fit Training Experimental Group|receiving Wii fit based abdomino-pelvic training
11150032|NCT03727269|Active Comparator|Conventional Training Control Group|receiving conventional pelvic floor exercises.
11150033|NCT03727256|Active Comparator|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
11150034|NCT03727256|Active Comparator|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
11150035|NCT03727243||Septic/septic shock patients|Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.
11150036|NCT03727243||Non-septic/sterile inflammation patients|Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.
11150037|NCT03727243||Healthy control patients|Active comparator group.
11150038|NCT03727230|Other|"Asia type DEL recipients"|"To identify Asia type DEL patients by phenotyping and gentoyping methods in the Chinese recipients and then blood transfusion of D+ blood rather than the rare D negative blood to the identified Aisa type DEL recipients."
11150039|NCT03727217|Experimental|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
11150040|NCT03727204||Patients undergoing cardiac surgery|On-pump cardiac surgery at Aarhus University Hospital
11150041|NCT03727191|Active Comparator|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
11150042|NCT03727191|Experimental|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
11150043|NCT03727165|Active Comparator|Continuous infusion|Patients with continuous infusion enteral nutrition in the intensive care unit at San Ignacio University Hospital
11150044|NCT03727165|Experimental|Cyclic infusion|Patients formulated with cyclic enteral nutrition infusion, administrated at night hours, from 4pm until 7am.
11150045|NCT03727152|Other|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
11150046|NCT03727139||Rasagiline 1 mg|Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
11150047|NCT03727126|Experimental|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
11150048|NCT03727126|Active Comparator|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
11150049|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
11150050|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
11150088|NCT03726866|Experimental|Sequence 3|Sequence 3
11150053|NCT03727087||Melanoma|Subjects with clinically confirmed melanoma or high suspicion of a primary malignancy of melanoma based on skin exam or imaging and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11150054|NCT03727074|Experimental|5-FU Cream|topical cream
11150055|NCT03727074|Active Comparator|Efudex®|topical cream
11150056|NCT03727074|Placebo Comparator|Vehicle|topical cream
11150057|NCT03727061|Active Comparator|Arm A (standard of care chemotherapy at doctor's discretion)|Patients receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion
11150058|NCT03727061|Experimental|Arm B(porfimer sodium, I-PDT, SoC chemotherapy)|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later. Patients also receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion at either 7 days, 14 days, or 28 days later.
11150059|NCT03727048|Active Comparator|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
11150060|NCT03727048|Experimental|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
11150061|NCT03727035||Group I|Group I :40 Generalized chronic periodontitis subjects without type II diabetes mellitus
11150062|NCT03727035||Group II|Group II: 40 Generalized chronic periodontitis subjects diagnosed with type II diabetes mellitus
11150063|NCT03727022|Experimental|0.07 mg SM04690|Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
11150064|NCT03727022|Placebo Comparator|Vehicle|Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
11150065|NCT03727009||Hematologic Malignancy|Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
11150066|NCT03726996|Experimental|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
11150067|NCT03726983|Experimental|eHMP experimental group|"The experimental group received health management support and counseling,including:
~GDM health care knowledge
~self-awareness of health
~self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)
~participation in discussions or browsing forums
~healthy lifestyle guidance and counseling
~reminder systems
~a token system of earning points in exchange for prizes."
11150068|NCT03726983|No Intervention|Control group|only received usual care
11150069|NCT03726970|Experimental|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
11150070|NCT03726970|Experimental|MAR tool|MAR option in the software off and on
11150071|NCT03726957|Experimental|Intervention group|The intervention arm included households which received improved cookstoves
11150072|NCT03726957|No Intervention|Control group|The control group included households, which did not receive improved cookstoves, and cooked in their usual traditional cookstoves.
11150073|NCT03726944|Other|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
11150074|NCT03726944|Other|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
11150075|NCT03726944|Other|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
11150076|NCT03726944|Other|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
11150077|NCT03726931|Experimental|[18F]FES|All patients will receive an additional PET/CT scan: [18F]FES PET/CT scan.
11150078|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
11150079|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
11150080|NCT03726905|Experimental|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
11150081|NCT03726905|Sham Comparator|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
11150082|NCT03726892|Active Comparator|The SYNERGY stent|
11150083|NCT03726892|Active Comparator|Xience|
11150084|NCT03726879|Experimental|Atezolizumab +ddAC-PacHP|Participants will receive atezolizumab 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV), followed by atezolizumab 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W for 4 cycles, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W for 4 cycles. During the adjuvant phase, participants will continue to receive the following study treatments Q3W to complete up to 1 year of HER2-target therapy inclusive of therapy given both in the neoadjuvant and adjuvant setting: atezolizumab 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have the option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles.
11150085|NCT03726879|Placebo Comparator|Placebo + ddAC-PacHP|Participants will receive placebo 840 mg IV Q2W for 4 cycles during neoadjuvant phase with ddAC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV), followed by placebo 1200 mg IV Q3W for 4 cycles with paclitaxel 80 mg/m2 IV weekly for 12 continuous weeks, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W for 4 cycles, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W for 4 cycles. During the adjuvant phase, participants will continue to receive the following study treatments Q3W to complete up to 1 year of HER2-target therapy inclusive of therapy given both in the neoadjuvant and adjuvant setting: placebo 1200 mg IV Q3W, trastuzumab 6 mg/kg IV (with an initial 8-mg/kg IV loading dose) Q3W, and pertuzumab 420 mg IV (with an initial 840-mg IV loading dose) Q3W. Participants who do not achieve pCR have the option of receiving blinded atezolizumab + trastuzumab emtansine post surgery for 14 cycles.
11150095|NCT03726853|Placebo Comparator|Placebo|CKD-497 placebo and comparator placebo
11150096|NCT03726840|No Intervention|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
11150097|NCT03726840|Experimental|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
11150098|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
11150099|NCT03726814|Experimental|EPC treatment group|
11150100|NCT03726801|Experimental|Stratum C|"N 32 C
~Women who are going to be mastectomized, conservate surgery and ostomy who attend the health education together with their immediate family member prior to surgery"
11150101|NCT03726801|Placebo Comparator|Stratum E|"N 32 E
~Patients who are going to be subjected to a mastectomized, conservate surgery and ostomy who come alone to the health education prior to surgery"
11150102|NCT03726788|Experimental|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
11150103|NCT03726788|Experimental|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
11150104|NCT03726788|Active Comparator|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
11150105|NCT03726775|Experimental|RT-durvalumab|durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.
11150106|NCT03726762|Experimental|Diet Beverages|'Diet beverages' after the main meal
11150107|NCT03726762|Experimental|Water|'Water' after the main meal
11150108|NCT03726749|Experimental|Tocilizumab and prednisone|"TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.
~Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
11150109|NCT03726736|Experimental|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
11150110|NCT03726736|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
11150111|NCT03726710|Experimental|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
11150112|NCT03726697|Experimental|Tahneek|Infants receiving a single dose of soft date, prepacked by the pharmacy containing glucose equivalent to 200mg/kg at 1 hour after birth in the nursery.
11150113|NCT03726697|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
11150114|NCT03726684|Experimental|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
11150115|NCT03726671|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11150116|NCT03726671|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11150117|NCT03726671|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11150118|NCT03726671|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11150119|NCT03726671|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11150120|NCT03726671|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11150121|NCT03726658|Experimental|AGN-241751 3mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
11150122|NCT03726658|Experimental|AGN-241751 10mg|AGN-241751, oral administration, once per day
11150123|NCT03726658|Experimental|AGN-241751 25mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
11150124|NCT03726658|Placebo Comparator|Placebo|Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
11150125|NCT03726645|Active Comparator|Study group|Allogeneic fecal microbiota transplantation (from donor)
11150126|NCT03726645|Placebo Comparator|Control group|Autologous fecal microbiota transplantation (own stool)
11150127|NCT03726619|Experimental|e-CHEC-uP|Group 1 will receive the education study intervention after the first baseline questionnaire. Participants will be asked to take part in a one-time, 1 to 1.5-hour online education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker to help address any barriers in order to help receive a mammogram or a Pap test.
11150128|NCT03726619|Active Comparator|CHEC-uP|Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
11150129|NCT03726606|Experimental|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
11150130|NCT03726606|Active Comparator|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
11150131|NCT03726593|Experimental|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
11150132|NCT03726593|Experimental|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
11150133|NCT03726593|Experimental|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
11150134|NCT03726580||control group|regional anesthesia
11150135|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
11150136|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
11150137|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
11150138|NCT03726567|Active Comparator|Bariatric surgery group|Patients who are undergoing bariatric surgery for weight loss
11150139|NCT03726567|No Intervention|Non bariatric surgery group|Patients who are undergoing abdominal surgery for non-weight loss reasons
11150140|NCT03726554||Comp. Rev. Porous Augmented Glenoid|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Porous Augmented Glenoid.
11150141|NCT03726554||Comp. Rev. Mini Humeral Tray|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Mini Humeral Tray
11150142|NCT03726541|Experimental|Early physiotherapy group|breathing exercise incentive spirometry training ambulation coughing
11150143|NCT03726515|Experimental|CART-EGFRvIII + Pembrolizumab|
11150144|NCT03726502|Active Comparator|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
11150145|NCT03726502|Placebo Comparator|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
11150146|NCT03726502|Active Comparator|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
11150147|NCT03726502|Placebo Comparator|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
11150148|NCT03726489|Other|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
11150149|NCT03726489|Active Comparator|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
11150150|NCT03726476|Experimental|Patient Centered pre-op education|Patient centered pre-operative education and patient centered post-operative care.
11150151|NCT03726476|Active Comparator|Routine Pre-op education|Participants will receive routine pre-operative education and post-op will receive a standardized number of narcotics
11150152|NCT03726463||polycystic kidney disease|patients with polycystic kidney disease who receive kidney transplantation at Asan Medical Center
11150153|NCT03726450|Experimental|Andrositol Plus|all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
11150154|NCT03726437|Experimental|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
11150155|NCT03726437|Placebo Comparator|Stress and Mood Management|A 3-hour general mental health web-based program.
11150156|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
11150157|NCT03726424||control|patients not carrying the pathogenic mutation(s)
11150158|NCT03726411|Experimental|periodontitis group|in this group, prolactin in GCF will be assessed at baseline and after 3 months of receiving non-surgical periodontal treatment
11150159|NCT03726411|No Intervention|control group|in this group of systemically and periodontally healthy participants, prolactin in GCF will be assessed at baseline only
11150160|NCT03726398|Experimental|Opsumit|Opsumit 10 mg tablet by mouth once daily
11150161|NCT03726385||Group I|Group I: The control group. Participants in this group received only NDT based upper extremity rehabilitation. Number of the participants were 19.
11150162|NCT03726385||Group II|Group II: The study group. Participants in this group received NDT based upper extremity rehabilitation + Cogniboard® Light Trainer training. Number of the participants were 19.
11150163|NCT03726372|Experimental|deep neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given by continuous infusion at a dose that reaction to train of four (TOF) stimulation is depressed to zero
11150164|NCT03726372|Experimental|moderate neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given at a dose by intermittent injection that reaction to train of four (TOF) stimulation is kept 1 to 2
11150165|NCT03726359|Experimental|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
11150166|NCT03726346|Experimental|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
11150167|NCT03726333|Active Comparator|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
11150168|NCT03726333|Active Comparator|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
11150169|NCT03726333|Experimental|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic imapirment
11150170|NCT03726333|Experimental|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
11150171|NCT03726333|Experimental|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
11150172|NCT03726320|Experimental|Intervention Group|a decision aid along with decision coaching on PSA screening from a Community Health Worker (CHW)
11150769|NCT03722134|Active Comparator|RFA|The refluxing GSV was treated with radiofrequency ablation.
11150173|NCT03726320|Active Comparator|Control Group|a decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control.
11150174|NCT03726307|Experimental|DCreg: 0.5 million cells/kg+SOC|"N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion.
~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:
~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).
~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
11150175|NCT03726307|Experimental|DCreg: 1.2 million cells/kg+SOC|"N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion.
~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:
~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).
~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
11150176|NCT03726307|Experimental|DCreg:2.5 to 5.0 million cells/kg+SOC|"N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion.
~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:
~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and
~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).
~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
11150177|NCT03726294|Experimental|NBM-BMX|
11150178|NCT03726281|Experimental|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
11150179|NCT03726268|Active Comparator|IV methadone|Intraoperative and post-operative IV methadone
11150180|NCT03726268|Active Comparator|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
11150181|NCT03726255||Stromal Vascular fraction|31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)
11150182|NCT03726255||Autologous mesenchymal stem cells|9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)
11150183|NCT03726255||Allogenic mesenchymal stem cells|12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)
11150184|NCT03726242|Active Comparator|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
11150185|NCT03726242|Placebo Comparator|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
11150186|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
11150187|NCT03726216||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in France
11150188|NCT03726203|Experimental|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
11150189|NCT03726203|Active Comparator|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
11150190|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
11150191|NCT03726177|Active Comparator|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
11150192|NCT03726177|Active Comparator|aspirin 81 mg plus placebo|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
11150193|NCT03726164|Active Comparator|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
11150194|NCT03726164|Placebo Comparator|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
11150195|NCT03726151|No Intervention|Usual Care|
11150196|NCT03726151|Experimental|Parent Reminders|
11150197|NCT03726151|Experimental|Multicomponent clinic-system strategies|
11150198|NCT03726151|Experimental|Combined Condition|
11150199|NCT03726125|Experimental|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
11150200|NCT03726125|Experimental|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
11150201|NCT03726125|Experimental|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
11150202|NCT03726125|Experimental|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
11150203|NCT03726125|Experimental|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
11150204|NCT03726125|Experimental|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
11150205|NCT03726112|Active Comparator|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
11150206|NCT03726112|Sham Comparator|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
11150207|NCT03726099|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy containing esomeprazole, amoxicillin, tetracycline and furazolidone.
11150208|NCT03726073|Experimental|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
11150209|NCT03726073|Sham Comparator|Non-intervention group|Usual care
11150210|NCT03726060|Other|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.
~The splint will be subsequently delivered to the patient with the relative indications of use.
~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
11150211|NCT03726060|Other|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.
~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.
~The cycle will consist of 10 sessions distributed over 3 months."
11150212|NCT03726047|No Intervention|Control|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).
11150213|NCT03726047|Experimental|Exercise|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
11150214|NCT03726034|Experimental|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
11150215|NCT03726034|Active Comparator|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
11150216|NCT03726021|Experimental|experimental arm|Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.
11150217|NCT03726008|Experimental|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
11150218|NCT03726008|No Intervention|Control group|The control group will receive the regular perinatal care
11150219|NCT03725995|Active Comparator|A (Midazolam)|21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
11150220|NCT03725995|Experimental|B (Lidocaine-Midazolam)|21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
11150221|NCT03725995|Placebo Comparator|C (Placebo)|21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.
11150222|NCT03725982|Experimental|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
11150223|NCT03725982|Experimental|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
11150224|NCT03725969|Experimental|Healthy individuals (camel milk)|
11150225|NCT03725969|Experimental|Healthy individuals (cow milk)|
11150226|NCT03725956|Experimental|endoscopic sinus surgery|Single group of patients with nasal polyposis eligible for endoscopic sinus surgery
11150227|NCT03725943|Experimental|Healthy adults|Dreem
11150228|NCT03725930|Active Comparator|Clonidine|This arm will receive intra nasal Clonidine as a premedication before surgery
11150229|NCT03725930|Placebo Comparator|Placebo|This arm will receive intra nasal Placebo as a premedication before surgery
11150230|NCT03725917|Experimental|Experimental Group|The intervention will be a progressive physiotherapy protocol formed by therapeutic exercise and manual therapy
11150231|NCT03725917|No Intervention|Control Group|The control group will not receive physiotherapy treatment.
11150232|NCT03725904|Experimental|IVF/FET|
11150233|NCT03725891|Active Comparator|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
11150234|NCT03725891|Active Comparator|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
11150235|NCT03725878|Experimental|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
11150236|NCT03725878|Active Comparator|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
11150237|NCT03725865|Experimental|iNSC treatment group|
11150238|NCT03725852|Experimental|GLPG1205 dose A|GLPG1205 will be taken as 2 capsules, once daily (q.d.), administered for 26 weeks on top of local standard of care.
11150239|NCT03725852|Placebo Comparator|Placebo|Matching placebo once daily (q.d.) administered for 26 weeks on top of local standard of care.
11150240|NCT03725839|Experimental|Arm|F&P Interface will be used by OSA participants in-home for 2 weeks.
11150241|NCT03725826||Acute Myocardial Infarction|Patients (aged 18 and above) with either ST segment elevation or Non-ST segment elevation MI by biomarkers of cardiac injury and symptoms. Cut-off for CPK >2 times and troponin >3 times the upper limit for the lab. Only Patients who undergo coronary revascularization (PCI, CABG), New York Heart Association (NYHA) functional class I-III, and with LVEF < 45% will be enrolled.
11150242|NCT03725813|Experimental|Person-centred inpatient care|Person-centred inpatient care
11150243|NCT03725800||Aspirin|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using aspirin for mono-antiplatelet therapy.
11150244|NCT03725800||Clopidogrel|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using clopidogrel for mono-antiplatelet therapy.
11150245|NCT03725800||ASIDE|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using ASIDE for mono-antiplatelet therapy.
11150246|NCT03725787|Experimental|CuroCell S.A.M. ® pro mattress|Mattresses of eligible participants will be replaced by a static air pressure redistribution mattress (CuroCell S.A.M. ® Pro).
11150247|NCT03725774|Experimental|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
11150248|NCT03725761|Experimental|IMMU-132 Treatment|Subjects enrolled in this study will receive IMMU-132 as treatment for Castrate-Resistant Prostate Cancer. Dose will be calculated per protocol in milligrams based on the subject's body weight at the beginning of each cycle or more frequently if weight changes >10%. Subjects will be treated on days 1 and 8 in a 21-day cycle, minimum 3 cycles.
11150249|NCT03725748|No Intervention|no irrigation group|nothing used for irrigation of cs scar
11150250|NCT03725748|Placebo Comparator|saline irrigation group|saline used for irrigation the cs scar before closure
11150251|NCT03725748|Experimental|betadine irrigation group|betadine used for irrigation of cs scar
11150252|NCT03725735|Experimental|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
11150253|NCT03725722|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
11150254|NCT03725722|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
11150255|NCT03725722|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
11150256|NCT03725722|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
11150257|NCT03725722|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
11150258|NCT03725709||All patients|spinal anesthesia
11150259|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
11150260|NCT03725683|Experimental|Incrementing groups|Each of the Increased caliber balloon capsules was predilated one by one, and the order of the increased balloon capsules was as follows: Balloon 2 diameter = target lesion reference vessel diameter minus 1; Balloon 3 diameter = target lesion reference vessel diameter;
11150261|NCT03725683|Experimental|matching groups|Pre-dilatation of the matched caliber balloon, whose diameter = the target lesion's diameter as a reference vessel, was applied.
11150262|NCT03725670|Experimental|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
11150263|NCT03725657||Pediatric|Pediatric Type1 Diabetes Mellitus patients
11150264|NCT03725644|Experimental|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
11150265|NCT03725644|Experimental|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
11150266|NCT03725631|Experimental|Biopsy proven NAFLD patients|150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.
11150267|NCT03725618|Experimental|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
11150268|NCT03725618|Experimental|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
11150269|NCT03725618|Experimental|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
11150270|NCT03725605|Experimental|LTX-315 plus TIL infusion|LTX-315 intratumoural 5mg per injection time point (number of injections per dosing days is dependent upon lesion size), TILs expansion and infusion.
11150271|NCT03725592|Active Comparator|Standard Treatment|Receives arsenic removal device and written instructions and phone calls on how to use the device (Arsenic Removal Device)
11150272|NCT03725592|Experimental|Intensive Education|Receives the Standard Treatment plus in-person visits and phone calls for follow-up (Community Participatory Arsenic Mitigation)
11150273|NCT03725579|Experimental|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
11150307|NCT03725358|Experimental|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
11150274|NCT03725579|Active Comparator|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
11150275|NCT03725566|Experimental|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
11150276|NCT03725553|Experimental|Intramyometrial Vasopressin|the experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
11150277|NCT03725553|Placebo Comparator|Placebo|the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)immediately after delivery, as soon as the umbilical cord was clamped.
11150278|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
11150279|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
11150280|NCT03725527|Active Comparator|Rectus sheath catheter block|Patients will receive ultrasound-guided rectus sheath block with catheter insertion performed after induction of general anesthesia and before surgery.
11150281|NCT03725527|Active Comparator|Epidural Catheter block|Patients will receive thoracic epidural at the level of T7 performed before anesthesia induction.
11150282|NCT03725514|Active Comparator|conventional|Conventional blood clot technique
11150283|NCT03725514|Experimental|PRF|Platelet Rich Fibrin Technique
11150284|NCT03725501|Experimental|Ranibizumab + ALS-L1023 600mg|"ALS-L1023 600 mg - Take 2 tablets orally twice a day.
~Ranibizumab (Lucentis®)
~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.
~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
11150285|NCT03725501|Experimental|Ranibizumab + ALS-L1023 1200mg|"ALS-L1023 1200 mg - Take 2 tablets orally twice a day.
~Ranibizumab (Lucentis®)
~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.
~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
11150286|NCT03725501|Placebo Comparator|Ranibizumab + Placebo|"Placebo - Take 2 tablets orally twice a day.
~Ranibizumab (Lucentis®)
~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.
~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
11150287|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
11150288|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
11150289|NCT03725475||Stage III|stage III Non-small Cell Lung Cancer (NSCLC )
11150290|NCT03725462|Experimental|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
11150291|NCT03725462|Experimental|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
11150292|NCT03725449|Experimental|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
11150293|NCT03725449|Experimental|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
11150294|NCT03725449|Experimental|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
11150295|NCT03725436|Experimental|Treatment (paclitaxel, ALRN-6924)|Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11150296|NCT03725423|Experimental|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
11150297|NCT03725410|Active Comparator|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
11150298|NCT03725410|Placebo Comparator|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
11150299|NCT03725397|Experimental|Outpatients with a transcervical Foley catheter|Women with a transcervical Foley catheter in place that will spend the night at home.
11150300|NCT03725397|Active Comparator|Inpatients with a transcervical Foley catheter|"Women to be admitted to the hospital overnight which has been a standard of care."
11150301|NCT03725384|Experimental|Ferrous Sulfate and Vitamin C every other day|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every other day for 12 weeks
11150302|NCT03725384|Active Comparator|Ferrous Sulfate and Vitamin C daily|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every day for 12 weeks
11150303|NCT03725358|Experimental|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
11150304|NCT03725358|Experimental|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
11150305|NCT03725358|Experimental|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
11150306|NCT03725358|Experimental|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
11150308|NCT03725358|Experimental|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
11150309|NCT03725358|Experimental|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
11150310|NCT03725358|Experimental|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
11150311|NCT03725358|Experimental|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
11150312|NCT03725345|Experimental|Alcohol Group|Participants will consume an alcoholic beverage consisting of a 1:5 ratio of 95% ethyl alcohol and orange juice
11150313|NCT03725345|Placebo Comparator|Placebo Group|Participants will consume a placebo beverage of orange juice
11150314|NCT03725332|Experimental|Telemedicine Education|This is a stratified cluster randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (>500 deliveries/year) and 'low volume' (<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to telemedicine will be recruited by research staff.
11150315|NCT03725332|Active Comparator|Group Care Education|This is a stratified cluster randomized controlled trial with randomization of participating clusters into a 'telemedicine' or 'group care' arm. Sites will be stratified into 'high volume' (>500 deliveries/year) and 'low volume' (<500 deliveries per year). Randomization will be within each strata. Patients attending sites randomized to group care will be recruited by research staff.
11150316|NCT03725319||Epinephrin injection|Diluted Epinephrin (1:100) in small amounts from 1 to 5 ml is injected into apex of the papilla to stop post sphincterotomy-bleeding
11150317|NCT03725319||Plastic stent insertion|A plastic stent (diameter: 8-11,5F and length of 50 -100mm) is inserted into the common bile duct to stop post sphincterotomy-bleeding
11150318|NCT03725306|Experimental|Librata|Librata Endometrial Ablation Device
11150319|NCT03725293|Active Comparator|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
11150320|NCT03725293|Active Comparator|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
11150321|NCT03725280||Transgender men I|Transgender men after testosterone treatment
11150322|NCT03725280||Transgender men II|Transgender men before testosterone treatment
11150323|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
11150324|NCT03725280||Egg donors|IVF- egg donors patients
11150325|NCT03725267|Experimental|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
11150326|NCT03725267|Placebo Comparator|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
11150327|NCT03725254|Active Comparator|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
11150328|NCT03725254|Experimental|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
11150329|NCT03725241|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
11150330|NCT03725241|Experimental|Experimental: Glutathione|Intervention: Dietary Supplement: Glutathione supplement
11150331|NCT03725228|Active Comparator|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
11150332|NCT03725228|Experimental|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
11150333|NCT03725215|Experimental|Split-Belt Treadmill Training 1:2|Split-Belt Training with a steady ratio of 1:2.
11150334|NCT03725215|Experimental|Split-Belt Treadmill Training 3:4|Split-Belt Training with a steady ratio of 3:4.
11150335|NCT03725215|Experimental|Split-Belt Treadmill Training Changing|Split-Belt Training with changing ratios between 3:4 to 1:2.
11150336|NCT03725215|Active Comparator|Split-Belt Treadmill Training Tied-Belt|Split-Belt Training with tied belts.
11150337|NCT03725202|Experimental|Arm A|Upadacitinib dose A administered daily + 26-week CS taper regimen
11150338|NCT03725202|Experimental|Arm B|Upadacitinib dose B administered daily + 26-week CS taper regimen
11150339|NCT03725202|Placebo Comparator|Arm C|Placebo administered daily + 52-week CS taper regimen
11150340|NCT03725189|Experimental|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
11150341|NCT03725163|Experimental|Treatment|This arm will begin treatment immediately after completing the initial intake assessment.
11150342|NCT03725163|Other|Waitlist Control|Participants assigned to the waitlist control condition will begin a 12-week waiting period after completing the initial intake assessment before starting treatment.
11150343|NCT03725137||Group A (young stroke)|Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI
11150344|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
11150345|NCT03725124||Partners|Partners of women with IBD.
11150346|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
11150347|NCT03725111|Experimental|arterio venous leg ulcers|
11150348|NCT03725098|Experimental|HEMOBLAST Bellows (Hemostatic Device)|Bleeding sites will be treated with HEMOBLAST Bellows per its approved Indications for Use
11150349|NCT03725098|Active Comparator|FLOSEAL (Hemostatic Device)|Bleeding sites will be treated with FLOSEAL per its approved Indications for Use
11150350|NCT03725085|Experimental|Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)|"2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.
~GGE = Guaifenesin
~BID = Twice in a day"
11150351|NCT03725072|Experimental|Evobrutinib|
11150352|NCT03725059|Experimental|Pembrolizumab+Chemotherapy (KX/KA[E]C)|In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion Q3W for 4 cycles (Treatment 2). At 3 to 6 weeks after last cycle of neoadjuvant treatment, participants will undergo definitive surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
11150353|NCT03725059|Placebo Comparator|Placebo+Chemotherapy (PX/PA[E]C)|In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion Q3W for 4 cycles (Treatment 2). At 3 to 6 weeks after last cycle of neoadjuvant treatment, participants will undergo definitive surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.
11150354|NCT03725046|No Intervention|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
11150355|NCT03725046|Experimental|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
11150356|NCT03725033|Experimental|Subetta|Oral administration. 2 tablets 2 times a day 15 minutes before meals. Keep the tablets in your mouth, not swallowing, until completely they are dissolved.
11150357|NCT03725033|Placebo Comparator|Placebo|Oral administration. 2 tablets 2 times a day 15 minutes before meals. Keep the tablets in your mouth, not swallowing, until completely they are dissolved.
11150358|NCT03725020|Experimental|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
11150359|NCT03725020|Placebo Comparator|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
11150360|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose A|Participants of age group 12 to <18 years administered with upadacitinib dose A(weight dependent) as described in the protocol
11150361|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose B|Participants of age group 12 to <18 years administered with upadacitinib dose B(weight dependent) as described in the protocol
11150362|NCT03725007|Experimental|Participants of age group 6 to <12 years receiving dose A|Participants of age group 6 to <12 years administered with upadacitinib dose A(weight dependent) as described in the protocol
11150363|NCT03725007|Experimental|Participants of age group 6 to <12 years receiving dose B|Participants of age group 6 to <12 years administered with upadacitinib dose B(weight dependent) as described in the protocol
11150364|NCT03725007|Experimental|Participants of age group 2 to <6 years receiving dose A|Participants of age group 2 to <6 years administered with upadacitinib dose A(weight dependent) as described in the protocol
11150365|NCT03725007|Experimental|Participants of age group 2 to <6 years receiving dose B|Participants of age group 2 to <6 years administered with upadacitinib dose B(weight dependent) as described in the protocol
11150366|NCT03724994||Study cohort|All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö
11150367|NCT03724981|Experimental|Dulaglutide Pen|Injection of commercial dulaglutide pen on a practice pad.
11150368|NCT03724981|Experimental|Semaglutide Pen|Injection of commercial semaglutide pen on a practice pad.
11150369|NCT03724968|Experimental|Arm A|Nivolumab and Relatlimab
11150370|NCT03724968|Experimental|Arm B|Nivolumab and Ipilimumab
11150371|NCT03724955|Experimental|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
11150372|NCT03724955|Placebo Comparator|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
11150373|NCT03724942|Experimental|Brexpiprazole|
11150407|NCT03724708|Active Comparator|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
11150408|NCT03724708|Active Comparator|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
11150409|NCT03724695|No Intervention|Control|Usual Care
11150465|NCT03724318|Active Comparator|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
11150374|NCT03724929|Experimental|Ulcerative Colitis patients|"To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :
~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.
~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization."
11150375|NCT03724916|Experimental|TAK-079|TAK-079 injection, subcutaneously, once every 3 weeks for up to 12 weeks in combination with principal investigator-directed background therapy for SLE. Dose escalation of TAK-079 dose will be based on PK, safety and tolerability data.
11150376|NCT03724916|Placebo Comparator|Placebo|TAK-079 placebo-matching injection, subcutaneously, once every 3 weeks for up to 12 weeks in combination with principal investigator-directed background therapy for SLE.
11150377|NCT03724903|Experimental|Ductal lavage|Ductal lavage and breast massage for two weeks.
11150378|NCT03724903|Active Comparator|Corticosteroids therapy|Oral corticosteroids therapy for 6 months.
11150379|NCT03724890|Experimental|Part A: M3814 + Avelumab|
11150380|NCT03724890|Experimental|Part B: M3814 + Avelumab + Radiotherapy (RT)|
11150381|NCT03724890|Experimental|Part FE: M3814 + Avelumab (fasted/fed state)|
11150382|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
11150383|NCT03724864|Experimental|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
11150384|NCT03724864|Active Comparator|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
11150385|NCT03724864|Placebo Comparator|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
11150386|NCT03724851|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
11150387|NCT03724838|Active Comparator|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
11150388|NCT03724838|Active Comparator|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
11150389|NCT03724838|Placebo Comparator|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
11150390|NCT03724825||obese men|Adult obese men (BMI ≥ 30 kg/m2)
11150391|NCT03724825||normal men|normal weight men (18.5 ≤ BMI < 25 kg/m2 )
11150392|NCT03724812|Experimental|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
11150393|NCT03724799|Experimental|single arm|Intravenous low level laser therapy
11150394|NCT03724786|Experimental|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
11150395|NCT03724786|No Intervention|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
11150396|NCT03724773|Active Comparator|Long-Arm Cast|Reduction and long-arm cast application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
11150397|NCT03724773|Active Comparator|Sugar-Tong Splint|Reduction and sugar-tong splint application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
11150398|NCT03724760|Experimental|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
11150399|NCT03724760|No Intervention|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
11150400|NCT03724747|Experimental|BAY 2315497 dose Escalation|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
11150401|NCT03724747|Experimental|BAY 2315497 dose expansion:Dose regimen 1|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY 2315497 Injection, observed in the course of the dose escalation.
11150402|NCT03724747|Experimental|BAY 2315497 dose expansion:Dose regimen 2|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY 2315497 Injection, observed in the course of the dose escalation.
11150403|NCT03724734|Experimental|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
11150404|NCT03724734|Active Comparator|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
11150405|NCT03724721|Experimental|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
11150406|NCT03724708|Experimental|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
11150410|NCT03724695|Experimental|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
11150411|NCT03724682|Experimental|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
11150412|NCT03724669|Placebo Comparator|psychiatry knowledge|
11150413|NCT03724669|Experimental|Benzodiazepines knowledge|
11150414|NCT03724656|Experimental|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
11150415|NCT03724656|Sham Comparator|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
11150416|NCT03724643|Experimental|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
11150417|NCT03724643|No Intervention|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
11150418|NCT03724617|Experimental|stem cell therapy|
11150419|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
11150420|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
11150421|NCT03724591|Experimental|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
11150422|NCT03724591|Active Comparator|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
11150423|NCT03724578|Sham Comparator|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
11150424|NCT03724578|Active Comparator|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
11150425|NCT03724578|Experimental|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
11150426|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
11150427|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
11150428|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
11150429|NCT03724552|Experimental|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
11150430|NCT03724539|Experimental|STRIPA intervention|"GPs in the intervention group will perform a STRIPA analysis for each of their 8-10 patients after the recruitment of the patient into the OPTICA trial, so that the results can be discussed in the next consultation and a shared decision-making can be performed.
~STRIPA is a structured method to perform pharmacotherapy optimization. The STRIPA intervention in the OPTICA trial consists of 4 steps:
~recording medication and diagnoses in STRIPA (upload from data from the 'Family medicine ICPC Research using Electronic medical records' (FIRE) database)
~structured drug review through the GP based on the STRIPA with the integrated STOPP/START criteria
~shared decision-making between GP and patient with possible adaptation of the recommendation
~follow-up through study team"
11150431|NCT03724539|Sham Comparator|Sham intervention|Patients in the control group will receive a sham intervention, which consists of a usual medication review by their GP as well as a shared decision making of the latter.
11150432|NCT03724526|Experimental|Intervention-Text messaging|Participates will receive regular 6 text messages per week for 12 months. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week. Each message will be sent on 6 of 7 randomly selected weekdays and arrived at random times the day during working hours.
11150433|NCT03724526|No Intervention|Control|Participates in control group will not receive text messages.
11150434|NCT03724487|Experimental|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
11150435|NCT03724487|Experimental|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
11150463|NCT03724331|Experimental|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
11150537|NCT03723798|Experimental|3|SA001 High dose
11150436|NCT03724474|Experimental|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
11150437|NCT03724474|Active Comparator|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
11150438|NCT03724461|Active Comparator|High intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg is established as control.
11150439|NCT03724461|Active Comparator|Light intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes light-moderate intensity resistance training (12 weeks) and the other leg is established as control.
11150440|NCT03724461|Experimental|High vs Light intensity (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg undergoes light-moderate intensity resistance training.
11150441|NCT03724461|Experimental|High intensity (Acute)|Analysis of the effects of one High Intensity resistance training session, with a crossover design.
11150442|NCT03724461|Experimental|Light intensity (Acute)|Analysis of the effects of one Light-moderate Intensity resistance training session, with a crossover design.
11150443|NCT03724448|Experimental|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
11150444|NCT03724448|Placebo Comparator|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
11150445|NCT03724435||Pancreatic Cancer Participants|No intervention will be administered. Assessments are performed as standard of care.
11150446|NCT03724422|No Intervention|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
11150447|NCT03724422|Experimental|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
11150448|NCT03724409|Experimental|Cohort 1|Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
11150449|NCT03724409|Experimental|Cohort 2|Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
11150450|NCT03724409|Experimental|Cohort 3|Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
11150451|NCT03724409|Experimental|Cohort 4|Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
11150452|NCT03724409|Experimental|Cohort 5|Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
11150453|NCT03724409|Experimental|Cohort 6|Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
11150454|NCT03724396|Experimental|Novel Executive Function Training - NEXT|Same as BWL with some additional strategies targeted at improving executive function to help adherence to BWL skills.
11150455|NCT03724396|Active Comparator|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
11150456|NCT03724383|No Intervention|Control|Participants in the control arm will receive standard care.
11150457|NCT03724383|Experimental|Intervention|Participants in the intervention group will receive risk factor management consultations and take part in 1-hour biweekly diet classes and stress management classes for the first 3 months. This will be followed by 3 months of 1-hour biweekly high intensity interval training exercise classes. At the 6-month time point, participants will be prescribed a home based exercise program and will have the option of participating in weekly group walking sessions. During the final 6 months, participants will use a step/activity tracker to track their steps and heart rate.
11150458|NCT03724370|Experimental|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
11150459|NCT03724370|Active Comparator|VHA-SRM|VHA-SRM will be active comparator
11150460|NCT03724357|Experimental|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
11150461|NCT03724344||Dimensions with Behavioral and psychological symptoms|
11150462|NCT03724331|Experimental|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
11150464|NCT03724331|Active Comparator|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
11150466|NCT03724318|No Intervention|Control|The left atrium appendage will remain open in patients randomized to the control group
11150467|NCT03724305|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
11150468|NCT03724305|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
11150469|NCT03724292|Placebo Comparator|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
11150470|NCT03724292|Experimental|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
11150471|NCT03724292|Experimental|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
11150472|NCT03724292|Experimental|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
11150473|NCT03724292|Experimental|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
11150474|NCT03724292|Experimental|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
11150475|NCT03724279|Experimental|ByCross Atherectomy and Thrombectomy|Percutaneous intervention including ByCross atherectomy and Thrombectomy potentially followed with PTA and/or stent placement
11150476|NCT03724266|Experimental|chitosan|chitosan as intracanal medication 0.2% in form of gel
11150477|NCT03724266|Active Comparator|calcium hydroxide|intracanal medication
11150478|NCT03724253|Experimental|Phase II dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
11150479|NCT03724253|Experimental|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
11150480|NCT03724240|Placebo Comparator|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
11150481|NCT03724240|Experimental|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
11150482|NCT03724214|No Intervention|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
11150483|NCT03724214|Active Comparator|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
11150484|NCT03724175|Experimental|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
11150485|NCT03724149|Experimental|Direct-acting antiviral treatment for HCV|
11150486|NCT03724136|Active Comparator|Arm 1|Intravenous Bone Marrow Stem Cell (BMSC) Fraction
11150487|NCT03724136|Active Comparator|Arm 2|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Near Infrared Light exposure .
11150488|NCT03724136|Active Comparator|Arm 3|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Intranasal topical Bone Marrow Stem Cell (BMSC) Fraction.
11150489|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
11150490|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
11150491|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
11150492|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
11150493|NCT03724097||Group 3|Patients receiving palliative care
11150494|NCT03724084|Experimental|Treatment (pinometostat)|"Patients receive pinometostat IV continuously on days 1-35, daunorubicin hydrochloride IV over 10-30 minutes on days 8-10 and cytarabine IV continuously on days 8-14 in the absence of disease progression or unacceptable toxicity.
~Patients who do not achieve CR/CRi after treatment receive pinometostat IV continuously on days 1-28, daunorubicin hydrochloride IV over 10-30 minutes on days 1 and 2 and cytarabine IV continuously on days 1-5 in the absence of disease progression or unacceptable toxicity."
11150495|NCT03724071|Experimental|TG6002 and flucytosine combination|
11150496|NCT03724058|Experimental|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
11150497|NCT03724058|Active Comparator|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
11150498|NCT03724045|Experimental|Back Side of the Moon|"Patients will be screened and enrolled at the ICU. Extraordinary measurements concerning nutritional status will be performed, to investigate whether patients at the ICU actually meet their nutritional needs. The same patients as above will be followed up, once discharge from ICU to a low-care ward has taken place. From there, they will be followed up until discharge from the hospital. The procedures are the same as in the ICU. The results obtained at the low-care ward will be compared to those from the ICU. 6 months after hospital discharge, morbidity and mortality will be assessed.
~A substudy of included COVID-19 positive patients will be analysed and compared to non COVID-19 patients."
11150499|NCT03724032|Active Comparator|TMD Patients Active Group: Active Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
11150500|NCT03724032|Sham Comparator|TMD Patients Sham Group: Sham Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
11150501|NCT03724032|No Intervention|Healthy Control Group|"20 Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).
~Healthy volunteer data (n </= 10) may be used from a prior study (NIDCR-R56-DE022637 project [IRBMED #HUM00080911; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
11150502|NCT03724019||Group Q|20 milliliter of ketamine (0.5mg / kg ideal body weight) at induction of anesthesia.
11150503|NCT03724019||Group S|20 milliliter of sodium chloride at induction of anesthesia.
11150504|NCT03724006|Experimental|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
11150505|NCT03724006|No Intervention|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
11150506|NCT03723993|Placebo Comparator|Control group|control group will have non inflated cuff around the arm.
11150507|NCT03723993|Active Comparator|RIPC group|Inflated cuff will be done systematically and regularly
11150508|NCT03723980|Active Comparator|Control Group or Group I or Calcium hydroxide Group|
11150509|NCT03723980|Experimental|Experimental Group or Group II or Propolis Group|
11150510|NCT03723967|Experimental|Durvalumab with Carboplatin/Paclitaxel|Combination of Durvalumab with Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
11150511|NCT03723941|Experimental|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
11150512|NCT03723941|Other|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
11150513|NCT03723928|Active Comparator|Arm I (usual care)|Patients will have imaging studies (modality and frequency per treating physician, however at a minimum frequency of every 12 weeks) alone or in conjunction with STMs (frequency determined by treating physician). Patients will continue with usual care disease monitoring for up to 312 weeks in the absence of disease progression.
11150514|NCT03723928|Experimental|Arm II (serum tumor directed disease monitoring)|Patients undergo disease specific serum tumor marker evaluation (CEA and either CA 15-3 or CA 27.29, whichever were tested at Step 1 Registration and Step 2 Registration) every 4-8 weeks (starting from randomization) without imaging until an elevation of at least one disease specific STM. In the event of an elevated STM, the patient will have imaging within 4 weeks to evaluate for disease progression. Patients continue with STMDDM for up to 312 weeks in the absence of disease progression.
11150515|NCT03723915|Experimental|Treatment (pembrolizumab, wild-type reovirus)|See Detailed Description
11150516|NCT03723902|Experimental|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
11150517|NCT03723902|No Intervention|Control|No intervention
11150518|NCT03723889||PDA|Evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
11150519|NCT03723889||noPDA|No evidence of patent ductus arteriosus at echocardiography evaluation before enteral feeding introduction.
11150520|NCT03723876|Active Comparator|Intervention group|Twelve occasions of Basic body awareness therapy, administered once a week, alongside treatment as usual (such as structured everyday support, medicine, contact with social worker).
11150521|NCT03723876|No Intervention|Control group|No extra intervention except treatment as usual.
11150522|NCT03723863|Experimental|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
11150523|NCT03723850|Experimental|Older, active tDCS, dlPFC|"Older adults (ages 60-75) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
~2."
11150524|NCT03723850|Sham Comparator|Older, sham tDCS, dlPFC|Older adults (ages 60-75) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
11150525|NCT03723850|Experimental|Younger, active tDCS, dlPFC|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex. One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
11150526|NCT03723850|Sham Comparator|Younger, sham tDCS, dlPFC/parietal|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of sham tDCS stimulation (Soterix Medical) delivered to either the left dorsolateral prefrontal cortex (area F3 using the 10-20 EEG system, n = 25), or the left parietal cortex (area P5 using the 10-20 EEG system, n = 25). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
11150527|NCT03723850|Active Comparator|Younger, active tDCS, parietal cortex|Younger adults (ages 18-30) randomized to this arm will receive 2 sessions of active tDCS stimulation (Soterix Medical) delivered to the left parietal cortex (area P5 using the 10-20 EEG system). One session will occur in the morning (8 or 9am) and one will occur on a separate day in the afternoon (3 or 4pm).
11150528|NCT03723837|Active Comparator|Study Arm A|Children {Age > 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
11150529|NCT03723837|Active Comparator|Study arm B|Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month
11150530|NCT03723824|Experimental|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
11150531|NCT03723811|Experimental|1|SJP002 BID
11150532|NCT03723811|Experimental|2|SJP002 QID
11150533|NCT03723811|Placebo Comparator|Placebo 1|SJP002 Placebo 1
11150534|NCT03723811|Placebo Comparator|Placebo 2|SJP002 Placebo 2
11150535|NCT03723798|Experimental|1|SA001 Low dose
11150536|NCT03723798|Experimental|2|SA001 Mid dose
11150539|NCT03723785|Experimental|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
11150540|NCT03723785|Experimental|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
11150541|NCT03723785|Experimental|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
11150542|NCT03723785|Experimental|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
11150543|NCT03723785|Experimental|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
11150544|NCT03723772|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling where subjects are treated with once daily (OD) insulin glargine.
~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
11150545|NCT03723772|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 4 weeks): The basal insulin glargine dose for each subject will be established and optimised.
~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.
~After insulin glargine treatment, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic sampling."
11150546|NCT03723759|Experimental|Group A|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E.
~The dosing visits will be separated by wash-out periods (2-21 days)."
11150547|NCT03723759|Experimental|Group B|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL.
~The dosing visits will be separated by wash-out periods (2-21 days)."
11150548|NCT03723759|Experimental|Group C|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D.
~The dosing visits will be separated by wash-out periods (2-21 days)."
11150549|NCT03723759|Experimental|Group D|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B.
~The dosing visits will be separated by wash-out periods (2-21 days)."
11150550|NCT03723759|Experimental|Group E|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C.
~The dosing visits will be separated by wash-out periods (2-21 days)."
11150551|NCT03723759|Experimental|Group F|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:
~formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A.
~The dosing visits will be separated by wash-out periods (2-21 days)."
11150552|NCT03723746|Experimental|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day [SD] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
11150553|NCT03723746|Experimental|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
11150554|NCT03723746|Experimental|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day [MD] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
11150555|NCT03723746|Experimental|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
11150556|NCT03723746|Experimental|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
11150557|NCT03723746|Experimental|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
11150558|NCT03723746|Experimental|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
11150559|NCT03723746|Experimental|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
11150560|NCT03723746|Experimental|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
11150561|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
11150562|NCT03723707|Experimental|Intervention (INT)|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
11150563|NCT03723707|Placebo Comparator|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
11150564|NCT03723694|Active Comparator|650 mg of Cocoapro flavanols|Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
11150565|NCT03723694|Placebo Comparator|0mg Cocoapro flavanols|Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
11150566|NCT03723681|Experimental|Quizartinib 20 mg|Participants receive 20 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
11150567|NCT03723681|Experimental|Quizartinib 40 mg|Participants receive 40 mg quizartinib in combination with standard induction therapy and consolidation therapy once daily in the fasted state in the morning (at least 1 hour before or two hours after a meal)
11150568|NCT03723668||OPTN data system|In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
11150569|NCT03723668||CRISTAL registry|In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
11150570|NCT03723655|Experimental|Group 1|Active Treatment for participants with base target trough concentration
11150571|NCT03723655|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
11150572|NCT03723655|Experimental|Group 3|Active Treatment for participants dose titrated to clinical response
11150573|NCT03723642|Active Comparator|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
11150574|NCT03723642|Active Comparator|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
11150575|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
11150576|NCT03723616|Active Comparator|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
11150577|NCT03723616|Active Comparator|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
11150578|NCT03723603|Experimental|Fibrillar Collagen Powder Dressing|
11150579|NCT03723590|Experimental|Esterified hyaluronic acid matrix|
11150580|NCT03723577|Experimental|Fibrillar Collagen Powder Dressing|
11150581|NCT03723564|Experimental|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
11150582|NCT03723551|Experimental|Afabicin|Participants will be administered with open label Afabicin intravenous (IV) at a dose of 160 milligram (mg) twice daily (BID) for a minimum of 1 day (2 doses) and up to a maximum of 14 days (2 weeks), followed by a switch to oral Afabicin at a dose of 240 mg BID for the remaining treatment duration.
11150583|NCT03723551|Active Comparator|Standard of Care (SOC)|Participants will be administered with SOC in accordance with the approved regional labeling, without exceeding the maximum dosing schedule.
11150584|NCT03723525|Experimental|Package of HIV care|Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.
11150585|NCT03723525|Experimental|Standard HIV care|Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.
11150586|NCT03723512|Experimental|Whole group|Whole group
11150587|NCT03723499||endoscopic treatment|Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.
11150588|NCT03723486||Roux-en-Y gastric bypass surgery (RYGB)|Morbidly obese patients undergoing gastric bypass surgery
11150589|NCT03723473||PAOD patients statin (+)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) and statin treatment.
~They will have Magnetic Resonance Imaging (MRI; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
11150590|NCT03723473||PAOD patients statin (-)|"Patients with Peripheral Arterial Occlusive Disease (PAOD) without statin treatment .
~They will have Magnetic Resonance Imaging (MRI ; muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise. It will be performed before surgery (within 48h) and after surgery (first week)"
11150591|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
11150592|NCT03723447|Active Comparator|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
11150593|NCT03723447|Active Comparator|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
11150594|NCT03723434|Active Comparator|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
11150595|NCT03723434|Experimental|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
11150596|NCT03723421|Experimental|Rapid Injection Group Without Aspiration|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position by rapid injection technique without aspiration.
11150597|NCT03723421|Experimental|Control|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position with the standard injection technique.
11150598|NCT03723408|Other|Single Arm post-approval study|Single Arm post-approval study.
11150599|NCT03723395|Experimental|Part A|Tucatinib plus Itraconazole
11150600|NCT03723395|Experimental|Part B|Tucatinib plus Rifampin
11150601|NCT03723395|Experimental|Part C|Tucatinib plus Gemfibrozil
11150602|NCT03723395|Experimental|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
11150603|NCT03723395|Experimental|Part E|Tucatinib plus Digoxin
11150604|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
11150605|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
11150606|NCT03723356||MS Patients|Definite diagnosis of RRMS
11150607|NCT03723356||Healthy Controls|gender aged match healthy
11150608|NCT03723343||Experimental: GP+IMRT|Test group: GP-induced chemotherapy (Gemcitabine 1000 mg/m2 d1, 8+Cisplatin 80 mg/m2 d1, once every 3 weeks, 4/6 course) + IMRT radiotherapy alone
11150609|NCT03723343||Active Comparator: TPF+IMRT|Control group: TPF-induced chemotherapy (Docetaxel: 75 mg/m2d1, Cisplatin 75 mg/m2, d1~d5, 5-fluorouracil 750 mg/m2/dd1~d5, 4/6 course) + IMRT radiotherapy alone
11150610|NCT03723330|Experimental|Plant sterol with a healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
11150611|NCT03723330|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
11150612|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
11150613|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
11150614|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
11150615|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
11150616|NCT03723291|Active Comparator|Arm A|The current best standard of care [rehabilitation exercises]
11150617|NCT03723291|Experimental|Arm B|The current best standard of care [rehabilitation exercises] + the experimental intervention
11150618|NCT03723278||Healthy individuals|Young, male and healthy volunteers without any significant disease
11150619|NCT03723252|Experimental|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
11150620|NCT03723252|Placebo Comparator|Placebo group|Participants will receive placebo po qd.
11150621|NCT03723239|Experimental|TricValve® System Single-Arm|Minimally invasive catheter-supported, bicaval tricuspid valve (self-expanding) replacement
11150622|NCT03723226|Active Comparator|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 5 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
11150623|NCT03723226|Experimental|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 5 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
11150624|NCT03723187|Experimental|experimental group|use Normal saline
11150625|NCT03723187|Active Comparator|comparator group|use Heparin
11150626|NCT03723174||Single Arm|baseline data will be calculated before the oral health educational program using gingival index and after 3 months from the intervention
11150627|NCT03723161||Treatment|Bone Anchored Hearing surgery using a BHX implant manufactured by Oticon Medical
11150628|NCT03723122|Experimental|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
11150629|NCT03723122|No Intervention|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
11150630|NCT03723070|Experimental|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
11150631|NCT03723044|Experimental|healthy volunteers|
11150632|NCT03723031|Active Comparator|rectal misopristol|will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion.
11150633|NCT03723031|Active Comparator|intrauterine misopristol|will receive 400 microgram misoprostol inserted intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta.
11150634|NCT03723018|Experimental|Meditation - Headspace|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by the commercially available app/website Headspace (provided to participants for free). Participants in this arm will have access to the other meditation arm once they finish the study.
11150635|NCT03723018|Experimental|Meditation - Respite|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
11150636|NCT03723018|No Intervention|Observational|Participants in this arm will not receive any intervention. Their only study activity will be taking online surveys. They will have access to the two meditation arms once they finish the study.
11150637|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
11150638|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
11150639|NCT03722992|Other|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
11150640|NCT03722979|Other|All patients|
11150641|NCT03722966|Experimental|Varenicline/Counseling + Med Reminders|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and automated medication reminders via their smartphones.
11150642|NCT03722966|Experimental|Varenicline/Counseling|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and no automated medication reminders.
11150643|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and no automated medication reminders.
11150644|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT + Med Reminders|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and automated medication reminders via their smartphones.
11150645|NCT03722953|Other|Aerobic Exercise|"Control: Cerebrovascular function and peripheral vascular function will be measured.
~Aerobic Exercise: Across four separate visits, participants will perform light intensity exercise, light intensity exercise plus an additional task, vigorous intensity exercise and vigorous intensity exercise to match the energy expenditure of light intensity exercise visit."
11150646|NCT03722940|Active Comparator|Magnesium sulphate|Group M
11150647|NCT03722940|Placebo Comparator|Na CL 0.9%|group C
11150648|NCT03722927|Experimental|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
11150649|NCT03722927|Experimental|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
11150650|NCT03722914|Active Comparator|benzonatate soft capsules group|
11150651|NCT03722914|Placebo Comparator|control group|
11150652|NCT03722901||Late preterm infants|34 weeks and 0-6 days gestational age
11150653|NCT03722901||Moderate preterm infants|32 weeks and 0-6 days gestational age
11150654|NCT03722901||Reference|Term infants 9m/39-40
11150655|NCT03722888|Experimental|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
11150656|NCT03722875|Experimental|SHR-1210+ apatinib|"SHR-1210 (200mg fixed dose every 3 weeks, one cycle is three weeks, total
~1 year ) will be administered as an intravenous infusion over 30 minutes.
~apatinib 250 mg qd ， one cycle is three weeks, total 1 year"
11150657|NCT03722862|Placebo Comparator|Control Arm|Healthy volunteers will continue normal healthy diet with a placebo.
11150658|NCT03722862|Experimental|Low fiber|Healthy volunteers will be randomized to receive 3 grams of Sunfiber.
11150659|NCT03722862|Experimental|High fiber|Healthy volunteers will be randomized to receive 6 grams of Sunfiber.
11150660|NCT03722849|Experimental|Chronic cough participant|"Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.
~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
11150661|NCT03722849|Experimental|Healthy control participant|"Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.
~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
11150662|NCT03722823|Active Comparator|Group 1: Healthy|Match-controlled healthy subjects with normal hepatic function
11150663|NCT03722823|Experimental|Group 2: Mild Hepatic Impairment|Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)
11150664|NCT03722823|Experimental|Group 3: Moderate Hepatic Impairment|Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)
11150665|NCT03722823|Experimental|Group 4: Severe Hepatic Impairment|Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)
11150666|NCT03722810|Active Comparator|Active comparator: patient interview|This intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
11150667|NCT03722810|Sham Comparator|Sham comparator: document|In this intervention, the student's allocated GP teacher will give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher.
11150668|NCT03722797||Unilateral Transtibial Amputation|Individuals with a unilateral, transtibial amputation.
11150669|NCT03722797||Controls|Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.
11150670|NCT03722784|Experimental|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
11150671|NCT03722784|Active Comparator|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
11150672|NCT03722771|Experimental|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.
~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
11150673|NCT03722771|Sham Comparator|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
11150674|NCT03722758|Active Comparator|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
11150675|NCT03722758|Active Comparator|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
11150676|NCT03722745|Experimental|Study group 1|Juvenile offenders will attend 4-session Trauma Affect Regulation: Guide for Education & Treatment (TARGET) groups led by one or two juvenile staff members
11150677|NCT03722745|Active Comparator|study group 2|Juvenile offenders will receive treatment-as-usual (TAU).
11150678|NCT03722732|Active Comparator|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
11150679|NCT03722732|Active Comparator|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
11150680|NCT03722719|Experimental|Group I (the Knack)|
11150681|NCT03722719|Active Comparator|Group II (PFMT)|
11150682|NCT03722719|Active Comparator|Group III (the Knack + PFMT)|
11150683|NCT03722706|Experimental|Handbook|handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
11150684|NCT03722706|No Intervention|Control|standard management alone
11150685|NCT03722693||Experimental group|Experimental group included subacute stroke patients with initial wrist extension. Each participant will receive 28 therapy sessions in total, that are divided into four blocks of 7 sessions. During the first 7 sessions the participant will receive standard care treatment (S), this block will be followed by first Functional electrical stimulation based treatment (FES intervention) block with 7 sessions of protocol A (AUTO or FUNCTION). Third block will consider additional 7 sessions of standard care (S). Fourth block will include 7 sessions of Functional electrical stimulation based treatment (FES intervention) with other type of treatment B (FUNCTION or AUTO).
11150686|NCT03722680|Experimental|Riluzole|The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
11150687|NCT03722680|Placebo Comparator|Placebo|Posology, administration and duration of treatment will be equivalent to riluzole group.
11150688|NCT03722667|Placebo Comparator|Technology-Based Component|A Technology-based interventions comprised of three technolgy components accessible via smartphone to support self-managing hypertension.
11150689|NCT03722667|Experimental|TechSupport|A Technology-based interventions comprised of three technolgy components plus positive psychological training accessible by smartphone to support self-managing hypertension.
11150690|NCT03722654|Experimental|MTFS|MTFS-I Installation
11150691|NCT03722654|No Intervention|Control|
11150692|NCT03722641|Placebo Comparator|Bread reference|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread.
11150693|NCT03722641|Experimental|Product 1: Milk|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on milk.
11150694|NCT03722641|Experimental|Product 2: Full fat milk + oat|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on full fat milk and oat with high fiber content.
11150695|NCT03722641|Experimental|Product 3: Skim milk + oat, high fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with high fiber content.
11150696|NCT03722641|Experimental|Product 4: Skim milk + oat, low fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with low fiber content.
11150697|NCT03722628||HCC with TTT|Blood sample from all HCC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
11150698|NCT03722628||HCC without TTT|Blood sample from all HCC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
11150699|NCT03722628||LC with TTT|Blood sample from all LC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
11150700|NCT03722628||LC without TTT|Blood sample from all LC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
11150701|NCT03722628||Healthy control|MMP1-genotype polymorphism will be applied on those healthy people to detect which type of mutation occur in healthy rather than diseased.
11150702|NCT03722602|Experimental|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
11150703|NCT03722589|Active Comparator|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
11150704|NCT03722589|Active Comparator|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
11150705|NCT03722589|Active Comparator|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
11150706|NCT03722589|Active Comparator|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
11150707|NCT03722589|Active Comparator|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
11150708|NCT03722576|Experimental|Vidofludimus Calcium|Active drug
11150709|NCT03722563|Active Comparator|TLHS|total laparoscopic hysterectomy with sacrocolpopexy will be performed
11150710|NCT03722563|Experimental|TLHLS|total laparoscopic hysterectomy with lateral suspension will be performed
11150711|NCT03722550|Active Comparator|Control Group|Standard Starter Infant Formula, Standard Follow-up Formula, and Standard Growing-up Milk
11150712|NCT03722550|Experimental|Test Group 1|Starter Infant Formula (same as Control Group) supplemented with 1.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
11150713|NCT03722550|Experimental|Test Group 2|Starter Infant Formula (same as Control Group) supplemented with 2.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
11150714|NCT03722550|Active Comparator|Breastfed Group|Non-randomized Breastfed reference group
11150715|NCT03722537|Active Comparator|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
11150716|NCT03722537|Experimental|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
11150717|NCT03722524||Patients with arterial hypertension|
11150718|NCT03722511|Active Comparator|NET with carcinoid syndrome|Participants with NET and carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
11150719|NCT03722511|Active Comparator|NET w/o cardinoid syndrome|Participants with NET w/o carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
11150720|NCT03722498|Experimental|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2 on days 1, and 5-fluorouracil 2800 mg/m2 on days 1 and 2, repeated every 21 days
11150721|NCT03722498|Active Comparator|Sorafenib|Sorafenib 400 mg orally twice a day
11150722|NCT03722485|Experimental|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|V.A.C. VeraFlo Cleanse Choice Dressing, V.A.C.Ulta Therapy Unit and saline solution
11150723|NCT03722485|Active Comparator|Collagenase Ointment|Collagenase Ointment
11150724|NCT03722472|Experimental|Single-vial ID93 + GLA-SE|Single-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
11150725|NCT03722472|Active Comparator|Two-vial ID93 + GLA-SE|Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
11150726|NCT03722459|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
11150727|NCT03722446|Other|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
11150728|NCT03722446|Other|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
11150729|NCT03722433|Experimental|probiotic plus 14-day sequential therapy|D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
11150730|NCT03722433|Placebo Comparator|placebo plus 14-day sequential therapy|D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
11150731|NCT03722420|Experimental|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
11150732|NCT03722420|Active Comparator|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
11150733|NCT03722407|Experimental|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
11150734|NCT03722394|Experimental|Pain Neuroscience Education|Subjects received a 15-minute verbal, one-on-one Pain Neuroscience Education (PNE) session
11150735|NCT03722368|Experimental|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
11150736|NCT03722368|Experimental|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
11150767|NCT03722134|Experimental|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
11150737|NCT03722368|Other|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
11150738|NCT03722355|Active Comparator|Arm 1: Conventional RT + Carmustine|Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
11150739|NCT03722355|Experimental|Arm 2: Hyperfractionated RT + Carmustine|Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
11150740|NCT03722342|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
11150741|NCT03722329|Experimental|SB12|SB12 (proposed eculizumab biosimilar)
11150742|NCT03722329|Active Comparator|EU Soliris|EU sourced Soliris (eculizumab)
11150743|NCT03722329|Active Comparator|US Soliris|US sourced Soliris (eculizumab)
11150744|NCT03722316|Experimental|MCI/Mild Dementia|"Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
11150745|NCT03722316|Active Comparator|Healthy Older Adults|"Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
11150746|NCT03722303|Active Comparator|Steroid Injection|Subjects with CTS will receive steroid injection.
11150747|NCT03722303|Experimental|Fat Injection|Subjects with CTS will receive fat injection.
11150748|NCT03722290|Experimental|Metformin|Metformin 500mg twice a day per os for 9 weeks
11150749|NCT03722277|Experimental|Variable load training|"The participants will be training two times per week in 10 weeks. Training will consist of variable load training in knee flexion- and extension.
~Training will be based on symptoms in isometric strength at five different angles of flexion- and extension."
11150750|NCT03722277|Active Comparator|Conventional strength training|The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
11150751|NCT03722264|Experimental|OpalSeal|"OpalSeal will be applied
~to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or
~to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
11150752|NCT03722264|Placebo Comparator|Transbond XT|"TransbondXT will be applied
~to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or
~to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
11150753|NCT03722251|Experimental|Glucose Beverage|50 g of glucose in solution
11150754|NCT03722251|Experimental|Control Beverage|Sucralose in solution
11150755|NCT03722251|Experimental|Glucose beverage and active video game playing|50 g of glucose in solution and 30 min of active video game playing
11150756|NCT03722251|Experimental|Control Beverage and active video game playing|Sucralose in solution and 30 min of active video game playing
11150757|NCT03722238|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
11150758|NCT03722225|Experimental|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
11150759|NCT03722212|Other|Patients for METAglut1|"The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.
~Already diagnosed patients are included retrospectively."
11150760|NCT03722199|Experimental|Healthy persons|In this interventional study the investigators ask the patient (healthy persons) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
11150761|NCT03722199|Experimental|Persons with essential hypertension|In this interventional study the investigators ask the patient (persons with essential hypertension) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
11150762|NCT03722199|Experimental|Persons with type 2 diabetes|In this interventional study the investigators ask the patient (persons with type 2 diabetes) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
11150763|NCT03722186|Experimental|SHR-1603|Multiple escalating doses of SHR-1603
11150764|NCT03722173|Experimental|All subjects|Period 1:Treatment R (BI 894416 alone) followed by Period 2:Treatment T (BI 894416 + itraconazole)
11150765|NCT03722160|Other|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
11150766|NCT03722147|Experimental|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
11150768|NCT03722134|Active Comparator|EVLA|The refluxing GSV was treated with endovenous laser ablation.
11150770|NCT03722108|Experimental|Regorafenib and Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.
11150771|NCT03722108|Active Comparator|Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity
11150772|NCT03722095|Active Comparator|active tDCS + active iTBS|Participants will receive 20 minutes of active tDCS, during the last 7 minutes active iTBS will be applied.
11150773|NCT03722095|Sham Comparator|sham tDCS + active iTBS|Participants will receive 20 minutes of sham tDCS, during the last 7 minutes active iTBS will be applied.
11150774|NCT03722082|Experimental|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
11150775|NCT03722082|Placebo Comparator|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
11150776|NCT03722069|Other|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
11150777|NCT03722069|Other|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
11150778|NCT03722056||gastric GIST|patients with suspected gastric GIST with size > 2cm are subjected for laparoscopic resection.
11150779|NCT03722043|Experimental|Parenting Program|"All study participants will receive our parenting program curriculum. There will not be a control group.
~The parenting program will include the topics of mindful parenting strategies, emotional regulation, positive discipline, and positive parenting/attachment. Participants will be provided skills to develop strategies for each of the modules. Each session will contain elements of group troubleshooting and practice in-session. Practice at home will be assigned so that participants can continue to practice and implement these skills and strategies in their homes.
~The program is taken from a published, empirically based program called Everyday Parenting: A Professional's Guide to Building Family Management Skills written by Thomas Dishion, Elizabeth Stormshak, and Kathryn Kavanagh."
11150780|NCT03722030|Experimental|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
11150781|NCT03722030|Placebo Comparator|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
11150782|NCT03722017|No Intervention|Control--usual care|"Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:
~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, [OTC medications] and active in-hospital medications. Pre-hospital [and OTC] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event."
11150783|NCT03722017|Experimental|Intervention--deprescribing protocol|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.
~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
11150784|NCT03722004|Active Comparator|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
11150785|NCT03722004|Active Comparator|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
11150786|NCT03722004|Active Comparator|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
11150787|NCT03722004|Active Comparator|bOPV only|bOPV administered at 6, 10, and 14 weeks.
11150788|NCT03721991|Active Comparator|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
11150789|NCT03721991|Placebo Comparator|PLACEBO|Matching placebo capsules to GABA
11150790|NCT03721978|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
11150791|NCT03721978|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
11150792|NCT03721965|Experimental|Itacitinib + Corticosteroids|
11150793|NCT03721952|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
11150794|NCT03721952|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
11150795|NCT03721939|Experimental|FLEX Scoring Catheter plus DEB|The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
11150842|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
11150915|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
11150796|NCT03721926|Experimental|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
11150797|NCT03721926|Active Comparator|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
11150798|NCT03721913|Experimental|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
11150799|NCT03721913|No Intervention|Control group|The control group will not receive the intervention during the study.
11150800|NCT03721900|Experimental|SHX-001 Active Low Dose|Ketamine transdermal patch
11150801|NCT03721900|Placebo Comparator|Placebo|placebo transdermal patch
11150802|NCT03721900|Experimental|SHX-001 Active high dose|ketamine transdermal patch
11150803|NCT03721887|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
11150804|NCT03721887|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
11150805|NCT03721874|Active Comparator|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.
~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
11150806|NCT03721874|Placebo Comparator|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.
~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
11150807|NCT03721848|Experimental|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
11150808|NCT03721848|Active Comparator|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
11150809|NCT03721848|No Intervention|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
11150810|NCT03721835|Other|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
11150811|NCT03721822|Experimental|Electronic Nicotine Delivery System (ENDS)|Reported daily use of an ENDS product and have not smoked combustible cigarettes or cannabis for at least 12 months prior to study enrollment and total smoking history of < 5 pack years
11150812|NCT03721822|Experimental|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 10 cigarettes per day for at least 1 year with no history of ENDS use or cannabis use for at least 12 months prior to study enrollment
11150813|NCT03721822|Experimental|Non-smokers|Reported non-smoking history or < 100 lifetime cigarettes smoked and/or < 100 lifetime cannabis use episodes with no current use of tobacco/nicotine or cannabis
11150814|NCT03721809|Other|macrophage activation syndrome secondary to bacterial sepsis|Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
11150815|NCT03721809|Other|bacterial sepsis/septic shock|Patients hospitalized in medical intensive care for sepsis / septic shock
11150816|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
11150817|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
11150818|NCT03721783||children with soft tissue lesions|All children who undergo cryoablation therapy for benign soft tissue lesions
11150819|NCT03721770||Relatives|Relative or adult companion (age <18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
11150820|NCT03721757|Other|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.
~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.
~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).
~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).
~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
11150843|NCT03721575|Active Comparator|Scarpa's preserving hernio-abdominoplasty|Hernio-abdominoplasty is performed with preservation of Scarpa's fascia.
11150844|NCT03721575|Active Comparator|Classical hernio-abdominoplasty|Hernio-abdominoplasty is performed with removalof Scarpa's fascia.
11150821|NCT03721757|Other|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.
~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.
~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).
~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.
~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
11150822|NCT03721744|Experimental|Napabucasin+Paclitaxel+Gemcitabine|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose).Paclitaxel 80 mg/m^2 will be administered intravenously. Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on RECIST 1.1 criteria
11150823|NCT03721744|Active Comparator|Standard of care treatment options|Patients will receive standard of care treatment options treatment, including Fluorouracil and Leucovorin, Gemcitabine, Onivyde plus Fluorouracil and Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region), or best supportive care (BSC) alone, one of which will be assigned by the investigator for each patient.
11150824|NCT03721718|Experimental|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
11150825|NCT03721718|Experimental|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
11150826|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
11150827|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
11150828|NCT03721705|Experimental|Treatment Arm|The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
11150829|NCT03721705|Sham Comparator|Sham Arm|The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
11150830|NCT03721692|Experimental|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
11150831|NCT03721692|No Intervention|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
11150832|NCT03721679|Experimental|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections
~Weeks 3-25:
~Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND
~ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:
~Nivolumab (Opdivo), OR
~Pembrolizumab (Keytruda), OR
~Cemiplimab (Libtayo) OR
~Atezolizumab (Tecentriq) OR
~Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
11150833|NCT03721653|Active Comparator|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)
~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.
~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
11150834|NCT03721653|Experimental|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)
~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.
~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
11150835|NCT03721640||Preterm neonates (< 33 weeks GA)|Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.
11150836|NCT03721627|Experimental|Treatment group|Ledipasvir/sofosbuvir fixed dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily for 12 weeks for those 12-18 years, Wt 35 kg or more and half the dose (45 mg ledipasvir, 200 mg sofosbuvir) once daily for 12 weeks for those 6-11 years, Wt Less than 35 kg.
11150837|NCT03721614|Experimental|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
11150838|NCT03721614|Active Comparator|Xience family Everolimus Coronary Stent Systems|
11150839|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
11150840|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
11150841|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
11150845|NCT03721549|Experimental|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10^5 genome copies
11150846|NCT03721549|Experimental|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10^6 genome copies
11150847|NCT03721536|Active Comparator|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
11150848|NCT03721536|Active Comparator|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
11150849|NCT03721510|Active Comparator|Group 1A|HIV-uninfected volunteers receiving one IV infusion
11150850|NCT03721510|Active Comparator|Group 1B|HIV-uninfected volunteers receiving one IV infusion
11150851|NCT03721510|Active Comparator|Group 2|HIV-infected volunteers on ART receiving three or six IV infusions
11150852|NCT03721497|Active Comparator|Testosterone Undecanoate|Inj. Testosterone undecanoat (Nebido®), 1000 mg im preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
11150853|NCT03721497|Placebo Comparator|Placebo|Inj. placebo preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
11150854|NCT03721471||Frail, non-frail|"Frail Group: Those individuals identified as frail by low hand-grip-strength and/or the Clinical Frailty Scale.
~Non-frail Group: Those individuals identified as not frail by hand-grip-strength and/or the Clinical Frailty Scale."
11150855|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
11150856|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
11150857|NCT03721432|Experimental|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
11150858|NCT03721432|Placebo Comparator|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
11150859|NCT03721419|Experimental|High Flow High Humidity device|High Flow High Humidity device arm subjects will be placed on a High Flow Airvo device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen. This device has its own flow generator built in.
11150860|NCT03721419|Active Comparator|Low Flow High Humidity Device|Low Flow High Humidity device arm patients will be placed on a Low Flow device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen.
11150861|NCT03721406|Other|Ropivacaine|"25 ml single dose of 0.5% ropivacaine
~continuous infusion of ropivacaine 0.2% with a constant infusion rate of 14 ml/h"
11150862|NCT03721393||Group 1: Syncope patients|Patients that have undergone an ARS assessment and diagnosed with orthostatic hypotension or reflex syncope.
11150863|NCT03721393||Group 2: Control patients|Patients that have undergone an ARS assessment and are control subjects.
11150864|NCT03721380|Experimental|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
11150865|NCT03721380|Other|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
11150866|NCT03721367||Urea Cycle Disorders|
11150867|NCT03721354|Experimental|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
11150868|NCT03721341|Active Comparator|Standard arm|Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.
11150869|NCT03721341|Experimental|Stereotactic Arm|Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.
11150870|NCT03721328|Experimental|Experimental|Joint irrigation with vancomycin and tobramycin
11150871|NCT03721315|No Intervention|Control|This group will receive the standard of care for this condition.
11150872|NCT03721315|Experimental|Intervention|This group will receive additional education along with their designated health support person prior to hospital discharge. This intervention does not include drugs/or devices.
11150873|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
11150874|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
11150875|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
11150876|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
11150877|NCT03721276|Experimental|Therapy|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
11150878|NCT03721276|No Intervention|Waitlist|Individuals assigned to waitlist will be put on a waitlist for 3 months after baseline assessment, after which they will also receive the same treatment as the therapy group.
11150879|NCT03721263|Experimental|ASLAN004 Single Ascending Dose|"Up to 10 dose levels are planned.
~ASLAN004 by IV route: 0.1 mg/kg (Cohort 1), 0.3 mg/kg (Cohort 2), 1 mg/kg (Cohort 3), 3 mg/kg (Cohort 4) and 10 mg/kg (Cohort 5), 20 mg/kg (Cohort 6 [optional]).
~ASLAN004 SC route: 75 mg (Cohort 7), 150 mg (Cohort 8), 300 mg (Cohort 9), and 600 mg (Cohort 10 [optional])."
11150880|NCT03721250||thoracic epidural|patients receiving thoracic epidural
11150881|NCT03721237|Experimental|EBC-assisted|A nasogastric tube, equipped with esophageal and gastric balloons, will be inserted in each patient enrolled in the study. After definitive catheter positioning has been obtained, Esophageal ballon calibration will be run in volume-controlled ventilation, pressure support ventilation and sigh + pressure support ventilation.
11150882|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
11150883|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
11150884|NCT03721211|Experimental|[11C]Martinostat|"Subjects will be administered [11C]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center
~All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake
~All subjects will be scanned using [11C]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner
~PET imaging will begin concomitant with radiotracer administration"
11150885|NCT03721198|Active Comparator|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
11150886|NCT03721198|Experimental|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
11150887|NCT03721185|Active Comparator|LC|Lypolitic cream with hypocaloric diet and physicial activity in 51 patients
11150888|NCT03721185|Placebo Comparator|NLC|Hypocaloric diet and physicial activity alone in 51 patients
11150889|NCT03721172|Experimental|Apremilast 30 mg or Placebo|Oral Apremilast 30 mg or placebo twice daily (BID) from Week 0 to Week 16
11150890|NCT03721172|Experimental|Apremilast 30 mg, extension|Apremilast 30 mg twice daily (BID) from Week 16 to Week 32
11150891|NCT03721159||Group I|30 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease.
11150892|NCT03721159||Group II|30 Generalized chronic periodontitis subjects without coronary heart disease.
11150893|NCT03721159||Group III|30 Systemically healthy patients with no chronic periodontitis or coronary heart disease.
11150894|NCT03721133|Other|circulating tumor cell|Recurrent predictive power of circulating tumor cell in non small cell lung cancer patients who receive curative
11150895|NCT03721120|Experimental|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
11150896|NCT03721120|No Intervention|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
11150897|NCT03721107|Experimental|Cohort C Active|two capsules Blautix administered twice daily to subjects diagnosed with IBS-C
11150898|NCT03721107|Placebo Comparator|Cohort C Placebo|two capsules placebo administered twice daily to subjects diagnosed with IBS-C
11150899|NCT03721107|Experimental|Cohort D Active|two capsules Blautix administered twice daily to subjects diagnosed with IBS-D
11150900|NCT03721107|Placebo Comparator|Cohort D Placebo|two capsules placebo administered twice daily to subjects diagnosed with IBS-D
11150901|NCT03721094|Other|Immersive virtual reality|Completing the procedures in immersive virtual reality
11150902|NCT03721094|No Intervention|Conventional virtual reality|Completing the procedures in conventional virtual reality
11150903|NCT03721081|Placebo Comparator|Na Cl 0.9%/Epi 1:200000|Subcutaneous infiltration of Na Cl 0.9%/Epi 1:200000
11150904|NCT03721081|Active Comparator|Lidocaine 1%/Epi 1:200000|Subcutaneous infiltration of Lidocaine 1%/Epi 1:200000
11150905|NCT03721068|Experimental|iC9.GD2.CAR.IL-15 T-cells|The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10^6 cells/kg, 1.0 x 10^6 cells/kg, 1.5 x 10^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10^6 cells/kg.
11150906|NCT03721055|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
11150907|NCT03721042|Experimental|exhaled air|exhaled air analysis of patients
11150908|NCT03721029|Experimental|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
11150909|NCT03721029|Active Comparator|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
11150910|NCT03721016|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
11150911|NCT03721016|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
11150912|NCT03721016|Placebo Comparator|Placebo|Placebo will be injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
11150913|NCT03720990|Experimental|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
11150914|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
11150916|NCT03720951|Experimental|Group I(Pudendal n.)|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
11150917|NCT03720951|Experimental|Group II(Sacral n.)|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
11150918|NCT03720938|No Intervention|Control Group|Physically inactive children who did not play AVGs.
11150919|NCT03720938|Experimental|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
11150920|NCT03720925|Experimental|TDI treatment|"The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and from between 3 to 6 months after the TDI treatment ."
11150921|NCT03720912|Experimental|Online Family Education Modules|Patients will receive online family education modules.
11150922|NCT03720912|No Intervention|Control|Patients will not receive any intervention.
11150923|NCT03720899|Experimental|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
11150924|NCT03720899|Active Comparator|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
11150925|NCT03720886|Experimental|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
11150926|NCT03720886|Experimental|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
11150927|NCT03720886|Active Comparator|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
11150928|NCT03720873|Experimental|EGFR-TKIs and Anlotinib|Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d
11150929|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
11150930|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
11150931|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
11150932|NCT03720847|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
11150933|NCT03720847|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
11150934|NCT03720834||Patients|Questionnaire on risk perception
11150935|NCT03720834||Clinicians|Questionnaire on risk perception
11150936|NCT03720821|Experimental|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A & B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.
~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
11150937|NCT03720808|Experimental|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
11150938|NCT03720808|Experimental|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
11150939|NCT03720808|Experimental|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
11150940|NCT03720808|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
11150941|NCT03720795|Other|Stepped Care CBT|Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
11150942|NCT03720769|Experimental|Step-by-Step|
11150943|NCT03720769|Active Comparator|Enhanced care as usual|
11150944|NCT03720756|Experimental|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
11150945|NCT03720756|Active Comparator|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
11150946|NCT03720743|Experimental|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
11150947|NCT03720743|No Intervention|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
11150948|NCT03720730|Experimental|Study participants|Patients with a recent history of suicidal crisis (within the last 7 days) will use a smartphone application to evaluate sleep, appetite and social parameters.
11150949|NCT03720717|Experimental|Opioid Tolerant - baclofen|
11150950|NCT03720717|Placebo Comparator|Opioid Tolerant - placebo|
11150951|NCT03720717|Experimental|Opioid Naive - baclofen|
11150952|NCT03720717|Placebo Comparator|Opioid Naive - placebo|
11150953|NCT03720704||GORE VIABAHN VBX Balloon Expandable Endoprosthesis|The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.
11150954|NCT03720691|Active Comparator|Real rTMS Supplementary motor area|Real rTMS will be applied over the supplementary motor area
11150955|NCT03720691|Sham Comparator|Sham rTMS Supplementary motor area|Sham rTMS will be applied over the supplementary motor area
11150956|NCT03720678|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
11150957|NCT03720678|Experimental|Dose Expansion-GE|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal cancer
11150958|NCT03720678|Experimental|Dose Expansion-CRC|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with colorectal cancer
11150959|NCT03720665|Active Comparator|Caffeine group|"200mg caffeine tablet
~transcranial alternating current stimulation (140 Hz tACS) at 1 mA
~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA
~transcranial alternating current stimulation (140 Hz tACS) sham
~paired associative stimulation (PAS 25)"
11150960|NCT03720665|Placebo Comparator|Placebo group|"Non-active tablet
~transcranial alternating current stimulation (140 Hz tACS) at 1 mA
~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA
~transcranial alternating current stimulation (140 Hz tACS) sham
~paired associative stimulation (PAS 25)"
11150961|NCT03720652|Experimental|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
11150962|NCT03720652|Experimental|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
11150963|NCT03720639|Active Comparator|Abbott, Inc Confirm Rx™|Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.
11150964|NCT03720639|Active Comparator|Medtronic, Inc Reveal LINQTM|Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.
11150965|NCT03720613||Naldemedine|Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
11150966|NCT03720613||Lubiprostone|Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
11150967|NCT03720613||Naloxegol|Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
11150968|NCT03720600|Experimental|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
11150969|NCT03720600|Other|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
11150970|NCT03720600|No Intervention|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
11150971|NCT03720574|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
11150972|NCT03720574|Placebo Comparator|Matching Placebo BID|Matching Placebo tablet each morning and evening
11150973|NCT03720561||Group: Ibrutinib Treatment|Participants will not receive any intervention as a part of this study. This study will collect retrospective and prospective real-world data to describe retention rates for participants of chronic lymphocytic leukemia (CLL) receiving ibrutinib in routine Italian clinical practice over a 2-year follow-up period. Participants with CLL who have started ibrutinib treatment within 3 months before enrollment visit or in case ibrutinib was prescribed before or on the enrollment day as per routine clinical practice within the 30 days after enrollment visit will be included in the study. The primary data source for this observational study will be the medical records of each enrolled participant, as well as questionnaires concerning quality of life and treatment adherence. Data will be collected every 3 months for the first year and every 6 months for the second year during prospective period.
11150974|NCT03720548|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
11150975|NCT03720548|Placebo Comparator|Placebo (Part A)|Placebo administered IV to healthy participants.
11150976|NCT03720548|Experimental|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
11150977|NCT03720548|Placebo Comparator|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
11150978|NCT03720535||HF patients|HF patients will use the Cordio Medical app to record
11151098|NCT03719664|Experimental|Cohort 1: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
11150979|NCT03720522||Group 1: Patients suffering from acute myocardial infarction|Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
11150980|NCT03720522||Group 2: Patients suffering from chronic myocardial infarction|Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
11150981|NCT03720522||Group 3: Patients suffering from stunned neurogenic myocardium|"Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.
~These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.
~Patients with normal (< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3."
11150982|NCT03720522||Group 4: Control|Patients with normal (< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
11150983|NCT03720509||Heart Failure Patients|
11150984|NCT03720496|Experimental|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
11150985|NCT03720483|Experimental|N-acetyl cysteine then placebo|This arm will receive NAC followed by placebo
11150986|NCT03720483|Experimental|Placebo then N-acetyl cysteine|This arm will receive placebo followed by NAC
11150987|NCT03720470|Experimental|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
11150988|NCT03720470|Experimental|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
11150989|NCT03720470|Active Comparator|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
11150990|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
11150991|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
11150992|NCT03720457|Experimental|Human CD19 targeted T Cells Injection|
11150993|NCT03720444||MDT (mechanical diagnosis and therapy) method|
11150994|NCT03720431|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
11150995|NCT03720418|Experimental|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
11150996|NCT03720418|Experimental|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
11150997|NCT03720418|Experimental|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
11150998|NCT03720418|Experimental|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
11150999|NCT03720418|Sham Comparator|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
11151000|NCT03720392|Experimental|FMT Capsules|"Two doses of FMT: one standard dose starting within four (4) days from the start of the conditioning regimen prior to HCT and one non-standard dose starting within 4 weeks after engraftment after HCT.
~A standard dose of oral FMT is 15 capsules per day for two consecutive days,"
11151001|NCT03720392|Placebo Comparator|Placebo Capsules|"Two doses of placebo, instead of FMT: one starting within four (4) days from the start of the conditioning regimen prior to HCT and the second one starting within 4 weeks after engraftment after HCT.
~A standard dose of oral Placebo is 15 capsules per day for two consecutive days,"
11151002|NCT03720379|Active Comparator|Fluoride Varnish - Fluor PROTECTOR S|"Fluor Protector S - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor, 1.5% ammonium fluoride (7700 ppm fluoride), additional ingredients
~APPLICATION OF Fluor Protector S will be performed AT BASELINE, after 3,6 months (control 1) and after 9 and 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
11151003|NCT03720379|Placebo Comparator|PLACEBO|"- Placebo - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor.
~APPLICATION OF PLACEBO will be performed AT BASELINE, after 3,6 months (control 1) and after 9 AND 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
11151004|NCT03720366|Experimental|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
11151005|NCT03720366|Experimental|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
11151099|NCT03719664|Experimental|Cohort 2: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
11151006|NCT03720366|Experimental|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
11151007|NCT03720353|Active Comparator|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
11151008|NCT03720353|Active Comparator|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
11151009|NCT03720353|Placebo Comparator|Placebo|Participants will take placebo for 10 days.
11151010|NCT03720340|Active Comparator|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
11151011|NCT03720340|Placebo Comparator|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
11151012|NCT03720327|Active Comparator|Get FIT|The Get FIT intervention
11151013|NCT03720327|Experimental|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
11151014|NCT03720314||IBS|Irritable bowel syndrome patients
11151015|NCT03720314||control|healthy controls
11151016|NCT03720301|Experimental|Treatment|Study arm who will receive pre operative and intraoperative treatments intended to effect POST severity.
11151017|NCT03720301|Sham Comparator|Sham|Sham are who will receive a preoperative treatment not intended to effect POST outcomes.
11151018|NCT03720288|Experimental|Acetazolamide|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.
11151019|NCT03720288|Experimental|Placebo|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
11151020|NCT03720275|Experimental|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
11151021|NCT03720262|Experimental|Mesh reinforcement|Retro muscular mesh at the stoma site.
11151022|NCT03720262|Placebo Comparator|No reinforcement|Standard closure of the abdominal wall
11151023|NCT03720249|Experimental|supplementation of compound nutrients|Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.
11151024|NCT03720249|Placebo Comparator|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.
11151025|NCT03720236|Experimental|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
11151026|NCT03720236|Experimental|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
11151027|NCT03720236|Experimental|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
11151028|NCT03720236|Experimental|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
11151029|NCT03720223|Experimental|Liposomal Bupivacaine|20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.
11151030|NCT03720223|No Intervention|Control|No local anesthetics injected to the buccal mucosal graft harvest site
11151031|NCT03720210|Experimental|RFA group|RFA
11151032|NCT03720197||Participants aged less than 14 years old|
11151033|NCT03720197||Participants aged 14 years old and older|
11151034|NCT03720184|Experimental|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the circuit, reducing the haemodilution down to 300ml of crystalloid due to the cardiopulmonary bypass initiation
11151035|NCT03720184|No Intervention|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
11151036|NCT03720184|Other|HAR group 2 (extinguished)|In the begining, there were 4 arms, considering two different types of oxygenator in the two treatment branches, but current analysis did not found signifficant differences between oxygenator types and arms are reduced to HAR and Control Group
11151037|NCT03720184|Other|Control Group (extinguished)|In the begining, there were 4 arms, considering two different types of oxygenator in the two treatment branches, but current analysis did not found signifficant differences between oxygenator types and arms are reduced to HAR and Control Group
11151038|NCT03720171|Experimental|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb.
11151039|NCT03720158|Experimental|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
11151040|NCT03720158|Placebo Comparator|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
11151041|NCT03720145|Experimental|Treatment Group|lifestyle medicine group
11151042|NCT03720145|No Intervention|CAU group|Care-As-Usual group
11151043|NCT03720132|Experimental|Patients with port catheter: flushing|In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.
11151044|NCT03720106|Other|treatment arm|In this arm the GOAL therapy plan is used.
11151045|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
11151046|NCT03720067|Active Comparator|Phase 1: Propranolol (PPL)|Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
11151047|NCT03720067|Active Comparator|Phase 1: Carvedilol (CVD)|HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
11151048|NCT03720067|Active Comparator|Phase 2: PPL non-responders/rosuvastatin|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
11151049|NCT03720067|Placebo Comparator|Phase 2: PPL non-responders/placebo|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
11151050|NCT03720067|Active Comparator|Phase 2: CVD non-responders/rosuvastatin|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
11151051|NCT03720067|Placebo Comparator|Phase 2: CVD non-responders/placebo|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
11151052|NCT03720054|Experimental|MapTrek|Veterans in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so veterans can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
11151053|NCT03720054|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the veterans a Fitbit.
11151054|NCT03720041|Active Comparator|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
11151055|NCT03720041|Experimental|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
11151056|NCT03720041|Active Comparator|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
11151057|NCT03720041|Experimental|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
11151058|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
11151059|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
11151060|NCT03720015|Experimental|Concurrent training|Three sessions per week of concurrent training during radiotherapy period. Each session will begin with warm-up (5-min cardiovascular activity at low-moderate intensity, joint mobility and one set of resistance exercises circuit at 30-40% 1RM). Resistance training will follow the warm-up, including 9 standard exercises involving major muscle groups of the lower and upper body: vertical bench press, parallel bar dip for triceps, seated rowing, standing dumbbell curl for biceps, leg press, deadlift and shoulder press. All these exercises will be realized following circuit training with 4 sets of 8-12 repetitions, using a training load of 70-80% RM. When patient will able to complete more than 12 repetitions, load will be increased progressively 10%. Cardiovascular training will be completed 20-30 min after resistance training, and it will include High-Intensity Interval Training (HIIT) of 3 min near to the second ventilatory threshold and 2 min near to the first ventilatory threshold.
11151061|NCT03720015|Experimental|Nutritional management|Prescribed diet controlling macronutrients according to patient body weight (~4g/kg/day for carbohidrates, ~2g/kg/day for proteins, and ~1g/kg/day for fats). Patient will take one single dosage per day of probiotics (Arkoprobiotics® Defenses), 1 or 2 capsules of omega-3 fish oil concentrate (Solgar®, 600-1200mg depending on fat sources intake during the day), and a combine ingestion of 3g beta-hydroxybeta-methylbutyrate (HMB), 14g arginine, and 14g glutamine (HSN Raw Series®, all pure ingredients and making the ingestion adding each of them individually in a solution with 300-400 ml of water). During concurrent training sessions, between resistance exercise and HIIT, patient will also take 6g of BCAA's (HSN Raw Series®, 2:1:1) along with a banana. Additionally, patient could take whey isolated protein (Amix® IsoPrime CFM) to meet with some of the prescribed proteins intakes.
11151062|NCT03720002|Experimental|Active treatment|Will receive HF2 add-on
11151063|NCT03720002|Placebo Comparator|Placebo|Will receive placebo
11151064|NCT03719989|Experimental|Treatment arm|This study is sing-arm study. Therefore, all enrolled patients will be treated with azacitidine plus R-GDP regimen
11151065|NCT03719976|Experimental|Healthcare navigation workshops|All enrolled caregivers and parents will partake in the group-based educational intervention.
11151100|NCT03719664|Active Comparator|Control Arm 1: Baseline ART|Subjects continuing on baseline ART
11151066|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
11151067|NCT03719937|Experimental|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
11151068|NCT03719924|Experimental|arm A: ONIVYDE|ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours
11151069|NCT03719924|Active Comparator|Arm B: TAXOL|TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15
11151070|NCT03719911|Experimental|Live diabetes coaching program|Live diabetes coaching program
11151071|NCT03719898|Experimental|Brigatinib|90 mg daily orally for 7 days, then 180 mg daily orally during first cycle; 180 daily orally thereafter during every subsequent cycle. Each cycle has 28 days
11151072|NCT03719885|Experimental|Intervention|
11151073|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
11151074|NCT03719859|Experimental|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
11151075|NCT03719859|Active Comparator|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
11151076|NCT03719833||1-control group-T1-T2 N0 M0|"Breast cancer patients in T1 N0 M0 stage at time of diagnose who initial undergo surgical treatment (quadrantectomy/mastectomy + sentinel lymph node biopsy).
~All patients will be followed for 5 years after surgery"
11151077|NCT03719833||2-T2-T3 N0 M0|"Breast cancer patients in T2-T3 N0 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by surgery (quadrantectomy/mastectomy + sentinel lymph node biopsy). For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made.
~All patients will be followed for 5 years after surgery"
11151078|NCT03719833||3-T1-T3 N1-N2 M0|"Breast cancer patients in T1-T3 N1-N2 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by ultrasound reevaluation of axillary lymph nodes that indicate complete clinical axillary remission. Surgical procedure that would be performed is quadrantectomy/mastectomy + sentinel lymph node biopsy.
~Before initiating neoadjuvant treatment biopsy (FNA) proven positive node will be marked with titanium clip and at the time of surgery removed and pathological examined regardless presenting as a sentinel node or not.
~For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made All patients will be followed for 5 years after surgery"
11151079|NCT03719820||Intracranial Atherosclerosis|First-ever stroke patients attributed to intracranial artery stenosis (> 50% or occlusion) who receive aggressive medical management
11151080|NCT03719807|Active Comparator|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
11151081|NCT03719807|Experimental|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
11151082|NCT03719794|Active Comparator|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
11151083|NCT03719794|Placebo Comparator|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
11151084|NCT03719781||Group1|patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
11151085|NCT03719768|Experimental|Avelumab and Whole Brain Radiotherapy|Avelumab 800 mg intravenously (IV) and 3000 centriGray units (cGy) Whole Brain Radiotherapy once every 2 weeks
11151086|NCT03719755|Active Comparator|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
11151087|NCT03719755|Placebo Comparator|Normal Saline|Cystoscopic distention media of normal saline.
11151088|NCT03719742|Experimental|Sponsor Test Products|"Baby Bee Foaming Cleanser(at least once daily)
~BB Baby Ultra Gentle Lotion (twice daily)"
11151089|NCT03719729|Experimental|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
11151090|NCT03719716|Experimental|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
11151091|NCT03719716|No Intervention|Usual care group|No change to standard care from oncology services and primary care
11151092|NCT03719703||Case 1|Children conceived by frozen embryo transfer
11151093|NCT03719703||Case 2|Children conceived by fresh embryo transfer
11151094|NCT03719703||Control|Naturally conceived children
11151095|NCT03719690|Experimental|AIM-HN|Tipifarnib, Oral Tablet. Dose Level 1 orally, bid on days 1-7 and 15-21 of 28-day treatment cycles
11151096|NCT03719690|No Intervention|SEQ-HN|To obtain historical information of first line therapy in subjects enrolled in AIM-HN, in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
11151097|NCT03719677|Experimental|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
11151101|NCT03719664|Experimental|Cohort 3: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
11151102|NCT03719664|Experimental|Cohort 4: albuvirtide & 3BNC117|albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
11151103|NCT03719664|Experimental|Optimal Dose: albuvirtide & 3BNC117|albuvirtide and 3BNC117 every 2 or 4 weeks
11151104|NCT03719664|Active Comparator|Control Arm 2: Baseline ART|Subjects continuing on baseline ART
11151105|NCT03719651|Experimental|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.
~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
11151106|NCT03719651|Active Comparator|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).
~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
11151107|NCT03719638|Active Comparator|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
11151108|NCT03719638|Active Comparator|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
11151109|NCT03719625|Experimental|norepinephrin group|The patients of this group will recieve 0.5 micro gr/kg of norepinephin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
11151110|NCT03719625|Experimental|Ephedrin group|The patients of this group will recieve 0,3mg/kg of Ephedrin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
11151111|NCT03719612|Experimental|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
11151112|NCT03719599||Children|Children 6-12 months of age presenting for routine clinic visits
11151113|NCT03719599||Pregnant Women|Pregnant women 18 years of age and older and presenting for routine clinic visits
11151114|NCT03719586|Experimental|A|Remdesivir plus optimized Standard of Care (oSOC)
11151115|NCT03719586|Experimental|B|MAb114 plus optimized Standard of Care (oSOC)
11151116|NCT03719586|Experimental|C|REGN-EB3 plus optimized Standard of Care (oSOC)
11151117|NCT03719586|Experimental|Control|Zmapp plus optimized Standard of Care (oSOC)
11151118|NCT03719573|Experimental|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
11151119|NCT03719573|No Intervention|control.|Usual treatment and care.
11151120|NCT03719560|Experimental|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
11151121|NCT03719547|Experimental|Robot-assisted radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
11151122|NCT03719547|Active Comparator|Abdominal radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
11151123|NCT03719534|Active Comparator|Haplo-SCT|people enrolled in this arm will receive a typical haplo-identical donor SCT
11151124|NCT03719534|Experimental|Haplo-cord SCT|people enrolled in this arm will receive a co-infusion of cord blood unit in addition to a typical haplo-identical donor SCT
11151125|NCT03719521|Experimental|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.
~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
11151126|NCT03719521|Active Comparator|Control Arm|Routine existing services
11151127|NCT03719495||Cohort 1|Pre-menopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
11151128|NCT03719495||Cohort 2|Postmenopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
11151129|NCT03719495||Cohort 3|Pre-menopausal women initiating tamoxifen after standard of care local-regional therapy after surgery +/- radiation.
11151130|NCT03719495||Cohort 4|Pre-menopausal women initiating ovarian suppression plus aromatase inhibition after surgery +/- radiation.
11151131|NCT03719495||Cohort 5|Postmenopausal women initiating endocrine therapy with aromatase inhibition after standard of care surgery +/- radiation.
11151132|NCT03719482|Experimental|[18F]MNI-1054|To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
11151133|NCT03719469||Green tea group|A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University,After starting green tea supplement (4 to 6 cups/day; 60 to 125 mg catechins), patients were evaluated for therapeutic response at baseline and 12, and 24 weeks.
11151134|NCT03719469||control group|fifty healthy normal subjects were included in this study as controls.
11151135|NCT03719456|Experimental|Flexible ureteroscope|
11151136|NCT03719443|Experimental|VIS649|A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
11151137|NCT03719443|Placebo Comparator|Placebo|Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
11151138|NCT03719430|Experimental|Doxorubicin/APX005M|"Patients will be treated with doxorubicin and APX005M in 21 day cycles. All patients receive the same treatment (there is no placebo arm). After completing 8 cycles of study treatment, patients without evidence of disease progression or unacceptable toxicity may continue treatment with APX005M alone. Doxorubicin will not be continued beyond cycle 8 due to the risk for cardiac toxicity from cumulative dosing."
11151139|NCT03719417|Active Comparator|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
11151140|NCT03719417|Active Comparator|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
11151141|NCT03719404|Experimental|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
11151142|NCT03719404|Experimental|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
11151143|NCT03719391|Experimental|JUUL 5% Virginia Tobacco ENDS|Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.
11151144|NCT03719391|Experimental|JUUL 5% Cool Mint ENDS|Treatment with JUUL Cool Mint flavored 5.0% ENDS product.
11151145|NCT03719391|Experimental|JUUL 5% Mango ENDS|Treatment with JUUL Mango flavored 5.0% ENDS product.
11151146|NCT03719391|Experimental|JUUL 5% Creme Brulee ENDS|Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.
11151147|NCT03719391|Active Comparator|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine product.
11151148|NCT03719391|Active Comparator|Nicotine Gum|Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.
11151149|NCT03719391|Active Comparator|Usual Brand Combustible Cigarette|Treatment with usual brand combustible cigarette.
11151150|NCT03719378|No Intervention|Traditional Fluid|"NPO Clears and Food after midnight.
~2 Liters of lactated ringers administered by anesthesia intraoperatively.
~Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).
~Normal diet postoperatively."
11151151|NCT03719378|Experimental|Oral Fluid|"Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)
~NPO Food/Milk: none beginning 8 hours prior to procedure time.
~Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)
~Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.
~PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
11151152|NCT03719365|Experimental|NAVAPSV|Each patient enrolled in the study will be submitted to 3 ventilation trials during PSV and NAVA ventilation modes, assigned in a randomized order.
11151153|NCT03719352|Experimental|Deep dry needling|Deep dry needling will be applied in the upper trapezius myofascial trigger point
11151154|NCT03719352|Experimental|Superficial dry needling|Superficial dry needling will be applied in the upper trapezius myofascial trigger point
11151155|NCT03719352|Placebo Comparator|Placebo Gastrocnemius dry needling|A technique simulating dry needling will be applied in the gastrocnemius myofascial trigger point with a needle guard guide tube, without any therapeutic manoeuvre will be applied.
11151156|NCT03719326|Experimental|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
11151157|NCT03719326|Experimental|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
11151158|NCT03719326|Experimental|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
11151159|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
11151160|NCT03719326|Experimental|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
11151161|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
11151162|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
11151163|NCT03719313|Experimental|Group 1|Lonafarnib 50 mg BID + Ritonavir 100 mg BID
11151164|NCT03719313|Experimental|Group 2|Lonafarnib 50 mg BID + Ritonavir 100 mg BID + PEG IFN alfa-2a 180 mcg QW
11151165|NCT03719313|Active Comparator|Group 3|placebo Lonafarnib + placebo Ritonavir + PEG IFN-alfa-2a 180 mcg QW
11151166|NCT03719313|Placebo Comparator|Group 4|placebo Lonafarnib + placebo Ritonavir
11151167|NCT03719300|Experimental|Single Arm BC-819|inodiftagene vixteplasmid
11151168|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
11151169|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
11151170|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
11151171|NCT03719274|Experimental|non-surgical vitamin c depigmentation|locally injected vitamin c is used to depigment the hyperpigmented gingival tissues
11151172|NCT03719274|Active Comparator|surgical depigmentation|the conventional scalpel surgical technique is used to depigment the hyperpigmented gingival tissues
11151173|NCT03719261|Active Comparator|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
11151174|NCT03719261|Experimental|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
11151175|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
11151176|NCT03719248|Active Comparator|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
11151177|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
11151178|NCT03719248|Active Comparator|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
11151179|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
11151180|NCT03719248|No Intervention|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
11151181|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
11151182|NCT03719248|No Intervention|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
11151183|NCT03719235|Other|column|ultra-low dose CBCT versus digital panoramic radsiography
11151184|NCT03719209|Placebo Comparator|Standard Practice|Patients and families will be shown images of their endoscopic procedure per standard practice.
11151185|NCT03719209|Experimental|Virtual Reality|Patients and families will be showed the results of their endoscopic procedure via a virtual reality application called HealthVoyager, in addition to standard practice images.
11151186|NCT03719196|Experimental|Reading glass provided|"Randomization took place after conducting the census survey. Participants were selected based on the inclusion criteria.
~555 random households were surveyed at the baseline. These households have been given reading glasses free of cost."
11151187|NCT03719196|No Intervention|Non-reading glass|A total of 1086 households were surveyed at the baseline survey. Among them, 555 households have been provided reading glasses. The 531 remaining households were not given reading glasses during the baseline survey. The endline survey will be conducted in May 2018. Upon completing the endline survey, the non-reading glasses group will be provided reading glasses.
11151188|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.
~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
11151189|NCT03719170|Experimental|De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to the PPI de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
11151190|NCT03719170|No Intervention|No De-prescribing Program|Veterans Integrated Service Networks (VISNs) randomly assigned to usual care and will not receive the national de-prescribing program. VISNs are the 19 geographical regions that make up the VHA.
11151191|NCT03719157|Active Comparator|Unilateral ESP Block|Before general anaesthesia, Ultrasound guided unilateral ESP block will perform with15 ml bupivacain+ 5ml lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
11151192|NCT03719157|Active Comparator|Unilateral OSTAP block|Under general anaesthesia, Ultrasound guided unilateral OSTAP block will perform with15 ml bupivacain+ 5ml lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
11151193|NCT03719157|Active Comparator|Injection of Local Anesthetic to Trocar Insertion|After the laparoscopic surgery was completed, the trocar incision sites were closed. For subjects randomized to receive a local anesthesia block, bupivacaine (0.25%) was injected.Incisions 8 mm or greater were injected with 10 cc of 0.25% bupivacaine. Incisions 5 mm or less were infiltrated with 5 mL. Injecting the local anesthetic through all pre-peritoneal layers provided a full thickness local injection.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
11151194|NCT03719157|Sham Comparator|multimodal analgesia|Perioperative and postoperative routine analgesic protocol will be performed with no additional regional anesthesia method.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
11151195|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
11151196|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
11151197|NCT03719131|Active Comparator|Arm A (standard of care)|Each cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. All patients will receive nivolumab every 4 weeks for up to 13 doses (52 weeks) until disease progression or intolerable adverse events. All treatments will have a +/-3 business day window for administration.
11151198|NCT03719131|Experimental|Arm B (rituximab, hyaluronidase human)|Each cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). Rituxan will be administered on day 2 of each cycle after infusion of ipilimumab/nivolumab on weeks 1 and 4. All treatments will have a +/-3 business day window for administration.
11151199|NCT03719118|Experimental|Genotyping group|The patients undergo pretreatment of genotyping for three genes (TPMT, NUDT15 and FTO)
11151200|NCT03719118|Active Comparator|Non-genotyping group|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping.
11151201|NCT03719105|Experimental|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.
~Chemotherapy Regimen:
~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.
~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.
~Allogeneic Stem Cell Transplant if donor available and not in PD."
11151202|NCT03719105|Experimental|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).
~Chemotherapy Regimen:
~Cycle 1 & 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 & 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 & 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
11151203|NCT03719092|Experimental|Prevention (vitamin A compound)|Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.
11151204|NCT03719079||Heart Failure Patients|Patients with primary diagnosis as heart failure
11151256|NCT03718689|No Intervention|Group A|The first group of teeth (Group A) were not etched with Er:YAG laser.
11151205|NCT03719066|Active Comparator|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
11151206|NCT03719066|Experimental|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
11151207|NCT03719066|Experimental|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
11151208|NCT03719053|Experimental|Truvada|single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)
11151209|NCT03719027|Experimental|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
11151210|NCT03719014|Experimental|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
11151211|NCT03719001|Experimental|Phenylephrine|Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg
11151212|NCT03719001|Experimental|Dexmedetomidine|Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg
11151213|NCT03719001|Experimental|Clevidipine|Clevidipine infusion will be used to increase blood pressure by 20 mmHg
11151214|NCT03719001|Experimental|Calcium Chloride|Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration
11151215|NCT03719001|Experimental|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone
11151216|NCT03719001|Experimental|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.
11151217|NCT03718988|Experimental|Meat Phase first|Participants will be asked to consume traditional meat products for 8 weeks, then switch to plant-based meat alternative products for another 8 weeks.
11151218|NCT03718988|Experimental|Plant Alternative Phase first|Participants will be asked to consume plant-based meat alternative products for 8 weeks, then switch to traditional meat products for another 8 weeks.
11151219|NCT03718975|Experimental|Successor of Phonak Audéo B90|The successor of the Phonak Audéo B90 is a Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
11151220|NCT03718975|Active Comparator|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
11151221|NCT03718962|Active Comparator|needling|needling + phototherapy
11151222|NCT03718962|Placebo Comparator|phototherapy|phototherapy
11151223|NCT03718884|Experimental|Drug Cocktail|Drug cocktail administered orally once in Period 1
11151224|NCT03718884|Experimental|Mirikizumab + Drug Cocktail|Drug cocktail administered orally once in Period 2 (day 116). Mirikizumab administered subcutaneously (SC) on multiple occasions in Period 2.
11151225|NCT03718871|Experimental|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
11151226|NCT03718871|No Intervention|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
11151227|NCT03718858|Experimental|Interscalene block|Under sterile precautions, a high frequency linear array transducer [6-13 MHz (megahertz), Sonosite M-Turbo] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is adjacent to the C5 and C6 roots. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
11151228|NCT03718858|Active Comparator|Superior Trunk Nerve block|Under sterile precautions, a high frequency linear array transducer [6-13 MHz (megahertz), Sonosite M-Turbo] probe will be placed in the transverse plane over the interscalene groove to visualize the carotid artery and the C5 and C6 nerve roots of the brachial plexus between the anterior and middle scalene muscles. The superior trunk will be identified by tracing the C5 and C6 nerve roots caudally towards the supraclavicular fossa on the anterior lateral portion of the neck. A 5 cm 22 G insulated needle will then be inserted in line with the US probe in a lateral-to-medial approach until the needle tip is properly positioned. After negative aspiration for blood, 15 mL ropivacaine 0.5% will be injected in 5 mL aliquots.
11151229|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
11151230|NCT03718832|Experimental|Treatment Group-Begin Now|"Group 1- Will be randomized to the treatment (Begin Now) group for the Fresh Food Farmacy program. Subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program right away when the program opens in their geographic area. Data will be collected during the first 12 months of subject participation and EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total)."
11151231|NCT03718832|No Intervention|Control Group-Begin Later|"Group 2- Will be randomized to the control (Begin Later) group for the FFF program. These subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program approximately 6 months after the program opens in their geographic area. Data will be collected during the first 6 months of subject participation and used as control data for the study. EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total from the start of the trial)."
11151232|NCT03718806|Experimental|Regimen A|3 g zoliflodacin oral suspension; oral administration after an overnight fast
11151233|NCT03718806|Experimental|Regimen B|3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
11151234|NCT03718806|Experimental|Regimen C|4 g zoliflodacin oral suspension; oral administration after an overnight fast
11151235|NCT03718806|Experimental|Regimen D|4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
11151236|NCT03718793|Experimental|All subjects with asthma|In addition to normal diagnostic work out we will measure small airway inflammation based on peripheral exhaled nitric oxide and assess small airway dysfunction using impulse oscillometry. In addition, inflammatory markers in peripheral blood and genotype will be assessed.
11151237|NCT03718780|Experimental|A1: Patient in intensive care|"Patient in intensive care (n=10):
~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).
~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
11151238|NCT03718780|Experimental|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.
~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
11151239|NCT03718780|Experimental|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.
~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
11151240|NCT03718780|Experimental|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
11151241|NCT03718780|Experimental|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
11151242|NCT03718780|Experimental|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
11151243|NCT03718780|Experimental|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
11151244|NCT03718780|Experimental|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
11151245|NCT03718767|Experimental|1/Nivolumab|Nivolumab is given IV as flat dose of 240 mg for Cycles 1-4 and 480 mg for Cycles 5-16.
11151246|NCT03718754|Active Comparator|En-Bloc TURB|
11151247|NCT03718754|Active Comparator|Conventional TURB|
11151248|NCT03718741|Experimental|Adiuvant Radiotherapy +/- CT|"The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:
~R0: PTVb + PTVn 50 Gy in 25 fractions
~R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).
~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:
~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy
~Patients with ECOG PS<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery."
11151249|NCT03718728|Active Comparator|Standard group|A personalized diet and physical exercise recommendations.
11151250|NCT03718728|Experimental|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
11151251|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
11151252|NCT03718702|Experimental|Intervention group|ePain will be accessible by the intervention group.
11151253|NCT03718702|No Intervention|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
11151254|NCT03718689|Experimental|Group L|The second group of teeth (Group L) were etched with Er:YAG laser.
11151255|NCT03718689|Experimental|Group A+L|The third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid.
11151257|NCT03718676|Other|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
11151258|NCT03718676|Experimental|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
11151259|NCT03718676|Experimental|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
11151260|NCT03718663||Knee OA patients (part 1)|Painful knee OA patients signed up for standardized exercise therapy
11151261|NCT03718663||Healthy subjects (part 2)|Healthy subjects (age 18-28) signed up military service in Defence Command Denmark
11151262|NCT03718650|Experimental|Scans, Surgical Resection and Assessment|Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m^2 pimonidazole (HydroxyProbe).
11151263|NCT03718637|Active Comparator|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
11151264|NCT03718637|Experimental|Experimental|Identical surgical treatment plus Smith & Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
11151265|NCT03718624|Experimental|paclitaxel,apatinib and S-1|
11151266|NCT03718611|Experimental|Sequence 1|BR900A - Wash out - BR9001
11151267|NCT03718611|Experimental|Sequence 2|BR9001 - Wash out - BR900A
11151268|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
11151269|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
11151270|NCT03718585||nocturnal group|Chronic kidney disease patients with nocturnal hypertension
11151271|NCT03718585||non-nocturnal group|Chronic kidney disease patients without nocturnal hypertension
11151272|NCT03718585||non-CKD group|patients without chronic kidney disease
11151273|NCT03718572||Scoring factors|
11151274|NCT03718572||Difficulty criteria|
11151275|NCT03718559|Experimental|Edoxaban alone|
11151276|NCT03718559|Active Comparator|Combination of edoxaban plus single antiplatelet|
11151277|NCT03718546||Sibling pediatric donors|
11151278|NCT03718546||Sibling recipients and caregivers|
11151279|NCT03718546||Non-donor sibling|From the donor-recipient families
11151280|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
11151281|NCT03718546||Healthy comparison|A matched sample
11151282|NCT03718533|Experimental|Eltrombopag|Patients will receive eltrombopag orally once daily up to 36 weeks.
11151283|NCT03718520||prenatal exposed to cannabis|50 mother-infant pairs with self-reported maternal chronic cannabis use during pregnancy
11151284|NCT03718520||prenatal not-exposed to cannabis|60 mother-infant pairs with no self-reported maternal cannabis use during pregnancy
11151285|NCT03718507|Active Comparator|GROUP 1|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
11151286|NCT03718507|Experimental|GROUP 2|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
11151287|NCT03718494|Experimental|Follow up|Subjects will receive F-18 Florbetapir PET
11151288|NCT03718494|Experimental|Follow up - Mayo Clinic Sites only|Subjects will receive F-18 AV-1451 PET and F-18 Florbetapir PET
11151289|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
11151290|NCT03718468|Experimental|GC Flu Quadrivalent|
11151291|NCT03718468|Active Comparator|Fluarix tetra|
11151292|NCT03718455|Experimental|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
11151293|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
11151294|NCT03718429|Experimental|aspirin|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
11151295|NCT03718429|Experimental|aspirin and clopidogrel|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
11151296|NCT03718429|Experimental|aspirin and ticagrelor|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
11151297|NCT03718429|No Intervention|rivaroxaban|A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg/qd) as per standard of care will be recruited and will undergo a single PD assessment.
11151298|NCT03718403|Experimental|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
11151299|NCT03718390|Experimental|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
11151300|NCT03718390|Experimental|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
11151301|NCT03718390|Experimental|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
11151302|NCT03718390|Experimental|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
11151303|NCT03718390|Experimental|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
11151304|NCT03718377|Experimental|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
11151305|NCT03718377|Active Comparator|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
11151306|NCT03718351|Active Comparator|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
11151307|NCT03718351|Experimental|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
11151308|NCT03718338||Clinical Evaluations|Participants undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, electrocardiograms, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and Quality-of-life assessment.
11151309|NCT03718325|Other|Burst-SCS/sham SCS|First, participants will receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation. Then, participants will have their stimulation adjusted to receive sham (no) SCS. Study evaluations will be completed prior to and after this sham.
11151310|NCT03718325|Other|Sham SCS/Burst-SCS|First, participants will receive sham (no) SCS. Study evaluations will be completed prior to and after this sham. Then, participants will have their stimulation adjusted to receive clinically-effective Burst-SCS per their standard of care. Study evaluations will be completed prior to and after stimulation.
11151311|NCT03718312|Experimental|Arm 1|Patients with aortic clamping withpre-conditioning
11151312|NCT03718312|No Intervention|Arm 2|Patients with aortic clamping without pre-conditioning
11151313|NCT03718299|Other|tildrakizumab 100 mg|
11151314|NCT03718286|Experimental|Alirocumab|
11151315|NCT03718286|Sham Comparator|Sham Control|
11151316|NCT03718273|Active Comparator|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance <60ml / min,
11151317|NCT03718273|Experimental|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
11151318|NCT03718260|Experimental|Cohort 1|Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
11151319|NCT03718260|Experimental|Cohort 2|Men with biochemical failure after initial prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
11151320|NCT03718260|Experimental|Cohort 3|Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
11151321|NCT03718260|Experimental|Cohort 4|Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
11151322|NCT03718260|Experimental|Cohort 5|Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
11151323|NCT03718260|Experimental|Cohort 6|Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
11151324|NCT03718260|Experimental|Cohort 7|[18F]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.
11151325|NCT03718234|Experimental|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
11151326|NCT03718234|Active Comparator|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
11151327|NCT03718221|Active Comparator|Usual Care FIT Screening Strategy|"Mailed outreach invitation to complete FIT include: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage). Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion. Centralized processes to promote guideline-based follow-up."
11151328|NCT03718221|Experimental|GeoMail FIT Screening Strategy|The experimental arm differs from the active comparator in one way: patients living in treated ZIP codes will receive the mailed outreach at the same time.
11151329|NCT03718208|Experimental|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.
~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
11151330|NCT03718195|Other|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.
~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
11151331|NCT03718182|Active Comparator|Arm A - Cholecalciferol 400iu|Vitamin D3 (Cholecalciferol) 400 iu. Daily oral capsule. To be taken for 24 weeks (6 months)
11151332|NCT03718182|Experimental|Arm B - Cholecalciferol 3200iu/800iu|"Vitamin D3 (Cholecalciferol) supplement 3,200iu daily oral capsule. To be taken for 12 weeks (3 months).
~Then switch to vitamin D3 supplement 800iu daily oral capsule. To be taken for 12 weeks (3 months)."
11151333|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
11151334|NCT03718156|Experimental|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
11151335|NCT03718156|No Intervention|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
11151336|NCT03718143|Experimental|Arm A: Elderly Newly diagnosed AML|"Combination AZD1775 with AraC
~Elderly, newly diagnosed AML"
11151337|NCT03718143|Experimental|Arm B:Relapsed AML and MDS|"Combination AZD1775 with AraC
~Relapsed/Refractory AML & HMA failure AML/ MDS"
11151338|NCT03718143|Active Comparator|Arm C: Relapsed AML, MDS and MF|"AZD1775 only
~Relapsed/Refractory AML & HMA failure AML/ MDS and Relapsed/Refractory Primary & Secondary MF"
11151339|NCT03718130|Experimental|Group 1: 0.6 mg HTNV - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
11151340|NCT03718130|Experimental|Group 2: 3.0 mg HTNV - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
11151341|NCT03718130|Experimental|Group 3: 0.6 mg PUUV - Intradermal (ID)|0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
11151342|NCT03718130|Experimental|Group 4: 3.0 mg PUUV - Intramuscular (IM)|0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
11151343|NCT03718130|Experimental|Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
11151344|NCT03718130|Experimental|Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
11151345|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
11151346|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
11151347|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
11151348|NCT03718091|Experimental|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151349|NCT03718091|Experimental|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151350|NCT03718091|Experimental|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151351|NCT03718091|Experimental|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151352|NCT03718091|Experimental|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151353|NCT03718091|Experimental|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151354|NCT03718091|Experimental|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151355|NCT03718091|Experimental|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151356|NCT03718091|Experimental|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151357|NCT03718091|Experimental|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151358|NCT03718091|Experimental|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151359|NCT03718091|Experimental|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
11151360|NCT03718078|Experimental|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
11151361|NCT03718065|Experimental|Lofexidine Men|Men will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
11151362|NCT03718065|Experimental|Lofexidine Women|Women will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
11151363|NCT03718065|Placebo Comparator|Placebo Men|Men will receive matching placebo for five weeks.
11151364|NCT03718065|Placebo Comparator|Placebo Women|Women will receive matching placebo for five weeks.
11151365|NCT03718052|Experimental|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
11151366|NCT03718052|Active Comparator|Conventional care|Conventional care according to the 2015 European guidelines.
11151367|NCT03718039|Experimental|Treatment Group 1|HTX-011
11151368|NCT03718039|Experimental|Treatment Group 2|aprepitant
11151369|NCT03718039|Experimental|Treatment Group 3|HTX-011 and a scheduled multimodal analgesic regimen (oral ibuprofen and acetaminophen).
11151370|NCT03718026||Patients with Multiple Sclerosis|"The timed 360° turn test
~Berg Balance Scale
~Timed Up and Go test
~Functional Reach Test
~One-leg stance test
~Four square step test"
11151371|NCT03718026||Healthy Controls|-The timed 360° turn test
11151372|NCT03718013|Experimental|accelerated dTMS|
11151373|NCT03718013|Active Comparator|standard dTMS|
11151374|NCT03718000|No Intervention|Control|Participants in this group received no intervention during t he holiday season
11151375|NCT03718000|Experimental|Daily Self-Weighing (DSW)|Participants in this group performed daily self-weighing using digital WiFi scales during the holiday season
11151376|NCT03717987|Active Comparator|Botulinum toxin A injection|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
11151377|NCT03717987|Active Comparator|Zinc supplementationj prior to Botulinum toxin A injection|"Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
11151378|NCT03717974|Experimental|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
11151379|NCT03717974|Active Comparator|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
11151380|NCT03717961|Experimental|" BTX-A group"|"BOTOX® solution
~Saline serum
~lidocaine/prilocaine cream
~Nitrous oxide/oxygen (50%/50%)
~Intervention Description :
~BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)
~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer
~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
11151381|NCT03717961|Placebo Comparator|Placebo group|"Saline serum
~lidocaine/prilocaine cream
~Nitrous oxide/oxygen (50%/50%)
~Intervention Description :
~Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).
~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.
~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
11151382|NCT03717948|Experimental|CTL - BFR|CTL Exercise then BFR Exercise
11151383|NCT03717948|Experimental|BFR - CTL|BFR Exercise then CTL Exercise
11151384|NCT03717935|Experimental|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
11151385|NCT03717935|Placebo Comparator|Placebo|4 weeks: Placebo- 15g 2/day
11151386|NCT03717922|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MR data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
11151387|NCT03717922|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
11151388|NCT03717909|Experimental|Experimental Group|Sodium Valproate 200Mg E/C Tablet (active treatment)
11151389|NCT03717909|Placebo Comparator|Control Group|Sodium Valproate matched placebo (inactive treatment)
11151390|NCT03717896|Experimental|Thiamine|200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
11151391|NCT03717896|Placebo Comparator|Placebo|100mL 0.9% saline twice daily for two days
11151392|NCT03717883||Healthy subjects|
11151393|NCT03717883||Subjects with ADPKD|
11151394|NCT03717870|Experimental|Surgery|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
11151395|NCT03717870|Active Comparator|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
11151396|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
11151397|NCT03717857||Focus Groups|"Three focus groups with middle school students [N = 5], caregivers [N =5], and school staff [N = 5] will be conducted to inform the development of the intervention.
~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.
~The school staff focus group will include school personnel from the targeted schools."
11151398|NCT03717831||Healthy|Healthy subjects will be enrolled as age and activity matched controls for muscle power assessment at one time-point to establish normative values.
11151399|NCT03717831||ICU|Observational, subjects enrolled initially in the ICU and followed for six months after hospital discharge. ICU subdivided based on diagnosis
11151400|NCT03717818|Experimental|Good Psychiatric Management-Brief|
11151401|NCT03717818|Placebo Comparator|Treatment as Usual-Brief|
11151402|NCT03717805|Experimental|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
11151403|NCT03717805|No Intervention|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
11151404|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
11151405|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
11151406|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
11151407|NCT03717753|No Intervention|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
11151408|NCT03717753|Experimental|After Group|We plan to have 70 patients studied after initiation of a pathway.
11151409|NCT03717740|Experimental|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
11151410|NCT03717740|Placebo Comparator|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
11151411|NCT03717727|Experimental|Exergame|Home-based exergame intervention and usual treatment.
11151412|NCT03717727|Experimental|Control|Home-exercise by standard protocol and usual treatment.
11151413|NCT03717714|Active Comparator|Glucosamine 1500mg|Glucosamine 1500 mg per day for 12 weeks
11151414|NCT03717714|Experimental|Polycan & Glucosamine 750mg|Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
11151415|NCT03717714|Experimental|Polycan & Glucosamine 1500mg|Polycan 50 mg + Glucosamine 1500 mg per day
11151416|NCT03717701|Experimental|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
11151417|NCT03717701|Placebo Comparator|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
11151418|NCT03717688|Placebo Comparator|Placebo|No treatment. Participants are subjected to a standardized meal
11151419|NCT03717688|Active Comparator|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
11151420|NCT03717688|Active Comparator|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
11151421|NCT03717688|Active Comparator|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
11151422|NCT03717675|Experimental|Interventional|Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure.
11151423|NCT03717662|Experimental|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
11151424|NCT03717649|Active Comparator|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
11151425|NCT03717649|Active Comparator|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
11151426|NCT03717649|Experimental|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
11151427|NCT03717636|Experimental|Hospital Day|Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.
11151428|NCT03717636|Other|Outpatient clinic|The patients in control group will return for medical evaluation 30 days at the outpatient clinic.
11151429|NCT03717623|Experimental|Posaconazole prophylaxis|Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
11151430|NCT03717610|Experimental|radical surgery with HIPEC|After achieved macroscopically radical surgery, HIPEC procedure will be performed
11151431|NCT03717597|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
11151432|NCT03717571||Control group|age and sex matched healthy control persons
11151433|NCT03717571||isolated tear|patients with isolated complete supraspinatus muscle tear
11151434|NCT03717571||combined tear|patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
11151435|NCT03717558|Active Comparator|Stromectol R|Stromectol R = ivermectin 3mg (tablet)
11151436|NCT03717558|Experimental|ivermectin T1|T1= ivermectin low grade particle Size Distribution
11151437|NCT03717558|Experimental|ivermectin T2|T2= ivermectin medium grade particle Size Distribution
11151438|NCT03717558|Experimental|ivermectin T3|T= ivermectin high grade particle Size Distribution
11151439|NCT03717545|Experimental|intervention arm|second allogeneic stem cell transplantation
11151440|NCT03717532|Experimental|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
11151441|NCT03717532|Placebo Comparator|Patients with Patellopain syndrome with Placebo Cuff|
11151442|NCT03717519||s-CRLM|Patients with synchronous colorectal liver metastases who underwent surgical resection
11151443|NCT03717506|Experimental|Test product|GDC 268 Lotion applied topically as directed.
11151444|NCT03717506|Active Comparator|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
11151445|NCT03717506|Placebo Comparator|Placebo|GDC Vehicle lotion applied topically as directed.
11151446|NCT03717493|Experimental|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking & Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
11151447|NCT03717493|No Intervention|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
11151448|NCT03717480|Experimental|TCR α/β Reagent System|"The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.
~CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
11151449|NCT03717467|Placebo Comparator|S group|Isotonic saline as placebo will be given.
11151450|NCT03717467|Active Comparator|M group|Magnesium sulfate will be given
11151451|NCT03717454|Experimental|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
11151452|NCT03717454|Experimental|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
11151453|NCT03717428|Experimental|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
11151454|NCT03717428|Active Comparator|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
11151455|NCT03717415|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
11151456|NCT03717415|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin
~Triple-negative breast cancer
~Ovarian cancer
~Mesothelioma"
11151457|NCT03717402|Other|Activity 3 Participants (UAT)|"Activity 3 (User acceptability testing):
~Patients will utilize the STAMP app in an observed setting.
~Patients will complete a validated usability survey
~A series of 6 patients will be video-recorded as they are asked to think aloud for 30 minutes as they use STAMP
~Laboratory UAT will be conducted within the DFCI HCC communications laboratory, among (1) patients using opioids for chronic cancer pain, and (2) oncology providers"
11151458|NCT03717402|Other|Activity 4 Participants (Pilot Testing)|"Activity 4 (pilot testing):
~Participants will utilize the STAMP app for 4-weeks.
~STAMP will prompt patients to complete tdaily pain assessments
~The nurse will review PRO's in the STAMP portal and call patients to discuss symptoms, self-management challenges, assist patients in problem-solving, and offer medical advice
~The nurse will monitor the STAMP dashboard daily (Mon-Fri), review clinical alerts, contact patients for symptom problems, and confer with oncologists as needed"
11151459|NCT03717402|Other|Activity 5 Participants (Patient Qualitative Interviews)|"Activity 5 (patient qualitative interviews):
~Eligible patients will take part in a one-time, 1-hour interview with the study team
~Up to 30 patients (including DFCI inpatients and outpatients) will be interviewed about their experiences with a cancer diagnosis and chronic pain management."
11151460|NCT03717363|Active Comparator|Control group|Educational talk: an educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
11151461|NCT03717363|Experimental|Interventional group|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
11151462|NCT03717350|Placebo Comparator|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
11151463|NCT03717350|Active Comparator|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
11151464|NCT03717337|Experimental|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
11151465|NCT03717337|Active Comparator|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
11151466|NCT03717324||First evaluation group (survey_1)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA)
11151467|NCT03717324||Co-creation group|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA) who want to participate in the co-creation workshop
11151468|NCT03717324||Second evaluation group (survey_2)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA), after improvements are made
11151469|NCT03717311|Experimental|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
11151470|NCT03717298|Experimental|Ocoxin-Viusid|It will be used at a rate of 60 ml daily (1 vial every 12 hours).
11151471|NCT03717285|Experimental|Group 1:Under direct vision|Patients in Group 1 insert the UAS under direct vision.In this procedure,the investigators will insert the ureteroscope into urinary bladder beside the guidewire to observe the process of uas insertion into the ureter.
11151472|NCT03717285|Active Comparator|Group 2:Under non direct vision|Patients in Group 2 insert the UAS under non direct vision.In this procedure,the investigators will insert the UAS under fluoroscopy control.
11151473|NCT03717272|Experimental|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
11151474|NCT03717272|Placebo Comparator|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
11151475|NCT03717259|Active Comparator|Open nephrectomy|These patients will undergo an open nephrectomy.
11151476|NCT03717259|Active Comparator|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
11151477|NCT03717259|Active Comparator|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
11151478|NCT03717246|Experimental|Sleep Smart Latino|Sleep Smart Latino is a sleep hygiene intervention culturally tailored to be consistent with the beliefs, behaviors and needs of urban Latino middle school children and families. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting, and 2 60-minute long home based sessions that involve the student and their caregiver. The intervention focuses on sleep education, including effective sleep hygiene practices, use of electronics and caffeine and their impact on sleep.
11151479|NCT03717246|Active Comparator|Basic Sleep Education and Child Health|The basic sleep education and child health condition includes education regarding sleep hygiene , and the effects of sleep on child functioning integrated with additional child health topics such as nutrition, physical activity and safety. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting
11151480|NCT03717246|No Intervention|No treatment control|Students randomly assigned to this arm, will receive standard of care , which is no treatment and will not participate in any group sessions.
11151481|NCT03717233|Experimental|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
11151482|NCT03717220|Other|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
11151483|NCT03717207||type 2 diabetes mellitus (T2DM) patients|T2DM patients affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
11151484|NCT03717207||patients without T2DM|Patients without T2DM affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
11151485|NCT03717194|Experimental|Ertugliflozin|Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
11151486|NCT03717194|Placebo Comparator|Control group|Placebo in addition to their preexisting metformin and/or DPP4 inhibitor
11151487|NCT03717181|Experimental|Lixivaptan|Lixivaptan capsule, up to 200 mg PO BID
11151488|NCT03717168|Active Comparator|Recombinant human growth hormone|Patients who received growth hormone immediately after tracheostomy.
11151489|NCT03717168|Active Comparator|Control|Patients who did not receive growth hormone and followed the conventional weaning trials
11151490|NCT03717155|Experimental|Avelumab + Cetuximab + Gemcitabine + Cisplatin|
11151491|NCT03717142|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
11151492|NCT03717142|Experimental|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
11151493|NCT03717142|Experimental|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
11151494|NCT03717142|Experimental|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
11151495|NCT03717129|Active Comparator|Genvoya Oral dose|Single observed oral dose of Genvoya whole tablet
11151496|NCT03717129|Experimental|Genvoya Crushed Dose|Single observed oral dose of Genvoya crushed tablet
11151497|NCT03717116||control-normocalcemia group|
11151498|NCT03717116||hypocalcemia group|
11151499|NCT03717103|Experimental|IBI188|
11151500|NCT03717090||Patients with PJI|
11151501|NCT03717077|Experimental|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
11151502|NCT03717077|No Intervention|Usual home care service|The control group maintains home care service
11151503|NCT03717064|Experimental|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.
~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
11151504|NCT03717051|Experimental|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
11151505|NCT03717051|Active Comparator|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
11151506|NCT03717038|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
11151507|NCT03717038|Active Comparator|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
11151508|NCT03717025|Active Comparator|Mini Punch Grafting|
11151509|NCT03717025|Active Comparator|Suction Blister Epidermal Grafting|
11151510|NCT03717025|Active Comparator|Non Cultured Epidermal Cell Suspension|
11151511|NCT03717012|Active Comparator|Nintedanib treatment alone|
11151512|NCT03717012|Experimental|Nintedanib with a pulmonary rehabilitation program|
11151513|NCT03716999|Other|Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
11151514|NCT03716986|Other|SatO2|
11151515|NCT03716973|Experimental|High density programming|High density programming of spinal cord stimulator for paraesthesia-free therapy.
11151516|NCT03716960|Experimental|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
11151517|NCT03716960|Placebo Comparator|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
11151518|NCT03716947|Active Comparator|ORBIT Mechanical disc prosthesis|"Surgical procedure with total disc replacement using mechanical disc prosthesis device, ORBIT, Globus Medical"
11151519|NCT03716947|Experimental|ZACK viscoelastic disc prosthesis|"Surgical procedure with total disc replacement using viscoelastic disc prosthesis device, ZACK, FH Orthopaedics"
11151520|NCT03716947|Active Comparator|ORBIT SASCA|Surgical procedure with total disc replacement (TDR) using ORBIT disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
11151521|NCT03716947|Experimental|ZACK SASCA|Surgical procedure with total disc replacement (TDR) using ZACK disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
11151522|NCT03716934|Experimental|Cryoablation|Cryoablation for bidirectional block of all pulmonary veins
11151523|NCT03716934|Active Comparator|Antiarrythmics|The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.
11151524|NCT03716921|Experimental|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
11151525|NCT03716921|No Intervention|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
11151526|NCT03716908||P51S+ group|"Group 1 affected subjects (P51S+) Family member P51S mutation carrier
~interventions/ Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP"
11151527|NCT03716908||P51S- group (healthy control)|"Group 2: healthy control Family member P51S non-carrier
~interventions: Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP"
11151528|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.
~At every cry, parent should answer the questionnaire of cry in infant."
11151529|NCT03716869|No Intervention|Targeted Screening Arm (Current Process)|Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
11151530|NCT03716869|Experimental|Universal Screening Arm (Intervention)|"Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores >10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm."
11151531|NCT03716856|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
11151570|NCT03716609|Placebo Comparator|placebo group|Subjects receive citrate acid drinks without additional magnesium
11151532|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients
~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
11151533|NCT03716830|Experimental|verum acupuncture + real tDCS|
11151534|NCT03716830|Experimental|sham acupuncture + real tDCS|
11151535|NCT03716830|Experimental|verum acupuncture + sham tDCS|
11151536|NCT03716830|Sham Comparator|sham acupuncture + sham tDCS|
11151537|NCT03716817|Experimental|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
11151538|NCT03716804|Experimental|Intervention group|"Intervention:
~To the prescribers- Educational intervention about guideline and present sensitivity trend.
~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
11151539|NCT03716804|Active Comparator|Control Group|"Intervention:
~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
11151540|NCT03716791|Placebo Comparator|Placebo Control Group|pill capsules containing white rice flour
11151541|NCT03716791|Active Comparator|Methylsulfonylmethane Group|pill capsules containing MSM
11151542|NCT03716778|Other|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
11151543|NCT03716778|Experimental|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
11151544|NCT03716765|Experimental|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
11151545|NCT03716765|Active Comparator|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
11151546|NCT03716752|Active Comparator|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
11151547|NCT03716752|Experimental|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
11151548|NCT03716739|Active Comparator|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
11151549|NCT03716739|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks.
11151550|NCT03716726|Experimental|Intervention-WE CARE|"The WE CARE SDoH Screening Survey will be given at all visits by the front desk staff to all parents of Sickle Cell Anemia patients who present to the pediatric hematology clinic. They will also be provided the Family Resource Book.
~Clinical team members (i.e. medical assistants and providers) will be trained to review the WE CARE Social Determinants of Health survey at visits and to provide community resource information sheets to parents with needs. The completed surveys will be scanned into the electronic health record."
11151551|NCT03716726|Experimental|Control-Standard of Care|Standard of care for pediatric patients with sickle cell anemia will be delivered.
11151552|NCT03716713|Experimental|CeraShield Endotracheal Tube|Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.
11151553|NCT03716700||Cohort 1|Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.
11151554|NCT03716700||Cohort 2|Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.
11151555|NCT03716700||Cohort 3|Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.
11151556|NCT03716687|Experimental|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.
~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
11151557|NCT03716687|No Intervention|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
11151558|NCT03716674|Experimental|Parkinson's Disease patients|
11151559|NCT03716661|No Intervention|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
11151560|NCT03716661|No Intervention|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.
~Arm 2: Patients randomized to conservative plaster treatment"
11151561|NCT03716661|Other|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.
~Arm 3: Patients randomized to operative treatment (ORIF)"
11151562|NCT03716648|Active Comparator|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
11151563|NCT03716648|Experimental|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
11151564|NCT03716648|Experimental|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
11151565|NCT03716635|Experimental|cryotherapy|2.5c cold saline as a final flush after chemicomechanical debridement
11151566|NCT03716635|Other|normal saline|room temperature saline is used as a final flush after chemicomechanical preparation
11151567|NCT03716622|Active Comparator|bismuth-clarithromycin-containing group|Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d
11151568|NCT03716622|Experimental|bismuth-furazolidone-containing quadruple group|patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d
11151569|NCT03716609|Experimental|Magnesium supplement group|Subjects receive citrate acid drinks with additional magnesium citrate (300mg magnesium)
11151571|NCT03716596|Experimental|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
11151572|NCT03716583|Experimental|Melatonin/DMSO|25 mg melatonin in 1 g cream twice daily for the duration of the radiation therapy
11151573|NCT03716583|Placebo Comparator|Placebo|1 g of cream once daily
11151574|NCT03716570|Experimental|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
11151575|NCT03716570|Experimental|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
11151576|NCT03716570|Experimental|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
11151577|NCT03716570|Placebo Comparator|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
11151578|NCT03716557|Experimental|Spinal Cord Stimulation 4000Hz|Patients will trial Spinal Cord Stimulation 4000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
11151579|NCT03716557|Experimental|Spinal Cord Stimulation 10000Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
11151580|NCT03716557|Active Comparator|Spinal Cord Stimulation 40Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
11151581|NCT03716544|No Intervention|Waiting list control group|There will be no treatment for 12 months.
11151582|NCT03716544|Experimental|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
11151583|NCT03716544|Active Comparator|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
11151584|NCT03716531|Experimental|IORT|"IORT will be administered as determined to be best practice by the treating radiation oncologist,
~Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
11151585|NCT03716518|Experimental|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
11151586|NCT03716518|Placebo Comparator|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
11151587|NCT03716505|Active Comparator|gammaCore Sapphire active|"Treatment 3 times per day, every day for the 12-week treatment period
~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
11151588|NCT03716505|Sham Comparator|gammaCore Sapphire Sham|"Treatment 3 times per day, every day for the 12-week treatment period
~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
11151589|NCT03716479|Experimental|0 fiber|0 grams fiber added to orange juice
11151590|NCT03716479|Experimental|low fiber|20 grams of acacia gum added to orange juice
11151591|NCT03716479|Experimental|high fiber|40 grams of acacia gum added to orange juice
11151592|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
11151593|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
11151594|NCT03716453|Placebo Comparator|Control group|Intraoperative fentanyl administration will be guided by standard protocol
11151595|NCT03716453|Experimental|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
11151596|NCT03716440|Experimental|Nature group|Nature exposure intervention.
11151597|NCT03716440|Active Comparator|Non-nature group|Non-nature exposure intervention.
11151598|NCT03716427|Experimental|Active Treatment- CT1812 560 mg|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)
11151599|NCT03716414||Experimental SLN arm|"Experimental SLN arm
~Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.
~Full bilateral laparoscopic lymphadenectomy and hysterectomy:
~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.
~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
11151600|NCT03716401||Bari: Biopsy Arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Additionally, participants at the Bari site will have an additional renal biopsy at baseline."
11151601|NCT03716401||Bordeaux: MRI Follow-up arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Additionally, participants at the Bordeaux site will have an additional ultrasound US and MRI in Follow-up year 2."
11151602|NCT03716401||Exeter: Microvascular arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Participants at the Exeter site will undergo microvascular measurements including estimating glycocalyx thickness at baseline and at 2 years follow-up."
11151630|NCT03716167|Experimental|Laser Treatment|K-Laser treatment with infrared light
11151631|NCT03716167|Sham Comparator|Sham treatment|Sham K-Laser treatment with no infrared light
11151603|NCT03716401||Leeds: Microstructure MRI arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection.
~Participants at the Leeds' site will have an extended MRI scan at baseline including novel microstructure MRI measurements."
11151604|NCT03716401||Turku: PET arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.
~Additionally, participants at the Turku site will undergo a renal Positron Emission Tomography (PET) scan at the baseline timepoint."
11151605|NCT03716388|Experimental|FMT Vs Placebo|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)
11151606|NCT03716388|Active Comparator|FMT Vs Mesalamine|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
11151607|NCT03716388|Active Comparator|Placebo Infusion Vs Mesalamine|Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
11151608|NCT03716375|Experimental|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
11151609|NCT03716375|No Intervention|no use of any drug|Chest tube drainage
11151610|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
11151611|NCT03716349|Experimental|System A|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system w/Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan), informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment, clinical assessment
11151612|NCT03716349|Active Comparator|System B|ScotchBond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M) will randomly be applied to the other tooth informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment and clinical assessment at periodic timepoints.
11151613|NCT03716336|Other|aerobic exercise|walking on treadmill
11151614|NCT03716336|Other|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
11151615|NCT03716323|Experimental|immediate premolar implant with xenograft and allograft|Immediate Implant Placement in Maxillary Premolar zone with grafting the jumping gap using xenograft and allograft
11151616|NCT03716310||septic shock patients|Inclusion criteria of the study were diagnosis of septic shock and a platelet count >150*103/mcL.
11151617|NCT03716245|Experimental|supraclavicular lymph node dissection and raidiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
11151618|NCT03716245|Active Comparator|supraclavicular area radiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
11151619|NCT03716232|Active Comparator|Multiple plastic stents|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.
~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
11151620|NCT03716232|Experimental|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..
~- Stent will be extracted endoscopically after 6 months."
11151621|NCT03716219|Other|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
11151622|NCT03716219|Experimental|Subjects with Asthma|Subjects with asthma who received exercise training
11151623|NCT03716206|Experimental|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
11151624|NCT03716206|Active Comparator|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
11151625|NCT03716193|Experimental|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
11151626|NCT03716193|Experimental|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
11151627|NCT03716193|Experimental|Cohort 3|Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
11151628|NCT03716193|Experimental|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
11151629|NCT03716180|Experimental|Paclitaxel+Trastuzumab+Pertuzumab|Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
11151632|NCT03716154|Experimental|SRP and diode laser|In a split mouth design either left or right sites randomly treated by SRP and diode laser as an adjunct
11151633|NCT03716154|No Intervention|SRP alone|The other sites in the other side will be treated by SRP alone
11151634|NCT03716141|Active Comparator|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
11151635|NCT03716141|Active Comparator|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
11151636|NCT03716128||Low turnover bone disease|PTH<150 pg/ml
11151637|NCT03716128||High turnover bone disease|PTH>300 pg/ml
11151638|NCT03716128||Normal renal function|Patients under examination for prostate cancer
11151639|NCT03716115|Experimental|Colostrum|Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
11151640|NCT03716115|Experimental|GInNAC|N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
11151641|NCT03716115|Experimental|Teduglutide|Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
11151642|NCT03716115|Experimental|Budenoside|Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
11151643|NCT03716115|No Intervention|Standard care|Standard care following WHO guidelines for management of SAM.
11151644|NCT03716102|Experimental|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
11151645|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
11151646|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
11151647|NCT03716076|Other|C50|Participant receives 50 mcg of carbetocin post-delivery.
11151648|NCT03716076|Other|C100|Participant receives 100 mcg of carbetocin post-delivery.
11151649|NCT03716063|Experimental|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
11151650|NCT03716063|Placebo Comparator|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
11151651|NCT03716050|Other|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
11151652|NCT03716050|Active Comparator|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
11151653|NCT03716050|Active Comparator|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
11151654|NCT03716050|Active Comparator|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
11151655|NCT03716050|Active Comparator|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
11151656|NCT03716050|Active Comparator|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
11151657|NCT03716050|Active Comparator|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
11151658|NCT03716050|Active Comparator|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
11151659|NCT03716037|Experimental|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
11151660|NCT03716037|No Intervention|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
11151661|NCT03716024|Experimental|PTK 0796|
11151662|NCT03716024|Active Comparator|Linezolid|
11151663|NCT03716011|Other|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
11151664|NCT03715998|Experimental|Group 1: firibastat 50 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
11151665|NCT03715998|Experimental|Group 2: firibastat 250 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
11151666|NCT03715998|Active Comparator|Group 3: ramipril 2.5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
11151667|NCT03715985|Experimental|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
11151668|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
11151876|NCT03714737|Experimental|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
11152390|NCT03711318|Experimental|Short-term treatment with buprenorphine|Short-term treatment with buprenorphine
11151669|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.
~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
11151670|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
11151671|NCT03715959|Experimental|Diagnostic (nipple aspiration fluid)|Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
11151672|NCT03715946|Experimental|Radiotherapy (RT) + Nivolumab Injection|RT of 45 or 50 Gy in 25 daily fractions, 6 fractions per week. Nivolumab will be administered at 240 mg every 2 weeks during radiotherapy, and at 480 mg every 4 weeks for 6 doses after radiotherapy.
11151673|NCT03715933|Experimental|Dose Escalation|INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.
11151674|NCT03715933|Experimental|Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
11151675|NCT03715933|Experimental|Expansion Gastric Adenocarcinoma|Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
11151676|NCT03715933|Experimental|Expansion Colorectal Adenocarcinoma|Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
11151677|NCT03715933|Experimental|Expansion Sarcomas|Subjects with certain sarcoma subtypes will be treated with single-agent INBRX-109 at either the MTD or RP2D.
11151678|NCT03715933|Experimental|Combination Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with INBRX-109 in combination with chemotherapies (carboplatin, cisplatin, carboplatin and pemetrexed, or cisplatin and pemetrexed)
11151679|NCT03715933|Experimental|Combination Expansion Pancreatic Adenocarcinoma|Subjects with pancreatic adenocarcinoma will be treated with INBRX-109 in combination with 5FU/irinotecan based chemotherapy
11151680|NCT03715920|Active Comparator|High Voltage Pulsed Galvanic Current|HVPG current is a new form of neuromuscular electrical stimulation.The total output voltage of the device ranged from 0 to 500 volts and the current intensity was increased until the sensible contraction of the applied muscle was achieved without causing too much sense of discomfort
11151681|NCT03715920|Placebo Comparator|Russian Current|"Russian currents are a high frequency current of 2500 Hz and reduce the resistance of the skin and it would penetrate deeper and reach deeper motor nerves.Russian movement, a protocol developed by Kots, also known as Russian Technique, was used in the literature. There were 10 muscle contractions per treatment session in this protocol. Each contraction lasted for 10 seconds and a resting time of 50 seconds were given for the next contraction (transition: rest ratio was 1/5)."
11151682|NCT03715920|Sham Comparator|Isometric Exercise|"Isometric or static strength training is exercises performed without joint movement and changing muscle length during muscle contraction.
~The body and knee of the participants in the isometric exercise group were positioned and stabilized at 75 ° flexion and 60 ° flexion angle, respectively as in the stimulation groups. Participants were asked to do 10 repetitions as 10 seconds of maximum voluntary contractions and 10 seconds of rest."
11151683|NCT03715907|No Intervention|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
11151684|NCT03715907|Experimental|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
11151685|NCT03715907|Experimental|Incentives: W34|Informational W34 mailer and incentive to close gap
11151686|NCT03715907|No Intervention|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
11151687|NCT03715907|Experimental|Information only: LSC|Informational LSC mailer and incentive to close gap
11151688|NCT03715907|Experimental|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
11151689|NCT03715907|No Intervention|Control: IMA|No mailer for IMA (immunizations) gap
11151690|NCT03715907|Experimental|Information only: IMA|Informational IMA mailer
11151691|NCT03715907|Experimental|Incentives: IMA|Informational IMA mailer and incentive
11151692|NCT03715907|No Intervention|Control: CDC|No mailer for CDC (clinical diabetes care) gap
11151693|NCT03715907|Experimental|Information only: CDC|Informational CDC mailer
11151694|NCT03715907|Experimental|Incentives: CDC|Informational CDC mailer and incentive
11151695|NCT03715907|No Intervention|Control: CCS|No mailer for CCS (cervical cancer screening)
11151696|NCT03715907|Experimental|Information only: CCS|Informational CCS mailer
11151697|NCT03715907|Experimental|Incentives: CCS|Informational CCS mailer and incentive
11151698|NCT03715907|No Intervention|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
11151699|NCT03715907|Experimental|Information only: AWC|Informational AWC mailer
11151700|NCT03715907|Experimental|Incentives: AWC|Informational AWC mailer and incentive
11151701|NCT03715894||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI
11151702|NCT03715881|Active Comparator|Oral prednisolone administration|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
11151703|NCT03715881|Active Comparator|Intravenous Erythropoietin injection|2. 1000 units of erythropoietin every 12 hours for three days
11151704|NCT03715868|Active Comparator|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
11151705|NCT03715868|No Intervention|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
11151706|NCT03715855|Experimental|exhaled air|exhaled air analysis of patients
11604529|NCT00615303|Placebo Comparator|2|
11151707|NCT03715842|Experimental|Tub shaped design|The tub-shaped preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
11151708|NCT03715842|Active Comparator|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
11151709|NCT03715829|Experimental|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
11151710|NCT03715829|Experimental|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
11151711|NCT03715829|Experimental|Cohort 3|Maintenance dose A given QD for 24 weeks
11151712|NCT03715829|Experimental|Cohort 4|Maintenance dose B given QD for 24 weeks
11151713|NCT03715829|Experimental|Cohort 5|Maintenance dose C given QD for 24 weeks
11151714|NCT03715829|Placebo Comparator|Cohort 6|Placebo given QD for 24 weeks
11151715|NCT03715829|Experimental|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
11151716|NCT03715829|Experimental|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
11151717|NCT03715829|Experimental|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
11151718|NCT03715829|Experimental|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
11151719|NCT03715829|Experimental|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
11151720|NCT03715829|No Intervention|Extension Cohort 6|Observation period for 24 weeks
11151721|NCT03715816|No Intervention|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
11151722|NCT03715816|Experimental|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
11151723|NCT03715816|Experimental|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
11151724|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
11151725|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
11151726|NCT03715790||EP Referred Group|Subjects with EF ≤ 40% or meeting one of the referral criteria
11151727|NCT03715790||Non-Referred Group|Subjects with 40%< EF <50%.
11151728|NCT03715777|Experimental|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.
~Name of each active substance (INN or proposed INN if available):
~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
11151729|NCT03715764|Other|Physical therapy assessment|Patients allocated to the intervention group will be assigned to an assessment and evaluation by a physical therapist. If they are diagnosed with knee osteoarthritis they will get an offer to participate in a patient education program and physical training with an individualized exercise program made by a physical therapist. Patients will be offered individual treatment if they decline to participate in the education program, or if they have another diagnosis than osteoarthritis. Anytime after the first assessment by the physical therapist, the patient will be able to contact a physician if they want to.
11151730|NCT03715764|Other|Physician assessment|Allocation to the control group will involve an assessment and evaluation made by a physician. Further measures will then be determined by attending physician and the procedures that might get included are drug prescriptions, referral to x-ray examination, referral to a physical therapist or another health care provider. Anytime after the first assessment by the physician, the patient will be able to contact a physical therapist if they want to, even though if they have not been referred by the physician.
11151731|NCT03715751|Active Comparator|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
11151732|NCT03715751|Active Comparator|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
11151753|NCT03715582|Experimental|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
11151908|NCT03714568|Experimental|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
11151733|NCT03715738|Experimental|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).
~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.
~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.
~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.
~Once this measurement is completed, participation in the study is complete"
11151734|NCT03715725||Registry cohort|Registries in Norway are nation-wide and provision of the information is mandatory, which eliminates the risk of both selection and re-call bias. The large and detailed dataset also makes it possible to adjust for other risk factors on which information is available.
11151735|NCT03715725||Electronic Medical Records (EMR) cohort|Patients with NVAF diagnosis will be identified through extraction of patient-level data from EMRs from a number of hospitals in Norway, in order to describe these patients more closely regarding their clinical characteristics that are not available in nation-wide registers (e.g., in-patient treatments, anthropometric data and laboratory test results).
11151736|NCT03715712|Experimental|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
11151737|NCT03715712|Active Comparator|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
11151738|NCT03715699|Experimental|Group 1|Patients treated with single glucocorticoid
11151739|NCT03715699|Experimental|Group 2|Patients treated with Leflunomide and glucocorticoid
11151740|NCT03715686|Experimental|Wire localization|Intervention: procedure: wire localization
11151741|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
11151742|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
11151743|NCT03715660|Experimental|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
11151744|NCT03715647||Sepsis|"The puerperal / postpartum women who evolved with sepsis, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
11151745|NCT03715647||HELLP Syndrome|"The puerperal / postpartum women who evolved with HELLP syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
11151746|NCT03715647||Respiratory Distress Syndrome, Adult|"The puerperal / postpartum women who evolved with Adult Respiratory Distress Syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
11151747|NCT03715634|Experimental|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
11151748|NCT03715634|Placebo Comparator|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
11151749|NCT03715608|No Intervention|Control group|Patients in the control group received routine TKA surgery and perioperative management without any other interventions.
11151750|NCT03715608|Experimental|Intervention group|The patients in the intervention group received professional psychological interventions include psychological counseling and corresponding medication after the operation. Other perioperative treatments were the same as the patients in the control group. Psychotherapy was based on the clinical expertise of the psychosocial specialist, who selected the most appropriate plan for each patient.
11151751|NCT03715595|Experimental|SSDM group|The patients in will use the SSDM at home every month for one year.
11151752|NCT03715595|No Intervention|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
11151871|NCT03714737|Experimental|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
11151754|NCT03715582|Experimental|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
11151755|NCT03715569||Cohort with CNS infections|"Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.
~Biomarker is a protein found in the inner ear examined in the cerebral fluid."
11151756|NCT03715569||OAE/WBT control: Healthy individuals|Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.
11151757|NCT03715569||OAE/WBT control: Systemic infection|Otoacoustic emission during admission
11151758|NCT03715569||OAE/WBT control: ICP changes|Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).
11151759|NCT03715569||Biomarker control|Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.
11151760|NCT03715556|Active Comparator|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
11151761|NCT03715556|Placebo Comparator|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
11151762|NCT03715543|Experimental|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
11151763|NCT03715530|Experimental|Pregnant subjects|These are pregnant women that are admitted to Labor &Delivery (L&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
11151764|NCT03715530|Active Comparator|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
11151765|NCT03715530|Sham Comparator|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
11151766|NCT03715517|Experimental|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine
~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)"
11151767|NCT03715517|Active Comparator|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia
~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)
~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)
~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)
~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)."
11151768|NCT03715504|Experimental|Single Arm TP-3654|TP-3654 by oral administration
11151769|NCT03715478|Experimental|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
11151770|NCT03715465|Active Comparator|Estimated DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before estimated dim light melatonin onset.
11151771|NCT03715465|Experimental|Measured DLMO|Four weeks (28 days) of nightly melatonin 0.5 mg fast dissolve tablets timed to be administered 3 hours before measured dim light melatonin onset.
11151772|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
11151773|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
11151774|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
11151775|NCT03715426|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
11151776|NCT03715426|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
11151777|NCT03715413|Other|Tamoxifen group|they was received Tamoxifen 10 mg daily.
11151778|NCT03715413|Active Comparator|Tamoxifen and pulsed radiofrequency group|they was received Tamoxifen 10 mg daily and pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.
11151779|NCT03715400|No Intervention|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
11151872|NCT03714737|Active Comparator|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
11151780|NCT03715400|Experimental|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
11151781|NCT03715387|Experimental|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
11151782|NCT03715387|Placebo Comparator|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
11151783|NCT03715374|Experimental|PRF+ABB treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A prf membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
11151784|NCT03715374|Active Comparator|Collagen Membrane + ABB treated patients|Periodontal surgery with collagen membrane is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A collagen membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
11151785|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
11151786|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
11151787|NCT03715348|Active Comparator|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)
~FFP will be provide as a solution for intravenous administration, once thawed.
~The dose of the FFP will be ~ 15 mL/kg.
~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
11151788|NCT03715348|Experimental|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at ~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.
~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
11151789|NCT03715335|No Intervention|Baseline|Current STI screening rates.
11151790|NCT03715335|Active Comparator|Targeted STI Screening|"Data from the Sexual Health Screen (SHS) will be integrated into the Electronic Health Record (EHR) and will provide Clinical Decision Support (CDS) for GC/CT testing based on SHS-calculated STI risk. Patients will be classified as at high risk for STIs, at risk or low risk if they deny any history of sexual activity. When patients classify as at high risk, clinicians will receive CDS that STI testing is highly recommended; when they care for patients who classify as at risk, they will receive CDS that STI testing is recommended; when caring for patients who classify as at low risk, they will receive CDS that STI testing is not necessary at this time. If the clinician chooses to follow the recommendation for screening based on patient's risk assessment, and the patient consents to testing on the tablet device, urine GC/CT testing will be performed."
11151791|NCT03715335|Active Comparator|Universally Offered STI Screening|During the universally offered screening intervention, STI screening will be offered to all eligible adolescents, regardless of risk. All eligible patients will also complete the SHS, will be informed of the CDC GC/CT testing recommendations and then be given the option to decline STI testing using the tablet device. During this phase, the SHS results will not be available to the clinician. STI testing recommendations will be based only on the patient's decision to undergo GC/CT testing. Like the process followed in the targeted screening phase, if the clinician follows the CDS that informs the clinician that the patient agreed to GC/CT screening and consequently orders testing, urine GC/CT testing will be performed.
11151792|NCT03715322|Active Comparator|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
11151793|NCT03715322|Placebo Comparator|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
11151794|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
11151795|NCT03715309|Experimental|Revlimd|
11151796|NCT03715283|Experimental|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
11151797|NCT03715283|Experimental|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
11151798|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
11151799|NCT03715257|Active Comparator|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.
~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.
~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
11151800|NCT03715257|Active Comparator|Tube changing catheter|"Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.
~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
11151801|NCT03715244||Study group 1|n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
11151802|NCT03715244||Study group 2|n= 220 patients for routine data of general anesthesia (current standard)
11151873|NCT03714737|Experimental|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
11151976|NCT03714048||Cardiogenic shock plus arrest|
11151977|NCT03714048||Preventive|
11151803|NCT03715244||No intervention: Control group postoperative cognitive deficit|n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
11151804|NCT03715231|Experimental|Glaucoma & Glaucoma Suspect Patients|Patients with Glaucomatous optic neuropathy
11151805|NCT03715218|Experimental|Mother Touch Program|Post natal care provided by trained carer after the birth. 6 weeks of care included massage, special diet, physical and mental relaxations.
11151806|NCT03715218|Other|Usual care Program|Usual care and supervision was provided as usual.
11151807|NCT03715205|Experimental|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
11151808|NCT03715205|Experimental|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
11151809|NCT03715192|Experimental|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
11151810|NCT03715192|Placebo Comparator|Placebo|Normal saline administered as a single IV infusion in healthy participants
11151811|NCT03715192|Experimental|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
11151812|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
11151813|NCT03715166|Experimental|Bumetanide/S95008|
11151814|NCT03715166|Placebo Comparator|Placebo|
11151815|NCT03715153|Experimental|BUMETANIDE/S95008|
11151816|NCT03715153|Placebo Comparator|PLACEBO|
11151817|NCT03715140|Experimental|Patients who will recieve crucumin|patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.
11151818|NCT03715140|Placebo Comparator|Patients who will receive placebo|Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.
11151819|NCT03715127|Placebo Comparator|Placebo|one oral dose of 100% mannitol (placebo)
11151820|NCT03715127|Active Comparator|Psilocybin|one oral dose of 0.215mg/kg psilocybin (verum)
11151821|NCT03715114|Experimental|GV-971 900 mg|900 mg oral
11151822|NCT03715114|Experimental|GV-971 1200 mg|1200 mg oral
11151823|NCT03715114|Experimental|GV-971 1500 mg|1500 mg oral
11151824|NCT03715114|Placebo Comparator|Placebo|Oral placebo
11151825|NCT03715101|Experimental|Rosuvastatin 20 mg PO|Rosuvastatin 20 mg daily for 21 days
11151826|NCT03715088|Experimental|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
11151827|NCT03715088|Experimental|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
11151828|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
11151829|NCT03715062|Experimental|Intervention group|Receives education in diagnosing urinary tract infection and use of observation, reflection and communication tool.
11151830|NCT03715062|No Intervention|Control group|No intervention
11151831|NCT03715049|Other|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
11151832|NCT03715036|No Intervention|Fundal height|Patients will have routine fundal height measurement
11151833|NCT03715036|Experimental|Point-of-care US|Patients will receive POC US for DVP and AC.
11151834|NCT03715023|Experimental|Active + SoC|Daily doses of PC786 for 3 days + SoC
11151835|NCT03715023|Placebo Comparator|Placebo + SoC|Daily doses of Placebo for 3 days + SoC
11151836|NCT03715010|Active Comparator|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
11151837|NCT03715010|Placebo Comparator|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
11151838|NCT03714997|Experimental|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
11151839|NCT03714997|Active Comparator|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
11151840|NCT03714984|Experimental|Pre operative exercise|The educational pelvic floor intervention group will receive one months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction. Patients and care giver will receive a daily exercise diary to fill at home and will be advised to follow the exercise program.
11151841|NCT03714984|Active Comparator|Control group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
11151874|NCT03714737|Experimental|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
11151875|NCT03714737|Active Comparator|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
11151842|NCT03714971|Experimental|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
11151843|NCT03714971|No Intervention|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
11151844|NCT03714958|Experimental|combination HDM201 - Trametinib|"HDM201: Therapeutic class HDM2 inhibitor, given Per Os every D1 and D8 over a 28 day cycle. Four dose-levels possible in dose escalation part: 40 mg, 80mg, 100 mg, 120mg.
~Trametinib: Therapeutic class Protein kinase inhibitor of MEK1 and MEK2 activation and kinase activity. Administrated daily, countinous dosing , One dose-level possible in dose escalation: 2mg"
11151845|NCT03714945||Case Group with Allergic Rhinitis|"- Inclusion Criteria
~Both genders of 11-14 years, diagnosed with allergic rhinitis on basis of screening instruments, medical history, clinical assessment (by general ORL examination including nasal endoscopy)
~Chinese in ethnicity
~Positive skin prick test with wheal diameter >= 3mm
~Ability to understand the nature, scope, and possible consequences of the study
~Capability and willingness to comply with the requirements of the protocol"
11151846|NCT03714945||Control Group without Allergic Rhinitis|"- Inclusion Criteria
~Both genders of 11-14 years
~Chinese in ethnicity
~Subjects who have not been diagnosed with a long term medical or psychiatric problem
~Subjects who are not currently undergoing any long term medical treatment."
11151847|NCT03714919|Experimental|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan & acetaminophen and intraoperative intravenous dexmedetomidine & ketamine.
11151848|NCT03714906|Experimental|Treatment|Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
11151849|NCT03714906|No Intervention|Control|Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
11151850|NCT03714880|Experimental|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
11151851|NCT03714880|Placebo Comparator|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
11151852|NCT03714867|Experimental|Treatment|Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
11151853|NCT03714867|Placebo Comparator|Control|Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
11151854|NCT03714854|Active Comparator|Deep brain stimulation ON|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
11151855|NCT03714854|Placebo Comparator|Deep brain stimulation OFF|Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
11151856|NCT03714841|Experimental|CRP value|The patients point of care CRP value is known by the treating physician
11151857|NCT03714841|Active Comparator|CRP value unknown|The patients point of care CRP value is not known by the treating physician
11151858|NCT03714828|Experimental|Treatment (talimogene laherparepvec)|The subject participation period will be approximately 48 weeks. This will include a screening visit, 4 injection visits and 5 follow up visits. Total length of study/patient is 8.5 to 10.5 months. TVEC will be administered by injection with a needle directly into one or more tumors.
11151859|NCT03714815|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
11151860|NCT03714802|Experimental|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
11151861|NCT03714802|Placebo Comparator|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
11151862|NCT03714789||Meropenem|Patients requiring dialysis and receiving meropenem for infection or suspended infection.
11151863|NCT03714789||Vancomycin|Patients requiring dialysis and receiving vancomycin for infection or suspended infection.
11151864|NCT03714789||Ceftriaxone|Patients requiring dialysis and receiving ceftriaxone for infection or suspended infection.
11151865|NCT03714776|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx injected subcutaneously once-weekly
11151866|NCT03714776|Placebo Comparator|Placebo|Placebo matching solution injected subcutaneously once-weekly
11151867|NCT03714763|Experimental|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
11151868|NCT03714763|Experimental|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
11151869|NCT03714750|Active Comparator|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
11151870|NCT03714750|Experimental|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
11151978|NCT03714022|Experimental|Treatment A|Manufacturing Process A
11151877|NCT03714737|Active Comparator|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
11151878|NCT03714737|Experimental|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
11151879|NCT03714737|Active Comparator|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
11151880|NCT03714724|Active Comparator|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.
~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
11151881|NCT03714724|Active Comparator|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
11151882|NCT03714724|Active Comparator|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
11151883|NCT03714711||Total hip arthroplasty|Patient who are scheduled to undergo total hip replacement.
11151884|NCT03714711||Total knee arthroplasty|Patient who are scheduled to undergo total knee replacement.
11151885|NCT03714698|Active Comparator|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
11151886|NCT03714698|Placebo Comparator|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
11151887|NCT03714685|Experimental|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
11151888|NCT03714672|Experimental|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
11151889|NCT03714672|Experimental|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
11151890|NCT03714672|Active Comparator|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
11151891|NCT03714672|Active Comparator|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
11151892|NCT03714659|Experimental|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
11151893|NCT03714646|Placebo Comparator|Placebo|
11151894|NCT03714646|Active Comparator|beta glucan|
11151895|NCT03714646|Experimental|beta glucan and Resistant Starch|
11151896|NCT03714633|Experimental|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Home-based post-discharge intervention for extreme premature babies and their parents. The intervention consists of one hospital visit, nine home-visits and two telephone calls during the first year corrected age, specifically from one week before discharge to 12 months corrected age. The intervention is strengths-based working with the infant-parent interaction, supporting infant development and strengthening the parent in his/her role.
11151897|NCT03714633|No Intervention|Control|The participants of the Control Group receives treatment as usual, which consists of a regular follow-up program with neurodevelopmental assessment at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 66 months corrected age. Compared to children not participating in the study, the control group will receive an extended follow-up program, with assessment and questionnaires at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 36 months corrected age. Participants in the control group will be referred to specialized care when needed.
11151898|NCT03714620|Active Comparator|0.15 mg/kg IV Ketamine|
11151899|NCT03714620|Active Comparator|0.3 mg/kg IV Ketamine|
11151900|NCT03714607|Experimental|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
11151901|NCT03714607|No Intervention|Control|No intervention
11151902|NCT03714594|Active Comparator|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
11151903|NCT03714594|Active Comparator|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
11151904|NCT03714594|Active Comparator|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
11151905|NCT03714581|Experimental|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
11151906|NCT03714581|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
11151907|NCT03714568|Experimental|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
11151909|NCT03714555|Active Comparator|Nab-Paclitaxel/Gemcitabine + DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
11151910|NCT03714555|Active Comparator|FOLFIRINOX +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
11151911|NCT03714555|Active Comparator|Single-Agent Gemcitabine +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
11151912|NCT03714542|Other|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
11151913|NCT03714529|Experimental|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.
~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
11151914|NCT03714516|Experimental|Online psychological intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
11151915|NCT03714503|Other|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
11151916|NCT03714490|Experimental|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
11151917|NCT03714490|Active Comparator|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
11151918|NCT03714477|Active Comparator|Treatment Arm|immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list
11151919|NCT03714477|No Intervention|Control Arm|delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later
11151920|NCT03714464|Experimental|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.
~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
11151921|NCT03714464|Experimental|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.
~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
11151922|NCT03714464|Experimental|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.
~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
11151923|NCT03714451|Experimental|Onyx Group|Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).
11151924|NCT03714451|Active Comparator|Wheat Flour Group|Patients with T2DM will receive food products with wheat flour.
11151925|NCT03714438|Experimental|Medicago sativa|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
11151926|NCT03714438|Placebo Comparator|Placebo|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
11151927|NCT03714425|Active Comparator|High frequency device|Subjects will use high frequency Quell devices.
11151928|NCT03714425|Sham Comparator|Low frequency device|Subjects will use low frequency Quell devices.
11151929|NCT03714412|Experimental|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
11151930|NCT03714399||ICUAW group|The physical and psychological effects of ICUAW on patients undergoing aortic valvular surgery will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
11151931|NCT03714386|Experimental|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
11151932|NCT03714386|Active Comparator|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
11151933|NCT03714373|Experimental|DCCR|75 - 450 mg DCCR
11151934|NCT03714360|Experimental|TXA tranexamic acid|a single dose of 10 mg/kg of TXA, with a maximum dose of 1g. Administered as IV injection and marked as 'project-drug' and amount (mL) in the medical record.
11151935|NCT03714360|Placebo Comparator|Sodium Chloride 0,9%|an equivalent volume 0.9 % Sodium Chloride.
11151936|NCT03714347|Active Comparator|Group Control|routine monitoring will be applied to this group
11151937|NCT03714347|Active Comparator|Group Oxygen|cerebral oxygen monitoring is applied to this group
11151938|NCT03714334|Experimental|DNX-2440 injection|all the patients included will be treated with the experimental agent
11151979|NCT03714022|Experimental|Treatment B|Manufacturing Process B
11152273|NCT03712111|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
11151939|NCT03714321|Experimental|Mechanical insufflation-exsufflation arm|MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
11151940|NCT03714321|No Intervention|CPAP arm|CPAP will be given as prescribed by the physician responsible at the intermediate care unit, typically every 4 hours. CPAP will be administered with standard settings of H2O and an oxygen flow of 15L/min.
11151941|NCT03714308||Patients with nAMD_Treatment-naive (anti-VEGF naive)|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
11151942|NCT03714308||Patients with nAMD_Pre-treated with IVT-AFL|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
11151943|NCT03714308||Patients with nAMD_Pre-treated with any anti-VEGF|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
11151944|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
11151945|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
11151946|NCT03714282|Experimental|Noninvasive Spinal Stimulation with Gait Training|May receive up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
11151947|NCT03714282|Active Comparator|Conventional Gait Training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
11151948|NCT03714282|Other|Healthy Control Group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
11151949|NCT03714269|Experimental|Children with cerebral palsy of the spastic type|
11151950|NCT03714256|Experimental|Children 6-17 months|"Device, patient mobility, powered:
~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
11151951|NCT03714256|Experimental|Children 18 - 36 months|"Device, patient mobility, powered:
~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
11151952|NCT03714243|Experimental|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
11151953|NCT03714217|Experimental|Intervention|Telenutrition counseling
11151954|NCT03714204|Experimental|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
11151955|NCT03714204|No Intervention|Control Group|Participants assigned to this group served as wait-list controls
11151956|NCT03714191|Other|Improved outcomes|
11151957|NCT03714191|Other|Regulatory reminder|
11151958|NCT03714191|Other|Billing and documentation|
11151959|NCT03714178|Experimental|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
11151960|NCT03714152|Experimental|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
11151961|NCT03714152|Placebo Comparator|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
11151962|NCT03714139|Experimental|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
11151963|NCT03714139|No Intervention|non implant loading|there is not immediate prosthetic restoration
11151964|NCT03714126||HF patients|HF patients will use the Cordio Medical app to record in their hospital visits and at home.
11151965|NCT03714113|Experimental|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
11151966|NCT03714100|Experimental|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
11151967|NCT03714087|Experimental|T1 Conventional treatment before aligner|T1 before aligner: Conventional orthodontic treatment patients before the essix aligner
11151968|NCT03714087|Experimental|T2 After essix aligner|T2 after the aligner: Essix aligner appliance with setup for 3 weeks full time
11151969|NCT03714087|Active Comparator|Historic control group|Conventional orthodontic treatment without finishing protocol UdeA2
11151970|NCT03714074|Experimental|PEEK abutment|PEEK abutment restored with PEEK superstructure
11151971|NCT03714074|Experimental|Zirconia abutment|zirconia abutment restored with PEEK superstructure
11151972|NCT03714061|Experimental|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
11151973|NCT03714061|Active Comparator|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
11151974|NCT03714048||Perioperative|
11151975|NCT03714048||Cardiogenic shock minus arrest|
11151980|NCT03714009|Active Comparator|Fasting group|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. They should take adequate water and non calorie beverages intake daily (2-3 liters)"
11151981|NCT03714009|Other|Non fasting group|no fasting, patients will have usual balanced diet as 3 meals and 2 snacks all over the day. They should take adequate water and non calorie beverages intake daily (2-3 liters)
11151982|NCT03713996|Experimental|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
11151983|NCT03713996|Active Comparator|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
11151984|NCT03713970|Experimental|Celtra duo press|Celtra duo press ingot 20g for three laminate veneers
11151985|NCT03713970|Active Comparator|IPS e.max press|IPS e.max press ingot 20g for three laminate veneers
11151986|NCT03713957|Experimental|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
11151987|NCT03713957|Placebo Comparator|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
11151988|NCT03713944|Experimental|Carboplatin, Pemetrexed, Atezolizumab plus Bevacizumab|"Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.
~Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities."
11151989|NCT03713918|Experimental|Reinforced lithium silicate endocrown|Device: Endocrown restoration
11151990|NCT03713918|Active Comparator|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
11151991|NCT03713905|Experimental|GLS-010|Use Full-human anti-pd-1 monoclonal antibodies for treatment
11151992|NCT03713892|Experimental|CKD-504|investigational Drug
11151993|NCT03713892|Placebo Comparator|Placebo|investigational Drug
11151994|NCT03713879|Experimental|indomethacin|rectal indomethacin 100 mg to be administered before or after ERCP
11151995|NCT03713879|Experimental|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
11151996|NCT03713879|Experimental|indomethacin plus pancreatic stenting|"[rectal indomethacin 100 mg to be administered before or after ERCP] plus [a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire]"
11151997|NCT03713866|Experimental|EP Imaging and Testing|MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.
11151998|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
11151999|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
11152000|NCT03713840|Experimental|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
11152001|NCT03713840|No Intervention|Control|Child care centers in the control arm received access to intervention materials at a later date.
11152002|NCT03713827|Active Comparator|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
11152003|NCT03713827|Active Comparator|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
11152004|NCT03713814|Experimental|Experimental Group|8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.
11152005|NCT03713814|No Intervention|Control group|After the 8 weeks of intervention, the pilots will receive explanation and handbook demonstration of the same exercises.
11152006|NCT03713801|Experimental|Metformin|Dosage is increased over the first 3 weeks up to three 500 mg tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
11152007|NCT03713801|Placebo Comparator|Placebo|Placebo tablet dosage is increased over the first 3 weeks up to three tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
11152008|NCT03713788|Experimental|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
11152009|NCT03713788|No Intervention|Control group|Participants rested in a seated position for 5 minutes.
11152010|NCT03713775|Experimental|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
11152045|NCT03713567|Placebo Comparator|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
11152046|NCT03713567|Experimental|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
11152011|NCT03713775|Active Comparator|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
11152012|NCT03713762|Experimental|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
11152013|NCT03713762|Experimental|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
11152014|NCT03713749|Experimental|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
11152015|NCT03713749|No Intervention|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
11152016|NCT03713736|Other|Female patients with spondyloarthritis or rheumatoid arthritis|Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.
11152017|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
11152018|NCT03713710|Experimental|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
11152019|NCT03713710|Experimental|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
11152020|NCT03713697|Experimental|Pap testing|Women assigned to this arm were invited to get a Pap testing at the Basic Health Unit
11152021|NCT03713697|Experimental|Self-Collection for HPV testing|Women assigned to this arm were provided with a kit to engage in self-collection for HPV testing
11152022|NCT03713697|Experimental|Choice|Women assigned to this arm were given a choice between a Pap testing at the local Basic Health Unit or self-collection for HPV testing
11152023|NCT03713684|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (prefilled syringe) administered once weekly for 56 weeks
11152024|NCT03713684|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (prefilled syringe) administered once weekly for 56 weeks
11152025|NCT03713684|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (prefilled syringe) administered once weekly for 56 weeks
11152026|NCT03713684|Placebo Comparator|Placebo|Matching placebo (prefilled syringe) administered once weekly for 56 weeks
11152027|NCT03713671|Other|Study Group|Spatio-Temporal gait analysis and balance assessment of subjects with Primary Hyperparathyroidism
11152028|NCT03713671|Other|Control Group|Spatio-Temporal gait analysis and balance assessment of healthy subjects
11152029|NCT03713658|Experimental|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
11152030|NCT03713658|Experimental|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
11152031|NCT03713658|Experimental|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
11152032|NCT03713645|Experimental|Tacrolimus extended-release 0.13mg/kg/day|Tacrolimus extended-release is initiated within post-operative day 3 of kidney transplant
11152033|NCT03713632|Active Comparator|Secukinumab 1|Secukinumab 300mg every 2 weeks
11152034|NCT03713632|Active Comparator|Secukinumab 2|Secukinumab 300mg every 4 weeks
11152035|NCT03713632|Placebo Comparator|Placebo 1|Placebo group to secukinumab 300mg every 2 weeks
11152036|NCT03713632|Placebo Comparator|Placebo 2|Placebo group to secukinumab 300mg every 4 weeks
11152037|NCT03713619|Active Comparator|secukinumab 1|Secukinumab 300mg every 2 weeks
11152038|NCT03713619|Active Comparator|secukinumab 2|Secukinumab 300mg every 4 weeks
11152039|NCT03713619|Placebo Comparator|placebo 1|Placebo group to secukinumab 300mg every 2 weeks
11152040|NCT03713619|Placebo Comparator|placebo 2|Placebo group to secukinumab 300mg every 4 weeks
11152041|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
11152042|NCT03713593|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
11152043|NCT03713593|Active Comparator|lenvatinib plus placebo|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
11152044|NCT03713580|Experimental|Venetoclax+BEAM x 1 cycle prior to ASCT|"Venetoclax dose escalation cohorts + BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) begin with dose level 1 (800mg on Day -7 and Day -6). The dosing cohorts are escalated in a 3 + 3 design but with increasing duration instead of increasing dosage.
~Carmustine 300 mg/m2 by IV over 2 hours on Day -7.
~Etoposide 100 mg/m2 by IV over 6 hours daily for 4 consecutive days, Day-6 through Day-3.
~Cytarabine 200 mg/m2 by IV over 2 hours every 12 hours for 3 consecutive days, Day-6 through Day-4.
~Melphalan 140 mg/m2 by IV over 30 minutes or IV push once on Day -2.
~Following V+BEAM therapy, participants will receive Autologous Stem Cell Transplant (ASCT): infusion of previously collected autologous stem cells and supportive care per institutional guidelines"
11604530|NCT00615303|Active Comparator|1|
11152047|NCT03713541||Patients with Anorexia nervosa (AN)|Female patients with Anorexia nervosa (AN, ICD-10: F50.0/1) of 14 years and older, receiving an initial treatment due to their AN (start of initial treatment no longer than 3 months ago, inpatient care: at least 7 days inpatient; outpatient care: at least 5 sessions with the same therapist) with sufficient language skills and no serious organic or psychiatric illnesses and no acute suicidality will be consecutively included in the study. No intervention.
11152048|NCT03713541||Carers of patients with AN|Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
11152049|NCT03713541||Physicians of patients with AN|Resident general practitioner, pediatrician, internist or gynecologist with at least one medical patient contact within the last 12 months. No intervention.
11152050|NCT03713528|Active Comparator|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, or acute hematogenous infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
11152051|NCT03713528|No Intervention|Comparison Group|The control group includes any patient with an acute perioperative periprosthetic, or acute hematogenous infection with a vancomycin sensitive gram positive organism treated with intravenous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics, and indefinite antibiotic chronic suppression under guidance of an infectious disease specialist.
11152052|NCT03713515|Experimental|Practice Faciliation|Will be supported by a practice facilitator
11152053|NCT03713515|No Intervention|Usual Care|Using a stepped wedge design, all practice sites begin as part of the Usual Care (UC) control condition and will receive standard hypertension management that is part of the current clinic procedure. No practice facilitation will occur at this time.
11152054|NCT03713489|Experimental|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
11152055|NCT03713489|No Intervention|standard medical treatment group|standard medical treatment
11152056|NCT03713476|Experimental|Robot-assisted training|The participants will receive 20 minutes of robot assisted tenodesis-grip therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
11152057|NCT03713476|Active Comparator|Traditional occupational therapy|The participants will receive 20 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
11152058|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
11152059|NCT03713450|Experimental|Control with imaging guidance|
11152060|NCT03713450|Active Comparator|Control without imaging guidance|
11152061|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
11152062|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
11152063|NCT03713424|Active Comparator|Clav|4-day 125 bid oral capsule administration
11152064|NCT03713424|Placebo Comparator|Placebo|4-day, twice-daily oral capsule administration
11152065|NCT03713411|No Intervention|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
11152066|NCT03713411|Active Comparator|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
11152067|NCT03713398|Experimental|T4C-SMI Group|Participants will receive the T4C-SMI intervention, in addition to standard prison mental health services
11152068|NCT03713398|No Intervention|Control Group|The control group receives standard prison mental health services
11152069|NCT03713385||Aged group (n =49)|Determined the optimal endotracheal tube size according to age of the child (internal diameter [ID] in mm = [age in years + 16] /4) suggested by Cole
11152070|NCT03713385||Subglottic diameter group (n =49)|The subglottic transverse diameter was estimated with ultrasonography on the middle of the anterior region of the neck at the level of cricoid cartilage
11152071|NCT03713385||Epiphyseal diameter group (n =49)|The epiphyseal transverse diameter of the distal radius was estimated with ultrasonography.
11152072|NCT03713372|Experimental|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11152073|NCT03713359|Active Comparator|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:
~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
11152074|NCT03713359|Active Comparator|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.
~Subcutaneous injection"
11152075|NCT03713346|Other|Lactose digester|
11152076|NCT03713346|Other|Lactose maldigester|
11152077|NCT03713333|Experimental|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
11152078|NCT03713333|No Intervention|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
11152079|NCT03713320|Experimental|Cobomarsen|
11152080|NCT03713320|Active Comparator|Vorinostat|
11152142|NCT03712891|No Intervention|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
11604531|NCT00615277|Active Comparator|1|1: omega-3 fatty acid supplement
11604532|NCT00615277|Placebo Comparator|2|2: olive oil
11152081|NCT03713294|Experimental|Treatment (dexamethasone, elotuzumab, pomalidomide)|Patients receive dexamethasone IV on days 1, 8, 15, and 22 of courses 1-2 and IV on day 1 and orally (PO) on days 8, 15, and 22 of subsequent courses and elotuzumab IV on days 1, 8, 15, and 22 of courses 1-2 and day 1 of subsequent courses. Patients also receive pomalidomide PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11152082|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.
~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
11152083|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
11152084|NCT03713268||Surgical patients|Adult and minor (> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
11152085|NCT03713255|Active Comparator|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
11152086|NCT03713255|Experimental|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
11152087|NCT03713255|Sham Comparator|control group|local anesthetic infiltration subcutaneous 1% lidocaine
11152088|NCT03713242|Experimental|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
11152089|NCT03713242|Experimental|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
11152090|NCT03713242|Experimental|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
11152091|NCT03713242|Experimental|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
11152092|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
11152093|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
11152094|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
11152095|NCT03713216|Experimental|Naldebain|Subjects will receive one dose of Naldebain before surgery.
11152096|NCT03713216|Active Comparator|Morphine|Subjects will receive morphine after surgery.
11152097|NCT03713203|Experimental|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
11152098|NCT03713190|Active Comparator|Empagliflozin|SGLT-2 inhibitor
11152099|NCT03713190|Placebo Comparator|placebo|A substance without specific pharmacology principles.
11152100|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
11152101|NCT03713177||Interns|Dental interns of Cairo University
11152102|NCT03713164|Active Comparator|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
11152103|NCT03713164|Active Comparator|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
11152104|NCT03713151|Experimental|Dividat FIT: Computer based exercise|One arm with 10-15 Haemophilia patients and 10-15 Myositis patients.
11152105|NCT03713138|Experimental|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
~Intervention/ Dietary Supplement:
~Flax seed powder
~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
~Other Name: intervention"
11152106|NCT03713138|No Intervention|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.
~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
11152107|NCT03713125|Active Comparator|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
11152108|NCT03713125|No Intervention|Business as Usual|Instruction as usual within schools
11152109|NCT03713112|Active Comparator|Weekly MDT deprescribing rounds|Weekly MDT deprescribing rounds for certain drugs will be performed on top of usual care.
11152110|NCT03713112|No Intervention|Control (Usual Care)|"Usual Care includes the following:
~De-prescribing at the discretion of the ward doctors
~Initial medication reconciliation by pharmacist on admission
~Ward rounds to be conducted 3 weekdays per week for rehabilitative patients and daily on weekdays for sub-acute patients."
11152111|NCT03713099|Experimental|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
11152112|NCT03713086|Active Comparator|Rabipur®|
11152113|NCT03713086|Experimental|CV7202 Dose level 1|
11152114|NCT03713086|Experimental|CV7202 Dose level 2|
11152115|NCT03713086|Experimental|CV7202 Dose level 3|
11152116|NCT03713073|Experimental|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
11152117|NCT03713073|Active Comparator|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
11152386|NCT03711344|Experimental|Culturally adapted Cognitive Behavioral therapy|The experimental group will receive the culturally adapted version of cognitive behavioral therapy.
11152118|NCT03713060|Other|Women with RYGB and fetus/ child|20 pregnant women with previous gastric bypass surgery. During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
11152119|NCT03713060|Other|Matched controls and fetus/ child|20 pregnant women matched on age, prepregnancy-BMI and parity (n = 20). During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
11152120|NCT03713034|Experimental|Active Game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.
~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
11152121|NCT03713034|Active Comparator|Control Game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.
~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
11152122|NCT03713021|Experimental|TraceIT Tissue Marker|"Following successful tumor resection, TraceIT Tissue Marker will be applied in 0.2 to 0.5 mL injections at 5 locations to mark the tumor bed: superiorly, inferiorly, laterally, medially, and center of resection. The marginal injections will be within 3 mm of the resection edge and within 5 mm deep. The center of the resection bed will be injected within 5 mm deep if possible.
~Within 6 weeks after surgery, a CT simulation scan will be performed per normal protocol for patients receiving surgery followed by adjuvant therapy. This scan will be used to generate the IMRT treatment plan
~Two treatment plans will be performed per patient using the simulation CT scan. One will be the standard of care treatment plan and will be the basis of the actual radiation treatment they receive. The second treatment plan will be based on utilizing the TraceIT hydrogel markers as a guide for the resection bed."
11152123|NCT03713008|Experimental|Fluid bolus|Patients included in the study will receive fluid bolus.
11152124|NCT03712995|Experimental|Cutler-Beard modified with graft|Reconstruction of Upper Eyelid With a Newly Modified Cutler-Beard Technique With Tarsoconjunctival Graf
11152125|NCT03712982|No Intervention|Waitlist Control|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2.
11152126|NCT03712982|Experimental|Attention to Variability - Patient Only|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. They will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
11152127|NCT03712982|Experimental|Attention to Variability - Partner Only|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. Partners of the infertile women will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
11152128|NCT03712982|Experimental|Attention to Variability - Patient & Partner|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. All participants (patients and partners) will also be instructed to complete a mindfulness intervention at home and respond to diary-type text messaging questions twice daily for two weeks (14 days).
11152129|NCT03712982|Active Comparator|Infertility Stories - Reading|All participants in this condition will complete all measures online at three different points in time, including one narrative response at T2. They will also be instructed to do an at-home reading activity several times over a period of 2 weeks.
11152130|NCT03712969|Experimental|Intervention group|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
11152131|NCT03712969|No Intervention|Control group|Patients receive conventional adjuvant chemotherapy.
11152132|NCT03712956|Experimental|Caelyx® for 8 courses|Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.
11152133|NCT03712943|Experimental|Regorafenib and Nivolumab Combination - Escalation|Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.
11152134|NCT03712943|Experimental|Regorafenib and Nivolumab Combination - Expansion|Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.
11152135|NCT03712930|Experimental|Pamiparib|Participants will receive pamiparib for a period up to 1 year
11152136|NCT03712917|Active Comparator|Greater Occipital Nerve Block|"The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼ (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood."
11152137|NCT03712917|Active Comparator|Topiramate|Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
11152138|NCT03712917|Active Comparator|Flunarizine|Flunarizine is introduced with a single dose of 10 mg/day.
11152139|NCT03712904|Experimental|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
11152140|NCT03712904|Experimental|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
11152141|NCT03712891|Experimental|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
11152143|NCT03712878|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.
~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.
~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.
~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.
~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
11152144|NCT03712852|Active Comparator|PRF+CAF treated patients|Blood samples are collected in four 10-ml tubes without anticoagulant and promptly centrifuged at 3,000 revolutions per minute for 10 minutes The clot, positioned in the middle of the vial, is cut off from the lower red corpuscles part (Fig). The clot is pressed through a calibrated compression system into the PRF box the folded membrane is transferred on a sterile gauze. A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the PRFs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
11152145|NCT03712852|Active Comparator|SCTG+ CAF treated patients|SCTG is taken from the opposite palate area of gingival defect. The graft is collected with a single incision technique and it is measured and adjusted to 1 mm by measuring with a standard caliper.A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the SCTGs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
11152146|NCT03712852|Active Comparator|CAF treated patients|A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the flap is sutured over the enamel in a tension free position.
11152147|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
11152148|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of < 5 on the PCRS Scale.
11152149|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
11152150|NCT03712826|Experimental|anti TNF|Crohn patient with antiTNF treatment
11152151|NCT03712826|Experimental|Ustekinumab|Crohn disease with ustekinumab treatment
11152152|NCT03712813|Experimental|Macrodyne LivMD plate|
11152153|NCT03712813|No Intervention|Wait-Listed Control|
11152154|NCT03712800|Experimental|Rhythmical massage|Participants who receive rhythmical massage for three months.
11152155|NCT03712800|Experimental|HRV biofeedback|Participants who perform HRV biofeedback for three months.
11152156|NCT03712800|No Intervention|Control group|Participants who do not receive an intervention during the three-month intervention period but are advised to stay with their usual care during menstrual pain. For ethical and compliance reasons, these participants receive a series of rhythmical massage treatments after the initial three-month intervention/control period.
11152157|NCT03712787|Experimental|ABBV-8E12 Dose 1|Participants will receive ABBV-8E12 Dose 1.
11152158|NCT03712787|Experimental|ABBV-8E12 Dose 2|Participants will receive ABBV-8E12 Dose 2.
11152159|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
11152160|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
11152161|NCT03712761||Supplementation with Enriched Protein®|Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
11152162|NCT03712761||Low protein breakfast|No supplementation
11152163|NCT03712761||High protein breakfast|No supplementation
11152164|NCT03712748|Experimental|Imaginal Exposure Session|
11152165|NCT03712735|Active Comparator|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:
~PIEB flow rate = high; interval = 60 min"
11152166|NCT03712735|Experimental|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
11152167|NCT03712735|Experimental|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
11152168|NCT03712722||rCDI|Adult patients with recurrect Clostridium difficile infection
11152169|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
11152170|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
11152171|NCT03712696|Experimental|DIGNICAP™|DigniCap® System
11152172|NCT03712683|Experimental|Sub clinical hypothyroid women|"Levothyroxine sodium(Euthyrox 50µg and 25 µg MerckSerono) treatment was initiated and the women were followed in a combined clinic of endocrinologist and Gynecologist.
~2.5 µg of Thyroxine daily was prescribed to women with TSH more than 2.5 mIU/L. Women with TSH more than 4mIU/L were given 50 µg daily . When pregnancy was confirmed Thyroxine was continued till 13 weeks gestation ."
11152173|NCT03712670|Active Comparator|AM group|Intravitreal aflibercept monotherapy
11152174|NCT03712670|Experimental|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
11152175|NCT03712670|Experimental|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
11152176|NCT03712657|Experimental|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
11152177|NCT03712657|No Intervention|conservative group|normal treatment
11604533|NCT00615264|Experimental|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
11152178|NCT03712644|No Intervention|Conservative|Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.
11152179|NCT03712644|Experimental|Invasive|"In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization
~All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR>0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.
~For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible."
11152180|NCT03712631|Active Comparator|bone without a collagen membrane|not covering bone with collagen membrane
11152181|NCT03712631|Experimental|bone with collagen membrane|covering bone with collagen membrane
11152182|NCT03712618|Active Comparator|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
11152183|NCT03712618|Active Comparator|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
11152184|NCT03712605|Experimental|Arm A (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1.
11152185|NCT03712605|Active Comparator|Arm B (standard of care observation, radiation therapy)|Patients receive standard of care observation every 3 months for 1 year, and then every 6 months for 5 years. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1.
11152186|NCT03712592|Experimental|160km|
11152187|NCT03712592|Experimental|40km|
11152188|NCT03712592|Experimental|100km|
11152189|NCT03712592|Experimental|4x40km|
11152190|NCT03712579|Experimental|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
11152191|NCT03712579|Experimental|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
11152192|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
11152193|NCT03712553|Active Comparator|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
11152194|NCT03712553|Experimental|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
11152195|NCT03712553|Experimental|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
11152196|NCT03712553|Experimental|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
11152197|NCT03712553|Active Comparator|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
11152198|NCT03712553|Experimental|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
11152199|NCT03712553|Active Comparator|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
11152200|NCT03712553|Experimental|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
11152201|NCT03712540|Experimental|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
11152202|NCT03712527|Experimental|Platelet-Rich Plasma|
11152203|NCT03712527|Placebo Comparator|Placebo|
11152204|NCT03712514|Other|Male rugby players|Destabilization of the upper cervical spine with Cervistab
11152205|NCT03712514|Other|Healthy males non rugby players|Destabilization of the upper cervical spine with Cervistab
11152206|NCT03712501|Experimental|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
11152207|NCT03712501|No Intervention|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
11152208|NCT03712475|Experimental|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
11152209|NCT03712475|Active Comparator|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
11152210|NCT03712462|Experimental|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
11152211|NCT03712462|Active Comparator|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
11152212|NCT03712449|Experimental|Juvéderm, BOTOX, BELKYRA, and SkinMedica|"BELKYRA may be administered by injections at least 1 month apart for up to 6 treatments from V1 to V6.
~From V7to V9, the subject will begin Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study At V10 an 11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)"
11152213|NCT03712436|Experimental|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
11152214|NCT03712436|Active Comparator|patients receiving standard oncological care|Patients receiving standard oncologic care.
11152215|NCT03712423|Experimental|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed < 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
11152216|NCT03712410|Active Comparator|Group 1 (PISCES face to face)|"Family caregivers will receive three sessions of the PISCES intervention in person. The agenda for the first face to face visit for caregivers (suggested timeline 5-7 days after hospice admission) includes an explanation of the purpose of the visit/call. During the first session, the interventionist works on steps one and two of the ADAPT model, namely Attitude and Defining the Problem and Setting Realistic Goals. During the second visit (suggested timeline 11-13 days after hospice admission) the interventionist covers steps three and four of the ADAPT model. Step three encourages caregivers in being creative and generating alternative solutions. Step four focuses on predicting the consequences and developing a solution plan. The third visit (suggested timeline 16-18 days after hospice admission) focuses on step five, namely trying out the solution plan and determining if it works."
11152217|NCT03712410|Experimental|Group 2 (PISCES delivered in a hybrid format)|In this group, participants will receive the PISCES intervention in three sessions; however, the first session will be delivered face to face and the other two via video. The three intervention sessions will be scheduled with a suggested timeline between days 5 and 18 of the hospice admission. The first session will take place in person (suggested timeline 5-7 days after hospice admission). After the first session where the in-person encounter will allow for the establishment of rapport between the interventionist and the caregiver, the second session (suggested timeline 11-13 days after hospice admission) and the third session (suggested timeline 16-18 days after hospice admissions) will be conducted via live videoconferencing. If the caregiver already has access to a computer and Internet, they will utilize the videoconferencing solution. If videoconferencing is not feasible, the sessions will be delivered over the regular phone.
11152218|NCT03712410|Experimental|Group 3 (PISCESplus)|"PISCESplus is meant to be an enhanced version of the PISCES intervention including the original problem solving therapy modules with the addition of positive reappraisal elements. The suggested timeline for the first session which will be in person is 5-7 days after hospice admission. At the end of the first session, the interventionist will ask the caregiver to take the time to think about and identify some positive aspects of caregiving.
~At the end of the second session (which is scheduled to take place via video approx. 11-13 days after admission) the interventionist will ask the caregiver to go over the benefits or positive aspects of caregiving that they had identified and ask them to comment as to why they perceive these as positive or beneficial.
~The third session will also take place via video."
11152219|NCT03712397|Experimental|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
11152220|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
11152221|NCT03712371|Experimental|Chitosan dose escalation|
11152222|NCT03712358|Experimental|Cohort 0 (PVSRIPO)|A single dose of PVSRIPO into a single lesion.
11152223|NCT03712358|Experimental|Cohort 1 (PVSRIPO)|A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
11152224|NCT03712358|Experimental|Cohort 2 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
11152225|NCT03712358|Experimental|Cohort 3 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
11152226|NCT03712358|Experimental|Cohort 4 (PVSRIPO)|A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
11152227|NCT03712345|Experimental|Group A|Will receive IFX-1 low dose regimen diluted in sodium chloride solution
11152228|NCT03712345|Experimental|Group B|Will receive IFX-1 high dose regimen diluted in sodium chloride solution
11152229|NCT03712345|Placebo Comparator|Group C|Will receive placebo
11152230|NCT03712332|Experimental|Distress Tolerance Group|6 session inpatient distress tolerance group intervention twice a week for 1.5 hours for up to three weeks.
11152231|NCT03712319|Experimental|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
11152232|NCT03712319|Active Comparator|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
11152233|NCT03712319|No Intervention|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
11152234|NCT03712306|No Intervention|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
11604534|NCT00615264|Placebo Comparator|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
11152235|NCT03712306|Experimental|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
11152236|NCT03712306|Experimental|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
11152237|NCT03712293|Experimental|BBB Disruption with Chemotherapy Arm|All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
11152238|NCT03712280|Experimental|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
11152239|NCT03712280|Experimental|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
11152240|NCT03712280|Experimental|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
11152241|NCT03712280|Active Comparator|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
11152242|NCT03712267|Experimental|Electronic Media Enhanced|Research assistants will collect information on participants' electronic messaging behavior and content and provide that for use to participants' clinicians.
11152243|NCT03712267|Placebo Comparator|Treatment As Usual|Participants will not have their electronic messaging reviewed prior to their typically scheduled clinical appointments.
11152244|NCT03712241|Experimental|Treatment A|K-285 dose/application method A
11152245|NCT03712241|Experimental|Treatment B|K-285 dose/application method B
11152246|NCT03712241|Experimental|Treatment C|K-285 dose/application method C
11152247|NCT03712241|Active Comparator|Treatment D|Indomethacin capsule
11152248|NCT03712228|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
11152249|NCT03712228|Active Comparator|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
11152250|NCT03712228|Active Comparator|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
11152251|NCT03712228|Active Comparator|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
11152252|NCT03712228|Active Comparator|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
11152253|NCT03712228|Active Comparator|CSL312-F|Subjects with FXII or plasminogen mutation (FXII/PLG) HAE receiving CSL312
11152254|NCT03712215|Experimental|Experimental Group 1|synchronized FES mode, according to the parameters based on the Gueddes et al., (1991): current frequency (F) 30 Hz; pulse width (T) 0,4 ms; upload time (Rise) 1s; time of muscle contraction (On time) 1 s; down time (Decay) 2s e muscle relaxation time (Off time) 1 s.
11152255|NCT03712215|Experimental|Experimental Group 2|the same apparatus will be used, differing in the parameters that will be based on the studies of Cancelliero et al., (2012) for the EDET procedure, being used in synchronized FES mode, with frequency of 30 Hz; pulse width (T) 0,4 ms, climb (ramp) of 0,7 s (maximum value). The support was of 0.4 s, already standardized and fixed in the apparatus
11152256|NCT03712215|No Intervention|Control Group|The control group (CG) with the same characteristics of the experimental groups will perform conventional physiotherapy
11152257|NCT03712202|Experimental|Group I Arm A (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11152258|NCT03712202|Experimental|Group I Arm B (ABVD, nivolumab)|Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11152259|NCT03712202|Experimental|Group II (AVD, brentuximab vedotin, nivolumab)|Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11152260|NCT03712189|No Intervention|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
11152261|NCT03712189|Experimental|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
11152262|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
11152263|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
11152264|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 1)|
11152265|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 2)|
11152266|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 3)|
11152267|NCT03712163|Experimental|Norketotifen or Placebo (Multiple Dose)|
11152268|NCT03712150||Healthy|"Healthy adults
~- Participants will receive single session of tdcs after application"
11152269|NCT03712137|Experimental|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional maintenance treatment at Month 12.
11152270|NCT03712137|Experimental|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
11152271|NCT03712124|Experimental|CNSA-001|Patients will receive CNSA-001 (sepiapterin) 20 mg/kg/day (10 mg/kg twice daily) for 14 days as an oral suspension.
11152272|NCT03712124|Placebo Comparator|Placebo|Patients will receive a placebo oral suspension twice daily for 14 days.
11152387|NCT03711344|Active Comparator|Non-adapted Cognitive Behavioral therapy|The control group will receive the original (non-adapted) version of cognitive behavioral therapy.
11152274|NCT03712111|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
11152275|NCT03712098|Experimental|Smoking Cessation Counseling & Liraglutide|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of the medication liraglutide. Liraglutide comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which follows FDA guidelines and is documented to be safe and well-tolerated in prior clinical studies, will begin at 0.6 mg and increase weekly by 0.6 mg until the recommended dose of 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
11152276|NCT03712098|Active Comparator|Smoking Cessation Counseling & Placebo|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of placebo. The placebo comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which is the same as the liraglutide regimen, will begin at 0.6 mg and increase weekly by 0.6 mg until 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
11152277|NCT03712085|Active Comparator|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
11152278|NCT03712085|Sham Comparator|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
11152279|NCT03712085|No Intervention|Control Group|Upper limb rehabilitation only
11152280|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
11152281|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
11152282|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
11152283|NCT03712059||Screening group|All 20000 patients receive FIT test and colonoscopy, whose age, sex, family history, smoking history, body mass index (BMI), and diabetes history of the patients are collected by researchers through pad, equipped with a specially designed database and app. Using colonoscopy results as the gold standard, the screening value of the APCS score and FIT test for the Chinese population is explored, and the optimal screening strategy of colorectal cancer for the Chinese established initially.
11152284|NCT03712059||Adenoma resection group|During the polypectomy of 5000 patients, for all pathologically confirmed or NBI-predicted adenomas with size<10mm, 1-2 biopsies were randomly performed on the edge after resection to determine the completion rate of the polypectomy.
11152285|NCT03712059||Identification and classification group|For 25000 patients regardless of cancer screening or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
11152286|NCT03712046|Experimental|Main arm|PET-CT imaging of the ankles and feet following injection of 18F-FDG
11152287|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.
~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
11152288|NCT03712007|Experimental|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
11152289|NCT03712007|Active Comparator|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
11152290|NCT03711994|No Intervention|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
11152291|NCT03711994|Active Comparator|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
11152292|NCT03711994|No Intervention|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
11152293|NCT03711994|Active Comparator|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
11152294|NCT03711981|Active Comparator|TAP block of 10cc Liposomal bupivacaine|Patients in this arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery.
11152295|NCT03711981|No Intervention|Routine pre-incisional injections at trocar incision sites|The patients in the control arm of the study would receive routine pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.
11152296|NCT03711968|Active Comparator|Treatment group|"Rehabilitative treatment protocol:
~Therapeutic exercise 8 mono-weekly sessions, 5 patients per group, duration 60 minutes and two sessions of single treatment, duration 60 minutes (duration of treatment about two months, considering also any recovery sessions)"
11152297|NCT03711968|No Intervention|Waiting list|Intervention: The WL patients will be taken into the same treatment at the end of the experimental protocol, after T2 evaluation. In this period they act like a control group.
11152298|NCT03711955|Experimental|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
11152299|NCT03711955|Experimental|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
11152300|NCT03711942|Active Comparator|Periodontally Healthy IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar.
11152301|NCT03711942|Experimental|Periodontally Healthy Base|2mm thick base was applied in periodontally health teeth.
11152302|NCT03711942|Experimental|Periodontally healthy control|coronal access was restored with composite resin without any base.
11152303|NCT03711942|Active Comparator|Periodontally diseased IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar
11152304|NCT03711942|Active Comparator|Periodontally diseased Base|2mm thick Base of GIC was applied under composite restoration
11152305|NCT03711942|Active Comparator|Periodontally diseased control|coronal access was restored with composite resin without any base
11152306|NCT03711929|Experimental|Test Arm: DE-109 Injectable Solution|Intravitreal injection of DE-109 440 µg in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects).
11152307|NCT03711929|Sham Comparator|Control Arm: Sham Procedure|Sham procedure administered to the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 80 subjects). The sham procedure mimics an intravitreal injection without penetrating the eye.
11152308|NCT03711929|Other|Dummy Arm: DE-109 Injectable Solution|Dummy Arm: Intravitreal injection of DE-109 at an undisclosed, fixed dose (within the range of 44 µg to 880 µg) in the study eye(s) every 2 months (Day 1, Month 2, and Month 4) (approximately 40 subjects). This study arm (which has the same route of administration and frequency as the test arm).
11152309|NCT03711916|Experimental|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
11152310|NCT03711916|No Intervention|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
11152311|NCT03711903|Experimental|Treatment arm|The study drug, CN-105, will be administered at 1.0 mg/kg every 6 + 2 hours. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
11152312|NCT03711903|Placebo Comparator|Placebo arm|The Placebo arm will be given 0.9% NaCL
11152313|NCT03711890|Experimental|Diagnostic (resection, OCT)|Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
11152314|NCT03711877|Experimental|scalp cooling system|'Scalp cooling device' will be used to prevent alopecia during chemotherapy regimen infusion.
11152315|NCT03711877|Active Comparator|cold cap|'Cold cap' will be used to prevent alopecia during chemotherapy regimen infusion.
11152316|NCT03711864|Experimental|IM21 CAR-T cells|IM21 CAR-T cells
11152317|NCT03711851|Experimental|Web-based|Self-help Acceptance and commitment therapy (Web-based)
11152318|NCT03711851|Experimental|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
11152319|NCT03711851|Active Comparator|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
11152320|NCT03711838|Experimental|N-Acetylcysteine|N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
11152321|NCT03711838|Active Comparator|Placebo|Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).
11152322|NCT03711825|Experimental|Sentinel/Main|Sentinel dosing of two subjects in clinic of LYN-057 (50 mg), followed by Main, i.e. remaining 6 subjects, for total of 8 subjects doses; followed by imaging assessment (MRI/abdominal U/S)
11152323|NCT03711812|Active Comparator|Serratus Anterior Plane Catheter|
11152324|NCT03711812|Placebo Comparator|Thoracic Epidural|
11152325|NCT03711799|No Intervention|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
11152326|NCT03711799|Experimental|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
11152388|NCT03711331|Experimental|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
11604535|NCT00615251|Experimental|1|
11152327|NCT03711786|Active Comparator|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
11152328|NCT03711786|Experimental|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
11152329|NCT03711773|Experimental|Group Physical Therapy Class|Group Physical Therapy Classes. Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
11152330|NCT03711760|Experimental|intervention|telepsychology treatment
11152331|NCT03711760|No Intervention|usual care|standard of care
11152332|NCT03711747||Post-traumatic Ankle OA|Post-traumatic ankle OA and requiring osteochondral allograft to tibia and/or talus in ankle
11152333|NCT03711734|Experimental|Acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.
~Patients will have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally with electrostimulation at Shen men and Hypothalamus at 30 hz."
11152334|NCT03711734|No Intervention|No acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.
~Patients will not have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally."
11152335|NCT03711721|Experimental|Food basket|
11152336|NCT03711721|Experimental|Ready-to-Use Therapeutic Food|
11152337|NCT03711708|Experimental|Zoloft Oral Solution|50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
11152338|NCT03711708|Active Comparator|Zoloft Tablets|Zoloft 50 mg tablet.
11152339|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
11152340|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
11152341|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
11152342|NCT03711682|Experimental|Cinnamon (Intervented)|
11152343|NCT03711682|Placebo Comparator|Wheat Flour (Placebo)|
11152344|NCT03711656|Experimental|isCGM and Physical exercise tracker|"Participants will perform CGM during 12 weeks using an isCGM (intermittently scanned Continuous Glucose Monitoring), Freestyle Libre, (Abbott Diabetes Care, Witney, Oxon, UK). Insulin dose (rapid-acting and long acting), carbohydrates and Self-monitoring blood glucose (SMBG) per day will be recorded by the patient in the reader or in the App (LibreLink, Abbott Diabetes Care, Witney, Oxon, UK). Moreover, participants will be instructed to collect data about moderate or high intensity exercise, illness and other disturbances occurring during the study period at home.
~Patients will wear a physical exercise tracker (Fitbit Alta HR® wristband (Fitbit, Inc., San Francisco, California, USA)) to track physiological variables such as heart rate, steps, activity level and sleep quality."
11152345|NCT03711643|Experimental|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
11152346|NCT03711643|Active Comparator|standard pain management|
11152347|NCT03711630|Experimental|Meditation|The study cohort will participate in self-guided meditation practice over the course of eight weeks.
11152348|NCT03711617||CKD-ND|patients with non-dialysis CKD
11152349|NCT03711617||CKD-MHD|patients with maintenance hemodialysis
11152350|NCT03711604|Experimental|Tenalisib|Participants receive Tenalisib (RP6530) BID Orally
11152351|NCT03711578|Experimental|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
11152352|NCT03711565|Active Comparator|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
11152353|NCT03711565|Active Comparator|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
11152354|NCT03711552||Quality of recovery|All enrolled patients will be asked to complete the ObsQoR-11 and QoR-15 questionnaires pre-surgery if feasible and at 24 and 48 hours post-surgery.
11152355|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
11152356|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
11604536|NCT00615251|Active Comparator|2|
11152357|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than >3 hours / week, ii) have a history of smoking (> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
11152358|NCT03711513|Experimental|Exposure only|Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
11152359|NCT03711513|Experimental|Cognitive restructuring plus exposure|PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
11152360|NCT03711513|Experimental|Relaxation plus exposure|PE (plus homework) + Relaxation (RE) (plus homework) + RE (plus homework) + EX (plus homework) + EX: 20 participants will receive two relaxation exercises group sessions after the psycho-education session. In these two session they will practice muscle relaxation and breathing exercises. After the relaxation sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
11152361|NCT03711500|Experimental|D-serine|
11152362|NCT03711500|Placebo Comparator|Placebo|
11152363|NCT03711487|Experimental|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
11152364|NCT03711487|No Intervention|No intervention|No intervention.
11152365|NCT03711474|Experimental|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
11152366|NCT03711474|Placebo Comparator|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
11152367|NCT03711461|Active Comparator|nonintubated|patients received nonintubated during thoracoscopy
11152368|NCT03711461|Experimental|intubated|patients receiving intubated during thoracoscopy
11152369|NCT03711448|Active Comparator|Control group|
11152370|NCT03711448|Experimental|Experimental group|
11152371|NCT03711435||control group|15 subjects was enrolled in the control group，they are healthy controls
11152372|NCT03711435||training IPF group|30 subjects was enrolled in the training IPF group，they are IPF patients，the group is designed to identify differential metabolites between IPF and control groups.
11152373|NCT03711435||Validation group|15 subjects was enrolled in the Validation IPF group，they are IPF patients，the group is designed to validate differential metabolites identified in the previous groups.
11152374|NCT03711422|Experimental|Part A|Standard dose oral afatinib. If patients in Part A do not benefit from the regimen, they can be enrolled into Part B
11152375|NCT03711422|Experimental|Part B|Intermittent high dose oral afatinib
11152376|NCT03711409|Experimental|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
11152377|NCT03711409|Experimental|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
11152378|NCT03711396|Experimental|Advance Care Planning Group Visits|Participants will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
11152379|NCT03711383|Placebo Comparator|Placebo|isocaloric maltodextrin the day before CIDs
11152380|NCT03711383|Active Comparator|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
11152381|NCT03711383|Experimental|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
11152382|NCT03711370|Experimental|Opaque Bottle Group|This group will be given a set of opaque bottles that are to be used during infant feedings for a full 12-week period.
11152383|NCT03711370|Active Comparator|Clear Bottle Group|This group will be given a set of clear bottles that are to be used during infant feedings for a full 12-week period.
11152384|NCT03711357|Active Comparator|laser|980 nm diode laser (maximum output of 3 watts and coupled with a fiber optic tip of 200 µm diameter) will be used for four irradiations, of 5 seconds each, after chemo-mechanical preparation procedures.
11152385|NCT03711357|Placebo Comparator|Placebo|After chemo-mechanical preparation procedures, the diode laser fiber optic tip will be inserted inside the root canals but not activated.
11152389|NCT03711331|Sham Comparator|Standard care|patients benefiting from usual standard care
11152391|NCT03711305|Experimental|SHR-1316 + carboplatin + etoposide|Participants will receive SHR-1316 intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) SHR-1316 until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
11152392|NCT03711305|Active Comparator|Placebo + carboplatin + etoposide|Participants will receive placebo intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
11152393|NCT03711292|Experimental|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
11152394|NCT03711279|Experimental|SHR-1210 plus Apatinib|
11152395|NCT03711279|Active Comparator|ADM Plus IFO or IFO Alone|
11152396|NCT03711266|Experimental|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
11152397|NCT03711253|Other|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
11152398|NCT03711240|Experimental|bevacizumab+mFOLFOXIRI|
11152399|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
11152400|NCT03711214|Active Comparator|pSS patients|We will evaluate 40 patients with pSS (EULAR/ACR Classification Criteria, 2016) of both sexes before and after periodontal disease treatment.
11152401|NCT03711214|Active Comparator|Healthy individuals|We will evaluate 40 healthy controls before and after periodontal disease treatment.
11152402|NCT03711201|Active Comparator|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
11152403|NCT03711201|No Intervention|Group NoIORE|The patient's hemodynamic data will be measured in the evening service before surgery. The patient will be brought to the operating room by the anesthesiologist on the day of surgery and hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured in the preop unit. The hemodynamic data and the ST-STAI scale will measure the anxiety level in the operating room.
11152404|NCT03711188|Experimental|IMM-101 (and nivolumab or ipilimumab)|IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
11152405|NCT03711175|Other|Group A|The subscapularis is repaired. Receives device
11152406|NCT03711175|Other|Group B|The subscapularis is not repaired. Receives device
11152407|NCT03711162|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
11152408|NCT03711162|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
11152409|NCT03711162|Placebo Comparator|Placebo|Placebo to match will be administered as film-coated tablets for oral use once daily.
11152410|NCT03711149|Experimental|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
11152411|NCT03711149|No Intervention|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
11152412|NCT03711136||Frozen elephant trunk surgery|
11152413|NCT03711136||Standart surgery|
11152414|NCT03711123|Experimental|Group metacognitive therapy (GMCT)|10 weekly sessions of GMCT With 90 minutes duration
11152415|NCT03711123|Active Comparator|Clinical Management|10 weekly individual sessions with up to 60 minutes duration
11152416|NCT03711110|Experimental|Primary prevention strategy|Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.
11152417|NCT03711110|Other|Secondary prevention strategy (control)|Current clinical practice: cardiac care is based on the onco-hematologist criteria.
11152418|NCT03711097|No Intervention|Control|Upper left or right central and lateral incisor
11152419|NCT03711097|Experimental|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
11152420|NCT03711084|Placebo Comparator|Water|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
11152421|NCT03711084|Experimental|Natural high potency sweetener from leaf extract|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
11152422|NCT03711084|Experimental|Glucose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
11152423|NCT03711084|Experimental|Sucrose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
11152424|NCT03711084|Experimental|Maltodextrin|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
11152425|NCT03711071|Experimental|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
11152426|NCT03711071|No Intervention|Control Group|This group will not get the intervention before data collection.
11152427|NCT03711058|Experimental|Phase I - Copanlisib and Nivolumab (De-Escalation)|
11152428|NCT03711058|Experimental|Phase II - Copanlisib and Nivolumab|
11152429|NCT03711045||Suicide Risk Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) also have a history of suicide attempt in the past 6 months.
11152430|NCT03711045||Disorder Control Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) and without suicide ideation or behavior.
11152431|NCT03711045||Healthy Control Group|
11152432|NCT03711032|Experimental|BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)|Participants receive BCG (Induction and Maintenance) in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (~2 years).
11152433|NCT03711032|Experimental|BCG Monotherapy: Post-induction Cohort A (Arm A-2)|Participants receive BCG monotherapy (Induction and Maintenance).
11152434|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)|Participants receive BCG (Induction and reduced Maintenance) in combination with 400 mg pembrolizumab administered IV every 6 weeks (Q6W) for 9 doses (~1 year).
11152435|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)|Participants receive BCG (Induction and full Maintenance) in combination with 400 mg pembrolizumab administered IV Q6W for 9 doses (~1 year).
11152436|NCT03711032|Experimental|BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)|Participants receive BCG monotherapy (Induction and Maintenance).
11152437|NCT03711019|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
11152438|NCT03711019|Active Comparator|RUL-UB ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q
11152439|NCT03711019|Active Comparator|Bitemporal ECT|ECT treatments will be administered using the MECTA spECTrum 5000Q
11152440|NCT03711006|Experimental|FMT treated patients|Seven patients with active Ulcerative Colitis treated with 25 multi-donor FMT Capsules daily.
11152441|NCT03710980||Healthy Adult Volunteer|
11152442|NCT03710967|Experimental|Bilateral TMS|
11152443|NCT03710967|Active Comparator|Unilateral TMS|
11152444|NCT03710954|Experimental|Experimental Group|All the volunteers were evaluated through numerical evaluation of pain that assumes a subjective condition, the researcher showed the numerical scale of pain, being 0 without pain, 1 to 4 mild pain, 5 moderate pain, 6 to 9 severe pain and 10 worse pain possible pain, which was interpreted by the volunteer. In the Fuzzy Pain Scale, the evaluation of the range of motion was done where the evaluator used the goniometer (plastic instrument that verifies the angulation of the joint movement) and supplied the Fuzzy system with these data.
11152445|NCT03710941|Experimental|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
11152446|NCT03710941|Experimental|Placebo|Single, sequential, repeat-dose IV
11152447|NCT03710928|Experimental|very low carbohydrate diet|Dietary Intervention, food delivery
11152448|NCT03710928|Active Comparator|standard diet|Dietary Intervention, food delivery
11152449|NCT03710915|Experimental|HG146 capsule treat multiple myeloma|"Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).
~Intervention: Drug: HG146 capsule"
11152450|NCT03710902|Experimental|Intervention|
11152451|NCT03710902|No Intervention|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
11152452|NCT03710889|Experimental|Abaloparatide|Abaloparatide is provided in a pen for the subcutaneous delivery of 80 ug dose in 40 uL once daily for a 30 day supply.
11152453|NCT03710876|Active Comparator|Treatment Group|rAd-IFN (Study Day 1) + celecoxib oral product (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/early termination [ET]
11152454|NCT03710876|Placebo Comparator|Control Group|Celecoxib oral product (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 [i.e., Days 1 and 8 of the first gemcitabine treatment cycle], gemcitabine will be repeated every 3 weeks until disease progression/ET.
11152455|NCT03710863|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
11152456|NCT03710850|Experimental|Responders|Responders in terms of fecal butyrate production after acute inulin test.
11152457|NCT03710850|Experimental|Non-responders|Non-responders in terms of fecal butyrate production after acute inulin test.
11152458|NCT03710837|Experimental|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
11152459|NCT03710837|Experimental|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
11152460|NCT03710824||Subjects with Idiopathic Pulmonary Fibrosis|
11152461|NCT03710811||Type 2 Diabetes|drug naive Type 2 Diabetes received insulin therapy
11152462|NCT03710811||normal control|healthy volunteers as normal control
11152463|NCT03710798|Experimental|Low carbohydrate high fat diet|Low carbohydrate high fat (LCHF) diet
11152464|NCT03710785|Experimental|forward neck posture syndrome patients|Patients diagnosed with forward neck posture syndrome in cervical plain X-ray have a cervical spine extension exercise for 4 weeks
11152465|NCT03710772|Experimental|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.
~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours twice daily (BID) on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine IV over 15-30 minutes on day 5 of odd-numbered courses (1, 3, 5, and 7). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered courses (2, 4, 6, and 8). Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
11152466|NCT03710772|Experimental|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.
~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patience also receive maintenance therapy as in group I."
11152467|NCT03710772|Experimental|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
11152468|NCT03710759|Experimental|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
11152469|NCT03710746|Experimental|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
11152470|NCT03710746|Experimental|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
11152471|NCT03710746|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
11152472|NCT03710746|Experimental|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
11152473|NCT03710746|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
11152474|NCT03710746|Experimental|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
11152475|NCT03710733|Active Comparator|Sequential boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus sequential boost 10 Gy/4 fx (2.5 Gy/fx) to lumpectomy cavity
11152476|NCT03710733|Experimental|Concomitant boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus concomitant boost 8 Gy/15 fx (0.53 Gy/fx) to lumpectomy cavity
11152477|NCT03710720|Experimental|TF-CBT plus TIPS app|
11152478|NCT03710720|Active Comparator|TF-CBT|
11152479|NCT03710707|Experimental|DNL201 low dose|
11152480|NCT03710707|Experimental|DNL201 high dose|
11152481|NCT03710707|Placebo Comparator|Placebo|
11152482|NCT03710694|Experimental|DAV132 group|Patients randomized to the DAV132 arm will be administered DAV132 concomitantly with fluoroquinolones.
11152483|NCT03710694|No Intervention|No DAV132 group|Patients randomized to the No DAV132 arm will receive only fluoroquinolones, according to local standard of care.
11152484|NCT03710681|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
11152485|NCT03710681|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
11152486|NCT03710655|Experimental|treatment group|skin test, dose escalation, final dose of 1.5mg weekly over 16 weeks of Apitox pure honeybee toxin
11152487|NCT03710655|Placebo Comparator|placebo group|histamine placebo administered intradermally in dose escalation, final dose of 1.5mg weekly over 16 weeks
11152488|NCT03710642|Active Comparator|Treatment (Prazosin)|"Eligible participants will be randomized using a 2:1 schedule to prazosin or placebo and stratified by site and gender, and will follow a fixed titration scheme for the first 15 days, followed by a flexible does titration from days 15-29, then a maintenance phase stable dose from days 29 to the end of the 12 weeks study period.
~Prazosin Fixed titration dose schedule for Days 1 to 14 1 mg QHS for Days 1 to 3
~1 mg QAM and 1 mg QHS for days 4 to 7
~mg QAM and 2 mg QHS for days 8 to 10
~mg QAM and 2 mg QHS for days 11 to 14
~Prazosin Flexible titration dose schedule for Days 15 to 29. 3 mg QAM and 3 mg QHS on day 15, 4 mg QAM and 4 mg QHS on day 22, 4 mg QAH and 6 mg QHS on day 29,
~Dose increases will be allowed only during the fixed and flexible dosing periods."
11152489|NCT03710642|Placebo Comparator|Placebo oral capsule|Placebo medication will be administered in a titration schedule mimicking the active comparator treatment.
11152490|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
11152491|NCT03710603|Active Comparator|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
11152492|NCT03710603|Experimental|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
11152493|NCT03710590|Active Comparator|Cigarette smokers|
11152494|NCT03710590|Active Comparator|Electronic cigarette users|
11152495|NCT03710577|Experimental|Yoga|40 minutes of Vinyasa yoga
11152496|NCT03710577|Placebo Comparator|Quiet Rest|40 minutes of quiet rest
11152497|NCT03710564|Experimental|Masked Arm 1|Brolucizumab 6 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
11152498|NCT03710564|Active Comparator|Masked Arm 2|Aflibercept 2 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
11152499|NCT03710551|Experimental|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
11152500|NCT03710551|Active Comparator|Standard Infant Formula|Standard bovine milk-based infant formula.
11152501|NCT03710538|No Intervention|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
11152502|NCT03710538|Experimental|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
11604537|NCT00615238|Experimental|Diet plus continuous bouts|diet-plus-continuous bouts of vigorous aerobic exercise
11152503|NCT03710538|Experimental|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
11152504|NCT03710538|Experimental|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
11152505|NCT03710525|Experimental|Own-Price Elasticity|"The price of vegetables will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
11152506|NCT03710525|Experimental|Cross-Price Elasticity|"The price of vegetables will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
11152507|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
11152508|NCT03710512||Control|patients not receiving hydroset at osteotomy site
11152509|NCT03710499|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 8 consecutive weeks.
11152510|NCT03710486||Cohort 1: Vedolizumab|Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
11152511|NCT03710486||Cohort 2: Other Biologic|Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab [UC only]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.
11152512|NCT03710460|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
11152513|NCT03710460|Experimental|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
11152514|NCT03710460|Experimental|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
11152515|NCT03710447|Experimental|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
11152516|NCT03710447|Experimental|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
11152517|NCT03710447|Experimental|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
11152518|NCT03710447|Experimental|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
11152519|NCT03710434|Experimental|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
11152520|NCT03710434|Experimental|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
11152521|NCT03710434|Experimental|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
11152522|NCT03710434|Experimental|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
11152523|NCT03710434|Experimental|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
11152524|NCT03710434|Experimental|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
11152525|NCT03710434|Experimental|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional [14C] AZD4635 IV microtracer.
11152526|NCT03710434|Experimental|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
11152527|NCT03710421|Experimental|Treatment (leukapheresis, chemotherapy, CS-1 CAR T therapy)|Patients undergo leukapheresis over 2-4 hours. Beginning 3-4 weeks, patients receive cyclophosphamide IV on days -4 and/or -3 or fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients then undergo CS1-CAR T therapy over 10-15 minutes on day 0.
11152528|NCT03710408|Experimental|Subcutaneous hydration|
11152529|NCT03710408|Active Comparator|Intravenous hydration|
11152530|NCT03710395|Active Comparator|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
11152531|NCT03710395|Experimental|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.
11152532|NCT03710382|Experimental|Walking epidural|Parturients will receive a lower concentration of bupivacaine in their epidural infusion and will be encouraged to walk during labor.
11152533|NCT03710369|Sham Comparator|Normoxia|Exercise in room air (normoxia). Sildenafil
11152534|NCT03710369|Active Comparator|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
11152535|NCT03710356|Experimental|Danazol|Danazol
11152536|NCT03710343|Experimental|Metformin|Metformin oral tablet will be taken by mouth, once or twice a day for 16 weeks.
11152537|NCT03710343|Placebo Comparator|Placebo|The placebo oral tablet will be taken by mouth once or twice a day for 16 weeks.
11152538|NCT03710330|Placebo Comparator|normal saline|the patients receives 110 ml normal saline IV just before skin incision
11152672|NCT03709407|No Intervention|Control group|only lying down
11186900|NCT03474796|Experimental|Novice|
11152539|NCT03710330|Active Comparator|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
11152540|NCT03710330|Active Comparator|0.5 gm tranexamic acid|0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
11152541|NCT03710317|Active Comparator|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
11152542|NCT03710317|Experimental|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
11152543|NCT03710304|Active Comparator|oxytocin|20 IU oxytocin ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal(ranitidine) plus 110 ml saline iv
11152544|NCT03710304|Active Comparator|Tranexamic acid plus misoprostol|400 μg misoprostol (2 tablets of 200 μg) or two placebo tablets were given buccally after spinal anesthesia and few minutes before skin incision; then 1 gm TA will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision, plus 500 ml normal saline intravenous solution infusion over 15 min after delivery of the baby
11152545|NCT03710291|Experimental|TRC101|
11152546|NCT03710291|Placebo Comparator|Placebo|
11152547|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
11152548|NCT03710265|Experimental|SHR-1701|
11152549|NCT03710252|Experimental|Single|Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)
11152550|NCT03710239|Active Comparator|Dilapan-S|Synthetic osmotic dilator
11152551|NCT03710239|Active Comparator|Laminaria|Seaweed-based osmotic dilator
11152552|NCT03710226||cases|women with recurrent miscarriage (two or more consecutive miscarriages)
11152553|NCT03710226||controls|women without recurrent miscarriage and delivered at least once before
11152554|NCT03710213|No Intervention|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
11152555|NCT03710213|Experimental|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
11152556|NCT03710200|Active Comparator|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
11152557|NCT03710200|Experimental|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
11152558|NCT03710200|Experimental|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
11152559|NCT03710200|Experimental|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
11152560|NCT03710200|Experimental|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
11152561|NCT03710200|Experimental|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
11152562|NCT03710200|Experimental|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
11152563|NCT03710200|Experimental|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
11152564|NCT03710187|Experimental|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
11152565|NCT03710187|Active Comparator|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
11152566|NCT03710174|No Intervention|Control group|Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
11152567|NCT03710174|Experimental|LED group|The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
11152568|NCT03710174|Experimental|Occlusal splint group|They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
11152569|NCT03710174|Placebo Comparator|Placebo group|Subjects with bruxism. The same procedures as LED group, but the device will be turn off.
11152570|NCT03710161|Experimental|4000 IU Vitamin D|4000 IU Vitamin D taken daily for six months
11152571|NCT03710161|Active Comparator|800 IU Vitamin D|800 IU Vitamin D taken daily for six months
11152572|NCT03710122|Experimental|Vancomycin|
11152573|NCT03710122|Placebo Comparator|Placebo|
11152574|NCT03710109||Concussion|Individuals who have sustained a recent concussion
11152575|NCT03710109||Control Healthy Volunteers|No Intervention
11152576|NCT03710096|Experimental|Mac grath group|
11152577|NCT03710096|Active Comparator|Macintosh Group|
11152578|NCT03710083|Experimental|Study arm|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).
11152579|NCT03710070|Experimental|Intervention|In the presence of a significant coronary artery stenosis and randomization to the intervention group: Catheter-based permanent occlusion of the ipsilateral (to the culprit coronary lesion) IMA will be performed at the projected height of inferior vena cava confluence and right atrium using a dedicated occlusion device (Amplatzer vascular plug 4, CE0086).
11152580|NCT03710070|Sham Comparator|Sham-Control|In the presence of a significant coronary artery stenosis, and randomization to the sham-procedure: IMA will be selectively intubated using an appropriate catheter. Angiography of the IMA and the pericardiacophrenic branch will be performed.
11152581|NCT03710044|Experimental|Cyclosporine A treatment|Oral cyclosporine A treatment
11152582|NCT03710031||HSCT Survivors|PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
11152583|NCT03710018||A Patient who underwent open cavity BCS|Patients undergoing Open cavity Breast Conservative Surgery
11152584|NCT03710018||B Patient who underwent close cavity BCS|Patients undergoing Close cavity Breast Conservative Surgery
11152585|NCT03710018||C Patient who underwent oncoplasty|Patients undergoing oncoplasty for breast cancer
11152586|NCT03710005|Experimental|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
11152587|NCT03710005|Active Comparator|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
11152588|NCT03709992|Active Comparator|Trospium|Patients will receive 30 mg of Trospium chloride tablet twice daily
11152589|NCT03709992|Active Comparator|Tamsulosin|Patients will receive 0.4 mg of Tamsulosin tablet once daily
11152590|NCT03709979|Active Comparator|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
11152591|NCT03709979|Placebo Comparator|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
11152592|NCT03709966|Experimental|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
11152593|NCT03709966|Active Comparator|Routine|Physical activity promotion supported by a kinesiologist
11152594|NCT03709953|Experimental|apatinib|apatinib, 500 mg, po, QD; 28 days every cycle
11152595|NCT03709940|Experimental|Placebo, MPH|"Dose order: placebo, methylphenidate (MPH)
~Participants receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 and a clinically effective dose of short-acting MPH (20 mgs) on DAY 2."
11152596|NCT03709940|Experimental|MPH, Placebo|"Dose order: methylphenidate (MPH), placebo
~Participants receive a clinically effective dose of short-acting MPH (20 mgs) on DAY 1 and a placebo tablet (ascorbic acid 50 mgs) on DAY 2."
11152597|NCT03709927|Experimental|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
11152598|NCT03709927|Experimental|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
11152599|NCT03709927|Active Comparator|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
11152600|NCT03709927|Placebo Comparator|Placebo IV|IV 0.9% normal saline solution
11152601|NCT03709914|Experimental|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
11152602|NCT03709914|Experimental|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
11152603|NCT03709914|Experimental|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
11152604|NCT03709914|Experimental|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
11152605|NCT03709914|Experimental|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
11152606|NCT03709901|Experimental|Active Allograft|Injection of viable allograft
11152607|NCT03709901|Placebo Comparator|Placebo|Injection of saline
11152608|NCT03709901|No Intervention|Conservative Care|Continued conservative care treatment
11152609|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
11152610|NCT03709875|Experimental|TR Treatment|TR will be delivered by means of an advanced video-conferencing system, and patients will be provided with low-cost monitoring devices, able to collect data about the health status and QoL. All treatments from remote are based on scheduled videoconferences between the patient's home and the Clinical Units, and therapists can control and modify the exercises. A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech and cognitive exercises will be delivered from the two Research Institutes to the patient's home.
11152611|NCT03709875|Other|Conventional Treatment|"In this group patients will be treated with conventional physiotherapy and speech training, adjusted in reason of the clinical needs, as usually. Treatments for motor limbs activity will be focused on functional active-assistive and active exercises. Conventional paper and pencil training will be used to improve cognitive function."
11152612|NCT03709862||Syphilis|Patients with syphilis and detectable Treponema pallidum DNA in a routinely collected clinical sample
11152613|NCT03709849|Experimental|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
11152748|NCT03708939|Experimental|saccharin|
11152614|NCT03709849|Active Comparator|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
11152615|NCT03709823|Experimental|1.5 mg Cytisine, Commercial Schedule|1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
11152616|NCT03709823|Experimental|3.0 mg Cytisine, Commercial Schedule|3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
11152617|NCT03709823|Placebo Comparator|Placebo, Commercial Schedule|Placebo tablets using the commercial 25-day titration schedule + behavioral support
11152618|NCT03709823|Experimental|1.5 mg Cytisine, TID Schedule|1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
11152619|NCT03709823|Experimental|3.0 mg Cytisine, TID Schedule|3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
11152620|NCT03709823|Placebo Comparator|Placebo, TID Schedule|Placebo tablets for 25 days using a simplified TID schedule + behavioral support
11152621|NCT03709810|Experimental|Test Denture Adhesive|Test denture adhesive will be applied directly from the tubes using a continuous strip pattern to the upper and lower denture which will then be placed in mouth of the participants.
11152622|NCT03709810|Other|Control|Participants will not apply any denture adhesive in this treatment arm.
11152623|NCT03709797|Experimental|Experimental group|Experimental group will receive dry needling treatment.
11152624|NCT03709797|Sham Comparator|Control group|Control group will receive sham dry needling treatment.
11152625|NCT03709771||Patients receiving VEGF inhibitor, ICI, or combination|Assessments will be made before and after patients receive VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination ICI) treatment, or no treatment. Patients receiving the VEGF inhibitor, ICI, or combination as part of standard of care.
11152626|NCT03709758|Experimental|Venetoclax+Daunorubicin+Cytarabine|"Venetoclax administered orally on days 1 to 11 daily
~Daunorubicin administered intravenously on days 2-4
~Cytarabine administered on days 2-8 by continuous IV infusion"
11152627|NCT03709745|Active Comparator|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
11152628|NCT03709745|Active Comparator|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
11152629|NCT03709732||Spinal cord injury|Persons with a spinal cord injury. No intervention
11152630|NCT03709732||Caregivers spinal cord injury|Caregivers for persons with a spinal cord injury. No intervention
11152631|NCT03709732||Controls for patients|Control group for patient cohort. No intervention
11152632|NCT03709732||Controls for caregivers|Control group for caregivers cohort. No intervention
11152633|NCT03709719|Experimental|blinatumomab|
11152634|NCT03709706|Experimental|Arm A: letetresgene autoleucel monotherapy|In Arm A, participants will receive letetresgene autoleucel monotherapy, administered as a single IV infusion of 1 to 8 x10^9 transduced cells. Participants who subsequently progress by Week 25 will be offered pembrolizumab 200 milligrams once every three weeks.
11152635|NCT03709706|Experimental|Arm B: letetresgene autoleucel plus pembrolizumab|In Arm B, participants will receive a single IV infusion of letetresgene autoleucel on Day 1 followed by pembrolizumab 200 milligrams on Day 22 and thereafter once every three weeks.
11152636|NCT03709706|Experimental|Arm C: letetresgene autoleucel plus pembrolizumab|In Arm C, participants will receive a single IV infusion of letetresgene autoleucel on Day 1 followed by pembrolizumab 200 milligrams on Day 22 and thereafter once every three weeks.
11152637|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
11152638|NCT03709680|Experimental|Single Arm|Palbociclib in combination with temozolomide and irinotecan Palbociclib in combination with topotecan and cyclophosphamide
11152639|NCT03709667|Experimental|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
11152640|NCT03709667|Placebo Comparator|CON|The control condition is a health-education intervention.
11152641|NCT03709654|Experimental|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
11152642|NCT03709654|Placebo Comparator|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
11152643|NCT03709641|Experimental|Restylane Defyne receiver|Participants will receive Restyane Defyne injected into punctum of one eye.
11152644|NCT03709628|Experimental|Patients with active Crohn's disease|EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
11152645|NCT03709615|No Intervention|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
11152646|NCT03709615|Experimental|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
11152647|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
11152648|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
11152670|NCT03709407|Experimental|terminus|Vodder´s maneuver with medial and anterior traction in supraclavicular fossa
11152671|NCT03709407|Sham Comparator|placebo|maneuver with sliding ON clavicular
11152649|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
11152650|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
11152651|NCT03709589||Group-B|Patients with Modified Early Warning Score of < 5
11152652|NCT03709576|Experimental|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
11152653|NCT03709563|Active Comparator|Oral Nutraceutical Supplement|
11152654|NCT03709563|Placebo Comparator|Placebo|
11152655|NCT03709550|Experimental|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11152656|NCT03709537|Experimental|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
11152657|NCT03709537|No Intervention|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
11152658|NCT03709524|Active Comparator|insertion time|1 minute Airtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
11152659|NCT03709524|Active Comparator|intubation time|2 minutesAirtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
11152660|NCT03709511|No Intervention|Conventional Treatment Group|This arm will receive usual care. In accordance with current guidelines a cardiologist sees all patients 4 to 6 weeks after heart valve surgery. At the follow-up visit a clinical examination, biochemistry and echocardiography are performed. All patients are given general information on anticoagulation and endocarditis prophylaxis. During the trial period the patients will be seen by a physician at The Guangdong General Hospital, for the follow-up visit, after 1 and 12 months. All patients are instructed to initiate their usual activities of daily living. Patients in the control group have accepted not to receive local rehabilitation at the hospital or community setting in their written consent.
11152661|NCT03709511|Active Comparator|Cardiac Rehabilitation Group|Rehabilitation starts preoperatively with education and exercise management.After screening with cardiopulmonary exercise test,the participant will receive daily preoperative exercise rehabilitation till surgery.It lasts for 20 minutes per day, starting with a 40-60% anaerobic threshold and gradually advancing to 80%.Each patient was motivated to adhere to the basic protocol, but individual adjustments were allowed in case of slower progress. Physical exercise starts 1 month postoperative after the first cardiopulmonary exercise testing, and comprises the following three elements: individual planning of the physical exercise, a specially trained physiotherapist conduction, and integrating detailed information concerning medical treatment and diet.The exercise diary and the heart rate monitor recordings are essential in monitoring during the whole intervention.
11152662|NCT03709485|Experimental|prostate biopsy patients|a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.
11152663|NCT03709472|Experimental|Computer Assisted CIFFTA|CA CIFFTA (Computer Assisted Culturally Informed and Flexible Family Based Treatment for Adolescents) consists of a hybrid intervention utilizing office-based CIFFTA and technology-delivered material. Over 16 weeks CIFFTA participants receive 45 minutes of face-to-face sessions plus approximately 45 minutes of web-based intervention. During the continuing care phase participants access website resources and receive targeted messages (e.g., handling family conflicts). CA CIFFTA will: 1) deliver psycho-educational modules (e.g., depression, emotion regulation), 2) collect diary-card information, and 3) provide additional resources. During videos parents and adolescents can report symptoms and information that is automatically transmitted to therapists and used in the next session
11152664|NCT03709472|Active Comparator|Behavioral: Traditional face-to-face treatment-no technology|Participants randomized to Treatment-As-Usual (TAU) work over a 16-week period with their community agency. They may receive individual or family treatment. The team coordinates with the TAU agencies to minimize the overlap of data collected. The team will refer out to service locations that are most convenient for the participant. A great deal of thought has gone into the selection of the Treatment as Usual condition. The investigators wanted to compare CA CIFFTA's ability to retain and bring about change in participants with what is typically done in the community. Although running an in-house comparison condition gives more control of the delivery of services and tracking of clients, it is difficult to know how that compared to the services that are typically provided in the community
11152665|NCT03709446|Experimental|Leflunomide|Women with metastatic triple negative breast cancer. Leflunomide tablet orally daily
11152666|NCT03709433|Experimental|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
11152667|NCT03709420|Placebo Comparator|Placebo|Matching placebo capsule
11152668|NCT03709420|Experimental|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.
~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.
~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
11152669|NCT03709407|Experimental|cervical stimuli|Godoy´s maneuver with traction-sliding in supraclavicular fossa
11152673|NCT03709394|Active Comparator|Group A: Full utrasound guidance|Full utrasound guidance of cathether insertion. Intervention: Ultrasound portable device used for the identification of the target vein and for the ultrasound control of proper catheter placement during the procedure of peripheral venous cannula insertion.
11152674|NCT03709394|Active Comparator|Group B: Partial ultrasound guidance|Catheter insertion under partial ultrasound guidance. Intervention: Ultrasound portable device used only for the identification of the target vein, the catheter placement will be done by conventional approach.
11152675|NCT03709394|Active Comparator|Group C: No ultrasound guidance|Catheter insertion by conventional approach, without ultrasound guidance
11152676|NCT03709381|Experimental|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
11152677|NCT03709368|Experimental|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
11152678|NCT03709368|Experimental|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
11152679|NCT03709368|Active Comparator|Control|Hardware CLTS+PHAST Placebo
11152680|NCT03709355|Active Comparator|Elpida®|Single dose of Elpida® (capsule 20 mg)
11152681|NCT03709355|Experimental|Rifampin & Elpida®|Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose
11152682|NCT03709355|Experimental|Rifabutin & Elpida®|Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose
11152683|NCT03709355|Experimental|Clarithromycin & Elpida®|Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose
11152684|NCT03709355|Experimental|Omeprazole & Elpida®|Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose
11152685|NCT03709355|Experimental|Atorvastatin & Elpida®|Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose
11152686|NCT03709355|Experimental|Levonorgestrel+Ethinylestradiol & Elpida®|Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose
11152687|NCT03709342|Experimental|All Patients|
11152688|NCT03709329|Experimental|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
11152689|NCT03709329|Active Comparator|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
11152690|NCT03709316|Experimental|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
11152691|NCT03709316|Placebo Comparator|Placebo|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
11152692|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
11152693|NCT03709290||1st group|30 patients were diagnosed with MS according to revised MacDonald's criteria 2017 & collected from Neuropsychiatry department in Assuit university hospital
11152694|NCT03709290||2nd group|30 healthy volunteers subjects matched with age, sex & education level were recruited from outpatient clinic neuropsychiatry department and included only if they had no current or previous history of any neurological illness and their neurological examination was free
11152695|NCT03709277|Experimental|Pharmacist-Driven Intervention|The study group will receive a targeted, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
11152696|NCT03709277|No Intervention|Standard of Care|The Standard of Care Group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
11152697|NCT03709264|Experimental|Amino Acids infusion|
11152698|NCT03709264|Placebo Comparator|Placebo|
11152699|NCT03709251|Experimental|High Intensity Walking|HIW (70-80% Heart Rate max)
11152700|NCT03709251|Experimental|Casual Speed Walking|Self selected pace
11152701|NCT03709238||Alzheimers diseased patients|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
11152702|NCT03709238||Healthy participants|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
11152703|NCT03709225|Experimental|Music-based meditation|"The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:
~Introduction to music therapy and mindfulness
~Music-based meditation
~Using personal music to shift energy, mood, and support relaxation
~Mindfulness through active music making
~Discuss bringing mindfulness to daily activities"
11152704|NCT03709212||Individual semi-structured interview|"20 participants will undergo individual semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
~Participants will be recruited from three ethnic backgrounds; Black African/ Caribbean, South Asian and White Caucasian."
11152705|NCT03709212||Focus Group 1|10 participants female black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
11152706|NCT03709212||Focus Group 2|10 participants male Black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
11152707|NCT03709212||Focus Group 3|10 participants female South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
11152749|NCT03708939|Experimental|Stevia|
11152750|NCT03708939|Experimental|No supplement control|
11186901|NCT03474796|Experimental|Expert|
11152708|NCT03709212||Focus Group 4|10 participants male black South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
11152709|NCT03709212||Focus Group 5|10 participants female White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
11152710|NCT03709212||Focus Group 6|10 participants male White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
11152711|NCT03709173||Premanifest HDGEC participants|
11152712|NCT03709173||Early-manifest HDGEC participants|
11152713|NCT03709173||Companions of Premanifest HDGEC|
11152714|NCT03709173||Companions of Early-manifest|
11152715|NCT03709160|Experimental|BUMETANIDE|we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.
11152716|NCT03709160|Active Comparator|INDAPAMIDE|we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.
11152717|NCT03709147|Experimental|FAME arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles
~pemetrexed 500 mg/mq every three weeks
~pembrolizumab 200 mg flat dose every three weeks
~metformin hydrochloride up to a daily dosage of 1500 mg
~every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
11152718|NCT03709147|Experimental|MERCY arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles
~pemetrexed 500 mg/mq every three weeks
~pembrolizumab 200 mg flat dose every three weeks
~metformin hydrochloride up to a daily dosage of 1500 mg"
11152719|NCT03709147|No Intervention|BORN arm|Standard clinical approach.
11152720|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
11152721|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
11152722|NCT03709121|Placebo Comparator|Vehicle Ophthalmic Solution|
11152723|NCT03709108|Other|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
11152724|NCT03709108|Other|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
11152725|NCT03709095|Active Comparator|Moderate Intensity Continuous Training|Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
11152726|NCT03709095|Experimental|Sprint Interval Training|"The SIT protocol was adopted from Gillen and colleagues (See Ref), and consisted of 3 x 20 second all-out efforts at ≥ 100% of an individuals peak power output. Each sprint was interspersed by 120 seconds of active recovery at 10% of an individuals peak power output. Total training duration was 10 mins."
11152727|NCT03709082|Experimental|Phase 1: Palbociclib 75 mg|Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
11152728|NCT03709082|Experimental|Phase 1: Palbociclib 100 mg|Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
11152729|NCT03709082|Experimental|Phase 1: Palbociclib 125 mg|Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
11152730|NCT03709082|Experimental|Phase 2: RP2D|Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
11152731|NCT03709069|No Intervention|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.
~Wounds of patients will be managed by closed dressing to be changed on every third day."
11152732|NCT03709069|Experimental|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
11152733|NCT03709056|Experimental|HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg|
11152734|NCT03709056|Active Comparator|Propofol 2.0/1.0mg/kg group|
11152735|NCT03709043|Experimental|Kudzu|Standardized kudzu
11152736|NCT03709043|Placebo Comparator|Control|Placebo
11152737|NCT03709030|No Intervention|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
11152738|NCT03709030|Experimental|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
11152739|NCT03709004|Experimental|Pacifier|Mother given a pacifier during birth hospitalization, along with other baby items
11152740|NCT03709004|No Intervention|Control|Mother not given a pacifier, just the other baby items
11152741|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
11152742|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
11152743|NCT03708978||mammography group|women who receives mammography because of suspected breast lesion(s)
11152744|NCT03708965|Experimental|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.
~During the study, the dose of all subjects will be switched to the selected one."
11152745|NCT03708939|Experimental|glucose|
11152746|NCT03708939|Experimental|aspartame|
11152747|NCT03708939|Experimental|sucralose|
11152751|NCT03708926|Experimental|abaloparatide|abaloparatide 80 mcg subcutaneously once daily for 90 days
11152752|NCT03708926|Placebo Comparator|placebo|placebo formulated similarly but without active abaloparatide injected subcutaneously once daily for 90 days
11152753|NCT03708913|Experimental|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
11152754|NCT03708900|Experimental|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
11152755|NCT03708887|Experimental|Low dose group|Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.
11152756|NCT03708887|Experimental|High dose group|High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.
11152757|NCT03708887|Placebo Comparator|Control group|Control drug, matching placebo capsules, 1 gram per day for 1 year.
11152758|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
11152759|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
11152760|NCT03708861|Experimental|MVC + ATV/r|maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)
11152761|NCT03708848|Experimental|Tailored Therapy|Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.
11152762|NCT03708835|Experimental|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
11152763|NCT03708835|No Intervention|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
11152764|NCT03708822|Experimental|Docetaxel and Cisplatin and Nimotuzumab|
11152765|NCT03708809|Experimental|Immediate insertion|The intrauterine system will be inserted immediately after surgical termination of pregnancy, before awakening from anesthesia
11152766|NCT03708809|Experimental|Delayed insertion|The intrauterine system will be inserted on the first menstruation after termination of pregnancy. Women allocated to this arm will be asked to contact the study coordinator in order to visit the hospital on the proper timing for IUD insertion.
11152767|NCT03708809|Other|Control|Women who refuse to actively participate in the intervention groups will be offered consultation on other options for contraception during gynecological clinic visit after fist menstruation from termination of pregnancy.
11152768|NCT03708783|Experimental|No. 10 Lymph Node Dissection group|Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
11152769|NCT03708770|Other|endoAVF|
11152770|NCT03708757|Experimental|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles
~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
11152771|NCT03708757|Active Comparator|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.
~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
11152772|NCT03708744|Experimental|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
11152773|NCT03708744|Experimental|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
11152774|NCT03708744|Experimental|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
11152775|NCT03708744|Active Comparator|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
11152776|NCT03708731||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study.
11152777|NCT03708718|Active Comparator|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.
~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).
~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
11152778|NCT03708718|Placebo Comparator|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.
~From August 2020 - no placebo capsule will be administered."
11152779|NCT03708705||Relapse|Relapse of tumor within two years after liver transplantation
11152780|NCT03708705||Non-relapse|Non-relapse of tumor within two years after liver transplantation
11152781|NCT03708692||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
11152782|NCT03708692||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
11152783|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
11152784|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
11152785|NCT03708666|Other|Telemonitoring of blood pressure|Patients measure their blood pressure and register their results on the app or website.
11152786|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
11152787|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
11152788|NCT03708640|Placebo Comparator|Physical Activity Counseling|"Group receives baseline physical activity counseling.
~Group does not receive personalized, health coaching via smart text messages."
11152789|NCT03708640|Experimental|Digital Activity Tracker/Smart Text Messaging|"Group receives baseline physical activity counseling.
~Group receives personalized, health coaching via smart text messages informed by digital activity tracker."
11152790|NCT03708627|Experimental|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
11152791|NCT03708627|No Intervention|Control|Bimatoprost is not instilled in the patient's fellow eye
11152792|NCT03708614|Other|Controlled energy intake with elevated protein intake|Dietary intervention - Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks.
11152793|NCT03708588|Experimental|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
11152794|NCT03708588|Active Comparator|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL of water. (180mg)
11152795|NCT03708562|Other|endoAVF|
11152796|NCT03708549|Experimental|Berberine group|"Berberine 300mg（three times a day） plus Metformin simulant 250mg（three times a day）agent plus any atypical antipsychotic drug
~Metformin simulant were matched to metformin in shape, smell and colour were sealed in identical bottles"
11152797|NCT03708549|Active Comparator|Metformin group|"Metformin 250mg（three times a day） plus Berberine simulant 250mg（three times a day）agent plus any atypical antipsychotic drug
~Berberine simulant were matched to Berberine in shape, smell and colour were sealed in identical bottles"
11152798|NCT03708536|Experimental|bevacizumab plus s-1|
11152799|NCT03708536|Active Comparator|bevacizumab plus capecitabin|
11152800|NCT03708510|Experimental|Filtek Silorane-Er,Cr:YSGG Laser|
11152801|NCT03708510|Experimental|Filtek Silorane- Diamond Bur|
11152802|NCT03708510|Experimental|Kalore- Er,Cr:YSGG Laser|
11152803|NCT03708510|Experimental|Kalore- Diamond Bur|
11152804|NCT03708497|Active Comparator|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
11152805|NCT03708497|Experimental|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
11152806|NCT03708497|Active Comparator|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
11152807|NCT03708484|Active Comparator|Aerobic Interval Training|Aerobic Interval Training is active comparator
11152808|NCT03708484|Experimental|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
11152809|NCT03708471|Experimental|Two-stage hybrid abltaion|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will receive percutaneous catheter ablation and recommendations about cardiovascular risk control.
11152810|NCT03708471|Active Comparator|Thoracosopic surgical ablation|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will only receive recommendations about cardiovascular risk control.
11152811|NCT03708458|Active Comparator|Control group|Control group - patients receiving 100 mg indomethacin suppository immediately post ERCP
11152812|NCT03708458|Active Comparator|Group A|Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP
11152813|NCT03708458|Active Comparator|Group B|Group B - patients receiving indomethacin suppository 50 mg before and 50 mg after ERCP
11152814|NCT03708445|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
11152815|NCT03708432||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
11152816|NCT03708419|Experimental|Optimal diet|Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
11152817|NCT03708419|Experimental|Suboptimal diet|Participants will follow a diet for a total duration of 12 weeks, suboptimal for their metabolic phenotype. For participants with liver insulin resistance (LIR) this will be a diet high in monounsaturated fatty acids, for participants with muscle insulin resistance (MIR) this will be a diet high in protein and fiber and low in fat.
11152818|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
11152819|NCT03708406||Children with Cleft palate|Children with Cleft palate
11152820|NCT03708380|Experimental|Dietary intervention|Community-based dietary intervention to Black and African American barbers identified as having previously undiagnosed diabetes and prediabetes
11154497|NCT03697304|Experimental|Cohort 4 - Module C|
11152821|NCT03708367|Experimental|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
11152822|NCT03708367|Other|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
11152823|NCT03708354|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
11152824|NCT03708354|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
11152825|NCT03708341|Experimental|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
11152826|NCT03708341|Placebo Comparator|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
11152827|NCT03708328|Experimental|Dose Escalation Part A: Once Every 2 Weeks (Q2W)|RO7121661 will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.
11152828|NCT03708328|Experimental|Expansion Part B1: Metastatic Melanoma Cohort|This cohort will comprise participants with checkpoint inhibitor (CPI) experienced, second line and beyond metastatic melanoma. The starting dose of RO7121661 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
11152829|NCT03708328|Experimental|Expansion Part B2: NSCLC Cohort 1|This cohort will comprise participants with CPI and platinum experienced, second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
11152830|NCT03708328|Experimental|Expansion Part B3: NSCLC Cohort 2|This cohort will comprise participants with PD-L1 high, cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
11152831|NCT03708328|Experimental|Expansion Part B4: SCLC Cohort|This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of, progression on, or intolerance to, standard therapy. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
11152832|NCT03708328|Experimental|Expansion Part B5: ESCC Cohort|This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.
11152833|NCT03708315|Active Comparator|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
11152834|NCT03708315|Placebo Comparator|Order 2|Subjects will be given a sublingual film of placebo.
11152835|NCT03708302|Active Comparator|Study Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.2% ropivacaine.
11152836|NCT03708302|Sham Comparator|Control Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.9% saline.
11152837|NCT03708276|Experimental|My MS Toolkit|20 Participants asked to use My MS Toolkit.
11152838|NCT03708263|Active Comparator|532nm KTP Laser|Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.
11152839|NCT03708263|Experimental|585 nm yellow laser|PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.
11152840|NCT03708237|Placebo Comparator|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
11152841|NCT03708237|Experimental|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
11152842|NCT03708237|Experimental|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
11152843|NCT03708224|Experimental|Atezolizumab|All participants will receive atezolizumab over 15 days prior to definitive surgery. Following surgery, all patients will receive atezolizumab at a fixed dose of 1200 mg IV every 3 weeks. Patients will receive standard of care adjuvant radiation with or without concurrent, weekly cisplatin at 40 mg/m2 (as clinically indicated). All patients will then receive 12 cycles of adjuvant atezolizumab unless medically contraindicated.
11152844|NCT03708224|Experimental|Atezolizumab + Tocilizumab|All participants will receive atezolizumab over 15 days prior to definitive surgery. Following surgery, all patients will receive atezolizumab at a fixed dose of 1200 mg IV every 3 weeks. Patients enrolled in combination arms will receive atezolizumab combined with tocilizumab, or other immune-modulating agent(s) (TBA) at the recommended phase 2 dose (RP2D) of the drugs in combination during the surgical window. Patients will receive standard of care adjuvant radiation with or without concurrent, weekly cisplatin at 40 mg/m2 (as clinically indicated). All patients will then receive 12 cycles of adjuvant atezolizumab unless medically contraindicated
11152845|NCT03708211|Experimental|Part1: TAK-931 80 mg PIC + TAK-931 80 mg Tablet|TAK-931 80 milligram (mg), PIC, orally, once on Day 1 Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, tablet, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until progressive disease (PD), or unacceptable toxicity or any treatment discontinuation is determined.
11152846|NCT03708211|Experimental|Part1: TAK-931 80 mg Tablet + TAK-931 80 mg PIC|TAK-931 80 mg, tablet, orally, once on Day 1 of Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, PIC, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until PD, or unacceptable toxicity or any treatment discontinuation is determined.
11152847|NCT03708211|Experimental|Part 2: TAK-931 Fed + TAK-931 Fasted + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fed state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fasted state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
11152848|NCT03708211|Experimental|Part 2: TAK-931 Fasted + TAK-931 Fed + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fasted state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fed state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
11152849|NCT03708198|Other|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
11152850|NCT03708185|Experimental|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
11152851|NCT03708185|Experimental|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
11152852|NCT03708172|Active Comparator|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
11152853|NCT03708172|Sham Comparator|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
11152854|NCT03708159|Experimental|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
11152855|NCT03708159|Sham Comparator|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
11152856|NCT03708146|Experimental|Cohort 1 (BIA 5-1058 /50 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152857|NCT03708146|Experimental|Cohort 2 (BIA 5-1058 /25 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 25 mg (as 1 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152858|NCT03708146|Experimental|Cohort 3 (BIA 5-1058 /100 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152859|NCT03708146|Experimental|Cohort 4 (BIA 5-1058 /50 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo 12 active and 3 placebo)
11152860|NCT03708146|Experimental|Cohort 5 (BIA 5-1058 /150 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 150 mg (as 1 x 100 mg and 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152861|NCT03708146|Experimental|Cohort 6 (BIA 5-1058 /75 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 75 mg (as 3 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152862|NCT03708146|Experimental|Cohort 7 (BIA 5-1058 /200 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152863|NCT03708146|Experimental|Cohort 8 (BIA 5-1058 /100 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152864|NCT03708146|Experimental|Cohort 9 (BIA 5-1058 /400 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152865|NCT03708146|Experimental|Cohort 10 (BIA 5-1058 /200 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
11152866|NCT03708133|Experimental|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:
~Test treatment
~Reference treatment"
11152867|NCT03708133|Experimental|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:
~Reference treatment
~Test treatment"
11152868|NCT03708120|Experimental|Consumer Dose and Tick Repellency|Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
11152895|NCT03707925|Experimental|Diagnostic (bronchoscopic laser ablation, CBCT)|Patients undergo bronchoscopic laser ablation following standard bronchoscopy and endobronchial ultrasound. Patients also undergo CBCT before and after laser ablation. 48-72 hours after the procedure, patients undergo standard surgical resection of the lung tumor.
11152932|NCT03707652|Experimental|Cohort A (oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
11192989|NCT03433092||Jing Huang et. al, 2017|
11152869|NCT03708107|Experimental|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.
~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
11152870|NCT03708107|Experimental|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.
~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
11152871|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
11152872|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
11152873|NCT03708081||Group 1|Root canal treatments will be completed by ProTaper Next instruments with rotational motion
11152874|NCT03708081||Group 2|Root canal treatments will be completed TF Adaptive instruments with adaptive motion.
11152875|NCT03708068|Experimental|Early Exclusive Enteral Nutrition|"Feeds will start at least at 80% of reference daily fluid intake from day one of life.
~Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feed."
11152876|NCT03708068|No Intervention|Conventional Enteral Nutrition|"Infants will be fed as per current Neonatal Intensive Care Unit feeding tables:
~Infants with birth weight 1000-1500 g will be fed on 15-20 ml/kg human milk in day one. Feeds will be advanced by 15-20 ml/kg per day on second day onwards until infant reaches full enteral feeds.
~Infants with birth weight >1500 g will be started on 20-30 ml/kg per day on day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards until infant reaches full enteral feeds."
11152877|NCT03708055|Experimental|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
11152878|NCT03708042|Experimental|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day.
11152879|NCT03708042|Active Comparator|Neoadjuvant Radiochemotherapy|Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
11152880|NCT03708029|Experimental|Intervention Treatment|Will receive Revita allograft for wound treatment
11152881|NCT03708029|No Intervention|Control|Will receive current standard of care for wound treatment
11152882|NCT03708016|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
11152883|NCT03708016|Active Comparator|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
11152884|NCT03708003|Experimental|venetoclax + ibrutinib|Ibrutinib lead-in followed by venetoclax plus ibrutinib administered until cycle 31. The combination treatment will be continued as maintenance treatment or stopped depending on MRD-neg CR/CRi status.
11152885|NCT03707990|Experimental|NNC0165-1875|Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2).
11152886|NCT03707990|Placebo Comparator|Placebo|Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2).
11152887|NCT03707977|Experimental|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
11152888|NCT03707977|Experimental|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
11152889|NCT03707977|Experimental|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
11152890|NCT03707964|Placebo Comparator|Control|Subjects allocated to the control arm will receive standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles, as part of their regular teaching schedule.
11152891|NCT03707964|Experimental|Intervention|Subjects allocated to the intervention arm will receive education on crisis resource management (CRM) and teaching targeting the cognitive skills required to monitor and challenge a superior's decision, and conflict resolution tools, in addition to standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
11152892|NCT03707951|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
11152893|NCT03707951|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
11152894|NCT03707938|Experimental|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11152933|NCT03707652|Experimental|Cohort B (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
11152896|NCT03707912|Experimental|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.
~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
11152897|NCT03707912|Placebo Comparator|Placebo|Placebo using Anaferon regimen until the end of the study.
11152898|NCT03707899|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
11152899|NCT03707899|Active Comparator|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
11152900|NCT03707886|Experimental|Pain SMART (Intervention Arm)|The Intervention Arm will be invited to participate in a one-time group intervention, Pain SMART
11152901|NCT03707886|Placebo Comparator|Minimally Enhanced Usual Care|The Minimally Enhanced Usual Care group will receive educational information via mail.
11152902|NCT03707873|Experimental|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
11152903|NCT03707873|Experimental|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
11152904|NCT03707873|No Intervention|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
11152905|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
11152906|NCT03707847|Experimental|Crizotinib + etoposide capsule+Auto-HSCT|"Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.
~Crizotinib: 250mg, bis in die （BID）, PO.
~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.
~Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT."
11152907|NCT03707834|No Intervention|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
11152908|NCT03707834|Experimental|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
11152909|NCT03707821|Experimental|senofilcon A TEST Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
11152910|NCT03707821|Active Comparator|senofilcon A CONTROL Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
11152911|NCT03707795|Experimental|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
11152912|NCT03707795|Active Comparator|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
11152913|NCT03707782||Individuals with immune deficiencies|aged 18 years or older and have an immune deficiency
11152914|NCT03707782||Family members|aged 18 years or older and are related to a person who has an immune deficiency
11152915|NCT03707769|Experimental|Fistula treatment|Treatment of fistula with TIPS microspheres
11152916|NCT03707730|Experimental|AGY|capsule containing egg yolk with AGY
11152917|NCT03707730|Placebo Comparator|placebo|capsule containing plain egg yolk
11152918|NCT03707717|Experimental|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
11152919|NCT03707717|Experimental|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
11152920|NCT03707717|Experimental|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
11152921|NCT03707704||SCI patients in primary rehabilitation|
11152922|NCT03707691|Experimental|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
11152923|NCT03707691|Experimental|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
11152924|NCT03707691|Experimental|Control Participants|
11152925|NCT03707678|Experimental|Subjects receiving GSK2245035|Eligible subjects will be administered 20 nanograms (ng) of GSK2245035 nasal spray solution using a metered Valois VP7 pump (1 spray=10 ng per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol metered dose inhaler (MDI) will be given for symptom relief from screening to the end of the study.
11152926|NCT03707678|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.
11152927|NCT03707652|Experimental|Cohort A (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
11152928|NCT03707652|Experimental|Cohort A (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
11152929|NCT03707652|Experimental|Cohort A (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
11152930|NCT03707652|Experimental|Cohort A (oral supplement A)-1 or 4 capsules|Oral supplement A (1 or 4 capsules) administered daily for 3 days
11152931|NCT03707652|Experimental|Cohort A (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
11152934|NCT03707652|Experimental|Cohort B (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
11152935|NCT03707652|Experimental|Cohort B (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
11152936|NCT03707652|Experimental|Cohort B (oral supplement C)- 1 or 4 capsules|Oral supplement C (1 or 4 capsules) administered daily for 3 days
11152937|NCT03707652|Experimental|Cohort B (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
11152938|NCT03707652|Experimental|Cohort B(oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
11152939|NCT03707639|Experimental|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
11152940|NCT03707626||LAD with collaterals with and without wellens sign|
11152941|NCT03707613|Experimental|DWT learning curve|Initial cannulation is performed with a wire-guided sphincterotome by a trainee. If the cannulation proves difficult (cannulation time >10min, cannulation attemtps >5 or inadvertent PD cannulation >1) and PD is inadvertently entered, DWT will be performed by one of the two trainees. If DWT fails within 5min or 5 attempts, a trainer will take over and continue the cannulation. To prevent PEP, all patients receive prophylactic PD stent and post-ERCP rectal indomethacin. Aggressive hydartion will be administrated at the discretion of endoscopists.
11152942|NCT03707600|Sham Comparator|Sham|The sham coil setting is designed to mimic the auditory artifact and scalp sensations evoked by the real coil without stimulating the brain.
11152943|NCT03707600|Active Comparator|TMS|Active TMS
11152944|NCT03707587|Experimental|1200 mg intravenous (IV) of M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
11152945|NCT03707574||Ancillary-correlative (genetic analysis)|Patients undergo collection of blood and tumor prior to starting treatment and upon disease progression (second collection of blood and tumor only for patients who do not continue to progress and achieve either an OR or SD after 6 months of treatment). Samples are banked and analyzed via next generation sequencing.
11152946|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
11152947|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
11152948|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
11152949|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
11152950|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
11152951|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
11152952|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
11152953|NCT03707548|Experimental|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)
~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
11152954|NCT03707535|Experimental|CT-P13|
11152955|NCT03707535|Active Comparator|China-approved Remicade|
11152956|NCT03707522|Experimental|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
11152957|NCT03707522|Experimental|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
11152958|NCT03707522|Experimental|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
11152959|NCT03707522|Placebo Comparator|Control + Control|2 doses online daily activity scheduling interactive article (control)
11152960|NCT03707509|Experimental|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
11152961|NCT03707509|Active Comparator|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
11152962|NCT03707496||DeWinterCohort|Patients with de Winter syndrome pattern ECG
11152963|NCT03707483|Experimental|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
11152964|NCT03707483|Active Comparator|Comparator|using platelet rich fibrin alone
11152965|NCT03707470|Experimental|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
11152966|NCT03707470|Active Comparator|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
11152967|NCT03707470|Sham Comparator|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
11152968|NCT03707457|Experimental|Arm A: Nivolumab + anti-GITR|Patients receive nivolumab intravenously (IV) over 30 minutes and anti-GITR intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11152969|NCT03707457|Experimental|Arm B: Nivolumab + IDO1 inhibitor|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1 and IDO1 inhibitor daily by mouth. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11153025|NCT03707106|Active Comparator|PMR supported smoking cessation|an established CBT intervention for smoking cessation supported supported by specific stress reduction (Progressive Muscle Relaxation, Jacobson)
11153026|NCT03707093|Experimental|ADG106 Dose escalation|
11152970|NCT03707457|Experimental|Arm C: Nivolumab + Ipilimumab|Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab intravenously (IV) over 90 minutes on Day 1. Courses repeat every 21 days for up to 4 doses. After ipilimumab is discontinued, courses of nivolumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11152971|NCT03707444||Scrambler Therapy|All participants get the same device treatment with the Scrambler Therapy device, up to 10 treatments.
11152972|NCT03707431|Experimental|Web-based CBT (WebMAP)|Receives access to WebMAP
11152973|NCT03707431|Active Comparator|Pain Education (WebED)|Receives access to WebED
11152974|NCT03707418|Active Comparator|Bivalirudin Injection (Angiomax)|This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
11152975|NCT03707418|Active Comparator|Heparin Sodium|This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
11152976|NCT03707405|Active Comparator|ROC-sit|Ride-On Cars with Sitting Posture (ROC-sit) The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary. The natural play session can be divided into two 20-to-25 sessions depending on the participant's condition. Training will concentrate on building the concept of casual-effect on the switch and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person) in public spaces (e.g., hallways, convenient stores, garden, museum) and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying motor skills for mobility and socialization in natural play session. All the programs will be discussed by the family, the treating therapist and the research team.
11152977|NCT03707405|Active Comparator|ROC-sit45 and stand25|Ride-On Cars with 45-min Sitting and 25-min Standing Postures (ROC-sit45 and stand25) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 45-minute driving with sitting posture and then transfers to the standing posture for driving 25 minutes.
11152978|NCT03707405|Active Comparator|ROC-sit25 and stand45|Ride-On Cars with 25-min Sitting and 45-min Standing Postures (ROC-sit25 and stand45) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 25-minute driving with sitting posture and then transfers to the standing posture for driving 45 minutes.
11152979|NCT03707405|Active Comparator|ROC-stand|Ride-On Cars with Standing Postures (ROC-stand) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute standing session can be divided into two 30-minute sessions with 10-minute break, depending on the child's condition with the standing posture.
11152980|NCT03707392|Active Comparator|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
11152981|NCT03707392|Experimental|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
11152982|NCT03707379||common care group|diabetic patients under common care group
11152983|NCT03707366|Experimental|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
11152984|NCT03707366|No Intervention|Control group|Services as usual
11152985|NCT03707353|Experimental|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
11152986|NCT03707353|Experimental|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
11152987|NCT03707353|Experimental|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
11152988|NCT03707353|Experimental|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
11152989|NCT03707353|No Intervention|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
11152990|NCT03707353|No Intervention|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
11152991|NCT03707353|Experimental|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
11152992|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
11152993|NCT03707327|Experimental|Game Ready group|the participants performed cryotherapy by compression with Game Ready
11152994|NCT03707327|Experimental|Ice pack|the participants performed cryotherapy for ice pack
11152995|NCT03707314|Other|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
11152996|NCT03707314|Other|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
11152997|NCT03707301||Cancer patients performing sophrology sessions|Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
11152998|NCT03707288|Other|Spine exercise program|"The preclinical second year medical students will be prospectively randomized into two (2) groups, a control group (Group A) and an intervention group (Group B) that will be given a standardized spine exercise program. They will be asked to complete a Questionnaire B to evaluate changes in knowledge, attitude and practice towards musculoskeletal problem of the back and neck pain after intervention; the numeric rating scale (NRS), and the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) at eight (8) weeks.
~The standardized spine exercise program will be provided in a handout and given only to the intervention Group B subjects, these are basic low back exercises to be done three (3) times per week for 20mins, as well as a few very brief stretching exercises to be done during periods of sitting for greater than sixty (60) minutes."
11152999|NCT03707275|Experimental|Alexa+ Arm|
11153000|NCT03707275|Other|Standard of Care Arm|
11153064|NCT03706885|Active Comparator|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
11153001|NCT03707262|Experimental|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.
~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:
~5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)
~10 doses of TLI (120 centigray [cGY] x 10 fractions, starting the day after transplant)"
11153002|NCT03707249|Experimental|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
11153003|NCT03707249|Sham Comparator|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
11153004|NCT03707236|Experimental|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
11153005|NCT03707236|No Intervention|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
11153006|NCT03707223|Experimental|experimental|"The interfaces Program"
11153007|NCT03707223|Active Comparator|control group|supported employment using the individual placement and support (IPS) model
11153008|NCT03707210|Experimental|Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
11153009|NCT03707210|No Intervention|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
11153010|NCT03707197|Experimental|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
11153011|NCT03707197|No Intervention|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
11153012|NCT03707184|Experimental|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
11153013|NCT03707171|Active Comparator|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
11153014|NCT03707171|Placebo Comparator|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
11153015|NCT03707158|Active Comparator|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of three developmentally tailored programs, depending on the age of the child.
11153016|NCT03707158|Active Comparator|Face-to-Face CBT|The Cool Kids suite of face-to-face CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The office-based cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face=to-face suite of interventions is comprised of three developmentally tailored programs, depending on the age of the child.
11153017|NCT03707145|Active Comparator|Professional led with online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.
~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
11153018|NCT03707145|Active Comparator|Professional led without online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.
~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
11153019|NCT03707145|Experimental|Patient empowered with online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.
~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
11153020|NCT03707145|Active Comparator|Patient empowered without online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.
~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
11153021|NCT03707132||Tourniquet Group|'Tourniquet: Folley catheter in the low segment of the uterus
11153022|NCT03707132||Control Group|Standard hysterectomy is performed
11153023|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
11153024|NCT03707106|Experimental|VR based cue exposure smoking cessation|an established CBT intervention for smoking cessation supported by cue exposure in virtual reality
11154498|NCT03697304|Experimental|Cohort 5 - Module C|
11153027|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.
~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
11153028|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
11153029|NCT03707067|Experimental|Custom fitted compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
11153030|NCT03707067|Sham Comparator|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
11153031|NCT03707054|Experimental|Study Arm|Measurements of optic nerve diameter, Urine and plasma osmolality, Serum vasopressin.
11153032|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
11153033|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
11153034|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
11153035|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
11153036|NCT03707041|Experimental|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
11153037|NCT03707041|Active Comparator|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
11153038|NCT03707028|Experimental|Rivoceranib (apatinib) with Paclitaxel|Oral daily doses of rivoceranib (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on day 1, day 8, and day 15.
11153039|NCT03707002|Active Comparator|scFOS|scFOS consumed at 5g/day for 6 weeks
11153040|NCT03707002|Placebo Comparator|Placebo|maltodextrin consumed at 5g/day for 6 weeks
11153041|NCT03706989|Experimental|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to >75 years old.
11153042|NCT03706976|Experimental|CTOM|
11153043|NCT03706963|Experimental|Phone Call|"Patients will be provided with a Fitbit Charge HR & assistance to set up on smart phone
~Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery
~The group will receive a phone call 7 days into their preoperative period to identify barriers, provide available resources, & encourage continuation of prehabilitation activities
~The physician extender will talk with the patient to identify barriers to prehabilitation activities that the patient may have experienced during the first 7 days of activity tracking & provide recommendations & resources to overcome those barriers when possible. The physician extender will encourage the patient to continue prehabilitation activities until the day of operation to meet goals. Following surgery, we will analyze Fitbit data to determine if the intervention had an impact on the patient's prehabilitation activity with the non-intervened patient group used as a control"
11153044|NCT03706963|No Intervention|No Phone Call|"Eligible patients will be provided with a Fitbit Charge HR & assistance to set up on smart phone
~Preoperative baseline data (activity, sleep, heartrate) will be collected for at least 14 days until the day prior to surgery"
11153045|NCT03706950||Elpida® + 2 NRTIs|Elpida® 20mg qd in the first line of therapy for HIV-1 infected patients with a background standard ART.
11153046|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
11153047|NCT03706924|Experimental|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
11153048|NCT03706924|Active Comparator|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
11153049|NCT03706911|Experimental|VM-1500A-LAI 50mg|VM-1500A-LAI 50mg IM single dose
11153050|NCT03706911|Experimental|VM-1500A-LAI 150mg|VM-1500A-LAI 150mg IM single dose
11153051|NCT03706911|Experimental|VM-1500A-LAI 300mg|VM-1500A-LAI 300mg IM single dose
11153052|NCT03706911|Experimental|VM-1500A-LAI 600mg|VM-1500A-LAI 600mg IM single dose
11153053|NCT03706911|Experimental|VM-1500A-LAI 1200mg|VM-1500A-LAI 1200mg IM single dose
11153054|NCT03706911|Experimental|VM-1500A-LAI XXX5mg Multiple|VM-1500A-LAI selected dose IM, 2 injections monthly
11153055|NCT03706911|Experimental|VM-1500A-LAI XXX6mg Multiple|VM-1500A-LAI double selected dose IM, 2 injections monthly
11153056|NCT03706898|Experimental|Elpida® fasting|Elpida® 20 mg single dose fasting
11153057|NCT03706898|Experimental|Elpida® after meal|Elpida® 20 mg single dose after meals
11153058|NCT03706898|Experimental|Elpida® (in subjects with mild hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with mild hepatic impairment (Child - Pugh Class А)
11153059|NCT03706898|Experimental|Elpida® (in subjects with moderate hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with moderate hepatic impairment (Child - Pugh Class B)
11153060|NCT03706898|Experimental|Elpida® & sofosbuvir & daclatasvir|Drug-drug interactions of sofosbuvir 400 mg + daclatasvir 60 mg and Elpida® 20 mg, single dose fasting
11153061|NCT03706898|Experimental|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
11153062|NCT03706885|Placebo Comparator|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
11153063|NCT03706885|Active Comparator|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
11154499|NCT03697291|Experimental|PS wire|self-invented iECG wire
11153065|NCT03706872|Experimental|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care.
11153066|NCT03706872|No Intervention|Control Group|Provision of usual prenatal care
11153067|NCT03706859|Experimental|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=[SBP+10]/KTP)
11153068|NCT03706859|Active Comparator|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
11153069|NCT03706846|Other|Fasting 2 hours|Fasting 2 hours
11153070|NCT03706846|Other|Fasting 6 hours|Fasting 6 hours
11153071|NCT03706833|Experimental|Edwards PASCAL System - CLASP IID|Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation
11153072|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IID|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation
11153073|NCT03706833|Experimental|Edwards PASCAL System - CLASP IIF|Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation
11153074|NCT03706833|Active Comparator|Abbott Mitraclip System - CLASP IIF|Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation
11153075|NCT03706820||normal rest and exercise hemodynamics|
11153076|NCT03706820||normal rest and abnormal exercise hemodynamics|
11153077|NCT03706820||resting pulmonary hypertension|
11153078|NCT03706820||abnormal wedge pressure at exercise|
11153079|NCT03706807|Experimental|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
11153080|NCT03706807|Active Comparator|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
11153081|NCT03706807|No Intervention|Naïve|It's a waiting list group which will receive no intervention.
11153082|NCT03706794|Experimental|Clinical Decision Support Tool|Tailored education provided via a smartphone application
11153083|NCT03706794|Active Comparator|Headache Education|Non-tailored education provided via a smartphone application.
11153084|NCT03706781|Experimental|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
11153085|NCT03706781|Active Comparator|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
11153086|NCT03706768|Other|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
11153087|NCT03706755|Active Comparator|A|group A: will receive 1 mcg/Kg of Norepinephrine intravenously
11153088|NCT03706755|Active Comparator|B|group B: will receive 0.5 mcg/Kg of Norepinephrine intravenously
11153089|NCT03706742|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
11153090|NCT03706742|Active Comparator|Mailed outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
11153091|NCT03706729|Experimental|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
11153092|NCT03706716|Other|Intervention with use of decision aid in the consultation|With use of developed decision aid for pelvic organ prolapse / At the beginning of the consultation the IF will be opened within the patients electronic journal. The conversation will take its starting point from the generated IF which should define the area of interest rather for the patient.
11153093|NCT03706716|No Intervention|Control with no use of decision aid in the consultation|Without decision aid / The conversation during the consultation will follow the general standard for consultation conversations in the department.
11153368|NCT03704987|Active Comparator|Klinefelter|Male patients followed with the diagnosis of klinefelter
11153094|NCT03706703|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
11153095|NCT03706690|Experimental|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression)
11153096|NCT03706690|Placebo Comparator|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
11153097|NCT03706677|Active Comparator|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.
~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
11153098|NCT03706677|Active Comparator|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.
~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
11153099|NCT03706664|Other|Training of machine learning algorithm|113 MR Enterography images labelled by Radiologists will be used to develop a machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal.
11153100|NCT03706664|Other|Testing of machine learning algorithm|"113 MR Enterography images labelled by Radiologists will be used to test the accuracy of the machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal compared to Radiologists opinion.
~Cross Validation analysis will be used for data analysis."
11153101|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
11153102|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
11153103|NCT03706638|Other|Daily|Patients randomized to this arm will take ferrous sulfate 325 mg every day.
11153104|NCT03706638|Other|Intermittent (Every other day)|Patient's randomized to this arm will take ferrous sulfate 325 mg every other day.
11153105|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
11153106|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
11153107|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
11153108|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
11153109|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
11153110|NCT03706599|Experimental|Fever therapeutic education session|Therapeutic education session on fever
11153111|NCT03706599|Placebo Comparator|Control therapeutic education session|Control therapeutic education session (on household accidents)
11153112|NCT03706586|Active Comparator|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
11153113|NCT03706586|Experimental|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
11153114|NCT03706547|Experimental|anti-CD19/BCMA CAR-T cells|"Chemotherapy with a classic combination with fludarabine and cyclophosphamide;
~Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
11153115|NCT03706534|Active Comparator|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
11153116|NCT03706534|Experimental|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
11153117|NCT03706534|Experimental|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
11153118|NCT03706521|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
11153119|NCT03706495|Experimental|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
11153120|NCT03706495|Experimental|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
11153369|NCT03704987|Active Comparator|Control|healthy male subjects
11153121|NCT03706482|Experimental|Postnatal|Administration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
11153122|NCT03706482|Experimental|Prenatal|Administration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
11153123|NCT03706482|No Intervention|Prospective control (untreated)|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms.
11153124|NCT03706482|No Intervention|Historic control|Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018).
11153125|NCT03706469|Experimental|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
11153126|NCT03706469|Experimental|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
11153127|NCT03706469|Experimental|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
11153128|NCT03706469|Experimental|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
11153129|NCT03706456|Experimental|Darvadstrocel 24 mL|Darvadstrocel (Cx601) of cell suspension 24 milliliters (mL), intralesional injection, once dose on Day 1
11153130|NCT03706443|Active Comparator|Systane® Complete|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Complete, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
11153131|NCT03706443|Active Comparator|Systane® Ultra|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Ultra, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
11153132|NCT03706417|Experimental|Telemedicine|Babies that received telemedicine consult intervention.
11153133|NCT03706417|No Intervention|Historical control|Historical controls who have not received a telemedicine consult.
11153134|NCT03706404|Experimental|Point-of-care Testing and Ultrasound pathway|
11153135|NCT03706404|No Intervention|Classical pathway|
11153136|NCT03706391||ALS and PMA Reversals|
11153137|NCT03706378|Other|Glucose Reference 1|50g glucose dissolve in 250 ml of water
11153138|NCT03706378|Other|Glucose Reference 2|50g glucose dissolve in 250 ml of water
11153139|NCT03706378|Other|Glucose Reference 3|50g glucose dissolve in 250 ml of water
11153140|NCT03706378|Experimental|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
11153141|NCT03706378|Experimental|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
11153142|NCT03706378|Experimental|Rice Roll|Steamed 197.6g of rice roll
11153143|NCT03706378|Experimental|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
11153144|NCT03706378|Experimental|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
11153145|NCT03706378|Experimental|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
11153146|NCT03706365|Experimental|A1. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
11153147|NCT03706365|Experimental|A2. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
11153148|NCT03706365|Active Comparator|B1. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
11153149|NCT03706365|Active Comparator|B2. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
11153150|NCT03706365|Experimental|A. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
11153151|NCT03706365|Active Comparator|B. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
11153152|NCT03706352|Experimental|tunneling group|Epidural Catheter Insertion and fixation by subcutaneous tunneling procedure.
11153153|NCT03706352|Active Comparator|taping group|Epidural Catheter Insertion and fixation by use of adhesive tape without tunneling.
11153154|NCT03706339|Placebo Comparator|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
11153155|NCT03706339|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
11153156|NCT03706339|Experimental|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
11153157|NCT03706326|Experimental|Treatment with Anti-MUC1 CAR-T cells|Anti-MUC1 CAR-T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
11153158|NCT03706326|Experimental|Combination Therapy: CAR-T combining PD-1 knockout T Cells|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
11153159|NCT03706326|Experimental|Treatment with PD-1 knockout Engineered T cells|PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
11153160|NCT03706313|Active Comparator|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
11153161|NCT03706313|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.
~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
11153162|NCT03706300|Experimental|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
11153163|NCT03706300|Active Comparator|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
11153164|NCT03706287|Experimental|Anlotinib + AP/PC|
11153165|NCT03706274|Experimental|CX-188 Escalation|
11153166|NCT03706274|Experimental|CX-188 Alternative Dosing Schedule|
11153167|NCT03706261|Experimental|Offspring Cohort|Racially/ethnically diverse subjects with or without a positive family history of Alzheimer's disease (AD) will have one PET scan with 18F-MK-6240 over a 30 to 60-minute scanning period, and one PET scan with 18F-Florbetaben over a 20-minute scanning period.
11153168|NCT03706248||No recurrence|"CT scan has confirmed that subjects are without recurrence. Blood can be drawn up to 4 weeks after scan.
~Effective Feb 28, 2019, this group is closed to accrual as it has reached the goal."
11153169|NCT03706248||Recurrence|CT scan has confirmed that subjects are have recurrence of their colorectal cancer. Blood can be drawn prior to any treatment for the recurrent disease.
11153170|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
11153171|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
11153172|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
11153173|NCT03706209|Experimental|150 mg MP1032 bid|3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
11153174|NCT03706209|Experimental|300 mg MP1032 bid|6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
11153175|NCT03706209|Placebo Comparator|Placebo bid|6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
11153176|NCT03706196||high incidence crohn's disease area|subjects living in high incidence crohn's disease area coming in dentist for dental extraction linked to medical indication
11153177|NCT03706196||low incidence crohn's disease area|subjects living in low incidence crohn's disease area coming in dentist for dental extractionlinked to medical indication
11153178|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
11153179|NCT03706183||Control Group|The IMA levels will be determined.
11153180|NCT03706170|Experimental|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
11153181|NCT03706170|Experimental|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
11153182|NCT03706170|Experimental|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
11153183|NCT03706170|Experimental|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
11153184|NCT03706157|Active Comparator|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
11153185|NCT03706157|Active Comparator|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
11153186|NCT03706144|Experimental|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
11153187|NCT03706144|No Intervention|Control Group|Instruction as usual = TAU
11153188|NCT03706131|Experimental|experimental group|one session 15 minutes cervical mobilisation and home exercise
11153189|NCT03706131|No Intervention|control grup|no intervention
11153190|NCT03706118|Experimental|MRI and Neuropsychologic testing|"102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36.
~102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36."
11153191|NCT03706105|Experimental|Intervention - Cardiac Rehabilitation|
11153192|NCT03706092||Before|Elderly patients > = 70 in ICU without any intervention of the pharmacists and of the geriatricians
11153193|NCT03706092||After|Elderly patients > = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
11153194|NCT03706079|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
11153195|NCT03706079|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
11153196|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
11153197|NCT03706053|Placebo Comparator|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
11153198|NCT03706053|Experimental|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
11153199|NCT03706053|Experimental|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
11153200|NCT03706040|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for 16 weeks (Period A) followed by either DB risankizumab Dose 1 or DB risankizumab Dose 2 for 24 weeks (Period B).
11153201|NCT03706040|Experimental|Risankizumab Dose 1|Participants randomized to receive double-blind (DB) risankizumab Dose 1 for 16 weeks (Period A) followed by DB risankizumab Dose 1 for 24 weeks (Period B).
11153202|NCT03706040|Experimental|Risankizumab Dose 2|Participants randomized to receive double-blind (DB) risankizumab Dose 2 for 16 weeks (Period A) followed by DB risankizumab Dose 2 for 24 weeks (Period B).
11153203|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 3 fractions|
11153204|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 5 fractions|
11153205|NCT03706014|Experimental|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
11153206|NCT03706014|Placebo Comparator|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
11153207|NCT03706001|Experimental|Experimental Arm|Participants will receive psychotherapy for once a week.
11153208|NCT03706001|No Intervention|Control Arm|Participants will not receive any treatment for depression.
11153209|NCT03705988|Experimental|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA~2mA.
11153210|NCT03705988|Sham Comparator|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
11153211|NCT03705975|Active Comparator|edit arms|classical physiotherapy and manual treatment. Classical physiotherapy consisting of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Manual treatment is consist of scapular mobilization, glenohumeral joint inferior and posterior mobilization. Treatment modality is implemented by physical therapist three times a week for 8 weeks.
11153212|NCT03705975|Active Comparator|edit arm/intervention cross|classical physiotherapy and proprioceptive neuromusculer fasilitation. Classical physiotherapy consist of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Scapular PNF and upper extremity PNF (flexion-abduction-external rotation) pattern. Treatment programme was implemented by physical therapist three times a week for 8 weeks.
11153270|NCT03705598|Placebo Comparator|Light physical exercise|Normal walking, light intensity resistance exercise and stretching, and health education discussions.
11153213|NCT03705962|Experimental|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
11153214|NCT03705962|Placebo Comparator|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
11153215|NCT03705949|Active Comparator|Study group|Sodium Hyaluronate 0.1% drops
11153216|NCT03705949|Active Comparator|Control group|Sodium Hyaluronate 0.2% drops
11153217|NCT03705936|Sham Comparator|Sham 1Hz rTMS--5Hz rTMS|Participants will receive sham 1Hz rTMS, then immediately followed by 5Hz rTMS.
11153218|NCT03705936|Experimental|1Hz rTMS--5Hz rTMS|Participants will receive 1Hz rTMS, then immediately followed by 5Hz rTMS.
11153219|NCT03705936|Experimental|1Hz rTMS--30-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 30 minutes break, then followed by 5Hz rTMS.
11153220|NCT03705936|Experimental|1Hz rTMS--60-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 60 minutes break, then followed by 5Hz rTMS.
11153221|NCT03705936|Sham Comparator|Sham 5Hz rTMS--1Hz rTMS|Participants will receive sham 5Hz rTMS, then immediately followed by 1Hz rTMS.
11153222|NCT03705936|Experimental|5Hz rTMS--1Hz rTMS|Participants will receive 5Hz rTMS, then immediately followed by 1Hz rTMS.
11153223|NCT03705936|Experimental|5Hz rTMS--45-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 45 minutes break, then followed by 1Hz rTMS.
11153224|NCT03705936|Experimental|5Hz rTMS--90-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 90 minutes break, then followed by 1Hz rTMS.
11153225|NCT03705923|Experimental|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
11153226|NCT03705910|Active Comparator|Perceptive Rehabilitation (PR-group)|"This treatment will include small latex cones with different resistance. In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.
~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture."
11153227|NCT03705910|Active Comparator|Mobilisation Techniques (Mob-group)|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.
~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
11153228|NCT03705910|No Intervention|Control Group (C-group)|This group will not receive any intervention during this period. C-group will attend assessments.
11153229|NCT03705897|Other|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
11153230|NCT03705884|Other|Cardiac Sarcoidosis|Patients with an established diagnosis of cardiac sarcoidosis.
11153231|NCT03705884|Other|Healthy volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
11153232|NCT03705871|Experimental|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
11153233|NCT03705871|Active Comparator|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
11153234|NCT03705858|Experimental|Ac-lintuzumab|Subjects with AML will receive Ac-lintuzumab.
11153235|NCT03705845|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
11153236|NCT03705845|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
11153237|NCT03705832|Experimental|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
11153238|NCT03705832|Placebo Comparator|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
11153239|NCT03705819|Experimental|Healthy Volunteers|In Stage 1, five healthy volunteers will receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate [11C]-NOP46 biodistribution and derive dosimetry estimates.
11153240|NCT03705819|Experimental|Individuals with Focal Pain|In Stage 2, up to 30 subjects with focal pain will receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
11153241|NCT03705793|Experimental|Mometasone Furoate Nasal Irrigation|The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
11155860|NCT03687515|Active Comparator|budesonide aqueous nasal spray|
11153242|NCT03705793|Active Comparator|Mometasone Nasal Spray|The study intervention will be mometasone nasal spray (50 mcg/spray) and placebo nasal irrigation. The placebo will contain lactose monohydrate and will be supplied in capsules identical to the budesonide capsules. Participants will be required to dissolve the contents of the two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
11153243|NCT03705780|Other|the short OSAS scale|In preoperative interview，distributing the short OSAS screening scales to children's parents，and the scale was completed preoperative，calculate the score of the scale
11153244|NCT03705780|Experimental|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
11153245|NCT03705754|Active Comparator|Tattoo arm|Tattoo will be placed by endoscopic submucosal injection of carbon black suspension
11153246|NCT03705754|No Intervention|Control arm|Tattoo will not be placed but case will follow standard procedure
11153247|NCT03705741|Experimental|Exercise group|Resistance exercise twice a week
11153248|NCT03705741|No Intervention|Control group|
11153249|NCT03705728|Experimental|Intravenous group|"Propofol & remifentanil administration using the closed-loop controller with the Easy-TIVA platfrom."
11153250|NCT03705728|Active Comparator|volatile anesthesia group|Sevoflurane will be administered manually according to the BIS values. Remifentanil will be administered manually using a Target Controlled Infusion pump using the Minto model.
11153251|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28|PET with radiotracer [11C]PBR-28 will be performed. [11C]PBR-28 will be injected into subjects' veins during PET scanning.
11153252|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 and affective challenge|PET with radiotracer [11C]PBR-28 will be performed. [11C]PBR-28 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
11153253|NCT03705702|Active Comparator|Intervention Group (IG)|The intervention of active comparator will be education program plus behavioral intervention through physical activity counseling program combined with a monitoring-and-feedback tool.
11153254|NCT03705702|Sham Comparator|Control Group (CG)|The intervention of sham comparator will be an education program in asthma and physical activity recommendations.
11153255|NCT03705676|Active Comparator|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
11153256|NCT03705676|Experimental|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
11153257|NCT03705676|Active Comparator|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
11153258|NCT03705676|Experimental|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
11153259|NCT03705676|Active Comparator|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
11153260|NCT03705676|Experimental|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
11153261|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
11153262|NCT03705650|Experimental|Medicare Primary Care Provider (PCP) Patients|This is a non-randomized study of non-significant risk (NSR) that will be conducted at Northwestern's Central Dupage Hospital. Medicare patients > 65 years who are scheduled for a routine physical exam with their PCP that meet inclusion and exclusion criteria will be asked to participate in this study. Consenting patients will be scheduled for 2 back to back ultrasound scans including 5 standard 2D echocardiogram views each. The first scan will be performed by a non-ultrasound specialist using EchoGPS experimental guidance technology and the second control exam will be performed by a trained sonographer using a cleared conventional ultrasound platform.
11153263|NCT03705637|Experimental|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
11153264|NCT03705624|No Intervention|Standard of Care|Standard of care with passively monitored malaria incidence at health centers that receive appropriate diagnostic and clinical supplies and Seasonal Malaria Chemoprevention (SMC) for children less than 5 years of age
11153265|NCT03705624|Experimental|CCM|Standard of care supplemented with enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with artemether-lumefantrine (AL) according to national guidelines
11153266|NCT03705624|Experimental|CCM+MSAT|Standard of Care supplemented with CCM and Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
11153267|NCT03705611|No Intervention|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
11153268|NCT03705611|Experimental|HIV self-testing only|HIV self-testing only
11153269|NCT03705611|Experimental|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
11204704|NCT03351530||Pre-diabetes|
11153271|NCT03705598|Active Comparator|Tai Chi|Joint rotations and balance games, Tai Chi walking drills and the 8 forms.
11153272|NCT03705585|Experimental|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
11153273|NCT03705585|Experimental|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
11153274|NCT03705585|No Intervention|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
11153275|NCT03705572|Active Comparator|Dietary Supplement: Phospholipid drink.|Participant in an intervention parallel group consumed a drink with added phospholipids (Lacprodan PL20).
11153276|NCT03705572|Placebo Comparator|Dietary Supplement: Placebo milk drink.|Participant in an intervention parallel group consumed a drink without added phospholipids.
11153277|NCT03705559|Experimental|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
11153278|NCT03705559|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
11153279|NCT03705559|Experimental|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
11153280|NCT03705533|Other|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11153281|NCT03705533|Other|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
11153282|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
11153283|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
11153284|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
11153285|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
11153286|NCT03705494|Active Comparator|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
11153287|NCT03705494|No Intervention|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
11153288|NCT03705481|Other|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
11153289|NCT03705468||Ketamine sedation|Ketamine sedation
11153290|NCT03705468||Propofol sedation|Propofol sedation
11153291|NCT03705455|Active Comparator|ISAP SMS|ISAP SMS will be sent to enrolled caregivers
11153292|NCT03705455|No Intervention|No ISAP SMS|No ISAP SMS will be sent to enrolled caregivers
11153293|NCT03705442|Placebo Comparator|Placebo|Placebo
11153294|NCT03705442|Experimental|Probiotics|Omni-Biotic 10
11153295|NCT03705429|Active Comparator|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
11153296|NCT03705429|Placebo Comparator|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
11153297|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
11153329|NCT03705169|Experimental|Arm A, Cohort 1A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.
11153716|NCT03702816|Experimental|Control|"Control Group (N=10)
~GE180 PET Scan"
11153298|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
11153299|NCT03705403|Active Comparator|Control|Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
11153300|NCT03705403|Experimental|Experimental treatment|Standard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
11153301|NCT03705390|Experimental|ILB|ILB subcutaneous injection
11153302|NCT03705377||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360), family service staff (168)
11153303|NCT03705364|No Intervention|Wait List Control Group|Wait list control group
11153304|NCT03705364|Experimental|Fall Management program|Intervention arm
11153305|NCT03705351|Experimental|Treatment|Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.
11153306|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
11153307|NCT03705325|Experimental|Spirobank smart spirometer with VitalFlo mobile app|In this single arm study, all participants will be receive the spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app.
11153308|NCT03705312|Placebo Comparator|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
11153309|NCT03705312|Experimental|Transcatheter Mitral valve repair|MitraClip treatment
11153310|NCT03705299|Experimental|NeuMeDex NICVP (Non-Invasive CVP) vs Standard CVP|Three pressure readings recorded for both NeuMeDex NICVP and central line pressure catheter over a 10 minute period.
11153311|NCT03705286|Active Comparator|PVC-ETT|Polyvinylchloride endotracheal tube
11153312|NCT03705286|Experimental|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
11153313|NCT03705273|Experimental|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
11153314|NCT03705273|Active Comparator|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
11153315|NCT03705260|Active Comparator|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C > 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
11153316|NCT03705260|Active Comparator|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
11153317|NCT03705260|Experimental|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C > 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
11153318|NCT03705260|Experimental|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
11153319|NCT03705234|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
11153320|NCT03705234|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
11153321|NCT03705221|Experimental|Group programme|Healthy Parent Carers group programme: A group-based peer led manualised programme called Healthy Parent Carers. The programme content is organised into 12 modules, which can be delivered over six longer (4-hour) sessions or 12 shorter (2-hour) sessions.
11153322|NCT03705221|Active Comparator|Online resources|Healthy Parent Carers online resources: Online resources from the Healthy Parent Carers programme, including materials for 12 modules and related videos and audio files to illustrate the content.
11153323|NCT03705208|Experimental|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).
~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.
~The curriculum is imparted by school teachers are trained and certified by CorStone."
11153324|NCT03705208|No Intervention|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
11153325|NCT03705195|No Intervention|No Intervention|All participants in study will complete two matched clamp studies (OGTT + IGII). The first matched clamp without any intervention the second matched clamp with low dose gliclazide
11153326|NCT03705195|Experimental|Low Dose Gliclazide|"The first 8 participants will complete the dose-ranging phase of LOGIC study. Low dose gliclazide is being used a physiological stimulus. In the dose-ranging phase, 4 participants will receive 10mg gliclazide, the remaining 4 will receive 20mg gliclazide. The allocation to 10mg or 20mg will be randomised and unblinded. The study will analyse after the first 8 participants to assess which dose produces the greatest augmentation of insulin secretion when acting synergistically with the incretin effect.
~The further 12 participants will complete the study with the identified best dose."
11153327|NCT03705182|Experimental|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
11153328|NCT03705182|No Intervention|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
11153330|NCT03705169|Experimental|Arm A, Cohort 1B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
11153331|NCT03705169|Experimental|Arm A, Cohort 2A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
11153332|NCT03705169|Experimental|Arm A, Cohort 2B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
11153333|NCT03705169|Experimental|Arm A, Cohort 3A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
11153334|NCT03705169|Experimental|Arm A, Cohort 3B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
11153335|NCT03705169|Experimental|Arm A, Cohort 4A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
11153336|NCT03705169|Experimental|Arm A, Cohort 4B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
11153337|NCT03705169|Experimental|Arm B, Cohort 5: SAR441236|Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
11153338|NCT03705169|Experimental|Arm B, Cohort 6: SAR441236|Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
11153339|NCT03705169|Experimental|Arm B, Cohort 7: SAR441236|Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
11153340|NCT03705169|Experimental|Arm B, Cohort 8: SAR441236|Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
11153341|NCT03705169|Experimental|Arm B, Cohort 9: SAR441236|Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
11153342|NCT03705169|Experimental|Arm C, Cohort 10A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.
11153343|NCT03705169|Experimental|Arm C, Cohort 10B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.
11153344|NCT03705169|Experimental|Arm C, Cohort 11A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
11153345|NCT03705169|Experimental|Arm C, Cohort 11B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
11153346|NCT03705156|Experimental|ZL-2306|The starting dose is 300 mg or 200 mg based on patient's body weight.
11153347|NCT03705156|Placebo Comparator|Placebo|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
11153348|NCT03705143|Placebo Comparator|Treatment as Usual|Participants will receive no additional intervention besides the services they are currently receiving at the MMT clinic.
11153349|NCT03705143|Experimental|Chinese translated LETS ACT|In addition to services participants are currently receiving at the MMT clinic, individuals will attend six group-based one-hour behavioral activation treatment sessions.
11153350|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
11153351|NCT03705117|Experimental|V565|V565 orally three times daily for up to 7 days
11153352|NCT03705104|Experimental|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
11153353|NCT03705104|No Intervention|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
11153354|NCT03705091||Transplant|Incident patients receiving a kidney transplant for end stage kidney disease. Patients will undergo functional magnetic resonance imaging at 2 months, 6 months and 12 months following transplantation.
11153355|NCT03705078|Other|early TIPS|Transjugular portosytemic shunt within 72h
11153356|NCT03705078|Other|Glue obliteration|glue obliteration repeated sessions
11153357|NCT03705065|Experimental|Treatment Group 1|Bupivacaine HCI by instillation into each pectoral pocket.
11153358|NCT03705065|Experimental|Treatment Group 2|Bupivacaine HCI by injection into each pectoral pocket.
11153359|NCT03705052|Other|Intervention|Patients and caregivers were asked to complete a questionnaire
11153360|NCT03705039|Active Comparator|Treatment Group|pulsed ultrasound treatment
11153361|NCT03705039|Placebo Comparator|Control Group|sham ultrasound treatment
11153362|NCT03705013||Baseline Cologuard positive and negative colonoscopy|Those whose Cologuard T0 result was positive and colonoscopy result was negative.
11153363|NCT03705013||Baseline Cologuard positive and no colonoscopy|Those whose Cologuard T0 result was positive and subject declined to complete a colonoscopy per protocol.
11153364|NCT03705013||3-year follow-up Cologuard positive and negative colonoscopy|Those whose Cologuard result at T3 was positive and colonoscopy result at T3 was negative.
11153365|NCT03705013||3-year follow-up Cologuard positive and no colonoscopy|Those whose Cologuard result at T3 was positive and subject declined to complete a colonoscopy per protocol.
11153366|NCT03705000|Experimental|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
11153367|NCT03705000|Active Comparator|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
11204705|NCT03351530||Diabetes|
11153370|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
11153371|NCT03704961|Experimental|classical music|
11153372|NCT03704961|Experimental|Turkish music|
11153373|NCT03704961|Experimental|audiobook|
11153374|NCT03704948|Experimental|Listening Visits|Listening Visits delivered by a nurse.
11153375|NCT03704948|Active Comparator|Standard of Care (Social Work)|Standard mental health services provided by social workers.
11153376|NCT03704922|Experimental|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
11153377|NCT03704922|Experimental|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
11153378|NCT03704909|Active Comparator|Group Adrenaline: Group A|All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.
11153379|NCT03704909|Active Comparator|Group Ephedrine: Group E|All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E
11153380|NCT03704870|Active Comparator|Daily Chest Xray (standard)|
11153381|NCT03704870|Experimental|Chest Xray post chest tube removal only|
11153382|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
11153383|NCT03704857|Experimental|Foraminal enlargement with sodium hypochlorite and PDT|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, PDT, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
11153384|NCT03704857|Experimental|Foraminal enlargement with chlorhexidine as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, chlorhexidine as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
11153385|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with AH Plus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
11153386|NCT03704857|Active Comparator|Foraminal enlargement with conventional irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, conventional irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
11153387|NCT03704857|Experimental|Foraminal enlargement with passive ultrasonic irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, passive ultrasonic irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
11153388|NCT03704844||Patients with renal congestion|
11153389|NCT03704844||Patients without renal congestion|
11153390|NCT03704831||IPACK group|IPACK group
11153391|NCT03704831||Surgical infiltration group|Surgical infiltration group
11153392|NCT03704818|Experimental|Dapagliflozin 5mg|
11153393|NCT03704818|Experimental|Placebo|
11153394|NCT03704805|Experimental|Problem-Solving Therapy|Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.
11153395|NCT03704805|Active Comparator|Enhanced Standard of Care|Participants in the control group receive enhanced standard of care.
11153396|NCT03704792|Experimental|Adult CLD Group|Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.
11155861|NCT03687515|Active Comparator|oral steroids|
11153397|NCT03704779|Experimental|Multimodal Mindfulness Activity Program|Students assigned to the intervention will receive 8 weeks of the mindfulness activity intervention.
11153398|NCT03704779|No Intervention|Control Group|Students assigned to the control group will not receive any intervention.
11153399|NCT03704766|Experimental|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
11153400|NCT03704766|Active Comparator|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
11153401|NCT03704753|Active Comparator|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
11153402|NCT03704753|Placebo Comparator|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
11153403|NCT03704753|Active Comparator|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
11153404|NCT03704753|Active Comparator|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
11153405|NCT03704753|Active Comparator|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
11153406|NCT03704753|Placebo Comparator|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
11153407|NCT03704740|Experimental|NBP607-QIV|One or two doses of 0.5mL of NBP607-QIV by intramuscular injection
11153408|NCT03704740|Active Comparator|Agrippal|One or two doses of 0.25mL of Agrippal by intramuscular injection
11153409|NCT03704727|Experimental|probiotic treatment|Probiotic: VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus. Administred orally
11153410|NCT03704714|Experimental|Treatment (nivolumab and R-CHOP)|Participants receive nivolumab IV over 30 minutes on day 1. Participants also rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone PO on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11153411|NCT03704688|Experimental|Phase I: Dose Level -3|Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
11153412|NCT03704688|Experimental|Phase I: Dose Level -2|Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
11153413|NCT03704688|Experimental|Phase I: Dose Level -1|Trametinib 1.5 mg PO q daily 15mg PO q daily
11153414|NCT03704688|Experimental|Phase I: Dose Level 1|Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
11153415|NCT03704688|Experimental|Phase I: Dose Level 2|Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
11153416|NCT03704688|Experimental|Phase II|Maximum tolerated dose as established in Phase I portion
11153417|NCT03704675|Experimental|Group I (Fasted->Fed)|Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2
11153418|NCT03704675|Experimental|Group II(Fed->Fasted)|Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2
11153419|NCT03704662|Other|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (SBRT) five days a week for 1.5 weeks.
11153420|NCT03704662|Other|Preoperative Fractionated Radiation Therapy and Chemotherapy|Patients undergo Fractionated Radiation Therapy five days a week for 5.5 weeks, followed by a chemotherapy regimen.
11153421|NCT03704649|No Intervention|Standard nutrition education|The comparison group for the participatory video intervention.
11153422|NCT03704649|Experimental|Participatory nutrition education|Intervention arm integrates participatory video model to standard girls' club sessions to promote nutrition education.
11153423|NCT03704623|Active Comparator|Paracetamol|Patients will receive IV 1 g of Paracetamol
11153424|NCT03704623|Active Comparator|Parecoxib|Patients will receive 40 mg of Parecoxib IV
11153425|NCT03704610|Experimental|INFLIXIMAB|Infliximab 5 mg/kg D1-D15, then infliximab every 4 weeks W6-W10-W14
11153426|NCT03704610|Other|Placebo|placebo injection D1-D15 then infliximab 5 mg/kg W6-W8-W12-W16-W20
11153427|NCT03704597|Active Comparator|7-hour cryotherapy|Standard of care
11153428|NCT03704597|Experimental|2-hour cryotherapy|Experimental treatment
11153429|NCT03704584|Active Comparator|Treatment Group (corticosteroid injection plus lidocaine)|Treatment Group (corticosteroid injection plus lidocaine) subjects will receive (Methylprednisolone acetate injectable suspension and Lidocaine HCl) for their upper extremity condition for their upper extremity condition
11153430|NCT03704584|Other|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (Methylprednisolone acetate injectable suspension) for their upper extremity condition
11153431|NCT03704571|Experimental|Tailored Group|In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
11153432|NCT03704571|Active Comparator|Control Group|In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
11153433|NCT03704545|No Intervention|Control group|
11153434|NCT03704545|Experimental|Experimental group from the hospital|
11153435|NCT03704545|Experimental|Experimental group from the city|
11153436|NCT03704532||Operative treatment|Patients having undergone an operative treatment of achilles tendon rupture
11153437|NCT03704532||Nonoperative treatment|Patients having undergone a nonoperative treatment with functional rehabilitation of achilles tendon rupture
11153438|NCT03704519|Experimental|Men_EPD|Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
11153439|NCT03704519|Experimental|Men_DEP|Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
11153440|NCT03704519|Experimental|Men_PDE|Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
11153441|NCT03704519|Experimental|Men_DPE|Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
11153442|NCT03704519|Experimental|Men_EDP|Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
11153443|NCT03704519|Experimental|Men_PED|Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
11153444|NCT03704506|Experimental|treatment group 1|Reyanning mixture+amoxil capsule simulator
11153445|NCT03704506|Experimental|treatment group 2|Reyanning mixture +amoxil capsule
11153446|NCT03704506|Active Comparator|control group|Reyanning mixture simulator +amoxil capsule
11153447|NCT03704493|No Intervention|Image Group|The patients were looking at a static image of a lavender flower while exercising on the treadmill.
11153448|NCT03704493|Experimental|Video Group|The patients were watching a video of a group of amateur runners while exercising on the treadmill.
11153449|NCT03704480|Experimental|ARM A : Durvalumab plus tremelimumab|"One cycle equals 4 weeks (D1=D28);
~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.
~Tremelimumab: 75 mg by IV infusion on D1 for the first 4 cycles."
11153450|NCT03704480|Experimental|ARM B: Durvalumab plus tremelimumab plus paclitaxel|"One cycle equals 4 weeks (D1=D28); Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.
~Tremelimumab: 75 mg by IV infusion on D1 for the first 4 cycles. Paclitaxel: 80 mg/m2, every week for 3 weeks (D1-D8-D15), by IV infusion, until progression or unacceptable toxicity or withdrawal of consent (at least 6 cycles, at the discretion of the investigator)."
11153451|NCT03704467|Experimental|Part A: Carboplatin + M6620 + Avelumab|
11153452|NCT03704454|Experimental|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
11153453|NCT03704454|Experimental|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
11153454|NCT03704454|Experimental|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
11153455|NCT03704454|Experimental|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
11153456|NCT03704441|Other|bupivacaine 6mg|bupivacaine 6mg
11153457|NCT03704441|Other|bupivacaine 7mg|bupivacaine 7mg
11153458|NCT03704441|Other|bupivacaine 8mg|bupivacaine 8mg
11153459|NCT03704441|Other|bupivacaine 9mg|bupivacaine 9mg
11153460|NCT03704441|Other|bupivacaine 10mg|bupivacaine 10mg
11153461|NCT03704441|Other|bupivacaine 11mg|bupivacaine 11mg
11153462|NCT03704441|Other|bupivacaine 12mg|bupivacaine 12mg
11153463|NCT03704428|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
11153464|NCT03704428|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
11153465|NCT03704428|Experimental|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
11153466|NCT03704428|Experimental|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
11153467|NCT03704428|Experimental|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
11153468|NCT03704415|Active Comparator|Extended|Extended sinus surgery including all sinuses
11153469|NCT03704415|Active Comparator|Limited|Limited sinus surgery with partial ethmoidectomy
11153470|NCT03704402||alcohol policy group|High schools that introduced the policy
11153471|NCT03704402||control group|High schools that did not introduce the policy
11153472|NCT03704389|Experimental|Clinical decision support intervention|Participating clinicians will receive any of three clinical decision support nudges within the electronic health record when all eligibility criteria are met within a patient's chart.
11153473|NCT03704376|Active Comparator|Femoral Nerve Blockade|Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.
11153474|NCT03704376|Active Comparator|Adductor Canal Blockade|Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).
11153475|NCT03704363|Experimental|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
11153476|NCT03704363|Placebo Comparator|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
11153477|NCT03704350|Active Comparator|20-24.9 BMI|Participants with a BMI that falls between 20 and 24.9 who will receive the controlled diet
11153478|NCT03704350|Active Comparator|25-29.9 BMI|Participants with a BMI that falls between 25 and 29.9 who will receive the controlled diet
11153479|NCT03704350|Active Comparator|30-34.9 BMI|Participants with a BMI that falls between 30 and 34.9 who will receive the controlled diet
11153480|NCT03704350|Active Comparator|35-39.9 BMI|Participants with a BMI that falls between 35 and 39.9 who will receive the controlled diet
11153481|NCT03704350|Active Comparator|40-44.9 BMI|Participants with a BMI that falls between 40 and 44.9 who will receive the controlled diet
11153482|NCT03704350|Active Comparator|45-50 BMI|Participants with a BMI that falls between 45 and 50 who will receive the controlled diet.
11153483|NCT03704337|Experimental|Commercially Available Food Bar|62 g. Food Bar
11153484|NCT03704337|Placebo Comparator|Placebo|25 g. Dextrose
11155972|NCT03686735||Satisfaction measure 4|25% of the cohort
11153485|NCT03704311|Experimental|Single|Evaluation of mitochondrial function after muscle biopsy and follow-up for surgical complications.
11153486|NCT03704298|Experimental|Axicabtagene ciloleucel plus utomilumab|"Phase 1: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel treatment on Day 0 plus utomilumab on study Day 1 or study Day 21 and continuing once every 4 weeks (Q4W) for 6 months or until Progressive Disease, whichever comes first.
~Phase 2: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel and utomilumab based on the dose/regimen selected to move forward from the Phase 1 portion of the study as recommended by the internal Safety Review Team."
11153487|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
11153488|NCT03704272|No Intervention|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
11153489|NCT03704272|Experimental|Treatment|SunBrite
11153490|NCT03704246|Other|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
11153491|NCT03704233||Cryobiopsy|Transbronchial cryobiopsy is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
11153492|NCT03704220|Other|Single anti-thrombotic treatment|Single anti-thrombotic treatment
11153493|NCT03704207|Other|Nasal Nitric Oxide testing and collection of clinical data|Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
11153494|NCT03704194|Experimental|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
11153495|NCT03704194|Sham Comparator|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
11153496|NCT03704181|Experimental|colchicine|colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year
11153497|NCT03704181|Active Comparator|placebo|"placebo tablet by mouth every 12 hours, for 1 year
~pill manufactured to mimic coclchicine 0,5 mg tablet"
11153498|NCT03704168|Experimental|CRYOABLATION ARM|
11153499|NCT03704155|Experimental|Experimental group (EG)|The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
11153500|NCT03704155|Active Comparator|Control group (CG)|GC was treated with physiotherapy (stretching, balancing training, functional walking training).
11153501|NCT03704142|Experimental|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
11153502|NCT03704142|Experimental|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
11153503|NCT03704142|Experimental|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
11153504|NCT03704142|Experimental|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
11153505|NCT03704129|Experimental|"Tutor group"|"After a theoretical part through the administration of a video-tutorial, a 10-point questionnaire will be administered to evaluate the level of learning for each participant. Every single participant will pass the test if he/she correctly answer to >70% of the questions. Those passing the test, will be randomized to two groups.
~The interventional group will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself."
11153506|NCT03704129|No Intervention|"No tutor group"|This control group will directly perform the ultrasound examination of the diaphragm. The expert tutor will only show the learners how to use the various functions of the ultrasound, the linear and convex probes both in two-dimensional and in M-mode.
11153507|NCT03704116|Active Comparator|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
11153508|NCT03704116|Placebo Comparator|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
11153509|NCT03704103|Experimental|iSage for adjustment of insulin|The provider will prescribe the iSage app to the subject and choose a treatment algorithm within the app to make insulin dose adjustments.
11153510|NCT03704103|No Intervention|Conventional management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet.
11153511|NCT03704090|Active Comparator|Control|Standard non-pharmacological intervention during 5 days after surgery.
11153512|NCT03704090|Experimental|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
11153513|NCT03704077|Experimental|Cohort A: relatlimab + nivolumab + paclitaxel|
11153514|NCT03704077|Experimental|Cohort A: nivolumab + paclitaxel|
11153515|NCT03704077|Active Comparator|Cohort A: ramucirumab + paclitaxel|Standard-of-care
11153516|NCT03704077|Experimental|Cohort B: relatlimab + nivolumab|
11153517|NCT03704077|Active Comparator|Cohort B: nivolumab|Standard-of-care
11153518|NCT03704077|Experimental|Cohort C: relatlimab + nivolumab|
11153612|NCT03703466|Experimental|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
11153519|NCT03704064|Experimental|Stigma + BWL Intervention|Participants in this group will receive the standard behavioral weight loss (BWL) program, which will be combined with a stigma-reduction intervention (more details provided in the Intervention section). All group meetings will be 90 minutes. Beginning at week 5, the 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the monthly and every-other-month weight loss maintenance sessions from weeks 21-72, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically with physical activity.
11153520|NCT03704064|Active Comparator|Standard BWL Intervention|Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
11153521|NCT03704051|Experimental|Breast- versus Bottle-feeding|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
11153522|NCT03704038|Active Comparator|PEEP 5|
11153523|NCT03704038|Active Comparator|PEEP 0|
11153524|NCT03704038|Experimental|PEEP 10|
11153525|NCT03704025|Active Comparator|Current guidelines rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by diary.
11153526|NCT03704025|Experimental|Mobile device guided rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by virtual augmented reality glasses or by mobile device.
11153527|NCT03704012|No Intervention|Routine Care|Control Group receives routine care.
11153528|NCT03704012|Experimental|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
11153529|NCT03703999||type 1 diabetic patients freestyle Libre|group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria
11153530|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
11153531|NCT03703986||non-END group|The patients in this group had a slight increase of < 2 points or a decrease in NIHSS within 7 days of stroke onset.
11153532|NCT03703973||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.We also measure their preoperative leukocyte telomere length.
11153533|NCT03703973||control group|We enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
11153534|NCT03703960|Experimental|"Group 1 Hypnosis"|
11153535|NCT03703960|Active Comparator|"Group 2 music"|
11153536|NCT03703960|No Intervention|Control group|
11153537|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
11153538|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
11153539|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
11153540|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
11153541|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
11153542|NCT03703934||Healthy Controls|Patients without a painful condition
11153543|NCT03703908|Experimental|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
11153544|NCT03703895|Active Comparator|Active Comparator|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule. Subjects will complete up to 4 study visits where Topical AFX5931 will be applied twice daily for 28 days.
11153545|NCT03703895|Placebo Comparator|Placebo Comparator|Placebo Comparator, Topical Placebo. Subjects will complete up to 4 study visits where Topical Placebo will be applied twice daily for 28 days.
11153546|NCT03703882|Experimental|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
11153547|NCT03703882|Placebo Comparator|Placebo|Matching placebo
11153548|NCT03703869||Insulin glargine (U300)|Insulin glargine (U300) dosage and dosing time as per local product labeling
11153549|NCT03703856|Active Comparator|Memantine|
11153550|NCT03703856|Placebo Comparator|Placebo|
11153551|NCT03703843|Experimental|Active|ARTUS MONO
11153552|NCT03703830|Experimental|Experimental|Cerebellar transcranial current stimulation associated with locomotor training
11153553|NCT03703830|Sham Comparator|Sham comparator|Cerebellar transcranial current stimulation sham associated with locomotor training
11153554|NCT03703817||tofacitinib citrate users|patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
11153555|NCT03703817||adalimumab users|patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
11153556|NCT03703804||Women postpartum|Women -over 18 years, ability to understand Swedish in spoken and written terms, gave birth to a child approximately 3 months ago via vaginal delivery or cesarean section will be included. Exclusion criteria will be chronic pain in the pelvis or back (defined as pain in pelvic or back in more than 3 months before pregnancy), major rupture of the pelvic floor at delivery e.g. sphincter rupture grade III/IV or other diseases or surgery that prevents examination of the pelvic floor or abdominal muscles.
11153557|NCT03703791|Active Comparator|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
11153558|NCT03703791|No Intervention|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
11153559|NCT03703778||bilateral orchidectomy|Patients with advanced prostate cancer who receive surgical androgen deprivation therapy - bilateral orchidectomy
11153560|NCT03703778||GnRH agonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH agonist
11153561|NCT03703778||GnRH antagonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH antagonist
11153562|NCT03703765|Experimental|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.
~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
11153563|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
11153564|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
11153565|NCT03703739|Active Comparator|Reference meal 1|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
11153566|NCT03703739|Active Comparator|Reference 2|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with bean sauce.
11153567|NCT03703739|Experimental|Test meal A|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice cofortified with zinc oxide and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
11153568|NCT03703739|Experimental|Test meal B|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
11153569|NCT03703739|Experimental|Test meal C|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
11153570|NCT03703739|Experimental|Test meal D|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfafe and sodium pyrophosphate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
11153571|NCT03703739|Experimental|Test meal E|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with bean Sauce.
11153572|NCT03703726|Active Comparator|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
11153573|NCT03703726|Experimental|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
11153574|NCT03703726|Active Comparator|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
11153575|NCT03703726|Experimental|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
11153576|NCT03703726|Experimental|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
11153577|NCT03703726|Active Comparator|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
11153578|NCT03703726|Active Comparator|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
11153579|NCT03703713||Hyponatremia|Patients treated for hyponatremia (<125 mmol/L Sodium) in the intensive care department.
11153580|NCT03703700|Experimental|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
11153581|NCT03703700|Placebo Comparator|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
11153613|NCT03703466|Experimental|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
11153614|NCT03703453|Experimental|REBOA|Patients undergoing REBOA for medical cardiac arrest
11153655|NCT03703206|No Intervention|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
11153582|NCT03703687|Experimental|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
11153583|NCT03703674|Active Comparator|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
11153584|NCT03703674|Experimental|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
11153585|NCT03703661|Other|Control|primary closure with gauze and adhesive/occlusive dressing
11153586|NCT03703661|Experimental|Negative Pressure|primary closure with gauze and adhesive/occlusive dressing under negative pressure
11153587|NCT03703635|Experimental|Intracranial Angioplasty|Intracranial balloon angioplasty and aggressive medical care.
11153588|NCT03703635|No Intervention|Aggressive Medical Care|Aggressive medical care alone.
11153589|NCT03703622|Experimental|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
11153590|NCT03703622|Active Comparator|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
11153591|NCT03703609|Experimental|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
11153592|NCT03703609|No Intervention|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
11153593|NCT03703596|Experimental|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
11153594|NCT03703596|Experimental|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
11153595|NCT03703583||Exclusively/predominantly Breastfeeding group|
11153596|NCT03703583||Exclusively/predominantly Formula feeding group|
11153597|NCT03703570|Experimental|KW-6356 Low Dose|Oral administration
11153598|NCT03703570|Experimental|KW-6356 High Dose|Oral administration
11153599|NCT03703570|Placebo Comparator|placebo|Oral administration
11153600|NCT03703557|Experimental|Sorbstar®|Odour sampling: Rub hands with Sorbstar® before and post-surgery
11153601|NCT03703557|Experimental|Dog detection|Odour sampling: Sleep over a night with a compress on the affected breast before and after surgery
11153602|NCT03703544|Experimental|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
11153603|NCT03703544|Experimental|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
11153604|NCT03703531||Patients resuscitated in Istria county|Cardiopulmonary resuscitation performed for OHCA
11153605|NCT03703518|Experimental|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
11153606|NCT03703518|Active Comparator|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
11153607|NCT03703505|Experimental|AG-348|On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) [13C6]AG-348, 1 hour post-oral dose.
11153608|NCT03703492|Experimental|Research Arm|Directed breast PET/MRI with 18F-FES; 18F-FES uptake of the known malignancy to be measured on the PET/MRI examination
11153609|NCT03703479|Experimental|A-PRF group|Socket site that will receive A-PRF clot
11153610|NCT03703479|No Intervention|control|socket site that will not receive any intervention
11153611|NCT03703466|Experimental|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
11153615|NCT03703440|Experimental|Active|≥3 group education sessions (60 minutes per session) in addition to usual diabetes care, every 3 months for 12 months. Each group session (3-8 patients per group) will be facilitated by a diabetes nurse educator and/or dietitian. The group session content will be guided by the needs of the group participants. The group discussion will end with participants setting goals for their next appointment.
11153616|NCT03703440|Other|Control|Usual diabetes care, every 3 months for 12 months, which consists of visits with their diabetes care physician. In addition, as per usual diabetes care, an individual education session and written information will be provided before formal transfer.
11153617|NCT03703427|Experimental|Capecitabine|
11153618|NCT03703427|Experimental|Vinorelbine|
11153619|NCT03703414||Control|Healthy controls
11153620|NCT03703414||ECT|MDD patients receiving ECT treatment
11153621|NCT03703414||SSRI|MDD patients receiving SSRI treatment
11153622|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
11153623|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
11153624|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
11153625|NCT03703388|Experimental|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
11153626|NCT03703388|Experimental|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
11153627|NCT03703388|Experimental|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
11153628|NCT03703375|Experimental|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
11153629|NCT03703375|Active Comparator|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
11153630|NCT03703375|Active Comparator|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
11153631|NCT03703362|Experimental|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
11153632|NCT03703349|Experimental|Preoperative oral Magnesium|Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
11153633|NCT03703349|Placebo Comparator|Control|Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention
11153634|NCT03703336|Experimental|Study arm|ROTAVIN (liquid formulation) New formulation by POLYVAC. ROTAVIN is live attenuated human rotavirus G1P[8] strain at dose of 2 ml containing ≥ 2x 10^6 plaque focus units (PFU)
11153635|NCT03703336|Active Comparator|Control arm|ROTAVIN - M1 (frozen formulation) This vaccine produced by POLYVAC, licensed in 2012 in Vietnam. ROTAVIN-M1 is live attenuated human rotavirus G1P[8] strain at dose of 2 ml containing ≥ 2x 10^6 plaque focus units (PFU)
11153636|NCT03703323|Experimental|Rotative thromboelastometry analysis|Evaluation of diagnostic properties of coagulation by rotative thromboelastometry in patient with digestive hemorrhage in predictive value of mortality.
11153637|NCT03703310|Experimental|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
11153638|NCT03703310|Placebo Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
11153639|NCT03703297|Experimental|Durvalumab + Placebo|Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
11153640|NCT03703297|Experimental|Durvalumab + Tremelimumab|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
11153641|NCT03703297|Placebo Comparator|Placebo + Placebo|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
11153642|NCT03703284||LHI Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
11153643|NCT03703284||LHI Non-Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
11153644|NCT03703284||Healthy control|Healthy individuals
11153645|NCT03703271|Active Comparator|chemotherapy|Methotrexate 0.4mg/kg·d, im ,*5d started at the first day of cycle, two weeks a cycle
11153646|NCT03703271|Experimental|study group|hysteroscopic repeat curettage
11153647|NCT03703258|Experimental|Intervention|
11153648|NCT03703258|No Intervention|Assessment-only control|
11153649|NCT03703245||Experimental Dentifrice|Participants were advised to brush their teeth twice daily with a full strip of experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies covering the entire head of the toothbrush for 1 minute.
11153650|NCT03703245||Control Dentifrice|Participants were advised to brush their teeth with control dentifrice containing 0% w/w sodium bicarbonate covering the entire head of the toothbrush for 1 minute.
11153651|NCT03703232|Other|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
11153652|NCT03703219||Mother Touch Program|Forty days of rest period of the mother after delivery, Full body massage, diet and belly binding methods were administered by trained carer.
11153653|NCT03703219||Usual care Program|comparison cohort were followed in usual care under the supervision of health professionals.
11153654|NCT03703206|Experimental|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
11153656|NCT03703193|Experimental|Dry needling|The experimental group will receive a single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
11153657|NCT03703193|Active Comparator|Physical Therapy|This group will receive a single session of modulatory interventions targeting modulation of central nervous system.
11153658|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
11153659|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
11153660|NCT03703167|Experimental|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
11153661|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
11153662|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
11153663|NCT03703141|Experimental|Sucralose 48 mg|Sucralose 48 mg in 60 ml of water O.D. for ten weeks
11153664|NCT03703141|Experimental|Sucralose 96 mg|sucralose 96 mg in 60 ml of water O.D. for ten weeks
11153665|NCT03703141|Placebo Comparator|Placebo|60 ml of water as placebo O.D. for ten weeks
11153666|NCT03703128||Informants of suicide victims|Partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who received a definitive verdict of suicide in the Dutch-speaking part of Belgium (Flanders). The suicide should have taken place more than 3 months ago and less than 5 years ago.
11153667|NCT03703128||Control group|Informants i.e., partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who have mental health problems.
11153668|NCT03703115|Active Comparator|Fasting|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day."
11153669|NCT03703115|No Intervention|Nonfasting|Patients will have usual balanced diet as 3 meals and 2 snacks all over the day. Both groups should take adequate water and non calorie beverages intake daily ( 2-3 liters daily)
11153670|NCT03703102|Placebo Comparator|Arm A|Subcutaneous administration of placebo
11153671|NCT03703102|Experimental|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
11153672|NCT03703102|Experimental|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
11153673|NCT03703102|Experimental|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
11153674|NCT03703102|Experimental|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
11153675|NCT03703089|Experimental|Gemcitabine and Nab-Paclitaxel|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
11153676|NCT03703063|Experimental|Resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
11153677|NCT03703063|Experimental|Borderline resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
11153678|NCT03703050|Experimental|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
11153679|NCT03703050|Experimental|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
11153680|NCT03703037||Cohort|"This will be a nested case-control study. Women with low risk pregnancies at or beyond 41 weeks, who will be referred to our Maternal-fetal unit and admitted 1 to 2 days prior to induction of labour according institutional protocol will constitute the cohort.
~Then women with intrapartum abnormal fetal heart rate tracings (cases) will be identified and match with controls. The primary outcome will be to obtain odds ratios for the Doppler ultrasound parameters (middle cerebral artery pulsatility index, mean uterine artery pulsatility index and Middle cerebral artery pulsatility index to mean uterine artery pulsatility index ratio) and Ultrasound assessment of amniotic fluid index that would be associated with intrapartum category III fetal heart rate tracing."
11153681|NCT03703037||Cases|"Cases will be patients with abnormal intrapartum cardiotocogram (category III fetal heart rate tracing).
~Intervention: Ultrasound and Doppler ultrasound"
11153682|NCT03703037||Controls|"Those will be patients with normal intrapartum cardiotocogram (category I fetal heart rate tracing) or category II that converted into category I after intrauterine resuscitation methods.
~Intervention: Ultrasound and Doppler ultrasound"
11153683|NCT03703024|Placebo Comparator|Placebo|Maltodextrin
11153684|NCT03703024|Active Comparator|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
11153685|NCT03703024|Active Comparator|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
11153686|NCT03703011|Experimental|Interventional|Subjects aged >70 years, hospitalized in the rehabilitation geriatric ward in the Paul Brousse hospital, France, able to walk 10 meters, ready to be discharged, and a Mini mental state examination ≥ 20/30
11153687|NCT03702998||HIV-infected individuals +/- HBV/ HCV|"1 All HIV-infected individuals followed up in all public HIV clinics with and without HBV and/or HCV co-infection will be included in the analysis.
~1.1 Inclusion criteria for HIV-infected individuals with and without HBV or HCV co-infection: 1.1.1 Positive HIV antibody 1.1.2 At least one visit in one of the HIV clinics 1.1.3 Subjects with positive HBsAg and/or anti-HBc will be regarded as having HBV co-infection 1.1.4 Subjects with positive HCV antibody will be regarded as having HCV co-infection"
11153688|NCT03702998||HBV/HCV mono-infected individuals|"2 All HBV and/or HCV-infected individuals followed up in public hospitals will be identified from the Hospital Authority electronic database.
~2.1 Inclusion criteria for HBV/HCV mono-infected individuals 2.1.1 Documented diagnosis of hepatitis B or hepatitis C infection, or 2.1.2 Positive HBsAg and/or anti-HBc, or 2.1.3 Positive HCV antibody, and 2.1.4 Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription"
11153689|NCT03702985|Active Comparator|Capecitabine and Irinotecan without Amifostine|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
11153690|NCT03702985|Experimental|Capecitabine and Irinotecan with Amifostine|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) Amifostine: 400mg/m2 per week
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
11153691|NCT03702959||Betamethasone group 1|Betamethasone Group 1 (5am-11am)
11153692|NCT03702959||Betamethasone Group 2|Betamethasone Group 2 (11am-5pm)
11153693|NCT03702959||Betamethasone Group 3|Betamethasone Group 3 (5pm-11pm)
11153694|NCT03702959||Betamethasone Group 4|Betamethasone Group 4 (11pm-5am).
11153695|NCT03702946|Experimental|study group|
11153696|NCT03702946|No Intervention|control group|
11153697|NCT03702933||Placebo|starch
11153698|NCT03702933||High Dose|3.5 g/d D-serine adjuvant treatment
11153699|NCT03702933||Low Dose|2.1 g/d D-serine adjuvant treatment
11153700|NCT03702920|Experimental|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
11153701|NCT03702920|Active Comparator|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
11153702|NCT03702907||Normal Cognition|No diagnosis of a cognitive disorder
11153703|NCT03702907||Cognitive Disorder|Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
11153704|NCT03702894|Experimental|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
11153705|NCT03702894|Active Comparator|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
11153706|NCT03702881|Experimental|Bonded Spurs associated with posterior build-ups Group|The experimental group will consist of 25 patients treated with bonded spurs associated with build-ups.
11153707|NCT03702881|Active Comparator|Conventional bonded spurs Group|Active comparator group will consist of 25 patients treated with conventional bonded spurs
11153708|NCT03702855|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
11153709|NCT03702855|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
11153710|NCT03702842|Experimental|Immediate effects|All participants will complete 2 sessions of walking with tsDCS separated by at least 72 hours. The only difference between sessions will be the dosage of stimulation (higher or lower dosage tsDCS using the Soterix Medical tsDCS stimulator). During each session, participants will be asked to walk for up to 30 minutes on a treadmill while the stimulation is delivered. Assessments will be completed before and after the bout of treadmill walking.
11153711|NCT03702842|Experimental|Interventional effects: Higher dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the higher dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the higher dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
11153712|NCT03702842|Active Comparator|Interventional effects: Lower dosage|After completing the 2 sessions of the first part of the study, the participants will be randomized to two groups for the second part of the study. Those in the lower dosage group will receive 16 sessions of locomotor training with tsDCS stimulation applied at the lower dosage for up to 30 minutes using the Soterix Medical tsDCS stimulator. The training sessions will be scheduled 4 days per week for 4 weeks. All training will be overseen by a physical therapist with experience in SCI walking rehabilitation and will involve the use of an overhead support harness.
11153713|NCT03702829|Experimental|Experimental Drug|Inotersen, a transthyretin (TTR) antisense oligonucleotide. Administered subcutaneously weekly. Each dose shall contain 300 mg of active drug. Subsequent visits will occur at 3, 6, 12, 18 and 24 months. Every 2 weeks, blood will be monitored for renal function and platelet count and urine will be tested by dipstick for proteinuria.
11153714|NCT03702816|Experimental|AD|"Alzheimer's Disease (N=20)
~GE180 PET Scan"
11153715|NCT03702816|Experimental|PD|"Parkinson's Disease (N=20; 10 with PD-MCI, 10 PD with no cognitive impairment)
~GE180 PET Scan"
11153717|NCT03702816|Experimental|MCI|"Mild Cognitive Impairment (N=20; 10 florbetapir positive, 10 florbetapir negative)
~GE180 PET Scan"
11153718|NCT03702803|Experimental|Galphimia glauca standardized extract|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the experimental group and will be assigned the treatment consisting of hard gelatin capsules with a pharmaceutical formulation prepared with a standardized extract from G. glauca, which will be administered once a day.
11153719|NCT03702803|Active Comparator|alprazolam 1mg|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the control group and will be assigned the treatment consisting of hard gelatin capsules with the drug Alprazolam (1 mg ), which will be administered once a day.
11153720|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
11153721|NCT03702777|Experimental|ASP8302|Participants will receive ASP8302 capsules orally (once daily).
11153722|NCT03702777|Placebo Comparator|Matching placebo|Participants will receive matching placebo capsules orally (once daily).
11153723|NCT03702764||VP-SG 01|Study subjects that present concentric coronary plaques
11153724|NCT03702764||VP-SG 02|Study subjects that present eccentric coronary plaques
11153725|NCT03702751|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
11153726|NCT03702751|Active Comparator|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
11153727|NCT03702738|Experimental|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
11153728|NCT03702738|No Intervention|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
11153729|NCT03702725|Experimental|Dose Escalation|"Dose escalation will consist of three different drug levels of Ibrutinib, Lenalidomide, and Dexamethasone.
~Dose Escalation (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
11153730|NCT03702725|Experimental|Dose Expansion|"Dosage of the combination will depend on the determine of maximum tolerated dose learned from the Dose Escalation phase.
~Dose Expansion (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
11153731|NCT03702712|Active Comparator|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
11153732|NCT03702712|Active Comparator|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
11153733|NCT03702712|Experimental|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
11153734|NCT03702699||KOA group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
11153735|NCT03702699||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
11153736|NCT03702686|Experimental|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
11153737|NCT03702673|Experimental|Treatment A|K-877 CR Tablet A
11153738|NCT03702673|Experimental|Treatment B|K-877 CR Tablet B
11153739|NCT03702673|Experimental|Treatment C|K-877 CR Tablet E
11153740|NCT03702673|Experimental|Treatment D|K-877 IR Tablet
11153741|NCT03702660|Experimental|GIP(3-30)NH2|GIP receptor antagonist
11153742|NCT03702660|Placebo Comparator|Placebo|Placebo (saline infusions)
11153743|NCT03702647|Experimental|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
11153744|NCT03702647|Placebo Comparator|Normal Saline|30mL of normal saline placed in the POEM tunnel
11153745|NCT03702634|No Intervention|Control (Usual Care)|Surrogate will receive usual care in the hospital, which could include visits from the unit chaplain or other staff from the spiritual care department.
11153746|NCT03702634|Experimental|Intervention|Spiritual Care Assessment and Intervention (SCAI) framework
11153747|NCT03702621|Active Comparator|Liposomal Bupivacaine|"LB (Liposomal Bupivacaine) group - This group will be receiving 20ml EXPAREL (266mg) and 40ml of 0.125% bupivacaine in total, 30ml on each side.
~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
11153748|NCT03702621|Active Comparator|Standard Bupivacaine|"SB (Standard Bupivacaine) group - This group will be receiving 60ml of 0.25% bupivacaine in total, 30ml on each side.
~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
11153749|NCT03702608|Other|EluNIR 38mm|
11153750|NCT03702595|Experimental|Interventional group|Hip flexors stretching protocol
11153802|NCT03702166|Other|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
11153751|NCT03702582|Experimental|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)
~Dosage form: Per Os (Oral)
~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.
~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
11153752|NCT03702582|Active Comparator|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors
~Dosage form: Per Os (Oral)
~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.
~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
11153753|NCT03702569||Patients needing a volume expansion|
11153754|NCT03702556|Active Comparator|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
11153755|NCT03702556|Active Comparator|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
11153756|NCT03702556|Active Comparator|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
11153757|NCT03702530|Experimental|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
11153758|NCT03702530|Placebo Comparator|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
11153759|NCT03702517|Experimental|lateral stair walking exercise|The experimental group received 15 minutes of lateral stair walking exercise
11153760|NCT03702517|Active Comparator|traditional physiotherapy|strengthening exercise, balance training and gait training
11153761|NCT03702491|Experimental|Apatinib with SOX(Tegafur,Oxaliplatin)|Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
11153762|NCT03702491|Active Comparator|SOX( Tegafur,Oxaliplatin)|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
11153763|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
11153764|NCT03702465|Active Comparator|Control Arm|Pre-diabetic participants will receive general health guidelines according to the NICE guidelines, as per standard care. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
11153765|NCT03702465|Active Comparator|Intervention Arm|DNA-based dietary intervention: participants will receive DNA-based health guidelines via a genetic report. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
11153766|NCT03702465|Experimental|Exploratory Arm|DNA-based dietary intervention using an app: participants will receive DNA-based health guidelines via the DnaNudge App.
11153767|NCT03702452|Experimental|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
11153768|NCT03702452|Experimental|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
11153769|NCT03702426|Experimental|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
11153770|NCT03702426|Active Comparator|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
11153771|NCT03702413|No Intervention|Best medical treatment|
11153772|NCT03702413|Experimental|Endovascular treatment|Best medical treatment plus endovascular treatment
11153773|NCT03702400|Active Comparator|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
11153774|NCT03702400|Experimental|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
11153775|NCT03702387|No Intervention|Control Group|Patients in this group will have standard intravenous regional anesthesia (IVRA) performed before the start of their surgery.
11153776|NCT03702387|Experimental|Esmarch Reapplication Group|Patients in this group will have all the standard intravenous regional anesthesia (IVRA) procedures performed before the start of their surgery with one exception: After standard intravenous regional anesthesia (IVRA) is performed, The elastic Esmarch bandage will be reapplied again on the same arm then will be released. then the surgery will be initiated. the only difference between groups is that the Esmarch reapplied group will be applied the esmach two times. First time, at the standard standard intravenous regional anesthesia (IVRA) before the lidocaine injection and second time, after the injection is completed.
11153777|NCT03702374|Experimental|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
11153778|NCT03702374|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
11153779|NCT03702361|Experimental|Rapid infusion of Vpriv|Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease
11153832|NCT03701919|Placebo Comparator|Normal saline pyloric injection|Intraoperative laparoscopic intramuscular injection of 10cc normal saline into the pylorus
11153780|NCT03702348|Experimental|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
11153781|NCT03702348|No Intervention|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
11153782|NCT03702335|Experimental|Dietary Counselling|Each subject will receive a comprehensive dietary counselling for the first 12-weeks of the study, which will be followed by another 12-weeks without dietary counselling.
11153783|NCT03702335|No Intervention|No Dietary Counselling|Subjects in the control group will be followed for 24-weeks without any dietary counselling.
11153784|NCT03702322|Other|Participants|All participants will undergo each treatment.
11153785|NCT03702309||LIBERATE|Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
11153786|NCT03702296|Other|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
11153787|NCT03702296|No Intervention|Control|No ear plugs or eye masks provided.
11153788|NCT03702283|Experimental|Penicillin Allergic ICU Patients|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
11153789|NCT03702270|Experimental|Penicillin Allergic Floor Patients- Experimental|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
11153790|NCT03702270|No Intervention|Penicillin Allergic Floor Patients- Control|Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
11153791|NCT03702257|Other|Bronchial fibroscopy|Bronchial fibroscopy with trans-bronchial biopsies
11153792|NCT03702244|No Intervention|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging [including PET], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
11153793|NCT03702244|Other|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
11153794|NCT03702231|Experimental|Arm 1|Patients with CLL
11153795|NCT03702218|Experimental|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.
~Liver Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6
~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30
~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30
~Kidney Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6
~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
11153796|NCT03702218|Experimental|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is >1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.
~Liver Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6
~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30
~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30
~Kidney Transplant:
~• Combinations of choice:
~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6
~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
11153797|NCT03702218|Active Comparator|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
11153798|NCT03702205|Experimental|Betaine supplementation|The experimental procedure for each athlete includes a 3-week betaine supplementation either 2.5 g or 5 g daily. Betaine will be administered in the form of capsules containing either 0.5 or 1 g betaine. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 5 betaine capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
11153799|NCT03702205|Experimental|Placebo treatment|The experimental procedure for each athlete included a 3-week placebo administration. Placebo will be capsules with starch. Placebo will be ingested with at least 250 mL of water. Each athlete will ingest 5 placebo capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
11153800|NCT03702192|Experimental|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
11153801|NCT03702179|Experimental|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.
~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
11153863|NCT03701659|Active Comparator|MAB Group|These patient will be treated by MAB only.
11156827|NCT03681119|Experimental|Hospice IDT Members|
11153803|NCT03702153|Experimental|Infected abdominal wall group|A cohort of 40 patients carrying an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with synthetic mesh.
11153804|NCT03702153|Active Comparator|Clean control group|A cohort of 40 patients with ventral hernias, and submitted to clean ventral hernia repair with synthetic mesh.
11153805|NCT03702140|Active Comparator|TPTD 6M|
11153806|NCT03702140|Active Comparator|TPTD 6-12M|
11153807|NCT03702140|Active Comparator|TPTD 12-24M|
11153808|NCT03702127|Experimental|NIBS in patients with intracranial electrodes|We will administer NIBS to neurosurgical patients with intracranial electroencephalography in order to better understand the effects NIBS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
11153809|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
11153810|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
11153811|NCT03702101||Orofacial pain group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
11153812|NCT03702101||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
11153813|NCT03702075|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
11153814|NCT03702075|No Intervention|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
11153815|NCT03702062|Experimental|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
11153816|NCT03702049|Experimental|RN/CHW TBI|Nurse-led Community Health Worker TBI (RN/CHW TBI) program
11153817|NCT03702023|Active Comparator|Intervention Group|Patients in the intervention group with receive the study medication 1000mg acetaminophen orally one time prior to their scheduled electrophysiology procedure.
11153818|NCT03702023|Placebo Comparator|Placebo Oral Tablet|Patients in the control group will receive a placebo orally one time prior to their scheduled electrophysiology procedure.
11153819|NCT03702010|Active Comparator|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
11153820|NCT03702010|Experimental|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
11153821|NCT03701997||EXCOR Pediatric|Pediatric (age 0 - 21) patients who are transplant eligible in need of mechanical circulatory support and are supported with the EXCOR® Pediatric
11153822|NCT03701984|Experimental|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
11153823|NCT03701984|Active Comparator|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
11153824|NCT03701984|Placebo Comparator|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
11153825|NCT03701971|Experimental|Music Therapy|"a medical examination
~Before and after music therapy, patients will have to answer questionnaires :
~Before :
~Questionnaire 5D itch scale Itchy Quality of Life Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC
~• Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :
~Before :
~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC"
11153826|NCT03701971|Active Comparator|Emollient cream|"a medical examination
~Before and after music therapy, patients will have to answer questionnaires :
~Before :
~Questionnaire 5D itch scale
~Itchy Quality of Life
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~PGIC
~Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :
~Before :
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~After :
~Pruritus assessment on the digital scale
~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)
~PGIC"
11153827|NCT03701958|Other|Exalt DScope 01|Subjects will have a clinically indicated per standard of care ERCP procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
11153828|NCT03701945|Experimental|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to every patient that accepts the intervention and presents an acute exacerbation
11153829|NCT03701932|Experimental|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
11153830|NCT03701932|Active Comparator|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
11153831|NCT03701919|Experimental|Botulinum toxin pyloroplasty|Intraoperative laparoscopic intramuscular injection of 100units (10cc) of Botulinum toxin into the pylorus
11153833|NCT03701906|Active Comparator|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
11153834|NCT03701906|Active Comparator|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
11153835|NCT03701893|Experimental|Lactobacillus PS11610|Lactobacillus PS11610 for couples with genital dysbiosis and infertility. Each dose contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610.Two daily doses for her and one daily dose for him until pregnancy or end of study period (6 months).
11153836|NCT03701880|Experimental|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least <70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
11153837|NCT03701880|Active Comparator|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
11153838|NCT03701867|Experimental|Metabolic Flexibility Tests Group|
11153839|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
11153840|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
11153841|NCT03701841||PEG-rhG-CSF primary prophylaxis|Patients receiving chemotherapy who have a overall FN risk >=20% receive PEG-rhG-CSF for primary prophylaxis
11153842|NCT03701841||PEG-rhG-CSF secondary prophylaxis|Patients receiving chemotherapy who had FN or dose-limited neutropenia receive PEG-rhG-CSF for secondary prophylaxis
11153843|NCT03701828|Experimental|Weight loss|Participants will undergo weight loss surgery
11153844|NCT03701815|Experimental|Post-stroke|Patients will receive a 12-week lifestyle medicine program.
11153845|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
11153846|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
11153847|NCT03701789|Other|Patients with Rheumatoid Arthritis|In-label treatment with Baricitinib
11153848|NCT03701776|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
11153849|NCT03701776|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
11153850|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 20mg|Apremilast 20mg Twice Daily (BID)
11153851|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 30mg|Apremilast 30mg Twice Daily (BID)
11153852|NCT03701763|Placebo Comparator|Administration of Placebo|Placebo tablet Twice Daily (BID)
11153853|NCT03701750|Experimental|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
11153854|NCT03701750|No Intervention|Control Arm|routine luteal phase support
11153855|NCT03701724|Experimental|Systematic maintenance rTMS (arm A)|Active rTMS treatment followed, for responders, by systematic maintenance rTMS Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
11153856|NCT03701724|Experimental|rTMS course in case of relapse (arm B)|Active rTMS treatment followed, for responders, by additional rTMS courses, in case of relapse Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
11153857|NCT03701724|Sham Comparator|Sham rTMS (arm C)|sham rTMS followed, for responders, by either systematic sham mTMS (50%) or additional sham rTMS course in case of relapse(50%) Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
11153858|NCT03701711|Experimental|Lenalidomide escalation and expansion|Among the participants who will be receiving lenalidomide, the first 12 participants will be in the dose escalation phase; with the subsequent 8 participants anticipated to receive dose expansion.
11153859|NCT03701698|Experimental|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.
~Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.
~Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days."
11153860|NCT03701685|Other|nerve grafting|The stumps of digital nerve are connected with nerve graft
11153861|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
11153862|NCT03701659|Experimental|TUPKRP+MAB Group|These patient will be treated by TUPKRP and MAB.
11153864|NCT03701646||arterial line|Pediatric patients admitted tot he ICU with a medically indicated arterial line.
11153865|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
11153866|NCT03701633||Prior to breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
11153867|NCT03701633||After breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
11153868|NCT03701607||PD-L1|
11153869|NCT03701594|Experimental|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
11153870|NCT03701594|Active Comparator|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
11153871|NCT03701594|Active Comparator|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
11153872|NCT03701581|Experimental|Group A: Investigational Treatment|"4-Aminopyridine (FDA-approved drug)
~Subjects will not take more than 2 tablets in a 24-hour period
~Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.
~The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.
~Study drug can be taken with or without food.
~If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.
~Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine)."
11153873|NCT03701581|Placebo Comparator|Group B: Placebo|"Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by The University of Iowa Pharmaceuticals, 115 South Grand Avenue G-20, Iowa City, IA 52242. The Investigational Drug Service at the University of Rochester will manage the placebos.
~Placebo composition will include:
~97% Microcrystalline Cellulose, NF (Avicel Ph 102) 2% Sodium Starch Glycolate, NF
~1% Magnesium Stearate, NF
~The placebo will be covered in White Opadry, formulation OY-S-9603 and tooled to look similar to the investigational treatment."
11153874|NCT03701555|Experimental|Part 1, Cohort 1A-1 to 1D-1 Healthy Participants|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
11153875|NCT03701555|Experimental|Part 1, Cohort 1E-1 Healthy Participants|A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
11153876|NCT03701555|Experimental|Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
11153877|NCT03701555|Experimental|Part 1, Cohort 1E-2 Celiac Disease (CeD)|A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
11153878|NCT03701555|Experimental|Part 2, Cohort 2A - Cohort 2C Healthy Participants|Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
11153879|NCT03701555|Experimental|Part 2, Cohort 2D Healthy Participants|Participants will receive PvP001 placebo or MFD of PvP001.
11153880|NCT03701555|Experimental|Part 2, Cohort 2E Healthy Participants|Participants will receive PvP002 placebo or MFD of PvP002.
11153881|NCT03701555|Experimental|Part 2, Cohort 2F- Cohort 2H Healthy Participants|Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
11153882|NCT03701555|Experimental|Part 2, Cohort 2I and Cohort 2J Healthy Participants|Participants will receive the PvP001 placebo and 900 mg of PvP001.
11153883|NCT03701555|Experimental|Part 3, Cohorts 3A and 3B Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
11153884|NCT03701555|Experimental|Part 3, Cohorts 3C and 3D Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
11153885|NCT03701555|Experimental|Part 3, Cohorts 3E and 3F Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
11153886|NCT03701555|Experimental|Part 3, Cohorts 3G and 3H Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
11153887|NCT03701555|Experimental|Part 4, Cohorts 4A and 4B Healthy Participants|Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
11153888|NCT03701555|Experimental|Part 3, Cohorts 3I and 3J Healthy Participants|Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
11153889|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
11153890|NCT03701529|Experimental|Sevoflurane|1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.
11153891|NCT03701529|Active Comparator|Propofol|2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.
11153892|NCT03701516|Experimental|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
11153893|NCT03701516|Experimental|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
11153894|NCT03701503|Experimental|Obese|"Women age 20-40, with BMI ≥ 25-35 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.
~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
11153895|NCT03701503|Active Comparator|Non Obese|"Women age 20-40, with BMI 18,5-23 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.
~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
11153896|NCT03701490|Experimental|Prolutex|
11153897|NCT03701490|Experimental|Progeffik|
11153898|NCT03701477|Experimental|Trans-diagnostic approach|Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
11153899|NCT03701477|Sham Comparator|Control|General relaxation/stress management therapeutic session In this arm, patients will attend a 3-hour meeting in which basic techniques of relaxation and overcoming stress and anxiety will be discussed.
11153900|NCT03701464|Experimental|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
11153901|NCT03701464|Active Comparator|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
11153902|NCT03701451|Experimental|decitabin and cisplatin induced chemotherapy followed by CC|Treated by demethylated drug decitabine injection combined with cisplatin induced chemotherapy followed by concurrent chemoradiotherapy
11153903|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
11153904|NCT03701425|Experimental|Mediterranean diet and exercise plan|"Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the distribution of macronutrients: Protein contribution 0.8-1.2 gram, Carbon Hydrates 45-50% Lipids 30% An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
11153905|NCT03701425|Experimental|Mediterranean diet|Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the following distribution of macro nutrients: Protein contribution 0.8-1.2 gram Carbon Hydrates 45-50% Lipids 30%
11153906|NCT03701425|Active Comparator|Only exercise|"An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
11153907|NCT03701425|Active Comparator|Low standard low fat diet|Random assignment, through software, to 4 groups of treatment: consume the low standard low fat diet: according to the definition, with the following distribution of macro nutrients:Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 20%
11153908|NCT03701399|Experimental|Arm 1: BHV-4157|Troriluzole 200mg PO
11153909|NCT03701399|Placebo Comparator|Arm 2: Placebo|Placebo 200mg PO
11153910|NCT03701386|Active Comparator|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
11153911|NCT03701386|Experimental|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
11153912|NCT03701373|Experimental|S-1 maintenance group|S-1 maintenance
11157150|NCT03679065|Placebo Comparator|Placebo|
11153913|NCT03701373|Other|Observation group|Observation without anti-tumor treatment
11153914|NCT03701360||Aspirin alone group|- Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
11153915|NCT03701360||Aspirin + Clopidogrel resinate group|"Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
~Clopidogrel resinate: 75mg once per day, initial loading dose of 300mg/d is allowed"
11153916|NCT03701347|Active Comparator|Reeve's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Reeve's simulators
11153917|NCT03701347|Active Comparator|Hefler's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Hefler's simulators
11153918|NCT03701347|Experimental|Ida's Model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Ida's simulators
11153919|NCT03701334|Experimental|Ribociclib + Endocrine Therapy|"ribociclib 400 mg once daily on days 1-21 of a 28 day cycle followed by 7 days off and endocrine therapy (ET) once daily continuously"
11153920|NCT03701334|Active Comparator|Endocrine Therapy|endocrine therapy (ET) only once daily continuously
11153921|NCT03701321|Experimental|Phase I (DVd, venetoclax)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11153922|NCT03701321|Experimental|Phase II Arm D (DVd, venetoclax)|Patients receive venetoclax PO QD on days 1-21, daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11153923|NCT03701321|Active Comparator|Phase II Arm E (DVd)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11153924|NCT03701308|Active Comparator|Arm I (daunorubicin, cytarabine)|"INDUCTION: Patients receive daunorubicin IV on days 1-3 and cytarabine via CIVI over 168 hours on days 1-7. Patients with residual disease indicated by bone marrow examination receive a second induction including daunorubicin IV on days 1-3 and cytarabine CIVI over 12 hours on days 1-5.
~CONSOLIDATION: Patients receive cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
11153925|NCT03701308|Experimental|Arm II (uproleselan, daunorubicin, cytarabine)|"INDUCTION: Patients receive uproleselan IV QD on day 1 and then every 12 hours on days 2-10. Patients also receive daunorubicin IV on days 2-4 and cytrarabine CIVI over 168 hours on days 2-8 over 168 hours. Patients with residual disease indicated by bone marrow examination receive a second induction including uprleselan IV QD on day 1 and then every 12 hours on days 2-8, daunorubicin IV on days 2-3, and cytarabine CIVI over 120 hours on days 2-6.
~CONSOLIDATION: Patients who achieve a CR or CRi receive uproleselan IV QD on day 1 and every 12 hours on days 2-8 and cytarabine IV over 3 hours on days 2-6. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
11153926|NCT03701295|Experimental|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
11153927|NCT03701282|Experimental|Arm A (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO daily on days 1-28 and obinutuzumab IV over 4 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-28 of cycles 3-14. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity.
11153928|NCT03701282|Active Comparator|Arm B (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO and obinutuzumab as in arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11153929|NCT03701256|Experimental|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
11153930|NCT03701256|Active Comparator|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
11153931|NCT03701243|Experimental|mNT-BBAVF|These patients will receive a modified non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) at elbow for hemodialysis acess.
11153932|NCT03701243|Active Comparator|RCAVF|These patients will receive a radiocephalic arteriovenous fistula (RCAVF) at wrist for hemodialysis acess.
11153933|NCT03701230|Experimental|low temperature rota-flush solution|A total of 55 patients are assigned to low temperature rota-flush solution group after randomization schedule.
11153934|NCT03701230|No Intervention|room temperature rota-flush solution|A total of 55 patients are assigned to room temperature rota-flush solution group after randomization schedule.
11153935|NCT03701217|Experimental|Eltrombopag treatment|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
11153936|NCT03701217|Active Comparator|Eltrombopag free|Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
11153937|NCT03701204|Experimental|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
11153938|NCT03701204|No Intervention|Control|Treatment as usual
11153939|NCT03701191|Experimental|Grpup A (Test group)|Inverted periosteal pedicle flap will be carried out
11153940|NCT03701191|Active Comparator|Group B (Control group)|Coronally advanced flap with subepithelial connective tissue graft
11153941|NCT03701178|Active Comparator|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
11157151|NCT03679052|Active Comparator|Group I (Mirtazapine group): (n=100)|
11153942|NCT03701178|Experimental|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
11153943|NCT03701165|Other|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
11153944|NCT03701152|Experimental|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
11153945|NCT03701152|Experimental|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
11153946|NCT03701139|Experimental|posterior capsulotomy|Primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing during phacoemulsification.
11153947|NCT03701139|Active Comparator|Nd:YAG laser capsulotomy|Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
11153948|NCT03701126|Active Comparator|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
11153949|NCT03701126|Active Comparator|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
11153950|NCT03701113|Active Comparator|Milk-based protein matrix (MBPM)|Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
11153951|NCT03701113|Other|CONTROL|Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
11153952|NCT03701100|Active Comparator|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
11153953|NCT03701100|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
11153954|NCT03701087|No Intervention|normal serum vitamin D|normal serum vitamin D
11153955|NCT03701087|Experimental|low serum level of vitamin D|this arm will intake vitamin D 2800 IU daily
11153956|NCT03701087|Placebo Comparator|low serum vitamin D|this arm will intake placebo omega 3
11153957|NCT03701074|Experimental|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
11153958|NCT03701074|Active Comparator|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
11153959|NCT03701061|Experimental|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
11153960|NCT03701061|Active Comparator|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
11153961|NCT03701048|Active Comparator|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
11153962|NCT03701048|Active Comparator|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
11153963|NCT03701035|Experimental|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
11153964|NCT03701035|Active Comparator|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
11153965|NCT03701022|Experimental|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
11153966|NCT03701009|Other|Stone removal (Saline 50ml each time)|After CBD stone removal via lithotripsy, and the cholangiogram showed normal, residual CBD stones were detected by SpyGlass in the first round, if CBD not clean, sterile saline 50ml were intermittently irrigated into the CBD. After that, if bile duct clearance was not achieved, another 50ml saline will be irrigated into CBD again until the clear bile duct determined by SpyGlass.
11153967|NCT03700983|Experimental|Nutri-PEITC jelly|a single serving of 200 g Nutri-PEITC jelly
11153987|NCT03700814|Experimental|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
11153988|NCT03700814|No Intervention|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
11153968|NCT03700970|Experimental|TAP block with liposomal bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
11153969|NCT03700970|Active Comparator|TAP block with regular bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of 0.25% bupivacaine injected on each side.
11153970|NCT03700957|Experimental|Docosahexaenoic Acid Group|participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
11153971|NCT03700957|Placebo Comparator|Control Group|participants will recieve placebo
11153972|NCT03700944|Experimental|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
11153973|NCT03700944|No Intervention|CON|The control group (CON) had normal life.
11153974|NCT03700931|Experimental|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
11153975|NCT03700931|Active Comparator|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
11153976|NCT03700918|Experimental|DaVingiTR System Single Arm|single-arm, open label, multi-center study.
11153977|NCT03700905|Experimental|Neoadjuvant/adjuvant Nivolumab and Ipilimumab|"Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
~Surgical resection of primary tumor including neck dissection according to standard of care
~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery
~Arm Ia:
~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
~Arm Ib:
~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months"
11153978|NCT03700905|Active Comparator|Surgical resection + adjuvant radio(-chemo)therapy|"Surgical resection of primary tumor including neck dissection according to standard of care
~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery
~Standard follow-up"
11153979|NCT03700892|Experimental|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
11153980|NCT03700892|Experimental|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
11153981|NCT03700866|Experimental|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.
~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
11153982|NCT03700866|Active Comparator|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
11153983|NCT03700840|Other|Clinical examination and sample|"Cross-sectional observational study
~Measure of 6 indices:
~Bleeding on Intergental Brush Index (BOIB)
~Gingivitis Score (GI)
~Plaque index score (PI)
~ICDAS
~Salivary test
~Individual caries risk assessment
~Determination of interdental brushes adapted to each interdental site
~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.
~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.
~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
11153984|NCT03700827|Experimental|Resistance Training Group|Resistance training will consist of 3 whole body circuits per week for 3 weeks lasting approximately 1 hour per session. All major muscle groups will be involved (leg press, bent-over-row, bench press, back squat, dumbbell jump squats, dead-lifts, and weighted abdominal crunches). Each participant will go through each circuit three times with 30 seconds between each exercise and 2 minutes between each set.
11153985|NCT03700827|Experimental|Aerobic Training Group|Aerobic interval training will consist of 3 sessions/week for 3 weeks for approximately 45-50 minutes per session depending on exercise energy expenditure. There will be two periods of intervals. The first period will be 3 minutes of high-intensity activity and the second period will be reduced to moderate-intensity for 2 minutes. The speed/incline will change depending on the participants perception or Borg's rating of perceived exertion. Intensity will be measured using Lactate levels after each session.
11153986|NCT03700827|No Intervention|Control Group|The control group must attend sessions but will not exercise.
11154144|NCT03699761|No Intervention|Without Pelvic Peritonization|
11153989|NCT03700801|Experimental|Triple combination therapy group|triple combination therapy group: Triple oral hypoglycemic therapy based on metformin 0.5mg twice a day, dapagliflozin 10mg per day plus saxagliptin 5mg per day.
11153990|NCT03700801|Active Comparator|Premixed insulin therapy group|premixed insulin therapy group: The initial total dose is 0.3U-0.5U/Kg, twice a day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level detected by the blood glucose meter
11153991|NCT03700788|Experimental|Clorhexidine|2% Chlorhexidine
11153992|NCT03700788|Active Comparator|Calcium Hydroxide|Calcium Hydroxide
11153993|NCT03700775|Experimental|Telemonitoring intervention|
11153994|NCT03700762||pathologically results|finally proved by pathologically results
11153995|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
11153996|NCT03700749|Active Comparator|2%chlorhexidine + non-coated suture|2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
11153997|NCT03700749|Active Comparator|2%chlorhexidine + coated suture|2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
11153998|NCT03700749|Active Comparator|10% povidone-iodine + non-coated suture|10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
11153999|NCT03700749|Active Comparator|10%povidone-iodine + coated suture|10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
11154000|NCT03700736|Active Comparator|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
11154001|NCT03700736|Active Comparator|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
11154002|NCT03700723|Experimental|Resusix|The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
11154003|NCT03700723|Active Comparator|FP24 (Frozen Plasma)|The active comparator FP24 will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
11154004|NCT03700710|Active Comparator|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.
~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to BMIQ (www.bmiq.com), an evidence-based program developed by Dr. Louis Aronne at Columbia University, which includes program materials for weight loss and leading a healthy lifestyle; 3) LoseIt (www.loseit.com), a meal-logging app that integrates seamlessly with the BMIQ website."
11154005|NCT03700710|Experimental|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants. The BMIQ website will be used to share participant dietary data (LoseIt) and weight data with dietitians.
~Participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure. The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to BMIQ; 3) LoseIt (www.loseit.com), a meal-logging app that integrates seamlessly with the BMIQ website."
11154006|NCT03700697|Experimental|Family Stress Module Intervention|Primary care clinicians will use the CHADIS Family Stress Module including the reviewing ACE, Positive Childhood Experiences, and FASS Plus questionnaires at designated child ages; address family stressors revealed using the motivational interviewing teleprompter and refer parents with stressors as indicated using the care coordination functionality.
11154007|NCT03700697|No Intervention|Controls|Control primary care providers will provide care as usual.
11154008|NCT03700684|Experimental|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
11154009|NCT03700684|Experimental|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
11154010|NCT03700684|Active Comparator|Control|Persons with Parkinsons disease do not receive voice intervention
11154011|NCT03700671|Experimental|High intensity interval training|HIIT was set at > 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
11154012|NCT03700671|Active Comparator|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
11154013|NCT03700658|Experimental|TV-46046 - 1|One of 24 sequences
11154014|NCT03700658|Experimental|TV-46046 - 2|One of 24 sequences
11154015|NCT03700658|Active Comparator|medroxyprogesterone acetate injectable suspension|One of 24 sequences
11154016|NCT03700658|Placebo Comparator|TV-46046 Placebo|One of 24 sequences
11154017|NCT03700645|No Intervention|PCI and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.
11154018|NCT03700645|Active Comparator|PCI, standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.
11154019|NCT03700645|No Intervention|CABG and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.
11154020|NCT03700645|Active Comparator|CABG standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.
11154021|NCT03700632|Experimental|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
11154022|NCT03700632|No Intervention|Control|no intervention will be done
11154023|NCT03700606|Active Comparator|Nasal CPAP - Period 1|"Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater bubble system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP."
11154024|NCT03700606|Active Comparator|High Flow Nasal Cannula (HFNC) - Period 2 & 3|Respiratory support will be crossed over to a HFNC Optiflow Jr 2 (Fisher & Paykel Healthcare, Auckland, New Zealand) at a flow rate of 8 LPM. The size of the nasal cannula will be determined according to the manufacturer's instructions in order to maintain a leak at the nares. Identical data collection will occur for two 15 minute periods on HFNC, at the beginning and end of the six hour Study period.
11154025|NCT03700606|Active Comparator|Nasal CPAP - Period 4|After 6 hours of HFNC of 8 LPM, or sooner if the infant meets failure criteria, the infant will then be crossed back to the nCPAP device and at the settings previously utilized in Study Period 1. The infant will remain on the nCPAP device with identical data collection for 15 minutes. The total duration of the study and data collection will be 8 hours. The infant's body position will be similar for each lung volume measurement during the study periods.
11154026|NCT03700593||Single Port Robotic Colorectal Surgery Patients|All patients who undergo a single port robot colorectal surgery.
11154027|NCT03700580|Active Comparator|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
11154028|NCT03700580|Experimental|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
11154029|NCT03700567|Experimental|low temperature contrast|A total of 150 patients are assigned to low temperature contrast group after randomization schedule.
11154030|NCT03700567|No Intervention|room temperature contrast|A total of 150 patients are assigned to room temperature contrast group after randomization schedule.
11154031|NCT03700554|Experimental|Pleuralvent™|Patients treated with Pleuralvent™ device
11154032|NCT03700554|Active Comparator|Chest tube|Patients treated with Chest tube
11154033|NCT03700541|Active Comparator|Morphine|Morphine-based perioperative analgesia
11154034|NCT03700541|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
11154035|NCT03700528|Experimental|Intervention|This is a single-cohort ACT based intervention.
11154036|NCT03700515|Placebo Comparator|Placebo|Saline infusion
11154037|NCT03700515|Experimental|EPO|Erythropoetin infusion (9 IU/kg)
11154038|NCT03700515|Experimental|EPO II|Erythropoetin infusion (20 IU/kg)
11154039|NCT03700502||patients with painful diabetic neuropathy|
11154040|NCT03700502||diabetics with non-pain neuropathy|
11154041|NCT03700502||gender and age matched healthy controls|
11154042|NCT03700489|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
11154043|NCT03700489|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
11154044|NCT03700476|Experimental|Sintilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 70Gy will be given in seven weeks. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
11154045|NCT03700476|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
11154046|NCT03700450|Experimental|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
11154047|NCT03700437|Experimental|Fasting-Mimicking Diet (FMD)|"Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides ~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements
~Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy."
11154048|NCT03700437|Placebo Comparator|Regular Diet Control Arm|Participants in the control arm will receive dietary advice per the standard practice of treating physician, nutritionist and dietitian and will consume regular diet during first 4 cycles of chemo-immunotherapy
11154049|NCT03700424|Experimental|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
11154050|NCT03700424|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
11154051|NCT03700411|Active Comparator|Morphine|Morphine-based perioperative analgesia
11154052|NCT03700411|Active Comparator|Piritramid|Piritramid-based perioperative analgesia
11154053|NCT03700411|Active Comparator|Epidural|Perioperative epidural analgesia containing an opioid
11154054|NCT03700398|Experimental|first OE|
11154055|NCT03700398|Other|First WLI|
11154056|NCT03700385|Experimental|IOWA Approach Endocardial Ablation|Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.
11154057|NCT03700359|Experimental|Anlotinib/Lobaplatin/Etoposide|EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
11154058|NCT03700359|Active Comparator|Lobaplatin/Etoposide|EL regimen for 4 cycles
11154059|NCT03700346|Other|survivors|survivor at ICU discharge muscle microdialysis
11154060|NCT03700346|Other|Non survivors|death before ICU discharge muscle microdialysis
11154061|NCT03700333|Experimental|S-1 Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Tegafur,Gimeracil and Oteracil Potassium Capsules (S-1)
11154062|NCT03700333|Active Comparator|Pemetrexed Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Pemetrexed
11154063|NCT03700320|Active Comparator|Atogepant 60 mg|Taken once daily
11154064|NCT03700320|Active Comparator|Oral SOC migraine prevention medication|Taken once daily
11154065|NCT03700307|Experimental|pulmonary vein isolation|patients will receive circumferential pulmonary vein isolation using cryoballoon ablation
11154066|NCT03700307|Experimental|pulmonary vein and left atrial roof linear isol|patients will receive circumferential pulmonary vein and left atrial roof linear isolation using cryoballoon ablation
11154067|NCT03700294|Experimental|ADCT-601|
11154068|NCT03700281|No Intervention|Control|No intervention
11154069|NCT03700281|Experimental|Messaging|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail
11154070|NCT03700281|Experimental|Messaging plus incentive|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail, and will be eligible to receive a gift card as incentive for receiving flu vaccine
11154071|NCT03700268|Experimental|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
11154072|NCT03700268|Experimental|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
11154073|NCT03700255|Experimental|Group A|Group A will undergo the PickUpSimTM simulation training program
11154074|NCT03700255|No Intervention|Group B|Group B will only have the classic training with no simulation.
11154075|NCT03700242|Experimental|Group 1|1 IM dose of human diploid cell vaccine (HDCV) on D0 and D7 (short HDCV IM PrEP regimen), followed by 1 IM dose of HDCV on Year (Y)1 and Y1 + 3 days
11154076|NCT03700242|Active Comparator|Group 2|1 IM dose of HDCV on D0, D7, and D21 (reference), followed by 1 IM dose of HDCV on Y1 and Y1 + 3 days
11154077|NCT03700242|Experimental|Group 3|2 intradermal (ID) doses of HDCV on D0 and D7 (short HDCV ID PrEP regimen), followed by 1 ID dose of HDCV on Y1 and Y1 + 3 days
11154078|NCT03700242|Experimental|Group 4|1 IM dose of purified Vero cell rabies vaccine (PVRV) on D0 and D7 (short PVRV IM PrEP regimen), followed by 1 IM dose of PVRV on Y1 and Y1 + 3 days
11154079|NCT03700242|Experimental|Group 5|2 ID doses of PVRV on D0 and D7 (short PVRV ID PrEP regimen), followed by 1 ID dose of PVRV on Y1 and Y1 + 3 days
11154080|NCT03700229|Experimental|Bortezomib +Rituximab|Bortezomib +Rituximab
11154081|NCT03700203||Early cardiac arrest patients|Cases will be consecutive adult patients with EMS-treated OHCA and transport to the 14 emergency departments of participating hospitals. A prospective OHCA patient cohort will be developed and all survived OHCA cases will be followed at 1-month and 6-month after ED discharge by telephone. During the study period, the investigators aim to recruit a total 1,780 cases (200 cases between September 2017 and August 2018, 600 cases between September 2018 and August 2020, 80 cases between September 2020 and December 2020, and 900 cases between January 2021 and December 2023).
11154082|NCT03700203||Matched community-based controls|Matched community-based controls (2:1 matching) will be selected from two health screening centers. Controls are those who visit the participating health screening centers for their annual routine physical examinations. During the study period, the investigators aim to recruit a total 3,560 controls (400 controls between September 2017 and August 2018, 1200 controls between September 2018 and August 2020, 160 controls between September 2020 and December 2020, and 1800 controls between January 2021 and December 2023).
11154083|NCT03700190||Control|Healthy child
11154084|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
11154085|NCT03700177|Active Comparator|ropivacaine + dexamethasone|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
11154086|NCT03700177|Placebo Comparator|ropivacaine + placebo|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).
11154500|NCT03697291|Active Comparator|Certodyn|Commercially available iECG system - Certodyn
11154087|NCT03700164|Experimental|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
11154088|NCT03700164|Other|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.
~The duration will be matched to that during the cold exposure."
11154089|NCT03700151|Experimental|Children with SSD|Participants will receive a piloted treatment programme for children with severe speech sound disorders, especially childhood apraxia of speech.
11154090|NCT03700138|Experimental|Privigen|TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).
11154091|NCT03700138|Placebo Comparator|Placebo|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
11154092|NCT03700125|Experimental|ECMO resuscitation|6 patients who meet the eligibility criteria will be treated by pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable and can establish ECMO flow within 30 minutes of collapse
11154093|NCT03700112|Experimental|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method
~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
11154094|NCT03700112|Experimental|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method
~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
11154095|NCT03700112|Experimental|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method
~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
11154096|NCT03700112|Experimental|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method
~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
11154097|NCT03700112|Experimental|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method
~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
11154098|NCT03700112|Experimental|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method
~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
11154099|NCT03700112|Experimental|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method
~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
11154100|NCT03700112|Experimental|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
11154101|NCT03700099|Other|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
11154102|NCT03700086|Experimental|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
11154103|NCT03700086|Active Comparator|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
11154104|NCT03700073|Experimental|Walk training plus virtual reality|Experimental group (GTVR): The intervention consisted of treatment with the robotic CL1Walker gait training system in combination with virtual reality
11154105|NCT03700073|Active Comparator|Walk training|Control group (GT): The intervention consisted of treatment with the robotic CL1Walker gait training system
11154106|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
11154107|NCT03700034|Experimental|mHealth Integrated Antenatal Care|The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.
11154108|NCT03700034|No Intervention|Routine Antenatal Care|In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs).
11154109|NCT03700008|Other|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.
~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
11154110|NCT03700008|Other|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
11154111|NCT03699995|Experimental|Screening (MoleMapper, Visiomed, confocal microscopy, biopsy)|Participants undergo imaging of suspected melanomas via iPhone app MoleMapper, Visiomed, and confocal microscopy. Participants then receive lidocaine SC and undergo shave or punch biopsy of suspected melanomas.
11154112|NCT03699982|Experimental|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
11154113|NCT03699969|Experimental|Hypofractionated dose escalated VMAT|Hypofractionated dose escalated VMAT radiotherapy
11154114|NCT03699969|No Intervention|Conventional concurrent chemoradiation|Conventional concurrent chemoradiation
11154115|NCT03699956|Experimental|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks
~Cisplatin/carboplatin plus etoposide (up to 4 cycles):
~Cisplatin or Carboplatin:
~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR
~Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks
~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
11154116|NCT03699956|Active Comparator|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):
~Cisplatin or Carboplatin:
~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR
~Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks
~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
11154117|NCT03699943|Active Comparator|CaverStem 1.0 - Low|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
11154118|NCT03699943|Active Comparator|CaverStem 1.0 - High|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
11154119|NCT03699943|Active Comparator|Caverstem 2.0 - Clinical Registry|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
11154120|NCT03699930|Active Comparator|tDCS intervention group|"Participants will randomly be assigned either to the tDCS group or to the sham (placebo) group. The only person knowing about this assignment will be the research coordinator. Both groups will include five consecutive days of 20 minutes session. Behavioral, EEG and DTI MRI data acquisition will be performed within a week before/after the tDCS/sham intervention. Behavioral measures will be performed again 3 months following tDCS/sham treatment to assess long-term benefits.
~The tDCS device that will be used in this study (Soterix; https://soterixmedical.com/research/1x1/ct) has received full clearance from the FDA and, therefore, does not present significant risks for the patients."
11154121|NCT03699930|Placebo Comparator|sham placebo group|"Participants will randomly be assigned either to the tDCS group or to the sham (placebo) group. The only person knowing about this assignment will be the research coordinator. Both groups will include five consecutive days of 20 minutes session. Behavioral, EEG and DTI MRI data acquisition will be performed within a week before/after the tDCS/sham intervention. Behavioral measures will be performed again 3 months following tDCS/sham treatment to assess long-term benefits.
~The tDCS device that will be used in this study (Soterix; https://soterixmedical.com/research/1x1/ct) has received full clearance from the FDA and, therefore, does not present significant risks for the patients."
11154122|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
11154123|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
11154124|NCT03699904|Experimental|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
11154125|NCT03699904|Placebo Comparator|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
11154126|NCT03699878||patients undergoing robotic esophagectomy|Patients 20 years or older who undergo robotic esophagectomy
11154127|NCT03699865|Experimental|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
11154128|NCT03699865|Experimental|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
11154129|NCT03699865|Experimental|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
11154130|NCT03699852|Experimental|LED group|The volunteer will be positioned so that the skin graft donor area is accessible. In addition to Membracel®, a porous regenerating membrane of crystalline cellulose (conventional treatment), LED photobiomodulation will be performed in this group. The LED board will be covered with waterproof and transparent film and re-covered with sterile, waterproof and transparent film to prevent contamination. The LED board will cover the entire skin donor area and will be irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED board will be applied in contact with the operative wound in the immediate postoperative period and applied through the Membracel® in the 1st, 3rd, 5th and 7th postoperative days.
11154131|NCT03699852|Other|Control group|The volunteers will be in the same condition. The only difference between the groups is that no LED photobiomodulation will be applied to the control group; only Membracel®, a porous regenerating membrane of crystalline cellulose (conventional treatment).
11154132|NCT03699839|Experimental|High dose influenza vaccine|Administration of high-dose influenza vaccine
11154133|NCT03699839|Experimental|MF59-adjuvanted influenza vaccine|Administration of MF59-adjuvanted vaccine
11154134|NCT03699839|Active Comparator|Standard influenza vaccine|Administration of standard intramuscular influenza vaccine
11154135|NCT03699826|Experimental|TMS|
11154136|NCT03699813||scoliosis bleeding management based on aPTT/PT|"Bleeding and coagulopathy during surgery managed by clinical approach and aPTT/PT tests.
~Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed."
11154137|NCT03699813||scoliosis bleeding management based on ROTEM|Bleeding and coagulopathy during surgery managed by ROTEM. Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed.
11154138|NCT03699800|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
11154139|NCT03699800|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
11154140|NCT03699787|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
11154141|NCT03699787|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
11154142|NCT03699774|Experimental|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.
~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
11154143|NCT03699761|Experimental|Pelvic Peritonization|
11154145|NCT03699748|Experimental|Intervention Group Arm|"Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice).
~The intervention arm will also receive usual care as provided by Unite Here Health and their local oncologists."
11154146|NCT03699748|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by Unite Here Health and their local oncologists.
11154147|NCT03699735|Active Comparator|Hearing Aid with beam form principle_A|Device: Hearing Aid beam former principle_A (simulation of real ear condition). Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
11154148|NCT03699735|Experimental|Hearing Aid with beam form principle_B|Device: Hearing Aid beam former principle_B. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
11154149|NCT03699735|Experimental|Hearing Aid with beam form principle_C|Device: Hearing Aid beam former principle_C. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
11154150|NCT03699722|Experimental|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
11154151|NCT03699722|Active Comparator|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
11154152|NCT03699709|Experimental|Intervention Arm|
11154153|NCT03699709|No Intervention|Control Arm|
11154154|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
11154155|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
11154156|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
11154157|NCT03699683|Experimental|Physical Combined Activity Program|Before and after a 6-months supervised and individualized program that combined aerobic and resistance training were performed in post bariatric patients. Body composition, physical fitness and cardiovascular risk factors were measured before, after the physical activity program and 6 months later (13 months sinde the program started)
11154158|NCT03699657|Active Comparator|RFA with DSM mode|RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
11154159|NCT03699657|Active Comparator|RFA with SSM mode|RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
11154160|NCT03699644|Active Comparator|Healthy Control|Healthy controls will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all healthy controls will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
11154161|NCT03699644|Active Comparator|Alzheimer's Dementia|Subjects with Alzheimer's Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all subjects with Alzheimer's Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
11154162|NCT03699644|Active Comparator|Frontotemporal Dementia|Subjects with Frontotemporal Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, subjects with Frontotemporal Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
11154163|NCT03699631|Experimental|Tacrolimus/Methotrexate/Tocilizumab|"Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.
~Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.
~Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days)."
11154164|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
11154165|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
11154166|NCT03699605|Experimental|VESMP|"Participants used VESMP at least half hour session thrice a week over an average of 4 months. The instruction before every domain included using it independently on the participant's own smart phone, or with a trained person either in the clinic or on their phone brought to the participant's home.
~Total 25 patients with diagnosis of severe non-fluent aphasia included, ages 40+, at least 3 months post-onset of single unilateral CVA affecting the language dominant hemisphere at the time of baseline testing also including, Participant demographics, aphasia classification and severity. All subjects participated in an intensive 2-week VESMP treatment program prior to beginning the individualized programs."
11154203|NCT03699306|Active Comparator|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
11154167|NCT03699605|Active Comparator|Traditional Therapy|Control group received traditional therapy total 25 patients with diagnosis of severe non-fluent aphasia included, All subjects participated in an traditional therapy group in routine and received language therapy for 4 months of periods with three sessions per week.
11154168|NCT03699592|No Intervention|Control|
11154169|NCT03699592|Experimental|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
11154170|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.
~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
11154171|NCT03699553|Experimental|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
11154172|NCT03699553|Active Comparator|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
11154173|NCT03699540|Experimental|Active Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of active marijuana, under double-blind conditions
11154174|NCT03699540|Placebo Comparator|Inactive Marijuana Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive marijuana, under double-blind conditions
11154175|NCT03699540|Active Comparator|Active Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of active alcohol, under double-blind conditions
11154176|NCT03699540|Placebo Comparator|Inactive Alcohol Dose|Participants will receive experimental/non-therapeutic dose(s) of inactive alcohol, under double-blind conditions
11154177|NCT03699514||Subject who completed or will complete a BNA test|
11154178|NCT03699501||Patients|
11154179|NCT03699501||Voluntary patients|
11154180|NCT03699475|Experimental|A: haplo-HSCT plus rivogenlecleucel|"αβ T-cell and CD19+ B-cell-depleted haploidentical stem cell transplantation plus rivogenlecleucel
~Rimiducid will be administered to inactivate rivogenlecleucel in the event of GVHD not responsive to standard of care treatment"
11154181|NCT03699475|Active Comparator|B: haplo-HSCT followed by cyclophosphamide|haploidentical stem cell transplantation followed by cyclophosphamide post-transplant
11154182|NCT03699462|Active Comparator|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
11154183|NCT03699462|Experimental|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
11154184|NCT03699449|Experimental|olaparib + cediranib|olaparib+cediranib combination therapy
11154185|NCT03699449|Experimental|durvalumab + olaparib|durvalumab + olaparib combination therapy
11154186|NCT03699449|Experimental|durvalumab + chemotherapy|durvalumab +chemotherapy
11154187|NCT03699449|Experimental|durvalumab + tremelimumab + chemotherapy|durvalumab + tremelimumab + chemotherapy
11154188|NCT03699449|Experimental|durvalumab + tremelimumab + paclitaxel|durvalumab + tremelimumab + paclitaxel
11154189|NCT03699436|Experimental|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
11154190|NCT03699436|Active Comparator|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
11154191|NCT03699423|Active Comparator|0.01% atropine eye drops|Participants will receive one drop per eye every night for two weeks
11154192|NCT03699423|Active Comparator|0.02% atropine eye drops|Participants will receive one drop per eye every night for two weeks
11154193|NCT03699423|Active Comparator|0.03% atropine eye drops|Participants will receive one drop per eye every night for two weeks
11154194|NCT03699397|Experimental|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
11154195|NCT03699384|Experimental|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
11154196|NCT03699371|Experimental|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of continuous renal replacement therapy (CRRT) 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU for the purpose of the study.
11154197|NCT03699371|No Intervention|Late Supplemental Parenteral Nutrition|Control group: would receive EN reaching up to 20 % of daily nutritional requirements and late (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day ) in SPN on 7th day of stay in ICU if it is not already met via enteral route.
11154198|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
11154199|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
11154200|NCT03699345||Edwards CENTERA THV|
11154201|NCT03699332|Experimental|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
11154202|NCT03699319|Experimental|CPI-613 + modified FOLFIRINOX|Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.
11154271|NCT03698799||Non-LPV|Patients do not receive LPV strategy at the initiation of MV support.
11154204|NCT03699306|Active Comparator|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
11154205|NCT03699306|Active Comparator|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
11154206|NCT03699293|Active Comparator|ASA and Celecoxib|Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
11154207|NCT03699293|Active Comparator|ASA and Naproxen|Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
11154208|NCT03699280|Experimental|Virtual Reality|VR video to be played during the procedure
11154209|NCT03699280|No Intervention|Standard Procedure|Routine protocol outpatient hysteroscopy
11154210|NCT03699267||UBR TRAM / GBA|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
11154211|NCT03699267||UBR TRAM / GBA + TAP|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
11154212|NCT03699267||M + UBR TRAM / GBA|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
11154213|NCT03699267||M + UBR TRAM / GBA + TAP|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
11154214|NCT03699254|Active Comparator|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:
~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.
~Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above> 38 copies/mL (> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
11154215|NCT03699254|Experimental|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):
~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.
~Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
11154216|NCT03699241|Placebo Comparator|Group 1|HIV-Uninfected participants
11154217|NCT03699241|Placebo Comparator|Group 2|HIV-Uninfected participants
11154218|NCT03699241|Placebo Comparator|Group 3|HIV-Uninfected participants
11154219|NCT03699241|Placebo Comparator|Group 4|HIV-Uninfected participants
11154220|NCT03699241|Placebo Comparator|Group 5|HIV-Uninfected participants
11154221|NCT03699215|Placebo Comparator|placebo|solution for intravenous infusion, with similar organoleptic characteristics than active treatment.
11154222|NCT03699215|Experimental|levosimendan|Concentrate for solution for perfusion. Pack with a 5 ml vial
11154223|NCT03699202|Experimental|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
11154224|NCT03699202|Experimental|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
11154225|NCT03699202|Experimental|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
11154226|NCT03699202|Placebo Comparator|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
11154227|NCT03699189|Experimental|Immediate ANAIS|Participants that attend the training course immediately.
11154228|NCT03699189|No Intervention|Delayed ANAIS|Participants that attend the training course a year later.
11154229|NCT03699176|Experimental|Vilaprisan|2 treatment periods of 12 weeks without a break
11154230|NCT03699176|Placebo Comparator|Placebo|2 treatment periods of 12 weeks without a break
11154231|NCT03699163||Endoscopy patients|Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure.
11154232|NCT03699163||Colorectal cancer patients|Patients who have known pre-diagnosed colorectal cancer (adenocarcinoma) attending hospital as part of their clinical care will be asked to give a breath sample prior to their cancer operation.
11154233|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
11154234|NCT03699137||Cases with confirmed ACS|Cases with confirmed diagnosis of acute coronary syndrome in the MINAP database (national registry of ACS patients). No interventions apply to this group as this is an observational study.
11154235|NCT03699137||EMS personnel|Emergency Medical Service (EMS) personnel will take part in the focus group. No intervention applies to this group in this qualitative component of the study.
11154236|NCT03699124|Active Comparator|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
11154237|NCT03699124|Active Comparator|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
11154238|NCT03699124|Active Comparator|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
11154239|NCT03699085|Experimental|ED-LINC Intervention Condition|Patients in this arm will receive the ED-LINC intervention. Elements of ED-LINC are based on evidence-based treatments and are central components of collaborative care. ED-LINC will be supported by a novel Emergency Department Information Exchange (EDIE) technology platform that allows for the creation of ED care plans and electronic alerts and will assist in care coordination of this complex population.
11154240|NCT03699085|No Intervention|Usual Care Condition|Patients in this arm may receive a spectrum of consulting services visits including social work services, psychiatric consultation, inpatient psychiatry consult, rehabilitation psychology consultation, addiction intervention services, pain team consultation services that include MD psychiatric and PhD psychologist providers, spiritual care or other consulting services which shall count as usual care.
11154241|NCT03699059|Other|Health Care Professionals|A purposeful sample of 5 HCP's from the transplant team will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
11154242|NCT03699059|Other|Kidney Transplant Patients|A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
11154243|NCT03699046|Active Comparator|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
11154244|NCT03699046|Sham Comparator|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
11154245|NCT03699033|Experimental|Radiation|2.5 Gy/Fraction
11154246|NCT03699020|Experimental|Acceptance and Commitment Therapy (ACT)|The intervention will consists of eight weekly two hour group ACT sessions led by trained lay personnel and followed by homework. ACT is a behavioral therapy.
11154247|NCT03699020|Experimental|Education Control|Consists of eight weekly two hour group chronic pain education sessions led by trained lay personnel and followed by homework.
11154248|NCT03699007|Experimental|Graded Exposure Therapy (GET Living)|GET Living is jointly delivered by a pain psychologist and a physical therapist. The GET Living treatment was based on a published graded in-vivo exposure treatment manual for adults with adaptations to target a pediatric audience.
11154249|NCT03699007|Active Comparator|Typical Pain Management (TPM)|TPM is a treatment intervention that is representative of current standards of care in a multidisciplinary pain clinic setting. It consists of Cognitive Behavioral Therapy (CBT) and Physical Therapy (PT) sessions, delivered separately by a pain psychologist and a physical therapist.
11154250|NCT03698994|Experimental|Treatment (ulixertinib)|Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11154251|NCT03698981|Experimental|Mothers Moving towards Empowerment (MME)|The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
11154252|NCT03698981|No Intervention|Treatment As Usual (TAU)|Control condition participants will receive Treatment as usual (TAU), including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the MME intervention group.
11154253|NCT03698968|Other|Single prospective intervention|
11154254|NCT03698955|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
11154255|NCT03698955|Active Comparator|Mediterranean diet|The diet group will be asked to follow a Mediterranean diet for 16 weeks.
11154256|NCT03698929|Active Comparator|Dietary Effect of Cholesterol - Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the egg phase participants will consume two egg yolks a day for four weeks. Each week, participants will be given a week's worth of baked goods containing two egg yolks each.
11154257|NCT03698929|Placebo Comparator|Dietary Effect of Cholesterol - No-Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the no-egg phase participants will consume an egg-free product for four weeks. Each week participants will be given a week's worth of egg-free baked goods.
11154258|NCT03698903|Experimental|Take a STAND 4 Health: Immediate|Receives the coaching calls + mHealth intervention first, then receives only the mHealth intervention after the 4 week assessment.
11154259|NCT03698903|Active Comparator|Take a STAND 4 Health: Delayed|Will receive no intervention for the first 4 weeks but then after assessment will be provided the opportunity to receive the full coaching calls + mHealth intervention.
11154260|NCT03698890|No Intervention|Control|Usual care of 3 to 6-monthly clinic visit
11154261|NCT03698890|Experimental|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
11154262|NCT03698864|Experimental|PCS499 900mg twice a day|
11154263|NCT03698851|Experimental|Test Group|Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).
11154264|NCT03698851|Active Comparator|Control Group (C)|Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).
11154265|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
11154266|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
11154267|NCT03698825|Experimental|Dose Escalation of TEW-7197|TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
11154268|NCT03698812||CTL group|control group
11154269|NCT03698812||EXP group|Colonoscope
11154270|NCT03698799||LPV|Patients receive LPV strategy at the initiation of MV support. The LPV strategy is defined as ventilation with tidal volume of <8 mL/kg of PBW plus applying PEEP of at least 5 cm H2O.
11157152|NCT03679052|Active Comparator|Group II (Clonidine group): (n=100)|
11154272|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.
~Participants will be required to exercise on one occasion."
11154273|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.
~Participants will be required to exercise on one occasion."
11154274|NCT03698773|Active Comparator|Baseline Group|Access to existing educational materials about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
11154275|NCT03698773|Experimental|Website Group|Access to a tablet computer set to display an educational website (thepainlesspush.com) with information about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
11154276|NCT03698760|Experimental|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
11154277|NCT03698760|Experimental|Control Group|Participants without cognitive disorders
11154278|NCT03698747||mTBI Study Group with McDESPOT sequence|Study group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
11154279|NCT03698747||Control Group|Control group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)
11154280|NCT03698734|Active Comparator|Evening primrose oil|
11154281|NCT03698734|Placebo Comparator|placebo|
11154282|NCT03698708|Experimental|CARES Intervention|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
11154283|NCT03698695|Experimental|THN201|THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days
11154284|NCT03698695|Active Comparator|Donepezil|Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days
11154285|NCT03698695|Placebo Comparator|Placebo|Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days
11154286|NCT03698682|Experimental|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
11154287|NCT03698682|Experimental|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
11154288|NCT03698669|Experimental|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
11154289|NCT03698669|Active Comparator|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
11154290|NCT03698630|Experimental|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
11154291|NCT03698630|Active Comparator|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
11154292|NCT03698617|Experimental|HSK3486|"Dose Escalation Cohort:
~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg."
11154293|NCT03698617|Active Comparator|Propofol|Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg
11154294|NCT03698604|Active Comparator|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
11154295|NCT03698604|Active Comparator|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
11154296|NCT03698591|Experimental|Transcranial magnetic stimulation (TMS), then Sham TMS.|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes after stimulation, experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
11154297|NCT03698591|Sham Comparator|Sham TMS, then Transcranial magnetic stimulation (TMS)|Experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject. Experimenters have defined the target coordinates for the stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes post sham stimulation, experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates.
11154298|NCT03698578|Experimental|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
11154633|NCT03696381|Sham Comparator|Sham tRNS|Sham tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
11154299|NCT03698578|Experimental|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
11154300|NCT03698565|Experimental|PPI and ANI measurements|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.
~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
11154301|NCT03698552|Experimental|ADCT-602|Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
11154302|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.
~Spontaneous hand gestures and stutter frequency are investigated in this group."
11154303|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.
~Spontaneous hand gestures are investigated in this group"
11154304|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
11154305|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
11154306|NCT03698526|Active Comparator|Palliative care I|Palliative care
11154307|NCT03698526|Active Comparator|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
11154308|NCT03698526|Active Comparator|Control III|Patients before colonoscopy
11154309|NCT03698513|Experimental|BMS-986177 + Aspirin + Clopidogrel|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 4-5)
11154310|NCT03698513|Experimental|BMS-986177 (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5)
11154311|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin + Clopidogrel|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
11154312|NCT03698513|Experimental|BMS-986177 (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5)
11154313|NCT03698513|Placebo Comparator|BMS-986177 placebo + Clopidogrel|BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
11154314|NCT03698513|Experimental|BMS-986177 + Clopidogrel|BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
11154315|NCT03698513|Experimental|BMS-986177 (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5)
11154316|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
11154317|NCT03698513|Experimental|BMS-986177 + Aspirin|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
11154318|NCT03698500|Other|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
11154319|NCT03698487|No Intervention|Retrospective Chart Review|"Specifically, it consists of:
~A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).
~A before/after intervention
~A multiple case study (a sub-study of the before/after intervention)"
11154320|NCT03698487|Active Comparator|Intervention|"A before/after intervention
~A multiple case study (a sub-study of the before/after intervention)"
11154321|NCT03698474|Active Comparator|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
11154322|NCT03698474|Active Comparator|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
11154323|NCT03698474|Active Comparator|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
11154324|NCT03698474|Active Comparator|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
11154325|NCT03698474|Active Comparator|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
11154326|NCT03698474|Active Comparator|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
11154327|NCT03698461|Experimental|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
11154328|NCT03698448|Placebo Comparator|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
11154329|NCT03698448|Active Comparator|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
11154330|NCT03698448|Active Comparator|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
11154331|NCT03698448|Active Comparator|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
11154332|NCT03698435||Prophylaxis|Patients who receive (val)ganciclovir for prophylaxis of cytomegalovirus
11154333|NCT03698435||Treatment|Patients who receive (val)ganciclovir for treatment of cytomegalovirus
11154334|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) > 60 mL/min for > 3 months and no known current or chronic medical or surgical conditions.
~Blood and urine samples are collected for every 3rd hour during 24 hours"
11154360|NCT03698292|Active Comparator|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
11154335|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for > 3 months (i.e. CKD stage 4).
~Blood and urine samples are collected for every 3rd hour during 24 hours"
11154336|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for > 3 months for ESKD and with anuria (urine excretion < 100 mL/day).
~Blood and urine samples are collected for every 3rd hour during 24 hours"
11154337|NCT03698409|No Intervention|Botox in preservative-free saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative-free saline, as recommended by the manufacturer. 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites)
11154338|NCT03698409|Active Comparator|Botox in preserved saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative saline (i.e. bacteriostatic saline). 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites).
11154339|NCT03698396|Experimental|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
11154340|NCT03698383|Experimental|Herzuma plus Gedatolisib|
11154341|NCT03698370|Experimental|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
11154342|NCT03698370|Experimental|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
11154343|NCT03698357|Experimental|Interactive video balance-based exercise|Fifteen participants in group A will undergo 30 minutes a day and 3 days a week interactive video balance-based exercise intervention for four weeks.
11154344|NCT03698357|Active Comparator|Conventional physiotherapy|Another 15 participants allocated to the group B will receive 30 minutes a day and 3 days a week conventional rehabilitation for four weeks.
11154345|NCT03698344|Experimental|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
11154346|NCT03698331|Experimental|Valbenazine|Valbenazine or placebo oral capsules administered once daily for 7 weeks.
11154347|NCT03698331|Placebo Comparator|Placebo|Placebo oral capsules administered once daily for 7 weeks.
11154348|NCT03698318|Experimental|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154349|NCT03698318|Experimental|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154350|NCT03698318|Experimental|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154351|NCT03698318|Experimental|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154352|NCT03698318|Experimental|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154353|NCT03698318|Experimental|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154354|NCT03698318|Experimental|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154355|NCT03698318|Experimental|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154356|NCT03698318|Experimental|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154357|NCT03698318|Experimental|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
11154358|NCT03698305|Experimental|ASP5354 Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.
11154359|NCT03698305|Placebo Comparator|Placebo Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.
11154361|NCT03698292|Active Comparator|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
11154362|NCT03698279|Experimental|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11154363|NCT03698279|Experimental|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11154364|NCT03698279|Experimental|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11154365|NCT03698279|Active Comparator|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11154366|NCT03698279|Experimental|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than [<] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11154367|NCT03698279|Active Comparator|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to <24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11154368|NCT03698266|Other|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
11154369|NCT03698253|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followedby Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).
~Regorafenib is administered at adjusted doseage of 120 mg daily for 3 weeks in a 4-week cycle."
11154370|NCT03698240|Experimental|Mindfulness-based program|Children and parents receive the program
11154371|NCT03698240|No Intervention|Waiting-list|Children and parents receive no-interventions.
11154372|NCT03698227|Experimental|Study treatment|"Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.
~Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles
~Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles
~Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle"
11154373|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1.
11154374|NCT03698201||Cohort 1 / High grade Glioma|"Cohort 1:
~Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV)
~Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
11154375|NCT03698201||Cohort 2 / Low grade Glioma|"Cohort 2:
~Histologically confirmed low grade (grade II) glioma
~Planned treatment either
~expectant monitoring or
~RT alone or
~Chemotherapy alone or
~a combination of RT/Chemotherapy"
11154376|NCT03698188|Experimental|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
11154377|NCT03698188|Active Comparator|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
11154378|NCT03698175|Experimental|Three good things exercise|
11154379|NCT03698175|Placebo Comparator|Unspecific childhood memory recall exercise|
11154380|NCT03698162|Experimental|Cohort I (STAR DCE-MRI)|Participants with recurrent high-grade glioma undergo STAR DCE-MRI every 2 months, and just prior to and 4-6 weeks after starting bevacizumab treatment. Participants may undergo more frequent MRI if there is concern for tumor progression.
11154381|NCT03698162|Experimental|Cohort II (STAR DCE-MRI)|Participants with melanoma brain metastases undergo STAR DCE-MRI at baseline and 4-6 weeks after therapy. Participants may undergo more frequent MRI if there is concern for tumor progression.
11154382|NCT03698149|Experimental|Electrocorticography-based brain computer interface|
11154383|NCT03698136|Experimental|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
11154384|NCT03698123|Experimental|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
11154385|NCT03698110|Experimental|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
11154386|NCT03698110|No Intervention|Control Group|Participated in one introductory session and in a closing session.
11154387|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
11154388|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
11154389|NCT03698071|Experimental|ANCA associated vasculitis|
11154390|NCT03698058|Experimental|A2 Growing Up Milk|
11154391|NCT03698058|No Intervention|Traditional non-A2 milk|
11154392|NCT03698058|Active Comparator|Other Growing Up Milk|
11154393|NCT03698045|Experimental|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
11154394|NCT03698032|Active Comparator|Water Arm|Participants will consume water only as the intervention
11154395|NCT03698032|Active Comparator|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
11154396|NCT03698032|Active Comparator|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
11154397|NCT03698019|Experimental|Arm I (adjuvant pembrolizumab)|Within 84 days after surgical resection, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity.
11154398|NCT03698019|Active Comparator|Arm II (adjuvant and neoadjuvant pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity.
11154399|NCT03698006|Experimental|Tibial nerve block|Adductor canal and tibial nerve blocks performed by the anesthetist under ultrasound guidance before spinal block.
11154400|NCT03698006|Active Comparator|Local infiltration analgesia|Adductor canal block by the anesthetist under ultrasound guidance before spinal block. Infiltration of the knee by the surgeon with local anesthetic at the end of the surgery.
11154401|NCT03697993|Experimental|Strategy 1|Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317
11154402|NCT03697993|Experimental|Strategy 2|Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317
11154403|NCT03697980||HVAD|
11154404|NCT03697967|Experimental|Supine|Infant placed supine for 120 seconds before cord clamping
11154405|NCT03697967|Experimental|Prone|Infant placed prone for 120 seconds before cord clamping
11154406|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
11154407|NCT03697941||Surgical cut-down and arterial puncture under direct vision|
11154408|NCT03697941||Percutaneous arteriotomy closed with closure device|
11154409|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.
~Subjects will be classified as trained, physical active and untrained according to their VO2max.
~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
11154410|NCT03697915|Experimental|Experimental group|Experimental group, in which a physical therapy programme supplemented by the James lift system was applied
11154411|NCT03697915|Placebo Comparator|Control|Control group, in which a conventional physical therapy programme was applied.
11154412|NCT03697889|Experimental|Treatment Sequence AB|Participants will receive Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 1 followed by Treatment B (reference product Nalgesin, 1 x 275 mg) dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
11154413|NCT03697889|Experimental|Treatment Sequence BA|Participants will receive Treatment B (reference product Nalgesin, 1 x 275 mg) at dosing period 1 followed by Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
11154414|NCT03697876|Experimental|PRO-165|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
11154415|NCT03697876|Active Comparator|1. Artelac® Nightime Gel|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
11154416|NCT03697863||Noninvasive Adjusted Ventilatory Assist|
11154417|NCT03697863||Noninvasive Pressure Support|
11154418|NCT03697850|Experimental|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
11154419|NCT03697837|Experimental|Parent Management Training|Parents will receive a web-based parenting intervention for tantrums and disruptive behavior in young children
11154420|NCT03697824|Experimental|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
11154421|NCT03697811|Experimental|DE-117 Ophthalmic Solution 0.002%|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
11154422|NCT03697798|Active Comparator|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
11154423|NCT03697798|Active Comparator|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
11154491|NCT03697304|Experimental|Cohort 1 - Module A|
11154424|NCT03697798|Active Comparator|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
11154425|NCT03697798|Active Comparator|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
11154426|NCT03697785|Experimental|Beacon Caresystem with weaning advice|Beacon care system set up to give weaning advice and options to accept or reject advice.
11154427|NCT03697785|Other|Beacon Caresystem for monitoring only|Beacon care system attached but only for data collection purposes. No advice will be given.
11154428|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
11154429|NCT03697759|Experimental|Usual care + selfBACK|Participants will use the selfBACK system and app
11154430|NCT03697746|Active Comparator|Paracetamol|1000 mg Paracetamol vial intravenously
11154431|NCT03697746|Active Comparator|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
11154432|NCT03697746|Active Comparator|Ibuprofen|400 mg Ibuprofen vial intravenously
11154433|NCT03697733|Experimental|Oral Etoricoxib group|Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure
11154434|NCT03697733|Placebo Comparator|Intravenous Fentanyl group|Subjects will receive oral placebo [folic acid] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure
11154435|NCT03697720|Experimental|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
11154436|NCT03697707|Experimental|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
11154437|NCT03697707|Experimental|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
11154438|NCT03697694|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
11154439|NCT03697694|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
11154440|NCT03697681|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
11154441|NCT03697681|Placebo Comparator|Placebo|placebo
11154442|NCT03697668|Experimental|imatinib-Dihydroartemisinin-piperaquine|triple combination
11154443|NCT03697668|Active Comparator|Dihydroartemisinin-piperaquine|standard of care
11154444|NCT03697655|Experimental|PREDATOR-BR Cohort A|n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
11154445|NCT03697655|No Intervention|PREDATOR-BR Cohort B|n=46, Control Group, Observation (no treatment)
11154446|NCT03697655|Experimental|PREDATOR-MRD Cohort A|n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
11154447|NCT03697655|No Intervention|PREDATOR-MRD Cohort B|n=59, Control Group, Observation (no treatment)
11154448|NCT03697642|Experimental|NG tube placement with nasopharyngeal tube|
11154449|NCT03697642|Active Comparator|NG tube placement without nasopharyngeal tube|
11154450|NCT03697629|Experimental|Daratumumab|Increased infusion rate daratumumab monotherapy
11154451|NCT03697616|Experimental|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
11154452|NCT03697603|Experimental|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
11154453|NCT03697603|Experimental|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
11154454|NCT03697603|Placebo Comparator|Placebo|Tablets, Oral, once daily, 14 weeks
11154455|NCT03697590|Experimental|PDT with no curettage|
11154456|NCT03697590|Active Comparator|Standard PDT|
11154457|NCT03697577||ER+/HER2- metastatic breast cancer|Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)
11154458|NCT03697564|Experimental|gemcitabine +nivolumab + cabiralizumab|
11154459|NCT03697551|Experimental|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
11154460|NCT03697538|Experimental|Adductor Canal Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
11154492|NCT03697304|Experimental|Cohort 2 - Module A|
11154493|NCT03697304|Experimental|Cohort 3 - Module A|
11154494|NCT03697304|Experimental|Cohort 1 - Module C|
11154495|NCT03697304|Experimental|Cohort 2 - Module C|
11154496|NCT03697304|Experimental|Cohort 3 - Module C|
11154461|NCT03697538|Active Comparator|Femoral Nerve Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
11154462|NCT03697525|Experimental|Vibration Group (VG)|VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
11154463|NCT03697525|Sham Comparator|Control Group (CG)|CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
11154464|NCT03697512|Experimental|Ibrutinib and Rituximab|"Induction PART A, from Day 1 to Day 56.
~Patients will be treated with:
~Ibrutinib 560 mg/day continuously up to Day 56;
~Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.
~Induction PART B, from Day 57 to Day 196.
~Patients will be treated with:
~Ibrutinib 560 mg/day continuously up to Day 196;
~Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.
~Maintenance PART C, from Day 197 to Day 730.
~Patients will be treated with:
~- Ibrutinib 560 mg/day continuously up to Day 730."
11154465|NCT03697499|Experimental|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
11154466|NCT03697499|Sham Comparator|fish oil and shame exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
11154467|NCT03697499|Placebo Comparator|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
11154468|NCT03697499|Other|soy oil and shame exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
11154469|NCT03697486|Experimental|High Protein|(40,6% protein)
11154470|NCT03697486|Experimental|Moderate Protein|(23.5% protein)
11154471|NCT03697486|Experimental|Low Protein|(12.4% protein)
11154472|NCT03697473|Active Comparator|Nordic Hamstring Exercise Group|Participants were required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they could no longer lower themselves as such, they were instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touched the ground they were instructed to immediately return to the starting position by pushing up with their hands.
11154473|NCT03697473|Experimental|Hip Extension Exercise Group|The participant lay on an exercise bench at a 45° angle with their hips held just over the top of the bench, their trunk erect and hips extended and their heel supported. Participants slowly flexed their hip until they reached 90° from the starting position and were then required to return to the starting position by extending through the hip while maintaining a neutral pelvic and trunk posture throughout. This exercise was then repeated on the opposite leg
11154474|NCT03697460|Experimental|INCB018424|INCB018424 Cream
11154475|NCT03697447|Experimental|Endermotherapy treated scar|Endermotherapy massage treatment
11154476|NCT03697447|No Intervention|Control scar|No intervention, standard of care
11154477|NCT03697434|Experimental|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
11154478|NCT03697421||Local Evaluation|The SHR program intends to serves couples who are over 18 years of age, are in a romantic relationship, and have at least one child (biological or adopted) under the age of 18 residing in the home or are expecting.
11154479|NCT03697408|Experimental|Itacitinib and everolimus|
11154480|NCT03697382|Experimental|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
11154481|NCT03697382|Experimental|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
11154482|NCT03697382|Experimental|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
11154483|NCT03697369||Observation group|Individuals with T1D ages 0-20 years who switched management modality from MDI to pump as part of their clinical care and were followed up prospectively in the next 12 months.
11154484|NCT03697356|Experimental|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|
11154485|NCT03697343|Other|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
11154486|NCT03697343|Other|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
11154487|NCT03697330|Active Comparator|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:
~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
11154488|NCT03697330|Active Comparator|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:
~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
11154489|NCT03697317|Experimental|Televideo Lifestyle Coaching|
11154490|NCT03697317|Active Comparator|Enhanced Usual Care|
11154501|NCT03697278|No Intervention|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
11154502|NCT03697278|Experimental|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
11154503|NCT03697265|Experimental|Sepranolone (UC1010) low dose|Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase
11154504|NCT03697265|Experimental|Sepranolone (UC1010) high dose|Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase
11154505|NCT03697265|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) during the luteal phase
11154506|NCT03697252|Experimental|KarXT|
11154507|NCT03697252|Placebo Comparator|Placebo|
11154508|NCT03697239|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
11154509|NCT03697226|Experimental|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
11154510|NCT03697226|Experimental|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
11154511|NCT03697226|Experimental|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
11154512|NCT03697226|Experimental|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
11154513|NCT03697226|Experimental|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
11154514|NCT03697213||General Practitioners|Registered General Practitioners in one of the six participating countries.
11154515|NCT03697200|Active Comparator|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
11154516|NCT03697200|Sham Comparator|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
11154517|NCT03697200|Other|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
11154518|NCT03697187||Hereditary Angioedema|Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).
11154519|NCT03697174|Experimental|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
11154520|NCT03697174|Sham Comparator|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
11154521|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 1|Once Daily
11154522|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 2|Twice Daily
11154523|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 3|Three Times Daily
11154524|NCT03697148|Experimental|Diagnostic (mpMRI)|Patients undergo mpMRI within 3 months prior to schedule surgery.
11154525|NCT03697135||Seed Contacts|Initial participants who will invite previous injecting contacts to take a hepatitis C test using a respondent driven sampling method
11154526|NCT03697135||Initial Nominations for Testing|Contacts of initial participants who consent to be tested and enrol in the study using a respondent driven sampling method
11154527|NCT03697135||Second Level Nominations for testing|Contacts of wave one participants who consent to be tested and enrol in the study using a respondent driven sampling method
11154528|NCT03697122|Experimental|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
11154529|NCT03697109|Experimental|Relacorilant (open-label phase)|The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
11154530|NCT03697109|Experimental|Relacorilant (randomized-withdrawal phase)|Patients who meet any of the response criteria will advance to the randomized-withdrawal phase of the study and receive the same highest dose as in the open-label phase.
11154531|NCT03697109|Placebo Comparator|Placebo (randomized-withdrawal phase)|Placebo matched to study drug
11154532|NCT03697096|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
11154533|NCT03697096|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
11154534|NCT03697083|Experimental|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
11154535|NCT03697083|Active Comparator|Active Control Arm|Participants will be asked to think about where they will store their prescription.
11154536|NCT03697083|Active Comparator|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
11154537|NCT03697070|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
11154538|NCT03697070|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
11154664|NCT03696173||Participants taking abatacept with methotrexate|
11154539|NCT03697057||patients|Patients scheduled for elective ambulatory gynaecological surgery, which was performed under standardised general anaesthesia
11154540|NCT03697057||healthy volunteers|Female healthy volunteers matched to the patient group regarding the age
11154541|NCT03697031||REKOVELLE®|Follitropin Delta
11154542|NCT03697018|Experimental|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
11154543|NCT03697018|Active Comparator|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
11154544|NCT03697005|Experimental|BioHPP PEEK single posterior crowns|BioHPP PEEK copings veneered with composite resin
11154545|NCT03697005|Active Comparator|zirconia-based single posterior crowns|yttria stabilized tetragonal zirconia used as copings to be veneered with porcelain
11154546|NCT03696992|Experimental|NBI|Tandem colonoscopy with NBI follow by WL
11154547|NCT03696992|Active Comparator|BLI|Tandem colonoscopy with BLI follow by WLI
11154548|NCT03696992|Experimental|WLI|Tandem colonoscopy with WLI follow by WL
11154549|NCT03696979|Active Comparator|myofascial induction|Twice a week for 8 weeks. Lumbar interfacial field stroke application, Lumbar interfacial field to deep application, Lumbar region cross-hands induction technique, Hip flexor region induction.
11154550|NCT03696979|Active Comparator|Therapeutic Pain education|Pain education,twice a week for 8 weeks. The mechanism of pain,Pain processing in the center, How sensitive the central nervous system is in chronic pain, Pain becomes chronic with the contribution of factors, Problems related to fear of pain will be explained in detail.
11154551|NCT03696966|Active Comparator|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
11154552|NCT03696966|Experimental|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
11154553|NCT03696953|Experimental|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule
~1 capsule daily from 28 weeks until the time of birth."
11154554|NCT03696953|No Intervention|Placebo|Microcrystalline Cellulose
11154555|NCT03696940|Experimental|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
11154556|NCT03696940|Active Comparator|Control Group|2 tablets of: Atorvastatin 10 mg
11154557|NCT03696927|Experimental|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
11154558|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
11154559|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
11154560|NCT03696901||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in Germany
11154561|NCT03696888|Experimental|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
11154562|NCT03696888|Active Comparator|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
11154563|NCT03696875|Experimental|Multilevel Guided Discharge Planning|
11154564|NCT03696875|Active Comparator|Standard of care|
11154565|NCT03696862|Experimental|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
11154566|NCT03696849|Active Comparator|glazed emax Press|
11154567|NCT03696849|Experimental|Polished emax Press|
11154568|NCT03696836|Experimental|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
11154569|NCT03696810|Other|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
11154570|NCT03696797|Active Comparator|Treatment Group|Will have a Unit of blood (two cups, the same amount donated at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure your blood count to be sure you are not anemic, and blood pressure to be sure no dehydration. During or after donation, a sports drink is provided to replace the fluid loss. Phlebotomy
11154571|NCT03696797|Sham Comparator|Control Group|Will not donate blood, but will have a needle inserted into a vein in your arm. Both groups will not know which group assignment they have been randomized. Sham Phlebotomy
11154572|NCT03696784|Experimental|Single Arm iC9.CAR19 T cells|"The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)
~-1 1 x 10^5
~1 x 10^6
~2 x 10^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks, then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1, 3 more subjects will be enrolled. If DL 1 is not tolerable, a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.
~Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.
~AP1903 (0.4 mg/kg), a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)."
11154573|NCT03696784|Experimental|Expansion Cohort iC9-CAR19 cells|After the tolerable cell dose (TCD) has been determined in adults, up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).
11154574|NCT03696771|Experimental|NJH395|Includes non-breast HER2-positive advanced malignancies
11154575|NCT03696758|Experimental|Young adults born premature|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. Subjects will also undergo pulmonary function testing and electrocardiogram.
11157153|NCT03679052|Placebo Comparator|Group III (Control group): (n=100)|
11154576|NCT03696745|Placebo Comparator|Placebo|preterm infants with severe hypoxic ischemic encephalopathy receive only 0.9% Sodium-chloride
11154577|NCT03696745|Experimental|infusion|preterm infants with severe hypoxic ischemic encephalopathy will receive up to 4 infusions of their own volume reduced cord blood stem cells. The number of doses will be determined by the amount of available cord blood stem cells. The dose for each infusion is 5x107 cells/kg
11154578|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
11154579|NCT03696719|Active Comparator|Undergoing surgery under general anesthesia|Patients will undergo the surgery under general anesthesia, anesthetic regime will be according to standard clinical practice.
11154580|NCT03696719|Active Comparator|Undergoing surgery under regional anesthesia|Patients will undergo the surgery under neuroaxial anesthesia.
11154581|NCT03696706|Active Comparator|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
11154582|NCT03696706|Placebo Comparator|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
11154583|NCT03696706|No Intervention|Control group|In this group, the participants will only be evaluated. No intervention will take place.
11154584|NCT03696693||children with chronic rhinosinusitis|Children aged 6-18 years presented with symptoms of chronic rhinosinusitis will be recruited from the otorhinolaryngology out-patient clinic and department at Assiut University Hospital from October, 2018 to October, 2019.
11154585|NCT03696693||children without chronic rhinosinusitis|Children have the same age and number in the study group which are presented with vocal symptoms and have not chronic rhinosinusitis will be recruited for the same duration.
11154586|NCT03696680|Experimental|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
11154587|NCT03696667|Active Comparator|Affective BCI training|15 participants in the intervention group will undergo 24 sessions of BCI-based emotion regulation training over an 8-week period. Each session will take about 30-minute to complete where participants will listen to music with audio feedback to regulate emotions toward positive affect.
11154588|NCT03696667|No Intervention|Control group|15 participants in the control group will take part in 24 music sessions (with no audio feedback) over an 8-week period. Each session will take about 30-minute to complete.
11154589|NCT03696654|No Intervention|Before treatment|
11154590|NCT03696654|Active Comparator|After treatment|
11154591|NCT03696641|Active Comparator|glazed IPS e.max|lithium disilicate glazed crowns that proved to have a good color stability
11154592|NCT03696641|Experimental|polished IPS e.max|polished lithium disilicate crowns with the polishing kit
11154593|NCT03696628|Other|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
11154594|NCT03696628|Other|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
11154595|NCT03696615|Experimental|Tabata Kettlebell Swings|"Participants in this group performed:
~A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)
~Receive instruction on the kettlebell swing
~Performed a high-intensity workout in a Tabata Kettlebell Swings format, which involves 20 seconds of all out effort followed by 10 seconds of rest, repeated for a total of 8 times."
11154596|NCT03696615|Active Comparator|Control Group|"Participants in this group performed:
~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)"
11154597|NCT03696602||test with methacholine|
11154598|NCT03696602||test with exercise|
11154599|NCT03696576|Active Comparator|PhoRTE|This group will undergo standard PhoRTE therapy.
11154600|NCT03696576|Experimental|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
11154601|NCT03696563|Active Comparator|Control group|In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
11154602|NCT03696563|Experimental|FreeO2 group|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration to reach the SpO2 target set by paramedic.
11154603|NCT03696550|Experimental|Cohort 1|"Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age.
~Age group (years) Dose (mg/kg) 12 to <18 (Cohort 1) 1.50"
11154604|NCT03696550|Experimental|Cohort 2|"Eravacycline will be administered as a single 60 minute IV infusion according to age.
~Age group (years) Dose (mg/kg) 8 to <12 (Cohort 2) 1.75"
11154605|NCT03696537|Experimental|Fludarabine + Total Marrow Irradiation|
11154606|NCT03696524|Experimental|Intervention Group|This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
11154607|NCT03696524|No Intervention|Usual Care|The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
11154608|NCT03696511|Active Comparator|group 1:maxillary insertion|Orthodontic miniscrew insertion; maxillary insertion. buccal
11154609|NCT03696511|Active Comparator|group 2: mandible insertion|Orthodontic miniscrew insertion; mandible insertion.
11154610|NCT03696511|Active Comparator|group 3: palatal insertion|Orthodontic miniscrew insertion; palatal insertion
11154611|NCT03696498|Experimental|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.
~Intervention: A permanent resin restoration is placed on top of the remained caries."
11154612|NCT03696498|Active Comparator|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.
~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
11154613|NCT03696485|Experimental|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
11154614|NCT03696485|Experimental|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
11154615|NCT03696472|Experimental|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
11154616|NCT03696472|Active Comparator|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
11154617|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 1|Participants will receive single oral dose of JNJ-53718678, 2000 milligram (mg) suspension or matching placebo on Day 1, under fasted conditions.
11154618|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 2|Participants will receive single oral dose of JNJ-53718678, of maximum 3000 mg suspension or matching placebo on Day 1, under fasted conditions.
11154619|NCT03696459|Experimental|Part 1 (Dose escalation): Panel 3|Participants will receive single oral dose of JNJ-53718678 4500 mg suspension (this dose may be used in Part 2, Treatment F) or matching placebo on Day 1, under fasted condition.
11154620|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 4 (Optional)|Participants will receive single oral dose of JNJ-53718678 (dose to be decided [this dose may be used in Part 2, Treatment F]) suspension or matching placebo on Day 1, under fasted condition, if 4500 mg dose in Panel 3 is considered safe and tolerable and if pharmacokinetic data require further dose escalation to reach the target exposure.
11154621|NCT03696459|Experimental|Part 2 Group 1: Treatment Sequence EHFG|Participants will receive single oral dose of JNJ-53718678, 500 mg suspension with single oral dose of moxifloxacin placebo and JNJ 53718678 placebo (Treatment E) in Period 1, then participants will receive single oral dose of moxifloxacin 400 mg with single oral dose of JNJ-53718678 placebo (Treatment H) in Period 2 then will receive single oral dose of JNJ-53718678, 4500 mg (dose will be based on review of safety, tolerability, and PK data obtained in Part 1 [either from Panel 3 or 4], this dose may be lower/higher) suspension with single oral dose of moxifloxacin placebo (Treatment F) in Period 3 followed by single oral dose of JNJ-53718678 placebo with single oral dose of moxifloxacin placebo (Treatment G) in Period 4, on Day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
11154622|NCT03696459|Experimental|Part 2 Group 2: Treatment Sequence FEGH|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment G in Period 3 followed by Treatment H in Period 4 on Day 1 of each treatment period.
11154623|NCT03696459|Experimental|Part 2 Group 3: Treatment Sequence GFHE|Participants will receive Treatment G in Period 1, then Treatment F in Period 2, then Treatment H in Period 3 followed by Treatment E in Period 4 on Day 1 of each treatment period.
11154624|NCT03696459|Experimental|Part 2 Group 4: Treatment Sequence HGEF|Participants will receive Treatment H in Period 1, then Treatment G in Period 2, then Treatment E in Period 3 followed by Treatment F in Period 4 on Day 1 of each treatment period.
11154625|NCT03696446|Experimental|Virtual Cardiac Rehabilitation Program|This group will receive access to the NWC (NexJ Connected Wellness TM (NCW) and will be provided with a fitness tracker (Garmin Vivofit 3) to monitor their exercise, sedentary behaviours, and sleep patterns. The NWC platform includes components for education (health library, workbooks etc), collaboration (personal care plan, appointment scheduler, secure messaging system etc), and motivation (motivational messages on their homepage etc). With the Health Coach, participants will engage in: reviews of their risk factor profile and health priorities; goal setting and action planning; problem solving and skill building; and discussions of relapse prevention. Participants will receive a total of seven hours of health coaching delivered across nine sessions over a 26-week period
11154626|NCT03696446|Other|Case Managed Home Program|The Case Managed Home Program (CMHP) is delivered primarily via telephone. Following their CR intake, patients are linked with their CMHP Health Coach and attends their visit (in person or over the phone) which includes a comprehensive review of their health history, current symptoms, medications, activity, and individual concerns. Following this visit, participants will receive a total of 10 individualized telephone calls over a 26 week period. The program action plan is individually formulated based on the participant's goals and learning needs. Participants are provided with educational kits (exercise, nutrition, stress management or prevention) that are based on the principle of single point learning and incorporate behavioural change techniques.
11154627|NCT03696433|Experimental|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
11154628|NCT03696433|Experimental|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
11154629|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
11154630|NCT03696394|No Intervention|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
11154631|NCT03696394|Active Comparator|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
11154632|NCT03696381|Experimental|Real tRNS|Real tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
11154634|NCT03696355|Experimental|Stratum A1|"Dose Escalation Phase:
~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
~Dose Expansion Phase
~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
11154635|NCT03696355|Experimental|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
11154636|NCT03696342|Experimental|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic
~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
11154637|NCT03696342|Active Comparator|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic
~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
11154638|NCT03696329|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
11154639|NCT03696329|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
11154640|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
11154641|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
11154642|NCT03696290|Active Comparator|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
11154643|NCT03696290|Placebo Comparator|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
11154644|NCT03696290|Active Comparator|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
11154645|NCT03696290|Placebo Comparator|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
11154646|NCT03696277|Experimental|Stereotactic ablative body radiation (SABR)|SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
11154647|NCT03696264|Experimental|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
11154648|NCT03696251||master's nursing program|the graduates of master's nursing program in recent three years in Taiwan
11154649|NCT03696238|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
11154650|NCT03696238|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
11154651|NCT03696225|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
11154652|NCT03696225|Active Comparator|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
11154653|NCT03696212|Experimental|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
11154654|NCT03696199|No Intervention|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
11154655|NCT03696199|Experimental|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
11154656|NCT03696199|Experimental|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
11154657|NCT03696186|Active Comparator|Luminal type-1|Standard treatment
11154658|NCT03696186|Experimental|Luminal type-2|Experimental treatment
11154659|NCT03696186|Active Comparator|Neuroendocrine type-1|Standard treatment
11154660|NCT03696186|Experimental|Neuroendocrine type-2|Experimental treatment
11154661|NCT03696186|Active Comparator|Atypical type-1|Standard treatment
11154662|NCT03696186|Experimental|Atypical type-2|Experimental treatment
11154663|NCT03696173||Participants taking abatacept|
11154665|NCT03696160|Experimental|Biktarvy|"Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.
~Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.
~Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).
~Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food."
11154666|NCT03696160|Experimental|Symtuza|"Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.
~Symtuza® received marketing authorisation valid throughout the EU in September 2017.
~Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)
~Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food."
11154667|NCT03696121|Experimental|Intervention|Desmopressin injection
11154668|NCT03696121|Placebo Comparator|Control|Normal Saline
11154669|NCT03696108|Experimental|Geapixant 45 mg BID|Participants will receive a gefapixant 45 mg film-coated tablet twice daily (BID) during the study period (52 weeks).
11154670|NCT03696108|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg film-coated tablet BID during the study period (52 weeks).
11154671|NCT03696095|Active Comparator|Continous infusion ropivacaine|Continuous infusion via peri-neural femoral nerve catheter of Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode) at rate of 6ml/h + patient controlled bolus of 3ml ...
11154672|NCT03696095|Experimental|PIB ropivacaine|Programmed intermittent bolus of Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode) : 6ml each 60min + patient controlled bolus 3ml ...
11154673|NCT03696082|Experimental|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
11154674|NCT03696082|Experimental|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
11154675|NCT03696082|Experimental|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
11154676|NCT03696082|Experimental|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
11154677|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
11154678|NCT03696056|Experimental|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
11154679|NCT03696056|Active Comparator|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
11154680|NCT03696043|Active Comparator|EVD placement|Catheter placement is most commonly performed via a freehand approach using external anatomical landmarks to help identify the location of the lateral ventricle within the brain without the aid of imaging. Proper identification of the ventricles on pre-procedure imaging, surgeon skill, and estimation of pathologic perturbations to the normal location of the ventricles all factor into the success of catheter placement. Multiple passes are often required. The accuracy rate from the freehand technique has been reported to range from 40 to 98 percent.
11154681|NCT03696043|Experimental|Axium Stealth Image Guidance|The novelty of this study is to investigate whether using image guidance technology can improve EVD catheter placement. Image guidance is used very commonly for EVD and shunt placement in the operating room with excellent accuracy and precision. We hypothesize that using this same workflow at the bedside will improve accuracy; decrease the number of passes needed for a successful placement, decrease the number of post-placement hemorrhagic events, and help improve the effectiveness of the catheter as well as patient outcomes.
11154682|NCT03696030|Experimental|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
11154683|NCT03696017||Group 1|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse opioids (40 patients per group).
11154684|NCT03696017||Group 2|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse benzodiazepines (BZD) (40 patients per group).
11154685|NCT03696017||Group 3|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse BZD/opioid (40 patients per group).
11154686|NCT03696004|Active Comparator|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
11154687|NCT03696004|Active Comparator|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
11154688|NCT03695991||Study group|Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital
11154689|NCT03695978||Nuwiq|All patients receiving Nuwiq (recombinant FVIII)
11154690|NCT03695978||Octanate|All patients receiving Octanate (plasma derived FVIII)
11154691|NCT03695978||Wilate|All patients receiving Wilate (plasma derived FVIII/von Willebrand factor [VWF])
11154692|NCT03695965||study group|patients with history of ankle trauma or chronic lateral ankle pain
11154693|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
11154694|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
11154695|NCT03695939|Experimental|Xeno-Skin™|Single arm trial
11154696|NCT03695926|Experimental|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
11154697|NCT03695913|Experimental|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:
~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.
~Phase II (part 2) - low carb diet:
~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
11154698|NCT03695900|Other|Targeting SpO2 at 93-95% followed by targeting at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
11154699|NCT03695900|Other|Targeting SpO2 at 90-92% followed by targeting at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours.
11154700|NCT03695887|Experimental|Nitrous Oxide Inhalant Product|Nitrous oxide
11154701|NCT03695887|Placebo Comparator|Placebo|placebo comparator
11154702|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:
~over 18 years
~able to read French
~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology
~who received the information and did not object to participate in the study"
11154703|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:
~over 18 years
~able to read French
~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology
~who received the information and did not object to participate in the study"
11154704|NCT03695861|Experimental|Whole-body 18F-FDG PET-CT scan|
11154705|NCT03695835||Adenocarcinoma treated with MyVaccx|MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
11154706|NCT03695822|Experimental|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
11154707|NCT03695796|Other|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
11154708|NCT03695783|Experimental|Online decision aid called IBD&me|IBD&me is an online, freely available tool that allows patients to explore decision-making around biologic therapies for IBD at their own pace. It includes an educational component and an interactive exercise with a series of ratings tasks that generates a personalized preferences report for patients to share and discuss with their physician.
11154709|NCT03695783|Active Comparator|Standardized educational material|PDF file corresponding to the CCFA's online resource on biologic therapies, which is a well-researched and clearly presented overview of IBD biologic therapies, but without an active shared-decision making component.
11154710|NCT03695770|Experimental|target population|All the target population should be included in the experimental arm
11154711|NCT03695757|Experimental|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
11154712|NCT03695757|Experimental|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
11154713|NCT03695744|Experimental|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
11154714|NCT03695731|Experimental|Patients without Neuropathy|activation of cold induced brown adipose tissue
11154715|NCT03695731|Experimental|Patients with Neuropathy|activation of cold induced brown adipose tissue
11154716|NCT03695705|Other|Primary prophylaxis arm|28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
11154717|NCT03695705|Other|Secondary prophylaxis arm|26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
11154718|NCT03695692|Experimental|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
11154719|NCT03695692|Experimental|Control group|Pelvic floor exercises alone have been applied
11154720|NCT03695679|Experimental|Intervention group|Interactive computer-based intervention
11154721|NCT03695679|No Intervention|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
11154722|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
11154723|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
11154724|NCT03695653|Active Comparator|Drink Tracking (MA) Condition|Ps will receive weekly mobile assessment trick tracking described above for six months in addition to the guidelines on safe drinking.
11154725|NCT03695653|Experimental|TA Intervention|The TA intervention is tailored but will adapt over time too
11154726|NCT03695653|Experimental|Tailored Content Only (TO)|The TO treatment arm includes tailored text messages sent at 6pm daily based on the baseline assessment.
11154727|NCT03695640|Active Comparator|Group L|continuous femoral nerve block with levobupivacaine
11154728|NCT03695640|Experimental|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
11154828|NCT03694964|Placebo Comparator|Placebo|Patients will receive placebo (one tablet by day) during 45 days
11154729|NCT03695627|Experimental|Meditation Group|Participants in the meditation group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks
11154730|NCT03695627|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
11154731|NCT03695614|Experimental|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
11154732|NCT03695601||HeartCare|Diagnostic Test: Heart Care 1600 patients managed with HeartCare (AlloMap® and AlloSure-Heart® )
11154733|NCT03695601||Control|A historical control group will be matched to the estimated 800 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
11154734|NCT03695588|Active Comparator|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
11154735|NCT03695588|Sham Comparator|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
11154736|NCT03695575|Other|Study sample|A repeated-measures model will be used. This means that participants in a single arm will be tested in all conditions. Speech recognition and listening effort outcomes will be measured in two conditions: with and without a bone-conduction headset.
11154737|NCT03695562|Experimental|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
11154738|NCT03695562|Active Comparator|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
11154739|NCT03695549|Active Comparator|intervention|CAF+ APRF
11154740|NCT03695549|Active Comparator|control|CAF+SCTG
11154741|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
11154742|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
11154743|NCT03695523|Experimental|PLAY (PhysicaL ActivitY) Policy Intervention|The childcare physical activity policy will be adopted for 8 weeks within participating toddler and preschool classrooms of facilities allocated to the experimental group.
11154744|NCT03695523|No Intervention|Control group|Childcare centres will maintain their typical daily programming and standard of care for the duration of the 8-week intervention period.
11154745|NCT03695510|Experimental|Study arm|afatinib + pembrolizumab
11154746|NCT03695497|Experimental|Direct anterior approach|total hip arthroplasty with direct anterior approach
11154747|NCT03695497|Experimental|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
11154748|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
11154749|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
11154750|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.
~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
11154751|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.
~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
11154752|NCT03695471|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity. Patients receiving complete response during courses 2-9 are held for the remaining courses. If patients relapse while treatment is being held, the patient will then complete remaining courses.
11154753|NCT03695458|Placebo Comparator|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
11154754|NCT03695458|Active Comparator|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
11154755|NCT03695458|Active Comparator|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
11154756|NCT03695445||Peripheral Norepinephrine|Patients who will undergo surgery with need for vasopressor support.
11154757|NCT03695432|Experimental|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
11154758|NCT03695432|Experimental|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
11154759|NCT03695432|Placebo Comparator|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
11154760|NCT03695432|Placebo Comparator|Placebo probiotic|capsul
11154761|NCT03695406|Experimental|Mind-Body Group Intervention|
11154762|NCT03695393|Experimental|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
11154763|NCT03695393|No Intervention|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
11154764|NCT03695380|Experimental|Arm A: Cobimetinib - Niraparib|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.
11154862|NCT03694704|Experimental|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
11154765|NCT03695380|Experimental|Arm B: Cobimetinib - Niraparib - Atezolizumab|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.
11154766|NCT03695380|Experimental|Cohort 1 - Cobimetinib - Niraparib|"Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.
~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.
~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle."
11154767|NCT03695380|Experimental|Cohort 2 - Cobimetinib - Niraparib - Atezolizumab|"Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.
~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.
~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.
~Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle."
11154768|NCT03695367|Experimental|Cohort 1|HTX-011; Ibuprofen and Acetaminophen (alternating)
11154769|NCT03695367|Experimental|Cohort 2|HTX-011; Ibuprofen and Acetaminophen (alternating) and IV ketorolac
11154770|NCT03695354|Experimental|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
11154771|NCT03695354|Active Comparator|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
11154772|NCT03695341||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
11154773|NCT03695341||Everolimus plus Exemestane|Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day
11154774|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
11154775|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
11154776|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
11154777|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
11154778|NCT03695289|Experimental|iOTA-SMI|Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.
11154779|NCT03695289|Active Comparator|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.
11154780|NCT03695276|Experimental|PuSHCon model|A health coach will contact patients referred by their primary care clinician for a pulmonary specialty visit. The health coach will gather information from the patient and medical record and review the case with a pulmonary specialist. The specialist will provide recommendations to the primary care clinician based on the case review; the specialist may request an in-person patient visit if needed. The health coach will follow up with the primary care clinician and will support implementation of recommendations that the the primary care clinician accepts,
11154781|NCT03695276|Active Comparator|Usual care|Patients referred by their primary care clinician for a pulmonary specialty consultation will receive a case review electronically or in person. The pulmonary specialist will send recommendations to the primary care clinician.
11154782|NCT03695263|Experimental|N-of-1 Trial|Multiple crossovers between one of the available intervention options (mindfulness meditation, gratitude journaling, physical activity, laughter therapy, or random acts of kindness) and usual activities
11154783|NCT03695250|Experimental|Treatment (BMS-986205 and nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-14 and nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11154784|NCT03695237|Experimental|Participants receiving Leuprolide Acetate (LA)|Participants with Central Precocious Puberty receiving LA
11154785|NCT03695224||Group A|Subjects with normal topological perception
11154786|NCT03695224||Group B|Subjects with abnormal topological perception
11154787|NCT03695211|Active Comparator|LM group|LM group use conventional landmark technique, which selects the midpoint of the posterior border of the sternocleidomastoid muscle as the puncture point of superficial cervical plexus block
11154788|NCT03695211|Experimental|GAN Group|This group firstly locate the superficial cervical plexus by ultrasound scanning of the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle (GAN Point). GAN Group apply the precise block technique, selects the GAN Point as the puncture point of superficial cervical plexus block
11154789|NCT03695198|Experimental|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
11154790|NCT03695198|Placebo Comparator|Placebo - SC|Placebo administered SC
11154791|NCT03695198|Experimental|LY3361237 - Intravenous (IV)|LY3361237 administered IV
11154792|NCT03695198|Placebo Comparator|Placebo - IV|Placebo administered IV
11154793|NCT03695185|Experimental|ABBV-323|Participants administered with ABBV-323 dose A IV at Week 0 and ABBV-323 dose B for 12 Weeks. Participants who achieve clinical response may enter the maintenance period in which participants are administered with ABBV-323 dose B
11154794|NCT03695172|Active Comparator|TAP block|Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
11154795|NCT03695172|Active Comparator|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
11154796|NCT03695172|Active Comparator|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
11154863|NCT03694691|Experimental|Biopsy|Biopsies taken at protocol specified time points
11154997|NCT03693729|Active Comparator|Active DLPFC after task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min after the memory and metamemory task and during a filler task.
11154797|NCT03695146|Experimental|Paced breathing|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
11154798|NCT03695146|Active Comparator|Relaxing music|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
11154799|NCT03695146|No Intervention|No intervention|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
11154800|NCT03695133|Experimental|intervention group|"Group-based interventions Group-based interventions include physical activity, sightseeing, picnics, theater, cinema, group educations.
~Individual interventions Individual interventions include interventions in the Omaha System Nursing Interventions Scheme that is specific to health problems of elderly women."
11154801|NCT03695133|No Intervention|control group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks.
11154802|NCT03695120|No Intervention|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
11154803|NCT03695120|Active Comparator|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
11154804|NCT03695107||XBDP1-|
11154805|NCT03695107||XBDP2-|
11154806|NCT03695094|Experimental|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
11154807|NCT03695094|Experimental|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
11154808|NCT03695081|Experimental|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital
~Medication review post surgery
~Optimised list of drugs in the discharge summary, in accordance with hospital procedures
~Medication reconciliation, six weeks after discharge
~Medication review, six weeks after discharge"
11154809|NCT03695081|No Intervention|No intervention|Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
11154810|NCT03695068|Experimental|RISE Intervention|Reading Instruction for Students who are English Learners (El) with Reading Difficulties (RISE): The RISE intervention is a multi-phase treatment that first accelerates basic skills through an emphasis on word reading (e.g., multi-syllable words, morphology, high-frequency words commonly misread; Phase 1), and then provides a longer-term emphasis on fluency and comprehension through systematically varying text difficulty and genre (Phase 2). To assure that students have minimal loss during the summer, RISE adds a summer Book Club that includes provision of books with comprehension activities for students in the RISE intervention arm (Phase 3). This entire approach takes two full academic years and two summers to be replicated across two cohorts.
11154811|NCT03695068|No Intervention|Business as Usual Comparison Condition|Participants assigned to the Business as Usual (BAU)or comparison condition will participate in an elective class that includes such options as music, cooking, film, study time, or high stakes test preparation.
11154812|NCT03695055|Experimental|Arm 1|Rituximab maintenance
11154813|NCT03695055|Active Comparator|Arm 2|DPP/DCEP-G alternation regimen
11154814|NCT03695055|No Intervention|Arm 3|
11154815|NCT03695042|Experimental|BFR THEN without BFR|Will perform exercises with BFR at the first visit and without BFR at the second visit
11154816|NCT03695042|Experimental|Without BFR THEN with BFR|Will perform exercises without BFR at the first visit and with BFR at the second visit
11154817|NCT03695029|Experimental|treatment group|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
11154818|NCT03695029|No Intervention|control group|control group receive no drug, only follow-up
11154819|NCT03695016|Experimental|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
11154820|NCT03695016|Other|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
11154821|NCT03695003|Active Comparator|600 mg sage/polyphenol combination|600 mg of this sage/polyphenol combination will be consumed, via capsule, per day for 29 days.
11154822|NCT03695003|Placebo Comparator|Placebo|The same number of aesthetically similar capsules will be consumed per day for 29 days.
11154823|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
11154824|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
11154825|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
11154826|NCT03694977|Experimental|MCS110/PDR001 combination|
11154827|NCT03694964|Experimental|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
11154829|NCT03694951|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of reducing their daily sedentary behaviour to <7 hours per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for reducing their daily sedentary behaviour. Strategies may include: setting an alarm while studying to break up sedentary behaviour, to stand rather than sit on transit, and/or to achieve an active step profile (i.e., ≥10,000 steps a day) through pedometer self-monitoring.
11154830|NCT03694951|No Intervention|Control Group|The control group will not receive any behavioural intervention.
11154831|NCT03694938|Experimental|Magnetic resonance imaging|Annual MRI during 3 years
11154832|NCT03694925||Primary total knee arthroplasty|There will be n=30 primary TKA patients included in the study, to provide a baseline level for calprotectin.
11154833|NCT03694925||Aseptic revision total knee arthroplasty|There will be n=70 aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
11154834|NCT03694925||Revision septic total knee arthroplasty|There will be n=50 septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
11154835|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
11154836|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
11154837|NCT03694899|Experimental|one|acetaminophen 650 mg three times/day ibuprofen 600 mg three times/day opioid dose based on use in hospital day prior to discharge
11154838|NCT03694886|Active Comparator|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
11154839|NCT03694886|Active Comparator|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
11154840|NCT03694886|Placebo Comparator|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
11154841|NCT03694886|Placebo Comparator|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
11154842|NCT03694873|Experimental|tramadol|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
11154843|NCT03694873|Active Comparator|celecoxib|one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
11154844|NCT03694847||Asthma with CRSwNP|Asthmatic patients with a diagnosis of CRSwNP
11154845|NCT03694847||Asthma without CRSwNP|Asthmatic patients without a diagnosis of CRSwNP
11154846|NCT03694834|Experimental|Single Arm - Pembrolizumab|Single dose of Pembrolizumab 200mg IV administered prior to hysterectomy and surgical staging.
11154847|NCT03694821|Experimental|Ketorolac|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
11154848|NCT03694821|Active Comparator|Corticosteroid|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
11154849|NCT03694821|Active Comparator|Hyaluronic Acid|One knee injection of Hylan G-F 20 (Synvisc-One)
11154850|NCT03694808|Active Comparator|Fluad Vaccine|A single adjuvanted dose (AD) intramuscular injection
11154851|NCT03694808|Active Comparator|Fluzone Vaccine|A single high dose (HD) intramuscular injection
11154852|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
11154853|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
11154854|NCT03694769||All participants|Semi-structured interview and drop attack diary
11154855|NCT03694756|Other|Pre-biopsy patients|Patients identified by a radiologist at the time of diagnostic evaluation. Once consent is obtained, the TMEM-MRI will be scheduled. After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA at the time of core biopsy (preceding the core biopsy). MenaINV and MenaCalc will be calculated from the FNA material. After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be also calculated from the specimen obtained at the time of definitive surgery. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
11154856|NCT03694756|Other|Post-biopsy patients|Patients after breast biopsy. Once consent is obtained, patients will undergo TMEM-MRI. The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
11154857|NCT03694743|Experimental|2Shape rotary system|root canal preparation using 2Shape rotary system in mandibular molars with symptomatic pulpitis
11154858|NCT03694743|Active Comparator|Protaper Next rotary system|root canal preparation using Protaper Next rotary system comparing to 2Shape rotary system in mandibular molars with symptomatic pulpitis
11154859|NCT03694730|Experimental|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
11154860|NCT03694730|Active Comparator|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
11154861|NCT03694717||Patients|The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
11157808|NCT03674489|Sham Comparator|Sham Neurodynamic Mobilization|
11154864|NCT03694678|Experimental|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
11154865|NCT03694678|No Intervention|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
11154866|NCT03694665|Other|Morbidly anesthetized obese|Morbidly obese patients undergoing bariatric surgery (single-arm study) will receive a Lung recruitment maneuver to treat atelectasis..
11154867|NCT03694652|Experimental|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
11154868|NCT03694652|Active Comparator|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
11154869|NCT03694639|No Intervention|Pregabaline group|where patients received pregabaline 150 mg twice daily.
11154870|NCT03694639|Active Comparator|Pregabaline plus ganglion impar block group|where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.
11154871|NCT03694626|Active Comparator|Healthy Control subjects|
11154872|NCT03694626|Active Comparator|TBI Patients without photosensitivity|
11154873|NCT03694626|Active Comparator|Migraine patients without photosensitivity|
11154874|NCT03694626|Active Comparator|Migraine patients with photosensitivity|
11154875|NCT03694626|Active Comparator|TBI patients with photosensitivity|
11154876|NCT03694613|Other|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
11154877|NCT03694600||men or women between 21-84|IvyGene DX Liver Cancer Test screening alone and as combination with IvyGene DX Liver Cancer Test and Ultrasound in subjects diagnosed with liver cirrhosis
11154878|NCT03694587|Active Comparator|Test IMP|
11154879|NCT03694587|Active Comparator|Reference IMP|
11154880|NCT03694574|Other|Low schizotypy|Schizotypy score < 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
11154881|NCT03694574|Other|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
11154882|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
11154883|NCT03694548|Experimental|Yoga program: Instructor-led group yoga sessions (Part B)|Participants enrolled in Part B will receive eight in-person instructor-led group yoga sessions.
11154884|NCT03694535|Experimental|Bladder wall thermochemotherapy|Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer
11154885|NCT03694522|Active Comparator|bemarituzumab (FPA144)+mFOLFOX6|"15mg/kg of bemarituzumab (FPA144) given intravenously and mFOLFOX6 administered after the end of the bemarituzumab (FPA144) infusion
~*Cycle 1 will consist of a one-time dose of 7.5 mg/kg of bemarituzumab (FPA144) given intravenously on Day 8
~Treatment is repeated every 2 weeks."
11154886|NCT03694522|Placebo Comparator|Placebo+mFOLFOX6|"Placebo given intravenously and mFOLFOX6 administered after the end of the placebo infusion
~* Cycle 1 will consist of a one-time dose of placebo given intravenously on Day 8
~Treatment is repeated every 2 weeks."
11154887|NCT03694509|Experimental|Breakfast tea with full fat milk|Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
11154888|NCT03694509|Active Comparator|Water|Water 250ml
11154889|NCT03694496|Experimental|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
11154890|NCT03694496|No Intervention|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
11154891|NCT03694483||Patient population|Male individuals with elevated PSA and a positive MRI-driven biopsy AND male individuals with diagnosed prostate cancer (but prior to any treatment)
11154892|NCT03694483||Control Population|Male individuals with elevated PSA and a negative MRI-driven biopsy
11154893|NCT03694457|Active Comparator|deltopectoral approach|the patients are treated with deltopectoral approach surgery
11154894|NCT03694457|Other|lateral approach|the patients are treated with a lateral approach surgery
11154895|NCT03694444|Active Comparator|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
11154896|NCT03694444|Placebo Comparator|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
11154897|NCT03694431|Active Comparator|Standard HBPC|Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
11155156|NCT03692468|Experimental|Intervention Group|Participants will engage in a 5 session psychotherapy intervention focused on improving pain and mood.
11154898|NCT03694431|Experimental|Tech-supported HBPC|Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.
11154899|NCT03694418|Other|Cluster 1|Cluster 1 is 1 school on the Fort Peck Reservation that will be randomized into the intervention in 2019. Cluster 1 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
11154900|NCT03694418|Other|Cluster 2|Cluster 2 includes 2 schools on the Fort Peck Reservation that will be randomized in the intervention in 2019-2020. Cluster 2 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
11154901|NCT03694418|Other|Cluster 3|Cluster 3 are the remaining 2 schools on the Fort Peck reservation that will be randomized into the intervention in 2020-2021. Cluster 3 will receive all four levels of the intervention including: 1) A school-based SRH curriculum called Native Stand, designed to address individual-level factors that lead to sexual risk behaviors; 2) a family-level curriculum called Native Voices, tailored to increase communication between adult family members and youth about SRH topics; 3) a cultural mentoring component at the community level that pairs AI youth with adults and elders to discuss traditional AI beliefs and practices about SRH; and 4) a mobilizing strategy to activate a multi-sectoral network of youth-servicing organizations at the systems level in Fort Peck to coordinate SRH services for AI youth.
11154902|NCT03694405|Experimental|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
11154903|NCT03694405|Experimental|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
11154904|NCT03694405|Experimental|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
11154905|NCT03694405|Experimental|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
11154906|NCT03694405|Experimental|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
11154907|NCT03694405|Experimental|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
11154908|NCT03694405|Experimental|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
11154909|NCT03694405|Experimental|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
11154910|NCT03694405|Experimental|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
11154911|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
11154912|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
11154913|NCT03694379|Experimental|Apneic Oxygenation|Participants receiving apneic oxygenation
11154914|NCT03694379|No Intervention|No Apneic Oxygenation|Participants not receiving apneic oxygenation
11154915|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
11154916|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
11154917|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
11154918|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
11154919|NCT03694353|Experimental|Pegvaliase|
11154920|NCT03694340|Other|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 3 months before follow up.
11154921|NCT03694327|Experimental|Treatment A Mobile Application|Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
11154922|NCT03694327|Active Comparator|Treatment B Mobile Application|Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
11154923|NCT03694314|Experimental|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
11154924|NCT03694314|Placebo Comparator|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
11154925|NCT03694288|Active Comparator|Removal Group|The implant removal group will have surgery scheduled 6 months after their initial surgical fixation.
11154926|NCT03694288|No Intervention|Retention Group|The implant retention group will retain their implant for a minimum of 2 years from the time of their initial surgery.
11154927|NCT03694275|Experimental|TAK-935 (OV935)|Treatment: 8 weeks dose optimization followed by 12 weeks maintenance period.
11154928|NCT03694262|Experimental|Treatment|Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing
11154929|NCT03694249|Experimental|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
11154930|NCT03694249|Placebo Comparator|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
11154931|NCT03694236|Experimental|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
11154932|NCT03694223|Experimental|Booklets|Health education delivery method: Booklet. Patients will be given 2 leaflets on the low FOMDAP diet produced by the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London. These booklets have been produced by dietitians and are commonly used in clinical practice across the UK.
11154933|NCT03694223|Experimental|Mobile application|Health education delivery method: Mobile application. Patients will be asked to download an application on their mobile phones or tablets. This application has been produced by dietitians from the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London.
11154934|NCT03694223|Active Comparator|One to one consultation with dietitian|Health education delivery method:One-to-one consultation with dietitian. Patients will attend a clinic visit for a one-to-one consultation with a dietitian. As per current clinical practice, the initial visit will last for 1 hour. During the visit, tailored information on the low FOMDAP diet will be given to match patients' individual needs. During the visit, either the leaflets (used in group 1) or the application (used in group 2) will be used to facilitate the visit. The choice of using the leaflets or the app during the visit will be based on the dietitian's judgment based on the patients' needs.
11154935|NCT03694210|Experimental|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
11154936|NCT03694197|Experimental|Open label|
11154937|NCT03694158|Experimental|Treatment group|Dupilumab (Dupixent®) administered subcutaneously every two weeks. An initial dose of 400 mg (two 200 mg injections) followed by 200 mg given every other week or an initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every other week for patients requiring concomitant oral corticosteroids or with comorbid moderate-to-severe atopic dermatitis for which DUPIXENT is indicated, start with an initial dose of 600 mg followed by 300 mg given every other week.
11154938|NCT03694158|Placebo Comparator|Placebo group|Placebo (preparation, administration, packaging, and labeling all equivalent to the treatment) administered subcutaneously every two weeks.
11154939|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
11154940|NCT03694132|Experimental|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
11154941|NCT03694132|Experimental|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
11154942|NCT03694132|Experimental|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
11154943|NCT03694119|Active Comparator|Phenelzine|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Phenelzine arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 31, then receiving Phenelzine 15mg BID plus ozanimod placebo QD from Days 32 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
11154944|NCT03694119|Placebo Comparator|Placebo|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Placebo arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
11154945|NCT03694119|Experimental|ozanimod|Following tyramine challenging in Period 1, eligible subjects randomly assigned to ozanimod arm are receiving Phenelzine placebo BID plus ozanimod 1.84mg QD from Days 11 to 38, including dose escalation days. Subjects receive second tyramine challenge from Day 39 to up to Day 49
11154946|NCT03694093||Patients with Hyperhidrosis|Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
11154947|NCT03694080|Experimental|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
11154948|NCT03694067||Androgenetic alopecia patients|Two 1 mm scalp punch skin biopsy will be taken per patient
11154949|NCT03694054|Experimental|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
11154950|NCT03694054|No Intervention|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
11154951|NCT03694054|Experimental|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
11154952|NCT03694041|Experimental|SAD: APX-115|Experimental: APX-115 SAD group
11154953|NCT03694041|Placebo Comparator|SAD: Placebo|Experimental: Placebo group
11154954|NCT03694041|Experimental|MAD: APX-115|Experimental: APX-115 MAD group
11154955|NCT03694041|Placebo Comparator|MAD: Placebo|Experimental: Placebo group
11154956|NCT03694041|Active Comparator|Food effect - Fasting condition|Experimental: APX-115 under fasting condition
11154957|NCT03694041|Active Comparator|Food effect - fed condition|Experimental: APX-115 under fed condition
11154958|NCT03694041|Placebo Comparator|Drug Interaction - metabolic probe|Experimental: metabolic probe
11154959|NCT03694028|Experimental|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
11154960|NCT03694028|Active Comparator|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
11154961|NCT03694015|Active Comparator|SUPR (Arm 1)|"Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard.
~Minimum of kV image matching on unit daily."
11154995|NCT03693742|Placebo Comparator|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
11154996|NCT03693729|Experimental|Active DLPFC during task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
11154962|NCT03694015|Active Comparator|VMAT rapid (Arm 2)|"Contouring:
~GTV: based on available imaging; expected to be between 1.5 cm and 20 cm clinically or from diagnostic imaging CTV = GTV + 0.5 to 0.7 cm (RO preference), adjusted to anatomy.
~if only bone involvement: no margin outside the bone
~if bone and soft tissue involvement: no margin outside the bone, only adapt CTV margin in soft tissue to organs. No CTV adaptation in i.e. muscle.
~CTV maybe optional and if used can encompasses whole vertebral body as per RO's discretion PTV = CTV or GTV + (1 to 1.5) cm as per RO/centre preference. PTV_eval = PTV cropped 0.5 cm below skin. OAR's: maximum 2 OARs permitted for VMAT arm. OAR contouring/constraints are at discretion of treating RO. However, if lung/kidneys are within 5 cm of PTV, absence of constraints for these contours should be documented in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at radiation oncologist's discretion. Kidneys are considered 1 organ."
11154963|NCT03694002|Experimental|Arm A (ramucirumab, carboplatin, paclitaxel)|Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
11154964|NCT03694002|Active Comparator|Arm B (carboplatin, paclitaxel)|Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11154965|NCT03693989|Experimental|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
11154966|NCT03693989|Active Comparator|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
11154967|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
11154968|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
11154969|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
11154970|NCT03693963|Other|Single Arm, treated with Serranator|Subjects treated with Serrantor
11154971|NCT03693950|Experimental|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
11154972|NCT03693950|Active Comparator|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
11154973|NCT03693911|Experimental|Prevention group|AcceptME- digital gamified Acceptance and Commitment Therapy prevention program
11154974|NCT03693911|No Intervention|Waitlist control|Waitlist control group
11154975|NCT03693898|Other|Persons with collagen VI defect|Observational
11154976|NCT03693885|Experimental|OCT-group|Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.
11154977|NCT03693885|No Intervention|Control|standard procedure before planned caesarean section
11154978|NCT03693872|Other|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
11154979|NCT03693872|Other|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
11154980|NCT03693859|Experimental|Behavioral Weight Loss + Gaming|Treatment will consist of 12-weekly, one-hour group sessions of approximately 15 participants per group. Participants will provide logs of serious gaming (intervention).
11154981|NCT03693859|Active Comparator|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
11154982|NCT03693846|Experimental|Nivolumab and Ipilimumab|Treatment will consist of nivolumab 480mg every 4 weeks and ipilimumab 1mg/kg every 8 weeks.
11154983|NCT03693833|Experimental|Intervention|10mg Cannabidiol (CBD) tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
11154984|NCT03693833|Placebo Comparator|Placebo|10mg Placebo Oral tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
11154985|NCT03693820|Active Comparator|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
11154986|NCT03693820|Placebo Comparator|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
11154987|NCT03693807|Experimental|Pump Therapy|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
11154988|NCT03693781|Active Comparator|Colchicine 0.01mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
11154989|NCT03693781|Active Comparator|Colchicine 0.005 mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
11154990|NCT03693781|Placebo Comparator|Placebo + Riluzole 100 mg|Placebo pills will be administered at fast, while taking Riluzole 100 mg/day
11154991|NCT03693768|Experimental|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
11154992|NCT03693755|Active Comparator|In-plane Group|In this Group the femoral nerve catheter will be placed with the in-plane technique.
11154993|NCT03693755|Active Comparator|Out-of-plane Group|In this Group the femoral nerve catheter will be placed with the out-of-plane technique.
11154994|NCT03693742|Experimental|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
11158770|NCT03668119|Experimental|Nivolumab + Ipilimumab Combination|
11154998|NCT03693729|Sham Comparator|Sham DLPFC during task|Sham HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
11154999|NCT03693716|Experimental|Dynamic Anterior Stabilization|Arthroscopic Dynamic Anterior Capsular Stabilization with Trans subscapular Long Head of the Biceps Tenodesis
11155000|NCT03693703|Experimental|bi-parametric MRI|Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)
11155001|NCT03693703|Active Comparator|multi-parametric MRI|Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)
11155002|NCT03693677|Experimental|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months
~Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
~Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)
~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :
~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).
~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
11155003|NCT03693677|Experimental|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
11155004|NCT03693677|Active Comparator|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)
~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :
~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).
~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
11155005|NCT03693651||Parent of a Premature infant / PP|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
11155006|NCT03693651||Parent of a baby born on time / PT|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
11155007|NCT03693638|Active Comparator|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
11155008|NCT03693638|Active Comparator|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
11155009|NCT03693625|Experimental|Parent Study: GDC-0853|Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
11155010|NCT03693625|Placebo Comparator|Parent Study: Placebo|Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
11155011|NCT03693612|Experimental|Part 1: GSK3359609+tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of GSK3359609 and tremelimumab in combination. GSK3359609 will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
11155012|NCT03693612|Experimental|Part 2: GSK3359609+tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered GSK3359609 in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
11155013|NCT03693612|Active Comparator|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
11155014|NCT03693599|Experimental|carbetocin|600 women received single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
11155015|NCT03693599|Active Comparator|Syntometrine|600 women received one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 micrograms of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
11155016|NCT03693573|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab in combination with bevacizumab.
11155017|NCT03693560|Experimental|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
11155018|NCT03693560|Experimental|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
11155019|NCT03693547|Experimental|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
11155020|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
11155021|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
11155022|NCT03693521|Experimental|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
11155023|NCT03693521|Active Comparator|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
11155024|NCT03693508|Experimental|Arm 1|Naive HIV patients with severe immunosuppression.
11155025|NCT03693495|Experimental|ellume·lab Group A Streptococcus Test|"ellume·lab Group A Streptococcus Test
~Pharyngeal samples from participants will be tested with:
~ellume.lab Group A Streptococcus Test; Polymerase Chain Reaction (PCR) and bacterial culture."
11155026|NCT03693469|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during immunization.
11155157|NCT03692468|No Intervention|Control Group|Patients will receive treatment as usual from their care providers.
11155027|NCT03693469|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
11155028|NCT03693456|Experimental|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
11155029|NCT03693456|Experimental|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
11155030|NCT03693456|Experimental|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
11155031|NCT03693430|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
11155032|NCT03693430|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
11155033|NCT03693417|Active Comparator|Control|
11155034|NCT03693417|Experimental|Heat|
11155035|NCT03693404|Experimental|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
11155036|NCT03693404|Active Comparator|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
11155037|NCT03693391|Experimental|Cohort 1: JNJ-64140284|Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.
11155038|NCT03693391|Experimental|Cohort 2: JNJ-64140284|Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
11155039|NCT03693391|Experimental|Cohort 3: JNJ-64140284|Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
11155040|NCT03693391|Experimental|Cohort 4: JNJ-64140284|Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
11155041|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.
~Classification ASA 2-4"
11155042|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
11155043|NCT03693339|Experimental|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
11155044|NCT03693326|Experimental|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
11155045|NCT03693313|Experimental|CrossFit KAMP Group 1|14 weeks of CrossFit Kids exercise program
11155046|NCT03693313|Active Comparator|CrossFit KAMP Wait-list Group|Waitlist group that waits 14 weeks while group 1 does exercise program. After first 14 weeks will then participate in 14 weeks of CrossFit Kids exercise program
11155047|NCT03693300|Experimental|WHO/ECOG PS 0 to 1 Cohort|100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
11155048|NCT03693300|Experimental|WHO/ECOG PS 2 Cohort|up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
11155049|NCT03693287|Active Comparator|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.
~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.
~Intravenous macronutrient intakes:
~PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.
~PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.
~PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.
~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.
~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
11155050|NCT03693287|Experimental|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).
~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.
~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
11155158|NCT03692455|Experimental|BPG Group|Patients will be submitted to Roux-en-Y Bypass Gastric Surgery.
11155051|NCT03693274|Experimental|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
11155052|NCT03693274|No Intervention|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
11155053|NCT03693261||Coronary Artery Disease (CAD)|Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.
11155054|NCT03693261||controls|Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).
11155055|NCT03693248|Experimental|Two cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.
~Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
11155056|NCT03693248|No Intervention|Three cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.
~Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
11155057|NCT03693235|Experimental|70 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 70 degrees.
11155058|NCT03693235|Experimental|80 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 80 degrees.
11155059|NCT03693235|Experimental|90 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 90 degrees.
11155060|NCT03693222|Experimental|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
11155061|NCT03693222|Experimental|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
11155062|NCT03693209|Experimental|General trigger|"VHS with one general trigger: If I am getting angry... and 10 strategies (e.g. Then I will take deep breaths). Participants are instructed to link trigger with strategies."
11155063|NCT03693209|Experimental|Specific triggers|"VHS with a list of 10 specific situations that can act as anger triggers (e.g. If I am getting angry when people act like they know it all) and 10 strategies. Participants are instructed to link triggers with strategies."
11155064|NCT03693209|No Intervention|Control|List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
11155065|NCT03693196|Other|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
11155066|NCT03693196|Other|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
11155067|NCT03693196|Other|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
11155068|NCT03693183|Experimental|Ketorolac/HPMC|"Drug: Ketorolac/HPMC Ophthalmic Solution
~1 drop administered in each eye 4 times per day for 2 days"
11155069|NCT03693183|Active Comparator|HPMC|"Drug: 0.80% Hydroxypropyl Methylcellulose(HMPC) Ophthalmic Solution
~1 Drop administered in each eye 4 times per day for 2 days"
11155070|NCT03693183|Placebo Comparator|Vehicle|"Drug: Vehicle Ophthalmic Solution
~1 drop administered in each eye 4 times a day for 2 days"
11155071|NCT03693170|Experimental|1 Arm|encorafenib plus binimetinib plus cetuximab
11155072|NCT03693144|Experimental|Intervention Group 1 Full LIITA3H App|Participants will be given the LIITA3H app, which is a combination product consisting of 3 main features that will track their visits to fast food restaurants (using the ELI feature), send tailored text messages to prompt healthy choices when they are in a fast food restaurant (using the POP feature), and allow them to submit pictures of their food (using the SNAP feature).
11155073|NCT03693144|Active Comparator|Control Group 2 Partial LIITA3H App|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) and they will submit pictures of their food (using the SNAP feature). However, they will not receive tailored text messages.
11155074|NCT03693144|Other|Control Group 3 LIITA3H Location only|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) but they will not receive tailored messages or submit pictures of their food.
11155075|NCT03693131|Experimental|MND-2119 2 g|MND-2119 2 g, orally, once daily after breakfast for 12 weeks.
11155076|NCT03693131|Experimental|MND-2119 4 g|MND-2119 4 g, orally, once daily after breakfast for 12 weeks.
11155077|NCT03693131|Active Comparator|EPADEL CAPSULES 300 1.8 g|EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.
11155078|NCT03693131|Active Comparator|EPADEL CAPSULES 300 2.7 g|EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.
11155079|NCT03693118|Experimental|Grup1, Grup2|
11155080|NCT03693118|Experimental|Grup1,Grup2|
11155081|NCT03693105|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
11155082|NCT03693105|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
11155083|NCT03693079|Experimental|Wet Cupping|wet cupping therapy will be applied to all participants
11155159|NCT03692455|Experimental|Sleeve Group|Patients will be submitted to Vertical Sleeve Gastrectomy Surgery.
11155160|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
11158771|NCT03668119|Experimental|Nivolumab Monotherapy|
11155084|NCT03693066|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
11155085|NCT03693066|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
11155086|NCT03693066|Active Comparator|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
11155087|NCT03693040|Experimental|DHFS with IS-Truvada|Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
11155088|NCT03693027|Experimental|PTx800|Qualified subjects will dissolve one oral lozenge (PTx800 lozenges) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
11155089|NCT03693027|Placebo Comparator|Placebo|Qualified subjects will dissolve one oral lozenge (placebo control) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
11155090|NCT03693014|Experimental|Stereotactic Body Radiotherapy|Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity.
11155091|NCT03693001|Experimental|IC/FM Patients|All patients had been diagnosed with fibromyalgia and were suffering from IC by standard criteria.
11155092|NCT03692988|Experimental|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
11155093|NCT03692988|No Intervention|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
11155094|NCT03692975|Experimental|CIS patients|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation
11155095|NCT03692975|Active Comparator|Control|50 Healthy controls
11155096|NCT03692962|Sham Comparator|Sleep restriction without acoustic stimulation|
11155097|NCT03692962|Experimental|Sleep restriction with acoustic stimulation|
11155098|NCT03692949|Experimental|LY3451838 Part A|Single ascending doses, administered intravenously (IV)
11155099|NCT03692949|Experimental|LY3451838 Part B|Single doses administered subcutaneously (SC)
11155100|NCT03692949|Placebo Comparator|Placebo Part A|Matching single doses administered intravenously (IV)
11155101|NCT03692949|Placebo Comparator|Placebo Part B|Matching single doses administered subcutaneously (SC)
11155102|NCT03692923|No Intervention|control group|participants received ordinary prenatal care.
11155103|NCT03692923|Experimental|virtual community group|participants were invited to join a virtual community to interact with peers in addition to their ordinary prenatal care.
11155104|NCT03692910|Experimental|SAGE-217|
11155105|NCT03692897||tenofovir alafenamide|Patients with a medication history of tenofovir alafenamide (TAF).
11155106|NCT03692871|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of double-blind V114 at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
11155107|NCT03692871|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
11155108|NCT03692858|Active Comparator|Group A|
11155109|NCT03692858|Active Comparator|Group B|
11155110|NCT03692845|Other|O-TLIF group|Spinal fusion ,Transforaminal lumbar interbody fusion procedure will be performed through open surgery.
11155111|NCT03692845|Other|MI-TLIF group|Spinal fusion,Transforaminal lumbar interbody fusion procedure will be performed through minimally invasive surgery using a tubular retractor.
11155112|NCT03692832|Experimental|Group L|
11155113|NCT03692832|Active Comparator|Group V|
11155114|NCT03692819|Active Comparator|placebo|Periodontal debridement treatment will be performed in a single session after the therapy will be administered the Placebo Oral Tablet twice a day for 21 days.
11155115|NCT03692819|Experimental|Metronidazole and Amoxicillin|Periodontal debridement treatment in a single session Metronidazole 400mg + Amoxicillin 500mg every 8 hours for 7 days.
11155116|NCT03692819|Experimental|Lactobacillus reuteri|Periodontal debridement treatment in a single session Lactobacillus reuteri Oral Drops twice a day for 21 days.
11155117|NCT03692806|Experimental|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
11155118|NCT03692806|Placebo Comparator|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
11155119|NCT03692793|Experimental|Pulmonary rehabilitation|The PRP (24-session, three times for week) will be delivered according to ATS/ERS (Spruit et al, 2013),
11155120|NCT03692780|Experimental|Careseng 1370|
11155121|NCT03692780|Placebo Comparator|Matched Placebo|
11155122|NCT03692767|Experimental|Anti-CD22 CAR NK cells|Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0
11155123|NCT03692754|Active Comparator|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d
11155124|NCT03692754|Active Comparator|AT with 20 mg/d|The patients will be given receive atorvastatin in 20 mg/d
11155125|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
11155126|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: >6.0 Diopters; astigmatism: >3.0 Diopters) were excluded from NV group.
11155127|NCT03692715|Experimental|ciprofloxacin|Single dose oral or intravenous ciprofloxacin prior to shockwave lithotripsy
11155128|NCT03692715|Placebo Comparator|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
11155129|NCT03692702|Experimental|WE PLAY|Teachers in this condition received the WE PLAY training.
11155130|NCT03692702|No Intervention|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
11155131|NCT03692689|Experimental|SCT200|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11155132|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
11155133|NCT03692663|Experimental|anti-PSMA CAR NK cells treatment group|
11155134|NCT03692637|Experimental|anti-Mesothelin Car NK Cells|Total dose of 0.5-3 million /kg cells will be administered at day0
11155135|NCT03692624|Experimental|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
11155136|NCT03692624|No Intervention|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
11155137|NCT03692611|Experimental|Skills to Manage Pain (STOMP)|The intervention group will receive treatment as usual plus the STOMP behavioral intervention. The STOMP behavioral intervention consists of 12 intervention sessions (6 group and 6 individual sessions). The sessions will be completed over a period of 12-16 weeks from enrollment. The first intervention session will be a group session for all participants followed by individual and then alternating group and individual sessions for the rest of the intervention. The intervention group will utilize a study manual on pain management in which they will use with each session.
11155138|NCT03692611|Active Comparator|comparison group|The comparison group will receive treatment as usual.The comparison group will also be provided with the intervention manual, however, no additional treatment will be provided to participants allocated to the control group. The group will not receive the PSM intervention.
11155139|NCT03692598|Experimental|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
11155140|NCT03692598|Experimental|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
11155141|NCT03692572|Active Comparator|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
11155142|NCT03692572|Placebo Comparator|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
11155143|NCT03692559|Experimental|full sterile dressing|Patients receive full sterile dressing
11155144|NCT03692559|No Intervention|usual standard care|Patients receive usual standard care
11155145|NCT03692546|Experimental|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
11155146|NCT03692546|No Intervention|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
11155147|NCT03692533|Active Comparator|Group A|Group (A) [study cases] Adult patients who will undergo radical or partial nephrectomy.for primary renal cell carcinoma.
11155148|NCT03692533|Active Comparator|Group B|Group (B) [control cases] Adult patients who will undergo simple nephrectomy for benign causes
11155149|NCT03692520|Experimental|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
11155150|NCT03692507|Experimental|HMB only|Taking HMB supplements three times a day
11155151|NCT03692507|Experimental|Protein and HMB|Drinking Ensure Enlive shakes
11155152|NCT03692494|Experimental|Unilateral vocal fold paralysis standard of care voice therapy|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.
11155153|NCT03692494|Experimental|Unilateral paralysis standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
11155154|NCT03692494|Experimental|Parkinson's disease standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
11155155|NCT03692481|Experimental|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
11155161|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
11155162|NCT03692429|Experimental|CYAD-101 with FOLFOX|Infusion after standard FOLFOX chemotherapy
11155163|NCT03692429|Experimental|CYAD-101 with FOLFIRI|Infusion after standard FOLFIRI chemotherapy
11155164|NCT03692416|Active Comparator|Ibuprofen|"Patients in this group will receive:
~Ibuprofen
~Oral
~At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.
~Duration of therapy: 4 - 6 weeks."
11155165|NCT03692416|Active Comparator|Prednisone Oral or Methylprednisolone IV|"Steroids:
~Pednisone (for mild/moderate cases):
~Oral
~Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.
~Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.
~Methylprednisolone (for severe/acute cases):
~IV
~10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.
~The duration is variable according to the condition of the patient."
11155166|NCT03692416|Active Comparator|Methotrexate|"Patients in this group will receive:
~Methotrexate
~Oral
~At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.
~Duration of therapy: 6 - 12 weeks."
11155167|NCT03692403|Experimental|Quinagolide 360 µg|Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
11155168|NCT03692403|Experimental|Quinagolide 720 µg|Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
11155169|NCT03692403|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
11155170|NCT03692403|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
11155171|NCT03692390|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
11155172|NCT03692390|No Intervention|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
11155173|NCT03692377||Children Aged 2-6|Children 2 to 6 years of age who are arriving with a guardian to the Emergency Department with a low acuity condition (Canadian Triage scale (CTAS) 4 or 5) and are waiting to be seen by the doctor, or are waiting for test results.
11155174|NCT03692364|Active Comparator|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
11155175|NCT03692364|Experimental|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
11155176|NCT03692351|Active Comparator|Cup with screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US), screw fixation (2 or 3 screws)
11155177|NCT03692351|Experimental|Cup without screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US) without screw holes, press-fit fixation
11155178|NCT03692338|Experimental|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).
~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
11155179|NCT03692338|Experimental|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.
~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
11155180|NCT03692338|No Intervention|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
11155181|NCT03692325|Experimental|Nivolumab|"Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle
~Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
11155182|NCT03692312|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
11155183|NCT03692312|Placebo Comparator|Placebo|Matching placebo, orally, once daily
11155184|NCT03692299|Active Comparator|Saccaromyces boulardii oral tablet|Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
11155185|NCT03692299|Active Comparator|Metronidazole plus S. boulardii|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
11155186|NCT03692299|Active Comparator|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.
11155187|NCT03692286|Active Comparator|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
11155188|NCT03692286|Active Comparator|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
11155189|NCT03692286|Active Comparator|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
11155190|NCT03692273|Experimental|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
11155191|NCT03692273|Experimental|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
11155192|NCT03692273|No Intervention|No treatment|3x3cm2 area designated as no treatment that will serve as a control
11155193|NCT03692260|Active Comparator|intervention group|3D stent in Herbert screw insertion vs titanium plate
11155194|NCT03692260|No Intervention|control group|titanium plate
11155195|NCT03692247|Other|Quantitative Sensory Testing|After answering brief questionnaires assessing psychosocial factors related to anxiety, catastrophizing, and pain, participants will undergo quantitative sensory tests where they will use a simple numeric rating scale (0-10) to rate pain and anxiety at several points during two QST sessions. During the second QST session, participants will use Unwind, a smartphone-based music intervention.
11155196|NCT03692234|Placebo Comparator|placebo|placebo capsules containing lactose - oral once weekly administration for six month
11155197|NCT03692234|Active Comparator|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
11155198|NCT03692221|Experimental|MSC treatment group 1|Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution
11155199|NCT03692221|Active Comparator|MSC treatment group 2|High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution
11155200|NCT03692221|Active Comparator|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
11155201|NCT03692208|Experimental|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
11155202|NCT03692208|Active Comparator|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
11155203|NCT03692195|Experimental|Wear WHOOP 1 week prior to sleep study|Participants will wear the WHOOP strap 2.0 7 days prior to their sleep study.
11155204|NCT03692195|Experimental|Wear WHOOP 1 week after sleep study|Participants will wear the WHOOP strap 2.0 for 7 days after their sleep study.
11155205|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
11155206|NCT03692169||CSC patients|Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
11155207|NCT03692143||teriparatide group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide
11155208|NCT03692143||PVP group plus alendronate|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.
11155209|NCT03692143||teriparatide and PVP group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty
11155210|NCT03692130|Active Comparator|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
11155211|NCT03692130|Sham Comparator|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
11155212|NCT03692091|Active Comparator|Anterior portal|Injection in to subacromial space from anterior portal
11155213|NCT03692091|Active Comparator|Lateral portal|Injection in to subacromial space from lateral portal
11155214|NCT03692078|No Intervention|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
11155215|NCT03692078|Experimental|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
11155216|NCT03692078|Experimental|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
11155217|NCT03692078|Experimental|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
11155218|NCT03692078|Experimental|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
11155219|NCT03692078|Experimental|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
11155220|NCT03692065|Active Comparator|Apixaban film coated tablets 2.5 mg|Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.
11155221|NCT03692065|Active Comparator|Apixaban film coated tablets 5 mg|Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.
11155222|NCT03692052|Experimental|AG-348|"Core period: Participants will receive AG-348 for up to 24 weeks. Depending on the safety observations and hemoglobin (Hb) concentrations, they may undergo one potential dose-level increase from 50 to 100 mg BID.
~Extension Period: Eligible participants will continue to receive AG-348 for up to an additional 10 years at the same dose they were receiving at the Week 24 visit."
11155223|NCT03692039|Experimental|M-pro files|Instrumentation using M-pro files in rotating motion
11155224|NCT03692039|Active Comparator|ProTaper Next files|Instrumentation using ProTaper Next files in rotating motion
11155225|NCT03692026|Experimental|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
11155226|NCT03692026|Active Comparator|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
11155227|NCT03692013|Experimental|nighttime group|patients with nocturnal hypertension taking losartan at nighttime
11155228|NCT03692013|Active Comparator|daytime group|patients with nocturnal hypertension taking losartan at daytime
11155229|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
11155230|NCT03691987|Experimental|Preprocessed thawed donor FMT|"The active transplants are processed in a 2-3 weeks period before treatment of the first participant. Fifty to eighty grams of freshly delivered feces from donors is mixed with 100 mL isotonic saline and 25 mL 85% glycerol, homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60 ml luerlock syringes and stored at -40°C.
~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the FMT-syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in an enema bag prior to installation."
11155231|NCT03691987|Placebo Comparator|Preprocessed thawed autologous FMT|"The placebo transplant from each participant is prepared during the inclusion process four to six weeks before intervention and stored at -40°C. Fifty to eighty grams of freshly delivered feces from participants is mixed with 100 mL isotonic saline and 25 mL 85% glycerol is homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60ml Luerlock syringes.
~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the Luerlock syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in the enema bag prior to installation."
11155232|NCT03691974|Experimental|Fasinumab|
11155233|NCT03691974|Placebo Comparator|Placebo|
11155234|NCT03691961|Experimental|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.
~Hair sampling after 4 months treatment.
~Analysis of hair's drug concentrations."
11155235|NCT03691961|Experimental|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.
~Hair sampling after 4 months treatment.
~Analysis of hair's drug concentrations."
11155236|NCT03691948|Experimental|ROPEs|
11155237|NCT03691948|Active Comparator|Control|
11155238|NCT03691935|Experimental|Ropivicaine|Erector Spinae Block of 20ml 0.5% ropivicaine bolus, connected to a pump containing 0.2% ropivicaine receiving 15ml every 3 hrs.
11155239|NCT03691935|Sham Comparator|Normal Saline|Erector Spinae Block of 20ml normal saline placebo bolus, then connected to pump of normal saline receiving 15ml every 3 hrs.
11155240|NCT03691922|Active Comparator|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
11155241|NCT03691922|Other|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
11155242|NCT03691909|Experimental|Treatment Arm|Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.
11155243|NCT03691896|Experimental|Lower dose|cholecalciferol 400UNT, oral solution
11155244|NCT03691896|Active Comparator|Middle dose|cholecalciferol 800UNT, oral solution
11155245|NCT03691896|Experimental|Higher dose|cholecalciferol 1200UNT, oral solution,
11155246|NCT03691883||TB patients|TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.
11155247|NCT03691870|Active Comparator|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.
~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.
~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.
~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
11155248|NCT03691870|Experimental|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.
~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).
~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
11155249|NCT03691857|Other|Acute non-traumatic dyspnea patients|Patients with acute non-traumatic dyspnea managed in the emergency department to assess the diagnostic accuracy of an ultrasound algorithm (EMERALD-US) dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation)
11155250|NCT03691844|Experimental|AMZ001 + Placebo|on the target knee
11155251|NCT03691844|Experimental|AMZ001|on the target knee
11155252|NCT03691844|Placebo Comparator|Placebo|on the target knee
11155253|NCT03691844|Active Comparator|Comparator|Diclofenac gel on the target knee
11155585|NCT03689543|Active Comparator|Arm 2|LY500307 at 75mg per day
11155254|NCT03691831|Active Comparator|Active|A-101 45% (Topical solution, hydrogen peroxide 45%)
11155255|NCT03691831|Placebo Comparator|Vehicle|Topical solution, isopropyl alcohol and water
11155256|NCT03691818|Experimental|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
11155257|NCT03691818|Active Comparator|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
11155258|NCT03691818|Placebo Comparator|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
11155259|NCT03691818|Experimental|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
11155260|NCT03691818|Active Comparator|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
11155261|NCT03691818|Placebo Comparator|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
11155262|NCT03691818|Experimental|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
11155263|NCT03691818|Active Comparator|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
11155264|NCT03691818|Placebo Comparator|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
11155265|NCT03691805|Active Comparator|anodal tDCS over rDLPFC|Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).
11155266|NCT03691805|Sham Comparator|sham tDCS|Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.
11155267|NCT03691792|Experimental|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
11155268|NCT03691792|Active Comparator|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
11155269|NCT03691779|Experimental|Part A: Triple Combination|Subjects will receive 100 mg VX-445/ 50 mg TEZ/ 75 mg IVA as an FDC tablet in the morning and 75 mg IVA as mono tablet in the evening.
11155270|NCT03691779|Experimental|Part B: Triple Combination|Subjects will receive VX-445/TEZ/IVA as FDC tablet in the morning and IVA as mono tablet in the evening with the dose to be based on the outcome of Part A.
11155271|NCT03691766|Experimental|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
11155272|NCT03691766|Placebo Comparator|Control|Placebo device with different wavelengths of light without known physiologic effect.
11155273|NCT03691753|Experimental|Experimental arm|Patients will be treated with Fitaya Vena Cava Filter System.
11155274|NCT03691753|Active Comparator|Control arm|Patients will be treated with Aegisy Vena Cava Filter.
11155275|NCT03691740|Experimental|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
11155276|NCT03691740|Placebo Comparator|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
11155277|NCT03691727|Experimental|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.
~MRI Neurological Exam Vital Signs Questionnaires"
11155278|NCT03691727|Active Comparator|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
11155279|NCT03691714|Experimental|Durvalumab and Cetuximab|Durvalumab 1500mg IV every 4 weeks Cetuximab 400mg/m2 IV loading dose followed by weekly Cetuximab 250mg/m2 IV Treatment with Durvalumab continues for a maximum of 24 months while Cetuximab may continue as maintenance
11155280|NCT03691701|Experimental|Strict SBP Target|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
11155281|NCT03691701|No Intervention|Usual SBP Target|Usual care, no home SBP target
11155282|NCT03691688||Aspirin|Aspirin 100mg
11155283|NCT03691688||Clopidogrel|Clopidogrel 75mg
11155284|NCT03691675|Experimental|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
11155285|NCT03691662|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
11155286|NCT03691662|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
11155287|NCT03691649|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
11155288|NCT03691649|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
11155289|NCT03691636|Experimental|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
11155290|NCT03691636|Active Comparator|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
11155291|NCT03691623|Experimental|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
11155292|NCT03691623|Experimental|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
11155293|NCT03691623|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
11155294|NCT03691623|Experimental|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
11155295|NCT03691623|Experimental|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
11155296|NCT03691623|Placebo Comparator|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
11155297|NCT03691610|Experimental|Group 1|MenACYW conjugate vaccine + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
11155298|NCT03691610|Active Comparator|Group 2|MENVEO® + routine pediatric vaccines at 6 to 7 months of age and 12 to 13 months of age
11155299|NCT03691610|Experimental|Group 3|MenACYW conjugate vaccine at 17 to 19 months of age and 20 to 23 months of age
11155300|NCT03691610|Active Comparator|Group 4|Menactra® at 17 to 19 months of age and 20 to 23 months of age
11155301|NCT03691597|Active Comparator|Adhesive resin cement|type of cement used for cementation of crowns have a good adhesion bond
11155302|NCT03691597|Experimental|Bioactive cement|recent cement improve the marginal integrity
11155303|NCT03691584|Experimental|BAL PK study|Bronchoalveolar lavage procedure performed at either 2, 4, 8, or 24 hours after final dose of TP-6076 on Day 4
11155304|NCT03691571|Experimental|Esophageal Cooling|Patients randomized to Group A receive the EnsoETM (Attune Medical Esophageal Heat Transfer Device).
11155305|NCT03691571|Active Comparator|Control|Patients randomized to Group B receive standard of care treatment (standard temperature probe monitoring).
11155306|NCT03691558|Experimental|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
11155307|NCT03691558|Active Comparator|Western Diet|Subjects followed 5 weeks of a western diet
11155308|NCT03691545|Experimental|Intervention Group|(1) 12 weekly interactive sessions with a health coach to help them set goals and make changes toward becoming physically active and consuming the recommended number of fruits and vegetables.
11155309|NCT03691532|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~60 min (duration of exercise performed in other arm). Following the intervention they are fed a liquid meal.
11155310|NCT03691532|Experimental|Arm cycle exercise (ACE)|Participants complete continuous arm cycle exercise (ACE) for ~60 min. Following the intervention they are fed a liquid meal.
11155311|NCT03691519|Placebo Comparator|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.
~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
11155312|NCT03691519|Experimental|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
11155313|NCT03691506|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
11155314|NCT03691506|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
11155315|NCT03691493|Experimental|Radiation, palbociclib, hormone therapy|Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21. At the discretion of treating physician, patients also receive letrozole, anastrozole, exemestane, or tamoxifen PO QD on days 1-28, or fulvestrant IM on days 1 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11155316|NCT03691480|Experimental|simple exsufflation|
11155317|NCT03691480|Experimental|Fuhrman catheter and ambulatory care|
11155318|NCT03691467|Experimental|immediate implant with hyaluronic acid.|immediate dental implant with topical application of hyaluronic acid.
11155319|NCT03691467|Active Comparator|immediate implant.|immediate dental implant placement with placebo gel
11155320|NCT03691454|Experimental|DOS|Docetaxel+Oxaliplatin+S-1
11155321|NCT03691454|Active Comparator|SOX|Oxaliplatin+S-1
11155322|NCT03691441|Experimental|Resection/adjuvant radio(-chemo)therapy|"Transoral surgical resection within 4 weeks after randomization
~Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization
~6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery"
11155323|NCT03691441|Active Comparator|Adjuvant radio(-chemo)therapy/salvage neck dissection|"6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization
~70-72 Gy, SIB possible
~Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33
~+/- Salvage neck dissection 12±2 weeks after treatment"
11155324|NCT03691428|Experimental|Intervention|
11155325|NCT03691428|Other|Wait-list|Participants will get the WOOP training after the last outcome assessment.
11155326|NCT03691415||BELKYRA Inj.|Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
11155327|NCT03691402|Experimental|MCT-Silver|Metacognitive training for depression in later life is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and (re-)defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
11155328|NCT03691402|Active Comparator|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
11155329|NCT03691376|Experimental|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
11155330|NCT03691363|Experimental|M-STEP|Mobile exercise intervention
11155586|NCT03689543|Placebo Comparator|Arm 3|Matched placebo
11155331|NCT03691350|Active Comparator|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
11155332|NCT03691350|Experimental|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
11155333|NCT03691350|Experimental|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
11155334|NCT03691350|Experimental|Group IV (usual cigarette brand, nicotine-containing SREC)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the nicotine-containing SREC for 2 weeks and use both their usual brand of cigarettes and the nicotine-containing SREC starting day 15 for 8 weeks with the intention of smoking reduction to 5 cigarettes or less per day. Participants undergo a second bronchoscopy on day 71.
11155335|NCT03691350|Experimental|Group V (NRT)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 2 days before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
11155336|NCT03691337|Active Comparator|Low dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.11 mL x subject height)
11155337|NCT03691337|Active Comparator|High dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.22 mL x subject height)
11155338|NCT03691337|Placebo Comparator|Placebo|Preoperative fascia iliaca block with Sodium Chloride 0.9% (0.11 mL x subject height)
11155339|NCT03691324|Experimental|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
11155340|NCT03691324|No Intervention|Standard care|Patients receive standard care and follow up of their COPD-treatment
11155341|NCT03691311|Experimental|Denosumab|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
11155342|NCT03691311|No Intervention|Control|Control group
11155343|NCT03691298||Arthroscopic hip repair|
11155344|NCT03691285|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
11155345|NCT03691285|Active Comparator|Two-implant mandibular overdenture|Participants allocated to this group will have two implants placed in the inter-foraminal region after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
11155346|NCT03691272|Experimental|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
11155347|NCT03691272|Sham Comparator|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
11155348|NCT03691259|Experimental|Dance Group|Dance group will participate in one-hour ballet classes twice per week for 10 weeks
11155349|NCT03691259|No Intervention|Control Group|The control group will not participate in the ballet classes
11155350|NCT03691220|Experimental|Telemetric Intervention Arm|Adolescent with MLVI>2 to receive the telemetric intervention.
11155351|NCT03691220|No Intervention|Standard of Care Arm|Adolescent with MLVI>2 to receive standard of care.
11155352|NCT03691207|Experimental|SINGLE-ARM|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
11155353|NCT03691194|Experimental|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
11155354|NCT03691194|Active Comparator|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
11155355|NCT03691181|Experimental|Open Ambulatory Ventilation|"monitoring with the use of the Life2000 Open Ventilation System for a period of six months with measures of nutrition, feeling of breathlessness, exercise tolerance, and quality of life.
~BODE Index B - BMI - BMI stands for body mass index, a calculation made by comparing height vs weight.
~O - Airway obstruction - Airway obstruction is measured by evaluating FEV1 - the amount of air that can be forcefully exhaled in 1 second after a deep breath.
~D - Dyspnea - Dyspnea refers to the degree of breathlessness someone experiences while living with COPD.
~E - Exercise tolerance - Exercise testing refers to how well some does on a 6-minute walk test.
~Modified Medical Research Council Dyspnea Scale"
11155356|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
11155357|NCT03691129|Experimental|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
11155358|NCT03691129|No Intervention|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
11155359|NCT03691116|Experimental|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
11158947|NCT03666910||children of normal mothers|
11155360|NCT03691116|Active Comparator|Treatment as usual|Psychological assessment and treatment as usual.
11155361|NCT03691090|Experimental|SHR-1210 + paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
11155362|NCT03691090|Active Comparator|placebo+paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance
11155363|NCT03691077|Experimental|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
11155364|NCT03691064||LUTATHERA|Treated per labeled LUTATHERA dosing regimen.
11155365|NCT03691051|Experimental|Pyrotinib Plus Capecitabine|Pyrotinib + Capecitabine
11155366|NCT03691038|Active Comparator|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
11155367|NCT03691038|Experimental|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
11155368|NCT03691025||RALPD|
11155369|NCT03690999|Placebo Comparator|Placebo group|Placebo product
11155370|NCT03690999|Experimental|Prebiotic Supplement, low dose|
11155371|NCT03690999|Experimental|Prebiotic Supplement, high dose|
11155372|NCT03690986|Experimental|Group A (VX15/2503)|Patients receive VX15/2503 IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
11155373|NCT03690986|Experimental|Group B (VX15/2503, ipilimumab)|Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
11155374|NCT03690986|Experimental|Group C (VX15/2503, nivolumab)|Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
11155375|NCT03690986|Experimental|Group D (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
11155376|NCT03690986|Experimental|Group E (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, patients undergo standard of care surgery.
11155377|NCT03690986|No Intervention|Group F (no treatment)|Patients undergo standard of care surgery.
11155378|NCT03690973|Active Comparator|Alveolar socket preservation with graft and flap surgery|
11155379|NCT03690973|Experimental|Immediate implant placement with bone using flapless surgery|
11155380|NCT03690973|Experimental|Immediate implant placement with bone and flap surgery|
11155381|NCT03690973|Experimental|Alveolar socket preservation with graft and flapless surgery|
11155382|NCT03690960|Experimental|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
11155383|NCT03690960|Active Comparator|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
11155384|NCT03690947|Experimental|Combination Therapy Group|
11155385|NCT03690947|Active Comparator|Intravitreal Ranibizumab Group|
11155386|NCT03690934|Experimental|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
11155387|NCT03690934|Active Comparator|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
11155388|NCT03690921|Experimental|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11155389|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
11155390|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
11155391|NCT03690895||Cases|
11155392|NCT03690882||Cases of unclassified acute cervical pain|
11155393|NCT03690869|Experimental|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive REGN2810 monotherapy. Each Cohort will have 2 subgroups by age (0 to <12 years, 12 to <18 years).
11155394|NCT03690869|Experimental|Efficacy with Newly Diagnosed DIPG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
11155395|NCT03690869|Experimental|Efficacy with Newly Diagnosed HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
11155396|NCT03690869|Experimental|Efficacy with Recurrent HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
11155397|NCT03690856|Experimental|depressiv people|
11155398|NCT03690843||DCD Group|Children diagnosed with DCD or at-risk DCD at two or three years of age
11155399|NCT03690843||Control Group|Typically developing children
11155400|NCT03690830|Experimental|Case group RIF|blood samples, analyzing endometrial cells
11155401|NCT03690830|Experimental|Case group IRPL|blood samples, analyzing endometrial cells
11155402|NCT03690830|Active Comparator|Control group|blood samples, analyzing endometrial cells
11155403|NCT03690817||Bilateral vestibulopathy|Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).
11155404|NCT03690817||Healthy controls|Subjects without vestibular or neurological diseases (DHI<5), and with normal hearing thresholds according to their age.
11155405|NCT03690804|Experimental|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
11155406|NCT03690791|Active Comparator|MediCabilis CBD Oil|
11155407|NCT03690791|Placebo Comparator|Placebo Oil|
11155408|NCT03690778|Experimental|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
11159068|NCT03666078||emergency cesarean delivery|
11155409|NCT03690778|Experimental|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
11155410|NCT03690765||Endometriosis/Dydrogesterone|Females aged 18 to 45 years, suffering external genital endometriosis confirmed by laparoscopy, for whom were prescribed treatment with Duphaston®
11155411|NCT03690752|Sham Comparator|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.
~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
11155412|NCT03690752|Experimental|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.
~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
11155413|NCT03690739|Active Comparator|platinum-based chemotherapy|According to the investigator's discretion
11155414|NCT03690739|Active Comparator|PLD + Trabectedin|PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
11155415|NCT03690726|Experimental|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
11155416|NCT03690726|Sham Comparator|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
11155417|NCT03690713||Patient and Vessels underwent physiologic evaluation|The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.
11155418|NCT03690700|Active Comparator|active BFRE|14 consecutive paraplegic SCI patients are block-randomized to active arm
11155419|NCT03690700|Sham Comparator|sham BFRE|14 consecutive paraplegic SCI patients are block-randomized to sham arm
11155420|NCT03690687||Group I. Primary anastomosis|Resection of the small bowel to place primary anastomosis into small intestine or transverse colon during relaparotomy.
11155421|NCT03690687||Group II. Delayed anastomosis|Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
11155422|NCT03690687||Group III. Enterostomy|Resection of the small intestine with enterostomy. In case there was no postoperative peritonitis relief and was organ dysfunction progression, anastomosis was not placed. The surgery was completed with enterostomy to perform open abdomen.
11155423|NCT03690674|Experimental|Lifestyle Enhancement for ADHD Program|There is no comparison/control arm.
11155424|NCT03690661|Experimental|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
11155425|NCT03690661|Placebo Comparator|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
11155426|NCT03690648||Saliva collection|"Clinical examination;
~Quality of life survey;
~Saliva collection for genetical analysis"
11155427|NCT03690648||Saliva and Blood collection|"Clinical examination;
~Quality of life survey;
~Saliva and blood collection for genetical analysis"
11155428|NCT03690635|Experimental|VISTA technique|evolution of a newer approach known as Vestibular Incision Subperiosteal Tunnel Access (VISTA) was proposed to avoid some of the potential complications occurring with other intrasulcular tunneling techniques
11155429|NCT03690635|Active Comparator|tunneling technique|Several modifications of tunnel technique have been described in order to preserve esthetics, avoid relapse of gingival recession and maintain papillary integrity. These modifications also attend to avoid scar formation and delayed healing related to vertical releasing incision
11155430|NCT03690622|Sham Comparator|BSS|Balanced salt solution
11155431|NCT03690622|Active Comparator|Dexmedetomidine|dexmedetomidine (0.0055%)
11155432|NCT03690609|Active Comparator|Nutraceutical intervention, 3 capsules daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 3 capsules daily in the morning.
11155433|NCT03690609|Active Comparator|Nutraceutical intervention, 2 capsules twice daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 4 capsules daily: Two in the morning and two later in the day.
11155434|NCT03690596|Experimental|NRT + QuitBuddy|This smartphone app will identify high-risk situations through real-time EMA data collected before and during a quit attempt. One week of pre-quit smoking behaviors will be integrated with passively sensed GPS data to create hotspot maps. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
11155435|NCT03690596|Experimental|NRT + QuitBuddy-Recall|This smartphone app will identify high-risk situations through retrospective recall of locations where the patient typically smoked. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
11155436|NCT03690596|Active Comparator|NRT Control (treatment as usual)|Standard Care Control is intended to approximate the real-world experience where smokers obtain over-the-counter NRT and, after brief instructions at the outset (~1 lozenge per hour, during cravings, and <20 per day), determine usage for themselves.
11155437|NCT03690583|Experimental|Zinc group|Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
11155438|NCT03690583|Placebo Comparator|Placebo group|Glucose
11155439|NCT03690557|Experimental|IncentaHealth|All patients who decide to join the weight loss program will be enrolled in the commercially-available IncentaHealth program - a comprehensive, evidence-based, behavioral weight management program designed to help patients initiate and maintain weight loss. The program is delivered completely online, via website, emails, mobile app, and (if requested by the participant) text messaging over 12 months. Each participant will be given a digital scale that wirelessly syncs with a smartphone app. Participants' weights are automatically uploaded to the Incentahealth online portal. In the informed consent process, participants will need to agree to release their weight data to researchers at the University of Nebraska Medical Center in order to participate in this program.
11155440|NCT03690544|Experimental|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
11155441|NCT03690531||Take Pause Virtual Reality Head Set|The mbVR intervention arm will be a Take-Pause virtual reality simulation will be for 5 minutes shown through a virtual reality goggle, headset and iPhone.
11155442|NCT03690531||Passive Distraction Group_IPAD|The Passive Distraction group will utilize the standard or passive distraction technique of using an IPAD lasting 5 minutes.
11155443|NCT03690518|No Intervention|Control|Controls will have a regular follow-up without any intervention (no rehabilitation program)
11155444|NCT03690518|Active Comparator|Rehabilitaiton|Cardiac rehabilitation: Rehabilitation will have a regular follow-up with intervention (rehabilitation program)
11155445|NCT03690505|Other|Assessment|Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
11155446|NCT03690492|Experimental|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
11155447|NCT03690492|No Intervention|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
11155448|NCT03690479|Active Comparator|Ball Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the new trial tip (ball-end probe, 0.6mm diameter).
11155449|NCT03690479|Active Comparator|Florida Probe Straight Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip (straight-end probe, 0.45mm diameter).
11155450|NCT03690466|Experimental|Study device treatment|Transcutaneous non-invasive ultrasound will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
11155451|NCT03690466|Sham Comparator|Sham device treatment|Sham treatment will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
11155452|NCT03690453|Experimental|Healthy volunteer for Clinical Trial|
11155453|NCT03690453|No Intervention|Healthy volunteer for blood donor|
11155454|NCT03690427|Experimental|Endothelial function|Brachial artery flow-mediated dilation will be used to measure endothelial function
11155455|NCT03690427|Experimental|Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness
11155456|NCT03690427|Experimental|Biomarkers of|Prooxidant and inflammatory plasma biomarkers will be used to assess oxidative stress and inflammatory status
11155457|NCT03690414|Active Comparator|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
11155458|NCT03690414|Active Comparator|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
11155459|NCT03690414|Active Comparator|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
11155460|NCT03690401||Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed before treatment and after completion of treatment. Moving On assessments will be performed at first and last study visits.
11155461|NCT03690401||Non-Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed at first and last study visits.
11155462|NCT03690388|Experimental|Cabozantinib|Oral cabozantinib (60 mg) qd
11155463|NCT03690388|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo qd
11155464|NCT03690375|Experimental|BBL Only|Treatment with BBL only
11155465|NCT03690375|Active Comparator|BBL with RFM|Treatment with BBL and Radiofrequency Microneedling
11155466|NCT03690362|Experimental|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
11155467|NCT03690362|Experimental|Group 2 - Mild Renal Impairment|Mild renal impairment
11155468|NCT03690362|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
11155469|NCT03690362|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
11155470|NCT03690362|Experimental|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
11155471|NCT03690349||Skin test in severe asthma exacerbation|Skin test in asthmatic children hospitalized due to severe asthma exacerbation in a preceding year
11155472|NCT03690349||skin test in outpatient|Skin test in asthmatic children without severe asthma exacerbation in a preceding year
11155473|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
11155474|NCT03690323|Experimental|RFA|"RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.
~After recovery of the RFA patients will continue chemotherapy:
~FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy"
11155475|NCT03690323|Active Comparator|Chemotherapy|"Patients will continue chemotherapy:
~FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy"
11155476|NCT03690310|Experimental|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
11155477|NCT03690297|Experimental|LCI|Linked Color Imaging
11155478|NCT03690297|Active Comparator|WL|White Light
11155479|NCT03690284|Active Comparator|Conventional Double Lumen Tube|Patient will be intubated with conventional double lumen endotracheal tube for single lung ventilation during thoracic surgery.
11155480|NCT03690284|Experimental|VivaSight Double Lumen Tube|Patient will be intubated with VivaSight double lumen endotracheal tube for single lung ventilation during thoracic surgery.
11155481|NCT03690271||Groupe 5-5|"Patients for whom the clinician has prescribed local anesthetics in the epidural:
~fixed dose administered every hour in a systematic way : 5 ml
~dose to be administered every hour by the patient : 5 ml"
11155482|NCT03690271||groupe 6-6|"Patients for whom the clinician has prescribed local anesthetics in the epidural:
~fixed dose administered every hour in a systematic way : 6 ml
~dose to be administered every hour by the patient : 6 ml"
11155483|NCT03690271||groupe 7-7|"Patients for whom the clinician has prescribed local anesthetics in the epidural:
~fixed dose administered every hour in a systematic way :7 ml
~dose to be administered every hour by the patient :7 ml"
11155484|NCT03690258|Experimental|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.
~Data available at: http://nhance.se/"
11155485|NCT03690258|Experimental|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.
~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
11155486|NCT03690245|Active Comparator|Control|Infants will have immediate cord clamping and respiratory support afterwards
11155487|NCT03690245|Experimental|Initiation of Resuscitation While Attached to the Cord|Infants will receive respiratory support for 120 seconds while attached to the cord.
11155488|NCT03690232|Experimental|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
11155489|NCT03690232|Active Comparator|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
11155490|NCT03690206|Experimental|Glepaglutide SC injections twice weekly|Intervention: Glepaglutide
11155491|NCT03690206|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|Intervention: Glepaglutide
11155492|NCT03690206|Placebo Comparator|Placebo SC injections twice weekly|Intervention: Placebo
11155493|NCT03690193|Experimental|Ketogenic Diet Arm|All participants will be assigned to the 3-month ketogenic diet intervention. Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein). Participants will be provided medium chain triglyceride oil with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
11155494|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.
~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
11155495|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.
~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
11155496|NCT03690167|Active Comparator|Concentrated Growth Factor (CGF)|Participants with impacted lower third molar
11155497|NCT03690167|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|Participants with impacted lower third molar
11155498|NCT03690167|Sham Comparator|Control|Participants with impacted lower third molar
11155499|NCT03690154|Experimental|FN-1501|
11155500|NCT03690141|Experimental|tomivosertib (eFT508)|Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.
11155501|NCT03690128|Active Comparator|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
11155502|NCT03690128|Active Comparator|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.
~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
11155503|NCT03690115|Experimental|Experimental|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
11155504|NCT03690102|Experimental|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.
~During the scenario test, the participant will receive T-CPR."
11155505|NCT03690102|Experimental|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.
~During the scenario test, the participant will not receive T-CPR."
11155506|NCT03690102|Experimental|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.
~During the scenario test, the participant will receive T-CPR."
11156012|NCT03686449|Experimental|study group 2|Adipose-Derived Stem cell-Keratinocyte Suspension
11155507|NCT03690089|Experimental|Intervention Group (Atropine 0.01%)|The intervention group will receive 0.01% atropine sulfate eye drops, administered once daily for two years.
11155508|NCT03690089|Placebo Comparator|Placebo Group|The control group will receive placebo eye drops, administered once daily for two years.
11155509|NCT03690076||Control|patients with normal weight (23 < BMI < 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
11155510|NCT03690076||Endocarditis|patients with normal weight (23 < BMI < 27) carriers of endocarditis with surgery indication
11155511|NCT03690076||Obese|obese patients (BMI > 30 with waist to hip ratio > or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
11155512|NCT03690050|Experimental|Diode Subthreshold Micropulse Laser|"DSML is a relatively new laser technology aimed at minimising damage (tissue-sparing) to choroid and retina but maintaining treatment efficacy by its selective effect on the retinal pigment epithelium (RPE). It is performed using laser that, instead of delivering a continuous-wave laser beam, as the standard laser, it provides very small, repetitive, low energy pulses of laser separated by a brief rest period. This rest period allows the tissue to cool down between laser pulses avoiding the increased tissue heat that would be produced by continuous laser and allowing the use of lower laser energy power to achieve an effect. The reduced heat produced in the tissue and the reduced energy power required for the treatment may reduce side effects."
11155513|NCT03690050|Active Comparator|Standard threshold laser (532 nm laser)|Green-yellow argon laser photocoagulation at threshold levels has been used for many years as the standard laser for the treatment of many retinal disorders including DMO. The ETDRS demonstrated the efficacy of laser in preventing visual loss in patients with DMO.
11155514|NCT03690037|Experimental|Intervention Group 1|Intervention Group 1: 1g intravenous Tranexamic Acid 100 milligrams (MG)/ML peri-operatively plus 1g oral Tranexamic Acid 500mg Tablets every 8hrs for up to 24hrs
11155515|NCT03690037|Experimental|Intervention Group 2|Intervention Group 2: 1g intravenous Tranexamic Acid 100 MG/ML peri-operatively
11155516|NCT03690037|No Intervention|Control Group 3|Standard care - no TXA
11155517|NCT03690011|Experimental|CD7.CAR/28zeta CAR T Cells|Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.
11155518|NCT03689998|Experimental|implant placement with melatonine|immediate implant placement with melatonine
11155519|NCT03689998|Active Comparator|immediate implant placement alone|immediate implant placement alone
11155520|NCT03689985|Experimental|General|One arm study: smART Feeding Tube System.
11155521|NCT03689972|Experimental|Part 1: Standard Interval Dosing (SID) IV|Participants will receive natalizumab 300 milligram (mg) intravenous (IV) infusion every 4 weeks (-2/+5 days) up to Week 72.
11155522|NCT03689972|Experimental|Part 1: Extended Interval Dosing (EID) IV|Participants will receive natalizumab 300 mg IV infusion every 6 weeks (-2/+5 days) up to Week 72.
11155523|NCT03689972|Experimental|Part 2: EID SC, then EID IV|Participants will receive natalizumab 300 mg SC injection every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion every 6 weeks from Week 132 through Week 150.
11155524|NCT03689972|Experimental|Part 2: EID IV, then EID SC|Participants will receive natalizumab 300 mg IV infusion every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg SC injection every 6 weeks from Week 132 through Week 150.
11155525|NCT03689959|Experimental|Patients|13 child with fixed knee flexion deformity more than 10° on one or both sides with 12 months or more predicted growth remaining subjected to eight plate hemiepiphysiodesis of the distal femur
11155526|NCT03689946|Experimental|Evolocumab, F18-NaF PET, CCTA|Evolocumab self-administration for 18 months. Baseline (pre-treatment) and follow-up 18F-NaF PET and CCTA (possible beta-blocker and nitroglycerin, if medically safe).
11155527|NCT03689933|Experimental|root analog implant|The tooth indicated for extraction will be extracted atraumatically using periotome, socket preservation using Iodoform packing strips, and then optical scanning of the remaining tooth structure with optical scanner will be made to obtain a 3D virtual model, this model will be modified by addition of macro-retentions strictly to the interdental area to avoid any fracture in thin cortical bone, the cervical portion of implant circumference will be decreased by 0.1 to 0.2 mm to avoid pressure resorption of alveolar crest of bone and addition of prepared crown stump for the future crown to be placed.
11155528|NCT03689933|Active Comparator|conventional stock root-form titanium implant|Using a conventional implant as a comparator as it's the gold stander in restoring the non-restorable teeth.
11155529|NCT03689920|Active Comparator|WaveWriter Settings|WaveWriter Programming
11155530|NCT03689920|Active Comparator|Conventional Settings|Conventional Programming
11155531|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.
~At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
11155532|NCT03689894|Experimental|Ibrutinib plus Rituximab|"Rituximab
~*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)
~Ibrutinib
~420 mg (140 mg capsule x3) by mouth daily
~May be given beyond 3-6 months (for maintenance)."
11155533|NCT03689881|Experimental|Tomosynthesis|Tomosynthesis of SI joints
11155534|NCT03689868|Experimental|Virtual Reality|
11155535|NCT03689868|No Intervention|Control|
11155536|NCT03689855|Experimental|Ramucirumab + Atezolizumab|"Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.
~Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
11155537|NCT03689842|Experimental|Couple donor - recipient|
11155538|NCT03689829|Experimental|MOR106 Single Dose A, i.v. infusion, Part 1|A single dose of MOR106 will be administered by i.v. infusion.
11155539|NCT03689829|Experimental|MOR106 Single Dose B, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
11155540|NCT03689829|Experimental|MOR106 Single Dose C, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
11155541|NCT03689829|Experimental|MOR106 Single Dose D, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
11155542|NCT03689829|Experimental|MOR106 Repeated Doses E, s.c. injection, Part 2|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
11155543|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 2|Corresponding Placebo will be administered by s.c. injection.
11155544|NCT03689829|Experimental|MOR106 Repeated Doses F, s.c. injection, Part 3|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
11155545|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 3|Corresponding Placebo will be administered by s.c. injection.
11155546|NCT03689816|Experimental|bone density|bone density
11155547|NCT03689803|Active Comparator|Lipidemia|
11155548|NCT03689790|Active Comparator|liver function|liver function
11155549|NCT03689777|Active Comparator|Glomerular Filtration Rate|
11155550|NCT03689764|Experimental|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
11155551|NCT03689764|Experimental|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
11155552|NCT03689751|No Intervention|LSCS Control Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
11155553|NCT03689751|Experimental|LSCS Intervention ArmIntervention Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (LSCS Video) as an additional educational resource.
11155554|NCT03689751|No Intervention|TVT/TOT Control Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
11155555|NCT03689751|Experimental|TVT/TOT Interventional Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (TVT/TOT Video) as an additional educational resource.
11155556|NCT03689738|Experimental|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
11155557|NCT03689738|Active Comparator|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
11155558|NCT03689725|Experimental|Preterm music group|Music exposure with headphones
11155559|NCT03689725|No Intervention|Preterm control group|headphones without music
11155560|NCT03689725|No Intervention|Full-term control group|
11155561|NCT03689712|Experimental|GC4419|
11155562|NCT03689712|Placebo Comparator|Placebo|
11155563|NCT03689699|Experimental|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
11155564|NCT03689699|Experimental|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
11155565|NCT03689686|Experimental|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
11155566|NCT03689660|Experimental|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
11155567|NCT03689660|Experimental|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
11155568|NCT03689660|Other|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
11155569|NCT03689647|Experimental|Single Group Experimental|Each participant will act as their own control with variables of interest measured while walking without the assistive device and while walking with the assistive device.
11155570|NCT03689634|Experimental|Move For Surgery Preconditioning Program Intervention Group|
11155571|NCT03689634|No Intervention|Standard Preoperative Care Group|
11155572|NCT03689621|Active Comparator|Transcutaneous vagal nerve stimulation (tVNS)|tVNS administered for 4 hours each day and behaviour is recorded.
11155573|NCT03689621|Placebo Comparator|Baseline|tVNS worn but not switched on whilst collecting behavioural data.
11155574|NCT03689608|Experimental|Intermittent Fasting (IF)|3 days fasting per week
11155575|NCT03689608|Experimental|Daily Restriction (DR)|daily energy restriction
11155576|NCT03689608|Other|standard care (SC)|usual care
11155577|NCT03689595||Specimen Collection|"Samples of blood (2-4 tablespoons) from 3 tubes will be collected
~Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute"
11155578|NCT03689582|Experimental|68Ga-PSMA|PET/CT imaging
11155579|NCT03689569|Experimental|Exercise|Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.
11155580|NCT03689569|Experimental|Resistant Starch|Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training
11155581|NCT03689569|Experimental|Exercise & Resistant Starch|Exercise & resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period
11155582|NCT03689569|Placebo Comparator|Starch|Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks
11155583|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
11155584|NCT03689543|Experimental|Arm 1|LY500307 at 25mg per day
11155587|NCT03689530|Experimental|Peer Support Arm.|Participants randomized to peer support will be matched with a peer supporter.
11155588|NCT03689530|Active Comparator|Enhanced Usual Care|Participants randomized to enhanced usual care will receive brief education and folder of information and resources.
11155589|NCT03689517|Experimental|placebo arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. Participants took placebos (pills made by starch) that were told to be an effective analgesic
11155590|NCT03689517|Sham Comparator|sham arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. But participants do not take placebos
11155591|NCT03689504|Active Comparator|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
11155592|NCT03689504|Experimental|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
11155593|NCT03689491|Experimental|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
11155594|NCT03689491|Active Comparator|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
11155595|NCT03689491|Active Comparator|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
11155596|NCT03689478|Experimental|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
11155597|NCT03689465|Active Comparator|PTCy-ATG group|PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).
11155598|NCT03689465|Active Comparator|ATG group|ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).
11155599|NCT03689452|Placebo Comparator|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
11155600|NCT03689452|Experimental|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
11155601|NCT03689413|Experimental|1 mg/kg|"For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.
~We will use Sugammadex 200 MG in 2 ML Injection for this."
11155602|NCT03689413|Active Comparator|2 mg/kg|"For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.
~We will use Sugammadex 200 MG in 2 ML Injection for this."
11155603|NCT03689374|Experimental|Semaglutide|"Run-in period (12 weeks): subjects will be treated with metformin and insulin glargine (IGlar) U100.
~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in will receive semaglutide for 52 weeks in addition to metformin and IGlar U100.
~Metformin will be considered as background therapy during the trial."
11155604|NCT03689374|Active Comparator|Insulin aspart|"Run-in period (12 weeks): subjects will be treated with metformin and insulin IGlar U100.
~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in receive insulin aspart for 52 weeks in addition to metformin and IGlar U100.
~Metformin will be considered as background therapy during the trial."
11155605|NCT03689361|Other|with migraine aura.|patient with migraine aura detected by MRI, then MRI control 3 month after
11155606|NCT03689361|Other|without migraine aura|patient without migraine aura detected by MRI, then telephone consultation 3 month after
11155607|NCT03689348|Placebo Comparator|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
11155608|NCT03689348|Experimental|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
11155609|NCT03689348|Experimental|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
11155610|NCT03689348|Experimental|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
11155611|NCT03689335|Active Comparator|Operative|Surgical fixation of the humeral shaft fracture
11155612|NCT03689335|Active Comparator|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
11155613|NCT03689322|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
11155614|NCT03689322|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
11155615|NCT03689322|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
11155616|NCT03689309|No Intervention|1. Classic SBT (C-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but oxygen delivered through a heat humidifier filter that is usually connected on tracheotomy.
11155617|NCT03689309|Experimental|2. High Flow Oxygen SBT (HFO-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
11155618|NCT03689296||Users|Person with a long-term mental disorder
11155619|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
11155620|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
11155621|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
11155622|NCT03689283|Experimental|Dry Needling Group|Individuals in the DN arm will receive two treatment sessions of DN to latent trigger points of the gastrocnemius muscle.
11155623|NCT03689283|Sham Comparator|Control Group|Individuals in the control group will receive two treatment sessions of sham dry needling.
11155624|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
11155625|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
11155626|NCT03689244|Experimental|Selexipag DB|During the double blind treatment period, subjects in this group will receive selexipag. Each subject will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
11155627|NCT03689244|Placebo Comparator|Placebo DB|During the double-blind treatment period, subjects in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
11155628|NCT03689244|Experimental|Selexipag OL|All subjects who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
11155629|NCT03689218|No Intervention|Control|The control arm will receive routine public and private health services available in the area.
11155630|NCT03689218|Experimental|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
11155631|NCT03689205||Patients that BMI> 30kg / m2 (Group A)|Venous puncture pain on patients that Body mass index > 30kg / m2
11155632|NCT03689205||Patients that BMI< 30kg / m2 (Group B)|Venous puncture pain on patients that Body mass index < 30kg / m2
11155633|NCT03689192|Experimental|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
11155634|NCT03689179|Experimental|Treatment with Follow-up (Group A)|"After an initial orientation/control period (4 weeks), group A will receive access to the Time for Living & Caring (TLC) intervention for 8 weeks, followed by an optional 8-week control period where they can continue to use the TLC intervention if they choose."
11155635|NCT03689179|Experimental|Wait-List Control w/Treatment (Group B)|"After the initial 4-week orientation period, Group B will receive 8 weeks of waitlist (no treatment) control, followed by access to the Time for Living & Caring (TLC) intervention for 8 weeks."
11155636|NCT03689166|Active Comparator|Probiotics group|Probiotic drug
11155637|NCT03689166|Placebo Comparator|Control group|This group will receive placebo
11155638|NCT03689153|Experimental|Cohort 1: JNJ-63733657 or Placebo|Participants will receive a single intravenous (IV) low dose of JNJ-63733657 or matching placebo.
11155639|NCT03689153|Experimental|Cohort 2: JNJ-63733657 or Placebo|Participants will receive a single IV middle dose of JNJ-63733657 or matching placebo.
11155640|NCT03689153|Experimental|Cohort 3: JNJ-63733657 or Placebo|Participants will receive a single IV high dose of JNJ-63733657 or matching placebo.
11155641|NCT03689140|Experimental|App-only|The intervention will consist of participants will only use a smoking cessation app
11155642|NCT03689140|Experimental|Telemedicine counseling only|The intervention will consist of participants will only use telemedicine counseling
11155643|NCT03689140|Experimental|App + telemedicine counseling|The intervention will consist of participants will only use a smoking cessation app + telemedicine counseling
11155644|NCT03689140|No Intervention|Usual Care|The participants will continue with usual care
11155645|NCT03689127|Active Comparator|Control|Heated breathing circuit will be turned off.
11155646|NCT03689127|Experimental|Heat|Heated breathing circuit will be turned on.
11155647|NCT03689114|Experimental|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
11155648|NCT03689114|Active Comparator|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
11155649|NCT03689101|Experimental|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
11155650|NCT03689088|Experimental|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
11155651|NCT03689088|Active Comparator|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
11155652|NCT03689075|No Intervention|Immediate release tacrolimus|Patients will continue on immediate release tacrolimus
11155653|NCT03689075|Active Comparator|Extended release tacrolimus|
11155686|NCT03688880|Experimental|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
11156013|NCT03686449|Active Comparator|Control group|Split skin graft
11155654|NCT03689062|Active Comparator|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
11155655|NCT03689062|Experimental|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
11155656|NCT03689049|Experimental|SPIDER|QI Learning Collaboratives.
11155657|NCT03689049|Placebo Comparator|Usual Care|Standard primary care.
11155658|NCT03689023|Experimental|A controlled multimodal intervention|A uniform and systematic patient education about cardiovascular risk factors, physical activity and a healthy diet lifestyle starting early in the primary rehabilitation process with 6 months of follow up.
11155659|NCT03689010|Active Comparator|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
11155660|NCT03689010|Active Comparator|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
11155661|NCT03689010|Placebo Comparator|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
11155662|NCT03688997|Experimental|Experts|"For the novice group, the investigators recruited 30 residents within their first year of surgical residency (Post-Graduate Year [PGY]-1) in general surgery, vascular surgery, plastic surgery, orthopedic surgery, cardio-thoracic surgery, gynecology and urology.
~The intervention administered was the use of a simulator by the participants."
11155663|NCT03688997|Experimental|Novice|"The expert's group included 15 attending surgical faculty members in the general surgery, vascular surgery, cardio-thoracic surgery and gynecology services.
~The intervention administered was the use of a simulator by the participants."
11155664|NCT03688984|Experimental|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
11155665|NCT03688984|No Intervention|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
11155666|NCT03688971|Experimental|Omiganan Topical Gel|Omiganan 1.75%
11155667|NCT03688971|Active Comparator|Ketoconazole Topical Cream|Ketoconazole 2.0%
11155668|NCT03688971|Placebo Comparator|Vehicle|
11155669|NCT03688958|Placebo Comparator|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.
~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
11155670|NCT03688958|Experimental|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
11155671|NCT03688958|Placebo Comparator|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.
~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
11155672|NCT03688958|Experimental|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.
~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
11155673|NCT03688945|Experimental|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
11155674|NCT03688945|Active Comparator|Arm II (standard of care)|Participants receive standard of care for 2 years.
11155675|NCT03688932|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
11155676|NCT03688932|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
11155677|NCT03688932|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
11155678|NCT03688919|No Intervention|Comparison|Adolescents and their families in this group will not receive any of the interventions.
11155679|NCT03688919|Experimental|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
11155680|NCT03688906||Cohort A|"Blood and stool specimen collection.
~Study samples must be collected prior to any treatment."
11155681|NCT03688906||Cohort B|"Blood and stool specimen collection.
~Samples must be collected prior to performing bowel preparation for the colonoscopy."
11155682|NCT03688906||Cohort C|"Blood and stool specimen collection.
~Study samples must be collected prior to any treatment."
11155683|NCT03688893|Experimental|Laser Application|35% Hydrogen Peroxide (Whitening HP, FGM SC Brazil) 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes Laser Application and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. Experimental
11155684|NCT03688893|No Intervention|No Laser Application|35% Hydrogen Peroxide (Whitening HP FGM SC Brazil), 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes waiting and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. No Laser Application No Intervention
11155685|NCT03688880|Active Comparator|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
11155687|NCT03688867|Experimental|At-home prehabilitation regimen|"Grip strength: Squeeze a stress ball in your hand, holding it squeezed for 5 seconds. Perform this at least thirty times with each hand over the course of a day.
~Lower body strength: Perform at least one hundred chair sit-stands in a day.
~Endurance: Walking at least 7,500 steps in a day."
11155688|NCT03688854|Placebo Comparator|Placebo|Placebo are capsules containing cellulose.
11155689|NCT03688854|Experimental|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
11155690|NCT03688854|Experimental|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
11155691|NCT03688841|Experimental|Bridged V.A.C.® with compression therapy|A vacuum assisted closure device will be placed on the ulcer. A compression dressing will be placed over the V.A.C.® device
11155692|NCT03688841|Active Comparator|Conventional compression therapy|A Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings will be applied and changed once to three times per week (dependant on exudate).
11155693|NCT03688828|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate
11155694|NCT03688828|Active Comparator|Quadruple Therapy|Esomeprazole + Amoxicillin + Clarithromycin + Bismuth potassium citrate
11155695|NCT03688815||Patients with ischemic heart disease|Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
11155696|NCT03688802|Active Comparator|OC-01|
11155697|NCT03688802|Placebo Comparator|Placebo|
11155698|NCT03688789|Experimental|Hydrocortisone supplementation|
11155699|NCT03688776|Experimental|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
11155700|NCT03688776|Experimental|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
11155701|NCT03688763|Other|Digital CBTi administered|Participants will receive 6 sessions of digitally administered CBTi using the Sleepio platform over the course of 12 weeks. Each session lasts on average 30-60 minutes, and is tailored to participant's progress and problems. During the treatment phase, between sessions, participants complete the Consensus Sleep Diary to track their progress.
11155702|NCT03688737|Placebo Comparator|control group|"A) Control group:
~Has Surgical procedures von Langenbeck technique  to repair cleft palate and will come for follow up visit at day of surgery, 1st day and 3rd day for placebo device like LLL and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
11155703|NCT03688737|Active Comparator|study group|"B) Study group:
~This group will be subjected to the same surgical procedure von Langenbeck technique to repair cleft palate but low level laser Therapy will be at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
11155704|NCT03688711|Experimental|dasiglucagon|single fixed dose (sc injection) of dasiglucagon
11155705|NCT03688711|Placebo Comparator|Placebo|single fixed dose (sc injection) of placebo
11155706|NCT03688698||PAH|
11155707|NCT03688698||Controls|
11155708|NCT03688685|Experimental|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
11155709|NCT03688672|Other|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
11155710|NCT03688659|Other|vancomycin,gentamycin in endocarditis|patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks
11155711|NCT03688646|Experimental|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
11155712|NCT03688646|No Intervention|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
11155713|NCT03688633|Experimental|Candesartan|
11155714|NCT03688633|Active Comparator|Usual care|
11155715|NCT03688620|Other|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
11155716|NCT03688620|Other|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
11155717|NCT03688620|Other|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
11155718|NCT03688607||POKE|All babies in NICU at Intermountain Healthcare hospitals
11155719|NCT03688594|Experimental|couple : man and pregnant women|
11155720|NCT03688568|Experimental|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
11155721|NCT03688555|Experimental|ACT-774312|Subjects will receive ACT-774312 400 mg b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.
11155722|NCT03688555|Placebo Comparator|Placebo|Subjects will receive placebo b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.
11155723|NCT03688542|Experimental|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
11155724|NCT03688542|No Intervention|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
11155725|NCT03688516|Experimental|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
11155726|NCT03688516|Sham Comparator|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
11155727|NCT03688503|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
11155728|NCT03688503|Placebo Comparator|placebo|placebo supplement
11155729|NCT03688477|Experimental|iovera°|Patients will receive iovera° prior to stand of care ACL
11155730|NCT03688477|No Intervention|Standard of Care|Patients will receive standard of care ACL procedure without iovera° treatment.
11155731|NCT03688464|Active Comparator|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
11155732|NCT03688464|Active Comparator|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
11155733|NCT03688464|Placebo Comparator|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
11155734|NCT03688451|Experimental|Intrathecal rituximab|Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5
11155735|NCT03688438|No Intervention|Standard of Care|Standard of care wound closure and dressing No active interventions
11155736|NCT03688438|Experimental|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
11155737|NCT03688425|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
11155738|NCT03688425|Active Comparator|IOL implantation active comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
11155739|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
11155740|NCT03688399|Experimental|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
11155741|NCT03688399|Active Comparator|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
11155742|NCT03688386|Experimental|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback
~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
11155743|NCT03688386|Active Comparator|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings
~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
11155744|NCT03688373|Experimental|Exposure-in-big-steps|In the big steps exposure sessions the adolescent moves in three a set pace of big steps from bottom to top (1-5-10) in their fear hierarchy. From 0-5 in the first session and from 5-10 in the second session.
11155745|NCT03688373|Experimental|Exposure-in-small-steps|In the small steps exposure sessions the adolescent moves in a step-by-step pace of their own choice from bottom to top in their fear hierarchy, for example from 1 to 2 to 3 to in the first session and from 4 to 5 to 6 etc. in the second session.
11155746|NCT03688360|Experimental|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
11155747|NCT03688360|Experimental|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
11155748|NCT03688360|Experimental|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
11155749|NCT03688334|Active Comparator|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
11155750|NCT03688334|Sham Comparator|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
11156268|NCT03684811|Experimental|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
11155751|NCT03688321|Active Comparator|Probiotic capsule GR-1 and RC-14|The intervention for study group is taking 2 capsules containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
11155752|NCT03688321|Placebo Comparator|Placebo capsule|The intervention for placebo group is taking 2 capsules not containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
11155753|NCT03688308|Experimental|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
11155754|NCT03688308|Active Comparator|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
11155755|NCT03688295|Other|experimental group|no antibiotherapy post surgery for complicated acute appendicitis (CAA)
11155756|NCT03688295|Active Comparator|control group|antibiotherapy post surgery for complicated acute appendicitis (CAA)
11155757|NCT03688282|Sham Comparator|Sham & Wearable vibration belt|Device will be worn but not turned on for 18 minute treatment.
11155758|NCT03688282|Experimental|Wearable vibration belt (9)|Device will be worn and turned on for 9 minute treatment.
11155759|NCT03688282|Experimental|Wearable vibration belt (18)|Device will be worn and turned on for 18 minute treatment.
11155760|NCT03688269|Experimental|Intravenous dexamethasone|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.
~Intravenous injection of 8mg/2ml Dexamethasone during the regional anesthesia"
11155761|NCT03688269|Placebo Comparator|Intravenous saline|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.
~Intravenous injection of 2ml Saline 0.9% during the regional anesthesia"
11155762|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
11155763|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
11155764|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
11155765|NCT03688230|Experimental|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:
~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
~(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min
~(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
11155766|NCT03688230|Placebo Comparator|Placebo + Cetuximab + FOLFIRI|"Cetuximab:
~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
~(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min
~(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
11155767|NCT03688217|Experimental|Philani Intervention Model+MOVIE (PIM+M)|Participants will receive the standard PIM perinatal home visiting program together with the MOVIE intervention (13 entertainment-education videos about infant feeding). The PIM is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others. The MOVIE videos will be integrated into the regular home visiting program.
11155768|NCT03688217|Active Comparator|Philani Intervention Model (PIM)|Participants will receive the standard PIM perinatal home visiting program, which is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
11155769|NCT03688191|Experimental|Study Group|participants who received sirolimus treatment
11155770|NCT03688178|Experimental|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 20) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning. Patients will then receive 111In-labeled DCs as the 4th vaccine to compare the effects of different skin preparations on DC migration followed by SPECT/CT imaging immediately and at 1 and 2 days after injections.
11155771|NCT03688178|Experimental|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 20) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site. Patients will then receive 111In-labeled DCs as the 4th vaccine to compare the effects of different skin preparations on DC migration followed by SPECT/CT imaging immediately and at 1 and 2 days after injection.
11155799|NCT03687970|Active Comparator|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
11155824|NCT03687762|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
11156077|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
11155772|NCT03688178|Experimental|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 20) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (iv) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side. Patients will then receive 111In-labeled DCs at the 4th vaccine to compare the effects of varlilumab with the different skin preparations on DC migration followed by SPECT/CT imaging immediately and at 1 and 2 days after injection.
11155773|NCT03688165||Treadmill-based Robotic Gait Training|The Treadmill-based Robotic Gait Training (TRGT) period will last 20 sessions, 3-5 days/week for at least 400' of exercise totally. The parameters to be respected for the robotic training will be the following for all patients: 0.9 km / h starting speed up to a maximum of 2.5 km / h; weight support not exceeding 40-45% of the body weight at the beginning and gradual progressive reduction depending on the case; for Lokomat: maximum assistance required at the start of treatment and gradual decrease during the treatment. The TRGT will always be associated with the traditional gait rehabilitation, and will be part of the Individual Rehabilitation Project which normally includes 3 hours of rehabilitation treatments for patients in the subacute phase, 60' of treatment for those in chronic phase.
11155774|NCT03688165||Traditional Over-ground Gait Training|"The Traditional Over-ground Gait Training (TOGT) period will last 20 sessions, 3-5 days / week for a total time that corresponds to the same total time of traditional overground gait training, or at least 400' totally at the end of the period.
~By Traditional Therapy we mean any technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids."
11155775|NCT03688152|Experimental|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
11155776|NCT03688139|Experimental|Engage Therapy|Participants receive Engage therapy for 9 weeks.
11155777|NCT03688139|Active Comparator|Supportive Therapy|Participants receive supportive therapy for 9 weeks.
11155778|NCT03688126|Experimental|Self-Guided Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
11155779|NCT03688126|Experimental|Structured Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
11155780|NCT03688113|Experimental|Treatment|
11155781|NCT03688113|Other|Wait list|
11155782|NCT03688100|Active Comparator|Medication Management group|The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
11155783|NCT03688100|Active Comparator|Behavioral Activation Therapy|BA is an evidence-based psychotherapy with more than 25 randomized trials showing effectiveness in depression. The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
11155784|NCT03688087|Placebo Comparator|placebo|"Smartphone application placebo"
11155785|NCT03688087|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
11155786|NCT03688074|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
11155787|NCT03688074|Placebo Comparator|Placebo|Placebo subcutaneous injection
11155788|NCT03688061|Experimental|Group 1 (low dose/healthy volunteers)|5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10*7 pfu) IM at week 8
11155789|NCT03688061|Experimental|Group 2 (higher dose/healthy volunteers)|10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10*8 pfu) IM at week 8
11155790|NCT03688061|Experimental|Group 3 (higher dose/HCV cured volunteers)|10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10*8 pfu) IM at week 8
11155791|NCT03688048|Experimental|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
11155792|NCT03688048|Placebo Comparator|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
11155793|NCT03688022|Experimental|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
11155794|NCT03688022|Experimental|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
11155795|NCT03688009|Experimental|Mindfulness-Based Family Psycho-Education (MBFBE)|A programme focuses on non-judgmental attitudes, collaborative inquiry and self-care, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
11155796|NCT03688009|Active Comparator|Family Psycho-Education (FPE)|A programme focuses on information giving, problem-solving and mutual support, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
11155797|NCT03687983|Experimental|Intervention arm|Participants will be treated with GoldenFlow Peripheral Stent System.
11155798|NCT03687970|Experimental|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
11156261|NCT03684850|Active Comparator|Exercise therapy group|(n = 40)
11155800|NCT03687957|Experimental|Phase I: rhIL-7-hyFc|"Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 5 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned
~The phase I part will begin with an Accelerated Phase with 1 patient per cohort at the first 2 doses (60 mcg/kg and 120 mcg/kg) followed by a standard 3+3 design on the remaining 4 dose levels"
11155801|NCT03687957|Experimental|Phase II: Placebo|-Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. Placebo will be given by intramuscular injection starting at the end of RT/TMZ (within 5 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of placebo injections are planned.
11155802|NCT03687957|Experimental|Phase II: rhIL-7-hyFc|Per standard treatment, patients will receive concurrent RT/TMZ followed by adjuvant TMZ on Days 1-5 of a 28-day cycle for a total of 6 cycles. rhIL-7hyFc will be given by intramuscular injection starting at the end of RT/TMZ (within 5 days after last day of RT/TMZ). The 2nd injection will be administered 3-5 days after the last dose of cycle 3 TMZ treatment (~week 13). The 3rd injection will be given 3-5 days after the last dose of cycle 6 TMZ treatment (~week 25). Note the 2nd and 3rd injections should be administered once between Day 3 through 5 following the last dose of TMZ to achieve the strongest response. The 4th injection (last injection in the study) will be given after completion of monthly TMZ (~Week 37). A total of 4 doses of rhIL-7-hyFc injections are planned.
11155803|NCT03687931|Experimental|Arm 1|Dexamethasone suspension dose level 1
11155804|NCT03687931|Experimental|Arm 2|Dexamethasone suspension dose level 2
11155805|NCT03687905||Lupus nephritis III or IV/chloroquine|receiving chloroquine with daily dose 5 mg/kg
11155806|NCT03687905||Lupus nephritis III or IV/hydroxychloroquine|receiving hydroxycholorquine with daily dose 5 mg/kg
11155807|NCT03687905||Systemic lupus erythematosus|not received hydroxychloroquine nor chloroquine .
11155808|NCT03687892|Experimental|continuous Theta Burst Stimulation|The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
11155809|NCT03687892|Experimental|intermittent Theta Burst Stimulation|The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
11155810|NCT03687853|Experimental|Intrahepatic Arterial Infusion chemotherapy|chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.
11155811|NCT03687853|No Intervention|control|chemotherapy through Peripheral venous is one of the regularly used method.
11155812|NCT03687840|Other|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
11155813|NCT03687840|Other|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
11155814|NCT03687827|Experimental|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
11155815|NCT03687827|Active Comparator|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
11155816|NCT03687814|Experimental|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
11155817|NCT03687814|Sham Comparator|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
11155818|NCT03687801|Experimental|Online hearing support|The intervention group will have access to online hearing support for five weeks. The online hearing support will include a program that consists of three elements: 1) reading material; 2) reading instructions and weekly assignments related to the reading material; and 3) online and telephone interaction with a professional.
11155819|NCT03687801|Active Comparator|Standard care|"The control group will have access to traditional support that the Hearing Organization provides (standard care)."
11155820|NCT03687788|Experimental|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
11155821|NCT03687788|No Intervention|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
11155822|NCT03687775||DSG-Stabi|The group consists of patients with primary trapeziometacarpal osteoarthritis and an indication for trapeziectomy alone or in combination with the resection-suspension-interposition arthroplasty.
11155823|NCT03687762|Active Comparator|Cognitive Therapy (CT) Condition|"Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
11155858|NCT03687528||Patient with minor head injury trauma|The emergency protocol for antiplatelet inhibitors treated patient with head injury trauma and meeting others NICE criteria involves a clinical exam followed by a CT-scanner.
11155859|NCT03687515|Experimental|budesonide inhalation suspension|
11155825|NCT03687762|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
11155826|NCT03687749||Women with breast cancer-related lymphedema|Individuals with upper limb lymphedema developed after breast cancer treatment
11155827|NCT03687749||Healthy control subjects|Healthy individuals without breast cancer-related lymphoedema.
11155828|NCT03687736|Other|AbobotulinumtoxinA|Open-label
11155829|NCT03687697|Experimental|Global vs. G-TL Media|Global medium will be compared with G-TL (Time-Lapse) medium.
11155830|NCT03687697|Experimental|Global vs. Cornell's C3 Media|Global medium will be compared with Cornell's C3 single step medium.
11155831|NCT03687697|Experimental|Global vs. Cornell's sequential Media|Global medium will be compared with Cornell's C1/C2 sequential medium.
11155832|NCT03687684|Experimental|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
11155833|NCT03687684|Experimental|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
11155834|NCT03687684|Experimental|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
11155835|NCT03687684|Experimental|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
11155836|NCT03687684|Experimental|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
11155837|NCT03687684|Experimental|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
11155838|NCT03687684|Experimental|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
11155839|NCT03687671|Experimental|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
11155840|NCT03687671|Active Comparator|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
11155841|NCT03687658|Experimental|Binge Eating Group|All participants in the study will be invited to use Laddr, described in the intervention section.
11155842|NCT03687658|Experimental|Smoking Group|All participants in the study will be invited to use Laddr, described in the intervention section.
11155843|NCT03687645|Experimental|Prostate Cancer|Patients with biopsy-proven prostate cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
11155844|NCT03687645|Experimental|Renal Cancer|Patients with biopsy-proven renal cell carcinoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
11155845|NCT03687645|Experimental|Breast Cancer|Patients with biopsy-proven breast cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
11155846|NCT03687645|Experimental|Lymphoma|Patients with biopsy-proven lymphoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
11155847|NCT03687632|Experimental|Single arm - active|ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
11155848|NCT03687619|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a top-down approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
11155849|NCT03687619|Experimental|Conductive Education|Conductive Education is a down-top approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
11155850|NCT03687606|Active Comparator|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for 3 years.
11155851|NCT03687606|Experimental|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for six months, then 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
11155852|NCT03687606|Experimental|hCG and hMG|Human Chorionic Gonadotropin 2000U~6000U and 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
11155853|NCT03687580|Experimental|B-Cure Laser Pro|Subjects from the B-Cure Laser Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
11155854|NCT03687580|Sham Comparator|Sham laser|Subjects from the Sham laser group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
11155855|NCT03687567||HBA|alpha-Thalassemia
11155856|NCT03687567||HBB|beta-Thalassemia
11155857|NCT03687554|Experimental|Venglustat|Single dose of Venglustat is given, orally under fasting conditions
11155862|NCT03687502|Experimental|Experimental|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, up to 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
11155863|NCT03687489|Experimental|Intervention arm|Participants will be treated with Abdominal Aortic Aneurysm Stent Graft System
11155864|NCT03687476|Experimental|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
11155865|NCT03687476|Experimental|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
11155866|NCT03687450|Experimental|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
11155867|NCT03687450|No Intervention|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
11155868|NCT03687424|Active Comparator|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11155869|NCT03687424|Active Comparator|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11155870|NCT03687424|Active Comparator|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11155871|NCT03687424|Experimental|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11155872|NCT03687424|Experimental|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11155873|NCT03687424|Experimental|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11155874|NCT03687411|Experimental|ULTRA-SINE (phases 1-4)|"There will be four phases in this proposed uSINE system. In first phase attending anaesthetist will use the automated spinal landmark system for neuraxial needle insertion to place the neuraxial anaesthesia in non-obese patients.
~For the second phase, obese patients will have ultrasound scan of their lumbar back and no needle insertion is involved.
~In third phase, conventional ultrasonography is used prior to the needle insertion, and needle insertion is conducted manually as per routine practice. The images collected in the system will be used for annotation and evaluation which serves as training material for uSINE to optimize its algorithm to improve landmark identification for obese patients. The fourth phase will have uSINE system used prior to the needle insertion, with the neuraxial needle insertion conducted manually as per routine practice. The identification accuracy and first-attempt puncture success rate of uSINE will be determined."
11155875|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
11155876|NCT03687398||patient|has laparoscopically proven endometriosis
11155877|NCT03687385|Active Comparator|ASA I / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11155878|NCT03687385|Active Comparator|ASA II / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11155879|NCT03687385|Active Comparator|ASA III / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
11155880|NCT03687385|Experimental|ASA I / HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11155881|NCT03687385|Experimental|ASA II/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11155882|NCT03687385|Experimental|ASA III/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
11155883|NCT03687372|Experimental|A-101|topical solution
11155884|NCT03687372|Other|Vehicle|topical solution
11155885|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
11155886|NCT03687346||High Risk Group|Parental history of eating pathology
11155887|NCT03687346||Low Risk Group|No parental history of eating pathology
11155888|NCT03687333|Experimental|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
11155889|NCT03687320|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
11155890|NCT03687320|Sham Comparator|Standard and Sham|Subjects from the Standard and sham group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
11155891|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
11155892|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
11155893|NCT03687281||Male patients living with HIV and having sex with men|Male patients living with HIV and having sex with men followed at Universitary Hospital Center of Reunion Island
11155894|NCT03687268|Placebo Comparator|Placebo|
11155895|NCT03687268|Experimental|Naloxone 24 mg|
11155896|NCT03687268|Experimental|Naloxone 48 mg|
11155897|NCT03687255|Experimental|cefepime/AAI101 combination|Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)
11155898|NCT03687255|Active Comparator|piperacillin/tazobactam|Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)
11155899|NCT03687242|Experimental|SPR001|SPR001 at Dose A
11155900|NCT03687229||Patient|"Chronic HCV patients before treatment & 3 months after starting of treatment. not known to be:
~Cirrhosis
~Diabetes Mellitus.
~Hemochromatosis
~HBV
~HIV.
~Hepatocellular carcinoma (HCC)
~Chemotherapy
~Organ transplantation"
11155901|NCT03687229||Control|Apparently healthy individuals
11155902|NCT03687216|Experimental|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
11155903|NCT03687216|Active Comparator|Routing group|Routing therapy (EVL plus NSBB)
11155904|NCT03687190|Experimental|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
11155905|NCT03687190|Active Comparator|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
11156262|NCT03684850|Experimental|Knee brace and exercise group|(n = 40)
11155906|NCT03687177|Other|Control group|Nurses from intensive care informed on the prevention of VAP and without visual cue to estimate the angle of elevation of the head of intubated patients
11155907|NCT03687177|Other|Experimental group|Nurses from intensive care informed on the prevention of VAP with visual cue to estimate the angle of elevation of the head of intubated patients.
11155908|NCT03687164|Experimental|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
11155909|NCT03687164|No Intervention|Usual Care|Usual clinical office visits
11155910|NCT03687151||patients with a diagnosis of invasive or in situ cancer|patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005
11155911|NCT03687138||Control 1|This is the control population. The analysis will be done with a 24h urin sample. We will compare this population with the other two.
11155912|NCT03687138||Control 2|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
11155913|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the other two controls populations.
11155914|NCT03687125|Experimental|Treatment Arm|Conditioning Treatment with TINOSTAMUSTINE for salvage ASCT and Relapse/Refractory Multiple Myeloma
11155915|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
11155916|NCT03687086|Experimental|Program A|cognitive behavioral therapy type A plus medications in packaging type A
11155917|NCT03687086|Active Comparator|Program B|cognitive behavioral therapy type B plus medications in packaging type B
11155918|NCT03687073|Experimental|Single-dose PK study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
11155919|NCT03687073|Experimental|Multi-dose PK Study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
11155920|NCT03687073|Experimental|Safety Study|Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.
11155921|NCT03687073|Experimental|Cohort 4 PD Study|The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.
11155922|NCT03687060|Other|Organization Level|
11155923|NCT03687060|Other|Provider Level|
11155924|NCT03687060|Other|Patient Level|
11155925|NCT03687047|Experimental|New complete dentures|"Steps: 1) Preliminary impressions will be done using stock trays and impression compound; 2) primary casts will be fabricated to make custom trays for definitive impressions; 3) definitive impressions will be made using zinc oxide eugenol impression paste;4) definitive impressions will be poured with type III dental stone to obtain mastercasts; 5)jaw relations will be recorded, and the casts will be mounted on the articulator; 6) the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up. After denture insertion, post-denture insertion instructions such as oral hygiene will be explained to the patients.
~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and at 3, 6, 9, 12 and 18 months after treatment."
11155926|NCT03687034|Experimental|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
11155927|NCT03687021|No Intervention|endometriosis|tissue biopsy from patients (n=10) with endometriosis
11155928|NCT03687021|No Intervention|without endometriosis|tissue biopsy from patients (n=10) without endometriosis
11155929|NCT03687021|Experimental|Intramuscular progesterone|Intramuscular progestin(20mg)
11155930|NCT03687021|Experimental|vaginal progesterone|vaginal progestin (90mg)
11155931|NCT03687021|Experimental|oral progesterone|oral progestin(40mg)
11155932|NCT03687008|Experimental|Adolescents with SVHD|All adolescents will receive the intervention Cogmed. This is an in home, computer based, cognitive intervention to improve working memory, supervised by trained coaches, [25 sessions, each 30-45 minutes, 5 days a week / 5 week duration].
11155933|NCT03686982|Experimental|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
11155934|NCT03686982|Placebo Comparator|Placebo Bar|Containing no active ingredients
11155935|NCT03686969|Experimental|Octanorm|0.5g/kg/week octanorm 16.5%
11155936|NCT03686969|Placebo Comparator|Placebo|Placebo
11155973|NCT03686722|Active Comparator|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
11155974|NCT03686722|Experimental|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
11156043|NCT03686176|Experimental|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
11156263|NCT03684850|Experimental|Footwear device group|(n = 40)
11155937|NCT03686956|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
11155938|NCT03686956|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
11155939|NCT03686943||Elderly|Patient over 75 years seen with the mobile extra hospital geriatric team
11155940|NCT03686930|Active Comparator|Cohort 1 - FP-045 oral solution|FP-045 powder for oral solution, will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
11155941|NCT03686930|Placebo Comparator|Cohort 1 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
11155942|NCT03686930|Active Comparator|Cohort 2 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
11155943|NCT03686930|Placebo Comparator|Cohort 2 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
11155944|NCT03686930|Active Comparator|Cohort 3 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
11155945|NCT03686930|Placebo Comparator|Cohort 3 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
11155946|NCT03686917||CHAT-P|Survey
11155947|NCT03686904|Placebo Comparator|SOC GROUP [Cohort A]|Debridement, SOC irrigation & SOC topical gel
11155948|NCT03686904|Active Comparator|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation & SOC topical gel
11155949|NCT03686904|Active Comparator|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation & benzalkonium gel
11155950|NCT03686904|Active Comparator|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation & benzalkonium gel
11155951|NCT03686878|Experimental|Intervention Group|Lifitegrast 5% ophthalmic solution group
11155952|NCT03686865||dental implants|
11155953|NCT03686852|Active Comparator|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
11155954|NCT03686852|Active Comparator|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
11155955|NCT03686852|Active Comparator|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
11155956|NCT03686839|Experimental|SMR neurofeedback training to MCI|"Sensorimotor rhythm neurofeedback protocol consisted of 20 individual sessions, twice a week, during 11 weeks maximum. For each subject MCI, NF was planned and conducted by a neuropsychologist experienced in neurophysiology and neurofeedback. Each session lasted 1h10-15min and was conducted as follows:
~Preparation and installation of the electrodes, verification of the impedance, adjustment of the calibration and thresholds (15 minutes).
~NF training (tasks and video described below) (45 minutes).
~Feedback and debriefing about the session (15 minutes)."
11155957|NCT03686826||multiple sclerosis patients|
11155958|NCT03686826||healthy volunteers|
11155959|NCT03686813|Placebo Comparator|Placebo|Each participant will be studied with active drug and placebo.
11155960|NCT03686813|Active Comparator|Sildenafil|Sildenafil 50 mg orally one hour (once) before immersed exercise
11155961|NCT03686800|Experimental|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
11155962|NCT03686774|Experimental|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
11155963|NCT03686774|Other|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
11155964|NCT03686761|Experimental|Study|A Involvement with the osteotomy site of the surgery, osteotomy was performed then GCF were collected from teeth neighboring the
11155965|NCT03686761|Active Comparator|Control|Involvement with the osteotomy site of the surgery, surgical osteotomy was performed then GCF were collected from teeth away from the osteotomy site
11155966|NCT03686748|Experimental|Two-point intervention|Two point discrimination training.
11155967|NCT03686748|Active Comparator|One-point intervention|One point discrimination of size of probe
11155968|NCT03686748|No Intervention|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
11155969|NCT03686735||Satisfaction measure 1|25% of the cohort
11155970|NCT03686735||Satisfaction measure 2|25% of the cohort
11155971|NCT03686735||Satisfaction measure 3|25% of the cohort
11155975|NCT03686709|Experimental|SIR-Spheres Therapy Selection|Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
11155976|NCT03686709|Experimental|TheraSpheres Therapy Selection|Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
11155977|NCT03686696|No Intervention|No Beta blocker and no ACEI/ARB|No Beta blocker and no ACEI/ARB
11155978|NCT03686696|Experimental|Beta blocker and ACEI/ARB|Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
11155979|NCT03686696|Experimental|Beta blocker alone|Beta blocker alone
11155980|NCT03686696|Experimental|ACEI/ARB alone|Either ACE inhibitor or Angiotensin receptor blocker alone
11155981|NCT03686683|Experimental|Treatment Group: Sipuleucel-T|Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals.
11155982|NCT03686683|No Intervention|Control Arm: Active Surveillance|Subjects randomized to the control arm will be followed on Active Surveillance described in the schedule of events.
11155983|NCT03686657|No Intervention|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
11155984|NCT03686657|Active Comparator|Metformin|Patients receive metformin once daily
11155985|NCT03686657|Experimental|Val, Cel and Met XR Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
11155986|NCT03686657|Experimental|Val, Cel and Met XR High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
11155987|NCT03686644|Experimental|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
11155988|NCT03686631|No Intervention|Passive Arm|This arm uses a passive tracking device to assess the number of times a patient uses their prescribed incentive spirometer.
11155989|NCT03686631|Experimental|Smartphone Arm|This arm uses a smartphone connected device and smartphone application to remind and encourage patients to use the spirometer as well as track the number of times they utilize the spirometer.
11155990|NCT03686618|No Intervention|Cohort X|no secretin administered. All observations
11155991|NCT03686618|Active Comparator|Cohort 1|32 mcg (<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
11155992|NCT03686618|Active Comparator|Cohort 2|32 mcg (<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
11155993|NCT03686618|Active Comparator|Cohort 3|32 mcg (<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
11155994|NCT03686605||Cancer pain patients|
11155995|NCT03686592|Experimental|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
11155996|NCT03686592|Active Comparator|Volunteers|
11155997|NCT03686579||chest trauma|"Early detection and diagnosis of associated thoracic injuries .
~decrease of costs required for investigations . 3- sensitivity and specificity of the investigations"
11155998|NCT03686566||13C-glucose infusion|All participants consented to the study will receive the 13C-glucose infusion.
11155999|NCT03686553||infected, with SSI|patients with SSI
11156000|NCT03686553||non-infected|patients without SSI
11156001|NCT03686527||Echocardiography|
11156002|NCT03686527||MRI Fibrosis|
11156003|NCT03686514|Experimental|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
11156004|NCT03686514|Experimental|H1N1 birth cohort|The H1N1 cohort consist of participants born between 1948-1957.
11156005|NCT03686501|Experimental|PF-06412562|To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.
11156006|NCT03686488|Experimental|TAS 102 and Ramucirumab|TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.
11156007|NCT03686475|Experimental|Biodentine pulpotomy|Biodentine (Septodont, France) Pulpotomy for primary molars Clinical and radiographic evaluation Follow up at 1,3,6 and 12 months
11156008|NCT03686475|Active Comparator|MTA pulpotomy|"MTA (Angelus- Londrina, Brazil) Pulpotomy for primary molars . it is fine hydrophilic powder consisting of tricalcium silicate, tricalicum aluminate, tricalcium oxide, silicate oxide and bismuth oxide11.
~It is currently being used in pulpotomy of primary molars with a high rate of success.
~Clinical and radiographic evaluation. Follow up at 1,3,6 and 12 months"
11156009|NCT03686462|Experimental|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
11156010|NCT03686462|Sham Comparator|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
11156011|NCT03686449|Experimental|study group 1|Non-cultured Autologous Keratinocyte Suspension
11156264|NCT03684837|Active Comparator|D vitamine|a dose for week
11156014|NCT03686410|Experimental|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.
~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
11156015|NCT03686410|Active Comparator|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
11156016|NCT03686397|Experimental|SVT-15652|1 vial twice daily
11156017|NCT03686397|Placebo Comparator|Placebo|1 vial twice daily
11156018|NCT03686384|Experimental|SVT-15652|1 vial twice daily
11156019|NCT03686384|Placebo Comparator|Placebo|1 vial twice daily
11156020|NCT03686345|Experimental|Core binding factor acute myeloid leukemia (CBF-AML)|Patients must have an unequivocal diagnosis of de novo-CBFL, prior to start midostaurin, documented by rearrangement of Core Binding Factor (CBF) genes, namely AML1-ETO and CBFB-MYH11. The experimental arm involves the administration of Midostaurin orally 50 mg (two 25 mg tablets) twice a day, from the end of induction chemotherapy, for 14 days. Patients should take Midostaurin at approximately 12 hours intervals. During all consolidation cycles, Midostaurin 50 mg (two 25 mg tablets) is administered orally twice a day, on days 8-21. Patients in complete remission after 3 cycles of remission consolidation therapy, will receive Midostaurin continuation therapy for 12 months. Midostaurin 50 mg (two 25 mg tablets) will be given orally twice a day for 12 months.
11156021|NCT03686332|Other|Arm A: Atezolizumab and Radiotherapy|"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.
~Drug: Arm A: Atezolizumab and Radiotherapy
~Atezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation."
11156022|NCT03686332|Other|Arm B: Atezolizumab|Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
11156023|NCT03686319|No Intervention|control groups|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).
~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
11156024|NCT03686319|Experimental|"intervention (foot reflexology)"|Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
11156025|NCT03686306|Experimental|Experimental group|Sildenafil 100 mg/day (single morning oral dose of 100 mg) + advice to walk for a total duration of 6 months.
11156026|NCT03686306|Placebo Comparator|Control group|Placebo (single morning oral dose) + advice to walk for a total duration of 6 months.
11156027|NCT03686293|Experimental|Paracetamol and breakfast|One tablet of paracetamol (500 mg) and a standardized breakfast will be consumed within 15 minutes one morning upon 10 hours of fasting
11156028|NCT03686280|Experimental|Robot in combination with traditional reeducation|
11156029|NCT03686280|Active Comparator|Standard rehabilitation|
11156030|NCT03686267|Experimental|intervention (I1)|Lithium disilicate crowns over titanium abutments covered by a layer of opaque porcelain
11156031|NCT03686267|Experimental|Intervention (I2)|Lithium disilicate crowns over titanium abutments covered by lithium disilicate (high opacity) coping
11156032|NCT03686267|Active Comparator|Lithium disilicate crowns over uncovered titanium abutments|Lithium disilicate crowns over uncovered titanium abutments directly without masking
11156033|NCT03686254|Active Comparator|The control Arm|bevacizumab and second-line chemotherapy
11156034|NCT03686254|Experimental|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
11156035|NCT03686228|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb and Aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
11156036|NCT03686228|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
11156037|NCT03686215|Experimental|Device Intervention: LUM Imaging System used during surgery|The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015.
11156038|NCT03686215|No Intervention|Standard of Care Arm|The LUM Imaging Device will not be used to guide additional tissue removal. Patients in this arm will receive the study drug, LUM015.
11156039|NCT03686202|Experimental|Group A: Safety Cohort|Subjects with advanced solid tumors already on ICI will receive treatment with MET-4 in addition to SOC ICI. MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until unacceptable toxicity, progression of disease
11156040|NCT03686202|Experimental|Group B|Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
11156041|NCT03686202|Experimental|Group C|In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
11156042|NCT03686189|Experimental|Intervention arm|Participants will be treated with Iliac Bifurcation Stent Graft System
11156044|NCT03686176|No Intervention|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
11156045|NCT03686176|No Intervention|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
11156046|NCT03686163|Experimental|IN-NGF group|Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly
11156047|NCT03686163|Placebo Comparator|Control group|Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly
11156048|NCT03686150|Experimental|Part 1, Cohort 1 Vitamin D3 oral regimen|Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
11156049|NCT03686150|Experimental|Part 1, Cohort 2 Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
11156050|NCT03686150|Experimental|Part 1, Cohort 3 Vitamin D3 oral regimen|Vitamin D: 6000 IU daily dose
11156051|NCT03686150|Active Comparator|Part 1, Cohort 4 Vitamin D3 oral regimen|Vitamin D: 600 IU daily dose
11156052|NCT03686150|Experimental|Part 2, Cohort A Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
11156053|NCT03686150|Active Comparator|Part 2, Cohort B Vitamin D oral regimen|Vitamin D: 600 IU daily dose
11156054|NCT03686137||Institut Paoli-Calmettes patients undergoing liver surgery|
11156055|NCT03686124|Experimental|IMA203 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~One dose of IMA203 product will be infused intravenously. Three dose levels will be evaluated. At least three patients per cohort will be treated.
~Post-infusion of IMA203 product, administration of low dose recombinant human interleukin-2"
11156056|NCT03686124|Experimental|IMA203 Product + atezolizumab|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~One dose of IMA203 product will be infused intravenously. Two dose levels will be evaluated. At least three patients per cohort will be treated.
~Post-infusion of IMA203 product, administration of low dose recombinant human interleukin-2
~Treatment with atezolizumab: starting 2 lower doses every 2 weeks, followed by every 4 weeks for 1 year"
11156057|NCT03686111||infertile patientes with medical assistance to procreation|
11156058|NCT03686111||Infertile patientes with induction of ovulation to give their|
11156059|NCT03686098|Experimental|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
11156060|NCT03686098|Active Comparator|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
11156061|NCT03686098|No Intervention|Control Arm|No diet or supplement changes
11156062|NCT03686085|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
11156063|NCT03686085|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
11156064|NCT03686072|Other|Cataract surgery with goniosynechialysis|
11156065|NCT03686059|Experimental|punctal plug|SOFT PLUG® Preloaded Silicone Plugs by OASIS®
11156066|NCT03686059|Experimental|Combined|SOFT PLUG® Preloaded Silicone Plugs by OASIS® plus Daily intake of DHA (docosahexaenoic acid)
11156067|NCT03686059|No Intervention|control|no medication was given
11156068|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
11156069|NCT03686033|Experimental|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
11156070|NCT03686033|Experimental|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
11156071|NCT03686033|Experimental|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
11156072|NCT03686033|Experimental|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
11156073|NCT03686033|Experimental|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
11156074|NCT03686033|Experimental|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
11156075|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
11156076|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
11156078|NCT03686007|Experimental|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
11156079|NCT03686007|Active Comparator|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
11156080|NCT03685994||the patients who will undergo TIPS|
11156081|NCT03685981|Experimental|Incentives information provided|
11156082|NCT03685981|No Intervention|No incentives information provided|
11156083|NCT03685968|Experimental|Glidescope AVL|
11156084|NCT03685968|Experimental|King Vision Channeled VL|
11156085|NCT03685968|Experimental|King Vision Non-Channeled (Standard) VL|
11156086|NCT03685955||Genitourinary Reconstruction with Amniotic Membranes|Patients who undergo genitourinary reconstruction with amniotic membranes
11156087|NCT03685942|Experimental|active light therapy|Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
11156088|NCT03685942|Placebo Comparator|placebo light therapy|People receive usual treatment and use a placebo light therapy device (50 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
11156089|NCT03685929||Pressure ulcers|Patients with pressure ulcers category II/III at sacrum or trochanter
11156090|NCT03685929||Incontinence-associated dermatitis|Patients with incontinence-associated dermatitis category IIA at sacrum (or trochanter)
11156091|NCT03685929||Combined lesion|Patients with pressure ulcer category II/III and incontinence-associated dermatitis category IIA at sacrum or trochanter
11156092|NCT03685916|Other|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
11156093|NCT03685916|Experimental|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
11156094|NCT03685916|Experimental|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
11156095|NCT03685916|Experimental|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
11156096|NCT03685916|Experimental|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
11156097|NCT03685916|Experimental|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
11156098|NCT03685916|Experimental|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
11156099|NCT03685916|Experimental|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
11156100|NCT03685916|Experimental|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
11156101|NCT03685903|Experimental|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
11156102|NCT03685890|Experimental|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
11156103|NCT03685890|Placebo Comparator|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
11156104|NCT03685864|Experimental|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
11156105|NCT03685864|Sham Comparator|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
11156106|NCT03685851||UT-DSAEK|With graft 6 months thick less than 100 µm
11156107|NCT03685851||DSAEK|With graft thicker than 100 µm
11156108|NCT03685838|Active Comparator|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
11156109|NCT03685838|No Intervention|No Compression|Patient will not receive any compression stockings.
11156110|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
11156111|NCT03685799||DHG on Barrett's esophagus|patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
11156112|NCT03685786|Experimental|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
11156113|NCT03685773|Experimental|MRI: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
11156114|NCT03685773|Placebo Comparator|MRI: Non-diabetic transplant (Placebo)|Taste-matched placebo for diazoxide
11156115|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
11156116|NCT03685773|Placebo Comparator|MRI: T2D transplant (Placebo)|Taste-matched placebo for diazoxide
11156117|NCT03685773|Experimental|Clamp: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
11156118|NCT03685773|Placebo Comparator|Clamp: Non-diabetic transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
11156119|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
11156120|NCT03685773|Placebo Comparator|Clamp: T2D transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
11156121|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study
11156122|NCT03685773|Experimental|Clamp: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study
11156123|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg)
11156124|NCT03685773|Experimental|MRI: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide)
11156125|NCT03685760|Experimental|Reiki|Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
11156126|NCT03685760|Sham Comparator|Sham Reiki|Sham Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily sham Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
11156127|NCT03685760|No Intervention|Usual Care|Twice per day, 30 minutes apart, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data. Usual care will also involve a 5-day period.
11156128|NCT03685747|Experimental|Vancomycin|A single 20 mg/kg intraperitoneal dose in 1-liter of 7.5% icodextrin solution of vancomycin will be administered. Sparse blood sampling will be obtained during an overnight 12-hour dwell and during the exchange period.
11156129|NCT03685721||HbAS|HbAS genotype, of African American descent; Between 18 and 80 years of age
11156130|NCT03685721||Healthy Control|African American descent; Between 18 and 80 years of age
11156131|NCT03685721||SCD|HbSS, HbSC, HbSbeta-thal has sickle cell disease and is of African American descent; Between 18 and 80 years of age
11156132|NCT03685708|Experimental|Arm 1|Patients with CLL
11156133|NCT03685695|Experimental|Supportive care (physical activity)|Participants wear Fitbit Charge 2 to monitor physical activity for 3 courses (9-12 weeks). Participants then increase their activity minutes to 30 minutes, 5 times a week or by 30% for 6 additional months.
11156134|NCT03685682|Experimental|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
11156135|NCT03685669||Lung nodule group|
11156136|NCT03685669||Healthy Control group|
11156137|NCT03685656|Experimental|ANACA3|ANACA3 slimming gel
11156138|NCT03685656|Placebo Comparator|Placebo|Slimming gel contening no active ingredient
11156139|NCT03685643|Experimental|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
11156140|NCT03685643|Placebo Comparator|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
11156141|NCT03685630|Experimental|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
11156142|NCT03685617|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.
~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;
~Patients with acute myocardial infarction (AMI) and AVB:
~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
11156143|NCT03685617|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
11156144|NCT03685604|Active Comparator|Cardiothoracic surgery - PI disinfection|
11156145|NCT03685604|Active Comparator|Cardiothoracic surgery - CHX disinfection|
11156146|NCT03685604|Active Comparator|Abdominal surgery - PI disinfection|
11156147|NCT03685604|Active Comparator|Abdominal surgery - CHX disinfection|
11156148|NCT03685591|Experimental|Dose Level 1|PF-06952229 at 20mg twice daily (BID)
11156149|NCT03685591|Experimental|Dose Level 2|PF-06952229 at 40 mg BID
11156150|NCT03685591|Experimental|Dose Level 3|PF-06952229 at 80 mg BID
11156151|NCT03685591|Experimental|Dose Level 4|PF-06952229 at 150 mg BID
11156152|NCT03685591|Experimental|Dose Level 5|PF-06952229 at 250 mg BID
11156153|NCT03685591|Experimental|Dose Level 6|PF-06952229 at 375 mg BID
11156154|NCT03685591|Experimental|Dose Level 7|PF-06952229 at 500 mg BID
11156155|NCT03685591|Experimental|Dose Level 8|PF-06952229 at 625 mg BID
11156156|NCT03685591|Experimental|Breast Cancer (Part 2)|PF-06952229 at recommended part 2 dose (RP2D) in combination with palbociclib and letrozole
11156157|NCT03685591|Experimental|Prostate Cancer Part 2|PF-06952229 at recommended part 2 dose (RP2D) in combination with enzalutamide
11156158|NCT03685578||Mechanical Thrombectomy|EmboTrap® Revascularization Device
11156159|NCT03685565|Experimental|Dermabond with underlying steristrips|
11156160|NCT03685565|Active Comparator|Dermabond|
11156161|NCT03685552|Experimental|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
11156162|NCT03685539|Experimental|Diagnostic (DECT)|Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
11156163|NCT03685526|Experimental|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
11156164|NCT03685513|Active Comparator|Metal ceramic single posterior crowns|Metal copings veneered with feldspathic porcelain
11156165|NCT03685513|Experimental|BioHPP PEEK-based single posterior crowns|BioHPP PEEK copings veneered with composite resin
11156166|NCT03685500|Active Comparator|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
11156167|NCT03685500|Experimental|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
11156168|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
11156169|NCT03685474|Experimental|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
11156170|NCT03685474|Active Comparator|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
11156171|NCT03685461|Other|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
11156172|NCT03685461|Experimental|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
11156173|NCT03685448|Experimental|Experimental: Cabozantonib|Cabozantinib 60 mg/day, continuous dosing, taken orally.
11156174|NCT03685435||Non-fasting patients|We will examine non-fasting patients using bedside ultrasound. First we examine the gaster in a supine position. Then we repeat the procedure in a right lateral position.
11156175|NCT03685422|Experimental|Virtual Reality|Patient will be given a Samsung Gear VR3 headset fitted with a smartphone. She will choose the desired playlist on calming scenario and experience the Virtual Reality (VR) for about 10 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Patient will be asked on their satisfaction on the VR experience after the intervention. Questionnaires will be conducted during this period. During and after the gynecologic surgery, baseline demographic data and analgesia usage will be recorded. Patient will be sent to the recovery room after the surgery, and the study team members will collect their questionnaire scorings. All the headsets will be disinfected following the hospital's infection control guideline.
11156176|NCT03685409|Active Comparator|Metformin-Group|Metformin hydrochloride tablets 500 mg taken orally once daily for 3 months
11156177|NCT03685409|Placebo Comparator|Placebo-Group|Starch placebo tablets taken orally once daily for 3 months
11156178|NCT03685396|Experimental|Test Group|In the Test Group venous blood sampling was done in order to prepare PRF membranes used to cover the donor site of the connective tissue graft.
11156179|NCT03685396|Active Comparator|Control Group|In Control Group hemostatic agents with oxidized and regenerated cellulosa were used to cover the donor site.
11156180|NCT03685383|Experimental|intervention group: eCPR + CytoSorb|In addition to standard treatment in patients undergoing eCPR in the intervention group the CytoSorb removal column will be added to the ECLS-system (intervention: CytoSorb removal column in eCPR).
11156181|NCT03685383|Active Comparator|control group: eCPR - CytoSorb|Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
11156182|NCT03685370|Active Comparator|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
11156183|NCT03685370|Experimental|X-ray group|Patients randomized for X-ray placement of epidural catheter
11156184|NCT03685357||Idiopathic Parkinson's|"Oral glucose tolerance test
~The Unified Parkinson's Disease Rating Scale (UDPRS)."
11156185|NCT03685357||Diabetics receive sulphonylurea group|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
11156186|NCT03685357||Diabetics on sulphonylurea and metformin|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
11156187|NCT03685357||Healthy|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score
~Oral glucose tolerance test"
11156188|NCT03685344|Experimental|ADCT-402|"Dose escalation phase: Ascending doses of Loncastuximab tesirine will be administered using a traditional 3+3 design. Dose level 1: 90 µg/kg, every 3 weeks (Q3W). Dose level 2: 120 µg/kg, Q3W. Dose level 3: 150 µg/kg, Q3W. Loncastuximab tesirine will be given for 2 doses, 3 weeks apart.
~Dose expansion phase: Loncastuximab tesirine will be administered at the recommended dose determined in the dose escalation phase. Durvalumab will also be administered at a dose of 1500 mg once every 4 weeks (Q4W) throughout the dose escalation phase and dose expansion phase."
11156189|NCT03685331|Experimental|Phase I Level 0|"(28-day cycle)
~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
11156190|NCT03685331|Experimental|Phase I Level 1|"(28-day cycle)
~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1
~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
11156191|NCT03685331|Experimental|Phase I Level 2|"(28-day cycle)
~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1
~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
11156265|NCT03684837|Placebo Comparator|D vitamine placebo|a dose for week
11156266|NCT03684824|Other|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
11156192|NCT03685331|Experimental|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21
~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
11156193|NCT03685318|Active Comparator|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
11156194|NCT03685318|Active Comparator|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
11156195|NCT03685305|Experimental|Hypocaloric diet with hunger reduction strategy|Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
11156196|NCT03685305|Active Comparator|Hypocaloric diet without hunger reduction strategy|Participants will only be prescribed a hypocaloric diet. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
11156197|NCT03685292||Group A|Subject(s): A Subgroup
11156198|NCT03685292||Group B|Subject(s): B Subgroup
11156199|NCT03685292||Group C|Subject(s): C Sub Group
11156200|NCT03685279|Experimental|NHA Group|"Six-week, online intervention with weekly, sequential, content knowledge and skills practice. Each week included recorded, slide presentations (narrated by the developer of the NHA, Howard Glasser); readings from The Transforming the Intense Child Workbook by Howard Glasser with Melissa Lowenstein; participants' skills practice, web postings, and live sessions with Howard Glasser and Advanced NHA Trainers."
11156201|NCT03685279|Other|Control Group|The Control Group received the same intervention after the collection of NHA Group post-intervention surveys.
11156202|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
11156203|NCT03685253|Placebo Comparator|Placebo|Participants randomized to placebo will take 2 capsules by mouth twice a day for 6 months. The placebo capsules are matched to the NR capsules.
11156204|NCT03685253|Experimental|Niagen®|Participants randomized to Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will take 250 mg capsules. Participants will take 2 capsules by mouth twice a day (1000 mg) for 6 months
11156205|NCT03685240|Experimental|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
11156206|NCT03685240|No Intervention|Control|No camera detection
11156207|NCT03685227|No Intervention|Control|Participant will lie quietly for 90 minutes. They will be allowed to sleep.
11156208|NCT03685227|Experimental|Yoga Nidra|Participant will practice yoga nidra (using a recording) during the first 30 minutes of the 90 minute measurement period. Then they will be allowed to sleep.
11156209|NCT03685214|Experimental|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
11156210|NCT03685214|Experimental|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
11156211|NCT03685201|Active Comparator|Orange Juice1|100% orange juice
11156212|NCT03685201|Experimental|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
11156213|NCT03685201|Placebo Comparator|Raw Orange|raw orange
11156214|NCT03685188|Experimental|Oxycodone group|PCIA is formulated at 0.4 mg/ml of oxycodone.
11156215|NCT03685188|Active Comparator|Sufentanil group|PCIA is formulated at 2 μg/ml of sufentanil.
11156216|NCT03685175|Experimental|Formal Study|Hyperpolarized 13C-pyruvate, is injected into patients before receiving doxorubicin and immediately after, for a cardiac MRI scan
11156217|NCT03685175|Experimental|Feasibility Study|Hyperpolarized 13C-pyruvate injection, is given to patients after completing doxorubicin treatment, and again at 1 to 6 six months after the first cardiac MRI scan
11156218|NCT03685149|Active Comparator|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
11156219|NCT03685149|Placebo Comparator|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
11156220|NCT03685123|Experimental|PA-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the minimum physical activity recommendations
11156221|NCT03685123|Experimental|WM-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the weight maintenance recommendations
11156222|NCT03685110||CoreHip|Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up
11156223|NCT03685097||Cardiac surgery patients|Patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.
11156224|NCT03685084|Placebo Comparator|0.9% saline infusion|Saline 0.9% infusion
11156225|NCT03685084|Experimental|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.
~Drug-Drug Interaction:
~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.
~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
11156226|NCT03685084|Experimental|Piperacillin i.v.|Piperacillin 3 g
11156227|NCT03685084|Experimental|Cefepime i.v.|Cefepime 1 g
11156228|NCT03685058|Active Comparator|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
11156267|NCT03684811|Experimental|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
11156229|NCT03685058|Experimental|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
11156230|NCT03685045|Experimental|Campaign Days|All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
11156231|NCT03685032|Experimental|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.
~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
11156232|NCT03685032|Placebo Comparator|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.
~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
11156233|NCT03685019|Experimental|Valgus stress - lateral compartment|Valgus stress radiograph. Joint space width measured in lateral compartment.
11156234|NCT03685019|Experimental|Varus stress - medial compartment|Varus stress radiograph. Joint space width measured in medial compartment.
11156235|NCT03685019|Experimental|0 degree flexion - medial compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
11156236|NCT03685019|Experimental|0 degree flexion - lateral compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
11156237|NCT03685019|Experimental|20 degree flexion - medial compartment|20 degree flexion radiograph. Joint space width measured in medial compartment.
11156238|NCT03685019|Experimental|20 degree flexion - lateral compartment|20 degree flexion radiograph. Joint space width measured in lateral compartment.
11156239|NCT03685019|Experimental|45 degree flexion - medial compartment|45 degree flexion radiograph. Joint space width measured in medial compartment.
11156240|NCT03685019|Experimental|45 degree flexion - lateral compartment|45 degree flexion radiograph. Joint space width measured in lateral compartment.
11156241|NCT03684993|Experimental|Arabic gum extract|natural product Arabic gum (acacia gum) prepared as a mouthwash
11156242|NCT03684993|Experimental|Licorice root extract|natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash
11156243|NCT03684993|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
11156244|NCT03684980|Experimental|MTX 3 g/m^2|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
11156245|NCT03684980|Experimental|MTX 8 g/m^2|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
11156246|NCT03684980|Experimental|COVID-19|In Arm COVID-19, the primary endpoint is HD-MTX levels <100 nmol/L 48 hours post-MTX administration. This will be determined via mass spectrometry/HPLC drawn 48 hours after start of MTX infusion +/- 2 hours.
11156247|NCT03684967|Experimental|fruquintinib|Fruquintinib treatment: administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.
11156248|NCT03684954|Other|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
11156249|NCT03684954|No Intervention|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
11156250|NCT03684941|Experimental|Treatment Period One|LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.
11156251|NCT03684941|Active Comparator|Treatment Period Two|CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.
11156252|NCT03684928|Active Comparator|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
11156253|NCT03684928|Active Comparator|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
11156254|NCT03684915|Experimental|rotary files|"Pre-operative radiograph showing all roots and their apices.
~Local anaesthetic (to enable use of rubber dam clamp).
~Rubber dam isolation.
~Removal of caries.
~Removal of roof of pulp chamber.
~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece.
~Identify root canals.
~Irrigate with normal saline (0.9%)
~Estimate working lengths of root canals keeping 2 mm short of the radiographic apex.
~Insert rotary files into canals and debride the canals lightly and gently.
~Irrigate the root canals.
~Dry canals with pre-measured paper points, keeping 2 mm from root apices.
~Canals will be dried with paper points, obturated by injecting Metapex. (Meta Biomed - Metapex Root Canal Filling Material)
~Stainless steel crown will be performed"
11156255|NCT03684915|Active Comparator|manual files|All steps as that of intervention group are to be followed except step (j) instead of it; a manual files will be inserted into the canals for debridement lightly and gently
11156256|NCT03684902|Experimental|xpolration|women who underwent emergency midline laprotomy
11156257|NCT03684889|Experimental|SCRI-huCAR19v2|Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
11156258|NCT03684889|Experimental|SCRI-huCAR19v1 - [CLOSED]|Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
11156259|NCT03684863|No Intervention|Standard therapy|
11156260|NCT03684863|Experimental|capecitabine|
11156269|NCT03684811|Experimental|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
11156270|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 2b)|
11156271|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 4b)|
11156272|NCT03684798|Experimental|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.
~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, & Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, & Gollwitzer, 2015)."
11156273|NCT03684798|Active Comparator|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
11156274|NCT03684785|Experimental|Dose Escalation Phase 1b|Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.
11156275|NCT03684785|Experimental|Dose Expansion Phase 2; Merkel cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.
11156276|NCT03684785|Experimental|Dose Expansion Phase 2, cutaneous squamous cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.
11156277|NCT03684785|Experimental|Exploratory Phase 2, Merkel cell carinoma, melanoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma or melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
11156278|NCT03684772|Experimental|ICVT|Digoxin and Furosemide (0.125%)
11156279|NCT03684772|Experimental|Furosemide|Furosemide (0.125%)
11156280|NCT03684772|Experimental|Digoxin|Digoxin (0.125%)
11156281|NCT03684772|Placebo Comparator|Placebo|Vehicle Gel
11156282|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
11156283|NCT03684746||Care specialist|including nurses - before/after care staff
11156284|NCT03684733||Arm 1: Cohort 1 - Retrospective Analysis|Participants attending MRI & XRM for a clinical indication with at least one normal breast
11156285|NCT03684733||Arm 2: Cohort 2 - Retrospective Analysis|"BRCA1 or BRCA2 mutation carriers attending MRI & XRM for breast screening:
~Genetic risk of breast cancer"
11156286|NCT03684733||Arm 2: Cohort 3 - Retrospective Analysis|"Participants attending MRI & XRM for breast screening post mantle radiotherapy:
~Environmental risk of breast cancer"
11156287|NCT03684733||Arm 2: Cohort 4 - Prospective|"General population attending XRM for breast investigation:
~Population risk of breast cancer MRI"
11156288|NCT03684720|Experimental|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
11156289|NCT03684720|No Intervention|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
11156290|NCT03684707|Active Comparator|Metformin Hcl 500Mg 24Hr Sa Tab|Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
11156291|NCT03684707|Placebo Comparator|control|starch tablets
11156292|NCT03684694|Experimental|Phase 1: Dose-Escalation of ADCT-402|A standard 3+3 dose escalation design will be used. The dose-limiting toxicity (DLT) period will be the 21 days following the first dose of ibrutinib. The dose escalation cohort will receive loncastuximab tesirine for Cycle 1 and 2 (3 weeks each) with concurrent ibrutinib (concomitant therapy) daily. Participants may continue to receive treatment up to 1 year after Cycle 1 Day 1 (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a frozen liquid.
11156293|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL|Participants with non-germinal center B-cell diffuse large B-cell lymphoma (Non-GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
11156294|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL|Participants with germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
11156295|NCT03684694|Experimental|Phase 2: MTD or RP2D of ADCT-402 in MCL|Participants with mantle cell lymphoma (MCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV), as a lyophilized formulation.
11156296|NCT03684681|Other|Peer Navigator|Current standard of care
11156297|NCT03684681|Other|Social Worker|Current standard of care
11156298|NCT03684668|Experimental|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
11156299|NCT03684668|No Intervention|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
11156300|NCT03684655|Experimental|[18F]F-AraG|"radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
~Trade name: VisAcT"
11156301|NCT03684642|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (autoinjector) administered once weekly for 56 weeks
11156302|NCT03684642|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (autoinjector) administered once weekly for 56 weeks
11156303|NCT03684642|Active Comparator|Dulaglutide|Dulaglutide (pen) administered once weekly for 56 weeks
11156304|NCT03684629|Experimental|the response of KPI and corresponding suggestion|The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month. The multifaceted quality improvement interventions include: 1) implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols; 2) feedback system of performance measures; 3) expert online consultation.
11156305|NCT03684629|No Intervention|a control arm|The control group indicated that the hospitals will not be provided with the multifaceted quality improvement interventions. They just provide patients with routine care.
11156306|NCT03684616||Statin treatment prior to cardiac arrest|
11156307|NCT03684616||No Statin treatment prior to cardiac arrest|
11156308|NCT03684603|Active Comparator|Acoustic cueing|The melody will be played during training and during slow wave sleep.
11156309|NCT03684603|Sham Comparator|Control|The melody will be played during training.
11156310|NCT03684590|Active Comparator|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
11156311|NCT03684590|Experimental|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
11156312|NCT03684577|Experimental|Hypnotherapy for Agoraphobia|A total of 8-12 individual sessions of hypnotherapy over 12 weeks will be delivered. Hypnotherapy consists of hypnotic activation and reinforcement of the patient's own resources, the use of relevant positive and negative experiences from the biography, and the development of positive solution imagery. The central technique is the work with a symptom regression and the resolution of old and actual experiences. Furthermore, formal trance induction, utilisation techniques, indirect techniques such as the use of metaphors or the representative technique, or work with time progression will be used.
11156313|NCT03684577|No Intervention|Wait-list control group|Patients in the wait-list control group will receive 8-12 sessions of individual hypnotherapy after a waiting period for 12 weeks.
11156314|NCT03684564|Experimental|Rivaroxaban (Treatment Arm)|
11156315|NCT03684564|Active Comparator|Warfarin (Control Arm)|
11156316|NCT03684551|Active Comparator|No dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. The supervisory feedback session for CHWs in the control arm was not facilitated by a visual Dashboard tool or any personalised quantitative feedback on quantity, speed, or quality of care. CHW supervisors were instructed to continue providing CHWs in the control arm with feedback informed by patient perspectives and direct observation during the individual supervision visit.
11156317|NCT03684551|Experimental|Dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. For CHWs randomised to the intervention arm, a visual feedback tool, the CHW Performance Dashboard, was employed during individual supervision, starting in January 2016. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month. The feedback provided to CHWs in the intervention arm, therefore, was both quantitative, informed by the Dashboard, and qualitative, informed by patient perspectives and direct observation of CHW service provision during the individual supervision visit.
11156318|NCT03684538|Experimental|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
11156319|NCT03684538|Experimental|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
11156320|NCT03684538|Active Comparator|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
11156321|NCT03684525|Experimental|Extraction of primary canines only|"A total of 43 patients with unilateral mesioangular displaced maxillary canines Interceptive treatment: Extraction of both maxillary primary canines will be held at baseline visit At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan
~Treatment Plan :
~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department
~If Canine is emerged to oral cavity: No further CBCT scan will be taken
~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
11156322|NCT03684525|No Intervention|Control group- no extraction|"A total of 43 patients with unilateral mesioangular displaced maxillary canines At Baseline (T0): Clinical examinatiion + CBCT scan , no extraction At 6 month follow-up (T1): Clinical examination At 12 month follow-up: Clinical examination +/- CBCT scan
~Treatment Plan :
~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department
~If Canine is emerged to oral cavity: No further CBCT scan will be taken
~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
11156323|NCT03684512|Experimental|Adolescent Only|Remote based physical activity intervention delivered to adolescents only. Adolescents will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity.
11156324|NCT03684512|Active Comparator|Adolescent and Parent|Remote based physical activity intervention delivered to adolescents and their parent. Adolescents and a parent will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity. Parents will have access to a Parent Facebook group.
11156374|NCT03684161||Small, persistent VSDs|Patients born with a small, hemodynamically insignificant ventricular septal defect.
11156375|NCT03684161||Healthy controls|Healthy control subjects.
11156325|NCT03684499|Other|study group (1)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
11156326|NCT03684499|No Intervention|control group( 2)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
11156327|NCT03684486|Experimental|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
11156328|NCT03684473|Experimental|Yoga Intervention|Participants in the intervention condition will be assigned to an 8-week online delivered trauma-informed yoga protocol focused on home-based daily practice of yoga and mindfulness meditation.
11156329|NCT03684473|No Intervention|Waitlist Control|Participants in the wait list control condition will be invited to attend a 60-minute online mental health education session to learn how to recognize signs and symptoms of PTSD and outline potential strategies to alleviate stress to reduce the risk of heightened severity of mental health challenges. The materials used will be based on the Canadian Mental Health Association resource hub on understanding symptoms of mental illness. All participants in the wait list control condition will be offered the opportunity to participate in the intervention free of charge after completion of the study.
11156330|NCT03684460|Experimental|Bright Light|"Intervention: Daytime Bright Light
~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 09:00 to 13:00 starting on study day 2 and continuing through study day 5 or MICU discharge whichever is longer up to 30 days. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor, if the patient is transferred (prior to study day 5). Feasibility metrics will also be collected."
11156331|NCT03684460|Active Comparator|Usual Light|"Intervention: Usual Care
~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), but otherwise, have usual care."
11156332|NCT03684447|Experimental|Propofol High Dose|high propofol injectable, individually dosed, three times per week
11156333|NCT03684447|Experimental|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
11156334|NCT03684434|Experimental|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
11156335|NCT03684434|Active Comparator|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
11156336|NCT03684421||Long Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Long Antagonist Protocol for COS
11156337|NCT03684421||Classical Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Classical Antagonist Protocol for COS
11156338|NCT03684408|Other|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
11156339|NCT03684408|Experimental|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
11156340|NCT03684408|Active Comparator|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
11156341|NCT03684395||DOACs (Direct Oral Anticoagulants)|
11156342|NCT03684395||Standard of care|
11156372|NCT03684187|Experimental|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
11156373|NCT03684161||Surgically closed VSDs|Patients born with a ventricular septal defect, which have been closed in early childhood.
11156343|NCT03684382|Experimental|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
11156344|NCT03684382|No Intervention|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
11156345|NCT03684369|Experimental|Augmented TENS|Transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions.
11156346|NCT03684369|Sham Comparator|Sham|Transient (10 s) application of transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions .
11156347|NCT03684356|Experimental|experimental|immediate implant with socket shield technique
11156348|NCT03684356|Active Comparator|control|immediate implant placement with filling the buccal gap with xenograft
11156349|NCT03684343|Other|Atopic Dermatitis patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
11156350|NCT03684343|Other|Healthy patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
11156351|NCT03684330|Active Comparator|Vitamin D supplementation|
11156352|NCT03684330|Placebo Comparator|Vitamin D placebo|
11156353|NCT03684304|No Intervention|Control / No Binder|Patients randomized to routine care / no abdominal binder use will not use an abdominal binder during their post operative course.
11156354|NCT03684304|Experimental|Abdominal binder|Patients randomized abdominal binder use will have an abdominal binder placed on them in the operating room once their surgery has been completed.
11156355|NCT03684291||Group V|The patients in this group are ventilated using VCV (Volume Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute, I/E ratio: 1/2, PEEP not applied)
11156356|NCT03684291||Group P|The patients in this group are ventilated using PCV-VG (Volume Guaranteed Pressure Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute (EtCO2 kept between 35-40 mmHg), Pressure limit: 30 cm H2O, I/E:1/2, PEEP not applied)
11156357|NCT03684278|Active Comparator|Infusion of 5 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 5 mg of Infliximab, per kg of patient body weight.
11156358|NCT03684278|Active Comparator|Infusion of 10 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 10 mg of Infliximab, per kg of patient body weight.
11156359|NCT03684278|Placebo Comparator|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) 0.9% Sodium Chloride to be administered as a one time intravenous infusion over a period of 2 hours.
11156360|NCT03684265|Experimental|Test to Reference|
11156361|NCT03684265|Experimental|Reference to Test|
11156362|NCT03684252|Other|Control|Treatment as usual
11156363|NCT03684252|Experimental|Intervention|CBT-based intervention
11156364|NCT03684239|Experimental|G-CBT group|G-CBT group has 40 patients, maybe will be divided them into 4 groups. Every group has 8-10 patients. Every group receive 10 times CBT group therapy and 1 times a week for 120 minutes each time.
11156365|NCT03684239|Active Comparator|Conventional treatment group|Conventional treatment group has 40 patients, received routine outpatient treatment. Once every two weeks for 45 minutes each time, including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
11156366|NCT03684213|Active Comparator|Control (Norepinephrine)|Subjects will be administered norepinephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
11156367|NCT03684213|Experimental|Norepinephrine + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
11156368|NCT03684213|Experimental|Norepinephrine + L-NAME|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) at the same rate and for the same time as the control arm.
11156369|NCT03684213|Experimental|Norepinephrine + L-NAME + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and combined L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
11156370|NCT03684200|Experimental|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
11156371|NCT03684200|No Intervention|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
11156548|NCT03682913|Experimental|P-CIT protocol|OCD patients who receive the P-CIT intervention.
11156376|NCT03684148|Experimental|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
11156377|NCT03684148|No Intervention|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
11156378|NCT03684135|Experimental|Use of cosmetics during chemotherapy and thermal cure|Use of cosmetics during chemotherapy and post-treatment thermal cure
11156379|NCT03684122|Experimental|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
11156380|NCT03684122|Experimental|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
11156381|NCT03684109|Experimental|IDH-Mutant Glioma Patients|MRI-based sequence data for 2HG quantification acquired from the image of the brain via 3T MRI scanner.
11156382|NCT03684096|Active Comparator|non-estrogenic pollen extract PCC-100|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
11156383|NCT03684096|Placebo Comparator|placebo|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
11156384|NCT03684083||Case|patients having received heterologous stem cell transplantation (HSCT)
11156385|NCT03684083||Control|patients without HSCT
11156386|NCT03684070|Experimental|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
11156387|NCT03684070|Active Comparator|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
11156388|NCT03684057|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
11156389|NCT03684057|Other|Wait list control|Individuals in the wait list group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control)
11156390|NCT03684044|Experimental|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
11156391|NCT03684044|Placebo Comparator|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
11156392|NCT03684031|Experimental|Cognitive Control Training|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
11156393|NCT03684031|Sham Comparator|Sham Cognitive Control Training Program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
11156394|NCT03684018|Experimental|IgPro10 (single dose)|
11156395|NCT03684018|Experimental|IgPro10 (multiple dose)|
11156396|NCT03684005|Other|Single-Arm Smartphone App Use|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
11156397|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
11156398|NCT03683979|Experimental|Interpretation bias modification program|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
11156399|NCT03683979|Sham Comparator|Control training program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
11156400|NCT03683953|Placebo Comparator|Placebo|0.9% sodium chloride intratracheal instillate on 14 days after birth
11156401|NCT03683953|Experimental|mesenchymal stem cells|mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg
11156402|NCT03683940|Other|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
11156403|NCT03683927|Experimental|Probiotics|Probiotics consist on Bacillus clausii in a plastic vial that will be administered to the infant 4 times a week
11156404|NCT03683927|Placebo Comparator|Placebo group|Sterile water contained in a plastic vial will be administered to the infant 4 times a week
11156405|NCT03683914|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
11156549|NCT03682913|Placebo Comparator|Placebo|OCD patients who don't receive the P-CIT intervention.
11156406|NCT03683914|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
11156407|NCT03683901|Experimental|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
11156408|NCT03683888|Experimental|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
11156409|NCT03683888|Active Comparator|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
11156410|NCT03683862|Experimental|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
11156411|NCT03683862|Active Comparator|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
11156412|NCT03683849|Experimental|Dancing group|Dance intervention group, inspired by the rhythm of Salsa. Training will be administered for an hour twice a week, for six months.
11156413|NCT03683849|Active Comparator|Strength training group|Strength training group. Training will be administered for an hour twice a week, for six months.
11156414|NCT03683849|No Intervention|Control|Control group
11156415|NCT03683836||Study Group|
11156416|NCT03683823|Experimental|Attention guidance|In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
11156417|NCT03683823|Active Comparator|Control intervention|"Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.
~On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.
~Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.
~Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.
~Between speeches participants will have a 1-minute break."
11156418|NCT03683810|Experimental|Lactoferrin|Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
11156419|NCT03683810|Active Comparator|Standard treatment|Participants will receive only the standard treatment for anemia
11156420|NCT03683797|Experimental|Post-discharge call|Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
11156421|NCT03683797|No Intervention|No post-discharge call|Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
11156422|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
11156423|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
11156424|NCT03683758|Experimental|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
11156425|NCT03683758|Active Comparator|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
11156426|NCT03683745||Maryland|Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute ~600 people (~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.
11156427|NCT03683732||Frenchteenagers|
11156428|NCT03683719|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
11156429|NCT03683719|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
11156430|NCT03683719|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
11156431|NCT03683719|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
11156432|NCT03683719|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 16 weeks.
11156433|NCT03683706|Active Comparator|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
11156434|NCT03683706|No Intervention|Treatment as Usual|Participants in this arm will be getting their usual treatment
11156435|NCT03683693|No Intervention|Standard of Care group|Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
11156436|NCT03683693|Experimental|Procalcitonin group|ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
11156520|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
11156437|NCT03683680|Experimental|MRiS|"The specimens to be collected will include at least five pleural biopsy samples
~MPT test and the CLDN15/VIM test will be performed"
11156438|NCT03683667|Placebo Comparator|Placebo & Control|Placebo / Nutrition education
11156439|NCT03683667|Experimental|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
11156440|NCT03683667|Placebo Comparator|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
11156441|NCT03683667|Experimental|Placebo & Egg|Placebo / Egg / Nutrition education
11156442|NCT03683667|Experimental|Azithromycin & Control|Azithromycin / Nutrition education
11156443|NCT03683667|Experimental|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
11156444|NCT03683667|Experimental|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
11156445|NCT03683667|Experimental|Azithromycin and Egg|Azithromycin Egg Nutrition education
11156446|NCT03683641|Active Comparator|Shock Wave group|Applying shock wave to patient's Achilles tendon insertion
11156447|NCT03683641|Sham Comparator|Sham Control group|Applying sham shock wave to patient's Achilles tendon insertion
11156448|NCT03683628|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
11156449|NCT03683628|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
11156450|NCT03683615|Other|patients with traumatic recent orbital blow out fractures|
11156451|NCT03683602|Experimental|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
11156452|NCT03683602|Active Comparator|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
11156453|NCT03683589||Study group|"Participants will receive deuterated water for 10 days before undergoing bariatric surgery.
~Liver biopsy collected, lipids extracted and DNL measured via GC/MS."
11156454|NCT03683576|Experimental|GB001 Dose 1 daily|
11156455|NCT03683576|Experimental|GB001 Dose 2 daily|
11156456|NCT03683576|Experimental|GB001 Dose 3 daily|
11156457|NCT03683576|Placebo Comparator|Placebo daily|
11156458|NCT03683563|Active Comparator|4% citrate|dialysis catheter locked with 4% sodium citrate
11156459|NCT03683563|Experimental|30% citrate|dialysis catheter locked with 30% sodium citrate
11156460|NCT03683550|Experimental|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
11156461|NCT03683550|Active Comparator|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
11156462|NCT03683537||Delayed Neurocognitive decline|Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically. DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
11156463|NCT03683537||Normal postop neurocognitive function|Patients in whom there is no clinical signs of DNR, defined as in previous group.
11156464|NCT03683524|Experimental|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
11156465|NCT03683524|Active Comparator|Control group|continuation of their current stable ART
11156466|NCT03683498|Experimental|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:
~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
11156467|NCT03683485|Experimental|long duration EPBD group|Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.
11156468|NCT03683485|Active Comparator|endoscopic sphincterotomy (EST) group|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.
11156469|NCT03683472|No Intervention|Treatment as usual (TAU)|Individuals will receive treatment as usual
11156470|NCT03683472|Active Comparator|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
11156471|NCT03683459|Experimental|interventional arm|Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.
11156472|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
11156473|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
11156474|NCT03683433|Experimental|Treatment (azacitidine, enasidenib mesylate)|Patients receive azacitidine SC or IV over 30 minutes on days 1-7 and enasidenib mesylate PO QD beginning on day 1. Cycles repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
11156521|NCT03683082|Active Comparator|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
11156475|NCT03683420|Experimental|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
11156476|NCT03683420|No Intervention|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
11156477|NCT03683407||Chemotherapy Group|All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.
11156478|NCT03683394|Active Comparator|SMARRT Intervention|The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
11156479|NCT03683394|Active Comparator|Health Education Intervention|Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.
11156480|NCT03683381|Experimental|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
11156481|NCT03683381|Experimental|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
11156482|NCT03683368|Experimental|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
11156483|NCT03683368|Experimental|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
11156484|NCT03683355||Edwards Sapien 3|Patients who underwent transcatheter aortic valve replacement with the Edwards Sapien 3 valve
11156485|NCT03683355||Core Valve Evolut R|Patients who underwent transcatheter aortic valve replacement with the Core Valve Evolut R valve
11156486|NCT03683342|Active Comparator|Ankle Block|Ankle block will be performed under ultrasound guidance.
11156487|NCT03683342|Active Comparator|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
11156488|NCT03683329|Experimental|Antibiotic de-escalation|"According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens,
~Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible,
~Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture."
11156489|NCT03683329|Active Comparator|Standard treatment without de-escalation|"The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription,
~Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines,
~The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment."
11156490|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
11156491|NCT03683303|Experimental|mobile applications (APP)|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
11156492|NCT03683303|Active Comparator|oral education|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
11156517|NCT03683121||Combine of Group1 and Group2|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding,and the patients were followed up by telephone or WeChat again on the same day.
11156518|NCT03683108|Experimental|Resveratrol and Carbossimetyl Beta Glucan|
11156519|NCT03683108|Placebo Comparator|Saline solution|
11156493|NCT03683277|Experimental|Ixazomib/Pomalidomide/Dexamethasone|"Single arm treatment organized in 2 separate phases
~Induction phase : association of Ixazomib, Pomalidomide & Dexamethasone (IPD) 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years
~Maintenance phase : association of Ixazomib and Pomalidomide (IP) 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
11156494|NCT03683264|Other|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
11156495|NCT03683264|Other|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
11156496|NCT03683251|Experimental|PDS Implant Cohort 1|"Participants with PDS implant from Study GX28228 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
11156497|NCT03683251|Experimental|PDS Implant Cohort 2|"Participants with PDS implant from Study GR40548 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
11156498|NCT03683251|Experimental|PDS Implant Cohort 3|"Participants in the intravitreal ranibizumab arm of Study GX28228 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
11156499|NCT03683251|Experimental|PDS Implant Cohort 4|"Participants in the intravitreal ranibizumab arm of Study GR40548 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W.
~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
11156500|NCT03683251|Experimental|PDS Implant Cohort 5|Participants from Study WR42221 who completed Week 24 but were not eligible to be randomized within WR42221 and who will be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
11156501|NCT03683251|Experimental|PDS Implant Cohort 6|Participants from Study WR42221 randomized to the Q24W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
11156502|NCT03683251|Experimental|PDS Implant Cohort 7|Participants from Study WR42221 randomized to the Q36W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q36W
11156503|NCT03683225|Experimental|CTC-413|Pramipexole with/with out aprepitant orally once daily
11156504|NCT03683212|Experimental|Intervention period : early and comprehensive care bundle|
11156505|NCT03683212|No Intervention|acute heart failure standard therapy|
11156506|NCT03683199|Experimental|Cleft lip nasal deformity|"•Anthropometric evaluation of the nose (will be measured pre and post-operative) This represents the objective evaluation. It will be done by measuring the angles and ratios of the nose and its relation to the face. Common parameters will be measured from the photos (frontal, oblique, lateral and basal views) for all the patients to compare the pre-operative measures with the post-operative ones.
~MSCT flesh mode will be used to measure nose related angels and ratios. It also gives idea about nasal skeleton pre-operative for proper design of the operative strategy, and it will be done post-operative for assessment and comparizon."
11156507|NCT03683186|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose (maximum dose of 1450 mcg)
11156508|NCT03683173|Experimental|Multilevel Intervention|Participants will receive the multilevel intervention consisting of community events, walking group formation, and short messaging service.
11156509|NCT03683173|No Intervention|Control|Does not receive the multilevel intervention.
11156510|NCT03683160|Experimental|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
11156511|NCT03683147|Experimental|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
11156512|NCT03683147|Experimental|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
11156513|NCT03683134|Experimental|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
11156514|NCT03683134|Active Comparator|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
11156515|NCT03683121||the traditional follow-up group|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding
11156516|NCT03683121||Non-traditional follow-up|The dose and notes for the use of the Non-selective beta blockers were informed during telephone or WeChat follow-ups for the patients with a history of esophageal variceal bleeding
11156522|NCT03683082|Sham Comparator|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
11156523|NCT03683069|Experimental|Epleronone Arm|
11156524|NCT03683069|Experimental|Amlodipine Arm|
11156525|NCT03683056|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
11156526|NCT03683056|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
11156527|NCT03683043|Active Comparator|Transabdominal guided transfer|In the trans-abdominal guided embryo transfer group, the patients' bladder were filled by 500-700 ml saline; in order to enhance the visualization. The trans-abdominal probe is applied on pelvis by an assistant nurse or the attending gynecologist intern
11156528|NCT03683043|Active Comparator|Transvaginal guided transfer|the trans-vaginal guided embryo transfer group had their bladder emptied by the gynecologist via catheter prior to transfer or else the patient was asked to void. The speculum is applied followed by insertion of the outer sheath of the transfer catheter. The speculum is removed with caution; to maintain the outer sheath in place. The TVUS probe is applied vaginally and endometrium is visualized before transfer. The transfer is done through an inner catheter applied to the already inserted outer sheath
11156529|NCT03683030|Experimental|Treatment Group|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
11156530|NCT03683017|Experimental|I-OP2.0|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
11156531|NCT03683017|Experimental|I-OP2.1|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.
11156532|NCT03683017|Experimental|F-OP2.0|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
11156533|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
11156534|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
11156535|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
11156536|NCT03682991|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
11156537|NCT03682991|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
11156538|NCT03682978|Experimental|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.
~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.
~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.
~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
11156539|NCT03682978|Placebo Comparator|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.
~Dosage level is n/a."
11156540|NCT03682965|Experimental|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
11156541|NCT03682965|Placebo Comparator|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
11156542|NCT03682952|Experimental|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
11156543|NCT03682952|No Intervention|Anemia control group|Anemia patients
11156544|NCT03682952|No Intervention|Control group|Healthy person
11156545|NCT03682939|Experimental|Single arm|Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.
11156546|NCT03682926|Experimental|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
11156547|NCT03682926|Active Comparator|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
11156550|NCT03682900|Experimental|Click City Tobacco Prevention Program|Click City program used as part of school curriculum
11156551|NCT03682900|No Intervention|Usual Tobacco Prevention Curriculum|Will vary by school district.
11156552|NCT03682887|Active Comparator|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.
~Esophageal temperature will be monitored to prevent esophageal injury.
~A 28mm cryoballoon catheter will be used.
~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.
~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.
~The procedure and ablation times will be evaluated.
~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11156553|NCT03682887|Experimental|Cryoballoon PV isolation w/ RA linear ablation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter as the same as cryoballoon PV isolation group.
~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.
~Additional SVC-right atrial septal linear ablation will be performed with a radiofrequency catheter.
~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local RF ablation will be followed.
~The procedure and ablation times will be evaluated.
~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
11156554|NCT03682861|Placebo Comparator|Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
11156555|NCT03682861|Experimental|Carbohydrate drinks|Sweet corn derived starch mixed in water at three different concentrations (6%, 12% and 18%) will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
11156556|NCT03682848|Experimental|Participants receiving DTG + 3TC FDC|Eligible participants will receive FDC of DTG + 3TC 50/300 milligrams, tablets, given orally once daily.
11156557|NCT03682835|Placebo Comparator|Placebo treatment arm|Placebo: 2 capsules per dose, 2 doses per study day.
11156558|NCT03682835|Experimental|POCO treatment arm|FDGard Capsule containing a combination of peppermint oil (41,5mg) and caraway oil (50mg); 2 capsules per dose, 2 doses per study day.
11156559|NCT03682822|Experimental|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
11156560|NCT03682822|Active Comparator|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
11156561|NCT03682809|Experimental|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
11156562|NCT03682809|No Intervention|No Treatment|Subjects randomized to this group will not receive a treatment.
11156563|NCT03682796|Experimental|Escalation|Estimated to be <31 subjects across multiple centers
11156564|NCT03682796|Experimental|Expansion|Estimated to be <121 subjects across multiple centers
11156565|NCT03682783||Fundus Image|Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
11156566|NCT03682770|Experimental|dupilumab + AR101|Participant randomization of a ratio of 2 active dupilumab arms
11156567|NCT03682770|Experimental|placebo matching dupilumab + AR101|Participant randomization of a ratio of 1 placebo arm
11156568|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)>=25, and base deficit (BD)>=6.
11156569|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)<25, and base deficit (BD) <6.
11156570|NCT03682757||Healthy Controls|Uninjured healthy volunteers
11156571|NCT03682744|Experimental|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
11156572|NCT03682718|Experimental|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
11156573|NCT03682718|Active Comparator|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.
~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
11156574|NCT03682705|Experimental|Group 6|Participants receiving upadacitinib placebo and ABBV-105 placebo
11156575|NCT03682705|Experimental|Group 5|Participants receiving upadacitinib and ABBV-105 placebo
11156576|NCT03682705|Experimental|Group 4|Participants receiving upadacitinib placebo and ABBV-105 dose C
11156577|NCT03682705|Experimental|Group 3|Participants receiving upadacitinib placebo and ABBV-105 dose B
11156578|NCT03682705|Experimental|Group 2|Participants receiving upadacitinib placebo and ABBV-105 dose A
11156579|NCT03682705|Experimental|Group 1|Participants receiving upadacitinib and ABBV-105 dose A
11156580|NCT03682692|Experimental|ACEI/CCB|
11156581|NCT03682692|Experimental|ACEI/DIU|
11156582|NCT03682666|Active Comparator|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
11156583|NCT03682666|Sham Comparator|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.
~And they will receive sham taping on the affected limb."
11156584|NCT03682666|Experimental|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
11156585|NCT03682653|Active Comparator|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
11156586|NCT03682653|Placebo Comparator|Placebo|a single dose of placebo will be administered to infants between their 8-27th days of life
11156587|NCT03682640|Experimental|AIDIT protocol|"Treatment as usual with the addition of:
~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight < 30 kg.
~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.
~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
11156588|NCT03682640|No Intervention|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
11156589|NCT03682627|Active Comparator|preventive fenestration|Fenestration is performed at the time of kidney transplantation
11156590|NCT03682627|Experimental|preventive fenestration and clipping|Fenestration and clipping of the edges are performed at the time of kidney transplantation
11156591|NCT03682614|Experimental|HCG group|All patients will accept HCG 500IU intrauterine injection 2 days before blastocyte transfer
11156592|NCT03682614|Placebo Comparator|control group|All patients will accept same dose of culture medium intrauterine injection 2 days before blastocyte transfer
11156593|NCT03682601|Placebo Comparator|Placebo|"30 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.
~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).
~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.
~The participant will fill out questionnaires during office visits with the gynecologist. In addition, 2 short questionnaires will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3."
11156594|NCT03682601|Active Comparator|10% Topical sinecatechins ointment|"30 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.
~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).
~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.
~The participant will fill out questionnaires during office visits with the gynecologist. In addition, 2 short questionnaires will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3."
11156595|NCT03682588|Experimental|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
11156596|NCT03682588|Active Comparator|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
11156597|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
11156598|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
11156599|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
11156600|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
11156601|NCT03682562||Normal Subjects|"Patients who give a history of:
~No smoking
~No alcohol
~No systemic disease; and who on conventional oral examination have:
~No visible oral lesions on conventional oral examination .
~Good oral hygiene."
11156602|NCT03682549||HCV positive Patients|"patients will be recruited from the outpatient's viral hepatitis clinic
~The patients will be diagnosed as HCV positive through (antiHCV-Ab) and (HCV-PCR) tests"
11156603|NCT03682549||Successfully treated former HCV patients|Patients formerly diagnosed as HCV positive who received DAA treatment successfully.
11156604|NCT03682549||Normal Individuals|healthy volunteers recruited from the outpatient clinic of the Faculty of Dentistry- Cairo University
11156605|NCT03682536|Experimental|Experimental Arm: luspatercept (ACE-536)|1.0 mg/kg subcutaneous (SC) every 3 weeks (Q3W)
11156606|NCT03682536|Active Comparator|Control Arm: epoetin alfa|450 IU/kg subcutaneous (SC) weekly
11156607|NCT03682523|No Intervention|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
11156608|NCT03682523|Experimental|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; real-time feedback on goal attainment provided on bedside tablet; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
11156609|NCT03682510|Active Comparator|stepwise devascularization|routine stepwise devascularization
11156632|NCT03682380|Experimental|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
11156749|NCT03681743|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
11156610|NCT03682510|Active Comparator|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.
~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
11156611|NCT03682510|Experimental|N&H technique|"In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:
~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.
~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
11156612|NCT03682497|Active Comparator|Spironolactone|Spironolactone treatment for 28 days
11156613|NCT03682497|Experimental|AZD9977|AZD9977 treatment for 28 days
11156614|NCT03682484|Experimental|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
11156615|NCT03682484|Placebo Comparator|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
11156616|NCT03682484|Experimental|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
11156617|NCT03682484|Experimental|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
11156618|NCT03682484|Placebo Comparator|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
11156619|NCT03682471||Deoxycholic Acid Injection, 5 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 5 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
11156620|NCT03682471||Deoxycholic Acid Injection, 10 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 10 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
11156621|NCT03682471||Placebo|Non-treatment observational follow-up study: Participants were previously treated with placebo in studies ATX-101-10-16 or ATX-101-10-17.
11156622|NCT03682445|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
11156623|NCT03682445|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
11156624|NCT03682445|No Intervention|Control group|The participants in the control group will make stretching exercise at home
11156625|NCT03682419|Experimental|VKA Patients|Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy
11156626|NCT03682419|Experimental|non-Vka Patients|Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy
11156627|NCT03682406|Experimental|CAMS-G|CAMS-G is an group-based adaptation of the Collaborative Assessment and Management of Suicidality (CAMS) that has been developed to address perceived burdensomeness and thwarted belongingness, two drivers of suicide risk. Ongoing assessment and treatment planning are completed using the CAMS Suicide Status Form in the group modality, with involvement from group members and group facilitators. Driver-focused intervention strategies and group process also occur in the group based upon the unique needs of the group members. Groups are 90-minutes in length and occur on a weekly basis.
11156628|NCT03682406|Other|Care as Usual|Care as usual includes access to all existing forms of treatment that currently exist at the Robley Rex VAMC and affiliated CBOCs, such as individual and group psychotherapy, suicide prevention programming and case management, psychiatric care, social work services, and substance use disorder counseling. We will essentially track the control condition over time as they engage in the typical services provided to suicidal Veterans through the Robley Rex VAMC. The CAMS-G study participants will have access to the same services delivered as part of care as usual, with the only difference being their participation in the CAMS-G treatment for suicidality.
11156629|NCT03682393|Experimental|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
11156630|NCT03682393|Placebo Comparator|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
11156631|NCT03682380|Experimental|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
11156715|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
11156633|NCT03682380|Experimental|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
11156634|NCT03682367|Placebo Comparator|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
11156635|NCT03682367|Experimental|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
11156636|NCT03682354|Active Comparator|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
11156637|NCT03682354|Experimental|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
11156638|NCT03682341||Group A|Patients with ovarian endometriosis cyst
11156639|NCT03682341||Group B|Patients with ovarian teratoma cyst
11156640|NCT03682328|Active Comparator|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
11156641|NCT03682328|Active Comparator|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
11156642|NCT03682315|Active Comparator|Biphasic phycogenic biomaterial|Biphasic phycogenic biomaterial and Autogenous cortical bone
11156643|NCT03682315|Experimental|Xenograft bovine hydroxyapatite|Xenograft bovine hydroxyapatite and Autogenous cortical bone
11156644|NCT03682302|Experimental|Part 1 (PK and Safety) Group 1 - Spine Surgery|EXPAREL 4 mg/kg [15 patients]
11156645|NCT03682302|Active Comparator|Part 1 (PK and Safety) Group 1 - Spine Surgery (Bupi)|Bupivacaine HCl 2 mg/kg [15 patients]
11156646|NCT03682302|Experimental|Part 1 (PK and Safety) Group 2 - Spine or Cardiac Surgery|EXPAREL 4 mg/kg [15 patients]
11156647|NCT03682302|Experimental|Part 2 (Safety) Group 1 - Spine Surgery|EXPAREL 4mg/kg [15 patients]
11156648|NCT03682302|Active Comparator|Part 2 (Safety) Group 1 - Spine Surgery (Bupi)|Bupivacaine HCl 2 mg/kg [15 patients]
11156649|NCT03682302|Experimental|Part 2 (Safety) Group 2 - Spine or Cardiac Surgery|EXPAREL 4mg/kg [15 patients]
11156650|NCT03682289|Experimental|Arm I (ATR kinase inhibitor AZD6738)|Participants who are BAF250a negative or ATM-Mutant receive ATR kinase inhibitor AZD6738 PO twice a day on days 1-14. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11156651|NCT03682289|Experimental|Arm II (ATR kinase inhibitor AZD6738, olaparib)|Participants who are BAF250a positive receive ATR kinase inhibitor AZD6738 PO every day on days 1-7 and olaparib PO twice a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11156652|NCT03682276|Experimental|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
11156653|NCT03682263|Experimental|Full Service Treatment|The Full Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services, as well as Medication Management Support (MMS) from a Nurse Care Coordinator (NCC).
11156654|NCT03682263|Experimental|Basic Service Treatment|The Basic Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services.
11156655|NCT03682263|No Intervention|Usual Services|Members of the Usual Service group seek services as they normally would (or would not) in their community. At the time of randomization, each Usual Services group member receives a comprehensive manual describing mental health and employment services in their local community, as well as state and national resources.
11156656|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
11156657|NCT03682237|No Intervention|A) Standard diabetes training (control)|"More specifically, group training in general diabetes health issues, how to do experienced based dosing, how to handle sick days, exercise etc. in general terms. The group will not be taught in carbohydrate counting or bolus calculation. They will be encouraged to measure SMBG at least 4 times daily with patients own preferred glucose meter.
~Patients will be offered 6 months treatment with FGM after study end."
11156658|NCT03682237|Active Comparator|B) Carbohydrate counting, automated bolus calculation|
11156659|NCT03682237|Active Comparator|C) Flash glucose monitoring (FGM)|Group training with same content as for group A.
11156660|NCT03682237|Active Comparator|D) Carbohydrate counting, automated bolus calculation, FGM|Group training as group B. A more sophisticated education concept will be developed for how FGM should be used to adjust settings and suggestions from the automated bolus calculator (MySugr app).
11156661|NCT03682224|Active Comparator|Exparel|
11156662|NCT03682224|Active Comparator|Marcaine|
11156663|NCT03682211|Experimental|Active Intranasal Fentanyl|Subjects will receive 50 μg/ml intranasal fentanyl citrate and a placebo matched to intravenous morphine (1 ml water for injection) at time 0
11156664|NCT03682211|Active Comparator|Active IV Morphine|Subjects will receive 10 mg/ml intravenous morphine sulphate and a placebo matched to intranasal fentanyl (2 ml water)
11156665|NCT03682198|Other|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
11156688|NCT03682081|Experimental|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
11156748|NCT03681756|Experimental|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
11156666|NCT03682185|Experimental|Timed Activity Intervention Protocol|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.
11156667|NCT03682185|Active Comparator|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
11156668|NCT03682172|Experimental|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
11156669|NCT03682172|Experimental|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
11156670|NCT03682172|Experimental|Placebo|A single four hour intravenous infusion with saline water (placebo)
11156671|NCT03682159|No Intervention|control|
11156672|NCT03682159|Experimental|intervention|
11156673|NCT03682146|Experimental|R-LRPE|robot-assisted laparoscopic prostatectomy
11156674|NCT03682146|Experimental|LRPE|conventional radical laparoscopic prostatectomy
11156675|NCT03682133||Prehabilitation|The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
11156676|NCT03682133||Usual care|Guideline based colon cancer surgery, without prehabilitation.
11156677|NCT03682120|Experimental|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
11156678|NCT03682120|Experimental|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
11156679|NCT03682120|Experimental|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
11156680|NCT03682120|Experimental|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
11156681|NCT03682107|Experimental|Arm 1 (2 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.
~11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
11156682|NCT03682107|Experimental|Arm 2 (2 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.
~11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
11156683|NCT03682107|Experimental|Arm 3 (4 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.
~11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
11156684|NCT03682107|Experimental|Arm 4 (4 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.
~11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
11156685|NCT03682094|Experimental|Probiotic|The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow.
11156686|NCT03682081|No Intervention|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
11156687|NCT03682081|Experimental|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
11156788|NCT03681431|Experimental|Ceftriaxone 4g/ 24h|Single intravenous dose of Ceftriaxone 4g/ 24h
11156689|NCT03682081|Experimental|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
11156690|NCT03682068|Experimental|Durvalumab in Combination with SoC Chemotherapy|"Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks.
~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
~cisplatin+ gemcitabine
~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
11156691|NCT03682068|Experimental|Durvalumab in Combination with Tremelimumab+SoC Chemotherapy|"Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks
~Tremelimumab will be provided for 4 cycles.
~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
~cisplatin+ gemcitabine
~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
11156692|NCT03682068|Active Comparator|SoC Chemotherapy|"Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:
~cisplatin+ gemcitabine
~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
11156693|NCT03682055|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC
11156694|NCT03682055|Experimental|Phase 1 Dose Escalation (Rolling Six)|VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.
11156695|NCT03682055|Experimental|Phase 1 Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.
11156696|NCT03682055|Experimental|Phase 2a Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.
11156697|NCT03682042|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
11156698|NCT03682042|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
11156699|NCT03682029|Experimental|Vitamin C|Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.
11156700|NCT03682029|Placebo Comparator|Placebo|Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.
11156701|NCT03681990|Experimental|3M CHG/IPA Prep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
11156702|NCT03681977|Experimental|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
11156703|NCT03681977|Active Comparator|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
11156704|NCT03681977|No Intervention|Healthy Participants|The control group for the kinematic assessment
11156705|NCT03681951|Experimental|Part 1: Dose Escalation - GSK3145095 monotherapy|In Part 1, advanced or metastatic PDAC will be enrolled. Part 1 will be using escalating doses of GSK3145095 (total daily dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1600 mg) orally as monotherapy for up to 2 years. For each dose level, subjects will receive a single dose of half the total daily dose on Day 1; and as BID (total daily dose divided in two equal doses) starting from Day 2.
11156706|NCT03681951|Experimental|Part 2: Dose Escalation - GSK3145095 + pembrolizumab|In Part 2, subjects with selected solid tumors, including but not limited to, PDAC, NSCLC, TNBC and/or melanoma will be enrolled. Part 2 will be using GSK3145095 combination escalation to start at least one dose level below the highest dose of GSK3145095 shown to be safe in Part 1, orally BID for up to 2 years along with pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) for up to 2 years.
11156707|NCT03681951|Experimental|Part 3: Dose Expansion - GSK3145095 + pembrolizumab|In Part 3, subjects with selected solid tumors will be enrolled. Part 3 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with pembrolizumab 200 mg IV Q3W for up to 2 years.
11156708|NCT03681951|Experimental|Part 4: Dose Expansion - GSK3145095 + anticancer agent|In Part 4, subjects with selected solid tumors will be enrolled. Part 4 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with combination of additional anticancer agents.
11156709|NCT03681938||Intensification treatment: Autograft|
11156710|NCT03681938||Standard chemotherapy (without autograft)|
11156711|NCT03681925|Experimental|Intervention|Dietitians randomized to the intervention arm will have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and base their intervention on these results.
11156712|NCT03681925|No Intervention|Control|Dietitians randomized to the control arm will not have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and will provide the standard-of-care intervention for their patients.
11156713|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
11156714|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
11156789|NCT03681431|Active Comparator|Ceftriaxone 2g/ 12h|Two intravenous doses of Ceftriaxone 2g/ 12h
11156716|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
11156717|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
11156718|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
11156719|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
11156720|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
11156721|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
11156722|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
11156723|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
11156724|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
11156725|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
11156726|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
11156727|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
11156728|NCT03681899||Subjects aged of 65 years or older|Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
11156729|NCT03681873|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
11156730|NCT03681860|Other|Group 1 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 5 x109 vp
11156731|NCT03681860|Other|Group 2 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 2.5 x1010 vp
11156732|NCT03681860|Other|Group 3 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 5 x109 vp
11156733|NCT03681860|Other|Group 4 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x1010 vp
11156734|NCT03681860|Experimental|Group 5/6 Randomised Comparison|30 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x1010 vp followed by MVA85A boost versus 30 adolescents who are EMaBS participants, to receive BCG revaccination
11156735|NCT03681847|Active Comparator|normal saline|Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.
11156736|NCT03681847|Active Comparator|Hydroxyethyl starch|Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
11156737|NCT03681847|Active Comparator|Hypertonic saline|Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.
11156738|NCT03681821|Experimental|The intervention group|Patients in the intervention group receiving the follow-up TTM-based intervention sessions.
11156739|NCT03681821|No Intervention|The control group|No interventions except conventional care were performed for the control group.
11156740|NCT03681808|Experimental|Test|Soft Contact Lens
11156741|NCT03681808|Active Comparator|Control|Contact lens
11156742|NCT03681795|Experimental|Experimental|Experimental MRI exam and PET scan exam without comparator. Patients evaluated on motor and behavioral symptoms.
11156743|NCT03681769|Experimental|Intermittent Theta Burst Stimulation (iTBS) to the left dlPFC|For intermittent theta burst stimulation (iTBS) (Aim 1), participants will receive 20 trains of stimulation over the dlPFC (middle frontal gyrus) (F3) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P).
11156744|NCT03681769|Sham Comparator|Sham iTBS to the left dlPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
11156745|NCT03681769|Experimental|cTBS to the mPFC|For continuous theta burst stimulation (Aim 2), participants will receive 1 train of stimulation over the left frontal pole (FP1) (each train: 3 pulse bursts presented at 5 hertz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% resting motor threshold, MagPro; 600 pulses total) using a figure 8 coil (Coil Cool-B65 A/P). This protocol has been shown to attenuate the mPFC and striatum in cocaine dependent individuals in the past (61-63) and has been more effective than 1200 or 1800 pulses of cTBS in attenuating depression (The time between the end of the TBS procedures and the beginning of the behavioral assessments, as well as the scalp-to-cortex distance (which effects the actual TMS dose given to the cortex) will be compiled and used as covariates in subsequent analyses.
11156746|NCT03681769|Sham Comparator|Sham cTBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
11156747|NCT03681756|No Intervention|Group 1|Participants will receive an in-person session and an activity monitor
11156826|NCT03681119|Experimental|Advanced Demential Patients|
11156750|NCT03681743|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors and/or parents.
11156751|NCT03681730|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
11156752|NCT03681730|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
11156753|NCT03681717|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during laceration repair with sutures.
11156754|NCT03681717|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
11156755|NCT03681704|Experimental|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
11156756|NCT03681704|Placebo Comparator|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
11156757|NCT03681691|Experimental|Post menopausal women with diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
11156758|NCT03681691|Experimental|Post menopausal women without diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
11156759|NCT03681678||fCO2 Laser Therapy Group|Women treated with the fCO2 laser
11156760|NCT03681665||Abscess|Patients group with abdominal abscess
11156761|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
11156762|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
11156763|NCT03681639|Experimental|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application with the Durom® Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
11156764|NCT03681626|Active Comparator|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
11156765|NCT03681626|Experimental|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
11156766|NCT03681613|Experimental|Exercise Therapy With CNS Treatment|NEMEX program combined with a CNS-focused protocol
11156767|NCT03681613|Experimental|Exercise Therapy alone|NEMEX program alone
11156768|NCT03681574|Experimental|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
11156769|NCT03681574|Experimental|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
11156770|NCT03681574|Experimental|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
11156771|NCT03681561|Experimental|Ruxolitinib and Nivolumab|
11156772|NCT03681548|Active Comparator|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
11156773|NCT03681548|Experimental|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
11156774|NCT03681535|Experimental|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
11156775|NCT03681522|Experimental|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
11156776|NCT03681522|Active Comparator|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
11156777|NCT03681509|Experimental|Pramipexole|Maximum daily dose: 1.0 mg of pramipexole salt
11156778|NCT03681509|Placebo Comparator|Placebo|Lactose
11156779|NCT03681483|Experimental|RO5126766 (CH5126766)|The study will begin with a standard 3+3 design. The study will enroll 3 patients at the previously identified MTD15 (4mg two times per week on days 1 and 4). The period of evaluation for dose limiting toxicity will be through completion of cycle 1. If ≤1 of the 3 initial patients at the proposed dose experience a DLT, then 3 additional patients will be enrolled for a total of 6 planned patients at that dose level. Otherwise, 3 patients will be enrolled at dose level -1. If ≤ 1 of these patients experience a DLT, then 3 additional patients will be enrolled at the same dose level. If more than 1 patient experiences a DLT in dose level -1, the study will be terminated.
11156780|NCT03681470|Experimental|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
11156781|NCT03681457|Other|Group 1 - Normal Hepatic Function|Normal hepatic function - Control - control group
11156782|NCT03681457|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment - Child-Pugh A (Score 5-6)
11156783|NCT03681457|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment - Child-Pugh B (Score 7-9)
11156784|NCT03681457|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment - Child-Pugh C (score 10-15)
11156785|NCT03681444|Experimental|Regular diet|no dietary restriction
11156786|NCT03681444|Placebo Comparator|Clear fluid diet|no solid material
11156787|NCT03681444|Experimental|Low residue diet|easy digestible food
11156790|NCT03681418|Other|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
11156791|NCT03681405|Experimental|Group I (eMMB)|Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
11156792|NCT03681405|Active Comparator|Group II (AC)|Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
11156793|NCT03681392|Experimental|Once daily then twice daily|One 6.5 cc scoop of S4S once a day for 7 days, then one 6.5 cc scoop of S4S twice a day for 7 days
11156794|NCT03681392|Experimental|Twice daily then once daily|One 6.5 cc scoop of S4S twice a day for 7 days, then one 6.5 cc scoop of S4S once a day for 7 days
11156795|NCT03681366|No Intervention|Single vision soft contact lens|single vision, spherical soft contact lens
11156796|NCT03681366|Experimental|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
11156797|NCT03681353|Experimental|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
11156798|NCT03681340|Experimental|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
11156799|NCT03681340|Active Comparator|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
11156800|NCT03681314|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
11156801|NCT03681314|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
11156802|NCT03681301|Experimental|Interventional|Additional self-directed learning and practice using virtual reality simulator, after conventional training session
11156803|NCT03681301|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
11156804|NCT03681288|Experimental|MSC|Mindful Self-Compassion Intervention
11156805|NCT03681275|Experimental|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
11156806|NCT03681275|Placebo Comparator|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
11156807|NCT03681262|Experimental|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
11156808|NCT03681262|Experimental|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
11156809|NCT03681249|Experimental|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
11156810|NCT03681249|Placebo Comparator|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
11156811|NCT03681236|No Intervention|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
11156812|NCT03681236|Active Comparator|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
11156813|NCT03681223|Active Comparator|Restorelle® Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
11156814|NCT03681223|Experimental|Vertessa® Lite Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
11156815|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
11156816|NCT03681197|Active Comparator|Metformin Group|Will receive metformin plus clomiphene citrate
11156817|NCT03681197|Placebo Comparator|Placebo|Will receive placebo plus clomiphene citrate.
11156818|NCT03681184|Experimental|Lumasiran (ALN-GO1)|
11156819|NCT03681184|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11156820|NCT03681171|Experimental|Children with CP|Children with CP (9-15 years old) participated in a therapeutic dance program to improve physical, physiological and cognitive outcomes.
11156821|NCT03681158|Experimental|sodium valproate|Single oral dose of sodium valproate containing [14C]-sodium VPA
11156822|NCT03681145|Experimental|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
11156823|NCT03681145|Experimental|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
11156824|NCT03681132|Other|Low-threshold re-start|Re-start antiviral therapy if HBV DNA viral load >2000 IU/ml and ALT >80 U/L.
11156825|NCT03681132|Other|High-threshold re-start|"Re-start antiviral therapy if:
~ALT >100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR
~ALT >400 U/L persisting for more than 2 months in consecutive assays."
11156828|NCT03681106|Experimental|Kinesiotaping|Kinesio Tex taping treatment for 10 days + usual care
11156829|NCT03681106|No Intervention|Control|usual care
11156830|NCT03681093|Experimental|fevipiprant Dose 1|QAW039 Dose 1 once daily orally
11156831|NCT03681093|Experimental|fevipiprant Dose 2|QAW039 Dose 2 once daily orally
11156832|NCT03681093|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
11156833|NCT03681080|No Intervention|lying|cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)
11156834|NCT03681080|No Intervention|standing|cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)
11156835|NCT03681080|Experimental|crossed legs|cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)
11156836|NCT03681067|Experimental|GSK10708060|Humanised antibody GSK1070806
11156837|NCT03681067|Placebo Comparator|Placebo - sodium chloride|Placebo
11156838|NCT03681054|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
11156839|NCT03681054|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
11156840|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
11156841|NCT03681028|Other|Individualized therapy|Study treatment for a given patient will consist of a regimen chosen from agents implicated in critical molecular signaling pathways and/or from signature-based predictions of drug efficacy. All agents are listed in the current pharmacopoeia for human use, but will differ amongst individual subjects. The study treatment will consist of up to 4 FDA approved drugs that have known dosing. This study is not only looking at 4 drugs. It is selecting up to 4 drugs per patient but the drugs chosen can be any FDA-approved drug. Therefore, it is not possible to pre-specify the medications.
11156842|NCT03681002|Other|structured lifestyle program|individual counseling focusing on Lifestyle habits
11156843|NCT03680989|Placebo Comparator|Natural Light|"Participants will use a therapy light that provides ~500 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
11156844|NCT03680989|Active Comparator|Bright Light|"Participants will receive Bright Light Exposure using a therapy light that provides ~10,000 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
11156845|NCT03680976|Experimental|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
11156846|NCT03680976|Placebo Comparator|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
11156847|NCT03680963|Experimental|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
11156848|NCT03680963|Other|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
11156849|NCT03680950|Experimental|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
11156850|NCT03680937||Immature oocytes vitrified before in vitro maturation|Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
11156851|NCT03680937||Immature oocytes vitrified after in vitro maturation|A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
11156852|NCT03680937||Fresh oocytes|The culture of immature oocytes will be performed during 36 hours
11156853|NCT03680911|Experimental|NAC|NAC will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
11156854|NCT03680911|Placebo Comparator|Placebo|Placebo will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
11156855|NCT03680898|Experimental|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
11156856|NCT03680898|Active Comparator|Reference Method|The other swab will be used in the Reference Method.
11156857|NCT03680885|Active Comparator|Reports getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
11156858|NCT03680885|Active Comparator|Reports trouble getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
11156859|NCT03680872|Experimental|Spinal Cord Injury Participants|This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.
11156860|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
11156861|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
11156862|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
11156863|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
11156864|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
11156865|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
11156866|NCT03680846|Other|CMM|Conventional Medical Management
11156867|NCT03680846|Active Comparator|HF10 + CMM|Addition of HF10 therapy to CMM
11156868|NCT03680833|Other|prospective cohort study|"Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.
~The intervention is the detection and removal of sentinel lymph nodes"
11156869|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
11159376|NCT03663998|Active Comparator|C|CN54ENV IM EP 4000 g
11156870|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
11156871|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
11156872|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
11156873|NCT03680807||Older adults with knee osteoarthritis (>50 years)|
11156874|NCT03680807||Healthy older adults (> 50 years)|
11156875|NCT03680794|Experimental|Patients with ophthalmic surgery|
11156876|NCT03680781|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
11156877|NCT03680755|Experimental|Tr1 group|Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
11156878|NCT03680755|Experimental|Tr2 group|Participants assigned to Tr2 will complete the experimental dental anxiety management program, which will be facilitated by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
11156879|NCT03680755|No Intervention|Active control|Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
11156880|NCT03680729|Experimental|aBSB|aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.
11156881|NCT03680729|Active Comparator|Street Outreach|Standard street outreach was used as the control in the original BSB trial.
11156882|NCT03680716|Experimental|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
11156883|NCT03680716|Active Comparator|Local infiltration analgesia|Periarticular infiltration by surgeon
11156884|NCT03680703|Experimental|Internet|Guided self-help behavioral weight loss treatment delivered via the internet
11156885|NCT03680703|Experimental|Internet Plus Phone|Guided self-help behavioral weight loss treatment delivered via the internet with weekly phone consultations
11156886|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
11156887|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
11156888|NCT03680677||Cancer Directed Therapy or Best Supportive Care|Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
11156889|NCT03680677||Transplant|Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
11156890|NCT03680664|Experimental|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.
~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
11156891|NCT03680664|Sham Comparator|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
11156892|NCT03680638|Sham Comparator|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
11156893|NCT03680638|Experimental|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
11156894|NCT03680638|Experimental|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
11156925|NCT03680404|Active Comparator|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
11157042|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
11156895|NCT03680638|Experimental|Allopurinol|This site will only be infused with tempol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
11156896|NCT03680625|Active Comparator|Passive Distraction|The child will watch a video on an iPad® during the pin removal procedure and/or removal of sutures.
11156897|NCT03680625|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment using an Oculus Quest® head-mounted device throughout the pin removal procedure and/or removal of sutures.
11156898|NCT03680612|Experimental|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
11156899|NCT03680612|Active Comparator|cefepime monotherapy|cefepime 1 g or cefepime 2 g
11156900|NCT03680599|Experimental|Connection to Health for Smokers|Participants in this arm will participate in the Connection to Health for Smokers Arm of the study, wherein an electronic survey will be administered and participants will be guided through an evidence-based action planning sequence, taking into account each patient's unique social environment, health related behaviors, and behavioral health status, with multimodal follow up.
11156901|NCT03680599|Active Comparator|Enhanced Standard of Care|Participants in this arm will participate in Enhanced Standard Care, wherein participants will receive a brief electronic survey and receive standard smoking cessation program that does not include formal action planning and multimodal follow up.
11156902|NCT03680586|Experimental|Treatment (low-dose radiation therapy)|Patients undergo low-dose radiation therapy over 2 fractions for 2 consecutive days in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease at 12-16 weeks post-treatment, or persistent disease at 1 year may undergo higher-dose radiation therapy at the discretion of treating physician.
11156903|NCT03680573|Active Comparator|Control- Lactated Ringers|This site will serve as the control site and will receive lactated Ringer's (saline solution) at an infusion rate of 2 µl/min.
11156904|NCT03680573|Experimental|Apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone)|This site will receive 100 µM apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone) at an infusion rate of 2 µl/min.
11156905|NCT03680573|Experimental|Allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)|This site will receive 10 µM allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.
11156906|NCT03680573|Experimental|BH4 ((6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride)|This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.
11156907|NCT03680560|Experimental|ACTR T cell product in combination with trastuzumab|
11156908|NCT03680534|Experimental|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
11156909|NCT03680534|Experimental|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
11156910|NCT03680534|Experimental|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
11156911|NCT03680521|Experimental|Sitravatinib and nivolumab|Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks.
11156912|NCT03680508|Experimental|TSR-022 and TSR-042|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11156913|NCT03680495||AECOPD with Respiratory Failure|The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
11156914|NCT03680495||Stable COPD|The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
11156915|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
11156916|NCT03680482|No Intervention|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
11156917|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
11156918|NCT03680469|Active Comparator|standard early rehabilitation|The standard early rehabilitation program after acute stroke is an intervention regularly utilized in the stroke center of National Taiwan University Hospital.
11156919|NCT03680469|Experimental|adding early out-of-bed mobilization|The adding early out-of-bed mobilization treatment will be defined as the patients with acute ischemic stroke who receive out-of-bed mobilization treatment in addition to standard early rehabilitation care.
11156920|NCT03680456|Active Comparator|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
11156921|NCT03680456|Placebo Comparator|Placebo|Natriumchlorid is the placebo
11156922|NCT03680430|Experimental|limb soft tissue sarcoma|
11156923|NCT03680417|Active Comparator|Safety Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
11156924|NCT03680417|Active Comparator|Sub Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
11156926|NCT03680404|Experimental|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10^-4 M) at the same rate and for the same time as the control arm.
11156927|NCT03680404|Experimental|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10^-5 M) at the same rate and for the same time as the control arm.
11156928|NCT03680404|Experimental|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10^-5 M) at the same rate and for the same time as the control arm.
11156929|NCT03680391||early postoperative feeding|103 patients will have early postoperative oral fluids and semisolid food after 6 hours of cesarean section irrespective to intestinal sounds ,flatus or stool passage
11156930|NCT03680391||Late postoperative feeding|97 patient will start oral fluids 6 hours with no solid or semi solid until after passage of flatus or stool
11156931|NCT03680378|Experimental|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
11156932|NCT03680352|Experimental|cefepime/AAI101 combination|Investigational drug
11156933|NCT03680339|Active Comparator|Routine ecbolic group|100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
11156934|NCT03680339|Active Comparator|Misoprostol group|The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
11156935|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
11156936|NCT03680313||Hypertension group|"All adult patients (above 18 year of age) were recruited between May, 2016 and June 2017, at Duc Giang General Hospital. The inclusion criteria are as followed:
~Patients have never been diagnosed with hypertension.
~Has been diagnosed with primary hypertension, but not take any treatment."
11156937|NCT03680313||Control group|A group of normal people with the similar age to hypertension group was recruited as control group at the same time
11156938|NCT03680300|Experimental|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
11156939|NCT03680300|Experimental|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
11156940|NCT03680300|Experimental|Frictional Massage|Frictional massage will be given to 3rd group
11156941|NCT03680287|Active Comparator|Uninterrupted Sleep|Participants will be permitted to sleep without interruption for 8 hours.
11156942|NCT03680287|Experimental|Sleep Disruption|Participants will be repeatedly awakened throughout the night according to a standardized protocol.
11156943|NCT03680274|Experimental|Vitamin C|Vitamin C: 50 mg/kg every 6 hours for 96 hours.
11156944|NCT03680274|Placebo Comparator|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
11156945|NCT03680261|Experimental|Adjuvant chemoradiotherapy group|Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
11156946|NCT03680261|Active Comparator|Adjuvant chemotherapy group|Adjuvant chemotherapy (6 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
11156947|NCT03680248|Experimental|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
11156948|NCT03680248|Experimental|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
11156949|NCT03680248|Other|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
11156950|NCT03680248|Other|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
11156951|NCT03680248|Experimental|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
11156952|NCT03680248|Experimental|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
11156953|NCT03680248|Experimental|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
11156954|NCT03680248|Experimental|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
11156955|NCT03680248|Experimental|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
11156956|NCT03680248|Experimental|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
11156957|NCT03680248|Experimental|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
11156958|NCT03680248|Experimental|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
11156959|NCT03680235|Active Comparator|Group I: (standard information about pregnancy, breastfeeding)|Participants receive standard information about pregnancy and breastfeeding. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
11156960|NCT03680235|Experimental|Group II (information about breastfeeding and cancer)|Participants receive standard information about pregnancy and breastfeeding as well as information about breastfeeding and breast cancer. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
11156961|NCT03680222|No Intervention|Standard method|Standard method recommended by the guide
11156962|NCT03680222|Experimental|Reversed Tracking Method|Reversed Tracking Method
11157001|NCT03679949|Experimental|Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
11156963|NCT03680196|Experimental|cerebral palsy patients|cerebral palsy patients who have GMFCS level3,4,5 and 2 years old and under 10 years old apply an A injection of medication Botulinum A injection
11156964|NCT03680183||Pre-exposure|Entecavir 1Mg Oral Tablet
11156965|NCT03680183||Post-exposure|Entecavir 1Mg Oral Tablet
11156966|NCT03680170|Experimental|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.
~Intervention Device: web-based cognitive training"
11156967|NCT03680170|Placebo Comparator|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).
~Intervention Device: Web-based cognitive training"
11156968|NCT03680144|Experimental|Diagnostic (MRI, DSC-MRI)|Participants undergo diagnostic magnetic resonance imaging (MRI) with and without contrast and treatment planning dynamic susceptibility contrast-MRI (DSC-MRI) series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.
11156969|NCT03680131|Active Comparator|EB01 Cream Placebo|EB01 Cream containing 0% EB01 w/w applied BID
11156970|NCT03680131|Experimental|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
11156971|NCT03680131|Experimental|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
11156972|NCT03680131|Experimental|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
11156973|NCT03680118|Experimental|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
11156974|NCT03680105|Experimental|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
11156975|NCT03680105|Experimental|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
11156976|NCT03680105|Experimental|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
11156977|NCT03680105|Experimental|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
11156978|NCT03680105|Experimental|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
11156979|NCT03680105|Experimental|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
11156980|NCT03680105|Experimental|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
11156981|NCT03680105|Experimental|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
11156982|NCT03680105|Experimental|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
11156983|NCT03680092|Experimental|Cyclophosphamide and abatacept|The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
11156984|NCT03680092|Active Comparator|methotrexate and tacrolimus|The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus
11156985|NCT03680079|Other|Youth with type 1 diabetes|A group of 16 teens (ages 13-18) with poorly -controlled type 1 diabetes will be recruited to participate in this study.
11156986|NCT03680066|Experimental|Foods with traces|Oral food challenge with foods with traces
11156987|NCT03680053|Experimental|PPOS group|Ovarian stimulation will use the progestin-primed ovarian stimulation (PPOS) protocol.Women will receive progesterone (oral duphaston 20mg) daily from Day 3 till the day of ovulation trigger.
11156988|NCT03680053|Active Comparator|Antagonist group|Ovarian stimulation will use the antagonist protocol. Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
11156989|NCT03680027|No Intervention|Control Group|In 'Control group' participants had 6 week follow-up without any intervention.
11156990|NCT03680027|Experimental|Interventional Group|In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
11156991|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
11156992|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
11156993|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
11156994|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
11156995|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
11156996|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
11156997|NCT03679975|Experimental|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
11156998|NCT03679962|Experimental|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
11156999|NCT03679962|Active Comparator|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
11157000|NCT03679949|Placebo Comparator|Placebo|Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
11157002|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0)|Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
11157003|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
11157004|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
11157005|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
11157006|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
11157007|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
11157008|NCT03679936||Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
11157009|NCT03679936||Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
11157010|NCT03679936||Multiple primary lung cancer group|PET/CT dynamic scan,needle biopsy and gene detection
11157011|NCT03679936||Intrapulmonary metastases group|PET/CT dynamic scan,needle biopsy and gene detection
11157012|NCT03679923|Experimental|NEM® brand eggshell membrane|NEM, 500 mg, #0 capsule, once daily orally for 2 weeks
11157013|NCT03679923|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks
11157014|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
11157015|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
11157016|NCT03679897|Experimental|Ropivacaine group|BPB with 0.375% ropivacaine solution
11157017|NCT03679897|Active Comparator|Levobupivacaine group|BPB with 0.25% levobupivacaine solution
11157018|NCT03679884|Experimental|ACT-541468 10 mg|Tablets administered orally, once daily in the evening
11157019|NCT03679884|Experimental|ACT-541468 25 mg|Tablets administered orally, once daily in the evening
11157020|NCT03679884|Experimental|ACT-541468 50 mg|Tablets administered orally, once daily in the evening
11157021|NCT03679884|Placebo Comparator|Placebo|Tablets administered orally, once daily in the evening
11157022|NCT03679871|Other|Questionnaire validation|"22-items questionnaire Spiritual Resources and Distress"
11157023|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
11157024|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
11157025|NCT03679845|Experimental|Sarilumab Arm|200 mg of sarilumab every two weeks
11157026|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
11157027|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
11157028|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
11157029|NCT03679819||HR-TRUS|HR-TRUS for the detection of prostate cancer in men scheduled for radical prostatectomy for localized prostate cancer
11157030|NCT03679806|Experimental|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
11157031|NCT03679806|Experimental|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
11157032|NCT03679793|Active Comparator|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger.
11157033|NCT03679793|Experimental|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
11157034|NCT03679780|Active Comparator|Control|This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
11157035|NCT03679780|Experimental|Inhibitor of Endothelin Type B Receptor|This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
11157036|NCT03679780|Experimental|Inhibition of Endothelin Type A Receptor|This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
11157037|NCT03679780|Experimental|L-Arginine|This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
11157038|NCT03679767|Experimental|INCMGA00012|INCMGA00012 administered to cohorts of specific tumor types.
11157039|NCT03679754|Experimental|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
11157040|NCT03679741|Experimental|TEST/CONTROL/CONTROL|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
11157041|NCT03679741|Experimental|CONTROL/TEST/TEST|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
11157149|NCT03679065|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
11157043|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
11157044|NCT03679715|Experimental|Intervention group|The participants in the Intervention group will be participants of the museum participatory art-based activity.
11157045|NCT03679715|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the museum participatory art-based activity.
11157046|NCT03679702|Other|Active treatment|
11157047|NCT03679689|No Intervention|Control group|no changes in their alimentary habits
11157048|NCT03679689|Experimental|intervention group|no intake of artificially sweetened beverages
11157049|NCT03679676|Other|Cohort A: Omalizumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo
11157050|NCT03679676|Other|Cohort B: Omalizumab/Dupilumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.
11157051|NCT03679676|Other|Cohort C: Dupilumab|Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.
11157052|NCT03679663|No Intervention|Palpation|Anesthesia performed without ultrasound
11157053|NCT03679663|Experimental|Ultrasound|Anesthesia performed after ultrasound
11157054|NCT03679650|Experimental|AML Patient who are undergoing allogeneic transplantation|"Patients will be vaccinated with DC/AML fusion cells
~Four days of GM-CSF given subcutaneously at the site of vaccination
~Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine
~Patients will be treated with 5 days of decitabine in the post-transplant setting"
11157055|NCT03679650|Experimental|AML Patient who are undergoing transplantation|"Patients will be vaccinated with DC/AML fusion cells
~Four days of GM-CSF given subcutaneously at the site of vaccination
~Patients will receive 2 vaccines, 3 weeks apart, with the potential for a booster vaccine"
11157056|NCT03679637|Experimental|Intervention group|Each participant will receive a tablet-based aphasia therapy
11157057|NCT03679624|Experimental|Cohort A - Ibrutinib naive|Cohort A will consist of subjects who are ibrutinib naïve and appropriate for ibrutinib based treatment. Treatment naïve subjects will be eligible to enroll in this cohort. All subjects in this cohort will receive ibrutinib plus daratumumab
11157058|NCT03679624|Experimental|Cohort B - Ibrutinib response plateau|Cohort B will consist of subjects who have had at least 6 months of exposure to single agent ibrutinib and who have demonstrated an IgM response plateau defined by two IgM measurements, at least 8 weeks apart that have changed <15% from the previous mark. All subjects in this cohort will receive ibrutinib plus daratumumab
11157059|NCT03679611|Experimental|Interventional Arm|Interventional Arm will receive sugammadex sodium 2 mg/kg actual body weight, At the end of surgery Sugammadex will be administered when the TOF reveals at least 2 responses
11157060|NCT03679611|Active Comparator|Standard drug Arm|standard drug Arm will receive neostigmine 2.5 mg and glycopyrrolate 0.4 mg, At the end of surgery neostigmine and glycopyrrolate will be administered when the TOF reveals at least 2 responses
11157061|NCT03679598|Active Comparator|Alvelestat (MPH966)|Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks
11157062|NCT03679598|Placebo Comparator|Placebo|4 Placebo tablets twice daily by mouth for 12 weeks
11157063|NCT03679585|Experimental|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
11157064|NCT03679572|Experimental|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
11157065|NCT03679572|Active Comparator|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
11157066|NCT03679559|Experimental|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
11157067|NCT03679559|Experimental|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
11157068|NCT03679559|Experimental|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
11157069|NCT03679559|Active Comparator|Arm IV (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
11157070|NCT03679546|Experimental|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
11157071|NCT03679546|Experimental|Vedolizumab|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
11157072|NCT03679533|Active Comparator|Active Cranberry Study Food|
11157073|NCT03679533|Placebo Comparator|Placebo Study Food|
11157074|NCT03679520|Experimental|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
11157075|NCT03679520|Active Comparator|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
11157076|NCT03679507|Active Comparator|Group A|The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
11157077|NCT03679507|Placebo Comparator|Group B|"Will be treated with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light."
11157078|NCT03679507|Active Comparator|Group B1|The first patient group will receive high CBD oil applied topically to the affected knee joint.
11157079|NCT03679507|No Intervention|Group B2|This group of patients will not receive high CBD oil to the affected joint.
11157080|NCT03679494|Experimental|SDM intervention group|Using shared decision making support tool for intervention
11157081|NCT03679494|No Intervention|Usual care group|No intervention, just continue using usual care
11157082|NCT03679481|Experimental|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
11157083|NCT03679481|Placebo Comparator|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
11157084|NCT03679468|Sham Comparator|Cognitive Rehab & Sham Exercise|Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
11157085|NCT03679468|Sham Comparator|Sham Cognitive Rehab & Sham Exercise|Sham cognitive Rehabilitation will consist of basic internet searches and learning to use a computer, and sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
11157086|NCT03679468|Sham Comparator|Sham Cognitive rehab & Aerobic Exercise|Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
11157087|NCT03679468|Active Comparator|Cognitive Rehab & Aerobic Exercise|Cognitive Rehabilitation by computer based brain tasks and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
11157088|NCT03679455|Experimental|Treatment arm|Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.
11157089|NCT03679442|Experimental|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
11157090|NCT03679429||Control group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
11157091|NCT03679429||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.
11157092|NCT03679403||ADHD Probands|Subjects with DSM-IV ADHD who received the same MRI and CANTAB+CPT assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at the estimated age of 15-25.
11157093|NCT03679403||Unaffected siblings of ADHD|The unaffected siblings received the MRI and CANTAB+CPT assessments during 2013.8-2015.7 (NCT01682915) will be recruited and assessed.
11157094|NCT03679403||Neurotypicals Follow-up|Subjects without any lifetime diagnosis of DSM-IV ADHD or other psychiatric disorders as the control group of the ADHDFU group around 4-8 years ago when they received the same MRI and neuropsychological assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at their estimated age of 15-25.
11157095|NCT03679390|Experimental|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
11157096|NCT03679390|Experimental|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
11157097|NCT03679390|Experimental|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
11157098|NCT03679377|Experimental|Mandibular slotplate|Mandibular slotplates are placed during BSSO surgery and their clinical usefullness is tested. Afterwards the plates are removed and the osteotomy is fixated by three bicortical screws.
11157099|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
11157100|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
11157101|NCT03679338|Other|Ablation Therapy With Bipolar Radio Frequency|
11157102|NCT03679325|Active Comparator|vitamine D|a dose once a week
11157103|NCT03679325|Placebo Comparator|vitamine D placebo|a dose once a week
11157104|NCT03679312|Experimental|COPD Group|COPD to receive either placebo or inhaled nitric oxide (40ppm)
11157105|NCT03679312|Experimental|Control Group|Control group to receive either placebo or inhaled nitric oxide (40ppm)
11157106|NCT03679299||Healthy Control|Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
11157107|NCT03679299||Asthma|Individuals experiencing an asthma exacerbation will be recruited from the University of Alberta Hospital Emergency Department. Once discharged, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity. Participants will complete the same assessments at a follow up date 48 hours and 14 days post-discharge, with the addition of a full pulmonary function test, physical activity assessment via a Fitbit, and the completion of two questionnaires: Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire.
11157108|NCT03679286||All subjects|No intervention
11157146|NCT03679091|Active Comparator|clopidogrel|To observe the safety and efficacy between low-dose ticagrelor and standard-dose clopidogrel.
11157147|NCT03679078|Experimental|IDDSI nutritional supplement drink|Single arm designed, 28day on IDDSI nutritional supplement drink
11157109|NCT03679273|Experimental|Abound supplement|The participant will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
11157110|NCT03679273|No Intervention|Traditional supplement|The participant will take traditional diabetes-specific formula as provided by dietitians.
11157111|NCT03679260|Experimental|Arm A|Carbohydrate restricted diet and phone counseling with dietitian. After 6 months, patients will crossover to a non-restricted diet.
11157112|NCT03679260|Experimental|Arm B|Non-restricted diet and after 6 months, patients will crossover to a carbohydrate restricted diet and phone counseling with dietitian
11157113|NCT03679247|Experimental|Intervention|Intervention arm will receive guidance within electronic health record from clinical decision support system for the first phase of the study, after which they will continue providing usual care.
11157114|NCT03679247|Experimental|Control|The control arm will continue to provide usual care until the second phase of the study when they will begin to receive intervention.
11157115|NCT03679234|Experimental|Intervention|Routine infant formula
11157116|NCT03679221||Group 45-54 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
11157117|NCT03679221||Group 54-64 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
11157118|NCT03679221||Group 65-74 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
11157119|NCT03679221||Group 75-85 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
11157120|NCT03679208|Experimental|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
11157121|NCT03679208|Experimental|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
11157122|NCT03679208|Active Comparator|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
11157123|NCT03679195|Experimental|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
11157124|NCT03679195|Placebo Comparator|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
11157125|NCT03679182|Experimental|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
11157126|NCT03679169|Experimental|Group RAMPS|Radical antegrade modular pancreatosplenectomy
11157127|NCT03679169|Active Comparator|Group SPS|standard pancreatosplenectomy
11157128|NCT03679143|Experimental|ZSP1273(single dose)-100 mg(Cohort 1)|ZSP1273 100 mg /Placebo
11157129|NCT03679143|Experimental|ZSP1273(single dose)-200 mg(Cohort 2)|"ZSP1273 200mg/Placebo
~Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1."
11157130|NCT03679143|Experimental|ZSP1273(single dose)-400 mg(Cohort 3)|"ZSP1273 400mg/Placebo
~Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2."
11157131|NCT03679143|Experimental|ZSP1273(single dose)-600 mg(Cohort 4)|"ZSP1273 600 mg/Placebo
~Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3."
11157132|NCT03679143|Experimental|ZSP1273(single dose)-900 mg(Cohort 5)|"Drug:ZSP1273 900 mg/Placebo 900mg；
~Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4."
11157133|NCT03679143|Experimental|ZSP1273(single dose)-1200 mg(Cohort 6)|"ZSP1273 1200 mg/Placebo
~Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5."
11157134|NCT03679143|Experimental|ZSP1273(Food Effect)-Cohort 7|"Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.
~Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8."
11157135|NCT03679143|Experimental|ZSP1273(multiple doses)-Low Dose(Cohort 8)|"while fasted or fed according to the results of Cohort FE
~ZSP1273 /Placebo for 5 Days."
11157136|NCT03679143|Experimental|ZSP1273(multiple doses)-Median Dose(Cohort 9)|"while fasted or fed according to the results of Cohort FE
~ZSP1273/Placebo for 5 Days."
11157137|NCT03679143|Experimental|ZSP1273(multiple doses)-High Dose(Cohort 10)|"while fasted or fed according to the results of Cohort FE
~ZSP1273/Placebo for 5 Days."
11157138|NCT03679130|Experimental|Structured exercise training (EXE)|Structured supervised exercise training (EXE) contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
11157139|NCT03679130|Experimental|Motivational counseling (MOT)|Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
11157140|NCT03679130|No Intervention|Control group (CON)|Control group receiving standard treatment.
11157141|NCT03679117|Experimental|Mindfulness Training|Phone-delivered mindfulness training
11157142|NCT03679117|No Intervention|Treatment as Usual|Prenatal care
11157143|NCT03679104|Active Comparator|Endoscopic clips|Closure of mucosotomy using endoscopic clips
11157144|NCT03679104|Active Comparator|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
11157145|NCT03679091|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
11157148|NCT03679065|Active Comparator|P (Paracetamol) group:(n=100)|
11157154|NCT03679026||CVRF|individuals with cardio-vascular risk factors and diseases
11157155|NCT03679026||WCVRF|individuals without cardio-vascular risk factors and diseases
11157156|NCT03679013|Other|Opoid based standard of care regimen.|Inova Heart and Vascular Institute (IHVI) opioid based standard of care regimen given for post operative cardiac surgery pain.
11157157|NCT03679013|Experimental|Opioid sparing pain regimen.|Multimodal pain regimen consisting of PO Gabapentin paired with intravenous Acetaminophen given for post operative cardiac surgery pain.
11157158|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
11157159|NCT03678987||SSc on MMF|"Patients with systemic sclerosis using mycophenolate mofetil (mycophenolic acid, MMF) since >3 months.
~During a 6 hour time period, P-MPA concentration will be measured 4 times."
11157160|NCT03678974|Experimental|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
11157161|NCT03678961||Group N|Neutral position
11157162|NCT03678961||Group E|External rotation of leg by 45 degrees
11157163|NCT03678961||Group EF45|External rotation of leg by 45 degrees, hip flexion by 45 degrees, and knee flexion by 45 degrees
11157164|NCT03678961||Group EF15|External rotation of leg by 45 degrees, hip flexion by 15 degrees, and knee flexion by 15 degrees
11157165|NCT03678948|Active Comparator|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
11157166|NCT03678948|Active Comparator|Mechanical Debridement|
11157167|NCT03678935|Active Comparator|Low FODMAP diet (LFD)|The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
11157168|NCT03678935|No Intervention|Control|Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
11157169|NCT03678909||Hypoplastic Left Heart Disease|Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure
11157170|NCT03678896|Experimental|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.
~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.
~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
11157171|NCT03678896|Active Comparator|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.
~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.
~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
11157172|NCT03678883|Experimental|9-ING-41|Drug: 9-ING-41
11157173|NCT03678883|Experimental|9-ING-41 plus Gemcitabine|Drugs: Gemcitabine - 21 day cycle. 9-ING-41
11157174|NCT03678883|Experimental|9-ING-41 plus Doxorubicin|Drugs: Doxorubicin. 9-ING-41
11157175|NCT03678883|Experimental|9-ING-41 plus Lomustine|Drugs: Lomustine. 9-ING-41.
11157176|NCT03678883|Experimental|9-ING-41 plus Carboplatin|Drugs: Carboplatin. 9-ING-41.
11157177|NCT03678883|Experimental|9-ING-41 plus nab paclitaxel Gemcitabine|Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
11157178|NCT03678883|Experimental|9-ING-41 plus Paclitaxel/Carboplatin|Drugs: Paclitaxel. Carboplatin. 9-ING-41.
11157179|NCT03678883|Experimental|9-ING-41 plus Irinotecan|Drugs: Irinotecan. 9-ING-41.
11157180|NCT03678870|Experimental|Education|Opioid Education
11157181|NCT03678870|No Intervention|Control|standard discharge instructions, which lists medications prescribed at discharge
11157182|NCT03678857|Experimental|Creatine Before|
11157183|NCT03678857|Experimental|Creatine After|
11157184|NCT03678844|Experimental|Taekwondo practice|
11157185|NCT03678844|Placebo Comparator|CONTROL|
11157186|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
11157187|NCT03678818|Experimental|Handling Medium Supplemented with Latrunculin A|
11157188|NCT03678818|No Intervention|Handling Medium as it is.|
11157189|NCT03678805|Experimental|Acceleration|The impacted canines will undergo acceleration by corticotomy accompanied with traditional traction techniques.
11157190|NCT03678805|Active Comparator|Traditional Traction|"Traditional traction will be employed in this group of patients with impacted canines.
~Traditional withdrawal techniques will be used."
11157191|NCT03678792|Other|Buprenorphine-Naloxone|Standard of Care
11157192|NCT03678792|Experimental|Morphine|
11157193|NCT03678792|Experimental|Tramadol|
11157194|NCT03678779|Experimental|Incentive|Each week parents received one $5 grocery store gift card per child in the household, intended for the purchase of healthy snacks, donated to the study by a partnering grocery store
11157195|NCT03678779|Experimental|Education|Parents received brief weekly nutrition education videos (approximately one minute in length, uploaded on YouTube and viewable on most operating systems and on mobile devices
11157196|NCT03678779|Experimental|Combined|Parents received both the Incentive and Education arm interventions
11157197|NCT03678766|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experimental learning.
11157198|NCT03678766|Experimental|Cognitive Behavior Therapy (CBT)|CBT provides coping skills, self-monitoring, and goal setting.
11157199|NCT03678753|Experimental|Cenobamate|Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks
11157200|NCT03678753|Placebo Comparator|Placebo|Matching placebo
11157201|NCT03678714|Experimental|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
11157202|NCT03678714|Experimental|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
11157203|NCT03678714|No Intervention|Control|Resting control
11157204|NCT03678701|Experimental|Protein group|The protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
11157205|NCT03678701|No Intervention|Control group|Control group will not consume any protein supplements. They will continue the usual feeding habits
11157206|NCT03678688|Active Comparator|Stage 1 and Stage 2: RHEZ|
11157207|NCT03678688|Experimental|Stage 1 Cohort 1|
11157208|NCT03678688|Experimental|Stage 1 Cohort 2|
11157209|NCT03678688|Experimental|Stage 1 Cohort 3|
11157210|NCT03678688|Experimental|Stage 1 Cohort 4|
11157211|NCT03678688|Experimental|Stage 2: Low dose OPC-167832/delamanid|
11157212|NCT03678688|Experimental|Stage 2: High dose OPC-167832/delamanid|
11157213|NCT03678688|Active Comparator|Stage 2: delamanid|
11157214|NCT03678675|No Intervention|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain.
11157215|NCT03678675|Experimental|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 5 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room.
11157216|NCT03678662|Experimental|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
11157217|NCT03678662|Experimental|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
11157218|NCT03678662|Active Comparator|Neutral|In this group the subjects expectations are not manipulated
11157219|NCT03678649|Experimental|the treatment arm|"1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
~it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
11157220|NCT03678649|No Intervention|the control arm|clinical observation
11157221|NCT03678636|Experimental|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
11157222|NCT03678636|Active Comparator|Control|The wound will be treated as per usual care.
11157223|NCT03678623||Office-based workers|Individuals working in an office environment with their main tasks involving use of a computer, reading, phoning, making presentations and participating in meetings, who perform more than 30 hours per week mostly sitting at a computer.
11157224|NCT03678610|Experimental|ICSI medium supplemented with Ionomycin and Latrunculin A|
11157225|NCT03678610|No Intervention|ICSI medium as it is|
11157226|NCT03678597|Experimental|Handling Medium Supplemented with Latrunculin B|
11157227|NCT03678597|No Intervention|handling Medium as it is.|
11157228|NCT03678584|Experimental|Handling Medium Supplemented with Chaetoglobosin A|
11157229|NCT03678584|No Intervention|handling Medium as it is.|
11157230|NCT03678571|Experimental|Latrunculin A supplemented vitrification medium|
11157231|NCT03678571|No Intervention|Vitrification medium with no supplementation|
11157232|NCT03678558|Experimental|Cytochalasin B supplemented vitrification medium|
11157233|NCT03678558|No Intervention|Vitrification medium with no supplementation|
11157234|NCT03678545|Active Comparator|Dupilumab|
11157235|NCT03678545|Placebo Comparator|Placebo|
11157236|NCT03678532|Experimental|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
11157237|NCT03678532|Experimental|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
11157238|NCT03678519||Exposed workers|Flour mills workers exposed to health hazards
11157239|NCT03678506|Experimental|Positive D-Dimer|At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
11157240|NCT03678506|No Intervention|Negative D-Dimer|Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.
11157241|NCT03678493|Experimental|AML Patients undergoing Intensive Chemothera|
11157242|NCT03678493|Placebo Comparator|AML Patients undergoing Intensive Chemotherapy Control|
11157243|NCT03678493|Experimental|AML Patients undergoing Allo-HCT Patients|
11157244|NCT03678493|Placebo Comparator|AML Patients undergoing Allo-HCT Patients Control|
11157245|NCT03678480|Experimental|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
11157246|NCT03678480|Active Comparator|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
11157247|NCT03678467|Experimental|EB-CMF Implant|Subject receiving EB-CMF implant
11157248|NCT03678441|Experimental|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
11157249|NCT03678441|Active Comparator|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
11157250|NCT03678428|Experimental|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:
~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
11157251|NCT03678428|Active Comparator|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:
~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
11157252|NCT03678415|Experimental|Control|In the control arm, the community healthcare providers serve usual health education like counseling as they provided in perinatal period of enrolled mothers regular follow up basis. This health education is different from developed intervention. But service provider does not know. The investigators select community clinic before provide training regarding training manual. For this, the investigators selected 11 cluster randomly among the 23 community clinics' in the primary health care in study area and provide common health education instructions to the enrolled mothers. But service providers does not know the intervention package services that will provide in intervention arm's service providers.
11157253|NCT03678402|Experimental|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
11157254|NCT03678389|Experimental|1|ENDOSPHENOIDAL COIL
11157255|NCT03678376|Other|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
11157256|NCT03678363|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
11157257|NCT03678363|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
11157258|NCT03678350|Experimental|Treatment (porfimer sodium, IO-PDT)|Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.
11157259|NCT03678337||Observational cohort with plasma samples|
11157260|NCT03678324|Other|Fabry|Must be 18 or older and able to have an MRI.
11157261|NCT03678311|Other|Sleep Apnea ahi > 5|If Sleep Apnea index is > 5 and diagnosed with Long QT Syndrome
11157262|NCT03678285|Experimental|HIFRT Workout|Consecutive completion of; 1 mile run, 100 pull ups, 200 push-ups, 300 bodyweight squats, 1 mile run.
11157263|NCT03678272|Active Comparator|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
11157264|NCT03678272|Active Comparator|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
11157265|NCT03678272|Active Comparator|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
11157266|NCT03678272|Active Comparator|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
11157267|NCT03678259|Experimental|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
11157268|NCT03678246|Experimental|LSFOI (Ramped)|LSFOI (Ramped)
11157269|NCT03678246|Active Comparator|LSFOI (Supine)|LSFOI (Supine)
11157270|NCT03678233|Active Comparator|Intervention|AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
11157271|NCT03678233|No Intervention|Control|In the control group, AndroGel will not be administered.
11157272|NCT03678220|Experimental|Patients using LapAR system|
11157273|NCT03678207||Potential Undiagnosed HTN|
11157274|NCT03678194|Experimental|Smartphone application|This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
11157275|NCT03678194|No Intervention|Standard services|This group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.
11157276|NCT03678181|Active Comparator|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
11157314|NCT03677960|Experimental|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
11157277|NCT03678181|Experimental|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question & answer platform.
11157278|NCT03678181|Experimental|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
11157279|NCT03678168|Other|Control|Standard care (Throat pack) which will be used as a control.
11157280|NCT03678168|Experimental|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
11157281|NCT03678155|Active Comparator|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
11157282|NCT03678155|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
11157283|NCT03678129|Experimental|Placebo, AZD7325_10, AZD7325_20|Dose order: Placebo, AZD7325 10mg, AZD7325 20mg
11157284|NCT03678129|Experimental|Placebo, AZD7325_20, AZD7325_10|Dose order: Placebo, AZD7325 20mg, AZD7325 10 mg
11157285|NCT03678129|Experimental|AZD7325_20, Placebo, AZD7325_10|Dose order: AZD7325 20mg, Placebo, AZD7325 10mg
11157286|NCT03678129|Experimental|AZD7325_10, Placebo, AZD7325_20|Dose order: AZD7325 10mg, Placebo, AZD7325 20mg
11157287|NCT03678129|Experimental|AZD7325_10, AZD7325_20, Placebo|Dose order: AZD7325 10mg, AZD7325 20mg, Placebo
11157288|NCT03678129|Experimental|AZD7325_20, AZD7325_10, Placebo|Dose order: AZD7325 20mg, AZD7325 10mg, Placebo
11157289|NCT03678116|Placebo Comparator|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
11157290|NCT03678116|Experimental|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
11157291|NCT03678116|Experimental|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
11157292|NCT03678090|Active Comparator|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
11157293|NCT03678090|Experimental|tPA low dosage|tPA dose of 2.5mg
11157294|NCT03678077||Mild traumatic brain injury|"Patients between 18-60 years, who were hospital admitted, emergency or outpatient treated with mild traumatic brain injury (ICD-10 S06.0). Data were extracted from the Danish national patient register from January 2003 - December 2007.
~Patients who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
11157295|NCT03678077||Matching controls|"Matching controls without concussion of the same age, from the same municipality and of same gender as the included cases. Controls were included during 2003 - 2007. Data were extracted from the population register.
~Controls who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
11157296|NCT03678064|Experimental|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
11157297|NCT03678051|Active Comparator|Treatment as Usual (TAU)|Standard of care
11157298|NCT03678051|Experimental|TAU+CBT4CBT|TAU with access to the CBT4CBT program
11157299|NCT03678038|Experimental|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
11157300|NCT03678038|Active Comparator|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
11157301|NCT03678025|Active Comparator|Arm I (SST)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone.
11157302|NCT03678025|Experimental|Arm II (SST, prostatectomy or radiation therapy)|Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization.
11157303|NCT03678025|Active Comparator|Step 1 (pre-randomization)|Standard treatment data collection prior to randomization
11157304|NCT03678012|Active Comparator|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
11157305|NCT03678012|Placebo Comparator|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
11157306|NCT03678012|Sham Comparator|Water|Sham solution (water; negative control)
11157307|NCT03677999||Brain tumor patients with Glioma|"Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.
~Passed the safety screen for MRI
~Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
11157308|NCT03677986|No Intervention|Usual Care|Participants in this group will be referred to receive office-based buprenorphine treatment
11157309|NCT03677986|Experimental|Video DOT+|Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
11157310|NCT03677973|Active Comparator|Active: Dose Escalation|Healthy volunteers will receive AB680 as a single intravenous (IV) infusion at 7 dose levels and as multiple IV infusions at 1 dose level. Assignment to receive AB680 or matching placebo will be random.
11157311|NCT03677973|Placebo Comparator|Placebo: Dose Escalation|Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
11157312|NCT03677960|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
11157313|NCT03677960|Experimental|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
11157315|NCT03677947|Active Comparator|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning and overvalued ideas. IBCT does not include exposure, but aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
11157316|NCT03677947|Active Comparator|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, patients will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention).
11157317|NCT03677934|Experimental|PDS Implant Arm|Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
11157318|NCT03677934|Active Comparator|Intravitreal Arm|Participants will receive ranibizumab 0.5 mg monthly intravitreal injections of 10 mg/mL formulation at Day 1 and every month thereafter.
11157319|NCT03677921|Experimental|Investigational Group- Bio-Germanium|"Ingredient: Bio-Germanium
~Type: HPMC capsule
~Weight: 300mg/capsule
~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)
~Duration of use: 8 weeks"
11157320|NCT03677921|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Corn starch
~Type: HPMC capsule
~Weight: 300mg/capsule
~Directions: 2 capsules, twice a day
~Duration of use: 8 weeks"
11157321|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
11157322|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
11157323|NCT03677895|Experimental|patients with rotator cuff disorders|patients with rotator cuff disorders, including impingment, rotator cuff disorders and rotator cuff tear receiving hyaluronic acid injection over subacromial bursa
11157324|NCT03677882|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
11157325|NCT03677882|Experimental|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator.
11157326|NCT03677869|Experimental|Intraocular gas (C3F8) injection|"Informed consent will be obtained.
~Eligibility will be assessed, including reading center confirmation of VMT and MH on OCT.
~Eligible eyes with VMT and MH will be treated with C3F8 injection.
~Follow-up visits will occur at 1, 4, 8, and 24 weeks and consist of visual acuity testing, ocular exam, and OCT."
11157327|NCT03677856|Experimental|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
11157328|NCT03677856|Active Comparator|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
11157329|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
11157330|NCT03677830|Active Comparator|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; >39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
11157331|NCT03677830|Placebo Comparator|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
11157332|NCT03677817|Active Comparator|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
11157333|NCT03677817|Placebo Comparator|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
11157334|NCT03677791|Experimental|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
11157335|NCT03677791|Active Comparator|Control group|counselling in accordance with current practice
11157336|NCT03677778|Placebo Comparator|Placebo group|This control group will have no normal saline injected into their nerve catheter (no intervention). This group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
11157337|NCT03677778|Active Comparator|Treatment group|This group will have 30ml normal saline injected into their nerve catheter. The treatment group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
11157338|NCT03677765|Active Comparator|Infraclavicular group|In the infraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle.
11157339|NCT03677765|Active Comparator|Supraclavicular group|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
11157340|NCT03677752|Experimental|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
11157341|NCT03677752|No Intervention|Control|Participants in the control arm will receive usual care.
11157342|NCT03677739|Experimental|Arm 1 Young melanoma Family Facebook focusing on skin cancer|Participants join a secret Young melanoma Family Facebook Group and view post messages focusing on skin cancer for 12 weeks.
11157343|NCT03677739|Experimental|Arm 2 Healthy Lifestyle Facebook focusing on healthy lifestyle|Participants join a secret Healthy Lifestyle Facebook Group and view post messages focusing on healthy lifestyle for 12 weeks.
11157344|NCT03677726|Experimental|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
11157345|NCT03677726|Active Comparator|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
11157346|NCT03677713|Active Comparator|Nasal Packing|Nasal packing will be placed at the end of surgery.
11157347|NCT03677713|Experimental|No Nasal Packing|No nasal packing will be placed during or after the surgery.
11157348|NCT03677687|Experimental|Mindfulness for Physical Activity|A 6-week mindfulness programme (2 hours per week) aimed at increasing physical activity in underactive participants.
11157349|NCT03677674|Experimental|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
11157350|NCT03677674|No Intervention|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
11157351|NCT03677661|Active Comparator|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
11157352|NCT03677661|Experimental|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
11157353|NCT03677648|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 24.
11157354|NCT03677648|Experimental|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 24.
11157355|NCT03677648|Experimental|SHR0302 dose C|Participants randomized in this arm will receive dose C of SHR0302 until end of study at week 24.
11157356|NCT03677648|Placebo Comparator|Placebo|Participants randomized in this arm will receive placebo until week 12, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 24.
11157357|NCT03677635|Experimental|Intervention|Guided autobiographical memory recall to enhance specificity and links to the future.
11157358|NCT03677635|No Intervention|Control|Recall without prompts or psychoeducation video.
11157359|NCT03677622|Experimental|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:
~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.
~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
11157360|NCT03677622|Active Comparator|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.
~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.
~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.
~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.
~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
11157361|NCT03677609|Experimental|Intervention|Physicians will receive a training or trainings to improve their communication and interaction with patients. The primary trainings will involve teaching physicians how to understand and leverage patient psychology as part of clinical care. Impact on patient health will then be assessed.
11157362|NCT03677609|No Intervention|Control|
11157363|NCT03677596|Experimental|Dose Level 2|Inotuzumab ozogamicin at starting dose 1.2 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
11157364|NCT03677596|Active Comparator|Dose Level 1|Inotuzumab ozogamicin at starting dose 1.8 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
11157365|NCT03677583|Experimental|Duckweed|daily lunch with 150-180g wet weight duck weed
11157366|NCT03677583|Active Comparator|Spinach|daily lunch with 150-180g wet weight spinach
11157367|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
11157368|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
11157369|NCT03677557|Other|Cutaquig Intervention|Participants with primary or secondary immunodeficiency disease who are currently on subcutaneous immunoglobulin treatment but have developed adverse events including allergic reaction and are willing to change the treatment product to 16.5% Cutaquig.
11157370|NCT03677544||exploratory cohort (A)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
11157371|NCT03677544||exploratory cohort (B)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
11157372|NCT03677531|Experimental|Other (radiation therapy, videos)|Participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.
11157373|NCT03677505|Experimental|KoMAC group|Orotracheal intubation with KoMAC videolaryngoscope
11157374|NCT03677505|Active Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscope
11157375|NCT03677492|Experimental|Handling Medium Supplemented with Cytochalasin D|
11157376|NCT03677492|No Intervention|Handling Medium as it is.|
11157377|NCT03677479|Experimental|socket preservation with camelline bone|natural hydroxyapatite derived from camels prepared by investigator
11157378|NCT03677479|Active Comparator|socket preservation with bovine bone|natural hydroxyapatite derived from cows (Bio-Oss)
11157379|NCT03677466|Experimental|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
11157380|NCT03677466|Active Comparator|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
11157381|NCT03677453|Active Comparator|IPTP|Patients will have access to the web-based interactive teaching tool.
11157382|NCT03677453|No Intervention|Non-IPTP|Patients will not have access to the web-based interactive teaching tool.
11157383|NCT03677440|Experimental|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.
~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
11157384|NCT03677440|Active Comparator|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
11157385|NCT03677427|Experimental|5 fractions|
11157386|NCT03677427|Experimental|15 fractions|
11157387|NCT03677401|Experimental|5 mg Serlopitant Tablets|
11157388|NCT03677401|Placebo Comparator|Matching Placebo Tablets|
11157389|NCT03677375|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
11157390|NCT03677362|Experimental|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
11157391|NCT03677349|Experimental|Resensitized group|Patients with resensitized free flap by neurorrhaphy
11157392|NCT03677349|Experimental|Non Resensitized group|Patients without resensitized free flap by neurorrhaphy.
11157393|NCT03677336|Other|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 3 to 6 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.
~1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.
~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
11157394|NCT03677336|Other|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 3 to 6 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.
~1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.
~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
11157395|NCT03677323|Experimental|Virtual reality|The virtual reality device will consist of the virtual reality headset and headphones for full immersion.
11157396|NCT03677323|Active Comparator|Drug sedation|The sedation group will benefit from drug sedation used in current practice, that is to say an association of Sufentanil, Droleptan and Propofol.
11157397|NCT03677310|Experimental|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
11157398|NCT03677310|Sham Comparator|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
11157399|NCT03677297|Experimental|ROSUVASTATIN|1.2% Rosuvastatin Gel. Insertion in infrabony defects once
11157400|NCT03677297|Placebo Comparator|placebo|No intervention used on control site
11157401|NCT03677284|Experimental|Intervention group|"Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
~Time assistive product. Time assistive products for time perception are products making the passage of time visible and understandable, to know for how long to perform an activity or how long to wait until the next activity starts e.g a time log.
~Time assistive products for time orientation includes the use of schedules, calendars and other visual aids to promote orientation to the time of the day, week, or year.
~Time assistive products for time management would compensate for deficits in time management and focus on self-scheduling skills."
11157402|NCT03677284|Active Comparator|Control group|Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
11157403|NCT03677271|Other|Physical Activity|
11157404|NCT03677258|Experimental|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
11157405|NCT03677258|Active Comparator|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
11157406|NCT03677245|Experimental|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
11157407|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
11157408|NCT03677219|No Intervention|Control|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, and do not view an educational video.
11157409|NCT03677219|Experimental|Video|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, then view a 2 minute educational video and respond to a second survey.
11157410|NCT03677206|Sham Comparator|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
11157411|NCT03677206|Experimental|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
11157412|NCT03677206|Other|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
11157413|NCT03677193|Experimental|Experimental arm|
11157414|NCT03677167|Experimental|walking on a treadmill barefoot group|26 Patients in this group will walk barefoot on the treadmill and will be asked to walk barefoot at home and report the time of barefoot walking at home
11157415|NCT03677167|Active Comparator|Walking on a treadmill with shoes group|26 Patients in this group will walk with shoes on the treadmill
11157416|NCT03677154|Experimental|Consolidation Therapy Dose-Finding|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
11157417|NCT03677154|Experimental|Consolidation Therapy Expansion Cohort|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab at the recommended consolidation dose (RCD) determined in the dose-finding stage.
11157418|NCT03677154|Experimental|Previously Untreated DLBCL Safety Cohort|Participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
11157419|NCT03677154|Experimental|Previously Untreated DLBCL|Participants with previously untreated DLBCL will receive mosunetuzumab up to the dose confirmed by the safety cohort.
11157420|NCT03677141|Experimental|Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding|Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
11157421|NCT03677141|Experimental|Phase Ib: M-CHP-Pola Dose-Finding|Participants will receive M-CHP-Pola up to the RP2D.
11157422|NCT03677141|Experimental|Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort|Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
11157423|NCT03677141|Experimental|Phase II: M-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
11157424|NCT03677141|Active Comparator|Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL|Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
11157425|NCT03677141|Experimental|Phase II: M-CHOP 1L DLBCL|Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage.
11157426|NCT03677128|Experimental|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
11157427|NCT03677128|No Intervention|Historical controls|BL/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL and Rb were introduced at BMC.
11157428|NCT03677115|Experimental|dexmedetomidine group|a combination of ropivacaine and dexmedetomidine
11157429|NCT03677102|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
11157430|NCT03677102|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
11157431|NCT03677089|Experimental|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
11157432|NCT03677076||Ancillary/Correlative|Patients will complete questionnaires and have research blood drawn.
11157463|NCT03676881||Cognitively normal subjects (CN)|30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
11157464|NCT03676855|Active Comparator|bladder dissection before uterine incision|
11157465|NCT03676855|Experimental|bladder dissection after uterine incision|
11157466|NCT03676842|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
11157699|NCT03675256|Active Comparator|Arm 3|immediate MenVeo, delayed Gardasil 9 vaccine
11157433|NCT03677063|No Intervention|Dressing|"It is the historical cohort which is composed of patients over 18 years of age treated by peritoneal dialysis in the nephrology department of Universty Hospital of Caen Normandie. Patients with the same non-inclusion criteria as the experimental group will not be included. The data will be extracted from the Registry of Peritoneal Dialysis of French Language. The number of patients included from the register can not be fixed in advance; this number will correspond to the 4-year follow-up at the start date of the study to ensure at least two years of patient follow-up
~Usually care
~First dressing 5 or 10 days after the pose of the catheter :
~Cleaning emergence with antiseptic soap
~Rinsing with saline
~Drying
~Application of a hazelnut mupirocin on the exit-site
~Application of an occlusive dressing on the exit-site Then, care is the same. Exit-site care is performed daily if the patient takes a shower or twice a week."
11157434|NCT03677063|Experimental|No dressing|No application of sterile dressing at the exit-site of periotoneal dialysis catheter for all patients (30 days after the placement of the peritoneal dialysis catheter)
11157435|NCT03677050|No Intervention|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
11157436|NCT03677050|Experimental|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
11157437|NCT03677037|Experimental|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
11157438|NCT03677037|Active Comparator|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
11157439|NCT03677024|Experimental|SLN arm|"Experimental:
~Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.
~Full bilateral laparoscopic lymphadenectomy and hysterectomy:
~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.
~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.
~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
11157440|NCT03677024|No Intervention|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
11157441|NCT03677011|Other|category 1|Low responder
11157442|NCT03677011|Other|category 2|Medium Responder and High Responder
11157443|NCT03676998|Other|Measurement of diaphragm function|Patients will be followed up from admission to weaning with twice a week a diaphragm function multimodal evaluation (ultrasound, phrenic nerves stimulation technique)
11157444|NCT03676985|Experimental|ZKAB001 5 mg/kg/time|Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
11157445|NCT03676985|Experimental|ZKAB001 10 mg/kg/time|Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
11157446|NCT03676985|Experimental|ZKAB001 15 mg/kg/time|Three or six patients will treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
11157447|NCT03676972|Experimental|LithoVue ureteroscope system|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
11157448|NCT03676959|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
11157449|NCT03676959|Experimental|ZKAB001 10 mg/kg|Three or six patients will be treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
11157450|NCT03676959|Experimental|ZKAB001 15 mg/kg|Three or six patients will be treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
11157451|NCT03676946|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
11157452|NCT03676946|Experimental|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
11157453|NCT03676946|Experimental|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
11157454|NCT03676933|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
11157455|NCT03676933|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
11157456|NCT03676920|Experimental|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
11157457|NCT03676907|No Intervention|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
11157458|NCT03676907|Experimental|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
11157459|NCT03676894|Sham Comparator|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
11157460|NCT03676894|Active Comparator|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
11157461|NCT03676894|Experimental|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
11157462|NCT03676881||Mild Cognitive Impairment (MCI)|30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
11157582|NCT03676010||Breast cancer|
11157583|NCT03676010||Pancreatic cancer|
11157584|NCT03676010||Renal cell carcinoma|
11157467|NCT03676829|Experimental|Arterial Embolization of the Shoulder (AES)|Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
11157468|NCT03676816|Experimental|Vaginal self-sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
11157469|NCT03676816|Active Comparator|Provider-performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
11157470|NCT03676803|Experimental|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
11157471|NCT03676803|Placebo Comparator|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
11157472|NCT03676790|Experimental|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
11157473|NCT03676790|Experimental|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
11157474|NCT03676790|Experimental|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
11157475|NCT03676790|Experimental|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
11157476|NCT03676790|Experimental|Group V|(patients received only exercise sessions three times a week for eight weeks)
11157477|NCT03676777||Infection|Patients admitted or developed bacterial/fungal infection while hospitalization
11157478|NCT03676777||Non-infection|Patients without bacterial/fungal infection
11157479|NCT03676764|Active Comparator|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
11157480|NCT03676764|Placebo Comparator|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
11157481|NCT03676764|Placebo Comparator|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
11157482|NCT03676764|Active Comparator|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
11157483|NCT03676751|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
11157484|NCT03676751|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
11157485|NCT03676738||In-patient spine surgery|Scheduled for an in-patient, elective spine surgery where subject will receive general anesthesia
11157486|NCT03676738||Non-surgical spine care|Presenting to spine clinic and undergoing conservative, non-surgical management of spine disorder
11157487|NCT03676725|Experimental|General population|Subjects will be tested with lidocaine gel.
11157488|NCT03676712|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
11157489|NCT03676686|Experimental|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
11157490|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
11157491|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
11157492|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
11157493|NCT03676647||Diagnostic (biospecimen collection)|Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay.
11157494|NCT03676634|Experimental|Vaccine|rBV A/B
11157495|NCT03676621|Experimental|study group|patients will receive buccal misoprostol
11157496|NCT03676621|Active Comparator|control group|patients will receive intravenous oxytocin
11157497|NCT03676608|Experimental|Bee wax mammary areolae|"Usual educational care plus the product.
~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
11157498|NCT03676608|Active Comparator|Control|Usual educational care.
11157499|NCT03676595|Experimental|Group A|Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
11157500|NCT03676595|Experimental|Group B|Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
11157501|NCT03676569|Experimental|Experimental group|Autologous ADRC transplantation in autoimmune refractory epilepsy
11157502|NCT03676556|Active Comparator|Topical lidocaine|23 patients will recieve lidocaine solution before wound treatment
11157503|NCT03676556|Placebo Comparator|Saline serum|23 patients will recieve saline solution before wound treatment
11157504|NCT03676543|Experimental|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
11157505|NCT03676530|No Intervention|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
11157506|NCT03676530|Experimental|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
11157585|NCT03676010||Colon Cancer (adjuvant setting)|
11157586|NCT03676010||Solid tumours undergoing image-guided tumor ablation|
11157507|NCT03676517|Experimental|Preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
11157508|NCT03676504|Experimental|Stratum I|Adult patients with relapsed or refractory ALL
11157509|NCT03676504|Experimental|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
11157510|NCT03676504|Experimental|Stratum III|Pediatric patients with relapsed or refractory ALL
11157511|NCT03676491|Experimental|Experimental Group|"Music Intervention: Participants listen to music minimum 30 minutes at bedtime for a period of 4 weeks wearing accelerometer.
~Participants are monitored for a 4 week follow up period wearing accelerometer"
11157512|NCT03676491|No Intervention|Waitlist Control Group|"No intervention: Participants are monitored for a period of 4 weeks wearing accelerometer.
~Participants are monitored for a 4 week follow up period wearing accelerometer."
11157513|NCT03676478|No Intervention|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
11157514|NCT03676478|Active Comparator|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of 4.000 kCal in the immediate postoperative course.
11157515|NCT03676465|Experimental|Experimental Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will receive a weekly CloudConnect Report based on analysis of the weekly data gathered for each participant. The report will be sent via email once a week to both the subject and their parent(s). Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:
~the communication within the family about the information shared in this report
~how subjects feel when blood sugar is high or low
~who takes responsibility of how diabetes care is managed"
11157516|NCT03676465|Active Comparator|Control Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will not receive a CloudConnect Report. Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:
~the communication within the family about the information shared in this report
~how subjects feel when blood sugar is high or low
~who takes responsibility of how diabetes care is managed"
11157517|NCT03676452|Experimental|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
11157518|NCT03676452|No Intervention|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
11157519|NCT03676439|Active Comparator|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
11157520|NCT03676439|Placebo Comparator|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
11157521|NCT03676426|Experimental|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
11157522|NCT03676426|Active Comparator|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
11157523|NCT03676413|Experimental|Test (T)|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals
11157524|NCT03676413|Active Comparator|Reference (R)|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
11157525|NCT03676413|Placebo Comparator|Placebo|
11157526|NCT03676400|Experimental|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.
~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
11157527|NCT03676400|Placebo Comparator|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
11157528|NCT03676387|No Intervention|Aged based group (group AB) (n = 27)|ETT size was determined according to age
11157529|NCT03676387|Active Comparator|Ultrasound based group (group UB) (n = 27): ETT was determined|ETT was determined according to the subglottic transverse diameter that was estimated with ultrasonography.
11157530|NCT03676374|Experimental|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
11157531|NCT03676374|Placebo Comparator|Placebo|Placebo once a day as add-on for PPI 2x/d
11157532|NCT03676361|Experimental|Desmopressin|All ten subjects will be evaluated pre and post nephrectomy at 6 months.
11157533|NCT03676335|Experimental|0.3 g: 0.15 mg（1)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
11157534|NCT03676335|Experimental|0.3 g: 0.15mg（2)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
11157535|NCT03676335|Experimental|0.3 g: 0.3 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
11157806|NCT03674489|Active Comparator|Neurodynamic Slider Mobilization|
11157536|NCT03676335|Active Comparator|0.4 ml: 0.2 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
11157537|NCT03676322|Experimental|Part A: M5049|
11157538|NCT03676322|Placebo Comparator|Part A: Placebo|
11157539|NCT03676322|Experimental|Part B: M5049|
11157540|NCT03676322|Placebo Comparator|Part B: Placebo|
11157541|NCT03676322|Experimental|Part C: M5049|
11157542|NCT03676309|Placebo Comparator|placebo|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
11157543|NCT03676309|Active Comparator|nutraceutical oral capsule|nutraceutical oral capsule 920 mg twice a day for 12 weeks
11157544|NCT03676296|Experimental|Puerarin|Puerarin (90.2 mg daily) in granules
11157545|NCT03676296|Placebo Comparator|Placebo|Placebo in granules
11157546|NCT03676283|Experimental|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
11157547|NCT03676244|Experimental|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
11157548|NCT03676231|Experimental|High-dose SGM-1019|
11157549|NCT03676231|Experimental|Low-dose SGM-1019|
11157550|NCT03676231|Placebo Comparator|Placebo|
11157551|NCT03676218||Elderly cancer patients|
11157552|NCT03676205|Experimental|Platelet-Rich Plasma|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 6-7 ml of PRP .
~After 4-5 days from the injury the patient starts physiotherapy adapted by stages, according to the muscular group affected.
~After 7 days from the first infiltration, the patient will recived the second infiltration of 6-7 ml of PRP."
11157553|NCT03676205|Other|Traumel ®|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 4 ml of a homeopathic product (Traumeel ®) After 4-5 days from the date of injury, the patient starts physiotherapy adapted by stages, according to the muscular group affected.
~After 7 days from the first infiltration, the patient will receive the second infiltration of 4 ml of a homeopathic product."
11157554|NCT03676192|Experimental|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
11157555|NCT03676192|Active Comparator|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
11157556|NCT03676179|Active Comparator|unicompartment knee arthroplasty and patella denervation|UKA and patella denervation
11157557|NCT03676179|Experimental|unicompartment knee arthroplasty and patella non-denervation|UKA and patella non-denervation
11157558|NCT03676166|Experimental|0mg THC smoked cannabis|placebo smoked cannabis
11157559|NCT03676166|Experimental|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
11157560|NCT03676166|Experimental|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
11157561|NCT03676166|Experimental|0mg THC vaporized cannabis|placebo vaporized cannabis
11157562|NCT03676166|Experimental|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
11157563|NCT03676166|Experimental|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
11157564|NCT03676153|Experimental|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
11157565|NCT03676153|Active Comparator|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
11157566|NCT03676140|Active Comparator|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
11157567|NCT03676140|Experimental|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
11157568|NCT03676127||Study Group|ultrasonographic dermal thickness measurements in patients with unilateral breast cancer related lymphedema
11157569|NCT03676114|Experimental|ketamine group|
11157570|NCT03676114|Placebo Comparator|normal saline group|
11157571|NCT03676101|Experimental|9-valent HPV Recombinant Vaccine|
11157572|NCT03676101|Placebo Comparator|Placebo|
11157573|NCT03676088|Experimental|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
11157574|NCT03676088|Active Comparator|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
11157575|NCT03676062|Active Comparator|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
11157576|NCT03676062|Active Comparator|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
11157577|NCT03676062|Active Comparator|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked&progressed in each control sessions.
11157578|NCT03676036|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
11157579|NCT03676036|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
11157580|NCT03676023||Pulmonary Hemorrhage|Patients treated for pulmonary hemorrhage with inhaled Transexamic Acid
11157581|NCT03676010||Sarcoma and GIST|
11157587|NCT03675997||Autografted patients|Patients hospitalized in the hematological department of the Institute will complete the first day of conditioning and then weekly HAD (Hospital Anxiety and Depression) scale.
11157588|NCT03675984|Experimental|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
11157589|NCT03675971|Experimental|Medical Cannabis|Drug: Cannabidiol
11157590|NCT03675971|Placebo Comparator|Placebo|Placebo comparator
11157591|NCT03675958|Experimental|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
11157592|NCT03675958|Active Comparator|GS|Control group (GS): Just Stretching in 4 different treatment postures.
11157593|NCT03675932|Experimental|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
11157594|NCT03675919|Active Comparator|Control group|The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.
11157595|NCT03675919|Experimental|TeLIPro group|The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.
11157596|NCT03675906||preoperative albumin levels <3.8|
11157597|NCT03675906||preoperative albumin level >3.8|
11157598|NCT03675906||postoperative Day 2 albumin level <2.9|
11157599|NCT03675906||postoperative Day 2 albumin level >2.9|
11157600|NCT03675893|Experimental|Cohort 1A|"Abemaciclib is administered by mouth twice daily
~Letrozole is administered by mouth once daily"
11157601|NCT03675880|Experimental|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
11157602|NCT03675880|Experimental|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
11157603|NCT03675880|Experimental|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
11157604|NCT03675880|Experimental|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
11157605|NCT03675880|Experimental|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
11157606|NCT03675880|Experimental|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
11157607|NCT03675867||Obese teenagers|
11157608|NCT03675854|Experimental|Extended Group|3 weeks of antibiotics
11157609|NCT03675854|Active Comparator|Conventional Group|2 weeks of antibiotics
11157610|NCT03675841|Experimental|0.1% single-dose pre|Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
11157611|NCT03675841|Experimental|0.1% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
11157612|NCT03675841|Experimental|0.3% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose
11157613|NCT03675841|Experimental|0.5% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose
11157614|NCT03675828|Experimental|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
11157615|NCT03675828|No Intervention|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
11157616|NCT03675815|Active Comparator|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
11157617|NCT03675815|Experimental|Dolutegravir + TDF + either 3TC or FTC|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
11157618|NCT03675815|Experimental|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
11157619|NCT03675802|Active Comparator|Arm number one ,misoprostol|
11157620|NCT03675802|Active Comparator|Arm number 2 dinoprostone|
11157621|NCT03675789||STEMI|50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
11157622|NCT03675789||Stable angina|50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
11157623|NCT03675789||Controls|50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
11157624|NCT03675776|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
11157625|NCT03675776|Experimental|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
11157626|NCT03675776|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration).
11157627|NCT03675763|Experimental|Craniosacral therapy|Craniosacral therapy and parent information on how to manage colic.
11157628|NCT03675763|No Intervention|Parent information|Parent information on how to manage colic.
11157629|NCT03675737|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
11157667|NCT03675438|Experimental|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
11157630|NCT03675737|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
11157631|NCT03675724|Experimental|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
11157632|NCT03675724|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
11157633|NCT03675711|Active Comparator|Midline Catheter|Pt. will receive midline catheters.
11157634|NCT03675711|Active Comparator|Standard Peripheral venous Catheter|Pt. will receive a standard Peripheral venous catheter
11157635|NCT03675685|Experimental|CCH (Collagenase clostridium histolyticum)|
11157636|NCT03675672|Active Comparator|Group 1|Misoprostol Oral tablet, 200mcg, QID
11157637|NCT03675672|Placebo Comparator|Group 2|Placebo Oral Tablet, 1 tab, QID
11157638|NCT03675659|Active Comparator|intra-articular injection|intra-articular injection with magnesium sulfate at weekly interval for four weeks
11157639|NCT03675659|Placebo Comparator|control|intra-articular injection with saline
11157640|NCT03675646|Experimental|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
11157641|NCT03675646|No Intervention|Control group C|No intervention
11157642|NCT03675633||FEUrea in decompensated liver cirrhosis|FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS
11157643|NCT03675620|Active Comparator|Standard Rehabilitation (Control Group)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
11157644|NCT03675620|Experimental|Blood Flow Restriction (BFR)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to the BFR group will begin combining BFR with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for the first 6 weeks post-operative care. Standard rehabilitation will continue until discharge.
11157645|NCT03675607||Caregivers infants <2years old|Caregivers of infants under 2 years of age (parents or other), of any gender, who prepare complementary feeding regularly (more than once a week).
11157646|NCT03675594|Experimental|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
11157647|NCT03675594|Experimental|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
11157648|NCT03675581|Experimental|All subjects|
11157649|NCT03675568|Experimental|study group|Non-Cultured autologous keratinocyte suspension
11157650|NCT03675568|Active Comparator|Control group|Split skin Graft
11157651|NCT03675555|Active Comparator|M (Mirtazapine) (Merta) group:(n=100)|
11157652|NCT03675555|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
11157653|NCT03675555|Placebo Comparator|C (Control) group: (n=100)|
11157654|NCT03675542|Experimental|Study medication|HSP90 inhibitor (CUDC-305)
11157655|NCT03675529|Experimental|High Intensity Interval Training bout|Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
11157656|NCT03675529|No Intervention|Controls (usual care)|Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
11157657|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
11157658|NCT03675516||Controls|Age, gender and primary care practice-matched controls
11157659|NCT03675503|No Intervention|Control|No change in the standard of care.
11157660|NCT03675503|Experimental|Fall Prevention Decision Support|"Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.
~Decision support aimed at preventing hospital falls and empowering nurses."
11157661|NCT03675490|Experimental|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
11157662|NCT03675477|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 16.
11157663|NCT03675477|Active Comparator|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 16.
11157664|NCT03675477|Active Comparator|SHR0302 dose C|Participants randomized in this arm will receive dose D of SHR0302 until end of study at week 16.
11157665|NCT03675477|Placebo Comparator|palcebo|Participants randomized in this arm will receive placebo until week 8, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 16.
11157666|NCT03675451|Experimental|Interventional|"Injection of study drug followed by PET/CT imaging.
~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
~Followed by prostatectomy"
11157668|NCT03675425|Experimental|Group 1: non chest shielding|non chest shielding generic name: non dosage: non frequency and duration: in first 48 h eco with pad diameter will be measured in before and after phototherapy,
11157669|NCT03675425|Placebo Comparator|Group 2: chest shielding|chest shielding generic name: Phototrephy dosage: non frequency and duration: in first 48 h echo with pad diameter will be measured in before and after phototherapy,
11157670|NCT03675412|Active Comparator|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
11157671|NCT03675412|Active Comparator|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
11157672|NCT03675399|Experimental|Supra-threshold isometric exercise|Participants will perform 10 isometric external rotation supra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
11157673|NCT03675399|Experimental|Infra-threshold isometric exercise|Participants will perform 10 isometric external rotation infra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
11157674|NCT03675399|No Intervention|Control|Participants will remain resting.
11157675|NCT03675386|Active Comparator|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
11157676|NCT03675386|Experimental|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
11157677|NCT03675373|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
11157678|NCT03675373|Active Comparator|control group|Alcohol brief intervention
11157679|NCT03675360|Experimental|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.
~At baseline, participants will receive written information with standard physical activity recommendations."
11157680|NCT03675360|No Intervention|Usual Diet|"No dietary intervention.
~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
11157681|NCT03675334|Active Comparator|Test Group|"Active comparator: gingival recession
~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
11157682|NCT03675334|Placebo Comparator|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
11157683|NCT03675321|Experimental|Auricular Neurostimulation|Intervention: Active Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks
11157684|NCT03675321|Sham Comparator|Sham Auricular Neurostimulation|Intervention: Sham (Inactive) Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks.
11157685|NCT03675308|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
11157686|NCT03675308|Experimental|Risankizumab|Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
11157687|NCT03675295|Active Comparator|Comparator: Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
11157688|NCT03675295|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
11157689|NCT03675282|Experimental|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
11157690|NCT03675282|Experimental|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
11157691|NCT03675282|Experimental|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
11157692|NCT03675282|Experimental|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
11157693|NCT03675282|Experimental|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
11157694|NCT03675282|Experimental|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
11157695|NCT03675269|Experimental|Treatment|HBOT
11157696|NCT03675269|Active Comparator|Control|Standard wound care
11157697|NCT03675256|Experimental|Arm 1|immediate Cervarix, delayed MenVeo vaccine
11157698|NCT03675256|Experimental|Arm 2|immediate Gardasil 9, delayed MenVeo vaccine
11157700|NCT03675230|Active Comparator|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
11157701|NCT03675230|Experimental|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
11157702|NCT03675217|Experimental|PE and PCFPC|Physical Exercise and primary care family caregivers program
11157703|NCT03675217|Active Comparator|Usual Care|Usual Care: PCFPC (primary care family caregivers program)
11157704|NCT03675191|Experimental|orlistat|Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
11157705|NCT03675191|Placebo Comparator|placebo|placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
11157706|NCT03675178|Experimental|treatment group|Anerning particle +ceftriaxone sodium
11157707|NCT03675178|Placebo Comparator|control group|Anerning particle placebo+ceftriaxone sodium
11157708|NCT03675165|Experimental|Intervention|Participants receive a tailored version of Laura King's 'Best Possible Self' intervention: a brief, self-administered, psychological intervention. It is fundamentally a writing exercise, whereby recipients are asked to spend 10 minutes writing about their best possible future self and the steps they need to take to become that person. This helps the individual set goals while facilitating positive affect. Our version of the task has people focus on their health-related goals in particular.
11157709|NCT03675165|No Intervention|Waiting List Control|Participants are informed that they are on a waiting list and will receive the intervention at the end of the study.
11157710|NCT03675152|Experimental|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
11157711|NCT03675152|Active Comparator|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
11157712|NCT03675139|Experimental|Medroxyprogesterone Acetate|EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. All of the findings will be recorded.
11157713|NCT03675139|Experimental|dydrogesterone|EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium. All of the findings will be recorded.
11157714|NCT03675126|Experimental|SRP-5051|Patients will receive SRP-5051 via intravenous (IV) infusion. Dosage and frequency will be determined from the safety profile of other ongoing SRP-5051 studies.
11157715|NCT03675113|Experimental|upper extremity aerobic group|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
11157716|NCT03675113|Sham Comparator|control group|Deep breathing exercises combination with arm movements will be given as a home program in the control group. Training duration will be 3 day per a week through 6-weeks.
11157717|NCT03675100|Sham Comparator|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
11157718|NCT03675100|Active Comparator|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
11157719|NCT03675074|Experimental|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
11157720|NCT03675061|Other|Control group|Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
11157721|NCT03675061|Other|PartoSure group|"Each women have a biochemical test = PartoSure Test.
~PartoSure test negative : For a negative test, the patient will be able to benefit from a nifedipine tocolysis, if the uterine contractions require it, then she will return home with a control by a midwife at home twice a week up to 34 weeks of amenorrhea.
~PartoSure test positive : For a positive test, the patient will be hospitalized 7 days with a care identical to the control group."
11157722|NCT03675048|Experimental|Intervention group|The intervention group will receive 5 drops (10^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
11157723|NCT03675048|Placebo Comparator|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
11157724|NCT03675048|No Intervention|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
11157725|NCT03675035|Experimental|Endomina|Reduction trough sutures of the gastro-jejunal anastomosis
11157726|NCT03675022|Experimental|Dupilumab|Dupilumab injections every 2 weeks.
11157727|NCT03675009|Other|Early Intervention|Educational curriculum will be delivered earlier in the timeframe after IAQ monitoring has initiated.
11157728|NCT03675009|Other|Late Intervention|Educational curriculum will be delivered later in the timeframe after IAQ monitoring has initiated.
11157729|NCT03674996|Experimental|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
11157730|NCT03674996|Experimental|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
11157731|NCT03674996|Other|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
11157732|NCT03674983|Experimental|CEI Group|CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
11157733|NCT03674983|No Intervention|SOC Group|SOC Group will receive the standard of care only (information, prescription, free PrEP.)
11157734|NCT03674970|Experimental|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
11157735|NCT03674970|Active Comparator|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
11157807|NCT03674489|Active Comparator|Neurodynamic Tensioner Mobilization|
11157736|NCT03674970|Placebo Comparator|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
11157737|NCT03674944|Experimental|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
11157738|NCT03674944|Active Comparator|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
11157739|NCT03674931|Experimental|musical practice|Intensive weekly musical keyboard training over 12 months
11157740|NCT03674931|Active Comparator|music education|Recreative weekly musical courses without practice over 12 months
11157741|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
11157742|NCT03674905|Other|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
11157743|NCT03674905|Other|Peripheral nerve block|Pre-operative peripheral nerve block.
11157744|NCT03674879|No Intervention|Phone Call|Follow up contact is attempted via phone call.
11157745|NCT03674879|Experimental|Text Message|Follow up contact is attempted via text message.
11157746|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
11157747|NCT03674853|Experimental|Wuling Capsule group|Patients who were treated with Wuling Caspule
11157748|NCT03674853|Active Comparator|Oryzanol group|Patients who were treated with oryzanol
11157749|NCT03674840|Other|control group|Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
11157750|NCT03674840|Experimental|design group|Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
11157751|NCT03674827|Experimental|PF-06936308|Dose escalation
11157752|NCT03674814|Experimental|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
11157753|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
11157754|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
11157755|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
11157756|NCT03674775|Active Comparator|Intervention Group Providers|DART QI Program Participation
11157757|NCT03674775|No Intervention|Control Group Providers|Usual Care
11157758|NCT03674762|Experimental|dental implants|microgrooved dental implants submerged
11157759|NCT03674762|Experimental|dentale implants|microgrooved dental implants nonsubmerged
11157760|NCT03674749|Active Comparator|Hyperbaric Oxygen|Hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks
11157761|NCT03674749|Experimental|Meditation with Hyperbaric Oxygen|Meditation session combined with each hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks,
11157762|NCT03674736|Experimental|Methionine bioavailability in Rice|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Rice which will be provided by the investigators
11157763|NCT03674736|Experimental|Lysine bioavailability in Chickpeas|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Chickpeas which will be provided by the investigators
11157764|NCT03674736|Experimental|Methionine bioavailability in Wheat|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Wheat bread which will be provided by the investigators
11157765|NCT03674736|Experimental|Lysine bioavailability in Lentils|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 7 times. You could be expected to participate in up to 7 different sets of experiments which will take 8 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or Lentils which will be provided by the investigators
11157766|NCT03674723|Experimental|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
11157767|NCT03674710|Experimental|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
11157768|NCT03674710|Experimental|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
11157769|NCT03674710|Experimental|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
11157770|NCT03674710|Experimental|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
11157771|NCT03674710|Experimental|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
11157772|NCT03674710|Experimental|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
11157773|NCT03674697|Experimental|Active Treatment Group (Green LED)|Subjects will be exposed to a Green LED light for 3 weeks prior to surgery, during their hospital stay and for an additional 10 weeks after hospital discharge. Wattage: 8W; Voltage: 120V; Wavelength: 525 nm; Intensity: 4-100 Lux
11157774|NCT03674697|Placebo Comparator|Control Group (White LED)|Subjects will be exposed to a White LED light for 3 weeks prior to surgery, during their hospital stay and for an additional 10 weeks after hospital discharge. Wattage: 9.6W; Voltage: 120V. Intensity: 4-100 Lux
11157775|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
11157776|NCT03674684||gelatin|Patients who received gelatin
11157777|NCT03674684||crystalloids|Patients who received crystalloids
11157778|NCT03674671|Experimental|Intravenous Ketamine|
11157779|NCT03674671|Active Comparator|Electroconvulsive Therapy|
11157780|NCT03674658|Experimental|A drug|Rhynorm(A drug)
11157781|NCT03674658|Active Comparator|B drug|Rytmonorm (B drug)
11157782|NCT03674645|Experimental|MRI|MRI exam performed on 200 healthy volunteers
11157783|NCT03674632|Experimental|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
11157784|NCT03674632|No Intervention|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
11157785|NCT03674619|Active Comparator|Surgical treatment|Anterior discectomy
11157786|NCT03674619|Active Comparator|Conservative treatment|Patients will attend an experienced specialist in physical medicine and rehabilitation and a physiotherapist.
11157787|NCT03674606|Experimental|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
11157788|NCT03674606|No Intervention|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
11157789|NCT03674606|Active Comparator|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk > 1:8 must start low-dose aspirin treatment immediately. Participants with a risk < 1:8 will be excluded.
11157790|NCT03674593|Experimental|Mitral valve chordae prosthesis|"Patients of this group receive mitral valve chordae replacement performed in five stages:
~Measure the required length of the chordae.
~Forming loops.
~Fixation of the loop group to the papillary muscles.
~Fixation of chordal loops to the free edge of the valve.
~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse."
11157791|NCT03674593|Active Comparator|Mitral valve chordae translocation|"The technique of translocation of secondary chordae:
~The method consists essentially of three stages:
~Selection of the secondary chordae.
~Fixation of secondary chordae to the free edge of the valve.
~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
11157792|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
11157793|NCT03674567|Experimental|Part 1a: Monotherapy Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy.
11157794|NCT03674567|Experimental|Part 1b: Combination Dose Escalation|Eligible subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 in combination with pembrolizumab.
11157795|NCT03674567|Experimental|Part 2a: Monotherapy Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy; additional subjects in each cohort may be enrolled in Stage 2.
11157796|NCT03674567|Experimental|Part 2b: Combination Expansion Cohorts|Eligible subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 in combination with pembrolizumab; additional subjects in each cohort may be enrolled in Stage 2.
11157797|NCT03674554|Experimental|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
11157798|NCT03674554|Experimental|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
11157799|NCT03674541|Active Comparator|Study Drug - Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
11157800|NCT03674541|Placebo Comparator|Placebo|Placebo by mouth as a one time dose
11157801|NCT03674528||Control Group|Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.
11157802|NCT03674528||Patient Group|Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.
11157803|NCT03674515|Placebo Comparator|placebo|"Smartphone application placebo"
11157804|NCT03674515|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
11157805|NCT03674502|Experimental|ADU-1604|ADU-1604 administered as an IV infusion
11157809|NCT03674476|Experimental|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
11157810|NCT03674476|Experimental|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
11157811|NCT03674476|Experimental|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
11157812|NCT03674476|Other|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
11157813|NCT03674463|Experimental|LCAR-B4822M treatment group|r/r multiple myeloma patients will be treated with LCAR-B4822M CAR-T cells with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
11157814|NCT03674450|Experimental|Interventional|
11157815|NCT03674437||Breast Cancer Survivors|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
11157816|NCT03674437||Healthy Controls|Each main cohort has 2 sub-groups: One sub-group in each main cohort will complete the traditional neurocognitive assessments and the Cogsuite Assessment at the MSK Counseling Center, and the other sub-group will complete the Cogsuite Assessment off-site, on their own computers, in a quiet space that is free of distractions.
11157817|NCT03674437||Healthy 21-25 year olds|Healthy participants between the ages of 21 and 25 will be administered the Cogsuite Battery remotely. These participants will not be matched to any other groups and will not be asked for their full medical histories. They will only complete the assessment only once.
11157818|NCT03674424|Experimental|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.
~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.
~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
11157819|NCT03674424|Experimental|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.
~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
11157820|NCT03674424|Experimental|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.
~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
11157821|NCT03674424|Experimental|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.
~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
11157822|NCT03674411|Experimental|FLU, CY, TBI + MGTA-456 infusion|
11157823|NCT03674411|Experimental|BU/ FLU/ MEL + MGTA-456 infusion Suspended: No|
11157824|NCT03674398|Experimental|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
11157825|NCT03674398|Active Comparator|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
11157826|NCT03674385|Experimental|vitamin E group|30 patient
11157827|NCT03674385|Active Comparator|control group|clomiphene
11157828|NCT03674372|Experimental|Fetuses with Left CDH (O/E LHR < 25%)|Fetuses with Left CDH (O/E LHR < 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
11157829|NCT03674372|Experimental|Fetuses with L- sided CDH with O/E LHR <30%.|Fetuses with Left CDH (O/E LHR < 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
11157830|NCT03674372|Experimental|Fetuses with R- sided CDH with O/E LHR < 45%|Fetuses with Right CDH (O/E LHR < 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
11157831|NCT03674359||Cohort|Patients hospitalized in intensive care, meeting the inclusion criteria. BDG analysis
11157832|NCT03674346|Experimental|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
11157833|NCT03674346|Other|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
11157834|NCT03674333|Experimental|Group A|Folic acid 1mg daily will be given to the participants of Group A.
11157835|NCT03674333|Placebo Comparator|Group B|A Placebo (a sugar pill) will be given to the participants of the Group B.
11157836|NCT03674320|Placebo Comparator|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
11157837|NCT03674320|Active Comparator|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
11157838|NCT03674307|Experimental|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
11157839|NCT03674307|Active Comparator|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
11157840|NCT03674294|Experimental|Palonosetron/Dexamethasone/Aprepitant|
11157841|NCT03674294|Placebo Comparator|Palonosetron/Dexamethasone/Placebo|
11157842|NCT03674281|Experimental|Sensor Augmented Pump (SAP)-Closed-Loop Control (CLC)|"SAP: Subjects will be utilizing their own insulin pumps (without automated insulin delivery) plus Dexcom G6 CGM to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period.
~CLC with Control-IQ plus CGM: Following SAP, subjects will be utilizing the Tandem t:slim X2 with Control-IQ along with a Dexcom G6 continuous glucose monitor to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period."
11158558|NCT03669510|Experimental|Classical technique|Non computer guided surgical technique
11157843|NCT03674255||1|Participants in group 1 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained, in addition to venous blood samples obtained from the cannula inserted as part of the standard clinical procedure. These blood samples will be collected before and after the stress echocardiogram. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
11157844|NCT03674255||2|Participants in group 2 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
11157845|NCT03674255||3|Participants in group 3 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
11157846|NCT03674255||4|Participants in group 4 will be recruited at their stress echocardiogram appointment, regardless of the type of investigation. A simplified data set and an anonymised version of the stress echocardiography report will be collected as a part of this registry phase. Participants will be followed up over a 10-year period.
11157847|NCT03674242|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with
~Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.
~Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
11157848|NCT03674242|Active Comparator|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
11157849|NCT03674229|Active Comparator|Group I (information about weight management programs)|Participants receive information about commercially-available weight management programs and encouragement to participate in one of the programs for 6 months.
11157850|NCT03674229|Experimental|Group II (information, call from patient navigator)|Participants receive information about commercially-available weight management programs encouragement to participate in one of the programs for 6 months. Participants also receive 6 phone calls over 20-30 minutes each from an assigned patient navigator for 6 months.
11157851|NCT03674203|Experimental|Application of platelet-rich plasma|The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
11157852|NCT03674190|Experimental|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
11157853|NCT03674190|Active Comparator|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
11157854|NCT03674177|Experimental|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
11157855|NCT03674177|Experimental|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
11157856|NCT03674177|Experimental|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
11157857|NCT03674177|Placebo Comparator|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
11157858|NCT03674151|Active Comparator|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
11157859|NCT03674151|Active Comparator|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
11157860|NCT03674151|Active Comparator|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
11157861|NCT03674151|Active Comparator|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
11157862|NCT03674138|Active Comparator|DNA-guided choice of therapy|DNA-guided choice of antidepressant therapy
11157863|NCT03674138|Active Comparator|Clinical management|Clinical management
11157864|NCT03674125|Experimental|Group 1|GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
11157865|NCT03674125|Experimental|Group 2|GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
11157866|NCT03674125|Experimental|Group 3|GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
11157867|NCT03674125|Experimental|Group 4|GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
11157868|NCT03674112|Experimental|A: Pertuzumab and Trastuzumab - IV Followed by FDC SC|In the Treatment Cross-Over Period of the study, participants randomized to Arm A will first receive pertuzumab IV and trastuzumab IV for 3 treatment cycles followed by pertuzumab and trastuzumab FDC SC for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants will choose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment).
11157961|NCT03673579|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
11158080|NCT03672903|Placebo Comparator|Control|Subjects in this arm will carry light weight vests for three weeks.
11157869|NCT03674112|Experimental|B: Pertuzumab and Trastuzumab - FDC SC Followed by IV|In the Treatment Cross-Over Period of the study, participants randomized to Arm B will first receive pertuzumab and trastuzumab FDC SC for 3 treatment cycles followed by pertuzumab IV and trastuzumab IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants will choose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment).
11157870|NCT03674099|Experimental|Imatinib|Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
11157871|NCT03674099|Active Comparator|Methylprednisolone|Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
11157872|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
11157873|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
11157874|NCT03674073|Experimental|Microwave Ablation + Neoantigen Vaccines|The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.
11157875|NCT03674073|Active Comparator|Microwave Ablation|The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.
11157876|NCT03674060|Experimental|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
11157877|NCT03674060|Experimental|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
11157878|NCT03674060|Experimental|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
11157879|NCT03674060|Active Comparator|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
11157880|NCT03674047|Experimental|newly-diagnosed BOS|-Participants will take ruxolitinib twice every day
11157881|NCT03674047|Experimental|Established BOS|-Participants will take ruxolitinib twice every day
11157882|NCT03674034||term|50 CTscan and MRI images of children aged at term
11157883|NCT03674034||one month|50 CTscan and MRI images of children aged one month
11157884|NCT03674034||two months|50 CTscan and MRI images of children aged two months
11157885|NCT03674021|Experimental|Intervention Arm|Patients in the intervention arm will receive the Chest Pain Choice visual aid prior to discussion with their primary physician regarding disposition.
11157886|NCT03674021|No Intervention|Control Arm|Patients in the control arm will not receive the Chest Pain Choice visual aid and will receive standard care.
11157887|NCT03674008|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
11157888|NCT03674008|Active Comparator|Propofol|1.5mg/kg/0.75mg/kg
11157889|NCT03673995|Experimental|Myo-inositol+L-tyrosine|One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.
11157890|NCT03673982|Experimental|iCASK Group|Materials and support to aid transitions.
11157891|NCT03673969|Active Comparator|MGB|Mini gastric bypass
11157892|NCT03673969|Active Comparator|Roux enY gastric bypass|Roux enY gastric bypass
11157893|NCT03673956|Experimental|Topical Antibiotic Nasal Saline Rinse|The topical antibiotics will prescribed to the patient in capsule form as compounded by the Mayo Clinic pharmacy, or suitable licensed 3rd party compounding pharmacy. One capsule will subsequently be added to a nasal saline irrigation bottle, and the patient will administer this irrigation to him or herself in the usual fashion twice per day.
11157894|NCT03673943|Experimental|PET/CT imaging with 64Cu-DOTATATE|64Cu-DOTATATE is an investigational radioactive drug that binds to somatostatin receptors on NETs cancer cells.
11157895|NCT03673930|Active Comparator|Zanthozylum armatum|fruit extract
11157896|NCT03673930|Placebo Comparator|Placebo|placebo
11157897|NCT03673917|Experimental|Educational video|The educational video on skin cancer for cosmetologists
11157898|NCT03673917|Active Comparator|Control video|A publicly accessible healthy lifestyle video on YouTube, which did not contain any information on skin cancer
11157899|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
11157900|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5%
11157901|NCT03673891|No Intervention|Control|After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
11157902|NCT03673891|Experimental|LifeFlow group|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
11157903|NCT03673865|Experimental|Treatment Group|Patients undergo orbital reconstruction using pre-adjusted patient-specific orbital implants with office-based 3-dimensional printers (OB3DP)
11157904|NCT03673865|Active Comparator|Control Group|Patients undergo orbital reconstruction with non-patient-specific orbital implants (traditional approach, Control Group) which is a standard stock orbital plate
11157990|NCT03673345|Experimental|Cohort 1B|0.25 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 after primary influenza infection in study year 1 in children 3-12 months of age, who have not previously had an influenza vaccination, n=20
11157905|NCT03673852|Other|Peer Wellness Enhancement (WE Harambee)|This project employs a pragmatic, stepped wedge experimental design in which 60 BHH participants are randomly assigned to one of 3 waves of WE Harambee implementation (20 in each wave) during the 2 year study. Participants in this arm receive the WE Harambee Wellness Enhancement and are enrolled in a Behavioral Health Home. WE Harambee is a 6-month peer-delivered whole health intervention intended to address the 8 dimensions of wellness and the social determinants of health.
11157906|NCT03673852|Other|Behavioral Health Home enrollment|"In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a health home option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness."
11157907|NCT03673839|Active Comparator|Animal proteins (crossover)|
11157908|NCT03673839|Experimental|Plant-based protein blends type 1 (crossover)|
11157909|NCT03673839|Experimental|Plant-based protein blends type 2 (crossover)|
11157910|NCT03673839|Experimental|Plant-based protein blends type 3 (crossover)|
11157911|NCT03673826|Experimental|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
11157912|NCT03673826|Experimental|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
11157913|NCT03673800|Experimental|Cognitive Training|Online Cognitive training on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
11157914|NCT03673800|Sham Comparator|Online sensorial program|Online sensorial program on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
11157915|NCT03673787|Experimental|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
11157916|NCT03673787|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in three patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma
11157917|NCT03673774|Experimental|cardiac impedancemetry|"Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for PH. Patients are included via the competence center of the PHP of the Midi Pyrenees region. The cardiac output is measured by impedance measurement at rest and during the walking test. The NO / CO coupled transfer measurement is performed at rest. The physician performing the consultation will not know the results of the IPC and these results will not influence the subsequent management.
~The patient will be followed for 18 months as part of the research."
11157918|NCT03673761||Cushing's syndrome|"a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.
~This group will under go the following procedures:
~muscle MRI
~dual-energy x-ray absorptiometry
~muscle ultrasounds
~blood testing"
11157919|NCT03673761||acromegaly|"b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.
~This group will under go the following procedures:
~muscle MRI
~dual-energy x-ray absorptiometry
~muscle ultrasounds
~blood testing"
11157920|NCT03673761||Healthy controls|"Controls: n = 40; normal healthy control paired by age, sex and BMI will be included.
~This group will under go the following procedures:
~muscle MRI
~dual-energy x-ray absorptiometry
~muscle ultrasounds
~blood testing"
11157921|NCT03673748|Experimental|Mesenchymal stromal cells (MSC)|Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid
11157922|NCT03673748|Placebo Comparator|Placebo|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups.
11157923|NCT03673735|Experimental|Experimental Arm|Patients will receive 1 infusion of 1500 mg Durvalumab within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with Durvalumab will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
11157924|NCT03673735|Placebo Comparator|Control arm|Patients will receive 1 infusion of placebo within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with placebo will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
11157925|NCT03673722|Experimental|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
11157926|NCT03673722|Experimental|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
11157927|NCT03673722|Placebo Comparator|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
11157991|NCT03673345|Experimental|Cohort 2A|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=60
11157928|NCT03673709|No Intervention|Individual Antenatal Care (usual care)|Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
11157929|NCT03673709|Experimental|Group Antenatal Care (intervention)|Women have the same number of visits as those in individual care. Their first antenatal care (intake) and first postnatal visit is done individually (identical to individual care). Women in group care bypass the waiting area and have a 2-hour visit with the same provider in a group of 8-12 women at a similar stage of pregnancy. Women assess their blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
11157930|NCT03673696|Experimental|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
11157931|NCT03673696|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
11157932|NCT03673696|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
11157933|NCT03673696|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
11157934|NCT03673696|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
11157935|NCT03673696|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
11157936|NCT03673696|Experimental|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
11157937|NCT03673696|Experimental|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
11157938|NCT03673696|Experimental|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
11157939|NCT03673683|Active Comparator|Usual Care|Sedation and ventilation weaning that is non-protocol-based and primarily medically-driven.
11157940|NCT03673683|Experimental|SANDWICH protocol|A protocol-based intervention for managing sedation and ventilation weaning.
11157941|NCT03673670|Experimental|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
11157942|NCT03673670|Experimental|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
11157943|NCT03673670|Experimental|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
11157944|NCT03673657|Experimental|A|"ONS from the start of radiotherapy; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.
~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
11157945|NCT03673657|Experimental|B|"ONS from the time of grade 2 radiation esophagitis; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.
~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
11157946|NCT03673657|Experimental|C|ONS from the start of radiotherapy; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
11157947|NCT03673657|Experimental|D|ONS from the time of grade 2 radiation esophagitis; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
11157948|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:
~Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
~Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
11157949|NCT03673631||NFHC-O2 Group|NFHC-O2 therapy alone with gas flow at least 40L/min,
11157950|NCT03673631||NIV/Standard-O2 Group|NIV sessions with at least 30% FiO2 and standard oxygen therapy
11157951|NCT03673631||NFHC-O2/NIV Group|combination of NIV sessions and NFHC-O2 therapy,
11157952|NCT03673618|Experimental|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
11157953|NCT03673618|Placebo Comparator|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
11157954|NCT03673605|Experimental|Rivaroxaban|
11157955|NCT03673605|Active Comparator|Warfarin|
11157956|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
11157957|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (<50%). This embryos will be considered for transfer to the uterus.
11157958|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
11157959|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
11157960|NCT03673579|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.
~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
11157962|NCT03673579|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.
~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
11157963|NCT03673566|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.
~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
11157964|NCT03673566|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
11157965|NCT03673566|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.
~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
11157966|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
11157967|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
11157968|NCT03673540|Experimental|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
11157969|NCT03673527|Experimental|topical formulation of tacrolimus|
11157970|NCT03673514|Active Comparator|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
11157971|NCT03673514|Active Comparator|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
11157972|NCT03673501|Experimental|DCC-2618|150 mg QD DCC-2618
11157973|NCT03673501|Active Comparator|sunitinib|50 mg QD sunitinib
11157974|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
11157975|NCT03673475||fluid responsiveness|Assessment of fluid responsiveness using pleth variebility index and jugular vein distensibility in patients undergoing major abdominal surgery
11157976|NCT03673462|Experimental|MenACYW conjugate vaccine|MenACYW conjugate vaccine, 4 doses at 2, 4, 6, and 12 months of age, co-administered with routine vaccines
11157977|NCT03673462|Active Comparator|MENVEO®|MENVEO®, 4 doses at 2, 4, 6, and 12 months of age, co-administered with routine vaccines
11157978|NCT03673449|Experimental|SilkBridge treatment|Surgery for digital nerve reconstruction with SilkBridge
11157979|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
11157980|NCT03673410|Active Comparator|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
11157981|NCT03673410|Experimental|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
11157982|NCT03673397|Experimental|Aerobic exercise|Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
11157983|NCT03673397|No Intervention|Control|Individuals allocated to the control group will be placed in a room with analogous conditions to the exercise group concerning light, temperature and absence of music at the same time as individuals performing the exercise intervention. The control group will be asked to remain seated and read magazines.
11157984|NCT03673384|Experimental|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.
~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
11157985|NCT03673384|Placebo Comparator|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
11157986|NCT03673371||Women Veterans with Lower Limb Amputations|Questionnaire
11157987|NCT03673358|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
11157988|NCT03673358|No Intervention|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
11157989|NCT03673345|Experimental|Cohort 1A|0.25 mL dose of IIV-4 administered intramuscularly on days 0 and 28 of study year 1 and on day 0 of study year 2 in children 6-12 months of age who have not previously had an influenza infection or vaccination, n=20
11158035|NCT03673111|Experimental|36.0 mg|Y14 single dose, subcutaneous
11158036|NCT03673111|Placebo Comparator|Placebo|0.9% saline
11157992|NCT03673345|Experimental|Cohort 2B|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
11157993|NCT03673345|Experimental|Cohort 3A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2006 and 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=30
11157994|NCT03673345|Experimental|Cohort 3B|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2006 and 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
11157995|NCT03673345|Experimental|Cohort 4A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2003 and 2006, who have previously received 2 doses of influenza vaccine prior to the study, n=30
11157996|NCT03673345|Experimental|Cohort 4B|0.5 mL does of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2003 and 2006, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
11157997|NCT03673332|Experimental|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
11157998|NCT03673319|Experimental|Positive expectative|"Participants in the positive expectation group will be told that DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
11157999|NCT03673319|Experimental|Neutral expectatives|"Participants in the neutral expectation group will be told that DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
11158000|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
11158001|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
11158002|NCT03673280|Placebo Comparator|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
11158003|NCT03673280|Experimental|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
11158004|NCT03673280|Experimental|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
11158005|NCT03673267|Experimental|Nutricity|
11158006|NCT03673241|No Intervention|Control Group|The Control Group will receive the standard support surface mattresses/bed surfaces and recovery chairs without the non-invasive perfusion enhancement system (The Guardian System)
11158007|NCT03673241|Experimental|Study Arm|The Study Arm will have the non-invasive perfusion enhancement system placed on their beds and recovery chairs. Patients will be utilizing the systems while lying in bed or sitting in the chair.
11158008|NCT03673228|Experimental|Intervention Group|"Participants randomized to the Intervention Arm will receive counseling that includes:
~A Visit prior to discharge
~Follow up calls after discharge
~Text Messaging Support
~Caregiver Support"
11158009|NCT03673228|Active Comparator|Standard treatment|Patients will receive current usual care.
11158010|NCT03673215|Experimental|A|
11158011|NCT03673215|Experimental|B1|
11158012|NCT03673215|Placebo Comparator|B2|
11158013|NCT03673215|Experimental|C1-1|
11158014|NCT03673215|Placebo Comparator|C1-2|
11158015|NCT03673215|Experimental|C2-1|
11158016|NCT03673215|Placebo Comparator|C2-2|
11158017|NCT03673215|Experimental|C3-1|
11158018|NCT03673215|Placebo Comparator|C3-2|
11158019|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
11158020|NCT03673189|Experimental|Healthy volunteers|Sensors assigned for 3 weeks
11158021|NCT03673189|Experimental|Patients with arythmic disease or peripheral vascular disease|Sensors assigned for 3 weeks
11158022|NCT03673176|Experimental|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
11158023|NCT03673163|Experimental|Lidocaine|Lidocaine treatment
11158024|NCT03673163|Placebo Comparator|Control|Placebo treatment
11158025|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
11158026|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
11158027|NCT03673137|Experimental|Synchronous treatment group|Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
11158028|NCT03673137|Active Comparator|Traditional treatment group|The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
11158029|NCT03673124|Other|Ribociclib and letrozole|Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
11158030|NCT03673111|Experimental|1.0 mg|Y14 single dose, subcutaneous
11158031|NCT03673111|Experimental|2.0 mg|Y14 single dose, subcutaneous
11158032|NCT03673111|Experimental|6.0 mg|Y14 single dose, subcutaneous
11158033|NCT03673111|Experimental|9.0 mg|Y14 single dose, subcutaneous
11158034|NCT03673111|Experimental|18.0 mg|Y14 single dose, subcutaneous
11158037|NCT03673111|Experimental|26.0 mg (B1)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 12mg on day 8, 16mg on day 15, 20mg on day 22 and 26mg on day 29.
11158038|NCT03673111|Experimental|36mg (B2)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
11158039|NCT03673111|Experimental|36mg (B3)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 12mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
11158040|NCT03673098|Experimental|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
11158041|NCT03673098|No Intervention|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
11158042|NCT03673085|Experimental|Group 1-1|The dose of CN128 is 2.5 mg/kg bw.
11158043|NCT03673085|Placebo Comparator|Group 1-2|The dose of placebo is 2.5 mg/kg bw.
11158044|NCT03673085|Experimental|Group 2-1|The dose of CN128 is 5 mg/kg bw.
11158045|NCT03673085|Placebo Comparator|Group 2-2|The dose of placebo is 5 mg/kg bw.
11158046|NCT03673085|Experimental|Group 3-1|The dose of CN128 is 10 mg/kg bw.
11158047|NCT03673085|Placebo Comparator|Group 3-2|The dose of placebo is 10 mg/kg bw.
11158048|NCT03673085|Experimental|Group 4-1|The dose of CN128 is 15 mg/kg bw.
11158049|NCT03673085|Placebo Comparator|Group 4-2|The dose of placebo is 15 mg/kg bw.
11158050|NCT03673085|Experimental|Group 5-1|The dose of CN128 is 20 mg/kg bw.
11158051|NCT03673085|Placebo Comparator|Group 5-2|The dose of placebo is 20 mg/kg bw.
11158052|NCT03673085|Experimental|Group 6-1|The dose of CN128 is 30 mg/kg bw.
11158053|NCT03673085|Placebo Comparator|Group 6-2|The dose of placebo is 30 mg/kg bw.
11158054|NCT03673085|Experimental|Group 7-1|The dose of CN128 is 45 mg/kg bw.
11158055|NCT03673085|Placebo Comparator|Group 7-2|The dose of placebo is 45 mg/kg bw.
11158056|NCT03673085|Experimental|Group 8-1|The dose of CN128 is 60 mg/kg bw.
11158057|NCT03673085|Placebo Comparator|Group 8-2|The dose of placebo is 60 mg/kg bw.
11158058|NCT03673072|Experimental|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
11158059|NCT03673072|Active Comparator|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
11158060|NCT03673059|Experimental|OTC Eczema Moisturizer Regimen|Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
11158061|NCT03673059|Experimental|Cosmetic Moisturizer Regimen|Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).
11158062|NCT03673046|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
11158063|NCT03673046|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
11158064|NCT03673020|Experimental|ASV® AGEN2017|ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine
11158065|NCT03673007|Experimental|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
11158066|NCT03673007|No Intervention|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
11158067|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
11158068|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
11158069|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
11158070|NCT03672994||Heart failure|Patients with confirmed heart failure
11158071|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
11158072|NCT03672981|Experimental|Supportive Care (aerobic exercise and resistance training)|Patients undergo moderately intense aerobic/cardiovascular exercise over 30-60 minutes and complete 1-2 sets of 8 to 10 resistance/strength training exercises, 8 to 12 repetitions of each exercise, 3 days per week for 12 weeks. Patients also participate in weekly phone calls with an exercise physiologist to ensure adherence to the program and to provide support.
11158073|NCT03672942|Experimental|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
11158074|NCT03672942|Experimental|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
11158075|NCT03672942|Placebo Comparator|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
11158076|NCT03672929|No Intervention|Full cohort|Prospective non Controlled to Document long term performance of Allofit IT Shell in combination with the Longevity® Liner when used in primary total hip arthroplasty.
11158077|NCT03672929|Other|Subgroup RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years and will only be conducted on 40 patients.
11158078|NCT03672916||Patients who received the Allofit IT with BIOLOX delta|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the BIOLOX delta Taper Liners
11158079|NCT03672903|Experimental|Intervention|Subjects in this arm will carry heavy weight vests for three weeks.
11158676|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
11158081|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
11158082|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
11158083|NCT03672877|Experimental|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
11158084|NCT03672877|No Intervention|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
11158085|NCT03672864|Experimental|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
11158086|NCT03672864|No Intervention|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
11158087|NCT03672851|Experimental|anti-CD123 CAR-T treatment|
11158088|NCT03672838|Active Comparator|Cohort 1|Patients with NF1
11158089|NCT03672838|Active Comparator|Cohort 2|Patients with NF2
11158090|NCT03672825|Experimental|RECLAIM|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
11158091|NCT03672812|No Intervention|placebo|0,5ml
11158092|NCT03672812|Experimental|liraglutide|0,5ml
11158093|NCT03672799|Experimental|Rehabilitation Planning Consult (RPC)|"The RPC is a trans-disciplinary, consultative intervention. In the RPC, individualized rehabilitation needs are established, goals are set, strategies to achieve the goals are developed, and follow-through with strategies and goal attainment is facilitated by a rehabilitation professional who consults and collaborates with the survivor. The Rehabilitation Consultant does not provide hands-on treatment, but rather determines the survivors' priority individualized rehabilitation goals, and then helps devise a plan for the survivor to meet those goals independently.
~Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consultant and second consultation 2 to 12 weeks later."
11158094|NCT03672799|Active Comparator|Wait list control (WLC)|"There is no standard rehabilitation care for survivors of head and neck cancer at the Princess Margaret Cancer Centre.
~Participants allocated to WLC will enter a 12 week waiting period after which they will crossover to the RPC group."
11158095|NCT03672786|Active Comparator|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
11158096|NCT03672786|Experimental|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
11158097|NCT03672773|Experimental|Treatment (temozolomide, talazoparib)|Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11158098|NCT03672760|Active Comparator|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.
~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
11158099|NCT03672760|Placebo Comparator|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.
~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
11158100|NCT03672760|Active Comparator|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
11158101|NCT03672747|Active Comparator|Anodal|Participants will receive occipital anodal stimulation using high-definition tDCS
11158102|NCT03672747|Active Comparator|Cathodal|Participants will receive occipital cathodal stimulation using high-definition tDCS
11158103|NCT03672747|Placebo Comparator|Sham|Participants will receive occipital sham stimulation (placebo) using high-definition tDCS
11158104|NCT03672721|Experimental|IA Carbo + radiation|Intraarterial carboplatin + radiation
11158105|NCT03672708|Other|Cresyl violet|
11158106|NCT03672695|Experimental|S64315 and venetoclax administered in combination|
11158107|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
11158108|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
11158109|NCT03672682||Healthy patients|15 healthy patients
11158110|NCT03672669|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF was applied into the tooth socket after mandibular third molar surgery.
11158111|NCT03672669|Active Comparator|Leukocyte- and platelet-rich fibrin (L-PRF)|L-PRF was applied into the tooth socket after mandibular third molar surgery.
11158112|NCT03672656|Experimental|pattern scanning laser system Pascal|
11158113|NCT03672656|Active Comparator|conventional laser|
11158114|NCT03672643|Other|single arm|Crizotinib
11158115|NCT03672630|Active Comparator|2-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
11158116|NCT03672630|Active Comparator|3-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
11159377|NCT03663998|Active Comparator|D|CN54ENV ID EP 600 g
11158117|NCT03672617||Children and adolescents|Children and adolescents, who administer growth hormone (GH) themselves (self-injections) will be asked to complete the questionnaire.
11158118|NCT03672617||Parents/legal guardians|Parents/legal guardians who administer the GH to their child will be asked to complete the questionnaire.
11158119|NCT03672604|Placebo Comparator|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01
~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
11158120|NCT03672604|Placebo Comparator|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.
~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
11158121|NCT03672604|Placebo Comparator|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.
~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
11158122|NCT03672591||HFpEF patients|Patients suffering from heart failure with preserved ejection fraction
11158123|NCT03672591||Control group|Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
11158124|NCT03672578|Experimental|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
11158125|NCT03672578|Experimental|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
11158126|NCT03672578|Experimental|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
11158127|NCT03672578|Experimental|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
11158128|NCT03672578|Experimental|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
11158129|NCT03672578|Experimental|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
11158130|NCT03672578|Experimental|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
11158131|NCT03672578|Experimental|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
11158132|NCT03672578|Placebo Comparator|No label|Participant will not see a label
11158133|NCT03672565|Active Comparator|Hospital setting|ERPs may be conducted in various settings on hospital grounds (e.g., cafeteria, hallways) but will not be conducted off property.
11158134|NCT03672565|Active Comparator|Community setting|Community ERP sessions will be conducted locations deemed most relevant to the child's symptom presentation such as in the home or at other community locations (e.g., church, downtown).
11158135|NCT03672552|Experimental|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
11158136|NCT03672552|No Intervention|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
11158137|NCT03672539|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.
~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.
~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
11158138|NCT03672526|Experimental|device compuflo|
11158139|NCT03672513|Placebo Comparator|Placebo Supplemented Group|Placebo control
11158140|NCT03672513|Experimental|Magnesium Supplemented Group|Magnesium Group
11158141|NCT03672513|Experimental|Zinc Supplemented Group|Zinc Group
11158142|NCT03672500|Active Comparator|Bupivacaine arm|The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
11158143|NCT03672500|Placebo Comparator|Saline arm|The edges of the 2PT/Epi will be infiltrated with 10ml of NaCl 0.9% prior to suture placement.
11158144|NCT03672500|Sham Comparator|Control arm|Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.
11158145|NCT03672487|Active Comparator|60/300mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). The investigators will purchase the drug at full cost.
~Interventions: The standard 60d course will be 300 mg per day, which is similar to the dose used in the second phase of the BENEFIT trial. The drug will be administered orally in two doses per day: the standard course will be one 100mg and one 50mg tablet in the morning and in the evening for 60 days."
11158146|NCT03672487|Experimental|30/150mg|"The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). ELEA laboratories will prepare the placebo oral tablets, which will be identical to the drug tablets in aspect and taste. The investigators will purchase the drug and placebo at full cost.
~Interventions: The BZN short course low dose scheme will be 150 mg per day for 30 days. The drug will be administered orally in two doses per day: the short course treatment will start with the active drug and then placebo oral tablet; one 100 mg tablet and one placebo tablet in the morning and one 50 mg tablet and one placebo tablet in the evening for the first 30 days. The last 30 days will be two placebo tablets in the morning and the evening."
11158147|NCT03672474|Experimental|Photobiomodulation REGEnLIFE RGn530 device group|
11158148|NCT03672474|Sham Comparator|Sham REGEnLIFE RGn530 device group|
11158287|NCT03671460|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
11158149|NCT03672461|Experimental|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
11158150|NCT03672461|Active Comparator|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
11158151|NCT03672448||Neurocognitive disorder|Dementias
11158152|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
11158153|NCT03672435||proparacaine|Received topical proparacaine 0.5% with routine antibiotic-steroid ointment in operative eye(s) following strabismus surgery
11158154|NCT03672435||No proparacaine|Received no topical proparacaine 0.5% but did receive routine antibiotic-steroid ointment in the operative eye(s) following strabismus surgery
11158155|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month pain-free interval between episodes.
11158156|NCT03672422||Chronic Pancreatitis|"Children with at least:
~1) One irreversible structural change* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.
~*irreversible structural changes:
~Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).
~Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.
~Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.
~Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
11158157|NCT03672409|Other|Intervention in knowledge|All participants will be offered learning sessions to improve knowledge in diabetes
11158158|NCT03672396|Experimental|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour.
11158159|NCT03672383|Experimental|BAY987534 (Treated Arm)|Subjects with quiescent atopic dermatitis. Right or left volar forearm with test product applied.
11158160|NCT03672383|No Intervention|Untreated Arm|Subjects with quiescent atopic dermatitis. Right or left volar forearm without test product applied.
11158161|NCT03672370||Alloclassic Variall Cup|Subjects who received the Alloclassic Variall Cup Ceramic Bearing System
11158162|NCT03672357|Experimental|Laparoscopic liver resection|Laparoscopic hepatectomy
11158163|NCT03672357|Other|Open liver resection|Open hepatectomy
11158164|NCT03672344|Active Comparator|BioStream Training|
11158165|NCT03672344|Placebo Comparator|Alternative Game|
11158166|NCT03672331|Other|Standard arm|Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly.
11158167|NCT03672331|Experimental|Risk-based arm|Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer.
11158168|NCT03672318|Experimental|CAR138 T cells|The first 3 patients enrolled in the study will receive 5x10^6 CAR138 T-cells/m^2 via infusion. The number of cells for the infusion will be increased to 1x10^7 CAR138 T-cells/m^2 and then, 2.5x10^7 CAR138 T-cells/m^2, 5x10^7 CAR138 T-cells/m^2, 1x10^8 CAR138 T-cells/m^2 and 2x10^8 CAR138 T-cells/m^2 in subsequent cohorts of 3 patients provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each patient to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another patient is allowed to enroll in the cohort.
11158169|NCT03672305|Other|c-Met/PD-L1 CAR-T cells treating group|Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 * 10^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
11158170|NCT03672292|Experimental|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).
~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
11158171|NCT03672292|Placebo Comparator|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).
~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).
~Treatment duration = minimum 6 weeks/Max 13 weeks"
11158172|NCT03672279||Mild neurocognitive disorder|
11158173|NCT03672279||Major neurocognitive disorder|
11158288|NCT03671447|Active Comparator|ICU usual care|control condition
11158289|NCT03671447|Experimental|"Intervention ERIC"|intervention condition
11158174|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
11158175|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
11158176|NCT03672253|Experimental|CAR-T Re-treatment group|Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
11158177|NCT03672240|Experimental|APL-1202|"APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).
~Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
11158178|NCT03672227|Experimental|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
11158179|NCT03672227|No Intervention|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
11158180|NCT03672214|Experimental|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
11158181|NCT03672214|Active Comparator|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
11158182|NCT03672201|Active Comparator|The Integrated Care Pathway (ICP) Arm|The ICP consists of 1) a cleanup phase during which a thorough assessment of pharmacotherapy to discontinue unnecessary medications, is performed; 2) Structured non-pharmacological interventions, which would have started as soon as randomization occurred and would continue before any pharmacological intervention for 2 weeks as stand-alone interventions; and 3) a pharmacological intervention phase: in this phase the medications algorithm for AD-AA is initiated.
11158183|NCT03672201|No Intervention|Treatment-As-Usual (TAU) Arm|Following eligibility and baseline assessments, half of the participants will be randomized to TAU. TAU will consist of the typical care that the interdisciplinary team provides at each site for AD-AA. No predetermined cleanup phase, non-pharmacological interventions, algorithmic pharmacological interventions will be systematically part of TAU.
11158184|NCT03672188|Experimental|VIR-2218|
11158185|NCT03672188|Placebo Comparator|Placebo|
11158186|NCT03672175|Experimental|SAGE-217 (low dose)|
11158187|NCT03672175|Experimental|SAGE-217 (high dose)|
11158188|NCT03672175|Placebo Comparator|Placebo|
11158189|NCT03672162|Active Comparator|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
11158190|NCT03672162|Active Comparator|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
11158191|NCT03672162|Placebo Comparator|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
11158192|NCT03672149|Other|Infection needing cefazolin|a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
11158193|NCT03672149|Other|Infection not needing cefazolin|b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
11158194|NCT03672149|Other|No infection|c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
11158195|NCT03672136|Experimental|Concurrent Chemoradiotherapy+Anlotinib|"Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.
~Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.
~Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1~14, day22~36.
~Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.
~During the course of study, it's not allowed to receive other anti-tumor therapy."
11158196|NCT03672123||APE with RVD|RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
11158197|NCT03672123||APE without RVD|RVD defined according to ESC criteria
11158198|NCT03672110|Active Comparator|Standard tacrolimus group|Control group: Advagraf will be administered as usual (0.2mg/kg bodyweight), trough levels will be measured every day in the first week after kidney transplantation (TX) and Advagraf dose will be adjusted accordingly.
11158199|NCT03672110|Experimental|Fixed dose tacrolimus group|Study group: Advagraf will be administered per fix dose 5mg/day, trough levels will be blinded during the first week, there will be no adjustments in the first week after TX.
11158200|NCT03672097|Experimental|Prasugrel|Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)
11158290|NCT03671434|Experimental|RPC Researchers|Researchers who are assigned to the experimental group that is eligible to receive the full RPC intervention
11158201|NCT03672071|Other|Group E|If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Ephedrine i.v. will be administered to patient will be performed. In the case of hypotension,
11158202|NCT03672071|Other|Group NE|.If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Noradrenaline, i.v. will be administered to patient will be performed. In the case of hypotension,
11158203|NCT03672071|Other|Group N|. If a 20% decrease in parameter compared to their baseline levels is sustained, necessary interventions mg Ephedrine + 2.5 mg Noradrenaline i.v. will be administered to patient will be performed. In the case of hypotension,
11158204|NCT03672058|Experimental|Fitbit plus personalised text messaging & Goal Setting|
11158205|NCT03672058|Active Comparator|Fitbit Only|
11158206|NCT03672045|Active Comparator|Carbetocin 10mcg|Patient is given 10 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11158207|NCT03672045|Active Comparator|Carbetocin 20mcg|Patient is given 20 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11158208|NCT03672045|Active Comparator|Carbetocin 40mcg|Patient is given 40 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11158209|NCT03672045|Active Comparator|Carbetocin 60mcg|Patient is given 60 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11158210|NCT03672045|Active Comparator|Carbetocin 80mcg|Patient is given 80 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11158211|NCT03672045|Active Comparator|Carbetocin 100mcg|Patient is given 100 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
11158212|NCT03672032|Active Comparator|SharkCore Needle|
11158213|NCT03672032|Active Comparator|Acquire Needle|
11158214|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
11158215|NCT03672006|Experimental|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
11158216|NCT03672006|Active Comparator|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
11158217|NCT03671993|Experimental|EPNS group|Electrical pudendal nerve stimulation (EPNS) is a type of conservative treatment which can directly modulate the pudendal nerve and produce a regulation effects on both the sensory fibers and the motor fibers of pudendal nerve.
11158218|NCT03671993|Active Comparator|II group|Intravesical instillation (II) are mixture solution administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects.
11158219|NCT03671980|Experimental|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
11158220|NCT03671967|Experimental|piperacillin tazobactam|
11158221|NCT03671967|Active Comparator|meropenem|
11158222|NCT03671954|Experimental|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
11158223|NCT03671954|Active Comparator|TKA Control Group|The TKA control group will receive standard physical therapy alone.
11158224|NCT03671954|Active Comparator|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
11158225|NCT03671941|Active Comparator|Group A|D578 Tab. 1T
11158226|NCT03671941|Experimental|Group B|CKD-357 Tab. 1T
11158227|NCT03671928|Other|bowel ischemia|
11158228|NCT03671928|Other|non-digestive abdominal pain|
11158229|NCT03671915|Active Comparator|Usual System (Open-loop)|In open loop: sensor-augmented pump (SAP) therapy using standard insulin pump setting combined with the six-generation glucose sensor (Dexcom G6).
11158230|NCT03671915|Experimental|DIABELOOP System (Closed-loop)|"In the closed loop: Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.
~A remote monitoring system managed by specialized nurse on behalf diabetologist, is provided in closed-loop session."
11158231|NCT03671902|Other|Lower Body Negative/Positive Pressure|
11158232|NCT03671889|Experimental|Blood Brain Barrier (BBB) Disruption|ExAblate Model 4000 Type 2.0 System
11158233|NCT03671876|Active Comparator|Intervention plus therapy|"Case group:
~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.
~Intervention with the Selfit system include a set of mobility task exercises."
11158234|NCT03671876|No Intervention|Therapy and no intervention|"Control group:
~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
11158235|NCT03671863||Infants who are treated for clubfoot|Infants who are treated for clubfoot in the reference reeducation center
11158236|NCT03671850|Experimental|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
11158237|NCT03671850|Placebo Comparator|Placebo|Peripheral blood mononuclear cell, PBMC
11158238|NCT03671837|Experimental|Oyxgen|Nasal Insufflation with 15 L/min O2 and a nasopharyngeal airway
11158239|NCT03671837|Active Comparator|Air|Nasal Insufflation with 15 L/min air and a nasopharyngeal airway
11158240|NCT03671824||Lean|BMI ≤ 30 kg/m2
11158241|NCT03671824||Obese|BMI ≥30 kg/m2
11158242|NCT03671811|Experimental|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
11158243|NCT03671811|Experimental|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
11158291|NCT03671434|Experimental|RPC Congressional Offices|Congressional offices that are assigned to the experimental group that is eligible to receive the full RPC intervention
11158244|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
11158245|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
11158246|NCT03671785|Experimental|Active group treated with healthy fecal microbiota|
11158247|NCT03671785|Experimental|Placebo group|
11158248|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
11158249|NCT03671772||FDRs of controls|First-degree relatives of controls
11158250|NCT03671759|Experimental|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
11158251|NCT03671746|Placebo Comparator|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
11158252|NCT03671746|Experimental|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
11158253|NCT03671733|Experimental|Liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
11158254|NCT03671733|Experimental|Exenatide|Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
11158255|NCT03671733|Experimental|Exenatide Microspheres for Injection|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
11158256|NCT03671720|Experimental|personalized vaccine|
11158257|NCT03671707|Experimental|Intervention group|Brief AWARD advice + Nicotine replacement therapy sampling + Active referral
11158258|NCT03671707|Active Comparator|Control group|Very brief advice (VBA) + Leaflet
11158259|NCT03671694|Active Comparator|laser treatment|Erbium-YAG laser treatment to the vagina
11158260|NCT03671694|Placebo Comparator|sham treatment|sham treatment with laser placebo
11158261|NCT03671681|Experimental|MT group|Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and six group sessions of 45 minutes of mindfulness-based treatment.
11158262|NCT03671681|Other|MED group|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (i.e. clinical features, previous failures and contraindications)
11158263|NCT03671668|Active Comparator|Screw retained prosthesis on transmucosal abutments|
11158264|NCT03671668|Experimental|Screw retained prosthesis on titanium bases|
11158265|NCT03671655|Experimental|Drug-eluting stent|Drug-eluting stent is nitinol stent coated with Paclitaxel drug Other Names: Zilver PTX stent Zilver Paclitaxel stent
11158266|NCT03671655|Active Comparator|Bare metal stent|Bare metal stentis Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
11158267|NCT03671642|Experimental|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
11158268|NCT03671629|Experimental|Intervention group|In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.
11158269|NCT03671629|No Intervention|Control group|This group receives standard care, which might include a medication review at the hospital.
11158270|NCT03671616|Experimental|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
11158271|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
11158272|NCT03671590|Experimental|Arm 1|TG-1701 oral daily dose
11158273|NCT03671590|Experimental|Arm 2|TG-1701 + Ublituximab + Umbralisib
11158274|NCT03671577|Experimental|Active Treatment|four week computerized intervention designed to reduce fear of intimacy
11158275|NCT03671577|No Intervention|Wait List Control|Participants will continue as usual and will be given the option to receive the active treatment after completion of the study
11158276|NCT03671564|Experimental|Dose Escalation - Milademetan|All participants enrolled for dose escalation receive a single oral dose of 90 mg milademetan, followed by escalated doses, based on mCRM with EWOC
11158277|NCT03671551||Psychomotor/psychological evaluation|Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
11158278|NCT03671538|Experimental|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
11158279|NCT03671525|Experimental|Nimodipine|One 60mg capsule of nimodipine on first or second study visit
11158280|NCT03671525|Placebo Comparator|Placebo|One placebo capsule on first or second study visit
11158281|NCT03671512|Experimental|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
11158282|NCT03671512|Active Comparator|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
11158283|NCT03671499|Experimental|Social Cognitive Theory based text messages|The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
11158284|NCT03671486||GBS-negative pregnant women|One Hundred Healthy GBS-negative pregnant women will be follow-up since the first trimester of pregnancy until one month post-delivery
11158285|NCT03671473|Experimental|Focused|fESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
11158286|NCT03671473|Active Comparator|Radial|rESWT (2000shocks, 4 Bar, 5Hz)
11159378|NCT03663998|Active Comparator|E|CN54ENV ID EP 1200 g
11158292|NCT03671434|Active Comparator|Control Researchers|Researchers who are assigned to an Active Comparator control group that is enrolled in a light-touch intervention
11158293|NCT03671434|No Intervention|Control Congressional Offices|Congressional offices that are assigned to the control group that receives no intervention
11158294|NCT03671421|Active Comparator|Quads tendon|The graft tissue will be quadriceps tendon
11158295|NCT03671421|Active Comparator|Hamstring|Semitendinosus and gracilis will be used for graft
11158296|NCT03671421|Active Comparator|BPTB|Bone patellar tendon bone graft to be used.
11158297|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
11158298|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
11158299|NCT03671382|Experimental|Intervention Arm|Communication Training Program and Patient Prompt Sheet
11158300|NCT03671382|No Intervention|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
11158301|NCT03671369||Cervarix Group|The study group comprises of 9-25 year-old male and female subjects who will be administered 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects can be vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose is administered before 5 months after the first dose, the third dose vaccination is required. In the 3 doses schedule, if the vaccination schedule requires flexibility, the second dose can be administered between 1 and 2.5 months and the third dose can be administered between 5 and 12 months after the first dose.
11158302|NCT03671343|Experimental|Intervention : Physical rehabilitation|"The Arm Physical rehabilitation will benefit from the implementation of the Loss of Mobility Prevention program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY."
11158303|NCT03671343|No Intervention|Control : optimized medical treatment|"The Arm Optimized medical treatment will not benefit from the implementation of the Loss of Mobility Prevention program."
11158304|NCT03671330|Experimental|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.
~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.
~It is the investigators choice for NSAI based on patient's past medical history.
~Postmenopausal experimental arm:
~Letrozole + Ribociclib
~PK Cohort: Open-label ribociclib + Letrozole treatment combination.
~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
11158305|NCT03671330|Placebo Comparator|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.
~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.
~It is the investigators choice for NSAI based on patient's past medical history.
~Postmenopausal control arm:
~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
11158306|NCT03671317|Experimental|Intervention group|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
11158307|NCT03671317|No Intervention|Non-intervention group|This arm will continue usual care with no intervention from medical clowns. They will be asked to complete pre and post surveys about the blood draw process.
11158308|NCT03671304|Experimental|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
11158309|NCT03671291|Experimental|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
11158310|NCT03671278|Other|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
11158311|NCT03671265|Experimental|SHR-1210 + Chemotherapy + Radiotherapy|"Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.
~SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
~Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.
~Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )"
11158312|NCT03671252|Experimental|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
11158406|NCT03670654|Sham Comparator|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
11158559|NCT03669497|Experimental|Hypo fractionated radiotherapy|Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour
11158313|NCT03671252|Active Comparator|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
11158314|NCT03671239|Other|Product Sequence A|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
11158315|NCT03671239|Other|Product Sequence B|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
11158316|NCT03671239|Other|Product Sequence C|Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.
11158317|NCT03671239|Other|Product Sequence D|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.
11158318|NCT03671239|Other|Product Sequence E|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
11158319|NCT03671239|Other|Product Sequence F|Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
11158320|NCT03671226|Experimental|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
11158321|NCT03671213|Experimental|Calypso|Calypso Knee System
11158322|NCT03671187|Experimental|Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
11158323|NCT03671187|Experimental|Ex- Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
11158324|NCT03671174|Experimental|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
11158325|NCT03671174|Experimental|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
11158326|NCT03671174|Active Comparator|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
11158327|NCT03671161|Experimental|Patients with poorly controlled diabetes type 1|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring
11158328|NCT03671148|Experimental|Risankizumab|Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
11158329|NCT03671148|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
11158330|NCT03671135|Experimental|TCA Intrastromal Inlay|A monocular intrastromal corneal inlay will be implanted.
11158331|NCT03671122||PREFERS main study|500 patients with new onset heart failure will be characterized into those with HFpEFand HFrEF at baseline and undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis
11158332|NCT03671122||CABG PREFERS|500 Patients undergoing elective by pass surgery with or without diastolic or systolic dysfunction as Proxy for HFpEF and HFrEF will undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis and cardiac biopsies
11158333|NCT03671109|Experimental|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
11158334|NCT03671109|Placebo Comparator|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
11158335|NCT03671096|Experimental|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
11158336|NCT03671083||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
11158337|NCT03671083||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
11158338|NCT03671070|Active Comparator|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
11158339|NCT03671070|Placebo Comparator|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
11158340|NCT03671057|Experimental|HospiAvontuur|Intervention group - Non-pharmacological (HospiAvontuur) preparation HospiAvontuur is a simple point and click adventure game on a I-pad. The game describes the pathway which a child and his parents will take before, during and just after a hospital admission for an elective otorhinolaryngeal procedure under general anaesthesia.
11158442|NCT03670381||ASD group|ASD patients with HDAC4 CNVs
11158443|NCT03670381||TD group|Typically developing controls without lifetime ASD or a family history of ASD
11158341|NCT03671057|Active Comparator|Midazolam|control group: The children of the control group will not play the game HospiAvontuur as an at home preparation for surgery. These children will be prepared for surgery according to the current practice at the Jessa hospital. Children receive only the basic information during the consultation with the surgeon. There is no specific at home preparation required. When admitted at the hospital, children receive a pharmacological preparation, 45 - 60 minutes prior to the induction of the anaesthesia. The medication is administered orally by a small syringe in the mouth and contains Dormicum 0.3mg/kg body weight and atropine 0.02mg/kg body weight supplemented with raspberry syrup.
11158342|NCT03671044|Experimental|Nanosomal Docetaxel Lipid Suspension - 75 mg/m2|Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
11158343|NCT03671044|Experimental|T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
11158344|NCT03671044|Active Comparator|R, Taxotere® (100 mg/m2)|Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
11158345|NCT03671031||isolated roux loop|isolated roux loop reconstruction following pancreaticoduodenectomy as the first group.
11158346|NCT03671031||single loop|single loop reconstruction following pancreaticoduodenectomy as the second group.
11158347|NCT03671018|Experimental|Dose Finding|Participants will receive mosunetuzumab in combination with polatuzumab vedotin. Dose finding will be guided by the observed incidence of dose-limiting toxicities (DLTs) at each dose level.
11158348|NCT03671018|Active Comparator|Bendamustine + Rituximab + Polatuzumab Vedotin|Participants with DLBCL randomized to this arm will receive bendamustine + rituxumab + polatuzumab vedotin.
11158349|NCT03671018|Experimental|Mosunetuzumab DLBCL|Participants with DLBCL randomized to this arm will receive mosunetuzumab at the RP2D as a single agent.
11158350|NCT03671018|Experimental|Expansion Phase|Participants with R/R FL and participants with R/R DLBCL will receive mosunetuzumab and polatuzumab vedotin at the RP2D.
11158351|NCT03671018|Experimental|Mosunetuzumab + Polatuzumab Vedotin DLBCL|Participants with DLBCL randomized to this arm will receive mosunetuzumab + polatuzumab vedotin.
11158352|NCT03671005|Experimental|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
11158353|NCT03671005|Active Comparator|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
11158354|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
11158355|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
11158356|NCT03670979|Experimental|bone swaging alone|xenograft alone
11158357|NCT03670979|Experimental|bone swaging plus EDTA|bone swaging with EDTA
11158358|NCT03670966|Experimental|Treatment (211At-BC8-B10, chemotherapy, TBI, MMF, G-CSF)|"PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion over 6-8 hours on day -8, fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on days -6 and -5. Patients also undergo TBI on day -1.
~TRANSPLANT: Patients undergo PBSC or bone marrow transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID on days 5-35, and sirolimus PO daily on days 5-180 with taper beginning on day 84 per physician discretion. Patients also begin G-CSF IV or SC on day 5 to continue until ANC > 1000/mm^3 x 3 days."
11158359|NCT03670953|Experimental|IPX203 ER CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to investigational product IPX203 ER CD-LD and IR CD-LD placebo.
~IR CD-LD active and placebo are tablets and IPX203 ER CD-LD active is capsules. Dosage and frequency is patient specific."
11158360|NCT03670953|Active Comparator|IR CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to IPX203 placebo and IR CD-LD active comparator.
~IR CD-LD active is tablets and IPX203 active and placebo are capsules. Dosage and frequency is patient specific."
11158361|NCT03670940||COPD patients|COPD patients without bronchiectasis
11158362|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
11158363|NCT03670927||Cases|Cases (incident patients with a diagnosis of primary sarcoma and histologically confirmed by an expert pathologist of the RRePS or ResOs networks in the 15 districts of France participating to this study) Environmental, occupational and lifestyle-related exposures
11158364|NCT03670927||Controls|"Subjects never diagnosed with a primary sarcoma and individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list.
~Environmental, occupational and lifestyle-related exposures"
11158555|NCT03669549|Experimental|Nevanimibe hydrochloride|Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID
11158593|NCT03669237|Experimental|end-to-side anastomosis|
11158365|NCT03670914|Experimental|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
11158366|NCT03670901|Experimental|JHL1101|375 mg/m2 of JHL1101 is given intravenously on D1 of each cycle
11158367|NCT03670901|Active Comparator|MabThera|375 mg/m2 of Rituximab is given intravenously on D1 of each cycle
11158368|NCT03670888|Experimental|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
11158369|NCT03670888|Active Comparator|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
11158370|NCT03670875|Experimental|Agave inulin|Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
11158371|NCT03670875|Experimental|Curcumin|Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
11158372|NCT03670875|Experimental|Omega 3 Fatty Acids|O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
11158373|NCT03670875|Other|Control|Recommendations to decrease calories intake an do exercise.
11158374|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
11158375|NCT03670849|Experimental|Patients using LapAR system|
11158376|NCT03670836|Experimental|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
11158377|NCT03670836|Experimental|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
11158378|NCT03670823||Healthy subjects|50 healthy subjects for a control group
11158379|NCT03670823||Patients with Major Depression|50 patients with major depression for a research group
11158380|NCT03670810|Experimental|Lasmiditan High Dose|Lasmiditan administered orally. Placebo administered orally to maintain blind.
11158381|NCT03670810|Experimental|Lasmiditan Low Dose|Lasmiditan administered orally. Placebo administered orally to maintain blind.
11158382|NCT03670810|Placebo Comparator|Control|Placebo and lasmiditan administered orally.
11158383|NCT03670797||controlled diabetic patients|
11158384|NCT03670797||uncontrolled diabetic patients|
11158385|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
11158386|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
11158387|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
11158388|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
11158389|NCT03670745|Experimental|Pre-visit Planning Tool|To determine the effectiveness an electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit. Interviews will also explore approaches to implement and evaluate such a tool.
11158390|NCT03670745|Active Comparator|control group|Will not be receiving an electronic self-administered pre-visit planning tool.
11158391|NCT03670732|Active Comparator|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
11158392|NCT03670732|Active Comparator|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
11158393|NCT03670719|Experimental|Manual Therapy and Exercise Group|Combination of manual therapy and exercises for chronic cervical pain
11158394|NCT03670719|Active Comparator|Exercise Group|Only exercises for chronic cervical pain
11158395|NCT03670706|Active Comparator|Group A|Exercise training, then crossover to analgesic optimisation
11158396|NCT03670706|Active Comparator|Group B|Analgesic optimisation, then crossover to exercise training
11158397|NCT03670706|No Intervention|Group C|Control group
11158398|NCT03670693|Experimental|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 >14, and a score of >4 in the Fatigue questionnaire.)
11158399|NCT03670693|Experimental|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 <14, and a score of <4 in the Fatigue questionnaire.)
11158400|NCT03670693|Experimental|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
11158401|NCT03670680|Experimental|Lina LibrataTM|Use of the Lina LibrataTM
11158402|NCT03670667||RA patients treated with abatacept|
11158403|NCT03670667||RA patients treated with anti-TNFi's|
11158404|NCT03670667||RA patients treated with other biologics|
11158405|NCT03670654|Active Comparator|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
11158407|NCT03670641|Experimental|Insulin and CGM Intervention|10 individuals with newly diagnosed type 2 diabetes will be started on basal (glargine) bolus (lispro) insulin therapy for up to 4 weeks with titrations guided by continuous glucose monitor (Dexcom G6) to achieve euglycemia and then insulin stopped after 4 weeks with hopes of diabetes remission.
11158408|NCT03670628|Active Comparator|720 shockwave therapy|5 Daily sessions of shockwave therapy within a week.( Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shock of treatment energy will be applied in every session to each region ( left and right corpora cavernosa and crura)
11158409|NCT03670628|Sham Comparator|None shockwave therapy|5 Daily sessions of shockwave therapy within a week.( Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shock of treatment energy will be applied in every session to each region ( left and right corpora cavernosa and crura. The device probe, will be covered with a cap that will stopped the transmission of shockwaves.
11158410|NCT03670615|Experimental|Exercise and tDCS|Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
11158411|NCT03670615|Other|Exercise Education and tDCS|Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
11158412|NCT03670615|Other|Exercise and Sham tDCS|Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
11158413|NCT03670602|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
11158414|NCT03670602|Other|Control Thinking|Participants will generate or be provided with non-future cues.
11158415|NCT03670589||radiosurgery gammaknife group|Patient treated by radiosurgery gammaknife for a one side vestibular schwannoma
11158416|NCT03670589||microsurgery resection group|Patient treated by microsurgery resection for a one side vestibular schwannoma
11158417|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
11158418|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
11158419|NCT03670563|Experimental|Exercise 1|Short foot exercise protocol instructed utilizing verbal instruction, passive modeling, active-assisted modeling, and active modeling.
11158420|NCT03670563|Active Comparator|Exercise 2|Short foot exercises plus NMES. Short foot exercise protocol instructed utilizing verbal instruction, passive modeling assisted by neuromuscular electric stimulation (NMES), active-assisted modeling assisted by neuromuscular electric stimulation, and active modeling.
11158421|NCT03670563|No Intervention|Control|No exercise intervention; continue normal physical activity, but do not start any new exercise programs
11158422|NCT03670550|Experimental|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.
~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
11158423|NCT03670537||First trimester pregnant women|
11158424|NCT03670524|Experimental|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
11158425|NCT03670524|No Intervention|Control Group|No intervention
11158426|NCT03670511|Experimental|sit-to-stand|
11158427|NCT03670511|Active Comparator|six minute walking test|
11158428|NCT03670498|Experimental|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
11158429|NCT03670498|Active Comparator|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
11158430|NCT03670485|Experimental|Revised sequential activation protocol|"Apply 4 channel electrical stimulation device with a revised sequential activation protocol.
~It sequentially activates Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device."
11158431|NCT03670485|No Intervention|control subject|Apply 4 channel electrical stimulation device without any stimulation
11158432|NCT03670459|Experimental|Group 1|Patients in G1 will receive traditional physical therapy program (balance exercises) for twelve sessions; day after day
11158433|NCT03670459|Experimental|Group 2|Patients in G2 will receive Cawthorne Cooksey Exercises in addition to traditional physical therapy program for twelve sessions; day after day .
11158434|NCT03670459|Experimental|Group 3|Patients in G3 will receive vestibular habituation exercises in addition to traditional physical therapy program for twelve sessions; day after day.
11158435|NCT03670446|Experimental|Pharmacists' intervention|A group of participants assigned to a pharmaceutical intervention
11158436|NCT03670446|No Intervention|Routine therapy|A group of participants assigned to a control (routine therapy)
11158437|NCT03670433||Patients admitted in the Polyvalent Internal Medical Unit|"Patients over 65 years old admitted in the Polyvalent Internal Medical Unit (UMIP) of Rennes University Hospital between 09/04/2017 and 10/31/2017 or going back home or to a rehabilitation service during the same period.
~Cost analysis of medication reconciliation."
11158438|NCT03670420|Experimental|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
11158439|NCT03670420|No Intervention|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
11158440|NCT03670407|No Intervention|Control group|Participants who opt not to go ahead with ovarian fragmentation.
11158441|NCT03670407|Experimental|Study group|Participants who opt for ovarian fragmentation.
11158444|NCT03670368|Experimental|Intervention (Mentor/Mentee)|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on social relationships, coping behaviors, and healthy lifestyles.
11158445|NCT03670368|Active Comparator|Comparison group - written materials|Youth in the comparator group will receive written versions of all materials covered in the mentoring sessions.
11158446|NCT03670355|Experimental|Tenofovir (TFV) Intravaginal Ring (IVR)|The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
11158447|NCT03670355|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
11158448|NCT03670329|Experimental|URGO2875|Dressing
11158449|NCT03670316|Experimental|Algorithm Treatment plus referral to quitline (AT)|will be assigned a pharmacotherapy treatment regimen recommended to their provider.
11158450|NCT03670316|Active Comparator|Quitline (eTAU)|will be referred to quitlines, telephone-based tobacco cessation services.
11158451|NCT03670303|Experimental|Intervention group|This group will include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance will be assessed at 3 months follow-up after baseline assessment than educational intervention will be given. Three months after intervention compliance will be assessed again.
11158452|NCT03670303|No Intervention|Control group|This group will also include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance towards spectacle use will be assessed at 3 months and 6 months after baseline assessment. No intervention will be given in this group.
11158453|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
11158454|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
11158455|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
11158456|NCT03670264|Experimental|Quitline Incentive|The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
11158457|NCT03670264|Experimental|Tobacco Cessation Incentive|The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
11158458|NCT03670264|Placebo Comparator|No Financial Incentive|No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.
11158459|NCT03670251|Other|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
11158460|NCT03670238|Experimental|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
11158461|NCT03670238|Active Comparator|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
11158462|NCT03670225|Other|Invia Motion Endure|
11158463|NCT03670212|Placebo Comparator|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
11158464|NCT03670212|Experimental|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
11158465|NCT03670199|Experimental|Experimental group|nutritional and functional management coordinated by dieticians and physiotherapists, with adapted nutritional and physical advice and support, realized with the use of Nutrimus booklet in order to facilitate coordination and delivration of cares proposed to the patients
11158466|NCT03670199|Active Comparator|Control group|usual preoperative advice for patients who undergoing surgical procedure concerning nutritional cares and physical activity
11158467|NCT03670186|Experimental|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
11158468|NCT03670186|Experimental|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
11158469|NCT03670173|Experimental|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
11158470|NCT03670160|Active Comparator|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
11158471|NCT03670160|Active Comparator|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
11158594|NCT03669237|No Intervention|end-to-end anastomosis|
11158472|NCT03670147|Experimental|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
11158473|NCT03670147|Experimental|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
11158474|NCT03670134|Experimental|Volumetric laser Endomicroscopy (VLE)|Volumetric laser Endomicroscopy (VLE) is a second-generation optical coherence tomography platform that can image the human esophagus in cross-section at microscopic resolution this will performed by using the Nvision VLE Imaging System.
11158475|NCT03670121|Experimental|BTVA Treatment|All patients that will receive Bronchoscopic Thermal Vapor Ablation (BTVA) Treatment
11158476|NCT03670108||patients receiving an individualized SMS|
11158477|NCT03670108||patients receiving a standard SMS|
11158478|NCT03670095|Experimental|Lactose-free memantine tablet|(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
11158479|NCT03670095|Experimental|Lactose-containing memantine tablet (Ebixa®)|(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
11158480|NCT03670082|Experimental|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
11158481|NCT03670082|Experimental|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
11158482|NCT03670069|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11158483|NCT03670056|Experimental|Nivolumab and Ipilimumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
11158484|NCT03670043|Active Comparator|Metformin ER|The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
11158485|NCT03670043|Experimental|Psyllium|The subjects developing GI-related symptoms with metformin will be randomized to Psyllium
11158486|NCT03670030|Experimental|ABI-009|In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.
11158487|NCT03670017|Other|Time In Range during OptiScanner Connection|Participants will be connected to the OptiScanner 5000 for up to 72 hours.
11158488|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
11158489|NCT03670004||Non-Impaired|Able-bodied controls
11158490|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.
~Creation of a bone and arterial panorama using EndoNaut® software."
11158491|NCT03669965|Experimental|Part A Arm 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
11158492|NCT03669965|Experimental|Part A Arm 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
11158493|NCT03669965|Experimental|Part A Arm 3|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
11158494|NCT03669965|Experimental|Part B KRT-232 Arm|Recommended KRT-232 dose and schedule from Part A
11158495|NCT03669965|Active Comparator|Part B Ruxolitinib Arm|Ruxolitinib per approved prescribing label
11158496|NCT03669965|Experimental|Part A Arm 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
11158497|NCT03669965|Experimental|Part A Arm 2b|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
11158498|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
11158499|NCT03669939||Communication strategy|Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
11158500|NCT03669939||Standard of Care|Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
11158501|NCT03669926|Other|DBT+SM|Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
11158502|NCT03669913|Experimental|Intervention|Intervention arm will receive a pre evaluation survey, 11 lessons on CSE sequentially in a period of one year and a post evaluation survey
11158503|NCT03669913|No Intervention|Control arm|This is a control arm that receives no intervention but will have and pre and post evaluation in one year
11158504|NCT03669900|Other|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
11158505|NCT03669887|Experimental|Lifestyle Modification Program|
11158506|NCT03669887|No Intervention|Control|
11158507|NCT03669861|Experimental|Abatacept|To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
11158508|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
11158509|NCT03669835|Experimental|Dietary supplement and standard therapy.|Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
11158510|NCT03669835|Other|Standard therapy only.|Patients would be given standard treatment for 1 month.
11158556|NCT03669523|Experimental|Denosumab-nivolumab combination|Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years
11158557|NCT03669510|Active Comparator|computer gaiuded IAN|Computer guided surgical technique
11158511|NCT03669822||Inpatient ulcerative colitis patients|Patients hospitalized for acute severe ulcerative colitis will be invited to enroll. Participants will be treated at the discretion of their treating physicians per standard of care. We expect some participants will be treated with standard versus accelerated infliximab dosing, permitting comparison, in addition to other treatment strategies.
11158512|NCT03669809||male, non-obese|male with BMI<28
11158513|NCT03669809||male, obese|male with BMI≥28
11158514|NCT03669809||female, non-obese|female with BMI<28
11158515|NCT03669809||female, obese|female with BMI≥28
11158516|NCT03669796|Experimental|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
11158517|NCT03669796|Placebo Comparator|control|20 mg powder per kg body weight of casein/maltodextrin
11158518|NCT03669783|Active Comparator|treatment VAD|Vincristin, Actinomycin-D and Doxorubicin
11158519|NCT03669783|Experimental|treatment VCE|Vincristin, Carboplatin and Etoposide
11158520|NCT03669757|Experimental|LEO 134310 Dose A|Once daily application
11158521|NCT03669757|Experimental|LEO 134310 Dose B|Once daily application
11158522|NCT03669757|Experimental|LEO 134310 Dose C|Once daily application
11158523|NCT03669757|Experimental|LEO 134310 Dose D|Once daily application
11158524|NCT03669757|Placebo Comparator|LEO 134310 vehicle|Once daily application
11158525|NCT03669757|Active Comparator|0.1% betamethasone valerate ointment (class III steroid)|Once daily application
11158526|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
11158527|NCT03669731|Experimental|Group 1|Urinary urea 24 hours and food diary
11158528|NCT03669731|Experimental|Group 2|Urinary urea 24 hours and food diary
11158529|NCT03669731|Experimental|Group 3|Urinary urea 24 hours and food diary
11158530|NCT03669718|Experimental|Active ISA101b and cemiplimab.|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
11158531|NCT03669718|Placebo Comparator|Placebo and cemiplimab|Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
11158532|NCT03669692|Active Comparator|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
11158533|NCT03669692|Experimental|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.
~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
11158534|NCT03669679|Active Comparator|Group A|"participants undergoing superomedial pedicle breast reduction Hall-Findlay technique"
11158535|NCT03669679|Active Comparator|Group B|"participants undergoing inferior pedicle breast reduction Robbins technique"
11158536|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
11158537|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
11158538|NCT03669653|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
11158539|NCT03669653|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
11158540|NCT03669640|Experimental|Part A: Monotherapy|Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
11158541|NCT03669640|Experimental|Part B: Add-On Therapy|Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).
11158542|NCT03669627|Active Comparator|Group 1: aTIV primer, QIV booster|Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.
11158543|NCT03669627|Other|Group 2: QIV primer, QIV booster|"Standard of care control group:
~Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2."
11158544|NCT03669627|Experimental|Group 3: aTIV primer, aTIV booster|"This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.
~Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2."
11158545|NCT03669614|Active Comparator|AR-501 inhaled|low , medium, high dose of inhaled AR-501
11158546|NCT03669614|Placebo Comparator|inhaled AR-501 Placebo|low, medium, high dose of inhaled placebo
11158547|NCT03669601|Experimental|Continuous AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.
~Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg."
11158548|NCT03669601|Experimental|Intermittent AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.
~Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg."
11158549|NCT03669588|Experimental|ARGX-113|
11158550|NCT03669588|Placebo Comparator|Placebo|
11158551|NCT03669575|Experimental|omega 7 - placebo|Receiving the active first then switch to the placebo after three weeks
11158552|NCT03669575|Active Comparator|placebo - omega 7|Receiving the placebo first then switch to the active after three weeks
11158553|NCT03669562|Experimental|Alprostadil liposome|
11158554|NCT03669562|Placebo Comparator|Placebo|
11158560|NCT03669484|Experimental|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.
~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.
~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
11158561|NCT03669484|Active Comparator|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.
~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.
~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.
~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
11158562|NCT03669471||FAIS group|Subjects who have had a hip arthroscopy for femoroacetabular impingement during the preceding 6-30 months
11158563|NCT03669458|Experimental|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
11158564|NCT03669458|Experimental|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
11158565|NCT03669458|Experimental|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
11158566|NCT03669445|Experimental|four drugs combination|21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
11158567|NCT03669432|Experimental|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.
~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.
~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
11158568|NCT03669432|Other|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
11158569|NCT03669406|Experimental|Autograft fat|Paraplegic patients with healed pelvic eschar
11158570|NCT03669393|Experimental|THR-317|
11158571|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
11158572|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
11158573|NCT03669367|Experimental|abatacept|abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
11158574|NCT03669367|Active Comparator|hydroxycloroquina|Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
11158575|NCT03669354||Cohort A|SMS for long-term management initiated in 2013, with no concurrent PDT
11158576|NCT03669354||Cohort B|PDT for long-term management initiated in 2013, with no concurrent SMS
11158577|NCT03669354||Cohort A2B|Any occurrence of SMS in 2013, followed by PDT for long-term management initiated in 2013
11158578|NCT03669354||Cohort B2A|Any occurrence of PDT in 2013, followed by SMS for long-term management initiated in 2013.
11158579|NCT03669341|Experimental|Deep Inspiration Breath Hold (DIBH)|DIBH extended by prior hyperventilation while breathing 100% O2
11158580|NCT03669341|Active Comparator|High Frequency Percussive Ventilation (HFPV)|passive Ventilation by a jet ventilator
11158581|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
11158582|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
11158583|NCT03669315|Active Comparator|Active cTBS treatment|Active cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. TBS consists of bursts of 3 pulses separated by 20ms (i.e. 50 Hz), with each triplet being repeated every 200 ms (i.e. 5 Hz). Stimulus intensities will be set at 80% of AMT. The investigators will use 2 trains of 600 pulses each separated by 1 minute (a total of 1200 pulses).
11158584|NCT03669315|Sham Comparator|Sham cTBS treatment|Sham cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same active cTBS configuration will be used.
11158585|NCT03669302|Sham Comparator|Robotic gait training|Robotic gait training only
11158586|NCT03669302|Experimental|Robotic gait training & low-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at low frequency (0.3 Hz).
11158587|NCT03669302|Experimental|Robotic gait training & high-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at high frequency (30 Hz).
11158588|NCT03669289|Experimental|Enhanced model of primary care|
11158589|NCT03669263|Experimental|Fentanyl buccal soluble film (FBSF)|Single arm
11158590|NCT03669250|Active Comparator|CVN058, 15 mg|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg.
11158591|NCT03669250|Active Comparator|CVN058, 150 mg|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
11158592|NCT03669250|Placebo Comparator|Placebo|Matching placebo.
11158595|NCT03669224|Experimental|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
11158596|NCT03669224|Active Comparator|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
11158597|NCT03669211|Experimental|Cardiac stress test|
11158598|NCT03669198|Active Comparator|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
11158599|NCT03669198|No Intervention|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
11158600|NCT03669185|Placebo Comparator|Placebos|Placebos, 2 times daily 1 tablet, intake max. 133 days
11158601|NCT03669185|Active Comparator|Pentalong|Pentalong, 2 times daily 1 tablet, intake max. 133 days
11158602|NCT03669172|Experimental|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
11158603|NCT03669146|Experimental|Hyperopic subjects receiving glasses|Randomized +5.00 to +7.00 diopter hyperopic subjects that will receive partial refractive correction and will be instructed to do accommodation exercises on a daily basis.
11158604|NCT03669146|No Intervention|Hyperopic subjects uncorrected|Randomized +5.00 to +7.00 diopter hyperopic subjects that will serve as the control to the experimental arm who will receive no correction but be observed for the duration of the study.
11158605|NCT03669146|Active Comparator|Highly hyperopic subjects corrected|If a subject is found to be greater than +7.00 diopters hyperopic during the screening phase of the study, they will receive glasses correction and be followed during the study period.
11158606|NCT03669133|Active Comparator|Group A|Vitamin E 800 IU/daily for 24 weeks
11158607|NCT03669133|Placebo Comparator|Group B|Matching placebo for 24 weeks
11158608|NCT03669120|Active Comparator|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
11158609|NCT03669120|Experimental|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
11158610|NCT03669107|Experimental|Gum chewing|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.
~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
11158611|NCT03669107|No Intervention|Control group|no gum
11158612|NCT03669094|Active Comparator|L. salivarius V4II-90|Lactobacillus salivarius V4II-90; approximately 1*10E9 colony forming unit (CFU) of L. salivarius V4II-90 in 1 oral capsule per day for 12 weeks.
11158613|NCT03669094|Placebo Comparator|Control group|Placebo supplement in 1 oral capsule per day for 12 weeks.
11158614|NCT03669081|Experimental|Toradol and Lyrica|Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
11158615|NCT03669081|Placebo Comparator|Placebo and Standard of Care|Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
11158616|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
11158617|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
11158618|NCT03669055|Experimental|Pre-operative and post operative Magnetic Resonance Imaging|Realization of an angio-MRI with 4D phase contrast sequence before and after the endovascular treatment of the aortic dissection
11158619|NCT03669042|Experimental|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
11158620|NCT03669029|Experimental|Week 6 Responders|In patients with clinical response at week 6, serum golimumab levels and anti-golimumab antibody levels will be correlated with clinical response.
11158621|NCT03669029|Experimental|Week 6 Non Responders|In patients without clinical response at week 6, golimumab treatment will be optimized.
11158622|NCT03669016|Experimental|Face-to-face group-based mindfulness|8 weeks training.
11158623|NCT03669016|Experimental|Internet-based mindfulness|8 weeks training.
11158624|NCT03669016|No Intervention|Waiting-list control group|No training during the study.
11158625|NCT03669003|Experimental|Gelfoam|Gelfoam slurry will be injected at the end of the biopsy procedure.
11158626|NCT03669003|Active Comparator|Standard procedure|Standard procedure of lung biopsy
11158627|NCT03668990|Other|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
~Funcitonal-oriented upper limb movements are performed at two different test days."
11158674|NCT03668808|Active Comparator|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
11158628|NCT03668990|Other|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
~Funcitonal-oriented upper limb movements are performed at two different test days."
11158629|NCT03668990|Other|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
~Funcitonal-oriented upper limb movements are performed at two different test days."
11158630|NCT03668977|No Intervention|Routine care|"In all four groups, the following antenatal and post-natal interventions will be offered:
~Women encouraged to enroll in routine antenatal care at their local health post/center.
~A clean birthing kit consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump.
~Women encouraged to deliver at a certified birthing facility and participate in the government's incentive scheme.
~Nutritional, hygiene, and infant care counseling.
~Tetanus toxoid (if needed) and iron-folic acid supplements."
11158631|NCT03668977|Experimental|Supplementation-pregnancy|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing throughout pregnancy. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
11158632|NCT03668977|Experimental|Supplementation-lactation|A daily fortified balanced protein-energy nutritional supplement beginning after delivery and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
11158633|NCT03668977|Experimental|Supplementation-pregnancy & lactation|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
11158634|NCT03668964|Experimental|Vitamin B2|Daily dose of 75 mg Vitamin B2
11158635|NCT03668964|Experimental|Vitamin C|Daily dose of 500 mg Vitamin C
11158636|NCT03668964|Experimental|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
11158637|NCT03668964|Experimental|Vitamin A|Daily dose of 250 µg Vitamin A
11158638|NCT03668964|Experimental|Vitamin D3|Daily dose of 60 µg Vitamin D3
11158639|NCT03668964|Experimental|Vitamin E|Daily dose of 100 mg Vitamin E
11158640|NCT03668964|Placebo Comparator|Placebo|Daily dose of 575 mg microcrystalline cellulose
11158641|NCT03668951|Experimental|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
11158642|NCT03668951|Experimental|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
11158643|NCT03668951|Experimental|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
11158644|NCT03668938|Experimental|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
11158645|NCT03668938|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
11158646|NCT03668925|Experimental|"Group Case"|patient diagnosed with hidrosadenitis suppurativa
11158647|NCT03668925|Active Comparator|"Group control"|patient without hidrosadenitis suppurativa
11158648|NCT03668912|Experimental|Guided participation group|
11158649|NCT03668912|No Intervention|Usual care group|
11158650|NCT03668899|Experimental|Chitosan NPs group|irrigation with Chitosan nanoparticles (final flush)
11158651|NCT03668899|Experimental|Chlorhexidine group|irrigation with CHX (final flush)
11158652|NCT03668899|Experimental|Combination group|irrigation with CHX/ nano Chitosan combination (final flush)
11158653|NCT03668899|Active Comparator|Hypochlorite group|irrigation with NaOCL (final flush)
11158654|NCT03668886|Experimental|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
11158655|NCT03668886|No Intervention|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
11158656|NCT03668873|Experimental|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-weeks. In addition to the five sessions, there are three home visits conducted via Express Care Online (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
11158657|NCT03668873|Active Comparator|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
11158658|NCT03668860|Active Comparator|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
11158659|NCT03668860|Active Comparator|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
11158660|NCT03668860|Active Comparator|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
11158661|NCT03668860|Active Comparator|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
11158662|NCT03668860|Active Comparator|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
11158663|NCT03668860|Active Comparator|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
11158664|NCT03668860|Active Comparator|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)
~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
11158665|NCT03668860|Active Comparator|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)
~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
11158666|NCT03668847|Experimental|DM-CHOC-PEN|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 75 or 98.7 mg/m2 emulsion will be administered IV once every 21-days until relapse
11158667|NCT03668834|Active Comparator|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
11158668|NCT03668834|Active Comparator|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
11158669|NCT03668834|Active Comparator|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
11158670|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
11158671|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
11158672|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
11158673|NCT03668808|Experimental|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
11158675|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
11158677|NCT03668769|Experimental|Prevention (smoking reduction, Quitting Schedule mobile app)|"AIM I: Participants follow an individually tailored gradual reduction of smoking schedule for 5 weeks while MDACC eHealth adapts WebCASSI into a smartphone app: Quitting Schedule.
~AIM II: Participants pre-test the Quitting Schedule mobile smartphone app for 5 weeks."
11158678|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
11158679|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
11158680|NCT03668730|Experimental|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
11158681|NCT03668730|Experimental|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
11158682|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
11158683|NCT03668678|Experimental|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
11158684|NCT03668678|No Intervention|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
11158685|NCT03668665|Active Comparator|Conventionell Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):
~1st half: conventional treatment with moist dressings (mepilex and fixomull)"
11158686|NCT03668665|Experimental|Treatment with Ready Medical Post Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):
~2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment"
11158687|NCT03668652|Experimental|Focal prostate cancer treatment by HIFU|Patients with target lesion distance < 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion > 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
11158688|NCT03668652|Active Comparator|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
11158689|NCT03668639|Other|Akynzeo plus dexamethasone|Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
11158690|NCT03668626|No Intervention|Term infants|Healthy term infants
11158691|NCT03668626|No Intervention|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
11158692|NCT03668626|Experimental|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
11158693|NCT03668613|Experimental|secukinumab low dose|secukinumab low dose
11158694|NCT03668613|Experimental|secukinumab high dose|secukinumab high dose
11158695|NCT03668600|Experimental|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
11158696|NCT03668574|Experimental|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
11158697|NCT03668574|Placebo Comparator|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
11158698|NCT03668561|Experimental|Treatment (CALIGALOC)|Wearing of the Caligaloc orthosis
11158699|NCT03668548|Experimental|Leucine group|To receive leucine on a daily basis for 10 weeks
11158700|NCT03668548|Placebo Comparator|Control group|To receive a placebo supplement on a daily basis for 10 weeks
11158701|NCT03668535|Active Comparator|Bladder Filling arm|Group A have triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
11158702|NCT03668535|Active Comparator|Bladder deflation arm|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
11158703|NCT03668522||children|age<=17
11158704|NCT03668522||adult|age>17
11158705|NCT03668509|Experimental|Cohort 1|oral adminstration of SHR1459, dose 1
11158706|NCT03668509|Experimental|Cohort 2|oral adminstration of SHR1459, dose 2
11158707|NCT03668509|Experimental|Cohort 3|oral adminstration of SHR1459, dose 3
11158708|NCT03668496|Experimental|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
11158709|NCT03668496|Active Comparator|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
11158747|NCT03668275|No Intervention|Control|standard oncological ambulatory hospital care
11158942|NCT03666923|Experimental|THR-687 dose level 1|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
11158710|NCT03668483|Experimental|Pulmonary Rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
11158711|NCT03668470|Experimental|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
11158712|NCT03668470|Placebo Comparator|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
11158713|NCT03668457|Experimental|Intervention to Patients|Only patients receive intervention
11158714|NCT03668457|Experimental|Intervention to Psychiatrists|Psychiatrists receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
11158715|NCT03668457|Experimental|Mixed Intervention|Patients and Psychiatrists associated with these patients receive intervention
11158716|NCT03668457|Other|Control|Psychiatrists provide the usual care Patients receive usual care
11158717|NCT03668444|Experimental|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
11158718|NCT03668444|Placebo Comparator|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
11158719|NCT03668431|Experimental|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.
~After the screening procedures confirm participation in the research study:
~Dabrafenib will be taken twice a day for 28 consecutive days
~Trametinib will be taken once a day for 28 consecutive days
~PDR001 will be administered IV every 28 days."
11158720|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
11158721|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
11158722|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
11158723|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
11158724|NCT03668405|Experimental|Lu AF20513 high dose|
11158725|NCT03668392|Experimental|Patients on Oncospar|
11158726|NCT03668379|Active Comparator|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 & 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 & 5 will review progress, challenges & maintenance strategies."
11158727|NCT03668379|Experimental|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
11158728|NCT03668366|Experimental|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
11158729|NCT03668353|Experimental|treatment 1|Recombinant SeV-hFGF2/dF Injection 2×10 8CIU
11158730|NCT03668353|Experimental|treatment 2|Recombinant SeV-hFGF2/dF Injection 1×10 9CIU
11158731|NCT03668353|Experimental|treatment 3|Recombinant SeV-hFGF2/dF Injection 5×10 9CIU
11158732|NCT03668353|Experimental|treatment 4|Recombinant SeV-hFGF2/dF Injection 1×10 10CIU
11158733|NCT03668340|Experimental|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
11158734|NCT03668340|Experimental|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
11158735|NCT03668340|Experimental|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
11158736|NCT03668314|Experimental|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
11158737|NCT03668314|Placebo Comparator|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
11158738|NCT03668314|Experimental|Cohort 2:1|Fed/Fast RDN-929
11158739|NCT03668314|Experimental|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
11158740|NCT03668314|Placebo Comparator|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
11158741|NCT03668301||Group CPB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery with cardiopulmonary bypass
11158742|NCT03668301||Group OPCAB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery without cardiopulmonary bypass
11158743|NCT03668301||Group CPB-C|Control patients undergoing cardiac surgery with cardiopulmonary bypass
11158744|NCT03668301||Group OPCAB-C|Control patients undergoing cardiac surgery without cardiopulmonary bypass
11158745|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
11158746|NCT03668275|Experimental|Intervention|(partial) oncological home-hospitalization
11158748|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
11158749|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
11158750|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
11158751|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
11158752|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
11158753|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
11158754|NCT03668249||All Participants|Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.
11158755|NCT03668236|Experimental|Fluid restriction group|"No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:
~In case of severe hypoperfusion or severe circulatory impairment defined by either:
~Lactate≥4 mmol/L
~MAP<50 mmHg (with or without vasopressor/inotrope)
~Mottling beyond the kneecap (mottling score >2) OR
~Urinary output<0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation
~A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation
~In case of overt fluid losses (e.g. vomiting, large aspirates,…) IV fluid may be given to correct for the loss, but not above the volume lost.
~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:
~Correct dehydration or electrolyte deficiencies
~Ensure a total fluid input of 1L per 24hrs
~IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible"
11158756|NCT03668236|Active Comparator|Standard-care|"There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:
~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.
~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid
~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
11158757|NCT03668223|Experimental|Promoting Resilience in Stress Management (PRISM)|Resilience Skills Training
11158758|NCT03668223|No Intervention|Usual Care|Standard psychosocial care
11158759|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.
~Isokinetic evaluation."
11158760|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.
~Isokinetic evaluation."
11158761|NCT03668171|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks
11158762|NCT03668171|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2
11158763|NCT03668158||recurrent HCC|recurrent HCC after LT
11158764|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
11158765|NCT03668145|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.
11158766|NCT03668145|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.
11158767|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
11158768|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
11158769|NCT03668132||Normal control|Not have the ischemic brain damage
11158772|NCT03668106|Active Comparator|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
11158773|NCT03668106|Active Comparator|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.
~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
11158774|NCT03668106|Active Comparator|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.
~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.
~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
11158775|NCT03668093|Experimental|ICCMS|Intervention
11158776|NCT03668093|Active Comparator|CAMBRA|Comparator
11158777|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
11158778|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
11158779|NCT03668067||2WIN|Accommodation, refraction and ocular alignment are estimated by infrared photoscreener using the 2WIN photoscreener device. Photoscreener screening makes use of light crescent quantification from off-axis flash-to-lens in a camera.
11158780|NCT03668067||school bus skiascopy|Refractive error estimated by child-friendly skiascopy rack holding lenses from +1.00 D to +10.00 D and -5.00 D. Skiascopy is a common, old-fashioned form of retinoscopy.
11158781|NCT03668054|Experimental|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
11158782|NCT03668041|Active Comparator|Trazodone|Participants who are assigned to take trazodone, an active study medication.
11158783|NCT03668041|Active Comparator|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
11158784|NCT03668041|Active Comparator|Gabapentin|Participants who are assigned to take gabapentin, an active study medication.
11158785|NCT03668041|Placebo Comparator|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
11158786|NCT03668028|Experimental|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
11158787|NCT03668028|Placebo Comparator|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
11158788|NCT03668015|Experimental|Group A (Xylitol then sorbitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol"
11158789|NCT03668015|Experimental|Group B (Sorbitol then xylitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol"
11158790|NCT03668002|Placebo Comparator|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
11158791|NCT03668002|Active Comparator|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
11158792|NCT03667989|Other|123I-MIBG CZT SPECT|Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
11158793|NCT03667976|No Intervention|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
11158943|NCT03666923|Experimental|THR-687 dose level 2|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
11158944|NCT03666923|Experimental|THR-687 dose level 3|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
11158794|NCT03667976|Experimental|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
11158795|NCT03667963|Other|Low Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
11158796|NCT03667963|Other|High Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
11158797|NCT03667950|Experimental|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
11158798|NCT03667937|Experimental|CUTIMED|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.
~If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.
~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
11158799|NCT03667937|Active Comparator|AQUACEL silver|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.
~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
11158800|NCT03667924|Experimental|PorchLight Project Intervention Group|Participants in the intervention group will receive home-based support and respite services from PorchLight Project trained Senior Companion volunteers of the Lutheran Social Services of Minnesota.
11158801|NCT03667911|No Intervention|Control Group|Only routine patient education on bowel preparation of colonoscopy. Give oral instructions on bowel preparation(including definition, significance, correct steps as well as dietary limitations) by a well-trained nurses or doctors. Written instructions are offered, which have the some contents.
11158802|NCT03667911|Experimental|Virtual-reality Group|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
11158803|NCT03667898|Experimental|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
11158804|NCT03667898|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
11158805|NCT03667885||Small renal Masses|patients with a renal mass of 4 cm or less. Typically incidentally found. Blood and urine samples will be collected from each patient at baseline before a biopsy of the tumor is collected and 14 days later. In addition, all patients will be offered a Multi planar MRI before the biopsy. Patients elected for curative treatment for malignant tumors will have another set of blood and urine samples collected at 1 month and 6 months after the intervention.
11158806|NCT03667872|Experimental|Device|MRI compatible and LFP recordable implantable stimulator
11158807|NCT03667859||Women undergoing Brachytherapy|Women with either uterine or cervical malignancy treated primarily by brachytherapy.
11158808|NCT03667859||Women undergoing Pelvic Radiation|Women with either uterine or cervical malignancy treated primarily by pelvic radiation.
11158809|NCT03667846|Placebo Comparator|Placebo|Placebo
11158810|NCT03667846|Experimental|Topiramate|Week 0-1: 25 mg qhs Week 1-2: 25 mg qAM, 25 mg qhs Week 2-3: 25 mg qAM, 50 mg qhs Week 3-4: 50 mg qAM, 50 mg qhs Week 4-5: 50 mg qAM, 75 mg qhs Week 5-6: 75 mg qAM, 75 mg qhs Week 6-7: 75 mg qAM, 100 mg qhs Week 7-8: 100 mg qAM, 100 mg qhs Week 8-10: 100 mg qAM, 100 mg qhs Week 10-12: 100 mg qAM, 100 mg qhs Week 12-14: 2-week taper
11158811|NCT03667833|Experimental|shoulder brace with comfortable tension|"Self-comfortable tension of strap will be adjusted by subject's feedback with comfortable feeling as please feel postural correction by shoulder brace without tight pressure."
11158812|NCT03667833|Experimental|shoulder brace with forced tension|Forced tension, the self-comfortable tension of strap will be increased till forced tension of strap using buckles.
11158813|NCT03667820|Experimental|Osimertinib|Osimertinib in combination with Stereotactic Ablative Radiation (SABR)
11158814|NCT03667807|Experimental|rTMS condition 1|
11158815|NCT03667807|Experimental|rTMS condition 2|
11158816|NCT03667807|Experimental|rTMS condition 3|
11158817|NCT03667794||PH patients|Patients with known or first diagnosis of PH
11158818|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
11158819|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
11158820|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
11158821|NCT03667781||Providers Interviewed|Providers in cardiology clinic
11158822|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
11158845|NCT03667625|Experimental|Aquatic group|Aquatic multidimensional mobility exercises were given in the treatment pool at Balcova Thermal Centre, Izmir, Turkey. Group of 6-7 patients was instructed by a specialized physiotherapist twice in a week for eight weeks. The water temperature was 33-340C and the depth was between 110-140 cm, patients were asked to keep T11 level submersion during vertical exercises. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
11158823|NCT03667768|Experimental|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
11158824|NCT03667768|Other|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
11158825|NCT03667755|Experimental|fast track recovery|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Subjects are given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3 hours prior to operation drink) of a lactose-free clear tea-colour fruit flavoured fluid contains 14% whey protein, 86% carbohydrates and 0% lipids. Participants fast for solids for 6 hours from the operation. Participants will be given clear fluid (2 packs Resource peach) within 24 hours post-surgery (without present of bowel sound) and reviewed by dietitian. Staff nurse in-charged will monitor anesthetic risk of drinking whey protein and ensure subject to finish specific drinks prior surgery. When they tolerated at least 500ml of clear fluids, they were given a regular solid diet.
11158826|NCT03667755|No Intervention|conventional|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
11158827|NCT03667729|Experimental|progressive muscle relaxation|The experimental group received PMR once a week for a total of 12 weeks. Subjects completed measures at baseline, 3-month, and 3-month follow-up.
11158828|NCT03667729|No Intervention|Control group|treatment-as-usual(TAU)
11158829|NCT03667716|Experimental|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
11158830|NCT03667716|Experimental|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
11158831|NCT03667716|Experimental|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
11158832|NCT03667716|Experimental|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial cancer and Colorectal cancer).
11158833|NCT03667703|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
11158834|NCT03667703|Active Comparator|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
11158835|NCT03667690|Experimental|Group 1: Rezafungin for Injection|"Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.
~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day."
11158836|NCT03667690|Active Comparator|Group 2: Caspofungin|"Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.
~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
11158837|NCT03667677|Experimental|Group 1|Tandospirone + Amlodipine
11158838|NCT03667677|Experimental|Group 2|Tandospirone placebo + Amlodipine
11158839|NCT03667677|Experimental|Group 3|Tandospirone + Amlodipine placebo
11158840|NCT03667677|Placebo Comparator|Group 4|Tandospirone placebo + Amlodipine placebo
11158841|NCT03667664|Other|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
11158842|NCT03667651|Active Comparator|Twice daily use treatment with EpiCeram|They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
11158843|NCT03667651|No Intervention|Standard skin care|Parents are to follow standard skin care practices
11158844|NCT03667638|Experimental|PRP Intervention|PRP injection into wound border
11158945|NCT03666910||children of rheumatic diseased mothers not on treatment|
11158846|NCT03667625|Experimental|Land group|Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
11158847|NCT03667625|Active Comparator|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks.
11158848|NCT03667612||Patients with breast cancer|"Patients clinical data collection
~Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres
~Realization of tumor samples series of cuts and paraffin shavings for:
~Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)
~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)
~Characterization of lymphocyte populations
~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
11158849|NCT03667612||Patients with colorectal cancer|"Patients clinical data collection
~Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments
~Realization of series of cuts and paraffin shavings of the tumor samples for:
~Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)
~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)
~Characterization of lymphocyte populations
~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
11158850|NCT03667599|Experimental|Home care|This is the arm for patients who receive their transplant care in their homes.
11158851|NCT03667599|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
11158852|NCT03667599|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
11158853|NCT03667586|Experimental|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
11158854|NCT03667586|Placebo Comparator|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
11158855|NCT03667573|Experimental|tsDCS Dosage A and textured insoles|"tsDCS dosage A and textured shoe insoles"
11158856|NCT03667573|Experimental|tsDCS Dosage B and textured insoles|"tsDCS dosage B and textured shoe insoles"
11158857|NCT03667573|Experimental|tsDCS Dosage A and smooth insoles|"tsDCS dosage A and smooth shoe insoles"
11158858|NCT03667573|Experimental|tsDCS Dosage B and smooth insoles|"tsDCS dosage B and smooth shoe insoles"
11158859|NCT03667560|Experimental|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
11158860|NCT03667560|Active Comparator|FlexHD|FDA-approved FlexHD Pliable
11158861|NCT03667547|Experimental|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
11158862|NCT03667521||non-nerve-sparing laparaoscopic sacrocolpopexy.|
11158863|NCT03667521||nerve-sparing laparaoscopic sacrocolpopexy.|
11158864|NCT03667508|Experimental|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
11158865|NCT03667508|Active Comparator|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
11158866|NCT03667495||Relapse|Patients who suffered colorectal cancer or adenoma relapse after curative surgery
11158867|NCT03667495||Remission|Patients who get remission after curative surgery
11158868|NCT03667482|Experimental|Cabozantinib in Combination With Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week. Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
11158869|NCT03667469|Experimental|Stapleless one anastomosis gastric bypass|Laparoscopic stapleless-separated one anastomosis (mini-) gastric bypass procedures
11158870|NCT03667469|Active Comparator|Staple use mini-gastric bypass|Laparoscopic stapler-separated one anastomosis (mini-) gastric bypass procedures
11158871|NCT03667469|Active Comparator|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
11158872|NCT03667456|Experimental|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
11158873|NCT03667443|Active Comparator|Myo-inositol plus folic|
11158874|NCT03667443|Active Comparator|Myo-inositol + folic a. + α-lactalbumin|
11158875|NCT03667430|Experimental|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
11159379|NCT03663998|Active Comparator|F|CN54ENV ID EP 1800 g
11158876|NCT03667430|Experimental|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
11158877|NCT03667417||subjects carrying a BRCA gene mutation|subjects carrying a BRCA gene mutation
11158878|NCT03667404|Experimental|Resistant Maltodextrin|Resistant maltodextrin (RM) powder 25 g during days 1-7 and 50g during days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
11158879|NCT03667404|Placebo Comparator|Maltodextrin|Maltodextrin 25g for days 1-7 and 50 g for days 8-28, each dose dissolved in 8 oz of water once daily in the morning.
11158880|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
11158881|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
11158882|NCT03667365|Experimental|aortic valve replacement|
11158883|NCT03667365|Active Comparator|strict clinical surveillance|
11158884|NCT03667352|Experimental|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
11158885|NCT03667352|Active Comparator|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
11158886|NCT03667339||outpatients group|Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
11158887|NCT03667339||inpatients group|Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty
11158888|NCT03667326|Active Comparator|Low-Dose Aspirin (LDA) Intervention Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
11158889|NCT03667326|Placebo Comparator|Placebo Control Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.
11158890|NCT03667313|Experimental|sirolimus-eluting balloon (SEB)|treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB
11158891|NCT03667313|Active Comparator|paclitaxel-eluting balloon (PEB)|treatment of BMS- or DES-ISR with PEB
11158892|NCT03667300|Active Comparator|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
11158893|NCT03667300|Active Comparator|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
11158894|NCT03667287|Experimental|Full-thickness skin graft|Repair of parastomal hernia with full-thickness skin graft, placed intraperitoneally, as reinforcement.
11158895|NCT03667287|Active Comparator|Synthethic mesh|Repair of parastomal hernia with best available conventional method, using synthetic mesh material as reinforcement
11158896|NCT03667261|Active Comparator|cover screw|extraction of hopeless mandibular molars followed by immediate implants that will be covered using cover screw
11158897|NCT03667261|Experimental|sealing socket abutment|extraction of hopeless mandibular molars followed by immediate implants that will be covered using sealing socket abutment
11158898|NCT03667222|Experimental|BPX-04 Active|BPX-04 1% minocycline topical gel
11158899|NCT03667222|Placebo Comparator|BPX-04 Vehicle|BPX-04 topical gel vehicle
11158900|NCT03667209|Experimental|Traditional exercise and pain neuroscience education|Will include exercises of the neck and scapular regions using traditional methods and pain neuroscience education
11158901|NCT03667209|Active Comparator|Suspension exercise and pain neuroscience education|Will include suspension exercises of the neck and scapular regions using traditional methods and pain education.
11158902|NCT03667196||Observational|
11158903|NCT03667183|Experimental|Pilates Group|Female adolescents with eating disorders who receive Pilates for 10 weeks.
11158904|NCT03667170|Experimental|Cohort1: MSI-H Colorectal Cancer|Cohort 1 patients receive KN035 150 mg Subcutaneously on Day 1, 8, 15, 22 of every 4-week cycle (Q4W)
11158905|NCT03667170|Experimental|Cohort2: dMMR Non-Colorectal Cancer|Cohort 1 patients receive KN035 150 mg Subcutaneously on Day 1, 8, 15, 22 of every 4-week cycle (Q4W)
11158906|NCT03667157|Active Comparator|moderate-to-severe Graves Orbitopathy|active, moderate-to-severe Graves Orbitopathy according to EUGOGO.
11158907|NCT03667157|Active Comparator|Dysthyroid Orbit Neuropathy|Dysthyroid Orbit Neuropathy according to EUGOGO
11158908|NCT03667131|Experimental|Enalapril Maleate|Enalapril Maleate 5 mg every 12 hrs for 90 days.
11158909|NCT03667131|Experimental|Placebo|Substance that lacks in itself therapeutic action.
11158910|NCT03667118|Experimental|Food Supplement|Infants who received the active food supplement powder
11158911|NCT03667118|Placebo Comparator|Placebo|Infants who received the placebo powder
11158912|NCT03667105|Experimental|CAF+XDM|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous dermal collagen matrix graft (AXDM - Mucoderm®, Botiss,) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
11158946|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
11158913|NCT03667105|Experimental|CAF+MC|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Mucograft®, Geistlich Pharma) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
11158914|NCT03667105|Active Comparator|CAF|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Then, the flap will be coronally positioned and sutured to completely cover the graft. This group will be the control group.
11158915|NCT03667092|Experimental|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.
~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
11158916|NCT03667079|Experimental|Integrated|Intervention 'integrated delivery of deworming and vaccination' will be delivered to this arm of the study
11158917|NCT03667079|Active Comparator|Deworming only|Intervention 'Mass deworming only' will be delivered to villages in this arm of the study
11158918|NCT03667079|Active Comparator|Rabies vaccination only|Villages assigned to this arm received mass vaccination of dogs against rabies only
11158919|NCT03667053|Experimental|dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
11158920|NCT03667053|Placebo Comparator|placebo|Single fixed dose (s.c.injection) of placebo
11158921|NCT03667053|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
11158922|NCT03667040|No Intervention|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
11158923|NCT03667040|Active Comparator|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
11158924|NCT03667027||Patients undergoing LTx with respiratory failure (cases)|Patients are receiving a respiratory support modality (mechanical ventilation and/or extracorporeal life support) as a bridge to lung transplantation (LTx).
11158925|NCT03667027||Patients undergoing LTx without prior respiratory support|Patients undergoing lung transplantation but do not require prior bridging respiratory support.
11158926|NCT03667027||Elective thoracic surgical patients|Patients undergoing elective thoracic surgery for planned lung or esophageal resection.
11158927|NCT03667014|Experimental|Dupilumab treatment|30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
11158928|NCT03667001|Experimental|Lidocaine Hydrochloride|"1.5 mg/kg lean body mass lidocaine (lidocaine 1%) bolus I.V. as general anesthesia steady state concentration is accomplished
~1.5 mg/kg lean body mass/h lidocaine I.V. with beginning of surgical procedures
~after completion of surgery: transfer to PACU, pain evaluation for 48 hours
~duration of intervention: lidocaine infusion up to four hours from completion of surgery, or till transfer to surgical ward"
11158929|NCT03667001|Placebo Comparator|Saline Solution|"0.15 ml/kg lean body mass saline 0.9% bolus I.V. as general anesthesia steady state concentration is accomplished
~0.15 ml/kg lean body mass/h saline 0.9% I.V. with beginning of surgical procedure
~after completion of surgery: transfer to PACU, pain evaluation for 48 hours
~duration of intervention: saline infusion up to four hours from completion of surgery, or till transfer to surgical ward"
11158930|NCT03666988|Experimental|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
11158931|NCT03666988|Experimental|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
11158932|NCT03666988|Experimental|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
11158933|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
11158934|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
11158935|NCT03666975|Experimental|LIV 30 Hz, 0.4 g|LIV 30 Hz, 0.4 g Low intensity vibration to short leg 3x / week x 10 wks
11158936|NCT03666975|Experimental|LIV 30 Hz, 1.0 g|LIV 30 Hz, 1.0 g Low intensity vibration to short leg 3x/week x 10 wks
11158937|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
11158938|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
11158939|NCT03666949|Other|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
11158940|NCT03666949|Other|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
11158941|NCT03666936|Experimental|Intervention|Social-health care intervention
11158948|NCT03666897|Other|DTI Outcomes and Biomarkers|Imaging and Lab Collection
11158949|NCT03666884|Active Comparator|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
11158950|NCT03666884|Active Comparator|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
11158951|NCT03666871|Experimental|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
11158952|NCT03666871|Active Comparator|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
11158953|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
11158954|NCT03666845||Sciatic nerve block|Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease
11158955|NCT03666832|Experimental|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
11158956|NCT03666819|Experimental|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11158957|NCT03666806|Experimental|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
11158958|NCT03666806|Placebo Comparator|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
11158959|NCT03666793|No Intervention|Control|Standard healthcare procedures
11158960|NCT03666793|Experimental|experimental: Reconciliation group|medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital
11158961|NCT03666780||Subject|"All patients who signed informed consent and are implanted with a LAmbre occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post implant:
~At discharge (+/- 1 day)
~1-3 months (+/- 1 week)
~6 months (+/- 2 weeks)
~12 months (+/- 1 month)
~2 years (+/- 3 month)
~3 years(+/- 3 month) Patients who have undergone a LAmbre explant should remain in the study and adhere to the above mentioned follow-up time point until completion of 3 years follow-up period.
~After the patient has completed the 3 years follow-up assessments, the patient is considered to have completed the study. A study exit eCRF needs to be completed and the patient will receive routine care."
11158962|NCT03666767||Oesophageal atresia (OA) +/- tracheo-oesophageal fistula (TOF)|
11158963|NCT03666767||Congenital diaphragmatic hernia (CDH)|
11158964|NCT03666767||Intestinal atresia (IA)|
11158965|NCT03666767||Gastroschisis|
11158966|NCT03666767||Exomphalos|
11158967|NCT03666767||Anorectal malformation (ARM)|
11158968|NCT03666767||Hirschsprung's disease|
11158969|NCT03666754|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
11158970|NCT03666754|Experimental|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
11158971|NCT03666728|Experimental|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
11158972|NCT03666715||Participants with Schizophrenia|Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
11158973|NCT03666702|Experimental|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
11158974|NCT03666702|Active Comparator|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
11158975|NCT03666689||MHV reconstruction|Both ends of middle hepatic vein tributaries V8 and/or V5 of modified right lobe graft will be anastomosed to side of a single synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice.
11158976|NCT03666689||Separate tributaries reconstruction|End of V8 middle hepatic vein tributary of modified right lobe graft; if present, will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice, and end of V5; if present; will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's Inferior Vena Cava directly.
11158977|NCT03666676|Active Comparator|Normal Hearing|Signal processing to improve intelligibility
11158978|NCT03666676|Active Comparator|Mild hearing loss|Signal processing to improve intelligibility
11158979|NCT03666676|Active Comparator|Moderate hearing loss|Signal processing to improve intelligibility
11158980|NCT03666663|Experimental|Lidocaine|Participants will receive SPG blocks with lidocaine.
11158981|NCT03666663|Experimental|Bupivacaine|Participants will receive SPG blocks with bupivacaine
11158982|NCT03666663|Experimental|Ropivacaine|Participants will receive SPG blocks with ropivacaine
11158983|NCT03666663|Placebo Comparator|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
11158984|NCT03666650|Other|Rotem|
11159025|NCT03666364|Experimental|Magnetic nanoparticle selection for teratozoospermia|
11158985|NCT03666624|Experimental|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
11158986|NCT03666624|No Intervention|Routine medical care|No intervention
11158987|NCT03666598|No Intervention|No tourniquet|No use of tourniquet during surgery
11158988|NCT03666598|Experimental|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
11158989|NCT03666585|Active Comparator|mobile application actuated rehabilitation exercise guidance|
11158990|NCT03666585|Active Comparator|routine rehabilitation exercise guidance|
11158991|NCT03666572|Active Comparator|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
11158992|NCT03666572|Active Comparator|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose [LNnT] (Bif+prebiotic) in Severe Acute Malnourished infants
11158993|NCT03666572|Placebo Comparator|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
11158994|NCT03666572|Active Comparator|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
11158995|NCT03666559|Experimental|Azacitidine|Azacitidine is administered by sub-cutaneous injection at 75 mg/m2 per day for seven consecutive days every 4 weeks until progression, intolerance or end of the study.
11158996|NCT03666546|Experimental|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
11158997|NCT03666546|Experimental|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
11158998|NCT03666546|Experimental|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
11158999|NCT03666546|Experimental|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
11159000|NCT03666546|Active Comparator|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
11159001|NCT03666546|Placebo Comparator|Water|Still water, oral intake, 250 mL single dose
11159002|NCT03666533|Active Comparator|Active tDCS|active tDCS plus gait training
11159003|NCT03666533|Sham Comparator|Sham tDCS|sham tDCS plus gait training
11159004|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
11159005|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
11159006|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
11159007|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
11159008|NCT03666494|Active Comparator|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
11159009|NCT03666494|Active Comparator|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
11159010|NCT03666481|Experimental|MPAI group|Patients in this group participated in a 6-months Motivational Physical Activity Intervention (MPAI) to explore its effects on different variables related to PA levels and psychosocial aspects of life of bariatric patients. Concretely, the fundamental goals of the MPAI group were three: to increase the self-determined forms of motivation of the patients towards exercise or reduce those related to non-self-determined motivation; to improve post-operative levels of PA with respect to pre-operative levels, and; transfer the benefits of the intervention on different variables related to the perceived health-related quality of life.
11159011|NCT03666481|No Intervention|Control group|Patients in this group did not participate in any intervention, but the same measurements were made in them as in the MPAI group in the same temporal spaces.
11159012|NCT03666468|Experimental|PlayMed|"PlayMed, a highly immersive role-playing computer game
~- Focus on Paediatric Asthma and Seizure management"
11159013|NCT03666468|Active Comparator|Online Package (OP)|"Online package (OP) of NSW Health Guidelines
~- Focus on Paediatric Asthma and Seizure management"
11159014|NCT03666468|Placebo Comparator|Paper Guidelines|"Paper NSW Health Guidelines
~- Focus on Paediatric Asthma and Seizure management"
11159015|NCT03666455|Experimental|Acceptance and Commitment Therapy|The intervention consists of eight individual (one-on-one) acceptance and commitment therapy sessions approximately one week apart over a 12-week period.
11159016|NCT03666442|Experimental|chemotherapy group|patients receive 4 cycles of Xelox
11159017|NCT03666429|Active Comparator|Bulb suction|Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.
11159018|NCT03666429|Experimental|NoseFrida|Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.
11159019|NCT03666416|Experimental|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
11159020|NCT03666403|Experimental|Patients|This prospective one-year study enrolled consecutive 30 children of ≤3 years-old with suspected major airway diseases and therefore scheduled for diagnostic FB. During FB, PIP measurements and associated lumen images were obtained at six airway locations using three studied NIV modes, including 1) NIV rate: 0/min, 2) NIV rate: 10-20/min, 3) NIV rate: 5-10/min.
11159021|NCT03666390|Experimental|0.5mg/kg Ketamine|Anesthesia
11159022|NCT03666390|Active Comparator|0.045mg/kg Midazolam|Benzodiazepine
11159023|NCT03666377|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
11159024|NCT03666377|Experimental|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
11159026|NCT03666364|No Intervention|Density gradient centrifugation for teratozoospermia|
11159027|NCT03666351|Experimental|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.
~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
11159028|NCT03666351|Experimental|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.
~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
11159029|NCT03666338|Active Comparator|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
11159030|NCT03666338|No Intervention|Standard of Care|Standard of Care regarding mobilization
11159031|NCT03666325|Experimental|Pembrolizumab|Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
11159032|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all >18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
11159033|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
11159034|NCT03666299|Experimental|Lidocaine|Lidocaine treatment
11159035|NCT03666299|Placebo Comparator|Control|Placebo treatment
11159036|NCT03666286||Intensive Care Patients|Patients >24h on intensive care
11159037|NCT03666273|Experimental|Dose escalation_Monotherapy|Patients with solid tumor types considered immunosensitive
11159038|NCT03666273|Experimental|Dose escalation_Combination therapy|Patients with solid tumor types considered immunosensitive
11159039|NCT03666273|Experimental|Expansion HNSCC_Combination therapy|Patients with head and neck squamous cell carcinoma (HNSCC)
11159040|NCT03666260|Experimental|Quadratus Lumborum Block arm|
11159041|NCT03666260|Active Comparator|Femoral block arm|
11159042|NCT03666247|Experimental|HealthMindr Application|Participants in this study arm will have access to the mobile messaging platform (HealthMindr) for 3 months.
11159043|NCT03666247|Other|Waitlist|Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
11159044|NCT03666221|Experimental|Nimotuzumab plus IMRT|Patients with recurrent nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent intensity modulated radiation therapy(IMRT) , folowing weekly nimotuzumab (200 mg/week) for totally 8 weeks concurrent with IMRT.
11159045|NCT03666208|Experimental|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
11159046|NCT03666195|Active Comparator|Group A|complete dentures will be fabricated using poly methyl methacrylate resin denture base material modified with 5%wt titanium dioxide nanoparticles.
11159047|NCT03666195|No Intervention|Group B|complete dentures will be fabricated with poly methyl methacrylate resin denture base material.
11159048|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
11159049|NCT03666169||Whole Cohort|UK Citizens, aged 18-65 years
11159050|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
11159051|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC|
11159052|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody naïve NSCLC|
11159053|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant RCC|
11159054|NCT03666143|Experimental|Metastatic or advanced RCC without prior systemic therapy|
11159055|NCT03666143|Experimental|Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC|
11159056|NCT03666143|Experimental|Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC|
11159057|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody R/R melanoma|
11159058|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC|
11159059|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, sq NSCLC|
11159060|NCT03666130|Active Comparator|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
11159061|NCT03666130|Active Comparator|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
11159062|NCT03666117||Study group|children and adolescents with type 1 diabetes
11159063|NCT03666104|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11159064|NCT03666104|No Intervention|No Intervention: Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11159065|NCT03666078||normal vaginal delivery|
11159066|NCT03666078||assisted vaginal delivery|
11159067|NCT03666078||elective cesarean delivery|
11159069|NCT03666065|Active Comparator|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
11159070|NCT03666065|Experimental|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
11159071|NCT03666039|Experimental|Sensorimotor training|The participants will receive a tablet-based app for at home training that contains sensorimotor components.
11159072|NCT03666039|Active Comparator|Control training|The participants will receive a tablet-based app for at home training that contains relaxing components.
11159073|NCT03666026|No Intervention|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
11159074|NCT03666026|Experimental|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
11159075|NCT03666026|Experimental|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
11159076|NCT03666026|Experimental|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
11159077|NCT03666013||Young healthy subjects|20-30 years old, max 1h of exercise per week
11159078|NCT03666013||Elderly with a normal physical function|65-80 years old, max 1h of exercise per week
11159079|NCT03666013||Elderly with a decreased physical function|65-80 years old, max 1h of exercise per week, SPPB under 9 or frailty score lower then 10
11159080|NCT03666013||Active elderly|65-80 years old, minimal 3h of exercise per week
11159081|NCT03666000|Experimental|Dose Level 1|"PBCAR0191, 3 x 10^5 CAR T cells per kg body weight.
~In this study, PBCAR0191, allogeneic anti-CD19 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia.
~Route of Administration: Intravenous infusion.
~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR0191 infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
11159082|NCT03666000|Experimental|Dose Level 2|PBCAR0191, 1 x 10^6 CAR T cells per kg body weight.
11159083|NCT03666000|Experimental|Dose Level 3a|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight.
11159084|NCT03666000|Experimental|Dose Level 3b|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight as 3 administrations of 1 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
11159085|NCT03666000|Experimental|Dose Level 4|PBCAR0191, 6 x 10^6 CAR T cells per kg body weight as 2 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
11159086|NCT03666000|Experimental|Dose Level 5|PBCAR0191, 9 x 10^6 CAR T cells per kg body weight as 3 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
11159087|NCT03665987||properative assessment clinic group|The treatment group will be seen in the preoperative clinic before hospitalization.
11159088|NCT03665987||Control group|The control group will get anesthetic consultation after hospitalization without clinic service.
11159089|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
11159090|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
11159091|NCT03665961||Central obesity|Cases with central obesity as defined by waist circumference cut-offs ≥ 90 cm in men and ≥ 80 cm in women for Asians
11159092|NCT03665961||No central obesity|Controls with no central obesity
11159093|NCT03665948|Experimental|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
11159094|NCT03665948|Active Comparator|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about ~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
11159095|NCT03665922|Experimental|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
11159096|NCT03665922|Placebo Comparator|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
11159097|NCT03665909|Experimental|Remote activity monitoring|"Receive the remote activity monitoring system (i.e., eNeighbor; see intervention description) over an 18-month period."
11159098|NCT03665909|No Intervention|Control|Control participants do not receive the remote activity monitoring intervention.
11159099|NCT03665896|Active Comparator|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
11159100|NCT03665896|Placebo Comparator|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
11159101|NCT03665883|Active Comparator|Diathermy preferred|Monopolar energy is the preferred dissection approach in this group of patients undergo TEP. Total time of activation of monopolar machine will recorded by specially designed device
11159289|NCT03664596|Experimental|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
11159102|NCT03665883|Active Comparator|Blunt dissection preferred|Blunt dissection is the preferred dissection approach in this group of patients undergo TEP. Use of monopolar energy for haemostasis is still allowed upon surgeons' decision. Total time of activation of monopolar machine will recorded by specially designed device
11159103|NCT03665870|Experimental|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
11159104|NCT03665857|Experimental|multicomponent intervention|"Schools in the intervention arm will receive a multicomponent intervention at the school-, parent- and student-level, with a mobile application to promote the collaboration between investigators, school teachers, parents and students.
~The school-level intervention elements will include school policies and health education for teachers.
~The parent-level intervention elements will include health education for parents and promoting students' physical activity at home.
~The student-level intervention elements will include health education for students, promoting students' physical activity in school and monthly monitoring of weight and height."
11159105|NCT03665857|No Intervention|usual-care control|Schools assigned to the control group will have usual education provision throughout their participation in the trial, and after finishing the study they will be offered the health education package, policy suggestion and materials as the schools in the multicomponent intervention group.
11159106|NCT03665844|Placebo Comparator|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
11159107|NCT03665844|Active Comparator|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
11159108|NCT03665831|Experimental|Active H1 Coil deep rTMS active treatment|
11159109|NCT03665818|Experimental|Oral appliance intervention|
11159110|NCT03665818|No Intervention|Without oral appliance intervention|
11159111|NCT03665779|Experimental|isosorbide mono-nitrate group|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
11159112|NCT03665779|Placebo Comparator|placebo group|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.
11159113|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
11159114|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
11159115|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
11159116|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
11159117|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
11159118|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
11159119|NCT03665753|Experimental|Ketorolac 10mg|Subjects will be administered 10 mg of Ketorolac.
11159120|NCT03665753|Experimental|Ketorolac 20mg|Subjects will be administered 20 mg of Ketorolac
11159121|NCT03665753|Experimental|Ketorolac 30mg|As a part of standard care, subjects will be administered 30 mg of Ketorolac.
11159122|NCT03665740|Experimental|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
11159123|NCT03665740|Placebo Comparator|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
11159124|NCT03665727|Experimental|Mindfulness|15 minute mindfulness session
11159125|NCT03665727|Experimental|Suggestion|15 minute therapeutic suggestion session
11159126|NCT03665727|Active Comparator|Psychoeducation|15 minute psychoeducation session
11159127|NCT03665727|No Intervention|Usual Care|The usual care comparison group was comprised of patients who underwent total joint arthroplasty of the hip or knee at the same academic medical center during the study period but who did not attend Joint Academy.
11159128|NCT03665714|Experimental|Impact Oral|"Preoperatively:
~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.
~Postoperatively:
~Patient should receive:
~1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.
~2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.
~3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.
~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
11159129|NCT03665714|Active Comparator|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:
~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.
~Postoperatively:
~Patient should receive:
~272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.
~544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.
~816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.
~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
11159380|NCT03663998|Active Comparator|G|"CN54ENV IM1 EP
~+ pIL-12 (500 g)"
11159381|NCT03663998|Active Comparator|H|"CN54ENV IM1 EP
~+ pIL-12 (1500 g)"
11159130|NCT03665701|Experimental|Inhibitory effects of Fevipiprant|in vitro experiments: The reaction of the innate lymphoid cells by cytokine secretion in response to the stimulation by Prostagalandin D2 metabolites and the measurement of a potential suppressive effect of Fevipiprant will be assessed.
11159131|NCT03665688|Experimental|Outpatient Dilapan-S|"After Dilapan-S® placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue.
~Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours"
11159132|NCT03665688|Active Comparator|Inpatient Dilapan-S|"After Dilapan-S® placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
11159133|NCT03665675|Experimental|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with partial response, may receive up to 2 additional doses at monthly intervals.
11159134|NCT03665662|Experimental|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
11159135|NCT03665662|No Intervention|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
11159136|NCT03665649|Other|CD133+ human donors|CD133+ cells isolation
11159137|NCT03665636|Experimental|Triheptanoin|Open Label Study
11159138|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
11159139|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
11159140|NCT03665597|Experimental|Pembrolizumab Sequence 1|Participants receive a single dose of pembrolizumab (pembro) in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A subcutaneously (SC); Cycle 2 Day 1: pembro Dose B intravenously (IV); Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
11159141|NCT03665597|Experimental|Pembrolizumab Sequence 2|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A SC; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
11159142|NCT03665597|Experimental|Pembrolizumab Sequence 3|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
11159143|NCT03665597|Experimental|Pembrolizumab Sequence 4|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose B IV; Cycle 3 Day 1: pembro Dose A SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
11159144|NCT03665597|Experimental|Pembrolizumab Sequence 5|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose A SC: Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
11159145|NCT03665597|Experimental|Pembrolizumab Sequence 6|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
11159146|NCT03665597|Experimental|Pembrolizumab Dose D|Participants receive a single dose of pembro Dose D IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
11159147|NCT03665584|Active Comparator|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
11159148|NCT03665584|Sham Comparator|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
11159149|NCT03665571||Conventional Activation method|NK cell was incubated with either K562 cells
11159150|NCT03665571||Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
11159151|NCT03665558|No Intervention|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
11159152|NCT03665558|Active Comparator|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
11159153|NCT03665545|Active Comparator|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
11159154|NCT03665545|Experimental|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
11159155|NCT03665532|Experimental|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
11159156|NCT03665532|Active Comparator|Passive text reminders|Automated weekly text message health care reminders
11159283|NCT03664635|Experimental|Phase II|The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I
11159157|NCT03665519|Experimental|Dietary supplement and ursodeoxycholic acid therapy.|Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
11159158|NCT03665519|Other|Ursodeoxycholic acid therapy only.|Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
11159159|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications ON|Idiopathic Parkinson's patient's with Hoehn and Yahr score of 1.5- 2 i.e. in an early stage of the disease, under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
11159160|NCT03665493|Experimental|PD patients H&Y=3 Medications ON|Parkinson's patient's with Hoehn and Yahr score of 3, i.e. in moderate-to-advanced stages of the disease under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
11159161|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications OFF|Same as above described
11159162|NCT03665493|Experimental|PD patients H&Y=3 Medications OFF|Same as above described
11159163|NCT03665493|Experimental|Healthy age-matched controls|Healthy controls. Right-handed healthy subjects (it will be assessed by the Edinburgh handedness inventory) with normal or corrected-to-normal vision, without a history of neurological diseases. Age range: 40-70.
11159164|NCT03665480|Experimental|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
11159165|NCT03665480|No Intervention|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
11159166|NCT03665454|Experimental|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
11159167|NCT03665454|Active Comparator|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
11159168|NCT03665441|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with
~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:
~Abraxane (125 mg/m2) IV
~Gemcitabine (1000 mg/m2) IV
~Or
~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:
~Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1*28 is 50 mg/m2)
~Leucovorin 400 mg/m2 IV
~5 FU 2400 mg/m2
~Or
~FOLFIRI: Irinotecan 180 mg/m2 IV
~Leucovorin 400 mg/m² IV
~5 FU 400 mg/m² IV bolus
~5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
11159169|NCT03665441|Active Comparator|Chemotherapy alone|Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
11159170|NCT03665428|Experimental|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
11159171|NCT03665428|Active Comparator|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
11159172|NCT03665415|Other|Formative|This stage represents an initial formative phase to implement the NDGame Squad intervention with small samples of youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase. Three (n=3) participants from the school site only will participate in an initial 4-week Game Squad intervention in the first formative phase. Participant feedback including barriers to engagement and suggestions for improvements will be obtained via parent/caregiver and child interviews post-intervention.
11159173|NCT03665415|Experimental|Pilot Intervention|Participants in the pilot intervention arm will receive either 10 or 14 weeks of the NDGameSquad intervention. School site participants will receive 10 weeks during the school year, followed by another 4 weeks during summer vacation. Clinic site participants will receive 10 weeks only.
11159174|NCT03665415|Other|Pilot Waitlist Control|Participants at both sites randomized to the waitlist control arm will be asked to maintain current physical activity levels during the first 10-week period. They will then be provided the intervention equipment and training. School site control arm participants will then participate in a 4-week, unsupported summer NDGame Squad intervention. Clinic site control arm participants will not be required to participate in the NDGameSquad intervention.
11159175|NCT03665402|Active Comparator|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
11159176|NCT03665402|Active Comparator|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
11159177|NCT03665402|Experimental|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
11159178|NCT03665389|Other|Single Arm|Among patients who undergo TAVR at the kobe university hospital, those who are found to have moderate or severe stenosis on cCTA performed before surgery and judged to clinically require ischemia evaluation will be included in this study.
11159179|NCT03665376|Experimental|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
11159284|NCT03664622|Experimental|group K|patients with a ketamine infusion intraoperative
11159382|NCT03663998|Active Comparator|I|"CN54ENV IM1 EP
~+ ID2 EP"
11159180|NCT03665376|No Intervention|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest… Pain control was managed with medication of choice by surgeon and anesthesiologist.
11159181|NCT03665363|Experimental|SCOPE|Participants allocated to SCOPE, will receive an internet-based psychoeducation intervention, eight weeks of ASD-theme modules with coaching.
11159182|NCT03665363|Active Comparator|Self-study|Participants allocated to self-study will receive eight weekly emails containing informative and relevant websites about ASD. The emails are accessed on the same platform as the experimental condition (SCOPE), no active contact with the coaches is available.
11159183|NCT03665363|No Intervention|Wait-list controls/Treatment as usual|Participants allocated to wait-list will receive prompts to answer outcome measures but otherwise no other contact with the study coordinators or coaches. Participants may receive treatment as usual.
11159184|NCT03665350|No Intervention|non insulin|standard care + antidiabetic therapy non insulin
11159185|NCT03665350|Experimental|Insulin|standard care including insulin
11159186|NCT03665337|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
11159187|NCT03665337|Active Comparator|inJOY|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
11159188|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) with documented paroxysmal supraventricular arrhythmias.
11159189|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) without documented supraventricular arrhythmia.
11159190|NCT03665311|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED and another 100 mL 0.9% Normal Saline after 4 hours of treatment
11159191|NCT03665311|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of SLED and another 100 mL 25% Albumin fluid after 4 hours of treatment
11159192|NCT03665298|Experimental|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
11159193|NCT03665285|Experimental|NC318|NC318 for injection of various dose strengths administered in 14 day dosing cycles
11159194|NCT03665272|Experimental|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
11159195|NCT03665272|Experimental|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
11159196|NCT03665259|Active Comparator|Pure oxygen group|The patients receive 100% oxygen therapy during the induction phase of induction
11159197|NCT03665259|Experimental|Lower oxygen group|The patients received 60% oxygen therapy during the induction phase of induction
11159198|NCT03665246|Experimental|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
11159199|NCT03665246|No Intervention|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
11159200|NCT03665233|Sham Comparator|Sh-group|The patients in this arm get standard treatment, together with a sham version of a VR session.
11159201|NCT03665233|Active Comparator|VR-group|These patients get a VR session with the standard treatment
11159202|NCT03665220|Experimental|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
11159203|NCT03665220|Experimental|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
11159204|NCT03665220|Active Comparator|Healthcare education|A conservative intervention program for post-stroke patients
11159205|NCT03665207|Experimental|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
11159206|NCT03665207|Active Comparator|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
11159207|NCT03665194|Experimental|Cortexolone 17α-propionate 7.5% solution|
11159208|NCT03665194|Placebo Comparator|Vehicle solution|
11159209|NCT03665181||without modification of dose and without bismuth mask|The cranial CT imaging presrcibed in usual care will be performed without modification of dose and without bismuth mask
11159210|NCT03665181||with modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and with bismuth mask
11159211|NCT03665181||without modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed without modification of dose and with bismuth mask
11159212|NCT03665181||with modification of dose and without bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and without bismuth mask
11159213|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
11159285|NCT03664622|Experimental|group M|patients with a Morphine infusion intraoperative
11159286|NCT03664609||Parkinson's Disease|Subjects with Parkinson's disease, implanted with a Boston Scientific Deep Brain Stimulation System
11159214|NCT03665155|Experimental|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.
~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
11159215|NCT03665142|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
11159216|NCT03665142|Placebo Comparator|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
11159217|NCT03665129|Experimental|Dose escalation|IPH5401 at different doses and schedule + Durvalumab
11159218|NCT03665129|Experimental|Cohort expansion NSCLC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients
11159219|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 naive|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients
11159220|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients
11159221|NCT03665116|Experimental|Arginine|L-arginine 1.5 g capsule by mouth, once daily for 6 months
11159222|NCT03665116|No Intervention|No Intervention|no supplement for 6 months
11159223|NCT03665103|Experimental|Laser-assisted ICSI|
11159224|NCT03665103|No Intervention|conventional ICSI|
11159225|NCT03665077|Experimental|Participants|Patients with breast cancer who have completed all their primary treatments (surgery±radiation therapy) and are scheduled to start their adjuvant hormonal therapy.
11159226|NCT03665051|Other|Young adults|Obtain muscle biopsy specimens from young adults (ages 20-40) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
11159227|NCT03665051|Other|Older adults|Obtain muscle biopsy specimens from older adults (ages 60-80) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
11159228|NCT03665038|Experimental|Brexanolone|
11159229|NCT03665025|Experimental|immediate implant placement with xenograft|Immediate implant placement with the use of xenograft as grafting material
11159230|NCT03665025|Experimental|immediate implant using mixed allograft and xenograft|Immediate implant placement with using mixture of allograft and xenograft material
11159231|NCT03664999||Parturients physiologic pregnancy|Parturients undergoing caesarean delivery with physiologic pregnancy
11159232|NCT03664999||Parturients with risk pregnancy|Parturients undergoing caesarean with risk of complications (pre-eclampsia, HELLP syndrom, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
11159233|NCT03664986|Experimental|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
11159234|NCT03664986|No Intervention|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
11159235|NCT03664973|Experimental|continuous|continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.
11159236|NCT03664973|Active Comparator|single-shot|Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml
11159237|NCT03664960|Experimental|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 20 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
11159238|NCT03664947|Experimental|exercise|The exergaming training programs have included recent daily living activities in games. In our study we have planned the Nintendo Wii Fit Plus Game Console in the therapy training.
11159239|NCT03664947|No Intervention|control|No exercise training applied for the control group.
11159240|NCT03664934|Experimental|Patients, Neck-specific exercises|Patients before and after neck-specific exercises, subgroup to NCT01528579 with additional measures
11159241|NCT03664934|No Intervention|Healthy controls|Healthy controls, no treatment
11159242|NCT03664921|Experimental|Omnitram|Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
11159243|NCT03664921|Placebo Comparator|Placebo|Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
11159244|NCT03664908|Experimental|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
11159245|NCT03664908|Experimental|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
11159246|NCT03664908|Experimental|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
11159247|NCT03664895|No Intervention|observation arm(TMX, MDR≥5%)|keep go on TMX
11159248|NCT03664895|No Intervention|control arm(TMX, MDR<5%)|keep go on TMX
11159249|NCT03664895|Active Comparator|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
11159250|NCT03664882|Experimental|Fexofenadine|Fexofenadine, single administration
11159251|NCT03664882|Placebo Comparator|Placebo|Placebo, single administration
11159287|NCT03664609||Essential Tremor|Subjects with Essential Tremor, implanted with a Boston Scientific Deep Brain Stimulation System
11159288|NCT03664609||Dystonia|Subjects with dystonia, implanted with a Boston Scientific Deep Brain Stimulation System
11159945|NCT03660267|Experimental|water group|
11159252|NCT03664869|Active Comparator|Group A|"BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used."
11159253|NCT03664869|Experimental|Group B|"Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3
~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.
~Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water"
11159254|NCT03664856|Experimental|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
11159255|NCT03664843||The chemotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
11159256|NCT03664843||The radiotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
11159257|NCT03664843||The targeted therapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
11159258|NCT03664830|Experimental|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
11159259|NCT03664817|Experimental|social capital intervention|This group will receive intervention developed from Phase 1 study and based on photovoice project
11159260|NCT03664817|Active Comparator|group-based health promotion intervention|"The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)"
11159261|NCT03664804|Other|Participants with Early Manifest Stage I or II HD|No study drug was administered in this study
11159262|NCT03664791||Vanguard Rocc knee implant|Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant
11159263|NCT03664765|Active Comparator|Intervention exercise arm|daily oropharyngeal and respiratory muscle exercises
11159264|NCT03664765|Sham Comparator|Control arm|Daily sham exercises
11159265|NCT03664752|Experimental|IDP-120 Gel|Component A
11159266|NCT03664752|Placebo Comparator|IDP-120 vehicle gel|Vehicle
11159267|NCT03664739|Experimental|IDP-120 Gel|Component A
11159268|NCT03664739|Placebo Comparator|IDP-120 Vehicle Gel|Gel
11159269|NCT03664726|Experimental|Episodic Future Thinking (EFT)|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months)
11159270|NCT03664726|Active Comparator|Episodic Recent Thinking (ERT)|Participants will complete an episodic task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties). ERT participants will list positive recent events that have already happened and that they have enjoyed, at different general recent time points (e.g., a few hours ago, 1 day ago, 2-6 days ago, 7-12 days ago)
11159271|NCT03664713|Experimental|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
11159272|NCT03664713|No Intervention|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
11159273|NCT03664700||LMA Protector|The LMA Protector will be used
11159274|NCT03664687|Active Comparator|Zoledronate one dose (4 mg)|One 4 mg dose of Zoledronate
11159275|NCT03664687|Active Comparator|Zoledronate 4 mg every 6 months x 3 years|One 4 mg dose of Zoledronate given every 6 months for 3 years
11159276|NCT03664674|Experimental|OTO-104|
11159277|NCT03664674|Placebo Comparator|placebo|
11159278|NCT03664661|Experimental|experimental group|BCMA nanobody CAR-T cells
11159279|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
11159280|NCT03664635|Experimental|Phase I - Safety Dose Level|In phase I three (3) + 3 patients will be treated with 1x10^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level
11159281|NCT03664635|Experimental|Phase I - Dose Level 1|In phase I six (6) + 3 patients will be treated with 1x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1
11159282|NCT03664635|Experimental|Phase I - Dose Level 2|In phase I six (6) + 3 patients will be treated with 3x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2
11159290|NCT03664596|Other|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
11159291|NCT03664596|Active Comparator|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
11159292|NCT03664583|Experimental|Intervention Group|Patients randomly assigned to the intervention group will be offered the ACHRU-Community Partnership Program (CPP) intervention in addition to usual primary care services offered by their local diabetes education centre or primary care setting. The CPP is a 6-month self-management intervention consisting of six core components: 1) home or virtual visits (up to 3) supported by phone calls by either a Registered Nurse (RN) or Registered Dietician (RD); 2) wellness sessions (up to 6, one per month) provided to patients and their caregivers at the location of the community partner or virtually; 3) monthly team case conferences with the provider team; 4) caregiver support; 5) collaboration with the primary care interprofessional team and other specialists; 6) nurse-led care coordination/system navigation.
11159293|NCT03664583|No Intervention|Control Group|Those who are randomly assigned to the control group will continue to be offered usual primary care services through their local diabetes education centre or primary care setting. The services that comprise usual diabetes care vary across the provinces e.g., length and focus of educational sessions, whether classes are strongly recommended versus optional (e.g., foot care, cardiac health, eating and exercise interventions), home visits, access to on-site professionals (e.g., endocrinologist, dietitian, physiotherapist, exercise specialist, pharmacist), connections with support services and community resources, and type of follow-up services available. Details of usual care provided at each site will be recorded.
11159294|NCT03664570|Experimental|Condition A|"Infusion rate = 25 ml/h
~Radiography: confirmation balloon position
~VIPUN Balloon Catheter
~13C-Octanoate Breath Test o"
11159295|NCT03664570|Experimental|Condition B|"Infusion rate = 75 ml/h
~Magnetic resonance imaging
~VIPUN Balloon Catheter
~13C-Octanoate Breath Test"
11159296|NCT03664570|Experimental|Condition C|"Infusion rate = 250 ml/h
~Magnetic resonance imaging
~VIPUN Balloon Catheter
~13C-Octanoate Breath Testt"
11159297|NCT03664557|Experimental|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
11159298|NCT03664544|Experimental|Subjects with severe hepatic impairment|HP PK MCI-186
11159299|NCT03664544|Experimental|Subjects with normal hepatic function|NHV PK MCI-186
11159300|NCT03664531|Experimental|Gluten, ATIs, nocebo|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
11159301|NCT03664531|Experimental|Gluten, nocebo, ATIs|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of nocebo muesli bars (with nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
11159302|NCT03664531|Experimental|ATIs, gluten, nocebo|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
11159303|NCT03664531|Experimental|ATIs, nocebo, gluten|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of nocebo muesli bars (containing nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
11159304|NCT03664531|Experimental|Nocebo, ATIs, gluten|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars containing non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
11159305|NCT03664531|Experimental|Nocebo, gluten, ATIs|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
11159306|NCT03664518|Experimental|Eltrombopag|58 enrolled patients are picked up to take eltrombopag at the indicated dose.
11159307|NCT03664505|Active Comparator|Garment based on manual measurement|Garment based on manual measurement is used on burn scar
11159308|NCT03664505|Experimental|Garment based on scan measurement|Garment based on scan measurement is used on burn scar
11159309|NCT03664492|Other|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
11159310|NCT03664479|Experimental|classical electrical stimulation protocol|"apply 4 channel electrical stimulation device with protocol 1.
~It will simultaneously stimulate suprahyoid, thyrohyoid and sternothyroid m with 4 channel electrical stimulation device.
~during apply the device, we evaluate the manometry and videofluoroscopic swallowing study for evaluation of deglutition function."
11159311|NCT03664479|Experimental|revised sequential activation protocol|"apply 4 channel electrical stimulation device with protocol 2
~Is a revised sequential activation protocol, it sequentially stimulate bilateral suprahyoid m (channel 1), pharyngeal constrictors (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
~during apply the synchronized electrical stimulation device, we will evaluate the parameters same as group 1."
11159312|NCT03664466|Experimental|Astaxanthin|Astaxanthin 12mg twice daily by mouth
11159313|NCT03664466|Placebo Comparator|Placebo|Placebo twice daily by mouth
11159339|NCT03664271|Experimental|in-clinic video intervention|Intervention: Caregivers will watch an educational video in clinic, and also be given information about how to access the video from home (ideal condition). The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
11160291|NCT03657888|Experimental|Family Club Denmark (FCD)|Participation in FCD
11159314|NCT03664453|Experimental|Food Effect (Fasted)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fasted state (Period 1) with a crossover and then in the fed state (Period 2).
~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
11159315|NCT03664453|Experimental|Effect (Fed)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fed state (Period 1) with a crossover and then in the fasted state (Period 2).
~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
11159316|NCT03664453|Experimental|Dose Proportionality|"Subjects will be randomly assigned to one of two omaveloxolone dosages. A single dose of omaveloxolone (in either 50 mg or 100 mg) will be administered to the subjects in 50 mg capsules in a fasted state.
~Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 6."
11159317|NCT03664440|Placebo Comparator|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
11159318|NCT03664440|Active Comparator|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
11159319|NCT03664427||Group 1: Patients with VOD|paediatric patients with Veno-Occlusive Disease (VOD) complicating haematological stem cell transplantation
11159320|NCT03664427||Group 2: matched controls|Paediatric patients defined as matched controls without veno-occlusive disease complicating haematological stem cell transplantation
11159321|NCT03664414|Placebo Comparator|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
11159322|NCT03664414|Active Comparator|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
11159323|NCT03664401|Experimental|Kerecis Oral™|The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
11159324|NCT03664401|Active Comparator|Autogenous Free Gingival Graft|"The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.
~The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed."
11159325|NCT03664375|Experimental|Experimental Group|The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients. It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
11159326|NCT03664375|Placebo Comparator|Control Group|The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
11159327|NCT03664362|Experimental|The BSHAPE Intervention|Participants in the BSHAPE intervention attend a 9 sessions program post-assessments which is a combination of individualized and group-based sessions.
11159328|NCT03664362|No Intervention|Usual care or no treatment control|Participants in the control arm either are receiving no services or are engaged in usual care provided by community-based/health care organizations
11159329|NCT03664349||Older Adult Participants and Informal/Formal Caregiver Pairs|A sub-cohort of approximately 10 participant-caregiver pairs will utilize SE9000 and communication strategies over a 4-6-week period between LVR visits.
11159330|NCT03664349||Older Adult Participants|The pilot cohort of approximately 100 adults over age 60, with vision impairment, will complete the Hearing Handicap Inventory for the Elderly (HHIE), an assessment of perceived impact of hearing impairment, and an objective hearing evaluation.
11159331|NCT03664349||Formal/Informal Caregivers|Identified persons who assist willing and eligible older adult pilot participants with two or more ADLs/IADLs.
11159332|NCT03664323||Group 1 Sequential strategy|Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
11159333|NCT03664323||Group 2 Concomitant strategy|Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
11159334|NCT03664310|Experimental|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
11159335|NCT03664310|Active Comparator|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, & Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
11159336|NCT03664297|Experimental|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
11159337|NCT03664284|Active Comparator|intervention group|
11159338|NCT03664284|No Intervention|control group|
11159340|NCT03664271|Active Comparator|at home video intervention|Intervention: Caregivers will be given information about how to watch the video at home, but will not watch it in clinic (real-world condition).The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
11159341|NCT03664271|No Intervention|usual care|Control: Caregivers will not watch the educational video, but will be given access to it at the conclusion of the study.
11159342|NCT03664245||experimental group|Critically ill patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
11159343|NCT03664232|Experimental|JNJ-42165279|Participants will self-administer 25 milligram (mg) JNJ-42165279 tablets orally twice daily for 12 weeks.
11159344|NCT03664232|Placebo Comparator|Placebo|Participants will self-administer matching placebo tablets orally twice daily for 12 weeks.
11159345|NCT03664219|Active Comparator|isolation of IAN nerve with collagen membrane|
11159346|NCT03664219|Experimental|without isolation of the IAN with collagen|
11159347|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS
~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
11159348|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS
~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
11159349|NCT03664193|Other|Single Arm|Patients will receive 35 Gy in 5 fractions. In addition, patients will also receive 0.5-2 Gy per fx for a total dose 37.5, 40, 42.5 or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
11159350|NCT03664180|Experimental|anticoagulation|
11159351|NCT03664180|Placebo Comparator|No anticoagulation|
11159352|NCT03664167|Experimental|intervention|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
11159353|NCT03664167|No Intervention|control|usual care
11159354|NCT03664154|Experimental|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
11159355|NCT03664141|Placebo Comparator|Placebo group|1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
11159356|NCT03664141|Experimental|Cannabis oil group|1 drop of 3% cannabis oil once a day during 3 months
11159357|NCT03664128||pregnant women positive for anxiety|"100 pregnant women who screen positive for anxiety symptoms (>21 on the Perinatal Anxiety Screening Scale). Participants are matched for age, parity, and gestational age at enrollment.
~Coping with Anxiety through Living Mindfully (CALM) Pregnancy: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants)"
11159358|NCT03664128||healthy pregnant controls|100 matched healthy pregnant women. Participants are matched for age, parity, and gestational age at enrollment.
11159359|NCT03664115|Experimental|Itraconazole Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.
~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
11159360|NCT03664115|Active Comparator|Control Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.
~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
11159361|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
11159362|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
11159363|NCT03664089|Experimental|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
11159364|NCT03664089|Placebo Comparator|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
11159365|NCT03664063|Active Comparator|Azithromycin for Yaws|Patients will receive standard treatment for yaws alone
11159366|NCT03664063|Active Comparator|IDA for Lymphatic Filariasis|Patients will receive standard IDA (Ivermectin & Diethylcarbamazine & Albendazole) treatment for Lymphatic Filariasis alone
11159367|NCT03664063|Experimental|Combination Therapy of Azithromycin for Yaws and IDA for LF|Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.
11159368|NCT03664050|Experimental|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
11159369|NCT03664050|Active Comparator|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
11159370|NCT03664037|Active Comparator|D group, (n=55)|
11159371|NCT03664037|Placebo Comparator|C group, (n=55)|
11159372|NCT03664024|Experimental|Pembrolizumab Standard of Care|Participants will receive standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then pembrolizumab plus pemetrexed maintenance for up to 31 additional cycles. The platinum doublet would be pemetrexed plus the investigator's choice of either cisplatin or carboplatin.
11159373|NCT03664011|Experimental|All Subjects|
11159374|NCT03663998|Active Comparator|A|CN54ENV IM EP 400 g
11159375|NCT03663998|Active Comparator|B|CN54ENV IM EP 1000 g
11159383|NCT03663972|Active Comparator|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
11159384|NCT03663972|Active Comparator|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
11159385|NCT03663959||Vaginal Sacrospinous Fixation group|Women who had vaginal sacrospinous fixation procedure with Dr.Aksakal's Desta suture carrier in our clinic between January 2014 and June 2018.
11159386|NCT03663959||Laparoscopic Pectopexy Group|Women who had Laparoscopic Pectopexy procedure in our clinic between January 2014 and June 2018
11159387|NCT03663946||Patients taking combination therapy with Yervoy and Opdivo|Medical records will be reviewed for safety and treatments for specific ADR
11159388|NCT03663933|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm
11159389|NCT03663933|Experimental|2/IOC Arm|Immunosuppression Only Conditioning Arm
11159390|NCT03663907|Experimental|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
11159391|NCT03663907|No Intervention|Usual Care|Patients with usual care follow-up in a heart failure program.
11159392|NCT03663881|Experimental|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
11159393|NCT03663868|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
11159394|NCT03663868|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
11159395|NCT03663868|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
11159396|NCT03663855|Experimental|Cystinuria Patients|
11159397|NCT03663842|Experimental|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
11159398|NCT03663829||Participants RA who have received a TNFi|
11159399|NCT03663829||Participants with RA who have received abatacept|
11159400|NCT03663816|Experimental|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
11159401|NCT03663803|Experimental|Intervention|Participants in the intervention group received the offer of four 2h group sessions during five weeks, and two further sessions after one and six months. The attendance rates of the sessions were 95%, 88%, 87%, 73%, 67% and 51%, respectively. The course was delivered by health care staff in the Holstebro Health Care Centre, including a dietitian and an occupational therapist, both with health pedagogic competences. It was delivered to seven intervention groups, which varied in size from 5 to 15 participants.
11159402|NCT03663803|No Intervention|Control|Usual practice
11159403|NCT03663790|No Intervention|Control|No intervention
11159404|NCT03663790|Experimental|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
11159405|NCT03663790|Experimental|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
11159406|NCT03663777|Experimental|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
11159407|NCT03663777|Other|Control group|Control gorup will be recommended to increase daily physical activity level
11159408|NCT03663764|Experimental|Expeiment|Patients in experimental group received four cycles of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 66 Gy/22 fractions. Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
11159409|NCT03663751|Experimental|Treatment|The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (>98%).
11159410|NCT03663738|Active Comparator|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
11159411|NCT03663738|No Intervention|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
11159412|NCT03663725|Experimental|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
11159413|NCT03663725|Active Comparator|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
11159414|NCT03663712|Experimental|Dose|"Drug: Talimogene Laherparepvec
~There will be two parts to this phase I study: 1) Dose Escalation Cohort; 2.) Dose Expansion Cohort
~In the Dose Escalation Cohort, three subjects will be enrolled at the starting dose of 4x106 PFU, and the dosing will continue in the standard '3+3' dose escalation scheme. If the starting dose is tolerated, enrollment will continue at 4x107 and 4x108 PFU. Once the MTD is determined, six subjects will be enrolled to the Dose Expansion Cohort at the MTD. All subjects will be dosed with talimogene laherparepvec intraperitoneal (IP) once every 2 weeks for up to 4 doses (in addition to the initial seroconversion dose, which all patients will receive)."
11159415|NCT03663699|Experimental|Exergaming|24 week access to the exergaming platform PlayPulse
11159416|NCT03663699|No Intervention|Control|Asked to continue with their normal daily routine
11159417|NCT03663686|Placebo Comparator|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159418|NCT03663686|Placebo Comparator|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159419|NCT03663686|Placebo Comparator|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159420|NCT03663686|Placebo Comparator|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159421|NCT03663686|Placebo Comparator|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159422|NCT03663686|Placebo Comparator|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159423|NCT03663686|Placebo Comparator|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
11159424|NCT03663673|Other|Clinical pilot study|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
11159425|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
11159426|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
11159427|NCT03663634|Experimental|Handling Medium Supplemented with Cytochalasin B|
11159428|NCT03663634|No Intervention|Handling Medium as it is.|
11159429|NCT03663621||Initial survey and interview (Aim 2)|Participants in Aim 2 will be asked to complete an initial 15-minute survey and 20-30 minute semi-structured interview. The purpose of this study is to learn the best ways to support healthful behaviors and weight loss prior to pregnancy. Researchers are also interested in what motivates or prevents women of reproductive age from engaging in a structured weight loss program.
11159430|NCT03663621||Formal weight loss program (Aim 3)|Participants in Aim 3 have expressed interest in referral to the Mass General Weight Center. The purpose of this study is to learn what motivates or prevents women of reproductive age from engaging in a structured weight loss program. Researchers will ask for no more than a half hour of participant's time to complete a 5- minute interview following Orientation at the Weight Center and another 10-minute interview after a participant has participated in a program offered at the Weight Center.
11159431|NCT03663595|No Intervention|Control Group|Females asymptomatic for patellofemoral pain syndrome
11159432|NCT03663595|Experimental|PFPS: Proximal factors - Model 1 (Hip and Knee)|Females symptomatic for PFPS with modification in proximal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
11159433|NCT03663595|Experimental|PFPS: Proximal factors - Model 2 (knee, foot and ankle)|Females symptomatic for PFPS with modification in proximal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in distal (foot and ankle) and local (knee) factors.
11159434|NCT03663595|Experimental|PFPS: Distal factors - Model 1(Hip and Knee)|Females symptomatic for PFPS with modification in distal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
11159435|NCT03663595|Experimental|AKP: Distal factors - Model 2 (knee, foot and ankle)|Females symptomatic for PFPS with modification in distal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in local (knee) and distal (foot and ankle) factors.
11159436|NCT03663582|Experimental|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
11159437|NCT03663569||subjects with COPD|
11159438|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
11159439|NCT03663543|Active Comparator|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
11159440|NCT03663543|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
11159441|NCT03663530|Experimental|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
11159442|NCT03663530|Active Comparator|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
11159443|NCT03663517||pregnant women|pregnant women in Hong Kong
11159444|NCT03663504|Active Comparator|No Preparation|No preparation before surgery
11159445|NCT03663504|Active Comparator|Oral Antibiotics|Oral antibiotics (neomycin and flagyl), to be taken the day before the surgery
11159446|NCT03663491|Experimental|Unsedated Nasal Gastroscopy|Transnasal Endoscopy. No sedation used. Use of local anesthesia.
11159447|NCT03663491|Active Comparator|Oral Gastroscopy, unsedated|Transoral Endoscopy. No sedation used. Use of local anesthesia.
11159448|NCT03663491|Active Comparator|Oral Gastroscopy, sedated|Transoral Endoscopy. Intravenous sedation used.
11159449|NCT03663478|Active Comparator|Intervention|Ropivacaine
11159450|NCT03663478|Placebo Comparator|Control|Isotonic saline
11159451|NCT03663465|Experimental|Hawthorn and SGAs|SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
11159452|NCT03663465|Active Comparator|Hawthorn|Hawthorn at a dose of 3 gm/day for six months.
11159453|NCT03663452|Active Comparator|Prolonged exposure training|
11159454|NCT03663452|Experimental|TACTICS|
11159455|NCT03663439|Experimental|modified shell technique|block of bone from the mandibular ramus divided into two shells ,grafting one shell in the anterior maxilla to increase width
11159456|NCT03663439|Active Comparator|onlay bone graft|grafting block of bone from the mandibular ramus in the atrophic anterior maxilla
11159457|NCT03663426|Active Comparator|control group opioid anesthesia|standard anesthesia using opioids
11159458|NCT03663426|Experimental|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
11159459|NCT03663413||BIS|Monitored with BIS (bispectral index) monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
11159460|NCT03663413||Narcotrend|Monitored with Narcotrend monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
11159461|NCT03663400||Patients Treated with Tofacitinib|Microbiota profiling by 16S sequencing RNA-seq transcriptional profiling of the blood and biopsy samples Immunological profiling by multi-parameter flow cytometry
11159462|NCT03663387||Normal subjects|70
11159463|NCT03663374|Experimental|Odelepan|One tablet once daily
11159464|NCT03663374|Placebo Comparator|Placebo|One tablet once daily
11159465|NCT03663361|Experimental|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
11159466|NCT03663361|Active Comparator|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
11159467|NCT03663335|Experimental|Arm 1/Cohort 1|CFZ533 dose A+ MMF + Corticosteroids
11159468|NCT03663335|Experimental|Arm 2/Cohort 1|CFZ533 dose B + MMF + Corticosteroids
11159469|NCT03663335|Active Comparator|Arm 3/Cohort 1|Control/Standard of Care: TAC + MMF + Corticosteroids
11159470|NCT03663335|Experimental|Arm 1/Cohort 2|CFZ533 dose C + MMF ± Corticosteroids
11159471|NCT03663335|Active Comparator|Arm 2/Cohort 2|Tac + MMF ± Corticosteroids
11159472|NCT03663322|Experimental|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
11159473|NCT03663322|Sham Comparator|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
11159474|NCT03663309||study group|"Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease
~Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year."
11159475|NCT03663309||control group|Healthy controls aged 2-17 years old matched for age and sex.
11159476|NCT03663296|Experimental|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
11159477|NCT03663296|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
11159478|NCT03663283|Experimental|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
11159479|NCT03663283|Active Comparator|Control Group|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
11159480|NCT03663270|Active Comparator|Intervention arm|HPI monitoring to predict hypotension
11159481|NCT03663270|No Intervention|Control arm|blinded HPI monitoring
11159482|NCT03663257||AneurysmFlow Observational Cohort|Subjects with unruptured, >5mm saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent enrolled at the centers participating in this CARO study.
11159483|NCT03663244|Experimental|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
11159484|NCT03663244|Experimental|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
11159485|NCT03663244|No Intervention|Wait-list|Usual practice
11159486|NCT03663231|Experimental|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
11159487|NCT03663231|Placebo Comparator|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
11159488|NCT03663218|Other|Single Arm|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
11159489|NCT03663205|Experimental|Tislelizumab combined with Platinum and Pemetrexed|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Cisplatin 75 mg/m2 administered as an intravenous (IV) infusion over 2 hours Q3W (every 3 weeks) for 4 to 6 cycles or Carboplatin AUC 5 administered as an IV infusion over 15 minutes Q3W for 4 to 6 cycles. Pemetrexed 500 mg/m2 administered as an IV infusion over 10 minutes Q3W.
11159490|NCT03663205|Active Comparator|Cisplatin or Carboplatin and Pemetrexed|
11159491|NCT03663179|Experimental|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
11159492|NCT03663179|Sham Comparator|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
11159493|NCT03663166|Experimental|Radiation and Chemotherapy|Thoracic Radiotherapy with cytotoxic platinum based chemotherapy with cytotoxic platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology) and Ipilimumab.
11159494|NCT03663166|Experimental|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) after completion of radiation and chemotherapy for up to 12 cycles until progression.
11159495|NCT03663153||SEMA4C high value follow-up group|Postoperative SEMA4C value is higher than 5.00 ng/ml.
11159496|NCT03663153||SEMA4C low value follow-up group|Postoperative SEMA4C value is lower than 5.00 ng/ml.
11159497|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
11159498|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
11159499|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
11159500|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
11159501|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
11159502|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
11159503|NCT03663127|Experimental|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage."
11159504|NCT03663127|Placebo Comparator|Placebo|Subjects receive two bottles placebo per day for 8 weeks of a stage.
11159505|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
11159506|NCT03663101|Experimental|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
11159507|NCT03663101|Experimental|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
11159508|NCT03663101|Experimental|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
11159509|NCT03663101|Experimental|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
11159510|NCT03663101|Placebo Comparator|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
11159511|NCT03663088|Active Comparator|GPR-A|The 6-months supervised GPR-A group will receive a 1-hour-long individual session once a week plus a home program (1 or 2 exercises, 2 times a week).
11159512|NCT03663088|Experimental|GPR-B|The 6-months supervised GPR-B group will receive a 1-hour long individual session once per two weeks alternately with a 1-hour-long class of exercises once per two weeks plus a home program (1 or 2 exercises, 2 times a week).
11159513|NCT03663075|Experimental|Group 1|This group will receive the intervention Group information (GI).
11159514|NCT03663075|Experimental|Group 2|This group will receive the intervention Group information (GI) followed by Structured person-centered support (PCS)
11159515|NCT03663075|Experimental|Group 3|This group will receive the intervention Structured person-centered support (PCS)
11159516|NCT03663075|No Intervention|Group 4|This is a control group.
11159517|NCT03663049|No Intervention|Usual care|These patients will continue as statins as usual.
11159518|NCT03663049|Experimental|Discontinue statin|Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.
11159519|NCT03663036|Experimental|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
11159520|NCT03662997|Active Comparator|Hydropolymer vs Five-layer|Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-Layer Foam Dressing for 2 weeks
11159521|NCT03662997|Active Comparator|Five-layer vs Hydropolymer|Bordered Five-Layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks
11159522|NCT03662997|Active Comparator|Hydrocellular vs Five-layer|Foam Hydrocellular Multi-Layer Foam Dressing for 2 weeks followed by Bordered Five-Layer Foam Dressing for 2 weeks
11159523|NCT03662997|Active Comparator|Five-layer vs Hydrocellular|Bordered Five-Layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-Layer Foam Dressing for 2 weeks
11159524|NCT03662984|Active Comparator|Ciprofibrate|1dd100mg at breakfast
11159525|NCT03662984|Placebo Comparator|Placebo|1dd0mg at breakfast
11159526|NCT03662971|Experimental|0.0005% single-dose|Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.
11159527|NCT03662971|Experimental|0.001% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).
11159528|NCT03662971|Experimental|0.002% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).
11159529|NCT03662971|Experimental|0.004% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).
11159530|NCT03662971|Experimental|0.008% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).
11160292|NCT03657888|Other|Wait-list|Wait-list control
11159531|NCT03662971|Experimental|0.002% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).
11159532|NCT03662971|Experimental|0.004% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).
11159533|NCT03662971|Experimental|0.008% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).
11159534|NCT03662958|Experimental|Lutrate|a novel leuprolide acetate 3.75mg depot
11159535|NCT03662958|Active Comparator|Enantone|market reference leuprolide acetate 3.75 mg depot
11159536|NCT03662945|Experimental|Intervention group|Mobile Geriatric Team intervention including physicians and nurses with the aim of developing person-centered, safe, sustainable and coordinated care plans. These care plans are developed in collaboration with the patient, his/her relatives and staff from the municipality. Among the main ambitions of this concept are improved communication flows between patients, their relatives and healthcare providers in combination with the delivery of medical as well as care measures. Other ambitions are to avoid unnecessary traditional healthcare utilization in the form of inpatient care and EMR visits, for example.
11159537|NCT03662945|No Intervention|Control group|Standard care including primary care units, home care and home help.
11159538|NCT03662932|Experimental|Early intensive mobilization|Progressed mobilization from postoperative day 0.
11159539|NCT03662919||Flixabi|Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
11159540|NCT03662919||Imraldi|Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.
11159541|NCT03662906|Experimental|Electroacupuncture|Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.30 mm in diameter, 75 mm in length or 0.40 mm diameter, 100 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
11159542|NCT03662906|Sham Comparator|Sham electroacupuncture|Sham Bilateral Shenshu (BL23), Ciliao (BL32), Zhongliao (BL33), Huiyang (BL35), and Sanyinjiao (SP6) will be inserted by the needles (0.20 mm in diameter, 25 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China).
11159543|NCT03662893|Sham Comparator|Behavioural therapy with written guideline|Patients were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist over six-month period.
11159544|NCT03662893|Active Comparator|Behavioural therapy with checklist|Patients were instructed to apply behavioural therapy with a written checklist for patients to fully complete over six-month period.
11159545|NCT03662893|Active Comparator|antimuscarinic drug plus verbal behavioural therapy|Patients received medical treatment (once or twice per day) plus behavioural therapy without checklist over six-month period.
11159546|NCT03662893|Active Comparator|antimuscarinics plus checklist|Patients received medical treatment (once or twice per day) with a written checklist to fully complete over six-month period.
11159547|NCT03662880|Other|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
11159548|NCT03662867|Experimental|Family-based mindfulness intervention|Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
11159549|NCT03662867|Other|Wait-list control|Intervention group participants were assessed at baseline (T1) and after the intervention (T2). Control group participants were assessed at the same time with the intervention group, and would receive the same program after posttest of intervention groups.
11159550|NCT03662854|Experimental|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
11159551|NCT03662854|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
11159552|NCT03662841|Other|ACE for HCC of size >10cm|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
11159553|NCT03662815|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;
~Peptides: 0.1 or 0.3 mg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses. Additional booster vaccines might be administered depending on ethics and patients' potential benefit.
~GM-CSF: 40 mcg given 30 minutes before iNeo-Vac-P01."
11159554|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
11159555|NCT03662789|Active Comparator|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
11159556|NCT03662789|Placebo Comparator|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
11159557|NCT03662776||retinoblastoma survivors treated with enucleation|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and CHLA between 2006-2017 for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
11159558|NCT03662776||retinoblastoma survivors treated with intra-arteria chemo|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and CHLA between 2006-2017 for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
11159559|NCT03662763|Placebo Comparator|Placebo|
11159560|NCT03662763|Experimental|Extended-release Guanfacine Hydrochloride (SPD503)|
11159656|NCT03662191|Experimental|Treatment D|a dose of tafamidis free acid projected to be an equivalent of 5 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
11159561|NCT03662737||Group 1 -Chronic cannabis use|Individuals between 18 and 50 years old who have been using at least 2 joints per day for at least 3 years. They should have used cannabis during the last 24h but not during the 3h prior to participation to the study and they should test positive for cannabis in their urine. Individuals with another substance use or severe mental disorder will be excluded (except tobacco use)
11159562|NCT03662737||Group 2 - Alcohol dependence|Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
11159563|NCT03662737||Control Group|Individuals matched in gender and age with the experimental groups and with no diagnosis of substance use or severe mental disorder (except tobacco use)
11159564|NCT03662711|Active Comparator|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
11159565|NCT03662711|Experimental|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
11159566|NCT03662698|Experimental|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
11159567|NCT03662698|Active Comparator|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to RT from the clinic nurse coordinator.
11159568|NCT03662685|Active Comparator|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
11159569|NCT03662685|Active Comparator|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
11159570|NCT03662685|Active Comparator|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
11159571|NCT03662672|Experimental|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
11159572|NCT03662672|Sham Comparator|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
11159573|NCT03662659|Experimental|BMS-986213 + investigator's choice chemotherapy|BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX
11159574|NCT03662659|Experimental|Nivolumab + investigator's choice chemotherapy|Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX
11159575|NCT03662646||IBD patients|
11159576|NCT03662646||Healthy controls|
11159577|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
11159578|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
11159579|NCT03662620|Experimental|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
11159580|NCT03662620|Experimental|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
11159581|NCT03662607|No Intervention|Control|Standard pre-procedural education for cardiac catheterization.
11159582|NCT03662607|Experimental|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
11159583|NCT03662594|Other|ECMO tube|
11159584|NCT03662581|Experimental|Mindfulness Group Program|A primary care mindfulness-based rolling admissions program where subjects must attend 4 of 8 consecutive group sessions, to be considered to have completed the program.
11159585|NCT03662568|Experimental|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
11159586|NCT03662568|Experimental|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
11159587|NCT03662568|Experimental|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
11159588|NCT03662568|Experimental|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
11159589|NCT03662555|Experimental|NMES and BFR (80%)|Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.
11159590|NCT03662555|Experimental|NMES and BFR (40%)|Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.
11159591|NCT03662555|Active Comparator|NMES alone|Group 3, participants will undergo NMES applied to the quadriceps for 25 min.
11159592|NCT03662542|Experimental|Combination Therapy|Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
11159593|NCT03662542|Experimental|Monotherapy: Guselkumab|Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
11159594|NCT03662542|Active Comparator|Monotherapy: Golimumab|Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
11159595|NCT03662529|Experimental|Mind Freedom Plan therapy sessions|The Four-Session Mind Freedom Plan (MFP) is cognitive behavioral therapy (CBT)-based, client-centered, manualized individual therapy that functions as part of intensive outpatient substance abuse treatment. The MFP model is based on efficacious brief interventions, with content and format driven from military veteran feedback. The four 60-minute MFP sessions were one-on-one private consultations with a therapist that were focused on identifying and changing unhealthy thinking and behavioral patterns as core elements of CBT, but with an emphasis on problem-solving, coping skills, goal setting, and psychosocial functioning. At each session, structured worksheets were utilized and homework was assigned to facilitate this CBT-based skill building.
11159687|NCT03662009||Parkinson Disease|Observation of individuals with idiopathic Parkinson disease performing a multilimb dual task using the arm and the leg.
11159688|NCT03662009||Control|Observation of healthy age-matched individuals will perform a multilimb dual task using the arm and the leg.
11159596|NCT03662529|Active Comparator|Treatment as usual therapy|The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
11159597|NCT03662516|Other|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
11159598|NCT03662516|Other|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
11159599|NCT03662503||nutrition not aggressive group|"Children will be grouped according to their calorie and protein during the first week of life. The tertile 1 will represent the group of children with the lowest nutritional intake (called the nutrition not aggressive )"
11159600|NCT03662503||aggressive nutrition group|"Children will be grouped according to their calorie and protein during the first week of life. the tertile 3 will define the group of children presenting the contributions highest nutritional levels (called the aggressive nutrition group)"
11159601|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
11159602|NCT03662477|Experimental|EGFR+NK+|The EGFR mutation positive patients were with the principles of randomized and NK cells treatment.
11159603|NCT03662477|No Intervention|EGFR+NK-|The EGFR mutation positive patients were with the principles of randomized and without NK cells treatment .
11159604|NCT03662477|Experimental|EGFR-NK+|The EGFR mutation negative patients were with the principles of randomized and NK cells treatment .
11159605|NCT03662477|No Intervention|EGFR-NK-|The EGFR mutation negative patients were with the principles of randomized and without NK cells treatment.
11159606|NCT03662451|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
11159607|NCT03662451|Active Comparator|Robotic multi-site hysterectomy|Robotic multi-site hysterectomy is performed in this arm
11159608|NCT03662438|Other|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).
~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
11159609|NCT03662425|Experimental|schizophrenia with oxytocin|
11159610|NCT03662425|Placebo Comparator|schizophrenia with Placebo|
11159611|NCT03662425|Experimental|healthy controls with oxytocin|
11159612|NCT03662425|Placebo Comparator|healthy controls with Placebo|
11159613|NCT03662412|Experimental|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
11159614|NCT03662399|Experimental|Insole A|Investigational product - Insole A
11159615|NCT03662399|Experimental|Insole B|Investigational product - Insole B
11159616|NCT03662399|Experimental|Insole C|Investigational product - Insole C
11159617|NCT03662399|Experimental|Insole D|Investigational product - Insole D
11159618|NCT03662399|Experimental|Insole E|Investigational product - Insole E
11159619|NCT03662399|Experimental|Insole F|Investigational product - Insole F
11159620|NCT03662399|Experimental|Insole G|Non-Investigational product - Standard shoe
11159621|NCT03662386||Patients with suspicion of hereditary retinal dystrophy|
11159622|NCT03662373||carbon ions radiation therapy|the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
11159623|NCT03662373||protons radiation therapy|the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
11159624|NCT03662360|No Intervention|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs.
11159625|NCT03662360|Experimental|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs and, in a complementary way, with diffusion aromatherapy
11159626|NCT03662334|Experimental|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
11159627|NCT03662334|Sham Comparator|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
11159628|NCT03662321||sexual behavior on the internet|this group of teenagers use internet for sexuality
11159629|NCT03662321||not sexual behavior on the internet|this group of teenagers doesn't use internet for sexuality
11159689|NCT03661996|Experimental|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
11159690|NCT03661996|Experimental|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
11159630|NCT03662308|Other|Heated Vest Safety & Comfort (able-bodied subjects)|Able-bodied controls will be fitted with an appropriately sized heated vest, while wearing only a standard cotton T-shirt and shorts, and will remain seated in a wheelchair. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for 2 hours with the heated vest on full power. Outcome Variables for Visit 1: Skin thermocouple temperatures, subjective ratings of thermal sensation.
11159631|NCT03662308|Experimental|Heated Vest Efficacy (persons with tetraplegia)|Subjects with tetraplegia, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized heated vest. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the self-regulating heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
11159632|NCT03662308|Active Comparator|Non-Heated Vest control condition (persons with tetraplegia)|The same subjects with tetraplegia from the experimental arm, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized, similarly insulated, but non-heated vest (control condition). Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the non-heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
11159633|NCT03662282|Experimental|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
11159634|NCT03662269|Experimental|indomethacin treatment group|indomethacin (75mg, bid) + omeprazole (20mg, qd)
11159635|NCT03662269|Placebo Comparator|placebo treatment group|placebo (75mg, bid) + omeprazole (20mg, qd)
11159636|NCT03662256|Active Comparator|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
11159637|NCT03662256|Experimental|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
11159638|NCT03662243||Acquired brain injury participants|People with acquired alexia and/or agraphia secondary to brain injury who participate in the reading/writing intervention.
11159639|NCT03662217|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
11159640|NCT03662217|Other|ADA- based diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes
11159641|NCT03662204||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159642|NCT03662204||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159643|NCT03662204||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159644|NCT03662204||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159645|NCT03662204||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159646|NCT03662204||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159647|NCT03662204||Kidney & Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159648|NCT03662204||Pancreatic|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159649|NCT03662204||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159650|NCT03662204||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159651|NCT03662204||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159652|NCT03662204||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
11159653|NCT03662191|Experimental|Treatment A|4 × 20 mg commercial tafamidis meglumine administered as soft gelatin capsules under fasted conditions
11159654|NCT03662191|Experimental|Treatment B|10 mgA tafamidis free acid administered as a wet-milled suspension under fasted conditions
11159655|NCT03662191|Experimental|Treatment C|a dose of tafamidis free acid projected to be an equivalent of 4 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
11159942|NCT03660280|Placebo Comparator|Placebo|
11159657|NCT03662165|Experimental|Intervention|"The primary intervention consisted of a text message informing participants that HIV self-test kits were available at all North Star Alliance clinics in Kenya. The message was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority."
11159658|NCT03662165|Experimental|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
11159659|NCT03662165|Active Comparator|Traditional Standard of Care|"Those randomized to the traditional SOC arm received the SOC message one time sent simultaneously in both Kiswahili and English. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
11159660|NCT03662152|Experimental|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
11159661|NCT03662152|Experimental|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
11159662|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
11159663|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
11159664|NCT03662126|Experimental|Part A Cohort 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
11159665|NCT03662126|Experimental|Part A Cohort 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
11159666|NCT03662126|Experimental|Part A Cohort 3|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
11159667|NCT03662126|Experimental|Part B|Recommended KRT-232 dose and schedule from Part A
11159668|NCT03662126|Experimental|Part A Cohort 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
11159669|NCT03662113|Experimental|Experimental: Domperidone|5ml domperidone prior to VCE
11159670|NCT03662113|Other|Control: water|5ml warm water prior to VCE
11159671|NCT03662100|Experimental|LY3074828 Reference 1|Solution formulation in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm
11159672|NCT03662100|Experimental|LY3074828 Reference 2|Solution formulation in PFS administered as SC injection in thigh
11159673|NCT03662100|Experimental|LY3074828 Reference 3|Solution formulation in PFS administered as SC injection in abdomen
11159674|NCT03662100|Experimental|LY3074828 Test 1|Solution formulation administered SC via an auto-injector (AI) in arm
11159675|NCT03662100|Experimental|LY3074828 Test 2|Solution formulation administered SC via an AI in thigh
11159676|NCT03662100|Experimental|LY3074828 Test 3|Solution formulation administered SC via an AI in abdomen
11159677|NCT03662087|Experimental|HMA+DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day +60 post-transplantation, HMA and DLI were given. DLI was given 48 hours after administration of HMA. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, HMA and DLI were given as shown above.
11159678|NCT03662087|Experimental|DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60 post-transplantation. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day+60 post-transplantation, DLI was given. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, DLI was given as shown above.
11159679|NCT03662074|Experimental|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
11159680|NCT03662048|Active Comparator|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
11159681|NCT03662048|Placebo Comparator|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
11159682|NCT03662035|Experimental|single-arm|Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2) until their disease have progressed.
11159683|NCT03662022|No Intervention|No PEP|No PEP will be distributed
11159684|NCT03662022|Other|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
11159685|NCT03662022|Experimental|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
11159686|NCT03662022|Other|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
11159691|NCT03661996|Experimental|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
11159692|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
11159693|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
11159694|NCT03661983|Experimental|Aripiprazole (OPC-14597)|2.0-20.0 mg/day; Start at 2.0 mg/day, increase to 5.0 mg after 2 days, titrate (based on 2 weight groups [<50 kg (5-10 mg/day) and >=50 kg (5-20 mg/day)]) to max of 20.0 mg/day
11159695|NCT03661983|Placebo Comparator|Placebo|Matching placebo, daily
11159696|NCT03661970||Normal subjects hearing group|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
11159697|NCT03661970||Cochlear implant subjects with good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
11159698|NCT03661970||Cochlear implant subjects without good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
11159699|NCT03661957|Active Comparator|Non grafted maxillary sinus floor elevation with implant pacem|
11159700|NCT03661957|Experimental|using short dental implants for posterior atrophic maxilla|
11159701|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
11159702|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
11159703|NCT03661931|Experimental|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a User Experience Questionnaire for each dietary assessment method.
11159704|NCT03661918|Other|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
11159705|NCT03661918|Other|Group 2|In-person first session, no second caregiver, wifi-enabled scale
11159706|NCT03661918|Other|Group 3|In-person first session, second caregiver, no wifi-enabled scale
11159707|NCT03661918|Other|Group 4|In-person first session, second caregiver, wifi-enabled scale
11159708|NCT03661918|Other|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
11159709|NCT03661918|Other|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
11159710|NCT03661918|Other|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
11159711|NCT03661918|Other|Group 8|No in-person first session, second caregiver, wifi-enabled scale
11159712|NCT03661905|Experimental|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
11159713|NCT03661905|Active Comparator|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
11159714|NCT03661892|Experimental|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
11159715|NCT03661879|Experimental|NNC9204-1706|Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period.
11159716|NCT03661879|Placebo Comparator|Placebo (NNC9204-1706)|Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period.
11159717|NCT03661853|Active Comparator|Control|This microintervention is intended to control for the effect of nonspecific therapy factors such as therapeutic alliance, time spent with a therapist, talking about alcohol, and/or effects related to assessment reactivity, and consists of 60 minutes of psycho-education on alcohol and drugs. The therapist will talk about historical and scientific information on different types of alcohol and drugs and will not overlap with CBT treatment. The participants will not be encouraged to personalize this information, make any behavioral changes, or do homework. The control does not have any active interventions that would specifically target or affect our outcome variables.
11159718|NCT03661853|Experimental|Functional Analysis|"Functional Analysis (FA) is a core intervention in Cognitive Behavioral Therapy (CBT) for AUD, and helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use. The FA microintervention teaches the patient to think and behave in new, more controlled ways in response to triggers, to identify maladaptive, impulsive behavior chains and to replace them with more deliberate ones."
11159719|NCT03661853|Experimental|Cognitive Restructuring|"Cognitive Restructuring of Thoughts About Alcohol (CR) is a core technique in CBT to help patients identify automatic (habituated) thoughts that happen quickly and are often not noticed, and change automatic thoughts occurring in response to alcohol triggers."
11159720|NCT03661853|Experimental|Dealing with Cravings|Dealing with Cravings (DC) is designed to directly target the reward and arousal systems, helping the patient accept the nature of cravings as time limited and deflated by continued abstinence so that craving is no longer associated with urgency. DC also teaches skills to reduce cravings by conjuring images such as a spider floating in a glass of wine, or of older versions of oneself sitting alone and dejected in a bar. Distraction techniques and breathing skills to reduce physiological arousal occurring in response to alcohol cues are also taught.
11159721|NCT03661840|Experimental|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
11159722|NCT03661840|Active Comparator|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
11159723|NCT03661827|Experimental|Patients with heart failure|Patients with heart failure
11159724|NCT03661814|Experimental|Prevena|This group will receive the negative pressure wound therapy device.
11159725|NCT03661814|No Intervention|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
11159726|NCT03661788|Experimental|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
11159727|NCT03661788|Experimental|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
11159728|NCT03661775|Experimental|controlled group|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour
11159729|NCT03661775|Experimental|Experimental group|group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
11159730|NCT03661762||Healthy Volunteers|All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
11159731|NCT03661749|Experimental|Clean catch|women in this group will collect urine for PR/CR using a clean catch technique
11159732|NCT03661749|Placebo Comparator|Non-clean catch|women in this group will not employ clean catch technique
11159733|NCT03661723|Experimental|Pembrolizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
11159734|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)
~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
11159735|NCT03661723|Experimental|Pembrolizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
11159736|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks
~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks
~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
11159737|NCT03661697|Experimental|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
11159738|NCT03661697|Active Comparator|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
11159739|NCT03661684|Experimental|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
11159740|NCT03661684|Experimental|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
11159741|NCT03661671|Experimental|LCI+white light|Using white light firstly to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
11159742|NCT03661671|No Intervention|White light|Using white light only.
11159743|NCT03661658|Active Comparator|Inferior alveolar nerve lateralization with implant placement|
11159744|NCT03661658|Experimental|Using short dental implant with atrophic mandible|
11159745|NCT03661645|Active Comparator|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone & 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
11159746|NCT03661645|Other|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
11159747|NCT03661632|Experimental|Dose Escalation|"Part 1: BMS-986310 + Nivolumab Combination Dose Escalation
~Sub-Study A: A cohort of Cisplatin Ineligible Muscle Invasive Bladder Cancer patients will receive either monotherapy BMS-986310, or BMS-986310 + Nivolumab, or Nivolumab monotherapy.
~Sub-Study B: A cohort of PD[L]1 relapsed / refractory tumor cancer patients will be treated with monotherapy BMS-986310 followed by BMS-986310 + nivolumab"
11159748|NCT03661632|Experimental|Cohort Expansion|"Part 2: Cohort Expansion will initiate upon consideration of the totality of data from Part 1.
~BMS-986310 + Nivolumab combination will be administered in specific patient populations."
11159749|NCT03661619|Experimental|Control Group|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
11159750|NCT03661619|Experimental|Test Group|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
11159751|NCT03661606|Experimental|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
11159752|NCT03661593|Experimental|Cataract guideline|In this patients we follow cataract guideline and correct the patients ametropia during the cataract surgery
11159753|NCT03661593|No Intervention|Standard refraction|The patients gets an IOL ensuring his preoperatively refraction
11159754|NCT03661580|Experimental|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
11159943|NCT03660267|Experimental|coffee group|caffeine coffee
11159755|NCT03661580|Active Comparator|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
11159756|NCT03661567|Experimental|Methylprednisolone|Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
11159757|NCT03661567|Active Comparator|Observation|Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).
11159758|NCT03661554|Experimental|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
11159759|NCT03661541|Experimental|Group A|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:
~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.
~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.
~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
11159760|NCT03661541|No Intervention|Group B|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:
~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
11159761|NCT03661541|No Intervention|Group C|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:
~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
11159762|NCT03661515|Experimental|Fludarabine-Idarubicine-Cytarabine- Selinexor|"fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:
~Level -1: Selinexor 40 mg/day, once weekly
~Level 1: Selinexor 60 mg/day, once weekly
~Level 2: Selinexor 80 mg/day, once weekly
~Level 3: Selinexor 100 mg/day, once weekly"
11159763|NCT03661502|Experimental|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
11159764|NCT03661502|Experimental|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
11159765|NCT03661489|Experimental|Intravenous Remimazolam 50 mg|"For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.
~For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
11159766|NCT03661489|Active Comparator|Intravenous Propofol 2%|"For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.
~For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
11159767|NCT03661476|Experimental|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
11159768|NCT03661463|Experimental|Aspirin|Aspirin (Acetylsalicylic Acid [ASA]) tablets, 300mg once a day, for 90 days.
11159769|NCT03661463|No Intervention|No Treatment|No medical treatment
11159770|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
11159771|NCT03661437|Experimental|Arm I (BWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
11159772|NCT03661437|Experimental|Arm II (DWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
11159773|NCT03661424|Experimental|Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)|Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
11159774|NCT03661411|Experimental|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
11159775|NCT03661411|Active Comparator|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
11159776|NCT03661398|Experimental|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
11159777|NCT03661385|Active Comparator|Intervention arm|• Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
11160456|NCT03656952|Experimental|Seq 6|Moxifloxacin->placebo->PF-06700841
11159778|NCT03661385|No Intervention|Control arm|Control arm will not receive nitric oxide, they will receive standard bypass as per local policy
11159779|NCT03661372|Active Comparator|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
11159780|NCT03661372|Active Comparator|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
11159781|NCT03661359|Experimental|Social Determinants of Health|Intervention will be the Social Determinants of Health Referrals.
11159782|NCT03661346|Experimental|Esmolol|Patients receiving esmolol when intra-operative MAP > 80 mmHg.
11159783|NCT03661346|Active Comparator|Labetalol|Patients receiving labetalol when intra-operative MAP > 80 mmHg
11159784|NCT03661333|Experimental|Adolescents with bipolar disorder|40 adolescents aged 13 to 19 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
11159785|NCT03661320|Active Comparator|Arm A|Chemotherapy alone followed by radical cystectomy
11159786|NCT03661320|Experimental|Arm B|BMS-986205 Placebo + Nivolumab + Chemotherapy followed by BMS-986205 Placebo + Nivolumab post radical cystectomy
11159787|NCT03661320|Experimental|Arm C|BMS-986205 + Nivolumab + Chemotherapy followed by Nivolumab plus BMS-986205 post radical cystectomy
11159788|NCT03661307|Experimental|Treatment (decitabine, quizartinib, venetoclax)|Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11159789|NCT03661294|Other|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
11159790|NCT03661281|Experimental|Simulated Thumb Arthrodesis|Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
11159791|NCT03661268|Experimental|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
11159792|NCT03661255|Experimental|PC CARES Intervention|Participants will attend 1-4 sessions of the PC CARES curriculum. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
11159793|NCT03661255|No Intervention|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
11159794|NCT03661242|No Intervention|Standard of care|No intervention
11159795|NCT03661242|Active Comparator|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
11159796|NCT03661229||Patients receiving CVInsight Monitoring|All participants (n=50) will belong to the dialysis population and will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
11159797|NCT03661229||Patients undergoing echocardiography and finometer application|Twenty of the above patient cohort will also have assessment with echocardiography assessing left ventricular segmental wall movement using the GE Healthcare Vivid q cardiovascular ultrasound system and continuous blood pressure monitoring using a finometer - Finapres Medical Systems.
11159798|NCT03661216|Placebo Comparator|Placebo|3g of non-GMO maltodextrin
11159799|NCT03661216|Active Comparator|Nephure|3g of Nephure
11159800|NCT03661203||Qualitative cohort|The cohort consists of MSM with late HIV diagnosis. The person from this cohort will participate to round table called also focus group or individual interview.
11159801|NCT03661203||Quantitative cohort|MSM community will be invited to participate to an online self questionnaire established from the information gathered from the previous cohort.
11159802|NCT03661190|Other|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
11159803|NCT03661190|Other|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
11159804|NCT03661177|Experimental|Diet intervention|
11159805|NCT03661177|No Intervention|Control|
11159806|NCT03661151||Antireflux surgery following PPI|A single cohort with the GERD patients who had acid suppressive medication with proton pump inhibitor (PPI) followed by laparoscopic antireflux surgery
11159807|NCT03661138|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
11159808|NCT03661138|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
11159809|NCT03661138|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
11159810|NCT03661138|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
11159811|NCT03661125|Experimental|Saracatinib or placebo|In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
11159812|NCT03661125|Experimental|Placebo or Saracatinib (Cross-over)|The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
11159813|NCT03661112||All of Us Research Program (AoURP) consortium members|
11159814|NCT03661086|Active Comparator|O2matic|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
11159815|NCT03661086|No Intervention|Manual|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.
11159816|NCT03661073|Experimental|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
11159817|NCT03661073|Sham Comparator|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
11159818|NCT03661047|Active Comparator|Omega-3 treatment|Daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl)
11159819|NCT03661047|Placebo Comparator|Placebo|Identical placebo
11159820|NCT03661034|Experimental|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
11159821|NCT03661034|Experimental|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
11159822|NCT03661034|Experimental|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
11159823|NCT03661034|Experimental|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
11159824|NCT03661008||Adolescents with paternal involvement|
11159825|NCT03661008||Adolescents without paternal involvement|
11159826|NCT03660995|Experimental|SLI children|
11159827|NCT03660995|Active Comparator|Control children|
11159828|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
11159829|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
11159830|NCT03660956|Experimental|Exercise and back counselling group|
11159831|NCT03660956|Active Comparator|Back counselling group|
11159832|NCT03660943|Placebo Comparator|Placebo|Intra-articular Placebo Injection
11159833|NCT03660943|Experimental|CNTX-4975-05 (trans-capsaicin)|Intra-articular 1.0 mg CNTX-4975-05 Injection
11159834|NCT03660930|Experimental|Treatment (ABI-009, pazopanib)|Participants receive nanoparticle albumin-bound rapamycin IV on days 1 and 8 and pazopanib hydrochloride PO daily on days 1-21. Courses repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
11159835|NCT03660917|Experimental|Riluzole|Riluzole 50 mg twice daily for 12 months in the treated group. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
11159836|NCT03660917|Placebo Comparator|Placebo + riluzole|Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
11159837|NCT03660904|Experimental|Home made media|home made vitrification & thawing kit
11159838|NCT03660904|Active Comparator|Commercial media|commercially available vitrification & thawing kit
11159839|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
11159840|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
11159841|NCT03660878|Placebo Comparator|Vehicle Ophthalmic Solution|
11159842|NCT03660865|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's primary eye will receive the light adjustable lens.
11159843|NCT03660865|Active Comparator|Control monofocal IOL|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's fellow eye will receive the control monofocal IOL.
11159844|NCT03660852||Before dedicated MRI|
11159845|NCT03660852||After dedicated MRI|
11159846|NCT03660839|Experimental|Ferroquine (FQ)|single dose FQ
11159847|NCT03660839|Experimental|OZ439 dose 1 + ferroquine|single dose OZ439 dose 1 and FQ
11159848|NCT03660839|Experimental|OZ439 dose 2 + ferroquine|single dose OZ439 dose 2 and FQ
11159849|NCT03660839|Experimental|OZ439 dose 3 + ferroquine|single dose OZ439 dose 3 and FQ
11159850|NCT03660826|Experimental|Arm I (cediranib maleate)|Patients receive cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11159851|NCT03660826|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11159852|NCT03660826|Experimental|Arm III (cediranib maleate, olaparib)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11159853|NCT03660813|Experimental|HCG triggering|Ovitrelle ( hCG 250 mcg)
11159854|NCT03660813|Experimental|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )
11159855|NCT03660800|Experimental|CTAP101 Capsules 450mcg/weekly fasted|
11159856|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fasted|
11159857|NCT03660800|Experimental|CTAP101 Capsules 1800mcg/weekly fasted|
11159858|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fed|
11159859|NCT03660787|Placebo Comparator|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
11159860|NCT03660787|Placebo Comparator|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
11159861|NCT03660787|Experimental|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
11159862|NCT03660787|Experimental|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
11159863|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
11159864|NCT03660761|Experimental|apatinib 500mg|
11159865|NCT03660748|Experimental|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
11159866|NCT03660748|Experimental|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
11159867|NCT03660735||Male Factor Subfertility|Participant is undergoing first or second cycle of IVF and ICSI for male factor subfertility
11159868|NCT03660735||Recurrent Implantation Failure|Participant is undergoing an IVF cycle to treat subfertility with a history of Recurrent Implantation Failure (RIF).
11159869|NCT03660735||Female Subfertility|Participant is undergoing an IVF cycle to treat at least 1 year of subfertility
11159870|NCT03660722|Other|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
11159871|NCT03660709|Experimental|Intervention|enhanced version of HIV testing and counseling
11159872|NCT03660709|Active Comparator|Control|standard-of-care HIV testing and counseling
11159873|NCT03660683|Experimental|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
11159874|NCT03660683|Active Comparator|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
11159875|NCT03660683|Placebo Comparator|Placebo|Placebo Oral Tablet
11159876|NCT03660670|Experimental|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
11159877|NCT03660670|Sham Comparator|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
11159878|NCT03660657|Experimental|Ozone Group:|Standard treatment + Ozone therapy (O3/O2)
11159879|NCT03660657|Placebo Comparator|Control Group:|Standard treatment + Oxygen (O2)
11159880|NCT03660644|Experimental|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
11159881|NCT03660644|No Intervention|Control|Usual care following pulmonary rehabilitation.
11159882|NCT03660631|Experimental|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
11159883|NCT03660631|Other|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
11159884|NCT03660618|Other|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
11159885|NCT03660605|Experimental|Rhythmic Auditory Stimulation|Participants will walk on treadmill to metronome set at 85% of typical cadence, followed by overground walking with metronome set at 115% of typical cadence.
11159886|NCT03660592||operator 1|ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
11159887|NCT03660592||operator 2|a different ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
11159888|NCT03660579|No Intervention|HIIT-CON|No intervention: Control
11159889|NCT03660579|Experimental|HIIT-AB Group|"Intake:
~330ml (women) or 2x300 ml (men) of beer with 5.4% alcohol. The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
11159890|NCT03660579|Experimental|HIIT-NAB Group|"Intake:
~330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%). The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
11159891|NCT03660579|Experimental|HIIT-SW Group|"Intake:
~330 ml (women) or 2x300 ml (men) of sparkling water. The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
11159892|NCT03660579|Experimental|HIIT-ASW Group|"Intake:
~330 ml (women) or 2x300 ml (men) of sparkling water with 5.4% alcohol.The beverage intakes will be programmed from Monday to Friday.
~Training:
~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).
~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
11159944|NCT03660267|Experimental|decaffeinete coffee group|decaffeinete coffee group
11159893|NCT03660566|Experimental|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
11159894|NCT03660566|Active Comparator|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
11159895|NCT03660553|Active Comparator|Multiple Subcutaneous Injection (MSI)|MSI group will receive four insulin injections per day that will include a long acting and a short acting insulin. Short acting insulin will be either insulin aspart or insulin lispro.
11159896|NCT03660553|Experimental|Basal Insulin (BI)|BI group will receive only one injection of insulin glargine in the morning.
11159897|NCT03660540|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
11159898|NCT03660540|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
11159899|NCT03660527||6-17 year old|
11159900|NCT03660527||18-44 year old|
11159901|NCT03660527||45-59 year old|
11159902|NCT03660527||above 60 year old|
11159903|NCT03660514|No Intervention|Standard Family Planning|Counseling Clients receive standard FP counseling services.
11159904|NCT03660514|Experimental|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
11159905|NCT03660488|Active Comparator|Benzathine Penicillin G|"Patients of the Penicillin Group will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients."
11159906|NCT03660488|Experimental|Cefixime Group|"Patients of the Cefixime Group will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.
~The group will consist of 50 patients."
11159907|NCT03660475|Experimental|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
11159908|NCT03660475|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
11159909|NCT03660462|Active Comparator|FeSO4 fortified rice test meal|
11159910|NCT03660462|Experimental|FePO4 fortified rice test meal|
11159911|NCT03660462|Experimental|HiFePO4 1 fortified rice test meal|
11159912|NCT03660462|Experimental|HiFePO4 2 fortified rice test meal|
11159913|NCT03660449|Experimental|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
11159914|NCT03660436|Experimental|BMS-986165 + MMF|Oral administration
11159915|NCT03660423|Experimental|Dance Group|Dance group will participate in a 60 minute integrative dance class two times per week
11159916|NCT03660423|No Intervention|Control Group|The Control group will continue with normal activities, not participating in the dance intervention.
11159917|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
11159918|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
11159919|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
11159920|NCT03660397|Experimental|Intervention|Selective endovascular chemical ablation of adrenal gland after adrenal angiography.
11159921|NCT03660397|Active Comparator|Control|No intervention, but treated with standard antihypertensive drugs
11159922|NCT03660384|Experimental|SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
11159923|NCT03660384|Experimental|C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
11159924|NCT03660371|Experimental|PPV/MP|Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
11159925|NCT03660371|Active Comparator|PPV without MP|Control Group: Subjects do not undergo ILM peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
11159926|NCT03660358|Experimental|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
11159927|NCT03660358|No Intervention|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
11159928|NCT03660345|Experimental|PPV/MP|Study Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo pars plana vitrectomy with internal limiting membrane peeling
11159929|NCT03660345|Active Comparator|Intravitreal Injection|Control Group: Treatment-naïve subjects with center-involved diabetic macular edema undergo intravitreal ziv-aflibercept monotherapy according to a fixed treatment schedule
11159930|NCT03660332|Active Comparator|IL-6 infusion|Healthy young men will receive IL-6 infusion
11159931|NCT03660332|Placebo Comparator|Placebo infusion|Healthy young men will receive saline infusion
11159932|NCT03660319|Experimental|Environmental Music Therapy|Music Therapy Intervention (EMT)
11159933|NCT03660319|No Intervention|Control|Control - No Environmental Music Therapy. Does not experience Environmental Music Therapy during wait time in radiation oncology waiting room.
11159934|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
11159935|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
11159936|NCT03660293|No Intervention|diabetic- no cardioprotectives|25 child with type 1 diabetes mellitus will not receive any cardio protective drug
11159937|NCT03660293|Experimental|diabetic-Atorvastatin|25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
11159938|NCT03660293|Experimental|diabetic-Captopril|25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
11159939|NCT03660293|Experimental|diabetic-L-Carnitine|25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
11159940|NCT03660293|No Intervention|Controls|50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
11159941|NCT03660280|Experimental|Probiotics|
11159946|NCT03660254|Experimental|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
11159947|NCT03660254|No Intervention|no intervention|no intervention
11159948|NCT03660241|Experimental|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
11159949|NCT03660228|Experimental|Peri-Transfusion QOL Assessment|"Participants will be given a study packet containing a paper copy of the QUALMS
~Study participants will fill out the survey on the day before their first/next pRBC transfusion.
~Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site
~The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results"
11159950|NCT03660215|No Intervention|control group|usual charge
11159951|NCT03660215|Experimental|experimental group|"Mediation:
~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
11159952|NCT03660202|Experimental|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
11159953|NCT03660189|No Intervention|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
11159954|NCT03660189|Experimental|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
11159955|NCT03660176|Active Comparator|routine management|Children in the control group receive no additional treatment
11159956|NCT03660176|Experimental|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
11159957|NCT03660137|Experimental|MOLLI Localization|All patients will be implanted with a MOLLI magnetic seed in addition to the standard-of-care RSL seed. Both systems will be use to localize the respective seeds during the lumpectomy surgery.
11159958|NCT03660124|Experimental|Deep Brain Stimulation Treatment|
11159959|NCT03660111|Other|spirometry|single spirometry: only a routine diagnostic test
11159960|NCT03660085|Experimental|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
11159961|NCT03660085|Active Comparator|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
11159962|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
11159963|NCT03660059|Experimental|ASP015K dose-A|Participants will receive dose-A of ASP015K once daily after breakfast for 52 weeks.
11159964|NCT03660059|Experimental|ASP015K dose-B|Participants will receive dose-B of ASP015K once daily after breakfast for 52 weeks.
11159965|NCT03660059|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks, then either dose-A or dose-B of ASP015K for 28 weeks as determined randomly at Week 0 in advance.
11159966|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
11159967|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
11159968|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
11159969|NCT03660033|Experimental|With ECG|These teams will have access to ECG monitoring (intervention) during the scenario
11159970|NCT03660033|No Intervention|Without ECG|These teams will NOT have access to ECG monitoring during the scenario
11159971|NCT03660020|Sham Comparator|local anaesthetic group|
11159972|NCT03660020|Active Comparator|hyalorounidase group|
11159973|NCT03660007||Fresh embryo transfer|This exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
11159974|NCT03660007||Frozen embryo transfer|This exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
11159975|NCT03660007||Natural pregnancy|Spontaneous pregnancy without IVF
11159976|NCT03659994|Experimental|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
11159977|NCT03659994|Experimental|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
11159978|NCT03659994|Experimental|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
11159979|NCT03659994|Placebo Comparator|Placebo|3 Capsules of Placebo
11159980|NCT03659981|Experimental|MS Patients|Multiple sclerosis patients MRI 7T will be performed
11159981|NCT03659968|Experimental|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
11159982|NCT03659955|Experimental|Autologous blood|"Patients with severe dry eye and ocular surface disease who attend the corneal service within NHS Lanarkshire and who are unresponsive to conservative treatment measures will be considered for treatment of their condition with autologous blood.
~Intervention is application of autologous blood."
11159983|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
11159984|NCT03659929|Experimental|Arm 1: 20 mg/day|Amphetamine Sulfate
11159985|NCT03659929|Experimental|Arm 2: 40 mg/day|Amphetamine Sulfate
11159986|NCT03659929|Placebo Comparator|Arm 3: Placebo|Placebo, no active drug
11159987|NCT03659916|Experimental|A4250|Capsules for oral administration (120 ug/kg) once daily for 72 weeks
11159988|NCT03659903||younger patients (age < 80)|age < 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
11160293|NCT03657862|Experimental|SDF treated|application of 38% silver diamine fluoride solution
11159989|NCT03659903||older patients (age≥ 80 )|age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
11159990|NCT03659890|Placebo Comparator|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
11159991|NCT03659890|Experimental|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
11159992|NCT03659890|Experimental|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
11159993|NCT03659877|Experimental|Heart failure patients|Patients will be required to perform a number of physical activity tasks such as laying down, sitting and walking. During these activities, acceleration, oxygen consumption, rating of perceived exertion and heart rate will be recorded.
11159994|NCT03659864|Sham Comparator|Exposure 1|filtered air
11159995|NCT03659864|Experimental|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
11159996|NCT03659864|Experimental|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
11159997|NCT03659851||Levosimendan before LVAD implantation|Levosimendan use 24 hrs. before LVAD implantation
11159998|NCT03659851||Dobutamine/milrinone before LVAD implantation|Dobutamine/milrinone use 24 hrs. before LVAD implantation
11159999|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
11160000|NCT03659825|Placebo Comparator|Placebo + Normoxia|Taste, volume and appearance matched drink given before cognitive testing in normoxia
11160001|NCT03659825|Placebo Comparator|Placebo + Hypoxia|Taste, volume and appearance matched drink given before cognitive testing in hypoxia
11160002|NCT03659825|Experimental|Ketone Ester + Normoxia|Ketone ester drink given before cognitive testing in normoxia
11160003|NCT03659825|Experimental|Ketone Ester + Hypoxia|Ketone ester drink given before cognitive testing in hypoxia
11160004|NCT03659812|Experimental|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
11160005|NCT03659812|No Intervention|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
11160006|NCT03659799|Active Comparator|Aspart - 60-minutes postprandial exercise|
11160007|NCT03659799|Active Comparator|Aspart - 120-minutes postprandial exercise|
11160008|NCT03659799|Active Comparator|FiAsp - 60-minutes postprandial exercise|
11160009|NCT03659799|Active Comparator|FiAsp - 120-minutes postprandial exercise|
11160010|NCT03659786|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
11160011|NCT03659786|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
11160012|NCT03659786|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
11160013|NCT03659773|Experimental|hematopoietic stem cell transplant (HSCT)|immune biomarkers to evaluate vaccine response in HSCT recipients
11160014|NCT03659760|Experimental|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
11160015|NCT03659760|No Intervention|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
11160016|NCT03659747|Experimental|Probiotic|"6 g sachet containing probiotic powder (1.8 x 10^12 colony forming units (CFU) Probiotic) in sachet
~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
11160017|NCT03659747|Active Comparator|Lactrase|"6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier
~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
11160018|NCT03659747|Placebo Comparator|Placebo|"6 g sachet containing placebo powder (maltodextrin) in sachet
~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
11160019|NCT03659734|Experimental|Motivational Interviewing and Gradual Opioid Weaning|
11160020|NCT03659734|Experimental|Enhanced Usual Care|
11160021|NCT03659734|No Intervention|Observation|
11160022|NCT03659721|Experimental|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
11160023|NCT03659721|Active Comparator|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
11160056|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
11160057|NCT03659487|Active Comparator|Nissen|Surgery of GERD with 360 degrees total fundoplication
11160058|NCT03659487|Active Comparator|Toupét|Surgery of GERD with 270 degrees partial fundoplication
11160294|NCT03657862|Placebo Comparator|Placebo|application of a placebo (tonic water)
11160024|NCT03659708|Experimental|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :
~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:
~A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;
~A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);
~A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.
~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).
~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
11160025|NCT03659708|Experimental|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
11160026|NCT03659695|Experimental|Grape Powder|69 g/d freeze dried grape powder
11160027|NCT03659695|Placebo Comparator|Placebo powder|69 g/d placebo powder matched for taste and appearance
11160028|NCT03659682|Active Comparator|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
11160029|NCT03659682|Placebo Comparator|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
11160030|NCT03659669||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label.
11160031|NCT03659656|Other|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
11160032|NCT03659656|Experimental|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
11160033|NCT03659643||Retrospective MCI cohort|EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
11160034|NCT03659643||Prospective MCI cohort|New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
11160035|NCT03659630|Experimental|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
11160036|NCT03659630|Placebo Comparator|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
11160037|NCT03659617|Experimental|Implant placement 3 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 3 mo. after tooth ext.
11160038|NCT03659617|Active Comparator|Implant placement 6 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 6 mo. after tooth ext.
11160039|NCT03659617|Active Comparator|Implant placement 9 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 9 mo. after tooth ext.
11160040|NCT03659604|Experimental|Experimental with tailored feedback|'SmartLife' with tailored feedback: School classes will receive the developed 'SmartLife' intervention with tailored feedback, that is based on data from a sensors that is integrated in a T-shirt.
11160041|NCT03659604|Active Comparator|Active control without tailored feedback|'SmartLife' without tailored feedback: School classes will receive the developed 'SmartLife' intervention without tailored feedback.
11160042|NCT03659604|Other|Passive control|School classes will not receive any intervention, thus no game.
11160043|NCT03659591|Active Comparator|Cognitive Behaviour Therapy|10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
11160044|NCT03659591|Active Comparator|Adaptive Psychological Training|5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
11160045|NCT03659578|Experimental|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
11160046|NCT03659565|Experimental|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
11160047|NCT03659565|Active Comparator|Usual Care Control|Patients continue to receive usual care from their cardiologist.
11160048|NCT03659552|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
11160049|NCT03659539|Active Comparator|CLADS group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with propofol, with its administration controlled with CLADS tuned to consistent anesthetic depth (BIS-50) feedback from the patients.
11160050|NCT03659539|Active Comparator|Desflurane group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
11160051|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
11160052|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
11160053|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (>50%).
11160054|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
11160055|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
11160059|NCT03659474|Experimental|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
11160060|NCT03659474|Experimental|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
11160061|NCT03659474|Experimental|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
11160062|NCT03659461|Experimental|low GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
11160063|NCT03659461|Active Comparator|normal GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
11160064|NCT03659448|Active Comparator|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
11160065|NCT03659448|No Intervention|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
11160066|NCT03659435|Experimental|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
11160067|NCT03659435|Active Comparator|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
11160068|NCT03659422|Other|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
11160069|NCT03659409|Experimental|Mindfulness Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
11160070|NCT03659409|Other|Treatment Waitlist Group|Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
11160071|NCT03659396|Experimental|individualized Tai Chi|patient received individualized Tai Chi program training.
11160072|NCT03659396|Active Comparator|Entire Tai Chi|patient received Entire Tai Chi program training.
11160073|NCT03659396|Placebo Comparator|home-based program|patient received home-based program training.
11160074|NCT03659383|Experimental|Optimal hypoglycemic treatment|The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
11160075|NCT03659370|Active Comparator|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
11160076|NCT03659370|Active Comparator|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
11160077|NCT03659370|Active Comparator|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
11160078|NCT03659357||A-first CTE examination|
11160079|NCT03659357||B-first MRE examination|
11160080|NCT03659344|Active Comparator|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
11160081|NCT03659344|No Intervention|vicryl|In this group, vicryl sutures were used to close flaps
11160082|NCT03659331|Experimental|unexplained elevation of liver enzymes|patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again.
11160083|NCT03659318|Experimental|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
11160084|NCT03659318|Active Comparator|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
11160085|NCT03659305|Experimental|RPH-001|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
11160086|NCT03659305|Active Comparator|Avastin|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
11160087|NCT03659292|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
11160088|NCT03659292|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
11160089|NCT03659279|Experimental|Let's Get Organized|Group intervention with 10 weekly sessions, each lasting 1.5 hours.
11160090|NCT03659266|Active Comparator|Group 1|"D0: Injection of Botulinum toxin A in triceps surae, according to pre-established modalities (no influence of the experimental protocol on this stage) W2-W4: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization)"
11160091|NCT03659266|Active Comparator|group 2|"D0: Injection of Botulinum toxin A in triceps surae W2-W4: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization)"
11160092|NCT03659253|Experimental|Oral Fluid Based Self Testing|All study participants that received intervention and meet inclusion criteria intervention that will be offered OFT
11160093|NCT03659253|No Intervention|Control Group|All HIV Patients in the clinic that not received any intervention
11160094|NCT03659253|Experimental|Simplified ART Initiation|All study participants that received intervention and meet inclusion criteria intervention that will be offered SAI
11160378|NCT03657381|Experimental|F520 1mg/kg multiple dosing, every 2 weeks|F520 1mg/kg every 2 weeks
11160095|NCT03659253|Experimental|CBO AND BROTHEL-BASED ART SERVICE|All patients coming to brothel or Community Based Organization services will be offered to get tested and received ART
11160096|NCT03659253|Experimental|SMS Reminder|"All patients that recently found HIV Positive HIV Naive offered to get SMS Reminder"
11160097|NCT03659253|Experimental|Motivational Interviewing|PWID in Jakarta and Bandung that recently found HIV Positive or lost to follow up ARV offered MI intervention
11160098|NCT03659240|Experimental|Cranberry beverage|
11160099|NCT03659240|Placebo Comparator|Placebo beverage|
11160100|NCT03659214||Treated group|Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
11160101|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
11160102|NCT03659201|Experimental|Neosil complete|"The patient will take the tablets, as follow:
~3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and
~2 tablets of Neosil Oral, per day - during the last 12 weeks."
11160103|NCT03659201|Experimental|Pantogar|"The patient wil take the tablets, as follow:
~3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and
~3 tablets of Pantogar, Oral, per day - during the last 12 weeks."
11160104|NCT03659201|Experimental|Neosil|"The patient will take the tablets, as follow:
~2 tablets of Neosil Oral, per day - during the 12 weeks."
11160105|NCT03659188|Experimental|Corticotomy with drills|Patients will undergo orthodontic treatment plus an acceleration procedure employing corticotomy with drills.
11160106|NCT03659188|Experimental|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
11160107|NCT03659188|No Intervention|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
11160108|NCT03659175||male elderly with SIBO|"male elderly who was diagnosed as SIBO via 'lactulose breath test' (LBT). At the same time, they meet the following criteria:
~no use of antibiotics in the past 1 month.
~no use of prokinetic drugs and probiotics in the past 1 week.
~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
11160109|NCT03659175||male elderly without SIBO|"male elderly without SIBO after 'lactulose breath test'. At the same time, they meet the following criteria:
~no use of antibiotics in the past 1 month.
~no use of prokinetic drugs and probiotics in the past 1 week.
~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
11160110|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
11160111|NCT03659149|Experimental|Group 1|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Test drug 2(CKD-333 formulation II) Period 3: Reference drug(CKD-330 + D086)
11160112|NCT03659149|Experimental|Group 2|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 2(CKD-333 formulation II)
11160113|NCT03659149|Experimental|Group 3|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 1(CKD-333 formulation I)
11160114|NCT03659149|Experimental|Group 4|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Reference drug(CKD-330 + D086)
11160115|NCT03659149|Experimental|Group 5|Period 1: Reference drug(CKD-330 + D086) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Test drug 2(CKD-333 formulation II)
11160116|NCT03659149|Experimental|Group 6|Period 1: Reference drug(CKD-330 + D086) Period 2: Test durg 2(CKD-333 formulation II) Period 3: Test drug 1(CKD-333 formulation I)
11160117|NCT03659136|Experimental|Xentuzumab/everolimus/exemestane|
11160118|NCT03659136|Placebo Comparator|Placebo/everolimus/exemestane|
11160119|NCT03659123|Experimental|Intervention|"The intervention is designed to be implemented at different times of patients' care
~During the prehabilitation time:
~Nutritional care
~Total-body rehabilitation
~Pharmaceutical conciliation During peri-operative time
~Management of enhances rehabilitation of the elderly. During rehabilitation time
~Nutritional, medication conciliation and functional follow-up During hospital-home transition time
~Nutritional and functional follow-up
~Optimisation of symptoms management: abdominal pain, nausea, vomiting…"
11160120|NCT03659110||1000 subjects receive the HPV 4 vaccine|
11160121|NCT03659097|Experimental|Periodontally accelerated osteogenic orthodontics|Patients in this group will undergo orthodontic treatment plus periodontally accelerated osteogenic orthodontics in order to induce tooth movement.
11160122|NCT03659097|No Intervention|Traditional orthodontics|Patients in this group will undergo traditional orthodontics without any surgical interventions
11160123|NCT03659071|Experimental|DONORS|donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
11160124|NCT03659071|Other|NON DONORS|non-donor siblings. questionnaire VSP-A will be performed
11160125|NCT03659058|Active Comparator|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
11160126|NCT03659058|Placebo Comparator|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
11160127|NCT03659045|Experimental|Mifegyne® 600MG|Patients assigned to this group will receive three 200 mg tablets of Mifegyne® taken during the consultation Patients will answer to a scale of pain
11160128|NCT03659045|Placebo Comparator|Mifegyne® 200MG|"Patients assigned to this group will receive one 200 mg Mifegyne® tablet and two placebo tablets that will be taken during the consultation.
~Patients will answer to a scale of pain"
11160379|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 2 weeks|F520 3mg/kg every 2 weeks
11160129|NCT03659032|Experimental|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
11160130|NCT03659032|Active Comparator|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
11160131|NCT03659019||ventilatory paralysis|dependence on mechanical ventilatory support
11160132|NCT03659019||central hypoventilation|documented permanent or nocturnal hypoventilation
11160133|NCT03659006|Experimental|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
11160134|NCT03658993|Active Comparator|Rifaxamine 550 mg|Study drug Oral Rifaximin 550 mg TID for 4 weeks .
11160135|NCT03658993|Placebo Comparator|Placebo|Placebo TID for 4 weeks
11160136|NCT03658980|Experimental|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
11160137|NCT03658980|No Intervention|Control Group|No Intervention will be conducted in this control group
11160138|NCT03658967|Active Comparator|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
11160139|NCT03658967|Placebo Comparator|Placebo (0.9% physiological saline)|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
11160140|NCT03658954|Active Comparator|Advice|Participants receive only web-based sleep hygiene advice
11160141|NCT03658954|Experimental|Advice + Self-monitoring|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring
11160142|NCT03658954|Experimental|Advice + Self-monitoring + Feedback|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback
11160143|NCT03658941|Experimental|No dural tenting sutures|No dural tenting techniques
11160144|NCT03658941|Active Comparator|Dural tenting sutures|Dural tenting techniques
11160145|NCT03658915||Osteoarthritis|"Thirty symptomatic knee with osteoarthritis will be recruited according to the following criteria:
~INCLUSION CRITERIA:
~Referred with a confirmed diagnosis of unilateral or bilateral OA of the knee based on the following criteria.
~1.1. Morning stiffness < 30 minutes, 1.2. Crepitus on active knee movement. 1.3. Bony enlargement either palpable or visible in radiographs. 1.4. Bony tenderness.
~Age 40-60 years old.
~EXCLUSION CRITERIA:
~Steroid injection within the past 2 months.
~Presence of neurologic disorders.
~Presence of of orthopedic diseases or trauma in the lower extremity or spine within the past year.
~6. Severe pain with active movement 7. Poor memory or cognitive function"
11160146|NCT03658915||Control|Thirty asymptomatic knee will be recruited for this study. Control group participants will be age-matched to the osteoarthritis group, and should have no pain or other relevant clinical symptoms in lower quadrant.
11160147|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
11160148|NCT03658876|Active Comparator|EPO group|
11160149|NCT03658876|Active Comparator|Iron group|
11160150|NCT03658863|Active Comparator|Endoscopy first|Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
11160151|NCT03658863|Active Comparator|Cholecystectomy first|Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).
11160152|NCT03658850|Active Comparator|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
11160153|NCT03658850|Placebo Comparator|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
11160154|NCT03658824|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
11160155|NCT03658824|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
11160156|NCT03658824|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
11160157|NCT03658824|Other|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
11160158|NCT03658824|Other|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
11160159|NCT03658824|Other|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
11160160|NCT03658811|Experimental|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
11160161|NCT03658798|Experimental|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
11160162|NCT03658785|Experimental|TIL,IL-2,Cyclophosphamide,Fludarabine|"Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).
~Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
~Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days."
11160163|NCT03658772|Experimental|Cohort 1|Single Agent run-in with grapiprant and then combination treatment of grapiprant and pembrolizumab.
11160164|NCT03658772|Experimental|Cohort 2|Participants will be treated with grapiprant in combination with pembrolizumab.
11160186|NCT03658629|Experimental|Quad-NIV without Adjuvant|Alternating deltoid injections of 2018-2019 Quad-NIV-5 (Day 0) and Licensed 2018-2019 Influenza vaccine (Day 28)
11160165|NCT03658746|Experimental|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
11160166|NCT03658746|Active Comparator|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
11160167|NCT03658733|Experimental|Esomeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole,amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
11160168|NCT03658733|Active Comparator|Rabeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
~Drugs: 1. rabeprazole 20mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
11160169|NCT03658720|Experimental|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
11160170|NCT03658720|Experimental|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
11160171|NCT03658694|Experimental|rTMS high dose - stage 1|In stage 1 patients were randomly allocated to receive real repetitive transcranial magnetic stimulation.
11160172|NCT03658694|Experimental|rTMS sham - stage 1|In stage 1 patients were randomly allocated to receive sham repetitive transcranial magnetic stimulation.
11160173|NCT03658694|Experimental|high dose rTMS - stage 2|In stage 2, after the end of the first trial will be allocated to receive high dose of repetitive transcranial magnetic stimulation.
11160174|NCT03658694|Experimental|low dose rTMS - stage 2|In stage 2, after the end of the first trial will be allocated to receive low dose of repetitive transcranial magnetic stimulation.
11160175|NCT03658681|Experimental|Test meal 1: Saturated fat 14.9 E%|Test meal with saturated fat 14.9 E%
11160176|NCT03658681|Experimental|Test meal 2: Polyunsaturated fat 13.6 E%|Test meal with polyunsaturated fat 13,6 E%
11160177|NCT03658668|Experimental|active tDCS+PA|
11160178|NCT03658668|Sham Comparator|sham tDCS+PA|
11160179|NCT03658655|Experimental|Stem Cells From Human Exfoliated Teeth|According to the weight of 0.1IU /kg with Stem Cells From Human Exfoliated Teeth, three injections will be given respectively at the time of enrollment, one week and four weeks after enrollment.
11160180|NCT03658642|Experimental|Clinical Decision Support for BUP|The Clinical Decision Support (CDS) will be available for clinician use for Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) with referral for ongoing medication assisted treatment (MAT) if: ED chief complaint or urine drug screen indicate opioid use. The clinician will then be prompted to complete DSM-5 checklist for OUD. If DSM-5 OUD Score>5 and urine drug screen is positive for opioids, then the clinician is prompted to complete COWS scale. If COWS score >12, then the clinician is prompted to order BUP. Regardless of COWS score, the clinician will be prompted to schedule an MAT appointment with BUP provider. The CDS will interface with outside MAT facilities so that making an appointment is easy and to capture data on whether an appointment has been scheduled.
11160181|NCT03658642|No Intervention|Usual Care|The CDS will not be activated and patients will receive care as usual.
11160182|NCT03658629|Experimental|Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-1 (Day 0) and Placebo (Day 28)
11160183|NCT03658629|Experimental|Quad-NIV Preformulated with Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-2 (Day 0) and Placebo (Day 28)
11160184|NCT03658629|Experimental|Quad-NIV Preformulated with Adjuvant Dose B|Alternating deltoid injections of 2018-2019 Quad-NIV-3 (Day 0) and Placebo (Day 28)
11160185|NCT03658629|Experimental|Quad-NIV Preformulated with Increased B HA Adjuvant Dose A|Alternating deltoid injections of 2018-2019 Quad-NIV-4 (Day 0) and Placebo (Day 28)
11162256|NCT03644979|No Intervention|Negative control|No skydiving
11160187|NCT03658629|Active Comparator|Licensed High-Dose Trivalent Influenza Vaccine|Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine (Day 0) and Placebo (Day 28)
11160188|NCT03658629|Active Comparator|Licensed Quadrivalent Influenza Vaccine|Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine (Day 0) and Placebo (Day 28)
11160189|NCT03658616|Experimental|WO3970|Formulation containing WO3979 for topical application
11160190|NCT03658616|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
11160191|NCT03658603|Experimental|Study group|Thoracodorsal artery perforator flap
11160192|NCT03658603|Active Comparator|control group|Conventional free flaps
11160193|NCT03658590|Active Comparator|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
11160194|NCT03658590|Placebo Comparator|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
11160195|NCT03658564|Experimental|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
11160196|NCT03658564|No Intervention|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
11160197|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
11160198|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
11160199|NCT03658538|Active Comparator|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
11160200|NCT03658538|Sham Comparator|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
11160201|NCT03658525|Experimental|MR LINAC RADIOTHERAPY|RADIOTHERAPY DELIVERED ON MR LINAC
11160202|NCT03658512||TUEDID cohort|
11160203|NCT03658499|Experimental|Experimental|"Those assigned to the experimental condition will be provided with treatment as usual (the two day skills group) and exposure to the video intervention adjuncts.
~two day skills group plus treatment adjuncts"
11160204|NCT03658499|Other|control|"Those in the control condition will be provided with treatment as usual (the two day skills group) without access to the video intervention adjuncts.
~two day skills group control group"
11160205|NCT03658486|Other|Exercise|12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
11160206|NCT03658473|Active Comparator|Treatment A|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
11160207|NCT03658473|Active Comparator|Treatment B|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole 1x daily over 7 days.
11160208|NCT03658473|Active Comparator|Treatment C|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
11160209|NCT03658473|Placebo Comparator|Treatment D|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
11160210|NCT03658447|Experimental|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
11160211|NCT03658434|Experimental|feasibilty|Palliative Radiotherapy
11160212|NCT03658421|Experimental|H group|H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
11160213|NCT03658421|Experimental|L group|L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
11160214|NCT03658421|Experimental|LD group|LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
11160215|NCT03658408|Experimental|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
11160216|NCT03658408|Placebo Comparator|Placebo|Participants with recent prostatectomies receiving placebo
11160217|NCT03658395|Active Comparator|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
11160249|NCT03658174|Active Comparator|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
11162512|NCT03643146|Experimental|Wedge 2-Step 2|
11160218|NCT03658395|Active Comparator|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.
~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
11160219|NCT03658382|No Intervention|Telephone Results Disclosure|
11160220|NCT03658382|Experimental|Virtual Visit Results Disclosure|
11160221|NCT03658369|Active Comparator|Lanconone®|Lanconone®: 2 Capsules once a day after breakfast
11160222|NCT03658369|Placebo Comparator|Methyl Crystalline Cellulose|2 Capsules once a day after breakfast
11160223|NCT03658356|Placebo Comparator|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.
~Intervention: Pt will be given verbal instruction to collect urine"
11160224|NCT03658356|Active Comparator|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture
~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
11160225|NCT03658343|Experimental|T2* Imaging|Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
11160226|NCT03658330|Experimental|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
11160227|NCT03658317|Active Comparator|cases|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
11160228|NCT03658317|Active Comparator|controls|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
11160229|NCT03658304|Experimental|Mitomycin C|
11160230|NCT03658291|Experimental|Sanjin tablets group|Sanjin tablets+ levofloxacin simulants
11160231|NCT03658291|Placebo Comparator|Levofloxacin group|Sanjin tablets simulants +levofloxacin
11160232|NCT03658291|Active Comparator|Sanjin tablets+ Levofloxacin group|Sanjin tablets+ levofloxacin
11160233|NCT03658278|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
11160234|NCT03658278|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
11160235|NCT03658265|Active Comparator|7 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
11160236|NCT03658265|Experimental|7 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
11160237|NCT03658265|Experimental|3 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
11160238|NCT03658265|Experimental|3 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
11160239|NCT03658252|Experimental|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.
~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
11160240|NCT03658252|No Intervention|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
11160241|NCT03658239|Experimental|Experimental|"Subjects will undergo 4-5 visits total over the course of 6 months. There will be 3-4 visits that will be done at the Flaum Eye Institute. During these sessions the subject will be measured with a stationary topographer (GALILEI G4), with a rotatable topography measurement (Oculus Topographer) and a Tonometer. The subject's heart rate and blood pressure will also be measured (using a commercially available blood pressure and heart rate meter).
~The GALILEI measurement will only be done once. The rest of the measurements will be done up to 4 times. Once at the start of the study session then, after the subject has been inverted using a commercially available inversion table to first 135 degrees, then 150 degrees and finally to 165 degrees.
~The blood pressure and heart rate will be monitored to ensure subject safety.
~There will also be one visit at the Massachusetts General Hospital. The visit will be 2 hours and will involve a Brillouin Microscopy measurement."
11160242|NCT03658226|Experimental|Therapy|Psychodynamic Interpersonal Therapy (PIT)
11160243|NCT03658213|Experimental|ZOLADEX 10.8 mg depot group|• ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
11160244|NCT03658213|Active Comparator|ZOLADEX 3.6 mg depot group|• ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks
11160245|NCT03658200|Active Comparator|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
11160246|NCT03658200|Active Comparator|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
11160247|NCT03658187|Placebo Comparator|Placebo|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
11160248|NCT03658187|Experimental|IP|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
11160290|NCT03657901|Active Comparator|Music listening|Guided music listening for 30 minutes before sleep onset
11160250|NCT03658174|Placebo Comparator|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
11160251|NCT03658161|Experimental|CASCADE|Oncology providers will receive the CASCADE coaching intervention.
11160252|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
11160253|NCT03658135|Experimental|BIIB092|The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
11160254|NCT03658135|Placebo Comparator|Placebo|Inactive ingredient
11160255|NCT03658122|Experimental|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
11160256|NCT03658122|Other|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
11160257|NCT03658109|Active Comparator|Lidocaine Bolus Infusion|"Patients will also undergo a loading dose of lidocaine, followed by continuous lidocaine infusion in the lidocaine group.
~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.
~Patients will undergo a simulated QL block."
11160258|NCT03658109|Active Comparator|QL Block & Saline Bolus Infusion|"Patients will undergo a posterior QL block.
~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.
~Patients will receive a saline bolus infusion."
11160259|NCT03658109|No Intervention|Intrathecal Morphine Alone|"Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.
~Patients will undergo a simulated QL block.
~Patients will receive a saline bolus infusion."
11160260|NCT03658096|Active Comparator|Healthy volunteer|
11160261|NCT03658096|Active Comparator|DRUJ instability patients|
11160262|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
11160263|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
11160264|NCT03658070|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
11160265|NCT03658070|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
11160266|NCT03658070|Experimental|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
11160267|NCT03658070|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
11160268|NCT03658070|Experimental|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
11160269|NCT03658070|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
11160270|NCT03658057|Active Comparator|ROC|Neuromuscular blockade is performed in the ROC group by administering rocuronium 0.4~0.8mg/kg before the insertion of laryngeal airway.
11160271|NCT03658057|No Intervention|Control|Neuromuscular blockade is not performed.
11160272|NCT03658044|Experimental|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
11160273|NCT03658044|Active Comparator|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
11160274|NCT03658031|Experimental|Dapagliflozin|Dapagliflozin 10mg per/day in prediabetes cases with MI before breakfast
11160275|NCT03658031|No Intervention|Placebo|Antiplatelet, ACEI and Betablockers
11160276|NCT03658018|Experimental|Intracept System Ablation|
11160277|NCT03658005||Study cohort|"Adult (>18 years, <90 years) patients admitted and treated for acute myocardial infarction, and whose treatment includes ticagrelor in association with aspirin.
~Blood samples will be taken at 3 timepoints between two doses of ticagrelor (taken at 12 hours interval)."
11160278|NCT03657979|Experimental|Ropivacaine|Conventional PCA morphine +TAP-block ropivacaine 0.2%
11160279|NCT03657979|Placebo Comparator|TAP-block with placebo|Conventional PCA morphine treatment with TAP-block with placebo
11160280|NCT03657966|Experimental|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
11160281|NCT03657953|Active Comparator|anterior (MI-A) surgical approach|The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
11160282|NCT03657953|Active Comparator|anterolateral (MI-AL) surgical approach|For the minimally invasive anterolateral surgical approach, a modified Watson-Jones approach according to Röttinger (Rottinger et al. 2006) was applied with the patient in supine position.
11160283|NCT03657953|Active Comparator|direct lateral (DLA) surgical approach|The direct lateral surgical approach was performed according to the technique described by Hardinge et al. (Hardinge et al. 1982) with the patient positioned supine
11160284|NCT03657940|Experimental|Exercise intervention|multicomponent exercise training program [VIVIFRAIL],
11160285|NCT03657940|No Intervention|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
11160286|NCT03657927|Active Comparator|C-MAC Videolaryngoscope|Morbidly obese patients intubated with C-MAC Videolaryngoscope
11160287|NCT03657927|Active Comparator|McGrath MAC Videolaryngoscope|Morbidly obese patients intubated with McGrath MAC Videolaryngoscope
11160288|NCT03657914|Experimental|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
11160289|NCT03657901|Experimental|Breathing|Guided slow breathing for 30 minutes before sleep onset
11162513|NCT03643146|Experimental|Wedge 2-Step 3|
11160295|NCT03657849|Experimental|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
11160296|NCT03657836|Experimental|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
11160297|NCT03657836|Other|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
11160298|NCT03657823||Fetal growth cohort|Longitudinal measurements of fetal growth, fetal circulation and maternal circulation
11160299|NCT03657823||Hypertensive cohort|Retrospective cohort of women with heart disease that underwent oregnancy and childbirth
11160300|NCT03657810|Experimental|CL-108 5 mg|Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
11160301|NCT03657810|Active Comparator|Norco|hydrocodone 5 mg/APAP 325 mg
11160302|NCT03657810|Placebo Comparator|Placebo|Placebo 0 mg matching CL-108
11160303|NCT03657797|Experimental|NCX 470 0.021%|NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
11160304|NCT03657797|Experimental|NCX 470 0.042%|NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
11160305|NCT03657797|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
11160306|NCT03657797|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks
11160307|NCT03657784|Experimental|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
11160308|NCT03657784|Experimental|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
11160309|NCT03657784|Experimental|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
11160310|NCT03657784|Experimental|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
11160311|NCT03657784|Experimental|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
11160312|NCT03657771|Active Comparator|DED|Diet eliminating dairy
11160313|NCT03657771|Active Comparator|FREE|Diet eliminating dairy and food additives
11160314|NCT03657758|Active Comparator|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
11160315|NCT03657758|Active Comparator|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
11160316|NCT03657758|No Intervention|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
11160317|NCT03657745||Participants who adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants adhere to the protocol if they exercise with AlzLife the minimum of 1hour/week.
11160318|NCT03657745||Participants who do not adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants do not adhere to the protocol if they exercise with AlzLife less than 1hour/week.
11160319|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
11160320|NCT03657732||Normal control group|Normal cognitive control people
11160321|NCT03657719|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
11160322|NCT03657719|Active Comparator|Active Comparator: GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
11160323|NCT03657706|Active Comparator|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
11160324|NCT03657706|Active Comparator|group B|tunnel procedure with modified free gingival graft (mFGG)
11160325|NCT03657693||BPD|Infants born premature requiring oxygen
11160326|NCT03657693||Controls|
11160327|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
11160328|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
11160329|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
11160330|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
11160331|NCT03657641|Experimental|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11160332|NCT03657628|Experimental|Physical activity|"The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.
~Will receive social/behavioral support
~Will receive research staff contact time to encourage them to increase their physical activity level
~The participants will be given the option of a third supervised session each week"
11160333|NCT03657615|Active Comparator|Control|Hearing Aid Fitting Patients with hearing loss but no tinnitus paired by age and hearing loss degree Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
11160334|NCT03657615|Experimental|Tinnitus|Hearing Aid Fitting Patients with tinnitus and hearing loss associated Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
11160335|NCT03657602|Experimental|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
11160336|NCT03657602|Experimental|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
11160337|NCT03657589||patients with 1 missing tooth|Patients with 1 missing anterior or premolar tooth and planned for implant surgery were recruited. Gingiva and alveolar bone were ultrasound scanned and compared to CT scans and direct measures during implant surgery.
11160338|NCT03657576|Experimental|C134 Treatment|All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)
11160339|NCT03657563|Experimental|Intervention group|Nurses with burnout are recruited in the intervention group and participate in positive psychological intervention.
11160340|NCT03657563|No Intervention|Control group|Nurses with burnout are recruited in the control group and none interventions are conducted to them.
11160341|NCT03657550|Experimental|Part 1 Period 1|Levamlodipine Malate Tablets (test drug, 5mg) or Amlodipine Besylate Tablets (NORVASC®, reference drug, 10mg) administered as a single oral dose.
11160342|NCT03657550|Experimental|Part 1 Period 2|Levamlodipine Maleate Tablets (test drug, 5mg) or Amlodipine Besylate Tablets (NORVASC®, reference drug, 10mg) administered as a single oral dose, alternative from what same subjects received from Period 1, under fasted conditions
11160343|NCT03657550|Experimental|Part 2 Food Effect|Levamlodipine Malate Tablets (test drug, 5mg) administered as a single oral dose under a high-fat / high-calorie meal
11160344|NCT03657537|Experimental|Hyperketonemia - Placebo|Participants are randomly assigned to initially receive ketone infusion and then saline infusion
11160345|NCT03657537|Experimental|Placebo - Hyperketonemia|Participants are randomly assigned to initially receive saline infusion and then ketone infusion
11160346|NCT03657524|Experimental|Resuscitation patients|
11160347|NCT03657524|Active Comparator|healthy volunteers|
11160348|NCT03657511|Other|Educational Interventions to Promote Tobacco Cessation|
11160349|NCT03657498|Experimental|Study group|Combined orthodontic-orthognathic treatment
11160350|NCT03657498|No Intervention|Control Group I|No intervention
11160351|NCT03657498|Active Comparator|Control Group II|Standard orthodontic treatment
11160352|NCT03657485|Experimental|interventional|In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFbaby, IBSS Biomed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
11160353|NCT03657485|No Intervention|control|No intervention. Feeding with mother milk
11160354|NCT03657485|No Intervention|comperative|Comparing stool composition of vaginally born newborns
11160355|NCT03657472|Experimental|Sequence 1(RTR)|
11160356|NCT03657472|Experimental|Sequence 2(RRT)|
11160357|NCT03657472|Experimental|Sequence 3(TRR)|
11160358|NCT03657459|No Intervention|usual care group|Usual care consists of patient's receiving a Heart Failure Handbook before hospital discharge + verbal education delivered by multiple care providers (including a group education class at 1 site). The handbook is consistent; however, verbal education may vary between care providers based on their knowledge and time available, and perceived patient needs
11160359|NCT03657459|Active Comparator|video education group|"Will receive usual care, plus will watch 2 short Wellflix, Inc. Danger Signs of Heart Failure videos (via iPAD) on dyspnea, fatigue + a Danger Sign edema video, when applicable. Each video describes how to recognize if the sign/symptom is new or worsening and how to self-manage at home (via diet, fluid management and activity instructions)"
11160360|NCT03657446|Experimental|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
11160361|NCT03657446|Experimental|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
11160362|NCT03657446|Experimental|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
11160363|NCT03657446|Experimental|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
11160364|NCT03657446|Experimental|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
11160365|NCT03657446|Experimental|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
11160366|NCT03657433|Experimental|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.
~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
11160367|NCT03657433|Active Comparator|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.
~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
11160368|NCT03657420|Experimental|ABI-009 + Pomalidomide + Dexamethasone|"Pomalidomide is given orally daily on days 1-21, 7 days off
~ABI-009 is given intravenously on days 1, 8, and 15
~Dexamethasone is given orally weekly on days 1, 8, 15, 22"
11160369|NCT03657407|Active Comparator|B&O|29 women randomized to Belladonna & Opium suppository
11160370|NCT03657407|Sham Comparator|Placebo|27 women randomized to Glycerin suppository
11160371|NCT03657394|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ICC.
11160372|NCT03657394|No Intervention|Immediate Cord Clamping|Umbilical cord will be clamped immediately after birth.
11160373|NCT03657381|Experimental|F520 0.2mg/kg single-dose|F520 0.2mg/kg single-dose
11160374|NCT03657381|Experimental|F520 1.0mg/kg single-dose|F520 1.0mg/kg single-dose
11160375|NCT03657381|Experimental|F520 3.0mg/kg single-dose|F520 3.0mg/kg single-dose
11160376|NCT03657381|Experimental|F520 200mg/times single-dose|F520 200mg/times single-dose
11160377|NCT03657381|Experimental|F520 10mg/kg single-dose|F520 10mg/kg single-dose
11160380|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 2 weeks|F520 200mg/times every 2 weeks
11160381|NCT03657381|Experimental|F520 10mg/kg multiple dosing, every 2 weeks|F520 10mg/kg every 2 weeks
11160382|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 3 weeks|F520 3mg/kg every 3 weeks
11160383|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 3 weeks|F520 200mg/times every 3 weeks
11160384|NCT03657368|Experimental|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
11160385|NCT03657368|Experimental|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
11160386|NCT03657368|Experimental|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
11160387|NCT03657368|Experimental|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
11160388|NCT03657355|Experimental|50 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
11160389|NCT03657355|Experimental|100 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
11160390|NCT03657355|Experimental|150 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
11160391|NCT03657355|Active Comparator|150 mg suvorexant|Suvorexant will be administered as tablets for oral use.
11160392|NCT03657355|Active Comparator|30 mg zolpidem|Zolpidem will be administered as tablets for oral use.
11160393|NCT03657355|Placebo Comparator|Placebo|Placebo will be administered as tablets for oral use.
11160394|NCT03657342|Experimental|L-CsA treatment plus SoC|L-CsA 5 mg twice daily for 48 weeks Standard of Care Therapy
11160395|NCT03657342|No Intervention|Standard of Care alone|Standard of Care Therapy
11160396|NCT03657329|Experimental|Suspicion of sleep-disordered breathing|Dreem
11160397|NCT03657316|Experimental|experimental school 1|"The experimental school 1 will receive the following:
~Nutritional and physical activity educational workshop
~Enhanced physical education
~Involvement of the morning broadcast
~Educational brochure will be sent to the parents
~A monthly telephone call or a text message will be sent to the parents
~Message to school administration to prevent selling of soft drinks and to sell healthy food
~A monthly session (3 months)"
11160398|NCT03657316|Experimental|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
11160399|NCT03657316|No Intervention|control|The control school will receive no intervention
11160400|NCT03657303||Healthy volunteers|
11160401|NCT03657303||Osteoarthritis patients|
11160402|NCT03657290|Active Comparator|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
11160403|NCT03657290|Active Comparator|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
11160404|NCT03657290|Active Comparator|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
11160405|NCT03657277|Other|Micropatch Application|Five sites on each the upper arm, volar forearm, and abdomen will be identified, and baseline measurements of trans-epidermal water loss, electrical resistance, hydration, and color of the skin will be made at every site. At each body location, three of the sites will have a micropatch applied to the skin. The micropatches will then be discarded and the skin sites will be covered with an occlusive material secured in place with medical tape. The two remaining sites at each body location will not receive micropatch application, and one of these two sites will be covered with an occlusive material. Subjects will only receive micropatch application on the first day of the study. Measurements will be repeated daily at all sites for three consecutive days after the day of initial application (trans-epidermal water loss measurements will only be made on day 1).
11160406|NCT03657264|Experimental|Sequence 1|"The sequence of administration is: P/ScD/PC/CD
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
11160407|NCT03657264|Experimental|Sequence 2|"The sequence of administration is: CD/PC/ScD/P
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
11160408|NCT03657264|Experimental|Sequence 3|"The sequence of administration is: ScD/CD/P/PC
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
11160409|NCT03657264|Experimental|Sequence 4|"The sequence of administration is: PC/P/CD/ScD
~Where:
~P = Placebo (Nacl 0.9%)
~CD = P03277 tested at 0.1 mmol/kg
~ScD = P03277 tested at 0.3 mmol/kg
~PC = Positive control (moxifloxacin 400 mg - per os)."
11160410|NCT03657251||CureCloud Direct to Patient|
11160411|NCT03657238|Experimental|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
11160412|NCT03657238|Placebo Comparator|Placebo|
11160413|NCT03657225|Active Comparator|Mini CPB (ECCO, Sorin, Italy)|Utilization of the mini CPB circuit (Extra Corporeal Circuit Optimized; Phisio, Sorin Group, Italy)
11160414|NCT03657225|Placebo Comparator|Conventional|Use of conventional CPB circuit
11160415|NCT03657212|Active Comparator|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
11160450|NCT03656965|Other|Chemoradiotherapy|Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
11160451|NCT03656952|Experimental|Seq 1|PF-06700841-> placebo-> moxifloxacin
11160452|NCT03656952|Experimental|Seq 2|PF-06700841->moxifloxacin->placebo
11160453|NCT03656952|Experimental|Seq 3|Placebo->PF-06700841->moxifloxacin
11160416|NCT03657212|Placebo Comparator|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
11160417|NCT03657199||Bypass graft failure|Patients with at least one detected graft failure after routine cardiac computed tomography before discharge
11160418|NCT03657199||No bypass graft failure|Patients without occluded bypass grafts after routine cardiac computed tomography before discharge
11160419|NCT03657186|Experimental|ProbioSatys™|
11160420|NCT03657186|Placebo Comparator|Placebo|
11160421|NCT03657160|Experimental|Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background graft-versus-host disease (GvHD) prophylaxis regimen.
11160422|NCT03657160|Placebo Comparator|Placebo|Vedolizumab placebo-matching, intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background GvHD prophylaxis regimen.
11160423|NCT03657147|Experimental|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
11160424|NCT03657147|No Intervention|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
11160425|NCT03657134|Experimental|EP Procedure|Patient will continuously wear the CoVa TM 2 system until they are discharged for period of about 24 hours. During this period, data from the sensor will be sent to the Gateway and Cloud- based System, and then analyzed retrospectively.
11160426|NCT03657108|Experimental|group 1 of 60 Gy dose|The first 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
11160427|NCT03657108|Experimental|group 2 of 60 Gy dose|The second 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
11160428|NCT03657108|Experimental|group 1 of 75 Gy dose|The third 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
11160429|NCT03657108|Experimental|group 2 of 75 Gy dose|The fourth 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
11160430|NCT03657095|Experimental|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
11160431|NCT03657095|Placebo Comparator|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
11160432|NCT03657082|Experimental|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
11160433|NCT03657082|Experimental|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
11160434|NCT03657069|Experimental|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
11160435|NCT03657056|Experimental|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
11160436|NCT03657043|Experimental|Safety Run-In (3Q4W Schedule)|28-day, 3 dose cycle
11160437|NCT03657043|Experimental|Part A: Tisotumab Vedotin|21-day, single dose cycle
11160438|NCT03657043|Experimental|Part A: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
11160439|NCT03657043|Experimental|Part B: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
11160440|NCT03657030|Active Comparator|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
11160441|NCT03657030|Active Comparator|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
11160442|NCT03657017|Other|PET/MR|Patients are examined with PET/MR.
11160443|NCT03656991|Experimental|0 month group|Receive the bicycle intervention at 0 months after enrollment.
11160444|NCT03656991|Experimental|2 month group|Receive the bicycle intervention at 2 months after enrollment.
11160445|NCT03656991|Experimental|4 month group|Receive the bicycle intervention at 4 months after enrollment.
11160446|NCT03656991|Experimental|6 month group|Receive the bicycle intervention at 6 months after enrollment.
11160447|NCT03656978|Active Comparator|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
11160448|NCT03656978|Placebo Comparator|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
11160449|NCT03656965|Experimental|Antiviral Drug with Chemoradiotherapy|Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.
11160454|NCT03656952|Experimental|Seq 4|Placebo->moxifloxacin->PF-06700841
11160455|NCT03656952|Experimental|Seq 5|Moxifloxacin->PF-06700841->placebo
11160457|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
11160458|NCT03656926|Experimental|L-CsA treatment plus SoC|L-CsA 10 mg twice daily for 48 weeks, plus Standard of Care Therapy
11160459|NCT03656926|No Intervention|Standard of Care alone|Standard of Care Therapy
11160460|NCT03656913|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose CT exams
11160461|NCT03656900|Experimental|BA9/BA46|
11160462|NCT03656900|Experimental|BA46/BA9|
11160463|NCT03656874|No Intervention|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
11160464|NCT03656874|Experimental|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
11160465|NCT03656861||Athletes|122 were athletes (41 females and 81 males). Of the 41 female athletes, 32 were endurance athletes, and 9 strength athletes. From 81 male athletes, 56 were endurance athletes, and 25 were strength athletes.
11160466|NCT03656861||Non-athletes|29 were non-athletes (14 females and 15 males)
11160467|NCT03656848|Experimental|QFR-guided PCI group|If the patient is assigned to QFR-guided PCI, QFR is first measured in all coronary arteries with DS% ≥ 50% and ≤ 90%. Then PCI treatment is performed in lesions with QFR ≤ 0.80, and optimal medicine treatment is prescribed to those with QFR > 0.80. It is strongly recommended to select the device size based on the 3D-QCA measurements in this group.
11160468|NCT03656848|Active Comparator|Angiography-guided PCI group|If the patient is assigned to angiography-guided PCI, then the investigator performs PCI according to the stenosis severity based on visual assessment of the angiogram. No other functional tests such as FFR/iFR can be used for further assessment of the lesion before PCI.
11160469|NCT03656835|Experimental|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
11160470|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
11160471|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
11160472|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
11160473|NCT03656796|Experimental|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
11160474|NCT03656796|Experimental|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
11160475|NCT03656796|Experimental|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
11160476|NCT03656783|Other|HIV patients on stable therapy|Open-label, multicenter, single-arm study
11160477|NCT03656770|No Intervention|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
11160478|NCT03656770|Experimental|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
11160479|NCT03656770|Experimental|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
11160480|NCT03656770|Experimental|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
11160481|NCT03656770|Experimental|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
11160482|NCT03656770|Experimental|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
11160483|NCT03656770|Experimental|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
11160484|NCT03656770|Experimental|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
11160485|NCT03656770|Experimental|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
11160486|NCT03656770|Experimental|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
11160487|NCT03656744|Experimental|500mg HTD1801, bid|
11160488|NCT03656744|Experimental|1000mg HTD1801, bid|
11160489|NCT03656744|Placebo Comparator|placebo, bid|
11160490|NCT03656731|Experimental|Intervention group (n=50)|Patients in the intervention group will receive standard care and a 12-week exercise-based intervention.
11162514|NCT03643146|Experimental|Wedge 2-Step 4|
11160491|NCT03656731|No Intervention|Control group (n=50)|Patient in the control group will receive standard care.
11160492|NCT03656718|Experimental|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
11160493|NCT03656718|Experimental|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
11160494|NCT03656718|Experimental|Part B, Group 2: nivolumab (dose 1)|
11160495|NCT03656718|Experimental|Part B, Group 4: nivolumab (dose 2)|
11160496|NCT03656718|Experimental|Part C: nivolumab (dose 3) + rHuPH20|
11160497|NCT03656718|Experimental|Part D: nivolumab (dose 3)|
11160498|NCT03656705|Experimental|CCCR-NK92 cells immunotherapy|Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
11160499|NCT03656692|Other|Acthar Gel|Participants receive Acthar Gel as follows: 1 mL 2x/week for 36 weeks, followed by a taper to 1 mL/week for two weeks, and then 0.5 mL/week for an additional 2 weeks
11160500|NCT03656679|Active Comparator|Pectoralis Blockade(PECs)|Participants undergo pectoralis nerve block (PEC II) will received anesthesia between the pectoralis major and minor in the chest while lying flat.
11160501|NCT03656679|Active Comparator|Paravertebral Blockade (PVB)|Participants undergoing paravertebral nerve block (PVB) consisting of receiving anesthesia in the back while sitting upright.
11160502|NCT03656666|Active Comparator|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.
~Initial titration:
~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
11160503|NCT03656666|Placebo Comparator|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
11160504|NCT03656653|Experimental|Future-based recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future without cocaine use
11160505|NCT03656653|Experimental|Future-based cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future where cocaine is causing significant distress
11160506|NCT03656653|Experimental|Past recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event without cocaine use
11160507|NCT03656653|Experimental|Past cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event where cocaine use has caused significant distress
11160508|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
11160509|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:
~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis
~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
11160510|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:
~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.
~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
11160511|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
11160512|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
11160513|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
11160514|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
11160515|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
11160516|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
11160517|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
11160518|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
11160519|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
11160520|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
11160521|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
11160522|NCT03656601||Vaginal delivery|Women that had only vaginal delivery
11160523|NCT03656601||Cesarean-section|Women that had only cesarean-section
11160524|NCT03656601||Nulliparous|Women without delivery
11160525|NCT03656588|Active Comparator|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
11160526|NCT03656588|Active Comparator|b. Iodine scrub and ChloraPrep alone|
11160527|NCT03656575|Active Comparator|intra-articular alpha-2-macroglobulin|intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)
11160528|NCT03656575|Active Comparator|intra-articular Platelet-rich Plasma (PRP) injection|Standard of care PRP treatment
11160529|NCT03656575|Active Comparator|Intra-articular corticosteroid|Standard of Care steroid treatment
11160530|NCT03656562|Experimental|Cohort 1 VAY736|multiple doses of VAY736, s.c.
11160531|NCT03656562|Placebo Comparator|Cohort 1 VAY736 Placebo|multiple doses of matching placebo s.c. until week 29. Multiple doses of VAY736, s.c from week 29 until week 53.
11160532|NCT03656562|Experimental|Cohort 2 CFZ533|multiple doses of CFZ533, i.v.
11160533|NCT03656562|Placebo Comparator|Cohort 2 CFZ533 Placebo|multiple doses of matching placebo i.v. until week 29. Multiple doses of CFZ533, i.v. from week 29 until week 53.
11160534|NCT03656549|Experimental|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function.
11160535|NCT03656536|Experimental|Pemigatinib|
11160536|NCT03656536|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
11160537|NCT03656523||Acute Coronary Syndrome|Patients with Aute coronary syndrome trated with Percutaneous Coronary Intervention plus Stent implantation and Atrial Fibrillation
11160538|NCT03656510|Experimental|High Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 2.5 milligram per kilogram (mg/kg) (Age Group 1: greater than or equal to [>=] 28 days and less than [<] 3 months of age), 3 mg/kg (Age Group 2: >=3 months and <6 months of age) and 4.5 mg/kg (Age Group 3: >=6 months and less than or equal to [<=3] years of age) orally twice daily for 7 days.
11160539|NCT03656510|Experimental|Low Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 0.83 mg/kg (Age Group 1: >=28 days and <3 months of age), 1 mg/kg (Age Group 2: >=3 months and <6 months of age) and 1.5 mg/kg (Age Group 3: >=6 months and 3 years of age) orally twice daily for 7 days.
11160540|NCT03656510|Placebo Comparator|Placebo|Participants will be randomized to receive matching placebo (i.e. high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose) orally twice daily for 7 days.
11160541|NCT03656484|Active Comparator|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
11160542|NCT03656484|Experimental|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
11160543|NCT03656471||Clear aligner group|Patients receiving clear aligner treatments for their malocclusions
11160544|NCT03656471||Fixed appliance group|Patients receiving fixed appliance treatments for their malocclusions
11160545|NCT03656458|Active Comparator|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
11160546|NCT03656458|No Intervention|Control Group B|Control group. No intervention given to participants.
11160547|NCT03656458|Experimental|Experimental Group|Warm Up followed by Biodex Balance Training
11160548|NCT03656445|Active Comparator|Group A - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
11160549|NCT03656445|Active Comparator|Group B - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
11160550|NCT03656445|Active Comparator|Group C - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively
11160551|NCT03656432|Experimental|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
11160552|NCT03656432|Experimental|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
11160553|NCT03656432|Active Comparator|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
11160554|NCT03656419|Experimental|aPDT group|For photodynamic therapy will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² .One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points, considering the scattering halo and the effectiveness of aPDT. The LED apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
11160555|NCT03656419|Active Comparator|Tongue Scraper|Tongue scraper 10 times in the tongue, from the back to the front.
11160556|NCT03656419|Experimental|aPDT and tongue scraper|Tongue scraper 10 times in the tongue, from the back to the front. For aPDT will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² . One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points. Based on previous studies carried out with the aPDT for the treatment of halitosis the apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
11160557|NCT03656393|Experimental|Gefitinib therapy group|Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
11160558|NCT03656393|Active Comparator|Vinorelbine combination therapy group|Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
11160559|NCT03656380|Experimental|Mepolizumab 300 mg|Subjects will receive Mepolizumab 300 mg subcutaneously (SQ) monthly for 6 months
11160560|NCT03656380|Other|Placebo, followed by Mepolizumab 100 mg|This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
11160561|NCT03656367|Experimental|All subjects|"Cross-over study (all subjects receive all interventions)
~Cheddar cheese
~Blended and homogenized cheddar cheese
~An analog milk
~An analog cheese"
11160858|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
11160562|NCT03656367|Other|Healthy subjects only (subgroup)|"If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects.
~All subjects receive all interventions)
~Cheddar cheese
~Blended and homogenized cheddar cheese
~An analog milk
~An analog cheese"
11160563|NCT03656341|Experimental|2 Feet 4 Life|Intervention group will receive one hour intervention weekly for four consecutive weeks. Outcomes will be measured at baseline (before the intervention), immediately after the intervention (1 month), three months post-intervention, and six months post-intervention
11160564|NCT03656341|No Intervention|True control group|Will complete the same four assessment visits as the intervention group.
11160565|NCT03656341|No Intervention|Bias control group|Will complete outcome assessments at baseline and the final assessment.
11160566|NCT03656328|Experimental|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
11160567|NCT03656328|Placebo Comparator|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
11160568|NCT03656315|Other|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
11160569|NCT03656302||Case offspring|"Inclusion criteria:
~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form
~Exclusion criteria:
~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
11160570|NCT03656302||Control offspring|"Inclusion criteria:
~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.
~Exclusion criteria:
~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
11160571|NCT03656289|Experimental|Etonogestrel Contraceptive|Etonogestrel contraceptive implant; consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. The implant must be removed no later than by the end of the third year.
11160572|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
11160573|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
11160574|NCT03656263||High risk cardiac surgery patients|"Defined as either:
~Multiple surgical procedures planned and/or,
~EuroSCORE ≥ 5% and/or,
~Known pulmonary hypertension (mPAP>25 mmHg or sPAP > 40 mmHg)"
11160575|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
11160576|NCT03656237|Experimental|Usual training + Audits + LDHF training|"Usual training of health workers, in classroom, following standard curriculum
~+ Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits"
11160577|NCT03656237|Experimental|Audits + LDHF training|Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits
11160578|NCT03656237|Active Comparator|Usual Training|Control Arm exposed to usual training of health workers, in classroom, following standard curriculum
11160579|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
11160580|NCT03656211||Patients with UAVM|"All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination.
~Telephone interview"
11160581|NCT03656198|Experimental|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
11160582|NCT03656198|Placebo Comparator|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
11160583|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood balance (NFS, reticulocytes with RET-He , a martial balance sheet (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
11160584|NCT03656159|Active Comparator|Non-directive support group|This intervention will provide time and space to discuss the impact of AD. The objective will be to help participants feel less alone and better understood and to address the implications of AD in their daily life.
11160585|NCT03656159|Experimental|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
11160586|NCT03656146|Active Comparator|Tablet Screening|Food insecurity screening conducted via electronic tablet
11160587|NCT03656146|Active Comparator|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
11160588|NCT03656133|Active Comparator|Standard Fractionation|Standard Radiotherapy Fractionation
11160589|NCT03656133|Active Comparator|Hyperfractionation|Hyperfractionation
11160590|NCT03656120|Experimental|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
11160591|NCT03656120|Experimental|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
11160592|NCT03656120|Placebo Comparator|placebo control group|Participants only taking placebo once a day for 12 weeks.
11160593|NCT03656107|Experimental|Cognitive training|Participants selected to brain training will be given instructions on how to access and use the program at home for 15-30minutes, 3-5 times per week for 8-12 weeks.
11160594|NCT03656107|No Intervention|Waiting-list control|Control participants will be waiting listed to receive the brain training program at the end of the study. control participants will undergo usual care.
11160595|NCT03656094|Experimental|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
11160596|NCT03656094|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
11160597|NCT03656081|Placebo Comparator|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
11160598|NCT03656081|Experimental|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
11160599|NCT03656068|Experimental|Open label NTZ|Open label study. All patients will receive study drug.
11160600|NCT03656042|Experimental|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
11160601|NCT03656042|No Intervention|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
11160602|NCT03656029|Placebo Comparator|Placebo|Participants will smoke a single smoked placebo (<0.1% THC) cannabis cigarette
11160603|NCT03656029|Active Comparator|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
11160604|NCT03656029|Active Comparator|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
11160605|NCT03656029|Active Comparator|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
11160606|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
11160607|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
11160608|NCT03656003|Experimental|Procore needle|EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
11160609|NCT03656003|Active Comparator|Conventional needle|Conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
11160610|NCT03655990||Treatment with the JUVORA™ Dental Disc|Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
11160611|NCT03655977|Experimental|Cervical cancer patients|This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.
11160612|NCT03655964|Experimental|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
11160613|NCT03655964|Experimental|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
11160614|NCT03655964|Experimental|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
11160615|NCT03655951|Experimental|Resource 1|Web-based resource on adolescent sexual health
11160616|NCT03655951|Active Comparator|Resource 2|Alternate web-based resource on adolescent sexual health
11160617|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction <40
11160618|NCT03655912|Active Comparator|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
11160619|NCT03655912|Experimental|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
11160620|NCT03655912|Experimental|Red/Green Glasses|Red/green glasses and a electronic tablet
11160621|NCT03655886|Experimental|Radical prostatectomy|
11160622|NCT03655886|Experimental|Radiotherapy|
11160623|NCT03655873|Experimental|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .
~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
11160624|NCT03655873|Placebo Comparator|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .
~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
11160625|NCT03655860|Experimental|SIMEOX|
11160626|NCT03655847|Experimental|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
11160627|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
11160628|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
11160629|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
11160630|NCT03655808|Experimental|BBCs transplantation|Autologous Bronchial basal cells transplantation
11160631|NCT03655795|Experimental|Bronchial basal cells|Autologous transplantation of bronchial basal cells
11160721|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
11160722|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
11160632|NCT03655782|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether dim gray stripes in fish-shaped window move left or right relative to stationary background stripes. The subject reports which way center stripes move by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, 15 minutes, 3 times each week for 12 weeks.
11160633|NCT03655782|Sham Comparator|Orientation Discrimination training|The sham treatment will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings, see patterns in Fig. 4 below. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key component of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
11160634|NCT03655769|Sham Comparator|sham tDCS|tDCS delivered for only 30 sec to replicate tingling sensation and blind subject
11160635|NCT03655769|Experimental|cathodal tDCS|cathodal tDCS, 2 milliamps (mA), delivered to right parietal region
11160636|NCT03655756|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:
~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator
~Route of Administration:
~Intratumoral injection of cutaneous, subcutaneous or nodal lesions
~Mechanism of Action:
~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.
~Physiological Effect:
~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
11160637|NCT03655743||Patients after refractive surgery|Patients have had any type of corneal or lens refractive surgery.
11160638|NCT03655743||Patients before refractive surgery|Patients will have any type of corneal or lens refractive surgery.
11160639|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
11160640|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
11160641|NCT03655717|Experimental|Placebo Dronabinol + Ethanol|single dose of Placebo Dronabinol + Ethanol See protocol for dosing
11160642|NCT03655717|Experimental|Dronabinol + Placebo Ethanol|single dose of Dronabinol + Placebo Ethanol See protocol for dosing
11160643|NCT03655717|Experimental|Dronabinol + Ethanol|single dose of Dronabinol + Ethanol See protocol for dosing
11160644|NCT03655717|Placebo Comparator|Placebo Dronabinol + Placebo Ethanol|single dose of Placebo Dronabinol + Placebo Ethanol See protocol for dosing
11160645|NCT03655704|Experimental|Apabetalone|100mg BID for 16 weeks.
11160646|NCT03655691|Placebo Comparator|Vehicle|Vehicle / Placebo formulation
11160647|NCT03655691|Experimental|Dose 1|lower dose of ET-01
11160648|NCT03655691|Experimental|Dose 2|higher dose of ET-01
11160649|NCT03655678|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
11160650|NCT03655665|Experimental|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
11160651|NCT03655665|No Intervention|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
11160652|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
11160653|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
11160654|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
11160655|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
11160656|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
11160657|NCT03655600|No Intervention|Usual care|Usual care
11160658|NCT03655587|Experimental|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
11160659|NCT03655587|Active Comparator|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
11162515|NCT03643146|Experimental|Wedge 2-Step 5|
11160660|NCT03655574|Experimental|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.
~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
11160661|NCT03655574|Placebo Comparator|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
11160662|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
11160663|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
11160664|NCT03655535|Experimental|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
11160665|NCT03655535|Placebo Comparator|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
11160666|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
11160667|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
11160668|NCT03655509|Other|ACTH stimulation test|
11160669|NCT03655496|No Intervention|Control group|Subject to standard care.
11160670|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
11160671|NCT03655483|Experimental|GLS-010|GLS-010
11160672|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
11160673|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
11160674|NCT03655457|Experimental|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
11160675|NCT03655457|Active Comparator|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
11160676|NCT03655444|Experimental|Phase I: Abemaciclib + Nivolumab|-Abemaciclib will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle
11160677|NCT03655444|Experimental|Phase II: Abemaciclib + Nivolumab|"Phase II Lead-in: Patients will be treated with abemaciclib monotherapy at the recommended phase II dose on Day -7 through Day -1 prior to starting Cycle 1 with the combination of abemaciclib and nivolumab. Patients will proceed directly from Day -1 to Cycle 1 Day 1 of combination abemaciclib + nivolumab, there is not a Day 0.
~Patients will be treated with abemaciclib at the RP2D (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle."
11160678|NCT03655431|Experimental|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
11160679|NCT03655431|Active Comparator|Standard treatment|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via in-person appointments for treatment. Appointments will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to the control arm will receive standard home exercise program handouts and complete an exercise log to monitor exercise frequency. Exercises and progression will be administered and adjusted during in-person appointments.
11160680|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
11160681|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
11160682|NCT03655405|Experimental|Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
11160683|NCT03655405|No Intervention|Control|Participants allocated to the control group will receive usual care.
11160723|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
11160724|NCT03655145|Experimental|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
11160684|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
11160685|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
11160686|NCT03655379|Experimental|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
11160687|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
11160688|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
11160689|NCT03655353|Experimental|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
11160690|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
11160691|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
11160692|NCT03655327||stroke patients|stroke patients with upper limb paresis
11160693|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
11160694|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
11160695|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
11160696|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
11160697|NCT03655275|Active Comparator|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
11160698|NCT03655275|Active Comparator|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
11160699|NCT03655262|Experimental|1 Session|1 neuro-reinforcement session
11160700|NCT03655262|Experimental|3 Sessions|3 neuro-reinforcement sessions
11160701|NCT03655262|Experimental|5 sessions|5 neuro-reinforcement sessions
11160702|NCT03655249|Experimental|Asl + CPT|Aerosotherapy + Autogenic drainage
11160703|NCT03655249|Active Comparator|Asl|Aerosoltherapy alone
11160704|NCT03655236|Experimental|K0706, low dose|
11160705|NCT03655236|Experimental|K0706, high dose|
11160706|NCT03655236|Placebo Comparator|Placebo|
11160707|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
11160708|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
11160709|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
11160710|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
11160711|NCT03655197|No Intervention|Healthy Subjects|Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.
11160712|NCT03655197|Experimental|Ocular Rosacea Subjects|Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.
11160713|NCT03655197|Other|Cutaneous Rosacea Subjects|Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxycycline intervention.
11160714|NCT03655184||MOH group|Patients with medication overuse headache
11160715|NCT03655184||Episodic migraine group|Patients with episodic migraine
11160716|NCT03655184||Healthy group|No headache or other special medical history
11160717|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
11160718|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
11160719|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
11160720|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.
~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
11160725|NCT03655145|Active Comparator|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
11160726|NCT03655132|No Intervention|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
11160727|NCT03655132|Experimental|VACT-CP Group|Veterans randomized to VACT-CP will receive 8 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
11160728|NCT03655119|No Intervention|Baseline|Youth and parents will complete surveys at index PES visit regarding suicide related risk and protective factors. Parents and youth will complete a follow-up survey at 3 days (parents only) and 2 weeks (parents and youth) post discharge. At 3 days and 2 weeks, parents will complete a survey that evaluates adherence to safety recommendations. The 2-week follow-up survey for parents will also re-assess self-efficacy, parental distress, and mental health treatment stigma. The 2-week follow-up survey for youth assesses mood and suicidal thoughts, perceptions of parent support post discharge, and outpatient treatment. It reassesses suicidal risk, depression, connectedness, and alcohol use.
11160729|NCT03655119|Experimental|Phase I|Families will complete baseline measures, and receive enhanced usual care from PES clinical staff during their visit as well as a parent toolkit that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth. The same follow-up methodology as in Baseline will be utilized.
11160730|NCT03655119|Experimental|Phase II|Families will complete baseline measures and receive Phase I interventions (enhanced care and parent toolkit). Parents will receive caring contacts post discharge, which may occur by phone, text, or email. Caring follow-up messages will provide support, additional education, and problem solving assistance. The same follow-up methodology as in Baseline will be utilized.
11160731|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
11160732|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
11160733|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
11160734|NCT03655080|Experimental|nab-Paclitaxel and Radiation Therapy|"10 fractions of 3Gy radiation therapy will be delivered.
~A total of 4 chemoradiation blocks should be delivered ideally in consecutive days
~On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)
~On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day
~There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
11160735|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
11160736|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
11160737|NCT03655054|Experimental|eCoin Tibial Nerve Stimulation|
11160738|NCT03655041|Experimental|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
11160739|NCT03655041|Placebo Comparator|Placebo|6.4 g/day of maltodextrin for 24 weeks
11160740|NCT03655028|Experimental|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
11160741|NCT03655028|Active Comparator|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
11160742|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
11160743|NCT03654989|Experimental|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)
~Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².
~Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
11160744|NCT03654989|Placebo Comparator|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
11160745|NCT03654989|No Intervention|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests <1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
11160746|NCT03654976|Experimental|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
11160747|NCT03654976|Placebo Comparator|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
11160748|NCT03654963|No Intervention|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
11160784|NCT03654716|Experimental|ALRN-6924 -- Cohort C|"Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.
~Cytarabine is administered intravenously.
~ALRN-6924 will be administered intravenously.
~Participants with TP53 wild type acute leukemia will participate in this cohort."
11160785|NCT03654703|Experimental|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
11160749|NCT03654963|Experimental|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
11160750|NCT03654937|Active Comparator|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
11160751|NCT03654937|Active Comparator|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
11160752|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
11160753|NCT03654911||aMCI subjects|EEG recording, ApoE testing
11160754|NCT03654898|Active Comparator|VITAL Start|VITAL Start: Video-based pre-ART counseling
11160755|NCT03654898|Placebo Comparator|Standard of Care|pre-ART education as conducted via routine facility methods
11160756|NCT03654885|Active Comparator|XEN group|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation
11160757|NCT03654885|Active Comparator|Trabeculectomy|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.
11160758|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:
~verbal description of location
~telephone-assisted CPR"
11160759|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:
~automated geolocalisation
~video-assisted CPR"
11160760|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
11160761|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
11160762|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:
~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
11160763|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
11160764|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
11160765|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
11160766|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
11160767|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
11160768|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.
~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.
~Cell pharmacokinetics of tacrolimus"
11160769|NCT03654781|Active Comparator|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
11160770|NCT03654781|Experimental|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
11160771|NCT03654768|Active Comparator|Arm I (dasatinib, nilotinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11160772|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11160773|NCT03654755|Experimental|ASN002 40 mg|ASN002 40 mg
11160774|NCT03654755|Experimental|ASN002 60 mg|ASN002 60 mg
11160775|NCT03654755|Experimental|ASN002 80 mg|ASN002 80 mg
11160776|NCT03654742|Active Comparator|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
11160777|NCT03654742|Experimental|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
11160778|NCT03654742|Experimental|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
11160779|NCT03654729|Experimental|PledOx (2 µmol/kg)|Calmangafodipir (2 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
11160780|NCT03654729|Experimental|PledOx (5 µmol/kg)|Calmangafodipir (5 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
11160781|NCT03654729|Placebo Comparator|Placebo|Placebo will be given to patients as an intravenous infusion, on top of mFOLFOX6 chemotherapy.
11160782|NCT03654716|Experimental|ALRN-6924 -- Cohort A|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.
~ALRN-6924 will be administered intravenously.
~Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
11160783|NCT03654716|Experimental|ALRN-6924 -- Cohort B|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.
~ALRN-6924 will be administered intravenously.
~Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
11162516|NCT03643146|Experimental|Wedge 3-Step 1|
11160786|NCT03654703|Experimental|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
11160787|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
11160788|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
11160789|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
11160790|NCT03654677|Experimental|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
11160791|NCT03654677|Active Comparator|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
11160792|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
11160793|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
11160794|NCT03654651|Experimental|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
11160795|NCT03654651|Active Comparator|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
11160796|NCT03654638|Experimental|Arm I Soy Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of soy bread daily for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
11160797|NCT03654638|Active Comparator|Arm II Wheat Bread Intervention|Men who are scheduled to begin androgen deprivation therapy for prostate cancer will begin an intervention to consume 2 slices of wheat bread for approximately 20 weeks. Blood, urine and toxicity data will be collected at regularly scheduled medical oncology visits.
11160798|NCT03654625|Experimental|Standard Written Exposure|Four writing sessions at the laboratory
11160799|NCT03654625|Experimental|Enhanced Written Exposure|Four writing sessions at the laboratory
11160800|NCT03654625|Placebo Comparator|Control Condition|Four writing sessions at the laboratory
11160801|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
11160802|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
11160803|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
11160804|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
11160805|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
11160806|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
11160807|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
11160808|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
11160809|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
11160810|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
11160811|NCT03654547|Experimental|Dose Escalation|Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts and treated with TT-00420 at different dose cohorts. Starting dose will be 1 mg p.o., q.d. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose Escalation Teleconference will be held after the last evaluable patient complete Cycle 1 treatment in each dose cohort to evaluate DLT, determine MTD and/or DRDE.
11160812|NCT03654547|Experimental|Dose Expansion|"TNBC Cohort: TNBC Dose-Expansion cohort will be opened to enroll the patients with advanced TNBC and evaluate the safety, PK and preliminary efficacy of TT-00420 and identify the optimal biological dose (OBD), when feasible, in patients with advanced TNBC.
~SAT Cohort: A parallel basket SAT Dose Expansion Cohort will be open to enroll patients with SATs to evaluate the safety, PK and preliminary efficacy of TT-00420 and identify the optimal biological dose (OBD), when feasible, in patients with SATs."
11160813|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
11160814|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
11160815|NCT03654521|Active Comparator|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
11160816|NCT03654521|Active Comparator|Control group|Women without gestational or pre-gestational diabetes mellitus.
11160817|NCT03654508|Active Comparator|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
11160818|NCT03654508|Active Comparator|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
11160819|NCT03654495|Experimental|Exergame Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.
11160820|NCT03654495|Active Comparator|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation.
11160821|NCT03654482|Experimental|SuperSeton arm|
11160822|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
11160823|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
11160824|NCT03654443|Experimental|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
11160825|NCT03654443|Experimental|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
11160826|NCT03654430|Other|Healthy Newborns|
11160827|NCT03654417|Active Comparator|EMLA|
11160828|NCT03654417|Active Comparator|Lidocaine|
11160829|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.
~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).
~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
11160830|NCT03654391|Active Comparator|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
11160831|NCT03654391|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
11160832|NCT03654365|Active Comparator|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
11160833|NCT03654365|Experimental|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
11160834|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
11160835|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
11160836|NCT03654339|Experimental|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach
~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
11160837|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant tablet twice a day for 8 weeks. Naproxen sodium tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
11160838|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for 8 weeks. Naproxen sodium tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
11160839|NCT03654313|Experimental|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
11160840|NCT03654313|Experimental|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
11160841|NCT03654313|Experimental|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
11160842|NCT03654313|Experimental|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
11160843|NCT03654313|Placebo Comparator|Part A Placebo|Part A Placebo
11160844|NCT03654313|Experimental|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
11160845|NCT03654313|Experimental|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
11160846|NCT03654313|Experimental|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
11160847|NCT03654313|Placebo Comparator|Part B Placebo|Part B Placebo
11160848|NCT03654313|Experimental|Part A MEDI6570 Cohort 5|Part A MEDI6570 Cohort 5 Dose level
11160849|NCT03654313|Experimental|Part A MEDI6570 Cohort 6|Part A MEDI6570 Cohort 6 dose level
11160850|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
11160851|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
11160852|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
11160853|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
11160854|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
11160855|NCT03654274|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 80 weeks.
11160856|NCT03654261|Experimental|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
11160857|NCT03654261|Experimental|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
11160859|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
11160860|NCT03654235|Experimental|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
11160861|NCT03654235|Active Comparator|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
11160862|NCT03654222||Cardiac surgery|Direct procedures in heart
11160863|NCT03654222||Organ preservation|Mainly renal autograft
11160864|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
11160865|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
11160866|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
11160867|NCT03654222||Other|Any surgery that does not include the previous ones
11160868|NCT03654209|Experimental|Argon Plasma Coagulation|Following polyp removal using standard of care methods, Argon Plasma Coagulation (APC) will be applied to the perimeter of the resection site before any clips are added.
11160869|NCT03654209|Experimental|Snare Tip Soft Coagulation|Following polyp removal using standard of care methods, Snare Tip Soft Coagulation (STSC) will be applied to the perimeter of the resection site before any clips are added.
11160870|NCT03654209|No Intervention|No treatment|Following polyp removal using standard of care methods, neither APC nor STSC will be applied to the perimeter of the resection site. Clips may be added at the discretion of the PI.
11160871|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
11160872|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
11160873|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
11160874|NCT03654144|Experimental|Study group|women will receive dienogest
11160875|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
11160876|NCT03654131|Active Comparator|MWA|Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.
11160877|NCT03654131|Active Comparator|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
11160878|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points
~Phone follow-up"
11160879|NCT03654105|Experimental|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
11160880|NCT03654105|Experimental|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
11160881|NCT03654105|Experimental|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
11160882|NCT03654105|Other|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
11160883|NCT03654092|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
11160884|NCT03654092|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment decisions, including participation in other exercise training programs).
11160885|NCT03654079|Active Comparator|Simulation Arm|Subjects in this arm will participate in Interventions (In- Utero Simulation, Cesarean Section Simulation, and Pushing Simulation).
11160886|NCT03654079|No Intervention|Control Arm|Subjects in this arm will not participate in any simulations.
11160887|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
11160888|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
11160889|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
11160890|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
11160891|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells
~The investigational product is donor alloantigen-specific T regulatory cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.
~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <100 x10^6 total cells will be included in intent-to-treat analysis."
11160892|NCT03654027|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
11160893|NCT03654027|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
11160894|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
11160895|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
11160896|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
11160897|NCT03654001|Experimental|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
~Balanced crystalloid solutions
~According to the preference and the standard use of the participating center:
~Ringer Lactate
~Ringer Acetate
~Crystalsol"
11160898|NCT03654001|Experimental|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
11160899|NCT03654001|Experimental|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
11160900|NCT03654001|No Intervention|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
11160901|NCT03653988|Active Comparator|PEC I/II block - pre-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction case. The intervention administered to Group I will having the block performed by the anesthesiologist after induction of general anesthesia and prior to surgical incision.
11160902|NCT03653988|Experimental|PEC I/II block - intra-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction.
11160903|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria
~Major criteria
~Age 3 to 18 y at onset of head nodding
~Nodding frequency 5 to 20 times per min
~Minor criteria
~Other neurologic abnormalities
~Clustering in space or time with similar cases
~Triggering by eating or cold weather
~Delayed sexual or physical development
~Psychiatric manifestations
~As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions."
11160904|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)
~confirmed or suspected generalized and idiopathic epilepsy
~confirmed active infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
11160905|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)
~confirmed or suspected generalized and idiopathic epilepsy
~excluded active or past infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
11160906|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)
~no evidence for epilepsy or other neurological diseases
~confirmed active infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
11160907|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)
~no evidence for epilepsy or other neurological diseases
~excluded active or past infection with O. volvulus (microscopy, PCR and serology)
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
11160908|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)
~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed
~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
11160909|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
11160910|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
11160911|NCT03653949|Experimental|High Intensity Interval Training|The subjects will participate of an educational intervention and a High Intensity Interval Training.
11160912|NCT03653949|Active Comparator|Control Group|The subjects will participate of an educational intervention.
11160913|NCT03653923|Experimental|Waiting-List|
11160914|NCT03653923|Experimental|Treatment|
11160915|NCT03653923|No Intervention|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
11160916|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
11160917|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
11160918|NCT03653897|Experimental|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
11160919|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
11160920|NCT03653871|Experimental|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
11160921|NCT03653871|No Intervention|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
11161593|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
11160922|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.
~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.
~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
11160923|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.
~2ND STAGE: See group A."
11160924|NCT03653845|Experimental|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
11160925|NCT03653845|Active Comparator|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
11160926|NCT03653832|Experimental|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7µg.kg-1.hour-1 titrated to a maximum dose 1.4µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
11160927|NCT03653832|Experimental|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
11160928|NCT03653832|Active Comparator|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
11160929|NCT03653819|Other|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
11160930|NCT03653819|Other|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
11160931|NCT03653793|Experimental|LivRelief Varicose Veins Cream|"Intervention:
~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
11160932|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
11160933|NCT03653767|No Intervention|Control Group|The control group will use conventional school furniture.
11160934|NCT03653767|Experimental|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
11160935|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
11160936|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
11160937|NCT03653741|Experimental|Healthy males|healthy males will undergo EEG, VEP, BAER, and SEP testing, then take a single dose of Perampanel 6 MG pill (intervention), then have blood drawn and undergo the 4 tests mentioned previously for a second time
11160938|NCT03653728||Traumatic brain injury with cerebral contusions|
11160939|NCT03653715|Experimental|Test Device|Within this arm the Clerio Vision LIRIC-modified Bifocal Contact Lens is administered.
11160940|NCT03653715|Active Comparator|Control Devices|Within this arm the Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, and Clerio Vision Single Vision Contact Lens are administered.
11160941|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
11160942|NCT03653689|Active Comparator|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
11160943|NCT03653689|Active Comparator|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
11160944|NCT03653689|Placebo Comparator|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
11160945|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
11160946|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
11160947|NCT03653663|Placebo Comparator|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
11160948|NCT03653663|Active Comparator|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
11160949|NCT03653650|Experimental|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
11160950|NCT03653650|Active Comparator|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
11160951|NCT03653650|Active Comparator|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
11160979|NCT03653455|Experimental|Pre-operative discussion group|At a pre-operative visit, patients and their care provider will discuss what assigned surveys are and why they are important. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
11160952|NCT03653637|Experimental|Project Life Force|"A novel, 10-session intervention to enhance currently mandated VA suicide safety planning in a group setting to support its implementation. PLF is a manualized, weekly 90-minute group treatment lasting 10 weeks coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. Session content is described in Table 1 (see appendix A). Six of the PLF sessions correspond to a step of the safety plan and teach skills to maximize the use of that particular step of the plan. The use of emotion regulation skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation, distraction and developing social support in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on physical health management, education pertaining to suicide risk, promoting positive emotion and suicide prevention mobile apps. PLF patients also receive usual care."
11160953|NCT03653637|Active Comparator|Treatment-As-Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Research team will track number of individual mental health appointments, SPC outreach contacts, and usage patterns of safety plans. Veterans in both randomized conditions will be receiving the mandated monitoring, outreach, and involvement of SPC staff and clinical team management that constitutes standard VA care for suicidal individuals.
11160954|NCT03653611||Clinician Participants|Two Aim 2 practices are selected by each of their 5 affiliated PBRNs based upon willingness to participate and variability of primary care practice type within the PBRN. Differences in practice size, staffing, ownership, prior quality improvement engagement, geography, patient population socioeconomic status (SES) or languages spoken are among the among the selection criteria the PBRNs will utilize to choose.
11160955|NCT03653611||Patient Participants|200 patients, who are enrolled in Aim 1 (approximately 40 from each PBRN) will be invited to take a CAPTURE opinion survey
11160956|NCT03653598||AF patients|Patients with Atrial Fibrillation
11160957|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
11160958|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
11160959|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:
~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
11160960|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
11160961|NCT03653559|Experimental|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and < 30% lipids.
11160962|NCT03653559|Active Comparator|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
11160963|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
11160964|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
11160965|NCT03653533|Other|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
11160966|NCT03653533|Other|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
11160967|NCT03653533|Other|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
11160968|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
11160969|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
11160970|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
11160971|NCT03653507|Experimental|Arm A (zolbetuximab plus CAPOX)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After 8 treatments of CAPOX, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
11160972|NCT03653507|Placebo Comparator|Arm B (placebo plus CAPOX)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After 8 treatments of CAPOX, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
11160973|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
11160974|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
11160975|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
11160976|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
11160977|NCT03653468|No Intervention|Control group|No-exercise
11160978|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
11161051|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
11160980|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
11160981|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
11160982|NCT03653455|Experimental|control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
11160983|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
11160984|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
11160985|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
11160986|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
11160987|NCT03653403|Experimental|IDP-126 Gel|Component A
11160988|NCT03653403|Active Comparator|Control Gel|Gel
11160989|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
11160990|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
11160991|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
11160992|NCT03653377||Patients with self-administered questionnaire|
11160993|NCT03653364|Experimental|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
11160994|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
11160995|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
11160996|NCT03653338|Experimental|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.
~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
11160997|NCT03653325|Experimental|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:
~Interventional arm (FiO2 adaptation every 2-3 min) :
~ORI >0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.2 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.1 ORI >0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1
~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
11160998|NCT03653325|Active Comparator|Observational arm|"Observational arm (adaptation every 2-3 min):
~oxygen saturation measurement SatO2>98% and FiO2>0.5 reduction of FiO2 by 0.1 SatO2>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1"
11160999|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.
~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
11161000|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
11161001|NCT03653299|Experimental|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
11161002|NCT03653299|Experimental|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
11161003|NCT03653299|Experimental|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
11161004|NCT03653299|Experimental|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.
~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
11161005|NCT03653286|Experimental|NMES and Run|NMES and run
11161006|NCT03653286|Other|Only Run|Only Run
11161007|NCT03653273|Experimental|DMT withdrawal|DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
11161008|NCT03653273|Active Comparator|DMT continuation|The previously established therapy will be continued at the same dose during two years.
11161009|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
11161010|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
11161052|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
11162045|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
11161011|NCT03653247|Experimental|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
11161012|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
11161013|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
11161014|NCT03653221|Experimental|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
11161015|NCT03653221|Placebo Comparator|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
11161016|NCT03653208|Experimental|Group 1|"Drug: hzVSF-v13 10 mg, IV administration
~Drug: Placebo, IV administration"
11161017|NCT03653208|Experimental|Group 2|"Drug: hzVSF-v13 20 mg, IV administration
~Drug: Placebo, IV administration"
11161018|NCT03653208|Experimental|Group 3|"Drug: hzVSF-v13 50 mg, IV administration
~Drug: Placebo, IV administration"
11161019|NCT03653208|Experimental|Group 4|"Drug: hzVSF-v13 100 mg, IV administration
~Drug: Placebo, IV administration"
11161020|NCT03653208|Experimental|Group5|"Drug: hzVSF-v13 200 mg, IV administration
~Drug: Placebo, IV administration"
11161021|NCT03653208|Experimental|Group6|"Drug: hzVSF-v13 400 mg, IV administration
~Drug: Placebo, IV administration"
11161022|NCT03653208|Experimental|Group 7|"Drug: hzVSF-v13 800 mg, IV administration
~Drug: Placebo, IV administration"
11161023|NCT03653208|Experimental|Group 8|"Drug: hzVSF-v13 1200 mg, IV administration
~Drug: Placebo, IV administration"
11161024|NCT03653195|Other|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
11161025|NCT03653195|Active Comparator|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
11161026|NCT03653182||normal|A normal constitution condition in TCM.
11161027|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
11161028|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
11161029|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
11161030|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
11161031|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
11161032|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
11161033|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
11161034|NCT03653182||Special|One of an abnormal constitution condition in TCM.
11161035|NCT03653169|Experimental|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
11161036|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
11161037|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
11161038|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
11161039|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
11161040|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
11161041|NCT03653143|Experimental|Treatment Group|Assessment #1 Baseline Visit >> 3 month JASPER intervention (weekly) >> Assessment #2 Research Visit >> 3 month treatment as usual >> Assessment #3 Research Visit
11161042|NCT03653143|Experimental|Control/Wait-list Group|Assessment #1 Baseline Visit >> 3 month treatment as usual >> Assessment #2 Research Visit >> 3 month JASPER intervention >> Assessment #3 Research Visit
11161043|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
11161044|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
11161045|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
11161046|NCT03653117|Experimental|TPLA|TPLA procedure
11161047|NCT03653104|Experimental|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
11161048|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
11161049|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
11161050|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
11161245|NCT03651713|Active Comparator|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
11161053|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
11161054|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
11161055|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
11161056|NCT03653039|Experimental|Tritube|
11161057|NCT03653039|Active Comparator|Standard endotracheal tube|
11161058|NCT03653026|Experimental|Upadacitinib|Administered once daily (QD)
11161059|NCT03653026|Experimental|Placebo|Administered once daily (QD)
11161060|NCT03653013|Active Comparator|Control Group|Usual standard of care from their diabetes care team
11161061|NCT03653013|Experimental|Neuropsychological Consultation Group|Children will be administered a number of neuropsychological tests. Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL, Generic Scale and Diabetes Module), diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
11161062|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
11161063|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Drug: sodium valproate with Clozapine"
11161064|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
11161065|NCT03652974|Experimental|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Drug: amisulpride with Clozapine"
11161066|NCT03652974|Placebo Comparator|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.
~Intervention: Drug: placebo with Clozapine"
11161067|NCT03652961|Other|Open Label|Open Label abatacept for Intravenous Infusion Abatacept intravenous will be administered as a 30-minute intravenous infusion utilizing the weight range-based dosing. Following the initial intravenous administration, an intravenous infusion will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for a total of 7 doses.
11161068|NCT03652948|Experimental|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.
~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
11161069|NCT03652935|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
11161070|NCT03652935|Active Comparator|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
11161071|NCT03652922|Experimental|Propranolol|
11161072|NCT03652922|Placebo Comparator|Placebo|
11161073|NCT03652909||PSAD|Patients try the personal sound amplification device.
11161074|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
11161075|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
11161076|NCT03652883|Experimental|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
11161244|NCT03651713|Experimental|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
11161077|NCT03652883|Active Comparator|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
11161078|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
11161079|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
11161080|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
11161081|NCT03652857|Experimental|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
11161082|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
11161083|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
11161084|NCT03652831|Active Comparator|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.
~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
11161085|NCT03652831|Active Comparator|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.
~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
11161086|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;
~Post-op Placebo 1;
~Post-op Placebo 2"
11161087|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;
~Post-op Placebo 2;
~Post-op acetaminophen."
11161088|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;
~Post-op pregabalin;
~Post-op Placebo 2."
11161089|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;
~Post-op pregabalin
~Post-op acetaminophen."
11161090|NCT03652818|Experimental|Group E|"Pre-op pregabalin;
~Post-op Placebo 1;
~Post-op acetaminophen."
11161091|NCT03652805|Experimental|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
11161092|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
11161093|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
11161094|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
11161095|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
11161096|NCT03652779|Experimental|Tecarfarin 10mg|
11161097|NCT03652779|Experimental|Tecarfarin 20mg|
11161098|NCT03652779|Experimental|Tecarfarin 30mg|
11161099|NCT03652779|Experimental|Tecarfarin 40mg|
11161100|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
11161101|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
11161102|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
11161103|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
11161104|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
11161105|NCT03652727|Experimental|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance [Site~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)]
11161106|NCT03652727|Active Comparator|FX Guidance|PICC insertion using fluoroscopic guidance
11161107|NCT03652714|Experimental|Local anesthetic|
11161108|NCT03652714|Placebo Comparator|Isotonic NaCl|
11161109|NCT03652701|Experimental|Hair Up|
11161110|NCT03652701|Placebo Comparator|Placebo|
11161111|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
11161112|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
11161113|NCT03652675|Experimental|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
11161114|NCT03652675|No Intervention|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
11161115|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:
~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
11161116|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:
~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
11161117|NCT03652649|Experimental|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet
11161118|NCT03652636|Other|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
11161119|NCT03652623|Experimental|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
11161120|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Approximately 486 healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
11161121|NCT03652610|Active Comparator|ACWY Group|Approximately 486 healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK' MenACWY vaccine formulation (Menveo).
11161122|NCT03652597|Active Comparator|Left|Subjects are ascribed to left hemispheric stimulation
11161123|NCT03652597|Active Comparator|Right|Subjects are ascribed to right hemispheric stimulation
11161124|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
11161125|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
11161126|NCT03652571|Experimental|Nortriptyline|"Nortriptyline in an escalating dose regimen:
~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
11161127|NCT03652571|Placebo Comparator|Placebo|Placebo
11161128|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
11161129|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
11161130|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.
~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2
~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.
~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.
~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
11161131|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
11161132|NCT03652532|Experimental|Alternate Day Fasting|
11161133|NCT03652532|Experimental|Exercise|
11161134|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
11161135|NCT03652519|Experimental|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x one-and-a-half Minute high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 minutes with the aim to achieve 60% HRmax.
11161136|NCT03652519|Active Comparator|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
11161137|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
11161138|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
11161139|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
11161140|NCT03652493|Experimental|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
11161141|NCT03652467|Experimental|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
11161142|NCT03652467|Active Comparator|Conventional TACE|Patients are treated with conventional TACE.
11161143|NCT03652454|Experimental|micro-osteoperforation|Propel device (ABD)
11161144|NCT03652454|Other|conventional treatment|conventional fixed appliance treatment
11161145|NCT03652441|Experimental|Maintenance|Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
11161146|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:
~Gemcitabine + nab-paclitaxel:
~• Administered per institutional standard every 7 days for 3 weeks
~Part II:
~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.
~Part III:
~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy
~OR
~Chemo per discretion of MD if not resectable"
11161147|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
11161148|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
11161149|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
11161150|NCT03652363|Placebo Comparator|Placebo|Placebo administered via convection enhanced delivery
11161151|NCT03652363|Experimental|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
11161152|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
11161153|NCT03652337|Experimental|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
11161154|NCT03652337|Experimental|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
11161155|NCT03652324|Other|randomized|
11161156|NCT03652311|Experimental|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
11161157|NCT03652311|Sham Comparator|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
11161158|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
11161159|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
11161160|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
11161161|NCT03652272|Experimental|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:
~Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks
~Patients will receive a Medication Guide + Summary with their After Visit Summary
~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)
~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
11161162|NCT03652272|No Intervention|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
11161163|NCT03652259|Experimental|Cohort 1|Single IV infusion of SRP-9003.
11161164|NCT03652259|Experimental|Cohort 2|Patients will receive SRP-9003 via intravenous (IV) infusion. Dosage will be determined based on the findings from Cohort 1.
11161165|NCT03652233|Experimental|Afatinib and Nivolumab|
11161166|NCT03652220|Experimental|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation
~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
11161167|NCT03652220|Active Comparator|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment
~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
11161168|NCT03652220|Active Comparator|Control 2|"Definitions 24 weeks Multimodal specific treatment
~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
11161169|NCT03652207|Placebo Comparator|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
11161170|NCT03652207|Experimental|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
11161171|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
11161172|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
11161173|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
11161270|NCT03651557|Placebo Comparator|saline|
11161174|NCT03652181||CASH (Cavernous Angiomas with Symptomatic Hemorrhage)|The adjudicated definition of CASH (Cavernous Angiomas with Symptomatic Hemorrhage) requires diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms.
11161175|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
11161176|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
11161177|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
11161178|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.
~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
11161179|NCT03652129|Experimental|Laser Group|Disinfection using biostimulating LASER
11161180|NCT03652129|Experimental|Nano irrigant Group|Disinfection using Nano irrigant
11161181|NCT03652129|Active Comparator|Conventional irrigation protocol group|disinfection using normal irrigation protocols
11161182|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
11161183|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
11161184|NCT03652103|No Intervention|GCont|Only dressing will be applied to patients without actually nerve catheter performed
11161185|NCT03652103|Experimental|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution* will be administered initially.
~20 ml Bupivacaine %0.25 Injectable Solution** will be administered 20 minutes before mobilization at postoperative day(POD) 1 and before removal of nephrostomy at POD 2
~*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
11161186|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
11161187|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
11161188|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
11161189|NCT03652077|Experimental|INCAGN02390|
11161190|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
11161191|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
11161192|NCT03652051|Experimental|AZR-MD-001 Low Dose|AZR-MD-001 Low Dose will be dosed up to once daily.
11161193|NCT03652051|Experimental|AZR-MD-001 Mid Dose|AZR-MD-001 Mid Dose will be dosed up to once daily.
11161194|NCT03652051|Experimental|AZR-MD-001 High Dose|AZR-MD-001 High Dose will be dosed up to once daily.
11161195|NCT03652051|Sham Comparator|AZR-MD-001 Vehicle|AZR-MD-001 Vehicle will be dosed up to once daily.
11161196|NCT03652038|Experimental|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
11161197|NCT03652038|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
11161198|NCT03652038|Experimental|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
11161199|NCT03652038|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
11161200|NCT03652038|Experimental|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
11161201|NCT03652038|Placebo Comparator|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
11161202|NCT03652025|Experimental|Study group|perimenopausal women
11161203|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.
~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
11161204|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.
~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
11161243|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:
~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
11161379|NCT03650907|Experimental|Group exercise program by coach|
11161205|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
11161206|NCT03651999||control|"No dream workshop"
11161207|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
11161208|NCT03651973|Experimental|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
11161209|NCT03651973|Other|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
11161210|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
11161211|NCT03651947|Experimental|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
11161212|NCT03651947|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
11161213|NCT03651934|Experimental|Normal iron|
11161214|NCT03651934|Experimental|Weak iron|
11161215|NCT03651934|Experimental|Normal selenium|
11161216|NCT03651934|Experimental|Weak selenium|
11161217|NCT03651921|No Intervention|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
11161218|NCT03651921|Experimental|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
11161219|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
11161220|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
11161221|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
11161222|NCT03651895|Placebo Comparator|Placebo Group|Placebo
11161223|NCT03651882|Active Comparator|Oxytocin|
11161224|NCT03651882|Active Comparator|Carbetocin|
11161225|NCT03651869|Experimental|Condition 1|
11161226|NCT03651869|Experimental|Condition 2|
11161227|NCT03651869|Experimental|Condition 3|
11161228|NCT03651869|Experimental|Condition 4|
11161229|NCT03651856|Experimental|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
11161230|NCT03651843||Healthy subjects|
11161231|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
11161232|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
11161233|NCT03651817|Active Comparator|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
11161234|NCT03651817|Active Comparator|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
11161235|NCT03651804|Active Comparator|Control Group|"The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks."
11161236|NCT03651804|Active Comparator|Treatment Group|The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
11161237|NCT03651804|Active Comparator|Crossover Group|This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.
11161238|NCT03651791|Experimental|USPIO labeled MSC injection|USPIO labeled MSC injection
11161239|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
11161240|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
11161241|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect during their knee classes at the Holland Centre
11161242|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:
~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
11161246|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
11161247|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
11161248|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
11161249|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
11161250|NCT03651661|Active Comparator|nasal insulin|160 U of human insulin as nasal spray
11161251|NCT03651661|Placebo Comparator|nasal placebo|placebo as nasal spray
11161252|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
11161253|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
11161254|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
11161255|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
11161256|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
11161257|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
11161258|NCT03651609|Experimental|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
11161259|NCT03651609|Active Comparator|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
11161260|NCT03651609|Experimental|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
11161261|NCT03651609|Active Comparator|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
11161262|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
11161263|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
11161264|NCT03651583|Other|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
11161265|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
11161266|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
11161267|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
11161268|NCT03651557|Experimental|Neu2000KWL high dose|
11161269|NCT03651557|Experimental|Neu2000KWL low dose|
11161271|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
11161272|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
11161273|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
11161274|NCT03651531|Active Comparator|insulin|
11161275|NCT03651531|Active Comparator|insulin and metformin|
11161276|NCT03651518|Experimental|Kineret|
11161277|NCT03651518|Experimental|Humira|
11161278|NCT03651518|Experimental|Stelara|
11161279|NCT03651518|Experimental|Cosentyx|
11161280|NCT03651518|Experimental|Roactemra|
11161281|NCT03651518|Experimental|Rituximab|
11161282|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
11161283|NCT03651505||Not from Prior Burosumab Clinical Trial|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
11161284|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
11161285|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
11161286|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
11161287|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
11161288|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
11161289|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
11161290|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
11161291|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
11161292|NCT03651453|Active Comparator|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
11161293|NCT03651453|Experimental|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
11161294|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
11161295|NCT03651440|Experimental|PNF training|PNF training exercises
11161296|NCT03651440|Experimental|physical therapy|HP,TENS US
11161297|NCT03651440|Sham Comparator|control|NO APPLİCATİON
11161298|NCT03651427|Experimental|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.
~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.
~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
11161299|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
11161300|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
11161301|NCT03651401||Subacromial impingement syndrome|Participants were assessed for SME, pain (rest, activity, night), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA). In addition, Constant & Murley score, the Shoulder Pain and Disability Index (SPADI), and the Nottingham Health Profile (NHP) were administered.
11161302|NCT03651401||partial rotator cuff tears|Participants were assessed for SME, pain (rest, activity, night), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA). In addition, Constant & Murley score, the Shoulder Pain and Disability Index (SPADI), and the Nottingham Health Profile (NHP) were administered.
11161303|NCT03651401||healthy controls|Participants were assessed for SME, shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA). In addition, Constant & Murley score, the Shoulder Pain and Disability Index (SPADI), and the Nottingham Health Profile (NHP) were administered.
11161304|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
11161305|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
11161306|NCT03651375|Experimental|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
11161307|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161308|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161309|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161310|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161311|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161312|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161380|NCT03650907|Sham Comparator|Self exercise|
11162517|NCT03643146|Experimental|Wedge 3- Step 2|
11161313|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161314|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
11161315|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
11161316|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
11161317|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
11161318|NCT03651297|Experimental|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
11161319|NCT03651297|Experimental|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
11161320|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
11161321|NCT03651284|Other|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
11161322|NCT03651271|Experimental|"Hot tumors"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
11161323|NCT03651271|Experimental|"Cold tumors"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
11161324|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
11161325|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
11161326|NCT03651245||Participants with suspicion for Alpha-Mannosidosis|Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years
11161327|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
11161328|NCT03651232|Active Comparator|support|weekly group support class
11161329|NCT03651219|Experimental|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
11161330|NCT03651219|Active Comparator|controlled group|Patients use Irinotecan
11161331|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
11161332|NCT03651206|Experimental|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose
~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
11161333|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)
~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days
~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
11161334|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
11161335|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
11161336|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
11161337|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
11161338|NCT03651154|Experimental|Hypovolemic Phlebotomy|"Hypovolemic Phlebotomy will consist of the withdrawal of 7-10 mL/kg of whole blood from the patient, as tolerated (e.g. for a 70kg patient, 490 to 700 mL of whole blood will be removed) The volume of removed blood will not be replaced by the administration of intravenous fluids.
~Removed blood will be transfused back to participant at the end of surgery. The phlebotomized whole blood will be transfused back after liver transection regardless of blood loss."
11161339|NCT03651154|No Intervention|Control (Standard of Care)|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
11161340|NCT03651141|Experimental|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
11161341|NCT03651141|Experimental|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
11161342|NCT03651141|Sham Comparator|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
11161343|NCT03651128|Experimental|Arm A - Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
11161407|NCT03650647|Active Comparator|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.
~Intervention: Total soft and leathery caries removal. Carious dentin removal"
11161344|NCT03651128|Experimental|Arm B- standard regimens as per Investigator's discretion|"The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen:
~Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR
~DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR
~Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR
~Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR
~Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)"
11161345|NCT03651115||Neonates with gentamicin|
11161346|NCT03651115||Neonates with vancomycin|
11161347|NCT03651102|Experimental|Patients Receiving Thalidomide Therapy|All the study patients will be given thalidomide at an average dose of 2mg/kg/day (range 1-3mg/kg/day). The patients will be followed at 4 weeks interval by a haematologist for monitoring of potential side effects and for evaluation of clinical and laboratory response.
11161348|NCT03651089|Active Comparator|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
11161349|NCT03651089|Active Comparator|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
11161350|NCT03651089|Active Comparator|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
11161351|NCT03651089|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
11161352|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
11161353|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
11161354|NCT03651063|Experimental|social robot group|
11161355|NCT03651063|Active Comparator|computer group|
11161356|NCT03651063|Active Comparator|self-training group|
11161357|NCT03651063|No Intervention|contro: no intervention|This group will only be a follow up: clinical examination at the entrance and follow 5 weeks with clinical examination 5 weeks post, with no intervention.
11161358|NCT03651050|Experimental|intervention FBOs receive the P-MHDT|
11161359|NCT03651050|Experimental|control FBOs receive no P-MHDT|
11161360|NCT03651037|Experimental|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
11161361|NCT03651037|Experimental|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
11161362|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
11161363|NCT03651011|Active Comparator|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
11161364|NCT03651011|Active Comparator|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
11161365|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.
~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
11161366|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.
~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
11161367|NCT03650985|Experimental|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
11161368|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
11161369|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
11161370|NCT03650959|Experimental|Faculty-led|
11161371|NCT03650959|Experimental|Peer tutor-led|
11161372|NCT03650959|Experimental|Computer augmented self-directed learning|
11161373|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
11161374|NCT03650946||2|men with rising PSA after local definitive treatments
11161375|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
11161376|NCT03650933|Experimental|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
11161377|NCT03650933|Active Comparator|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
11161378|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
11161381|NCT03650894|Experimental|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
11161382|NCT03650881|Experimental|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
11161383|NCT03650881|Active Comparator|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
11161384|NCT03650868|No Intervention|Control Group|No intervention will be applied to control group
11161385|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
11161386|NCT03650842|Experimental|Laparoscopic pyloromyotomy|Infants undergoing laparoscopic pyloromyotomy.
11161387|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)
~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
11161388|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.
~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
11161389|NCT03650803|Experimental|3D MR Fingerprinting scan|Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.
11161390|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
11161391|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
11161392|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
11161393|NCT03650764|Experimental|Phase I: Ramucirumab + Pembrolizumab|-Ramucirumab will be administered IV over 1 hour on Day 1 of each 21-day cycle. Pembrolizumab will be administered as per standard of care (IV at a dose of 200 mg over 30 minutes on Day 1 of each 21-day cycle). On Day 1, pembrolizumab will be given after ramucirumab.
11161394|NCT03650764|Experimental|Phase II: Ramucirumab + Pembrolizumab|-Patients will be treated with ramucirumab at the RP2D on Day 1 and SOC pembrolizumab (200 mg IV over 30 minutes) on Day 1 of each 21-day cycle.
11161395|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
11161396|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
11161397|NCT03650725||Mandatory Split bowel preparation|Patients will be advised to take 4 liters of polyethylene glycol (PEG), split into two 2 liter doses. The first 2 liters are to be taken starting at 1800 hours the day before the colonoscopy, and the second dose is to be taken starting 4-5 hours prior to the scheduled time for the colonoscopy. Each dose will be taken within a 2-hour time span.
11161398|NCT03650725||Optional Split bowel preparation|Patients will be advised on split-dose bowel preparation (as per option 1), but will also receive instructions on day before bowel preparation. The instructions will indicate that split-dose bowel preparation is the optimal preparation for cleansing the bowel and for visualizing polyps, but they may choose day before bowel preparation if the split dose preparation is too difficult for them.
11161399|NCT03650712|Other|frequently sampled oral glucose tolerance testing|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit
11161400|NCT03650712|Other|Frequently sampled oral glucose tolerance testing anc CGM|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back
11161401|NCT03650712|Other|frequently sampled oral glucose tolerance testing and DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + a DXA scan will be done at the same visit
11161402|NCT03650712|Other|frequently sampled oral glucose tolerance testing, CGM & DXA|frequently sampled oral glucose tolerance testing will be performed in a one-time cross sectional visit + continuous glucose monitor will be placed after the visit and mailed back + a DXA scan will be done at the same visit
11161403|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.
~Assessments will be taken during the beginning, middle, and end of each study arm."
11161404|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.
~Assessments will be taken during the beginning, middle, and end of each study arm."
11161405|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
11161406|NCT03650660||Patients with liver cirrhosis|
11162518|NCT03643146|Experimental|Wedge 3- Step 3|
11162519|NCT03643146|Experimental|Wedge 3- Step 4|
11161408|NCT03650647|Experimental|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.
~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
11161409|NCT03650647|Experimental|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.
~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
11161410|NCT03650621|Experimental|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.
~Total duration of study 2.5-3 hours"
11161411|NCT03650621|Placebo Comparator|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.
~Total duration of study 2.5-3 hours"
11161412|NCT03650608|Experimental|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
11161413|NCT03650608|Experimental|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
11161414|NCT03650608|Experimental|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
11161415|NCT03650608|Placebo Comparator|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
11161416|NCT03650595|Experimental|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
11161417|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
11161418|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
11161419|NCT03650556|Experimental|Ablation|Pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the persistent AF population.
11161420|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
11161421|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 *1/*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 *1/*2 or *1/*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 *2/*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
11161422|NCT03650530|Experimental|The Family Talk Intervention|These families will participate in a psychosocial support program.
11161423|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.
~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
11161424|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.
~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
11161425|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.
~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
11161426|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.
~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
11161427|NCT03650504|Experimental|Above Artery Group|
11161428|NCT03650504|Active Comparator|Between Artery and Vein Group|
11161429|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
11161430|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
11161431|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
11161432|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
11161462|NCT03650257|Active Comparator|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
11161463|NCT03650244||Patients fitted with REMEEX|
11161464|NCT03650218|Experimental|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)
~THIODERM STRONG injected into nasolabial folds (cohort 2)"
11161433|NCT03650465|Experimental|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck & Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
11161434|NCT03650465|Experimental|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden & DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
11161435|NCT03650465|Experimental|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
11161436|NCT03650452|Experimental|TAK-935|Treatment: Eight weeks Dose Optimization Period followed by 12 weeks Maintenance Period.
11161437|NCT03650452|Placebo Comparator|Placebo|Treatment: Eight weeks Dose Optimization Period followed by 12 weeks Maintenance Period.
11161438|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
11161439|NCT03650426|Experimental|Inlay patellar resurfacing technique|
11161440|NCT03650413|Experimental|UTTR1147A|All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
11161441|NCT03650400|Experimental|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
11161442|NCT03650400|Experimental|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
11161443|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
11161444|NCT03650374|Active Comparator|Group 1|standard of care postoperative rehabilitation.
11161445|NCT03650374|Experimental|Group 2|experimental strength training
11161446|NCT03650361|Experimental|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
11161447|NCT03650361|Active Comparator|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
11161448|NCT03650361|Placebo Comparator|Placebo Control|Vehicle of the test product, applied for 84 days
11161449|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
11161450|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
11161451|NCT03650335||group II|with a total of 30 mL 0.25% bupivacaine injection to be administered
11161452|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
11161453|NCT03650322|Active Comparator|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
11161454|NCT03650322|Experimental|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
11161455|NCT03650309|Experimental|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
11161456|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
11161457|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
11161458|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
11161459|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
11161460|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
11161461|NCT03650257|Experimental|gp96 group|"Patients receive standard treatment with radiation and temozolomide after surgery.
~Then 6 times of autologous gp96 vaccination are administered via subcutaneous injection in 25μg doses at the 2nd week after the end of postoperative radiotherapy.
~( gp96 is administered once a week for the first 4 weeks, the 5th injection is administered 2 weeks after the 4th injection, and the 6th injection is administered 3 weeks after the 5th injection. )
~The first adjunctive temozolomide startes on the day of the fifth gp96 injection.
~(150-200 mg/m2/day for 5 days, then stop for 23 days, one cycle is 28 days for a total of 6 cycles)"
11162520|NCT03643146|Experimental|Wedge 3- Step 5|
11162521|NCT03643146|Experimental|Wedge 4-Step 1|
11161465|NCT03650205|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
11161466|NCT03650205|Placebo Comparator|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
11161467|NCT03650192|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
11161468|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
11161469|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
11161470|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
11161471|NCT03650153|Active Comparator|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
11161472|NCT03650153|Active Comparator|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
11161473|NCT03650140|Active Comparator|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
11161474|NCT03650140|Active Comparator|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
11161475|NCT03650114|Experimental|Ofatumumab|Subcutaneous injection
11161476|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
11161477|NCT03650075|Placebo Comparator|Single Ascending Dose (SAD)|
11161478|NCT03650075|Placebo Comparator|Multiple Ascending Dose (MAD)|
11161479|NCT03650075|Experimental|Food Effect Part|
11161480|NCT03650036|Experimental|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
11161481|NCT03650036|Experimental|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
11161482|NCT03650023|Experimental|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
11161483|NCT03650023|Placebo Comparator|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
11161484|NCT03649997|Experimental|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
11161485|NCT03649997|Experimental|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
11161486|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
11161487|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
11161488|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
11161489|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
11161516|NCT03649880|Experimental|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive ¹⁸F-fluoromisonidazole IV and 1.5 - 2 hours later undergo PET (Positron Emission Tomography) /CT (Computed Tomography) or PET/MRI (Magnetic Resonance Imaging) over 20-40 minutes and a retest examination within 7 days. Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks.
11161748|NCT03648229|Experimental|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
11161490|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
11161491|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
11161492|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
11161493|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
11161494|NCT03649997|Experimental|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
11161495|NCT03649997|Experimental|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
11161496|NCT03649984|Experimental|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
11161497|NCT03649984|No Intervention|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
11161498|NCT03649971|Experimental|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
11161499|NCT03649971|Experimental|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
11161500|NCT03649971|Placebo Comparator|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
11161501|NCT03649958|Active Comparator|HIRREM-SOP|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time..
11161502|NCT03649958|Placebo Comparator|random notes|Participants randomized to the control will be seated in a comfortable zero-gravity chair identical to those in the active arm, and will also listen to a pattern of musical notes, but they will be random, and not linked to their brain activity patterns.
11161503|NCT03649945|Active Comparator|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
11161504|NCT03649945|Active Comparator|Test Group 2|Docetaxel plus Nedaplatin
11161505|NCT03649945|No Intervention|Control Group|No medicine intervention
11161506|NCT03649932|Experimental|Low Dose|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
11161507|NCT03649932|Experimental|Medium Dose|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
11161508|NCT03649932|Experimental|High Dose|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
11161509|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
11161510|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
11161511|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
11161512|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
11161513|NCT03649906|Experimental|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
11161514|NCT03649893|No Intervention|Control Group|The control group will use conventional siiting-desk office.
11161515|NCT03649893|Experimental|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
11161517|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
11161518|NCT03649841|Active Comparator|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
11161519|NCT03649841|Experimental|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
11161520|NCT03649828|Experimental|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
11161521|NCT03649828|Experimental|control group|control group (CG) that received only curd
11161522|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
11161523|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
11161524|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
11161525|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
11161526|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
11161527|NCT03649763|Active Comparator|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
11161528|NCT03649763|Active Comparator|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
11161529|NCT03649763|Active Comparator|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
11161530|NCT03649763|Active Comparator|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
11161531|NCT03649750|Experimental|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
11161532|NCT03649750|Experimental|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
11161533|NCT03649737|Experimental|Supportive care (exercise)|Participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. Participants also attend home-based unsupervised exercise sessions via an instructional DVD once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.
11161534|NCT03649724|Placebo Comparator|Placebo|0.25 ml of sterile normal saline administered subcutaneously / 12 weeks
11161535|NCT03649724|Experimental|Leuprolide|Eligard 22.5mg administered subcutaneously / 12 weeks
11161536|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
11161537|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
11161538|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
11161539|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
11161540|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
11161541|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
11161542|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
11161543|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
11161544|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
11161545|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
11161546|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
11161547|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
11161548|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
11161549|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
11161550|NCT03649659|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
11161551|NCT03649659|Placebo Comparator|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
11161552|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
11161553|NCT03649633|Experimental|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
11161554|NCT03649633|Placebo Comparator|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
11161555|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
11161556|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
11161557|NCT03649607|Other|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
11161558|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
11161559|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
11161560|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
11161561|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
11161562|NCT03649581|Active Comparator|healthy volunteers|
11161563|NCT03649568|Experimental|Pork|1 ounce lean pork
11161564|NCT03649568|Active Comparator|Egg|1 large whole egg
11161565|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
11161566|NCT03649568|Experimental|Almonds|1 ounce almonds
11161567|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
11161568|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
11161569|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
11161570|NCT03649529|Experimental|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
11161571|NCT03649516|Experimental|iCKD APP Group|Use iCKD APP
11161572|NCT03649516|No Intervention|Traditional Care Group|Accept traditional care
11161573|NCT03649490||Smooth PEEK Interbody Implants in XLIF|Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth. Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence. Additionally, lordotic profiles are available to induce proper sagittal alignment.
11161574|NCT03649490||3D-Printed Titanium Interbody Implants in XLIF|3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging. The advanced microporous surface topography creates an ideal environment for bone in-growth.
11161575|NCT03649490||Porous PEEK Interbody Implants in XLIF|Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants. The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
11161576|NCT03649477|Placebo Comparator|Placebo|matched placebo during first 8-weeks; randomized to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
11161577|NCT03649477|Experimental|Dose 1 of LV-101|
11161578|NCT03649477|Experimental|Dose 2 of LV-101|
11161579|NCT03649464|Experimental|OKN-007|Oral OKN-007
11161580|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
11161581|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
11161582|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
11161583|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
11161584|NCT03649399|Experimental|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
11161585|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
11161586|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
11161587|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
11161588|NCT03649347|Experimental|AR therapy intervention for spider phobia|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
11161589|NCT03649347|No Intervention|No treatment control group for spider phobia|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (1 months).
11161590|NCT03649347|Experimental|AR therapy intervention for fear of snakes|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
11161591|NCT03649347|No Intervention|No treatment control group for fear of snakes|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (1 months).
11161592|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
11161594|NCT03649321|Experimental|Part 1 - Safety Run|BGB324 200 mg oral daily, plus chemotherapy. Nab-paclitaxel 125 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
11161595|NCT03649321|Experimental|Part 2 - BGB324 plus chemotherapy|BGB324 200 mg oral daily. Nab-paclitaxel 125 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
11161596|NCT03649321|Experimental|Part 2 - Chemotherapy Alone|Nab-paclitaxel 125 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
11161597|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
11161598|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
11161599|NCT03649295|Experimental|Functional Electrical Stimulation|"- Functional electrical stimulation device obeying the following steps: Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure. Conventional therapy should be performed in conjunction with functional electrostimulation
~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
11161600|NCT03649295|Placebo Comparator|Placebo|"Sham.The electrodes are placed at 0 Hz
~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
11161601|NCT03649282|Experimental|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
11161602|NCT03649282|Experimental|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
11161603|NCT03649269|Experimental|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
11161604|NCT03649269|Active Comparator|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
11161605|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
11161606|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
11161607|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
11161608|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
11161609|NCT03649217|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
11161610|NCT03649204|Experimental|HY-PAD|"People in the HY-PAD group will participate in the clinical on-site therapist-supervised exercise (3 times/week for weeks 1-4).
~At the end of week 4, participants in the HY-PAD group will receive an updated home exercise prescription for the duration of the program (weeks 5-12), following the same principles as above. The therapist will call the participants once a week (15min/call) for weeks 5-12."
11161611|NCT03649204|No Intervention|Wait List Control (WLC)|Participants assigned to the WLC will continue their usual care for the next 12 weeks. After completion of the 3-month follow-up data gathering, WLC participants will be offered the clinical PAD walking program.
11161612|NCT03649191|Other|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
11161613|NCT03649191|Other|Control ACP Group|Control group Advance Care Planning
11161614|NCT03649178|Other|low salt diet|low-sodium diet (50mmol/24hours x 8 weeks ) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
11161615|NCT03649178|Other|high salt diet|high-sodium diet (200mmol/24hours x 8weeks) Subjects will choose a rotation of low-sodium meals from a predetermined list from a commercial vendor (Mom's Meals) that will be used to provide 2 meals (lunch and dinner)/day that the vendor will deliver at approximately 7 day intervals. Staff of the Vanderbilt Diet,Body Composition, and Human Metabolism Core determine breakfast and snacks appropriate for theHS andLS diets and provide instructions to subjects.
11161616|NCT03649165|Experimental|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
11161617|NCT03649165|Experimental|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
11161618|NCT03649165|Experimental|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
11161619|NCT03649165|Experimental|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
11161620|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
11161621|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
11161622|NCT03649139|Active Comparator|artemisia annua (sweet sagewort) allergen extract drops|Drug: sublingual immunotherapy drops
11161623|NCT03649139|Placebo Comparator|Placebo drops|Drug: sublingual placebo drops
11161624|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
11161625|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
11161626|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
11161627|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
11161628|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
11161629|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:
~Urological cancer Gynaecological cancer Gastro intestinal cancer"
11161630|NCT03649113|Experimental|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
11161631|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
11161632|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
11161633|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
11161634|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
11161635|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
11161636|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
11161637|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
11161638|NCT03649009|Placebo Comparator|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.
~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
11161639|NCT03649009|Active Comparator|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.
~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
11161640|NCT03648996|Experimental|Low-fructose diet, isocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.
11161641|NCT03648996|Experimental|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)
11161642|NCT03648996|Placebo Comparator|Placebo|Subjects assigned to this arm will receive placebo
11161643|NCT03648996|Experimental|Low-fructose diet, hypocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.
11161644|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
11161645|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
11161646|NCT03648970|Experimental|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
11161647|NCT03648970|No Intervention|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
11161827|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
11161648|NCT03648957|Experimental|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
11161649|NCT03648957|Active Comparator|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
11161650|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
11161651|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
11161652|NCT03648931||Pregnant or Breastfeeding Women|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
11161653|NCT03648931||Male Partners|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
11161654|NCT03648931||Grandmothers|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
11161655|NCT03648931||Key Informants|No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures.
11161656|NCT03648905|Active Comparator|Control patients (iatrogenic CAF)|Patients with iatrogenic chronic autonomic failure (CAF) (e.g., status-post cardiac transplantation, pre/post renal sympathetic ablation, pre/post bilateral thoracic sympathectomies)
11161657|NCT03648905|Active Comparator|Control patients (PD No OH)|Patients with Parkinson's disease (PD) without orthostatic hypotension (PD no OH)
11161658|NCT03648905|Active Comparator|Healthy Volunteers|Despiramine
11161659|NCT03648905|Active Comparator|Healthy Volunteers as Controls|Healthy Volunteers
11161660|NCT03648905|Experimental|Healthy Volunteers with genetic risk of PD|Healthy Volunteers with genetic risk of PD
11161661|NCT03648905|Experimental|Patients with neurodegenerative chronic autonomic failure (CAF|Includes patients with orthostatic hypotension (OH) due to sympathetic neurocirculatory failure (nOH), and people with multiple system atrophy (MSA).
11161662|NCT03648892|Other|1|Healthy Volunteers with a BMI greater than or equal to 18.5 kg/m^2 and less than 25 kg/m^2
11161663|NCT03648892|Other|2|Healthy Volunteers with a BMI greater than or equal to 25 kg/m^2 and less than 35 kg/m^2
11161664|NCT03648892|Other|3|Healthy Volunteers with a BMI greater than or equal to 35 kg/m^2
11161665|NCT03648879|Experimental|1/Arm 1|Upper white-light endoscopy and confocal endoscopic microscopy
11161666|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
11161667|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
11161668|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
11161669|NCT03648866||Patients|interview patients who have participated in compassion rounds
11161670|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
11161671|NCT03648853|Experimental|intervention|all participants receive the same intervention
11161672|NCT03648840|Other|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
11161673|NCT03648840|Other|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
11161674|NCT03648840|Other|Resting state connectivity|Some participants will also complete a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All participants in this Arm will have completed both of the iv alcohol self-administration sessions (Aversive cue, Neutral cue).
11161675|NCT03648827|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
11161676|NCT03648814|Experimental|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
11161677|NCT03648814|Experimental|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
11161678|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
11161679|NCT03648762|Other|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
11161680|NCT03648749|Experimental|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
11161681|NCT03648736||HOCM patients|selected for routine TASH procedure
11161682|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
11161683|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
11161684|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
11161717|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
11162522|NCT03643146|Experimental|Wedge 4- Step 2|
11161685|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
11161686|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
11161687|NCT03648697|Experimental|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.
~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
11161688|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
11161689|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
11161690|NCT03648684|No Intervention|Control|
11161691|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
11161692|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
11161693|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
11161694|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
11161695|NCT03648658|Experimental|Paracetamol 15mg/kg|
11161696|NCT03648645|Experimental|AH Telemonitoring|Self measurement of blood pressure
11161697|NCT03648645|Active Comparator|AH face-to-face follow up|Standard follow-up consultation in the hospital
11161698|NCT03648632|Experimental|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
11161699|NCT03648619|Other|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
11161700|NCT03648593|Experimental|behavioral|work recovery intervention
11161701|NCT03648593|Experimental|waiting list control|work recovery intervention after 6 months
11161702|NCT03648580|Experimental|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
11161703|NCT03648580|Other|Control group|just give the verbal nutrition education.
11161704|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
11161705|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
11161706|NCT03648541|Experimental|All Patients|1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
11161707|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
11161708|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
11161709|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.
~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
11161710|NCT03648502|Experimental|dementia (D-HI)|hearing impaired dementia
11161711|NCT03648502|Other|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
11161712|NCT03648502|Active Comparator|normal (N-HI)|normal cognition with hearing loss
11161713|NCT03648489|Active Comparator|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
11161714|NCT03648489|Experimental|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
11161715|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
11161716|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
11162046|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
11161718|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
11161719|NCT03648450||Hailie Smart Inhaler EMD|All enrolled participants will be given the Hailie Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
11161720|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
11161721|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
11161722|NCT03648437|Experimental|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
11161723|NCT03648437|Placebo Comparator|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
11161724|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
11161725|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
11161726|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
11161727|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
11161728|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
11161729|NCT03648385|Experimental|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
11161730|NCT03648385|Placebo Comparator|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
11161731|NCT03648372|Experimental|Dose Escalation and Cancer Treatment Expansions: TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 for 2 consecutive weeks, followed by 1 week rest in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. If TAK-981-related cumulative toxicity is observed or clinical safety, pharmacokinetics, and pharmacodynamics are supportive, the dosing schedule may be modified to evaluate a less intensive administration of TAK-981 on Days 1 and 8 in cycles of 21 days. Dose levels will be escalated based on the safety, and available PK and pharmacodynamics data. The dose expansion phase will evaluate the safety of TAK-981 at the selected MTD/BED from dose escalation phase in two cohorts of participants with solid tumors or lymphomas.
11161732|NCT03648372|Experimental|COVID-19 Expansion: TAK-981|"Covid-19 safety lead-in: TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1 and 4. The starting dose of TAK-981 will be 60 milligram (mg). The initial dosing schedule for COVID-19 expansion cohorts will be for a single cycle with TAK-981 administered on Days 1 and 4. If PK, pharmacodynamics, decrease in viral load and safety data are supportive, the schedule can be modified in Safety Lead-in. A ramp-up schedule of TAK-981, intravenously, administered as 60 minute-infusion, 40 mg on Day 1 and 60 mg on Day 4 may be evaluated.
~COVID-19 proof of concept: Once the Safety Lead-in is complete and a TAK-981 dose and regimen is selected by the Safety Monitoring Committee (SMC), the randomized COVID-19 proof of concept will begin with participants randomized to Arm A: COVID-19 standard of care (SOC), or Arm B: COVID-19 SOC + TAK-981."
11161733|NCT03648359|Other|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
11161734|NCT03648346|Experimental|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
11161735|NCT03648346|Experimental|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
11161736|NCT03648346|Placebo Comparator|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
11161737|NCT03648333|Experimental|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
11161738|NCT03648333|Active Comparator|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
11161739|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
11161740|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
11161741|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
11161742|NCT03648281||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
11161743|NCT03648268|Active Comparator|Active DLPFC rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC at 80% of active motor threshold.
11161744|NCT03648268|Sham Comparator|Sham DLPFC rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC
11161745|NCT03648268|Active Comparator|Active cerebellum rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum at 100% of active motor threshold.
11161746|NCT03648268|Sham Comparator|Sham cerebellum rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum
11161747|NCT03648242|Experimental|Interruptive Clinical Decision Support|
11162047|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
11161749|NCT03648229|Active Comparator|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
11161750|NCT03648229|Active Comparator|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
11161751|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
11161752|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
11161753|NCT03648203|Experimental|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
11161754|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.
~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
11161755|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
11161756|NCT03648177|Active Comparator|Treatment as Usual|"Active Comparator: (n=15) Treatment as Usual
~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
11161757|NCT03648177|Experimental|IPGT|"Experimental: IPGT (n=15) Integrated Psychosocial Group Treatment
~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
11161758|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
11161759|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
11161760|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
11161761|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
11161762|NCT03648125|Other|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :
~with artificial occlusal disturbance and
~without artificial occlusal disturbance"
11161763|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
11161764|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~These oat flakes were roasted at 150°C for 20 minutes.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
11161765|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
11161766|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.
~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
11161767|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.
~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
11161768|NCT03648099|Experimental|Labor Dance and music groups|"Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.
~The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
11161769|NCT03648099|No Intervention|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
11161770|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
11161771|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
11161772|NCT03648073|Experimental|Untreated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
11161773|NCT03648073|Experimental|Previously treated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
11161774|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
11161775|NCT03648047|Experimental|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
11161776|NCT03648047|Active Comparator|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
11161777|NCT03648034|Experimental|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
11161778|NCT03648034|Placebo Comparator|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
11161779|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
11161780|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
11161781|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
11161782|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
11161783|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
11161784|NCT03647995|Active Comparator|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
11161785|NCT03647995|Placebo Comparator|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
11161786|NCT03647982|Experimental|botulinum toxin 1U|
11161787|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
11161788|NCT03647982|Experimental|botulinum toxin 5U|
11161789|NCT03647982|Experimental|botulinum toxin 10U|
11161790|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
11161791|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
11161792|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab A1|"Nivolumab 240mg Flatdose i.v. d1 over 30 min every 2 weeks followed by Ipilimumab 1mg/kg i.v. d1 over 30 min every 6 weeks followed by FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
11161793|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab sequential A2|"3 cycles of induction chemotherapy with FOLFOX: FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks followed by immunotherapy consisting of: 4 administrations of Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks and 2 administrations of Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks
~Sequence as described may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision. After discontinuation of chemotherapy, immunotherapy will be continued consisting of:
~Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks until disease progression or inacceptable toxicity or end of study treatment."
11161794|NCT03647969|Active Comparator|mFOLFOX|FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
11161795|NCT03647956|Experimental|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
11161796|NCT03647943|Experimental|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
11161797|NCT03647943|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
11161798|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
11161799|NCT03647930|No Intervention|Control|No MPH
11161800|NCT03647917|Experimental|Platelet Rich Plasma, Left face and hands|"Subjects will receive PRP on left half of face and saline solution on right half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of left hand and saline solution on dorsal part of right hand through injections via filler injection technique. Microneedling will not be performed on the hands.
~Injections will take place every 4 weeks for a total of 3 treatments."
11161828|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
11161829|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
11161801|NCT03647917|Experimental|Platelet Rich Plasma, Right face and hands|"Subjects will receive PRP on right half of face and saline solution on left half of face through injections via filler injection technique followed by microneedling, and will also receive PRP on dorsal part of right hand and saline solution on dorsal part of left hand, through injections via filler injection technique. Microneedling will not be performed on the hands.
~Injections will take place every 4 weeks for a total of 3 treatments."
11161802|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
11161803|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
11161804|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.
~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
11161805|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
11161806|NCT03647865|Experimental|Patients need genioplasty|
11161807|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
11161808|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
11161809|NCT03647839|Experimental|Arm 1|Nivolumab and BNC105
11161810|NCT03647839|Experimental|Arm 2|Nivolumab and BBI-608
11161811|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.
~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
11161812|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.
~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
11161813|NCT03647813|Active Comparator|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
11161814|NCT03647813|Placebo Comparator|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
11161815|NCT03647800|Experimental|Dose Escalation|CD123 and CD3 epsilon bispecific antibody
11161816|NCT03647800|Experimental|Expanded Cohort (Phase 1b)|48 patients will receive the recommended dose of APVO436 determined from Phase 1.
11161817|NCT03647774|Experimental|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
11161818|NCT03647774|No Intervention|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
11161819|NCT03647761|No Intervention|Control|Standard of care
11161820|NCT03647761|Experimental|Treatment|Tetra-grip applied
11161821|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
11161822|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.
~Sham Device, or Placebo."
11161823|NCT03647735|Experimental|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
11161824|NCT03647735|Active Comparator|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
11161825|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
11161826|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
11161830|NCT03647683|Experimental|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
11161831|NCT03647683|Experimental|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
11161832|NCT03647683|Experimental|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
11161833|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
11161834|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
11161835|NCT03647657|Experimental|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
11161836|NCT03647657|Experimental|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
11161837|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
11161838|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
11161839|NCT03647631||Patients affected to porocarcinoma|
11161840|NCT03647631||patients affected to porocarcinoma in our centre|
11161841|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
11161842|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
11161843|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
11161844|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
11161845|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
11161846|NCT03647605|Experimental|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
11161847|NCT03647592||Cohorts 1|patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
11161848|NCT03647579|Active Comparator|midazolam plus ketamine|
11161849|NCT03647579|Active Comparator|dexmedetomidine plus ketamine|
11161850|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
11161851|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
11161852|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
11161853|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
11161854|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
11161855|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
11161856|NCT03647501|Active Comparator|3D-printed titanium cage|Subjects enrolled in this arm will have the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
11162048|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
11161857|NCT03647501|Active Comparator|Poly-ether-ether-ketone (PEEK) cage|Subjects enrolled in this arm will have the HonourTM poly-ether-ether-ketone (PEEK) cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
11161858|NCT03647488|Experimental|Capmatinib plus spartalizumab|Combination arm
11161859|NCT03647488|Active Comparator|Docetaxel|Comparator arm
11161860|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal will be evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
11161861|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.
~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
11161862|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
11161863|NCT03647449|Experimental|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
11161864|NCT03647449|Experimental|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
11161865|NCT03647449|Experimental|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
11161866|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.
~Intervention:
~Comprehensive Geriatric Assesment (CGA). Both groups.
~CGA includes measuring of:
~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
11161867|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission
~Intervention:
~Comprehensive Geriatric Assesment (CGA). Both groups.
~CGA includes measuring of:
~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
11161868|NCT03647423|Experimental|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
11161869|NCT03647423|Active Comparator|Controlled Arm - Radiation|SBRT
11161870|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
11161871|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
11161872|NCT03647397|Experimental|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
11161873|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
11161874|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
11161875|NCT03647371|Other|Macintosh laryngoscope|direct laryngoscope - laryngoscope with Macintosh blade
11161876|NCT03647371|Other|McGrath videolaryngoscope|McGrath Videolaryngoscope
11161901|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy. CML patients must meet the ELN criteria for warning and failure ) or have high SOKAL score (>0.8) or presence of additional chromosomal abnormalities (ACAs) and have detectable BCR-ABL levels. Ph+ALL patients need detectable BCR-ABL levels only.
11161902|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
11161903|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
11161877|NCT03647358|Experimental|Lesion Dosimetry With Iodine-124|Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In a set of 10 patients, consent will be sought to obtain additional PET/CT scans during the week of 131I therapy. In this study group, patients will receive an additional 4 to 7 mCi 124I tracer dose, alongside the 131I radioiodine therapy dose, for the purpose of imaging radioiodine lesional uptake during therapy. This will be the first study to compare the predicted lesion radiation absorbed doses in Gray derived from a pre-therapy test imaging dose to an imaging dose administered concomitant with 131I radioiodine therapy. Patients will be taken off-treatment on day 8, as days 9 and 10 are standard of care intervention. Subjects may remain on-study and be followed for up to 1.5 years with standard of care anatomical imaging, or until they receive their next standard of care anatomical imaging (PET, CT, MRI, ultrasound) or are deemed lost to follow up by the study doctor.
11161878|NCT03647345|Experimental|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
11161879|NCT03647345|Experimental|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
11161880|NCT03647345|Active Comparator|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
11161881|NCT03647332|Active Comparator|Cooled RFA treatment|
11161882|NCT03647332|Active Comparator|Steroid injection|
11161883|NCT03647319|Experimental|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
11161884|NCT03647319|Experimental|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
11161885|NCT03647319|Active Comparator|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.
~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
11161886|NCT03647306|Active Comparator|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
11161887|NCT03647306|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
11161888|NCT03647306|Experimental|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
11161889|NCT03647293|Active Comparator|Control Group|Neonates who underwent a peripherally inserted central catheter
11161890|NCT03647293|Active Comparator|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
11161891|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
11161892|NCT03647267|Active Comparator|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
11161893|NCT03647267|Placebo Comparator|Observation|Participants randomized to the observation group will receive a sham injection.
11161894|NCT03647254|Experimental|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
11161895|NCT03647254|No Intervention|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
11161896|NCT03647241|Experimental|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
11161897|NCT03647241|Experimental|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
11161898|NCT03647241|Active Comparator|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
11161899|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
11161900|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
11161904|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
11161905|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
11161906|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
11161907|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
11161908|NCT03647189|Experimental|Treatment Arm|Subjects will be treated with hybrid fractional laser
11161909|NCT03647189|Placebo Comparator|Control Arm|
11161910|NCT03647176|Active Comparator|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
11161911|NCT03647176|Experimental|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
11161912|NCT03647163|Experimental|Safety Run-in Dose Level 1|Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
11161913|NCT03647163|Experimental|Safety Run-in Dose Level 2|Patients with pembrolizumab refractory Head and Neck Squamous Cell Carcinoma (HNSCC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.7e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
11161914|NCT03647163|Experimental|Expansion HNSCC arm|Patients with pembrolizumab refractory Head and Neck Squamous Cell Carcinoma (HNSCC) will receive a single IV dose of 1.7e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
11161915|NCT03647163|Experimental|Expansion NSCLC arm|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.7e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
11161916|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
11161917|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
11161918|NCT03647137||Parkinson's disease with FoG|Subjects with Parkinson's disease that have freezing of gait (FoG) who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
11161919|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
11161920|NCT03647124||Lenalidomide treated R/R-MCL patients in Denmark and Sweden|Retrospective data collection for Lenalidomide treated R/R-MCL patients from Nordic registries and national health databases
11161921|NCT03647124||Lenalidomide treated R/R-MCL patients in the rest of EU|Retrospective data collection for Lenalidomide treated R/R-MCL patients from sites in the rest of European Union
11161922|NCT03647111||Cohorts 1|
11161923|NCT03647098||Cohorts 1|Treatment plan
11161924|NCT03647098||Cohorts 2|brain metastases
11161925|NCT03647098||Cohorts 3|Concomitant KRAS mutation
11161926|NCT03647085||Group 1 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, persistent atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
11161927|NCT03647085||Group 2 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, paroxysmal atrial fibrillation at the time of enrollment and are scheduled for an ablation or cardioversion.
11161928|NCT03647085||Group 3 Wearable Cardiac Monitor|Patients diagnosed with, and currently in, atrial flutter at the time of enrollment and are scheduled for an ablation or cardioversion.
11161929|NCT03647072|Active Comparator|CHOP|CHOP only
11161930|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
11161931|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
11161932|NCT03647059||LSCM examination|
11161933|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
11161934|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
11161935|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
11161936|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
11161937|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
11161938|NCT03646994||Cohorts 1|ROS1 fusion positive NSCLC patients who received crizotinib
11162043|NCT03646201|No Intervention|Control Group|Data are collected at baseline and post intervention session.
11161939|NCT03646968|Experimental|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
11161940|NCT03646955|Active Comparator|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
11161941|NCT03646955|No Intervention|No partial breast irradiation|No radiation therapy
11161942|NCT03646942|Active Comparator|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
11161943|NCT03646942|Experimental|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
11161944|NCT03646929|Other|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
11161945|NCT03646929|Other|patients with multiple sclerosis|MEP in patients with multiple sclerosis are measured using modified facilitation technique
11161946|NCT03646916|Active Comparator|Dexamethasone|
11161947|NCT03646916|No Intervention|Non-treatment|
11161948|NCT03646903|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
11161949|NCT03646903|Placebo Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
11161950|NCT03646903|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
11161951|NCT03646877|Experimental|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
11161952|NCT03646877|Placebo Comparator|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
11161953|NCT03646864|Experimental|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
11161954|NCT03646864|Placebo Comparator|Treatment B|Placebo from Day 1 to Day 5 of Period B
11161955|NCT03646851|Experimental|COPD|COPD patients GOLD stage III and IV
11161956|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
11161957|NCT03646812|Other|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
11161958|NCT03646812|Other|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
11161959|NCT03646812|Other|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
11161960|NCT03646812|Experimental|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
11161961|NCT03646812|Experimental|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
11161962|NCT03646812|Experimental|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
11161963|NCT03646812|Experimental|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
11161964|NCT03646812|Experimental|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
11161965|NCT03646812|Experimental|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
11161966|NCT03646799|Experimental|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
11161967|NCT03646799|Experimental|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
11161968|NCT03646786|Experimental|visually impaired patients|
11161969|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
11161970|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
11161971|NCT03646747|Experimental|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.
~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
11161972|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
11161973|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
11161974|NCT03646721|Experimental|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
11161975|NCT03646721|Placebo Comparator|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
11161976|NCT03646721|Experimental|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
11162044|NCT03646188|Placebo Comparator|Placebo-containing MNA|Placebo
11161977|NCT03646721|Placebo Comparator|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
11161978|NCT03646721|Active Comparator|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
11161979|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
11161980|NCT03646695|Experimental|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
11161981|NCT03646695|Active Comparator|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
11161982|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
11161983|NCT03646682|Active Comparator|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
11161984|NCT03646669|Experimental|Asthma education and PEF feedback|Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
11161985|NCT03646669|Placebo Comparator|Asthma education|No PEF feedback arm
11161986|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
11161987|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
11161988|NCT03646643|Active Comparator|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
11161989|NCT03646643|Active Comparator|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
11161990|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
11161991|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
11161992|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks until disease progression.
11161993|NCT03646617|Experimental|HFRT|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
11161994|NCT03646604|Experimental|Cohort 1|Study participants, 6 to <12 years of age, receiving low dose of upadacitinib
11161995|NCT03646604|Experimental|Cohort 2|Study participants, 6 to <12 years of age, receiving high dose of upadacitinib
11161996|NCT03646604|Experimental|Cohort 3|Study participants, 2 to <6 years of age, receiving low dose of upadacitinib
11161997|NCT03646604|Experimental|Cohort 4|Study participants, 2 to <6 years of age, receiving high dose of upadacitinib
11161998|NCT03646604|Experimental|Cohort 5|Study participants, 6 months to <2 years of age, receiving low dose of upadacitinib
11161999|NCT03646604|Experimental|Cohort 6|Study participants, 6 months to <2 years of age, receiving high dose of upadacitinib
11162000|NCT03646591||Neoadjuvant chemotherapy|"FLOT Chemotherapy regimen
~A cycle consist of Day 1: 5-fluorouracil (5-FU) 2600mg/M2 intravenous Via peripherally inserted central catheter (PICC) for 24 hour Day 1: Leucovorin 200mg/M2 intravenous Day 1: Oxaliplatin 85mg/ M2 intravenous Day 1: Docetaxel 50mg/M2 intravenous Repeated every 15th day"
11162001|NCT03646552|Experimental|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
11162002|NCT03646539|Experimental|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
11162003|NCT03646539|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
11162004|NCT03646526|Experimental|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .
~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
11162005|NCT03646526|Experimental|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.
~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
11162006|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
11162007|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
11162008|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
11162009|NCT03646487|Experimental|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
11162010|NCT03646487|Placebo Comparator|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
11162011|NCT03646474|Active Comparator|tranexamic acid group|
11162012|NCT03646474|Placebo Comparator|placebo group|
11162013|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
11162014|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
11162015|NCT03646448|Experimental|Intervention group|Counseling based on Motivational Interviewing and elements of Cognitive Behavioral Therapy
11162016|NCT03646448|No Intervention|Control group|Control group receiving a booklet on problematic Internet use
11162017|NCT03646435|Experimental|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
11162018|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients > 18 years with esophageal cancer receiving neoadjuvant chemotherapy
11162019|NCT03646396|Experimental|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
11162020|NCT03646383|Experimental|Treatment with radiofrequency|Treatment of symptomatic benign nodules with radiofrequency ablation as an alternative to surgical treatment
11162021|NCT03646357|Active Comparator|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
11162022|NCT03646357|Experimental|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
11162023|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
11162024|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
11162025|NCT03646331|Experimental|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
11162026|NCT03646331|Experimental|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
11162027|NCT03646318|Experimental|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent [Dabire 1990]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
11162028|NCT03646318|Placebo Comparator|Placebo|The placebo is a standard glucose 5% solution.
11162029|NCT03646305|Experimental|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
11162030|NCT03646305|Experimental|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
11162031|NCT03646305|No Intervention|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
11162032|NCT03646305|No Intervention|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
11162033|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
11162034|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
11162035|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
11162036|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
11162037|NCT03646266|No Intervention|Control|Standard of care
11162038|NCT03646253||Patients with proximal humerus fracture|
11162039|NCT03646240|Experimental|Dosing arm|
11162040|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
11162041|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
11162042|NCT03646201|Experimental|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
11162049|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
11162050|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
11162051|NCT03646162|Experimental|Veru-944 10 mg|Veru-944 10 mg daily
11162052|NCT03646162|Experimental|Veru-944 50 mg|Veru-944 50 mg daily
11162053|NCT03646162|Experimental|Veru-944 100 mg|Veru-944 100mg daily
11162054|NCT03646162|Placebo Comparator|Placebo|Placebo daily
11162055|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
11162056|NCT03646149||Control Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and not participating in a Housing Skills Training Group due to limited staff resources.
11162057|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
11162058|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
11162059|NCT03646123|Experimental|Part A: A+AVD|Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
11162060|NCT03646123|Experimental|Part B: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
11162061|NCT03646123|Experimental|Part C: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
11162062|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
11162063|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
11162064|NCT03646097|Active Comparator|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
11162065|NCT03646097|Active Comparator|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
11162066|NCT03646097|Experimental|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
11162067|NCT03646084|Experimental|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
11162068|NCT03646084|Active Comparator|Control|Rehabilitation according to current clinical practice.
11162069|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
11162070|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
11162071|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
11162072|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
11162073|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
11162074|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
11162075|NCT03646045||Control|Preterm infants receiving gastric feeding
11162076|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
11162077|NCT03646032|Active Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
11162078|NCT03646019||Normal coronary arteries|
11162079|NCT03646019||Non significant coronary artery disease|
11162080|NCT03646019||Significant coronary artery disease|
11162081|NCT03646006|Experimental|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
11162082|NCT03646006|Sham Comparator|Sham block|10 mL normal saline
11162083|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
11162084|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
11162085|NCT03645980|Experimental|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
11162139|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
11162086|NCT03645980|Experimental|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
11162087|NCT03645967|Other|ReadyCleanse for IUC|ReadyCleanse Cloths will be used for the standard of care for indwelling urinary catheter care and maintenance. The old standard of care will no longer be used.
11162088|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
11162089|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.
~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.
~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
11162090|NCT03645941|No Intervention|Quitline/Treatment Referral|•Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)
11162091|NCT03645941|Experimental|Facebook+Quitline/Treatment Referral|"Participants join a secret/private, culturally relevant Facebook group moderated by an AN tobacco research counselor for 3 months
~Once daily moderator postings for 30 days, repeated each month for 3 months; plus 3-4 daily check-ins/postings to respond to participant generated content and encourage sharing of personal stories/experiences relevant to all stages of the quitting process and treatment engagement
~Description of tobacco treatment services, phone numbers and web links sent via postal mail (printed materials) and email. Treatment options provide free, professional assistance based on U.S. clinical practice guidelines: (1)AK quitline, (2)regional tribal tobacco cessation programs, and (3)smokefree.gov resources (e.g., free texting program and smartphone application, quit guide)"
11162092|NCT03645928|Experimental|Cohort 1A|TIL LN-144 therapy in combination with pembrolizumab in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma (MM) with ≤ 3 prior lines of systemic therapy, excluding immune checkpoint inhibitor (CPI) therapy.
11162093|NCT03645928|Experimental|Cohort 1B|TIL LN-145-S1 therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or MM, who have previously received systemic therapy with a PD-1 blocking antibody prior systemic therapy. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor or BRAF inhibitor in combination with a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.
11162094|NCT03645928|Experimental|Cohort 2A|TIL LN-145 therapy in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding CPIs.
11162095|NCT03645928|Experimental|Cohort 3A|TIL LN-145 therapy in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III-IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding CPIs.
11162096|NCT03645928|Experimental|Cohort 3B|TIL LN-145 therapy as a single agent in NSCLC, (Stage III-IV), who have previously received 1-3 lines of prior systemic therapy.
11162097|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
11162098|NCT03645889|Experimental|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
11162099|NCT03645889|Placebo Comparator|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
11162100|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
11162101|NCT03645863|Experimental|Cohort 1|Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.
11162102|NCT03645863|Experimental|Cohort 2|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.
11162103|NCT03645863|Experimental|Cohort 3|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.
11162104|NCT03645850|Experimental|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
11162105|NCT03645850|Active Comparator|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
11162106|NCT03645837|Experimental|10 minutes|Compression clamp release start after 10 minutes
11162107|NCT03645837|Experimental|20 minutes|Compression clamp release start after 20 minutes
11162108|NCT03645837|Active Comparator|30 minutes|Compression clamp release start after 30 minutes
11162109|NCT03645824|Experimental|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
11162140|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
11162141|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
11162110|NCT03645811|Experimental|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
11162111|NCT03645811|Experimental|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.
~The content of each EFT session was as follows:
~Preparation
~Tapping Series
~The Nine Gamut Sequence and Eye Movements"
11162112|NCT03645811|No Intervention|Control|For the control group, 15 minutes of free time was given.
11162113|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
11162114|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
11162115|NCT03645785|Active Comparator|Normal drinking habits|Normal fluid intake without True lemon
11162116|NCT03645785|Experimental|Increased fluid Intake|Double fluid intake plus 3 bottles of water with True Lemon
11162117|NCT03645772|Experimental|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
11162118|NCT03645772|Active Comparator|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
11162119|NCT03645772|Active Comparator|Walking|12-week progressive walking program.
11162120|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
11162121|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
11162122|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
11162123|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
11162124|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
11162125|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
11162126|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
11162127|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
11162128|NCT03645746|Experimental|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
11162129|NCT03645733|No Intervention|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
11162130|NCT03645733|Experimental|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
11162131|NCT03645733|No Intervention|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
11162132|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
11162133|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
11162134|NCT03645707|Experimental|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.
~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
11162135|NCT03645694|Experimental|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
11162136|NCT03645694|No Intervention|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
11162137|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
11162138|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
11162523|NCT03643146|Experimental|Wedge 4-Step 3|
11162142|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
11162143|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
11162144|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
11162145|NCT03645629|Active Comparator|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
11162146|NCT03645629|Active Comparator|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
11162147|NCT03645629|Active Comparator|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
11162148|NCT03645616|Experimental|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
11162149|NCT03645603|Experimental|Dexmedetomidine|Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
11162150|NCT03645603|Placebo Comparator|Placebo|saline solution for IV infusion. The administration of infusion will follow the experimental drug.
11162151|NCT03645590|Experimental|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
11162152|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
11162153|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
11162154|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
11162155|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
11162156|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
11162157|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
11162158|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
11162159|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
11162160|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
11162161|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
11162162|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
11162163|NCT03645499|Experimental|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
11162164|NCT03645499|Experimental|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
11162165|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
11162166|NCT03645473|Experimental|Monarch device settings assessment group|"Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.
~The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures."
11162167|NCT03645460|Experimental|TYF-ADA-modified autologous stem cells|Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene
11162168|NCT03645447|Experimental|Taste test|Participants will be presented with a series of tastants of 4 different modalities (sweet, salt, sour, bitter) of 9 different concentrations in pseudo-random order. The threshold at which each participant reliably identifies the taste is determined for each tastant. Mood Questionnaires will be used to determine whether a participant is clinically depressed.
11162169|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
11162170|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:
~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
11162252|NCT03645005|Experimental|My Guide (psychoeducation & self-management program)|
11162253|NCT03645005|Active Comparator|My Health (health education program)|
11162524|NCT03643146|Experimental|Wedge 4-Step 4|
11162171|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:
~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
11162172|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
11162173|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.
~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
11162174|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:
~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®
~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.
~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
11162175|NCT03645421|Placebo Comparator|placebo|Placebo per day,SC injection on 48 days.
11162176|NCT03645421|Experimental|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
11162177|NCT03645421|Experimental|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
11162178|NCT03645421|Experimental|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
11162179|NCT03645408|Experimental|Exenatide injection|Subjects in this arm will receive a 5 mcg dose of immediate release exenatide on the day of the alcohol challenge. The 5mcg dose of exenatide is approved as the first dose to be administered to patients at the start of their treatment with this drug for FDA-approved indications.
11162180|NCT03645408|Placebo Comparator|Placebo|Subjects in this arm will receive a sham injection on the day of the alcohol challenge. The sham injection will be a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects will sense this volume of fluid (or lack thereof) during the injection. Subjects will be shielded from seeing the injection to maintain the blind.
11162181|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
11162182|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
11162183|NCT03645395|Experimental|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
11162184|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
11162185|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
11162186|NCT03645382|Placebo Comparator|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
11162187|NCT03645382|Experimental|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
11162188|NCT03645369|Experimental|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
11162189|NCT03645369|Experimental|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
11162190|NCT03645369|No Intervention|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
11162191|NCT03645356|Active Comparator|fixed appliances|patients will be treated using fixed appliances in order to align their teeth after extraction of four premolars
11162192|NCT03645356|Experimental|clear aligners|patients will be treated using clear aligners in order to align their teeth after extraction of four premolars
11162193|NCT03645343|Active Comparator|Activator|Patients will be treated using the Activator appliance for one and a half year
11162194|NCT03645343|Experimental|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
11162195|NCT03645343|No Intervention|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
11162196|NCT03645317|Other|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
11162197|NCT03645304|Experimental|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
11162254|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
11162255|NCT03644979|Experimental|Skydiving|Tandem skydiving
11162198|NCT03645304|Placebo Comparator|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
11162199|NCT03645291|Active Comparator|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
11162200|NCT03645291|Sham Comparator|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
11162201|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
11162202|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
11162203|NCT03645265|Experimental|Gestures|Use of hand gestures to improve speech rhythm and speech production
11162204|NCT03645265|Experimental|Auditory|Use of auditory cues to improve speech rhythm and speech production
11162205|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
11162206|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
11162207|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
11162208|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
11162209|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
11162210|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
11162211|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above
~Being capable of giving informed consent for participation of the study
~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.
~Onset of PD symptoms of < 3years
~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
11162212|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects
~Chinese aged 50 or above
~Being capable of giving informed consent for participation of the study
~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
11162213|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;
~Age-and sex-matched with PD subjects
~Chinese aged 50 or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Not cohabiting with proband"
11162214|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;
~Chinese aged 50 or above;
~Being capable of giving informed consent for participation of the study;
~Without a personal history or a family history of PD or RBD;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Absence of RSWA as measured by v-PSG."
11162215|NCT03645226||Spouses of patients with iRBD|"Spouses of patients with iRBD;
~Age-and sex-matched with PD subjects;
~Chinese aged 50 or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Cohabiting with proband."
11162216|NCT03645226||First degree relatives of healthy controls|"First degree relatives of healthy controls;
~Age-and sex-matched with PD subjects;
~Chinese aged 50 or above ;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;"
11162217|NCT03645226||Spouses of healthy controls|"Spouses of healthy controls;
~Age-and sex-matched with PD subjects;
~Chinese aged 50 or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;
~Cohabiting with proband."
11162218|NCT03645213|Experimental|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
11162219|NCT03645213|Experimental|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
11162220|NCT03645213|No Intervention|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
11162221|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.
~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
11162222|NCT03645187|Active Comparator|FOLFOX|FOLFOX regien
11162223|NCT03645187|Active Comparator|Folfox and celecoxib|Folfox and celecoxib
11162224|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
11162225|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
11162226|NCT03645161|Active Comparator|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
11162227|NCT03645161|Active Comparator|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
11162228|NCT03645148|Experimental|iNeo-Vac-P01|"Personal Cancer Vaccine: iNeo-Vac-P01 (peptides)+ GM-CSF;
~Peptides: 4 x 100 mcg per peptide given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses;
~GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 78, and 162 for a total of 7 doses"
11162229|NCT03645135|No Intervention|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
11162230|NCT03645135|Experimental|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
11162231|NCT03645122|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneurlonal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be invited to participate.
11162232|NCT03645122|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
11162233|NCT03645109|Experimental|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
11162234|NCT03645109|Placebo Comparator|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
11162235|NCT03645096|Experimental|Pregnenolone 500 > Pregnenolone 800 > Placebo|"3 exposures in order:
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days."
11162236|NCT03645096|Experimental|Pregnenolone 500 > Placebo > Pregnenolone 800|"3 exposures in order:
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
11162237|NCT03645096|Experimental|Pregnenolone 800 > Pregnenolone 500 > Placebo|"3 exposures in order:
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days."
11162238|NCT03645096|Experimental|Pregnenolone 800 > Placebo > Pregnenolone 500|"3 exposures in order:
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
11162239|NCT03645096|Experimental|Placebo > Pregnenolone 500 > Pregnenolone 800|"3 exposures in order:
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days."
11162240|NCT03645096|Experimental|Placebo > Pregnenolone 800 > Pregnenolone 500|"3 exposures in order:
~Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
~Pregnenolone 500 mg capsule by mouth, daily for 7 days."
11162241|NCT03645083|Experimental|Telephone call|Participants receive a telephone call reminder three days after their initial visit
11162242|NCT03645083|Experimental|Text message|Participants receive a text message reminder three days after their initial visit
11162243|NCT03645083|No Intervention|Control|Participants do not receive any intervention after their initial visit
11162244|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
11162245|NCT03645070|Active Comparator|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
11162246|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
11162247|NCT03645057|Experimental|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
11162248|NCT03645057|Active Comparator|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
11162249|NCT03645031|Experimental|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
11162250|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
11162251|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.
~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
11162257|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
11162258|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
11162259|NCT03644953|Experimental|Hydroxyurea and Transfusion (HAT)|Combination hydroxyurea and simple chronic transfusion therapy
11162260|NCT03644940|Experimental|Subpopulation-specific Algorithm|
11162261|NCT03644940|No Intervention|Control Algorithm|
11162262|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual.."
11162263|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
11162264|NCT03644914|Experimental|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
11162265|NCT03644914|No Intervention|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
11162266|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
11162267|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
11162268|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
11162269|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
11162270|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
11162271|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
11162272|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
11162273|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
11162274|NCT03644849|Sham Comparator|Sham laser intervention group|
11162275|NCT03644836|Experimental|Retraining with respiratory effort+ amino acids|
11162276|NCT03644836|Placebo Comparator|Retraining with respiratory effort+ placebo|
11162277|NCT03644823|Experimental|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
11162278|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed
~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
11162279|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale
~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
11162280|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
11162281|NCT03644784||Yamaguchi University Hospital|
11162282|NCT03644784||Erasmus Medical Center|
11162283|NCT03644784||Academic Medical Center - Amsterdam|
11162284|NCT03644784||Segeberger Kliniken Gruppe|
11162285|NCT03644784||McGill University - Montreal|
11162286|NCT03644758||professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
11162287|NCT03644745|Experimental|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
11162288|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
11162289|NCT03644719|Experimental|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
11162290|NCT03644719|No Intervention|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
11162291|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
11162292|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
11162293|NCT03644693|Experimental|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
11162294|NCT03644693|Placebo Comparator|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
11162295|NCT03644680|Experimental|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
11162296|NCT03644680|Placebo Comparator|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
11162297|NCT03644667|Experimental|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.
~Standard of care triple maintenance immunosuppression includes:
~a calcineurin inhibitor (tacrolimus),
~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and
~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.
~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
11162298|NCT03644667|Placebo Comparator|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.
~Standard of care triple maintenance immunosuppression includes:
~a calcineurin inhibitor (tacrolimus),
~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and
~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.
~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
11162299|NCT03644654|Active Comparator|Standard care group|Fluid management will be done according standard care
11162300|NCT03644654|Experimental|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
11162301|NCT03644641|Experimental|Desflurane Group|Induction and anesthesia will be held by using desflurane
11162302|NCT03644641|Experimental|Propofol Group|Induction and anesthesia will be held by using target-control anesthesia with propofol
11162303|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
11162304|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
11162305|NCT03644615|Experimental|Mindfluness and usual care|
11162306|NCT03644615|Other|Usual Care|
11162307|NCT03644602|Active Comparator|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI <150), and with Ulcerative colitis in clinical remission (defined in the presence of <3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.
~The low FODMAPs diet was administered for 3 months."
11162308|NCT03644602|Active Comparator|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
11162309|NCT03644602|Active Comparator|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
11162310|NCT03644589|Experimental|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).
~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
11162311|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
11162312|NCT03644576|Placebo Comparator|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
11162313|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
11162314|NCT03644550|Experimental|1/LMB- 100+pembrolizumab|LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles
11162315|NCT03644537|Other|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
11162316|NCT03644537|Other|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
11162317|NCT03644537|Other|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
11162471|NCT03643367|Active Comparator|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
11162318|NCT03644524|Experimental|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, ~4-5 weeks), and post (after all 30 heat sessions; ~8-10 weeks).
11162319|NCT03644524|No Intervention|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
11162320|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
11162321|NCT03644498||Adults treated with a CPI therapy for cancer|
11162322|NCT03644485|Experimental|Standard Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 1 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
11162323|NCT03644485|Experimental|Delayed Prograf group|Participants will receive induction therapy, tacrolimus immediate-release formulation (Prograf) from Day 3 - 5 after kidney transplant surgery to Month 1 and convert to tacrolimus prolonged-release formulation (Advagraf) up to Month 6.
11162324|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
11162325|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
11162326|NCT03644459|Experimental|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
11162327|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
11162328|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
11162329|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
11162330|NCT03644433|Placebo Comparator|Single layer|Single layer closure
11162331|NCT03644433|Active Comparator|Double layer with resection|Double layer closure after resection uterine scar
11162332|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:
~Clinical evaluation
~Radiographic assessment of osteoarthritis
~Magnetic resonance imaging (MRI)
~Histological evaluation of the surgical piece"
11162333|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
11162334|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
11162335|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
11162336|NCT03644355|Experimental|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
11162337|NCT03644355|Active Comparator|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
11162338|NCT03644355|Active Comparator|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
11162339|NCT03644355|No Intervention|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
11162340|NCT03644342|Experimental|Niraparib Arm|For the purposes of this study, two dose levels of Niraparib (100 mg and 200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
11162341|NCT03644329|Other|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
11162342|NCT03644329|Experimental|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
11162343|NCT03644329|Experimental|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
11162344|NCT03644329|Experimental|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
11162345|NCT03644316|Experimental|BandGrip|Topical skin closure device
11162346|NCT03644303|Experimental|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
11162347|NCT03644290|Experimental|Cognitive training|Semantic categorization training sessions
11162348|NCT03644290|Active Comparator|Control condition|Five sessions of behavioral control condition with information and education
11162403|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
11162349|NCT03644277|Experimental|Massed practice training with dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
11162350|NCT03644277|Experimental|Massed practice training with Sham dAIH|"Seek to address gross upper extremity movements, grip and pinch strength, and coordination.The ultimate goal of the session is to achieve a total of 300 repetitions during training.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
11162351|NCT03644277|Experimental|Rapael glove with dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
11162352|NCT03644277|Active Comparator|Rapael glove with Sham dAIH|"The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement, hand function, and dexterity. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. The number of total repetitions and activity outcomes will be recorded.
~Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%."
11162353|NCT03644277|Placebo Comparator|No training with dAIH|"Once fitted with the mask, initial recordings of heart rate, blood pressure, and arterial oxygen saturation (SpO2) will be taken. The sequence of hypoxia will consist of 60- 90 seconds of 9-10% O2 (FiO2 0.09), alternating with 60- 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes, to maintain SpO2 at 80-90%.
~Hearth rate and pulse oximetry will be continuously monitored throughout, and recording will be taken at each alteration in sequence. Blood pressure will be taken upon completion of the total sequence"
11162354|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
11162355|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
11162356|NCT03644251|Experimental|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
11162357|NCT03644251|Experimental|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
11162358|NCT03644251|Experimental|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
11162359|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
11162360|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
11162361|NCT03644225|Other|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
11162362|NCT03644225|Other|Systemic sclerosis patients|"SSc patients who signed an Informed consent
~Age ≥18 years old
~Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria
~Skin thickening diagnosed by clinical expert"
11162363|NCT03644212|Active Comparator|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
11162364|NCT03644212|No Intervention|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
11162365|NCT03644199|Other|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
11162366|NCT03644199|Other|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
11162367|NCT03644186|Active Comparator|Paclitaxel plus trastuzumab and pertuzumab|Receiving paclitaxel 80mg/m2 i.v. on day 1, 8, 15 every 28 days for 4 cycles, trastuzumab 600mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for a total of 5 doses.
11162368|NCT03644186|Experimental|Palbociclib plus letrozole plus trastuzumab and pertuzumab|Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
11162435|NCT03643666|Active Comparator|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
11162506|NCT03643146|Experimental|Wedge 1- Step 1|
11162507|NCT03643146|Experimental|Wedge 1-Step 2|
11162508|NCT03643146|Experimental|Wedge 1-Step 3|
11162369|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 7 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 7 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
11162370|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
11162371|NCT03644147|Experimental|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
11162372|NCT03644147|No Intervention|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
11162373|NCT03644134|Experimental|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
11162374|NCT03644134|No Intervention|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
11162375|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
11162376|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
11162377|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
11162378|NCT03644082|Experimental|Epilepsy Patients|
11162379|NCT03644069|Experimental|Nexvax2|
11162380|NCT03644069|Placebo Comparator|Placebo|
11162381|NCT03644056|Experimental|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
11162382|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
11162383|NCT03644017|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
11162384|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
11162385|NCT03643991|Experimental|Weighted Blanket Cohort|First 15 subjects enrolled have access to sleep with weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
11162386|NCT03643991|No Intervention|Control Cohort|Last 15 subjects enrolled receive treatment as usual while inpatient.
11162387|NCT03643978|Experimental|Decision Aid Group|These patients review a decision aid.
11162388|NCT03643978|No Intervention|Control Group|These patients do not review a decision aid.
11162389|NCT03643965|Experimental|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
11162390|NCT03643965|Placebo Comparator|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
11162391|NCT03643952|Experimental|Daptomycin-cSSTI or Bacteremia: Age 1-17|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours (q24hrs) for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
11162392|NCT03643939|Experimental|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
11162393|NCT03643939|Active Comparator|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
11162394|NCT03643926|Experimental|Arthroscopic Brostrom|
11162395|NCT03643926|Active Comparator|Open Brostrom|
11162396|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.
~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.
~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
11162397|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
11162398|NCT03643900|Experimental|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
11162399|NCT03643900|Active Comparator|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
11162400|NCT03643887|Experimental|FMT Capsule DE|FMT Capsule DE
11162401|NCT03643887|Placebo Comparator|Placebo Oral Capsule|Placebo Capsule
11162402|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
11162436|NCT03643666|Active Comparator|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
11162404|NCT03643861|Experimental|5 Fraction Breast Stereotactic Body Radiation Therapy|This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fraction stereotactic body radiation therapy at a dose of 30 gy for treatment. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
11162405|NCT03643848|Experimental|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
11162406|NCT03643848|Sham Comparator|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
11162407|NCT03643835|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
11162408|NCT03643835|Active Comparator|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
11162409|NCT03643835|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
11162410|NCT03643822|Active Comparator|Dexamethasone vs. Control comparison|Freezing + dexamethasone(4mg)+1 ml of saline
11162411|NCT03643822|Active Comparator|Dexmedetomidine vs. Control comparison|Freezing + dexmedetomidine(50ug) + 1.5 ml of saline
11162412|NCT03643822|Active Comparator|Dexamethasone and Dexmedetomidine|Freezing+dexamethasone(4mg)+dexmedetomidine(50ug) + 0.5 ml of saline
11162413|NCT03643822|Sham Comparator|Control Group-Placebo|Freezing + 2ml saline
11162414|NCT03643796|Active Comparator|Remifentanil Group|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
11162415|NCT03643796|Active Comparator|Ketamine and Dexmedetomidine group|"dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
~Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation."
11162416|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
11162417|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
11162418|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
11162419|NCT03643770|Active Comparator|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
11162420|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
11162421|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
11162422|NCT03643757|Active Comparator|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
11162423|NCT03643757|Active Comparator|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
11162424|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
11162425|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
11162426|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
11162427|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
11162428|NCT03643731|Experimental|HeatTens|"After baseline measurements and during 4 weeks of follow up
~Composition and dosing of the device:
~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
11162429|NCT03643731|No Intervention|Control group|No intervention
11162430|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
11162431|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
11162432|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
11162433|NCT03643679|Experimental|Kwit smartphone app|This arm will receive the Kwit smartphone app.
11162434|NCT03643666|Placebo Comparator|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
11162470|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
11162437|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
11162438|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
11162439|NCT03643627|Placebo Comparator|Placebo|
11162440|NCT03643627|Experimental|1 mg/kg|
11162441|NCT03643627|Experimental|3 mg/kg|
11162442|NCT03643627|Experimental|10 mg/kg|
11162443|NCT03643627|Experimental|30 mg/kg|
11162444|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
11162445|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
11162446|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
11162447|NCT03643588|Experimental|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
11162448|NCT03643588|Active Comparator|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
11162449|NCT03643575|Experimental|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
11162450|NCT03643575|Experimental|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
11162451|NCT03643575|Experimental|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
11162452|NCT03643562|Experimental|Adrabetadex|Participants receive prescribed adrabetadex by intra-thecal injection
11162453|NCT03643549|Experimental|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
11162454|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
11162455|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
11162456|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
11162457|NCT03643510|Experimental|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
11162458|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
11162459|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
11162460|NCT03643445|Experimental|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
11162461|NCT03643445|Active Comparator|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
11162462|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
11162463|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
11162464|NCT03643419|Sham Comparator|Laminectomy|
11162465|NCT03643419|Experimental|Laminectomy & Irradiation|
11162466|NCT03643406|Experimental|Mental Fatigue Condition|
11162467|NCT03643406|Placebo Comparator|Control Condition|
11162468|NCT03643393|Other|incarceration rectal prolapse|
11162469|NCT03643380|Experimental|Investigational SNS device|
11162472|NCT03643354|Experimental|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
11162473|NCT03643341|Experimental|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
11162474|NCT03643341|No Intervention|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
11162475|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
11162476|NCT03643315|Experimental|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
11162477|NCT03643315|Experimental|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
11162478|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
11162479|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
11162480|NCT03643289||Cohort A|Patients with stage 4 melanoma due to commence immunotherapy. Patients should be naïve to immunotherapy.
11162481|NCT03643289||Cohort B|Patients with stage 3 melanoma who are naïve to immunotherapy
11162482|NCT03643276|Active Comparator|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)
~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]
~Erwinase is given in case of allergy to pegaspargase."
11162483|NCT03643276|Experimental|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]
~Erwinase is given in case of allergy to pegaspargase."
11162484|NCT03643276|Experimental|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
11162485|NCT03643276|Experimental|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX
~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)
~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
11162486|NCT03643276|Active Comparator|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms
~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX
~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide
~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX
~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)."
11162487|NCT03643276|Experimental|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide
~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
11162509|NCT03643146|Experimental|Wedge 1-Step 4|
11162510|NCT03643146|Experimental|Wedge 1-Step 5|
11162511|NCT03643146|Experimental|Wedge 2- Step 1|
11162488|NCT03643276|Experimental|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms
~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX
~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)
~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX
~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
11162489|NCT03643276|Experimental|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms
~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)
~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)
~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
11162490|NCT03643276|Other|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
11162491|NCT03643276|Active Comparator|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM
~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR
~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
11162492|NCT03643276|Experimental|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM
~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR
~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
11162493|NCT03643276|Other|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX
~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX
~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
~Erwinase is given in case of allergy to pegaspargase."
11162494|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
11162495|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
11162496|NCT03643250|Experimental|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
11162497|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
11162498|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
11162499|NCT03643237|Experimental|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
11162500|NCT03643237|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
11162501|NCT03643224|Experimental|Experimental|Radiofrequency Ablation. Catheter ablation to treat persistent atrial fibrillation using temperature-controlled ablation catheter
11162502|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
11162503|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
11162504|NCT03643159|Experimental|Abilify MyCite|Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
11162505|NCT03643159|Active Comparator|Virtual Matched Controls|Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.
11162525|NCT03643146|Experimental|Wedge 4-Step 5|
11162526|NCT03643133|Active Comparator|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :
~M-API regimen (≤25 years) :
~Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2
~EI regimen (26-50 years) :
~Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4"
11162527|NCT03643133|Experimental|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
11162528|NCT03643120|Other|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
11162529|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.
~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
11162530|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
11162531|NCT03643081|Experimental|"use of camera Fluobeam"|
11162532|NCT03643081|No Intervention|"Without use of the camera Fluobeam"|
11162533|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
11162534|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
11162535|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
11162536|NCT03643042|Experimental|Restrictive group|Transfusion with: Hb < 80g/L and Hb maintain between 80 and 100g/L
11162537|NCT03643042|Experimental|Liberal group|Transfusion with: Hb < 100g/L and Hb maintain between 100 and 120g/L
11162538|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
11162539|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
11162540|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
11162541|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
11162542|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
11162543|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
11162544|NCT03642964|Experimental|treatment|CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily
11162545|NCT03642964|Placebo Comparator|placebo|generic placebo tablets given orally twice daily
11162546|NCT03642951|Active Comparator|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.
~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
11162547|NCT03642951|Sham Comparator|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.
~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.
~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
11162548|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
11162549|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
11162550|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
11162551|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
11162552|NCT03642925|Experimental|Meal replacement diet|Obese subjects (BMI>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
11162553|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
11163106|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11162554|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
11162555|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
11162556|NCT03642886|No Intervention|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
11162557|NCT03642886|Experimental|Prescribed Detraining|"Detraining period of 8-weeks which is defined as:
~a 75% decrease in the amount of exercise (from baseline)
~a 50% decrease in the intensity of exercise as measured in METS (from baseline)
~Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
11162558|NCT03642873|Experimental|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
11162559|NCT03642873|Experimental|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
11162560|NCT03642873|Experimental|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
11162561|NCT03642860|Experimental|Active treatment|Triheptanoin oil
11162562|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
11162563|NCT03642847|Active Comparator|Prevnar 13|13 valent Pneumococcal Conjugate
11162564|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
11162565|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
11162566|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
11162567|NCT03642808|Experimental|rehabilitation program|"Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week
~Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
11162568|NCT03642795||Patients with rheumatoid polyarthritis|
11162569|NCT03642782|Experimental|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
11162570|NCT03642769|Active Comparator|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
11162571|NCT03642769|Experimental|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
11162572|NCT03642756|Placebo Comparator|20 gauge|
11162573|NCT03642756|Active Comparator|22 gauge|
11162574|NCT03642756|Active Comparator|24 gauge|
11162575|NCT03642743|Experimental|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
11162576|NCT03642743|Experimental|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
11162577|NCT03642730|Experimental|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
11162578|NCT03642730|Experimental|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
11162579|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
11162580|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
11162581|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.
~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
11162582|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
11162583|NCT03642665|Experimental|Natural cycle|no medication
11162584|NCT03642665|Active Comparator|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
11162620|NCT03642353|Experimental|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
11162621|NCT03642353|Placebo Comparator|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
11162585|NCT03642652|Experimental|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
11162586|NCT03642652|No Intervention|Control|Routine care
11162587|NCT03642639|Other|Coils|MICRUSFRAME and GALAXY coils
11162588|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leuk|
11162589|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphom|
11162590|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphom|
11162591|NCT03642600|Active Comparator|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
11162592|NCT03642600|Active Comparator|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
11162593|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
11162594|NCT03642574|Experimental|PMS group|Subjects in the PMS group will have blastocyst biopsy and whole genome bisulfate sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by DNA methylation level.The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
11162595|NCT03642574|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
11162596|NCT03642561|Experimental|RFA group|Patients in RFA group will accept RFA treatment
11162597|NCT03642561|Active Comparator|TACE group|Patients in TACE group will accept TACE treatment
11162598|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
11162599|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
11162600|NCT03642535|Experimental|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
11162601|NCT03642535|Active Comparator|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
11162602|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
11162603|NCT03642509|Experimental|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
11162604|NCT03642509|Experimental|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
11162605|NCT03642496|Experimental|The low dose group|
11162606|NCT03642496|Experimental|The middle dose group|
11162607|NCT03642496|Experimental|The high dose group|
11162608|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
11162609|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
11162610|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
11162611|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
11162612|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
11162613|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
11162614|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
11162615|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
11162616|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
11162617|NCT03642366|Active Comparator|Active Arm 1|
11162618|NCT03642366|Active Comparator|Active Arm 2|
11162619|NCT03642366|Sham Comparator|Sham Arm|
11162622|NCT03642353|Experimental|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
11162623|NCT03642353|Placebo Comparator|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
11162624|NCT03642327|Active Comparator|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
11162625|NCT03642327|Experimental|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
11162626|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
11162627|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
11162628|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
11162629|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
11162630|NCT03642275|Experimental|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
11162631|NCT03642275|No Intervention|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
11162632|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
11162633|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
11162634|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);
~online learning delirium care activities (20 minutes in duration); and
~delirium care OSCE and reflective activity (30 minutes in duration)."
11162635|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);
~online learning delirium care activities (20 minutes in duration)"
11162636|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
11162637|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
11162638|NCT03642223|Active Comparator|normal-weight|
11162639|NCT03642223|Experimental|peripheral adiposity|
11162640|NCT03642223|Experimental|central adiposity|
11162641|NCT03642210|Experimental|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system, inserted for use up to 6 months
11162642|NCT03642197|Experimental|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
11162643|NCT03642197|No Intervention|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
11162644|NCT03642197|Experimental|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
11162645|NCT03642197|No Intervention|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
11162646|NCT03642184|Active Comparator|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
11162647|NCT03642184|Active Comparator|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
11162648|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
11162649|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
11162650|NCT03642145|Experimental|Arm A: Deflazacort 0.9 mg/kg|Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
11162651|NCT03642145|Experimental|Arm B: Deflazacort 0.45 mg/kg|Participants will receive approximately 0.45 mg/kg deflazacort once daily orally for 52 weeks in Period 1. Participants will either continue to receive 0.45 mg/kg deflazacort or escalated dose of deflazacort (0.9 mg/kg) once daily orally in Period 2 at the investigator's discretion and in consultation with the caregiver. The target dose could be varied +/- 20% depending upon the available tablet strengths and change in participant's weight.
11162652|NCT03642145|No Intervention|Natural History Control Group|Control participants matching to the study population as closely as possible, will be used as a comparator to characterize the safety and tolerability of deflazacort.
11162653|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
11162654|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
11162655|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
11162656|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
11162657|NCT03642106|Active Comparator|Unidos Se Puede|Unidos Se Puede: consists of 5-weekly Family Workshops, 15 monthly booster sessions, 14-months success coaching, adolescent group activities and will be compared to an attention placebo control.
11162658|NCT03642106|Placebo Comparator|Attention placebo control|Placebo consists of 17 financial planning classes for parents and youth.
11162659|NCT03642093|Experimental|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
11162660|NCT03642093|Active Comparator|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
11162661|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
11162662|NCT03642067|Experimental|Nivolumab and Relatlimab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle). Relatlimab will be administered IV on day 1 (28 day cycle).
11162663|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
11162664|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
11162665|NCT03642028|Experimental|Suvorexant|Suvorexant is a dual orexin receptor antagonist that is FDA approved to treat insomnia.
11162666|NCT03642028|Placebo Comparator|Identical Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
11162667|NCT03642015|Experimental|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
11162668|NCT03642015|No Intervention|Control|control group rested only by sitting on a comfortable chair
11162669|NCT03642002|Experimental|Toning|Vocal Tonal Holding
11162670|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
11162671|NCT03642002|Experimental|SOK|Song of kin with lyric content
11162672|NCT03642002|Experimental|Process|Processing of experience
11162673|NCT03642002|Experimental|Holding Harmonic Container|
11162674|NCT03641989|Active Comparator|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
11162675|NCT03641989|Placebo Comparator|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
11162676|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
11162677|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
11162678|NCT03641963|Experimental|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
11162679|NCT03641950|Experimental|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
11162680|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
11162681|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
11162746|NCT03641417|Experimental|GLWL-01|Oral administration of GLWL-01 300mg BD for 10 days
11162682|NCT03641885|Experimental|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
11162683|NCT03641885|Experimental|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
11162684|NCT03641885|Active Comparator|active control|mothers and adolescents are in active control group and only receive the questionnaires
11162685|NCT03641872||Acute-on-Chronic Liver Disease|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.
~ALI(acute liver injury): including [ALT > 3 ULN(upper limited of normal),AST > 3 ULN or TB > 2 ULN within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB > 5 ULN) within 1 month before enrollment)].
~Standary therapy for chronic liver disease with ATI and/or AD"
11162686|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.
~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:
~- Arm 1 (usual care): the procedure of care will be the same as usual."
11162687|NCT03641859|Experimental|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.
~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:
~- Arm 2 (intervention): local anesthesia + virtual reality"
11162688|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
11162689|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
11162690|NCT03641807|Experimental|Acupuncture|
11162691|NCT03641807|Sham Comparator|Sham acupuncture|
11162692|NCT03641794|Experimental|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
11162693|NCT03641794|Placebo Comparator|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
11162694|NCT03641781|Active Comparator|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
11162695|NCT03641781|Active Comparator|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
11162696|NCT03641781|No Intervention|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
11162697|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
11162698|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
11162699|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
11162700|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
11162701|NCT03641755|Experimental|Olaparib + Sapacitabine|"Olaparib will be administered orally twice daily for each 28-day cycle
~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle
~Olaparib will be given at a predetermined dose
~Sapacitabine will be given at a predetermined dose"
11162702|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
11162703|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
11162704|NCT03641729|Other|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
11162705|NCT03641716|Experimental|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
11162706|NCT03641703|Experimental|FLT180a|Participants who have received gene therapy vector (FLT180a)
11162707|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
11162708|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
11162709|NCT03641677|Experimental|EVLP|
11162710|NCT03641677|Active Comparator|Control|
11163107|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11162711|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
11162712|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
11162713|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
11162714|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 34-102 IU/ml.
11162715|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 103-204 IU/ml.
11162716|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb >205IU/ml.
11162717|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L.
11162718|NCT03641625|Experimental|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
11162719|NCT03641625|No Intervention|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
11162720|NCT03641612|Experimental|one shape|single file rotary system
11162721|NCT03641612|Active Comparator|protaper next|multiple file rotary system
11162722|NCT03641599||heart failure with preserved ejection fraction|
11162723|NCT03641599||heart failure with mid range ejection fraction|
11162724|NCT03641599||heart failure with reduced ejection fraction|
11162725|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
11162726|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
11162727|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
11162728|NCT03641573|Experimental|[14C] ASN002|[14C] ASN002
11162729|NCT03641560|Experimental|Enzalutamide group|Participants will receive Enzalutamide once daily in addition to continued androgen deprivation therapy until discontinuation criteria is met
11162730|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.
~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
11162731|NCT03641534||Sepsis|
11162732|NCT03641534||Severe malaria|
11162733|NCT03641534||Uncomplicated malaria|
11162734|NCT03641521|Experimental|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
11162735|NCT03641521|No Intervention|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
11162736|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
11162737|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
11162738|NCT03641495|Experimental|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler
~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
11162739|NCT03641495|Active Comparator|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
11162740|NCT03641482|Active Comparator|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
11162741|NCT03641482|Placebo Comparator|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
11162742|NCT03641469|Experimental|Green Sun Dynamic Brace|Historical measures of brace effectiveness (in- and out-of-brace Cobb angles), wear time, and brace-related quality of life will be compared to those measured after the subject is fit with a Green Sun dynamic brace.
11162743|NCT03641456|Experimental|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
11162744|NCT03641443|Experimental|Non-invasive measurement of intracranial pressure|Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement
11162745|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
11162747|NCT03641417|Placebo Comparator|Placebo|Identical oral capsules with no active ingredient, administered BD for 10 days
11162748|NCT03641404|Experimental|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
11162749|NCT03641404|Placebo Comparator|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
11162750|NCT03641391|Experimental|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
11162751|NCT03641378|Experimental|Inpatient Palliative Care Intervention|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent
~Palliative Care Intervention
~Therapeutic Relationship
~--Develop a strong therapeutic relationship with patients and caregivers
~Assessment and Treatment of Patient Symptoms
~--Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms
~Managing Patients and Caregivers Expectations
~--Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects
~Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
11162752|NCT03641378|Experimental|Transplant Care Alone|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.
~Standard Transplant Care"
11162753|NCT03641365|Experimental|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
11162754|NCT03641365|Active Comparator|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
11162755|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
11162756|NCT03641352|Placebo Comparator|Placebo|Placebo
11162757|NCT03641339|Other|1|Participants will be assigned to groups that differ by type of vector and number of feedings. Participants will undergo either 1 feeding (Cohort A) or 4 feedings, each about 2 weeks apart (Cohort B), with the same vector type.
11162758|NCT03641326|Experimental|1|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest.Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
11162759|NCT03641313|Experimental|Treatment (irinotecan and M6620)|Patients receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11162760|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
11162761|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q
11162762|NCT03641287|Experimental|Arm I (aerobic exercise)|Participants meet with exercise physiologist for 1, 60 minute session. Participants then receive individualized exercise prescription with goal of moderate aerobic exercise over 150 minutes per week at home for up to 24 weeks. Participants also receive telephone-based motivational support by exercise physiologist weekly for 24 weeks.
11162763|NCT03641287|Active Comparator|Arm II (habitual level of physical activity)|Participants maintain habitual levels of physical activity and receive general education material about ovarian cancer and survivorship for 24 weeks. After 24 weeks, participants are offered exercise intervention.
11162764|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
11162765|NCT03641261|Experimental|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
11162766|NCT03641248|Experimental|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
11162767|NCT03641248|Active Comparator|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
11162768|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
11162769|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
11162770|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
11162771|NCT03641209|Experimental|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
11162772|NCT03641209|Placebo Comparator|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
11162773|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
11162774|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
11162775|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
11162776|NCT03641170|Experimental|Experimental intervention|Fixed diet and physical activity.
11162777|NCT03641170|Other|Control intervention|Fixed diet and inactivity.
11162778|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
11162779|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
11162780|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
11162781|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
11162782|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
11162783|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
11162784|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
11162785|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
11162786|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
11162787|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
11162788|NCT03641079|Experimental|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
11162789|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
11162790|NCT03641053|Experimental|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
11162791|NCT03641053|Active Comparator|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
11162792|NCT03641053|Active Comparator|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
11162793|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
11162794|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
11162795|NCT03641027|Experimental|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
11162796|NCT03641027|Other|Standard care|Standard care
11162797|NCT03641014|Experimental|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
11162798|NCT03641014|No Intervention|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
11162799|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
11162800|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
11162801|NCT03640988|Experimental|dermaPACE|Non-sterile, single, Benchtop System that is comprised of a dermaPACE Control Console, PACE Applicator and foot pedal. The PACE applicator uses shockwave technology on acute and chronic defects.
11162802|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
11162803|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
11162804|NCT03640949|Experimental|Vasopressin and methylprednisolone|The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
11162805|NCT03640949|Placebo Comparator|Placebo|"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl."
11162806|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
11162807|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronyssinus, tested by prick test or specific IgE
11162808|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronyssinus, with negative prick test or specific IgE
11162809|NCT03640923|Experimental|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
11162810|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
11162811|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
11162812|NCT03640897|Experimental|Liniderm|"Oleocalcareous liniment Liniderm:
~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
11162813|NCT03640897|Active Comparator|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
11162814|NCT03640897|Active Comparator|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
11162815|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
11162816|NCT03640871|Experimental|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
11162817|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
11162818|NCT03640845|Experimental|experimental group|Patient living in nursing homes a tele-expertise will be performed
11162819|NCT03640845|No Intervention|control group|Patient living in nursing homes will performed a normal care.
11162820|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
11162821|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
11162822|NCT03640819|Experimental|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
11162823|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
11162824|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
11162825|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
11162826|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
11162827|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
11162828|NCT03640767|Experimental|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
11162829|NCT03640767|No Intervention|Control|no intervention
11162830|NCT03640754|Active Comparator|Experimental: G-CSF|Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim
11162831|NCT03640754|Placebo Comparator|Comparator: Placebo/Saline|Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline
11162832|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
11162833|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
11162834|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
11162835|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
11162836|NCT03640715|Other|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
11162837|NCT03640715|Other|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
11162838|NCT03640715|Other|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
11162839|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
11162840|NCT03640689|Experimental|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
11162841|NCT03640689|Active Comparator|Control Group|Endovenous ablation of Great Saphenous Vein
11162842|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
11162843|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
11162844|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
11162845|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
11162846|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
11162847|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
11162848|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
11162881|NCT03640390|Experimental|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
11162882|NCT03640390|Active Comparator|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
11162883|NCT03640390|Placebo Comparator|Saline group|This group will receive normal saline infusion
11163108|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11162849|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
11162850|NCT03640624|Experimental|Intervention|Multidisciplinary treatment
11162851|NCT03640624|Active Comparator|Control|Treatment as usual
11162852|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
11162853|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
11162854|NCT03640585|Experimental|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
11162855|NCT03640585|Placebo Comparator|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
11162856|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
11162857|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
11162858|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
11162859|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
11162860|NCT03640533|Experimental|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
11162861|NCT03640533|No Intervention|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
11162862|NCT03640520|Experimental|Intervention|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
11162863|NCT03640520|Active Comparator|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
11162864|NCT03640507|Active Comparator|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
11162865|NCT03640507|Active Comparator|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
11162866|NCT03640507|Placebo Comparator|Saline|Subjects will receive vaginal preparation with sterile saline.
11162867|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
11162868|NCT03640481|Experimental|Arm A: KD025 200mg QD|Eligible subjects randomized to arm A will take KD025 200mg once daily
11162869|NCT03640481|Experimental|Arm B: KD025 200mg BID|Eligible subjects randomized to arm B will take KD025 200mg twice daily
11162870|NCT03640468|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
11162871|NCT03640468|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
11162872|NCT03640455|Placebo Comparator|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; dummy stimulation will be given.
11162873|NCT03640455|Experimental|Anodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in anodal polarity.
11162874|NCT03640455|Experimental|Cathodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in cathodal polarity.
11162875|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
11162876|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
11162877|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
11162878|NCT03640403|Experimental|DP|Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
11162879|NCT03640403|Active Comparator|ASAQ|Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
11162880|NCT03640403|No Intervention|Control|No intervention drugs will be given, but normal routine standard of care will be provided.
11162884|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
11162885|NCT03640377|Active Comparator|Praziquantel 60 mg/kg dose only baseline treatment|150 children will receive 60 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
11162886|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
11162887|NCT03640377|Active Comparator|Praziquantel 60 mg/kg dose at baseline and 6 months|150 children will receive 60 mg/kg Praziquantel at baseline and again six months later.
11162888|NCT03640351|Active Comparator|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
11162889|NCT03640351|Active Comparator|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
11162890|NCT03640351|Active Comparator|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
11162891|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
11162892|NCT03640338|No Intervention|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
11162893|NCT03640325|Experimental|PRISM (Promoting Resilience in Stress Management)|Resilience Skills Training
11162894|NCT03640325|No Intervention|Usual Care|Usual psychosocial care (control arm, no intervention)
11162895|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
11162896|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
11162897|NCT03640299|Experimental|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.
~Extensive preoperative counselling and education by surgeon and anesthetists.
~No Bowel preparation.
~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.
~Oral nonselective NSAIDs premedication.
~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).
~Minimally invasive surgery.
~Maintenance of normothermia.
~Avoidance of surgical drains and nasogastric tubes.
~Nonselective NSAIDs postoperative medication.
~Postoperative nausea and vomiting active control.
~Early oral feeding and ambulation.
~VTE prophylaxis postoperative."
11162898|NCT03640299|No Intervention|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.
~Conventional preoperative visits and education.
~Mechanical bowel preparation.
~Fasting overnight, and no fluids before surgery.
~No oral nonselective NSAIDs premedication.
~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.
~Minimally invasive surgery.
~No maintenance of normothermia.
~Drainage tube insertion if needed.
~Postoperative patient-controlled intravenous analgesia.
~Postoperative Nausea Control if needed.
~Conventional oral feeding and mobilization.
~No bowel routine.
~VTE prophylaxis postoperative."
11162899|NCT03640286|Active Comparator|VeSTAL - active device|The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
11162900|NCT03640286|Sham Comparator|Sham device|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
11162901|NCT03640273|Experimental|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
11162902|NCT03640273|Experimental|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
11162903|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
11162904|NCT03640260|No Intervention|controlled|
11162905|NCT03640247|Other|Narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with
~Ibuprofen tablet 800 mg by mouth every 8 hours
~Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
11162906|NCT03640247|Active Comparator|Non-narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with
~Ibuprofen tablet 800 mg by mouth every 8 hours"
11162907|NCT03640221|Experimental|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
11162908|NCT03640221|Active Comparator|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
11162909|NCT03640208|Experimental|Complete colorectal screening|11 step process divided into three phases: 1. Community Outreach Event; 2. Data Collection; 3. Navigation and Program Monitoring
11162910|NCT03640195|Experimental|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
11162911|NCT03640195|No Intervention|Control group|without intervention
11162912|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
11162913|NCT03640169|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
11162950|NCT03639883|Placebo Comparator|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
11162914|NCT03640156|Experimental|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
11162915|NCT03640156|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
11162916|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
11162917|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
11162918|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
11162919|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
11162920|NCT03640091|Experimental|Pre-extractive inter-radicular implant bed preparation|
11162921|NCT03640078|Experimental|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
11162922|NCT03640065|Experimental|freeze-dried probiotic sachets|
11162923|NCT03640065|Active Comparator|fermented dairy product (yogurt)|
11162924|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
11162925|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
11162926|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
11162927|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
11162928|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
11162929|NCT03640039|Experimental|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
11162930|NCT03640039|Active Comparator|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
11162931|NCT03640026|Experimental|Tacrolimus treatment|
11162932|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
11162933|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
11162934|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
11162935|NCT03639987|Experimental|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
11162936|NCT03639987|Experimental|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
11162937|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
11162938|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
11162939|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
11162940|NCT03639961|Experimental|Staff of facilities for intervention|Intervention: Participants have been trained two times in six months period with integrated leading, managing and governing for results model.
11162941|NCT03639961|Active Comparator|Staff of facilities for control|Intervention: Participants have been trained two times in six months period with traditional model.
11162942|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.
~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
11162943|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
11162944|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
11162945|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
11162946|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
11162947|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
11162948|NCT03639896|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
11162949|NCT03639896|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
11162951|NCT03639883|Placebo Comparator|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
11162952|NCT03639883|Placebo Comparator|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
11162953|NCT03639883|Placebo Comparator|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
11162954|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
11162955|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
11162956|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
11162957|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
11162958|NCT03639831|Experimental|Active group|Proprietary, standardized botanical extract
11162959|NCT03639831|Placebo Comparator|Placebo group|Placebo (maltodextrin)
11162960|NCT03639818|Experimental|experimental group|HIV patients
11162961|NCT03639805|Active Comparator|non interventional arm|Standard Of Care
11162962|NCT03639805|Experimental|interventional arm|Standard of Care + music therapy program MUSIC CARE®
11162963|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
11162964|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
11162965|NCT03639766|Experimental|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
11162966|NCT03639766|Placebo Comparator|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
11162967|NCT03639753|Experimental|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
11162968|NCT03639753|Other|Usual Practice|
11162969|NCT03639740|Other|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
11162970|NCT03639727|Active Comparator|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
11162971|NCT03639727|Active Comparator|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
11162972|NCT03639714|Experimental|Phase 1|"GRT-C901
~GRT-R902
~nivolumab
~ipilimumab"
11162973|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901
~GRT-R902
~nivolumab
~ipilimumab"
11162974|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
11162975|NCT03639688|Active Comparator|Left sided|
11162976|NCT03639688|Active Comparator|Right sided|
11162977|NCT03639675|Experimental|NVG patients|Japanese patients with neovascular glaucoma
11162978|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.
~Patients will also be able to share their feelings and ask questions"
11162979|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
11162980|NCT03639649|Experimental|STHLM3|
11162981|NCT03639649|Active Comparator|PSA|
11162982|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
11162983|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
11162984|NCT03639610|Experimental|Single arm|Melphalan flufenamide 40 mg iv Day 1 of each 28 day cycle Dexamethasone 40 mg po Day 1,8, 15 and 22 of each 28 day cycle. If > 75 years of age 20 mg.
11162985|NCT03639597|Experimental|Study device|VytronUS Ablation System
11162986|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
11162987|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
11162988|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
11162989|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
11162990|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
11162991|NCT03639571|Experimental|Test|Ibuprofen 200mg TEPI medicated plaster
11162992|NCT03639571|Placebo Comparator|Placebo|Placebo TEPI Plaster
11162993|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|
11162994|NCT03639558|Experimental|Haloperidol + Promethazine|
11162995|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
11162996|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
11162997|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
11162998|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
11162999|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
11163000|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
11163001|NCT03639519|Experimental|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
11163002|NCT03639519|Placebo Comparator|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
11163003|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
11163004|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
11163005|NCT03639493|Experimental|Sequence 1|"Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg
~Period 2: receive CJ-30060 10/160/20mg"
11163006|NCT03639493|Experimental|Sequence 2|"Period 1: receive CJ-30060 10/160/20mg
~Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
11163007|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
11163008|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
11163009|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
11163010|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.
~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.
~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
11163011|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11163012|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11163013|NCT03639441|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11163014|NCT03639441|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11163015|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
11163016|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
11163017|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
11163018|NCT03639415|Experimental|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.
~Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.
~Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
11163019|NCT03639402|Experimental|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).
~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
11163020|NCT03639402|No Intervention|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
11163021|NCT03639389|Active Comparator|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
11163022|NCT03639389|Experimental|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
11163023|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
11163024|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
11163025|NCT03639363|Experimental|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
11163026|NCT03639363|Active Comparator|Control Arm|daily bathing with standard soap
11163027|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
11163070|NCT03639051|Experimental|Active Treatment|Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
11163028|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
11163029|NCT03639337|Experimental|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.
~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
11163030|NCT03639337|No Intervention|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
11163031|NCT03639337|No Intervention|Controls|Healthy controls ages between 10 and 14 months
11163032|NCT03639324|Experimental|Dose Combination 1-1|idelalisib + venetoclax
11163033|NCT03639324|Experimental|Dose Combination 1-2|idelalisib + venetoclax
11163034|NCT03639324|Experimental|Dose Combination 1-3|idelalisib + venetoclax
11163035|NCT03639324|Experimental|Dose Combination 1-4|idelalisib + venetoclax
11163036|NCT03639324|Experimental|Sub-Trial Dose Combination 2-1|idelalisib + venetoclax
11163037|NCT03639324|Experimental|Sub-Trial Dose Combination 2-2|idelalisib + venetoclax
11163038|NCT03639311|Experimental|Subjects receiving Injection CAB LA plus RPV LA|The eligible subjects in the arm (subjects from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Subjects will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
11163039|NCT03639311|Experimental|Subjects receiving Oral DTG plus RPV|The eligible subjects in the arm (subjects from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Subjects will continue to receive the treatment until the study intervention is locally approved and commercially available.
11163040|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
11163041|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
11163042|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
11163043|NCT03639246|Experimental|Phase 1b: AVB-S6-500+PLD|
11163044|NCT03639246|Experimental|Phase 1b: AVB-S6-500+Pac|
11163045|NCT03639246|Experimental|Phase 2: AVB-S6-500+PLD|
11163046|NCT03639246|Experimental|Phase 2: AVB-S6-500+Pac|
11163047|NCT03639246|Active Comparator|Phase 2: Placebo+PLD|
11163048|NCT03639246|Active Comparator|Phase 2: Placebo+Pac|
11163049|NCT03639233|Other|Arm 1|Intervention access
11163050|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
11163051|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
11163052|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
11163053|NCT03639194|Experimental|Part A: ABBV-011 Dose Escalation|ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.
11163054|NCT03639194|Experimental|Part B: ABBV-011 Dose Expansion|ABBV-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A.
11163055|NCT03639194|Experimental|Part C: ABBV-011 + Budigalimab Escalation and Expansion|ABBV-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of ABBV-011 for Part B plus Budigalimab via intravenous administration at fixed doses and various dosing regimens.
11163056|NCT03639181|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
11163057|NCT03639168|Experimental|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
11163058|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
11163059|NCT03639155|Experimental|Regimen B|vadadustat test tablets
11163060|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
11163061|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
11163062|NCT03639129|Experimental|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
11163063|NCT03639116|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post first-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be recruited to participate.
11163064|NCT03639116|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
11163065|NCT03639077|Experimental|Allograft bone alone|
11163066|NCT03639077|Experimental|Allograft and xenograft mixture|
11163067|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
11163068|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
11163069|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
11163105|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
11163071|NCT03639051|Sham Comparator|Sham Control|Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
11163072|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
11163073|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
11163074|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
11163075|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
11163076|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
11163077|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
11163078|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
11163079|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
11163080|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
11163081|NCT03639025||Standard Donor Lungs Primary Analysis Population|The first 289 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
11163082|NCT03639025||Initially Unacceptable Donor Lung Primary Analysis Pop.|The first 266 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
11163083|NCT03639025||All Other Enrolled Patients|All OCS Lung transplanted patients that do not meet any of the above analysis populations.
11163084|NCT03639012|Active Comparator|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
11163085|NCT03639012|No Intervention|No Carbohydrate loading|Current standard of care
11163086|NCT03638999|Active Comparator|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
11163087|NCT03638999|Placebo Comparator|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
11163088|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
11163089|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
11163090|NCT03638973|Experimental|Biopsy with Er: YAG|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
11163091|NCT03638973|Active Comparator|Biopsy with Scalpel|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
11163092|NCT03638960|Active Comparator|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
11163093|NCT03638960|Experimental|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
11163094|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
11163095|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
11163096|NCT03638934|Experimental|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
11163097|NCT03638934|Active Comparator|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
11163098|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
11163099|NCT03638908|Other|Fluoxetine|"Dosing will be
~Week 1-4: 20 mg daily
~Week 5-8: 40 mg daily
~Week 9-12: 60 mg daily
~Week 13-24: 80 mg daily"
11163100|NCT03638895|Active Comparator|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
11163101|NCT03638895|Placebo Comparator|SC group|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
11163102|NCT03638882|Experimental|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
11163103|NCT03638882|Active Comparator|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
11163104|NCT03638882|Placebo Comparator|Passive Control|No intervention.
11163109|NCT03638856|Experimental|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
11163110|NCT03638856|No Intervention|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
11163111|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
11163112|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
11163113|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
11163114|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
11163115|NCT03638817|Experimental|Eltrombopag|
11163116|NCT03638804|Experimental|89Zr-KN035 injection|
11163117|NCT03638791||Healthy controls|Matched Controls without treatment
11163118|NCT03638791||OCD with washing compulsion|Exposure and response inhibition
11163119|NCT03638791||OCD without washing compulsion|Exposure and response inhibition
11163120|NCT03638778|Active Comparator|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
11163121|NCT03638778|Experimental|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
11163122|NCT03638778|Experimental|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
11163123|NCT03638778|Experimental|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
11163124|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
11163125|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:
~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;
~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,
~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,
~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,
~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,
~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
11163126|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:
~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,
~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
11163127|NCT03638739|Experimental|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
11163128|NCT03638739|Experimental|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
11163129|NCT03638726|Experimental|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
11163130|NCT03638726|Other|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
11163131|NCT03638713|Experimental|colonoscopy first group|Patients received water-exchange colonoscopy first and followed by esophagogastroduodenoscopy
11163132|NCT03638713|Active Comparator|EGD first group|Patients received esophagogastroduodenoscopy first and followed by water-exchange colonoscopy
11163133|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
11163134|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
11163135|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
11163136|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
11163137|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
11163138|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
11163139|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
11163439|NCT03636581|No Intervention|Control|This group will receive a smart watch to track activity only with no intervention.
11163140|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
11163141|NCT03638674|Active Comparator|2nd lumbar spine acquisition in same position|spine and hip STRATOS DR + 2nd lumbar spine acquisition in same position (with template)
11163142|NCT03638674|Active Comparator|2nd lumbar spine acquisition|spine and hip STRATOS DR + 2nd lumbar spine acquisition (no template)
11163143|NCT03638674|Active Comparator|2nd hip acquisition in same position|spine and hip STRATOS DR + 2nd hip acquisition in same position (with template)
11163144|NCT03638674|Active Comparator|2nd hip acquisition|spine and hip STRATOS DR + 2nd hip acquisition (without template)
11163145|NCT03638661|Experimental|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).
~vegetable (canola, flaxseed) derived n-3 fatty acid"
11163146|NCT03638661|Placebo Comparator|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.
~soybean used formula"
11163147|NCT03638648|Active Comparator|Low risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk receiving capecitabine.
11163148|NCT03638648|No Intervention|Low risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk NOT receiving any additional chemotherapy.
11163149|NCT03638648|Experimental|High risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk receiving capecitabine.
11163150|NCT03638648|No Intervention|High risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk NOT receiving any additional chemotherapy.
11163151|NCT03638635|Active Comparator|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
11163152|NCT03638635|Experimental|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
11163153|NCT03638622|Experimental|Treatment|"aminolevulinic acid and photodynamic therapy
~Patients receive aminolevulinic acid orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one."
11163154|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
11163155|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
11163156|NCT03638596|Experimental|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
11163157|NCT03638596|Placebo Comparator|Control|Incentive delivery not contingent on transdermal alcohol concentration
11163158|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;
~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.
~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
11163159|NCT03638544|Active Comparator|Reduced Gluten-Normal Gluten|
11163160|NCT03638544|Active Comparator|Normal Gluten-Reduced Gluten|
11163161|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
11163162|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
11163163|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.
~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.
~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
11163164|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
11163165|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
11163166|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
11163167|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
11163168|NCT03638492|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
11163169|NCT03638492|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
11163170|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
11163171|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor or other Movement Disorders
11163172|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD, ET or other Movement Disorders
11163173|NCT03638466|Experimental|Single dose of SPN-810|Subjects will be treated with medium dose of SPN-810
11163174|NCT03638466|Placebo Comparator|Placebo|Subjects will be treated with a matching Placebo
11163175|NCT03638453|Experimental|PediCARE|"PediCARE Administered x6 mos
~Resource Provision: Monthly Groceries (delivery via Instacart)
~Resource Provision: Transport to/from home/hospital 8x per month (via RideHealth)"
11163176|NCT03638453|Active Comparator|Usual Care|The control group will receive usual supportive care
11163177|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
11163178|NCT03638414|Experimental|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
11163179|NCT03638414|No Intervention|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
11163180|NCT03638401|No Intervention|Standard treatment|
11163181|NCT03638401|Active Comparator|Intervention arm|
11163182|NCT03638388|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.
~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
11163183|NCT03638388|Active Comparator|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.
~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
11163184|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.
~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion
~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
11163185|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.
~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion
~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion
~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
11163186|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
11163187|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
11163188|NCT03638336|Experimental|flexible ureteroscopy|
11163189|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
11163190|NCT03638310|Experimental|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
11163191|NCT03638310|Active Comparator|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
11163192|NCT03638297|Experimental|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
11163193|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
11163194|NCT03638271|Other|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
11163195|NCT03638258|Experimental|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% topically applied once daily
11163196|NCT03638258|Experimental|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% topically applied once daily
11163197|NCT03638258|Placebo Comparator|ARQ-151 Vehicle cream|Matching vehicle cream containing only excipients of ARQ-151 cream applied once daily
11163198|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
11163199|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
11163200|NCT03638232||Patients with multiple myeloma|"Data to be collected are :
~Drug exposition data
~Administrative data
~Medical data"
11163201|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
11163202|NCT03638193|Experimental|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10^7/m^2 CART positive cells(chort 1)or 1-3×10^8/m^2 CART positive cells(chort 2).
11163203|NCT03638180|Experimental|Single Ascending Doses|Single ascending doses, 6 dose levels
11163204|NCT03638180|Experimental|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
11163205|NCT03638167|Experimental|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
11163206|NCT03638167|Experimental|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
11163207|NCT03638154|Placebo Comparator|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
11163366|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
11163208|NCT03638154|Active Comparator|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.
~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
11163209|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort A dose)|"Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).
~Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted."
11163210|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort B dose)|Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.
11163211|NCT03638128|Experimental|Denosumab|70 mg/mL solution containing 1.7 mL administered subcutaneously with a frequency of: day 1, at week 12, week 24, week 36, week 48, week 60, week 72, and week 84
11163212|NCT03638115|Experimental|VaSecure™ Drug Coated PTA Balloon Catheter|
11163213|NCT03638102|Experimental|Sleep intervention|Sleep extension
11163214|NCT03638102|Active Comparator|Healthy living|Health education
11163215|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
11163216|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
11163217|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
11163218|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
11163219|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
11163220|NCT03638063||Control|healthy controls
11163221|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
11163222|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
11163223|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
11163224|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
11163225|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
11163226|NCT03638011|No Intervention|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
11163227|NCT03638011|Active Comparator|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
11163228|NCT03637998|Experimental|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
11163229|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
11163230|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
11163231|NCT03637972|Experimental|Ventilated cigarettes only|Filters with approximately 30-36% filter ventilation
11163232|NCT03637972|Experimental|Unventilated cigarettes only|Filters with approximately 3.0-4.6% filter ventilation
11163233|NCT03637972|Experimental|Ventilated cigarettes + alternative nicotine delivery systems|Filters with approximately 30-36% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
11163234|NCT03637972|Experimental|Unventilated cigarettes + ANDS|Filters with approximately 3.0-4.6% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
11163235|NCT03637959|Experimental|MR Elastography comparision study|Evaluate the efficacy of liver stiffness measured by ultrasound for fibrosis staging, using clinically indicated MRE as the gold standard.
11163236|NCT03637946|Experimental|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
11163237|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
11163238|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
11163239|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
11163240|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
11163241|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
11163242|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.
~The breastfeeding infants were the reference group"
11163243|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
11163244|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
11163245|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.
~The breastfeeding infants were the reference group."
11163246|NCT03637881||Other|Daily or non-daily Consumers
11163247|NCT03637868|Experimental|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
11163248|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
11163249|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
11163250|NCT03637829|Placebo Comparator|Control|250 mL of water
11163251|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
11163252|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
11163253|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
11163254|NCT03637816|Experimental|Arm I (anamorelin hydrochloride)|Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
11163255|NCT03637816|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
11163256|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
11163257|NCT03637790|Other|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
11163258|NCT03637790|Other|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
11163259|NCT03637764|Experimental|Phase1|"Isatuximab and atezolizumab combination in patients with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN), platinum-resistant/refractory epithelial ovarian cancer (EOC), or recurrent glioblastoma multiforme (GBM):
~Isatuximab dose 1 depending on DLT observed and atezolizumab predefined dose Q3W"
11163260|NCT03637764|Experimental|Phase2-Cohort A: HCC|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
11163261|NCT03637764|Experimental|Phase2-Cohort B: SCCHN|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
11163262|NCT03637764|Experimental|Phase2-Cohort C: EOC|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
11163263|NCT03637764|Experimental|Phase2-Cohort D-1:GBM|Isatuximab and atezolizumab combination: Isatuximab dose determined in Phase 1 part of study and atezolizumab predefined dose Q3W
11163264|NCT03637764|Experimental|Phase2-Cohort D-2: GBM, isatuximab monotherapy|Isatuximab dose 2
11163265|NCT03637764|Experimental|Phase2-Cohort E|Isatuximab and atezolizumab combination: Isatuximab dose 3 and atezolizumab predefined dose Q3W in participants with one tumor type (HCC, SCCHN, EOC, or GBM), or isatuximab monotherapy (GBM only) dose 3
11163266|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
11163267|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
11163268|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.
~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
11163269|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
11163270|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
11163271|NCT03637712|Experimental|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
11163272|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
11163273|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
11163274|NCT03637660|Active Comparator|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
11163275|NCT03637660|Experimental|2|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
11163276|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
11163277|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
11163437|NCT03636594|Experimental|Dance|This was a single arm study with all participants receiving the same intervention.
11163278|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
11163279|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
11163280|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
11163281|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
11163282|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.
~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
11163283|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
11163284|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
11163285|NCT03637556|Experimental|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
11163286|NCT03637556|Active Comparator|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
11163287|NCT03637556|Active Comparator|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
11163288|NCT03637543|Experimental|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
11163289|NCT03637543|Experimental|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
11163290|NCT03637530|Experimental|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
11163291|NCT03637530|No Intervention|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
11163292|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
11163293|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
11163294|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
11163295|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
11163296|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
11163297|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
11163298|NCT03637491|Experimental|Avelumab and binimetinib|Open label
11163299|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
11163300|NCT03637491|Experimental|Binimetinib and talazoparib.|Open label.
11163301|NCT03637478|Experimental|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
11163302|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
11163303|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
11163304|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
11163305|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
11163306|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
11163307|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
11163308|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
11163309|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
11163310|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.
~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
11163311|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
11163312|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
11163313|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
11163314|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
11163315|NCT03637387|Experimental|BIIB074|Administered orally three times daily (TID)
11163316|NCT03637387|Placebo Comparator|Placebo|Placebo matching BIIB074
11163317|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
11163318|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
11163319|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
11163320|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11163321|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11163322|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11163323|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11163324|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
11163325|NCT03637348|Other|TrueTear|Use of TrueTear device to stimulate tear production
11163326|NCT03637335|Experimental|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
11163327|NCT03637335|Placebo Comparator|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
11163328|NCT03637309|Experimental|BeReady2Smile Video and App|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
11163329|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
11163330|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
11163331|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
11163332|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
11163333|NCT03637270|Experimental|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
11163334|NCT03637270|Active Comparator|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
11163335|NCT03637257|Experimental|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
11163336|NCT03637257|Experimental|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
11163337|NCT03637244|Experimental|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
11163338|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
11163339|NCT03637218|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
11163340|NCT03637218|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11163341|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
11163342|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
11163343|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
11163344|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11163345|NCT03637179|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
11163346|NCT03637179|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11163347|NCT03637166|Experimental|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
11163348|NCT03637166|Experimental|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
11163349|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
11163350|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
11163351|NCT03637140|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
11163352|NCT03637140|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11163353|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
11163354|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11163355|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
11163356|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11163357|NCT03637088|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
11163358|NCT03637088|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11163359|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
11163360|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
11163361|NCT03637062|Experimental|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
11163362|NCT03637062|Active Comparator|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
11163363|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
11163364|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
11163365|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
11163617|NCT03635372|Experimental|Alginate|10 cc of Alginate peroral
11163367|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
11163368|NCT03637023|Experimental|Virtual Reality|Virtual Reality will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
11163369|NCT03637023|Active Comparator|Exercise Therapy|Exercise Therapy will be applied in addition to the Anti-parkinsonian medication given by the Neurologist.
11163370|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
11163371|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
11163372|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
11163373|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
11163374|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
11163375|NCT03636971|Experimental|hyaluronic acid with mannitol|
11163376|NCT03636971|Experimental|hyaluronic acid with sorbitol|
11163377|NCT03636971|Active Comparator|saline|
11163378|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
11163379|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
11163380|NCT03636945|Experimental|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
11163381|NCT03636932|Active Comparator|N-acetylcysteine (NAC) group|
11163382|NCT03636932|Placebo Comparator|Placebo group|
11163383|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
11163384|NCT03636906|Experimental|1 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Bexsero vaccine
11163385|NCT03636906|Experimental|2 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Bexsero vaccine
11163386|NCT03636906|Active Comparator|Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive the Bexsero vaccine comparator and placebo
11163387|NCT03636906|Experimental|1 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Nimenrix vaccine
11163388|NCT03636906|Experimental|2 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Nimenrix vaccine
11163389|NCT03636906|Active Comparator|Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Nimenrix comparator vaccine and placebo.
11163390|NCT03636906|Experimental|1 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Menveo vaccine
11163391|NCT03636906|Experimental|2 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Menveo vaccine
11163392|NCT03636906|Active Comparator|Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Menveo comparator vaccine and placebo.
11163393|NCT03636906|Experimental|1 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive1 dose of the experimental GSK3389245A vaccine followed by placebo and Synflorix vaccine
11163394|NCT03636906|Experimental|2 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive2 doses of the experimental GSK3389245A vaccine followed by Synflorix vaccine
11163395|NCT03636906|Active Comparator|Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Synflorix comparator vaccine and placebo
11163396|NCT03636906|Experimental|1 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 1 dose of the GSK3389245A experimental vaccine followed by placebo.
11163397|NCT03636906|Experimental|2 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 2 doses of the GSK3389245A experimental vaccine followed by placebo.
11163398|NCT03636906|Placebo Comparator|Placebo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Placebo vaccine
11163438|NCT03636581|Experimental|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
11163399|NCT03636893|Experimental|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered
~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous
~Repeated every 15th day"
11163400|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered
~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)
~Repeated every 21st day"
11163401|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
11163402|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
11163403|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
11163404|NCT03636854|Experimental|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
11163405|NCT03636854|Experimental|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
11163406|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
11163407|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
11163408|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
11163409|NCT03636789|Experimental|Neurological consultation group|
11163410|NCT03636776|Experimental|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.
~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.
~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.
~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
11163411|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
11163412|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
11163413|NCT03636750|Experimental|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
11163414|NCT03636750|Experimental|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
11163415|NCT03636750|Experimental|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
11163416|NCT03636750|Experimental|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
11163417|NCT03636750|Experimental|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
11163418|NCT03636750|Experimental|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
11163419|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
11163420|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
11163421|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
11163422|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
11163423|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
11163424|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
11163425|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I
~Anlotinib combined with pemetrexed and carboplatin, phase II"
11163426|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I
~Anlotinib combined with paclitaxel and carboplatin, phase II"
11163427|NCT03636672|Experimental|experimental|Perturbation training during stationary bicycle riding
11163428|NCT03636672|Active Comparator|control|stationary bicycle riding training
11163429|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
11163430|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
11163431|NCT03636633|Active Comparator|Control Group|"Standard respiratory physiotherapy
~Patients in this group will receive standard respiratory physiotherapy two times a day, 7 days a week for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
11163432|NCT03636633|Experimental|Training Group|"Standard respiratory physiotherapy and inspiratory muscle train
~In addition to the standard respiratory physiotherapy program, patients in this group will receive 3 sets of inspiratory muscle training with 10 repetitions twice a day for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
11163433|NCT03636620|Active Comparator|TACE group|Transcatheter arterial chemoembolization
11163434|NCT03636620|Experimental|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
11163435|NCT03636607|Experimental|Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
11163436|NCT03636607|Experimental|Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
11163618|NCT03635372|Experimental|Sucralfate|10 cc of Sucralfate peroral
11163440|NCT03636568|Experimental|Fluid restricted|Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg)
11163441|NCT03636568|No Intervention|Non Fluid Restricted|No fluid restriction
11163442|NCT03636555|Active Comparator|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
11163443|NCT03636555|Placebo Comparator|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
11163444|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
11163445|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
11163446|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
11163447|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
11163448|NCT03636516|Active Comparator|jj stent yes|
11163449|NCT03636516|Active Comparator|jj stent no|
11163450|NCT03636503|Experimental|Rituximab +Utomilumab+Avelumab|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
~Utomilumab is administered intravenously over 1 hour once every 4 weeks
~Avelumab is administered intravenously over 1 hour once every 2 weeks"
11163451|NCT03636503|Experimental|Rituximab+Utomilumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
~Utomilumab is administered intravenously over 1 hour once every 4 weeks
~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
11163452|NCT03636503|Experimental|Rituximab+Avelumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only
~Avelumab is administered intravenously over 1 hour once every 2 weeks
~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
11163453|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
11163454|NCT03636477|Experimental|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
11163455|NCT03636451|Experimental|40cc 0.5% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing 38mL of 0.5% lidocaine buffered with 2mL 8.4% sodium bicarbonate and 2 units Vasopressin
11163456|NCT03636451|Active Comparator|20cc 1% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing 18mL of 1% lidocaine buffered with 2mL 8.4% sodium bicarbonate in and 2 units Vasopressin
11163457|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
11163458|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
11163459|NCT03636399|Experimental|Standard GIST|Standard Group Interactive Structured Treatment.
11163460|NCT03636399|Experimental|Intensive GIST|Intensive Group Interactive Structured Treatment.
11163461|NCT03636386|Experimental|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
11163462|NCT03636386|Active Comparator|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
11163463|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
11163464|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
11163465|NCT03636360|Experimental|LED - Sunlike|LED lighting with spectral pattern similar to that of sunlight
11163466|NCT03636360|Active Comparator|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
11163467|NCT03636360|Placebo Comparator|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
11163468|NCT03636360|Active Comparator|LED|Standard LED lighting
11163469|NCT03636347|Placebo Comparator|Placebo oral tablet|
11163470|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
11163471|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
11163472|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
11163473|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
11163474|NCT03636321|Experimental|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis with internal biliary stent
11163475|NCT03636321|Active Comparator|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without internal biliary
11163619|NCT03635372|Experimental|Hydrotalcite|10 cc of Hydrotalcite peroral
11163476|NCT03636308|Experimental|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.
~S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
11163477|NCT03636308|Active Comparator|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.
~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
11163478|NCT03636295|Experimental|Reduced INR Target|Warfarin therapy will be titrated to a target INR in the range of 1.5 to 2.5.
11163479|NCT03636295|Active Comparator|Standard INR Target|"Warfarin therapy will be titrated to a standard of care target INR range."
11163480|NCT03636282|Experimental|Hockey FIT Program (Immediate Delivery)|Hockey FIT Program: A gender-sensitized, weight loss and healthy lifestyle program that engages men using the power of being a sports fan.
11163481|NCT03636282|No Intervention|Wait-List Control (Delayed Delivery)|No intervention for 12 months. After 12 months, Hockey FIT program is offered.
11163482|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
11163483|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
11163484|NCT03636256|Experimental|Non-Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL and additional Induction (6 weekly NanoDoce intravesical instillations, followed by 6 weeks of rest) and Maintenance (3 weekly NanoDoce intravesical instillations, followed by 9 weeks of rest) instillations at 2.0 or 3.0 mg/mL.
11163485|NCT03636256|Experimental|Muscle Invasive Bladder Cancer|Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.
11163486|NCT03636243|Other|Group of obese patients with type-2 diabetes|
11163487|NCT03636243|Other|Group of non-diabetic obese patients|
11163488|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
11163489|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
11163490|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
11163491|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
11163492|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
11163493|NCT03636204|Experimental|AL001|Up to six single ascending doses of AL001
11163494|NCT03636204|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
11163495|NCT03636191|Experimental|Probiotic|
11163496|NCT03636191|Placebo Comparator|Placebo|
11163497|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
11163498|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
11163499|NCT03636165|Experimental|MP plus RP group|Patients in RP/MP group will receive a peri-incisional scalp infiltration with 0.125% methylprednisolone and 0.2% ropivacaine and normal saline miscible liquids. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
11163500|NCT03636165|Active Comparator|RP group|Patients in RP group will receive peri-incisional scalp infiltration with 0.2% ropivacaine alone. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
11163501|NCT03636152|Active Comparator|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
11163502|NCT03636152|Placebo Comparator|Placebo Group|These patients will receive a matching placebo for 18 months
11163503|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
11163504|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
11163505|NCT03636126|Experimental|VR + TACS|"Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).
~Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
11163506|NCT03636126|No Intervention|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
11163507|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
11163508|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
11163509|NCT03636087|Active Comparator|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
11163510|NCT03636087|Experimental|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
11163511|NCT03636074||Hearth-valve surgery|
11163512|NCT03636074||Hearth bypass surgery|
11163513|NCT03636061|Active Comparator|OC-01 Low Dose|
11163514|NCT03636061|Active Comparator|OC-01 Mid Dose|
11163515|NCT03636061|Active Comparator|OC-01 High Dose|
11163516|NCT03636061|Placebo Comparator|Placebo|
11163620|NCT03635359||positive for fetal aneuploidy|
11163517|NCT03636048|Experimental|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
11163518|NCT03636048|Active Comparator|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
11163519|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
11163520|NCT03636022|Experimental|Virtual Reality|Virtual Reality exposure therapy system to deliver homework and in-office exposures.
11163521|NCT03636022|Other|Traditional therapy|Traditional treatment using exposure therapy
11163522|NCT03636009|Experimental|Concurrent traction|Concurrent traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
11163523|NCT03636009|Active Comparator|Sequential traction|Sequential traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
11163524|NCT03635996|Experimental|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
11163525|NCT03635983|Experimental|Combination|NKTR-214 + Nivolumab
11163526|NCT03635983|Experimental|Monotherapy|Nivolumab
11163527|NCT03635970|Placebo Comparator|conventional treatment|receive the best conventional therapy
11163528|NCT03635970|Active Comparator|experimental treatment|The best medical treatment possible plus celular therapy
11163529|NCT03635957|Experimental|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.
~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
11163530|NCT03635944||Group A|Infants born in Lyon (France)
11163531|NCT03635944||Group B|Infants born in Stockholm (Sweden)
11163532|NCT03635931|Active Comparator|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
11163533|NCT03635931|No Intervention|Control Group|plaque control, scaling and root planing if required
11163534|NCT03635918|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
11163535|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
11163536|NCT03635905|Placebo Comparator|Placebo|
11163537|NCT03635892|Experimental|cabozantinib in combination with nivolumab|Cycle length will be defined as 28 days. Treatment will include cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28), and nivolumab 240mg, administered intravenously on days 1 and 15 of each cycle ± 3 days. Patients will also apply Clobetasol topically to their hands and feet twice a day for the first 12 weeks of therapy. Treatment will be continued until confirmed disease progression, major toxicity, or withdrawal from the study for any reason. Continuation of Clobetasol beyond 12 weeks at investigator discretion as per standard management of Hand Foot Syndrome.
11163538|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
11163539|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
11163540|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
11163541|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
11163542|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
11163543|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
11163544|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
11163545|NCT03635853|Experimental|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
11163546|NCT03635840|No Intervention|Control|Group of patients not receiving IABP
11163547|NCT03635840|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
11163548|NCT03635827|Active Comparator|NBTX-001|
11163549|NCT03635827|Placebo Comparator|Placebo|
11163550|NCT03635814|Experimental|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
11163551|NCT03635814|Placebo Comparator|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
11163552|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.
~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.
~An ECG is performed under controlled conditions."
11163553|NCT03635788|Experimental|Arm A: LA ART|In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 3, participants will receive a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 52 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
11163582|NCT03635528|Experimental|Test 1\Test 2\Control 2\Test 3\Control 1\Test 4\Test 5|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163554|NCT03635788|Active Comparator|Arm B: SOC Oral ART|In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will continue SOC oral ART regimen for 52 weeks. In Step 3, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
11163555|NCT03635775|Experimental|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
11163556|NCT03635775|Experimental|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
11163557|NCT03635775|Experimental|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
11163558|NCT03635775|Sham Comparator|Sham tDCS|Sham tDCS applied in one of the above configurations
11163559|NCT03635762|Experimental|Be In Charge|behavioral + nutrition education program
11163560|NCT03635749|Active Comparator|DAPT + early intensive statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
11163561|NCT03635749|Other|DAPT + delayed intensive statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
11163562|NCT03635749|Other|Aspirin+early intensive statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
11163563|NCT03635749|Placebo Comparator|Aspirin+delayed intensive statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
11163564|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
11163565|NCT03635697|Experimental|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
11163566|NCT03635697|No Intervention|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
11163567|NCT03635684|Experimental|SC Acetaminophen|Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
11163568|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
11163569|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
11163570|NCT03635658|Active Comparator|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
11163571|NCT03635658|Experimental|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
11163572|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
11163573|NCT03635632|Experimental|Arm A: High-risk group of patients with lung metastases|"Patients will be treated at 4 dose levels. At dose level 0, patients will only receive C7R-GD2.CART cells without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
~Starting at dose level 1, the protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Starting with dose level 1, each arm will undergo separate dose escalation."
11163574|NCT03635632|Experimental|Arm B: Standard risk group of all other patients|"Patients will be treated at 4 dose levels. At the dose level 0, patients will only receive C7R-GD2.CART cells without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated with lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by C7R.GD2.CART cell infusion at 3 dose levels.
~Starting at dose level 1, the protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Starting with dose level 1, each arm will undergo separate dose escalation."
11163575|NCT03635593|Active Comparator|CBD|10mg capsules Cannabidiol (CBD)
11163576|NCT03635593|Active Comparator|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
11163577|NCT03635593|Placebo Comparator|Placebo|10mg capsules placebo
11163578|NCT03635580|Experimental|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
11163579|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
11163580|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
11163581|NCT03635541||observational group of NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
11163615|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
11163616|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
11163583|NCT03635528|Experimental|Test 2\Test 3\Test 1\Test 4\Control 2\Test 5\Control 1|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163584|NCT03635528|Experimental|Test 3\Test 4\Test 2\Test 5\Test 1\Control 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163585|NCT03635528|Experimental|Test 4\Test 5\Test 3\Control 1\Test 2\Control 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163586|NCT03635528|Experimental|Test 5\Control 1\Test 4\Control 2\Test 3\Test 1\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163587|NCT03635528|Experimental|Control 1\Control 2\Test 5\Test 1\Test 4\Test 2\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163588|NCT03635528|Experimental|Control 2\Test 1\Control 1\Test 2\Test 5\Test 3\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163589|NCT03635528|Experimental|Test 5\Test 4\Control 1\Test 3\Control 2\Test 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163590|NCT03635528|Experimental|Control 1\Test 5\Control 2\Test 4\Test 1\Test 3\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163591|NCT03635528|Experimental|Control 2\Control 1\Test 1\Test 5\Test 2\Test 4\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163592|NCT03635528|Experimental|Test 1\Control 2\Test 2\Control 1\Test 3\Test 5\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163593|NCT03635528|Experimental|Test 2\Test 1\Test 3\Control 2\Test 4\Control 1\Test 5|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163594|NCT03635528|Experimental|Test 3\Test 2\Test 4\Test 1\Test 5\Control 2\Control 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163595|NCT03635528|Experimental|Test 4\Test 3\Test 5\Test 2\Control 1\Test 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
11163596|NCT03635515|Active Comparator|Standard Protocol (Control) Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
11163597|NCT03635515|Active Comparator|Gentlewave Treatment Group|Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed through working length verification. For the Gentlewave treatment group, each canal will be shaped to a canal size of 20.06 and to 0.5 - 1mm short of the apical terminus. An occlusal platform will be prepared using the Kool-dam material recommended by Sonendo. The Gentlewave system will be held on the tooth by the clinician and will cycle through five minutes of 3% sodium hypochlorite, two minutes of 8% EDTA, and a final rinse of distilled water. Canals will be obturated with root canal sealer and gutta-percha. The same VAS scale from pretreatment to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.
11163598|NCT03635502||Stroke Group|
11163599|NCT03635502||Healthy Group|
11163600|NCT03635489|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab for a total of 21 cycles of bevacizumab in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
11163601|NCT03635489|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and placebo IV infusion starting from Cycle 2 for a total of 5 cycles, followed by maintenance therapy placebo for a total of 21 cycles of placebo in the absence of disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.
11163602|NCT03635463|Experimental|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
11163603|NCT03635463|Experimental|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
11163604|NCT03635450|Experimental|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
11163605|NCT03635450|Experimental|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
11163606|NCT03635437|Experimental|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
11163607|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
11163608|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA) + Alprazolam|Oral Alprazolam treatment 0.5 mg daily combined with oral GABA treatment 600 mg daily for 3 months. Alprazolam treatment thereafter ended, and study subjects will continue with oral GABA treatment 600 mg daily only for another 3 months.
11163609|NCT03635424|Experimental|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
11163610|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
11163611|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
11163612|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
11163613|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
11163614|NCT03635398|Active Comparator|oral administration of midazolam|
11163621|NCT03635359||negative for fetal aneuploidy|
11163622|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
11163623|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
11163624|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
11163625|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
11163626|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
11163627|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
11163628|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
11163629|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
11163630|NCT03635307||Operated patients with volume expansion|
11163631|NCT03635294|Experimental|Blood sample|Blood sample for analyses
11163632|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
11163633|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers
~set FIO2 at 1.0
~Ppeak limit at 45 cmH2O
~Respiratory rate set at 6
~I:E set at 1:1
~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O
~If the maximum VT is set without rasing the Pplat, raise PEEP
~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O
~End of RM
~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
11163634|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
11163635|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.
~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
11163636|NCT03635190|Experimental|Interventional|Orbital Circumferential Atherectomy
11163637|NCT03635177|Experimental|Remote ischemic conditioning|The participant will conduct remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates to 200 mmHg and occludes blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min occlusion period is interspersed by 5 min.
11163638|NCT03635177|Sham Comparator|Sham occlusion|The participant will conduct a sham procedure of remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates minimally and does not occlude blood flow. The procedure is conducted on one arm 4 x 5 min per day. Each 5 min of sham occlusion is interspersed by 5 min.
11163639|NCT03635164|Experimental|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.
~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.
~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
11163640|NCT03635151|Experimental|TASK III Group|The Telephone Assessment and Skill-Building Kit (TASK III) group
11163641|NCT03635151|Active Comparator|ISR Group|The Information, Support, and Referral (ISR) group
11163642|NCT03635138|Experimental|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
11163643|NCT03635138|Active Comparator|Adhesive control|Adhesive conventional
11163644|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
11163645|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
11163646|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
11163647|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
11163648|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose A|"1 oral Dose A daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.
~Subjects who complete Induction will continue to receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
11163649|NCT03635112|Active Comparator|Active Treatment TD-1473 with Dose B|"1 oral Dose B daily of TD-1473 for 12 weeks in subjects with moderately to-severely active CD.
~Subjects who complete Induction will continue to receive TD-1473 at Dose B in the Active Treatment Arm for up to 48 additional weeks."
11163650|NCT03635112|Placebo Comparator|Placebo|"1 oral dose daily of placebo for 12 weeks in subjects with moderately to-severely active CD.
~Subjects who complete Induction will receive TD-1473 at Dose A in the Active Treatment Arm for up to 48 additional weeks."
11163651|NCT03635099|Experimental|Dose group A|
11163652|NCT03635099|Experimental|Dose group B|
11163653|NCT03635099|Experimental|Dose group C|
11163654|NCT03635099|Experimental|Dose group D|
11163655|NCT03635099|Placebo Comparator|Placebo|
11163656|NCT03635099|Experimental|Dose group V|
11163657|NCT03635099|Experimental|Dose group U|
11163658|NCT03635099|Placebo Comparator|Placebo W|
11163659|NCT03635086|Experimental|Treatment group A|"MV-CHIK lyophilised formulation, low dose, treatment group A:
~12 subjects will receive two low dose treatments with MV-CHIK 5x10^4 (+/- 0.5 log) TCID50 /dose on day 0 and 28"
11163660|NCT03635086|Experimental|Treatment group B|MV-CHIK liquid frozen formulation, low dose, treatment group B: 12 subjects will receive two low dose treatments with MV-CHIK 1x10^5 (+/-0.5 log) TCID50 /dose on day 0 and 28
11163661|NCT03635086|Experimental|Treatment group C|MV-CHIK SPS® formulation, low dose, treatment group C: 12 subjects will receive two low dose treatments with MV-CHIK 1x10^5 (+/-0.5 log) TCID50 /dose on day 0 and 28
11163662|NCT03635086|Experimental|Treatment group D|MV-CHIK liquid frozen formulation, high dose, treatment group D: 12 subjects will receive two high dose treatments with MV-CHIK 1x10^6 (+/-0.5 log) TCID50 /dose on day 0 and 28
11163663|NCT03635086|Placebo Comparator|Treatment group E|MV-CHIK liquid frozen formulation, high dose and placebo, treatment group E: 12 subjects will receive one high dose treatment with MV-CHIK 1x10^6 (+/-0.5 log) TCID50 /dose on day 0 and placebo on day 28
11163664|NCT03635073|Experimental|TAK-935|Treatment: 0 to 2 Weeks Dose Optimization Period followed by 103 weeks Maintenance Period.
11163665|NCT03635060|Active Comparator|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
11163666|NCT03635060|Active Comparator|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
11163667|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
11163668|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
11163669|NCT03635034|Experimental|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.
~Intervention: No catheter"
11163670|NCT03635034|Active Comparator|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.
~Intervention: bladder catheter inserted"
11163671|NCT03635021|Experimental|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
11163672|NCT03635021|Experimental|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
11163673|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.
~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
11163674|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.
~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
11163675|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
11163676|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
11163677|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
11163678|NCT03634982|Experimental|RMC-4630|RMC-4630 for oral administration
11163679|NCT03634969|Experimental|Normal Renal Function|
11163680|NCT03634969|Experimental|Mild Renal Impairment|
11163681|NCT03634969|Experimental|Moderate Renal Impairment|
11163682|NCT03634969|Experimental|Severe Renal Impairment|
11163683|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
11163684|NCT03634956|Experimental|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
11163685|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
11163686|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
11163687|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
11163688|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium
~oral use
~3 times / day (morning, noon, evening)
~666 mg per capsule
~14 - 19 days"
11163689|NCT03634917|Active Comparator|Calcium Carbonate|"1 capsule with Calcium Carbonate
~oral use
~3 times / day (morning, noon, evening)
~1500 mg Calcium Carbonate (= 600 mg Calcium 2+)
~14 - 19 days"
11163690|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,
~oral use
~3 times / day (morning, noon, evening)
~14 - 19 days"
11163691|NCT03634904|Experimental|Drug Blood sampling|"Drug Blood sampling
~Pharmacokinetic study measuring total and free ceftazidime concentrations"
11163692|NCT03634878|Experimental|Perineal ultrasound to visualize the strips and their position|
11163693|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
11163694|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
11163695|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet non-menthol|Nicotine 0 mg combined with sweet non-menthol flavor
11163696|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet non-menthol|Nicotine 3 mg combined with sweet non-menthol flavor
11163697|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet non-menthol|Nicotine 12 mg combined with sweet non-menthol flavor
11164147|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
11163698|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet menthol|Nicotine 0 mg combined with sweet menthol flavor
11163699|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet menthol|Nicotine 3 mg combined with sweet menthol flavor
11163700|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet menthol|Nicotine 12 mg combined with sweet menthol flavor
11163701|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco non-menthol|Nicotine 0 mg combined with tobacco non-menthol flavor
11163702|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco non-menthol|Nicotine 3 mg combined with tobacco non-menthol flavor
11163703|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco non-menthol|Nicotine 12 mg combined with tobacco non-menthol flavor
11163704|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco menthol|Nicotine 0 mg with tobacco menthol flavor
11163705|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco menthol|Nicotine 3 mg combined with tobacco menthol flavor
11163706|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco menthol|Nicotine 12 mg combined with tobacco menthol flavor
11163707|NCT03634813|Experimental|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
11163708|NCT03634813|Active Comparator|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
11163709|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
11163710|NCT03634787||Healthy|No major systemic illness
11163711|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
11163712|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
11163713|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
11163714|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
11163715|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
11163716|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
11163717|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
11163718|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
11163719|NCT03634722|No Intervention|The observational group|routine nursing
11163720|NCT03634709|Experimental|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
11163721|NCT03634709|No Intervention|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
11163722|NCT03634696|Experimental|Field test participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to participate in mPCL application field test
11163723|NCT03634696|Active Comparator|Control participants|Late-stage adult cancer patients seeking care at Ocean Road Cancer Center, consenting to serve as controls for mPCL field test
11163724|NCT03634683|Experimental|LioCyx|"This is a single-arm study.
~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
11163725|NCT03634657|Active Comparator|Plain X-ray protection shield|
11163726|NCT03634657|Experimental|Protection shield & X-ray protective strips|
11163727|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
11163728|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
11163729|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
11163730|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
11163731|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
11163732|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
11163733|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
11163734|NCT03634579|Experimental|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
11163735|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
11163736|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
11163737|NCT03634553|Experimental|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
11163738|NCT03634553|Active Comparator|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
11163739|NCT03634540|Experimental|Cohort 1: Belzutifan and cabozantinib|Cohort 1: Patients must not have received prior systemic therapy for advanced or metastatic ccRCC
11163740|NCT03634540|Experimental|Cohort 2: Belzutifan and cabozantinib|Cohort 2: Patients must have received prior immunotherapy and no more than two prior treatments for advanced or metastatic ccRCC
11163741|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
11163742|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
11163743|NCT03634514|Experimental|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
11163744|NCT03634514|Active Comparator|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
11163745|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
11163746|NCT03634488|Experimental|Nutritional Supplement and Hydroxyurea|50 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive nutritional supplement and hydroxyurea (20mg/kg/day)
11163747|NCT03634488|Placebo Comparator|Nutritional Supplement alone|50 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive nutritional supplement alone
11163748|NCT03634488|Placebo Comparator|non-SCD AND severe malnutrition|To decrease the likelihood of sharing limited food resources, we will enroll 100 malnourished non-SCD siblings.
11163749|NCT03634475|Experimental|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
11163750|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
11163751|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
11163752|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
11163753|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
11163754|NCT03634436|Experimental|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
11163755|NCT03634436|Experimental|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
11163756|NCT03634436|Experimental|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
11163757|NCT03634436|Experimental|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
11163758|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
11163759|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
11163760|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
11163761|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
11163762|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
11163763|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
11163798|NCT03634202|Experimental|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
11163764|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
11163765|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
11163766|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
11163767|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
11163768|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
11163769|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
11163770|NCT03634410||Employed|people aged +50 and currently employed
11163771|NCT03634410||Unemployed|people aged +50 and currently unemployed
11163772|NCT03634410||Early retirement|people aged +50 and currently on early retirement
11163773|NCT03634410||Disability pension|people aged +50 and currently on disability pension
11163774|NCT03634397|Experimental|Less-Impaired Arm Training|Intervention condition includes therapy of the less-impaired (ipsilesional) arm.
11163775|NCT03634397|Sham Comparator|Contralesional Arm Comparison|Comparison control condition includes therapy of the paretic (contralesional) arm.
11163776|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).
~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
11163777|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).
~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
11163778|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
11163779|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
11163780|NCT03634358|Active Comparator|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
11163781|NCT03634358|Active Comparator|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
11163782|NCT03634345|Experimental|PF-04965842|investigational drug
11163783|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
11163784|NCT03634306|Active Comparator|ARM 1|Laparoscopic hysterectomy with use of the Ultravision System
11163785|NCT03634306|Placebo Comparator|ARM 2|Laparoscopic Hysterectomy per Standard of Care/no Ultravision System
11163786|NCT03634306|Active Comparator|ARM 3|Laparoscopic myomectomy with use of the Ultravision System.
11163787|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
11163788|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
11163789|NCT03634280|Placebo Comparator|Splinting|Splinting was applied to the patients' ankle in the second group(n=120). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
11163790|NCT03634280|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 120 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
11163791|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
11163792|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
11163793|NCT03634241|Active Comparator|Arm A (standard of care)|Participants receive standard of care.
11163794|NCT03634241|Experimental|Arm B (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11163795|NCT03634228|Experimental|Arm A (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10 and milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11163796|NCT03634228|Experimental|Arm B (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10, milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11163797|NCT03634215||Multiple Trauma patients|
11163799|NCT03634189|Experimental|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
11163800|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
11163801|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
11163802|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
11163803|NCT03634163|Experimental|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
11163804|NCT03634163|Active Comparator|Delayed|Quality of Life Assessment
11163805|NCT03634150|Experimental|Single arm Nerofe followed by Doxorubicin|IV treatment of Nerofe 96 mg\m2 followed by IV Doxorubicin 10mg\m2 Once weekly
11163806|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
11163807|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
11163808|NCT03634124|Experimental|interventional group|
11163809|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
11163810|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
11163811|NCT03634098|Experimental|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:
~MRI
~Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
11163812|NCT03634098|Experimental|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :
~sample for analysis and biocollection
~MRI
~Ultrasound AixPlorer"
11163813|NCT03634098|No Intervention|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
11163814|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
11163815|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
11163816|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
11163817|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
11163818|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
11163819|NCT03634046|Experimental|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 ~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
11163820|NCT03634046|Active Comparator|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
11163821|NCT03634033|Experimental|MiCAP with IF|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
11163822|NCT03634033|Experimental|MiCAP with IF and EF|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
11163823|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
11163824|NCT03634007|Experimental|Cohort I: 8.0 x 10^10 gc/kg|Subjects will receive 8.0 x 10^10 gc/kg of AAVrh.10hAPOE2.
11163825|NCT03634007|Experimental|Cohort II: 2.5 x 10^11 gc/kg|Subjects will receive 2.5 x 10^11 gc/kg of AAVrh.10hAPOE2.
11163826|NCT03634007|Experimental|Cohort III: 8.0 x 10^11 gc/kg|Subjects will receive 8.0 x 10^11 gc/kg of AAVrh.10hAPOE2.
11163827|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
11163828|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
11163868|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
11163829|NCT03633968|Active Comparator|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.
~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
11163830|NCT03633968|Active Comparator|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.
~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
11163831|NCT03633955|Active Comparator|Standard therapy|This Arm will accrue patients receiving standard therapy (e.g. chemotherapy for leukemia).
11163832|NCT03633955|Experimental|Immunotherapy|The other Arm will include patients receiving immunotherapy
11163833|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.
~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
11163834|NCT03633929||KIOS OUD|
11163835|NCT03633916|Experimental|Intervention|Classroom sensitization session (plus school-level sensitization activities)
11163836|NCT03633916|Active Comparator|Control|School-level sensitization activities only
11163837|NCT03633903|Active Comparator|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks
11163838|NCT03633903|No Intervention|Control|
11163839|NCT03633890|Experimental|DaZhu Rhodiola Rosea Capsule|
11163840|NCT03633890|Placebo Comparator|DaZhu Rhodiola Rosea Simulation Capsule|
11163841|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
11163842|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
11163843|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
11163844|NCT03633851|Experimental|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
11163845|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
11163846|NCT03633825|No Intervention|Control|
11163847|NCT03633825|Experimental|Intervention|
11163848|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
11163849|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
11163850|NCT03633799|Experimental|VeraCept|VeraCept™ Intrauterine Contraceptive
11163851|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
11163852|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
11163853|NCT03633773|Experimental|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
11163854|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
11163855|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
11163856|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
11163857|NCT03633734|Experimental|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.
~Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m^2 + gemcitabine 1000mg/m^2 (days 1, 8, 15, 28)
~Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m^2 continuous intravenous drip 46h + calcium folinate 400 mg/m^2 + irinotecan 135 mg/m^2 + oxaliplatin 68 mg/m^2 (day 1, 15, a total of 28 days).
~Repeat the cycle above until progression or intolerance of toxicity."
11163858|NCT03633721|Active Comparator|HIV positive; cannabis|HIV positive women will be given cannabis and tested
11163859|NCT03633721|Active Comparator|HIV positive; placebo|HIV positive women will be given placebo and tested
11163860|NCT03633721|Active Comparator|HIV negative; cannabis|HIV negative women will be given cannabis and tested
11163861|NCT03633721|Active Comparator|HIV negative; placebo|HIV negative women will be given placebo and tested
11163862|NCT03633708|Experimental|Etelcalcetide|Randomized in a 3:1 ratio to receive etelcalcetide in addition to standard of care
11163863|NCT03633708|Active Comparator|Control|Randomized in a 3:1 ratio to receive etelcalcetide in addition standard of care alone (control arm)
11163864|NCT03633695|Experimental|IC-8 IOL|The AcuFocus IC-8 intraocular lens will be surgically implanted in one eye of each subject. A monofocal or monofocal toric intraocular lens will be surgically implanted in the fellow eye of each subject.
11163865|NCT03633695|Active Comparator|Monofocal|A monofocal or monofocal toric intraocular lens will be surgically implanted in both eyes of each subject.
11163866|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
11163867|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
11163869|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
11163870|NCT03633656|Experimental|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
11163871|NCT03633643|Placebo Comparator|Group A|Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
11163872|NCT03633643|Active Comparator|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
11163873|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
11163874|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
11163875|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
11163876|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
11163877|NCT03633617|Experimental|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
11163878|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
11163879|NCT03633578|Experimental|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
11163880|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
11163881|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
11163882|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
11163883|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
11163884|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
11163885|NCT03633539|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
11163886|NCT03633539|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
11163887|NCT03633526|Experimental|VX-659/TEZ/IVA|Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
11163888|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
11163889|NCT03633513||Caregivers|Environmentally matched healthy control subjects
11163890|NCT03633500|Placebo Comparator|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
11163891|NCT03633500|Experimental|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
11163892|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
11163893|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
11163894|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
11163895|NCT03633461|Active Comparator|OC-02|
11163896|NCT03633461|Placebo Comparator|Placebo|
11163897|NCT03633448|Experimental|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
11163898|NCT03633448|Experimental|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
11163899|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
11163900|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
11163901|NCT03633396|Placebo Comparator|Placebo|Placebo as subcutaneous (SC) injection every 4 weeks
11163902|NCT03633396|Experimental|Group 1|ANB019 subcutaneous (SC) injection every 4 weeks
11163903|NCT03633383||Transfemoral Approach|
11163904|NCT03633383||Transapical Approach|
11163905|NCT03633370|No Intervention|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
11163906|NCT03633370|Other|Test Group|"Multifaceted intervention
~Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone
~Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)
~Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
11163907|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
11163908|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
11163909|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
11163910|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
11163911|NCT03633331|Experimental|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11163912|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
11163913|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
11163914|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
11163915|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
11163916|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
11163917|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
11163918|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
11163919|NCT03633305|No Intervention|No additional treatment|
11163920|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
11163921|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month
~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
11163922|NCT03633279|Experimental|Branched Chain Amino Acid|Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.
11163923|NCT03633279|Placebo Comparator|Placebo|Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
11163924|NCT03633266|Experimental|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
11163925|NCT03633266|Active Comparator|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
11163926|NCT03633253||MCR syndroms|
11163927|NCT03633253||Non MCR syndroms|
11163928|NCT03633227|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|
11163929|NCT03633227|Placebo Comparator|Placebo|
11163930|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
11163931|NCT03633214|No Intervention|No training module (Control)|
11163932|NCT03633201|Active Comparator|Cruciate Retaining|
11163933|NCT03633201|Active Comparator|Medial Congruent|
11163934|NCT03633201|No Intervention|Healthy Controls|
11163935|NCT03633188|Experimental|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
11163936|NCT03633175|Active Comparator|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
11163937|NCT03633175|No Intervention|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
11163938|NCT03633149|Experimental|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
11163939|NCT03633149|Experimental|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
11163940|NCT03633149|Active Comparator|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
11163941|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
11163942|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
11163943|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
11163944|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
11163945|NCT03633110|Experimental|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).
~Part A will consist of approximately 9 participants."
11163946|NCT03633110|Experimental|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).
~Part B will consist of up to 90 participants."
11163947|NCT03633097|Experimental|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
11163948|NCT03633097|Active Comparator|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
11163949|NCT03633084|Experimental|RBM-007 Injectable Solution - Dose 1|No additional information.
11163950|NCT03633084|Experimental|RBM-007 Injectable Solution - Dose 2|No additional information.
11163951|NCT03633084|Experimental|RBM-007 Injectable Solution - Dose 3|No additional information.
11163952|NCT03633058|Experimental|0.75 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
11163953|NCT03633058|Experimental|1.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
11163954|NCT03633058|Experimental|3.0 mg/kg|ketamine will be dosed orally twice daily for 5 days at 3.0 mg/kg, in addition to 5 days of placebo
11163955|NCT03633058|Experimental|4.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 4.5 mg/kg, in addition to 5 days of placebo
11163956|NCT03633019|Experimental|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
11163957|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.
~A second blood draw will be collected at 12 months."
11163958|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.
~Diagnostic information will be collected to confirm the final diagnosis."
11163959|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.
~Subject will be enrolled and provide a blood sample."
11163960|NCT03632993|Active Comparator|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 mL aliquots (for a total injection volume of 0.3 mL).
~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
11163961|NCT03632993|Active Comparator|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.
~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
11163962|NCT03632993|Active Comparator|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.
~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
11163963|NCT03632993|Active Comparator|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).
~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
11163964|NCT03632993|Active Comparator|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).
~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2mL of CCH (4 aliquots of 0.3mL each). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
11163965|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).
~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices
~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
11163966|NCT03632967|Experimental|Device: TriCinch Coil System treatment|
11163967|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®
~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.
~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
11163968|NCT03632941|Active Comparator|VRP-HER2 Vaccine|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)
11163969|NCT03632941|Active Comparator|Pembrolizumab|5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
11163970|NCT03632941|Experimental|VRP-HER2 Vaccine + Pembrolizumab|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)+ 5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
11163971|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.
~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
11163972|NCT03632889|No Intervention|Control Arm|Subjects randomized to the control group will receive a sleep hygiene handout .
11163973|NCT03632889|Other|Computerized Group|Subjects randomized to GoToSleep program will receive a sleep hygiene handout and a unique code for home access to the GoToSleep program.
11163974|NCT03632876|Active Comparator|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
11163975|NCT03632876|Active Comparator|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
11163976|NCT03632876|No Intervention|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
11163977|NCT03632863|Experimental|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
11163978|NCT03632863|Sham Comparator|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
11163979|NCT03632850||Doctors|This is a group of oncologists who have experience in treatment deliberations with patients of advanced cancer.
11163980|NCT03632850||Nurses|This is a group of clinical nurse specialists who have experience in treatment deliberations with patients of advanced cancer
11163981|NCT03632850||Patients|this is a group of adult patients who have been diagnosed with advanced pancreatic cancer
11163982|NCT03632850||Relatives|this is a group of adults who are involved in providing support for their loved ones who are diagnosed with advanced pancreatic cancer
11163983|NCT03632837|Experimental|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
11163984|NCT03632837|No Intervention|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
11163985|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
11163986|NCT03632824|Placebo Comparator|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
11163987|NCT03632798|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (Bevacizumab plus standard-of-care chemotherapy chosen by the Physician from the provided list).
~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
~Liposomal Doxorubicin;
~Docetaxel;
~Paclitaxel;
~Carboplatin;
~Cisplatin;
~Gemcitabine;
~Topotecan;
~Carboplatin, Gemcitabine;
~Cisplatin, Gemcitabine;
~Carboplatin, Liposomal Doxorubicin;
~Carboplatin, Paclitaxel;
~Carboplatin, Docetaxel.
~The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
11163988|NCT03632798|Experimental|ChemoID-guided treatment|"Participants will be treated with Bevacizumab plus ChemoID-guided standard-of-care chemotherapy drugs from the provided list.
~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:
~Liposomal Doxorubicin;
~Docetaxel;
~Paclitaxel;
~Carboplatin;
~Cisplatin;
~Gemcitabine;
~Topotecan;
~Carboplatin, Gemcitabine;
~Cisplatin, Gemcitabine;
~Carboplatin, Liposomal Doxorubicin;
~Carboplatin, Paclitaxel;
~Carboplatin, Docetaxel.
~The treating physician will receive the ChemoID assay results from the ChemoID lab."
11163989|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
11163990|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
11163991|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
11163992|NCT03632759|Experimental|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
11163993|NCT03632759|Experimental|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
11163994|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
11163995|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
11163996|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
11163997|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
11163998|NCT03632720|Experimental|Group 1|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
11163999|NCT03632720|Experimental|Group 2|MenACYW conjugate vaccine at 3 months and at 12 to 13 months of age; meningococcal Group B vaccine at 2 and 4 months of age; routine pediatric vaccines
11164000|NCT03632720|Active Comparator|Group 3|Meningococcal Group B vaccine at 2, 4, and 12 to 13 months of age; routine pediatric vaccines
11164001|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
11164002|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
11164062|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
11164148|NCT03631589|Experimental|MSCs treated|
11164003|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
11164004|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
11164005|NCT03632681|Active Comparator|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
11164006|NCT03632681|Placebo Comparator|Placebo|In this arm a single-dose intranasal placebo will be administrated
11164007|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
11164008|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
11164009|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
11164010|NCT03632642|Active Comparator|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
11164011|NCT03632642|Active Comparator|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
11164012|NCT03632629|Active Comparator|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
11164013|NCT03632629|No Intervention|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
11164014|NCT03632603|Experimental|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
11164015|NCT03632603|Active Comparator|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
11164016|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
11164017|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
11164018|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
11164019|NCT03632590|Placebo Comparator|Placebo|
11164020|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
11164021|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
11164022|NCT03632564|Experimental|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
11164023|NCT03632551|Active Comparator|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
11164024|NCT03632551|Experimental|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
11164025|NCT03632551|Experimental|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
11164026|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
11164027|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
11164028|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
11164029|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
11164030|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
11164031|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
11164032|NCT03632473||clinically isolated syndrome (CIS)|"Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
11164033|NCT03632473||early relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting early disease course (RRMS) </= 10 years, Expanded Disability Status Scale (EDSS) </=3.5
~EDSS:
~1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
11164063|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
11164034|NCT03632473||late relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive
~EDSS:
~4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
11164035|NCT03632473||primary progressive disease course (PPMS)|"MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive
~EDSS:
~6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.
~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
11164036|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
11164037|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
11164038|NCT03632447|Experimental|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
11164039|NCT03632447|Active Comparator|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
11164040|NCT03632434|Experimental|tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
11164041|NCT03632421|Experimental|Intervention group|
11164042|NCT03632421|Active Comparator|Control group|
11164043|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
11164044|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
11164045|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
11164046|NCT03632356|Experimental|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
11164047|NCT03632356|Active Comparator|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
11164048|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
11164049|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
11164050|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
11164051|NCT03632330||Dexmedetomidine|Dexmedetomidine group
11164052|NCT03632330||Midazolam|Midazolam group
11164053|NCT03632330||propofol|propofol group
11164054|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
11164055|NCT03632317|Experimental|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
11164056|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
11164057|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
11164058|NCT03632291|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
11164059|NCT03632291|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
11164060|NCT03632291|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
11164061|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
11164064|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.
~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
11164065|NCT03632252|Experimental|Powered ankle prosthesis|We will use data from various sensors to optimize the amount of power provided by custom ankle ankle prosthesis. This is a single session study lasting about 4 hours.
11164066|NCT03632239||GAPP|Individuals undergoing phenotyping by GAPP
11164067|NCT03632226||1|Healthy Volunteers
11164068|NCT03632213|Active Comparator|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
11164069|NCT03632213|Placebo Comparator|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
11164070|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.
~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.
~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
11164071|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
11164072|NCT03632187|Experimental|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
11164073|NCT03632187|Placebo Comparator|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
11164074|NCT03632174|Experimental|Topical Ointment with L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
11164075|NCT03632174|Experimental|Topical Ointment without L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
11164076|NCT03632161|Active Comparator|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
11164077|NCT03632161|Other|Bupivacaine|Bupivacaine only in the paravertebral block
11164078|NCT03632135|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).
~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
~Carboplatin;
~Irinotecan;
~Etoposide;
~BCNU;
~CCNU;
~Temozolomide;
~Procarbazine;
~Vincristine;
~Imatinib;
~Procarbazine, CCNU, Vincristine;
~Carboplatin, Irinotecan;
~Carboplatin, Etoposide;
~Temozolomide, Etoposide;
~Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
11164079|NCT03632135|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.
~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:
~Carboplatin;
~Irinotecan;
~Etoposide;
~BCNU;
~CCNU;
~Temozolomide;
~Procarbazine;
~Vincristine;
~Imatinib;
~Procarbazine, CCNU, Vincristine;
~Carboplatin, Irinotecan;
~Carboplatin, Etoposide;
~Temozolomide, Etoposide;
~Temozolomide, Imatinib.
~The treating physician will receive the ChemoID assay results from the ChemoID lab."
11164080|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
11164081|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
11164082|NCT03632096|Active Comparator|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
11164083|NCT03632096|Sham Comparator|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
11164084|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
11164114|NCT03631849|Active Comparator|not peri implantitis patient|
11164149|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
11164085|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
11164086|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
11164087|NCT03632057|Active Comparator|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
11164088|NCT03632057|Active Comparator|Fixed Pulse Width|This is the Study group.
11164089|NCT03632044|Experimental|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
11164090|NCT03632044|Sham Comparator|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
11164091|NCT03632031|Experimental|Oasis Extracellular Matrix|Application of Oasis ECM on non-healing ulcers of any etiology present for at least 1 month
11164092|NCT03632018|Active Comparator|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
11164093|NCT03632018|Experimental|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
11164094|NCT03632005|Other|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
11164095|NCT03632005|Active Comparator|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
11164096|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
11164097|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
11164098|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
11164099|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
11164100|NCT03631966|Experimental|BTX-A injection|
11164101|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
11164102|NCT03631940|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
11164103|NCT03631940|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
11164104|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
11164105|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
11164106|NCT03631901|Active Comparator|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
11164107|NCT03631901|Active Comparator|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
11164108|NCT03631888||patients scheduled for elective laparoscopic surgery|
11164109|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
11164110|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
11164111|NCT03631862|Experimental|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
11164112|NCT03631862|Experimental|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
11164113|NCT03631849|Experimental|Peri implantitis patients|
11164115|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
11164116|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
11164117|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
11164118|NCT03631823||Healthy volunteer group|The volunteers for control group
11164119|NCT03631797|Experimental|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.
~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
11164120|NCT03631784|Experimental|Cohort A|Participants will receive 1 cycle of pembrolizumab 200 mg on Day 1 with paclitaxel 200 mg/m^2, and carboplatin area under the curve (AUC) AUC6. Approximately 3 weeks later, participants will receive 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) and carboplatin AUC2 with paclitaxel 45 mg/m^2 administered weekly for 6 weeks in conjunction with standard thoracic radiotherapy (60 Gray [Gy]). To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
11164121|NCT03631784|Experimental|Cohort B|Participants will receive 3 cycles of pembrolizumab 200 mg on Day 1 of each 3-week cycle and 3 cycles of pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2. Treatment will be given in conjunction with standard thoracic radiotherapy (60 Gy) in Cycles 2 and 3. To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
11164122|NCT03631771|Experimental|Iodixanol, iohexol, iopromide, or ioversol|Investigational medicinal product administered intravascularly per usual clinical practice at each participating institution. Doses will be per usual practice. The dose of ICM, timing of ICM administration in relation to the diagnostic procedure, rate of ICM administration, and route of ICM administration will be determined by the physician performing the enhanced radiologic procedure per medical need and local clinical practice.
11164123|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
11164124|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
11164125|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
11164126|NCT03631745|Experimental|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
11164127|NCT03631745|No Intervention|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
11164128|NCT03631732|Experimental|B/F/TAF|Participants received FDC tablet of B/F/TAF (50/200/25 mg) orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
11164129|NCT03631732|Active Comparator|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily with a delayed switch to FDC tablet of B/F/TAF (50/200/25 mg) administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
11164130|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
11164131|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
11164132|NCT03631706|Experimental|M7824|
11164133|NCT03631706|Active Comparator|Pembrolizumab|
11164134|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
11164135|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
11164136|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
11164137|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
11164138|NCT03631667|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
11164139|NCT03631667|Experimental|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene
11164140|NCT03631654|Placebo Comparator|Control|
11164141|NCT03631654|Experimental|Intervention|
11164142|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
11164143|NCT03631628|Experimental|MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + MT and 1 hour conventional training.
11164144|NCT03631628|Placebo Comparator|sham-MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + sham-MT and 1-hour conventional training.
11164145|NCT03631615|Experimental|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
11164146|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
11164150|NCT03631563|Experimental|Arm 1|ATG-F treated
11164151|NCT03631563|Active Comparator|Arm 2|ATG treated
11164152|NCT03631537|Experimental|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
11164153|NCT03631537|No Intervention|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
11164154|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
11164155|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
11164156|NCT03631511|Experimental|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
11164157|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
11164158|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
11164159|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
11164160|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
11164161|NCT03631485||parents having children with cancer|No intervention.
11164162|NCT03631472|Experimental|RheOx Treatment|RheOx Treatment (i.e., Bronchial Rheoplasty)
11164163|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
11164164|NCT03631446||Patients administered Picoprep® for bowel cleansing|Patients administered Sodium Picosulfate, Magnesium Oxide and Citric Acid for bowel cleansing
11164165|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
11164166|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
11164167|NCT03631420|Experimental|UMC119-01|UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product
11164168|NCT03631407|Experimental|Vicriviroc QD at Dose Level 1 + Pembrolizumab|Participants vicriviroc (dosed orally; once daily [QD]) at dose level 1 in combination with 200 mg pembrolizumab (intravenous [IV] infusion; every 3 weeks [Q3W]) for up to 35 cycles (cycle length: 3 weeks).
11164169|NCT03631407|Experimental|Vicriviroc QD at Dose Level 2 + Pembrolizumab|Participants receive vicriviroc (dosed orally; QD) at dose level 2 in combination with 200 mg pembrolizumab (IV infusion; Q3W) for up to 35 cycles (cycle length: 3 weeks).
11164170|NCT03631394|Experimental|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
11164171|NCT03631394|Placebo Comparator|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
11164172|NCT03631368|Experimental|Botox|
11164173|NCT03631355|Active Comparator|ACL Reconstruction w/ BTB Autograft + IV TXA|
11164174|NCT03631355|No Intervention|ACL Reconstruction w/ BTB Autograft, no IV TXA|
11164175|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
11164176|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
11164177|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
11164178|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
11164179|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
11164180|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
11164181|NCT03631316|Experimental|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
11164182|NCT03631316|Active Comparator|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
11164183|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who received appropriate ICD therapy during follow-up.
11164184|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who were free from appropriate ICD therapy during follow-up.
11164185|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF >50%).
11164186|NCT03631290|Experimental|Deprescribing Intervention|
11164187|NCT03631277|Experimental|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
11164188|NCT03631277|Active Comparator|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
11164189|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
11164190|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
11164191|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
11164192|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
11164193|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
11164194|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
11164195|NCT03631212|No Intervention|Waitlist control|Wait-list control group
11164196|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
11164197|NCT03631199|Experimental|canakinumab|canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy
11164198|NCT03631199|Other|canakinumab matching-placebo|canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
11164199|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
11164200|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
11164201|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
11164202|NCT03631160|Experimental|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
11164203|NCT03631160|Sham Comparator|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
11164204|NCT03631147|Experimental|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
11164205|NCT03631147|No Intervention|The control group|
11164206|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
11164207|NCT03631121|Experimental|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
11164208|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.
~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
11164209|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.
~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
11164210|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.
~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
11164211|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.
~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
11164212|NCT03631082|Experimental|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.
~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.
~Patients will perform 10 repetitions of each exercise."
11164251|NCT03630835|Experimental|99mTc-Annexin-V-128 uptake on scintigraphy|
11164252|NCT03630822|Experimental|beneficiary of the advance directive program|
11164253|NCT03630822|Active Comparator|beneficiary of standard Support|
11165745|NCT03620409||Healthy subjects|Healthy controls
11164213|NCT03631082|Active Comparator|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.
~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.
~Patients will perform 10 repetitions of each exercise."
11164214|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
11164215|NCT03631069||Normal|
11164216|NCT03631043|Experimental|Treatment (personalized vaccine)|Participants undergo collection of blood and bone marrow for making the vaccine. Participants then receive personalized vaccine SC on days 1 and 15 of courses 1-2 and on day 1 of courses 3-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11164217|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
11164218|NCT03631017|Experimental|[18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
11164219|NCT03631004|Experimental|olanzapine tablets|PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
11164220|NCT03631004|Placebo Comparator|Starch tablets|PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
11164221|NCT03630991|Experimental|Cohort I (edetate calcium disodium, multivitamin)|During standard of care chemotherapy, patients receive edetate calcium disodium IV over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
11164222|NCT03630991|Experimental|Cohort II (succimer, multivitamin)|During standard of care chemotherapy, patients receive succimer PO for 8 days of each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
11164223|NCT03630978||Liver resection|
11164224|NCT03630965|No Intervention|Group A|No CPR video
11164225|NCT03630965|Experimental|Group B|CPR video
11164226|NCT03630952|Experimental|0.5 mg Conbercept|
11164227|NCT03630952|Experimental|1.0 mg Conbercept|
11164228|NCT03630952|Active Comparator|Aflibercept|
11164229|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
11164230|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
11164231|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
11164232|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
11164233|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
11164234|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
11164235|NCT03630913|Experimental|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.
~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
11164236|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
11164237|NCT03630900|No Intervention|5% O2 culture|
11164238|NCT03630887|No Intervention|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
11164239|NCT03630887|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
11164240|NCT03630887|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
11164241|NCT03630887|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
11164242|NCT03630874|Experimental|Experimental arm|
11164243|NCT03630874|No Intervention|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
11164244|NCT03630861||GBM|Primary glioblastoma (GBM)
11164245|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
11164246|NCT03630861||Brain metastases|Brain metastases (BM)
11164247|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
11164248|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
11164249|NCT03630848|Experimental|10 mg/ml protein concentration in Embryo Culture Media|
11164250|NCT03630848|No Intervention|5 mg/ml protein concentration in Embryo Culture Media|
11164254|NCT03630809|Experimental|HER2 DC1 Vaccine|HER2 DC1 vaccine given in 3 booster injections administered every 3 months for the treatment of participants with nonmetastatic HER2pos breast cancer (BC) with low HER2 immunity and history of prior treatment with HER2 DC1 vaccines.
11164255|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.
~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.
~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.
~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
11164256|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.
~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.
~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.
~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
11164257|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
11164258|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
11164259|NCT03630770|No Intervention|Control|This group receives no feeding supplement.
11164260|NCT03630770|Experimental|MCT Oil|This group is supplemented with MCT oil
11164261|NCT03630757|Experimental|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
11164262|NCT03630757|Placebo Comparator|Group 2|reaching to the feet while sitting together with warming and cooling periods
11164263|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
11164264|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
11164265|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
11164266|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
11164267|NCT03630705|Experimental|Group 1 (Mexico)|MenACYW conjugate vaccine at 2, 6, and 12 months of age + routine pediatric vaccines at 2, 4, 6, and 12 months of age
11164268|NCT03630705|Active Comparator|Group 2 (Mexico)|Menveo® at 2, 4, 6, and 12 months of age + routine pediatric vaccines at 2, 4, 6, and 12 months of age
11164269|NCT03630705|Experimental|Group 3 (Russian Federation)|MenACYW conjugate vaccine at 3, 6, and 12 months of age + routine pediatric vaccines at 2, 3, 4.5, 6, and 12 months of age
11164270|NCT03630705|Other|Group 4 (Russian Federation)|Routine pediatric vaccines at 2, 3, 4, 5, 6, and 12 months of age
11164271|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
11164272|NCT03630679||Preterm|born at <37 weeks of gestation
11164273|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
11164274|NCT03630666|Active Comparator|IADT|one injection of IADT. The overall duration of IADT will be six months.
11164275|NCT03630666|Experimental|IADT+ radiotherapy|One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.
11164276|NCT03630653|Experimental|Sentinel LN in breast cancer recurrence|"Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.
~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.
~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND."
11164277|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
11164278|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
11164279|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
11164280|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
11164281|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
11164282|NCT03630614|Experimental|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
11164283|NCT03630614|Active Comparator|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
11166287|NCT03616587|Experimental|AZD9833 with palbociclib dose escalation|
11164284|NCT03630614|Placebo Comparator|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
11164285|NCT03630601|Experimental|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
11164286|NCT03630588|Placebo Comparator|Placebo|
11164287|NCT03630588|Experimental|Surimi intervention|
11164288|NCT03630575|Experimental|Newborns exposed in-utero to psychoactive substances|
11164289|NCT03630562|Other|Patients with exudative AMD|
11164290|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation
~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing
~No SMS intervention"
11164291|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation
~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing
~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)
~Offer of Individually customized SMS
~Monthly reminder SMS: to pick up ART
~SMS communicating VL result"
11164292|NCT03630523|Other|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
11164293|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
11164294|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
11164295|NCT03630497|Experimental|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164296|NCT03630497|Experimental|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164297|NCT03630497|Experimental|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164298|NCT03630497|Experimental|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164299|NCT03630497|Experimental|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164300|NCT03630497|Experimental|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164301|NCT03630497|Experimental|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164302|NCT03630497|Experimental|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)
~Comparison of BN201 treatment with Placebo"
11164303|NCT03630497|Experimental|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days
~Comparison of BN201 treatment with Placebo"
11164304|NCT03630497|Experimental|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days
~Comparison of BN201 treatment with Placebo"
11164305|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
11164306|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
11164307|NCT03630471|Active Comparator|Control|Enhanced usual care (problem-solving booklets only).
11164308|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
11164309|NCT03630458|Experimental|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
11164310|NCT03630458|Experimental|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
11164311|NCT03630458|Experimental|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
11164312|NCT03630458|Experimental|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
11164313|NCT03630458|Active Comparator|White rice|White rice - medium-grain prepared using a rice cooker
11164314|NCT03630445|Experimental|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.
~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
11164315|NCT03630445|Experimental|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.
~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
11164316|NCT03630445|Experimental|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
11166288|NCT03616587|Experimental|AZD9833 with palbociclib dose expansion|
11164317|NCT03630445|Experimental|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.
~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
11164318|NCT03630445|Experimental|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.
~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
11164319|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
11164320|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
11164321|NCT03630419|Experimental|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
11164322|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
11164323|NCT03630393|Experimental|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
11164324|NCT03630393|Active Comparator|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
11164325|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
11164326|NCT03630367|Experimental|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
11164327|NCT03630367|Active Comparator|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
11164328|NCT03630354|Experimental|Arm I (supervised exercise together)|Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting for 6 months.
11164329|NCT03630354|Experimental|Arm II (supervised exercise separately)|Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting for 6 months.
11164330|NCT03630354|Experimental|Arm III (unsupervised exercise separately)|Survivors and partners undergo 2 training sessions over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
11164331|NCT03630341|Experimental|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
11164332|NCT03630341|Active Comparator|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
11164333|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
11164334|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
11164335|NCT03630315|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
11164336|NCT03630315|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
11164337|NCT03630315|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
11164338|NCT03630315|Experimental|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
11164339|NCT03630289|Experimental|Surgical tissue autograft: TPF flap/pericranial flap|Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
11164340|NCT03630276|Other|Neutrophil/lymphocyte ratio|
11164341|NCT03630276|Other|Platelet/lymphocyte ratio|
11164342|NCT03630276|Other|CRP|
11164343|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
11164344|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
11164345|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).
~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.
~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.
~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
11164346|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
11164347|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).
~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.
~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.
~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
11164348|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
11164349|NCT03630224|Experimental|Plasmalyte Viaflo|Intervention type: drug (Plasmalyte Viaflo) Intervention name: plasmalyte Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
11164350|NCT03630224|Active Comparator|NaCl 0.9%|Intervention type: drug (NaCl 0.9%) Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
11164351|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
11164352|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
11164353|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
11164354|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
11164355|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
11164356|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
11164357|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
11164358|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
11164359|NCT03630146|Experimental|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
11164360|NCT03630146|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
11164361|NCT03630133|Experimental|Intracept System Ablation|Single Arm
11164362|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
11164363|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
11164364|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
11164365|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
11164366|NCT03630107|Experimental|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
11164367|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
11164368|NCT03630081|Experimental|FEP-TAZ 4 g|FEP-TAZ Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
11164369|NCT03630081|Active Comparator|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
11164370|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
11164371|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
11164372|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
11164373|NCT03630042|Experimental|Pembrolizumab and Rituximab|
11164374|NCT03630029|Other|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.
11164375|NCT03630029|Other|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.
11164376|NCT03630029|Other|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.
11164377|NCT03630029|Other|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.
11164378|NCT03630029|Other|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
11164379|NCT03630016|Active Comparator|Reference CO-Oximetry|Reference Co-Oximetry
11164380|NCT03630016|Experimental|Owlet BabySat v1.0|Owlet BabySat v1.0
11164381|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
11164382|NCT03630003|Experimental|Use of MOCS with post-use interview|"The patients in this arm will be asked to utilize the Manually Operated Communication System (MOCS) device and will then be asked to provide feedback on their experiences.
~Subjects will be asked to complete up to 3 sessions using the device. Each session is expected to last between 10 and 30 minutes. If the subject is interested in continuing, the session may last up to one hour.
~The study team will perform post-study interviews with each subject to ask about their experience with MOCS. The data collection forms will be filled out during the session by a member of the research team."
11164383|NCT03629990|Experimental|Active ABM + CBT/MET|"Participants in the Active ABM condition will receive approach bias modification (ABM) training sessions aimed at reducing cognitive bias for cannabis cues.
~All participants will receive MET/CBT therapy."
11166289|NCT03616587|Experimental|AZD9833 with everolimus dose expansion|
11164384|NCT03629990|Sham Comparator|Sham ABM + CBT/MET|"Participants in the Sham ABM condition will undergo similar computerized tasks without the manipulation of response contingencies that target modification of approach bias.
~All participants will receive MET/CBT therapy."
11164385|NCT03629977||early RRT|A patient where initiation of RRT is started without the absolute indications
11164386|NCT03629977||late RRT|"CRRT based on absolute indications.
~Absolute indications:
~hyperkalemia (serum potassium≥6 mEq/L),
~severe acidosis (pH≤7.15),
~plasma urea>36 mmol/L (equals BUN=100.8 mg/dl),
~oliguria or anuria (urine output<0.3 ml/kg per hour for ≥24 hours or anuria for ≥12 hours), and
~fluid overload with pulmonary edema as defined by the presence of all the following factors: (a) >10% fluid accumulation (cumulative fluid balance/baseline weight>10%), (b) oliguria (urine output<0.5 ml/kg per hour for ≥12 hours), and (c) severely impaired oxygenation (PaO2/FiO2<200 indicated by respiratory Sequential Organ Failure Assessment [SOFA] score≥3)"
11164387|NCT03629977||never RRT|RRT is never started, matched against early RRT group.
11164388|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
11164389|NCT03629951||Participants with Schizophrenia|Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram [mg] once daily [OD] to twice a day [BID]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day [TID]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.
11164390|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Experimental: Sintilimab Injection (Dosage form:10ml:100mg; Frequency: 200mg Q3W; Duration: until first documented tumor progression per RECIST v1.1 criteria) Sintilimab 200mg + gemcitabine plus platinum for 4 cycles followed by Sintilimab 200mg Q3W until first documented tumor progression per RECIST v1.1 criteria
11164391|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo + gemcitabine plus platinum Q3W for 4 cycles followed by placebo (Conditional crossover to sintilimab 200mg Q3W)
11164392|NCT03629912|Experimental|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
11164393|NCT03629912|Active Comparator|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
11164394|NCT03629912|Active Comparator|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
11164395|NCT03629912|No Intervention|Bingo Only|Participants use the Bingocize app to play bingo only.
11164396|NCT03629899|Experimental|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
11164397|NCT03629886|No Intervention|Vaccinated-HPV-039 Group|Healthy Chinese female subjects, who previously received Cervarix vaccine in HPV-039 study (NCT00779766), will undergo cervical sample collection in the current study.
11164398|NCT03629886|Experimental|Cervarix Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received control vaccine in HPV-039 study (NCT00779766), will undergo cervical sample collection before vaccination and will receive Cervarix vaccine in the current study.
11164399|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient
~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.
~A disc bur will be used to make a rectangular osteotomy
~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws
~Doner site flap is closed by using interrupted internal sutures.
~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done
~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
11164400|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient
~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.
~A disc bur will be used to make a rectangular osteotomy
~The block bone graft is removed from chin to recipient site the fixed by mini screws
~Doner site flap is closed by using interrupted internal sutures
~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done
~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
11164401|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
11164402|NCT03629821|Experimental|Ballet|Subjects who will receive the experimental protocol.
11164403|NCT03629821|No Intervention|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
11164404|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
11164405|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
11164406|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
11164407|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RDE will be determined in this part with escalating doses of etrumadenant in combination with a fixed dose of zimberelimab.
11164408|NCT03629756|Experimental|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RDE + zimberelimab
11164409|NCT03629756|Experimental|Dose Expansion-mCRPC|Etrumadenant at RDE + zimberelimab
11164410|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
11164411|NCT03629730|Experimental|High dose|Will receive the greatest duration of coordination intervention training.
11164412|NCT03629730|Experimental|Intermediate dose|Will receive a moderate duration of coordination intervention training.
11164413|NCT03629730|Experimental|Low dose|Will receive a short duration of coordination intervention training.
11164414|NCT03629730|Active Comparator|Active control|Will perform the same number and duration of physical exercises as the High Dose group, but while moving one body segment at a time.
11164415|NCT03629717|Experimental|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
11164416|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
11164417|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
11164418|NCT03629678|No Intervention|Control group (Booklets)|Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
11164419|NCT03629678|Active Comparator|mobile health application|Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
11164420|NCT03629665|Active Comparator|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
11164421|NCT03629665|Sham Comparator|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
11164422|NCT03629652|Experimental|Head down position|head-down position treatment combined with conventional rehabilitation.
11164423|NCT03629652|Sham Comparator|Conventional Rehabilitation|Conventional rehabilitation treatment
11164424|NCT03629639|Experimental|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
11164425|NCT03629639|Placebo Comparator|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
11164426|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
11164427|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
11164428|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.
~During baseline testing, no supplement or placebo intake will be used."
11164429|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.
~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
11164430|NCT03629600|Experimental|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) [COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
11164431|NCT03629600|Active Comparator|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin [Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA] just after the completion of ERCP procedure.
11164432|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
11164433|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
11164434|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
11164435|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
11164436|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
11164437|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
11164438|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
11164631|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
11164439|NCT03629522|Active Comparator|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
11164440|NCT03629522|Placebo Comparator|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
11164441|NCT03629509|Other|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)
~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
11164442|NCT03629509|Experimental|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:
~We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.
~We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
11164443|NCT03629509|Other|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
11164444|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
11164445|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
11164446|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
11164447|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
11164448|NCT03629470|Active Comparator|Group 1|standard conservative treatment
11164449|NCT03629470|Experimental|Group 2|nerve gliding exercises along with the standard conservative treatment.
11164450|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2.5 hours. Participants must practice at home for 15 minutes a day
11164451|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2.5 hours. Participants must practice at home for 30 minutes a day
11164452|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
11164453|NCT03629431|Active Comparator|postoperative standard care|Standard care after surgery in postoperative unit
11164454|NCT03629431|Experimental|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
11164455|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
11164456|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
11164457|NCT03629405|No Intervention|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
11164458|NCT03629405|No Intervention|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
11164459|NCT03629405|Experimental|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
11164460|NCT03629405|Experimental|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
11164461|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
11164462|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
11164463|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
11164464|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
11164465|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
11164466|NCT03629366|Experimental|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
11164467|NCT03629366|Active Comparator|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
11164468|NCT03629353|Experimental|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
11164469|NCT03629353|Experimental|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
11164470|NCT03629340|Experimental|Drug: Metformin|500mg PO (by mouth) BID (two times daily) x 1 week then increase to 1000mg PO BID x 11 weeks
11164471|NCT03629340|Placebo Comparator|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
11164472|NCT03629327|Active Comparator|ASA 300mg|Daily uptake of 300mg ASA
11164473|NCT03629327|Placebo Comparator|placebo|daily uptake of a placebo
11164474|NCT03629327|Active Comparator|ASA 100mg|daily uptake of 100mg ASA
11164475|NCT03629314|Experimental|Educational Pamphlet arm|Educational Pamphlet will be provided to all participants to review, questionnaire will be provided to complete before and after review of the pamphlets
11164476|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
11164477|NCT03629301|Other|Wait-list Group|
11164478|NCT03629288|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
11164479|NCT03629288|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
11164480|NCT03629275|Experimental|CTX0E03 Drug Product and delivery device|20 million neural stem cells
11164481|NCT03629275|Sham Comparator|Placebo|Sham Surgery
11164482|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
11164483|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
11164484|NCT03629249|Experimental|QAW039 Dose 1|QAW039 Dose 1 once daily orally
11164485|NCT03629249|Experimental|QAW039 Dose 2|QAW039 Dose 2 once daily orally
11164486|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
11164487|NCT03629236|Experimental|GrafixPL|
11164488|NCT03629236|Active Comparator|Control|
11164489|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
11164490|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
11164491|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
11164492|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
11164493|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
11164494|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
11164495|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
11164496|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
11164497|NCT03629210|Experimental|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
11164498|NCT03629210|Active Comparator|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
11164499|NCT03629197|Experimental|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
11164500|NCT03629197|Active Comparator|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
11164599|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
11164739|NCT03627611|Active Comparator|T4|
11164501|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
11164502|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
11164503|NCT03629171|Experimental|Treatment (CPX-351, venetoclax)|"INDUCTION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of course 1 and on days 1 and 3 of course 2. Participants also receive venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Participants receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and venetoclax PO QD on days 2-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11164504|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
11164505|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
11164506|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
11164507|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
11164508|NCT03629132|Experimental|PRP|Platelet-rich plasma
11164509|NCT03629132|Sham Comparator|Gel|Self-crosslinking sodium hyaluronate gel
11164510|NCT03629119|Experimental|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
11164511|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
11164512|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
11164513|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
11164514|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
11164515|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
11164516|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
11164517|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
11164518|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
11164519|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
11164520|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
11164521|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)
~There will be a 14 washout of days between the each period."
11164522|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)
~There will be a 14 washout of days between the each period."
11164523|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)
~There will be a 14 washout of days between the each period."
11164524|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
11164525|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
11164526|NCT03629041|Experimental|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
11164595|NCT03628573|Other|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
11164596|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
11164527|NCT03629041|Sham Comparator|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
11164528|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
11164529|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
11164530|NCT03629015|Experimental|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
11164531|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
11164532|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
11164533|NCT03628989|Experimental|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
11164534|NCT03628989|Experimental|Allergy Patients|Participants will use technology based distraction during procedure
11164535|NCT03628989|No Intervention|Procedure-Only Patients|
11164536|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
11164537|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
11164538|NCT03628963|Experimental|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
11164539|NCT03628963|No Intervention|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
11164540|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
11164541|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
11164542|NCT03628937|Experimental|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.
~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
11164543|NCT03628937|Placebo Comparator|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
11164544|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
11164545|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
11164546|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
11164547|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
11164548|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
11164549|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
11164550|NCT03628872|Active Comparator|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
11164551|NCT03628872|Experimental|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
11164552|NCT03628846||Traumatically Injured Adolescent|
11164553|NCT03628846||Not Traumatically Injured Adolescent|
11164554|NCT03628833|Experimental|Incontinence Management system|
11164555|NCT03628820|Experimental|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
11164597|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
11164598|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
11164556|NCT03628820|Experimental|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
11164557|NCT03628820|No Intervention|No Intervention|This group is not exposed to the therapy dog or handler.
11164558|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
11164559|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
11164560|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
11164561|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
11164562|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
11164563|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
11164564|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
11164565|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
11164566|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
11164567|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
11164568|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
11164569|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
11164570|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
11164571|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
11164572|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.
~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
11164573|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
11164574|NCT03628729|Experimental|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
11164575|NCT03628729|Active Comparator|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
11164576|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
11164577|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
11164578|NCT03628690|Experimental|BandGrip|Topical skin closure device
11164579|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
11164580|NCT03628677|Experimental|AB154 Monotherapy|Varying Doses of AB154 Monotherapy
11164581|NCT03628677|Experimental|AB154 + zimberelimab Q2W Combination Therapy|Varying Doses of AB154 in Combination With Varying Doses of zimberelimab
11164582|NCT03628677|Experimental|AB154 + zimberelimab Q3W Combination Therapy|Varying Doses of AB154 in Combination With Varying Doses of zimberelimab
11164583|NCT03628677|Experimental|AB154 + zimberelimab Q4W Combination Therapy|Varying Doses of AB154 in Combination With Varying Doses of zimberelimab
11164584|NCT03628664|Active Comparator|CT planned total knee arthroplasty|Surgeon will follow the CT plan
11164585|NCT03628664|No Intervention|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
11164586|NCT03628651||HCC Surveillance|Approximately 1400 HCC surveillance subjects (controls) will be enrolled.
11164587|NCT03628651||HCC|Approximately 700 subjects with untreated clinically diagnosed HCC will be enrolled.
11164588|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
11164589|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
11164590|NCT03628625|Experimental|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
11164591|NCT03628625|Placebo Comparator|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
11164592|NCT03628612|Experimental|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
11164593|NCT03628599|Experimental|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
11164594|NCT03628599|Active Comparator|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
11164600|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
11164601|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
11164602|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
11164603|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
11164604|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
11164605|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
11164606|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
11164607|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
11164608|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
11164609|NCT03628534|Experimental|single arm|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
11164610|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
11164611|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
11164612|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
11164613|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
11164614|NCT03628495|Experimental|SSCP + SPMS|
11164615|NCT03628495|Active Comparator|PG|
11164616|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
11164617|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
11164618|NCT03628469|Experimental|Proactive Health Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
11164619|NCT03628469|No Intervention|Usual care|Usual care
11164620|NCT03628456|Experimental|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
11164621|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
11164622|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
11164623|NCT03628430|Placebo Comparator|Group C|"For patients of this group, the intervention was a Local Anesthesia with:
~10 mL of 2% lidocaine with epinephrine 0.005mg/ml
~and 5 mL of 0.9% NaCl"
11164624|NCT03628430|Active Comparator|Group A|"For patients of this group, the intervention was a Local Anesthesia with:
~10 mL of 2% lidocaine with epinephrine 0.005mg/ml
~and 5 mL of 4.2 % sodium bicarbonate"
11164625|NCT03628417|Experimental|Calcium Electroporation|"Calcium
~Calcium chloride 220 mmol/L (9 mg/ml):
~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume
~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
11164626|NCT03628417|Experimental|Bleomycin based electrochemotherapy|"Bleomycin
~Bleomycin 1000 IU/ml:
~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume
~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)
~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
11164627|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.
~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
11164628|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.
~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
11164629|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
11164630|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
11164632|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
11164633|NCT03628352|Experimental|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
11164634|NCT03628339|Experimental|Midazolam, then tepotinib followed by midazolam + tepotinib|Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
11164635|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
11164636|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
11164637|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
11164638|NCT03628300||piperacillin serum measurement|patient that underwent at least one piperacillin serum concentration monitoring
11164639|NCT03628300||included for analysis|patient that have been included for analysis according to previously described criteria
11164640|NCT03628287|Active Comparator|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
11164641|NCT03628287|Experimental|Revised Care Coordination Program|"The revised model includes the original intervention components without program track assignments or the three-month induction period of weekly visits. Program additions include a set of tools for assessment and counseling around client HIV self-management capacity; allowance of video chat for delivery of some services; and optional iART (immediate ART: ensuring the client has a filled prescription within 4 days of enrollment or diagnosis). Other changes include greater guidance on recruiting individuals with unsuppressed VL and a switch from per-member-per-day reimbursement to fee-for-service reimbursement that accounts for resource demands, such as staff travel to clients' homes, and offers higher rates for meeting performance standards."
11164642|NCT03628274|Experimental|Magnetic Resonance Imaging (RMI) 7 Tesla|
11164643|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
11164644|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
11164645|NCT03628248|Experimental|embolization|
11164646|NCT03628248|Other|No embolization|
11164647|NCT03628235||Early stage HDGECs|CAG length ≥ 40; DCL = 4, TFC ≥ 11
11164648|NCT03628235||Middle stage HDGECs|CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
11164649|NCT03628235||Late stage HDGECs|CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6
11164650|NCT03628235||Companions of early stage HDGECs|
11164651|NCT03628235||Companions of middle stage HDGECs|
11164652|NCT03628235||Companions of late stage HDGECs|
11164653|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
11164654|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
11164655|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
11164656|NCT03628196||Quality Improvement Program Basic and Enhanced Phase|Patients that meet the eligibility criteria and participate in the QIP.
11164657|NCT03628196||Retrospective Group|Patients seen a year prior to the QIP period at the clinic but that did not participate in the QIP.
11164658|NCT03628196||Concurrent Group|Patients seen during the QIP period at the clinic but that did not participate in the QIP.
11164659|NCT03628183|Active Comparator|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
11164660|NCT03628183|Experimental|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
11164661|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
11164662|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
11164663|NCT03628157|Experimental|intervention|using a bio-oss bovine bone alone
11164664|NCT03628157|Active Comparator|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
11164665|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
11164740|NCT03627611|Experimental|T3|
11164840|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
11164666|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
11164667|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
11164668|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
11164669|NCT03628105|Experimental|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
11164670|NCT03628105|Experimental|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
11164671|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
11164672|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
11164673|NCT03628079|Experimental|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.
~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
11164674|NCT03628066|Experimental|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue
~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
11164675|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
11164676|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
11164677|NCT03628040|Sham Comparator|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
11164678|NCT03628040|Active Comparator|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane
11164679|NCT03628027|Experimental|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
11164680|NCT03628027|No Intervention|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
11164681|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
11164682|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
11164683|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
11164684|NCT03627988|Experimental|Patients with breast cancer|
11164685|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
11164686|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
11164687|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
11164688|NCT03627962|Experimental|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
11164689|NCT03627962|No Intervention|control|No intervention: participants in control read ordinary Chinese textbooks.
11164690|NCT03627949|Experimental|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
11164691|NCT03627949|Experimental|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
11164692|NCT03627949|No Intervention|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
11164693|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
11164694|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
11164695|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
11164696|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
11164741|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
11164697|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
11164698|NCT03627897|Sham Comparator|Control group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 mlt/kg salin (Group S).
11164699|NCT03627884|Active Comparator|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
11164700|NCT03627884|Active Comparator|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
11164701|NCT03627871|Experimental|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
11164702|NCT03627871|Experimental|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
11164703|NCT03627871|Experimental|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
11164704|NCT03627871|Experimental|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
11164705|NCT03627871|Experimental|Control|Participants receive information about exercise unrelated to social norms or recent trends.
11164706|NCT03627845|Experimental|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
11164707|NCT03627845|Placebo Comparator|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
11164708|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
11164709|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
11164710|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
11164711|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
11164712|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
11164713|NCT03627793|Active Comparator|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
11164714|NCT03627793|Active Comparator|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
11164715|NCT03627793|Experimental|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
11164716|NCT03627793|Experimental|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
11164717|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
11164718|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
11164719|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
11164720|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
11164721|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
11164722|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
11164723|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
11164724|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
11164725|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
11164726|NCT03627728|Experimental|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
11164727|NCT03627728|Placebo Comparator|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
11164728|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
11164729|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.
~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
11164730|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
11164731|NCT03627689|Experimental|Active air purifier arm|Active portable air purifier for 1 month at bedside
11164732|NCT03627689|Sham Comparator|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
11164733|NCT03627676|Experimental|Intervention|
11164734|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
11164735|NCT03627650|Experimental|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
11164736|NCT03627650|Experimental|Same group of 15 patients|procedure/surgery: placebo injection of scar
11164737|NCT03627637|Experimental|Experimental: Soy nuts|
11164738|NCT03627637|No Intervention|Control - no soy nuts|
11164742|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
11164743|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
11164744|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
11164745|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
11164746|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
11164747|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
11164748|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
11164749|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
11164750|NCT03627533|Experimental|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on MA-IC3 endocrine (ear points), GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
11164751|NCT03627533|Sham Comparator|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
11164752|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
11164753|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
11164754|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
11164755|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164756|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164757|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164758|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164759|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164760|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164761|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164762|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164763|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164764|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
11164765|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
11164766|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164767|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
11164768|NCT03627481|Experimental|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
11164769|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, q.d. for 48 weeks
11164770|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 48 weeks
11164771|NCT03627455||Male, with DM|
11164772|NCT03627455||Male, without DM|
11164773|NCT03627455||Female, with DM|
11164774|NCT03627455||Female, without DM|
11164775|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
11164776|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
11164777|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
11164778|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
11164779|NCT03627403|Experimental|Selinexor, all patients|Single Arm Study, all patients will get selinexor
11164780|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
11164781|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
11164782|NCT03627377|No Intervention|Control Phase|3-month initial control phase (no intervention, month 1-3)
11164783|NCT03627377|Experimental|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
11164784|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
11164785|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
11164786|NCT03627351||Healthy Women and Men|Group of healthy women and men
11164787|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
11164788|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
11164789|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
11164790|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
11164791|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
11164792|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
11164793|NCT03627299|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
11164794|NCT03627273|Experimental|walker|'6 minutes walking test' with a walker
11164795|NCT03627273|Active Comparator|no walker|'6 minutes walking test' without walker
11164796|NCT03627247|Experimental|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
11164797|NCT03627247|No Intervention|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
11164798|NCT03627234|Experimental|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
11164799|NCT03627234|Experimental|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
11164800|NCT03627221|Experimental|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
11164801|NCT03627221|No Intervention|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
11164802|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
11164803|NCT03627195|Experimental|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
11164804|NCT03627195|Placebo Comparator|Placbo|placebo injection
11164805|NCT03627182|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
11164806|NCT03627182|Placebo Comparator|Placebo|Placebo
11164807|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
11164808|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
11164809|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
11164810|NCT03627143|Other|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
11164811|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
11164812|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
11164813|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
11164814|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
11164815|NCT03627104|Other|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
11164816|NCT03627104|Other|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
11164817|NCT03627104|Other|High-protein diet with animal protein|The patient will intake the diet assigned for a month
11164818|NCT03627104|Other|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
11164819|NCT03627091|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous (SC) injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
11164820|NCT03627091|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
11164821|NCT03627091|Placebo Comparator|Placebo|Participants will receive placebo matched with ontamalimab SC injection using prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
11164822|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
11164823|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
11164824|NCT03627065|Experimental|Parsaclisib|
11164825|NCT03627052|Experimental|Itacitinib|
11164826|NCT03627052|Placebo Comparator|Placebo|
11164827|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
11164828|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
11164829|NCT03627013|Experimental|Kidney Custodiol-N|
11164830|NCT03627013|Active Comparator|Kidney Custodiol|
11164831|NCT03627013|Experimental|Liver Custodiol-N|
11164832|NCT03627013|Active Comparator|Liver Custodiol|
11164833|NCT03627013|Experimental|Kidney/Pancreas Custodiol-N|
11164834|NCT03627013|Active Comparator|Kidney/Pancreas Custodiol|
11164835|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
11164836|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
11164837|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
11164838|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
11164839|NCT03626961||discharge|patients discharged from icu
11164841|NCT03626948|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
11164842|NCT03626935|Experimental|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
11164843|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.
~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.
~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
11164844|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.
~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.
~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
11164845|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
11164846|NCT03626883|Experimental|1 hamstring|Patients will receive the intervention of 'single-bundle, single-hamstring ACL reconstruction'.
11164847|NCT03626883|Active Comparator|2 hamstrings|Patients will receive the intervention of 'single-bundle, double-hamstring ACL reconstruction'.
11164848|NCT03626857|Experimental|NMES+ECC|Neuromuscular electrical stimulation (NMES) and Eccentric Exercise (ECC). Patients randomized to the NMES+ECC group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive eccentric exercise 2x/week for an additional 8 weeks. For NMES, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For eccentric exercise, patients will train for 4 sets of 10 repetitions. This group will also receive standard of care ACL rehabilitation alongside the study interventions.
11164849|NCT03626857|Placebo Comparator|NMES placebo + ECC placebo|"Neuromuscular electrical stimulation (NMES) placebo + Eccentric Exercise (ECC)placebo arm. Patients randomized to the NMES placebo + ECC placebo group will first receive NMES placebo for 2x/week for 8 weeks, beginning at the first post-operative physical therapy visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.
~For the NMES placebo, patients will have NMES placebo delivered to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Fifteen isometric actions lasting 10 seconds each will be elicited during each session.
~For the eccentric exercise placebo, patients will begin to receive eccentric exercise two times per week for 8 weeks. Patients will train for 4 sets of 10 repetitions."
11164850|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
11164851|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
11164852|NCT03626831|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
11164853|NCT03626831|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
11164854|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
11164855|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
11164856|NCT03626805||Healthy Controls|Age and sex matched
11164857|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
11164858|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
11164859|NCT03626779|Other|immediate placment and loading with prf|Immediat placment and loading with prf
11164860|NCT03626779|No Intervention|immediate implant placment and loading|Immediate implant placment and loading without prf
11164861|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
11164862|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
11164863|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
11164864|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
11164865|NCT03626753|Active Comparator|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
11165218|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
11164866|NCT03626753|Active Comparator|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
11164867|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
11164868|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
11164869|NCT03626727|Experimental|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
11164870|NCT03626714|Experimental|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
11164871|NCT03626701|Experimental|RECELL® Autologous Cell Harvesting Device|"RECELL + Telfa™ Clear and Xeroform™ dressings
~Conventional autografting (only when indicated)"
11164872|NCT03626701|Active Comparator|Mepilex® Ag Wound Dressing|"Mepilex® Ag Wound Dressing
~Conventional autografting (only when indicated)"
11164873|NCT03626688|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose (maximum dose of 1450 mcg)
11164874|NCT03626688|Placebo Comparator|Placebo|Matching placebo tablets (oral)
11164875|NCT03626675|Other|study group|"They will be subjected to:
~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS-OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.
~Surgery combined Phaco trabeculectomy
~Post operative:
~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.
~and biometric parameters measured with the AS-OCT before and after the surgery will be used to collect the data.
~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
11164876|NCT03626662|Placebo Comparator|Placebo|Single Ascending Dose Cohorts
11164877|NCT03626662|Experimental|AMG 890|Single Ascending Dose Cohorts
11164878|NCT03626649|Experimental|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
11164879|NCT03626636|Active Comparator|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
11164880|NCT03626636|Placebo Comparator|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
11164881|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
11164882|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
11164883|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
11164884|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
11164885|NCT03626597|Active Comparator|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
11164886|NCT03626597|Active Comparator|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
11164887|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
11164888|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
11164889|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
11164890|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
11164891|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
11164892|NCT03626558|Experimental|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.
~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
11164893|NCT03626545|Experimental|Canakinumab|Blinded Canakinumab administered at the recommended Phase III regimen (defined in the safety run-in part). Canakinumab will be given in combination with docetaxel (standard of care)
11164894|NCT03626545|Placebo Comparator|Placebo|Matching placebo, administered at the recommended Phase III regimen (defined in the safety run-in part), in combination with docetaxel (standard of care)
11164895|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
11164896|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
11164897|NCT03626519|Experimental|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
11164898|NCT03626519|Placebo Comparator|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
11164899|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
11164900|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
11164901|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
11164902|NCT03626467|Experimental|Arm 1|Men infected by HIV who have sex with men
11164903|NCT03626454|Active Comparator|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
11164904|NCT03626454|Active Comparator|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
11164905|NCT03626441|Placebo Comparator|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
11164906|NCT03626441|Experimental|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
11164907|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
11164908|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
11164909|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
11164910|NCT03626389||Patients receiving physiotherapy|Physiotherapy, without predetermined selection of specific modalities
11164911|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
11164912|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
11164913|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
11164914|NCT03626363|Active Comparator|Stress Management Education|
11164915|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
11164916|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
11164917|NCT03626324|Experimental|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
11164918|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
11164919|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
11164920|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
11164921|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
11164922|NCT03626285|Experimental|Treatment (BMT with CD34 peripheral blood stem cells)|Donor stem cells undergo CD34 selection ex vivo using the CliniMACS CD34 Reagent System using SOPs from the manufacturer. Recipients undergo standard of care preparative regimen, bone marrow transplantation with CD34-selected peripheral blood stem cells via infusion over 1 to 2 hours on day 0, and then receive standard of care GVHD prophylaxis.
11164923|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
11164924|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
11164925|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
11164926|NCT03626259|Other|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
11164927|NCT03626259|Active Comparator|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
11164928|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
11164929|NCT03626233||Vascular group|Pregnant women with vascular pathology
11164930|NCT03626233||Control group|"Pregnancy without any vascular complication
~Delivery before or after 37 weeks of gestation (GW)
~In case of delivery after 37GW: birth by cesarean delivery"
11164931|NCT03626220||acupuncture group|acupuncture with de-chi sensation
11164932|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
11164933|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
11164934|NCT03626181|Experimental|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
11164935|NCT03626168|Active Comparator|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
11164936|NCT03626168|Placebo Comparator|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
11164937|NCT03626155|Experimental|Seated Control|
11164938|NCT03626155|Experimental|Morning Exercise (walking)|
11164939|NCT03626155|Experimental|Afternoon Exercise (walking)|
11164940|NCT03626155|Experimental|Evening Exercise (walking)|
11164941|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
11164942|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
11164943|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
11164970|NCT03625973|Experimental|16 Weeks of 3D-RT|Participants will receive 16 weeks of Reminiscence Therapy using 3D printed objects as stimuli.
11164971|NCT03625973|Experimental|8 Weeks of 3D-RT|Participants will receive 8weeks of Reminiscence Therapy using 3D printed objects as stimuli and 8 weeks of RT using verbal stimuli.
11164944|NCT03626129|No Intervention|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
11164945|NCT03626129|Experimental|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
11164946|NCT03626103|Experimental|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
11164947|NCT03626103|Experimental|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
11164948|NCT03626103|Experimental|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
11164949|NCT03626103|No Intervention|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
11164950|NCT03626090|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
11164951|NCT03626077|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
11164952|NCT03626077|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
11164953|NCT03626077|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
11164954|NCT03626064|Other|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
11164955|NCT03626051|Active Comparator|rigid tape group|
11164956|NCT03626051|Experimental|fibular tape group|
11164957|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.
~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
11164958|NCT03626025|No Intervention|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
11164959|NCT03626025|Other|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
11164960|NCT03626012|Experimental|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
11164961|NCT03626012|Experimental|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
11164962|NCT03626012|Experimental|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
11164963|NCT03626012|Experimental|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
11164964|NCT03626012|Experimental|Cohort 5: BIIB078 Fifth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
11164965|NCT03626012|Placebo Comparator|Cohorts 1-5: Placebo|Matching placebo will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days (Cohorts 1 through 3) and five maintenance doses on five later days (Cohorts 4 and 5).
11164966|NCT03625999|Experimental|Training Group|Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
11164967|NCT03625999|No Intervention|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on a loaned laptop), walked through the game's operation and controls, and encouraged to use it as often as they or their child like. If the child plays the game for a minimum of 20 minutes, 3 times per week, for 4 weeks, the family will be invited back to CARE for post-testing.
11164968|NCT03625986|Experimental|Nicotine-Containing Electronic Cigarette|The experimental group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 15 mg/ml nicotine for the duration of 6 weeks.
11164969|NCT03625986|Placebo Comparator|Non-Nicotine Electronic Cigarette|The placebo group will be provided with and encouraged to use a Standardized Research Electronic Cigarette (SREC) with liquid containing 0 mg/ml nicotine for the duration of 6 weeks.
11166290|NCT03616587|Experimental|AZD9833 with everolimus dose escalation|
11164972|NCT03625973|Active Comparator|16 Weeks of RT using Verbal Stimuli|Participants will receive 16 weeks of RT using verbal stimuli to reminiscence.
11164973|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
11164974|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
11164975|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
11164976|NCT03625934|Experimental|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
11164977|NCT03625934|Placebo Comparator|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
11164978|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
11164979|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
11164980|NCT03625908|Active Comparator|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
11164981|NCT03625908|Active Comparator|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
11164982|NCT03625895||Agrylin|Participants who received treatment with Agrylin will be evaluated for this study.
11164983|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
11164984|NCT03625869|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
11164985|NCT03625869|Experimental|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
11164986|NCT03625856|Experimental|Intervention|1500 mg Chlorella Vulgaris capsule
11164987|NCT03625856|Placebo Comparator|Control|1500 mg placebo (starch)
11164988|NCT03625843|Experimental|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
11164989|NCT03625843|No Intervention|Control|Sitting quietly in a room alone.
11164990|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
11164991|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
11164992|NCT03625817|No Intervention|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
11164993|NCT03625817|Experimental|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
11164994|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
11164995|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
11164996|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
11164997|NCT03625791||radiation-induced sarcomas|
11164998|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
11164999|NCT03625791||primary sarcomas|
11165000|NCT03625778|Experimental|MEDI0382 1 week titration|MEDI0382 administered subcutaneously (up to 7 week titration period dose escalated weekly)
11165001|NCT03625778|Placebo Comparator|Placebo|Placebo administered subcutaneously
11165002|NCT03625778|Experimental|MEDI0382 2 week titration|MEDI0382 administered subcutaneously (up to 10 week titration period dose escalation every 2 weeks)
11165003|NCT03625778|Experimental|MEDI0382 4 week titration|MEDI0382 administered subcutaneously (up to 16 week titration period dose escalated every 4 weeks)
11165004|NCT03625765|Experimental|SmartGoggles|The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. Investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nanomolar (nM) concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with optical density (OD) 6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
11165005|NCT03625752|Active Comparator|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
11165006|NCT03625752|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
11165007|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
11165008|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
11165009|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
11165149|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
11165010|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation <94 % irrespective of supplemental oxygen
~Patients with chronic obstructive pulmonary disease: blood oxygen saturation <88% irrespective of supplemental oxygen"
11165011|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.
~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
11165012|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation >98% in combination with supplemental oxygen
~Patients with chronic obstructive pulmonary disease: blood oxygen saturation >92% in combination with supplemental oxygen"
11165013|NCT03625687|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
11165014|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
11165015|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
11165016|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
11165017|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
11165018|NCT03625661|Experimental|Arm with Ferinject|Ferinject will be administered once at inclusion
11165019|NCT03625648|Experimental|PTX|Active drug
11165020|NCT03625648|Placebo Comparator|Placebo|Placebo
11165021|NCT03625635|Experimental|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
11165022|NCT03625622|Placebo Comparator|Placebo|Placebo, orally administered once daily for 26 weeks.
11165023|NCT03625622|Active Comparator|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
11165024|NCT03625622|Active Comparator|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
11165025|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
11165026|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
11165027|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
11165028|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
11165029|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
11165030|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
11165031|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
11165032|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
11165033|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
11165034|NCT03625544|Active Comparator|Autograft|Autologous bone graft
11165035|NCT03625531|Experimental|Personalized acupuncture|Two sets of acupoints will be selected for the two types. The basic acupoint-prescription includes CV 4, CV 6, CV 12 and SP 6 bilaterally, ST 25 bilaterally, EX-CA 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points K 13, LR 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients special symptoms.
11165036|NCT03625531|Experimental|Fixed acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
11165037|NCT03625531|Active Comparator|Letrozole|Women in the letrozole group will be given letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
11165038|NCT03625531|Placebo Comparator|Placebo letrozole|Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
11165039|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
11165040|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
11165041|NCT03625505|Experimental|Dose Escalation Venetoclax + Gilteritinib|Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
11165042|NCT03625505|Experimental|Dose Expansion Venetoclax + Gilteritinib|Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.
11165117|NCT03624985|Placebo Comparator|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
11165043|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
11165044|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
11165045|NCT03625466|Experimental|Part 1: Double Blind Period|Subjects will receive LUM/IVA as FDC granules dependent upon weight or matched placebo at Day 1.
11165046|NCT03625466|Experimental|Part 2: Open Label Period|Subjects will receive LUM/IVA as FDC tablets or granules dependent upon weight at Day 1.
11165047|NCT03625453|Experimental|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
11165048|NCT03625453|Placebo Comparator|Placebo|Oral use of hard capsule
11165049|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.
~The Digit span test and PASAT with waterpipe smoking"
11165050|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.
~The Digit span test and PASAT without waterpipe smoking"
11165051|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
11165052|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
11165053|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
11165054|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
11165055|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
11165056|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
11165057|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
11165058|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
11165059|NCT03625401|Experimental|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
11165060|NCT03625401|Placebo Comparator|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
11165061|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
11165062|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
11165063|NCT03625375|Experimental|Treatment Group|Individuals will perform exercises 3 times a week.
11165064|NCT03625375|No Intervention|Control Group|Individuals will not perform exercises
11165065|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
11165066|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
11165067|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
11165068|NCT03625336||Prostate Calcifications|Men with prostate calcifications
11165069|NCT03625323|Experimental|1st line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).
~Pembrolizumab: 200 mg every 3 weeks."
11165070|NCT03625323|Experimental|2nd line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).
~Pembrolizumab: 200 mg every 3 weeks."
11165071|NCT03625323|Experimental|HNSCC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).
~Pembrolizumab: 200 mg every 3 weeks."
11165072|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
11165073|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
11165074|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
11165075|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
11165076|NCT03625297|No Intervention|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
11165077|NCT03625297|Experimental|shelter cat adoption|Families of children with autism will adopt a shelter cat
11165078|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
11165079|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
11165080|NCT03625271|No Intervention|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
11165081|NCT03625271|Experimental|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
11165082|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
11165083|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
11165084|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
11165085|NCT03625219|Active Comparator|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
11165086|NCT03625219|Placebo Comparator|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
11165087|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
11165088|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
11165089|NCT03625193||Ambulatory patients with SCI|"Age at least 18 years
~Body mass index (BMI) between 18.5 - 29.9 kg/m2
~Having an incomplete SCI from traumatic or non-traumatic causes
~Ability of independent standing up from a chair with or without hand support
~Ability of independent walking with or without walking device over at least 10 meters continuously.
~Ability to follow commands used in the studies"
11165090|NCT03625180||Treatment|NAMIC technique
11165091|NCT03625167|Experimental|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
11165092|NCT03625167|No Intervention|Control|The control forearm will remain untreated throughout the study.
11165093|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
11165094|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
11165095|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
11165096|NCT03625141|Experimental|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
11165097|NCT03625141|Experimental|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
11165098|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
11165099|NCT03625115|No Intervention|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
11165100|NCT03625115|Experimental|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
11165101|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
11165102|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
11165103|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
11165104|NCT03625089|Active Comparator|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Framingham Risk Score >10%
11165105|NCT03625089|Experimental|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
11165106|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
11165107|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
11165108|NCT03625063|Active Comparator|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
11165109|NCT03625063|Sham Comparator|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
11165110|NCT03625050|Experimental|Chuna + Usual care|
11165111|NCT03625050|Active Comparator|Usual care|
11165112|NCT03625037|Experimental|Epcoritamab (GEN3013, DuoBody®-CD3xCD20)|Open label, single arm trial where Epcoritamab will be administered.
11165113|NCT03625011|Placebo Comparator|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
11165114|NCT03625011|Active Comparator|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
11165115|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
11165116|NCT03624985|Experimental|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
11165148|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
11165118|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
11165119|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
11165120|NCT03624972|No Intervention|Clinician Arm|Seven clinicians will be consented to this study in order to have their clinic visits with the participating patients audio recorded. Only demographic information will be collected from the clinicians via self-report.
11165121|NCT03624959|Experimental|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
11165122|NCT03624959|Experimental|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
11165123|NCT03624959|Experimental|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
11165124|NCT03624959|Experimental|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
11165125|NCT03624959|Experimental|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
11165126|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
11165127|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
11165128|NCT03624933|Experimental|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
11165129|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
11165130|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
11165131|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
11165132|NCT03624907|Other|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
11165133|NCT03624907|Other|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
11165134|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
11165135|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
11165136|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
11165137|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
11165138|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
11165139|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
11165140|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
11165141|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
11165142|NCT03624816|No Intervention|Control|no-treatment control
11165143|NCT03624790|Experimental|Group 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
11165144|NCT03624777|Experimental|Stroll Safe Program|
11165145|NCT03624777|Active Comparator|Outdoor Fall Prevention Brochure|
11165146|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
11165147|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
11165150|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
11165151|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
11165152|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
11165153|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
11165154|NCT03624686||healthy volunteer|
11165155|NCT03624686||luekemia patient|
11165156|NCT03624673|Experimental|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
11165157|NCT03624673|Active Comparator|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
11165158|NCT03624660|Experimental|HR-A (High-risk A)|"Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.
~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
11165159|NCT03624660|Experimental|HR-B (High-risk B)|"Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.
~Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.
~Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.
~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
11165160|NCT03624647|Experimental|Power toothbrush|
11165161|NCT03624647|Placebo Comparator|Manual toothbrush|
11165162|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
11165163|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
11165164|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
11165165|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
11165166|NCT03624595|Experimental|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
11165167|NCT03624595|Placebo Comparator|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
11165168|NCT03624569|Sham Comparator|Bagel diet|Bagel consumed daily for 2 weeks
11165169|NCT03624569|Experimental|Potato diet|Potato consumed daily for 2 weeks
11165170|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
11165171|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
11165172|NCT03624543|Experimental|Cohort 1: TNBC|N=9 to 24 patients
11165173|NCT03624543|Experimental|Cohort 2: PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
11165174|NCT03624543|Experimental|Cohort 3: Not PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
11165175|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
11165176|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
11165177|NCT03624517|Experimental|24-hour octreotide infusion|Patients will receive octreotide infusion over 24 hours
11165178|NCT03624517|Active Comparator|72-hour octreotide infusion|Patients will receive octreotide infusion over 72 hours
11165179|NCT03624504|Experimental|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
11165180|NCT03624491|No Intervention|Standard of care mechanical ventilation|Anesthesia and surgical procedures will be performed following standard of care for mechanical ventilation during surgery.
11165181|NCT03624491|Active Comparator|Transpulmonary pressure guided mechanical ventilation|Same treatment as the control group with the addition of esophageal pressure measurements used to guide mechanical ventilation during surgery.
11165182|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
11165183|NCT03624465|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
11165184|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
11165185|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
11165186|NCT03624439|Experimental|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
11165187|NCT03624439|Experimental|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
11165188|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
11165189|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
11165190|NCT03624413|Experimental|Receives social media intervention|40 adolescents receiving the social media intervention
11165191|NCT03624413|No Intervention|Receives standard of care|40 adolescents receiving standard of care
11165192|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
11165193|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
11165194|NCT03624387|No Intervention|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
11165195|NCT03624387|Experimental|Intervention Group( Painting Session)|Painting sessions for participants
11165196|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.
~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
11165197|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
11165198|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
11165199|NCT03624335|Experimental|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.
~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
11165200|NCT03624335|Experimental|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
11165201|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
11165202|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
11165203|NCT03624309|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
11165204|NCT03624309|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
11165205|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
11165206|NCT03624283|Experimental|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
11165207|NCT03624283|Experimental|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
11165208|NCT03624283|Experimental|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
11165209|NCT03624270|Experimental|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:
~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days
~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)
~Hydroxyurea 2-4g per day if WBC > 5 x 10^9/L during the first 7 days of induction.
~Consolidation (for all patients):
~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles
~Maintenance (for all patients):
~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
11165210|NCT03624257|Experimental|Scaling and root planning + Laser treatment|
11165211|NCT03624257|Active Comparator|Mucosal flap surgery|
11165212|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
11165213|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
11165214|NCT03624231|Experimental|Arm 1|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.
~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
11165215|NCT03624231|Experimental|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.
~Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
11165216|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
11165217|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
11165219|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
11165220|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
11165221|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
11165222|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
11165223|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
11165224|NCT03624153|Experimental|Robotic-assisted training|Participants in robotic-assisted training group will receive 1.5 hours/ day, 3 days a week, for 4 continuous weeks at the clinical setting. Participants will receive 10-minute of muscle tone normalization preparation and passive range of motion, then an 80-minute robotic-assisted training. After the end of the robotic-assisted training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.Before and after the treatment, the evaluations were conducted. One month after the end of the treatment course, a follow-up evaluation will be assessed.
11165225|NCT03624153|Active Comparator|Clinic-based therapy|"Participants in clinic-based training group will receive 1.5 hours/ day, 3 days a week, for 4 continuous weeks at the clinical setting. Participants will receive traditional occupational therapy for 90 minutes. After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the Robot-assisted training for 4 continuous weeks.
~Before and after the treatment, the evaluations were conducted. One month after the end of the treatment course, a follow-up evaluation will be assessed."
11165226|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
11165227|NCT03624127|Experimental|BMS-986165|BMS-986165 oral administration
11165228|NCT03624127|Placebo Comparator|Placebo|Placebo oral administration
11165229|NCT03624127|Active Comparator|Active comparator|Active comparator oral administration
11165230|NCT03624101|Experimental|tezacaftor/ivacaftor|After a 4-week screening period to confirm eligibility based on study inclusion and exclusion criteria subjects will receive Symdeko in 3 intermittent four-week intervals, followed by a 4-week follow-up period (for safety and to detect efficacy changes upon washout) Symdeko (Ivacaftor (150 mg daily) Tezacaftor (100 mg daily) will be administered at the approved dose in combination pill, and alternated with ivacaftor.
11165231|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
11165232|NCT03624075|No Intervention|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
11165233|NCT03624075|Placebo Comparator|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
11165234|NCT03624075|Experimental|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
11165235|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
11165236|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
11165237|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
11165238|NCT03624062|Other|TBD ug IBC in 0.5 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the maximum safe IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.5 mL MAS-1 emulsion
11165239|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
11165240|NCT03624036|Experimental|brexucabtagene autoleucel (KTE-X19)|Participants will receive conditioning chemotherapy (fludarabine and cyclophosphamide), followed by the investigational treatment, brexucabtagene autoleucel (KTE-X19).
11165241|NCT03624023|Experimental|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
11165242|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
11165243|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
11166441|NCT03615560||Gestational hypertension|
11166442|NCT03615560||Control group|
11165244|NCT03623984|Experimental|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
11165245|NCT03623971|Experimental|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
11165246|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
11165247|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
11165248|NCT03623945||Cohort A|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.
11165249|NCT03623945||Cohort B|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.
11165250|NCT03623945||Cohort C|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH).
11165251|NCT03623945||Cohort D|Patients who have had a normal screening mammogram within the last 6 months will be invited to participate.
11165252|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
11165253|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
11165254|NCT03623919|Experimental|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.
~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.
~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
11165255|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
11165256|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
11165257|NCT03623893|Other|Intervention group|Unilateral inguinal hernia repair with contralateral exploration.
11165258|NCT03623893|No Intervention|Control group|Unilateral inguinal hernia repair.
11165259|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
11165260|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
11165261|NCT03623867|Experimental|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
11165262|NCT03623867|Placebo Comparator|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 48
11165263|NCT03623854|Experimental|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11165264|NCT03623841|Experimental|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
11165265|NCT03623841|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
11165266|NCT03623828|Experimental|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.
~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
11165267|NCT03623815|Other|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
11165268|NCT03623815|Other|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
11165269|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
11165270|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
11165271|NCT03623789|Active Comparator|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
11165272|NCT03623789|Active Comparator|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
11165273|NCT03623789|Placebo Comparator|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
11165274|NCT03623776|Experimental|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
11165275|NCT03623776|Experimental|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
11165276|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
11165277|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
11165278|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
11165279|NCT03623750|Experimental|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
11165280|NCT03623737|Experimental|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
11165281|NCT03623737|Active Comparator|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
11165282|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
11165283|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
11165284|NCT03623711|Experimental|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
11165285|NCT03623711|Experimental|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
11165286|NCT03623711|Experimental|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
11165287|NCT03623711|Placebo Comparator|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
11165288|NCT03623698||Before treatment|Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
11165289|NCT03623698||After treatment|Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)
11165290|NCT03623685|Experimental|voluson 8|
11165291|NCT03623659|Active Comparator|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
11165292|NCT03623659|No Intervention|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
11165293|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
11165294|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
11165295|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
11165296|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
11165297|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
11165298|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
11165299|NCT03623594|Experimental|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
11165300|NCT03623581|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
11165301|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
11165302|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.
~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
11165339|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
11170590|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
11165303|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.
~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
11165304|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
11165305|NCT03623529|Experimental|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
11165306|NCT03623529|Placebo Comparator|Placebo Comparator: Placebo|0.9% sodium chloride solution
11165307|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
11165308|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
11165309|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
11165310|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
11165311|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
11165312|NCT03623477|Active Comparator|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
11165313|NCT03623477|Experimental|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
11165314|NCT03623464|Active Comparator|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
11165315|NCT03623464|Other|Standard of care|Participants will receive standard of care
11165316|NCT03623451|Experimental|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for three menstrual cycles.
11165317|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
11165318|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
11165319|NCT03623425|Experimental|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
11165320|NCT03623425|Experimental|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
11165321|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
11165322|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
11165323|NCT03623399|No Intervention|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
11165324|NCT03623399|Other|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.
~Low gas pressure laparoscopy"
11165325|NCT03623399|Other|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.
~Low gas pressure laparoscopy"
11165326|NCT03623386|Experimental|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
11165327|NCT03623386|Active Comparator|Patients with PD control|Patients will not receive neurofeedback training.
11165328|NCT03623373|Experimental|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"Patients will receive (6) 28 day cycles
~Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.
~Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard
~After Cycle 6, patients will undergo leukapheresis"
11165329|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.
~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
11165330|NCT03623334|Other|Image Guided Radiation Therapy|Image-guided radiation therapy (IGRT) is a process of using various imaging technologies to locate a tumor target prior to each treatment with radiation therapy.As a result, the amount of healthy tissue exposed to radiation can be reduced, minimizing the incidence of side effects. An example of three-dimensional (3D) IGRT is localization of a cone-beam computed tomography (CBCT) dataset with the planning computed tomography (CT) dataset from planning.
11165331|NCT03623321|Experimental|Drug - pimavanserin|Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
11165332|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
11165333|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
11165334|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
11165335|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
11165336|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
11165337|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
11165338|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
11165340|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
11165341|NCT03623243|Experimental|Siponimod 2 mg|Siponimod 2mg tablets taken once daily after a 5 day titration
11165342|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
11165343|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.
~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
11165344|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.
~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
11165345|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
11165346|NCT03623204||Patients with bariatric surgery for obesity|
11165347|NCT03623191||Patients with erosive pustular dermatosis of the leg|
11165348|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.
~or (2) difficulties to attend their health care appointments, during the last 3 months."
11165349|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
11165350|NCT03623165||Arm|Cordella™ Heart Failure System
11165351|NCT03623139|Active Comparator|Standard nutritional education|Control group
11165352|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
11165353|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
11165354|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
11165355|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
11165356|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
11165357|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
11165358|NCT03623087|Experimental|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
11165359|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
11165360|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
11165361|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
11165362|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
11165363|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
11165364|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
11165365|NCT03623048|Experimental|Propolis extract|intervention
11165366|NCT03623048|Experimental|Pomegranate extract|intervention
11165367|NCT03623048|Active Comparator|Chlorhexidine|comparator
11165368|NCT03623048|Placebo Comparator|Saline|comparator
11165369|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
11165370|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
11165371|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
11165372|NCT03623009|Experimental|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
11165373|NCT03623009|Sham Comparator|Control|The control arm will receive a neutral article prior to completing the assessment.
11165374|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
11170591|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
11165375|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:
~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
11165376|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:
~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
11165377|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
11165378|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
11165379|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
11165380|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
11165381|NCT03622931|Experimental|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
11165382|NCT03622931|Placebo Comparator|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
11165383|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
11165384|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
11165385|NCT03622905|Experimental|DBS On|DBS system On
11165386|NCT03622905|Sham Comparator|DBS Off|DBS System Off
11165387|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
11165388|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
11165389|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
11165390|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
11165391|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
11165392|NCT03622866|Active Comparator|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
11165393|NCT03622853|Experimental|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
11165394|NCT03622840|Other|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
11165395|NCT03622827|Experimental|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：
~Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.
~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
11165396|NCT03622814|Experimental|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
11165397|NCT03622814|Placebo Comparator|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
11165398|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
11165399|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
11165400|NCT03622788|Experimental|Treatment (chemotherapy, PBSCT, cytokine-treated veto cells)|"CONDITIONING REGIMEN: Patients receive ATG IV over 4 hours on days -9 to -7, and fludarabine IV over 1 hour on days -6 to -3, then undergo TBI on day -1.
~TRANSPLANT: Patients undergo PBSCT IV over 30-60 minutes on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7."
11165401|NCT03622775|Experimental|Treatment (daratumumab)|Beginning 60-120 days after transplant, participants receive daratumumab IV over 4-8 hours on days 1, 8, 15 and 22 of courses 1 and 2 and days 1 and 15 of courses 3-6, then on day 1 of subsequent courses. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11165402|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
11165403|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
11165404|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
11165405|NCT03622749|No Intervention|Controls|Healthy controls
11165406|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
11165407|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
11165408|NCT03622697|Experimental|Mindfulness Meditation Arm|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation phone application intervention.
11165409|NCT03622697|No Intervention|Non-Intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
11165410|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
11165411|NCT03622671|Active Comparator|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
11165412|NCT03622671|Active Comparator|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
11165413|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeksx
11165414|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeksx
11165415|NCT03622645|Experimental|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
11165416|NCT03622619|Experimental|Manuka eye drops|
11165417|NCT03622619|Active Comparator|Systane Ultra|
11165418|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).
~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.
~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
11165419|NCT03622593|Experimental|A: Faricimab Q8W|
11165420|NCT03622593|Experimental|B: Faricimab As Specified in Protocol|
11165421|NCT03622593|Active Comparator|C: Aflibercept Q8W|
11165422|NCT03622580|Experimental|A: Faricimab Q8W|
11165423|NCT03622580|Experimental|B: Faricimab As Specified in Protocol|
11165424|NCT03622580|Active Comparator|C: Aflibercept Q8W|
11165425|NCT03622567|Other|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
11165426|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
11165427|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists
~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
11165428|NCT03622541|Experimental|sorafenib|
11165429|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
11165430|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
11165431|NCT03622515|No Intervention|Group C|Bispectral index (BIS)/Sedline monitoring
11165432|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
11165433|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
11165434|NCT03622489|Experimental|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:
~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3
~IV Tramal 100 mg, once
~After Admitted to Maternity ward:
~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr
~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.
~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
11165495|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
11165435|NCT03622489|Experimental|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:
~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3
~IV Tramal 100 mg, once
~After Admitted to Maternity ward:
~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr
~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.
~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
11165436|NCT03622489|Experimental|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:
~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3
~IV Tramal 100 mg, once
~After Admitted to Mternity ward:
~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:
~Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.
~PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.
~Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
11165437|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
11165438|NCT03622463|Experimental|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
11165439|NCT03622463|Experimental|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
11165440|NCT03622463|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, once a day
11165441|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
11165442|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
11165443|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
11165444|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
11165445|NCT03622424|Active Comparator|Gelesis200|Subjects on this ARM will receive Gelesis200
11165446|NCT03622424|Placebo Comparator|Placebo|Subjects on this ARM will receive a placebo device
11165447|NCT03622424|Active Comparator|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
11165448|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
11165449|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
11165450|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
11165451|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
11165452|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
11165453|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.
~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
11165454|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.
~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
11165455|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
11165456|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
11165457|NCT03622359|Experimental|SPECT/CT perfusion imaging|Patients with peripheral arterial disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo SPECT/CT imaging as part of the research protocol.
11165458|NCT03622359|Experimental|PET/CT perfusion imaging|Patients with peripheral arterial disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo PET/CT imaging as part of the research protocol.
11165459|NCT03622333|Experimental|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
11165460|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
11165461|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
11165462|NCT03622307|Experimental|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
11165562|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
11165463|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.
~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.
~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.
~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
11165464|NCT03622281|Experimental|Colonoscopists who received quality intervention|
11165465|NCT03622281|No Intervention|Colonoscopists who did not received quality intervention|
11165466|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
11165467|NCT03622255|Other|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
11165468|NCT03622255|Active Comparator|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
11165469|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
11165470|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
11165471|NCT03622229|Active Comparator|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.
~Diagnostic Test: Histologic evaluation"
11165472|NCT03622229|Active Comparator|EUS-FNB with fork-tip needle|"Intervention: like above.
~Diagnostic Test: Histologic evaluation."
11165473|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
11165474|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
11165475|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
11165476|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
11165477|NCT03622203||STEMI|Patients with STEMI
11165478|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
11165479|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
11165480|NCT03622177||HIV+|
11165481|NCT03622177||HIV- STI+|
11165482|NCT03622177||HIV- STI-|
11165483|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
11165484|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
11165485|NCT03622151|Experimental|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
11165486|NCT03622151|No Intervention|Control group|"Treatment as usual:
~attention from the resources of the homeless network in Barcelona."
11165487|NCT03622138|Experimental|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
11165488|NCT03622138|Experimental|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
11165489|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
11165490|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
11165491|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
11165492|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
11165493|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
11165494|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
11170592|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
11165496|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
11165497|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
11165498|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
11165499|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
11165500|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
11165501|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
11165502|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
11165503|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
11165504|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
11165505|NCT03622047|Experimental|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
11165506|NCT03622047|Experimental|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
11165507|NCT03622047|Experimental|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
11165508|NCT03622021|Experimental|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
11165509|NCT03622021|Experimental|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
11165510|NCT03622021|Experimental|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
11165511|NCT03622021|Experimental|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
11165512|NCT03622021|Experimental|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
11165513|NCT03622021|Experimental|AK111 600mg|Single dose of 600mg AK111 or placebo is administered subcutaneously to healthy subjects
11165514|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
11165515|NCT03622008|Placebo Comparator|Placebo|placebo IV
11165516|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
11165517|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
11165518|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
11165519|NCT03621982|Experimental|ADCT-301 Monotherapy|In Part 1 (dose escalation) patients will receive escalating doses of camidanlumab tesirine as monotherapy.
11165520|NCT03621982|Experimental|ADCT-301 Combination Therapy|"When the recommended dose of camidanlumab tesirine as single agent is determined, newly enrolled patients will receive escalating dose of camidanlumab tesirine in combination with pembrolizumab.
~In Part 2 (expansion), there will be two groups:
~Group 1: an indication for which camidanlumab tesirine in combination with pembrolizumab was shown in Part 1 to have preliminary activity.
~Group 2: a basket group with the same indications allowed in Part 1, where patients will be treated with camidanlumab tesirine in combination with pembrolizumab with the exception for the one selected for Group 1."
11165521|NCT03621969|Experimental|Group 1|"Group 1 will receive:
~Medical History and Brief Physical Exam
~Diagnostic Assessments
~Patient Instruction and use of RePlay Device
~two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,
~then will rest for 2 weeks (weeks 3-4),
~then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
11165522|NCT03621969|Experimental|Group 2|"Group 2 will receive:
~Medical History and Brief Physical Exam
~Diagnostic Assessments
~Patient Instruction and use of RePlay Device
~two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,
~then will rest for 2 weeks (weeks 3-4),
~then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
11165523|NCT03621956|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
11165524|NCT03621956|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
11165525|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
11165526|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
11165527|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
11165528|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
11165529|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
11165530|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
11165531|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
11165532|NCT03621878|Active Comparator|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
11165533|NCT03621878|Experimental|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
11165534|NCT03621878|Experimental|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
11165535|NCT03621865|Experimental|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165536|NCT03621865|Experimental|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165537|NCT03621865|Experimental|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165538|NCT03621865|Experimental|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165539|NCT03621865|Experimental|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165540|NCT03621865|Experimental|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165541|NCT03621865|Experimental|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165542|NCT03621865|Experimental|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165543|NCT03621865|Experimental|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165544|NCT03621865|Experimental|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
11165545|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
11165546|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
11165547|NCT03621813|Other|Control|Participants maintain their current activity level.
11165548|NCT03621813|Active Comparator|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
11165549|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
11165550|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
11165551|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
11165552|NCT03621774|Experimental|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
11165553|NCT03621774|Placebo Comparator|Supportive Contact|An active group leader- and device-contact control group.
11165554|NCT03621761|Active Comparator|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
11165555|NCT03621761|Active Comparator|Modafinil|50-400 mg per day (oral)
11165556|NCT03621761|Active Comparator|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
11165557|NCT03621748|Active Comparator|Non-Awake Cohort|Cohort undergoing craniotomy utilizing general anesthesia protocol
11165558|NCT03621748|Experimental|Awake Cohort|Cohort undergoing craniotomy utilizing awake anesthesia protocol
11165559|NCT03621735|Other|Sham then Active|"Active: Bimodal auditory-somatosensory stimulation
~Sham: Sham Bimodal auditory-somatosensory stimulation
~Subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.
~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
11165560|NCT03621735|Other|Active then Sham|"Active: Bimodal auditory-somatosensory stimulation
~Sham: Sham Bimodal auditory-somatosensory stimulation
~Subjects receive both an active treatment and a sham treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.
~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
11165561|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
11165563|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
11165564|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
11165565|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
11165566|NCT03621696|Experimental|Arm 1: POAmCRT|"Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease
~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
~Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.
~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
11165567|NCT03621696|Experimental|Arm 2: POAmRT|"Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease
~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
~Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses
~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
11165568|NCT03621696|Experimental|Arm 3: POACRT|"Patients with clinical or pathologic T4 or clinical N3 disease
~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes
~Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margina)
~The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.
~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection
~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
11165569|NCT03621683|Experimental|ovarian bio-stimulation|"Intervention:
~ovarian bio-stimulation: blood rich plasma platelets"
11165570|NCT03621683|Active Comparator|Antioxidant therapy|"Intervention:
~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
11165571|NCT03621670|Experimental|MenB+PCV Group|Approximately 1800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age
11165572|NCT03621670|Placebo Comparator|Placebo+PCV Group|Approximately 900 subjects enrolled in this group will receive PCV13 concomitantly with placebo and other RIV at 2, 4, 6 and 12 months of age.
11165573|NCT03621657|Experimental|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
11165574|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
11165575|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
11165576|NCT03621631|Experimental|optimized Tai Chi intervention|
11165577|NCT03621631|Active Comparator|traditional Tai Chi intervention|
11165578|NCT03621618|Other|dobutamine|Cardiac failure
11165579|NCT03621618|Other|norepinephrine|Sepsis
11165580|NCT03621605|Experimental|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.
~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
11165581|NCT03621605|Placebo Comparator|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
11165582|NCT03621592|Experimental|Cutimed® Sorbact®|
11165583|NCT03621592|Active Comparator|Acticoat®|
11165584|NCT03621579|Other|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
11165585|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
11165586|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.
~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
11165587|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.
~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
11165588|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.
~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
11165589|NCT03621540|Active Comparator|Verum arm|25 min anodal tDCS + adaptive working memory training
11165590|NCT03621540|Sham Comparator|Sham arm|sham tDCS + adaptive working memory training
11165591|NCT03621527|Active Comparator|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.
~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
11165592|NCT03621527|Experimental|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.
~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.
~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
11166812|NCT03613116|Active Comparator|Standard Dose Vitamin D3|Receives 600 IU Vitamin D3 tablets.
11165593|NCT03621514|Other|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
11165594|NCT03621514|Other|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
11165595|NCT03621501|Placebo Comparator|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Control arm)
11165596|NCT03621501|Active Comparator|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Experimental arm)
11165597|NCT03621488|Experimental|Efficacy of Behavioral Self-Activation with virtual reality|
11165598|NCT03621488|Sham Comparator|Efficacy of Behavioral Self-Activation without virtual reality|
11165599|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
11165600|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
11165601|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
11165602|NCT03621436|Experimental|TRVD Therapy|
11165603|NCT03621397|Experimental|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
11165604|NCT03621397|No Intervention|Control Group|Research participants in the control group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
11165605|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
11165606|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
11165607|NCT03621371|Experimental|Metacognitive therapy|
11165608|NCT03621371|Experimental|Intolerance of uncertainty therapy|
11165609|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
11165610|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
11165611|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
11165612|NCT03621345|Active Comparator|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.
~Interventions:
~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
11165613|NCT03621345|Sham Comparator|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.
~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
11165614|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
11165615|NCT03621319|Active Comparator|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
11165616|NCT03621319|Active Comparator|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
11165617|NCT03621306||Men and women aged 18+|Men and women over the age of 18
11165618|NCT03621293|Active Comparator|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
11165619|NCT03621293|Experimental|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
11165620|NCT03621280|Experimental|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
11165621|NCT03621267|Experimental|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)
~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.
~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
11167004|NCT03611751|Experimental|BMS-986165|BMS-986165 oral administration
11165622|NCT03621267|Active Comparator|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
11165623|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
11165624|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
11165625|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
11165626|NCT03621228|No Intervention|Control|Standard care only
11165627|NCT03621215|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
11165628|NCT03621215|Placebo Comparator|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).
~once per day (250 mL total volume per day)"
11165629|NCT03621202|Experimental|Saranas Early Bird Bleed Monitoring System (EBBMS)|
11165630|NCT03621189|Active Comparator|posterior superior temporal sulcus|iTBS 1200
11165631|NCT03621189|Sham Comparator|Sham control|iTBS 1200
11165632|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
11165633|NCT03621163|Experimental|bleaching agent|intervention : bleaching agent ( Boost 40%)
11165634|NCT03621163|Active Comparator|laminate veneers|laminate veneers ( monolithic lithium - silicate)
11165635|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
11165636|NCT03621137||Patients with moderate-to-severe atopic eczema|Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
11165637|NCT03621124|Other|Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
11165638|NCT03621124|Other|Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
11165639|NCT03621111|Experimental|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
11165640|NCT03621111|No Intervention|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
11165641|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
11165642|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.
~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
11165643|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
11165644|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
11165645|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
11165646|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
11165647|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
11165648|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
11165649|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
11165650|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
11165651|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
11165652|NCT03621033|Other|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
11165653|NCT03621033|Other|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
11165654|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
11165655|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
11165656|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
11165657|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
11165658|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
11165659|NCT03621007||POMC deficiency obesity|
11165660|NCT03621007||LEPR deficiency obesity|
11165661|NCT03621007||PCSK1 deficiency obesity|
11165662|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
11165663|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
11165664|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
11165665|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
11165666|NCT03620968|No Intervention|Group 1|Control, no intervention
11165667|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
11165668|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
11165669|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after three courses of chemo therapy.
11165670|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
11165671|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
11165672|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
11165673|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
11165674|NCT03620916|Experimental|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
11165675|NCT03620916|Active Comparator|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
11165676|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:
~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;
~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;
~Maintenance I (1 cycle = 56 days):
~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);
~Maintenance II (1 cycle = 84 days):
~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
11165677|NCT03620890|Active Comparator|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
11165678|NCT03620890|Active Comparator|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
11165679|NCT03620877|Experimental|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
11165680|NCT03620864|Active Comparator|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
11165681|NCT03620864|Experimental|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
11165682|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
11165683|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
11165684|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period
11165744|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
11165685|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period
11165686|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment
11165687|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
11165688|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
11165689|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
11165690|NCT03620825|No Intervention|Negative control|No intervention is performed
11165691|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
11165692|NCT03620812|Active Comparator|soy protein|
11165693|NCT03620812|Placebo Comparator|no protein|
11165694|NCT03620799|Experimental|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
11165695|NCT03620799|No Intervention|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
11165696|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
11165697|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.
~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
11165698|NCT03620760|Experimental|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg once daily.
11165699|NCT03620760|Active Comparator|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
11165700|NCT03620747|Experimental|Dupilumab|One dose administered every two weeks. A loading dose may be administered at the start of treatment for some patients (e.g., due to previous Dupilumab treatment discontinuation for more than 6 weeks).
11165701|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
11165702|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
11165703|NCT03620721|Experimental|M-Body|mindfulness group intervention
11165704|NCT03620721|No Intervention|Usual Care|treatment as usual
11165705|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
11165706|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
11165707|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
11165708|NCT03620682|Experimental|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
11165709|NCT03620669|Experimental|Durvalumab|Durvalumab until progression or unacceptable toxicity
11165710|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
11165711|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
11165712|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] monotherapy|Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule [Xalkori] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
11165713|NCT03620643|Active Comparator|Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection|Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule [Xalkori] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe [Faslodex] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
11165714|NCT03620630|No Intervention|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
11165715|NCT03620630|Active Comparator|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
11165716|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
11165717|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
11165718|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
11165719|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.
~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
11165720|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
11165721|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
11165722|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
11165723|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
11165724|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
11165725|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
11165726|NCT03620552|Experimental|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
11165727|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
11165728|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
11165729|NCT03620526|Experimental|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
11165730|NCT03620526|Placebo Comparator|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
11165731|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
11165732|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
11165733|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
11165734|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
11165735|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
11165736|NCT03620474|Experimental|PRI-724|"Dose: 140, 280, 380 mg / m 2/4 hr
~Administration method:
~【Phase I Phase】 (Level 1) 140 mg / m 2/4 hr (Level 2) 280 mg / m 2/4 hr (Level 3) 380 mg / m 2/4 hr Twice weekly, continuous 4-hour intravenous administration (tolerance of administration time: ± 15 minutes). This is one cycle and 12 cycles (12 weeks in total) are carried out. However, in Phase I phase, single dose is administered on Day - 7 (tolerance: - 7 days).
~【Phase IIa phase】 Continuous intravenous administration for 4 hours twice a week at the recommended dose determined in Phase I. This is one cycle and 12 cycles (12 weeks in total) are carried out."
11165737|NCT03620448|Experimental|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:
~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
11165738|NCT03620448|Other|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
11165739|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
11165740|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
11165741|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
11165742|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
11165743|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection
11165746|NCT03620396|Experimental|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
11165747|NCT03620396|Experimental|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
11165748|NCT03620383|Experimental|Heat|Distal topical heat application
11165749|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
11165750|NCT03620370|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
11165751|NCT03620370|No Intervention|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
11165752|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
11165753|NCT03620357|Active Comparator|SMBG Group|
11165754|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
11165755|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
11165756|NCT03620331|Active Comparator|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
11165757|NCT03620331|Experimental|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
11165758|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
11165759|NCT03620292|Experimental|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma
~IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.
~Peroperative open air NIR fluorescence imaging
~Ex vivo endoscopic and histopathological NIR fluorescence imaging"
11165760|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
11165761|NCT03620266|Experimental|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
11165762|NCT03620266|Placebo Comparator|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
11165763|NCT03620266|Experimental|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
11165764|NCT03620266|Experimental|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
11165765|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
11165766|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
11165767|NCT03620240|Experimental|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
11165768|NCT03620240|No Intervention|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
11165769|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
11165770|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
11165771|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
11165772|NCT03620201|Experimental|Treatment (M7824)|Participants receive anti-PD-L1/TGFbetaRII fusion protein M7824 IV over 1 hour on days 1 and 15. During days 28-56 participants receive planned neoadjuvant chemotherapy.
11165773|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
11165774|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
11165775|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
11165776|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
11165800|NCT03619993|Experimental|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
11166192|NCT03617315|Experimental|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
11165777|NCT03620162|Active Comparator|Group 1: Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of double-blind Prevnar 13™ at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
11165778|NCT03620162|Experimental|Group 2: Prevnar 13™ Switch to V114 at Dose 4|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4) and double-blind V114 at approximately 12-15 months of age (Study Month 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
11165779|NCT03620162|Experimental|Group 3: Prevnar 13™ Switch to V114 at Dose 3|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2 and 4 months of age (Study Day 1 and Month 2) and double-blind V114 at approximately 6 and 12-15 months of age (Study Month 4 and 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
11165780|NCT03620162|Experimental|Group 4: Prevnar 13™ Switch to V114 at Dose 2|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2 months of age (Study Day 1) and double-blind V114 at approximately 4, 6 and 12-15 months of age (Study Month 2, 4 and 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
11165781|NCT03620162|Experimental|Group 5: V114|Participants will receive a single 0.5 mL IM injection of double-blind V114 at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Other licensed pediatric vaccines will be administered open-label concomitantly with the study vaccines according to the recommended schedule: RotaTeq™, Pentacel™, and Recombivax HB™ at approximately 2, 4, and 6 months of age (Study Day 1, Month 2, and Month 4), and Hiberix™, M-M-R™ II, and Varivax™ at approximately 12-15 months of age (Study Month 10-13).
11165782|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
11165783|NCT03620136|Experimental|locoregional analgesia by a block on the adductor channel|
11165784|NCT03620136|Experimental|locoregional analgesia by periarticular local infiltrations|
11165785|NCT03620123|Experimental|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
11165786|NCT03620123|Other|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
11165787|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
11165788|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
11165789|NCT03620084|Experimental|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
11165790|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
11165791|NCT03620071|Experimental|Control|Standard Care
11165792|NCT03620058|Experimental|CART22-65s monotherapy|
11165793|NCT03620058|Experimental|CART22-65s in combination with huCART19|
11165794|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
11165795|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
11165796|NCT03620032|Other|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
11165797|NCT03620032|Experimental|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
11165798|NCT03620019|Experimental|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
11165799|NCT03619993|Experimental|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
11165801|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
11165802|NCT03619967|Experimental|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
11165803|NCT03619954|Experimental|NK cells infusion|
11165804|NCT03619941|Placebo Comparator|Placebo|
11165805|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
11165806|NCT03619928|Experimental|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
11165807|NCT03619928|Active Comparator|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
11165808|NCT03619915||Greater dependence|
11165809|NCT03619915||Less dependence|
11165810|NCT03619915||Independent|
11165811|NCT03619902|Experimental|ANB019 Biological/Vaccine|ANB019 subcutaneous (SC) injection every 4 weeks
11165812|NCT03619889|Sham Comparator|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
11165813|NCT03619889|Experimental|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
11165814|NCT03619876|Active Comparator|Non-TNF inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
11165815|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
11165816|NCT03619850|Experimental|Ferumoxytol|
11165817|NCT03619850|Active Comparator|Iron sucrose|
11165818|NCT03619837|Experimental|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir
~Dosage: 400mg/100mg. Once daily for 12 weeks."
11165819|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
11165820|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
11165821|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
11165822|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
11165823|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
11165824|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
11165825|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
11165826|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15~20mg intravenous, at the end of surgery, before extubation
11165827|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
11165828|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
11165829|NCT03619720|Experimental|Participants|
11165830|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
11165831|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
11165832|NCT03619681|Experimental|KN026|
11165833|NCT03619655|Experimental|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
11165834|NCT03619655|Experimental|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
11165835|NCT03619655|Experimental|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
11165836|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
11165837|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
11165838|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
11165839|NCT03619629|Experimental|Kinesio-taping|Kinesiotape will be applied both ankles.
11165840|NCT03619629|Experimental|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
11165841|NCT03619629|Sham Comparator|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
11165842|NCT03619629|Sham Comparator|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
11165843|NCT03619616|Experimental|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
11165844|NCT03619616|Experimental|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.
~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
11165845|NCT03619616|Experimental|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.
~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
11165846|NCT03619616|Experimental|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.
~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
11165847|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
11165848|NCT03619577|Experimental|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
11165849|NCT03619577|Experimental|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
11165850|NCT03619564||No protein restriction|No protein restriction
11165851|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
11165852|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
11165853|NCT03619551|Experimental|Low Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg*h/L .
~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
11165854|NCT03619551|Experimental|Medium Dose Busulfan|"Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg*h/L.
~Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks."
11165855|NCT03619538|Placebo Comparator|control group|
11165856|NCT03619538|Experimental|Nefopam group|
11165857|NCT03619525|Active Comparator|recruitment group|will receive intermittent lung recruitment during CPB
11165858|NCT03619525|No Intervention|control group|will recieve no intervention
11165859|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
11165860|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
11165861|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
11165862|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
11165863|NCT03619499|Experimental|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
11165864|NCT03619499|No Intervention|invasive|infants who were connected to invasive mechanical ventilation
11165865|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
11165866|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
11165867|NCT03619473|Experimental|intervention|"the group
~assessed for proper helmet usage (type, chinstrap, standard helmet usage)
~evaluated for the behavioral of helmet usage
~underwent the educational session under helmet initiative program
~received one standard motorcycle child safety helmet per family
~assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet
~evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
11165868|NCT03619473|No Intervention|control|"the group
~assessed for proper helmet usage (type, chinstrap, standard helmet usage)
~evaluated for the behavioral of helmet usage
~assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months
~do not receive any educational session or standard motorcycle child safety helmet"
11165869|NCT03619460|Experimental|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
11165870|NCT03619460|Active Comparator|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
11165871|NCT03619447|Active Comparator|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
11165915|NCT03619161|Experimental|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
11166039|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
11165872|NCT03619447|Active Comparator|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
11165873|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
11165874|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
11165875|NCT03619421|Experimental|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
11165876|NCT03619421|Experimental|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
11165877|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
11165878|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.
~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
11165879|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
11165880|NCT03619369|Active Comparator|Early Circumcision|
11165881|NCT03619369|Placebo Comparator|Routine Circumcision|
11165882|NCT03619369|Active Comparator|Delayed Circumcision|
11165883|NCT03619343|Experimental|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
11165884|NCT03619343|Active Comparator|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
11165885|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
11165886|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
11165887|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
11165888|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
11165889|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
11165890|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
11165891|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
11165892|NCT03619291|Experimental|High-intensity functional training|all-out exercise
11165893|NCT03619291|Active Comparator|Aerobic exercise|walking
11165894|NCT03619291|Sham Comparator|control|sitting
11165895|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
11165896|NCT03619278|Placebo Comparator|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
11165897|NCT03619265|Experimental|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
11165898|NCT03619265|Placebo Comparator|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
11165899|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
11165900|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
11165901|NCT03619239|Experimental|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
11165902|NCT03619239|Experimental|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
11165903|NCT03619239|Experimental|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
11165904|NCT03619239|Experimental|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
11165905|NCT03619239|Experimental|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
11165906|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
11165907|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
11165908|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
11165909|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
11165910|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
11165911|NCT03619187|Experimental|Single Arm|Study Product
11165912|NCT03619174|Active Comparator|Active Treatment|Treatment dose
11165913|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
11165914|NCT03619161|No Intervention|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
11165916|NCT03619161|Active Comparator|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
11165917|NCT03619148|Other|High-Flow Humidified Nasal Oxygen - TOE participants|High-Flow Humidified Nasal Oxygen - standard care
11165918|NCT03619148|Active Comparator|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
11165919|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
11165920|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
11165921|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
11165922|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
11165923|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
11165924|NCT03619096|Active Comparator|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
11165925|NCT03619096|Placebo Comparator|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
11165926|NCT03619083||Breast cancer patients treated with chemotherapy|
11165927|NCT03619083||patients not exposed to chemotherapy|
11165928|NCT03619083||healthy controls|
11165929|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
11165930|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
11165931|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
11165932|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
11165933|NCT03619057||> 18 years|
11165934|NCT03619057||10 to 18 years|
11165935|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
11165936|NCT03619031|Experimental|LONG LEAVENING|Acute test meal
11165937|NCT03619031|Experimental|SHORT LEAVENING|Acute test meal
11165938|NCT03619031|Active Comparator|TRADITIONAL|Acute test meal
11165939|NCT03619005|Placebo Comparator|Placebo|
11165940|NCT03619005|Active Comparator|Prasterone|
11165941|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
11165942|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
11165943|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
11165944|NCT03618979|Experimental|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
11165945|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
11165946|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
11165947|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
11165948|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
11167005|NCT03611751|Placebo Comparator|Placebo|Placebo oral administration
11165949|NCT03618953|Experimental|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.
~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
11165950|NCT03618953|Experimental|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 & 29.
~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
11165951|NCT03618940|Experimental|School-based educational intervention|"assessed for knowledge and attitude on burn injury prevention
~underwent the School-based educational intervention
~impact evaluation
~Output evaluation 3 months after School-based educational intervention"
11165952|NCT03618927|Experimental|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
11165953|NCT03618927|No Intervention|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
11165954|NCT03618914||Non-anemic women|
11165955|NCT03618914||anemic women|anemia due to iron deficiency
11165956|NCT03618901|Experimental|Rock Steady Boxing|Non-contact boxing program.
11165957|NCT03618901|Active Comparator|PD SAFEx|Sensory attention focused exercise.
11165958|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
11165959|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
11165960|NCT03618875|Active Comparator|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
11165961|NCT03618875|Placebo Comparator|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
11165962|NCT03618849|Experimental|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments and EEG recording.
11165963|NCT03618849|Experimental|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
11165964|NCT03618849|Experimental|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
11165965|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
11165966|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
11165967|NCT03618823|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary.
11165968|NCT03618823|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
11165969|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
11165970|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
11165971|NCT03618797|Experimental|HL-PIF cap.160/2mg + Placebo|"Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
~once a day"
11165972|NCT03618797|Active Comparator|Livalo tab. 2mg + Placebo|"Pitavastatin ca 2mg
~once a day"
11165973|NCT03618784|Experimental|FURESTEM-RA Inj.|
11165974|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
11165975|NCT03618771|Experimental|Medacta GMK Sphere|Half of the patients will be implanted with the Medacta GMK Sphere total knee arthroplasty
11165976|NCT03618771|Experimental|DePuy Synthes Attune|Half of the patients will be implanted with the DePuy Attune total knee arthroplasty
11165977|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
11165998|NCT03618550|Experimental|pembrolizumab plus GVD|"Part 1: Patients will receive 2-4 cycles of pembrolizumab plus GVD
~Part 2: an additional 25 patients will be enrolled onto an expansion cohort. On the expansion, patients who achieve CR to 4 cycles of pembro-GVD will receive 13 cycles of pembrolizumab maintenance (instead of HDT/ASCT)."
11165978|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
11165979|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
11165980|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
11165981|NCT03618719||Control|Healthy controls without OSA
11165982|NCT03618706|Experimental|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
11165983|NCT03618693|Experimental|spinal analgesia SSS|"Patients will receive a spinal analgesia (group SSS) with a single shot of bupivacaine 0.5% combined with fentanyl intrathecally during induction of anaesthesia. The technique used is referred to daily practice.
~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.
~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).
~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
11165984|NCT03618693|Experimental|TAP block|"Patients will receive a TAP block with a single shot of ropivacaine 0.375% combined with clonidine bilaterally. The technique used is referred to daily practice. The blocks will be performed under ultrasound guidance.
~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.
~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).
~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
11165985|NCT03618693|Active Comparator|Standard|"Standard care for prostatectomy in the investigators institution consists in the concomitant systemic administration of lidocaine to standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.
~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets.
~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
11165986|NCT03618667|Experimental|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
11165987|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.
~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
11165988|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
11165989|NCT03618641|Experimental|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 10 mg will be administered Weeks 2 -7.
~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
11165990|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
11165991|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
11165992|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
11165993|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
11165994|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
11165995|NCT03618589|Placebo Comparator|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
11165996|NCT03618589|Experimental|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
11165997|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
11166038|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
11166222|NCT03617029|Experimental|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
11165999|NCT03618537|Experimental|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days
~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
11166000|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
11166001|NCT03618511|Experimental|Financial Incentive Group|
11166002|NCT03618511|Experimental|Reminders Group|
11166003|NCT03618511|Experimental|Financial Incentive and Reminders Group|
11166004|NCT03618511|No Intervention|Control Group|
11166005|NCT03618511|Experimental|Information Group|
11166006|NCT03618511|Experimental|Stigma-relieving Group|
11166007|NCT03618511|Experimental|Information and Stigma-relieving Group|
11166008|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
11166009|NCT03618472|Experimental|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
11166010|NCT03618472|Placebo Comparator|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
11166011|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
11166012|NCT03618446||Survivors|Patients whose pelvic fracture and survived till time of discharge from the hospital.
11166013|NCT03618446||Non-Survivors|Patients whose pelvic fracture and died while in hospital.
11166014|NCT03618433|Experimental|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy
~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
11166015|NCT03618433|Active Comparator|Control group|"Standart exercise protocol and Upper extremity rehabilitation
~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
11166016|NCT03618420|Other|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
11166017|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
11166018|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
11166019|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
11166020|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
11166021|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
11166022|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
11166023|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
11166024|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
11166025|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
11166026|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
11166027|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
11166028|NCT03618355|Experimental|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
11166029|NCT03618355|Experimental|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
11166030|NCT03618355|Experimental|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
11166031|NCT03618355|Experimental|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.
~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
11166032|NCT03618342||PCOS|PCOS women
11166033|NCT03618342||Healthy controls|Healthy control women
11166034|NCT03618329|Active Comparator|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
11166035|NCT03618329|No Intervention|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
11166036|NCT03618316|Experimental|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
11166037|NCT03618303|Experimental|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
11166040|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
11166041|NCT03618277|Other|Intra individual|Before and after being treated by a product (outside the study)
11166042|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
11166043|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
11166044|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
11166045|NCT03618238|Experimental|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
11166046|NCT03618225|Active Comparator|duloxetine group|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
11166047|NCT03618225|Placebo Comparator|placebo pill group|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure.
11166048|NCT03618212||Myeloma patients|
11166049|NCT03618199|Experimental|Efficacy of vibrating system on healthy volunteers|
11166050|NCT03618199|Experimental|Efficacy of vibrating system on vestibular patients|
11166051|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
11166052|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
11166053|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
11166054|NCT03618173|Experimental|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
11166055|NCT03618173|Placebo Comparator|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
11166056|NCT03618160|Experimental|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
11166057|NCT03618160|Experimental|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
11166058|NCT03618160|Experimental|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
11166059|NCT03618134|Experimental|Cohort I (SBRT, durvalumab, TORS, neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11166060|NCT03618134|Experimental|Cohort II (SBRT, durvalumab,tremelimumab,TORS,neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive tremelimumab IV and durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11166061|NCT03618121|Experimental|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
11166062|NCT03618121|Active Comparator|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
11166063|NCT03618121|Active Comparator|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
11166191|NCT03617315|Experimental|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
11166064|NCT03618121|Active Comparator|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
11166065|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
11166066|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
11166067|NCT03618095|Experimental|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
11166068|NCT03618095|Experimental|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
11166069|NCT03618095|Experimental|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
11166070|NCT03618082|Active Comparator|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
11166071|NCT03618082|Experimental|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.
~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
11166072|NCT03618069|No Intervention|routine investigation|
11166073|NCT03618069|Active Comparator|study protocol CCI (CTA, cardiac CT) and MRI scans|
11166074|NCT03618056|Experimental|AIDSVAX® B/E|Participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.
11166075|NCT03618043|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
11166076|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
11166077|NCT03618030|Placebo Comparator|Placebo Treatment|Matched placebo
11166078|NCT03618017|Experimental|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
11166079|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
11166080|NCT03618004|Experimental|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.
~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
11166081|NCT03618004|Active Comparator|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.
~The subjects in the control group did not use pressure cuffs."
11166082|NCT03617991|Experimental|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
11166083|NCT03617991|No Intervention|Control Group|The control group will be contacted weekly to check on health status.
11166084|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
11166085|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
11166086|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
11166087|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
11166088|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
11166089|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
11166090|NCT03617965||Severe thrombocytopenia|Patients with a platelet count<50 × 10e9/L
11166091|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
11166092|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.
~The P3 Bio Intervention is implemented in this group."
11166093|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.
~The P3 Bio Intervention is implemented in this group."
11166094|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
11166095|NCT03617926|Experimental|Test product|Water-based lotion (internal code (X92001666)
11166096|NCT03617926|Active Comparator|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
11166097|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11166098|NCT03617900|Placebo Comparator|Placebo|
11166099|NCT03617900|Experimental|Ginger|
11166100|NCT03617900|Active Comparator|Paracetamol|
11166101|NCT03617887|Experimental|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
11166102|NCT03617887|Experimental|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
11166103|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
11166104|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
11166105|NCT03617861|Experimental|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
11166106|NCT03617861|Experimental|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
11166107|NCT03617861|Experimental|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
11166108|NCT03617861|Experimental|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
11166109|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
11166110|NCT03617835|Experimental|Spesolimab|
11166111|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
11166112|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
11166113|NCT03617783|Active Comparator|Prebiotin|
11166114|NCT03617783|Placebo Comparator|Placebo|
11166115|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
11166116|NCT03617770|Active Comparator|Healthy Living|Health education
11166117|NCT03617757|Experimental|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
11166118|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
11166119|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
11166120|NCT03617731|Active Comparator|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
11166121|NCT03617731|Experimental|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
11166122|NCT03617731|Active Comparator|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
11166123|NCT03617731|Experimental|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
11166124|NCT03617718|Experimental|Glycine Buffer|All participants will be asked to inhale a glycine buffer at visit 2 prior to the research bronchoscopy that is performed at visit 3.
11166125|NCT03617705|Active Comparator|HIV+ drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
11166126|NCT03617705|Active Comparator|HIV- drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
11166127|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
11166128|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
11166129|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
11166130|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
11166131|NCT03617653|Other|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
11166132|NCT03617653|Other|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis & End of 3 month assessment.
11166133|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
11166134|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
11166135|NCT03617627|Experimental|Experimental group|Patients will be included in a self-management intervention.
11166136|NCT03617627|No Intervention|Control group|Patients will receive a booklet with information.
11166137|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
11166138|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
11166139|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
11166140|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
11166141|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
11166142|NCT03617575|Placebo Comparator|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1
11166143|NCT03617575|Placebo Comparator|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1
11166144|NCT03617575|Placebo Comparator|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
11166145|NCT03617575|Placebo Comparator|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
11166146|NCT03617575|Placebo Comparator|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
11166147|NCT03617575|Placebo Comparator|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
11166148|NCT03617562|Experimental|Superior Capsule Reconstruction|Patients will be treated with the new technique of superior capsule reconstruction with dermal allograft.
11166149|NCT03617562|Active Comparator|Partial Repair|Patients will have a partial repair with residual defect as an established standard procedure.
11166150|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
11166151|NCT03617536|Experimental|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
11166152|NCT03617536|Experimental|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
11166153|NCT03617536|Experimental|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
11166154|NCT03617536|Placebo Comparator|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
11166155|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to <36 months|Participants (aged 6 to <36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11166156|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to <9 years|Participants (aged 3 to <9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
11166157|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 3: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
11166158|NCT03617523|Experimental|Flublok Quadrivalent vaccine Group 4: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.
11166159|NCT03617523|Experimental|Fluzone High-Dose vaccine Group 5: >=65 years|Participants (aged >=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
11166160|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
11166223|NCT03617029|Active Comparator|Contrast|Needle localization for deep-seated lung nodules with contrast injection
11166161|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
11166162|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
11166163|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
11166164|NCT03617497|Active Comparator|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
11166165|NCT03617497|Active Comparator|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
11166166|NCT03617497|Experimental|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
11166167|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
11166168|NCT03617471|Experimental|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
11166169|NCT03617471|Experimental|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
11166170|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
11166171|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
11166172|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.
~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
11166173|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
11166174|NCT03617445|Active Comparator|FMT enema/ oral vancomycin placebo|FMT plus placebo vancomycin
11166175|NCT03617445|Active Comparator|Placebo FMT/ Active oral vancomycin|Vancomycin plus FMT enema placebo
11166176|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
11166177|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
11166178|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System
~The following post-market products will be used on label:
~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
11166179|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
11166180|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
11166181|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
11166182|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose > 8 mmol/L.
11166183|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
11166184|NCT03617380|Experimental|PHARMD-TOC i|PharmD Follow-Up Post Discharge
11166185|NCT03617380|Active Comparator|USUAL CARE|Usual Post Discharge Procedures
11166186|NCT03617367|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
11166187|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;
~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).
~Will be able to attend each of the 10 training days."
11166188|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
11166189|NCT03617328|Experimental|Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously/intradermally on days 1, 8, 15, 36, 57 and 78. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.
11166190|NCT03617328|Experimental|Arm B: 6MHP/Montanide ISA-51 + polyICLC|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously/intradermally on days 1, 8, 15, 36, 57 and 78. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.
11166286|NCT03616587|Experimental|AZD9833 monotherapy dose expansion|
11166193|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
11166194|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
11166195|NCT03617289|Experimental|Treatment|Receiving Magnesium Sulfate
11166196|NCT03617289|Placebo Comparator|Placebo|Receiving D5W
11166197|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
11166198|NCT03617263|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
11166199|NCT03617263|Placebo Comparator|Placebo|Placebo tablet once daily in the morning before breakfast
11166200|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
11166201|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
11166202|NCT03617224|Experimental|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
11166203|NCT03617224|Experimental|Radiation: TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
11166204|NCT03617198|Experimental|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
11166205|NCT03617198|Experimental|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
11166206|NCT03617185|Active Comparator|Bariatric Surgery/HIIT|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
11166207|NCT03617185|Active Comparator|Bariatric Surgery/Routine Exercise|Patients who have undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
11166208|NCT03617185|Active Comparator|No Bariatric Surgery/HIIT|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a high intensity interval training (HIIT) protocol for 24 months. Patients will complete 2 supervised HIIT sessions and 1 unsupervised HIIT session a week.
11166209|NCT03617185|Active Comparator|No Bariatric Surgery/Routine Exercise|Patients who have not undergone bariatric surgery will be randomized to this arm and will follow a standard routine exercise regimen for 24 months.
11166210|NCT03617172|Experimental|Study Drug (Misoprostol)|
11166211|NCT03617172|Placebo Comparator|Placebo|
11166212|NCT03617146|Experimental|Intervention Arm|"Participants in the intervention arm will receive the following interventions:
~Month 1: Diabetes Distress-specific Education.
~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.
~Month 3: Follow up distress-specific education.
~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
11166213|NCT03617146|Active Comparator|Control Arm|"Participants in the control arm will receive the following interventions:
~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).
~Month 3: Follow up distress-specific education (same as for the intervention arm)."
11166214|NCT03617133|Other|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
11166215|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.
~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
11166216|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
11166217|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
11166218|NCT03617081|Experimental|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
11166219|NCT03617081|Placebo Comparator|Placebo|Participants will receive placebo (NNC0113-2023)
11166220|NCT03617068|Active Comparator|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
11166221|NCT03617068|Placebo Comparator|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
11166224|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
11166225|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
11166226|NCT03617003|Experimental|phototherapy with WST11|Patients with urothelial cancer that includes involvement of the upper urinary tract and have failed prior endoscopic treatment, refuse standard treatment, or are ineligible for curative surgical resection of the kidney or ureter will be offered WST11 VTP treatment to be provided at the time of scheduled endoscopic procedure. At the time of endoscopy, patients will be treated with VTP therapy applied to the site of the tumor.
11166227|NCT03616990|Active Comparator|Usual Care (Control)|"Usual care. These individuals will receive linkages to community-based services only. These linkages will be made while in the Discharge Area of the Cook County Jail. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.
~Receives: TASC Service Linkages - Discharge Area Only"
11166228|NCT03616990|Experimental|Supportive Release Center (Treatment)|"These individuals will receive SRC services: an overnight stay at the SRC, linkages to community-based services made at the SRC or in the discharge area of the CCJ if they choose not to visit the SRC facility, and access to an Advanced Practice Nurse. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.
~Receives: TASC Service Linkages - Discharge Area Only -OR- SRC Overnight Stay, TASC Services Linkages - SRC Onsite, APN Appointment"
11166229|NCT03616977|Experimental|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
11166230|NCT03616977|Experimental|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
11166231|NCT03616964|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11166232|NCT03616964|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11166233|NCT03616964|Placebo Comparator|Placebo|Placebo administered orally.
11166234|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
11166235|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
11166236|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
11166237|NCT03616925|Experimental|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
11166238|NCT03616925|Active Comparator|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
11166239|NCT03616912|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11166240|NCT03616912|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11166241|NCT03616912|Placebo Comparator|Placebo|Placebo administered orally.
11166242|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
11166243|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
11166244|NCT03616886|Experimental|Phase I and Phase II Arm A|Patients are treated with paclitaxel, carboplatin, durvalumab and oleclumab.
11166245|NCT03616886|Active Comparator|Phase II Arm B|Patients are treated with paclitaxel, carboplatin and durvalumab.
11166246|NCT03616873||Adults aged 60 or older|
11166247|NCT03616860|Experimental|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
11166248|NCT03616847|Experimental|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
11166249|NCT03616847|Experimental|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
11166250|NCT03616834|Experimental|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
11166251|NCT03616821|Experimental|Brazikumab Dose 1|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71
11166252|NCT03616821|Experimental|Brazikumab Dose 2|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71.
11166253|NCT03616821|Experimental|Brazikumab Dose 3|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71.
11166254|NCT03616821|Active Comparator|Vedolizumab|Intravenous vedolizumab on day 1, day 15, and day 43 followed by IV vedolizumab every 8 weeks beginning at day 99.
11166255|NCT03616821|Placebo Comparator|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous every 4 weeks beginning at day 71.
11166256|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
11166257|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
11166258|NCT03616795|Experimental|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and [14C]-LY3154207administered orally.
11166259|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
11166260|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
11166261|NCT03616756|Experimental|Intervention group|
11166262|NCT03616756|Active Comparator|Control group|
11166263|NCT03616743|Experimental|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
11166264|NCT03616743|Active Comparator|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
11166265|NCT03616730||Heart Disease in pregnancy group|Fifty women will be recruited with structurally and functionally abnormal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Women who are unable to give informed consent will not be included.
11166266|NCT03616730||Control Group|Fifty women will be recruited with structurally normal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Any woman on cardiac or antihypertensive medications (beta blockers, calcium channel blockers, hydralazine) will be excluded. Women who are unable to give informed consent will not be included.
11166267|NCT03616717|Active Comparator|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
11166268|NCT03616717|Active Comparator|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
11166269|NCT03616717|Placebo Comparator|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
11166270|NCT03616691|Experimental|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
11166271|NCT03616691|Experimental|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
11166272|NCT03616678|Experimental|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
11166273|NCT03616665|Other|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
11166274|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
11166275|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
11166276|NCT03616639|Experimental|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
11166277|NCT03616639|Active Comparator|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
11166278|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
11166279|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
11166280|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
11166281|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
11166282|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
11166283|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
11166284|NCT03616600|No Intervention|Control|Not wearing any contact lenses
11166285|NCT03616587|Experimental|AZD9833 monotherapy dose escalation|
11166291|NCT03616574|Experimental|Dose Escalation - CA102N Monotherapy|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
11166292|NCT03616574|Experimental|Dose Escalation - CA102N plus LONSURF|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
11166293|NCT03616574|Experimental|Dose Expansion - CA102N plus LONSURF|The preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
11166294|NCT03616561||Apremilast|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
11166295|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
11166296|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
11166297|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
11166298|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
11166299|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
11166300|NCT03616509|Experimental|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
11166301|NCT03616496|Experimental|ATTR amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq 300 Mega Becquerel (MBq)/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy
11166302|NCT03616496|Experimental|AL amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq 300 Mega Becquerel/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy
11166303|NCT03616496|Active Comparator|control subjects|"Intervention by this arm: PET with injection of Neuraceq 300MBq/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy.
~Control subjects are patients with left ventricular hypertrophy"
11166304|NCT03616470|Experimental|Uproleselan (GMI-1271)|Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
11166305|NCT03616470|Placebo Comparator|Placebo (Saline, 0.9% Sodium Chloride)|Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
11166306|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
11166307|NCT03616444|Experimental|TCM-Xiaoai Jiedu Decoction|Xiaoai Jiedu Decoction：Oldenlandia 20g,kuh-seng 9g,Codonopsis pilosula 15g,bighead atractylodes rhizome 12g,smoked plum 9g,the rhizome of Chinese goldthread 3g,RHIZOMA ZINGIBERIS PREPARATA 6g,Semen Coicis 20g. Take one pack a day, divided into twice one day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year， last two years.
11166308|NCT03616444|Placebo Comparator|TCM-Xiaoai Jiedu Decoction Placebo|The control group took placebo twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year，last two years.
11166309|NCT03616431||Demographic cohort|A prospective cross-sectional assessment of the prevalence of PEI-related symptoms in up to n=150 patients with pancreatic malignancy.
11166310|NCT03616431||Diagnosis cohort|"A sub-set (up to n=50) of the Demographic cohort patients will be tested to elucidate the most efficient diagnostic panel for PEI in pancreatic malignancy.
~An extra assessment for PEI diagnosis consisting of a breath test (Pancreo-KIT breath test) will be carried out during the following 1-2 weeks after the first appointment (which takes around six hours to complete and involves the administration of bread spread with 13C butter followed by collection of the patient's breath in small plastic vials at timed intervals. The vials will subsequently be analyzed for 13C quantity; details in Appendix 6). Following these diagnostic tests, patients will complete an acceptability questionnaire to assess their opinion regarding the burden that these diagnostic tests may add."
11166311|NCT03616431||Follow-up cohort|Validation of the diagnostic panel designed and tested in Step-1 of this study and evaluation of dietician intervention (including Pancreatic Enzyme Replacement Therapy; PERT) and its impact in weight loss, symptom evolution, chemotherapy receiving rate, quality of life and overall survival.
11166312|NCT03616405|Experimental|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
~Drugs: 1. rabeprazole 10mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
11166313|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
11166314|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
11166315|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
11166443|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
11166316|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
11166317|NCT03616379|Placebo Comparator|Psychoeducational Control|
11166318|NCT03616379|Experimental|Affect Regulation Condition|
11166319|NCT03616379|Experimental|Affect Labelling Condition|
11166320|NCT03616353|Experimental|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
11166321|NCT03616353|Experimental|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
11166322|NCT03616340|Experimental|Ketorolac|
11166323|NCT03616340|Experimental|Kenalog|
11166324|NCT03616327|Other|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
11166325|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
11166326|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
11166327|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
11166328|NCT03616301|Experimental|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
11166329|NCT03616301|Active Comparator|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
11166330|NCT03616288|Placebo Comparator|Negative Control|placebo; 0 mg thiamine
11166331|NCT03616288|Experimental|EAR Group|1.2 mg thiamine as thiamine hydrochloride
11166332|NCT03616288|Experimental|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
11166333|NCT03616288|Experimental|Positive Control|10 mg thiamine as thiamine hydrochloride
11166334|NCT03616275|Experimental|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
11166335|NCT03616275|No Intervention|control group|1 session of healthy lifestyle education
11166336|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
11166337|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
11166338|NCT03616249|Experimental|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
11166339|NCT03616249|Experimental|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
11166340|NCT03616249|Active Comparator|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
11166341|NCT03616249|Active Comparator|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
11166342|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
11166343|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
11166344|NCT03616223|Experimental|FX-322 Low Dose|Single intratympanic injection of a hydrogel formulation
11166345|NCT03616223|Experimental|FX-322 High Dose|Single intratympanic injection of a hydrogel formulation
11166346|NCT03616223|Placebo Comparator|Placebo|Single intratympanic injection of a hydrogel formulation
11166347|NCT03616210|Experimental|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
11166348|NCT03616210|No Intervention|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
11166349|NCT03616197|Active Comparator|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.
~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
11166350|NCT03616197|Active Comparator|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.
~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
11166351|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
11166370|NCT03616028|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the CLAAS device will be performed according to the device Instructions for Use, based on TEE, ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
11166438|NCT03615586|Active Comparator|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
11166439|NCT03615560||Preeclampsia (mild)|
11166352|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:
~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)
~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
11166353|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
11166354|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
11166355|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
11166356|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
11166357|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.
~In-person Study Assessments Include:
~Medical History and Physical Exams
~Quality of Life Questionnaires
~Collection of blood
~Radiology
~Lung Function Test
~6 Minute Walk Test
~Bronchoscopy (Clinically indicated)
~Sputum (Optional)
~Musculoskeletal ultrasound (Optional)"
11166358|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
11166359|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
11166360|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
11166361|NCT03616132|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
11166362|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
11166363|NCT03616093|Experimental|Test Beet shot|Active supplement containing 6.2 mmol nitrate
11166364|NCT03616093|Placebo Comparator|Placebo beverage|Placebo supplement containing negligible nitrate
11166365|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
11166366|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
11166367|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
11166368|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
11166369|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
11166371|NCT03616015|Experimental|Patient|"For all patients included in the study, the following interventions will be performed :
~several blood samples (quantity collected requiring classification of this study as interventional according to French law)
~several fecal samples
~anxiety tests
~stress tests"
11166372|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
11166373|NCT03615989|Placebo Comparator|Exercise and Carbohydrate (CHO)|Participants will have a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They will then complete a supervised resistance and plyometric exercise bout. Immediately following exercise, 51g of carbohydrate (maltodextrin) + water will be consumed. Two more blood samples will follow the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 51g of carbohydrate will be consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) will be taken 24 and 48 hours later.
11166374|NCT03615989|Experimental|Exercise and Milk (Milk)|Participants will have a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They will then complete a supervised resistance and plyometric exercise bout. Immediately following exercise, 555 ml of skim milk will be consumed. Two more blood samples will follow the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 555 ml of skim milk will be consumed 1 hour post exercise. Two more fasting blood samples (10ml) will be taken 24 and 48 hours later.
11166375|NCT03615989|Experimental|Exercise, Milk and Creatine (Cre)|Participants will complete a 6-day creatine loading phase (5 grams x 4 times/day) before they come in for the exercise bout. Participants will have a fasted, baseline blood sample (10ml) taken upon arrival to the lab. Before the exercise bout, 5 grams of creatine will be taken. They will then complete a supervised resistance and plyometric exercise bout. Immediately following exercise, 555 ml of skim milk + 5g of creatine will be consumed. Two more blood samples will follow the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 555ml of skim milk will be consumed 1 hour post exercise without creatine. 5g of creatine will then be consumed with the participant's last meal of the day. Two more fasting blood samples (10ml) will be taken 24 and 48 hours later. On the day after exercise, participants will consume a 5g maintenance dose of creatine with their last meal of the day (between the 24 and 48h blood sample).
11166376|NCT03615976|Experimental|pre operative group|pre operative group with patellofemoral pain resistant to medical and physiotherapy assessment by pre operative knee score arthroscopic circumpatellar denervation with or without lat. Patellar facetectomy
11166377|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
11166378|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
11166379|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
11166380|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
11166381|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:
~Child interactive intervention (dialogic reading and play intervention)
~Family Empowerment (positive parenting and grandparenting)
~Access to Community Hub and its services
~Enhancement to the kindergartens
~Health education, screening, and support"
11166382|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.
~1. Health education, screening, and support"
11166383|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:
~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day
~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day
~>48 kg: Ticagrelor 45 mg, twice a day."
11166384|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:
~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day
~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day
~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
11166385|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28
~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
11166386|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28
~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
11166387|NCT03615885|Placebo Comparator|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
11166388|NCT03615885|Experimental|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
11166389|NCT03615885|Experimental|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
11166390|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
11166391|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
11166392|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
11166393|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
11166394|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
11166395|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.
~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
11166396|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.
~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
11166440|NCT03615560||Preeclampsia (severe)|
11166397|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
11166398|NCT03615833|Experimental|Patients with Vitamin D deficiency|Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
11166399|NCT03615820|Experimental|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
11166400|NCT03615820|Placebo Comparator|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
11166401|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
11166402|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
11166403|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
11166404|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
11166405|NCT03615781|Experimental|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
11166406|NCT03615781|Active Comparator|Four week's arm - surgery|The investigators surgically remove the infected implant.
11166407|NCT03615781|Experimental|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
11166408|NCT03615781|Active Comparator|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
11166409|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
11166410|NCT03615768|Active Comparator|Adapalene Gel|
11166411|NCT03615768|Active Comparator|Clindamycin Gel|
11166412|NCT03615755|No Intervention|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
11166413|NCT03615755|Active Comparator|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
11166414|NCT03615742|Placebo Comparator|Placebo and Filtered Air|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours.
11166415|NCT03615742|Active Comparator|Budesonide and Filtered Air|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to HEPA filtered air for 2 hours.
11166416|NCT03615742|Active Comparator|Placebo and Diesel Exhaust|Volunteers will use an inhaler that does not contain any medication, before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
11166417|NCT03615742|Experimental|Budesonide and Diesel Exhaust|Volunteers will inhale 1.6mg of budesonide before sitting in a booth and being exposed to 300µg/m³ concentration of diesel exhaust for 2 hours.
11166418|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
11166419|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
11166420|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
11166421|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
11166422|NCT03615690|Experimental|Fasting Mimicking Diet|Three cycles of a 5-day reduced calorie diet
11166423|NCT03615690|Placebo Comparator|Regular Diet Control Arm|
11166424|NCT03615677|Experimental|LXI-15028 50mg group (n=130)|
11166425|NCT03615677|Active Comparator|Esomeprazole 40mg group (n=130)|
11166426|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
11166427|NCT03615651|Placebo Comparator|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
11166428|NCT03615651|Experimental|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
11166429|NCT03615638|Experimental|Fall prevention group|Fall prevention program
11166430|NCT03615638|No Intervention|Usual care group|Usual postoperative care
11166431|NCT03615638|No Intervention|Asymptomatic control|No intervention
11166432|NCT03615625|No Intervention|Control session|Control session without any exercise. The participants remain in seated rest throughout 40 min
11166433|NCT03615625|Experimental|Power Training Session|The power training session will last 40 min, in which the participants will perform a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
11166434|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
11166435|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
11166436|NCT03615599||Seventh-day Adventists|This is a prospective cohort study of 96,000 members of the Seventh-day Adventists Church in the United States and Canada age 30 and older at the time of enrollment who are proficient in English language.
11166437|NCT03615586|Active Comparator|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
11166444|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
11166445|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
11166446|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
11166447|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
11166448|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
11166449|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
11166450|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.
~3 Session for 6 weeks."
11166451|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.
~3 session for 6 weeks."
11166452|NCT03615508|Other|10% phenylephrine|All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
11166453|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
11166454|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
11166455|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
11166456|NCT03615469|Active Comparator|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
11166457|NCT03615469|Sham Comparator|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
11166458|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
11166459|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
11166460|NCT03615443|Other|Treatment-naive metastatic non-squamous NSCLC|
11166461|NCT03615430|Placebo Comparator|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
11166462|NCT03615430|Experimental|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
11166463|NCT03615417|Experimental|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
11166464|NCT03615417|Active Comparator|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
11166465|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
11166466|NCT03615378|Placebo Comparator|Placebo|
11166467|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
11166468|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
11166469|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.
~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
11166470|NCT03615352|Experimental|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
11166471|NCT03615352|Experimental|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
11166472|NCT03615339|Experimental|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening).
~Total duration was 6 weeks."
11166473|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
11166474|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
11166475|NCT03615313|Experimental|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
11166476|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
11166477|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
11166478|NCT03615287||Group A|40 subjects undergoing Medical Treatment
11166479|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
11166480|NCT03615287||Group C|40 control subjects
11166481|NCT03615274|Experimental|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
11166482|NCT03615274|Active Comparator|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
11166483|NCT03615261|Experimental|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
11166484|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.
~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
11166485|NCT03615235||Recipients of a Kidney Transplant|APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.
11166486|NCT03615235||Living Kidney Donors|APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.
11166487|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
11166488|NCT03615209|Active Comparator|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
11166489|NCT03615209|Sham Comparator|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
11166490|NCT03615196|Experimental|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
11166491|NCT03615196|Experimental|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
11166492|NCT03615196|Experimental|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
11166493|NCT03615196|Experimental|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
11166494|NCT03615196|Placebo Comparator|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
11166495|NCT03615183|Experimental|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
11166496|NCT03615183|Experimental|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
11166497|NCT03615183|Experimental|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
11166498|NCT03615183|Experimental|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
11166499|NCT03615183|Experimental|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
11166500|NCT03615157|Experimental|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
11166501|NCT03615157|Active Comparator|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
11166502|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
11166503|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
11166504|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
11166505|NCT03615118|Experimental|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
11166506|NCT03615118|Active Comparator|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
11166507|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
11166508|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
11166509|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
11166510|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion
~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
11166511|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
11166512|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
11166513|NCT03615066|Placebo Comparator|Placebo (Cohort 1)|HBeAg-positive participants will receive tenofovir alafenamide (TAF) and selgantolimod placebo for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/Early Discontinuation (ED). The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the Treatment Free Follow-Up (TFFU) phase.
11166514|NCT03615066|Experimental|Selgantolimod 1.5 mg (Cohort 1)|HBeAg-positive participants will receive TAF and selgantolimod 1.5 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.
11166515|NCT03615066|Experimental|Selgantolimod 3 mg (Cohort 1)|HBeAg-positive participants will receive TAF and selgantolimod 3 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.
11166516|NCT03615066|Placebo Comparator|Placebo (Cohort 2)|HBeAg-negative participants will receive TAF and selgantolimod placebo for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.
11166517|NCT03615066|Experimental|Selgantolimod 1.5 mg (Cohort 2)|HBeAg-negative participants will receive TAF and selgantolimod 1.5 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.
11166518|NCT03615066|Experimental|Selgantolimod 3 mg (Cohort 2)|HBeAg-negative participants will receive TAF and selgantolimod 3 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.
11166519|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
11166520|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
11166521|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
11166522|NCT03615027|Experimental|Intervention|see detailed description
11166523|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
11166524|NCT03615001|Experimental|Urodynamics Arm|
11166525|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
11166526|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
11166527|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
11166528|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
11166529|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
11166530|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
11166531|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
11166532|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
11166533|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
11166534|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
11166535|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
11166536|NCT03614923|Active Comparator|Dose 1|SC administration, Q4W
11166537|NCT03614923|Active Comparator|Dose 2|SC administration, Q8W
11166538|NCT03614923|Placebo Comparator|Placebo|SC administration, Q4W
11166539|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:
~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein
~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery
~abutment or encasement of the celiac axis
~involvement of lymph nodes outside the area of resection"
11166540|NCT03614897|Experimental|Education|Providers participating in education related to guidelines for treating patients at risk of falling
11166541|NCT03614884|Experimental|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
11166542|NCT03614884|Active Comparator|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
11166543|NCT03614871||No arms|There are no interventions
11166544|NCT03614858|Experimental|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
11166545|NCT03614845|Active Comparator|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
11166546|NCT03614845|Active Comparator|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
11166547|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
11166548|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
11166549|NCT03614819|Experimental|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
11166550|NCT03614819|Active Comparator|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
11166551|NCT03614806|Experimental|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
11166552|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
11166553|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
11166554|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
11166555|NCT03614767||Successes|Patients with >50% improvement during test procedure of sacral neuromodulation.
11166556|NCT03614767||Failures|Patients with <50% improvement during test procedure of sacral neuromodulation.
11166557|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
11166558|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
11166559|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
11166560|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
11166561|NCT03614728|Experimental|Part 1: GSK3326595|Participants will receive GSK3326595 400 mg oral capsule once a day. The dose may be reduced due to toxicity in the myeloid population, or escalated if required.
11166562|NCT03614728|Experimental|Part 2A: GSK3326595|Participants in this treatment arm will start at the dose identified as the myeloid monotherapy dose in Part 1 of the study.
11166563|NCT03614728|Experimental|Part 2A: Best available care|Participants will receive BAC as treatment of choice considered by the investigator.
11166808|NCT03613129|Active Comparator|D0.03|Subcutaneous infusion of CT38 at 0.03 μg/kg/hour, for 3.5 hours on each of 3 days
11166564|NCT03614728|Experimental|Part2B:GSK3326595+5-azacitidine(dose escalation and expansion)|Participants with newly-diagnosed MDS will receive GSK3326595 oral capsule once a day along with 5-azacitidine administered at a dose of 75 mg/meter square (m^2) seven days in a 28-day cycle. The initial dose of GSK3326595 administered in Part 2B of this study will be reduced by two dose levels from the recommended myeloid monotherapy dose, as determined in Part 1, and escalate up to the Recommended Myeloid Monotherapy Dose.
11166565|NCT03614728|Experimental|Part 2C: GSK3326595|Participants with relapsed and/or refractory AML will receive GSK3326595 oral capsule at the dose identified as the myeloid monotherapy dose in Part 1 of the study, until progression, unacceptable toxicity, or withdrawal of consent.
11166566|NCT03614715|Experimental|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
11166567|NCT03614715|Active Comparator|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
11166568|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
11166569|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
11166570|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
11166571|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose
~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
11166572|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
11166573|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose
~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
11166574|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
11166575|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
11166576|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
11166577|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose
~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
11166607|NCT03614533|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
11166608|NCT03614533|Active Comparator|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
11166578|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose
~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
11166579|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose
~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
11166580|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age and with pre-pregnancy body mass index (BMI) ≥18.5 and ≤ 39.9 kg/m2 enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV). Collection of maternal blood samples and cord blood samples at delivery are planned for determination of antibody titers.
11166581|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-40 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization
11166582|NCT03614663|Experimental|ZYN002 - CBD transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg CBD Q12H or placebo.
~Patients weighing greater than 35 kg will be randomized to receive 250 mg CBD Q12H or placebo."
11166583|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
11166584|NCT03614650|Experimental|EIE cells to treat cancer|EIE cells to treat cancer
11166585|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
11166586|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
11166587|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
11166588|NCT03614611|Experimental|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
11166589|NCT03614598|Active Comparator|LMA-UNIQUE™|
11166590|NCT03614598|Active Comparator|LMA-SUPREME™|
11166591|NCT03614598|Active Comparator|I-GEL®|
11166592|NCT03614585|Experimental|High-intensity interval training|Intensity will be determined using a percentage of the workload associated with VO2peak (pVO2peak) from the graded exercise test and ratings of perceived exertion (RPE). The protocol will involve 10 30-second intervals of high intensity interspersed with 8 60-second low-intensity intervals. The workload during the high intensity intervals will start at 70% of the pVO2peak (RPE=14-17) and progressed by 10% every 4 weeks. Low intensity intervals will be performed at 30% pVO2peak (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% pVO2peak. Total HIIT time including warm-up and cool-down is 18 minutes.
11166593|NCT03614585|Experimental|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
11166594|NCT03614572|Experimental|Group MI|The structure and content of the active intervention programme will be developed and adopted on the basis of previous research on sleep educational programme and motivational interviewing techniques. The whole treatment package consists of 4 sessions of group therapy (n=6-8) followed by 3 week daily text reminders.
11166595|NCT03614572|No Intervention|Control group|Control group will no receive any intervention
11166596|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
11166597|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
11166598|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
11166599|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
11166600|NCT03614546|Other|A（surgery） group|Hepatectomy
11166601|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
11166602|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
11166603|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
11166604|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
11166605|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
11166606|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
11166809|NCT03613129|Active Comparator|D0.06|Subcutaneous infusion of CT38 at 0.06 μg/kg/hour, for 3.5 hours on each of 3 days
11166609|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
11166610|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
11166611|NCT03614507|Experimental|FreeO2 Arm|Automatic adjustment of oxygen
11166612|NCT03614507|Active Comparator|Manual Arm|Manual adjustment of oxygen
11166613|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
11166614|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
11166615|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.
~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
11166616|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.
~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
11166617|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
11166618|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
11166619|NCT03614455|Experimental|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
11166620|NCT03614455|Other|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
11166621|NCT03614455|Other|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
11166622|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
11166623|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
11166624|NCT03614429|No Intervention|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)
~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.
~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
11166625|NCT03614429|Experimental|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)
~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.
~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
11166626|NCT03614416|Experimental|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
11166627|NCT03614403|Experimental|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
11166628|NCT03614403|No Intervention|control|Control patients will not be received any intervention
11166629|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.
~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.
~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
11166630|NCT03614377||Patients with low burden of sleep-disordered breathing|
11166631|NCT03614377||Patients with high burden of sleep-disordered breathing|
11166632|NCT03614364|Experimental|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
11166633|NCT03614351|Experimental|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
11167006|NCT03611751|Active Comparator|Active comparator|Active comparator oral administration
11166634|NCT03614351|Active Comparator|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
11166635|NCT03614338|Experimental|Core Participants Weight Loss Program|Small changes weight loss program
11166636|NCT03614325|Experimental|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.
~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
11166637|NCT03614325|No Intervention|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
11166638|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
11166639|NCT03614299||pSS cohort|Patients with pSS included in the study
11166640|NCT03614273|Active Comparator|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
11166641|NCT03614273|Active Comparator|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
11166642|NCT03614260|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (Paradise Renal Denervation System)
11166643|NCT03614260|Sham Comparator|Sham Control|Renal Angiogram
11166644|NCT03614247|Active Comparator|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
11166645|NCT03614247|Active Comparator|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size <10 F) for lower calyceal stone between 1cm and 2cm in size
11166646|NCT03614247|Active Comparator|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size <15 F) for lower calyceal stone between 1cm and 2cm in size
11166647|NCT03614247|Active Comparator|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size <20 F) for lower calyceal stone between 1cm and 2cm in size
11166648|NCT03614247|Active Comparator|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size >25 F) for lower calyceal stone between 1cm and 2cm in size
11166649|NCT03614234|Experimental|Experimental open label|Pegunigalsidase alfa
11166650|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will terminate participation in this trial.
11166651|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will terminate participation in this trial.
11166652|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.
~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
11166653|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
11166654|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
11166655|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
11166656|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
11166657|NCT03614182|Experimental|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
11166658|NCT03614182|Active Comparator|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
11166659|NCT03614182|Active Comparator|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
11166660|NCT03614169|Experimental|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
11166689|NCT03613935|Active Comparator|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
11166810|NCT03613129|Active Comparator|D0.01|Subcutaneous infusion of CT38 at 0.01 μg/kg/hour, for 3.5 hours on each of 3 days
11166661|NCT03614169|Active Comparator|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold)
11166662|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
11166663|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
11166664|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
11166665|NCT03614117|Active Comparator|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
11166666|NCT03614117|Active Comparator|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
11166667|NCT03614117|Placebo Comparator|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
11166668|NCT03614104|Active Comparator|mobile health technology|Health education with mobile health technology
11166669|NCT03614104|Sham Comparator|Without mobile health technology|Health education without mobile health technology
11166670|NCT03614091|Active Comparator|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
11166671|NCT03614091|Active Comparator|Erector spinae plane block group|the transducer will be placed in a transverse orientation to identify the spinous process, lamina,and transverse process.The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superfacial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudad Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process.following which a total of 20 mL of 0.5%bupivacaine will be injected.
11166672|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
11166673|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
11166674|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
11166675|NCT03614065|Placebo Comparator|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
11166676|NCT03614065|Experimental|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
11166677|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
11166678|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
11166679|NCT03614039|Active Comparator|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
11166680|NCT03614039|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
11166681|NCT03614026|Experimental|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
11166682|NCT03614026|No Intervention|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
11166683|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
11166684|NCT03614000|Experimental|positive screenings|
11166685|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
11166686|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
11166687|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
11166688|NCT03613935|Placebo Comparator|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
11166690|NCT03613935|Active Comparator|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
11166691|NCT03613935|Active Comparator|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
11166692|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
11166693|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
11166694|NCT03613909|Experimental|CP950|CP950 Off The Ear (OTE) sound processor
11166695|NCT03613909|Active Comparator|BTE|Behind the Ear (BTE) sound processor (either a CP810 or CP900 series)
11166696|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
11166697|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
11166698|NCT03613883|Experimental|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
11166699|NCT03613883|Experimental|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
11166700|NCT03613870|Active Comparator|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
11166701|NCT03613870|Active Comparator|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
11166702|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
11166703|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
11166704|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
11166705|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
11166706|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
11166707|NCT03613818|No Intervention|Control|Assessment only
11166708|NCT03613805|Active Comparator|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
11166709|NCT03613805|Experimental|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
11166710|NCT03613792|Active Comparator|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
11166711|NCT03613792|Active Comparator|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
11166712|NCT03613779|Experimental|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.
~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
11166713|NCT03613779|Active Comparator|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).
~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
11166714|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
11166715|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
11166716|NCT03613753|Experimental|Arm A|Chemotherapy:irinotecan plus lobaplatin
11166717|NCT03613753|Active Comparator|Arm B|Chemotherapy:irinotecan
11166718|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
11166719|NCT03613740|Placebo Comparator|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
11166720|NCT03613727|Experimental|IV Vitamin C followed by oral Vitamin C|All study participants will receive the same treatment. Each participant will be given intravenous, which means by vein (IV), vitamin C three times a day for 14 days. Then participants will take vitamin C orally (by mouth in pill form) twice a day each day until 6 months after transplant. The treatment is IV vitamin C 50 mg/kg/day. After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day.
11166721|NCT03613714|Active Comparator|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
11166807|NCT03613129|Active Comparator|D0.20|Subcutaneous infusion of CT38 at 0.20 μg/kg/hour, for 3 hours on each of 2 days
11166722|NCT03613714|No Intervention|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
11166723|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
11166724|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
11166725|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
11166726|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
11166727|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
11166728|NCT03613675|Experimental|Video games|All participants will be asked to play 4 video games.
11166729|NCT03613662|Experimental|SP-102|SP-102
11166730|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
11166731|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
11166732|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
11166733|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
11166734|NCT03613636||CAP cohort|"Children of age 3 to 16 years;
~In- and outpatients;
~Clinically diagnosed community-acquired pneumonia (CAP)."
11166735|NCT03613636||Healthy control cohort|"Healthy asymptomatic children of age 3 to 16 years;
~undergoing an elective surgical procedure."
11166736|NCT03613636||Family control cohort|- Family members of index CAP patients.
11166737|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
11166738|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
11166739|NCT03613610|Active Comparator|Three needles group|
11166740|NCT03613610|Active Comparator|Single needle group|
11166741|NCT03613597|Experimental|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
11166742|NCT03613597|Active Comparator|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
11166743|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
11166744|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
11166745|NCT03613571|Experimental|ILB|ILB treatment
11166746|NCT03613558|Experimental|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
11166747|NCT03613558|Placebo Comparator|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
11166748|NCT03613545|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
11166749|NCT03613545|Sham Comparator|placebo fecal microbiota transplantation|Infusion of sham
11166750|NCT03613545|Sham Comparator|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
11166751|NCT03613532|Experimental|Venetoclax|"This study has three periods: 1) Screening, 2) Treatment including venetoclax + FluBu2 conditioning chemotherapy and transplantation; and 3) Post-Transplant follow up. For Part 1, the post-transplant period will include routine follow-up. For Part 2, the post-transplant period will include investigational therapy with azacitidine and venetoclax and follow-up.
~Dose escalation in Part 1 will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation/de-escalation.
~Venetoclax: 6-7 total doses depending on dose level assigned
~FLuBu2
~Busulfan: given twice daily for 4 days
~Fludarabine: given once daily for 4 days
~Dose escalation in Part 2 will occur using a 10+10 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation/de-escalation.
~Venetoclax: 14 doses for 8-12 cycles depending on dose level assigned
~Azacitidine: 5 doses for 8-12 cycles depending on dose level assigned"
11166752|NCT03613519|Placebo Comparator|Usual care (sleep hygiene)|A web-based program that presents ways to improve behaviors and environments that can affect sleep.
11166753|NCT03613519|Active Comparator|SHUTi (Sleep Healthy Using the Internet)|SHUTi is a publicly available standard web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
11166754|NCT03613519|Active Comparator|modified SHUTi (SHUTi modified for Black women)|The CBT-I instrument tailored for Black women.
11166755|NCT03613506|Experimental|Peripheral blood TGF-β content before and after radiotherapy|
11166756|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
11166757|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
11166758|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
11166759|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
11166760|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
11166761|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
11166762|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
11166763|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
11166764|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
11166765|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
11166766|NCT03613441|Experimental|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
11166767|NCT03613441|No Intervention|Control|Waitlist control (intervention will be available to this group at the end of the study period)
11166768|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
11166769|NCT03613415|Experimental|Expansion by Densah bur|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.
~A mid crestal flap will be reflected.
~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.
~Sequential use of Densah bur under copious irrigation.
~An implant of 3.9*10 mm will be inserted.
~Smart peg will be placed on implant and Osstell will be used to record ISQ.
~Healing collars will be placed on implants.
~Flap will be prepared for closure and suturing."
11166770|NCT03613415|Active Comparator|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.
~A mid crestal flap will be reflected.
~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.
~Sequential use of screw expanders.
~An implant of 3.9*10 mm will be inserted.
~Smart peg will be placed on implant and Osstell will be used to record ISQ.
~Healing collars will be placed on implants.
~Flap will be prepared for closure and suturing."
11166771|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
11166772|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
11166773|NCT03613389|Experimental|oral topical vitamin E|
11166774|NCT03613389|No Intervention|voriconazole and levofloxacin|
11166775|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
11166776|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
11166777|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
11166778|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
11166779|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
11166780|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
11166781|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
11166782|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
11166783|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
11166784|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was <12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
11166785|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was <12 mL/s and PdetQmax was <10 cmH2O during voiding cystometry.
11166786|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
11172676|NCT03571932||Comparison facilities|Infludes 18 health facilities
11166787|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
11166788|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
11166789|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
11166790|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:
~Evaluate its ability to locate and assess the volume of the endometriosic lesion
~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.
~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
11166791|NCT03613285|Active Comparator|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
11166792|NCT03613285|Active Comparator|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
11166793|NCT03613285|Active Comparator|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
11166794|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
11166795|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
11166796|NCT03613259|Experimental|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
11166797|NCT03613233|Active Comparator|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
11166798|NCT03613233|Active Comparator|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
11166799|NCT03613220|Experimental|ribociclib + letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
11166800|NCT03613207|Experimental|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.
~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.
~Each subject will have 9 test sites in total which are treated with:
~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)
~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)
~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)
~test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)
~2 test sites: untreated test site"
11166801|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.
~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:
~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal
~Peritoneal liquid
~none tumoral peritoneum
~Portal blood
~Peripheral blood
~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.
~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
11166802|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
11166803|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
11166804|NCT03613168|Experimental|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
11166805|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
11166806|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
11166811|NCT03613116|Experimental|High Dose Vitamin D3|Receives 4000 IU daily Vitamin D3 tablets.
11166813|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
11166814|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
11166815|NCT03613090|Experimental|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
11166816|NCT03613090|Active Comparator|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
11166817|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
11166818|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
11166819|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
11166820|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
11166821|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
11166822|NCT03613038|Other|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
11166823|NCT03613025|Other|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
11166824|NCT03613025|Other|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
11166825|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
11166826|NCT03612999|Experimental|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
11166827|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)
~1 tablet/day, oral administration"
11166828|NCT03612986|Placebo Comparator|B: Placebo|"Placebo
~1 tablet/day, oral administration"
11166829|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture
~Liver and renal function tests
~Prothrombin time and concentration
~HCV quantitative polymerase chain reaction
~Hepatitis B surface Ag
~lipid profile
~fasting blood glucose level
~fasting insulin level
~homeostasis model for the assessment of insulin resistance (HOMA-IR)
~fibrosis (FIB- 4) index
~Aspartate aminotransferase (AST)/platelet ratio index (APRI)
~Abdominal ultrasound to assess liver and spleen
~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
11166830|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture
~Liver and renal function tests
~Prothrombin time and concentration
~HCV quantitative polymerase chain reaction
~Hepatitis B surface Ag
~lipid profile
~fasting blood glucose level
~fasting insulin level
~homeostasis model for the assessment of insulin resistance (HOMA-IR)
~Fibrosis (FIB- 4) index
~Aspartate aminotransferase (AST)/platelet ratio index (APRI)
~Abdominal ultrasound to assess liver and spleen
~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
11166831|NCT03612960|Experimental|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
11166832|NCT03612960|Placebo Comparator|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
11166833|NCT03612947|Active Comparator|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
11166834|NCT03612947|Placebo Comparator|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
11166835|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
11166836|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
11166837|NCT03612921|Active Comparator|oral group|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline
11166838|NCT03612921|Active Comparator|I.V group|the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery
11166839|NCT03612921|Placebo Comparator|control group (group C)|the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery
11166840|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
11166841|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
11166842|NCT03612895|Experimental|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
11166843|NCT03612895|Experimental|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
11166844|NCT03612895|Other|Usual Care|Passive referral to quitline and referral to primary care physician.
11166845|NCT03612882||Western University Students|Online questionnaire
11166846|NCT03612869|Experimental|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
11166847|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 1|Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
11166848|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 2|Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
11166849|NCT03612856|Placebo Comparator|placebo|Participants will receive a single dose of placebo.
11166850|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
11166851|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
11166852|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
11166853|NCT03612817|Active Comparator|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
11166854|NCT03612817|Active Comparator|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
11166855|NCT03612804|No Intervention|Unstructured care|Providers in this arm will continue to provide care as usual during lung cancer screening, with no intervention from the study team.
11166856|NCT03612804|Experimental|Proactive care|Providers in this arm will receive guidance from the study team about offering lung cancer screening patients proactive cessation care, including cessation medications and behavioral telephone counseling.
11166857|NCT03612791|Active Comparator|Standard Treatment Arm|"Radiotherapy (RT):
~Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).
~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).
~Total duration of RT (including brachytherapy) should be ≤ 55 days.
~Chemotherapy:
~- Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5)."
11166858|NCT03612791|Experimental|Experimental Treatment Arm|"Same treatment as described above (CRT, followed by uterovaginal brachytherapy), plus
~atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles."
11166859|NCT03612778|Experimental|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
11166860|NCT03612778|Active Comparator|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
11166861|NCT03612765|Experimental|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
11166862|NCT03612765|No Intervention|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
11166863|NCT03612752|Experimental|Active arm|CMI-168
11166864|NCT03612752|Placebo Comparator|Placebo arm|Placebo
11166865|NCT03612739|Experimental|Cohort 1|5-azacytidine + 1x10^8 NKR-2 CAR-T Cells
11166866|NCT03612739|Experimental|Cohort 2|5-azacytidine + 3x10^8 NKR-2 CAR-T Cells
11166867|NCT03612739|Experimental|Cohort 3|5-azacytidine + 1x10^9 NKR-2 CAR-T Cells
11166868|NCT03612713|Active Comparator|Oxycodone Medication First|one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
11166869|NCT03612713|Placebo Comparator|Placebo First|one hour before fMRI scan participants will be given a single dose placebo.
11166870|NCT03612700|Experimental|CPFA-rich diet|Free living diet controlled in CPFA intake
11166871|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
11166872|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
11166873|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
11166874|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
11166875|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
11166876|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
11166877|NCT03612661|Experimental|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
11167108|NCT03611062|Experimental|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
11166878|NCT03612661|Experimental|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have ~20 minute weekly phone call with a study interventionist.
11166879|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR
~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
11166880|NCT03612622|Active Comparator|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
11166881|NCT03612622|Placebo Comparator|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
11166882|NCT03612609|Other|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
11166883|NCT03612596|Experimental|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
11166884|NCT03612596|Active Comparator|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
11166885|NCT03612583|Experimental|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
11166886|NCT03612583|Experimental|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
11166887|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
11166888|NCT03612557|Experimental|active treatment arm|penicillin G benzathine treatment
11166889|NCT03612544|Experimental|Intervention group|
11166890|NCT03612544|Active Comparator|Control group|
11166891|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
11166892|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
11166893|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
11166894|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
11166895|NCT03612505|Active Comparator|Intervention|
11166896|NCT03612505|No Intervention|Control|
11166897|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
11166898|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
11166899|NCT03612479|Experimental|KIDFIT Healthy|
11166900|NCT03612479|Active Comparator|KIDFIT Safe|
11166901|NCT03612466|Experimental|Dose Escalation Arm|"Dose Levels 1-3 will consist of treatment with radiopharmaceutical (153Sm-DOTMP) alone. If the maximally tolerated dose (MTD) has not been reached at Level 3, external beam radiotherapy will be added to each of Levels 4-6. Participants enrolled on Dose Levels 4-6 will be treated with external beam radiotherapy to all radiographically evident sites of disease. If an MTD has not been determined at Level 6, the study will end and Dose Level 6 will be declared the Recommended Phase 2 Dose.
~Participants will be given prophylactic / supportive treatment protocols including Calcium Carbonate, mozobil, and neupogen injectable product."
11166902|NCT03612453|Experimental|Intervention group|
11166903|NCT03612453|Active Comparator|Control group|
11166904|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
11166905|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
11166906|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
11166907|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
11166908|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
11166909|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
11166910|NCT03612401|Other|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
11166911|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
11166912|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
11166913|NCT03612375|Experimental|Intervention group|
11166914|NCT03612375|Active Comparator|Control group|
11166915|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
11166916|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
11166917|NCT03612349|Other|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
11166918|NCT03612349|Other|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
11166919|NCT03612336|Experimental|Intervention group|
11166920|NCT03612336|Active Comparator|Control group|
11166921|NCT03612323|Experimental|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
11168430|NCT03601559|Active Comparator|Lactobacillus paracasei Lpc-37|Probiotic
11166922|NCT03612323|Active Comparator|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
11166923|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
11166924|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
11166925|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN
~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC
~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
11166926|NCT03612271|Experimental|mGlide Intervention|Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
11166927|NCT03612271|No Intervention|Clinical Care Comparison|Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
11166928|NCT03612258|Experimental|Functional Magnetic Resonance Imaging|
11166929|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
11166930|NCT03612219|Experimental|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
11166931|NCT03612219|Active Comparator|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
11166932|NCT03612193||Study A: Chronic >1 year|
11166933|NCT03612193||Study A: Acute <1 year|
11166934|NCT03612193||Study A: Household Control|
11166935|NCT03612193||Study B: Newly Diagnosed <6 months|
11166936|NCT03612193||Study B: Household Controls|
11166937|NCT03612167|Experimental|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
11166938|NCT03612167|Active Comparator|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
11166939|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
11166940|NCT03612128|Other|control group|Children continued their traditional physiotherapy
11166941|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
11166942|NCT03612115|Experimental|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
11166943|NCT03612115|No Intervention|Control|No additional intervention
11166944|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
11166945|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
11166946|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
11166947|NCT03612089||Healthy control group|Healthy individuals without low back pain
11166948|NCT03612076||Global cost of management of PJI|
11166949|NCT03612063|Experimental|Fitbit Iconic HR and Garmin Vivosmart HR|
11166950|NCT03612063|Experimental|Fitbit Iconic HR and TomTom Spark 3|
11166951|NCT03612063|Experimental|Garmin Vivosmart HR and TomTom Spark 3|
11166952|NCT03612063|Experimental|Fitbit Iconic HR and Apple Watch III|
11166953|NCT03612063|Experimental|Apple Watch III and Garmin Vivosmart HR|
11166954|NCT03612063|Experimental|Apple Watch III and TomTom Spark 3|
11166955|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
11166956|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
11166957|NCT03612037|Placebo Comparator|Control Phase|cellulose (600 mg)
11166958|NCT03612037|Experimental|Experimental Phase|alpha lipoic acid (600 mg)
11166959|NCT03612024||request for organ donation approved|
11166960|NCT03612024||request for organ donation rejected|
11166961|NCT03612011|Experimental|Onco-Repair|Onco-Repair tube of 150 ml
11166962|NCT03612011|Placebo Comparator|Placebo|Placebo tube of 150 ml
11166963|NCT03611998|Experimental|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
11166964|NCT03611985|Experimental|Epidiferphane + taxane chemotherapy|
11166965|NCT03611972|Experimental|Sugar-sweetened beverage (SSB)|SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks
11166966|NCT03611946|Experimental|rZIKV/D4Δ30-713|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
11166967|NCT03611946|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11166968|NCT03611933|No Intervention|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
11167110|NCT03611049|Placebo Comparator|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
11166969|NCT03611933|Experimental|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
11166970|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
11166971|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
11166972|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
11166973|NCT03611907|Active Comparator|SL2 ( Kitazato® Single Lumen 327350)|Oocyte retrieval with only aspiration system
11166974|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
11166975|NCT03611907|Active Comparator|DL2 ( Kitazato® Single flushing Lumen)|Oocyte retrieval with aspiration and flushing system
11166976|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
11166977|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
11166978|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
11166979|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
11166980|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
11166981|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
11166982|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
11166983|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
11166984|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
11166985|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
11166986|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
11166987|NCT03611868|Experimental|APG-115+Pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
11166988|NCT03611855|Experimental|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
11166989|NCT03611855|Active Comparator|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
11166990|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
11166991|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
11166992|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
11166993|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
11166994|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
11166995|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
11166996|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
11166997|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
11166998|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
11166999|NCT03611803|Experimental|Ekso Group|
11167000|NCT03611803|Active Comparator|Control|
11167001|NCT03611790|Experimental|Intervention|NeVa VS
11167002|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
11167003|NCT03611764|Experimental|Arm 1: Body Scan|"The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes
~Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.
~Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
11167007|NCT03611738|Experimental|Phase I Dose Escalation|"The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).
~Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m^2 docetaxel"
11167008|NCT03611738|Experimental|Phase Ib Dose Expansion|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
11167009|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
11167010|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
11167011|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
11167012|NCT03611712|No Intervention|CCRT alone arm|
11167013|NCT03611699|Active Comparator|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
11167014|NCT03611699|Placebo Comparator|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
11167015|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
11167016|NCT03611673|Experimental|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
11167017|NCT03611673|Active Comparator|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
11167018|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
11167019|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
11167020|NCT03611647|Active Comparator|Probiotic|
11167021|NCT03611647|Placebo Comparator|Placebo|
11167022|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
11167023|NCT03611608|Experimental|LY3316531 Dose 1|LY3316531 administered IV
11167024|NCT03611608|Experimental|LY3316531 Dose 2|LY3316531 administered IV
11167025|NCT03611608|Placebo Comparator|Placebo|Placebo administered IV
11167026|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
11167027|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
11167028|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
11167029|NCT03611569|Experimental|Lu AF82422|"Part A:
~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)
~Part B:
~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
11167030|NCT03611569|Placebo Comparator|Placebo|"Part A:
~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)
~Part B:
~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
11167031|NCT03611556|Active Comparator|Arm A1|gemcitabine and nab-paclitaxel
11167032|NCT03611556|Experimental|Arm A2|oleclumab (MEDI9447), gemcitabine and nab-paclitaxel
11167033|NCT03611556|Experimental|Arm A3|oleclumab (MEDI9447), durvalumab (MEDI4736), and gemcitabine/nab-paclitaxel
11167034|NCT03611556|Active Comparator|Arm B1|mFOLFOX (oxaliplatin, leucovorin, 5-FU)
11167035|NCT03611556|Experimental|Arm B2|oleclumab (MEDI9447) and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
11167036|NCT03611556|Experimental|Arm B3|oleclumab (MEDI9447), durvalumab (MEDI4736), and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
11167037|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
11167109|NCT03611062|Placebo Comparator|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
11168431|NCT03601559|Placebo Comparator|Placebo|Inert placebo
11167038|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
11167039|NCT03611530|Experimental|CoQun®|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
11167040|NCT03611530|Placebo Comparator|Placebo|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
11167041|NCT03611517|Experimental|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
11167042|NCT03611517|No Intervention|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
11167043|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
11167044|NCT03611491|Experimental|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
11167045|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
11167046|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
11167047|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
11167048|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients schedulded for a cardiac defibrillator implantation in primary prevention.
11167049|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
11167050|NCT03611452|Experimental|Simple continuous|the sutures will be taken continuously by simple method
11167051|NCT03611452|Active Comparator|subcuticular|the sutures will be taken subcuticular
11167052|NCT03611452|Active Comparator|interrupted|the sutures will be taken interrupted method
11167053|NCT03611439|Active Comparator|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
11167054|NCT03611439|Placebo Comparator|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
11167055|NCT03611426|Experimental|rhThrombin ( Topical )|The first part:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; The second part:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; The third part:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
11167056|NCT03611426|Placebo Comparator|placebo|The first part: the same volume of saline during segmental hepatectomy; The second part:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; The third part:the same volume of saline during segmental hepatectomy;
11167057|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
11167058|NCT03611413||conventional care|Patients who have been treated under an conventional care
11167059|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
11167060|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
11167061|NCT03611387||Normal|Patients without any type of glaucoma
11167062|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
11167063|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
11167064|NCT03611374|Experimental|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
11167065|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
11167066|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
11167067|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
11167068|NCT03611335||Site 2 H+H|Bellevue Hospital
11167069|NCT03611335||Site 3 H+H|Metropolitan Hospital
11167070|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
11167071|NCT03611335||Site 5 H+H|Coney Island Hospital
11167072|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
11167073|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
11167074|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
11168432|NCT03601546||Patients with HCV infection|
11167075|NCT03611309|Experimental|Surgeon-palliative care team co-management|In the Surgeon-palliative care team co-management arm, all patients receive the surgical care of surgeon alone management, which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will also be provided by a specialist team. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed for 12 weeks following surgery.
11167076|NCT03611309|Other|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery. The surgeon team is given guidelines published by the National Cancer Coalition Network as to when palliative care specialist consultation is recommended
11167077|NCT03611283|Experimental|Test group|"Patients had to use:
~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.
~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
11167078|NCT03611283|Placebo Comparator|Placebo group|"Patients had to use:
~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.
~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
11167079|NCT03611257|Experimental|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
11167080|NCT03611257|Active Comparator|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
11167081|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
11167082|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
11167083|NCT03611231|Experimental|Experimental|chidamide
11167084|NCT03611218|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
11167085|NCT03611205|Experimental|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
11167086|NCT03611192|Experimental|Multicomponent exercise group|
11167087|NCT03611192|Active Comparator|Home-program exercise group|
11167088|NCT03611179|Experimental|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 & Carboplatin AUC 5 every 21 days)
11167089|NCT03611153|Experimental|Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
11167090|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
11167091|NCT03611140|Experimental|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
11167092|NCT03611140|Placebo Comparator|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
11167093|NCT03611127|Experimental|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
11167094|NCT03611127|No Intervention|Usual care (UC)|No pulmonary rehabilitation for this group
11167095|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
11167096|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
11167097|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
11167098|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
11167099|NCT03611075|Experimental|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
11167100|NCT03611075|Experimental|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
11167101|NCT03611075|Experimental|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
11167102|NCT03611075|Experimental|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
11167103|NCT03611075|Experimental|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
11167104|NCT03611075|Experimental|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
11167105|NCT03611075|No Intervention|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
11167106|NCT03611075|No Intervention|TD Healthy Participant Adolescents|Participants will be 13-17 years old
11167107|NCT03611075|No Intervention|TD Healthy Participant Adults|Participants will be 18-45 years old
11167111|NCT03611049|Active Comparator|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
11167112|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
11167113|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
11167114|NCT03611010|Experimental|10 mg oral atorvastatin|Subjects taking 10 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
11167115|NCT03611010|Experimental|20 mg oral atorvastatin|Subjects taking 20 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
11167116|NCT03611010|Experimental|40 mg oral atorvastatin|Subjects taking 40 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
11167117|NCT03611010|Experimental|80 mg oral atorvastatin|Subjects taking 80 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
11167118|NCT03610997|Other|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
11167119|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
11167120|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
11167121|NCT03610971|Experimental|Combination Therapy + Remission Phase|"Combination therapy followed by treatment free remission (TFR) phase.
~Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).
~All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. They will continue combination therapy for a total of 12 cycles. Each cycle will be 28 days. At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment."
11167122|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.
~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
11167123|NCT03610945|Experimental|EDP-305 and fluconazole interaction (Part 1)|
11167124|NCT03610945|Experimental|EDP-305 and quinidine interaction (Part 2)|
11167125|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
11167126|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
11167127|NCT03610919|Experimental|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
11167128|NCT03610919|Experimental|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
11167129|NCT03610919|Placebo Comparator|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
11167130|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
11167131|NCT03610893|Active Comparator|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
11167132|NCT03610893|Active Comparator|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
11167133|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
11167134|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
11167135|NCT03610867|Experimental|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
11167136|NCT03610867|Placebo Comparator|Placebo (SAD)|"Single ascending oral dose of Furaprevir similar capsule.
~."
11167137|NCT03610867|Experimental|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
11167138|NCT03610867|Placebo Comparator|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
11167139|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
11167140|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
11167141|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
11167142|NCT03610815|Experimental|mSBIRT|Mobile Screening, Brief Intervention, Referral to Treatment (mSBIRT)
11167143|NCT03610815|Active Comparator|SBIRT-CTS),|Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision strategy
11167144|NCT03610802||1|Patient with a clinical diagnosis of suspected or known PID
11167145|NCT03610802||2|Biological Relative of a patient with suspected or known PID
11167146|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems and/or Acetabular Components
11167147|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
11167148|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
11167149|NCT03610763|Active Comparator|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
11167313|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
11167150|NCT03610763|Active Comparator|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
11167151|NCT03610763|No Intervention|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
11167152|NCT03610750|Active Comparator|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
11167153|NCT03610750|Experimental|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
11167154|NCT03610750|Experimental|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
11167155|NCT03610737|Active Comparator|MILD with CMM|The MILD procedure is an image-guided minimally-invasive lumbar decompression with conventional medical managment
11167156|NCT03610737|Active Comparator|CMM alone|Patient in the CMM alone group can have physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
11167157|NCT03610724|Experimental|Tisagenlecleucel|CAR-positive viable T cells infusion
11167158|NCT03610711|Experimental|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
11167159|NCT03610711|Experimental|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
11167160|NCT03610698|Experimental|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
11167161|NCT03610698|Experimental|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
11167162|NCT03610698|Active Comparator|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
11167163|NCT03610685|Placebo Comparator|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
11167164|NCT03610685|Active Comparator|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
11167165|NCT03610672|Active Comparator|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
11167166|NCT03610672|Experimental|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
11167167|NCT03610646|Experimental|MYL-1701P|MYL-1701P
11167168|NCT03610646|Active Comparator|Eylea|Eylea
11167169|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
11167170|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
11167171|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
11167172|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
11167173|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
11167174|NCT03610594|Experimental|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
11167175|NCT03610594|No Intervention|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
11167176|NCT03610581|Experimental|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
11167177|NCT03610581|Experimental|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
11167178|NCT03610581|Experimental|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
11167179|NCT03610581|Placebo Comparator|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
11167180|NCT03610568|Experimental|Growing up GREAT! Intervention|
11167181|NCT03610568|No Intervention|Control|
11167182|NCT03610555|No Intervention|Current website|
11167183|NCT03610555|Active Comparator|New patient centered website|
11167395|NCT03609125|Experimental|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
11167184|NCT03610542|Experimental|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
11167185|NCT03610542|Experimental|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
11167186|NCT03610542|No Intervention|Control|This is a no intervention control arm
11167187|NCT03610529|Experimental|ECG monitoring system CardioSenseSystem group|
11167188|NCT03610529|Active Comparator|ECG monitoring system Philips Intellivue|
11167189|NCT03610516|Experimental|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
11167190|NCT03610516|Placebo Comparator|Placebo|Investigational drug matching placebo will be administered as multiple doses
11167191|NCT03610503|Experimental|Music|Patients listen to music during EMG test
11167192|NCT03610503|No Intervention|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
11167193|NCT03610490|Experimental|Treatment (autologous tumor infiltrating lymphocytes MDA-TIL)|"LYMPHODEPLETION REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, and fludarabine IV over 15-30 minutes on days -5 to -1 in the absence of disease progression or unacceptable toxicity.
~T-CELL INFUSION: Patients receive autologous tumor infiltrating lymphocytes MDA-TIL IV over 45 minutes on day 0. Patients then receive IL-2 IV over 30 minutes on days 1-4 for up to 6 doses in the absence of disease progression or unacceptable toxicity."
11167194|NCT03610477|Active Comparator|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
11167195|NCT03610477|Placebo Comparator|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
11167196|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
11167197|NCT03610451|Experimental|Floatation-REST|Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.
11167198|NCT03610451|Other|Usual care|Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
11167199|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
11167200|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
11167201|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
11167202|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
11167203|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
11167204|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
11167205|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
11167206|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
11167207|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
11167208|NCT03610386|Active Comparator|Control|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours and then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes .
11167209|NCT03610386|Experimental|Treatment with menthoxypropanediol|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. Thy will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours. Then the menthoxypropanediol (200 µM) will be applied topically on this explant and left for 6 hours. Then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes.
11167210|NCT03610373|Experimental|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
11167211|NCT03610373|Active Comparator|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
11167212|NCT03610360|Active Comparator|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
11167213|NCT03610360|No Intervention|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
11167214|NCT03610347|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
11167215|NCT03610347|Active Comparator|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
11167451|NCT03608618|Experimental|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
11167216|NCT03610334|Experimental|IFB-088|"IFB-088 oral capsule:
~In SAD phase: single daily dose of IFB-088 will be administered to 6 successive cohorts while increasing dose exposure.
~In MAD phase: multiple doses of IFB-088 will be administered daily during 14 days to 3 succesive cohorts while increasing dose exposure."
11167217|NCT03610334|Placebo Comparator|Placebo|"Placebo oral capsule:
~In SAD phase: single daily dose of placebo (cellulose microcrystalline) will be administered in equivalent-weight.
~In MAD phase: multiple doses of placebo (cellulose microcrystalline) will be administered daily during 14 days."
11167218|NCT03610321|Active Comparator|Statin group|Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.
11167219|NCT03610321|Experimental|Gefarnate group|Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.
11167220|NCT03610295|Experimental|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
11167221|NCT03610295|Active Comparator|historical control group|cataract extraction surgery
11167222|NCT03610282|Experimental|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
11167223|NCT03610282|Placebo Comparator|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
11167224|NCT03610269|Experimental|INVSENSOR00026|All enrolled subjects receive INVSENSOR00026 Pulse CO-Oximeter and sensor for the noninvasive measurement of hemoglobin (SpHb).
11167225|NCT03610256|Experimental|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).
~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
11167226|NCT03610256|Active Comparator|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).
~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
11167227|NCT03610243|Experimental|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).
~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
11167228|NCT03610243|No Intervention|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
11167229|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
11167230|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
11167231|NCT03610217|Experimental|Interstitial lung disease induction|
11167232|NCT03610217|Experimental|Pulmonary arterial hypertension|
11167233|NCT03610217|Experimental|Raynaud's phenomenon|
11167234|NCT03610217|Experimental|Digital ulcers|
11167235|NCT03610217|Experimental|Inflammatory arthritis|
11167236|NCT03610217|Experimental|Gastroesophageal reflux|
11167237|NCT03610217|Experimental|Bacterial overgrowth|
11167238|NCT03610217|Experimental|Constipation|
11167239|NCT03610217|Experimental|Skin involvement|
11167240|NCT03610217|Experimental|Pain|
11167241|NCT03610204|Experimental|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
11167242|NCT03610204|Active Comparator|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. A small rod that has an end in a larger surface area (5 times as that used in the DM group). By pressuring the rod end against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
11167243|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
11167244|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
11167245|NCT03610178|Active Comparator|very tight glycemic targets|
11167246|NCT03610178|Active Comparator|tight-moderate glycemic targets|
11167247|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
11167248|NCT03610165|Placebo Comparator|Arterial line - Control|Arterial line waveform and pressure
11167249|NCT03610165|Experimental|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
11167250|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
11167251|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
11167452|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
11167252|NCT03610139|Active Comparator|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
11167253|NCT03610139|Experimental|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.
~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
11167254|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
11167255|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
11167256|NCT03610113|No Intervention|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
11167257|NCT03610113|Experimental|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.
~It is followed by the same rehabilitation protocol than conservative treatment"
11167258|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.
~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
11167259|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.
~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
11167260|NCT03610087|Other|Low Intensity Intervention|The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
11167261|NCT03610087|Experimental|High Intensity Intervention|The intervention group (high intensity) receives a technology-enabled CCM intervention. Participants receive access to an online platform and infographic modules to learn more about nutrition, physical activity, and smoking cessation. Also, they are assigned a personal health coach who collaboratively schedules weekly virtual sessions via the platform to discuss the educational materials, goal setting and motivation, and provide support in the 12-week program. The participant's health coach reviews the participant's concerns and goals weekly with a virtual care team (VCT; including a psychiatrist, addictions specialist, nutrition specialist, peer mentor, and recreational therapist), who provides individualized recommendations to include in the participant's treatment plan. Participants have access to online resources and online webinars about nutrition, physical activity and smoking.
11167262|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.
~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
11167263|NCT03610061|Experimental|Radiotherapy plus Durvalumab|"A minimum of 3 patients will initially be enrolled in each cohort of this arm. Patients will be allocated to a radiotherapy dose and site cohort from the schedule at registration. There will be no intra-patient dose or site escalations.
~Cohorts will escalate in number of anatomical sites of radiotherapy and dose of radiotherapy given subject to safety. Durvalumab will be administered at a fixed dose every 4 weeks IV."
11167264|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
11167265|NCT03610035|Experimental|Experimental|NPT189
11167266|NCT03610035|Placebo Comparator|Placebo Comparator|Placebo
11167267|NCT03610022|Experimental|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
11167268|NCT03610009|Active Comparator|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
11167269|NCT03610009|Active Comparator|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
11167270|NCT03609996||PDR treated with Laser|
11167271|NCT03609996||PDR treated with Lucentis|
11167272|NCT03609983|Experimental|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
11167273|NCT03609983|Experimental|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
11167274|NCT03609983|No Intervention|No Weighing|Participants will refrain from weighing themselves.
11167275|NCT03609970|No Intervention|Control|No intervention
11167276|NCT03609970|Experimental|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
11167277|NCT03609970|Experimental|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
11167278|NCT03609957|Experimental|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
11167279|NCT03609957|Experimental|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
11167280|NCT03609957|No Intervention|Control|Control (no exercise intervention) group
11167453|NCT03608579|Experimental|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
11179258|NCT03526822|Experimental|patients with newly diagnosed glioblastoma|
11167281|NCT03609944|Sham Comparator|EUS + Sham|Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
11167282|NCT03609944|Experimental|EUS + ERCP with miES|Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
11167283|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
11167284|NCT03609905|Experimental|Intervention group|interventions: The MSCs of 5×10*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
11167285|NCT03609905|Other|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
11167286|NCT03609892|Experimental|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
11167287|NCT03609892|Active Comparator|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
11167288|NCT03609879|No Intervention|without cervical collar|baseline - without cervical collar
11167289|NCT03609879|Experimental|with cervical collar|scenarios with cervical collars
11167290|NCT03609866|Active Comparator|control|will be performed ankle passive mobilization
11167291|NCT03609866|Experimental|experimental|abdominal thoracic compression technique will be applied
11167292|NCT03609853|Placebo Comparator|Placebo|Placebo (5mL distilled water)
11167293|NCT03609853|Experimental|Vaporized low THC|15mg of pure THC
11167294|NCT03609853|Experimental|Vaporized high THC|30mg of pure THC
11167295|NCT03609853|Experimental|Vaporized low d-limonene|1mg of d-limonene
11167296|NCT03609853|Experimental|Vaporized high d-limonene|5mg of d-limonene
11167297|NCT03609853|Experimental|Low THC and low d-limonene|15mg of THC paired with 1mg of d-limonene
11167298|NCT03609853|Experimental|High THC and low d-limonene|30mg of THC paired with 1mg of d-limonene
11167299|NCT03609853|Experimental|Low THC and high d-limonene|15mg of THC paired with 5mg of d-limonene
11167300|NCT03609853|Experimental|High THC and high d-limonene|30mg of THC paired with 5mg of d-limonene
11167301|NCT03609801|Experimental|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new Batterers Intervention Program (BIP) for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is an innovative BIP in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
11167302|NCT03609801|Active Comparator|The Duluth Model|The Duluth Model Men's Nonviolence Classes is the most widely used BIP. The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model's Men's Nonviolence Classes (The Duluth Model for short) help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
11167303|NCT03609775|Experimental|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
11167304|NCT03609775|Experimental|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
11167305|NCT03609775|Experimental|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
11167306|NCT03609775|Experimental|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
11167307|NCT03609762|Experimental|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
11167308|NCT03609762|No Intervention|Control group|usual care. All subjects attending the control clinics will not need to complete the electronic EQ-5D-5L before seeing the doctor during their follow-up visits. The doctor will manage the patient as usual, based on the usual clinical information. The doctor will complete the clinician-reported follow-up clinical data form (CRF) for each subject at the end of the consultation.
11167309|NCT03609749|Experimental|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
11167310|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
11167311|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
11167312|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
11167658|NCT03607305|Active Comparator|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
11167314|NCT03609697|Experimental|Community-based lifestyle intervention|Participants will attend 7 community-based group intervention sessions plus 2 individual face-to-face dietician consultation sessions during the first 6 months, followed by a 6-month maintenance phase which they will receive monthly phone support from the research team.
11167315|NCT03609697|Other|Minimal intervention (SMS intervention)|Participants will receive one SMS per month during the first 6 months, followed by a 6-month maintenance phase which participants will receive one SMS every 2 months.
11167316|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
11167317|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
11167318|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
11167319|NCT03609671|Experimental|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
11167320|NCT03609671|Other|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
11167321|NCT03609658|Experimental|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
11167322|NCT03609658|Sham Comparator|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
11167323|NCT03609645|Active Comparator|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
11167324|NCT03609645|Experimental|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
11167325|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
11167326|NCT03609619|Experimental|AEVI-001|
11167327|NCT03609619|Placebo Comparator|Placebo|
11167328|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7
~Period 2: Treatment of D013 on Day22~Day28"
11167329|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7
~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
11167330|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7
~Period 2: Treatment of D326 and D337 on Day22~Day28"
11167331|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7
~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
11167332|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
11167333|NCT03609567|Experimental|Aromatherapy|Aromatherapy using essential oils
11167334|NCT03609567|Placebo Comparator|Placebo|Aromatherapy using odorless placebo
11167335|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
11167336|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
11167337|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
11167338|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
11167339|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
11167340|NCT03609515|Experimental|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
11167341|NCT03609502|Experimental|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
11167342|NCT03609502|Experimental|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
11167343|NCT03609489|Experimental|Test Group|Apatinib combined with Capetabine
11167344|NCT03609489|Active Comparator|Control Group|Capecitabine
11167345|NCT03609476|Active Comparator|Standard of care group|No saline instillation
11167346|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
11167347|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
11167348|NCT03609463|Experimental|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
11167349|NCT03609463|Active Comparator|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
11167350|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
11167396|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
11167659|NCT03607305|Experimental|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
11167351|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
11167352|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
11167353|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
11167354|NCT03609424|Experimental|PDR001 plus Imatinib|
11167355|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
11167356|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
11167357|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
11167358|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
11167359|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
11167360|NCT03609359|Experimental|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
11167361|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
11167362|NCT03609333|Experimental|Internal arm|
11167363|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
11167364|NCT03609307|Active Comparator|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
11167365|NCT03609307|Active Comparator|injection Intravitreal bevacizumab|patients receive only Bevacizumab
11167366|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)
~There will be a washout of 35 days between the each period."
11167367|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)
~There will be a washout of 35 days between the each period."
11167368|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)
~There will be a washout of 35 days between the each period."
11167369|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
11167370|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
11167371|NCT03609268|Active Comparator|MWA|Patients receive microwave ablation (MWA)
11167372|NCT03609268|Experimental|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
11167373|NCT03609255|Active Comparator|Control group (C)|
11167374|NCT03609255|Experimental|Sedentary behavior group (SB)|
11167375|NCT03609255|Experimental|Stress management group (SR)|
11167376|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
11167377|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
11167378|NCT03609229|Experimental|Study group|Abdominal Sacrocolpopexy with burch technique
11167379|NCT03609229|Active Comparator|control group|Abdominal Sacrocolpopexy without burch technique
11167380|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
11167381|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
11167382|NCT03609203||Patients|
11167383|NCT03609203||Controls|
11167384|NCT03609190|Experimental|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
11167385|NCT03609190|Placebo Comparator|Placebo|i.v. infusion of NaCl over 40 min
11167386|NCT03609177|Experimental|Advance Care Planning|"-Survey:
~A group of older patients with advanced cancer (N=450) will have a survey over the course of the 36 months of recruitment.
~Participants will be provided written copies of the questions to follow along during the interviews"
11167387|NCT03609177|Experimental|Advance Care Planning-Video Declaration|"Video Declaration:
~From among this group of 450 participants, the video declaration of preferences activity will be conducted with 240 patients.
~For those participants that agree to the video declaration, they will proceed with recording of their video declarations
~The RA will begin by reading a standardized introduction to aid the subject do the video"
11167388|NCT03609177|Other|Comprehensive Record Review of ACP|"A review of Medical orders for resuscitation preferences in the electronic health record
~A review of Medical orders for Palliative care consultations preferences in the electronic health record
~A review of Medical orders for Hospice use preferences in the electronic health record"
11167389|NCT03609177|Experimental|Main Study Arm|Patients with cancer being seen at the 36 oncology clinics will be exposed to clinicians who have had communication skills training (Vital Talk) and who are using video decision aids (ACP Decisions). Our main outcome is advance care planning documentation.
11167390|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
11167391|NCT03609164|Active Comparator|single-row repair|
11167392|NCT03609151|Active Comparator|group A|laparoscopic hepatectomy (surgery)
11167393|NCT03609151|Experimental|group B|stereotactic body radiotherapy (SBRT)
11167394|NCT03609138||Study Cohort|
11167397|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
11167398|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.
~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
11167399|NCT03609099|Active Comparator|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
11167400|NCT03609099|Experimental|Placebo|Placebo treatment to patients treated during the 5 previous days.
11167401|NCT03609073|Experimental|Intervention|
11167402|NCT03609060|Experimental|DEXAML|"Induction therapy:
~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.
~Post remission therapy:
~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).
~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
11167403|NCT03609047|Experimental|experimental palbociclib arm|Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
11167404|NCT03609047|Active Comparator|control chemotherapy arm|"Adjuvant chemotherapy:
~4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w
~Followed by standard adjuvant endocrine therapy for a duration of at least 5 years."
11167405|NCT03609021||Observational (bilateral screening mammogram)|Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
11167406|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
11167407|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
11167408|NCT03608995|Experimental|Premaquick©|
11167409|NCT03608995|Other|Quikcheck|
11167410|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
11167411|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
11167412|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
11167413|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:
~hydrocortisone to prednisolone or;
~prednisolone to hydrocortisone"
11167414|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
11167415|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
11167416|NCT03608917|Experimental|Treatment group|"Drug:Total Glucosides of Paeony (TGP)
~Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)
~Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
11167417|NCT03608917|Placebo Comparator|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue
~Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)
~Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
11167418|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
11167419|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
11167420|NCT03608891|Active Comparator|Control Arm|Conventional titanium miniplates
11167421|NCT03608891|Experimental|Intervention arm|Patient specific 3D plates
11167422|NCT03608878|Active Comparator|TACE alone arm|TACE (Transarterial Chemoembolization)
11167423|NCT03608878|Experimental|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
11167424|NCT03608865|Experimental|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
11167425|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
11167426|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
11167427|NCT03608839|Experimental|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
11167428|NCT03608839|Experimental|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
11167429|NCT03608839|Experimental|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
11167430|NCT03608826|Experimental|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
11167431|NCT03608813||Controls|Healthy subjects
11167432|NCT03608813||Case|PCOS affected subjects
11167433|NCT03608800|Experimental|Intermittent fasting|two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
11167434|NCT03608800|No Intervention|Control diet|maintain the energy intake as usual
11167435|NCT03608787|Experimental|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
11167436|NCT03608787|Experimental|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
11167437|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
11167438|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
11167439|NCT03608761|Experimental|Rebamipide 2%|"- wash-out: 2 weeks
~- rebamipide 2% four times a day for 3 months
~- controls will be taken at day zero, 30 and 90.
~- wash-out: 2 weeks
~- autologous serum for 3 months"
11167440|NCT03608761|Experimental|Autologous serum|"- wash-out: 2 weeks
~- autologous serum four times a day for 3 months
~- controls will be taken at day zero, 30 and 90.
~- wash-out: 2 weeks
~- rebamipe 2% for 3 months"
11167441|NCT03608761|Experimental|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
11167442|NCT03608722|Experimental|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
11167443|NCT03608722|Experimental|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
11167444|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution
~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
11167445|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
11167446|NCT03608657||Psoriatic Arthritis patients treated with Apremilast|Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
11167447|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
11167448|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
11167449|NCT03608618|Experimental|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
11167450|NCT03608618|Experimental|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
11167660|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
11167454|NCT03608579|Experimental|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
11167455|NCT03608553|Experimental|ExAblate|ExAblate MR Guided Focused Ultrasound
11167456|NCT03608540|Experimental|Intervention|Suturing system with suture apposition then bulging formation then cutting the lesion
11167457|NCT03608527|Experimental|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
11167458|NCT03608527|Active Comparator|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
11167459|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.
~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.
~Patients will be followed for 48 hours."
11167460|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.
~Patients will be followed for 48 hours."
11167461|NCT03608501|Experimental|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
11167462|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement|Vitamin D replacement (50.000 IU/per week, for 8 weeks)
11167463|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|Vitamin D replacement (50.000 IU/per week, for 8 weeks) and Core and balance exercises for 8 weeks.
11167464|NCT03608488|Experimental|Vitamin D<10 ng/ml; exercise|Core and balance exercises for 8 weeks.
11167465|NCT03608488|Active Comparator|Vitamin D>30ng/ml; exercise|Core and balance exercises for 8 weeks.
11167466|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
11167467|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
11167468|NCT03608462|Sham Comparator|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
11167469|NCT03608462|Sham Comparator|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
11167470|NCT03608462|No Intervention|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
11167471|NCT03608449|Active Comparator|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
11167472|NCT03608449|Placebo Comparator|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
11167473|NCT03608436|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
11167474|NCT03608436|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
11167475|NCT03608423|Experimental|Surgical treatment|Minimally-invasive endoscopy-guided surgery or hematoma aspiration, additional to standard medical treatment.
11167476|NCT03608423|No Intervention|Standard medical management|Standard medical treatment (treatment of bloodpressure, admission to stroke unit and supportive care, surgical treatment if necessary in case of deterioration)
11167477|NCT03608410|Experimental|PRO intervention|Weekly PRO questionnaires Quality of life every 2 months
11167478|NCT03608410|No Intervention|Standard of care|Quality of life every 2 months
11167479|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
11167480|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
11167481|NCT03608397|Placebo Comparator|Placebo|Placebo Group
11167482|NCT03608371|Experimental|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
11167483|NCT03608371|Experimental|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
11167484|NCT03608371|Experimental|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
11167485|NCT03608371|Placebo Comparator|Placebo Cohorts 1-3|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
11167486|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
11167487|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
11167488|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
11167489|NCT03608332|No Intervention|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-
~Resolution of acute phase of disease for which patient was intubated
~Adequate cough
~Absence of excessive tracheobronchial secretions
~B) Objective criteria:-
~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200
~Respiratory rate <30
~PH and PaCO2 appropriate for patients' baseline respiratory status
~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia
~HR<140 beats/minute
~Patient is arousable or Glasgow coma scale (GCS)>13"
11167490|NCT03608332|Experimental|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-
~Resolution of acute phase of disease for which patient was intubated
~Adequate cough
~Absence of excessive tracheobronchial secretions
~B) Objective criteria:-
~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200
~Respiratory rate <30
~PH and PaCO2 appropriate for patients' baseline respiratory status
~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia
~HR<140 beats/minute
~Patient is arousable or Glasgow coma scale (GCS)>13
~C) Ultrasound criteria:-
~• Diaphragmatic excursion >11 mm"
11167491|NCT03608319|Experimental|Single dose following overnight fast|
11167492|NCT03608319|Experimental|Single dose following high fat breakfast|
11167493|NCT03608319|Experimental|Single dose sprinkled on applesauce following overnight fast|
11167494|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
11167495|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
11167496|NCT03608293|Experimental|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
11167497|NCT03608293|Active Comparator|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
11167498|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
11167499|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).
~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
11167500|NCT03608267|Experimental|Intervention|
11167501|NCT03608241|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
11167502|NCT03608241|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
11167503|NCT03608228||Parkinson's Disease|
11167504|NCT03608215|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
11167505|NCT03608215|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
11167506|NCT03608202|Experimental|POCUS protocol group|"POCUS protocol group
~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:
~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
11167507|NCT03608202|Active Comparator|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
11167508|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
11167509|NCT03608176|Experimental|PASO diet group|
11167510|NCT03608176|Active Comparator|Low-fat diet group|
11167511|NCT03608176|Other|Waiting list group|
11167512|NCT03608163|No Intervention|No intervention (Susceptibility to HAAF evaluation)|Susceptibility to HAAF evaluation: No intervention medication will be given during episodes of hypoglycemia.
11167513|NCT03608163|Experimental|Naloxone|Naloxone evaluation: Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
11167514|NCT03608163|Placebo Comparator|Placebo (for Naloxone)|Naloxone evaluation: Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
11167542|NCT03607994|Other|nonspecific acoustic stimulation (NCC)|Continued current care and acoustic stimulation that is not linked to brainwave activity.
11167566|NCT03607877|Experimental|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
11167661|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
11167515|NCT03608163|Experimental|Naloxone + diazoxide|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
11167516|NCT03608163|Active Comparator|Diazoxide + placebo (for naloxone)|Naloxone/Diazoxide evaluation: Up to 7 mg/kg oral diazoxide 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
11167517|NCT03608163|Active Comparator|Naloxone + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Intranasal naloxone (4 mg NARCAN Nasal Spray) via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Intranasal naloxone (4 mg NARCAN Nasal Spray) will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
11167518|NCT03608163|Placebo Comparator|Placebo (for naloxone) + placebo (for diazoxide)|Naloxone/Diazoxide evaluation: Oral placebo (for diazoxide) 3 hours before the first hypoglycemic episode. Placebo (for naloxone) nasal spray via a nostril twice during the first hypoglycemia episode; once at the start of insulin administration and again after one hour. Placebo (for naloxone) nasal spray will again be given via a nostril twice during the second period of hypoglycemia; once at the start of insulin administration and again after one hour.
11167519|NCT03608150|Experimental|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
11167520|NCT03608150|Active Comparator|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
11167521|NCT03608137|Experimental|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
11167522|NCT03608137|Active Comparator|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
11167523|NCT03608111|Active Comparator|single task balance training|
11167524|NCT03608111|Active Comparator|dual task balance training|
11167525|NCT03608098|Active Comparator|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
11167526|NCT03608098|Active Comparator|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
11167527|NCT03608085|Experimental|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
11167528|NCT03608085|Experimental|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
11167529|NCT03608072|Experimental|Dose group 1|
11167530|NCT03608072|Experimental|Dose group 2|
11167531|NCT03608072|Experimental|Dose group 3|
11167532|NCT03608059|Experimental|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
11167533|NCT03608059|Active Comparator|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
11167534|NCT03608059|Active Comparator|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
11167535|NCT03608046|Experimental|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.
~Irinotecan: administrated every 2 weeks (180 mg/m2)."
11167536|NCT03608033|Experimental|OMS721|Administration of OMS721
11167537|NCT03608033|Placebo Comparator|Placebo|Administration of Vehicle (D5W or Saline Solution)
11167538|NCT03608020|Active Comparator|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
11167539|NCT03608020|No Intervention|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
11167540|NCT03608007|Experimental|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
11167541|NCT03607994|Active Comparator|HIRREM-SOP (BCC|Acoustic stimulation linked to brainwave activity and continued current care.
11168493|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
11167543|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline [i.e., 100 * (postoperative pad weight - baseline pad weight)/baseline pad weight].
11167544|NCT03607955|Experimental|AVB-S6-500 + Paclitaxel + Carboplatin|"Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle
~Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy
~AVB-S6-500 will be given at doses based on the dose escalation schema
~The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
11167545|NCT03607942|Experimental|Experimental Formula|The experimental group will receive a liquid supplement containing 2 specific HMOs
11167546|NCT03607942|Placebo Comparator|Control Formula|The control group will receive a liquid placebo
11167547|NCT03607929|Experimental|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
11167548|NCT03607929|Active Comparator|variability and hydration|Other Solutions >o < 300 ml/h AND uncontrolled drink during labor
11167549|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167550|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167551|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167552|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167553|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167554|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167555|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167556|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167557|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167558|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
11167559|NCT03607903|Active Comparator|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
11167560|NCT03607903|Active Comparator|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
11167561|NCT03607903|Experimental|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
11167562|NCT03607903|Experimental|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
11167563|NCT03607890|Experimental|Nivolumab and Relatlimab|
11167564|NCT03607877|Active Comparator|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
11167565|NCT03607877|Active Comparator|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
11167567|NCT03607864|Experimental|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
11167568|NCT03607851|Active Comparator|Conventional titration group|
11167569|NCT03607851|Experimental|Rapid titration group 1|
11167570|NCT03607851|Experimental|Rapid titration group 2|
11167571|NCT03607838|Experimental|SI-6603|
11167572|NCT03607838|Sham Comparator|Sham injection|
11167573|NCT03607825|Experimental|Neurapheresis System|CSF filtration
11167574|NCT03607799|Experimental|Dietary Intervention|"A dietitian develops personalized diet advice for each intervention group participant. She sets 2-4 SMART goals according to the following principles: 1) Replace fried foods and meat with vegetable protein, raw and cooked vegetables; 2) Reduce refined carbohydrate intake; 3) Improve carbohydrate quality (replace high glycemic index, refined grain foods with lower glycemic index, whole-grain foods; 4) Reduce trans fats; 5) Schedule regular mealtimes, 3-4 hours apart; 6) Reduce high-carbohydrate snacks; 7) Reduce desserts and/or drinks high in starch and sugar. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
11167575|NCT03607799|Active Comparator|Control|"Control group participants will be provided with paper copies and website links to The Sensible Guide to a Healthy Pregnancy, which provides advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the SA community. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
11167576|NCT03607786|Active Comparator|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
11167577|NCT03607786|Active Comparator|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
11167578|NCT03607773|Active Comparator|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
11167579|NCT03607773|No Intervention|Control group|Standard of care.
11167580|NCT03607760||ECMO|severe respiratory failure with ECMO
11167581|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
11167582|NCT03607734|Other|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:
~50mg amoxicillin (10% total dose)
~250mg amoxicillin (50% total dose)
~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
11167583|NCT03607721|Experimental|DBS Patients Group|Body Motion Evaluation DARI
11167584|NCT03607721|Active Comparator|Control Group|Body Motion Evaluation DARI
11167585|NCT03607708|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
11167586|NCT03607708|Active Comparator|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
11167587|NCT03607695|Experimental|Gait training|1 hour walking exercise on a treadmill
11167588|NCT03607682|Experimental|Prevention (TTF therapy, NovoTTF-200A device)|
11167589|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
11167590|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
11167591|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
11167592|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
11167593|NCT03607656|Experimental|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.
~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
11167594|NCT03607656|Active Comparator|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
11167595|NCT03607643|Placebo Comparator|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
11167630|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
11167596|NCT03607643|Experimental|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
11167597|NCT03607643|Placebo Comparator|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
11167598|NCT03607643|Experimental|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
11167599|NCT03607643|Placebo Comparator|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
11167600|NCT03607643|Experimental|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
11167601|NCT03607643|Placebo Comparator|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
11167602|NCT03607643|Experimental|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
11167603|NCT03607643|Placebo Comparator|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
11167604|NCT03607643|Experimental|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
11167605|NCT03607630|No Intervention|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
11167606|NCT03607630|Experimental|Imagery Rescripting|3 Sessions of Imagery Rescripting
11167607|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
11167608|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
11167609|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
11167610|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
11167611|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
11167612|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
11167613|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)
~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
11167614|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus
~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
11167615|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
11167616|NCT03607591|Active Comparator|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
11167617|NCT03607591|Placebo Comparator|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
11167618|NCT03607578|Other|Control Group - Minimal Intervention|Minimal intervention
11167619|NCT03607578|Experimental|Protection Routine 1|
11167620|NCT03607578|Experimental|Protection Routine 2|
11167621|NCT03607578|Experimental|Protection Routine 1+2|
11167622|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(good perfusion)
11167623|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(middle perfusion)
11167624|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(poor perfusion)
11167625|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
11167626|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
11167627|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
11167628|NCT03607539|Experimental|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
11167629|NCT03607539|Placebo Comparator|Sitilimab Placebo Comparator|placebo 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
11167631|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
11167632|NCT03607513|Experimental|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.
11167633|NCT03607513|Experimental|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
11167634|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
11167635|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
11167636|NCT03607487|Experimental|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
11167637|NCT03607487|Experimental|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
11167638|NCT03607487|Experimental|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
11167639|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.
~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
11167640|NCT03607461|Experimental|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
11167641|NCT03607461|Active Comparator|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
11167642|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
11167643|NCT03607435|Experimental|Test Article Scanning|Spectroscopy for Analyte Quantification
11167644|NCT03607422|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
11167645|NCT03607422|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
11167646|NCT03607422|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
11167647|NCT03607422|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
11167648|NCT03607383|Experimental|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
11167649|NCT03607383|Active Comparator|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
11167650|NCT03607370|No Intervention|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
11167651|NCT03607370|Experimental|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
11167652|NCT03607357|Experimental|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
11167653|NCT03607357|Placebo Comparator|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
11167654|NCT03607331|Experimental|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
11167655|NCT03607331|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
11167656|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
11167657|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
11167662|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
11167663|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
11167664|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
11167665|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
11167666|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
11167667|NCT03607253|Other|Men|Healthy young men aged between 18-25 years
11167668|NCT03607253|Other|Women|Healthy young women aged between 18-25 years
11167669|NCT03607240|Experimental|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
11167670|NCT03607240|Active Comparator|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
11167671|NCT03607227|Active Comparator|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
11167672|NCT03607227|Placebo Comparator|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
11167673|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
11167674|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
11167675|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
11167676|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
11167677|NCT03607188|Experimental|ZG0418 200mg QD|ZG0418 200mg/day,oral
11167678|NCT03607188|Experimental|ZG0418 300mg QD|ZG0418 300mg/day,oral
11167679|NCT03607188|Experimental|ZG0418 400mg QD|ZG0418 400mg/day,oral
11167680|NCT03607188|Experimental|ZG0418 500mg QD|ZG0418 500mg/day,oral
11167681|NCT03607188|Experimental|ZG0418 600mg QD|ZG0418 600mg/day,oral
11167682|NCT03607175|Active Comparator|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
11167683|NCT03607175|Experimental|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
11167684|NCT03607162|No Intervention|Usual care|Local usual management of FWS (pragmatic approach)
11167685|NCT03607162|Experimental|DIAFEVER algorithm|New DIAFEVER sequential algorithm PCT rapid test-based will be applied
11167686|NCT03607149|Active Comparator|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
11167687|NCT03607149|Experimental|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
11167688|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
11167689|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
11167690|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
11167691|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
11167692|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
11167693|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
11167694|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
11167695|NCT03607110||ketamine|ketamine used
11167696|NCT03607110||fentanyl|fentanyl used
11168232|NCT03602937|Experimental|Renastep|All participants to incorporate Renastep into their usual dietary regime.
11167697|NCT03607097|Experimental|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
11167698|NCT03607097|No Intervention|Usual care (control group)|The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit
11167699|NCT03607084|Experimental|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
11167700|NCT03607084|No Intervention|Control|The control group receives regular school programming.
11167701|NCT03607071|Experimental|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
11167702|NCT03607058|Active Comparator|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 10 weeks washout period only exercise training will be applied for 8 weeks.
11167703|NCT03607058|Active Comparator|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 10 weeks washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
11167704|NCT03607045|Placebo Comparator|control group|bouquet technique
11167705|NCT03607045|Active Comparator|test group|headless screw
11167706|NCT03607032|Experimental|RespinPad and usual treatment|
11167707|NCT03607032|Active Comparator|only usual treatment|
11167708|NCT03607006|Experimental|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
11167709|NCT03607006|Active Comparator|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
11167710|NCT03606993|Experimental|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one ~ 200g iron ingot.
11167711|NCT03606993|No Intervention|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
11167712|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
11167713|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
11167714|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
11167715|NCT03606967|Experimental|Arm I (neoantigen vaccine, durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 for 2 cycles at the discretion of the treating physician.
~PART B: Patients receive personalized synthetic long peptide vaccine and poly-ICLC SC on days 1, 4, 8, 15, 22, 50, and 78 in the absence of disease progression or unacceptable toxicity. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11167716|NCT03606967|Active Comparator|Arm II (durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each remaining cycle.
~PART B: Patients receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11167747|NCT03606746|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
11167748|NCT03606733|Experimental|A custom made Suprachoroidal needle for macular diseases|A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
11168233|NCT03602911|Other|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
11167717|NCT03606954|Active Comparator|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.
~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
11167718|NCT03606954|Active Comparator|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.
~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
11167719|NCT03606941|Experimental|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
11167720|NCT03606941|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
11167721|NCT03606928|Experimental|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
11167722|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
11167723|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
11167724|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
11167725|NCT03606902|Active Comparator|(Group f):|"Intervention:
~Procedure: Epidural catheter insertion
~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
11167726|NCT03606902|Active Comparator|(Group Lf):|"Intervention:
~Procedure:Epidural catheter insertion
~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
11167727|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
11167728|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
11167729|NCT03606876|Experimental|BAT1806 injection|BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
11167730|NCT03606876|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
11167731|NCT03606876|Active Comparator|Actemra(US-licensed)|Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min
11167732|NCT03606863|Experimental|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
11167733|NCT03606863|No Intervention|Standard fluid therapy|Standard fluid therap
11167734|NCT03606850|Experimental|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
11167735|NCT03606837|Experimental|PET/CT Imaging|
11167736|NCT03606824|Placebo Comparator|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
11167737|NCT03606824|Experimental|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
11167738|NCT03606811|Active Comparator|fluroscopic guided block|
11167739|NCT03606811|Experimental|double modality guided block|
11167740|NCT03606798|Experimental|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
11167741|NCT03606798|No Intervention|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
11167742|NCT03606785|Active Comparator|tranexamic acid group|
11167743|NCT03606785|Placebo Comparator|placebo group|
11167744|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
11167745|NCT03606759|Experimental|Traitment as usual adjusted on ATI information|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
11167746|NCT03606759|Active Comparator|Traitment as usual|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
11167944|NCT03605173|Experimental|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
11179259|NCT03526809||Ovarian cancer patients|MRI and FDG-PET imaging
11167749|NCT03606720|Experimental|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
11167750|NCT03606720|Active Comparator|group(B) pelvic stabilization exercises only|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
11167751|NCT03606720|Active Comparator|group (C) low level laser therapy only|composed of 30 patients who low level laser therapy only For 12 sessions over six week's period by 2 sessions per week.
11167752|NCT03606707|Experimental|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
11167753|NCT03606707|No Intervention|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
11167754|NCT03606694|Experimental|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
11167755|NCT03606694|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
11167756|NCT03606681|Active Comparator|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
11167757|NCT03606681|Experimental|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
11167758|NCT03606681|Experimental|Theracal LC|Indirect pulp capping treatment with Theracal LC
11167759|NCT03606668|Experimental|Virtual Reality Therapy|eligible participants will receive a full session of VR therapy that may extend as long as an hour in length.
11167760|NCT03606655|Experimental|Kava|This is a single-arm pre- and post- Phase 0/1 study with one primary goal to explore the feasibility of recruitment of participants, adherence rate, acceptability of treatment and completion rate with 14 day dietary supplement kava treatment in head and neck cancer patients who continue to smoke. The other primary goal is to evaluate distribution of change in nicotine and NNK metabolism after 14 day kava treatment..
11167761|NCT03606642|Experimental|PCI with 30 day DAPT Therapy|Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose [if applicable] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
11167762|NCT03606629||Endoprosthesis implantation|Device implantation
11167763|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
11167764|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
11167765|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
11167766|NCT03606577|Experimental|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
11167767|NCT03606564||paediatric patients undergoing day care surgery|
11167768|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.
~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
11167769|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
11167770|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
11167771|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
11167772|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
11167773|NCT03606512|Experimental|Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)|Respiratory syncytial virus (RSV) seronegative toddlers will receive intramuscular (IM) injection of 2.5*10^10 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F-protein on Days 1, 29, and 57.
11167774|NCT03606512|Placebo Comparator|Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)|RSV seronegative toddlers will receive IM injection of placebo on Days 1, 29 and 57. Placebo can be replaced with Nimenrix on Day 57 in countries where applicable.
11167775|NCT03606499||CD Participants with EIMs and/or IMIDs|Crohn's Disease (CD) participants with suspected extra-intestinal manifestations (EIMs) and/or immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on each type of CD associated with EIMs and/or IMIDs. Participants will receive ustekinumab at study entry (Week 0) as treatment for CD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
11167776|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
11167777|NCT03606473|Experimental|Prenatal cocaine exposed subjects|[C-11]NPA PET at baseline and post d-amphetamine
11167778|NCT03606473|Experimental|Comparison subjects|[C-11]NPA PET at baseline and post d-amphetamine
11167779|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
11167780|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
11167781|NCT03606447|Experimental|Single IV administration of [14C]-Uproleselan|
11167782|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
11167783|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
11167784|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
11167785|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
11167786|NCT03606395|Experimental|Single ascending dose_healthy subjects|"NV-5138:
~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
11167787|NCT03606395|Experimental|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
11167788|NCT03606369|Experimental|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.
~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
11167789|NCT03606369|Active Comparator|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.
~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
11167790|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
11167791|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
11167792|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
11167793|NCT03606304|Experimental|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
11167794|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:
~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
11167795|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
11167796|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
11167797|NCT03606265|Experimental|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
11167798|NCT03606265|Active Comparator|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
11167799|NCT03606252|Other|pneumocystosis with favourable evolution|patients with a favourable pneumocystosis outcome
11167800|NCT03606252|Other|pneumocystosis with unfavourable outcome|patients with unfavourable pneumocystosis outcome
11167801|NCT03606252|Other|Pneumocystis colonization|subject colonized by Pneumocystis jirovecii
11167802|NCT03606239|Experimental|isotoxic hypofractionated group|"Hypofractionated radiation:
~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:
~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy.
~Chemotherapy:
~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.
~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
11167803|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
11167804|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
11167805|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
11167806|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
11167807|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
11167808|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
11181938|NCT03509233|Experimental|FMD|Full mouth disinfection
11167809|NCT03606174|Experimental|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167810|NCT03606174|Experimental|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167811|NCT03606174|Experimental|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167812|NCT03606174|Experimental|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167813|NCT03606174|Experimental|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167814|NCT03606174|Experimental|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167815|NCT03606174|Experimental|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167816|NCT03606174|Experimental|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
11167817|NCT03606174|Experimental|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
11167818|NCT03606161|Experimental|Supportive care (nrTMS)|Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
11167819|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.
~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
11167820|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.
~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
11167821|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
11167822|NCT03606135||The Control Group|Healthy subjects
11167823|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
11167824|NCT03606109|Active Comparator|TTO + IV TXA|
11167825|NCT03606109|No Intervention|TTO, no IV TXA|
11167826|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
11167827|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
11167828|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
11167829|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
11167830|NCT03606070|Other|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.
~Patients will realize:
~a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)
~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
11167831|NCT03606057|Experimental|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
11167832|NCT03606057|Active Comparator|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
11167833|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
11167834|NCT03606018|Experimental|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
11167835|NCT03606018|Active Comparator|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
11167836|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea [Modified Medical Research Council dyspnea scale (MMRC)], submaximal exercise capacity [6-minute walk test (6-MWT)], physical activity level [metabolic holter], quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] and pulmonary functions [spirometry] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
11167837|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
11167838|NCT03605992|Experimental|Home-based Rehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
11167839|NCT03605992|Active Comparator|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
11167840|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
11167841|NCT03605940|Experimental|Experimental group|corticosteroids + ECP
11167842|NCT03605940|Active Comparator|Contrôl group|corticosteroids alone
11167843|NCT03605927|Experimental|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.
~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
11167844|NCT03605914|Experimental|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
11167845|NCT03605914|Active Comparator|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
11167846|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
11167847|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 4 breaths/min, induction of general anesthesia and intubation will proceed.
11167848|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
11167849|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
11167850|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
11167851|NCT03605875|Experimental|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
11167852|NCT03605875|Active Comparator|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
11167853|NCT03605862|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
11167854|NCT03605862|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
11167855|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
11167856|NCT03605836|Experimental|Centanafadine Treatment 1|Total daily dose of 200 mg
11167857|NCT03605836|Experimental|Centanafadine Treatment 2|Total daily dose of 400 mg
11167858|NCT03605836|Placebo Comparator|Placebo|
11167859|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
11167860|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.
~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
11167861|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
11167862|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
11167863|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
11167864|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:
~Disease onset as metastatic or unresectable disease.
~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
11167865|NCT03605758|Active Comparator|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
11167866|NCT03605758|Active Comparator|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
11167867|NCT03605745|Experimental|Treatment|Prostatic Vapor Ablation with Rezum
11167868|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
11167869|NCT03605732|Active Comparator|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
11167870|NCT03605719|Experimental|Arm 1|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11167871|NCT03605719|Experimental|Arm 2|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11167945|NCT03605173|Experimental|total vitamin d|Total vitamin d is measured routinely from blood serum
11167872|NCT03605719|Experimental|Arm 3 (expansion)|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11167873|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
11167874|NCT03605706|Experimental|CONTROL|SHR-1210+Placebo
11167875|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
11167876|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
11167877|NCT03605680|Experimental|Centanafadine Treatment 1|Total daily dose of 200 mg
11167878|NCT03605680|Experimental|Centanafadine Treatment 2|Total daily dose of 400 mg
11167879|NCT03605680|Placebo Comparator|Placebo|
11167880|NCT03605667|Experimental|BHV-4157|troriluzole, 280 mg capsules, QD
11167881|NCT03605667|Placebo Comparator|Placebo|matching 280 mg placebo capsules, QD
11167882|NCT03605654|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
11167883|NCT03605654|Active Comparator|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
11167884|NCT03605654|Experimental|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
11167885|NCT03605641|Experimental|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
11167886|NCT03605641|Active Comparator|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
11167887|NCT03605641|Active Comparator|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
11167888|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
11167889|NCT03605615|No Intervention|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
11167890|NCT03605615|Experimental|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
11167891|NCT03605589|Experimental|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).
~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)
~Cycle 1 (Days 1-7):
~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day
~Cycle 1(Days 8-28):
~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day
~Cycle 2 (Days 1-28):
~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day
~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
11167892|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11167893|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11167894|NCT03605563|Experimental|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11167895|NCT03605563|Active Comparator|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
11167896|NCT03605550|Experimental|Treatment (PTC596)|PTC596 administered orally twice weekly (M/Th or T/F schedule) concomitantly with radiotherapy. One cycle is defined as 28 days. Post RT patients will continue to receive PTC596 twice weekly for up to 25 cycles.
11167897|NCT03605537|Experimental|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).
~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
11167898|NCT03605537|No Intervention|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).
~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
11167979|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
11168301|NCT03602469|Experimental|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
11167899|NCT03605524|Other|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.
~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
11167900|NCT03605485|Experimental|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
11167901|NCT03605472|Experimental|Patients|
11167902|NCT03605459|Experimental|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
11167903|NCT03605446|Experimental|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
11167904|NCT03605446|Experimental|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
11167905|NCT03605446|Experimental|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
11167906|NCT03605446|Experimental|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
11167907|NCT03605446|Placebo Comparator|Wheat biscuit|
11167908|NCT03605433|Experimental|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
11167909|NCT03605433|Experimental|Oral Anticoagulation|Rivaroxaban 20 mg once daily
11167910|NCT03605433|Active Comparator|Antiplatet|Aspirin 100 mg once daily
11167911|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
11167912|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
11167913|NCT03605407|Experimental|Experimental group|Patient receiving one visit prior to hospital admission
11167914|NCT03605407|No Intervention|Control group|Patient without receiving one visit prior to hospital admission
11167915|NCT03605368|Active Comparator|Video Modeling|
11167916|NCT03605368|Experimental|Virtual Reality Intervention|
11167917|NCT03605342|Active Comparator|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
11167918|NCT03605342|Active Comparator|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
11167919|NCT03605329|Other|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
11167920|NCT03605303|Active Comparator|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
11167921|NCT03605303|Experimental|TEST- etafilcon A novel molding|Investigational Contact Lens
11167922|NCT03605290|Active Comparator|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
11167923|NCT03605290|Experimental|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
11167924|NCT03605277|Experimental|Normal renal function|healthy volunteers with normal renal function
11167925|NCT03605277|Experimental|Severe renal impairment|subjects with severe renal impairment
11167926|NCT03605277|Experimental|Moderate renal impairment|subject with moderate renal impairment
11167927|NCT03605277|Experimental|Mild renal impairment|subjects with mild renal impairment
11167928|NCT03605264||Slow Graft Function|Slow Graft function(SGF) is defined as a failure of serum creatinine to fall by 70% at postoperative day 7 after renal transplantation.
11167929|NCT03605264||Immediate Graft Function|Immediate graft function(IGF) is defined as a fall of serum creatinine of 70% at postoperative day 7 after renal transplantation.
11167930|NCT03605251|Experimental|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
11167931|NCT03605251|Experimental|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
11167932|NCT03605251|Placebo Comparator|Placebo group|Placebo and Methotrexate as specified
11167933|NCT03605238|Experimental|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
11167934|NCT03605225|Experimental|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
11167935|NCT03605225|Active Comparator|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
11167936|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
11167937|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
11167938|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
11167939|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
11167940|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
11167941|NCT03605199|Experimental|Denosumab active treatment|Denosumab active treatment
11167942|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).
~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.
~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.
~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
11167943|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.
~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.
~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.
~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
11167946|NCT03605160|Active Comparator|traditional group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents. All operations are videotaped during the whole operation. The total polish time is recorded as the time of all polish procedures.
11167947|NCT03605160|Experimental|fluid-jet group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.
11167948|NCT03605147|Experimental|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
11167949|NCT03605147|Active Comparator|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
11167950|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
11167951|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:
~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
11167952|NCT03605108|Placebo Comparator|Placebo|Rice flour only
11167953|NCT03605095|Active Comparator|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
11167954|NCT03605095|Active Comparator|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
11167955|NCT03605082|Experimental|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
11167956|NCT03605082|Placebo Comparator|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
11167957|NCT03605069|Other|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.
~In the first arm; randomization of the first selected TWA to active treatment or placebo"
11167958|NCT03605069|Other|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
11167959|NCT03605056|Experimental|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
11167960|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
11167961|NCT03605030|Active Comparator|Novel Lead Based Armboard|
11167962|NCT03605030|Placebo Comparator|Standard Armboard|
11167963|NCT03605017|Experimental|VREFT: Wonderkin Treatment|Administered by computer
11167964|NCT03605017|Active Comparator|VREFT: Attention Control|Administered by computer
11167965|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
11167966|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
11167967|NCT03604991|Experimental|Arm A (carboplatin, paclitaxel, radiation therapy)|Patients receive carboplatin IV and paclitaxel IV once weekly and undergo radiation therapy once daily (Monday-Friday) beginning on day 1. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity.
11167968|NCT03604991|Experimental|Arm B (carboplatin, paclitaxel, radiation therapy, nivolumab)|Patients receive carboplatin, paclitaxel, and radiation therapy as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity.
11167969|NCT03604991|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11167970|NCT03604991|Experimental|Arm D (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm C and receive ipilimumab IV over 90 minutes on day 1 of cycles 1, 4, 7, and 10. Treatment repeats every 2 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11167971|NCT03604978|Experimental|Cohort A (nivolumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
11167972|NCT03604978|Experimental|Cohort B (nivolumab, ipilimumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
11167973|NCT03604965|Experimental|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
11167974|NCT03604965|Active Comparator|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
11167975|NCT03604926||chemo-naive patients|
11167976|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
11167977|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
11167978|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
11167980|NCT03604874|Active Comparator|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
11167981|NCT03604874|Experimental|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
11167982|NCT03604848|Experimental|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
11167983|NCT03604848|Experimental|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
11167984|NCT03604848|Experimental|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
11167985|NCT03604848|Active Comparator|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
11167986|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
11167987|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
11167988|NCT03604822|Experimental|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
11167989|NCT03604809|Experimental|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
11167990|NCT03604809|No Intervention|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
11167991|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
11167992|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
11167993|NCT03604783|Experimental|Single Arm TP-1287|TP-1287 by oral administration
11167994|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
11167995|NCT03604757|Experimental|PET/CT Imaging|
11167996|NCT03604744|Experimental|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11167997|NCT03604744|Placebo Comparator|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11167998|NCT03604744|Placebo Comparator|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11167999|NCT03604744|Placebo Comparator|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11168000|NCT03604744|Placebo Comparator|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11168001|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
11168002|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
11168003|NCT03604705|Experimental|APX001 Treatment|
11168004|NCT03604692|Experimental|Cohorts of escalating dose levels of SNDX-6352|"Escalating dose levels of SNDX-6352 to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).
~IV infusion; SNDX-6352 at a dose of 0.15 mg/kg to 3 mg/kg."
11168005|NCT03604692|Experimental|Phase 2 Dose Expansion|"Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size.
~IV infusion; SNDX-6352 at a dose of 1 mg/kg."
11168006|NCT03604679|Experimental|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.
~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
11168007|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:
~Be present at the announcement consultation
~Give information on the outpatient circuit
~Offer assistance for patients over 75 years
~Complete onco-geriatric orientation questionnaires
~Take care of patients on the ambulatory circuit"
11168008|NCT03604666||Health care process|Health care process
11168009|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
11168010|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
11168011|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
11168012|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
11168013|NCT03604640|No Intervention|standard care|
11168014|NCT03604640|Experimental|Physical and educational program|
11168015|NCT03604627|Other|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg / m²)
11168016|NCT03604614|Experimental|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
11168017|NCT03604614|Sham Comparator|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
11182939|NCT03502278|No Intervention|Waitlist|Waitlist
11168018|NCT03604588|Other|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.
~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
11168019|NCT03604575|Experimental|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
11168020|NCT03604575|Active Comparator|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
11168021|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
11168022|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
11168023|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
11168024|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
11168025|NCT03604510|Experimental|Electroencephalographic recordings|Electroencephalographic recordings
11168026|NCT03604497|Experimental|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
11168027|NCT03604497|No Intervention|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
11168028|NCT03604497|Other|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
11168029|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
11168030|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
11168031|NCT03604471|Other|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
11168032|NCT03604445|Experimental|BI 905677|Schedule A: 3 week cycle (treatment every 3 weeks). Schedule B: 4 week cycle (treatment every 2 weeks). Recruitment into Schedule B will start after the MTD of Schedule A is reached.
11168033|NCT03604419|Experimental|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
11168034|NCT03604419|Experimental|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
11168035|NCT03604419|Experimental|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
11168036|NCT03604419|Placebo Comparator|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
11168037|NCT03604406|Experimental|Varicella Zoster Vaccine|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
11168038|NCT03604406|Placebo Comparator|Placebo Injection|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
11168039|NCT03604393|Experimental|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
11168040|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
11168041|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
11168042|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
11168043|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
11168044|NCT03604380|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
11168045|NCT03604380|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
11168046|NCT03604367||GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
11168047|NCT03604354|Active Comparator|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
11168048|NCT03604354|Experimental|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
11168049|NCT03604341|Experimental|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
11168050|NCT03604341|Placebo Comparator|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
11168051|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
11168052|NCT03604315|Experimental|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.
11168231|NCT03602950|Active Comparator|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
11168053|NCT03604302|Experimental|Functional Magnetic Resonance Imaging (fMRI)|The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
11168054|NCT03604289|Experimental|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
11168055|NCT03604289|Placebo Comparator|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
11168056|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
11168057|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
11168058|NCT03604237|Experimental|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
11168059|NCT03604237|No Intervention|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
11168060|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
11168061|NCT03604198|Experimental|relacorilant (CORT125134)|
11168062|NCT03604185|Experimental|Choir Singing Group|Choir participants will take part in weekly two-hour group choral sessions over the course of fourteen weeks, during which time they will receive pitch training and vocal direction. In addition to the weekly group choir sessions, participants will be offered optional individual online musical and vocal training exercises (up to one hour weekly).
11168063|NCT03604185|Active Comparator|Music Appreciation Group|Participants assigned to the music appreciation class will take part in a fourteen week course which will emphasize analytic listening to musical excerpts, which will match the choir class in terms of duration, homework demands, and instructor - both classes will be taught by the same person.
11168064|NCT03604185|No Intervention|Do-Nothing Control Group|The do-nothing control group will not receive any active training.
11168065|NCT03604172|Experimental|Cognitive behavioral therapy|16-week cognitive behavioral therapy intervention for binge eating disorder
11168066|NCT03604172|Other|Waitlist control|16-weeks on waitlist then participants will be provided with 16-weeks of cognitive behavioral therapy
11168067|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
11168068|NCT03604159|Active Comparator|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
11168069|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
11168070|NCT03604146||Intervention group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
11168071|NCT03604133||Patients receiving ICD devices|
11168072|NCT03604120|Experimental|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
11168073|NCT03604120|Active Comparator|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
11168074|NCT03604094||Group I|0-1 month old newborns
11168075|NCT03604094||Group II|1 month-2 year-old pediatric patients
11168076|NCT03604081|Experimental|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
11168077|NCT03604081|Placebo Comparator|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
11168078|NCT03604068|Active Comparator|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
11168079|NCT03604068|Sham Comparator|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
11168080|NCT03604055|Other|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
11168081|NCT03604042|Active Comparator|Weight-driven protein fortification|Individualized protein fortification based on weight gain
11168082|NCT03604042|Experimental|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
11168083|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
11168084|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
11168085|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
11168086|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
11168087|NCT03604003|Experimental|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
11168088|NCT03604003|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
11168089|NCT03603990|Experimental|Vitrectomy|"Patient with standard pars plana vitrectomy
~During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.
~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
11168090|NCT03603990|Active Comparator|Usual care|"Patients with usual care according to the investigator choice :
~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.
~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
11168091|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
11168092|NCT03603964|Experimental|Guadecitabine|Subjects will receive guadecitabine treatment at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol. Treatment may continue as long as the subject continues to benefit based on investigator judgment.
11168093|NCT03603951|Experimental|SHR2554 treated group|treated with escalated doses of EZH2 inhibitor SHR2554 respectively
11168094|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
11168095|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
11168096|NCT03603925||PET/MR + PET/CT|The interventions for participating in this research are centered around steps needed to safely and ethically collect a research PET/MR scan following a standard-of-care PET/CT scan. The patient will be imaged in at least one of several standard anatomic areas: head/neck, thorax, abdomen, pelvis or whole-body.
11168097|NCT03603912|No Intervention|Control|Written educational literature on healthy eating and exercise guideline
11168098|NCT03603912|Experimental|Metformin|Metformin ER up to 750 mg twice daily
11168099|NCT03603912|Experimental|Lifestyle/Risk Factor Modification|Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
11168100|NCT03603912|Experimental|Metformin + LRFM|Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
11168101|NCT03603912|No Intervention|No Atrial Fibrillation|Written educational literature on healthy eating and exercise guideline
11168102|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
11168103|NCT03603886|Experimental|Telemedicine Pain Management|
11168104|NCT03603886|Other|Waitlist Control|Treatment as usual comparator
11168105|NCT03603873||Patients|
11168106|NCT03603834|Experimental|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:
~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection
~each 14 day cycle, for 6 cycles"
11168107|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
11168108|NCT03603808|Experimental|Treatment (VGX-3100, electroporation)|Patients receive HPV DNA plasmids therapeutic vaccine VGX-3100 IM and then undergo electroporation over 10 seconds for 4 doses in week 0, 4, 12, and 24 in the absence of disease progression or unacceptable toxicity.
11168109|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.
~Chemotherapy administration would be performed among standard practice:
~Daunorubicin: 60 mg/m² D1 to D3
~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
~Lomustine (CCNU): 200 mg/m² per os, at D1.
~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.
~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
11168110|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)
~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.
~Chemotherapy administration would be performed among standard practice:
~Daunorubicin: 60 mg/m² D1 to D3
~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
~Lomustine (CCNU): 200 mg/m² per os, at D1."
11168111|NCT03603782|Experimental|1|
11168112|NCT03603782|Experimental|2|
11168113|NCT03603782|Experimental|3|
11168114|NCT03603782|Experimental|4|
11168193|NCT03603249|Experimental|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
11168115|NCT03603769|Experimental|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)
~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.
~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
11168116|NCT03603769|Placebo Comparator|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.
~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.
~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
11168117|NCT03603756|Experimental|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
11168118|NCT03603756|Experimental|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
11168119|NCT03603743|Experimental|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
11168120|NCT03603743|Active Comparator|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
11168121|NCT03603730|Experimental|taVNS|Active or inactive taVNS
11168122|NCT03603717|Experimental|CBT-I|Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
11168123|NCT03603717|Active Comparator|SH|Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
11168124|NCT03603704|Experimental|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.
~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
11168125|NCT03603704|Active Comparator|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
11168126|NCT03603691|Active Comparator|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
11168127|NCT03603691|Active Comparator|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
11168128|NCT03603691|Active Comparator|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
11168129|NCT03603678|Experimental|Part A single dose BAY2253651|Single dose BAY2253651
11168130|NCT03603678|Placebo Comparator|Part A single dose Placebo|Single dose matching placebo
11168131|NCT03603678|Experimental|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
11168132|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
11168133|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
11168134|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
11168135|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
11168136|NCT03603639|Experimental|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
11168137|NCT03603639|Experimental|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
11168138|NCT03603639|Experimental|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
11168139|NCT03603639|Experimental|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
11168140|NCT03603639|Experimental|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
11168141|NCT03603639|Experimental|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
11168142|NCT03603626|Experimental|Preemptive pregabalin|
11168143|NCT03603626|Placebo Comparator|Placebo|
11168144|NCT03603613|Experimental|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
11168145|NCT03603613|Experimental|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
11168146|NCT03603613|No Intervention|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
11168147|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
11168148|NCT03603600|Sham Comparator|enVista MX60E|enVista MX60E monofocal IOL
11168149|NCT03603587|Experimental|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.
~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
11168150|NCT03603574|Experimental|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
11168151|NCT03603574|Experimental|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
11168152|NCT03603561|Active Comparator|Active cTBS|
11168153|NCT03603561|Sham Comparator|Sham cTBS|
11168154|NCT03603548|Active Comparator|Advagraf|
11168155|NCT03603548|Experimental|Envarsus|
11168156|NCT03603522|Experimental|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
11168157|NCT03603522|Placebo Comparator|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
11168158|NCT03603509|Active Comparator|Fluad vaccine|Subjects receive a single dose of the Fluad influenza vaccine.
11168159|NCT03603509|Active Comparator|Fluzone vaccine|Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.
11168160|NCT03603496|Experimental|Personalized Tobacco Care Management|PTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call +/- text messaging +/- email. At each contact the patient is offered a return call from the hospital-based tobacco coach forcounseling, medication advice, and coordination of care with the patient's outpatient health care team.
11168161|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the quitline will be included in the patient's medical chart.
11168162|NCT03603483|Active Comparator|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
11168163|NCT03603483|Active Comparator|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
11168164|NCT03603470|Other|Patients with previous prothesis instability|
11168165|NCT03603470|Other|Patients without prothesis instability|
11168166|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.
~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
11168194|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
11168195|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
11168336|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
11168167|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.
~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
11168168|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.
~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
11168169|NCT03603431|Experimental|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
11168170|NCT03603431|Placebo Comparator|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
11168171|NCT03603431|Experimental|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
11168172|NCT03603431|Placebo Comparator|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
11168173|NCT03603418|Experimental|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
11168174|NCT03603418|Placebo Comparator|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
11168175|NCT03603405|Experimental|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)
~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol.
~Patient can receive second treatment of HSV-tk after 6 months."
11168176|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
11168177|NCT03603379|Experimental|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
11168178|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.
~Subgroups:
~Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD
~Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
11168179|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.
~Subgroups:
~Patients eligible for and using low-dose aspirin for secondary prevention of CVD
~Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
11168180|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
11168181|NCT03603353|Experimental|Intervention group|
11168182|NCT03603353|Active Comparator|Control group|
11168183|NCT03603340|Experimental|Intervention group|
11168184|NCT03603340|Active Comparator|Control group|
11168185|NCT03603327|Other|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
11168186|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
11168187|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
11168188|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
11168189|NCT03603288|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
11168190|NCT03603275||Patient/caregiver of Kovaltry or Jivi|Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
11168191|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
11168192|NCT03603262|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
11168196|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
11168197|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.
~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
11168198|NCT03603197|Experimental|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
11168199|NCT03603197|Placebo Comparator|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
11168200|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
11168201|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
11168202|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
11168203|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
11168204|NCT03603145|Experimental|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
11168205|NCT03603145|No Intervention|Standard Insertion|Insertion at 2-4 weeks post medical abortion
11168206|NCT03603132|Active Comparator|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
11168207|NCT03603132|Active Comparator|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
11168208|NCT03603132|Active Comparator|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
11168209|NCT03603119|Active Comparator|Group A|Dexamethasone-ondansetron
11168210|NCT03603119|Experimental|Group B|Midazolam
11168211|NCT03603106|Experimental|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
11168212|NCT03603106|Experimental|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
11168213|NCT03603080|Experimental|Medication arm|
11168214|NCT03603080|No Intervention|No medication arm|
11168215|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
11168216|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
11168217|NCT03603054|Active Comparator|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
11168218|NCT03603054|Experimental|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
11168219|NCT03603041|No Intervention|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
11168220|NCT03603041|Experimental|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
11168221|NCT03603041|Experimental|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
11168222|NCT03603041|Experimental|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
11168223|NCT03603041|Placebo Comparator|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
11168224|NCT03603028|Experimental|Exergaming|
11168225|NCT03603015|Other|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
11168226|NCT03603002|Experimental|Stage I NSCLC with SABR Therapy|Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
11168227|NCT03602976|No Intervention|Observation|
11168228|NCT03602976|Experimental|UDCA at Month 6|
11168229|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
11168230|NCT03602950|No Intervention|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
11185398|NCT03485222|Experimental|Empagliflozin|10mg once a day
11168234|NCT03602898|Experimental|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
11168235|NCT03602898|Experimental|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
11168236|NCT03602898|Experimental|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
11168237|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
11168238|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
11168239|NCT03602872|Experimental|Group 1|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
11168240|NCT03602872|Experimental|Group 2|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
11168241|NCT03602872|Experimental|Group 3|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
11168242|NCT03602859|Placebo Comparator|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+bevacizumab) in cycle 1 followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab along with niraparib placebo and dostarlimab placebo.
11168243|NCT03602859|Active Comparator|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab with niraparib and dostarlimab placebo.
11168244|NCT03602859|Experimental|Participants receiving SOC+dostarlimab|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of bevacizumab with niraparib and dostarlimab.
11168245|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
11168246|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
11168247|NCT03602833|Experimental|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
11168248|NCT03602807|Experimental|Active treatment|
11168249|NCT03602794|Active Comparator|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%
~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
11168250|NCT03602794|Placebo Comparator|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
11168251|NCT03602781|Placebo Comparator|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:
~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day
~Long Term Open Label Extension Period:
~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
11168252|NCT03602781|Active Comparator|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:
~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day
~Long Term Open Label Extension Period:
~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
11168253|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
11168254|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
11168255|NCT03602768|Placebo Comparator|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
11168256|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
11168257|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
11168258|NCT03602742|Other|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
11168259|NCT03602729|No Intervention|Group 1|No study related education given
11168260|NCT03602729|Experimental|Group 2|Written BF education
11168261|NCT03602729|Experimental|Group 3|Verbal BF education
11168262|NCT03602729|Experimental|Group 4|Video BF education
11168263|NCT03602716|Experimental|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
11168264|NCT03602716|Sham Comparator|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
11168265|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
11168266|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
11168267|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
11168268|NCT03602703||Control group|Healthy subjects
11168269|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:
~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
11168270|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
11168271|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
11168272|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
11168273|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
11168274|NCT03602638|Experimental|Sitagliptin|
11168275|NCT03602638|Active Comparator|CONTROL|Acarbose
11168276|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
11168277|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
11168278|NCT03602612|Experimental|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
11168279|NCT03602612|Experimental|2/Conditioning chemotherapy plus CAR T-cells expansion phase|6.0x10^6 dose (maximum feasible dose) of CAR T Cells + Cyclophosphamide: 300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
11168280|NCT03602599||Healthy-controls Longitudinal Cohort|"(Cohort HL; approximate n=20) includes subjects who will participate in up to the full set of 8 study visits across 3 years."
11168281|NCT03602599||Healthy-controls Short-term Cohort|"(Cohort HS; approximate n=80) will participate in a single baseline visit."
11168282|NCT03602599||New Transplant Cohort|"(Cohort NT; approximate n=300) consists of patients who are scheduled to undergo allogeneic HSCT (under another protocol at the NIH)."
11168283|NCT03602599||Prior Transplant Cohort|"(Cohort PT; approximate n=100) consists of patients who have already undergone allogeneic HSCT."
11168284|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11168285|NCT03602573||pre-menopause|
11168286|NCT03602573||post-menopause|
11168287|NCT03602560|Experimental|Seladelpar 5-10 mg|
11168288|NCT03602560|Experimental|Seladelpar 10 mg|
11168289|NCT03602560|Placebo Comparator|Placebo|
11168290|NCT03602547|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
11168291|NCT03602534||cases with variable acne severity scores|"group will include 50 females
~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)
~Assessment of body mass index (BMI)
~blood serum samples will be collected from all patients to do thyroid function test"
11168292|NCT03602534||healthy controls|"group will include 29 females
~Assessment of body mass index (BMI)
~blood serum samples will be collected from all healthy controls to do thyroid function test"
11168293|NCT03602521|Experimental|BPD|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
11168294|NCT03602521|Active Comparator|HC|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
11168295|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
11168296|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
11168297|NCT03602495|Experimental|Donafenib|Donafenib 300mg bid for each 28 days cycle.
11168298|NCT03602495|Placebo Comparator|Placebo|Placebo 300mg bid for each 28 days cycle.
11168299|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
11168300|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
11168302|NCT03602469|Active Comparator|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
11168303|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
11168304|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
11168305|NCT03602443|Experimental|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
11168306|NCT03602443|Other|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
11168307|NCT03602430|Experimental|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
11168308|NCT03602430|Placebo Comparator|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
11168309|NCT03602417|Experimental|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
11168310|NCT03602417|Active Comparator|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
11168311|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
11168312|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
11168313|NCT03602404||Marrakesh: School aged children|Generally healthy 9 to 12 years old children
11168314|NCT03602404||Marrakesh: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
11168315|NCT03602391|Experimental|SCP Plus|
11168316|NCT03602391|No Intervention|Services as usual|
11168317|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
11168318|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
11168319|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
11168320|NCT03602365|Experimental|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
11168321|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions will undergo unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
11168322|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) will undergo a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
11168323|NCT03602326|Experimental|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
11168324|NCT03602326|Active Comparator|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
11168325|NCT03602313|Active Comparator|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
11168326|NCT03602313|Experimental|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
11168327|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
11168328|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
11168329|NCT03602287|Active Comparator|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
11168330|NCT03602287|Placebo Comparator|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
11168331|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
11168332|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
11168333|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
11168334|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
11168335|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
11168337|NCT03602248|Experimental|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:
~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
11168338|NCT03602248|Experimental|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
11168339|NCT03602248|No Intervention|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
11168340|NCT03602235|Experimental|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.
~HDAA + Melphalan:
~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.
~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
11168341|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
11168342|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
11168343|NCT03602209|Experimental|4 weeks of treatment|
11168344|NCT03602209|Active Comparator|6 weeks of treatment|
11168345|NCT03602196|Experimental|pregnant women|"pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)
~For the ancillary study: non-pregnant nulliparous women"
11168346|NCT03602183|Experimental|Normal airway scenario|intubation in normal airway scenario
11168347|NCT03602183|Experimental|Tongue edema scenario|intubation in the tongue edema scenario. Tongue edema was obtain using simulator indicators
11168348|NCT03602183|Experimental|Spinal immobilization with normal airway scenario|intubation in spinal immobilization with normal airway scenario
11168349|NCT03602183|Experimental|Spinal immobilization with tongue edema scenario|endotracheal intubation with immobilized cervical spine and tongue edema scenario
11168350|NCT03602170|Experimental|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
11168351|NCT03602170|Active Comparator|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
11168352|NCT03602157|Experimental|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 5 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
11168353|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
11168354|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
11168355|NCT03602131|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
11168356|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
11168357|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
11168358|NCT03602105|Active Comparator|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
11168359|NCT03602105|No Intervention|Control group|Care as usual
11168360|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
11168361|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
11168362|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
11168363|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
11168364|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
11168365|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
11168366|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
11168367|NCT03602053|Experimental|ROTAVAC 5D|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
11168368|NCT03602053|Experimental|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
11168369|NCT03602053|Active Comparator|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
11168370|NCT03602040|Experimental|PISICC group|Psychoeducational intervention
11168371|NCT03602027|Experimental|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
11168372|NCT03602014|Experimental|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
11168373|NCT03602014|Placebo Comparator|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
11168374|NCT03602001|Experimental|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
11168375|NCT03602001|Active Comparator|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
11168376|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
11168377|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
11168378|NCT03601975|Experimental|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
11168379|NCT03601975|Placebo Comparator|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
11168380|NCT03601962|Experimental|Aqualief® tablets|oral mucoadesive tablets
11168381|NCT03601962|Placebo Comparator|Placebo tablets|oral mucoadesive tablets
11168382|NCT03601949|Experimental|SInergy Cooled Radiofrequency|Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management
11168383|NCT03601949|Active Comparator|Medical Management|Standard Medical Management
11168384|NCT03601936|Other|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
11168385|NCT03601923|Experimental|Niraparib|"Niraparib will be administered orally once daily
~Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment"
11168386|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T
~Period 2: CKD-380 10mg Tab. 1T"
11168387|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T
~Period 2: D308 10mg Tab. 1T"
11168388|NCT03601897|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
11168389|NCT03601897|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel
~Triple-negative and Stage IV inflammatory breast cancer
~Ovarian cancer
~Endometrial cancer
~Gynecological Carcinosarcoma"
11168390|NCT03601884|Experimental|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.
~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.
~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.
~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
11168391|NCT03601884|Other|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.
~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
11168392|NCT03601871|Active Comparator|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
11168393|NCT03601871|Experimental|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
11168394|NCT03601845|Other|MRE-IA (no stimuli)|Additional sequencing only
11168395|NCT03601845|Active Comparator|MRE-IA with stimuli|Visual stimulation while using additional sequencing
11168396|NCT03601832|Experimental|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
11168397|NCT03601819|Experimental|Pacritinib|200 mg twice daily (with possible dose reduction to 100 mg twice daily)
11168398|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11168399|NCT03601793|Experimental|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
11168400|NCT03601793|Active Comparator|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
11168401|NCT03601780|Active Comparator|Local wound infiltration|local wound infiltration plus usual care
11168402|NCT03601780|Placebo Comparator|Control|usual care only
11168403|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
11168404|NCT03601741|Active Comparator|Antimicrobial Stethoscope Diaphragm Covers|
11168405|NCT03601741|Active Comparator|Uncovered Stethoscopes|
11168406|NCT03601728|Experimental|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
11168407|NCT03601728|No Intervention|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
11168408|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
11168409|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
11168410|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
11168411|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
11168412|NCT03601676|Active Comparator|Intervention|
11168413|NCT03601676|No Intervention|Control|
11168414|NCT03601663|Experimental|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
11168415|NCT03601663|Active Comparator|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
11168416|NCT03601663|Active Comparator|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
11168417|NCT03601650|Experimental|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
11168418|NCT03601650|Active Comparator|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
11168419|NCT03601650|No Intervention|No strategy control|Participants will simply complete the measures
11168420|NCT03601637|Experimental|Part A Cohort 1 [aged 18 to <24 months]|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
11168421|NCT03601637|Experimental|Part A Cohort 2 [12 to <18months]|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
11168422|NCT03601637|Experimental|Part B|Subjects will receive LUM/IVA as FDC granules dependent upon weight at Day 1.
11168423|NCT03601624|Experimental|Experimental|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle
~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.
~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
11168424|NCT03601611|Experimental|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
11168425|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
11168426|NCT03601585|Experimental|Rolly Brush|Chew for 1 minute
11168427|NCT03601585|Experimental|Chewing gum|Chew for 1 minute
11168428|NCT03601585|Experimental|Apple|Chew for 1 minute
11168429|NCT03601585|Active Comparator|Brush|brush for 1 minute
11185399|NCT03485222|Placebo Comparator|Placebos|placebo once a day
11168433|NCT03601533|Other|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
11168434|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
11168435|NCT03601494|Active Comparator|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
11168436|NCT03601494|Placebo Comparator|Control|medical treatment only
11168437|NCT03601455|Experimental|Regimen A (radiation therapy and durvalumab)|Participants receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo EBRT for 5 fractions beginning on day 8 of course 1.
11168438|NCT03601455|Experimental|Regimen B (radiation therapy, durvalumab, tremelimumab)|Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1.
11168439|NCT03601429|Experimental|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
11168440|NCT03601429|Placebo Comparator|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
11168441|NCT03601416|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.
11168442|NCT03601416|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.
11168443|NCT03601403|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
11168444|NCT03601403|Experimental|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
11168445|NCT03601390||PET/CT and EBV DNA|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT protocol 12 weeks after the end of IMRT (primary endpoint).Plasma EBV DNA test will be performed 4, 12, 24 weeks after the end of IMRT. In patients with negative PET/CT results, 2 follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA test in the frist year. All patients will undergo annual PET/CT or traditional follow-up examination and plasma EBV DNA test 1 year after completing chemoradiation unless recurrent/residual disease is histopathologically-confirmed.
11168446|NCT03601377|Experimental|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (< or >) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.
~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
11168447|NCT03601377|Experimental|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.
~Experiment 2: received 4 times (2 times for 2 weeks)"
11168448|NCT03601377|Placebo Comparator|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.
~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
11168449|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
11168450|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),
~FIO2 50%, Flow: 2L / min,
~Frequency; 10-12 applied group."
11168451|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,
~Tidal Voltage 3-4ml / kg (TV),
~FIO2 50%, Flow: 2L / min,
~Frequency; 10-12 applied group."
11168452|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
11168453|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
11168454|NCT03601338|Active Comparator|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery
~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
11168455|NCT03601338|Placebo Comparator|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
11168456|NCT03601312|Active Comparator|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
11168457|NCT03601312|Experimental|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
11168458|NCT03601299|Experimental|Traditional food arm|Traditional food-focused menu
11168459|NCT03601299|No Intervention|Non-intervention arm|Standard RurAL CAP menu
11168460|NCT03601286|Experimental|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
11185626|NCT03483649|Active Comparator|European Union (EU) Avastin®|
11168461|NCT03601260|Other|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
11168462|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
11168463|NCT03601234|Experimental|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
11168464|NCT03601234|Experimental|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
11168465|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
11168466|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
11168467|NCT03601169|Experimental|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: ~22mg/kg LBM/day) for 6 weeks
11168468|NCT03601169|Experimental|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: ~33mg/kg LBM/day) for 6 weeks
11168469|NCT03601169|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 6 weeks
11168470|NCT03601156|Experimental|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
11168471|NCT03601156|Active Comparator|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
11168472|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
11168473|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
11168474|NCT03601117|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
11168475|NCT03601117|Active Comparator|Anterior cingulate cortex|The accelerated theta burst stimulation protocol will be applied to the anterior cingulate cortex(ACC)
11168476|NCT03601104|Active Comparator|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
11168477|NCT03601104|Experimental|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
11168478|NCT03601104|Experimental|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
11168479|NCT03601104|Active Comparator|LIET (n= 15)|Low intensity eccentric training: A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
11168480|NCT03601091|Active Comparator|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
11168481|NCT03601091|Active Comparator|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
11168482|NCT03601078|Experimental|bb2121 in relapsed and refractory multiple myeloma patients|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
11168483|NCT03601065||Routine colonoscopy Cohort|
11168484|NCT03601052|Experimental|Cohort 1 - Remlarsen (L) vs. Placebo (R)|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound (left side) and six doses Placebo over a period of 2 weeks at the site of a second excisional skin wound (right side). Each subject will serve as their own control.
11168485|NCT03601052|Experimental|Cohort 1 - Remlarsen (R) vs. Placebo (L)|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound (right side) and six doses Placebo over a period of 2 weeks at the site of a second excisional skin wound (left side). Each subject will serve as their own control.
11168486|NCT03601039|Experimental|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
11168487|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
11168488|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
11168489|NCT03601000|Experimental|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
11168490|NCT03601000|Placebo Comparator|Placebo|Placebo given three times every day for 16 weeks.
11168491|NCT03600987|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
11168492|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
11168494|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
11168495|NCT03600974||Acid-A(-)|Subjects with DeMeester scores<14.72
11168496|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number > 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
11168497|NCT03600974||impedance-I（-）|Subjects with total reflux number < 80 in 24h pH-impedance monitoring.
11168498|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
11168499|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
11168500|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
11168501|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
11168502|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
11168503|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
11168504|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
11168505|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
11168506|NCT03600935|Experimental|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
11168507|NCT03600922|Experimental|Intervention group|
11168508|NCT03600909|Experimental|Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
11168509|NCT03600909|Experimental|Intermediate risk patients|Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
11168510|NCT03600909|Experimental|High risk patients|Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
11168511|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.
~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
11168512|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
11168513|NCT03600883|Experimental|Dose Exploration Part 1 monotherapy|"Cohorts with food effect and alternative dosing regimens
~Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort"
11168514|NCT03600883|Experimental|Dose Expansion Part 2 monotherapy|Upon completing the dose exploration part of the study, dose expansion may proceed with 2 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors Dose expansion in these 2 groups may be done concurrently
11168515|NCT03600883|Experimental|Phase 2 monotherapy|Additional subjects will be enrolled in the dose expansion to confirm the recommended phase 2 dose. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose
11168516|NCT03600883|Experimental|Combination arm with AMG 510 and anti PD-1/L1|Additional subjects will be enrolled into the combination arm with AMG 510 in combination with an anti (PD-1/L1)
11168517|NCT03600883|Experimental|Monotherapy treatment naive advanced NSCLC|Separate cohort of part 1 dose expansion patients to evaluate the safety and clinical activity of AMG 510 administered orally once daily in patients with previously untreated advanced NSCLC
11168518|NCT03600870|Experimental|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
11168519|NCT03600857|Experimental|Home administration|Home administration of 0.8 mg misoprostol pv
11168520|NCT03600857|No Intervention|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
11168521|NCT03600844|Experimental|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
11168522|NCT03600844|Active Comparator|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
11168523|NCT03600831|Experimental|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
11168524|NCT03600831|Active Comparator|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
11168525|NCT03600818|Experimental|Group 1|Sarilumab once every 2 weeks plus prednisone taper regimen of 14 weeks
11168526|NCT03600818|Placebo Comparator|Group 2|Placebo matching sarilumab once every 2 weeks plus prednisone taper regimen of 52 weeks
11168527|NCT03600805|Experimental|Group A|Sarilumab dose 1, once every 2 weeks plus 26-week prednisone taper regimen
11168528|NCT03600805|Experimental|Group B|Sarilumab dose 2, once every 2 weeks plus 26-week prednisone taper regimen
11168529|NCT03600805|Placebo Comparator|Group C|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 26 weeks
11168530|NCT03600805|Placebo Comparator|Group D|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 52 weeks
11168531|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
11168532|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
11168533|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
11168534|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
11168535|NCT03600766|Active Comparator|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
11168536|NCT03600766|Active Comparator|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
11168537|NCT03600753|Experimental|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
11168538|NCT03600753|Active Comparator|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.
~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
11168539|NCT03600753|Other|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
11168540|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
11168541|NCT03600727|Experimental|Propofol group|Patients in this arm will be sedated by propofol.
11168542|NCT03600727|Experimental|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
11168543|NCT03600714|Experimental|Treatment|Treatment with Lonafarnib, Ritonavir, and Peginterferon lambda
11168544|NCT03600701|Experimental|Treatment (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1, and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11168545|NCT03600675||South Asian Indians|No intervention will be applied for any group
11168546|NCT03600675||Caucasians|No intervention will be applied for any group
11168547|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
11168548|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
11168549|NCT03600649|Experimental|SP-2577|Twice-daily administration of oral SP-2577
11168550|NCT03600636|Other|Control|
11168551|NCT03600636|Other|antiphospholipid syndrome patients|
11168552|NCT03600623|Experimental|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
11168553|NCT03600623|Experimental|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
11168554|NCT03600610|Experimental|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
11168555|NCT03600610|Active Comparator|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
11168556|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
11168557|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
11168558|NCT03600571|Experimental|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
11168559|NCT03600571|Experimental|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
11168560|NCT03600571|Experimental|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
11168599|NCT03600311|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
11168561|NCT03600571|Experimental|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
11168562|NCT03600545|Experimental|Active|4 weeks daily practice of the brain exercises
11168563|NCT03600545|Placebo Comparator|control|no brain exercises
11168564|NCT03600532|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
11168565|NCT03600532|No Intervention|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
11168566|NCT03600532|No Intervention|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
11168567|NCT03600519||AMD Patients|OCT scan
11168568|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
11168569|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
11168570|NCT03600493|Active Comparator|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
11168571|NCT03600493|Active Comparator|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
11168572|NCT03600480|Experimental|NNC0174-0833+Semaglutide|Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
11168573|NCT03600480|Active Comparator|Placebo (NNC0174-0833)+Semaglutide|Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
11168574|NCT03600467|Experimental|Adrogen Postive Solid Tumours|
11168575|NCT03600454|Experimental|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
11168576|NCT03600454|Experimental|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
11168577|NCT03600454|Experimental|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
11168578|NCT03600454|Experimental|Colectomy: general anesthesia|Patients will receive general anesthesia.
11168579|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
11168580|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
11168581|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
11168582|NCT03600415|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
11168583|NCT03600415|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11168584|NCT03600402|Experimental|Experimental Group|
11168585|NCT03600402|Other|Control Group|
11168586|NCT03600389|Experimental|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
11168587|NCT03600389|No Intervention|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
11168588|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
11168589|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
11168590|NCT03600363|Experimental|metformin arm|
11168591|NCT03600363|Placebo Comparator|control arm|
11168592|NCT03600350|Experimental|Treatment Group|"Nivolumab 240 mg IV every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12
~pTVG-HP (100 µg) administered intradermally (i.d.) every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12
~rhGM-CSF (208 µg) administered intradermally (i.d.) every two weeks x 4 beginning week 4, then every four weeks x 9 beginning week 12 NOTE: Only administered to patients for whom serum PSA obtained week 4 > serum PSA obtained at day 1."
11168593|NCT03600337|Experimental|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
11168594|NCT03600337|No Intervention|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
11168595|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
11168596|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
11168597|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
11168598|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
11168600|NCT03600311|Active Comparator|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
11168601|NCT03600311|Experimental|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
11168602|NCT03600298|Other|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.
~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
11168603|NCT03600285|Experimental|TB1-K|TB1-K preservation arm
11168604|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
11168605|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
11168606|NCT03600259||Acute Myocardial Infarction|
11168607|NCT03600233|Experimental|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
11168608|NCT03600220|No Intervention|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
11168609|NCT03600220|Experimental|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
11168610|NCT03600207|Active Comparator|Control group -complex training|complex training
11168611|NCT03600207|Active Comparator|Experimental group -diaphragm training|diaphragm training
11168612|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
11168613|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11168614|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11168615|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11168616|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
11168617|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
11168618|NCT03600129|Experimental|QLB with 0,375% ropivacaine|
11168619|NCT03600129|Placebo Comparator|QLB with 0,9% NaCl|
11168620|NCT03600116|Other|Study Visit|Subjects will arrive to the study visit having fasted the night before. Subjects will be given an insulin injection based on their meal to carbohydrate ratio for their breakfast meal as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL. Following the insulin injection, subjects will eat breakfast. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
11168621|NCT03600103|No Intervention|Control|Participants will receive standard of care.
11168622|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
11168656|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
11168657|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
11168623|NCT03600090|Experimental|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).
~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.
~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
11168624|NCT03600064|Other|Misoprostol group|
11168625|NCT03600064|No Intervention|NO intervention|
11168626|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
11168627|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
11168628|NCT03600025|Other|non-randomized|Responses will be compared before and after vaccination
11168629|NCT03600012|Experimental|intervention group|"intervention group: Cycling Functional Electrical Stimulation & Physiotherapy
~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
11168630|NCT03600012|Active Comparator|control group|"control group: Physiotherapy
~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
11168631|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
11168632|NCT03599960|Experimental|Chemotherapy|
11168633|NCT03599934|Experimental|LiFE training and home safety assessment|The participants will receive Lifestyle Integrated Functional Exercise Program and Home safety assessment
11168634|NCT03599934|No Intervention|Control group|The control group will continue their usual daily routine.
11168635|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
11168636|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
11168637|NCT03599921||Family-based Treatment for ARFID|Participants will receive family-based treatment modified for Avoidant/Restrictive Food Intake Disorder (ARFID).
11168638|NCT03599921||FBT + UP for ARFID|Participants will receive family-based treatment with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents, named FBT + UP for ARFID.
11168639|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
11168640|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
11168641|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
11168642|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
11168643|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
11168644|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
11168645|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
11168646|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
11168647|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
11168648|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
11168649|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
11168650|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
11168651|NCT03599765|Experimental|Arm I (LCT, routine therapy)|Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.
11168652|NCT03599765|Experimental|Arm II (routine therapy)|Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.
11168653|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
11168654|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
11168655|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
11168785|NCT03598777|Placebo Comparator|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
11168658|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
11168659|NCT03599726|Experimental|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
11168660|NCT03599726|Placebo Comparator|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
11168661|NCT03599713|Experimental|INCMGA00012|
11168662|NCT03599700||myeloproliferative neoplasms|"history taking
~physical examination
~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
11168663|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
11168664|NCT03599661|Experimental|Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
11168665|NCT03599648|Experimental|BPT-E|"Behavioral parent training (BPT) plus a psychoeducation program.
~Includes a 10-week standard BPT, plus a 6-week psychoeducation program delivered prior to the standard BPT."
11168666|NCT03599648|Experimental|BPT-M|"Behavioral parent training (BPT) plus mindfulness-based stress reduction (MBSR).
~Includes a 10-week standard BPT, plus a 6-week MBSR delivered prior to the standard BPT."
11168667|NCT03599635|Experimental|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
11168668|NCT03599635|Active Comparator|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
11168669|NCT03599622|Experimental|BMS-986165 Dose 1|
11168670|NCT03599622|Experimental|BMS-986165 Dose 2|
11168671|NCT03599622|Placebo Comparator|Placebo|
11168672|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
11168673|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
11168674|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
11168675|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
11168676|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
11168677|NCT03599570|Experimental|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
11168678|NCT03599570|No Intervention|Control|Arm 2 will receive standard of care
11168679|NCT03599557|Experimental|Intervention|Arm 1 will receive the STOP-HPV communication intervention
11168680|NCT03599557|No Intervention|Control|Arm 2 will receive standard of care
11168681|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
11168682|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
11168683|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 250 mg oral dose of gefitinib
11168684|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
11168685|NCT03599479|Experimental|Virtual reality group|"After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.
~After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).
~After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.
~Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
11168686|NCT03599479|No Intervention|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
11168687|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
11168688|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
11168689|NCT03599453|Experimental|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
11168690|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
11168691|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
11168692|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
11168693|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
11168694|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
11168850|NCT03598400|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
11168695|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
11168696|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)
~Fitbit 24/7
~Phone/videoconference (weekly with study team)
~Epworth Sleepiness Scale (weekly)
~PROMIS fatigue scale-morning (weekly)
~PROMIS fatigue scale-evening (weekly)"
11168697|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
11168698|NCT03599362|Experimental|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
11168699|NCT03599349|Experimental|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 0.75 joules for the 7-4.5mm transducer)
11168700|NCT03599336|Other|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
11168701|NCT03599336|Other|Operative Course for rTSA|Surgical management
11168702|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
11168703|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
11168704|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
11168705|NCT03599297|Experimental|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
11168706|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
11168707|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
11168708|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
11168709|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
11168710|NCT03599258|Other|Arm 1|Skylife device
11168711|NCT03599258|Active Comparator|Arm 2|Standard therapy
11168712|NCT03599245|Experimental|Ocrelizumab|Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.
11168713|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).
~assessed at end of the module(7 weeks) through summative OSCE"
11168714|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
11168715|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
11168716|NCT03599219|Other|control|donors with an hemorrhagic score <2.
11168717|NCT03599206|Experimental|Ozone|
11168718|NCT03599206|Placebo Comparator|Filtered Air|
11168719|NCT03599193|Experimental|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
11168720|NCT03599193|Active Comparator|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for ~12 hours. 29 subjects will be enrolled into this arm.
11168721|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
11168722|NCT03599180||Control group|Heathly volunteers
11168723|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
11168724|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
11168725|NCT03599128|Placebo Comparator|Placebo|Placebo
11168726|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
11168727|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
11168728|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
11168786|NCT03598777|Active Comparator|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
11168787|NCT03598764|Other|Classic head extraction group|
11168729|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
11168730|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
11168731|NCT03599102|Experimental|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
11168732|NCT03599102|No Intervention|Standard Care|Standard interaction with transplant center and physician care.
11168733|NCT03599089|Active Comparator|CA-008 0.7 mg|Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
11168734|NCT03599089|Active Comparator|CA-008 2.1 mg|Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
11168735|NCT03599089|Active Comparator|CA-008 4.2 mg|Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
11168736|NCT03599089|Placebo Comparator|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
11168737|NCT03599076||Manifest HD|
11168738|NCT03599076||Premanifest HD|
11168739|NCT03599076||Control|
11168740|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
11168741|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
11168742|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
11168743|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
11168744|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
11168745|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
11168746|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
11168747|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
11168748|NCT03599050|Experimental|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
11168749|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
11168750|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
11168751|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
11168752|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
11168753|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
11168754|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
11168755|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
11168756|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11168788|NCT03598764|Other|External Pop out group|
11168789|NCT03598751|Experimental|BCD-085|"Blinded period:
~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22
~Open-label period:
~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
11168757|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.
~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
11168758|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.
~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
11168759|NCT03598972||control|teeth of children of non vitamin taking mother
11168760|NCT03598972||intervention|children teeth of vitamin taking mother
11168761|NCT03598959|Experimental|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
11168762|NCT03598946|Experimental|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
11168763|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
11168764|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
11168765|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
11168766|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
11168767|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP >145mmHg at baseline and a decline of <10% between mean day time and night time systolic pressures)
11168768|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP <120mmHg)
11168769|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP >145mmHg and a decline of >10% between mean day time and night time systolic pressures)
11168770|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
11168771|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
11168772|NCT03598868|Experimental|Vortioxetine|Vortioxetine 5-20 mg
11168773|NCT03598868|Placebo Comparator|Placebo|Placebo augmentation
11168774|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
11168775|NCT03598855|No Intervention|Control|
11168776|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
11168777|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
11168778|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
11168779|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
11168780|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses
~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles
~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab
~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
11168781|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses
~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
11168782|NCT03598790|Experimental|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 or dose regimen 2, those on dose regimen 1 will switch to dose regimen 2 at Week 24 or later.
~Intervention Name: Bimekizumab"
11168783|NCT03598790|Experimental|Bimekizumab dose regimen 2|Subjects will receive bimekizumab dose regimen 2. Intervention Name: Bimekizumab
11168784|NCT03598777|Experimental|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
11168790|NCT03598751|Placebo Comparator|Placebo|"Blinded period:
~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14
~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22
~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22
~Open-label period:
~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
11168791|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
11168792|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
11168793|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
11168794|NCT03598712|Experimental|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.
~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.
~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.
~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
11168795|NCT03598712|Active Comparator|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.
~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
11168796|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
11168797|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
11168798|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
11168799|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
11168800|NCT03598686|No Intervention|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:
~For present household members: blood-based HIV testing
~For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
11168801|NCT03598686|Experimental|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:
~For present household members: blood-based HIV testing
~a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)
~For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
11168802|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
11168803|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.
~The followings markers must be estimated:
~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
11168804|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.
~The followings markers must be estimated:
~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
11168805|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.
~The followings markers must be estimated:
~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
11168806|NCT03598647|Active Comparator|Physical activity information|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
11168807|NCT03598647|Experimental|Affect and physical activity|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
11168808|NCT03598634|Active Comparator|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
11168809|NCT03598634|Active Comparator|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
11168810|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
11168811|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
11168812|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
11168813|NCT03598608|Experimental|Part A: MK-4280 Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by MK-4280 Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
11168814|NCT03598608|Experimental|Part A: MK-4280 Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by MK-4280 Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
11168815|NCT03598608|Experimental|Part A: MK-4280 Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by MK-4280 Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
11168816|NCT03598608|Experimental|Part B: cHL|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
11168817|NCT03598608|Experimental|Part B: DLBCL|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
11168818|NCT03598608|Experimental|Part B: iNHL|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of MK-4280 by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
11168819|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11168820|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
11168821|NCT03598569||lung cancer|
11168822|NCT03598569||other lung diseases|
11168823|NCT03598556|Experimental|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
11168824|NCT03598556|Placebo Comparator|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
11168825|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
11168826|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
11168827|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
11168828|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
11168829|NCT03598504|Active Comparator|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
11168830|NCT03598504|Active Comparator|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.
~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
11168831|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
11168832|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
11168833|NCT03598478|Experimental|TC-MPT group|Tai Chi-muscle power training group
11168834|NCT03598478|Active Comparator|TC group|Tai Chi group
11168835|NCT03598478|Active Comparator|MPT group|Muscle power training group
11168836|NCT03598478|No Intervention|Control group|Usual medical care is allowed.
11168837|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
11168838|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
11168839|NCT03598452|Experimental|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
11168840|NCT03598439|Experimental|Recombinant (RIV4) Influenza Vaccine|A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
11168841|NCT03598439|Experimental|Cell-culture (ccIIV4) Influenza Vaccine|A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20
11168842|NCT03598439|Active Comparator|Standard (IIV4) Influenza Vaccine|A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
11168843|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
11168844|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
11168845|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
11168846|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
11168847|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
11168848|NCT03598400|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
11168849|NCT03598400|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
11185627|NCT03483649|Active Comparator|China (CN) Avastin®|
11168851|NCT03598387|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
11168852|NCT03598387|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
11168853|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.
~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
11168854|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.
~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
11168855|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
11168856|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
11168857|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
11168858|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
11168859|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
11168860|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
11168861|NCT03598322|Active Comparator|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
11168862|NCT03598322|Experimental|Dextrose 2mL|Dextrose injection, Dextrose 2mL
11168863|NCT03598322|Experimental|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
11168864|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza®|"Group A:
~4 grams Lovaza®, 2 grams twice a day (BID). 8,000 mgs CUR Curcumin C3 complex® tablets, 4,000 mgs BID."
11168865|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:
~2 grams Lovaza®, 1 gram BID. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs BID.
~1 placebo capsule BID."
11168866|NCT03598309|Active Comparator|Placebo only|Placebo: Two matching placebo capsules twice a day (BID).
11168867|NCT03598296|Experimental|Group A:Group Tube|Patients are inserted the large size tube (28F).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
11168868|NCT03598296|Experimental|Group B:Group Ball|Patients are inserted the small size tube connects with a negative pressure ball(drainage ball).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
11168869|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
11168870|NCT03598270|Placebo Comparator|Arm A (Control Arm)|"Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:
~Carboplatin (AUC = 5, d1) plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks
~Carboplatin (AUC = 4, d1) plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.
~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks."
11168871|NCT03598270|Experimental|Arm B (experimental arm)|"Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:
~Carboplatin (AUC = 5, d1) plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.
~Carboplatin (AUC = 4, d1) plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.
~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks."
11168872|NCT03598257|Experimental|Group I (olaparib, radiation therapy)|Patients receive olaparib PO BID the day before standard RT commences (Day 0) and throughout the RT course until the last day of RT administration. Olaparib is also continued on weekends (routine days without RT) throughout the RT course. Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unaccepted toxicity.
11168873|NCT03598257|Active Comparator|Group II (radiation therapy)|Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unaccepted toxicity
11168874|NCT03598244|Experimental|Treatment (volitinib)|Participants receive volitinib PO QD. Treatment repeats every 28 days for up to 39 cycles in the absence of disease progression or unacceptable toxicity.
11168875|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.
~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.
~Specific scales will be passed after each sequence crossing."
11168928|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
11168929|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
11186308|NCT03478826||Healthy|100 healthy participants as a control group.
11168876|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.
~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.
~Specific scales will be passed after each sequence crossing."
11168877|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
11168878|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
11168879|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
11168880|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
11168881|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.
~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
11168882|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
11168883|NCT03598166|No Intervention|Control|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Patients who call will speak to a research assistant who is trained in patient navigation and can facilitate referrals for colonoscopy or FIT. Patients will receive a follow-up telephone call that reiterates information in the letter.
~Patients will also be asked to complete a questionnaire about their beliefs and attitudes regarding CRC screening. The questionnaire will be mailed with the invitation letter and will also be administered over the telephone by the research assistant."
11168884|NCT03598166|Experimental|Septin9|"Patients will receive a letter noting that they are not up-to-date on screening and encouraging them to contact a study number if they choose to screen with colonoscopy or FIT. Letters will also include an option to participate in the blood test, with instructions to call the study number to schedule the blood draw. This option will not appear in the letters sent to the control group. Patients will also receive a follow-up telephone call and a questionnaire.
~Participants who choose to the blood test (Septin9) will undergo phlebotomy. The blood sample will be run by an off-site commercial laboratory. The study team will notify patients and their primary care physicians of blood test results and will facilitate a colonoscopy referral for those with positive tests."
11168885|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
11168886|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
11168887|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
11168888|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
11168889|NCT03598114|Experimental|Program Sustainability Training|"Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.
~The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
11168890|NCT03598114|No Intervention|Control Condition|"In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training
~The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
11168891|NCT03598101|Experimental|Test group|
11168892|NCT03598088|Other|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya PCT cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
11168893|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
11168894|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
11168895|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
11168896|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
11168897|NCT03598036|Experimental|Voclosporin|"Cohort 1:
~Maximum dose of 3 capsules (7.9mg) BID
~Cohort 2
~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
11168898|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
11168899|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
11168954|NCT03597620|Experimental|Patients with stable dose of biologic treatment & 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
11169024|NCT03597139|Experimental|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twice Daily (BID), both eyes for 28 days
11168900|NCT03598010|Experimental|Lenodiar Pediatric in Acute/Prolonged Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.
~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:
~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;
~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
11168901|NCT03598010|Experimental|Lenodiar Pediatric in Chronic Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.
~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:
~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;
~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
11168902|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
11168903|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
11168904|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
11168905|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases
~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:
~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
11168906|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
11168907|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
11168908|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.
~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.
~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
11168909|NCT03597945|Placebo Comparator|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:
~15 ml of lidocaine with epinephrine (300 mg)
~and 3 ml of normal saline as adjuvant."
11168910|NCT03597945|Active Comparator|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:
~15 ml of lidocaine with epinephrine (300 mg)
~and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
11168911|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
11168912|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
11168913|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
11168914|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
11168915|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
11168916|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
11168917|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
11168918|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
11168919|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
11168920|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
11168921|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
11168922|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
11168923|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
11168924|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
11168925|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
11168926|NCT03597841||Patients with CRKp BSI:Combination therapy|
11168927|NCT03597841||Patients with CRKp BSI: Monotherapy|
11168930|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
11168931|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
11168932|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
11168933|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
11168934|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
11168935|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
11168936|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
11168937|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
11168938|NCT03597776|Experimental|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
11168939|NCT03597776|Placebo Comparator|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
11168940|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
11168941|NCT03597750|Experimental|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:
~Repose® Mattress
~Repose® Cushion
~Repose® Wedge or Foot Protectors
~The frequency of repositioning remains unchanged."
11168942|NCT03597750|No Intervention|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.
~The frequency of repositioning remains unchanged."
11168943|NCT03597737|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app
11168944|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
11168945|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
11168946|NCT03597711|Active Comparator|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
11168947|NCT03597711|Active Comparator|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
11168948|NCT03597711|Active Comparator|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
11168949|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).
~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.
~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
11168950|NCT03597646|Experimental|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
11168951|NCT03597646|Active Comparator|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
11168952|NCT03597646|No Intervention|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
11168953|NCT03597620|Experimental|Patients with plaque psoriasis 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions.
11169022|NCT03597152|Experimental|Treatment|WelTract
11169023|NCT03597152|Placebo Comparator|Control|Inert Placebo
11168955|NCT03597620|Experimental|Patients with Scalp Psoriasis|For the subgroup for scalp psoriasis, patient will use the shampoo Head & Shoulders formula with 1% Pyrithione Zinc as the active ingredient
11168956|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
11168957|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
11168958|NCT03597607|No Intervention|Usual care group|The usual care group will be given a package of independent resources that could aid them to quit smoking on their own. They will not receive intervention by a clinic pharmacist.
11168959|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System
~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD
~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0
~Regimen 2 - RAG1, RAG2 (Haplocompatible)
~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0
~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)
~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
11168960|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:
~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0
~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.
~Phase II:
~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.
~Cells for infusion are prepared using the CliniMACS System."
11168961|NCT03597581|Experimental|Single agent RGX-202-01|RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
11168962|NCT03597581|Experimental|RGX-202-01 in combination with FOLFIRI|"RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle."
11168963|NCT03597581|Experimental|RGX-202-01 in combination with FOLFIRI plus bevacizumab|"RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle.
~Bevacizumab is administered as follows: 5 mg/kg on Days 1 and 15 of each 28-day cycle."
11168964|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening
11168965|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
11168966|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.
~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.
~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
11168967|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
11168968|NCT03597542|Experimental|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
11168969|NCT03597542|Experimental|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
11168970|NCT03597529|Experimental|melatonin 2mg (equal to or over 40kg)|melatonin 2mg (equal to or over 40kg)
11168971|NCT03597529|Experimental|melatonin 8mg (equal to or over 40kg)|melatonin 8mg (equal to or over 40kg)
11168972|NCT03597529|Experimental|melatonin 1mg (under 40kg)|melatonin 1mg (under 40kg)
11168973|NCT03597529|Experimental|melatonin 4mg (under 40kg)|melatonin 4mg (under 40kg)
11168974|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
11168975|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
11168976|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects will be treated with flexible dose of SPN-810
11168977|NCT03597503|Placebo Comparator|Placebo|Subjects will be treated with Placebo
11168978|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
11168979|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
11168980|NCT03597477||Control|Patients with no developmental diagnoses
11168981|NCT03597464|Experimental|Voclosporin|Voclosporin
11168982|NCT03597464|Placebo Comparator|Placebo Oral Capsule|Placebo
11168983|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
11168984|NCT03597451||Control|Healthy individuals of similar age and sex to patients
11168985|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
11168986|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
11168987|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
11168988|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
11168989|NCT03597386||All Participants|
11168990|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
11168991|NCT03597373||not reintubation|Favourable respiratory function
11168992|NCT03597360|Experimental|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
11168993|NCT03597347|Experimental|Inhaled molgramostim|Molgramostim nebulizer solution (300 µg/dose) administered once daily for 48 weeks utilizing the PARI eFlow nebulizer system
11168994|NCT03597334||critical ill patients|critical ill patients who admit to ICU
11168995|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
11168996|NCT03597321|No Intervention|Arm B- No intervention|
11168997|NCT03597308|Active Comparator|Opioid Group|
11168998|NCT03597308|Active Comparator|NSAID group|
11168999|NCT03597308|Active Comparator|Acetaminophen|
11169000|NCT03597295|Experimental|INCMGA00012|
11169001|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
11169002|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
11169003|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
11169004|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
11169005|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
11169006|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
11169007|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
11169008|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
11169009|NCT03597256|No Intervention|Control Group|No treatment
11169010|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
11169011|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
11169012|NCT03597230|Experimental|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
11169013|NCT03597217|Experimental|Cohort A_Active|3 single doses treatment of PF-05221304
11169014|NCT03597217|Experimental|Cohort B_Active|Repeated doses of PF-05221304
11169015|NCT03597217|Placebo Comparator|Cohort B_Placebo|Repeated doses of placebo
11169016|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
11169017|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.
~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
11169018|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
11169019|NCT03597178|Experimental|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
11169020|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
11169021|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
11169025|NCT03597139|Active Comparator|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
11169026|NCT03597126|Active Comparator|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
11169027|NCT03597126|Active Comparator|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
11169028|NCT03597100|Experimental|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
11169029|NCT03597087|Experimental|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
11169030|NCT03597087|Experimental|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
11169031|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
11169032|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
11169033|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
11169034|NCT03597061|Experimental|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
11169035|NCT03597061|No Intervention|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
11169036|NCT03597048|Experimental|Curriculum|Participants received only the curriculum intervention
11169037|NCT03597048|Active Comparator|Contact|Participants received only the contact intervention
11169038|NCT03597048|Active Comparator|Materials|Participants received only the materials intervention
11169039|NCT03597048|Experimental|Curriculum and Contact|Participants received both curriculum and contact interventions
11169040|NCT03597048|Experimental|Curriculum and Materials|Participants received curriculum and materials interventions
11169041|NCT03597048|Active Comparator|Contact and Materials|Participants received contact and materials intervention
11169042|NCT03597048|Active Comparator|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
11169043|NCT03597048|No Intervention|No intervention|Participants received no intervention
11169044|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
11169045|NCT03597022|Experimental|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
11169046|NCT03597022|Experimental|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
11169047|NCT03597022|Experimental|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
11169048|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
11169049|NCT03596996|Experimental|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
11169050|NCT03596996|Placebo Comparator|Placebo|
11169051|NCT03596983|Experimental|Short Sleep Patients|
11169052|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
11169053|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
11169054|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
11169055|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
11169056|NCT03596944||Statin|History of statin use for primary prevention
11169057|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
11169058|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
11169059|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
11169060|NCT03596918|Experimental|Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11169061|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
11169062|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
11169063|NCT03596905|Experimental|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
11169064|NCT03596905|Experimental|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
11169065|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
11169066|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11169067|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11169068|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
11169069|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
11169174|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
11169070|NCT03596866|Experimental|Brigatinib|Brigatinib 90 milligram (mg), tablets, orally, once daily 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
11169071|NCT03596866|Active Comparator|Alectinib|Alectinib 600 mg, capsules, orally twice daily until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.
11169072|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
11169073|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
11169074|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
11169075|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
11169076|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
11169077|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
11169078|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
11169079|NCT03596801|Experimental|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
11169080|NCT03596801|Experimental|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
11169081|NCT03596801|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
11169082|NCT03596801|Experimental|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
11169083|NCT03596801|Experimental|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
11169084|NCT03596801|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
11169085|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
11169086|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
11169087|NCT03596775|Experimental|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
11169088|NCT03596775|Placebo Comparator|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
11169089|NCT03596762|Experimental|160 mg BAY3427080|
11169090|NCT03596762|Experimental|120 mg BAY3427080|
11169091|NCT03596762|Experimental|80 mg BAY3427080|
11169092|NCT03596762|Experimental|40 mg BAY3427080|
11169093|NCT03596762|Placebo Comparator|Placebo|
11169094|NCT03596749|Experimental|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
11169095|NCT03596749|No Intervention|Control|blank-control
11169096|NCT03596736|Experimental|Elbow Hemiarthroplasty|
11169097|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
11169098|NCT03596723|Experimental|KPI-121 1% BID (twice daily)|
11169099|NCT03596723|Active Comparator|Prednisolone acetate QID (four times daily)|
11169100|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
11169101|NCT03596697|Experimental|CRV431|Either single or multiple doses of varying dose levels
11169102|NCT03596697|Placebo Comparator|Placebo|
11169103|NCT03596697|Experimental|TDF|300 mg TDF
11169104|NCT03596684|Experimental|citrulline|citrulline 5g/d
11169105|NCT03596684|Placebo Comparator|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
11169106|NCT03596671|Experimental|Treatment arm|RENOVA iStim™ System implanted patients
11169107|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
11169108|NCT03596645|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
11169269|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
11169109|NCT03596645|Experimental|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
11169110|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
11169111|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
11169112|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
11169113|NCT03596606|Experimental|Myofunctional Motor Control Exercises|"Both groups will be treated with Osteopathic treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.
~The patient will receive five sessions, one session every week."
11169114|NCT03596606|Active Comparator|Osteopathic Treatment|The control group will receive only osteopathic treatment (TO). The patient will receive five sessions, one session every week.
11169115|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
11169116|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
11169117|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
11169118|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
11169119|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
11169120|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
11169121|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
11169122|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
11169123|NCT03596528|Other|Lung biopsy|Lung biopsy
11169124|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
11169125|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
11169126|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
11169127|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
11169128|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
11169129|NCT03596463||Group A|Patients treated according to suggestions of tumor board
11169130|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
11169131|NCT03596450|Experimental|Semaglutide|Participants will receive semaglutide in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
11169132|NCT03596450|Active Comparator|Standard of care|Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
11169133|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
11169134|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
11169135|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
11169136|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
11169137|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
11169138|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
11169139|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.
~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
11169140|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
11169305|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
11169141|NCT03596372|Experimental|Patients with Solid tumors|Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.
11169142|NCT03596372|Experimental|Patients with Gastric cancer|"Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:
~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
11169143|NCT03596372|Experimental|Patients with Colorectal cancer|"Expansion with patients having colorectal cancer:
~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
11169144|NCT03596372|Experimental|Patients with Non-small-cell-lung cancer|"Expansion with patients having adeno Non-small-cell-lung cancer:
~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
11169145|NCT03596372|Experimental|Low-dose expansion|Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).
11169146|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
11169147|NCT03596359|Active Comparator|Control group|The control group received routine treatment
11169148|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
11169149|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
11169150|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
11169151|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
11169152|NCT03596294|Experimental|Treatment sequence AB|"Period A:
~Saline + clazosentan
~Period B:
~Rifampicin + clazosentan"
11169153|NCT03596294|Experimental|Treatment sequence BA|"Period B:
~Rifampicin + clazosentan
~Period A:
~Saline + clazosentan"
11169154|NCT03596281|Experimental|Cohort A|
11169155|NCT03596281|Experimental|Cohort B|
11169156|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
11169157|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
11169158|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
11169159|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
11169160|NCT03596242|Experimental|High Blood Pressure Monitoring by SMS|Will receive the text message intervention and will be provided with a blood pressure cuff in addition to standard blood pressure control education received at clinic visits
11169161|NCT03596242|Active Comparator|Usual Care Plus Standard Blood Pressure Monitoring|Will receive standard blood pressure care and education, as well as a blood pressure cuff at their clinic visits
11169162|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.
~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
11169163|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.
~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
11169164|NCT03596203|Experimental|Treatment group|
11169165|NCT03596190|Other|Assessment arm|
11169166|NCT03596177|Experimental|MEDI0382|MEDI0382 administered subcutaneously
11169167|NCT03596177|Placebo Comparator|Placebo|Placebo administered subcutaneously
11169168|NCT03596164|Experimental|Teduglutide 0.05 mg|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
11169169|NCT03596151|Experimental|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
11169170|NCT03596125|Experimental|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.
~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
11169171|NCT03596125|Placebo Comparator|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.
~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
11169172|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
11169173|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
11186902|NCT03474783|Experimental|multidisciplinary intervention|
11169175|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
11169176|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.
~Patient can receive second treatment of HSV-tk after 6 months"
11169177|NCT03596073|Experimental|Topical Calcipotriene Ointment|-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
11169178|NCT03596073|Placebo Comparator|Topical Vaseline|-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
11169179|NCT03596060|Active Comparator|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
11169180|NCT03596060|Active Comparator|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
11169181|NCT03596047|Experimental|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
11169182|NCT03596047|Placebo Comparator|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
11169183|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
11169184|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
11169185|NCT03596008|Placebo Comparator|Placebo|Placebo drink
11169186|NCT03595995|Experimental|Cohort 1|"Placebo (volume equivalent to 2.5 mg/kg UB-621)
~2.5 mg/kg UB-621"
11169187|NCT03595995|Experimental|Cohort 2|"Placebo (volume equivalent to 5 mg/kg UB-621)
~5 mg/kg UB-621"
11169188|NCT03595982|Experimental|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
11169189|NCT03595982|Active Comparator|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
11169190|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
11169191|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
11169192|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
11169193|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
11169194|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
11169195|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
11169196|NCT03595917|Experimental|ABL001, Dasatinib, Prednisone|"- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)
~Dasatinib-Fixed doses oral once a day per cycle
~ABL001 is administered orally daily per cycle
~Prednisone-Fixed doses oral once a day per cycle. --- Prednisone will be tapered and stop during cycle 2."
11169197|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
11169198|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
11169199|NCT03595891||Adult with acute PE before the introduction of apixaban|
11169200|NCT03595891||Adult with acute PE after the introduction of apixaban|
11169201|NCT03595878|Active Comparator|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
11169202|NCT03595878|Experimental|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
11169203|NCT03595878|No Intervention|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
11169204|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
11169205|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
11169206|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
11169207|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
11169208|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
11169209|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
11169210|NCT03595826|Experimental|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
11188785|NCT03462290|Experimental|Botulinum toxin|
11169211|NCT03595826|Experimental|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
11169212|NCT03595826|Experimental|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
11169213|NCT03595826|Experimental|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
11169214|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
11169215|NCT03595800|Experimental|haploidentical related donors|
11169216|NCT03595800|Active Comparator|Matched unrelated donor|
11169217|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
11169218|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
11169219|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*
~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
11169220|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate
~Other names:Beet It Sport Nitrate 400"
11169221|NCT03595748|Experimental|Peer mentorship intervention|This arm of mentees will be assigned to weekly telephone calls with a matched mentor over a period of 3 months.
11169222|NCT03595748|No Intervention|Usual Care|This arm of mentees will not get a telephone intervention by an assigned mentee
11169223|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
11169224|NCT03595722|Experimental|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
11169225|NCT03595722|Experimental|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
11169226|NCT03595709|Experimental|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
11169227|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
11169228|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
11169229|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
11169230|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
11169231|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist
~standardized questionnaires and interview will be performed"
11169232|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
11169233|NCT03595644|Experimental|SBRT+TKI|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
11169234|NCT03595644|Active Comparator|TKI|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
11169235|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
11169236|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
11169237|NCT03595618|Experimental|GLPG1972 Dose A|A daily dose of 1 film-coated tablet of GLPG1972 for oral use.
11169238|NCT03595618|Experimental|GLPG1972 Dose B|A daily dose of 2 film-coated tablets of GLPG1972 for oral use.
11169239|NCT03595618|Experimental|GLPG1972 Dose C|A daily dose of 4 film-coated tablets of GLPG1972 for oral use.
11169240|NCT03595618|Placebo Comparator|Placebo|A daily dose of film-coated tablets for oral use.
11169241|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
11169242|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
11169270|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
11169271|NCT03595410||Recurrence laryngeal cancer|
11169272|NCT03595410||No recurrence laryngeal cancer|
11169273|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
11169243|NCT03595592|Active Comparator|HPCT|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin and paclitaxel as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8. Paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 12 additional cycles as adjuvant therapy.
11169244|NCT03595592|Experimental|ACy followed by HPCT and atezolizumab|Patients will receive a combination of doxorubicin (A, 60 mg/m2 i.v.), cyclophosphamide (C, 600 mg/m2 i.v.) and atezolizumab (1200 mg i.v.) on day 1 every 3 week for 3 cycles. Subsequently they will be given trastuzumab on day 1 (H, at the loading dose of 8 mg/kg i.v. then 6 mg/kg i.v.), pertuzumab on day 1 (P, at the loading dose of 840 mg .v., then 420 mg i.v.), carboplatin (C) at AUC 2 i.v. on day 1 and day 8, paclitaxel (T) at 90 mg/m2 i.v. on day 1 and day 8, and atezolizumab 1200 mg i.v. on day 1 for 3 cycles every 3 weeks. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 15 additional cycles and atezolizumab for 12 additional cycles as adjuvant therapy.
11169245|NCT03595592|Experimental|HPCT and atezolizumab|Patients will receive a combination of trastuzumab, pertuzumab, carboplatin, paclitaxel and atezolizumab as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8; paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8; atezolizumab at the dose of 1200 mg i.v. on day 1. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab, pertuzumab and atezolizumab will then be delivered for 12 additional cycles as adjuvant therapy.
11169246|NCT03595579|Experimental|AXS-05|
11169247|NCT03595579|Active Comparator|Bupropion|
11169248|NCT03595566|Experimental|ridinilazole|
11169249|NCT03595566|Active Comparator|vancomycin|
11169250|NCT03595553|Experimental|ridinilazole|
11169251|NCT03595553|Active Comparator|vancomycin|
11169252|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
11169253|NCT03595527|Experimental|Patients consulting in the emergency room|Patients consulting in the emergency room.
11169254|NCT03595514|Active Comparator|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
11169255|NCT03595514|Experimental|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
11169256|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
11169257|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
11169258|NCT03595488|Experimental|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.
~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
11169259|NCT03595475||Psychiatric RBD cases|"Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);
~The onset of mental symptoms preceded the onset of RBD:
~Onset of RBD symptom was younger than 50 years old (as most patients with pRBD tended to be younger at mid-40s with an earlier age onset than typical iRBD)."
11169260|NCT03595475||Psychiatric cases|"Age- and sex- matched with pRBD proband;
~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);
~Free of narcolepsy and other neurological diseases;
~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG;
~Free of neurodegenerative diseases."
11169261|NCT03595475||Age- & sex-matched health control|"Age- and sex- matched with pRBD proband;
~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);
~Free of narcolepsy and other neurological diseases;
~Absence of any RBD features as based on RBDQ-HK and v-PSG;
~Free of neurodegenerative diseases."
11169262|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
11169263|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
11169264|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
11169265|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
11169266|NCT03595436|Experimental|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to ~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
11169267|NCT03595436|Placebo Comparator|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
11169268|NCT03595436|Active Comparator|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
11169274|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
11169275|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
11169276|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Participants taking part in a 24 week soccer program as part of diabetes prevention.
11169277|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
11169278|NCT03595358|Experimental|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test
~Upper respiratory tract samples from participants will be tested with:
~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
11169279|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
11169280|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
11169281|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
11169282|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
11169283|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
11169284|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
11169285|NCT03595319|Experimental|Elder patients|Older than 65
11169286|NCT03595306|Experimental|Prebiotic A|
11169287|NCT03595306|Experimental|Prebiotic B|
11169288|NCT03595306|Experimental|Prebiotic C|
11169289|NCT03595293|Experimental|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
11169290|NCT03595293|Sham Comparator|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
11169291|NCT03595293|Experimental|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
11169292|NCT03595293|Sham Comparator|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
11169293|NCT03595280|No Intervention|Control|Participants in the control group receive no study messages
11169294|NCT03595280|Experimental|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
11169295|NCT03595280|Experimental|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
11169296|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
11169297|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
11169298|NCT03595254|No Intervention|Waitlist Control|Wait 8 weeks before receiving program access
11169299|NCT03595241|Experimental|Group A - active treatment|
11169300|NCT03595241|No Intervention|Group B - conservative management|
11169301|NCT03595228|Experimental|BN-Brachyury plus radiation|MVA-BN-Brachyury then treatment of the tumor(s) with radiation followed by FPV-Brachyury
11169302|NCT03595215|Experimental|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
11169303|NCT03595202|Other|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
11169304|NCT03595202|Other|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
11170298|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
11169306|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
11169307|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
11169308|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
11169309|NCT03595176|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
11169310|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
11169311|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
11169312|NCT03595150|Active Comparator|Diclofenac|100 mg Diclofenac rectally prior to the ERCP
11169313|NCT03595150|No Intervention|No prophylaxis|No prophylaxis
11169314|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
11169315|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
11169316|NCT03595124|Experimental|Arm A (axitinib, nivolumab)|Patients receive axitinib PO BID on days 1-28 and nivolumab intravenously (IV) over 30 minutes, or per institutional guidelines, on days 1 and 15 (if < 18 years old) or on day 1 (if >= 18 years old). Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
11169317|NCT03595124|Experimental|Arm B (axitinib)|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AS OF 1/23/2020 - PROSPECTIVE PATIENTS ARE RANDOMLY ASSIGNED TO ARMS A OR C)
11169318|NCT03595124|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes, or per institutional guidelines, on days 1 and 15 (if < 18 years old) or on day 1 (if >= 18 years old). Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
11169319|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
11169320|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
11169321|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
11169322|NCT03595085|Experimental|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
11169323|NCT03595085|Active Comparator|systemic thrombolysis|Those patients will receive systemic streptokinase
11169324|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
11169325|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
11169326|NCT03595059|Experimental|Escalation 1a: ABBV-155|Participants will be administered ABBV-155 (various doses).
11169327|NCT03595059|Experimental|Escalation 1b: ABBV-155 + paclitaxel or docetaxel|Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .
11169328|NCT03595059|Experimental|Expansion 2a: ABBV-155 in SCLC|Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
11169329|NCT03595059|Experimental|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
11169330|NCT03595059|Experimental|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
11169331|NCT03595046|Experimental|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
11169332|NCT03595046|Active Comparator|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
11169333|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
11169334|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
11169335|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
11169336|NCT03595007||Phase 1|
11169337|NCT03595007||Phase 2|
11169338|NCT03595007||Phase 3|
11169339|NCT03594994|No Intervention|Control|Normal sleep habits < 6h
11169340|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed to 8 hours
11169341|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
11169393|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
11169394|NCT03594604|Experimental|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
11188786|NCT03462290|Placebo Comparator|placebo|
11169342|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:
~oligomenorrhea and/or anovulation
~Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
11169343|NCT03594968||healthy|healthy patients who had no polycystic ovary
11169344|NCT03594955|Experimental|SAR440234|SAR440234 as weekly intravenous injection; a cycle is defined as 6 weeks of study treatment; (Additionally infusion on day 4 is planned for dose level ≥ 3). One dose escalation scheme will be used. Treatment may be continued as long as it is clinically beneficial.
11169345|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
11169346|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
11169347|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
11169348|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
11169349|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
11169350|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations
~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
11169351|NCT03594890|Experimental|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.
~3 Dose levels tested: 30µg, 90 µg and 180 µg."
11169352|NCT03594890|Placebo Comparator|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
11169353|NCT03594890|Experimental|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.
~3 Dose levels tested: 30µg, 90 µg and 180 µg."
11169354|NCT03594890|Placebo Comparator|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
11169355|NCT03594877|Experimental|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
11169356|NCT03594877|No Intervention|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
11169357|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
11169358|NCT03594851|Experimental|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :
~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living
~& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
11169359|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
11169360|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
11169361|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
11169362|NCT03594825|Experimental|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
11169363|NCT03594825|Active Comparator|daytime group|patients with nocturnal hypertension taking valsartan at daytime
11169364|NCT03594812|Experimental|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
11169365|NCT03594812|Placebo Comparator|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
11169366|NCT03594799|Experimental|Bed Rest Control Group|60 days of strict head-down tilt bed rest
11169367|NCT03594799|Experimental|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
11169368|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
11169479|NCT03594006|Other|Cancer patients on active therapy|
11169369|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
11169370|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
11169371|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
11169372|NCT03594747|Experimental|Tislelizumab combined with carboplatin and paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
11169373|NCT03594747|Experimental|Tislelizumab combined with carboplatin and nab-paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Nab-paclitaxel 100 mg/m2, D1, D8, and D15 of each cycle, administered as an IV infusion over 30 minutes, for 4 to 6 cycles
11169374|NCT03594747|Active Comparator|Carboplatin and paclitaxel|Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
11169375|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
11169376|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
11169377|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
11169378|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
11169379|NCT03594708|Placebo Comparator|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
11169380|NCT03594708|Active Comparator|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
11169381|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
11169382|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
11169383|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
11169384|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
11169385|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).
~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
11169386|NCT03594656|Experimental|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
11169387|NCT03594656|Placebo Comparator|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
11169388|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
11169389|NCT03594643||control|patient not smoking nor using electronic cigarette
11169390|NCT03594630|Active Comparator|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
11169391|NCT03594630|Experimental|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
11169392|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
11169395|NCT03594604|Active Comparator|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
11169396|NCT03594578|Experimental|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
11169397|NCT03594578|Sham Comparator|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
11169398|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.
~Dosage: 2 puffs."
11169399|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
11169400|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
11169401|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
11169402|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
11169403|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
11169404|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
11169405|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
11169406|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
11169407|NCT03594526|Experimental|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:
~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.
~Four Educational sessions and support sessions for maternal empowerment in each home visit.
~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
11169408|NCT03594526|Active Comparator|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
11169409|NCT03594513|Active Comparator|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
11169410|NCT03594513|Experimental|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
11169411|NCT03594500|Experimental|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
11169412|NCT03594500|Other|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
11169413|NCT03594487|Experimental|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.
~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
11169414|NCT03594487|Active Comparator|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.
~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
11169415|NCT03594474|No Intervention|control group|Begins treatment with 0.5 g/kg per day of 20% Intravenous Lipid Emulsion (IVLE) after birth if the birth weight is less or equal 1000g or 1 g/kg per day if birth weight is more than 1000g. The IVLE dose in this group will be increased by 0.5 g/kg per day daily until reaching 3 g/kg per day.
11169416|NCT03594474|Experimental|experimental group|"The experimental group will begin treatment with 2 g/kg per day of 20% Intravenous Lipid Emulsion after birth.
~The dose of IVLE will be increased directly from 2 to 3 g/kg per day the next day in this group."
11169417|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
11169418|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
11169419|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
11169420|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
11169421|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
11169422|NCT03594422|Experimental|HQP1351 30mg|30 mg QOD
11169423|NCT03594422|Experimental|HQP1351 40mg|40 mg QOD
11169424|NCT03594422|Experimental|HQP1351 50mg|50 mg QOD
11169425|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.
~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.
~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
11169426|NCT03594370||control|Limbal image by OCT in normal subjects.
11169427|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
11169428|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
11169429|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
11169430|NCT03594357||Control|Healthy individuals without chronic disease
11169431|NCT03594344|Experimental|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
11169432|NCT03594344|No Intervention|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
11169433|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
11169434|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
11169435|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
11169436|NCT03594305|Experimental|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
11169437|NCT03594305|No Intervention|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
11169438|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
11169439|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
11169440|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
11169480|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
11169481|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
11169573|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
11169441|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
11169442|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
11169443|NCT03594266|Experimental|Therapy A Spinal Cord Stimulation Parameter Set|
11169444|NCT03594266|Experimental|Therapy B Spinal Cord Stimulation Parameter Set|
11169445|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
11169446|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
11169447|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
11169448|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
11169449|NCT03594227|Active Comparator|400mg BID (Low dose)|ATI-501 low dose - oral administration
11169450|NCT03594227|Active Comparator|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
11169451|NCT03594227|Active Comparator|800mg BID (High dose)|ATI-501 high dose - oral administration
11169452|NCT03594227|Placebo Comparator|Placebo|Placebo - oral administration
11169453|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
11169454|NCT03594201||group1|A+B grade sperm count after treatment=0
11169455|NCT03594201||group2|0<A+B grade sperm count after treatment≤10^6
11169456|NCT03594201||group3|10^6<A+B grade sperm count after treatment<2*10^6
11169457|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
11169458|NCT03594188|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
11169459|NCT03594188|Active Comparator|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
11169460|NCT03594175|Experimental|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants will receive the first dose at minute (min) 0, and the second dose, if needed, at min 90.
11169461|NCT03594175|Placebo Comparator|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
11169462|NCT03594175|Active Comparator|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
11169463|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
11169464|NCT03594149|No Intervention|control|No levofloxacin will be given.
11169465|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
11169466|NCT03594123|Experimental|Brexpiprazole Arm 1|Oral tablet; taken once daily. Total daily dose of 2 mg/day
11169467|NCT03594123|Experimental|Brexpiprazole Arm 2|Oral tablet; taken once daily. Total daily dose of 3 mg/day
11169468|NCT03594110|Experimental|Empagliflozin|
11169469|NCT03594110|Placebo Comparator|Placebo|
11169470|NCT03594097|Experimental|Treatment cookies|
11169471|NCT03594097|Active Comparator|Control cookies|
11169472|NCT03594058|Experimental|Solabegron modified release tablets low dose|
11169473|NCT03594058|Experimental|Solabegron modified release tablets high dose|
11169474|NCT03594058|Placebo Comparator|Placebo Comparator|
11169475|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
11169476|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
11169477|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
11169478|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
11169482|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
11169483|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
11169484|NCT03593954|Experimental|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
11169485|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents >65y No interventions as this is a pilot project
11169486|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents >65y No interventions as this is a pilot project
11169487|NCT03593941||Older adults without dementia|Care home residents >65y No interventions as this is a pilot project
11169488|NCT03593915|Experimental|Ph 1b and 2: MDS|"Patients with previously untreated MDS
~Patients with MDS who have received <6 cycles of HMAs (during dose escalation only)
~Patients with de novo (cause unknown) or secondary MDS (treatment-related) who are not eligible for intensive induction chemotherapy or stem cell transplant
~All French-American-British (FAB) subtypes
~Intermediate and above per IPSS-R groups"
11169489|NCT03593902|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
11169490|NCT03593889|Experimental|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
11169491|NCT03593889|Other|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
11169492|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
11169493|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
11169494|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
11169495|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
11169496|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
11169497|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
11169498|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
11169499|NCT03593824|Experimental|dense cataract group|
11169500|NCT03593824|Experimental|non-dense nuclear cataract group|
11169501|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
11169502|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
11169503|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
11169504|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
11169505|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 8mg disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine (0.04-0.62 mg/kg/day).
11169506|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
11169507|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
11169508|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
11169509|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
11169510|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
11169511|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
11169512|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
11169513|NCT03593759|Active Comparator|Prednisone|Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg)
11169514|NCT03593759|Experimental|Methotrexate|Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid 2 mg po daily for 6 months.
11169515|NCT03593746|Experimental|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
11169516|NCT03593746|Sham Comparator|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
11169517|NCT03593746|Experimental|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
11169518|NCT03593746|Sham Comparator|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
11169519|NCT03593733|Experimental|Cold Water Immersion|Cold Water Immersion
11169520|NCT03593733|Experimental|Photobiomodulation Therapy|Photobiomodulation Therapy
11169521|NCT03593720||Hypospadias|Patients with hypospadias
11169522|NCT03593720||Control|Patients without hypospadias
11169523|NCT03593707|Experimental|Metformin Alone|Metformin alone
11169524|NCT03593707|Experimental|Metformin + PF-06865571|Co-administer metformin and PF-06865571
11169525|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
11169526|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
11169527|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
11169528|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
11169529|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
11169530|NCT03593655|Experimental|Sequence A: Dapivirine vaginal ring + FTC/TDF|Participants will receive one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
11169531|NCT03593655|Experimental|Sequence B: FTC/TDF + Dapivirine vaginal ring|Participants will receive one FTC/TDF oral tablet taken by mouth daily for 24 weeks, followed by one 25 mg dapivirine vaginal ring inserted vaginally each month for 24 weeks, followed by participant's choice of either or neither study product for 24 weeks.
11169532|NCT03593642|Placebo Comparator|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
11169533|NCT03593642|Experimental|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
11169534|NCT03593629|No Intervention|Standard of Care|Participants receive standard of care for PrEP, including 3-months of PrEP supply and HIV testing at clinic every three months
11169535|NCT03593629|Experimental|Blood-based HIV self-testing|Participants receive 6-months of PrEP supply and blood-based HIV self-tests for quarterly HIV testing.
11169536|NCT03593629|Experimental|Oral fluid HIV self-testing|Participants receive 6-months of PrEP supply and oral fluid HIV self-tests for quarterly HIV testing.
11169537|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
11169538|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
11169539|NCT03593590||Ocrelizumab|Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
11170299|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
11169540|NCT03593564|Experimental|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
11169541|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
11169542|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
11169543|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
11169544|NCT03593538|Placebo Comparator|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
11169545|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
11169546|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
11169547|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
11169548|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
11169549|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
11169550|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
11169551|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
11169552|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
11169553|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
11169554|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
11169555|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
11169556|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
11169557|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
11169558|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
11169559|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
11169560|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
11169561|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
11169562|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
11169563|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
11169564|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
11169565|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
11169566|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
11169567|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
11169568|NCT03593408||Pediatric Patients on ECMO Support|
11169569|NCT03593395|Active Comparator|Arm 1-A|Small sized Program Structured Education Based Transition Program [STE]
11169570|NCT03593395|Experimental|Arm 1-B|Small sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
11169571|NCT03593395|Active Comparator|Arm 2-A|Large sized program Structured Education Based Transition Program [STE]
11169572|NCT03593395|Experimental|2-B|Large sized program Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
11188996|NCT03460977|Experimental|DL 6|PF-06821497 625 mg BID
11169574|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
11169575|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
11169576|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
11169577|NCT03593356|Experimental|Monthly cash gift payments of $333|These subjects receive $333 each month for 40 months via debit card.
11169578|NCT03593356|Active Comparator|Monthly cash gift payments of $20|These subjects receive $20 each month for 40 months via debit card.
11169579|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
11169580|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
11169581|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
11169582|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
11169583|NCT03593317|Experimental|Ramipril group|
11169584|NCT03593317|Placebo Comparator|Placebo group|
11169585|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
11169586|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
11169587|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
11169588|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
11169589|NCT03593252|Experimental|Combination bowel prep|Patients will received mechanical bowel preparation (age appropriate dose, starting 2 days before surgery) and prophylactic oral antibiotics (3 doses, 1 day before surgery). The standard care will also be delivered (NPO for anesthesia and intravenous antibiotics on induction) Patients/parents will be provided with stool diary to document the adequacy of preparation. This will include frequency and character of stool according to Bristol grade.
11169590|NCT03593252|Active Comparator|Oral antibiotics|The patients will receive prophylactic oral antibiotics (3 doses, 1 day before surgery)as well as standard care (NPO for anesthesia and intravenous antibiotics on induction).
11169591|NCT03593252|Placebo Comparator|No prep|Patients will receive no pre-operative bowel prep. The will receive the standard care only.
11169592|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
11169593|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
11169594|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
11169595|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
11169596|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
11169597|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
11169598|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
11169599|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
11169600|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
11169601|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
11169602|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
11169603|NCT03593213|Experimental|Cariprazine 3.0 mg/day|Cariprazine capsules, oral administration, once daily.
11169604|NCT03593213|Experimental|Cariprazine 4.5 mg/day|Cariprazine capsules, oral administration, once daily.
11169605|NCT03593213|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
11169606|NCT03593200|Experimental|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364*
11169607|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
11169608|NCT03593174|Experimental|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
11169609|NCT03593174|Active Comparator|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
11169610|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
11169611|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
11169612|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
11169645|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
11189110|NCT03460054||Membranous Nephropathy (MGN)|Biopsy-Proven MGN
11169613|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
11169614|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
11169615|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
11169616|NCT03593109|Experimental|LCAR-L10D treatment group|In LCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 4 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 5.0×10^6 CAR-T cells/kg.
11169617|NCT03593096|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
11169618|NCT03593096|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11169619|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
11169620|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11169621|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
11169622|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
11169623|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, one every 15 days.
11169624|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
11169625|NCT03593044|Experimental|One Week Atropine|0.01% concentration atropine drops
11169626|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
11169627|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
11169628|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
11169629|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
11169630|NCT03593018|Experimental|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
11169631|NCT03593018|Active Comparator|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
11169632|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
11169633|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
11169634|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
11169635|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
11169636|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11169637|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
11169638|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
11169639|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
11169640|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
11169641|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
11169642|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
11169643|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
11169644|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11169646|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
11169647|NCT03592888|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
11169648|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
11169649|NCT03592862|Experimental|HTL0018318 high dose|oral capsule, once daily
11169650|NCT03592862|Experimental|HTL0018318 mid dose|oral capsule, once daily
11169651|NCT03592862|Experimental|HTL0018318 low dose|oral capsule, once daily
11169652|NCT03592862|Placebo Comparator|Placebo|oral capsule, once daily
11169653|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
11169654|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
11169655|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
11169656|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
11169657|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
11169658|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
11169659|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
11169660|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
11169661|NCT03592784|Experimental|Food Order Therapy + Medical Nutrition Therapy|
11169662|NCT03592784|Active Comparator|Medical Nutrition Therapy Alone|
11169663|NCT03592771|No Intervention|Usual Care|Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication.
11169664|NCT03592771|Active Comparator|App|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.
~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
11169665|NCT03592771|Active Comparator|App+Feedback|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.
~In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase.
~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
11169666|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
11169667|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
11169668|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
11169669|NCT03592732||A|Patients with atrial fibrillation
11169670|NCT03592732||B|Patients without atrial fibrillation
11169671|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
11169672|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
11169673|NCT03592706|Experimental|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
11169674|NCT03592706|Active Comparator|TACE|TACE (Transcatheter Arterial Chemoembolization)
11169675|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
11169676|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
11169677|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
11169678|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
11169679|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
11169680|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
11169681|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
11169682|NCT03592641|Experimental|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11169683|NCT03592628|Placebo Comparator|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
11169684|NCT03592628|Experimental|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
11170300|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
11169685|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
11169686|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
11169687|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
11169688|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
11169689|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
11169690|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions
~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
11169691|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:
~family history (first degree relative) one or more neurological and/or psychiatric conditions;
~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.
~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
11169692|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.
~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
11169693|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
11169694|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
11169695|NCT03592537|Active Comparator|fentanyl|Group F: will receive intrathecal 0.5% bupivacaine 0.2-0.4 mg/kg) + 0.2 mic/kg of fentanyl intrathecally
11169696|NCT03592537|Active Comparator|midazolam|Group M: will receive intrathecal 0.5% bupivacaine 0.2-0.4 mg/kg) + 0.5 mg of midazolam intrathecally
11169697|NCT03592537|Placebo Comparator|Bupivacaine|Group B:intrathecal 0.5% bupivacaine 0.2-0.4 mg/kg)
11169698|NCT03592511|Experimental|Intervention|WGPF-burger group
11169699|NCT03592511|Placebo Comparator|Control|Control-burger group
11169700|NCT03592498|Active Comparator|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
11169701|NCT03592498|Experimental|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
11169702|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
11169703|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
11169704|NCT03592472|Experimental|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
11169705|NCT03592472|Placebo Comparator|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
11169706|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
11169707|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
11169708|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
11169709|NCT03592433|Experimental|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
11169710|NCT03592433|No Intervention|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
11169711|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions
~On-site supervised group exercise program (11 weeks)
~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)
~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards
~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.
~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
11169712|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
11169913|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
11170301|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
11169713|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
11169714|NCT03592394|Active Comparator|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
11169715|NCT03592394|Active Comparator|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
11169716|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
11169717|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
11169718|NCT03592368|Active Comparator|Active IBT, Out of MRI|
11169719|NCT03592368|Sham Comparator|Sham IBT, Out of MRI|
11169720|NCT03592368|Active Comparator|Active IBT, In MRI|
11169721|NCT03592368|Sham Comparator|Sham IBT, In MRI|
11169722|NCT03592355|Experimental|Intervention|"If enrolled in the intervention arm, the following steps will occur:
~The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.
~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
11169723|NCT03592355|No Intervention|Control|"If enrolled in the control arm, the following steps will occur:
~Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.
~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
11169724|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
11169725|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
11169726|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
11169727|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
11169728|NCT03592329|Experimental|active tVNS + SRT A|active tVNS and Stress Reduction Training A
11169729|NCT03592329|Experimental|active tVNS + SRT B|active tVNS and Stress Reduction Training B
11169730|NCT03592329|Other|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
11169731|NCT03592329|Other|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
11169732|NCT03592316|Experimental|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
11169733|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
11169734|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
11169735|NCT03592277|Experimental|Intervention Arm|Patients in this arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
11169736|NCT03592277|No Intervention|Control Arm|Patients in the control arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
11169737|NCT03592264|Experimental|Dose escalation phase|OBI-3424 (1.0 mg/m^2 to 14.0 mg/m^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle or Day 1 of each 21-day cycle to determine the MTD and RP2D with a classic 3+3 dose escalation design.
11169738|NCT03592264|Experimental|Cohort expansion phase|Once the MTD and RP2D is determined then OBI-3424 (dosage TBD) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
11169739|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
11169740|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
11169741|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
11169742|NCT03592238|Experimental|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
11169743|NCT03592238|Active Comparator|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
11169744|NCT03592238|Placebo Comparator|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
11169745|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
11169746|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
11169747|NCT03592199|Experimental|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
11169748|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
11169749|NCT03592186|Active Comparator|Treatment as Usual|The active comparator is defined as residential treatment services as usual.
11169750|NCT03592173|Experimental|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
11169751|NCT03592173|Active Comparator|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
11169752|NCT03592173|Active Comparator|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
11169753|NCT03592160|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
11169754|NCT03592160|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
11169755|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
11169756|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
11169757|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
11169758|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
11169759|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
11169760|NCT03592108|Experimental|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
11169761|NCT03592095|Experimental|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
11169762|NCT03592095|Placebo Comparator|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
11169763|NCT03592082|Active Comparator|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
11169764|NCT03592082|Experimental|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
11169765|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:
~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
11169766|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:
~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
11169767|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
11169768|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
11169769|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
11169770|NCT03592004||Guangdong General Hospital|
11169771|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
11169772|NCT03592004||Beijing Friendship Hospital|
11169773|NCT03592004||Yunnan Cancer Hospital|
11169774|NCT03592004||Liaoning Cancer Hospital|
11169775|NCT03592004||The First Hospital Of China Medical University|
11169776|NCT03592004||Affiliated Hospital Of Hebei University|
11169777|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
11169914|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
11169778|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
11169779|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
11169780|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
11169781|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
11169782|NCT03591965|Experimental|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
11169783|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
11169784|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
11169785|NCT03591939||1|cases of Diabetic type two nephropathy
11169786|NCT03591939||2|controls of normal subjects
11169787|NCT03591926|Experimental|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
11169788|NCT03591926|Experimental|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
11169789|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
11169790|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
11169791|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:
~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).
~B-Therapeutic intervention:
~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
11169792|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:
~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et
~B-Therapeutic intervention:
~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
11169793|NCT03591887|Experimental|ABY-035 2 mg|2 mg ABY-035 SC
11169794|NCT03591887|Experimental|ABY-035 20 mg|20 mg ABY-035 SC
11169795|NCT03591887|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
11169796|NCT03591887|Experimental|ABY-035 160 mg|160 mg ABY-035 SC
11169797|NCT03591887|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
11169798|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
11169799|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
11169800|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)
~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months
~Laboratory studies prior to hospital admission and then at each follow-up visit
~Hospital admission (3-5 day) to start the ketogenic diet
~Standard of care chemotherapy with BCNU for up to 2 years
~Ketogenic diet can continue for up to 2 years"
11169801|NCT03591848|Experimental|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
11169802|NCT03591848|Active Comparator|IRIS|Exposed to a standard oral information
11169803|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
11169804|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
11169805|NCT03591822|Other|Arm AB : Intervention under study x Control intervention|Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
11169806|NCT03591822|Other|Arm BA: Control intervention x Intervention under study|Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
11169807|NCT03591809|Experimental|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
11169808|NCT03591809|No Intervention|Control group|The patients in the control group will not apply an exercise training.
11169809|NCT03591796|Experimental|HFOV|Ventilated infants were randomized to HFOV.
11169810|NCT03591796|Active Comparator|CMV|Ventilated infants were randomized to CMV.
11169811|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
11169812|NCT03591770|Experimental|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
11169915|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
11169813|NCT03591770|Active Comparator|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
11169814|NCT03591770|Active Comparator|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
11169815|NCT03591770|Active Comparator|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
11169816|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
11169817|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
11169818|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
11169819|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
11169820|NCT03591718|Experimental|BI 456906|
11169821|NCT03591718|Experimental|Placebo|
11169822|NCT03591705|Experimental|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
11169823|NCT03591705|Active Comparator|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
11169824|NCT03591692|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
11169825|NCT03591692|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
11169826|NCT03591679|Experimental|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
11169827|NCT03591679|Active Comparator|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
11169828|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11169829|NCT03591653|Experimental|LXI-15028 50mg group|
11169830|NCT03591653|Placebo Comparator|Placebo group|
11169831|NCT03591640|Active Comparator|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
11169832|NCT03591640|Active Comparator|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
11169833|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
11169834|NCT03591614|Experimental|Dendritic cell DKK1 vaccine|5-10x106 DKK1 loaded dendritic cells. Three doses will be given two weeks apart, followed by 11 months of observations.
11169835|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
11169836|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
11169837|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
11169838|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
11169839|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
11169840|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
11169841|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
11169842|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
11169843|NCT03591549|Experimental|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
11169844|NCT03591536|Other|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
11169845|NCT03591536|Placebo Comparator|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
11169846|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
11169847|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|Midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing Fludarabine, cytarabine, daunorubicin/daunorubicin liposomal(idarubicin ) and consolidation (Block 3: cytarabine+ mitoxantrone, Block 4:cytarabine + etoposide, Block 5:Cytarabine) chemotherapy followed by single agent midostaurin post-consolidation therapy
11170144|NCT03589430||3 child C|child C liver cirrhosis
11170302|NCT03588208|Experimental|Intervention Group|
11169848|NCT03591497|Experimental|Intervention Group|"Instrument to be used:
~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.
~Programme schedule:
~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
11169849|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
11169850|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
11169851|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
11169852|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
11169853|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
11169854|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.
~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
11169855|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.
~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
11169856|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
11169857|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
11169858|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
11169859|NCT03591432|Experimental|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
11169860|NCT03591432|Active Comparator|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
11169861|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
11169862|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
11169863|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
11169864|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
11169865|NCT03591393|Experimental|Pregnant women|"questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum
~pelvic floor ultrasound at 1st trimester and at 3rd trimester"
11169866|NCT03591380|Experimental|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
11169867|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
11169868|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 3 months.
~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)
~Objective 2: This arm is participants who had 6 months of SAP in the primary trial (DCLP3 Pivotal Trial)
~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
11169869|NCT03591354|Active Comparator|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ & Dexcom G6 CGM for 3 months.
~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)
~Objective 2: This arm is not applicable to objective 2
~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
11169870|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
11169871|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
11169872|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
11169873|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
11169874|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
11169875|NCT03591302|Experimental|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
11169876|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
11169877|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
11169878|NCT03591276|Experimental|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.
~Reduced Dose Cohort (R1)*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.
~*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
11169879|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
11169880|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
11169881|NCT03591224|Active Comparator|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
11169882|NCT03591224|Placebo Comparator|Control|Pharmacist optimizing antidepressant therapy based on standard of care
11169883|NCT03591211|Experimental|Qigong Training|
11169884|NCT03591211|Active Comparator|Cognitive Training|
11169885|NCT03591198|Experimental|Qigong Training|
11169886|NCT03591198|Active Comparator|Cognitive Training|
11169887|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
11169888|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
11169889|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
11169890|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
11169891|NCT03591159|Active Comparator|Membrane Sweeping Group|
11169892|NCT03591159|No Intervention|Control Group|
11169893|NCT03591146|Experimental|TLC590|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
11169894|NCT03591146|Active Comparator|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
11169895|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
11169896|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
11169897|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
11169898|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
11169899|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
11169900|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
11169901|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
11169902|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
11169903|NCT03591094|Active Comparator|PTI-428 dose level 1|
11169904|NCT03591094|Active Comparator|PTI-428 dose level 2|
11169905|NCT03591094|Placebo Comparator|Placebo PTI-428|
11169906|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
11169907|NCT03591068|Experimental|OPN-375 186 mcg BID|
11169908|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
11169909|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
11169910|NCT03591042|Experimental|cervical length screening|cervical length screening
11169911|NCT03591042|No Intervention|no screening|no screening
11169912|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
11169916|NCT03590964|Active Comparator|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
11169917|NCT03590964|Experimental|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
11169918|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
11169919|NCT03590912|No Intervention|Wait and watch (Group D)|Wait and watch for 1 month
11169920|NCT03590912|Experimental|Mometasone spray (Group B)|Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given
11169921|NCT03590912|Experimental|antibiotic + histaminic + oxymetazoline drops (Group A)|This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given
11169922|NCT03590912|Experimental|Oral steroid (Group C)|Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week
11169923|NCT03590899||Healthy patients|
11169924|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
11169925|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
11169926|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
11169927|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.
~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
11169928|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
11169929|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
11169930|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
11169931|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
11169932|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
11169933|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
11169934|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
11169935|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
11169936|NCT03590834|Active Comparator|Active Control|Active comparison group
11169937|NCT03590821|Experimental|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
11169938|NCT03590821|Experimental|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
11169939|NCT03590808|Experimental|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients
~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
11169940|NCT03590808|Active Comparator|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy
~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
11169941|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
11169942|NCT03590769|Experimental|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
11169943|NCT03590756|Experimental|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
11169944|NCT03590756|Other|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
11169945|NCT03590743|Active Comparator|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
11169946|NCT03590743|Placebo Comparator|Placebo|Patients will receive matching placebo.
11169947|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
11169948|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
11169949|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
11169950|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
11169951|NCT03590704|Experimental|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
11170168|NCT03589196|Active Comparator|Photoselective Vaporization|
11169952|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
11169953|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.
~PLUS
~Three selected enhancements integrated into routine clinical care:
~expanded community health worker services;
~home blood pressure self-monitoring; and
~a storytelling intervention."
11169954|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
11169955|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
11169956|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
11169957|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
11169958|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
11169959|NCT03590626|Experimental|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
11169960|NCT03590626|No Intervention|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
11169961|NCT03590613|Experimental|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
11169962|NCT03590613|Experimental|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
11169963|NCT03590613|Experimental|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
11169964|NCT03590613|Experimental|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
11169965|NCT03590600|Experimental|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
11169966|NCT03590600|Placebo Comparator|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
11169967|NCT03590600|Experimental|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
11169968|NCT03590600|Placebo Comparator|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
11169969|NCT03590600|Experimental|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
11169970|NCT03590600|Placebo Comparator|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
11169971|NCT03590600|Experimental|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
11169972|NCT03590600|Placebo Comparator|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
11169973|NCT03590600|Experimental|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
11169974|NCT03590600|Placebo Comparator|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
11169975|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
11169976|NCT03590574|Experimental|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
11169977|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
11169978|NCT03590561|No Intervention|Control diet|Participants will eat regular diet.
11169979|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
11169980|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
11169981|NCT03590522||Group I:|Thirty heart failure patients
11169982|NCT03590522||Group II:|Twenty healthy controls
11169983|NCT03590509|Experimental|Telemedicine Program*|"Integrated Telemedicine-Home Visitation* Program.
~*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
11169984|NCT03590509|Active Comparator|Control|Usual Comprehensive Care
11169985|NCT03590496|Active Comparator|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
11169986|NCT03590496|Placebo Comparator|Arm 2|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
11169987|NCT03590470|Experimental|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
11169988|NCT03590470|No Intervention|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
11169989|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
11169990|NCT03590444|Active Comparator|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).
~Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
11169991|NCT03590444|Active Comparator|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).
~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
11169992|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
11169993|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
11169994|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
11169995|NCT03590418||Intestinal stoma output|No interventions.
11169996|NCT03590418||Colonic feaces|No interventions.
11169997|NCT03590418||Healthy Control|No interventions.
11169998|NCT03590405|Experimental|uterus transplantation|uterus transplantation from living donor with the donor being close relative
11169999|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
11170000|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
11170001|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
11170002|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
11170003|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
11170004|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
11170005|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle
~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
11170006|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle
~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
11170007|NCT03590353|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.
~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;
~Patients with acute myocardial infarction (AMI) and AVB:
~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
11170008|NCT03590353|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
11170009|NCT03590340|Experimental|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 113.
~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
11170010|NCT03590340|Experimental|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
11170011|NCT03590340|Experimental|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
11170012|NCT03590340|Experimental|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
11170013|NCT03590340|Placebo Comparator|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
11170014|NCT03590340|Placebo Comparator|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
11170015|NCT03590340|Placebo Comparator|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
11170016|NCT03590340|Placebo Comparator|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.
~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
11170017|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
11170018|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
11170019|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
11170020|NCT03590314|Experimental|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
11170021|NCT03590314|Active Comparator|Control group|The control group was treated using a conventional training, without end effector robot.
11170022|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
11170023|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
11170024|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
11170025|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
11170026|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
11170027|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
11170028|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
11170029|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
11170030|NCT03590236|No Intervention|Control group|Waiting list patients
11170031|NCT03590210|Experimental|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
11170032|NCT03590210|Experimental|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
11170033|NCT03590197|Placebo Comparator|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
11170034|NCT03590197|Experimental|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
11170035|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
11170036|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
11170037|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
11170038|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
11170039|NCT03590158|Experimental|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
11170040|NCT03590145||Qatari athletes|Participants meeting general criteria and included from site 1 in Doha, Qatar.
11170041|NCT03590145||Irish athletes|Participants meeting general criteria and included from site 2 in Dublin, Ireland.
11170042|NCT03590132|Experimental|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
11170043|NCT03590132|Experimental|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
11170044|NCT03590132|Experimental|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
11170045|NCT03590132|No Intervention|Control|These participants receive no interventions.
11170169|NCT03589196|Active Comparator|Plasma Kinetic Vaporization|
11170170|NCT03589196|Active Comparator|Transurethral Resection Of The Prostate|
11170046|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
11170047|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
11170048|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:
~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.
~Demonstrate negative drug screens done randomly during their hospitalization.
~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).
~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.
~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
11170049|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
11170050|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
11170051|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
11170052|NCT03590067||Heamodialysis group|
11170053|NCT03590067||Kidney transplantation group|
11170054|NCT03590054|Experimental|Treatment (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days 1-21 and pembrolizumab IV on over 30 minutes day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11170055|NCT03590041|Active Comparator|Standardized SMA|The standardized SMA model includes the same TTIM curriculum as in the patient-driven model, but it is delivered in a standardized way (order of and time spent on topics are set) across all participating practices.
11170056|NCT03590041|Active Comparator|Patient-driven SMA|In the patient-driven SMA model, patients receive the same TTIM curriculum, but patients at each practice are able to set the order of the curriculum and dictate how long to spend on each topic.
11170057|NCT03590028|Experimental|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
11170058|NCT03590028|Active Comparator|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
11170059|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
11170060|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
11170061|NCT03590002|Experimental|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
11170062|NCT03590002|No Intervention|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
11170063|NCT03589989|Experimental|Intervention group|
11170064|NCT03589989|Active Comparator|Control group|
11170065|NCT03589976|Experimental|Sirolimus|2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).
11170066|NCT03589976|Placebo Comparator|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
11170067|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
11170068|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
11170069|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
11170070|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
11170071|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
11170072|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
11170073|NCT03589898|Experimental|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
11170074|NCT03589885|Placebo Comparator|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
11170075|NCT03589885|Placebo Comparator|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 * 1 ml prefilled syringe form
11170076|NCT03589885|Experimental|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
11170077|NCT03589885|Active Comparator|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
11170078|NCT03589872||Study Group|patients with parkinson disease
11170079|NCT03589859||Normal Volunteers|Testing motor learning
11170080|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
11170081|NCT03589846|Experimental|Muscle stimulation|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) and the Grass S88 muscle stimulator.
11170082|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
11170083|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
11170084|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
11170085|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
11170086|NCT03589820|Active Comparator|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
11170087|NCT03589820|No Intervention|Control group|30 patients will receive treatment of internal medicine.
11170088|NCT03589807|Experimental|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
11170089|NCT03589807|Experimental|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
11170090|NCT03589807|Experimental|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
11170091|NCT03589807|Experimental|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
11170092|NCT03589807|Experimental|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
11170093|NCT03589807|Experimental|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
11170094|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
11170095|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
11170096|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
11170097|NCT03589794|Experimental|Group 4|10 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
11170098|NCT03589794|Experimental|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
11170099|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
11170100|NCT03589781|Experimental|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
11170101|NCT03589781|Placebo Comparator|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
11170102|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).
~N=133"
11170103|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.
~N=67"
11170104|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
11170105|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
11170106|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
11170107|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
11170108|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
11170109|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
11170110|NCT03589703|Active Comparator|APA|Patients with active points related to cLBP. Will receive acupressure within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain.
11170111|NCT03589703|Sham Comparator|Comparison Group (CG-1)|"The same procedure for APA will be applied but the tapes/seeds will be placed on five different ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.
~These points are chosen for the sham APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group."
11170112|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|Participants in the enhanced educational control group will be given the cLBP educational booklet and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA groups.
11170113|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
11170114|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
11170115|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:
~quality of life evaluation
~exam of neuroimaging
~study of myomiRNAs before and after rehabilitation"
11170116|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
11170117|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
11170118|NCT03589651|Experimental|Group A|INCMGA00012 with epacadostat.
11170119|NCT03589651|Experimental|Group B|INCMGA00012 with INCB050465.
11170120|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
11170121|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
11170122|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
11170123|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
11170124|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
11170125|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
11170126|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
11170127|NCT03589586|Experimental|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
11170128|NCT03589586|No Intervention|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
11170129|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
11170130|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
11170131|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).
~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors
~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
11170132|NCT03589534|Other|pregnancy test|pregnancy tests
11170133|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
11170134|NCT03589508|Experimental|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
11170135|NCT03589508|Experimental|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
11170136|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
11170137|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
11170138|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
11170139|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
11170140|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
11170141|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
11170142|NCT03589430||1 child A|child A liver cirrhosis
11170143|NCT03589430||2 child B|child B liver cirrhosis
11170145|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
11170146|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
11170147|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
11170148|NCT03589378|Experimental|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
11170149|NCT03589378|No Intervention|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
11170150|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
11170151|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
11170152|NCT03589339|Experimental|NBTXR3 activated by SABR|
11170153|NCT03589326|Experimental|Cohort A: Ponatinib 30 milligram (mg)|Ponatinib 30 mg, tablets, orally, once daily (QD), along with vincristine 1.4 mg/m^2 (maximum [max] 2 mg) intravenous(IV), on Days 1 and 14 and dexamethasone 40 mg(<60 years [yrs]) and 20 mg (>=60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 in 28-day cycle for up to 3 cycles in induction phase followed by ponatinib last dose of induction phase tablets, orally, QD, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour IV infusion (<=60 yrs) and 250 mg/m^2 every 12 hours (>60 yrs), IV on Days 1, 3, and 5 of 28-day even cycles(Cycles 2, 4, and 6) and methotrexate, 1000 mg/m^2 (<=60 yrs) and 250 mg/m^2 (>60 yrs), IV infusion, on Day 1 of 28-day odd cycles(Cycle 1, 3, and 5) in consolidation phase followed by ponatinib last dose of consolidation phase, tablets, orally, QD, along with vincristine 1.4 mg/m^2,(max 2 mg) IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (>=60-69 yrs) and 50 mg(>=70 yrs) on Days 1 to 5 in 28-day cycle for up to 11 cycles in maintenance phase.
11170154|NCT03589326|Active Comparator|Cohort B: Imatinib 600 mg|Imatinib 600 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2 (max 2 mg) IV, on Days 1 and 14 and dexamethasone 40 mg (<60 yrs) and 20 mg (>=60 yrs), orally, once on Days 1 through 4 and Days 11 through 14 in each 28-day cycle for up to 3 cycles in induction phase followed by imatinib 600 mg, tablets, orally, once daily, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (<=60 yrs) and 250 mg/m^2 every 12 hours (>60 yrs), IV on Days 1, 3, and 5 of each 28-day even cycles (Cycles 2, 4, and 6) and methotrexate, 1000 mg/m^2 (<=60 yrs) and 250 mg/m^2 (>60 yrs), IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1, 3, and 5) in consolidation phase followed by imatinib 600 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2, (max 2 mg) IV, on Day 1 and prednisone 200 mg (<60 yrs), 100 mg (>=60-69 yrs) and 50 mg (>=70 yrs) on Days 1 through 5 in each 28-day cycle for up to 11 cycles in maintenance phase.
11170155|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
11170156|NCT03589300|Other|Persona TM Tibia subjects|Subjects that receive the Persona TM Tibia implant
11170157|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
11170158|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
11170159|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
11170160|NCT03589274|Experimental|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
11170161|NCT03589274|Experimental|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
11170162|NCT03589261|Other|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
11170163|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
11170164|NCT03589248||US score|assess the AGI by ultrasonography(US) score
11170165|NCT03589235|Experimental|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
11170166|NCT03589235|Experimental|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
11170167|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
11170171|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
11170172|NCT03589157|Experimental|Drug-coated balloon group|
11170173|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
11170174|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
11170175|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.
~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
11170176|NCT03589118|Experimental|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
11170177|NCT03589118|No Intervention|Control|Usual well defined medical and psychological support
11170178|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
11170179|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.
~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
11170180|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).
~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
11170181|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
11170182|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
11170183|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
11170184|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
11170185|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
11170186|NCT03589040|Other|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
11170187|NCT03589040|Other|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
11170188|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
11170189|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
11170190|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
11170191|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
11170192|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
11170193|NCT03588988|Experimental|Dexmedetomidine group|
11170194|NCT03588988|Placebo Comparator|Control group|
11170195|NCT03588975|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
11170196|NCT03588975|Active Comparator|microfracture|surgical procedure
11170197|NCT03588962|Experimental|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
11170198|NCT03588962|Placebo Comparator|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
11170199|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
11170200|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
11170201|NCT03588936|Experimental|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).
~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
11170303|NCT03588208|Active Comparator|Control Group|
11170304|NCT03588195|Experimental|Education Group|
11170202|NCT03588936|Experimental|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).
~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
11170203|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
11170204|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
11170205|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
11170206|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
11170207|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
11170208|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
11170209|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
11170210|NCT03588884|Active Comparator|CTAP101|CTAP101/Calcifediol Capsules 60 mcg once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
11170211|NCT03588884|Experimental|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 mcg capsule before breakfast on the mornings of Day 1 and Day 29
11170212|NCT03588884|Experimental|Cholecalciferol|Cholecalciferol/Capsules 300,000 IU (high-dose) before breakfast on the mornings of Day 1 and Day 29
11170213|NCT03588884|Active Comparator|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and 29 when dosing will occur before breakfast
11170214|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
11170215|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
11170216|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
11170217|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.
~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
11170218|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
11170219|NCT03588819|Experimental|2-fraction SABR|
11170220|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
11170221|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
11170222|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
11170223|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
11170224|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
11170225|NCT03588741|Experimental|Turoctocog alfa|
11170226|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
11170227|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
11170228|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
11170229|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
11170230|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
11170231|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
11170232|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
11170233|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
11170234|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.
~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
11170235|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
11170236|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
11170237|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
11170238|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
11170239|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
11170240|NCT03588650|Experimental|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
11170241|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
11170242|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
11170243|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
11170244|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
11170245|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
11170246|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
11170247|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
11170248|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
11170249|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
11170250|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
11170251|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
11170252|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
11170253|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)
~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks
~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
11170254|NCT03588520|Experimental|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
11170255|NCT03588520|No Intervention|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
11170256|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
11170257|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
11170258|NCT03588494|Active Comparator|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
11170259|NCT03588494|Experimental|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
11170296|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
11170305|NCT03588195|Active Comparator|Control Group|
11190585|NCT03449589||Non smokers|Non smoking RA patients
11170260|NCT03588494|Experimental|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
11170261|NCT03588481||Coronary stenosis|
11170262|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
11170263|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.
~Electrophysiological biomarkers and MRI biomarkers will be performed"
11170264|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.
~Electrophysiological biomarkers and MRI biomarkers will be performed"
11170265|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
11170266|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
11170267|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
11170268|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
11170269|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
11170270|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
11170271|NCT03588390|Experimental|Dose Group 1|
11170272|NCT03588390|Experimental|Dose Group 2|
11170273|NCT03588390|Experimental|Dose Group 3|
11170274|NCT03588390|Experimental|Dose Group 4|
11170275|NCT03588390|Experimental|Dose Group 5|
11170276|NCT03588390|Experimental|Dose Group 6|
11170277|NCT03588390|Experimental|Dose Group 7|
11170278|NCT03588390|Experimental|Dose Group 8|
11170279|NCT03588377|Active Comparator|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
11170280|NCT03588377|No Intervention|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
11170281|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
11170282|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
11170283|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
11170284|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
11170285|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
11170286|NCT03588338|Active Comparator|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
11170287|NCT03588338|Other|Control|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
11170288|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
11170289|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
11170290|NCT03588299|Experimental|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
11170291|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).
~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.
~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
11170292|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
11170293|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
11170294|NCT03588260||Idiopathic pulmonary fibrosis|The patients who have agreed to participate in the study from patients diagnosed with idiopathic pulmonary fibrosis referred to the center of pulmonary rehabilitation from the interstitial lung disease polyclinic.
11170295|NCT03588260||Healthy subjects|The healthy adults without additional disease
11170297|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
11170306|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
11170307|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
11170308|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
11170309|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
11170310|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
11170311|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
11170312|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
11170313|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
11170314|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
11170315|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
11170316|NCT03588130|Active Comparator|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
11170317|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
11170318|NCT03588104|Experimental|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
11170319|NCT03588104|Active Comparator|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
11170320|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
11170321|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
11170322|NCT03588078|Experimental|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
11170323|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
11170324|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.
~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
11170325|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
11170326|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin
~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
11170327|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
11190945|NCT03447093||Incipient group|30 untreated GD patients
11170328|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170329|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170330|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170331|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170332|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170333|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170334|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170335|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170336|NCT03588039|Experimental|Dose expansion-Urothelial cancer|The dose expansion period will enroll subjects with advanced/metastatic urothelial to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
11170337|NCT03588026|Experimental|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
11170338|NCT03588026|Experimental|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
11170339|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
11170340|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
11170341|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
11170342|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
11170343|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
11170344|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
11170345|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
11170346|NCT03587987|Active Comparator|Neopuff|neopuff
11170347|NCT03587987|Experimental|r PAP|rPap device
11170348|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
11170349|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
11170350|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
11170351|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
11170352|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
11170353|NCT03587948||Case group|Children and adolescents with diabetes mellitus
11170354|NCT03587948||Control group|Children and adolescents without diabetes mellitus
11170355|NCT03587922|Experimental|Treatment Arm|Single arm study with treatment of Fantom scaffold
11170356|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
11170357|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
11170358|NCT03587896|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
11170359|NCT03587896|No Intervention|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
11170360|NCT03587883|Experimental|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
11170361|NCT03587883|Placebo Comparator|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
11170362|NCT03587870|Experimental|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
11170363|NCT03587870|Active Comparator|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
11170364|NCT03587857|Experimental|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
11170365|NCT03587844|Experimental|not been previously treated with brentuximab vedotin.|Patients with MF/SS who have not been previously treated with brentuximab vedotin. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study.
11170366|NCT03587844|Experimental|treated with reduced dose brentuximab vedotin|Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. If neither dose is found promising, cohort 2 will not start. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study.
11170367|NCT03587844|Experimental|Patients with LyP|Patients with LyP patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1. Treatment may be held if felt to be in patient's best interest (for example: for toxicity or no active disease). Treatment can be reinitiated after discussion with MSK PI as long as the study is still open and patient has not received alternate systemic therapy.
11170368|NCT03587831|Experimental|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.
~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
11170369|NCT03587831|Active Comparator|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
11170370|NCT03587818|No Intervention|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.
~Communication between patients and professionals during consultations occurred according to conventional care practice."
11170371|NCT03587818|Experimental|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:
~generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility
~arena of dialogues between patient and professionals; voicing concerns, share perspectives
~for the patient to personally reflect on generic information.
~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:
~professionals guiding the patient through the care process
~communicating an introduction, agenda and closing
~being sensitive to the patient's questions, beliefs, experiences and resources
~dialogue based on story, posing open-ended questions, and following up."
11170372|NCT03587805|Experimental|Tralokinumab, all subjects|"Week 0: subcutaneous (SC) injection of tralokinumab loading dose.
~From Week 2 up to Week 140*: SC injection of tralokinumab maintenance dose.
~* The length of treatment for each subject will depend on when they enter the trial."
11170373|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
11170374|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
11170375|NCT03587766|Experimental|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
11170376|NCT03587766|Experimental|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
11170409|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
11170410|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
11170377|NCT03587766|Experimental|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
11170378|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
11170379|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
11170380|NCT03587740|Experimental|T-DM1|T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
11170381|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
11170382|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
11170383|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
11170384|NCT03587675|Other|EVH in high-school elite athletes|EVH-test, skin prick test, sputum induction in all subjects Interventional but no drug or device tested
11170385|NCT03587662|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Patients receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ixazomib PO and gemcitabine IV over 90 minutes. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
11170386|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
11170387|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
11170388|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
11170389|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date
~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
11170390|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date
~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
11170391|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
11170392|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
11170393|NCT03587584|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
11170394|NCT03587584|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
11170395|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
11170396|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
11170397|NCT03587558|Experimental|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
11170398|NCT03587558|Active Comparator|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
11170399|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
11170400|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
11170401|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.
~Placebo nasal spray."
11170402|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
11170403|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
11170404|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
11170405|NCT03587532|Experimental|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
11170406|NCT03587519|Experimental|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
11170407|NCT03587519|Active Comparator|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
11170408|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
11170411|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
11170412|NCT03587493|Experimental|EXPERIMENTAL GROUP|"110 adults, on national waiting list for a first lung transplantation in the centers of Marseille and Strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets T lymphocytes will be included.
~Blood sample analysis will be performed"
11170413|NCT03587480|Other|TME+LLND group|Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
11170414|NCT03587480|Other|TME+nCRT group|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
11170415|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~smooth and soft stool like sausage or snake
~Voluntary participate in this study"
11170416|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
11170417|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
11170418|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female
~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
11170419|NCT03587441|Active Comparator|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
11170420|NCT03587441|Placebo Comparator|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
11170421|NCT03587428|Experimental|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
11170422|NCT03587428|Experimental|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
11170423|NCT03587428|Other|Mineral Water|In this arm, participants received mineral water.
11170424|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
11170425|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
11170426|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
11170427|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
11170428|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.
~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.
~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
11170429|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
11170430|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
11170431|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
11170432|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
11170433|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
11170434|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
11170435|NCT03587350|Active Comparator|Interventional Treatment|
11170436|NCT03587350|No Intervention|Usual care|
11170437|NCT03587337||Prophylaxis|
11170438|NCT03587337||Antibiotic tp|
11170439|NCT03587324|Experimental|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
11170440|NCT03587311|Experimental|GROUP I (anetumab ravtansine, bevacizumab)|Patients receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11170441|NCT03587311|Experimental|GROUP II (paclitaxel, bevacizumab)|Patients receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11170442|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
11170443|NCT03587298||Group 2|Control group: matched age; no NAFKL
11170444|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
11170445|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
11170446|NCT03587272|Experimental|SUN regimen|"Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
~HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, SUN) can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD)."
11170447|NCT03587259|Active Comparator|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
11170448|NCT03587259|Experimental|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
11170449|NCT03587246||Pregnant women|
11170450|NCT03587246||non-pregnant women|
11170451|NCT03587233|Active Comparator|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
11170452|NCT03587233|Active Comparator|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
11170453|NCT03587233|Active Comparator|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
11170454|NCT03587233|Active Comparator|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.
~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
11170455|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
11170456|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
11170457|NCT03587207|Experimental|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
11170458|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
11170459|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
11170460|NCT03587207|Active Comparator|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
11170461|NCT03587207|Active Comparator|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
11170462|NCT03587194|Experimental|Otezla|Otezla BID
11170463|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
11170464|NCT03587168||Healthy Controls|Healthy People
11170465|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
11170466|NCT03587155||Control|Embryo or infant without ASNS mutation.
11170467|NCT03587142|Active Comparator|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
11170468|NCT03587142|Placebo Comparator|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
11170469|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
11170470|NCT03587116|Other|Standard of Care FIX replacement therapy|
11170471|NCT03587116|Other|Standard of Care FVIII replacement therapy|
11170472|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
11170473|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
11170474|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
11170475|NCT03587077|Experimental|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
11170476|NCT03587077|Placebo Comparator|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
11170477|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
11170478|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
11170479|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
11170480|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
11170481|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
11170482|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
11170483|NCT03587025|Active Comparator|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
11170484|NCT03587025|Placebo Comparator|Placebo|Patients who will be take placebo 30min before surgery.
11170485|NCT03587012|Experimental|Exercising|Practicing with the brain exercises
11170486|NCT03586999|Experimental|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
11170487|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
11170488|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
11170489|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
11170490|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state. Participants who have received first/second line anticancer therapy with sorafenib before this study will be assigned to Cohort A.
11170491|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Cabozantinib 60 mg, tablet orally, once daily in the fasted state. Participants who have not received first/second line anticancer therapy with sorafenib before this study will be assigned to Cohort B..
11170492|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
11170493|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
11170494|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
11170495|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
11170496|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.
~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
11170523|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
11190946|NCT03447093||Hashimoto's thyroiditis group|30 HT patients
11170497|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
11170498|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
11170499|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
11170500|NCT03586895|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
11170501|NCT03586882|Experimental|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
11170502|NCT03586882|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
11170503|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
11170504|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
11170505|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
11170506|NCT03586843|Experimental|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
11170507|NCT03586843|Experimental|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
11170508|NCT03586843|Experimental|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
11170509|NCT03586843|Experimental|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
11170510|NCT03586843|Experimental|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
11170511|NCT03586843|Experimental|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
11170512|NCT03586843|Experimental|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
11170513|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
11170514|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
11170515|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
11170516|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
11170517|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
11170518|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
11170519|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
11170520|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
11170521|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
11170522|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
11170524|NCT03586778|Experimental|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
11170525|NCT03586778|Active Comparator|MTEX|manual therapy and therapeutic exercise
11170526|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
11170527|NCT03586752|Experimental|On-line group|On-line program course
11170528|NCT03586752|Active Comparator|Standard group|Standard program course
11170529|NCT03586739|Experimental|"Covered stents strategy"|
11170530|NCT03586739|Active Comparator|"Bare metal stents strategy"|
11170531|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
11170532|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
11170533|NCT03586700|Experimental|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
11170534|NCT03586700|Placebo Comparator|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
11170535|NCT03586687|Active Comparator|20 mg|20mg Triamcinolone with 3cc of 1% Lidocaine
11170536|NCT03586687|Active Comparator|40 mg|40mg Triamcinolone with 3cc of 1% Lidocaine
11170537|NCT03586687|Active Comparator|80 mg|80mg Triamcinolone with 3cc of 1% Lidocaine
11170538|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
11170539|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
11170540|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11170541|NCT03586648|Experimental|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
11170542|NCT03586648|Experimental|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
11170543|NCT03586635||Patients with Multiple Sclerosis|
11170544|NCT03586622|Experimental|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
11170545|NCT03586622|Experimental|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
11170546|NCT03586609|Experimental|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
11170547|NCT03586596|Experimental|The Decídetext program|Participants will receive a tablet-based interactive educational session, 6 months of text-messaging based counseling, which includes prompts to access free pharmacotherapy.
11170548|NCT03586596|Active Comparator|Standard Care Control|Participants will receive an adapted version of standard printed smoking cessation educational materials from the American Cancer Society and, the National Cancer Institute, which include information about the health risks of smoking, benefits & strategies for quitting and access to free pharmacotherapy by calling a free number.
11170549|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
11170550|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
11170551|NCT03586570|Experimental|Aprocitentan|
11170552|NCT03586570|Placebo Comparator|Placebo|
11170553|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
11170554|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
11170555|NCT03586544|Experimental|Experimental|Children will complete an exercise induced bronchoconstriction test preceded by: 1) pretreatment with 'Albuterol' 2) interval warm-up exercise and 3) Control
11170588|NCT03586284|Placebo Comparator|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
11170589|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
11170556|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.
~Inclusion:
~Prevalent haemodialysis patient (more than 3 months)
~Active on the supportive care register with anticipated death in the subsequent 12 months
~Able to give informed consent
~Consent to donation of heart for research following death
~Able to understand written and verbal explanations in English
~Exclusion:
~Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)
~Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)
~Unable to give informed consent
~Unable to understand written and verbal explanations in English"
11170557|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.
~The patients switch off the light when the discomfort is too elevated"
11170558|NCT03586492|Other|Patient with myocardial ischemia|
11170559|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
11170560|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
11170561|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
11170562|NCT03586466|Experimental|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
11170563|NCT03586466|Active Comparator|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
11170564|NCT03586466|Active Comparator|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
11170565|NCT03586453|Experimental|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
11170566|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
11170567|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree
~distance between on table and acromion ≥ 2.5 cm"
11170568|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree
~distance between on table and acromion < 2.5 cm"
11170569|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
11170570|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
11170571|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
11170572|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
11170573|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
11170574|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
11170575|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
11170576|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
11170577|NCT03586388|Experimental|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
11170578|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
11170579|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
11170580|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
11170581|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
11170582|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
11170583|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
11170584|NCT03586310|Other|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
11170585|NCT03586310|Other|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.
~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
11170586|NCT03586284|Active Comparator|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
11170587|NCT03586284|Active Comparator|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
11170593|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
11170594|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
11170595|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.
~57FePP (95.8%) 3.49 mg
~Aspergillus oryzae (unenriched) 0.025 mg
~FePP natural abundance 0.685 mg.
~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
11170596|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.
~ASP-p (8% Fe; natural abundance) 3.516 mg
~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg
~4.2 total mg of Fe"
11170597|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .
~Aspergillus oryzae (unenriched) 0.027 mg
~57FeSO4 (95.4%) 3.18 mg
~4.2 total mg of Fe"
11170598|NCT03586232|Placebo Comparator|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
11170599|NCT03586232|Experimental|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
11170600|NCT03586232|Experimental|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
11170601|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
11170602|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
11170603|NCT03586206||Mild-moderate C.difficile infection|
11170604|NCT03586206||severe C.difficile infection|
11170605|NCT03586206||severe complicated/fulminant C.difficile infection|
11170606|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
11170607|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
11170608|NCT03586180||Dr. Clowns|they will perform shows for children and parents
11170609|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
11170610|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
11170611|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
11170612|NCT03586128||HIV serodiscordant couples|
11170613|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
11170614|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
11170615|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
11170616|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
11170617|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
11170618|NCT03586076|Experimental|JHL1922|
11170619|NCT03586076|Active Comparator|Pulmozyme|
11170620|NCT03586050|Experimental|Microwave Ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
11170621|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
11170622|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
11170623|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
11170624|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
11170625|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
11170626|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
11170627|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
11170628|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
11170629|NCT03585998|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
11170630|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
11170631|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
11170632|NCT03585972|Experimental|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
11170633|NCT03585972|No Intervention|Educational materials|Participants receive publicly available educational materials
11170634|NCT03585959|Experimental|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
11170635|NCT03585946||Cyclosporine|
11170636|NCT03585946||Intravenous Immunoglobulin|
11170637|NCT03585946||Etanercept|
11170638|NCT03585946||Steroids|
11170639|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
11170640|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
11170641|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
11170642|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
11170643|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
11170644|NCT03585894|Other|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
11170645|NCT03585894|Active Comparator|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
11170646|NCT03585881|Experimental|window bracket positioning tray|
11170647|NCT03585881|No Intervention|conventional indirect boning tray|
11170648|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
11170649|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
11170650|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
11170651|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
11170652|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
11170653|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
11170654|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
11170655|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
11170656|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
11170657|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
11170658|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
11170659|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 3
11170660|NCT03585803|Other|KMRC011 30μg or Placebo|Cohort 4
11170661|NCT03585803|Other|KMRC011 45μg or Placebo|Cohort 5
11170662|NCT03585803|Other|KMRC011 60μg or Placebo|Cohort 6
11170663|NCT03585803|Other|KMRC011 75μg or Placebo|Cohort 7
11170664|NCT03585790|Other|Multifocal Optics first, then Single Vision Optics|First Intervention (1 week) Second Intervention (1 week)
11170665|NCT03585790|Other|Single Vision Optics first, then Multifocal Optics|First Intervention (1 week) Second Intervention (1 week)
11170666|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
11170667|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
11170668|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
11170669|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
11170670|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
11170671|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
11170672|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
11170673|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
11170674|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
11170675|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
11170676|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
11170677|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
11170678|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
11170679|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, visit 2R: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, visit V3R: missed pill of Norgestrel 75 mcg
11170781|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
11170680|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, visit 2R: missed pill of Norgestrel 75 mcg Treatment period 3, visit V3R: 6 hour delayed intake of the pill of Norgestrel 75 mcg
11170681|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
11170682|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
11170683|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
11170684|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.
~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
11170685|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
11170686|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
11170687|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.
~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
11170688|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
11170689|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
11170690|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
11170691|NCT03585595|Experimental|Intensive treatment group|Systolic BP target <120 mmHg for the intensive treatment group
11170692|NCT03585595|Active Comparator|Standard treatment group|Systolic BP <140 mmHg for the standard treatment group
11170693|NCT03585582||PARDS survivors|"Children <18 years
~diagnosed with PARDS, as defined by PALICC
~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
11170694|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
11170695|NCT03585543|Experimental|Single group intervention arm|
11170696|NCT03585530|Experimental|treatment group|
11170697|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
11170698|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
11170699|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
11170700|NCT03585491|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
11170701|NCT03585491|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
11170702|NCT03585478|Active Comparator|Latiglutenase|IMGX003
11170703|NCT03585478|Placebo Comparator|Placebo|Placebo
11170704|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|First stage
11170705|NCT03585465|Experimental|B: Capecitabine Nivolumab|First stage
11170706|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|First stage
11170707|NCT03585465|Experimental|Metronomic Arm (Second stage)|Arm retained at first stage (A, B or C)
11170708|NCT03585465|Experimental|Metronomic + Nivolumab Arm (Second stage)|Nivolumab + Arm retained at the end of first stage (A, B or C)
11170734|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
11170735|NCT03585231|Active Comparator|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
11170709|NCT03585452||Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
11170710|NCT03585452||Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
11170711|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
11170712|NCT03585426|Experimental|Vancomycin 1g q12h|
11170713|NCT03585426|Experimental|Vancomycin 1g q8h|
11170714|NCT03585413|Active Comparator|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.
~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
11170715|NCT03585413|Placebo Comparator|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.
~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
11170716|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
11170717|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
11170718|NCT03585374|Experimental|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
11170719|NCT03585374|Active Comparator|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.
~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.
~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.
~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .
~Maximum time of infusion 10 minutes."
11170720|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
11170721|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
11170722|NCT03585348||Study cohort|The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
11170723|NCT03585322|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a escalation scheme at the dose escalation phase.
11170724|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
11170725|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
11170726|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
11170727|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
11170728|NCT03585270|Experimental|Clazosentan|Participants will receive clazosentan for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
11170729|NCT03585270|Placebo Comparator|Placebo|Participants will receive clazosentan matching-placebo for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
11170730|NCT03585257|Experimental|IV albumin|25% IV albutein (albumin) formulation will be infused 1.5g/kg IV over one hour weekly for 4 weeks
11170731|NCT03585257|Placebo Comparator|Placebo|Normal saline will be infused 1.5g/kg IV over one hour weekly for 4 weeks
11170732|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
11170733|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
11170736|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
11170737|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
11170738|NCT03585205|Experimental|Stress and cognitive load Induction|Participants will engage in a computerized task which induces cognitive load. Each participant will perform the task once under a stress condition and once under a neutral (non-stress) condition.
11170739|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
11170740|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
11170741|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
11170742|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
11170743|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
11170744|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
11170745|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
11170746|NCT03585153||T1D|Individuals with type 1 diabetes
11170747|NCT03585153||Control|Individuals without type 1 diabetes
11170748|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
11170749|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
11170750|NCT03585140|Active Comparator|Normal Diet|Participants will receive a normal diet according to their metabolic status.
11170751|NCT03585140|Experimental|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
11170752|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
11170753|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
11170754|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
11170755|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
11170756|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
11170757|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
11170758|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure
~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
11170759|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure
~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
~."
11170760|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
11170761|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
11170762|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
11170763|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
11170764|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
11170765|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
11170766|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
11170767|NCT03584984|Experimental|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
11170768|NCT03584984|Active Comparator|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
11170769|NCT03584984|Active Comparator|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
11170770|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
11170771|NCT03584971||control group|random sample of male students
11170772|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
11170773|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
11170774|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
11170775|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
11170776|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
11170777|NCT03584945|Experimental|Obsessive Compulsive Disorder|
11170778|NCT03584945|Other|Subclinical Obsessive-Compulsive symptoms (OCS)|
11170779|NCT03584945|No Intervention|Healthy Control|
11170780|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
11170782|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
11170783|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
11170784|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
11170785|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
11170786|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.
~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
11170787|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.
~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
11170788|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.
~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
11170789|NCT03584893||Epidemiologic observational study cohort|All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
11170790|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
11170791|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
11170792|NCT03584867|Experimental|study Group|refresher CPR
11170793|NCT03584867|No Intervention|control|NO refresher
11170794|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
11170795|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
11170796|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
11170797|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
11170798|NCT03584841|Active Comparator|Healthy volunteers|
11170799|NCT03584828|Experimental|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
11170800|NCT03584828|No Intervention|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
11170801|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:
~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
11170802|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.
~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
11170803|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
11170804|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
11170805|NCT03584789|No Intervention|Standard Practice|
11170806|NCT03584789|Experimental|Clinical Decision Support|
11170807|NCT03584789|Experimental|Clinical Decision Support + Education|
11170808|NCT03584776|Experimental|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
11170809|NCT03584776|No Intervention|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery. This will include 15-30 minutes of movie viewing during research visits.
11170810|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
11170811|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
11170812|NCT03584750|Active Comparator|Intervention group|Floating
11170813|NCT03584750|Placebo Comparator|Control group|Placebo floating
11170814|NCT03584750|No Intervention|No-treatment group|Waiting list
11170853|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
11170815|NCT03584737||Symptomatic for bacterial sinusitis|Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
11170816|NCT03584737||Healthy - no symptoms of sinusitis|Samples from healthy participants showing no symptoms of sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
11170817|NCT03584724|Experimental|Norflo Oro|Box of 30 packets of Norflo Oro. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
11170818|NCT03584724|Placebo Comparator|Placebo for Norflo Oro|Box of 30 packets of Placebo. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
11170819|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours
~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
11170820|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
11170821|NCT03584698|Active Comparator|control group|Misoprostol only group
11170822|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
11170823|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
11170824|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score < 7)
11170825|NCT03584672||Healthy Controls|Healthy people
11170826|NCT03584659|No Intervention|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
11170827|NCT03584659|Experimental|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
11170828|NCT03584646|Experimental|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
11170829|NCT03584646|Experimental|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
11170830|NCT03584633|Other|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with Indocyanine Green Lymphography.
11170831|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
11170832|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
11170833|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
11170834|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
11170835|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
11170836|NCT03584581|Experimental|Olive polyphenols|
11170837|NCT03584581|Placebo Comparator|Control|
11170838|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
11170839|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
11170840|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
11170841|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
11170842|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
11170843|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
11170844|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
11170845|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
11170846|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
11170847|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
11170848|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
11170849|NCT03584516|Experimental|Part 1 : Dose determination of itacitinib|itacitinib administered in combination with corticosteroids.
11170850|NCT03584516|Experimental|Part 1 : Dose expansion of itacitinib|itacitinib administered in combination with corticosteroids or corticosteroids alone.
11170851|NCT03584516|Placebo Comparator|Part 2 : itacitinib recommended dose from part 1|itacitinib or placebo administered in combination with corticosteroids
11170852|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
11170854|NCT03584490|Active Comparator|Pen-and-paper format|Based on randomization, participants in this group will receive traditional pen-and-paper questionnaires about health.
11170855|NCT03584490|Experimental|Computerized Talking Touchscreen|"This group will receive the Computerized Talking Touchscreen intervention.
~Based on randomization, participants in this group will receive a computerized talking touchscreen version of our health questionnaires, which allows the participant to have questions and answer choices read aloud to them by the computer."
11170856|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
11170857|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
11170858|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
11170859|NCT03584464|Other|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
11170860|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
11170861|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
11170862|NCT03584438|Experimental|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
11170863|NCT03584438|Experimental|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
11170864|NCT03584438|Experimental|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
11170865|NCT03584438|Experimental|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
11170866|NCT03584438|Sham Comparator|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
11170867|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
11170868|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
11170869|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
11170870|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
11170871|NCT03584386|Experimental|V-CAMS|"In Phase I (formative), all enrolled participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.
~In Phase II (summative), enrolled patient participants will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days."
11170872|NCT03584386|No Intervention|Care As Usual|In Phase II (summative), enrolled patient participants will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days).
11170873|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).
~Acetaminophen - Oral; patient directed as needed. Not prescribed.
~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
11170874|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).
~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
11170875|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
11170876|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
11170877|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
11170878|NCT03584334|Other|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
11170879|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
11170880|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
11170881|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
11170913|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
11190947|NCT03447080|Other|Control 1|White bread
11170882|NCT03584295|Active Comparator|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
11170883|NCT03584295|Experimental|Extracorporeal carbon dioxide Removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide Removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (20-22Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-2 L/min.
11170884|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
11170885|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
11170886|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
11170887|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
11170888|NCT03584269|Experimental|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
11170889|NCT03584269|Active Comparator|LTOT|standard treatment, without NIV
11170890|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
11170891|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
11170892|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.
~The intervention administrated is a cross-linking with oxygen treatment"
11170893|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.
~Intervention: Assigned to positive group"
11170894|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.
~Intervention: Assigned to negative group"
11170895|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
11170896|NCT03584217|Other|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
11170897|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
11170898|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
11170899|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
11170900|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
11170901|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
11170902|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
11170903|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
11170904|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
11170905|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
11170906|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
11170907|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
11170908|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
11170909|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
11170910|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
11170911|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
11170912|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
11170914|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
11170915|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
11170916|NCT03584061|Experimental|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
11170917|NCT03584048||HIV-1|HIV-1+, males, females, transgender, ≥18 years of age, residing in the Charlotte Metropolitan Area and with at least a single entry in the EHR in the last 2 years.
11170918|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
11170919|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
11170920|NCT03584022|Experimental|Biopsy + Nerve Repair|Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.
11170921|NCT03584022|Sham Comparator|Biopsy Only|Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.
11170922|NCT03584009|Experimental|Venetoclax + Fulvestrant|As of 9th October 2020, Participants in the Venetoclax + Fulvestrant arm, have all discontinued Venetoclax treatment and have continued on Fulvestrant treatment alone. Fulvestrant study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last participant is enrolled) which ever occur first.
11170923|NCT03584009|Active Comparator|Fulvestrant|Participants will receive fulvestrant administered as IM (intramuscular) injections. No crossover to the venetoclax arm is permitted. Study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined end of the study (2 years after the last participant is enrolled) which ever occur first.
11170924|NCT03583996|Experimental|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
11170925|NCT03583983|Other|Personalized Health Recommendations|
11170926|NCT03583983|Other|No Health Recommendations|
11170927|NCT03583957||Entire Study|
11170928|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
11170929|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
11170930|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
11170931|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
11170932|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
11170933|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
11170934|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
11170935|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
11170936|NCT03583892||Group B|In the group B gabapentin was not administered.
11170937|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
11170938|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
11170939|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
11170940|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
11170941|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
11170942|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
11170943|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
11170944|NCT03583840|No Intervention|Control group|Participants who will not be directed to the ScreenMen website
11170945|NCT03583840|Experimental|Intervention group|Participants who will be directed to the ScreenMen website
11170946|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
11170947|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
11170948|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
11170978|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
11170979|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
11170980|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
11172284|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
11170949|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
11170950|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
11170951|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :
~sweet orange (Citrus sinensis L. Persoon)
~fine lavender (Lavandula angustifolia P. Miller)
~little seed from the mandarin tree (Citrus reticulata blanco)"
11170952|NCT03583801|Placebo Comparator|without aromatherapy|
11170953|NCT03583788|Experimental|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson's (permissive) hypnosis (17). It began with a conversation about patient's past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
11170954|NCT03583788|Active Comparator|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
11170955|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
11170956|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
11170957|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
11170958|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
11170959|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
11170960|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
11170961|NCT03583736|Active Comparator|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
11170962|NCT03583736|Placebo Comparator|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
11170963|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
11170964|NCT03583710|Experimental|Arm A (mitotane)|Participants receive mitotane PO daily on days 1-21. Courses repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
11170965|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Participants receive mitotane as in Arm A. Participants also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11170966|NCT03583697|Experimental|Active BMN111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111 daily
11170967|NCT03583697|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
11170968|NCT03583684|Experimental|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
11170969|NCT03583684|No Intervention|Delayed Treatment Group (DTG)|Child continues stable treatments as usual in the community.
11170970|NCT03583658|Active Comparator|Ambroxol hydrochloride (BIH1526)|One lozenge 20 mg on as-needed basis, up to 6 times per day
11170971|NCT03583658|Placebo Comparator|Placebo|One lozenge on as-needed basis, up to 6 times per day
11170972|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
11170973|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
11170974|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
11170975|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
11170976|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
11170977|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
11170981|NCT03583580|Experimental|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
11170982|NCT03583567|Placebo Comparator|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
11170983|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
11170984|NCT03583554|Placebo Comparator|Placebo|Placebo
11170985|NCT03583554|Active Comparator|AV-101 720 mg|One time 720 mg L-4-Chlorokynurenine
11170986|NCT03583554|Active Comparator|AV-101 1440 mg|One time 1440 mg L-4-Chlorokynurenine
11170987|NCT03583541|Experimental|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
11170988|NCT03583541|Experimental|Treatment arm: HIVRR+S|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate).
11170989|NCT03583541|Experimental|Treatment arm: HIVRR+S+FLM|Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.
11170990|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
11170991|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
11170992|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
11170993|NCT03583502|Experimental|Supplemented|krill oil and fish oil supplement
11170994|NCT03583502|No Intervention|Controls|The control group did not receive any supplementation.
11170995|NCT03583489|Placebo Comparator|Placebo|
11170996|NCT03583489|Experimental|APD421|
11170997|NCT03583489|Experimental|APD421 + ondansetron|
11170998|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
11170999|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
11171000|NCT03583476||Concomitant therapy|Patients with concomitant therapy
11171001|NCT03583476||Sequential therapy|Patients with sequential therapy
11171002|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
11171003|NCT03583450|No Intervention|Control|Routine anesthetic care
11171004|NCT03583437|Experimental|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
11171005|NCT03583437|Experimental|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
11171006|NCT03583424|Experimental|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
11171007|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
11171008|NCT03583398||TAVI TAo|
11171009|NCT03583398||TAVI TF|
11171010|NCT03583398||AVR|
11171011|NCT03583385|Experimental|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
11171012|NCT03583385|Experimental|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
11171013|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
11171014|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
11171015|NCT03583359|Experimental|Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
11171174|NCT03582215|Experimental|Part 1: Spray 2|"Part 1: Spray 2
~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
11171016|NCT03583359|Other|Delayed Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
11171017|NCT03583346|Experimental|M6495|
11171018|NCT03583346|Placebo Comparator|Placebo|
11171019|NCT03583333|Experimental|IMI/REL FDC|Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL/500 mg Cilastatin, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
11171020|NCT03583333|Active Comparator|PIP/TAZ FDC|Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
11171021|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
11171022|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.
~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
11171023|NCT03583307|Experimental|Sirolimus|
11171024|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
11171025|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
11171026|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
11171027|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
11171028|NCT03583281|Active Comparator|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid [ALA] per day) for 4 weeks
11171029|NCT03583281|Active Comparator|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
11171030|NCT03583268|Active Comparator|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
11171031|NCT03583268|Experimental|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
11171032|NCT03583268|Experimental|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
11171033|NCT03583268|Experimental|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
11171034|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Participants receive dexamethasone PO BID for 7 days. Participants also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
11171035|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Participants receive placebo PO BID for 7 days. Participants also complete resistance training and moderate intensity walking as in Arm I.
11171036|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
11171037|NCT03583229|Other|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
11171038|NCT03583229|Experimental|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
11171039|NCT03583229|No Intervention|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
11171040|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
11171041|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
11171042|NCT03583203|Experimental|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
11171043|NCT03583203|No Intervention|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
11171044|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
11171045|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
11171046|NCT03583177||healthy volunteers|
11171047|NCT03583177||cancer patients|
11171048|NCT03583177||undergoing chronic hemodialysis patients|
11171049|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
11171050|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
11171051|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
11171052|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
11171053|NCT03583138||No buprenorphine|No buprenorphine
11171054|NCT03583125|Experimental|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.
~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
11171055|NCT03583112|Active Comparator|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
11171056|NCT03583112|Placebo Comparator|Placebo|In this group, patients received placebo tablet before MRI scan.
11171057|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
11171058|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
11171059|NCT03583086|Experimental|Treatment (vorolanib, nivolumab)|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
11171060|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
11171061|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
11171062|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
11171063|NCT03583060|No Intervention|Control|
11171064|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
11171065|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
11171066|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
11171067|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
11171068|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
11171069|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
11171070|NCT03582982|Experimental|Eccentric overload exercise|
11171071|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
11171072|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
11171073|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
11171074|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
11171075|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
11171076|NCT03582943|Experimental|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
11171077|NCT03582943|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
11171078|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
11171079|NCT03582917|No Intervention|No treatment|
11171080|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
11171081|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
11171082|NCT03582891|Other|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
11171083|NCT03582891|Other|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
11171084|NCT03582891|Other|Dystonia patients|Isolated dystonia patients
11171085|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
11171086|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
11171087|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
11171088|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
11171089|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
11171090|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
11171091|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
11171092|NCT03582839|Experimental|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
11171093|NCT03582826|Experimental|Study Participants|Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes
11171094|NCT03582813|Experimental|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
11171095|NCT03582813|Active Comparator|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
11171096|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
11171097|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
11171098|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
11171099|NCT03582774|Active Comparator|Arm I (standard of care)|Participants receive standard of care SRT.
11171100|NCT03582774|Experimental|Arm II (68Ga-PSMA-11 PET/CT)|Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.
11171101|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
11171102|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
11171103|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
11171104|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
11171105|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
11171106|NCT03582735|No Intervention|Control|No intervention according to current practice.
11171107|NCT03582722|Experimental|Weight loss aid|One-month supply of orlistat capsules (60mg) to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
11171108|NCT03582722|Placebo Comparator|Placebo|One-month supply of placebo capsules to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
11171109|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
11171110|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
11171111|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
11171112|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
11171113|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
11171114|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
11171115|NCT03582644|Experimental|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
11171116|NCT03582618|Experimental|Sorafenib + CVM-1118|"Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)
~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.
~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)
~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
11171117|NCT03582605|Placebo Comparator|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
11171118|NCT03582605|Experimental|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
11171119|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
11171120|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
11171121|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
11171122|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
11171123|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
11171124|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
11171125|NCT03582566|Experimental|Phonological Awareness|Children will play games to practice their rhyming, sound sequencing, and letter-sound knowledge. These games are all implemented in the Earobics program.
11171126|NCT03582566|Experimental|Working Memory|Children will play games designed to help them hold and manipulate objects in memory. These games are implemented in Cogmed.
11171127|NCT03582566|Experimental|Phonological Awareness + Working Memory|Children will practice both their sound skills (Earobics) and their memory skills (Cogmed).
11171128|NCT03582566|Active Comparator|Active Control|Children will play games to practice their addition and subtraction skills (Splashmath).
11171129|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
11171130|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
11171131|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
11171132|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
11171133|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
11171134|NCT03582540|Active Comparator|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
11171135|NCT03582540|Active Comparator|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
11171136|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
11171175|NCT03582215|Experimental|Part 2: Lotion|"Part 2: Lotion
~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
11171176|NCT03582215|Experimental|Part 2: Aerosol Spray|"Part 2: Aerosol Spray
~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
11171177|NCT03582215|Experimental|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray
~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
11171137|NCT03582514|Experimental|Dose or volume radiation escalation|"Patients with a biopsy proven GBM referred to our hospital or patients who are diagnosed with GBM based on the MRI (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.
~This GBM study assesses the feasibility, safety and efficacy of a preoperative single fraction. The phase-I part has a 3+3 dose or volume escalation design. The choice of dose or volume escalation is based on tumor volume and location. After the single fraction of radiotherapy, patients will receive the standard treatment."
11171138|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
11171139|NCT03582488|Experimental|Dementia with Lewy Bodies|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
11171140|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11171141|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
11171142|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
11171143|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
11171144|NCT03582436||Prospective cohort|Kidney transplantation
11171145|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
11171146|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
11171147|NCT03582410|Active Comparator|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
11171148|NCT03582410|Active Comparator|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
11171149|NCT03582397|Experimental|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
11171150|NCT03582384|Experimental|Treatment|
11171151|NCT03582371|Experimental|Aqua SUP|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
11171152|NCT03582371|Active Comparator|Physiotherapy|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
11171153|NCT03582358||Verrine|Patients served verrines
11171154|NCT03582358||CNO|Patients served wrapped supplements
11171155|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
11171156|NCT03582332|Active Comparator|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
11171157|NCT03582332|Active Comparator|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
11171158|NCT03582332|Active Comparator|Group A in phase 2|Etoricoxib 90 mg once daily
11171159|NCT03582332|Active Comparator|Group B in phase 2|Etoricoxib 60 mg once daily
11171160|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
11171161|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
11171162|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
11171163|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
11171164|NCT03582293|Active Comparator|Tranexamic Acid|Tranexamic acid 500mg two times a day orally for a total of 28 days
11171165|NCT03582293|Placebo Comparator|PLACEBO|Placebo capsules two times a day orally for a total of 28 days
11171166|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:
~Amor powder, each eppendorf contains 200mg Calcium
~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
11171167|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
11171168|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
11171169|NCT03582254|Experimental|[18F]-FDG PET/MR|[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
11171170|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).
~Weekly sessions will follow a standardized format:
~15 minutes- Social support group (guided discussion of experiences related to weekly topic)
~20 minutes- Didactic instruction
~15 minutes- Role playing
~10 minutes- Debriefing and group feedback"
11171171|NCT03582215|Experimental|Part 1: Cream|"Part 1: Cream
~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
11171172|NCT03582215|Experimental|Part 1: Lotion|"Part 1: Lotion
~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
11171173|NCT03582215|Experimental|Part 1: Spray 1|"Part 1: Spray 1
~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
11171178|NCT03582215|Experimental|Part 2: Pump Spray|"Part 2: Pump Spray
~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
11171179|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
11171180|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
11171181|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
11171182|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
11171183|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
11171184|NCT03582176|Placebo Comparator|Lactose Placebo|Lactose Placebo by mouth twice per day
11171185|NCT03582176|Active Comparator|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
11171186|NCT03582176|Active Comparator|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
11171187|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
11171188|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
11171189|NCT03582150|Experimental|Receiving Soberlink Device|
11171190|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
11171191|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
11171192|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
11171193|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
11171194|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
11171195|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
11171196|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
11171197|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
11171198|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
11171199|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
11171200|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
11171201|NCT03582046|No Intervention|Monitoring Group|Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
11171202|NCT03582046|Active Comparator|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
11171203|NCT03582046|Experimental|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
11171204|NCT03582033|Experimental|Monotherapy|SEA-BCMA
11171205|NCT03582033|Experimental|Combination Therapy|SEA-BCMA + dexamethasone
11171206|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
11171207|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
11171208|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
11171209|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
11171210|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
11171211|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
11171212|NCT03581994|No Intervention|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
11171213|NCT03581994|Experimental|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
11171214|NCT03581994|Experimental|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
11171215|NCT03581981|Experimental|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
11171216|NCT03581981|Active Comparator|Treatment as Usual (TAU)|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
11171217|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
11171238|NCT03581812|Active Comparator|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
11171239|NCT03581812|Active Comparator|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
11171218|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
11171219|NCT03581955|Experimental|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
11171220|NCT03581955|Experimental|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
11171221|NCT03581955|Experimental|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
11171222|NCT03581942|Experimental|Copanlisib in combination with Ibrutinib|"The 3+3 design will be applied in the phase Ib portion of the trial. Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off).In the phase II portion a Simon two-stage design will be used. At the first stage, 14 patients will be enrolled at the MTD. If at least 11 patients respond then an additional 19 patients will be accrued to the second stage.Up to 15 patients with newly diagnosed PCNSL not eligible to receive standard first-line therapy(based on the treating physicians assessment) as these patients might benefit from first-line therapy without significant chemotherapy-associated adverse events). Participants will remain on treatment until tumor progression, as long as there are no unacceptable toxicities."
11171223|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
11171224|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
11171225|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
11171226|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
11171227|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
11171228|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
11171229|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
11171230|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
11171231|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11171232|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
11171233|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
11171234|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
11171235|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
11171236|NCT03581825|Experimental|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
11171237|NCT03581825|Experimental|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
11171240|NCT03581812|Placebo Comparator|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
11171241|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
11171242|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|
11171243|NCT03581786|Experimental|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|
11171244|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
11171245|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
11171246|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
11171247|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
11171248|NCT03581747||Subjects with atopic dermatitis|
11171249|NCT03581747||Controls|
11171250|NCT03581734|Active Comparator|OPV only|The vaccine will be available in prefilled vials containing 10 doses. Each vial will be labelled with the study ID of the participant. Therefore, for participants randomized to arm A and arm C, there will be 3 vials per participant for the 3 doses of the bOPV vaccine to be given 28 weeks apart. Any remaining, non-used doses of vaccine in the vial will be discarded.
11171251|NCT03581734|Active Comparator|Shanchol only|Each dose of vaccine is 1.5ml in volume. Each vial will be labelled with the study ID of the participant. One vial will be used per participant per study visit. OCV was studied in a double-blind, randomized, placebo-controlled trial in Kolkata, India. Participants were 1 year and above in age. In these studies, 100 children aged 1-17 were administered 2-doses of OCV or placebo separated by an interval of two weeks, with 80% of vaccinated showing over 4 fold rise in serum V. cholerae O1 antibody titers, showing that the 2-dose regimen was well-tolerated, safe and immunogenic
11171252|NCT03581734|Experimental|OPV-OCV co-administered|"Our primary analysis will be to compare seroconversion (defined as a change of status from seronegative to seropositive titers, or a ≥4-fold rise in antibody titer) for OPV1 and OPV 3 antibodies between Arm A and Arm C, to determine whether seroconversion to bOPV when administered with Shanchol is non-inferior to seroconversion to bOPV when bOPV is administered alone.
~Our second objective will be to compare vibriocidal antibody seroconversion (also, ≥4-fold rise in antibody titers) to Shanchol when co-administered with OPV or when Shanchol is administered alone, Arm B compared to Arm C"
11171253|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
11171254|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
11171255|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
11171256|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
11171257|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
11171258|NCT03581695||Healthy Controls|Healthy Controls
11171259|NCT03581682|Experimental|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
11171260|NCT03581669||THA + cerclage acetabulum|
11171261|NCT03581656|Experimental|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
11171262|NCT03581630|Experimental|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
11171263|NCT03581630|Experimental|Breast cancer subjects-Mediterranean Diet|
11171264|NCT03581630|Active Comparator|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
11171265|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
11171266|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
11171267|NCT03581604|Other|Patients labeled as penicillin allergic|Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples and Microbiological samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.
11171268|NCT03581604|Other|Healthy Controls|Healthy Controls, blood samples and microbiological samples.Clinical history
11171269|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
11171270|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown
~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
11171271|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown
~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
11171721|NCT03578458|Other|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
11171272|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown
~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
11171273|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
11171274|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
11171275|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
11171276|NCT03581513|Experimental|IMR<40 and defer PCI|Patients whose IMR<40 undergo anticoagulation and antiplatelet therapy for stent implantation one week later
11171277|NCT03581513|Active Comparator|IMR<40 and immediately PCI|Patients whose IMR<40 undergo immediately stent implantation
11171278|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation
11171279|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo anticoagulation and antiplatelet therapy for stent implantation one week later
11171280|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
11171281|NCT03581487|Experimental|Arm I (intermittent selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11171282|NCT03581487|Experimental|Arm II (continuous selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11171283|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
11171284|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
11171285|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.
~The intervention Sensory Restoration During Prosthesis Control will be used."
11171286|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
11171287|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
11171288|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
11171289|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
11171290|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
11171291|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
11171292|NCT03581383|No Intervention|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
11171293|NCT03581383|Experimental|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
11171294|NCT03581383|Experimental|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
11171295|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.
~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
11171296|NCT03581370|Experimental|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.
~."
11171297|NCT03581357|Active Comparator|Mobile App Group|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
11171298|NCT03581357|Active Comparator|Wait-List Control Group|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
11171299|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
11171300|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
11171301|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
11171302|NCT03581318||Adults with cardiac disease|Subjects will undergo MRI scans
11171303|NCT03581318||Children with Cardiac Disease|Subjects will undergo MRI scans
11171304|NCT03581318||Gadolinium Deposition within the Brain in Healthy and Pt Subj|Subjects will undergo MRI scans
11171305|NCT03581318||Healthy Adults|Subjects will be used as controls for adults with cardiac disease
11171306|NCT03581318||Healthy Children|Healthy children will be used as controls for children with cardiac disease
11171307|NCT03581305|Active Comparator|Dopaminergic arm|25 eligible HIVinfected individuals and 50 eligible HIVnegative (HIV-) individuals for the dopaminergic arm
11171308|NCT03581305|Active Comparator|Serotonergic arm|20 HIV-infected individuals and 20 HIV-negative individuals for the serotonergic arm
11171309|NCT03581292|Experimental|Treatment (veliparib, radiation therapy, temozolomide)|"CHEMORADIOTHERAPY PHASE: Patients receive veliparib PO BID and undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE CHEMOTHERAPY: Beginning 4 weeks after chemoradiotherapy phase, patients receive veliparib PO BID and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
11171310|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
11171311|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
11171312|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
11171313|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
11171314|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
11171315|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
11171316|NCT03581214|Active Comparator|Room air|Room air (no mask)
11171317|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
11171318|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
11171319|NCT03581201||No contraception|Healthy females without any contraception at all.
11171320|NCT03581188|Experimental|Self-examination of the skin|Participants will perform self-surveillance of the skin using a dermatoscope device. They will receive guidance from the ASICA skin checker and receive reminders every 2 months to perform self-examination. They will receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
11171321|NCT03581188|No Intervention|Control|Participants will receive an educational booklet 'Your guide to early melanoma'and scheduled visits to their clinician as required.
11171322|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
11171323|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
11171324|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
11171325|NCT03581162||Controls|Healthy, age-and sex-matched controls
11171326|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
11171327|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
11171328|NCT03581136|Experimental|Prescription Isodose Surface Coverage|"The dose fractionation to the CTV (1cm expansion on cavity) will be 40Gy/ 5 fractions and the PTV (3 mm expansion of CTV) will be a minimum dose of 30Gy/5 fractions.
~If PTV >100cc or if dose constraints cannot be met on higher dose prescribe CTV (1.0cm) to 35Gy/5 fractions and PTV (3mm) to 30Gy/5 fractions. This is to potentially reduce risk of fat necrosis."
11171329|NCT03581123|Experimental|Supported-Self management (SSM)|Supported-Self management
11171330|NCT03581123|Experimental|Spinal Manipulation Therapy (SMT)|Spinal Manipulation Therapy
11171331|NCT03581123|Experimental|SMT + SSM|Spinal Manipulation Therapy + Supported Self-Management
11171332|NCT03581123|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care
11171333|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
11171334|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
11171335|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
11171336|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
11171337|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
11171338|NCT03581084|Experimental|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
11171339|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
11171340|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
11171341|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
11171342|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
11171343|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
11171344|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
11171345|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
11171346|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
11171347|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
11171348|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
11171349|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
11171350|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
11171351|NCT03581019|Experimental|Uterus transplantation|Uterus transplantation
11171352|NCT03581006||Intervention Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.
~This intervention group will undergo technology based monitoring and behavioral participation in a dietary and exercise program with the intent of weight loss and compliance with a low-calorie Mediterranean diet."
11171353|NCT03581006||Control (Usual care) Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.
~This group will receive no dietary or behavioral intervention. They will continue usual care with their home physicians."
11171354|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
11171355|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
11171356|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
11171357|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
11171358|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
11171359|NCT03580967|Other|Drug: Vortioxetine|
11171360|NCT03580954|Experimental|Repetitive TMS (estimulation)|
11171361|NCT03580954|Active Comparator|Repetitive TMS (inhibition)|
11171362|NCT03580928|Experimental|Acalabrutinib/Venetoclax/Obinutuzumab|"Acalabrutinib will be administered orally twice daily at 100 mg bid
~Venetoclax will be administered orally once daily, with dose ramp-up from 20 mg up to a final dose of 400 mg
~Obinutuzumab will be administered as per standard of care for 6 months with dosing at 100 mg on cycle 1 day 1, 900 mg on cycle 1 day 2, and then 1,000 mg on cycle 1 days 8, 15, and day 1 of cycles 2-6"
11171363|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
11171364|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
11171365|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
11171366|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
11171367|NCT03580889|Active Comparator|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
11171368|NCT03580889|Active Comparator|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
11171472|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.
~No treatment after the collagenase injection and extension treatment."
11171369|NCT03580889|Active Comparator|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
11171370|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)
~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
11171371|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine
~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR
~Loss of response under Adalimumab: 40mg EW SC Randomization to:
~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
11171372|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm).
11171373|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
11171374|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).
~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
11171375|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
11171376|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
11171377|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
11171378|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
11171379|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
11171380|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
11171381|NCT03580772||Control participants|Patients will not have recieved a primary TKR
11171382|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
11171383|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
11171384|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
11171385|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
11171386|NCT03580733|Placebo Comparator|placebo|placebo
11171387|NCT03580733|Experimental|antifungal therapy|caspofungin
11171388|NCT03580720|Experimental|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
11171389|NCT03580707|Active Comparator|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) & brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
11171390|NCT03580707|Active Comparator|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose & BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
11171391|NCT03580694|Experimental|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
11171392|NCT03580694|Experimental|Combination Therapy|"Dose Escalation cohorts:
~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.
~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.
~Dose Expansion cohorts:
~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
11171393|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
11171394|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
11171395|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
11171396|NCT03580655|Experimental|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
11171397|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
11171398|NCT03580642|No Intervention|Control|Habitual treatment.
11172632|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
11171399|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
11171400|NCT03580616|Experimental|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
11171401|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
11171402|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
11171403|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
11171404|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
11171405|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
11171406|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).
~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.
~Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.
~Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
11171407|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.
~- Protein C, protein S and antithrombin III level will be assessed at baseline."
11171408|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
11171409|NCT03580551|Experimental|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
11171410|NCT03580551|Active Comparator|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
11171411|NCT03580538|Experimental|elastic tube group|
11171412|NCT03580525|Experimental|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
11171413|NCT03580525|Experimental|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
11171414|NCT03580525|Experimental|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
11171415|NCT03580525|Experimental|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
11171416|NCT03580525|Experimental|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
11171417|NCT03580512||Group 1|- 800 existing clients who already received PrEP
11171418|NCT03580512||Group 2|"800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP
~600 clients who will refuse PrEP
~200 clients who will receive PrEP"
11171419|NCT03580512||Group 3|- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive
11171420|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
11171421|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
11171422|NCT03580486||Healthy controls|Healthy people
11171423|NCT03580473|Experimental|SATURNO II|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
11171424|NCT03580473|Active Comparator|Vigadexa®|1 drop, 4 times a day, in the eye to be operated, 1 day before surgery until 15 days after surgery
11171425|NCT03580460|No Intervention|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
11171426|NCT03580460|Experimental|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
11171427|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
11171428|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
11171429|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
11171430|NCT03580421|Active Comparator|standard pathway group|this group will benefit from standard care including: one surgical consultation, one anesthesia consultation, surgery followed by 2-4 days of hospitalization and 3 post-operative consultations (M1, M6, M12) during the first operative year
11171431|NCT03580421|Experimental|ambulatory pathway group|Preoperative and postoperative protocols will be applied for optimizing same-day discharge. Gynaecologists, anaesthetists, and nursing staff will work as a team. A specific anesthesia consultation will focus on ambulatory surgery management. A geriatric evaluation will be offered to women over 70 years old with a score ≤14 according to G8 screening tool. A dietetic evaluation will be offered to women with BMI ≥ 35. A nursing consultation will be offered, as patient and their family preparation prior to ambulatory surgery is important.
11171470|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.
~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
11171762|NCT03578146|Experimental|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (~30 mg/min)
11171432|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)
~Consolidation treatment:
~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :
~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.
~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)
~In case of progressive disease , patients will be considered in treatment failure."
11171433|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
11171434|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
11171435|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
11171436|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
11171437|NCT03580369|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
11171438|NCT03580369|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
11171439|NCT03580369|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
11171440|NCT03580369|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
11171441|NCT03580356|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
11171442|NCT03580356|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
11171443|NCT03580356|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
11171444|NCT03580356|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
11171445|NCT03580343|Experimental|Tofacitinib Treatment|
11171446|NCT03580330|Experimental|Intervention Group|
11171447|NCT03580330|No Intervention|Control Group|
11171448|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
11171449|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
11171450|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
11171451|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
11171452|NCT03580304|Experimental|industrial-physical-cognitive|
11171453|NCT03580304|Experimental|industrial- cognitive-physical|
11171454|NCT03580304|Experimental|physical- industrial- cognitive|
11171455|NCT03580304|Experimental|physical-cognitive- industrial|
11171456|NCT03580304|Experimental|cognitive- industrial-physical|
11171457|NCT03580304|Experimental|cognitive-physical-industrial|
11171458|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.
~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.
~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
11171459|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
11171460|NCT03580278|Experimental|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
11171461|NCT03580278|Experimental|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
11171462|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
11171463|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
11171464|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.
~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
11171465|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
11171466|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
11171467|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
11171468|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
11171469|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.
~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
11171471|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.
~No treatment after the collagenase injection and extension treatment."
11171473|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
11171474|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
11171475|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.
~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
11171476|NCT03580174|Active Comparator|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
11171477|NCT03580174|Active Comparator|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
11171478|NCT03580161||18-F FDG PET/CT|Patients receiving routine diagnostic scan
11171479|NCT03580161||Ga-68 PSMA PET/CT|Patients receiving routine diagnostic scan
11171480|NCT03580161||68-Ga Dotatate PET/CT|Patients receiving routine diagnostic scan
11171481|NCT03580161||99mTc Pertechnetate Thyroid Scan|Patients receiving routine diagnostic scan
11171482|NCT03580161||99mTc DMSA(III) Renal Scan|Patients receiving routine diagnostic scan
11171483|NCT03580161||99mTc MAG3 Renal Scan|Patients receiving routine diagnostic scan
11171484|NCT03580161||99mTc MDP Bone Scan|Patients receiving routine diagnostic scan
11171485|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
11171486|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
11171487|NCT03580135|Experimental|Propolis powder|"resin (50%),
~vegetable Balsam, wax
~essential aromatic oils (30%)
~salivary secretions (10%)
~pollen(5%)
~other substances (5%) including amino acids
~,ethanol vitamin A, B complex, and E, minerals, steroids
~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.
~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
11171488|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.
~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
11171489|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
11171490|NCT03580109|Active Comparator|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
11171491|NCT03580109|Sham Comparator|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
11171492|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
11171493|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
11171494|NCT03580083|Experimental|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
11171495|NCT03580083|Experimental|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
11171496|NCT03580057|Experimental|Breastfeeding promotion intervention (BPI)|
11171497|NCT03580057|Experimental|Diet- and weight loss intervention (D)|
11171498|NCT03580057|Experimental|BPI and D|Both interventions.
11171499|NCT03580057|No Intervention|Control|
11171500|NCT03580044|Experimental|ATM- AVI|Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm
11171501|NCT03580044|Active Comparator|BAT|Best Available Therapy (BAT) Comparator Treatment Arm
11171502|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
11171503|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
11171504|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
11171505|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
11171506|NCT03580005|Active Comparator|Quillichew ERCT|Quillichew ERCT
11171507|NCT03580005|Placebo Comparator|Placebo to match Quillichew ERCT|Placebo to match Quillichew ERCT
11171508|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
11171509|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
11171510|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
11171511|NCT03579979|Experimental|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.
~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
11171512|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
11171513|NCT03579953|Experimental|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
11171514|NCT03579953|Sham Comparator|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
11171515|NCT03579940|Experimental|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
11171516|NCT03579940|Placebo Comparator|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
11171517|NCT03579940|Experimental|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
11171518|NCT03579940|Placebo Comparator|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
11171519|NCT03579927|Experimental|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10^9/L per 3 consecutive days.
11171520|NCT03579914|Placebo Comparator|Placebo group|Patients receive intravenous placebo injection.
11171521|NCT03579914|Experimental|Intravenous metoprolol group|Patients receive intravenous metoprolol injection.
11171522|NCT03579914|Experimental|RIPC group|Patients receive RIPC treatment.
11171523|NCT03579914|Experimental|Intravenous metoprolol and RIPC group|Patients receive intravenous metoprolol injection and RIPC treatment.
11171524|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
11171525|NCT03579901|Other|Primary Breast Reconstruction|Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
11171526|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
11171527|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
11171528|NCT03579888|Experimental|Treatment (fludarabine, cyclophosphamide, CD19 T cell)|"CHEMOTHERAPY: Patients receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.
~T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0."
11171529|NCT03579875|Experimental|Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP|"Given to:
~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR
~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia"
11171530|NCT03579875|Experimental|Treatment Plan 2: CY, FLU and MP|"Given to:
~• HLA-identical sibling donor recipients with aplastic anemia"
11171531|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
11171532|NCT03579862||Pulmonary Embolism (PE)|
11171533|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
11171534|NCT03579849|Experimental|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.
~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
11171535|NCT03579836|Experimental|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
11171536|NCT03579836|Experimental|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
11171537|NCT03579836|Experimental|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
11171538|NCT03579823|Experimental|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
11171539|NCT03579823|Active Comparator|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) [HUMIRA]
11171540|NCT03579810|Experimental|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.
~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).
~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).
~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
11171541|NCT03579810|Active Comparator|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.
~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.
~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
11171542|NCT03579784|Experimental|Durvalumab+Olaparib+Paclitaxel|"st cycle : Paclitaxel+Olaparib
~Olaparib 150mg bid on D1-28
~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15
~nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :
~Olaparib 150mg bid on D1-28
~Durvalumab 1.5 g iv on D1
~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
11171716|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
11171543|NCT03579771|Experimental|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
11171544|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11171545|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11171546|NCT03579745|Active Comparator|Conventional lingual mechanics|
11171547|NCT03579745|Experimental|Lever arm lingual mechanics|
11171548|NCT03579732||Long-term users|Adults using low-dose aspirin for > 3 years
11171549|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but < 3 years
11171550|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
11171551|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
11171552|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
11171553|NCT03579706|Experimental|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
11171554|NCT03579706|Placebo Comparator|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
11171555|NCT03579693|Active Comparator|CoQ10|Coenzyme Q10, 2 - 250 mg tablets twice a day (1000 mg total daily dose) for 6 weeks
11171556|NCT03579693|Active Comparator|Nicotinamide riboside|Nicotinamide riboside, 1 - 600 mg tablet twice a day (1200 mg total daily dose) for 6 weeks
11171557|NCT03579693|Placebo Comparator|Placebo|Placebo, inactive sugar pill for 6 weeks
11171558|NCT03579680||Providers|Urologists and other providers who have experience caring for more than 10 prostate cancer patients on ADT and express interest in prostate cancer care for prostate cancer will be eligible to participate. Providers will engage in a 30-45 minute interview to identify key preferences and de-implementation barriers, as well as facilitators, for reducing low value ADT as prostate cancer (PC) treatment.
11171559|NCT03579680||Patients|Patients receiving ADT as primary prostate cancer treatment will engage in a 30-45 minute interview regarding to better understand patient perspectives into not initiating or stopping castration with ADT
11171560|NCT03579680||cRCT Facility|We will conduct a 6-month cluster randomized clinical trial of Or vs. Sc de-implementation strategies across 40 facilities with high rates of low value ADT.
11171561|NCT03579667|Experimental|Diet intervention|
11171562|NCT03579667|No Intervention|Control|
11171563|NCT03579654|Experimental|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
11171564|NCT03579654|No Intervention|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
11171565|NCT03579641||Implantable Cardiac device with HeartLogic feature|Patients with Heart Failure, implanted with Boston Scientific Implantable Cardioverter Defibrillator or Defibrillator with Cardiac Resynchronization device with HeartLogic feature
11171566|NCT03579628|Experimental|AsiDNA|"Part A: AsiDNA as a single agent:
~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).
~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.
~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):
~Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.
~Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
11171567|NCT03579615|Experimental|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
11171568|NCT03579615|Active Comparator|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
11171569|NCT03579602|Active Comparator|Arm 1 (no tozuleristide)|Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
11171570|NCT03579602|Experimental|Arm 2 (tozuleristide treated)|Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
11171571|NCT03579589|Active Comparator|Sugammadex|"If spontaneous recovery has reached second twitch after TOF: 2 mg/kg
~If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg
~When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
11171572|NCT03579589|Active Comparator|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
11171573|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
11171574|NCT03579563|Active Comparator|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide hearing aids.
11171575|NCT03579563|Experimental|OTC (over-the-counter)|In this group, the over-the-counter fitting will be used to provide hearing aids.
11171576|NCT03579563|Experimental|OTC-Plus|In this group, the hybrid fitting will be used to provide hearing aids.
11171577|NCT03579550|Active Comparator|Intervention arm: Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception Intervention arm for hysteroscopy group
11171578|NCT03579550|No Intervention|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
11171579|NCT03579537|Experimental|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
11171580|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
11171581|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
11171582|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
11171583|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
11171584|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
11171585|NCT03579472|Experimental|Treatment (M7824, eribulin mesylate)|Patients receive anti-PD-L1/TGFbetaRII fusion protein M7824 IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11171586|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
11171587|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
11171588|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
11171589|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
11171590|NCT03579446|Experimental|Supportive care (levorphanol, opioid regimen)|Patients receive levorphanol PO every 8 or 12 hours for 30 days. Patients may receive opioid regimen including hydrocodone, morphine sulfate, hydromorphone hydrochloride, oxycodone, and oxymorphone hydrochloride for breakthrough pain.
11171591|NCT03579433|Experimental|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
11171592|NCT03579433|Active Comparator|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
11171593|NCT03579420|Experimental|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
11171594|NCT03579420|Active Comparator|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
11171595|NCT03579407|Active Comparator|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
11171596|NCT03579407|Experimental|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
11171597|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
11171598|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
11171599|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
11171600|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
11171601|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
11171602|NCT03579355|Experimental|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
11171603|NCT03579355|No Intervention|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
11171763|NCT03578146|Experimental|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (~30 mg/min)
11171604|NCT03579342|Experimental|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
11171605|NCT03579342|Experimental|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
11171606|NCT03579342|No Intervention|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
11171607|NCT03579316|Active Comparator|Arm I (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11171608|NCT03579316|Experimental|Arm II (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11171609|NCT03579303|Active Comparator|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
11171610|NCT03579303|Active Comparator|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
11171611|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:
~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
11171612|NCT03579277|Active Comparator|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
11171613|NCT03579277|Active Comparator|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
11171614|NCT03579264|No Intervention|Standard Arm|No use of My Viva Plan.
11171615|NCT03579264|Experimental|Intervention Arm|Use of My Viva Plan.
11171616|NCT03579251|Other|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
11171617|NCT03579238|No Intervention|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
11171618|NCT03579238|No Intervention|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
11171619|NCT03579238|Sham Comparator|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
11171620|NCT03579238|Experimental|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
11171621|NCT03579225||MATRx plus test|
11171622|NCT03579199|Experimental|exploration of abdominal cavity using a NIR/ICG camera|
11171623|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
11171624|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
11171625|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
11171626|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
11171627|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed
~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft
~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
11171628|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC
~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
11171629|NCT03579147|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
11171630|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
11171631|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
11171632|NCT03579121|Experimental|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
11171717|NCT03578471|Active Comparator|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
11171633|NCT03579121|Active Comparator|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
11171634|NCT03579095|Experimental|American ginseng|200mg Cereboost and Maltodextrin
11171635|NCT03579095|Placebo Comparator|Placebo|Placebo
11171636|NCT03579082|Experimental|Arm A|"R±DHAP + decitabine:
~decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle."
11171637|NCT03579082|No Intervention|Arm B|R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.
11171638|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
11171639|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
11171640|NCT03579043|Experimental|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
11171641|NCT03579043|Experimental|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
11171642|NCT03579043|Experimental|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
11171643|NCT03579030|Experimental|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.
~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
11171644|NCT03579030|Experimental|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.
~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
11171645|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
11171646|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
11171647|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
11171648|NCT03579004|Experimental|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).
~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
11171649|NCT03578991|No Intervention|Arm 1|"Control group - Treatment as usual:
~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
11171650|NCT03578991|Experimental|Arm 2|"Intervention - Smart pillbox:
~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
11171651|NCT03578991|Experimental|Arm 3|"Intervention - Smart pillbox & Interactive digital platform:
~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
11171652|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
11171653|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
11171654|NCT03578965|Experimental|Arm 1: Antibiotic prophylaxis prior to skin incision|-Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
11171655|NCT03578965|No Intervention|Arm 1: No antibiotic prophylaxis prior to skin incision|-Women randomized to no antibiotic prophylaxis will not receive any antibiotics prior to skin incision.
11171656|NCT03578952|Experimental|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
11171657|NCT03578926|Experimental|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
11171658|NCT03578926|Active Comparator|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
11171659|NCT03578913|Active Comparator|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
11171660|NCT03578913|Experimental|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
11171718|NCT03578471|Experimental|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
11171719|NCT03578471|Experimental|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
11171661|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.
~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
11171662|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.
~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
11171663|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.
~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
11171664|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.
~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
11171665|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.
~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
11171666|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
11171667|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
11171668|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
11171669|NCT03578874|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
11171670|NCT03578861|Experimental|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.
~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
11171671|NCT03578848|Active Comparator|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
11171672|NCT03578848|Experimental|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
11171673|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
11171674|NCT03578822|Experimental|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
11171675|NCT03578822|Other|Group B|rhPro-UK simulation agent and Aspirn
11171676|NCT03578809|Experimental|Cohort A|MEDI6012
11171677|NCT03578809|Experimental|Cohort B|MEDI6012
11171678|NCT03578809|Placebo Comparator|Placebo|
11171679|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
11171680|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
11171681|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
11171682|NCT03578757|Experimental|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
11171683|NCT03578757|Active Comparator|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
11171684|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
11171685|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
11171686|NCT03578731||Consilium-APP|Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies.
11171687|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
11171688|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
11171689|NCT03578679|Experimental|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
11171690|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
11171691|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
11171692|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
11171693|NCT03578653|Experimental|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
11171694|NCT03578640|Experimental|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
11171695|NCT03578627|No Intervention|Assessment-only|
11171696|NCT03578627|Experimental|Intervention|
11171697|NCT03578614|No Intervention|Control Group|There is no intervention for Control Group
11171698|NCT03578614|Experimental|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
11171699|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
11171700|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
11171701|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
11171702|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
11171703|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
11171704|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
11171705|NCT03578575|Experimental|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
11171706|NCT03578575|Placebo Comparator|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
11171707|NCT03578562|Experimental|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
11171708|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.
~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
11171709|NCT03578536|Experimental|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.
~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
11171710|NCT03578536|No Intervention|Standard of Care|As part of standard care, participants will receive a minimum of daily OT, PT and Speech for a total of three hours. Current occupational therapy intervention options for inpatient stroke rehab patients with UE neuromotor impairments include active assisted range of motion exercise, morning bedside ADL sessions, high-repetition task-specific training, mirror therapy, Digi-flex, theraputty, theraband, free weights, weighted therapy bars for strengthening exercises in clinic and use with home exercise programs (HEP). Additional tools used as determined by therapist include FES modalities to assist with upper extremity neuromotor re-education, unweighted reaching tasks via the ArmeoSpring, and functional work task training/strengthening. They also participate in recreation therapy as appropriate.
11171711|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).
~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.
~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.
~Iohexol clearance to measure GFR within 1 week of the scan session"
11171712|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).
~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.
~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.
~Iohexol clearance to measure GFR within 1 week of the scan session"
11171713|NCT03578510|Active Comparator|SHD|Standard hemodialysis
11171714|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
11171715|NCT03578497|Experimental|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
11171720|NCT03578458|Other|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
11171722|NCT03578458|Other|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
11171723|NCT03578445|Experimental|Patients with a pancreatic cystic lesion|
11171724|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
11171725|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
11171726|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
11171727|NCT03578406|Experimental|HPV TCR-T|HPV E6-specific TCR-T cell
11171728|NCT03578406|Experimental|HPV TCR-T with anti-PD1|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element
11171729|NCT03578393|Experimental|Intervention|Will visualize an Educational Virtual Reality video in preoperative period to reduce perioperative anxiety.
11171730|NCT03578393|No Intervention|Usual treatment|Will be applied the usual treatment (provide information on the anaesthetic-surgical process).
11171731|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
11171732|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
11171733|NCT03578367|Experimental|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
11171734|NCT03578367|Experimental|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
11171735|NCT03578367|Active Comparator|Imatinib 400mg QD|Imatinib 400 mg taken once daily
11171736|NCT03578367|Active Comparator|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
11171737|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
11171738|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
11171739|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
11171740|NCT03578341|Experimental|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
11171741|NCT03578341|Placebo Comparator|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
11171742|NCT03578328||Cardiac arrest with targeted temperature management|
11171743|NCT03578315|Experimental|Solar lentigo|25 Patients with Solar lentigo
11171744|NCT03578315|Experimental|Nevus zygomaticus|25 Patients with Nevus zygomaticus
11171745|NCT03578289|Experimental|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
11171746|NCT03578289|Experimental|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
11171747|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
11171748|NCT03578276|Active Comparator|Standard of Care|"Gatifoxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.
~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
11171749|NCT03578263|Experimental|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
11171750|NCT03578263|Active Comparator|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
11171751|NCT03578250|Experimental|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.
~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
11171752|NCT03578250|Experimental|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.
~During training the robotic device will not apply any perturbations on the participant's arm."
11171753|NCT03578237|Experimental|Treatment|Receiving active cryoneurolysis
11171754|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
11171755|NCT03578224|Experimental|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
11171756|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
11171757|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
11171758|NCT03578198|Experimental|Rituximab + MG4101|"Drug: Rituximab + MG4101
~Induction phase:
~Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase
~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)"
11171759|NCT03578172|Experimental|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
11171760|NCT03578172|Active Comparator|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
11171761|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
11171863|NCT03577418|Active Comparator|Enhanced usual care|
11171764|NCT03578146|Experimental|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (~30 mg/min)
11171765|NCT03578146|Experimental|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes [~30 mg/min] followed by 240 mg continuous IV infusion [4 mg/min over 60 min)
11171766|NCT03578146|Experimental|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes [~30 mg/min] followed by 960 mg continuous IV infusion [8 mg/min over 120 min]
11171767|NCT03578146|Experimental|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
11171768|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
11171769|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
11171770|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
11171771|NCT03578107|Other|Improvement intervention1|receive the following improvement intervention for 18 months：
11171772|NCT03578107|Other|Improvement intervention2|receive the following improvement intervention for 12 months：
11171773|NCT03578107|Other|Improvement intervention3|receive the following improvement intervention for 6 months：
11171774|NCT03578081|Experimental|Arm I (fosaprepitant dimeglumine, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, fosaprepitant dimeglumine IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11171775|NCT03578081|Active Comparator|Arm II (placebo, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, placebo IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment (with no placebo) may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11171776|NCT03578055|Active Comparator|BDD with UDCA|Postoperative BDD with UDCA treatment
11171777|NCT03578055|Placebo Comparator|Placebo|Placebo
11171778|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
11171779|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
11171780|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
11171781|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
11171782|NCT03578016|Experimental|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
11171783|NCT03578016|Other|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
11171784|NCT03578003|Experimental|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
11171785|NCT03578003|No Intervention|Control|Subjects who do not engage in morning bright light therapy
11171786|NCT03577990|Experimental|ITEC|Fitbit Plus monitoring will include BP, weight measurements, daily food intake, self-report medication-taking, and physical activity plus weekly Interactive Technology-Enhanced Coaching (ITEC) for 3 months, then biweekly ITEC for 3 months, followed by another 3 months with no coaching to assess for sustainability.
11171787|NCT03577990|Active Comparator|No ITEC|Participants will receive usual care for 3 months followed by 6 months of only Fitbit Plus monitoring (with no ITEC) of BP, weight measurements, daily food intake, self-report medication-taking, and physical activity to be used for comparative data with the treatment arm.
11171788|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
11171789|NCT03577951|Experimental|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
11171790|NCT03577951|Experimental|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
11171791|NCT03577938|Experimental|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
11171792|NCT03577938|Other|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
11171793|NCT03577925||HSIL|the patients with HSIL
11171794|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
11171795|NCT03577912|Active Comparator|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
11171796|NCT03577912|Active Comparator|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
11171797|NCT03577899|Experimental|0.5 mg Conbercept|
11171798|NCT03577899|Experimental|1.0 mg Conbercept|
11171799|NCT03577899|Active Comparator|Aflibercept|
11171800|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
11171801|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
11171802|NCT03577873|Placebo Comparator|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
11171803|NCT03577873|Experimental|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
11172021|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
11171804|NCT03577860|Active Comparator|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
11171805|NCT03577860|Active Comparator|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
11171806|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
11171807|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
11171808|NCT03577834|Experimental|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
11171809|NCT03577834|Placebo Comparator|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
11171810|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
11171811|NCT03577782|Experimental|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
11171812|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
11171813|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
11171814|NCT03577743|Experimental|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
11171815|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
11171816|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
11171817|NCT03577717|Experimental|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
11171818|NCT03577717|Active Comparator|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
11171819|NCT03577704|Experimental|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).
~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
11171820|NCT03577704|Experimental|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).
~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
11171821|NCT03577704|Experimental|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).
~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
11171822|NCT03577691|Experimental|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
11171823|NCT03577691|Placebo Comparator|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
11171824|NCT03577678|Experimental|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
11171825|NCT03577665|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
11171826|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
11171827|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
11171828|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
11171829|NCT03577626|Experimental|Hemay005 Fast|
11171830|NCT03577626|Experimental|Hemay005 Fed|
11171831|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
11171832|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
11171833|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
11171834|NCT03577600|Experimental|QMRT using the Cytotron®|Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
11171835|NCT03577587|Experimental|Verum|Silitidil for 21 days
11171836|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
11171837|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
11171838|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
11171839|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
11171840|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
11171841|NCT03577561|No Intervention|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
11171842|NCT03577561|Active Comparator|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
11171843|NCT03577561|Active Comparator|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.
~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
11171844|NCT03577535|Experimental|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
11171845|NCT03577535|No Intervention|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
11171846|NCT03577522|Active Comparator|Avenir cementless hip stem|Total hip arthroplasty: Avenir vs Corail
11171847|NCT03577522|Active Comparator|Corail HA-coated hip stem|Total hip arthroplasty: Corail vs Avenir
11171848|NCT03577509|Experimental|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
11171849|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
11171850|NCT03577483|Other|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
11171851|NCT03577483|Other|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
11171852|NCT03577483|Other|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
11171853|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
11171854|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
11171855|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
11171856|NCT03577457|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
11171857|NCT03577457|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
11171858|NCT03577457|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
11171859|NCT03577457|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
11171860|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
11171861|NCT03577431|Experimental|arTreg-CSB|"arTreg CSB: alloantigen-reactive T regulatory cells costimulatory blockade per protocol.
~The investigational product is donor alloantigen-specific T regulatory cells (arTreg-CSB). Supportive regimen for receipt of arTregs-CSB includes everolimus, leukapheresis, cyclophosphamide, and mesna.
~Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10^6 total cells. arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes.
~Note: Participants who receive at least the minimum Treg product (arTreg-CSB) dose of 1 to < 2.5 x 10^6 cells will be included in intent-to-treat analysis."
11171862|NCT03577418|Experimental|Clinician-facilitated educational intervention|
11171864|NCT03577392|Experimental|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
11171865|NCT03577392|Active Comparator|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
11171866|NCT03577379|No Intervention|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
11171867|NCT03577379|Experimental|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
11171868|NCT03577353|Experimental|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
11171869|NCT03577353|Active Comparator|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
11171870|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
11171871|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
11171872|NCT03577327||Adults with vitiligo|
11171873|NCT03577327||Healthy adults|
11171874|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
11171875|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
11171876|NCT03577301|Active Comparator|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
11171877|NCT03577301|Active Comparator|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
11171878|NCT03577301|Active Comparator|Multi-modal Delivery|A 4 session MI intervention. Session 1 is always delivered in person immediately after baseline. Session 2-4 can be delivered in person or remotely based upon youth preference. This arm is open to enrollment as of 11/15/2019.
11171879|NCT03577301|No Intervention|Treatment as Usual|Treatment as usual control = individual HIV testing with referrals and link age to care as provided by the sites under routine circumstances. This arm is open to enrollment as of 11/15/2019.
11171880|NCT03577288|Experimental|Experiment 1 A, B - Level of realism of EVR|Participants (50 children and 50 young adults for part A, and 50 other children and 50 other young adults) will be exposed to virtual experience having different level of realism. In one condition the realism will be high (very close to the real word) and in the second condition the realism will be low (comparable to cartoon). The stimuli of interest included in virtual experience will be of three emotional categories : negative, positive and neutral.
11171881|NCT03577288|Experimental|Experiment 2 - Presence and size of avatar|"Participants (50 children and 100 young adults) will be exposed to virtual experiences in which in one condition they will be part of the virtual environment in a body of an avatar and in another condition the avatar will not be present.
~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar."
11171882|NCT03577288|Experimental|Experiment 3 - Interaction in virtual experience|Participants (50 children and 50 young adults) will be submitted to two conditions of virtual experience, one condition in which it is possible to interact with the stimuli presented in the virtual environment and another condition in which it is not possible to interact. In addition, the stimuli of interest will be of one of three emotional categories : negative, positive and neutral. Thus participants will be exposed to six short virtual experiences.
11171883|NCT03577288|Experimental|Experiment 4 - Animate/Inanimate nature of interactive objects|Participants (30 children and 30 young adults) will be exposed to the virtual experience during which they will be able to interact in one condition with animated (e.g., dog, bird) stimuli and in another condition with inanimate (e.g., book, jacket) stimuli. The animate and inanimate stimuli of interest will be of three emotional categories : negative, positive and neutral.
11171884|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
11171885|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
11171886|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
11171887|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
11171888|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
11171889|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
11171890|NCT03577249|Experimental|Single arm|
11171891|NCT03577236|Experimental|Zenflow Spring System|Receives treatment with the investigational device
11171892|NCT03577223|Experimental|Whole Eggs|
11171893|NCT03577223|Active Comparator|Egg White-Based Egg Substitute|
11171894|NCT03577210|Other|computer-guided augmentation genioplasty|patient-specific PEEK implant
11171895|NCT03577171|Experimental|ABI-H0731 & SOC NUC|Participants with chronic HBV who are currently not being treated will receive ABI-H0731 along with SOC NUC (entecavir [ETV]) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
11171896|NCT03577171|Experimental|Placebo & SOC NUC|Participants with chronic HBV who are currently not being treated will receive matching placebo along with SOC NUC (entecavir [ETV]) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
11171897|NCT03577158|Experimental|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.
~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
11171898|NCT03577158|Experimental|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
11171899|NCT03577158|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
11171900|NCT03577145|Experimental|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) & lovage (20g) with 10g inulin will be given to subjects in the form of a soup
11171901|NCT03577145|Experimental|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) & lovage (20g) will be given to subjects in the form of a soup
11171902|NCT03577145|Experimental|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
11171903|NCT03577132|Experimental|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
11171904|NCT03577132|Experimental|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
11171905|NCT03577119|Experimental|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
11171906|NCT03577119|Experimental|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
11171907|NCT03577106|Experimental|Transcranial magnetic stimulation (TMS)|
11171908|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
11171909|NCT03577093||control|healthy controls
11171910|NCT03577080|Active Comparator|ET+RT+ NMES|neuromuscular electrical training NMES
11171911|NCT03577080|Placebo Comparator|ET+RT|placebo neuromuscular electrical training NMES
11171912|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
11171913|NCT03577054|Experimental|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.
~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.
~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
11171914|NCT03577054|Placebo Comparator|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.
~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
11171915|NCT03577028|Experimental|Experimental: HPN424-1001|"In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.
~In Part 2 (Dose Expansion), patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added."
11171916|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
11171917|NCT03577002|Active Comparator|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
11171918|NCT03577002|Active Comparator|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
11171919|NCT03576989|Experimental|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (three opaque softgels to provide a total daily intake of 1.87 g of EPA + 1.0 g of DHA)
11171920|NCT03576989|Placebo Comparator|Placebo Group|12 weeks of daily oral therapy with placebo (three opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
11171921|NCT03576976|Active Comparator|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
11171922|NCT03576976|Experimental|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
11171923|NCT03576963|Experimental|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
11171924|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
11172022|NCT03576287|Experimental|apremilast|apremilast standard doses
11172633|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
11171925|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
11171926|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
11171927|NCT03576924|Active Comparator|Imposed-MICT|Continuous exercise for 30 minutes per session at 60-65% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
11171928|NCT03576924|Active Comparator|Imposed-HIIT|Five repeated vigorous intervals of 1-min duration at 85-90% of heart rate max with 1-min recovery periods, with 3-min warm-up and 2-min cool-down, making the total session duration 15 min for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
11171929|NCT03576924|Experimental|CHOICE|Participants will always self-select the exercise type that they will do, either the IM-HIIT or the IM-MICT protocols, which will be matched to the parallel imposed conditions.
11171930|NCT03576911|Experimental|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
11171931|NCT03576911|Placebo Comparator|Placebo|Placebo capsule taken orally three times per day for 6 months
11171932|NCT03576885|Active Comparator|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
11171933|NCT03576885|Placebo Comparator|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
11171934|NCT03576885|No Intervention|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
11171935|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.
~Teach session will occur prior and during administration of chemo
~A small quiz will be conducted to asses understanding of the educational binder"
11171936|NCT03576859|Other|cirrhotic patients with chronic liver failure|
11171937|NCT03576859|Other|cirrhotic patients without chronic liver failure|
11171938|NCT03576846|Experimental|Intervention|Stretching and Spinal Manipulative Therapy
11171939|NCT03576846|Active Comparator|Comparator|Stretching
11171940|NCT03576833|Experimental|Balloon|
11171941|NCT03576820|Experimental|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
11171942|NCT03576820|Placebo Comparator|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
11171943|NCT03576807|Experimental|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
11171944|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
11171945|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
11171946|NCT03576781|Experimental|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
11171947|NCT03576781|Sham Comparator|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
11171948|NCT03576781|Experimental|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
11171949|NCT03576781|Sham Comparator|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
11171950|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
11171951|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
11172049|NCT03576144|Experimental|BI 1265162|
11172050|NCT03576144|Placebo Comparator|Placebo|
11172051|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|Open label, single arm trial where GEN1029 will be administered
11171952|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
11171953|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
11171954|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
11171955|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
11171956|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
11171957|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
11171958|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
11171959|NCT03576729||Healthy Controls|Age-matched healthy controls
11171960|NCT03576716|Experimental|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
11171961|NCT03576703|Experimental|EX+H2O|Exercise and diet that did not include SSB
11171962|NCT03576703|Experimental|EX+SSB|Exercise and diet that includes SSB
11171963|NCT03576703|No Intervention|CONTROL|No exercise and diet that did not include SSB
11171964|NCT03576677|Active Comparator|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
11171965|NCT03576677|Placebo Comparator|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
11171966|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
11171967|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
11171968|NCT03576651|Experimental|JHL1149|
11171969|NCT03576651|Active Comparator|US-sourced-Avastin™|
11171970|NCT03576651|Active Comparator|EU-sourced Avastin™|
11171971|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
11171972|NCT03576638|Experimental|AP CD/LD|
11171973|NCT03576625|Placebo Comparator|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
11171974|NCT03576625|Experimental|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
11171975|NCT03576612|Experimental|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
11171976|NCT03576612|Experimental|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
11171977|NCT03576599|Active Comparator|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
11171978|NCT03576599|Placebo Comparator|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
11171979|NCT03576586|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
11171980|NCT03576586|Placebo Comparator|Control|Attention placebo control (cognitive task for same amount of time) plus usual care in the maternity department
11171981|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
11171982|NCT03576547|Experimental|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
11171983|NCT03576534|No Intervention|Control|Standard of care
11171984|NCT03576534|Active Comparator|Study|PBUF used prior to Cardiopulmonary bypass
11171985|NCT03576521|Experimental|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
11171986|NCT03576521|Placebo Comparator|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
11171987|NCT03576508|Experimental|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
11171988|NCT03576508|Active Comparator|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
11171989|NCT03576495|Experimental|Early Intervention / Retention Group|"The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).
~Follow-up testing will be conducted after one year to evaluate learner retention.
~Further, the investigators will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
11171990|NCT03576495|Active Comparator|Delayed Intervention Group|"The investigators will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.
~Both between- and within-group differences will be examined based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
11171991|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
11171992|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
11171993|NCT03576469|Experimental|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:
~6 - 8 weeks - subjects will receive 2 infusions of IVIG
~9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion"
11171994|NCT03576456|Active Comparator|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
11171995|NCT03576456|Placebo Comparator|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
11171996|NCT03576443|Experimental|Treatment arm|Idelalisib 150 mg x 2 p o, until progression
11171997|NCT03576430|Active Comparator|active|active stress handling
11171998|NCT03576430|No Intervention|control|no stress handling
11171999|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
11172000|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"360 mg of nivolumab 3 weeks before RT-Cisplatin
~360 mg of novolumab on days 1, 22,43 of -RT-cisplatin"
11172001|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
11172002|NCT03576391|Experimental|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
11172003|NCT03576391|Experimental|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
11172004|NCT03576391|Experimental|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
11172005|NCT03576378|Experimental|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
11172006|NCT03576365|Experimental|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
11172007|NCT03576365|Sham Comparator|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
11172008|NCT03576352|Experimental|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
11172009|NCT03576352|Experimental|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
11172010|NCT03576352|Experimental|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
11172011|NCT03576352|Experimental|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
11172012|NCT03576339|Sham Comparator|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
11172013|NCT03576339|Experimental|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
11172014|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
11172015|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
11172016|NCT03576313|Experimental|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
11172017|NCT03576313|Active Comparator|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
11172018|NCT03576300||control|subjects without dry eye and diabetes
11172019|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
11172020|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
11190948|NCT03447080|Other|Control 2|White bread
11172023|NCT03576274|Experimental|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
11172024|NCT03576274|Experimental|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.
~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).
~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
11172025|NCT03576274|Experimental|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.
~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.
~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
11172026|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
11172027|NCT03576274|Active Comparator|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.
~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).
~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
11172028|NCT03576261|Experimental|Preoperative echo + fluids|20 individuals investigated by preoperative transthoracic echocardiography. Preoperative colloid fluid bolus (Gelofusine, Fresenius Kabi AB, Sweden) 6 ml/kg lean body weight, is infused intravenously immediately before anesthesia induction.
11172029|NCT03576261|Active Comparator|Preoperative echo, control|20 individuals investigated by preoperative transthoracic echocardiography. No intravenous fluids are infused before anesthesia induction.
11172030|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
11172031|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
11172032|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
11172033|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
11172034|NCT03576235|Experimental|a treatment group|PG102P 1.5 g/day
11172035|NCT03576235|Placebo Comparator|a control group|placebo
11172036|NCT03576222|Active Comparator|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
11172037|NCT03576222|Placebo Comparator|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
11172038|NCT03576209|Active Comparator|Intervention Group|12 week Walking intervention
11172039|NCT03576209|No Intervention|Control Group|No walking program
11172040|NCT03576196|Experimental|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.
~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
11172041|NCT03576196|Other|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.
~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
11172042|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
~The vaccine is administered orally in 2 doses about 1 week apart."
11172043|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.
~The vaccine is administered orally in 2 doses about 1 week apart."
11172044|NCT03576170|Active Comparator|aromatherapy-scent|
11172045|NCT03576170|Active Comparator|aromatherapy-touch|
11172046|NCT03576170|No Intervention|wait-list control|
11172047|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
11172048|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
11172052|NCT03576118|Experimental|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
11172053|NCT03576118|Active Comparator|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
11172054|NCT03576105|Experimental|experimental group|G1 - 32 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
11172055|NCT03576105|Active Comparator|positive control group|G2 - 32 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
11172056|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
11172057|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
11172058|NCT03576079|Experimental|Laser therapy|12 laser sessions over 3 months
11172059|NCT03576079|Active Comparator|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
11172060|NCT03576079|Placebo Comparator|inactive laser therapy|placebo laser for 12 sessions over 3 months
11172061|NCT03576066|Experimental|ABI-H0731 & SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
11172062|NCT03576066|Active Comparator|Placebo & SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
11172063|NCT03576053|Experimental|Histamine+cowhage+heat|
11172064|NCT03576053|Experimental|Histamine+cowhage+serotonin+pre-heating|
11172065|NCT03576053|Placebo Comparator|lidocaine and saline+heat|
11172066|NCT03576027|Experimental|Hyperbaric oxygen therapy|
11172067|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).
~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
11172068|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
11172069|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
11172070|NCT03575988||Diabetes group|
11172071|NCT03575988||Control group|
11172072|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
11172073|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
11172074|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
11172075|NCT03575962|Experimental|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
11172076|NCT03575962|Experimental|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
11172077|NCT03575949|Experimental|Diagnostic (FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard CRT completion.
11172078|NCT03575936|Active Comparator|Standard of Care Group|Standard of Care arm. Pharmacist intervention in clinic
11172079|NCT03575936|Experimental|Home Monitoring Group|Pharmacist intervention with home INR monitoring
11172080|NCT03575923||Intervention site 1|2 planted trees; bulb planting
11172081|NCT03575923||Comparison site 1A|
11172082|NCT03575923||Comparison site 1B|
11172083|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
11172084|NCT03575923||Comparison site 2A|
11172085|NCT03575923||Comparison site 2B|
11172086|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
11172087|NCT03575923||Comparison site 3A|
11172088|NCT03575923||Comparison site 3B|
11172089|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
11172090|NCT03575923||Comparison site 4A|
11172091|NCT03575923||Comparison site 4B|
11172092|NCT03575910||Acute Rejection (AR)|Heart transplant patients diagnosed with an ISHLT grade 2R or 3R via endomyocardial biopsy.
11172093|NCT03575910||Mild Rejection (MR)|Heart transplant patients diagnosed with an ISHLT grade 1R via endomyocardial biopsy.
11172094|NCT03575910||Non-Rejection (NR)|Heart transplant patients diagnosed with an ISHLT grade 0R via endomyocardial biopsy.
11172095|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
11172096|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
11172097|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
11172098|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
11172099|NCT03575871|Experimental|PF-04965842 100 mg|
11172100|NCT03575871|Experimental|PF-04965842 200 mg|
11172101|NCT03575871|Placebo Comparator|Placebo|
11172102|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
11172103|NCT03575858|Active Comparator|Tapered interdental brushes|control group
11172104|NCT03575845|Experimental|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
11172105|NCT03575832|Experimental|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
11172106|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
11172107|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
11172108|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
11172109|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
11172110|NCT03575793|Experimental|Phase I: nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).
~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.
~Plinabulin escalation is as follows:
~Level -1 : 13.5mg/m^2
~Level 1 (start) : 20mg/m^2
~Level 2 : 30mg/m^2"
11172111|NCT03575793|Experimental|Phase II Arm A: nivolumab and ipilimumab|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV).
~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg (maintenance period) until one of the end of treatment criteria occur ."
11172112|NCT03575793|Experimental|Phase II Arm B: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).
~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
11172113|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
11172114|NCT03575754|Experimental|Interventional|This arm utilizes the investigational device, as specified in protocol.
11172115|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
11172116|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
11172117|NCT03575728|Other|Mood disorder|Participants who screen positive for a history of mood disorders
11172118|NCT03575728|Other|Other|Participants who do not screen positive for a history of mood disorders
11172119|NCT03575715|Experimental|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
11172120|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
11172121|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
11172122|NCT03575689|Experimental|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
11172123|NCT03575689|No Intervention|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
11172124|NCT03575676|Experimental|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
11172125|NCT03575676|Experimental|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
11172126|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
11172127|NCT03575637|Experimental|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
11172128|NCT03575637|No Intervention|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
11172281|NCT03574493||Laparoscopic surgery|A minimally-invasive technique in which operations are performed via small incisions (usually 0.5-1.5 cm) at a location distant to the site of interest.
11172129|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
11172130|NCT03575611|Experimental|Treatment (SBRT)|Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist.
11172131|NCT03575598|Experimental|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.
~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
11172132|NCT03575585|Experimental|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
11172133|NCT03575585|Experimental|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
11172134|NCT03575585|Experimental|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
11172135|NCT03575585|Experimental|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
11172136|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
11172137|NCT03575559|Experimental|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
11172138|NCT03575559|Experimental|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
11172139|NCT03575559|Active Comparator|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
11172140|NCT03575559|Active Comparator|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
11172141|NCT03575520|Experimental|Peg group|
11172142|NCT03575507|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
11172143|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
11172144|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
11172145|NCT03575481||Post stroke patients|
11172146|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
11172147|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
11172148|NCT03575455|Experimental|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.
~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
11172149|NCT03575455|No Intervention|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.
~Healthy participants will participate in a single 20' treatment session of seated rest."
11172150|NCT03575442|Other|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
11172151|NCT03575429|Active Comparator|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
11172282|NCT03574493||Robot-assisted surgery using the da Vinci® Surgical System|A minimally-invasive approach that allows good precision, flexibility, and control.
11172152|NCT03575429|Active Comparator|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
11172153|NCT03575403|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules one time daily.
11172154|NCT03575403|Experimental|Low Dose Duloxetine|Subjects will receive 30 mg oral duloxetine one time daily.
11172155|NCT03575403|Experimental|High Dose Duloxetine|Subjects will receive 60 mg oral duloxetine one time daily.
11172156|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
11172157|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
11172158|NCT03575377|Experimental|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
11172159|NCT03575377|No Intervention|Control|These families will receive routine postoperative instructions only.
11172160|NCT03575364||Primary Analytic|Patients with unilateral acute and/or chronic DVT of less than six weeks' duration.
11172161|NCT03575364||Registry|Patients with iliac and/or femoral DVT
11172162|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
11172163|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
11172164|NCT03575338|Active Comparator|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
11172165|NCT03575338|Experimental|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
11172166|NCT03575325|Experimental|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.
~This may be followed by consolidation with CPX-351 at a dose of 65 u/m^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
11172167|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
11172168|NCT03575299|Experimental|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
11172169|NCT03575299|Placebo Comparator|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
11172170|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
11172171|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
11172172|NCT03575273|Experimental|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
11172173|NCT03575273|Experimental|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
11172174|NCT03575273|Active Comparator|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
11172175|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
11172176|NCT03575260||Exemestane|Exemestane 25mg per day
11172177|NCT03575234|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
11172178|NCT03575221||Enrollees|Individuals with Osteogenesis Imperfecta
11172179|NCT03575208|Experimental|HBIG followed by Peginterferon alfa-2a|HBIg x 12 weeks followed by peginterferon alfa-2a180mcg x 24 weeks
11172180|NCT03575208|Active Comparator|Peginterferon alfa-2a|Peginterferon alfa-2a 180mcg x 24 weeks
11172181|NCT03575195|Experimental|Intervention|Rifaximin
11172182|NCT03575195|Placebo Comparator|Placebo|Matching placebo
11172183|NCT03575182|Experimental|Gait retraining program|
11172184|NCT03575182|No Intervention|Physical therapy standard care|
11172185|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
11172186|NCT03575156|Experimental|Systemic lupus erythematosus (SLE)|
11172187|NCT03575156|Experimental|systemic scleroderma (SSc)|
11172188|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea
11172189|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea
11172190|NCT03575130|Experimental|Glanatec|
11172191|NCT03575130|Placebo Comparator|Placebo|
11172253|NCT03574675|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
11172283|NCT03574493||Transanal surgery through the anus|Where the protectomy is performed down to up until the Douglas pouch
11172192|NCT03575117|Experimental|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
11172193|NCT03575117|Other|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
11172194|NCT03575104|Experimental|ACT-541468 10 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
11172195|NCT03575104|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
11172196|NCT03575104|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
11172197|NCT03575091|No Intervention|control group|The infants will receive the standard care at the ward.
11172198|NCT03575091|Experimental|Changing positions|The parents will be guided manually and receive written information of how to change body positions of their child regularly.
11172199|NCT03575091|Experimental|Physiotherapy|The child will be given physiotherapy including light chest compressions, change of body positions and stimulation to deep breathing.
11172200|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
11172201|NCT03575065|Experimental|TNBC|Locally advanced or metastatic TNBC with confirmed either deleterious or suspected deleterious germline BRCA1/2 mutation.
11172202|NCT03575065|Experimental|HR(+)/HER2(-) breast cancer|Locally advanced or metastatic HR(+)/HER2(-) breast cancer with confirmed either deleterious or suspected deleterious germline BRCA1/2 mutation.
11172203|NCT03575052|Experimental|Drug - Pimavanserin|
11172204|NCT03575052|Placebo Comparator|Placebo|
11172205|NCT03575039|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
11172206|NCT03575026|Experimental|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
11172207|NCT03575026|Placebo Comparator|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
11172208|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:
~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles
~Maintenance phase:
~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
11172209|NCT03575000|Experimental|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
11172210|NCT03574987|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
11172211|NCT03574987|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
11172212|NCT03574987|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
11172213|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
11172214|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
11172215|NCT03574961|Experimental|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
11172216|NCT03574961|Placebo Comparator|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
11172217|NCT03574948|Experimental|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
11172218|NCT03574948|Placebo Comparator|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
11172219|NCT03574935|Experimental|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:
~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
11172220|NCT03574935|Active Comparator|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
11172221|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
11172222|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
11172223|NCT03574922|No Intervention|Control|Assessments only
11172224|NCT03574909|Experimental|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).
~There is no requirement for the first dose to be administered in the clinic under observation.
~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.
~No specific precautions are required in relation to concomitant food intake."
11172280|NCT03574493||Open laparotomy|A surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity.
11172225|NCT03574909|Placebo Comparator|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.
~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.
~No specific precautions are required in relation to concomitant food intake."
11172226|NCT03574883|Experimental|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
11172227|NCT03574883|Active Comparator|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
11172228|NCT03574883|Sham Comparator|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
11172229|NCT03574883|Experimental|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
11172230|NCT03574883|Sham Comparator|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
11172231|NCT03574870|Experimental|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):
~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
11172232|NCT03574870|Experimental|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)
~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery
~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)
~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
11172233|NCT03574857|Active Comparator|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
11172234|NCT03574857|Active Comparator|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
11172235|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
11172236|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
11172237|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
11172238|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
11172239|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).
~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).
~The regimen will be given for a total of 3 cycles.
~The regimen will be given for a total of 3 cycles."
11172240|NCT03574805|Active Comparator|PRS-060|PRS-060 or Placebo
11172241|NCT03574805|Placebo Comparator|Placebo|PRS-060 or Placebo
11172242|NCT03574792|Active Comparator|Arm I (gabapentin, methadone, oxycodone)|Participants receive gabapentin PO daily or TID. Participants may also receive methadone PO TID and oxycodone PO every 8 hours as needed. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
11172243|NCT03574792|Experimental|Arm II (gabapentin, methadone, oxycodone, venlafaxine)|Participants receive gabapentin, methadone, and oxycodone as in Arm I and venlafaxine PO BID or venlafaxine hydrochloride extended release daily for up to 12 months in the absence of disease progression or unacceptable toxicity.
11172244|NCT03574779|Experimental|Cohort A: 1-2 prior lines of therapy|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered every 3 weeks for 4 cycles (each cycle is 21 days), followed by every 6 weeks beginning on cycle 5 day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
11172245|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
11172246|NCT03574766|No Intervention|Control Group|Routine lactation support.
11172247|NCT03574753|Experimental|ABBV-399|"C-MET overexpression is seen in 30% of patients with lung squamous cell carcinoma (SCCA). ABBV-399 (Process II) is a first-in-class antibody-drug conjugate (ADC) comprised of ABT-700, an anti-c-Met monoclonal antibody linked to monomethyl auristatin E (MMAE), which is a potent microtubule inhibitor. This delivers a direct anti-mitotic effect without relying on MET pathway inhibition.
~ABBV-399 will be administered intravenously on day 1 of each 21-day cycle. Treatment will continue in consenting patients until disease progression or intolerable toxicity."
11172248|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
11172249|NCT03574701|Experimental|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
11172250|NCT03574701|Experimental|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
11172251|NCT03574701|No Intervention|C: Standard of Care|Group C: This study group will receive only standard of care .
11172252|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
11172254|NCT03574675|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
11172255|NCT03574662|Experimental|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
11172256|NCT03574649|Experimental|NANT NSCLC Combination Immunotherapy regimen|
11172257|NCT03574649|Active Comparator|Standard of Care|
11172258|NCT03574636|Active Comparator|OCT guidance|"Firehawk stent implantation will be performed with Optical Coherence Tomography guidance.
~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.
~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
11172259|NCT03574636|Active Comparator|IVUS guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.
~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.
~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
11172260|NCT03574636|Active Comparator|QCA guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.
~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.
~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
11172261|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
11172262|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
11172263|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
11172264|NCT03574610|Experimental|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
11172265|NCT03574597|Experimental|Semaglutide|Participants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
11172266|NCT03574597|Placebo Comparator|Placebo (semaglutide)|Participants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
11172267|NCT03574584|Experimental|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
11172268|NCT03574584|Experimental|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
11172269|NCT03574571|Experimental|Docetaxel|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.
11172270|NCT03574571|Experimental|Docetaxel with Radium-223|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
11172271|NCT03574558|Experimental|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for personalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
11172272|NCT03574545|Active Comparator|Reference VAY736 Drug Product|Powder for solution for injection / infusion
11172273|NCT03574545|Experimental|Test VAY736 Drug Product|Solution for injection
11172274|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
11172275|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
11172276|NCT03574519|Experimental|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
11172277|NCT03574519|Experimental|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
11172278|NCT03574519|Experimental|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
11172279|NCT03574519|Experimental|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
11172285|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations
~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
11172286|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
11172287|NCT03574467||Bobath Approach Applied to Patient with Stroke|
11172288|NCT03574454|Other|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
11172289|NCT03574454|Other|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
11172290|NCT03574454|Other|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
11172291|NCT03574441|Active Comparator|TegadermTM only|
11172292|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
11172293|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
11172294|NCT03574428|Active Comparator|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
11172295|NCT03574428|Active Comparator|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
11172296|NCT03574428|Active Comparator|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
11172297|NCT03574428|Active Comparator|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
11172298|NCT03574415|Experimental|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
11172299|NCT03574415|Experimental|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
11172300|NCT03574415|Experimental|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
11172301|NCT03574415|Experimental|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
11172302|NCT03574415|Experimental|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
11172303|NCT03574415|Experimental|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
11172304|NCT03574415|Experimental|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
11172305|NCT03574415|Placebo Comparator|Placebo|DWP14012 placebo-matching tablets
11172306|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
11172307|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.
~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
11172308|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11172309|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11172310|NCT03574402|Experimental|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
11172311|NCT03574402|Experimental|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
11172312|NCT03574402|Experimental|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
11172313|NCT03574402|Experimental|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
11172314|NCT03574402|Experimental|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.
~This arm was divided into three groups:
~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
11172315|NCT03574402|Experimental|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.
~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
11172316|NCT03574402|Experimental|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1.
~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
11172317|NCT03574402|Experimental|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.
~This arm was divided into two groups:
~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
11172634|NCT03572127|Experimental|Non-animal derived diet|High protein diet derived from non-animal sources.
11172318|NCT03574402|Experimental|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
11172319|NCT03574402|Experimental|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
11172320|NCT03574402|Experimental|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1<50% without EGFR mutation or ALK rearrangement.
~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
11172321|NCT03574402|Experimental|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement.
~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
11172322|NCT03574402|Experimental|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.
~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
11172323|NCT03574402|Experimental|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.
~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
11172324|NCT03574389|Experimental|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|"Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.
~Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).
~Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.
~Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age."
11172325|NCT03574389|Active Comparator|Haemophilus influenzae type b (Hib)|"No participants in cohort 1 will receive Hib vaccine.
~Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.
~Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age."
11172326|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
11172327|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.
~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
11172328|NCT03574363|Experimental|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
11172329|NCT03574363|Experimental|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
11172330|NCT03574363|Placebo Comparator|Placebo tablet|Placebo tablet QD orally, 84 days
11172331|NCT03574350|Experimental|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
11172332|NCT03574350|Active Comparator|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
11172333|NCT03574337|Active Comparator|Sugammadex|Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
11172334|NCT03574337|Active Comparator|Neostigmine/glycopyrrolate|Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
11172335|NCT03574337|No Intervention|No reversal administered|No reversal administered at the end of the case
11172336|NCT03574324|Experimental|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
11172337|NCT03574324|Other|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
11172338|NCT03574311|Experimental|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
11172339|NCT03574311|Placebo Comparator|Placebo|Preoperative 100 ml saline as 30 minute infusion
11172340|NCT03574285|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
11172341|NCT03574285|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
11172342|NCT03574272|Experimental|Patient Transfer Monitoring System|
11172343|NCT03574246|Experimental|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
11172344|NCT03574246|Active Comparator|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
11172345|NCT03574233||patients who are ready to wean ventilator off|
11172635|NCT03572127|Active Comparator|Animal derived diet|High protein diet derived from animal sources.
11172346|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.
~Adjuvant Therapy:
~Pembrolizumab 200mg IV every 21 days for 6 months"
11172347|NCT03574207|Other|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
11172348|NCT03574207|Other|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
11172349|NCT03574194|Experimental|Methionine-restricted diet|6-10 weeks methionine-restricted diet (MRD) curative intent radiation therapy course of 6 weeks or less.
11172350|NCT03574168|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
11172351|NCT03574155|No Intervention|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.
~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
11172352|NCT03574155|Experimental|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.
~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
11172353|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
11172354|NCT03574129|Experimental|Adolescent transition package|Adolescent transition package
11172355|NCT03574129|No Intervention|Standard of care|Standard of care adolescent services
11172356|NCT03574103|Active Comparator|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
11172357|NCT03574103|Experimental|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
11172358|NCT03574103|Experimental|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
11172359|NCT03574090|Experimental|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
11172360|NCT03574090|Active Comparator|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
11172361|NCT03574077|Experimental|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
11172362|NCT03574077|Active Comparator|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
11172363|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
11172364|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
11172365|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
11172366|NCT03574064|Placebo Comparator|Placebo|Placebo
11172367|NCT03574051|Experimental|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
11172368|NCT03574038|Active Comparator|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
11172369|NCT03574038|Sham Comparator|Sham Stimulation|Sham Stimulation
11172370|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
11172371|NCT03574012|Active Comparator|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
11172372|NCT03574012|Experimental|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
11172373|NCT03573999|Active Comparator|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
11172374|NCT03573999|Experimental|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
11172375|NCT03573986|Experimental|Arm A|
11172376|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
11172377|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
11172378|NCT03573960|Experimental|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
11172379|NCT03573947|Experimental|nivolumab, ipilimumab and paclitaxel|
11172380|NCT03573934|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
11172381|NCT03573934|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
11172382|NCT03573934|Experimental|GLP-2+GIP|GLP-2+GIP injection
11172383|NCT03573934|Placebo Comparator|Placebo|Placebo injection
11172384|NCT03573921|Experimental|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
11172385|NCT03573921|Experimental|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
11172386|NCT03573908|Experimental|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
11172387|NCT03573908|Placebo Comparator|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
11172388|NCT03573895|Experimental|Foam-Roller|
11172389|NCT03573895|Experimental|Neuromuscular Stretching|
11172390|NCT03573895|Experimental|Pasive stretching|
11172391|NCT03573895|No Intervention|Control|
11172392|NCT03573882|Other|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
11172393|NCT03573869|Experimental|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
11172394|NCT03573869|No Intervention|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
11172395|NCT03573856|Active Comparator|Active Living|Three component behavioral intervention consisting of group-based classes, individual motivational interviewing-based sessions, and resource toolbox
11172396|NCT03573856|Placebo Comparator|Health and Safety|One component health and safety program consisting of group classes
11172397|NCT03573843|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
11172398|NCT03573843|Experimental|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
11172399|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
11172400|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
11172401|NCT03573817|Experimental|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
11172402|NCT03573817|Experimental|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
11172403|NCT03573817|Placebo Comparator|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
11172404|NCT03573817|Placebo Comparator|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
11172405|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
11172406|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
11172407|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
11172408|NCT03573778|Experimental|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
11172409|NCT03573778|Active Comparator|Usual Care|Information about Community Services
11172410|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
11172439|NCT03573544|Experimental|OBI-888 Expansion Phase|Part B: Five cohorts at dose level 20 mg/kg of liquid form OBI-888 for intravenous infusion.
11172411|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
11172412|NCT03573726|Other|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
11172413|NCT03573713|Experimental|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
11172414|NCT03573713|Other|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
11172415|NCT03573700|Experimental|SJCAR19 Therapy|"Patients in both the Phase I and Phase II portion of the study will receive lymphodepleting chemotherapy (unless determined by PI that lymphodepletion is not necessary), followed by a single infusion of the patient-derived SJCAR19 cellular product. The most commonly used lymphodepleting chemotherapy regimen will consist of the agents: Fludarabine and Cyclophosphamide. They will also receive Mesna. Dosing of SJCAR19 on the Phase I study will follow a dose escalation schema, with dose changes based on dose-limiting toxicities. In the Phase II study, SJCAR19 dosing with follow the maximum tolerated dose, as determined in the Phase I portion.
~Cells for infusion are prepared using the CliniMACS System."
11172416|NCT03573687|Experimental|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
11172417|NCT03573687|Experimental|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
11172418|NCT03573687|Experimental|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
11172419|NCT03573674|Experimental|Cognitive ergonomics Intervention|
11172420|NCT03573674|Active Comparator|Stress management Intervention|
11172421|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
11172422|NCT03573661|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
11172423|NCT03573648|Active Comparator|Tamoxifen|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive tamoxifen (T) versus tamoxifen with palbociclib (PT) in a 1:1 ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
11172424|NCT03573648|Active Comparator|Tamoxifen with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive tamoxifen (T) versus tamoxifen with palbociclib (PT) in a 1:1 ratio. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
11172425|NCT03573635|Other|Supratube|Patient with orotracheal intubation and supratube device
11172426|NCT03573622|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
11172427|NCT03573622|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
11172428|NCT03573609|No Intervention|Control|Usual respiratory care
11172429|NCT03573609|Active Comparator|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
11172430|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
11172431|NCT03573583|Experimental|Resistance Training group (RT)|"The resistance training intervention will include a full body, resistance training performed three days per week.
~The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines"
11172432|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
11172433|NCT03573570|Experimental|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
11172434|NCT03573570|No Intervention|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
11172435|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
11172436|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
11172437|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
11172438|NCT03573544|Experimental|OBI-888 Escalation Phase|Part A: Three cohorts of escalating dose levels of OBI-888 5, 10, and 20 mg/kg liquid form for intravenous infusion to establish maximum tolerated dose (MTD).
11191205|NCT03445234|Experimental|Banana|Acute banana ingestion
11172440|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
11172441|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
11172442|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
11172443|NCT03573518|Experimental|BTX 1503 Dose 1 BID|BTX 1503 Dose 1 twice daily
11172444|NCT03573518|Experimental|BTX 1503 Dose 1 QD|BTX 1503 Dose 1 once daily
11172445|NCT03573518|Experimental|BTX 1503 Dose 2 QD|BTX 1502 Dose 2 once daily
11172446|NCT03573518|Placebo Comparator|Vehicle BID|Vehicle twice daily
11172447|NCT03573518|Placebo Comparator|Vehicle QD|Vehicle once daily
11172448|NCT03573505|Experimental|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
11172449|NCT03573505|Placebo Comparator|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
11172450|NCT03573492|Active Comparator|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
11172451|NCT03573492|Active Comparator|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
11172452|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
11172453|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
11172454|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
11172455|NCT03573453|Experimental|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
11172456|NCT03573453|Experimental|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
11172457|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.
~They will inform the investigator verbally when they are feeling full.
~After they have decided to end their meal, they will be asked to fill out a questionnaire"
11172458|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.
~They will inform the investigator verbally when they are feeling full.
~After they have decided to end their meal, they will be asked to fill out a questionnaire"
11172459|NCT03573414|Experimental|Healthy men and women|"Intervention:
~2*breakfast containing 40 g of raspberry powder, 30 g milled flax seeds and 250 mL of soy Milk."
11172460|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).
~Photodynamic therapy (PDT)"
11172461|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
11172462|NCT03573388||Optical coherence tomography (OCT)|
11172463|NCT03573375|Experimental|Cancer Patients in Supportive Care Clinic (SCC)|
11172464|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
11172465|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
11172466|NCT03573349|Other|Ketamine|Open-label, non-randomized
11172467|NCT03573336|Experimental|Vilaprisan (BAY1002670) 2 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
11172468|NCT03573336|Experimental|Vilaprisan (BAY1002670) 4 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
11172469|NCT03573336|Placebo Comparator|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
11172470|NCT03573323|Experimental|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.
~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
11172471|NCT03573323|Experimental|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.
~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
11172472|NCT03573310|Experimental|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
11172473|NCT03573310|Experimental|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
11172474|NCT03573297|Experimental|Cariprazine 3 mg/day|Cariprazine capsules, oral administration, once daily
11172475|NCT03573297|Experimental|Cariprazine 1.5 mg/day|Cariprazine capsules, oral administration, once daily
11172476|NCT03573297|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily
11172674|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
11172477|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
11172478|NCT03573271|Experimental|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
11172479|NCT03573258|Experimental|Fiber|"300 ml of orange juice plus Intervention
~6 g of oat beta glucan = FIBER (study A) or
~25 g inulin/FOS = FIBER (study B)"
11172480|NCT03573258|Placebo Comparator|Placebo|"300 ml of orange juice plus Placebo:
~13.5 g maltodextrin = PLACEBO (study A) or
~15.5 g maltodextrin = PLACEBO (study B)"
11172481|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
11172482|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
11172483|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
11172484|NCT03573219|Experimental|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
11172485|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
11172486|NCT03573193|Active Comparator|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
11172487|NCT03573193|Other|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
11172488|NCT03573167|Active Comparator|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
11172489|NCT03573167|Experimental|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
11172490|NCT03573167|No Intervention|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
11172491|NCT03573154|Other|e-liquid 1|
11172492|NCT03573154|Other|e-liquid 2|
11172493|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
11172494|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
11172495|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
11172496|NCT03573115|Experimental|Acne patients|
11172497|NCT03573102|Active Comparator|control|ACE inhibitor , aspirin , statins will be given once daily
11172498|NCT03573102|Experimental|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
11172499|NCT03573089|Active Comparator|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
11172500|NCT03573089|Experimental|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
11172501|NCT03573076|Experimental|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
11172502|NCT03573076|Experimental|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
11172503|NCT03573076|Active Comparator|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
11172504|NCT03573076|Active Comparator|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
11172505|NCT03573076|No Intervention|Control|Control receiving no intervention
11172506|NCT03573063|Other|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
11172507|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
11172508|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
11172509|NCT03573037|Experimental|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
11172510|NCT03573037|Active Comparator|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
11172511|NCT03573024|Experimental|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
11172636|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
11172512|NCT03573011|Experimental|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal [18F]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.
~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.
~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
11172513|NCT03573011|Experimental|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of [18F]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
11172514|NCT03572998|Other|Breast cancer patients|study subject
11172515|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
11172516|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
11172517|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
11172518|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
11172519|NCT03572972||Patients prescribed apixaban|
11172520|NCT03572972||Patients prescribed dabigatran|
11172521|NCT03572972||Patients prescribed rivaroxaban|
11172522|NCT03572972||Patients prescribed warfarin|
11172523|NCT03572972||Patients prescribed antiplatelet|
11172524|NCT03572959|Active Comparator|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
11172525|NCT03572959|Experimental|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.
~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
11172526|NCT03572946|Experimental|target biopsy group|Targeted prostate biopsy
11172527|NCT03572946|Active Comparator|standard biopsy group|Standard prostate biopsy
11172528|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
11172529|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
11172530|NCT03572920||Patients with hip/knee arthroplasty.|Objective sleep evaluation by actigraphy. Pittsburgh Sleep Quality Index (PSQI). Epworth Sleepiness Scale (ESS).
11172531|NCT03572881|Experimental|Asymptomatic|
11172532|NCT03572881|Experimental|Symptomatic|
11172533|NCT03572855|Experimental|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
11172534|NCT03572842|Other|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
11172535|NCT03572829|Experimental|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
11172536|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)
~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
11172537|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)
~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
11172538|NCT03572803|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
11172539|NCT03572803|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
11172540|NCT03572803|Sham Comparator|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
11172541|NCT03572790|Experimental|Prucalopride|
11172542|NCT03572790|Placebo Comparator|Placebo|
11172543|NCT03572777|Active Comparator|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
11172544|NCT03572777|Active Comparator|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
11172545|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction
~If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3
~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
11172546|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.
~Bed-, wrist- and ECG-sensor monitoring"
11172547|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.
~Bed-, wrist- and ECG-sensor monitoring"
11172548|NCT03572738||Patients with HS|The set of all Hidradenitis Suppurativa patients (ICD-10 code: L73.2) who visited Wake Forest Baptist Medical Center's dermatology clinic during the last 5 years will either be recruited in person or be mailed the HS Severity Self-Assessment tool and a survey about their demographics, symptoms, treatments, psychological aspects, and lifestyle.
11172549|NCT03572725|Active Comparator|Gas tamponade|Gas as intraocular tamponade.
11172550|NCT03572725|Experimental|Air tamponade|Air as intraocular tamponade.
11172551|NCT03572686|Sham Comparator|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
11172552|NCT03572686|Placebo Comparator|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
11172553|NCT03572686|Experimental|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
11172554|NCT03572673|Active Comparator|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
11172555|NCT03572673|Experimental|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
11172556|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
11172557|NCT03572647|Experimental|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
11172558|NCT03572647|Active Comparator|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
11172559|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:
~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
11172560|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:
~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
11172561|NCT03572621|Experimental|Experimental group|Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
11172562|NCT03572621|Sham Comparator|Control group|Patient without therapeutic education.
11172563|NCT03572621|Other|Partner|Patient's partner.
11172564|NCT03572608|Experimental|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
11172565|NCT03572608|No Intervention|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
11172566|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
11172567|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.
~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.
~comparing the results with histopathology ."
11172568|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
11172569|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
11172570|NCT03572569||First-degree family members|Parents and siblings of index patients
11172571|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
11172572|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
11172573|NCT03572543|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
11172574|NCT03572543|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
11172575|NCT03572530|Experimental|group 1|5-Azacytidine (5-AZA) group 1: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (20 mg) into the fourth ventricle. Patients in Group 1 will receive two 5-AZA infusions every week.
11172673|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
11172576|NCT03572530|Experimental|group 2|5-Azacytidine (5-AZA) group 2: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (20 mg) into the fourth ventricle. Patients in Group 2 will receive three 5-AZA infusions every week.
11172577|NCT03572530|Experimental|group 3|5-Azacytidine (5-AZA) group 3: Enrolled patients will undergo surgical placement of a ventricular catheter into the fourth ventricle that will be attached to a subcutaneously placed reservoir. Patients will be divided into 3 dose groups and receive 8 weeks of intraventricular 5-AZA (20 mg) into the fourth ventricle. Patients in Group 3 will receive four 5-AZA infusions every week.
11172578|NCT03572517|Active Comparator|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.
~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.
~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
11172579|NCT03572517|Active Comparator|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.
~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
11172580|NCT03572491|Experimental|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
11172581|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
11172582|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
11172583|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
11172584|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
11172585|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:
~Acoustic Radiation Force Impulse (ARFI)
~Magnetic Resonance Elastography (MRE)"
11172586|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:
~Acoustic Radiation Force Impulse (ARFI)
~Magnetic Resonance Elastography (MRE)"
11172587|NCT03572452|Experimental|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
11172588|NCT03572452|Active Comparator|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
11172589|NCT03572439|Active Comparator|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
11172590|NCT03572439|Active Comparator|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
11172591|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
11172592|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
11172593|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
11172594|NCT03572413|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
11172595|NCT03572413|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
11172596|NCT03572400|Experimental|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab
~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
11172597|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
11172598|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
11172599|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
11172631|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
11172600|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
11172601|NCT03572361|Experimental|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
11172602|NCT03572348|Active Comparator|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
11172603|NCT03572348|Active Comparator|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
11172604|NCT03572335||HIV positive with normal PFT's|HIV positive with normal baseline DLco. Subjects with DLco>80% predicted after adjustments for Hgb and Co
11172605|NCT03572335||HIV positive with mild DLco impairment|HIV positive with mild DLco impairment DLco <80% predicted after adjustments for Hgb and Co.
11172606|NCT03572322||Doctors|
11172607|NCT03572322||Patients|
11172608|NCT03572296|Placebo Comparator|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
11172609|NCT03572296|Experimental|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
11172610|NCT03572296|Experimental|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
11172611|NCT03572283|Experimental|Bethanechol|Patients with pancreatic adenocarcinoma will receive bethanechol prior to pancreatic surgery
11172612|NCT03572270|Experimental|case|PLWH
11172613|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
11172614|NCT03572257|Experimental|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
11172615|NCT03572257|Placebo Comparator|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
11172616|NCT03572244|Experimental|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
11172617|NCT03572244|Active Comparator|Machine|A machined implant will be placed.
11172618|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
11172619|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
11172620|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
11172621|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
11172622|NCT03572205|Experimental|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
11172623|NCT03572205|Experimental|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
11172624|NCT03572205|Experimental|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
11172625|NCT03572205|Experimental|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
11172626|NCT03572179|Active Comparator|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
11172627|NCT03572179|No Intervention|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
11172628|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
11172629|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
11172630|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
11172637|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
11172638|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
11172639|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
11172640|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
11172641|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
11172642|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
11172643|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
11172644|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
11172645|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
11172646|NCT03572088|Active Comparator|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
11172647|NCT03572088|Placebo Comparator|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
11172648|NCT03572075|Experimental|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
11172649|NCT03572075|Experimental|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
11172650|NCT03572062|Experimental|Arm 1|Low dose formulation A and SIIV
11172651|NCT03572062|Experimental|Arm 2|Low dose formulation B and SIIV
11172652|NCT03572062|Experimental|Arm 3|Mid dose formulation A and SIIV
11172653|NCT03572062|Experimental|Arm 4|Mid dose formulation B and SIIV
11172654|NCT03572062|Experimental|Arm 5|High dose formulation A and SIIV
11172655|NCT03572062|Experimental|Arm 6|High dose formulation B and SIIV
11172656|NCT03572062|Experimental|Arm 7|High dose formulation C and SIIV
11172657|NCT03572062|Placebo Comparator|Arm 8|Placebo and SIIV
11172658|NCT03572049|Experimental|SUBA itraconazole|"Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.
~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food"
11172659|NCT03572049|Active Comparator|Conventional itraconazole|"Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.
~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food"
11172660|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
11172661|NCT03572023|Active Comparator|MINOCA|"This group will include patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).
~Integrative characterization of MINOCA patients:
~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
11172662|NCT03572023|Active Comparator|MI with coronary obstruction|"This group will include patients with myocardial infarction and obstructive coronary arteries.
~Characterization of MI patients with coronary obstruction:
~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
11172663|NCT03572010|Placebo Comparator|FeFum fortified maize test meal|
11172664|NCT03572010|Placebo Comparator|FeSO4 fortified LNS|
11172665|NCT03572010|Placebo Comparator|FeSO4 supplement|
11172666|NCT03572010|Placebo Comparator|FeSO4 fortified fruit juice|
11172667|NCT03571984|Experimental|Moving on ABC Plus|Moving on ABC Plus is combination of two interventions. The culturally adapted CBT and Moving on ABC. CBT will be integrated with The Moving on After Breast Cancer (ABC), which has been developed by Dr Anneela Saleem who suffered from breast cancer. The integrated intervention will consist of 12 sessions (60-90 minutes). The first 8 sessions will be delivered weekly and the last four sessions will be delivered fortnightly
11172668|NCT03571984|No Intervention|Routine Care|This will consist of routine assessment and management as usually conducted by oncology clinics and general practice. GP's will be informed about the psychiatric diagnosis.
11172669|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
11172670|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
11172671|NCT03571958|No Intervention|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
11172672|NCT03571958|Experimental|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
11172675|NCT03571932||Intervention Facilities|Includes 18 health facilities
11172677|NCT03571919|Placebo Comparator|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
11172678|NCT03571919|Active Comparator|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
11172679|NCT03571906|Experimental|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.
~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
11172680|NCT03571906|No Intervention|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up
~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
11172681|NCT03571893|Experimental|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
11172682|NCT03571893|Active Comparator|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
11172683|NCT03571880|Experimental|CNSLBP group|
11172684|NCT03571880|Active Comparator|Healthy control group|
11172685|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
11172686|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
11172687|NCT03571854|Experimental|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
11172688|NCT03571854|Active Comparator|Group VCV|Volume controlled ventilation
11172689|NCT03571841|Experimental|Educational Intervention|"For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.
~Group Session
~Telephone Booster Session"
11172690|NCT03571828|Experimental|Part 1: Dose Exploration|Dose exploration cohorts to estimate the MTD, safety, tolerability, and PK of different doses of AMG 562 in subjects with relapsed/refractory DLBCL, MCL or FL using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).
11172691|NCT03571828|Experimental|Part 2: Dose Expansion|dose expansion part to gain further clinical experience, safety and efficacy data for AMG 562 in subjects with relapsed / refractory DLBCL. The dose to be evaluated will be at or below the MTD estimated in the dose exploration cohorts.
11172692|NCT03571815|Experimental|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
11172693|NCT03571815|Placebo Comparator|control group|application of water on teeth in the control group
11172694|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
11172695|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
11172696|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
11172697|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
11172698|NCT03571763||acute ischemic stroke patient|acute ischemic stroke patient acute ischemic stroke patient Patient age ≥18 years .Acute ischemic stroke patient confirmed by imaging(SWI sequence) .Time of onset: within 3 months
11172699|NCT03571750|Experimental|Building Stronger Allies Condition|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
11172700|NCT03571750|Placebo Comparator|Health Education Training Condition|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
11172701|NCT03571737|Active Comparator|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
11172702|NCT03571737|Experimental|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
11172703|NCT03571724|Experimental|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
11172704|NCT03571724|Experimental|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
11172705|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
11172706|NCT03571698|No Intervention|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
11191206|NCT03445234|Experimental|No banana|No banana ingestion
11172707|NCT03571698|Active Comparator|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
11172708|NCT03571698|Active Comparator|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
11172709|NCT03571685|Experimental|Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting.
11172710|NCT03571672|Experimental|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
11172711|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
11172712|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
11172713|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
11172714|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
11172715|NCT03571633|Experimental|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).
~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
11172716|NCT03571633|Active Comparator|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).
~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
11172717|NCT03571620|Placebo Comparator|Vehicle|
11172718|NCT03571620|Experimental|1.0% Q301 Cream|
11172719|NCT03571620|Experimental|1.4% Q301 Cream|
11172720|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
11172721|NCT03571594|Experimental|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
11172722|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
11172723|NCT03571594|Experimental|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
11172724|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
11172725|NCT03571594|Experimental|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
11172726|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
11172727|NCT03571594|Experimental|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
11172728|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
11172729|NCT03571594|Experimental|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
11172730|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
11172731|NCT03571594|Active Comparator|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
11172732|NCT03571581|Experimental|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
11172733|NCT03571568|Experimental|BI-1206|BI-1206 IV Standard 3+3 Dose-Escalation Design
11172734|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
11172735|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
11172736|NCT03571529|Active Comparator|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation
~Protocol with EMG-driven hand exoskeleton (Hand of Hope):
~Warm-up: 10 min passive mode 2 min resting
~Training: According to residual muscle power:
~10 min active-assistive, 2 min resting, 10 min Active-assistive or
~5 min active, 2 min resting, 15 min active assistive or
~10 min active, 2 min resting, 10 min active and
~10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
11172737|NCT03571529|Active Comparator|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).
~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
11172738|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
11172739|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
11172740|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
11172801|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen.
~If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen."
11173730|NCT03564821|Experimental|Ivosidenib (250mg/day)|-Ivosidenib will be administered orally every day
11172741|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
11172742|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
11172743|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
11172744|NCT03571464|Experimental|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
11172745|NCT03571464|Active Comparator|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
11172746|NCT03571438|Experimental|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
11172747|NCT03571438|Active Comparator|Sunitinib|Treatment of cell culture with Sunitinib
11172748|NCT03571438|Active Comparator|Pazopanib|Treatment of cell culture with Pazopanib
11172749|NCT03571438|Active Comparator|Temsirolimus|Treatment of cell culture with Temsirolimus
11172750|NCT03571425|Placebo Comparator|Oral Placebo|Placebo drink
11172751|NCT03571425|Active Comparator|Oral Protein|Protein drink, ingested orally
11172752|NCT03571425|Active Comparator|Enteral Protein|Protein drink, administered via enteral tube
11172753|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
11172754|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
11172755|NCT03571386||Mild to Moderate Depression|Patients who currently have mild to moderate severity of depression symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
11172756|NCT03571386||Mild to Moderate Anxiety|Patients who currently have mild to moderate severity of anxiety symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
11172757|NCT03571386||High Stress|Patients with a history of reported stress who are receiving Mindfulness-Based Stress Reduction (MBSR) in a group setting as standard of care will be recruited for this study. All patients are eligible.
11172758|NCT03571360|Other|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
11172759|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
11172760|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
11172761|NCT03571334|Experimental|IncobotulinumtoxinA|"IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units.
~Study participants in this arm will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)
~Hands: INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).
~Feet: INA will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
11172762|NCT03571334|Placebo Comparator|saline control|"Study participants in this arm will 2.5mL normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.)
~Hands: saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site).
~Feet: Saline will be injected across the dorsal surface of the feet also in a grid like pattern covering a total of 25 sites per limb (0.1mL/site)."
11172763|NCT03571321|Experimental|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.
~Standard Chemotherapy Consists of:
~Remission consolidation therapy (lasting 8 weeks)
~Interim Maintenance (lasting 8 weeks)
~Delayed Intensification (lasting 8 weeks
~Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)
~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
11172764|NCT03571308|Experimental|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.
~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
11172765|NCT03571295|Experimental|videolaryngoscopy|
11172766|NCT03571295|Experimental|direct laryngoscopy|
11172767|NCT03571282|Experimental|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
11172768|NCT03571269||OCT-guided group|OCT examination methods and precautions are the same as above. The operator judges the lesion according to the feature of culprit lesions from OCT. If a stent is implanted, postoperative OCT examination is performed. Based on the operator's experience, it is judged whether post-dilatation is necessary. Patients undergoing stent implantation should be treated with aspirin for at least 12 months.
11172769|NCT03571269||angiography-guided group|CAG examination methods and precautions are the same as above. Patients undergoing conventional angiography and/or thrombus aspiration do not undergo OCT. The operator judges the lesion according to the current treatment standard and decides whether to implant the stent. If a stent is implanted, postoperative angiography (also required to meet the above body position requirements) is performed. Based on the operator's experience, it is judged whether post-dilatation is necessary. Patients undergoing stent implantation should be treated with aspirin for at least 12 months.
11172770|NCT03571256|Experimental|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
11172771|NCT03571256|Experimental|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
11172772|NCT03571256|Placebo Comparator|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
11172773|NCT03571243||smokers|no intervention
11172774|NCT03571243||never-smokers|no intervention
11172775|NCT03571230|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
11172776|NCT03571230|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
11172777|NCT03571230|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
11172778|NCT03571230|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.
~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
11172779|NCT03571217||Diabetic retinopathy cohort|
11172780|NCT03571217||Mild visual impairment cohort|
11172781|NCT03571204|Active Comparator|Group-1 active treatment|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with 3BNC117 plus 10-1074. Study staff and participants will be blinded to Group 1 treatment assignments.
11172782|NCT03571204|Placebo Comparator|Group-1 placebo|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with normal saline placebo. Study staff and participants willbe blinded to Group 1 treatment assignments.
11172783|NCT03571204|Experimental|Group-2 active treatment|Group 2, up to 15 viremic individuals not taking ARTwill receive 3BNC117 combined with 10-1074.
11172784|NCT03571191|Experimental|1|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
11172785|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
11172786|NCT03571165|Experimental|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
11172787|NCT03571152|Experimental|Educational videos|Subjects allocated in this arms will receive the educational videos.
11172788|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
11172789|NCT03571126|Placebo Comparator|Placebos group|"Patients will be administered with dexamethasone plus tropisetron from D1 to D3.
~Patients will also be administrated with placebos from D1-D4"
11172790|NCT03571126|Experimental|Experimental group|Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
11172791|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
11172792|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
11172793|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
11172794|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
11172795|NCT03571087|Experimental|HL140 5/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
11172796|NCT03571087|Experimental|HL140 10/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
11172797|NCT03571087|Experimental|HL140 20/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
11172798|NCT03571087|Experimental|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg
~Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
11172799|NCT03571087|Experimental|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg
~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
11172800|NCT03571087|Experimental|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg
~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
11172802|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen.
~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen."
11172803|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen.
~If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen."
11172804|NCT03571061|Active Comparator|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
11172805|NCT03571061|Experimental|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
11172806|NCT03571061|Placebo Comparator|carbon dioxide (CO2) insufflation|carbon dioxide (CO2) insufflation group: carbon dioxide (CO2) was insufflated through out the whole procedure for advancement and inspection when needed.
11172807|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
11172808|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
11172809|NCT03571035|Experimental|Example|Mandibular movements recordings by a mono vision system.
11172810|NCT03571022|Experimental|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
11172811|NCT03571009|Experimental|utilization of PAAS|conventional treatment utilization of PAAS
11172812|NCT03571009|No Intervention|Conventional care|conventional treatment only
11172813|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
11172814|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
11172815|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
11172816|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
11172817|NCT03570970|Experimental|Banapenem C1 group|250mg Once daily for 7
11172818|NCT03570970|Experimental|Banapenem C2group|500mg Once daily for 7
11172819|NCT03570970|Experimental|Banapenem C3group|1000mg Once daily for 7
11172820|NCT03570957|Experimental|MT-2990, Low dose|Single intravenous dose
11172821|NCT03570957|Experimental|MT-2990, Low-middle dose|Single intravenous dose
11172822|NCT03570957|Experimental|MT-2990, High-middle dose|Single intravenous dose
11172823|NCT03570957|Experimental|MT-2990, High dose|Single intravenous dose
11172824|NCT03570957|Placebo Comparator|Placebo|Single intravenous dose
11172825|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
11172826|NCT03570931|Experimental|RT001|RT001, oral, 3.84 g/day
11172827|NCT03570918|Experimental|MGD014|HIV-1 x CD3 bispecific DART molecule
11172828|NCT03570905|Experimental|Sugartong Splint|
11172829|NCT03570905|Experimental|Clam Shell Splint|
11172830|NCT03570892|Experimental|Tisagenlecleucel treatment strategy|Patients will receive investigator's choice of optional platinum-based immunochemotherapy followed by lymphodepleting chemotherapy and a single dose of tisagenlecleucel
11172831|NCT03570892|Active Comparator|Standard of care treatment strategy|Patients will receive investigator's choice of platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
11172832|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
11172833|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
11172834|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
11172835|NCT03570853|Experimental|Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
11172836|NCT03570853|No Intervention|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
11172837|NCT03570840||obese children and adolescents|
11172838|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
11172865|NCT03570658|Placebo Comparator|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
11172839|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
11172840|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
11172841|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
11172842|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
11172843|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.
~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
11172844|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
11172845|NCT03570775|Experimental|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
11172846|NCT03570775|Active Comparator|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
11172847|NCT03570749|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11172848|NCT03570749|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11172849|NCT03570749|Placebo Comparator|Placebo|Placebo administered orally.
11172850|NCT03570736|Experimental|Minimal Invasive Surgical Technique|
11172851|NCT03570736|Active Comparator|Open Flap Debridement|
11172852|NCT03570723|Active Comparator|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
11172853|NCT03570723|Experimental|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
11172854|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
11172855|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
11172856|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
11172857|NCT03570697|Experimental|Evolucumab|Participants receive Evolocumab subcutaneous injection once every month (QM=every 4 weeks + 3 days) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy and not expected to change for the duration of the study participation.
11172858|NCT03570697|Placebo Comparator|Placebo|Participants receive placebo subcutaneous injection once every month (QM=every 4 weeks + 3 days) for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy and not expected to change for the duration of the study participation.
11172859|NCT03570684|Experimental|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
11172860|NCT03570684|No Intervention|non-tie group|
11172861|NCT03570671|Experimental|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
11172862|NCT03570671|Placebo Comparator|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
11172863|NCT03570658|Experimental|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
11172864|NCT03570658|Experimental|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
11172900|NCT03570450|Experimental|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10^6cells/kg
11172866|NCT03570645|Experimental|dexmedetomidine group|thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time
11172867|NCT03570645|Experimental|dexamethasone Group|thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time
11172868|NCT03570645|Sham Comparator|control group|thoracic paravertebral blocks using only ropivacaine
11172869|NCT03570632|No Intervention|Usual care|
11172870|NCT03570632|Experimental|Metformin|
11172871|NCT03570619|Experimental|Metastatic CRPC|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
11172872|NCT03570619|Experimental|Solid Tumors (non-prostate)|Patients with all other metastatic subtypes will be enrolled in cohort B
11172873|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures
~o Spinal cage filling"
11172874|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:
~Filling bone defects after cyst removal
~Filling distal radius fractures
~Filling defects such as tibial plateau fractures
~Filling defects created by osteotomy procedures"
11172875|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures
~o Spinal cage filling"
11172876|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:
~Filling bone defects after cyst removal
~Filling distal radius fractures
~Filling defects such as tibial plateau fractures
~Filling defects created by osteotomy procedures"
11172877|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures
~o Spinal cage filling"
11172878|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:
~Filling bone defects after cyst removal
~Filling distal radius fractures
~Filling defects such as tibial plateau fractures
~Filling defects created by osteotomy procedures"
11172879|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:
~o High tibial osteotomies with fixation"
11172880|NCT03570593|No Intervention|Retrospective Group|
11172881|NCT03570593|Experimental|Prospective Group|
11172882|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
11172883|NCT03570567|Other|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
11172884|NCT03570554|Experimental|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
11172885|NCT03570554|Experimental|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
11172886|NCT03570554|Experimental|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
11172887|NCT03570554|Experimental|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
11172888|NCT03570541|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.
~Every six hours postoperative, all patients are administered 1 g of acetaminophen.
~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.
~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.
~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.
~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
11172889|NCT03570541|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.
~Every six hours postoperative, all patients are administered 1 g of acetaminophen.
~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.
~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.
~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.
~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
11172890|NCT03570528||Maxillary Retrusion|CT
11172891|NCT03570528||Healthy Patients|
11172892|NCT03570515|Experimental|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
11172893|NCT03570515|Active Comparator|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
11172894|NCT03570489|Active Comparator|Exercise|Use of an ergometric bicycle where patients will bicycle 5 Days a week for 20 minutes at a predetermine level
11172895|NCT03570489|Sham Comparator|Relaxation|Patients will listen to a relaxation exercise involving muscle relaxation. This takes about 20 minutes and will be performed 5 Days/week
11172896|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
11172897|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
11172898|NCT03570450|Experimental|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10^6cells/kg
11172899|NCT03570450|Experimental|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10^6cells/kg
11172901|NCT03570450|Experimental|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10^6cells/kg
11172902|NCT03570450|Placebo Comparator|placebo|Placebo
11172903|NCT03570437|Active Comparator|Arm 1: Paclitaxel|Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.
11172904|NCT03570437|Experimental|Arm 2: Cediranib and paclitaxel|Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue cediranib once daily until disease progression.
11172905|NCT03570437|Experimental|Arm 3: Cediranib and olaparib|Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue with olaparib and cediranib until disease progression.
11172906|NCT03570424|Placebo Comparator|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
11172907|NCT03570424|Experimental|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
11172908|NCT03570424|Experimental|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
11172909|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.
~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.
~The amount of blood collected at each visit will be based on age."
11172910|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol
~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
11172911|NCT03570398|Other|Abdominal CT|
11172912|NCT03570398|Other|Abdominal Ultrasound|
11172913|NCT03570385|Experimental|Patient with Optic Neuritis|
11172914|NCT03570372|Experimental|Intervention group|36 week internet-based CBT with therapist support. Regular online group discussions.
11172915|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
11172916|NCT03570359|Active Comparator|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation
~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
11172917|NCT03570359|Placebo Comparator|Placebo|"Part 1- placebo once a day for 3 days via inhalation
~Part 2 - placebo once a day for 14 days via inhalation"
11172918|NCT03570346|Experimental|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
11172919|NCT03570346|Placebo Comparator|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
11172920|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
11172921|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
11172922|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
11172923|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
11172924|NCT03570307|Other|drug treatment|Misoprostol for uterine evacuation
11172925|NCT03570307|Other|surgical treatment|dilatation and curettage for uterine evacuation
11172926|NCT03570294|Other|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
11172927|NCT03570281|Experimental|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
11172928|NCT03570281|Active Comparator|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
11172929|NCT03570268|Experimental|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
11172930|NCT03570268|Active Comparator|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
11172931|NCT03570255|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
11172932|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
11172933|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
11172934|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
11172935|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
11172936|NCT03570216|Experimental|Exercise|All participants will perform 3 exercise sessions: one session to assess their cardiorespiratory fitness, one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
11172937|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of admission.
11172938|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of recruitment.
11172939|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
11172940|NCT03570177||all subject|the all population (described in eligibility criteria)
11172941|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
11172942|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
11172943|NCT03570138|Experimental|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
11172944|NCT03570138|Active Comparator|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
11172945|NCT03570125|Experimental|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).
~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
11172946|NCT03570125|No Intervention|no intervention|Control/Placebo with multivitamin supplementation
11172947|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
11172948|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
11172949|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
11172950|NCT03570086||migraineurs without aura|
11172951|NCT03570086||health controls|
11172952|NCT03570073|Active Comparator|Manual vitrification|
11172953|NCT03570073|Experimental|Automatic vitrification|
11172954|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
11172955|NCT03570021|Active Comparator|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].
11172956|NCT03570021|Experimental|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
11172957|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
11172958|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
11172959|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
11172960|NCT03569995|Experimental|Induction+Consolidation chemotherapy|"[Induction phase]
~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation
~Complete, partial response or stable disease-> next step
~Progressive disease-> eliminated
~② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation
~Complete response -> consolidation therapy(Rituximab-Cytarabine) progress
~Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations
~Progressive disease-> eliminated
~③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation
~Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)
~Progressive disease-> eliminated"
11172961|NCT03569982|No Intervention|Control|Patients receiving best supportive care
11172962|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
11172963|NCT03569969|Experimental|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
11172964|NCT03569969|Experimental|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
11173731|NCT03564808|Experimental|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
11172965|NCT03569956|Active Comparator|Razor Group|Subject will use the 556 razor with regular shaving products, and shave at least 5 or more times per week
11172966|NCT03569956|Experimental|Regimen|Subject will use the 556 razor with the Pre-shave Gel, Cleaning Brush, and Shaving Gel and shave at least 5 or more times per week.
11172967|NCT03569943|Experimental|Robotol|
11172968|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
11172969|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
11172970|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
11172971|NCT03569917|Experimental|patient under Ceftriaxone treatment|
11172972|NCT03569891|Experimental|AMT-061|"Single infusion of AMT-061
~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
11172973|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
11172974|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
11172975|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
11172976|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
11172977|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
11172978|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
11172979|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
11172980|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
11172981|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
11172982|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
11172983|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
11172984|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (>500mU/L).
11172985|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
11172986|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
11172987|NCT03569761|Experimental|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
11172988|NCT03569761|Active Comparator|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
11172989|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
11172990|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
11172991|NCT03569722||Older adults|Older adults, ages 65+
11172992|NCT03569709|Active Comparator|Aerobic Exercise|Sub-threshold aerobic exercise.
11172993|NCT03569709|Placebo Comparator|Stretching|Stretching program that will not raise heart rate.
11172994|NCT03569709|Placebo Comparator|Rest|Relative rest. Avoid all structured exercise.
11172995|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
11172996|NCT03569683|Experimental|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.
~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.
~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
11172997|NCT03569670|Experimental|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
11172998|NCT03569670|Active Comparator|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
11173039|NCT03569449|Experimental|Group 13- Monkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and individually-tailored visits
11191356|NCT03444207|Experimental|Group A|Endurance training
11172999|NCT03569657|Other|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
11173000|NCT03569644|Other|qualitative study|heterogeneous group of patients
11173001|NCT03569631|Experimental|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
11173002|NCT03569631|Placebo Comparator|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
11173003|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
11173004|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
11173005|NCT03569605|Active Comparator|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
11173006|NCT03569605|Experimental|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
11173007|NCT03569592|Experimental|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
11173008|NCT03569579|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.
~Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.
~Each treatment period was separated by a washout period of at least 21 dyas."
11173009|NCT03569579|Experimental|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.
~Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.
~Each treatment period was separated by a washout period of at least 21 dyas."
11173010|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
11173011|NCT03569553||AIGIV|Inhalational anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
11173012|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
11173013|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
11173014|NCT03569527|Active Comparator|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
11173015|NCT03569527|Active Comparator|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
11173016|NCT03569527|Active Comparator|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
11173017|NCT03569514||AIGIV|Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
11173018|NCT03569501|No Intervention|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
11173019|NCT03569501|Active Comparator|oat grains|90 mg oat, per day.
11173020|NCT03569501|Experimental|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
11173021|NCT03569501|Active Comparator|DHA tablets|500 mg DHA oral tablets, per day.
11173022|NCT03569475|Experimental|Levomilnacipran ER|patients will take levomilnacipran 10 mg/day on Days 1-3, 20 mg/day on Days 4-7, and 40 mg/day during weeks 2 through 8 of the double blinded treatment and 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days in the down-taper period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day is permitted at Week 3 through 8 of the double blinded treatment. in the down-taper period. the patient will take levomilnacipran 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days
11173023|NCT03569475|Active Comparator|Fluoxetine 20 mg|Patients randomized to the Fluoxetine 20 mg arm will take Week 1, 10mg/day; week 2 through week 8, 20 mg/day
11173024|NCT03569475|Placebo Comparator|Placebo|Patients randomized to the placebo arm will take placebo capsules once daily through week 8
11173025|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
11173026|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
11173027|NCT03569449|Experimental|Group 1- Goat|Clinic-based visit, usual care, standard pediatric surveillance, and structured visits
11173028|NCT03569449|Experimental|Group 2- Cow|Clinic-based visit, usual care, enhanced pediatric surveillance, and structured visits
11173029|NCT03569449|Experimental|Group 3- Horse|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and structured visits
11173030|NCT03569449|Experimental|Group 4- Pig|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and structured visits
11173031|NCT03569449|Experimental|Group 5- Sheep|Clinic-based visit, usual care, standard pediatric surveillance, and individually-tailored visits
11173032|NCT03569449|Experimental|Group 6- Llama|Clinic-based visit, usual care, enhanced pediatric surveillance, and individually-tailored visits
11173033|NCT03569449|Experimental|Group 7- Cat|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and individually-tailored visits
11173034|NCT03569449|Experimental|Group 8- Dog|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and individually-tailored visits
11173035|NCT03569449|Experimental|Group 9- Donkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and structured visits
11173036|NCT03569449|Experimental|Group 10- Bear|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and structured visits
11173037|NCT03569449|Experimental|Group 11- Tiger|Clinic and community visits, technology enhanced care coordination, standard pediatric surveillance, and structured visits
11173038|NCT03569449|Experimental|Group 12- Lion|Clinic and community visits, technology enhanced care coordination, enhanced pediatric surveillance, and structured visits
11173182|NCT03568539|Experimental|IBI308|
11173040|NCT03569449|Experimental|Group 14- Zebra|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and individually-tailored visits
11173041|NCT03569449|Experimental|Group 15- Elephant|Clinic and community visits, technology-enhanced care, standard pediatric surveillance, and individually-tailored visits
11173042|NCT03569449|Experimental|Group 16- Giraffe|Clinic and community visits, technology-enhanced care, enhanced pediatric surveillance, and individually-tailored visits
11173043|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
11173044|NCT03569423|Experimental|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
11173045|NCT03569423|Active Comparator|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
11173046|NCT03569410|Active Comparator|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
11173047|NCT03569410|Experimental|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
11173048|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
11173049|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
11173050|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):
~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
11173051|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
11173052|NCT03569371|Experimental|INCB054707|
11173053|NCT03569358|Experimental|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
11173054|NCT03569358|Active Comparator|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
11173055|NCT03569358|Active Comparator|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
11173056|NCT03569345|Experimental|Arm|Basal cell carcinoma (BCC) patients Patients (>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on face/scalp, <50 mm on trunk/extremities)
11173057|NCT03569332|Experimental|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
11173058|NCT03569332|No Intervention|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
11173059|NCT03569319|Experimental|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
11173060|NCT03569319|Experimental|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
11173061|NCT03569319|Placebo Comparator|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
11173062|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
11173063|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
11173064|NCT03569293|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
11173065|NCT03569293|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
11173066|NCT03569293|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
11173067|NCT03569293|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
11173068|NCT03569280|Experimental|KPG-121|Safety and Antitumor Activity of KPG-121 capsules 1.5, 2.5, 5.0, 10, 20, and 30 mg/day daily for 21 days
11173069|NCT03569267|Experimental|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
11173070|NCT03569267|Placebo Comparator|Placebo|placebo
11173224|NCT03568240||15 men without complaints|
11173071|NCT03569254|Experimental|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
11173072|NCT03569254|Active Comparator|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
11173073|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
11173074|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
11173075|NCT03569228|Experimental|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
11173076|NCT03569228|Experimental|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
11173077|NCT03569228|No Intervention|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
11173078|NCT03569228|Active Comparator|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
11173079|NCT03569228|Active Comparator|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
11173080|NCT03569228|Experimental|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
11173081|NCT03569228|Experimental|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
11173082|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
11173083|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
11173084|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
11173085|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
11173086|NCT03569189|Experimental|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
11173087|NCT03569176|Experimental|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
11173088|NCT03569176|Other|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
11173089|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
11173090|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
11173091|NCT03569124||Training group|
11173092|NCT03569124||Non-Training group|
11173093|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
11173094|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
11173095|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
11173096|NCT03569085|Experimental|Sevoflurane then isoflurane|
11173097|NCT03569072|Experimental|Dose escalated functionally adapted radiation therapy|This is a single arm study
11173098|NCT03569059|Experimental|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
11173099|NCT03569059|Experimental|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
11173100|NCT03569059|No Intervention|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
11173101|NCT03569059|Experimental|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
11173255|NCT03568058|Experimental|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
11173102|NCT03569046|Active Comparator|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
11173103|NCT03569046|Placebo Comparator|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
11173104|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
11173105|NCT03569033|Placebo Comparator|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
11173106|NCT03569020|Experimental|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
11173107|NCT03569020|No Intervention|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
11173108|NCT03569007|Active Comparator|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
11173109|NCT03569007|Active Comparator|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
11173110|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID
11173111|NCT03568994|Experimental|ADE 10+3+5 plus Atovaquone (AQ)|Induction I ADE: cytarabine, daunorubicin, etoposide 10+3+5, atovaquone daily
11173112|NCT03568994|Experimental|DA 3+10 with GO plus AQ|Induction I DA: daunorubicin, cytarabine 3+10 with GO: gemtuzumab ozogamicin, atovaquone daily
11173113|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
11173114|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
11173115|NCT03568968|Experimental|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is tablets.
11173116|NCT03568968|Placebo Comparator|Placebo Comparator|Placebo tablets, no active ingredients.
11173117|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
11173118|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
11173119|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
11173120|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
11173121|NCT03568929||Idelalisib|Participants who have been or are currently being treated with 100 or 150 mg of idelalisib
11173122|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
11173123|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
11173124|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
11173125|NCT03568903|Experimental|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
11173126|NCT03568903|No Intervention|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it's dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
11173127|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.
11173128|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.
11173129|NCT03568877|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
11173130|NCT03568877|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
11173131|NCT03568864|Placebo Comparator|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (~ 2% nucleotides)
11173132|NCT03568864|Experimental|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (~ 10% nucleotides)
11173133|NCT03568838|Experimental|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
11173134|NCT03568838|No Intervention|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
11173135|NCT03568825|Experimental|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
11173136|NCT03568825|Experimental|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
11173256|NCT03568058|Experimental|anti-PD1 and vaccine|anti-PD-1 antibody followed by personalized vaccine therapy
11173137|NCT03568812|Experimental|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
11173138|NCT03568812|Placebo Comparator|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
11173139|NCT03568799|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
11173140|NCT03568786|Experimental|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
11173141|NCT03568786|Experimental|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
11173142|NCT03568773|Experimental|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.
~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
11173143|NCT03568773|Experimental|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
11173144|NCT03568773|Experimental|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
11173145|NCT03568760|Experimental|SFA treatment|Semantic feature analysis
11173146|NCT03568760|Placebo Comparator|Comprehension training|Comprehension training
11173147|NCT03568747|Experimental|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
11173148|NCT03568747|Experimental|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
11173149|NCT03568734|Experimental|Transplant arm|Fecal transplant sample given to child at delivery
11173150|NCT03568721|Experimental|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
11173151|NCT03568721|Experimental|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
11173152|NCT03568721|Experimental|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
11173153|NCT03568721|No Intervention|control|control (no reliever for orthodontic pain)
11173154|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
11173155|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
11173156|NCT03568695|Other|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
11173157|NCT03568682|Experimental|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
11173254|NCT03568058|Experimental|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
11173158|NCT03568682|No Intervention|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
11173159|NCT03568656|Experimental|CCS1477 Dose Escalation|Dose escalation of CCS1477 in patients with mCRPC
11173160|NCT03568656|Experimental|CCS1477 Monotherapy - Prostate|CCS1477 expansion phase in patients with mCRPC
11173161|NCT03568656|Experimental|CCS1477 and Abiraterone|CCS1477 plus abiraterone acetate in patients with mCRPC
11173162|NCT03568656|Experimental|CCS1477 and Enzalutamide|CCS1477 plus enzalutamide in patients with mCRPC
11173163|NCT03568656|Experimental|CCS1477 Monotherapy - Solid tumours|CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition
11173164|NCT03568643|Experimental|Azithromycin|children in this arm will receive one dose of azithromycin
11173165|NCT03568643|Active Comparator|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
11173166|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:
~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician
~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
11173167|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:
~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended
~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
11173168|NCT03568630||Inherited Risk|"Must meet one of the following criteria:
~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)
~One 1st degree relative with PDAC diagnosed before age 60
~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR
~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
11173169|NCT03568617|Experimental|rTMS group|
11173170|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
11173171|NCT03568591|Experimental|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
11173172|NCT03568591|No Intervention|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
11173173|NCT03568578|Active Comparator|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
11173174|NCT03568578|Experimental|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
11173175|NCT03568565|Experimental|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
11173176|NCT03568565|Experimental|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
11173177|NCT03568565|Experimental|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
11173178|NCT03568565|Experimental|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
11173179|NCT03568565|No Intervention|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
11173180|NCT03568552|Experimental|Patient Decision Aid|Participating clinics (and their patients) will be randomly selected to implement the intervention, at which time their patients will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
11173181|NCT03568552|No Intervention|Prior to intervention|All participating clinics will start with a baseline period without the intervention. The clinics and their patients will remain in the no intervention condition until randomly selected to crossover to receive the intervention.
11173183|NCT03568526|Experimental|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
11173184|NCT03568513|Experimental|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
11173185|NCT03568513|Placebo Comparator|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
11173186|NCT03568500|Experimental|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
11173187|NCT03568500|Experimental|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
11173188|NCT03568500|Experimental|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
11173189|NCT03568500|Experimental|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
11173190|NCT03568487|Experimental|Intensive scapula-focused approach|
11173191|NCT03568487|Active Comparator|Control therapy|
11173192|NCT03568474|Experimental|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
11173193|NCT03568474|Active Comparator|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
11173194|NCT03568461|Experimental|CTL019|tisagenlecleucel infusion
11173195|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
11173196|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
11173197|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
11173198|NCT03568409|Placebo Comparator|Group B: Placebo|
11173199|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
11173200|NCT03568383|Experimental|Arm A: Delamanid (DLM)|HHCs will receive delamanid (DLM) for 26 weeks.
11173201|NCT03568383|Experimental|Arm B: Isoniazid (INH)|HHCs will receive isoniazid (INH) and pyridoxine (vitamin B6) for 26 weeks.
11173202|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
11173203|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
11173204|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
11173205|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
11173206|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
11173207|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
11173208|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
11173209|NCT03568331|Experimental|Tradipitant|
11173210|NCT03568331|Placebo Comparator|Placebo|
11173211|NCT03568318|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical corticosteroids (TCS).
11173212|NCT03568318|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical corticosteroids (TCS).
11173213|NCT03568318|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
11173214|NCT03568318|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
11173215|NCT03568292|Experimental|Arm I: Virtual Reality|Participants receive the VR intervention during bone marrow biopsy or lumbar puncture lasting until completion of the procedure. Participants will be trained to use VR equipment prior to the bone marrow biopsy or lumbar puncture. The headset will cover both eyes with a strap along the back to hold the headset in place. The headset will be attached by a wire to a laptop which will power the headset and provide content. A remote control will be available for assistance in setting up or stopping the content in the case of an event. The VR content will consist of meditation and relaxing techniques through visual and auditory input which can last up to one hour. There will be minimal stimulatory effort to decrease excess movement for the procedure.
11173216|NCT03568292|Active Comparator|Arm II: No Virtual Reality|Participants receive standard of care during bone marrow biopsy or lumbar puncture.
11173217|NCT03568279|Active Comparator|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
11173218|NCT03568279|Experimental|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
11173219|NCT03568266||Biospecimen Collection|Buccal swabs of prospective participants' saliva will be collected when participant achieves complete remission (during regular clinical visit) from their asparaginase treatment.
11173220|NCT03568253|Active Comparator|Bulk fil composite|
11173221|NCT03568253|Active Comparator|High viscosity glass ionomer|
11173222|NCT03568240||30 men suffering from apnea|
11173223|NCT03568240||15 men defined as snorers|
11173225|NCT03568227|Experimental|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 & 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:
~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2
~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2
~Volunteers will be randomly allocated to the two sequence types."
11173226|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)
~4 days per week of MICT for 50 minutes per session
~1 day per week of HIIT for 35 minutes per session
~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)
~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
11173227|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT
~5 days per week of MICT for 50 minutes per session
~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
11173228|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
11173229|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
11173230|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
11173231|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
11173232|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
11173233|NCT03568162|Experimental|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
11173234|NCT03568162|Experimental|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
11173235|NCT03568162|Experimental|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
11173236|NCT03568162|Placebo Comparator|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
11173237|NCT03568162|Experimental|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
11173238|NCT03568162|Placebo Comparator|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
11173239|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
11173240|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
11173241|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
11173242|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
11173243|NCT03568123|Experimental|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
11173244|NCT03568123|Active Comparator|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
11173245|NCT03568097|Experimental|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
11173246|NCT03568084|Experimental|MEFAP|MEFAP (multicomponent physical activity program) for 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
11173247|NCT03568084|Active Comparator|Control: usual practice|No intervention. Individuals allocated to this arm, will be look after as usual in their health Centers.
11173248|NCT03568071|Experimental|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
11173249|NCT03568071|Experimental|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
11173250|NCT03568071|Experimental|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
11173251|NCT03568071|Experimental|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
11173252|NCT03568071|Experimental|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen E) will be administered on Day 1.
11173253|NCT03568071|Placebo Comparator|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
11173257|NCT03568058|Experimental|vaccine|personalized vaccine therapy
11173258|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
11173259|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.
~Feasibility metrics will be collected."
11173260|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.
~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.
~Feasibility metrics will be collected."
11173261|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
11173262|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
11173263|NCT03568006|Experimental|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.
~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
11173264|NCT03568006|Active Comparator|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
11173265|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
11173266|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
11173267|NCT03567980|Experimental|topical crisaborole 2%|
11173268|NCT03567967|Experimental|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
11173269|NCT03567967|Active Comparator|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
11173270|NCT03567941|Placebo Comparator|Placebo|Single dose
11173271|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
11173272|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
11173273|NCT03567941|Active Comparator|Reference|Single dose
11173274|NCT03567928|Active Comparator|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
11173275|NCT03567928|Experimental|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
11173276|NCT03567915||Rice|Group that healthy volunteers eat rice.
11173277|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
11173278|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
11173279|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
11173280|NCT03567889|Experimental|Daromun plus Surgery and Adjuvant therapy (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
11173281|NCT03567889|Active Comparator|Surgery and adjuvant therapy (Arm 2)|Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
11173282|NCT03567876|Experimental|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.
~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
11173283|NCT03567863|Active Comparator|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
11173284|NCT03567863|Active Comparator|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
11173285|NCT03567850|Experimental|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
11173314|NCT03567616|Experimental|Expansion Phase: Arm A t(11;14) Positive|Expansion Phase Arm A in participants positive for t(11;14) translocation will administer venetoclax + pomalidomide + dexamethasone .
11173732|NCT03564808|Experimental|Fat graft only|Fat graft withiut enrichment with MSCs
11173286|NCT03567850|Active Comparator|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
11173287|NCT03567837|Active Comparator|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
11173288|NCT03567837|Experimental|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
11173289|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
11173290|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
11173291|NCT03567811|Other|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
11173292|NCT03567811|Other|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
11173293|NCT03567798|Experimental|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract
~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
11173294|NCT03567798|Placebo Comparator|B|"Placebo
~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
11173295|NCT03567772|Experimental|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
11173296|NCT03567772|Active Comparator|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
11173297|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
11173298|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
11173299|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
11173300|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)
11173301|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab with chemotherapy|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab and nab-paclitaxel chemotherapy
11173302|NCT03567707|Experimental|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.
~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
11173303|NCT03567707|Experimental|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.
~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
11173304|NCT03567707|Active Comparator|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .
~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
11173305|NCT03567694|Experimental|Single Ascending Dose and Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
11173306|NCT03567694|Experimental|Multiple Ascending Dose|For the MAD portion, 3 dose levels will be selected based on SAD results.
11173307|NCT03567681|Experimental|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
11173308|NCT03567681|Experimental|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
11173309|NCT03567655|Experimental|Single group|Farlutal tab. 500mg/ Pfizer to be administered
11173310|NCT03567642|Experimental|Osimertinib, Platinum (cisplatin or carboplatin) and Etoposide|Initially, 6 patients will be enrolled and will begin treatment with osimertinib 80mg orally daily (3 who will be receiving cisplatin and 3 who will be receiving carboplatin). Cisplatin or carboplatin treatment will be decided by the treating physician prior to study registration. After 9 weeks (+/- 1 week)( 3 cycles) on osimertinib alone, carboplatin or cisplatin and etoposide will be added. Carboplatin is doses at an AUC of 5 or cisplatin at 60mg/m2 will be given on C4D1. Etoposide is dosed at 100mg/m2 given on Days 1-3 of C4. Only patients on osimertinib 80mg orally daily at the start of cycle 4 will be included in the 3+3 dose de-escalation portion of the study. Chemotherapy and osimertinib will be administered concurrently during cycles 4-7, and from cycle 8 onward, osimertinib monotherapy will be continued. Patients will present every 2 cycles post-chemo (Cycles 8, 10, 12, etc.)
11173311|NCT03567629|Experimental|Irinotecan-based chemotherapy|
11173312|NCT03567629|Active Comparator|Oxaliplatin-based chemotherapy|
11173313|NCT03567616|Experimental|Dose-Escalation Phase|Dose-Escalation Phase participants will administer venetoclax (various doses) + pomalidomide + dexamethasone.
11191357|NCT03444207|Experimental|Group B|Endurance-strength training
11173315|NCT03567616|Experimental|Expansion Phase: Arm B t(11;14) Negative|Expansion Phase Arm B in participants negative for t(11;14) translocation will administer venetoclax + pomalidomide + dexamethasone.
11173316|NCT03567603||opioid exposed neonates|prenatal opioid exposure
11173317|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
11173318|NCT03567590|Experimental|Pulsed Radiofrequency Group|This group will undergo pulsed radiofrequency treatment.
11173319|NCT03567590|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment.
11173320|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
11173321|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
11173322|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
11173323|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
11173324|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
11173325|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
11173326|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
11173327|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: <140/90
11173328|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
11173329|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
11173330|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
11173331|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
11173332|NCT03567499|Experimental|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
11173333|NCT03567499|Experimental|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
11173334|NCT03567499|Experimental|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
11173335|NCT03567499|Experimental|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
11173336|NCT03567499|Experimental|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
11173337|NCT03567499|Experimental|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
11173338|NCT03567499|Experimental|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
11173339|NCT03567499|Experimental|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
11173340|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
11173341|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine
11173342|NCT03567473|Placebo Comparator|Control Arm|Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.
11173343|NCT03567460|Experimental|10,000 Steps/day for Pediatric Marfan Patients|Participants will be given a Garmin VivoFit and asked to take at least 10,000 steps per day. A study coordinator will reach out at least once per week to check in on progress made and help make weekly goals.
11173344|NCT03567447|Experimental|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
11173345|NCT03567447|Placebo Comparator|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
11173346|NCT03567408|Experimental|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
11191358|NCT03444194|Experimental|Biopsi arm|
11173347|NCT03567408|Placebo Comparator|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
11173348|NCT03567395|Active Comparator|Melatonin|Melatonin (5 mg sublingual tablet)
11173349|NCT03567395|Experimental|Honey|raw honey (1.5 tablespoons)
11173350|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
11173351|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
11173352|NCT03567369|Experimental|Dexamethasone|Dexamethasone 4,0 mg / mL
11173353|NCT03567369|Experimental|Traumeel S|Traumeel 2,2 mg / mL
11173354|NCT03567356|No Intervention|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
11173355|NCT03567356|Experimental|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
11173356|NCT03567343|Active Comparator|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
~A subset of this group will undergo 2 overnight polysomnography studies"
11173357|NCT03567343|Placebo Comparator|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
~A subset of this group will undergo 2 overnight polysomnography studies"
11173358|NCT03567343|Active Comparator|Proprietary Blend And Melatonin|Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the proprietary spearmint extract blend and 1 Mg of melatonin by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
11173359|NCT03567343|Active Comparator|Melatonin|Subjects randomized into the active treatment group will be asked to consume 1 Mg of melatonin by mouth every night 30 mins before bed and complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
11173360|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
11173361|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
11173362|NCT03567317|No Intervention|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
11173363|NCT03567317|Experimental|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
11173364|NCT03567304|No Intervention|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.
~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
11173365|NCT03567304|Experimental|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.
~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
11173366|NCT03567291|Experimental|TEV-50717- Part A|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
11173367|NCT03567291|Experimental|TEV-50717- Part B RW|TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
11173368|NCT03567291|Placebo Comparator|Placebo- Part B RW|Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.
11173369|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
11173370|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
11173371|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
11173372|NCT03567239|Experimental|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
11173373|NCT03567226|Experimental|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
11173374|NCT03567226|Active Comparator|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
11173375|NCT03567213|Experimental|Surgical implantation of the CortiCom system|
11173376|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
11191359|NCT03444181|Experimental|Music lessons|
11173377|NCT03567187|Experimental|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (cryoprobe) and disposable nitrous oxide (N2O) cartridges (cryogen). The smart tip is composed of closed-tip stainless steel needles, thereby fully enclosing the cryogen. There are 2 types of smart tips that will be utilized during this study, depending on the depth of the nerves being treated. The shorter smart tip comes in 2 variants - three X 6.9 mm or 8.9 mm, 27-gauge needles, with an attached skin warmer to prevent damage to the underlying skin. The longer smart tip also comes in 2 variants - 55 mm 22-gauge needle or a 90 mm 20G needle.
~The effect is by initiation of a cooling cycle, by fully inserting the smart tip into the procedure site and activating the cryogen flow. As the gas travels through the length of the needle, an ice ball develops around the needle freezing the surrounding tissue."
11173378|NCT03567174|Experimental|Integrated care van (ICV)|ICV visits neighborhoods served by the mobile syringe service program weekly. ICV provides a range of services targeted to people who inject drugs - HIV testing, HCV testing, PrEP, MAT, wound care, case work services, on-site medical management and linkage.
11173379|NCT03567174|No Intervention|Control|No additional services provided.
11173380|NCT03567161|Experimental|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.
~Inclusion criteria:
~Having received a diagnosis of chronic periodontitis (Armitage 1999)
~Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)
~Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm
~Exclusion criteria:
~Smoking more than ten cigarettes per day
~Pregnancy
~Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
11173381|NCT03567148|Active Comparator|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
11173382|NCT03567148|Active Comparator|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
11173383|NCT03567148|Active Comparator|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
11173384|NCT03567148|Active Comparator|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
11173385|NCT03567148|Active Comparator|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
11173386|NCT03567148|No Intervention|Control group|Palatal wounds were left for spontaneous healing
11173387|NCT03567135||Experimental 1|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
11173388|NCT03567135||control|concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
11173389|NCT03567135||Experimental 2|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
11173390|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
11173391|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
11173392|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
11173393|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
11173394|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
11173395|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
11173396|NCT03567109||control|healthy subjects
11173397|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
11173398|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
11173399|NCT03567083|Experimental|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
11173435|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
11173400|NCT03567083|No Intervention|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
11173401|NCT03567070|Other|qualitative study based on an individual clinical interview|
11173402|NCT03567057|Experimental|ADS-5102|
11173403|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
11173404|NCT03567031|Experimental|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
11173405|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
11173406|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
11173407|NCT03567005|Other|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
11173408|NCT03567005|Other|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
11173409|NCT03566992|Active Comparator|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
11173410|NCT03566992|Experimental|Small bowel|Nasoenteric tube placed in the small bowel.
11173411|NCT03566979|Experimental|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
11173412|NCT03566979|Active Comparator|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
11173413|NCT03566979|Active Comparator|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
11173414|NCT03566979|Placebo Comparator|Placebo tablet|Single dose of two Placebo tablets
11173415|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
11173416|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
11173417|NCT03566940|Experimental|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
11173418|NCT03566940|Experimental|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
11173419|NCT03566940|Experimental|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
11173420|NCT03566940|Active Comparator|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
11173421|NCT03566927|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
11173422|NCT03566914|Experimental|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
11173423|NCT03566914|Placebo Comparator|Placebo|Tablet placebo once daily per oral for 3 months
11173424|NCT03566901|Experimental|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
11173425|NCT03566901|Active Comparator|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
11173426|NCT03566888||Single Group|85 eligible study participants
11173427|NCT03566875|Experimental|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
11173428|NCT03566875|Active Comparator|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
11173429|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
11173430|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
11173431|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
11173432|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
11173433|NCT03566849|Experimental|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
11173434|NCT03566849|Experimental|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
11175057|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
11173436|NCT03566823|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
11173437|NCT03566823|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
11173438|NCT03566823|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
11173439|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
11173440|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
11173441|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
11173442|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
11173443|NCT03566797||SC-CIP|Patients developing SC-CIP
11173444|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
11173445|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
11173446|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
11173447|NCT03566771|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 12 months
11173448|NCT03566771|Active Comparator|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 12 months
11173449|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
11173450|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
11173451|NCT03566732||Bereaved relatives|Bereaved relatives after cancer deaths in hospitals
11173452|NCT03566719|Experimental|Intervention group|
11173453|NCT03566719|No Intervention|Control group|
11173454|NCT03566706|Experimental|Unhealthy Eating|
11173455|NCT03566706|Experimental|Marijuana Use|
11173456|NCT03566706|Experimental|Sedentary Behavior|
11173457|NCT03566693|Experimental|Continous Glucose Monitor|
11173458|NCT03566693|Active Comparator|Self Monitoring Blood Glucose|
11173459|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
11173460|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
11173461|NCT03566667|Other|Standard care|Usual standard care
11173462|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
11173463|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
11173464|NCT03566641|Experimental|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
11173465|NCT03566641|Active Comparator|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
11173466|NCT03566628|Experimental|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
11173467|NCT03566628|Active Comparator|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
11173468|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
11173469|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
11173470|NCT03566615|Experimental|CAP-daisy|A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
11173471|NCT03566602|Other|Dura Sealant Patch|Application of Dura Sealant Patch after closure of the dura mater
11173472|NCT03566589|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
11173501|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
11173502|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
11173503|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
11173473|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
11173474|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
11173475|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
11173476|NCT03566550||CF|people with cystic fibrosis
11173477|NCT03566550||Control|people without cystic fibrosis
11173478|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
11173479|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
11173480|NCT03566524|Experimental|Arginine|In this experimental arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary arginine for 21 days. Arginine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The arginine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
11173481|NCT03566524|Active Comparator|Citrulline|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 21 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
11173482|NCT03566524|Placebo Comparator|alanine|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 21 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
11173483|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
11173484|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
11173485|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
11173486|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
11173487|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
11173488|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
11173489|NCT03566485|Experimental|Arm I (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11173490|NCT03566485|Experimental|Arm II (atezolizumab, idasanutlin)|Participants without TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and idasanutlin PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11173491|NCT03566459||Veterans with opioid use disorder (OUD)|Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
11173492|NCT03566446|Experimental|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
11173493|NCT03566433|Active Comparator|TEP|Routine total extraperitoneal technique surgery for inguinal hernia
11173494|NCT03566433|Active Comparator|Lichtenstein|Routine lichtenstein surgery for inguinal hernia
11173495|NCT03566407|Other|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
11173496|NCT03566394|Experimental|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
11173497|NCT03566394|No Intervention|Observation|
11173498|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
11173499|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
11173500|NCT03566355|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
11173767|NCT03564613||HIV positive pregnant women|Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.
11173504|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
11173505|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
11173506|NCT03566329|Active Comparator|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
11173507|NCT03566329|Active Comparator|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
11173508|NCT03566329|Placebo Comparator|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
11173509|NCT03566316|Experimental|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
11173510|NCT03566316|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
11173511|NCT03566316|Active Comparator|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
11173512|NCT03566303|Active Comparator|Rivaroxaban|Rivaroxaban 15mg BID
11173513|NCT03566303|Placebo Comparator|Warfarin|Warfarin dose adjusted
11173514|NCT03566290|Experimental|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
11173515|NCT03566277|Experimental|Single-arm trial|All participants will undergo each of three conditions during the study.
11173516|NCT03566264||Participants hospitalized with ADHF|
11173517|NCT03566251|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
11173518|NCT03566251|No Intervention|Healthy individuals|29 healthy volunteers with matching ages and genders
11173519|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
11173520|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
11173521|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
11173522|NCT03566225|Active Comparator|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
11173523|NCT03566225|Placebo Comparator|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
11173524|NCT03566212|Experimental|conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
11173525|NCT03566212|Experimental|camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
11173526|NCT03566199|Experimental|Treatment (MTX110)|Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
11173527|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
11173528|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
11173529|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
11173530|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
11173531|NCT03566147|Experimental|low dose group|300,000 HuRPE cells
11173532|NCT03566147|Experimental|middle dose group|500,000 HuRPE cells
11173533|NCT03566147|Experimental|high dose group|1,000,000 HuRPE cells
11173534|NCT03566134|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
11173535|NCT03566134|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
11173536|NCT03566134|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
11173537|NCT03566134|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
11173538|NCT03566121|Other|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
11173539|NCT03566121|Experimental|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
11173540|NCT03566108|Experimental|VISTA|VISTA incision with CAF and ADM
11173541|NCT03566108|Active Comparator|Sulcular Tunnell access|Sulcular tunnel surgery with CAF and ADM
11173542|NCT03566095|Active Comparator|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
11173543|NCT03566095|Sham Comparator|Voices for Food Kit|The comparison community received the Voices for Food kit.
11173544|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.
~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
11173545|NCT03566069|Experimental|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
11173768|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
11173769|NCT03564600||UC Group|Veterans with back pain for at least the past 6 months.
11173546|NCT03566069|Placebo Comparator|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
11173547|NCT03566043|Experimental|Dose 1|1.3x10^10 GC/g brain mass of RGX-121
11173548|NCT03566043|Experimental|Dose 2|6.5x10^10 GC/g brain mass of RGX-121
11173549|NCT03566043|Experimental|Dose 2 Expanded Cohort|6.5x10^10 GC/g brain mass of RGX-121
11173550|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
11173551|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
11173552|NCT03566017|Experimental|Experimental open label|pegunigalsidase alfa
11173553|NCT03566004|Other|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
11173554|NCT03565991|Experimental|Combination of avelumab and talazoparib|Single arm open label
11173555|NCT03565978|Experimental|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
11173556|NCT03565978|No Intervention|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
11173557|NCT03565965|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
11173558|NCT03565965|Active Comparator|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
11173559|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
11173560|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
11173561|NCT03565939|Active Comparator|Trichuris suis ova (TSO)|7500 TSO suspension, orally every second week for 24 weeks.
11173562|NCT03565939|Placebo Comparator|Placebo|Solution without TSO orally every second week for 24 weeks
11173563|NCT03565926|Active Comparator|Manual Therapy|"Manual Therapy Protocol
~Articulation technique L4-S1
~Lumbar neuromuscular technique
~Fascial technique of crossed hands
~Posteroanterior mobilizations of the lumbar vertebrae"
11173564|NCT03565926|Experimental|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
11173565|NCT03565913|Experimental|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
11173566|NCT03565913|Active Comparator|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
11173567|NCT03565900|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
11173568|NCT03565900|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.
11173569|NCT03565887|Experimental|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
11173570|NCT03565887|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
11173571|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
11173572|NCT03565861|Placebo Comparator|Placebo|Placebo intravenous 30 minute infusion on day 1
11173573|NCT03565861|Experimental|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
11173574|NCT03565861|Experimental|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
11173575|NCT03565861|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
11173576|NCT03565861|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
11173577|NCT03565861|Experimental|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
11173578|NCT03565861|Experimental|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
11173579|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
11173580|NCT03565835|Experimental|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
11173581|NCT03565822|Other|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
11173582|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
11173583|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
11173584|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
11173585|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
11173586|NCT03565783|Experimental|Treatment (cemiplimab)|Participants receive cemiplimab IV over 30 minutes every 3 weeks. Courses repeat every 3 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11173587|NCT03565770|Experimental|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
11173588|NCT03565770|Sham Comparator|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
11173589|NCT03565757|Experimental|SMART intervention|90-minute SMART small group session
11173590|NCT03565744|Experimental|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
11173591|NCT03565744|No Intervention|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
11173592|NCT03565744|No Intervention|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
11173593|NCT03565731|Experimental|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
11173594|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
11173595|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.
~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
11173596|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
11173597|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
11173598|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients treated by LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) Patients over 6 years who are currently able to benefit from LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) according the mutation eligibility criteria and for whom conventional microbiological analysis of sputum samples and stool will be collected during their follow-up after the treatment onset.
11173599|NCT03565679|Experimental|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
11173600|NCT03565679|Sham Comparator|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
11173601|NCT03565666|Active Comparator|Adult RCT: Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule
11173602|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
11173603|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet using Fiasp|Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
11173604|NCT03565653|Experimental|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
11173605|NCT03565653|Experimental|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
11173606|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
11173607|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
11173608|NCT03565627|Experimental|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
11173609|NCT03565627|Experimental|Running App|One You Couch to 5K by Public Health England
11173610|NCT03565614|Experimental|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
11173611|NCT03565614|Active Comparator|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
11173612|NCT03565601||CTD patients with anti-Ro52 antibodies|Connective tissue disease patients with anti-Ro52 antibodies at diagnosis
11173613|NCT03565601||CTD patients without anti-Ro52 antibodies|Connective tissue disease patients without anti-Ro52 antibodies at diagnosis
11173614|NCT03565588|Experimental|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
11173615|NCT03565588|Experimental|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
11173616|NCT03565588|No Intervention|Control arm|No intervention will be administered to the control arm
11173617|NCT03565575|Experimental|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
11173618|NCT03565575|No Intervention|Control arm|No intervention will be administered to the control arm
11173619|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
11173620|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
11173621|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
11173622|NCT03565549|Experimental|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
11173623|NCT03565549|Active Comparator|CCHR rule|The control group will receive the CCHR only
11173624|NCT03565536|Experimental|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
~then External radiation therapy after surgery."
11173625|NCT03565523|Experimental|Test Beet shot|Containing 385 mg nitrate
11173626|NCT03565523|Placebo Comparator|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
11173627|NCT03565510|No Intervention|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
11173628|NCT03565510|Experimental|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based total diet replacement.
11173629|NCT03565497|Placebo Comparator|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
11173630|NCT03565497|Experimental|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
11173631|NCT03565497|Experimental|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
11173632|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
11173633|NCT03565484|Experimental|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
11173634|NCT03565484|Other|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
11173635|NCT03565484|Other|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
11173636|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.
~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
11173637|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.
~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
11173638|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.
~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
11173639|NCT03565458|Experimental|gemigliptin|gemigliptin single dose
11173640|NCT03565458|Experimental|dapagliflozin|dapagliflozin single dose
11173641|NCT03565458|Experimental|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
11173642|NCT03565458|Experimental|empagliflozin|empagliflozin single dose
11173643|NCT03565458|Experimental|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
11173644|NCT03565445|Experimental|ASP1948 Dose Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1948. Each dose level will enroll approximately 3 or 4 participants. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
11173645|NCT03565445|Experimental|ASP1948 Dose Expansion|If a confirmed response (iRECIST partial response (iPR) or iRECIST confirmed response (iCR)) per iRECIST occurs in a monotherapy escalation cohort, a tumor specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been cleared. Up to 5 expansion cohorts may be opened.
11173646|NCT03565445|Experimental|ASP1948 Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that they meet all the re-treatment eligibility criteria.
11173647|NCT03565445|Experimental|ASP1948 plus nivolumab Combination Therapy|ASP1948 will be administered in combination with a fixed dose of nivolumab every 2 weeks.
11173648|NCT03565445|Experimental|ASP1948 plus pembrolizumab Combination Therapy|After the completion of the nivolumab combination escalation, a fixed dose of ASP1948 will be administered every 2 weeks in combination with a fixed dose of pembrolizumab every 6 weeks. An every 3 week schedule will also be evaluated with the highest fixed dose of ASP1948 in combination with fixed dose of pembrolizumab after the monotherapy cohort is cleared.
11173649|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
11173650|NCT03565419|No Intervention|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
11173651|NCT03565419|Experimental|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
11173652|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
11173653|NCT03565393|Placebo Comparator|Fibersol-2|Receive Fibersol-2 twice daily
11173654|NCT03565393|Placebo Comparator|Placebo|Receive placebo twice daily
11173655|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
11173656|NCT03565380|Experimental|Patients without intervention|usual post-operative care
11173657|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
11173658|NCT03565367|Experimental|Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
11173659|NCT03565354|Active Comparator|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: > 50kg: 1000mg; <50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
11173660|NCT03565354|No Intervention|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
11173661|NCT03565341|Experimental|Melasma|Treatment of Melasma Using PiQo4 Laser System
11173662|NCT03565328|Experimental|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
11173663|NCT03565315|Experimental|Group 1: 10E8VLS 5 mg/kg SC Single Dose|5 mg/kg SC; Day 0
11173664|NCT03565315|Experimental|Group 2: 10E8VLS 5 mg/kg SC Multiple Doses|5 mg/kg SC; Day 0, Week 12, Week 24
11173665|NCT03565315|Experimental|Group 3: 10E8VLS+VRC07-523LS 5 mg/kg SC Single Dose|5 mg/kg SC; Day 0
11173666|NCT03565315|Experimental|Group 4: 10E8VLS+VRC07-523LS 5 mg/kg SC Multiple Doses|5 mg/kg SC; Day 0, Week 12, Week 24
11173667|NCT03565302|Placebo Comparator|Control|Subjects receive placebo treatment
11173668|NCT03565302|Experimental|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
11173669|NCT03565302|Experimental|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
11173670|NCT03565289||All patients|All
11173671|NCT03565276|Experimental|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
11173672|NCT03565263||FGID-IBD|"Patients aged 9-18 years
~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)
~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy
~followed for IBD for at least 1 year
~with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
11173673|NCT03565263||No FGID-IBD|"Patients aged 9-18 years
~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)
~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy
~followed for IBD for at least 1 year
~not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
11173674|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
11173675|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
11173676|NCT03565237|Experimental|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
11173677|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
11173678|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
11173679|NCT03565185|Active Comparator|End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.
~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
11173680|NCT03565185|Active Comparator|Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.
~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
11173681|NCT03565185|Placebo Comparator|conventional treatment|conventional treatment methods for stroke rehabilitation 5 days a week Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level.
11173682|NCT03565172|Experimental|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:
~Baseline: 4, 5 or 6 evaluations
~Intervention: 9 evaluations before and after every stretching session
~Follow-up: 4, 5 or 6 evaluations
~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
11173683|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
11173684|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
11173685|NCT03565146|Experimental|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
11173686|NCT03565133|Experimental|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
11173687|NCT03565133|Experimental|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
11173688|NCT03565133|Experimental|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
11173689|NCT03565133|Placebo Comparator|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
11173690|NCT03565120|Experimental|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
11173691|NCT03565107||Female Patients|ICSI treatment because of male subfertility
11173692|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose
~Part A:
~Cohort 1: single oral dose of Lu AF28996
~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between
~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects
~Part B: 8 subjects (randomised to one of four treatment sequences)"
11173693|NCT03565081|Experimental|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
11173694|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189|Healthy participants receive MK-8189 (4 mg oral tablet; once daily [QD]), titrated from 4 mg to 24 mg over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet (4 mg total); Days 4-6: 2 tablets (8 mg total); Days 7-9: 3 tablets (12 mg total); Days 10-12: 4 tablets (16 mg total); Days 13-15: 5 tablets (20 mg total); Days 16-18: 6 tablets (24 mg total).
11173695|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo|Healthy participants receive placebo (oral tablet; QD) over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet; Days 4-6: 2 tablets; Days 7-9: 3 tablets; Days 10-12: 4 tablets; Days 13-15: 5 tablets; Days 16-18: 6 tablets.
11173696|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy|Participants with schizophrenia receive MK-8189 (4 mg oral tablet; QD) as a monotherapy, titrated from 4 mg to 24 mg over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet (4 mg total); Days 4-6: 2 tablets (8 mg total); Days 7-9: 3 tablets (12 mg total); Days 10-12: 4 tablets (16 mg total); Days 13-15: 5 tablets (20 mg total); Days 16-18: 6 tablets (24 mg total).
11173697|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with schizophrenia receive placebo (oral tablet; QD) as a monotherapy over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet; Days 4-6: 2 tablets; Days 7-9: 3 tablets; Days 10-12: 4 tablets; Days 13-15: 5 tablets; Days 16-18: 6 tablets.
11173728|NCT03564834|Active Comparator|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
11173698|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy|In combination with background atypical antipsychotic (AAP) treatment, participants with schizophrenia receive MK-8189 (4 mg oral tablet; QD) as add-on therapy, titrated from 4 mg to 24 mg over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet (4 mg total); Days 4-6: 2 tablets (8 mg total); Days 7-9: 3 tablets (12 mg total); Days 10-12: 4 tablets (16 mg total); Days 13-15: 5 tablets (20 mg total); Days 16-18: 6 tablets (24 mg total).
11173699|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In combination with background AAP treatment, participants with schizophrenia receive placebo (oral tablet; QD) as add-on therapy over the course of an 18-day treatment period as follows: Days 1-3: 1 tablet; Days 4-6: 2 tablets; Days 7-9: 3 tablets; Days 10-12: 4 tablets; Days 13-15: 5 tablets; Days 16-18: 6 tablets.
11173700|NCT03565068|Experimental|Panel D (Schizophrenia Participants): MK-8189 15-Day Titration|Participants with schizophrenia receive MK-8189 (4 mg oral tablet; QD) as a monotherapy, titrated from 8 mg to 48 mg over the course of a 15-day treatment period as follows: Days 1-3: 2 tablets (8 mg total); Days 4-6: 4 tablets (16 mg total); Days 7-9: 6 tablets (24 mg total); Days 10-12: 9 tablets (36 mg total); Days 13-15: 12 tablets (48 mg total).
11173701|NCT03565068|Placebo Comparator|Panel D (Schizophrenia Participants): Placebo 15-Day Titration|Participants with schizophrenia receive placebo (oral tablet; QD) as a monotherapy over the course of a 15-day treatment period as follows: Days 1-3: 2 tablets; Days 4-6: 4 tablets; Days 7-9: 6 tablets; Days 10-12: 9 tablets; Days 13-15: 12 tablets.
11173702|NCT03565055|Experimental|IPCST|Intervention = Patients that participate in IPCST programme
11173703|NCT03565055|Active Comparator|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
11173704|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
11173705|NCT03565029|Experimental|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
11173706|NCT03565003|Experimental|JAB-3068 (SHP2 inhibitor)|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
11173707|NCT03564990|Experimental|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
11173708|NCT03564990|Sham Comparator|conventional approach|conventional follow-up with oral healthy education
11173709|NCT03564977|Experimental|CD19-targeted CAR-T cells|
11173710|NCT03564951|Active Comparator|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
11173711|NCT03564951|Experimental|Isochrone|ablation of concordance zones using isochrone and voltage maps
11173712|NCT03564938|Experimental|Regorafenib (Stivarga, BAY 73-4506)|Patients with metastatic colorectal cancer
11173713|NCT03564925|Active Comparator|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
11173714|NCT03564925|Experimental|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
11173715|NCT03564912|Experimental|2 week group|
11173716|NCT03564912|Active Comparator|3 week group|
11173717|NCT03564899|No Intervention|control|Receive no physical activity intervention (maintain baseline physical activity participation)
11173718|NCT03564899|Experimental|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
11173719|NCT03564899|Active Comparator|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
11173720|NCT03564886|Experimental|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
11173721|NCT03564886|Placebo Comparator|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
11173722|NCT03564873|Experimental|Phase I|Up to 18 patients will be enrolled to one of three cohorts to receive various doses of omacetaxine over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
11173723|NCT03564873|Experimental|Phase II|Up to 33 patients will be enrolled to receive the maximum tolerated dose (determined in phase I) over a 28 day cycle. Azacitidine will be given at the standard dose over a 28 day cycle.
11173724|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
11173725|NCT03564847|Experimental|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
11173726|NCT03564847|No Intervention|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
11173727|NCT03564834|Experimental|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
11173729|NCT03564821|Experimental|Ivosidenib (500mg/day)|-Ivosidenib will be administered orally every day
11175058|NCT03555487|Experimental|18F-choline PET|PET/CT
11173733|NCT03564795|Experimental|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
11173734|NCT03564795|Active Comparator|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
11173735|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
11173736|NCT03564769|Experimental|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
11173737|NCT03564769|Experimental|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
11173738|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
11173739|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
11173740|NCT03564730|Active Comparator|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
11173741|NCT03564730|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
11173742|NCT03564717|Experimental|Segmented Three dimensionally printed transfer tray|
11173743|NCT03564717|No Intervention|Full arch three dimensionally printed transfer tray|
11173744|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
11173745|NCT03564691|Experimental|Dose Escalation, Part A: MK-4830 Monotherapy|MK-4830 monotherapy (with MK-4830 doses determined by an accelerated titration design [ATD]) will be administered intravenously (IV), every 3 weeks (Q3W), starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pancreatic adenocarcinoma.
11173746|NCT03564691|Experimental|Dose Escalation, Part B: MK-4830 Monotherapy|MK-4830 monotherapy (with MK 4830 doses determined by a modified toxicity probability interval [mTPI] method) will be administered IV, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Participants enroll with histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes,
11173747|NCT03564691|Experimental|Dose Escalation, Part C: MK-4830 and Pembrolizumab|Combination therapy with MK-4830 and pembrolizumab (with MK-4830 doses determined by an mTPI design). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173748|NCT03564691|Experimental|Dose Expansion, Arm A: Pancreatic Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed pancreatic adenocarcinoma. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173749|NCT03564691|Experimental|Dose Expansion, Arm B: Glioblastoma (GBM)|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants with histologically or cytologically confirmed GBM. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173750|NCT03564691|Experimental|Dose Expansion, Arm C: R/M HNSCC|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease progressed on an anti-programmed cell death 1/programmed cell death ligand 1 (PD1/L1) therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173751|NCT03564691|Experimental|Dose Expansion, Arm D: PD-L1 positive HNSCC|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed advanced programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (HNSCC). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173766|NCT03564626|Experimental|Health IT + Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
11173752|NCT03564691|Experimental|Dose Expansion, Arm E: First-Line Advanced NSCLC, Dose A|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173753|NCT03564691|Experimental|Dose Expansion, Arm F: First-Line Advanced NSCLC, Dose B|Combination therapy with the preliminary recommended phase 2 dose (RP2D) B of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173754|NCT03564691|Experimental|Dose Expansion, Arm G: NSCLC, +Carboplatin/Pemetrexed|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, pembrolizumab, and carboplatin/pemetrexed in participants with advanced non-squamous non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Carboplatin and pemetrexed will be administered IV Q3W, starting with Cycle 1, Day 1, for 4 cycles, followed by pemetrexed Q3W continuous with MK-4830 and pembrolizumab, up to 35 cycles. Each cycle is 21 days.
11173755|NCT03564691|Experimental|Dose Expansion, Arm H: RCC, +Lenvatinib|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, pembrolizumab, and lenvatinib in participants with advanced renal cell carcinoma (RCC). MK-4830 will be administered IV, Q3W, starting with Cycle 1 following pembrolizumab infusion, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles. Lenvatinib will be administered orally once daily for up to 35 cycles of 21 days.
11173756|NCT03564691|Experimental|Dose Expansion, Arm I: R/M Gastric/GE Junction Adenocarcinoma|Combination therapy with the preliminary recommended phase 2 dose (RP2D) A of MK-4830, and pembrolizumab, in participants who have histologically or cytologically-confirmed recurrent or metastatic (R/M) gastric or gastroesophageal (GE) junction adenocarcinoma and who have been previously treated with at least 2 prior lines of therapy. MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles.
11173757|NCT03564678|Experimental|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
11173758|NCT03564665|Experimental|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
11173759|NCT03564665|Placebo Comparator|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
11173760|NCT03564652|No Intervention|Arm A|Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
11173761|NCT03564652|Experimental|Arm B|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
11173762|NCT03564652|Experimental|Arm C|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
11173763|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
11173764|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
11173765|NCT03564626|Experimental|Health IT only|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline and at 30 days.Follow-up will be for 30 days
11175155|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
11173770|NCT03564587|Experimental|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
11173771|NCT03564587|No Intervention|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
11173772|NCT03564574|Experimental|Study group|"Inclusion criteria
~History of consumption of OP compound.
~Symptom complex consistent with OP poisoning
~Age > 18 years
~Informed consent from the patient or next kin.
~Exclusion criteria
~History of combined poisoning with a non OP compound.
~All other patients not fitting in the organophosphate symptom complex.
~Patients with underlying liver and kidney disease.
~History suggestive of acute pancreatitis in the past.
~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.
~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
11173773|NCT03564574|No Intervention|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
11173774|NCT03564548|Experimental|CAUMZ PPP011|Inhaled synthetic cannabinoids (PPP011)
11173775|NCT03564548|Active Comparator|Morphine sulfate|Oral morphine sulfate at the previous stabilized dosage
11173776|NCT03564535|Experimental|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
11173777|NCT03564535|Active Comparator|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
11173778|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
11173779|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
11173780|NCT03564509|Experimental|FE 999302 (dose 1) and follitropin delta|
11173781|NCT03564509|Experimental|FE 999302 (dose 2) and follitropin delta|
11173782|NCT03564509|Experimental|FE 999302 (dose 3) and follitropin delta|
11173783|NCT03564509|Experimental|FE 999302 (dose 4) and follitropin delta|
11173784|NCT03564509|Experimental|FE 999302 (dose 5) and follitropin delta|
11173785|NCT03564509|Placebo Comparator|Placebo and follitropin delta|
11173786|NCT03564496|Active Comparator|Healthy Controls|20 Healthy Controls
11173787|NCT03564496|Experimental|MS Patients|40 individuals diagnosed with MS recruited from the MS Center/ Neurology Department at NYULMC
11173788|NCT03564483||Registry Observational Study|
11173789|NCT03564470|Experimental|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
11173790|NCT03564470|Experimental|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
11173791|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
11173792|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
11173793|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
11173794|NCT03564431||controls|
11173795|NCT03564431||T2DM patients|
11173796|NCT03564431||depression patients|
11173797|NCT03564431||T2DM with depression patients|
11173798|NCT03564418|Active Comparator|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
11173799|NCT03564418|Active Comparator|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
11173800|NCT03564405|Experimental|UNI-DEB|
11173801|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
11173802|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
11173803|NCT03564379|Experimental|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
11173804|NCT03564379|Experimental|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
11173805|NCT03564353|Experimental|memory task with tDCS location 1|memory task paired with tDCS targeting C2 nerve (anode left c2; cathode right C2)
11173806|NCT03564353|Experimental|memory task with tDCS location 2|memory task paired with tDCS targeting C2 nerve (anode right c2; cathode left C2)
11173807|NCT03564353|Experimental|memory task with tDCS location 3|memory task paired with tDCS targeting C5/6 nerve
11173808|NCT03564353|Experimental|memory task with tDCS location 4|memory task paired with tDCS targeting trigeminal nerve dermatomes (left and right temple/jaw)
11173809|NCT03564340|Experimental|Monotherapy|REGN4018 administration
11173810|NCT03564340|Experimental|Combination Therapy|REGN4018 and cemiplimab administration
11173811|NCT03564327||Patients with sinus rhythm|
11173812|NCT03564327||patients with atrial fibrillation|
11173813|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
11173814|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
11173815|NCT03564301|Active Comparator|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
11173816|NCT03564301|Placebo Comparator|Placebo|Placebo: same shape, size and dosis as test
11173817|NCT03564288|Experimental|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
11173818|NCT03564275|Experimental|Prospective Treatment Group|Proton Boost
11173819|NCT03564275|No Intervention|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
11173820|NCT03564262|Experimental|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.
~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
11173821|NCT03564262|Experimental|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
11173822|NCT03564249|Experimental|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
11173823|NCT03564249|Experimental|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
11173824|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:
~oral prednisolone 40 mg/day for 5 days;
~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;
~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.
~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
11173825|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:
~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.
~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.
~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
11173826|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.
~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
11173827|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.
~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
11173828|NCT03564210|Active Comparator|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
11173829|NCT03564210|Active Comparator|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
11173830|NCT03564197|Other|Nivolumab|nivolumab containing treatment according to label
11173831|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
11173832|NCT03564184|Experimental|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
11173833|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
11173834|NCT03564184|Experimental|No MT|Consists of standard care.
11173835|NCT03564171|No Intervention|Standard of Care|Patients will receive standard treatment without added intervention.
11173963|NCT03563326|Active Comparator|chemotherapy|Chemotherapy: determined by medical Oncologist
11173836|NCT03564171|Experimental|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :
~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
11173837|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
11173838|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
11173839|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
11173840|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
11173841|NCT03564145|Experimental|S5G4T-1|Topical cream
11173842|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
11173843|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
11173844|NCT03564119|Experimental|S5G4T-1|topical cream
11173845|NCT03564119|Placebo Comparator|S5G4T-2|topical cream
11173846|NCT03564106|Experimental|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
11173847|NCT03564106|Experimental|group C|receive intraarticular methylprednisolone (30 mg)
11173848|NCT03564093|Experimental|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
11173849|NCT03564093|Placebo Comparator|Placebo|0,01ml/kg intranasal 4,5% saline
11173850|NCT03564080|No Intervention|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
11173851|NCT03564080|Experimental|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
11173852|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
11173853|NCT03564054|Experimental|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
11173854|NCT03564054|Experimental|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
11173855|NCT03564041|Experimental|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
11173856|NCT03564041|Other|Health Enhancement Program (HEP)|"Arm type: Active control group
~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
11173857|NCT03564028|Experimental|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
11173858|NCT03564028|Other|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
11173859|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
11173860|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
11173861|NCT03564002||obese subjects|
11173862|NCT03564002||lean subjects|
11173863|NCT03563989|Experimental|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
11173864|NCT03563989|Active Comparator|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
11173865|NCT03563963|Active Comparator|Lidocaine 2% in Endotracheal Tube cuff|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
11173964|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
11173866|NCT03563963|Experimental|Ropivacaine 0.5% Endotracheal Tube cuff|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
11173867|NCT03563963|Active Comparator|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
11173868|NCT03563950|Experimental|Rifampin + BMS-986224|Oral administration
11173869|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
11173870|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
11173871|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
11173872|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
11173873|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
11173874|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
11173875|NCT03563911|Experimental|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
11173876|NCT03563911|Active Comparator|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
11173877|NCT03563885|Experimental|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
11173878|NCT03563885|No Intervention|Lean|Lean control subjects doing baseline testing only.
11173879|NCT03563872|Active Comparator|Active Comparator|Team-based care
11173880|NCT03563872|Experimental|Intervention|Enhanced team-based care
11173881|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
11173882|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
11173883|NCT03563833|Other|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.
~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
11173884|NCT03563833|Other|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.
~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
11173885|NCT03563807|Experimental|Golf|Group golf lessons will be led by professional golf instructors.
11173886|NCT03563807|Active Comparator|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
11173887|NCT03563794|Experimental|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
11173888|NCT03563794|Active Comparator|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
11173889|NCT03563781|Other|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
11173890|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
11173891|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
11173892|NCT03563755|Experimental|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
11173893|NCT03563755|No Intervention|Treatment as usual|Participants will continue to receive their usual treatment.
11173894|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
11173895|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
11173896|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
11173897|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
11174051|NCT03562676|Experimental|weightlessness|
11175156|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
11173898|NCT03563729|Experimental|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
11173899|NCT03563716|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
11173900|NCT03563716|Experimental|MTIG7192A + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and MTIG7192A at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
11173901|NCT03563703|Experimental|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
11173902|NCT03563703|Experimental|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
11173903|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
11173904|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
11173905|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
11173906|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
11173907|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
11173908|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
11173909|NCT03563677|No Intervention|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
11173910|NCT03563677|Experimental|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
11173911|NCT03563664|Experimental|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
11173912|NCT03563651||Ancillary-Correlative (biospecimen collection, biopsy)|Participants undergo collection of blood and urine at baseline, on day 1 of courses 1, 2, and 3, at restaging, and at disease progression. Participants may undergo collection of stool at baseline, on day 1 of course 2, and at disease progression. Participants also undergo biopsy within 4 weeks of disease progression.
11173913|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
11173914|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
11173915|NCT03563625|Active Comparator|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
11173916|NCT03563625|Active Comparator|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
11173917|NCT03563612|Active Comparator|cpap first, differential ventilation later|
11173918|NCT03563612|Active Comparator|differential ventilation first, cpap late|
11173919|NCT03563599|Experimental|Telacebec (Q203) tablet|
11173920|NCT03563599|Active Comparator|Rifafour e-275|
11173921|NCT03563586|Active Comparator|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
11173922|NCT03563586|Other|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
11173923|NCT03563573|Active Comparator|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
11173924|NCT03563573|Placebo Comparator|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
11173925|NCT03563573|Active Comparator|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
11173926|NCT03563573|Placebo Comparator|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
11173927|NCT03563560|Experimental|ACM regimen|ACM regimen is for Japanese patients with relapsed or refractory AML.
11173928|NCT03563560|Experimental|A+7+3 regimen|A+7+3 regimen is for Japanese newly diagnosed AML patients.
11173929|NCT03563547|Active Comparator|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
11173930|NCT03563547|Experimental|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
11173931|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
11173932|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
11173933|NCT03563521||Atopic, eosinophilic|
11173934|NCT03563521||Atopic, non-eosinophilic|
11173935|NCT03563521||Non-atopic, eosinophilic|
11173936|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
11173937|NCT03563521||Non-atopic, non-eosinophilic|
11173938|NCT03563521||Control|Without asthma, atopy and eosinophilia
11173939|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
11173940|NCT03563495|Active Comparator|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
11173941|NCT03563495|Active Comparator|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
11173942|NCT03563482|Experimental|Experimental|Biopsy and PET scan
11173943|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
11173944|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
11173945|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
11173946|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
11173947|NCT03563430|Experimental|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
11173948|NCT03563430|Experimental|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
11173949|NCT03563430|Experimental|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
11173950|NCT03563417|Active Comparator|PCI|
11173951|NCT03563417|Other|OMT|
11173952|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
11173953|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
11173954|NCT03563391|Experimental|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
11173955|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
11173956|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
11173957|NCT03563365|Experimental|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
11173958|NCT03563365|Experimental|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
11173959|NCT03563365|Active Comparator|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
11173960|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
11173961|NCT03563339|Experimental|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
11173962|NCT03563326|Experimental|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
11173965|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
11173966|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
11173967|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
11173968|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs before surgery|
11173969|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
11173970|NCT03563261|Active Comparator|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
11173971|NCT03563261|Placebo Comparator|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
11173972|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~SBRT should be administered 2-6 weeks after completing chemotherapy
~All participants will undergo an attempt at definitive surgical resection following SBRT"
11173973|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~Losartan will be administered orally as a tablet to be taken by the patient at home every day
~SBRT should be administered 2-6 weeks after completing chemotherapy
~All participants will undergo an attempt at definitive surgical resection following SBRT"
11173974|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~Losartan will be administered orally as a tablet to be taken by the patient at home every day
~SBRT should be administered 2-6 weeks after completing chemotherapy
~Participants will receive nivolumab during SBRT
~All participants will undergo an attempt at definitive surgical resection following SBRT"
11173975|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion
~SBRT should be administered 2-6 weeks after completing chemotherapy
~Participants will receive nivolumab during SBRT
~All participants will undergo an attempt at definitive surgical resection following SBRT"
11173976|NCT03563235|Experimental|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
11173977|NCT03563235|Active Comparator|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
11173978|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
11173979|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
11173980|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
11173981|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
11173982|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
11173983|NCT03563170|Experimental|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.
11173984|NCT03563170|Active Comparator|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.
11173985|NCT03563157|Experimental|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
11173986|NCT03563157|Active Comparator|Regorafenib|In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.
11173987|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1
~A combination of agents will be administered to subjects in this study:
~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
11173988|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
11173989|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
11173990|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
11173991|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
11173992|NCT03563118||Group OSAS|We included 56 with OSAS [13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
11173993|NCT03563118||control group|simple snoring
11173994|NCT03563105|Experimental|Desaturation|Vascular Occlusion Test
11173995|NCT03563092|Experimental|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
11173996|NCT03563092|Active Comparator|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
11173997|NCT03563079|Experimental|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
11173998|NCT03563079|Active Comparator|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
11173999|NCT03563066|Experimental|Benralizumab|Fixed dose 30mg benralizumab.
11174000|NCT03563066|Placebo Comparator|Placebo Control|Will appear identical in form to benralizumab arm.
11174001|NCT03563053|Experimental|active drug|~14-22 mg dexamethasone sodium phosphate (DSP)
11174002|NCT03563040|Experimental|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
11174003|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
11174004|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
11174005|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
11174006|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
11174007|NCT03563001|Experimental|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
11174008|NCT03563001|Experimental|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
11174009|NCT03562988|Experimental|vitafusion Power C gummy|A single oral dose of gummy vitamin C to monitor vitamin C blood levels
11174010|NCT03562988|Active Comparator|Nature Made vitamin C caplet|A single oral dose of gummy vitamin C to monitor vitamin C blood levels
11174011|NCT03562962|Other|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland & Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).
~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
11174012|NCT03562949|Experimental|Test Product|Test Product, 40 mcg, 2 x daily
11174013|NCT03562949|Active Comparator|Reference Product|Reference Product, 40 mcg, 2 x daily
11174014|NCT03562949|Placebo Comparator|Placebo|Placebo Product 2 x daily
11174015|NCT03562923|Experimental|Test Product|Test Product, 100/50 mcg, 2 x daily
11174016|NCT03562923|Active Comparator|Reference Product|Reference Product, 100/50 mcg, 2 x daily
11174017|NCT03562923|Placebo Comparator|Placebo|Placebo Product 2 x daily
11174018|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
11174019|NCT03562897|Experimental|Ocoxin-Viusid®|Ocoxin-Viusid® before, during and after the Chemotherapy treatment.
11174020|NCT03562884|Experimental|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
11174021|NCT03562884|Active Comparator|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
11174022|NCT03562871|Experimental|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
11174023|NCT03562871|Active Comparator|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
11174083|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
11174024|NCT03562871|Experimental|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
11174025|NCT03562871|Active Comparator|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
11174026|NCT03562858|Active Comparator|Delayed dentine sealing|
11174027|NCT03562858|Experimental|Immediate dentin sealing|
11174028|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:
~Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved
~Patients with a good and stable clinical evolution
~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
11174029|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
11174030|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
11174031|NCT03562819||NSCLC|Non-small cell lung cancer
11174032|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
11174033|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
11174034|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
11174035|NCT03562780|Experimental|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
11174036|NCT03562780|Active Comparator|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
11174037|NCT03562767|Experimental|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
11174038|NCT03562767|Experimental|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
11174039|NCT03562767|Placebo Comparator|Usual Care|Subjects receiving usual care from their primary care providers
11174040|NCT03562754|Active Comparator|Control|
11174041|NCT03562754|Experimental|Prometheus System|
11174042|NCT03562741|Experimental|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
11174043|NCT03562728|Active Comparator|ECMO- Bridge to Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
11174044|NCT03562728|Other|ECMO- Bridge to Transplant Control Group|"Interventions: standard of care
~Patients are not going to receive any additional intervention."
11174045|NCT03562728|Active Comparator|Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
11174046|NCT03562728|Other|Transplant Control Group|"Interventions: standard of care.
~Patients are not going to receive any additional intervention."
11174047|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
11174048|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
11174049|NCT03562702|Active Comparator|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
11174050|NCT03562702|Experimental|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
11174052|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
11174053|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
11174054|NCT03562650|Experimental|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
11174055|NCT03562650|Active Comparator|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
11174056|NCT03562637|Experimental|Adagloxad simolenin + OBI-821 in conjunction with SOC|"Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks.
~Patient will also receive standard of care (SOC) treatment."
11174057|NCT03562637|Active Comparator|Standard of Care treatment|"Study visit intervals will be identical to those in Arm 1.
~Patient will receive standard of care (SOC) treatment."
11174058|NCT03562624|Experimental|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
11174059|NCT03562624|Experimental|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
11174060|NCT03562624|Experimental|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
11174061|NCT03562624|Active Comparator|Marketed comparator|Marketed comparator IUS
11174062|NCT03562611|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
11174063|NCT03562611|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
11174064|NCT03562611|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
11174065|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
11174066|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
11174067|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
11174068|NCT03562559||TKA Patients|
11174069|NCT03562546|Experimental|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
11174070|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve [AUC] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
11174071|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
11174072|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
11174073|NCT03562507|Experimental|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
11174074|NCT03562507|Experimental|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
~Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle"
11174075|NCT03562494|Experimental|VY-AADC02 (NBIb-1817)|Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02
11174076|NCT03562494|Placebo Comparator|Sham (Placebo) Surgery|Sham surgical procedure
11174077|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
11174078|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
11174079|NCT03562468|Placebo Comparator|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
11174080|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
11174081|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
11174082|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
11174084|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).
~Intervention: Smoking cessation"
11174085|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
11174086|NCT03562429|Experimental|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
11174087|NCT03562429|Placebo Comparator|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
11174088|NCT03562416|Experimental|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
11174089|NCT03562416|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 24 months
11174090|NCT03562403|Experimental|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
11174091|NCT03562390|Experimental|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
11174092|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >
~> Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
11174093|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections. >
~> Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
11174094|NCT03562364|No Intervention|Standard of Care|The standard of care group will remain non-weight bearing for 10-12 weeks following definitive fixation and receive physical therapy in accordance with standard practice at the treating center.
11174095|NCT03562364|Experimental|Early Advanced Weight Bearing (EAWB)|The Early Advanced Weight Bearing (EAWB) group will receive early weight-bearing treatment using the antigravity AlterG treadmill. These sessions will begin 14-28 days following definitive fixation and last for a total of 10 weeks
11174096|NCT03562351|Experimental|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
11174097|NCT03562351|Experimental|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
11174098|NCT03562351|Experimental|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
11174099|NCT03562338|Experimental|Manual Therapy and Exercise|
11174100|NCT03562338|Active Comparator|Usual Care|
11174101|NCT03562325|Other|ACT|Acceptance & Commitment Therapy (ACT)
11174102|NCT03562312|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
11174103|NCT03562312|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
11174104|NCT03562299|Experimental|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
11174105|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
11174106|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
11174107|NCT03562260|Experimental|children who had bipolar release|children who had bipolar release are included
11174108|NCT03562247|Active Comparator|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
11174109|NCT03562247|Experimental|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
11174110|NCT03562247|Experimental|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
11174111|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.
~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
11174112|NCT03562221|Experimental|Gluten free diet|Gluten free diet
11174113|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
11174114|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
11174115|NCT03562195|Experimental|Subjects receiving Mepolizumab|Eligible subjects will randomized in 1:1 ratio to Mepolizumab group or Placebo group. Subjects in Mepolizumab group will receive Mepolizumab 100mg subcutaneously into the upper arm or thigh every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC of asthma treatment. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an needed basis in this study.
11174116|NCT03562195|Placebo Comparator|Subjects receiving Placebo|Eligible subjects in placebo group will receive placebo (0.9 percent sodium chloride) matching to Mepolizumab administered subcutaneously into the upper arm or thigh every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC of asthma treatment. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an as needed basis in this study.
11191360|NCT03444181|Active Comparator|Training intervention|
11174117|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
11174118|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
11174119|NCT03562169|Active Comparator|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
11174120|NCT03562169|Experimental|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
11174121|NCT03562156|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
11174122|NCT03562156|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
11174123|NCT03562143|Experimental|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
11174124|NCT03562143|Active Comparator|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
11174125|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
11174126|NCT03562117|Experimental|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
11174127|NCT03562117|Experimental|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
11174128|NCT03562117|Experimental|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
11174129|NCT03562117|Experimental|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
11174130|NCT03562117|Experimental|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
11174131|NCT03562104|Experimental|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
11174132|NCT03562078|Experimental|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
11174133|NCT03562078|No Intervention|Control Group for Type 2 Diabetes|diabetic patients care education
11174134|NCT03562065|Experimental|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:
~1.10^6 CSM / kg
~2.10^6 CSM / kg
~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
11174135|NCT03562039|Experimental|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
11174136|NCT03562039|Active Comparator|M-MIST (group B)|conventional M-MIST.
11174137|NCT03562000|Experimental|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
11174138|NCT03562000|Other|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
11174139|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.
~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.
~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
11174140|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.
~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.
~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
11174141|NCT03561974|Experimental|Humidification|
11174142|NCT03561974|No Intervention|Control group without humidification|
11174143|NCT03561961|Active Comparator|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. Patients with node positive disease will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
11174183|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
11174184|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
11174144|NCT03561961|Experimental|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. Patients with node positive disease will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
11174145|NCT03561948|Experimental|Experimental group|Surgery and Intraperitoneal Chemotherapy
11174146|NCT03561948|Placebo Comparator|Control group|only surgery
11174147|NCT03561935|Experimental|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
11174148|NCT03561935|Active Comparator|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
11174149|NCT03561922|Experimental|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
11174150|NCT03561909|Other|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
11174151|NCT03561896|Experimental|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
11174152|NCT03561896|Experimental|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
11174153|NCT03561883|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals.
11174154|NCT03561883|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals.
11174155|NCT03561870|Experimental|Olaparib|
11174156|NCT03561857|Experimental|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
11174157|NCT03561844|Active Comparator|aromatherapy-scent|
11174158|NCT03561844|Active Comparator|aromatherapy-touch|
11174159|NCT03561844|No Intervention|waiting-list control|
11174160|NCT03561831|Active Comparator|propofol group|patients who anesthesized by propofol
11174161|NCT03561831|Active Comparator|sevoflurane group|patients who anesthesized by sevoflurane
11174162|NCT03561818|Experimental|Hospital-based group|2 months hospital-based pulmonary rehabilitation program
11174163|NCT03561818|Experimental|Home-based group|2 months home-based pulmonary rehabilitation program
11174164|NCT03561805|Other|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
11174165|NCT03561792|No Intervention|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI < 105 predicts successful weaning)
11174166|NCT03561792|Experimental|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI < 1.3 predicts successful weaning)
11174167|NCT03561779|Experimental|YYD302|YYD302 (2ml)
11174168|NCT03561779|Active Comparator|Synovian Inj.|Synovian Inj. (3ml)
11174169|NCT03561753|Active Comparator|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
11174170|NCT03561753|Experimental|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ [high dose] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
11174171|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
11174172|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
11174173|NCT03561727|Experimental|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
11174174|NCT03561727|Active Comparator|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
11174175|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
11174176|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
11174177|NCT03561701|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
11174178|NCT03561701|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
11174179|NCT03561688|Sham Comparator|Standard insole|a flat insole
11174180|NCT03561688|Experimental|Foot orthotics|Custom-made foot orthoses
11174181|NCT03561675|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11174182|NCT03561675|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
11174185|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
11174186|NCT03561649|Experimental|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.
~The patients will be seen as part of their follow-up consultation in Rheumatology.
~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.
~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
11174187|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
11174188|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
11174189|NCT03561610|Active Comparator|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
11174190|NCT03561610|Experimental|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
11174191|NCT03561597|Experimental|Mobile health application|Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
11174192|NCT03561584|Active Comparator|Active Drug (Sulfasalazine)|
11174193|NCT03561584|Placebo Comparator|Placebo|
11174194|NCT03561571|Active Comparator|Butter based breakfast|
11174195|NCT03561571|Active Comparator|Chocolate spread based breakfast|
11174196|NCT03561558|Experimental|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
11174197|NCT03561558|Active Comparator|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
11174198|NCT03561545|Experimental|Functional capillary density|Functional capillary density during weightlessness
11174199|NCT03561532|Active Comparator|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
11174200|NCT03561532|Placebo Comparator|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
11174201|NCT03561519|Active Comparator|FMT|IBS patients randomized to receive FMT from a healthy donor.
11174202|NCT03561519|Placebo Comparator|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
11174203|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
11174204|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
11174205|NCT03561493|Experimental|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
11174206|NCT03561493|No Intervention|non zumba exercise group|The participants in the control group did not receive any intervention.
11174207|NCT03561480|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
11174208|NCT03561480|Active Comparator|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
11174209|NCT03561441|Active Comparator|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
11174210|NCT03561441|Experimental|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
11174211|NCT03561415|Experimental|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
11174212|NCT03561415|Experimental|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
11174213|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
11191361|NCT03444181|No Intervention|No intervention|
11174214|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
11174215|NCT03561376|Other|Single arm - split scar study|Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
11174216|NCT03561363|Experimental|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.
~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.
~Carbohydrate comprise 20 E% and protein 15 E%."
11174217|NCT03561363|Experimental|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
11174218|NCT03561337|Experimental|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
11174219|NCT03561337|Placebo Comparator|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
11174220|NCT03561324|Experimental|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
11174221|NCT03561311|Experimental|Remote ischemic conditioning group|
11174222|NCT03561311|Sham Comparator|Sham remote ischemic conditioning group|
11174223|NCT03561298|Experimental|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
11174224|NCT03561285||Stroke with antiphospholipid|
11174225|NCT03561285||stroke without antiphospholipid|
11174226|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
11174227|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
11174228|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
11174229|NCT03561259|Experimental|131I-MIBG|131I-MIBG
11174230|NCT03561246|Active Comparator|Personalized training effect on SSWS|"Determine the efficacy of motor control deficit guided personalized training on SSWS compared to non-personalized and CONTROL interventions.
~Incline treadmill walking Decline treadmill walking"
11174231|NCT03561246|Active Comparator|Personalized training effect on Pp|"Determine the efficacy of motor control deficit guided personalized training on increasing symmetry of Pp compared to non-personalized and CONTROL interventions.
~Incline treadmill walking Decline treadmill walking"
11174232|NCT03561246|Active Comparator|Positive response|"Determine if the personalized intervention increase the positive response rate compared to non-personalized and CONTROL interventions, and to further advance personalize interventions by identifying factors that predict response.
~Incline treadmill walking Decline treadmill walking"
11174233|NCT03561233|Experimental|proton pump inhibitor|omeprazole 20 mg twice daily
11174234|NCT03561220|Active Comparator|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
11174235|NCT03561220|Active Comparator|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
11174236|NCT03561220|Experimental|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
11174237|NCT03561220|Experimental|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
11174238|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.
11174239|NCT03561181|Experimental|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
11174240|NCT03561181|Experimental|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
11174241|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
11174242|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
11174243|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
11174244|NCT03561155|Experimental|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
11174245|NCT03561155|Active Comparator|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
11174246|NCT03561142|Experimental|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
11174247|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
11174248|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
11174249|NCT03561103|Experimental|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
11174250|NCT03561103|No Intervention|RCT: Control|Participants in the RCT control group will receive the standard of care.
11174251|NCT03561103|Experimental|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
11174252|NCT03561103|No Intervention|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
11174253|NCT03561090|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals.
11174254|NCT03561090|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals.
11174255|NCT03561077|Experimental|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
11174256|NCT03561064|Experimental|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
11174257|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
11174258|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
11174259|NCT03561025|Active Comparator|18F-FDG-PET/MRI|
11174260|NCT03561025|Experimental|18F-GE180-PET/MRI|
11174261|NCT03561012|Experimental|Intervention arm|
11174262|NCT03561012|Active Comparator|Control Arm|
11174263|NCT03560986|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
11174264|NCT03560986|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
11174265|NCT03560973|Experimental|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
11174266|NCT03560973|Placebo Comparator|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
11174267|NCT03560960|Experimental|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
11174268|NCT03560960|Active Comparator|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
11174269|NCT03560960|Active Comparator|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
11174270|NCT03560947|Experimental|Manual Therapy and Exercise|
11174271|NCT03560947|Active Comparator|Usual Care|
11174272|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.
~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
11174273|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
11174274|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
11174275|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
11174276|NCT03560908|Experimental|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
11174277|NCT03560895|Active Comparator|Group I|Patients will be anesthetized using low-volume cuffed Kimberly-Clark * MICROCUFF * endotracheal tube (Microcuff, Halyard Health Inc., Atlanta, GA, USA), with its outer diameter determined by ultrasonography.
11174278|NCT03560895|Active Comparator|Group II|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
11174279|NCT03560895|Active Comparator|Group III|Patients will be anesthetized using uncuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
11174280|NCT03560882|Experimental|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
11174281|NCT03560869|Active Comparator|Normal Hydration|Participants will consume water to maintain proper hydration for three days prior to testing.
11174282|NCT03560869|Experimental|Dehydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing.
11174283|NCT03560856|Other|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
11174284|NCT03560843|Experimental|MBSR treatment|MBSR will be administered over 8 week period.
11174285|NCT03560843|No Intervention|Control group|Usual care will continue for this group.
11174286|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
11174287|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
11174288|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.
~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
11174488|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
11174289|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.
~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
11174290|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
11174291|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
11174292|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
11174293|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
11174294|NCT03560765|Experimental|Using MED assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen to purchase an MED following training
11174295|NCT03560765|Active Comparator|Using MED training only|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen to purchase an MED following training
11174296|NCT03560765|Active Comparator|No MED, assigned buddy|Participant has been randomly assigned a student volunteer buddy, and has chosen not to purchase an MED following training
11174297|NCT03560765|No Intervention|No MED, no buddy|Participant has been randomly assigned to not have a student volunteer buddy, and has chosen not to purchase an MED following training
11174298|NCT03560752|Experimental|Prevention(multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
11174299|NCT03560739|Other|OMB 20mg PFS abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen
11174300|NCT03560739|Other|OMB 20mg AI abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen
11174301|NCT03560739|Other|OMB 20mg PFS thigh|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh
11174302|NCT03560739|Other|OMB 20mg AI thigh|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh
11174303|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
11174304|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).
~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
11174305|NCT03560713|Experimental|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
11174306|NCT03560713|Sham Comparator|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
11174307|NCT03560700|Experimental|lactobacillus probiotic strain|60 billion CFU/day
11174308|NCT03560700|Placebo Comparator|placebo|
11174309|NCT03560687|Experimental|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
11174310|NCT03560687|No Intervention|Control|
11174311|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
11174312|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
11174313|NCT03560661||Kennedy's disease (KD) patients|
11174314|NCT03560648|Other|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
11174315|NCT03560648|Other|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
11174316|NCT03560635|Active Comparator|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
11174317|NCT03560635|Experimental|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
11174360|NCT03560375|Experimental|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
11174318|NCT03560622|Active Comparator|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
11174319|NCT03560622|Experimental|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
11174320|NCT03560609|Active Comparator|Subjects With Keratoconus|
11174321|NCT03560609|Active Comparator|Subjects with Glaucoma|
11174322|NCT03560596|Experimental|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
11174323|NCT03560596|Active Comparator|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
11174324|NCT03560583|Experimental|Metoclopramide 10 mg BID|
11174325|NCT03560583|Placebo Comparator|Placebo 10 mg BID|
11174326|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
11174327|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
11174328|NCT03560570||Control|Healthy subject
11174329|NCT03560544|Experimental|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
11174330|NCT03560544|No Intervention|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
11174331|NCT03560531|Experimental|ZN-c5 monotherapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.
11174332|NCT03560531|Experimental|ZN-c5 + palbociclib combination therapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 in combination with palbociclib as well as a Phase 2 cohort.
11174333|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
11174334|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
11174335|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
11174336|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.
~Intervention: Ultrasound protocol."
11174337|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.
~Intervention: Ultrasound protocol."
11174338|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
11174339|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
11174340|NCT03560479|Experimental|alpha1H, 7.4 mg/mL|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
11174341|NCT03560479|Placebo Comparator|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
11174342|NCT03560479|Experimental|alpha1H, 37 mg/mL|alpha1H (37 mg/mL), solution for instillation, 30 mL
11174343|NCT03560479|Experimental|alpha1H, 74 mg/mL|alpha1H (74 mg/mL), solution for instillation, 30 mL
11174344|NCT03560466|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
11174345|NCT03560453|No Intervention|Control|Attend assigned high school for 9 months
11174346|NCT03560453|Experimental|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
11174347|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
11174348|NCT03560427|Experimental|duloxetine+morphine|
11174349|NCT03560427|Placebo Comparator|placebo+morphine|
11174350|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
11174351|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
11174352|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
11174353|NCT03560401|Experimental|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor [chairback] brace) full-time for 12 weeks, except when bathing or lying in bed.
11174354|NCT03560401|No Intervention|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
11174355|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
11174356|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
11174357|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
11174358|NCT03560375|Experimental|Circuit resistance training (CRT)|2-3 circuits * 10 exercises * 3 times per week
11174359|NCT03560375|Experimental|Empagliflozin 10 MG|10 mg once daily
11174489|NCT03559361|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
11174361|NCT03560362|Active Comparator|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
11174362|NCT03560362|Experimental|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
11174363|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
11174364|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
11174365|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
11174366|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
11174367|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
11174368|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
11174369|NCT03560310|Experimental|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75-100 mg daily for 12 months
11174370|NCT03560310|Active Comparator|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
11174371|NCT03560297|Experimental|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
11174372|NCT03560297|Experimental|Delayed/Waitlist Program|Participants do not participate in the program for a time period
11174373|NCT03560271|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
11174374|NCT03560271|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
11174375|NCT03560271|Placebo Comparator|Dose C|Placebo
11174376|NCT03560258|Experimental|Arm 1: p24CE1/2 pDNA + full-length p55^gag pDNA vaccine|Participants will receive p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24.
11174377|NCT03560258|Experimental|Arm 2: Full-length p55^gag pDNA vaccine|Participants will receive full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
11174378|NCT03560258|Placebo Comparator|Arm 3: Placebo|Participants will receive placebo at Weeks 0, 4, 12, and 24.
11174379|NCT03560245|Experimental|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
11174380|NCT03560245|Placebo Comparator|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
11174381|NCT03560232|Active Comparator|Cefazolin + Gentamicin|"[Cefazolin]
~Initial dose:
~Cefazolin 2g IV x1 dose (patient weight < 120kg)
~Cefazolin 3g IV x1 dose (patient weight >/= 120kg)
~Subsequent dose:
~Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min)
~Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)
~Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min)
~Duration:
~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first
~[Gentamicin]
~Initial dose:
~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)
~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)
~Subsequent dose:
~Pharmacy Consult to dose gentamicin
~Duration:
~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
11174382|NCT03560232|Active Comparator|Ceftriaxone|"Initial dose:
~Ceftriaxone 2g IV x1 dose
~Subsequent dose:
~Ceftriaxone 2g IV every 24 hours
~Duration:
~One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
11174383|NCT03560232|Active Comparator|Ampicillin/Sulbactam|"Initial dose:
~Ampicillin/Sulbactam 3g IV x1 dose
~Subsequent dose:
~Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min)
~Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)
~Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min)
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
11174384|NCT03560232|Active Comparator|Piperacillin/Tazobactam|"Initial dose:
~Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes
~Subsequent dose:
~Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min)
~Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min)
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
11174385|NCT03560232|Other|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:
~[Clindamycin]
~Initial dose:
~Clindamycin 900mg IV x1 dose
~Subsequent dose:
~Clindamycin 600mg IV every 8 hours
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
~[Gentamicin]
~Initial dose:
~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)
~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)
~Subsequent dose:
~Pharmacy Consult to dose gentamicin
~Duration:
~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
11174386|NCT03560206|Experimental|Family SWaP intervention with mini iPad|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
11174420|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
11174387|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
11174388|NCT03560193|Experimental|Chlorhexidine Group|
11174389|NCT03560193|Active Comparator|Povidone Iodine Group|
11174390|NCT03560167|Experimental|AccuCinch® Ventricular Repair System|
11174391|NCT03560154|Experimental|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
11174392|NCT03560154|No Intervention|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
11174393|NCT03560128|Experimental|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
11174394|NCT03560128|Experimental|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
11174395|NCT03560102|Experimental|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat& resect model
11174396|NCT03560089|Active Comparator|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
11174397|NCT03560089|Placebo Comparator|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
11174398|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
11174399|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
11174400|NCT03560063|Experimental|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
11174401|NCT03560063|Active Comparator|Standard care arm|Total hip replacement with standard templating to guide implant positioning
11174402|NCT03560050|Experimental|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
11174403|NCT03560050|Experimental|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
11174404|NCT03560037|No Intervention|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
11174405|NCT03560037|Experimental|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
11174406|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
11174407|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
11174408|NCT03560011|No Intervention|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
11174409|NCT03560011|Experimental|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
11174410|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
11174411|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
11174412|NCT03559972|Experimental|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.
~SkinMedica Facial Cleanser
~Hulk (cosmetic investigational)
~Marvel AM (cosmetic investigational)
~Marvel PM (cosmetic investigational)
~SkinMedica HA5 Rejuvenating Hydrator
~SkinMedica Rejuvenative Moisturizer
~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
11174413|NCT03559972|Experimental|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.
~SkinMedica Facial Cleanser
~SkinMedica TNS Essential Serum
~Marvel AM (cosmetic investigational)
~Marvel PM (cosmetic investigational)
~SkinMedica HA5 Rejuvenating Hydrator
~SkinMedica Rejuvenative Moisturizer
~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
11174414|NCT03559959|Experimental|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
11174415|NCT03559959|Experimental|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
11174416|NCT03559959|Experimental|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
11174417|NCT03559959|Experimental|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
11174418|NCT03559959|Experimental|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
11174419|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
11174421|NCT03559933|Experimental|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
11174422|NCT03559920|Experimental|Sevoflurane group|Patients who are sedated using sevoflurane
11174423|NCT03559920|Active Comparator|Intravenous sedation group|Patients who are sedated using propofol
11174424|NCT03559907|Experimental|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
11174425|NCT03559907|Experimental|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
11174426|NCT03559907|Experimental|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
11174427|NCT03559881|No Intervention|Observation|Participants with a habitual protein intake >1.2 g/kg body weight/day will be allocated to the observational arm of the study
11174428|NCT03559881|Experimental|Intervention|Participants with a habitual protein intake <1.2 g/kg body weight/day will be allocated to the interventional arm of the study
11174429|NCT03559868|Active Comparator|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
11174430|NCT03559868|Active Comparator|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
11174431|NCT03559868|Placebo Comparator|Placebo|oral placebo
11174432|NCT03559855|Experimental|Real Essentials|The Real Essentials curriculum is delivered in class to students by the Center for Relationship Education staff. It consists of 5 to 6 hours of healthy relationship education.
11174433|NCT03559855|No Intervention|Class as Usual|For the Class-as-Usual condition, there is no change in class content. Teachers offer what they typically offer.
11174434|NCT03559842||Surgery patients|Obese patients undergoing laparoscopic sleeve gastrectomy
11174435|NCT03559842||Non-surgery patients|Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)
11174436|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
11174437|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
11174438|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
11174439|NCT03559803|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
11174440|NCT03559777|Active Comparator|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally
~A full thickness flap will be elevated
~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.
~The widening drills can be sequentially used to widen the osteotomy site to the same level
~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.
~The osteotome will be tapped gently to fracture up the sinus floor.
~Xenograft will be added to the osteotomy as the grafting material.
~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.
~Smart peg will be placed on implant and Ostell will be used to record ISQ.
~Healing collar will be placed on implant.
~Suturing the flab around healing collar."
11174441|NCT03559777|Experimental|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally
~A full thickness flap will be elevated
~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.
~Change the drill motor to reverse- densifying Mode
~Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.
~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.
~densah burs (3.5mm) advance in the osteotomy.
~Xenograft will be added to the osteotomy .
~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.
~Smart peg will be placed on implant and Ostell will be used to record ISQ.
~Healing collar will be placed on implant.
~Suturing the flab around healing collar."
11174442|NCT03559764|Experimental|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
11174443|NCT03559751|Experimental|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
11174444|NCT03559751|Experimental|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
11174445|NCT03559751|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
11174446|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
11174447|NCT03559725|Experimental|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
11174448|NCT03559725|Experimental|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
11174449|NCT03559725|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
11174450|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
11174451|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
11175777|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
11174452|NCT03559699|Experimental|Part 1: Dose Optimization AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for up to 16 weeks.
~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual participant's transfusion cycle and response to AG-348 in Part 1."
11174453|NCT03559647||Cohort 1|Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
11174454|NCT03559647||Cohort 2|Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab
11174455|NCT03559634|Experimental|Intervention group|Using an electronic application, participants answer survey questions about their sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception. Then, based on survey answers, they will be able to watch more in-depth educational videos on methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to survey screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. Participants will then be given the opportunity to initiate contraception in the ED. All participants will be referred for follow up outpatient health services. Subjects who have medical contraindications to certain contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s) while in the ED.
11174456|NCT03559634|Other|Control Group|Using an electronic application, participants answer survey questions about their background, sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants medical history and contraceptive preferences they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. After these videos they will be given information on where they will be able to follow up to receive these contraceptive methods if they wish to start a method. Subjects who have medical contraindications to certain hormonal contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s), should this come up in future discussions with their providers.
11174457|NCT03559621|No Intervention|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
11174458|NCT03559621|Other|intervention group|A mobile-based lifestyle intervention
11174459|NCT03559595|Experimental|Intervention group|All study participants will be exposed to the intervention
11174460|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
11174461|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
11174462|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
11174463|NCT03559543|Experimental|Ocoxin-Viusid®|
11174464|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
11174465|NCT03559517|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
11174466|NCT03559517|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
11174467|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
11174468|NCT03559504||Group 1|Infant period: 1 month-1 year old
11174469|NCT03559504||Group 2|Toddler period:1-3 years old
11174470|NCT03559504||Group 3|Preschool age period:3-6 years old
11174471|NCT03559504||Group 4|School age period:7-18 years old
11174472|NCT03559504||Group 5|Adults:18-65 years old
11174473|NCT03559504||Group 6|Elderly:65-80 years old
11174474|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
11174475|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
11174476|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
11174477|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
11174478|NCT03559465|Sham Comparator|healthy subject|
11174479|NCT03559452|Experimental|Muscle damage|
11174480|NCT03559439|Experimental|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
11174481|NCT03559426|Active Comparator|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
11174482|NCT03559426|Experimental|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
11174483|NCT03559413|Experimental|Intervention group|
11174484|NCT03559400|Experimental|gentamicin injection at fracture site|Subjects with an open tibia fracture who receive gentamicin in saline solution administered after closure at the time of initial debridement.
11174485|NCT03559400|Placebo Comparator|placebo saline injection at fracture site|Subjects with an open tibia fracture who receive placebo saline solution administered after closure at the time of initial debridement.
11174486|NCT03559387|Experimental|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
11174487|NCT03559387|Active Comparator|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
11174490|NCT03559361|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
11174491|NCT03559361|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
11174492|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
11174493|NCT03559335||Patients after colorectal cancer surgery|
11174494|NCT03559309|Other|Alirocumab|Medical Treatment (Clinical Routine)
11174495|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
11174496|NCT03559283|Experimental|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
11174497|NCT03559270|Experimental|Baricitinib|Baricitinib administered orally.
11174498|NCT03559257|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
11174499|NCT03559257|Placebo Comparator|Placebo|Placebo administered SC.
11174500|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
11174501|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
11174502|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
11174503|NCT03559231|Experimental|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
11174504|NCT03559231|Active Comparator|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
11174505|NCT03559218|Other|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
11174506|NCT03559218|Experimental|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
11174507|NCT03559205|No Intervention|MSK-Tracker (before)|Usual Care in clinic consultations
11174508|NCT03559205|Active Comparator|MSK-Tracker (after)|Use of the MSK-Tracker in clinic consultations
11174509|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
11174510|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
11174511|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
11174512|NCT03559179|Experimental|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
11174513|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
11174514|NCT03559179|Experimental|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
11174515|NCT03559166|Experimental|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
11174516|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
11174517|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
11174518|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
11174519|NCT03559166|Placebo Comparator|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
11174520|NCT03559166|Placebo Comparator|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
11174521|NCT03559166|Placebo Comparator|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
11174522|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
11174523|NCT03559166|Placebo Comparator|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
11174524|NCT03559166|Placebo Comparator|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
11174525|NCT03559166|Placebo Comparator|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
11174526|NCT03559153|No Intervention|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
11174527|NCT03559153|Experimental|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
11174528|NCT03559153|Active Comparator|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
11191699|NCT03441893|Active Comparator|UC patients (cohort 1)|
11174529|NCT03559140|Experimental|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.
~After the procedure cryotherapy will be applied as follows:
~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
11174530|NCT03559140|Experimental|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)
~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:
~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
11174531|NCT03559140|Experimental|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).
~The group will receive the irrigant solution at room temperature. as follows:
~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
11174532|NCT03559127|Experimental|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.
~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
11174533|NCT03559127|Experimental|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution
~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
11174534|NCT03559127|Experimental|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution
~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
11174535|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
11174536|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
11174537|NCT03559101|Active Comparator|Beverage 1 - Control|Distilled Water
11174538|NCT03559101|Experimental|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
11174539|NCT03559101|Experimental|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
11174540|NCT03559101|Experimental|Beverage 4|Pedialyte
11174541|NCT03559101|Experimental|Beverage 5|Gatorade
11174542|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
11174543|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
11174544|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174545|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174546|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174547|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174548|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174549|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174550|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174551|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
11174552|NCT03559062|Other|Placebo|Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
11174553|NCT03559062|Experimental|TEZ/IVA|Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
11174554|NCT03559062|Experimental|Ivacaftor|Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
11174610|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
11191700|NCT03441893|Active Comparator|UC patients (cohort 2)|
11174555|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).
~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
11174556|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
11174557|NCT03559023|Active Comparator|Ultrasound Only|Ultrasound assisted epidural placement
11174558|NCT03559023|Active Comparator|Manometry Only|Manometry confirmation in epidural placement
11174559|NCT03559023|Active Comparator|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
11174560|NCT03559023|Sham Comparator|Usual Care/Management|Usual epidural technique placement
11174561|NCT03559010|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
11174562|NCT03558997|Experimental|Placebo|Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
11174563|NCT03558997|Experimental|Dupilumab|Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
11174564|NCT03558997|Experimental|SCIT|Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
11174565|NCT03558997|Experimental|Dupilumab + SCIT|Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
11174566|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
11174567|NCT03558984|Other|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
11174568|NCT03558971|Experimental|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
11174569|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
11174570|NCT03558945|Experimental|Personalized neoantigen vaccine|"Patients will receive radical surgery and at least one circle of post-operative chemotherapy.
~Personalized neoantigen vaccines will be injected on day 1 of weeks 1, 3, 5, 7, 9, short interval or 1-2 months after the end of their post-operative chemotherapy, and two boosts will be on day 1 of weeks 12, 20.
~Vaccines will be given in a total volume of up to 1.0ml/shot consisting of 0.3mg peptide+0.5mg ployICLC injected subcutaneously into two to four separate sites of the subject's thighs.
~Patients will be called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
11174571|NCT03558945|No Intervention|Conventional treatment|Patients will receive radical surgery and conventional post-operative chemotherapy.
11174572|NCT03558919|Experimental|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
11174573|NCT03558919|Active Comparator|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
11174574|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
11174575|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.
11174576|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.
11174577|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was <15% in the whole mouth.
11174578|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
11174579|NCT03558880|Active Comparator|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
11174580|NCT03558880|Active Comparator|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
11174581|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
11174582|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
11174583|NCT03558854|Active Comparator|ASA group|Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
11174584|NCT03558854|Placebo Comparator|Placebo oral capsule group|Identical pill containing placebo, taken once daily for 04 weeks
11174585|NCT03558841|Experimental|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
11174586|NCT03558841|Active Comparator|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
11175257|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
11174587|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
11174588|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).
~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
11174589|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
11174590|NCT03558815||Adults with mild, moderate, severe or profound ID|Adults with mild, moderate, severe or profound ID in contact with either a sheltered workshop and/ or sheltered living Institution in Saxony.
11174591|NCT03558789||MT|patients complaining about metallic taste before, during or after treatment of head and neck cancer.
11174592|NCT03558789||No-MT|patients not complaining about metallic taste before, during or after treatment of head and neck cancer.
11174593|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
11174594|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
11174595|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
11174596|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
11174597|NCT03558763|Active Comparator|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
11174598|NCT03558763|Active Comparator|Telemonitoring|"Twice a week subject will perform additional vital functions:
~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.
~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And
~Complete two PRO´s (integrated in the application):
~CAT MRC All this is estimated to take approximately 20-30 min each time.
~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.
~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
11174599|NCT03558750|Experimental|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
11174600|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
11174601|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
11174602|NCT03558724|Experimental|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.
~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.
~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
11174603|NCT03558724|Experimental|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.
~IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.
~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
11174604|NCT03558724|Experimental|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.
~IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.
~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
11174605|NCT03558711|Experimental|study group|
11174606|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
11174607|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
11174608|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
11174609|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
11174704|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
11175812|NCT03550339|Active Comparator|SURG|subjects attending bariatric surgery
11174611|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm
~One night of good ventilation with high levels of CO2 (3000 ppm)
~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
11174612|NCT03558685|Experimental|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
11174613|NCT03558659|Experimental|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
11174614|NCT03558659|No Intervention|Standard Care|No positional therapy belt provided for use during sleep.
11174615|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand -> one hand with an endoscopic bite block -> held by two hands
11174616|NCT03558620|Experimental|Group 12O|A fitting mask is held by one hand -> held by two hands-> one hand with an endoscopic bite block
11174617|NCT03558620|Experimental|Group O12|A fitting mask is held by one hand with an endoscopic bite block->by one hand -> by two hands
11174618|NCT03558620|Experimental|Group O21|A fitting mask is held by one hand with an endoscopic bite block -> by two hands-> one hand
11174619|NCT03558620|Experimental|Group 21O|A fitting mask is held by two hands -> one hand -> one hand with an endoscopic bite block
11174620|NCT03558620|Experimental|Group 2O1|A fitting mask is held by two hands ->one hand with an endoscopic bite block-> by one hand
11174621|NCT03558607|Experimental|Experimental arm|
11174622|NCT03558594|Experimental|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
11174623|NCT03558594|Experimental|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
11174624|NCT03558594|No Intervention|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
11174625|NCT03558581|No Intervention|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
11174626|NCT03558581|Experimental|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
11174627|NCT03558568|Active Comparator|DBS off|
11174628|NCT03558568|Active Comparator|DBS on 60 Hz.|
11174629|NCT03558568|Active Comparator|DBS on 99 Hz.|
11174630|NCT03558568|Active Comparator|DBS on 130 Hz.|
11174631|NCT03558568|Active Comparator|DBS on 230 Hz.|
11174632|NCT03558555|Active Comparator|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
11174633|NCT03558555|Active Comparator|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
11174634|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
11174635|NCT03558516|Experimental|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
11174636|NCT03558516|Placebo Comparator|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
11174637|NCT03558503|Experimental|UGN-102|75 mg Mitomycin C (MMC) in 56 mL admixture (1.33 mg MMC per 1 mL of admixture).
11174638|NCT03558490|Experimental|ZEMY software|
11174639|NCT03558477|Experimental|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 & Nexium
11174640|NCT03558477|Experimental|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 & Nexium
11174641|NCT03558477|Experimental|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 & Nexium
11174642|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package
~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
11174643|NCT03558464|Active Comparator|Control|(agriculture-focused package)
11174644|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
11174645|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
11174646|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
11174647|NCT03558425|Experimental|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
11174648|NCT03558425|Experimental|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
11191701|NCT03441893|Active Comparator|UC patients (cohort 3)|
11174649|NCT03558412|Experimental|Arm A|Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.
11174650|NCT03558399|Experimental|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
11174651|NCT03558399|Active Comparator|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
11174652|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:
~6 months to 1 year ago
~1 year to 3 years ago
~3 years ago or more"
11174653|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:
~6 months to 1 year ago
~1 year to 3 years ago
~3 years ago or more"
11174654|NCT03558360||Bariatric surger|Bariatric surgery and impedance measurement
11174655|NCT03558347|Experimental|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
11174656|NCT03558347|Experimental|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
11174657|NCT03558334|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
11174658|NCT03558334|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
11174659|NCT03558321|Experimental|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
11174660|NCT03558308|Experimental|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
11174661|NCT03558308|Experimental|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
11174662|NCT03558308|Experimental|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
11174663|NCT03558308|Sham Comparator|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
11174664|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
11174665|NCT03558269|Experimental|Study group|This group will receive UCB after the first palliative surgery
11174666|NCT03558269|No Intervention|Control group|This group will not receive any treatment
11174667|NCT03558256|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
11174668|NCT03558256|Active Comparator|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
11174669|NCT03558243|Active Comparator|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
11174670|NCT03558243|Experimental|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
11174671|NCT03558243|Experimental|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
11174672|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
11192409|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
11174673|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.
~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
11174674|NCT03558217|Experimental|Collared Femoral Implant|Participants will have the Corail collared femoral implant used during their surgery.
11174675|NCT03558217|Active Comparator|Collarless Femoral Implant|Participants will have the Corail collarless femoral implant used during their surgery.
11174676|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
11174677|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
11174678|NCT03558191|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
11174679|NCT03558178|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
11174680|NCT03558178|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
11174681|NCT03558165||Stage IV Lung Adenocarcinoma|
11174682|NCT03558152|Experimental|Arm 1a: UTTR1147A Dose Level 1 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.
~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
11174683|NCT03558152|Experimental|Arm 1b: UTTR1147A Dose Level 1 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.
~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
11174684|NCT03558152|Experimental|Arm 2a: UTTR1147A Dose Level 2 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.
~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
11174685|NCT03558152|Experimental|Arm 2b: UTTR1147A Dose Level 2 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.
~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
11174686|NCT03558152|Experimental|Arm 3a: UTTR1147A Dose Level 3 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.
~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
11174687|NCT03558152|Experimental|Arm 3b: UTTR1147A Dose Level 3 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.
~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
11174688|NCT03558152|Active Comparator|Arm 4: Vedolizumab|Parts A and B: Vedolizumab and UTTR1147A Placebo.
11174689|NCT03558152|Placebo Comparator|Arm 5: Placebo|Parts A and B: UTTR1147A Placebo and Vedolizumab Placebo.
11174690|NCT03558139|Experimental|Magrolimab + Avelumab (Part 1, Safety Run-in)|"Dose Level 1: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 30 mg/kg weekly for 4 doses (Cycle 1). Starting in Cycle 2, magrolimab 30 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.
~Based on Dose Limiting Toxicities (DLTs) assessment in Dose Level 1 Cycle 1; additional participants will be enrolled and administered Dose Level 2.
~Dose Level 2: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 45 mg/kg on Days 8,11,15, 22 and 29 for Cycle 1, continuing weekly in Cycle 2 on Days 1, 8, 15 and 22. Starting in Cycle 3, magrolimab 45 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.
~Additional lower or higher dose levels may be explored after reviewing all available clinical data."
11174691|NCT03558139|Experimental|Magrolimab + Avelumab (Part 2, Ovarian Cancer Expansion)|After Part 1 Safety Run-in has completed and the recommended expansion dose(s) for magrolimab is determined, participants with ovarian cancer will be administered the recommended magrolimab dose(s) combined with avelumab 800 mg given once every 2 weeks.
11174692|NCT03558113|Other|visual tactile method|visual tactile method using the modified USHPS critiria
11174693|NCT03558100|Experimental|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
11174694|NCT03558087|Experimental|Gemcitabine, Cisplatin and Nivolumab|Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with > cTa status will undergo cystectomy.
11174695|NCT03558074|Experimental|Active|ALK4290 800 mg daily (400 mg tablet twice a day)
11174696|NCT03558061|Experimental|Active|ALK4290 800 mg daily (400 mg tablet twice a day)
11174697|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
11174698|NCT03558035|Experimental|Induction chemotherapy and concurret chemoradiotherapy group|Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
11174699|NCT03558035|Active Comparator|Concurrent chemoradiotherapy group|Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy
11174700|NCT03558022|Experimental|Salt Pills|One week on low salt diet plus salt pills
11174701|NCT03558022|Placebo Comparator|Placebo Pills|One week on low salt diet plus placebo pills
11174702|NCT03558009||Participants with abdominal pain attacks|Participants experiencing recurrent abdominal pain attacks without a clear etiolgy aged between 2-60 years
11174703|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
11192410|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
11174705|NCT03557983|Experimental|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
11174706|NCT03557983|Placebo Comparator|Saline|Saline is topically spread three times per day for one week.
11174707|NCT03557970|Experimental|Treatment (JNJ-40346527)|Participants receive JNJ-40346527 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11174708|NCT03557957|Experimental|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
11174709|NCT03557957|Active Comparator|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
11174710|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:
~Medication reconciliation
~Identification of patient priorities for care
~Identification of medications that are potentially appropriate for discontinuation/dose reduction
~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
~Identification of medications for trial of discontinuation/dose reduction (shared decision making)
~Pause of medication and clinical monitoring"
11174711|NCT03557931|Experimental|ASP4345 50 milligram (mg)|Participants on stable doses of antipsychotic medication received ASP4345 50 mg, capsules, orally, once daily for 12 weeks.
11174712|NCT03557931|Experimental|ASP4345 150 mg|Participants on stable doses of antipsychotic medication received ASP4345 150 mg, capsules, orally, once daily for 12 weeks.
11174713|NCT03557931|Placebo Comparator|Placebo|Participants on stable doses of antipsychotic medication received ASP4345 placebo matching capsules, orally, once daily for 12 weeks.
11174714|NCT03557918|Experimental|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
11174715|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
11174716|NCT03557905|Active Comparator|Group II|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.5.
11174717|NCT03557892|Experimental|CSII+CGM|
11174718|NCT03557892|Active Comparator|MDI with degludec|
11174719|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
11174720|NCT03557866|Experimental|pronated group|individuals with pronated foot
11174721|NCT03557866|Active Comparator|control group|individuals with normal foot posture
11174722|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
11174723|NCT03557840|Experimental|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
11174724|NCT03557827|Sham Comparator|control|Mechanical debridement by periodontal curets alone
11174725|NCT03557827|Active Comparator|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
11174726|NCT03557814|Active Comparator|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
11174727|NCT03557814|Active Comparator|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
11174728|NCT03557814|Sham Comparator|Control|Conventional non-surgical periodontal therapy without LED light irradiation
11174729|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
11174730|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
11174731|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
11174732|NCT03557788|Experimental|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
11174733|NCT03557775|Experimental|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).
~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
11174795|NCT03557411|Experimental|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
11174796|NCT03557398|Experimental|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
11174734|NCT03557775|Experimental|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).
~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
11174735|NCT03557775|Active Comparator|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
11174736|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
11174737|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
11174738|NCT03557749||Immune and Microbial Reconstitution|
11174739|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
11174740|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
11174741|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
11174742|NCT03557749||Immune Response Triggered by Relapse|
11174743|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
11174744|NCT03557749||Allogeneic Related Donor Samples|
11174745|NCT03557749||Cellular Therapy Products|
11174746|NCT03557736|Experimental|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
11174747|NCT03557736|Experimental|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
11174748|NCT03557736|Experimental|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
11174749|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
11174750|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
11174751|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
11174752|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
11174753|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
11174754|NCT03557684|Experimental|PO leucine & IV LPS|Oral (PO) leucine 6 g twice a day for 2 weeks followed by a single intravenous (IV) bolus of lipopolysaccharide (LPS) 0.8 ng/kg of body weight
11174755|NCT03557684|Experimental|PO placebo & IV LPS|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of LPS 0.8 ng/kg of body weight
11174756|NCT03557684|Experimental|PO leucine & IV placebo|PO leucine 6 g twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
11174757|NCT03557684|Placebo Comparator|PO placebo & IV placebo|PO maltodextrin (placebo) twice a day for 2 weeks followed by a single IV bolus of 0.9% saline
11174758|NCT03557671|Experimental|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
11174759|NCT03557671|Placebo Comparator|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
11174760|NCT03557658|Experimental|Hepatic Impaired|
11174761|NCT03557658|Experimental|Healthy Volunteer|
11174762|NCT03557645|Sham Comparator|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
11174763|NCT03557645|Experimental|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
11174797|NCT03557385|Other|aFFR vs cFFR|All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System
11174798|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
11174764|NCT03557645|Experimental|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
11174765|NCT03557632|Experimental|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
11174766|NCT03557632|Active Comparator|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
11174767|NCT03557619|Experimental|Ethinyl estradiol/Levonorgestrel and Venetoclax|Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.
11174768|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
11174769|NCT03557580|Active Comparator|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
11174770|NCT03557580|Experimental|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
11174771|NCT03557580|Experimental|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
11174772|NCT03557567||MO patients|
11174773|NCT03557567||OI patients|
11174774|NCT03557554|Experimental|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
11174775|NCT03557541|Experimental|Sardine group|
11174776|NCT03557541|Active Comparator|Control group|
11174777|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
11174778|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
11174779|NCT03557515|Experimental|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
11174780|NCT03557515|Experimental|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
11174781|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
11174782|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
11174783|NCT03557489|Experimental|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
11174784|NCT03557489|No Intervention|Control group|patients use gel pad(in usual) during surgery.
11174785|NCT03557476|Experimental|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
11174786|NCT03557476|Placebo Comparator|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
11174787|NCT03557463|Active Comparator|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
11174788|NCT03557463|Experimental|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
11174789|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
11174790|NCT03557437|Active Comparator|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
11174791|NCT03557437|Experimental|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
11174792|NCT03557424|Experimental|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
11174793|NCT03557424|Experimental|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
11174794|NCT03557424|Placebo Comparator|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
11175813|NCT03550339|Active Comparator|DIET|subjects attending dietary weight loss program
11174799|NCT03557359|Experimental|Nivolumab|Nivolumab 240 mg will be given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg will be given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab will be administered as a 30-minute infusion. A finite treatment duration with immune therapies in this participant population remains an area of ongoing research; therefore the treatment duration chosen was 2 years.
11174800|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
11174801|NCT03557307|Experimental|Benralizumab|Benralizumab subcutaneous injection
11174802|NCT03557294|Experimental|1.0mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.
11174803|NCT03557294|Experimental|0.5mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study
11174804|NCT03557294|Placebo Comparator|0.0mg placebo varenicline b.i.d.|Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.
11174805|NCT03557281|Experimental|Subjects receiving GSK3036656|Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
11174806|NCT03557281|Active Comparator|Subjects receiving RIFAFOUR e-275|Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
11174807|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
11174808|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
11174809|NCT03557255|Active Comparator|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of > 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP < 80 mmHg) or tachycardia (heart rate > 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
11174810|NCT03557255|Active Comparator|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
11174811|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
11174812|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
11174813|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
11174814|NCT03557229|Experimental|Melatonin|
11174815|NCT03557229|Experimental|Vitamin C|
11174816|NCT03557229|Experimental|Vitamin E|
11174817|NCT03557229|Experimental|N-acetylcysteine|
11174818|NCT03557229|No Intervention|Control|
11174819|NCT03557216|Experimental|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
11174820|NCT03557216|Experimental|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
11174821|NCT03557151|Active Comparator|Usual Care|Usual Care participants will receive the same excellent multidisciplinary care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
11174822|NCT03557151|Experimental|Transdisciplinary Care-In Person & Telehealth|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person or by telehealth at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
11174823|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
11174824|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
11174825|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
11174826|NCT03557112|Experimental|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
11174827|NCT03557112|Active Comparator|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
11192411|NCT03437122|Experimental|All|
11174828|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
11174829|NCT03557086|Experimental|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
11174830|NCT03557086|Active Comparator|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
11174831|NCT03557073|Experimental|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
11174832|NCT03557073|No Intervention|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
11174833|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
11174834|NCT03557034|No Intervention|Standard of Care Monitoring|
11174835|NCT03557034|Experimental|Kardia Monitoring|
11174836|NCT03557021|Experimental|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
11174837|NCT03557021|Active Comparator|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
11174838|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
11174839|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
11174840|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
11174841|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
11174842|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
11174843|NCT03556956|Experimental|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).
~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
11174844|NCT03556956|No Intervention|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
11174845|NCT03556943|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11174846|NCT03556943|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11174847|NCT03556930|Experimental|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
11174848|NCT03556917|Active Comparator|group 1|topical gel base + caffeine.
11174849|NCT03556917|Active Comparator|group 2|iontophoresis + caffeine
11174850|NCT03556917|Active Comparator|Group 3|iontophoresis
11174851|NCT03556904|Active Comparator|Standard of Care|The choice of agent will be up to the treating medical oncologist and is not the study intervention. Current first line systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although docetaxel is allowed. Patients should begin systemic treatment within 3 weeks of randomization.
11174852|NCT03556904|Experimental|Standard of Care + Radiotherapy|"Standard of care therapy will be up to the treating medical oncologist and is not the study intervention. Current systemic therapy is most commonly a second generation androgen pathway inhibitor, including enzalutamide or abiraterone, although docetaxel is allowed.
~Radiotherapy will be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions. Patients should start systemic therapy within 3 weeks of randomization (unless radiation is begun within 3 weeks and the provider may hold systemic therapy until completion of radiation) and receive radiotherapy within 8 weeks of randomization."
11174853|NCT03556891|Experimental|eCoin Tibial Nerve Stimulation|
11174854|NCT03556878|Experimental|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
11174855|NCT03556852|Active Comparator|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
11174856|NCT03556852|Active Comparator|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
11174857|NCT03556839|Active Comparator|Arm A|Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
11174858|NCT03556839|Experimental|Arm B|cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
11175814|NCT03550339|Active Comparator|HAES|subjects attending Health At Every Size weight management program
11174859|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
11174860|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
11174861|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
11174862|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
11174863|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
11174864|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
11174865|NCT03556800|Active Comparator|1.25 EstroGel|
11174866|NCT03556787|Experimental|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
11174867|NCT03556774|Experimental|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
11174868|NCT03556774|No Intervention|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
11174869|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
11174870|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
11174871|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),
~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
11174872|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)
~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
11174873|NCT03556735|Other|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
11174874|NCT03556722|Active Comparator|repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
11174875|NCT03556722|Sham Comparator|Sham repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
11174876|NCT03556709|Experimental|Treadmill Ankle Robot Training|
11174877|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
11174878|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
11174879|NCT03556683|Experimental|7% Hypertonic Saline|Subjects will inhale 4 mL of 7% hypertonic saline before having a Mucociliary Clearance (MCC) scan
11174880|NCT03556670|Experimental|Total Worker Health Intervention|
11174881|NCT03556670|Active Comparator|Control|
11174882|NCT03556657|Experimental|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
11174883|NCT03556657|No Intervention|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
11174884|NCT03556644|Other|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
11174885|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
11174886|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
11174887|NCT03556618|Experimental|Whole Person Care (WPC) Reentry Program|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24)."
11174921|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
11175969|NCT03549156|Active Comparator|HIPRO RUSF|New RUSF product
11174888|NCT03556618|No Intervention|Control|Participants in the control arm will receive usual care reentry healthcare planning, including correctional health provider and court-referred SUD and mental health treatment recommendations, medication prescriptions, written instructions for reinstating Medicaid, and written health discharge summaries. Participants in this branch will include youth exiting the adult justice system (ages 18-24) and youth exiting the juvenile justice system (ages 16-18).
11174889|NCT03556605|Other|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
11174890|NCT03556605|Other|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
11174891|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:
~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.
~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.
~CYP substrates - non-investigational medicinal products:
~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
11174892|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
11174893|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
11174894|NCT03556566|Experimental|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
11174895|NCT03556553|Experimental|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
11174896|NCT03556553|Experimental|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
11174897|NCT03556540|Placebo Comparator|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
11174898|NCT03556540|Experimental|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
11174899|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
11174900|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=90)
11174901|NCT03556475||Disease type 2-1)|Patients with Mild/moderate AECOPD (n=60)
11174902|NCT03556475||Disease type 2-2)|Patients with Severe AECOPD( n=60)
11174903|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=90)
11174904|NCT03556462|Experimental|Sleep Health Interventions|"Sleep Health Interventions:
~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.
~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
11174905|NCT03556462|No Intervention|Control Period|No Intervention, but data collection
11174906|NCT03556449||Patients|High resolution ultrasound
11174907|NCT03556449||Healthy subjects|High resolution ultrasound
11174908|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
11174909|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
11174910|NCT03556410|Placebo Comparator|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
11174911|NCT03556410|Experimental|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
11174912|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
11174913|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
11174914|NCT03556397|Experimental|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
11174915|NCT03556397|Experimental|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
11174916|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.
~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.
~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
11174917|NCT03556371|Experimental|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
11174918|NCT03556371|Placebo Comparator|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
11174919|NCT03556358|Experimental|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles
~Followed by:
~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
11174920|NCT03556358|Active Comparator|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles
~Followed by:
~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
11175055|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
11174922|NCT03556332|Experimental|Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab & HCT|After receiving four 28-day cycles of Dara-CRd, eligible patients will then undergo HCT with high dose melphalan conditioning. Sixty to ninety days after HCT, patients will receive another 4 cycles of Dara-CRd.
11174923|NCT03556319|Placebo Comparator|Placebo|Placebo
11174924|NCT03556319|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
11174925|NCT03556319|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
11174926|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
11174927|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
11174928|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
11174929|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
11174930|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
11174931|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
11174932|NCT03556267|Other|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
11174933|NCT03556267|Other|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
11174934|NCT03556254|Experimental|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
11174935|NCT03556254|Active Comparator|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
11174936|NCT03556241|Experimental|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
11174937|NCT03556241|No Intervention|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
11174938|NCT03556228|Experimental|VMD-928 300 mg Tablet or 100 mg Capsule|
11174939|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
11174940|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
11174941|NCT03556215|Experimental|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
11174942|NCT03556202|Experimental|Mirikizumab Dose 1|Mirikizumab administered subcutaneously (SC).
11174943|NCT03556202|Experimental|Mirikizumab Dose 2|Mirikizumab administered SC.
11174944|NCT03556189|Experimental|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
11174945|NCT03556189|No Intervention|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
11174946|NCT03556176|Active Comparator|5-HTTLPR or BDNF polymorphisms|
11174947|NCT03556176|Active Comparator|Control ( without 5-HTTLPR or BDNF polymorphisms )|
11174948|NCT03556163|Experimental|Test Group|Modified vertical internal mattress sutures + MWF surgery.
11174949|NCT03556163|Active Comparator|Control Group|Simple loop interrupted sutures + MWF surgery.
11174950|NCT03556150|Experimental|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
11174951|NCT03556150|Active Comparator|Effleurage|Superficial massage in the most painful joint.
11174952|NCT03556137|Experimental|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
11174953|NCT03556137|Experimental|Healthy Volunteers|Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
11174954|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
11174955|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
11175987|NCT03549000|Experimental|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
11174956|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
11174957|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
11174958|NCT03556111|Experimental|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.
~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
11174959|NCT03556111|Experimental|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.
~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.
~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.
~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
11174960|NCT03556098|Active Comparator|GIP|Infusion of Glucose-dependent insulinotropic peptide
11174961|NCT03556098|Active Comparator|GIP[3-30]|Infusion of GIP[3-30]
11174962|NCT03556098|Placebo Comparator|Saline|Infusion of saline
11174963|NCT03556085|Experimental|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
11174964|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
11174965|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
11174966|NCT03556059|Active Comparator|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
11174967|NCT03556059|Active Comparator|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
11174968|NCT03556059|Active Comparator|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
11174969|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
11174970|NCT03556033|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
11174971|NCT03556033|Placebo Comparator|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
11174972|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
11174973|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
11174974|NCT03556007|Experimental|LY3471851|SLE participants in each cohort will receive multiple subcutaneous doses of LY3471851.
11174975|NCT03556007|Placebo Comparator|Placebo|SLE participants in each cohort will receive the placebo comparator.
11174976|NCT03555994|Experimental|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
11174977|NCT03555994|Placebo Comparator|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
11174978|NCT03555994|Active Comparator|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
11174979|NCT03555994|Experimental|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
11174980|NCT03555994|Placebo Comparator|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
11174981|NCT03555981|Experimental|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
11174982|NCT03555981|Active Comparator|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at >24h of hospital admission until hospital discharge with encouragement of KMC at home
11174983|NCT03555968|Placebo Comparator|THC 0 + BAC 0|Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%.
11174984|NCT03555968|Experimental|THC 5 + BAC 0|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%.
11174985|NCT03555968|Experimental|THC 10 + BAC 0|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%.
11174986|NCT03555968|Experimental|THC 5 + BAC .025|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%.
11174987|NCT03555968|Experimental|THC 10 + BAC .025|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%.
11174988|NCT03555968|Experimental|THC 0 + BAC .049|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%.
11174989|NCT03555968|Experimental|THC 5 + BAC .049|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%.
11174990|NCT03555968|Experimental|THC 10 + BAC .049|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%.
11174991|NCT03555968|Experimental|THC 0 + BAC .025|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%.
11174992|NCT03555955|Experimental|Cohort 1|Normal renal function
11174993|NCT03555955|Experimental|Cohort 2|Moderate renal impairment
11174994|NCT03555955|Experimental|Cohort 3|Severe renal impairment
11174995|NCT03555942|Active Comparator|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
11176172|NCT03547921||non operative|non operative
11174996|NCT03555942|Experimental|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
11174997|NCT03555929|Experimental|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
11174998|NCT03555929|Placebo Comparator|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
11174999|NCT03555916|Experimental|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
11175000|NCT03555916|Placebo Comparator|Placebo|2 mL of saline solution (0.9% NaCl) treatment
11175001|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
11175002|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
11175003|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
11175004|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
11175005|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
11175006|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant, tamoxifen.
11175007|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant, tamoxifen.
11175008|NCT03555864||Obese|Patients need two intravenous access with infra red
11175009|NCT03555851||Recipient|Cyclophosphamide
11175010|NCT03555851||Donor|Specimen collection
11175011|NCT03555838|Experimental|Active tDCS|Participants in this arm will receive 20 minutes of 2 mA transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
11175012|NCT03555838|Sham Comparator|Sham tDCS|Participants in this arm will receive 20 minutes of sham transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
11175013|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
11175014|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
11175015|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
11175016|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
11175017|NCT03555812|Experimental|Healthy volunteers|"a medical examination
~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
11175018|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:
~a medical examination
~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
11175019|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
11175020|NCT03555773|Experimental|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
11175021|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
11175022|NCT03555747|Other|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
11175023|NCT03555747|Other|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
11175024|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
11175025|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
11175056|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
11175026|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
11175027|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
11175028|NCT03555695|Experimental|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
11175029|NCT03555682|Placebo Comparator|Placebo|Placebo
11175030|NCT03555682|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
11175031|NCT03555682|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
11175032|NCT03555669|No Intervention|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
11175033|NCT03555669|Experimental|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
11175034|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
11175035|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
11175036|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
11175037|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
11175038|NCT03555630||Post-cesarean preeclampsia|
11175039|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
11175040|NCT03555617|Experimental|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
11175041|NCT03555617|Experimental|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
11175042|NCT03555617|Experimental|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
11175043|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
11175044|NCT03555591||Trelagliptin 100 mg|Trelagliptin 100 mg tablet, orally, once weekly for up to 36 months. Participants received interventions as part of routine medical care.
11175045|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
11175046|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
11175047|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
11175048|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
11175049|NCT03555539|Experimental|Part 1: Healthy Match|Single 200 mg dose of ACH-0144471 on Day 1 in healthy participants (matched control group with normal hepatic function)
11175050|NCT03555539|Experimental|Part 1: Moderate HI|Single 200 mg dose of ACH-0144471 on Day 1 in participants with moderate HI
11175051|NCT03555539|Experimental|Part 2: Severe HI|Single 200 mg dose of ACH-0144471 on Day 1 in participants with severe HI
11175052|NCT03555539|Experimental|Part 2: Mild HI|Single 200 mg dose of ACH-0144471 on Day 1 in participants with mild HI
11175053|NCT03555526|Experimental|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
11175054|NCT03555526|Active Comparator|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
11192412|NCT03437096|Other|venipuncture pain|pain during venipuncture
11175059|NCT03555474|Experimental|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.
~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
11175060|NCT03555474|Experimental|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 [Grasp/Flexion/Extension, PATT (pattern movement)] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10~50 mA.
~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
11175061|NCT03555474|Active Comparator|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.
~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
11175062|NCT03555448|Active Comparator|Once daily regimen|Once daily medication regimen (Envarsus and azathioprine)
11175063|NCT03555448|Active Comparator|Twice daily regimen|Twice daily medication regimen (Tacrolimus and mycophenolic acid)
11175064|NCT03555435|Experimental|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
11175065|NCT03555435|Experimental|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
11175066|NCT03555435|Placebo Comparator|Wait|Participants in this group will wait 6 weeks.
11175067|NCT03555422|Experimental|Selinexor|Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index [BMI] less than [<] 20 kilogram per meter square [kg/m^2]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
11175068|NCT03555422|Placebo Comparator|Matching placebo for selinexor|Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
11175069|NCT03555396|Experimental|Intervention|Subjects will receive an intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
11175070|NCT03555396|Active Comparator|Standard of Care|Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
11175071|NCT03555370|Experimental|Standard of Care Group|"Standard of Care:
~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
11175072|NCT03555370|Experimental|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
11175073|NCT03555357|Active Comparator|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
11175074|NCT03555357|Experimental|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
11175075|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
11175076|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
11175077|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
11175078|NCT03555318|Experimental|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
11175079|NCT03555318|Active Comparator|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
11175080|NCT03555305|Experimental|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
11175081|NCT03555305|Active Comparator|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
11175082|NCT03555292|Experimental|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
11175083|NCT03555292|Experimental|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
11175084|NCT03555292|Experimental|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
11176173|NCT03547908|Experimental|B/F/TAF|B/F/TAF + placebo to match DTG + placebo to match F/TDF
11175085|NCT03555292|Experimental|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
11175086|NCT03555292|Experimental|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
11175087|NCT03555279|Experimental|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
11175088|NCT03555279|Experimental|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
11175089|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
11175090|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
11175091|NCT03555253|Experimental|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
11175092|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
11175093|NCT03555227|Active Comparator|Group X|"PECS group
~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
11175094|NCT03555227|Active Comparator|Group Y|"LA (local anaesthetic) infiltration group
~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
11175095|NCT03555214|Experimental|Manual Therapy based on soft tissue|
11175096|NCT03555214|Placebo Comparator|Control Group|
11175097|NCT03555214|Experimental|Manual Therapy based on structural techniques|
11175098|NCT03555214|Experimental|Manual Therapy based on soft tissue and structural techniques|
11175099|NCT03555201|Experimental|Manual therapy|Protocol of soft tissue techniques
11175100|NCT03555201|Active Comparator|Regular treatment control.|Regular treatment control.
11175101|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
11175102|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
11175103|NCT03555175|Other|Group one|This participants group must do eccentric exercise for 12 weeks
11175104|NCT03555175|Other|Group two|This participants group must do proprioception exercise for 12 weeks
11175105|NCT03555175|Other|Group 3|This participants group mustn't do exercise extra
11175106|NCT03555162|Other|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
11175107|NCT03555162|Other|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
11175108|NCT03555149|Active Comparator|Regorafenib (Control)|Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
11175109|NCT03555149|Experimental|Atezolizumab + Imprime PGG + Bevacizumab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
11175110|NCT03555149|Experimental|Atezolizumab + Isatuximab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
11175111|NCT03555149|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
11175112|NCT03555149|Experimental|Atezolizumab + Idasanutlin|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
11175113|NCT03555149|Experimental|Atezolizumab + Regorafenib|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
11175114|NCT03555149|Experimental|Atezolizumab + Regorafenib + AB928|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
11175115|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
11175116|NCT03555123|Experimental|SIMDAX|Levosimendan2.5mg/mL
11175117|NCT03555123|Placebo Comparator|SIMDAX Placebo|Water for injection
11175118|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
11175119|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:
~Three evaluation and preparation sessions,
~Eight EMDR sessions weekly with variable length of 60 minutes and
~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
11175120|NCT03555097|Experimental|COPD Group|incremental pressure support
11175121|NCT03555084|Experimental|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
11175122|NCT03555084|Active Comparator|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
11175123|NCT03555071|Experimental|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.
~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
11175124|NCT03555071|Experimental|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.
~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
11175125|NCT03555071|Experimental|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.
~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
11175126|NCT03555071|Active Comparator|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.
~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
11175127|NCT03555058|Other|High risk- TDM|Treatment escalation per TDM and physician's decision.
11175128|NCT03555058|No Intervention|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
11175129|NCT03555058|No Intervention|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
11175130|NCT03555045|Active Comparator|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
11175131|NCT03555045|Active Comparator|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
11175132|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
11175133|NCT03555019|Experimental|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
11175134|NCT03555019|Active Comparator|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
11175135|NCT03555006|Other|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
11175136|NCT03555006|Other|Local vs local group|The examination will be interpreted by two department's radiologists
11175137|NCT03554993|Experimental|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
11175138|NCT03554993|Experimental|Placebo|Placebo under fasted conditions
11175139|NCT03554993|Experimental|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
11175140|NCT03554980|Experimental|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.
~SDF is a brush-on liquid."
11175141|NCT03554980|Active Comparator|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
11175142|NCT03554941|Experimental|noise stimulation|noise stimulation
11175143|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
11175144|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
11175145|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
11175146|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
11175147|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
11175148|NCT03554889|Experimental|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
11175149|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
11175150|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
11175151|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
11175152|NCT03554863|Active Comparator|Facial mask|
11175153|NCT03554863|Experimental|Optiflow anesthesia|
11175154|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
11175157|NCT03554811|Experimental|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
11175158|NCT03554811|Active Comparator|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
11175159|NCT03554798|Experimental|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.
~6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
11175160|NCT03554798|Experimental|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.
~Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
11175161|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)
~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)
~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
11175162|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)
~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)
~CHC staff leadership key informant interviews (up to 5 at each site)
~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
11175163|NCT03554772|Experimental|DFN-15 Active Dose A|Single dose
11175164|NCT03554772|Experimental|DFN-15 Active Dose B|Single dose
11175165|NCT03554772|Experimental|DFN-15 Active Dose C|Single dose
11175166|NCT03554772|Placebo Comparator|Placebo|Single dose
11175167|NCT03554746|Experimental|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
11175168|NCT03554746|Experimental|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
11175169|NCT03554733|Experimental|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
11175170|NCT03554733|No Intervention|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
11175171|NCT03554720|Active Comparator|Standard implants|ATTUNE PS Knee
11175172|NCT03554720|Active Comparator|Enhanced-Fixation|ATTUNE S+ PS Knee
11175173|NCT03554707|Experimental|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.
~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
11175174|NCT03554694|Experimental|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
11175175|NCT03554694|Experimental|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
11175176|NCT03554668||1|Post total knee replacement patients
11175177|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
11175178|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
11175179|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
11175180|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
11175181|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
11175182|NCT03554629|Other|Capnography CO2 Sampling Filterline|Change capnography CO2 sampling Filterline by code name for scripted activities
11175183|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
11175184|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
11175185|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
11175186|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
11175187|NCT03554603|Experimental|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
11175188|NCT03554603|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
11175189|NCT03554590|Experimental|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
11175190|NCT03554590|Active Comparator|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
11175191|NCT03554577|Active Comparator|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
11175192|NCT03554577|Experimental|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
11175193|NCT03554577|Experimental|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
11175194|NCT03554577|Experimental|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
11175195|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
11175196|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
11175197|NCT03554551||Patients with Parkinsons disease|Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
11175198|NCT03554551||Healthy controls|50-85 years
11175199|NCT03554538|Experimental|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
11175200|NCT03554538|Active Comparator|Exercises|An evidence based exercise program for the shoulder pain.
11175201|NCT03554525|Experimental|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
11175202|NCT03554525|Placebo Comparator|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
11175203|NCT03554512|No Intervention|Standard of Care|No Intervention
11175204|NCT03554512|Experimental|Telehealth|Telehealth virtual appointment
11175205|NCT03554499|Experimental|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
11175206|NCT03554499|Active Comparator|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
11175207|NCT03554486|Experimental|Group 1|Group 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
11175208|NCT03554486|Experimental|Group 2|Group 2 will use Novolog insulin for 2 weeks, followed by Fiasp for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
11175209|NCT03554473|Experimental|Arm A/M7824 Monotherapy|M7824 (IV) monotherapy once every 21 days on a 21-day cycle. If patients have progressive disease on arm A, they may receive combination therapy of M7824 and Temozolomide.
11175210|NCT03554473|Experimental|Arm B/M7824 plus topotecan|M7824 (IV) on day 1 plus topotecan (IV) on days 1-5 of a 21- day cycle. At least 6 subjects to receive M7824 plus topotecan to determine safety. 4 more patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 subjects enrolled.
11175211|NCT03554473|Experimental|Arm C/M7824 plus temozolomide safety|M7824 (IV) days 1 and 15 plus temozolomide (oral) on days 1-5 of a 28- day cycle. At least 6 subjects with SCLC to receive M7824 plus temozolomide to determine safety. 4 more SCLC patients enrolled at initial or lower dose for efficacy. If efficacious, an additional 12 SCLC subjects enrolled. After the 6 safety SCLC cohort, subjects with extrapulmonary small cell cancers will be enrolled.
11175212|NCT03554460|Experimental|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
11175213|NCT03554447|Experimental|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
11175214|NCT03554447|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
11175215|NCT03554421|Experimental|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
11175216|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
11175217|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
11175218|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
11175219|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
11175220|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
11175221|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
11175222|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
11175439|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
11175223|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
11175224|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
11175225|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
11175226|NCT03554408|Experimental|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
11175227|NCT03554408|Experimental|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
11175228|NCT03554408|Experimental|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
11175229|NCT03554408|Experimental|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
11175230|NCT03554395|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11175231|NCT03554395|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11175232|NCT03554395|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11175233|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
11175234|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
11175235|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
11175236|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)
11175237|NCT03554330|Active Comparator|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
11175238|NCT03554330|Experimental|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
11175239|NCT03554330|Experimental|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
11175240|NCT03554317|Experimental|Bipolar Androgen Therapy + Nivolumab|All participants must have a rising PSA and/or radiographic progression and prior treatment with at least one novel androgen receptor (AR) targeted therapy (i.e. abiraterone acetate, enzalutamide). Up to one taxane agent for metastatic castration-resistant prostate cancer is permitted. Patients will be treated with testosterone cypionate 400mg IM every 4 weeks for a lead-in period of 12 weeks. After the lead-in period, all patients will be treated with nivolumab 480mg IV every 4 weeks and maintained on testosterone cypionate 400mg IM every 4 weeks. Treatment [with a minimum drug exposure of 12 weeks] will be continued until PSA progression (PCGW3 criteria) or clinical/radiographic progression (whichever comes first), or until unmanageable toxicity requiring drug cessation.
11175241|NCT03554304|Experimental|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
11175242|NCT03554304|Placebo Comparator|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
11175243|NCT03554304|Active Comparator|Moxifloxacin 400-mg|positive control
11175244|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily
~Other names: Pepcid"
11175245|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
11175246|NCT03554278||Anemia|Stool samples from infants with anemia. Severe anemia defined as hematocrit less than 25%. Anemia defined as hematocrit greater than or equal to 25% and less than 30%.
11175247|NCT03554278||No Anemia|Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
11175248|NCT03554265|Experimental|mTBI subjects|"mTBI subjects will receive recombinant human growth hormone replacement therapy daily for 6 months.
~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin
~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 6 will be dosed at 0.6 mg / day"
11175249|NCT03554265|No Intervention|Household Control Subjects|household control subjects will not receive any intervention.
11175250|NCT03554252|Experimental|Frequencies|
11175251|NCT03554252|Experimental|Percentages|
11175252|NCT03554239|Other|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
11175253|NCT03554226|Experimental|AD Patients with NeuroPsychiatric Inventory Clinician (NPI-C)|The investigation aims to study the natural evolution of type A / A SPCDs in patients with AD. In this study, patients will receive optimized management based on existing best practice recommendations (HAS Recommendations 2009). It will therefore be a standard care study, since this survey applies the current recommendations on tools for the evaluation of SPCDs and the management of behavioral disorders in Alzheimer's disease (Recommendations HAS 2009).
11175254|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
11175255|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
11175256|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
11175258|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)
~Interventions :
~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
11175259|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)
~Intervention(s) :
~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
11175260|NCT03554174|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
11175261|NCT03554174|Experimental|Placebo/Medium Dose Psilocybin|Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
11175262|NCT03554174|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
11175263|NCT03554174|Experimental|Medium Dose Psilocybin/Placebo|Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
11175264|NCT03554161|Experimental|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
11175265|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
11175266|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
11175267|NCT03554122|Active Comparator|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
11175268|NCT03554122|Placebo Comparator|Placebo Group|Patients spinal injections were performed without Shotblocker
11175269|NCT03554109|Experimental|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine
~A combination of agents will be administered to subjects in this study:
~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
11175270|NCT03554109|Active Comparator|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
11175271|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
11175272|NCT03554083|Experimental|Arm A (vemurafenib, cobimetinib, atezolizumab)|"Participants receive vemurafenib PO BID on days 1-28, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15 of courses 2 and 3. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~Within 2-4 weeks after treatment, participants undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
11175273|NCT03554083|Experimental|Arm B (cobimetinib, atezolizumab)|Participants receive cobimetinib as in Arm A, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, participants undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11175274|NCT03554070|Experimental|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS > 20, Qmax < 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
11175275|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
11175276|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
11175277|NCT03554044|Experimental|Cohort I (talimogene laherparepvec, chemotherapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with one of the following chemotherapies: paclitaxel (IV), nab-paclitaxel IV, or gemcitabine / carboplatin IV.
~Cycles repeat every 21 days until disease progression or unacceptable toxicity"
11175278|NCT03554044|Experimental|Cohort II (talimogene laherparepvec, endocrine therapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-21 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.
~Cycles repeat every 28 days until disease progression or unacceptable toxicity"
11175279|NCT03554031|Experimental|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
11175280|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
11175281|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
11175282|NCT03554005|Experimental|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
11175531|NCT03552302||Cases|Yoga exercise for 12 weeks
11176174|NCT03547908|Experimental|DTG+F/TDF|DTG + F/TDF + placebo to match B/F/TAF
11175283|NCT03554005|Experimental|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
11175284|NCT03554005|Experimental|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
11175285|NCT03554005|Experimental|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
11175286|NCT03554005|Experimental|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
11175287|NCT03554005|Experimental|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
11175288|NCT03553992|Experimental|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
11175289|NCT03553992|Experimental|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
11175290|NCT03553979|Experimental|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
11175291|NCT03553979|Experimental|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
11175292|NCT03553979|No Intervention|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
11175293|NCT03553966|Experimental|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).
~Procedure: Tooth Brushing HA"
11175294|NCT03553966|Active Comparator|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).
~Intervention:
~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
11175295|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
11175296|NCT03553940|Experimental|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
11175297|NCT03553940|Placebo Comparator|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
11175298|NCT03553927|Other|Low Energy Diet|Commercially available diet products
11175299|NCT03553927|Other|NHS advice on healthy eating|Dietary / lifestyle advice programme
11175300|NCT03553914|Experimental|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m^2 dose.
11175301|NCT03553914|Experimental|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m^2 dose.
11175302|NCT03553914|Experimental|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m^2 dose.
11175303|NCT03553901|Experimental|Acupressure|Acupressure is applied before injection
11175304|NCT03553901|No Intervention|Control group|acupressure is not applied before injection
11175305|NCT03553888||HS patient|patients with HS
11175306|NCT03553888||no HS patients|patients without HS
11175307|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
11175308|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
11175309|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
11175310|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
11192990|NCT03433092||Max Leenders et. al,2014|
11175311|NCT03553849|Experimental|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
11175312|NCT03553849|No Intervention|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
11175313|NCT03553836|Experimental|Pembrolizumab|Pediatric participants receive 2 mg/kg (200 mg maximum) pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Adult participants receive 200 mg pembrolizumab by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of pembrolizumab and experience disease recurrence may be eligible to receive additional cycles of pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for unresectable disease recurrence. Participants with distant metastasis who undergo complete resection will receive 17 cycles (up to ~1 year) of pembrolizumab but can receive up to 35 cycles (up to ~2 years) of pembrolizumab under certain circumstances.
11175314|NCT03553836|Placebo Comparator|Placebo|Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of placebo and experience disease recurrence may be eligible to receive pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for disease that cannot be resected or metastatic disease.
11175315|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
11175316|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
11175317|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
11175318|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
11175319|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
11175320|NCT03553784|No Intervention|Control Group|No intervention.
11175321|NCT03553758|Experimental|Ketamine|15 subjects undergoing ketamine general anesthesia.
11175322|NCT03553745|Experimental|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
11175323|NCT03553745|Experimental|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
11175324|NCT03553745|Experimental|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
11175325|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
11175326|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
11175327|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.
~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
11175328|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
11175329|NCT03553693|Experimental|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
11175330|NCT03553693|No Intervention|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
11175331|NCT03553680|Experimental|Emotion-Focused CBT|Ten CBT sessions with a therapist.
11175332|NCT03553680|No Intervention|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
11175333|NCT03553667|Active Comparator|Standard group|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
11175334|NCT03553667|Experimental|ClearSight|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
11175335|NCT03553654|Experimental|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
11175336|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
11175337|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
11175338|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
11175339|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
11175340|NCT03553615|Experimental|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
11175341|NCT03553602|Experimental|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.
~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.
~6 months hormonal therapy(LHRH agonist and antiandrogen [until the end of radiotherapy])"
11175342|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
11175343|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
11175344|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
11175345|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
11175346|NCT03553563|Experimental|Group1|Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
11175347|NCT03553563|Experimental|Group2|Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
11175348|NCT03553563|Experimental|Group3|D961H 10 mg once-daily (32 or 52 weeks)
11175349|NCT03553563|Experimental|Group4|D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)
11175350|NCT03553537|Experimental|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
11175351|NCT03553537|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
11175352|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.
~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
11175353|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.
~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
11175354|NCT03553511|Experimental|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
11175355|NCT03553511|Active Comparator|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
11175356|NCT03553498|Experimental|IV Acetaminophen|1000 mg IV acetaminophen administered over 5-10 minutes
11175357|NCT03553498|Placebo Comparator|IV hydromorphone and placebo|100 ml IV normal saline administered over 5-10 minutes
11175358|NCT03553485|Experimental|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
11175359|NCT03553485|Sham Comparator|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
11175360|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
11175361|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
11175362|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
11175363|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
11175364|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.
~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
11175365|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
11175366|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
11175367|NCT03553459|Experimental|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
11175368|NCT03553446|Experimental|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
11175369|NCT03553433|Experimental|Verum|Apremilast 30mg bd
11175370|NCT03553433|Placebo Comparator|Placebo Oral Tablet|Excipiens
11175371|NCT03553407|Experimental|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
11175372|NCT03553407|Experimental|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
11175373|NCT03553407|Placebo Comparator|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
11175374|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
11175375|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
11175376|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
11175377|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
11175378|NCT03553368|Experimental|Step 1: Healthy volunteers|"Experimental intervention:
~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).
~Control intervention:
~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
11175408|NCT03553121|Active Comparator|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
11175379|NCT03553368|Experimental|Step 2: Patients (arm A)|"Experimental intervention:
~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).
~Control intervention:
~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
11175380|NCT03553368|Experimental|Step 2: Patients (arm B)|"Experimental intervention:
~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).
~Control intervention:
~Data from the clinically indicated PET/CT acquisition will be used as reference.
~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
11175381|NCT03553368|Experimental|Step 1 bis: Healthy volunteers|"Experimental intervention:
~MRI data will be acquired with the use of CPAP (CPAP-MR).
~Control intervention:
~MRI data will be acquired without the use of CPAP, as a reference (MR)."
11175382|NCT03553355|Experimental|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
11175383|NCT03553355|Sham Comparator|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
11175384|NCT03553355|No Intervention|Waitlist Controls|The patients maintain their usual treatment and self-care,
11175385|NCT03553342|Experimental|Corticoids|
11175386|NCT03553342|Placebo Comparator|Placebo|
11175387|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24
~Wash out Period: over 7 days (between each period)
~Investigators Products(IPs) for Period1: A (Single)= PK101-002
~IPs for Period2: B (Combination)= PK101-001, PK101-002"
11175388|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24
~Wash out Period: over 7 days (between each period)
~IPs for Period1: B (Combination)= PK101-001, PK101-002
~IPs for Period2: A (Single)= PK101-002"
11175389|NCT03553303|Experimental|Intervention|Increasing doses of Sacubitril/Valsartan
11175390|NCT03553290|Sham Comparator|control|Mechanical debridement alone
11175391|NCT03553290|Active Comparator|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy
~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
11175392|NCT03553277|Experimental|Transfluthrin|transfluthrin
11175393|NCT03553277|Placebo Comparator|Placebo|inert ingredients
11175394|NCT03553264|Experimental|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
11175395|NCT03553264|Active Comparator|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
11175396|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
11175397|NCT03553225|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
11175398|NCT03553225|Active Comparator|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
11175399|NCT03553225|Active Comparator|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
11175400|NCT03553212|Experimental|High dose external beam Radiotherapy|Image-guided tomotherapy
11175401|NCT03553199|Experimental|TRS|TRS, Tissue resection system
11175402|NCT03553186|Experimental|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
11175403|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
11175404|NCT03553173|Active Comparator|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.
~Prescribed treatments:
~Bupropion pills + Psychological advice
~Varenicline pills + Psychological advice"
11175405|NCT03553173|Experimental|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.
~Prescribed treatments:
~Bupropion pills + Psychological advice + So-Lo-Mo
~Varenicline pills + Psychological advice + So-Lo-Mo"
11175406|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
11175407|NCT03553147|Experimental|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
11192991|NCT03433092||Yusuke Okuyama et. al,2014|
11175409|NCT03553121|Active Comparator|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
11175410|NCT03553108|Experimental|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
11175411|NCT03553108|Experimental|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
11175412|NCT03553108|Experimental|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
11175413|NCT03553108|Experimental|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.
~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
11175414|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
11175415|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
11175416|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
11175417|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
11175418|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
11175419|NCT03553056|Experimental|Intervention|NZ Step Away app
11175420|NCT03553056|Active Comparator|Control|Modified NZ Step Away app
11175421|NCT03553043|Experimental|Energy Label 1|Alcoholic beverage displayed with Energy label 1
11175422|NCT03553043|Experimental|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
11175423|NCT03553043|Experimental|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
11175424|NCT03553043|Placebo Comparator|Unlabelled|Alcohol beverage displayed unlabelled.
11175425|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
11175426|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
11175427|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
11175428|NCT03553004|Experimental|Niraparib Treatment|"Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)
~(Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL))."
11175429|NCT03552991|Other|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
11175430|NCT03552978|Experimental|Tech-facilitated IC intervention|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.
~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.
~Receive 8 video or telephone counseling sessions for smoking cessation. The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min.
~Be asked to use the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation.
~Be asked to use the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The Covita mobile app (compatible with iOS and Android) is used with the iCO Smokerlyzer to display CO readings."
11175431|NCT03552978|Active Comparator|Treatment as usual (VA Quitline)|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.
~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.
~Receive weekly proactive telephone sessions through the VA telephone Quitline, a proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor."
11175432|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
11175433|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
11175434|NCT03552952||Preterm infants|100 preterm infants
11175435|NCT03552952||Term infants|100 term healthy infants
11175436|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
11175437|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
11175438|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
11175440|NCT03552900|Active Comparator|App 1 Study group (7 Cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7 Cups) which allows participants access to direct online social support via the app."
11175441|NCT03552900|Active Comparator|App 2 Study Group (Bliss)|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app (Bliss) which provides participants an informational app about mental health resources at Harvard."
11175442|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
11175443|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
11175444|NCT03552874||Healthy Group|Healthy peers
11175445|NCT03552861|Active Comparator|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
11175446|NCT03552861|Active Comparator|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
11175447|NCT03552861|Active Comparator|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
11175448|NCT03552861|Sham Comparator|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
11175449|NCT03552848|Experimental|Mesenchymal stem cell|Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
11175450|NCT03552848|No Intervention|Control|Patients in the control arm will not be given MSC.
11175451|NCT03552835|Experimental|no caries removal|mandibular occlusal caries were treated with placement of stainless steel crown with no caries removal
11175452|NCT03552835|Experimental|partial caries removal upto soft dentin|mandibular occlusal caries were treated by partial caries removal upto soft dentin
11175453|NCT03552835|Experimental|partial caries removal upto firm dentin|mandibular occlusal caries were treated by partial caries removal upto firm dentin
11175454|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
11175455|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
11175456|NCT03552809|Active Comparator|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
11175457|NCT03552809|Experimental|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
11175458|NCT03552809|Experimental|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
11175459|NCT03552796|Experimental|sEphB4-HSA|Cohorts of at least 3 participants each will be treated with escalating doses of sEphB4-HAS at 25mg, 50 mg, 75mg, 100 mg, and 125 mg administered intravesically over 2 hours once a week for 6 consecutive weeks to determine the maximum tolerated dose (MTD) and recommended phase II dosing (RP2D). Cycle repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11175460|NCT03552783|Active Comparator|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
11175461|NCT03552783|Experimental|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
11175462|NCT03552770|Active Comparator|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
11175463|NCT03552770|Active Comparator|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
11175464|NCT03552757|Experimental|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
11175465|NCT03552757|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
11175466|NCT03552757|Placebo Comparator|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
11175467|NCT03552744|Experimental|Intervention group|
11175468|NCT03552744|No Intervention|Control group|
11175469|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
11175470|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
11175471|NCT03552718|Experimental|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
11175472|NCT03552705|Experimental|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
11175473|NCT03552705|Placebo Comparator|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
11175474|NCT03552692|Experimental|ARM1 - Venetoclax (ABT-199)|"Venetoclax (ABT-199) will be administered orally at the dose of 800 mg once daily.
~Response evaluation will be performed initially after 3 cycles from the beginning of treatment with ABT-199 and then every 3 cycles during the first 12 cycles, every 4 cycles from cycle 13 to 24; for those patients still on therapy after 24 cycles, the response evaluation, after this time, will be performed every 6 cycles."
11175475|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
11175476|NCT03552666|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
11175477|NCT03552666|Active Comparator|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
11175478|NCT03552653|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
11175479|NCT03552653|Active Comparator|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
11175480|NCT03552627|Active Comparator|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
11175481|NCT03552627|Active Comparator|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
11175482|NCT03552627|Experimental|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
11175483|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
11175484|NCT03552601|Other|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
11175485|NCT03552601|Other|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
11175486|NCT03552575|Experimental|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
11175487|NCT03552575|Experimental|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
11175488|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
11175489|NCT03552562|Other|30 patients with mild diabetic retinopathy|
11175490|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
11175491|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
11175492|NCT03552549|Experimental|PEG-Intron|Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
11175493|NCT03552549|Experimental|INTRON A|Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks post-surgery.
11175494|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
11175495|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
11175496|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
11175497|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
11175591|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
11175498|NCT03552523|Experimental|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
11175499|NCT03552510|Active Comparator|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.
~Then, infants will receive regular gavage feeding only for the next 24 hours."
11175500|NCT03552510|Active Comparator|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.
~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
11175501|NCT03552484|Active Comparator|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.
~[Completion of Home Visit Program]"
11175502|NCT03552484|Active Comparator|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.
~[Completion of Usual Care/Online Survey]"
11175503|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11175504|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
11175505|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
11175506|NCT03552445|Active Comparator|Tetanus-diphtheria (Td) and PCV13|
11175507|NCT03552445|Active Comparator|PCV13 alone|
11175508|NCT03552445|Active Comparator|Td alone|
11175509|NCT03552432|Experimental|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
11175510|NCT03552432|No Intervention|standard statin therapy group|start with only rosuvastatin 10mg per day
11175511|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
11175512|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
11175513|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
11175514|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
11175515|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
11175516|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
11175517|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
11175518|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
11175519|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
11175520|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 1: Monotherapy)|ISU104 20 mg/kg to be administered every three weeks (Q3W) as monotherapy
11175521|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 2: Combination therapy)|ISU104 20 mg/kg (or decreased dose) Q3W in combination with cetuximab* 250 mg/m2 QW (*Initial dose: 400 mg/m2)
11175522|NCT03552393|Experimental|Mircera|Mircera will be administered subcutaneously once every 4 weeks
11175523|NCT03552380|Experimental|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1
~Each cycle is 21 days"
11175524|NCT03552367|Experimental|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.
~Intervention: Non-personalized non-structured exercise"
11175525|NCT03552367|Active Comparator|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
11175526|NCT03552354|Experimental|Argatroban combined with antiplatelet|
11175527|NCT03552328|Experimental|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
11175528|NCT03552328|Placebo Comparator|Control|Seniors receiving daily meals from Meals on Wheels
11175529|NCT03552315|Active Comparator|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
11175530|NCT03552315|Placebo Comparator|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
11192992|NCT03433092||GC Kabat et. al,2012|
11175532|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
11175533|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
11175534|NCT03552276|Experimental|tildrakizumab 200 mg q4 weeks|Psoriatic arthritis subjects
11175535|NCT03552276|Experimental|tildrakizumab 200 mg q12 weeks|Psoriatic arthritis subjects
11175536|NCT03552276|Experimental|100 mg q12 weeks|Psoriatic arthritis (PsA) subjects
11175537|NCT03552276|Experimental|tildrakizumab 200 mg|Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis (AS/nr-axSpA) subjects
11175538|NCT03552263|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.
~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
11175539|NCT03552263|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.
~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
11175540|NCT03552263|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
11175541|NCT03552250|Other|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
11175542|NCT03552237|Experimental|dietary fiber intervention group|
11175543|NCT03552224|Experimental|Subjects with no hearing loss|Subjects referred for cerebellopontine angle surgery with no hearing loss with recording of auditory nerve activity by contact electrode
11175544|NCT03552224|Experimental|Subjects with hearing loss|Subjects referred for cerebellopontine angle surgery with hearing loss with recording of auditory nerve activity by contact electrode
11175545|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
11175546|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
11175547|NCT03552198|No Intervention|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
11175548|NCT03552198|Experimental|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
11175549|NCT03552198|No Intervention|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
11175550|NCT03552198|Experimental|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
11175551|NCT03552172||Prescription physical activity|
11175552|NCT03552172||No prescription for physical activity or suspension|
11175553|NCT03552159|Experimental|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
11175554|NCT03552159|Active Comparator|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
11175555|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
11175556|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
11175557|NCT03552133|Experimental|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
11175558|NCT03552133|No Intervention|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
11175559|NCT03552120|Experimental|Mindfulness-Oriented Recovery Enhancement|
11175560|NCT03552120|Active Comparator|Supportive Psychotherapy|
11175561|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
11175562|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
~Blood bag (volume of blood: from 450 to 500 mL)."
11175563|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
11175564|NCT03552081|Experimental|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
11175565|NCT03552068|Placebo Comparator|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
11175566|NCT03552068|Active Comparator|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
11175567|NCT03552042|Experimental|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
11175568|NCT03552042|Active Comparator|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
11175569|NCT03552042|No Intervention|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
11175570|NCT03552029|Experimental|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
11175571|NCT03552029|Experimental|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
11175572|NCT03552029|Experimental|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
11175573|NCT03552016|Experimental|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
11175574|NCT03552016|Experimental|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
11175575|NCT03552016|Placebo Comparator|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
11175576|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
11175577|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
11175578|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
11175579|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
11175580|NCT03551977|Experimental|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
11175581|NCT03551977|Active Comparator|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
11175582|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
11175583|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
11175584|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
11175585|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.
~Lung cancer screening subjects"
11175586|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
11175587|NCT03551938|No Intervention|Control|Receive only the standard HIV Counseling, Testing, and Referral or Couples HIV Testing and Counseling (CHTC) Session.
11175588|NCT03551938|Experimental|Intervention|Receive one 45-minute Relationship skills session for YMSM individuals and couples (the intervention) as an addition to the standard HIV Counseling, Testing, and Referral (CTR) or Couples HIV Testing and Counseling (CHTC) Session.
11175589|NCT03551925|Experimental|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
11175590|NCT03551925|Active Comparator|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
11175592|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
11175593|NCT03551860|Experimental|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
11175594|NCT03551860|Active Comparator|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
11175595|NCT03551847|Experimental|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
11175596|NCT03551847|Active Comparator|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
11175597|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
11175598|NCT03551834|Active Comparator|Using short tunnel small flap technique|
11175599|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
11175600|NCT03551808|Active Comparator|installation of Ketorolac Tromethamine Eye Drop|
11175601|NCT03551808|No Intervention|not receiving placebo|
11175602|NCT03551795|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells.
11175603|NCT03551782|Experimental|Cohort 1|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer [t-SCNC]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
11175604|NCT03551782|Experimental|Cohort 2|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.
11175605|NCT03551782|Experimental|Cohort 3|Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
11175606|NCT03551782|Experimental|Cohort 4|Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
11175607|NCT03551782|Experimental|Cohort 5|Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
11175608|NCT03551769|Experimental|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
11175609|NCT03551769|Experimental|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
11175610|NCT03551769|Experimental|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
11175611|NCT03551769|Experimental|Cohort 1, Period 4|Study drug administered after an overnight fast
11175612|NCT03551769|Experimental|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
11175613|NCT03551769|Experimental|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
11175614|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
11175615|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
11175616|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
11175617|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
11175618|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
11175619|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
11175620|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
11175621|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
11175622|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
11175623|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
11175624|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
11175625|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.
~The age balance of the patients included in the two groups will be checked regularly."
11175626|NCT03551704|Active Comparator|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.
~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
11175627|NCT03551704|Experimental|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
11175628|NCT03551691|Active Comparator|Treatment Arm|Subjects will take omeprazole 40mg daily for 28 days, then undergo assessments of fat absorption.
11192993|NCT03433092||Christina Persson et. al,2008|
11175629|NCT03551691|Placebo Comparator|Placebo Arm|Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
11175630|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
11175631|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
11175632|NCT03551652||Young patients|Patients aged 18 - 50 years
11175633|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
11175634|NCT03551626|Experimental|Dabrafenib and trametinib combination therapy|Subjects will receive dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
11175635|NCT03551613|Active Comparator|honey group|malnourished children supplemented with honey in dose of 2ml/kg
11175636|NCT03551613|Placebo Comparator|malnourished control group|no honey supplementation only nutrition rehabilitation
11175637|NCT03551613|No Intervention|healthy children|healthy children with no suplementation
11175638|NCT03551600||Preterm, no PDA|"Babies </= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA
~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
11175639|NCT03551600||Preterm, moderate to large PDA|Babies </= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
11175640|NCT03551600||>/= 34 wk infants, no CHD|"Babies >/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)
~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
11175641|NCT03551600||>/= 34 week infants, CHD|"Babies >/= to 34 weeks gestation at birth with ductal dependent CHD
~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
11175642|NCT03551587|Experimental|Irrigant delivered by the Vibringe|"Experimental group:
~The irrigant will be delivered and sonically activated with the Vibringe system."
11175643|NCT03551587|No Intervention|Irrigation by Conventional needle|"Control group:
~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
11175644|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
11175645|NCT03551561|Active Comparator|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
11175646|NCT03551561|Active Comparator|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
11175647|NCT03551548|Placebo Comparator|Reference treatment|
11175648|NCT03551548|Experimental|experimental treatment|Spironolactone 25 mg
11175649|NCT03551535|Experimental|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
11175650|NCT03551535|No Intervention|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
11175651|NCT03551522|Experimental|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
11175652|NCT03551522|Experimental|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
11175653|NCT03551522|Experimental|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
11175654|NCT03551522|Placebo Comparator|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
11175655|NCT03551509|No Intervention|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
11175656|NCT03551509|Active Comparator|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
11175657|NCT03551509|Other|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
11175658|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
11175659|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
11175660|NCT03551483|Experimental|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
11175661|NCT03551483|Active Comparator|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
11175662|NCT03551483|Other|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
11175663|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
11175709|NCT03551132|No Intervention|Group 2|Control group The CG not participated in the RTC program.
11176288|NCT03547089|Experimental|Viveve treatment|Group of women who receive Viveve treatment
11175664|NCT03551444|Active Comparator|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:
~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.
~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
11175665|NCT03551444|Experimental|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
11175666|NCT03551431|Experimental|Video EEG with verbal suggestion|
11175667|NCT03551431|Experimental|video EEG with verbal suggestion and tuning fork|
11175668|NCT03551431|Experimental|video EEG with verbal suggestion and cotton swab|
11175669|NCT03551418|Experimental|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
11175670|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.
~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
11175671|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
11175672|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
11175673|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
11175674|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
11175675|NCT03551379||Endoscopic procedure|A double balloon endoscopic platform will be used during an ESD procedure
11175676|NCT03551366|No Intervention|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
11175677|NCT03551366|Experimental|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
11175678|NCT03551366|Experimental|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
11175679|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
11175680|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
11175681|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
11175682|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
11175683|NCT03551327|Experimental|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
11175684|NCT03551327|Other|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
11175685|NCT03551314|Active Comparator|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.
~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
11175775|NCT03550573|Experimental|hypertrophic cardiomyopathy without sudden death history|
11175776|NCT03550573|Experimental|hypertrophic cardiomyopathy with sudden death history|
11175686|NCT03551314|Active Comparator|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.
~CPAP: Continuous Positive Airway Pressure"
11175687|NCT03551288|Experimental|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
11175688|NCT03551288|Experimental|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
11175689|NCT03551288|Experimental|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
11175690|NCT03551275|Experimental|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.
~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.
~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
11175691|NCT03551275|Experimental|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.
~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.
~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
11175692|NCT03551275|Experimental|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.
~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.
~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
11175693|NCT03551275|Experimental|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.
~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
11175694|NCT03551262|Experimental|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
11175695|NCT03551262|Active Comparator|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
11175696|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
11175697|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
11175698|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
11175699|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.
~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
11175700|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.
~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
11175701|NCT03551197|Experimental|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
11175702|NCT03551184|Active Comparator|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
11175703|NCT03551184|Placebo Comparator|Placebo|Saline injection
11175704|NCT03551171|Experimental|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
11175705|NCT03551158|Other|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
11175706|NCT03551145|Experimental|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
11175707|NCT03551145|Active Comparator|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
11175708|NCT03551132|Experimental|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).
~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
11192994|NCT03433092||M Jenab et. al,2006|
11175710|NCT03551119|Experimental|Exercise|"Personnel experienced in training people with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be prescribed based on the most recent exercise test.
~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.
~Phase 2: a 16-week home-based exercise program overseen by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.
~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.
~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
11175711|NCT03551119|Other|Enhanced usual care|Participants in the control group will perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
11175712|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
11175713|NCT03551093|Experimental|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
11175714|NCT03551080|Active Comparator|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
11175715|NCT03551080|Placebo Comparator|Placebo|Saline injection
11175716|NCT03551067|Active Comparator|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
11175717|NCT03551067|Active Comparator|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
11175718|NCT03551054|Experimental|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
11175719|NCT03551054|Active Comparator|Pregnancy Health Education|Single health education visit with study staff member
11175720|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
11175721|NCT03551015|Experimental|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
11175722|NCT03551015|No Intervention|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
11175723|NCT03551002||Retrospective|
11175724|NCT03551002||Prospective|
11175725|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.
~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.
~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
11175726|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.
~Used at least 100 cigarettes
~Smokes cigarettes daily > 1/day
~Uses IQOS less than daily
~Uses less than 30 HeatSticks/month
~Cigarette is > 95% of tobacco/nicotine product (all product use)"
11175727|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.
~Used at least 100 HeatSticks
~Uses IQOS daily > 1/day
~Smokes a cigarette less than daily
~Smokes less than 30 cigarettes/month
~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
11175728|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.
~Used at least 100 HeatSticks
~Uses IQOS daily > 1/day
~Smokes a cigarette less than daily
~Smokes less than 30 cigarettes/month
~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
11175729|NCT03550976|Experimental|High risk intervention group|
11175730|NCT03550976|No Intervention|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
11175731|NCT03550976|No Intervention|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
11175732|NCT03550963|Other|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
11175733|NCT03550963|Other|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
11175734|NCT03550950|Experimental|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
11175735|NCT03550950|Experimental|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
11175736|NCT03550924|Active Comparator|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
11175737|NCT03550924|Experimental|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
11175738|NCT03550898|Other|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
11175739|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
11175740|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
11175741|NCT03550872|No Intervention|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
11175742|NCT03550872|Experimental|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
11175743|NCT03550859|Experimental|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
11175744|NCT03550859|Active Comparator|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
11175745|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
11175746|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)
11175747|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
11175748|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
11175749|NCT03550781|Experimental|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
11175750|NCT03550781|No Intervention|Control group|No intervention
11175751|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
11175752|NCT03550755|Experimental|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
11175753|NCT03550742|Experimental|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
11175754|NCT03550729|Experimental|Training|12-weeks of supervised endurance training program.
11175755|NCT03550716|Active Comparator|mTESE|Patients randomized to mTESE
11175756|NCT03550716|Active Comparator|TESA|Patients randomized to TESA
11175757|NCT03550703|Experimental|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
11175758|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
11175759|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
11175760|NCT03550677|Experimental|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
11175761|NCT03550677|Experimental|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
11175762|NCT03550664|Experimental|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
11175763|NCT03550651|Experimental|Licorice extract mouthrinse|10ml twice a day for 4 Days.
11175764|NCT03550651|Experimental|Hypertonic salt solution|10ml twice a day for 4 Days.
11175765|NCT03550651|Active Comparator|Essential oil mouthrinse|10ml twice a day for 4 Days.
11175766|NCT03550651|Active Comparator|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
11175767|NCT03550651|Placebo Comparator|Distilled water|10ml twice a day for 4 Days.
11175768|NCT03550638|Experimental|group A|Coil system(Ton-bridgeMT)
11175769|NCT03550638|Active Comparator|group B|Axium Detachable Coil(Medtronic)
11175770|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
11175771|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
11175772|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
11175773|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
11175774|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
11192995|NCT03433092||Kenji Wakai et. al,2005|
11175778|NCT03550547|Experimental|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :
~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
11175779|NCT03550547|Active Comparator|spa therapy|Approved Spa therapy
11175780|NCT03550534|Experimental|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
11175781|NCT03550534|Placebo Comparator|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
11175782|NCT03550521|Experimental|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
11175783|NCT03550521|No Intervention|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
11175784|NCT03550508|Experimental|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
11175785|NCT03550495|No Intervention|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
11175786|NCT03550495|Experimental|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
11175787|NCT03550482|Experimental|Oncoxin®|
11175788|NCT03550482|No Intervention|Control|
11175789|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
11175790|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
11175791|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).
~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).
~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.
~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.
~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
11175792|NCT03550443|Experimental|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
11175793|NCT03550443|Placebo Comparator|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
11175794|NCT03550430|Experimental|ADR neurofeedback|Ten ADR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions consists of five training blocks each. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
11175795|NCT03550430|Active Comparator|BTR neurofeedback|Ten BTR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions each consists of five training blocks. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
11175796|NCT03550430|Active Comparator|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
11175797|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
11175798|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011, 2013 cohorts & July16/June17.
11175799|NCT03550417||July2016/Jun17 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010 & 2014. Comparison of 2011, 2013 cohorts & July16/June17.
11175800|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
11175801|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
11175802|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
11175803|NCT03550391|Experimental|Hippocampal-avoidant (HA-WBRT) plus Memantine|WBRT 30Gy in 10 fractions + memantine
11175804|NCT03550391|Experimental|Stereotactic Radiosurgery (SRS)|SRS 18-20 or 22Gy in single fraction
11175805|NCT03550378|Experimental|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
11175806|NCT03550378|Placebo Comparator|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
11175807|NCT03550365|Experimental|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
11175808|NCT03550365|Experimental|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
11175809|NCT03550365|Active Comparator|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
11175810|NCT03550352|Experimental|Low CBD|Low CBD dose TN-TC11LM oral capsules (THC 2.5 mg / CBD 2.5 mg).
11175811|NCT03550352|Experimental|High CBD|High CBD dose TN-TC19LM oral capsules (THC 5 mg / CBD 45 mg).
11175815|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
11175816|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
11175817|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
11175818|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
11175819|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
11175820|NCT03550300||Control participants|Control participants
11175821|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
11175822|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
11175823|NCT03550274|Experimental|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
11175824|NCT03550248|Other|Intervention group|Participants will receive the intervention - Healthy Together (HT).
11175825|NCT03550209|Experimental|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
11175826|NCT03550209|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
11175827|NCT03550183|Experimental|mesenchymal stem cells|Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
11175828|NCT03550170|Active Comparator|Teleconference|Teleconference Intervention arm
11175829|NCT03550170|Active Comparator|Internet|Internet Intervention arm
11175830|NCT03550170|Active Comparator|I-to-1, in-person|1-to-1, in-person intervention arm
11175831|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
11175832|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
11175833|NCT03550131|Active Comparator|Standard intervention|"Reducing Disabilities in Alzheimer's Disease (RDAD):
~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
11175834|NCT03550131|Experimental|Personalized intervention|"Innovations in Dementia Empowerment and Action (IDEA):
~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
11175835|NCT03550118|Experimental|Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
11175836|NCT03550118|Experimental|Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
11175837|NCT03550118|Experimental|Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
11175838|NCT03550118|Experimental|Stress-Sensing Liner|An adjustable socket is tested in addition to a prosthetic liner with embedded stress sensors to measure mechanical stresses as the socket is adjusted.
11175839|NCT03550118|Experimental|Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
11175840|NCT03550118|Experimental|Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
11175841|NCT03550105|Experimental|GJ-Only|Study Subjects with Baseline Glucose of > 150mg/dl, will have Gentle Jogger Only for 7 days
11175842|NCT03550105|Experimental|GJ-OGTT|Study Subjects with Baseline Glucose of < 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
11175843|NCT03550092|Experimental|Aphasia|Abstract Semantic Association Network Training (AbSANT) Each session will be 2 hours long and will occur twice each week for a total of 20 sessions.
11175844|NCT03550079|Experimental|three screws fixation|femoral neck fractures were fixed with three converted screws
11175845|NCT03550079|Experimental|four screws fixation|femoral neck fractures were fixed with four screws
11175846|NCT03550066|Experimental|Values affirmation|In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.
11175847|NCT03550066|Active Comparator|No affirmation|"In the no affirmation condition, the health outreach message appeared alone, with no values affirmation."
11175848|NCT03550053|Active Comparator|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
11175849|NCT03550053|Active Comparator|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
11175850|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
11175851|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
11175852|NCT03550027|Experimental|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
11175853|NCT03550027|Experimental|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
11176330|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
11175854|NCT03550014|Active Comparator|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
11175855|NCT03550014|Active Comparator|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
11175856|NCT03550001|Experimental|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
11175857|NCT03550001|No Intervention|No injection|Do not inject carbon nanoparticle during the treatment.
11175858|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.
~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
11175859|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.
~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
11175860|NCT03549975|Experimental|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
11175861|NCT03549936|Active Comparator|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
11175862|NCT03549936|Active Comparator|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
11175863|NCT03549923|Experimental|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
11175864|NCT03549923|Experimental|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (> 6.5 mmol/L), metabolic acidosis (pH < 7.2), pulmonary edema, blood urea nitrogen level >112 mg/dL, or oliguria (urine output < 200 mL/12 h) for more than 72 hours.
11175865|NCT03549923|Experimental|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
11175866|NCT03549923|Experimental|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
11175867|NCT03549910|Experimental|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
11175868|NCT03549910|Other|Low tidal volume ventilation|Low tidal volume lung protective ventilation
11175869|NCT03549897|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
11175870|NCT03549897|Active Comparator|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
11175871|NCT03549897|Active Comparator|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
11175872|NCT03549897|Experimental|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
11175873|NCT03549884|Experimental|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
11175874|NCT03549884|Active Comparator|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
11175875|NCT03549871|Experimental|Fitusiran|Fitusiran fixed dose, once-monthly sub-cutaneous injection for 7 months
11175876|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
11175877|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
11175878|NCT03549832|Active Comparator|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
11175879|NCT03549832|Active Comparator|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
11175880|NCT03549819|Experimental|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
11175881|NCT03549819|Placebo Comparator|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
11176331|NCT03546790|Experimental|Flavor 1|Grape flavored tobacco cigar wrapper
11175882|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
11175883|NCT03549793|Experimental|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
11175884|NCT03549793|Active Comparator|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
11175885|NCT03549780|Other|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
11175886|NCT03549767|Experimental|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
11175887|NCT03549767|Active Comparator|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
11175888|NCT03549741|Experimental|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
11175889|NCT03549741|Active Comparator|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
11175890|NCT03549728|Experimental|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
11175891|NCT03549728|Placebo Comparator|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
11175892|NCT03549715|Experimental|ARM A: durvalumab + ddMVAC|Durvalumab + ddMVAC Durvalumab 1500 mg IV D1 every 28 days Durvalumab will be administered at the hospital every 28 days prior to administration of ddMVAC on D1.
11175893|NCT03549715|Experimental|ARM B: durvalumab + tremelimumab+ ddMVAC|"durvalumab + tremelimumab + ddMVAC Tremelimumab 75 mg IV D1 every 28 days Tremelimumab will be administered first, with durvalumab infusion starting approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion.
~Infusion of ddMVAC will start approximately 1 hour after completion of durvalumab."
11175894|NCT03549702|Active Comparator|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
11175895|NCT03549702|No Intervention|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
11175896|NCT03549689|Experimental|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
11175897|NCT03549689|Active Comparator|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
11175898|NCT03549676|Experimental|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
11175899|NCT03549663|Experimental|Tacrolimus monotherapy|
11175900|NCT03549663|Active Comparator|Tacrolimus combined with hormone therapy|
11175901|NCT03549650|Experimental|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
11175902|NCT03549650|Placebo Comparator|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
11175903|NCT03549637|Experimental|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).
~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.
~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
11175904|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.
~Patients will be treated with an perioperative regime/protocol consisting of:
~Early so called NEWS-monitoring (measuring of standard physiological parameters);
~Early start of antibiotics;
~Rapid (within 6 hours) start of operation;
~Goal-directed fluid therapy;
~Intensified post-operative monitoring;
~The presence of both surgical and anesthesiological specialists in the early care of the patients."
11175905|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
11175906|NCT03549611|Experimental|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia
~Tylenol, 975mg (3 tabs)
~800mg Gabapentin
~400mg Celecoxib
~10mg Oxycodone"
11175907|NCT03549611|Active Comparator|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia
~1. Tylenol, 975mg (3 tabs)"
11192996|NCT03433092||Christian C. Abnet et. al,2003|
11175908|NCT03549598|Experimental|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan, 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed on each subject
11175909|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
11175910|NCT03549559|Active Comparator|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
11175911|NCT03549559|Active Comparator|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
11175912|NCT03549559|Experimental|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
11175913|NCT03549546|Other|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
11175914|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
11175915|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
11175916|NCT03549507|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection (if there are two injections of contrast) of the contrast agent.
11175917|NCT03549494|Experimental|Ocoxin-Viusid®|
11175918|NCT03549468|Experimental|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
11175919|NCT03549455|Experimental|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
11175920|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
11175921|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
11175922|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
11175923|NCT03549442|Experimental|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
11175924|NCT03549429|Experimental|TegadermTM on R eye, EyeGard® on L eye|Patients will get TegadermTM on Right eye, EyeGard® on Left eye
11175925|NCT03549429|Experimental|TegadermTM on L eye, EyeGard® on R eye|Patients will get TegadermTM on Left eye, EyeGard® on Right eye
11175926|NCT03549403|Experimental|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
11175927|NCT03549403|No Intervention|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
11175928|NCT03549390|Experimental|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A & B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A & B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
11175929|NCT03549390|Experimental|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
11175930|NCT03549390|No Intervention|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
11175931|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
11175932|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
11175933|NCT03549364|Experimental|Endurance race|"baseline investigations with CT and lab tests
~the same CT and lab tests < 24h after an endurance race
~CT and lab tests again about 1-2weeks after the race"
11175934|NCT03549338|Experimental|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.
~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
11175935|NCT03549338|Experimental|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
11175936|NCT03549338|Experimental|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
11175937|NCT03549325|Experimental|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.
~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.
~Follow up visits occur on Days 5, 14 and 32."
11175938|NCT03549325|Experimental|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.
~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.
~Follow up visits occur on Days 15, 24 and 42."
11175939|NCT03549312|Experimental|Switch to Genvoya Followed By HCV Therapy Then Start Biktarvy|Oral Genvoya 150/150/200/10 mg & Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
11175940|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
11175941|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
11175942|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
11175943|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
11175944|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
11175945|NCT03549273|Experimental|Treatment|Glizigen® spray + Ocoxin-Visuid® oral solution
11175946|NCT03549260|Experimental|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
11175947|NCT03549260|Experimental|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
11175948|NCT03549260|Experimental|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
11175949|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
11175950|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
11175951|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
11175952|NCT03549234|Experimental|Erector Spinae (single injection)|
11175953|NCT03549234|Active Comparator|Paravertebral (single injection)|
11175954|NCT03549221|Experimental|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
11175955|NCT03549221|No Intervention|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
11175956|NCT03549208|Experimental|LBVE01|Multivalent pneumococcal conjugate vaccine
11175957|NCT03549208|Experimental|LBVE02|Multivalent pneumococcal conjugate vaccine
11175958|NCT03549208|Active Comparator|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
11175959|NCT03549195|Active Comparator|ICG|
11175960|NCT03549195|Active Comparator|ICG-CP|CP, control peptide
11175961|NCT03549195|Experimental|ICG-TMTP1|also named as TMTP1-ICG
11175962|NCT03549182|Experimental|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
11175963|NCT03549182|Experimental|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
11175964|NCT03549182|Experimental|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
11175965|NCT03549182|Experimental|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
11175966|NCT03549169|Experimental|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
11175967|NCT03549169|Other|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
11175968|NCT03549156|Active Comparator|C-RUSF|Control/Standard RUSF
11192997|NCT03433092||N Malila et. al,2002|
11175970|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
11175971|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
11175972|NCT03549117|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
11175973|NCT03549117|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
11175974|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
11175975|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
11175976|NCT03549091|Experimental|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
11175977|NCT03549078|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
11175978|NCT03549065|Active Comparator|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
11175979|NCT03549065|Active Comparator|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
11175980|NCT03549065|Active Comparator|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
11175981|NCT03549065|Sham Comparator|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
11175982|NCT03549026|Experimental|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
11175983|NCT03549026|Placebo Comparator|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
11175984|NCT03549000|Experimental|NZV930 Monotherapy|Single Agent NZV930
11175985|NCT03549000|Experimental|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
11175986|NCT03549000|Experimental|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
11175988|NCT03548987|Experimental|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.
~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).
~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
11175989|NCT03548987|Placebo Comparator|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.
~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).
~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
11175990|NCT03548974|Active Comparator|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
11175991|NCT03548974|Active Comparator|Interventiongroup2|intermittent active and passive training followed by no intervention
11175992|NCT03548961|Experimental|Neoadjuvant chemotherapy|
11175993|NCT03548948|Other|High heme iron diet|
11175994|NCT03548948|Other|Low iron diet|
11175995|NCT03548948|Other|Plant-based high non-heme iron diet|
11175996|NCT03548935|Experimental|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
11175997|NCT03548935|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
11175998|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
11175999|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
11176000|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
11176001|NCT03548896|Experimental|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
11176002|NCT03548896|Experimental|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
11176003|NCT03548896|Experimental|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
11176004|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
11176005|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
11176006|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
11176007|NCT03548870|Experimental|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
11176008|NCT03548870|Sham Comparator|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
11176009|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
11176010|NCT03548844|Experimental|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
11176011|NCT03548844|Active Comparator|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
11176012|NCT03548831||MLH|Minilaparotomy Hysterectomy
11176013|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
11176014|NCT03548805|Experimental|Trabeculectomy with Ologen|ologen® Collagen Matrix
11176015|NCT03548805|Active Comparator|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC (0.02%)
11176016|NCT03548792|Other|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
11176017|NCT03548792|Other|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
11176018|NCT03548779|Experimental|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.
~Participants will receive usual care and will be offered research exome sequencing."
11176019|NCT03548779|Experimental|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.
~Participants will receive usual care."
11176020|NCT03548779|Experimental|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.
~Participants will receive usual care and will be offered research exome sequencing."
11176021|NCT03548779|No Intervention|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.
~Participants will receive usual care."
11176022|NCT03548766|Experimental|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
11176023|NCT03548766|Experimental|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
11176024|NCT03548753||Patients with Agatston score > 399|"Coronary computed tomography angiography with FFR-CT
~Invasive coronary angiography with FFR"
11176025|NCT03548740||Group A|
11176026|NCT03548740||Group B|
11176027|NCT03548727|Experimental|Repeatability of FLT kinetics|Radiotracer: 18F-FLT Dose: 10 mCi Frequency: Two baseline PET/CT at baseline up to 3 days apart.
11176028|NCT03548727|Experimental|Pseudo-Simultaneous FMISO/FLT PET/CT Imaging|Radiotracer: 18F-FLT and 18F-FLT Dose and Frequency: 8 mCi 18F-FLT and 8 mCi 18F-FLT on Day1, the 8mCi 18F-FLT on Day2
11176029|NCT03548714|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
11176030|NCT03548714|Placebo Comparator|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
11176031|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
11176032|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
11176033|NCT03548675|Experimental|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
11176034|NCT03548675|Active Comparator|Standard TCA treatment|Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
11176035|NCT03548662|Experimental|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
11176036|NCT03548662|Active Comparator|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
11176037|NCT03548649|Experimental|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
11176038|NCT03548636|Experimental|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
11176039|NCT03548610|Experimental|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical & local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film & 3 layers of dressings. Topical application creates a fine <1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 & 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours & suture removal (if not absorbed) at 7 days.
11176040|NCT03548610|No Intervention|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
11176041|NCT03548584|Experimental|Low Dose Brexpiprazole Arm|Tablet
11176042|NCT03548584|Experimental|High Dose Brexpiprazole Arm|Tablet
11176043|NCT03548584|Placebo Comparator|Placebo|Tablet
11176044|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
11176045|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
11176046|NCT03548558|Experimental|"Arm 1 (group sessions)"|Group meetings only
11176047|NCT03548558|Experimental|"Arm 2 (group+home sessions)"|Group meetings with a limited number of individual home visits and booster sessions
11176048|NCT03548558|No Intervention|Arm 3|This arm will serve as the control group to identify the effects of a parenting intervention and the most effective mode of delivery, as well as the sustained impacts from the intervention
11176049|NCT03548558|Experimental|Arm B (Father villages)|In one half of Arm 1 and Arm 2 villages above, fathers will be invited to attend the ECD sessions along with mothers.
11176050|NCT03548558|Other|Arm A (Mother-only villages)|In the other half of Arm 1 and Arm 2 villages, only mothers will be invited.
11176051|NCT03548545|Experimental|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
11176052|NCT03548545|Sham Comparator|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
11176053|NCT03548532|Active Comparator|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
11176054|NCT03548532|Experimental|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
11176332|NCT03546790|Experimental|Flavor 2|Chocolate flavored tobacco cigar wrapper
11192998|NCT03433092||G Pappalardo et. al,1997|
11176055|NCT03548519|Experimental|Attention Training|MCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
11176056|NCT03548519|Active Comparator|Active placebo training|MCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
11176057|NCT03548519|Experimental|PSE and Attention Training|MCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
11176058|NCT03548506|Active Comparator|STN_O|Omnidirectional Deep Brain Stimulation of STN
11176059|NCT03548506|Experimental|STN_D|Directional Deep Brain Stimulation of STN
11176060|NCT03548493|Experimental|Magnesium (M) group|Magnesium (M) group (n=17) , in which magnesium sulphate is given as adjuvant to propofol for sedation
11176061|NCT03548493|Active Comparator|Fentanyl (F) group|Fentanyl (F) group (n=17), in which fentanyl is given as adjuvant to propofol for sedation
11176062|NCT03548480|Placebo Comparator|Placebo|
11176063|NCT03548480|Experimental|Probiotic|
11176064|NCT03548467|Experimental|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
11176065|NCT03548467|Experimental|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
11176066|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
11176067|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
11176068|NCT03548441||Surgery|Exposed
11176069|NCT03548441||Non-surgical management|Non-exposed
11176070|NCT03548428|Experimental|A|SBRT + Atezolizumab
11176071|NCT03548428|Active Comparator|B|SBRT
11176072|NCT03548415|Experimental|IONIS-GHR-LRx|Single Dose of IONIS GHR-LRx administered subcutaneously once every 28 days for 16 weeks
11176073|NCT03548415|Placebo Comparator|Placebo|Placebo (sterile saline 0.9%) Calculated volume to match active comparator administered subcutaneously every 28 days for 16 weeks
11176074|NCT03548389|Experimental|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
11176075|NCT03548389|No Intervention|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
11176076|NCT03548376|Experimental|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
11176077|NCT03548363|Active Comparator|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
11176078|NCT03548363|Active Comparator|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
11176079|NCT03548363|Placebo Comparator|Placebo|200 mg/d maltodextrin for 4-weeks
11176080|NCT03548350|Experimental|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:
~A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).
~'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week
~After schools club (not compulsory) featuring mind-set component delivered by external facilitators
~Healthy kidz app with reward system"
11176081|NCT03548350|No Intervention|Control|The control group will continue doing physical activity including physical education as is normal for their school
11176082|NCT03548337|Active Comparator|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
11176083|NCT03548337|Active Comparator|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
11176084|NCT03548324|Active Comparator|HHHFNC|Heated Humidified High Flow Nasal Cannulae
11176085|NCT03548324|Active Comparator|NCPAP|Nasal Continuous Positive Air Pressure
11176086|NCT03548311|Placebo Comparator|Placebo|intramuscular injection of saline solution
11176087|NCT03548311|Active Comparator|methylcobalamin|intramuscular injection of methylcobalamin
11176088|NCT03548298|Experimental|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
11176089|NCT03548285|Experimental|patient with low risk|"Low-risk is defined by:
~Planning target volume (PTV) less than 10 cc, AND
~No reported smoking within 1 month from registration
~Radiation Therapy will be delivered twice per week for 5 fractions (total 42.5 Gy)"
11176090|NCT03548285|Experimental|patient with moderate risk|"Moderate-risk is defined by:
~Planning target volume (PTV) greater than or equal to 10 cc, OR
~Smoking within 1 month from registration (no more than 1 pack per day)
~Radiation Therapy will be delivered daily for 16 fraction (total 58.08 Gy)"
11176091|NCT03548272|Experimental|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.
~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
11176092|NCT03548272|Active Comparator|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).
~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
11176093|NCT03548259|Experimental|Experimental|Platelet-rich plasma
11176094|NCT03548259|Placebo Comparator|Platelet-poor plasma|Platelet-poor plasma
11176095|NCT03548246|Placebo Comparator|Placebo|Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
11176096|NCT03548246|Experimental|Abiraterone acetate|Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
11176097|NCT03548233|Other|bcg vaccinated|children under five year vaccinated by bcg vaccine
11176098|NCT03548220|Experimental|AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.
~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual's response in Part 1."
11176099|NCT03548220|Placebo Comparator|Placebo|"Part 1 (Dose Optimization Period): Participants will receive placebo matching AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.
~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of placebo matching AG-348 as determined by the individual's response in Part 1."
11176100|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
11176101|NCT03548194|Experimental|BNC210|Administered orally b.i.d. for 5 days.
11176102|NCT03548194|Placebo Comparator|Placebo|Administered orally b.i.d. for 5 days.
11176103|NCT03548181|Experimental|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.
~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
11176104|NCT03548181|Active Comparator|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
11176105|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
11176106|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
11176107|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
11176108|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
11176109|NCT03548155|Experimental|berberine group|
11176110|NCT03548155|Placebo Comparator|control group|
11176111|NCT03548129|Active Comparator|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.
~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.
~Response to treatment will be assessed by post-treatment urine culture."
11176112|NCT03548129|Active Comparator|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.
~Response to treatment will be assessed by post-treatment urine culture."
11176113|NCT03548116|Sham Comparator|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
11176114|NCT03548116|Experimental|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
11176115|NCT03548116|Experimental|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
11176116|NCT03548116|Sham Comparator|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
11176117|NCT03548116|Experimental|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
11176118|NCT03548116|Experimental|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
11176119|NCT03548116|Sham Comparator|Group 7|Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
11176120|NCT03548103|Experimental|Green Tea Extract|Green Tea Extract 500 mg per capsule
11176121|NCT03548103|Placebo Comparator|Placebo|Identical Placebo capsule
11176122|NCT03548090|Experimental|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
11176123|NCT03548090|Experimental|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
11176124|NCT03548090|Experimental|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
11176125|NCT03548090|Experimental|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
11176126|NCT03548090|Experimental|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
11176127|NCT03548090|Experimental|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
11176128|NCT03548090|Experimental|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
11176129|NCT03548090|Experimental|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
11176130|NCT03548090|Experimental|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
11176131|NCT03548090|Experimental|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
11176132|NCT03548090|Experimental|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
11176133|NCT03548090|Experimental|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
11176134|NCT03548090|Experimental|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
11176135|NCT03548090|Experimental|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
11176136|NCT03548090|Experimental|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
11176137|NCT03548090|Experimental|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
11176138|NCT03548090|Experimental|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
11176139|NCT03548090|Experimental|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
11176140|NCT03548090|Experimental|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
11176141|NCT03548090|Experimental|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
11176142|NCT03548090|Experimental|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
11176333|NCT03546790|Experimental|Flavor 3|Tobacco flavored tobacco cigar wrapper
11193104|NCT03432312|Experimental|Nicotine 4 mg mint lozenges|
11176143|NCT03548090|Experimental|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
11176144|NCT03548090|Experimental|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
11176145|NCT03548090|Experimental|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
11176146|NCT03548077|Experimental|Intervention group|Powerplay, a workplace wellness program designed for male-dominated work sites, is the intervention. The program focuses on physical activity, healthy eating, mental wellness, and smoking cessation as well as promoting changes in workplace environments to support employee health and wellness. Program delivery is supported with a detailed program manual and web-based resources. More information about the intervention is available here: http://www.powerplayatwork.com/
11176147|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
11176148|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
11176149|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
11176150|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
11176151|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
11176152|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
11176153|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
11176154|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
11176155|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
11176156|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
11176157|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
11176158|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
11176159|NCT03548025|Experimental|Treatment Group|Treated group of subjects, serves as its own control
11176160|NCT03548012|Experimental|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
11176161|NCT03548012|No Intervention|Control|('Standard' basic palliative care). No intervention offered.
11176162|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
11176163|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
11176164|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
11176165|NCT03547986|Experimental|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
11176166|NCT03547973|Experimental|Cohort 1 and Cohort 2|"All subjects will receive sacituzumab govitecan (IMMU-132) 10 mg/kg intravenously on Days 1 and 8 of a 21 day cycle.
~Cohort 1: Subjects with urothelial cancers, after platinum-based regimen (cisplatin or carboplatin) and anti-PD-1/anti-PD-L1 based therapy.
~Cohort 2: Subjects in second line therapy of urothelial cancers, ineligible for platinum-based therapy and anti-PD-1/anti-PD-L1 based therapies failure."
11176167|NCT03547973|Experimental|Cohort 3|"All subjects in Cohort 3 will receive sacituzumab govitecan (IMMU-132) 10 mg/kg intravenously on Days 1 and 8 of a 21 day cycle followed by pembrolizumab at the standard approved dose (200 mg) only on Day 1 of a 21 day cycle.
~Subjects who have had progression or recurrence of urothelial cancer following a platinum-containing regimen in the metastatic setting, or progression or recurrence of urothelial cancer within 12 months of completion of platinum-based therapy as neoadjuvant or adjuvant therapy."
11176168|NCT03547960|Experimental|Guar gum in women with early GDM|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
11176169|NCT03547960|Placebo Comparator|Control/Cellulose in women with early GDM|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
11176170|NCT03547934|Experimental|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
11176171|NCT03547921||operative|operative
11176175|NCT03547895|Active Comparator|cases|"patients with decompensated cirrhosis
~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
11176176|NCT03547895|Placebo Comparator|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
11176177|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
11176178|NCT03547882||Patients|Ten interviews were conducted with VA patients receiving ORT.
11176179|NCT03547869|Experimental|Active tDCS|Active tDCS
11176180|NCT03547869|Sham Comparator|Sham tDCS|Sham tDCS
11176181|NCT03547843|Experimental|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
11176182|NCT03547843|Active Comparator|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
11176183|NCT03547830|Experimental|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
11176184|NCT03547817|Experimental|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
11176185|NCT03547804|Experimental|experimental arm|apatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
11176186|NCT03547791|Active Comparator|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
11176187|NCT03547791|Placebo Comparator|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
11176188|NCT03547778|Experimental|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
11176189|NCT03547778|Placebo Comparator|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
11176190|NCT03547752|Active Comparator|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
11176191|NCT03547752|Experimental|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
11176192|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
11176193|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
11176194|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
11176195|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
11176196|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
11176197|NCT03547713|Experimental|Study group|social feedback and neuropsychological assessment
11176198|NCT03547700|Experimental|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
11176199|NCT03547687|Experimental|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
11176200|NCT03547674|Active Comparator|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
11176201|NCT03547674|Active Comparator|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
11176202|NCT03547674|Active Comparator|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
11176203|NCT03547674|Experimental|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
11176204|NCT03547661|No Intervention|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
11176232|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
11176334|NCT03546764|Experimental|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
11176205|NCT03547661|Active Comparator|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.
~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
11176206|NCT03547661|Active Comparator|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.
~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
11176207|NCT03547648|Active Comparator|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
11176208|NCT03547648|Active Comparator|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
11176209|NCT03547648|Active Comparator|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
11176210|NCT03547635|Experimental|AMNIOEXCEL Plus Amniotic Membrane|
11176211|NCT03547635|Active Comparator|A Marketed Comparator|
11176212|NCT03547635|Other|Standard of Care|
11176213|NCT03547622|Active Comparator|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
11176214|NCT03547622|Placebo Comparator|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
11176215|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
11176216|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
11176217|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
11176218|NCT03547570|Experimental|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
11176219|NCT03547557|Experimental|ExAblate MRgFUS|
11176220|NCT03547531|Active Comparator|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
11176221|NCT03547531|Experimental|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
11176222|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
11176223|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
11176224|NCT03547505|Experimental|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
11176225|NCT03547505|Experimental|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
11176226|NCT03547505|Experimental|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
11176227|NCT03547492|Experimental|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback
~Assessments:
~Ages and Stages Questionnaire at 4 and 12 months
~Maternal Peabody Picture Vocabulary test at 4 months
~Edinburgh Post-partum Depression Scale at 4 months
~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12
~Participants receive a book at each interaction."
11176228|NCT03547492|Active Comparator|Motor Control|"Baseline LENA recording
~Review motor curriculum with study personnel
~2nd LENA recording completed and analyzed
~4- monthly text messages
~4 month LENA recording
~12 month LENA recording with mailed linguistic feedback of all recordings
~Assessments:
~Ages and Stages Questionnaire at 4 and 12 months
~Maternal Peabody Picture Vocabulary test at 4 months
~Edinburgh Post-partum Depression Scale at 4 months
~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12
~Participants receive a toy at each interaction."
11176229|NCT03547479|No Intervention|Control|Participants receive current standard of care (DOTS)
11176230|NCT03547479|Experimental|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
11176231|NCT03547479|Experimental|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
11176287|NCT03547102|Placebo Comparator|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
11176233|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
11176234|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
11176235|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
11176236|NCT03547427|Experimental|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
11176237|NCT03547427|Active Comparator|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
11176238|NCT03547427|Experimental|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
11176239|NCT03547427|Active Comparator|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
11176240|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
11176241|NCT03547388|Experimental|Single Arm|Additional application of weekly moderate whole-body hyperthermia concurrent to re-irradiation plus chemotherapy
11176242|NCT03547375|Experimental|treatment group|Apatinib 500mg/d po,28 days as one cycle
11176243|NCT03547362|Experimental|Casein|Single oral administration
11176244|NCT03547362|Experimental|Dairy protein blend 1|single oral administration
11176245|NCT03547362|Experimental|Whey protein|Single oral administration
11176246|NCT03547362|Experimental|Dairy protein blend 2|Single oral administration
11176247|NCT03547362|Experimental|Dairy protein blend 3|Single oral administration
11176248|NCT03547362|Experimental|Dairy protein blend 4|Single oral administration
11176249|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
11176250|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
11176251|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
11176252|NCT03547336|Experimental|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
11176253|NCT03547336|Active Comparator|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
11176254|NCT03547323|Experimental|Theranova 400 Dialyzer|One treatment session in an in-center setting.
11176255|NCT03547323|Active Comparator|FX80 Dialyzer|One treatment session in an in-center setting.
11176256|NCT03547310|Experimental|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
11176257|NCT03547284|Active Comparator|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
11176258|NCT03547284|No Intervention|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool)
11176259|NCT03547271|Experimental|Group 1|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and measles, mumps, and rubella [MMR] vaccine) at 2, 4 and 12 to 18 months of age
11176260|NCT03547271|Active Comparator|Group 2|Licensed meningococcal vaccine (Nimenrix®), 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV- HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
11176261|NCT03547271|Experimental|Group 3|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
11176262|NCT03547271|Experimental|Group 4|MenACYW conjugate vaccine, 4 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4, and 12 to 18 months of age and administered alone at 6 months of age
11176263|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
11176264|NCT03547245|Active Comparator|HIV-uninfected, healthy adults|
11176265|NCT03547245|Placebo Comparator|HIV-uninfected, healthy adults - placebo|
11176266|NCT03547232|Experimental|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
11176267|NCT03547232|Sham Comparator|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
11176268|NCT03547219|Experimental|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
11176269|NCT03547206|Experimental|RPh201 Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
11176270|NCT03547206|Placebo Comparator|Placebo Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
11176271|NCT03547206|Experimental|RPh201 Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
11176272|NCT03547206|Placebo Comparator|Placebo Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the vehicle control.
11176273|NCT03547180|Active Comparator|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
11176274|NCT03547180|Active Comparator|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
11176275|NCT03547180|Other|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
11176276|NCT03547167|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
11176277|NCT03547167|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
11176278|NCT03547154|Experimental|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
11176279|NCT03547154|Active Comparator|Interferon alfa-2b|Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
11176280|NCT03547141|Experimental|botulinum toxin 1U|
11176281|NCT03547141|Experimental|botulinum toxin 5U|
11176282|NCT03547141|Experimental|botulinum toxin 15U|
11176283|NCT03547141|Experimental|botulinum toxin 30U|
11176284|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
11176285|NCT03547115|Experimental|voruciclib|Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)
11176286|NCT03547102|Active Comparator|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
11176289|NCT03547076|Experimental|Focused ultrasound diagnostics|"Intervention: Focused ultrasound Diagnostics
~All participants will first be examined twice with handheld ultrasound, With separate examinations performed by general practioners and nurses (random order). Both will utilize automatic analyses of left ventricular function and telemedicine support for best possible diagnosis of heart failure. Subsequently, reference imaging and diagnostics will be performed by experts (cardiologists). Handheld ultrasound examinations will be compared to Reference."
11176290|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
11176291|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
11176292|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
11176293|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
11176294|NCT03547050||Controls|People without a lifetime history of seizures.
11176295|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
11176296|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
11176297|NCT03547024|Experimental|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
11176298|NCT03547024|Experimental|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
11176299|NCT03547024|Experimental|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
11176300|NCT03547011|Active Comparator|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
11176301|NCT03547011|Active Comparator|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
11176302|NCT03546985|Experimental|Group A|
11176303|NCT03546985|Active Comparator|Group B|
11176304|NCT03546972|Active Comparator|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
11176305|NCT03546972|Experimental|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
11176306|NCT03546959|Experimental|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
11176307|NCT03546959|Active Comparator|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
11176308|NCT03546946|Experimental|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
11176309|NCT03546946|Placebo Comparator|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
11176310|NCT03546946|No Intervention|No-Train Group|No active training.
11176311|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
11176312|NCT03546920|No Intervention|Control Phase|Usual care for patients admitted to the SNF.
11176313|NCT03546920|Experimental|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
11176314|NCT03546907|Experimental|SAR440340|Administration of SAR440340 monotherapy injection
11176315|NCT03546907|Placebo Comparator|Placebo|Administration of matching placebo for injection of SAR440340
11176316|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
11176317|NCT03546894||Any FDA Approved ALK Inhibitor|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
11176318|NCT03546881|Experimental|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
11176319|NCT03546881|Active Comparator|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
11176320|NCT03546868|Experimental|Ulcerative Colitis|Patients with ulcerative colitis undergoing [18F]FSPG PET/CT scan
11176321|NCT03546868|Experimental|Crohn's disease|Patients with Crohn's disease undergoing [18F]FSPG PET/CT scan
11176322|NCT03546855|Experimental|treatment group|apatinib 500mg/d po.28d as one cycle
11176323|NCT03546842|Experimental|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
11176324|NCT03546829|Experimental|Arm 1 - Experimental|
11176325|NCT03546829|Active Comparator|Arm 2 - Control Arm|
11176326|NCT03546816|Experimental|5 mg Serlopitant Tablets|
11176327|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
11176328|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
11176329|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
11176335|NCT03546764|Active Comparator|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
11176336|NCT03546751|Experimental|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
11176337|NCT03546751|Active Comparator|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
11176338|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
11176339|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
11176340|NCT03546725|Experimental|Leg with compression stocking|Leg wearing compression stocking during the flight
11176341|NCT03546725|No Intervention|Leg without compression stocking|Leg not wearing compression stocking during the flight
11176342|NCT03546686|Experimental|Intervention Arm|Ipilimumab + Nivolumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery Nivolumab
11176343|NCT03546686|Active Comparator|Control Arm|Breast Surgery
11176344|NCT03546673|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
11176345|NCT03546673|Experimental|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
11176346|NCT03546673|Experimental|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
11176347|NCT03546660|Experimental|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
11176348|NCT03546647|Experimental|Toric|Soft toric contact lens
11176349|NCT03546647|Active Comparator|Sphere|Soft sphere contact lens
11176350|NCT03546634|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
11176351|NCT03546634|Experimental|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
11176352|NCT03546621|Experimental|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
11176353|NCT03546621|Experimental|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
11176354|NCT03546621|Experimental|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
11176355|NCT03546621|Active Comparator|Arm D|tenofovir treatment for 48 weeks
11176356|NCT03546608|Experimental|Part 1, Child-Pugh Class A: Tepotinib|
11176357|NCT03546608|Experimental|Part 1, Child-Pugh Class B: Tepotinib|
11176358|NCT03546608|Experimental|Part 1, Healthy Participants: Tepotinib|Healthy participants matched to Child-Pugh Class B participants.
11176359|NCT03546595|Experimental|Auricular acupoints acupressure|
11176360|NCT03546595|Sham Comparator|Sham auricular acupoints acupressure|
11176361|NCT03546582|Experimental|Arm I|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years.
11176362|NCT03546582|Other|Arm II|Patients receive Stereotactic Body Radiation Therapy (SBRT) over 2 weeks. Arm II patients who experience progressive disease within 2 years after the start of SBRT will be allowed to cross over to receive pembrolizumab for up to 2 years.
11176363|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
11176364|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
11176365|NCT03546543|Experimental|Supine|
11176366|NCT03546543|Experimental|Prone|
11176367|NCT03546530|Experimental|Interferon|Interferon 1.5ug/kg/week, 48weeks
11176368|NCT03546530|Experimental|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
11176369|NCT03546517|Experimental|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
11176370|NCT03546517|Sham Comparator|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
11176371|NCT03546504|Experimental|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
11176372|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
11176373|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
11176374|NCT03546478|Experimental|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
11176375|NCT03546465|Experimental|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
11176376|NCT03546465|Experimental|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
11193105|NCT03432312|Active Comparator|NiQuitin 4 mg mint lozenges|
11176377|NCT03546465|Experimental|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
11176378|NCT03546465|Experimental|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
11176379|NCT03546465|Experimental|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
11176380|NCT03546465|Experimental|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
11176381|NCT03546465|Experimental|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
11176382|NCT03546465|Experimental|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
11176383|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
11176384|NCT03546426|Experimental|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
11176385|NCT03546413||LEAP Participants|LEAP participants are followed during an extended period of ad-libitum peanut consumption and then assessed for peanut allergy and other allergic outcomes. Target accrual is 630.
11176386|NCT03546413||LEAP Siblings|LEAP participant siblings will be randomly assigned to the intervention or control group based on the allocation of their LEAP participants sibling.Target accrual is 746.
11176387|NCT03546413||LEAP Parents|Any parent of a child who enrolled in the LEAP study. Target accrual is 945.
11176388|NCT03546400|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
11176389|NCT03546374|Experimental|Primary Cohort|Patients with a history of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) who are undergoing concomitant cardiac surgery
11176390|NCT03546361|Experimental|1 Dose Escalation|three patients will be assigned to the cohort. All three will receive the same Ad-CCL21-DC dose by CT-guided or bronchoscopic intratumoral injection followed by intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year. for cohort (1) The Ad-CCL21-DC dose is 1 x 107 cells/injection in the first cohort.
11176391|NCT03546361|Experimental|2 Dose Escalation|three patients will be assigned to the cohort. All three will receive the same Ad-CCL21-DC dose by CT-guided or bronchoscopic intratumoral injection followed by intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year. for cohort (2) The Ad-CCL21-DC dose is 3 x 107 cells/injection in the second cohort.
11176392|NCT03546361|Experimental|-1 Dose Escalation|If the dose regimen in cohort 1 (Ad-CCL21-DC 1 x 107 cells/injection) is not well tolerated, de-escalation to Ad-CCL21-DC 0.5 x 107 cells/injection will be allowed (-1). three patients will be assigned to the cohort. All three will receive the same Ad-CCL21-DC dose by CT-guided or bronchoscopic intratumoral injection followed by intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year. for cohort (-1) The Ad-CCL21-DC dose is 0.5 x 107 cells/injection in the third cohort.
11176393|NCT03546361|Experimental|Dose Expansion|"After completion of the dose-escalation phase, all safety and tolerability data will be reviewed and the ExD will be determined. A dose expansion cohort of 24 patients will be enrolled and treated at ExD for up to a year (note: only intravenous pembrolizumab is given after day 42).
~Ad-CCL21-DC dose at determined maximum tolerated dose (MTD) or maximum administered dose (MAD)"
11176394|NCT03546335|Experimental|1mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
11176395|NCT03546335|Experimental|0.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
11176396|NCT03546335|Experimental|1.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
11176397|NCT03546335|Experimental|2mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
11176398|NCT03546322||Registry|Head and neck cancer patients monitored on registry
11176399|NCT03546309|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
11176400|NCT03546309|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
11176401|NCT03546283|Placebo Comparator|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
11176402|NCT03546283|Experimental|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
11176403|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
11176404|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
11176405|NCT03546257||EUS|group using conventional WLE and EUS
11176406|NCT03546257||ME-NBI|group using WLE and ME-NBI.
11176407|NCT03546244|Experimental|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
11176408|NCT03546244|Active Comparator|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
11178370|NCT03532789|Placebo Comparator|placebo patch group|using placebo patch as an intervention
11176409|NCT03546218|Experimental|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
11176410|NCT03546218|Active Comparator|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
11176411|NCT03546205|Experimental|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter/minute [mL/min]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
11176412|NCT03546205|Experimental|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than [<] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
11176413|NCT03546205|Experimental|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to <60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
11176414|NCT03546205|Experimental|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR <30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
11176415|NCT03546205|Experimental|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
11176416|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
11176417|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
11176418|NCT03546166|Experimental|TREATMENT|
11176419|NCT03546153|Experimental|Aerobic exercise program|Participants will complete 12 week exercise program.
11176420|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
11176421|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
11176422|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age>18 years, first visit at osteopathic clinic (Centro di Medicina Osteopatica)
11176423|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
11176424|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
11176425|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
11176426|NCT03546088|Experimental|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam and 3 mcg/kg fentanyl. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
11176427|NCT03546075|Experimental|500 mg Resveratrol|
11176428|NCT03546075|Experimental|250 mg Resveratrol|
11176429|NCT03546075|Placebo Comparator|Placebo|
11176430|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant.
11176431|NCT03546049|Active Comparator|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
11176432|NCT03546049|Experimental|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
11176433|NCT03546036|Experimental|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
11176434|NCT03546036|Sham Comparator|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
11176435|NCT03546010|Experimental|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
11176436|NCT03545997|Experimental|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
11176437|NCT03545997|Placebo Comparator|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
11176469|NCT03545854|Experimental|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
11176470|NCT03545854|Experimental|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
11177059|NCT03541564|Experimental|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
11176438|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
11176439|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
11176440|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
11176441|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
11176442|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
11176443|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
11176444|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
11176445|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
11176446|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
11176447|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
11176448|NCT03545958|Experimental|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
11176449|NCT03545958|Active Comparator|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
11176450|NCT03545945|Experimental|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
11176451|NCT03545945|Other|Control arm|Patients having only endometrial biopsy
11176452|NCT03545932|Experimental|Hydrogymnastics|Hydrogymnastics Program
11176453|NCT03545906|Experimental|TEAM-UP Intervention Group|
11176454|NCT03545906|Active Comparator|Enhanced Care Comparison Group|
11176455|NCT03545893|Active Comparator|Ibuprofen|
11176456|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
11176457|NCT03545880|Experimental|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
11176458|NCT03545880|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
11176459|NCT03545867|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
11176460|NCT03545867|Experimental|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and ~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
11176461|NCT03545867|Experimental|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
11176462|NCT03545867|Experimental|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
11176463|NCT03545854|Experimental|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
11176464|NCT03545854|Experimental|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
11176465|NCT03545854|Experimental|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
11176466|NCT03545854|Experimental|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
11176467|NCT03545854|Experimental|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
11176468|NCT03545854|Experimental|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
11176719|NCT03543982|Experimental|Oral probiotic product|
11176471|NCT03545854|Experimental|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
11176472|NCT03545841|Experimental|HIT training|6 weeks of high-intensity interval training (HIT)
11176473|NCT03545841|Experimental|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
11176474|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
11176475|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
11176476|NCT03545815|Experimental|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.
~Patients receive anti-mesothelin-CAR T cells on day 0."
11176477|NCT03545802|Experimental|Training|6 weeks of home-based high intensity interval training
11176478|NCT03545789|Experimental|[18F]MNI-958|To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
11176479|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.
~Training will be followed by an online teaching consisting on additional questions and answers quizzes based on the 10 educational goals already described elsewhere.
~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
11176480|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
11176481|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
11176482|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
11176483|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
11176484|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
11176485|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.
~The depth of intubation = 0.1977* height-4.2423"
11176486|NCT03545724|Experimental|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
11176487|NCT03545711|Experimental|Anlotinib plus Irinotecan|
11176488|NCT03545698|Active Comparator|Telehealth Intervention|
11176489|NCT03545698|No Intervention|Non-Telehealth Intervention|
11176490|NCT03545685|Experimental|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
11176491|NCT03545685|Other|Control group|Participants in this group will serve as control group
11176492|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
11176493|NCT03545672||Control group|The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
11176494|NCT03545646|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
11176495|NCT03545633|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
11176496|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
11176497|NCT03545607|Experimental|MultiStem|1.2 billion cells
11176498|NCT03545607|Placebo Comparator|Placebo|
11176499|NCT03545594|Experimental|Patient-centered in home rehabilitation|Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
11176500|NCT03545594|Active Comparator|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
11176501|NCT03545581|Other|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
11176502|NCT03545581|Other|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
11176503|NCT03545568|Other|Experimental: sialic acid|
11176504|NCT03545555|Experimental|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
11176505|NCT03545555|Experimental|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
11176506|NCT03545555|Experimental|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
11176507|NCT03545555|Placebo Comparator|Placebo|"5 capsules with placebo per day for 8 weeks"
11176508|NCT03545542|Experimental|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.
~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).
~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
11177060|NCT03541564|Active Comparator|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
11176509|NCT03545542|Other|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.
~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).
~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
11176510|NCT03545529|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
11176511|NCT03545529|No Intervention|conventional supported|Patients benefit from usual care
11176512|NCT03545516|Placebo Comparator|Placebo|Wound infiltration with a placebo
11176513|NCT03545516|Experimental|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
11176514|NCT03545516|Experimental|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
11176515|NCT03545503|Active Comparator|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
11176516|NCT03545503|Active Comparator|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
11176517|NCT03545490|Experimental|Intervention oral or tube feeding group|Ensure 3 times/day
11176518|NCT03545490|No Intervention|Control oral or tube feeding group|Only nutrition education
11176519|NCT03545477|Experimental|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
11176520|NCT03545477|Active Comparator|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
11176521|NCT03545464|Experimental|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.
~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally
~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).
~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
11176522|NCT03545464|Active Comparator|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.
~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.
~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).
~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
11176523|NCT03545451|Experimental|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
11176524|NCT03545438|Placebo Comparator|cohort 1|LIB003 dose 1 SC
11176525|NCT03545438|Placebo Comparator|cohort 2|LIB003 dose 2 SC
11176526|NCT03545438|Placebo Comparator|cohort 3|LIB003 dose 4 SC
11176527|NCT03545438|Placebo Comparator|cohort 4|LIB003 dose 4 SC
11176528|NCT03545438|Placebo Comparator|cohort 5|LIB003 dose 5 SC
11176529|NCT03545438|Placebo Comparator|cohort 6|LIB003 dose 4 IV
11176530|NCT03545438|Placebo Comparator|cohort 7|LIB003 dose 5 IV
11176531|NCT03545438|Placebo Comparator|cohort 8|LIB003 dose 3 SC - statin treated
11176532|NCT03545438|Placebo Comparator|cohort 9|LIB003 dose 4 SC - statin treated
11176533|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
11176534|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
11176535|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
11176536|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
11176537|NCT03545412|Experimental|Microfocused ultrasound with visualization|
11176538|NCT03545399|Experimental|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
11176539|NCT03545399|Placebo Comparator|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
11176540|NCT03545386|Experimental|FMT|
11176541|NCT03545386|Placebo Comparator|Placebo|
11176542|NCT03545373|Experimental|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
11176543|NCT03545373|Experimental|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
11176544|NCT03545373|No Intervention|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
11176545|NCT03545360|Experimental|Treatment Group|Treated group of subjects, serves as its own control
11176546|NCT03545347|Experimental|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
11176547|NCT03545347|Placebo Comparator|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
11176548|NCT03545334|Experimental|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.
~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
11176549|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
11176550|NCT03545295|Experimental|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
11176551|NCT03545295|Experimental|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
11176552|NCT03545295|Experimental|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
11176553|NCT03545295|Experimental|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
11176554|NCT03545295|Experimental|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
11176555|NCT03545295|Experimental|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
11176556|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
11176557|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
11176558|NCT03545269|Experimental|CartiLife®|
11176559|NCT03545269|Active Comparator|Microfracture|
11176560|NCT03545256|Other|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
11176561|NCT03545243|Other|Pantoprazole 40mg in healthy volunteers|Peroral Pantoprazole 40mg once daily for 4 weeks
11176562|NCT03545243|Other|Pantoprazole 40mg in functional dyspepsia|Peroral Pantoprazole 40mg once daily for 4 weeks
11176563|NCT03545243|Other|PPI-withdrawal in functional dyspepsia|no PPI for 8 weeks
11176564|NCT03545230|Experimental|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
11176565|NCT03545217|Experimental|intervention group|
11176566|NCT03545217|No Intervention|control group|
11176567|NCT03545204|Other|Intervention Clusters|Community based Kangaroo Mother Care,KMC package in low birth weight infants of randomly selected union councils.
11176568|NCT03545204|Other|Control clusters|Essential newborn and routine standard care in low birth weight infants of randomly selected union councils.
11176569|NCT03545191|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
11176570|NCT03545191|Experimental|ACT-541468 50 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
11176571|NCT03545191|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
11176572|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
11176573|NCT03545165|Experimental|All Subjects|"177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration
~177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration
~68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
11176574|NCT03545152|No Intervention|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
11176575|NCT03545152|Experimental|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
11176576|NCT03545152|Experimental|cognitive training group|Consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
11176577|NCT03545139|Experimental|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
11176578|NCT03545139|Active Comparator|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
11176579|NCT03545126||Progressive Supranuclear Palsy (PSP)|N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
11176580|NCT03545126||Corticobasal Degeneration (CBD)|N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
11176581|NCT03545126||Frontotemporal Dementia: MAPT|N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
11176582|NCT03545113|Experimental|Upper extremity arteriovenous graft (AVG) - first|Participants randomized to receive an AVG will undergo surgery to have an AVG placed.
11176583|NCT03545113|Active Comparator|Upper extremity arteriovenous fistula (AVF) - first|Participants randomized to receive an AVF will undergo surgery to have an AVF created.
11176584|NCT03545100|Experimental|experimental group|motor control therapy
11176585|NCT03545100|Active Comparator|control group|regular physical therapy
11176586|NCT03545087|Experimental|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
11176587|NCT03545087|Experimental|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
11177061|NCT03541564|Placebo Comparator|Placebo Dose 4 oral administration|Placebo single dose
11176588|NCT03545074|Experimental|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston & Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
11176589|NCT03545074|Experimental|Mindfulness English|The MAPs program was developed at UCLA (Winston & Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
11176590|NCT03545074|Active Comparator|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
11176591|NCT03545074|Active Comparator|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
11176592|NCT03545048|Experimental|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.
~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.
~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
11176593|NCT03545048|No Intervention|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
11176594|NCT03545035||Study group|All patients being observed during the study duration.
11176595|NCT03545022|Active Comparator|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
11176596|NCT03545022|Placebo Comparator|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
11176597|NCT03545009|Experimental|Beetroot Juice|
11176598|NCT03545009|Active Comparator|Beetroot Juice no Nitrate|
11176599|NCT03545009|Active Comparator|Sodium Nitrate|
11176600|NCT03545009|No Intervention|Control|
11176601|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
11176602|NCT03544983|Experimental|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Counseling
11176603|NCT03544983|No Intervention|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
11176604|NCT03544944|Experimental|TJP-008-1|
11176605|NCT03544944|Experimental|TJP-008-2|
11176606|NCT03544944|Active Comparator|Coolprep powder|
11176607|NCT03544931|Experimental|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
11176818|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
11176608|NCT03544931|Active Comparator|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
11176609|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
11176610|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
11176611|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
11176612|NCT03544892|Experimental|Experimental: Low carbohydrate diet|
11176613|NCT03544892|Active Comparator|Experimental: Standard of care diet|
11176614|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
11176615|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
11176616|NCT03544853|Experimental|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
11176617|NCT03544840|Experimental|Dynamic Standing Device|Home program using the Upsee
11176618|NCT03544827|Experimental|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
11176619|NCT03544827|Experimental|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
11176620|NCT03544814|Experimental|Concurrent therapy group|Icotinib combined with pemetrexed plus cisplatin.
11176621|NCT03544814|Experimental|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
11176622|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
11176623|NCT03544801||control group,100|community population
11176624|NCT03544788|Experimental|Cirvo™ Therapy|
11176625|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
11176626|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
11176627|NCT03544762|Experimental|18F-FES PET|PET/CT
11176628|NCT03544749|Experimental|Ambu® AuraGain™ group|
11176629|NCT03544749|Active Comparator|I-gel group|
11176630|NCT03544736|Experimental|Cohort A|"Subjects having palliative radiotherapy towards esophageal tumor will receive concomitant therapy With Nivolumab i.v. 240mg Q2W, 360mg Q3W or 480mg Q4W, treatment to progression or up to 2 years of treatment.
~Radiotherapy: 2 Gy / day, (5 fx/week) to a total of 30 - 50 Gy at the decision of the responsible physician."
11176631|NCT03544736|Experimental|Cohort B|"Subjects receiving definitive chemoradiotherapy for esophageal cancer will receive concomitant therapy with Nivolumab 240mg Q2W, 360mg Q3W or 480mg Q4W, treatment to progression or up to 1 year of after radiotherapy.
~Chemotherapy: Paclitaxel i.v. 175mg/m2 and Carboplatin AUC5, then after 21 days Radiotherapy 1,8 Gy / day (5 fx/week) to 41,4 Gy and concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Nivolumab as described above."
11176632|NCT03544736|Experimental|Cohort C|"Subjects with operable esophageal cancer eligible for neoadjuvant chemoradiotherapy will receive Nivolumab 240mg Q2W, 360mg Q3W or 480mg Q4W, concomitant with neoadjuvant chemoradiotherapy and 1 year adjuvant after surgery.
~Neoadjuvant chemotherapy: Concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Radiotherapy: 41,4 Gy in 23 fractions."
11176633|NCT03544723|Experimental|Ad-p53 with anti-PD-1/anti-PD-L1 100% of patients|Up to 40 patients, all patients treated with intra-tumoral Ad-p53 (dose determined by tumor size) in combination with IV physician's choice of approved immune checkpoint inhibitor
11176634|NCT03544710|Experimental|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
11176635|NCT03544710|No Intervention|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.
~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
11176636|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
11176637|NCT03544684|Experimental|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
11176638|NCT03544684|Experimental|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
11176819|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
11176639|NCT03544684|Experimental|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
11176640|NCT03544671|Experimental|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
11176641|NCT03544671|Experimental|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
11176642|NCT03544671|Experimental|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
11176643|NCT03544671|Placebo Comparator|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
11176644|NCT03544658|Experimental|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
11176645|NCT03544645|Active Comparator|control group|"This group received a printed material brochure as an educational material"
11176646|NCT03544645|Experimental|intervention group|"This group received an audiovisual material video as an educational material"
11176647|NCT03544632|Experimental|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
11176648|NCT03544606|Experimental|isosorbide mononitrate group|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
11176649|NCT03544606|Placebo Comparator|placebos group|70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction
11176650|NCT03544580|Experimental|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments & scraping all enamel & cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant & thin buccal bone
11176651|NCT03544580|Active Comparator|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
11176652|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
11176653|NCT03544554|Experimental|Intervention group and control group|This research is planned with semi experimental design
11176654|NCT03544528|Experimental|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
11176655|NCT03544528|No Intervention|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
11176656|NCT03544515|Sham Comparator|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
11176657|NCT03544515|Experimental|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
11176658|NCT03544502|Experimental|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
11176659|NCT03544502|Experimental|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.
~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
11176660|NCT03544502|Placebo Comparator|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.
~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
11176661|NCT03544489|Experimental|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Digi-walker, Borg scale, and exercise logs), and 3) telephone coaching by clinic RNs. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months. Participants will record walking sessions each week in the exercise logs that will be collected again at 6 months.
11176720|NCT03543969|Experimental|BRAF-MEK Inhibitor Therapy|"Vemurafenib twice a day and cobimetinib daily, 3 weeks on / 2 weeks off / 3 weeks on, for an 8-week cycle.
~After 8 week cycle, response to these study drugs will be analyzed based on several parameters to determine if participants will proceed in the study.
~Participants will be invited for post-treatment follow-up visits for up to 5 years."
11176662|NCT03544489|No Intervention|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3 and 6 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3 and 6 months."
11176663|NCT03544476|Experimental|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
11176664|NCT03544476|Active Comparator|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
11176665|NCT03544463|Experimental|Treated|iNAP® Sleep Therapy System Treatment Intervention
11176666|NCT03544463|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline condition
11176667|NCT03544450|Experimental|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
11176668|NCT03544450|Active Comparator|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
11176669|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
11176670|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
11176671|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
11176672|NCT03544398|Active Comparator|exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
11176673|NCT03544398|Active Comparator|end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
11176674|NCT03544398|Placebo Comparator|conventional physiotherapy|
11176675|NCT03544385|Experimental|Treatment Group|
11176676|NCT03544385|Placebo Comparator|Placebo Group|
11176677|NCT03544359|Active Comparator|Active tES|
11176678|NCT03544359|Sham Comparator|Sham/Inactive tES|
11176679|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.
~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
11176680|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.
~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
11176681|NCT03544333|Experimental|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
11176682|NCT03544333|Placebo Comparator|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
11176683|NCT03544320|Active Comparator|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
11176684|NCT03544320|Active Comparator|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
11176685|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
11176686|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
11176687|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
11176688|NCT03544281|Experimental|Arm A: Belantamab mafodotin+lenalidomide +dexamethasone|"Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion.
~SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle.
~STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, & 22 of each cycle."
11176721|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
11176857|NCT03542968|Sham Comparator|2D magnetic resonance imaging|MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI
11176689|NCT03544281|Experimental|Arm B: Belantamab mafodotin+bortezomib+dexamethasone|Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 & 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 & 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 & so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, & so on). Bortezomib will be administered at 1.3 mg/m^2 SC/IV on Days 1,4,8, & 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, & 12 of every 21-day cycle.
11176690|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
11176691|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 15 participants will be recruited to aid in optimizing the imaging parameters.
11176692|NCT03544242|Active Comparator|Control group|
11176693|NCT03544242|Experimental|Pre-Isolation Infusion|
11176694|NCT03544242|Experimental|Post-Isolation Infusion|
11176695|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, twice daily (BID) for up to 12 weeks.
11176696|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, twice daily for up to 12 weeks.
11176697|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, twice daily for up to 12 weeks.
11176698|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily for up to 12 weeks.
11176699|NCT03544216|Experimental|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
11176700|NCT03544216|Experimental|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.
11176701|NCT03544177|Experimental|BFR-Walking|Interval walking training with blood flow restriction.
11176702|NCT03544177|Active Comparator|Conventional therapy|Conventional therapy
11176703|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
11176704|NCT03544125|Experimental|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
11176705|NCT03544112||ED and OUD treatment providers and staff|"ED patients will be recruited to participate in interviews or focus groups.
~ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.
~Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
11176706|NCT03544112||Community Stakeholders|"Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.
~Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
11176707|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
11176708|NCT03544099|Experimental|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
11176709|NCT03544086||test group|First group is the first 10 patients
11176710|NCT03544086||study group|following 150 patients
11176711|NCT03544073|Placebo Comparator|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
11176712|NCT03544073|Experimental|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
11176713|NCT03544047|Experimental|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
11176714|NCT03544034|No Intervention|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
11176715|NCT03544034|Experimental|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
11176716|NCT03544021|Experimental|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
11176717|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
11176718|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
11176722|NCT03543943|Experimental|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
11176723|NCT03543943|Active Comparator|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
11176724|NCT03543943|Active Comparator|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
11176725|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
11176726|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
11176727|NCT03543917|Experimental|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
11176728|NCT03543904|Experimental|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
11176729|NCT03543904|Experimental|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
11176730|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
11176731|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
11176732|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
11176733|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
11176734|NCT03543865|Experimental|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days.
~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
11176735|NCT03543865|Experimental|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days
~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
11176736|NCT03543865|Other|Control Condition|"The control condition will only receive Case Management (CM) (n=76).
~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
11176737|NCT03543865|Experimental|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
11176942|NCT03542344|Experimental|BI 1015550|
11176943|NCT03542344|Placebo Comparator|Placebo|
11176738|NCT03543852|Experimental|SurvivorLink|Participants receiving treatment at a pediatric cancer survivor clinic randomized to this study arm will receive education on how to use SurvivorLink, late effects of treatment, and survivorship care through the system.
11176739|NCT03543852|No Intervention|Usual care|Participants receiving treatment at a pediatric cancer survivor clinic randomized to the usual care study arm will receive the SurvivorLink intervention beginning at Month 12.
11176740|NCT03543839|Active Comparator|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
11176741|NCT03543839|Experimental|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
11176742|NCT03543839|Placebo Comparator|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
11176743|NCT03543826|Other|Protocol|Patients will have perioperative nuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed subjectively at adductor pollicis with standard train-of-four stimulation of the ulnar nerve.
11176744|NCT03543813|Experimental|CX-2029 Escalation|Dose Escalation and Determination
11176745|NCT03543813|Experimental|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
11176746|NCT03543813|Experimental|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
11176747|NCT03543800|Experimental|ABP|(test treatment)
11176748|NCT03543800|Active Comparator|PRP|(active control)
11176749|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
11176750|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
11176751|NCT03543774|Active Comparator|simvastatin treatment|
11176752|NCT03543774|Sham Comparator|EZE/simvastatin 10/20 mg treatment|
11176753|NCT03543774|Sham Comparator|EZE/simvastatin 10/40 mg treatment|
11176754|NCT03543761|Sham Comparator|A|Sham group
11176755|NCT03543761|Active Comparator|B|LiST active treatment group
11176756|NCT03543761|Active Comparator|C|LiST active treatment group
11176757|NCT03543748|Experimental|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
11176758|NCT03543748|Sham Comparator|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
11176759|NCT03543735|Experimental|Wisepill+SMS|
11176760|NCT03543735|Active Comparator|Wisepill-only|
11176761|NCT03543735|No Intervention|Disulfiram-only|
11176762|NCT03543722|Experimental|National Career Coach Program|This program has four main components: a 4-day in-person introductory seminar held in Alpharetta, GA, up to 18 months of job coaching provided by telephone and Skype, a human capital fund to pay for expenses of securing a job (e.g., travel, clothing, computers, professional organization fees), and an opportunity for two years to earn a bonus for employment earnings above a certain level.
11176763|NCT03543722|Active Comparator|Local Community Resources Program|Consists of referral to three local face-to-face service providers offering veterans training, financial assistance, and paid work experiences: The Department of Veterans Affairs Compensated Work Therapy Program, the state Vocational Rehabilitation program, and the Department of Labor America's Job Center.
11176764|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
11176765|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
11176766|NCT03543696|Experimental|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
11176767|NCT03543683||osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
11176768|NCT03543683||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
11176769|NCT03543670|Experimental|Oncoxin-Viusid|
11176770|NCT03543657|Experimental|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
11176771|NCT03543657|Active Comparator|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
11176772|NCT03543644|Active Comparator|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
11176773|NCT03543644|Experimental|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
11176774|NCT03543644|Experimental|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
11176775|NCT03543618|Sham Comparator|Control|Installation of conventional design dental implant
11176776|NCT03543618|Active Comparator|Sloped|Installation of sloped design dental implant
11176816|NCT03543202|Sham Comparator|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
11176817|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
11176777|NCT03543605|Experimental|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.
~The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.
~These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.
~They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.
~The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
11176778|NCT03543605|Other|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:
~Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.
~Presentation of the project by the local team in its own center.
~Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.
~Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).
~Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
11176779|NCT03543592|Other|3 dimensional power Doppler|100 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study and 3 dimensional ultrasonography and Doppler will be done for them
11176780|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
11176781|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
11176782|NCT03543553||HC|Healthy control participants
11176783|NCT03543540|Experimental|Nexvax2 (Arm A)|
11176784|NCT03543540|Experimental|Nexvax2 (Arm B)|
11176785|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm C)|
11176786|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm D)|
11176787|NCT03543527||Takayashu|
11176788|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
11176789|NCT03543501|Experimental|Real-time ultrasound imaging group|See intervention
11176790|NCT03543501|Experimental|PBU group|See intervention
11176791|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
11176792|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
11176793|NCT03543475|Experimental|Pessary|Silicon device applied on the cervix
11176794|NCT03543475|Active Comparator|No Pessary|standard care, no pessary
11176795|NCT03543462|Sham Comparator|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
11176796|NCT03543462|No Intervention|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
11176797|NCT03543436|Experimental|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)
11176798|NCT03543436|Active Comparator|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
11176799|NCT03543423|Experimental|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
11176800|NCT03543423|Experimental|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
11176801|NCT03543410|Experimental|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
11176802|NCT03543410|Experimental|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
11176803|NCT03543410|Placebo Comparator|Placebo|Placebo (supplied in two tablets/day
11176804|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
11176805|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
11176806|NCT03543358|Experimental|Arm A|Arm A includes subjects who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per subject per retreatment period.
11176807|NCT03543358|Experimental|Arm B|Arm B includes subjects who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
11176808|NCT03543332||Cardiac arrest|
11176809|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
11176810|NCT03543267|Experimental|epilectic Patients|
11176811|NCT03543254|Experimental|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
11176812|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
11176813|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
11176814|NCT03543202|Experimental|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
11176815|NCT03543202|Active Comparator|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
11176820|NCT03543163|Active Comparator|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
11176821|NCT03543163|Experimental|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
11176822|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
11176823|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
11176824|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
11176825|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
11176826|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
11176827|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
11176828|NCT03543111|No Intervention|Control|No intervention
11176829|NCT03543098|Experimental|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
11176830|NCT03543098|Experimental|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
11176831|NCT03543098|Experimental|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
11176832|NCT03543098|Experimental|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
11176833|NCT03543098|Experimental|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
11176834|NCT03543098|Experimental|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
11176835|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
11176836|NCT03543072||exposure group|exposed to some factors
11176837|NCT03543072||control group|not exposed to some factors
11176838|NCT03543059||exposure group|exposed to some factors
11176839|NCT03543059||control group|not exposed to some factors
11176840|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
11176841|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
11176842|NCT03543033|Experimental|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
11176843|NCT03543033|No Intervention|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
11176844|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
11176845|NCT03542994|Other|Cohort 1|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days
11176846|NCT03542994|Other|Cohort 2|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days
11176847|NCT03542994|Other|Cohort 3|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days
11176848|NCT03542994|Other|Cohort 4|12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days
11176849|NCT03542994|Other|Cohort 5|24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days
11176850|NCT03542994|Other|Cohort 6|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
~Dose=up to a maximum of 660 mg, capsule, once daily, 29 days"
11176851|NCT03542994|Other|Cohort 7|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
11176852|NCT03542994|Other|Cohort 8|up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days
11176853|NCT03542994|Other|Cohort 9|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.
~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
11176854|NCT03542981|Active Comparator|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
11176855|NCT03542981|Sham Comparator|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
11176856|NCT03542968|Experimental|4D magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
11178501|NCT03531879||subject with plaques and without plaques|Subject with plaques and without plaques
11176858|NCT03542955|Active Comparator|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
11176859|NCT03542955|Placebo Comparator|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
11176860|NCT03542942|Other|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
11176861|NCT03542929|Active Comparator|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
11176862|NCT03542929|Experimental|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
11176863|NCT03542916|Experimental|CJ-40001|CJ-40001 60ug SC, IV injection
11176864|NCT03542916|Active Comparator|NESP|NESP 60ug SC, IV injection
11176865|NCT03542903|Active Comparator|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
11176866|NCT03542903|Active Comparator|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
11176867|NCT03542890|Active Comparator|Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
11176868|NCT03542890|Active Comparator|I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
11176869|NCT03542877|Experimental|Stage 1|Up to 16 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
11176870|NCT03542877|Experimental|Stage 2|Up to 28 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks.
11176871|NCT03542864|Experimental|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
11176872|NCT03542864|Active Comparator|Controls|Change from Baseline Body Composition values at 1 and 3 months
11176873|NCT03542864|Other|Data analysis|Analysis and publication of data
11176874|NCT03542851|Experimental|Subject Receives BTD001 first|
11176875|NCT03542851|Experimental|Subject Receives Placebo first|
11176876|NCT03542838|Experimental|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at a dose level of 5ug, 12.5ug, 20ug, 25ug, or 30ug.
11176877|NCT03542838|Placebo Comparator|Saline|Saline is administered as a one-time dose, intra-articularly.
11176878|NCT03542825|Active Comparator|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
11176879|NCT03542825|Active Comparator|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
11176880|NCT03542825|Active Comparator|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
11176881|NCT03542812|Experimental|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.
~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
11176882|NCT03542812|Experimental|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
11176883|NCT03542799|Experimental|3|anti-tumor response of EGFR IL12 CART
11176884|NCT03542786|Experimental|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
11176885|NCT03542786|Experimental|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
11176886|NCT03542786|Placebo Comparator|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
11176887|NCT03542773|Experimental|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
11176888|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels > 30%.
11176889|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
11176890|NCT03542747|Experimental|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
11176891|NCT03542747|Experimental|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
11176944|NCT03542331|Other|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
11176892|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
11176893|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
11176894|NCT03542721|Placebo Comparator|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
11176895|NCT03542721|Experimental|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
11176896|NCT03542708|Experimental|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma.
11176897|NCT03542708|No Intervention|Control|The contralateral ovary will not be injected.
11176898|NCT03542695|Experimental|Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)|Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.
11176899|NCT03542682|Active Comparator|Individuals given Standard Bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
11176900|NCT03542682|Active Comparator|Individuals given Quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
11176901|NCT03542669|Other|6B11-OCIK injection|A total of 5 cycles of cell infusion were performed, respectively at about D1, D6, D11, D25 and D39. 6B11-OCIK for the 1st - 3rd infusion was prepared by once collection of peripheral lymphocytes. For the fourth and fifth time, sufficient peripheral lymphocytes was collected respectively.
11176902|NCT03542656|Experimental|amyloid PET|PET/CT
11176903|NCT03542643|Active Comparator|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
11176904|NCT03542643|Placebo Comparator|Placebo|olive oil ethyl esters
11176905|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.
~Interventions:
~salivary MMP8 test; periodontal examination; blood tests"
11176906|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.
~Interventions:
~salivary MMP8 test;periodontal examination;blood tests"
11176907|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.
~Interventions:
~salivary MMP8 test; periodontal examination;blood tests"
11176908|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.
~Interventions:
~salivary MMP8 test; periodontal examination; blood tests"
11176909|NCT03542617|Placebo Comparator|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
11176910|NCT03542617|Active Comparator|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
11176911|NCT03542617|Active Comparator|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
11176912|NCT03542604|Experimental|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
11176913|NCT03542604|Placebo Comparator|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
11176914|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
11176915|NCT03542565|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11176916|NCT03542565|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11176917|NCT03542552|Active Comparator|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
11176918|NCT03542552|Experimental|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
11176919|NCT03542500|No Intervention|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
11176920|NCT03542500|Experimental|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
11176921|NCT03542500|Experimental|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
11176922|NCT03542487|No Intervention|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
11176992|NCT03542084|No Intervention|Control|Control arm patients will receive usual care
11176923|NCT03542487|Experimental|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
11176924|NCT03542487|Experimental|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
11176925|NCT03542487|Experimental|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
11176926|NCT03542487|Experimental|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
11176927|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
11176928|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
11176929|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
11176930|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:
~Age into 3 groups:
~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: > 40 years old
~Axial length into 3 groups:
~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: > 26 mm
~Spherical equivalent of refractive error into :
~Group A : from zero to - 2 D Group B : from - 2 to > - 4 D Group C : from - 4 to > - 6 D Group D: from - 6 to - 8 D
~Minimum corneal thickness (MCT) into 3 groups:
~Group i: < 500 um Group ii: from 500 to 540 um Group iii: > 540 um
~Refractive power of cornea (Mean K) into 3 groups:
~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: > 46 D"
11176931|NCT03542435|Experimental|SXC-2023|Dose Escalation
11176932|NCT03542435|Placebo Comparator|Placebo|Dose Escalation
11176933|NCT03542422|Experimental|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
11176934|NCT03542409|Experimental|Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
11176935|NCT03542409|Experimental|Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
11176936|NCT03542396|Experimental|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
11176937|NCT03542396|No Intervention|Control|Participants do not receive any intervention. Participants receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual psychotherapeutic treatment
11176938|NCT03542383|Active Comparator|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
11176939|NCT03542383|Sham Comparator|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
11176940|NCT03542357|Active Comparator|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
11176941|NCT03542357|Placebo Comparator|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
11176945|NCT03542331|Experimental|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
11176946|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
11176947|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
11176948|NCT03542305|Experimental|Mild|Mild renal impairment
11176949|NCT03542305|Experimental|Moderate|Moderate renal impairment
11176950|NCT03542305|Experimental|Severe|Severe renal impairment
11176951|NCT03542305|Other|Normal|Normal renal function
11176952|NCT03542292|Experimental|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
11176953|NCT03542292|Active Comparator|no placental drainage group|In control group the umblical cord was clamped both sides.
11176954|NCT03542279|Experimental|Early PE group|PE (3-5 times in each course) combined with high-dose glucocorticoid, and IVIG after PE.
11176955|NCT03542279|Active Comparator|Non-early PE group|IVIG (0.4 g/kg/d for each course for 5 d) combined with high-dose glucocorticoid, and PE after IVIG 2 weeks.
11176956|NCT03542266|Experimental|CC486 +CHOP|CC486 +CHOP
11176957|NCT03542253||Age|
11176958|NCT03542253||Sex|
11176959|NCT03542253||triglyceride|
11176960|NCT03542253||Lipoprotein|
11176961|NCT03542253||CT|Target Reconstruction
11176962|NCT03542253||micorRNA-A Plasma exocrine|
11176963|NCT03542253||micorRNA-A Paracancerous tiusse|
11176964|NCT03542253||pathologic diagnosis|
11176965|NCT03542253||hemolysis|
11176966|NCT03542253||ct-DNA|
11176967|NCT03542253||micorRNA-A in plasma|
11176968|NCT03542253||Sample quality control|
11176969|NCT03542253||positive|
11176970|NCT03542253||negative|
11176971|NCT03542253||micorRNA-R in plasma|
11176972|NCT03542253||micorRNA-R in Plasma exocrine|
11176973|NCT03542253||Surgery|
11176974|NCT03542240|Experimental|Curcumin|
11176975|NCT03542214|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
11176976|NCT03542201|Experimental|PLS|Plain abstract about the Cochrane systematic review.
11176977|NCT03542201|Experimental|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
11176978|NCT03542188|Active Comparator|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
11176979|NCT03542188|Experimental|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-trombolysis and early EVT.
11176980|NCT03542175|Experimental|Rucaparib Administered With Radiation|"Treatment will consist of rucaparib at one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
~Radiotherapy will consist of 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician."
11176981|NCT03542162|Experimental|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
11176982|NCT03542149|Experimental|A|"200mg of OZ439 and 480 mgPQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
11176983|NCT03542149|Experimental|B|"200mg of OZ439 and 640 mg PQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
11176984|NCT03542149|Experimental|C|"400mg of OZ439 and 480 mg PQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
11176985|NCT03542149|Experimental|D|"400mg of OZ439 and 640 mg PQP.
~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).
~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
11176986|NCT03542136|Other|Patients receiving chemotherapy treatment with oxaliplatin.|
11176987|NCT03542123|Experimental|NeuroTronik CANS Therapy® System|
11176988|NCT03542110|Active Comparator|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
11176989|NCT03542110|Placebo Comparator|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
11176990|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
11176991|NCT03542084|Experimental|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
11178535|NCT03531645|Experimental|Fulvestrant + Abemaciclib|
11176993|NCT03542071|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
11176994|NCT03542071|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
11176995|NCT03542058|Experimental|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
11176996|NCT03542058|No Intervention|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
11176997|NCT03542032|Other|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.
~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.
~Patients' postoperative sore throat will be questioned and recorded."
11176998|NCT03542032|No Intervention|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.
~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.
~Patients' postoperative sore throat will be questioned and recorded."
11176999|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
11177000|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
11177001|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
11177002|NCT03542006|Experimental|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
11177003|NCT03541993|Experimental|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
11177004|NCT03541993|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
11177005|NCT03541993|Experimental|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
11177006|NCT03541993|Placebo Comparator|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
11177007|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
11177008|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
11177009|NCT03541967|Other|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
11177010|NCT03541967|Other|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
11177011|NCT03541954|Other|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria > 5)
11177012|NCT03541954|Other|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria < 5)
11177013|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
11177014|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
11177015|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
11177016|NCT03541928|Experimental|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.
~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).
~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).
~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
11177017|NCT03541915|Experimental|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
11177018|NCT03541915|Placebo Comparator|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
11177019|NCT03541902|Experimental|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11177020|NCT03541902|Experimental|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11177021|NCT03541889|Experimental|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
11177022|NCT03541889|Experimental|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
11177023|NCT03541876||children with H. pylori infection|
11177024|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
11177025|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
11177026|NCT03541850|Experimental|Treatment (SBRT, ADT)|Patients undergo SBRT QOD for 14 days. Patients may also receive ADT comprised of a luteinizing hormone-releasing hormone agonist or a gonadotropin-releasing hormone antagonist, and an oral anti-androgen for 6 months at the discretion of the treating physician.
11177027|NCT03541837|Other|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
11177028|NCT03541824|Experimental|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
11177029|NCT03541824|No Intervention|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
11177030|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
11177031|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
11177032|NCT03541798|Active Comparator|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
11177033|NCT03541798|Experimental|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.
~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
11177034|NCT03541798|Experimental|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .
~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
11177035|NCT03541772|Experimental|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
11177036|NCT03541772|Placebo Comparator|Placebo|Radiotherapy + Chemotherapy + Placebo
11177037|NCT03541759|Active Comparator|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) > 5.
11177038|NCT03541759|Active Comparator|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) > 5.
11177039|NCT03541746|Experimental|Study Group|Platelet Rich Plasma
11177040|NCT03541746|Active Comparator|Control Group|Intrauterine Foley's Catheter
11177041|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
11177042|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
11177043|NCT03541720|Experimental|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
11177044|NCT03541707|Active Comparator|Active Therapy|
11177045|NCT03541707|Sham Comparator|"As if Stimulation"|
11177046|NCT03541681|Active Comparator|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
11177047|NCT03541681|Active Comparator|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
11177048|NCT03541668|Experimental|Group A|Recombinant human urokinase (rhPro-UK)
11177049|NCT03541668|Active Comparator|Group B|Alteplase(rt-PA)
11177050|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
11177051|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
11177052|NCT03541642|Experimental|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
11177053|NCT03541642|Active Comparator|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
11177054|NCT03541616||Enrolled Patients|
11177055|NCT03541603|Experimental|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
11177056|NCT03541603|Placebo Comparator|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
11177057|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
11177058|NCT03541564|Experimental|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
11177062|NCT03541551|Experimental|CTT with ologen® Collagen Matrix|Experimental: Trabeculotomy with trabeculectomy with ologen implant
11177063|NCT03541551|Active Comparator|Trab Trab|Active Comparator: Trabeculotomy with trabeculectomy
11177064|NCT03541538|Active Comparator|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
11177065|NCT03541538|Experimental|Especific manipulation|manual therapy performed specifically on the C6-7 segment
11177066|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
11177067|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
11177068|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
11177069|NCT03541512|Active Comparator|Education only|Educational materials only
11177070|NCT03541499|Experimental|Group 1|800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
11177071|NCT03541499|Experimental|Group 2|800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
11177072|NCT03541499|Placebo Comparator|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
11177073|NCT03541499|Experimental|Group 4|800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
11177074|NCT03541486|Experimental|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
11177075|NCT03541486|Active Comparator|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
11177076|NCT03541473|Active Comparator|Peptamen® 1.5 Vanilla|
11177077|NCT03541473|Placebo Comparator|Boost Plus® Vanilla|
11177078|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
11177079|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
11177080|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
11177081|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
11177082|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
11177083|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
11177084|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
11177085|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
11177086|NCT03541421|Experimental|Intervention|The patients administers own drugs during hospital stay.
11177087|NCT03541421|No Intervention|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
11177088|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
11177089|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable
~Minimized fentanyl usage intraoperatively
~Intubation + GA adjunct total: 1-2 mcg/kg
~Sedation: 0-0.25 mcg/kg
~Post-op: 0.5-1 mcg/kg
~Avoid morphine
~Avoid ketamine
~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine
~Avoid H2-blockers (cimetidine, ranitidine, famotidine)
~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)
~Fluid repletion based on maintenance and losses"
11177090|NCT03541395|Other|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
11177091|NCT03541382|Active Comparator|HIVST campaign arm|Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.
11177092|NCT03541382|No Intervention|SOC arm|Standard HTS will be provided by MoH at health facilities.
11177093|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
11177094|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
11177095|NCT03541356|Placebo Comparator|Placebo|
11177096|NCT03541356|Active Comparator|L-dopa 35 mg|
11177097|NCT03541356|Active Comparator|L-dopa 70 mg|
11177098|NCT03541356|Active Comparator|L-dopa 140 mg|
11177099|NCT03541356|Active Comparator|L-dopa 70 mg/carbidopa 7 mg|
11177100|NCT03541343|Experimental|GreenBone|All patients will receive the GreenBone implant instead of bovine xenograft.
11177101|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
11178827|NCT03529773|Experimental|Expanded Arm 9|Mid dose formulation A and SIIV
11177102|NCT03541317|Experimental|Step 1: Optimal First Line Implementation Strategy|"All schools enrolled will first be randomized to an optimal first line treatment in order to compare REP vs. REP + Coaching. Schools assigned to Step 1 treatment REP will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation. Schools assigned to Step 1 treatment REP + Coaching will receive the REP components plus weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
11177103|NCT03541317|Experimental|Step 2: Added Value of Providing Facilitation|"After 2 months, schools will be assessed to determine whether they could benefit from augmenting their current strategy with a step-up strategy called Facilitation. Schools identified as potentially benefiting will be re-randomized to compare the added value of augmenting their current strategy with Facilitation, compared to continuing with their same strategy. Step 2 treatment strategy: step-up will include provision of an additional implementation strategy called Facilitation. A full-time Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support school professionals in strategic thinking and leadership skills to address organizational barriers. Sites receiving Facilitation will receive regular calls for up to a minimum of 10 weeks from the Facilitator. All schools will also continue to receive their first line treatment (i.e. REP or REP + Coaching)."
11177104|NCT03541291|Experimental|SMART-SYNC LM02|All participants
11177105|NCT03541278|Experimental|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
11177106|NCT03541265|Experimental|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
11177107|NCT03541265|Active Comparator|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
11177108|NCT03541252|Experimental|Basal Cell Carcinoma Patients|Patients (>18 years) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on the face/scalp, <50mm on the trunk/extremities)
11177109|NCT03541239|Active Comparator|non-ischemic preconditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation by the Single Cuff Tourniquet 8000 to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
11177110|NCT03541239|Experimental|ischemic preconditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Single Cuff Tourniquet 8000, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
11177111|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.
~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
11177112|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.
~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
11177113|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).
~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
11177114|NCT03541200|Experimental|Open Label|MT-8554
11177115|NCT03541187|Experimental|G. cockroach allergenic extract - Part A|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm. An interim analysis will be conducted when all Part A participants have completed their 12-month NAC. If an effect is seen for the Part A NAC analysis, the study will proceed to Part B.
~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
11177116|NCT03541187|Placebo Comparator|Placebo- Part A|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm. An interim analysis will be conducted when all Part A participants have completed their 12-month NAC. If an effect is seen for the Part A NAC analysis, the study will proceed to Part B.
~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
11177117|NCT03541187|Experimental|G. cockroach allergenic extract-Part B|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 110 participants 6 to 16 years of age who are sensitized to cockroach and have asthma will be randomized to this treatment arm. In contrast to Part A, a positive NAC will not be required for inclusion into Part B treatment.
~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
11177118|NCT03541187|Placebo Comparator|Placebo- Part B|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 110 participants 6 to 16 years of age who are sensitized to cockroach and have asthma will be randomized to this treatment arm. In contrast to Part A treatment, a positive NAC will not be required for inclusion into Part B treatment.
~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 24 months and up to a maximum of 36 months."
11177119|NCT03541174|Experimental|Aprocitentan 25 mg DB|Part 1: Double-blind, randomized (1:1:1 ratio), parallel-group and placebo-controlled and lasts for 4 weeks. Subjects will receive aprocitentan 25 mg
11177120|NCT03541174|Experimental|Aprocitentan 12.5 mg DB|Part 1: Double-blind, randomized (1:1:1 ratio), parallel-group and placebo-controlled and lasts for 4 weeks. Subjects will receive aprocitentan 12.5 mg
11177121|NCT03541174|Placebo Comparator|Placebo DB|Part 1: Double-blind, randomized (1:1:1 ratio), parallel-group and placebo-controlled and lasts for 4 weeks. Subjects will receive placebo
11177122|NCT03541174|Experimental|Aprocitentan 25 mg SB|Part 2: Single-blind and single-arm, lasts for 32 weeks. All subjects will receive aprocitentan 25 mg.
11177123|NCT03541174|Experimental|Aprocitentan 25 mg DB-WD|Part 3: Double-blind withdrawal. Subjects will be re-randomized to aprocitentan 25 mg
11177124|NCT03541174|Placebo Comparator|Placebo DB-WD|Part 3: Double-blind withdrawal. Subjects will be re-randomized to placebo.
11177125|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
11177126|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
11177127|NCT03541148|Experimental|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
11177128|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
11177129|NCT03541109|Experimental|Polypill|Polypill group will receive a fixed dose combinations of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg), prescribed once daily by moth for 34 months
11177130|NCT03541109|No Intervention|Control|The usual care arm will receive regular drug order at the time of discharge from the hospital.
11177131|NCT03541096|Experimental|Winter Swimmers|4 Months of supervised winter swimming.
11177132|NCT03541096|Placebo Comparator|Control group|No winter swimming activities.
11177133|NCT03541083|Experimental|Blinatumomab|After a 5-day steroid prephase patients will receive two weeks continuous infusion of blinatumomab. Then the first remission-induction course will be given after one week interruption. Subsequent therapy with 4 cycles of chemotherapy and two 4-week courses of blinatumomab will follow, and subsequently depending on risk group, eligibility and a suitable donor either allogeneic stem cell transplantation or 2 year maintenance treatment.
11177134|NCT03541070|Experimental|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
11177135|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
11177136|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
11177137|NCT03541031|Experimental|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
11177138|NCT03541031|Placebo Comparator|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
11177139|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
11177140|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
11177141|NCT03541005|Experimental|Obex|a nutritional supplement Obex® 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
11177142|NCT03541005|Placebo Comparator|Placebo|Placebo 8 g daily by oral route divided into two doses of 4g (between 15 and 20 minutes before lunch and dinner) diluted in water or juice for 6 months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
11177143|NCT03540979|Active Comparator|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
11177169|NCT03540810|Active Comparator|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
11195671|NCT03414931|Placebo Comparator|Placebo|Placebo
11177144|NCT03540979|Experimental|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
11177145|NCT03540966|Experimental|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
11177146|NCT03540966|Placebo Comparator|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
11177147|NCT03540953|Other|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
11177148|NCT03540940|Experimental|zero positive end expiratory pressure|
11177149|NCT03540940|Experimental|Positive end expiratory pressure|
11177150|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
11177151|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
11177152|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177153|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
11177154|NCT03540901|Active Comparator|ACETAZOLAMIDE oral capsule|375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m
11177155|NCT03540901|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3100m until the morning after the second night at 3100m.
11177156|NCT03540888|Experimental|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
11177157|NCT03540888|Active Comparator|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
11177158|NCT03540888|Active Comparator|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
11177159|NCT03540875|Experimental|Full automation group|Full automation control of propofol and remifentanil
11177160|NCT03540875|Other|Control group|Manual control of of propofol and remifentanil using TCI system
11177161|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging -20 to -30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
11177162|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
11177163|NCT03540849|Experimental|BV after allogeneic hematopoietic stem cell transplantation|
11177164|NCT03540836|Experimental|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
11177165|NCT03540836|Experimental|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
11177166|NCT03540836|Experimental|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
11177167|NCT03540823|Experimental|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
11177168|NCT03540823|Other|Healthy controls|Healthy children and adults
11177341|NCT03539770||Control|Children without scoliosis
11177170|NCT03540810|Placebo Comparator|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
11177171|NCT03540797||Intensive care unit (ICU) patients with sepsis|
11177172|NCT03540784|No Intervention|Control group|usual care treatment
11177173|NCT03540784|Experimental|Nutrition|high-protein nutrition therapy
11177174|NCT03540784|Experimental|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
11177175|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
11177176|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
11177177|NCT03540758|Experimental|Non-diabetic (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants.
11177178|NCT03540758|Placebo Comparator|Non-diabetic (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to non-diabetic participants.
11177179|NCT03540758|Experimental|T2D (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants.
11177180|NCT03540758|Placebo Comparator|T2D (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
11177181|NCT03540758|Experimental|T2D (Diazoxide + Nicotinic Acid)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion.
11177182|NCT03540758|Experimental|T2D (Nicotinic Acid Only)|Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in type 2 diabetic participants.
11177183|NCT03540745|Experimental|TES Treatment|Where subject is randomized to TES.
11177184|NCT03540745|Placebo Comparator|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
11177185|NCT03540732|No Intervention|1. Control|"Standard physiotherapy
~Empiric formula directed feeding (daily caloric requirement calculated by 25 kcal/kg/day)"
11177186|NCT03540732|Active Comparator|2. Intervention|"Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
~Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)"
11177187|NCT03540706|Experimental|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
11177188|NCT03540706|No Intervention|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
11177189|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
11177190|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
11177191|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
11177192|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
11177193|NCT03540693||Weight-loss failure|Subjects who lost <25% body weight (or lost more but then regain weight so that now are at <25%) by 2-5 years post-surgery
11177194|NCT03540680|Other|Term newborns (≥37GA)|Blood punction on the cordon
11177195|NCT03540680|Other|Premature newborns|Blood punction on the cordon
11177196|NCT03540680|Other|Child between 7 and 15 years old with BPD|Blood punction
11177197|NCT03540680|Other|Child between 7 and 15 years old without BPD|Blood punction
11177198|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
11177199|NCT03540654||Patients with CML discontinuing TKI treatment|
11177200|NCT03540641|Active Comparator|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
11177201|NCT03540641|Sham Comparator|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
11177202|NCT03540641|Active Comparator|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
11177203|NCT03540641|Sham Comparator|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
11177204|NCT03540628|No Intervention|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
11177205|NCT03540628|Experimental|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
11177206|NCT03540615|Experimental|BAY1830839|Single Dose escalations
11177207|NCT03540615|Placebo Comparator|Placebo|Matching Placebo
11177208|NCT03540602|Placebo Comparator|Placebo|Rice flour capsule
11177209|NCT03540602|Active Comparator|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
11177210|NCT03540589|Experimental|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
11178828|NCT03529773|Experimental|Expanded Arm 10|High dose formulation A and SIIV
11177211|NCT03540589|Experimental|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
11177212|NCT03540589|Experimental|Distraction plus vibration|Combination of the two interventions described above
11177213|NCT03540589|No Intervention|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
11177214|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
11177215|NCT03540550|Experimental|Dietary intervention|
11177216|NCT03540537|Other|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
11177217|NCT03540537|Experimental|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
11177218|NCT03540537|Experimental|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
11177219|NCT03540537|Other|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
11177220|NCT03540537|Experimental|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
11177221|NCT03540537|Experimental|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
11177222|NCT03540524|Experimental|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
11177223|NCT03540524|Experimental|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
11177224|NCT03540524|Experimental|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
11177225|NCT03540498|Experimental|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
11177226|NCT03540498|Placebo Comparator|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
11177227|NCT03540485|Experimental|Melatonin|Daily administration of 300 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
11177228|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
11177229|NCT03540472|Experimental|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.
~Medication time should last at least 6 months."
11177230|NCT03540446|Experimental|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
11177231|NCT03540446|Experimental|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
11177232|NCT03540446|Experimental|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)
11177233|NCT03540433||Study group|Surgical patients aged ≥70 years
11177234|NCT03540433||Control group|Healthy subjects, aged ≥70 years, American Society of Anesthesiologists (ASA) I+II+III, no surgery
11177235|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
11177236|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
11177237|NCT03540407|Experimental|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
11177238|NCT03540407|Placebo Comparator|Placebo|will receive a Placebo concomitant to the onco-specific treatment
11177239|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
11177240|NCT03540381||Not-identified neoatherosclerosis group|
11177241|NCT03540368|Experimental|Tranexamic acid injection|Group with tranexamic acid injection
11177242|NCT03540368|Placebo Comparator|Placebo|Group with Placebo
11177395|NCT03539315|No Intervention|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
11177243|NCT03540355|Experimental|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:
~1 tablet Cipros 20 association; and
~1 tablet crestor placebo. Oral, once a day"
11177244|NCT03540355|Active Comparator|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:
~1 tablet Crestor 20 mg; and
~1 tablet cipros association placebo. Oral, once a day"
11177245|NCT03540342|Experimental|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
11177246|NCT03540342|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
11177247|NCT03540329|Active Comparator|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
11177248|NCT03540329|Active Comparator|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
11177249|NCT03540329|Active Comparator|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
11177250|NCT03540329|Active Comparator|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
11177251|NCT03540329|Active Comparator|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
11177252|NCT03540329|Active Comparator|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
11177253|NCT03540329|Active Comparator|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
11177254|NCT03540329|Active Comparator|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
11177255|NCT03540316|Active Comparator|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
11177256|NCT03540316|Active Comparator|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
11177257|NCT03540316|Active Comparator|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
11177258|NCT03540316|Active Comparator|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
11177259|NCT03540303|Experimental|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
11177260|NCT03540290|Active Comparator|Mechanical instrumentation and oral hygiene instructions|
11177261|NCT03540290|Experimental|Modification of the implant supported prostheses|
11177262|NCT03540277|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
11177263|NCT03540277|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
11177264|NCT03540277|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
11177265|NCT03540264|Active Comparator|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Clearfil Majesty will be used in the present study.
11177266|NCT03540264|Active Comparator|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
11177267|NCT03540251|Active Comparator|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
11177268|NCT03540251|Sham Comparator|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
11177269|NCT03540225|Experimental|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
11177270|NCT03540225|Experimental|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
11177271|NCT03540225|Experimental|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
11177272|NCT03540225|Experimental|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
11177273|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir
~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
11177274|NCT03540199|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11178829|NCT03529773|Experimental|Expanded Arm 11|Low dose formulation B and SIIV
11177275|NCT03540199|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11177276|NCT03540199|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11177277|NCT03540186|Experimental|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
11177278|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p<0.1) were included in multivariate analysis.
11177279|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
11177280|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
11177281|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
11177282|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
11177283|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
11177284|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
11177285|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
11177286|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
11177287|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
11177288|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
11177289|NCT03540108|Experimental|Experimental: L. plantarum ECGC 13110402 (LPLDL®)|Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
11177290|NCT03540108|Placebo Comparator|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
11177291|NCT03540095|Experimental|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
11177292|NCT03540095|Experimental|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
11177293|NCT03540082|Active Comparator|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
11177294|NCT03540082|No Intervention|Control|Written instructions will be provided on the correct way to fall without physical practice.
11177295|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
11177296|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
11177297|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
11177298|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
11177299|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
11177300|NCT03540043|Placebo Comparator|Placebo|Administration of Placebo
11177301|NCT03540043|Experimental|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
11177302|NCT03540043|Experimental|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
11177303|NCT03540043|Experimental|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
11177304|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
11177305|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
11177306|NCT03540017|Experimental|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
11177307|NCT03539991|Experimental|Supportive care (online course, virtual meeting)|Participants complete an online course focusing on different aspects of tobacco prevention and cessation over 1 hour each per week for 4 weeks. They also engage in 6 virtual meetings over 1 hour about tobacco use once per month.
11177308|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
11177309|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
11177310|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
11177311|NCT03539952|Experimental|TETA 4HCL|Active Treatment
11177312|NCT03539952|Experimental|Penicillamine|Comparator: Penicillamine
11177313|NCT03539939|Experimental|Smoker Group|This group included smoker gingival recession patients.
11177314|NCT03539939|Active Comparator|Non-smoker Group|This group included non-smoker gingival recession patients.
11177315|NCT03539926|Experimental|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
11177316|NCT03539926|Placebo Comparator|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
11177317|NCT03539913|Active Comparator|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
11177318|NCT03539913|Active Comparator|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
11177319|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
11177320|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
11177321|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
11177322|NCT03539887|Experimental|Intranasal ketamine in alcohol abuse|Intranasal ketamine
11177323|NCT03539887|Placebo Comparator|Placebo|non-active placebo
11177324|NCT03539887|Placebo Comparator|Placebo in alcohol abuse|non-active placebo
11177325|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
11177326|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
11177327|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
11177328|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:
~Treatment 1 will be standard hemodialysis (no device).
~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
11177329|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
11177330|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
11177331|NCT03539835|Experimental|Resistance training|
11177332|NCT03539835|Active Comparator|Cognitively-based compassion training|
11177333|NCT03539822|Experimental|Cabozantinib combined with Durvalumab|"Cabozantinib
~By mouth (PO) once daily on days 1-28 of every 28 day cycle
~Dose will be 60mg
~Durvalumab
~*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle"
11177334|NCT03539809|Experimental|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
11177335|NCT03539796|Experimental|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
11177336|NCT03539796|Active Comparator|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
11177337|NCT03539796|Active Comparator|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
11177338|NCT03539783||PARDS|Children <18 years of age with PARDS and expected duration of hospitalization seven days or greater.
11177339|NCT03539783||Control|Children <18 years of age without PARDS or other lung disease and expected duration of hospitalization 7 days or greater.
11177340|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
11177342|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
11177343|NCT03539744|Experimental|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
11177344|NCT03539744|Active Comparator|Arm 2 PomDex|Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
11177345|NCT03539731|Active Comparator|Group I ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
11177346|NCT03539731|Experimental|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
11177347|NCT03539731|Experimental|Group III ([18F]DASA-23, PET)|Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one [18F]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final [18F]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
11177348|NCT03539731|Active Comparator|Group IV ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins
11177349|NCT03539718|Experimental|cases|Cases, taurolidine heparin 500 will be used at end of session
11177350|NCT03539718|Active Comparator|control|Controls, Heparin Sodium 5000 will be given at end of session
11177351|NCT03539679|Experimental|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
11177352|NCT03539679|No Intervention|CONTROL GROUP|No intervention.
11177353|NCT03539666|Experimental|Pork|Standard American Diet with meat source: lean pork. Diet adheres to 2015-2020 Guidelines for Americans.
11177354|NCT03539666|Experimental|Poultry|Standard American Diet with meat source: chicken. Diet adheres to 2015-2020 Guidelines for Americans.
11177355|NCT03539640|Active Comparator|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
11177356|NCT03539640|Active Comparator|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
11177357|NCT03539640|Active Comparator|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
11177358|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
11177359|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
11177360|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
11177361|NCT03539601|Experimental|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
11177362|NCT03539601|Active Comparator|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
11177363|NCT03539601|Active Comparator|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
11177364|NCT03539601|Placebo Comparator|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
11177365|NCT03539588|Active Comparator|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
11177366|NCT03539588|Active Comparator|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
11177367|NCT03539575|Other|Synthetic Psychoactive Cannabinoid Users|Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer [11-C]OMAR.
11177368|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
11177369|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
11177370|NCT03539549|Experimental|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
11177371|NCT03539536|Experimental|Telisotuzumab vedotin|Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.
11177372|NCT03539510|Experimental|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
11177394|NCT03539315|Experimental|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
11178830|NCT03529773|Experimental|Expanded Arm 12|Mid dose formulation B and SIIV
11177373|NCT03539510|No Intervention|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
11177374|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
11177375|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
11177376|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
11177377|NCT03539471||psychiatric resident in NTUH|
11177378|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
11177379|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
11177380|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
11177381|NCT03539432|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
11177382|NCT03539432|Placebo Comparator|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
11177383|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
11177384|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
11177385|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
11177386|NCT03539367|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177387|NCT03539367|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177388|NCT03539354|Active Comparator|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
11177389|NCT03539354|Experimental|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
11177390|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
11177391|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
11177392|NCT03539328|Other|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
11177393|NCT03539328|Experimental|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
11177396|NCT03539302|Experimental|Repeat dose inhaled flecainide acetate|One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.
11177397|NCT03539289|Other|MUFA Diet|Monounsaturated Fatty Acids Diet
11177398|NCT03539289|Other|SFA Diet|Saturated Fatty Acids Diet
11177399|NCT03539276|No Intervention|Pre-intervention|Usual care
11177400|NCT03539276|Experimental|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
11177401|NCT03539263|Experimental|Group 1|the subjects are treated with probiotics: Bifihappy
11177402|NCT03539263|Placebo Comparator|Group 2|the subjects are treated with a placebo
11177403|NCT03539250|Experimental|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
11177404|NCT03539237|Experimental|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
11177405|NCT03539237|No Intervention|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
11177406|NCT03539224|Experimental|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
11177407|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
11177408|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
11177409|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
11177410|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
11177411|NCT03539185|Active Comparator|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
11177412|NCT03539185|Active Comparator|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
11177413|NCT03539172|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
11177414|NCT03539159|Experimental|Allogeneic conventional sized serum eye drops|
11177415|NCT03539159|Experimental|Allogeneic micro sized serum eye drops|
11177416|NCT03539146|Active Comparator|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
11177417|NCT03539146|Experimental|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
11177418|NCT03539107|Experimental|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
11177419|NCT03539107|Active Comparator|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
11177420|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
11177421|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
11177422|NCT03539081|Experimental|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.
~Intervention: Use of epidural spinal cord stimulation."
11177423|NCT03539081|Other|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.
~Intervention: Use of epidural spinal cord stimulation."
11177424|NCT03539081|Other|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.
~Intervention: Use of epidural spinal cord stimulation."
11177425|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
11177426|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:
~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.
~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.
~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
11177475|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
11177476|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
11177755|NCT03537079|Active Comparator|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
11177427|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.
~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
11177428|NCT03539029||Control group|age and sex matched healthy control persons
11177429|NCT03539029||Surgery|patients with ankle fracture treated surgically
11177430|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
11177431|NCT03539003|Experimental|sevoflurane (Group S)|general anesthesia with sevoflurane
11177432|NCT03539003|Active Comparator|desflurane (Group D)|general anesthesia with desflurane
11177433|NCT03539003|Active Comparator|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
11177434|NCT03538990|Experimental|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
11177435|NCT03538977|Active Comparator|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
11177436|NCT03538977|Experimental|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
11177437|NCT03538964|Active Comparator|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
11177438|NCT03538964|Sham Comparator|Non toric intraocular lens (IOL)|non toric intraocular lens
11177439|NCT03538951|Experimental|Cohort 1|10% VDA-1102
11177440|NCT03538951|Experimental|Cohort 2|20% VDA-1102
11177441|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
11177442|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
11177443|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
11177444|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
11177477|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
11177478|NCT03538769|No Intervention|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
11177479|NCT03538769|Other|Alert group|This will be the phase when e-alerts will be sent to the provider
11177596|NCT03538080|Experimental|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
11177445|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
11177446|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
11177447|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
11177448|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
11177449|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
11177450|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
11177451|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
11177452|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
11177480|NCT03538756|Experimental|Group A--Walkasins On Then Off|"Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.
~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
11196220|NCT03410745|Experimental|Exercise group|
11177453|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
11177454|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
11177455|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
11177456|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
11177457|NCT03538925|Experimental|Treatment Group|AAC Generative Language Intervention
11177458|NCT03538925|Active Comparator|Business as Usual|Standard of Care / Business as Usual
11177459|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
11177460|NCT03538912|Other|Routine group|patient follow the routine strategy
11177461|NCT03538899|Experimental|Gene therapy (AProArt)|Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
11177462|NCT03538886|Active Comparator|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
11177463|NCT03538886|Experimental|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
11177464|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:
~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
11177465|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
11177466|NCT03538860|Other|Method A first then Method B|Conventional in-person interview with a psychiatrist with a live human interpreter with crossover to asynchronous telepsychiatry
11177467|NCT03538860|Other|Method B first then Method A|Asynchronous telepsychiatry - that is, video-recorded interviews that are subsequently processed with automated speech recognition and machine translation technologies, with crossover to conventional in-person interview with a psychiatrist with a live human interpreter
11177468|NCT03538834|Experimental|Cod meal from residual material|Dietary supplement: cod meal from residual material, 8 g protein daily for 8 weeks
11177469|NCT03538834|Placebo Comparator|Control|Control group receive tablet containing fillers and no protein
11177470|NCT03538821|Experimental|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
11177471|NCT03538821|Experimental|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
11177472|NCT03538821|Experimental|Control|Control group receive tablet containing fillers and no proteins
11177473|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
11177474|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
11177756|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
11177481|NCT03538756|Experimental|Group B--Walkasins Off Then On|"Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.
~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
11177482|NCT03538743|Placebo Comparator|Placebo|
11177483|NCT03538743|Experimental|PF-06882961 30 mg|
11177484|NCT03538743|Experimental|PF-06882961 100 mg|
11177485|NCT03538743|Experimental|PF-06882961 300 mg|
11177486|NCT03538743|Experimental|PF-06882961 600 mg|
11177487|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 5|
11177488|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 6|
11177489|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 7|
11177490|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 8|
11177491|NCT03538730|No Intervention|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
11177492|NCT03538730|Experimental|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
11177493|NCT03538704|Experimental|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
11177494|NCT03538704|No Intervention|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
11177495|NCT03538691|Experimental|Brexpiprazole & Citalopram Hydrobromide|Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
11177496|NCT03538691|Placebo Comparator|Placebo & Citalopram Hydrobromide|Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
11177497|NCT03538691|Experimental|Brexpiprazole & Escitalopram|Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
11177498|NCT03538691|Placebo Comparator|Placebo & Escitalopram|Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
11177499|NCT03538691|Experimental|Brexpiprazole & Fluoxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
11177500|NCT03538691|Placebo Comparator|Placebo & Fluoxetine|Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
11177501|NCT03538691|Experimental|Brexpiprazole & Paroxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
11177502|NCT03538691|Placebo Comparator|Placebo & Paroxetine|Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
11177503|NCT03538691|Experimental|Brexpiprazole & Sertraline|Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
11177504|NCT03538691|Placebo Comparator|Placebo & Sertraline|Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
11177505|NCT03538691|Experimental|Brexpiprazole & Duloxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
11177506|NCT03538691|Placebo Comparator|Placebo & Duloxetine|Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
11177507|NCT03538691|Experimental|Brexpiprazole & Venlafaxine extended-release (XR)|Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
11177508|NCT03538691|Placebo Comparator|Placebo & Venlafaxine extended-release (XR)|Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
11177509|NCT03538678|Experimental|Kwit app|Use of Kwit smartphone app
11177510|NCT03538678|No Intervention|Standard of care|Patient initiated follow-up post discharge
11177511|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
11177512|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
11177513|NCT03538652|Placebo Comparator|EMA only|Randomized control group undergoing mobile assessment without JITAI
11177514|NCT03538652|No Intervention|Formative Interviews|First stage, before content of mobile intervention is finalized
11177515|NCT03538652|Active Comparator|JITAI|Group receiving microrandomized active intervention: JITAI with both CBT and ACT
11177516|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
11177517|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
11177518|NCT03538639||3|Healthy adult volunteers
11177519|NCT03538626|Experimental|1|5 mg/kg IV x 1
11177520|NCT03538626|Experimental|2|5 mg/kg SC x 1
11177521|NCT03538626|Experimental|3|20 mg/kg IV x 1
11177522|NCT03538626|Experimental|4|40 mg/kg IV x 1
11177523|NCT03538626|Experimental|5|Smg/kg SC x 3
11177524|NCT03538626|Experimental|6|20mg/kg SC x 3
11177525|NCT03538626|Experimental|7|Smg/kg SC and 2000U /ml X 1
11177526|NCT03538626|Experimental|8|20mg/kg SC and 2000U/ml x 1
11177527|NCT03538600||Healthy Volunteers|healthy volunteers
11177528|NCT03538587|Active Comparator|1/EMI Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions
11177529|NCT03538587|Active Comparator|2/Control Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
11177530|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
11177595|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
11178831|NCT03529773|Experimental|Expanded Arm 13|High dose formulation B and SIIV
11177531|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
11177532|NCT03538548|Experimental|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
11177533|NCT03538535|Experimental|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
11177534|NCT03538522|Experimental|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
11177535|NCT03538522|Experimental|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
11177536|NCT03538522|Experimental|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
11177537|NCT03538522|Placebo Comparator|Placebo|Oral administration of placebo per day for 24 weeks
11177538|NCT03538496|Active Comparator|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
11177539|NCT03538496|Active Comparator|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
11177540|NCT03538483|Active Comparator|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
11177541|NCT03538483|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
11177542|NCT03538470|Experimental|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
11177543|NCT03538444|Experimental|Active rTMS|Participants will receive 18 sessions of active repetitive Transcranial Magnetic Stimulation over a period of three days. TMS consists of 3000 pulses of 10Hz stimulation applied to the left DLPFC using the beam F3 method
11177544|NCT03538444|Placebo Comparator|Sham rTMS|Participants will receive 18 sessions of sham rTMS over a period of three days.
11177545|NCT03538431|Experimental|Buspirone before Simulation 1|These subjects will receive and be instructed to take the buspirone for the 2 days preceding their first driving simulation visit. They will not take buspirone before their 2nd driving simulation visit.
11177546|NCT03538431|Experimental|Buspirone before Simulation 2|These subjects will receive and be instructed to take the buspirone for the 2 days preceding their second driving simulation visit. They will not take buspirone before their 1st driving simulation visit.
11177547|NCT03538418|Experimental|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
11177548|NCT03538418|No Intervention|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
11177549|NCT03538405|Experimental|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
11177550|NCT03538392||PAD|
11177551|NCT03538392||AV Fistula|
11177552|NCT03538392||AV Graft|
11177553|NCT03538379|Active Comparator|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
11177554|NCT03538379|Active Comparator|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
11177555|NCT03538379|Active Comparator|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
11177556|NCT03538379|Active Comparator|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
11177557|NCT03538379|Active Comparator|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
11177558|NCT03538366|Experimental|Donor FMT|Fecal transplant from unrelated, healthy volunteers
11177559|NCT03538353|Other|Pain Education Video|Participants will watch a pain education video and then answer several questions.
11177560|NCT03538340|Active Comparator|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
11177561|NCT03538340|Experimental|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
11177562|NCT03538327|Experimental|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.
11177563|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
11177564|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 1)|
11177565|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 2)|
11177566|NCT03538301|Placebo Comparator|Placebo|
11177567|NCT03538288|Experimental|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
11177568|NCT03538275||Unipolar depression cohort|
11177569|NCT03538275||Bipolar depression cohort|
11177570|NCT03538275||Healthy Control cohort|
11196221|NCT03410745|No Intervention|Control group|
11177571|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
11177572|NCT03538249|Experimental|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
11177573|NCT03538249|Experimental|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
11177574|NCT03538249|Experimental|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
11177575|NCT03538249|No Intervention|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
11177576|NCT03538249|Experimental|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
11177577|NCT03538249|Experimental|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
11177578|NCT03538236|Active Comparator|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
11177579|NCT03538236|Experimental|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
11177580|NCT03538223|Experimental|"Radioterapy+Melomics-Health Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
11177581|NCT03538223|Experimental|Radiotherapy+Individualized Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
11177582|NCT03538223|Other|Radiotherapy+No Music Listening|Patients will undergo the standard treatment (radiotherapy) without music support.
11177583|NCT03538197|Other|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
11177584|NCT03538184|Experimental|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
11177585|NCT03538184|Active Comparator|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
11177586|NCT03538171|Active Comparator|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11177587|NCT03538171|Placebo Comparator|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11177588|NCT03538158|Experimental|Intervention condition - Fittle Senior|Participants will have access to the Fittle Senior System which will provide guided exercises and social support.
11177589|NCT03538158|Placebo Comparator|Control condition - paper and pencil|Participants will have a written booklet with exercises that they may do it on their own.
11177590|NCT03538119|Experimental|HIIT program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
11177591|NCT03538119|Experimental|Moderate continuous training program|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
11177592|NCT03538119|No Intervention|Control Group|Usual care. The patients will receive nutritional counseling as well as physical activity.
11177593|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
11177594|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
11177597|NCT03538080|Sham Comparator|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
11177598|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
11177599|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
11177600|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
11177601|NCT03538041|Experimental|Cohort 1|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period, with a dose-increase option at Week 6 for participants who fulfill dose increase criteria.
11177602|NCT03538041|Experimental|Cohort 2|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period.
11177603|NCT03538028|Experimental|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
11177604|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
11177605|NCT03538015|Experimental|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
11177606|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
11177607|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
11177608|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
11177609|NCT03537989|Experimental|Restricted group|"Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.
~Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.
~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.
~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.
~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
11177610|NCT03537989|Active Comparator|Standard group|"Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.
~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.
~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.
~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
11177611|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
11177612|NCT03537963|Other|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
11177613|NCT03537963|Experimental|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
11177614|NCT03537963|Active Comparator|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
11177615|NCT03537963|Experimental|mHealth Stepped-care Intervention + virtual reality relaxation|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention + virtual reality relaxation component, post-intervention questionnaire and interview.
11177616|NCT03537950|Experimental|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
11177617|NCT03537950|Experimental|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
11177618|NCT03537950|Experimental|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
11177619|NCT03537950|Experimental|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
11177620|NCT03537950|Experimental|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
11177621|NCT03537950|Experimental|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
11177622|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
11177623|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
11177624|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
11177625|NCT03537924|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177626|NCT03537924|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177627|NCT03537911|Experimental|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
11177628|NCT03537898|Active Comparator|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
11177629|NCT03537898|Active Comparator|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
11177630|NCT03537885|Experimental|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.
~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
11177631|NCT03537872|Experimental|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.
~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
11177632|NCT03537872|Active Comparator|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.
~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
11177633|NCT03537859|Experimental|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
11177634|NCT03537859|Other|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
11177635|NCT03537846||Osteoporosis and women|Patient women over thirty years old
11177636|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
11177637|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
11177638|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
11177639|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
11177640|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
11177641|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
11177642|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
11177643|NCT03537781|Experimental|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
11177644|NCT03537781|Experimental|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
11177645|NCT03537781|Experimental|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
11177646|NCT03537781|Experimental|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
11177647|NCT03537768|Active Comparator|UPA 30mg|
11177648|NCT03537768|Active Comparator|LNG 1.5 mg|
11177649|NCT03537768|Active Comparator|LNG 3.0|
11177650|NCT03537742|Experimental|alirocumab|alirocumab 150mg subcutaneous every other week for one year following transplant
11177651|NCT03537742|Placebo Comparator|placebo|placebo to match alirocumab every other week for one year following transplant
11177652|NCT03537729|No Intervention|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
11177653|NCT03537729|Experimental|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
11177654|NCT03537729|Experimental|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
11177655|NCT03537716|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
11177656|NCT03537703|Experimental|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
11177657|NCT03537703|Active Comparator|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
11177658|NCT03537703|Active Comparator|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
11177659|NCT03537690|Experimental|Treatment (FID-007)|Participants receive FID-007 IV over 60 minutes on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11177660|NCT03537677|Experimental|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
11177685|NCT03537508|Experimental|Group 1a|MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age
11178832|NCT03529773|Experimental|Expanded Arm 14|Low dose formulation A and placebo
11177661|NCT03537664|Experimental|Total bacteria analysis after 1rst- and 2nd-visit procedures|DNA levels and activity (RNA/DNA ratio) of total bacteria after the first-visit procedures (root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation) and the second-visit protocol (intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation). Additionally, the composition of the active microbiome will be assessed by Next Generation Sequencing (NGS) analysis of the root canal samples, and the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
11177662|NCT03537664|Other|Bacterial species analysis after root canal preparation|DNA levels and activity (RNA/DNA ratio) of Bacteroidaceae sp. 272 , Cutibacterium acnes, Selenomonas spp., and Enterococcus faecalis after root canal preparation.Additionally, the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
11177663|NCT03537651|Experimental|TEZ + IVA|"Subjects <30 kg will receive 50 mg TEZ/ 75 mg IVA as a FDC tablet in the morning and 75 mg IVA as a mono tablet in the evening.
~Subjects >=30 kg will receive 100 mg TEZ/ 150 mg IVA FDC tablet in the morning and 150 mg IVA as a mono tablet in the evening."
11177664|NCT03537638|Experimental|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
11177665|NCT03537638|No Intervention|Control|Rheumatologist and internist provide the usual care
11177666|NCT03537625|Experimental|Green tea|Green tea extract 2 gram per day
11177667|NCT03537625|Experimental|Fermented green tea|Fermented green tea extract 2 gram per day
11177668|NCT03537625|Placebo Comparator|Placebo|Placebo
11177669|NCT03537612|Experimental|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
11177670|NCT03537612|Experimental|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
11177671|NCT03537612|Active Comparator|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
11177672|NCT03537612|Active Comparator|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
11177673|NCT03537599|Experimental|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
11177674|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells. Evaluation of the sublingual microvasculature with a side stream dark field imaging video microscope will be performed.
11177675|NCT03537573|Active Comparator|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
11177676|NCT03537573|Experimental|Guideline + Opioid Justification (OJ)|"Providers will be required to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR and the phrase no justification provided if the provider decides to enter no text and proceed with the prescription. The provider does not need to enter a justification if they choose to cancel the opioid prescription."
11177677|NCT03537573|Experimental|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
11177678|NCT03537573|Experimental|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
11177679|NCT03537547|Experimental|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
11177680|NCT03537547|Active Comparator|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
11177681|NCT03537534|Experimental|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
11177682|NCT03537534|Placebo Comparator|Placebo|Surgilube 5mL x 1 dose only
11177683|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
11177684|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
11177686|NCT03537508|Experimental|Group 1b|MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age
11177687|NCT03537508|Active Comparator|Group 2a|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
11177688|NCT03537508|Active Comparator|Group 2b|MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age
11177689|NCT03537495|No Intervention|Control arm|"Subjects in this arm will only receive high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (>37 kg: two 600 mg tablets) to reach ~35 mg/kg rifampicin in total."
11177690|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
11177691|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
11177692|NCT03537482|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
11177693|NCT03537469|Experimental|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
11177694|NCT03537469|Sham Comparator|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
11177695|NCT03537456|Experimental|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:
~Hypotrophic tissues
~Tissue hypotonicity
~Crow's feet
~Glogau III - IV
~Fiztpatrick I - VI
~WSRS (Wrinkle Severity Ranking Scale): 2-5"
11177696|NCT03537443|Placebo Comparator|Group A (Placebo)|Children whose mothers were randomized to receive a weekly dose of placebo from 17-24 weeks of gestation to 26 weeks postpartum.
11177697|NCT03537443|Experimental|Group B (4200:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 4200 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
11177698|NCT03537443|Experimental|Group C (16800:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 16800 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
11177699|NCT03537443|Experimental|Group D (28000:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
11177700|NCT03537443|Experimental|Group E (28000:28000 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by the same dose (28000 IU/week vitamin D3) from delivery to 26 weeks postpartum.
11177701|NCT03537430|Other|TNT Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent TNT uniportal VATS mediastinal tumor resection
11177702|NCT03537430|Other|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent traditional uniportal VATS mediastinal tumor resection
11177703|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
11177704|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
11177705|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
11177706|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
11177707|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
11177708|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
11177709|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:
~Traditional imaging (clinical standard imaging);
~Whole-body contrast enhanced computer tomography
~Planar bone scintigraphy
~Novel imaging (investigational imaging);
~SPECT/CT (investigational imaging)
~18F-PSMA-PET/CT (investigational imaging)
~Whole-body MRI (investigational imaging)
~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
11177710|NCT03537378|Experimental|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung neoplasms (severe dysplasia, carcinoma in situ, microinvasive carcinoma，mucoepidermoid carcinoma.etc.) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
11177711|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
11177754|NCT03537079|Active Comparator|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
11197117|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
11177712|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
11177713|NCT03537352||Surgical Disorders|"A. Surgical Disorders:
~Current Hospitalization at the Surgical Inpatient Department or at the Inpatient Department of Otorhinolaryngology or at the Inpatient Department of Cardiology OR
~Current Follow-up at the Surgical Outpatient Department or at the Outpatient Department of Otorhinolaryngology or at the Outpatient Department of Cardiology due to a disorder for which any appropriate surgical treatment (surgery) is a treatment option."
11177714|NCT03537352||Non-Surgical General Medical Disorders|"Current Hospitalization at the Internal Medicine Inpatient Department or at the Inpatient Department of Cardiology OR
~Current Follow-up at the Internal Medicine Outpatient Department or at the Outpatient Department of Cardiology due to a disorder for which surgery is not a treatment option and any appropriate drug or non-drug treatment excluding surgery is a treatment option."
11177715|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
11177716|NCT03537326|Experimental|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
11177717|NCT03537313|No Intervention|Control-douching group|No preoperative vagina douching
11177718|NCT03537313|No Intervention|Control-painting group|No intra-operative vagina painting
11177719|NCT03537313|Experimental|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
11177720|NCT03537313|Experimental|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
11177721|NCT03537300|Experimental|experimental group|
11177722|NCT03537300|Active Comparator|control group|
11177723|NCT03537287|Active Comparator|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
11177724|NCT03537287|Active Comparator|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
11177725|NCT03537287|Active Comparator|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
11177726|NCT03537274|Experimental|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
11177727|NCT03537274|Experimental|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
11177728|NCT03537274|Experimental|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
11177729|NCT03537274|Active Comparator|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
11177730|NCT03537261|Experimental|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
11177731|NCT03537261|No Intervention|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.
~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
11177732|NCT03537248|Experimental|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
11177733|NCT03537248|Active Comparator|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
11177734|NCT03537235|Experimental|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
11177735|NCT03537235|Placebo Comparator|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
11177736|NCT03537222||MyPOS|
11177737|NCT03537196|Other|All patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
11177738|NCT03537196|Other|HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (sofosbuvir 400 mg and daclatasvir 90 mg)
11177739|NCT03537196|Other|Cirrhosis|In case of cirrhosis : ribavirin will be added to sofosbuvir / daclatasvir 12 weeks
11177740|NCT03537196|Other|Cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : sofosbuvir and daclatasvir for 24 weeks
11177741|NCT03537183|No Intervention|Usual activity level|12 weeks of usual activity level
11177742|NCT03537183|Active Comparator|Exercise training|12 weeks of moderate intensity exercise training, 3 hours a week
11177743|NCT03537157|Experimental|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
11177744|NCT03537157|Placebo Comparator|Placebo|Two placebo tablets twice a day for 26 weeks
11177745|NCT03537144|Active Comparator|Indomethacin|Indomethacin as drug to treat PDA.
11177746|NCT03537144|Experimental|Acetaminophen|Acetaminophen as drug to treat PDA.
11177747|NCT03537131|Active Comparator|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
11177748|NCT03537131|Active Comparator|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
11177749|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
11177750|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
11177751|NCT03537105|Experimental|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
11177752|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
11177753|NCT03537079|Placebo Comparator|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
11178833|NCT03529773|Experimental|Expanded Arm 15|Mid dose formulation A and placebo
11177757|NCT03537053|Experimental|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.
~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
11177758|NCT03537040|Other|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
11177759|NCT03537027|Experimental|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
11177760|NCT03537014|Experimental|MDMA|Administration of 80 or 120 mg MDMA in combination with psychotherapy and a supplemental dose offered 1.5/2 hrs later of 40 or 60 mg MDMA respectively.
11177761|NCT03537014|Placebo Comparator|Placebo|Administration of inactive placebo in combination with psychotherapy
11177762|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
11177763|NCT03536988|Experimental|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
11177764|NCT03536988|Active Comparator|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
11177765|NCT03536975|Other|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
11177766|NCT03536975|No Intervention|Control|Group without any access to the web platform
11177767|NCT03536949|Experimental|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
11177768|NCT03536949|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
11177769|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
11177770|NCT03536910|Other|General anesthesia|
11177771|NCT03536910|Other|Spinal anesthesia|
11177772|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
11177773|NCT03536884|Experimental|Bimekizumab dosage regimen 1|Subjects randomized to this arm will receive bimekizumab dosage regimen 1. At Week 16 subjects will be re-randomized and continue to receive bimekizumab regimen 1 or to switch to bimekizumab regimen 2. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
11177774|NCT03536884|Experimental|Bimekizumab dosage regimen 2|Subjects randomized to this arm will receive bimekizumab dosage regimen 2 starting at Week 16 after initial treatment on bimekizumab regimen 1 for 16 weeks. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
11177775|NCT03536884|Active Comparator|Secukinumab|Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
11177776|NCT03536871|Active Comparator|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
11177777|NCT03536871|No Intervention|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
11177778|NCT03536871|No Intervention|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
11177779|NCT03536871|Experimental|Exercise - home based programme|Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
11177780|NCT03536858|Active Comparator|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
11177781|NCT03536858|Active Comparator|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
11177782|NCT03536845|Active Comparator|400 IU|
11177783|NCT03536845|Active Comparator|1000 IU|
11177784|NCT03536832|Active Comparator|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
11177785|NCT03536832|Active Comparator|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
11177786|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
11178834|NCT03529773|Experimental|Expanded Arm 16|High dose formulation A and placebo
11177787|NCT03536806|Placebo Comparator|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
11177788|NCT03536806|Experimental|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
11177789|NCT03536793||Pancreatic cysts|Samples (urine, serum and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to either the University of Hull or a commercial laboratory for analysis of Endo180 and urinary TF, respectively. Collection will occur on the same day of the participants routinely indicated procedure.
11177790|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable).
11177791|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing their 8-week review subsequent to cholecystectomy (normal control subgroup).
11177792|NCT03536780|Experimental|Avelumab and Gemcitabine|
11177793|NCT03536767|Experimental|Open-Label|
11177794|NCT03536754|Placebo Comparator|Group A|Placebo (N=10)
11177795|NCT03536754|Experimental|Group B|CCX140-B 5 mg once daily (N=10)
11177796|NCT03536754|Experimental|Group C|CCX140-B 10 mg twice daily (N=10)
11177797|NCT03536754|Experimental|Group D|CCX140-B 15 mg twice daily (N=10)
11177798|NCT03536741|Experimental|ALR|
11177799|NCT03536741|Active Comparator|EV|
11177800|NCT03536728|Experimental|Part 1|Dose escalation of AMXT1501 with a fixed low dose of DFMO will follow a 3 + 3 dose escalation design. The AMXT 1501 starting dose administered in the first cohort will be 80 mg (2 capsules); each capsule contains 40 mg of active drug. The dose will be given orally, once daily, fasted state alone for 14 days, and starting on Day 15 AMXT 1501 80 mg given in combination with fixed low-dose oral DFMO at 250mg 2x per day (BID), for an additional 14 days; for a total 28 days of treatment per cycle. Cycle 2 includes AMXT1501 + DFMO that will be administered for 28 days. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of AMXT1501 alone will increase per Part 1 cohort.
11177801|NCT03536728|Experimental|Part 2|"Dose escalation of DFMO with the Part 1 AMXT1501 RP2D fixed dose will follow a 3 + 3 dose escalation design.
~The AMXT 1501 starting dose administered in the first cohort will be one level below the AMXT 1501 Part 1 RP2D with 500 mg DFMO BID. The morning dose will be given orally of both AMXT1501 and DFMO, in a fasted state. The evening dose of DFMO alone will be given prior to bed-time for 28 days per cycle. The patient can be treated for additional 28 day treatment cycles as deemed appropriate by their study investigator. Dose escalation of DFMO alone will increase per Part 2 cohort."
11177802|NCT03536728|Experimental|Expansion|The expansion cohort will include up to 14 evaluable patients at a proposed RP2D level of AMXT1501 and DFMO defined by Part 2 to further characterize safety at proposed RP2D dose level with repeat dosing, and characterize early anti-tumor activity.
11177803|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
11177804|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
11177805|NCT03536689|Experimental|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
11177806|NCT03536689|Experimental|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
11177807|NCT03536676|Active Comparator|Traditional School Breakfast Program|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
11177808|NCT03536676|Experimental|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
11177809|NCT03536663|Other|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
11177810|NCT03536650|Experimental|DMR procedure|
11177811|NCT03536637|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
11177812|NCT03536637|Experimental|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
11177813|NCT03536637|Experimental|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
11177814|NCT03536637|Placebo Comparator|Control|Placebo powder mixed with Placebo Diluent
11177815|NCT03536624|Experimental|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
~After the program, participants will be followed for 12 months."
11178835|NCT03529773|Experimental|Expanded Arm 17|Low dose formulation B and placebo
11177816|NCT03536611|Experimental|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
11177817|NCT03536611|Active Comparator|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
11177818|NCT03536598|Experimental|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
11177819|NCT03536598|Active Comparator|Reference 1|Amlodipine 10mg + Valsartan 160mg
11177820|NCT03536598|Active Comparator|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
11177821|NCT03536585|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments; External mons pubis treatment monthly for 3 treatments; External labia treatment monthly for 3 treatments.
11177822|NCT03536585|No Intervention|Baseline|Subject's baseline photograph to act as their own control for the one-month and four-month post-treatment photograph of the mons pubis and labia.
11177823|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
11177824|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
11177825|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
11177826|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
11177827|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
11177828|NCT03536546|Experimental|Alcohol Peer-Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
11177829|NCT03536546|Active Comparator|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
11177830|NCT03536533|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
11177831|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177832|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177833|NCT03536507|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177834|NCT03536507|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177835|NCT03536494|Experimental|Mirabegron intervention|Review the use of mirabegron and its discontinuation
11177836|NCT03536494|No Intervention|Control group|Usual care
11177837|NCT03536481|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
11177838|NCT03536481|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
11177839|NCT03536481|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
11177840|NCT03536481|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
11177841|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
11177842|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177843|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177844|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
11177845|NCT03536429|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11178836|NCT03529773|Experimental|Expanded Arm 18|Mid dose formulation B and placebo
11177846|NCT03536429|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
11177847|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
11177848|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
11177849|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
11177850|NCT03536403|Experimental|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
11177851|NCT03536390|Placebo Comparator|Placebo|one chewable tablet once daily in morning.
11177852|NCT03536390|Experimental|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
11177853|NCT03536377|Experimental|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
11177854|NCT03536364|Experimental|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
11177855|NCT03536351|Experimental|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
11177856|NCT03536338|Active Comparator|Control|Sit-to-stand training alone
11177857|NCT03536338|Experimental|Treatment|Sit-to-stand training combined with Spinal Stimulation
11177858|NCT03536325|Experimental|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
11177859|NCT03536325|Experimental|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
11177860|NCT03536325|Experimental|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
11177861|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
11177862|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
11177863|NCT03536299|Active Comparator|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
11177864|NCT03536299|Experimental|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
11177865|NCT03536286|Experimental|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.
~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
11177866|NCT03536286|No Intervention|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
11177867|NCT03536286|Experimental|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.
~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
11177868|NCT03536286|No Intervention|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
11177869|NCT03536273|Experimental|Functional Movement Screen|
11177870|NCT03536273|Experimental|Posture Analysis|
11177871|NCT03536273|Experimental|Depression Level|
11177872|NCT03536273|Experimental|Quality of Life|
11177873|NCT03536260|Active Comparator|Immediate implant with Xenograft|
11177874|NCT03536260|Active Comparator|Immediate implant with Nanobone|
11177875|NCT03536247|Active Comparator|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
11177876|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
11177877|NCT03536234|Experimental|Triptorelin (GnRH analogue)|
11177878|NCT03536234|No Intervention|Control group|
11177879|NCT03536208|Experimental|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
11177880|NCT03536182|Active Comparator|Arm A: Carbon ion radiotherapy|"The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency
~Japan : 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of each CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose.
~European: . Patients treated in Europe should receive 57.6 GyE in 4.8 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose. This evaluation will occur in the LEM system"
11177881|NCT03536182|Active Comparator|Arm B: Photon radiotherapy|50.4-56 Gy in 1.8-2.0 Gy per fraction in 28 fractions delivered 5 days a week. The plan should be normalized such that 100% of the PTV receives at least 48.9 Gy (i.e. 97% of 50.4 Gy). In addition, 100% of the GTV should receive at least 50.4 Gy. The maximum dose allowed to a point volume (0.03 mL) is 115% of the prescribed dose.
11177882|NCT03536143|Experimental|Topical beremagene geperpavec|HSV1-COL7A1 vector (KB103)
11177883|NCT03536130|Experimental|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
11177884|NCT03536130|No Intervention|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
11177885|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
11177886|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
11177887|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
11177888|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
11177889|NCT03536104||Controls|"This group will include healthy person."
11177890|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
11177891|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
11177892|NCT03536078|No Intervention|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
11177893|NCT03536078|Experimental|Home phototherapy|Newborns with icterus receiving phototherapy at home.
11177894|NCT03536065|Active Comparator|Pre-Intervention|Current practice (unchanged)
11177895|NCT03536065|Experimental|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
11177896|NCT03536052|Experimental|Virtual Heart Guided Ablation|
11177897|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
11177898|NCT03536026|Experimental|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
11177899|NCT03536013|Experimental|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
11177900|NCT03536013|No Intervention|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
11177901|NCT03536000||Healthy women|"200 Pregnant women
~Over 18 years
~Healthy
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
11177902|NCT03536000||Intrauterine Growth restriction|"Pregnant women
~Over 18 years
~Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth <p3 or <p10 with vascular Doppler alteration.
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
11177903|NCT03536000||Preeclampsia|"Pregnant women
~Over 18 years
~Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine> 30 mg / mmol creatinin
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
11177904|NCT03536000||Diabetes Mellitus type 1|"Pregnant women
~Over 18 years
~Diabetes mellitus type1
~With the ability to understand and sign the informed Consent
~With the ability to attend the established controls
~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
11177905|NCT03535987||Observational|To determine the feasibility of using myocardial PET imaging
11177906|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
11177907|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
11177908|NCT03535961|Other|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
11177909|NCT03535935|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
11178364|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
11177910|NCT03535935|Experimental|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
11177911|NCT03535922|Experimental|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the ESAS-r:Renal or the IPOS-Renal.
11177912|NCT03535922|Experimental|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
11177913|NCT03535922|Experimental|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
11177914|NCT03535922|No Intervention|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
11177915|NCT03535896|Experimental|HSR and injection|HSR and corticosteroid injection
11177916|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
11177917|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
11177918|NCT03535870|Experimental|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
11177919|NCT03535870|Active Comparator|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
11177920|NCT03535870|Placebo Comparator|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
11177921|NCT03535857|Active Comparator|Unilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
11177922|NCT03535857|Experimental|Bilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
11177923|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
11177924|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
11177925|NCT03535831|Experimental|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.
~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
11177926|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
11177927|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
11177928|NCT03535805|Experimental|Mind My Mind (MMM)|Mind My Mind (MMM)
11177929|NCT03535805|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU)
11177930|NCT03535792|Active Comparator|Fentanyl/Hyperbaric Bupivacaine|"Group F:
~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
11177931|NCT03535792|Active Comparator|Nalbuphine/Hyerbaric Bupivacaine|"Group N:
~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
11177932|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
11177933|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
11177934|NCT03535753|Experimental|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
11177935|NCT03535740|Experimental|Brigatinib|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity.
11177936|NCT03535727|Experimental|Cohort 1|(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
11177937|NCT03535727|Experimental|Cohort 2|(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
11177938|NCT03535714|Active Comparator|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.
~Patients who who have already an existing psychotherapy are attached to the control group."
11177939|NCT03535714|No Intervention|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
11177940|NCT03535701|Active Comparator|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
11177941|NCT03535701|Experimental|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
11177942|NCT03535688|Experimental|D-cycloserine|D-cycloserine 200 mg BID (twice daily)
11177943|NCT03535688|Placebo Comparator|Placebo|Placebo BID (twice daily)
11177944|NCT03535675|Experimental|Muscadine Plus|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
11177945|NCT03535675|Experimental|Placebo|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
11177946|NCT03535662|Experimental|Orvepitant|Orvepitant single 20mg dose
11177947|NCT03535662|Experimental|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
11177948|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
11177949|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.
~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.
~A BMI under 35 and no pregnancy."
11177950|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
11177951|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
11177952|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
11177953|NCT03535610|Experimental|Embolization|Uterine Embolization with PVA Microspheres
11177954|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
11177955|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
11177956|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
11177957|NCT03535584|Experimental|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
11177958|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
11177959|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
11177960|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
11177998|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
11177999|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
11177961|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
11177962|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
11177963|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
11177964|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
11177965|NCT03535545|Experimental|Idiopathic Pulmonary Fibrosis Subjects|Idiopathic Pulmonary Fibrosis patients will receive [68Ga]CBP8 and undergo PET imaging.
11177966|NCT03535532|Experimental|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
11177967|NCT03535532|Active Comparator|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
11177968|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
11177969|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
11177970|NCT03535493|Active Comparator|Acceptance and Commitment Therapy (ACT)|
11177971|NCT03535493|Active Comparator|Float REST|
11177972|NCT03535493|Experimental|ACT + Float REST|
11177973|NCT03535480|Experimental|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
11177974|NCT03535480|Experimental|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
11177975|NCT03535467||Conventional Rehabilitation|
11177976|NCT03535467||Robotic Therapy|
11177977|NCT03535454||Factory workers|
11177978|NCT03535454||Nurses|
11177979|NCT03535454||Janitors|
11177980|NCT03535454||Data automation employees|
11177981|NCT03535441||voluteer group|No treatment, only blood sample collection
11177982|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, <15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
11177983|NCT03535428||VENOUS exploration|
11177984|NCT03535415|Experimental|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
11177985|NCT03535415|No Intervention|Non-treatment control group|Only follow-up without treatment
11177986|NCT03535402|Other|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
11177987|NCT03535389|Experimental|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
11177988|NCT03535389|Active Comparator|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).
~Does not have any clinical PFI syndrome
~Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
11177989|NCT03535363|Experimental|Maximum Tolerated Dose of Osimertinib with standard of care|For patients with 1-10 brain metastases, begin daily Osimeritinib 0-7 days prior to stereotactic radiosurgery (SRS), provide daily Osimeritinib concurrently with radiotherapy, followed by maintenance Osimeritinib until disease progression, withdrawal, or unacceptable toxicity. Dose Level 1: 80mg daily. Dose Level -1: 40mg daily
11177990|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
11177991|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
11177992|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
11177993|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
11177994|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
11177995|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
11177996|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
11177997|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
11178000|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
11178001|NCT03535324|Other|Control|There will be no intervention.
11178002|NCT03535298|Experimental|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab) as their initial disease modifying treatment.
~Interventions: one of the highly effective MS therapies
~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
11178003|NCT03535298|Experimental|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.
~Interventions: one of the MS therapies NOT in the highly effective group
~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
11178004|NCT03535298|No Intervention|OBS: Observational|"Participants will not be restricted to a group of MS therapies.
~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
11178005|NCT03535285|Experimental|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
11178006|NCT03535285|Active Comparator|Conventional surgery|Periodontal ligament distraction
11178007|NCT03535272|Active Comparator|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
11178008|NCT03535272|Placebo Comparator|Placebo|Placebo oral tablet 4 bid
11178009|NCT03535259|Experimental|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
11178010|NCT03535246|Experimental|Single arm|EIE cells to treat cancer.
11178011|NCT03535233|Active Comparator|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
11178012|NCT03535233|Active Comparator|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
11178013|NCT03535220||Observational/ Interventional|Hematologic Disease
11178014|NCT03535207|Experimental|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
11178015|NCT03535194|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC)
11178016|NCT03535194|Placebo Comparator|Placebo|Placebo administered SC
11178017|NCT03535194|Active Comparator|Secukinumab|Secukinumab administered SC
11178018|NCT03535168|Experimental|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
11178019|NCT03535168|Experimental|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
11178020|NCT03535168|Experimental|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
11178021|NCT03535168|Experimental|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
11178022|NCT03535168|Experimental|BAY1902607+Matching Placebo|"Part 2:
~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
11178023|NCT03535168|Experimental|Matching Placebo+BAY1902607|"Part 2:
~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
11178024|NCT03535142|Experimental|Intervention|The intervention is bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
11178025|NCT03535142|No Intervention|Control|Age, BMI and co-morbidity matched group who do not undergo surgery.
11178026|NCT03535129|No Intervention|Stage 1|Pilot portion to optimize intervention and achievecorrelational research aims
11178027|NCT03535129|Experimental|Stage 2|Main Clinical Trial with random assignment
11178028|NCT03535116|Experimental|Patients receiving ketorolac|Patient receives 30mg IV ketorolac(single dose) towards the end of the operation.
11178029|NCT03535116|Placebo Comparator|Control|Patients receive saline intravenously towards the end of the operation.
11178030|NCT03535103|Experimental|ARM A|Gonal-F®
11178031|NCT03535103|Experimental|ARM B|LM001
11178032|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
11178033|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
11178034|NCT03535064|Experimental|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
11178097|NCT03534648|Experimental|Effect of PF-05221304 on PF-06865571 PK|
11178035|NCT03535064|No Intervention|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
11178036|NCT03535051|Experimental|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
11178037|NCT03535051|Active Comparator|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
11178038|NCT03535038|Experimental|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
11178039|NCT03535038|Active Comparator|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
11178040|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
11178041|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
11178042|NCT03534999|Experimental|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
11178043|NCT03534999|No Intervention|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
11178044|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
11178045|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
11178046|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
11178047|NCT03534973|Active Comparator|Caffeine intake|Caffeine is given orally prior to cataract surgery
11178048|NCT03534973|Sham Comparator|No caffeine intake|Caffeine is not given orally prior to cataract surgery
11178049|NCT03534960|Other|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
11178050|NCT03534960|Other|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
11178051|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
11178052|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
11178053|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
11178054|NCT03534934|Experimental|Baseline|"Smokers, defined has having at least a 10 pack-year lifetime history, with and without COPD will participate in the following interventions:
~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
11178055|NCT03534934|Experimental|3 year follow-up|"All subjects who completed a baseline visit will return for a follow-up visit and participate in the following interventions:
~Vital Signs Urine Pregnancy Test on woman of child bearing potential Pre- and Post-Bronchodilator Spirometry Questionnaires Blood Test for Vitamin D level, Hemoglobin A1c, and creatinine level Duel-energy X-ray absorptiometry scan (DXA) of the whole body, spine, and hip Duel-energy X-ray absorptiometry scan (DXA) for vertebral fracture assessment Multi-detector computed tomography (MDCT) of the hip and ankle"
11178056|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged >=18 years with a record of severe mental illness so that at least one event occurs in the study period.
11178057|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
11178058|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
11178059|NCT03534908||NAFLD group|those with NAFLD
11178060|NCT03534908||Control group|those without NAFLD
11178061|NCT03534895|Placebo Comparator|PC1|5mL normal saline intravenous, single-administration, as pre-medication
11178062|NCT03534895|Experimental|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
11178063|NCT03534895|Experimental|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
11178098|NCT03534648|Experimental|Effect of PF-06865571 on PF-05221304 PK|
11178365|NCT03532815|Active Comparator|Lifestyle Modification group|
11178366|NCT03532815|No Intervention|Control group|
11178064|NCT03534882|Experimental|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
11178065|NCT03534882|No Intervention|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
11178066|NCT03534869|Experimental|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.
~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
11178067|NCT03534869|Active Comparator|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
11178068|NCT03534856|Experimental|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
11178069|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
11178070|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
11178071|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
11178072|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
11178073|NCT03534817|Experimental|Early Access CR|Participants begin cardiac rehabilitation (CR) after 1-week following discharge post-MI.
11178074|NCT03534817|No Intervention|Standard Access CR|Participants begin CR after 7-weeks following discharge post-MI, similar to the average Canadian wait time.
11178075|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
11178076|NCT03534791|Experimental|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
11178077|NCT03534791|No Intervention|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
11178078|NCT03534778||patients undergoing neck dissection|all patients undergoing neck dissection
11178079|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
11178080|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
11178081|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
11178082|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
11178083|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
11178084|NCT03534726||Patients|Patients with cardiomyopathy
11178085|NCT03534726||Normal subjects|No prior history of heart disease.
11178086|NCT03534713|Experimental|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
11178087|NCT03534713|Active Comparator|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
11178088|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
11178089|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
11178090|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
11178091|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
11178092|NCT03534674|Experimental|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
11178093|NCT03534674|No Intervention|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
11178094|NCT03534661|Placebo Comparator|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
11178095|NCT03534661|Active Comparator|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
11178096|NCT03534661|Placebo Comparator|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
11178099|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.
~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
11178100|NCT03534622|Experimental|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a
~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
11178101|NCT03534609|Experimental|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
11178102|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) controls for group support and morale, behavioural activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 5 days for 2.5-3 hours, and once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changesHEP will be delivered by a trained social worker (or equivalent).
11178103|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (group sizes of 6-8 participants). SKY training involves attending a 5-day course (Mon to Fri) that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency and any other
11178104|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
11178105|NCT03534518|Active Comparator|SCI-patients receiving overground training|
11178106|NCT03534518|Active Comparator|SCI-patients receiving treadmill training|
11178107|NCT03534505|Experimental|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
11178108|NCT03534505|Active Comparator|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
11178109|NCT03534492|Experimental|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
11178110|NCT03534479|Experimental|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
11178111|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
11178112|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
11178113|NCT03534453|Experimental|Olaparib 300mg tablets|Taken orally twice daily
11178114|NCT03534427|No Intervention|Control group|No exercise intervention
11178115|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
11178116|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
11178117|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
11178118|NCT03534401|No Intervention|Standard Family Planning Counseling|Clients receive standard FP counseling services.
11178119|NCT03534401|Experimental|ARCHES Kenya Intervention in FP Counseling|Clients receive the ARCHES Kenya intervention in addition to standard FP counseling services.
11178120|NCT03534388|Other|Prospective Subjects|
11178121|NCT03534375||Female Early Adolescents|
11178122|NCT03534375||Male Early Adolescents|
11178123|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
11178124|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
11178189|NCT03533868|Experimental|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
11197118|NCT03404388|Experimental|Experimental|Balance Training
11178125|NCT03534336|No Intervention|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.
~No financial incentives are given for losing weight or passing quizzes."
11178126|NCT03534336|Experimental|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.
~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
11178127|NCT03534336|Experimental|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.
~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
11178128|NCT03534323|Experimental|Duvelisib +Venetoclax,|"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.
~Duvelisib will be administered orally twice daily
~Venetoclax will be administered orally daily
~All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation"
11178129|NCT03534310|Active Comparator|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
11178130|NCT03534310|Experimental|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
11178131|NCT03534310|Active Comparator|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
11178132|NCT03534297|Experimental|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:
~Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days
~Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days
~Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days"
11178133|NCT03534297|Placebo Comparator|Placebo Capsules|"A total of 2 patients in each cohort will receive placebo capsules:
~Cohort 1 will receive 5 placebo capsules QD for 14 days
~Cohort 2 will receive 5 placebo capsules BID for 14 days
~Cohort 3 will receive 5 placebo capsules QID for 14 days"
11178134|NCT03534284|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
11178135|NCT03534284|Active Comparator|Medication- Trazodone|Trazodone (50-100 mg):
11178136|NCT03534284|Placebo Comparator|Medication- Placebo|Placebo (for trazodone)
11178137|NCT03534245||1|Healthy children aged 2 - 9 years
11178138|NCT03534219|Experimental|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.
~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6
~Administration:
~Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.
~Push button to start the airflow and swallow while the device is running.
~Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.
~Telephone call survey:
~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
11178139|NCT03534219|No Intervention|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)
~Telephone call survey:
~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
11178140|NCT03534206|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11178141|NCT03534206|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11178142|NCT03534193|Other|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
11178143|NCT03534193|Experimental|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
11178144|NCT03534180|Experimental|Treatment (venetoclax)|Patients receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11178145|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
11178146|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
11178147|NCT03534154||TBI - MRI / bloods / cognitive / clinical outcomes|Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months
11178148|NCT03534154||TBI - Advanced MRI / bloods / cognitive / clinical outcomes|Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.
11178190|NCT03533855|Experimental|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
11178149|NCT03534154||TBI - microdialysis / adv. MRI / cognitive / clinical|Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.
11178150|NCT03534154||Healthy volunteer|Single assessment using MRI, bloods and cognitive testing.
11178151|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
11178152|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
11178153|NCT03534128|Experimental|Spatial navigation evaluation|
11178154|NCT03534115|Placebo Comparator|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
11178155|NCT03534115|Experimental|Experimental Arm|solution containing NAC with buffers
11178156|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
11178157|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
11178158|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
11178159|NCT03534089|Placebo Comparator|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
11178160|NCT03534089|Experimental|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
11178161|NCT03534089|Experimental|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
11178162|NCT03534063|Active Comparator|genotype-guided opioid therapy|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
11178163|NCT03534063|No Intervention|usual care|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
11178164|NCT03534050|Experimental|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
11178165|NCT03534037|Experimental|Febuxostat 40mg|Febuxostat 40mg orally per day
11178166|NCT03534037|Active Comparator|Benzbromarone 50mg|Benzbromarone 50mg orally per day
11178167|NCT03534037|Other|Control|Dietary control only
11178168|NCT03534024|Active Comparator|nanomicielle curcumin|
11178169|NCT03534024|Placebo Comparator|plecebo|
11178170|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
11178171|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
11178172|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
11178173|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
11178174|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
11178175|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
11178176|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
11178177|NCT03533972|Experimental|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
11178178|NCT03533972|Placebo Comparator|Control group|subjects will be provided with placebo capsules.
11178179|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
11178180|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
11178181|NCT03533946|Experimental|Rucaparib, all patients|Single Arm study, all patients will get rucaparib
11178182|NCT03533933|Active Comparator|Autologous connective tissue graft|Soft tissue harvesting from patient palate
11178183|NCT03533933|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
11178184|NCT03533920|Experimental|UNI-DEB|
11178185|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
11178186|NCT03533881|Active Comparator|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
11178187|NCT03533881|Active Comparator|Nutritional changes|Subjects only follow minimal nutritional changes
11178188|NCT03533868|No Intervention|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1® v2 (Roche) assay.
11178367|NCT03532802|Active Comparator|Metoprolol Succinate|Metoprololsuccinat
11178191|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
11178192|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
11178193|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
11178194|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
11178195|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
11178196|NCT03533803|Active Comparator|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
11178197|NCT03533803|Placebo Comparator|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
11178198|NCT03533790|Experimental|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
11178199|NCT03533777|Active Comparator|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
11178200|NCT03533777|Experimental|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
11178201|NCT03533764|Experimental|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
11178202|NCT03533764|No Intervention|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
11178203|NCT03533751|Placebo Comparator|Placebo|Placebo
11178204|NCT03533751|Experimental|Group 1|etokimab (ANB020)
11178205|NCT03533751|Experimental|Group 2|etokimab (ANB020)
11178206|NCT03533751|Experimental|Group 3|etokimab (ANB020)
11178207|NCT03533751|Experimental|Group 4|etokimab (ANB020)
11178208|NCT03533738|Experimental|Food selection 1|To consume vegetables followed by meat & rice together
11178209|NCT03533738|Experimental|Food selection 2|To consume meat followed by vegetables & rice together
11178210|NCT03533738|Experimental|Food selection 3|To consume as follows: vegetables, meat, rice
11178211|NCT03533738|Experimental|Food selection 4|To consume vegetables followed by meat and rice together
11178212|NCT03533738|Experimental|Food selection 5|To consume rice followed by vegetables & meat together
11178213|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
11178214|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
11178215|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
11178216|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
11178217|NCT03533699|Active Comparator|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
11178218|NCT03533699|Placebo Comparator|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
11178219|NCT03533686|Experimental|Single-Sided Deafness Adult (Aim1) Group|Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
11178220|NCT03533686|Experimental|Conductive Hearing Loss Adult (Aim 2) Group|Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
11178221|NCT03533686|Experimental|Adhear followed by BAHA (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
11178276|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
11178222|NCT03533686|Experimental|BAHA followed by Adhear (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
11178223|NCT03533686|Experimental|Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group|Pediatric participants (aged 2-17 years) with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
11178224|NCT03533686|Experimental|Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group|Pediatric participants (aged 2-17 years) with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
11178225|NCT03533673|Experimental|Cohort 1|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 1)
11178226|NCT03533673|Experimental|Cohort 2|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 2)
11178227|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
11178228|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
11178229|NCT03533647||entire cohort (observational)|none (observational study)
11178230|NCT03533634|Experimental|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
11178231|NCT03533634|Experimental|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
11178232|NCT03533621|Experimental|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
11178233|NCT03533621|Placebo Comparator|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
11178234|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
11178235|NCT03533595|No Intervention|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
11178236|NCT03533595|Active Comparator|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
11178237|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
11178238|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
11178239|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity.
11178240|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity.
11178241|NCT03533582|Experimental|GROUP B2 (UNRESECTABLE)|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (4 pre-surgery, 2 post-surgery).
11178242|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
11178243|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
11178244|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
11178245|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
11178246|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
11178247|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
11178363|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
11178248|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
11178249|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment.
11178250|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment.
11178251|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
11178252|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
11178253|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
11178254|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
11178255|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
11178256|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
11178257|NCT03533530|Active Comparator|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
11178258|NCT03533530|Experimental|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
11178259|NCT03533530|Experimental|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
11178260|NCT03533517|Experimental|AccuCinch® Ventricular Repair System|
11178261|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
11178262|NCT03533491|Experimental|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
11178263|NCT03533478|Experimental|Group I|32 patients with mild or moderate diabetic macular edema.
11178264|NCT03533478|Placebo Comparator|Group II|32 patients with mild or moderate diabetic macular edema
11178265|NCT03533465|Experimental|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
11178266|NCT03533452|Active Comparator|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
11178267|NCT03533452|Sham Comparator|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
11178268|NCT03533426|Active Comparator|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg & the pump is sufficient for about 60 hours according to patient response."
11178269|NCT03533426|Active Comparator|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
11178270|NCT03533413|Active Comparator|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
11178271|NCT03533413|Active Comparator|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
11178272|NCT03533400|Active Comparator|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
11178273|NCT03533400|Experimental|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
11178274|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
11178275|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
11178277|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation
~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
11178278|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation
~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
11178279|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
11178280|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
11178281|NCT03533335|Active Comparator|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
11178282|NCT03533335|Experimental|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
11178283|NCT03533335|Placebo Comparator|Sterile water spray|Placebo
11178284|NCT03533309|Experimental|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.
~."
11178285|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
11178286|NCT03533296|Experimental|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
11178287|NCT03533283|Experimental|Atezolizumab|Participants will receive Glofitamab in combination with Atezolizumab up to the maximum tolerated dose (MTD).
11178288|NCT03533283|Experimental|Polatuzumab Vedotin|Participants will receive Glofitamab in combination with polatuzumab vedotin up to the MTD.
11178289|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
11178290|NCT03533257|Active Comparator|Active (AMX0035)|AMX0035--a combination of TUDCA and Phenylbutyrate
11178291|NCT03533257|Placebo Comparator|Placebo|Taste-matched Placebo
11178292|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
11178293|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
11178294|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
11178295|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
11178296|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
11178297|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
11178298|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
11178299|NCT03533192|Experimental|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
11178300|NCT03533192|No Intervention|Usual care|Students received their regular health education.
11178301|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.
~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
11178302|NCT03533179|Experimental|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.
~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
11178303|NCT03533179|Experimental|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.
~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
11178304|NCT03533179|Experimental|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.
~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
11178305|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.
~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
11178306|NCT03533166|Experimental|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
11178307|NCT03533166|Placebo Comparator|Placebo|Mechanical treatment + Placebo mouth rinse
11178368|NCT03532802|Placebo Comparator|Placebo oral capsule|Placebo
11178308|NCT03533153|Experimental|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
11178309|NCT03533153|Placebo Comparator|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
11178310|NCT03533140|Active Comparator|DUCEST Neurostimulator V Group A|
11178311|NCT03533140|Sham Comparator|DUCEST Neurostimulator V Group B|
11178312|NCT03533127|Experimental|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
11178313|NCT03533127|Experimental|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
11178314|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
11178315|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
11178316|NCT03533101|Experimental|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
11178317|NCT03533101|Active Comparator|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
11178318|NCT03533088|Experimental|Hospitalized rehabilitation|Patients in this group will recieve rehabilitation program twice in a week at our clinic after the surgical procedure until post-operative 12 weeks.
11178319|NCT03533088|Experimental|Home-based rehabilitation|Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
11178320|NCT03533075|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
11178321|NCT03533075|No Intervention|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
11178322|NCT03533062|Active Comparator|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
11178323|NCT03533062|Active Comparator|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
11178324|NCT03533049|Experimental|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.
~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
11178325|NCT03533049|Active Comparator|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
11178326|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
11178327|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
11178328|NCT03533023|Experimental|TRE + SOC|Time Restricted Eating + Standard of Care
11178329|NCT03533023|Other|SOC|Standard of Care
11178330|NCT03533010|Active Comparator|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
11178331|NCT03533010|Placebo Comparator|Placebo|Dietary Supplement: Placebo
11178332|NCT03532997|Experimental|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
11178369|NCT03532789|Experimental|herbal patch group|using herbal patch as an intervention
11178333|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
11178334|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
11178335|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
11178336|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
11178337|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
11178338|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
11178339|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
11178340|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength
~Cognitive tests Global cognition Attention, executive f. Processing speed Memory
~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
11178341|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
11178342|NCT03532958|Placebo Comparator|Placebo|Normal saline
11178343|NCT03532958|Experimental|Lowest Dose BNZ-1|
11178344|NCT03532958|Experimental|Low Dose BNZ-1|
11178345|NCT03532958|Experimental|Moderate Dose BNZ-1|
11178346|NCT03532958|Experimental|High Dose BNZ-1|
11178347|NCT03532945|Experimental|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
11178348|NCT03532945|Active Comparator|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
11178349|NCT03532932||UC Participants|Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
11178350|NCT03532932||CD Participants|Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.
11178351|NCT03532906|Active Comparator|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
11178352|NCT03532906|Other|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
11178353|NCT03532880|Experimental|Participants with Small Cell Lung Cancer|
11178354|NCT03532867|Experimental|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.
~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.
~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :
~Examination of pressures before stopping the exercise
~Examination of pressure during the exercise
~Examination of pressures after stopping the exercise"
11178355|NCT03532854|Experimental|Sequence A|Ezetimibe/Rosuvastatin -> Valsartan -> Valsartan and Ezetimibe/Rosuvastatin
11178356|NCT03532854|Experimental|Sequence B|Valsartan -> Valsartan and Ezetimibe/Rosuvastatin-> Ezetimibe/Rosuvastatin
11178357|NCT03532854|Experimental|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -> Ezetimibe/Rosuvastatin -> Valsartan
11178358|NCT03532854|Experimental|Sequence D|Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin-> Valsartan
11178359|NCT03532854|Experimental|Sequence E|Valsartan -> Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin
11178360|NCT03532854|Experimental|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -> Valsartan -> Ezetimibe/Rosuvastatin
11178361|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
11178362|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
11178371|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
11178372|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
11178373|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
11178374|NCT03532763|Experimental|Tocotrienol-rich fraction|
11178375|NCT03532763|Placebo Comparator|Placebo|
11178376|NCT03532750|No Intervention|Control|This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.
11178377|NCT03532750|Experimental|Particle|Randomized to receive either the Embozene or Embosphere particles
11178378|NCT03532750|Experimental|Coil|Randomized to receive either Ruby or Interlock detachable coils
11178379|NCT03532737|Experimental|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.
~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 21 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses
~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
11178380|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
11178381|NCT03532698||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
11178382|NCT03532698||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
11178383|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
11178384|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
11178385|NCT03532685|No Intervention|Severe Obese Patients|usual care
11178386|NCT03532672|Experimental|Acute Fasting|Eutrophic and obese women will fast 10 hours during daily activities after a standardized breakfast.
11178387|NCT03532659|Experimental|Active video game|The adolescents will be submitted to physical activity with active video game for 50 minutes, 3 times a week, for a period of eight weeks. The XBOX360® platform will be used with the Kinect accessory (Microsoft®) and Just Dance will be the selected game. The music used for intervention will be previously selected, including those that can lead to moderate intensity, and assembled in blocks of 10. For each week, a new block and challenges must be elaborated to increase the motivation to carry out the physical activity.
11178388|NCT03532659|No Intervention|control|A follow-up will be done for eight weeks to compare the variables. The adolescents in this group will be interviewed monthly to detect changes in eating habits and lifestyle.
11178389|NCT03532646|Other|group 1: RYGB|All patients who underwent RYGB and were readmitted to upper endoscopy are getting observed
11178390|NCT03532646|Other|group 2:MGB/OAGB|All patients who underwent MGB/OAGB and were readmitted to upper endoscopy are getting observed
11178391|NCT03532633||23-27w|preterm infants 23+0-27+6SSW
11178392|NCT03532633||28-31w|preterm infants 28+0-31+6SSW
11178393|NCT03532633||32-34w|preterm infants 32+0 - 34+6SSW
11178394|NCT03532633||35-36w|preterm infants 35+0-36+6 SSW
11178395|NCT03532633||37-42w|term infants 37+0-42+6
11178396|NCT03532620|Experimental|pitavastatin|Pitavastatin Calcium + lifestyle modification
11178397|NCT03532620|Active Comparator|atorvastatin|Atorvastatin Calcium + lifestyle modification
11178398|NCT03532607|Experimental|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
11178399|NCT03532607|No Intervention|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
11178400|NCT03532594|Other|Standard Care|At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
11178401|NCT03532594|Experimental|Algorithm|For patients in the intervention group, protamine will be administered according to the PRODOSE algorithm, which has been incorporated into an Excel spread sheet for ease of use (Microsoft Corporation).
11178402|NCT03532581|Experimental|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
11178403|NCT03532568|Experimental|CKD-aP patients|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue and their response to narrow band ultraviolet B
11178404|NCT03532568|Experimental|CKD patients without pruritis|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
11178405|NCT03532568|Experimental|normal healthy participants|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
11178406|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
11178407|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
11178408|NCT03532542|Experimental|Casimersen|Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
11178409|NCT03532542|Experimental|Golodirsen|Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
11178410|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:
~death within 30 days from VA ECMO liberation
~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation
~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal
~heart transplantation within 30 days from VA ECMO liberation"
11178411|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:
~death within 30 days from VA ECMO liberation
~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation
~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal
~heart transplantation within 30 days from VA ECMO liberation"
11178412|NCT03532503|Active Comparator|Foley catheter filled with 30 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 30 ml saline. A gentle traction will be applied.
11178413|NCT03532503|Active Comparator|Foley catheter filled with 50 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 50 ml saline. A gentle traction will be applied.
11178414|NCT03532490|Active Comparator|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
11178415|NCT03532490|Placebo Comparator|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
11178416|NCT03532464|Experimental|Patient treated by doxycycline|"The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
11178417|NCT03532464|Active Comparator|Patients treated by azithromycin|"The patients in the azithromycin group take 4 tablets of 250 mg in the morning as a single dose.
~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
11178418|NCT03532451|Experimental|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
11178419|NCT03532451|Experimental|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
11178420|NCT03532438||NTM patient group|NTM lung disease patients living together
11178421|NCT03532425|Experimental|B/F/TAF|"B/F/TAF + Atripla Placebo
~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
11178422|NCT03532425|Active Comparator|Atripla|"Atripla + B/F/TAF Placebo
~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
11178423|NCT03532412||HF+CSA+PB|Systolic heart failure with predominant central sleep apnea and periodic breathing
11178424|NCT03532399||Pediatric Cardiac Catheterization|
11178425|NCT03532399||Pediatric Cardiac Surgery|
11178426|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
11178427|NCT03532386||Study group|Infertile men with oligoasthenospermia with non-tense vaginal hydrocele subjected to ICSI
11178428|NCT03532386||Control group|infertile men with oligoasthenospermia without hydrocele subjected to ICSI
11178429|NCT03532373|No Intervention|Control|None- normal care
11178430|NCT03532373|Experimental|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
11178431|NCT03532360|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
11178432|NCT03532360|Active Comparator|Low-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
11178433|NCT03532360|Active Comparator|High-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
11178434|NCT03532347|Experimental|EUS tissue sampling|"Device: EUS-FNA needle (Beacon) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail
~Device:EUS-FNB needle (Beacon Sharkcore) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail"
11178435|NCT03532321||Caregivers|Caregivers in the participating hospital departments : medical (doctors, midwives) and paramedical (nurses' aides, registered nurses, specialized nurses and head nurses) staff, working in hospital departments drawn at random among five volunteer hospital centers in Paris, and who will be present at the time of investigator's passage, at a date drawn at random during the inclusion phase.
11178436|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
11178437|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
11199233|NCT03389607||control|the patients must not have diabetic
11178438|NCT03532295|Experimental|Regimen A: INCMGA00012+RT+bevacizumab|"INCMGA00012 will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.
~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction
~INCMGA00012 and bevacizumab will be started approximately two weeks before the first day of radiation therapy"
11178439|NCT03532295|Experimental|Regimen B: INCMGA00012+RT+bevacizumab+epacadostat|"INCMGA00012 will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.
~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction
~INCMGA00012 and bevacizumab will be started approximately two weeks before the first day of radiation therapy
~Epacadostat will be administered orally at 600 mg BID."
11178440|NCT03532282|Active Comparator|ONLINE ONLY|Online cognitive behavioral therapy for insomnia
11178441|NCT03532282|Experimental|STEPPED CARE|Cognitive behavioral therapy for insomnia online or therapist-led or sequentially both
11178442|NCT03532269|Experimental|A: 3rd night with acoustic stimulation|Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
11178443|NCT03532269|Experimental|B: 2nd night with acoustic stimulation|Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
11178444|NCT03532256||Treated Patients|This prospective, observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients treated for an acute injury and prescribed an opioid from the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
11178445|NCT03532256||Treated patients randomized to receive survey|A subset of patients (described above) will receive an automated SMS text message with a link to an online survey. This survey contains the script questions about pain management and opioid use.
11178446|NCT03532256||Treated patients randomized to receive text script|A subset of patients (described above) will receive an automated questionnaire conducted via text message. Questions will be about pain management and opioid use.
11178447|NCT03532243|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the threshold loading device with incremental inspiratory load.
11178448|NCT03532243|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the threshold loading device with incremental inspiratory load.
11178449|NCT03532230||Experimental Group|90 new patients seeking treatment for chronic low back pain. This group will receive standard care plus osteopathic manipulative treatment (OMT) for low back pain.
11178450|NCT03532230||Control Group|90 new patients seeking treatment for chronic low back pain. This group will receive only standard care without osteopathic manipulative treatment (OMT) for low back pain.
11178451|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.
~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
11178452|NCT03532204|Experimental|Chemotherapy + SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.
~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.
~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
11178453|NCT03532204|Active Comparator|Chemotherapy|Patients will receive chemotherapy as initially scheduled
11178454|NCT03532191|Experimental|PrEP-OI Intervention|All clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
11178455|NCT03532191|No Intervention|Control until randomized for intervention|All clinics that have not yet initiated the intervention at this time (i.e., control clinics). A new clinic will cross over to receive the intervention each month, with the order of clinic crossover determined at random, until all clinics are receiving the intervention.
11178456|NCT03532178|Experimental|Group A|rocuronium + sugammadex / succinylcholine + normal saline
11178457|NCT03532178|Experimental|Group B|succinylcholine + normal saline / rocuronium + sugammadex
11178458|NCT03532165|Other|Positive lower extremity ultrasound|This group found to to have a deep venous thrombosis on lower extremity ultrasound will not have a CT of the chest ordered from the emergency department, and will be treated for the DVT and presumed PE.
11178459|NCT03532165|Other|Negative lower extremity ultrasound|This group that does not have a deep venous thrombosis on lower extremity ultrasound will proceed to get the CT of the chest .
11178460|NCT03532152|Active Comparator|Pure Purr VR technology|"The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.
~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
11178461|NCT03532152|Sham Comparator|Sham VR technology|"The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
11178462|NCT03532139|Experimental|Enoxaparin|-Enoxaparin is administered subcutaneous daily
11178837|NCT03529773|Experimental|Expanded Arm 19|High dose formulation B and placebo
11178463|NCT03532139|Experimental|Enoxaparin + Rosuvastatin|"Enoxaparin is administered subcutaneous daily.
~Rosuvastatin is administered daily orally starting on day 15"
11178464|NCT03532139|Experimental|Thromboprophylaxis|-Thromboprophylaxis is administered per clinician discretion
11178465|NCT03532126||Dermal filler for midface deficit|There will be one group in this study, the actual treatment group.
11178466|NCT03532113|Experimental|Updating|The Updating intervention aims to improve the ability to monitor and quickly add or delete of content of working memory.
11178467|NCT03532113|Experimental|Inhibition|The Inhibition intervention aims to improve the ability to supersede responses that are prepotent or automatic for a given situation.
11178468|NCT03532113|Active Comparator|General Knowledge|The General knowledge intervention allows the learning of information on various topics. It does not involve attentional control but semantic knowledge.
11178469|NCT03532100|Experimental|Straight line walking|All participants will walk in a straight line while wearing the study prosthesis.
11178470|NCT03532100|Experimental|Circle walking with prosthesis inside|All participants will walk around a 1-meter radius circle with their prosthesis on the inside of the circle.
11178471|NCT03532100|Experimental|Circle walking with prosthesis outside|All participants will walk around a 1-meter radius circle with their prosthesis on the outside of the circle.
11178472|NCT03532087|No Intervention|No denosumab|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are not additionally treated with denosumab.
11178473|NCT03532087|Experimental|Denosumab 120 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 120 mg every 3 weeks. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
11178474|NCT03532087|Experimental|Denosumab 60 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 60 mg every 6 months. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
11178475|NCT03532074|Other|laparoscopic approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a laparoscopic approach; follow up and assessment of bowel symptoms after surgery
11178476|NCT03532074|Other|robot-assisted approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a robot-assisted approach; follow up and assessment of bowel symptoms after surgery
11178477|NCT03532061|Experimental|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
11178478|NCT03532061|Active Comparator|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
11178479|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
11178480|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
11178481|NCT03532035|Experimental|Brincidofovir (BCV)|"Cohort 1: BCV 10 mg twice weekly via IV infusion over 2 hours
~Cohort 2: BCV 15 mg twice weekly via IV infusion over 2 hours
~Cohort 3: BCV In Cohort 3, the actual dose may be higher or lower than doses administered in previous cohorts; the maximum dose of IV BCV will be ≤ 25 mg."
11178482|NCT03532035|Active Comparator|Standard of Care (SoC)|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV Cidofovir (CDV), ganciclovir, or ribavirin."
11178483|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
11178484|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
11178485|NCT03532009|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
11178486|NCT03532009|Placebo Comparator|Placebo|Powder for oral suspension
11178487|NCT03531970|Experimental|Dexamethasone|lidocaine & Dexamethasone
11178488|NCT03531970|Placebo Comparator|Non-dexamethasone|lidocaine & Placebo
11178489|NCT03531957|Experimental|ASN002 40 mg|40 mg ASN002
11178490|NCT03531957|Experimental|ASN002 60 mg|60 mg ASN002
11178491|NCT03531957|Experimental|ASN002 80 mg|80 mg ASN002
11178492|NCT03531957|Experimental|Placebo Oral Tablet|Matching placebo for ASN002 doses
11178493|NCT03531944|Experimental|Community pharmacist-involved care|Community pharmacist-involved collaborative care in the management of type 2 diabetes mellitus
11178494|NCT03531944|Placebo Comparator|Usual care|Usual care with physician and as needed referral to nurses
11178495|NCT03531918|Experimental|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first course of induction are eligible for a second course, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.
~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during course 1, and cytarabine IV every 12 hours on days 1-6 of courses 2-3. Treatment repeats every month for up to 3 courses in the absence of disease progression or unacceptable toxicity."
11178496|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
11178497|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
11178498|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsule
11178499|NCT03531892|Experimental|AJM300 960mg/dose|Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
11178500|NCT03531892|Placebo Comparator|Placebo|Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
11178502|NCT03531866|Experimental|Intervention Version A|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version A will include an additional topic area.
11178503|NCT03531866|Experimental|Intervention Version B|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version B will include an additional topic area (different than in Version A).
11178504|NCT03531866|No Intervention|Wait-List Control|Youth will not have access to DigiKnowIt News until after the post-test timepoint.
11178505|NCT03531853|Experimental|Imaging patients|Get uveitis patients and ER patients to image their eyes
11178506|NCT03531840|Experimental|1/Olaparib|Twice daily oral olaparib
11178507|NCT03531827|Experimental|1/Lead-In Safety|Combination treatment of increasing dose of CRLX101 with enzalutamide
11178508|NCT03531827|Experimental|2/Efficacy|Tolerable dose of CRLX101 in combination with enzalutamide (8 patients, expandable to 21 total patients)
11178509|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
11178510|NCT03531801||Recovered fracture group|The interventions will be conducted on both groups, on two experimental (approximately 45 minutes per session) sessions separated by 24 hours.Pressure algometry consists of measuring pressure pain thresholds at three bilateral muscle sites.Mapping referred pain areas consists of recording on an electronic body chart the area of pain induced by 60s pressure stimulation at 1.2 times the force needed to reach the pressure pain threshold, exerted on the extensor carpi radialis and the infraspinatus muscles.As group-differences can be attenuated at baseline but emerge on a sensitized (exercise-induced soreness) state, these procedures are performed at baseline and 24 hours after evoking exercise-induced muscle soreness. For further clarification see our recent publication PMID:29608510
11178511|NCT03531801||Control group|This group will receive the same intervention than the recovered fracture group
11178512|NCT03531788|Experimental|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
11178513|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
11178514|NCT03531775|Other|Upright MRI|All participants will be scanned using an upright MRI in seated/standing position and supine position. They will also be scanned supine using a conventional MRI.
11178515|NCT03531762|Experimental|Sequence 1: Treatment A-B-C|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
11178516|NCT03531762|Experimental|Sequence 2: Treatment A-C-B|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
11178517|NCT03531762|Experimental|Sequence 3: Treatment B-A-C|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
11178518|NCT03531762|Experimental|Sequence 4: Treatment B-C-A|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days between.
11178519|NCT03531762|Experimental|Sequence 5: Treatment C-A-B|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
11178520|NCT03531762|Experimental|Sequence 6: Treatment C-B-A|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days.
11178521|NCT03531749|Experimental|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
11178522|NCT03531749|Experimental|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
11178523|NCT03531749|Experimental|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
11178524|NCT03531749|Experimental|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
11178525|NCT03531749|No Intervention|HIV- Control|Unsupplemented
11178526|NCT03531749|No Intervention|HIV+ Control|Unsupplemented
11178527|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
11178528|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
11178529|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
11178530|NCT03531697|Experimental|Generic Loteprednol Etabonate - RLD|Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
11178531|NCT03531697|Active Comparator|RLD - Generic Loteprednol Etabonate|Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate
11178532|NCT03531684|Experimental|MMFS-205-SR|Oral MMFS-205-SR twice daily (2,000, 3,000, or 4,000 mg/day total, depending on lean body mass and response to initial dose at Week 12) for 24 weeks
11178533|NCT03531684|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 24 weeks
11178534|NCT03531671|Experimental|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
11178536|NCT03531632|Experimental|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
11178537|NCT03531619||Dizziness|Patients referred to a neuro-otological clinic due to dizziness who answer that they do not suffer from neck pain
11178538|NCT03531619||Dizziness and neck pain|Patients referred to a neuro-otological clinic due to dizziness who answer that they suffer from neck pain
11178539|NCT03531619||Neck pain|Patients referred to a rehabilitation center due to neck pain who answer that they do not suffer from dizziness
11178540|NCT03531619||Neck pain and dizziness|Patients referred to a rehabilitation center due to neck pain who answer that the suffer from dizziness
11178541|NCT03531619||Healthy Control|Healthy Controls without neck pain or dizziness
11178542|NCT03531606|Experimental|Experimental|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
~(1 week before surgery and 3 weeks after surgery)
~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
11178543|NCT03531606|Placebo Comparator|Placebo comparator|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.
~The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.
~(1 week before surgery and 3 weeks after surgery)
~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
11178544|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
11178545|NCT03531580|Experimental|Healthy volunteers|six healthy volunteers: 3 male (age 20-40; 40-60 and 60+) and 3 female (age 20-40; 40-60 and 60+)
11178546|NCT03531567|Experimental|Virtual Reality Mystic Isle Game|"Subjects in the treatment arm will complete a prescribed 2-month treatment using the virtual reality program Mystic Isle. The OT will follow the Treatment Arm Intervention Protocol, which provides standardized guidelines for grading the intensity, level of challenge, and types of games/activities of the intervention up or down. The OT will complete weekly phone calls with participant to discuss progress, answer any questions, and remotely make updates to the game as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the intervention will be 7 hours/week. The minimum amount of time spent on the intervention will be 3.5 hours/week."
11178547|NCT03531567|Active Comparator|Standard Home Exercise Program|"Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the Control Arm Intervention Protocol to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week."
11178548|NCT03531554|Experimental|ketone ester drink|Oral intake of ketone ester drink muscle biopsy exercise muscle biopsy Magnetic Resonance imaging
11178549|NCT03531554|Placebo Comparator|carbohydrate drink|Oral intake of isocaloric carbohydrate drinkmuscle biopsy exercise muscle biopsy Magnetic Resonance imaging
11178550|NCT03531541|Active Comparator|active TENS and CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.
~After application of TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust)."
11178551|NCT03531541|Placebo Comparator|placebos TENS and CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.
~Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies[42-44]. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect"
11178552|NCT03531541|Active Comparator|placebo TENS and active CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.
~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
11178553|NCT03531541|Active Comparator|active TENS and placebo CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.
~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
11178554|NCT03531528|Experimental|Experimental|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
11178555|NCT03531502|Active Comparator|Standard medical therapy|Patients who have a positive NIPS study and are randomized to the medical therapy arm will either be initiated on antiarrhythmic therapy or will have their antiarrhythmic therapy intensified. All medication therapy is considered usual standard therapy.
11178556|NCT03531502|Experimental|Ventricular Tachycardia Ablation|Patients who have a positive NIPS study and are randomized to the ablation arm will undergo ventricular tachycardia ablation procedure guided by CardioInsight.
11178557|NCT03531502|Other|Negative NIPS/Non-intervention|Patients who had a negative NIPS study will not be assigned to a treatment group and will be followed according to standard of care.
11178558|NCT03531489|Experimental|Part 1: Feasibility|Patients will perform 6-minute walk test with AIR-AD to allow for observation and real-time feedback.
11178559|NCT03531489|Experimental|Part 2: Crossover|Crossover design where investigator will compare wearing of AIR-AD during exercise to compare distance walked with and without it.
11178560|NCT03531476|Experimental|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
11178561|NCT03531463|Active Comparator|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.
~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
11178562|NCT03531463|No Intervention|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
11178563|NCT03531450|Experimental|Cognitive Behavioral Therapy|Patients in the cognitive behavioral therapy group will be asked to undergo a 8-week CBT trial. An online videoconferencing link will be used to deliver CBT virtual sessions that will be approximately 60 minutes in length. Each session will be conducted by a clinical psychology doctoral student, supervised by a licensed psychologist. Patients will also undergo careful phenotyping pre- and post intervention with brain MRI, AFT, WMC, and NDT.
11178564|NCT03531450|No Intervention|Standard Medical Treatment|Patients in the standard medical treatment group will not interact with any therapists and will not receive any education beyond typical clinical exposure. They will be treated by the standard of care.
11178565|NCT03531437|Active Comparator|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
11178566|NCT03531437|Active Comparator|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
11178567|NCT03531424|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
11178568|NCT03531424|Experimental|CTA guided PCI|CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
11178569|NCT03531398|Experimental|High fat meal|Muffin containing 30g fat
11178570|NCT03531398|Experimental|Medium fat meal|Muffin containing 20g fat
11178571|NCT03531385||Behcet|Patients diagnosed with Behcet disease
11178572|NCT03531385||Healthy controls|Individuals without any chronic disease
11178573|NCT03531372|Experimental|Mipolixin®|Mipolixin® (Advanced Natural Antacid - AdNA)
11178574|NCT03531372|Active Comparator|Poliprotect®|Poliprotect® (Neobianacid)
11178575|NCT03531359|Experimental|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
11178576|NCT03531359|Active Comparator|Midazolam|Children will be premedicated with usual treatmente (midazolam)
11178577|NCT03531346|Experimental|Hyperosmolarity group|Healthy, young, habitual contact lens wearers with initial increased tear osmolarity (hyperosmolarity)
11178578|NCT03531346|Experimental|Normal osmolarity|Healthy, young, habitual contact lens wearers with initial tear osmolarity reported as normal
11178579|NCT03531333|Experimental|Ultrasound|ultrasound navigation guided surgery.
11178580|NCT03531333|No Intervention|Non-ultrasound|standard surgery without ultrasound guidance.
11178581|NCT03531320|Experimental|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
11178582|NCT03531320|Experimental|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
11178583|NCT03531307||Lactate and Ki 67 levels|Neurosurgical patients between June 2017 and February 2018 for tumoral and non-tumoral craniectomy with lactate levels at the beginning of surgery and Ki-67 index in biopsies.
11178584|NCT03531294|Experimental|Group 1|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.
11178585|NCT03531294|Experimental|Group 2|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.
11178586|NCT03531281|Experimental|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell infusion on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
11178587|NCT03531281|Active Comparator|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
~TRANSPLANT: Patients undergo stem cell infusion on day 0.
~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
11178588|NCT03531268|Active Comparator|PGx testing has clinical utility|These are subjects whose PGx testing is judged to have clinical utility and whose clinical care may be modified. Modifications may include altering doses or types of drugs given based on metabolic profile of the patient.
11178589|NCT03531268|No Intervention|PGx testing has no clinical utility|"These are subjects whose PGx testing is judged to have no clinical utility. Care as usual is provided, and there are no changes in drug selection or dosing based on the results of PGx testing."
11178838|NCT03529773|Placebo Comparator|Expanded Arm 20|placebo and placebo
11178590|NCT03531255|Experimental|1,080 mg pegcetacoplan administered subcutaneously|1,080mg pegcetacoplan administered subcutaneously twice weekly or every three days.
11178591|NCT03531242|Experimental|Cohort A: Initial Non-responders to VEE TC-83 vaccinations|Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, to be administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area.
11178592|NCT03531242|Experimental|Cohort B: Responders to TC-83 or previous C-84 vaccinations|"Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.
~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
11178593|NCT03531229|Placebo Comparator|Placebo|Placebo to Lu AF76432
11178594|NCT03531229|Experimental|Lu AF76432|Lu AF76432
11178595|NCT03531216|Active Comparator|Topical application of rosemary oil|Rosemary essential oil (10% )
11178596|NCT03531216|Placebo Comparator|Placebo|Pharmaceutical quality olive oil
11178597|NCT03531203|Experimental|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
11178598|NCT03531203|Placebo Comparator|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
11178599|NCT03531190|Experimental|Nutritional supplement (Protein + MIX)|Patients are given: Nutritional Supplement of protein 2-3 times a day + MIX once daily for 35 days
11178600|NCT03531190|Active Comparator|Nutritional supplement (Protein)|Nutritional Supplement of protein as needed 2-3 times a day for 35 days
11178601|NCT03531177|Experimental|Intervention|HEAL-D diet and lifestyle education and behavioural change intervention, 7 sessions over 14 weeks.
11178602|NCT03531177|Active Comparator|Control|Usual care.
11178603|NCT03531164|Experimental|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
11178604|NCT03531164|Active Comparator|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
11178605|NCT03531138|Experimental|Pulmonary rehabilitation group|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week.
11178606|NCT03531112|Experimental|Appetite Awareness Treatment|Participants will receive an 8-week Appetite Awareness Training (AAT) program using a group format, will be provided a smart scale (with bluetooth connection) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessment will be conducted at 0, 2, and 6 months.
11178607|NCT03531112|No Intervention|Control|Control group participants will receive no intervention in months 1-6, but will be offered the chance to receive an abbreviated form of AAT (4 weeks) following the 6-month assessment.
11178608|NCT03531099|Experimental|HIFU treatment|"65 patients will receive the immediate treatment with focal HIFU in order to destroy the cancer without causing side effects. HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
11178609|NCT03531099|Active Comparator|Active surveillance|"65 patients will be randomized to active surveillance and will have exactly the same follow-up as treated patients excepting the HIFU treatment.
~Active surveillance is a therapeutic option that shifts the eventual moment of curative treatment while remaining within a window of curability of the disease.
~Patients randomized in this arm will also have PSA dosage, MRI exam, questionnaires and prostatic biopsies during their follow up."
11178610|NCT03531086||Ioflupane I123|Participants will receive Ioflupane I123 as an adjunct diagnostic tool in combination with single photon emission computer tomography (SPECT) to evaluate striatal dopamine transporter. Patients will serve as their own control longitudinally.
11178611|NCT03531073||Standard care cohort|This study is observational. Patients will receive standard treatment as given in usual clinical practice with no intervention as part of the study. As per current clinical practice guidelines and UK reimbursement rules for biologics in PsA, patients will receive a pragmatic treat to target approach using step up standard therapies. Patients will usually receive methotrexate first line, initially 15mg ow increasing to 25mg ow as tolerated. In case of non-response, an additional DMARD will be used (sulfasalazine up to 3g daily or leflunomide 20mg od). If two DMARDs are failed and patients are eligible for biologic therapy under UK National Institute of Health and Clinical Excellence (NICE) guidance, then biologics will be used.
11178612|NCT03531060|Experimental|IRL790|IRL790 Capsule 10 mg, oral administration
11178613|NCT03531060|Placebo Comparator|Placebo|Placebo capsule, identical appearance, oral administration
11178614|NCT03531047|Experimental|Refractive CXL|Tomography-customised CXL
11178615|NCT03531034|Experimental|Hypertensive Women|Group of hypertensive and controlled women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
11178616|NCT03531034|Active Comparator|Normotensive Women|Group of normotensive women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities.
11178617|NCT03531021|Experimental|Heart healthy intervention|The intervention group will receive 2 modules (one in in person and one by video conference) and will receive follow-up phone calls/emails by study staff 3 weeks following each visit to review education and strategies for and barriers to reaching goals. Intervention sessions must include teen; parents may attend if they wish. Participants will be placed on teams and encouraged to complete behavioral challenges to earn points towards a cash reward.
11178927|NCT03529084|Active Comparator|Investigator's Choice|Investigator's Choice (erlotinib or gefitinib).
11178618|NCT03531021|No Intervention|Attention Control|There will be a delayed intervention for the control group with study handouts after 3 months. The control group will meet with the RAs for demographic and survey completion and receive reminder phone calls/emails in order to match for attention.
11178619|NCT03531008||Treatment-resistant focal epilepsy|Individuals with treatment-resistant focal epilepsy
11178620|NCT03530995|Experimental|Part 1, Period 1|Drug: KD025 Subjects will receive KD025 200 mg single dose on Day 1
11178621|NCT03530995|Experimental|Part 1, Period 2|Drug: itraconazole Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7 Drug: KD025 Subjects will receive KD025 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9
11178622|NCT03530995|Experimental|Part 1, Period 3|Drug: rabeprazole Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3 Drug: KD025 Subjects will receive KD025 200 mg + rabeprazole 20 mg QD on Day 4
11178623|NCT03530995|Experimental|Part 1, Period 4|Drug: rifampicin Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9 Drug: KD025 Subjects will receive KD025 200 mg on Day 10
11178624|NCT03530995|Experimental|Part 2, Period 1|Drug: KD025 Subjects will receive KD025 200 mg BID on Day 1
11178625|NCT03530995|Experimental|Part 2, Period 2|Drug: omeprazole Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3 Drug: KD025 Subjects will receive KD025 200 mg BID + omeprazole 20 mg QD on Day 4
11178626|NCT03530982|Experimental|Intervention group|Intensive goal training of relevant activities reported by adolescents in the beginning of the study. Therapists will grade the level of complexity of the proposed activities, considering the relevant movements, task demands and contextual factors involved in the performance of each task. Adolescents will be asked to practice these activities at home (1 hour/daily) and to discuss their difficulties and improvements with the therapists. The intervention will be provided in a day-camp model.
11178627|NCT03530969|Experimental|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
11178628|NCT03530969|Active Comparator|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
11178629|NCT03530969|Active Comparator|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
11178630|NCT03530956|Active Comparator|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis
11178631|NCT03530956|Experimental|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis
11178632|NCT03530943|Active Comparator|Academic Stress Management|Students assigned to the Academic Stress Management (ASM) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks during which time they will receive 100% exposure to various evidence-based academic stress management tools.
11178633|NCT03530943|Experimental|Human Animal Interaction Enhanced|Students assigned to the Human Animal Interaction - Enhanced (HAI-E) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group receives 50% exposure to structured and unstructured animal assisted activities and 50% exposure to various evidence-based academic stress management tools.
11178634|NCT03530943|Experimental|Human Animal Interaction only|Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
11178635|NCT03530930|Experimental|Comarum Palustre|Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
11178636|NCT03530917|Experimental|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
11178637|NCT03530917|Experimental|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
11178638|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
11178639|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
11178640|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
11178641|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
11178642|NCT03530917|Experimental|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
11178643|NCT03530917|Experimental|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
11178644|NCT03530904|Active Comparator|early mobilization after cardiac device implantation|mobilization after 4 hours
11178645|NCT03530904|Active Comparator|Late mobilization after cardiac device implantation|Mobilization after 24 hours
11178646|NCT03530891|Experimental|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
11178647|NCT03530891|Active Comparator|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
11178648|NCT03530878|Experimental|Hip Arthroscopy (HA)|This approach addresses intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH 3. Furthermore, capsular plication can be performed through HA to reduce instability of the joint.
11178649|NCT03530878|No Intervention|Periacetabular Osteootmy (PAO)|The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization.
11178650|NCT03530852|Experimental|Relizorb treatment|Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition
11178651|NCT03530839|Experimental|Arthrodesis|Arthrodesis of the proximal interphalangeal joint by using a threaded K-wire
11178652|NCT03530839|Active Comparator|Resection arthroplasty|Resection arthroplasty of the proximal interphalangeal joint using a normal K-wire
11178653|NCT03530813|Active Comparator|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
11178654|NCT03530813|Experimental|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
11178655|NCT03530800|Active Comparator|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final six weeks. Dose escalations will only be done if the investigator deems necessary.
11178656|NCT03530800|Placebo Comparator|Placebo|Subjects will receive placebo for 10 weeks weeks.
11178657|NCT03530787|Active Comparator|Acetyl Zingerone Group|This group was given the topical with the active acetyl zingerone agent.
11178658|NCT03530787|Placebo Comparator|Control Group|This group was given the topical without the active acetyl zingerone agent and just the carrier lotion.
11178659|NCT03530774|Experimental|Egg while protein supplement|25 g of powdered egg white protein supplement daily for 6 months. Total of 20.6 g of protein in 25 g of supplement.
11178660|NCT03530774|Placebo Comparator|Maltodextrin supplement|25 g of powdered maltodextrin supplement daily for 6 months. Total 23.5 g of carbohydrate in 25 g of supplement.
11178661|NCT03530761||Acute kidney injury|Increase in serum creatinine more than 0.3 mg/dl within 48 hours or a percentage increase serum creatinine more than 50% from baseline.
11178662|NCT03530761||Hepatorenal syndrome|"Diagnosis of cirrhosis and ascites,
~Diagnosis of AKI according to ICA-AKI criteria
~No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight
~Absence of shock
~No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs, aminoglycosides, iodinated contrast media, etc.)
~No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (> 50 RBCs per high power field), normal findings on renal ultrasonography."
11178663|NCT03530748||Patients with Renal Artery Stenosis|Patients with simple renal artery stenosis or aortic dissection with renal artery obstruction
11178664|NCT03530735|Experimental|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.
~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
11178665|NCT03530709|Experimental|Experimental|videoconferencing
11178666|NCT03530709|No Intervention|Control|Usual care
11178667|NCT03530696|Experimental|T-DM1 with palbociclib|T-DM1 is given IV every 21 days Palbociclib is administered days 5-18
11178668|NCT03530696|Active Comparator|T-DM1|T-DM1 is given IV every 21 days
11178669|NCT03530683|Experimental|TTI-622 Monotherapy|Escalation Phase will include multiple doses of TTI-622
11178670|NCT03530683|Experimental|TTI-622 + Rituximab in DLBCL|Patients with CD20 positive diffuse large B-cell lymphoma may enter the TTI-622 + rituximab combination cohort; rituximab administered according to the institutional standard of care in accordance with the current FDA-approved package insert.
11178671|NCT03530683|Experimental|TTI-622 + PD-1 Inhibitor|Patients with classic Hodgkin Lymphoma may enroll in this cohort and will receive TTI-622 in combination with either nivolumab administered per institutional standard of care in accordance with the current FDA-approved package insert.
11178672|NCT03530683|Experimental|TTI-622 + Proteasome-Inhibitor Regimen|Patients with myeloma will receive TTI-622 in addition to a standard NCCN guideline recommended proteasome inhibitor (carfilzomib) + dexamethasone-containing regimen administered per institutional standard of care in accordance with the current FDA-approved package insert.
11178673|NCT03530683|Experimental|TTI-622 + Rituximab in iNHL|Patients with CD20 positive indolent NHL may enter the TTI-622 + rituximab combination cohort; rituximab administered according to the institutional standard of care in accordance with the current FDA-approved package insert.
11178674|NCT03530670|Active Comparator|oral midazolam (demizolam)|"To prevent preoperative anxiety patient premedicated by 0.5 mg/kg oral midazolam.
~In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale"
11178675|NCT03530670|Active Comparator|http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|To prevent preoperative anxiety by watching a short movie ( at http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
11178676|NCT03530670|Active Comparator|playing smartphone game|To prevent preoperative anxiety by playing smartphone game ( angry birds, subway surfers, snail Bob) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
11178677|NCT03530644|Experimental|RSP-14|"Comparative study of two Investigational Medical Devices (WM3.4NR and P0.1)
~Optical data will be obtained from T1D over a dynamic glycemic range. Data will be paired with references."
11178678|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
11178679|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
11178680|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
11178681|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
11178682|NCT03530618|Experimental|Flexible tip straight guidewire|
11178683|NCT03530618|Experimental|J-tip guidewire|
11178684|NCT03530605|Experimental|Optune TTF Device|Optune TTF treatment
11178685|NCT03530605|No Intervention|Historical matched control|age-matched historical controls
11178686|NCT03530592|Experimental|Seated Ankle Robot Training|
11178687|NCT03530579|Experimental|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
11178688|NCT03530579|Active Comparator|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
11178689|NCT03530566||Pnk group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
11178690|NCT03530566||Control group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
11178691|NCT03530553|Experimental|Treatment arm|The treatment arm will receive the HMS as well as standard of care of the weight management program.
11178692|NCT03530553|No Intervention|Control arm|The control arm will not receive the HMS and will receive standard of care.
11178693|NCT03530540|Experimental|Intervention|Active shockwaves
11178694|NCT03530540|Placebo Comparator|Placebo|Placebo shockwaves
11178695|NCT03530527|Active Comparator|ERCP with biliary stenting|Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.
11178696|NCT03530527|Active Comparator|EUS guided biliary drainage|Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.
11178697|NCT03530514|Experimental|Part A: Single dose cohort 1|Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
11178698|NCT03530514|Experimental|Part A: Single dose cohort 2|Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
11178699|NCT03530514|Experimental|Part A: Single dose cohort 3|Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
11178700|NCT03530514|Experimental|Part A: Single dose cohort 4|Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
11178701|NCT03530514|Experimental|Part A: Single dose cohort 5|Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
11178702|NCT03530514|Experimental|Part A: Single dose cohort 6|Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
11178703|NCT03530514|Experimental|Part A: Single dose cohort 7|Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
11178704|NCT03530514|Experimental|Part A: Single dose cohort 8|Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
11178705|NCT03530514|Experimental|Part A: Single dose cohort 9|Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
11178706|NCT03530514|Experimental|Part B: Repeated dose cohort 10|Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
11178707|NCT03530501|Placebo Comparator|Placebo|Very low calorie ketogenic diet followed by low calorie diet
11178708|NCT03530501|Experimental|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
11178709|NCT03530501|Experimental|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
11178710|NCT03530488|Active Comparator|Lidocaine group|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline 5 minutes before hystroscopy
11178711|NCT03530488|Placebo Comparator|control group|intrauterine and intracervical instillation of 19 ml normal saline 5 minutes before hystroscopy
11178712|NCT03530475|Active Comparator|placenta previa|cases diagnosed as placenta previa diagnosed by ultrasound and doppler
11178713|NCT03530475|Active Comparator|placenta accreta|placenta previa diagnosed as placenta accreta by ultrasound and doppler
11178714|NCT03530462||patient with first-line and second-line|patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)
11178715|NCT03530462||patients with first-line only|patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only
11178716|NCT03530462||healthy control|healthy individuals without a history of psychiatric or neurologic disease
11178717|NCT03530449||Subjects with Normal Eyes|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
11178718|NCT03530449||Subjects with Retinal Vascular Pathology|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology
11178719|NCT03530436|Other|Native turmeric extract|6 capsules of native curcumin (207 mg curcumin)
11178720|NCT03530436|Experimental|Native turmeric extract with 7-9% volatile turmeric oils|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178721|NCT03530436|Experimental|Turmeric extract plus mixture of phytochemicals|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178722|NCT03530436|Experimental|Cyclodextrin complex of curcuminoids|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178723|NCT03530436|Experimental|Turmeric oleoresin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178724|NCT03530436|Experimental|Liposomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178725|NCT03530436|Experimental|Phytosomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178726|NCT03530436|Experimental|Micellar turmeric extract|6 capsules of the formulation; dosage normalized to 207 mg curcumin
11178727|NCT03530410||Patients with intragastric balloon|Patients who will receive an intragastric balloon placement for weight loss
11178728|NCT03530397|Experimental|Arm A: MEDI5752|MEDI5752
11178729|NCT03530397|Experimental|Arm B: MEDI5752 and chemotherapy|MEDI5752, pemetrexed and carboplatin.
11178730|NCT03530397|Active Comparator|Arm C: Pembrolizumab and chemotherapy|pembrolizumab, pemetrexed, and carboplatin
11178731|NCT03530384|Experimental|Cognitive training|Computerized cognitive training program targeting inhibitory control
11178732|NCT03530384|Sham Comparator|Control Training|A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
11178733|NCT03530371|Experimental|Dexmedetomidine Hydrochloride|sedation of patients to perform auditory test
11199943|NCT03384758|Active Comparator|Diabetes mellitus|
11178734|NCT03530358|Experimental|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
11178735|NCT03530358|Active Comparator|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
11178736|NCT03530345|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
11178737|NCT03530345|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
11178738|NCT03530332|Experimental|Treatment|
11178739|NCT03530332|No Intervention|Control|
11178740|NCT03530319|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
11178741|NCT03530319|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
11178742|NCT03530306|Active Comparator|PS1-PS4|
11178743|NCT03530306|Active Comparator|PS6-PS10|
11178744|NCT03530306|Active Comparator|PS7-PS4|
11178745|NCT03530306|Active Comparator|PS9-PS6|
11178746|NCT03530293|Experimental|Valbenazine|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
11178747|NCT03530293|Placebo Comparator|Placebo|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
11178748|NCT03530280|Active Comparator|pregabalin (lyrica)|pregabalin (lyrica) 150 mg preoperative 1 hour before and the postoperative sham block will perform.
11178749|NCT03530280|Placebo Comparator|placebo group|a placebo capsule 1 hour before surgery and the postoperative sham block will perform.
11178750|NCT03530280|Active Comparator|adductor channel block group|A preoperative placebo capsule will be given.This group will receive postoperative adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
11178751|NCT03530267|Active Comparator|Arm A (mFOLFOX7)|"Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
~This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study."
11178752|NCT03530267|Experimental|Arm B (Aflibercept + mLV5FU2)|"Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
~The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7."
11178753|NCT03530254|Other|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
11178754|NCT03530254|Other|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
11178755|NCT03530241|Experimental|MRCP positive|
11178756|NCT03530241|Active Comparator|MRCP negative|
11178757|NCT03530228|Experimental|Treatment A: Tegoprazan (C1)|Tegoprazan QD, oral administration
11178758|NCT03530228|Experimental|Treatment B: Tegoprazan (C1)|Tegoprazan QD, oral administration
11178759|NCT03530228|Experimental|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
11178760|NCT03530228|Experimental|Group 1: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
11178761|NCT03530228|Experimental|Group 2: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
11178762|NCT03530228|Active Comparator|Group 3: Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days
11178763|NCT03530228|Experimental|Tegoprazan (C3)|Tegoprazan QD, oral administration
11178764|NCT03530215||Adverse Events with Antineoplastic and immunomodulating agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Antineoplastic and immunomodulating agents, with a chronology compatible with the drug toxicity
11178765|NCT03530202|Experimental|HVRT + Creatine Monohydrate|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume creatine monohydrate powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
11178766|NCT03530202|Placebo Comparator|HVRT + Maltodextrin Powder|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume maltodexterin powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
11178767|NCT03530189||Normoglycemic group|"The infant will enter this group if a single blood glucose concentration is between 2.1 and 2.5 mmol/l (38-45 mg/dL), or a single blood glucose concentration is between 8.6 - 10 mmol/l (155-180 mg/dL) with all other measures between 2.6 and 8.5 mmol/l (47-153 mg/dL).
~To all premature infants intravenous 10% dextrose at 60-90 mL/kg/day will be started as soon as possible after birth."
11178796|NCT03529968||Finnish Siewert I-II adenocarcinoma|All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
11178928|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
11178768|NCT03530189||Group with impaired glucose|"The infant can be hypoglycemic, hyperglycemic or unstable. The infant will be hypoglycemic if blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration is≤2,0 mmol/l (36 mg/dL). Hypoglycemia will be treated with intravenous bolus of 10% dextrose.
~The infant will be hyperglycemic if blood glucose concentration is ≥8,6 mmol/l (155 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration ≥10,1 mmol/l (182 mg/dL). Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.
~The infant will be unstable if at least 1 blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) and ≥1 blood glucose concentration is ≥8,6 mmol/l (155 mg/dL)."
11178769|NCT03530176|Experimental|single arm|18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms. Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer. Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability. Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest. After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes. A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
11178770|NCT03530163|Experimental|Respiratory Muscle Training|
11178771|NCT03530163|Sham Comparator|Sham Breathing Training|
11178772|NCT03530150|Active Comparator|Pirfenidone 600 mg|Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
11178773|NCT03530150|No Intervention|Usual Care|Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
11178774|NCT03530137|Other|families living at Families Moving Forward (FMF)|
11178775|NCT03530124|Other|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from randomization to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
11178776|NCT03530124|No Intervention|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
11178777|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving < 75 minutes of moderate-intensity or < 37 minutes of vigorous-intensity aerobic physical activity per week.
11178778|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving > 225 minutes of moderate-intensity or > 112 minutes of vigorous-intensity aerobic physical activity per week.
11178779|NCT03530098|No Intervention|Control (Without-AI)|This is the control arm where no intervention is provided; represents current standard of care.
11178780|NCT03530098|Experimental|Experiment (With-AI)|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
11178781|NCT03530085|Experimental|Dec+Flu+Bu Conditioning Regimen|For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -12 to -8；Fludarabine(Flu) 30mg/m2/day on days -5 to -2；Busulfan (BU) 3.2 mg/kg/day on days -5 to -4).
11178782|NCT03530072||Cases|Subjects with Fever and Neutropenia
11178783|NCT03530046|Experimental|High SID fluid|Group 1: half-normal saline with addition of 75mEq/L sodium bicarbonate
11178784|NCT03530046|Active Comparator|Hartmann's solution|Group 2: Hartmann's Solution
11178785|NCT03530033|No Intervention|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
11178786|NCT03530033|Experimental|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
11178787|NCT03530020|Active Comparator|monolithic zirconia crowns|Monolithic zirconia attracts many dentists worldwide due to its excellent mechanical properties, biocompatibility and appreciate aesthetics
11178788|NCT03530020|Experimental|lithium silicate crowns|A lithium silicate glass ceramic is newly introduced to the market. After crystallization, it exhibits an ideal combination of aesthetics and strength with translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns.
11178789|NCT03530007|Active Comparator|normal saline|patients received normal saline for prevention of shivering during spinal anesthesia
11178790|NCT03530007|Active Comparator|ondansetron 4MG|patients received 4 mg of ondansetron for prevention of spinal shivering
11178791|NCT03530007|Active Comparator|ondansetron 8MG|patients received 8 mg of ondansetron for prevention of spinal shivering
11178792|NCT03529994||Enrollment|
11178793|NCT03529981|Active Comparator|Stress incidents without TVS|a fraction of physiological detected stress incidents will not trigger TVS
11178794|NCT03529981|Experimental|TVS in response to participant initiation or stress detection|The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
11178795|NCT03529968||Italian Siewert I-II adenocarcinoma|Patients with Siewert type I adenocarcinoma underwent subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Patients with Siewert type II adenocarcinoma underwent total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy. A right anterolateral thoracotomy and an upper midline laparotomy were performed as previously described. Lymphadenectomy included chest stations classified according to the AJCC TNM 7th edition (L/R = left/right; 3, 4R, 7, 2R, 8 and 9 and abdominal stations classified according to the Japanese Classification of Gastric Carcinoma (stations 1-12)
11199944|NCT03384758|Placebo Comparator|Healthy volunteers|
11178797|NCT03529955|Experimental|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
11178798|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
11178799|NCT03529929|Experimental|Methylprednisolone|"Methylprednisolone glucocorticoid Medrol Dose Pack
~Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively)."
11178800|NCT03529916||CVD subjects|CVD will be defined as >50% stenosis of one or more coronary arteries as assessed by coronary angiography.
11178801|NCT03529916||healthy controls|healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.
11178802|NCT03529903|No Intervention|Control Group|*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. *Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). *Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. *Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
11178803|NCT03529903|Experimental|Experimental Group|*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. *Wear a Fitbit to track their daily physical activity and weight *Set a weekly active minutes goal and record their weight weekly. *Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). *Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. *Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
11178804|NCT03529890|Experimental|Radio-Immunotherapy before cystectomy|Single arm treatment with Nivolumab during a neoadjuvant radiation therapy of the pelvis before radical cystectomy with standardized pelvic lymphadenectomy
11178805|NCT03529877|Experimental|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)
11178806|NCT03529864|Experimental|Exercise therapy|The participants took part in a progressive exercise therapy program for 9 consecutive weeks, once a week. This consisted of group sessions with 8 or 9 students, with each session lasting 60 minutes, supervised by the principal researcher
11178807|NCT03529864|No Intervention|Control|The CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form
11178808|NCT03529851|Experimental|PRO intervention|Patients included will weekly fill in a 12 item questionaire via the internet during the 3 week study period.
11178809|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
11178810|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
11178811|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
11178812|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
11178813|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
11178814|NCT03529812|Experimental|Early-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education during the first unit of their year-long residency.
11178815|NCT03529812|Active Comparator|Delayed-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education midway through their year-long residency.
11178816|NCT03529799|Experimental|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
11178817|NCT03529799|Active Comparator|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
11178818|NCT03529786||Retrospective|An observational medical records review study (data collected retrospectively) in subjects with the severe form of MPS II.
11178819|NCT03529773|Experimental|Sentinel Arm 1|Low dose formulation A
11178820|NCT03529773|Experimental|Sentinel Arm 2|Mid dose formulation A
11178821|NCT03529773|Experimental|Sentinel Arm 3|High dose formulation A
11178822|NCT03529773|Experimental|Sentinel Arm 4|Low dose formulation B
11178823|NCT03529773|Experimental|Sentinel Arm 5|Mid dose formulation B
11178824|NCT03529773|Experimental|Sentinel Arm 6|High dose formulation B
11178825|NCT03529773|Placebo Comparator|Sentinel Arm 7|Placebo
11178826|NCT03529773|Experimental|Expanded Arm 8|Low dose formulation A and SIIV
11178839|NCT03529747|Experimental|Online self-help|A website providing information and psycho-education aimed at parents and carers of children with food allergies.
11178840|NCT03529747|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help once the RCT is complete.
11178841|NCT03529734|Experimental|12 min running group|This group will perform a 12 min high intensity running with the goal to cover maximal possible distance.
11178842|NCT03529734|Experimental|Local strengthening exercise group|This group will perform local strengthening exercises (curl-ups, left side trunk flexion, trunk extension, right side trunk flexion). Each participant will have to perform three sets of each exercise with the maximal possible number of repetitions with a slow tempo (1s concentric phase and 2 s eccentric phase). Between sets, minimal rest (15 s) will be administered.
11178843|NCT03529721|Experimental|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
11178844|NCT03529721|Placebo Comparator|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
11178845|NCT03529708|Experimental|SBRT boost|Standard radiotherapy (3D conformal, urgent palliative radiotherapy) plus stereotactic body radiotherapy (SBRT) boost
11178846|NCT03529695|Active Comparator|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
11178847|NCT03529695|Experimental|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
11178848|NCT03529682|Experimental|Circuit Training Group|Circuit exercise training will be given to the experimental group participants during 10 weeks, 60 minutes in a day and 3 times a week.
11178849|NCT03529682|Other|Control Group|The control group participants will continue to their own previous physiotherapy approaches as the same as minimum 3 times a week and total 3 hours.
11178850|NCT03529669|Experimental|Cytosponge™|All participants will receive the Cytosponge™ device.
11178851|NCT03529656|No Intervention|Pre-ERP|A group of patients who underwent liver transplantation surgery before the early rehabilitation program
11178852|NCT03529656|Experimental|Post-ERP|A group of immediate liver transplant patients who had an early rehabilitation program in ICU care
11178853|NCT03529643|Experimental|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine
~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
11178854|NCT03529643|Placebo Comparator|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil
~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
11178855|NCT03529630|Experimental|Inverted syringe|Participants in this arm will use of the inverted syringe before each breastfeeding starting from the first feed after delivery and continued as long as needed by the mother.
11178856|NCT03529630|No Intervention|Standard of care|Participants in the control group will receive standard medical care as dictated by their obstetricians. Any advice regarding infant nutrition or treatment of inverted nipples will be left to the primary physician, including possible use of the inverted syringe technique. .
11178857|NCT03529617||Critically ill patients|Patients admitted on ICU.
11178858|NCT03529617||Hematology patients|Patients admitted on the hematology ward.
11178859|NCT03529604||Oral Cancer group|Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
11178860|NCT03529604||PMOD group|Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
11178861|NCT03529604||Control|Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
11178862|NCT03529591|Active Comparator|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
11178863|NCT03529591|Active Comparator|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
11178864|NCT03529578|Experimental|dHACM|Standard of Care plus Weekly Application of dHACM
11178865|NCT03529565||Ancillary-Correlative (biospecimen collection)|Participants undergo collection of blood samples for histamine level analysis via ELISA.
11178866|NCT03529552|Experimental|Patients with anterior cruciate ligament rupture|
11178867|NCT03529526|Experimental|KN046|
11178868|NCT03529513||Depressed|Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
11178869|NCT03529513||Control|Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
11178870|NCT03529500||Adequate nutritional status|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
11178871|NCT03529500||Mild malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
11178872|NCT03529500||Moderate malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
11178873|NCT03529500||Severe malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
11178874|NCT03529487|Experimental|Oxymetazoline applied intra analy|
11178875|NCT03529474|Experimental|Psychology and Physiotherapy group|The psychological program consists of 4 sessions (2 hours each) comprising psychoeducation, training techniques of psychological management of pain and kinesiophobia resources The physiotherapy program consists of 3 domiciliary sessions per week, including physical exercise and stretching
11178876|NCT03529474|Placebo Comparator|Placebo Comparator: Control group|Usual daily activities
11178877|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
11178878|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
11178879|NCT03529448|Experimental|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)
~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
11178880|NCT03529435|Active Comparator|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
11178881|NCT03529435|Experimental|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
11178882|NCT03529422|Other|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments
11178883|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
11178884|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
11178885|NCT03529396|Experimental|1a: Chloroquine + 5th-day Primaquine|[ARM HALTED PREMATURELY DUE TO SAFETY CONCERNS]
11178886|NCT03529396|Experimental|1b: Chloroquine + 8-week Primaquine|26 G6PD deficient patients. Directly observed therapy.
11178887|NCT03529396|Active Comparator|1c: Chloroquine + 12-week Chloroquine|26 G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
11178888|NCT03529396|Active Comparator|2: Standard chloroquine + primaquine|52 G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
11178889|NCT03529383|Experimental|Connected device|"Women randomized to the connected device arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity."
11178929|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
11179089|NCT03527875|Experimental|ENBD group|Endoscopic Nasobiliary Biliary Drainage
11178890|NCT03529383|Experimental|Therapeutic education|"Women randomized to the therapeutic education arm will follow a 6-month program of therapeutic patient education. They will also receive international recommendations on physical activity."
11178891|NCT03529383|Experimental|Combined|"Women will benefit from both the connected device intervention and the therapeutic education intervention and receive international recommendations on physical activity."
11178892|NCT03529383|No Intervention|Control|Women will receive standard care, i.e., international recommendations on physical activity, without further intervention.
11178893|NCT03529344|Active Comparator|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
11178894|NCT03529344|Placebo Comparator|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
11178895|NCT03529331|Active Comparator|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
11178896|NCT03529331|Active Comparator|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
11178897|NCT03529331|Active Comparator|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
11178898|NCT03529305|Experimental|Low frequency rTMS|Patients receive low frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the unaffected side for two weeks, 5 consecutive days each week.
11178899|NCT03529305|Experimental|High frequency rTMS|Patients receive high frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the affected side for two weeks, 5 consecutive days each week.
11178900|NCT03529305|Active Comparator|Physical therapy|Patients receive physical therapy for two weeks.
11178901|NCT03529292|Experimental|Modified matrix obtained by the AmeaCell® device|
11178902|NCT03529279|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive CNG staging and CNG chemotherapy strategy and CNG radiation strategy
11178903|NCT03529279|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive the eighth edition of UICC/AJCC staging and NCCN chemotherapy strategy and NCCN radiation strategy
11178904|NCT03529266|Experimental|A(Surgery+PFS)|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal or coloesophageal anastomosis during Mckeown surgery .
11178905|NCT03529253|Experimental|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
11178906|NCT03529253|Active Comparator|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
11178907|NCT03529240|Experimental|Kinesiology taping|After performing the baseline assessments, kinesiology taping with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles of children. In both applications, the first and last 5 cm section of the bands were used as anchor and no tension was applied.
11178908|NCT03529214|Other|Implemented Health Facility|"Health facility that has piloted the Team Birth Project"
11178909|NCT03529201|Experimental|QLB|At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
11178910|NCT03529201|Experimental|Control|Standard care. No regional blocks.
11178911|NCT03529175|Active Comparator|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
11178912|NCT03529175|Active Comparator|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
11178913|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
11178914|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
11178915|NCT03529149|Experimental|Accurate blood pressure control|Implementing accurate blood pressure management under TCD monitoring
11178916|NCT03529149|Active Comparator|Guideline blood pressure control|Control blood pressure according to guidelines
11178917|NCT03529136|Experimental|MSC group 1|Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
11178918|NCT03529136|Experimental|MSC group 2|Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
11178919|NCT03529136|Experimental|Control group|Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
11178920|NCT03529123|Experimental|Tested Drug|Insulin glargine/lixisenatide fixed ratio combination (FRC)
11178921|NCT03529123|Active Comparator|Control Drug|Insulin glargine (Lantus®)
11178922|NCT03529110|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with DS-8201a
11178923|NCT03529110|Active Comparator|Ado-trastuzumab emtansine (T-DM1)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with T-DM1
11178924|NCT03529097|Active Comparator|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
11178925|NCT03529097|Placebo Comparator|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
11178926|NCT03529084|Experimental|EGF816|Investigational treatment arm of EGF816 (nazartinib).
11179090|NCT03527875|Experimental|EBS group|Endoscopic Biliary Stenting
11178930|NCT03529045||VNS Therapy|Any approved VNS Therapy System (according to local regulations) may be used in this registry.
11178931|NCT03529032|No Intervention|Fentanyl group|Drug: Fentanyl Fentanyl group 3µg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
11178932|NCT03529032|Experimental|methadone group|Drug: methadone methadone group 0.2mg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
11178933|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
11178934|NCT03529006|Active Comparator|Sequent Please Drug Coated Balloon Group|For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery. This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice. For bailout situation Xience stent implantation is possible.
11178935|NCT03529006|Active Comparator|Absorb Stent Group|Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb). Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
11178936|NCT03528993|Experimental|Exercise by hippotherapy device group|The experimental group receive conventional rehabilitation for 45 min/day following by use of a hippotherapy device for 15 min/day, 5 times/week for 4 weeks
11178937|NCT03528993|Other|Control group|The control group will receive conventional rehabilitation for 45 min/day, following by postural control exercises 15 min/day 5 times/week for 4 weeks.
11178938|NCT03528980||Bariatric surgery|
11178939|NCT03528980||standard nutritional management|
11178940|NCT03528967|Experimental|Arm 1|"Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:
~Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily
~Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily
~Start treatment from inclusion visit
~Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)"
11178941|NCT03528967|Other|Arm 2|"Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:
~Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily
~Administer orally
~Start treatment from inclusion visit
~Maintain treatment until 35 Weeks of Amenorrhea (WA)"
11178942|NCT03528954|Active Comparator|Propofol|Received intravenous 0.5mg/kg propofol
11178943|NCT03528954|No Intervention|Control|Do not received intravenous 0.5 mg/kg propofol
11178944|NCT03528941||Lamivudine|Patients who received lamivudine
11178945|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
11178946|NCT03528928|Experimental|Surface electrical stimulation|Each subject did a Kegel pelvic floor contraction, had the surface electrical stimulation turned on at highest comfortable intensity, did a Kegel contraction with surface electrical stimulation on, and had second electrical stimulation turned on.
11178947|NCT03528915||Prophylaxis group|Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
11178948|NCT03528915||no-antibiotic group|Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
11178949|NCT03528902|Experimental|Tamoxifen|20 mg po TID for 24 weeks
11178950|NCT03528902|Placebo Comparator|Placebo|Placebo arm
11178951|NCT03528889|Active Comparator|Goniometer|Extension FDO: classic procedure with goniometer controlled extension and derotation
11178952|NCT03528889|Experimental|EMT|Extension FDO: procedure with electromagnetic tracking (EMT) controlling extension and derotation
11178953|NCT03528876|Other|Single arm intervention study|Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)
11178954|NCT03528863|Experimental|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
11178955|NCT03528850|Experimental|Telehealth|The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
11178956|NCT03528850|No Intervention|Standard of Care|The Standard of Care will receive no interventions but will conduct surveys at enrollment and at the end of 30 days.
11178957|NCT03528837||Diagnosed as acute kidney injury|Sure diagnosed as acute kidney injury
11178958|NCT03528824|Experimental|Fenugreek wraps|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
11178959|NCT03528824|Active Comparator|Diclofenac gel|Daily application of diclofenac gel, 4 weeks application
11178960|NCT03528824|No Intervention|Usual care|no specific intervention
11178961|NCT03528811|Other|Five points test of Tongji university|"We established the evaluatation and follow-up system of diabetes vascular disease based on the method called Five points test of Tongji university ."
11178962|NCT03528785|Experimental|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
11178963|NCT03528772|Active Comparator|Minoxidil|Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
11178964|NCT03528772|Active Comparator|Glyceryl trinitrate|Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
11178965|NCT03528746|Experimental|Isometric exercise|Participants will complete isometric quadriceps exercise
11178966|NCT03528746|Active Comparator|Isotonic exercise|Participants will complete dynamic leg extension
11178967|NCT03528733|Experimental|Multi-Energy Detector|Multi-Energy Digital Radiography Detector System
11200338|NCT03382236|Placebo Comparator|Sham osteopathy|
11178968|NCT03528707|Active Comparator|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
11178969|NCT03528707|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
11178970|NCT03528694|Experimental|Durvalumab plus BCG (induction + maintenance)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
11178971|NCT03528694|Experimental|Durvalumab plus BCG (induction only)|Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
11178972|NCT03528694|Active Comparator|BCG treatment (Standard of care therapy)|Bacillus Calmette-Guerrin (BCG) standard of care treatment
11178973|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
11178974|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
11178975|NCT03528681|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
11178976|NCT03528655|Experimental|Decision aid group|Shared decision making using decision aid
11178977|NCT03528655|No Intervention|Controlled group|Standard oral explanation with booklet.
11178978|NCT03528642|Experimental|Treatment (CB-839, temozolomide, RT)|Patients receive CB-839 PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
11178979|NCT03528629|Experimental|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
11178980|NCT03528629|Experimental|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
11178981|NCT03528629|Experimental|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
11178982|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
11178983|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
11178984|NCT03528590|Active Comparator|size 3 i-gel®|size 3 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
11178985|NCT03528590|Experimental|size 4 i-gel®|size 4 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
11178986|NCT03528577|Experimental|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
11178987|NCT03528577|Active Comparator|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
11178988|NCT03528577|Placebo Comparator|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
11178989|NCT03528577|Placebo Comparator|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
11178990|NCT03528564|Experimental|Epoetin alfa|Preoperative treatment of anemia with iron sucrose (Venofer) plus Epoetin Alfa (Eprex)
11178991|NCT03528564|Placebo Comparator|Intravenous Iron|Preoperative treatment of anemia with iron sucrose (Venofer) plus placebo (saline)
11178992|NCT03528551|Experimental|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
11178993|NCT03528551|Experimental|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
11178994|NCT03528551|Experimental|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
11178995|NCT03528538|Placebo Comparator|Placebo|
11178996|NCT03528538|Active Comparator|AlphaFen fenugreek 400 mg|This group received 400 mg of fenugreek to be ingested daily for 60 days.
11178997|NCT03528538|Active Comparator|AlphaFen fenugreek 500 mg|This group received 500 mg of fenugreek to be ingested daily.
11178998|NCT03528525||Monogenic diseases cases|
11178999|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
11179000|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
11179001|NCT03528499|Experimental|Scapular Movement Training|Orientation and scapular exercises, performed twice a week, for 8 weeks.
11179002|NCT03528499|Active Comparator|General Exercises|Scapulothoracic muscle stretching and strengthening exercises, performed twice a week, for 8 weeks.
11179003|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
11179004|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
11179005|NCT03528473|Experimental|Exercise|Patients involved in the 6 months-physical training group.
11179006|NCT03528473|No Intervention|Control|Patients in control group carry on their usual follow-up programme.
11179007|NCT03528447|Experimental|Pulmonary Rehabilitation|Lung transplantation candidates who refered from Lung Transplantation surgery team will undergo the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Patient will evaluate at the beginning and end of the program.Cognitive functions and exercise capacities of the patients before and after the program will be evaluated.
11179008|NCT03528434|Experimental|Zinc|Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet
11179009|NCT03528434|Placebo Comparator|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
11179010|NCT03528421|Experimental|IM19 CAR-T cells|3*10^5/kg，1*10^6/kg，3*10^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
11179011|NCT03528408|Experimental|Nivolumab and Ipilimumab|All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.
11179012|NCT03528395|Experimental|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
11179013|NCT03528395|Active Comparator|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
11179014|NCT03528382|Experimental|period I group|
11179015|NCT03528382|Experimental|period II group|
11179016|NCT03528382|Experimental|period III group|
11179017|NCT03528369|Experimental|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
11179018|NCT03528369|Experimental|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
11179019|NCT03528369|Sham Comparator|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
11179020|NCT03528356|Placebo Comparator|Regular diet|
11179021|NCT03528356|Experimental|White diet|
11179022|NCT03528343|Experimental|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
11179023|NCT03528343|No Intervention|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
11179024|NCT03528330|Active Comparator|Internal hexagon connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.
~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.
~The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm."
11179025|NCT03528330|Experimental|Conical connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.
~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.
~The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm."
11179026|NCT03528317|Experimental|Alternate day fasting|Alternate day fasting with a high protein diet
11179027|NCT03528304|Experimental|Smoking arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking.
11179028|NCT03528304|Experimental|Weight loss arm|As part of the CM intervention women attend visits for smoking and weight loss assessment and are rewarded with prizes for losing some weight.
11179029|NCT03528304|Experimental|Smoking and weight loss arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking and for losing some weight.
11179030|NCT03528304|No Intervention|Control|Women attended clinic visits for smoking status and weight loss assessment.
11179031|NCT03528291||Cardiogenic shock treated with medical treatment|Patients with cardiogenic shock treated only by medical treatment
11179032|NCT03528291||Cardiogenic shock treated with transient circulatory support|Patients where transient circulatory support was implanted: veno-arterial extracorporeal circulatory life support (ECLS), Impella
11179033|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
11179034|NCT03528252|Active Comparator|LDL Cholesterol|Will receive dietary advice effective for reducing LDL cholesterol.
11179035|NCT03528252|Sham Comparator|Triglycerides|Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.
11179036|NCT03528226|Experimental|Exercise Training|
11179037|NCT03528226|Other|Control|
11179038|NCT03528213|Sham Comparator|Normal saline|at physician discretion
11179039|NCT03528213|Experimental|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
11179040|NCT03528213|Experimental|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
11179041|NCT03528200|Other|Dyna Embo|Contrast dye injected through the IV in their arm which helps to see the blood in the arteries using x-ray pictures
11179042|NCT03528187||Patient Cohort 1|"Age 18 or over
~BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)
~Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications [dietary change, behavioural therapy, increased physical activity], surgical intervention or pharmacological treatment) as part of their usual clinical care
~Informed written consent
~Able to tolerate MRI"
11179043|NCT03528187||Patient Cohort 2|"Age 18 or over
~Attending weight management service at UCLH
~Informed written consent
~Able to tolerate MRI"
11179044|NCT03528187||Controls|"Age 18 or over
~BMI less than 25
~Informed written consent
~Able to tolerate MRI"
11179045|NCT03528174|Experimental|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
11179046|NCT03528148|Experimental|active cycling group|effect of combine cycling and conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
11179047|NCT03528148|Active Comparator|control group|effect of combine conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
11179048|NCT03528135|Experimental|Project PRIDE|"Those in the Project PRIDE condition will receive 8 weekly sessions, each lasting 2.5 hours and consisting of approximately 10 men (estimated number given expected attrition). Each session will be co-led by two trained group facilitators. The intervention sessions are described in the Detailed Description section. The will complete a pre-test, post-test, and follow-up assessment."
11179087|NCT03527888|Other|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11179088|NCT03527875|Experimental|PTBD group|Percutaneous Transhepatic Biliary Drainage
11179049|NCT03528135|No Intervention|Wait-list|Those in the wait-list arm will wait approximately 5 months before receiving the intervention. They will complete the same pre-test, post-test, and follow-up assessments as those in the PRIDE arm. After they have completed the follow-up assessment, they will be offered the intervention.
11179050|NCT03528122|Experimental|Recurrent opened macular hole|Pars plana vitrectomy with internal limiting membrane peel if not peeled in the first surgery and application of amniotic membrane graft
11179051|NCT03528109|Experimental|patient-centered home CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
11179052|NCT03528109|Active Comparator|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
11179053|NCT03528109|Experimental|patient-centered telehealth CBT|60 minute telehealth exposure therapy with a PhD psychologist once per month and a 90 minute telehealth CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
11179054|NCT03528096|Experimental|Intervention night|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed. Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms. The stimulation frequency is in the range of 0.25-2 Hz.
11179055|NCT03528096|Sham Comparator|Baseline night|The sound of the moving bed is played back to the participant at the right sound intensity level.
11179056|NCT03528083|No Intervention|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
11179057|NCT03528083|Experimental|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
11179058|NCT03528070|Experimental|Tranilast|
11179059|NCT03528057|Active Comparator|Group 1|Patients undergoing RALPN with the use of HAs by a surgeon.
11179060|NCT03528057|No Intervention|Group 2|Patients undergoing RALPN without the use of HAs by a surgeon
11179061|NCT03528044|Experimental|Patients undergoing bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
11179062|NCT03528044|No Intervention|Control group|Healthy controls with normal BMI.
11179063|NCT03528031|Experimental|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
11179064|NCT03528031|No Intervention|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
11179065|NCT03528018|Other|Control|Conventional physical therapy
11179066|NCT03528018|Experimental|Experimental|Combined tDCS and VR-based intervention
11179067|NCT03528005|No Intervention|Control|A regular health education program was provided by case managers only.
11179068|NCT03528005|Experimental|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
11179069|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
11179070|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
11179071|NCT03527979|Active Comparator|PCOS women with history of LOD before IVF/ICSI|
11179072|NCT03527979|Active Comparator|PCOS women without history of drilling|
11179073|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
11179074|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
11179075|NCT03527953|Active Comparator|Tetric EvoCeram BulkFill resin|Randomly applied
11179076|NCT03527953|Active Comparator|Surefil SDR Flowable bulk-fill resin|Randomly applied
11179077|NCT03527953|Active Comparator|everX fiber-reinforced resin|Randomly applied
11179078|NCT03527940||Patients with STEMI|
11179079|NCT03527927|Experimental|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
11179080|NCT03527914|Active Comparator|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
11179081|NCT03527914|Experimental|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
11179082|NCT03527901||Chronic periodontitis|This groups participant has radiographically moderate alveolar bone loss, CAL > 5 mm and PD >6 mm in several sites of each quadrant
11179083|NCT03527901||Generalized aggressive periodontitis|This demonstrated a generalized pattern of severe breakdown and CAL > 5 mm and PD > 6 mm on 8 > teeth; minimum three of those were other than first incisors or first molars
11179084|NCT03527901||Gingivitis|This group has varying degrees of gingival inflammation, with CAL < 2 mm, without any radiographical bone loss due to periodontitis
11179085|NCT03527901||Implant|Implants classified PD < 5 mm, no bleeding on probing, no suppuration and no radiographic bone loss > 0.5 mm
11179086|NCT03527901||Health|Probing depth (PD) < 3mm, no gingival recession due to periodontal disease, and clinical attachment level (CAL) < 2 mm, BOP in < 10% of full-mouth score examination
11200974|NCT03377608||Non-hormonal contraception|
11179091|NCT03527875|No Intervention|Without PBD group|receive surgery without PBD
11179092|NCT03527862|No Intervention|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
11179093|NCT03527862|Experimental|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
11179094|NCT03527849|Experimental|In-Person MBSR Course|
11179095|NCT03527849|Experimental|Online MBSR Course|
11179096|NCT03527849|Active Comparator|In-Person HEP|
11179097|NCT03527836|Active Comparator|Lidocaine|Lidocaine brachial plexus block 0.4 ml/kg of 0.66% solution
11179098|NCT03527836|Active Comparator|Bupivacaine|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
11179099|NCT03527836|Active Comparator|Mixture|Mixture brachial plexus block 0.4 ml/kg of 0.33% bupivacaine and 0.33% lidocaine solution
11179100|NCT03527823||LH supplementation|luteinizing hormone administrated microdose flare up GnRH analog protocol in poor ovarian responders undergoing in vitro fertilization.
11179101|NCT03527823||without LH supplementation|microdose flare up GnRH analog protocol in poor ovarian responders
11179102|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
11179103|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
11179104|NCT03527797|No Intervention|Control|Standard of care
11179105|NCT03527797|Experimental|Intervention|Titration of support level
11179106|NCT03527784|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh.
11179107|NCT03527784|Active Comparator|Parietex Parastomal|Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.
11179108|NCT03527784|Active Comparator|Dynamesh IPST|Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.
11179109|NCT03527771|No Intervention|unassisted CPR|unassisted CPR
11179110|NCT03527771|Active Comparator|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
11179111|NCT03527771|Experimental|V-CPR|video-assisted CPR according to ERC Guidelines 2015
11179112|NCT03527758|No Intervention|Standard Invasive intraoperative monitoring|
11179113|NCT03527758|Experimental|Flo TracIQ with HPI software|
11179114|NCT03527745|Experimental|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
11179115|NCT03527745|Experimental|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
11179116|NCT03527745|Experimental|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
11179117|NCT03527745|Experimental|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
11179118|NCT03527745|Placebo Comparator|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
11179119|NCT03527732|Placebo Comparator|Arm A: albendazole|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
11179120|NCT03527732|Experimental|Arm B: albendazole and ivermectin|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally
11179121|NCT03527719|Experimental|Experimental Group|"All participants of intervention groups will receive a new comprehensive evidence-based medicine (EBM) management program including nine intervention measures.
~Strengthen the performance appraisal system for primary hypertension management.
~Establishing a chronic disease management system.
~Simulating medical insurance reform.
~Enhancing village doctors'ability for standardized diagnosis and treatment of hypertension.
~Establishing a supervision mechanism for the effect of hypertension management.
~Establishing a hierarchical management system for patients.
~Enhancing the awareness of blood pressure self-management.
~Establishing a self-management group for patients.
~Establishing patient encouragement system."
11179122|NCT03527719|No Intervention|Control Group|All participants in the routine management groups will receive the current management program.
11179123|NCT03527680|Experimental|Lactobacillus rhamnosus|received daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus
11179124|NCT03527680|Placebo Comparator|Placebo|received one placebo capsule per day Infant formula after meal for 28 days
11179125|NCT03527667|Experimental|Short term incentives|usual quit smoking treatment (counseling + medication) plus 6-weeks of payments for proof of smoking abstinence
11179126|NCT03527667|Experimental|Long term incentives|usual quit smoking treatment (counseling + medication) plus 12-weeks of payments for proof of smoking abstinence
11179127|NCT03527667|No Intervention|No incentives|usual quit smoking treatment (counseling + medication)
11179128|NCT03527654||Hispanic Immigrants|
11179154|NCT03527459|Experimental|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
11179129|NCT03527641|Experimental|Salud sin Barreras, Health without Barriers|"Salud sin Barreras is a manualized community-delivered program tailored for Latino families and their adolescent children at-risk for type 2 diabetes. Salud sin Barreras is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions that include parent education on nutrition, fitness, goal-setting, parenting, and a brief mindfulness curriculum, a teen group physical fitness class, and a teen mindfulness curriculum called Learning 2 BREATHe. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
11179130|NCT03527641|Active Comparator|La Vida Saludable, Healthy Living|The Health Living Program (HeLP) is a manualized community-delivered program tailored specifically for Latino families and children at-risk for adult obesity. HeLP includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions, that include parent education on nutrition, fitness, goal-setting, and parenting, a teen group physical fitness class, and a teen health knowledge curriculum derived from a health education curriculum called Hey DURHAM.
11179131|NCT03527628|Other|Patients with PET-2 Negative Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results
~PET-2 negative patients will be treated with 4 cycles of ACVD (Adriamycin, Cyclophosphamide, Vinblastine And Dacarbazine)"
11179132|NCT03527628|Other|Patients with PET-2 Positive Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results
~PET-2 positive patients will be treated with 4 cycles of ACVD with addition of Brentuximab Vedotin"
11179133|NCT03527602|Experimental|Intervention|Endodontic treatment will be performed in maxillary anterior teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with rotary files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
11179134|NCT03527602|No Intervention|Control|In the control group, no foraminal enlargement will be performed.
11179135|NCT03527589||Treated with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).
11179136|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
11179137|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
11179138|NCT03527563|Other|Internet Medical Model|Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
11179139|NCT03527563|No Intervention|Conventional Medical Model|Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
11179140|NCT03527550|Experimental|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
11179141|NCT03527550|No Intervention|Treatment as Usual|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
11179142|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with glyburide, metformin, or insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
11179143|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with glyburide, metformin, or insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
11179144|NCT03527524|Experimental|exercise with ball|The participant in core stabilization exercise with ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
11179145|NCT03527524|Other|exercise without ball|The participant in core stabilization exercise without ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
11179146|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
11179147|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
11179148|NCT03527485|Other|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
11179149|NCT03527485|Other|Cocaine Use Disorder (CUD)|30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
11179150|NCT03527485|Other|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
11179151|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
11179152|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
11179153|NCT03527459|Active Comparator|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
11179155|NCT03527446|Experimental|Normal Weight|BMI ≥ 18.5 < 25.0 km/m2 Sprint Interval Training
11179156|NCT03527446|Experimental|Individuals living with Obesity|BMI ≥ 30.0 km/m2 Sprint Interval Training
11179157|NCT03527433|No Intervention|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
11179158|NCT03527433|Experimental|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
11179159|NCT03527420|Active Comparator|Exercising|12 weeks of aerobic exercise training
11179160|NCT03527420|No Intervention|Non-exercising|standard of care
11179161|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.
~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include ~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
11179162|NCT03527381|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
11179163|NCT03527381|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
11179164|NCT03527368|Experimental|Time-restricted feeding|
11179165|NCT03527368|Other|Usual feeding pattern|Comparison
11179166|NCT03527355|Experimental|A (Single dose)|"One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).
~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).
~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months."
11179167|NCT03527355|Active Comparator|B (Two dose)|"Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).
~MMR for age group at 9-12 months."
11179168|NCT03527355|Placebo Comparator|C (Placebo/Comparator)|"One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).
~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).
~MMR for age group at 9-12 months."
11179169|NCT03527342||Dilated Cardiomyopathy|
11179170|NCT03527342||Myocarditis|
11179171|NCT03527342||Sarcoidosis Heart|
11179172|NCT03527342||Giant Cell Myocarditis|
11179173|NCT03527342||Amyloidosis Heart|
11179174|NCT03527342||Hypertrophic Cardiomyopathies|
11179175|NCT03527342||Left Ventricular Myocardial Noncompaction Cardiomyopathy|
11179176|NCT03527342||Arrhythmogenic Right Ventricular Cardiomyopathies|
11179177|NCT03527329||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
11179178|NCT03527329||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
11179179|NCT03527316|Experimental|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
11179180|NCT03527316|Experimental|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
11179181|NCT03527303|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
11179182|NCT03527303|No Intervention|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
11179183|NCT03527290|Experimental|Time Restricted Eating|Participants will be instructed and counseled to incorporate a 12-hour Time Restricted Eating (TRE) regimen that begins upon waking and concludes within a 12-hour period (e.g. if wake at 6:30 AM then all caloric intake occurs between 6:30 AM and 6:30 PM). Water and non-caloric beverages (e.g. herbal tea) outside the period are encouraged as desired. There are no specific content or energy intake changes to the diet counseled or recommended as the focus of the counseling in this arm is timing of eating with innate circadian patterns and developing plans and approaches to follow this plan.
11179184|NCT03527290|Active Comparator|Standard Cardiometabolic Health Diet|Participants will be instructed and counseled with standard clinical dietary guidance for improving cardiometabolic health, where the focus is on the content, specifically a dietary pattern that emphasizes vegetables, fruits, whole grains, legumes, nuts/seeds, low fat dairy, seafood, lean poultry and meat and avoidance of foods with high levels of sodium, added sugars, saturated fats, and trans fats. There is no prescription to reduce energy intake.
11179185|NCT03527277|Experimental|Naturally-sweetened orange juice|Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
11179186|NCT03527277|Active Comparator|Sugar-sweetened beverage|Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
11179187|NCT03527264|Experimental|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
11179188|NCT03527264|Experimental|Cohort 1B|Nivolumab during Chemo/RT with extended field
11179189|NCT03527264|Experimental|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
11179190|NCT03527264|Experimental|Cohort 3|Nivolumab during chemoradiation and then as maintenance
11179191|NCT03527251|Experimental|Sequential group|intravenous ipilimumab following by intravenous SHR-1210
11179192|NCT03527238|Active Comparator|Standard of Care|Standard of Care Tacrolimus Drug Dosing
11179193|NCT03527238|Experimental|Phenotypic Precision Medicine (PPM)|PPM-based Computation Assisted Drug Dosing
11179194|NCT03527225|Experimental|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
11179195|NCT03527225|No Intervention|No Music|These patient's will have no music playing during the first radiotherapy session.
11179196|NCT03527212|Experimental|SJP-0035 0.001% (ophthalmic solution)|
11179197|NCT03527212|Placebo Comparator|Placebo (ophthalmic solution)|
11179198|NCT03527186|Experimental|Risperidone ISM 100 mg|A single intramuscular (IM) dose of 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. A total of 4 IM doses will be given; each dose will be separated by 4 weeks
11179199|NCT03527173|Experimental|S. sonnei Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
11179200|NCT03527173|Placebo Comparator|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
11179201|NCT03527147|Experimental|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
11179202|NCT03527147|Experimental|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
11179203|NCT03527147|Experimental|Hu5F9-G4 + rituximab + Acalabrutinib|Hu5F9-G4/rituximab in combination with acalabrutinib
11179204|NCT03527147|Experimental|AZD5153 + Acalabrutinib|AZD5153 in combination with acalabrutinib
11179205|NCT03527134|Experimental|Amantadine treatment|To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.
11179206|NCT03527134|No Intervention|No-treatment|Patients will not receive any treatment.
11179207|NCT03527121|Experimental|R.I.C.E.+ (ESP physiotherapy)|Participants will receive a single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
11179208|NCT03527121|Active Comparator|R.I.C.E.(Usual care)|A single session with advice and instructions from a physician in rest, ice, compression and elevation.
11179209|NCT03527108|Experimental|Patients with prior IO therapy|
11179210|NCT03527095|Experimental|Regimen A|FDL169 200 mg reference tablet
11179211|NCT03527095|Experimental|Regimen B|FDL169 200 mg testing tablet 1
11179212|NCT03527095|Experimental|Regimen C|FDL169 200 mg testing tablet 2
11179213|NCT03527095|Experimental|Regimen D|FDL169 200 mg testing tablet 1 or 2 with high fat diet
11179214|NCT03527095|Experimental|Regimen E|FDL169 200 mg testing tablet 1 or 2, fasted
11179215|NCT03527095|Experimental|Regimen F|FDL169 200 mg testing tablet 1 or 2, with standard diet
11179216|NCT03527082||Women attending gynaecology clinics|"150 women attending gynaecology clinics that fulfil inclusion criteria
~Inclusion criteria:
~Inclusion criteria
~Over the age of 18
~attending gynaecology clinics
~Able to read and comprehend the details of the study in patient information sheet.
~Mentally competent at signing the consent form.
~English -speaking, if not then translator available"
11179217|NCT03527069|Experimental|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:
~1 tablet Cipros 10 association; and
~1 tablet crestor placebo Oral, once a day."
11179218|NCT03527069|Active Comparator|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:
~1 tablet Crestor 10mg; and
~1 tablet Cipros association placebo Oral, once a day."
11179219|NCT03527056|Experimental|Oral capsule fecal transplantation|Enrolled patients who have screened positive for CRE in the stool will receive fecal transplant via OpenBiome oral capsules. The patient is given 90 minutes to swallow all capsules and does not require any anesthesia or sedation. Stool samples to test for CRE will be taken 10 days and 30 days after the fecal transplant.
11179220|NCT03527056|No Intervention|Observation|Enrolled patients who have screened positive for CRE in the stool will have stool samples to test for CRE taken 10 days and 30 days after initial enrollment.
11179221|NCT03527043|Experimental|Escitalopram|10mg by mouth daily for 6 weeks
11179222|NCT03527043|Placebo Comparator|Placebo|Matched placebo control by mouth for 6 weeks.
11179223|NCT03527030||General Population|Adults living in a registered household in the Greater London area.
11179224|NCT03527030||IQOS users|Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.
11179225|NCT03527017||General Population|Adults living in Germany.
11179226|NCT03527017||IQOS Users|Adult current IQOS users (at the time of survey) living in Germany who are registered in the Germany IQOS User Database and agreed to be contacted for research purposes at the time of registration.
11179227|NCT03527004||General Population|Survey on use of tobacco products in the general population of adults living in Italy.
11179228|NCT03527004||IQOS Users|Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
11179229|NCT03526991|Experimental|Spinal Cord Stimulation (SCS)|The subjects will complete pre-operative visits, spinal cord stimulator placement (device implantation - Spinal Cord Stimulator (SCS)) and postoperative follow-up visits on an outpatient basis.
11179230|NCT03526978|Experimental|Experimental Group|"The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
~Intervention: investigational sIPV"
11179231|NCT03526978|Active Comparator|Control Group|The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
11179232|NCT03526965|Experimental|Yoga Chikitsa|YC group were given traditional combination of yoga therapy including loosening movements, physical postures, breathing, relaxation and yoga counselling.
11179233|NCT03526965|Active Comparator|Usual Care|Usual care were given exercise moves of necks, pain medications prescribed by physicians.
11179234|NCT03526952|Experimental|Intervention Group|Couples in this group will receive the Internet-Delivered Intervention for Sexual Re-Adjustment
11179235|NCT03526952|Active Comparator|Educational Comparison Group|Couples in this group will receive only written educational material about sexuality and intimacy with an ostomy.
11179236|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
11179237|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
11179238|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
11179239|NCT03526926||Vyxeos|A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.
11179240|NCT03526913|Experimental|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
11179241|NCT03526913|Active Comparator|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
11179242|NCT03526900|Experimental|Atezolizumab|Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition, folic acid, vitamin B12, and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle, approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab, patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity, progression of the disease, decision of the patient/physician or have Completed 2 years of treatment.
11179243|NCT03526887|Experimental|Cohort 1|Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
11179244|NCT03526887|Experimental|Cohort 2|Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
11179245|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.
~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
11179246|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.
~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
11179247|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA|"Week 0 to 16 (initial period):
~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.
~Week 16 to 52 (maintenance period):
~Tralokinumab (Dose 1) maintenance SC injection regimen A."
11179248|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB|"Week 0 to 16 (initial period):
~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.
~Week 16 to 52 (maintenance period):
~Tralokinumab (Dose 1) maintenance SC injection regimen B."
11179249|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA|"Week 0 to 16 (initial period):
~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.
~Week 16 to 52 (maintenance period):
~Tralokinumab (Dose 2) maintenance SC injection regimen A."
11179250|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB|"Week 0 to 16 (initial period):
~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.
~Week 16 to 52 (maintenance period):
~Tralokinumab (Dose 2) maintenance SC injection regimen B."
11179251|NCT03526861|Experimental|Placebo initial-> Placebo maintenance|"Week 0 to 16 (initial period):
~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.
~Week 16 to 52 (maintenance period):
~Placebo continuation SC injection regimen A."
11179252|NCT03526861|Experimental|Tralokinumab (Dose1) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):
~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.
~Week 16 to 52:
~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
11179253|NCT03526861|Experimental|Tralokinumab (Dose2) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):
~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.
~Week 16 to 52:
~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
11179254|NCT03526861|Experimental|Placebo initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):
~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.
~Week 16 to 52:
~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
11179255|NCT03526848|Experimental|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
11179256|NCT03526848|Experimental|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
11179257|NCT03526835|Experimental|MCLA-158|In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.
11179260|NCT03526796|Experimental|Hyperbaric oxygen therapy|Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
11179261|NCT03526783|Other|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
11179262|NCT03526783|Other|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
11179263|NCT03526770|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink."
11179264|NCT03526770|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
11179265|NCT03526770|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
11179266|NCT03526770|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the tooth paste as an intervention."
11179267|NCT03526770|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
11179268|NCT03526770|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.
~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
11179269|NCT03526757|Experimental|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
11179270|NCT03526757|Active Comparator|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
11179271|NCT03526744|Experimental|marine protein hydrolysate 1234|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
11179272|NCT03526744|Experimental|marine protein hydrolysate 2134|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
11179273|NCT03526744|Experimental|marine protein hydrolysate 3124|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with with up to 7 days-out in between. Random sequence of arms.
11179274|NCT03526744|Experimental|marine protein hydrolysate 4123|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
11179275|NCT03526731|Experimental|Group A (original QLB-2):|Local anesthetic will be injected between the quadratus lumborum muscle and the latissimus dorsi muscle guided by ultrasound.
11179276|NCT03526731|Experimental|Group B (trans-muscular OLB-3)|Local anesthetic will be injected between quadratus lumborum and psoas major after passing through the quadratus lumborum muscle guided by ultrasound.
11179277|NCT03526705|Experimental|nb-uvb|psoriasis patients will receive 26 sessions of nb-uvb phototherapy
11179278|NCT03526692|Experimental|Sensorimotor/delta NF training group|"Three interventions will be administered:
~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.
~The third intervention is the neurofeedback training sensorimotor/delta ratio that will be recorded at channel Cz according to the International 10-20 system."
11179279|NCT03526692|Experimental|Beta1/theta NF training group|"Three interventions will be administered:
~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.
~The third intervention is the neurofeedback training Beta1/theta ratio that will be recorded at channel Fz according to the International 10-20 system."
11179280|NCT03526692|No Intervention|Control group|"Three interventions will be administered:
~An electroencephalography recording for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.
~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.
~The psychopedagogical care : Each session will be organized using the same video material than for the NF training sessions."
11179281|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
11179282|NCT03526666||AML, MDS, and CMML patients|Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
11179283|NCT03526653|Other|Intervention 1|exercise on an ergometer or motomed in an environment without other visual stimuli
11179284|NCT03526653|Other|Intervention 2|exercise on an ergometer or motomed while watching the National Geografics channel on television
11179285|NCT03526653|Other|Intervention 3|exercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
11179286|NCT03526653|No Intervention|Control group|Rest during 30 minutes
11179287|NCT03526640|Experimental|Plug Arm|Participants randomized for plug arm will be treated with a plug after CT guided is conducted.
11179288|NCT03526640|No Intervention|Non Plug arm|No Intervention, i.a. CT guided biopsy without plug.
11179289|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.
11179290|NCT03526588|Experimental|Autologous umbilical cord blood|
11179291|NCT03526575|Placebo Comparator|10 mg Zolpidem and 10 mg Zaleplon|Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
11179292|NCT03526575|Placebo Comparator|5 mg Zolpidem and 10 mg Zaleplon|Experiment 2, which will involve N=20 subjects randomized to placebo, 5 mg zolpidem and 10 mg zaleplon. All females will be placed in experiment 2. Subjects are nested into group.
11179293|NCT03526562|Experimental|Single arm phase I trial with 3 exercise dose-escalation arms|exercise dose-escalation: aerobic, resistance and flexibility training
11179294|NCT03526549|Experimental|EN3835 Active|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
11179295|NCT03526536|Other|Patients with diabetes and ESRD|Patients with diabetes and end stage renal disease (ESRD)
11179296|NCT03526536|Other|Patients with diabetes and no ESRD|Patients with diabetes and no end stage renal disease (ESRD)
11179297|NCT03526523|Experimental|Active Treatment|Mindfulness-based stress reduction
11179298|NCT03526523|No Intervention|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
11179299|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
11179300|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
11179301|NCT03526484|Active Comparator|Standard of Care|The control group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will be reported to the doctor performing the procedure. The provider may require participants to take antibiotics and/or delay their procedure as a result of the urinalysis.
11179302|NCT03526484|Experimental|Experimental|The experimental group will have a urine sample taken for a urinalysis prior to their procedure, which will have a reflex urine culture done if urinalysis results are positive. The results of the urinalysis will NOT be reported to the doctor performing the procedure. Instead, the provider will conduct the procedure without looking at or acting upon the results of the urinalysis. The urinalysis and urine culture results will be monitored by the research team, and the participant will be informed if the urine culture results are positive for an infection.
11179303|NCT03526471|Experimental|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
11179304|NCT03526458|Active Comparator|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser.
11179305|NCT03526458|Experimental|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser.
11179306|NCT03526445|Active Comparator|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
11179307|NCT03526445|Placebo Comparator|Saline|3 hours i.v. infusion of saline
11179308|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
11179309|NCT03526406|Experimental|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
11179310|NCT03526406|Placebo Comparator|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
11179338|NCT03526172||Control|Patients undergoing HTO without the inclusion of any bone wedge
11179311|NCT03526393|Experimental|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
11179312|NCT03526380|Experimental|Treatment|Participants receive the OPT-IN Brief Intervention.
11179313|NCT03526380|No Intervention|Control|Participants will only complete the baseline and follow-up surveys.
11179314|NCT03526367|Experimental|hydration plus rosuvastatin therapy|"After randomized，hydration（3ml/kg/h, if patients had LVEF<40%, 1.5 ml/kg/h）last 12 hours;
~After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
11179315|NCT03526367|Active Comparator|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
11179316|NCT03526354|Experimental|Experimental|Brexpiprazole 4mg daily for 12 weeks
11179317|NCT03526354|Active Comparator|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
11179318|NCT03526328||DCLK1 post BE treatment|Effects of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
11179319|NCT03526315|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
11179320|NCT03526315|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
11179321|NCT03526315|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
11179322|NCT03526289|Active Comparator|GIP infusion|5 hours of continuously GIP1-42 infusion
11179323|NCT03526289|Placebo Comparator|Saline|5 hours of continuously saline infusion
11179324|NCT03526276|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
11179325|NCT03526276|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
11179326|NCT03526276|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
11179327|NCT03526263|Experimental|Gastric mucosal devitalization arm|"Patients will be enrolled into the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care at Johns Hopkins Bayview. The cost of the surgery will be covered by the patient's insurance and there will no extra procedural element that would add time to surgery.
~The intervention will occur on the excised specimen ex vivo (outside the body) and will involve devitalization of the gastric mucosa using Argon Plasma Coagulation."
11179328|NCT03526250|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11179329|NCT03526237|Experimental|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
11179330|NCT03526237|Other|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
11179331|NCT03526224||Aubagio|Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).
11179332|NCT03526224||Tecfidera|Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level
11179333|NCT03526211|Experimental|Experimental|Patients with FES Cycling
11179334|NCT03526198|Experimental|Group 1 (adult)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
11179335|NCT03526198|Experimental|Group 2 (elderly)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
11179336|NCT03526185|Experimental|Cohort 1|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.
~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400
~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)."
11179337|NCT03526185|Experimental|Cohort 2|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.
~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400
~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses).
~Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment."
11179339|NCT03526172||Allograft|Patients undergoing HTO with the inclusion of an allograft bone wedge
11179340|NCT03526159|Experimental|Gentamicin Sulfate|"IV Arm:
~7.5 mg/kg gentamicin once daily for 14 days.
~Topical Arm:
~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
11179341|NCT03526146|Experimental|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
11179342|NCT03526146|No Intervention|Usua Care|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the senior center, which include a combination of daily physical, mental and social activities.
11179343|NCT03526120|Experimental|Pistachio diet|Incorporates 44 g (1 serving) of pistachios into a daily diet
11179344|NCT03526120|No Intervention|Control|No pistachio consumption
11179345|NCT03526107|Active Comparator|CF Control|CF Control: 583 mg of cocoa flavanols, <1 mg caffeine and <1 mg theobromine
11179346|NCT03526107|Experimental|CF-Theobromine|CF-Theobromine: 566 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
11179347|NCT03526107|Experimental|CF-Caffeine|CF-Caffeine: 583 mg of cocoa flavanols, 112 mg caffeine and <1 mg theobromine(Experimental)
11179348|NCT03526094|Active Comparator|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
11179349|NCT03526094|Experimental|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
11179350|NCT03526094|Experimental|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
11179351|NCT03526094|Experimental|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
11179352|NCT03526094|Experimental|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
11179353|NCT03526094|Experimental|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
11179354|NCT03526094|Experimental|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
11179355|NCT03526094|Experimental|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
11179356|NCT03526094|Active Comparator|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
11179357|NCT03526094|Experimental|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
11179358|NCT03526081|Experimental|Chamomile Tea|Chamomile Tea in 300mL hot water
11179359|NCT03526081|Experimental|Parsley based drink|3.2 g dried parsley in 300mL hot water
11179360|NCT03526081|Experimental|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
11179361|NCT03526081|Experimental|Apigenin|Apigenin capsule mixed with 300mL hot water
11179362|NCT03526081|Experimental|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
11179363|NCT03526068|Experimental|SafeZoneUVC|Patients were subjected to 90s UV light therapy of 540 mW/cm2 sessions 2 times a week for 2 weeks for a total of 4 sessions. Pre and post UV light therapy swabs were taken after standard wound irrigation
11179364|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
11179365|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
11179366|NCT03526042|Experimental|Losartan|AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.
11179367|NCT03526042|Active Comparator|Enalapril|Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.
11179368|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
11179369|NCT03525990|Active Comparator|Intervention Arm|Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
11179370|NCT03525990|Placebo Comparator|Control Arm|Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
11179371|NCT03525977|No Intervention|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
11179372|NCT03525977|Experimental|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
11179402|NCT03525782|Placebo Comparator|Sham Control|Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.
11179403|NCT03525769||Type 2 Diabetes Mellitus|
11179466|NCT03525288|Active Comparator|Standard|Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
11179373|NCT03525964|Experimental|Individualized treatment|"The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast after surgery. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.
~The patient will follow standard functional rehabilitation and the follow-up evaluations."
11179374|NCT03525964|Active Comparator|Control group 1|"For the patients allocated to non-operative treatment the injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.
~The patient will follow standard functional rehabilitation and the follow-up evaluations."
11179375|NCT03525964|Active Comparator|Control group 2|"The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.
~The patient will follow standard functional rehabilitation and the follow-up evaluations."
11179376|NCT03525951|Active Comparator|Typically Developing Children|No-intervention comparison group.
11179377|NCT03525951|Experimental|Children with Dev Language Disorder|Enhanced Milieu Teaching
11179378|NCT03525951|Experimental|Children with Autism Spectrum Disorders|Enhanced Milieu Teaching
11179379|NCT03525938|Active Comparator|TAP group|
11179380|NCT03525938|Sham Comparator|SHAM group|
11179381|NCT03525925|Experimental|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11179382|NCT03525912|Experimental|Ketamine infusion|postoperative pain in adult population after abdominal, thoracic and orthopedic surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 24 to 48 hours in postoperative period.
11179383|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
11179384|NCT03525886|Experimental|NBI-74788 Dose Group 1|NBI-74788 administered orally for 14 consecutive days.
11179385|NCT03525886|Experimental|NBI-74788 Dose Group 2|NBI-74788 administered orally for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 2 will be dosed in parallel with Group 3.
11179386|NCT03525886|Experimental|NBI-74788 Dose Group 3|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 3 will be dosed in parallel with Group 2.
11179387|NCT03525886|Experimental|NBI-74788 Dose Group 4|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days.
11179388|NCT03525873|Experimental|ARM I (methylphenidate, physical activity)|Patients receive methylphenidate PO BID for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete physical activity consisting of walking and resistance exercise over 25-40 minutes QD 4 days a week. After 2 weeks, patients may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
11179389|NCT03525873|Placebo Comparator|ARM II (placebo, physical activity)|Patients receive a matched placebo PO BID and complete physical activity as in Arm I. Treatment continues for up to 2 weeks in the absence of disease progression or unacceptable toxicity.
11179390|NCT03525860|Experimental|Acupuncture Treatment|"20 subjects will be treated with standard of care and acupuncture.
~Will complete Symptom and Pain questionnaire (VAS) and a Was It Worth It (WIWI) questionnaire each day of study participation (3 days)."
11179391|NCT03525860|No Intervention|No Intervention|"20 subjects will be treated with standard of care only.
~Will complete Symptom and Pain questionnaire (VAS) each day of study participation (3 days)."
11179392|NCT03525847|Active Comparator|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
11179393|NCT03525847|Active Comparator|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
11179394|NCT03525834|Experimental|everolimus|Everolimus oral tablets, 10 mg per day
11179395|NCT03525821|Experimental|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
11179396|NCT03525808|Experimental|AXIOS|Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
11179397|NCT03525795|Experimental|CPI-1205 Combination with ipilimumab|
11179398|NCT03525782|Experimental|CAR-T|Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.
11179399|NCT03525782|Experimental|CAR-T combining PD-1 knockout|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
11179400|NCT03525782|Experimental|PD-1 knockout|PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
11179401|NCT03525782|Active Comparator|PD-1 mAb|Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.
11179404|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
11179405|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
11179406|NCT03525730|No Intervention|Control|This group receives no intervention.
11179407|NCT03525730|Experimental|Valproic acid|This group receives valproic acid (enteric) for 14 days.
11179408|NCT03525730|Experimental|Pyrimethamine|This group receives pyrimethamine for 14 days.
11179409|NCT03525730|Experimental|Valproic acid and Pyrimethamine|This group receives valproic acid and pyrimethamine for 14 days.
11179410|NCT03525717|Active Comparator|Routine Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at routine dinner time (18:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from late dinner. This arm will cross-over to late dinner in random order."
11179411|NCT03525717|Experimental|Late Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (22:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from routine dinner. This arm will cross-over to routine dinner in random order."
11179412|NCT03525691|Experimental|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
11179413|NCT03525691|Experimental|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
11179414|NCT03525691|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
11179415|NCT03525678|Experimental|Participants receiving frozen 2.5 mg/kg belantamab mafodotin|Participants will receive 2.5 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
11179416|NCT03525678|Experimental|Participants receiving frozen 3.4 mg/kg belantamab mafodotin|Participants will receive 3.4 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
11179417|NCT03525678|Experimental|Participants receiving lyophilized belantamab mafodotin|Participants in lyophilized arm will receive lyophilized belantamab mafodotin once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
11179418|NCT03525652|Active Comparator|Therapeutic vaccine|Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.
11179419|NCT03525652|Experimental|Therapeutic vaccine plus PD-1 knockout|Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
11179420|NCT03525652|Active Comparator|PD-1 knockout T cells|PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
11179421|NCT03525639|Experimental|Patients with Acute Myocarditis|Patients undergoing Cardiac Magnetic Resonance at baseline, 2 month, 1 year.
11179422|NCT03525626|Experimental|Online Mindfulness-based Tic Reduction|
11179423|NCT03525613|Experimental|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
11179424|NCT03525613|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
11179425|NCT03525613|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
11179426|NCT03525613|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
11179427|NCT03525600|Experimental|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
11179428|NCT03525600|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
11179429|NCT03525600|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
11179430|NCT03525600|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
11179431|NCT03525587|Active Comparator|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.
~Intervention: Use of MAGHD App/MAGHD Framework"
11179432|NCT03525587|Active Comparator|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).
~Intervention: Use of MAGHD App/MAGHD Framework"
11179433|NCT03525587|Active Comparator|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).
~Intervention: Use of MAGHD App/MAGHD Framework"
11179434|NCT03525574|Experimental|Open-label Triple Combination|"Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.
~Parent studies are Phase 3 Vertex studies investigating VX-445 in combination with TEZ and IVA. This includes Studies VX17-445-102 and VX17-445-103."
11179435|NCT03525561|Active Comparator|acetazolamide arm|This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill.
11179436|NCT03525561|Placebo Comparator|placebo arm|This is the arm of the study in which volunteers will take the placebo.
11179635|NCT03524092|Placebo Comparator|Placebo|Placebo administered SC
11179437|NCT03525548|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
11179438|NCT03525548|Experimental|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
11179439|NCT03525535||Pulmonary embolism|data from routine care will be collected for patient eligible and willing to participate
11179440|NCT03525522|Experimental|Nd:YAG Laser|Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)
11179441|NCT03525522|Active Comparator|Topical Corticosteroid Diprosone|Topical corticosteroid betamethasone (Diprosone, Merck Sharp & Dohme, d.o.o.) for 3 months.
11179442|NCT03525509|Experimental|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
11179443|NCT03525509|Active Comparator|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
11179444|NCT03525483|Experimental|Patients with ECMO|"Patients with circulatory assistance by ECMO Patients are included 48 hours after ECMO VA or VV therapy and after hemodynamic stabilization defined by blood pressure stability and cardiac output for at least 12 hours without significant changes in amine flow.
~When stable they will have an Ultrasound for renal resistivity index measurement"
11179445|NCT03525470|Experimental|Water|Subjects consumed water
11179446|NCT03525470|Experimental|No water|Subjects did not consume water
11179447|NCT03525457|Experimental|Experimental|Non surgical periodontal therapy
11179448|NCT03525444|Placebo Comparator|Placebo|Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
11179449|NCT03525444|Experimental|VX-445/TEZ/IVA TC|Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
11179450|NCT03525431|Experimental|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
11179451|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
11179452|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
11179453|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
11179454|NCT03525405|Experimental|Single Dose|
11179455|NCT03525392|Experimental|177Lu-3BP-227|"Screening: 177Lu-IPN01087 - 25 µg 3BP-227 (IPN01087) per 1 GBq of 177Lu. 1 GBq in a total volume of 10 mL.
~Treatment phase: 177Lu-IPN01087 - 2.5 to 7.5 GBq escalation dose of 177Lu-3BP-227 (IPN01087) in a total volume of 20 mL for each cycle of administration (2 cycles plus 4 optional additional)."
11179456|NCT03525379|Experimental|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
11179457|NCT03525379|Placebo Comparator|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
11179458|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
11179459|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
11179460|NCT03525340|No Intervention|Standard of Care|Participants in the standard of care arm will receive no navigation assistance to remain in care. They will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation, but no additional services to remain engaged in care other than what is provided as standard by the clinic.
11179461|NCT03525340|Experimental|Peer Navigation|Participants in the peer navigation arm will meet with a peer navigator at least once per month for nine months in-person, and have at least one other navigator contact per month. Like the standard of care arm, they will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation.
11179462|NCT03525327||Line Dance Class participants|The group will be participating in line dance classes as intervention.
11179463|NCT03525301|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
11179464|NCT03525301|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11179465|NCT03525288|Experimental|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
11179467|NCT03525275|Experimental|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
11179468|NCT03525275|Active Comparator|Physical Therapy alone|Intervention = Post-surgical protocol
11179469|NCT03525262|No Intervention|SAbR WITHOUT Neurovascular sparing|"GTV represents MR defined gross radiographic disease, if identifiable.
~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.
~PTV1_30Gy will not be used or created on this arm
~PTV2_SAbR will be generated by a 3mm expansion on the CTV. PTV2_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
11179470|NCT03525262|Experimental|SAbR WITH Neurovascular sparing|"GTV represents MR defined gross radiographic disease, if identifiable.
~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.
~PTV1_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
~PTV2_SAbR will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries. PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
11179471|NCT03525249|Experimental|Comparator Membraflex 500mg|experimental product one dose
11179472|NCT03525249|Experimental|Comparator Membraflex 300mg|experimental product two doses
11179473|NCT03525249|Placebo Comparator|Placebo Comparator|placebo product
11179474|NCT03525236|Experimental|Taste of 5 flavors|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.
~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)
~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.
~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
11179475|NCT03525223|Active Comparator|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate [Na+] from 138 mmol/l to 142 mmol/l The dialysate [Na+] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
11179476|NCT03525223|Active Comparator|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate [Na+] from 142 mmol/l to 135 mmol/l The dialysate [Na+] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate [Na+] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
11179477|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
11179478|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
11179479|NCT03525197|Experimental|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
11179480|NCT03525197|Active Comparator|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
11179481|NCT03525184|Placebo Comparator|Normal sleep|A normal sleep condition and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; NS)
11179482|NCT03525184|Placebo Comparator|72-h Sleep restriction with placebo beverage|Sleep restriction (72-h with 2-h of sleep per night) and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; SR),
11179483|NCT03525184|Experimental|72-h Sleep restriction with multi-nutrient beverage|Sleep restriction (72-h with 2-h of sleep per night) and the experimental treatment (1.5 g protein/kg body weight/day + multi-nutrient beverage; SR+).
11179484|NCT03525171|Active Comparator|GHD children|23 prepubertal children with isolated GHD consecutively admitted to the Section of Endocrinology of the University of Palermo during treated with GH for at least 12 months underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
11179485|NCT03525171|Placebo Comparator|controls|12 prepubertal healthy subjects with short stature recruited among children referred for assessment of short stature as a control group at baseline underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
11179486|NCT03525158|Other|Baseline phase ('A') and Intervention phase ('B')|"Baseline phase ('A'): Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
~Intervention phase ('B'): A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma)."
11179487|NCT03525132|Experimental|Healthy subjects|120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
11179488|NCT03525132|Experimental|Glaucoma|60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
11179489|NCT03525132|Experimental|Retinal vein occlusion|80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
11179490|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
11179491|NCT03525119|Experimental|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
11179492|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
11179493|NCT03525106|Experimental|Participants: Positive Psychology Intervention|Participants receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
11179494|NCT03525106|Experimental|Caregivers: Positive Psychology Intervention|Caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
11179495|NCT03525093|Active Comparator|Hypnosis + health education|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home plus health education booklet on coping with stress
11179496|NCT03525093|Other|Health education alone|Patients receive a health education booklet to improve coping with stress
11179497|NCT03525080|Experimental|PET Arm|
11179498|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
11179499|NCT03525041|Active Comparator|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
11179500|NCT03525041|Active Comparator|CABG|Participants will undergo CABG only.
11179501|NCT03525028|Experimental|Metformin group|Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
11179502|NCT03525028|Placebo Comparator|Placebo group|Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
11179503|NCT03525015|Experimental|A decision aid booklet|A decision aid booklet about cataract surgery choice
11179504|NCT03525015|Active Comparator|An usual booklet|An usual booklet about cataract and cataract surgery
11179505|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (AA), Placebo|Participants with FTO SNP rs8050136 AA receiving matching Placebo
11179506|NCT03525002|Active Comparator|FTO SNP rs8050136 (AA), Bromocriptine|Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg
11179507|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CA), Placebo|Participants with FTO SNP rs8050136 CA receiving matching Placebo
11179508|NCT03525002|Active Comparator|FTO SNP rs8050136 (CA), Bromocriptine|Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg
11179509|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CC), Placebo|Participants with FTO SNP rs8050136 CC receiving matching Placebo
11179510|NCT03525002|Active Comparator|FTO SNP rs8050136 (CC), Bromocriptine|Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg
11179511|NCT03524989|Active Comparator|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
11179512|NCT03524989|Sham Comparator|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
11179513|NCT03524976||Embolization with Squid|All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The
11179514|NCT03524963|Experimental|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
11179515|NCT03524963|Experimental|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
11179516|NCT03524950|No Intervention|no dexmedetomidine|
11179517|NCT03524950|Experimental|high dose dexmedetomidine|
11179518|NCT03524950|Experimental|low dose dexmedetomidine|
11179519|NCT03524937|Experimental|MELATONIN (LOW DOSE)|Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.
11179520|NCT03524937|Experimental|MELATONIN (HIGH DOSE)|Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.
11179521|NCT03524937|Placebo Comparator|PLACEBO|Daily administration of identical placebo up to 14 days.
11179522|NCT03524924||non-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: < 0.3151361243 Male: < 1.211878526
11179523|NCT03524924||pre-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 0.3151361243 to < 2.1301121973 Male: 1.211878526 to < 3.0052612772
11179524|NCT03524924||frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 2.1301121973 to < 6 Male: 3.0052612772 to < 7
11179525|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
11179526|NCT03524898|Experimental|nab-paclitaxel and gemcitabine|Treatment consists of the combination treatment of nab-paclitaxel and gemcitabine, which is given every 2 weeks during 28-day cycle intervals until disease progression.
11179527|NCT03524885|Active Comparator|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
11179528|NCT03524885|Experimental|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).
~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).
~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
11179529|NCT03524872|Active Comparator|Original CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and original (Sweden&Martina) CAD/CAM abutments.
11179530|NCT03524872|Experimental|Compatible CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and compatible (New Ancorvis) CAD/CAM abutments.
11179531|NCT03524859||Cystic fibrosis|Cystic fibrosis participants without experience on endurance or resistance training will be analyzed through a test battery and lung function test.
11179532|NCT03524859||Healthy Subjects|Healthy matched control group without experience on endurance or resistance training will be analyzed through a test battery.
11179533|NCT03524846|Active Comparator|Ascorbic acid 300 mg|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
11179534|NCT03524846|Active Comparator|Ascorbic acid 600 mg|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
11179535|NCT03524846|Placebo Comparator|Placebo|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
11179536|NCT03524833|Other|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
11179537|NCT03524833|Other|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
11179538|NCT03524820|Experimental|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
11179539|NCT03524807|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
11179540|NCT03524807|No Intervention|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
11179541|NCT03524768||patients presenting with Chagas cardiomyopathy|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
11179542|NCT03524768||control group|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
11179543|NCT03524755|Experimental|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (~6 weeks).
11179544|NCT03524755|No Intervention|Control Group|The control group received usual care.
11179545|NCT03524742|Experimental|Avocado-Mediterranean Diet|Avocado based Mediterranean diet with intake of ½ portion of a Hass avocado per day, during 3 months.
11179546|NCT03524742|Active Comparator|Control-Group Diet|Control-Group Diet consists of a low fat-high complex carbohydrate diet, during 3 months.
11179547|NCT03524729|Active Comparator|Ankle osteoarthritis patients|Ambulatory adult patients (18+) with ankle osteoarthritis.
11179548|NCT03524729|Other|Healthy control subjects|Ambulatory adults (18+) with no known ankle osteoarthritis.
11179549|NCT03524716|Experimental|Fitbit and Text Messages|Participants randomized to this arm receive print materials and a Fitbit Flex 2 at baseline and daily text messages for 12 weeks.
11179550|NCT03524716|No Intervention|Usual Care|Participants randomized to usual care receive print materials at baseline.
11179551|NCT03524703|Experimental|Chewing Gum Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
11179552|NCT03524703|No Intervention|Control Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Control Group receive standard cares and are asked not to chew gum within 5 days after surgery. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
11179553|NCT03524690|Active Comparator|SUSOPS Balance|Volunteers provided sufficient food to maintain energy balance.
11179554|NCT03524690|Experimental|SUSOPS Negative Balance|Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
11179555|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
11179556|NCT03524664|No Intervention|"Delayed tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
11179557|NCT03524664|Experimental|"Tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
11179558|NCT03524651|Active Comparator|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
11179559|NCT03524651|Active Comparator|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
11179560|NCT03524638|Active Comparator|ARM A|Colorectal surgery with administration of Visbiome
11179561|NCT03524638|Active Comparator|ARM B|Colorectal Surgery alone
11179562|NCT03524612|Other|eltrombopag|Participants will be treated with eltrombopagto to induce sustained remission to reach a target platelet count of ≥ 100×109/L (CR), after 1st line steroids have failed.
11179563|NCT03524599|Experimental|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
11179564|NCT03524599|No Intervention|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
11179565|NCT03524586|Experimental|Ipsilateral rotation of head|Head was laterally rotated to the same side against fixed tube
11179566|NCT03524586|Active Comparator|Contralateral rotation of head|Head was laterally rotated to the opposite side against fixed tube
11179567|NCT03524573|Experimental|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0530 - 0900.
11179636|NCT03524079||BrS Group|Ajmaline 17-(Chloroacetate) Monohydrochloride
11179568|NCT03524573|Active Comparator|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2000 - 0400.
11179569|NCT03524547|Experimental|J-shaped|Endotracheal tube will be molded into a J-shape that is similar to that of Macintosh type blade of a McGrath MAC® videolaryngoscope.
11179570|NCT03524547|Active Comparator|60-degrees|Endotracheal tube will be bent 60 degrees.
11179571|NCT03524534|Active Comparator|Telephone Follow-Up Intervention|
11179572|NCT03524534|Active Comparator|In-person follow-up intervention|
11179573|NCT03524521|Active Comparator|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
11179574|NCT03524521|Experimental|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
11179575|NCT03524508|Experimental|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), leucovorin (LV) 400 mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
11179576|NCT03524508|Active Comparator|5FU/LV|leucovorin (LV) 400 mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
11179577|NCT03524482|Experimental|Path2Quit|Culturally specific text message intervention
11179578|NCT03524482|Active Comparator|SmokeFreeText|The National Cancer Institute's publicly available, standard text messaging program for tobacco cessation
11179579|NCT03524469||Normal weight|"Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test."
11179580|NCT03524469||Insulin resistant|"Insulin Resistance will be defined as meeting any of the following:
~pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test
~pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth.
~pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy
~pre-pregnant BMI ≥ 30, and unmediated."
11179581|NCT03524456|Experimental|Home blood pressure monitoring|
11179582|NCT03524456|No Intervention|Usual monitoring|
11179583|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
11179584|NCT03524430|Experimental|Single Interventional Study Arm|There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.
11179585|NCT03524417|Experimental|RIG injection|RIG injection on day 7
11179586|NCT03524404|Active Comparator|Diabetes Prevention Program (DPP)|Live stream the first six sessions of the Diabetes Prevention Program (DPP) curriculum to Senior Planet on a weekly basis, The webinars will be about 1 hour long, led by a certified DPP educator, and live-streamed to the senior center. Participants will have weekly weigh-ins and meet with a research assistant led focus group following two out of the six sessions to discuss program acceptability.
11179587|NCT03524391|Experimental|Yoga Counselling Group|Yoga based psychological counselling delivered individually and in group along with conventional care
11179588|NCT03524391|Active Comparator|Usual Care Group|Usual care provided to patients
11179589|NCT03524378|Other|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
11179590|NCT03524365|Active Comparator|RYGB plus LM counselling|96 subjects with NASH
11179591|NCT03524365|Active Comparator|SG plus LM counselling|96 subjects with NASH
11179592|NCT03524365|Sham Comparator|ILM|96 subjects with NASH
11179593|NCT03524352|Experimental|fecal microbiota|
11179594|NCT03524352|Placebo Comparator|placebo|
11179595|NCT03524339|Placebo Comparator|Placebo|
11179596|NCT03524339|Experimental|Tamsulosin|
11179597|NCT03524326|Experimental|Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma|A 3+3 dose de-escalation design for three dose levels of lenvatinib combined with cetuximab will be used. A DLT will be defined as any toxicities of grade 3 or higher (per CTCAE v4 criteria) felt to be possibly, probably, or definitely related to lenvatinib, as well as grade 4 toxcities related to cetuximab, which occurs within 28 days following the first dose of lenvatinib in combination with cetuximab.
11179598|NCT03524300|Experimental|Robotic Assisted Total Gastrectomy|Robotic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
11179599|NCT03524300|Active Comparator|Laparoscopic Assisted Total Gastrectomy|Laparoscopic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
11179600|NCT03524287|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
11179601|NCT03524274|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11179602|NCT03524274|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11179603|NCT03524274|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11179604|NCT03524261|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11179605|NCT03524261|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11179606|NCT03524261|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11179607|NCT03524235|Experimental|Subjects|Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion
11179608|NCT03524235|No Intervention|Controls|Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.
11179609|NCT03524222|Experimental|Home Hospitalization|Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
11179610|NCT03524209|Other|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
11179611|NCT03524209|Other|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
11179612|NCT03524196|Experimental|MYLO|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.
~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
11179613|NCT03524183|Active Comparator|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
11179614|NCT03524183|Experimental|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
11179615|NCT03524170|Experimental|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
11179616|NCT03524157|Experimental|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
11179617|NCT03524157|Active Comparator|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
11179618|NCT03524157|Active Comparator|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
11179619|NCT03524144|Other|adult patients with Crohn's disease|All adult patients(18 years old or older) with Crohn's disease underwent gastroscopy; patients with diagnosed and treated Crohn's disease had gastroscopy performed during the re-examination, and patients diagnosed with Crohn's disease for the first time had gastroscopy performed during the initial consultation.
11179620|NCT03524131|Experimental|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
11179621|NCT03524131|Experimental|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
11179622|NCT03524131|Active Comparator|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
11179623|NCT03524118|Experimental|Panel A: Pre-term MK-1654 Dose 1|Pre-term infants will receive MK-1654 Dose 1 via intramuscular (IM) injection and will be followed for up to 365 days.
11179624|NCT03524118|Experimental|Panel B: Pre-term MK-1654 Dose 2|Pre-term infants will receive MK-1654 Dose 2 via IM injection and will be followed for up to 365 days.
11179625|NCT03524118|Experimental|Panel C: Pre-term MK-1654 Dose 3|Pre-term infants will receive MK-1654 Dose 3 via IM injection and will be followed for up to 365 days.
11179626|NCT03524118|Experimental|Panel D1: Pre-term MK-1654 Dose 4|Pre-term infants enrolled prior to AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 365 days.
11179627|NCT03524118|Experimental|Panel D2: Pre-term MK-1654 Dose 4|Pre-term infants enrolled after AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 545 days.
11179628|NCT03524118|Experimental|Panel E1: Full-term MK-1654 Dose 4|Full-term infants enrolled prior to AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 365 days.
11179629|NCT03524118|Experimental|Panel E2: Full-term MK-1654 Dose 4|Full-term infants enrolled after AM4 will receive MK-1654 Dose 4 via IM injection and will be followed for up to 545 days.
11179630|NCT03524118|Placebo Comparator|Placebo|Pre-term infants will receive placebo via IM injection.
11179631|NCT03524105|Active Comparator|Thrive Professional Learning plus ParentCorps|
11179632|NCT03524105|Active Comparator|Thrive Professional Learning track|
11179633|NCT03524092|Experimental|Mirikizumab Dose #1|Mirikizumab Dose #1 administered subcutaneously (SC)
11179634|NCT03524092|Experimental|Mirikizumab Dose #2|Mirikizumab Dose #2 administered intravenously (IV)
11179637|NCT03524079||No BrS group|Ajmaline 17-(Chloroacetate) Monohydrochloride
11179638|NCT03524066|Experimental|Inhaled + Bronchoscopy|One-time Inhalation of Salbutamol 200 µg, Salmeterol 50µg and Fluticasone 500µg. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and bronchoalveolar lavage (BAL) samples will be taken from each site.
11179639|NCT03524066|Experimental|Systemic + Bronchoscopy|One-time Salbutamol (8 mg) and Propranolol (40mg) administered orally. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples will be taken from each site.
11179640|NCT03524053|Experimental|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
11179641|NCT03524053|Active Comparator|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
11179642|NCT03524053|No Intervention|Control|Participants will attend the laboratory but no exercise trial will be performed.
11179643|NCT03524040|Experimental|Acne patients|Application of gold microparticles to 2-3 facial areas
11179644|NCT03524040|Experimental|Heatlhy volunteers|Application of gold microparticles to 2 facial areas
11179645|NCT03524027|Experimental|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
11179646|NCT03524014||HEV-infected patients with hepatitis|
11179647|NCT03524014||HEV-infected patients with neurological features|
11179648|NCT03524014||HEV-infected patients with kidney features|
11179649|NCT03524001|Active Comparator|Bifocal stimulation|Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
11179650|NCT03524001|Placebo Comparator|VVI 40|Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).
11179651|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
11179652|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
11179653|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
11179654|NCT03523975|Experimental|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
11179655|NCT03523962|Experimental|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
11179656|NCT03523962|Experimental|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
11179657|NCT03523949|Experimental|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
11179658|NCT03523936|Active Comparator|Prebiotic|
11179659|NCT03523936|Placebo Comparator|Placebo|
11179660|NCT03523923|No Intervention|Usual Care|If assigned to the Usual Care (UC) arm, participants receive the same care as they would normally received from the HMC or UWMC outpatient TBI clinics, which could include similar types of treatment (medication changes, referral to specialists, etc.).
11179661|NCT03523923|Active Comparator|Collaborative Care|If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
11179662|NCT03523910|Experimental|Patient|A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
11179663|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
11179664|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
11179831|NCT03522766||Healthy volunteers with no urinary tract infections|people who don't experience urinary tract infections
11179665|NCT03523884|Experimental|Exercise Program plus Education.|Rotator cuff stretching and strengthening exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
11179666|NCT03523884|Active Comparator|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
11179667|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
11179668|NCT03523858|Experimental|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion.
11179669|NCT03523845||Test group|Test group (patients diagnosed with early apical peri-implantitis diagnosed)
11179670|NCT03523845||Control group|Control group (patients whose implants had not developed any inflammatory/infectious process and were osseointegrated)
11179671|NCT03523832|Active Comparator|Group 1|celecoxib 400mg and pregabaline 150mg 1 hour before operation
11179672|NCT03523832|Active Comparator|Group 2|celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
11179673|NCT03523832|Placebo Comparator|Group 3|No treatment given
11179674|NCT03523819|Experimental|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
11179675|NCT03523819|Experimental|CS1003|Participants will receive CS1003 intravenously at fixed dose on specified days.
11179676|NCT03523806|Experimental|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
11179677|NCT03523806|No Intervention|Control Group|Half of the participants (n=15) will not be receiving coaching
11179678|NCT03523793|Experimental|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
11179679|NCT03523793|Active Comparator|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
11179680|NCT03523767|Experimental|Typhoid Vaccine, then Normal Saline|0.5 ml of S.typhi injection, then 0.5 ml of normal saline injection
11179681|NCT03523767|Placebo Comparator|Normal Saline, then Typhoid Vaccine|0.5 ml of normal saline injection, then 0.5 ml of S.typhi injection
11179682|NCT03523754|Other|Misoprostol only|This group will receive Intravaginal Misoprostol only.
11179683|NCT03523754|Other|Isosorbide Mononitrate & Misoprostol|This group will reveive intravaginal Isosorbide Mononitrate & Misoprostol.
11179684|NCT03523728|Experimental|Venglustat dose 1|Patients will receive venglustat dose 1 once daily for 24 months
11179685|NCT03523728|Experimental|Venglustat dose 2|Patients will receive venglustat dose 2 once daily for 24 months
11179686|NCT03523728|Placebo Comparator|Placebo|Placebo will be given once daily (Stage 1 and Stage 2) for 24 months
11179687|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
11179688|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
11179689|NCT03523702|Experimental|PembroRT Cohort|Subjects with PD-L1 expression ≥ 50% Combination of pembrolizumab and dose-painted radiotherapy for locally advanced NSCLC patients with high (≥ 50%) PD-L1 expression.
11179690|NCT03523702|Active Comparator|ChemoRT Cohort|Subjects with PD-L1 expression < 50% Subjects with PD-L1 expression below 50% will be enrolled and treated with standard concurrent chemoradiotherapy.
11179691|NCT03523689||Observational (bronchoscopy, RP-EBUS)|Patients undergo bronchoscopy per standard of care, RP-EBUS of the left and right lungs during bronchoscopy procedure, and RP-imaging over 3-5 minutes at the end of the bronchoscopy procedure.
11179692|NCT03523676||Group A|sepsis patients who did not develop atrial fibrillation during ICU stay
11179693|NCT03523676||Group B|sepsis patients with newly developed atrial fibrillation during ICU stay
11179694|NCT03523663||Control|healthy children without ADHD or other mental health issues
11179695|NCT03523663||ADHD|children diagnosed with ADHD
11179696|NCT03523650|Experimental|Group 1: Propranolol Group|Group 1: Propranolol - group of randomized patients will receive one propranolol pill tid for 36 months.
11179697|NCT03523650|Placebo Comparator|Group 2: Placebo Group|Group 2: Placebo - group of randomized patients will receive one placebo pill tid for 36 months.
11179698|NCT03523637|Experimental|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
11179699|NCT03523611||lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
11179700|NCT03523598|Placebo Comparator|Placebo gel + Normal Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
11179701|NCT03523598|Experimental|Placebo Gel + Potassium Nitrate Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the Potassium nitrate toothpaste (Sensodyne).
11179702|NCT03523598|Experimental|Potassium Nitrate Gel + Normal Toothpaste|The patient will receive the application of 5% Potassium nitrategel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
11179832|NCT03522766||Healthy volunteers with urinary tract infections|people who frequently experience urinary tract infections
11179703|NCT03523585|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
11179704|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
11179705|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
11179706|NCT03523572|Experimental|Dose Escalation|"Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle.
~The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles."
11179707|NCT03523572|Experimental|Dose Expansion - Cohort 1|"Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) [as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines]. These participants have received prior ado-trastuzumab emtansine (T-DM1).
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
11179708|NCT03523572|Experimental|Dose Expansion - Cohort 2|"Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive).
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
11179709|NCT03523572|Experimental|Dose Expansion - Cohort 3|"Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression.
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
11179710|NCT03523572|Experimental|Dose Expansion - Cohort 4|"Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression.
~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
11179711|NCT03523559||Interstitial Cystitis|
11179712|NCT03523559||normal|
11179713|NCT03523546|Experimental|Cancer Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
11179714|NCT03523546|No Intervention|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
11179715|NCT03523533|Experimental|Peripherally-inserted internal jugular catheter|All enrolled patients will receive a peripheral angiocatheter in the internal jugular vein, under dynamic ultrasound guidance.
11179716|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection
~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
11179717|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet
~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
11179718|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection
~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
11179719|NCT03523507|Experimental|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
11179720|NCT03523507|Sham Comparator|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
11179721|NCT03523494||Normal limb|Normal
11179722|NCT03523494||Abnormal limb|Lymph Edema
11179723|NCT03523481||NHF use|
11179724|NCT03523468|Experimental|uniportal sleeve lobectomy|locally advanced central lung cancer resection by uniportal VATS sleeve lobectomy
11179725|NCT03523468|Active Comparator|open sleeve lobectomy|locally advanced central lung cancer resection by open chest sleeve lobectomy
11179726|NCT03523455|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment) Taken once each day after breakfast, but before lunch.
11179727|NCT03523455|Active Comparator|Iron Aid IPS (Iron Protein Succinylate)|IronAid Iron Protein Succinylate 30 mg Taken once each day after breakfast, but before lunch.
11179728|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days.
11179729|NCT03523429|Experimental|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD < 0.1% (< 1×10-3) after induction therapy.
11179730|NCT03523416|Experimental|Edwards Transcatheter Atrial Shunt System|
11179731|NCT03523403|Experimental|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
11179732|NCT03523403|No Intervention|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
11179733|NCT03523403|Experimental|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
11179734|NCT03523403|No Intervention|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
11179735|NCT03523390|Experimental|Avelumab|
11179736|NCT03523377|Experimental|prolonged overnight fasting|The purpose of the intervention is to increase the nightly fasting duration to a minimum of 12 hours. Adherence to the intervention will be measured by the proportion of SMS text message-days reflecting 12 or more hours of fasting. The intervention protocol follows an approach using strategies outlined by social cognitive theory that focus on (a) goal setting & (b) building self-efficacy.Interim 1 lasts 14 days & begins 10-17 days before Study Visit 1.
11179737|NCT03523351|Active Comparator|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
11179738|NCT03523351|Experimental|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement.
11179739|NCT03523312|Experimental|HFA-IMRT|Eligible patients will receive HFA-IMRT to a total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions to areas of gross tumor with concurrent capecitabine. Cross-sectional imaging will be repeated 4-6 weeks after the end of CRT to assess for resectability.
11179740|NCT03523299|Experimental|Cryoablation|Participants in this arm will receive cryoablation of their breast tumor two weeks before their routine lumpectomy. They will undergo two blood draws: one before cryoablation (at the time of consent) and one after cryoablation (at the time of surgery).
11179741|NCT03523299|No Intervention|Control|Participants in this arm will undergo a blood draw at the time of consent and then will continue with their scheduled lumpectomy (standard of care).
11179742|NCT03523286|Experimental|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
11179743|NCT03523273|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
11179744|NCT03523273|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
11179745|NCT03523260|Active Comparator|Tunneled dialysis Split-tip catheter|High-flow tunneled Split-tip catheter for hemodialysis will be inserted by standard interventional technique
11179746|NCT03523260|Active Comparator|Tunneled dialysis Step-tip catheter|High-flow tunneled Step-tip catheter for hemodialysis will be inserted by standard interventional technique
11179747|NCT03523260|Active Comparator|Tunneled dialysis Symmetric tip catheter|High-flow tunneled Symmetric tip catheter for hemodialysis will be inserted by standard interventional technique
11179748|NCT03523247|Experimental|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
11179749|NCT03523234|Experimental|surgery group|
11179750|NCT03523234|Placebo Comparator|control group|
11179751|NCT03523221|Active Comparator|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
11179752|NCT03523221|Placebo Comparator|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
11179753|NCT03523195|Active Comparator|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
11179754|NCT03523195|Experimental|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
11179755|NCT03523182|Experimental|Spirulina (SP)|Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.
11179756|NCT03523182|Active Comparator|Control (CON)|Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.
11179757|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
11179758|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
11179833|NCT03522766||Intermittent catheter users with neurogenic bladder|
11179834|NCT03522766||Intermittent catheter users with enlarged prostate|
11201431|NCT03374605|Sham Comparator|Sham tDCS|
11179759|NCT03523143|Experimental|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
11179760|NCT03523143|Active Comparator|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
11179761|NCT03523130||HIV-infected|
11179762|NCT03523130||non-HIV-infected|
11179763|NCT03523117|Active Comparator|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
11179764|NCT03523117|Active Comparator|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants <12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to <4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to <12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
11179765|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
11179766|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
11179767|NCT03523039|Experimental|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
11179768|NCT03523039|No Intervention|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
11179769|NCT03523026|Experimental|NMES and Peripheral Muscle Training|"Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training
~NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week.
~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
11179770|NCT03523026|Experimental|IMT and Peripheral Muscle Training|"Inspirator Muscle Training (IMT) and Peripheral Muscle Training
~IMT will be applied 7 days per week, twice a day for 15 minutes.
~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks."
11179771|NCT03523026|Experimental|Peripheral Muscle Training|"Peripheral Muscle Training
~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
11179772|NCT03523013|Experimental|CPAP pressure (determied by DISE)|
11179773|NCT03523013|Active Comparator|CPAP pressure (determined by physician)|
11179774|NCT03523000|Active Comparator|Active Solution|Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml
11179775|NCT03523000|Placebo Comparator|Inactive Placebo Solution|Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline
11179776|NCT03522987|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
11179777|NCT03522974|Placebo Comparator|Placebo|40 g/d placebo powder
11179778|NCT03522974|Experimental|Strawberry powder (high dose)|40 g/d freeze dried strawberry powder
11179779|NCT03522974|Active Comparator|Strawberry powder (low dose)|13 g/d freeze dried strawberry powder
11179780|NCT03522961|Active Comparator|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
11179781|NCT03522961|Active Comparator|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
11179782|NCT03522948|Experimental|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
11179783|NCT03522935|Experimental|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
11179784|NCT03522935|Experimental|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
11179785|NCT03522935|Experimental|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
11179786|NCT03522935|Experimental|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
11179787|NCT03522935|Experimental|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
11179788|NCT03522935|Placebo Comparator|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
11179789|NCT03522922|Active Comparator|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
11179790|NCT03522922|Active Comparator|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
11179791|NCT03522922|Active Comparator|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
11179792|NCT03522909||Study|We will be reviewing records of parturients seen at Johns Hopkins Hospital in the Center for Peripartum Optimization (CPO) clinic between January 2017 to January 2018
11179793|NCT03522909||Control|A matched controlled group patients not seen at the CPO clinic
11179794|NCT03522896|Placebo Comparator|control meal|glucose, fructose, sucrose, malic acid and citric acid in water
11179795|NCT03522896|Experimental|test meal 1|orange juice with added hesperidin (low dose)
11179796|NCT03522896|Experimental|test meal 2|orange juice with added hesperidin (high dose)
11179797|NCT03522896|Experimental|test meal 3|diluted orange juice with added hesperidin
11179798|NCT03522883|Placebo Comparator|group control|the subjects will not take any type of nutrient intake
11179799|NCT03522883|Experimental|experimental group 1|carbohydrate intake prior to exercise
11179800|NCT03522883|Active Comparator|experimental group 2|carbohydrate intake prior to exercise
11179801|NCT03522870|Experimental|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
11179802|NCT03522870|Active Comparator|SMBG|People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
11179803|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
11179804|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
11179805|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
11179806|NCT03522857||University of Nottingham|Physiotherapy, nursing and midwifery
11179807|NCT03522857||Curtin University|Physiotherapy
11179808|NCT03522857||Notre Dame University|Physiotherapy
11179809|NCT03522857||University College Dublin|Physiotherapists
11179810|NCT03522857||Leeds Beckett University|Physiotherapists
11179811|NCT03522857||University College Cork|Physiotherapists
11179812|NCT03522857||Robert Gordon University|OT, Physio, Midwifery, Nursing, Diagnostic radiography
11179813|NCT03522857||University of Ulster|Physiotherapy
11179814|NCT03522857||University of Limerick|OT, Physio, Midwifery, Nursing, Diagnostic radiography, paramedic
11179815|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
11179816|NCT03522844|Active Comparator|Escitalopram|
11179817|NCT03522831|Active Comparator|Salbutamol meter-dose inhaler|Inhalation of 400 μg salbutamol
11179818|NCT03522831|Placebo Comparator|Placebo meter-dose inhaler|Inhalation of 400 μg placebo
11179819|NCT03522818|Active Comparator|Normal|Group will use the alarm as provided by the manufacture.
11179820|NCT03522818|Experimental|Manual trigger|Group will use the same model but will be instructed to manually trigger the alarm 1-2 hours after the child falls asleep.
11179821|NCT03522805|Experimental|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
11179822|NCT03522792|Experimental|Saline + ad libitum meal|This will serve as the placebo / control day for the NT + ad libitum meal study day.
11179823|NCT03522792|Experimental|NT + ad libitum meal|Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
11179824|NCT03522792|Experimental|Saline + liquid meal + ad libitum meal|Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
11179825|NCT03522792|Experimental|NT + liquid meal + ad libitum meal|NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
11179826|NCT03522792|Experimental|Neurotensin|Acclimatization day
11179827|NCT03522779|Placebo Comparator|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
11179828|NCT03522779|Experimental|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
11179829|NCT03522779|Placebo Comparator|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
11179830|NCT03522779|Experimental|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
11179835|NCT03522753|Experimental|Staples|For short single incisions, these patients will receive superficial closure using only metal skin staples. Closure will be performed by resident or fellow involved in the case.
11179836|NCT03522753|Active Comparator|Suture|For short single incisions, these patients will receive superficial closure using only nylon sutures. No metal skin staples will be used. Closure will be performed by resident or fellow involved in the case.
11179837|NCT03522753|Other|Half Staple Half Suture|Some patients will receive both nylon sutures and metal skin staples for superficial closure. If multiple incisions are involved, each incision will count as 1 in the alternation method (i.e. toe 1 will be all sutures, then toe 2 will be all staples). For long incisions, closure will alternate between nylon sutures and metal skin staples on the part of the incision which is closer (more proximal) or farther away (more distal) from the rest of the body.
11179838|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
11179839|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
11179840|NCT03522727|No Intervention|Control|Participants will be asked to complete a questionnaire.
11179841|NCT03522727|Experimental|Intervention 1|"Single self-incentivising implementation intention
~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:
~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.
~Please complete the following sentence with a reward of your own choosing.
~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…
~**Drop down menu**
~Learning a new skill..."
11179842|NCT03522727|Experimental|Intervention 2|"Multiple self-incentivising implementation intentions
~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:
~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.
~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by… and/or…
~**Drop down menu**
~Learning a new skill..."
11179843|NCT03522727|Experimental|Intervention 3|"Self-generated self-incentivising implementation intentions
~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:
~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.
~Please complete the following sentence with a reward of your own choosing.
~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…"
11179844|NCT03522714|Active Comparator|Fluid Immersion Simulation System (FIS)|Pressure ulcer patients are assigned to Fluid Immersion Simulation System (Dolphin) after operative debridement and closure.
11179845|NCT03522714|Active Comparator|Air Fluidized Bed System (AFB)|Pressure ulcer patients are assigned to Air Fluidized Bed (Clinitron) after operative debridement and closure
11179846|NCT03522701|Experimental|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
11179847|NCT03522701|Active Comparator|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
11179848|NCT03522701|No Intervention|Waiting-list control|Participants will not receive any active treatment.
11179849|NCT03522688|No Intervention|control group|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
11179850|NCT03522688|Active Comparator|treatment group|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
11179851|NCT03522675|Other|NeoMatriX and Two Comparators|NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
11179852|NCT03522649|Experimental|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours. For patients who have failed bevacizumab with irinotecan-based chemotherapies, bevacizumab may be administered with FOLFIRI. FOLFIRI infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks, starting on C1D1. If bevacizumab is added to FOLFIRI, bevacizumab infusion should start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion. 5-FU 400 mg/ m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/ m^2/day continuous infusion. For patients who could not tolerate FOLFIRI at the full dose previously, FOLFIRI should be started at the same dose level the patient tolerated FOLFIRI previously.
11179853|NCT03522649|Other|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
11179854|NCT03522636||Treatment|Prehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
11179855|NCT03522636||Historic control|No prehospital blood products available
11179856|NCT03522623||IBD|Children and families with IBD will be surveyed
11179857|NCT03522610|Experimental|ADAPT|Parents participate in a 14-week in person group based version of ADAPT with web-enhanced online ADAPT materials.
11204706|NCT03351530||Diabetes with periodontal disease|
11179858|NCT03522610|No Intervention|Comparison Group|Parents receive services as usual (pamphlets, brochures, etc) on parenting typically found at a VA or Dr.'s office.
11179859|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
11179860|NCT03522597||Obese|Obese (BMI) women and their infants
11179861|NCT03522597||Diabetic|Women with gestational diabetes and their infants
11179862|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
11179863|NCT03522571|Experimental|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
11179864|NCT03522571|Active Comparator|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
11179865|NCT03522558|Experimental|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
11179866|NCT03522558|Active Comparator|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
11179867|NCT03522545|Experimental|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
11179868|NCT03522545|Placebo Comparator|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
11179869|NCT03522532|Experimental|Amalgam (Amg)|Amalgam was sealed in 8-K2 patients and 6-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
11179870|NCT03522532|Experimental|Tetric EvoCeram (TEC)|Tetric EvoCeram was sealed in 12-K2 patients and 5-K5 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
11179871|NCT03522532|Experimental|Beautifil (BF)|Beautifil was sealed in 15-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
11179872|NCT03522532|Experimental|Zinc phosphate cement (ZPhC)|"Zinc phosphate cement was sealed in 7-K2 patients, 4-K3 patients, 1-K4 patients and 2-K5 patients.
~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
11179873|NCT03522532|Experimental|Zinc polycarboxylate cement (ZPoC)|"Zinc polycarboxylate cement was sealed in 5-K2 patients, 4-K3 patients and 5-K4 patients.
~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
11179874|NCT03522532|Experimental|Glass ionomer cement (GIC)|"Glass ionomer cement was sealed in 11-K2 patients, 2-K3 patients and 1-K5 patients.
~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
11179875|NCT03522519||Assessment of real world performance|
11179876|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
11179877|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
11179878|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
11179879|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
11179880|NCT03522493|Active Comparator|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
11179881|NCT03522493|Experimental|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
11179882|NCT03522480|Other|Group A: Education & Gaming|Children will participate in 1 initial training session where they will be taught by a RT to use autogenic drainage (AD). Patients will be sent home & prescribed to practice the technique 15 minutes 3 times / week. At week 8 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform the AD sequence (percent accuracy). At the 8 week visit, the Jamboxx gaming device will be introduced, which will contain a game to guide them through the proper sequence of breathing for the AD technique. Patients will be sent home with a Jamboxx device and requested to do 15 minutes of AD training 3 times / week. Patients will return at week 16 and again will be tested via software program for ability to perform the AD technique.
11179883|NCT03522480|Experimental|Group B: Gaming Only|Children will participate in an initial training session at Albany Med where they will be taught by a RT to use the Jamboxx respiratory therapy device to guide them through autogenic drainage (AD): a series of controlled breathing exercises that mobilizes mucous without inducing wheezing in patients with reactive airways. Patients will be sent home and prescribed to use the Jamboxx respiratory therapy device 15 minutes three times per week. At week 8 and week 16 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform AD sequence (percent accuracy).
11179884|NCT03522467|Experimental|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
11179885|NCT03522454|Experimental|Intervention group|Intervention group: Combination of a protein-rich oral nutritional supplement consumed twice daily for 4 weeks pre-TAVR and 12 weeks after the patient is discharged home post-TAVR, and a home-based supervised exercise program that combines walking and weight-bearing exercises to build strength and balance performed for 12 weeks after the patient is discharged home post-TAVR.
11179886|NCT03522454|No Intervention|Lifestyle counselling group|Lifestyle counselling group: Recommendation to perform moderate-intensity aerobic activity at least 30 minutes 5 days per week as tolerated and eat a balanced diet based on the AHA/ACC Guideline on Lifestyle Management.
11179887|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
11179888|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
11179889|NCT03522441|Placebo Comparator|Placebo|
11179890|NCT03522428|Active Comparator|Receiving treatment|Adding vitamin B12 at a dose of 5 μg / 100 days, custom folic acid therapy and iron supplements
11179891|NCT03522428|No Intervention|Control group|Standard prenatal care (custom folic acid therapy and iron supplements)
11179892|NCT03522415|Experimental|HLX01+MTX|
11179893|NCT03522415|Placebo Comparator|Placebo+MTX|
11179894|NCT03522402|Experimental|30 degree rotated lateral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
11179895|NCT03522402|Active Comparator|neutral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in the neutral position.The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
11179896|NCT03522389|Experimental|AOT with gait training group|Action observation training with gait training
11179897|NCT03522389|Active Comparator|Gait training group|Gait training
11179898|NCT03522389|Other|Control group|Education
11179899|NCT03522376||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic obstructive pulmonary disease, stable clinically, has no infection or acute exacerbation in the previous four weeks, and can cooperate with the measurements of this study, loaded inspiratory muscle test.
11179900|NCT03522363|Experimental|Monodose group|1 vial with 4E10 CFU/g Total dose treatment: 4E10 CFU
11179901|NCT03522363|Experimental|Multidose group|7 vials with 5,5E09 CFU/g Total dose treatment: 4E10 CFU
11179902|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
11179903|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
11179904|NCT03522337|Placebo Comparator|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
11179905|NCT03522337|Experimental|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
11179906|NCT03522298|Experimental|Dose Escalation and Expansion Cohorts|"This is an open-label study.
~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.
~The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).
~In stage 1, dose escalation will occur for QD dosing.
~In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.
~Patients will be randomized in a 1:1 ratio to fed or fasted schedules."
11179907|NCT03522272|Experimental|Ultrasonic cleaning with cetylpyridinium chloride|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with 0.07% cetylpyridinium chloride mouthrinse
11179908|NCT03522272|Active Comparator|Ultrasonic cleaning with water|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with distilled water
11180163|NCT03520530|No Intervention|Control|Patients will push in the second stage of labor without use of mouth guard
11179909|NCT03522272|Active Comparator|Conventional denture hygiene|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent (Control group)
11179910|NCT03522259|Active Comparator|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
11179911|NCT03522259|Active Comparator|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
11179912|NCT03522246|Experimental|Arm A|oral rucaparib + intravenous (IV) nivolumab
11179913|NCT03522246|Experimental|Arm B|oral rucaparib+IV placebo
11179914|NCT03522246|Experimental|Arm C|oral placebo+ IV nivolumab
11179915|NCT03522246|Placebo Comparator|Arm D|Oral placebo + IV placebo
11179916|NCT03522220|Experimental|3D Super Mario Game Condition|3D navigation video game intervention
11179917|NCT03522220|Active Comparator|2D Super Mario Game Condition|Video game intervention without 3D navigation
11179918|NCT03522220|Active Comparator|Kindle Device|No 3D navigation
11179919|NCT03522207|Experimental|Trazo1|After a baseline polysomnography (PSG), subject will receive 100 mg of trazodone 30 minutes prior to their 2nd PSG and will receive 100mg Placebo 30 minutes prior to their 3rd PSG.
11179920|NCT03522207|Experimental|Trazo2|After a baseline polysomnography (PSG), subject will receive 100 mg of placebo 30 minutes prior to their 2nd PSG and will receive 100mg trazodone 30 minutes prior to their 3rd PSG.
11179921|NCT03522194||Sevoflurane|Anesthesia maintenance
11179922|NCT03522194||Propofol|Anesthesia maintenance
11179923|NCT03522181|Placebo Comparator|control group|saline
11179924|NCT03522181|Experimental|GIK group|glucose-Insulin-Potassium(GIK) infusion
11179925|NCT03522168||Risperidone group|Rispridone, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have <90 days of prior treatment with any antipsychotic.
11179926|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
11179927|NCT03522155|Experimental|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
11179928|NCT03522155|No Intervention|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
11179929|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
11179930|NCT03522142|Experimental|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
11179931|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
11179932|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
11179933|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
11179934|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
11179935|NCT03522116||No intervention|
11179936|NCT03522090||No neck CT|Cohort of patients with suspected lung cancer where the lower neck is not routinely included in CT
11179937|NCT03522090||Neck CT|Cohort of patients with suspected lung cancer where the lower neck is routinely included in CT
11179938|NCT03522077|Experimental|RadAR EasyCLik plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
11179939|NCT03522077|Active Comparator|TR BAND® plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
11179940|NCT03522064|Experimental|High dose testosterone|500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy).
11179941|NCT03522051|Experimental|Patients with carious teeth|female or male patients with permanent teeth and deep caries will receive pulpotomy treatment and dressing with calcium silicate based material (Neo MTA plus material) followed by restoration.
11179942|NCT03522025|Active Comparator|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
11179943|NCT03522025|Experimental|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
11179944|NCT03522012|Experimental|LusiNex|4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)
11179945|NCT03522012|Active Comparator|RoActemra|4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )
11179946|NCT03522012|Active Comparator|Actemra|4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)
11179947|NCT03521999|Active Comparator|AboutFace|Veterans in the AboutFACe arm will receive access to an online peer-to-peer digital storytelling resource for Veterans with PTSD
11179948|NCT03521999|Placebo Comparator|Enhanced Usual Care (eUC)|Veterans in the Enhanced Usual Care (eUC) arm will receive an education brochure for PTSD
11179949|NCT03521986|Experimental|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
11179950|NCT03521986|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
11179951|NCT03521973|Experimental|Group 1- PfSPZ-Vaccine|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.
~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
11179952|NCT03521973|Placebo Comparator|Group 2|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.
~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
11204707|NCT03351530||Periodontal patient|
11179953|NCT03521973|Experimental|Group 3|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.
~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 1."
11179954|NCT03521973|Placebo Comparator|Group 4|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.
~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 2."
11179955|NCT03521973|Experimental|Group 5|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.
~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 3."
11179956|NCT03521973|Placebo Comparator|Group 6|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.
~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 4."
11179957|NCT03521960|Active Comparator|Buspirone oral capsule|Buspirone (15 milligrams) administered orally three times per day
11179958|NCT03521960|Placebo Comparator|Placebo oral capsule|Placebo administered orally three times per day
11179959|NCT03521947||One group of children below 18 years old|
11179960|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin dose 1, once daily with possible uptitration in the first 8 months to dose 2
11179961|NCT03521934|Placebo Comparator|Placebo|Placebo dose 1, once daily with possible uptitration in the first 8 months to dose 2
11179962|NCT03521908||Participants treated with apixaban|
11179963|NCT03521908||Participants treated with warfarin|
11179964|NCT03521895||Treatment naïve wAMD|Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW
11179965|NCT03521882||Stroke Symptom Participants|
11179966|NCT03521882||Healthy Controls|
11179967|NCT03521869|Active Comparator|Compression bandage group|
11179968|NCT03521869|Active Comparator|Standard gauze group|
11179969|NCT03521856|Experimental|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
11179970|NCT03521856|Active Comparator|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
11179971|NCT03521843|Experimental|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
11179972|NCT03521843|Experimental|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
11179973|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Arm A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
11179974|NCT03521830|Experimental|Progression after anti-PD-1 therapy|Arm B: ipilimumab 1mg/kg IV q4 weeks x 4 doses + nivolumab 480mg IV q4weeks followed by nivolumab 480mg IV q4weeks for up to 48 total weeks of therapy.
11179975|NCT03521817|Experimental|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the ~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
11179976|NCT03521817|Active Comparator|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
11179977|NCT03521804|Other|SoundBite™ Crossing System-Coronary|Crossing of coronary chronic total occlusions.
11179978|NCT03521791|Experimental|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
11179979|NCT03521791|Placebo Comparator|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
11179980|NCT03521778|Experimental|Fascial Distortion Model group|Patients will receive manual treatment complies with Fascial Distortion Model method.
11179981|NCT03521778|Experimental|Mulligan Concept group|Patients will receive manual treatment complies with Mulligan Concept method.
11179982|NCT03521778|Experimental|Traditional physiotherapy group|Patients will receive traditional physiotherapy.
11179983|NCT03521765|Experimental|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
11179984|NCT03521765|No Intervention|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
11179985|NCT03521752|Experimental|Experimental|Performed a specific program exercises (resistance training, balance, coordination and flexibility) during 4 weeks.
11179986|NCT03521752|No Intervention|Control|The control group wasn't subjected to any intervention
11179987|NCT03521726|Other|Intraluminal Amoxicillin eradication|20 Patients receive intraluminal Amoxicillin eradication of H. pylori.
11179988|NCT03521726|Other|Rabeprazole, Amoxicillin dual therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole and Amoxicillin) for 14 days.
11179989|NCT03521713|Experimental|EPORON|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.
~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
11180028|NCT03521440|Experimental|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
11180164|NCT03520517|Experimental|BHV-0223|riluzole 40 mg sublingual tablet
11204708|NCT03351530||Healthy person|
11179990|NCT03521713|Active Comparator|EPREX|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.
~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
11179991|NCT03521700|Experimental|Intensive lipid lowering group|10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L
11179992|NCT03521700|Other|Conventional lipid lowering group|5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L
11179993|NCT03521687|Experimental|Apremilast|Patients with CCCA
11179994|NCT03521674|Other|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
11179995|NCT03521674|Other|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
11179996|NCT03521661||Kyphoplasty|Patients underwent kyphoplasty with an intravertebral expander
11179997|NCT03521648||PAE|Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study.
11179998|NCT03521648||TURP|Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study.
11179999|NCT03521648||Other|Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study.
11180000|NCT03521635|Experimental|Pramipexole SR|
11180001|NCT03521635|Active Comparator|Pramipexole IR|
11180002|NCT03521622|Experimental|brief counseling interventions|"For smoking patients the brief intervention is 5 As model for motivated patients and 5Rs for not motivated patients.
~For risky alcohol drinkers the brief intervention is simple advise for motivated patients and brief intervention for not motivated patients."
11180003|NCT03521622|Placebo Comparator|Control group|written informative material about healthy lifestyles
11180004|NCT03521609|Experimental|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
11180005|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
11180006|NCT03521570|Experimental|Treatment (nivolumab, IMRT)|Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11180007|NCT03521557|Experimental|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.
~Gaze stability exercise will consist of progressive Vestibular-occular training.
~Postural stability exercises will consist of progressive static and dynamic postural training."
11180008|NCT03521557|Active Comparator|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
11180009|NCT03521544|Experimental|Plantar Fascia|Self-myofascial release in the plantar fascia.
11180010|NCT03521544|Experimental|Tricep surae fascia|Self-myofascial release in the triceps surae fascia.
11180011|NCT03521544|Experimental|Hamstrings fascia|Self-myofascial release in the hamstrings fascia.
11180012|NCT03521544|Experimental|Spine erectors and lumbar fascia|Self-myofascial release in the spine erectors and lumbar fascia.
11180013|NCT03521544|Experimental|Occipital and suboccipital fascia|Self-myofascial release in the occipital and suboccipital fascia.
11180014|NCT03521544|No Intervention|Control group|Lay on a stretcher.
11180015|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
11180016|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
11180017|NCT03521492|Experimental|caries group|
11180018|NCT03521492|Experimental|free caries group|
11180019|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
11180020|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
11180021|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
11180022|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
11180023|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
11180024|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
11180025|NCT03521453||Before|Conventionnel written information
11180026|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
11180027|NCT03521440|Experimental|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
11180029|NCT03521440|No Intervention|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
11180030|NCT03521427|Experimental|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
11180031|NCT03521427|Active Comparator|Neurodevelopmental treatment|Ninety hours of intensive neurodevelopmental therapy
11180032|NCT03521414|Active Comparator|Group I=13-15 mildly injured|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.
~Group I (n=15)=13-15 mildly injured"
11180033|NCT03521414|Active Comparator|Group 2 =9-12 moderately damaged|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery.use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.
~Group 2 (n=15)=9-12 moderately damaged"
11180034|NCT03521414|Active Comparator|Group 3=3-8 severely damaged.|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.
~Group 3 (n=15)=3-8 severely damaged."
11180035|NCT03521401|Experimental|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
11180036|NCT03521401|No Intervention|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
11180037|NCT03521401|No Intervention|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
11180038|NCT03521388|Experimental|Intervention group|"The intervention consists of an Internet-based program. The program will last 3 months, with subsequent monthly reinforcement sessions for other 3 months.
~The program is stepped, so that the more depressive symptomatology the more intensive program and consists of more components.
~The students will interact with the program via a monitoring and feedback e-mail with 3 questions of the PHQ--9- adolescent version (1st, 2nd & 9th question) that they will receive every 2 weeks and a Website that will allow them to access to psycho-educational videos and information. There will also in the Website sections that will provide emergency information, the possibility of a contact via e-mail, and group chats. Adolescents with more depressive symptoms or suicidal risk will be invited to participate in an online counselling appointment or a face to face assessment with a mental health professional of the program."
11180039|NCT03521388|Other|Control group|The comparison group will receive general psychoeducation of depression in adolescents and will be on the waiting list to receive the intervention in the event that its efficacy is demonstrated.
11180040|NCT03521375|Experimental|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
11180041|NCT03521375|Active Comparator|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
11180042|NCT03521362|Experimental|MyT1DHero App|Participants in this group will receive use of the MyT1DHero app.
11180043|NCT03521362|Active Comparator|"Other T1D App"|Participants in this group will receive use of a different app with less capabilities.
11180044|NCT03521349|Placebo Comparator|Egg White Snacks|Egg white-based snacks
11180045|NCT03521349|Experimental|Whole Egg Snacks|Whole egg-based snacks
11180046|NCT03521336|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
11180047|NCT03521336|Placebo Comparator|Control|Placebo: Sham operation, 10ml saline, once a month for 4 months
11180048|NCT03521323|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
11180049|NCT03521323|Placebo Comparator|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
11180050|NCT03521310|Experimental|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
11180051|NCT03521310|Active Comparator|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
11180052|NCT03521297|Placebo Comparator|Placebo group|Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months
11180053|NCT03521297|Experimental|Probiotics group|Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months
11180054|NCT03521284||Mothers with education program during their mat|
11180055|NCT03521284||Mothers without education program during their mat|
11180056|NCT03521258|Experimental|Human Amnion/Chorion Membrane + skin graft|Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
11180057|NCT03521258|Active Comparator|Flap Reconstruction (Standard of Care)|A negative pressure wound dressing (NPWD) will be applied at the time of debridement until the wound is clean and adequate for flap reconstruction. Flap-based reconstruction is performed. Following flap reconstruction,patient will have 5 days of bed rest to allow proper healing and coverage of the wounds. If flaps are successful, patients starts a limb dangle protocol which gradually increases the dependent position and allows the flap to acclimate to new physiologic demands. Following dangle protocol patient will require inpatient physical and occupational therapy prior to discharge.
11180058|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
11180059|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
11180060|NCT03521232|Experimental|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
11180061|NCT03521232|Experimental|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
11180062|NCT03521219|Experimental|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
11180063|NCT03521206|Experimental|Intervention group|"The ACP+ programme aims to improve or establish advance care planning (ACP) in the day-to-day routine of staff working in nursing homes.
~The intervention implementation period has a total duration of 8 months and is divided into:
~a four-month preparation and training phase. During this phase the ACP reference persons will attend a two-day training given by the ACP trainers. Other staff will receive training by the reference persons on conducting ACP conversation or recognizing triggers for an ACP conversation in nursing home residents.
~A four-month follow-up phase in which ACP conversations are held with residents. Additional training sessions will be organized to give more in-depth knowledge to the ACP reference persons."
11180064|NCT03521206|No Intervention|Control group|The staff of nursing homes in the control group will receive no additional training next to any standard education or continuous training. After the intervention and follow-up measures are finished, all nursing homes in the control group will be offered a shortened version of the ACP+ training programme as well as all ACP+ training materials.
11180065|NCT03521193|Experimental|Migraine evaluation in PFO patients|Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up
11180066|NCT03521180||Subjects with Celiac Disease|"Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses.
~Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once.
~The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes."
11180067|NCT03521167|No Intervention|T|traditional opioid based regimen
11180068|NCT03521167|Active Comparator|MD|multimodal group with dexmedetomidine
11180069|NCT03521167|Placebo Comparator|M|multimodal with saline placebo
11180070|NCT03521154|Experimental|Osimertinib|Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.
11180071|NCT03521154|Placebo Comparator|Placebo Osimertinib|Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule
11180072|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
11180073|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
11180074|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
11180075|NCT03521128|Experimental|the radiological tubal blockage group|
11180076|NCT03521128|Active Comparator|the laparoscopic salpingectomy group|
11180077|NCT03521115|Experimental|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component.
11180078|NCT03521115|No Intervention|Control condition|This group was provided with websites where information was available regarding the same topics.
11180079|NCT03521102|Experimental|Acetaminophen 1000mg IV|NRS pain scores will be obtained at 5, 15, 30, 45, 60, 75, 90, 105 and 120 minutes following completion of intervention. Adverse events will be recorded every 15 minutes for the duration of the study protocol. Participants will be reassessed for the need of additional pain control at 60 minutes.
11180080|NCT03521102|Active Comparator|Hydromorphone 0.5mg IV|NRS score will be checked at 5 minutes and every 15 minutes for 120 minutes. Adverse events will be recorded every 15 minutes for the duration of the study protocol. The need for additional pain control will be assessed at 60 minutes.
11180081|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
11180082|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
11180083|NCT03521076|Experimental|Virtual Reality for distraction|The application of VR during the putative painful treatment (botulinum toxin injections) will provide a) active and engaging distraction during the procedure, and will b) block the view and auditory noise related to the procedure.
11180084|NCT03521076|No Intervention|Standard of Care|Patients will receive the standard of care for the putative painful treatment (botulinum toxin injections).
11180085|NCT03521063|Experimental|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
11180086|NCT03521063|Active Comparator|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
11180087|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
11180088|NCT03521037|Experimental|no name|Group 1: patients with normal hepatic function Group 2: patients who have moderate hepatic impairment
11180089|NCT03521024|Active Comparator|lithium disilicate crowns|lithium disilicate crowns are well documented in the literatures as successful restoration modality.
11180090|NCT03521024|Experimental|poly ether ketone ketone crowns|pekkton
11180091|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
11180092|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
11180093|NCT03520985|Experimental|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
11180094|NCT03520972|Experimental|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
11180095|NCT03520972|Experimental|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
11180096|NCT03520972|Experimental|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
11180097|NCT03520972|Placebo Comparator|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
11180098|NCT03520959|Placebo Comparator|Placebo|A sequential regimen of LV305-matching placebo and G305-matching placebo.
11180099|NCT03520959|Experimental|CMB305|A sequential regimen of LV305 and G305.
11180100|NCT03520946|Experimental|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
11180101|NCT03520946|Active Comparator|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
11180102|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
11180103|NCT03520920|Experimental|Non-GCB DLBCL|Participants with non germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) will receive zanubrutinib plus rituximab for up to 24 months
11180104|NCT03520920|Experimental|R/R FL or MZL|Participants with relapsed/refractory (R/R) FL or MZL will receive zanubrutinib plus rituximab for up to 24 months
11180105|NCT03520907|Experimental|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
11180106|NCT03520907|Active Comparator|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
11180107|NCT03520894|Experimental|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
11180108|NCT03520881|Experimental|Pediatric ASTHMA-Educator arm|This arm corresponds to the pediatric version of the ASTHMA-Educator mobile application.
11180109|NCT03520868||Coumadin|Coumadin patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 70 U/kg
11180110|NCT03520868||Dabigatran|Dabigatran patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
11180111|NCT03520868||Rivaroxiban|Rivaroxiban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
11180112|NCT03520868||Apixaban|Apixaban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 10 U/kg
11180113|NCT03520855|Experimental|ETP + Serious game|patients receiving the serious game additionally to the classic therapeutic education
11180114|NCT03520855|Active Comparator|ETP|patients under classic therapeutic education
11180115|NCT03520842|Experimental|Treatment (regorafenib, methotrexate)|Participants receive regorafenib PO QD on days 1-21, and methotrexate PO twice weekly with 2-3 days apart on a 3 week on/ 1 week off cycle. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11180116|NCT03520829||Patient treated for Gamma Knife|
11180117|NCT03520816|Experimental|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
11180118|NCT03520816|No Intervention|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
11180119|NCT03520803|Experimental|Experimental|ERAS protocol
11180120|NCT03520803|No Intervention|Control|Standard of care
11180121|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine and Nab-paclitaxel is administered intravenously 3 times a cycle.
~Placebo is administered orally on a daily basis"
11180122|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.
~Paricalcitol is administered intravenously 3 times/week."
11180123|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.
~Paricalcitol is administered orally on a daily basis"
11180124|NCT03520777|Other|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
11180125|NCT03520764|Experimental|New infant formula with synbiotics|
11180126|NCT03520764|Active Comparator|Standard infant formula with prebiotics|
11180127|NCT03520764|No Intervention|human milk|
11180128|NCT03520751|Experimental|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
11180129|NCT03520738|Other|Chronic Kidney Disease|"Blood and urinary samples on the following patients:
~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
11180130|NCT03520738|Other|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:
~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
11180131|NCT03520738|Other|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:
~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
11180132|NCT03520725|Experimental|No Intervention|This group did not have an intervention
11180133|NCT03520725|Experimental|Intervention pineapple|Daily consumption of 30 g of pineapple snack bar for 4 weeks.
11180134|NCT03520725|Experimental|Intervention mango|Daily consumption of 30 g of mango snack bar for 4 weeks.
11180135|NCT03520712|Experimental|valoctocogene roxaparvovec Open Label|Single administration of BMN270 at a dose of 6E13 vg/kg
11180136|NCT03520686|Experimental|Cohort A (Experimental)|
11180137|NCT03520686|Experimental|Cohort B (Experimental)|
11180138|NCT03520686|Experimental|Cohort C (Experimental)|
11180139|NCT03520686|Active Comparator|Cohort A (Control)|
11180140|NCT03520686|Active Comparator|Cohort B (Control)|
11180141|NCT03520686|Active Comparator|Cohort C (Control)|
11180142|NCT03520673|Other|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
11180143|NCT03520660||Cured Hepatitis C|CHC and SVR (sustained virological response)
11180144|NCT03520647|Experimental|Transplant recipients|haplo-identical transplantation
11180145|NCT03520634|Experimental|PD-L1 PET imaging in melanoma patients|The main intervention of this study is a [18F]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
11180146|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
11180147|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
11180148|NCT03520595|Active Comparator|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
11180149|NCT03520595|Active Comparator|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
11180150|NCT03520595|Placebo Comparator|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
11180151|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
11180152|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
11180153|NCT03520569|Active Comparator|Octreotide- Euglycemia|octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min
11180154|NCT03520569|Active Comparator|Octreotide - Euglycemia- insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min
11180155|NCT03520569|Active Comparator|Octreotide- hyperglycemia|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
11180156|NCT03520569|Active Comparator|Octreotide- hyperglycemia - insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
11180157|NCT03520556||docosahexaenoic acid (DHA)|Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
11180158|NCT03520556||eicosapentaenoic acid (EPA)|Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
11180159|NCT03520556||control|Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
11180160|NCT03520543|Experimental|Part A : Imput function|Compartmental model of the volume of distribution of [11C]Yohimbine in Brain by PET
11180161|NCT03520543|Experimental|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of [11C]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
11180162|NCT03520530|Experimental|Mouth Guard|Patients will push in the second stage of labor without use of mouth guard
11180165|NCT03520504|Experimental|Proton Radiation|"Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
~The first 3 patients will be enrolled at dose level 30Gy (RBE) in 3Gy(RBE) fractions. If 1 or fewer patients develop dose-limiting toxicity (DLT), 3 additional patients will be enrolled. If 1 or fewer of the 6 patients experiences a DLT, the trial will proceed to the dose expansion cohort at 30Gy (RBE) . In contrast, if 2 or more patients experience a treatment DLT, 3 patients will be enrolled at dose level 25Gy (RBE) in 2.5Gy(RBE) fractions. If 1 or fewer patients develop a DLT, an additional three patients will be enrolled. If 2 or more patients experience a DLT at 25Gy, the study will be stopped. If 1 or fewer patients develop a DLT in these 6 patients, the trial will proceed to the dose expansion cohort at 25Gy (RBE) and the 6 patients who were treated in Phase Ib will be included in full assessment of safety and efficacy."
11180166|NCT03520491|Experimental|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
11180167|NCT03520491|Experimental|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
11180168|NCT03520491|Experimental|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
11180169|NCT03520491|Experimental|Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.
11180170|NCT03520478|Experimental|SHR3680|Participants will receive SHR3680 orally
11180171|NCT03520478|Active Comparator|bicalutamide|Participants will receive bicalutamide orally
11180172|NCT03520465|Experimental|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.
~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.
~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
11180173|NCT03520465|No Intervention|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
11180174|NCT03520452|Placebo Comparator|Placebo|Placebo
11180175|NCT03520452|Experimental|302 mg green coffee extract|Green coffee extract
11180176|NCT03520452|Experimental|604 mg green coffee extract|Green coffee extract
11180177|NCT03520452|Experimental|906 mg green coffee extract|Green coffee extract
11180178|NCT03520439|Experimental|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
11180179|NCT03520439|Placebo Comparator|control group|placebo，10mg，One tablet daily, oral treatment
11180180|NCT03520426|Experimental|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
11180181|NCT03520426|Sham Comparator|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
11180182|NCT03520413|Experimental|PRACTICE-DM|PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
11180183|NCT03520413|Active Comparator|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
11180184|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
11180185|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
11180186|NCT03520387|Experimental|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
11180187|NCT03520387|Active Comparator|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
11180188|NCT03520387|Experimental|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
11180189|NCT03520387|Active Comparator|TBSCE|Telephone-based self-directed CBT and education (TBSCE)
11180190|NCT03520374|Other|Ultrasonography- Novices|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. These results will be compared to the evaluation of experts in ultrasonography i.e interventional radiologists.
11180191|NCT03520374|Other|Ultrasonography-Expert Interventional Radiologists|Physician assessment i.e interventional radiologist evaluation of gastric contents using ultrasonography.
11180192|NCT03520361|Experimental|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
11204944|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
11180193|NCT03520361|Active Comparator|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
11180194|NCT03520348|Experimental|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
11180195|NCT03520348|Active Comparator|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
11180196|NCT03520322|Experimental|Mastoid Oscillator|patients with Menieres Disease
11180197|NCT03520322|Placebo Comparator|Control device|patients with Menieres Disease
11180198|NCT03520309|Experimental|International Dental Federation|Dental Treatment: according to the decision based on the International Dental Federation (FDI) criteria
11180199|NCT03520309|Experimental|Caries Around Restorations System|Dental Treatment: according to the decision based on the Caries Around Restorations System (CARS) and treatment decision proposed by the International Caries Classification and Management System (ICCMS)
11180200|NCT03520296||Patients hospitalized in the cardiology unit|
11180201|NCT03520296||Patients hospitalized in the orthopedic surgery unit|
11180202|NCT03520296||Patients hospitalized in the endocrinology unit|
11180203|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
11180204|NCT03520257|Experimental|Apatinib Plus Radiotherapy|
11180205|NCT03520257|Other|Apatinib|
11180206|NCT03520244|Experimental|Exercise + Holistic Education|A 12-week exercise program with 6 bi-weekly education sessions.
11180207|NCT03520244|No Intervention|Wait list control|Participants in the control group will be offered the exercise + education sessions after the study is complete.
11180208|NCT03520231|Experimental|Denosumab and Standard Chemotherapy|"Denosumab, given subcutaneously at a dose of 120 mg, every 4 weeks.
~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.
~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~Calcium, orally at a dose of 1000 mg, once daily.
~Vitamin D, orally at a dose of 400 IU, once daily."
11180209|NCT03520231|Placebo Comparator|Denosumab Placebo and Standard Chemotherapy|"Denosumab placebo, given subcutaneously, every 4 weeks.
~Gemcitabine, given intravenously at standard doses, on Days 1 and 8 of every 21 day cycle, for 3-4 cycles.
~Carboplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~OR Cisplatin, given intravenously at standard doses, on Day 1 of every 21 day cycle, for 3-4 cycles.
~Calcium, orally at a dose of 1000 mg, once daily.
~Vitamin D, orally at a dose of 400 IU, once daily."
11180210|NCT03520218|Experimental|Performance of R-PEM|"5miCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection.
~These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI"
11180211|NCT03520205|Active Comparator|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
11180212|NCT03520205|Active Comparator|Continuous Epidural|Patient will receive epidural anesthesia
11180213|NCT03520179||SMA TYPE 1|genetically confirmed SMA
11180214|NCT03520179||SMA TYPE 2|genetically confirmed SMA
11180215|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
11180216|NCT03520166|Placebo Comparator|Group-A|No treatment
11180217|NCT03520166|Experimental|Group-B|Medium frequency electrotherapy (interferential currents)
11180218|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
11180219|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
11180220|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
11180221|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.
~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
11180222|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
11180223|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
11180224|NCT03520114|Experimental|RP sling group|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
11180225|NCT03520114|Experimental|SIS group|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
11180226|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
11180227|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
11180228|NCT03520088|Experimental|Inferior mesenteric Vein dissection|To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis
11180229|NCT03520088|Active Comparator|Inferior mesenteric Artery dissection|As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis
11180230|NCT03520075|Experimental|Phase 1 Regimen 1|"Dose escalation and expansion:
~Regimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle."
11180231|NCT03520075|Experimental|Phase 1 Regimen 2|"Dose escalation and expansion:
~Regimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle."
11180367|NCT03519282|Experimental|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
11180232|NCT03520075|Experimental|Phase 2|ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.
11180233|NCT03520062|Experimental|GLP-1 Receptor Agonist (Liraglutide)|3.0mg daily dose
11180234|NCT03520049|Experimental|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
11180235|NCT03520049|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
11180236|NCT03520036|Experimental|MT-7117 low dose|
11180237|NCT03520036|Experimental|MT-7117 high dose|
11180238|NCT03520036|Placebo Comparator|Placebo|
11180239|NCT03520023|No Intervention|Standard Care|Standard care with consultant discretion regarding consult of palliative care medicine
11180240|NCT03520023|Experimental|Experimental|Early palliative care consult based upon meeting study inclusion criteria
11180241|NCT03520010|Active Comparator|Internally-driven implementation|
11180242|NCT03520010|Experimental|Externally-facilitated implementation|
11180243|NCT03519997|Experimental|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
11180244|NCT03519984|Experimental|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11180245|NCT03519984|Experimental|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11180246|NCT03519971|Experimental|Arm 1: Durvalumab + platinum-based chemotherapy and radiation|"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:
~cisplatin/etoposide
~carboplatin/paclitaxel
~pemetrexed/cisplatin
~pemetrexed/carboplatin
~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment."
11180247|NCT03519971|Placebo Comparator|Arm 2: Placebo + platinum-based chemotherapy and radiation|"Placebo in concurrence with platinum-based chemo-radiation therapy.
~All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:
~cisplatin/etoposide
~carboplatin/paclitaxel
~pemetrexed/cisplatin
~pemetrexed/carboplatin
~At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment."
11180248|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
11180249|NCT03519945|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC).
11180250|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
11180251|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
11180252|NCT03519919|Experimental|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
11180253|NCT03519880|Experimental|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
11180254|NCT03519867|Experimental|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
11180255|NCT03519867|Experimental|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180256|NCT03519867|Experimental|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180257|NCT03519867|Experimental|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180258|NCT03519867|Experimental|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180259|NCT03519867|Experimental|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180260|NCT03519867|Experimental|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180261|NCT03519867|Experimental|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180262|NCT03519867|Experimental|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180263|NCT03519867|Experimental|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
11180264|NCT03519854|Placebo Comparator|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180265|NCT03519854|Experimental|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180266|NCT03519854|Experimental|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180267|NCT03519854|Experimental|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180268|NCT03519854|Experimental|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180269|NCT03519854|Experimental|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180270|NCT03519854|Placebo Comparator|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180271|NCT03519854|Experimental|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180272|NCT03519854|Experimental|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180273|NCT03519854|Experimental|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180274|NCT03519854|Experimental|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180275|NCT03519854|Experimental|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180276|NCT03519854|Placebo Comparator|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180277|NCT03519854|Experimental|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180278|NCT03519854|Experimental|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180279|NCT03519854|Experimental|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180280|NCT03519854|Experimental|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180281|NCT03519854|Experimental|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
11180282|NCT03519841|Experimental|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
11180283|NCT03519841|Experimental|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
11180284|NCT03519828||Patients with post-stroke cognitive impairment|
11180285|NCT03519828||Patients without post-stroke cognitive impairment|
11180286|NCT03519815|Active Comparator|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device
~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
11180287|NCT03519815|Active Comparator|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days
~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
11180288|NCT03519789||Post-Traumatic Stress Disorders (PTSD)|30 patients with PTSD (diagnosis based on the standard DSM criteria)
11180289|NCT03519789||Controls|30 healthy controls without any psychiatric or neurological diagnosis
11180290|NCT03519763||Control group|Fifteen patients without isthmocele
11180291|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
11180292|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
11180293|NCT03519750|Active Comparator|Intravenous melatonin|Intravenous administration, making it possible to calculate bioavailability for other routes of administration
11180294|NCT03519750|Experimental|Rectal melatonin|Rectal administration of melatonin
11180295|NCT03519750|Experimental|Intravesical melatonin|Intravesical administration of melatonin
11180296|NCT03519750|Experimental|Vaginal melatonin|Vaginal administration of melatonin
11180297|NCT03519750|Experimental|Transdermal melatonin|Transdermal administration of melatonin
11180298|NCT03519737|Sham Comparator|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
11180299|NCT03519737|Active Comparator|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
11180300|NCT03519724|Experimental|SUG|
11180301|NCT03519724|Active Comparator|NEO|
11180302|NCT03519711|Experimental|Cohort 1: CNSA-001 2.5 mg/kg/day or 10 mg/kg/day|Participants will receive CNSA-001 suspension 2.5 milligrams (mg)/kilogram (kg)/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 10 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
11205485|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
11180303|NCT03519711|Experimental|Cohort 2: CNSA-001 5 mg/kg/day or 20 mg/kg/day|Participants will receive CNSA-001 suspension 5 mg/kg/day (dose divided in 2 for twice daily administration) orally for 7 days in Period 1, undergo a 3- to 4-day washout period, then escalate to 20 mg/kg/day (dose divided in 2 for twice daily administration) administered orally for 7 days in Period 2 (14 days total treatment).
11180304|NCT03519698|Placebo Comparator|Warm water|12 l footbath with warm water (40 °C)
11180305|NCT03519698|Experimental|Warm water & Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour
11180306|NCT03519698|Experimental|Warm water & Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour
11180307|NCT03519685|Experimental|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
11180308|NCT03519685|Placebo Comparator|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
11180309|NCT03519672||Participants with cTTP - adolescents|Adolescents aged 12 to 17 years
11180310|NCT03519672||Participants with cTTP - adults|Adults aged ≥18 years
11180311|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
11180312|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
11180313|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
11180314|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
11180315|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
11180316|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
11180317|NCT03519646|Experimental|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
11180318|NCT03519633|Experimental|SUG|
11180319|NCT03519633|Active Comparator|NEO|
11180320|NCT03519620|Experimental|SWWSV|Spirometric Values: Forced Vital Capacity; Forced Expiratory Volume in 1 second; Peak Expiratory Flow
11180321|NCT03519607|Active Comparator|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
11180322|NCT03519607|No Intervention|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
11180323|NCT03519594||Embolization group|The group that underwent embolization after pelvic injury.
11180324|NCT03519594||Non-embolization group|The observed group of pelvic injuries without embolization
11180325|NCT03519581|Active Comparator|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:
~Confirmation of the subject's identity and eye to be treated
~Subject's eye will be dilated
~Subject will be positioned at the slit lamp for treatment
~Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
11180326|NCT03519581|Placebo Comparator|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:
~Confirmation of the subject's identity and eye to be treated
~Subject's eye will be dilated
~Subject will be positioned at the slit lamp for treatment
~No Actual laser treatment will occur"
11180327|NCT03519568|Experimental|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
11180328|NCT03519568|Active Comparator|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
11180329|NCT03519568|Active Comparator|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
11180330|NCT03519542||Metastatic clear cell renal carcinoma (mRCC) patients|Metastatic clear cell renal carcinoma (mRCC) patients cadidates to receive Sunitinib 50 mg/day 4/2 schedule or Pazopanib 800mg/day until unaccetable toxicity or progression or death under standar clinical practice.
11180331|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%
~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
11180332|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
11180333|NCT03519490|Placebo Comparator|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
11180334|NCT03519490|Experimental|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
11180335|NCT03519477|Experimental|Heart failure care with Sano test|Scheduled outpatient care for patients at high risk of admission for heart failure, supplemented with the Sano Patient Medication Profile
11180336|NCT03519477|No Intervention|Heart failure care as-usual|Scheduled outpatient care for patients at high risk of admission for heart failure, care as-usual (i.e. without the Sano Patient Medication Profile).
11180337|NCT03519464|Other|ICL and Healthy Volunteers|Biological/Vaccine
11180338|NCT03519451|Experimental|Group I (KickAsh smartphone mobile application)|Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
11180339|NCT03519451|Experimental|Group II (Breathe2Relax smartphone mobile application)|Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
11180340|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
11180341|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
11180342|NCT03519425|No Intervention|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:
~Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.
~Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.
~Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.
~Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
11180343|NCT03519425|Active Comparator|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.
~HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.
~HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
11180344|NCT03519425|Active Comparator|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:
~A digital chest x-ray using the study MinXray unit.
~Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.
~Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.
~Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
11180345|NCT03519412|Experimental|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is > 20 Muts/Mb
11180346|NCT03519412|Other|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
11180347|NCT03519399||Cases and Controls|"Cases - Pregnant women with ICP defined as pruritus in pregnancy in association with raised serum bile acids (using hospital threshold for diagnosis), and in the absence of an alternative cause.
~Controls - Pregnant women not affected by ICP, or other liver, cardiac or hypertensive disorders."
11180348|NCT03519386|Experimental|Implant Group 1|G2TR intraocular implant containing travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
11180349|NCT03519386|Experimental|Implant Group 2|G2TR intraocular implant containing travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
11180350|NCT03519386|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
11180351|NCT03519373||PER001|HIV 1-infected pregnant women
11180352|NCT03519373||PER002|HIV 1-uninfected pregnant women
11180353|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
11180354|NCT03519360|Experimental|Restricted ultrafiltration rate (UFR)|UFR ≤10 ml/kg/hr
11180355|NCT03519360|Experimental|Standard of Care/ Unrestricted UFR|UFR as needed
11180356|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
11180357|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
11180358|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
11180359|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
11180360|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back & Neck Pain, Cancer, Ischemic Heart Disease
11180361|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
11180362|NCT03519321|Experimental|Treatment|MID-C EOS implant will be implanted for the correction of the spine deformity in children found eligible for the study
11180363|NCT03519308|Experimental|Arm A|
11180364|NCT03519308|Experimental|Arm B|
11180365|NCT03519295|Experimental|ARM A - mDCF + Atezolizumab|"MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.
~Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
11180366|NCT03519295|Active Comparator|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
11180368|NCT03519282|Active Comparator|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
11180369|NCT03519269|No Intervention|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
11180370|NCT03519269|Experimental|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
11180371|NCT03519256|Experimental|Nivolumab monotherapy|
11180372|NCT03519256|Experimental|Nivolumab + BCG|
11180373|NCT03519256|Experimental|Nivolumab + BMS-986205|
11180374|NCT03519256|Experimental|Nivolumab + BMS-986205 + BCG|
11180375|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
11180376|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
11180377|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
11180378|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
11180379|NCT03519230|Experimental|Treatment arm|
11180380|NCT03519230|Placebo Comparator|Placebo arm|
11180381|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
11180382|NCT03519204|Experimental|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
11180383|NCT03519204|Experimental|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
11180384|NCT03519191|Other|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
11180385|NCT03519191|Other|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
11180386|NCT03519178|Experimental|Dose Escalation|Single Agent Dose Escalation
11180387|NCT03519178|Experimental|Dose Finding Endocrine Therapy 1 Combination|Part 1B PF-06873600 plus Endocrine Therapy 1
11180388|NCT03519178|Experimental|Dose Finding Endocrine Therapy 2 Combination|Part 1B PF-06873600 plus Endocrine Therapy 2
11180389|NCT03519178|Experimental|Dose Expansion Arm A|PF-06873600 as a Single Agent
11180390|NCT03519178|Experimental|Dose Expansion Arm B|PF-06873600 as a Single Agent in Various Tumor Types
11180391|NCT03519178|Experimental|Dose Expansion Arm C|PF-06873600 in Combination with Endocrine Therapy 1
11180392|NCT03519178|Experimental|Dose Expansion Arm D|PF-06873600 in Combination with Endocrine Therapy 1
11180393|NCT03519178|Experimental|Dose Expansion Arm E|PF-06873600 in Combination with Endocrine Therapy 2
11180394|NCT03519165|No Intervention|Control group (Group C)|"Conventional Fluid therapy guided by clinical parameter
~Intraoperative fluid therapy will include maintenance fluid and replacement of the surgical loss. Aim to maintain MAP > 65 mmHg, CVP 8-12 cm H2O and urine output > 0.5 ml/kg/h."
11180395|NCT03519165|Active Comparator|Goal directed group (Group G)|"Intervention: Machine guided fluid therapy using EV1000 (FloTrac System 4.0 Edward Lifesciences, Irvine, CA, USA)
~Intraoperative fluid therapy will be targeted to SVV <13%, SVI > 35ml/m2/ beat, SVRI more than equal to 1900 dynes-sec/cm-5/m2 using EV1000 floTrac monitor in addition to clinical parameters like MAP, CVP and urine output"
11180396|NCT03519152|Experimental|study group one side|All patients were scheduled for open flap debridement surgery on at least two quadrants ≥1 weeks apart.One group will receive Low Dose Diclofenac tablets (25mg Diclofeanc and 325 mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis will be included in study. For each quadrant, a flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure will be recorded in the patient file. Patients will be instructed to complete a pain diary chart for 3 days.
11180397|NCT03519152|Placebo Comparator|study group second side|Other group will receive Diclofeanc (50mg Diclofenac and 325mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis were included in study. For each quadrant, aperiodontal flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure was recorded in the patient file. Patients were instructed to complete a pain diary chart for 3 days.
11180398|NCT03519139|Experimental|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
11180399|NCT03519139|No Intervention|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
11180400|NCT03519126|Experimental|vaginal|Group of volunteers who will be treated with vaginal electrostimulation
11180401|NCT03519126|Experimental|posterior tibial nerve|Group treated with transcutaneous electrostimulation of the posterior tibial nerve
11180402|NCT03519126|No Intervention|control|Group of volunteers who will not be treated
11180403|NCT03519113|Experimental|Test group 1|GC1102 80,000 IU
11180404|NCT03519113|Experimental|Test group 2|GC1102 100,000 IU
11180405|NCT03519113|Active Comparator|Control group|I.V HBIG
11180406|NCT03519087|Experimental|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
11205486|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
11180407|NCT03519087|No Intervention|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
11180408|NCT03519087|Experimental|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
11180409|NCT03519087|No Intervention|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
11180410|NCT03519087|Other|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
11180411|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
11180412|NCT03519061|Experimental|Treatment|This is the group of enrollees who receive budesonide
11180413|NCT03519048|Active Comparator|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of > 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
11180414|NCT03519048|Experimental|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
11180415|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.
~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
11180416|NCT03519022|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11180417|NCT03519022|Active Comparator|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
11180418|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
11180419|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
11180420|NCT03518996|Experimental|TMS/tACS|Subjects will receive 5 days of 3x daily rTMS (intermittent theta burst stimulation) or tACS (transcranial alternating current stimulation) targeted over the cerebellum.
11180421|NCT03518996|Sham Comparator|Sham TMS/tACS|Subjects will receive 5 days of 3x daily sham stimulation of the cerebellum.
11180422|NCT03518983|Sham Comparator|Sham Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) by the sham probe.
11180423|NCT03518983|Active Comparator|Active Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) at energy level 7.
11180424|NCT03518970|Experimental|Nursing intervention|The experimental group will receive the Nursing intervention to reduce uncertainty in illness and increase quality of life in family caregivers of patients with cancer in palliative care
11180425|NCT03518970|No Intervention|Conventional care|The control group will receive the nursing care conventionally given in the health care institution
11180426|NCT03518957|Experimental|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
11180427|NCT03518957|No Intervention|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
11180428|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion >4 weeks apart
11180429|NCT03518931|No Intervention|Control|This arm included individuals randomized to receiving fitness information only.
11180430|NCT03518931|Experimental|Intervention|This arm included individuals randomized to having fitness assessments performed.
11180431|NCT03518905|Sham Comparator|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
11180432|NCT03518905|Active Comparator|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
11180433|NCT03518892||Spinal Cord Injury Group|Body Composition, Resting Metabolic Rate, and dietary assessment will be assessed for participants with a spinal cord injury
11180434|NCT03518892||Healthy Controls|Body Composition, Resting Metabolic Rate, and dietary assessment will be assessed for healthy participants
11180435|NCT03518879|Experimental|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
11180436|NCT03518853|Experimental|Short-course Radiation Therapy|Short-course Hypofractionated Once-weekly Radiation Therapy: 35Gy in 5 fractions delivered once a week.
11180437|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
11180599|NCT03517657|Experimental|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
11180438|NCT03518827||Athletes|For Asymmetry measurement, the group will consist of 200 athletes of different sports (the proportion not strictly predefined) - track and field, racket sports, ball sports, other team sports, swimming, running, cycling, dancing, ice skating, etc.
11180439|NCT03518814||Multimetastatic melanoma in remission|Questionnaires
11180440|NCT03518801|Experimental|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
11180441|NCT03518801|Active Comparator|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
11180442|NCT03518788|Experimental|Pleur-X|Placement of a permanent drainage under local anesthesia
11180443|NCT03518788|Experimental|pleurodesis|Pleurodesis with talc in VATS
11180444|NCT03518775||Normal Eyes|Eyes with best-corrected visual acuity of 20/20 or better, and lens opacities of 1.0 or less in the study eye using the LOCS III system, and no prior Laser Vision Correction.
11180445|NCT03518775||Cataract Eyes|Cataract in the study eye greater than Grade 1 using the LOCS III system for one or more: nuclear opacity, nuclear color, cortical opacity, or PSC.
11180446|NCT03518775||Post LVC Eyes|History of Laser Vision Correction (LVC)
11180447|NCT03518762|Experimental|Sustained lung inflation|"Participants in this arm (n=80) received:
~Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.
~Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;
~Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.
~Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.
~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
11180448|NCT03518762|Other|Control|"Participants in this arm (n=80) received:
~Resuscitation according to the American academy of pediatrics guidelines.
~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
11180449|NCT03518749|Active Comparator|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
11180450|NCT03518749|Active Comparator|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
11180451|NCT03518749|Placebo Comparator|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
11180452|NCT03518736|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
11180453|NCT03518736|Experimental|SPEEDI_Early|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting in the hospital and lasting for 4 months. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.
~In addition they will continue with any intervention in the community recommended by their health care team."
11180454|NCT03518736|Experimental|SPEEDI_Late|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting at 4 months post baseline or approximately 3 months after discharge from the hospital. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.
~In addition they will continue with any intervention in the community recommended by their health care team."
11180455|NCT03518723|Experimental|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.
~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).
~All exercises will be performed using exercise equipment that are available at each included center.
~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
11180456|NCT03518723|Active Comparator|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.
~Progression of exercise is performance dependent and will be based on the previous 2 sessions.
~All exercises will be performed using exercise equipment that are available at each included center.
~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
11180457|NCT03518710|Experimental|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :
~Neuropsychological evaluation
~Evaluation of the reading assistance technique"
11180458|NCT03518697|Experimental|Exercise Group|"First 6 months supervised exercise program with telephone contact every two weeks
~Second 6 months exercise program without telephone contact
~Patients should increase habitual daily physical activity for 10-20 minutes per day 5 times per week
~Activities were chosen according to the preferences, interests, and severity of disease of the patients
~Activites should improve endurance, strength, coordination and flexibility
~Every three month regular vistit at the CF care center (medical examination, lung function, exercise testing, counselling and evaluation of activities by acceleometry and if appropirate adaption of exercise program)"
11180459|NCT03518697|No Intervention|Control-Group|"12 months usual routine care and habitual exercise in daily life.
~At start and after 12 month assessment of habitual exercise with accelerometry (Actigraph GTX3)"
11180460|NCT03518684|No Intervention|Group 1|Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel
11180461|NCT03518684|Experimental|Group 2|Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous [never delivered beyond 20 weeks of gestation in a previous pregnancy] or primiparous or more)
11180802|NCT03516487|Placebo Comparator|MAD PKU: Placebo|Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
11180462|NCT03518671|Experimental|CBT (face to face)|"Self-limited cognitive behavioral therapy (CBT) delivered via 5 weekly sessions, face-face
~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 5 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT."
11180463|NCT03518671|Experimental|CBT (telemedicine)|"Self-limited cognitive behavioral therapy (CBT) delivered via 5 weekly sessions, via tablet-based telemedicine platform
~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 5 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT. To overcome the expected travel distance-related barrier to receipt of CBT, patients will receive the intervention via tablet-based telemedicine delivery platform"
11180464|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
11180465|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
11180466|NCT03518645|Experimental|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016'' lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
11180467|NCT03518645|Active Comparator|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
11180468|NCT03518632|Active Comparator|Control group|
11180469|NCT03518632|Experimental|Interval training 1|
11180470|NCT03518632|Experimental|Interval training 2|
11180471|NCT03518619|Experimental|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
11180472|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
11180473|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
11180474|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
11180475|NCT03518606|Experimental|Prostate cohort|Patients presenting advanced refractory prostate cancer
11180476|NCT03518606|Experimental|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
11180477|NCT03518593|Experimental|Intervention|Additional cash transfer and nutritional counselling
11180478|NCT03518593|No Intervention|Control|Existing cash transfer only
11180479|NCT03518567|Experimental|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
11180480|NCT03518554|Experimental|JAB-3068 (SHP2 inhibitor)|Daily oral administration of JAB-3068
11180481|NCT03518541|Active Comparator|Goniometer|FDO: classic procedure with goniometer controlled derotation
11180482|NCT03518541|Experimental|EMT|FDO: procedure with electromagnetic tracking (EMT) controlling derotation
11180483|NCT03518528||transdermal|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
11180484|NCT03518528||vaginal|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
11180485|NCT03518515|Experimental|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
11180486|NCT03518515|Experimental|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
11180487|NCT03518515|Active Comparator|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
11180488|NCT03518502|Active Comparator|Sorafenib monotherapy arm|The sorafenib monotherapy group receives sorafenib immediately after randomization.
11180489|NCT03518502|Experimental|TACE-sorafenib sequential therapy arm|TACE(transarterial chemoembolization )-sorafenib group receives 2~4 times of TACE before starting sorafenib.
11180490|NCT03518489|Experimental|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
11180491|NCT03518489|Active Comparator|Control|Patients will be given standard care when oral pain is reported
11180492|NCT03518476|Experimental|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
11180493|NCT03518476|Active Comparator|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
11180518|NCT03518255|Experimental|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
11180600|NCT03517657|Active Comparator|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
11180494|NCT03518463|Experimental|Intervention|"ERAS arm received;
~Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg
~Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat
~Postoperative:
~Feeding within 1 hour
~urethral catheter removal at 6-8 hours
~Mobilization at 8-10 hours
~A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly
~Tablets Amoxicillin-clavulunate 850mg 12 hourly"
11180495|NCT03518463|Active Comparator|Control|"Standard care arm received;
~IV ceftriaxone 2g or ampiclox 2g
~Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.
~Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.
~Urethral catheters were removed between 12-24 hours after surgery.
~Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight."
11180496|NCT03518450|Active Comparator|Femoral Nerve Block|Ultrasound guided femoral nerve block, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
11180497|NCT03518450|Active Comparator|Adductor Canal Block|Ultrasound guided adductor canal block, at the proximal third of the canal, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
11180498|NCT03518450|Experimental|Apex Femoral Triangle Block|Ultrasound guided femoral triangle block, at the distal third of the triangle, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
11180499|NCT03518411|Experimental|Medical Students|Cognitive Behavioral Therapy Protocol
11180500|NCT03518398|Experimental|IPL group|IPL 9-13 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
11180501|NCT03518398|Sham Comparator|sham-IPL group|IPL 0 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
11180502|NCT03518385||Patients with intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, this group patients will have intracavitary fluid.
11180503|NCT03518385||Patients without intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, in this group patients will not have intracavitary fluid.
11180504|NCT03518359|Experimental|Mental Training for Residents|The intervention will be the modified form of Mindfulness-Based Stress Reduction (MBSR). For this study investigator named the experimental arm Enhanced Stress Resilience Training (ESRT).
11180505|NCT03518359|Active Comparator|Active Control|"Active control that emphasizes externalized attention via the shared reading and listening model."
11180506|NCT03518346|Experimental|Virtual Reality Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. For the VR group, we are using the Samsung VR Go (VR head set), Samsung S7 (phone) and programmed distraction (Spaceburgers, Pebbles the Penguin, and/or Happy Place). Spaceburgers and Pebbles the Penguin were designed by the Department of Anesthesiology at Lucile Packard Children's Hospital Stanford through the Stanford Chariot Program (Childhood Anxiety Reduction Through Innovation and Technology). Happy Place is a nongame immersive experience that will be offered to children uninterested in the previously mentioned game. Happy Place was designed by a Swedish Pharmacy Chain, Apotek Hjartat, aimed to distract patients from their pain with a peaceful, interactive environment. Each of the video games runs for the length of time needed to complete the venipuncture.
11180507|NCT03518346|Active Comparator|Standard of Care Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. The standard of care group will use various distractions. Distraction tools include books and movies using a wall mounted TV as standard practice.
11180508|NCT03518333|Experimental|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
11180509|NCT03518333|Experimental|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
11180510|NCT03518320|Experimental|TAR-200 and Nivolumab Combination|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. In combination, subjects are dosed intravenously with a Nivolumab Injection [Opdivo] within 3 days of TAR-200 placement. Subjects will receive four consecutive 21-day dosing cycles of the combination of TAR-200 and Nivolumab prior to radical cystectomy.
11180511|NCT03518294|No Intervention|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
11180512|NCT03518294|Experimental|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
11180513|NCT03518281|Placebo Comparator|Placebo|
11180514|NCT03518281|Experimental|Treatment|Whole Cell Euglena delivering βeta Glucan
11180515|NCT03518268|Active Comparator|Dietary supplement Vivomixx|Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731
11180516|NCT03518268|Placebo Comparator|Placebo|The placebo sachets contain the inactive ingredients maltose and silicon dioxides
11180517|NCT03518255|No Intervention|Control group|This control group will not receive an intervention.
11180596|NCT03517696|No Intervention|Control|Routine vaginal exam
11180597|NCT03517683|Experimental|Low speed|Patients will receive intrathecal injection of the anesthetic mixture in a slow speed (1ml in 15 seconds)
11205530|NCT03345589|Placebo Comparator|13-15mg/kg/d Ursodeoxycholic group|
11180519|NCT03518242|Experimental|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.
~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
11180520|NCT03518229|Experimental|Intervention|Microsoft Band 2 application with UV messaging activated
11180521|NCT03518229|Active Comparator|Control|Microsoft Band 2 application (UV messaging not active)
11180522|NCT03518216|Experimental|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT),a tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are in person with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist phone support.
11180523|NCT03518216|No Intervention|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
11180524|NCT03518203|Experimental|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
11180525|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
11180526|NCT03518177|Experimental|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
11180527|NCT03518177|Experimental|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
11180528|NCT03518164|Other|Allograft|Bone graft
11180529|NCT03518164|Other|Autograft|Bone from iliac crest
11180530|NCT03518151|Experimental|Intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section at store entrance; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
11180531|NCT03518151|Sham Comparator|Control|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
11180532|NCT03518138|Experimental|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
11180533|NCT03518138|Placebo Comparator|Group 2, placebo|65 patients treated with placebo
11180534|NCT03518125|Experimental|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
11180535|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
11180536|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
11180537|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
11180538|NCT03518125|Active Comparator|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
11180539|NCT03518125|Active Comparator|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
11180540|NCT03518112|Experimental|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
11180541|NCT03518099|Experimental|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
11180542|NCT03518099|Experimental|witness|
11180543|NCT03518086|Experimental|Mirikizumab|Mirikizumab administered intravenously (IV).
11180544|NCT03518086|Placebo Comparator|Placebo|Placebo administered IV.
11180545|NCT03518073|Experimental|LY3303560 Dose 1|LY3303560 administered intravenously (IV).
11180546|NCT03518073|Experimental|LY3303560 Dose 2|LY3303560 administered IV.
11180547|NCT03518073|Placebo Comparator|Placebo|Placebo administered IV.
11180548|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
11180549|NCT03518047|Placebo Comparator|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
11180550|NCT03518047|Experimental|Risankizumab|Risankizumab by subcutaneous (SC) injection.
11180551|NCT03518034|Active Comparator|Arm A|Participants receiving topical testosterone
11180552|NCT03518034|Placebo Comparator|Arm B|Participants receiving placebo
11180553|NCT03518021|Experimental|Naloxone, intranasal|
11180554|NCT03518021|Active Comparator|Naloxone, intramuscular|
11180555|NCT03518021|Placebo Comparator|placebo, intranasal|
11180556|NCT03518021|Placebo Comparator|placebo, intramuscular|
11180557|NCT03518008|Other|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
11180558|NCT03518008|Other|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
11180559|NCT03517995|Active Comparator|Sulforaphane Plus Surgery|Sulforaphane Administration prior to bladder cancer surgery.
11180560|NCT03517995|Placebo Comparator|Placebo Plus Surgery|Placebo Administration prior to bladder cancer surgery.
11180561|NCT03517969|Active Comparator|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
11180562|NCT03517969|Experimental|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11180598|NCT03517683|Active Comparator|High speed|Patients will receive intrathecal injection of the anesthetic mixture in a high speed (1ml in 5 seconds)
11180563|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:
~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.
~Dose expansion (urothelial cancer):
~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
11180564|NCT03517943|Experimental|Test treatment|Healthy adult subjects under fed conditions
11180565|NCT03517943|Active Comparator|Reference treatment|Healthy adult subjects under fed conditions
11180566|NCT03517930|Experimental|Test treatment|Healthy adult subjects under fasted conditions
11180567|NCT03517930|Active Comparator|Reference treatment|Healthy adult subjects under fasted conditions
11180568|NCT03517917||Arm 1|Tumour tissue collection and blood collection to enable a manufacturing process for immunotherapies to be developed.
11180569|NCT03517904|Experimental|IVUS-guided group|Intravascular ultrasound-guided intervention group
11180570|NCT03517904|Active Comparator|Angiography-guided group|Angiography-guided intervention group
11180571|NCT03517891|Experimental|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.
~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
11180572|NCT03517891|No Intervention|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
11180573|NCT03517878||Comprehensive CHW Cohort|Pregnant women who become mothers and their infants living in areas served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Control Cohort clinic areas.
11180574|NCT03517878||Control Cohort|Pregnant women who become mothers and their infants living in areas that are not served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Comprehensive CHW Cohort clinic areas.
11180575|NCT03517852|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
11180576|NCT03517839|Experimental|Training Group|
11180577|NCT03517839|Sham Comparator|Control Group|
11180578|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.
~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
11180579|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.
~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
11180580|NCT03517787|Experimental|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
11180581|NCT03517787|Active Comparator|TE|Participants receiving only therapeutic exercise
11180582|NCT03517787|Other|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
11180583|NCT03517787|Other|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
11180584|NCT03517774|Experimental|3D Printed Socket|All participants will received a 3D Printed Prosthetic
11180585|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
11180586|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
11180587|NCT03517748|Experimental|the investigational device: DM05|DM05 eye drops, multidose sterile emulsion, will be administered in the DM05 Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
11180588|NCT03517748|Active Comparator|The comparative device : Optive™|Optive™ eye drops, multidose sterile solution, will be administered in the Optive Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
11180589|NCT03517735|Experimental|Automated postoperative sedation|Automated administration of Propofol and Remifentanil.
11180590|NCT03517735|Active Comparator|Manual postoperative sedation|Manual administration of Propofol and Remifentanil.
11180591|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
11180592|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
11180593|NCT03517709|Other|Conventional|
11180594|NCT03517709|Other|Blood Pressure Monitor|
11180595|NCT03517696|Active Comparator|Membrane Sweeping|Membrane sweeping
11180601|NCT03517644|Experimental|Deceptive Placebo (DP)|After pretreatment heat pain assessment, participants are informed that they are about to receive an effective analgesic cream. In fact, they receive a placebo cream. Next, the posttreatment pain assessment is conducted.
11180602|NCT03517644|Experimental|OLP with Hope (OLP Hope)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect. Next, the posttreatment pain assessment is conducted.
11180603|NCT03517644|Experimental|OLP with Expectations (OLP Expectation)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to raise expectations among the participants that the cream will have a positive effect. Next, the posttreatment pain assessment is conducted.
11180604|NCT03517644|Experimental|Control|After pretreatment heat pain assessment, this group does not receive an intervention targeting pain sensation prior to the posttreatment pain assessment.
11180605|NCT03517631|Experimental|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
11180606|NCT03517631|Experimental|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
11180607|NCT03517631|Experimental|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
11180608|NCT03517618|Experimental|S-1 + leucovorin|Single arm
11180609|NCT03517605|Experimental|Exercise for cardiac rehabilitation|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
11180610|NCT03517592|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
11180611|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
11180612|NCT03517579|Experimental|Pilot Project|It is a Pilot study of 10 persons
11180613|NCT03517566|Placebo Comparator|placebo|Placebo
11180614|NCT03517566|Experimental|ZPL389 Dose 1|Dose 1 of ZPL389
11180615|NCT03517566|Experimental|ZPL389 Dose 2|Dose 2 of ZPL389
11180616|NCT03517566|Experimental|ZPL389 Dose 3|Dose 3 of ZPL389
11180617|NCT03517566|Experimental|ZPL389 Dose 4|Dose 4 of ZPL389
11180618|NCT03517553|Experimental|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
11180619|NCT03517540|Experimental|Arm A: Tropifexor (LJN452) - Dose 1|
11180620|NCT03517540|Experimental|Arm B: Cenicriviroc (CVC)|
11180621|NCT03517540|Experimental|Arm C: Tropifexor (LJN452) Dose 1 + CVC|
11180622|NCT03517540|Experimental|Arm D: Tropifexor Dose 2 + CVC|
11180623|NCT03517527|No Intervention|Control|
11180624|NCT03517527|Experimental|Intervention|
11180625|NCT03517501|Active Comparator|ART-123|
11180626|NCT03517501|Placebo Comparator|Placebo|
11180627|NCT03517488|Experimental|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
11180628|NCT03517475|Experimental|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
11180629|NCT03517475|Placebo Comparator|Services as Usual|Clients will receive home visiting services from Head Start
11180630|NCT03517462|Experimental|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
11180631|NCT03517449|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
11180632|NCT03517449|Active Comparator|Treatment of Physician's Choice|Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m^2 OR paclitaxel 80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
11180633|NCT03517436|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
11180634|NCT03517410||Smart phone Use Experimental group|Patients with CLBP
11180635|NCT03517397|Experimental|Mobile Contingency Management|
11180636|NCT03517384|Experimental|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
11180637|NCT03517371|Experimental|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
11180749|NCT03516747|Experimental|investigation group|participants that suffer hypercalcemia due to primary hyperparathyroidism. include all participants in the trial
11180638|NCT03517371|Active Comparator|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
11180639|NCT03517358|Active Comparator|Pharmacy|service of care: pharmacy
11180640|NCT03517358|Active Comparator|Case management|service of care: case management
11180641|NCT03517345|Experimental|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
11180642|NCT03517345|Experimental|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
11180643|NCT03517332||Cohort 1|"Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma
~Subjects of cohort 1 must not:
~• Have been treated for above diagnosed malignancy"
11180644|NCT03517332||Cohort 2|"Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).
~Subjects of cohort 2 must:
~• Meet the listed matching criteria
~Subjects of cohort 2 must not:
~• Have been diagnosed/treated for a malignancy previously"
11180645|NCT03517319|Placebo Comparator|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
11180646|NCT03517319|Experimental|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
11180647|NCT03517319|Experimental|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
11180648|NCT03517319|Experimental|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
11180649|NCT03517319|Experimental|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
11180650|NCT03517306||Beijing|No interventions
11180651|NCT03517306||Ningxia|No interventions
11180652|NCT03517306||Wenzhou|No interventions
11180653|NCT03517306||Changzhou|No interventions
11180654|NCT03517293|Experimental|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from ~16-40 weeks of pregnancy
11180655|NCT03517293|No Intervention|Control|usual daily activities - not exercise, not elevating heart rate
11180656|NCT03517280||Children with Neuroblastoma|Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
11180657|NCT03517254|Experimental|Glutamine and strength training program|Three times per week, standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks of follow up. At the beginning and at the end of the training session, the experimental group will receive by mouth 10 grams of glutamine dissolved in 120 milliliters of water, all participants and team of researchers will not be aware of the supplement.
11180658|NCT03517254|Placebo Comparator|Placebo and strength training program|Three times per week a standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks after discharge. At the beginning and at the end of the training session, the placebo group will receive by mouth10 grams of maltodextrin dissolved in 120 milliliters of water. All participants and team of researchers will not be aware of the supplement content.
11180659|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
11180660|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
11180661|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
11180662|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
11180663|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
11180664|NCT03517228|Experimental|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
11180665|NCT03517215|Experimental|Enhanced CB-ASP|If a site is randomized to the enhanced CB-ASP, prescribers at that site will be required to attend an education session. In the four months following the initial session, prescribers will be asked to complete one on-line eModule for each target condition (acute sinusitis, sore throat, acute bronchitis and acute uncomplicated cystitis) each month. Each module will take approximately 15 minutes to complete. Two audit and feedback reports (every 3 months) of their clinic's prescriptions for these conditions will be provided where they will be asked to review and discuss with their colleagues and study staff.
11180666|NCT03517215|Active Comparator|Standard CB-ASP|If a site is randomized to the standard CB-ASP strategy arm, prescribers will be offered the opportunity to attend the 1 hour introductory seminar by a web-link, provided with access to the short e-learning modules each month by email, and sent their clinic's audit and feedback reports by email for review two times during the study.
11180667|NCT03517215|No Intervention|Control|If a site is randomized to the control arm, the site will not receive any active interventions. Prescribers at the site will be offered access to the eModules at the completion of the study and provided with one audit and feedback report of their clinic's antibiotic prescribing patterns for local quality improvement needs as desired.
11180668|NCT03517189|Experimental|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
11180669|NCT03517176|Experimental|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m^2) / gemcitabine (1000mg/m^2) combination given on Days 1, 8, 15.
11180801|NCT03516487|Experimental|MAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
11180670|NCT03517176|Experimental|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m^2) and gemcitabine (1000mg/m^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
11180671|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
11180672|NCT03517150|Experimental|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
11180673|NCT03517150|Active Comparator|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
11180674|NCT03517137|Experimental|Treatment|
11180675|NCT03517124|Experimental|Zirconia restorations|Dental restorations in surface modified zirconia bonded to tooth substance by dual cure resin cement
11180676|NCT03517124|Active Comparator|e.max|Restorations in e.max bonded to tooth substance by dual cure resin cement
11180677|NCT03517111|Experimental|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
11180678|NCT03517111|Active Comparator|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
11180679|NCT03517111|Sham Comparator|Academic success program|Control program focused only on academic success.
11180680|NCT03517098|Experimental|The ERAS group|Patients will be treated with the ERAS pathway
11180681|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
11180682|NCT03517085|Experimental|DTX401 Dose 1|DTX401 solution for intravenous (IV) infusion
11180683|NCT03517085|Experimental|DTX401 Dose 2|DTX401 solution for intravenous (IV) infusion
11180684|NCT03517085|Experimental|DTX401 Dose 3|DTX401 solution for intravenous (IV) infusion
11180685|NCT03517085|Experimental|DTX401 Dose 4|DTX401 solution for intravenous (IV) infusion
11180686|NCT03517059||PD patients|30 PD patients in ON and OFF levodopa conditions
11180687|NCT03517059||Healthy control subjects|30 age matched healthy control subjects
11180688|NCT03517059||Neurological control subjects|10 patients with defined supra nuclear palsy
11180689|NCT03517046|Experimental|CartiLife (low-dose group)|Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
11180690|NCT03517046|Experimental|CartiLife (high-dose group)|Total defect volume in High-dose group is 2 ~ 4 ㎤.
11180691|NCT03517033|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
11180692|NCT03517033|Active Comparator|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
11180693|NCT03517020|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
11180694|NCT03517020|Active Comparator|Reference|Forest Pharmaceuticals Inc.'s Bystolic® Tablets 20 mg
11180695|NCT03517007|Experimental|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
11180696|NCT03517007|No Intervention|Standard of Care|Provider continues routine, standard of care on the patient.
11180697|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
11180698|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
11180699|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + MK-1308|Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180700|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180701|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
11180702|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + MK-1308|Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180703|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180704|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
11180705|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + MK-1308|Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11181939|NCT03509233|Experimental|FMDP|Full mouth disinfection with periopolishing
11180706|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180707|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
11180708|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + MK-1308|Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180709|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + MK-4280|Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
11180710|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
11180711|NCT03516968|Experimental|Monthly bolus arm|
11180712|NCT03516968|Active Comparator|Daily arm|
11180713|NCT03516968|Other|Control group|Group of obese patients without vitamin D deficiency
11180714|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
11180715|NCT03516929|Active Comparator|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
11180716|NCT03516929|Sham Comparator|low risk group|No history or stroke,TIA. NO left main stem disease
11180717|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
11180718|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
11180719|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
11180720|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
11180721|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
11180722|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
11180723|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
11180724|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
11180725|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
11180726|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
11180727|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
11180728|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
11180729|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
11180730|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
11180731|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
11180732|NCT03516903|Active Comparator|Methotrexate & Folic acid|ddMTX-LDE 40mg/m2 (100mL total volume) IV and Folic acid 5mg by mouth (the day after ddMTX-LDE) weekly for 6 weeks
11180733|NCT03516903|Placebo Comparator|Placebo & folic acid|Placebo-LDE IV 100mL and Folic acid 5mg by mouth (the day after Placedo-LDE) weekly for 6 weeks
11180734|NCT03516877|Experimental|ESRT|"Volunteer surgery and anesthesia faculty from UCSF working at Parnassus Hospital site and interested in training.
~Volunteer surgery and anesthesia faculty from UCSF working at Zuckerberg San Francisco General Hospital site and interested in training.
~Volunteer surgery and anesthesia faculty from UCSF working at Mission Bay Hospital site and interested in training."
11180735|NCT03516851|Active Comparator|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
11180736|NCT03516851|No Intervention|Empirical group|choosing the recipient vessel by the surgeon's own experience
11180737|NCT03516838|Experimental|ACTIVA™ BioACTIVE|Restoring cavity using ACTIVA filling material
11180738|NCT03516838|Active Comparator|Compomer|Restoring cavity using compomer filling material
11180739|NCT03516825|Experimental|Musical Neglect Training (MNT)|A single-subject design was used. All participants took Musical Neglect Training.
11180740|NCT03516812|Experimental|Treatment (olaparib, testosterone enanthate or cypionate)|Patients receive olaparib PO BID on days 1-28 and testosterone enanthate or cypionate IM on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11180741|NCT03516799|Experimental|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
11180742|NCT03516799|No Intervention|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
11180743|NCT03516773|Experimental|Treatment A|Intervention: EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID) (approximately 5 hours apart) for 4 doses, for a total dose of 9 mg per day
11180744|NCT03516773|Experimental|Treatment B|Intervention: EB612 (EBP05) 2.25 mg PO twice a day (BID) (approximately 10 hours apart) for 2 doses, for a total dose of 4.5 mg per day
11180745|NCT03516773|Active Comparator|Treatment C|Intervention: NATPARA/NATPAR PTH(1-84) 100 μg subcutaneous injection once daily (single dose)
11180746|NCT03516773|Experimental|Treatment D|Intervention: EB612 (EBP05) 2.25 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 6.75 mg per day
11180747|NCT03516773|Experimental|Treatment E - EB612 (EBP05)|Intervention: EB612 (EBP05) 0.75 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 2.25 mg per day
11180748|NCT03516760|Experimental|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
11180750|NCT03516734|Experimental|Iron fortified lentils|Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
11180751|NCT03516734|Active Comparator|Non iron-fortified lentils|It will be the same Saskatchewan (province of Canada) grown small cotyledon color lentil (Iron content 75-90ppm) without the iron fortification.
11180752|NCT03516734|Placebo Comparator|Usual Intake (no intervention)|It will be the usual intake of lentil- no additional lentil will be provided. However, participants will be free to consume lentils from anywhere (homemade or restaurants) if they want to, except our fortified lentils.
11180753|NCT03516721|Other|Obese adolescents|
11180754|NCT03516721|Other|Lean adolescents|
11180755|NCT03516708|Experimental|Dose Escalation Cohort|"Patients will receive epacadostat at the designated dose level starting the day of radiation therapy, throughout chemotherapy, and until the day of surgery
~Epacadostat is taken by mouth twice per day every day of each 21 day cycle
~Standard of care preoperative therapy will consist of a total of approximately 20 weeks' preoperative therapy followed by surgery. Breakdown of the 20 weeks of preoperative therapy are as follows:
~Short-course pelvic radiation therapy, 5 fractions over 1 week
~2 to 3 weeks of break; tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)
~6 cycles of CAPOX for a total of 18 weeks
~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy
~CAPOX is typically capecitabine at 1000 mg/m2 PO BID and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts (so may be more than 21 days long depending on when exactly CAPOX starts)."
11180756|NCT03516708|Experimental|Dose Expansion Cohort|"Patients will receive epacadostat at the designated dose level starting the day of radiation therapy, throughout chemotherapy, and until the day of surgery
~Epacadostat is taken by mouth twice per day every day of each 21 day cycle
~Standard of care preoperative therapy will consist of a total of approximately 20 weeks' preoperative therapy followed by surgery. Breakdown of the 20 weeks of preoperative therapy are as follows:
~Short-course pelvic radiation therapy, 5 fractions over 1 week
~2 to 3 weeks of break; tumor biopsy will be obtained on or after the last radiation day (D5-8) and before the start of chemotherapy (D21-28)
~6 cycles of CAPOX for a total of 18 weeks
~surgery will follow approximately 4 to 6 weeks after completion of chemotherapy
~CAPOX is typically capecitabine at 1000 mg/m2 PO BID and oxaliplatin 130 mg/m2 IV Q3W. The second cycle of epacadostat will begin when CAPOX starts (so may be more than 21 days long depending on when exactly CAPOX starts)."
11180757|NCT03516682|No Intervention|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
11180758|NCT03516682|Experimental|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
11180759|NCT03516669|Other|Intraluminal Clarithromycin eradication|20 Patients receive intraluminal Clarithromycin eradication of H. pylori.
11180760|NCT03516669|Other|Oral standard triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.
11180761|NCT03516656|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
11180762|NCT03516656|Active Comparator|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged
11180763|NCT03516643|Experimental|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
11180764|NCT03516630|Experimental|TRZ 20|Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
11180765|NCT03516630|Experimental|TRZ 60|Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
11180766|NCT03516630|Experimental|TRZ 140|Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
11180767|NCT03516630|Placebo Comparator|Placebo|Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
11180768|NCT03516630|Active Comparator|Moxifloxacin|Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
11180769|NCT03516617|Experimental|Arm A (acalabrutinib)|Participants receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 courses.
11180770|NCT03516617|Experimental|Arm B (acalabrutinib, obinutuzumab)|Participants receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of course 1 and days 1 of subsequent courses. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 courses.
11180771|NCT03516617|Active Comparator|Arm C (observation)|Participants will be observed every 6 months for up to 2 years.
11180772|NCT03516604|Experimental|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
~+ 1 placebo capsule, once daily for 7-9 days"
11180773|NCT03516604|Active Comparator|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days
~+ 3 placebo tablets, once daily for 7-9 days"
11180774|NCT03516604|Placebo Comparator|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
11180775|NCT03516591|Experimental|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
11180776|NCT03516591|Experimental|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
11180777|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
11180778|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
11180779|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
11180780|NCT03516552||Hemoglobin content on blood loss|Hemoglobin content on blood loss, to assess ratio hemoglobin/volume.
11180781|NCT03516539|Experimental|Group ML|Mcgrath videolaryngoscopy
11180782|NCT03516539|Active Comparator|Group DL|direct Macintosh laryngoscope
11180783|NCT03516526|Other|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
11180784|NCT03516513|Active Comparator|Problem Solving Therapy as Usual|"Clinicians in this arm of care will have access to the Case Management Tracking System which is already in use.
~Intervention: unguided PST"
11180785|NCT03516513|Experimental|Assisted Problem Solving Therapy|"This arm will be designed and finalized in Phase 1 and 2 of the project. We anticipate that the intervention will leverage clinical notes required to be completed by clinicians and will provide information to clinicians to help patients improve over time, as well as help clinicians implement PST to high quality.
~Intervention: guided PST"
11180786|NCT03516500|Experimental|Iron Sucrose injection group|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.
11180787|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^10 colony-forming units [CFU]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180788|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180789|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180790|NCT03516487|Experimental|SAD HV SB: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.
11180791|NCT03516487|Experimental|SAD HV: SYNB1618 (2 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (2 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180792|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180793|NCT03516487|Placebo Comparator|SAD HV: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180794|NCT03516487|Experimental|SAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180795|NCT03516487|Placebo Comparator|SAD PKU: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
11180796|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive oral SYNB1618 (1 x 10^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).
11180797|NCT03516487|Experimental|MAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive oral SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
11180798|NCT03516487|Experimental|MAD HV: SYNB1618 (7 x 10^10 CFU)|HV subjects receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
11180799|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive oral SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
11180800|NCT03516487|Placebo Comparator|MAD HV: Placebo|HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
11181940|NCT03509220|Experimental|PBK-1701TC|2-Day Split-Dosing Regimen
11180803|NCT03516474||St. Michael's Hospital|"St. Michael's Hospital is an Acute care centre for the diabetic lower extremity.
~n=100"
11180804|NCT03516474||South Riverdale Community Health Centre|South Riverdale is a Community Health Centre focused on prevention. n=100
11180805|NCT03516474||Westpark|Westpark is a rehabilitation site focused on post-operative/amputation care and preservation of the opposite limb. n=100
11180806|NCT03516474||Women's College Hospital|Women's College Hospital is an outpatient wound clinic focused on the management of DFUs. n=100
11180807|NCT03516461|Experimental|Selective Microbiota Transplant (SMT)|Patients undergo once SMT a day for three consecutive days.
11180808|NCT03516461|Experimental|Fecal Microbiota Transplantation (FMT)|Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.
11180809|NCT03516448|Active Comparator|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
11180810|NCT03516448|Placebo Comparator|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
11180811|NCT03516435|Experimental|Parasacral transcutaneous ES|20min./session, 2 sessions/week ,12 sessions of Parasacral transcutaneous electrical stimulation.
11180812|NCT03516435|Active Comparator|Intravaginal electrical stimulation|20min./session, 2 sessions/week ,12 sessions of Intravaginal electrical stimulation.
11180813|NCT03516422|Placebo Comparator|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
11180814|NCT03516422|Experimental|ULTRASOUND DEBRIDEMENT GROUP:|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
11180815|NCT03516409|Active Comparator|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
11180816|NCT03516409|Placebo Comparator|Placebo|1 sachet once a day mixed with milk, water or food.
11180817|NCT03516396|Experimental|Training Plus|"Intervention: Community Development
~Training plus enhanced community development activities"
11180818|NCT03516396|Active Comparator|Control|No inputs
11180819|NCT03516396|Experimental|Training Only|"Intervention: Training
~Training Only (livestock management and child nutrition)"
11180820|NCT03516383||Experimental|"ABI < 0.6, confirmed PAD
~50 - 90 years of age
~In-patients or out-patients
~Participants who understand the study and are able to give consent
~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
11180821|NCT03516383||Control|"ABI of 0.9 < ABI < 1.2
~50 - 90 years of age
~Participants who understand the study and are able to give consent
~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
11180822|NCT03516370|Experimental|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
11180823|NCT03516370|Placebo Comparator|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
11180824|NCT03516357||low myopia|-3.00D < spherical equivalent refractive error < -0.50D
11180825|NCT03516357||moderate myopia|-6.00D < spherical equivalent refractive error ≤ -3.0D
11180826|NCT03516357||high myopia|spherical equivalent refractive error ≤ -6.0D
11180827|NCT03516344|No Intervention|Control|Subjects will remain at rest in supine position for one minute.
11180828|NCT03516344|Experimental|Iliac psoas muscle|In supine position with a high-density foam cushion under the subject's feet, they will be asked to make a push in the caudal direction, against the cushion, alternating between both feet with their knees stretched out, for one minute
11180829|NCT03516344|Experimental|Diaphragmatic Breathing|Subjects perform five cycles of diaphragmatic breathing in the supine position.
11180830|NCT03516344|Experimental|Liver pumping|A technique of hepatic supine pumping is performed by simultaneous compression in the right hypochondrium and epigastrium, in the opposite direction, during the inspiratory phase, stopping during the expiratory phase and repeating the maneuver for five respiratory cycles.
11180831|NCT03516344|Experimental|Spinal manipulation|A semi-direct vertebral manipulation, type Dog Technique in extension, will be performed on level D8
11180832|NCT03516331|Experimental|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
11180833|NCT03516331|Experimental|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
11180834|NCT03516318|Experimental|SMART Connections|"The intervention components include:
~Informational messages that reflect the content of the structured group counseling curriculum and are posted to the Facebook group wall on a regular basis for approximately 4 to 5 months
~Moderated, closed group chats in a secret Facebook group where YLHIV can interact with their peers and with a trained support group facilitator
~Access to a trained facilitator via Facebook Messenger for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
11180876|NCT03516019|Experimental|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
11180835|NCT03516318|No Intervention|Control|All study participants, in both study arms, will receive standard services currently available to YLHIV in these facilities and communities. The services currently include: routine clinical care for HIV treatment including laboratory testing (CD4, viral load tests); active case management by community volunteers with intensive adherence support during the first 4 weeks of ART; adherence support through phone calls and SMS (short messaging service) reminders; and enhanced adherence counseling for patients with unsuppressed viral loads.
11180836|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
11180837|NCT03516292||OAB-POP group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
11180838|NCT03516292||POP only group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
11180839|NCT03516279|Experimental|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
11180840|NCT03516253|Experimental|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
11180841|NCT03516253|No Intervention|Control group|Dietary Supplement: Olive oil (5 gel capsules, each 1g olive oil), 3 months with lunch.
11180842|NCT03516240|Experimental|Experimental|Participants receive the topical analgesic, Biofreeze.
11180843|NCT03516240|Placebo Comparator|Placebo|Participants receive a placebo cream.
11180844|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
11180845|NCT03516227|No Intervention|Control|Usual Care
11180846|NCT03516214|Experimental|EGF816 (nazartinib) and trametinib|Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
11180847|NCT03516201||obese patients after bariatric surgery|obese adults (≥ 18 years) who underwent bariatric surgery
11180848|NCT03516201||obese adultes without bariatric surgery|obese adults (≥ 18 years) who did not underwent bariatric surgery at the time of the examination
11180849|NCT03516188|Experimental|Alginate-antacid group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
11180850|NCT03516188|Experimental|Non antacid alginate group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.
11180851|NCT03516175|Active Comparator|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
11180852|NCT03516175|Experimental|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
11180853|NCT03516162||Patients With Brain Tumors/AVMs|"Patients with a brain tumour/AVM scheduled for maximum safe resection via craniotomy.
~Participants fulfilling all of the following inclusion criteria are eligible for the study:
~Consent of the patient
~Age: ≥18
~Fluent language skills in German
~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months
~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
11180854|NCT03516162||Patients With Hydrocephalus|"Patients with hydrocephalus scheduled for VP-shunting
~Participants fulfilling all of the following inclusion criteria are eligible for the study:
~Consent of the patient
~Age: ≥18
~Fluent language skills in German
~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months
~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
11180855|NCT03516149|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
11180856|NCT03516149|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
11180857|NCT03516123|Experimental|CS3006|Participants will receive CS3006 orally at specified dose on specified days
11180858|NCT03516110||Prostate cancer subjects 60-<70 years|
11180859|NCT03516110||Prostate cancer subjects 70-<75 years|
11180860|NCT03516110||Prostate cancer subjects ≥ 75 years|
11180861|NCT03516097|Experimental|Experimental Group A|Structured school based intervention + mobile app usage
11180862|NCT03516097|Experimental|Experimental Group B|mobile app usage
11180863|NCT03516097|Active Comparator|Control Group|Structured school based intervention
11180864|NCT03516084|Experimental|ZL-2306(nirapairb)|
11180865|NCT03516084|Placebo Comparator|Placebo|
11180866|NCT03516071|Experimental|Brivanib 800 mg, QD + BSC|
11180867|NCT03516071|Experimental|Brivanib 400 mg, BID + BSC|
11180868|NCT03516045|Experimental|18F-AlF-NOTA-neurotensin PET/CT|One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
11180869|NCT03516032|Experimental|walking exercises|walking in the hospital corridor
11180870|NCT03516032|Experimental|balance exercises|heel rise exercises
11180871|NCT03516019|Experimental|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
11180872|NCT03516019|Experimental|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
11180873|NCT03516019|Experimental|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
11180874|NCT03516019|Experimental|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
11180875|NCT03516019|Experimental|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
11180877|NCT03516019|Experimental|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
11180878|NCT03516019|Experimental|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
11180879|NCT03516006|Experimental|UCMSC|infusion of aUCMSC and Ursodeoxycholic acid therapy
11180880|NCT03516006|Active Comparator|UDCA|Ursodeoxycholic acid therapy 15mg/kg/d
11180881|NCT03515980|Experimental|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
11180882|NCT03515980|Experimental|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
11180883|NCT03515980|Experimental|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
11180884|NCT03515980|Experimental|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
11180885|NCT03515967|Experimental|Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) after injury using the I-PAS goggles
11180886|NCT03515967|Active Comparator|Non-Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) with no injury using the I-PAS goggles
11180887|NCT03515941|Experimental|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 or 1000 mg/m2 by PO (BID) on 21 day-cycle or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
11180888|NCT03515941|Experimental|Arm 2: Adjuvant Chemoradiation|Three cycles of chemo with Capecitabine: 750 mg/m2 by PO BID on days 1-14 of a 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on days 1 and 15 of a 28 day cycle After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above.
11180889|NCT03515928|Active Comparator|Noise Exposed Group|
11180890|NCT03515928|Placebo Comparator|Control Group|
11180891|NCT03515902|Experimental|mouthguard|Mouthguard arm is application of mouthguard while swimming
11180892|NCT03515902|Experimental|mouthguard with desensitizing toothpaste|Mouthguard with desensitizing toothpaste arm is application of mouthguard with desensitizing toothpaste containing 8% arginine and calcium carbonate while swimming
11180893|NCT03515889|Experimental|Ideal Protein Weight Loss Protocol|This arm will follow the Ideal Protein method as documented in the Ideal Protein Clinic Manual and in the Ideal Protein Coaches Manual.
11180894|NCT03515889|Active Comparator|Standard Weight Loss|This arm utilizes evidence-based, low fat, low calorie strategies that have been shown to be effective for long-term weight loss and weight loss maintenance.
11180895|NCT03515876||Control|Patients will receive intravenous propofol infusion.
11180896|NCT03515876||Dexmedetomidine 0.5 microgram/kg group|Patients will receive dexmedetomidine 0.5 microgram/kg and then intravenous propofol infusion.
11180897|NCT03515876||Dexmedetomidine 1 microgram/kg group|Patients will receive dexmedetomidine 1 microgram/kg and then intravenous propofol infusion.
11180898|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
11180899|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
11180900|NCT03515837|Experimental|Pembro+Pemetrexed+Chemo|Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve [AUC] 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
11180901|NCT03515837|Active Comparator|Placebo+Pemetrexed+Chemo|Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
11180902|NCT03515824|Experimental|MK-1696 Dose Level A|Participants receive MK-1697 Dose Level A by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
11180903|NCT03515824|Experimental|MK-1697 Dose Level B|Participants receive MK-1697 Dose Level B by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
11180904|NCT03515824|Experimental|MK-1697 Dose Level C|Participants receive MK-1697 Dose Level C by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
11180905|NCT03515824|Experimental|Expansion Cohort|Participants with select tumor types receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
11180906|NCT03515811||Abdominal|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.
~Abdominal (approximately 53 subjects)."
11180907|NCT03515811||Thoracic|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.
~Thoracic (approximately 74 subjects)."
11180908|NCT03515798|Experimental|Pembrolizumab|EC Paclitaxel + Pembrolizumab Injection
11180909|NCT03515798|Active Comparator|Standard neoadjuvant chemotherapy|EC Paclitaxel alone
11180910|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
11180911|NCT03515772||Amlodipine with Dolutegravir|"This is the control group regarding HIV drug interaction potential on amlodipine"
11180912|NCT03515772||Amlodipine with Darunavir|"This is the case group regarding HIV drug interaction potential on amlodipine"
11180913|NCT03515772||Atorvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on atorvastatin"
11180914|NCT03515772||Atorvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on atorvastatin"
11180915|NCT03515772||Rosuvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on rosuvastatin"
11180916|NCT03515772||Rosuvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on rosuvastatin"
11181738|NCT03510572|Experimental|Alzheimer's Disease|Alzheimer's Disease Subjects will receive a single IV injection of [18F]PI-2620.
11180917|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
11180918|NCT03515746|Active Comparator|Exergaming2D|The participants will practise grab and grasp through exergaming in virtual environment (VE) on a laptop computer. During the task, they will sit in a comfortable chair in front of the screen.
11180919|NCT03515746|Active Comparator|Exergaming3D|The participants will practise grab and grasp through exergaming in virtual environment (VE) in 3D VE using Oculus Rift CV1 3D goggles. During the task, they will sit in a comfortable chair with head-mounted 3D display.
11180920|NCT03515733|Experimental|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
11180921|NCT03515733|Placebo Comparator|Placebo|3 placebo tablets, once daily for 7-9 days
11180922|NCT03515720|Experimental|Study group|Painful points will be located in the path of the sensory nerves of the knee in which asepsis and antisepsis will be performed, and then 0.5-1 ml of 5% dextrose solution will be applied subcutaneously at a 45º angle along the way. of the nerve with a 27 gauge needle of ½ inch. The number of injections will vary according to the symptoms to be treated. The application will be made once a week for 6 weeks. After the first application of neuroprolotherapy, the patient will be trained to perform a rehabilitation therapy program based on thermotherapy, kinesitherapy and knee strengthening exercises. At the end of the 6 sessions, a new assessment will be made with the WOMAC, EVA and measurement of movement arcs to assess the evolution after treatment.
11180923|NCT03515720|No Intervention|Control group|Physical therapy consisting of 10 sessions based on thermotherapy, kinesitherapy and muscle strengthening exercises to the knee. Subsequently, the patient will perform this therapy home until completing 6 weeks. At the end a new assessment will be made with measurement of movement arcs, WOMAC scale and EVA to assess the evolution after treatment.
11180924|NCT03515707|Experimental|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
11180925|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF1|
11180926|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF2|
11180927|NCT03515694|Experimental|Dose of 0 ,5mg/kg TOF1|
11180928|NCT03515694|Active Comparator|Dose of 0,5mg/kg TOF2|
11180929|NCT03515694|Experimental|Dose of 1mg/kg TOF1|
11180930|NCT03515694|Active Comparator|Dose of 1mg/kg TOF2|
11180931|NCT03515694|Experimental|Dose of 2mg/kg TOF1|
11180932|NCT03515694|Active Comparator|Dose of 2mg/kg TOF2|
11180933|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
11180934|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
11180935|NCT03515668|Experimental|Ritalin|20 mg Ritalin, 90 min before testing
11180936|NCT03515668|Placebo Comparator|Control|Identical size/taste placebo pill, 90 min before testing
11180937|NCT03515642|Experimental|HIIT group|The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max). Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6-weeks.
11180938|NCT03515642|Active Comparator|SIT group|The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
11180939|NCT03515629|Active Comparator|Pembrolizumab|Pembrolizumab
11180940|NCT03515629|Experimental|REGN2810/ipi|REGN2810/ipi
11180941|NCT03515629|Experimental|REGN2810/chemo/ipi|REGN2810/chemo/ipi
11180942|NCT03515603|Active Comparator|microsurgical technique|
11180943|NCT03515603|Active Comparator|endoscopic technique|
11180944|NCT03515590|Experimental|Emulsion with solid droplets|Emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
11180945|NCT03515590|Experimental|Emulsion with liquid droplets|Emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
11180946|NCT03515577|Experimental|Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)|Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.
11180947|NCT03515564|Experimental|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga, or HIIT
~90 minutes once weekly for 12 weeks"
11180948|NCT03515564|Active Comparator|Current standard care|12 weeks of therapy or clinical care as currently standard
11180949|NCT03515551|Experimental|IMCnyeso dose Escalation Phase with approximately 4-10 cohorts|Phase (Arm 1) n=approximately 27 patients to establish the MTD/RP2D
11180950|NCT03515551|Experimental|IMCnyeso expansion with 3 cohorts|n=9-24/cohort treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso
11180951|NCT03515538|Experimental|RRx-001 Pre-Treatment plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
11180952|NCT03515538|Experimental|RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
11180953|NCT03515538|Experimental|RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
11180988|NCT03515317|Experimental|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
11180954|NCT03515538|Active Comparator|Standard of Care|No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
11180955|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
11180956|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
11180957|NCT03515512|Experimental|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
11180958|NCT03515499|Active Comparator|Control|The control arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use.
11180959|NCT03515499|Experimental|Treatment arm|The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
11180960|NCT03515486|Experimental|Post-stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.
11180961|NCT03515473||CI532|Patients with CI532 cochlear implant
11180962|NCT03515473||CI522|Patients with CI522 cochlear implant
11180963|NCT03515473||CI512|Patients with CI512 cochlear implant
11180964|NCT03515460|Experimental|sugar oral load|oral ingestion of a high carbohydrate meal
11180965|NCT03515460|Experimental|fat oral load|oral ingestion of a high fat meal
11180966|NCT03515460|Experimental|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
11180967|NCT03515447||Before period|During this period no patient received Romiplostim.
11180968|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.
~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
11180969|NCT03515434|Active Comparator|ESP Block|Ultrasound-guided Erector spinae plane (ESP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
11180970|NCT03515434|Active Comparator|TAP Block|Ultrasound-guided Transversus abdominis plane (TAP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
11180971|NCT03515434|Sham Comparator|Control|The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11180972|NCT03515421|Experimental|Blood Glucose monitoring System (BGMS)|"Intervention: Blood Glucose monitoring Systems (BGMSs): Frazier 3 Verio and Frazier 3 UltraPLus.
~Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)"
11180973|NCT03515408|Experimental|Real rTMS (motor area)|Real rTMS targeting motor area for 30 min
11180974|NCT03515408|Experimental|Real rTMS (parietal gyrus)|Real rTMS targeting parietal gyrus for 30 min
11180975|NCT03515408|Experimental|Real rTMS (both brain area)|Real rTMS targeting motor area and parietal gyrus for 15 min, separately
11180976|NCT03515408|Sham Comparator|Sham rTMS|Sham rTMS targeting motor area and parietal gyrus for 15 min, separately
11180977|NCT03515382|Experimental|Treatment A|single dose GLPG1690.
11180978|NCT03515382|Experimental|Treatment B|Single dose itraconazole + single dose GLPG1690.
11180979|NCT03515382|Experimental|Treatment C|Single dose voriconazole + single dose GLPG1690.
11180980|NCT03515369|Experimental|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
11180981|NCT03515369|Placebo Comparator|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
11180982|NCT03515356|Experimental|MI-Walk Intervention|"Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T1), 2 weeks (T3), and 4 weeks (T4)."
11180983|NCT03515356|Active Comparator|PA Education Alone|Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
11180984|NCT03515343||Optical diagnosis with Optivista|Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
11180985|NCT03515343||Optical diagnosis with iScan|Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
11180986|NCT03515330|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressant medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth application.
11180987|NCT03515330|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to aid in immunosuppressant medication adherence post-transplant.
11181085|NCT03514628|Experimental|Valsalva Assist Device (VAD)|Intervention is the use of Valsalva Assist Device (VAD) to deliver the Valsalva strain
11180989|NCT03515317|Experimental|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
11180990|NCT03515317|No Intervention|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
11180991|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
11180992|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
11180993|NCT03515291|Experimental|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
11180994|NCT03515291|Placebo Comparator|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
11180995|NCT03515278|Experimental|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.
~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
11180996|NCT03515278|Active Comparator|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.
~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
11180997|NCT03515265|Experimental|Fiber resin composite|Fiber reinforced resin composite restoration used as dentin substitute covered by conventional resin composite
11180998|NCT03515265|Active Comparator|Microhybrid resin composite|Microhybrid resin composite restoration with lower strength compared to Fiber reinforced resin composite restoration
11180999|NCT03515252|Experimental|Late stage lung cancer and liver cancer|Immune Killer Cells (IKC)
11181000|NCT03515226|Active Comparator|Traditional Training|24 hours of didactic and simulated case role play training in CBT principles, depression assessment and cultural competency.
11181001|NCT03515226|Experimental|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
11181002|NCT03515213|Active Comparator|Active|
11181003|NCT03515213|Placebo Comparator|Placebo|
11181004|NCT03515200|Experimental|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.
~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability. If our highest dosing of 100mg/m2/day is tolerated, we will have a final dose level that receives an additional 10 days of palbociclib (Days 1-5, 11-15, and 21-30).
~For patients that are Ph+ or have Ph-like ALL that are also receiving dasatinib or ruxolitinib: palbociclib, initially at 75mg/m2/day, 60% of the adult MTD, will be administered on Days 1-5 and 11-15 and escalated based on tolerability.
~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
11181005|NCT03515187|Experimental|A1 Medicine treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
11181006|NCT03515187|Experimental|A2 Combined treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days
11181007|NCT03515187|Placebo Comparator|B1 Control group|Placebo
11181008|NCT03515187|Experimental|B2 Experiment group|0.3%sodium hyaluronate ophthalmic solution, 12 months
11181009|NCT03515174|Experimental|Interventional Program|Patients will participate in a structured supportive care program.
11181010|NCT03515174|Active Comparator|Control Group|Patients in the control group will receive usual care.
11181011|NCT03515161|Experimental|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
11181012|NCT03515148|Experimental|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
11181013|NCT03515148|Experimental|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
11181014|NCT03515135|Experimental|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
11181015|NCT03515135|No Intervention|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
11181016|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
11181017|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
11181018|NCT03515109|Active Comparator|group A|Altis tape surgical placement
11181019|NCT03515109|Placebo Comparator|group B|TVT transobturator tape placement
11181020|NCT03515096|Experimental|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
11181021|NCT03515096|Placebo Comparator|rhTPO|Recombinant human thrombopoietin (rhTPO)
11181086|NCT03514628|Active Comparator|Standard Care|Intervention is the use of Standard technique to deliver Valsalva strain eg blowing on empty syringe
11206618|NCT03337724|Experimental|Placebo + Paclitaxel|
11181022|NCT03515083|Experimental|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.
~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
11181023|NCT03515083|No Intervention|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.
~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
11181024|NCT03515057|Experimental|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
11181025|NCT03515057|No Intervention|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
11181026|NCT03515044|Experimental|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
11181027|NCT03515044|Experimental|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
11181028|NCT03515044|Experimental|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
11181029|NCT03515044|Experimental|Cohort 4 80 mg Rifaximin SSD twice daiy|Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose
11181030|NCT03515044|Experimental|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
11181031|NCT03515031|Experimental|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula Oxygenation with a minimum flow ≥ 60L / min, and an FiO2 such as to maintain a SpO2 ≥ 92% for at least 48 hours until clinical stability
11181032|NCT03515031|Active Comparator|Venturi Mask Oxygenation|Venturi Mask Oxygenation, with an FiO2 such as to maintain an SpO2 ≥ 92% for at least 48 hours until clinical stability
11181033|NCT03515018|Experimental|Hydroxyurea|Drug: hydroxyurea, pulse therapy
11181034|NCT03515018|Active Comparator|imatinib|Drug: imatinib, 400mg PO per day
11181035|NCT03515005|Experimental|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
11181036|NCT03515005|No Intervention|Usual Care|Control patients will receive usual care from their doctors.
11181037|NCT03514979|Experimental|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
11181038|NCT03514979|Experimental|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
11181039|NCT03514979|Experimental|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
11181040|NCT03514966|No Intervention|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
11181041|NCT03514966|Experimental|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
11181042|NCT03514953|Experimental|Reduced Physical Activity|Participants will reduce their physical activity level by >5000 steps per day for two weeks.
11181043|NCT03514927|Experimental|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.
~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
11181044|NCT03514914|Experimental|CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by female providers.
11181045|NCT03514914|No Intervention|Control|Control clusters will receive standard of care.
11181046|NCT03514901|Experimental|Experimental combination beyond Focal Progression|Local treatment (i.e. surgery, radiotherapy) + Vemurafenib 240mg tablets (4 tabs/twice daily for 28 consecutive days) + Cobimetinib 20mg tablets (3 tabs/day for 21 consecutive days) beyond focal progression.
11181047|NCT03514901|Active Comparator|Pembrolizumab or Nivolumab|Pembrolizumab daily dose 2 mg/kg milligram(s)/kilogram or Nivolumab daily dose 3 mg/kg milligram(s)/kilogram.
11181048|NCT03514888|Experimental|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
11181049|NCT03514875|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
11181050|NCT03514875|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
11181051|NCT03514862|Experimental|Intervention|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then will be invited to continue to participate in 4 additional Mindfulness Booster Training.
11181052|NCT03514862|Active Comparator|Control|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then continue to Self-Practice for 4 weeks.
11181053|NCT03514849|Experimental|PCI group|
11181054|NCT03514849|Placebo Comparator|Control group|
11181055|NCT03514836|Experimental|DCVac and ONCOS-102|ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
11181056|NCT03514823|Experimental|IMT Group|
11181057|NCT03514823|Sham Comparator|No IMT Group|
11181058|NCT03514810|Placebo Comparator|Sertralin & Ketoprofen in MDD|To compare the median of Beck Depression Inventory-II (BDI-II) score of MDD patients after treatment with sertralin (50mg) daily+placebo and after treatment with combination of (sertralin & ketoprofen) for two months.
11181059|NCT03514810|Experimental|Interleukins in MDD after treatment|Some Interleukines level were estimated before and after treatment with sertralin 50 mg in combination with either placebo or ketoprofen 100mg daily.
11181060|NCT03514797|Experimental|Combined technique|A single session of in-office tooth bleaching will be performed with 35% hydrogen peroxide for 45 minutes. Following, the teeth will be further bleached with customized trays filled with 10% carbamide peroxide and used for 1h per day.
11181061|NCT03514797|Active Comparator|At-home bleaching|The teeth will be bleached only with customized trays filled with 10% carbamide peroxide and used for 1h per day.
11181062|NCT03514784|Active Comparator|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs
11181063|NCT03514784|Placebo Comparator|Placebo|Maltodextrin
11181064|NCT03514784|Active Comparator|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
11181065|NCT03514771|Other|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
11181066|NCT03514758|Experimental|normal hearing participants|normal hearing participants with and without hearing aids
11181067|NCT03514745|Active Comparator|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
11181068|NCT03514745|Experimental|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
11181069|NCT03514732|Experimental|Novanuit® Triple Action|2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
11181070|NCT03514719|Experimental|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-avelumab PET
11181071|NCT03514706|Experimental|Volume controlled ventilation|Group V: Patients will receive volume controlled mechanical ventilation. (Vt 7ml/kg ideal body weight).
11181072|NCT03514706|Experimental|Pressure controlled ventilation|Group P: Patients will receive pressure controlled mechanical ventilation. (to achieve Vt 7 ml/kg ideal body weight, Pmax 30 cmH2O)
11181073|NCT03514693|Active Comparator|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
11181074|NCT03514693|Placebo Comparator|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
11181075|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
11181076|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.
~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
11181077|NCT03514667|Active Comparator|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
11181078|NCT03514667|Placebo Comparator|control group|placebo capsules once a day for 12 weeks
11181079|NCT03514654|Active Comparator|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
11181080|NCT03514654|Active Comparator|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
11181081|NCT03514641|Other|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
11181082|NCT03514641|Other|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
11181083|NCT03514641|Other|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
11181084|NCT03514641|Other|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
11181810|NCT03510039|Experimental|"After Group"|"Recruit 35 Thirds for the phase phase After : Early device / Follow up by nurses"
11181087|NCT03514615|Placebo Comparator|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
11181088|NCT03514615|Experimental|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
11181089|NCT03514602|Experimental|Multicomponent behavioral intervention|The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support.
11181090|NCT03514602|Active Comparator|Control|The control group will receive smoking cessation education only.
11181091|NCT03514589|Active Comparator|Arm 1|250 mcg IV synacthen
11181092|NCT03514589|Experimental|Arm 2|Nasal Synacthen
11181093|NCT03514576|Experimental|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
11181094|NCT03514576|Experimental|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
11181095|NCT03514563||Group A|MRI imaging, Optical scan and 3D photography for patients with Class I (non-skeletal) malocclusion with no facial asymmetry or other pathology.
11181096|NCT03514563||Group B|MRI imaging, Optical scan and 3D photography for patients with Class III (skeletal-based) malocclusion with maxillary deficiency and normal vertical facial relationships, with no facial asymmetry or other pathology
11181097|NCT03514563||Group C|MRI imaging, Optical scan and 3D photography for patients with Cleft lip and/or palate and a Class III malocclusion and no other pathology
11181098|NCT03514550|Experimental|total intravenous anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia
11181099|NCT03514550|Active Comparator|Volatile anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia
11181100|NCT03514537|Experimental|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
11181101|NCT03514537|Experimental|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
11181102|NCT03514537|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
11181103|NCT03514524|Experimental|healthy ageing|
11181104|NCT03514524|Experimental|TBI|
11181105|NCT03514524|Experimental|CTE|
11181106|NCT03514524|Experimental|Ischemic stroke|
11181107|NCT03514524|Experimental|aMCI and MBI|
11181108|NCT03514511|Experimental|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
11181109|NCT03514511|Experimental|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
11181110|NCT03514511|Experimental|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
11181111|NCT03514511|Experimental|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
11181112|NCT03514511|Experimental|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
11181113|NCT03514511|Experimental|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
11181114|NCT03514511|Experimental|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
11181115|NCT03514511|Experimental|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
11181116|NCT03514511|Experimental|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
11181117|NCT03514498||Autism Spectrum Disorder|Children aged 4-12 years with a clinical diagnosis of mild-to-moderate Autism Spectrum Disorder undergoing dental surgery
11181118|NCT03514498||Typically Developed Controls|Children with no neurodevelopmental delays matched to Autism Spectrum Disorder participants according to age (within 6 months), gender, and ASA physical status level, scheduled to undergo dental surgery
11181119|NCT03514485|Active Comparator|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
11181120|NCT03514485|Active Comparator|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
11181121|NCT03514485|Active Comparator|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
11181122|NCT03514485|No Intervention|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
11181123|NCT03514485|Active Comparator|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
11181124|NCT03514485|No Intervention|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
11181125|NCT03514472|Active Comparator|Group A (Below 18 years)|Dried Moringa oleifera leaves (15g/recipe)
11181126|NCT03514472|Active Comparator|Group B (Above 18)|Dried Moringa oleifera leaves (15g/recipe)
11181127|NCT03514459|No Intervention|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
11181164|NCT03514251|Experimental|Parathyroid marker group|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker.
11181128|NCT03514459|Experimental|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
11181129|NCT03514446|Experimental|Antibiotic therapy duration for 7 days|
11181130|NCT03514446|No Intervention|Antibiotic therapy duration for 14 days|
11181131|NCT03514433|No Intervention|Historical Control|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
11181132|NCT03514433|Experimental|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
11181133|NCT03514420|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
11181134|NCT03514407|Experimental|INCB059872|INCB059872
11181135|NCT03514394|Active Comparator|Problem Solving Therapy (PST)|6 weekly sessions to teach patients seven steps of problem solving (problem orientation, problem definition, goal setting, brain storming, decision making, action planning, solution evaluation).
11181136|NCT03514394|Experimental|Modified PST|This intervention will be a modification of PST, based on clinician feedback. It will be developed in phase 1 and 2 of this study. It will include elements of cognitive processing therapy, behavioral activation and distress tolerance. Anticipated number of sessions is 6.
11181137|NCT03514381|Other|Patients starting a treatment with Doxorubicin and Ifosfamide|
11181138|NCT03514368|Other|Patients treated with immune checkpoint blockade|
11181139|NCT03514355|Experimental|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
11181140|NCT03514355|No Intervention|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
11181141|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
11181142|NCT03514329|Experimental|Vapor Ablation|Patients treated with Bronchoscopic Thermal Vapor Ablation for lung cancer
11181143|NCT03514316|Active Comparator|Scalpel Gingivectomy|Patients treated with Scalpel Gingivectomy on the labial side of the anterior maxillary teeth
11181144|NCT03514316|Active Comparator|Laser Gingivectomy|Patients treated with Laser Gingivectomy on the labial side of the anterior maxillary teeth
11181145|NCT03514316|Active Comparator|Nonsurgical periodontal treatment|Patients treated with a full-mouth periodontal debridement
11181146|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
11181147|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
11181148|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
11181149|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
11181150|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
11181151|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
11181152|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
11181153|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
11181154|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
11181155|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
11181156|NCT03514290|Placebo Comparator|GPLACEBO|the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP).
11181157|NCT03514290|Experimental|GLASER|treated with Low-lever laser + tooth bleaching with 35% hydrogen peroxide (HP).
11181158|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
11181159|NCT03514277|Active Comparator|Local infiltration of Exparel|
11181160|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
11181161|NCT03514264|Experimental|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
11181162|NCT03514264|Experimental|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
11181163|NCT03514251|No Intervention|Control group|Routine thyroidectomy and central lymph node dissection
11181907|NCT03509428|Experimental|Psychological support|Psychological support prior to surgery
11181165|NCT03514238|Experimental|Adults (BMI: ≥30 kg/m2)|"Obese individuals will participate to three conditions:
~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
11181166|NCT03514238|Experimental|Adults (BMI: 18.5-24.9 kg/m2)|"Normal weight individuals will participate to three conditions:
~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
11181167|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
11181168|NCT03514212|Experimental|ProActiveS|As this was a feasibility study, all participants received the intervention.
11181169|NCT03514199|Experimental|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
11181170|NCT03514199|Active Comparator|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
11181171|NCT03514186|Experimental|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
11181172|NCT03514186|Active Comparator|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
11181173|NCT03514160|Active Comparator|Group exercise|Group exercise training at a community site. Exercises included supervised upper and lower-body strength and balance exercises twice per week. Hand-made, weighted bars were used for resistance props and balance. The exercises included: chair squats; standing single leg hip abduction; hip extension; balance heal-to-toe walking; seated hip adduction and knee extension; wall push-ups; bent-over rows; shoulder press; elbow flexion and extension).
11181174|NCT03514160|No Intervention|Attention-Control group|Attendance to community site usual activities offered to older adults. Participants in this group were offered the exercise routine after completing the 12-week study.
11181175|NCT03514147|Experimental|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
11181176|NCT03514147|Active Comparator|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
11181177|NCT03514134|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
11181178|NCT03514134|Active Comparator|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
11181179|NCT03514121|Experimental|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
11181180|NCT03514108|Active Comparator|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.
~Average treatment period 4 years."
11181181|NCT03514108|Placebo Comparator|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
11181182|NCT03514108|Active Comparator|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
11181183|NCT03514108|Placebo Comparator|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
11181184|NCT03514095|No Intervention|Control Group|The control group shall participate in the usual home-based care provided by their carer.
11181185|NCT03514095|Experimental|Individual Cognitive Stimulation Therapy|The experimental group shall participate in the Making a Difference 3 program (Yates et al., 2015) is aimed at elderly people with mild or major neurocognitive disorder, where informal caregiver (family, friend or neighbour) assume a partnering role in an one-to-one approach. The program is composed by a range of stimulating activities (sessions), each with two levels of difficulty. The carers are introduced to a set of key principles that guides them during individual cognitive stimulation sessions, tailoring the interventions to the needs and reality of the elderly participants.
11181186|NCT03514082||Adolescent Idiopathic Scoliosis|Subjects with AIS who are beginning to the conservative treatment.
11181187|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
11181188|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.
~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.
~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
11181189|NCT03514056||1|group Behcet
11181190|NCT03514056||2|group fibromyalgia
11181191|NCT03514043||Ambulatory care surgical patients|Patients who have attended the surgical assessment unit with an emergency general surgical condition and have their care completed without an inpatient stay.
11181192|NCT03514043||Surgical assessment unit staff|Staff who are involved in the care of patients on the surgical assessment unit. This includes senior and junior doctors, nurses, healthcare assistants and ward receptionists.
11181193|NCT03514030||positive|serum AQP4-antibody is positive
11181194|NCT03514030||negtive|serum AQP4-antibody is negtive
11181195|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.
~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
11181196|NCT03514004|Experimental|Intervention|"The ICT-based intervention is known as Project Clan. Each participant randomized to the intervention group will have access to the web platform and mobile applications of Project Clan - a virtual community that seeks to promote adolescent mental health and wellbeing as students interact, express themselves, and resolve concerns, with the support of peers and mental health professionals. During the three-month intervention, participants will have complete anonymity, unless trained psychologists supervising the platform as community counselors identify behaviors associated with suicide risk and proceed to follow an established emergency protocol. The counselors will be available to answer community questions and provide support on an individual basis."
11181197|NCT03514004|No Intervention|Control|Participants in the control group will also be assigned a username and password to access the website, but they will be met with a user interface that only displays a space to answer the corresponding assessments. In addition to the introductory presentation, they will be given a brochure with information regarding adolescent suicide and wellbeing and tips with regard to seeking help and assisting others. This will include the contact information for a telephone hotline, to ensure they can receive professional help if needed.
11181198|NCT03513991|Experimental|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
11181199|NCT03513991|Other|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
11181200|NCT03513991|Other|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
11181201|NCT03513991|No Intervention|HM (human milk)|Participants were exclusively breastfed
11181202|NCT03513978|Experimental|IAI Protocol|A progressive exercises with transference to sport protocol, oriented to improve the proprioception.
11181203|NCT03513978|Active Comparator|FIFA 11+ Protocol|A typical exercises protocol to soccer
11181204|NCT03513965|Experimental|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
11181205|NCT03513965|Experimental|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
11181206|NCT03513952|Experimental|Group 1 (CYT107, atezolizumab)|Patients receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11181207|NCT03513952|Experimental|Group 2 (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11181208|NCT03513939|Experimental|T1DM Cell Pouch™ Recipients|Eligible Type 1 Diabetes Mellitus (T1DM) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch™ intervention
11181209|NCT03513926||Non-OSA group|Patients with out sleep apnea.
11181210|NCT03513926||OSA group|Patients with OSA, without cardiovascular comorbidities who could be treated with Continuous Positive Airway Pressure
11181211|NCT03513926||OSA with hypertension group|Patients with OSA, with hypertension who could be treated with Continuous Positive Airway Pressure
11181212|NCT03513926||OSA with CVE group|Patients with OSA, with a previous ictus or stroke who could be treated with Continuous Positive Airway Pressure
11181213|NCT03513913|Experimental|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
11181214|NCT03513913|Experimental|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
11181215|NCT03513900||cirrhosis|In this cross-sectional study , we will collect all patients with cirrhosis who meet the inclusion and exclusion criteria criteria coming to The Second Affiliated Hospital, Xi'an Jiaotong University since March 2018 to December 2018.
11181216|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
11181217|NCT03513874|Experimental|Metformin + Insulin|
11181218|NCT03513874|Active Comparator|Insulin alone|
11181219|NCT03513861|Experimental|Aim 1: Parental FASTER tool training|The goal is to see whether the child's parent/ guardian can be trained in overall severity of illness assessment using the FASTER Tool, to match the performance of a professional.
11181220|NCT03513861|Active Comparator|Aim 2: Intervention group|The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
11207621|NCT03331848|Placebo Comparator|PLACEBO|
11181221|NCT03513861|No Intervention|Aim 2: Control Group|The control group parents will not be taught the FASTER assessment tool. Hence they will not be involved in monitoring their child, nor signaling severity of their child's illness per color-coded flag system. Control group parents will record the frequency of healthcare provider assessments of their child over the 24 hrs enrollment period.
11181222|NCT03513848|Experimental|Bright Light|
11181223|NCT03513848|Placebo Comparator|Dim Light|
11181224|NCT03513822|Active Comparator|Chronic neuropathic pain and bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).
~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.
~Maximum 100mg. One and only perfusion."
11181225|NCT03513822|Placebo Comparator|Chronic neuropathic pain and bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).
~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.
~One and only perfusion."
11181226|NCT03513822|Active Comparator|Chronic neuropathic pain without bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).
~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.
~Maximum 100mg. One and only perfusion."
11181227|NCT03513822|Placebo Comparator|Chronic neuropathic pain without bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).
~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).
~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.
~One and only perfusion."
11181228|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
11181229|NCT03513770|Experimental|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
11181230|NCT03513770|Placebo Comparator|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
11181231|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
11181232|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
11181233|NCT03513744|Experimental|infant formula containing five HMOs|
11181234|NCT03513744|No Intervention|infant formula|
11181235|NCT03513744|No Intervention|breast milk group|
11181236|NCT03513731|Experimental|Adipose-derived stem cell injection|ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
11181237|NCT03513731|Active Comparator|Corticosteroid injection|The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
11181238|NCT03513705|Experimental|Best practice|Enhanced implementation of best practices in pancreatic cancer care
11181239|NCT03513705|No Intervention|Current practice|Pancreatic cancer care according to current practice
11181240|NCT03513692|Active Comparator|Fill-Up composite resin|"In this arm of the study, participants will have the dental restoration completed with FillUp from Coltene, a composite resin a CE marked and licensed restorative material."
11181241|NCT03513692|Active Comparator|Conventional; composite|In this arm of the study, participants will have the dental restoration completed with a conventional composite resin using a CE marked and licensed restorative material.
11181242|NCT03513679|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
11181243|NCT03513679|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
11181244|NCT03513666|Experimental|treatment arm|Toripalimab 240 mg or 360 mg Q3W in combination with chemotherapy
11181245|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
11181246|NCT03513627||Implant|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at a dental implant born crown in the front region of the jaw
11181247|NCT03513627||Tooth|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at the contralateral natural tooth
11181248|NCT03513614|Active Comparator|ALND|Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.
11181249|NCT03513614|Active Comparator|No ALND|Tailored axillary surgery followed by regional nodal irradiation including the full axilla.
11181250|NCT03513601|Experimental|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
11181941|NCT03509220|Active Comparator|Standard oral preparation|2-Day Split-Dosing Regimen
11181251|NCT03513601|Experimental|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
11181252|NCT03513588|Placebo Comparator|Placebo|
11181253|NCT03513588|Experimental|PF-06865571 100 mg|
11181254|NCT03513588|Experimental|PF-06865571 600 mg|
11181255|NCT03513575|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
11181256|NCT03513575|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
11181257|NCT03513575|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
11181258|NCT03513575|Experimental|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
11181259|NCT03513575|Experimental|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
11181260|NCT03513575|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.
~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
11181261|NCT03513562|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
11181262|NCT03513549||Loxapine 10 MG|ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
11181263|NCT03513536|Experimental|Intervention 1|The women in this arm will receive the Citrus-Based Aromatherapy product to apply regularly for 6 days.
11181264|NCT03513536|Experimental|Intervention 2|The women in this arm will receive the Mint-Based Aromatherapy product to apply regularly for 6 days.
11181265|NCT03513536|Experimental|Intervention 3|The women in this arm will receive the Spice-Scented Aromatherapy product to apply regularly for 6 days.
11181266|NCT03513536|Placebo Comparator|Control|The women in this arm will receive a vegetable oil roll-on product to apply regularly for 6 days.
11181267|NCT03513523|Experimental|Group 1: 1X dose of NRPT|250 mg of NR and 50 mg of PT
11181268|NCT03513523|Experimental|Group 2: 2X dose of NRPT|500 mg of NR and 100 mg of PT
11181269|NCT03513523|Placebo Comparator|Group 3: Placebo|Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate
11181270|NCT03513510|Experimental|iChoose|6 biweekly family sessions, 6 biweekly telephone support calls to parents, 6 biweekly newsletters for children, and 3 supervised exercise sessions per week/3 months; delivers intervention to parents and children only
11181271|NCT03513497|Experimental|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
11181272|NCT03513497|Experimental|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
11181273|NCT03513484|Experimental|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
11181274|NCT03513471|Experimental|Anakinra then Placebo Treatment|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to the Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
11181275|NCT03513471|Experimental|Placebo then Anakinra Treatment|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
11181276|NCT03513458|Experimental|Anakinra then Placebo|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
11181277|NCT03513458|Experimental|Placebo then Anakinra|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
11181278|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
11181279|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
11181280|NCT03513432|Experimental|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day
11181281|NCT03513432|Experimental|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day
11181282|NCT03513432|Experimental|Non-alcoholic beer with 0.00 % alcohol|330 ml non-alcoholic beer (0.00 % alcohol)/day
11181283|NCT03513419|Experimental|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
11181284|NCT03513419|No Intervention|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
11181285|NCT03513406|Active Comparator|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
11181286|NCT03513406|Active Comparator|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
11181287|NCT03513393|Experimental|A: Epclusa + omeprazole + Coca Cola (test 1)|Day 1 - 6 40mg omeprazole QD; on Day 5 a single-dose of SOF/VEL with 250 mL of Coca Cola Classic is administered (test 1).
11181288|NCT03513393|Experimental|B: Epclusa + omeprazole + water (test 2)|Day 8 - 13: 40mg omeprazole QD; on Day 12 a single-dose of SOF/VEL is administered (test 2).
11181289|NCT03513393|Active Comparator|C: Epclusa + water (Reference)|Day 15 - 21: no treatment with omeprazole; on Day 19 a single-dose of SOF/VEL is administered (reference).
11181290|NCT03513380|Experimental|Exergaming|free access to the exergame PedalTanks
11181291|NCT03513380|No Intervention|Control|recommended to continue with their normal daily routine
11181292|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.
~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
11181293|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
11181294|NCT03513354|No Intervention|Control group|The control group did not perform any of the interventions.
11181295|NCT03513354|Experimental|Soil group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
11181296|NCT03513354|Experimental|Pool group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
11181297|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
11181942|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
11181298|NCT03513328|Experimental|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
11181299|NCT03513328|Experimental|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
11181300|NCT03513328|Active Comparator|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
11181301|NCT03513328|Active Comparator|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
11181302|NCT03513315|Experimental|Intervention Community Clusters|For the community-based arm of the study, 16 clusters will be randomized into intervention and control groups. Those in the intervention group will receive implementation of community-based Home Heat Bundle. This Bundle includes education from community health workers on the signs and symptoms of heat-related illness, how to prevent the illness, and when to seek treatment. In addition, the intervention group will receive SMS messaging with information about heatwaves. The education and Short Message Service (SMS) messaging will occur in March and April via meetings in households and in public spaces. There will be a total of 40 activities, each lasting approximately two hours.
11181303|NCT03513315|Experimental|Control Community Clusters|Eight community clusters of 1000 population each where regular community-based healthcare services will be provided without focused interventions on identification and management of heat-related illnesses. These clusters will receive regular community healthcare provision.
11181304|NCT03513302|Placebo Comparator|placebo|
11181305|NCT03513302|Active Comparator|nitrate|
11181306|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
11181307|NCT03513276|Experimental|Multimodal analgesia + Local Infiltration Anesthesia|100cc of 2% ropivacaine + Adrenaline 10mcg/ml + 20cc saline solution
11181308|NCT03513276|Active Comparator|Multimodal analgesia + saline solution|120cc of saline solution
11181309|NCT03513263|Active Comparator|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
11181310|NCT03513263|Sham Comparator|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
11181311|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
11181312|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
11181313|NCT03513237|Experimental|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
11181314|NCT03513237|No Intervention|no cervical dilation group|No cervical dilation will be done.
11181315|NCT03513224|Experimental|eDosette|
11181316|NCT03513211|Experimental|Dose escalation arm|Suba-itraconazole in combination dose escalating hydroxychloroquine H
11181317|NCT03513211|Experimental|Phase II: Dose expansion arm|Suba-itraconazole with recommended phase II dose of hydroxychloroquine as determined by phase I arm.
11181318|NCT03513198||Non-resectable pancreatic cancer|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months.
~Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included.
~Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment"
11181319|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
11181320|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
11181321|NCT03513172|Active Comparator|Brimonidine Pre-Administration During First Visit|
11181322|NCT03513172|Active Comparator|Brimonidine Pre-Administration During Second Visit|
11181323|NCT03513159|Experimental|Pathfinder support|Pathfinder support with development of an individual care plan for the intervention patients and their informal caregivers, with the hospital physicians already inside the hospital setting. This will then be developed and improved further during up to twelve months after hospital release with the primary physician. The pathfinders will coordinate the ambulatory care team services and closely involve the primary physicians. The patients and their informal caregivers will be empowered and educated to achieve a stabilization or improvement in functionality, independence, quality of life, coping with disease, nutritional status and wound healing process. In the regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
11181324|NCT03513159|No Intervention|Control without pathfinder support|Control patients will not be supported by pathfinders. In regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
11182063|NCT03508414|Experimental|Intermittent therapeutical fasting|
11181325|NCT03513146|Experimental|OPAMM group|"During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours.
~When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol.
~This practice will be continued till the infants reach full oral feeding."
11181326|NCT03513146|No Intervention|Control Group|"During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol.
~This practice will be continued till the infants reach full oral feeding."
11181327|NCT03513133|Experimental|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
11181328|NCT03513094|Experimental|Without and With Transversus Abdominis|"Without:
~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.
~With:
~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
11181329|NCT03513081|Experimental|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
11181330|NCT03513081|No Intervention|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
11181331|NCT03513068|No Intervention|Standard Of Care (SOC)|Standard of care long-term oxygen therapy
11181332|NCT03513068|Experimental|SOC + POC (Portable Oxygen Concentrator)|Standard of care long-term oxygen therapy + POC
11181333|NCT03513055|Experimental|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
11181334|NCT03513042||Cohort|"Intervention:
~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.
~Baseline measurements:
~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.
~Interim measurements conventional):
~FDG PET-CT will be repeated at the end of the second week of IMPT.
~FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.
~A subcohort will also undergo activation PET imaging three times during IMPT."
11181335|NCT03513029|Experimental|Study Device|VytronUS Ablation System
11181336|NCT03513016|Experimental|Part A: UBX0101|Part A: UBX0101, single intra-articular injection, ascending dose
11181337|NCT03513016|Placebo Comparator|Part A: Placebo|Part A: Placebo, single intra-articular injection, ascending dose
11181338|NCT03513016|Experimental|Part B: UBX0101|Part B: UBX0101, single intra-articular injection, fixed dose
11181339|NCT03513016|Placebo Comparator|Part B: Placebo|Part B: Placebo, single intra-articular injection, fixed dose
11181340|NCT03513003|Experimental|Functional pacifier|Swap from the habitual pacifier to a functional pacifier
11181341|NCT03513003|Active Comparator|Stop habit|Stop the use of the habitual pacifier and or baby bottle
11181342|NCT03512990|Experimental|Bupivacaine - Superior Trunk Block|"Patients scheduled for rotator cuff surgery received 6 mL of 0,5% bupivacaine in the superior Trunk.
~6 mL of methylene blue will be injected into cadavers with the same technique."
11181343|NCT03512977|Experimental|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
11181344|NCT03512977|Active Comparator|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
11181345|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
11181346|NCT03512951|Experimental|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
11181347|NCT03512951|Experimental|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
11181348|NCT03512951|Experimental|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
11181349|NCT03512938|Active Comparator|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
11181350|NCT03512938|Experimental|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
11181351|NCT03512925|Experimental|Standardized post-coercion review|Intervention: Standardized post-coercion review session. Patients allocated to this arm receive a standardized post-coercion review of the coercive measure they experienced using the developed guidelines.
11181352|NCT03512925|No Intervention|Control group|Patients allocated to this arm are treated following usual standards and routine. This might include some form of post-coercion review that doesn't follow the developed standardized guidelines.
11181353|NCT03512899|Active Comparator|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
11181354|NCT03512899|Active Comparator|Axilar vein access|Axilar vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
11181355|NCT03512886|Active Comparator|Single task training|The exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
11181356|NCT03512886|Experimental|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
11181357|NCT03512886|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
11181358|NCT03512873|Experimental|Tranilast|
11181359|NCT03512860|Experimental|E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)|Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.
11181360|NCT03512860|Experimental|E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)|Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
11181361|NCT03512834|Experimental|Paclitaxel+Avelumab|Paclitaxel combination with Avelumab for inoperable angiosarcoma
11181362|NCT03512821|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
11181363|NCT03512821|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
11181364|NCT03512808|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
11181365|NCT03512808|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
11181366|NCT03512782|No Intervention|CONTROL|
11181367|NCT03512782|Experimental|INTERVENTION|
11181368|NCT03512756|Experimental|Part 1 and Part 2 SM-88 Arm|"(Part 1 enrollment complete) SM-88 used with MPS (methoxsalen, phenytoin and sirolimus)
~(Part 2 actively enrolling) SM-88 (920 mg per day) used with MPS (methoxsalen, phenytoin and sirolimus) will be administered to 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met."
11181369|NCT03512756|Experimental|Physician's Choice|Physician's Choice therapy will be administered for a total of 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
11181370|NCT03512730|Experimental|Titanium brush, H2O2 3%, plastic curettes|
11181371|NCT03512730|Active Comparator|H2O2 3%, plastic curettes|
11181372|NCT03512717|Experimental|Potenfill|
11181373|NCT03512717|Active Comparator|Powerfill|
11181374|NCT03512691|Experimental|Information on CVD risk|Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
11181375|NCT03512691|Experimental|Lottery Incentive|Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage.
11181376|NCT03512691|No Intervention|Control|No intervention will be introduced to the participants in this arm.
11181377|NCT03512665|Experimental|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
11181378|NCT03512665|Experimental|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
11181379|NCT03512665|Other|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
11181380|NCT03512652|Other|Patello|
11181381|NCT03512639|Active Comparator|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
11181382|NCT03512639|Placebo Comparator|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
11181383|NCT03512626|Experimental|Multifocal IOL (OptiVis)|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.
~The randomly assigned IOL (in this arm: a hybrid (refractive-diffractive) multifocal IOL (OptiVis, Aaren Scientific) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
11181447|NCT03512210|Experimental|Oral fixed dose combination sofosbuvir/velpatasvir|Participants will receive fixed dose combination (FDC) sofosbuvir/velpatasvir (SOF/VEL) [Tradename: Epclusa] (400mg/100mg) orally once daily with or without food.
11207622|NCT03331848|Experimental|PXT002331 - 20mg|
11181384|NCT03512626|Active Comparator|Monofocal IOL|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.
~The randomly assigned IOL (in this arm: a monofocal IOL (AR40e, AMO) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
11181385|NCT03512600|Experimental|Study group|"All patients will follow four different dietary interventions (with or without cacao) for 1 day prior to the taking of a urine sample.
~After the sample is taken the patient will follow a washout period of 6 days before following a different diet and this process will be repeated for each patient until they have followed the four diets.
~."
11181386|NCT03512587|Experimental|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
11181387|NCT03512587|Placebo Comparator|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
11181388|NCT03512574|Experimental|Group PD|combination of pregabalin and dexmedetomidine
11181389|NCT03512574|Active Comparator|Group P|pregabalin +placebo
11181390|NCT03512574|Active Comparator|Group D|placebo + dexmedetomidine
11181391|NCT03512574|Placebo Comparator|Group C|placebo + placebo
11181392|NCT03512548|Experimental|Part 1 Period 1|Part 1 Period 1: Relacorilant 350mg will be given once on Day 1
11181393|NCT03512548|Experimental|Part 1 Period 2|Part 1 Period 2: Itraconazole 200mg will be given for three days
11181394|NCT03512548|Experimental|Part 1 Period 3|Part 1 Period 3: Relacorilant 350mg will be given once with concomitant itraconazole and itraconazole will continue for three additional days
11181395|NCT03512548|Experimental|Part 2 Period A|Part 2 Period A: Relacorilant 300mg will be given once daily for 10 days
11181396|NCT03512548|Experimental|Part 2 Period B|Part 2 Period B: Relacorilant 300mg will be given once daily in combination with itraconazole 200mg once daily for 10 days
11181397|NCT03512535||Stage 1|Samples from up to 20 participants will be used to finalise the analytical methods
11181398|NCT03512535||Stage 2|Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders
11181399|NCT03512522|Experimental|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
11181400|NCT03512522|Experimental|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Workbook Group will receive access to the course in a printed (workbook) format. A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
11181401|NCT03512522|No Intervention|Wait List Control Group|Participants who are randomly allocated to the wait list control group will be provided access to the course after the twelve-week period has passed.
11181402|NCT03512509|Experimental|A|Low glycaemic potato
11181403|NCT03512509|Experimental|B|High glycaemic potato
11181404|NCT03512496|Placebo Comparator|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
11181405|NCT03512496|Active Comparator|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
11181406|NCT03512496|Sham Comparator|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
11181407|NCT03512483|No Intervention|Usual Care|Control group participants will be notified of their assignment and will continue their usual care with the AF clinic receiving onsite care. Participants will be contacted at 3 time points (baseline, 3 months, and 6 months)
11181408|NCT03512483|Experimental|Virtual Atrial Fibrillation Clinic|Participants in the intervention group can expect to receive between 1 and 4 telehealth appointments over a 6 month period, as well as being contacted by the research team at 3 time points for data collection (baseline, 3 months, and 6 months). Telehealth appointments will consist of remote interactions with clinicians. Telehealth appointments will take place in participants' homes, using their personal computer/tablet/smartphone. Participants will also receive an orientation to the website and will be encouraged to visit often and utilize the resources. To promote and encourage website interaction, emails will be sent to participants once semi-monthly for the duration of the intervention with highlights and important messages from the website.
11181409|NCT03512470|Experimental|Sistema Prevena ™ (TVAC)|Negative topical pressure system (Sistema Prevena ™).
11181410|NCT03512470|Active Comparator|Standard medication|Standard medication with sterile gauzes and a TNT patch or medicated patch
11181411|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
11181412|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
11181413|NCT03512444|Experimental|Negative pressure|"Negative pressure system is applied with negative pressure (Active)
~at a participant's unilateral arm"
11181414|NCT03512444|No Intervention|No negative pressure|"Negative pressure system is applied without negative pressure (Inactive)
~at a participant's contralateral arm"
11181415|NCT03512431||Study group|Only one arm in the present study
11181416|NCT03512418|Experimental|PrEPsteps|Participants receive the PrEPsteps intervention that is programmed at the randomization study visit. They will use PrEPsteps and the digital pill to measure Truvada adherence for month 1, then they will revert to digital pill alone with Truvada for month 2 and 3.
11181417|NCT03512418|Active Comparator|Control|Participants receive digital pills with Truvada to measure PrEP adherence at the randomization study visit and continue with digital pills with Truvada for month 2 and 3.
11181546|NCT03511651|Experimental|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
11181418|NCT03512405|Experimental|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11181419|NCT03512392|Experimental|Conservative fluid and deresuscitation|"Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)
~Daily assessment of eligibility for deresuscitation for 3 days (eligible if oedema in more than 1 site and cumulative fluid balance > 2 litres)
~Deresuscitation to target negative daily fluid balance of 1 to 3 litres:
~5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
11181420|NCT03512392|Active Comparator|Usual care|Usual care at the discretion of the treating team
11181421|NCT03512379|Experimental|Robot assisted surgery group|Spinal surgery using TIANJI Robot system.
11181422|NCT03512379|Active Comparator|Free hand surgery group|Spinal surgery using fluoroscopy-based free hand technique
11181423|NCT03512379|Active Comparator|Navigation-assisted surgery group|Spinal surgery using Navigation-assisted technique
11181424|NCT03512366|Experimental|Desarsda's technique|"These patients wil be operated by the Desarda's technique without using any prosthetic mesh. A strip of external oblique aponeurosis will be used to strengthen the defect.
~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia
~Intervention:
~A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the muscle arch or conjoint tendon above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure it to the inguinal ligament inferiorly , and will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures."
11181425|NCT03512366|Active Comparator|Lichtenstein's technique|"These patients will be operated using prosthetic mesh described as Lichtenstein's tension free mesh hernioplasty.
~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia.
~Intervention :
~A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring. Laterally, 2 cm silt will be made through the mesh to accommodate the cord. while the two tails will be sutured to create a new deep ring made of mesh."
11181426|NCT03512353|Experimental|Carfilzomib Plus Dexamethasone|Describe the safety profile of carfilzomib plus dexamethasone regimen (Kd 56 mg/m2 twice weekly for cycles 1-6 followed by Kd 70 mg/m2 once weekly for cycles 7-12) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1-3 prior lines of therapy at study entry. Describe subjects' adherence by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.
11181427|NCT03512340|Experimental|Part A|Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SRF231 as a monotherapy in patients with advanced solid tumors and lymphoma/Chronic lymphocytic leukemia.
11181428|NCT03512340|Experimental|Part B Cohort 1|Depending upon the results from Part A of the study and the decision from the Safety Review Committee, 1 or 2 doses or dosing frequencies of SRF231 in select advanced solid and hematologic malignancies.
11181429|NCT03512327|Experimental|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
11181430|NCT03512314|Experimental|Tadekinig alfa|Active drug treatment during 26 weeks
11181431|NCT03512301|Experimental|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
11181432|NCT03512301|Experimental|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
11181433|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
11181434|NCT03512288|Active Comparator|Control|13vPnC
11181435|NCT03512275|Experimental|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
11181436|NCT03512275|Experimental|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
11181437|NCT03512262|Experimental|Abaloparatide (BA058)|Abaloparatide is an active synthetic peptide of parathyroid hormone
11181438|NCT03512262|Placebo Comparator|Placebo|Placebo with no peptide of parathyroid hormone
11181439|NCT03512249|Experimental|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.
~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
11181440|NCT03512249|Placebo Comparator|Placebo|Sterile saline for injection
11181441|NCT03512236|Experimental|BC Pram Ins|Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy
11181442|NCT03512236|Active Comparator|Symlin® and Humulin®|Simultaneous subcutaneous injections avec pramlintide and human insulin
11181443|NCT03512236|Active Comparator|Humalog®|Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy
11181444|NCT03512223|Experimental|Group A (IV dexamethasone)|Perineural (30ml of 0.75% ropivacaine + 0.5 ml normal saline) and IV (9.0 ml normal saline + 1 ml of 10 mg/ml Dexamethasone)
11181445|NCT03512223|Experimental|Group B (IV + perineural dexamethasone)|(IV + perineural dexamethasone): Perineural (30ml of 0.75% ropivacaine + 0.5 ml of 10 mg/ml Dexamethasone) and IV (9.5 ml normal saline + 0.5 ml of 10 mg/ml Dexamethasone)
11181446|NCT03512223|No Intervention|Group C (control with no adjuvant dexamethasone)|Perineural (30ml of 0.75 ropivacaine + 0.5 ml normal saline) and IV (10 ml normal saline)
11181547|NCT03511638|Experimental|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
11181548|NCT03511638|Active Comparator|Alcon VISCOAT®|Ophthalmic viscosurgical device
11181448|NCT03512197|Experimental|Midostaurin + chemotherapy|Participants will receive Midostaurin 50mg twice a day until not achieving CR nor CRi without adequate hematologic recovery for continuation of treatment, intolerable toxicity, relapse or consent withdrawal plus chemotherapy whichever occurs first during induction and consolidation followed by midostaurin monotherapy for 12 cycles of 28 days cycle duration.Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation.
11181449|NCT03512197|Placebo Comparator|Midostaurin Placebo + chemotherapy|Participants will receive matching placebo to midostaurin with same dose, plus chemotherapy. Chemotherapy consists of daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation
11181450|NCT03512184|Other|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
11181451|NCT03512171|Experimental|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in [18F]fallypride binding relative to baseline.
11181452|NCT03512171|Placebo Comparator|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
11181453|NCT03512171|Experimental|[18F]-FE-PE2I|[18F]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
11181454|NCT03512158|Experimental|High NCPAP|Administration of high NCPAP (> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
11181455|NCT03512158|Active Comparator|NIPPV|Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
11181456|NCT03512145|Experimental|VIPUN Balloon Catheter|Recording of gastric motility with the investigational medical device. Gastric emptying rate of a liquid meal is assessed with the 13C-octanoate breath test.
11181457|NCT03512132||control|
11181458|NCT03512132||T1D with normal albumin levels|
11181459|NCT03512132||T1D with macroalbuminuria|
11181460|NCT03512132||T1D with microalbuminuria|
11181461|NCT03512132||T1D with microalbuminuria and statins|
11181462|NCT03512119||Patient|Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
11181463|NCT03512106|Experimental|Acupuncture group|Chinese traditional acupuncture
11181464|NCT03512106|Placebo Comparator|Sham group|Sham
11181465|NCT03512093||Retrospective chart review|
11181466|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
11181467|NCT03512093||Interviews of mothers|
11181468|NCT03512080||Stable International Normalised Ratio|Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
11181469|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
11181470|NCT03512054|Experimental|Experimental procedure|
11181471|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
11181472|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
11181473|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
11181474|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
11181475|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
11181476|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
11181477|NCT03512015|Experimental|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.
~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
11181549|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
11207656|NCT03331627|Placebo Comparator|STR001-IT placebo/STR001- ER placebo|
11181478|NCT03512015|Active Comparator|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
11181479|NCT03512002|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
11181480|NCT03512002|Other|Continued Current Care|Participants will continue their current care.
11181481|NCT03511989|Active Comparator|Bone Borne distractor|The device being investigated, Boneborne distraction appliance
11181482|NCT03511989|Other|Tooth borne distractor|The control device Toothborne distraction appliance
11181483|NCT03511989|No Intervention|Segmental LF1 osteotomy group 1|Control Group, no stabilization of palatal vault
11181484|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 2|Testgroup, biodegradable plate at osteotomy site in palate
11181485|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 3|Testgroup, autologous bonegraft at palatal osteotomy site
11181486|NCT03511976|No Intervention|Business as Usual (BAU)|One-third of participants will be assigned to this condition and will receive academic accommodations and interventions as deemed appropriate by their teachers, school personnel, and parents. This condition is intended to mirror current standard procedures for youth with ADHD. Thus, the specific accommodations and interventions are expected to vary across students. Some students' parents and physicians may choose to start stimulant medication with a goal of improving classroom performance.
11181487|NCT03511976|Experimental|Response to Intervention (RTI): Tier 1|Two-thirds of participants will be assigned to the RTI Tier 1 Arm. Teachers of students in this arm will receive consultation in RTI Tier 1 Classroom Management strategies.
11181488|NCT03511976|Experimental|RTI: Daily Report Card (DRC)|Students assigned to the RTI Tier 1 Arm, who do not respond to the initial RTI Tier 1 Classroom Management strategies, will move to the RTI DRC Arm of the study. Teachers of students in this arm of the study will receive consultation to implement a daily report card.
11181489|NCT03511976|Experimental|RTI: Enhanced|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the RTI: Enhanced Arm. Students in this arm will receive a more intensive classroom behavioral intervention directed at individual target behaviors through an enhanced DRC.
11181490|NCT03511976|Experimental|Medication|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the Medication arm and will receive stimulant medication as an additional intervention.
11181491|NCT03511963|Experimental|HLX04|
11181492|NCT03511963|Active Comparator|Bevacizumab|
11181493|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
11181494|NCT03511937|Other|Neutral Label|
11181495|NCT03511924|Experimental|Intradialytic resistance training|During the 12-week intradialytic training plan subjects will be performed 3 to 5 sets of 3 different lower extremities exercises, each set will consist of 12 up to 18 repetitions of a single exercise. Subjects will take 1 to 2 minutes rest between each set. The resistance training will be realized 3 times per week and will be performed during haemodialysis therapy.
11181496|NCT03511924|No Intervention|Control programme|Control subjects will receive no intervention during the 12-weeks of the experiment. Through the 12-week control period, all participants will be instructed to maintain a standard treatment regimen and to maintain their customary dietary and physical activity patterns.
11181497|NCT03511911|Experimental|GROUP A1|In GROUP A1, participants are all healthy women.A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group A1 will be tested by inspector B twice in the same way as what they have done the first day.
11181498|NCT03511911|Experimental|GROUP A2|In GROUP A2,participants are all healthy women.A gynecological physician evaluates participant's pelvic floor muscle strength by vaginal palpation without telling the participant her result, and records it on a unique paper other than in the Case Report Form as what GROUP A1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group A2 will be tested by inspector A twice in the same way as what they have done the first day.
11181499|NCT03511911|Experimental|GROUP B1|In GROUP B1,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the patient her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,patients in group B1 will be tested by inspector B twice in the same way as what they have done the first day.
11181500|NCT03511911|Experimental|GROUP B2|In GROUP B2,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP B1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,patients in group B2 will be tested by inspector A twice in the same way as what they have done the first day.
11181550|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
11181551|NCT03511612|Other|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
11181552|NCT03511612|Other|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
11181501|NCT03511911|Experimental|GROUP C1|In GROUP C1,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group C1 will be tested by inspector B twice in the same way as what they have done the first day.
11181502|NCT03511911|Experimental|GROUP C2|In GROUP C2,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP C1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group C2 will be tested by inspector A twice in the same way as what they have done the first day.
11181503|NCT03511898|Experimental|THR-149 dose level 1|
11181504|NCT03511898|Experimental|THR-149 dose level 2|
11181505|NCT03511898|Experimental|THR-149 dose level 3|
11181506|NCT03511885||high cardiovascular risk patients|"Coronary patients
~Elective coronary artery bypass surgery (CABG).
~Elective percutaneous coronary intervention (PCI) .
~Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).
~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
11181507|NCT03511872|Experimental|Peers' group|"36 Medical students are allocated randomly to Peers' group where they are trained on BLS skills by senior students.
~Four students from the latest three years of study in medical schools in Syria (4th, 5th, and 6th) are randomly selected and enrolled to be instructors for basic life support training course to transfer the resuscitation skills to medical students from pre-clinical years."
11181508|NCT03511872|Experimental|Professionals' group|36 students are allocated randomly to professionals' group where they are trained on BLS skills by professional trainers in emergency. Four professionals (2 emergency doctors, cardiologist and anesthesiologist) are leading training to the control group to deliver the basic life support training course with the same duration and content as the intervention group.
11181509|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
11181510|NCT03511859||Cancer Group|The biopsy result is breast cancer.
11181511|NCT03511846|Experimental|Oral capsaicin|
11181512|NCT03511846|Sham Comparator|Oral capsaicin and Medical Air|
11181513|NCT03511846|Experimental|Oral Capsaicin and Low Flow Oxygen|
11181514|NCT03511846|Experimental|Oral capsaicin and High Flow Oxygen|
11181515|NCT03511846|Experimental|Topical capsaicin|
11181516|NCT03511846|Sham Comparator|Topical capsaicin and Medical Air|
11181517|NCT03511846|Experimental|Topical capsaicin and Low Flow Oxygen|
11181518|NCT03511846|Experimental|Topical capsaicin and High Flow Oxygen|
11181519|NCT03511846|Experimental|Intranasal capsaicin|
11181520|NCT03511846|Sham Comparator|Intranasal capsaicin and Medical Air|
11181521|NCT03511846|Experimental|Intranasal capsaicin and Low Flow Oxygen|
11181522|NCT03511846|Experimental|Intranasal capsaicin and High Flow Oxygen|
11181523|NCT03511846|Experimental|Cold water irrigation|
11181524|NCT03511846|Sham Comparator|Cold water irrigation and Medical Air|
11181525|NCT03511846|Experimental|Cold water irrigation and Low Flow Oxygen|
11181526|NCT03511846|Experimental|Cold water irrigation and High Flow Oxygen|
11181527|NCT03511833|Active Comparator|Morphine group|Morphine group will receive IV medication and IN saline.
11181528|NCT03511833|Experimental|Ketamine group|Ketamine group will receive IV saline and IN medication.
11181529|NCT03511807|Experimental|Electrical/ Acoustic stimulation|
11181530|NCT03511794||hep B vaccine|1. Patient must have received at least one dose of the hepatitis B vaccine
11181531|NCT03511781|Experimental|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
11181532|NCT03511768|Experimental|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
11181533|NCT03511755|Experimental|TEN 1-11 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-11 kHz)
11181534|NCT03511755|Active Comparator|TEN 1-3 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-3 kHz)
11181535|NCT03511729||A single exposure to general anesthesia|Participants who have surgery under general anesthesia (without anesthesia/surgery before)
11181536|NCT03511729||Multiple exposures to general anesthesia|Participants who have surgery under general anesthesia (had anesthesia/surgery before)
11181537|NCT03511703|Experimental|Apatinib|
11181538|NCT03511703|Other|TACE|
11181539|NCT03511690|Experimental|BRCA-Gist Intervention|Participants randomized to BRCA-gist will complete the adapted intervention. BRCA-gist is a web-based tutoring system that emulates one-to-one human tutoring via avatars to communicate risk of BRCA1/2. We estimate a completion time of 90 minutes.
11181540|NCT03511690|Active Comparator|NCI Arm|Participants randomized to the NCI arm will have up to 90 minutes to read the NCI webpage content that overlaps with BRCA-gist.
11181541|NCT03511677|Experimental|Intervention Group|Customized insole with metatarsal support
11181542|NCT03511677|Placebo Comparator|Control Group|Placebo flat insole
11181543|NCT03511664|Experimental|177Lu-PSMA-617 plus BS/BSC|Patients randomized to receive the investigational product will receive 7.4 GBq (±10%) 177Lu-PSMA-617 intravenously every 6 weeks (±1 week) for a maximum of 6 cycles. + Best supportive/best standard of care (BS/BSOC)
11181544|NCT03511664|Other|BS/BSC alone|Patients randomized to this arm will receive best supportive/best standard of care (BS/BSOC) as determined by the investigator
11181545|NCT03511651|Other|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
11181553|NCT03511599|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
11181554|NCT03511599|Active Comparator|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
11181555|NCT03511560|Active Comparator|Tacrolimus, Immediate release|Tacrolimus (immediate-release) will be administered twice daily per clinical judgment of supervising physician (dosing and monitoring in accordance with center protocol) to a minimum whole blood tacrolimus concentration of at least 8 ng/mL.
11181556|NCT03511560|Experimental|Envarsus XR|Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
11181557|NCT03511547|Active Comparator|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
11181558|NCT03511547|Active Comparator|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
11181559|NCT03511547|No Intervention|Control|
11181560|NCT03511534|Active Comparator|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
11181561|NCT03511534|Active Comparator|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
11181562|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:
~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
11181563|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:
~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
11181564|NCT03511508|Active Comparator|ChroPreg|The participants in the intervention Group receive the midwife-coordinated, individualized and specialized intervention plus standard care
11181565|NCT03511508|No Intervention|Standard care alone|"Participants in the control group receive the standard care for pregnant women with chronic disease.
~The standard care is given to the participants in the control group. The standard care for pregnant women with chronic disease include five routine visits at a non-specialized midwife and an individually scheduled number of visits with an obstetrician, depending on the type and severity of the chronic Medical disease and possible pregnancy complications.
~The women in the control Group have the same amount of ultrasound examinations as do the women in the intervention Group.
~Women in the control Group can attend auditorium antenatal classes at the hospital."
11181566|NCT03511495||Keratoconic Patients|
11181567|NCT03511482|Experimental|MyAsthma Application and Lloyds Pharmacy Online Doctor|Web based applications to support people with Asthma management
11181568|NCT03511482|Experimental|MyAsthma Application and Usual care|Web based application to support people with Asthma Management
11181569|NCT03511482|No Intervention|Usual care only (control)|Usual care of asthma management
11181570|NCT03511469|Experimental|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
11181571|NCT03511469|Experimental|Isokinetic Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
11181572|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
11181573|NCT03511443|Other|Diagnostic performance of hsRDT|Comparing diagnostic power of two diagnostics
11181574|NCT03511417|Experimental|Middle-aged adults|Participants will use an over-the-counter hearing device in one ear until asymptotic speech perception performance is noted (maximum 12 weeks). The same individuals will use over-the-counter hearing devices in each ear until asymptotic performance is noted (the order of these two phases will be randomized across participants). They will be asked to use these devices at least 4 hours/day.
11181575|NCT03511404|Experimental|Chronical LBP|Patients with chronic low back pain to be measured with Numeric Pain Rating Scale (NPRS).
11181576|NCT03511391|Experimental|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:
~Nivolumab or Pembrolizumab or Atezolizumab + SBRT"
11181577|NCT03511391|Active Comparator|Control arm|"Checkpoint inhibitor treatment only:
~Nivolumab or Pembrolizumab or Atezolizumab monotherapy"
11181578|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
11181579|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
11181580|NCT03511365|Experimental|Probiotic administration|After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
11181581|NCT03511352|No Intervention|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
11181582|NCT03511352|Experimental|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
11181583|NCT03511352|Experimental|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
11181584|NCT03511339|No Intervention|Control|Brain rest
11181585|NCT03511339|Experimental|TecTraum Device|Treatment with study device
11181586|NCT03511326|Experimental|Luxerm®|
11181587|NCT03511313|Experimental|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
11181588|NCT03511313|Sham Comparator|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
11181589|NCT03511300|Placebo Comparator|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
11181590|NCT03511300|Experimental|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
11181591|NCT03511287|Experimental|IMT group|"Group intervention: home-based interval inspiratory muscle training:
~during 8 weeks (two sessions per day, daily)
~two times 30 breaths with one-minute rest between them in each session
~training resistance set to the highest tolerable load according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher adjusted in the supervised weekly session"
11181592|NCT03511274|Experimental|Hygiene based educational film|Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
11181593|NCT03511274|No Intervention|Treatment as usual (TAU)|Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.
11181594|NCT03511261|Active Comparator|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel
~Group 1 patients:
~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
11181595|NCT03511261|Active Comparator|Curcumin capsules 500mg|"Group 2 patients:
~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
11181596|NCT03511261|Active Comparator|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:
~Drug: 5% Curcumin mucoadhesive gel & Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
11181597|NCT03511261|Placebo Comparator|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
11181598|NCT03511248|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
11181599|NCT03511248|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
11181600|NCT03511222|Experimental|Dose Escalation: Vorolanib + Nivolumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.
~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle
~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
11181601|NCT03511222|Experimental|Dose Escalation: Vorolanib + Pembrolizumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level
~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle
~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
11181602|NCT03511222|Experimental|Vorolanib + Nivolumab (Small Cell Lung Cancer)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at 300 mg daily
~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle
~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
11181603|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
11181604|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
11181626|NCT03511118||clindamycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181605|NCT03511196|Experimental|Adaptive ADT+ Standard of Care|Participants will undergo 12-16 weeks of GnRH analog, along with 8-12 weeks of combinational therapy with GnRH analog and abiraterone plus prednisone. 14 participants who achieve >75% PSA decline after the run-in period will be enrolled. GnRH analog and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 4 weeks during the run-in period, then every 6 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
11181606|NCT03511183|Experimental|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.
~The second stage: continue to apply another plan until there is progress or intolerance."
11181607|NCT03511183|Placebo Comparator|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
11181608|NCT03511170|Experimental|alternative regiment|The first stage:XELOX chemotherapy and XELIRI chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.
11181609|NCT03511170|Placebo Comparator|classical regiment|Use the XELOX chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI chemotherapy until there is progress or intolerance.
11181610|NCT03511157|Experimental|Ischemic Preconditioning|A standard blood pressure cuff will be placed on the right or left thigh, depending on the affected side, to occlude blood flow. The cuff will be inflated to 225 mmHg to prevent blood flow. Each session will consist of 4 cycles of 5 minute IPC applications, followed by 5 minutes of reperfusion for a total of 35 minutes.
11181611|NCT03511157|Sham Comparator|Control|The sham intervention protocol will be identical to the IPC protocol except blood flow to the affected leg is unchanged as cuff pressure will be raised to between the venous and diastolic pressures
11181612|NCT03511144|Active Comparator|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
11181613|NCT03511144|Active Comparator|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
11181614|NCT03511131|Other|QSE Resp (Only follow)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to no additional treatment, and then followed for the rest of the study.
11181615|NCT03511131|Other|QSE Resp (KIU at 6-month)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to receive Keep It Up (KIU), and then followed for the rest of the study.
11181616|NCT03511131|Other|QSE Non-Resp, KIU-Control Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), responded to KIU-Control at month-6, and then were followed for the rest of the study.
11181617|NCT03511131|Other|QSE Non-Resp, KIU-Control Non-Resp, KIU|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Keep It Up (KIU). After KIU, they were followed for the rest of the study.
11181618|NCT03511131|Other|QSE Non-Resp, KIU Control Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Young Men's Health Project (YMHP). After YMHP, they were followed for the rest of the study.
11181619|NCT03511131|Other|QSE Non-Resp, KIU Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), responded to KIU at month-6, and then were followed for the rest of the study.
11181620|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into no treatment/just follow for the rest of the study.
11181621|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into Young Men's Health Project. After YMHP, they were followed for the rest of the study.
11181622|NCT03511118||Tranexamic acid (TXA)|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181623|NCT03511118||labetalol|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181624|NCT03511118||metformin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181625|NCT03511118||nifedipine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181739|NCT03510572|Experimental|Frontotemporal dementia|frontotemporal dementia Subjects will receive a single IV injection of [18F]PI-2620.
11181627|NCT03511118||oxycodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181628|NCT03511118||azithromycin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181629|NCT03511118||escitalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181630|NCT03511118||sertraline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181631|NCT03511118||ondansetron|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181632|NCT03511118||Ciprofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181633|NCT03511118||Doxycycline|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181634|NCT03511118||Levofloxacin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181635|NCT03511118||Methylphenidate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181636|NCT03511118||Sumatriptan|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181637|NCT03511118||Citalopram|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181638|NCT03511118||Cyclobenzaprine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181639|NCT03511118||Furosemide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181640|NCT03511118||Gabapentin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181641|NCT03511118||Hydrochlorothiazide|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181642|NCT03511118||Hydroxyurea|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181643|NCT03511118||Rosuvastatin|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181644|NCT03511118||Topiramate|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181645|NCT03511118||Trazodone|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181646|NCT03511118||Valganciclovir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181647|NCT03511118||Venlafaxine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181740|NCT03510572|Experimental|Parkinson's disease|Parkinson's disease Subjects will receive a single IV injection of [18F]PI-2620.
11181648|NCT03511118||Verapamil|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181649|NCT03511118||Remdesivir|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181650|NCT03511118||Anakinra|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181651|NCT03511118||Tocilizumab|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181652|NCT03511118||Fluvoxamine|"No intervention, observational study and PK collections The study objectives are to characterize the PK and safety profile of DOIs that are commonly administered to lactating women.
~The primary focus of this analysis will be to determine drug concentrations in breastmilk and to estimate the relative infant dose."
11181653|NCT03511105|Experimental|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
11181654|NCT03511105|Placebo Comparator|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
11181655|NCT03511092|Experimental|HMB-FA|
11181656|NCT03511092|Experimental|HMB-Ca|
11181657|NCT03511092|Experimental|alfa-HICA|
11181658|NCT03511092|Placebo Comparator|Placebo|
11181659|NCT03511079|Experimental|Music|This group will be given a subscription to Pandora Plus for the duration of the study. Beginning two nights before surgery, they will listen to a music playlist they created for 30 minutes prior to going to sleep. This will continue each night with the final time being 6 nights after surgery.
11181660|NCT03511079|No Intervention|Control|This group will not listen to music each night for the duration of the study.
11181661|NCT03511066|Experimental|CT-P27 Dose1|CT-P27 will be administrated once in IV infusion.
11181662|NCT03511066|Experimental|CT-P27 Dose2|CT-P27 will be administrated once in IV infusion.
11181663|NCT03511066|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
11181664|NCT03511053|Experimental|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
11181665|NCT03511040|Experimental|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
11181666|NCT03511027|Experimental|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
11181667|NCT03511027|Active Comparator|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
11181668|NCT03511014|Experimental|microcurrent|
11181669|NCT03511014|Sham Comparator|control|
11181670|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
11181671|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
11181672|NCT03510988|Experimental|Women with newly diagnosed breast cancer|
11181673|NCT03510975|Sham Comparator|Verbal Behavioral Therapy|All children and their parents were instructed only a verbal behavioral therapy
11181674|NCT03510975|Experimental|Check-list|All participants were instructed a behavioral therapy with a written formed check-list for parents to complete
11181675|NCT03510975|Active Comparator|Desmopressin plus verbal therapy|All children in Group III received desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) plus verbal behavioral therapy.
11181676|NCT03510962|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice."
11181703|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
11181776|NCT03510325|Experimental|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
11182409|NCT03505970|Placebo Comparator|Placebo|Individuals will ingest 0.3 g/kg maltodextrin before undergoing exercise
11181677|NCT03510962|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
11181678|NCT03510962|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
11181679|NCT03510962|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will Brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the brushing as an intervention."
11181680|NCT03510962|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
11181681|NCT03510962|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.
~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.
~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
11181682|NCT03510949|Other|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
11181683|NCT03510949|Other|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
11181684|NCT03510936|No Intervention|blue light phototherapy|the patients in this arm will not receive probiotics.
11181685|NCT03510936|Experimental|probiotics concurrent with phototherapy|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks
11181686|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
11181687|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
11181688|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
11181689|NCT03510910|Experimental|Percocet only|
11181690|NCT03510897|Active Comparator|QPI-1002|QPI-1002 Injection, Single dose
11181691|NCT03510897|Placebo Comparator|Placebo|isotonic saline
11181692|NCT03510884|Experimental|Alirocumab|Alirocumab (one of 4 doses, depending on body weight and Q2W or Q4W dose regimens) will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
11181693|NCT03510884|Placebo Comparator|Palcebo|Alirocumab Placebo will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose
11181694|NCT03510871|Experimental|nivolumab plus ipilimumab|
11181695|NCT03510858|Experimental|Intervention group|
11181696|NCT03510858|Other|Control group with crossover|Participants in the control group will receive the intervention after 12 months, cross-over design
11181697|NCT03510845|Experimental|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
11181698|NCT03510845|Other|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
11181699|NCT03510832||STEMI patients undergoing Emergent PCI|
11181700|NCT03510806|Placebo Comparator|Placebo|taste, color, and calorie-matched to supplement
11181701|NCT03510806|Experimental|Supplement|Proprietary protein and fruit extract blend
11181702|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
11182755|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
11181704|NCT03510780|Active Comparator|EMD treated patients|"Periodontal surgery with Enamel Matrix Derivative is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers EMD will be applied to the entire root surfaces ; then, ABG will be applied alternatively with EMD into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositionated and sutures completed by interrupted sutures."
11181705|NCT03510780|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
11181706|NCT03510767|Experimental|TQ-B3525|
11181707|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
11181708|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
11181709|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
11181710|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
11181711|NCT03510728|No Intervention|No single-session intervention-EMA|Participants will be assessed both using a computer and using their phone. However, they will not receive an intervention at the start of the study and will only be using their phone for ecological assessment only data collection.
11181712|NCT03510728|Active Comparator|Standard single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will interact with their phone only for assessment purposes.
11181713|NCT03510728|Experimental|Augment single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will interact with their phone only for assessment purposes.
11181714|NCT03510728|Experimental|No single-session intervention-EMI|Participants in this group will not take a single-session intervention at baseline, but will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
11181715|NCT03510728|Experimental|Standard single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
11181716|NCT03510728|Experimental|Augment single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
11181717|NCT03510715|Experimental|Alirocumab|All patients will receive subcutaneously (SC) (one of 2 doses, depending on body weight) alirocumab Q2W at entry on top of background treatments.
11181718|NCT03510702||Periodontal patients.|Taking gingival Crevicular fluid.
11181719|NCT03510702||Periodontally healthy patients.|Taking gingival Crevicular fluid.
11181720|NCT03510689||Group 1|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
11181721|NCT03510689||Group 2|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer does not include anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
11181722|NCT03510689||Group 3|Subjects with genetic testing confirming no mutation in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
11181723|NCT03510676|Experimental|NiTiDES|Single arm
11181724|NCT03510663|Experimental|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
11181725|NCT03510663|Experimental|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
11181726|NCT03510663|Active Comparator|Moxifloxacin|400mg tablet will be administrated once a week.
11181727|NCT03510663|Placebo Comparator|Placebo|Placebo will be intravenously administered once a week.
11181728|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH [anticipated]
11181729|NCT03510624|Experimental|First rebaudioside A and then placebo|
11181730|NCT03510624|Experimental|First placebo and then rebaudioside A|
11181731|NCT03510611|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
11181732|NCT03510611|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
11181733|NCT03510598|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental area with a new applicator design.
11181734|NCT03510598|Experimental|Drug Treatment for Fat Reduction|Kybella will be used after two treatments with the ZELTIQ applicator.
11181735|NCT03510585|Experimental|saline and sniffing|This RRC is the combination of positioning (laying down), sniffing (only one side), throat vibration and saline instillation. And then the other side.
11181736|NCT03510585|Placebo Comparator|sniffing|Pacient will be in a lay down condition and will perform sniffing with throat vibration several times each side (but with no saline instillation)
11181737|NCT03510572|Experimental|Healthy volunteer|Cognitively healthy subjects will receive a single IV injection of [18F]PI-2620.
11181741|NCT03510559|Active Comparator|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
11181742|NCT03510559|Experimental|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
11181743|NCT03510546|Experimental|Active|"De-novo: Each capsule contains 60 mg. pyridostigmine. 1 capsule is administered twice within 4 hours.
~Chronic: Each capsule contains 60 mg. pyridostigmine. Number of administered capsules per dosage depend on the patient's usual dosage. Study drug is administered twice within 4 hours.
~Patients are examined/rated before 1st dose, 1 hour after 1st dose, 1 hour after 2nd dose (Visit 1). After cross-over (Visit 2), patients will be rated open-label at 1 month (Visit 3) and 3 months (Visit 4)."
11181744|NCT03510546|Placebo Comparator|Placebo|"Same as Active, however capsules contain placebo."
11181745|NCT03510533|Experimental|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
11181746|NCT03510533|Other|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
11181747|NCT03510520|Experimental|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
11181748|NCT03510520|Active Comparator|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
11181749|NCT03510494|Experimental|Intervention|Trebling of weekly curricular physical education (270 minutes per week)
11181750|NCT03510494|No Intervention|Control|Standard curriculum physical education (90 minutes per week)
11181751|NCT03510481|Experimental|Arm 1|Arm 1: (n=70) will receive 3 doses of PfSPZ Vaccine via DVI at 0, 8, and 16 weeks.
11181752|NCT03510481|Experimental|Arm 2|(N=70) Will receive 3 doses of PfSPZ
11181753|NCT03510481|Placebo Comparator|Arm 3a|(N=35) Will be the control Arm 1. Volunteers will receive 3 doses of placebo saline injection via DVI at 0, 8 and 16 weeks.
11181754|NCT03510481|Placebo Comparator|Arm 3b|(N=35) Will be the control Arm 2. Volunteers will receive 3 doses of placebo saline injection via DVI at 0, 1 and 4 weeks.
11181755|NCT03510468|Experimental|1|(1) TAF once daily alone (days 1-14) and (2) TAFonce daily + weight-based RPT + INH (withpyridoxine) once weekly (days 15-31)
11181756|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
11181757|NCT03510442||adult-onset Still's disease (AOSD)|Composed of patients with known or suspected AOSD as defined by Yamaguchi criteria.
11181758|NCT03510442||family members|Composed of family members of patients with systemic juvenile idiopathic arthritis, adultonset Still's disease and related conditions.
11181759|NCT03510442||healthy volunteers|Composed of healthy adults and children (above the age of 6 years) who volunteer to participate in this protocol.
11181760|NCT03510442||related inflammatory conditions|Composed of patients with suspected inflammatory disease as indicated by thepresence of episodic fever and/ or arthritis.
11181761|NCT03510442||systemic juvenile idiopathic arthritis (sJIA)|Composed of patients with known or suspected sJIA as defined by the international league of Associations for Rheumatology (ILAR) criteria
11181762|NCT03510429|Active Comparator|Routine post-op care|Routine post-op care (N=20)
11181763|NCT03510429|Experimental|Routine post-op care with Nutritional supplement|Routine post-op care + Nutritional supplement by specific product (N=20)
11181764|NCT03510416|Experimental|apatinib combined with TACE|Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.
11181765|NCT03510403|Experimental|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
11181766|NCT03510390|Experimental|Metformin|Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
11181767|NCT03510377|Experimental|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
11181768|NCT03510377|Experimental|On-land physical intervention|On-land physical intervention: Tai-Chi
11181769|NCT03510377|Experimental|Non physical intervention|Non physical intervention: Guided imagery
11181770|NCT03510364|Experimental|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
11181771|NCT03510351||Treated subjects|All patients with Pseudomonas infections treated with ceftolozane-taezobactam who meet the inclusion criteria
11181772|NCT03510338|Experimental|Sublingual sildenafil (fasted)|Subjects receive a single dose of 100 mg sildenafil
11181773|NCT03510338|Active Comparator|Oral sildenafil (fed)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
11181774|NCT03510338|Experimental|Sublingual sildenafil (fed)|Subjects receive a single dose of 100 mg sildenafil
11181775|NCT03510338|Active Comparator|Oral comparator (fasted)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
11182756|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
11181777|NCT03510325|Experimental|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
11181778|NCT03510325|Experimental|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
11181779|NCT03510325|Experimental|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
11181780|NCT03510325|Experimental|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
11181781|NCT03510312||Long-term follow up, observational|This cohort does not involve interventions, just follow up of prognosis of ischemic stroke/transient ischemic attack patients.
11181782|NCT03510299|Placebo Comparator|Control group|
11181783|NCT03510299|Experimental|McGrath group|
11181784|NCT03510286||Pregnant women|Pregnant women attending ANC clinics in Techiman Holy Family Hospital and Kintampo North and South districts (all hospitals and clinics inclusive where ANC services are provided) are the primary participant group- primarily women of reproductive age. Pregnant women attending routine ANC will be enrolled. In addition to routine ANC, pregnant women will be tested with the Test-it™ PrCr Urinalysis Strips. Pregnant women are a potentially vulnerable population whose participation in this research is necessary given the target use case for this diagnostic tool: providing reliable and accurate point of care screening of proteinuria in ANC settings. The legal age of consent in Ghana is 18 years and women under the age of 18 will not be recruited for this study.
11181785|NCT03510273|Other|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
11181786|NCT03510260|Placebo Comparator|Control Group|Subject will undergo regular consenting only. At our unit consent for an elective cesarean delivery occurs in the same day of surgery, few hours before the procedure in a private room in labor and delivery while awaiting surgery. The COMRADE questionnaire (our primary outcome) will be obtained after the completion of the paper consent form.
11181787|NCT03510260|Experimental|Study Group I|Subject will receive an electronic invitation to complete the consent process electronically and will proceed through the Confirmed Consent system prior to arrival to labor and delivery on day of surgery, which is the routine patient flow at this time. The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group) before the completion of the paper consent form, in order to assess satisfaction and understanding of the e-confirmed consenting process completed before the procedure. After completion of the survey, the subject will sign the regular paper consent for the procedure as standard in our institution.
11181788|NCT03510260|Experimental|Study Group II|Subject will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent is obtained in order to assess whether both methods combined together improve the subjects' satisfaction of the consenting methods and better understanding of the surgical procedure.
11181789|NCT03510221|Active Comparator|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
11181790|NCT03510221|Placebo Comparator|Placebo|Subjects received 3 placebo capsules during 4 weeks.
11181791|NCT03510208|Experimental|Cohort 1 -50mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
11181792|NCT03510208|Experimental|Cohort 2 -100mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
11181793|NCT03510208|Experimental|Cohort 3 -100mg panitumumab-IRDye800|Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery
11181794|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
11181795|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
11181796|NCT03510169|Experimental|NeoVest|Negative pressure ventilation using NeoVest
11181797|NCT03510156|Experimental|Treatment|
11181798|NCT03510156|No Intervention|Observation|
11181799|NCT03510143|No Intervention|Control|No use of Neoveil in the neck node dissection area
11181800|NCT03510143|Experimental|Neoveil|Use of Neoveil in the neck node dissection area
11181801|NCT03510130|Experimental|Routine leg movement|Intervention group- In the second stage of labor, attending physician or nurse will help the participant in routine leg movements every 20-30 minutes.
11181802|NCT03510130|No Intervention|Control group|Control group which includes women during the second stage of labor with no intervention (routine leg movement).
11181803|NCT03510117|Other|Mindfulness|Mindfulness
11181804|NCT03510104|Experimental|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
11181805|NCT03510091|Experimental|Video-Assisted Counseling|Patients receiving video-assisted counseling
11181806|NCT03510078|Experimental|Intensive glycemic control|With a target of blood glucose range of 130 mg/dL or less
11181807|NCT03510078|Experimental|Conventional glycemic control|With a target of blood glucose range of 130-180 mg/dL
11181808|NCT03510052|Other|Diet Modification Pilot Program|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
11181809|NCT03510039|Active Comparator|"Before Group"|35 Thirds benefiting from the usual care
11181811|NCT03510026|Other|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
11181812|NCT03510013|Experimental|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
11181813|NCT03510000|Experimental|Main arm|Single arm open-label cross-over study with random order of SGLT-2 inhibitor intervention (Empagliflozin 25mg po qd), in which each cross-over phase includes different meal strategies (carbohydrate counting, meal announcement, no meal announcement) on separate days in the setting of single hormone artificial pancreas
11181814|NCT03509987|Other|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
11181815|NCT03509974|Experimental|Bone Anchored Hearing Device (OSIA)|All subjects will receive the Bone Anchored Hearing Device (OSIA)
11181816|NCT03509961|Other|Observational Arm|"Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.
~If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome."
11181817|NCT03509961|Other|Treatment Arm|Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.
11181818|NCT03509948|Experimental|Schedule A: Fed Then Fasted|"Schedule A (6 participants):
~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)
~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
11181819|NCT03509948|Experimental|Schedule B: Fasted Then Fed|"Schedule B (6 participants):
~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)
~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
11181820|NCT03509935|Experimental|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:
~In the first 6 to 12 hours of admission to ICU
~Second US after 12-24 hours of inclusion.
~Third US after 24-48 hours of inclusion.
~Protocol:
~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.
~US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.
~Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.
~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
11181821|NCT03509935|No Intervention|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
11181822|NCT03509922|Experimental|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
11181823|NCT03509922|Experimental|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
11181824|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
11181825|NCT03509909|Active Comparator|Supportive physical activity|12-week group-based stretching and strengthening class
11181826|NCT03509896||Participants newly diagnosed with CML-CP|
11181827|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
11181828|NCT03509883|Active Comparator|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
11181829|NCT03509870|Other|mesenchymal stromal cells|mesenchymal stromal cells in collagen scaffold
11181830|NCT03509857|Placebo Comparator|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
11181831|NCT03509857|Experimental|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
11181832|NCT03509844|Experimental|Prolonged Exposure|Psychotherapy: 10 weeks, Prolonged Exposure (individual sessions) according to the manual developed by Foa et al., adapted for a residential care setting
11181833|NCT03509844|Experimental|STAIR|Psychotherapy: 10 weeks, Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting
11181834|NCT03509844|Experimental|STAIR/NT|Psychotherapy: 16 weeks, 10 weeks Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), followed by 6 weeks of Narrative Therapy (NT) (individual sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting.
11181835|NCT03509831|Other|INT2150-A|
11181836|NCT03509831|Other|INT2150-B|
11181837|NCT03509818|Experimental|Plyometric|Effects of plyometric acute exercise
11181838|NCT03509818|Experimental|Aerobic|Effects of aerobic acute exercise
11181839|NCT03509805|Experimental|OSA in obese patient during pregnancy|OSA in polysomnography
11181840|NCT03509805|Experimental|no OSA in obese patient during pregnancy|no OSA in polysomnography
11181841|NCT03509792|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
11181842|NCT03509792|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
11181843|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
11181844|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
11181845|NCT03509753|Experimental|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
11182527|NCT03505112|No Intervention|Control group|The patients in control group will be managed according to standard perioperative care.
11181846|NCT03509753|Active Comparator|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
11181847|NCT03509740|Experimental|tramadol|Intravenous 100 mg tramadol in 100 ml saline with slow infusion over 10 minutes.
11181848|NCT03509740|Active Comparator|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion over 10 minutes.
11181849|NCT03509714|Active Comparator|Experimental: Part 1 Oxaloacetate Random|Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
11181850|NCT03509714|Active Comparator|Experimental: Part 2 Oxaloacetate Second|Participants take 2 capsules of 250 mg rice flour (Placebo) per day during their entire menstrual cycle (approximately 28 days). After one menstrual cycle, they cross-over to 2 capsules of Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend.
11181851|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
11181852|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
11181853|NCT03509688|Experimental|entecavir|drug:entecavir 0.5mg/day, one time/day,144weeks
11181854|NCT03509688|Experimental|entecavir+resveratrol|entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks
11181855|NCT03509688|Experimental|entecavir+thymosin α1|entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks
11181856|NCT03509675|Placebo Comparator|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
11181857|NCT03509675|Active Comparator|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
11181858|NCT03509662|Placebo Comparator|Placebo group|Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
11181859|NCT03509662|Active Comparator|Vitamin C - 3 gr/day|Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
11181860|NCT03509662|Active Comparator|Vitamin C - 10 gr/day|Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
11181861|NCT03509649|Experimental|Experienced - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from an experienced clinician
11181862|NCT03509649|Experimental|Experienced - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from an experienced clinician
11181863|NCT03509649|Active Comparator|Novice - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from a novice clinician
11181864|NCT03509649|Active Comparator|Novice - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from a novice clinician
11181865|NCT03509636|Experimental|Treatment|Fluzoparib capsule
11181866|NCT03509623|Experimental|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
11181867|NCT03509610|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
11181868|NCT03509610|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
11181869|NCT03509610|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
11181870|NCT03509597|Experimental|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
11181871|NCT03509597|Experimental|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
11181872|NCT03509597|Sham Comparator|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
11181873|NCT03509584|Experimental|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
11181874|NCT03509584|Experimental|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
11181875|NCT03509584|Experimental|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
11181876|NCT03509584|Experimental|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
11181908|NCT03509428|Experimental|SRETP and psychological support|Structured Responsive Exercise Training Programme (SRETP) and psychological support prior to surgery
11181877|NCT03509571|Experimental|Ketogenic Diet Group|Ketogenic diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that included ≈72% total energy as fat, ≈25% as protein, and ≈3% as carbohydrate during enteral feeding and ≈65% total energy as fat, ≈27% as protein, and ≈8% as carbohydrate and fiber during solid feeding. Patients will start receiving ketogenic diet within the 72 hours injury, after completing their baseline measurements.
11181878|NCT03509571|Other|Standard Diet Group|Patients will start to receive standard hospital diet within 72 hours of injury after completing their baseline measurements. Standard diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
11181879|NCT03509558|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
11181880|NCT03509558|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
11181881|NCT03509545|Experimental|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
11181882|NCT03509545|Active Comparator|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
11181883|NCT03509519|Experimental|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
11181884|NCT03509519|Sham Comparator|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
11181885|NCT03509506|No Intervention|Non-App Group|"The participants will be instructed to continue their daily routine, track their daily steps with a pedometer, and record their daily steps on the Activity Log paper form."
11181886|NCT03509506|Experimental|App Group|The participants will be trained how to use the mobile application (Heart Failure Health Storyline (HFHS)) to track their health status, physical activity, manage their medications schedule, and explore the other features that the application has. Additionally, they will receive a pedometer to track their daily steps and record their data on the mobile application.
11181887|NCT03509493||Patients without structural heart disease|
11181888|NCT03509493||Patients with structural heart disease|
11181889|NCT03509493||Patients with high risk parameters for AF development|
11181890|NCT03509493||Patients post-cryptogenic stroke|
11181891|NCT03509493||Patients post-cardioversion therapy|
11181892|NCT03509493||Patients post-ablation therapy|
11181893|NCT03509480|Active Comparator|Curettage with Vitoss|ultraporous beta-tricalcium phosphate mixed with autologous bone marrow aspirate for patients undergoing surgical curettage for benign bone lesions
11181894|NCT03509480|Active Comparator|Curettage with Prodense|ultraporous beta-tricalcium phosphate mixed with calcium sulfate for patients undergoing surgical curettage for benign bone lesions
11181895|NCT03509467|Experimental|Intervention Group A|"Intervention Group A: Non-Hispanic White Population
~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.
~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
11181896|NCT03509467|Experimental|Intervention Group B|"Intervention Group B: Hispanic Population
~Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma.
~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk."
11181897|NCT03509467|Placebo Comparator|Control Group A|"Control Group A: Non-Hispanic White Population
~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.
~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
11181898|NCT03509467|Placebo Comparator|Control Group B|"Control Group B: Hispanic Population
~Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma.
~By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma."
11181899|NCT03509454||Type 1 DM, Normo albuminuric|Type 1 diabetics with no history of albumnuria (UACR < 30 mg/g in 2 out of 3 consecutive samples)
11181900|NCT03509454||Type 1 DM, Micro albuminuric|Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
11181901|NCT03509454||Type 1 DM, Macro albuminuric|Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
11181902|NCT03509454||Healthy subjects|Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.
11181903|NCT03509441||South Asians with Insulin Resistance|125 patients (anticipated)
11181904|NCT03509441||South Asians without Insulin Resistance|125 patients (anticipated)
11181905|NCT03509428|No Intervention|Control|Usual care plus additional monitoring
11181906|NCT03509428|Experimental|SRETP|Structured Responsive Exercise Training Programme (SRETP) prior to surgery
11181937|NCT03509233|Experimental|FMS|Full mouth scaling and root planing
11181909|NCT03509402|Experimental|Short implants|A full-arch screw-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6mm)
11181910|NCT03509402|Active Comparator|Long implants|A full-arch srew-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
11181911|NCT03509376|Experimental|Suture repair|Diastasis recti is repaired using nylon suture for the plication
11181912|NCT03509376|Experimental|Rolled mesh repair|Diastasis recti is repaired with self gripping mesh to reinforce the suture line
11181913|NCT03509363|Experimental|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
11181914|NCT03509363|No Intervention|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
11181915|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
11181916|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
11181917|NCT03509324|Other|duration of disease|different duration of disease receive insulin LISPRO
11181918|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.
~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
11181919|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
11181920|NCT03509298|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11181921|NCT03509298|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11181922|NCT03509298|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11181923|NCT03509285|Placebo Comparator|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
11181924|NCT03509285|Active Comparator|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
11181925|NCT03509285|Placebo Comparator|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
11181926|NCT03509285|Active Comparator|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
11181927|NCT03509285|Active Comparator|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
11181928|NCT03509285|Experimental|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
11181929|NCT03509285|Experimental|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
11181930|NCT03509272|No Intervention|Control Group|
11181931|NCT03509272|Experimental|remote monitoring group|
11181932|NCT03509259||Asthma|"If the doctor has been diagnosed with asthma and one or more of the following criteria is met;
~FEV1 (Forced expiratory volume in 1 second) increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)
~Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)
~FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer."
11181933|NCT03509259||Asthma-COPD overlap (ACO)|Satisfy the diagnostic criteria of asthma described above + post-bronchodilator FEV1/FVC (forced vital capacity) ratio < 70%
11181934|NCT03509259||Healthy control|Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)
11181935|NCT03509246|Experimental|Pegylated liposomal doxorubicin plus Bortezomib combination|At BRCA wild-type platinum-resistant recurrent ovarian cancer patients, Pegylated liposomal doxorubicin and Bortezomib combination therapy for six cycles.
11181936|NCT03509233|Active Comparator|Q-SRP|Quadrant scaling and root planing
11181943|NCT03509194||Pediatric liver disease patients|Comparison of outcome of pediatric liver disease and prognostic functional liver test results and gene expression in liver biopsies.
11181944|NCT03509181|Experimental|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
11181945|NCT03509181|Active Comparator|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
11181946|NCT03509168|Active Comparator|Misoprostol Pfizer Brand arm|participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy
11181947|NCT03509168|Other|No misoprostol arm|standard of care
11181948|NCT03509155|No Intervention|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
11181949|NCT03509155|Active Comparator|National portion & IYCF counseling|The second arm as the national portion & IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
11181950|NCT03509155|Experimental|Adjusted portion & local food counseling|the third arm as the adjusted portion & local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
11181951|NCT03509142|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to queue 1 (n=30) and queue 2 (n=15) as well as queue 3(n=20)
11181952|NCT03509129|Active Comparator|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
11181953|NCT03509129|Experimental|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
11181954|NCT03509116||Patient group 1|Observations only
11181955|NCT03509116||Patient group 2|Qualitative interview, key stakeholders, documentary analysis
11181956|NCT03509103|Experimental|Electronic partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.
~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
11181957|NCT03509103|Active Comparator|Paper Partograph|An standard training on how to use and fill out partograph was conducted
11181958|NCT03509090|Active Comparator|ESP block group|Unilateral ESP block will be applied as postoperative regional analgesia technique in addition to the multimodal therapy. Then she is positioned in a right lateral position to perform ESP blocks. The skin will be disinfected and ESP block at one side will be performed in the lateral decubitus position and at T4 transverse process level by using 10-MHz linear ultrasound probe (Logic Ebook XP General Electrics, USA). The probe will be located 3 cm lateral to T4 spinous process in longitudinal parasagittal orientation. An 8 cm 21 gauge needle (BRAUN Stimuplex A®, Germany) will be inserted by using out of the plane technique. The ESP blocks proceed with 15 ml of 0,25% bupivacaine, 7,5 ml 1 % lidocaine, ,7,5 ml 0,9 % NaCl as total 30 ml . The injections will be applied after the confirmation of location by hidrodisection developed anterior to erector spinae muscle with 1-2 ml of local anesthetic solution.
11181959|NCT03509090|Active Comparator|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia prepared with tramadol. Patient-controlled analgesia (PCA) with tramadol at 3mg/cc concentration is programmed with no basal infusion, demand dose 10 mg and 20-minute lock-out interval. Also, patients received 1 gr paracetamol in every 6 hours.
11181960|NCT03509064||1: Patients with small fiber neuropathy|patients with Sjogren syndrome have a definite small fiber neuropathy
11181961|NCT03509064||2: Patients without peripheral neuropathy|patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)
11181962|NCT03509051|Experimental|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
11181963|NCT03509038|Experimental|Urinary incontinence before bariatric surgery|All patients with urinary incontinence before bariatric surgery will be addressed for a urodynamic exam
11181964|NCT03509025|Experimental|Long Term Follow-up after Jointstem Transplantation|
11181965|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
11181966|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
11181967|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
11181968|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
11181969|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
11181970|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
11181971|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
11181972|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
11181973|NCT03508999|Experimental|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
11181974|NCT03508999|Other|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
11181975|NCT03508999|Placebo Comparator|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
11181976|NCT03508973|Experimental|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
11181977|NCT03508947|Experimental|WVE-210201 (Dose A) or placebo|
11181978|NCT03508947|Experimental|WVE-210201 (Dose B) or placebo|
11181979|NCT03508947|Experimental|WVE-210201 (Dose C) or placebo|
11181980|NCT03508947|Experimental|WVE-210201 (Dose D) or placebo|
11181981|NCT03508947|Experimental|WVE-210201 (Dose E) or placebo|
11181982|NCT03508934|Active Comparator|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
11181983|NCT03508934|Placebo Comparator|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
11181984|NCT03508921|Experimental|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
11181985|NCT03508921|Experimental|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
11181986|NCT03508908|No Intervention|Observation Period|HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
11181987|NCT03508908|Active Comparator|Intervention Period|Combination intervention with HIV-1 RNA testing followed by rapid tests if positive for HIV diagnosis, immediate ART if diagnosed, assisted partner notification with HIV-1 RNA testing of partners, and PrEP for uninfected partners in discordant relationships.
11181988|NCT03508895|Experimental|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
11181989|NCT03508895|Experimental|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
11181990|NCT03508895|Active Comparator|Casein protein|25 grams of protein powder, twice a day
11181991|NCT03508882|Active Comparator|Preseptal-pretarsal|The Preseptal-pretarsal group will receive injections of Botulinum Toxin Type A 100Unit/Vial (Product) in the preseptal site (Injection pattern A) and Saline Solution for Injection (placebo control) in the pretarsal site for 2 cycles at 3 months apart. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
11181992|NCT03508882|Active Comparator|Pretarsal-preseptal|The Pretarsal-preseptal group will initially receive injections Botulinum Toxin Type A 100Unit/Vial (Product) in the reverse with the intervention at the pretarsal site (Injection pattern B) for 2 cycles at 3 months apart. Groups 1 and 2 will crossover and receive the alternative intervention. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
11181993|NCT03508869|Active Comparator|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
11181994|NCT03508869|Active Comparator|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
11181995|NCT03508869|Active Comparator|Dysport® in conjunction with Mirvaso|Dysport® in conjunction with Mirvaso
11181996|NCT03508856|Experimental|Picato 0.015% gel|Picato 0.015% gel, is a topical treatment for actinic ketatoses.
11181997|NCT03508843|Experimental|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
11181998|NCT03508830|Experimental|Liposomal Bupivacaine|
11181999|NCT03508830|Active Comparator|Standard Bupivacaine|
11182000|NCT03508817|Experimental|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
11182001|NCT03508817|No Intervention|Control group|Control group will not receive any medication.
11182002|NCT03508804|Experimental|Lidocaine-prilocaine cream|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the lidocaine-prilocaine cream vaginally using a syringe
11182003|NCT03508804|Placebo Comparator|Placebo cream (pain lucubrating gel)|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the placebo cream vaginally using a syringe
11182004|NCT03508791|Active Comparator|Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the Trendelenberg position
11182005|NCT03508791|Active Comparator|reverse Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the reverse Trendelenberg position
11182006|NCT03508765|Experimental|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
11182007|NCT03508752|Experimental|Radiation|Stereotactic Radiosurgery
11182008|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
11182009|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
11182010|NCT03508726|Experimental|Phase I dose escalation/Phase II portion|"Phase 1 dose escalation:
~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
~Phase II portion:
~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation."
11182011|NCT03508713||early RA patients|patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
11182012|NCT03508700|Experimental|TNX-102 SL 5.6 mg|2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
11182013|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
11182014|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
11182015|NCT03508674|Experimental|Intervention|Levita Magnetic Surgical System
11182016|NCT03508661|Experimental|SPIN-SSLED Program|13-session SPIN-SSLED Program
11182017|NCT03508648|Placebo Comparator|Matching Placebo|Subjects previously enrolled in the placebo arm of study G201002.
11182018|NCT03508648|Active Comparator|1 mg GTx-024|Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
11182019|NCT03508648|Active Comparator|3 mg GTx-024|Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
11182020|NCT03508635|Experimental|SAD Cohorts 1 through 6|Participants will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
11182021|NCT03508635|Placebo Comparator|SAD Cohorts 1 through 6 Placebo|Participants will receive single doses of Matching Placebo of CORT125134 (capsule).
11182022|NCT03508635|Experimental|Food Effect Cohort 7|Participants will receive a single dose of CORT125134 (capsule) with a standard high fat breakfast. The dose will be chosen such that it has been previously administered in a prior SAD cohort.
11182023|NCT03508635|Experimental|Pharmacological Effect Cohort 8|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
11182024|NCT03508635|Experimental|Proof of Concept (POC) Cohort 9|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg of prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. An oral glucose tolerance test will be administered on each study day. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
11182025|NCT03508635|Experimental|MAD Cohorts 10 and 11|Participants will receive the selected dose of CORT125134 (capsule) following receipt of data from Cohorts 1-9 up to a maximum frequency of twice a day for a total of 14 days.
11182026|NCT03508635|Placebo Comparator|MAD Cohorts 10 and 11 Placebo|Participants will receive Matching Placebo of CORT125134 (capsule) up to a maximum frequency of twice a day for a total of 14 days.
11182027|NCT03508635|Experimental|MAD of PoPE Cohorts 12 and 13|Proof of Pharmacological Effect (PoPE+POC). Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the selected dose of CORT125134 (capsule) for a total of 13 days. Participants may either receive a higher dose level than previously administered or a repeat of a dose level given in 1 of the previous 2 MAD Cohorts. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
11182028|NCT03508635|Placebo Comparator|MAD of PoPE Cohort 12 and 13 Placebo|Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the Matching Placebo of CORT125134 (capsule) for a total of 13 days. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
11182029|NCT03508622|Experimental|Telehealth|This group will receive weight management treatment via 12 online group sessions, over 6 months. They will have Bluetooth-enabled scales that will allow them to transmit their weight data to the PI in between research visits. They will answer questionnaires and have research visits at baseline, 3 months, and 6 months.
11182030|NCT03508622|Other|Empower|This retrospective control group received standard in-clinic individualized weight management with a multi-disciplinary group of providers, via 6 monthly clinic visits, over 6 months.
11182031|NCT03508609|Experimental|Autologous CD34 cells|Open label active treatment arm. Subjects receive autologous CD34 cells.
11182032|NCT03508596|Experimental|Intervention|"Intervention group (IG)
~An educational intervention for the supervisors"
11182033|NCT03508596|No Intervention|Control|control group (CG)
11182034|NCT03508596|No Intervention|Non-Intervention|group without intervention (GWI)
11182035|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary
~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
11182036|NCT03508570|Experimental|Group I (nivolumab)|Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11182037|NCT03508570|Experimental|Group II (nivolumab and ipilimumab)|Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11182038|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
11182039|NCT03508544|Active Comparator|Lumbar ESP block|Ultrasound-guided lumbar Erector spinae plane (ESP) block performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
11182040|NCT03508544|Active Comparator|QLB Block|Ultrasound-guided transmuscular quadratus lumborum block (QLB) performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
11182041|NCT03508544|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11182042|NCT03508531|Active Comparator|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11182043|NCT03508531|Active Comparator|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11182044|NCT03508531|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
11182045|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
11182046|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :
~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
11182047|NCT03508492|Active Comparator|Knee surgeons|Four knee surgeons
11182048|NCT03508492|Active Comparator|Hip surgeons|Six hip surgeons
11182049|NCT03508492|Active Comparator|Cardiac surgeons|6 cardiac surgeons
11182050|NCT03508492|Active Comparator|Colon surgeons|6 colon surgeons
11182051|NCT03508479|Experimental|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
11182052|NCT03508466||Group 1|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject)
11182053|NCT03508466||Group 2|adult participants from 18-65 years of age previous intravenous ferric carboxymaltose (Ferinject) and no hypersensitivity reaction
11182054|NCT03508466||Group 3|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to iron sucrose (Venofer)
11182055|NCT03508466||Group 4|adult participants from 18-65 years of age previous intravenous iron sucrose (Venofer) and no hypersensitivity reaction
11182056|NCT03508453|Active Comparator|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
11182057|NCT03508453|Placebo Comparator|Placebo|Placebo intravenously twice weekly for 12 weeks
11182058|NCT03508440|Active Comparator|Standard of Care|Oral steroids (prednisone or prednisolone) 60mg per day for 10 days or 60mg/day for 5 days followed by a 5 day taper
11182059|NCT03508440|Experimental|SOC + injection|Oral steroids as described above + intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks.
11182060|NCT03508440|Other|Injection only|Only Intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks
11182061|NCT03508427|Experimental|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
~Tool: Toi Même mobile app"
11182062|NCT03508414|Experimental|Ketogenic diet|
11182064|NCT03508414|Active Comparator|Control group|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
11182065|NCT03508401|Experimental|ICU intubated patients|"After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR
~Patients will be classified in two groups according to the hemodynamic response to PLR :
~Patients are responders if LVOT VTI increases of at least 10% after PLR
~patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR."
11182066|NCT03508375|Experimental|SSc without ILD|
11182067|NCT03508375|Experimental|SSc with ILD|
11182068|NCT03508375|Active Comparator|patients with idiopathic pulmonary fibrosis|
11182069|NCT03508362|Experimental|Drug user|Regular use of cocaine
11182070|NCT03508362|Active Comparator|Healthy volunteers|non-drug user
11182071|NCT03508349|Experimental|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
11182072|NCT03508349|No Intervention|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
11182073|NCT03508336||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
11182074|NCT03508323|Experimental|Teneligliptin|
11182075|NCT03508323|Placebo Comparator|Placebo|
11182076|NCT03508310|Experimental|Intervention|29-minute clinic waiting room video intervention that includes three vignettes and a 2-part animation sequence about main characters who model overcoming challenges to optimal HIV care. The video was played on continuous loop in recognition of typically short patient wait times. Waiting room posters used images from the video to direct patients' attention to the video and reinforce prevention messages.
11182077|NCT03508310|No Intervention|Comparison|Historical comparison condition. Patients were exposed to standard waiting room environment (absent of intervention video and posters).
11182078|NCT03508284||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
11182079|NCT03508284||Healthy group|Healthy individuals without chronic disease
11182080|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
11182081|NCT03508258||Participants with NVAF starting Apixaban|
11182082|NCT03508258||Participants with NVAF starting Warfarin|
11182083|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength light therapy
11182084|NCT03508232|Placebo Comparator|Placebo control|Two placebo capsules upon enrollment, followed by one placebo capsule p.o. every 12 hours for 7 days
11182085|NCT03508232|Experimental|Doxycycline hyclate|Two 100mg doxycycline capsules (200 mg) p.o. upon enrollment, followed by one 100 mg capsule p.o. every 12 hours for 7 days
11182086|NCT03508219|Experimental|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
11182087|NCT03508206|Experimental|SBRP arm|Food supplement in hard gelatin capsule form containing a Standardized botanical blend rich in polyphenols (SBRP)
11182088|NCT03508206|Placebo Comparator|Placebo arm|Hard gelatin capsule form containing maltodextrin, with the same appearance as SBRP capsules
11182089|NCT03508193|Experimental|Intervention|Whole-foods based smoothie as nutritional therapy
11182090|NCT03508180|Experimental|foot reflexology|patients WITH foot reflexology session during chemotherapy treatments
11182091|NCT03508180|Placebo Comparator|platinum-based treatment|Patients WITHOUT ANY foot reflexology session during chemotherapy treatments
11182092|NCT03508167|Experimental|Thermal Band plus Dorilax®|
11182093|NCT03508167|Other|Thermal Band plus Placebo|
11182094|NCT03508154|Active Comparator|Control Meal 1|Control carbohydrate solution
11182095|NCT03508154|Active Comparator|Control Meal 2|Control carbohydrate solution
11182096|NCT03508154|Experimental|Experimental Nutritional Product|Study nutritional formulation
11182097|NCT03508141|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
11182098|NCT03508141|Active Comparator|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
11182099|NCT03508128||Micra subjects|Surgical procedure
11182100|NCT03508102|Experimental|Remifentanil 1 μg kg-1 (R1)|Received remifentanil 1μg/kg when induction of general anesthesia
11182101|NCT03508102|Experimental|Remifentanil 0.5 μg kg-1 (R0.5),|Received remifentanil 0.5μg/kg when induction of general anesthesia
11182102|NCT03508102|No Intervention|saline (control)|Injected the equal volume normal saline when induction of general anesthesia
11182103|NCT03508089|Other|Control Arm|
11182104|NCT03508089|Active Comparator|Multiple Sclerosis Arm|
11182105|NCT03508076|Sham Comparator|Sham Capsule|Patients swallowed 1 sham Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
11182106|NCT03508076|Experimental|Vibration Capsule of low level|Patients swallowed 1 low level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
11182795|NCT03503084|Experimental|TCC group|Classical Yang's TCC exercise
11182107|NCT03508076|Experimental|Vibration Capsule of high level|Patients swallowed 1 high level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
11182108|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
11182109|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
11182110|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
11182111|NCT03508037|Experimental|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
11182112|NCT03508037|Active Comparator|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
11182113|NCT03508011|Experimental|IMP4297|
11182114|NCT03507998|Experimental|CGX1321 Dosing|"Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned.
~Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321"
11182115|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
11182116|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.
~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
11182117|NCT03507972|Other|Ankle ultrasound & ankle MRI|Ankle ultrasound performed on the day of emergency consultation member MRI (without injection of contrast products) performed within 7 days following the trauma
11182118|NCT03507959|Experimental|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
11182119|NCT03507959|Experimental|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
11182120|NCT03507959|Experimental|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
11182121|NCT03507959|Experimental|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
11182122|NCT03507959|No Intervention|Control group|This group does not take the nasal spray.
11182123|NCT03507946|Experimental|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
~Plaque 2: No Intervention"
11182124|NCT03507920|Experimental|Neck passive mobilizations|
11182125|NCT03507920|Placebo Comparator|Manual contact|
11182126|NCT03507907|Experimental|Study Group|Mulligan mobilization techniques were applied to the older adults.
11182127|NCT03507907|Other|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
11182128|NCT03507894||m-health stroke rehabilitation|8-week multimodal exercise rehabilitation program (MERP) based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
11182129|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
11182130|NCT03507868||Group 1|Periodontally healthy individuals
11182131|NCT03507868||Group 2|Chronic periodontitis patients
11182132|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
11182133|NCT03507855|Active Comparator|Control|Normal operating room environment.
11182134|NCT03507842|Experimental|High-dose cytarabine|High-dose cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
11182135|NCT03507842|Experimental|high-dose daunorubicin|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7) plus high-dose daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
11182136|NCT03507829|Active Comparator|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
11182137|NCT03507829|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
11182138|NCT03507829|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
11182139|NCT03507803|Experimental|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
11182140|NCT03507803|No Intervention|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
11182141|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=40 group
11182142|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=40 group
11182143|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=40 group
11182202|NCT03507413|Active Comparator|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: Glucophage 500mg Tablet (2-0-2) daily for 1 year
11208721|NCT03324568|Experimental|Video plus educational handout|
11182144|NCT03507777|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.
~At the end of the procedure, a final OCT imaging run must be performed."
11182145|NCT03507777|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with angiography guidance according to local standard practice.
~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
11182146|NCT03507764|No Intervention|Control Group|"During the randomized study phase (6 months),subjects will perform their usual activity without access to the treadmill workstation in the dispatch center.
~After six months, all subjects will continue to be assessed with free access to the treadmill workstation at the workplace."
11182147|NCT03507764|Experimental|Experimental Group|"During the randomized study phase, subjects will have an open access to the treadmill workstation with the indication to use it for at least one hour (continuous or split) on working days.
~After six months, all subjects will continue to be assessed with free access to the treadmill workstation."
11182148|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
11182149|NCT03507738|Experimental|Adult MT-5625 middle dose|Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo
11182150|NCT03507738|Experimental|Adult MT-5625 high dose|Adult receiving intramuscular injection with either high dose of MT-5625 or placebo
11182151|NCT03507738|Experimental|Toddler MT-5625 middle dose|Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo
11182152|NCT03507738|Experimental|Toddler MT-5625 high dose|Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo
11182153|NCT03507738|Experimental|Infant MT-5625 low dose|Infant receiving intramuscular injection with either low dose of MT-5625 or placebo
11182154|NCT03507738|Experimental|Infant MT-5625 middle dose|Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo
11182155|NCT03507738|Experimental|Infant MT-5625 high dose|Infant receiving intramuscular injection with either high dose of MT-5625 or placebo
11182156|NCT03507738|Active Comparator|Rotarix|Infant receiving oral administration with Rotarix
11182157|NCT03507725|Experimental|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
11182158|NCT03507725|Active Comparator|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
11182159|NCT03507712|Active Comparator|Symmetrical IO weakening.|Same surgery in both eyes
11182160|NCT03507712|Active Comparator|Asymmetrical IO weakening.|Different amounts or different surgery in each eye
11182161|NCT03507699|Experimental|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
11182162|NCT03507699|Experimental|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.
~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
11182163|NCT03507686|Experimental|AAV2-REP1|Bilateral sub-retinal administration of AAV2-REP1.
11182164|NCT03507673||Progynova/Dydrogesterone|
11182165|NCT03507673||Spontaneous cycle|
11182166|NCT03507673||Progynova/Crinone|
11182167|NCT03507673||Others Medication|
11182168|NCT03507660|Experimental|verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~squeeze the pelvic floor muscles.
~squeeze and lift the pelvic floor muscles as if stopping the flow of urine
~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.
~squeeze the anus
~shorten the penis
~elevate the scrotum"
11182169|NCT03507647|Experimental|Mindfulness Based Cognitive Therapy added to usual care|Patients in the MBCT arm will be invited to participate in MBCT added to their usual care.
11182170|NCT03507647|Active Comparator|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse).
11182171|NCT03507634|Active Comparator|Opioid Based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl and Sevoflurane.
11182172|NCT03507634|Active Comparator|Opioid Free Anesthesia|General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine and Sevoflurane.
11182173|NCT03507621||Propofol Group|1- Propofol Group: Propofol group will use 1 mg / kg propofol for the patient.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete .
11182203|NCT03507413|Placebo Comparator|COMPARATIVE DRUG|Placebo matching M90 Oral Tablet treatment twice daily (2-0-2) for 1 year
11182204|NCT03507400|Experimental|non-waiting list group|Intervention: Introvision: mental and emotional self-regulation
11182205|NCT03507400|Experimental|waiting list group|"Intervention: Introvision: mental and emotional self-regulation
~Introvision is teached to participants of the waiting-list group at least 6 weaks or more after first group"
11183059|NCT03501316|Active Comparator|Hand Instrumentation|Root surface debridement using hand instruments.
11182174|NCT03507621||Sevoflurane Group|1- Sevofluran Group: sevoflurane was administered at one minimum alveolar concentration (MAC) to end-tidal concentrations of 3% to 5%.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete.
11182175|NCT03507608|Experimental|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
11182176|NCT03507608|Placebo Comparator|placebo|placebo prior to brachytherapy and prostatic biopsy
11182177|NCT03507595||Patients with initial diagnosis of PCa|"T2 stage: PSA>20ng/ml, Gleason Score >= 8;
~T3 or T4 stage;
~The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
11182178|NCT03507595||Patients with biochemical recurrent PCa|"After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;
~After the radiotherapy: the lowest PSA is up to 2 ng/ml."
11182179|NCT03507595||Patients with CRPC|"The serum testosterone is in the castration level (< 50 ng/dL or < 1.7 nmol/L);
~The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA > 2ng/mL(the interval is one week);
~The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;
~Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
11182180|NCT03507582|Active Comparator|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
11182181|NCT03507582|Active Comparator|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
11182182|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
11182183|NCT03507556|Experimental|Triple paste and induced bleeding|The triple paste is a mixture of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol will be used and next visit intracanal bleeding will be induced
11182184|NCT03507543|Experimental|IMP4297|
11182185|NCT03507504||care pathway with SCU-B|250 patients with dementia and behavioural and psychological symptoms of dementia (BPSD) followed up by six clinical centres with a Special Care Unit for BPSD (SCU-B)
11182186|NCT03507504||care pathway without SCU-B|250 patients with dementia and BPSD followed up by six clinical centres without SCU-B
11182187|NCT03507491|Experimental|Gemcitabine + Nab-paclitaxel|Participants receiving gemcitabine and nab-paclitaxel for refractory and/or relapsed solid tumors of childhood.
11182188|NCT03507478|Experimental|BPI1000013|Subjects suffering from pain associated with plantar fasciitis or general heel pain
11182189|NCT03507465|Experimental|Letrozole Plus Low-Dose Metronomic Capecitabine|
11182190|NCT03507465|Active Comparator|EC-T|
11182191|NCT03507452|Experimental|Dose escalation cohort a|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg."
11182192|NCT03507452|Experimental|Dose escalation cohort b|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg."
11182193|NCT03507452|Experimental|Dose Expansion Cohort 1|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options
~Dose / Regimen 1 (to be determined after completion of the dose escalation)"
11182194|NCT03507452|Experimental|Dose Expansion Cohort 2|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options
~Dose / Regimen 2 (to be determined after completion of the dose escalation)"
11182195|NCT03507452|Experimental|Dose expansion Cohort 3 (optional)|"Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma
~Dose / Regimen to be determined"
11182196|NCT03507452|Experimental|Dose escalation cohort c|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg."
11182197|NCT03507452|Experimental|Dose escalation cohort d|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.
~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg."
11182198|NCT03507439|Experimental|Heart failure patients|Patients with worsening heart failure (HF) and recent hospitalization for the treatment of HF or patients with chronic stable HF with either preserved (EF ≥ 45%) or reduced ejection fraction (EF ≤ 35%)
11182199|NCT03507426|Active Comparator|Retrobulbar group|Retrobulbar block
11182200|NCT03507426|Active Comparator|Ketamine group|Intravenous analgesia
11182201|NCT03507426|No Intervention|Control group|General anesthesia alone
11208722|NCT03324555|Experimental|ORIC-101|
11182206|NCT03507387|Experimental|Intramuscular phenylephrine group|Patients in intramuscular phenylephrine group will receive spinal anesthesia with bupivacaine. 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
11182207|NCT03507387|Active Comparator|Intravenous phenylephrine group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed.
11182208|NCT03507387|Placebo Comparator|Placebo group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia. 1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
11182209|NCT03507374|Placebo Comparator|Placebo Comparator|After review of eligibility criteria, 20 patients will be randomized to the placebo arm of the study where patient will administer one subcutaneous injection of placebo every two weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg.
11182210|NCT03507374|Active Comparator|Active Comparator|After review of eligibility criteria, 20 patients will be randomized to receive the investigational treatment of alirocumab 150mg which will be administered subcutaneously with a single-dose pre-filled pen syringe every 2 weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg
11182211|NCT03507361|Experimental|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
11182212|NCT03507361|No Intervention|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
11182213|NCT03507348|Other|Desensitization with Tocilizumab and rituximab (MFI >15000)|
11182214|NCT03507348|Other|Desensitization with Rituximab only (MFI<15000)|
11182215|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
11182216|NCT03507335||Sinus|Patients with sinus rhythm during measurements
11182217|NCT03507322||Ultrasound texturization|Application of ultrasound texturization (2D/3D ultrasound scanning)
11182218|NCT03507309||To be specified by Steering Committee.|
11182219|NCT03507296||Chronic low back pain patients|
11182220|NCT03507296||Asymptomatic subjects|
11182221|NCT03507270|Other|FABP group|Coronary angiography and PCI (according to indications).
11182222|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia
~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)
~CDR score ≤ 1.0
~flortaucipir (18F-AV-1451) PET scanning"
11182223|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living
~Mini-Mental State Exam score between 26-30
~CDR score = 0
~flortaucipir (18F-AV-1451) PET scanning"
11182224|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia
~Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)
~CDR score ≤ 1.0
~flortaucipir (18F-AV-1451) PET scanning"
11182225|NCT03507244|Experimental|Group 1,Intra-pemetrexed, radiotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.
11182226|NCT03507231|Active Comparator|Control|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination.
11182227|NCT03507231|Experimental|Direct Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for Vaccination ($5 Amazon Gift Card).
11182228|NCT03507231|Experimental|Indirect Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
11182229|NCT03507218||1|Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
11182230|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
11182231|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
11182232|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
11182233|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
11182234|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
11182235|NCT03507192|No Intervention|Arm 1|30 subjects In arm 1, no intervention is performed.
11182236|NCT03507192|Active Comparator|Arm 2|30 patients In arm 2 , active comparators, Muscle relaxation using full body massage machine is performed every morning and evening for 30 minutes.
11182237|NCT03507179|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
11182238|NCT03507179|Active Comparator|3d printed dentures|a complete denture made through 3D printing
11183791|NCT03496298|Experimental|Efpeglenatide Dose 1|Efpeglenatide dose 1 once weekly
11182239|NCT03507166|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
11182240|NCT03507153|Active Comparator|Bre-fllex group|Maxillary class III modification I edentulous patients that will recieve Bre-flex partial denture
11182241|NCT03507153|Experimental|PEEK group|Maxillary class III modification I edentulous patients that will recieve PEEK partial denture
11182242|NCT03507127|Active Comparator|Varenicline|
11182243|NCT03507127|Placebo Comparator|Placebo|
11182244|NCT03507114|Experimental|Rumination-Focused CBT (RFCBT)|RFCBT seeks to change the process of thinking as opposed to the content of thoughts as in standard CBT. The underlying idea is that shifting individuals repetitive negative thinking into the concrete mode will reduce unconstructive ruminations and worries.
11182245|NCT03507114|No Intervention|Wait List Control Group|This arm represents the wait-list comparison group.
11182246|NCT03507101||Invasive GAS infection study patients|
11182247|NCT03507088|Experimental|fulvestrant|500mg fulvestrant on days 0, 14, 28 and every 28 days thereafter Fluoroestradiol-PET is performed at baseline and after 28 days
11182248|NCT03507075|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
11182249|NCT03507075|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
11182250|NCT03507062|Experimental|Chloride-rich solution|Patients will receive two boluses of 10 and 20 ml/kg of the 0.9% saline in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
11182251|NCT03507062|Experimental|Low-chloride solution A|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's lactate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
11182252|NCT03507062|Experimental|Low-chloride solution B|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's acetate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
11182253|NCT03507062|Experimental|Very low-chloride solution|Patients will receive two boluses of 10 and 20 ml/kg of a plasmalyte-like solution (namely soluzione elettrolitica reintegrante [SER]) in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
11182254|NCT03507049|Active Comparator|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with Marcaine is performed under guidance of fluoroscopy after closure.
11182255|NCT03507049|Sham Comparator|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.
~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.
~An injection of the SIJ with Marcain is performed under guidance of fluorscopy after closure."
11182256|NCT03507049|Other|Functional MRI study|The Swedish patients will also undergo quantitative sensory testing at inclusion and at 6 month follow-up. At the same time they will undergo a cerebral MRI and a Functional MRI looking at activation of the CNS from pain in the sacroiliac joints induced by one leg lift. The purpose of this study is to look at contributing factors in treatment response. One hopes to map which CNS mechanisms are involved in causing the chronic pain these patients experience as well as how they respond to treatment.
11182257|NCT03507049|Sham Comparator|Pesudo sham arm|The Swedish sham patients will undergo general anesthesia., but will not be intubated. They will receive local anesthetics (ropivacain) at the incision site. . The surgeon will do a skin incision, do a blunt dissection With the iFuse guide pin in the direction of the SI-joint, but will not enter det bone. The wound will then be closed.
11182258|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.
~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
11182259|NCT03507023|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
11182260|NCT03507023|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
11182261|NCT03507010|Experimental|Radiotherapy|Patients assigned to the Radiotherapy group are treated with electrons and will receive a total dose of 30 Gy.
11182262|NCT03507010|Placebo Comparator|Sham Radiotherapy|Patients assigned to the sham-radiotherapy group will not actually receive radiation. For these patients the radiation is simulated.
11182263|NCT03506997|Experimental|Pembrolizumab|Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years
11182264|NCT03506984|Experimental|Group A|the participant will do a program of inspiratory muscle training for 10-15 minutes once daily using Threshold Inspiration Muscle Training Device
11182265|NCT03506984|Experimental|Group B|the participant will start cycling slowly for five minutes without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down using Electronic Bicycle Ergometer
11182266|NCT03506971|Experimental|Participants|"As part of this research, families will benefit from
~pediatric nurse's interventions : home visits by a pediatric nurse who will center around three times: a time of observation of the development and progress of the baby, a time for play with the baby and a time to listening the parents.
~psychologist's evaluation and joint home visits : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
11182267|NCT03506971|Other|Control|"psychologist's evaluation : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
11182268|NCT03506958||General Practice|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the general practice Zorgplein Lemmer.
11182269|NCT03506958||Hospital|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the Antonius Hospital Sneek.
11182270|NCT03506945|Experimental|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities
11182271|NCT03506945|Active Comparator|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills
11182272|NCT03506932|Experimental|Untreated|Bread containing 20% yellow pea flour.
11182273|NCT03506932|Experimental|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
11182274|NCT03506932|Experimental|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
11182275|NCT03506932|Active Comparator|Wheat|Bread made with 100% wheat flour
11182276|NCT03506919|Experimental|Arthitec 1|
11182277|NCT03506919|Experimental|Arthitec 2|
11182278|NCT03506906|Active Comparator|Conventional-approach|The non-invasive ventilation therapy will be optimized according to routine tests (blood gas analysis, lung function, ventilator's built-in software analysis)
11182279|NCT03506906|Experimental|Sleep studies-based approach|Additionally to the routine tests, the results of a nocturnal polysomnography and transcutaneous capnometry under the non-invasive ventilation therapy will be considered for the therapy optimization.
11182280|NCT03506893|Experimental|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
11182281|NCT03506893|Active Comparator|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
11182282|NCT03506880|Experimental|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
11182283|NCT03506880|Active Comparator|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
11182284|NCT03506880|No Intervention|Control|TAU
11182285|NCT03506867|Active Comparator|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
11182286|NCT03506867|Active Comparator|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
11182287|NCT03506854|Experimental|Normal Renal Function|Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
11182288|NCT03506854|Experimental|Moderate Renal Impairment|Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
11182289|NCT03506841|Active Comparator|Cerbrolysin|Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
11182290|NCT03506841|No Intervention|Control|Preterm infants with gestational age less than 32 weeks at birth will receive routine care.
11182291|NCT03506828|Active Comparator|Surgical sympathectomy|All patients in this group will have standard surgical procedure
11182292|NCT03506828|Active Comparator|Radiofrequency ablation with phenol injection|patient will receive radiofrequency ablation of T2 and T3 sympathetic ganglia + phenol 6% (0.5ml) injection
11182293|NCT03506815|Experimental|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
11182294|NCT03506815|No Intervention|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
11182295|NCT03506802|Experimental|Treatment (Genetically engineered PBMC and PBSC)|Refer to outline
11182296|NCT03506789|Active Comparator|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
11182297|NCT03506789|Active Comparator|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
11182298|NCT03506789|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
11182299|NCT03506776|Active Comparator|Education Only Group|The education only group will receive foot self-management education.
11182336|NCT03506568|No Intervention|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
11209061|NCT03322111|Experimental|Cyclofusion|
11182300|NCT03506776|Experimental|Education and Thermometer Group|The intervention group will receive foot self-management education. Additionally, the intervention group will receive a Commercially Available Infrared Thermometer (CAIT). Education on use of the CAIT will be provided through demonstration using a foot model and CAIT.
11182301|NCT03506763|Placebo Comparator|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
11182302|NCT03506763|Active Comparator|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
11182303|NCT03506763|Active Comparator|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
11182304|NCT03506750|Experimental|IVC-1day|patients with proliferative diabetic retinopathy receiving IVC 1 days before surgery
11182305|NCT03506750|Experimental|IVC-2day|patients with proliferative diabetic retinopathy receiving IVC 2 days before surgery
11182306|NCT03506750|Experimental|IVC-3day|patients with proliferative diabetic retinopathy receiving IVC 3 days before surgery
11182307|NCT03506750|Experimental|IVC-4day|patients with proliferative diabetic retinopathy receiving IVC 4 days before surgery
11182308|NCT03506750|Experimental|IVC-5day|patients with proliferative diabetic retinopathy receiving IVC 5 days before surgery
11182309|NCT03506750|Experimental|IVC-6day|patients with proliferative diabetic retinopathy receiving IVC 6 days before surgery
11182310|NCT03506750|Experimental|IVC-7day|patients with proliferative diabetic retinopathy receiving IVC 7 days before surgery
11182311|NCT03506750|Sham Comparator|IVC-sham|patients with proliferative diabetic retinopathy receiving sham IVC
11182312|NCT03506750|Placebo Comparator|non-DR|patients with other retinopathy (idiopathic macular hole or epiretinal membrane)
11182313|NCT03506737|Experimental|Conventional exercise protocol|Conventional global exercise
11182314|NCT03506737|Experimental|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
11182315|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
11182316|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
11182317|NCT03506711|Active Comparator|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
11182318|NCT03506711|Active Comparator|Healthy Children and adolescents|Healthy community-dwelling children on no medication
11182319|NCT03506685|No Intervention|control group Standard ACL protocol|This group will receive the standard ACL protocol rehab
11182320|NCT03506685|Experimental|Dry needling and STM group|This group will also receive the standard ACL protocol in addition to STM and DN
11182321|NCT03506672|Experimental|Experimental group|Approach based on the meanings of vocal behaviours
11182322|NCT03506672|Active Comparator|Control group|Usual practices of formal caregivers regarding vocal behaviours
11182323|NCT03506659|Active Comparator|Test|2000 patients healthy in anesthesiology consultation
11182324|NCT03506659|Experimental|Patients|2000 patients in pain clinic consultation
11182325|NCT03506646|Experimental|Beetroot juice-Placebo|Subjects will be tested on two different days. The first day will be beetroot juice and the second day will be a placebo. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
11182326|NCT03506646|Experimental|Placebo-Beetroot juice|Subjects will be tested on two different days. The first day will be a placebo and the second day will be beetroot juice. Testing will take place approximately one hour after intake. There will be a 14 day washout period between testing days.
11182327|NCT03506633|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.
11182328|NCT03506633|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.
11182329|NCT03506620|Placebo Comparator|Control|Subjects will be randomized to receive a single-injection QL block with normal saline (Saline Solution for Injection).
11182330|NCT03506620|Experimental|QL Block|Subjects will be randomized to receive a single-injection QL block with either local anesthetic (0.25% Ropivacaine injection).
11182331|NCT03506607|Experimental|Exercise in hypoxia 1500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%.
11182332|NCT03506607|Experimental|Exercise in hypoxia 2500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%.
11182333|NCT03506607|Placebo Comparator|Exercise in normoxia|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
11182334|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
11182335|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.
~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
11182337|NCT03506568|Active Comparator|Smart phone calendar app|For Group 2, their smart phone calendar app will be updated to give a scheduled medication alert, which patients uncommonly use but requires only a smart phone.
11182338|NCT03506568|Experimental|Integrated daily reminder using the D3 app|For Group 3, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
11182339|NCT03506555|Active Comparator|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
11182340|NCT03506555|Active Comparator|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
11182341|NCT03506542|Experimental|Ologen (OLO)|Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy
11182342|NCT03506542|Active Comparator|Mitomycin C (MMC)|Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)
11182343|NCT03506516|Experimental|single type|Restricted to drinking only one type of alcohol
11182344|NCT03506516|Active Comparator|mixed type|Drinking and mixing different types of alcohols freely
11182345|NCT03506503|Experimental|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
11182346|NCT03506490|Experimental|Experimental|The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
11182347|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
11182348|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
11182349|NCT03506464|Experimental|plantar fasciitis group|Myofascial release technique
11182350|NCT03506464|No Intervention|control group|None of the control group received the treatment
11182351|NCT03506451|Other|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
11182352|NCT03506438|Experimental|Mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
11182353|NCT03506438|Placebo Comparator|Usual care|Usual ICU care
11182354|NCT03506425|Experimental|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
11182355|NCT03506425|Experimental|Group 2|Standard care and Triheptanoin for 6 months.
11182356|NCT03506425|No Intervention|Group 3|Healthy controls for biomarkers
11182357|NCT03506412|Experimental|Entresto™|HFpEF patients will be given Entresto™
11182358|NCT03506399|Experimental|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
11182359|NCT03506399|Experimental|Lanabecestat|Single oral dose of lanabecestat
11182360|NCT03506399|Experimental|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
11182361|NCT03506386||MM participants|Participants diagnosed with MM and have initiated treatment will be observed since the diagnosis of MM (within the eligibility window of time, between January 1, 2008 and December 31, 2016) and the cut-off date for data collection (December 31, 2016), unless a participant has died or been lost to follow-up before that. The study is planned to last for approximately 24 months since its initiation. Initiation defined as the initiation visit for the first site.
11182362|NCT03506373|Experimental|Treatment (ixazomib citrate, ibrutinib)|Participants receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11182363|NCT03506360|Experimental|Treatment (ixazomib citrate, pembrolizumab, dexamethasone)|Participants receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Participants also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Courses with dexamethasone repeat every 84 days for up to 1 year and courses with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11182364|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
11182365|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
11182366|NCT03506334|Experimental|Pediatric Scoliosis Patients|Tether group
11182367|NCT03506334|Active Comparator|Pediatric Scoliosis Control Patients|Fusion (control) group
11182368|NCT03506321|Other|LANS|Lesions are assessed with chromoendoscopy, HD-WL & NBI
11182369|NCT03506308|Other|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
11182370|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
11182371|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
11182372|NCT03506282|No Intervention|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
11182408|NCT03505970|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
11182373|NCT03506282|Active Comparator|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
11182374|NCT03506282|Experimental|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
11182375|NCT03506282|Experimental|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
11182376|NCT03506256|Experimental|Norofloxacin|The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones. Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system. The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
11182377|NCT03506243|Experimental|Test group|Follitrope PFS
11182378|NCT03506243|Active Comparator|Control group|Gonal-F pen
11182379|NCT03506230|Experimental|Incentives group|a bonus to buy their medications if they improve their HbA1c
11182380|NCT03506230|No Intervention|Standard group|Will buy their medications as usual
11182381|NCT03506217||mitral valve prolaps|Hemodynamic recovery and anesthesia revealed by invasive arterial cardiac output (CO) measurement (Vigileo Flo-trac device) in 13 cases who underwent mitral valve (MV) repair with the transapical off-pump minimally invasive method in our clinic.
11182382|NCT03506178|Experimental|Obstructive sleep apnea patients|
11182383|NCT03506178|Other|Healthy controls|
11182384|NCT03506165|Experimental|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
11182385|NCT03506165|No Intervention|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
11182386|NCT03506152||Culture positive|
11182387|NCT03506152||Culture negative|
11182388|NCT03506139|Experimental|Radiation Therapy|External beam radiation therapy delivered to target volume.
11182389|NCT03506126|Experimental|Leucine Adults > 60|In this arm, all subjects will receive all 8 of the leucine test levels, assigned in random order.
11182390|NCT03506113|Active Comparator|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
11182391|NCT03506113|Active Comparator|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
11182392|NCT03506100|Other|water walking in spirometric values|Experimental: practice swimming complemented with water walking
11182393|NCT03506087|Experimental|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
11182394|NCT03506087|Active Comparator|Enhanced Control|Receives printed advance care planning materials only.
11182395|NCT03506074||General population|"Adult volunteers (≥18 years of age) selected as part of a project to investigate the role of lifestyle in preventing chronic diseases supported by the Campus Salute association (www.campussalute.it).
~All volunteers performed the flavor test as described in Maione et al, Endocrine, 2016 (doi:10.1007/s12020-015-0690-y)."
11182396|NCT03506061|Experimental|Trikafta|Participants will receive Trikafta for 28 days
11182397|NCT03506048|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
11182398|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
11182399|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
11182400|NCT03506035||Healthy controls|From health blood donors
11182401|NCT03506022|Other|patients with type 1 mellitus diabetes|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters
11182402|NCT03506009|Experimental|Argatroban combined with rt-PA|
11182403|NCT03506009|Active Comparator|rt-PA|
11182404|NCT03505996|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
11182405|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
11182406|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
11182407|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
11209191|NCT03321110|Experimental|Placebo|Placebo
11182410|NCT03505957|Experimental|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
11182411|NCT03505944|Experimental|Treatment|Venetoclax+lenalidomide+rituximab
11182412|NCT03505931||Eluvia|Patients treated with Eluvia stent
11182413|NCT03505918|No Intervention|Standard municipal rehabilitation|Standard care with postoperative rehabilitation at the municipal facility.
11182414|NCT03505918|Experimental|No referral for rehabilitation|No referral for supervised postoperative rehabilitation. Only standard information booklet and advice during hospitalization.
11182415|NCT03505905|Experimental|Pregnenlone (phase 1 and 2)|Participants will receive pregnenolone at phase 1 (baseline-WK 7) and 2 (WK 8-16). The titration schedule is as follows: at baseline a 50 mg (BID, 7 days). WK 1=150 mg (BID, 7 days); WK 2=250 mg (BID, 14 days) and WK 4=250 mg (BID, 14 days) (BID, 14 days). At phase 2 (WK 8) to maintain the double blind of rerandomization, treatment in all conditions recommence at a dosage frequency similar to phase 1. At WK 8=250 mg (BID, 7 days); at WK 9=250 mg (BID, 7 days); WK 10=250 mg (BID, 14 days) and WK 12=250 mg (BID, 14 days) . During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (BID, 4 days) and 50 mg (BID, 4 days), discontinue.
11182416|NCT03505905|Placebo Comparator|Placebo rerandom to placebo|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1= placebo (7 days); at WK 2=placebo (14 days) and WK 4=placebo (14 days). Placebo nonresponders rerandomized to placebo: At WK 8=placebo (7 days);WK 9=placebo (7 days);WK 10=placebo (14 days) and WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo (4 days) and placebo (4 days), discontinue.
11182417|NCT03505905|Experimental|Placebo rerandom to pregnenolone|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo nonresponders who are rerandomized to pregnenolone: At WK 8=250 mg (7 days);WK 9=250 mg (7 days);WK 10=250 mg (14 days) & WK 12=250 mg (14 days). During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (4 days) and 50 mg (4 days), discontinue.
11182418|NCT03505905|Placebo Comparator|Placebo responsive cont placebo|Participants will placebo throughout phase 1 (baseline- WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Responders continue to receive placebo at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo responders remain on placebo: At WK 8, placebo (7 days); WK 9=placebo (7 days); WK 10=placebo (14 days) & WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo= 4 days) and placebo=4 days, discontinue.
11182419|NCT03505892||Participants receiving adalimumab|Participants with AS receiving adalimumab
11182420|NCT03505866|Other|Mutual support groups of HIV|HIV-positive people who did not enroll in a community home-based care intervention and receiving regular HIV services and support from mutual support groups of HIV
11182421|NCT03505853|Experimental|Givosiran with 5-probe cocktail|
11182422|NCT03505840||antiphospholipid group|pregnant ladies in the third trimester who have antiphospholipid syndrome
11182423|NCT03505840||control group|pregnant ladies in the third trimester who have no medical disorders with pregnancy
11182424|NCT03505827||TECNIS Monofocal|This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
11182425|NCT03505827||TECNIS Symfony|This group of patients has chosen to undergo implantation of a TECNIS Symfony extended depth of focus lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 SITA standard Humphrey visual field test prior to surgery, and a 24-2 Humphrey visual field test after surgery at 1 month post-operatively.
11182426|NCT03505814|Experimental|Optiflow Group|high flow (6l/min), humidified oxygen administred into nasal cannula for post-extubation new born ventilated patients.
11182427|NCT03505814|Active Comparator|Control Group|Conventional oxygen therapy for post extubation care
11182428|NCT03505788|Placebo Comparator|high-dose loop diuretics+placebo|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of placebo.
~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of placebo. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
11182429|NCT03505788|Experimental|high-dose loop diuretics+acetazolamide|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of acetazolamide.
~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of acetazolamide. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
11182430|NCT03505775|Other|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
11182431|NCT03505762|Experimental|Arm I (tailored prednisone dose)|Participants receive rituximab IV, vincristine sulfate IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11182432|NCT03505762|Active Comparator|Arm II (usual care prednisone dose)|Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11182433|NCT03505749|Experimental|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
11182434|NCT03505749|Active Comparator|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
11182435|NCT03505736||Diagnostic (stress test)|Within 2 years of initiating anti-estrogen therapy or 2 years after completing chemotherapy, participants undergo a stress test which consists of receiving adenosine IV over 1-5 minutes or regadenoson IV over 2 minutes and then undergoing CMR imaging over 45-60 minutes at baseline, and again 3-6 months later.
11182436|NCT03505723|Active Comparator|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
11182437|NCT03505723|Placebo Comparator|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
11182438|NCT03505723|Active Comparator|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
11182439|NCT03505723|Placebo Comparator|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
11182440|NCT03505710|Experimental|Cohort 1: HER2 Overexpressing|Cohort 1 will enroll participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
11182441|NCT03505710|Experimental|Cohort 1a: HER2 Overexpressing|Cohort 1a will enroll participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
11182442|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Cohort 2 will enroll participants with HER2-mutated, unresectable and/or metastatic NSCLC to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
11182443|NCT03505697|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
11182444|NCT03505697|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
11182445|NCT03505684|Experimental|CTP group|1,000 mg of collagen tripeptide (CTP) was orally administered per day for 12 weeks.
11182446|NCT03505684|Placebo Comparator|Control group|1,000 mg of placebo (starch) was orally administered per day for 12 weeks
11182447|NCT03505671|Experimental|Group 1 (acupuncture)|Participants undergo 8 45-minute acupuncture treatments over 10 weeks.
11182448|NCT03505671|Active Comparator|Group 2 (usual care)|Participants receive usual care.
11182449|NCT03505658|Experimental|Intervention|The Intervention is educational with 6 workshops for 2 hrs a week. Data/ assessments are collected, pre and post the 6 weeks intervention and 6 months post follow-up.
11182450|NCT03505658|No Intervention|Control|One or two non-intervention related workshop talks are given; 1 hr each during the same 6 weeks as the intervention arm. Pre and post assessment/ data collection and 6 months follow-up are completed.
11182451|NCT03505645|Active Comparator|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
11182452|NCT03505645|Active Comparator|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
11182453|NCT03505632|Experimental|Recruitment with low PEEP|Recruitment maneuver ( RM) will carried out during 2 minutes with increasing PEEP in stepwise manner.PEEP increase from 5 to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths), PEEP to 20 cmH2O (10 breaths).Then decrease by 5 cmH2O every 3 breaths till back to preset PEEP 5 cmH2O .Recruitment carried out at the following times: post intubation(T1) , after insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O .
11182454|NCT03505632|Active Comparator|High PEEP without RM|"Patients will receive from the start during anesthesia high PEEP (15 cmH2O) with maintaining the peak airway pressure below 40 cm H2O.
~Monitoring times: after intubation(T1), post-insufflation(T2), after desuflation (T3) and before extubation(T4)."
11182455|NCT03505619|Experimental|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
11183792|NCT03496298|Experimental|Efpeglenatide Dose 2|Efpeglenatide dose 2 once weekly
11182456|NCT03505619|No Intervention|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
11182457|NCT03505606|Active Comparator|Control|Visual acuity tests on control participants
11182458|NCT03505606|Experimental|Amblyopic|Visual acuity tests on amblyopic participants.
11182459|NCT03505593|Experimental|EFT placement using ENVUE System|Placement of the ENvizion Medical™ Enteral Feeding Tube (EFT) in the stomach or small intestine of adult patients who require feedings via the oro/ nasoenteric route, using the ENVUE™ System.
11182460|NCT03505567|Other|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
11182461|NCT03505554|Experimental|Lorlatinib|100 mg QD
11182462|NCT03505541||Control group|Healthy, term, non-obese (BMI < 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
11182463|NCT03505541||Study group 1|Term pregnant, non-obese (BMI <30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
11182464|NCT03505541||Study group 2|Term pregnant, obese (BMI >30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
11182465|NCT03505528|Experimental|Cohort Group|There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D & E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
11182466|NCT03505515||Lung Cancer Patricipants in China|Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
11182467|NCT03505502|Placebo Comparator|placebo arm|group receive i/v saline plus irrigation of the myoma bed with normal saline
11182468|NCT03505502|Experimental|IV tranexamic acid group|group received IV tranexamic 1gm in normal saline
11182469|NCT03505502|Active Comparator|topical tranexamic acid group|group received topical tranexamic 2gm in normal saline
11182470|NCT03505489|Experimental|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
11182471|NCT03505489|Experimental|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
11182472|NCT03505489|Experimental|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
11182473|NCT03505489|Experimental|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
11182474|NCT03505476|Experimental|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
11182475|NCT03505463||Injured participants|
11182476|NCT03505463||Healthy participants|
11182477|NCT03505450||Population sample|
11182478|NCT03505450||Purposive Sample|
11182479|NCT03505437|Experimental|Stress + Exposure|Stress Condition: Cold water condition of the socially evaluated cold pressor test (SECPT; Schwabe et al, 2008).
11182480|NCT03505437|Active Comparator|Control + Exposure|Control condition: Warm water condition of the SECPT.
11182481|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
11182482|NCT03505424|Active Comparator|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
11182483|NCT03505424|Active Comparator|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
11182484|NCT03505411|Experimental|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
11182485|NCT03505398|Experimental|central vision disorder|
11182486|NCT03505398|Experimental|peripheral vision disorder|
11182487|NCT03505398|Other|control|
11182488|NCT03505385|Experimental|Co-created intervention|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:
~The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).
~The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).
~The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
11182489|NCT03505385|No Intervention|Usual care|
11182490|NCT03505372|Experimental|Contrast enhanced mammography|"The CESM images will be performed according to clinical protocol
~Images will be acquired within approximately 2-12 minutes of contrast injection
~A total of four images per breast will be acquired with low and high energy
~Two radiologists will prospectively review the CESM, and will use a third as tie-breaker
~The CESM will be evaluated for the biopsy site and up to two additional findings in either breast
~The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
11182491|NCT03505359|Experimental|Experimental group|Group treated by the new protocol with partial knee immobilization
11182492|NCT03505359|Active Comparator|Control group|Group treated by a standard protocol for ACL reconstruction.
11182493|NCT03505346|Experimental|percutanous coronary intervention(PCI)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
11182528|NCT03505099|Experimental|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10^14 vg/kg
11182494|NCT03505346|Experimental|Coronary artery bypass-graft(CABG)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
11182495|NCT03505333|Experimental|conventional suture ligature|use of conventional sutures for hysterectomy
11182496|NCT03505333|Active Comparator|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
11182497|NCT03505320|Experimental|zolbetuximab (Cohort 1A)|Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met.
11182498|NCT03505320|Experimental|mFOLFOX6 plus zolbetuximab (Cohort 2)|Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous [IV] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.
11182499|NCT03505320|Experimental|Pembrolizumab plus zolbetuximab (Cohort 3A/3B)|"Participants will be treated with zolbetuximab and pembrolizumab on a 21-day cycle. Cohort 3 consists of 2 parts: a safety lead in (Cohort 3A) and an expansion (Cohort 3B).
~Cohort 3A: Loading dose of zolbetuximab will be administered at cycle 1, day 1 followed by maintenance dose of zolbetuximab once every 3 weeks (Q3W). Pembrolizumab will be administered to 3 to 6 subjects at a intravenously on day 1 of every 21-day cycle and will be infused 1 hour after the zolbetuximab infusion is completed. Tolerability and safety of zolbetuximab in combination with pembrolizumab will be evaluated during the 3-week dose-limiting toxicity (DLT) assessment period. If this cycle 1 dose is not tolerable, a lower dose of zolbetuximab in combination with pembrolizumab will subsequently be evaluated.
~Cohort 3B: A zolbetuximab plus pembrolizumab combination expansion cohort (Cohort 3B) may be opened based on the tolerability of the dose in Cohort 3A."
11182500|NCT03505294|Experimental|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks will be applied."
11182501|NCT03505294|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform.
11182502|NCT03505268|Experimental|telemedicine intervention|The intervention group, in addition to usual care, will get 10 telemedicine interventions by a certified nurse and dietitian who both specialize in treatment of type 1 diabetes.
11182503|NCT03505268|No Intervention|usual care|Usual care consisted of visits to the diabetes center every three months and communication with their doctor by phone when needed.
11182504|NCT03505255|Active Comparator|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
11182505|NCT03505255|Active Comparator|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
11182506|NCT03505255|Active Comparator|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
11182507|NCT03505255|Placebo Comparator|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
11182508|NCT03505242|Experimental|BB|
11182509|NCT03505242|Experimental|DLT|
11182510|NCT03505229|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.
~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
11182511|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
11182512|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
11182513|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
11182514|NCT03505190|Experimental|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
11182515|NCT03505190|Experimental|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
11182516|NCT03505190|Experimental|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
11182517|NCT03505190|Experimental|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
11182518|NCT03505190|Placebo Comparator|Placebo|Participants will receive matching placebo.
11182519|NCT03505177|Experimental|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
11182520|NCT03505151|Experimental|All subjects|
11182521|NCT03505138|Experimental|Group intervention|Conventional management for COPD will take place in our health care system more telematics intervention.
11182522|NCT03505138|Active Comparator|Group control|Is performed only conventional management of COPD in our health care system.
11182523|NCT03505125||PKU Patients|Adults with PKU will be interviewed about the symptoms and impacts of PKU.
11182524|NCT03505125||Observers|Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
11182525|NCT03505125||Clinical Experts|Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
11182526|NCT03505112|Experimental|Goal-directed therapy group|The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
11182529|NCT03505086||cohort|All patients fulfilling the eligibility criteria who can be asked for consent. Basic register of only patient diagnosis, treatment and bleeding yes or no (without identifiable information).
11182530|NCT03505086||cases|Patient with clinically relevant bleeding, defined as major and clinically relevant non-major bleeding that leads to substantial additional medical care: WHO score 3-4 and part of the WHO score 2 bleedings (depending on the need for additional care).
11182531|NCT03505086||controls|Patient without clinically relevant bleeding matched to a case patient based on diagnosis and therapy.
11182532|NCT03505060|Experimental|Group 1: DNA CON-S env + IHV01|Participants will receive 4 mg of DNA CON-S env at Months 0 and 1. They will receive 4 mg of DNA CON-S env and 150 mcg of IHV01 at Months 3 and 6.
11182533|NCT03505060|Placebo Comparator|Group 2: Placebo|Participants will receive placebo at Months 0, 1, 3, and 6.
11182534|NCT03505047|Experimental|Immediate group:|The Copper Intrauterine device will be inserted within 24 hours of the expulsion of the fetus and placenta or after surgical evacuation for placental remains, and prior to discharge from the facility.
11182535|NCT03505047|No Intervention|Delayed Group|The Copper Intrauterine device will be inserted at a local community health centre 14-28 days after discharge.
11182536|NCT03505034|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
11182537|NCT03505021|Experimental|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
11182538|NCT03505021|Placebo Comparator|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
11182539|NCT03505008|Experimental|MTX-Monotherapy Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
11182540|NCT03505008|Experimental|ADA/MTX-Maximum Tolerated Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
11182541|NCT03505008|Experimental|ADA/MTX-Reduced Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.
11182542|NCT03504995|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
11182543|NCT03504982|Experimental|Treatment 1|Treatment sequences: A*-B-C-D
11182544|NCT03504982|Experimental|Treatment 2|Treatment sequences: D-A-B-C*
11182545|NCT03504956|Other|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
11182546|NCT03504956|Other|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
11182547|NCT03504943|Active Comparator|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
11182548|NCT03504943|Experimental|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
11182549|NCT03504930||Impact of biotherapy on postoperative morbidity|Impact of biotherapy on postoperative morbidity in ulcerative colitis
11182550|NCT03504917|Experimental|Balovaptan|
11182551|NCT03504917|Placebo Comparator|Placebo|
11182552|NCT03504904|Experimental|Internet-delivered ACT and CFT|8 week, guided internet- delivered acceptance and commitment therapy (ACT) and compassion focused therapy (CFT)
11182553|NCT03504904|No Intervention|Wait list control group|Wait list control group, received treatment at later point.
11182554|NCT03504891|Experimental|MRI Prior to CRT for Upgrades|MRI will be performed prior to CRT upgrade.
11182555|NCT03504891|Active Comparator|MRI Prior to de novo CRT Implants|MRI will be performed prior to de novo CRT implants.
11182556|NCT03504878||Patients undergoing laparoscopic appendectomy|Appendix removal via scope.
11182557|NCT03504878||Patients undergoing open appendectomy|Open operation for removal of appendix
11182558|NCT03504865|Experimental|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
11182559|NCT03504865|Active Comparator|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
11182560|NCT03504865|Placebo Comparator|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
11182561|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment
11182591|NCT03504618||Metastatic colon cancer patients|Colon cancer patients with metastase at the diagnostic time, impossibility of radical resection, adenocarcinoma, treated by at least 3 cycles of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department
11182562|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 4 weeks. Starting at Week 6, 2 secukinumab placebo (dummy drug) injections were alternated every 4 weeks to maintain the blind. Subjects in this arm who did not achieve PASI 90 response at Week 16 were randomized at Baseline to either remain on secukinumab 300 mg every 4 weeks or to receive secukinumab 300 mg every 2 weeks starting at Week 16 until the end of the treatment period
11182563|NCT03504839|Other|Intervention|S-ICD implantation.
11182564|NCT03504826|Experimental|Locomotor training using adaptive robot|The intervention will consist of 60 sessions of locomotor training using the HAL adaptive robot. The training sessions will be scheduled 5 days per week for 12 weeks. A physical therapist with expertise in SCI walking rehabilitation and use of the HAL will oversee all intervention sessions. The intervention sessions will include up to a total of 40 minutes of stepping time, which may take up to 2 hours to complete due to set up time and rest breaks.
11182565|NCT03504813|Experimental|Urinary Incontinence|"The involuntary loss of urine through the urethra, objectively demonstrable and constituting for the person who suffers it a social and hygienic problem.
~In this arm, participants will receive the following interventions: physical activities program, training of the pelvic floor and counseling about occupational performance"
11182566|NCT03504813|Experimental|Insomnia|"A condition characterized by an unsatisfactory amount or quality of sleep which persists for a considerable period. This disorder includes difficulties for the falling and/or staying asleep and early awakening in the final phase of sleep.
~In this arm, participants will receive the following interventions: physical activities program, relaxation training and counseling about occupational performance."
11182567|NCT03504813|Experimental|Risk of falls|"Involuntary events that cause people to lose balance and find themselves on the ground or other firm surfaces. The factor of falls can be intrinsic (related to the person) or extrinsic (derived from the activity or environment of the individual).
~In this arm, participants will receive the following interventions: physical activities program, and counseling about occupational performance"
11182568|NCT03504800||Group A: Classification of Corneal Irregularities|This group will consist of participants >14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
11182569|NCT03504800||Group B: Detection of Keratoconus Progression|Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
11182570|NCT03504800||Group C: OCT-and-Topography Guided PTK|Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
11182571|NCT03504774|Experimental|Cashew or Shrimp Oral Immunotherapy|Participants, ages 7 to 55 years, inclusive, with an allergy to Cashew or Shrimp.
11182572|NCT03504761|Experimental|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
11182573|NCT03504748|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
11182574|NCT03504748|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
11182575|NCT03504735|Placebo Comparator|Therapeutic Lifestyle Change+Placebo|Therapeutic Life-style change intervention with Placebo pills.
11182576|NCT03504735|Active Comparator|Therapeutic Lifestyle Change+Caduet|Therapeutic Lifestyle Change intervention with Caduet pills.
11182577|NCT03504722|Experimental|RESCUE+PE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area Society for the Prevention of Cruelty to Animals (SPCA) facilities.All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
11182578|NCT03504722|Active Comparator|PE+delayed RESCUE|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
11182579|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
11182580|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
11182581|NCT03504696||Patients with Advanced Melanoma|RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)
11182582|NCT03504683|Experimental|Early Time-Restricted Feeding|
11182583|NCT03504683|Experimental|Mid-day Time-Restricted Feeding|
11182584|NCT03504683|Placebo Comparator|Control Schedule|
11182585|NCT03504670|Experimental|Early amniotomy|Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
11182586|NCT03504670|Experimental|Late amniotomy|Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
11182587|NCT03504657|Experimental|Drug-coated balloon angioplasty|
11182588|NCT03504657|Active Comparator|stenting angioplasty|
11182589|NCT03504644|Experimental|Treatment (venetoclax, vincristine liposomal)|Patients receive venetoclax PO QD on days 1-42 of course 1 and days 43-70 of course 2. Patients also receive vincristine liposomal IV weekly for 4 weeks starting on day 14 of course 1.
11182590|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
11182592|NCT03504605|Experimental|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
11182593|NCT03504605|No Intervention|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
11182594|NCT03504592|Experimental|Glooko App|Glooko application and meter compatibility device (if required)
11182595|NCT03504592|Active Comparator|Traditional Care|Traditional clinic reporting system: paper/MyChart/emailed glucose logs
11182596|NCT03504579|Experimental|rt-fMRI neurofeedback aimed at STG|One session of rt-fMRI neurofeedback from the patient's STG.
11182597|NCT03504579|Sham Comparator|sham rt-fMRI|One session of rt-fMRI neurofeedback from the patient's motor cortex.
11182598|NCT03504566|Other|Intervention|All patients recieve, in randomomized order a four way treatment schedule. Due to the nature of the study, the individual patient will serve as his/hers own comparator.
11182599|NCT03504553|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
11182600|NCT03504553|No Intervention|Control|Normal operating room environment.
11182601|NCT03504540||Case (with pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits"
11182602|NCT03504540||Control (without pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, without pseudo-drusen-like deposits"
11182603|NCT03504527|Experimental|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
11182604|NCT03504527|Active Comparator|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
11182605|NCT03504514|No Intervention|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
11182606|NCT03504514|Experimental|Adapted mechanical ventilation|Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions
11182607|NCT03504501|Experimental|Exp. I: Noonan Syndrome - Lovastatin|200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
11182608|NCT03504501|Experimental|Exp. II: Noonan Syndrome - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
11182609|NCT03504501|Experimental|Exp. III: Neurofibromatosis Type 1 - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
11182610|NCT03504488|Experimental|BA3021|All patients will receive BA3021, CAB-ROR2-ADC.
11182611|NCT03504475|Experimental|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
11182612|NCT03504475|Active Comparator|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
11182613|NCT03504462|Experimental|Distal tibial nerve block|Patient receiving a specific block of medial and lateral plantar nerves in order to preserve the calcaneal nerve
11182614|NCT03504449|Experimental|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
11182615|NCT03504449|Experimental|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
11182616|NCT03504423|Experimental|CPI-613, mFolfirinox|"CPI-613, mFolfirinox
~CPI-613 at 500 mg/m2 IV infusion at a rate of 4mL/min via a central venous port on day 1 and 3 of a 14-day cycle.
~mFolfirinox (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 140mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
11182617|NCT03504423|Active Comparator|Folfirinox|"Folfirinox
~Folfirinox: Oxaliplatin (Eloxatin) at 85 mg/m2 given as a 2 hr IV infusion, Folinic acid at 400 mg/m2 given as a 90 min (1.5hr) infusion immediately after Oxaliplatin, and concurrently with Irinotecan (irinotecan at 180mg/m2 given as a 90 min IV infusion) via a Y-connector, Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2 starting immediately after completion of folinic acid and Irinotecan."
11182618|NCT03504410|Experimental|CPI-613 + HD Cytarabine and Mitoxantrone|"CPI-613 + High Dose Cytarabine and Mitoxantrone
~CPI-613 at 2,000 mg/m2/day from day 1 to 5.
~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine."
11182619|NCT03504410|Active Comparator|Control (HAM) and control sub-groups (MEC and FLAG)|"High Dose Cytarabine and Mitoxantrone
~Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine.
~Mitoxantrone, Etoposide and Cytarabine
~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6
~Fludarabine, Cytarabine and Filgrastim
~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
11182684|NCT03503942|Experimental|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
11182620|NCT03504397|Experimental|Arm A (zolbetuximab plus mFOLFOX6)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
11182621|NCT03504397|Placebo Comparator|Arm B (Placebo plus mFOLFOX6)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive up to 12 treatments of mFOLFOX6 (or components of mFOLFOX6 if some components are discontinued due to toxicity) over 4 or more cycles (each cycle is approximately 42 days) in which mFOLFOX6 is administered on Days 1, 15 and 29. After 12 mFOLFOX6 treatments, participants may continue to receive fluorouracil (5-FU) and folinic acid at the investigator's discretion until the subject meets study treatment discontinuation criteria.
11182622|NCT03504371|Active Comparator|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
11182623|NCT03504371|Sham Comparator|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
11182624|NCT03504358||Analysis before liver resection|Multivariate analysis of predictive factors associated with survival
11182625|NCT03504358||Different risk group|Low-risk group, moderate-risk group, high-risk group
11182626|NCT03504358||Model comparison|Comparison of models in predicting survival
11182627|NCT03504345|Active Comparator|Control Group|This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
11182628|NCT03504345|Experimental|Experimental Group|This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
11182629|NCT03504332|Experimental|Calcium Hydroxide in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Pure Calcium Hydroxide powder mixed with saline will be placed as intra-canal medication in the 1st visit of dental pulp revascularization.
11182630|NCT03504332|Active Comparator|Di-antibiotic paste in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Mix 1:1 ciprofloxacin: metronidazole to a final concentration of 0.1 mg/ml, placed as intra-canal medication in the 1st visit of dental pulp revascularization.
11182631|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
11182632|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
11182633|NCT03504280|Active Comparator|high dose IM|cholecalciferol 600,000 IU given intramuscularly
11182634|NCT03504280|Active Comparator|high dose oral|cholecalciferol 600,000 IU given orally
11182635|NCT03504280|Active Comparator|low dose oral|cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU
11182636|NCT03504267|Experimental|Physical Activity Group|The PAG (physical activity) group will receive evidence-based educational information as well as a list of local resources for pursuing physical activity.
11182637|NCT03504267|No Intervention|Standard of Care Group|The SOC (standard of care) group will receive no additional information beyond standard-of-care brochures and information
11182638|NCT03504254||CSM|A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
11182639|NCT03504241|Experimental|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
11182640|NCT03504241|Experimental|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
11182641|NCT03504241|Experimental|MSCs 10^6 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks.
11182642|NCT03504215|Experimental|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
11182643|NCT03504202|Experimental|Trimetazidine|
11182644|NCT03504189|Experimental|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
11182645|NCT03504176||Intervention|Patients will be ventilated according to the bundle; including ventilation targets, tidal volume, end expiratory pressure-fraction of inspired oxygen titration.
11182646|NCT03504176||Control|Standard of care prior to implementation of the ventilation bundle
11182647|NCT03504163|Experimental|Pembrolizumab (MK-3475)|Patients will receive Pembrolizumab (MK-3475) administered after TUR as single agent initial therapy. Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur.
11182648|NCT03504150|Experimental|SPHERE|It is an online self-guided comprehensive cognitive-behavioural therapy program that offers a headache diary, learning modules that teach a variety of cognitive and behavioural skills to cope better with their headaches, and a discussion forum where users may interact.
11183793|NCT03496298|Placebo Comparator|Placebo|Placebo once weekly
11182649|NCT03504150|Experimental|PRISM|It is an online self-guided brief cognitive-behavioural therapy program that offers a headache diary and helps users discover their headache triggers and non-triggers. Then the program provides the users with a few personalized recommendations to help them to cope with their triggers.
11182650|NCT03504150|No Intervention|Usual care|
11182651|NCT03504137|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
11182652|NCT03504124|Experimental|Intervention group|Patients will receive a multicomponent intervention.
11182653|NCT03504124|No Intervention|Control group|Patients will receive the usual care.
11182654|NCT03504111|Active Comparator|Needle Tenotomy|1 group will be assigned to get the standard treatment for chronic tendinopathy, percutaneous needle tenotomy (PNT). It is currently considered a standard treatment option. Ultrasound guided PNT with approximately 25 passes through the tendon and enthesis with approximately an 18 gauge needle with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used
11182655|NCT03504111|Active Comparator|Platelet Rich Plasma|1 group will be assigned to the PRP arm. Investigators will have a trained provider draw the blood, and prepare the PRP according to manufacturer and departmental (KP) protocol. Ultrasound guided injection of this PRP using approximately an 18 gauge needle with a single pass through the tendon into affected area as demonstrated on ultrasound. Adequate amount of anesthetic will be given in a separate syringe with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of amount and type of anesthetic used. The amount of anesthesia will be the same in both arms of the study
11182656|NCT03504098||Lung cancer patients tumor|Using to analysis metabolomic markers, one carbon folate nutrition levels in lung cancer patients.
11182657|NCT03504098||Lung cancer patients blood|Using to analysis folate, B12, homocysteine levels in plasma and RBC. Using to analysis cDNA gene test in buffy coat.
11182658|NCT03504098||Lung cancer patients|Supply nutrition counseling
11182659|NCT03504085|Experimental|Hatha Yoga|This arm will receive the active Hatha yoga intervention. Instructors lead participants through various yoga poses for 60-minutes, 1-2x weekly for 12 weeks, and daily home practice is recommended.
11182660|NCT03504085|Active Comparator|Restorative Yoga|This arm will receive a restorative yoga intervention. Instructors guide participants through relaxation exercises, typically with eyes closed, laying down, and minimal movement 60-minutes, 1-2x weekly for 12 weeks.
11182661|NCT03504072|Active Comparator|Tofacitinib 5mg|tofacitinib 5 mg 12 hourly daily for 9 months. Evaluation schedule will be baseline, 1st month, 3rd months and 3 monthly for 9 months. relevant investigations will be done at each visit. occurrence of tuberculosis and infections will be recorded at follow up visits.
11182662|NCT03504072|Active Comparator|Etanercept 50 mg|Etanercept 50 mg subcutaneously every 7 days interval for 1st month then, Etanercept 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval for 9 months. Occurrence of tuberculosis and infections will be recorded at follow up visits.
11182663|NCT03504059|No Intervention|Control|The usual educational program is applied
11182664|NCT03504059|Active Comparator|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
11182665|NCT03504059|Active Comparator|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
11182666|NCT03504046|Experimental|Artificial Pancreas App|After completing a 1 week open-loop run in period, subjects will use the APS APP for a 48-hour period in an observed transitional environment.
11182667|NCT03504033|Experimental|Xenon|Xenon concentration of 50-60 % will be used for maintenance of general anesthesia and will be adjusted to maintain Bispectral index (BIS) value between 40 and 60.
11182668|NCT03504033|Active Comparator|Desflurane|Desflurane concentrations of 4-5%/0.8 minimum alveolar concentration (MAC) respectively will be used for maintenance of general anesthesia and will be adjusted to maintain BIS index value between 40 and 60.
11182669|NCT03504020|Experimental|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
11182670|NCT03504020|No Intervention|Control Arm|Standard CRT through 6 months follow-up.
11182671|NCT03503994|Other|Drug|"Patients receiving inhaled beclomethasone diproprionate in four escalating doses:
~200 mcg bid
~400 mcg bid
~600 mcg bid
~800 mcg bid"
11182672|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
11182673|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
11182674|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
11182675|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
11182676|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
11182677|NCT03503968|Experimental|Phase I - 3 disease entities|MDG1011 administration of escalating doses
11182678|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 1|MDG1011 administration of Phase II recommended dose
11182679|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 1|Investigator Choice therapy
11182680|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 2|MDG1011 administration of Phase II recommended dose
11182681|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 2|Investigator Choice therapy
11182682|NCT03503955|Experimental|study group|fine motor skills activities and Leap-Motion virtual reality games
11182683|NCT03503955|Experimental|control group|fine motor skills activities
11182754|NCT03503396|Active Comparator|No Feedback|Participants will not receive any information on their BAC from their device.
11182685|NCT03503942|No Intervention|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
11182686|NCT03503929|Other|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
11182687|NCT03503903|Experimental|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
11182688|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
11182689|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
11182690|NCT03503864|Experimental|Arsenic Trioxide(+)|Patients receive arsenic trioxide combined with conventional induction chemotherapy.
11182691|NCT03503864|Other|arsenic trioxide(-)|Patients receive conventional induction chemotherapy without arsenic trioxide.
11182692|NCT03503851|Active Comparator|One CLIP|Implantation of single MitraClip
11182693|NCT03503851|Active Comparator|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
11182694|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
11182695|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
11182696|NCT03503825|Experimental|Healthy Volunteers|Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
11182697|NCT03503825|Experimental|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.
11182698|NCT03503812|No Intervention|No intervention to DDS exposure - Asthma in Children|
11182699|NCT03503812|Experimental|Intervention 1 - Asthma in Children|
11182700|NCT03503812|Experimental|Intervention 2 - Asthma in Children|
11182701|NCT03503812|No Intervention|No intervention to DDS exposure - Atrial Fibrillation|
11182702|NCT03503812|Experimental|Intervention 1 - Atrial Fibrillation|
11182703|NCT03503812|Experimental|Intervention 2 - Atrial Fibrillation|
11182704|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
11182705|NCT03503786|Active Comparator|Arm A|Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab
11182706|NCT03503786|Experimental|Arm B|Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
11182707|NCT03503773|Experimental|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
11182708|NCT03503773|Sham Comparator|Sham Control Arm|Only renal angiography performed
11182709|NCT03503760|Experimental|true-sham|"Patients first received the true LIMFA Therapy® treatment for 3 weeks followed by 3 weeks of washout and then six sham sessions for 3 weeks more."
11182710|NCT03503760|Experimental|sham-true|"Patients first received the sham treatment for 3 weeks followed by 3 weeks of washout and then six true LIMFA Therapy® sessions for 3 weeks more."
11182711|NCT03503734||Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.
~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.
~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.
~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
11182712|NCT03503721|Experimental|BipolEP|includes all patients undergoing BipolEP surgery
11182713|NCT03503721|Active Comparator|TURP|includes all patients undergoing TURP surgery
11182714|NCT03503708|Experimental|Intervention Group|All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
11182715|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
11182716|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
11182717|NCT03503682|Active Comparator|standard treatment|Patients in this group are treated with 3000 cGy in 10 daily fractions
11182718|NCT03503682|Experimental|short course treatment|Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
11182719|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
11182720|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
11182721|NCT03503656||CompuFlo|All the consecutive patients undergoing to an epidural catheter placement in Gynecological and Obstetric setting
11182722|NCT03503630|Experimental|Locally advanced rectal cancer patients|"Week 1: D1-5: radiotherapy 25 Gy in 5 fractions
~mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)
~Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
11182723|NCT03503617|Experimental|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
11182724|NCT03503617|Active Comparator|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
11182725|NCT03503604|Experimental|group 1|hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin)
11182726|NCT03503604|Experimental|group 2|hPV19 mAb plus paclitaxel/carboplatin
11182727|NCT03503604|Experimental|group 3|hPV19 mAb plus gemcitabine/carboplatin
11182728|NCT03503604|Experimental|group 4|hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
11182729|NCT03503578|Experimental|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
11182730|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
11182731|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
11182732|NCT03503539|Experimental|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
11182733|NCT03503539|Active Comparator|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
11182734|NCT03503526|Experimental|Music therapy treatment|"An intervention consisting of 12 weekly sessions of trauma-focused treatment in form of group music and imagery therapy.
~Receptive music therapy."
11182735|NCT03503526|No Intervention|Wait List Control|No treatment for approximately 12 weeks.
11182736|NCT03503513|Experimental|Gentamicin sulfate followed by saline|
11182737|NCT03503513|Experimental|Saline followed gentamicin sulfate|
11182738|NCT03503500|Experimental|Laid-back breastfeeding|Women will breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves, without following particular procedure to breastfed.
11182739|NCT03503500|Active Comparator|Standard care|Staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast,
11182740|NCT03503487|No Intervention|Control|Patients receiving standard informed consent procedure before intervention
11182741|NCT03503487|Experimental|Planner 1|Patients receiving 3D informed consent procedure before intervention with Surgical Theater
11182742|NCT03503487|Experimental|Planner 2|Patients receiving 3D informed consent procedure before intervention with Vesalius
11182743|NCT03503474||CDI cases|
11182744|NCT03503474||CDI negative controls|
11182745|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
11182746|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
11182747|NCT03503448|Other|space between 11/21|Osteotomy between the maxillary central incisors
11182748|NCT03503448|Other|space between 12/13 and 22/23|Osteotomy between the maxillary lateral incisors and canines
11182749|NCT03503435|Other|Art therapy intervention|Participants will then take part in six-weeks of group art therapy with a goal of increasing self-awareness and expression. During the intervention sessions, participants will have access to a wide range of materials conventionally used in art therapy excluding materials that may be abrasive or powdery and unsuitable around people wearing a stoma.
11182750|NCT03503422|Experimental|tDCS (anodal) + therapeutic exercises|"Real transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
11182751|NCT03503422|Sham Comparator|tDCS (sham) + therapeutic exercises|"Sham transcranial direct current stimulation associated with therapeutic exercises
~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
11182752|NCT03503409|Experimental|AG-120|Subjects enrolled will receive continuous 28-day cycles of AG-120 - 500 mg. AG-120 will be dispensed on Day 1 of each treatment cycle
11182753|NCT03503396|Experimental|BAC feedback|Participants will receive a warning when their BAC is above a set limit (cutpoint is not disclosed by well below legal limit). Warning will notify them that their results indicate it is not safe for them to drive.
11182757|NCT03503370|Experimental|chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
11182758|NCT03503370|Placebo Comparator|placebo|Participants randomized to the placebo will wash their feet using bath CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
11182759|NCT03503357|Experimental|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
11182760|NCT03503357|Experimental|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
11182761|NCT03503357|Experimental|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
11182762|NCT03503357|Experimental|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
11182763|NCT03503344|Experimental|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
11182764|NCT03503344|Active Comparator|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
11182765|NCT03503331|Experimental|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system. The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
11182766|NCT03503318|Experimental|TV-46000 - A|Dose regimen A
11182767|NCT03503318|Experimental|TV-46000 - B|Dose regimen B
11182768|NCT03503318|Placebo Comparator|Placebo|Matching Placebo
11182769|NCT03503305|Experimental|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
11182770|NCT03503305|Active Comparator|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
11182771|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
11182772|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
11182773|NCT03503279|No Intervention|Macintosh Laryngoscope|
11182774|NCT03503279|Active Comparator|McGrath MAC® Video Laryngoscope|
11182775|NCT03503266|Experimental|[14C] MT-7117|14-C MT-7117
11182776|NCT03503253|Other|Single-arm|LAA leak closure using detachable coils; Interlock-35 Fibered IDC Occlusion System, Concerto Helix Detachable Coil System
11182777|NCT03503227|Active Comparator|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
11182778|NCT03503227|Active Comparator|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
11182779|NCT03503214||Septic patients|Patients with sepsis or septic shock according to the SEPSIS-III (Singer M Jama 2016) admitted to the general Intensive Care Unit
11182780|NCT03503214||Healthy volunteers|Subjects without known respiratory, cardiovascular, hepatic, renal or hematologic diseases.
11182781|NCT03503201|Active Comparator|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
11182782|NCT03503201|No Intervention|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
11182783|NCT03503188|Experimental|All participants|
11182784|NCT03503175|Experimental|Novel urinary access system|Participants randomized to this arm will receive the novel urinary access system (CystoSureTM).
11182785|NCT03503175|Active Comparator|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and rigid cystoscopy.
11182786|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
11182787|NCT03503136|Experimental|A (TPF+P-RT)|Induction docetaxel, cisplatin, and fluorouracil plus concurrent chemoradiotherapy with cisplatin
11182788|NCT03503136|Experimental|B (TNF+N-RT)|Induction docetaxel, nedaplatin, and fluorouracil plus concurrent chemoradiotherapy with nedaplatin
11182789|NCT03503136|Experimental|C (TPX+P-RT)|Induction docetaxel, cisplatin, and capecitabine plus concurrent chemoradiotherapy with cisplatin
11182790|NCT03503136|Experimental|D (TNX+N-RT)|Induction docetaxel, nedaplatin, and capecitabine plus concurrent chemoradiotherapy with nedaplatin
11182791|NCT03503123||COPD patients with deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV with severe symptoms of deventilation dyspnoea (Borg Dyspnoea Scale ≥ 5)
11182792|NCT03503123||COPD patients without deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV without symptoms of deventilation dyspnoea, matched with the first cohort/group with regard to the degree of static lung hyperinflation and NIV settings.
11182793|NCT03503110|Experimental|dMRI and electrocorticography|Direct measurements of cortical electrical properties of patients operated on awake surgery for a brain tumor, using electrocorticography (ECoG), based on the dMRI tractography data previously acquired for each patient.
11182794|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
11182796|NCT03503058|Experimental|Group 1|N=140 will receive PfSPZ Vaccine; three doses of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals.
11182797|NCT03503058|Placebo Comparator|Group 2|N=70 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals.
11182798|NCT03503058|Experimental|Group 3|"N=140 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10^5 PfSPZ of PfSPZ Challenge administered by DVI at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.
~CQ will first be given as a loading dose of 620 mg base two days before the first administration of PfSPZ Challenge, followed by weekly 310 mg doses of CQ with the last dose 5 days after the last dose of PfSPZ Challenge."
11182799|NCT03503058|Placebo Comparator|Group 4|"N=70 will receive normal; three doses of NS administered by DVI given at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.
~CQ will first be given as a loading dose of 620 mg base two days before the first administration of NS, followed by weekly 310 mg doses of CQ with the last dose 5 days after the last dose of NS."
11182800|NCT03503032||Fenestrated|Standard extracardiac fontan undergoing Fontan fenestration creation
11182801|NCT03503032||Non fenestrated|Standard extracardiac fontan without fenestration
11182802|NCT03503019||Diabetic|
11182803|NCT03503019||Non-diabetic|
11182804|NCT03502993||MOFICHE|This is an observational study assessing the management and outcome of children presenting to Emergency Departments (ED) with fever across Europe. This study will use large departmental datasets to collect information on at least 50,000 febrile episodes . This study will use large-scale, pseudo-anonymized departmental data, and will not involve consented patient recruitment; nor will it use patient samples. Data included in MOFICHE will be based on that collected as part of routine clinical care. Antibiotic prescription, hospitalisation and number/type of investigations, re-attendance at ED within 5 days of the first hospital presentation will be recorded.
11182805|NCT03502993||BIVA studies|A minimum of 3,000 children will be recruited to the BIVA-ED study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
11182806|NCT03502980|Active Comparator|Peripherally inserted central venous catheters|Bard PowerPICC
11182807|NCT03502980|Active Comparator|Midline|Bard PowerMidline catheter
11182808|NCT03502967|Experimental|Hyperpolarized [1-13C] Pyruvate|Injection with hyperpolarized [1-13C] Pyruvate during MRI.
11182809|NCT03502967|Experimental|Hyperpolarized [2-13C] Pyruvate|Injection with hyperpolarized [2-13C] Pyruvate during MRI.
11182810|NCT03502954|Experimental|ABY-039 IV|
11182811|NCT03502954|Experimental|ABY-039 SC|
11182812|NCT03502954|Placebo Comparator|Placebo IV|
11182813|NCT03502954|Placebo Comparator|Placebo SC|
11182814|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
11182815|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
11182816|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
11182817|NCT03502928|Active Comparator|Conventional Treatment|Motor Control + Manual Therapy
11182818|NCT03502928|Experimental|Experimental Treatment|Motor Control + Manual Therapy + Dry Needling
11182819|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
11182820|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
11182821|NCT03502902|Experimental|HEC68498|administered once on first day in each Treatment Period， HEC68498 VS placebo 3:1 ratio
11182822|NCT03502902|Placebo Comparator|placebo|administered once on first day in each Treatment Period
11182823|NCT03502889|Active Comparator|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
11182824|NCT03502889|Experimental|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
11182825|NCT03502863|Experimental|Digital refraction|Web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone
11182826|NCT03502863|Active Comparator|Manual Refraction|Manual manifest refraction is performed by an eyesore specialist using a phoropter.
11182827|NCT03502850|Experimental|ASK120067|patients take ASK120067 orally once per day at different dose
11182828|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
11182829|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
11182830|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
11182831|NCT03502824|Active Comparator|PuraPly® AM plus Standard of Care|
11182832|NCT03502824|Active Comparator|Standard of Care (SOC) for Pressure Ulcers|
11182833|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
11182834|NCT03502798|Experimental|scanning a/LCI|
11182835|NCT03502785|Experimental|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
11182935|NCT03502291|Placebo Comparator|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
11182836|NCT03502785|Experimental|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
11182837|NCT03502772|Experimental|Pilates exercises group|
11182838|NCT03502772|Active Comparator|Home exercise program group|
11182839|NCT03502759|No Intervention|Pre-intervention|Seizure patients receive usual care.
11182840|NCT03502759|Experimental|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
11182841|NCT03502746|Experimental|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
11182842|NCT03502733|Experimental|Treatment (copanlisib, nivolumab, ipilimumab)|"DOUBLET TREATMENT PLAN: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~TRIPLET TREATMENT PLAN: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Beginning cycle 2, patients also receive ipilimumab IV over 90 minutes on day 1 for a total of 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11182843|NCT03502720||Control Patients|"Data obtained retrospectively from Scaphoid fixation surgeries performed at our center using the standard procedure (no device for guide wire positioning).
~This control group should have registered al parameters and variables to be studied."
11182844|NCT03502720||Case Patients|Prospective series of ten patients on which the external 3D guide system will be used.
11182845|NCT03502707|Placebo Comparator|Cohort (C)1 Group (G)1: Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
11182846|NCT03502707|Experimental|C1 G2: RSV preF Protein|Participants will receive intramuscular injection of 50 microgram (mcg) RSV preF protein on Day 1, Day 57 and at Month 12.
11182847|NCT03502707|Placebo Comparator|C1 G3: Placebo for Ad26.RSV.preF/RSV preF or RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
11182848|NCT03502707|Experimental|C1 G4: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 viral particles (vp) of Ad26.RSV.preF/RSV preF 50 mcg protein on Day 1, Day 57 and at Month 12.
11182849|NCT03502707|Experimental|C1 G5: RSV preF Protein|Participants will receive intramuscular injection of 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
11182850|NCT03502707|Placebo Comparator|C1 G6: Mixture of Placebo for Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1, Day 57 and at Month 12.
11182851|NCT03502707|Experimental|C1 G7: Mixture of Ad26.RSV.preF/RSV preF Protein|Participants will receive intramuscular injection of a mixture of 5*10^10 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein on Day 1, Day 57 and at Month 12.
11182852|NCT03502707|Placebo Comparator|C1 G8: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo on Day 1 and at Month 12 and in only 1 arm on Day 57.
11182853|NCT03502707|Experimental|C1 G9: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and at Month 12 and placebo in another arm on Day 1 and at Month 12.
11182854|NCT03502707|Experimental|C1 G10: Ad26.RSV.preF, RSV preF Protein and Placebo|Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and at Month 12 and placebo in 1 arm on Day 57.
11182855|NCT03502707|Experimental|C2 G11: Ad26.RSV.preF and Placebo|Participants will receive intramuscular injection of 1*10^11 vp of Ad26.RSV.preF in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
11182856|NCT03502707|Experimental|C2 G12: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
11182857|NCT03502707|Experimental|C2 G13: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 50 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
11182858|NCT03502707|Experimental|C2 G14: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 1*10^11 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
11182859|NCT03502707|Experimental|C2 G15: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Participants will receive intramuscular injection of a mixture of 5*10^10 vp Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm and placebo in another arm on Day 1 and placebo in 1 arm on Day 57.
11182860|NCT03502707|Experimental|C2 G16: Ad26.RSV.preF, RSV preF Protein and Placebo|Data from C1 G10 will be pooled with those of C2 G16. Participants will receive separate intramuscular injections of 1*10^11 vp of Ad26.RSV.preF in 1 Arm and 150 mcg RSV preF protein in another arm on Day 1 and placebo in 1 arm on Day 57.
11182861|NCT03502707|Experimental|C2 G17: Mixture of Ad26.RSV.preF/RSV preF Protein and Placebo|Data from C1 G9 will be pooled with those of C2 G17. Participants will receive intramuscular injection of a mixture of 1*10^11 vp of Ad26.RSV.preF plus 150 mcg RSV preF protein in 1 arm on Day 1 and 57 and placebo in another arm on Day 1.
11182862|NCT03502707|Placebo Comparator|C2 G18: Placebo for Ad26.RSV.preF/Placebo for RSV preF Protein|Participants will receive intramuscular injection of placebo in separate arms on Day 1 and in only 1 arm on Day 57.
11182863|NCT03502707|Experimental|C3 G19: Selected Regimen (SR)|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (the SR) at Month 12 and month 24. The participants who are randomized to two-dose regimen will receive SR on Day 1 and Day 57, and a booster (the selected regimen) at Month 12.
11182864|NCT03502707|Experimental|C3 G20: SR + Placebo for SR|If a one-dose regimen is selected, participants in this group will receive SR on Day 1 and a booster (placebo) at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive selected regimen on Day 1 and Day 57, and a booster (placebo) at Month 12.
11182936|NCT03502291|Active Comparator|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
11182865|NCT03502707|Placebo Comparator|C3 G21: Placebo for SR|If a one-dose regimen is selected, participants in this group will receive placebo for SR on Day 1 and at Month 12 and Month 24. The participants who are randomized to two-dose regimen will receive placebo for SR on Day 1, Day 57, and Month 12.
11182866|NCT03502694|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
11182867|NCT03502694|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
11182868|NCT03502694|Placebo Comparator|Regimen C (Placebo)|Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
11182869|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.
~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
11182870|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
11182871|NCT03502668|Experimental|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
11182872|NCT03502668|Experimental|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
11182873|NCT03502655|Other|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
11182874|NCT03502655|Active Comparator|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
11182875|NCT03502655|Other|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
11182876|NCT03502655|Active Comparator|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
11182877|NCT03502642|Placebo Comparator|Placebo (P)|Placebo group parturients will receive spinal anesthesia with intrathecal morphine and will have continuous normal saline wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
11182878|NCT03502642|Active Comparator|Ropivacaine (R)|Ropivacaine group parturients will receive spinal anesthesia without intrathecal morphine and will have continuous ropivacaine (Ropivacaina Molteni®) wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
11182879|NCT03502629|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
11182880|NCT03502616|Experimental|Tofacitinib|
11182881|NCT03502616|Placebo Comparator|Placebo|
11182882|NCT03502603|Active Comparator|Cerebral neurological illness (CNI) participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
11182883|NCT03502603|Active Comparator|Non-CNI participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
11182884|NCT03502590|Experimental|IGEL arm|
11182885|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
11182886|NCT03502564|Active Comparator|CBT for ED only|In this arm, participants will receive CBT for ED following intensive ED treatment (see intervention section for description).
11182887|NCT03502564|Experimental|Concurrent CBT for ED and PTSD|In this arm, participants will receive concurrent CBT for ED and PTSD following intensive treatment. (see intervention section for description).
11182888|NCT03502551|Experimental|Treatment with Ketamine|In this arm an IV infusion of 0.5 mg/kg of ketamine will be administered over 40 minutes.
11182889|NCT03502538|Experimental|Curaprox 5460 Ultra Soft|Brushing with a Curaprox Ultra Soft 5460 toothbrush for one minute timed without orientations about brushing techniques and without supervision
11182890|NCT03502538|Active Comparator|Oral-B Indicator Plus|Brushing with a Oral-B Indicator Plus toothbrush for one minute timed without orientations about brushing techniques and without supervision
11182891|NCT03502525|Experimental|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
11182892|NCT03502512|Experimental|Arm I (REVOLVE technique)|Patients undergo reconstructive surgery with REVOLVE technique.
11182893|NCT03502512|Experimental|Arm II (PureGraft technique)|Patients undergo reconstructive surgery with PureGraft technique.
11182894|NCT03502499|Experimental|Half-normal saline|
11182895|NCT03502499|Active Comparator|Normal saline|
11182896|NCT03502486|Experimental|Moderate exercise|20 minutes of cycle ergometry at 50 - 60% of heart rate max.
11182897|NCT03502486|Experimental|Intense Exercise|20 minutes of cycle ergometry at 70 - 80% of heart rate max.
11182898|NCT03502486|Active Comparator|Rest|20 minutes of seated reading.
11182899|NCT03502473|Experimental|One pass/no treatment arm|One random flank will be treated with UltraShape Power device with one pass or remained as a control (no treatment)
11182900|NCT03502473|Experimental|Multiple passes treatment arm|Second flank will be treated with UltraShape Power device with multiple passes.
11182937|NCT03502291|Placebo Comparator|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
11182901|NCT03502460|Other|ORFALU|"Lung ultrasound consists of the application of a high-frequency ultrasound probe type Trans Thoracic Echography (ETT) on the anterior and lateral chest of the patient. Since air and bone do not pass through the US, it is the artefacts due to these structures that constitute ultrasound lung semiology.
~Esophageal Doppler is a means of monitoring cardiac output measuring stroke volume (SV)."
11182902|NCT03502447|Experimental|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
11182903|NCT03502447|Active Comparator|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
11182904|NCT03502434|Experimental|90 mg/mL SM04755 in water|90 mg/mL SM04755 in water applied via patches
11182905|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle|90 mg/mL SM04755 in aqueous Vehicle applied via patches
11182906|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches
11182907|NCT03502434|Other|Vehicle|Aqueous Vehicle applied via patches
11182908|NCT03502434|Other|White petrolatum|White petrolatum (Negative control) applied via patches
11182909|NCT03502434|Other|Sodium lauryl sulfate|Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches
11182910|NCT03502421|Experimental|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
11182911|NCT03502421|No Intervention|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
11182912|NCT03502408|Experimental|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
11182913|NCT03502395|Active Comparator|Group I|Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
11182914|NCT03502395|Placebo Comparator|Group II|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
11182915|NCT03502382|Other|radilogical|Radiological: standing antero-posterior full-length digital images of the lower extremities
11182916|NCT03502369|Experimental|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
11182917|NCT03502369|No Intervention|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
11182918|NCT03502356|Active Comparator|Control Group|This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
11182919|NCT03502356|No Intervention|Study Group|This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)
11182920|NCT03502343|Experimental|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
11182921|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
11182922|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
11182923|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
11182924|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
11182925|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
11182926|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
11182927|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
11182928|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
11182929|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
11182930|NCT03502317|Experimental|Prehabilitation Study Arm|Patients will participate in a two-pronged prehabilitation strategy - physical prehabilitation and psychological prehabilitation. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before a patient's clinically indicated surgery.
11182931|NCT03502317|No Intervention|Usual Care Study Arm|No specific exercises or stress reduction techniques are prescribed and the patient will be counseled to continue their current level of activity, and will be given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in the Usual Care arm will also be given the same Fitbit activity tracker as patients in the Prehabilitation arm in order to eliminate the activity tracker as an intervention itself and to be able to track the activity (steps) for comparison. Patients in the Usual Care arm will be required to wear their Fitbit activity tracker from the day of randomization to 90 days post-surgery. Patients will record their steps in the diary provided.
11182932|NCT03502304|Active Comparator|Control group|No-exercise
11182933|NCT03502304|Experimental|Endurance training plus resistant training|To concurrent training (endurance training plus resistant training, RT) program will be use cycle ergometers adapted for obese adults (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Prior to the CT intervention, all subjects were familiarized (during 3 sessions) with the training protocols. The CT intervention included 3 weekly sessions of both ET and RT. The core part of each session included RT followed by ET exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
11182934|NCT03502291|Active Comparator|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
11182938|NCT03502278|Active Comparator|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
11182940|NCT03502265|Experimental|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
11182941|NCT03502252|Experimental|Treatment Group|Semillas de Apego is a group-based psychosocial program for victimized caregivers with children 2 to 5 in Colombia, a country devastated by violence. The program's builds upon scientific evidence on (i) the way in which violence hinders early childhood development and erodes mothers' mental health and their capacity to form nurturing relationships with their children, and (ii) the effectiveness of promoting healthy child-parent attachments to mitigate the effects of toxic stress on toddlers (Lieberman and Van Horn, 2011).
11182942|NCT03502252|No Intervention|Control Group|Centers and participants assigned to the this group continue to have access to the regular early childhood programs offered through the centers to which children are affiliated.
11182943|NCT03502239|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
11182944|NCT03502239|No Intervention|Control- wait list group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
11182945|NCT03502226|Experimental|Intervention group|Received tailored feedback regarding sexual health risks
11182946|NCT03502226|No Intervention|Control group|Did not receive tailored feedback.
11182947|NCT03502187|Active Comparator|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
11182948|NCT03502187|Experimental|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
11182949|NCT03502187|Experimental|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
11182950|NCT03502161||All subjects|Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.
11182951|NCT03502148|Experimental|Open-Label, Single Arm Study of PRV111|In Stage 1, subjects will receive 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery. Following review of Stage 1 subject data, additional subjects will be enrolled in Stage 2 and will receive 2, 3 or 5 treatment applications dependent on the results of Stage 1 at each of the 4 visits prior to their tumor surgery.
11182952|NCT03502135|Experimental|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
11182953|NCT03502122|Experimental|VR rehabilitation|Virtual Reality based rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
11182954|NCT03502122|Active Comparator|control- conventional rehabilitation|conventional rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
11182955|NCT03502109|Experimental|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
11182956|NCT03502109|No Intervention|Control group|Usual care by physicians, nurses and dietitians.
11182957|NCT03502096|Experimental|100% portion size|100% portion sizes of all foods served (baseline). To-go container and controls received this meal.
11182958|NCT03502096|Experimental|125% portion size|125% of baseline portions served. To-go container and controls received this meal.
11182959|NCT03502096|Experimental|150% portion size|150% of baseline portions served. To-go container and controls received this meal.
11182960|NCT03502096|Experimental|175% portion size|175% of baseline portions served. To-go container and controls received this meal.
11182961|NCT03502070|Other|Open-Label Placebo|One dose (4 capsules) of placebo
11182962|NCT03502044|Active Comparator|Arm 1, active KOS treatment|Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
11182963|NCT03502044|Placebo Comparator|Arm 2, 8 inactive KOS treatments then 8 active KOS treatments|Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
11182986|NCT03501862|Experimental|Mindfulness-based intervention|Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
11182987|NCT03501862|Active Comparator|Psychoeducation|Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
11182964|NCT03502031|Experimental|Renin-Angiotensin (RAAombination with Spironolactone|Patients with overt Type II diabetic nephropathy and >500 mg/gm UP/Cr ratio that wi to maximal RAAS blockade (ACE/ARB-such as Lisinopril 20 mg, Losartan in combination with Spironolactone (25 m Qday) for 24 months. The determination of maximum tolerated ACE-ARB therapy will be left to the discretion of the site principal investigator.
11182965|NCT03502018|Placebo Comparator|Saline|This arm will receive Saline along with Bupivacaine
11182966|NCT03502018|Experimental|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
11182967|NCT03502005|Experimental|BIKTARVY®|initiation of single pill once daily bictegravir/emtricitabine/tenofovir alafenamide from prior efavirenz/emtricitabine/tenofovir DF
11182968|NCT03501992|Other|Practice A|Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
11182969|NCT03501992|Other|Practice B|Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
11182970|NCT03501992|Other|Practice C|Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
11182971|NCT03501992|Other|Practice D|Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
11182972|NCT03501992|Other|Practice E|Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
11182973|NCT03501992|Other|Practice F|Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
11182974|NCT03501979|Experimental|Tucatinib + Trastuzumab + Capecitabine|Tucatinib will be taken orally at 300 mg twice a day starting with Cycle 1, Day 1. A cycle consists of 21 days. Capecitabine will be taken orally at 1000 mg/m2 twice a day on Days 1-14 starting with cycle 1. Trastuzumab is given intravenously as a loading dose of 8 mg/kg on Cycle 1, Day 1 and then at 6 mg/kg for all subsequent cycles.
11182975|NCT03501966|Active Comparator|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).
~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
11182976|NCT03501966|Active Comparator|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).
~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.
~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
11182977|NCT03501966|Active Comparator|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).
~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.
~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
11182978|NCT03501953|Experimental|Nature Exposure|6-week physical activity course in a natural environment
11182979|NCT03501953|Active Comparator|Urban Exposure|6-week physical activity course in an urban environment
11182980|NCT03501927|Active Comparator|FOCUS (focused cardiac ultrasound)|Patients allocated to FOCUS will receive a preoperative FOCUS examination in conjunction with a standard anesthetic preoperative evaluation.
11182981|NCT03501927|No Intervention|Control|Patients allocated til control arm will receive a standard anesthetic preoperative evaluation according to hospitals' standards.
11182982|NCT03501914|Experimental|Mindfulness Based Intervention|Mindfulness principles based manualized intervention will be provided to the participants which is developed by colleagues in Manchester. This intervention will be adapted to be accessible for people having intellectual disability (ID) in Pakistan.Sessions will take place once-weekly for 12 weeks including an initial orientation session. It will include breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking
11182983|NCT03501888|Active Comparator|Cognitive Behavior Therapy (CBT)|CBT: individually, ca 18 weeks.
11182984|NCT03501888|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT: given in a group setting: ca 18 weeks.
11182985|NCT03501875|Experimental|CAC Score|CAC Score evaluated by the Agatston method
11182988|NCT03501849|Experimental|Polypectomy using a cold snare|Polypectomy by cold-snare technique and Optivista imaging
11182989|NCT03501836|Experimental|Rapid Rhythm Handheld 8-lead ECG Device|Participants will have measurements taken with the 8 lead ECG system, which will be compared to the conventional standard care 12 lead ECG.
11182990|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.
~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.
~Photoacoustic tomography to be performed after ultrasound"
11182991|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.
~Photoacoustic tomography to be performed after ultrasound"
11182992|NCT03501797|Experimental|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
11182993|NCT03501797|Experimental|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
11182994|NCT03501784|Experimental|Novidia Dental bonding and flow|Nobio particles incorporated within Novidia Dental Bonding and Flow.
11182995|NCT03501784|Active Comparator|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
11182996|NCT03501771|Experimental|Acupuncture|Acupuncture needle will be administered.
11182997|NCT03501758||Remission with treatment|Patients randomized to continue medical treatment with biologics
11182998|NCT03501758||Remission without treatment|Patients randomized to stop medical treatment with biologics
11182999|NCT03501745|Other|Management Group|
11183000|NCT03501745|Other|control group|
11183001|NCT03501732|Experimental|Values Affirmation plus Risk Feedback|Values Affirmation with Risk Feedback in substance use and HIV domains of risk
11183002|NCT03501732|Active Comparator|Risk Feedback|Sham Values Affirmation with Risk Feedback in substance use and HIV domains of risk
11183003|NCT03501732|No Intervention|Sleep Control|Description of sleep habits in lieu of values affirmation/sham values affirmation. No risk feedback
11183004|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
11183005|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
11183006|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
11183007|NCT03501706|Experimental|Active Training (AT) Group|Participants will complete four computerized training programs to improve executive function (EF), including Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Words - Visual, Verbal Memory - Visual.
11183008|NCT03501706|No Intervention|Control Training (CT) Group|Participants will complete the four computerized programs relating to executive function (EF), but without memory requirements for control.
11183009|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
11183010|NCT03501693||FFDM alone|FFDM alone images
11183011|NCT03501680|Experimental|Group A: intensive insulin|Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)
11183012|NCT03501680|Active Comparator|Group B: standard insulin|Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),
11183013|NCT03501680|Active Comparator|Group C: plasmapheresis|Group C: plasmapheresis
11183014|NCT03501667|Active Comparator|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
11183015|NCT03501667|Active Comparator|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
11183016|NCT03501654|Experimental|TecnisSymfony intraocular lens insertion group|
11183017|NCT03501641|Experimental|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
11183018|NCT03501641|Active Comparator|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
11183019|NCT03501628|Placebo Comparator|Placebo|"2 servings daily
~Serving information:
~204 kcal
~2.8 g fat
~44.4 g carbohydrate
~0.4 g protein (0 g L-leucine)"
11183020|NCT03501628|Experimental|L-leucine + maltodextrin|"2 servings daily
~Serving information:
~200 kcal
~2.0 g fat
~43.1 g carbohydrate
~2.8 g protein (2.8 g L-leucine)"
11183021|NCT03501628|Experimental|Whey protein concentrate|"2 servings daily
~Serving information:
~184 kcal
~3.5 g fat
~12 g carbohydrate
~26.3 g protein (2.8 g L-leucine)"
11183022|NCT03501628|Experimental|Hydrolyzed whey protein concentrate|"2 servings daily
~Serving information:
~192 kcal
~4.6 g fat
~12.2 g carbohydrate
~25.4 g protein (2.9 g L-leucine)"
11183023|NCT03501628|Experimental|Soy protein concentrate|"2 servings daily
~Serving information:
~266 kcal
~4.5 g fat
~17.2 g carbohydrate
~39.2 g protein (2.9 g L-leucine)"
11183024|NCT03501602|Active Comparator|LMA protector group|The LMA Protector is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts
11183025|NCT03501602|Active Comparator|I-gel LMA group|The I-gel is an alternative supraglottic device which provides the seal over the airway versus an inflatable cuff.
11183026|NCT03501576|Experimental|Inactivated Influenza Vaccine|Patients receive seasonal inactivated influenza vaccine IM at day 0.
11183027|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.
~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
11183028|NCT03501550|Experimental|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
11209192|NCT03321110|Experimental|Q10-150|coenzyme Q10 150 mg/d.
11183029|NCT03501537|Experimental|Surgical treatment with free gingival graft|Free gingival graft harvested from the palate will be placed around the diseased implant
11183030|NCT03501524|Experimental|VATS evacuation|patients selected for VATS after failure of first thoracostomy tube drainage
11183031|NCT03501524|Experimental|thoracostomy tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube
11183032|NCT03501511|Active Comparator|IDF modules|Diabetes educations using IDF Arabic translated modules
11183033|NCT03501511|Experimental|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
11183034|NCT03501498|Experimental|loperamide|Slows intestinal transit time
11183035|NCT03501498|Experimental|senna|Speeds up intestinal transit time
11183036|NCT03501472|Experimental|Text-only PWL, immediate post|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
11183037|NCT03501472|Experimental|Text-only PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
11183038|NCT03501472|Experimental|Low-emot PWL, immed post|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
11183039|NCT03501472|Experimental|Low-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
11183040|NCT03501472|Experimental|High-emot PWL, immed posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
11183041|NCT03501472|Experimental|High-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
11183042|NCT03501459|Experimental|Rituximab|
11183043|NCT03501433|Experimental|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
11183044|NCT03501433|Placebo Comparator|Placebo|7 days of placebo supplementation (2/day)
11183045|NCT03501420||Physicians|A sample of 230 to 325 rheumatologists actively involved in management and treatment decisions of pSS subjects in France, Italy, Spain, Germany and the United States will be included in the survey.
11183046|NCT03501420||Subjects with pSS|Subjects with a confirmed diagnosis of pSS under consultation of the rheumatologists enrolled in the study will be included.
11183047|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
11183048|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:
~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
11183049|NCT03501394|Experimental|Single Arm|25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited. During the study, patients will receive the standard care and the current study will not alter the care plan offered to them. All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions. Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery. Health questionnaire will be completed by each patient.
11183050|NCT03501381|Active Comparator|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
11183051|NCT03501381|Experimental|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
11183052|NCT03501368|Experimental|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
11183053|NCT03501355|Active Comparator|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
11183054|NCT03501355|Active Comparator|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
11183055|NCT03501342|Experimental|Virtual reality group|In virtual reality group, 30 minutes of Pilates training, 10 minutes of rest and then 20 minutes of virtual reality will be applied.
11183056|NCT03501342|Active Comparator|Dynamic Balance Training|"In the Dynamic Balance Training group, 20 minutes of dynamic balance exercises will be applied after Pilates training."
11183057|NCT03501342|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
11183058|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.
~Treatment was not changed as a result of the investigation in itself."
11183060|NCT03501316|Active Comparator|Ultrasonic Instrumentation|Root surface debridement using ultrasonic scaler.
11183061|NCT03501303|Experimental|No touch|No touch technique. Patients are randomized to no touch vein harvesting. The technique is used as routine in Medical care by some hospitals.
11183062|NCT03501303|Other|Control|Control technique. Patients are randomized to Control vein harvesting. The technique is used as routine in Medical care.
11183063|NCT03501290|Other|Oral Nutritional Supplement Group|All patients will be in one group, receiving the active product, Oral Nutritional Supplement with 'Fortimel® Protein supplementation'
11183064|NCT03501277|Experimental|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 [milligram] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Regimen D).
11183065|NCT03501277|Experimental|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen A).
11183066|NCT03501277|Experimental|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Regimen B).
11183067|NCT03501277|Experimental|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen C).
11183068|NCT03501264|Experimental|Intervention group|This group receives the game
11183069|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
11183070|NCT03501251|Experimental|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
11183071|NCT03501251|Experimental|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
11183072|NCT03501251|Experimental|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
11183073|NCT03501251|Experimental|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
11183074|NCT03501251|Experimental|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
11183075|NCT03501251|Experimental|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
11183076|NCT03501251|Placebo Comparator|Placebo|A single tablet of placebo
11183077|NCT03501238|Experimental|BSG|Participant receives bovine milk, then milk substitute, then milk substitute treated with gelatin
11183078|NCT03501238|Experimental|BGS|Participant receives bovine milk, then milk substitute with gelatin, then milk substitute
11183079|NCT03501238|Experimental|SBG|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin.
11183080|NCT03501238|Experimental|SGB|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin
11183081|NCT03501238|Experimental|GSB|Participant receives milk substitute with gelatin, then milk substitute, then bovine milk.
11183082|NCT03501238|Experimental|GBS|Participant receives milk substitute with gelatin, then bovine milk, then milk substitute.
11183083|NCT03501225|Experimental|ozone|tooth extraction under irrigation with ozonated water
11183084|NCT03501225|Experimental|water|tooth extraction under irrigation with ozonated water or doubly distilled water
11183085|NCT03501212|Active Comparator|Interventional|EMLA group layer of 2.5 gr EMLA cream (standard adult dose) was applied to both wrists
11183086|NCT03501212|Placebo Comparator|Placebo|Placebo cream was applied to both wrists
11183087|NCT03501199|Experimental|PRF Group|PRF is will be used in immediate dental implant placement.
11183088|NCT03501199|Experimental|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
11183089|NCT03501199|Experimental|Control Group|No extra material is will be used in immediate dental implant placement.
11183090|NCT03501186|Experimental|Group 1|forward walking on leveled surface
11183091|NCT03501186|Active Comparator|Group 2|forward walking on sand.
11183092|NCT03501186|Experimental|Group 3|Backward walking on leveled surface
11183093|NCT03501186|Active Comparator|Group 4|Backward walking on sand.
11183094|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
11183095|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), and the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
11184284|NCT03492736|Placebo Comparator|Placebo|30 days placebo taken nightly 1 hour before bed
11183096|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
11183097|NCT03501147|Experimental|Intervention|15 minutes of resistance training at the work place every day
11183098|NCT03501147|No Intervention|Control|Usual work
11183099|NCT03501134||Tumor treating fields|Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device
11183100|NCT03501108|No Intervention|Control|Patients in the control arm receive usual pharmaceutical care in hospital i.e. daily medication review by the attending physicians and ward-assigned pharmacist.
11183101|NCT03501108|Experimental|Intervention|Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
11183102|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
11183103|NCT03501082|Experimental|L. Reuteri PB-W1 Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
11183104|NCT03501082|Experimental|L. Reuteri DSM20016T Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
11183105|NCT03501082|Placebo Comparator|Placebo Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
11183106|NCT03501082|Experimental|L. Reuteri PB-W1 Non-Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period.The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
11183107|NCT03501082|Experimental|L. Reuteri DSM20016T Non-West Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
11183108|NCT03501082|Placebo Comparator|Placebo Non-Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
11183109|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
11183110|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
11183111|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
11183112|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
11183113|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
11183114|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
11183115|NCT03501056|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11183116|NCT03501056|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11183117|NCT03501056|No Intervention|conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11183118|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
11183333|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
11183119|NCT03501030|Experimental|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
11183120|NCT03501030|No Intervention|No activity restriction|Women in the control group will not receive any reccomandation regarding activity restriction. Bed rest and abstain from sexual intercourse will also not recommended.
11183121|NCT03501017|Experimental|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
11183122|NCT03501017|Active Comparator|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
11183123|NCT03501004|Experimental|The Acupuncture Group|Sterile acupuncture needles for single use will be used.The intervention is going to be executed using the acupuncture points GV14（Dazhui）and GB20 (Fengchi) for 20 minutes.The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14（Dazhui）and GB20 (Fengchi).
11183124|NCT03501004|Sham Comparator|The Sham Acupuncture Group|Sterile acupuncture needles for single use will be used.The sham acupuncture group's acupuncture needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points for 20 minutes.
11183125|NCT03500991|Experimental|ARM A (Tumor Cavity Infusion)|"patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
11183126|NCT03500991|Experimental|ARM B (Ventricular System Infusion)|"patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
11183127|NCT03500978|Experimental|Peer CBT Intervention|Women allocated to the peer-specialist delivered CBT intervention group will be mailed an intervention workbook (CBT exercises) and have their first telephone-based intervention session scheduled. The CBT intervention group will receive 8 telephone-based CBT intervention sessions (over 9 weeks) delivered by peer specialists. Each session will last up to 30 minutes.
11183128|NCT03500978|No Intervention|Control|Women allocated to the observation-only control group will not receive any intervention.
11183129|NCT03500965|Experimental|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
11183130|NCT03500965|Experimental|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
11183131|NCT03500965|Experimental|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
11183132|NCT03500965|Experimental|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
11183133|NCT03500952|Experimental|Patient Decision Aid|Birth Control After Pregnancy patient decision aid and supporting document
11183134|NCT03500952|Active Comparator|Patient Information Leaflet|Postpartum Birth Control patient information leaflet
11183135|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
11183136|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
11183137|NCT03500926|Active Comparator|hype standard|total hip replacement with standard femoral stem
11183138|NCT03500926|Experimental|hype mini|total hip replacement with short uncemented femoral stem
11183139|NCT03500913||Adults with growth hormone deficiency|Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
11183140|NCT03500913||Control group|Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
11183141|NCT03500900|Experimental|Vildagliptin|DPP-4 inhibitor, acute administration (50 mg.)
11183142|NCT03500900|Placebo Comparator|Placebo|Placebo treatment, acute administration
11183143|NCT03500887|Other|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
11183144|NCT03500887|Other|2. Bag inflated to ¾ volume of 1|
11183145|NCT03500874|Experimental|Systematic Chemotherapy + HAI(FUDR)|"Patients will receive Systemic FOLFOX + HAI (FUDR) every 28 days:
~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15.
~floxuridine (FUDR) 0.12mg/Kg/d,d1-14 and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
11183146|NCT03500874|Active Comparator|Systematic Chemotherapy|"Patients will receive FOLFOX every every 28 days:
~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15."
11183205|NCT03500419|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes. After the 6 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired
11183147|NCT03500861|Experimental|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
11183148|NCT03500861|Sham Comparator|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
11183149|NCT03500848|Active Comparator|Tacrolimus-based group|Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids
11183150|NCT03500848|Experimental|Sirolimus-based group|Sirolimus-based immunosuppression regimen: Tacrolimus (Tacrolimus elimination 30 (± 5) days post LT)+Sirolimus+MMF and/or steroids
11183151|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
11183152|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
11183153|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
11183154|NCT03500822|Experimental|Metronome-paced tachypnea|Dynamic hyperinflation by the method of metronome-paced tachypnea.
11183155|NCT03500822|Experimental|Exspiratory-stenosis breathing|Dynamic hyperinflation by the method of expiratory-stenosis breathing.
11183156|NCT03500809|Experimental|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).
~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
11183157|NCT03500796|Other|Corneal perforation patients|"Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention.
~Patients will undergo:
~Platelet rich plasma clot implantation Wound closure with amniotic membrane"
11183158|NCT03500783|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
11183159|NCT03500783|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
11183160|NCT03500770|Experimental|Transcranial Direct Current Stimulator|The Transcranial Direct Current Stimulator device (tDCS) is a safe technique which poses a non-significant risk to study subjects. This technique uses weak current which is applied by using two electrodes. In the literature, no undesirable or long-lasting side effects due to device have been reported, nor have any participants reportedly abandoned a study due to discomfort.
11183161|NCT03500757||360-degree Display of solid tumors|Evaluate the feed back of using the HoloLens headset to have a 360 degree visualization of patient tumors during percutaneous liver tumor ablation
11183162|NCT03500744|Experimental|Erector spinae plane block|"The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.
~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
11183163|NCT03500744|Sham Comparator|Shame block|"A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.
~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
11183164|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.
~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
11183165|NCT03500718|Experimental|Pediatric patients with bilateral sensorineural hearing loss|One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.
11183206|NCT03500419|Experimental|Group 2 - PTT 1x daily x 5 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes once daily, 5 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
11183166|NCT03500705|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
11183167|NCT03500705|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
11183168|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
11183169|NCT03500679|Experimental|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram [mcg]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
11183170|NCT03500679|Placebo Comparator|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
11183171|NCT03500666|Experimental|Robot lateral neck lymph node dissection|Robot neck lateral lymph node dissection was performed in patients with thyroid cancer and lateral cervical lymph node metastasis.
11183172|NCT03500666|Experimental|Total endoscopic lateral cervical lymph node dissection|Patients with thyroid cancer and lateral cervical lymph node metastases underwent total endoscopic neck dissection.
11183173|NCT03500653|Active Comparator|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
11183174|NCT03500653|Placebo Comparator|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
11183175|NCT03500640|Active Comparator|DPP Plus: 30-minute calls|Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
11183176|NCT03500640|Placebo Comparator|DPP Minimal: 15-minute calls|Following the 6-month, 16-session, DPP core program, 15-minute group telephone calls will be implemented. Social-support sessions occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
11183177|NCT03500627|Experimental|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
11183178|NCT03500627|Experimental|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
11183179|NCT03500627|Experimental|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
11183180|NCT03500614|Experimental|Cohort 1|Participants (n=70) will receive either true or sham air cleaner treatment for 1 week and then alternate the treatment after a wash out interval (Air cleaner use method 1). Exposure monitoring for PM2.5 will continue throughout the treatment period and air and fine particle phase phthalates samples will be collected during the last day (24 hours) of the treatment period; and health variables will be measured and biological samples will be collected immediately after the completion of each intervention period.
11183181|NCT03500614|Experimental|Cohort 2|Participants (n=30) will undergo extended treatment period covering the start, peak and end phases of smog episodes in Beijing, with either true or sham air cleaner treatment and then alternate the treatment after a wash out interval (Air cleaner use method 2). Exposure monitoring for PM2.5 will continue throughout the treatment period and repeated health examinations will be conducted at time points corresponding to the start, peak and end phases of the smog episodes.
11183182|NCT03500601|Experimental|Active treatment|Nut components
11183183|NCT03500601|Placebo Comparator|Placebo|Placebo
11183184|NCT03500588||normotensive pregnant women more than 20 weeks gestation.|Twenty pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation by using PCR.
11183185|NCT03500588||Pregnant women after 20 weeks with preeclampsia.|Thirty pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR.
11183186|NCT03500575|Experimental|photopheresis|
11183187|NCT03500575|No Intervention|control|
11183188|NCT03500562||HCV participant population in China|
11183189|NCT03500549|Experimental|1,080mg APL-2 administered subcutaneously|1,080mg APL-2 administered subcutaneously twice weekly or every three days.
11183190|NCT03500549|Active Comparator|Eculizumab|Complement (C5) Inhibitor
11183191|NCT03500536|No Intervention|Waitlist Control|8 weeks of treatment as usual followed by 8 weeks of IntelliCare treatment.
11183192|NCT03500536|Experimental|Experimental|8 weeks of IntelliCare treatment followed by 8 weeks of treatment as usual.
11183193|NCT03500523|Experimental|1-study group|study group: pregnant women
11183194|NCT03500523|Experimental|2-control group|control group: healthy non pregnant women
11183195|NCT03500484|Experimental|obese subjects|Subjects will self-administer Liraglutide once daily for 12 weeks.
11183196|NCT03500484|No Intervention|lean subjects|no intervention
11183197|NCT03500471||Experimental: Robotic surgery|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy
11183198|NCT03500471||Compared: Laparoscopic surgery|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy
11183199|NCT03500458|No Intervention|Typical Sleep|All participants will sleep for 6 nights (Sunday - Thursday) in the home environment per their usual school schedule.
11183200|NCT03500458|Experimental|Sleep Extension|Participants will be prescribed a sleep schedule that allows them to obtain 1 hour more time in bed compared to Typical Sleep.
11183201|NCT03500445|Experimental|Treatment Arm (D-KRd)|
11183202|NCT03500432|Active Comparator|periprostatic group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periprostatic block
11183203|NCT03500432|Active Comparator|PAT group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periapical triangle (PAT) block
11183204|NCT03500432|Experimental|TPA switch group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+TPA switch (transperineal prostate biopsy local anesthesia switch) block
11183265|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy.
11184626|NCT03490617|Placebo Comparator|Placebo group|Vaginal placebo tablets 4 hours prior to IUD insertion
11183207|NCT03500419|Experimental|Group 3 - PTT 2x daily x 7 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes twice daily, 7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
11183208|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
11183209|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
11183210|NCT03500393|Active Comparator|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
11183211|NCT03500393|Experimental|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
11183212|NCT03500380|Experimental|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
11183213|NCT03500380|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
11183214|NCT03500367|Experimental|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
11183215|NCT03500354|Experimental|Nutrient|Nutrient drink
11183216|NCT03500328|Active Comparator|Early Aggressive Therapy|"Higher efficacy disease-modifying therapy (Early Aggressive Therapy) for treatment of multiple sclerosis
~Early Aggressive Therapy choices and maximum allowable doses:
~Natalizumab (Tysabri), 300 mg intravenously (IV) every 4 weeks
~Alemtuzumab (Lemtrada), 12 mg IV daily for 5 days; 1 year later: 12 mg IV daily for 3 days
~Ocrelizumab (Ocrevus), 300 mg IV every 2 weeks (for 2 doses) at initiation; subsequently, 600 mg IV every 6 months
~Rituximab (Rituxan), 1000 mg IV every 2 weeks (for 2 doses); may repeat every 16-24 weeks
~Cladribine (Mavenclad), 3.5 mg per kg body weight PO divided into 2 yearly treatment courses (1.75 mg per kg body weight each year); each yearly treatment course is divided into 2 treatment cycles; administer cycle dosage as 1 or 2 tablets once daily over 4-5 consecutive days
~Ofatumumab (Kesimpta), 20 mg SC weekly for weeks 0, 1 and 2; 20 mg SC monthly starting at week 4"
11183217|NCT03500328|Active Comparator|Traditional Therapy|"First-line disease-modifying therapy (Traditional Therapy) for treatment of multiple sclerosis
~Traditional Therapy choices and maximum allowable doses:
~Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg subcutaneously (SC) daily, or 40 mg SC three times a week
~Intramuscular interferon (Avonex), 30 mcg intramuscularly (IM) weekly
~Subcutaneous interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC three times a week (Rebif)
~Pegylated interferon (Plegridy), 125 mcg SC every 14 days
~Teriflunomide (Aubagio), 14 mg orally (PO) daily
~Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day
~Diroximel fumarate (Vumerity), 462 mg PO twice a day
~Fingolimod (Gilenya and generics), 0.5 mg PO daily
~Siponimod (Mayzent), 1 mg PO daily or 2 mg PO daily
~Ozanimod (Zeposia), 0.92 mg PO daily"
11183218|NCT03500315|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 80
11183219|NCT03500315|No Intervention|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 80
11183220|NCT03500315|No Intervention|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
11183221|NCT03500302|Experimental|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
11183222|NCT03500289|Experimental|Ketamine|
11183223|NCT03500289|Placebo Comparator|Midazolam|
11183224|NCT03500276|Experimental|Yoga program|"12 weeks of Yoga in daily life practice, 2x weekly for 90 minutes including physical exercises (asanas), breathing exercises (pranayama), relaxation and meditation exercises."
11183225|NCT03500276|Active Comparator|Arthritis-education control|12 weeks of arthritis - education classes, consisting of 1x weekly sessions for 120 minutes including lectures on arthritis and related issues followed by group discussion.
11183226|NCT03500263|Active Comparator|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
11183227|NCT03500263|Placebo Comparator|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
11183228|NCT03500263|Active Comparator|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
11183229|NCT03500263|Placebo Comparator|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
11183230|NCT03500263|Active Comparator|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
11183231|NCT03500263|Placebo Comparator|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
11183232|NCT03500250||Nurses|Nurses working on the neurological wards of three hospitals (one university hospital and two general hospitals)
11183233|NCT03500237|Experimental|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
11183234|NCT03500237|Active Comparator|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychological intervention will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
11183235|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
11183236|NCT03500211|Experimental|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
11183237|NCT03500211|Sham Comparator|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
11183238|NCT03500198|Experimental|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
11183239|NCT03500198|Active Comparator|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
11183240|NCT03500185|Experimental|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
11183241|NCT03500185|Active Comparator|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
11183242|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|
11183243|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|
11183244|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|
11183245|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|
11183246|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|
11183247|NCT03500172|Active Comparator|ICM, SoC if Responsive|
11183248|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|
11183249|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|
11183250|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
11183251|NCT03500159|Placebo Comparator|Placebo|Matching placebo
11183252|NCT03500146||Normal sexual function|Patients with an overall FSFI score equal to or above 26.5 will be in the normal sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
11183253|NCT03500146||Low sexual function|Female sexual dysfunction is defined as an overall FSFI score below 26.5, patients meeting this criteria will be in the low sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
11183254|NCT03500133|Experimental|Group A|"Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
~No radiotherapy if CR at the end of chemotherapy."
11183255|NCT03500133|Experimental|Group B|"Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
~No radiotherapy if CR at the end of chemotherapy"
11183256|NCT03500133|Experimental|Group B2|"Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
11183257|NCT03500133|Experimental|Group C|"Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
~No radiotherapy if CR at the end of chemotherapy."
11183258|NCT03500133|Experimental|Group D|"Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
11183259|NCT03500133|Experimental|Group E|"High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
~No radiotherapy if CR at the end of chemotherapy"
11183260|NCT03500133|Experimental|Group F|"High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
11183261|NCT03500120||Primary Aldosteronism|Aldosterone/renin concentration ratio(ARR)≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST≥6 ng/dl
11183262|NCT03500120||non Primary Aldosteronism|1. ARR≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST<6 ng/dl
11183263|NCT03500107|Experimental|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
11183264|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 mg capsule equivalent to 150 mg migalastat HCl (herein referred to as migalastat) will be administered with water every other day for 12 months."
11183266|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
11183267|NCT03500055|Experimental|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
11183268|NCT03500055|No Intervention|Control|Normal operative procedure. The abdominal closure bundle will not be used.
11183269|NCT03500042|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
11183270|NCT03500042|Experimental|normal respiratory muscle|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
11183271|NCT03500029|Experimental|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
11183272|NCT03500029|Active Comparator|medication group|In the medication group patients with severe depression are treated with anti-depressants.
11183273|NCT03500029|No Intervention|healthy control group|The control group don't accept intervention and treatment.
11183274|NCT03500016|Experimental|Acute exercise and exercise training|"Euglycemic-hyperinsulinemic clamp before and after 8 weeks supervised exercise training. Before exercise training the participants will also do an acute exercise on 1 hour with muscle biopsies taken before and after exercise and then again 4 hours into recovery."
11183275|NCT03500003|Experimental|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
11183276|NCT03500003|Experimental|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
11183277|NCT03499977|Experimental|Sitting|The participant will be asked to sit for 10 min (not increasing their heart rate) then do the anti-saccade task
11183278|NCT03499977|Experimental|Low-Intensity Cycling|Participant will be asked to cycle for 10 min (<40% VO2R) and then perform the anti-saccade task
11183279|NCT03499977|Experimental|Moderate-Intensity Cycling|The participant will be asked to do 10 min of cycling (40-59% VO2R) followed but the anti-saccade task
11183280|NCT03499977|Experimental|High-Intensity Cycling|The participant will be asked to do 10 min of cycling (60%-84% VO2R) followed but the anti-saccade task
11183281|NCT03499964|Experimental|Optilume Treatment|The treatment arm will be the Urotronic Optilume Drug Coated Balloon (DCB).
11183282|NCT03499964|Active Comparator|Control Treatment|The control arm will be treated by a urethral dilation method considered to be best standard of care for the study site and subject. A control treatment may be either a rod, uncoated balloon or DVIU.
11183283|NCT03499951|Other|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
11183284|NCT03499951|Other|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
11183285|NCT03499925|Experimental|Test Group|Telephone consultation effectiveness and cognitive behaviors
11183286|NCT03499925|No Intervention|Comparison Group|Routine product inspection
11183287|NCT03499899|Experimental|LAG525 + spartalizumab|"Patients in this arm were given LAG525 plus spartalizumab and approximately 20 patients were randomized to this arm.
~The sponsor and the study steering committee decided to prematurely stop enrollment of subjects to Arm 1 after data review showed an increased treatment discontinuation rate due to progressive disease in Arm 1 as compared to Arms 2 and 3 (both containing Carboplatin)."
11183288|NCT03499899|Experimental|LAG525+spartalizumab+carboplatin|Patients in this arm will be given LAG525 plus spartalizumab plus carboplatin and approximately 32 patients will be randomized to this arm.
11183289|NCT03499899|Experimental|LAG525 + carboplatin|Patients in this arm will be given LAG525 plus carboplatin and approximately 32 patients will be randomized to this arm.
11183290|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/1mL|"In the intervention group, Ketamine Hydrochloride 50Mg/1mL was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention."
11183291|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/mL|in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
11183292|NCT03499873|Experimental|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
11183293|NCT03499873|Active Comparator|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
11183294|NCT03499873|Placebo Comparator|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
11183295|NCT03499847|Active Comparator|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
11183296|NCT03499847|Active Comparator|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
11183297|NCT03499847|No Intervention|Control|
11183332|NCT03499548|Experimental|Intervention|10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
11183298|NCT03499834|Experimental|Study Group|26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment
11183299|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
11183300|NCT03499808|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
11183301|NCT03499795|Experimental|VGX-3100|Adult participants, who are HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, will receive VGX-3100 administered by IM injection followed immediately by EP using the CELLECTRA™ 5PSP device. Participants will receive at least 3 doses of VGX-3100 at Day 0, Week 4 and Week 12. For partial responders at Week 36, a fourth dose may be administered at Week 40. All participants are scheduled to be followed to Week 88.
11183302|NCT03499769|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
11183303|NCT03499769|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
11183304|NCT03499756|Experimental|Couple-based interpersonal psychotherapy|The intervention consists of three weekly 2-hour antenatal sessions and two 30-minute telephone follow-up sessions delivered within four weeks postpartum.
11183305|NCT03499756|No Intervention|Control|The control group will receive the standard prenatal and postnatal care.
11183306|NCT03499743|Experimental|group1 (hyoscine Butyl-bromide group)|group1 will receive hyoscine butyl bromide 10 mg (BUSCOPAN tablets, produced by Chemical Industries Development (CID), Giza - A.R.E. under licence of Boehringer Ingelheim International GmbH - Germany) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
11183307|NCT03499743|Placebo Comparator|group 3 (PLACEBO GROUP)|will receive a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
11183308|NCT03499743|Experimental|group 2(celecoxib group)|group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide 2 hours before IUD insertion.
11183309|NCT03499704|Experimental|Pioglitazone + Alogliptin + Metformin (PAM)|Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (>=) 500 mg, tablet, orally, twice a day for up to 52 weeks. At Week 12, if participants has HbA1c >=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 52.
11183310|NCT03499704|Active Comparator|Dapagliflozin + Alogliptin + Metformin (DAM)|Dapagliflozin 10 mg, tablet, orally, once daily with alogliptin 25 mg, tablet, orally, once daily, and metformin >=500 mg, tablet, orally, twice a day, for up to Week 52.
11183311|NCT03499691|Experimental|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
11183312|NCT03499691|Active Comparator|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
11183313|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
11183314|NCT03499678||Control|Age and sex matched control individuals
11183315|NCT03499665|Experimental|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|This group of patients received patients with bruxism. It was applied proprioceptive neuromuscular facilitation (PNF), myofascial releasing maneuvers and home exercises.
11183316|NCT03499665|Active Comparator|Myofascial Releasing Maneuvers and Home Exercises Group|This group of patients received patient with bruxism. It was applied myofascial releasing maneuvers and home exercises.
11183317|NCT03499665|Active Comparator|Control Group|This group of patients received patient with bruxism. It was applied conventional treatment and no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
11183318|NCT03499652||derivation cohort|The data of derivation cohort are used to derive the neonatal bacterial meningitis risk score
11183319|NCT03499652||validation cohort|The data of validation cohort are used to validate the neonatal bacterial meningitis risk score
11183320|NCT03499639|Other|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
11183321|NCT03499626|Experimental|ASLAN001|A 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdrawal of consent.
11183322|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
11183323|NCT03499600|Experimental|Clinical Assessment and CFI|CA and CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
11183324|NCT03499600|Active Comparator|Clinical Assessment Only|CA families will receive a standard Clinical Assessment during intake.
11183325|NCT03499587||Obese pregnant women|BMI >30 with early OB visit medical records accessible
11183326|NCT03499587||Normal weight pregnant women|BMI 18.5-25 with early OB visit medical records accessible.
11183327|NCT03499574|Experimental|Biofeedback group|Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.
11183328|NCT03499574|Other|Control group|This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education
11183329|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
11183330|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
11183331|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
11186309|NCT03478826||Pneumonia|25 patients with pneumonia as a control group.
11183334|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
11183335|NCT03499535|Experimental|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
11183336|NCT03499535|Experimental|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
11183337|NCT03499535|Experimental|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
11183338|NCT03499535|Other|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
11183339|NCT03499535|Active Comparator|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
11183340|NCT03499522||Observational group|"80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.
~The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.
~On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments."
11183341|NCT03499509|Experimental|Low Glycemic Diet|
11183342|NCT03499509|Placebo Comparator|High Glycemic Diet|
11183343|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
11183344|NCT03499470|Active Comparator|Intervention|"The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.
~Actions in structured discharge and follow up protocol:
~Patient education for disease severity and medications
~Education of family/relatives about medications and types of equipment
~Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)
~Preparation of home environment for patients needs
~Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed
~Outpatient control for the first month"
11183345|NCT03499470|No Intervention|Control|Control patients will receive usual care
11183346|NCT03499457|Experimental|treatment|penicillin chalange test, as descibed.
11183347|NCT03499444|Experimental|Oral Rucaparib monotherapy|Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)
11183348|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
11183349|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
11183350|NCT03499405|Experimental|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
11183351|NCT03499405|No Intervention|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
11183352|NCT03499392|Other|psychological investigation|
11183353|NCT03499379||Women initiating use of an intrauterine device|"Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.
~A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion."
11183354|NCT03499353|Experimental|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
11183355|NCT03499340|Experimental|Text-only PWL, absolute risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
11183356|NCT03499340|Experimental|Text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
11183357|NCT03499340|Experimental|Low arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
11183358|NCT03499340|Experimental|Low arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
11183359|NCT03499340|Experimental|High arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
11183360|NCT03499340|Experimental|High arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
11183361|NCT03499327|Active Comparator|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
11183362|NCT03499327|Placebo Comparator|Wheat germ oil (untreated)|Wheat germ oil (untreated)
11183363|NCT03499327|No Intervention|Control|no study products
11183364|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
11183365|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
11183366|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
11183367|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
11183368|NCT03499288||Children and youth with cerebral palsy|Subjects between 1 month and 18 years of age with Cerebral Palsy who visited the coordinating HCP within the past 12 months.
11183369|NCT03499275|Sham Comparator|Sham NMES|Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
11183370|NCT03499275|Experimental|Active NMES|Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
11183371|NCT03499262|Experimental|Group Social ABcs|Participants receiving Group Social ABCs intervention
11183372|NCT03499249|Experimental|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
11183373|NCT03499236|Experimental|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
11183374|NCT03499236|Other|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
11183375|NCT03499236|Experimental|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
11183376|NCT03499223|Experimental|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
11183377|NCT03499223|Active Comparator|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
11183378|NCT03499210|Experimental|Investigational group|All subjects will participate in study procedures involving use of the ReWalk ReStore device.
11183379|NCT03499184|Experimental|Local Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be delivered locally every 12 hours for 12 weeks
11183380|NCT03499184|Experimental|Systemic Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be administered every 12 hours for 12 weeks
11183381|NCT03499184|Active Comparator|Systemic Antibiotics|Amoxil 500 mg capsule and Flagyl 400 mg tablet by mouth, will be given every 8 hours for 5 days
11183382|NCT03499171|Experimental|Citalopram|20mg, once a day
11183383|NCT03499171|Placebo Comparator|Placebo|Once a day
11183384|NCT03499158||1|affected arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome
11183385|NCT03499158||2|healthy arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome in the other arms
11183386|NCT03499145||Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
11183387|NCT03499132||General anesthesia (with opioids)|orthopedic surgery plus general anesthesia
11183388|NCT03499132||Epidural anesthesia (without opioids)|orthopedic surgery plus epidural anesthesia (without opioids use)
11183389|NCT03499132||Subarachnoid anesthesia (with opioids)|orthopedic surgery plus subarachnoid anesthesia (plus intrathecal opioid)
11183390|NCT03499132||Regional anesthesia (without opioids)|orthopedic surgery plus regional anesthesia (peripheral nerve block, continous or single shot, without opioid use)
11183391|NCT03499119|Other|Cohort 1|Subjects with a body weight at Day 1 of less than weight threshold.
11183392|NCT03499119|Other|Cohort 2|Subjects with a body weight at Day 1 of weight threshold or more.
11183393|NCT03499106|Experimental|Healthy Volunteers|Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.
11183394|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
11183395|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
11183396|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
11183397|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
11183398|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
11183399|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
11183400|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
11183401|NCT03499067|Experimental|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
11183402|NCT03499067|Active Comparator|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
11183403|NCT03499054|No Intervention|control group|Hemodialysis patients in the control group who receive only routine nursing care during hemodialysis
11183404|NCT03499054|Experimental|exercise group|The exercise group are asked to perform breathing exercises during hemodialysis for the study period of 3 months.
11183405|NCT03499041|Experimental|LY3314814 Control|LY3314814 administered orally to participants with normal hepatic function
11183406|NCT03499041|Experimental|LY3314814 Mild|LY3314814 administered orally to participants with mild hepatic impairment
11183407|NCT03499041|Experimental|LY3314814 Moderate|LY3314814 administered orally to participants with moderate hepatic impairment
11183408|NCT03499041|Experimental|LY3314814 Severe|LY3314814 administered orally to participants with severe hepatic impairment
11183409|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
11183410|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
11183411|NCT03499015|No Intervention|Ear without BET|ear without BET treatment works as control
11183412|NCT03499015|Experimental|BET ear|ear with BET treatment works as intervention arm
11183413|NCT03499002|Experimental|Simulation Lab|
11183414|NCT03499002|Experimental|ER in situ Simulation|
11183415|NCT03498989|Experimental|preterm formula milk neoborn|will be given preterm formula milk
11183416|NCT03498989|Experimental|exclusive breast milk|will be given exclusive breast milk
11183417|NCT03498976|Other|Pulsed radiofrequency on SE nerve|Single technic
11183418|NCT03498976|Other|Pulsed radiofrequency on SE + CF nerves|Combinated technic
11183419|NCT03498963|Other|bronchoalveolar lavage|
11183420|NCT03498950|No Intervention|Placebo Group|submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae
11183421|NCT03498950|Experimental|Test Group|submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.
11183422|NCT03498937|Experimental|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
11183423|NCT03498937|Experimental|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
11183424|NCT03498924||CASES|Patients with endometrial cancer
11183425|NCT03498924||CONTROLS|Matched controls without neoplasm disease
11183426|NCT03498911|Active Comparator|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
11183427|NCT03498911|Experimental|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
11183428|NCT03498898|Active Comparator|Group A|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
11183429|NCT03498898|No Intervention|Group B|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
11183430|NCT03498898|Active Comparator|Group C|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement.
11183431|NCT03498898|No Intervention|Group D|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement
11183432|NCT03498885|Experimental|Low ligation|Left colic artery (LCA) is identified, tie the sigmoid artery and superior rectal artery,Apical lymph node dissection with the left colic artery preservation is performed.
11183433|NCT03498885|Active Comparator|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
11183434|NCT03498872|Active Comparator|Able-bodied individuals|
11183435|NCT03498872|Experimental|Transtibial amputee|
11183436|NCT03498872|Experimental|Transfemoral amputee|
11183437|NCT03498859|Other|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
11183438|NCT03498859|Other|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
11183439|NCT03498846|Experimental|Modified EA and AMLK|Modified corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe corneal burn.
11183440|NCT03498846|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe corneal burn.
11183441|NCT03498833|Other|Test-retest reliability testing|Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
11183442|NCT03498820|Experimental|Analgesia Nociception Index|Intraoperative remifentanil administration guided by the Analgesia Nociception Index
11183443|NCT03498820|Active Comparator|Usual practice|Intraoperative remifentanil administration managed in standard practice
11183444|NCT03498807|Experimental|Control group_Use Ventilator P/V tool|Use the Pressure/Volume Loop
11183445|NCT03498807|Active Comparator|Study group_Use EIT|Use the Electrical Impedance Tomography
11183446|NCT03498794|Active Comparator|Ureteral stent|"Technique of ureteral stent insertion:
~All patients will be in lithotomy position, and an endoscopy operating table with fluoroscopic imaging capability will be used. Before the procedures, all patients will have retrograde ureteropyelography. Then, a 0.035-inch hydrophilic guide wire will be placed into the renal pelvis under the guidance of flexible cystoscope.
~The ureteral stent will be inserted retrograde by using flexible cystoscope, under mild sedation or local anesthesia by instilling 2% xylocain gel per urethra. Patients will be covered by specific antimicrobial therapy according to urine and/or blood culture. This treatment will be continued until there was no fever and any evidence of infection disappeared. A Foley's catheter will be left in the bladder for 2 hours in all patients. In each case the type of stent will be that of 5 or 6 F, with side-holes and remain in place until definitive treatment of stone."
11183447|NCT03498794|Active Comparator|Percutaneous nephrostomy tube|"Technique of PCN insertion:
~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively. The patients will be placed on the ultrasound table with fluoroscopic imaging capability in prone position and a pillow placed under the abdomen on the affected side to support the kidney. Then the initial puncture site will be chosen, cleaned and draped. Local anesthesia was injected and a stab incision was given at the puncture site. The 18-gauge Chiba needle will be inserted at the renal angle or at the posterior axillary line under ultrasound guidance into dilated pelvicalyceal system. Urine or pus drained out spontaneously or will be sucked with a disposable syringe and sample was sent to the laboratory for culture and sensitively."
11183448|NCT03498781|Experimental|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
11183449|NCT03498781|Sham Comparator|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
11183450|NCT03498768||Inpatients with lung nodules|All inpatients in our department are invited to finish the questionnaire at inpatient education on the first day of hospitalization as the baseline date, then they are followed up by phone call to reevaluate their psychosocial status at 6 months and 1 year after the surgery.
11183451|NCT03498755|Experimental|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
11183452|NCT03498755|Experimental|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
11183453|NCT03498755|Experimental|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
11183454|NCT03498742||No SABA users|Asthmatic subjects that did not use short acting beta2 agonists in the last 3 months and being using none agent or ICS, systemic corticosteroids of combined ICS/LABA as relief symptoms agent.
11183455|NCT03498742||SABA users|Most of the asthmatic subjects usually inhale SABA as rescue medication and many times SABA is the only one prescribed treatment for asthma.
11183456|NCT03498729||Persistent AF|
11183457|NCT03498729||Paroxysmal AF|
11183458|NCT03498729||Psoriasis|
11183459|NCT03498729||Healthy Controls|
11183460|NCT03498716|Experimental|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose
~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
11183461|NCT03498716|Active Comparator|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
11183462|NCT03498703|Experimental|Azathioprine|
11183463|NCT03498703|Placebo Comparator|Control|
11183464|NCT03498690|Active Comparator|Integrative|
11183465|NCT03498690|Active Comparator|Role Specific|
11183466|NCT03498690|Active Comparator|Consecutive|
11183467|NCT03498677|Active Comparator|Method of presentation one|
11183468|NCT03498677|Active Comparator|Method of presentation two|
11183469|NCT03498664|Experimental|EMR-C group|"A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.
~After submucosal injection, the cap will be applied against the lesion which will be aspirated by controlled suction, avoiding excessive protrusion of tissue in order not to trap the muscular layer.
~The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan)."
11183470|NCT03498664|Active Comparator|EMR-S group|The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
11183471|NCT03498651|Experimental|CBM-I, low attrition|Computer- or phone-based Cognitive Bias Modification - Interpretation training
11183472|NCT03498651|Experimental|CBM-I, high attrition, coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training + Coaching
11183473|NCT03498651|Experimental|CBM-I, high attrition, no coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training
11183474|NCT03498651|Active Comparator|Psychoeducation|Online psychoeducation about anxiety
11183475|NCT03498638|Experimental|Couples Therapy|Couples Therapy
11183476|NCT03498638|Placebo Comparator|Control|Couples Therapy after an 8 week waiting period
11183477|NCT03498625|Other|Clinical remission CD|
11183478|NCT03498612|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
11183479|NCT03498599|Experimental|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
11183480|NCT03498599|Other|Standard extinction|The shock is omitted during standard extinction
11183481|NCT03498586|Experimental|Half-normal saline|
11183482|NCT03498586|Active Comparator|Normal saline|
11183483|NCT03498573|Experimental|tunneling surgical technique|
11183484|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
11183513|NCT03498326|Experimental|gemcitabine plus celecoxib|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection, and receive additional celecoxib every days during chemotherapy period.
11183485|NCT03498547|Active Comparator|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
11183486|NCT03498547|Active Comparator|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
11183487|NCT03498534|Active Comparator|Patients with a -TST|In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
11183488|NCT03498534|Active Comparator|Patients with a +TST|In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
11183489|NCT03498534|Active Comparator|HIV positive patients|The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
11183490|NCT03498521|Experimental|Molecularly-Guided Therapy|Participants will be assigned to molecularly-guided therapy based on genomic profile.
11183491|NCT03498521|Active Comparator|Platinum-Based Chemotherapy|Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).
11183492|NCT03498508||Healthcare professionals in Dalarna County Council|Healthcare professionals working in-hospital at the hospitals in Mora, Avesta and Falun, Sweden, n=1473.
11183493|NCT03498508||Healthcare professionals in Region Västmanland|Healthcare professionals working in-hospital at the hospital in Västerås, Region Västmanland, Sweden, n=1571.
11183494|NCT03498495|Experimental|SMART Intervention|
11183495|NCT03498495|No Intervention|Usual Care|
11183496|NCT03498482|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
11183497|NCT03498469|Active Comparator|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
11183498|NCT03498469|Experimental|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
11183499|NCT03498456|Experimental|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
11183500|NCT03498456|Active Comparator|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
11183501|NCT03498430|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle
11183502|NCT03498417||Graves' diseases|Patients with Graves' disease. No interventions foreseen
11183503|NCT03498417||Autoimmune thyroiditis|Patients with autoimmune thyroiditis. No interventions foreseen
11183504|NCT03498417||Healthy Subjects|Normal healthy subjects. No interventions foreseen
11183505|NCT03498404|Experimental|Photodynamic Therapy and SRP|"Procedure/Surgery: Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
~Treatment with TFDa in the Test Group maintained the protocol of applications in the periods of 2, 7 and 14 days post-surgical intervention."
11183506|NCT03498404|Sham Comparator|SRP and Sham Photodynamic Therapy|Procedure/Surgery: Sham Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
11183507|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
11183508|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
11183509|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
11183510|NCT03498365|Experimental|Online MCDA|
11183511|NCT03498365|Active Comparator|Online Delphi|
11183512|NCT03498326|Experimental|gemcitabine|one group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection.
11183514|NCT03498313|Experimental|Transdermal Estradiol + Placebo|.1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
11183515|NCT03498313|Experimental|Oral Micronized Progesterone + Placebo|100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
11183516|NCT03498313|Placebo Comparator|Placebos|Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
11183517|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
11183518|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
11183519|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
11183520|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
11183521|NCT03498274|Experimental|Fitting System|a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
11183522|NCT03498274|Active Comparator|Traditional Fitting System|A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.
11183523|NCT03498261|Active Comparator|Gabapentin|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
11183524|NCT03498261|Placebo Comparator|Placebo|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
11183525|NCT03498248|Experimental|Neutropenia in chemotherapy|Neutropenia after cytotoxic chemotherapy
11183526|NCT03498235|Experimental|Team Sevoflurane|
11183527|NCT03498235|Experimental|Team Propofol|
11183528|NCT03498222|Experimental|Dose Level -1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2
11183529|NCT03498222|Experimental|Dose Level 1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 18mg/m2
11183530|NCT03498222|Experimental|Dose Level 2|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 36mg/m2
11183531|NCT03498196|Experimental|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
11183532|NCT03498183|Experimental|ARM experimental|All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.
11183533|NCT03498170|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1
~Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7"
11183534|NCT03498157|Experimental|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
11183535|NCT03498157|Active Comparator|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
11183536|NCT03498157|Active Comparator|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
11183537|NCT03498157|No Intervention|Comparison group- women too active|Added comparison group: Women who are ineligible on the basis of 'engaging in systematic intense exercise training (at least 1h twice a week) will be recruited to complete measures only, with no randomization
11183538|NCT03498144||Patients with acquired punctal stenosis|Patients with acquired punctal stenosis with epiphora
11183539|NCT03498144||Control subjects|normal subjects, without evidence of any punctal abnormalities.
11183540|NCT03498131|Experimental|3 mg Melatonin|Subjects will receive 3 mg melatonin once a day.
11183541|NCT03498131|Experimental|5 mg Melatonin|Subjects will receive 5 mg melatonin once a day.
11183542|NCT03498118|Experimental|Transversus Abdominis Plane Block group|after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
11183543|NCT03498118|Active Comparator|Wound Infiltration group|at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure
11183544|NCT03498105||Emergency Department (ED)|"450-500 participants who will;
~self present to the Emergency Department (ED) will chest pain
~be brought in by ambulance to ED with acute chest pain
~be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
11183545|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
11183546|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
11183547|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
11183548|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
11183616|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
11209193|NCT03321110|Experimental|Q10-300|coenzyme Q10 300 mg/d.
11183549|NCT03498092|Experimental|Bupivacaine-Dexmedetomidine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline and 1mcg/kg dexmedetomidine in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
11183550|NCT03498092|Active Comparator|Bupivacaine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
11183551|NCT03498092|Placebo Comparator|Saline group|This group will serve as a control and blinding group and will receive saline infiltration in the same manner.
11183552|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
11183553|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
11183554|NCT03498053|Other|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.
~The content of an experimental day is described in the study design."
11183555|NCT03498040||Patients with or at risk of carcinoid heart disease|"Adult patients with well-differentiated metastatic ileum or bronchial neuroendocrine tumor
~Adult patients with carcinoid syndrome or elevated urinary 5HIAA regardless of primary site"
11183556|NCT03498027||Data Collection|
11183557|NCT03498014|Active Comparator|Prescription as standard|
11183558|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
11183559|NCT03498001|Experimental|Patients|
11183560|NCT03497988|Experimental|Syntocinon (=Oxytocin), then Placebo|"Single-Dose Intranasal Oxytocin
~Single-Dose Placebo"
11183561|NCT03497988|Experimental|Placebo, then Syntocinon (=Oxytocin)|"Single-Dose Placebo
~Single-Dose Intranasal Oxytocin"
11183562|NCT03497975|Active Comparator|Active|162 mg nalbuphine ER tablets, BID
11183563|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
11183564|NCT03497962||ITU patients|25 patients will be recruited from the Intensive Care Unit/ High dependency unit Inclusion- Adults (>18years) with community acquired pneumonia (CAP).
11183565|NCT03497962||Healthy volunteer|24 healthy adult volunteers will be recruited to establish a comparison data set and to extend the laboratory observations to include other bacterial pathogens.
11183566|NCT03497936|Experimental|Women's Stories|Participants in this group will be randomly assigned to use the Women's Stories intervention.
11183567|NCT03497936|No Intervention|Programming as usual|Participants in this group will be randomly assigned participate in their usual programming.
11183568|NCT03497923|Active Comparator|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
11183569|NCT03497923|Experimental|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
11183570|NCT03497897|Experimental|LYS006 high dose|
11183571|NCT03497897|Experimental|LYS006 low dose|
11183572|NCT03497897|Placebo Comparator|Placebo|
11183573|NCT03497884|Experimental|Real rTMS (low frequency)|Real rTMS (low frequency) is 1Hz.
11183574|NCT03497884|Sham Comparator|Sham rTMS|Sham rTMS session includes low frequency and high frequency stimulations.
11183575|NCT03497884|Experimental|Real rTMS (high frequency)|Real rTMS (high frequency) is 10Hz.
11183576|NCT03497871|Experimental|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).
~They use the HeartMan system in addition to receiving standard care."
11183577|NCT03497871|No Intervention|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).
~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
11183578|NCT03497858|Experimental|coconut water|participants will complete the simulated basketball game with coconut water supplementation
11183579|NCT03497858|Placebo Comparator|Placebo - water|participants will complete the simulated basketball game with water supplementation
11183580|NCT03497858|Experimental|Sports drink|participants will complete the simulated basketball game with sports drink supplementation
11183581|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
11183582|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
11183583|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
11183584|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
11183585|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
11186493|NCT03477630|Active Comparator|Hyaluronic Acid|Infiltration, injected 6 cc per session, 1 sessions.
11183586|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
11183587|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
11183588|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
11183589|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
11183590|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
11183591|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
11183592|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
11183593|NCT03497819|Experimental|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
11183594|NCT03497806|Experimental|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
11183595|NCT03497793|Experimental|Skin-to-skin care with SNUBY|Mothers providing skin-to-skin care with the use of SNUBY
11183596|NCT03497780||ACL Tear|Patients with ACL tears
11183597|NCT03497780||Healthy Subjects|Healthy subjects
11183598|NCT03497767|Experimental|Osimertinib|80mg Osimerinib taken once daily
11183599|NCT03497767|Experimental|Stereotactic Radiosurgery + Osimertinib|Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily
11183600|NCT03497754|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient
11183601|NCT03497715|Experimental|Experimental 1|Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)
11183602|NCT03497715|Experimental|Experimental 2|Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules
11183603|NCT03497715|Experimental|Experimental 3|Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine
11183604|NCT03497715|Experimental|Experimental 4|Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium
11183605|NCT03497702|Experimental|Experimental|Patients receive neoadjuvant chemotherapy (doxorubicin 60mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 every 3 weeks for 4 cycles followed by docetaxel 75mg/m2 IV on day 1 every 3 weeks for 4 cycles) plus letrozole with or without leuproelin depending on menopausal status
11183606|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Intravenous (IV) or subcutaneous (SC) treprostinil induction followed by transition to oral treprostinil
11183607|NCT03497676|Experimental|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.
~Step 2: CAB LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (600 mg/3 mL), and at Week 8 (600 mg/3 mL)."
11183608|NCT03497676|Experimental|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.
~Step 2: RPV LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (900 mg/3 mL), and at Week 8 (900 mg/3 mL)."
11183609|NCT03497676|Experimental|Cohort 2: CAB + RPV|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.
~Step 4: First injection: CAB LA administered as one 600 mg (3 mL) IM injection AND RPV LA administered as one 900 mg (3 mL) IM injection, at Week 4b (Step 4 Entry) and at Week 8. Subsequent injections: starting at Week 16, CAB LA administered as a 600 mg (3 mL) IM injection AND RPV LA administered as a 900 mg (3 mL) IM injection, every eight weeks through Week 96."
11183610|NCT03497663|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
11183611|NCT03497663|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
11183612|NCT03497650|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb while observing the reflection of the exercising limb in the mirror which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
11183613|NCT03497650|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
11183614|NCT03497637|Active Comparator|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
11183615|NCT03497637|Active Comparator|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
11183617|NCT03497598|Experimental|mannose|"2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.
~rUTI diary"
11183618|NCT03497598|Placebo Comparator|placebo|"2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.
~rUTI diary"
11183619|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
11183620|NCT03497559|Experimental|Music|Patients will received 30 minutes of classical music 3 times per day . Music will be delivered with noise cancellation headphones.
11183621|NCT03497559|Sham Comparator|Noise cancellation|Patients will received 30 minutes of silent recording 3 times per day . Music will be delivered with noise cancellation headphones.
11183622|NCT03497559|No Intervention|Control|Patients will receive standard of care.
11183623|NCT03497546|Experimental|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
11183624|NCT03497546|No Intervention|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
11183625|NCT03497533|Experimental|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
11183626|NCT03497520|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 10 degree perform asymmetric spinal stabilization exercise
11183627|NCT03497507|Placebo Comparator|Sham bracelet|Patients randomized to sham group will wear bracelets on both hands which will not apply acupressure
11183628|NCT03497507|Experimental|Acupressure bracelet|Patients randomized to the experimental group will wear bracelets on both hands which will apply acupressure to the P6 acupoint.
11183629|NCT03497494|Active Comparator|Without hiatal suture|the different distance of pylorus without hiatal suture
11183630|NCT03497494|Active Comparator|With hiatal suture|the different distance of pylorus without hiatal suture
11183631|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
11183632|NCT03497468|Active Comparator|Control group|Patients in this group will receive combined exercise training included aerobic and strengthening exercises, 3 times a week for 6 weeks. All exercise sessions will be performed under the supervision of a physiotherapist.
11183633|NCT03497468|Experimental|Training group|Patients in this group will receive task-oriented training additional to combined exercise training 3 times a week for 6 weeks. Task-oriented training included more functional daily life mobility activities like reaching, obstacle walking, stairs climbing. All exercise sessions will be performed under the supervision of a physiotherapist.
11183634|NCT03497442|Experimental|Treatment Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
11183635|NCT03497442|Placebo Comparator|Placebo Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
11183636|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
11183637|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
11183638|NCT03497416||Anemic|
11183639|NCT03497416||Non-anemic|
11183640|NCT03497403|Active Comparator|Control|Socket preservation control. After tooth extraction, bone graft is applied to socket and a non-cross-linked membrane is used in primary intentional healing.
11183641|NCT03497403|Experimental|Experimental|Socket preservation experimental. After tooth extraction, bone graft is applied to socket and a cross-linked membrane is used in secondary intention healing.
11183642|NCT03497390|Active Comparator|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 3 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
11183643|NCT03497390|Placebo Comparator|Usual care|Usual management without any workshop or program
11183644|NCT03497377|Experimental|18F-DCFPyL Injection & 18F-NaF|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
11183645|NCT03497364|Experimental|Bupivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. The dose of bupivacaine depended on height of subjects.
11183646|NCT03497364|Experimental|Ropivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting ropivacaine. The dose of ropivacaine depended on height of subjects).
11183647|NCT03497364|No Intervention|Control group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. 2ml bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection for all subjects.
11183648|NCT03497351|Experimental|Group N|the group treated with nicardipine
11183649|NCT03497351|Experimental|Group U|the group treated with Urapidil
11183650|NCT03497325|Experimental|PRP|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
11186619|NCT03476733||patient with drug related problem|patient with drug related problem
11183651|NCT03497325|Placebo Comparator|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
11183652|NCT03497299|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
11183653|NCT03497299|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
11183654|NCT03497286|Experimental|Treatment|Participants in the treatment condition will be enrolled in the text-based mentorship program and will be able to engage with their assigned mentor as much or as little as they choose.
11183655|NCT03497286|Active Comparator|Control|Participants in the control condition will receive periodic informational texts related to the growth and development of their new baby.
11183656|NCT03497273|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
11183657|NCT03497260|Experimental|Fructose in water first, water only second|Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
11183658|NCT03497260|Experimental|Water only first, Fructose in water second|Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
11183659|NCT03497247|Experimental|Mindfulness-Based Cognitive-Behavioral Therapy|
11183660|NCT03497247|Active Comparator|Cognitive-Behavioral Therapy|
11183661|NCT03497234|Experimental|All women eligible to participate|All women presenting who sign the consent and found eligible will have a VF and AF sample taken and analyzed on the Perilynx Analyzer to measure AF and VF fluid. This does not affect their regular standard of care and diagnosis
11183662|NCT03497221|Other|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
11183663|NCT03497221|Other|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
11183664|NCT03497208|Experimental|Microneedling+cell susp+phototherapy|Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
11183665|NCT03497208|Active Comparator|Microneedling and phototherapy|Technique involves only the abrasion with dermaroller equipped with 0,25mm on the lesion of vitiligo.
11183666|NCT03497195|Active Comparator|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
11183667|NCT03497195|Active Comparator|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
11183668|NCT03497182|Experimental|Breath sample collection|
11183669|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
11183670|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.
~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
11183671|NCT03497117|Other|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.
~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.
~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
11183672|NCT03497091||Enteral Tube fed children|Enteral Formula
11183673|NCT03497078|Other|Refered patients for scintigraphy|
11183674|NCT03497052||Group 1|Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
11183675|NCT03497052||Group 2|Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
11183676|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
11183677|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
11183678|NCT03497026|Experimental|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
11183679|NCT03497013|Experimental|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
11183680|NCT03497013|Sham Comparator|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
11183681|NCT03497000|Experimental|OCTA group|Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
11183682|NCT03497000|Active Comparator|ICGA group|Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
11183683|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
11183684|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
11183685|NCT03496974|Experimental|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
11183686|NCT03496974|Experimental|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
11183687|NCT03496961|Experimental|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
11183688|NCT03496961|Placebo Comparator|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
11183689|NCT03496961|No Intervention|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
11183690|NCT03496948|Experimental|TeGeCoach|Home-based exercise program consisting of telephone health coaching, remote walking exercise monitoring based on wearable monitors and intensified primary care.
11183691|NCT03496948|No Intervention|Usual care group (TAU)|Patients randomized to TAU receive written information about courses offered by their statutory health insurance. Health insurance companies offer a variety of courses to encourage regular exercise and to promote lifestyle changes, including SEPs (vascular and cardio exercise), physical therapy, nutritional assistance programs, smoking cessation programs, weight loss programs, and patient education programs for obesity and diabetes.
11183692|NCT03496935|Active Comparator|Tunneled dialysis catheter|In this arm, patients will be randomized to undergo tunneled dialysis catheter insertion.
11183693|NCT03496935|Active Comparator|Non-tunneled dialysis catheter|In this arm, patients will be randomized to undergo non-tunneled dialysis catheter insertion.
11183694|NCT03496922|Experimental|Tobacco Products|Participants will be asked to sample ventilated and unventilated cigarettes (and possibly alternative nicotine products such as cigarillos). During the experimental sessions, they will be given the opportunity to purchase ventilated and unventilated cigarettes (and possibly alternative nicotine products) using an account balance in the Experimental Tobacco Marketplace. However, besides the required sampling session, participants will not be required to purchase any nicotine products.
11183695|NCT03496909|Active Comparator|Standard OT|
11183696|NCT03496909|Experimental|PhysioTouch|
11183697|NCT03496896|Experimental|"TARGET intervention"|The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.
11183698|NCT03496896|No Intervention|Control|The group control will receive usual care without additional intervention.
11183699|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
11183700|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
11183701|NCT03496870|Experimental|Opicapone once daily with Carbidopa/Levodopa|Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 & 15
11183702|NCT03496857|Experimental|Photobiomodulation analgesia|"LED therapy sessions will be held in the pre-labor room. The patient who will undergo analgesia and the professional responsible for placing the LED plate on the patient's back, between T10 and L2, will be present at the time of the intervention. The LED plate will be covered with clear disposable plastic (PVC) to avoid cross-contamination and ensure hygiene. During the interventions, the patient will be allowed to choose the position that is the most comfortable for her.
~Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention."
11183703|NCT03496857|Active Comparator|bath therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
11183704|NCT03496844|No Intervention|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
11183705|NCT03496844|Active Comparator|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
11183706|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
11183707|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
11183708|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
11183709|NCT03496818||Crohn's Disease|Participants age 18-80 years old, diagnosed with Crohn's disease with active disease based on MR enterography or CT enterography confirmed within the prior 30 days.
11183710|NCT03496818||Healthy controls|Participants age 18-80 years old, with no diagnosis of inflammatory bowel disease.
11183711|NCT03496818||Inflammatory arthritis or skin inflammation|Participants age 18-80 years old, have the ability to provide informed consent, and taking a biologic targeting TNF (infliximab, adalimumab) for at least 4 weeks.
11183712|NCT03496805|Experimental|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
11183713|NCT03496805|Placebo Comparator|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
11183714|NCT03496792|Experimental|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
11183715|NCT03496792|Placebo Comparator|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
11183716|NCT03496792|Experimental|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
11183717|NCT03496792|Placebo Comparator|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
11183718|NCT03496779|Experimental|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.
~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.
~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
11183719|NCT03496766|Experimental|Experimental Arm|Tipifarnib 600 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months
11183720|NCT03496753|Experimental|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
11183721|NCT03496753|No Intervention|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
11183722|NCT03496740|Active Comparator|Penile Block|"Ultrasound guided dorsal penile nerve block will be administered after general anesthesia.
~0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks"
11183723|NCT03496740|Active Comparator|Pudendal Block|Nerve stimulator-guided pudendal block. 0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks
11183724|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
11183725|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
11183726|NCT03496714|Active Comparator|PSYED-T|In PSYED-T (psychoeducation on trauma symptoms), participants will receive a psychoeducation handout and watch a related video on common reactions to trauma. Participants in this condition will also receive a rationale stating that both learning about the nature of trauma reactions and monitoring symptoms are important for preventing development of PTSD.
11183727|NCT03496714|Experimental|PSYED-T+SB|Participants in PSYED-T+SB (Combined psychoeducation on trauma reactions and safety behaviors) will receive psychoeducation handouts and videos on the nature of trauma symptoms and the nature of safety behaviors and how to fade them. Participants in this condition will also receive a rationale stating that learning about the nature of trauma reactions and safety behaviors, learning to fade safety behaviors, and monitoring symptoms are important in the prevention of PTSD.
11183728|NCT03496714|No Intervention|Monitoring-only control|The third condition will be a monitoring-only control and thus will receive no psychoeducation information. Participants in the control condition will receive a rationale that monitoring symptoms is important in the prevention of PTSD development.
11183729|NCT03496701|Experimental|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
11183730|NCT03496688|Active Comparator|bone substitute material MCBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using mineralized sol-vent-dehydrated bone allograft material.
11183731|NCT03496688|Active Comparator|bone substitute material FDBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using freeze-dried mineralized bone allograft material.
11183732|NCT03496688|Active Comparator|bone substitute material ABB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using anorganic bovine bone material.
11183733|NCT03496688|Active Comparator|bone substitute material EB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using equine-derived bone material.
11183734|NCT03496688|Active Comparator|bone substitute material HA-β-TCP 30/70|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using synthetic micromacroporous bi-phasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hy-droxyapatite material.
11183735|NCT03496688|Active Comparator|bone substitute material BC|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using bioapatite-collagen material.
11183736|NCT03496675|Other|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
11183737|NCT03496675|Experimental|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
11183738|NCT03496675|Experimental|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
11183739|NCT03496675|Experimental|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
11183740|NCT03496662|Experimental|Part A - Experimental|"BMS-813160 daily oral pill
~Nivolumab will be given as a 30-minute intravenous infusion at a flat dose of 480 mg on Day 1 (+/- 2 days) of each 28-day cycle
~Gemcitabine will be given as a 30-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle
~Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle
~Post-treatment biopsy at the end of cycle 2
~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
11183741|NCT03496662|Active Comparator|Part A - Control|"Gemcitabine will be given as a 30-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the assigned dose on Days 1, 8, and 15 of each 28-day cycle
~Post treatment biopsy at the end of cycle 2
~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
11183742|NCT03496662|Experimental|Part B - Dose expansion|"BMS-813160 daily oral pill
~Nivolumab will be given as a 30-minute intravenous infusion at a flat dose of 480 mg on Day 1 (+/- 2 days) of each 28-day cycle
~Gemcitabine will be given as a 30-minute intravenous infusion at the maximum tolerated dose on Days 1, 8, and 15 of each 28-day cycle
~Nab-paclitaxel will be given as a 30-40-minute intravenous infusion at the maximum tolerated dose on Days 1, 8, and 15 of each 28-day cycle
~Post-treatment biopsy at the end of cycle 2
~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
11183743|NCT03496649|Experimental|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.
~At least 2 of the 4 muscles below will be injected, depending on which muscles are affected:
~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle 200 IU for the adductor brevis muscle
~These injections will be uni or bilateral, it will depend on clinical diagnosis.
~If necessary, the 4 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
11183744|NCT03496636|Experimental|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
11183745|NCT03496623|Experimental|Inhaled Treprostinil|Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 mcg) 4 times daily (QID)
11183746|NCT03496623|Placebo Comparator|Placebo|Placebo delivered via an ultrasonic nebulizer for QID administration
11183747|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
11183748|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 166 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
11183749|NCT03496597||Patients|type 1 diabetes patients
11183750|NCT03496597||Control|non diabetic control subjects of the same age
11183751|NCT03496584|Active Comparator|Pomegranate Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Pomegranate Juice , followed by 12 weeks of pomegranate juice consumption.
11183752|NCT03496584|Placebo Comparator|Placebo Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Placebo Juice , followed by 12 weeks of pomegranate juice consumption.
11183753|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
11183754|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
11183755|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
11183756|NCT03496558|Experimental|150 pregnant women with a history of risk|
11183757|NCT03496558|No Intervention|150 healthy pregnant women|
11183758|NCT03496545|Other|Acetaminophen|standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
11183759|NCT03496545|Experimental|Bromocriptine|bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
11183760|NCT03496532|Experimental|Pulse generator change under sedation|"The efficacy of every set will be measured on induced changes in LFP recorded from the STN electrodes.LFP will be compared between before, during and right after each stimulation conditions. The stimulation order will be randomized. All other stimulation parameters will be the same (macrocontact with most beta-oscillations, 1 minute, 1.5mA) .
~Hence 4 sets of 1 minutes of STN stimulation will be performed, for:
~Symmetrical biphasic pulses versus standard pseudo monophasic pulses (study I; 2 sets).
~Pseudorandom uniform distribution stimulation paradigms versus pseudorandom Poisson distribution stimulation paradigms (study II: 2 sets)."
11183790|NCT03496311||Control Group|Fertile, non-pregnant women undergoing spinal anesthesia for elective surgery.
11183761|NCT03496532|Experimental|First pulse generator implantation under general an|The depth of anesthesia will be documented, recording the BIS spectral analysis index. The difference in spectral amplitude density of LFP, in particular in beta band oscillations will be correlated with the depth of anesthesia as measured with the BIS index.
11183762|NCT03496519|Experimental|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.
~Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2
~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2
~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2
~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2
~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
11183763|NCT03496519|Experimental|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
11183764|NCT03496506|Experimental|Sequential treatment arm|Subjects receive 1 tablet of selexipag twice daily from Day 1 to Day 9 and 1 tablet in the morning of Day 10. In the morning of Day 4 and 1 hour before the administration of selexipag, they receive 4 tablets of clopidogrel. Then from Day 5 to Day 10, 1 hour before the morning administration of selexipag, they receive 1 tablet of clopidogrel .
11183765|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
11183766|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
11183767|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
11183768|NCT03496454|Other|PfSPZ Challenge|this is a basic sciences protocol designed to study the effect of pre-exposure to Plasmodium falciparum (Pf) on malaria parasite kinetics, clinical symptoms and immunity after Controlled Human Malaria Infection by administration of an injection PfSPZ Challenge in Gambian adults. Based on a well-defined serological profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection. The classification as a clinical trial results from the administration of the PfSPZ Challenge to the healthy volunteers
11183769|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
11183770|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
11183771|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
11183772|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
11183773|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.
~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
11183774|NCT03496415|Experimental|Remote ischemic conditioning|
11183775|NCT03496415|Sham Comparator|Sham remote ischemic conditioning|
11183776|NCT03496402|Experimental|High risk Cohorts|Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
11183777|NCT03496402|Experimental|Low risk Cohort|Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
11183778|NCT03496389|Experimental|Gabapentin + panadol|
11183779|NCT03496389|Active Comparator|Tramadol + panadol|
11183780|NCT03496376|Experimental|Kinesio Taping Group|Kinesio Taping Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set plus thoracic kinesio taping application.
11183781|NCT03496376|Active Comparator|Control Group|Control Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
11183782|NCT03496363||CHD with Hypothyroidism|
11183783|NCT03496350|Experimental|Internet CBT|Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.
11183784|NCT03496350|No Intervention|Wait-list|Wait-list control
11183785|NCT03496324|Active Comparator|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
11183786|NCT03496324|Active Comparator|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
11183787|NCT03496324|Experimental|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
11183788|NCT03496324|Experimental|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.
~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
11183789|NCT03496311||Pregnant Women|Pregnant women with gestational age > 35 weeks undergoing spinal anesthesia for elective cesarean section.
11183794|NCT03496259|Experimental|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
11183795|NCT03496259|Active Comparator|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
11183796|NCT03496246|Active Comparator|Group A|patients with vitamin D deficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
11183797|NCT03496246|Active Comparator|Group B|patients with vitamin D insufficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
11183798|NCT03496246|Active Comparator|Group C|patients with normal vitamin D level normal are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
11183799|NCT03496233|Experimental|All patients included|All patients included will be treated with Elbasvir/grazoprevir for 8 weeks
11183800|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
11183801|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
11183802|NCT03496207|Placebo Comparator|Placebo|Placebo SC every 21 days plus SOC for 24 weeks
11183803|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks
11183804|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks
11183805|NCT03496194||Head of Post Anaesthesia Care Unit|The chief physician of PACUs at all Danish Anaesthesia departments will receive electronic survey on postoperative pain treatment
11183806|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.
~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
11183807|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
11183808|NCT03496168|Experimental|mavacamten (MYK-461)|
11183809|NCT03496155|Experimental|Intervention Group (Arm 1- Main)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
11183810|NCT03496155|No Intervention|Control Group (Arm 1- Main)|Will receive usual care at well-child visit.
11183811|NCT03496155|Experimental|Intervention Group (Arm 1-asthma subgroup)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
11183812|NCT03496155|No Intervention|Control Group (Arm 1-asthma subgroup)|Will receive usual care at well-child visit.
11183813|NCT03496155|No Intervention|Control Group (Arm 2)|Convenience sample used for a post-hoc, exploratory analysis. Will receive usual care at well-child visit.
11183814|NCT03496142|Active Comparator|Transperineal prostate biopsy|Patient will have a transperineal prostate biopsy.
11183815|NCT03496142|Active Comparator|Transrectal prostate biopsy|Patient will have a transrectal prostate biopsy.
11183816|NCT03496129|Experimental|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
11183817|NCT03496129|Experimental|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
11183818|NCT03496129|Active Comparator|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
11183819|NCT03496116|Experimental|ECIG Session: 0.5 Ohms, 3 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
11183820|NCT03496116|Experimental|ECIG Session 0.5 Ohms, 8 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
11183821|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 3 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
11183822|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 8 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
11183823|NCT03496103|Other|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
11209824|NCT03316339|Active Comparator|Control|
11183824|NCT03496103|Other|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
11183825|NCT03496090|Experimental|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
11183826|NCT03496090|Active Comparator|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
11183827|NCT03496077|Experimental|Flavored LCCs|Half of the group will start with a flavored little cigar/cigarillo (LCC) and cross over to unflavored LCC. The LCCs will be a popular brand already available for sale on the market.
11183828|NCT03496077|Experimental|Unflavored LCCs|Half of the group will start with an unflavored little cigar/cigarillo (LCC) and cross over to flavored LCC. The LCCs will be a popular brand already available for sale on the market.
11183829|NCT03496064||Anterior circulation LVO patients with ASPECTS <6|
11183830|NCT03496064||Anterior circulation LVO patients with NIHSS<8|
11183831|NCT03496064||Posterior versus anterior circulation LVO patients|
11183832|NCT03496064||LVO patients with isolated PCA or ACA occlusions|
11183833|NCT03496064||Tandem lesions versus non-tandem lesion|
11183834|NCT03496064||Bridging vs Direct MT|
11183835|NCT03496038|Experimental|Leukocyte and Platelet Rich Fibrin (L-PRF)|"For the test group the sub-sinus cavity will be filled with Leukocyte en Platelet Rich Fibrin (L-PRF).
~Before starting the surgery, 8 tubes (9 ml) of venous blood will be collected from the patients. A centrifugation standard L-PRF protocol will be followed followed (12 minutes centrifugation, 2700 rpm/408g RCF).
~After full centrifugation of the tubes, the L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA)."
11183836|NCT03496038|Active Comparator|Deproteinized Bovine Bone Mineral (DBBM)|For the test group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland).
11183837|NCT03496025|Experimental|Electrical stimulation|
11183838|NCT03496012|Experimental|AAV2-REP1 High Dose|Subjects will receive a single administration of high-dose AAV2-REP1 in one eye.
11183839|NCT03496012|Experimental|AAV2-REP1 Low Dose|Subjects will receive a single administration of low-dose AAV2-REP1 in one eye.
11183840|NCT03496012|No Intervention|Untreated control group|Observation.
11183841|NCT03495999||Normouricemia|Serum uric of 7mg/dl or less in men or 6mg/dl or less in women
11183842|NCT03495999||Hyperuricemia|Serum uric of 7mg/dl or more in men or 6mg/dl or more in women
11183843|NCT03495986|Experimental|Home-Based Exercise & Diet Group|16-week home based functional electrical stimulation leg cycle ergometry exercise program and diet intervention
11183844|NCT03495986|Placebo Comparator|Home-Based Diet Alone Group|Diet intervention
11183845|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
11183846|NCT03495960|Experimental|Lenalidomide (experimental arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:
~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.
~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.
~Lenalidomide is given 25 mg/d per os, days 1 to 21 every 4 weeks for 24 courses"
11183847|NCT03495960|Active Comparator|Procarbazine (comparator arm of part A)|"Patients in part A will receive 2 courses of induction chemo-immunotherapy:
~Rituximab 375 mg/m2 i.v. on days -6, 1, 15, 29; Methotrexate 3 g/m2 0.5 g/m2 in 15 min. +2.5 g/m2 in 3-hr inf. on days 2,16,30; Procarbazine 60 mg/m2/d oral on days 2 to 11.
~The duration of each treatment course is 43 days. Patients will then be randomized to receive lenalidomide or procarbazine as maintenance therapy.
~Procarbazine is given 100 mg/d per os, days 1 to 5 every 4 weeks for 6 courses"
11183848|NCT03495960|Other|Radiotherapy, temozolomide and rituximab (single arm part B)|"Patients ineligible for high-dose-methotrexate will be treated in the single-arm phase II part B of the trial and will receive
~whole-brain radiotherapy (2340 cGy in 5 weekly fractions)
~temozolomide 75 mg/m2/d during radiotherapy
~4 weekly doses of rituximab 375 mg/m2, starting on day 2 of the whole-brain radiotherapy.
~Patients will then receive maintenance therapy with 12 courses of temozolomide administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses."
11183849|NCT03495934|Experimental|single oral administration of 14C-pracinostat in the fas|
11183850|NCT03495921|Experimental|Vigil + Irinotecan and Temozolomide|"Group A Schedule:
~Temozolomide 100 mg/m2 daily, oral, Days 1 - 5, every 21 days Irinotecan 50 mg/m2 daily, oral, Days 1 - 5, every 21 days Vigil 1.0 x 10e6 cells/injection, intradermal, Day 15, every 21 days for a minimum of 4 administrations to a maximum of 12 administrations depending on quantity of Vigil manufactured from surgical specimens and so long as the patient is clinically stable and without disease progression.
~Subjects may receive repeat cycles of treatment until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study."
11183851|NCT03495921|Active Comparator|Irinotecan and Temozolomide|"Group B Schedule:
~Temozolomide 100 mg/m2 daily, oral, Days 1 - 5, every 21 days Irinotecan 50 mg/m2 daily, oral, Days 1 - 5, every 21 days
~Subjects may receive repeat cycles of treatment until disease progression, unacceptable toxicity, withdrawal of consent or other criterion is met for discontinuation from study.
~Within 6 weeks of second relapse or progression, subjects randomized to Group B, will be allowed to cross-over to receive single agent Vigil every 21 days following End of Treatment assessments. Subjects who cross-over may receive up to 12 doses of Vigil depending upon the quantity of Vigil manufactured. Cross-over must occur within 2 years of End of Treatment assessments of Group B enrollment."
11183852|NCT03495908|Experimental|VGo with Regular Human Insulin|
11183853|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|
11183888|NCT03495635|No Intervention|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
11183854|NCT03495895|Experimental|Minding the Baby|Families are visited weekly beginning in the mother's third trimester of pregnancy up through the child's first birthday, at which point visits take place biweekly up through the child's second birthday.
11183855|NCT03495895|Other|Control|Usual care control condition. Families in the control Group receive the usual care that is offered to families in the target group
11183856|NCT03495882|Experimental|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
11183857|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).
~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
11183858|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
11183859|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
11183860|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
11183861|NCT03495856|Experimental|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
11183862|NCT03495830||Carotid endarterectomy|Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.
11183863|NCT03495830||Optimal medical therapy group|Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.
11183864|NCT03495817|Experimental|Open Label ATI-50002 Topical Solution|
11183865|NCT03495804|Active Comparator|mannitol|Participants are given a minimum of 1500 mL of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
11183866|NCT03495804|Experimental|polyethylene glycol|Participants are given a minimum of 1500 mL of a preparation of polyethylene glycol as oral contrast agent over an hour prior to the examination.
11183867|NCT03495791|Experimental|EI development phase.|
11183868|NCT03495791|No Intervention|Pilot-testing phase.|
11183869|NCT03495778|Experimental|Test Granola|50.5 g Test Granola
11183870|NCT03495778|Placebo Comparator|Control Granola|54.3 Control Granola
11183871|NCT03495765|Active Comparator|Well controlled|Eligibile people with diabetic macular oedema and HBA1C < 7.5
11183872|NCT03495765|Active Comparator|Poorly controlled|eligible people with Diabetic macular oedema and HBAIC >10.0
11183873|NCT03495752|Experimental|Pre/Post Repeated Measures|Performance on the forward-step-down test (FSDT) before and at one, five, and ten minutes following the Bruce Fatigue Protocol
11183874|NCT03495739|Experimental|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
11183875|NCT03495739|Active Comparator|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
11183876|NCT03495726|Experimental|Headspace app|Participants randomized to use the mindfulness app for 6 weeks.
11183877|NCT03495726|No Intervention|Waitlist control group|This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
11183878|NCT03495713|Experimental|Single Arm|Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
11183879|NCT03495700|Experimental|L-PRF block|"For the test group the sub-sinus cavity will be filled with L-PRF block and the window will be closed with L-PRF membranes.
~Eight tubes (9 ml) of venous blood will be collected from the patients. For 6 tubes (red cap) a 12 min centrifugation at 2700 rpm/408g RCF will be followed. Two tubes (white cap) will be centrifuged (IntraSpin, Intra-Lock, Florida, USA) for 3 minutes only to form the Liquid Fibrinogen.
~The L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA).
~To prepare the L-PRF Block, L-PRF membranes will be cut into small pieces and mixed with DBBM (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The Liquid Fibrinogen will be added to the homogeneous mix, and stirred gently for ± 10 seconds while shaping it to the L-PRF block"
11183880|NCT03495700|Active Comparator|DBBM|For the control group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The window will be closed with a collagen membrane (Bio-Gide, Geistlich AG, Wolhusen, Switzerland).
11183881|NCT03495674|Experimental|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
11183882|NCT03495674|Active Comparator|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
11183883|NCT03495661|Active Comparator|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
11183884|NCT03495661|No Intervention|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
11183885|NCT03495648|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
11183886|NCT03495648|Active Comparator|Non-walking Group|Subjects will drive themselves to the farmer's market.
11183887|NCT03495635|Experimental|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
11183889|NCT03495622|Experimental|Motivational Interviewing/Text messaging|Home visits by community health worker to deliver motivational interviewing and set up a structured text messaging strategy designed around a pre-determined quit date for smoking cessation.
11183890|NCT03495622|No Intervention|Control|All participants will receive brief verbal advice about the hazards of smoking and the benefits of smoking cessation.
11183891|NCT03495609|Experimental|Ovitrelle|
11183892|NCT03495596||Videolaryngoscopy patients|The patients who were attempted to be intubated with videolaryngoscopy
11183893|NCT03495583|Experimental|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
11183894|NCT03495583|No Intervention|Standard introduction|Infants followed UK DoH standard advice for weaning
11183895|NCT03495570||A|HIV-infected (chronic or acute infection) with a HIV viral load of >1000 copies/mL in the 6 months prior to study entry and not (yet) in receipt of combination antiretroviral therapy (cART) at study entry.
11183896|NCT03495570||B|HIV-infected on cART with HIV viral load <50 copies/mL within the 6 months prior to study entry, at least one measure of HCV (chronic or acute infection) showing a detectable HCV viral load and not in receipt of HCV treatment at study entry.
11183897|NCT03495570||C|HCV mono-infected (chronic or acute infection) with detectable HCV viral load (>lower limit of quantification) in the prior 6 months and not in receipt of HCV treatment at study entry.
11183898|NCT03495570||D|HBV mono-infected (chronic or acute infection) patients with detectable HBV viral load in the prior 6 months and not in receipt of HBV treatment at study entry.
11183899|NCT03495557|Sham Comparator|Control|Simple closure
11183900|NCT03495557|Experimental|Experimental|Simple closure + mesh
11183901|NCT03495544||Hereditary BC|Pathogenic germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
11183902|NCT03495544||Sporadic BC|Without germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
11183903|NCT03495531|No Intervention|Standard of Care|Standard of Care
11183904|NCT03495531|Experimental|VR Use|Obstetrics patients who use virtual reality
11183905|NCT03495518|Active Comparator|Symptom feedback to Health Care Provider|"For those randomized to the intervention arm, symptom screening using SPARK will be completed once daily for 5 days on an iPad using the approach refined in aim 2. Daily SSPedi reports will be printed and provided in the patient chart. On days 1 and 3±1, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical care"
11183906|NCT03495518|Active Comparator|Standard of care|For those randomized to the control arm, a clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
11183907|NCT03495505|Experimental|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
11183908|NCT03495492|Experimental|Participants|Group receiving dermal chelation and nutritional therapy
11183909|NCT03495479||OMN54 -Treated|Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.
11183910|NCT03495466|Active Comparator|Local only Anesthesia|The patient will receive local only anesthesia during the first surgery and local with sedation anesthesia for their second surgery.
11183911|NCT03495466|Active Comparator|Local with sedation anesthesia|The patient will receive local with sedation anesthesia during the first surgery and local only anesthesia for their second surgery.
11183912|NCT03495453|Active Comparator|CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)|OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
11183913|NCT03495453|Active Comparator|Medtronic's Hawkone Directional Atherectomy system (DAS)|DAS (using the Hawkone device) followed by DCB
11183914|NCT03495440|Experimental|Center Sessions|Treatment condition in which participants receive psychoeducation and communication coaching.
11183915|NCT03495440|Active Comparator|At-home|Active, self-study control condition in which participants receive regular communication with study personnel and self-study materials to review on their own.
11183916|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
11183917|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
11183918|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010)
11183919|NCT03495401|Experimental|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
11183920|NCT03495401|Placebo Comparator|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
11183921|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
11183922|NCT03495375|Experimental|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
11183923|NCT03495375|Placebo Comparator|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
11186620|NCT03476733||patient without drug related problem|patient without drug related problem
11183924|NCT03495362|Experimental|Intervention group|"Ingredients: yeast beta-glucan, and capsule shell Capsule, per capsule with 500mg insoluble beta-glucan, twice a day, 1 capsule each time.
~The intervention period is about 3 months."
11183925|NCT03495362|Placebo Comparator|Placebo group|Ingredients: starch, and capsule shell Capsule, per capsule with 500mg starch, twice a day, 1 capsule each time. The intervention period is about 3 months.
11183926|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
11183927|NCT03495336|Experimental|Washout period|Coffee abstention phase for 2 weeks.
11183928|NCT03495336|Experimental|Light roast coffee (LR)|Participants will follow LR Coffee consumption procedure and consume at least 3 cups of Light (LR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
11183929|NCT03495336|Experimental|Second washout period|coffee abstention phase for 2 weeks
11183930|NCT03495336|Experimental|Dark roast coffee (DR)|Participants will follow DR Coffee consumption procedure and consume at least 3 cups of Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
11183931|NCT03495323|Experimental|Prexasertib + LY3300054|"Prexasertib is administered intravenously twice per cycle
~LY3300054 is administered intravenously twice per cycle"
11183932|NCT03495310|Experimental|Mindfulness|"In this group, children and their parents will receive a mindfulness session once a week, with a duration of 90 minutes, during 8 weeks (sessions will be separated for children and parents). Mindfulness sessions will be coordinated by experts in mindfulness techniques in children and adults respectively from the collaborator Institution Spanish School of Transpersonal Development Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan if necessary. Also a 60-minute walk 3 times a week will be recommended"
11183933|NCT03495310|No Intervention|Control|In this group, children and their parents will receive information regarding what is a healthy diet and physical activity attached to the World Health Organization recommendations. The session will be coordinated by a pediatric endocrinologist. Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan when necessary. Also a 60-minute walk 3 times a week will be recommended
11183934|NCT03495297|No Intervention|S-ICD Implant with defibrillation test|Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant
11183935|NCT03495297|Experimental|S-ICD Implant without defibrillation test|Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant
11183936|NCT03495284|Experimental|Potato treatment|Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet. The potato-based side dish will be prepared at the Penn State Metabolic Kitchen. The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium. French fries will not be provided. The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
11183937|NCT03495284|Active Comparator|Refined grain treatment|Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
11183938|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:
~Patient's undergoing hemodialysis.
~Male and female of any race
~18 years/ older.
~Those with dysphagia were excluded.
~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.
~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.
~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
11183939|NCT03495271||Healthy Controls|"Inclusion Criteria
~No tongue, lip, or cheek piercings
~Over 18 years of age
~Normal taste and smell function
~No known issues with salivation or dry mouth
~Willing to comply with study protocol (taste samples and provide saliva)
~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
11183940|NCT03495258|Experimental|Clarion Evolve Laser Vaporization System|Clarion Evolve Laser Vaporization System
11183941|NCT03495258|Experimental|Olympus TURis Plasma Vaporization|Olympus TURis Plasma Vaporization
11183942|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
11183943|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
11183944|NCT03495219||Esophageal Manometry|Esophageal manometry is a test to assess motor function of the upper esophageal sphincter, esophageal body and lower esophageal sphincter
11183945|NCT03495206|Experimental|Y-2(Edaravone And Borneol) sublingual tablet|
11183946|NCT03495193|Active Comparator|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
11183947|NCT03495193|Active Comparator|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
11183948|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
11183949|NCT03495167|Experimental|SyB C-1101|
11183950|NCT03495154|Experimental|Parietene DS Composite Mesh|Patients treated with Parietene DS Composite Mesh
11184022|NCT03494673||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo BOLD MRI with prospective CO2 targeting
11183951|NCT03495141|Active Comparator|Supervised|Participants first take part in supervised/coached colonoscopy module session twice (case one and case two) and then transition to performing an unassisted colonoscopy module twice (case three and case four).
11183952|NCT03495141|Active Comparator|Unsupervised|Participants will either first partake in an unsupervised colonoscopy module twice (case one and case two) and then transition to a supervised/coached colonoscopy module session twice (case three and case four).
11183953|NCT03495128|Experimental|Bed rest|Three days of bed rest at -6 degrees of head-down tilt
11183954|NCT03495128|Experimental|Reconditioning|Three days of one-legged knee extension contractions to recondition one leg
11183955|NCT03495115|Active Comparator|SCREENING MRI|Standard MRI procedure will be used.
11183956|NCT03495115|Experimental|SCREENING MG BI-RADS 4/5|"RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.
~RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .
~The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
11183957|NCT03495102|Active Comparator|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
11183958|NCT03495102|Experimental|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
11183959|NCT03495102|Experimental|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
11183960|NCT03495089|Experimental|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.
~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
11183961|NCT03495089|Experimental|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.
~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
11183962|NCT03495089|Experimental|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
11183963|NCT03495076|Experimental|Saline injection|In the saline condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline solution.
11183964|NCT03495076|Sham Comparator|Sham injection|In the sham injection condition, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
11183965|NCT03495076|No Intervention|Control|Participants in the control condition will not receive any kind of pain or pinprick sensation.
11183966|NCT03495063|Experimental|Natural Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
11183967|NCT03495063|Experimental|Synthetic Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
11183968|NCT03495037|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
11183969|NCT03495037|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
11183970|NCT03495024|Other|Smoking cessation with varenicline|FDA-approved indication of varenicline for smoking cessation
11183971|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
11183972|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
11183973|NCT03494998||Children and young people|Aged 0-16 years
11183974|NCT03494985|Experimental|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
11183975|NCT03494985|Experimental|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
11183976|NCT03494985|Experimental|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
11183977|NCT03494985|Sham Comparator|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
11183978|NCT03494972|Active Comparator|drain|Tetracyclin drain
11183979|NCT03494972|Sham Comparator|No-drain|No drain
11183980|NCT03494959|Experimental|Treatment with Pentaglobin|Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days.
11183981|NCT03494946|Experimental|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
11183982|NCT03494946|Active Comparator|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
11183983|NCT03494933|Experimental|CRT-P group|Intervention: CRT-P implantation
11183984|NCT03494933|Active Comparator|CRT-D group|Intervention: CRT-D implantation
11183985|NCT03494920|Other|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
11183986|NCT03494920|Other|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
11183987|NCT03494907|Experimental|Seltorexant (Low and high dose)|Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
11183988|NCT03494907|Experimental|Moxifloxacin|Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
11183989|NCT03494907|Experimental|Placebo Matched to Seltorexant|Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
11183990|NCT03494907|Experimental|Placebo Matched to Moxifloxacin|Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
11183991|NCT03494894||patients with Cystic Fibrosis and Primary Ciliary Dyskinesia|
11183992|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
11183993|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
11183994|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
11183995|NCT03494855||Neonates|<1 month of age SyMRI software used for brain imaging and radiological interpretation
11183996|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
11183997|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
11183998|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
11183999|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
11184000|NCT03494842|Active Comparator|the active TENS group|Transcutaneous nerve stimulation (TENS)
11184001|NCT03494842|Placebo Comparator|the placebo TENS group|Placebo Transcutaneous nerve stimulation (TENS)
11184002|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
11184003|NCT03494803||Control|
11184004|NCT03494803||Prostate Cancer|
11184005|NCT03494777|Experimental|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.
~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.
~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
11184006|NCT03494777|Experimental|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.
~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
11184007|NCT03494777|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
11184008|NCT03494764|Active Comparator|5 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
11184009|NCT03494764|Active Comparator|3 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
11184010|NCT03494751|Experimental|Heart Monitor|We used the device (heart monitor) in the patients with myocardial infarction.
11184011|NCT03494751|Active Comparator|No Heart Monitor|No heart monitor device in the patients with myocardial infarction (control).
11184012|NCT03494738||Newborn infants|Neonates born from consented women at the study hospital
11184013|NCT03494725|Active Comparator|Lpc-37|"Lactobacillus paracasei Lpc-37
~1x 1 capsule in the morning for 5 weeks"
11184014|NCT03494725|Placebo Comparator|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule
~1x 1 capsule in the morning for 5 weeks"
11184015|NCT03494712|Experimental|S 95010|Increasing single doses of S 95010 to 5 subjects.
11184016|NCT03494712|Placebo Comparator|Placebo|Increasing single doses of Placebo to 2 subjects.
11184017|NCT03494699|Experimental|Intervention group|
11184018|NCT03494699|No Intervention|Control group|
11184019|NCT03494686|Experimental|LLETZ under local anaesthesia|The LLETZ procedure will be performed under local anaesthesia
11184020|NCT03494686|Active Comparator|LLETZ under general anaesthesia|The LLETZ procedure will be performed under general anaesthesia
11184021|NCT03494673||Control|Normal controls without headaches will undergo BOLD MRI with prospective CO2 targeting
11186621|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
11184023|NCT03494647|Active Comparator|Cheetah Heel Cup|Subjects randomly assigned to this group will receive the Cheetah Heel Cup at their initial visit.
11184024|NCT03494647|Active Comparator|The X Brace|Subjects randomly assigned to this group will receive the X Brace at their initial visit.
11184025|NCT03494634|Experimental|Chidamide|
11184026|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
11184027|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
11184028|NCT03494595||Thrombosis|Patients who will develop thrombosis perioperatively
11184029|NCT03494595||No thrombosis|Patients who will not develop thrombosis perioperatively
11184030|NCT03494582|Experimental|Sacral Hysteropexy|Abdominal approach for uterine suspension
11184031|NCT03494582|Experimental|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
11184032|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
11184033|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
11184034|NCT03494530|Other|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
11184035|NCT03494530|Other|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
11184036|NCT03494517||Preeclampsia|"Women aged 18-45 years
~Confirmed pregnancy > 30 weeks of gestation
~Singleton or multiple pregnancies
~Admission in maternity of the Women's hospital with clinically suspected signs of severe preeclampsia:
~Systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg and
~Proteinuria > 0.3 grams in a 24-hour urine or protein:creatinine ratio >0.3 or
~Signs of end-organ dysfunction (platelet count < 100'000G/l, serum creatinine >110 mg/l, or doubling of the serum creatinine, elevated serum transaminases to twice normal concentration)"
11184037|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
11184038|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
11184039|NCT03494504|Placebo Comparator|Vehicle Ophthalmic Solution|
11184040|NCT03494478|Experimental|Cohort group|All participants will have evaluations at inclusion and 12 months. Neuropsychological testing Actimetry Selfquestionnaires on emotional topics
11184041|NCT03494465|Active Comparator|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.
~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
11184042|NCT03494465|Experimental|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.
~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
11184043|NCT03494452||Low back pain - no intervention|Patients who perform sitting occupational activities for at least 4 hours/day and have had low back pain for at least the previous 6 months
11184044|NCT03494452||Healthy - no intervention|Healthy persons who perform sitting occupational activities for at least 4 hours/day
11184045|NCT03494426|Experimental|interventional group|patients will receive Radiofrequency thoracic sympathectomy then will receive pregabalin ,tramadol,and tricyclic antidepressants
11184046|NCT03494426|Active Comparator|control group|patients will receive pregabalin ,tramadol,and tricyclic antidepressants
11184047|NCT03494413|Experimental|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
11184048|NCT03494413|Experimental|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
11184049|NCT03494400|Experimental|Tamoxifen Aerobic Training Presential|A group of women with breast cancer who use Tamoxifen and will perform aerobic training presential.
11184050|NCT03494400|Experimental|Aromatase Inhibitor Training Presential|A group of women with breast cancer who use Aromatase Inhibitor and will perform aerobic training presential.
11184051|NCT03494400|Active Comparator|Training Presential without Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform aerobic training presential.
11184052|NCT03494400|No Intervention|Training with Breast Cancer|A group of women with breast cancer who use hormone therapy and will not perform any physical training
11184053|NCT03494400|Experimental|Tamoxifen Training Home-based|A group of women with breast cancer who use Tamoxifen and will perform aerobic training home-based.
11184054|NCT03494400|Experimental|Aromatase Inhibitor Home-based|A group of women with breast cancer who use Aromatase Inhibitor and will perform aerobic training presential.
11184055|NCT03494387|Experimental|1|
11184056|NCT03494387|Experimental|2|
11184057|NCT03494374|Experimental|treatment group|Treatment with UCBL and exercise therapy
11184058|NCT03494361||Young normal group|normal participants below 60 years
11184059|NCT03494361||Old normal group|normal participants above 60 years
11184060|NCT03494348|No Intervention|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
11210035|NCT03314935|Experimental|Treatment Group A|INCB001158 + FOLFOX
11184061|NCT03494348|Active Comparator|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
11184062|NCT03494335|Experimental|Volunteer participants|Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
11184063|NCT03494322|Experimental|Avelumab + cetuximab|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.
~Avelumab + cetuximab combination therapy:
~Cycle 1
~Day 1: Cetuximab 500* mg/m2 given IV over approx 3 hrs
~Day 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr
~All other cycles:
~- Days 1 and 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr
~*Cetuximab dose will be dependent on outcome of safety run-in.
~There must be a 60 minute break between the administration of cetuximab and avelumab."
11184064|NCT03494322|Other|Avelumab monotherapy|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.
~Avelumab monotherapy will be given as follows:
~All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour"
11184065|NCT03494309|Experimental|ORIF|Open Reduction & Internal Fixation
11184066|NCT03494309|Active Comparator|CREF|Closed Reduction & External Fixation
11184067|NCT03494296||Open, multi-center, prospective|All enrolled and relapsed patients received D-COP regimen chemotherapy
11184068|NCT03494283||CrossFit injuries|
11184069|NCT03494270|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
11184070|NCT03494270|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
11184071|NCT03494257|Active Comparator|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
11184072|NCT03494257|No Intervention|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
11184073|NCT03494244||ADM|Patients having undergone direct-to-implant breast reconstruction using acellular dermal matrix.
11184074|NCT03494244||Non-ADM (Vicryl)|Patients having undergone direct-to-implant breast reconstruction using non-acellular dermal matrix mesh (Vicryl mesh).
11184075|NCT03494231|Experimental|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
11184076|NCT03494218|Experimental|vegetative state|patients with vegetative state lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
11184077|NCT03494218|Experimental|minimally conscious state|Patients with minimally conscious state display inconsistent, but reproducible and discernible signs of awareness using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
11184078|NCT03494205|Experimental|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.
~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.
~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
11184079|NCT03494205|Active Comparator|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
11184080|NCT03494192|Experimental|scapula based|"Cold pack
~Stretching Exercises
~Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week"
11184081|NCT03494192|Experimental|scapula&rotator cuff based|"Cold pack
~Stretching Exercises
~Exercise training focus on scapulothoracic muscles
~Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week"
11184082|NCT03494179|Experimental|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
11184083|NCT03494179|Experimental|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
11184084|NCT03494166|No Intervention|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, they will receive baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone will assess symptoms. Approximately 35% of all participants will be in this group.
11184085|NCT03494166|Experimental|High Need A-SMH or TIP-C|Participants will be mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant will be called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. Calls will last approximately 10 minutes. After 4 weeks, participants will be re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIP-C) Intervention for the subsequent 8 weeks. If the TIP-C is added, the counselor will call the participant once per week for about 35-40 minutes to assess and discuss strategies for managing symptoms, provide survivorship education, and discuss interpersonal relationships, communication, and social support. At week 13, the participant will complete the second assessment.
11184086|NCT03494166|Experimental|High Need B-TIP-C+SMH|Participant will be called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor will assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls will focus be the SMH protocol. At week 13, the second assessment will be conducted.
11186622|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
11184087|NCT03494127|Experimental|Group A|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
11184088|NCT03494127|Experimental|Group B|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks followed by DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
11184089|NCT03494114|Experimental|COPD Patients|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ. In addition, PET imaging data will be compared with disease severity, based on pulmonary function testing.
11184090|NCT03494114|Experimental|Individuals without COPD|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ.
11184091|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
11184092|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
11184093|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
11184094|NCT03494088||Children with Autism with gastrointestinal (GI) symtpoms|
11184095|NCT03494088||Children with Autism without gastrointestinal (GI) symtpoms|
11184096|NCT03494088||Healthy Children|
11184097|NCT03494062|Experimental|Exercise|Home-based exercise intervention
11184098|NCT03494062|No Intervention|Control|Usual care
11184099|NCT03494049|Active Comparator|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.
~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
11184100|NCT03494049|Active Comparator|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
11184101|NCT03494036|Experimental|Synbiotic|Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days
11184102|NCT03494036|Placebo Comparator|Placebo|Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days
11184103|NCT03494010||prospective cohort|Patients will be followed to determine the impact of the hybrid closed-loop (HCL) system that was prescribed at part of clinical care.
11184104|NCT03494010||historical controls|Medical record data of these patients, who did not use the HCL system, will be compared with patients in the HCL cohort.
11184105|NCT03493997|Experimental|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
11184106|NCT03493997|Active Comparator|Radiotherapy only|Radiotherapy only
11184107|NCT03493984|Experimental|Ginger exosomes|
11184108|NCT03493984|Experimental|Aloe exosomes|
11184109|NCT03493984|Experimental|Ginger and aloe exosomes|
11184110|NCT03493984|Placebo Comparator|Placebo|
11184111|NCT03493971|Active Comparator|Carotid artery stenting (CAS)|Carotid revascularization performed using CAS
11184112|NCT03493971|Active Comparator|Carotid endarterectomy (CEA)|Carotid revascularization performed using CEA
11184113|NCT03493958|Other|Education/control|Education/monitor only (insomnia education web-based program that participants access and read at their own pace contains no customization of program based on sleep diary responses). Participants in the control group are given educational information (like they might see on WebMD or National Sleep Foundation websites), but are left to apply it themselves.
11184114|NCT03493958|Experimental|Intervention Group|6 sessions modules of SHUTi intervention (at least one module completed while inpatient, the rest while outpatient): In SHUTi, customization is based on multiple variables, including sleep diary responses. The SHUTi program tailors specific recommendations based on sleep diary responses or other input within the program (e.g., responses on the Dysfunctional Beliefsand Attitude Scale trigger recommendations for specific cognitive restructuring strategies).
11184115|NCT03493945|Experimental|Arm 1.1|M7824 + ALT-803
11184116|NCT03493945|Experimental|Arm 2.1A|M7824 + BN-Brachyury
11184117|NCT03493945|Experimental|Arm 2.1B|M7824 + BN-Brachyury
11184118|NCT03493945|Experimental|Arm 2.2A|M7824 + BN-Brachyury + ALT-803
11184119|NCT03493945|Experimental|Arm 2.2B|M7824 + BN-Brachyury + ALT-803
11184120|NCT03493945|Experimental|Arm 2.3A|M7824 + BN-Brachyury + ALT-803 + Epacadostat
11184121|NCT03493945|Experimental|Arm 2.3B|M7824 + BN-Brachyury + ALT-803 + Epacadostat
11184122|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
11184123|NCT03493919|Experimental|rMenB+OMV NZ Group|Approximately 510 healthy subjects vaccinated intramuscularly with Bexsero vaccine at Day 1 and Day 61 and have blood collected at Day -83, Day 8 and Day 98.
11184124|NCT03493919|Experimental|MenACWY 1 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -83, Day 8 and Day 151.
11184125|NCT03493919|Experimental|MenACWY 2 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -60, Day 31 and Day 151.
11184126|NCT03493919|Experimental|MenACWY 3 Group|Approximately 170 healthy subjects vaccinated intramuscularly with Menveo vaccine at Day 1 and have blood collected at Day -30, Day 61 and Day 151.
11184127|NCT03493906|Experimental|Intervention|Patient Ambassador Support
11184128|NCT03493893||Affixus|To compare Affixus to PFNA and TFNA
11184129|NCT03493893||PFNA|To compare PFNA to Affixus and TFNA
11184130|NCT03493893||TFNA|To compare TFNA toPFNA and Affixus
11184131|NCT03493880||naCT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
11184132|NCT03493880||naCRT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
11184133|NCT03493867|Other|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
11184134|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
11184135|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
11184136|NCT03493841|Experimental|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
11184137|NCT03493841|Experimental|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
11184138|NCT03493828|Active Comparator|TAP using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
11184139|NCT03493828|Active Comparator|TAP using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
11184140|NCT03493828|Placebo Comparator|Placebo|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
11184141|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
11184142|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
11184143|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
11184144|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
11184145|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
11184146|NCT03493776|Active Comparator|Pre-Transplant Group|VZV Subunit vaccine will be administered
11184147|NCT03493776|Experimental|Post-Transplant Group|VZV Subunit vaccine will be administered
11184148|NCT03493763||serum AFP negative HCC patients|"Patients who received liver resection within 3 months;
~Hepatocellular carcinoma confirmed pathologically;
~Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
11184149|NCT03493750|No Intervention|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.
~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.
~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.
~If care are indicated, they will be organized but outside this trial."
11184150|NCT03493750|Experimental|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.
~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.
~If care are indicated, they will be organised but outside this trial."
11184151|NCT03493737||HaH (Hospital-at-Home)|Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
11184152|NCT03493737||OH (Outpatient Hospital)|Bortezomib is always injected at Outpatient hospital
11184153|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
11184154|NCT03493711||Milk-based fomula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
11184155|NCT03493698|Experimental|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
11184156|NCT03493698|Experimental|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
11184157|NCT03493698|Experimental|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
11184158|NCT03493685|Experimental|sparsentan for double-blind and open-label extension|Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
11184159|NCT03493685|Active Comparator|Irbesartan|Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
11184160|NCT03493659|No Intervention|Sit-Sit|The participants will sit during the tutorials, and sit during the concept tests given to measure their learning.
11184161|NCT03493659|Active Comparator|Sit-Stand|The participants will sit during the tutorials. Intervention: Behavioral: Standing during Concept Test will be administered
11184162|NCT03493659|Active Comparator|Stand-Stand|The participants will stand during the tutorials, and stand during the concept tests given to measure their learning. Intervention: Behavioral: Standing during Concept Test and regular tutorial session will be administered.
11184163|NCT03493659|Active Comparator|Stand-Sit|"The participants will stand during the tutorials. Intervention: Behavioral: Standing during regular tutorial session will be administered.
~However, participants will sit during the concept tests given to measure their learning."
11184164|NCT03493646|Active Comparator|Azacitidine|6 cycles of azacitidine (28 day cycle)
11184165|NCT03493646|Experimental|CC 486|6 cycles CC 486 (28 day cycle)
11184166|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
11184167|NCT03493620|Experimental|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
11184168|NCT03493620|Sham Comparator|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
11184169|NCT03493607|Experimental|AMO-01|Intravenous Infusion
11184170|NCT03493594|No Intervention|Control|"Control group will receive standard health care.
~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
11184171|NCT03493594|Experimental|Nutrition education program|"The intervention group will receive an early nutrition program for 12 months. Workshops format will be mainly in form of talks and experience sharing groups which run by lactation consultants, nutritionists / dietitians. All classes and workshops will be run for 4-6 times to cater for subjects recruited in different phases.
~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
11184172|NCT03493581|Experimental|NSCLC patients|
11184173|NCT03493568|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Table|switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
11184174|NCT03493568|Active Comparator|Dolutegravir 50 mg plus one RTI (at label dose)|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
11184175|NCT03493555|Experimental|Intervention Development|Peer Health Navigator for PrEP
11184176|NCT03493542|Experimental|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
11184177|NCT03493542|Active Comparator|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
11184178|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
11184179|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
11184180|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
11184181|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
11184182|NCT03493503|Experimental|Salbutamol loading dose|Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.
11184183|NCT03493503|Placebo Comparator|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes.
11184184|NCT03493490|Experimental|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
11184185|NCT03493490|Active Comparator|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
11184186|NCT03493490|Placebo Comparator|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
11184187|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
11184188|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
11184189|NCT03493464|Experimental|Treatment|Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
11184213|NCT03493295||Levonogestrel IntraUterine System (LNG-IUS)|Women in childbearing age between 18 to 30 years old and who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at the routine clinical practice setting in Spain
11184214|NCT03493282|Active Comparator|Active Treatment- CT1812 100 mg|7 subjects randomized to 100 mg CT1812
11184190|NCT03493451|Experimental|NK/T cell lymphoma and with other mature T-cell neoplasms|"In this cohort, participants will be treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle.BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
~Cohort 1: Participants with relapsed or refractory extranodal NK/T cell lymphoma (nasal or non-nasal type)
~Cohort 2: other mature T-cell neoplasms (limited to the following histologies: peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, or anaplastic large-cell lymphoma)
~Cohort 3: cutaneous T-cell lymphoma (limited to mycosis fungoides and Sèzary syndrome)"
11184191|NCT03493438|Experimental|Relaxation Group|Patients performed Jacobson relaxation technique in supine position. Respiration control and various visual imaging techniques were used during the technique. Relaxation exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
11184192|NCT03493438|Experimental|Proprioceptive Neuromuscular Facilitation Group|Patients exercised with proprioceptive neuromuscular facilitation technique for trunk muscles using chopping and lifting patterns with ritmic initiation PNF exercises were made by the physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
11184193|NCT03493438|Experimental|Core stabilization group|Patients had core stabilization exercises that involved spinal mobility. The patients performed the drawing-in maneuver within various visual imaging techniques during all exercises, especially with respiratory control. Exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
11184194|NCT03493438|Other|control group|Patients in the control group were told the importance of a single session exercise
11184195|NCT03493425|Active Comparator|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
11184196|NCT03493425|Experimental|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
11184197|NCT03493412|Experimental|BH4-Placebo|Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
11184198|NCT03493412|Experimental|Placebo-BH4|Subjects will be tested on two different days, first day will be baseline and placebo and second day will be Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin). Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
11184199|NCT03493399|Experimental|Problem Gamblers|Interference
11184200|NCT03493386|Experimental|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
11184201|NCT03493386|Experimental|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
11184202|NCT03493386|Experimental|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
11184203|NCT03493386|Experimental|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
11184204|NCT03493373|Experimental|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
11184205|NCT03493373|Experimental|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
11184206|NCT03493360|Experimental|Visual feedback|Participants will be asked to perform movements of the low back while looking at a mirror for visual feedback.
11184207|NCT03493360|Active Comparator|No visual feedback|Participants will be asked to perform movements of the low back while the mirrors are covered and no visual feedback is provided.
11184208|NCT03493347|Experimental|Equine-assisted Occupational Therapy|All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
11184209|NCT03493334|Experimental|Visual feedback|Participants in this group will receive visual feedback of their neck when performing 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation).
11184210|NCT03493334|Active Comparator|No visual feedback|Participants in this group will perform 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation) without feedback.
11184211|NCT03493321|Experimental|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
11184212|NCT03493308|Experimental|Pain neuroscience and exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines, covering the neurophysiology of pain, transition from from acute to chronic pain and the nervous system ability to modulate the pain experience. exercise will include general exercise and dance.
11186623|NCT03476694|Experimental|20ml of 0.75% Ropivacine|
11184215|NCT03493282|Active Comparator|Active Treatment- CT1812 300 mg|7 subjects randomized to 300 mg CT1812
11184216|NCT03493282|Placebo Comparator|Placebo|7 subjects randomized to matching placebo
11184217|NCT03493269|Experimental|BAY1834845|"Part 1 in healthy male subjects:
~Dose Groups 1-4 : orally administered multiple ascending doses. The treatment will last 10 consecutive days (treatment period1) and 1 day (treatment period 2) Dose Group 5: The treatment will last 1 day (treatment period 1) and 10 consecutive days (treatment period 2)"
11184218|NCT03493269|Placebo Comparator|Matching Placebo|Part 1: Matching placebo in healthy male subjects.
11184219|NCT03493269|Experimental|Chosen dose of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with psoriasis
11184220|NCT03493269|Placebo Comparator|Placebo|Part 2: The placebo will be adminstered in female and male patients with psoriasis
11184221|NCT03493256||type 2 neurological complications present|The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
11184222|NCT03493256||type 2 neurological complications absent|The group of patients without neurological complications.
11184223|NCT03493243||Adolescents exposed|Only clinical questionnaires
11184224|NCT03493230|Experimental|Patient with malignant melanoma|Patient with advanced or metastatic malignant melanoma (stage IIIB inoperable or IIIC or stage IV) will have a first blood test before any treatment, then at day 15 or 30 after initiation of therapy, and every two months until recurrence or progression for a maximum of 22 months.
11184225|NCT03493217|Experimental|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
11184226|NCT03493204|Experimental|Home-delivered, salt restricted|Meal description: salt-restricted (1500 mg to 2000 mg daily), > 2100 kilocalorie, high protein (>80 g daily) in addition to receiving standard pamphlet receipt
11184227|NCT03493204|Active Comparator|Dietary Advice|Standard of care, advice on salt-restriction using standard pamphlet receipt
11184228|NCT03493191|Experimental|0.5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)
11184229|NCT03493191|Experimental|1 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)
11184230|NCT03493191|Experimental|2 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)
11184231|NCT03493191|Experimental|5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)
11184232|NCT03493191|Experimental|10 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
11184233|NCT03493191|Experimental|20 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
11184234|NCT03493178|Active Comparator|MCI-active|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
11184235|NCT03493178|Placebo Comparator|MCI-placebo|30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks
11184236|NCT03493139|Experimental|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
11184237|NCT03493139|Experimental|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
11184238|NCT03493126|Experimental|Estradiol|Estrace: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
11184239|NCT03493126|Placebo Comparator|Placebo|Placebo: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
11184240|NCT03493100|Experimental|oral nutritional supplementation|This group receives optimized nutritional support, by ONS for a period of four weeks.
11184241|NCT03493100|Other|Control|The control group will receive treatment according to usual care.
11184242|NCT03493087|Active Comparator|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
11184243|NCT03493087|Active Comparator|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
11184244|NCT03493061|Experimental|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:
~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
11184245|NCT03493048|Experimental|Cetuximab Plus FOLFOXIRI|Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
11184246|NCT03493048|Active Comparator|Cetuximab Plus FOLFOX|Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
11184247|NCT03493035||MCA aneurysm group|All patients with unruptured MCA aneurysm diagnosed on three-dimensional computed tomography angiography (3D CTA) and transcranial color-coded sonography (TCCS) .
11184248|NCT03493035||non-MCA aneurysm group|All patients with no evidence of intracranial pathologies on 3D CTA and diagnosed on transcranial color-coded sonography (TCCS).
11184249|NCT03493022|Experimental|Test Granola|50.5 g Test Granola
11184250|NCT03493022|Placebo Comparator|Control Granola|54.3 Control Granola
11184251|NCT03493009|Experimental|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
11184252|NCT03493009|Experimental|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
11184253|NCT03492996|Experimental|LCB01-0371 dose with a [14C]-LCB01-0371-tracer|A mass balance study to investigate the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose in healthy male subjects
11184254|NCT03492983|No Intervention|Control group|No intervention
11184255|NCT03492983|Experimental|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
11184256|NCT03492970|Other|10 adult patients with SMS|Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
11184257|NCT03492957|Experimental|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change. There is no control group ion this feasibility study.
11184258|NCT03492944||Ultrasound Microbubble Contrast Agent|All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results
11184259|NCT03492931|Experimental|Treatment arm|Single dose of ticagrelor based on age
11184260|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
11184261|NCT03492905|Experimental|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
11184262|NCT03492892|Experimental|Acupuncture|Use real acupuncture treatment for blood pressure management in patients with hypertension
11184263|NCT03492892|Sham Comparator|Sham Acupuncture|Use non-acupoint as the stimulating site in acupuncture for the treatment of hypertension
11184264|NCT03492879|Experimental|Biopsy: Routine tests & EIT Technology|The patients will undergo a routine liver biopsy and also routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
11184265|NCT03492879|Experimental|Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
11184266|NCT03492879|Experimental|NASH : Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and quantification of liver steatosis using the Electrical Impedance Technology (EIT).
11184267|NCT03492866|Active Comparator|Gentamicin Sulfate|All subjects will be treated with topical gentamycin applied twice daily (1 fingertip unit (FTU)) to the right half of the scalp. Total study period: 6 months.
11184268|NCT03492866|No Intervention|No treatment|The medication won't be applied to the left half of the scalp.
11184269|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
11184270|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
11184271|NCT03492840|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into the subcutaneous fat.
~Dercum's disease - dosing according to nodule size:
~Nodule of 2-2.9cm - 2 injections (0.1 mL each); total of 10 mg RZL-012.
~Nodules of 3-3.9cm - 3 injections (0.1 mL each); total of 15 mg RZL-012.
~Nodules of 4-8cm - 4 injections (0.1 mL each); total of 20 mg RZL-012.
~Lipedema -
~2 subjects will receive 20mg RZL-012 in 4 injections in each leg adding up to 8 injections of 40mg RZL-012.
~2 subjects will receive 30mg RZL-012 in 6 injections in each leg adding up to 12 injections of 60mg RZL-012.
~2 subjects will receive 40mg RZL-012 in 8 injections in each leg adding up to 16 injections of 80mg RZL-012."
11184272|NCT03492827|Experimental|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
11184273|NCT03492827|No Intervention|Control group|Control group will not be interventioned with gargle
11184274|NCT03492814|Experimental|Partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
11184275|NCT03492814|Active Comparator|Total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
11184276|NCT03492801||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.
11184277|NCT03492788|Active Comparator|ECGI-optimized VV-offset|
11184278|NCT03492788|Placebo Comparator|Zero VV-offset|
11184279|NCT03492775|Active Comparator|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1
~If at least 'stable disease':
~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
11184280|NCT03492775|Active Comparator|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles
~If at least 'stable disease':
~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
11184281|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
11184282|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
11184283|NCT03492736|Experimental|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
11186624|NCT03476694|Experimental|25ml of 0.75% Ropivacine|
11184285|NCT03492723|Experimental|garlic groupe|Concentrated Aged Garlic Extract Microcrystalline Cellulose 133 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
11184286|NCT03492723|Placebo Comparator|placebo groupe|Microcrystalline Cellulose 258.55 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Coloring Agent 0.45 mg Details: Gardenia Extractive 44.5%, Corn Syrup 55% Potassium pyrophosphate 0.5% Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
11184287|NCT03492710|Experimental|IGIV-SN|Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
11184288|NCT03492697|Experimental|PF-06882961|
11184289|NCT03492671|Experimental|Chemotherapy and SBRT|"Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.
~Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.
~Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy."
11184290|NCT03492658|Experimental|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
11184291|NCT03492658|Active Comparator|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
11184292|NCT03492645|Active Comparator|Office Group|
11184293|NCT03492645|Experimental|Telephone Group|
11184294|NCT03492632||Women with Psoriasis|Reproductive age women newly diagnosed with psoriasis
11184295|NCT03492632||Women without Psoriasis|Reproductive age women without psoriasis to serve as control
11184296|NCT03492619|Active Comparator|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
11184297|NCT03492619|Experimental|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
11184298|NCT03492606||multiple sclerosis patients|
11184299|NCT03492593|Experimental|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
11184300|NCT03492593|Experimental|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
11184301|NCT03492593|Placebo Comparator|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
11184302|NCT03492580||Cohort 1: Canagliflozin|A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
11184303|NCT03492580||Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)|A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184304|NCT03492580||Cohort 3: Empagliflozin|A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184305|NCT03492580||Cohort 4: Empagliflozin with CVD|A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184306|NCT03492580||Cohort 5: Dapagliflozin|A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184307|NCT03492580||Cohort 6: Dapagliflozin with CVD|A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184308|NCT03492580||Cohort 7: Empagliflozin or Dapagliflozin|A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184309|NCT03492580||Cohort 8: Empagliflozin or Dapagliflozin with CVD|A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184310|NCT03492580||Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA|A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184344|NCT03492385|Experimental|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
11184311|NCT03492580||Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184312|NCT03492580||Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184313|NCT03492580||Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
11184314|NCT03492567|Experimental|Blood monocyte precursors/osteoclasts|Blood test
11184315|NCT03492554|Other|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
11184316|NCT03492554|Other|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
11184317|NCT03492541|Experimental|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
11184318|NCT03492528|Experimental|Cardiovascular patients treated for a cancer|
11184319|NCT03492515|Experimental|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
11184320|NCT03492515|Active Comparator|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
11184321|NCT03492515|No Intervention|healthy control group|Healthy pregnant women and no use of any medicine。
11184322|NCT03492502|Experimental|Allo-SCT patients with GI related GVHD|"Allo-SCT patients above 18 years of age with acute steroid-resistant GI-related GVHD grade III-IV.
~The diagnosis of GVHD will be made on clinical grounds (in line with the major associations' recommendations) - the appearance of characteristic mucoid diarrhea within 100 days after Allo-SCT, with or without associated skin/liver involvement. In cases of atypical presentation - we will recommend biopsy or endoscopy for diagnosis. Patients suspected to have Clostridium difficille associated diarrhea will be tested for toxin (CDT).
~Steroid-resistant GI-related GVHD will be defined as lack of improvement (same stage) or worsening of GI symptoms after 7 days of steroid therapy (≥ 2 ml/kg of IV methylprednisolone)."
11184323|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
11184324|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
11184325|NCT03492463|Active Comparator|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
11184326|NCT03492463|Active Comparator|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
11184327|NCT03492463|Active Comparator|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
11184328|NCT03492463|Placebo Comparator|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
11184329|NCT03492450|No Intervention|Control Group|All subjects continue participating in their normal daily and physical activities.
11184330|NCT03492450|Experimental|Treadmill training Group|16 sessions (2 sessions/week for 8 weeks) of treadmill training as recommended in a review on this subject (Langeskov-Christensen, 2015) aimed at the reduction/stabilization of gait and balance disturbances.
11184331|NCT03492437|Experimental|Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib|Dabigatran etexilate in treatment period 1 followed by tepotinib alone for 7 days and then tepotinib co-administered with Dabigatran in treatment period 2. Two treatment periods will be separated by a 3-day wash-out period.
11184332|NCT03492424||Focal therapy for prostate cancer|"All men >18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.
~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
11184333|NCT03492411|Experimental|eHealth Intervention|This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
11184334|NCT03492411|No Intervention|Usual Care|This group will not receive any intervention. They will receive emails for 6 weeks reminding them that they are in the study.
11184335|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
11184336|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
11184337|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
11184338|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
11184339|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
11184340|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
11184341|NCT03492398|Experimental|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
11184342|NCT03492385|Experimental|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
11184343|NCT03492385|Experimental|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
11184345|NCT03492385|Experimental|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
11184346|NCT03492385|Experimental|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
11184347|NCT03492385|Experimental|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
11184348|NCT03492385|Experimental|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
11184349|NCT03492385|Experimental|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
11184350|NCT03492385|Experimental|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
11184351|NCT03492385|Experimental|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
11184352|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
11184353|NCT03492359|Active Comparator|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
11184354|NCT03492359|Active Comparator|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
11184355|NCT03492346||LGMD2E Subject Population|"Individuals:
~Confirmed LGMD2E diagnosis by genetic testing or
~Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types"
11184356|NCT03492333|Experimental|Gluten free diet|Single arm
11184357|NCT03492307|Active Comparator|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
11184358|NCT03492307|Experimental|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
11184359|NCT03492294||patients with disorders of consciousness|patients with disorders of consciousness from several brain injury have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state. These patients were scaned by functional magnetic resonance imaging.
11184360|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
11184361|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
11184362|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
11184363|NCT03492268|Experimental|BCMA-CART|Autologous T cells transduced to express anti-BCMA chimeric antigen receptor (CAR)
11184364|NCT03492255|Active Comparator|Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC|The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
11184365|NCT03492255|Experimental|Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC|CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
11184366|NCT03492242||Adverse drug reaction induced by immune checkpoint inhibitors|Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity
11184367|NCT03492229|Experimental|tDCS+AMT|TDCS in combination with movement training before treadmill training
11184368|NCT03492229|Active Comparator|tDCS|tDCS only before treadmill training
11184369|NCT03492229|Active Comparator|AMT|Movement training only before treadmill training
11184370|NCT03492229|Sham Comparator|Control|No priming before treadmill training
11184371|NCT03492216|No Intervention|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
11184372|NCT03492216|Experimental|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
11184373|NCT03492216|Experimental|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
11184374|NCT03492216|Experimental|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
11184375|NCT03492203|Experimental|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
11184376|NCT03492203|Active Comparator|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
11184377|NCT03492203|Placebo Comparator|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
11184409|NCT03491956|Other|DFPP group|self contrast (before and after DFPP)
11184378|NCT03492190||adults|"Select the individual:
~Healthy, non-pregnant adults 18-65 years of age, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range and stable weight.
~Exclusion criteria: children and elderly (over 65), pregnancy, diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, adults will be eat the bean enrichment of deuterium for availability protein, collected urine, saliva and blood."
11184379|NCT03492190||Children|"Fifty children will be recruited from ages varying from 1 to 3 years and of both sexes. Children who use medications, who do not habitually consume beans, will be excluded and when there is no explicit written authorization from the parents or guardians.
~All the children with different status of nutrition will be eaten the beans. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, children will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult)."
11184380|NCT03492190||Elderly|Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
11184381|NCT03492177|Experimental|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the subjects reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, subjects will be treated with selexipag as long as the treatment is beneficial to the subject, as per investigator's decision
11184382|NCT03492164|Other|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
11184383|NCT03492138|Experimental|Participants with relapsed/refractory multiple myeloma|ONC201, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Run-in phase of ONC201 and dexamethasone weekly until progression at 4 weeks, lack of response at 8 weeks, or progression followed by the addition of weekly ixazomib.
11184384|NCT03492125|Experimental|low dose|MS-533
11184385|NCT03492125|Experimental|mid low dose|MS-533
11184386|NCT03492125|Experimental|mid high dose|MS-533
11184387|NCT03492125|Experimental|high dose|MS-533
11184388|NCT03492112|Experimental|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
11184389|NCT03492099|Experimental|Buprenorphine Arm|This is the main and only arm of the study. All patients in this arm will undergo the steps outlined in the protocol to convert to buprenorphine treatment.
11184390|NCT03492086|Experimental|Rosemary and alkylglycerol capsules|
11184391|NCT03492086|Placebo Comparator|Control capsules|
11184392|NCT03492073|Experimental|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.
~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
11184393|NCT03492073|Active Comparator|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.
~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
11184394|NCT03492060||Variant in any hnRNP gene|Individuals with a variant in any hnRNP gene who present with neurodevelopmental abnormalities are eligible for the study.
11184395|NCT03492047|Active Comparator|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
11184396|NCT03492047|Experimental|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
11184397|NCT03492047|Experimental|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
11184398|NCT03492034|Active Comparator|IUD during CS|
11184399|NCT03492034|Active Comparator|IUD after puerperium|
11184400|NCT03492021|Experimental|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy [AP-CPT]
11184401|NCT03492021|Experimental|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy [OP-PPT]
11184402|NCT03492008|Active Comparator|Conventional technique|Nasogastric tube
11184403|NCT03492008|Experimental|Contralateral cricothyroid pressure|Nasogastric tube
11184404|NCT03492008|Experimental|Ipsilateral head turning|Nasogastric tube
11184405|NCT03491995|Experimental|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
11184406|NCT03491995|Active Comparator|Classic treatment|Omeprazole, clarithromycin, amoxicillin
11184407|NCT03491969|Experimental|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
11184408|NCT03491969|Placebo Comparator|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
11184410|NCT03491943|Experimental|Midline group|Preprocedural ultrasound-assisted midline approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
11184411|NCT03491943|Active Comparator|Paramedian group|Preprocedural ultrasound-assisted paramedian approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
11184412|NCT03491930|Experimental|Interventional Cohort|"VA MOVE! Coach app: Weight loss using the VA MOVE! Coach weight loss app which presents positive feedback, education in nutrition and portion sizes, coping mechanisms, charts and graphs. App will be used for three months.
~Telephone Coaching: Weekly phone coaching will provide further support and assist with problem solving and goal setting for a three month period.
~Standard of care for weight loss (the 2013 AHA/ACC/TOS guidelines). Followed for three months.
~Pre and post weight loss metabolic measurements will be obtained."
11184413|NCT03491930|Active Comparator|Control Cohort|"Standard of care for weight loss (2013 AHA/ACC/TOS guidelines). Followed for three months.
~Pre and post weight loss metabolic measurements will be obtained."
11184414|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
11184415|NCT03491917||FFDM alone|Breast images using FFDM alone only
11184416|NCT03491904|Experimental|Auto-injector (AI)|
11184417|NCT03491904|Experimental|Prefilled syringe (PFS)|
11184418|NCT03491891||derivation cohort|no interventions will be administrated
11184419|NCT03491891||validation cohort|no interventions will be administrated
11184420|NCT03491878|Experimental|3D approach|Three dimensional laparoscopic cholecystectomy including segments IVB and V
11184421|NCT03491878|Active Comparator|open approach|Open cholecystectomy including segments IVB and V
11184422|NCT03491865|Experimental|REAL media Plus|Participants in this group will be assigned to use the REAL media Plus curriculum.
11184423|NCT03491865|No Intervention|programming as usual|Participants in this group will participate in their usual school curriculum. They will have the opportunity to use the REAL media Plus curriculum at the conclusion of the study.
11184424|NCT03491852|Experimental|BOOST Intervention|"The BOOST intervention consists of 8 group-based, weekly one-hour sessions. While every BOOST session is different, in general they will focus on helping participants fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment. BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support worker to provide unique insights on living with and overcoming self-stigma. Content of sessions involve group discussions, exercises conducted in session, and between-session missions (i.e., home practice activities)."
11184425|NCT03491852|Active Comparator|Waitlist Controls|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis. Frequency of contact largely depends on the individual needs of patients. Waitlist controls will be offered the BOOST intervention 3 months post-enrollment.
11184426|NCT03491826||ROM before 34 weeks (A)|premature rupture of membrane before 34 weeks
11184427|NCT03491826||ROM after 34 weeks (B)|premature rupture of membrane after 34 weeks
11184428|NCT03491800|Other|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
11184429|NCT03491787||Ultrasound guidance|The ultrasound guidance was used to establish intraosseous access
11184430|NCT03491787||Not ultrasound guidance|The ultrasound guidance was not used to obtain intraosseous access
11184431|NCT03491774|Experimental|Montessori Intervention|Participants will receive Montessori intervention for three months,twice weekly sessions over the period of three months.
11184432|NCT03491761|Experimental|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
11184433|NCT03491761|Active Comparator|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Euflexxa will be prepared according to the package insert.
11184434|NCT03491748|Experimental|Part A (SAD): Cohort 1, 100 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 milligrams (mg) ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
11184435|NCT03491748|Experimental|Part A (SAD): Cohort 2, 200 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
11184436|NCT03491748|Experimental|Part A (SAD): Cohort 3, 400 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
11184437|NCT03491748|Experimental|Part A (SAD): Cohort 4, 800 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 800 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
11184438|NCT03491748|Experimental|Part A (SAD): Cohort 5, 600 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
11184556|NCT03491007|No Intervention|Placebo|Subjects will receive a one-time oral dose of PBO prior to initial brain imaging followed by sustained administration of PBO for 6 weeks.
11184439|NCT03491748|Experimental|Part A (SAD): Cohort 6 (Elderly), 300 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Elderly participants (aged 65 years or older) will be treated with a single oral dose of 300 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
11184440|NCT03491748|Experimental|Part B (Food Effect): Cohort 7, 100 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 100 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
11184441|NCT03491748|Experimental|Part C (MAD): Cohort 9, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed three times a day (TID) beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
11184442|NCT03491748|Experimental|Part C (MAD): Cohort 10, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed TID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
11184443|NCT03491748|Experimental|Part D: Cohort 12, ETX0282/Placebo plus Cefpodoxime Proxetil|Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fed state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fed state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fed state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fed state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
11184444|NCT03491748|Experimental|Part B (Food Effect): Cohort 14, 300 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 300 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 300 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
11184445|NCT03491748|Experimental|Part G: Cohort 17, 300 mg ETX0282/Placebo|Part G of the study will explore the tolerability and PK profile of oral ETX0282 when administered either as a single dose (i.e., 300 mg as a single dose) or in 4 equal, divided doses over a 6 hour period (i.e., 75 mg every 2 hours for 4 doses [a 300 mg total dose]) when administered in a fasted state. Participants will receive the 2 treatments in a cross-over design according to one of 2 randomized sequences: AB or BA. Treatment A: 0 hours, 4 × 75 mg ETX0282/placebo; 2, 4, and 6 hours, 1 × 75 mg placebo. Treatment B: 0 hours, 1 × 75 mg ETX0282/placebo and 3 × 75 mg placebo; 2, 4, and 6 hours, 1 × 75 mg ETX0282/placebo. Participants will be confined to the Study Unit from Day -1 and discharged following collection of the 24 hours post Day 4 dose assessments (Day 5).
11184446|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
11184447|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
11184448|NCT03491709|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
11184449|NCT03491709|Active Comparator|Cetuximab injection|Cetuximab,Erbitux 250mg/m2 single administration
11184450|NCT03491696|Experimental|Patients|It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
11184451|NCT03491683|Experimental|Cohort A: Unmethylated MGMT Promoter|Cohort A will include participants with a glioblastoma tumor with an unmethylated MGMT promoter. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ; only during radiation therapy), if clinically indicated.
11184452|NCT03491683|Experimental|Cohort B: Methylated MGMT Promoter|Cohort B will include participants with a glioblastoma tumor with a methylated MGMT promoter or with indeterminate MGMT status. Participants will receive INO-5401 and INO-9012 and cemiplimab as well as radiation and temozolomide (TMZ), if clinically indicated. Participants will continue to receive TMZ following radiation therapy, for up to six additional cycles, if clinically indicated.
11184453|NCT03491657|Experimental|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
11184454|NCT03491657|Active Comparator|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
11184455|NCT03491644|Active Comparator|Liberal oxygen|"Liberal oxygen administration (to mimic current practice) for the first 24 hours without interruption.
~In the trauma bay and during intrahospital transportation this implies administration of a FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the operating room, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."
11184456|NCT03491644|Experimental|Titrated oxygen|"Titrated oxygen administration for the first 24 hours without interruption. Lowest dosage of oxygen possible in order to achieve a saturation of at least 94%, either using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing.
~A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.
~The intervention will only be interrupted in case the saturation becomes unmeasurable - if this happens, the treating physician shall treat the patient as he/she judges best fit. As soon as the saturation is measurable again, the intervention will resume. The treating physician must document and explain the situation."
11184457|NCT03491631|Experimental|2 drugs combination group|
11184458|NCT03491631|Experimental|3 drugs combination group|
11184459|NCT03491618|Active Comparator|PARALLEL|Thick canulae (18 gauge) placed parallel to Medial Branch under fluoroscopy.
11184460|NCT03491618|Active Comparator|PERPENDICULAR|Thin canulae (22 gauge) placed perpendicular to Medial Branch under fluoroscopy.
11184461|NCT03491605||peripheral EBV-DNA load|subjects with high load (>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
11184462|NCT03491592|Experimental|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
11184463|NCT03491592|Active Comparator|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
11184464|NCT03491579|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
11184465|NCT03491566|Experimental|Clinic Pilates Group|Initial assessments of participants were made and they were taught key components of the Clinical Pilates exercises. Exercises were administered for 4 weeks, 3 days/week, 40-50 minutes/session under the supervision of a physiotherapist. Groups of 9-10 people with similar physical characteristics and fitness level for session times were created. The sessions were started with level 1 exercises requiring more support and less control. Each exercise was repeated 8-10 times; as the physical level of the participants increased, exercises progressed towards level 3 exercises requiring more attention, concentration and control. Each session consisted of an average of 10 minutes warm-up, 20 to 30 minutes of matt and 10 minutes cooling of of Clinical Pilates exercises.
11184466|NCT03491566|Experimental|Aerobic Exercise Group|"Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 4 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the 220-years. For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min."
11184467|NCT03491566|Other|Control Group|"Initial assessments of participants were made before the study. Participants were recruited groups of 10 people and for once 30-minutes training session was organized covering topics such as What is physical activity, what are the effects of physical activity on health, factors that blocking physical activities and ways of overcoming obstacles, and recommending physical activity appropriate to their ages. Participants were requested to save activity log to track of their physical activity levels. However, no intervention was made to change their daily routines. The purpose of the given training was to motivate participants to increase their level of physical activity."
11184468|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-positive CHB Participants|Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED).
11184469|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED.
11184470|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED.
11184471|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED.
11184472|NCT03491553|Experimental|Placebo: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED.
11184473|NCT03491553|Experimental|Placebo: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED.
11184474|NCT03491540|Experimental|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
11184475|NCT03491540|Placebo Comparator|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
11184476|NCT03491527|Active Comparator|Conventional Resin Cement|Resin cement without MTA
11184477|NCT03491527|Active Comparator|MTA Resin Cement|Resin cement with MTA
11184478|NCT03491514|Experimental|Test Granola|51 g of Test Granola
11184479|NCT03491514|Placebo Comparator|Control Granola|54.1 Control Granola
11184480|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
11184481|NCT03491488|Experimental|Intervention Group|"300 children in the randomly selected crèche classrooms receiving the Brain Games intervention.
~The Brain Games intervention we propose in this project is designed to complement and improve current government efforts. Given the importance of executive functioning skills and the high plasticity around age three, early programs like the ones proposed here may be the most effective tool to reduce socioeconomic and intergenerational disparities, and thus nicely complement current social protection policies."
11184482|NCT03491488|No Intervention|Control Group|300 children in the randomly selected creches classrooms receiving the regular Brazilian curriculum.
11184483|NCT03491475||Negative Ajmaline test|No appearance of a type 1 ECG during Ajmaline test
11184484|NCT03491475||Positive Ajmaline test|Appearance of a type 1 ECG during Ajmaline test
11184485|NCT03491462|Experimental|Arimoclomol|Arimoclomol, capsule
11184486|NCT03491462|Placebo Comparator|Placebo|Placebo oral capsule (matching to experimental Arm)
11184487|NCT03491449|Experimental|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
11184488|NCT03491449|Active Comparator|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure <185 mm Hg for 72 hours.
11184489|NCT03491436|Experimental|Remote monitoring group|Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
11184490|NCT03491423|Experimental|Patients|
11184491|NCT03491410|Placebo Comparator|1|Arm 1: standard Unit´s protocol + placebo
11184492|NCT03491410|Experimental|B|Arm 2: standard Unit´s protocol + aspirin
11184493|NCT03491397|Experimental|GAE OA|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
11184494|NCT03491371|Experimental|osteosarcoma|all patients had been given apatinib alone
11184495|NCT03491371|Experimental|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
11184496|NCT03491371|Experimental|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
11184497|NCT03491371|Experimental|Chondrosarcoma|Patients were given apatinib alone
11184498|NCT03491358|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
11184499|NCT03491358|Experimental|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
11184500|NCT03491345|Experimental|avelumab|
11184501|NCT03491332|Placebo Comparator|group C|general circuit group
11184502|NCT03491332|Active Comparator|group H|warm circuit group
11184503|NCT03491332|Experimental|group SH|new warm circuit group
11184504|NCT03491319|Placebo Comparator|Group C Control|spinal anaesthesia was given with table in neutral positon. Same position was maintained after spinal anaesthesia
11184505|NCT03491319|Active Comparator|Group X|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal
11184506|NCT03491319|Active Comparator|Group Y|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
11184507|NCT03491306|Active Comparator|Group 1|patients will receive partial denture constructed from breflex material
11184508|NCT03491306|Experimental|Group 2|patients will receive partial denture constructed from PEEK material
11184509|NCT03491293|Active Comparator|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
11184510|NCT03491293|Experimental|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
11184511|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
11184512|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
11184513|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
11184514|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
11184515|NCT03491254||Group A/exposure group|Huaier Granule & biliary drainage
11184516|NCT03491254||Group B/non-exposure group|biliary drainage.
11184517|NCT03491241|Experimental|pre-diabetics obese patients|These pre-diabetic obese patients will be treated by hypocaloric diet therapy. these patients were under metformine therapy at enrollment.
11184518|NCT03491241|Placebo Comparator|pre-diabetics patients|These pre-diabetic patients will be treated by hypocaloric diet therapy alone.
11184519|NCT03491241|Active Comparator|obese patients|These obese patients will be treated by hypocaloric diet therapy.
11184520|NCT03491215|Experimental|Ruxolitinib|All patients will receive ruxolitinib in addition to corticosteroids +/-calcineurin inhibitor (CNI)
11184521|NCT03491202||atrial fibrillation|Patients with a diagnosis of atrial fibrillation will be eligible for enrollment
11184522|NCT03491189|Active Comparator|Lag screw fixation|Lag screw fixation
11184523|NCT03491189|Active Comparator|Helical Blade fixation|Helical Blade fixation
11184621|NCT03490656|Experimental|Patient population|
11184622|NCT03490643|Other|TMD Group|people who has TMD
11184524|NCT03491176|Experimental|Diagnostic (MRI, blood sample collection)|Patients undergo MRI scans and collection of blood samples for biomarker testing pre-radiation therapy, weekly during radiation therapy, and at 2-3 months post-radiation therapy.
11184525|NCT03491163||Patients|Syndecan-1 concentration evaluation
11184526|NCT03491150|Placebo Comparator|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
11184527|NCT03491150|Experimental|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
11184528|NCT03491124|Sham Comparator|Sham Treatment|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will also receive a sham intervention, pointing a laser pointer to the ear without turning the laser on.
11184529|NCT03491124|Experimental|Auricular Acupuncture|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
11184530|NCT03491111|Experimental|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
11184531|NCT03491111|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
11184532|NCT03491111|Experimental|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
11184533|NCT03491098|Placebo Comparator|momestone furoate spray first group: will be given|Nasonex spray one puff in each nostril daily for 8 weeks
11184534|NCT03491098|Placebo Comparator|prednisolone sodium phosphate 15mg second group: will be given|Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks
11184535|NCT03491098|Placebo Comparator|hypertonic sea water solution spray third group: will be given|Nasal spray one puff in each nostril daily for 8 weeks
11184536|NCT03491085|Active Comparator|tonsillictomy with antibiotics|
11184537|NCT03491085|No Intervention|tonsillictomy Without Antibiotics|
11184538|NCT03491072|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
11184539|NCT03491072|Active Comparator|Fentanyl|Patients will receive IV fentanyl 1µg /Kg. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
11184540|NCT03491059|Experimental|Full Study - Radiation|
11184541|NCT03491059|No Intervention|Dress Rehearsal Only - No Radiation|
11184542|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
11184543|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
11184544|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
11184545|NCT03491020||Respiratory syncytial virus (RSV)|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify RSV.
11184546|NCT03491020||Enteroviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify enterovirus.
11184547|NCT03491020||Adenoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify adenovirus.
11184548|NCT03491020||Coronaviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify coronavirus.
11184549|NCT03491020||Metapneumoviruses|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify metapneumovirus.
11184550|NCT03491020||Chlamydia pneumoniae|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify chlamydia pneumoniae.
11184551|NCT03491020||Mycoplasma|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify mycoplasma.
11184552|NCT03491020||Parainfluenza|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify parainfluenza.
11184553|NCT03491020||Neisseria meningitides|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify neisseria meningitides.
11184554|NCT03491020||Bordetella pertussis|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify bordetella pertussis.
11184555|NCT03491020||Rhinovirus|Patients seen at the Emergency Department or admitted to the hospital with respiratory symptoms and diagnosed with a respiratory pathogen. A nasopharyngeal swab will be obtained to identify rhinovirus.
11184623|NCT03490643|Other|Control Group|individuals who dont have healthy temporomandibular joint
11184557|NCT03491007|Placebo Comparator|DHEA|Subjects will receive a one-time oral dose of DHEA prior to initial brain imaging followed by sustained administration of DHEA for 6 weeks.
11184558|NCT03490994|Experimental|Rivaroxaban|Rivaroxaban
11184559|NCT03490994|Active Comparator|Warfarin|warfarin + enoxaparin
11184560|NCT03490981|Other|TAU only|Primary care treatment as usual
11184561|NCT03490981|Experimental|TAU plus Brief CBT-CP|Primary care treatment as usual and Brief CBT-CP
11184562|NCT03490968|Other|Healthy Subjects|
11184563|NCT03490968|Experimental|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
11184564|NCT03490968|Active Comparator|PAD Subjects Who Undergo Revascularization of the Leg|This group of subjects are receiving leg revascularization as part of standard of care.
11184565|NCT03490955|Sham Comparator|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
11184566|NCT03490955|Active Comparator|Salad dressing|Subjects will consume a vegetable salad with dressing one time in the morning
11184567|NCT03490955|Active Comparator|black pepper|Subjects will consume a vegetable salad without dressing but with black pepper one time in the morning
11184568|NCT03490955|Active Comparator|Salad dressing and black pepper|Subjects will consume a vegetable salad with dressing and with black pepper one time in the morning
11184569|NCT03490942|Experimental|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
11184570|NCT03490942|Experimental|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
11184571|NCT03490942|Placebo Comparator|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
11184572|NCT03490942|Placebo Comparator|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
11184573|NCT03490929|Experimental|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
11184574|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
11184575|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
11184576|NCT03490903|Experimental|VR with or without Moderate Sedation|"Patients randomized to receive a Virtual Reality Intervention will be fitted with a VR headset and headphones and undergo a continuous immersive meditation experience. This will begin immediately prior to the start of the procedure, and continue until the procedure is completed.
~Patient pain and anxiety levels will be frequently assessed by procedure operator and circulating nurse, and pain medication or anxiolytic medications will be administered in the absence of contraindications. Baseline amounts of sedation pre-procedurally will not be used in either arm. Pain and Anxiety Scores will be assessed pre, intra, and post-procedurally. If no contraindications, the operator will decide upon how much sedation medication to administer if indicated or requested. This is the usual manner in which pain and anxiety is treated in the cath lab."
11184577|NCT03490903|Active Comparator|Moderate Sedation without VR|Subjects randomized to the comparison arm will not undergo the Virtual Reality Intervention. Baseline amounts of sedation pre-procedurally will not be used in either arm. Subjects will be assessed periodically by physicians and/or circulating nurses for their pain and anxiety levels. The patient may also prompt the staff that they are anxious or in pain, and if no contraindications, the operator will decide upon how much medication to administer. This is the usual manner in which pain and anxiety is treated in the cath lab.
11184578|NCT03490890|Experimental|Microwave ablation in the GGO|Patients with GGO were treated with microwave ablation.
11184579|NCT03490864|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
11184580|NCT03490864|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
11184581|NCT03490864|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
11184582|NCT03490864|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
11184583|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 1|2g β-glucan
11184584|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 2|4g β-glucan
11184585|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 3|4g β-glucan plus β-glucanase
11184586|NCT03490851|Placebo Comparator|Cream of Rice|27 grams of cream of rice
11184587|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 1|3.70 GBq (100 mCi) x 3 times
11184588|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 2|7.40 GBq (200 mCi) up to 4 times
11184589|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 3|11.1 GBq (300 mCi) up to 4 times
11184590|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 4|14.8 GBq (400 mCi) up to 4 times
11184591|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 5|18.5 GBq (500 mCi) up to 4 times
11184592|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 6|22.2 (600 mCi) up to 4 times
11184593|NCT03490838|Experimental|Phase II: Dose Expansion Cohort|Dose to be chosen from Phase I
11184594|NCT03490825|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
11184624|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
11184625|NCT03490617|Active Comparator|Vaginal Misoprostol Group|Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion
11184595|NCT03490825|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
11184596|NCT03490825|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
11184597|NCT03490825|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
11184598|NCT03490812|Experimental|Prospective population|
11184599|NCT03490812|Experimental|Retrospective population|
11184600|NCT03490786|Experimental|Dose escalation|Single arm dose escalation.
11184601|NCT03490760|Experimental|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
11184602|NCT03490747|Experimental|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
11184603|NCT03490747|Active Comparator|Usual care referral scheme|Comparative, usual care exercise referral scheme.
11184604|NCT03490747|No Intervention|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
11184605|NCT03490734|Active Comparator|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
11184606|NCT03490734|Active Comparator|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage with added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
11184607|NCT03490734|Active Comparator|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
11184608|NCT03490734|Active Comparator|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage no added sugar for 3 weeks.
~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
11184609|NCT03490721|Experimental|Intervention|Clustering care for 20 minutes.
11184610|NCT03490721|No Intervention|Control|Standard care non clustered.
11184611|NCT03490708|Experimental|Tranilast|Subjects who were treated with tranilast
11184612|NCT03490695|Experimental|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
11184613|NCT03490695|Experimental|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.
~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.
~During this 12 months period, practice facilitation will end in the Group A arm."
11184614|NCT03490682|Active Comparator|Non-pregnant control|adult females aged less than 40 years, not currently pregnant, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and 1 hour for clear fluids.
11184615|NCT03490682|Active Comparator|Pregnant control|adult females aged less than 40 years, pregnant in the third trimester (gestation greater than 32 weeks on the day of the study) according to dates and the calculation of term established at the start of the pregnancy by an obstetrician, without significant medical history (American Society of Anesthesiologists ASA 1), fasting for at least 6 hours for solids and I hour for clear fluids.
11184616|NCT03490682|Experimental|Analgesia|adult females aged less than 40 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, with a working epidural, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
11184617|NCT03490682|Experimental|Parturient|adult females aged less than 35 years, without significant medical history (American Society of Anesthesiologists ASA 1), in labour in the delivery suite, without any epidural analgesia, having consumed solid food more than 6 hours before inclusion in the study and clear fluids more than 1 hour before inclusion in the study, and allowed to ingest solids during labour (cervical dilatation strictly less than 8cm) conforming to local protocols.
11184618|NCT03490669|Experimental|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
11184619|NCT03490669|Experimental|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
11184620|NCT03490656|Experimental|Healthy volunteer population|
11184627|NCT03490591|Experimental|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
11184628|NCT03490578|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
11184629|NCT03490578|Active Comparator|Intensive treadmill training|Intensive treadmill training using an usual treadmill
11184630|NCT03490565|Active Comparator|EX group|Exercise training
11184631|NCT03490565|No Intervention|CON-group|Usual Care
11184632|NCT03490552|Sham Comparator|group A|include clots which have been extracted by mechanical thrombectomy and with definite stroke etiology and submitted to the RNA analysis in blinded coded label .
11184633|NCT03490552|Experimental|group B|include all clots which have been extracted by mechanical thrombectomy and with unknown stroke etiology and submitted to RNA analysis in cryptogenic label.
11184634|NCT03490539||azathioprine (AZT)|Patients with MG who are receiving azathioprine as part of routine clinical care
11184635|NCT03490539||mycophenolate mofetil (MMF)|Patients with MG who are receiving mycophenolate mofetil as part of routine clinical care
11184636|NCT03490526|Experimental|Root canal disinfection with XP-endo Finisher|
11184637|NCT03490526|Active Comparator|Root canal disinfection with passive ultrasonic irrigation|
11184638|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
11184639|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
11184640|NCT03490500||S100B protein dosage|Biological
11184641|NCT03490487|Active Comparator|A antiepileptic|will receive conventional antiepileptic drugs only
11184642|NCT03490487|Experimental|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
11184643|NCT03490474|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
11184644|NCT03490474|Active Comparator|Pain Free Massage|Participants will receive light touch applied to one myofascial trigger point.
11184645|NCT03490474|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
11184646|NCT03490461||Statin group|Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
11184647|NCT03490461||Non-statin group|the administration of statins for less than 30 days after liver transplantation
11184648|NCT03490448|Other|intervention group|aerobic exercise and appropriate caloric control
11184649|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
11184650|NCT03490422|Experimental|Pulpotomy|Pulpotomy is performed in carious-exposed pulp in mature permanent teeth
11184651|NCT03490409|Experimental|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
11184652|NCT03490409|No Intervention|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
11184653|NCT03490396|Experimental|Arm 1 (Gelclair at time of conditioning)|All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
11184654|NCT03490396|Active Comparator|Arm 2 (Gelclair when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
11184655|NCT03490396|Active Comparator|Arm 3 (MMW when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.
11184656|NCT03490383||patients without CBD calculi|patients without CBD calculi
11184657|NCT03490383||CBD calculi without ERCP history|patients with CBD calculi without ERCP history
11184658|NCT03490383||CBD calculi with ERCP history|patients with CBD calculi and ERCP history
11184659|NCT03490370|Experimental|Electronic Muscle Stimulation Activity|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
11184660|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
11184661|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
11184662|NCT03490344|Experimental|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
11184663|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.
~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
11184664|NCT03490318||Patients with DMO and/or PDR|
11184665|NCT03490305||Combatants|Men 16-50 years old or combatants by own admission.
11184666|NCT03490305||Civilians|Children <16 years, all women and men ≥50 years.
11184690|NCT03490162|Experimental|MAD 4|900 mg of DM1157 (6 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (6 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
11184667|NCT03490292|Experimental|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) [intravenous infusion on days 1, 8, 15, 22, & 29] while undergoing radiation therapy [23 fractions, M-F, estimated completion day 35].
~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.
~Trial enrollment will resume after at least 5 patients do not have a DLT during the DLT evaluation period or until all 6 patients are seen for post-operative evaluation. If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
11184668|NCT03490292|Experimental|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation & Avelumab combined with Chemoradiation).
11184669|NCT03490279|Experimental|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
11184670|NCT03490279|Placebo Comparator|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
11184671|NCT03490266|Active Comparator|Laparoscopic Repair|The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
11184672|NCT03490266|Experimental|Robotic Repair|Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
11184673|NCT03490253|Active Comparator|Static Messaging|We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
11184674|NCT03490253|Experimental|Adaptive Messaging|Patients in the adaptive messaging arm will receive the daily messages of the static arm, and additionally receive daily messages within different categories of feedback and motivational messages that are chosen using a reinforcement learning (RL) algorithm. Physical activity (step-count/day) will be actively monitored via the app on their smartphone.
11184675|NCT03490253|No Intervention|Control Condition|Control patients will only install the app on their phone and will not receive any feedback messages. They will receive one message a week, on a fixed day, asking them to assess their mood in the previous week on a scale of 1 to 9. The message will be sent daily at 10:00 am. Non-responders will receive reminders to submit their mood self-assessments in two hour intervals.
11184676|NCT03490240|Experimental|BIPAMS|The behavioral intervention consists of two primary components, a dedicated Internet website and one-on-one video chats with a behavioral coach via Skype. The behavioral intervention focuses on the skills, techniques, resources, and strategies for becoming and staying physically active with MS, but it does not provide a prescription for exercise or physical activity itself.
11184677|NCT03490240|Active Comparator|WELLMS|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
11184678|NCT03490214|Experimental|Muscular Dystrophia|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
11184679|NCT03490214|Active Comparator|Healthy Volunteer|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
11184680|NCT03490201|Active Comparator|Randomized - Control|
11184681|NCT03490201|Active Comparator|Randomized - Treatment|
11184682|NCT03490201|Experimental|Non-randomized - Treatment|
11184683|NCT03490188|Experimental|Treatment Arm|Patients assigned to treatment arm will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center. In addition, they will be matched with a mentor who will conduct 5 meetings with the patients (which includes one video chat meeting, 4 30-minute phone calls) and discuss the following topics related to post-discharge: Medications, Lab Work, Fluid Intake and Adherence to doctor's appointment
11184684|NCT03490188|No Intervention|Control Arm|Control arm recipient will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center
11184685|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
11184686|NCT03490162|Experimental|Food Effect|300 mg of DM1157 (2 capsules of 150 mg) orally with high fat diet, n=6, and matching placebo (2 capsules) orally with high fat diet, n=2
11184687|NCT03490162|Experimental|MAD 1|150 mg of DM1157 (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=2
11184688|NCT03490162|Experimental|MAD 2|300 mg of DM1157 (2 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (2 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
11184689|NCT03490162|Experimental|MAD 3|600 mg of DM1157 (4 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (4 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
11184691|NCT03490162|Experimental|SAD 1|9 mg of DM1157 (1 capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
11184692|NCT03490162|Experimental|SAD 2|27 mg of DM1157 (3 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (3 capsules) orally with 240 ml of water after an overnight fast, n=2
11184693|NCT03490162|Experimental|SAD 3|81 mg of DM1157 (9 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (9 capsule) orally with 240 ml of water after an overnight fast, n=2
11184694|NCT03490162|Experimental|SAD 4|150 mg of DM1157 (1capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
11184695|NCT03490162|Experimental|SAD 5|300 mg of DM1157 (2 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (2 capsules) orally with 240 ml of water after an overnight fast, n=2
11184696|NCT03490162|Experimental|SAD 6|600 mg of DM1157 (4 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (4 capsules) orally with 240 ml of water after an overnight fast, n=2
11184697|NCT03490162|Experimental|SAD 7|900 mg of DM1157 (6 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (6 capsules) orally with 240 ml of water after an overnight fast (n=2)
11184698|NCT03490149||ECT|
11184699|NCT03490149||Medication - Treatment as usual|
11184700|NCT03490149||Healthy controls|
11184701|NCT03490123|Experimental|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).
~Study interventions are:
~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
11184702|NCT03490123|Active Comparator|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.
~Study interventions are:
~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
11184703|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
11184704|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
11184705|NCT03490097|Experimental|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.
11184706|NCT03490097|Active Comparator|Group II|sofosbuvir plus daclatasvir
11184707|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
11184708|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
11184709|NCT03490058||Young women|Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
11184710|NCT03490045|Experimental|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
11184711|NCT03490045|Active Comparator|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will receive a conditional cash transfer of equivalent value of the diapers provided to the intervention group.
11184712|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
11184713|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
11184714|NCT03490032|Experimental|Metastatic Prostate Cancer (mPCa) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
11184715|NCT03490019|Experimental|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
11184716|NCT03490006|Active Comparator|Paravertebral Block|For this arm, the initial level will be at T3-4 and an out-of-plane technique to guide the needle tip to a point between the costotransverse ligament and the parietal pleura between the visualized transverse processes. Then, a few milliliters of 0.5% ropivacaine will be injected slowly to displace the pleura ventrally as the paravertebral space fills with local anesthetic. After negative aspiration, the rest of 0.5% ropivacaine (total 10 ml) will be injected in 5 ml increments to further fill the paravertebral space. The procedure will then be repeated in the same exact fashion at the T5-6 level. We will observe local anesthetic spread under real-time ultrasound imaging.
11184717|NCT03490006|Experimental|Erector Spinae Plane Block|For this arm, the needle tip will be directed under ultrasound guidance using an in-plane technique towards the T5 transverse process until the needle tip contacts os. Then, a few milliliters of ropivacaine will be injected slowly to separate the plane between the erector spinae muscle and the transverse process. After negative aspiration, the rest of the 0.5% ropivacaine will be injected (total 20ml)
11184718|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
11184719|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
11184720|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
11184721|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
11184722|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
11184723|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
11184724|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
11184725|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
11184726|NCT03489954||Non-specific chronic neck pain group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
11184727|NCT03489954||Healthy group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
11184728|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
11184729|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
11184730|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
11184731|NCT03489928|Experimental|Oral Misoprostol|50ug po q4h orally, as needed
11184732|NCT03489928|Experimental|Low dose vaginal misoprostol|25-50ug q6h, vaginally, as needed
11184733|NCT03489928|Experimental|Usual vaginal dinoprostone|1-2mg q6h, vaginally as needed
11184734|NCT03489915||Patients with macular edema due to RVO|assessment of visual acuity using Landolt chart and follow up of macular edema using OCT
11184735|NCT03489902|Experimental|Transobturator arm|Transobturator Paravaginal Repair
11184736|NCT03489902|Experimental|Transvaginal arm|traditional transvaginal Paravaginal Repair
11184737|NCT03489889|Experimental|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
11184738|NCT03489889|Experimental|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
11184739|NCT03489876|Experimental|Synthetic Cartilage Implant|Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.
11184740|NCT03489876|Active Comparator|Osteochondral Autograft Transfer|Participants receive the current standard osteochondral autograft transfer procedure.
11184741|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
11184742|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
11184743|NCT03489850|Active Comparator|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
11184744|NCT03489850|Placebo Comparator|Placebo|Matched to active
11184745|NCT03489837|Experimental|Levotuss CR tab|oral taken
11184746|NCT03489837|Active Comparator|Levotuss syrup|oral taken
11184747|NCT03489824|Experimental|modified-WIM colonoscopy in RLP|Modified-water immersion method colonoscopy is performed to patients with right-lateral starting position (RLP). Patients will lie in the right lateral position with both hips and knees flexed at the beginning and change the position into supine and at last left-lateral position when it is needed.
11184748|NCT03489824|Active Comparator|modified-WIM colonoscopy in LLP|Modified-water immersion method (WIM) colonoscopy is performed to patients with left-lateral starting position (LLP). Patients will lie in the left lateral position with right hip and knee flexed and left leg straight at the beginning and change the position into supine and at last right lateral position when it is needed.
11184749|NCT03489811|Experimental|Test Essential Oil Blend|Participants in this arm receive the test essential oil inhaler to administer during the 4-week intervention.
11184750|NCT03489811|Active Comparator|Active Essential Oil Blend|Participants in this arm receive an active essential oil inhaler to administer during the 4-week intervention.
11184751|NCT03489811|Placebo Comparator|Control|Participants in this arm receive a control inhaler to administer during the 4-week intervention.
11184752|NCT03489798|Experimental|6 Misoprostol|Up to six doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
11184753|NCT03489798|Active Comparator|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
11184754|NCT03489785||Movement|If there is unexpected movement
11184755|NCT03489785||No movement|If there is no unexpected movement
11184756|NCT03489772|Experimental|1 mg ITI-214|Single dose
11184757|NCT03489772|Experimental|10 mg ITI-214|Single dose
11184758|NCT03489772|Placebo Comparator|Placebo|Single dose
11184759|NCT03489759|Experimental|ViE15-A|The patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using ViE15-A hemofilter
11184760|NCT03489759|Active Comparator|REXEED-15A|TThe patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using REXEED-15A
11184761|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
11186830|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
11184762|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
11184763|NCT03489733|Experimental|Intervention Group|Infant Formula with hydrolyzed protein and breast milk until at least 120 days of life
11184764|NCT03489733|Experimental|Control Group|Infant Formula with intact protein and breast milk until at least 120 days of life
11184765|NCT03489733|No Intervention|Breast Fed Group|Exclusively breast ilk until at least 120 days of life
11184766|NCT03489720|Experimental|Arm A: Exercise intervention then usual exercise program|8 weeks of exercise intervention followed by 8 weeks of usual exercise program
11184767|NCT03489720|Active Comparator|Arm B: Usual Exercise Program then exercise intervention|8 weeks of usual exercise program followed by 8 weeks of exercise intervention
11184768|NCT03489707|Experimental|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
11184769|NCT03489707|Active Comparator|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
11184770|NCT03489694||Subjects|Each subject will undergo skin test endpoint titrations with three different testers.
11184771|NCT03489681|Experimental|Acupuncture, low dosage|treat as six acupoints
11184772|NCT03489681|Experimental|Acupuncture, high dosage|treat as 18 acupoints
11184773|NCT03489681|No Intervention|Control group|no acupuncture treatment, healthy control
11184774|NCT03489668|Active Comparator|PCOS|Metformin administration 1500mg/day
11184775|NCT03489668|No Intervention|Control|
11184776|NCT03489655|Experimental|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
11184777|NCT03489655|No Intervention|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
11184778|NCT03489642|Experimental|COPD Telehealth Program|Participants will take part in a structured telehealth program for 12 weeks. Web-based educational tools will be made available to participants. Study participants will meet with a registered respiratory therapist two times per week.
11184779|NCT03489629|Experimental|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.
~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
11184780|NCT03489616|Experimental|Radiotherapy+chemotherapy+ rhGM-CSF|Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be> 4Gy per time（or BED >45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
11184781|NCT03489616|Experimental|Single agent maintenance therapy|Maintenance treatment by single agent in a cycle of 21 days.
11184782|NCT03489590|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.
11184783|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
11184784|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
11184785|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
11184786|NCT03489538||RYGB Patients|Laparoscopic long limb roux-en-Y gastric bypass group. All consecutive patients eligible for bariatric surgery.
11184787|NCT03489525|Experimental|Dose Escalation, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
11184788|NCT03489525|Experimental|Dose Expansion, MEDI2228, ADC|Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
11184789|NCT03489512|Experimental|A (Chloraprep)|2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
11184790|NCT03489512|Active Comparator|B (Clorhexidine 2%)|2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
11184791|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
11184792|NCT03489460|Active Comparator|Receive sleep health messages + GAD|Procedures will be delivered to users of the GAD, individuals who have opted in via their smartphone application, to receive messages about various areas of health.
11184793|NCT03489460|Active Comparator|Sleep message No GAD|For two weeks participants agree to receive sleep health messages and wear the GAD
11184794|NCT03489447||Sepsis group|All adult (>= 18 years) patients with a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
11184795|NCT03489447||Non-sepsis group|All adult (>=18 years) patients without a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
11184796|NCT03489434|Experimental|Intervention Group|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
11184797|NCT03489434|No Intervention|Control|Assessment only control.
11184798|NCT03489421||HIV Infected|
11184799|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
11184836|NCT03489122|Active Comparator|Walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
11184800|NCT03489395|Experimental|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
11184801|NCT03489382|No Intervention|Control|Emergency Departments providing usual care, which includes assessment in hospital followed by placement on a wait list for psychiatric services and access to regional community resources for suicide prevention.
11184802|NCT03489382|Experimental|Smartphone Assisted PST|Emergency Departments providing the option to refer men who self-harm to a service that will deliver smartphone-assisted problem solving therapy.
11184803|NCT03489369|Experimental|Sym022|Sym022 will be administered at up to 4 planned dose levels.
11184804|NCT03489356|Experimental|Intervention|Addressing Behavior Change (ABC) intervention delivery method
11184805|NCT03489356|No Intervention|Control|Control
11184806|NCT03489343|Experimental|Sym023|Sym023 will be administered at up to 7 planned dose levels.
11184807|NCT03489330||Northwestern Memorial Hospital data|Inpatient intravenous vancomycin use
11184808|NCT03489330||Henry Ford Hospital data|Inpatient intravenous vancomycin use
11184809|NCT03489330||University of Michigan Hospital data|Inpatient intravenous vancomycin use
11184810|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
11184811|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
11184812|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
11184813|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
11184814|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
11184815|NCT03489278||Affected|Affected with ALS or a related disorder.
11184816|NCT03489265|Other|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
11184817|NCT03489265|Other|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
11184818|NCT03489252|Experimental|Device Feasibility (Fitbit Charge 3)|Participants wear the Fitbit Charge 3 device from the time of CT simulation for RT planning throughout the entire RT course.
11184819|NCT03489239|Experimental|Single Arm|SingleArm: TAF 25 mg
11184820|NCT03489226|Active Comparator|Capsimax 2 mg|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
11184821|NCT03489226|Placebo Comparator|Placebo|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
11184822|NCT03489226|Active Comparator|Capsimax 4 mg plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
11184823|NCT03489226|Placebo Comparator|Placebo plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
11184824|NCT03489213|Active Comparator|Arm I (DGA/AICR)|Patients receive DGA/AICR-based dietary intervention for 6 months consisting of 12 education sessions (60 minutes each) every other week. Lectures will take place in an urban garden where fruit, vegetable, and herb harvesting 1-2 times per week is encouraged. All participants will be given a FitBit and regular physical activity will be encouraged. Finally, remote health coaching is offered to all study subjects for the duration of the intervention (12 weeks).
11184825|NCT03489213|Experimental|Arm II (DGA/AICR plus Beef)|Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
11184826|NCT03489200|Experimental|EH301|
11184827|NCT03489200|Placebo Comparator|Placebo|
11184828|NCT03489187||VTTS as standard of care|VTTS as standard of care.
11184829|NCT03489174|Experimental|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
11184830|NCT03489174|Active Comparator|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
11184831|NCT03489161|Experimental|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
11184832|NCT03489148|Experimental|Tamarkoz®|A Sufi method to focus, called Tamarkoz®. Participants had met in class twice a week for two and a half hours total for three months. One day of the week, they met for theoretical teachings of Sufism, and for the second day in the week they met with a Tamarkoz® instructor to learn meditation techniques.
11184833|NCT03489148|Active Comparator|Stress Management Resources|The self-care stress management group used the campus resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, and online reading materials for stress management as needed for themselves.
11184834|NCT03489148|No Intervention|Waitlist|The waitlist control group did not receive Tamarkoz® and did not use the stress management resources on campus for the duration of the study.
11184835|NCT03489122|Experimental|Iyengar yoga and coherent breathing|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
11184837|NCT03489109|Experimental|Intermittent Fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet.
11184838|NCT03489109|Active Comparator|Standard of Care|Standard of care dietary and healthy lifestyle counseling
11184839|NCT03489096|Experimental|Cryoballoon Ablation|Cryoballoon Ablation: PVI + substrate modification. Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
11184840|NCT03489083|Experimental|Trained Group|Subjects performing strength training three times per week for twelve weeks.
11184841|NCT03489083|Placebo Comparator|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
11184842|NCT03489070|Active Comparator|Traumastem®|Oxidized nonregenerated cellulose hemostatic agents.Traumastem® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
11184843|NCT03489070|Active Comparator|Surgicel®|Oxidized regenerated cellulose hemostatic agents.Surgicle® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
11184844|NCT03489057|Experimental|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
11184845|NCT03489057|Active Comparator|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
11184846|NCT03489044|Experimental|Active treatment arm (Levetiracetam)|When in the active arm, after a baseline visit, participants will up-titrate Levetiracetam in 250mg steps at intervals of one week to Levetiracetam 500mg twice daily (two tablets twice daily). Participants will be maintained on Levetiracetam 500mg bd for four weeks and have a further full assessment at 8 weeks after being on Levetiracetam. Participants will then down-titrate Levetiracetam by 250mg every week until weaned to nil.
11184847|NCT03489044|Placebo Comparator|Control arm (placebo oral tablets)|When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
11184848|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
11184849|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
11184850|NCT03489005|Other|Treatment Period 1|"Interventions to be administered:
~Schema 1:
~400 mg BIA 5-1058
~1200 mg BIA 5-1058
~Placebo
~Moxifloxacin
~Schema 2:
~1200 mg BIA 5-1058
~Placebo
~400 mg BIA 5-1058
~Moxifloxacin"
11184851|NCT03489005|Other|Treatment Period 2|"Interventions to be administered:
~Schema 1
~1200 mg BIA 5-1058
~Placebo
~400 mg BIA 5-1058
~Moxifloxacin
~Schema 2:
~1200 mg BIA 5-1058
~Moxifloxacin
~400 mg BIA 5-1058
~Placebo"
11184852|NCT03489005|Other|Treatment Period 3|"Interventions to be administered:
~Schema 1
~Placebo
~400 mg BIA 5-1058
~Moxifloxacin
~1200 mg BIA 5-1058 Schema 2
~1. 400 mg BIA 5-1058 2. 1200 mg BIA 5-1058 3. Moxifloxacin 4. Placebo"
11184853|NCT03489005|Other|Treatment Period 4|"Interventions to be administered:
~Schema 1
~Moxifloxacin
~Placebo
~1200 mg BIA 5-1058
~400 mg BIA 5-1058 Schema 2
~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
11184854|NCT03488992|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
11184855|NCT03488992|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
11184856|NCT03488979||Educational Interventional Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
11184857|NCT03488979||Attention Control Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
11184858|NCT03488966|Experimental|MB-EAT|Behavioral: group psychotherapy. Eight weekly sessions, each session is 2 hours in duration.
11184859|NCT03488966|No Intervention|Waitlist Control|Wait list control.
11184860|NCT03488953|Other|Transplantation Arm|
11184861|NCT03488940|Active Comparator|24-hours group|"The septic patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
11184862|NCT03488940|Experimental|16-hours group|"The septic patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
11184863|NCT03488940|Experimental|intermittent group|"The septic patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.
~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
11184864|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
11184865|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
11184866|NCT03488914|Other|Intervention|
11184867|NCT03488914|Other|Enhanced Treatment as Usual|
11184868|NCT03488901||methotrexate sensitive|patients with gestational choriocarcinoma cured with methotrexate alone
11184869|NCT03488901||methotrexate resistant|patients with gestational choriocarcinoma not cured with methotrexate alone
11184870|NCT03488901||polychemotherapy sensitive|patients with gestational choriocarcinoma cured with polychemotherapy
11184871|NCT03488901||polychemotherapy resistant|patients with gestational choriocarcinoma not cured with polychemotherapy
11184872|NCT03488901||hydatidiform moles without malignant transformation|patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)
11184873|NCT03488901||placental site trophoblastic tumors|patients with placental site trophoblastic tumors not cured with polychemotherapy
11184906|NCT03488602|Experimental|F-SPS Intervention|This group will receive the F-SPS intervention.
11184874|NCT03488888|Sham Comparator|Normal Saline|"General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9%
~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles
~Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery.
~Visualization of Pectoralis menor and Serratil Muscles
~3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution"
11184875|NCT03488888|Experimental|Bupivacaine|"General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine
~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles
~Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery.
~Visualization of Pectoralis minor and Serratil Muscles
~3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution"
11184876|NCT03488875|Experimental|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
11184877|NCT03488875|No Intervention|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
11184878|NCT03488836|Active Comparator|race|race rotation protocol
11184879|NCT03488836|Active Comparator|reciproc|reciprocal endodontic treatment group
11184880|NCT03488823|Experimental|Young with Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
11184881|NCT03488823|Placebo Comparator|Young without Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
11184882|NCT03488823|Experimental|Old with Flavanol|Old patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
11184883|NCT03488823|Placebo Comparator|Old without Flavanol|Young patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
11184884|NCT03488810|Active Comparator|Arm A: ADT + radiation therapy|"Patient will receive 2 injections of a three-monthly LHRH agonist depot plus non-steroidal anti-androgen (rescue treatment) (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection.
~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
11184885|NCT03488810|Experimental|Arm B: ADT + radiation therapy + Apalutamide|"Patients will receive 2 injections of a three-monthly LHRH agonist depot. Apalutamide treatment: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months.
~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
11184886|NCT03488797|Experimental|Experimental|Supervised web- and home-based exercise intervention
11184887|NCT03488797|No Intervention|No Intervention|"Control group - Standard of Care
~Re-assessment 24 weeks (6 month) after enrolment.
~Afterwards crossover into experimental group"
11184888|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
11184889|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
11184890|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
11184891|NCT03488758|Active Comparator|CMF|infant formula based on cow milk protein fractions
11184892|NCT03488758|Experimental|GMF|infant formula based on whole goat milk
11184893|NCT03488745|Experimental|IntelliCare + Phone Coaching|Participants will receive IntelliCare apps with phone coaching for 7 weeks. In this arm, participants will pick two IntelliCare apps to use every week. Participants will receive a phone coaching call before they use the apps, for approximately 30 minutes, as well as 3 weeks after initiating app use (10 minute call).
11184894|NCT03488732||Patients undergonig transcatheter valvular interventions|
11184895|NCT03488719|Experimental|Cohort 1|Tesofensine 0.25mg
11184896|NCT03488719|Experimental|Cohort 2|Tesofensine 0.50mg
11184897|NCT03488719|Experimental|Cohort 3|Tesofensine 0.75mg
11184898|NCT03488706||Gray Zone Group|The gray zone group PSA between 4.00 to 10.99 ng/ml.
11184899|NCT03488693|Active Comparator|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
11184900|NCT03488693|Active Comparator|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
11184901|NCT03488680|Experimental|Intervention group|Behavior change communication
11184902|NCT03488680|No Intervention|Control group|No Behavior change communication
11184903|NCT03488667|Experimental|mFOLFOX6 (Leucovorin-Fluorouracil-Oxaliplatin) + Pembrolizumab|"Drug: Pembrolizumab Dose: 200 mg Dose Frequency: Every three weeks (Q3W) Route: Intravenous (IV) infusion
~Drug: Oxaliplatin Dose: 85 milligrams per meter squared (mg/m2) Dose Frequency: Every 2 weeks (Q2W) Route: IV infusion
~Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion
~Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus
~Drug: Fluorouracil Dose: 2,400 mg/m2 Dose Frequency: Q2W Route: IV continuous 46-hour infusion
~Pembrolizumab will be administered at a fixed dose of 200 mg IV over 30 minutes every 3 weeks. Participants will receive 3 doses of the drug on Days 1, 22, 43 during the neoadjuvant phase of the study, and 12 doses of the drug on Days 1, 22, 43 during the adjuvant phase of the study (total 15 doses). Participants will receive 4 doses of mFOLFOX6 regimen on Days 1, 15, 29, 43 during the neoadjuvant phase of the study, and 4 doses during the adjuvant phase of the study (total 8 doses)."
11184904|NCT03488628|Active Comparator|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternance with standard nasal oxygen therapy
11184905|NCT03488628|Experimental|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher & Paykel Healthcare,New Zealand) through nasal canula.
11184907|NCT03488602|Active Comparator|Enhanced Usual Care (EUC)|This group will receive Enhanced Usual Care (EUC)
11184908|NCT03488576|Active Comparator|Complete Peeling|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with complete macular peeling of the internal limiting membrane.
11184909|NCT03488576|Experimental|Foveal Sparing|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with partial peeling the internal limiting membrane (foveal sparing).
11184910|NCT03488563|Experimental|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
11184911|NCT03488563|Experimental|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
11184912|NCT03488563|Placebo Comparator|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
11184913|NCT03488550|Experimental|ANX007-GLA-01|
11184914|NCT03488537|Other|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
11184915|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
11184916|NCT03488511|Experimental|Intervention group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of six small protein and energy enriched meals and snacks that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
11184917|NCT03488511|No Intervention|Control group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
11184918|NCT03488498||Receiving NSAID medication|Receiving NSAID medication
11184919|NCT03488498||Receiving NSAID medication and weight bath therapy,|
11184920|NCT03488498||Receiving weight bath therapy,|
11184921|NCT03488485|Other|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).
~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks
~Cirrhotics:
~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
11184922|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
11184923|NCT03488459|Other|Routine preoperative information from a nurse|
11184924|NCT03488459|Experimental|Additional information support from a psychologist|
11184925|NCT03488433|Active Comparator|Antirotation sling|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
11184926|NCT03488433|Active Comparator|abduction brace|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
11184927|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
11184928|NCT03488381|Experimental|Soccer Heading|
11184929|NCT03488381|Sham Comparator|Kicking-Control|
11184930|NCT03488368||Supportive-care group|Observation of IgAN patients who received supportive care measures (without additional immunosuppression) during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
11184931|NCT03488368||Immunosuppression group|Observation of IgAN patients who received supportive care measures and additional immunosuppression during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
11184932|NCT03488355|Experimental|Modified Reporting|Modified laboratory report
11184933|NCT03488355|No Intervention|Standard Reporting|Standard laboratory report
11184934|NCT03488342|Other|Rives technique|Rives technique for primary inguinal hernia
11184935|NCT03488342|Other|Lichtenstein repair|Lichtenstein repair for primary inguinal hernia
11184936|NCT03488329|Experimental|Intervention|"Intervention group
~Individual nutritional therapy"
11184937|NCT03488329|No Intervention|Control|"Control group
~Standard treatment"
11184938|NCT03488316|Active Comparator|Calcium Hydroxide temporary filling material|Temporary filling with Ca(OH)2
11184939|NCT03488316|Active Comparator|MTA temporary filling material|Temporary filling with MTA
11184940|NCT03488303||Main group|Study has only one group
11184941|NCT03488290|Experimental|LTP Plus TF CBT|LTP Plus TF CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
11184942|NCT03488290|Other|Treatment as Usual|TAU group will receive routine care consisting of routine follow ups
11184943|NCT03488277|Experimental|LE: leg elevation group|the patients of this group will be positionned in supine with 15° left tilt and will have a leg elevation with a 30 cm pillow positionned under the heels. this position will be hold immediately after spinal anesthesia until fetal extraction
11184944|NCT03488277|No Intervention|CG: Control group|The patients of this group will be positiooned in supine with 15° left tlit after spinal anesthesia. no leg elevation
11184945|NCT03488264||United States|50 participants will be recruited from the United States.
11184946|NCT03488264||Jamaica|50 participants will be recruited from Jamaica.
11184947|NCT03488251|Experimental|MT-3724 10mcg/kg-GEMOX|MT-3724 10 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 10 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
11184986|NCT03487965|Experimental|Low dose Polyphenol|130 mg of Aronia Extract with 120 mg of licorice root combination blend provided to subjects once per day for 16 weeks.
11211019|NCT03308292|No Intervention|Control Group|
11184948|NCT03488251|Experimental|MT-3724 25mcg/kg-GEMOX|MT-3724 25 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 25 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
11184949|NCT03488251|Experimental|MT-3724 50mcg/kg- GEMOX|MT-3724 50 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 50 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
11184950|NCT03488225|Experimental|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
11184951|NCT03488212|Active Comparator|Basic Implementation Intervention|
11184952|NCT03488212|Experimental|Enhanced Implementation Intervention|
11184953|NCT03488212|Active Comparator|Online Treatment; Control Maintenance Intervention|
11184954|NCT03488212|Experimental|Online Treatment; Monthly Lessons & Feedback for Maintenance|
11184955|NCT03488212|Experimental|Online Treatment; Refresher Courses for Maintenance|
11184956|NCT03488199|Active Comparator|Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)|50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
11184957|NCT03488199|Experimental|Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))|50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
11184958|NCT03488186|Experimental|Lansoprazole Capsules|Lansoprazole Capsules of Beijing Sihuan Pharm, 30 mg
11184959|NCT03488186|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules of Takeda Pharmaceutical Company Limited, 30 mg
11184960|NCT03488173|Experimental|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
11184961|NCT03488173|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
11184962|NCT03488160|Experimental|Single arm|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:the first day,the second day Duration:total two times
11184963|NCT03488147|Experimental|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
11184964|NCT03488147|Active Comparator|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
11184965|NCT03488147|Placebo Comparator|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
11184966|NCT03488121|Experimental|Poster Only|This arm will only receive motivational posters.
11184967|NCT03488121|Experimental|Thank-you Letter Only|This arm will only receive thank-you letters.
11184968|NCT03488121|Experimental|Double Incentive|This arm will receive both motivational posters and thank-you letters.
11184969|NCT03488121|No Intervention|Control|This arm will not receive any intervention.
11184970|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
11184971|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
11184972|NCT03488095|Other|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
11184973|NCT03488095|No Intervention|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
11184974|NCT03488082|Experimental|Measurement of the bold signal|
11184975|NCT03488056|Experimental|Test - ICCMS|"The dentists will perform clinical examination on children following the ICCMS sequence:
~The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.
~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
11184976|NCT03488056|Active Comparator|Control - Standard care SESC|"The clinical sequence in this group will be:
~Caries Diagnosis Operative and non-operative treatments Indication of recall interval according to the dentist However, dentists will do that without a schematic guide to follow. They will do as they usually do in their practices."
11184977|NCT03488043||Retrospective cohort|All patients having a CT-guided transthoracic biopsy from September 2012 and September 2017.
11184978|NCT03488043||Prospective cohort|All patients having a CT-guided transthoracic biopsy from April 2018.
11184979|NCT03488030||All Participants|Participants diagnosed with moderate to severe UC or CD from the 7 participating sites will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years from the date of UC or CD diagnosis until Day 1 to assess the IBD treatments, medical history and comorbidities, treatment patterns and use of health resources.
11184980|NCT03488017|Experimental|Placebo Ocular Coil (left eye)|Left eye
11184981|NCT03488017|Experimental|Placebo Ocular Coil (right eye)|Right eye
11184982|NCT03487991|Experimental|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
11184983|NCT03487991|No Intervention|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
11184984|NCT03487978||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo 3-tesla resting-state functional MRI.
11184985|NCT03487978||Control|Normal controls without headaches will undergo 3-tesla resting-state functional MRI.
11184987|NCT03487965|Experimental|High dose Polyphenol|200 mg of Aronia extract provided to subjects once per day for 16 weeks
11184988|NCT03487965|Placebo Comparator|Placebo control|Inert tablet provided to subjects once per day for 16 weeks
11184989|NCT03487952||LDCT screening group|People receive questionnaire administration at baseline, then subsequent yearly chest LDCT scan and follow up.
11184990|NCT03487939|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
11184991|NCT03487926||Group 1 (IBD primary diagnosis)|Participants have active IBD
11184992|NCT03487926||Group 2( IBD + comorbid MDE)|1 [18F]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE
11184993|NCT03487926||Group 3-Controls|"Matched for Level of Depressive Symptoms and Otherwise Healthy
~-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available)."
11184994|NCT03487913|Experimental|High dose|Oral lixivaptan
11184995|NCT03487913|Experimental|Low dose|Oral lixivaptan
11184996|NCT03487900|Other|Clinical remission CD|
11184997|NCT03487874|Experimental|Interscalene block with C8 root block|The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
11184998|NCT03487874|Active Comparator|Conventional interscalene block|The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
11184999|NCT03487848|Experimental|Daclatasvir with Sofosbuvir|Specified dose on specified days for specified duration
11185000|NCT03487835|Experimental|Kinesiotape group|
11185001|NCT03487835|Experimental|Control group|
11185002|NCT03487822|Experimental|Path Pain|Path Pain participants will be receiving 8 weekly therapy session by license clinicians trained in the Path Pain intervention. They will also receive 4, 15-minute phone booster sessions, on a monthly basis after their final therapy session. They will also be invited to monthly group educational sessions. Both intervention and usual care participants will be receiving a pain educational booklet.
11185003|NCT03487822|No Intervention|Usual Care with Education|Usual Care with Education (UCE) will receive a pain educational booklet. Following completion of their 24 weeks in the study, they will also be invited to attend the monthly group educational sessions.
11185004|NCT03487822|No Intervention|Provider Feedback|Providers of patients in the study will take part in a short interview on their impressions of the intervention.
11185005|NCT03487809||NTUH|National Taiwan University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
11185006|NCT03487809||FJUH|Fu Jen University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
11185007|NCT03487809||CGH|Cathay General Hospital, all participants receive Alvesco (Ciclesonide, 160mcg/puff)
11185008|NCT03487796|Experimental|MySTYLE|MySTYLE is online, brief and encourages parent-adolescent communication about sex and HIV prevention. Participants (non-heterosexual Black adolescent males and parents/caregivers) will receive two texts per week (for eight weeks) with links to intervention content that includes video, games and graphics to improve knowledge, motivation and skills for HIV prevention. Topics include assertive communication, sexual safety, goal setting, and resilience.
11185009|NCT03487796|Other|Waitlist Control|Participants randomized to the waitlist control will be eligible to receive the eight-week MySTYLE intervention after the completion of the 4-month follow-up assessment. During their first four months of participation, waitlist control participants will not receive any intervention materials.
11185010|NCT03487783|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
11185011|NCT03487783|Placebo Comparator|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
11185012|NCT03487770|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
11185013|NCT03487770|Placebo Comparator|Placebo Oral Solution|2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
11185014|NCT03487757|Active Comparator|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
11185015|NCT03487757|Experimental|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
11185016|NCT03487744|Active Comparator|Promote without fiber|Lower osmolality enteral tube feed formulation
11185017|NCT03487744|Active Comparator|Osmolite 1.5|Higher osmolality enteral tube feed formulation
11185018|NCT03487731|Placebo Comparator|Group 1 - Placebo|Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.
11185019|NCT03487731|Experimental|Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.
11185020|NCT03487731|Experimental|Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.
11211081|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
11185021|NCT03487731|Placebo Comparator|Group B - Placebo|Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator.
11185022|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
11185023|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
11185024|NCT03487705|Other|child essential tremor|electromyogram with accelerometer
11185025|NCT03487692|Experimental|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
11185026|NCT03487692|Other|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
11185027|NCT03487679|Experimental|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
11185028|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
11185029|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
11185030|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
11185031|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
11185032|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
11185033|NCT03487627|Experimental|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
11185034|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
11185035|NCT03487614|Experimental|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
11185036|NCT03487614|No Intervention|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children <3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
11185037|NCT03487601|Active Comparator|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
11185038|NCT03487601|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
11185039|NCT03487588|Experimental|A-101 Topical Solution|Open Label Arm
11185040|NCT03487575|Experimental|Open trial|
11185041|NCT03487562|Experimental|Sequence 1|Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
11185042|NCT03487562|Experimental|Sequence 2|Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
11185043|NCT03487562|Experimental|Sequence 3|Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
11185044|NCT03487562|Experimental|Sequence 4|Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
11185045|NCT03487562|Experimental|A|Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
11185046|NCT03487562|Experimental|B|Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
11186831|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
11185047|NCT03487562|Experimental|C|Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
11185048|NCT03487549|Other|Open label|This is an open label study. All subjects will receive treatment to their common warts per protocol with VP-102, cantharidin topical film forming solution, using the VP-102 applicator.
11185049|NCT03487523|Active Comparator|Intervention 1|Text message (SMS Message)
11185050|NCT03487523|Active Comparator|Intervention 2|Text message (SMS Message)
11185051|NCT03487523|No Intervention|Intervention 3|no intervention
11185052|NCT03487510||NO groups|no groups apply.
11185053|NCT03487497||Patients|Patients who underwent lateral column lengthening osteotomy
11185054|NCT03487497||Healthy subjects|Healthy subjects without intervention
11185055|NCT03487484||With protective stoma|Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
11185056|NCT03487484||No stoma|"Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.
~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied."
11185057|NCT03487471|Active Comparator|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
11185058|NCT03487471|Active Comparator|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
11185059|NCT03487458|No Intervention|Control|participants receive no surgical treatment
11185060|NCT03487458|Experimental|Rib Fixation Surgery|participants receive surgical treatment
11185061|NCT03487445|Experimental|ACT-246475 - 8 mg|Single s.c. administration
11185062|NCT03487445|Experimental|ACT-246475 - 16 mg|Single s.c. administration
11185063|NCT03487432|Experimental|OPN NC|Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)
11185064|NCT03487432|Experimental|NSE Alpha|Patients receiving a Scoring PTCA Balloon (NSE Alpha)
11185065|NCT03487419||patients develop atrial fibrillation|patients post coronary artery bypass grafting who develop atrial fibrillation post operative
11185066|NCT03487419||patients who not develop atrial fibrillation|patients post coronary artery bypass grafting who don't develop atrial fibrillation post operative
11185067|NCT03487406|Placebo Comparator|Placebo Ticagrelor & placebo Aspirin|Placebo Ticagrelor 90 mg- one tablet, twice daily. Placebo Aspirin 75 mg- one tablet, once a day.
11185068|NCT03487406|Active Comparator|Aspirin & Placebo Ticagrelor|Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
11185069|NCT03487406|Active Comparator|Placebo Aspirin & Ticagrelor|Placebo Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
11185070|NCT03487406|Experimental|Aspirin & Ticagrelor|Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
11185071|NCT03487393|Experimental|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
11185072|NCT03487380|Experimental|Alzheimer with rapid DCR|
11185073|NCT03487380|Experimental|Alzheimer without rapid DCR|
11185074|NCT03487380|Sham Comparator|Control|
11185075|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
11185076|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
11185077|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
11185078|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
11185079|NCT03487354|Active Comparator|Single daily dose|
11185080|NCT03487354|Active Comparator|Multiple daily doses|
11185081|NCT03487341|Active Comparator|Cord drainage|
11185082|NCT03487341|Active Comparator|Cord clamping|
11185083|NCT03487328|Active Comparator|Modified technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
11185084|NCT03487328|Active Comparator|Conventional technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
11185085|NCT03487315|Experimental|specific IgE|Different level of specific IgE and immunoblot
11185086|NCT03487302||cCHD|
11185087|NCT03487302||CONTROLS|
11185088|NCT03487289|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
11185089|NCT03487289|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
11185090|NCT03487276|Placebo Comparator|Cohort 1|Placebo
11185091|NCT03487276|Experimental|Cohort 2|Minimum Dose IFX-1
11185092|NCT03487276|Experimental|Cohort 3|Low dose IFX-1
11185093|NCT03487276|Experimental|Cohort 4|Medium Dose IFX-1
11185094|NCT03487276|Experimental|Cohort 5|High Dose IFX-1
11185095|NCT03487263|Experimental|IC14 dose level 1|For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses
11185096|NCT03487263|Experimental|IC14 dose level 2|For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4
11185097|NCT03487250||TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
11186832|NCT03475251|Experimental|CS1003|
11185098|NCT03487237|Experimental|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
11185099|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
11185100|NCT03487224||Healthy Controls|Adults without mental illness
11185101|NCT03487211|Active Comparator|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
11185102|NCT03487211|Experimental|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
11185103|NCT03487198|Experimental|Brexpiprazole|2-3 mg/day, once daily for 6 weeks, oral administration
11185104|NCT03487198|Placebo Comparator|Placebo|2-3 mg/day, once daily for 6 weeks, oral administration
11185105|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
11185106|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
11185107|NCT03487172|Other|Right Side Treated|Subjects will be randomized to have their right side treated with PLLA and their left side treated with normal saline.
11185108|NCT03487172|Other|Left Side Treated|Subjects will be randomized to have their left side treated with PLLA and their right side treated with normal saline.
11185109|NCT03487159|Other|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
11185110|NCT03487159|Other|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
11185111|NCT03487146|No Intervention|HD(hemodialysis) group|HD group as conventional control arm
11185112|NCT03487146|Active Comparator|HD+HP(hemodialysis+hemoperfusion) group|HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.
11185113|NCT03487133|Experimental|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
11185114|NCT03487120|No Intervention|lumbar laminectomy|
11185115|NCT03487120|Active Comparator|lumbar laminectomy with denervation of the facet joint|
11185116|NCT03487107|Experimental|SOF 400 mg+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.
11185117|NCT03487094|Active Comparator|Growth, Tolerance of Infants-Exp|Infant Formula
11185118|NCT03487094|Active Comparator|Growth,Tolerance of Infants-Com|Infant Formula
11185119|NCT03487081|Experimental|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
11185120|NCT03487081|Active Comparator|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
11185121|NCT03487068|Other|Patients with NAFLD|
11185122|NCT03487055|Experimental|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
11185123|NCT03487042|Experimental|Generalized vitiligo patients|"Each patient with generalized vitiligo will be subjected to the following:
~One side will be treated by narrow band ultraviolet rays sessions twice weekly for 3 months + topical bimatoprost 0.03% ophthalmic solution solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% ophthalmic solution twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months."
11185124|NCT03487029|Experimental|short duration group|30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
11185125|NCT03487029|Experimental|long duration group|4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
11185126|NCT03487016|Active Comparator|A: Gemcitabine/nab-Paclitaxel (Standard)|"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.
~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
11185127|NCT03487016|Experimental|B: NAPOLI regimen|"On Day 1 of a 14-day cycle:
~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)
~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
11185128|NCT03487016|Experimental|C: seq-NAPOLI-FOLFOX|"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.
~NAPOLI:
~On Day 1 of a 14-day cycle:
~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)
~mFOLFOX6:
~On Day 1 of a 14-day cycle:
~Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)
~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
11185129|NCT03487003|Active Comparator|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
11185130|NCT03487003|Experimental|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
11185131|NCT03486990|Experimental|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
11185132|NCT03486990|Experimental|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
11185133|NCT03486990|Experimental|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
11185134|NCT03486990|Experimental|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
11185135|NCT03486990|Experimental|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
11185136|NCT03486990|Experimental|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
11185137|NCT03486990|Experimental|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
11185138|NCT03486990|Experimental|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
11185139|NCT03486990|Experimental|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
11185140|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
11185141|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.
~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
11185142|NCT03486964||DPP-4 plus other therapies|Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
11185143|NCT03486964||Other therapies|Patients in therapy with other hypoglycemic classes, such as sulphonylureas and/or biguanides and/or thiazolidinediones and/or insulin.
11185144|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
11185145|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
11185146|NCT03486925|Experimental|oxytocin group|
11185147|NCT03486925|Placebo Comparator|placebo group|
11185148|NCT03486912|Experimental|BMS-986036 Dose Level 1|
11185149|NCT03486912|Experimental|BMS-986036 Dose Level 2|
11185150|NCT03486912|Experimental|BMS-986036 Dose Level 3|
11185151|NCT03486912|Placebo Comparator|Placebo|
11185152|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
11185153|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
11185154|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
11185155|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection.
11185156|NCT03486886|Experimental|PSMA -PET/CT scanning|
11185157|NCT03486873|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
11185158|NCT03486873|Experimental|Pembrolizumab 400 mg|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants.
11185159|NCT03486873|Experimental|Pembrolizumab 200 mg + SOC: Per Parent Study)|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
11185160|NCT03486873|Experimental|Pembrolizumab 400 mg + SOC (Per Parent Study)|Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle PLUS SOC treatment (or per parent study if there is no SOC) for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
11185161|NCT03486873|Active Comparator|SOC (Per Parent Study)|Participants receive the dose matched non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving as per parent study protocol.
11185162|NCT03486860|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
11185163|NCT03486860|Other|Waitlist Control|Untreated comparison group during the study, received parent psychoeducation intervention after the active treatment group.
11185164|NCT03486847|Experimental|Repetitive recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
11185165|NCT03486847|Active Comparator|One recruitment with PEEP|One alveolar recruitment at before surgery
11185166|NCT03486834|Experimental|V160 3-Dose Regimen|Participants will receive V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
11185167|NCT03486834|Experimental|V160 2-Dose Regimen|Participants will receive V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.
11185168|NCT03486834|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 3, and Month 6.
11185200|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
11185201|NCT03486639||Patients undergoing urodynamic|All patients older than 18 who are refered for Urodynamics examination
11185202|NCT03486626|Experimental|Patients|
11185203|NCT03486613|Other|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
11185204|NCT03486613|Other|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
11185394|NCT03485248|Active Comparator|Beetroot juice|Beetroot Juice cotaining on average 9mmol of nitrate per dose
11185169|NCT03486821|Experimental|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.
~Each treatment should take about 10-20 minutes."
11185170|NCT03486808|Experimental|Dual stimulation|i) anodal stimulation of left inferior frontal cortex ii) anodal stimulation on left dorsolateral prefrontal cortex
11185171|NCT03486808|Active Comparator|IFG stimulation|anodal stimulation of left inferior frontal cortex
11185172|NCT03486808|Active Comparator|DLPFC stimulation|anodal stimulation on left dorsolateral prefrontal cortex
11185173|NCT03486808|Sham Comparator|Sham stimulation|sham stimulation
11185174|NCT03486795|Experimental|Dual stimulation|"anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
~anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area"
11185175|NCT03486795|Experimental|M1 stimulation|anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
11185176|NCT03486795|Experimental|PMC stimulation|anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
11185177|NCT03486795|Sham Comparator|Sham stimulation|Sham stimulation
11185178|NCT03486782|Active Comparator|Dual stimulation|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex and cathodal stimulation of contralesional supraorbital area
11185179|NCT03486782|Active Comparator|Single stimulation 1|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional inferior frontal cortex
11185180|NCT03486782|Active Comparator|Single stimulation 2|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area
11185181|NCT03486769|Experimental|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
11185182|NCT03486769|Experimental|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
11185183|NCT03486769|Experimental|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
11185184|NCT03486756|Experimental|Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
11185185|NCT03486743|Experimental|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
11185186|NCT03486743|No Intervention|Control arm|Participants in the intervention arm will only be asked to complete a survey.
11185187|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
11185188|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
11185189|NCT03486717|Experimental|Control|Study group that does not wear the virtual reality goggles. This group will serve as a control.
11185190|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
11185191|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
11185192|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
11185193|NCT03486704|Experimental|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
11185194|NCT03486704|Active Comparator|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
11185195|NCT03486691|Experimental|preoperative left lobe measurement|routine preoperative left lobe measurement
11185196|NCT03486691|Active Comparator|Control group|Control group without routine measurement of left lobe
11185197|NCT03486678|Experimental|SHR1210+GEMOX|This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.
11185198|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
11185199|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
11186833|NCT03475251|Experimental|CS1003 + regorafenib|
11185205|NCT03486600|Other|fluid resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
11185206|NCT03486587|Experimental|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
11185207|NCT03486574||Gastric cancer|Pathologically proven diseases after upper gastroendoscopy and biopsy. Previous pathological reports and endoscopic image can be used.
11185208|NCT03486574||non-gastric cnacer|Rull out gastric cancer by upper gastroendoscopy. The results 3 moths before enrollment is available.
11185209|NCT03486561|Other|Ranolazine|Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
11185210|NCT03486548|Sham Comparator|control group|adductor canal block with sham block
11185211|NCT03486548|Experimental|sciatic group|adductor canal block with popliteal sciatic nerve block
11185212|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
11185213|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
11185214|NCT03486509|Experimental|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
11185215|NCT03486496|Experimental|Gefitinib and Berberine|Experimental: Gefitinib and Berberine Patients will be treated with Gefitinib and Berberine. Gefitinib: 250 mg p.o., daily. Berberine: 50 mg p.o., tid.
11185216|NCT03486483|Experimental|Supervised Slackline Training|Supervised Slackline training in children and teenagers with spastic cerebral palsy (grade I and II of the Gross Motor Function Classification System). Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
11185217|NCT03486483|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine.
11185218|NCT03486457|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
11185219|NCT03486457|Placebo Comparator|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
11185220|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
11185221|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
11185222|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
11185223|NCT03486431|Experimental|Level I|5 x 7 Gy SABR
11185224|NCT03486431|Experimental|Level II|3 x 10 Gy SABR
11185225|NCT03486431|Experimental|Level III|1 x 20 Gy SABR
11185226|NCT03486405|Experimental|Intervention group|The experimental group will have no in person education by researchers. All education and running modification will be performed via video. Education on running form, a home exercise program, and a 4 week return to run program will be provided to the subjects through e-mail. They will also receive the same in person video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
11185227|NCT03486405|Active Comparator|Control group|This group will have the same 4 week return to run program, home exercise program, and video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
11185228|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
11185229|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
11185230|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
11185231|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
11185232|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
11185233|NCT03486366|Other|Workpackage1 WP1|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.
11185234|NCT03486366|Other|Workpackage2 WP2|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach criteria: Roach 1998) and epilepsy, aged up to 16 years, seizure free, in whom a decision to withdraw antiepileptic drugs was made. We plan to enroll 60 TSC patients into WP2 to Epimarker in 12 months. The data obtained in children seizure free at the end of follow-up and patients with recurrent seizures will be compare.
11185235|NCT03486353|Experimental|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
11185236|NCT03486353|Experimental|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
11185237|NCT03486340|Experimental|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
11185238|NCT03486340|No Intervention|Standard treatment|Standard chemotherapeutic treatment
11185239|NCT03486327|Experimental|0.03mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
11185240|NCT03486327|Experimental|0.05mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
11185241|NCT03486327|Experimental|0.08mL/kg Dose Group|A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
11185242|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), infusion, intravenously, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants will have opportunity to continue into optional Part B.
11185243|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat is given intravenously at 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin AUC5+paclitaxel 175 mg/m^2; pevonedistat is given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants will be treated for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) will be based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
11185244|NCT03486301|Experimental|Single Agent BDB001|"A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.
~Then dosage escalation will follow a traditional 3+3 dose escalation design.
~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached."
11185245|NCT03486301|Experimental|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.
~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
11185246|NCT03486288||Delirium|
11185247|NCT03486288||No Delirium|
11185248|NCT03486275|Active Comparator|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
11185249|NCT03486275|Active Comparator|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
11185250|NCT03486262||Lung carcinoma on IPF|Lung carcinoma on IPF
11185251|NCT03486249|Experimental|Patient difficult to wean|Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.
11185252|NCT03486236|Experimental|Cohort C1|
11185253|NCT03486236|Placebo Comparator|Cohort C1: Triple Placebo|
11185254|NCT03486236|Experimental|Cohort C2|
11185255|NCT03486236|Placebo Comparator|Cohort C2: Triple Placebo|
11185256|NCT03486223|Experimental|Placebo, GSK2256294|Subjects will receive placebo oral capsule daily by mouth for 7 days, then seven week washout and then GSK2256294 daily by mouth for 7 days.
11185257|NCT03486223|Experimental|GSK2256294, Placebo|Subjects will receive GSK2256294 daily by mouth for 7 days, then seven week washout and then placebo oral capsule daily by mouth for 7 days.
11185258|NCT03486223|Other|Genotype only, no study medication|New participants will receive genotyping only, no study medication
11185259|NCT03486210||Phase 1 Group 1|Healthy volunteers
11185260|NCT03486210||Phase 1 Group 2|Health professionals
11185261|NCT03486210||Phase 2 Group 1|Control group : patients obese without surgery
11185262|NCT03486210||Phase 2 Group 2|Patients who have underwent a sleeve gastrectomy
11185263|NCT03486210||Phase 2 Group 3|Patients who have underwent a gastric bypass
11185264|NCT03486197|Experimental|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
11185265|NCT03486158|Experimental|CalproSmart application|In addition to regular outpatient clinic visits and a routine CalproSmart test every 3 months, patients are instructed to obtain fecal samples if they experience symptoms suspect of recurrent IBD and to perform home analysis with CalproSmart™ system test kit
11185266|NCT03486158|No Intervention|Standard follow-up|In addition to regular outpatient clinic visits and a routine calprotectin test in the same week as the visit date, patients bring home an Fecal-calprotectin tube and envelope and are instructed to obtain fecal samples and send these to local lab if they experience symptoms suspect of recurrent IBD
11185267|NCT03486145|Experimental|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
11185268|NCT03486145|Placebo Comparator|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained <0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
11185269|NCT03486132|Other|interrupted repair of mediolateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.
~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut"
11185270|NCT03486132|Other|continous repair of mediolateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
11185271|NCT03486132|Other|interrupted repair of lateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.
~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity"
11185272|NCT03486132|Other|continuous repair of lateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
11185273|NCT03486106|Placebo Comparator|Headphones without music|Participants in the control group will receive noise-cancelling wireless headphones that will not play any noise throughout the procedure. They will also receive propofol for sedation as needed.
11185274|NCT03486106|Experimental|Headphones with music|Participants in the experimental group will receive the same noise-cancelling wireless headphones but will be permitted to listen to the music of their choice while in the operating room. They will also receive propofol for sedation as needed.
11185275|NCT03486093|Experimental|CVC managed by healthcare workers|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.
11185276|NCT03486093|Experimental|CVC managed by healthcare workers plus port protector|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices.
11185277|NCT03486080|Active Comparator|Dutogliptin/filgrastim combination|Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
11185278|NCT03486080|Placebo Comparator|Placebo control|Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
11185279|NCT03486067|Experimental|Administration of CC-93269|CC-93269 by intravenous (IV) infusion or subcutaneous (SC) injection on a 28 day cycle.
11185280|NCT03486054|Experimental|Experimental Arm A|Whole blood treated with amustaline and glutathione, a pathogen reduction technology (PRT), ordered and administered to study patients by their treating physicians
11185281|NCT03486054|Active Comparator|Control Arm B|Standard of Care (either red blood cells or whole blood)
11185282|NCT03486041|Experimental|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
11185283|NCT03486041|Placebo Comparator|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB [as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model].
11185284|NCT03486028||ASAM Counties/non-computerized|Pre- and 1115-waived counties that are implementing the ASAM. Intervention is adherence to ASAM protocols.
11185285|NCT03486028||ASAM Counties/computerized|Counties using a computerized system to assist in intervention determination according to ASAM protocols. Intervention is adherence to ASAM protocols.
11185286|NCT03486028||Non-ASAM Counties|"Pre- and non-waived control counties that are not implementing the ASAM. Intervention is non-adherence to ASAM protocols."
11185287|NCT03486015|Experimental|30% glucose|This group will be given 2 ml of 30% glucose in the mouth before the physical examination of the infant.
11185288|NCT03486015|Placebo Comparator|Sterile water|This group will be given 2 ml of sterile water in the mouth before the physical examination of the infant.
11185289|NCT03486002|Other|Cleansweep closed suction system|
11185290|NCT03486002|Other|Halyard closed suction system|
11185291|NCT03485989|Experimental|Hazelnuts|Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
11185292|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
11185314|NCT03485794||Diagnostic (biospecimen collection)|Patients undergo collection of blood for metabolic profiling via LC/Q-TOF/MS.
11185395|NCT03485248|Placebo Comparator|Placebo beet juice (Nitrate depleted)|Beetroot juice nitrate depleted
11185396|NCT03485235|Experimental|D&C|
11185293|NCT03485963|Experimental|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
11185294|NCT03485950|Experimental|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
11185295|NCT03485950|Active Comparator|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
11185296|NCT03485937|Experimental|Pre-Operative Videos + verbal/written instructions|This video contains the same instructions that the patient receives when they arrive at the clinic, as well as a video walk through of the clinic/patient room. Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions.
11185297|NCT03485937|Active Comparator|verbal/written instructions|This arm will receive the standard-of-care verbal/written instructions and the pre-operative video explanation. These instructions contain the same content as in the pre-operative videos
11185298|NCT03485924|Active Comparator|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
11185299|NCT03485924|Active Comparator|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
11185300|NCT03485911|Experimental|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
11185301|NCT03485911|Experimental|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
11185302|NCT03485911|Placebo Comparator|Placebo|Matching placebo administered as oral capsules once daily
11185303|NCT03485885||Maqui Berry Extract (MBE)|To be tested for the extracts bioavailability
11185304|NCT03485872|Experimental|Self-Screening and Referral Information|The intervention will include a combination of self-screening and UI specific information and resources. Older adults in the intervention group will complete a gender specific UI Self-Screening tool. Men will complete the International Consultation on Incontinence Modular Questionnaire (ICIQ) for Males and women will complete the ICIQ for Females. In addition, the intervention group will receive a fact sheet with UI specific information, contact information to the local incontinence clinic and a link to a website with patient incontinence resources and education.
11185305|NCT03485872|Active Comparator|Control Group|Older adults assigned to the control group will receive standard care from their physicians. Standard care may differ from general practitioner to general practitioner. Usual care for urinary incontinence (UI) from general practitioners is generally minimal. Most patients do not tell their physicians about UI, and most physicians do not ask about UI. If this topic does come up during a GP appointment, a patient may be offered no treatment, lifestyle advice (e.g., do not drink before bed), told to do Kegels (but likely not instructed how to do these properly) or in some cases, offered pharmacological therapies (which will be captured in our questionnaire with the participants). But standard of care is unfortunately very often no care.
11185306|NCT03485859|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
11185307|NCT03485859|Placebo Comparator|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
11185308|NCT03485846|Experimental|Narlaprevir + Ritonavir + Daclatasvir|All of enrolled patients receive equal study therapy with Narlaprevir/Ritonavir/Daclatasvir daily for 12 weeks
11185309|NCT03485833|Experimental|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
11185310|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
11185311|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
11185312|NCT03485807|Experimental|Mindfulness Training (MT)|
11185313|NCT03485807|Experimental|Active Coping Training (CT)|
11185397|NCT03485235|Other|No D&C|
11185315|NCT03485768|Experimental|percutaneous disc decompression with coblation nucleoplasty|PDCN will be performed in patients who are allocated to this group by using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA)
11185316|NCT03485768|Active Comparator|Manual Therapy|Participants who are allocated to this group will undergo manual therapy treatments containing two kinds: sustained natural apophyseal glides (SNAGs) plus passive joint mobilisations (PJMs)
11185317|NCT03485755||Children|Children 8-10 years of age
11185318|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
11185319|NCT03485729|Experimental|Biopsy-mandated|
11185320|NCT03485729|Experimental|Biopsy-optional|
11185321|NCT03485729|Experimental|Dosing twice per week on two consecutive days|
11185322|NCT03485716|Experimental|running under hypoxia - first|running under hypoxia (first day) and normoxia (second day)
11185323|NCT03485716|Active Comparator|running under normoxia - first|running under normoxia (first day) and hypoxia (second day)
11185324|NCT03485703|Experimental|azithromycin group|A control group composed of 40 newborns receiving azithromycin
11185325|NCT03485703|Placebo Comparator|placebo group|comparative group composed of 40 newborns who would receive saline 0.9%
11185326|NCT03485690||COPD|COPD patients with no restrictions. The study protocol does not consider ad-hoc different patient groups. Prospective follow-up will be equally done in all recruited patients
11185327|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.
~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.
~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
11185328|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for two years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
11185329|NCT03485664||Study Group|Severe pain on percussion of the relevant tooth was considered as basic criteria when deciding on acute infection phase. The acutely infected teeth were labelled as the study group
11185330|NCT03485664||Control Group|The asymptomatic teeth were labelled as the control group
11185331|NCT03485638||Cetuximab administration|
11185332|NCT03485625|Experimental|Lidocaine|Patients in group C will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
11185333|NCT03485625|Experimental|Lidocaine+ Ketorolac|Patients in group K receive 3 mg/kg of lidocaine 2% + 20 mg ketorolac diluted with saline to a total volume of 40 ml.
11185334|NCT03485625|Experimental|Lidocaine+Paracetamol|Patients in group P will receive 3 mg/kg of lidocaine 2% + 300 mg paracetamol diluted with saline to a total volume of 40 ml.
11185335|NCT03485612||change of the optic nerve sheath diameter|The test group will be male and female patients, aged over 18 and below 90 years of age. Each patient will be operated for urological reasons in the position for lithotomy.
11185336|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
11185337|NCT03485586||Group:Traditional ultrasonic biological|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use traditional ultrasonic biological combined with cornea curvimeter to measure the ocular parameter.
11185338|NCT03485586||Group:Lenstar|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use lenstar to measure the ocular parameter.
11185339|NCT03485560|Experimental|internvention of Chrinic skin conditions|All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
11185340|NCT03485547|Experimental|Venetoclax|"Venetoclax is administered on a daily basis orally.
~The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax."
11185341|NCT03485534|Experimental|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
11185342|NCT03485534|Placebo Comparator|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
11185343|NCT03485521|Active Comparator|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
11185344|NCT03485521|Experimental|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
11185345|NCT03485495|Experimental|Divaza|Oral administration. Dose per administration: 2 tablets (should be held in the mouth until dissolution is complete). Should be taken without food. Dosing: 2 tablets three times daily.
11185346|NCT03485495|Placebo Comparator|Placebo|Oral administration. Dose per administration: 2 tablets (should be held in the mouth until dissolution is complete). Should be taken without food. Dosing: 2 tablets three times daily.
11185347|NCT03485482|Experimental|Group Ivabradine|six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
11185348|NCT03485482|Experimental|Group Bisoprolol|six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
11185349|NCT03485482|Experimental|Group combination|six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
11185350|NCT03485469|Other|Usual Care|The control group will benefit from a standard care dietary consultation in the service and 9 dietary consultations by phone every 15 days.
11185391|NCT03485274|Active Comparator|Treatment as Usual|Any medication or Rx other than vortixoetine
11185392|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR <15ml/min/1.7m2 )
11185393|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
11185351|NCT03485469|Other|Hypnosis|The experimental group will benefit from a dietary consultation in the service, 9 dietary consultations by telephone every 15 days to which will be associated 7 individual sessions of hypnosis and 3 individual sessions of learning to autohypnosis. A recording containing the induction of a self-hypnosis session will be given to the subject at the end of the 10 sessions, in order to promote the continuation of home-made autohypnosis.
11185352|NCT03485456|Experimental|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
11185353|NCT03485443|Active Comparator|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.
~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
11185354|NCT03485443|Active Comparator|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.
~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
11185355|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
11185356|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
11185357|NCT03485417|Active Comparator|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
11185358|NCT03485417|Active Comparator|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
11185359|NCT03485417|Other|Treatment as Usual Arm|Treatment as Usual arm
11185360|NCT03485404|Experimental|VB12+FA|Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
11185361|NCT03485404|Placebo Comparator|Placebo|Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
11185362|NCT03485404|Other|Non-surgical controls|Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.
11185363|NCT03485391|Experimental|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
11185364|NCT03485391|Active Comparator|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
11185365|NCT03485378|Experimental|Treatment Arm: Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
11185366|NCT03485365|Experimental|Part A: Cohort 1: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 0.1 milligram/kilogram (mg/kg) via IV route.
11185367|NCT03485365|Placebo Comparator|Part A: Cohort 1: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
11185368|NCT03485365|Experimental|Part A: Cohort 2: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 0.3 mg/kg via IV route.
11185369|NCT03485365|Placebo Comparator|Part A: Cohort 2: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
11185370|NCT03485365|Experimental|Part A: Cohort 3: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 1 mg/kg via IV route.
11185371|NCT03485365|Placebo Comparator|Part A: Cohort 3: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
11185372|NCT03485365|Experimental|Part A: Cohort 4: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 3 mg/kg via IV route.
11185373|NCT03485365|Placebo Comparator|Part A: Cohort 4: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
11185374|NCT03485365|Experimental|Part A: Cohort 5: GSK3858279|Eligible subjects will receive GSK3858279 up to a dose of 10 mg/kg via IV route.
11185375|NCT03485365|Placebo Comparator|Part A: Cohort 5: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
11185376|NCT03485365|Experimental|Part A: Cohort 6: GSK3858279|Eligible subjects will receive GSK3858279 between 1 mg/kg and 3 mg/kg via SC route.
11185377|NCT03485365|Placebo Comparator|Part A: Cohort 6: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via SC route.
11185378|NCT03485365|Experimental|Part B: GSK3858279|Eligible subjects will receive GSK3858279 one or two dose levels, up to 10 mg/kg, to be determined based on data from Part A) via IV route.
11185379|NCT03485365|Placebo Comparator|Part B: Placebo|Eligible subjects will receive placebo matching to GSK3858279 via IV route.
11185380|NCT03485352||Bariatric Surgery patients|Patients attending a private clinic specialized in the treatment of obesity and bariatric surgery. Patients to be analyzed should have a medical indication for bariatric surgery.
11185381|NCT03485339||Case|Ketamine user with psychotic disorders
11185382|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
11185383|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
11185384|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
11185385|NCT03485326||Safety|Safety
11185386|NCT03485300||Patients with chronic liver or kidney diseases|"Patients with chronic liver diseases may affect warfarin therapeutic outcome as liver is the site of metabolism of the drug by cytochrome p 450 enzymes so it decrease warfarin absorption
~Kidney diseases also affect the clearance of the drug these patients will undergo liver function tests and kidney function tests"
11185387|NCT03485300||Non compliance of the patient|Missed dose of the warfarin or intermittent drug intake may affect drug therapeutic outcome as well as changing time of drug administration during the day
11185388|NCT03485300||Drugs or food interactions|Administration of other drugs beside warfarin may affect its therapeutic outcome either by inhibition or synergism certain food may also interfere with warfarin especially vitamin k and c rich food so patients will be followed up for drug or food interactions
11185389|NCT03485287|Experimental|MDMA and Psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
11185390|NCT03485274|Active Comparator|Vortioxetine Arm|Oral: 5-20mg daily
11185400|NCT03485209|Experimental|Tisotumab Vedotin - Q3W Regimen|Tisotumab Vedotin [2.0 mg/kg] every 3 weeks
11185401|NCT03485209|Experimental|Tisotumab Vedotin - 3Q4W Regimen|Tisotumab Vedotin [0.9 mg/kg or 1.2 mg/kg] on Days 1, 8, and 15 of 28-day cycle
11185402|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When two antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
11185403|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status. When one antibodies show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite unstable low (MSI-L).
11185404|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
11185405|NCT03485183|Experimental|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
11185406|NCT03485183|Other|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
11185407|NCT03485170|Other|PET|Hemophilia patients receive PET evaluation
11185408|NCT03485157|Experimental|Micronized dHACM|Injection of micronized dHACM
11185409|NCT03485157|Placebo Comparator|Saline|Injection of 0.9% Sodium Chloride Injection, USP
11185410|NCT03485144|Experimental|TV003|Live Attenuated Virus Vaccine-TetraVax-DV
11185411|NCT03485144|Placebo Comparator|Placebo for TV003|Placebo
11185412|NCT03485131|Experimental|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
11185413|NCT03485131|Sham Comparator|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
11185414|NCT03485118|Experimental|HS006+Chemotherapy|"Participants received six 21-day cycles of HS006(375 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
~Participants received six 21-day cycles of HS006(500 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles)."
11185415|NCT03485118|Active Comparator|Rituxan+Chemotherapy|Participants received six 21-day cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
11185416|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
11185417|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
11185418|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
11185419|NCT03485092|Active Comparator|Empagliflozin|Empagliflozin 10mg tablets for oral self-administration once daily
11185420|NCT03485092|Placebo Comparator|Placebo Oral Tablet|placebo tablets for oral self-administration once daily
11185421|NCT03485066|Experimental|Training|20 healthy participants, 4 week training of a challenging cognitive task (Tetris) between PET/MR measurements
11185422|NCT03485066|No Intervention|Control|20 healthy participants, no training between PET/MR measurements
11185423|NCT03485053|Experimental|IOP Injection / MPB-1514|Administered IV infusion
11185424|NCT03485027|Experimental|XELOX regimen|oxaliplatin 130mg/m2，intravenous，on Day1 capecitabine 1000mg/m2，oral，bid，on Day1-14 every three weeks
11185425|NCT03485027|Experimental|FOLFOX regimen|oxaliplatin 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
11185426|NCT03485027|Experimental|FOLFIRI regimen|irinotecan 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
11185427|NCT03485027|Experimental|IRI regimen|irinotecan single agent 180mg/m2，intravenous，on Day1 every two weeks
11185428|NCT03485014|Experimental|Experimental: EXPAREL 4 mg/kg|Single dose of EXPAREL 4 mg/kg
11185429|NCT03485001|Sham Comparator|Sham of Argon Laser Treatment|Slit lamp light exposure
11185430|NCT03485001|Experimental|Argon Laser Treatment|Argon Laser Treatment
11185431|NCT03484988|Placebo Comparator|Placebo oil|Ingredients: Corn oil, 500mg per capsule
11185432|NCT03484988|Experimental|Echium oil|Ingredients: Echium oil,500mg per capsule
11185433|NCT03484988|Experimental|Mixed oil|Ingredients:Mixed oil(Echium oil,camelina oil,safflower oil) 500mg per capsule
11185434|NCT03484975|Other|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
11185435|NCT03484962|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
11187628|NCT03469921||patients included in clinical trials|patients included in clinical trials
11185436|NCT03484962|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
11185437|NCT03484962|No Intervention|No intervention|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11185438|NCT03484949|Experimental|pre-endoscopic screening risk assessment|
11185439|NCT03484949|No Intervention|routine screening|
11185440|NCT03484936|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
11185441|NCT03484936|Placebo Comparator|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
11185442|NCT03484923|Experimental|Arm 1: LAG525 + Spartalizumab in unselected patients|Spartalizumab and LAG525 will be administered intravenously
11185443|NCT03484923|Experimental|Arm 2: Capmatinib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Capmatinib will be administered orally.
11185444|NCT03484923|Experimental|Arm 3: Canakinumab+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously.
11185445|NCT03484923|Experimental|Arm 4: Ribociclib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Ribociclib will be administered orally.
11185446|NCT03484923|Experimental|Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients|Spartalizumab and LAG525 will be administered intravenously
11185447|NCT03484910|Experimental|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
11185448|NCT03484910|Active Comparator|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
11185449|NCT03484897|Experimental|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
11185450|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
11185451|NCT03484858|Other|High glycaemic index meal and exercise|
11185452|NCT03484858|Other|High glycaemic index meal and rest|
11185453|NCT03484858|Other|Low glycaemic index meal and exercise|
11185454|NCT03484858|Other|Low glycaemic index meal and rest|
11185455|NCT03484845|Active Comparator|Oral lactoferrin|women who take oral lactoferrin sachets 100 mg twice daily for one month.
11185456|NCT03484845|Active Comparator|Oral ferrous fumarate|women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month.
11185457|NCT03484845|Active Comparator|Combined lactoferrin & ferrous fumarate|women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month.
11185458|NCT03484832|Experimental|Spray group|Using Walter Ritter Ethyl Chloride Spray and placebo cream
11185459|NCT03484832|Experimental|EMLA group|Using EMLA cream and placebo spray
11185460|NCT03484832|Placebo Comparator|Placebo group|Using placebo cream and placebo spray
11185461|NCT03484819|Experimental|Treatment (copanlisib hydrochloride, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11185462|NCT03484793|Experimental|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
11185463|NCT03484793|No Intervention|Non AESOP|19 were assigned to the traditional CPOE system
11185464|NCT03484780|Experimental|VisONE ADS|Patients implanted with a VisONE stimulator and leads for receiving continual Synchronized Diaphragmatic Stimulation
11185465|NCT03484767||Methylmalonic Acidemia Participants|Individuals with isolated MMA (mut0 and mut-)
11185466|NCT03484767||Propionic Acidemia Participants|Individuals with isolated PA
11185467|NCT03484754|Experimental|corrugator|single injection of 10 Units of botulinum toxina in the corrugator and procerus
11185468|NCT03484754|Active Comparator|orbicularis oculi|single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)
11185469|NCT03484741|Experimental|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
11185470|NCT03484728|Placebo Comparator|High-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
11185471|NCT03484728|Other|Low-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
11185472|NCT03484715|Experimental|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
11185473|NCT03484715|No Intervention|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
11185474|NCT03484702|Experimental|Administration of JCAR017|JCAR017 will be infused at a dose of 100 x 10^6 JCAR017-positive transfected viable T cells (50 × 10^6 CD8+ CAR+ T cells and 50 × 10^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of lymphodepleting chemotherapy (LD) chemotherapy)
11185475|NCT03484689|Other|MBCT arm|8-week MBCT program
11185476|NCT03484676|Other|Unilateral Non comminuted zygomatic complex fracture|Patient undergo treatment no control group
11185477|NCT03484663|Experimental|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
11185478|NCT03484663|No Intervention|Chest tube only after uniport vats|After uniport vats we put chest tube only
11185479|NCT03484650|Placebo Comparator|Control|Patients will receive standard care plus infusion of placebo
11185480|NCT03484650|Experimental|Lidocaine|Patients will receive lidocaine infusions peri-operatively
11185481|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
11185482|NCT03484624|Experimental|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
11185483|NCT03484611|Active Comparator|AMH < 0.3 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH < 0,3 ng/ml
11185484|NCT03484611|Active Comparator|AMH 0.3 to 0.7 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
11185485|NCT03484611|Active Comparator|AMH > 0.7 to 1 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
11185486|NCT03484598|Experimental|SPEAC Treatment Arm|All study participants will be provided with a SPEAC System to use in their home environment.
11185487|NCT03484585|Experimental|Rogaratinib (BAY1163877)|Healthy male subjects
11185488|NCT03484559||1|
11185489|NCT03484546||folicular|Women who will undergo endometrioma cystectomy in her follicular phase of menstrual period.
11185490|NCT03484546||ovulatory|Women who will undergo endometrioma cystectomy in her ovulatory phase (12-14th day of mestrual period cycle for women regular period) of menstrual cycle.
11185491|NCT03484546||luteal|Women who will undergo endometrioma cystectomy in her luteal phase of menstrual period.
11185492|NCT03484533|Active Comparator|HIV Self-test kit|
11185493|NCT03484533|Active Comparator|Invitation letter-standard of care|
11185494|NCT03484520|Experimental|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
11185495|NCT03484507|Active Comparator|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
11185496|NCT03484507|Experimental|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
11185497|NCT03484507|Experimental|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
11185498|NCT03484507|Experimental|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
11185499|NCT03484507|Placebo Comparator|Placebo|Artificial tears for weeks 4-11
11185500|NCT03484494|Other|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
11185501|NCT03484494|Other|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
11185502|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
11185503|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
11185504|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
11185505|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
11185506|NCT03484468||femtosecond_laser|participants had there lasik corneal flap creation using femtosecond laser
11185507|NCT03484468||moria_microkeratome|participants had there lasik corneal flap creation using moria microkeratome
11185508|NCT03484455|Experimental|Hypothermic Machine Perfusion|Hypothermic Machine Perfusion with LLT system
11185509|NCT03484455|Active Comparator|Static Cold Storage|Standard of Care - Static Cold Storage
11185510|NCT03484429|Experimental|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
11185511|NCT03484429|Active Comparator|Group 2|Standard medical therapy only
11185512|NCT03484416|Active Comparator|Routine calcium|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day
11185513|NCT03484416|No Intervention|control|Patients in the control group did not receive calcium or cholecalciferol for 2 weeks
11185514|NCT03484403|Active Comparator|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
11185515|NCT03484403|Experimental|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
11185516|NCT03484390|Experimental|Mindfulness-based stress reduction|The MBSR program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
11185517|NCT03484390|Active Comparator|Wellness Group|The Wellness control group uses a health education manual that provides information on various aspects of health, including diet, physical activity, sleep, stress management, and communication. The manual is used during weekly check-in phone calls for an 8-week period.
11185518|NCT03484377|Experimental|Anodal tDCS|The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
11185519|NCT03484377|Sham Comparator|Sham tDCS|The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
11187629|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
11185520|NCT03484364|Experimental|Intervention Group|The ENACTS intervention is eight weeks of peer-facilitated educational classes about hypertension self-management and autonomous support from family or friend enrolled as support person.
11185521|NCT03484364|No Intervention|Waitlist Group|Usual care and $30 in groceries each week for 8 weeks.
11185522|NCT03484351|Experimental|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
11185523|NCT03484338|Experimental|Intervention|
11185524|NCT03484338|Active Comparator|Wait list controlled|
11185525|NCT03484299|Other|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
11185526|NCT03484286|Other|Control group|Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.
11185527|NCT03484286|Experimental|Intervention group|Device: OPTILOGG
11185528|NCT03484273|Experimental|Full Compression|The LifeWrap compression garment will be fully secured with all straps.
11185529|NCT03484273|Experimental|Abdominal and Pelvic Compression|The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
11185530|NCT03484273|Experimental|Lower Limb Compression|The Lifewrap compression garment calf and ankle straps only will be secured.
11185531|NCT03484273|No Intervention|No Compression|None of the LifeWrap compression garment straps will be secured.
11185532|NCT03484260||Case group: Testosterone Product|Male subjects prescribed testosterone in UK
11185533|NCT03484260||Control group|Matched male subjects not prescribed testosterone in the UK
11185534|NCT03484247|Active Comparator|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
11185535|NCT03484247|Active Comparator|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
11185536|NCT03484234|Experimental|Ultimaster stent|
11185537|NCT03484234|Active Comparator|Xience alpine stent|
11185538|NCT03484221|Experimental|FOLFOXIRI+short-course radiation+XELOX|Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
11185539|NCT03484195|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
11185540|NCT03484182|Active Comparator|Standard Home Exercise Program|
11185541|NCT03484182|Experimental|Web-based Home Exercise Program|
11185542|NCT03484169|No Intervention|Control group|No intervention
11185543|NCT03484169|Experimental|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:
~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
11185544|NCT03484156|Experimental|Volunteers|"The Installation of 3PEGASE Sensor in elders volunteers to monitor clinical indicators at home.The instrument is for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home.
~The volunteers will have 70 years old or more, living alone at home, frail of disable (ADL> or =3) and able to walk by themselves."
11185545|NCT03484143|Active Comparator|Active Neuro RX Gamma device|Neuro RX Gamma device delivers low-energy near-infrared light, through 5 diodes, to the brain transcranially and intranasally
11185546|NCT03484143|Sham Comparator|Sham Neuro RX Gamma device|Sham Neuro RX Gamma device is identical in appearance and sound as the active Neuro RX Gamma device but does not emit low-energy near infrared light
11185547|NCT03484130||High-Risk Normotensives|These high-risk normotensives are considered to be enriched for subclinical autonomous aldosterone secretion and have a high risk for developing incident hypertension
11185548|NCT03484117|No Intervention|Treatment as Usual|Participants in this arm will receive bilingual written materials on healthy living with HIV at the baseline visit. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants.
11185549|NCT03484117|Experimental|Community Health Worker|Participants in the intervention arm will receive 5 one-on-one sessions over 24 weeks with a Spanish-speaking CHW. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants
11185550|NCT03484104||Hypothermic circulatory arrest|Patients undergoing cardiac surgery with hypothermic circulatory arrest and selective antegrade cerebral perfusion
11185551|NCT03484091|Experimental|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
11185552|NCT03484091|Active Comparator|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
11185553|NCT03484091|Placebo Comparator|N group|Single dose of normal saline 6 mL intra-articular knee injection.
11185554|NCT03484078|Experimental|Vibration Platform|The vibration group will stand on a platform that emits a mild vibration 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
11185555|NCT03484078|Placebo Comparator|Placebo Platform|The placebo group will stand on a placebo platform 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
11185556|NCT03484065||Afibrinogenemia|
11185557|NCT03484052|Other|Jugular ultrasound|
11185558|NCT03484039|Experimental|Epilepsy Patients|The group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
11211116|NCT03307681|Experimental|Meal skipping|No food given
11185559|NCT03484026|Experimental|BioFe Medical Food|Consumption of BioFe Medical Food in a single cohort of up to 8 female subjects with iron deficiency.
11185560|NCT03484000|Experimental|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
11185561|NCT03484000|Other|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
11185562|NCT03483987|Experimental|Sof+Ledi+R arm|"Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination
~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks
~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks
~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
11185563|NCT03483987|Experimental|Sof+Ledi+R+Peg-IFN arm|Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
11185564|NCT03483987|Experimental|Sof+Dacla+R arm|"Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin
~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks
~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks
~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
11185565|NCT03483987|Experimental|Sof+Dacla+R+Peg-IFN arm|Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
11185566|NCT03483987|Experimental|Sof+Velpa+R arm|"Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination
~who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or
~who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon"
11185567|NCT03483987|Experimental|Sof+Velpa+R+Peg-IFN arm|Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination
11185568|NCT03483974||neoplasm|neoplasm found in follow up
11185569|NCT03483974||non-neoplasm|non-neoplasm patients in follow up
11185570|NCT03483961|Experimental|Group 1: 20 mcg/unadjuvant (Day 1 & 29)|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
11185571|NCT03483961|Experimental|Group 2: 6 mcg/adjuvant (Day 1 & 29)|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
11185572|NCT03483961|Experimental|Group 3: 10 mcg/adjuvant (Day 1 & 29)|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
11185573|NCT03483961|Experimental|Group 4: 20mcg/adjuvant(Day 1 & 29);40mcg/adjuvant (Day 547)|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
11185574|NCT03483961|Experimental|Group 5: 6 mcg/adjuvant (Day 15 & 29)|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
11185575|NCT03483961|Experimental|Group 6: 10 mcg/adjuvant (Day 15 & 29)|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
11185576|NCT03483961|Experimental|Group 7: 20 mcg/adjuvant (Day 15 & 29)|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
11185577|NCT03483961|Experimental|Group 8: 40 mcg/adjuvant (Day 29)|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
11185578|NCT03483961|Experimental|Group 9: 20 mcg/adjuvant (Day 1 & 29)|20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
11185579|NCT03483961|Experimental|Group 10: 40 mcg/adjuvant (Day 1)|40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
11185580|NCT03483948|Experimental|HMPL-523 & Azacitidine|HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
11185581|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
11185582|NCT03483935|No Intervention|Control|No treatment will be given.
11185583|NCT03483922||chronic hepatitis B|This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline.
11185584|NCT03483922||HCC Cases|"This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma.
~HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"
11185585|NCT03483922||Healthy|This group will include 50 healthy sex and age matched controls.
11185586|NCT03483909|Experimental|left IFG iTBS|intermittent theta burst stimulation over the left inferior frontal gyrus
11185587|NCT03483909|Active Comparator|right IPL cTBS|continuous theta burst stimulation over the right inferior parietal cortex
11185588|NCT03483909|Placebo Comparator|placebo|Placebo TMS stimulation over the left inferior parietal cortex
11185589|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
11185660|NCT03483441|Active Comparator|Vitamin D pill prior to PDT|Patients will take oral Vit D supplements (10,000 IU/day) immediately prior to PDT of their BCC tumors.
11188028|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
11185590|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
11185591|NCT03483883|Experimental|Single Arm|
11185592|NCT03483870|Placebo Comparator|Morphine sulphate & Placebo|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of normal saline 0.9% (placebo) IV injection preoperative.
11185593|NCT03483870|Active Comparator|Morphine sulphate & Granisetron|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of 2 mg granisetron IV injection preoperative.
11185594|NCT03483857|Experimental|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
11185595|NCT03483857|No Intervention|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
11185596|NCT03483831|Experimental|Intervention group|Students of 5 secondary school classes aged 12-14
11185597|NCT03483831|No Intervention|Control group|Students of 5 secondary school classes aged 12-14
11185598|NCT03483818|Active Comparator|Pharmacist-Led Pathway|Assessment & Treatment of HCV infection with oral antivirals in a community pharmacy pathway
11185599|NCT03483818|Active Comparator|Conventional Care Pathway|Assessment & Treatment of HCV infection with oral antivirals in a conventional care pathway
11185600|NCT03483805|Experimental|Treatment|Protalsafe product, daily, 12 weeks
11185601|NCT03483805|Placebo Comparator|Placebo|Placebo product, daily, 12 weeks
11185602|NCT03483792||PCOS group|
11185603|NCT03483792||Control group|
11185604|NCT03483779|Experimental|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
11185605|NCT03483779|Placebo Comparator|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
11185606|NCT03483766|No Intervention|Baseline before robotic functional rehabilitation|Baseline spinal cord MRI scan
11185607|NCT03483766|Experimental|post rehabilitation|Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
11185608|NCT03483753|Experimental|Vasopressin group|Blinded vasopressin
11185609|NCT03483753|Active Comparator|Norepinephrine group|Blinded norepinephrine
11185610|NCT03483740|Experimental|Cognitive remediation group therapy|8 weekly 3-hour sessions of CRGT
11185611|NCT03483740|Active Comparator|Mutual aid support group|8 weekly 3-hour sessions of HIV group therapy
11185612|NCT03483727|Experimental|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
11185613|NCT03483727|Experimental|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
11185614|NCT03483714||Healthy Participants|Spinal manipulation
11185615|NCT03483714||Acute Low back pain participants|Spinal Manipulation
11185616|NCT03483714||Chronic low back pain participants|Spinal Manipulation
11185617|NCT03483701|Experimental|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
11185618|NCT03483701|No Intervention|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
11185619|NCT03483688|Experimental|CD19-directed CAR-T cells|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
11185620|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
11185621|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
11185622|NCT03483662|Experimental|Multicomponent Intervention|Protocol-based treatment using the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification
11185623|NCT03483662|Active Comparator|Enhanced Usual Care|Webinar education session for providers on the new ACC/AHA hypertensive clinical guideline and the SPRINT study findings
11185624|NCT03483649|Experimental|HLX04|
11185625|NCT03483649|Active Comparator|United States (US) Avastin®|
11185628|NCT03483636|Experimental|Lemborexant|Participants will be randomized to receive a 10 milligram (mg) lemborexant tablet administered with 50 milliliter (mL) water followed by a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
11185629|NCT03483636|Experimental|Lemborexant Plus Alcohol|Participants will be randomized to receive a 10 mg lemborexant tablet administered with 50 mL water followed by alcohol (0.6 grams per kilogram [g/kg] of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
11185630|NCT03483636|Experimental|Alcohol|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol (0.6 g/kg of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
11185631|NCT03483636|Placebo Comparator|Placebo|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
11185632|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
11185633|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
11185634|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
11185635|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
11185636|NCT03483610|Active Comparator|screening and referral|
11185637|NCT03483610|Active Comparator|behavioral intervention|
11185638|NCT03483597||rheumatologists|Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
11185639|NCT03483597||patients|Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
11185640|NCT03483558|Experimental|Control|Participants were fed a standardized diet (without any vegetables) in this experiment.
11185641|NCT03483558|Experimental|Spinach|Participants were fed a standardized diet with 200g spinach in this experiment.
11185642|NCT03483558|Experimental|Celery|Participants were fed a standardized diet with 200g celery in this experiment.
11185643|NCT03483558|Experimental|Onion|Participants were fed a standardized diet with 200g onion in this experiment.
11185644|NCT03483558|Experimental|Mixed Vegetables|Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
11185645|NCT03483545|Experimental|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
11185646|NCT03483532||Lit Control pH Up without cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract without cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
11185647|NCT03483532||Lit Control pH Up with dry cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract with cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
11185648|NCT03483519|Experimental|Prehabilitation|Patients in the Prehabilitation Group and are randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
11185649|NCT03483519|Active Comparator|Standard of Care|Patients in the Standard of Care will not receive an additional an exercise program, patients will receive the usual care received by all orthopaedic patients.
11185650|NCT03483506|Experimental|All subjects|
11185651|NCT03483493|Experimental|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
11185652|NCT03483493|Active Comparator|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
11185653|NCT03483480|Experimental|Non powered-NPWT|
11185654|NCT03483480|Active Comparator|Open Technique|
11185655|NCT03483467|Experimental|1|Application of Omnigen
11185656|NCT03483467|Placebo Comparator|2|Dummy Omnigen Packaging
11185657|NCT03483454|Experimental|Exercise classes|This group of children and their parents will participate in an exercise class for 8 weeks.
11185658|NCT03483454|Experimental|Home exercise|"This group of children and their parents will participate in exercise at home for 8 weeks. This is currently the standard of care in the weight management clinic (advise to continue increasing activity at home). This group is considered the control group."
11185659|NCT03483441|Placebo Comparator|Placebo pill prior to PDT|BCC tumors will be treated with ALA-PDT, without any active pretreatment
11186109|NCT03480126|Experimental|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
11185661|NCT03483428|Experimental|Parent Coaches|"Parent coaches will complete interventionist training and supervision in the Family Check-Up, an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads."
11185662|NCT03483428|Experimental|Parent-Child Dyads|"Parents and children will receive the adapted Family Check-Up behavioral parent training (BPT) intervention delivered by parent coaches."
11185663|NCT03483415|Experimental|Grup L|"IV patient-controlled analgesia (PCA) morphine
~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
11185664|NCT03483415|Active Comparator|Group P|IV patient-controlled analgesia (PCA) morphine
11185665|NCT03483402|Experimental|PEXG treated with MLT|Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)
11185666|NCT03483389|Experimental|Alcohol, placebo|Alcohol, ethyl - Placebo
11185667|NCT03483389|Experimental|Alcohol, low dose|Alcohol, ethyl - Low dose
11185668|NCT03483389|Experimental|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
11185669|NCT03483376|Active Comparator|Dental prophylaxis|Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste.
11185670|NCT03483376|Experimental|Dental prophylaxis + aPDT|"Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning, followed by antimicrobial photodynamic therapy (aPDT) to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste. The aPDT protocol is as follows:
~Patient will rinse the oral cavity with 20 ml of an aqueous solution of curcumin (photosensitizer; 1.5 g/L) for 30 seconds.
~Blue light from a Bluephase 20i curing lamp will be applied perpendicularly for 1 min per tooth (30 seconds on the vestibular side and 30 seconds on the palatal side).
~Remaining photosensitizer will be removed using the prophylaxis brush. The aPDT protocol is repeated following a rest period of 10 days."
11185671|NCT03483363|Experimental|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure. All groups with receive standard parenteral intravenous (IV) prophylactic antibiotic.
11185672|NCT03483363|Active Comparator|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
11185673|NCT03483350|Experimental|1- 1st group|1- 1st group will include 30 patients will receive intravenous granisetron 10 μg/kg after induction of anesthesia and before start of surgery
11185674|NCT03483350|Experimental|2- 2nd|2- 2nd group will include 30 patients will receive intravenous midazolam 50 μg/kg after induction of anesthesia and before start of surgery
11185675|NCT03483350|Experimental|3- 3rd group|3- 3rd group will include 30 patients will receive combination intravenous granisetron 5 μg/kg with midazolam 25 μg/kg after induction of anesthesia and before start of surgery
11185676|NCT03483337||recurrent or metastatic head and neck cancer patients|Patients will be imaged on a 1.5 T or 3 T MR scanner. Patients will receive a test-retest DWI scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at Memorial Sloan Kettering's main campus, will also be imaged weekly during their course of treatment.
11185677|NCT03483337||head and neck cancer or thyroid cancers|All patients, irrespective of treatment regimen, will be imaged on a 1.5T or 3T MR scanner prior to treatment initiation. Follow up imaging for patients undergoing surgery only will be as per clinical standard of care and not on this protocol. Patients undergoing treatment in radiation oncology and/or medicine will have imaging studies at two months (60 days) and four months (120 days) after completion of all treatments, including systemic therapy if (+/- 2 weeks or 14 days). Imaging on or immediately after systemic therapy treatment (+/- 2 weeks or 14 days) to derive MRI biomarkers indicative of therapeutic mechanisms of action or efficacy will also be performed. Patients who will be receiving radiation therapy treatment will also have recommended weekly imaging during their course of treatment.
11185678|NCT03483324|Experimental|Experimental|Unmanipulated umbilical cord blood plus AB-110
11185679|NCT03483311|Experimental|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
11185680|NCT03483311|Experimental|controls|Tissue levels of resolvin D1 in controls
11185681|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
11185682|NCT03483285|Active Comparator|heart rate|Effects of İntubation with Airtraq or Storz to heart rate
11185683|NCT03483285|Active Comparator|mean arterial pressure|Effect of intubation with Airtraq or Storz to mean arterial pressure
11185684|NCT03483259|Experimental|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
11185685|NCT03483259|Experimental|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
11185686|NCT03483246|Experimental|Group B - fecal microbiota transplantation|Patients receiving the fecal microbiota transplantation (FMT) in 3 times after inclusion and randomisation
11185687|NCT03483246|Placebo Comparator|Group A- Sham-transplantation|Patients receiving the sham-transplantation in 3 times after inclusion and randomisation
11185688|NCT03483233|Experimental|fMRI and EEG study|
11185689|NCT03483220||cases|patients with substance use disorder
11185690|NCT03483207|Experimental|MVT with anticoagulation therapy(heparin &warfarin)|patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively with anticoagulation(heparin &warfarin) while other cases will be for surgical management and not included in the study.
11185691|NCT03483207|Experimental|MVT with failure of anticoagulation therapy(heparin &warfarin)|patients who underwent conservative therapy with anticoagulation (heparin &warfarin) but showed no improvement .
11185872|NCT03481946|Experimental|BAY1093884 in subjects with Hemophilia|Single dose of BAY1093884 over 30 minutes administered in subjects with severe congenital Hemophilia A or B, with inhibitors or without inhibitors
11185692|NCT03483194|Active Comparator|Kalinox®|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
11185693|NCT03483194|Experimental|Virtual Reality|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
11185694|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
11185695|NCT03483168|Experimental|Culturally sensitive pain education|
11185696|NCT03483168|Active Comparator|Standard pain education|
11185697|NCT03483142|Experimental|misoprostol group|misoprostol group ( study group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
11185698|NCT03483142|Placebo Comparator|placebo group|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.
11185699|NCT03483129|Experimental|Consultation|The consultation will provide the participant with one to one information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide (Eatwell Guide, 2016). Furthermore, participants will have the opportunity to discuss pre-diabetes with a trained practice nurse and ask any questions they may have.
11185700|NCT03483129|No Intervention|Control|All participants will receive an information leaflet detailing pre-diabetes, the associated risks and steps that can be taken to avoid developing diabetes.
11185701|NCT03483116|Experimental|High dose RV3-BB neonatal schedule|High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
11185702|NCT03483116|Experimental|Mid dose RV3-BB neonatal schedule|Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
11185703|NCT03483116|Experimental|Low dose RV3-BB neonatal schedule|Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
11185704|NCT03483116|Experimental|High dose RV3-BB infant schedule|High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)
11185705|NCT03483103|Experimental|Treatment|Lisocabtagene maraleucel at a dose of 100×10^6 CAR+ T cells (50×10^6 CD8+ CAR+ T cells and 50×10^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
11185706|NCT03483090|Experimental|Treatment A|4000mg Swisse High Strength Deep Sea Krill Oil (Superba BOOST) (4 capsules containing 1000mg each)
11185707|NCT03483090|Placebo Comparator|Treatment B|4 capsules of matching Placebo orally daily (1000mg each of mixed vegetable Oil)
11185708|NCT03483077|Experimental|BI 730460|
11185709|NCT03483077|Placebo Comparator|Placebo|
11185710|NCT03483064|No Intervention|Control group|Subjects without low back pain to whom the electric current is put but it is not activated.
11185711|NCT03483064|Experimental|Healthy group|Subjects without low back pain to whom the electric current is put but it is activated.
11185712|NCT03483064|No Intervention|LBP-control group|Subjects with low back pain to whom the electric current is put but it is not activated.
11185713|NCT03483064|Experimental|LBP group|Subjects with low back pain to whom the electric current is put but it is activated.
11185714|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
11185715|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
11185716|NCT03483038|Experimental|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
11185717|NCT03483025|Other|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
11185718|NCT03483025|Other|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
11185719|NCT03483025|Other|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
11185720|NCT03483025|Other|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
11185721|NCT03483025|Other|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
11185722|NCT03483025|Other|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
11185723|NCT03483012|Experimental|Atezolizumab + Stereotactic radiosurgery (SRS)|"Atezolizumab administered intravenously once every 3 weeks
~Stereotactic radiosurgery (SRS) begin within 14 days after brain MRI obtained"
11185724|NCT03482999||Control|Standard Wound Closure with drains
11185725|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
11185726|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
11185727|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
11185728|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
11185729|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
11185730|NCT03482960|Experimental|129Xe MRI followed by 19F MRI with PFP|Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
11185731|NCT03482960|Experimental|19F MRI with PFP followed by 129Xe MRI|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
11185732|NCT03482947|Experimental|TAP|ultrasonography-guided transversus abdominis plane block administration of (0.3 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
11185733|NCT03482947|Experimental|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% &1 μ/kg dexmedetomidine
11185734|NCT03482934||hypertensive patients|
11185735|NCT03482908|Experimental|Responsive parenting treatment|Early Healthy Lifestyles (EHL) screening tool reported by participants to identify potentially obesogenic parenting practices and child behaviors; data sharing/coordination into electronic health records to inform counseling by trained providers; responsive parenting curriculum delivered by trained WIC nutritionists.
11185736|NCT03482908|No Intervention|Standard Care Control|Standard of pediatric and WIC care
11185737|NCT03482895||Patient: Blood sampling & Feces sampling|"Blood samplings at different times after a meal test: 0, 15, 30, 60, 90 and 120 minutes.
~Feces sampling: collection during 24 hours"
11185738|NCT03482882|Experimental|Drug - pimavanserin|
11185739|NCT03482869|Experimental|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
11185740|NCT03482856|Experimental|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
11185741|NCT03482856|Active Comparator|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
11185742|NCT03482843||Vitamin D Deficiency|25-Vitamin D level <25 ng/ml
11185743|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level >=25-70 ng/ml
11185744|NCT03482817|Experimental|Probe drug cocktail / Ze 117|One-sequence, Probe drug cocktail alone and in combination with Ze 117.
11185745|NCT03482791|Experimental|Arm 1: Resectable (proton beam therapy)|"Proton beam therapy: total dose of 50 or 50.4 Gy
~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision
~Surgery should ideally be performed no later than 8 to 10 weeks after completing chemoradiation
~Patient-reported outcome measures (PROs) performed at several time points"
11185746|NCT03482791|Experimental|Arm 2: Unresectable (proton beam therapy)|"Proton beam therapy: total dose of 59.4 or 60 Gy
~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision
~Patient-reported outcome measures (PROs) performed at several time points"
11185747|NCT03482778||AYA Patients|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA patients (n=36). AYA patients are eligible if they: (1) are 15 to 39 years of age, (2) were diagnosed with cancer at 15 to 39 years of age; (3) are able to read and understand English; (4) have a new cancer diagnosis and are receiving curative treatment OR are currently 0 to 5 years post-treatment. AYA patients will be excluded if they: (1) were diagnosed with basal cell skin cancer; (2) experienced a cancer recurrence; (3) are currently receiving palliative or hospice care; (4) had an infertility diagnosis prior to their cancer diagnosis, or (5) report a significant psychiatric history.
11185748|NCT03482778||AYA Providers|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA providers (n=36). Providers will be health professionals who provide supportive care for AYAs to help address financial, body image, and fertility/future parenthood concerns or needs. Psychosocial providers (e.g., social workers, patient navigators, psychologists) will all be eligible to participate. We will also include reproductive endocrinologists, nurse practitioners, and other medical professionals who have expertise in the appropriate area of health-related quality of life (HRQOL). Additional inclusion criteria will be: (1) provision of care to AYAs; (2) ≥2 years practicing; (3) English-speaking.
11185749|NCT03482778||Content Experts|Qualitative data collection will occur through one-on-one semi-structured interviews with content experts (n=36). Content experts are a purposive sample of scientists and clinicians who have recognized expertise in each of the three domains of interest to this project - financial burden, body image, and fertility/future parenthood.
11185750|NCT03482765|Experimental|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
11185751|NCT03482765|Experimental|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
11185752|NCT03482765|Placebo Comparator|Placebo|The Placebo contains MCC.
11185753|NCT03482726|Other|Cycling Cadence Modulation|3 initial visits to collect baseline information; 6-week HIIT indoor cycling program at the individual prescribed cadence; final study visit for post-intervention measures.
11185754|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
11185755|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
11185756|NCT03482700|Other|Intervention|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
11185757|NCT03482700|Other|Control|Usual standard of care
11188029|NCT03467191|Placebo Comparator|Placebo Beverage|
11185758|NCT03482687|Experimental|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
11185759|NCT03482687|No Intervention|Comparison Group|No intervention was provided, only usual care.
11185760|NCT03482674|No Intervention|Control Group|The control group will receive standard care as provided by the German statutory health insurance.
11185761|NCT03482674|Experimental|Intervention group|The intervention group receives the DIMINI lifestyle intervention for a period of three months.
11185762|NCT03482661|No Intervention|Control|The patients swallowed the capsule with water in the supine position. When the capsule reached the stomach, the capsule was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After completing the stomach examination, the capsule moved automatically without magnetic control and entered the duodenum under physiological conditions. The position of the capsule was verified through real-time viewer.
11185763|NCT03482661|Experimental|Magnetic steering|After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis.
11185764|NCT03482648|Experimental|Single Ascending Doses|
11185765|NCT03482648|Experimental|Multiple Ascending Doses|
11185766|NCT03482635|Experimental|Group 1- Placebo Group|
11185767|NCT03482635|Experimental|Group 2- Small Dose Group|
11185768|NCT03482635|Experimental|Group 3- Medium Dose Group|
11185769|NCT03482635|Experimental|Group 4 - High Dose Group|
11185770|NCT03482622||Patients undergoing Mohs surgery|Skin samples excised during Mohs surgery will be measured by the Fast Raman device. The Fast Raman measurements will be compared to gold standard histopathology to determine measurement accuracy.
11185771|NCT03482596|Experimental|Intervention|All participants will follow the personalised multifaceted intervention to reducing/breaking prolonged sitting.
11185772|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
11185773|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
11185774|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.
~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
11185775|NCT03482557|Experimental|CESM VS MRI|"Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.
~MRI: Breast MRI will be performed, if not already performed as part of clinical care.
~CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.
~Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.
~Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers."
11185776|NCT03482544|Active Comparator|Pregabalin Group|We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
11185777|NCT03482544|Active Comparator|Control Group|In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
11185778|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.
~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
11185779|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.
~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
11185780|NCT03482518|Experimental|Intervention Group|The intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover with elements in insoles. They will be advised to wear the slipper for 4 hours in the first week and up to 8 hours after that period. Should any part of you feel uncomfortable, the participant should return immediately so that the appropriate adjustments are made in the slipper
11185873|NCT03481933|Experimental|1:left-excitatory tDCS|20 SD patients who receive left-excitatory trans cranial stimulation
11185781|NCT03482518|Sham Comparator|Control group|"The control (sham) group volunteers will receive a pair of custom slippers with perforated synthetic leather cover as those used by GI.
~The difference will be that these slippers will not have the elements in the insoles."
11185782|NCT03482505|Experimental|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
11185783|NCT03482492|Active Comparator|Tramadol|Group Tramadol patients received tramadol 1 mg kg-1 iv
11185784|NCT03482492|Active Comparator|Tramadol-Paracetamol|Group Tramadol-Paracetamol patients received paracetamol 1 gr iv in addition to tramadol 1 mg kg-1 iv 30 minutes before the end of the operation and after the operation at 6 hour intervals for 24 hours
11185785|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
11185786|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
11185787|NCT03482466|Experimental|PTSD patients|12 PTSD patients will be recruited to undergo neurofeedback training .
11185788|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
11185789|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
11185790|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
11185791|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
11185792|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
11185793|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
11185794|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
11185795|NCT03482453|Experimental|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
11185796|NCT03482453|Experimental|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
11185797|NCT03482440|Placebo Comparator|Placebo|
11185798|NCT03482440|Experimental|Salsalate|
11185799|NCT03482427|Experimental|Intervention|After completion of the Healthy Hear Score assessment, participants will receive a lifestyle intervention based on the Healthy Heart Score results for 12-weeks by trained dietetic interns on-site. Participants will receive a check-in email or phone 6 weeks after the initial visit. A Registered Dietitian is also available to speak with patients. The intervention will consist on educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors
11185800|NCT03482427|No Intervention|Control|Participants in the control group will follow their usual care protocol after taking the Healthy Heart Score assessment. Researchers will provide the Healthy Heart Score survey results, but will not discuss or interpret the results with them. Participants can discuss any concern they have with their usual physician if they choose. After the follow-up visit and upon completion of the study, all participants in the control group may also receive the educational handouts and will be granted access to the Healthy Heart Score application if they wish.
11185801|NCT03482414|Active Comparator|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
11185802|NCT03482414|Experimental|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
11185803|NCT03482414|Experimental|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
11185804|NCT03482401|Experimental|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
11185805|NCT03482401|No Intervention|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
11185806|NCT03482388|Experimental|Crowdsourced intervention|A multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images.
11185807|NCT03482388|Other|Control|No images or videos will be viewed, and suggestions for improving hepatitis testing materials will not be collected.
11185808|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
11185809|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
11185874|NCT03481933|Active Comparator|2:right-inhibitory tDCS|20 SD patients who receive right-inhibotory trans cranial stimulation
11211117|NCT03307668|Experimental|CaReS-1S|
11185810|NCT03482362|Experimental|Cohort A; KRASmt, BRAFwt, BRAF-like CC|Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
11185811|NCT03482362|Experimental|Cohort B; KRASwt, BRAFmt, BRAF-like CC|Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
11185812|NCT03482349|Experimental|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
11185813|NCT03482349|No Intervention|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
11185814|NCT03482336|Other|Uninstructed Group|"For the first block of participants recruited (39, one of which withdrew from boredom), no overt reference was made regarding the FOP labels that were present on the images that participants viewed during the course of the video game. Participants comprising this block were referred to as uninstructed."
11185815|NCT03482336|Other|Minimally trained|"Realizing that subjects might not use the FOP during decision making when not informed that it contained nutrition information, we conducted a second experiment (N= 41) which provided minimal information about the FOP. These subjects (the minimally instructed group) were provided with further instruction. At the beginning of the experiment, in addition to being shown the basic premise of the game and told that Munchy preferred to eat healthy options, the researcher pointed to one of the FOPs and told children this information might be helpful when you decide what's healthy."
11185816|NCT03482323|Experimental|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
11185817|NCT03482323|Experimental|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
11185818|NCT03482323|No Intervention|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
11185819|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
11185820|NCT03482284|Experimental|Monosaccharide 1|Participants receive standardized meals with a defined amount of monosaccharide 1.
11185821|NCT03482284|Experimental|Monosaccharide 2|Participants receive standardized meals with a defined amount of monosaccharide 2.
11185822|NCT03482258|Experimental|Treatment Prebiotic|3 week daily dose of Vivinal-GOS (galacto-oligosaccharide)
11185823|NCT03482258|Placebo Comparator|Placebo|3 week daily dose of Maltodextrin
11185824|NCT03482245|Experimental|Pneumonia: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
11185825|NCT03482245|Experimental|Diverticulitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
11185826|NCT03482245|Experimental|Appendicitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
11185827|NCT03482245|No Intervention|Pneumonia: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
11185828|NCT03482245|No Intervention|Diverticulitis: Ambient Light|Standard ambient hospital lighting (~300 lux)for an initial 24 hour photoperiod after surgery for diverticulitis.
11185829|NCT03482245|No Intervention|Appendicitis: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod after surgery for diverticulitis.
11185830|NCT03482232||Patients visiting GP|All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
11185831|NCT03482232||Patient visiting pediatricians|All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
11185832|NCT03482219|Experimental|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:
~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations
~Application of the Physiotouch (a low-intensity negative pressure device)
~Passive Range of Motion
~Active Range of Motion
~Functional Activities"
11185833|NCT03482219|Active Comparator|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
11185834|NCT03482206|Experimental|Healthy subjects|Healthy adult volunteers (age 18 or greater) that are not claustrophobic, do not have hyperventilation or panic disorders, not pregnant, have no metal implants and can pass the MRI screening questions.
11185835|NCT03482193||Adolescents|Adolescents in 2nd or 4th year in secondary school, from 9 different schools in Liège, Belgium.
11185836|NCT03482180|Experimental|Investigational Group- KI1106|KI1106 tablet - daily administration
11185837|NCT03482180|Active Comparator|Control Group - Atorvastatin|Atorvastatin Calcium 20mg - daily administration
11185838|NCT03482167|Placebo Comparator|Placebo|placebo
11185839|NCT03482167|Experimental|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
11185840|NCT03482154||With Malglycemia|
11185841|NCT03482154||Without Malglycemia|
11185842|NCT03482141|Other|WES|Whole exome sequencing (WES) will take place.
11185843|NCT03482128||preAlgorithm|Standard coagulation management of patients undergoing cardiac surgery
11185844|NCT03482128||postAlgorithm|Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery
11185845|NCT03482115|Experimental|Comatose patient|Subject with coma of traumatic or anoxic aetiology : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
11185846|NCT03482115|Other|control volunteers|subject control : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
11185847|NCT03482102|Experimental|Tremelimumab + Durvalumab + Radiation|"Durvalumab via IV infusion every 28 days for up to 4 doses/cycles
~Tremelimumab via IV infusion every 28 days for up to 4 doses/cycles, and then continue durvalumab monotherapy every 4 weeks starting on Week 16 for up to 8 months.
~Radiation therapy will only be given during cycle 2"
11185848|NCT03482089|Experimental|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
11185849|NCT03482089|Active Comparator|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
11185850|NCT03482076|Other|transferrin receptor concentration|Prevelance of iron deficiency in this patients
11185851|NCT03482063|Experimental|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
11185852|NCT03482063|Placebo Comparator|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
11185853|NCT03482050|Experimental|AstroRx|
11185854|NCT03482037|Experimental|Rec 0/0438|Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks
11185855|NCT03482037|Placebo Comparator|Placebo|Placebo, to be administered by intravesical instillation once daily for four weeks
11185856|NCT03482024|Experimental|Tirzepatide - Healthy|Group 1 - Tirzepatide administered subcutaneously (SC) to healthy participants with normal renal function.
11185857|NCT03482024|Experimental|Tirzepatide - Mild Renal Impairment|Group 2 - Tirzepatide administered SC to participants with mild renal impairment.
11185858|NCT03482024|Experimental|Tirzepatide - Moderate Renal Impairment|Group 3 - Tirzepatide administered SC to participants with moderate renal impairment.
11185859|NCT03482024|Experimental|Tirzepatide - Severe Renal Impairment|Group 4 - Tirzepatide administered SC to participants with severe renal impairment.
11185860|NCT03482024|Experimental|Tirzepatide - End Stage Renal Disease (ESRD)|Group 5 - Tirzepatide administered SC to participants with ESRD.
11185861|NCT03482011|Experimental|Mirikizumab|"Induction Period:
~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).
~Maintenance Period:
~Participants received one of the four options below:
~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).
~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).
~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).
~250 mg mirikizumab administered SC Q8W for non-responders (<PASI 90)."
11185862|NCT03482011|Placebo Comparator|Placebo|"Induction Period: Participants received placebo administered SC Q4W.
~Maintenance Period:
~Participants received one of the two options below:
~Placebo administered SC Q8W for responders (≥PASI 90).
~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (< PASI 90)."
11185863|NCT03481998|Experimental|Cohort 1 (Part 1)|Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
11185864|NCT03481998|Experimental|Cohort 2 (Part 1)|SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
11185865|NCT03481998|Experimental|SHR6390 + Letrozole or anastrozole (Part 2)|SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
11185866|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 3 (Part 1)|SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
11185867|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 4 (Part 1)|SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
11185868|NCT03481972|Experimental|Doxy/TUDCA|"doxycicline (100 mg / BID)
~tauroursodeoxycholic acid (250 mg / TID)"
11185869|NCT03481972|Active Comparator|Standard of care|Standard of care therapies.
11185870|NCT03481959|Experimental|Methylphenidate|Methylphenidate delay shape, 10 and 30 mg capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).
11185871|NCT03481959|Placebo Comparator|Matching Placebo|
11185875|NCT03481933|Sham Comparator|3:sham tDCS|20 SD patients who receive sham stimulation
11211118|NCT03307668|Active Comparator|Microfracture|
11185876|NCT03481920|Experimental|PEGPH20 + Avelumab|PEGPH20, a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K/B or PEG) and recombinant human hyaluronidase (rHuPH20). PEGPH20 has a half-life of approximately 2 days, thereby enabling systemic activity and sustained duration of action to degrade HA. In many different tumor types tested in murine xenograft models, response to PEGPH20 has been shown to be more robust for tumors characterized by higher HA expression.
11185877|NCT03481907|Other|Internalized Control|Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
11185878|NCT03481894|Experimental|Kabiven®|Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
11185879|NCT03481894|Active Comparator|Compounded standard parenteral nutrition|"The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) <797> Pharmaceutical Compounding-Sterile Preparations."
11185880|NCT03481868||Chronic Myeloid Leukemia|Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
11185881|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
11185882|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
11185883|NCT03481842|Experimental|Vaginal Suppositories|"Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA
~The composition of the suppository:
~Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose
~Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose
~Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose"
11185884|NCT03481829||1|Women 18 and older who are getting prenatal care at Phoenix Indian Medical CenterMothers and children who were in the LIFE-Moms Phoenix study
11185885|NCT03481816|Experimental|1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts
11185886|NCT03481816|Experimental|2/Dose expansion|Subjects enrolled at the MTD after the MTD is established
11185887|NCT03481790|Experimental|Lactoferrin|100mg of bovine lactoferrin (Pravotin sachets, Hygint, Egypt) twice a day.
11185888|NCT03481790|Experimental|ferrous sulphate + folic acid (vitamin B9)|150mg of dried ferrous sulphate + folic acid (vitamin B9) 0.50mg (Ferrofol, E.I.P.I.C.O, Egypt) three capsules per day.
11185889|NCT03481777|Active Comparator|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.
~Initial remote ischemic conditioning: prehospital phase, all included patients
~Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres
~Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital
~Usual care with or without acute reperfusion therapy"
11185890|NCT03481777|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.
~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.
~Initial Sham remote ischemic conditioning: prehospital phase, all included patients
~Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres
~Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital
~Usual care with or without acute reperfusion therapy."
11185891|NCT03481764||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 5-14 years
11185892|NCT03481764||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
11185893|NCT03481764||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
11185894|NCT03481764||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
11185895|NCT03481764||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed epilepsia
11185896|NCT03481764||EFS: group of individuals with epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
11185897|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
11185898|NCT03481738||PKD Diagnosed|Patients diagnoses with PK Deficiency by PKLR genetic mutation analysis (either compound heterozygote or homozygous recessive) as well as clinical features
11185933|NCT03481491|Active Comparator|Real cerebellar stimulation|Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.
11185899|NCT03481725|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
11185900|NCT03481725|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
11185901|NCT03481699|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
11185902|NCT03481699|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
11185903|NCT03481686|Experimental|Patients with injections of ESA|Patients with injections of ESA
11185904|NCT03481673|Experimental|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
11185905|NCT03481660|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
11185906|NCT03481660|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
11185907|NCT03481647|Active Comparator|Intervention|The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
11185908|NCT03481647|No Intervention|Control|Professional oral care once a week according to existing routine
11185909|NCT03481634|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
11185910|NCT03481634|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
11185911|NCT03481634|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
11185912|NCT03481621|Active Comparator|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
11185913|NCT03481621|Active Comparator|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
11185914|NCT03481621|Active Comparator|Group2, Standard care or waiting lists|Standard care without acupuncture
11185915|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid
~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
11185916|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid
~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
11185917|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
11185918|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
11185919|NCT03481582|Active Comparator|Group without nitroglycerin|They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
11185920|NCT03481582|Experimental|Group with nitroglycerin|They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
11185921|NCT03481569|Experimental|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
11185922|NCT03481556|Experimental|A (melflufen+bortezomib+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
11185923|NCT03481556|Experimental|B (melflufen+daratumumab+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks until PD. Dexamethasone will be given day of and after daratumumab infusions, 20 mg i.v. pre daratumumab and 20 mg p.o. day after daratumumab (20 mg total for ≥ 75 years).
11185924|NCT03481543|Experimental|In-line nebulization through NIV mask|Bronchodilator nebulization is given through NIV circuit.
11185925|NCT03481543|Active Comparator|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished.
11185926|NCT03481530||Blinded|Continuing Glucose Monitoring System will be blinded
11185927|NCT03481530||Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
11185928|NCT03481517|Experimental|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
11185929|NCT03481517|No Intervention|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
11185930|NCT03481504|Experimental|ACT-ETP|Cognitive behavioral treatment
11185931|NCT03481504|No Intervention|Usual care|no intervention
11185932|NCT03481491|Sham Comparator|Sham cerebellar stimulation|Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.
11185934|NCT03481478||Patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
11185935|NCT03481478||Dislocation patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
11185936|NCT03481452|Experimental|psychotherapy intervention group|NBO behavioral intervention would be used to improve mother-infant dyad interaction and infants' disorders of regulation of states.
11185937|NCT03481452|No Intervention|control group|No behavioral intervention would be used.
11185938|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
11185939|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
11185940|NCT03481426|Experimental|Workplace intervention group|Workers with back problems receive both information/advice and participatory workplace intervention organized by Occupational Health Physioterapist.
11185941|NCT03481426|No Intervention|Information and advice group|Workers with back problems receive only information / advice by Occupational Health Physiotherapist, not the workplace intervention.
11185942|NCT03481400|Experimental|Calcitonin gene-related peptide|Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)
11185943|NCT03481400|Experimental|Placebo|Infusion with placebo (isotonic saline)
11185944|NCT03481387|Other|PERCEVAL S valve|patients to be treated with PERCEVAL S valve
11185945|NCT03481374|Active Comparator|subjects with Type 1 Diabetes mellitus|Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
11185946|NCT03481374|Placebo Comparator|Healthy controls|healthy people without known disease undergo autonomic function testing
11185947|NCT03481348|Experimental|Pharyngeal Electrical Stimulation|PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
11185948|NCT03481348|No Intervention|Control|Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
11185949|NCT03481335|Experimental|Intervention Community|Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
11185950|NCT03481335|No Intervention|Control Community|Control communities (barangays) will receive care as usual.
11185951|NCT03481322|Active Comparator|Cooked diet with controlled amount of salt|Patients will receive intervention diet (cooked with controlled amount of salt)
11185952|NCT03481322|Placebo Comparator|Cooked without salt|Patients will receive the standard diet (cooked without salt and 2 grams of salt separated will be added by the patient)
11185953|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
11185954|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
11185955|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
11185956|NCT03481296|Active Comparator|Advanced Control|The advanced control group receives a set of standard materials regarding colorectal cancer screening.
11185957|NCT03481296|Experimental|Culturally Adapted Decision Support Navigation Intervention|The culturally adapted decision support navigation intervention group receives everything advanced group receives as well as decision support and navigation contacts.
11185958|NCT03481270|Placebo Comparator|Discordant|Does not receive the concordant provider.
11185959|NCT03481270|Experimental|Concordant|The intervention is that the subject receives the concordant provider.
11185960|NCT03481257||Ticagrelor|ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
11185961|NCT03481257||Clopidogrel + very low dose rivaroxaban|ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
11185962|NCT03481218||Patients with type 1 diabetes|Young adults (male and female) between the ages of 18 and 35, who have type 1 diabetes for at least one year.
11185963|NCT03481218||Individuals without chronic diseases|Young adults (male and female) between the ages of 18 and 35, without chronic diseases.
11185964|NCT03481205|Experimental|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
11185965|NCT03481192|Experimental|A group using amnesic substances|"A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates.
~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
11185966|NCT03481192|Active Comparator|A control group|"A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant.
~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
11185967|NCT03481179|Experimental|Experimental: hf rTMS and Physical therapy|High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
11185968|NCT03481179|Sham Comparator|Control: Sham hf rTMS and Physical theraphy|In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
11185969|NCT03481166|Experimental|Education on breastfeeding pain|Both the experimental and control groups will receive usual prenatal education offered through our regional public health program. In addition to usual prenatal education, the experimental group will also receive a one-hour, nurse led (a Registered Nurse specially trained in perinatal care), small group-based education session with specific focus on breastfeeding pain. The goals of this educational intervention are to provide pregnant women with anticipatory guidance around pain which is commonly experienced while breastfeeding in the first two weeks postpartum. Education will include the prevalence, etiology and management of various types of breastfeeding-related pain experienced postpartum.
11185970|NCT03481166|No Intervention|Usual prenatal education|Women allocated to the usual prenatal education group will receive prenatal classes through their local public health unit. Women enrolled in classes will receive approximately 12 hours of combined in-class and online prenatal content. Topics include: discomforts of pregnancy, labor and birth, medical interventions, adjustment to parenting, breastfeeding, and caring for the newborn. Breastfeeding-related material includes basic mechanisms of milk production, benefits of breastfeeding, benefits of skin-to-skin, correct breastfeeding latch, breastfeeding positions, timing of feeds, responding to infant cues, and caring for nipples. Women in the usual prenatal education group will not receive education on the prevalence and etiology of nipple pain, nor specific pain management strategies.
11185971|NCT03481153|Placebo Comparator|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
11185972|NCT03481153|Active Comparator|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
11185973|NCT03481140||Control|donor site DIEP flap breast reconstruction procedure with standard wound closure with drains
11185974|NCT03481140||TissuGlu Surgical Adhesive|donor site DIEP flap breast reconstruction procedure with standard wound closure with TissuGlu Surgical Adhesive and no drains
11185975|NCT03481127|Active Comparator|Arm 1: Usual Care|-No psychosocial care in clinic
11185976|NCT03481127|Experimental|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
11185977|NCT03481114|Active Comparator|Standard chemoradiotherapy|Patients receiving standard radiotherapy will receive a total dose of 60 Gy in 30 fractions over 6 weeks, delivered to all involved lesions (tumors and lymph nodes).
11185978|NCT03481114|Experimental|PET-based, dose-painted, accelerated chemoradiotherapy,|For patients receiving PET-based, dose-painted, accelerated chemoradiotherapy, lesions with MTV exceeding 20 cc will be treated with 55 Gy in 20 fractions over 4 weeks, while lesions with MTV below 20 cc will receive 44 Gy in 20 fractions over the same 4 weeks.
11185979|NCT03481101|Other|All patients|Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
11185980|NCT03481088|Other|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.
~Stage- I (pre-treatment),
~Stage- II (after pre-functional therapy)
~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
11185981|NCT03481075|Experimental|Rigid and Elastic registration softwares|
11185982|NCT03481062||Neutral|
11185983|NCT03481062||abduction|
11185984|NCT03481062||pad|
11185985|NCT03481062||combination|
11185986|NCT03481049|Experimental|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
11185987|NCT03481049|Experimental|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
11185988|NCT03481049|Experimental|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
11185989|NCT03481036|Active Comparator|Non cirrhotic|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg), LDV (90 mg) and DCV (60 mg) per day
11185990|NCT03481036|Active Comparator|Genotype 1,4,5 and 6 with cirrhosis|Sofosbuvir (SOF)+ Ledipasvir (LDV) for 12-weeks + weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and LDV (90 mg) per day
11185991|NCT03481036|Active Comparator|Genotype 2 and 3 with Cirrhosis|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks+ weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and DCV (60 mg) per day
11185992|NCT03481023|Experimental|Esophageal thermal regulation device|
11185993|NCT03481023|Active Comparator|LET monitoring|
11185994|NCT03481010|Experimental|PAO with hip arthroscopy|"Patient's in the Scope PAO group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the Scope-PAO group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy."
11185995|NCT03481010|Active Comparator|PAO without hip arthroscopy|"Patient's in the PAO-only group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the PAO-only group have been randomized to receive a periacetabular osteotomy only."
11185996|NCT03480997|Experimental|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
11185997|NCT03480997|Active Comparator|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
11185998|NCT03480997|Experimental|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
11185999|NCT03480984|Active Comparator|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
11188548|NCT03463798||Patients|Patients with a suspicion of diaphragmatic dysfunction
11186000|NCT03480984|Active Comparator|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
11186001|NCT03480971|Active Comparator|Active 600 mg Tempol Solution|Patients will take 600 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
11186002|NCT03480971|Placebo Comparator|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
11186003|NCT03480958|Active Comparator|ESP group|Erector Spinae Plane Block administered group
11186004|NCT03480958|Active Comparator|TPVB group|Thoracic Paravertebral Block administered group
11186005|NCT03480958|Other|Control Group|No regional anesthesia technique will be applied to control group; but will be provided with iv PCA
11186006|NCT03480932|Active Comparator|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
11186007|NCT03480932|Active Comparator|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
11186008|NCT03480932|Active Comparator|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
11186009|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
11186010|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
11186011|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
11186012|NCT03480906|Experimental|Microdose administration|Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD
11186013|NCT03480906|Active Comparator|Eyedrop administration|Latanoprost ophthalmic solution administered as an eyedrop
11186014|NCT03480893|Experimental|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
11186015|NCT03480893|Active Comparator|Laminectomy|Patients will undergo laminectomy
11186016|NCT03480880|Experimental|Group BIS|Thiopentone dosing during induction of anaesthesia based on guidance of Bispectral Index values.
11186017|NCT03480880|No Intervention|Group Clinical|Thiopentone dosing during induction of anaesthesia based on clinical guidance targeted to loss of eyelash reflex or loss of response to noxious stimulus.
11186018|NCT03480867|Experimental|Pre-operative RT and TMZ|Single Arm: Pre-operative Radiation +Temozolomide followed by Surgery plus six cycles of Temozolomide
11186019|NCT03480854|No Intervention|Baseline Analysis|To conduct studies of variation in performance across microsystems and to utilize benchmarking analyses to identify top performers.
11186020|NCT03480854|Experimental|The effect of continuous quality improvements (CQI)|To study the comparative improvement of selected primary process performance indicators (DMT and MRI process measures) over a 3 year period (Years 2-3) in microsystems receiving CQI interventions versus those not receiving CQI intervention, and between two different CQI intervention types (IHI Breakthrough Series and Patient Centered Medical Home).
11186021|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
11186022|NCT03480815|Active Comparator|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
11186023|NCT03480815|Placebo Comparator|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
11186024|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
11186025|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
11186026|NCT03480789|Experimental|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
11186027|NCT03480789|Experimental|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
11186028|NCT03480789|Experimental|eye patch + DEX|given dexmedetomidine to meet RASS -1 and wearing the eye patch from 22:00 to 6:00 of the next day
11186029|NCT03480789|No Intervention|usual treatment|treatment as usual
11186030|NCT03480776|Active Comparator|Acetylsalicylic Acid (ASA)|
11186031|NCT03480776|Sham Comparator|Placebo|
11186032|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
11186033|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
11186034|NCT03480750|Experimental|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
11186035|NCT03480737|Experimental|10 Hz rTMS|
11186036|NCT03480737|Sham Comparator|Sham rTMS|
11186037|NCT03480737|Experimental|iTBS rTMS|
11186038|NCT03480724|Active Comparator|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
11186039|NCT03480724|Active Comparator|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
11186040|NCT03480724|No Intervention|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group
11186076|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
11186041|NCT03480711|Experimental|Group (A)|20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
11186042|NCT03480711|Experimental|group (B)|20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
11186043|NCT03480698||Cerebrolysin and standard stroke care|
11186044|NCT03480698||Standard stroke care|
11186045|NCT03480685|Active Comparator|IVUS catheter|A vessel segment will be imaged with an IVUS catheter.
11186046|NCT03480685|Active Comparator|OCT catheter|The same vessel segment will be imaged with an OCT catheter
11186047|NCT03480672|Experimental|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
11186048|NCT03480672|Active Comparator|aRCH|adjuvant radio-chemotherapy (aRCH)
11186049|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
11186050|NCT03480659||Control|Age matched control females
11186051|NCT03480646|Experimental|CPI-1205 Combination with Enzalutamide|
11186052|NCT03480646|Experimental|CPI-1205 Combination with Abiraterone/Prednisone|
11186053|NCT03480633||Control|Defined as no history of heart failure, with age and sex matched to the overall heart failure subjects.
11186054|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 45%.
11186055|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 45%.
11186056|NCT03480620|Experimental|Telerehabilitation|Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
11186057|NCT03480620|Active Comparator|Usual care|Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
11186058|NCT03480607|Active Comparator|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
11186059|NCT03480607|Active Comparator|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
11186060|NCT03480594|Experimental|Fatty Liver Patients|Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients
11186061|NCT03480594|Experimental|Healthy Control Subjects|Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects
11186062|NCT03480581|Experimental|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
11186063|NCT03480581|Experimental|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
11186064|NCT03480568|Experimental|alirocumab|Alirocumab 150 mg q 2 weeks for 12 weeks
11186065|NCT03480555|Active Comparator|Replenish Protein group|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
11186066|NCT03480555|Other|Standard Protein group|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
11186067|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
11186068|NCT03480516|Experimental|SDF arm|SDF arm is application of 38% silver diamine fluoride solution (SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained.
11186069|NCT03480516|Experimental|Fluoride varnish arm|Fluoride varnish arm is application of 5% sodium fluoride varnish on all surface of every tooth.
11186070|NCT03480516|Experimental|Combination arm|Combination arm is application of 38% silver diamine fluoride solution(SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained and then apply of 5% sodium fluoride varnish on all surface of every tooth.
11186071|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
11186072|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
11186073|NCT03480477||Pelvic Floor Disorders Group|Will collect patient information from new patients who present to the Urogynecology Clinic
11186074|NCT03480477||Control Group|Will collect patient information from patients who present to Gynecologic Clinic for their annual examination
11186075|NCT03480477||Chronic Pelvic Pain Group|Will collect patient information from patients who present to their Chronic Pelvic Pain Clinic appointment
11186108|NCT03480126|Experimental|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
11186077|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
11186078|NCT03480451|Other|Single Arm|"This project is being withdrawn. No revisions to ARM is available.
~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
11186079|NCT03480438|Experimental|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.
~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
11186080|NCT03480425|Experimental|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to >30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to >30cm water pressure, and force of extubation recorded.
11186081|NCT03480412||Follicular Phase|
11186082|NCT03480412||Luteal Phase|
11186083|NCT03480386|Experimental|Intervention|Patients randomized in this arm will start with the home based pulmonary rehabilitation program.
11186084|NCT03480386|Active Comparator|Control|Patients randomized in this arm will start the intervention after 12 weeks of usual care.
11186085|NCT03480360|Other|Johns Hopkins' conditioning regimen|Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant
11186086|NCT03480334|Experimental|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
11186087|NCT03480321|Active Comparator|Cilostazol 100 mg|
11186088|NCT03480321|Experimental|PMR 150 mg|
11186089|NCT03480321|Experimental|PMR 200 mg|
11186090|NCT03480308|Active Comparator|Bupivacaine fentanyl group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
11186091|NCT03480308|Active Comparator|Bupivacaine dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
11186092|NCT03480308|Active Comparator|Bupivacaine fentanyl dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
11186093|NCT03480295|Experimental|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
11186094|NCT03480295|Active Comparator|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
11186095|NCT03480282|Experimental|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
11186096|NCT03480256|Experimental|SHR6390 combined with pyrotinib|Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
11186097|NCT03480243|Experimental|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):
~Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4
~Padsevonil 100 mg single dose on Day 5
~1 week of wash-out (from evening of Day 5 to Day 11)
~Treatment Period 2 (Day 12 to 22):
~Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15
~Padsevonil 100 mg single dose on Day 16
~1 week of wash-out (from evening of Day 16 to Day 22)
~Treatment Period 3 (Day 23 to Day 38):
~Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25
~Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32
~Padsevonil 100 mg single dose on Day 33
~Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36
~Erythromycin 500 mg single dose on Day 37"
11186098|NCT03480230|Experimental|Treatment arm|"Non-squamous histology:
~Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.
~Compound 565994 500 mg/m2 administered over 10 minutes, and
~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.
~Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.
~Squamous histology:
~Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.
~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.
~Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.
~Platinum and Compound 343782 will be given for 3 cycles."
11186099|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
11186100|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
11186101|NCT03480191|Experimental|Patients|
11186102|NCT03480165|Experimental|20 mg Parecoxib + 0.75% Ropivacaine|1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine
11186103|NCT03480165|Active Comparator|0.75% Ropivacaine only|19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline
11186104|NCT03480152|Experimental|1/Phase - Escalating doses of mRNA vaccine|Escalating doses of messenger ribonucleic acid (mRNA) vaccine
11186105|NCT03480152|Experimental|2/Phase II -MTD of mRNA vaccine established in Phase I|Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I
11186106|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
11186107|NCT03480126|Placebo Comparator|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
11211325|NCT03306329|Experimental|DNS-7801 (low-dose)|
11186110|NCT03480126|Experimental|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
11186111|NCT03480113|Experimental|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
11186112|NCT03480113|Active Comparator|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
11186113|NCT03480100||Xylometazoline Nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
11186114|NCT03480100||Xylometazoline + Ectoin Nasal Douche|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
11186115|NCT03480087||Chemotherapy alone|Patient treated with anthracycline containing chemotherapy
11186116|NCT03480087||Chemotherapy plus radiotherapy|Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
11186117|NCT03480074|Active Comparator|Staple Ligation|Arm 1: Staple Ligation
11186118|NCT03480074|Active Comparator|Selective Suture Ligation|Arm 2: Selective Suture Ligation
11186119|NCT03480074|Active Comparator|Single Suture Ligation|Arm 3: Single Suture Ligation
11186120|NCT03480061|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
11186121|NCT03480061|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
11186122|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
11186123|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
11186124|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
11186125|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
11186126|NCT03480009|Experimental|Dextromethorphan, opted for narcotic prescription|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
11186127|NCT03480009|Placebo Comparator|Placebo, opted for narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)
11186128|NCT03480009|Experimental|Dextromethorphan, declined narcotic prescription|Dextromethorphan hydrobromide and patient declines narcotic
11186129|NCT03480009|Placebo Comparator|Placebo, declined narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
11186130|NCT03479996|Experimental|Anesthetic|
11186131|NCT03479996|No Intervention|Control|
11186132|NCT03479983|Experimental|AMX160|500 mg (one capsule) x 2 times daily for 90 days
11186133|NCT03479983|Placebo Comparator|Placebo|500mg (one capsule) x 2 times daily for 90 days.
11186134|NCT03479970|Experimental|GNPT + Social Cognition|"Experimental Group: will undertake a rehabilitation treatment integrated by a set of tasks aimed at working attention, memory and executive functions together with a computerized treatment for the rehabilitation of the Social Cognition. The treatment will be carried out through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT).
~The treatment will consist of the carrying out of 24 treatment sessions"
11186135|NCT03479970|Active Comparator|GNPT (only N-SC measures)|Control Group: will only conduct a cognitive rehabilitation treatment through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT) focused on attention, memory and executive functions.
11186136|NCT03479957|Experimental|REMOTE-CR|Remotely monitored and coached exercise training in real time using the REMOTE-CR system. The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link.
11186137|NCT03479957|Other|Usual care|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care).
11186138|NCT03479944|Experimental|FLACS|Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
11186139|NCT03479944|Active Comparator|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
11186140|NCT03479931|Experimental|Without placement of a catheter|Without preoperatively placement of an indwelling catheter during Caesarean section
11186141|NCT03479931|Active Comparator|With placement of a catheter|Normal pre-operative routines with placement of an indwelling catheter during Caesarean section
11186142|NCT03479918|Active Comparator|R-DA-EPOCH-21|The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.
11186143|NCT03479918|Active Comparator|R-BL-M-04|"Course A:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.
~Course C:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.
~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
11186216|NCT03479541|Experimental|Physical Therapy (Early)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
11186144|NCT03479918|Active Comparator|R-DA-EPOCH-21 + auto-SCT|"The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.
~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
11186145|NCT03479918|Active Comparator|R-BL-M-04 + auto-SCT|"The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.
~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
11186146|NCT03479905|Sham Comparator|Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 36%
11186147|NCT03479905|Sham Comparator|Face mask group|A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
11186148|NCT03479905|Experimental|High Floow Oxygen delivery|Oxygen will be delivered by using high flow nasal cannula
11186149|NCT03479892|Experimental|NNC0194-0499|Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
11186150|NCT03479892|Placebo Comparator|Placebo|Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
11186151|NCT03479879|Experimental|Estradiol + Misoprostol|
11186152|NCT03479879|Placebo Comparator|Placebo + Misoprostol|
11186153|NCT03479866|Experimental|Dietary intervention|2 week dietary intervention using standardized test meals
11186154|NCT03479853||Cases : suffering from ocular or oculo-cutaneous rosacea|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
11186155|NCT03479853||Witnesses|"Without any present or past palpebral meibomian Gland Dysfunction
~Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device."
11186156|NCT03479840||Patients undergoing PCI|all-comer population undergoing PCI
11186157|NCT03479827|Experimental|Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
11186158|NCT03479814|Experimental|IMRT-SIB plus sequential IG-RT boost|45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET
11186159|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
11186160|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
11186161|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
11186162|NCT03479788||DM|Observational study. NO intervention
11186163|NCT03479788||non-DM|Observational study. NO intervention
11186164|NCT03479775||Youth female athletes with poor muscle function|Youth female athletes (floorball, football and handball) with assessed poor muscle function at baseline.
11186165|NCT03479775||Youth female athletes with good muscle function|Youth female athletes (floorball, football and handball) with assessed good muscle function at baseline.
11186166|NCT03479762||Liraglutide|
11186167|NCT03479749|Placebo Comparator|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
11186168|NCT03479749|Placebo Comparator|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
11186169|NCT03479749|Placebo Comparator|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
11186170|NCT03479749|Placebo Comparator|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
11186171|NCT03479736||Cohort 1: Participants with Achilles Tendon Rupture (ATR)|Participants will be defined as having ATR if they receive a diagnosis for ATR as well as one of the following procedures: tenotomy or primary ruptured Achilles Tendon (AT) repair (with or without graft) within 7 days of diagnosis. Index will be based on the earlier date of diagnosis or procedure. Participants with ATR, and exposures to Fluoroquinolone (FQ) or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
11186172|NCT03479736||Cohort 2: Participants with Retinal Detachment (RD)|Participants will be defined as having a RD if they received a diagnosis of RD and a procedure for RD, e.g.: sclera buckle, vitrectomy, retinopexy, retinal cryotherapy, silicone oil fill, air gas fluid exchange or pneumatic retinopexy, within 14 days of index. Index will be defined as the earlier date of diagnosis or procedure. Participants with RD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
11186217|NCT03479541|Experimental|Physical Therapy (Standard of Care)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
11186218|NCT03479528||Dyspepsia|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an jiaotong university,Xijing Hospital, Tangdu Hospital, Xi'an No.3 Hospital, and received investigation.
11186173|NCT03479736||Cohort 3: Participants with Aortic Aneurysm & Dissection (AAD)|Participants will be defined as having AAD if they received a primary diagnosis for aortic aneurysm, aortic rupture or dissection and have also received an aortic repair surgical procedure concurrently to the AAD diagnosis, in an inpatient or emergency department (ED) setting. Index will be defined as the earlier date of diagnosis or procedure. Participants with AAD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
11186174|NCT03479710|Experimental|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
11186175|NCT03479710|No Intervention|Control|No FMT infusion.
11186176|NCT03479697|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
11186177|NCT03479697|Other|Continued Current Care|Participants will continue their current care.
11186178|NCT03479684|Experimental|Gene-directed group|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
11186179|NCT03479684|Active Comparator|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
11186180|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
11186181|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
11186182|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
11186183|NCT03479658|Experimental|HIIT two sessions|Two sessions per week of HIIT + nutritional education (1 session/week)
11186184|NCT03479658|Experimental|HIIT one session|One session per week of HIIT + nutritional education (1 session/week)
11186185|NCT03479658|Active Comparator|Nutritional education|Nutritional education (1 session/week)
11186186|NCT03479645|No Intervention|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
11186187|NCT03479645|Experimental|Intervention|Serial text messages and mailed FIT kit
11186188|NCT03479632|Experimental|Intervention Group|The intervention group will undergo an aerobic walking program using a treadmill, a body-weight support system, and an assistive device.
11186189|NCT03479632|Active Comparator|Control Group|The control group will receive standard physical therapy (PT).
11186190|NCT03479619|Experimental|A/28/1|Lancing device A with personal lancet of size 28 G and minimum puncture depth.
11186191|NCT03479619|Experimental|A/28/5|Lancing device A with personal lancet of size 28 G and maximum puncture depth.
11186192|NCT03479619|Experimental|A/30/1|Lancing device A with personal lancet of size 30 G and minimum puncture depth.
11186193|NCT03479619|Experimental|A/30/5|Lancing device A with personal lancet of size 30 G and maximum puncture depth.
11186194|NCT03479619|Experimental|A/33/1|Lancing device A with personal lancet of size 33 G and minimum puncture depth.
11186195|NCT03479619|Experimental|A/33/5|Lancing device A with personal lancet of size 33 G and maximum puncture depth.
11186196|NCT03479619|Experimental|B/28/1|Lancing device B with personal lancet of size 28 G and minimum puncture depth.
11186197|NCT03479619|Experimental|B/28/5|Lancing device B with personal lancet of size 28 G and maximum puncture depth.
11186198|NCT03479619|Experimental|B/30/1|Lancing device B with personal lancet of size 30 G and minimum puncture depth.
11186199|NCT03479619|Experimental|B/30/5|Lancing device B with personal lancet of size 30 G and maximum puncture depth.
11186200|NCT03479619|Experimental|B/33/1|Lancing device B with personal lancet of size 33 G and minimum puncture depth.
11186201|NCT03479619|Experimental|B/33/5|Lancing device B with personal lancet of size 33 G and maximum puncture depth.
11186202|NCT03479619|Experimental|C/28/1|Lancing device C with personal lancet of size 28 G and minimum puncture depth.
11186203|NCT03479619|Experimental|C/28/5|Lancing device C with personal lancet of size 28 G and maximum puncture depth.
11186204|NCT03479619|Experimental|C/30/1|Lancing device C with personal lancet of size 30 G and minimum puncture depth.
11186205|NCT03479619|Experimental|C/30/5|Lancing device C with personal lancet of size 30 G and maximum puncture depth.
11186206|NCT03479619|Experimental|C/33/1|Lancing device C with personal lancet of size 33 G and minimum puncture depth.
11186207|NCT03479619|Experimental|C/33/5|Lancing device C with personal lancet of size 33 G and maximum puncture depth.
11186208|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
11186209|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
11186210|NCT03479593||CMR and OCT in NSTEMI patients with MVD|NSTEMI patients with multi vessel disease
11186211|NCT03479567|Other|HC|Healthy controls, i.e. older adults without cognitive impairment
11186212|NCT03479567|Other|MiD|older adults with mild dementia
11186213|NCT03479567|Other|MoD|older adults with moderate dementia
11186214|NCT03479554|Experimental|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
11186215|NCT03479554|Active Comparator|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
11188549|NCT03463798||Healthy volunteers|Subjects without any medical condition
11186219|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
11186220|NCT03479502|Active Comparator|Methylprednisolone|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.
11186221|NCT03479502|Active Comparator|Doxycycline|Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.
11186222|NCT03479489|Experimental|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
11186223|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
11186224|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
11186225|NCT03479463||Treatment with Dehydrated Human Amnion Chorion Allograft|
11186226|NCT03479463||Standard of Care|
11186227|NCT03479424||Training Set|n = 333
11186228|NCT03479424||Validation Set|n = 167
11186229|NCT03479411|Experimental|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
11186230|NCT03479411|Experimental|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
11186231|NCT03479411|Active Comparator|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
11186232|NCT03479398||App Condition|Although we will be mostly observing routine practice, we will randomize patients into either an App condition or paper condition. The App condition refers to patients completing routine Cognitive Behavioral Therapy (CBT) worksheets on a mobile application during session. Everything else that occurs in treatment sessions will be consistent with routine care practices.
11186233|NCT03479398||Paper Condition|Although we will be mostly observing routine practice, we do randomize patients into either an App condition or paper condition. The paper condition refers to patients completing routine CBT worksheets on paper (the current standard) during session.
11186234|NCT03479385|Experimental|Integrative Medicine Intervention|Study participants randomized to the Integrative Medicine intervention will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months potentially followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
11186235|NCT03479385|Experimental|Health Education Intervention|Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
11186236|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 1|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
11186237|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 2|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
11186238|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 3|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
11186239|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
11186240|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
11186241|NCT03479346|Experimental|GGT group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
11186242|NCT03479346|Placebo Comparator|Placebo group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
11186243|NCT03479333|Experimental|Short implant|
11186244|NCT03479333|Active Comparator|standard implant with sinus lift|
11186245|NCT03479320|Experimental|Lidocaine group|Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery
11186246|NCT03479320|Placebo Comparator|Placebo|They will receive the same volume of 0.9% of normal saline as calculated for the experimental group
11186247|NCT03479307|Experimental|Bilastine Ophthalmic Solution 0.6%|
11186248|NCT03479307|Active Comparator|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|
11186249|NCT03479307|Placebo Comparator|Vehicle of Bilastine Ophthalmic Solution|
11186250|NCT03479294||Exposure group|Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
11186251|NCT03479294||Control group|Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.
11186279|NCT03479060|No Intervention|Discontinue WCT Application|No intervention in this arm.Only MIDAS applied
11186252|NCT03479268|Experimental|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11186253|NCT03479255|Experimental|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.
~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
11186254|NCT03479255|Active Comparator|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
11186255|NCT03479229|Experimental|Geneveve Treatment|Active Treatment
11186256|NCT03479229|Placebo Comparator|Sham Treatment|Sham Treatment
11186257|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
11186258|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
11186259|NCT03479203|Experimental|Healthy, Non-Smokers|Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)
11186260|NCT03479190|Active Comparator|Platelet rich plasma|ultrasound guided injection of Platelet rich plasma
11186261|NCT03479190|Placebo Comparator|Normal saline|ultrasound guided injection of Normal saline
11186262|NCT03479177|Experimental|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
11186263|NCT03479177|No Intervention|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
11186264|NCT03479164|Experimental|Ultra Low-Dose CT|One non-contrast gated aortic (NCGA) computer tomography scan, a low radiation, non-contrast, low cost CT based study
11186265|NCT03479151|Experimental|MR-HIFU of painful bone metastases|Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
11186266|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
11186267|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
11186268|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
11186269|NCT03479112|Experimental|Flashcards|Study participants in this arm of the trial received bleeding control flashcards that contain diagrams and figures to correctly identify the severity of the injury and visual instructions on the appropriate application of pressure dressing, hemostatic packing, and tourniquet.
11186270|NCT03479112|Experimental|Audio-kit|Study subjects in this arm received a commercially available audio bleeding control kit. The kit included a diagram and visual aids to identify the correct severity of the injury and determine the appropriate method of bleeding control. The kit also had buttons on it to play stepwise audio instructions on the application of compression dressing, hemostatic packing and tourniquet application in two languages (English and Spanish). The audio kits were bought at the market price and the name of the manufacturer was not mentioned in the manuscript to avoid conflict of interest.
11186271|NCT03479112|Experimental|Bleeding Control (B-Con) training|Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
11186272|NCT03479112|No Intervention|Control|Study subjects in this arm of the trial received no intervention (no training or access to point-of-care prompts) to assess baseline competence in hemorrhage control.
11186273|NCT03479112|Experimental|Retention of B-Con course|Control, Audio-kit, and flashcard arms undergo B-Con training at the completion of the initial evaluation, and the B-Con arm completed training prior to testing in order that all participants obtain training and then can be evaluated at retention testing. a. 3-9 months after the trial, investigators planned to test all study subjects with a simulated mass causality scenario for retention of knowledge and skills. This test will be the same as the initial test for competence at tourniquet placement in the trial and the same evaluation form will be used to evaluate the study subjects.
11186274|NCT03479086|Experimental|Topiramate|Topiramate 200mg/day
11186275|NCT03479086|Experimental|Naltrexone|Naltrexone 50mg/day
11186276|NCT03479073||Stroke group|Patients who experienced stroke or systemic embolic event following catheter ablation for AF.
11186277|NCT03479073||Control group|Patients who did not experienced stroke or systemic embolic event following catheter ablation for AF.
11186278|NCT03479060|Active Comparator|Continue WCT Application|From the 3rd month to the 12th month Wet cupping applied as an intervention MIDAS was applied at the end of the 6th and 12th months.
11186280|NCT03479047|Experimental|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
11186281|NCT03479034||Group 1|"Ages 18-85
~Cognitively able to understand instructions and care for themselves
~Lives in the community (not institutionalised)
~Owner of a smartphone and able to use Apps
~On 3 or more chronic prescription medications
~Has had experience with prescriptions in Australia for at least 1 year
~Current patient attending Holdsworth House Medical Practice
~Willing to use the ScalaMed ePrescription application"
11186282|NCT03479008||Phase I|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. Volunteers will be randomized to receive alternating 5 minute episode of various vibration frequencies.
11186283|NCT03479008||Phase 2|Based on data collected from Phase I used to determine optimal vibration strategies, the investigators will recruit critically ill patients from the Intensive Care unit who are expected to be immobilized for a prolonged period of time due to the nature of their illness. these patient subjects will undergo up to three 5-10 minute vibration sessions a day for 5 days. Similar physiologic responses will be measured in these patients. Baseline blood values will be taken at prior to the first day of vibration and then additional samples taken at the end of each day of vibration. No randomization will take place in this phase.
11186284|NCT03478995|Experimental|GX-I7|Determined dose of GX-I7 on Day1 of each cycle
11186285|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
11186286|NCT03478982|Experimental|Staccato Alprazolam 2.0 mg|single dose for inhalation
11186287|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
11186288|NCT03478969|Experimental|Group A|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
11186289|NCT03478969|Experimental|Group B|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
11186290|NCT03478969|Experimental|Group C|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
11186291|NCT03478956|Experimental|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
11186292|NCT03478956|Experimental|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
11186293|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
11186294|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
11186295|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
11186296|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
11186297|NCT03478917||Arm 1|Subjects previously enrolled onto protocol 05-H-0019 who were hospitalized with vasoocclusivecrisis.
11186298|NCT03478904|Experimental|A/ Sequence AB|Enzalutamide capsule (Treatment A) followed byenzalutamide liquid (Treatment B)
11186299|NCT03478904|Experimental|B/Sequence BA|Enzalutamide liquid (Treatment B) followed byenzalutamide capsule (Treatment A)
11186300|NCT03478891|Experimental|Group 1: 5 mg/kg IV|Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
11186301|NCT03478891|Experimental|Group 2: 25 mg/kg IV|Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
11186302|NCT03478891|Experimental|Group 3: 50 mg/kg IV|Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.
11186303|NCT03478878|Experimental|Participants|Participants with reticular pseudodrusen
11186304|NCT03478865|Experimental|Participants|Participants with age-related macular degeneration
11186305|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
11186306|NCT03478839||CRF completion|Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.
11186307|NCT03478826||ILD|250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
11186310|NCT03478813|Experimental|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
11186311|NCT03478813|No Intervention|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
11186312|NCT03478800|Experimental|High school football players and acupuncture|50 healthy high school football players without active musculoskeletal injury
11186313|NCT03478787|Experimental|Risankizumab|Risankizumab administered by subcutaneous (SC) injection.
11186314|NCT03478787|Active Comparator|Secukinumab|Secukinumab administered by subcutaneous (SC) injection.
11186315|NCT03478774|Active Comparator|Control|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, continuous videolaryngoscopy will be performed.
11186316|NCT03478774|Experimental|High flow|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
11186317|NCT03478774|Experimental|medium flow|These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
11186318|NCT03478774|Experimental|low flow|These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
11186319|NCT03478774|Experimental|minimal flow|These patients will receive a standard tracheal tubes after induction of general anesthesia, with 100% Oxygen and Minimum-flow 0.25l/min. The measurement period is 15 or 30 minutes.
11186320|NCT03478748|Active Comparator|one-to-one dental health education|Conventional oral health education programme that mainly focuses at child level, which has been the normal practice at the Ministry of Health, were provided to the control participants.
11186321|NCT03478748|Experimental|anticipatory guidance technique|Anticipatory guidance technique were applied where appropriate dental health education (according to the children's milestones) were provided to mothers and their children.
11186322|NCT03478735|Experimental|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
11186323|NCT03478735|Active Comparator|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
11186324|NCT03478722||Maintenance Hemodialysis Patients|Protein meal, stable isotope amino acid infusion
11186325|NCT03478722||Control Subjects|Protein meal, stable isotope amino acid infusion
11186326|NCT03478709||Volume expansion|
11186327|NCT03478709||norepinephrine|
11186328|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
11186329|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
11186330|NCT03478683|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
11186331|NCT03478683|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
11186332|NCT03478670||ADA-SCID subjects treated with Strimvelis|Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy
11186333|NCT03478657|Experimental|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
11186334|NCT03478644|Experimental|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
11186335|NCT03478644|Placebo Comparator|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
11186336|NCT03478631|Experimental|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
11186337|NCT03478631|Active Comparator|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
11186338|NCT03478618|Active Comparator|Group R|30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative.
11186339|NCT03478618|Active Comparator|Group L|30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative.
11186340|NCT03478605|Experimental|Olanzapine|Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;
11186341|NCT03478605|Active Comparator|Aprepitant|Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;
11186342|NCT03478592|Experimental|reference technique slow freezing|In reference technique slow freezing arm, embryon will be frozen with the conventional slow freezing procedure with the Freezal device apply a slow decreasing in temperature with moderate cryoprotector concentration
11186343|NCT03478592|Experimental|vitrification technique|In vitrification technique arm, embryon will be frozen with automated vitrification system
11186344|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
11186345|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
11186346|NCT03478553||People with IPF|
11186347|NCT03478553||Family members without IPF|
11186348|NCT03478527|Experimental|verum condition probiotics|The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
11186349|NCT03478527|Placebo Comparator|placebo condition|In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
11186350|NCT03478514|Experimental|Single Arm|"All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.
~Ibrutinib will be administered at 560 mg oral continuously."
11186351|NCT03478501|Experimental|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
11186352|NCT03478501|No Intervention|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
11186353|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.
~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
11186354|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
11186355|NCT03478475|Experimental|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
11186356|NCT03478475|Placebo Comparator|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
11186357|NCT03478462|Experimental|CLR 131|CLR 131 intravenous administration
11186358|NCT03478449|Experimental|Fine sorting lymph node group|
11186359|NCT03478449|No Intervention|Regional sorting lymph node group|
11186360|NCT03478436|Other|fed group|14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
11186361|NCT03478436|Other|fasting group|14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
11186362|NCT03478423|Experimental|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.
~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
11186363|NCT03478423|Experimental|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.
~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
11186364|NCT03478423|Experimental|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.
~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
11186365|NCT03478410|Other|Atrial fibrillation|An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
11186366|NCT03478410|Other|Control|An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
11186367|NCT03478397|Active Comparator|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
11186368|NCT03478397|No Intervention|Usual Care|Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
11186369|NCT03478384|Experimental|Coaching group|Patient coaching
11186370|NCT03478384|No Intervention|Control group|Control group - no additional coaching provided
11186371|NCT03478371|Sham Comparator|Marketed Tampon D|Regular absorbency tampon
11186372|NCT03478371|Sham Comparator|Marketed Tampon M|Regular absorbency tampon
11186373|NCT03478371|Sham Comparator|Marketed Tampon T|Regular absorbency tampon
11186374|NCT03478371|Sham Comparator|Marketed Tampon V|Regular absorbency tampon
11188550|NCT03463785||Chinese|Chinese mild or moderate OSA patients
11186375|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
11186376|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
11186377|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
11186378|NCT03478358|Experimental|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
11186379|NCT03478345|Experimental|THRIVE Study|
11186380|NCT03478332|Active Comparator|Treatment group|The aim of the arm is to test if the addition of Yangxinshi pills to the conventional coronary heart disease medicine will improve the exercise tolerance of the coronary heart disease
11186381|NCT03478332|Placebo Comparator|Control group|The patients of the control group are treated with conventional coronary heart disease medicine plus the placebos-Yangxinshi simulant
11186382|NCT03478319|Experimental|Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
11186383|NCT03478319|Experimental|Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
11186384|NCT03478319|Experimental|Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
11186385|NCT03478319|Experimental|Cohort 4|ACE-2494 or placebo 1.0 mg/kg SC Day 1
11186386|NCT03478319|Experimental|Cohort 5|ACE-2494 or placebo 2.0 mg/kg SC Day 1
11186387|NCT03478319|Experimental|Cohort 6|ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1
11186388|NCT03478306|Active Comparator|Arm 1|Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
11186389|NCT03478306|Placebo Comparator|Arm 2|Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
11186390|NCT03478293|Experimental|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
11186391|NCT03478280|Active Comparator|Brodalumab|Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
11186392|NCT03478280|Placebo Comparator|Placebo|Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
11186393|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
11186394|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
11186395|NCT03478254||Influenza Vaccination|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status.
11186396|NCT03478254||Pneumococcal Vaccination|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Pneumococcal Vaccination status.
11186397|NCT03478254||Hepatitis B Virus (HBV) Vaccination|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Hepatitis B Virus (HBV) status.
11186398|NCT03478241|Active Comparator|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
11186399|NCT03478241|Active Comparator|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
11186400|NCT03478241|Active Comparator|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
11186401|NCT03478228|Experimental|Multi-Sensory Training (MST)|Multi-Sensory Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
11186402|NCT03478228|Active Comparator|Wrist Stabilisation Training (WT)|Wrist Stabilisation Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
11186403|NCT03478215|Experimental|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.
~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
11186404|NCT03478215|Placebo Comparator|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
11186405|NCT03478202|Experimental|Open Label RELEASE Supplement|
11186406|NCT03478176||Patients|
11186407|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
11186408|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
11186409|NCT03478150|Experimental|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol and applied in the cavity, where the ethanol evaporates, while the zinc oxide nano-particles infiltrate into the carious floor of the cavity.
11186410|NCT03478150|Experimental|laser diode|Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
11186411|NCT03478137|Experimental|CPAP intervention|Over the course of 4-7 months, participants will have to wear the CPAP every night, at least 4 hours per night.
11186412|NCT03478137|No Intervention|Control 1|Eligible participants who declined to participate in the study. Their main study visit data will be used to compare with the intervention group.
11186413|NCT03478137|No Intervention|Control 2|Eligible participants who were not approached, hence not given the opportunity to accept or decline. Their main study visit data will be used to compare with the intervention group.
11186414|NCT03478124||PSP patients|Patients suffering from Progressive Supranuclear Palsy (PSP)
11186415|NCT03478124||PD Patients|Patients suffering from Parkinson's disease (PD)
11186416|NCT03478111|Experimental|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.
~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
11186417|NCT03478111|Active Comparator|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.
~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
11186418|NCT03478098|Experimental|10 Roux-en-Y Gastric Bypass patients|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
11186419|NCT03478098|Experimental|10 control subjects|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
11186420|NCT03478085|Active Comparator|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
11186421|NCT03478085|Experimental|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by >50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
11186422|NCT03478085|Placebo Comparator|Control|Patients will be advised to walk independently.
11186423|NCT03478059|Experimental|Mild Traumatic Brain Injury|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.
~Subjects with mTBI residuals will be gently progressed through exercise stations in an individually tailored fashion."
11186424|NCT03478059|Other|Healthy Control|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.
~In addition to providing comparison data, the healthy control, athletic 18-34 year old subjects will be used to identify levels and intensity of progressions of dual-task training stations appropriate for highly trained athletes and military personnel recovering from concussion."
11186425|NCT03478046|Experimental|Obese individuals|Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
11186426|NCT03478033|Active Comparator|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.
~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
11186427|NCT03478033|Experimental|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.
~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W<50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
11186428|NCT03478020|Experimental|Pre-Treatment, Treatment Cycles A & B|"Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.
~Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.
~Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days"
11186429|NCT03478007|No Intervention|Usual Treatment|Usual standard of care (exercises)
11186430|NCT03478007|Experimental|Intervention Technology Only|Exercises with technology alone
11186431|NCT03478007|Experimental|Intervention Technology Plus Coaching|Exercises with technology plus coaching
11186459|NCT03477851|Placebo Comparator|Placebo|Patients randomized to receive 0,9% sodium hydrochloride solution 5ml i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
11186460|NCT03477851|Experimental|Tramadol|Patients randomized to receive 100mg of Tramadol hydrochloride in 5ml 0,9% sodium hydrochloride i.m. (gluteus muscle) after spinal anesthesia, simultaneously with the sciatic nerve block.
11188551|NCT03463785||Dutch|Dutch mild or moderate OSA patients
11186432|NCT03477994|Active Comparator|dexmedetomidine group|"Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
~+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur."
11186433|NCT03477994|Sham Comparator|clonidine group|In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
11186434|NCT03477981|Other|Study cohort|Participants will receive standard white bread for two weeks and then alginate bread for two weeks. All participants will receive the bread in the same order.
11186435|NCT03477968||PE|Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.
11186436|NCT03477968||DVT|Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.
11186437|NCT03477955|Active Comparator|Peek Group|Patients that received PEEK interspinous spacer
11186438|NCT03477955|Active Comparator|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
11186439|NCT03477955|Active Comparator|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
11186440|NCT03477942|Experimental|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
11186441|NCT03477942|Experimental|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
11186442|NCT03477929|Experimental|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
11186443|NCT03477929|Experimental|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
11186444|NCT03477916|Other|Control (Placebo FMT and cellulose)|
11186445|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
11186446|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
11186447|NCT03477916|Experimental|FMT + prebiotic fiber|
11186448|NCT03477903|Experimental|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
11186449|NCT03477903|Experimental|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
11186450|NCT03477903|Experimental|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
11186451|NCT03477903|Active Comparator|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
11186452|NCT03477890|Active Comparator|Intervention group (coronary function test results disclosed)|Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter >=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
11186453|NCT03477890|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored.
11186454|NCT03477877|Experimental|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
11186455|NCT03477877|Active Comparator|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
11186456|NCT03477864|Experimental|Arm A (REGN2810, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
11186457|NCT03477864|Experimental|Arm B (ipilimumab, SBRT, surgery)|Participants receive ipilimumab via intraprostatic injection on day 1 of week 1, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
11186458|NCT03477864|Experimental|Arm C (REGN2810, ipilimumab, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 as in Arm A and ipilimumab as in Arm B. Participants also undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
11186492|NCT03477630|Experimental|Platelet Rich Plasma|Infiltration injected 8 cc per session, 4 sessions, 1 session every 15 days.
11186461|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
11186462|NCT03477825|Placebo Comparator|Placebo|"Group A: Placebo group (n = 10)
~Supplement appearing similar to Herbal formulations
~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.
~Dose: subjects in this group will take 4 placebo tablets per day"
11186463|NCT03477825|Experimental|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)
~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)
~Each tablet contains 500 mg of R. cordifolia per tablet."
11186464|NCT03477825|Experimental|Triphala|"Group C: Triphala group (n= 10)
~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)
~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula
~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
11186465|NCT03477812||Healthy children|Healthy children 7-14 years of age.
11186466|NCT03477812||Nocturnal enuresis with polyuria|Children with nocturnal enuresis and polyuria aged 7-14 years.
11186467|NCT03477812||Nocturnal enuresis without polyuria|Children without nocturnal enuresis and polyuria aged 7-14 years.
11186468|NCT03477799|Active Comparator|Active|anodal stimulation over the right dlPFC
11186469|NCT03477799|Placebo Comparator|Sham|sham stimulation over the right dlPFC
11186470|NCT03477786|Active Comparator|tight BP|"Interventions: anti-hypertension drug prescription by physician and case management by health educator.
~Blood pressure is targeted at 120/80 mmHg in the tight BP control group."
11186471|NCT03477786|Placebo Comparator|usual BP|"Interventions: The physicians follow their usual care patterns to prescribe anti-HT drugs.
~Blood pressure is targeted at < 140/90 mmHg in the usual BP control group."
11186472|NCT03477773|Experimental|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
11186473|NCT03477773|No Intervention|Control|Continue with their normal habitual lifestyle over the 6-week intervention
11186474|NCT03477747|Experimental|Resistance Training Microcurrent|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of microcurrent after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
11186475|NCT03477747|Sham Comparator|Resistance Training Shadow|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of sham comparator after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
11186476|NCT03477747|Experimental|Endurance Training Microcurrent|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
11186477|NCT03477747|Sham Comparator|Endurance Training Shadow|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.
~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
11186478|NCT03477734|Experimental|CS1 & heart monitor - AF patients|Males and females diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
11186479|NCT03477734|Active Comparator|CS1 & heart monitor -Healthy volunteers|Males and females not diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
11186480|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
11186481|NCT03477721||Group without cancer cachexia (TB)|
11186482|NCT03477708||Study group|TCCO2 monitoring
11186483|NCT03477708||Control group|Routine monitoring
11186484|NCT03477695|Experimental|Upright device|Ambulatory use of the Upright device
11186485|NCT03477682|Experimental|Early Ambulation Group|The patient will remain on bed rest for one day following surgery and will be encouraged to be out of bed and ambulating on the second day following surgery.
11186486|NCT03477682|No Intervention|Standard Group|The patient will remain on bed rest for five days following surgery and will be encouraged to be out of bed and ambulating on the sixth day following surgery.
11186487|NCT03477669|Experimental|chamomile/probiotic arm|Infant will receive 5 drops of the study product once per day with a feeding at midday.
11186488|NCT03477669|Placebo Comparator|Placebo of chamomile/probiotic arm|Infant will receive 5 drops of a placebo product once a day at midday.
11186489|NCT03477656|Experimental|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption according to the initial isoagglutinin titer.
11186490|NCT03477656|Experimental|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis according to the initial isoagglutinin titer.
11186491|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between 01/01/2015 to 01/04/2018
11186494|NCT03477617|Experimental|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
11186495|NCT03477617|Active Comparator|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
11186496|NCT03477604|Experimental|MicroStent and Standard PTA|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
11186497|NCT03477604|Active Comparator|Standard PTA|
11186498|NCT03477591|Experimental|Evidence + PDA|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
11186499|NCT03477591|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
11186500|NCT03477591|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
11186501|NCT03477578||FoG+|Parkinsonian patients with Freezing of Gait
11186502|NCT03477578||FoG-|Parkinsonian patients withou Freezing of Gait
11186503|NCT03477565|Experimental|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.
~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
11186504|NCT03477565|No Intervention|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
11186505|NCT03477552|Experimental|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
11186506|NCT03477552|Active Comparator|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
11186507|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Participants receive IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab course 2, participants undergo ASCT.
~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, participants receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
11186508|NCT03477526|Experimental|COPD patients (GOLD stage III-IV)|
11186509|NCT03477526|Active Comparator|IPF patients|
11186510|NCT03477513|Experimental|Single Arm|Dose-escalated radiation therapy
11186511|NCT03477500|Experimental|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.
~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.
~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.
~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
11186512|NCT03477500|Active Comparator|Alemtuzumab|Alemtuzumab 12 mg iv daily on 5 consecutive days at first alemtuzumab treatment cycle, followed by 3 consecutive days at the second alemtuzumab treatment cycle 12 months later.
11186513|NCT03477487|Experimental|Lowest dose|The lowest dose of XT-150 in the escalation schedule
11186514|NCT03477487|Experimental|Second dose|The 2nd dose of XT-150 in the escalation sequence
11186515|NCT03477487|Experimental|Third dose|The 3rd dose of XT-150 in the escalation sequence
11186516|NCT03477487|Experimental|Highest dose|The highest dose of XT-150 in the escalation sequence
11186517|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
11186518|NCT03477448|Active Comparator|PPD group|"This group will include 20 patients who will be treated with IL injection of PPD at a dose of 10 IU (0.1 ml) supplied an insulin syringe in the largest wart.
~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions"
11186519|NCT03477448|Active Comparator|Bleomycin group|"This group will include 20 patients who will be treated with IL injection of bleomycin.
~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions, if needed."
11186520|NCT03477435|Experimental|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
11186521|NCT03477435|Experimental|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
11186522|NCT03477422|Experimental|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|"CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was an Experimental drug in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. It was administered twelve hourly through intravenous route as infusion over 30 minutes. The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the Principal Investigator (PI).
~Interventions:
~Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)
~Drug: Matching Placebo"
11186581|NCT03477019|Other|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
11186523|NCT03477422|Active Comparator|Meropenem|"Meropenem was the active comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg. It was administered eight hourly through intravenous route as infusion over 30 minutes.The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the PI.
~Interventions:
~Drug: Meropenem
~Drug: Matching Placebo"
11186524|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
11186525|NCT03477396|Experimental|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11186526|NCT03477383||Adult patients|Adult patients (18 years or older) undergoing heart transplantation
11186527|NCT03477383||Pediatric patients|Pediatric patients (0-17 years) undergoing heart transplantation
11186528|NCT03477344|Active Comparator|Dexmédétomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
11186529|NCT03477344|Placebo Comparator|Sodium Chloride 0,9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
11186530|NCT03477318||Patients undergoing screening colonoscopy|Patients undergoing first-time colonoscopy using white light with at least 1 polyp resected.
11186531|NCT03477305|Experimental|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
11186532|NCT03477292|Experimental|Long duration of antibiotics|14 days of Colistin
11186533|NCT03477292|Active Comparator|Short duration of antibiotics|7 days of Colistin
11186534|NCT03477279|No Intervention|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
11186535|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
11186536|NCT03477279|No Intervention|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
11186537|NCT03477266|Experimental|Mouth dissolving mosapride|Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
11186538|NCT03477266|Placebo Comparator|Placebo mouth dissolving tablets|Dummy identical tablets taken in the same way
11186539|NCT03477253|Active Comparator|LC within the first 3 days of disease|
11186540|NCT03477253|Active Comparator|LC after the first 3 days of disease|
11186541|NCT03477227|Experimental|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
11186542|NCT03477227|Active Comparator|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
11186543|NCT03477214||Normal|No UI, no OAB conditions. Transvaginal biomechanical and electromyography mapping will be completed.
11186544|NCT03477214||Urinary incontinence|Urinary incontinence conditions. Transvaginal biomechanical and electromyography mapping will be completed.
11186545|NCT03477214||Overactive bladder|Overactive bladder conditions
11186546|NCT03477201|Experimental|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Intervention: 30 patients will undergo a robotic assisted laparoscopic inguinal hernia repair. This will be done using the DaVinci Robotic Platform by Intuitive Surgical. This an accepted safe method of repairing inguinal hernia. This platform uses special robotic ports produced and supplied by Intuitive Surgical required to dock the machine to the patient. Monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
11186547|NCT03477201|Active Comparator|Standard Laparoscopic inguinal hernia repair|Intervention: 30 patients will undergo a laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia. This platform uses standard laparoscopic ports. In our institution we use plastic ports made by Covidien, Boulder, CO. The operation will require two 5mm VersaPort (Covidien) and a Hassan Port. As in the robotic arm, monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
11186548|NCT03477188|Experimental|Somatosensorial and Vestibular Exercises Group|This group of patients received patients with acute stroke. It will be applied somatosensorial and vestibular rehabilitation additional conventional therapy
11186549|NCT03477188|Active Comparator|Conventional Group|This Group patients received patient with acute stroke. It will be applied classical physiotherapy and conventional exercises.
11186550|NCT03477175|Experimental|Cohort A : Lenvatinib|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
11186551|NCT03477175|Experimental|Cohort B: Lenvatinib plus Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
11186580|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
11186552|NCT03477175|Experimental|Cohort C: Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo.
11186553|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
11186554|NCT03477149|Experimental|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
11186555|NCT03477136||First group: semen parameter showing normospermic|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
11186556|NCT03477136||second group: semen parameter asthenozoospermic|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
11186557|NCT03477136||Third group: semen parameter oligozoospermic|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
11186558|NCT03477136||Forth groupsemen parameter: astheno-teratozoospermic,|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
11186559|NCT03477136||Fifth group semen parameter: oligo asthenoteratozoospermia|"group will include 30 male
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
11186560|NCT03477123|Experimental|Intervention|Walking therapy with Exo-H2 exoskeleton
11186561|NCT03477123|No Intervention|Control|Group receiving conventional walking therapy without robotic exoskeleton
11186562|NCT03477110|Experimental|Treatment (temozolomide, radiation, NovoTTF-200A device)|Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11186563|NCT03477097|No Intervention|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
11186564|NCT03477097|Experimental|Control group w/ social network intervention|Subjects only received the intervention of social network.
11186565|NCT03477097|Experimental|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
11186566|NCT03477097|Experimental|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
11186567|NCT03477097|Experimental|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
11186568|NCT03477097|Experimental|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
11186569|NCT03477097|Experimental|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
11186570|NCT03477097|Experimental|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
11186571|NCT03477097|Experimental|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
11186572|NCT03477097|Experimental|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
11186573|NCT03477097|Experimental|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
11186574|NCT03477097|Experimental|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
11186575|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
11186576|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
11186577|NCT03477058|Experimental|WO 3308 cosmetic product for topical use|WO 3308 is used to treat acute or chronic pruritus
11186578|NCT03477045|Active Comparator|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
11186579|NCT03477045|Experimental|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
11186582|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
11186583|NCT03477019|Other|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
11186584|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
11186585|NCT03477006|No Intervention|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
11186586|NCT03476993|Experimental|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
11186587|NCT03476980|Active Comparator|Randomized to Umbilical Cord Milking at birth|Milking the umbilical cord towards the infant at a speed of 20cm/2seconds at birth.
11186588|NCT03476980|Active Comparator|Randomized to Delayed Cord Clamping at birth|Delayed clamping of the umbilical cord at birth.
11186589|NCT03476967||Pretreatment x Posttreatment|The group was evaluated through non-invasive complementary examinations before laser therapy and at the 1-year follow-up visit to analyze possible optical disc alterations that may occur after retinal panretinal photocoagulation in patients with proliferative diabetic retinopathy.
11186590|NCT03476941|Experimental|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
11186591|NCT03476941|Placebo Comparator|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
11186592|NCT03476928|Experimental|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
11186593|NCT03476928|Experimental|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
11186594|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
11186595|NCT03476902|Experimental|Integrated Mobile Treatment|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
11186596|NCT03476889|Experimental|Intervention|Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
11186597|NCT03476889|Active Comparator|Control|Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
11186598|NCT03476889|No Intervention|Breastfed reference|Exclusively breastfed from birth to study completion
11186599|NCT03476876|Experimental|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
11186600|NCT03476876|Active Comparator|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
11186601|NCT03476863|Experimental|Alveolar Recruitment Maneuver|
11186602|NCT03476863|Active Comparator|Conventional mechanical ventilation|
11186603|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
11186604|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
11186605|NCT03476837|Experimental|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample and WCG's carbon monoxide.
11186606|NCT03476837|Active Comparator|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
11186607|NCT03476811|No Intervention|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
11186608|NCT03476811|Active Comparator|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
11186609|NCT03476811|Placebo Comparator|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
11186610|NCT03476798|Experimental|Bevacizumab + Rucaparib|
11186611|NCT03476785|Experimental|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
11186612|NCT03476785|Placebo Comparator|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
11186613|NCT03476772||A|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % via caudal route to achieve post operative analgesia
11186614|NCT03476772||B|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % plus 0.1 mg nalbuphine via caudal route to achieve post operative analgesia
11186615|NCT03476759|Active Comparator|Tubal adhesiolysis|laparoscopic tubal adhesiolysis and\or tuboplasty
11186616|NCT03476759|Active Comparator|IVF/ICSI|These patients will undergo IVF/ICSI
11186617|NCT03476746|Experimental|LEO 90100 foam|"LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g).
~Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total).
~Pivotal part: To be decided based on the result of the pilot part"
11186618|NCT03476746|Active Comparator|Dovobet® ointment|"Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total).
~Pivotal part: To be decided based on the result of the pilot part"
11211326|NCT03306329|Experimental|DNS-7801 (high-dose)|
11186625|NCT03476681|Experimental|NEO-201|Subjects will receive the assigned dose of NEO-201 intravenously, once every 2 weeks for a total of 4 doses (57 days). This course will be repeated in the absence of disease progression or unacceptable toxicity.
11186626|NCT03476668|Active Comparator|RPD PD patients|Right-side affected PD patients. Intervention: MIRT
11186627|NCT03476668|Active Comparator|LPD PD patients|Left-side affected (LPD) PD patients. Intervention: MIRT
11186628|NCT03476655||Participants with Chronic Lymphocytic Leukemia (CLL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
11186629|NCT03476655||Participants with Mantle Cell Lymphoma (MCL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
11186630|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
11186631|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
11186632|NCT03476629|Experimental|Combined Training|Combined Training with 2 types of physical activity
11186633|NCT03476629|Experimental|Standard Training|Physical activity with aerobic exercise
11186634|NCT03476629|Experimental|Respiratory Muscle Training|Respiratory muscle performance
11186635|NCT03476616|Active Comparator|Eplerenone (-based therapy) arm|"Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.
~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.
~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
11186636|NCT03476616|Active Comparator|Valsartan (-based therapy) arm|"Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.
~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.
~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
11186637|NCT03476590|No Intervention|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
11186638|NCT03476590|Experimental|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -> (7') summary visit (12th month after the enrolment) performed by physician.
~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
11186639|NCT03476564|Experimental|intervention group|intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
11186640|NCT03476564|No Intervention|comparison group|. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
11186641|NCT03476499|Experimental|Planned skin flap procedure|"Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent.
~Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure.
~The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care.
~The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.
~One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery.
~One set of intra-operative Images that will be taken intra-operatively following the mastectomy.
~One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care."
11186642|NCT03476486|Experimental|Treatment|The hand that was subject to thread carpal tunnel release surgery
11186643|NCT03476486|No Intervention|Control|The hand that was not treated
11186644|NCT03476460|Experimental|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
11186645|NCT03476460|Active Comparator|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
11186646|NCT03476447|Active Comparator|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
11186647|NCT03476447|Active Comparator|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
11186648|NCT03476447|Active Comparator|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
11186649|NCT03476447|Placebo Comparator|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
11186650|NCT03476434|No Intervention|group A (HR-WLE)|Two tandem colonoscopies: first inspection was on high-resolution white-light endoscopy from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection also on HR-WLE.
11186651|NCT03476434|Experimental|group B (HR_CE)|two tandem colonoscopies: first inspection was on HR-WLE from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection with panchromoendoscopy on indigo carmine.
11186652|NCT03476421||R0 hepatectomy|Those HCC patients operated with standard R0 hepatectomy
11186653|NCT03476421||R1par hepatectomy|Those HCC patients operated with R1par hepatectomy
11186654|NCT03476421||R1vasc hepatectomy|Those HCC patients operated with R1vasc hepatectomy
11186655|NCT03476421||R1par+R1vasc hepatectomy|Those HCC patients operated with both R1par and R1vasc hepatectomy
11186656|NCT03476408|Experimental|Single Group Correlation|Correlation between these topics.
11186657|NCT03476382|Experimental|Experimental Group|Participants use active Ultrasound Bone Growth Stimulator device according to Investigational Protocol.
11186658|NCT03476369|Experimental|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
11186659|NCT03476369|Active Comparator|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
11186660|NCT03476356|Experimental|Group L|This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.
11186661|NCT03476356|Active Comparator|Group C|This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.
11186662|NCT03476343|Experimental|MRI for Neonates|MRI
11186663|NCT03476330|Experimental|Quercetin|All patients will be treated with oral quercetin.
11186664|NCT03476317|Experimental|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
11186665|NCT03476317|Placebo Comparator|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
11186666|NCT03476317|No Intervention|Group 2|
11186667|NCT03476304|Experimental|Semi-direct composite endocrown restorations|
11186668|NCT03476304|Active Comparator|Post retained direct composite restoration|
11186669|NCT03476304|Active Comparator|Post retained ceramic restoration|
11186670|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
11186671|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
11186672|NCT03476278||regional, questionnaire|patients who underwent surgery under regional anesthesia.
11186673|NCT03476265|Experimental|Ineffective Esophageal Motility and GERD|Patients with gastroesophageal reflux disease (GERD) refractory to proton pump inhibitors (PPI) and ineffective esophageal motility (IEM) according to the Chicago classification v3.0.
11186674|NCT03476252|Experimental|patients|ST elevation myocardial infarction
11186675|NCT03476239|Experimental|Blinatumomab|"Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders.
~In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment.
~In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks."
11186676|NCT03476226|Experimental|Group 1|"The research team will provide the intervention to subjects. Intervention: The nursing-driven Cognitive Dysfunction Coping Strategy Teaching Sheet and provide education as to its use.
~QOL survey administered"
11186677|NCT03476226|No Intervention|Group 2|Provide current standard of education for cognitive dysfunction. QOL survey administered
11186678|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
11186679|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
11186680|NCT03476200|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy consisting of fourteen weekly group sessions, one hour and a half each, directed by two clinical psychologist.
11186681|NCT03476200|No Intervention|Control Group|Control Group with no intervention.
11186682|NCT03476187|Experimental|µCor wearers|Wear the µCor device
11186683|NCT03476174|Experimental|Pembrolizumab and HD Interleukin 2|Pembrolizumab 200 mg IV over 30 minutes; Day 1 of each cycle 3 weeks (21 days) for 2 cycles. IL-2 600,000 IU/kg2 IV over 15 minutes every 8 hours for up to 14 doses over 5 days; Days 1-5 = Cycle 1; 9 days of rest in between; Days 15-19 = Cycle 2
11186684|NCT03476161|Other|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive
~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
11186685|NCT03476161|Other|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive
~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
11186686|NCT03476148|Experimental|Interactive Device Rehabilitation|
11186687|NCT03476148|Active Comparator|Inpatient Rehabilitation|
11186688|NCT03476135|Experimental|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
11187436|NCT03471208|Experimental|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
11186689|NCT03476135|Experimental|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
11186690|NCT03476122||Disease Group|The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
11186691|NCT03476122||Control Group|The control group will receive Colonoscopy
11186692|NCT03476109|Active Comparator|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).
~Non responders will be switched to mepolizumab arm."
11186693|NCT03476109|Active Comparator|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).
~Non responders will be switched to omalizumab arm."
11186694|NCT03476096||Control|healthy pregnant women
11186695|NCT03476096||Pre-eclampsia|high-risk pregnant women
11186696|NCT03476083|Experimental|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
11186697|NCT03476083|Active Comparator|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
11186698|NCT03476070||AYA cancer patients|Patients (aged between 15-39) diagnosed with breast cancer, lymphoma or germ cell tumor
11186699|NCT03476070||Healthy controls|Healthy controls
11186700|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
11186701|NCT03476044|Active Comparator|Group Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
11186702|NCT03476044|Active Comparator|Group Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
11186703|NCT03476031||study group|patients with hepatitis c nephropathy detected by lab and renal biopsy
11186704|NCT03476018|Placebo Comparator|Placebo|
11186705|NCT03476018|Experimental|0.2 microgram Z-100|
11186706|NCT03476018|Experimental|2 microgram Z-100|
11186707|NCT03476018|Experimental|20 microgram Z-100|
11186708|NCT03476005|Active Comparator|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
11186709|NCT03476005|No Intervention|Historical controls|no extra training provided
11186710|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.
~Core needle biopsy performed ≥14 days before the microwave breast investigation"
11186711|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.
~No prior biopsy"
11186712|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.
~Core needle biopsy performed ≥14 days before the microwave breast investigation"
11186713|NCT03475966|Experimental|Prehabilitation|Exercise, nutrition and relaxation techniques all beginning four weeks prior to surgery date.
11186714|NCT03475966|Active Comparator|Rehabilitation|Exercise, nutrition and relaxation techniques all beginning immediately after surgery.
11186715|NCT03475953|Experimental|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186716|NCT03475953|Experimental|Phase 2 : cohort A Regorafenib + Avelumab|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186717|NCT03475953|Experimental|Phase 2 : cohort B Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186718|NCT03475953|Experimental|Phase 2 : cohort C Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186719|NCT03475953|Experimental|Phase 2 : cohort D Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186720|NCT03475953|Experimental|Phase 2 : cohort E Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186721|NCT03475953|Experimental|Phase 2 : cohort F Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186722|NCT03475953|Experimental|Phase 2 : cohort G Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
11186723|NCT03475914||Psoriasis vulgaris|Pathological conditions stable for at least 1 month before collection. One punch biopsy from each patient, was taken from a big reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
11186724|NCT03475914||Psoriasis guttate|One punch biopsy from each patient, was taken from a small reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
11186725|NCT03475914||Healthy skin of psoriasis vulgaris|Healthy skin area of 2mm2 belonging to the left gluteus from patients affected by psoriasis vulgaris
11186726|NCT03475914||Healthy skin of psoriasis guttate|Healthy skin area of 2mm2 belonging to the left gluteus rom patients affected by psoriasis guttate
11186727|NCT03475901|Experimental|Virtualy Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
11186728|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
11186729|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization
11186730|NCT03475888|Active Comparator|Group C|Patients with an untreated CTO
11186731|NCT03475875|Experimental|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
11186732|NCT03475875|Experimental|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
11186733|NCT03475862|Experimental|PTI-821 Manipulated|oxycodone 40 mg capsule
11186734|NCT03475862|Active Comparator|Oxycodone|Oxycodone 40 mg IR tablet crushed
11186735|NCT03475862|Active Comparator|OxyContin|Oxycodone ER 40 mg tablet crushed
11186736|NCT03475862|Placebo Comparator|Placebo|Matching placebos for experimental and active comparator arms
11186737|NCT03475862|Experimental|PTI-821 Non-manipulated|Oxycodone 40 mg non-manipulated
11186738|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
11186739|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
11186740|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
11186741|NCT03475836|Placebo Comparator|Placebo|Vegetable oil
11186742|NCT03475836|Active Comparator|High-dose mint essential oil|100 μL Mentha piperita essential oil (in vegetable oil)
11186743|NCT03475836|Active Comparator|Low-dose mint essential oil|50 μL Mentha piperita essential oil (in vegetable oil)
11186744|NCT03475823|Placebo Comparator|Placebo control|Inert comparator indistinguishable from active interventions
11186745|NCT03475823|Active Comparator|Active control|240 mg ginkgo biloba
11186746|NCT03475823|Experimental|Low dose sideritis scardica|475 mg sideritis scardica
11186747|NCT03475823|Experimental|High dose sideritis scardica|950 mg sideritis scardica
11186748|NCT03475810|Experimental|VR GROUP|Patients watches 3D documentary videos on virtual reality glasses
11186749|NCT03475810|Active Comparator|midazolam|Patients do not watch virtual reality videos but will be administered iv sedative drugs before spinal attempt.
11186750|NCT03475797|Experimental|Occipital Nerve Stimulation (ONS)|Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
11186751|NCT03475797|Active Comparator|Optimal Medical Management (OMM)|Optimal Medical Management according to what is done in routine clinical practice
11186752|NCT03475784|Experimental|Restricted fluid therapy group|Restrictive fluid therapy: this group will not receive fluid pre-load, and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2mL/Kg/hour.
11186753|NCT03475784|Active Comparator|Liberal fluid therapy group|Liberal fluid therapy: this group will receive fluid pre-load (5 mL/Kg), and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
11186754|NCT03475758|No Intervention|chemotherapy without goserelin|these patients will receive their chemotherapy without addition of Goserelin
11186755|NCT03475758|Experimental|chemotherapy with goserelin|these patients will receive their chemotherapy with addition of Goserelin
11186756|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
11186757|NCT03475745||Control|Healthy controls
11186758|NCT03475732|Experimental|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
11186759|NCT03475719|Active Comparator|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
11186760|NCT03475719|Experimental|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
11186761|NCT03475706|Experimental|Solabegron immediate release tablets low dose|
11186762|NCT03475706|Experimental|Solabegron immediate release tablets high dose|
11186763|NCT03475706|Placebo Comparator|Placebo Comparator|
11186764|NCT03475693|Experimental|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
11186765|NCT03475693|Placebo Comparator|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
11186766|NCT03475680|Experimental|"1)  MBP and oral antibiotics  group"|"Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
~Sennosides colonic preparation (X-PREP) :
~1 per day, on day -2 and day -1.
~Gentamycin :
~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.
~Ornidazole :
~g per day (2 tablet per day), on day -2 and day -1; In tablets."
11186767|NCT03475680|Placebo Comparator|"2)  MBP alone  group"|"Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
~Sennosides colonic preparation (X-PREP) :
~1 per day, on day -2 and day -1.
~Placebo for oral gentamycin:
~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole
~1g per day (2 tablet per day) on day -2 and day -1."
11186768|NCT03475680|Experimental|"3)  Oral antibiotics alone  group"|"Oral Gentamycin Oral Ornidazole
~Gentamycin :
~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.
~Ornidazole :
~g per day (2 tablet per day), on day -2 and day -1; In tablets."
11186834|NCT03475238||Cohort for nursing care|Patients in ICU under oxygen and/or mechanical ventilation and/or vasoactive drugs and/or non-invasive ventilation
11187437|NCT03471208|Active Comparator|Freehand|Dental implant surgery via conventional freehand
11186769|NCT03475680|Placebo Comparator|"4)  No preparation  group"|"Oral placebo Gentamycin Oral placebo Ornidazole
~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1
~- Placebo for oral ornidazole : Same presentation as oral ornidazole
~1g per day (2 tablet per day) on day -2 and day -1"
11186770|NCT03475654|Experimental|technology-assisted rehabilitation|The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
11186771|NCT03475654|Active Comparator|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
11186772|NCT03475641|Active Comparator|The current standard anesthesia|Standard treatment during procedure
11186773|NCT03475641|Experimental|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
11186774|NCT03475628|Experimental|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
11186775|NCT03475615|Experimental|SOXP|
11186776|NCT03475615|Active Comparator|SOX|
11186777|NCT03475602||Cyclophosphamide|Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
11186778|NCT03475602||Cyclosporin|Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
11186779|NCT03475589|Other|single group|
11186780|NCT03475576|Other|all participants|The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian.
11186781|NCT03475563||Patients with coronary artery disease|(coronary artery disease)
11186782|NCT03475550|Active Comparator|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
11186783|NCT03475550|Active Comparator|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
11186784|NCT03475537|Experimental|the treatment of transcranial direct current stimulation|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
11186785|NCT03475524|Experimental|study Metformin 1000 mg|
11186786|NCT03475524|Experimental|study Metformin 500 mg|
11186787|NCT03475524|Placebo Comparator|control group|
11186788|NCT03475485|Experimental|ID-Capsules- Active|"Randomly-assigned ingestions of ID-Capsules containing ingestible sensors (ID-Capsule- Active) while wearing the ID-Cap Reader (Wearable Sensor) under direct observation
~• Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded."
11186789|NCT03475485|Placebo Comparator|ID-Capsules- Inactive|"Randomly-assigned ingestions of ID-Capsules containing no ingestible sensors while wearing the ID-Cap Reader under direct observation
~• Subjects will also ingest empty placebo capsules that do not contain ingestible sensors. In the absence of an ingested sensor, no signal is received by the Reader after the capsule is ingested, and the ingestion event is not recorded."
11186790|NCT03475459|Experimental|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
11186791|NCT03475446|Placebo Comparator|sham tES healthy elderly|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
11186792|NCT03475446|Placebo Comparator|sham tES MCI|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
11186793|NCT03475446|Placebo Comparator|sham tES AD|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
11186794|NCT03475446|Experimental|real anodal tDCS healthy elderly|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11186795|NCT03475446|Experimental|real anodal tDCS MCI|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11186796|NCT03475446|Experimental|real anodal tDCS AD|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11186835|NCT03475225|Experimental|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
11186797|NCT03475446|Experimental|real tACS healthy elderly|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11186798|NCT03475446|Experimental|real tACS MCI|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11186799|NCT03475446|Experimental|real tACS AD|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11186800|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
11186801|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
11186802|NCT03475420||National Cancer Database|Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
11186803|NCT03475407|Experimental|Treatment Group|Ozurdex intravitreal injection
11186804|NCT03475394|Active Comparator|Group 1 (Chlorhexidine gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 1% chlorhexidine gel administered in subsequent visits.
11186805|NCT03475394|Experimental|Group 2 (Morus alba gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 16% Morus alba gel administered in subsequent visits.
11186806|NCT03475394|Placebo Comparator|Group 3 (Placebo)|Non surgical periodontal treatment at baseline and no gel is applied.
11186807|NCT03475381||Orkambi treated patients|All patients with CF who started ivacaftor+lumacaftor outside of a clinical trial between January 22nd 2016 and January 22nd 2017.
11186808|NCT03475368|Experimental|Vegetarian diet|People randomized to interventional groups will take a vegetarian diet (i.e. without animal products, except milk and eggs)
11186809|NCT03475368|Experimental|Low carbs|People randomized to interventional groups will take a low carbs diet (i.e. with a limited amount of carbohydrates).
11186810|NCT03475368|Active Comparator|Mediterranean diet|People randomized to interventional groups will take a mediterranean diet (i.e. with low glycemic index carbohydrates and vegetables).
11186811|NCT03475355|Experimental|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
11186812|NCT03475355|Experimental|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
11186813|NCT03475355|Experimental|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
11186814|NCT03475355|Experimental|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
11186815|NCT03475355|Active Comparator|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.
~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
11186816|NCT03475355|Active Comparator|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.
~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
11186817|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
11186818|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
11186819|NCT03475329||adenoidectomy with bilateral partial tonsillectomy|
11186820|NCT03475329||adenoidectomy with complete unilateral tonsillectomy|
11186821|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
11186822|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
11186823|NCT03475303|Experimental|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
11186824|NCT03475290|Experimental|Self-Efficacy and Perceived Social Support|
11186825|NCT03475290|Experimental|Perceived Social Support and Self-Efficacy|
11186826|NCT03475290|Active Comparator|Self-Efficacy|
11186827|NCT03475290|Active Comparator|Perceived Social Support|
11186828|NCT03475277||Volunteers|"Participants will receive an IV infusion of ketamine (~.05mg/kg and 0.5mg/kg) or placebo.
~Ketamine is an FDA-approved dissociative anesthetic. The study doses are in the subanesthetic range. During the infusion, an ACLS-certified psychiatrist or anesthesiologist will provide continuous monitoring.
~Afterwards, patients will be monitored on-site by an ACLS-certified MD or highly skilled research nursing staff, and an on-call emergency response team for 4 hours (ketamine's half-life is 15 min; 4 hrs= 16 half-lives)."
11186829|NCT03475264||Healthy|Healthy Participants
11186836|NCT03475225|Placebo Comparator|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
11186837|NCT03475212|Experimental|Virus specific T cell lines (VSTs) against three viruses|The study will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, activated using overlapping peptide libraries spanning immunogenic antigens from CMV, adenovirus and EBV, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy.
11186838|NCT03475199|Experimental|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
11186839|NCT03475199|No Intervention|Control group|General dietary recommendations.
11186840|NCT03475186|Experimental|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
11186841|NCT03475173|Experimental|Laser Speckle Blood Flow Group|
11186842|NCT03475160|Active Comparator|Sildenafil Citrate|Sildenafil Citrate vaginal suppositories: 25 mg every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
11186843|NCT03475160|Placebo Comparator|Placebo|Placebo vaginal suppositories: every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
11186844|NCT03475147|Active Comparator|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
11186845|NCT03475147|Experimental|eyeFusion Patients|Scotoma subjects aged 18-80.
11186846|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
11186847|NCT03475121|Experimental|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
11186848|NCT03475121|Experimental|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
11186849|NCT03475121|Experimental|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
11186850|NCT03475121|Experimental|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
11186851|NCT03475108|Experimental|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
11186852|NCT03475108|Other|Standard Diabetes Care Group|Patients receive standard diabetes care for one year. They receive a community health worker for the second year (as part of a crossover trial).
11186853|NCT03475095|Experimental|LDH patients|"ribs and bones Tuina therapy According to the diagnostic criteria ofvertebral dislocation,determine the position,degree and direction of the dislocation,assess the activity of the affected vertebrae.Treated with combining Tuina of muscle-loosing and bone-setting such as reinforcing ribs，kneading and plucking method,20 min every treatment,twice a week for a total time of 4 weeks."
11186854|NCT03475082|Placebo Comparator|Placebo TENS|30 minute TENS treatment where the stimulation ramps slowly to zero after 45 seconds. The lights/display on the unit are identical to the Active unit.
11186855|NCT03475082|Active Comparator|High Frequency TENS|30 minute TENS treatment at 100 Hertz (HZ). Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
11186856|NCT03475082|Active Comparator|Alternating frequency TENS|30 minute TENS treatment with a pre programed mode alternating from 4 Hz and 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
11186857|NCT03475082|Active Comparator|Modulated frequency TENS|30 minute TENS treatment at a pre programmed mode that ramps between 4 and 125 HZ over 12 seconds. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
11186858|NCT03475082|Active Comparator|High frequency TENS - increasing intensity|30 minute TENS treatment at 100 HZ. Intensity set at initial strong but comfortable setting on day one as above, then subjects asked for possible increases in intensity every 5 minutes on all five days.
11186859|NCT03475069|Experimental|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
11186860|NCT03475069|Experimental|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
11186861|NCT03475069|Experimental|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
11186862|NCT03475056|Experimental|cAd3-Marburg vaccine at 1x10(10) PU dose|Twenty (20) subjects enrolled in Group 1 will receive a 1x10(10) PU dose of cAd3-Marburg vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
11186863|NCT03475056|Experimental|Ad3-Marburg vaccine at 1x10(11) PU dose|Twenty (20) subjects enrolled in Group 2 will receive a 1x10(11) PU dose of cAd3-Marburg vaccine administered intramuscular (IM) with needle and syringe in a volume of 1 mL.
11186864|NCT03475043|Experimental|Auditory training: temporal contrasts|Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.
11186865|NCT03475043|Active Comparator|Auditory training: non-temporal contrasts|Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.
11186866|NCT03475043|No Intervention|Passive control group|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
11186867|NCT03475030|No Intervention|Usual Care|Patients receive usual care and can continue using their existing pharmacy.
11186868|NCT03475030|Experimental|Smart Pillbox|Patients receive pre-filled medication trays from Curant Health Pharmacy or the Brigham and Women's Hospital Outpatient Pharmacy. The smart pillbox in which pre-filled medication trays are housed provide automated medication reminders.
11186869|NCT03475017|Active Comparator|Supplement A|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
11186870|NCT03475017|Placebo Comparator|Supplement B|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
11186871|NCT03475004|Experimental|Combination Therapy|"Cohort A: Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.
~Cohort B: Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles."
11186872|NCT03474991|Active Comparator|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
11186873|NCT03474991|Placebo Comparator|Placebo|oral placebo matched to the product described above
11186874|NCT03474978|Experimental|Upper Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity
11186875|NCT03474978|Experimental|Lower Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity
11186876|NCT03474965|Experimental|Crizanlizumab|SEG101 (crizanlizumab) administered on Week 1 Day 1, Week3 Day 1 and Day 1 of every 4-week cycle
11186877|NCT03474952|Experimental|Remote ischemic preconditioning (RIPC)|Intervention is remote ischemic preconditioning (RIPC) consists of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) and subsequent 5-min reperfusion applied to upper arm.
11186878|NCT03474952|Sham Comparator|Control (Sham-RIPC)|Intervention is Sham-RIPC (ischemia pressure < 10 mmHg) applied to upper arm.
11186879|NCT03474939|Active Comparator|MIDAZOLAM|Patients receive midazolam 7,5mg night before and 60 minutes prior to surgery as part of preanesthetic medication
11186880|NCT03474939|Placebo Comparator|PLACEBO|Patients receive 1000mg Glucose tablets night before and 60 minutes prior to surgery during premedication
11186881|NCT03474926|Experimental|Routine lymph node dissection (LND) during nephroureterectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
11186882|NCT03474926|Active Comparator|LND for lymph nodes enlargement found before or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery.
11186883|NCT03474913||Standard MRI first|Patients will have a standard of care MRI, then consent to study participation and have an upright MRI.
11186884|NCT03474913||MRIs in random order|Patients will consent to participate in the study, then do two MRIs in random order.
11186885|NCT03474900|Experimental|PLGA implant, Bioretec ltd. Finland|Treatment with biodegradable elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
11186886|NCT03474900|Active Comparator|Titanium elastic stable nail|Treatment with titanium elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
11186887|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
11186888|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
11186889|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
11186890|NCT03474887||PHYSI-Throat+CONTROL-Throat|"Patients choosing to seek primary care through physical consultation with chief complaint sore throat.
~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat."
11186891|NCT03474887||PHYSI-Resp+CONTROL-Resp|"Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.
~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza."
11186892|NCT03474887||PHYSI-Dysuria+CONTROL-Dysuria|"Patients choosing to seek primary care through physical consultation with chief complaint dysuria
~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria."
11186893|NCT03474874|Other|Collagen Dressing and Comparator|NeoMatriX Collagen Dressing and Comparators - positive control and normal saline will be applied to the absorbent pad portion of the exclusive dressing.
11186894|NCT03474861|Experimental|Combination therapy|The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).
11186895|NCT03474848|Experimental|HABIT|Protocol of 90-hour of Hand-Arm Bimanual Intensive Training - 6 hours/day; 5 days/week, for 3 weeks
11186896|NCT03474848|Active Comparator|Conventional Occupational Therapy (OT)|Provision of 2 sessions/week (45 minutes), for 3 weeks
11186897|NCT03474835|Other|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
11186898|NCT03474835|No Intervention|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
11186899|NCT03474822|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 30 patients in each type cancer and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
11186903|NCT03474770|Experimental|BIS-001ER|Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
11186904|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
11186905|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
11186906|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
11186907|NCT03474744|Experimental|Experimental Arm|Copanlisib 60 mg i.v. fixed dose days 1,8,15 Rituximab 375 mg/m2 day 1 i.v.
11186908|NCT03474731|Experimental|Diabetes Self Management Program only|group education classes of the Diabetes Self-Management Program, (DSMP)
11186909|NCT03474731|Experimental|Tailored Patient Navigation (PN) only|assisting patients in navigation to physician offices, allowing for standard of care to follow.
11186910|NCT03474731|Experimental|DSMP AND Tailored Patient Navigation|Both group education classes and patient navigation
11186911|NCT03474718|Experimental|Group A|At the baseline visit subjects will be randomized to either group A or group B. Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
11186912|NCT03474718|Experimental|Group B|At the baseline visit subjects will be randomized to either group A or group B. Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
11186913|NCT03474705|Experimental|Eccentric Training Group|Eccentric training of the upper trapezius muscles. The intervention will consist of ten sessions of 25-30 minutes (twice a week over 5 consecutive weeks) of eccentric exercises of the shoulder muscles, as neural activation increases after 4 weeks of eccentric training. The total duration of the intervention will be 2 hours and a half.
11186914|NCT03474679|Experimental|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
11186915|NCT03474666|Active Comparator|Strict Glycemic Control Group|Intravenous insulin as described by Keegan and Cols. 2010.
11186916|NCT03474666|Active Comparator|Standard Glycemic Control Group|Subcutaneous insulin as instititional protocol.
11186917|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
11186918|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
11186919|NCT03474640|Experimental|Toripalimab 80 mg repeat dose every 14 days|3-6 subjects (Part A)
11186920|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 14 days|3-6 subjects (Part A)
11186921|NCT03474640|Experimental|Toripalimab 480 mg repeat dose every 14 days|3-6 subjects (Part A)
11186922|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 21 days|240 subjects (Part B)
11186923|NCT03474627|Active Comparator|Non-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
11186924|NCT03474627|Experimental|PLGA-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
11186925|NCT03474614|Experimental|treatment group|A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
11186926|NCT03474614|Other|Control Group|A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
11186927|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
11186928|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
11186929|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
11186930|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
11186931|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
11186932|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
11186933|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
11186934|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
11186935|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:
~Teaching about the treatment program
~Teaching important ideas about recovery
~Increasing knowledge about specific problems about addiction
~Demonstrating new ways of coping with skills designed to fit each participant"
11186936|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:
~Teaching about the treatment program
~Teaching important ideas about recovery
~Increasing knowledge about specific problems about addiction
~Demonstrating new ways of coping with skills designed to fit each participant PLUS
~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
11186937|NCT03474575|Other|COPD patient|Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation
11186938|NCT03474562|Experimental|Duowell Tab|Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks
11186939|NCT03474562|Active Comparator|Monorova Tab + Amlopin Tab|Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks
11186940|NCT03474549|Experimental|Tigertriever revascularization device|Mechanical thrombectomy with Tigertriever
11211327|NCT03306329|Placebo Comparator|Placebo|
11186941|NCT03474523|Experimental|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
11186942|NCT03474523|Active Comparator|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
11186943|NCT03474510|Experimental|EXPAREL|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
11186944|NCT03474510|Active Comparator|interscalene nerve block|Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
11186945|NCT03474497|Experimental|Pembrolizumab/IL-2/Radiotherapy|All patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.
11186946|NCT03474484||np-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
11186947|NCT03474484||p-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission
11186948|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
11186949|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
11186950|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
11186951|NCT03474458|Experimental|Experimental intervention|doxycycline (100 mg bid)
11186952|NCT03474458|Active Comparator|Control intervention|Standard of care therapy
11186953|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
11186954|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
11186955|NCT03474432|Other|Optical Coherence Tomography|Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.
11186956|NCT03474393|No Intervention|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
11186957|NCT03474393|Experimental|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
11186958|NCT03474380|Experimental|Intervention|"Implementation of iHI-FIVES program
~Intervention: Behavioral: iHI-FIVES"
11186959|NCT03474380|No Intervention|Usual Care|Pre-implementation before iHI-FIVES program
11186960|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
11186961|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
11186962|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.
~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
11186963|NCT03474328|Experimental|Treatment arm|
11186964|NCT03474315||CHF and CIED patients|600 CHF patients with ICD or CRT admitted to regulatory ambulatory visit.
11186965|NCT03474302|Experimental|Physical Activity|The intervention will be a 12-week community-based physical activity promotion program
11186966|NCT03474302|Active Comparator|Successful Aging|Those randomized to the successful aging group will receive health information pertinent to African Americans over the 12 weeks
11186967|NCT03474289|Experimental|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
11186968|NCT03474289|Experimental|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
11186969|NCT03474276|Active Comparator|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).
~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
11186970|NCT03474276|Active Comparator|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
11186971|NCT03474276|Active Comparator|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
11186972|NCT03474263|Experimental|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
11186973|NCT03474237||Non-functioning adrenal incidentaloma|patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
11186974|NCT03474237||Pheochromocytoma|patients who were diagnosed with pheochromocytoma biochemically or histologically
11186975|NCT03474237||Primary aldosteronism|patients who were diagnosed with primary aldosteronism by saline loading test
11186976|NCT03474237||Adrenal cushing syndrome|patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
11186977|NCT03474237||Adrenocortical carcinoma|patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
11186978|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
11186979|NCT03474211||vaccinated|
11186980|NCT03474211||non vaccinated|
11186981|NCT03474198|Active Comparator|Standard TB Management Strategy|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only
11186982|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen B|"TRUNCATE-TB Management Strategy: 8 weeks* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment.
~*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment.
~Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid"
11186983|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen C|"TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B.
~Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine"
11186984|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen D|"TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B.
~Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin"
11186985|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen E|"TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B.
~Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline"
11186986|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
11186987|NCT03474172|Experimental|Genuine Tuina|Participants will receive genuine tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
11186988|NCT03474172|Sham Comparator|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
11186989|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Ecocardiogrphy, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
11186990|NCT03474146|Experimental|Ocimum sanctum extract as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
11186991|NCT03474146|Active Comparator|Chlorhexidine Gluconate as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
11186992|NCT03474146|Placebo Comparator|Propylene Glycol as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
11186993|NCT03474133|Experimental|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
11186994|NCT03474120||IVF treatment group|Patients treated with IVF. IVF promotion process, ovulation, fertilization, embryo quality, transplantation and final outcome were collected after the treatment cycle was completed.
11186995|NCT03474120||No IVF treatment group|the patients who did not have received IVF treatment .Patients were followed up to collect hormone levels, ultrasound results.
11186996|NCT03474107|Experimental|Arm A: enfortumab vedotin|Participants will receive enfortumab vedotin (EV) on days 1, 8 and 15 of each 28 day cycle.
11186997|NCT03474107|Active Comparator|Arm B: chemotherapy|Participants will receive either docetaxel, vinflunine or paclitaxel as determined prior to participant's randomization. Participants will receive the assigned drug on day 1 of every 21 day cycle. Based on the outcome of interim analysis, participants will be evaluated for eligibility for crossover extension (COE) EV treatment at the discretion of the participant and investigator. In the COE, participants will receive EV on days 1, 8 and 15 of each 28 day cycle. Participants who do not participate in the COE will continue to follow Arm B protocol procedures.
11186998|NCT03474094|Experimental|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
11186999|NCT03474094|Experimental|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
11187000|NCT03474094|Active Comparator|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
11187001|NCT03474081|Experimental|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI at a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
11189111|NCT03460054||Mesangioproliferative Glomerulonephritis (MPGN)|Biopsy-Proven MPGN
11187002|NCT03474081|Experimental|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium at a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
11187003|NCT03474055|Experimental|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
11187004|NCT03474055|Experimental|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
11187005|NCT03474055|Experimental|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
11187006|NCT03474055|Active Comparator|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
11187007|NCT03474042|Experimental|GLPG2737|GLPG2737 will be provided as capsules for oral use.
11187008|NCT03474042|Placebo Comparator|Placebo|Placebo will be provided as capsules for oral use.
11187009|NCT03474029|Experimental|6 weeks of daily rifapentine (6wP)|Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks
11187010|NCT03474029|Active Comparator|12-16 week rifamycin-based regimen|"A 12-16 week rifamycin-based regimen available at the participant's site:
~Rifapentine and Isoniazid weekly for 12 weeks (3HP) or Rifampin and Isoniazid daily for 12 weeks (3HR) or Rifampin daily for 16 weeks (4R)"
11187011|NCT03474016||Patients with early breast cancer(30)|
11187012|NCT03474016||Patients with advanced breast cancer(30)|
11187013|NCT03474016||Patients with benign breast diseases(20)|
11187014|NCT03474016||Apparently healthy females as a control group(36)|
11187015|NCT03473990|Active Comparator|Laboratory HIT|Supervised (Laboratory HIT) exercise in the lab up to 4 times per week for 4 weeks
11187016|NCT03473990|Active Comparator|Home HIT|Unsupervised (Home HIT) exercise at home up to 4 times per week for 4 weeks
11187017|NCT03473990|No Intervention|Control Group|No intervention
11187018|NCT03473977|Experimental|Benralizumab|This Arm is a subcutaneous dose of 30 mg of Benralizumab
11187019|NCT03473977|Placebo Comparator|Placebo|This Arm is a subcutaneous dose of 30 mg of Placebo
11187020|NCT03473964||Treatment|The study intervention is the observation of study subjects who have received H.P. Acthar® Gel (adrenocorticotrophic hormone), 40 units twice weekly injections in patients who have sarcoid uveitis and to assess it's effectiveness by measuring changes the degree of aqueous and vitreous inflammatory cells present, the degree of aqueous flare, and changes in visual acuity, macular thickness, intraocular pressure and quality of life measures assessed by using the National Eye Institute Visual Function Questionnaires (VFQ-25)
11187021|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
11187022|NCT03473938||Spatz3 AIGB|Patients with implanted Spatz3 AIGB balloon.
11187023|NCT03473925|Experimental|Navarixin Dose A + Pembrolizumab|Participants receive navarixin Dose A via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
11187024|NCT03473925|Experimental|Navarixin Dose B + Pembrolizumab|Participants receive navarixin Dose B via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
11187025|NCT03473912||RA patients|before or after medication
11187026|NCT03473912||Systemic sclerosis patients|before or after medication
11187027|NCT03473912||IgG4 RD patients|before or after medication
11187028|NCT03473912||Lupus patients|before or after medication
11187029|NCT03473899|Active Comparator|rESWT + RP|Device: rESWT
11187030|NCT03473899|Placebo Comparator|sham-rESWT + RP|Device: sham-rESWT
11187031|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
11187032|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
11187033|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.
~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:
~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).
~There will be a break of about 30 minutes.
~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
11187034|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.
~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:
~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).
~There will be a break of about 30 minutes.
~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
11187035|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.
~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
11187036|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.
~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
11187037|NCT03473834|Experimental|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
11187038|NCT03473834|Active Comparator|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
11187039|NCT03473821|No Intervention|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
11187040|NCT03473821|Experimental|MOTIFS|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS). In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
11187041|NCT03473808|Experimental|therapy + vibration|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
11187042|NCT03473795||healthy participants and participants diagnosed with NCDs|This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls.
11187043|NCT03473782||Voiding Diary|
11187044|NCT03473782||Urodynamics Correlation Study|
11187045|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
11187046|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
11187047|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.
~Patients will receive rogaratinib plus atezolizumab combination treatment."
11187048|NCT03473756|Placebo Comparator|Placebo + Atezolizumab|Part B:Patients will receive placebo in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
11187049|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part B|Part B:Patients will receive rogaratinib in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
11187050|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
11187051|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
11187052|NCT03473730|Experimental|Cohort 1 Renal (daratumumab, biopsy, surgery)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter during weeks 1-8. Treatment repeats every week for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo biopsy, nephrectomy, or metastasectomy during weeks 10-12. Patients may then restart treatment with daratumumab beginning 2 weeks after biopsy or 4-6 weeks after nephrectomy or metastasectomy. Cycles repeat every 2 weeks for 4 months and then monthly for 1 year in the absence of disease progression or unacceptable toxicity.
11187053|NCT03473730|Experimental|Cohort 2 Bladder (daratumumab)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter beginning at week 1. Cycles repeat every week for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
11187054|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
11187055|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
11187056|NCT03473704|Experimental|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
11187057|NCT03473704|Placebo Comparator|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
11187058|NCT03473691|Experimental|Glembatumumab vedotin (GV)|
11187059|NCT03473678|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
11187060|NCT03473678|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
11187061|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
11187062|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
11187063|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
11187064|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
11187065|NCT03473652|Other|Adapted walking platform|
11187094|NCT03473457|Experimental|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
11187095|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
11187096|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
11187097|NCT03473418|Experimental|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
11187066|NCT03473639|Experimental|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.
~The dose combinations include:
~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine
~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
11187067|NCT03473626|Experimental|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
11187068|NCT03473626|Experimental|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
11187069|NCT03473613|Active Comparator|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
11187070|NCT03473613|Active Comparator|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
11187071|NCT03473600|Experimental|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
11187072|NCT03473600|Active Comparator|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
11187073|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
11187074|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
11187075|NCT03473574|Experimental|Arm A|Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
11187076|NCT03473574|Experimental|Arm B|Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
11187077|NCT03473574|Other|Arm C|Gemcitabine in combination with Cisplatin
11187078|NCT03473574|Experimental|Arm D|Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
11187079|NCT03473574|Experimental|Arm E|Durvalumab in combination with Gemcitabine and Cisplatin
11187080|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|
11187081|NCT03473548|Experimental|Portable Sleep Monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
11187082|NCT03473535|Experimental|Smartphone Assisted PST|Emergency departments providing the option to refer men who self-harm to a service that will deliver smartphone-assisted PST.
11187083|NCT03473522|Experimental|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
11187084|NCT03473522|Sham Comparator|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
11187085|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
11187086|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
11187087|NCT03473496|Experimental|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
11187088|NCT03473483|Experimental|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
11187089|NCT03473483|Experimental|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
11187090|NCT03473483|Experimental|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
11187091|NCT03473470|No Intervention|not warmed|Not warming system
11187092|NCT03473470|Active Comparator|warmed group 1|forced air warming and warmed intravenous fluids
11187093|NCT03473470|Active Comparator|warmed group 2|warmed intravenous fluids
11187098|NCT03473418|Active Comparator|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
11189112|NCT03460054||Minimal Change Disease (MCD)|Biopsy-Proven MCD
11187099|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
11187100|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
11187101|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
11187102|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
11187103|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
11187104|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
11187105|NCT03473366|Experimental|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
11187106|NCT03473366|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
11187107|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
11187108|NCT03473340|Experimental|Pirfenidone Capsule|"Method of Administration: Oral (capsule)
~Dosing:
~Days 1 through 7, 267 mg three times daily;
~Days 8 through 14, 534 mg three times daily;
~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
11187109|NCT03473340|Placebo Comparator|Placebo Capsule|"Method of Administration: Oral (capsule)
~Dosing:
~Days 1 through 7, 267 mg three times daily;
~Days 8 through 14, 534 mg three times daily;
~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
11187110|NCT03473314|Experimental|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
11187111|NCT03473301|Experimental|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
11187112|NCT03473301|Experimental|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
11187113|NCT03473301|Active Comparator|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
11187114|NCT03473288|Active Comparator|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
11187115|NCT03473288|Placebo Comparator|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
11187116|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
11187117|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).
~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
11187118|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.
~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
11187119|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
11187120|NCT03473262||EMPA|Empagliflozin 25 mg/day
11187121|NCT03473262||INS|Insulin Glargine dose-titrated
11187122|NCT03473249|No Intervention|Retrospective Review|Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).
11187123|NCT03473249|No Intervention|Prospective Observation|Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.
11187124|NCT03473249|Other|Contrast-Enhanced Ultrasound using Lumason|Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.
11187125|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187126|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187127|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187128|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187129|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187130|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187131|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187132|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
11187133|NCT03473223|Experimental|CSL112|Apolipoprotein A-I [human]
11187134|NCT03473223|Placebo Comparator|Placebo|25% albumin solution diluted to 4.4%
11187135|NCT03473210|Active Comparator|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
11187136|NCT03473210|Active Comparator|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
11187137|NCT03473197|Other|Single Cohort (Healthy Volunteers)|Diacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
11187138|NCT03473184|Experimental|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
11187139|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
11187140|NCT03473158|Active Comparator|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
11187141|NCT03473158|Active Comparator|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
11187142|NCT03473145|Active Comparator|Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive one in-person health coaching sessions and 6 phone counseling sessions.
11187143|NCT03473145|Experimental|Reduce Sitting|Participants in the Reduce Sitting condition will receive an intervention aimed at reducing daily sitting time. This group will receive five in-person health coaching sessions and two phone counseling sessions.
11187144|NCT03473145|Experimental|Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive five in-person health coaching sessions and two phone counseling sessions.
11187145|NCT03473132|Experimental|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
11187146|NCT03473119||Control|Healthy individuals
11187147|NCT03473119||Asthma|Asthma acute exacerbations
11187148|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
11187149|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
11187150|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
11187151|NCT03473119||CAP|Community-acquired pneumonia
11187152|NCT03473106|Experimental|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
11187153|NCT03473106|No Intervention|Non Surgical Side|Contralateral side (Control Thigh).
11187154|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
11187155|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
11187156|NCT03473080|Other|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
11187157|NCT03473067|Experimental|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
11187158|NCT03473067|Active Comparator|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
11187159|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
11187160|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
11187161|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
11187162|NCT03473028|Active Comparator|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
11187163|NCT03473028|Active Comparator|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
11187164|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
11187165|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
11187166|NCT03473002|Placebo Comparator|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
11187167|NCT03473002|Experimental|SeVRSV|1 x 10^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
11187168|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
11187169|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
11187170|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
11187171|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
11187172|NCT03472976|Experimental|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
11187201|NCT03472833|Active Comparator|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.
~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
11187173|NCT03472976|Experimental|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
11187174|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
11187175|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
11187176|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
11187177|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
11187178|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
11187179|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
11187180|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
11187181|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
11187182|NCT03472950|Experimental|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
11187183|NCT03472950|Experimental|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
11187184|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
11187185|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
11187186|NCT03472924|Experimental|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
11187187|NCT03472924|No Intervention|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
11187188|NCT03472885|Experimental|Group 1: 100 mg ACH-0144471 TID + Eculizumab|100 mg ACH-0144471 TID to start in combination with eculizumab.
11187189|NCT03472885|Experimental|Group 2: 150 mg ACH-0144471 TID + Eculizumab|150 mg ACH-0144471 TID to start in combination with eculizumab.
11187190|NCT03472885|Experimental|Group 3: 200 mg ACH-0144471 TID + Eculizumab|200 mg ACH-0144471 TID to start in combination with eculizumab.
11187191|NCT03472885|Experimental|Group 4: Optimal Dose of ACH-0144471 TID + Eculizumab|Optimal dose (100 mg, 150 mg or 200 mg, as determined from Groups 1-3) of ACH-0144471 TID to start, in combination with eculizumab.
11187192|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
11187193|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
11187194|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
11187195|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
11187196|NCT03472846|Active Comparator|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
11187197|NCT03472846|Active Comparator|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
11187198|NCT03472846|Active Comparator|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
11187199|NCT03472846|Active Comparator|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
11187200|NCT03472833|Experimental|High-dose|"Intervention with high dose oral vitamin D3 supplementation.
~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
11187202|NCT03472820|Experimental|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
11187203|NCT03472820|No Intervention|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
11187204|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva
~Collection of a tumor sample taken before the participation of the patient in study
~Collection of blood sample if tumor sample is not available"
11187205|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
11187206|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
11187207|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
11187208|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
11187209|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
11187210|NCT03472755|Other|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
11187211|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
11187212|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
11187213|NCT03472716||Samples|Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).
11187214|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
11187215|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
11187216|NCT03472690|Experimental|Active|0.1 mL, self-administered subcutaneous injection, every second day
11187217|NCT03472690|Placebo Comparator|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
11187218|NCT03472677|Experimental|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
11187219|NCT03472677|Experimental|Cohort 2|Controlled cooling wrap versus ice pack cooling.
11187220|NCT03472677|Experimental|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
11187221|NCT03472677|Experimental|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
11187222|NCT03472664|Experimental|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of <20 grams total carbohydrates per day.
~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
11187223|NCT03472664|Experimental|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
11187224|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
11187225|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
11187226|NCT03472638|Experimental|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
11187227|NCT03472638|Experimental|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
11187228|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
11187229|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
11187260|NCT03472430|Active Comparator|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
11187438|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
11187230|NCT03472599|Experimental|Genital Nerve Stimulation|Study participants in this arm will use take-home genital nerve stimulation for 24+ months in order to assess its effectiveness at decreasing urinary incontinence. In order to set effective genital nerve stimulation parameters, study participants will undergo clinical urodynamics every 6 months in which sensitivity to and tolerance of electrical stimulation are assessed.
11187231|NCT03472586|Experimental|Treatment (ipilimumab, nivolumab, immunoembolization)|Participants receive ipilimumab IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Participants also undergo immunoembolization on day 2. Courses repeat every 3 weeks for 12 weeks in the absence of disease progression or unacceptable toxicity. Participants with complete response, partial response, or stable disease may receive nivolumab IV over 30 minutes on day 1 and undergo immunoembolization on day 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11187232|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.
~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11187233|NCT03472560|Experimental|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
11187234|NCT03472547|Experimental|Single cohort (Healthy Volunteers)|diacerein 1% ointment
11187235|NCT03472534|Other|study in healthy volunteers|diacerein 1% ointment
11187236|NCT03472521|Experimental|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
11187237|NCT03472521|Placebo Comparator|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
11187238|NCT03472508|Sham Comparator|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
11187239|NCT03472508|Active Comparator|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
11187240|NCT03472508|Active Comparator|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
11187241|NCT03472508|Active Comparator|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
11187242|NCT03472508|Active Comparator|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
11187243|NCT03472508|Active Comparator|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
11187244|NCT03472508|Active Comparator|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
11187245|NCT03472508|Active Comparator|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
11187246|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
11187247|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
11187248|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
11187249|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
11187250|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
11187251|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
11187252|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
11187253|NCT03472482||LBD patients|"patients with Lewy Body Dementia
~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
11187254|NCT03472469|Active Comparator|Treatment Strategy #1 - descending dose arm|Treatment Strategy #1 is the descending dose arm. Inclusion in this arm will involve one of the following 6 drug combinations, and the treating physician will choose strategy. The 6 strategies are: 1. Acetaminophen 1g intravenous (IV)/ per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
11187255|NCT03472469|Active Comparator|Treatment Strategy #2 - escalating dose arm|Treatment Strategy #2 is the escalating dose arm. Inclusion in this arm will involve one of the following 6 drug combinations, and the treating physician will choose strategy. The 6 strategies are: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 4. Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
11187256|NCT03472456||Articaïne|
11187257|NCT03472456||Eugénol|
11187258|NCT03472443|Experimental|Sinew Acupuncture|
11187259|NCT03472443|No Intervention|Waitlist|
11189113|NCT03460041|Placebo Comparator|Control|
11187261|NCT03472430|Sham Comparator|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
11187262|NCT03472417|Active Comparator|Active partial rebreathing device|
11187263|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
11187264|NCT03472404|Experimental|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
11187265|NCT03472404|Active Comparator|Control Group|Brostrom-Gould ankle Ligament reconstruction
11187266|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
11187267|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
11187268|NCT03472378|Experimental|Active Treatment Group|DFN-15
11187269|NCT03472378|Placebo Comparator|Placebo Group|
11187270|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd.
11187271|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continous oral. Study treatment will be started on Day 1 of each 3-week cycle.
11187272|NCT03472352|Experimental|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
11187273|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
11187274|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
11187275|NCT03472326|Experimental|Part 1: Sentinel Cohort 1|Treatment experienced participants will receive open label GS-9131 60 mg (2 x 30 mg tablets) once daily + current failing antiretroviral therapy (ART) regimen for 10 days
11187276|NCT03472326|Experimental|Part 1: Sentinel Cohort 2|Treatment experienced participants will receive open-label GS-9131 180 mg (6 x 30 mg tablets) once daily + current failing ART for 14 days.
11187277|NCT03472326|Experimental|Randomized Cohort (Treatment Arm A: GS-9131)|Participants will receive GS-9131 up to 180 mg once daily + current failing ART regimen for 14 days
11187278|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm B: GS-9131)|Participants will receive GS-9131 up to 180 mg once daily + current failing ART regimen for 14 days
11187279|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm C: GS-9131)|Participants will receive GS-9131 up to 180 mg once daily + current failing ART regimen for 14 days
11187280|NCT03472326|Experimental|Part 1: Randomized Cohort (Treatment Arm D: GS-9131 Placebo)|Participants will receive GS-9131 placebo + current failing ART regimen for 14 days
11187281|NCT03472326|Experimental|Part 2: GS-9131 60 mg + BIC + DRV + RTV Regimen|Participants from Treatment Sentinel Cohort 1 in Part 1 will receive GS-9131 60 mg (2 x 30 mg tablet) + bictegravir (BIC) + darunavir (DRV) + ritonavir (RTV) for 24 weeks
11187282|NCT03472326|Experimental|Part 2: GS-9131 up to 180 mg + BIC + TAF Regimen|Participants from Sentinel Cohort 2 and Randomized Cohort (A-D) in Part 1 will receive GS-9131 up to 180 mg + BIC + TAF for 24 weeks
11187283|NCT03472326|Experimental|Open-label Extension Phase|Participants in Part 2 may have the option to receive open-label GS-9131 + BIC + TAF for an additional 24 weeks or until the product becomes accessible to participants through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
11187284|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
11187285|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
11187286|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
11187287|NCT03472287|Experimental|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
11187288|NCT03472274|Active Comparator|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:
~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
11187289|NCT03472274|Experimental|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
11187290|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
11187291|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
11187292|NCT03472248|Experimental|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
11187293|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
11187294|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
11187295|NCT03472222|Experimental|Arsha Vidya Program|Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays.
11187296|NCT03472209||Group A|ETCO2=26-35 mmHg
11187297|NCT03472209||Group B|ETCO2=36-45 mmHg
11187298|NCT03472196|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.
~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
11189114|NCT03460041|Active Comparator|Magnesium|
11187299|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
11187300|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
11187301|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
11187302|NCT03472170|Experimental|Experimental Arm|"The nutritional supplement used will be bovine lactoferrin, a product marketed according to the regulations of the European Union, and approved by the European Food Safety Agency (EFSA) in 2012, and by the American Agency for Food and Drug Administration ( FDA) in 2013. It will be acquired after purchase from Dicofarm® (Rome, Italy).
~The Hospital Pharmacy Service will provide the established dose of lactoferrin, according to the administration schedule of 150 mg / kg / day (maximum 300 mg / day).
~The treatments will be administered in liquid form, in the least amount possible. The administration of lactoferrin will be carried out enterally, orally or by nasogastric tube.
~The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
11187303|NCT03472170|Placebo Comparator|Control Arm|"Placebo with similar visual and taste characteristics to the nutritional supplement of bovine lactoferrin.
~It will be administered in liquid form, in the least amount possible. The administration of placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
11187304|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.
~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
11187305|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
11187306|NCT03472144|Experimental|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
11187307|NCT03472144|Experimental|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
11187308|NCT03472144|Experimental|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
11187309|NCT03472144|Experimental|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
11187310|NCT03472144|Experimental|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
11187311|NCT03472144|Experimental|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
11187312|NCT03472144|Active Comparator|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
11187313|NCT03472144|Active Comparator|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
11187314|NCT03472144|Active Comparator|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
11187315|NCT03472144|Active Comparator|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
11187316|NCT03472144|Active Comparator|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
11187317|NCT03472144|Active Comparator|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
11187318|NCT03472131|Experimental|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
11187319|NCT03472118|Experimental|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
11187320|NCT03472105|Other|Habitual diet|18 participants were on a habitual diet for 7 days
11187321|NCT03472105|Active Comparator|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
11187322|NCT03472092|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
11187323|NCT03472092|Placebo Comparator|Placebo|The placebo pill will be administered once a day at home, to be taken by mouth.
11187324|NCT03472092|Active Comparator|Amitriptyline|Amitriptyline will be administered once a day at home, to be taken by mouth. Dosage will be weight-based.
11187325|NCT03472092|Active Comparator|Biofeedback-Assisted Relaxation Training (BART)|Biofeedback-Assisted Relaxation Training (BART) is a mind and body based intervention that focuses specifically on mind and body techniques such as deep breathing, muscle relaxation, and guided imagery skills to manage pain.
11187439|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
11187326|NCT03472092|Active Comparator|Cognitive Retraining (CR)|Cognitive Retraining (CR) is a mind and body based intervention that focuses on the use of tests of evidence and other cognitive strategies such as positive coping statements and pleasant activities and mindfulness to manage pain.
11187327|NCT03472066||a group of women who have been conized|Previous conization
11187328|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
11187329|NCT03472053|Experimental|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
11187330|NCT03472053|Experimental|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
11187331|NCT03472040|Experimental|BCX7353 150 mg once daily|
11187332|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 1|
11187333|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 2|
11187334|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 3|
11187335|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 4|
11187336|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 5|
11187337|NCT03472014|Experimental|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
11187338|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
11187339|NCT03472001|Active Comparator|Lecture group|1-hour lecture
11187340|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
11187341|NCT03471988|Experimental|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
11187342|NCT03471988|Active Comparator|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
11187343|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
11187344|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.
~Trainer and Trainee both see the monitor."
11187345|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
11187346|NCT03471936|Other|Acquisition of pressure-volume loops|
11187347|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
11187348|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
11187349|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
11187350|NCT03471910|Experimental|Diosmin|Diosmin 600mg, one tablet once daily
11187351|NCT03471910|Active Comparator|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
11187352|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
11187353|NCT03471897||Controls|Subjects self-reported as healthy
11187354|NCT03471884|Experimental|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
11187355|NCT03471884|Active Comparator|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
11187356|NCT03471871|Experimental|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
11187357|NCT03471871|Experimental|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
11187358|NCT03471871|Experimental|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
11187359|NCT03471871|Experimental|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
11187432|NCT03471247|Experimental|In-Bed Cycle Ergometer + Routine PT|Patients will receive 30 minutes of in-bed cycling once per day, 5 days per week, while they remain in the ICU, for up to a maximum of 28 days. They will also receive routine physiotherapy.
11187617|NCT03469947|No Intervention|Matched Controls|Retrospective matched controls
11187360|NCT03471871|Experimental|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
11187361|NCT03471858|Active Comparator|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline [1]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
11187362|NCT03471858|Active Comparator|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
11187363|NCT03471845|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
11187364|NCT03471832|Experimental|stenfilcon A lens|MyDay contact lens
11187365|NCT03471832|Active Comparator|narafilcon A lens|1-Day Acuvue TruEye
11187366|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
11187367|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
11187368|NCT03471806|Experimental|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
11187369|NCT03471806|Experimental|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
11187370|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
11187371|NCT03471767|Experimental|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
11187372|NCT03471767|Active Comparator|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
11187373|NCT03471754|Experimental|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
11187374|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
11187375|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
11187376|NCT03471728||Irritable Bowel Syndrome|Patients with Irritable Bowel Syndrome with Constipation (IBS-C) who have used linaclotide for the first time
11187377|NCT03471728||Chronic Constipation|Patients with Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time
11187378|NCT03471702|Experimental|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
11187379|NCT03471689|Experimental|Mindfulness|
11187380|NCT03471689|Active Comparator|Positive reappraisal|
11187381|NCT03471676||Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
11187382|NCT03471663|Experimental|D-0502|D-0502
11187383|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
11187384|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
11187385|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
11187386|NCT03471624|Experimental|Tenofovir Alafenamide for 24 months|Subjects on any antiviral treatment for chronic HBV who plan to be switched by their physician to be treated with TAF 25 mg for 24 months.
11187387|NCT03471611|Experimental|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
11187388|NCT03471585|Placebo Comparator|Placebo oral capsule|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the THC arm.
11187433|NCT03471247|Active Comparator|Routine PT|Patients will receive routine physiotherapy interventions per current institutional practice
11187434|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.
~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.
~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
11187435|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
11187389|NCT03471585|Experimental|THC|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the placebo arm.
11187390|NCT03471572||1|Ovarian Cancer
11187391|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
11187392|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
11187393|NCT03471546|Experimental|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
11187394|NCT03471533|Experimental|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.
~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
11187395|NCT03471533|Placebo Comparator|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
11187396|NCT03471520|Experimental|Earplugs and eye masks|
11187397|NCT03471507|Experimental|Bonipar|
11187398|NCT03471507|Active Comparator|Diclofenac topical solution 1.5%|
11187399|NCT03471494||Breast cancer|
11187400|NCT03471494||Gastric cancer|
11187401|NCT03471494||Colon cancer|
11187402|NCT03471468|Experimental|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
11187403|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
11187404|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
11187405|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
11187406|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
11187407|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
11187408|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
11187409|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
11187410|NCT03471429||No Dog|Patient receives standard of care
11187411|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
11187412|NCT03471403||FAP|FAP patients with duodenal adenomas
11187413|NCT03471390|Experimental|ProQuaS 2- Intervention|
11187414|NCT03471377||standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
11187415|NCT03471377||assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
11187416|NCT03471364|Experimental|Arm I (ketoconazole)|Participants apply ketoconazole topically BID on days 1-28.
11187417|NCT03471364|Placebo Comparator|Arm II (placebo)|Participants apply placebo topically BID on days 1-28.
11187418|NCT03471351|Experimental|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
11187419|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
11187420|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
11187421|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
11187422|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
11187423|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
11187424|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
11187425|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
11187426|NCT03471312||treated with placebo drug|will receive placebo drug
11187427|NCT03471286|Experimental|Sub-Protocol A|Epacadostat
11187428|NCT03471273|Other|endoscopic management|
11187429|NCT03471273|Other|follow up|
11187430|NCT03471273|Other|surgery|
11187431|NCT03471260|Experimental|Treatment (venetoclax, ivosidenib, azacitidine)|Participants receive venetoclax PO daily on days 1-14. Participants also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Participants may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11187618|NCT03469934|Experimental|ANB020|ANB020, administration of ANB020
11187440|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
11187441|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
11187442|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
11187443|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
11187444|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
11187445|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
11187446|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
11187447|NCT03471143|Experimental|IV VTS-270 for NPC1 infants|"Phase 1: Dosing frequency will be twice a week administered via a peripherally inserted central catheter (PICC) for six weeks for a total of 12 administrations. Doses 3-12 will occur as an outpatient.
~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6 will receive 500 mg/kg Cohort 2: Subjects 7-12 will receive 1000 mg/kg Subjects who demonstrate significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin:total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open-label phase of six months duration. In the this phase of the study, dosing frequency will be monthly with IV VTS-270 administered via peripheral IV access for six months for a total of six administrations."
11187448|NCT03471130|Experimental|Low dose MT-8554 or placebo to match|Low dose MT-8554
11187449|NCT03471130|Experimental|High dose MT-8554 or placebo to match|High dose MT-8554
11187450|NCT03471117|Active Comparator|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
11187451|NCT03471117|Placebo Comparator|Placebo|Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills
11187452|NCT03471104|Experimental|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
11187453|NCT03471104|No Intervention|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
11187454|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.
~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
11187455|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
11187456|NCT03471078|Experimental|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
11187457|NCT03471078|Placebo Comparator|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
11187458|NCT03471065|Experimental|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV using the SAPIEN 3 Ultra Delivery System
11187459|NCT03471052|Experimental|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
11187460|NCT03471052|No Intervention|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
11187461|NCT03471039|Active Comparator|Active|PACAP-27
11187462|NCT03471039|Placebo Comparator|Placebo|Saline
11187463|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
11187464|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
11187465|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
11187466|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
11187467|NCT03471000|Experimental|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed without sinus lift and augmentation procedure.
11187619|NCT03469934|Placebo Comparator|Placebo|Placebo, administration of Placebo
11187620|NCT03469921||15-17 years old|15-17 years old
11187621|NCT03469921||18-25 years old|18-25 years old
11187468|NCT03471000|Active Comparator|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® [Geistlich AG, Wolhusen, Switzerland]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
11187469|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
11187470|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
11187471|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
11187472|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
11187473|NCT03470974|Experimental|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
11187474|NCT03470974|No Intervention|Control Group|The control group receives usual care and lifestyle education.
11187475|NCT03470961|Experimental|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
11187476|NCT03470961|Active Comparator|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
11187477|NCT03470922|Experimental|Arm A: Relatlimab + Nivolumab|Combination
11187478|NCT03470922|Experimental|Arm B: Nivolumab|Monotherapy
11187479|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
11187480|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
11187481|NCT03470896|Active Comparator|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
11187482|NCT03470896|Active Comparator|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
11187483|NCT03470896|Other|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
11187484|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
11187485|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
11187486|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
11187487|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
11187488|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
11187489|NCT03470844||5-10 years post severe burn injury|"Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
11187490|NCT03470844||2-5 years post severe burn injury|"Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
11187491|NCT03470844||1-2 years post severe burn injury|"Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
11187492|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.
~Interventions:
~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.
~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.
~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.
~Quality of Life Self-Assessment data."
11187493|NCT03470818|Experimental|Intervention group|"Preparatory instructional videos (flipped classroom model)
~32 participants
~Application of a flipped classroom model
~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.
~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
11187622|NCT03469921||26-30 years old|26-30 years old
11187494|NCT03470818|Sham Comparator|Control group|"Sham videos
~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.
~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
11187495|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
11187496|NCT03470792|Experimental|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
11187497|NCT03470792|Active Comparator|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
11187498|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
11187499|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
11187500|NCT03470766|Active Comparator|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
11187501|NCT03470766|Sham Comparator|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
11187502|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
11187503|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
11187504|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
11187505|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
11187506|NCT03470740|Other|intervention group|An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
11187507|NCT03470740|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
11187508|NCT03470727|Experimental|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
11187509|NCT03470714|Experimental|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
11187510|NCT03470714|Active Comparator|Control group|The group in which the participants only perform the the force irradiation experiment.
11187511|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
11187512|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
11187513|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
11187514|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
11187515|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
11187516|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
11187517|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
11187518|NCT03470662|Experimental|experimental group|Care bundle
11187519|NCT03470662|No Intervention|control group|routine care
11187520|NCT03470649|Experimental|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
11187521|NCT03470649|No Intervention|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
11187522|NCT03470636|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
11187523|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
11187524|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
11187525|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
11187526|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
11187527|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
11187528|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
11187529|NCT03470545|Experimental|mavacamten (MYK-461)|
11187530|NCT03470545|Placebo Comparator|Placebo|
11187531|NCT03470532|Experimental|Group A|buccal infiltration of 4% Articaine with epinephrine
11187532|NCT03470532|Active Comparator|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
11187533|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Neurologist
11187534|NCT03470493|Experimental|Participants|ApneaLink Air
11187623|NCT03469921||acute leukemia|acute leukemia
11187624|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
11187535|NCT03470480|Experimental|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
11187536|NCT03470480|Active Comparator|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
11187537|NCT03470480|Sham Comparator|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
11187538|NCT03470480|Sham Comparator|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
11187539|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
11187540|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
11187541|NCT03470441|Experimental|FDY-5301 Low Dose|Anticipated n=20
11187542|NCT03470441|Experimental|FDY-5301 Intermediate Dose|Anticipated n=20
11187543|NCT03470441|Experimental|FDY-5301 High Dose|Anticipated n=20
11187544|NCT03470441|Placebo Comparator|Placebo|Anticipated n=20
11187545|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
11187546|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
11187547|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
11187548|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
11187549|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
11187550|NCT03470402|Experimental|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
11187551|NCT03470402|Active Comparator|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
11187552|NCT03470389|Experimental|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
11187553|NCT03470376|Experimental|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
11187554|NCT03470376|Active Comparator|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
11187555|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia
~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
11187556|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia
~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
11187557|NCT03470350|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
11187558|NCT03470337|Experimental|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
11187559|NCT03470337|Placebo Comparator|Placebo|Placebo equates Phlogenzym but without active ingredients
11187560|NCT03470324|Active Comparator|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
11187561|NCT03470324|Experimental|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
11187562|NCT03470311|Active Comparator|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
11187563|NCT03470311|Placebo Comparator|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
11187564|NCT03470298|Active Comparator|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
11187565|NCT03470298|Active Comparator|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
11187566|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
11187567|NCT03470272|Experimental|Active Device|"Active Device: The FB Professional LED red light therapy system
~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.
~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
11187625|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
11187626|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
11187568|NCT03470259|Experimental|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
11187569|NCT03470259|Experimental|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
11187570|NCT03470259|Experimental|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
11187571|NCT03470259|Experimental|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.
~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.
~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
11187572|NCT03470246|No Intervention|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
11187573|NCT03470246|Experimental|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
11187574|NCT03470246|No Intervention|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
11187575|NCT03470246|Experimental|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
11187576|NCT03470246|No Intervention|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
11187577|NCT03470246|Experimental|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
11187578|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
11187579|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
11187580|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
11187581|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
11187582|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
11187583|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
11187584|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
11187585|NCT03470168|Experimental|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
11187586|NCT03470168|Placebo Comparator|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
11187587|NCT03470155||functional mitral insufficiency op|Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)
11187627|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
11187588|NCT03470142|Active Comparator|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
11187589|NCT03470142|Experimental|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
11187590|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
11187591|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
11187592|NCT03470116|Experimental|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
11187593|NCT03470116|Active Comparator|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
11187594|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
11187595|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
11187596|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
11187597|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
11187598|NCT03470090|Experimental|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
11187599|NCT03470090|Active Comparator|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
11187600|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
11187601|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
11187602|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
11187603|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
11187604|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.
~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.
~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
11187605|NCT03470038|Experimental|NGF condition + Control condition|"All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg
~After 4 weeks:
~All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
11187606|NCT03470038|Experimental|Control condition + NGF condition|"All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg
~After 4 weeks:
~All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
11187607|NCT03470025|Experimental|Psychological Intervention|A weekly combined face to face & telephone-based PI (F-TPI); Psychological Intervention and medical therapy
11187608|NCT03470025|Experimental|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
11187609|NCT03470025|No Intervention|Optimal medical therapy|Patients will receive optimal medical therapy
11187610|NCT03470012|Experimental|Treatment Arm|Investigational tape
11187611|NCT03469999|Experimental|Dysport Injectable Product|All participants will participate in baseline data collection of energy expenditure, gait analysis, and lower limb spasticity assessment. All participants will receive single event multi level chemoneurolysis with Dysport and will have repeat data collection at 4 weeks and 12 weeks post injection.
11187612|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
11187613|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
11187614|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
11187615|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
11187616|NCT03469947|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
11187630|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.
~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
11187631|NCT03469882|Experimental|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.5 g/kg/day of protein and in-bed cycle ergometry exercise.
11187632|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
11187633|NCT03469869|Experimental|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
11187634|NCT03469869|Active Comparator|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
11187635|NCT03469856|Other|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
11187636|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
11187637|NCT03469830|Experimental|SSCP & SPMS|"The smart scar care pad (SCCP):
~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.
~The smart pressure monitored suit(SPMS):
~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
11187638|NCT03469830|Active Comparator|SPMS|"The smart pressure monitored suit(SPMS):
~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
11187639|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
11187640|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
11187641|NCT03469804|Experimental|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
11187642|NCT03469791|Active Comparator|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
11187643|NCT03469791|Active Comparator|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
11187644|NCT03469778|Experimental|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
11187645|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
11187646|NCT03469752|Experimental|Intervention group|8 weekly education sessions 2.5 hours
11187647|NCT03469752|No Intervention|Wait-list control group|No education sessions
11187648|NCT03469726|Other|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.
~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
11187649|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .
~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
11187650|NCT03469700|Experimental|GA+PVB|Patients will receive general anesthesia with paravertebral block
11187651|NCT03469700|Active Comparator|GA+placebo PVB|Patients will receive general anesthesia with placebo block
11187652|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
11187653|NCT03469674|Experimental|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
11187654|NCT03469674|Active Comparator|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
11187655|NCT03469661||Immune Thrombocytopenia Diagnosis|
11187656|NCT03469661||Myelodysplastic Syndrome Diagnosis|
11187657|NCT03469622|Active Comparator|EndoRings|Colonoscopy is performed with the EndoRings attached
11187658|NCT03469622|Active Comparator|Standard Colonoscopy|Standard colonoscopy without any additional devices
11187659|NCT03469609|Experimental|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
11187660|NCT03469609|No Intervention|No mucous fistula refeeding|No perioperative mucous fistula refeeding
11187661|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
11187662|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
11187663|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
11187664|NCT03469570|Experimental|Assisted Fluid Management|
11187665|NCT03469557|Experimental|Esophageal Squamous Cell Carcinoma (ESCC)|
11187666|NCT03469557|Experimental|Gastric (GC) and Gastroesophageal Junction (GEJ) Carcinoma|
11187667|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .
~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
11187668|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .
~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
11187669|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .
~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
11187670|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
11187671|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
11187672|NCT03469518|Sham Comparator|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
11187673|NCT03469518|Active Comparator|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
11187674|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
11187675|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
11187676|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
11187677|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
11187678|NCT03469479|Experimental|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
11187679|NCT03469479|Active Comparator|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
11187680|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
11187681|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
11187682|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
11187683|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
11187684|NCT03469440|Active Comparator|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
11187685|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy.
11187686|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
11187687|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
11187688|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
11187689|NCT03469388|Experimental|elective EVAR patients|Elective EVAR patients will be included in one arm only
11187690|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
11187691|NCT03469362|Experimental|Extracorporal Urinary Diversion (ECD)|"Study participants receiving standard-of-care Extracorporal Urinary Diversion after robot assisted radical cystectomy (RARC):
~Post-operative care involving use of a standardized enhanced-recovery after surgery (ERAS) protocol.
~Activities of Daily Living questionnaire
~Instrumental Activities of Daily Living questionnaire
~Hand Grip Strength Test
~Timed Up and Go Walking Test
~SF-8 Questionnaire
~FACT-VCI Questionnaire"
11187864|NCT03468296|Experimental|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
11187692|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|"Study participants receiving standard-of-care Intracorporal Urinary Diversion after robot assisted radical cystectomy (RARC):
~Post-operative care involving use of a standardized enhanced-recovery after surgery (ERAS) protocol.
~Activities of Daily Living questionnaire
~Instrumental Activities of Daily Living questionnaire
~Hand Grip Strength Test
~Timed Up and Go Walking Test
~SF-8 Questionnaire
~FACT-VCI Questionnaire"
11187693|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
11187694|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
11187695|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
11187696|NCT03469323|Experimental|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
11187697|NCT03469323|Placebo Comparator|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
11187698|NCT03469310|Experimental|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
11187699|NCT03469310|Active Comparator|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
11187700|NCT03469297|Experimental|Brown Glaucoma Implant|
11187701|NCT03469284|Experimental|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
11187702|NCT03469284|Experimental|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
11187703|NCT03469284|Experimental|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
11187704|NCT03469284|Active Comparator|Group 4 (standard of care)|Patients receive standard of care therapy.
11187705|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
11187706|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
11187707|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
11187708|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
11187709|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.
~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
11187710|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
11187711|NCT03469232|Experimental|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
11187712|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
11187713|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
11187714|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
11187715|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
11187716|NCT03469206|Sham Comparator|Direct MT|Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
11187717|NCT03469206|Active Comparator|IVT combine with MT|Intravenous thrombolysis before mechanical thrombectomy
11187718|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
11187719|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
11187720|NCT03469180|Active Comparator|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
11187721|NCT03469180|Experimental|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
11187722|NCT03469167|Experimental|CEGP003|
11187723|NCT03469167|Active Comparator|Injection Tx|
11187724|NCT03469154|Experimental|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
11187820|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
11187967|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
11187725|NCT03469154|Active Comparator|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.
~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
11187726|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
11187727|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
11187728|NCT03469128|Active Comparator|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
11187729|NCT03469128|Active Comparator|Medication|Medication group in which patients with co-occurrence PTSD & SUD disorders were treated by medicine (Disulfiram).
11187730|NCT03469128|Placebo Comparator|Control group|Control group that consists of patients with co-occurrence PTSD & SUD disorders who were not treated yet (waiting lists in the hospital).
11187731|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
11187732|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
11187733|NCT03469089|Placebo Comparator|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
11187734|NCT03469089|Experimental|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
11187735|NCT03469089|Experimental|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
11187736|NCT03469089|Experimental|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
11187737|NCT03469076|Experimental|ACN Cream|Patients with mild to moderate acne using ACN Cream
11187738|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
11187739|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
11187740|NCT03469050|Experimental|Rifaximin delayed released 800 mg b.i.d.|(i.e. 2 x 400 mg tablet twice a day; total daily dose: 1600 mg) for 10 consecutive days a month, for 12 months
11187741|NCT03469050|Experimental|Rifaximin delayed released 400 mg b.i.d|(i.e. 1x400 mg tablet plus 1 placebo tablet twice a day; total daily dose: 800 mg) for 10 consecutive days a month, for 12 months
11187742|NCT03469050|Placebo Comparator|Placebo b.i.d.|(i.e. 2 x placebo tablets twice a day) for 10 consecutive days a month, for 12 months.
11187743|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
11187744|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
11187745|NCT03469024|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
11187746|NCT03469024|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
11187747|NCT03469011|Experimental|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.
~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
11187748|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
11187749|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
11187750|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
11187751|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
11187752|NCT03468985|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11187753|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib s-malate)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11187754|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib s-malate, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11187755|NCT03468985|Experimental|Arm T (nivolumab, cabozantinib s-malate, ipilimumab)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11187756|NCT03468972|Experimental|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
11187757|NCT03468972|Active Comparator|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
11189115|NCT03460041|Active Comparator|Dexmetedomedine|
11187758|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
11187759|NCT03468946|Other|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
11187760|NCT03468946|Other|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
11187761|NCT03468946|Other|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
11187762|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
11187763|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
11187764|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
11187765|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
11187766|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
11187767|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
11187768|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
11187769|NCT03468894|No Intervention|Control|The control group will continue to work as usual at their regular workstations.
11187770|NCT03468894|Experimental|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
11187771|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
11187772|NCT03468868|Active Comparator|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
11187773|NCT03468868|Active Comparator|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
11187774|NCT03468855|Experimental|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
11187775|NCT03468842|Placebo Comparator|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
11187776|NCT03468842|Active Comparator|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
11187777|NCT03468829|Experimental|ALX-0171 Dose 1|
11187778|NCT03468829|Experimental|ALX-0171 Dose 2|
11187779|NCT03468829|Placebo Comparator|Placebo|
11187780|NCT03468816|Experimental|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
11187781|NCT03468816|Experimental|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
11187782|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
11187783|NCT03468790|Experimental|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
11187784|NCT03468790|Placebo Comparator|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
11187785|NCT03468777|Experimental|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187786|NCT03468777|Experimental|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187787|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187788|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187789|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187790|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187791|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187792|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
11187793|NCT03468751|Experimental|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
11187794|NCT03468751|Experimental|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
11187795|NCT03468725|Experimental|XPF-008|Single oral dose
11187796|NCT03468725|Active Comparator|Placebo|Single oral dose
11187797|NCT03468712|Experimental|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
11187798|NCT03468699|Experimental|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
11187799|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
11187800|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
11187801|NCT03468686|Active Comparator|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
11187802|NCT03468660|Experimental|Experimental group|Auditory training with feedback
11187803|NCT03468660|Active Comparator|Active control group|Listening paradigm with no feedback.
11187804|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
11187805|NCT03468634||Adenocarcinoma|patients diagnosed with adenocarcinoma
11187806|NCT03468634||Squamous cell cancer|patients diagnosed with squamous cell cancer
11187807|NCT03468634||Other|patients diagnosed with another condition
11187808|NCT03468634||Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
11187809|NCT03468634||Low-grade dysplasia|patients diagnosed with low-grade dysplasia
11187810|NCT03468634||High-grade dysplasia|patients diagnosed with high-grade dysplasia
11187811|NCT03468634||Indefinite for dysplasia|patients where the diagnosis is unclear
11187812|NCT03468634||no dysplasia|patients not diagnosed with any cancer
11187813|NCT03468621|Other|Intradermal wound closure|Intradermal wound closure of the groin wound
11187814|NCT03468621|Other|Transdermal wound closure|Wound closure of the groin wound with metal staples
11187815|NCT03468608||Phase 1: Instrument Development|An initial set of questionnaire items will be created based on the questionnaires noted in the literature review as well as the semi-structured interviews conducted with parents and healthcare team members in our facility.
11187816|NCT03468608||Phase 2: Pre-Test Evaluation|Parents and healthcare team members will be asked to comment on the quality of the draft questionnaire created in phase 1 of this study.
11187817|NCT03468608||Phase 3: Pilot|"Parents will be asked to complete the questionnaire developed during phase 2 of this study. Upon completing the questionnaire, parents will be asked to rate the overall face validity of the tool using a 5-point Likert scale.
~Healthcare team members will be asked to rate the content validity of each item on the questionnaire."
11187818|NCT03468608||Phase 4: Validation|Parents will be asked to complete the questionnaire developed during phase 3 of this study.
11187819|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
11187821|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
11187822|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
11187823|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
11187824|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
11187825|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
11187826|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
11187827|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
11187828|NCT03468556|Experimental|test drug|2 tabs of SNP-610
11187829|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
11187830|NCT03468543|Experimental|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
11187831|NCT03468543|Experimental|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
11187832|NCT03468543|Experimental|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
11187833|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
11187834|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
11187835|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.
~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
11187836|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.
~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
11187837|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
11187838|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
11187839|NCT03468478|Experimental|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
11187840|NCT03468478|Experimental|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
11187841|NCT03468478|Active Comparator|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
11187842|NCT03468465|Experimental|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
11187843|NCT03468465|Active Comparator|Solifenacin|10 mg tablet daily during 75 days maximum
11187844|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
11187845|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.
~The catheter is inserted again within 48h."
11187846|NCT03468439|Other|femoral nerve block|
11187847|NCT03468426|Experimental|BI 836880 + BI 754091|
11187848|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
11187849|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
11187850|NCT03468387|Active Comparator|Primary realignment|
11187851|NCT03468387|Active Comparator|Suprapubic cystostomy|
11187852|NCT03468374|Active Comparator|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
11187853|NCT03468374|Active Comparator|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
11187854|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
11187855|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
11187856|NCT03468348|Placebo Comparator|placebo group|
11187857|NCT03468348|Active Comparator|duloxetine 30|
11187858|NCT03468348|Active Comparator|duloxetine 60|
11187859|NCT03468348|Active Comparator|duloxetine 90|
11187860|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:
~Nal-IRI 80 mg/m2 as 1.5 hour infusion
~5-FU 2400 mg/m2 as 46 hour infusion
~Folinic acid 400 mg/m2 as 0.5 hour infusion
~all on D1 of each cycle; Cycle q2w ± 5 days
~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
11187861|NCT03468322|Experimental|AC-203 1% ointment|AC-203 1% ointment, QD
11187862|NCT03468322|Placebo Comparator|Vehicle ointment|Vehicle ointment, QD
11187863|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
11187865|NCT03468296|Active Comparator|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
11187866|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
11187867|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
11187868|NCT03468257|Active Comparator|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
11187869|NCT03468257|Experimental|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
11187870|NCT03468244|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
11187871|NCT03468231|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
11187872|NCT03468231|Experimental|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
11187873|NCT03468218|Experimental|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11187874|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
11187875|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
11187876|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
11187877|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
11187878|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
11187879|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
11187880|NCT03468153|Experimental|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
11187881|NCT03468140|Experimental|Current end stage liver disease patients|Eculizumab
11187882|NCT03468140|Other|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
11187883|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
11187884|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
11187885|NCT03468101||Dairy farmers COPD|
11187886|NCT03468101||Non farmers COPD|
11187887|NCT03468088|Experimental|Hand grip strengthening|This group will receive handgrip strengthening exercises.
11187888|NCT03468088|Active Comparator|Conventional treatment|This group will receive conventional exercises.
11187889|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
11187890|NCT03468062|Experimental|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
11187891|NCT03468062|Placebo Comparator|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
11187892|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
11187893|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
11187921|NCT03467932|Active Comparator|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
11187922|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
11187894|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
11187895|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
11187896|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
11187897|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
11187898|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
11187899|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
11187900|NCT03468010|Active Comparator|The control group (Group A)|In Group A, observation is given after chemoradiation
11187901|NCT03468010|Experimental|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
11187902|NCT03467997|No Intervention|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
11187903|NCT03467997|Active Comparator|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
11187904|NCT03467997|Active Comparator|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
11187905|NCT03467997|Active Comparator|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
11187906|NCT03467984|Experimental|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
11187907|NCT03467984|Active Comparator|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
11187908|NCT03467971|Experimental|Metformin-Gliclazide (fasted), Then Metformin-Gliclazide (fed)|Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
11187909|NCT03467971|Experimental|Metformin-Gliclazide (fed), Then Metformin-Gliclazide (fasted)|Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
11187910|NCT03467958|Experimental|Administration of oral Ozanimod|Subjects will receive a single 0.92 mg capsule [equivalent to ozanimod HCl 1 mg] once daily x 48 weeks
11187911|NCT03467945|Experimental|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
11187912|NCT03467945|Experimental|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
11187913|NCT03467945|Experimental|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
11187914|NCT03467945|Experimental|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
11187915|NCT03467932|Active Comparator|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
11187916|NCT03467932|Active Comparator|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
11187917|NCT03467932|Active Comparator|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
11187918|NCT03467932|Placebo Comparator|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
11187919|NCT03467932|Placebo Comparator|Cohort A: Excipient-Matched Placebo three times daily-TID|Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
11187920|NCT03467932|Active Comparator|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
11187966|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
11187923|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
11187924|NCT03467932|Placebo Comparator|Excipient matched placebo once daily - QHS|Excipient matched placebo once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
11187925|NCT03467919|Experimental|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
11187926|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
11187927|NCT03467906||Poor weight loss group|Sleeve gastrectomy surgery patients with poor weight loss outcomes will take part in in-laboratory assessment.
11187928|NCT03467906||Good weight loss group|Sleeve gastrectomy surgery patients with good weight loss outcomes will take part in in-laboratory assessment.
11187929|NCT03467880||Healthy subjects|Healthy subjects.
11187930|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
11187931|NCT03467880||Asthma|Patience with asthma.
11187932|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
11187933|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
11187934|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
11187935|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
11187936|NCT03467828|Experimental|Study Group|Infants diagnosed with BPD.
11187937|NCT03467828|No Intervention|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
11187938|NCT03467789|Experimental|Group A: D3 prior to first PDT|Group A will take D3 pills prior to the first PDT treatment, and placebo pills prior to the second PDT treatment. Both Group A and Group B will take no study drug prior to their third PDT visit.
11187939|NCT03467789|Experimental|Group B: D3 prior to second PDT visit|GROUP B will receive placebo prior to their first PDT visit, and Vitamin D3 prior to their second PDT visit. Both Group A and Group B will take no study drug prior to their third PDT visit.
11187940|NCT03467776||healthy|healthy control, 5 months to 3 years
11187941|NCT03467776||wheezing with atopy|suspected asthma with wheezing (>3 episodes per year) and atopy
11187942|NCT03467776||wheezing without atopy|wheezing without atopy
11187943|NCT03467763|Active Comparator|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
11187944|NCT03467763|Placebo Comparator|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
11187945|NCT03467750|Experimental|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
11187946|NCT03467750|Active Comparator|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
11187947|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
11187948|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
11187949|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
11187950|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
11187951|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
11187952|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
11187953|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
11187954|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
11187955|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
11187956|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
11187957|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
11187958|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
11187959|NCT03467672||Infected patients|
11187960|NCT03467672||Control group|
11187961|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
11187962|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
11187963|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
11187964|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
11187965|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
11187968|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
11187969|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
11187970|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
11187971|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
11187972|NCT03467620|Experimental|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
11187973|NCT03467620|Placebo Comparator|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
11187974|NCT03467607|Active Comparator|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
11187975|NCT03467607|Active Comparator|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
11187976|NCT03467607|Active Comparator|control|15 patients ventilated using the anaesthetists usual ventilation strategy
11187977|NCT03467594|Experimental|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.
~Outcome measures assessed at baseline and follow-up (8 weeks)"
11187978|NCT03467594|No Intervention|Control|Outcome measures only at baseline at follow-up (8 weeks)
11187979|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
11187980|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
11187981|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
11187982|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
11187983|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
11187984|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
11187985|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
11187986|NCT03467503|No Intervention|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
11187987|NCT03467503|Experimental|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
11187988|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
11187989|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
11187990|NCT03467477|Experimental|Flortaucipir PET Scan|
11187991|NCT03467464|Experimental|Intervention|EMDR treatment
11187992|NCT03467438|Experimental|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
11187993|NCT03467438|Placebo Comparator|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
11187994|NCT03467425|Experimental|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
11187995|NCT03467425|Active Comparator|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
11211328|NCT03306316|Experimental|Experimental|Experimental Arm
11187996|NCT03467412|Experimental|0.00625 μg FOL-005|0.00625 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
11187997|NCT03467412|Experimental|0.025 μg FOL-005|0.025 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
11187998|NCT03467412|Experimental|0.050 μg FOL-005|0.050 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
11187999|NCT03467412|Experimental|0.100 μg FOL-005|0.100 μg FOL-005, solution. 50 μl injected sub-cutaneous three times per week for 12 weeks.
11188000|NCT03467412|Placebo Comparator|Placebo|Placebo. 50 μl injected sub-cutaneous three times per week for 12 weeks.
11188001|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
11188002|NCT03467386|Experimental|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.
11188003|NCT03467373|Experimental|Part 1: Dose Escalation r/r NHL|"Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.
~The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts."
11188004|NCT03467373|Experimental|Part 2: Dose Expansion r/r NHL|Participants with r/r NHL will be assigned to an expansion cohort to further explore glofitamab at the MTD/OBD determined in Part I.
11188005|NCT03467373|Experimental|Part 2: DLBCL G/R-CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
11188006|NCT03467373|Experimental|Part 2: DLBCL CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
11188007|NCT03467360|Experimental|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
11188008|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
11188009|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
11188010|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
11188011|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
11188012|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
11188013|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
11188014|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
11188015|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
11188016|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
11188017|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
11188018|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
11188019|NCT03467282|Experimental|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
11188020|NCT03467282|Placebo Comparator|Placebo|1g polydextrose/maltodextrin - twice day
11188021|NCT03467256|Experimental|experimental|Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.
11188022|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
11188023|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
11188024|NCT03467243|Other|Treatment as usual|Veterans receive treatment as usual
11188025|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
11188026|NCT03467217|Active Comparator|Losartan potassium capsule|Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to <150 kg.
11188027|NCT03467217|Placebo Comparator|Placebo losartan capsule|Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to <150 kg.
11188030|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
11188031|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
11188032|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
11188033|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
11188034|NCT03467152|Experimental|E2027|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of E2027 for 12 weeks.
11188035|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of E2027-matched placebo for 12 weeks.
11188036|NCT03467139|Experimental|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
11188037|NCT03467139|No Intervention|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
11188038|NCT03467113|Experimental|ZX008 0.2 and 0.8 mg/kg/day|FZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (0.2 mg/kg/day titrated to 0.8 mg/kg/day)
11188039|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
11188040|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
11188041|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
11188042|NCT03467061|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
11188043|NCT03467061|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
11188044|NCT03467061|Other|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
11188045|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
11188046|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
11188047|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test
~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
11188048|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test
~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
11188049|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.
~Eight-week longitudinal tailored CBT-based text-message program."
11188050|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
11188051|NCT03467009|Experimental|iPACT Intervention- App|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.
~Eight-week longitudinal tailored CBT-based message program delivered via app."
11188052|NCT03466996|Experimental|Intervention group|The intervention group will participate in face-to-face video telemedicine visits, in addition to routine annual visits to the Spina Bifida Clinic. These 30-minute visits will occur at 2 weeks, 3 months, 6 months and 9 months from last in-person clinic appointment. The visits will consist of structured counseling using a plan-do-study-act cycle approach to incrementally adopt elements of a well-planned transition. Using qualitative notes from each session, we will identify common themes or challenges across patients and develop adjunctive education, support, and monitoring tools for patients and families in transition.
11188053|NCT03466996|Active Comparator|Standard of care group|The control group will receive the current standard of care transition program. In addition to this, they will receive encouraging text messages and e-mails relating to their transition goals. These messages will be sent 2 weeks, 3 months, 6 months and 9 months from the last in-person clinic appointment.
11188054|NCT03466983|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
11188055|NCT03466983|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
11188056|NCT03466970||IgG4 patient|20 samples of IgG4 patients
11188057|NCT03466970||healthy donors|20 healthy donors
11188058|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
11188059|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
11188060|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
11188061|NCT03466931|No Intervention|Historical cohort|Standard care
11188062|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
11188063|NCT03466905|Active Comparator|Intervention|Assessment of Ambulance Medical Service
11188064|NCT03466905|No Intervention|Control|Local treatment guidelines
11188065|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
11188066|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
11188098|NCT03466632|Active Comparator|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
11189667|NCT03455998||pre and post surgery|Patient consultation Questionnaires
11188067|NCT03466866|Experimental|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
11188068|NCT03466866|Active Comparator|Intensive Diabetes Education|In-home diabetes education
11188069|NCT03466840|Experimental|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
11188070|NCT03466840|Active Comparator|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
11188071|NCT03466814||JIA participants|
11188072|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
11188073|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
11188074|NCT03466788|Other|Patients treated with chemotherapy|
11188075|NCT03466788|Other|Patients not treated with chemotherapy|
11188076|NCT03466749|Experimental|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
11188077|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with [18F]flutemetamol
11188078|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with [18F]flutemetamol
11188079|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with [18F]flutemetamol
11188080|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
11188081|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
11188082|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
11188083|NCT03466697|Other|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
11188084|NCT03466684|Experimental|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL > 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
11188085|NCT03466684|Active Comparator|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
11188086|NCT03466671|Other|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
11188087|NCT03466671|Other|Low dose twice per day and placebo|Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
11188088|NCT03466671|Other|High dose once per day and placebo|"Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
11188089|NCT03466671|Other|High dose twice per day and placebo|Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
11188090|NCT03466671|Other|Placebo and low dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
11188091|NCT03466671|Other|Placebo and low dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
11188092|NCT03466671|Other|Placebo and high dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
11188093|NCT03466671|Other|Placebo and high dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.
11188094|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
11188095|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
11188096|NCT03466645|Active Comparator|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
11188097|NCT03466645|Active Comparator|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
11188099|NCT03466632|Active Comparator|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
11188100|NCT03466619|Experimental|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
11188101|NCT03466606|Experimental|Prehabilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
11188102|NCT03466606|No Intervention|Control|Conventional treatment
11188103|NCT03466593|Experimental|Prospective cohort-prehabilitation|A prehabilitation program including advice about diet, increased physical activity and cessation of smoking and drinking alcohol.
11188104|NCT03466593|Active Comparator|Retrospective cohort|Routine care before the prehabilitation program was introduced
11188105|NCT03466593|Experimental|Extra early mobilization|Mobilization the day of surgery
11188106|NCT03466593|Active Comparator|Traditional mobilization|Routine care with mobilization the day after surgery
11188107|NCT03466580|Experimental|Intervention|('Standard' specialized palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
11188108|NCT03466580|No Intervention|Control|('Standard' specialized palliative care). No intervention offered.
11188109|NCT03466567|Experimental|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
11188110|NCT03466567|Experimental|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
11188111|NCT03466567|Experimental|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
11188112|NCT03466554|Experimental|hyperbaric oxygen therapy (HBOT) active treatment|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
11188113|NCT03466554|No Intervention|Control-follow up|"The standard of care of psychological and mediational support .
~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
11188114|NCT03466541|Experimental|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
11188115|NCT03466541|Experimental|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
11188116|NCT03466541|No Intervention|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
11188117|NCT03466528|Active Comparator|Standard treatment - Pabrinex alone|Pabrinex alone
11188118|NCT03466528|Active Comparator|Pabrinex + magnesium sulphate|standard treatment and magnesium sulphate
11188119|NCT03466528|Experimental|Magnesium sulphate alone|This group receives the study intervention and delayed Pabrinex
11188120|NCT03466515|Experimental|intervention|Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
11188121|NCT03466502|No Intervention|No oral vancomycin|
11188122|NCT03466502|Experimental|Oral vancomycin 125 mg twice daily|
11188123|NCT03466502|Experimental|Oral vancomycin 125 mg daily|
11188124|NCT03466489|Experimental|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
11188125|NCT03466489|No Intervention|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
11188126|NCT03466476|Experimental|Wearable Technology|Patients in this arm will be provided with their own Consensus TracPatch wearable device as well as instructions on its use.
11188127|NCT03466476|No Intervention|Current Standard|Patients in this arm will not be provided with any wearable device.
11188128|NCT03466463|Experimental|GNT0003|2 doses of the IMP assessed in a dose escalation, open-label, phase 1/2 study
11188129|NCT03466450|Experimental|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.
~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
11188130|NCT03466437|Experimental|Glass-fiber post + composite resin restoration|
11188131|NCT03466437|Experimental|Glass-fiber post + metalceramic crown|
11188132|NCT03466437|Active Comparator|Cast-metal post + metalceramic crown|
11188133|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
11188134|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
11188135|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
11188190|NCT03466151|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
11188787|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
11188136|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
11188137|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
11188138|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
11188139|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
11188140|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
11188141|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
11188142|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
11188143|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
11188144|NCT03466398|Experimental|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
11188145|NCT03466398|No Intervention|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
11188146|NCT03466385|Experimental|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min-1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
11188147|NCT03466385|Active Comparator|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
11188148|NCT03466372|Experimental|biofeedback 1|biofeedback training with progression of targets
11188149|NCT03466372|Active Comparator|biofeedback 2|biofeedback training with progression of targets and speeds
11188150|NCT03466359|Experimental|DEF-EI|these adolescents will follow a dietary restriction of 10% of their daily energy intake.
11188151|NCT03466359|Experimental|DEF-EX|these adolescents will increase their physical activity-induced energy expenditure by 10% per day.
11188152|NCT03466346|Active Comparator|Interpersonal psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
11188153|NCT03466346|Active Comparator|fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
11188154|NCT03466346|Active Comparator|Fluoxetine after IPT|participants who do not remit from MDD and PTSD after treatment with IPT may be randomized to fluoxetine.
11188155|NCT03466346|Active Comparator|IPT after fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT.
11188156|NCT03466346|Active Comparator|IPT + fluoxetine|participants who do not remit from MDD and PTSD after treatment with fluoxetine may be randomized to IPT + fluoxetine.
11188157|NCT03466333|Experimental|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
11188158|NCT03466333|Placebo Comparator|Placebo|Oral placebo once daily for 6 months postpartum
11188159|NCT03466333|No Intervention|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
11188160|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.
~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
11188161|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.
~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
11188947|NCT03461315|No Intervention|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
11188162|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.
~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
11188163|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL3|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.
~Dose 3: 1x109 NKR-2 (adjusted at 1.5x107 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
11188164|NCT03466320|Experimental|Phase I Dose Escalation - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
11188165|NCT03466320|Experimental|Phase II Segment 1|This extension segment will enroll more patients (to reach 13 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
11188166|NCT03466320|Experimental|Phase II Segment 2|Enrollment in the Phase II part of the study will be divided in 2 consecutive segments, with 13 patients in total in the segment 1 and 30 new patients in segment 2 (43 patients in total) if the study is not terminated due to futility, according a Simon's two-stage optimal design
11188167|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
11188168|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
11188169|NCT03466307||Group C|Healthy controls
11188170|NCT03466294|Experimental|Azacitidine and Venetoclax|On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
11188171|NCT03466281|Active Comparator|IBS School|Patient education provided in a group setting
11188172|NCT03466281|Active Comparator|Internet patient education|Patient education provided via the internet
11188173|NCT03466268|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
11188174|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
11188175|NCT03466242|Experimental|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
11188176|NCT03466242|Active Comparator|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
11188177|NCT03466229|Active Comparator|Antioxidant|Androferti - 1 twice per day
11188178|NCT03466229|Placebo Comparator|Placebo|Placebo - 1 twice per day
11188179|NCT03466216|Experimental|AlphaMedix|There is only a single treatment arm.
11188180|NCT03466203|Experimental|LLF580|LLF580 every 28 days * 3
11188181|NCT03466203|Placebo Comparator|Placebo|Placebo to LLF580 every 28 days * 3
11188182|NCT03466190|Experimental|Custom made PEEK plate fixation|Open Reduction Internal Fixation using Custom made PEEK plates.
11188183|NCT03466190|Active Comparator|Titanium plate fixation|Open Reduction Internal Fixation using conventional titanium plating system.
11188184|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients
~Venous blood sampling Hematology and chemistry
~Genotyping: apolipoprotein E (apoE) polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
11188185|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients
~Venous blood sampling Hematology and chemistry
~Genotyping: apoE polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
11188186|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers
~Venous blood sampling Hematology and chemistry
~Genotyping: apoE polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
11188187|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers
~Venous blood sampling Hematology and chemistry
~Genotyping: apoE polymorphism Cerebral imaging
~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence
~18F-Flutemetamol PET CT
~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)
~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
11188188|NCT03466164|Experimental|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
11188189|NCT03466164|No Intervention|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
11188191|NCT03466151|Active Comparator|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
11188192|NCT03466138||General Anesthesia|subjects requiring a surgical procedure under general anesthesia. monitored by PMD-200
11188193|NCT03466125||Adult patients who underwent cardiac surgery in Massachusetts|No interventions. A retrospective cohort study of patients who underwent cardiac surgery in Massachusetts in calendar years 2012 - 2016.
11188194|NCT03466112|Experimental|endurance training|endurance training with stationary bicycles
11188195|NCT03466112|Active Comparator|balance and tone program|flexibility, core strength, balance, relaxation
11188196|NCT03466099|Experimental|KVD001 Injection (high dose)|
11188197|NCT03466099|Experimental|KVD001 Injection (low dose)|
11188198|NCT03466099|Sham Comparator|Sham Procedure|
11188199|NCT03466086|Experimental|Test/Control|Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
11188200|NCT03466086|Experimental|Control/Test|Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
11188201|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
11188202|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
11188203|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
11188204|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
11188205|NCT03466060|Active Comparator|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
11188206|NCT03466060|Active Comparator|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
11188207|NCT03466060|Active Comparator|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
11188208|NCT03466047|Experimental|Protein stomach|Encapsulated protein released in the stomach
11188209|NCT03466047|Experimental|Protein distal small intestine|Encapsulated protein released in the distal small intestine
11188210|NCT03466047|Experimental|CHO stomach|Encapsulated CHO released in the stomach
11188211|NCT03466047|Experimental|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
11188212|NCT03466047|Experimental|Fat stomach|Encapsulated Fat released in the stomach
11188213|NCT03466047|Experimental|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
11188214|NCT03466034||Endometriod|Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
11188215|NCT03466034||Serous|Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
11188216|NCT03466021|Active Comparator|Liraglutide|Liraglutide injection 3.0 mg daily
11188217|NCT03466021|Placebo Comparator|Placebo|Placebo, matching injection pen
11188218|NCT03466008|Experimental|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
11188219|NCT03466008|No Intervention|Usual treatment arm|usual care
11188220|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
11188221|NCT03465982|Active Comparator|Standard Interval Time Arm|Minimally invasive surgery after 8 weeks from chemoradiation treatment
11188222|NCT03465982|Active Comparator|Delayed Interval Time Arm|Minimally invasive surgery after 12 weeks from chemoradiation treatment
11188223|NCT03465969|Other|Liver or kidney transplant participants of Advagraf|Transplant participants will provide 1 whole blood venepuncture sample and 1 whole blood finger prick MITRA sample at pre-dose of participant's usual oral dose of commercial Advagraf and at approximately 1 and 3 hours post-dose.
11188224|NCT03465956|Other|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy for patients with morbid obesity using the gastro-intestinal anastomosis stapler.
11188225|NCT03465943|Active Comparator|Ringer|This group will receive 1 L of Ringer's solution as a preload
11188226|NCT03465943|Active Comparator|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
11188227|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
11188228|NCT03465917|Experimental|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
11188229|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
11188230|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
11188231|NCT03465891|Experimental|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
11188232|NCT03465891|Experimental|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
11188233|NCT03465878|Experimental|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
11188234|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
11188235|NCT03465878|Experimental|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
11188236|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
11188237|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
11188238|NCT03465852|Experimental|Intervention arm|"Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.
~."
11188239|NCT03465852|Other|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
11188240|NCT03465839|Experimental|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
11188241|NCT03465839|Active Comparator|Control|Education for improving handovers quality
11188242|NCT03465826|Experimental|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
11188243|NCT03465826|Active Comparator|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
11188244|NCT03465813|Experimental|CaringGuidance Intervention|Three months of web-based CaringGuidance psychoeducational program use, independently on home computer in addition to usual care.
11188245|NCT03465813|No Intervention|Usual Care|Three months of care as usual from subjects' clinics and community as the subject chooses.
11188246|NCT03465800|Active Comparator|Self-Monitoring|Participants self-monitor their physical activity
11188247|NCT03465800|Experimental|Daily Incentives|daily payments for physical activity
11188248|NCT03465800|Experimental|Delayed Lump Sum Incentives|lump sum payments for physical activity
11188249|NCT03465787|Experimental|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
11188250|NCT03465787|Active Comparator|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
11188251|NCT03465774||Group 2 (IPC alone)|Patients undergo IPC placement.
11188252|NCT03465774||Group I (IPC, doxycycline)|Patients undergo IPC placement and receive doxycycline via IPC 5 days later.
11188253|NCT03465761|Experimental|ExAblate 4000 System|ExAblate treatment of Bilateral Essential Tremor
11188254|NCT03465748|Experimental|Experimental-OrthoK|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles or soft contact lenses (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
11188255|NCT03465748|No Intervention|Control|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
11188256|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
11188257|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:
~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
11188258|NCT03465722|Experimental|avapritinib|300 mg PO QD
11188259|NCT03465722|Active Comparator|regorafinib|160 mg PO QD
11188260|NCT03465709|Experimental|Pegcetacoplan Study Drug|
11188261|NCT03465696|No Intervention|Group #1 (Control)|"Group #1 (Control)
~Oral survey 1 will be administered and patients will be asked:
~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis.
~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
11188262|NCT03465696|Experimental|Group #2 (Intervention)|"Group #2 (Intervention)
~Survey 2 will be administered, and patients will be asked the following primer:
~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.
~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
11188295|NCT03465462|Active Comparator|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
11188263|NCT03465696|Experimental|Group #3 (Intervention)|"Group #3 (Intervention)
~Survey 3 will be administered, and patients will be asked the following primer:
~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.
~What do you think would be the best way to describe this to a patient?
~Stelara® acts in an almost all-natural way to help control psoriasis.
~Stelara® blocks one of the genetic causes of psoriasis.
~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance
~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis
~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
11188264|NCT03465670|Active Comparator|CHX|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse (10 ml for 1 minute, t.i.d. for 21 days)
11188265|NCT03465670|Experimental|CHX+HA+ADS|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) (10 ml for 1 minute, t.i.d. for 21 days)
11188266|NCT03465644|Experimental|Tailored arm|early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy
11188267|NCT03465644|Active Comparator|Conventional arm|clopidogrel + aspirin for 12months
11188268|NCT03465631|Experimental|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
11188269|NCT03465631|Sham Comparator|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
11188270|NCT03465618|Experimental|surgical patients|Patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans will be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.
11188271|NCT03465618|Experimental|non-surgical patients|Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging
11188272|NCT03465592|Experimental|Nivolumab|"Adults: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.
~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks.A maximum of 24 cycles will be given on study."
11188273|NCT03465579|Other|Cohort 1|Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
11188274|NCT03465579|Other|Cohort 2|Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
11188275|NCT03465579|Other|Cohort 3a|Men with high-risk PCa (HR-PCa) prior to radical surgery.
11188276|NCT03465579|Other|Cohort 3b|Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
11188277|NCT03465566||Children with BECTS|"Children with active BECTS according to state-of-the-art diagnostic criteria of ILAE (International League Against Epilepsy). Eligible subjects will be recruited at their first clinical observation in the epilepsy centers involved in the study.
~All subjects will perform five diagnostic evaluations named:
~IDS (Intelligence and Development Scale) MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
11188278|NCT03465566||Healthy children|"Healthy controls matched for sex, age range, and education with no family history for epilepsy or other neuropsychiatric disorders.
~All subjects will perform the following tests:
~MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
11188279|NCT03465553|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
11188280|NCT03465540|Experimental|Part 1A: AMG 397 Dose Escalation|This arm includes subjects with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL).
11188281|NCT03465540|Experimental|Part 1B: AMG 397 Dose Escalation|This arm includes subjects with acute myeloid leukemia (AML).
11188282|NCT03465540|Experimental|Part 2A: AMG 397 Monotherapy|This arm includes subjects with AML or myelodysplastic syndrome (MDS).
11188283|NCT03465540|Experimental|Part 2B: AMG 397 Monotherapy|This arm includes subjects with AML in Japan only.
11188284|NCT03465540|Experimental|Part 2C: AMG 397 Monotherapy|This arm includes subjects with MM.
11188285|NCT03465540|Experimental|Part 3A: AMG 397 + Azacitidine Combotherapy|This arm includes subjects MDS.
11188286|NCT03465540|Experimental|Part 3B: AMG 397+ Azacitidine Combotherapy|This arm includes subjects AML.
11188287|NCT03465540|Experimental|Part 3C: AMG 397+ Dexamethasone Combotherapy|This arm includes subjects MM.
11188288|NCT03465527|Experimental|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
11188289|NCT03465501||Low Dose Rate|Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
11188290|NCT03465501||High Dose Rate|Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
11188291|NCT03465488|Experimental|Subjects|All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.
11188292|NCT03465475||Group 1|The patient who receive 5 mL/kg (ideal body weight) fresh gas flow during the general anesthesia
11188293|NCT03465475||Group 2|The patient who receive 10 mL/kg (ideal body weight) fresh gas flow during the general anesthesia
11188294|NCT03465462|Active Comparator|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
11188296|NCT03465462|Active Comparator|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
11188297|NCT03465449|Active Comparator|usual care|
11188298|NCT03465449|Experimental|CKD-EDU arm|
11188299|NCT03465436|Experimental|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
11188300|NCT03465436|Experimental|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
11188301|NCT03465436|Placebo Comparator|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
11188302|NCT03465436|Active Comparator|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
11188303|NCT03465423||patients with nonfunctioning pituitary tumor|patients with nonfunctioning pituitary tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
11188304|NCT03465423||patients with pituitary somatotroph tumor|patients with pituitary somatotroph tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
11188305|NCT03465410|Active Comparator|GROUP I Standard adjustment|Standard dosage of Tacrolimus
11188306|NCT03465410|Experimental|GROUP II Bayesian prediction adjustment|Bayesian prediction Tacrolimus dosage
11188307|NCT03465397|Experimental|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
11188308|NCT03465397|No Intervention|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
11188309|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
11188310|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
11188311|NCT03465371|Experimental|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
11188312|NCT03465371|Active Comparator|InPerson Intervention|Participants receiving the InPerson Intervention
11188313|NCT03465345|Experimental|Metformin + OPC dose escalation|
11188314|NCT03465332||Lung specialist|Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
11188315|NCT03465332||Subjects with COPD|Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
11188316|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
11188317|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
11188318|NCT03465306|Experimental|Intensive digital CBT|
11188319|NCT03465306|Active Comparator|Standard digital CBT|
11188320|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
11188321|NCT03465267|Experimental|Armeo power|Armeo power robot for upper extremity
11188322|NCT03465267|Experimental|Armeo spring|Armeo spring robot for upper extremity
11188323|NCT03465254||Cohort|Recruited members of the cohort are children aged 9-14 years old and eligible to receive the dengue vaccine at the time of the initiation of community-based dengue immunization program of the Department of Health.
11188324|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
11188325|NCT03465228|Experimental|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
11188326|NCT03465228|Experimental|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
11188327|NCT03465228|Experimental|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
11188328|NCT03465215|Experimental|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
11188329|NCT03465202|Experimental|Capecitabine|
11188330|NCT03465176|Experimental|Intervention|The women in this arm will receive an essential oil blend to inhale each afternoon for two weeks.
11188331|NCT03465176|Placebo Comparator|Control|The women in this arm will receive an odorless vegetable based oil to inhale each afternoon for two weeks as a control/placebo.
11188332|NCT03465163|No Intervention|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
11188333|NCT03465163|No Intervention|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
11188334|NCT03465163|Experimental|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.
~We require a minimum of 5 seizures to occur during this phase."
11188335|NCT03465163|Experimental|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
11188475|NCT03464214|Active Comparator|Stabilization Group|Cervical stabilization exercises on cervical region
11188336|NCT03465163|Experimental|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
11188337|NCT03465137|Experimental|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
11188338|NCT03465137|No Intervention|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
11188339|NCT03465124|Active Comparator|Femtosecond Laser assisted Cataract Surgery|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.
11188340|NCT03465124|Active Comparator|Manual Cataract Surgery|Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.
11188341|NCT03465111|Experimental|Twice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U twice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.
11188342|NCT03465111|Experimental|Thrice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U thrice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 16, the treatment will be administered on as needed basis, based on the retreatment criteria.
11188343|NCT03465098|Experimental|enrolled patients|All enrolled patients will be received a strict low carbohydrate (< 3gr/day of carbohydrate) and 12h fasting before 18F-FDG PET/CT exam and 24h after a 18F-FDG PET/CT preceded by a low carbohydrate diet with 12h fasting
11188344|NCT03465085|Experimental|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
11188345|NCT03465085|Experimental|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
11188346|NCT03465085|No Intervention|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
11188347|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
11188348|NCT03465059|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
11188349|NCT03465059|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
11188350|NCT03465059|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
11188351|NCT03465059|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
11188352|NCT03465046|Experimental|low performance group 1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
11188353|NCT03465046|Experimental|low performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
11188354|NCT03465046|Experimental|moderate-high performance group1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
11188355|NCT03465046|Experimental|moderate-high performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
11188356|NCT03465033|No Intervention|Usual Care|Patients will receive basic indications of rehabilitation consisting of daily mobilization of the jaw (perform several movements a day opening movements, laterotrusion and mouth protrusion).
11188357|NCT03465033|Experimental|Early Physiotherapy|
11188358|NCT03465020||ITP patients|On active treatment
11188359|NCT03465007|Active Comparator|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
11188360|NCT03465007|Placebo Comparator|Placebo|100mg normal saline will be administered prior to hemodialysis
11188361|NCT03464994|Other|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
11188362|NCT03464994|Other|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
11188363|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
11188364|NCT03464968|Experimental|mFOLFOX|D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
11188365|NCT03464968|Experimental|mFOLFIRI|D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
11188366|NCT03464955|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
11188367|NCT03464955|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
11188476|NCT03464214|No Intervention|Control Group|Individuals performed only daily living activities
11188368|NCT03464955|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
11188369|NCT03464942|Active Comparator|Single Dose|SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
11188370|NCT03464942|Active Comparator|Fractionated Dose|SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
11188371|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
11188372|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
11188373|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
11188374|NCT03464890|Experimental|LICHTENA DermAD|"Comparison within subjects of P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO versus placebo and versus untreated control area. Study products were applied once, on experimentally induced erythema by repeated tape stripping on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side)"
11188375|NCT03464877|Experimental|Intervention group|Standardized six-week duration multi-station full-body supervised exercise program. The frequency was 2-3 sessions per week. The duration of each session was 60 minutes.
11188376|NCT03464864|Experimental|Treprostinil Inhalation Powder 30 mcg|
11188377|NCT03464864|Experimental|Treprostinil Inhalation Powder 60 mcg|
11188378|NCT03464864|Experimental|Treprostinil Inhalation Powder 90 mcg|
11188379|NCT03464864|Experimental|Treprostinil Inhalation Powder 120 mcg|
11188380|NCT03464864|Experimental|Treprostinil Inhalation Powder 150 mcg|
11188381|NCT03464864|Experimental|Treprostinil Inhalation Powder 180 mcg|
11188382|NCT03464864|Experimental|Treprostinil Inhalation Powder 240 mcg|
11188383|NCT03464864|Experimental|Treprostinil Inhalation Powder 300 mcg|
11188384|NCT03464851||Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV <= 125 cm/sec)
11188385|NCT03464851||Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
11188386|NCT03464851||Known ICA Fibromuscular Dysplasia|
11188387|NCT03464838|Experimental|Real Stimulation tDCS with CBT|16 participants will attend to one weekly tDCS stimulation session with intensity 1.8 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
11188388|NCT03464838|Sham Comparator|Sham tDCS with CBT|16 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
11188389|NCT03464825|Other|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
11188390|NCT03464825|No Intervention|Control|Care as usual
11188391|NCT03464812|Other|DSMES Group|Patients with type 2 diabetes will undergo a diabetes education program (DSMES) and evaluated for outcomes before and after completing the program.
11188392|NCT03464786|Experimental|absorbable collagen membrane|Subjects randomized in this arm will receive Lando® absorbable collagen membrane after tooth extraction.
11188393|NCT03464786|Active Comparator|Bio-Gide resorbable bilayer membrane|Subjects randomized in this arm will receive Bio-Gide resorbable bilayer membrane after tooth extraction.
11188394|NCT03464773|Other|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
11188395|NCT03464773|No Intervention|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
11188396|NCT03464760|Placebo Comparator|Placebo|
11188397|NCT03464760|Experimental|Spirulina-Silicon supplementation|
11188398|NCT03464734|Experimental|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
11188399|NCT03464721||Surgery Outpatients|
11188400|NCT03464708|Experimental|HMB|HMB 3 g/day until hospital discharge or 28-days (whichever comes first). HMB to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
11188401|NCT03464708|Placebo Comparator|Placebo|Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
11188402|NCT03464695|Active Comparator|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
11188403|NCT03464695|No Intervention|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
11188404|NCT03464682|Experimental|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
11188405|NCT03464682|Experimental|HS-25 20mg|HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
11188406|NCT03464682|Experimental|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks
11188407|NCT03464682|Experimental|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks
11188408|NCT03464682|Active Comparator|Aorvastatin 10mg|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks
11188409|NCT03464682|Placebo Comparator|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks
11188410|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
11188411|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
11188412|NCT03464669||Control group|Absence of prenatal education
11188477|NCT03464201|Experimental|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
11188413|NCT03464656|Experimental|Patients|"Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study.
~Interventions:
~Patients will be given Fairhaven Pro for Men as antioxidant in a dose of 3 tablets twice daily for 3 months.
~Full assessment of fertility will be done."
11188414|NCT03464643|Other|Single embryo culture|Embryo is cultured individually in 25 ul media
11188415|NCT03464643|Other|Group embryo culture|2-3 Embryos are group cultured in 50 ul media
11188416|NCT03464630|Experimental|Mom & Baby Net|Skills based maternal depression treatment and targeted infant social-communication promotion
11188417|NCT03464630|Active Comparator|Developmental Awareness System|Depression and infant develop awareness
11188418|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
11188419|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:
~Sign an Information and Authorization form
~Demographic data: gender, date of birth, ethnicity
~Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
11188420|NCT03464565||Patients with acute ischemic stroke secondary to LVO|
11188421|NCT03464552|Active Comparator|Celecoxib group|will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy
11188422|NCT03464552|Placebo Comparator|Placebo group|will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy
11188423|NCT03464539|Other|CD patients|PG low molecular weight chitosan 3 times per day
11188424|NCT03464526|Active Comparator|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
11188425|NCT03464526|Active Comparator|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
11188426|NCT03464526|Active Comparator|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
11188427|NCT03464526|Placebo Comparator|Placebo|Placebo tablet, once daily for 12 weeks
11188428|NCT03464513|Other|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
11188429|NCT03464500|Active Comparator|AMAZ-02 Low dose|
11188430|NCT03464500|Active Comparator|AMAZ-02 High Dose|
11188431|NCT03464500|Active Comparator|Placebo|
11188432|NCT03464487|Active Comparator|Daily LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy diet everyday along with the antiepileptic drugs.
11188433|NCT03464487|Active Comparator|Intermittent LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy Diet on five days of each week along with antiepileptic drugs. Rest of the two days, they will receive a liberal diet.
11188434|NCT03464474|Experimental|Assessment of inflammation grade|Colonic biopsies will be acquired. Biopsies from all patients will be examined using digital holographic microscopy as well as performing a histopathological analysis using the Nancy-score (Goldstandard).
11188435|NCT03464461|Placebo Comparator|0 mg|0 mg ketorolac - placebo
11188436|NCT03464461|Active Comparator|10 mg|10 mg ketorolac - low dose ketorolac
11188437|NCT03464461|Active Comparator|30 mg|30 mg ketorolac - usual dose ketorolac
11188438|NCT03464448||1|Patients with RRMS who have been newly prescribed Teriflunomide.
11188439|NCT03464448||2|Healthy Controls
11188440|NCT03464435|Experimental|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
11188441|NCT03464422|Active Comparator|HIV Positive MSM|15 HIV+ MSM will take part in 12 group sessions.
11188442|NCT03464422|Active Comparator|HIV Negative MSM|15 HIV- MSM will take part in 12 group sessions.
11188443|NCT03464409|Active Comparator|SCI Patient - Nerve Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking nerve transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
11188444|NCT03464409|Active Comparator|SCI Patient - Tendon Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking tendon transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
11188445|NCT03464409|Active Comparator|SCI Patient - No Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury who did not chose to have surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline, Early Followup (1 month later), and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
11188446|NCT03464396||Preterm infant study visits|"Preterm infants Study Visits
~Bedside Physiology Study at 28, 32, 36, 40, and 52 weeks GA.
~Respiratory tests:
~Carotid Body Function Test will be completed at 32, 36, 40 and 52 weeks GA
~Room Air Challenge (RAC) or Hypoxia Challenge Test (HCT) will be completed at 36 weeks GA
~Effects of nasal cannula flow be completed at 28, 32, 36, 40 and 52 weeks GA
~Magnetic Resonance Imaging (MRI): Completed on a subset of infants between 37-40 weeks GA or before discharge, whichever comes first.
~Echocardiogram (Echo): Completed at 32, 36 and 52 weeks GA
~Blood sample: Obtained at 32, 36 and 52 weeks GA"
11188447|NCT03464383|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
11188448|NCT03464383|Active Comparator|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
11188449|NCT03464383|Other|Survey Arm|This option will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are found to be ineligible for intervention arms of the study, or those who are eligible for the intervention arm but decline to participate in the intervention.
11188450|NCT03464370|Experimental|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
11188451|NCT03464370|Active Comparator|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
11188452|NCT03464370|Active Comparator|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
11188453|NCT03464370|Active Comparator|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
11188454|NCT03464357|Active Comparator|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
11188455|NCT03464357|Active Comparator|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.
~The fMRI will be carried out following the inclusion visit after all the necessary checks"
11188456|NCT03464344|Other|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
11188457|NCT03464344|Other|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
11188458|NCT03464331|Experimental|EXP group|Participants in EXP group (EXP) will be asked to practise Zero-time exercises (ZTE) at least 20-30 minutes per day, and on most and preferably all days of the week.
11188459|NCT03464331|Placebo Comparator|CON group|Participants in CON group (CON) will be asked to practise relaxation exercises (RE) and deep-breathing exercises (DBE) at least 30 mins every day.
11188460|NCT03464305|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
11188461|NCT03464305|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
11188462|NCT03464292|Placebo Comparator|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
11188463|NCT03464292|Active Comparator|Capsaicin Patch 8% or 0.1% Capsaicin Cream|8% capsaicin topical patch or 0.1% capsaicin cream. The patch will applied to the hand for 30 - 60 min. The cream will be applied similarly on a 3 cm2 area of the arm. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
11188464|NCT03464279|Experimental|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
11188465|NCT03464279|Active Comparator|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
11188466|NCT03464266|Active Comparator|DMPA and PrEP|
11188467|NCT03464266|Active Comparator|DMPA and no PrEP|
11188468|NCT03464266|Active Comparator|Condoms only and PrEP|
11188469|NCT03464266|Active Comparator|Condoms only and no PrEP|
11188470|NCT03464240|Active Comparator|Glucose|50 grams glucose in 50 ml water
11188471|NCT03464240|Placebo Comparator|Water|50 ml water
11188472|NCT03464227|Experimental|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
11188473|NCT03464227|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
11188474|NCT03464214|Active Comparator|Vibration Group|Local vibration on neck muscles
11189724|NCT03455634|Active Comparator|Sander|Sander bite jumping appliance
11188478|NCT03464188|No Intervention|Usual Care|Usual care family caregiver participants will be informed of the UAB Comprehensive Cancer Center Patient and Family Resources webpage.
11188479|NCT03464188|Experimental|Project Cornerstone|The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician. Regular caregiver distress thermometer screening and problem support and self-care coaching. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions.
11188480|NCT03464175|Active Comparator|Heated-humidifier left on during nebulization|
11188481|NCT03464175|Active Comparator|Heated-humidifier turned off 30 minutes before nebulization|
11188482|NCT03464175|Active Comparator|Use of a heat and moisture exchanger (HME) filter|
11188483|NCT03464175|Active Comparator|Use of a dry ventilator circuit specific for aerosol therapy|
11188484|NCT03464162|Experimental|Social Network Meetings Group|"This arm will receive Social Network Meetings for a 6 month period. Meetings may occur as often as 3 times a week when there is a crisis or more commonly would occur once every other week. These meetings will last between 60 and 90 minutes and will take place for however long the clients and their social networks would like within the project period. Ideally, each client and his/her Social Network would participate in 4 meetings during the 6 month period. This group would continue to receive care as usual with the addition of these meetings.
~*Final sample in this arm was N=3."
11188485|NCT03464162|No Intervention|No Social Network Meetings Group|"This arm will not receive the Social Network Meetings intervention. Clients in this arm will participate in the study for 6 months and receive care as usual during this time.
~*Final sample in this arm was N=1."
11188486|NCT03464162|Other|Social Network Members|"This arm is comprised of individuals who are social network members of clients who are receiving the Social Network Meetings intervention.
~*Final sample in this arm was N=3 (social network members of arm 1)."
11188487|NCT03464149||Study Arm|"One armed study, blood from each patient is analysed by the following assays:
~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
11188488|NCT03464136|Experimental|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram [mg/kg]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
11188489|NCT03464136|Active Comparator|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
11188490|NCT03464110|No Intervention|Standard of Care|Investigator will compare patients randomized into the intervention group to those who receive standard of care.
11188491|NCT03464110|Experimental|Communication Intervention|The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
11188492|NCT03464097|Experimental|Administration of oral Ozanimod 0.92mg|Subjects will receive a single 0.92 mg capsule [equivalent to ozanimod HCl 1 mg] once daily x 52 weeks
11188493|NCT03464097|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally once daily x 52 weeks
11188494|NCT03464097|Experimental|Administration of oral Ozanimod 0.46mg|Subjects will receive a single 0.46 mg capsule [equivalent to ozanimod HCl .5 mg] once daily x 52 weeks
11188495|NCT03464084|Other|bright light placebo|
11188496|NCT03464084|Other|bright light melatonin|
11188497|NCT03464084|Other|dim light|
11188498|NCT03464071|Experimental|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
11188499|NCT03464071|Experimental|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
11188500|NCT03464058|Experimental|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
11188501|NCT03464058|Experimental|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
11188502|NCT03464058|Experimental|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
11188503|NCT03464058|Experimental|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
11188504|NCT03464058|Experimental|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
11188505|NCT03464058|Experimental|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
11188506|NCT03464058|Experimental|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
11188507|NCT03464058|Experimental|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
11188508|NCT03464058|Experimental|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
11188509|NCT03464058|Experimental|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
11188510|NCT03464058|Experimental|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
11188511|NCT03464058|Experimental|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
11188512|NCT03464058|Experimental|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
11188513|NCT03464045||type 2 diabetes patients|
11188514|NCT03464032|Experimental|BCD-135|Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)
11188515|NCT03464019|Experimental|Etripamil 70 mg Single Dose|Self- administration of a single dose of 70 mg of etripamil.
11188516|NCT03464019|Placebo Comparator|Placebo Single Dose|Self- administration of a single dose of placebo.
11188517|NCT03464019|Experimental|Etripamil 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of etripamil 70 mg
11188518|NCT03464019|Placebo Comparator|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo.
11188519|NCT03464006|Experimental|Online Support Module|Patients in the online support module group will receive a tablet which has the developed peripheral arterial disease platform installed on it. The platform helps the patient to monitor factors related to their peripheral arterial disease such as exercise, smoking, and diet and helps them to track and modify these behaviours.
11188520|NCT03464006|Active Comparator|Standard of Care|Patients in this arm will receive the standard of care as provided by the institution.
11188521|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
11188522|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
11188523|NCT03463980|Experimental|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
11188524|NCT03463980|Active Comparator|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
11188525|NCT03463967|Active Comparator|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
11188526|NCT03463967|Sham Comparator|Calories Restricted|Energy-restricted diet
11188527|NCT03463954|Experimental|Novilase Laser Ablation and excision|Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
11188528|NCT03463941|Experimental|African American church members|
11188529|NCT03463915|Active Comparator|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
11188530|NCT03463915|Placebo Comparator|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
11188531|NCT03463902|Experimental|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
11188532|NCT03463902|Active Comparator|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
11188533|NCT03463902|Active Comparator|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
11188534|NCT03463902|Active Comparator|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
11188535|NCT03463902|Placebo Comparator|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
11188536|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
11188537|NCT03463876|Experimental|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
11188538|NCT03463850|Experimental|Non-fracture|subjects without a lumbar fracture will have a Dexa scan and Dual Energy CT (DECT) scan for observation/evaluation
11188539|NCT03463850|Experimental|Fracture|subjects with one or more lumbar fractures will have a Dexa scan andDual Energy CT (DECT) scan for observation/evaluation
11188540|NCT03463837|Experimental|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco [5 days] in confinement.
11188541|NCT03463837|Experimental|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint [5 days] in confinement.
11188542|NCT03463837|Experimental|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango [5 days] in confinement.
11188543|NCT03463837|Experimental|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele [5 days] in confinement.
11188544|NCT03463837|Active Comparator|Combustible cigarette|Exclusive use of combustible cigarette [5 days] in confinement.
11188545|NCT03463837|Sham Comparator|Smoking cessation (no smoking)|Smoking cessation (no smoking).
11188546|NCT03463824|Experimental|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
11188547|NCT03463824|Experimental|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
11188552|NCT03463772|Active Comparator|standard IVF|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group A will receive standard IVF procedure. Other standard assisted reproductive treatments are similar and parallel between two groups.
11188553|NCT03463772|Active Comparator|In vitro maturation|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
11188554|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
11188555|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
11188556|NCT03463746|Experimental|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
11188557|NCT03463746|Active Comparator|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
11188558|NCT03463733|Experimental|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.
~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
11188559|NCT03463720||Extremity wound|Patients with extremity wounds. Infected and not infected patients will be compared.
11188560|NCT03463707|Experimental|Treatment with BP101|
11188561|NCT03463707|Placebo Comparator|Treatment with placebo|
11188562|NCT03463694|Experimental|Hypertonic Saline ~2.6% NaCl|3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
11188563|NCT03463694|No Intervention|Standard Care|Control arm of standard symptomatic care only
11188564|NCT03463681|Experimental|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
11188565|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
11188566|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
11188567|NCT03463642|Experimental|Vitamin D3 pill|100 pills = 100,000IU + Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
11188568|NCT03463642|Placebo Comparator|Pill placebo|100 pills = Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
11188569|NCT03463642|Experimental|Vitamin D3 oral liquid|100 drops = 100,000IU in orange syrup
11188570|NCT03463642|Placebo Comparator|Oral liquid placebo|100 drops orange syrup
11188571|NCT03463642|Experimental|Skin oil + Vitamin D3 + penetrator|100,000IU + mineral oil+ Tangerine essential oil (10ml)
11188572|NCT03463642|Experimental|Skin oil + Vitamin D3|100,000IU + mineral oil
11188573|NCT03463642|Placebo Comparator|Skin oil placebo|Skin application: 100ml of mineral oil coloured with food colourant to match active oil sample
11188574|NCT03463629|Experimental|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.
~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.
~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
11188575|NCT03463629|Active Comparator|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services. Data for this arm will be collected through retrospective chart review.
11188576|NCT03463616||CT abdomen|Patients who had a CT abdomen as primary work-up before treatment planning for rectal cancer.
11188577|NCT03463616||MRI Abdomen|Patients who had a MRI abdomen as primary work-up before treatment planning for rectal cancer.
11188578|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
11188579|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
11188580|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
11188581|NCT03463590|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
11188582|NCT03463577||Exposed Group|Pregnant women vaccinated with Boostrix on or after the 1st day of the 27th week of pregnancy; who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy are in scope of this study.
11188583|NCT03463577||Unexposed Group|Women matched to the exposed cohort and pregnant sometime during the approximate estimated period between 1/1/2012-12/31/2013 who did not receive any Tdap vaccine during the pregnancy are in scope of this study.
11188584|NCT03463564|Active Comparator|Insulin pump|Insulin Pump with rapid acting insulin analog lispro
11188585|NCT03463564|Active Comparator|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection at bed-time of basal insulin glargine or degludec
11188948|NCT03461315|Experimental|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
11188586|NCT03463551|Experimental|ABL-101 IV as per dosing cohort + Supplementary O2 for 24h|"Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.
~In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.
~Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.
~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
11188587|NCT03463551|Placebo Comparator|IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h|"Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.
~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
11188588|NCT03463538|Active Comparator|Arthroscopic capsular release|Surgical release performed under general anesthetic
11188589|NCT03463538|Active Comparator|Hydro-dilatation|injection of water under local anesthetic in to shoulder joint
11188590|NCT03463525|Experimental|[11C]osimertinib + oral osimertinib|IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.
11188591|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
11188592|NCT03463512|Active Comparator|ORS (standard treatment)|
11188593|NCT03463499|Experimental|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
11188594|NCT03463473|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 0.3 mg/kg and may be escalted to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
11188595|NCT03463460|Experimental|Treatment (pembrolizumab, sunitinib malate)|Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
11188596|NCT03463447|Experimental|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
11188597|NCT03463434|Experimental|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
11188598|NCT03463434|Active Comparator|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
11188599|NCT03463408|Experimental|Immunotherapy arm|"Cohort A will comprise adult soft tissue sarcoma patents who consent to and receive ipilimumab + nivolumab concurrently with standard of care radiation. Ipilimumab will be given at a dose of 1 mg/kg every 6 weeks (total two doses) and nivolumab given as a flat dose of 240 mg every 2 weeks (total four doses).
~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
11188600|NCT03463408|No Intervention|no immunotherapy arm|"Cohort B will comprise patients eligible for the trial who do not wish to receive immunotherapy but consent to the same blood draws, surveys, and specimen analysis as Cohort A. Cohort B will serve as a non-randomized but pragmatic and clinically relevant control group.
~Standard surgical resection will be done 2 to 4 weeks after completion of radiotherapy. Accrual is expected to occur over 2 years. Follow up data will be collected for up to 3 years post-treatment."
11188601|NCT03463395|No Intervention|Standard of Care|Group A will receive standard of care
11188602|NCT03463395|Experimental|Reza band use|Group B will receive standard care plus the Reza band (worn as recommended by the manufacturer)
11188603|NCT03463382|Active Comparator|ESP Group|"Erector Spinae Plane Block Group
~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
11188604|NCT03463382|Active Comparator|QLB Group|"Quadratus Lumborum Block Group
~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
11188605|NCT03463369|Experimental|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
11188606|NCT03463369|Experimental|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
11188607|NCT03463356|Experimental|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
11188608|NCT03463343|Experimental|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
11188609|NCT03463343|Active Comparator|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
11188610|NCT03463343|Placebo Comparator|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
11188611|NCT03463343|No Intervention|Control|The subjects stayed in supine position and no intervention occurred.
11188612|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
11188613|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
11188614|NCT03463317|Experimental|LAA closure group|Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)
11188949|NCT03461302|Experimental|Topical Coal Tar treatment|
11188615|NCT03463317|Active Comparator|Best medical care group|No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)
11188616|NCT03463291||Study group|All patients with bony lesions
11188617|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
11188618|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
11188619|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of >7 blastocysts vitrified
11188620|NCT03463265|Experimental|ABI-009|
11188621|NCT03463265|Experimental|ABI-009 + bevacizumab|
11188622|NCT03463265|Experimental|ABI-009 + temozolamide|
11188623|NCT03463265|Experimental|ABI-009 + lomustine|
11188624|NCT03463265|Experimental|ABI-009 + temozolamide + radiotherapy|
11188625|NCT03463265|Experimental|ABI-009 + marizomib|
11188626|NCT03463252|Active Comparator|MPA for EC without progesterone contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
11188627|NCT03463252|Experimental|MPA+Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
11188628|NCT03463252|Experimental|Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
11188629|NCT03463252|Active Comparator|GnRH agonist+Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
11188630|NCT03463252|Experimental|Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
11188631|NCT03463252|Active Comparator|Mirena® for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
11188632|NCT03463252|Experimental|MPA for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
11188633|NCT03463252|Active Comparator|Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
11188664|NCT03463083|Active Comparator|Bupivacaine dexmedetomidine group|Group 1 (bupivacaine + dexmedetomidine (BD) group); will Receive an epidural study solution of 18 ml of 0.25% of bupivacaine hydrochloride plus 1 ml of dexmedetomidine (1 mcg/kg) plus 1 ml normal saline keeping the total volume of 20 ml in a syringe pump .
11188950|NCT03461302|Active Comparator|Topical Corticosteroids treatment|
11188634|NCT03463252|Experimental|GnRH-a+Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
11188635|NCT03463239|Experimental|Autologous tissue engineered corpora|All subjects enrolled will undergo a corpora cavernosum biopsy. Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
11188636|NCT03463226||Low testosterone|"Patients with HF and testosterone deficiency.
~Cardiopulmonary exercise test
~Muscle Sympathetic Nerve Activity
~Dual-energy X-ray absorptiometry
~Venous occlusion plethysmography
~Blood sample collection
~Dynamometers for Handgrip Strength"
11188637|NCT03463226||Normal testosterone|"Patients with HF and normal plasma levels of testosterone.
~Cardiopulmonary exercise test
~Muscle Sympathetic Nerve Activity
~Dual-energy X-ray absorptiometry
~Venous occlusion plethysmography
~Blood sample collection
~Dynamometers for Handgrip Strength"
11188638|NCT03463213|Experimental|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
11188639|NCT03463200|No Intervention|Control group|It will not apply any tape.
11188640|NCT03463200|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
11188641|NCT03463200|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
11188642|NCT03463200|Experimental|Experimental group 3|Apply Micropore tape in the erector spine muscles.
11188643|NCT03463187|Experimental|80mg SHR-1314-Part A|SHR-1314 80mg, subcutaneously
11188644|NCT03463187|Experimental|160mg SHR-1314-Part A|SHR-1314 160mg, subcutaneously
11188645|NCT03463187|Experimental|240mg SHR-1314-Part A|SHR-1314 240mg, subcutaneously
11188646|NCT03463187|Experimental|40mg SHR-1314 (Part B)|SHR-1314 40mg, subcutaneously
11188647|NCT03463187|Experimental|80mg SHR-1314 (Part B)|SHR-1314 80mg, subcutaneously
11188648|NCT03463187|Experimental|160mg SHR-1314 (Part B)|SHR-1314 160mg, subcutaneously
11188649|NCT03463187|Experimental|240mg SHR-1314 (Part B)|SHR-1314 240mg, subcutaneously
11188650|NCT03463187|Experimental|SHR-1314 Placebo (Part B)|SHR-1314 Placebo, subcutaneously
11188651|NCT03463174|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have a dental implant placed in the mandibular midline followed by the immediately insertion of a ball attachment and the incorporation of a retention matrix to the mandibular denture.
11188652|NCT03463174|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment besides the new set of conventional complete dentures. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
11188653|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.
~Participants will receive Pembrolizumab and Epacadostat."
11188654|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.
~Participants will receive Pembrolizumab and Epacadostat."
11188655|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
11188656|NCT03463135|Experimental|SAR439794 [PE SLIT + GLA)]|GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
11188657|NCT03463135|Experimental|Placebo for GLA + SLIT PE|Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
11188658|NCT03463135|Placebo Comparator|Placebo for GLA + Placebo for SLIT PE|Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks
11188659|NCT03463122|Other|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
11188660|NCT03463122|Other|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
11188661|NCT03463109|Other|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
11188662|NCT03463109|Other|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.
~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
11188663|NCT03463096|Experimental|Centrifuge study|High G acceleration on a long-arm human centrifuge
11188704|NCT03462823|Active Comparator|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
11188665|NCT03463083|Active Comparator|Bupivacaine fentanyl group|Group 2 (bupivacaine + fentanyl (BF) group) ; will Receive an epidural study solution of 18 ml of 0.25% bupivacaine plus 2 ml fentanyl (1 mcg/kg) keeping the total volume of 20 ml in a syringe pump .
11188666|NCT03463070|Active Comparator|preoperative misoprostol group|70 women who received 600 mg misoprostol rectally preoperatively before cesarean section
11188667|NCT03463070|Active Comparator|postoperative misoprostol group|70 women who received 600 mg misoprostol postoperatively at operating theatre after cesarean section
11188668|NCT03463057|Other|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
11188669|NCT03463044|Placebo Comparator|Placebo|
11188670|NCT03463044|Experimental|MOTREM 1|
11188671|NCT03463044|Experimental|MOTREM 2|
11188672|NCT03463044|Experimental|MOTREM 3|
11188673|NCT03463044|Experimental|MOTREM 4|
11188674|NCT03463044|Experimental|MOTREM 5|
11188675|NCT03463044|Experimental|MOTREM 6|
11188676|NCT03463044|Experimental|MOTREM 7|
11188677|NCT03463044|Experimental|MOTREM 8|
11188678|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
11188679|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
11188680|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
11188681|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
11188682|NCT03463005|Experimental|Royal jelly|The study subjects included healthy women who had husbands with male-factor infertility problems.
11188683|NCT03463005|Active Comparator|IUI group|The study subjects included in IUI group were healthy women who had husbands with male-factor infertility problems.
11188684|NCT03462992||FIT-positive individuals|Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
11188685|NCT03462979|Experimental|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
11188686|NCT03462979|No Intervention|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 8 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
11188687|NCT03462966|Experimental|Therapeutic|40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.
11188688|NCT03462953|Placebo Comparator|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
11188689|NCT03462953|Placebo Comparator|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
11188690|NCT03462940|Experimental|TUDCA Group|All subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period of of the nutritional supplement Tauroursodeoxycholic acid (TUDCA).
11188691|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
11188692|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
11188693|NCT03462901|Experimental|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
11188694|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
11188695|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
11188696|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
11188697|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
11188698|NCT03462862|Experimental|Group 1|patients will receive partial denture constructed from PEEK material
11188699|NCT03462862|Active Comparator|Group 2|patients will receive partial denture constructed from breflex material
11188700|NCT03462849|Other|Patients with EFL at PEP 5|Patients with EFL at PEP 5 at the time of inclusion either in supine or semi-recumbent position
11188701|NCT03462849|Other|Patients with no EFL at PEP 5|Patients with no EFL at PEP 5 at the time of inclusion in both supine and semi-recumbent positions
11188702|NCT03462836|Experimental|IV ketamine/lidocaine/IV PCA (MA) group|In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
11188703|NCT03462836|Active Comparator|IV PCA only (CA) group|In addition to basic anesthetic methods, only IC PCA apply for pain control
11188784|NCT03462303|Experimental|tDCS anodal +tyrosine depleted drink|
11188705|NCT03462823|Experimental|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
11188706|NCT03462784||Cases|
11188707|NCT03462771|Experimental|Group exercise fish oil|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive omega-3 fatty acid supplements to be ingested 2g in the main meals, totaling 4g daily.
11188708|NCT03462771|Placebo Comparator|Group exercise placebo|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive sunflower oil to be ingested 2g in the main meals, totaling 4g daily.
11188709|NCT03462758|Other|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
11188710|NCT03462758|Experimental|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
11188711|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
11188712|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
11188713|NCT03462732|Active Comparator|Group I|Endotracheal tube plus Nelaton catheter
11188714|NCT03462732|Active Comparator|Group II|Endotracheal tube
11188715|NCT03462719|Experimental|Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)|Participants will initially receive ibrutinib (420 mg [milligrams]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
11188716|NCT03462719|Active Comparator|Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)|Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
11188717|NCT03462706|Experimental|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
11188718|NCT03462706|Experimental|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
11188719|NCT03462706|Experimental|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
11188720|NCT03462706|Experimental|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
11188721|NCT03462693||Group 1|Dry needling plus standard physiotherapy treatment
11188722|NCT03462693||Group 2|Standard physiotherapy treatment
11188723|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
11188724|NCT03462680|Placebo Comparator|placebo|placebo
11188725|NCT03462667|Experimental|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
11188726|NCT03462667|Active Comparator|Regular Care|Participants will receive normal standard of care prior to surgery.
11188727|NCT03462654|Active Comparator|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
11188728|NCT03462654|Experimental|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
11188729|NCT03462641|Active Comparator|Flumazenil|Flumazenil 1mg in 10cc normal saline will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
11188730|NCT03462641|Placebo Comparator|Placebo|10 cc of normal saline placebo will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
11188731|NCT03462628|Experimental|Study Group|PVI with additional low-voltage substrate modification
11188732|NCT03462628|Active Comparator|Control Group|PVI
11188733|NCT03462602|Experimental|NGT group|NGT group
11188734|NCT03462602|Experimental|non-NGT group|non-NGT group
11188735|NCT03462589|Experimental|SY-008 dose 1|A single dose of SY-008 (2~30mg) taken orally.
11188736|NCT03462589|Experimental|SY-008 dose 2|A single dose of SY-008 (2~30mg) taken orally.
11188737|NCT03462589|Experimental|SY-008 dose 3|A single dose of SY-008 (2~30mg) taken orally.
11188738|NCT03462589|Experimental|SY-008 dose 4|A single dose of SY-008 (2~30mg) taken orally.
11188739|NCT03462589|Experimental|SY-008 dose 5|A single dose of SY-008 (2~30mg) taken orally.
11188740|NCT03462589|Placebo Comparator|SY-008 matching placebo|from 6mg to 30mg
11188741|NCT03462563|Experimental|INTERCEED™|patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen).
11188742|NCT03462563|Placebo Comparator|standard of care treatment|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
11188743|NCT03462550|Active Comparator|LMA Supreme|
11188744|NCT03462550|Experimental|LMA Protector|
11188745|NCT03462537|Experimental|Experimental group 1|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line.
11188746|NCT03462537|Experimental|Experimental group 2|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line, but low level laser therapy device was switched off.
11188747|NCT03462537|Placebo Comparator|Placebo group|Low level laser therapy without power. This group performed the low level laser therapy protocol, but low level laser therapy device was switched off.
11188748|NCT03462524||Neoadjuvant chemotherapy|
11188749|NCT03462524||Neoadjuvant chemoradiation|
11188750|NCT03462511|No Intervention|Control Group|Dyads randomized to the control group will receive standard care and education handouts.
11188751|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
11188752|NCT03462498|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
11188753|NCT03462498|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
11188754|NCT03462485|Experimental|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
11188755|NCT03462485|No Intervention|Control|Control participants will continue their normal activities.
11188756|NCT03462472|Experimental|15 minute lower leg heating|
11188757|NCT03462472|Experimental|45 minute lower leg heating|
11188758|NCT03462472|No Intervention|Control|
11188759|NCT03462472|Experimental|15 minute lower leg TENS|
11188760|NCT03462472|Experimental|45 minute lower leg TENS|
11188761|NCT03462459|Experimental|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
11188762|NCT03462459|Placebo Comparator|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
11188763|NCT03462446||Treatment group with Rivaroxaban|Patients treated with Rivaroxaban
11188764|NCT03462446||Control group with VKAs|Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
11188765|NCT03462420|Experimental|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
11188766|NCT03462420|Active Comparator|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
11188767|NCT03462407|Experimental|DAID|Trained assistants will help participants train their dog to engage in imitation based dog training, using positive reinforcement training (operant conditioning) focused on physical activities.
11188768|NCT03462407|Active Comparator|Dog walking|Trained assistants will help children train their dog to walk on a loose leash (eliminate pulling behavior) during this period using positive training techniques. The focus of this group will be on appropriate walking behavior to facilitate enjoyable independent dog-walking at home.
11188769|NCT03462407|No Intervention|Control|This group will all own family dogs but will not participate in either intervention during year 1. All participants assigned to the waitlist will be offered the DAID intervention the subsequent summer.
11188770|NCT03462394|Active Comparator|Current Script Version|This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health.
11188771|NCT03462394|Active Comparator|Script Iterations|This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script.
11188772|NCT03462381|Experimental|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
11188773|NCT03462381|Placebo Comparator|Carbohydrate|Three endurance training sessions weekly with carbohydrate supplementation post-exercise and before sleep.
11188774|NCT03462368|Active Comparator|Control|Root surface treatment by scaling and root planing
11188775|NCT03462368|Experimental|antimicrobial photodynamic therapy|Root surface treatment by antimicrobial photodynamic therapy
11188776|NCT03462368|Active Comparator|Photobiomodulation|Treatment of the whole surgical site with laser
11188777|NCT03462342|Experimental|1- Olaparib Pill + AZD6738.|"All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.
~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
11188778|NCT03462329|Active Comparator|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
11188779|NCT03462329|No Intervention|controls|Control subjects will not be given antibiotics.
11188780|NCT03462316|Experimental|NY-ESO-1 TCR Specific T cell Therapy|NY-ESO-1 TCR specific T cells are prepared by lentiviral infection. Seven days before TCR-T cell reinfusion, the subjects received low-dose cyclophosphamide (15mg/kg/d x 3 days) and low-dose fludarabine (15mg/m2/d x 3 days) lymphocyte clearance. Four days later, TCR-T cells were transfused back (1 x 109-5 x 1010 was administered once or in stages). Then interleukin (IL)-2 subcutaneous injections (250,000 IU/twice/day) will be subcutaneously administered for 14 days concomitantly to each subject within 15-30 minutes after cell reinfusion. If the first three patients had no severe bone marrow suppression side effects (CTCAE was above grade 3) on low-dose lymphocyte clearance therapy, the dosage of cyclophosphamide (20 mg/kg/d x 3 days) and fludarabine (25 mg/m2/d x 3 days) could be increased for follow-up patients.
11188781|NCT03462303|Placebo Comparator|tDCS sham + balanced drink|
11188782|NCT03462303|Experimental|tDCS sham + tyrosine depleted drink|
11188783|NCT03462303|Experimental|tDCS anodal + balanced drink|
11188788|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
11188789|NCT03462264|No Intervention|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
11188790|NCT03462264|Experimental|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
11188791|NCT03462264|Experimental|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
11188792|NCT03462251|Experimental|Arm A|Combination of ribociclib and aromatase inhibitor or fulvestrant
11188793|NCT03462251|Active Comparator|Arm B|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
11188794|NCT03462238|Other|Kidney transplant patients|Group of renal transplant patients for 24 months
11188795|NCT03462238|Other|Dialysis patients|Group of dialysis patients for 24 months
11188796|NCT03462212|Other|Standard treatment|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
11188797|NCT03462212|Experimental|Carboplatin + Paclitaxel + Bevacizumab + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
11188798|NCT03462212|Experimental|Carboplatin + Paclitaxel + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
11188799|NCT03462199|Placebo Comparator|Placebo|
11188800|NCT03462199|Experimental|Actazin High Dose|
11188801|NCT03462199|Experimental|Actazin Low Dose|
11188802|NCT03462199|Active Comparator|Control Formula|
11188803|NCT03462199|Experimental|Livaux High Dose|
11188804|NCT03462199|Experimental|Livaux Low Dose|
11188805|NCT03462186|Experimental|Intervention|Invitation to use healthfinder website
11188806|NCT03462186|No Intervention|Control|No intervention
11188807|NCT03462173|Experimental|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
11188808|NCT03462173|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
11188809|NCT03462173|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
11188810|NCT03462173|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
11188811|NCT03462173|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
11188812|NCT03462173|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
11188813|NCT03462173|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
11188814|NCT03462160|Placebo Comparator|Placebo supply for 90 days|Patients will receive placebo (in blinded sachets)
11188815|NCT03462160|Experimental|Probiotic supply for 90 days|Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).
11188816|NCT03462147|Sham Comparator|SHAM|No stimulation will be given
11188817|NCT03462147|Experimental|High Density Stimulation|New way of spinal cord stimulation
11188818|NCT03462147|Active Comparator|Conventional stimulation|the most used stimulation of the spinal cord
11188819|NCT03462134||Survey amongst orthopaedic surgeons|Selected of 20 patients from the Escape trial (NCT01850719)
11188820|NCT03462121|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
11188821|NCT03462121|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
11188822|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Adult|1 doses of 1 ml of Rotavirus vaccine per oral
11188823|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Children|1 doses of 1 ml of Rotavirus vaccine per oral
11188824|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
11188825|NCT03462108|Placebo Comparator|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
11188826|NCT03462095|No Intervention|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
11188827|NCT03462095|Experimental|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
11188828|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
11188829|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
11188830|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
11188831|NCT03462069|Experimental|Treatment A (Test)|Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
11188832|NCT03462069|Active Comparator|Treatment B (Reference)|Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
11188833|NCT03462056|Experimental|CF Ready to Use Supplemental Food.|Participants will receive Cystic Fibrosis Ready to Use Supplemental Food sufficient to provide approximately 20% of estimated daily caloric needs up to 500kcal of total calories, 18.5 grams of protein and 28g of fat. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition
11188834|NCT03462043|Active Comparator|Sequence A|
11188835|NCT03462043|Active Comparator|Sequence B|
11188836|NCT03462043|Active Comparator|Sequence C|
11188837|NCT03462043|Active Comparator|Sequence D|
11188838|NCT03462030|Experimental|Baked Milk Immunotherapy|Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
11188839|NCT03462030|Placebo Comparator|Placebo|Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
11188840|NCT03462017|Experimental|SAR247799|SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design
11188841|NCT03462017|Placebo Comparator|Placebo|Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days
11188842|NCT03462017|Active Comparator|Sildenafil|Sildenafil once daily in the morning under fasted condition for 28 days
11188843|NCT03462004|Experimental|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
11188844|NCT03462004|Placebo Comparator|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
11188845|NCT03462004|Experimental|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
11188846|NCT03462004|Placebo Comparator|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
11188847|NCT03461991|Other|Patients scheduled for corneal transplantation|
11188848|NCT03461978|Other|10 patients with meibomian gland dysfunction|
11188849|NCT03461978|Other|10 patients with cataract|
11188850|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
11188851|NCT03461978|Other|10 patients after partial corneal transplantation|
11188852|NCT03461978|Other|5 patients with demodicosis|
11188853|NCT03461978|Other|5 patients with conjunctival pathologies|
11188854|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
11188855|NCT03461978|Other|5 patients with aniridia|
11188856|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
11188857|NCT03461965|Active Comparator|Verbal Counselling|Patients in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
11188858|NCT03461952|Experimental|Nivolumab|240mg Q2W
11188859|NCT03461952|Experimental|Nivolumab + Ipilimumab|Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W
11188860|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.
~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
11188861|NCT03461926|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
11188862|NCT03461926|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
11188863|NCT03461913|Active Comparator|normal pregnancy|women at full term healthy pregnancy who underwent elective Cesarean section
11188864|NCT03461913|Active Comparator|pregnancy hypertension|women at full term pregnancy associated with hypertension who underwent elective Cesarean section
11188865|NCT03461900|Experimental|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
11188866|NCT03461900|Experimental|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
11188867|NCT03461887|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
11188868|NCT03461887|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment or treatment decisions, including participation in other exercise training programs or rehabilitation programs)
11188869|NCT03461874|Active Comparator|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
11188870|NCT03461874|Experimental|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.
~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
11188871|NCT03461861|Experimental|AGB101 220 mg, then Placebo|AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
11188872|NCT03461861|Experimental|Placebo, then AGB101 220 mg|Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.
11188873|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
11188874|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
11188875|NCT03461835|Active Comparator|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
11188952|NCT03461276|Experimental|ABvac40|Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
11188876|NCT03461835|Active Comparator|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
11188877|NCT03461822||SRT in primary-inoperable solid tumors|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
11188878|NCT03461822||Classic radiotherapy in primary-inoperable solid tumors|Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
11188879|NCT03461822||SRT in oligometastatic cancer|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
11188880|NCT03461822||Classic radiotherapy in oligometastatic cancer|Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
11188881|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
11188882|NCT03461783|Experimental|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
11188883|NCT03461783|Active Comparator|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
11188884|NCT03461770|No Intervention|Control group|Patients will receive anesthesia induction with Sevoflurane using a circular circuit without CPAP. Protective ventilation with 5 cmH20 of positive end-expiratory pressure (PEEP) will be initiated after induction. At the end of surgery, mechanical ventilation will stop allowing spontaneous ventilation. Patients will be extubated without CPAP. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
11188885|NCT03461770|Experimental|CPAP group|Patients will receive anesthesia induction using 5 cmH20 of CPAP until the moment of intubation. After induction patients will receive the same protective ventilation than the control group. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery. At the end of surgery, patients will be extubated under the modality of CPAP with 5 cmH20. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
11188886|NCT03461757|Experimental|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
11188887|NCT03461757|Placebo Comparator|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
11188888|NCT03461731|Sham Comparator|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
11188889|NCT03461731|Experimental|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
11188890|NCT03461731|Experimental|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
11188891|NCT03461731|Experimental|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
11188892|NCT03461718|Experimental|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
11188893|NCT03461718|Active Comparator|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
11188894|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
11188895|NCT03461679|Experimental|Intervention|Adductor canal block Femoral triangle block
11188896|NCT03461679|Active Comparator|Standard|Femoral triangle block
11188897|NCT03461666|Active Comparator|Cognitive Behavior Therapy-Insomnia|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
11188898|NCT03461666|Active Comparator|Focus Of Attention|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
11188899|NCT03461666|Active Comparator|Combined-CBT-I and FOA Group|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
11188900|NCT03461666|Active Comparator|Sleep Hygiene|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
11188901|NCT03461653|Other|Telemedicine counselling|intervention group Women who will receive telemedicine counselling
11188902|NCT03461653|No Intervention|Standard care|Women who will receive standard face-to-face counselling
11188903|NCT03461640|Experimental|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.
~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.
~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
11188951|NCT03461289|Experimental|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
11188995|NCT03460977|Experimental|DL 5|PF-06821497 500 mg BID
11188904|NCT03461640|Active Comparator|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.
~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
11188905|NCT03461627|Experimental|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
11188906|NCT03461627|Active Comparator|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
11188907|NCT03461614|Experimental|Exercise Group|In addition to the service routine rehabilitation program, in this group all participant receive as group training with instructor supervising 5-6 participants. The specific days of the week and time of day in which the participants trained remained constant throughout each training protocol. Training programs lasted 6 weeks and comprised 2 training sessions per week with a total of 12 training sessions. A 45-60 min training sessions per week with a 2 day gap between each session.
11188908|NCT03461614|Other|Control Group|In addition to the service routine rehabilitation program, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
11188909|NCT03461601|Active Comparator|HCG uterine flushing group|Uterine flushing was done one day before Intrauterine insemination (IUI) with HCG (500 IU) in 10 ml of saline followed by Intrauterine insemination (IUI).
11188910|NCT03461601|Placebo Comparator|IUI alone group|Intrauterine insemination alone plus vaginal flushing with 10 ml normal saline
11188911|NCT03461588|Active Comparator|Free-breathing|standard treatment
11188912|NCT03461588|Experimental|Deep inspiratory breath-holding|new technique
11188913|NCT03461575|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%
~1 drop b.i.d at 12hr interval for 12 weeks"
11188914|NCT03461575|Active Comparator|Restasis|"Cyclosporine 0.05%
~1 drop b.i.d at 12hr interval for 12 weeks"
11188915|NCT03461575|Active Comparator|Moisview|"trehalose 3%
~1 drop b.i.d at 12hr interval for 12 weeks"
11188916|NCT03461562|Experimental|Experimental|
11188917|NCT03461562|Active Comparator|Control|
11188918|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
11188919|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
11188920|NCT03461536|Active Comparator|Clinical Decision Support|Participants in this arm will receive the study intervention, the clinical decision support.
11188921|NCT03461536|No Intervention|Usual care|Participants in this arm will not receive the the clinical decision support tool.
11188922|NCT03461510|Experimental|Type 2 Diabetes|Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
11188923|NCT03461510|No Intervention|Lean Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
11188924|NCT03461510|No Intervention|Obese Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
11188925|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
11188926|NCT03461471|Experimental|Intervention Group|Exercise intervention
11188927|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
11188928|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
11188929|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
11188930|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
11188931|NCT03461432|Experimental|Personalised Cognitive Remediation Therapy (pCRT)|A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
11188932|NCT03461419|Experimental|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
11188933|NCT03461419|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
11188934|NCT03461419|Experimental|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
11188935|NCT03461406|Experimental|Fibrin Sealant Grifols|human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution)
11188936|NCT03461406|Active Comparator|EVICEL|human fibrinogen (55-85 mg/mL) and human thrombin (800-1200 IU/mL)
11188937|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
11188938|NCT03461380|Experimental|Menopause Relief EP-40|Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients
11188939|NCT03461380|Active Comparator|High Dose Black Cohosh|Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient
11188940|NCT03461380|Placebo Comparator|Placebo|Placebo capsule 600 mg excipients orally twice daily
11188941|NCT03461380|Active Comparator|Low Dose Black Cohosh|Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient
11188942|NCT03461354|Experimental|A|Mucolox Arm
11188943|NCT03461354|Active Comparator|B|Sodium Bicarb Control Arm
11188944|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
11188945|NCT03461328|Experimental|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
11188946|NCT03461328|No Intervention|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
11188953|NCT03461276|Placebo Comparator|Placebo|Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
11188954|NCT03461263|Active Comparator|Group A|phonophoresis treatment using pumpkin seeds oil
11188955|NCT03461263|No Intervention|Group B|Low intensity Ultrasound
11188956|NCT03461263|No Intervention|Group C|Placebo Low intensity Ultrasound
11188957|NCT03461250||HCV serology negative in HD|Risk factors
11188958|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
11188959|NCT03461224||MARA-1: accelerated hypofractionated RT|A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
11188960|NCT03461224||CG: conventional fractionated RT|In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
11188961|NCT03461211|Experimental|Teprotumumab 20 mg/kg|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
11188962|NCT03461198|Experimental|Treatment|Restylane® Silk to a defined area of mid to low cheeks.
11188963|NCT03461185|Experimental|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
11188964|NCT03461185|Active Comparator|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
11188965|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
11188966|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
11188967|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
11188968|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
11188969|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
11188970|NCT03461146|Experimental|MT-6548|
11188971|NCT03461133||Reference|All patients admitted to the participating surgical wards from 2015-01-01 to 2015-12-31
11188972|NCT03461133||Intervention|All patients admitted to the participating surgical wards from 2016-07-01 to 2017-06-30
11188973|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% [or ropivacaine 0.5%] infusion for 7 days via femoral and sciatic perineural catheters
11188974|NCT03461120|Other|Control|Bupivacaine 0.1% [or ropivacaine 0.2%] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
11188975|NCT03461107||patients with heart failure|
11188976|NCT03461081|Experimental|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
11188977|NCT03461081|Experimental|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
11188978|NCT03461068|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
11188979|NCT03461068|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
11188980|NCT03461055|Experimental|Lavender|Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
11188981|NCT03461055|Placebo Comparator|Water|1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
11188982|NCT03461042|Experimental|Arm R|Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
11188983|NCT03461042|Placebo Comparator|Arm PL|Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
11188984|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
11188985|NCT03461016|Experimental|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
11188986|NCT03461016|No Intervention|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
11188987|NCT03461003|Experimental|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
11188988|NCT03461003|Active Comparator|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
11188989|NCT03460990|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
11188990|NCT03460990|Experimental|VX-659/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
11188991|NCT03460977|Experimental|DL 1|PF-06821497 75 mg BID
11188992|NCT03460977|Experimental|DL 2|PF-06821497 150 mg BID
11188993|NCT03460977|Experimental|DL 3|PF-06821497 250 mg BID
11188994|NCT03460977|Experimental|DL 4|PF-06821497 375 mg BID
11188997|NCT03460964|Experimental|Patients with Diabetes|All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.
11188998|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
11188999|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
11189000|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
11189001|NCT03460938|Experimental|RIPC|
11189002|NCT03460938|No Intervention|Control|
11189003|NCT03460925|Experimental|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
11189004|NCT03460912||All participants|
11189005|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
11189006|NCT03460886|Experimental|Bihemispheric stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
11189007|NCT03460886|Experimental|Ipsilesional stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Sham on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
11189008|NCT03460886|Experimental|Contralesional stimulation|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
11189009|NCT03460886|Active Comparator|Sham|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area
~Sham stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
11189010|NCT03460860|Experimental|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
11189011|NCT03460860|Placebo Comparator|Placebo|
11189012|NCT03460834||Obese asthmatic patients|Observational Cohort
11189013|NCT03460821||Employees|Male and female employees (≥ 18 years of age) of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin experienced in the field of neurocognitive testing: residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects
11189014|NCT03460808|Experimental|atorvastatin, acetylcysteine & danazol|atorvastatin 20mg qd po plus acetylcysteine 400mg tid po plus danazol 200mg bid po for 12 weeks
11189015|NCT03460795|Experimental|Conventional plus MSC and Tregs treatment|
11189016|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
11189017|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
11189018|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
11189019|NCT03460756|Experimental|Ganaxolone|Oral
11189020|NCT03460756|Placebo Comparator|Placebo|Oral
11189021|NCT03460743|Experimental|Study group|single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine
11189022|NCT03460743|Active Comparator|Control group|single or two doses of quadrivalent inactivated influenza vaccine.
11189023|NCT03460730|Experimental|Immunised children|Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)
11189024|NCT03460717|Experimental|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
11189025|NCT03460717|No Intervention|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
11189026|NCT03460704|Experimental|Drug: Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45% Other Name: Promixin
11189027|NCT03460704|Placebo Comparator|Drug: Saline Solution|1 ml saline solution 0.45%
11189028|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
11189029|NCT03460678|Other|Pemetrexed Arm|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
11189030|NCT03460678|Other|Erlotinib Arm|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)
11189031|NCT03460665|Experimental|Microparticles|arteriography and an injection of inert microparticles of 75 µm in neovessels
11189032|NCT03460665|Placebo Comparator|Placebo|knee arteriography and injection of saline solution in neovessels
11189033|NCT03460652|Experimental|Active Treatment|KP415 oral capsule 20, 30 or 40 mg (total d-MPH from IR d-MPH and KP415 prodrug)
11189034|NCT03460639|Active Comparator|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
11189035|NCT03460639|Sham Comparator|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
11189036|NCT03460639|Other|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
11189037|NCT03460626|Placebo Comparator|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
11189038|NCT03460626|Experimental|Group-II (Treated group)|This group will be administered lavender oil.
11189039|NCT03460626|No Intervention|Group-III (Untreated group)|No intervention will be provided in this group.
11189040|NCT03460613|Other|FGID Patients|
11189041|NCT03460613|No Intervention|Hepatology Control Group|
11189042|NCT03460613|No Intervention|Healthy Volunteers|
11189043|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
11189044|NCT03460574|Experimental|INFORMATION|"Participants in this condition receive a manipulation suggesting that the performance test TEMINT, they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted."
11189045|NCT03460574|Experimental|SALIENCE|Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
11189046|NCT03460574|Experimental|ATTENTION|Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
11189047|NCT03460574|Experimental|CONTROL|Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
11189048|NCT03460561|Active Comparator|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
11189049|NCT03460561|Active Comparator|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
11189050|NCT03460548|Experimental|Remogen|
11189051|NCT03460548|Active Comparator|Cationorm|
11189052|NCT03460522|Experimental|Induction Therapy with Inotuzumab Ozogamicin|Patients will receive up to 3 cycles Inotuzumab with applications on day 1, 8 and 15 in each cycle. First dose will be 0.8 mg/m² on Day 1. All subsequent doses will be 0,5 mg/m².
11189053|NCT03460509|Placebo Comparator|Sugammadex 0 mg/kg|Placebo NaCl 0,9%
11189054|NCT03460509|Active Comparator|Sugammadex 0,25 mg/kg|Sugammadex 0.25 mg/kg IBW
11189055|NCT03460509|Active Comparator|Sugammadex 0,5 mg/kg|Sugammadex 0.50 mg/kg IBW
11189056|NCT03460509|Active Comparator|Sugammadex 1mg/kg|Sugammadex 1.0 mg/kg IBW
11189057|NCT03460509|Active Comparator|Sugammadex 2mg/kg|Sugammadex 2 mg/kg IBW
11189058|NCT03460496|Experimental|APN-led Intervention|"Intervention group being provided with the interventions described below.
~Advanced practice nurses' interventions
~Neonatologists: neonatal outpatient consultation
~psychological support
~lactation consultant
~physiotherapeutic interventions
~collaboration with social workers
~music therapy
~close collaboration with other health care professionals
~interprofessional roundtable meetings"
11189059|NCT03460496|No Intervention|Control, Standard Care|Control group receiving standard care
11189060|NCT03460483|Experimental|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
11189061|NCT03460470|Active Comparator|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
11189062|NCT03460470|Placebo Comparator|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
11189063|NCT03460457|Experimental|TQB2450|
11189064|NCT03460444|Experimental|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days while consuming a diet similar to the recommended health guidelines (40-50% carbohydrate; 30-40% fat; 20-25% protein).
11189065|NCT03460431|Experimental|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm one session every month for 4 months
11189066|NCT03460431|Experimental|Nd YAG laser 1064nm|Nd YAG laser 1064nm
11189067|NCT03460431|Experimental|combined two laser types|combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
11189068|NCT03460418||Multiloc nail|Fracture treated with a Multiloc nail (patients treated between 2012 and 2017)
11189069|NCT03460418||Philos plate|Fracture treated with a Philos plate (patients treated between 2012 and 2017)
11189070|NCT03460418||arthroplasty|Fracture treated by arthroplasty (patients treated between 2012 and 2017)
11189071|NCT03460405|Experimental|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
11189072|NCT03460405|Active Comparator|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
11189073|NCT03460405|Experimental|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
11189074|NCT03460405|Active Comparator|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
11189075|NCT03460405|Experimental|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
11189076|NCT03460405|Active Comparator|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
11189077|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
11189078|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
11189079|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
11189080|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
11189081|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
11189082|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
11189083|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
11189084|NCT03460340|Experimental|FM group|patients diagnosed with Fibromyalgia receiving dTMS treatment.
11189085|NCT03460340|Sham Comparator|placebo group|patients diagnosed with Fibromyalgia receiving sham- treatment.
11189086|NCT03460288|Experimental|Intervention Group|The training-program includes ten pictures related to slot-machine gambling and 10 neutral pictures that need to be either pushed (i.e., avoidance) or pulled (i.e., approach) with the computer mouse or finger (when a tablet is used) according to a non-affective dimension (color of the frame). Pictures are presented in random order.
11189087|NCT03460288|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive the retraining intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including pharmacological treatment. Participants in the wait-list control condition receive full access to the training program after completion of the post-assessment.
11189088|NCT03460275|Other|single group|Osimertinib Mesylate Tablets 80 mg, one time a day until disease progression
11189089|NCT03460262|Active Comparator|Standard dressing-Cutiplast®|
11189090|NCT03460262|Experimental|Negative pressure wound therapy-PICO®|
11189091|NCT03460249|Active Comparator|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
11189092|NCT03460249|Active Comparator|as above|as above
11189093|NCT03460236||PRP|Symptomatic early knee osteoarthritis subjects who have elected to receive PRP treatment.
11189094|NCT03460223|Experimental|Conventional plus MSC treatment|
11189095|NCT03460184||G.A Group A|Group A: n= 30 Parturiant patients will receive general anesthesia. General anesthesia will be conducted After pre-oxygenation for 3-5 minutes. 5% thiopental (5 mg/kg) will be administered intravenously over 30s, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium as needed. After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by intravenous infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake, the anesthesia is adequately reversed, and the patient is following commands
11189096|NCT03460184||Spinal A Group B|"Group B: n= 30 Parturiant patients will receive spinal anesthesia. In the sitting position and after complete aseptic precaution are taken, 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, either via midline or paramedian approaches using 22 guage Quinke needle with the bevel directed laterally. 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl (0.5 ml) will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.
~The patient will be put flat in the supine position with left uterine displacement using wedge under the right loin and the surgeon will be allowed to sterilize and wrap the field after confirmation of the solidity of the block its level.
~All patiens will be observed for cardiac complications in the form of non-fatal MI, arrhythmias and sudden cardiac death until discharged after at least 72h."
11189097|NCT03460158|Experimental|Restylane-L®, Restylane-L® Lyft, and Restylane Silk®|Hyaluronic acid
11189098|NCT03460145|Experimental|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.
~VAS- Anxiety scores pre and post inhalation."
11189099|NCT03460145|Placebo Comparator|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
11189100|NCT03460132|Experimental|Extraction cases|patients receive Tomas orthodontic miniscrew implant as a mean of anchorage augmentation
11189101|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
11189102|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
11189103|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
11189104|NCT03460080||Hepatic hemangioma patients|
11189105|NCT03460067|Experimental|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
11189106|NCT03460067|No Intervention|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
11189107|NCT03460067|No Intervention|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
11189108|NCT03460054||IgA Nephropathy (IgAN)|Biopsy-Proven IgAN
11189109|NCT03460054||Focal Segmental Glomerulosclerosis (FSGS)|Biopsy-Proven FSGS
11189116|NCT03460028|Experimental|Yoga Condition|Participants randomized to the Yoga Condition will participate in a specialized yoga intervention.
11189117|NCT03460028|No Intervention|Wait-List Control Condition|Participants randomized to the Wait-List Control Condition will participate in a specialized yoga intervention once the Yoga Condition has completed their assigned intervention.
11189118|NCT03460015|Experimental|Sevoflurane group|
11189119|NCT03460015|Active Comparator|Propofol group|
11189120|NCT03460002|Experimental|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
11189121|NCT03460002|Experimental|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
11189122|NCT03460002|No Intervention|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
11189123|NCT03460002|No Intervention|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
11189124|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
11189125|NCT03459976||2 groups|control group case group
11189126|NCT03459963|Experimental|group C|indwelling urinary catheter
11189127|NCT03459963|No Intervention|group N|Non cathetrized patients
11189128|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
11189129|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
11189130|NCT03459937|Experimental|Hatha Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Hatha Yoga.
11189131|NCT03459937|Experimental|Vinyasa Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Vinyasa Yoga.
11189132|NCT03459911|Experimental|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
11189133|NCT03459911|Active Comparator|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
11189134|NCT03459898|Other|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
11189135|NCT03459898|Other|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
11189136|NCT03459885|Experimental|PAS|The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
11189137|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
11189138|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
11189139|NCT03459859|Experimental|Pevonedistat 10 LDAC 20|Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
11189140|NCT03459859|Experimental|Pevonedistat 15 LDAC 20|Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
11189141|NCT03459859|Experimental|Pevonedistat 20 LDAC 20|Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
11189142|NCT03459859|Experimental|Pevonedistat 25 LDAC 20|Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
11189143|NCT03459846|Experimental|Arm 1: Durvalumab/Placebo|Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1.
11189144|NCT03459846|Experimental|Arm 2: Durvalumab/Olaparib|Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
11189145|NCT03459833|Experimental|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
11189146|NCT03459833|Placebo Comparator|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
11189147|NCT03459820|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
11189148|NCT03459807|Experimental|Home systolic blood pressure (SBP) <140 mmHg|"Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.
~Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.
~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
11189149|NCT03459807|Active Comparator|Pre-dialysis SBP <140 mmHg|"Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.
~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
11189150|NCT03459794|Active Comparator|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
11189151|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
11189152|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
11189153|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
11189154|NCT03459755|Experimental|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
11189155|NCT03459755|No Intervention|Usual care|Patients will complete questionnaires and have research blood drawn.
11189156|NCT03459742|Experimental|Intervention|Gamification strategy. In 2018, the intervention group are 15 schools from Municipality of Santiago. In 2019, the intervention will cover all eligible schools in the Municipality of Santiago.
11189157|NCT03459742|No Intervention|Control|In 2018, the control group will be 5 randomly selected schools from Municipality of Santiago and 4 schools from Municipality of Estación Central. In 2019, the control group will be 4000 participants chosen from neighboring municipalities
11189158|NCT03459729|Experimental|Antitumor B|ATB will be administered on an outpatient basis.
11189159|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
11189160|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
11189161|NCT03459703|Experimental|Early Time-Restricted Feeding|
11189162|NCT03459703|Active Comparator|Control Schedule|
11189163|NCT03459690|Experimental|Experienced meditators|Meditation ≥ 30 min per day for at least 5 days per week over the past 1 year
11189164|NCT03459690|Experimental|Novice meditators|No meditation practice in the previous year and < 20 entire lifetime hours
11189165|NCT03459677|Experimental|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.
~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
11189166|NCT03459677|Active Comparator|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.
~The TAU condition will last for 4 months."
11189167|NCT03459664|Experimental|RECOVER|The intervention in the RECOVER stepped-care model includes specific evidence-based treatment options for severity grade 1 to 4.
11189168|NCT03459664|Active Comparator|Treatment As Usual|The active comparator is treatment as usual (TAU) and provides all common care options within the German health care system, depending on the severity grade 1 to 4.
11189169|NCT03459651|Experimental|ANS training|
11189170|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
11189171|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
11189172|NCT03459625|Experimental|Mindfulness-Based Stress Reduction (MSBR)|MSBR (Kabat-Zinn, 1990), 8-week group-based intervention where participants learn mindfulness skills to help alleviate parenting stress among parents of young children with Autism Spectrum Disorder.
11189173|NCT03459625|Active Comparator|Psychoeducational Support Group (PE)|PE is a 8-week group-based intervention to provide psychosocial support and resources for parents of young children with Autism Spectrum Disorder.
11189174|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
11189175|NCT03459612|Experimental|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
11189176|NCT03459612|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
11189177|NCT03459612|Active Comparator|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
11189178|NCT03459599|Active Comparator|Prophylaxis|Current protocol of administering antibiotics maintained
11189179|NCT03459599|Active Comparator|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
11189180|NCT03459586|Experimental|9zest app facilitated exercise|App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
11189181|NCT03459573|Active Comparator|T2D: One Drop with Fitbit Ionic|
11189182|NCT03459573|Active Comparator|T2D: One Drop without Fitbit Ionic|
11189183|NCT03459573|No Intervention|T2D: Waitlist Control|
11189184|NCT03459573|Active Comparator|T1D: One Drop with Fitbit Ionic|
11189185|NCT03459573|Active Comparator|T1D: One Drop without Fitbit Ionic|
11189186|NCT03459573|Active Comparator|PD: One Drop with Fitbit Charge 2|
11189187|NCT03459573|Active Comparator|PD: One Drop without Fitbit Charge 2|
11189188|NCT03459560|Experimental|PolyPill|Single daily dose of PolyPill and 6-monthly visits
11189189|NCT03459560|No Intervention|Control|Only 6-monthly visits
11189190|NCT03459547|Experimental|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
11189191|NCT03459547|Active Comparator|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
11189192|NCT03459547|Active Comparator|dental implant + zirconia (control)|dental implant insertion, material zirconia
11189193|NCT03459547|Active Comparator|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
11189194|NCT03459534|Experimental|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.
~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
11189590|NCT03456648|Experimental|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
11189195|NCT03459521|Experimental|Fendrix HBV vaccine|Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 0.5 ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline, 1, 2 and 6 months.
11189196|NCT03459508||Primary antiphospholipid syndrome women|"Informed consent
~Detailed history emphasizing on
~a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis
~Revision of diagnosis of primary antiphospholipid syndrome:
~Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies.
~Ophthalmological examination:"
11189197|NCT03459495|Active Comparator|Group A|Group A: ultrasound group
11189198|NCT03459495|Placebo Comparator|Group P|Group P: placebo ultrasound group
11189199|NCT03459482|Experimental|Group 1 - True Food Elimination Diet|Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
11189200|NCT03459482|Sham Comparator|Group 2 - Sham Food Elimination Diet|"Group 2 (control group): Subjects will be given a Sham elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates."
11189201|NCT03459469|Experimental|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
11189202|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:
~Provocation OC task (Provoc)
~Trier Social Stress Test (TSST)
~Exposure provocation task"
11189203|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:
~Provocation OC task (Provoc)
~Trier Social Stress Test (TSST)
~Exposure provocation task"
11189204|NCT03459430|Experimental|Low Intensity training group|Low Intensity training group will complete a 6 week core stability training program with low intensity/oscillation exercises
11189205|NCT03459430|Experimental|High Intensity training group|High Intensity training group will complete a 6 week core stability training program with high intensity/oscillation exercises
11189206|NCT03459430|No Intervention|Control group|Control group will have 6 weeks with no intervention before post-test
11189207|NCT03459417|Active Comparator|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
11189208|NCT03459417|Active Comparator|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
11189209|NCT03459417|Active Comparator|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
11189210|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg
~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
11189211|NCT03459391|Experimental|XC221 60 mg|Cohort 1:16 subjects were randomized in a 3:1 ratio to be treated either with 60 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
11189212|NCT03459391|Experimental|XC221 200 mg|Cohort 2: 16 subjects were randomized in a 3:1 ratio to be treated either with 200 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
11189213|NCT03459391|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (4 subjects from each cohort).
11189214|NCT03459365|Experimental|Euflexxa|Two sets of Euflexxa injection at 0 and 6 months. Each set consists of 3 injections 1 week apart.
11189215|NCT03459352|Experimental|ePRO|There is no therapeutic intervention. Patients will use ePRO system to report systems. We will describe use in patients to determine compliance in reporting symptoms.
11189216|NCT03459339|Experimental|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
11189217|NCT03459326||control group|men in relation
11189218|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
11189219|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
11189220|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
11189221|NCT03459313|Experimental|Active group|The active group will be provided the intervention program, i.e. access to a website.
11189222|NCT03459313|No Intervention|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
11189223|NCT03459287|Experimental|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
11189224|NCT03459287|Active Comparator|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
11189591|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
11189225|NCT03459274||VR-Biofeedback Feedback Sharers|These participants would express either interest or a lack of interest in trying biofeedback/virtual reality therapy. They will be instructed on how to use the virtual reality equipment and program. Then, they will have the option to participate in the biofeedback/virtual reality experience, if they choose to do so, before sharing their feedback.
11189226|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
11189227|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
11189228|NCT03459248|Experimental|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
11189229|NCT03459248|Active Comparator|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
11189230|NCT03459235|Experimental|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
11189231|NCT03459222|Experimental|Arm A|Relatlimab + Nivolumab + BMS-986205
11189232|NCT03459222|Experimental|Arm B|Relatlimab + Nivolumab + Ipilimumab
11189233|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
11189234|NCT03459183|Experimental|Infrasound - verum|In this condition, participants are exposed with non-audible infrasound from the Infrasound (85dB; 6Hz) source, for 8 constant hours during their night sleep. The source is placed close to the participant's bed (approximately 1-2 meters).
11189235|NCT03459183|Placebo Comparator|Infrasound - placebo|In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
11189236|NCT03459183|Experimental|Ultrasound - verum|In this condition, participants are exposed to non-audible ultrasound, emitted by the Ultrasound (10dB below hearing threshold; 22.4 kHz) source for 8 constant hours during their night sleep. The source is placed close to the participant's bed (1-2 meters), at the level of the participant's head (for instance on a nightstand).
11189237|NCT03459183|Placebo Comparator|Ultrasound - placebo|In this condition, participants are not exposed to any sound. The Ultrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Ultrasound dummy source looks exactly like the active ultrasound source, but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
11189238|NCT03459170|Experimental|BPX-501 T cells and rimiducid|"All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).
~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
11189239|NCT03459157|Other|HIV prevention package including PrEP|
11189240|NCT03459144|Experimental|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
11189241|NCT03459144|Experimental|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
11189242|NCT03459144|Experimental|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
11189243|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
11189244|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
11189245|NCT03459118|Experimental|Function Focused Care|FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the champion and stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
11189246|NCT03459118|Placebo Comparator|Education Only|Education only sites are exposed to Step II of the Four step approach described under the treatment arm. They receive baseline education of staff.
11189247|NCT03459105|Experimental|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
11189248|NCT03459105|Active Comparator|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
11189249|NCT03459092|Experimental|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
11189250|NCT03459092|Active Comparator|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
11189251|NCT03459079|Active Comparator|lanifibranor arm|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
11189252|NCT03459079|Placebo Comparator|Placebo|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
11189253|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
11189254|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
11189255|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
11189256|NCT03459053|Experimental|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
11189257|NCT03459053|No Intervention|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
11189258|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
11189259|NCT03459027|Active Comparator|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
11189260|NCT03459027|Placebo Comparator|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
11189261|NCT03459014|Experimental|Stimulus rich VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
11189262|NCT03459014|Active Comparator|Stimulus poor VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
11189263|NCT03459001||Tube Fed Malnourished Outpatients|Outpatients that are malnourished or at risk of malnutrition and have been placed on a nutritional care plan, which includes a complete tube feeding formula as sole source nutrition
11189264|NCT03458988|Other|All patients|Nellcor™ Adult SpO2 Sensor
11189265|NCT03458975|Active Comparator|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
11189266|NCT03458975|Placebo Comparator|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
11189267|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
11189268|NCT03458923|Active Comparator|Group A|15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.
11189269|NCT03458923|Active Comparator|Group B|15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.
11189270|NCT03458910|Experimental|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
11189271|NCT03458910|Experimental|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
11189272|NCT03458897|Experimental|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
11189273|NCT03458884|Experimental|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
11189274|NCT03458884|No Intervention|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
11189275|NCT03458871|Experimental|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
11189276|NCT03458858|Other|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
11189277|NCT03458858|Other|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
11189278|NCT03458858|Other|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
11189279|NCT03458858|Other|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
11189280|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
11189281|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
11189282|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
11189283|NCT03458819||Control|Patients on neither active Vitamin D or a statin
11189284|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
11189285|NCT03458819||Statin|Patients on a statin but not active Vitamin D
11189286|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
11189287|NCT03458806||Control|Subjects with echocardiographically confirmed valvular disease of less than moderate-to-severe grading with regards to aortic stenosis (AS) and mitral regurgitation (MR). Note that within this cohort will be a sub cohort consisting of subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
11189288|NCT03458806||AS Case|Subjects with echocardiographically confirmed aortic stenosis (AS) of moderate-to-severe or greater grading.
11189289|NCT03458806||MR Case|Subjects with echocardiographically confirmed mitral regurgitation (MR) of moderate-to-severe or greater grading.
11189290|NCT03458806||Control Subgroup|Subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
11189291|NCT03458793|Experimental|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
11189292|NCT03458793|No Intervention|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
11189293|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
11189294|NCT03458767|Experimental|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
11189295|NCT03458767|No Intervention|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
11189296|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
11189297|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
11189298|NCT03458728|Experimental|Dose escalation of BAY806946 in Phase 1|It is estimated that 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Safety and MTD/RP2D dose will be evaluated in 2 age groups (< 1 year old and ≥ 1 year old).
11189299|NCT03458728|Experimental|Patients with Neuroblastoma in Phase 2|Recommended Phase 2 dose (RP2D) for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
11189300|NCT03458728|Experimental|Patients with Osteosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
11189301|NCT03458728|Experimental|Patients with Rhabdomyosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
11189302|NCT03458728|Experimental|Patients with Ewing sarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
11189303|NCT03458715|Experimental|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
11189304|NCT03458715|Active Comparator|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
11189305|NCT03458702|Experimental|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
11189306|NCT03458702|Experimental|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
11189307|NCT03458689|Other|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
11189308|NCT03458689|Active Comparator|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
11189309|NCT03458689|Active Comparator|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
11189310|NCT03458676|Experimental|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.
~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
11189311|NCT03458663|Experimental|Prevena|Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
11189312|NCT03458663|No Intervention|Conentional postoperative care|patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.
11189637|NCT03456258|Experimental|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
11189313|NCT03458650|Experimental|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
11189314|NCT03458650|Experimental|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
11189315|NCT03458650|Experimental|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
11189316|NCT03458637|Experimental|LITE Program with usual care.|LITE Program with usual care. LITE program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. The key aspects covered in the LITE program are in keeping with Health Promotion Board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. The parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes.
11189317|NCT03458637|Active Comparator|Usual Care|Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
11189318|NCT03458624||Not applicable-observational study|Not applicable-observational study
11189319|NCT03458611|Experimental|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
11189320|NCT03458611|Experimental|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
11189321|NCT03458598|Experimental|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
11189322|NCT03458598|Sham Comparator|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
11189323|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
11189324|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
11189325|NCT03458572|Experimental|Intervention|1.5mm Seirin Pyonex needle at LI11 point
11189326|NCT03458572|Sham Comparator|Control|0.3mm Seirin Pyonex needle at TB10 point
11189327|NCT03458559|Active Comparator|Radium-223-chloride|Radium-223-chloride 50kBg/kg, every 4 weeks intravenously, for a total of 6 administrations.
11189328|NCT03458559|Experimental|Rhenium-188-HEDP|Rhenium-188-HEDP 40MBq/kg, every 8 weeks intravenously, for a total of 3 administrations.
11189329|NCT03458546|Experimental|Roflumilast and R-CHOP|
11189330|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
11189331|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
11189332|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
11189333|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
11189334|NCT03458507|Active Comparator|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.
~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
11189335|NCT03458507|Active Comparator|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.
~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
11189336|NCT03458494|Experimental|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
11189337|NCT03458494|Experimental|Low-fat diet|during one week participants will receive food products low in fat content
11189338|NCT03458481|Experimental|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
11189339|NCT03458481|Experimental|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
11189340|NCT03458468|Experimental|Group A|Tranexamic Acid 1g IV
11189341|NCT03458468|Placebo Comparator|Group B|Saline injection
11189342|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
11189343|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
11189344|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
11189345|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
11189346|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
11189347|NCT03458442|Experimental|Intervention Arm|Standard surgical training + simulation-based surgical training
11189348|NCT03458442|Active Comparator|Control Arm|Standard surgical training
11189349|NCT03458429|Experimental|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
11189350|NCT03458416|Experimental|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
11189351|NCT03458403|Experimental|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
11189352|NCT03458390|Experimental|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
11189353|NCT03458377|Experimental|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
11189354|NCT03458377|No Intervention|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
11189355|NCT03458364|Experimental|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
11189356|NCT03458364|Active Comparator|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
11189357|NCT03458351|Active Comparator|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction
~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
11189358|NCT03458351|Sham Comparator|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
11189359|NCT03458325|Experimental|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
11189360|NCT03458325|No Intervention|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
11189361|NCT03458312|No Intervention|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.
~Test time points:
~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
11189362|NCT03458312|Experimental|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
11189363|NCT03458299|Experimental|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
11189364|NCT03458299|Experimental|Psychoeducation|The Psychoeducation session will consist of therapist assisted viewing and discussion of four educational DVDs about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
11189365|NCT03458286|No Intervention|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
11189366|NCT03458286|Experimental|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
11189367|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
11189368|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.
~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
11189369|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.
~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
11189370|NCT03458260|Experimental|Experimental|Pixantrone plus rituximab, ifosfamide and etoposide.
11189371|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
11189372|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
11189373|NCT03458234|Experimental|Focal SBRT with intra-urethral radiotransponder|This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
11189374|NCT03458221|Experimental|itraconazole / tamoxifen|In case of HedgeHog pathway positivity itraconazole will be administered in case of ER pathway positivity tamoxifen will be adminisered
11189375|NCT03458208|Experimental|Metformin|"First aIntervention Period:
~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition
~Third Intervention Period:
~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
11189376|NCT03458208|Active Comparator|Glucophage®|"Second Intervention Period:
~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition
~Fourth Intervention Period:
~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
11189377|NCT03458195|Experimental|Crohn's disease patients|Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.
11189378|NCT03458182|Experimental|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
11189379|NCT03458182|No Intervention|No intervention|No added exercise period (normal exercise test).
11189380|NCT03458169|Experimental|LEAP usability|"Therapist LEAP session feedback
~Participant LEAP session feedback
~LEAP risk control validation"
11189381|NCT03458156|Experimental|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
11189382|NCT03458156|Experimental|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
11189383|NCT03458156|Experimental|the control group|The patients will be assigned to the control group.
11189384|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
11189385|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
11189386|NCT03458130|Active Comparator|AG10 Low Dose|Low dose group
11189387|NCT03458130|Active Comparator|AG10 High Dose|High dose group
11189388|NCT03458130|Placebo Comparator|Placebo|
11189389|NCT03458117|Experimental|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
11189390|NCT03458104|Experimental|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
11189391|NCT03458104|Active Comparator|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
11189392|NCT03458091|Active Comparator|Intubation|The patients will be intubated and ventilated
11189393|NCT03458091|Experimental|THRIVE|The patients will be oxygenated during apnea using THRIVE
11189394|NCT03458078|Placebo Comparator|Group C|Control group
11189395|NCT03458078|Active Comparator|Group Mg|Magnesium sulfate group
11189396|NCT03458078|Active Comparator|Group MDZ|Midazolam group
11189397|NCT03458065||S-ICD|
11189398|NCT03458065||T-ICD|
11189399|NCT03458039|Active Comparator|Standard TTT|This is the standard of care train-the-trainer approach for experienced counselors
11189400|NCT03458039|Experimental|Technology TTT|This is an experimental technology-based train-the-trainer approach for experienced counselors
11189401|NCT03458026|Experimental|connected object + SMS of physical activity reminders|"The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises.
~At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks.
~At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.
~In 36 week, they return the watch and finish the study."
11189402|NCT03458026|Other|Without connected object|"The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks.
~At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.
~In 36 week, the study will be finished."
11189403|NCT03458013|Experimental|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
11189404|NCT03458013|No Intervention|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
11189405|NCT03458000|Active Comparator|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
11189406|NCT03458000|Experimental|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
11189407|NCT03457974|Experimental|congenital heart disease|42 patients
11189408|NCT03457974|Other|helathy children|42 children
11189409|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
11189410|NCT03457948|Experimental|Group I [pembrolizumab, 177Lu DOTATATE]|Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index > 20% (well-differentiated grade 3) and may have any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor < 75%
11189473|NCT03457519|No Intervention|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
11189411|NCT03457948|Experimental|Group II [pembrolizumab, TAE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
11189412|NCT03457948|Experimental|Group III [pembrolizumab, yttrium-90 microsphere RE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
11189413|NCT03457948|Experimental|Group IV [pembrolizumab, CT-guided cryoablation]|Patients receive pembrolizumab as in Group I. Patients with up to 6 liver lesions, largest being no larger than 4 cm who have < 25% liver parenchyma replacement by tumors, undergo CT-guided cryoablation over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
11189414|NCT03457935||Control|No lung diseases
11189415|NCT03457935||Non-IPF ILD|non-IPF ILD diagnosis
11189416|NCT03457935||IPF|Naive patients with no IPF treatment
11189417|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
11189418|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
11189419|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.
~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:
~• Neratinib daily + Trastuzumab weekly until disease progression"
11189420|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:
~• Neratinib daily + Cetuximab weekly until disease progression"
11189421|NCT03457883|Experimental|group A|accepted herniamesh mesh
11189422|NCT03457883|Experimental|group B|accepted biological graft of cook
11189423|NCT03457870|Experimental|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
11189424|NCT03457870|Experimental|Chewing|Mastication intervention: chewing
11189425|NCT03457870|Experimental|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
11189426|NCT03457870|No Intervention|Control|No intervention: Control
11189427|NCT03457857|Other|Group 1 - Cleanser|Regimen with Baby Cleanser Only
11189428|NCT03457857|Other|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
11189429|NCT03457844|Experimental|Anlotinib|
11189430|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
11189431|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
11189432|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
11189433|NCT03457805|Other|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
11189434|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
11189435|NCT03457779|Experimental|Non Glucose Arm|4 patients without glucose infusion
11189436|NCT03457779|Experimental|Glucose Arm|12 Patients with glucose infusion
11189437|NCT03457766|Experimental|Patients with skin lesions|Using HIFU in identification of safety margins of lesions clinically apparent locally malignant, or malignant
11189438|NCT03457753|Experimental|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
11189439|NCT03457740|Experimental|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
11189440|NCT03457740|Experimental|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
11189441|NCT03457740|Placebo Comparator|Placebo|Placebo, 4 capsules daily, 6 weeks
11189442|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
11189443|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
11189444|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
11189445|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
11189446|NCT03457701|Experimental|rhEPO+57Fe followed by Daprodustat+58Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
11189474|NCT03457506|Other|Patients undergo a digital PET/CT|Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner.
11189475|NCT03457493|Experimental|Healthy Controls, DPA-714-PET/MRI|
11189476|NCT03457493|Experimental|Early Parkinson's Disease, DPA-714-PET/MRI|
11189666|NCT03455998||post surgery|Patienst consultation Questionnaires
11189447|NCT03457701|Experimental|rhEPO+58Fe followed by Daprodustat+57Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
11189448|NCT03457701|Experimental|Daprodustat+57Fe followed by rhEPO+58Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
11189449|NCT03457701|Experimental|Daprodustat+58Fe followed by rhEPO+57Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 28 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
11189450|NCT03457688|Active Comparator|prebiotic inulin-type fructans|
11189451|NCT03457688|Placebo Comparator|placebo maltodextrin|
11189452|NCT03457675|Experimental|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
11189453|NCT03457675|Experimental|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
11189454|NCT03457675|Experimental|Summit RC+S DBS Implant for OCD|all subjects will receive surgical implantation of DBS system
11189455|NCT03457662|Active Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
11189456|NCT03457662|Experimental|OMC and SDT|OMC and SDT are administrated in this arm.
11189457|NCT03457649|Active Comparator|ARGX-113|SAD and MAD with test product at different increasing doses
11189458|NCT03457649|Placebo Comparator|Placebo|SAD and MAD with placebo at different increasing doses
11189459|NCT03457636|Experimental|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
11189460|NCT03457623|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
11189461|NCT03457623|No Intervention|conventional supported|Patients benefit from usual care
11189462|NCT03457610|Experimental|Speech and language intervention|
11189463|NCT03457597|Experimental|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
11189464|NCT03457597|Experimental|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
11189465|NCT03457597|Experimental|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
11189466|NCT03457584|Active Comparator|BSS arm|BSS is given at the end of surgery
11189467|NCT03457584|Experimental|air arm|air-tamponade is given at the end of surgery
11189468|NCT03457545|Experimental|Intervention|Eligible participants will take part in the home-based pulmonary rehabilitation using the Aidcube platform in-person assessment and training with a research coordinator (i.e. physical exercise capacity assessment, SPPB, disability survey, exercise prescription determination, exercise training, dyspnea control techniques) and complete an follow-up assessment at the 8th week.
11189469|NCT03457545|No Intervention|No Intervention|Ineligible participants will receive standard of care
11189470|NCT03457532|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
11189471|NCT03457519|Active Comparator|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.
~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
11189472|NCT03457519|Active Comparator|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.
~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
11189588|NCT03456648|Experimental|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
11189477|NCT03457480|Experimental|Prevention (text messages, computer messages)|"PHASE I: Participants attend focus group over 2 hours.
~PHASE II: Participants receive 2 text messages per day for 30 days at baseline and after 3 months.
~PHASE III: Participants read 64 computer messages with or without images over 30 minutes and have their facial expressions assessed."
11189478|NCT03457467|Experimental|SBRT+apatinib group|Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.
11189479|NCT03457454|Experimental|Participant Level Education|-Participants receive low-literacy educational and instructional brochures at the time of fecal occult blood test (FOBT) referral. Participants with a positive FOBT receive a second low-literacy brochure on bowel preparation for colonoscopy and the importance of follow-up, and assist with scheduling and completing colonoscopy
11189480|NCT03457441|Other|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
11189481|NCT03457441|Other|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
11189482|NCT03457441|Other|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
11189483|NCT03457415||Healthy Cohort|Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
11189484|NCT03457415||High-risk Cohort|High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
11189485|NCT03457415||Cancer Cohort|Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
11189486|NCT03457402|Experimental|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
11189487|NCT03457402|Active Comparator|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
11189488|NCT03457389|Experimental|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
11189489|NCT03457389|Active Comparator|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
11189490|NCT03457363|Experimental|Double Trunk Mask|DTM will be add above nasal cannula
11189491|NCT03457363|Active Comparator|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
11189492|NCT03457350|Experimental|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
11189493|NCT03457350|Experimental|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
11189494|NCT03457337|Experimental|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA <1.25 m2, 80 mg / day; BSA 1.25 m2 to <1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.
~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
11189495|NCT03457337|Active Comparator|Gefitinib|Gefitinib 250 mg/day oral daily
11189496|NCT03457324|Experimental|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
11189497|NCT03457324|Placebo Comparator|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
11189498|NCT03457311|Other|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
11189499|NCT03457298|Experimental|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
11189500|NCT03457298|Active Comparator|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
11189501|NCT03457285|Experimental|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.
~This will continue for the 6-month duration of the intervention."
11189502|NCT03457272|Experimental|New risk assessment|New risk assesment
11189503|NCT03457272|No Intervention|Standard|Standard risk assessment
11189504|NCT03457259|Active Comparator|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
11189505|NCT03457259|Active Comparator|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
11189506|NCT03457246|Experimental|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
11189507|NCT03457246|Placebo Comparator|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
11189508|NCT03457233|Active Comparator|Normal weight|18.5- 24.9 kg/m2
11189509|NCT03457233|Active Comparator|Overweight|BMI 25-29.9 kg/m2
11189510|NCT03457233|Active Comparator|Obese|BMI ≥ 30 kg/m2
11189511|NCT03457207|Experimental|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
11189512|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.
~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.
~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.
~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
11189513|NCT03457181|Active Comparator|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
11189514|NCT03457181|Active Comparator|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
11189515|NCT03457168|Active Comparator|Intensive asleep SBP control|To reduce the asleep SBP mean up to a target <110 mmHg. Treatment of elevated asleep SBP mean
11189516|NCT03457168|Active Comparator|Conventional asleep SBP control|To reduce the asleep SBP mean up to a target <120 mmHg. Treatment of elevated asleep SBP mean
11189517|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11189518|NCT03457129|Active Comparator|Fycompa 2 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
11189519|NCT03457129|Experimental|Fycompa 3 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
11189520|NCT03457116|Active Comparator|Test Arm|400mg of Ibuprofen or
11189521|NCT03457116|Active Comparator|Control Arm|Norco( hydrocodone 5mg- acetaminophen 325mg)
11189522|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
11189523|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
11189524|NCT03457090|Experimental|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
11189525|NCT03457077|Experimental|Brief Intervention|Participants will receive a brief intervention at week 0
11189526|NCT03457077|Other|Delayed Intervention|Participants will receive a brief intervention at 6 months
11189527|NCT03457064|No Intervention|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
11189528|NCT03457064|Active Comparator|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
11189529|NCT03457051|Active Comparator|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
11189530|NCT03457051|Experimental|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
11189531|NCT03457038|Experimental|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
11189532|NCT03457025|Active Comparator|Standard of Care Therapy|Reference Therapy
11189533|NCT03457025|Experimental|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
11189534|NCT03457012||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
11189535|NCT03456999|Active Comparator|MAU868|BKV-specific, pan-serotype neutralizing antibody
11189536|NCT03456999|Placebo Comparator|Placebo|Matching placebo
11189725|NCT03455634|No Intervention|Control|no intervention
11189537|NCT03456986|Experimental|PATH neurotraining (treatment)|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
11189538|NCT03456986|Active Comparator|Orientation Discrimination (control)|Subject looks at computer screen to determine whether bars in center circular window are tilted left or right relative to vertically oriented background bars. The subject reports which way center pattern is tilted by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes orientation of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern colored or black and white, and by increasing pattern's complexity level. This Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
11189539|NCT03456973|Experimental|Nurse AMIE|
11189540|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
11189541|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
11189542|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
11189543|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
11189544|NCT03456960|Experimental|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
11189545|NCT03456960|Experimental|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
11189546|NCT03456947|No Intervention|control group|the patients receive routine preoperative preparation without having Pregabalin
11189547|NCT03456947|Experimental|Pregabalin150mg group|the patients receive 150mg pregabalin 60 minutes prior to the surgery
11189548|NCT03456947|Experimental|Pregabalin300mg group|the patients receive 300mg pregabalin 60 minutes prior to the surgery
11189549|NCT03456934|Experimental|Experimental Group|Modified infant formula given from 3 to 12 months of age, as per standard requirement.
11189550|NCT03456934|Active Comparator|Control Group|Standard infant formula given from 3 to 12 months of age, as per standard requirement.
11189551|NCT03456934|No Intervention|Breast-fed Reference Group|Non-randomized infants who are predominantly breast-fed at time of enrollment.
11189552|NCT03456921|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
11189553|NCT03456908|Experimental|myeloma before MV-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
11189554|NCT03456908|Experimental|endometrial cancer before VSV-hINF-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
11189555|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:
~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)
~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
11189556|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
11189557|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
11189589|NCT03456648|Experimental|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
11189558|NCT03456882|Active Comparator|RNS60|RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
11189559|NCT03456882|Placebo Comparator|NORMAL SALINE|"Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months.
~RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site)."
11189560|NCT03456869|Experimental|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
11189561|NCT03456856|Experimental|Ivabradine|The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
11189562|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
11189563|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
11189564|NCT03456830|Experimental|ALLN-177|ALLN-177 3,750 units per capsule
11189565|NCT03456830|Placebo Comparator|Placebo|Placebo capsule
11189566|NCT03456817|Experimental|Treatment Arm - high dose ATG|High dose ATG at 10 mg/kg will be infused on days -4, -3, -2, -1 and 0. Before each infusion of ATG (thymoglobulin), patient will receive medications preventing side effects from the ATG, including diphenhydramine (Benadryl), acetaminophen (Tylenol) and methylprednisolone (Solumedrol). The high dose ATG will be given into patient's vein via central venous catheter. Each infusion of ATG will take 4-8 hours. No CSA (cyclosporine A) will be given. Standard dose methotrexate will be given.
11189567|NCT03456817|Other|Control Arm - standard of care|Low dose ATG (thymoglobulin) at 4.5 mg/kg will be infused on days -2, -1 and 0, and CSA (cyclosporine A) will be given from day -1 through day 84. Standard dose methotrexate will also be given.
11189568|NCT03456804|Experimental|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
11189569|NCT03456791||endometrial carcinoma( cases)|42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
11189570|NCT03456791||benign diseases(control)|42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
11189571|NCT03456778|Experimental|Platelet-Rich Plasma Injection|Participants will receive a Platelet-Rich Plasma (PRP) injection to treat chronic tendinopathy
11189572|NCT03456752|Experimental|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
11189573|NCT03456752|Placebo Comparator|Control|Normal Saline 8mg intravenously prior to anesthesia induction
11189574|NCT03456739||suppurative otitis media with effusion|
11189575|NCT03456739||non suppurative otitis media with effusion|
11189576|NCT03456726|Experimental|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
11189577|NCT03456726|Experimental|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
11189578|NCT03456713|Experimental|LY3074828 Formulation A|LY3074828 solution formulation in two prefilled syringes, administered as subcutaneous (SC) injection
11189579|NCT03456713|Experimental|LY3074828 Formulation B|LY3074828 solution formulation in a prefilled syringe, administered as a SC injection
11189580|NCT03456713|Experimental|LY3074828 Formulation C|LY3074828 solution formulation in an auto-injector
11189581|NCT03456713|Experimental|LY3074828 Formulation D|LY3074828 solution formulation in an auto-injector
11189582|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11189583|NCT03456687|Experimental|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
11189584|NCT03456674|Experimental|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
11189585|NCT03456661|Active Comparator|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
11189586|NCT03456661|Active Comparator|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
11189587|NCT03456648|Experimental|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
11189592|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
11189593|NCT03456609|Experimental|shenqifuzheng|
11189594|NCT03456609|Placebo Comparator|0.9%sodium chloride|
11189595|NCT03456596||Institution|Community cancer centers implementing ENABLE
11189596|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
11189597|NCT03456570|Active Comparator|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
11189598|NCT03456570|Placebo Comparator|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
11189599|NCT03456557|Experimental|Computed tomography.|
11189600|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
11189601|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
11189602|NCT03456531|Active Comparator|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
11189603|NCT03456531|Placebo Comparator|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
11189604|NCT03456505|Experimental|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
11189605|NCT03456505|Active Comparator|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
11189606|NCT03456492||case|Hyponatremic elderly patients (>70 years) with hip fractures
11189607|NCT03456492||control|Normonatremic elderly patients(>70 years) undergoing joint replacement
11189608|NCT03456466|Experimental|TQB2303|
11189609|NCT03456466|Active Comparator|Rituximab|
11189610|NCT03456453|Experimental|NIDA Standard via Facebook|30 participants will receive the NIDA Standard via Facebook
11189611|NCT03456453|No Intervention|Re-entry services as usual|30 participants will receive re-entry services as usual
11189612|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
11189613|NCT03456440||normal individuals|controls cases are examined with MRI
11189614|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
11189615|NCT03456414|Experimental|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
11189616|NCT03456414|No Intervention|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
11189617|NCT03456401|Other|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
11189618|NCT03456388|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
11189619|NCT03456388|Active Comparator|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
11189620|NCT03456362|Active Comparator|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
11189621|NCT03456362|Sham Comparator|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
11189622|NCT03456349|Experimental|Low dose|HTL0018318
11189623|NCT03456349|Experimental|Medium dose|HTL0018318
11189624|NCT03456349|Experimental|High dose|HTL0018318
11189625|NCT03456349|Placebo Comparator|Placebo|Placebo
11189626|NCT03456336|Active Comparator|Active Treatment Group|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other.
11189627|NCT03456336|Active Comparator|Expectant Management Group|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
11189628|NCT03456323|Experimental|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
11189629|NCT03456323|Placebo Comparator|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
11189630|NCT03456310|Experimental|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
11189631|NCT03456297|Experimental|Experimental cluster|The Web-based clinical pedagogy program (WCP) will be provided to the participants in the experimental cluster.
11189632|NCT03456297|No Intervention|Control cluster|The participants in the control cluster will receive the current face-to-face preceptorship course.
11189633|NCT03456284|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device
11189634|NCT03456271||fracture group|
11189635|NCT03456271||non-fracture group|
11189636|NCT03456258|Experimental|Lactoferrin|To measure hemoglobin difference and serum ferritin
11189638|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
11189639|NCT03456232|Experimental|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
11189640|NCT03456232|Active Comparator|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
11189641|NCT03456219|Experimental|Shift workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the normal protein diet.
11189642|NCT03456219|Experimental|Night workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the high-protein diet.
11189643|NCT03456206||"Diet, Cancer and Health cohort"|"Participants from the Diet, Cancer and Health (DCH) cohort with no CID diagnosis at entry to the DCH study. The number of persons developing a CID (defined as at least one of the mentioned CIDs) during follow up (1993/1997 - 2018) and the number of persons not developing a CID will be investigated.
~Based on the participants reporting of dietary habits in the Food Frequency Questionnaire (FFQ) from the DCH study, the exposure intake of red and processed meat and fibres will be investigated in both CID cases and non-cases.
~Other exposure variables are Lifestyle factors independently or combined and are also obtained from the data in the DCH cohort."
11189644|NCT03456193|Experimental|LA transplantation|The left atrium and pulmonary veins will be transplanted into the recipient
11189645|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
11189646|NCT03456167|Experimental|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op & weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 & 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory & surgeon.
11189647|NCT03456167|No Intervention|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 & 6 weeks post-op and attend all scheduled follow up appointments.
11189648|NCT03456154|Experimental|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
11189649|NCT03456154|Active Comparator|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
11189650|NCT03456128|Experimental|Intervention|The experimental group will receive CAPABLE services. These include ≤10 sessions: ≤ 6 with an Occupational Therapist (OT) and ≤ 4 sessions with a Registered Nurse (RN) and up to ≤ $1,500 of home safety and home modifications from a licensed handyman who is guided by the OT. The OT and RN sessions will target participants' self-identified functional goals (e.g., getting safely into the tub, getting upstairs to sleep in own bed).
11189651|NCT03456128|No Intervention|Usual Care|Participants in the usual care group will not receive visit from study clinicians and will continue to receive their usual VNSNY CHOICE benefits and healthcare.
11189652|NCT03456115|Experimental|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
11189653|NCT03456102|Other|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
11189654|NCT03456102|Other|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
11189655|NCT03456102|Other|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
11189656|NCT03456102|Other|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 80 mg is not tolerated as specified in protocol.
11189657|NCT03456089|Other|Neurogenic Bladder Patients|Patients with neurogenic bladder undergoing urodynamics testing
11189658|NCT03456076|Experimental|Alectinib|
11189659|NCT03456076|Active Comparator|Platinum-Based Chemotherapy|
11189660|NCT03456063|Experimental|Arm A: Atezolizumab + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy
~Platinum-based chemotherapy may include:
~carboplatin + pemetrexed
~carboplatin + nab-paclitaxel
~cisplatin + pemetrexed
~cisplatin + gemcitabine
~Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab"
11189661|NCT03456063|Placebo Comparator|Arm B: Placebo + platinum-based chemotherapy|"Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy
~Platinum-based chemotherapy may include:
~carboplatin + pemetrexed
~carboplatin + nab-paclitaxel
~cisplatin + pemetrexed
~cisplatin + gemcitabine
~Participants will receive best supportive care and monitoring after surgery"
11189662|NCT03456050|Experimental|FRC group|This group will receive FRC exercise.
11189663|NCT03456050|Experimental|Conventional treatment|This group will receive conventional exercise.
11189664|NCT03456011|Other|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.
~Intervention: BFA"
11189665|NCT03456011|No Intervention|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider
~No interventions"
11189668|NCT03455985|Experimental|Discharge Order Set (DOS)|Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.
11189669|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
11189670|NCT03455972|Experimental|CART-anti-CD19/BCMA|
11189671|NCT03455959|Experimental|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
11189672|NCT03455946|Experimental|Interventional|DASH Cloud with Alexa
11189673|NCT03455933|Experimental|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
11189674|NCT03455933|Experimental|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
11189675|NCT03455933|Other|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
11189676|NCT03455920|Experimental|Multidisciplinary arm|Patients randomized in this group will have their first sleep clinic evaluation with the clinical nurse. She will then discuss each case with the pulmonologist and validate the diagnostic and therapeutic avenue.
11189677|NCT03455920|Active Comparator|Pulmonologist arm|Patients randomized in this group will have their first sleep clinic evaluation with the pulmonologist.
11189678|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
11189679|NCT03455894|Experimental|Smart carpet|
11189680|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
11189681|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
11189682|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
11189683|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
11189684|NCT03455868||Sleeve gastrectomy diabetes|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Sleeve gastrectomy
11189685|NCT03455868||Roux-in-Y gastric bypass diabetes|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Roux-in-Y gastric bypass
11189686|NCT03455868||Sleeve gastrectomy no diabetes|35 Men and women without type 2 diabetes and with obesity undergoing bariatric surgery : Sleeve gastrectomy
11189687|NCT03455868||Control|30 Men and women with a normal BMI and normoglycemia matched for age and sex with bariatric groups
11189688|NCT03455855|Experimental|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
11189689|NCT03455842|Experimental|BCD-089 weekly|
11189690|NCT03455842|Experimental|BCD-089 biweekly|
11189691|NCT03455842|Placebo Comparator|Placebo|
11189692|NCT03455829|Experimental|Part 1: G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
11189693|NCT03455829|Experimental|Part 2: G1T38 + Osimertinib|Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.
11189694|NCT03455829|Active Comparator|Part 2: Osimertinib|"Patients will be randomized to receive osimertinib 80 mg once-daily.
~At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib."
11189695|NCT03455816|Experimental|Group that uses the Social Diabetes App (research group)|This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month
11189696|NCT03455816|Active Comparator|Usual clinical monitoring group (control group)|This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
11189697|NCT03455790|Experimental|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
11189726|NCT03455621|Placebo Comparator|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
11189698|NCT03455790|Experimental|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
11189699|NCT03455790|Other|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
11189700|NCT03455790|Other|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
11189701|NCT03455790|Other|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
11189702|NCT03455790|Other|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
11189703|NCT03455790|Other|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
11189704|NCT03455777|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
11189705|NCT03455764|Experimental|MCS110+ Trametinib + Dabrafenib|"For Phase 1 MCS110 will be administered intravenously every 3 weeks.
~Dabrafenib is given orally every 12 hours.
~Trametinib is given orally daily"
11189706|NCT03455764|Experimental|MCS110 + Trametinib + Dabrafenib Phase 2|"MCS110 will be administered intravenously every 3 weeks.
~The Dosage will be determine by the DLT of Phase 1
~Dabrafenib is given orally every 12 hours.
~Trametinib is given orally daily"
11189707|NCT03455751|No Intervention|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
11189708|NCT03455751|Experimental|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
11189709|NCT03455725|Active Comparator|CardiAMP cell therapy system|"Roll-in phase:
~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.
~In the subsequent randomized phase:
~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
11189710|NCT03455725|Sham Comparator|Sham procedure control|"Randomized phase:
~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
11189711|NCT03455712|Experimental|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
11189712|NCT03455712|No Intervention|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
11189713|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
11189714|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
11189715|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
11189716|NCT03455686|Experimental|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
11189717|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
11189718|NCT03455660||Pre-January 2015|Patients who underwent cesarean delivery between February 2013 and December 2014.
11189719|NCT03455660||Post-January 2016|Patients who underwent cesarean delivery between February 2016 and December 2017.
11189720|NCT03455647|Experimental|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
11189721|NCT03455647|No Intervention|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
11189722|NCT03455647|No Intervention|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
11189723|NCT03455634|Active Comparator|Twin Block|Twin Block functional appliance
11189727|NCT03455621|Experimental|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
11189728|NCT03455621|Experimental|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
11189729|NCT03455621|Experimental|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
11189730|NCT03455621|Active Comparator|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
11189731|NCT03455608|Active Comparator|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
11189732|NCT03455608|Active Comparator|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
11189733|NCT03455608|Active Comparator|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
11189734|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
11189735|NCT03455582|Active Comparator|Control|30 Healthy controls
11189736|NCT03455582|Active Comparator|Control - 2|30 Healthy controls
11189737|NCT03455569|Experimental|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
11189738|NCT03455569|Experimental|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
11189739|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11189740|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
11189741|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
11189742|NCT03455530|Experimental|Intervention Group|The intervention group will receive the IH-enhanced CHW intervention before (~3 months) the other arm (Delayed Intervention Group).
11189743|NCT03455530|Other|Delayed Intervention Group|The delayed intervention group will receive the IH-enhanced CHW intervention after (~3 months) the other arm (Intervention Group).
11189744|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.
~Step 2. All patients will receive 6 courses of the VR combination.
~Step 3. After 6 courses of VR combination:
~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
11189745|NCT03455504|Experimental|Cohort 1|FLAI + V400 mg
11189746|NCT03455504|Experimental|Cohort 2|FLAI + V600 mg
11189747|NCT03455491|Experimental|XC221 100 mg|"XC221 100 mg orally.
~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
11189748|NCT03455491|Experimental|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
11189749|NCT03455491|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
11189750|NCT03455478|Experimental|corrected refractive error|
11189751|NCT03455478|No Intervention|uncorrected refractive error|
11189752|NCT03455465|No Intervention|No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
11189753|NCT03455465|Active Comparator|Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
11189754|NCT03455452||Renal Cell Carcinoma (RCC) Participants|Participants diagnosed with advanced RCC and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
11189755|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
11189756|NCT03455426|Experimental|letrozole group|letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days
11189757|NCT03455426|No Intervention|natural cycle group|
11189758|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
11189759|NCT03455374|Experimental|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
11189760|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
11189761|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
11189762|NCT03455348|No Intervention|cathete to less than 4 four centimeters to the wrist joint|
11189763|NCT03455348|Active Comparator|catheter to more than four centimeters to the wrist joint|
11189764|NCT03455335|Experimental|low dose cohort|20 million hMSCs .
11189765|NCT03455335|Experimental|mid dose cohort|40 million hMSCs
11189766|NCT03455335|Experimental|high dose cohort|80 million hMSCs .
11189767|NCT03455322|Active Comparator|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days.
11189768|NCT03455322|Active Comparator|midodrine & octreotide|midodrine 5mg three times/day orally & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6hS.C. for 7-10 days
11189769|NCT03455309|Active Comparator|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
11189770|NCT03455309|Placebo Comparator|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
11189771|NCT03455296|Active Comparator|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
11189772|NCT03455296|Active Comparator|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
11189773|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
11189774|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
11189775|NCT03455270|Experimental|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.
~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
11189776|NCT03455270|Experimental|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.
~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
11189777|NCT03455270|Experimental|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
11189778|NCT03455270|Experimental|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
11189779|NCT03455257|No Intervention|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
11189780|NCT03455257|Experimental|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
11189781|NCT03455231|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
11189782|NCT03455218|Experimental|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
11189783|NCT03455218|Placebo Comparator|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
11189784|NCT03455205|Experimental|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:
~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
11189785|NCT03455205|Placebo Comparator|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
11189786|NCT03455192|Experimental|Synbiotic supplements|One synbiotic tablet, per day, during 30 days
11189787|NCT03455192|Placebo Comparator|Placebo Oral Tablet|One placebo tablet , per day, during 30 days
11189788|NCT03455179|Experimental|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
11189789|NCT03455179|Experimental|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (''as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
11189790|NCT03455179|Experimental|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
11189791|NCT03455179|No Intervention|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
11189792|NCT03455166|Other|Psoriasis|
11189793|NCT03455166|Other|Psoriatic arthropathy|
11189794|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
11189795|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
11189796|NCT03455140|Experimental|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
11189797|NCT03455140|Experimental|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
11189798|NCT03455140|Experimental|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
11189799|NCT03455140|Experimental|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
11189800|NCT03455127|No Intervention|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
11189839|NCT03454893|Experimental|Single Assignment AVR-RD-01|AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
11211329|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
11189801|NCT03455127|Experimental|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
11189802|NCT03455114|Experimental|capsular fixation surgery|patients required capsule centration safely undergo capsular fixation surgery with AssiAnchor under local anesthesia .
11189803|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
11189804|NCT03455088|Experimental|DBT group|DBT group has 55 patients, maybe will be divided them into 6 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
11189805|NCT03455088|Active Comparator|Drug therapy group|Drug therapy group has 55 patients, and the investigator may use fluoxetine as treatment drug.
11189806|NCT03455088|Experimental|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe the investigator can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, the investigator use fluoxetine as treatment drug.
11189807|NCT03455075|Experimental|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
11189808|NCT03455075|Experimental|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
11189809|NCT03455075|Experimental|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
11189810|NCT03455075|Experimental|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
11189811|NCT03455075|Placebo Comparator|Placebo|Placebo administered orally capsules.
11189812|NCT03455049|Experimental|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
11189813|NCT03455049|Placebo Comparator|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
11189814|NCT03455049|Experimental|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
11189815|NCT03455049|Placebo Comparator|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
11189816|NCT03455036|Experimental|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
11189817|NCT03455023|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
11189818|NCT03455023|No Intervention|control group|Patients will receive usual medical care.
11189819|NCT03455010|No Intervention|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
11189820|NCT03455010|Experimental|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
11189821|NCT03455010|Experimental|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
11189822|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
11189823|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
11189824|NCT03454984|Experimental|SGI-110|"SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.
~Initial dose will be 30/m2/day SQ for 5 days
~total 10 cycles of SGI-110"
11189825|NCT03454971|Experimental|MinOS arm|Patients are followed according to MinOS protocol:
11189826|NCT03454958||Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
11189827|NCT03454945|Experimental|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
11189828|NCT03454945|Active Comparator|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
11189829|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
11189830|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
11189831|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
11189832|NCT03454919|Other|Palbociclib|single arm
11189833|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
11189834|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
11189835|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
11189836|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
11189837|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
11189838|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
11189881|NCT03454594|Experimental|low level laser hemotherapy|Watch laser acupuncture and nasal irradiation
11189840|NCT03454867|Experimental|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
11189841|NCT03454867|Active Comparator|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
11189842|NCT03454854|Experimental|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
11189843|NCT03454841||Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
11189844|NCT03454841||Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
11189845|NCT03454828|Experimental|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) >95th percentile.
11189846|NCT03454828|Active Comparator|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) <85th percentile.
11189847|NCT03454815|Experimental|Patency Group|apical patency was maintained during chemomechanical preparation
11189848|NCT03454815|No Intervention|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
11189849|NCT03454802|Active Comparator|Normal subjects|Normal subjects 'Passive Leg Raising'
11189850|NCT03454802|Active Comparator|ICU patients|ICU patients 'Passive Leg Raising'
11189851|NCT03454802|Active Comparator|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
11189852|NCT03454789|Active Comparator|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
11189853|NCT03454789|Active Comparator|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
11189854|NCT03454789|Active Comparator|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
11189855|NCT03454789|Active Comparator|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
11189856|NCT03454776|Active Comparator|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
11189857|NCT03454776|Placebo Comparator|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
11189858|NCT03454763|Experimental|Arm A, Intensive|Arm A, Intensive every 5 weeks
11189859|NCT03454763|Experimental|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
11189860|NCT03454750|Experimental|177Lu-PSMA|177Lu PSMA
11189861|NCT03454737|Experimental|mesenchymal stem cells|
11189862|NCT03454737|Active Comparator|Pure platelet-rich plasma|
11189863|NCT03454724|Experimental|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
11189864|NCT03454724|Active Comparator|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
11189865|NCT03454711|Experimental|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.
~Three clinical visits will be realized in less than two months"
11189866|NCT03454711|Experimental|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.
~Three clinical visits will be realized in less than two months"
11189867|NCT03454698|Other|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
11189868|NCT03454685||NCSLC group|NSCLC patients,including stage I to stage IV.
11189869|NCT03454685||Healthy subjects|healthy subjects
11189870|NCT03454672|Experimental|Tixel|Tixel Treatment.
11189871|NCT03454672|Active Comparator|Laser|Laser Treatment.
11189872|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
11189873|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
11189874|NCT03454646|Experimental|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.
~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
11189875|NCT03454646|No Intervention|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
11189876|NCT03454633|Experimental|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
11189877|NCT03454633|Active Comparator|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
11189878|NCT03454620|Experimental|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
11189879|NCT03454620|Experimental|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
11189880|NCT03454607|Experimental|FREE robot|Patients undergoing sinus surgery with the FREE robot
11189882|NCT03454594|No Intervention|control|all the participants in this group did not receive low level laser irradiation during the study period
11189883|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.
~18 individuals"
11189884|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.
~16 individuals."
11189885|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
11189886|NCT03454555|Active Comparator|Arm 1|Arm 1 patients will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision-Making (SDM) intervention.
11189887|NCT03454555|Active Comparator|Arm 2|Arm 2 patients will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT+CP) Intervention.
11189888|NCT03454542|Experimental|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
11189889|NCT03454542|Active Comparator|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
11189890|NCT03454529|Experimental|Treatment (simvastatin)|Patients receive simvastatin PO daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
11189891|NCT03454516|No Intervention|Standard Care|This group is the usual standard treatment group
11189892|NCT03454516|Other|Telemonitoring group|This group will followed up with telemonitoring
11189893|NCT03454503||First cohort|Newly diagnosed patients
11189894|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
11189895|NCT03454477|Experimental|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
11189896|NCT03454477|Experimental|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
11189897|NCT03454477|Experimental|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
11189898|NCT03454464|Sham Comparator|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
11189899|NCT03454464|Experimental|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
11189900|NCT03454451|Experimental|Cohort 1a|CPI-006
11189901|NCT03454451|Experimental|Cohort1b|CPI-006 + ciforadenant
11189902|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
11189903|NCT03454451|Experimental|Cohort 2a|CPI-006
11189904|NCT03454451|Experimental|Cohort 2b|CPI-006 + ciforadenant
11189905|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
11189906|NCT03454438|Experimental|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
11189907|NCT03454438|Experimental|Triage|Triage by rheumatologist in a primary care setting.
11189908|NCT03454438|No Intervention|Usual care|Control group consisting of usual care.
11189909|NCT03454425|Experimental|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
11189910|NCT03454425|Sham Comparator|Sham ExAblate Subthalamotomy|
11189911|NCT03454399|No Intervention|TEE image before suction|Suction orogastric tube which is attached to TEE probe
11189912|NCT03454399|Experimental|TEE image after suction|Suction orogastric tube which is attached to TEE probe
11189913|NCT03454386|Active Comparator|Active Treatment|"Stress Management and Resilience Training Program
~This group will be initially enrolled in the program."
11189914|NCT03454386|Other|Control|"Self-Management Stress Reduction Program
~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
11189915|NCT03454373|Experimental|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
11189916|NCT03454373|No Intervention|Comparator|Standard of care HIV primary care services, including counseling to return to care.
11189917|NCT03454347|Experimental|Protein Supplementation Group|Participants in this group will complete two weeks of lower limb suspension and receive 75g/day of supplemental protein in addition to education aimed at increasing protein intake through their diet.
11189918|NCT03454347|Active Comparator|Non-Supplemental Group|Participants in this group will complete two weeks of lower limb suspension and will receive no supplementation or nutritional education.
11189919|NCT03454334|Active Comparator|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic
~-0.20
~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
11189920|NCT03454334|Active Comparator|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).
~6.0mm Silicone
~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
11190010|NCT03453762|Active Comparator|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
11189921|NCT03454334|Active Comparator|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
11189922|NCT03454334|Active Comparator|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic
~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
11189923|NCT03454308|Experimental|SMASH|Automated reminder functions activated on pill monitoring device, motivational text messages, at home BP monitoring
11189924|NCT03454308|Other|Enhanced SC|No reminder functions on the pill monitoring device, attention control text messages
11189925|NCT03454295|Experimental|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
11189926|NCT03454295|Experimental|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
11189927|NCT03454282|Experimental|FMD Arm|The intervention consists in 5-day FMD (Fasting Mimicking Diet) to be followed for one cycle (Cohorts A and B) or for 4 consecutive every-four week cycles postoperatively.
11189928|NCT03454269|Active Comparator|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
11189929|NCT03454269|Active Comparator|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
11189930|NCT03454269|Active Comparator|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
11189931|NCT03454256|Experimental|Virtual Reality Group (VRG)|The Virtual Reality Group (VRG) will perform the rehabilitation trough the Virtual Reality Rehabilitation system (VRRS, Khymeia,Italy). The patient standing upright on a balance board will practice exercises of vertical position control with a visual biofeedback received from the VRRS and interacting with the serious video-games. The difficulty level of the exercises will increase gradually session by session. Every session will last 45 minutes with a frequency of at least 5 times a week.
11189932|NCT03454256|No Intervention|Control Group (CG)|The Control Group (CG) will perform the traditional treatment consisting of the exercises of rehabilitation of gait and postural passages, exercises for postural control, and proprioceptive exercises in a vertical position according to the method chosen by the physiotherapist. Every session will last 45 minutes with a frequency of at least 5 times a week.
11189933|NCT03454243|Experimental|RXDX-106|
11189934|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.
~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
11189935|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
11189936|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
11189937|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
11189938|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
11189939|NCT03454191|Experimental|Erector spinae plane block|
11189940|NCT03454191|Placebo Comparator|Placebo|
11189941|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
11189942|NCT03454165|Experimental|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
11189943|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
11189944|NCT03454139|Active Comparator|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
11190011|NCT03453762|Experimental|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
11189945|NCT03454139|No Intervention|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
11189946|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
11189947|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
11189948|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
11189949|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
11189950|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
11189951|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
11189952|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
11189953|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
11189954|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
11189955|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
11189956|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
11189957|NCT03454100|Experimental|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
11189958|NCT03454100|No Intervention|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
11189959|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
11189960|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
11189961|NCT03454074|Experimental|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
11189962|NCT03454074|Active Comparator|Education Only|Provide group education about healthy behavior changes without problem-solving component.
11189963|NCT03454074|No Intervention|Wait-list|No intervention administered. Will be offered intervention following a delay.
11189964|NCT03454061|Experimental|Intervention|Physical activity intervention
11189965|NCT03454061|No Intervention|Control|Keep usual activities in kindergarten
11189966|NCT03454048|Experimental|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
11189967|NCT03454048|Experimental|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
11190045|NCT03453476|Experimental|SRP and Fotosan 630|Scaling and root planing, photodynamic therapy using Fotosan 630
11189968|NCT03454048|Experimental|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
11189969|NCT03454048|Experimental|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
11189970|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
11189971|NCT03454022|Active Comparator|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
11189972|NCT03454022|Experimental|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
11189973|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.
~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
11189974|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
11189975|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
11189976|NCT03453996|Other|Control|Usual care.
11189977|NCT03453983|Experimental|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
11189978|NCT03453983|Sham Comparator|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
11189979|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:
~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).
~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.
~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
11189980|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
11189981|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
11189982|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
11189983|NCT03453944|Experimental|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
11189984|NCT03453944|Sham Comparator|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
11189985|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
11189986|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
11189987|NCT03453905|Experimental|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
11189988|NCT03453905|Other|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
11189989|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
11190012|NCT03453749|Other|Salovum|Patients will be given Salovum 1g/kg body weight/24 hours, divided into 6 dosages and given during 5 consecutive days.
11189990|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
11189991|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
11189992|NCT03453866|Experimental|Warmed Arthroscopic Fluids|Arthroscopic Fluids will be warmed to 38 degrees Celsius during procedure with active warming device. Temperature will be measured in real time.
11189993|NCT03453866|Active Comparator|Room Temperature Arthroscopic Fluids|Arthroscopic fluids will be kept at room temperature and will not be warmed per current standard of care. Temperature will be measured in real time.
11189994|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
11189995|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
11189996|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
11189997|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
11189998|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
11189999|NCT03453827||PEX|Patients after Cataract surgery with PES
11190000|NCT03453827||Control|Patients after Cataract surgery without PES
11190001|NCT03453814|Experimental|Interventional|Music therapy.
11190002|NCT03453814|No Intervention|Comparison|No music therapy.
11190003|NCT03453801|Experimental|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
11190004|NCT03453801|Experimental|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
11190005|NCT03453801|Experimental|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
11190006|NCT03453788|Experimental|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
11190007|NCT03453788|No Intervention|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
11190008|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
11190009|NCT03453775|Active Comparator|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
11190046|NCT03453476|No Intervention|Control|Scaling and root planing only
11190013|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
11190014|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.
~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
11190015|NCT03453723|Experimental|magic glove hypnosis|Magic glove hypnosis technique use before propofol infusion
11190016|NCT03453723|Active Comparator|lidocaine|extemporaneous mixture with lidocaine for propofol infusion
11190017|NCT03453710|Active Comparator|Bankart Repair and Remplissage|Patients randomized to the all-arthroscopic group (Bankart repair and remplissage) will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
11190018|NCT03453710|Active Comparator|Latarjet Coracoid Transfer|Patients randomized to the open Latarjet coracoid transfer will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
11190019|NCT03453697|Experimental|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
11190020|NCT03453684|Experimental|Administration of Vancomycin|Administration of Vancomycin 15 mg/kg over 1 hour prior to surgical incision
11190021|NCT03453671|Experimental|Mindfulness|Participants will use the strategy of mindfulness, i.e., present moment awareness with nonjudgment and acceptance, while exercising.
11190022|NCT03453671|Experimental|Distraction|Participants will use the strategy of distraction, i.e., directing their attention to something other than exercise (specifically a podcast) while exercising.
11190023|NCT03453671|Active Comparator|Self-Monitoring|Participants will monitor their internal experience while exercising, without distraction and without being taught mindfulness skills of nonjudgment and acceptance.
11190024|NCT03453658|Active Comparator|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
11190025|NCT03453658|Experimental|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
11190026|NCT03453632|Experimental|Botulinic toxin|Injections of botulinic toxin (Dysport®, Allergan) 200 UI
11190027|NCT03453632|Placebo Comparator|Placebo|Injections of physiological serum
11190028|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
11190029|NCT03453606|Active Comparator|home group|
11190030|NCT03453606|Active Comparator|center group|
11190031|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
11190032|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
11190033|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
11190034|NCT03453554|Experimental|DMN/Smart Home Partnership|Participants will learn how to use a digital memory notebook partnered with smart environment prompting technology to support everyday activities of daily living and reduce problems associated with memory deficits.
11190035|NCT03453554|Active Comparator|Digital Memory Notebook app|Participants will learn how to use a Digital Memory Notebook app to support everyday activities of daily living and reduce problems associated with memory deficits.
11190036|NCT03453541|Experimental|Ketorolac Tromethamine|This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
11190037|NCT03453541|Placebo Comparator|0.9% Normal Saline|This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.
11190038|NCT03453528|Experimental|68Ga-PSMA|68Ga-PSMA
11190039|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
11190040|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
11190041|NCT03453502|No Intervention|Before-intervention phase|All the very low birth weight (VLBW) and extremely low birth weight (ELBW) infants who were admitted from January 2017 to December 2017 to the NICUs of different hospitals.
11190042|NCT03453502|Experimental|Intervention phase|All the VLBW and ELBW infants who were admitted from January 2018 to December 2018 to the NICUs.During this phase,multiple intervention bundles of quality improvement will be implemented.
11190043|NCT03453502|Experimental|Sustainability intervention phase|All the VLBW and ELBW infants who were admitted from January 2019 to December 2019to the NICUs.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
11190044|NCT03453489|Experimental|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
11212518|NCT03297645|Active Comparator|Arm 3|enhanced standard of care
11190047|NCT03453463|Experimental|exercise and protein supplementation|Predominately resistance exercise training 2-3x week for 18 months; 1.5-1.7 g/kg/d total protein supplementation, Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
11190048|NCT03453463|No Intervention|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
11190049|NCT03453450||Health TAPESTRY volunteers|Volunteers in a primary care setting connecting with Health TAPESTRY clients
11190050|NCT03453450||Health TAPESTRY Volunteer Coordinators|The coordinators of volunteers
11190051|NCT03453437|No Intervention|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
11190052|NCT03453437|Experimental|Active group|Receiving Mindful Self-Compassion intervention
11190053|NCT03453424|Active Comparator|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.
~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
11190054|NCT03453424|Active Comparator|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.
~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
11190055|NCT03453411||Non interventional study|
11190056|NCT03453398|Experimental|Group 1|Shifts over 24-hours, shift cycle of 5 days (morning, afternoon, night, night off, rest).
11190057|NCT03453398|Experimental|Group 2|Shifts over 24-hours, shift cycle of 10 days (morning, morning, afternoon, afternoon, rest, night, night, night off, rest, rest).
11190058|NCT03453398|Active Comparator|Group 3|Only diurnal shifts, shift cycle of 5 days (morning, afternoon, morning, afternoon, morning, rest, rest).
11190059|NCT03453385|No Intervention|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
11190060|NCT03453385|Experimental|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
11190061|NCT03453372|Experimental|Active|MRgFUS treatment of pain caused by knee osteoarthritis
11190062|NCT03453372|Placebo Comparator|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
11190063|NCT03453359|Experimental|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
11190064|NCT03453359|Active Comparator|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
11190065|NCT03453346|Experimental|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for <75 kg, and 1200 mg for >=75 kg) twice daily with meal, orally given, for 12 successive weeks
11190066|NCT03453333|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
11190067|NCT03453333|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
11190068|NCT03453320|Experimental|Rapid - Slow|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.
~First time rapid (30 minutes), second time slow (120 minutes). Albumin solution"
11190069|NCT03453320|Experimental|Slow - Rapid|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.
~First time rapid (120 minutes), second time slow (30 minutes). Albumin solution"
11190070|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
11190071|NCT03453294|Experimental|Apnoeic oxygenation using THRIVE|Oxygenation by apnoea oxygenation using THRIVE
11190072|NCT03453294|Active Comparator|Endotracheal intubation and mechanical ventilation|Ventilation and oxygenation by an endotracheal tub and mechanical ventilation
11190073|NCT03453281|Experimental|Aflibercept Injection [Eylea]|Intravitreal injection of 2 mg in 0.05 ml Aflibercept. Frequency: once Duration: 10-15 minutes
11190074|NCT03453268|Other|1: Interventional (drug reduction)|"STEP DOWN strategy.
~Proposition of reduction of the number of antihypertensive medication according to:
~the systolic blood pressure levels,
~co-morbidities"
11190075|NCT03453268|Other|2: Control|Usual treatment
11190076|NCT03453255|Experimental|t(8;21)AML|chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(<60 year old) 500mg/m2(>60 year old) IV q12h d1,3,5
11190077|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
11190078|NCT03453203|Placebo Comparator|Control|"Both arms with be diagnosed using tenderpoints In the control arm the tenderpoint will Be palpated for 90 secs with no counterstrain treatment applied.
~Both treatment and control groups will remain on their current migraine medication regiment."
11190079|NCT03453203|Other|Treatment (conterstrain)|Both arms with be diagnosed using tenderpoints. Treatment arm will be treated with counterstrain technique. Counterstrain is a passive manipulative technique which the tissue being treated is positioned at a point of balance, or ease, AWAY from the restrictive barrier (The most thought of form of manipulative technique is high velocity low amplitude which is typically performed by chiropractors in spinal manipulation which goes TOWARD the restrictive barrier and actually pass through the restrictive barrier). Once a tenderpoint is found in the muscles the area of treatment is placed in a (three dimensional) position that will eliminate the sensation (tenderness).The treatment position is held for 90 seconds or until a release is felt (a decrease in muscle tension). Both treatment and control groups will remain on their current migraine medication regiment.
11190080|NCT03453190|Other|Psoriasis Patients on Comb. Treatment|Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
11190142|NCT03452748|Experimental|FTIR arm|all excised membranes are examined with FTIR spectroscopy
11190081|NCT03453177|No Intervention|Standard of Care|ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).
11190082|NCT03453177|Experimental|Standard of Care plus Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
11190083|NCT03453164|Experimental|Radiotherapy + Nivolumab|Localized short-term radiotherapy (22.5 Gy/5 fractions/5 days, Day 1-5) + nivolumab (starting on Day 15-22, a dose of 3 mg/kg (body weight), every 2 weeks to a total of 6 courses)
11190084|NCT03453151|Experimental|Regional nerve anesthesia|
11190085|NCT03453138|Experimental|LMA Protector Group|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
11190086|NCT03453138|Experimental|Tracheal Intubation Group|Patients will be intubated after standart anesthesia induction and we will record heamodynamic variables. including mean blood pressure and heart rate
11190087|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
11190088|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
11190089|NCT03453112|Experimental|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)
11190090|NCT03453112|Active Comparator|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.
11190091|NCT03453099||Study Cohort|Any ASA I or II patients scheduled for elective day case general anaesthesia at Chelsea & Westminster Hospital, involving a standard propofol-fentanyl induction regimen, aged between 18-65 years . See specific exclusion criteria below.
11190092|NCT03453086|Active Comparator|Group I:|These patients will receive single ipsilateral Ultrasound TPVB which performed with the patient in the sitting position at the level of the T4 with the probe in a vertical position 2.5-3 cm lateral to the midline. The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes which visualized with the superior costo-transverse ligament and the pleura visible in between . After this, 15-20 cc of bupivacaine 0.25% will be injected
11190093|NCT03453086|Active Comparator|Group II :|These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
11190094|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate <1 time/month
11190095|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and <1.5 times/month
11190096|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and <3.5 times/month,
11190097|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and <3 times/week
11190098|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate >3 times/week
11190099|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
11190100|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
11190101|NCT03453073||Younger|Age<65 years at follow-up baseline
11190102|NCT03453073||Older|Age>=65 years at follow-up baseline
11190103|NCT03453060|Experimental|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
11190104|NCT03453060|Experimental|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
11190105|NCT03453060|Experimental|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
11190106|NCT03453060|Experimental|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
11190107|NCT03453060|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
11190108|NCT03453047||1|Healthy volunteers. Liver donor groups; Course of the research: Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
11190109|NCT03453047||2|Liver transplant groups;Course of the research Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
11190110|NCT03453034|Experimental|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
11212593|NCT03297190|No Intervention|Usual Care|
11190111|NCT03453021||mepolizumab|Patients will receive a subcutaneous injection of mepolizumab 100 mg every 4 weeks for one year, for a total of 12 injections
11190112|NCT03452995|Active Comparator|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
11190113|NCT03452995|Active Comparator|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
11190114|NCT03452995|Experimental|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
11190115|NCT03452982|Experimental|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
11190116|NCT03452956||FTD Cohort|No intervention-observation only
11190117|NCT03452943|Experimental|TEV-50717|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 12 weeks
11190118|NCT03452943|Placebo Comparator|Placebo|Placebo matched to TEV-50717 BID for a total of 12 weeks
11190119|NCT03452930|Experimental|Stage 1A (tinostamustine)|Patients receive tinostamustine IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11190120|NCT03452930|Experimental|Stage 1B (tinostamustine)|Patients receive tinostamustine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11190121|NCT03452930|Experimental|Stage 2 (RT, tinostamustine)|Patients undergo RT 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive tinostamustine IV on day 1 or days 1 and 15 (to be determined following stage 1). Treatment repeats every 21 days (day 1) or 28 days (days 1 and 15) for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11190122|NCT03452917|Placebo Comparator|Placebo|2 ml of normal saline (n=500)
11190123|NCT03452917|Experimental|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
11190124|NCT03452904|Experimental|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
11190125|NCT03452904|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
11190126|NCT03452891|Experimental|SIM-MCL|
11190127|NCT03452891|Placebo Comparator|MCL|
11190128|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
11190129|NCT03452865|Experimental|Esomeprazole|Patients randomized to Esomeprazole Group will receive a bolus of 160 mg of esomeprazole (diluted in 100 ml of 0.9% sodium chloride for intravenous use and administered over 60 minutes) and an intravenous infusion of 12 mg/hr (diluted in 0.9% sodium chloride at a concentration of 8 mg/ml will be injected at a rate of 1.5 ml/hr) for 72 hours .
11190130|NCT03452865|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive a bolus of 100 ml of 0.9% sodium chloride for intravenous use administered over 60 minutes with no active principle and an intravenous infusion of 0.9% sodium chloride at a rate of 1.5 ml/hr with no active principle for 72 hours .
11190131|NCT03452852|Other|NPWT (PICO device)|In this arm, investigators will use the PICO system (Smith and Nephew) for compression therapy after split thickness skin graft of leg ulcers.
11190132|NCT03452852|Other|Compression bandaging (Coban 2 lite)|In this arm, investigators will use the Coban 2 lite compression bandaging for compression therapy after split thickness skin graft of leg ulcers.
11190133|NCT03452839|Experimental|Continuous infusion|"Patient randomized to continuous infusion group, will receive a continuous infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula and study day
~for ClCr > 50 ml/min: 3 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 12,5 ml/h.
~for ClCr < 50 ml/min: 2 g / day, prepared as follows: 10 mg/ml of meropenem in NaCl 0.9% at 8,3 ml/h.
~This solution will be replaced every time its duration exceeds the stability in use stated by the producer"
11190134|NCT03452839|Active Comparator|Bolus|"Patient randomized to bolus group, will receive a bolus infusion of meropenem according to their renal function (creatinine clearance -ClCr- estimated by Cockcroft-Gault formula):
~for Cl-Cr > 50 ml/min 1 g every 6 hours on first 24 hours, every 8 hours after
~for Cl-Cr < 50 ml/min 1 g every 8 hours on first 24 hours, every 12 hours after"
11190135|NCT03452826|Experimental|Antibiotic therapy according to the result of mPCR|Combined use of a respiratory broad panel Multiplex polymerase chain reaction (mPCR) (performed on a lower respiratory tract sample : bronchoalveolar lavage fluid or tracheal aspirate, otherwise sputum) and procalcitonin.
11190136|NCT03452826|No Intervention|Antibiotic therapy at discretion of ICU physicians|Antibiotic therapy at discretion of ICU physicians
11190137|NCT03452813||ischemic stroke or intracerebral hemorrhage patients|patients discharged from hospital to home or discharged to rehab will be called at 30 day and 90 day to monitor their transition of care outcomes.
11190138|NCT03452787||Boston Puerto Rican Health Study (NCT01231958)|40 with CC and 40 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
11190139|NCT03452787||GOLDN (NCT00083369)|107 participants with CC genotype and 272 with TT genotype for APOA2 rs5082.
11190140|NCT03452787||Framingham Heart Study (NCT00005121)|73 with CC and 170 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
11190141|NCT03452774||Study Group|Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
11190143|NCT03452735||patients diagnosed before age 40|Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
11190144|NCT03452735||Control Group|Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility
11190145|NCT03452722||Study group|Applied rtPA
11190146|NCT03452722||Control study|rtPA not applied
11190147|NCT03452709|No Intervention|Control group: no intervention|Only the normal practise
11190148|NCT03452709|Experimental|therapeutic exercise|In this group the intervention is the prescription of physical activity. The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
11190149|NCT03452709|Experimental|ABPM|In this group the arterial pressure is evaluated with ABPM.
11190150|NCT03452709|Experimental|therapeutic exercise + ABPM|
11190151|NCT03452696|Experimental|Calcium supplement 10/90|Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
11190152|NCT03452696|Experimental|Calcium supplement 5/95|Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element
11190153|NCT03452696|Active Comparator|Calcium carbonate supplement|1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.
11190154|NCT03452696|Active Comparator|Calcium citrate supplement|1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element
11190155|NCT03452683|No Intervention|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
11190156|NCT03452683|Experimental|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
11190157|NCT03452670|Experimental|Active Group|Participants in this group will use a contemplative wellness application for 8 weeks.
11190158|NCT03452670|Other|Waitlist Group|The waitlist group will receive no intervention during the study but will be able to use the wellness application after completion of the study.
11190159|NCT03452657|Experimental|Ranibizumab|Participants received 0.5mg intravitreal ranibizumab injection
11190160|NCT03452657|Sham Comparator|Sham-injection|No drug involved in the sham procedure; patient's eye is anesthetized and a syringe without needle gently pressed on the conjunctival surface to simulate the force of an actual injection
11190161|NCT03452618|Experimental|patients with a NIV equipment|Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
11190162|NCT03452618|Active Comparator|patients without a NIV equipment|Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
11190163|NCT03452605|Experimental|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
11190164|NCT03452605|Placebo Comparator|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
11190165|NCT03452592|Experimental|The way patients take Alflutinib|patients take Alflutinib orally once per day at dose of 80mg or160mg
11190166|NCT03452579|Active Comparator|Nivolumab + Standard Dose Bevacizumab|nivolumab 240 mg and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity
11190167|NCT03452579|Experimental|Nivolumab + Reduced Dose Bevacizumab|nivolumab 240 mg and reduced dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity
11190168|NCT03452566|Experimental|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
11190169|NCT03452553|Experimental|Open Label Treatment|Chemoembolization using LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
11190170|NCT03452540|Experimental|DS102|Participants in this group will receive 2000mg DS102 capsules daily.
11190171|NCT03452540|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules daily.
11190172|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
11190173|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
11190174|NCT03452514||Cohort 1 - Low Dose CT (LDCT) Scan|Individuals undergoing their first or subsequent annual LDCT screening study
11190175|NCT03452514||Cohort 2 - Diagnostic CT Scan|Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
11190176|NCT03452501||Naïve group|Newly diagnosed patients
11190177|NCT03452501||Switched group|Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®
11190178|NCT03452488|Placebo Comparator|Arm 1 - Placebo oral capsule|"4 capsules taken twice a day: in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.
~Component : Microcrystalline cellulose, Colloidal anhydrous silica"
11190179|NCT03452488|Experimental|Arm 2 - BIO101 - Half daily dose 350 mg|"4 capsules taken twice a day (2 placebo and 2 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.
~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20-hydroxyecdysone (20E) containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
11190223|NCT03452176|Sham Comparator|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
11190259|NCT03451916|Placebo Comparator|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
11212663|NCT03296709|Experimental|PPC z|
11190180|NCT03452488|Experimental|Arm 3 - BIO101 - Full daily dose 700 mg|"4 capsules taken twice a day (4 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.
~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
11190181|NCT03452475|Active Comparator|Arterolane-piperaquine|Arterolane-piperaquine for 3 days
11190182|NCT03452475|Active Comparator|Arterolane-piperaquine+mefloquine|Arterolane-piperaquine + mefloquine for 3 days
11190183|NCT03452475|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine for 3 days
11190184|NCT03452462|Experimental|Direct His Bundle Pacing|Pacing from the His bundle lead
11190185|NCT03452462|Active Comparator|Biventricular Pacing|Pacing from the right ventricular and coronary sinus leads
11190186|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
11190187|NCT03452436||Testicular cancer patients|Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
11190188|NCT03452436||Prostate cancer patients|Forty prostate cancer patients included prior to medical castration and radiotherapy.
11190189|NCT03452436||Healthy controls|Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
11190190|NCT03452423|Experimental|ACRFP|Patient suffering from osteoarthritis of knee joints, and planning to receive ACRFP, are enrolled into this study. Gait pattern is obtained preoperatively, 3 months, and 6 months postoperatively.
11190191|NCT03452397|Active Comparator|OC-02 Low Dose|
11190192|NCT03452397|Active Comparator|OC-02 Mid Dose|
11190193|NCT03452397|Active Comparator|OC-02 High Dose|
11190194|NCT03452397|Placebo Comparator|Placebo|
11190195|NCT03452384|Experimental|acupucture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface.
11190196|NCT03452384|Sham Comparator|control|For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
11190197|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
11190198|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
11190199|NCT03452345|Experimental|MEDITOXIN|
11190200|NCT03452345|Placebo Comparator|Placebo|
11190201|NCT03452332|Experimental|Treatment (tremelimumab, durvalumab, SABR)|Participants receive tremelimumab IV over 1 hour followed by durvalumab IV over 1 hour on day 1 of each cycle. Participants also undergo SABR over 30-45 minutes on days 8, 10, and 12 of cycle 1. Treatment with tremelimumab repeats every 4 weeks for up to 4 cycles, and treatment with durvalumab repeats every 4 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11190202|NCT03452319|Experimental|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
11190203|NCT03452319|Active Comparator|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
11190204|NCT03452306|Experimental|Metformin|"First aIntervention Period:
~Single administered dose of Metformin (750 mg tablet extended-release in a fasting condition
~Third Intervention Period:
~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
11190205|NCT03452306|Active Comparator|Glucophage® Long|"Second Intervention Period:
~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fasting condition
~Fourth Intervention Period:
~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fed condition"
11190206|NCT03452267|Experimental|Metformin|
11190207|NCT03452267|Experimental|Pioglitazone|
11190208|NCT03452267|Placebo Comparator|Placebo|
11190209|NCT03452254|Active Comparator|Experimental Group|Active bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
11190210|NCT03452254|Sham Comparator|Control Group|Sham bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
11190211|NCT03452241|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
11190212|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use
11190213|NCT03452241|Experimental|Intervention Group 1|The medical staffs who received the training will use the manual of brief intervention twice to deliver it and other materials about the harm of substance use.
11190214|NCT03452228|Experimental|evinacumab|
11190215|NCT03452228|Experimental|Placebo|
11190216|NCT03452215|Experimental|Study|
11190217|NCT03452215|Sham Comparator|Control|
11190218|NCT03452202|Experimental|Active Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
11190219|NCT03452202|Sham Comparator|Sham Stimulation|crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
11190220|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
11190221|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
11190222|NCT03452176|Experimental|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
11190224|NCT03452163|Experimental|Anesthesia, General|Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
11190225|NCT03452150|Experimental|Daily oral dose of D-0316|
11190226|NCT03452137|Active Comparator|Atezolizumab|Participants will receive Atezolizumab for 16 cycles, or up to 1 year (whichever occurs first)
11190227|NCT03452137|Experimental|Placebo|Participants will receive Placebo for 16 cycles, or up to 1 year (whichever occurs first).
11190228|NCT03452124|Active Comparator|IQOS|I quit ordinary smoking (IQOS) assistes cessation program
11190229|NCT03452124|Active Comparator|Smoker control|Conventional cigarette smoking continuation
11190230|NCT03452111|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day). This daily gel volume will contain approximately 62 mg of T that will deliver 6 mg T to the body per day and will also contain 8 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/day + T 62 mg/day (NES-8/T-62) gel).
11190231|NCT03452085|Active Comparator|artificial saliva spray (AS)|"The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.
~After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment."
11190232|NCT03452085|Placebo Comparator|maritime throat spray (TT)|"The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.
~After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment."
11190233|NCT03452072|Experimental|0.25% Timolol gel under the paraffin gauzes|"Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied
~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
11190234|NCT03452072|Active Comparator|Standard of Care dressings|"Vaseline will be applied to wound bed immediately after surgery before dressing is applied
~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
11190235|NCT03452059|Experimental|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
11190236|NCT03452059|Active Comparator|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
11190237|NCT03452046||PS 10 mmHg, PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
11190238|NCT03452046||PS 10 mmHg PEEP 0 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
11190239|NCT03452046||PS 0 mmHg PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
11190240|NCT03452046||t tube (PS 0 mmHg PEEP 0mmHg)|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
11190241|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
11190242|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
11190243|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
11190244|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
11190245|NCT03452020|Other|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:
~Tyto Thermometer
~Standard of Care thermometer
~Predicate IR thermometer"
11190246|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
11190247|NCT03451994||Body odor|individuals self-reporting idiopathic body odor with or without bad breath
11190248|NCT03451994||Breath odor|individuals self-reporting idiopathic bad breath but no body odor
11190249|NCT03451981|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine.
11190250|NCT03451981|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant surface.
11190251|NCT03451981|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant surface.
11190252|NCT03451968|Experimental|critically ill|"amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive).
~it is a single bolus, no other elements or drug will be administered."
11190253|NCT03451968|Active Comparator|control|amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive) it is a single bolus, no other elements or drug will be administered.
11190254|NCT03451955|Experimental|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
11190255|NCT03451955|No Intervention|Control group|Patients in the control group follow their usual diet for six months
11190256|NCT03451942|Experimental|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
11190257|NCT03451942|Placebo Comparator|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
11190258|NCT03451916|Experimental|PLX-PAD|• Arm 1 - PLX-PAD (120 subjects): 150×10^6 PLX-PAD cells (10×10^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte.
11212766|NCT03295968|Experimental|Water and High Intensity Exercise|
11190260|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
11190261|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
11190262|NCT03451890|Experimental|Cohort 1: E2730 40 mg|Participants will receive a single oral dose of E2730 40 milligrams (mg) under fasted conditions.
11190263|NCT03451890|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
11190264|NCT03451890|Experimental|Cohort 2: E2730 80 mg|Participants will receive a single oral dose of E2730 80 mg under fasted conditions.
11190265|NCT03451890|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
11190266|NCT03451890|Experimental|Cohort 3: E2730 120 mg|Participants will receive a single oral dose of E2730 120 mg under fasted conditions.
11190267|NCT03451890|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
11190268|NCT03451890|Experimental|Cohort 4: E2730 160 mg|Participants will receive a single oral dose of E2730 160 mg under fasted conditions.
11190269|NCT03451890|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
11190270|NCT03451877|Active Comparator|Study group|Children with cycloplegia refractive error more than -6 D TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
11190271|NCT03451877|Other|Control group|Emmetropic children TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
11190272|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
11190273|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
11190274|NCT03451851|Experimental|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (>=) 12 - less than (<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose >=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
11190275|NCT03451851|Placebo Comparator|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age >= 12 - <18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose >=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
11190276|NCT03451851|Active Comparator|Part 1 Group 3: Etanercept|Participants in Part 1a (age >= 12 - <18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
11190277|NCT03451851|Experimental|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter until drug approval for pediatric psoriasis or discontinuation of drug development.
11190278|NCT03451838||Diabetes mellitus|Pregnant women with diabetes mellitus will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
11190279|NCT03451838||control group|Pregnant women with no medical disorders will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
11190280|NCT03451825|Experimental|Phase 1: Avelumab|
11190281|NCT03451825|Experimental|Phase 2, Cohort 1: Avelumab|
11190282|NCT03451825|Experimental|Phase 2, Cohort 2: Avelumab|
11190283|NCT03451812||prostate cancer|The newly diagnostic number for the high-risk PCa patients in our hospital annually is ~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.
11190284|NCT03451799|Experimental|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
11190285|NCT03451773|Experimental|1/ Arm 1|Gemcitabine (dose based on genetic testing results) + de-escalating dose of M7824
11190286|NCT03451773|Experimental|2/ Arm 2|Gemcitabine (dose based on genetic testing results) + RP2D of M7824
11190287|NCT03451760|Experimental|Feru-guard|Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
11190288|NCT03451760|Placebo Comparator|Placebo|Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
11190289|NCT03451747||postmenopausal hypertensive women|
11190290|NCT03451747||mached hypertensive men|
11212767|NCT03295968|Experimental|Ibuprofen and Rest|
11190291|NCT03451734||Olanzapine|participants are randomized into this group,we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
11190292|NCT03451734||Risperidone|participants are randomized into this group,we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
11190293|NCT03451734||Aripiprazole|participants are randomized into this group,we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
11190294|NCT03451734||Ziprasidone|participants are randomized into this group,we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
11190295|NCT03451734||Amisulpride|participants are randomized into this group,we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
11190296|NCT03451734||Haloperidol|participants are randomized into this group,we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
11190297|NCT03451721||ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology
~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
11190298|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
11190299|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
11190300|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
11190301|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
11190302|NCT03451695|Experimental|Morphine group|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
11190303|NCT03451695|Placebo Comparator|Placebo group|Placebo group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1 ml).
11190304|NCT03451682|Experimental|procyanidine group|
11190305|NCT03451682|No Intervention|Control group|
11190306|NCT03451669||Shunt suspected to be functioning|
11190307|NCT03451669||Shunt suspected to not be functioning|
11190308|NCT03451643|Experimental|Endoscopic Expandable Stent|Procedure/Surgery. Endeosocpically a self-expandable metal stent will be placed in the colon rectum. Chemotherapy will be added
11190309|NCT03451643|Active Comparator|Colorectal Resection|Procedure/Surgery. A standard open or laparoscopic surgery will be performed to remove the colorectal cancer. Chemotherapy will be added
11190310|NCT03451630|Active Comparator|High-Touch|Delivered primarily via face-to-face interactions, with telephonic interactions and information sharing that does not require access to mobile devices or the Internet. In-person support and/or telephonic interactions to occur at least four times over at least a four-month period.
11190311|NCT03451630|Active Comparator|High-Tech|Delivered via a remote care management platform and digital health tools. Remote care support interactions to occur for at least a four-month period.
11190312|NCT03451630|Active Comparator|Usual Care|Delivered via Health Plan support and resources within 14 days of an initial home or telephonic visit.
11190313|NCT03451617|Other|Xpedition stent delivery system|
11190314|NCT03451617|Other|Alpine stent delivery system|
11190315|NCT03451591|Active Comparator|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning & evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
11190316|NCT03451591|Active Comparator|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning & evening. Day 11-15 / 50mg daily morning dose & 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning & evening. Week 53 / 50mg twice daily morning & evening. Week 54 / NIL dose.
11190317|NCT03451591|Active Comparator|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning & evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning & 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning & evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning & evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning & evening. Week 54 / NIL dose
11190318|NCT03451591|Placebo Comparator|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
11190319|NCT03451578|Other|Advanced Dry macular degeneration|
11190320|NCT03451552|No Intervention|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
11190321|NCT03451552|Experimental|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
11190322|NCT03451526||Surgeries+adjuvant chemotherapies|Patients who received radical resection of lung cancer + adjuvant chemotherapies
11190323|NCT03451526||Perioperative chemotherapies|Patients who received perioperative chemotherapies
11190324|NCT03451513|Experimental|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
11190325|NCT03451513|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
11190326|NCT03451500|Experimental|Carbidopa-levodopa 2 tablets daily|carbidopa-levodopa 25-100 mg 2 tablets daily hs
11190327|NCT03451500|Experimental|carbidopa-levodopa 6 tablets daily|carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
11190328|NCT03451500|Placebo Comparator|Placebo|Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
11190329|NCT03451487|Placebo Comparator|Reference drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.
~Panadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
11190330|NCT03451487|Experimental|Test drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.
~SafeTynadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
11190331|NCT03451487|Placebo Comparator|Reference drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.
~Panadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
11190332|NCT03451487|Experimental|Test drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.
~SafeTynadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study"
11190333|NCT03451474|Experimental|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
11190334|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
11190335|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
11190336|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
11190337|NCT03451435|No Intervention|Control|No intervention will be administered in this group as it serves as a control group.
11190338|NCT03451435|Experimental|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
11190339|NCT03451422|Experimental|AMG 592|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to AMG 592 or placebo in addition to standard of care therapy. AMG 592 or placebo will be administered either weekly (QW) or biweekly (Q2W).
11190340|NCT03451422|Placebo Comparator|Placebo|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to AMG 592 or placebo in addition to standard of care therapy. AMG 592 or placebo will be administered either weekly (QW) or biweekly (Q2W).
11190341|NCT03451409|Active Comparator|OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
11190342|NCT03451409|Active Comparator|OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
11190343|NCT03451409|Active Comparator|Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
11190344|NCT03451396|Active Comparator|Mild Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
11190345|NCT03451396|Active Comparator|Moderate to Severe Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
11190346|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
11190347|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
11190348|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
11190349|NCT03451344|Experimental|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
11190350|NCT03451344|Active Comparator|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
11190351|NCT03451331|Experimental|Arm A|Gemcitabine plus carboplatin plus nivolumab
11190352|NCT03451331|Experimental|Arm B|Gemcitabine plus oxaliplatin plus nivolumab
11190353|NCT03451318|Active Comparator|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
11190354|NCT03451318|Active Comparator|tonsillar adenoidectomy|tonsillar adenoidectomy
11190355|NCT03451318|Active Comparator|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
11190356|NCT03451318|Active Comparator|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
11190706|NCT03448809|Experimental|MMM (Mind My Mind training)|Mind My Mind training
11190357|NCT03451305|Experimental|Pillow group|Before surgery, with the patient lying in the supine position, a soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position. 12 hours duration suggested from 11:00 pm 1 night before the surgery till next day.
11190358|NCT03451305|No Intervention|No pillow group|No intervention was given in this group before surgery.
11190359|NCT03451292|Experimental|SMT + Albutein 20%|
11190360|NCT03451292|Active Comparator|SMT|
11190361|NCT03451266|Experimental|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
11190362|NCT03451266|Placebo Comparator|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
11190363|NCT03451253|Experimental|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
11190364|NCT03451253|Active Comparator|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
11190365|NCT03451240|Experimental|Intervention|
11190366|NCT03451227|Experimental|Dexmedetomidine Group|The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
11190367|NCT03451227|Active Comparator|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)
11190368|NCT03451214|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 11 mg/d and 25 mg supplemental zinc/d
11190369|NCT03451201|Experimental|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
11190370|NCT03451201|Active Comparator|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
11190371|NCT03451201|Other|Non-exercise|Sedentary Type 1 Diabetes Controls.
11190372|NCT03451162|Experimental|Dose Escalation Cohort: DHES0815A|Participants will receive DHES0815A in escalating doses in the dose-escalation cohort of the study. Participants will receive additional infusions of DHES0815A on Day 1 of subsequent cycles provided that they meet the protocol specified criteria for acceptable toxicity and ongoing clinical benefit.
11190373|NCT03451162|Experimental|Dose Expansion Cohort: DHES0815A|Participants will be treated at or below the Maximum Tolerated Dose (MTD) of DHES0815A (based on the review of the totality of the data) to obtain additional safety, tolerability, PK, and anti-tumor activity data.
11190374|NCT03451149|Experimental|Intervention|Undergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
11190375|NCT03451123|Experimental|FET-PET/MRI|O-(2-[F-18]FET)-L-tyrosine (FET) for brain PET/MRI
11190376|NCT03451110|Experimental|Part 1: Lemborexant plus Loestrin|Healthy female participants will receive a single oral dose of Loestrin 1.5/30 (containing ethinyl estradiol [EE] 0.030 milligrams [mg] and norethindrone [NE] 1.5 mg) in the evening of Day 1 after a fast of at least 3 hours. After a washout period of at least 4 days, participants will receive 10 mg lemborexant orally for 10 days. Lemborexant will continue to be administered in the evening on Days 15 through 18, followed by a single oral dose of Loestrin on Day 15 when administered with lemborexant after fasting in the evening for at least 3 hours.
11190377|NCT03451110|Experimental|Part 2: Lemborexant plus Famotidine|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. On Day 15, participants will receive a single oral dose of 40 mg famotidine, followed at least 2 hours later by a single dose of 10 mg lemborexant. After a washout period of up to 14 days participants will receive 10 mg lemborexant orally for 10 days.
11190378|NCT03451110|Experimental|Part 3: Lemborexant plus Fluconazole|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. After a washout interval of approximately 10 days, on Day 11, participants will be administered 400 mg fluconazole followed by 200 mg fluconazole once daily from Days 12 to 26. During this time a single dose of 10 mg lemborexant will be administered following an overnight fast of at least 10 hours along with fluconazole on Day 15 only.
11190379|NCT03451084|Experimental|Part 1: Dose Level 1|
11190380|NCT03451084|Experimental|Part 1: Dose Level 2|
11190381|NCT03451084|Experimental|Part 1: Dose Level 3|
11190382|NCT03451084|Experimental|Part 1: Dose Level 4|
11190383|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
11190384|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
11190385|NCT03451071|Experimental|Gardasil9|
11190386|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
11190387|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
11190388|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
11190389|NCT03451045|Experimental|Lenabasum 20 mg BID|
11190390|NCT03451045|Experimental|Lenabasum 5 mg BID|
11190391|NCT03451045|Placebo Comparator|Placebo BID|
11190392|NCT03451019|Active Comparator|sevelamer hydrochloride|the subject receive a single dose of 2,4 g
11190393|NCT03451019|Active Comparator|lanthanum carbonate|the subject receive a single dose of 1.0 g
11190394|NCT03451006|Experimental|Metformin|Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
11190395|NCT03451006|Active Comparator|Placebo|Placebo by mouth every 6 to 8 hours for one year
11190396|NCT03450993|Experimental|Immediate SMART Program Intervention|Subjects will receive the SMART-3RP intervention following study enrollment.
11190531|NCT03449992|Experimental|Intervention group|Participants in this group ingested nitrate-rich beetroot juice for 15 days
11190397|NCT03450993|Other|Delayed SMART Program Intervention|Subjects will record symptoms following enrollment and receive the SMART-3RP intervention approximately 3 months following study enrollment.
11190398|NCT03450980|Other|EyeTurn App|All participants will have their eye alignment measured with both the experimental device (EyeTurn app) and the clinical gold standard tests or ground truth (simulated strabismus gaze angles).
11190399|NCT03450967|Experimental|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
11190400|NCT03450954||Case(AMT patients)|patients who have undergone amniotic membrane transplant in our unit up till 2016.
11190401|NCT03450954||Control(Patients without AMT)|bullous keratopathy patients awaiting endothelial keratoplasty
11190402|NCT03450928|Active Comparator|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
11190403|NCT03450928|Active Comparator|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
11190404|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
11190405|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
11190406|NCT03450902|Experimental|Chinese herb & acupuncture|Participants will take Yiqi Suoquan granule and receive acupuncture.
11190407|NCT03450902|Active Comparator|Chinese herb & sham acupuncture|Participants will take Yiqi Suoquan granule and receive sham acupuncture.
11190408|NCT03450902|Active Comparator|Placebo & acupuncture|Participants will take placebo granule and receive acupuncture.
11190409|NCT03450902|Placebo Comparator|Placebo & sham acupuncture|Participants will take placebo granule and receive sham acupuncture.
11190410|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
11190411|NCT03450876||Healthy Control|Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
11190412|NCT03450876||24 to < 36 months post-ipilimumab treatment|24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
11190413|NCT03450876||≥ 36 to < 48 months post-ipilimumab treatment|36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
11190414|NCT03450876||≥ 48 months post-ipilimumab treatment|Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
11190415|NCT03450863||Fast-acting insulin aspart|Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.
11190416|NCT03450850|Other|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
11190417|NCT03450837||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.
~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
11190418|NCT03450837||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.
~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
11190419|NCT03450837||Sedentary control|"This group were sedentary men without cardiovascular disease.
~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
11190420|NCT03450824||The study group|The participants with patellofemoral pain.
11190421|NCT03450824||The control group|The participants without patellofemoral pain.
11190422|NCT03450811|Active Comparator|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
11190423|NCT03450811|No Intervention|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
11190424|NCT03450798|Active Comparator|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
11190425|NCT03450798|Sham Comparator|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
11190426|NCT03450772|Experimental|Creon® 25000 then Creon® 10000|Pancreatic enzyme
11190427|NCT03450772|Active Comparator|Creon® 10000 then Creon® 25000|Pancreatic enzyme
11190428|NCT03450759|Experimental|Treatment sequence 1|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate)"
11190460|NCT03450486|Experimental|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
11190583|NCT03449589||Smokers|RA patients currently smoking
11190429|NCT03450759|Experimental|Treatment sequence 2|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 oral suspension (reference)"
11190430|NCT03450759|Experimental|Treatment sequence 3|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule"
11190431|NCT03450759|Experimental|Treatment sequence 4|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:
~AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate)"
11190432|NCT03450746||Healthy patients for orthopaedic surgery|Standard general anaesthesia and ventilation with FiO2 0.50 for at least 45 minutes following the standard settings in our department.
11190433|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
11190434|NCT03450733||Control (Group 2)|Control, non-implanted subjects
11190435|NCT03450720|Experimental|GLPG2737 single dose.|Single dose of GLPG2737 oral suspension.
11190436|NCT03450707|Experimental|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
11190437|NCT03450707|Placebo Comparator|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
11190438|NCT03450681|Placebo Comparator|No pulsed radiofrequency|Procedure consists of a mock incision at the pulsed radiofrequency needle insertion site and standard perioperative pain management by the pain clinic (femoral catheter and PCA)
11190439|NCT03450681|Experimental|Pulsed Radiofrequency|Procedure consists in pre-operative pulsed radiofrequency under ultrasound guidance of the saphenous nerve and standard postoperative pain management by the pain clinic (femoral catheter and PCA)
11190440|NCT03450668|Active Comparator|standard incubator|routinely used standard incubator already used in the neonatal unit
11190441|NCT03450668|Experimental|mOm incubator|new test incubator
11190442|NCT03450655|Experimental|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
11190443|NCT03450655|Experimental|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
11190444|NCT03450642||Observation|Patients presenting with right Iliac Fosse pain
11190445|NCT03450629|Experimental|Brimonidine Tartrate Ophthalmic Suspension|
11190446|NCT03450629|Active Comparator|Brimonidine Tartrate Ophthalmic Solution|
11190447|NCT03450616|Experimental|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
11190448|NCT03450616|Active Comparator|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
11190449|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
11190450|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
11190451|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
11190452|NCT03450564|Experimental|Women Education|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
11190453|NCT03450564|Experimental|Male Involvement|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, model who allows his wife to use FP, religious leader, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
11190454|NCT03450564|Other|Control group|The third arm in this community-based intervention was following the community without provision of male and married women education. In this arm, there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
11190455|NCT03450551|Experimental|Twin Block|61 patients will receive the Twin Block appliance (one of the three appliances being studied)
11190456|NCT03450551|Active Comparator|Herbst|61 patients will receive the Herbst appliance (one of the three appliances being studied)
11190457|NCT03450551|Active Comparator|Frog distalising appliance|61 patients will receive the Frog distalising appliance (one of the three appliances being studied)
11190458|NCT03450499|Experimental|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
11190459|NCT03450499|Placebo Comparator|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
11190461|NCT03450486|Active Comparator|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
11190462|NCT03450473|Other|SurgiMend® MP|Patients will not be randomized as this is a case series study involving the evaluation of only 1 type of mesh (SurgiMend MP®).
11190463|NCT03450460|Experimental|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
11190464|NCT03450460|No Intervention|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
11190465|NCT03450434|Experimental|XC8 2 mg|XC8 2mg orally
11190466|NCT03450434|Experimental|XC8 10 mg|XC8 10 mg orally
11190467|NCT03450434|Experimental|XC8 100 mg|XC8 100 mg orally
11190468|NCT03450434|Placebo Comparator|Placebo|Placebo 2 mg, 10 mg or 100 mg orally
11190469|NCT03450421|Experimental|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
11190470|NCT03450421|No Intervention|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
11190471|NCT03450408|Active Comparator|Placement with gloved hand|The Foley bulb transcervical dilator will be placed blindly with a gloved hand.
11190472|NCT03450408|Active Comparator|Placement with sterile speculum|The cervix will be directly visualized using a sterile speculum, and an instrument will be used to advance the Foley bulb transcervical dilator into the cervical os.
11190473|NCT03450395|Placebo Comparator|Cereal - Cream of Rice|40 g cream of rice
11190474|NCT03450395|Experimental|Cereal - Oats containing beta-glucan|40 g oats
11190475|NCT03450382|Experimental|Hans Kai Participant|Participants receiving Hans Kai intervention
11190476|NCT03450382|No Intervention|Control|Participants not enrolled in Hans Kai
11190477|NCT03450369|Experimental|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.
~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
11190478|NCT03450343|Experimental|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
11190479|NCT03450330|Experimental|daily dose of AZD4205|daily dose of AZD4205
11190480|NCT03450317|Experimental|Aspirin|Aspirin 80mg once daily
11190481|NCT03450317|No Intervention|Non-treatment group|No intervention
11190482|NCT03450291|Experimental|Recovered from anorexia nervosa|Those who have a past diagnosis of AN (defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria) but are currently recovered, as shown by BMI over 18.5 throughout the last 12 months (self-report and current weight measured). Defined as either 'fully recovered'and: score must be within the 'normal range' of the Eating Disorders Examination Questionnaire (EDE-Q) global mean scores for young women, below 20 on the EAT-26 and below 16 on the Clinical Impairment Assessment for Eating Disorders (CIA); or partially recovered where one or more of these scores may be above the above-mentioned cutoffs.
11190483|NCT03450291|Experimental|High scoring on the EAT-26|Those who score above 20 on the EAT-26, but who do not declare a former diagnosis of an eating disorder (though they may meet criteria for a current diagnosis during the Structured Clinical Interview for the DSM-5).
11190484|NCT03450291|Experimental|Healthy controls|No history of or current diagnosis of any psychiatric disorder (especially eating disorders) which could impact study results.
11190485|NCT03450278|No Intervention|control|canine retraction without any means of acceleration.
11190486|NCT03450278|Experimental|micro-osteoperforation|canine retraction accelerated with micro-osteoperforation
11190487|NCT03450265|Experimental|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
11190488|NCT03450265|Active Comparator|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
11190489|NCT03450252|Experimental|Active pacing|Active ventricular pacing. The pacemaker is set-up with a short atrio-ventricular delay to allow for appropriate pacing capture of the ventricle.
11190490|NCT03450252|Sham Comparator|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
11190491|NCT03450239|Experimental|Recovered from anorexia nervosa|Women who have recovered from Anorexia Nervosa for over a year. BMI over 18.5, aged 18-40, scores on Eating Disorder Examination (EDE) within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
11190492|NCT03450239|Experimental|Healthy controls|Healthy control women. BMI over 18.5, aged 18-40, scores on EDE within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
11190493|NCT03450226|Experimental|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
11190494|NCT03450226|No Intervention|control|patients will be controlled
11190495|NCT03450213|Active Comparator|Patients with keratoconus|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
11190496|NCT03450213|Placebo Comparator|Normal people at the same age and sex|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
11190497|NCT03450200|Experimental|Exercises Group|three times daily exercises of hands and fingers exercises and foot exercises which last for 10 minutes in eight weeks, and health education about diabetic foot care
11190498|NCT03450200|Other|Control Group|health education about diabetic foot care
11190499|NCT03450187|Active Comparator|Cohort A|50 mg TP-271 q24 (n=6), a novel, broad-spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
11190500|NCT03450187|Active Comparator|Cohort B|100 mg TLP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
11190501|NCT03450187|Active Comparator|Cohort C|200 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
11190502|NCT03450187|Active Comparator|Cohort D|300 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
11190503|NCT03450187|Active Comparator|Cohort E|400 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
11190504|NCT03450174|Placebo Comparator|Control|this group, only placebo product will be given
11190505|NCT03450174|Experimental|Formative messages|this group will be received only daily formative messages on diet diversity, healthy and best nutrition practices
11190506|NCT03450174|Experimental|Fortified product|this group will be received only fortified product on alternate day up to 6 months
11190507|NCT03450174|Experimental|Fortified product plus|this group will receive fortified product along with daily messages on diet diversity and healthy nutrition practices
11190508|NCT03450161|Experimental|High-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 20 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.
~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
11190509|NCT03450161|Experimental|Low-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 3 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.
~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
11190510|NCT03450161|Experimental|Continuous Dose of Fentanyl|"5 minutes prior to sternotomy, patients will receive a NaCl 0.9% bolus (placebo) and a perfusion pump with fentanyl (verum) will be begun according to the Shibutani dosing scheme.
~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
11190511|NCT03450148|Experimental|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
11190512|NCT03450148|Placebo Comparator|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
11190513|NCT03450135||Mid-pubertal girls|Adolescent girls (ages 11-14) who are undergoing a healthy pubertal transition (Tanner developmental stage 3 or 4) will perform Trier Social Stress Test and Emotional go/no-go task.
11190514|NCT03450122|Experimental|Cohort 0 (cyclophosphamide, T cells, aldesleukin)|Participants receive cyclophosphamide IV over 30-60 minutes on day -2 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV over 60 minutes on day 0. Then, 6 hours later and twice a day for 14 days, receive aldesleukin SC in the absence of disease progression or unacceptable toxicity.
11190515|NCT03450122|Experimental|Cohort 1 (cyclophosphamide, T cells, aldesleukin, LV305)|Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes, and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 ID on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
11190516|NCT03450122|Experimental|Cohort 2(cyclophosphamide,T cells, aldesleukin, LV305, CMB305)|Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 injection on days 1, 14, 43, and 70, and immunotherapeutic combination product CMB305 IM on days 29, 57, and 85 in the absence of disease progression or unacceptable toxicity.
11190517|NCT03450109|Experimental|LY01005|One LY01005 3.6 mg gluteal IM injection.
11190518|NCT03450109|Active Comparator|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
11190519|NCT03450096|Active Comparator|Treatment group|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
11190520|NCT03450096|No Intervention|Control group|Patients in the control group (and in the active treatment group) will receive an opioid-based analgesia with a hydromorphone-patient controlled analgesia (PCA) depending on their analgesic demand
11190521|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
11190522|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
11190523|NCT03450070|Experimental|Test Panel|Light Therapy Mask Cream
11190524|NCT03450057|Experimental|Daratumumab + Dexamethasone|"Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
~Dexamethasone 40 mg (20 mg for patients>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle"
11190525|NCT03450044|Experimental|Vaccinated|Transfer of autologous dendritic cells interspersed with chemotherapy doses
11190526|NCT03450044|No Intervention|Control|Control patients who follow their basic treatment with chemotherapy with the A/C scheme
11190527|NCT03450031|Experimental|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
11190528|NCT03450031|Experimental|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
11190529|NCT03450018|Experimental|SLC-0111 + Gemcitabine|"Dose Level 1 - SLC-0111 (500 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)
~Dose Level 2 - SLC-0111 (750 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)
~Dose Level 3 - SLC-0111 (1000 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)"
11190530|NCT03450005||emerging Candida isolates|Web-based registry of invasive infections by Candida species
11190584|NCT03449589||Former smokers|RA patients who previously smoked
11190532|NCT03449992|Placebo Comparator|Placebo group|Participants in this group ingested a placebo drink for 15 days
11190533|NCT03449979|Experimental|alpha stimulation in participants in a depressive episode|Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
11190534|NCT03449979|Placebo Comparator|sham stimulation in participants in a depressive episode|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.
11190535|NCT03449979|Experimental|alpha stimulation in healthy participants|Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
11190536|NCT03449979|Placebo Comparator|sham stimulation in healthy participants|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.
11190537|NCT03449966|Experimental|Target biopsy under pCLE|(Cellvisio® with confocal minoprobe™, Mauna Kea Technologies, France)
11190538|NCT03449966|Active Comparator|Random biopsy at cancer lesion under WLE|WLE (GIF-HQ290, Olympus, Japan) group
11190539|NCT03449940|Active Comparator|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.
~1g Ceftriaxone IV was given.
~Incision-- Subcoronal, circumferential & degloving.
~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.
~All patients were discharged from hospital within 24 hours."
11190540|NCT03449940|Active Comparator|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.
~In an ambulatory setting, surgery was done 7 - 10 days later.
~1g Ceftriaxone IV was given.
~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.
~Incision--- 2 - 3cm localized incision over the site of the rolling sign.
~Repair--- Continuous technique with inverted knots using 3-0 polyglactin suture."
11190541|NCT03449927|Active Comparator|Control Arm: Regular menu|"Calorie count initiated on day +1 of transplant and ending upon count recovery
~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)
~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea
~Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
11190542|NCT03449927|Experimental|Intervention Arm: Specialized Menu|"Calorie count and tool provided on day +1 and ending upon count recovery
~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)
~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea
~Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
11190543|NCT03449901|Experimental|Cohort 1: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.
~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level
~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.
~Treatment may continue for up to 34 cycles (103 weeks)"
11190544|NCT03449901|Experimental|Cohort 2: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.
~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level
~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.
~Treatment may continue for up to 34 cycles (103 weeks)"
11190545|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
11190546|NCT03449862|Experimental|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
11190547|NCT03449862|Active Comparator|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
11190548|NCT03449849|Other|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
11190549|NCT03449849|Other|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
11190550|NCT03449836|Experimental|Streptococcus salivarius 24SMBc + Strept.oralis 89a|spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
11190551|NCT03449836|Active Comparator|fluticasone + mometasone|spray with fluticasone and mometasone
11190552|NCT03449836|Placebo Comparator|placebo|spray with isotonic solution
11190553|NCT03449823||TTTS Cases|Cases of monochorionic / diamniotic twin pregnancies diagnosed with twin-twin transfusion syndrome.
11190554|NCT03449823||MCDA Controls|Controls of monochorionic / diamniotic twin pregnancies without a diagnosis of twin-twin transfusion syndrome.
11190555|NCT03449810|Experimental|Muscles Energy Technique (Group A)|Muscles Energy Technique: the participant will be asked to lie supine on a couch with the hip at the edge and both lower limbs freely off the couch. The participant would place one of his legs over the therapist's shoulder and push up with the opposite leg into therapist's hand. A total of 4 contractions will be resisted by force equal to the participant's, held for 5sec with 5sec rest b/w each contraction. Also, restriction barrier (i.e. where movement is not possible due to impairment resulting from LBP) will be identified and the patient will be instructed to make a contraction of about 20-30% 0f maximal voluntary isometric contraction, held for 8-10secs, relaxed for 2-3secs and the limb will be moved to a new barrier. The procedure is repeated for about 4-6 times.
11190556|NCT03449810|Experimental|Core Stability Exercises (Group B)|Core Stability Exercises involves 4 different exercises; 1) Upper-body roll-out. 2) Inclined press-up. 3) Contralateral single-leg hold. 4) Quadruped exercise
11190557|NCT03449810|Experimental|MET plus CSE (Group C)|This group would receive a combination of Both Muscles Energy Technique plus Core Stability Exercise procedure.
11190558|NCT03449810|Active Comparator|Education and Counselling|Patient Education and Counselling involves Educating participant in-home care treatment program and Recommendation of strategies to prevent recurrent problems e.g. Functional movement training/re-education, this commonly involves identifying movements that are associated with low back pain, such as excessive flexion of the lumbar spine when rising from a chair instead of utilizing flexion of the hip for executing the movement, then providing cuing and education on movement options that enable the activity to be performed with fewer, or no, symptoms.
11190559|NCT03449797|Sham Comparator|Group A|AAVS performed with no intraprocedural rapid cortisol assay
11190560|NCT03449797|Experimental|Group B|AVS performed plus intraprocedural rapid cortisol assay
11190561|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
11190562|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
11190563|NCT03449771|Experimental|Single Arm|To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.
11190564|NCT03449758|Experimental|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
11190565|NCT03449732|Experimental|PDR measurement group A|Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)
11190566|NCT03449732|Experimental|PDR measurement group B|Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)
11190567|NCT03449732|Experimental|PDR measurement group C|Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)
11190568|NCT03449719|Active Comparator|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
11190569|NCT03449719|Experimental|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.
~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.
~Considering an Alfa/beta of 3, a BED3 > 100 Gy is recommended"
11190570|NCT03449693|Experimental|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
11190571|NCT03449693|No Intervention|No Supplement|No Intervention
11190572|NCT03449680|Experimental|Femoral Articular Branch Block|Patients will receive an ultrasound-guided femoral articular branch block with an injection of 20ml of ropivicaine 0.5%
11190573|NCT03449680|Placebo Comparator|Placebo Block|Patients will receive an ultrasound simulation of the location of a femoral articular branch block , this is to maintain blinding. A subcutaneous injection of 1ml of normal sterile saline will be administered
11190574|NCT03449667|Active Comparator|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
11190575|NCT03449667|Sham Comparator|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
11190576|NCT03449654|Other|Liraglutide|
11190577|NCT03449654|Other|placebo|
11190578|NCT03449641|Other|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
11190579|NCT03449628|Experimental|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)
~1 capsule, b.i.d. for 12 weeks"
11190580|NCT03449628|Placebo Comparator|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.
~1 capsule, b.i.d. for 12 weeks"
11190581|NCT03449602|Experimental|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
11190582|NCT03449602|Active Comparator|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
11190586|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
11190587|NCT03449576|Active Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
11190588|NCT03449563|Placebo Comparator|Placebo group (group G)|
11190589|NCT03449563|Active Comparator|Ultrasound-guided TPVB group (group U)|
11190590|NCT03449563|Experimental|open TPVB group(group E)|
11190591|NCT03449550|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
11190592|NCT03449550|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
11190593|NCT03449537|Experimental|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
11190594|NCT03449537|Active Comparator|AAF|hypoallergenic formula based on amino acid-based formula
11190595|NCT03449524|Active Comparator|75mg CXA-10|Once daily dosing of 75mg CXA-10 in the morning
11190596|NCT03449524|Active Comparator|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
11190597|NCT03449524|Placebo Comparator|Placebo|Once daily dosing in the morning
11190598|NCT03449511|Active Comparator|Ginger aromatherapy|Ginger essential oil (GIN-106) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
11190599|NCT03449511|Active Comparator|Orange aromatherpy|Orange essential oil (ORG-114) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
11190600|NCT03449511|Active Comparator|Lavender aromatherapy|Lavender essential oil (LAV-110) in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles.
11190601|NCT03449511|Placebo Comparator|Jojoba aromatherapy|"Jojoba oil in an aromatherapy inhaler. Subject will take 3 sniffs of the inhaler four times daily (morning, noon, evening, bedtime) for 7 consecutive days during two chemotherapy cycles. One drop of jojoba oil is on the other three aromatherapy inhalers. Jojoba oil is a carreir oil for essential oils which will be used as a comparator and placebo in this study."
11190602|NCT03449498|Experimental|study group|Intensive qualitative functional therapy
11190603|NCT03449498|Experimental|control group|Intensive functional therapy
11190604|NCT03449459|Experimental|oral probiotics|
11190605|NCT03449459|Experimental|aerosol inhaled amikacin|
11190606|NCT03449459|Experimental|combined vaccination|
11190607|NCT03449459|No Intervention|conventional therapy (blank control)|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.
11190608|NCT03449446|Experimental|SEL+ Firsocostat + Cilofexor Placebo|SEL + Firsocostat + Cilofexor Placebo for 48 weeks
11190609|NCT03449446|Experimental|SEL+ Firsocostat Placebo + Cilofexor|SEL + Firsocostat Placebo + Cilofexor for 48 weeks
11190610|NCT03449446|Experimental|SEL+ Firsocostat Placebo + Cilofexor Placebo|SEL + Firsocostat Placebo + Cilofexor Placebo for 48 weeks
11190611|NCT03449446|Experimental|SEL Placebo + Firsocostat + Cilofexor Placebo|SEL Placebo + Firsocostat + Cilofexor Placebo for 48 weeks
11190612|NCT03449446|Experimental|SEL Placebo + Firsocostat Placebo + Cilofexor|SEL Placebo + Firsocostat Placebo + Cilofexor for 48 weeks
11190613|NCT03449446|Experimental|SEL Placebo + Firsocostat Placebo + Cilofexor Placebo|SEL Placebo + Firsocostat Placebo + Cilofexor Placebo for 48 weeks
11190614|NCT03449446|Experimental|SEL Placebo + Firsocostat + Cilofexor|SEL Placebo + Firsocostat + Cilofexor for 48 weeks
11190615|NCT03449433|Experimental|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
11190616|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
11190617|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
11190618|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
11190619|NCT03449433|No Intervention|Healthy Participants|Healthy participants who received no study drug.
11190620|NCT03449420||Post Partum Hemorrhage|Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge
11190621|NCT03449394|Active Comparator|Delusions (Tx)|
11190622|NCT03449394|No Intervention|Delusions (TAU)|
11190623|NCT03449394|Active Comparator|Depression (Tx)|
11190624|NCT03449394|No Intervention|Depression (TAU)|
11190625|NCT03449381|Experimental|Dose Escalation|
11190626|NCT03449381|Experimental|Dose Expansion|
11190627|NCT03449368||Cohort 1|Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.
11190628|NCT03449368||Cohort 2|Includes age group 11-15 with a cap of 50 subjects. This is a retrospective, observational study.
11190629|NCT03449368||Cohort 3|Includes age group 16-20 with a cap of 40 subjects. This is a retrospective, observational study.
11190630|NCT03449368||Cohort 4|Includes age group 21-30 with a cap of 40 subjects. This is a retrospective, observational study.
11190631|NCT03449368||Cohort 5|Includes age group 31-40 with a cap at 40 subjects. This is a retrospective, observational study.
11190632|NCT03449368||Cohort 6|Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
11190633|NCT03449368||Cohort 7|Includes age group 51-70 with a cap at 40 subjects. This is a retrospective, observational study.
11190634|NCT03449355||vaginal group|
11190635|NCT03449355||cesarean section group|
11190636|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
11190637|NCT03449329|Placebo Comparator|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
11190638|NCT03449329|Active Comparator|Locoregional SIP block|"This group will receive a SIP block using:
~3mg/kg Ropivacain 1%
~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
11190639|NCT03449316|Experimental|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
11190640|NCT03449316|No Intervention|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.
~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
11190641|NCT03449303|Active Comparator|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
11190642|NCT03449303|Placebo Comparator|Placebo|Simmondsia chinensis
11190643|NCT03449290|Experimental|Kinesio taping group|Kinesio taping was applied on trunk muscles
11190644|NCT03449290|Sham Comparator|Control group|Sham Kinesio taping was applied on trunk muscles
11190645|NCT03449277|Active Comparator|take oral nifedipine tablets|Women who take the oral tablets of nifedipine till discharge of hospital
11190646|NCT03449277|Active Comparator|take oral labetalol tablets|Women who take the oral tablets of labetalol till discharge of hospital
11190647|NCT03449264|Experimental|Biological collection|"samples of different natures:
~Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.
~Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
~In parallel to this biological collection, standardized clinical data will be entered into a database"
11190648|NCT03449251|Experimental|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
11190649|NCT03449251|Experimental|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
11190650|NCT03449251|Experimental|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
11190651|NCT03449251|Experimental|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
11190652|NCT03449251|Experimental|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
11190653|NCT03449251|Experimental|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
11190654|NCT03449251|Experimental|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
11190655|NCT03449238|Other|pembrolizumab and SRS|Pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
11190656|NCT03449225|No Intervention|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
11190657|NCT03449225|Experimental|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
11190658|NCT03449212||SOD1 ALS|
11190659|NCT03449212||Sporadic ALS|
11190660|NCT03449212||Asymptomatic SOD1 gene carriers|
11190661|NCT03449199|Experimental|TMX-049 dose 1|
11190662|NCT03449199|Experimental|TMX-049 dose 2|
11190663|NCT03449199|Placebo Comparator|TMX-049 Placebo|
11190664|NCT03449186||Pregnancy group|Women, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
11190665|NCT03449186||Postpartum group|Postpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
11190666|NCT03449173|Experimental|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
11190667|NCT03449160|Active Comparator|Physical Therapy|Receive standard physical therapy
11190668|NCT03449160|Experimental|posture training device|Receive a posture training device in addition to standard physical therapy
11190669|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
11190670|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
11190671|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
11190672|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants received a gefapixant 45 mg tablet BID during the main study period (12 weeks) and also during the extension period (40 weeks).
11190673|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants received a gefapixant 15 mg tablet BID during the during the 12-week main study period and during the 40-week extension period.
11190674|NCT03449134|Placebo Comparator|Placebo|Participants received a matched placebo tablet BID during the 12-week main study period and during the 40-week extension period.
11190675|NCT03449121|Experimental|Slow breathing|Slow breathing techniques with exhale greater than inhale
11190676|NCT03449108|Experimental|Ovarian Cancer and Sarcomas (LN-145-S1)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 30 minutes daily on days -5 to -1, LN-145-S1 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses.
11190677|NCT03449108|Experimental|Thyroid Cohort (LN-145)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine IV over 30 minutes daily on days -5 to -1, autologous tumor infiltrating lymphocytes LN-145 IV over 45 minutes on day 0 and aldesleukin IV over 30 minutes on days 1-4 for up to 6 doses.
11190678|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
11190679|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
11190680|NCT03449082|Experimental|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
11190681|NCT03449082|Experimental|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
11190682|NCT03449082|Placebo Comparator|Placebo Comparator (Fibrin) group|Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
11190683|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
11190684|NCT03449056|Experimental|TREATMENT|salbutamol nebulization
11190685|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
11190686|NCT03449030|Experimental|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
11190687|NCT03449030|Experimental|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
11190688|NCT03449017|Experimental|E-cig use condition|Participants self-administer their own electronic cigarette device
11190689|NCT03448978|Experimental|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
11190690|NCT03448939|Experimental|S5G4T-1|topical cream
11190691|NCT03448939|Placebo Comparator|S5G4T-2|topical cream
11190692|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
11190693|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
11190694|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
11190695|NCT03448900|Experimental|Multicomponent intervention|The intervention group consisted in face-to-face 50-minute meeting [motivational interviewing (MI)]; online self-help material focused on: (1) decisions; (2) moods; (3) social life; (4) smoking health effects; and (5) quitting; e-mail 15 days before the MI, group therapy 2 months after the MI (60 minutes), a second follow-up visit 4 months after the MI (20 minutes).
11190696|NCT03448900|Active Comparator|Brief advice|The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
11190697|NCT03448887|Experimental|Study group|Extended HD with MCO dialyzer
11190698|NCT03448887|Active Comparator|Control group|Online hemodiafiltration
11190699|NCT03448874|Experimental|Seal-G MIST System|Seal-G MIST System is a surgical sealant that will be applied adjunctively to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
11190700|NCT03448874|No Intervention|Standard of care|Patients in the control arm will receive the standard of care [SOC] for colorectal resection surgery with primary anastomosis (no additional intervention)
11190701|NCT03448861|Experimental|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
11190702|NCT03448848|Experimental|study|
11190703|NCT03448848|Placebo Comparator|control|
11190704|NCT03448835|Experimental|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
11190705|NCT03448822||sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure.
11190707|NCT03448809|Active Comparator|TAU (Treatment as Usual)|Treatment as Usual
11190708|NCT03448796|Active Comparator|HTO-group|Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
11190709|NCT03448796|Active Comparator|FT -group|Group receives only supervised physiotherapeutic rehabilitation.
11190710|NCT03448770|Active Comparator|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
11190711|NCT03448770|Experimental|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
11190712|NCT03448757|Experimental|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.
~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.
~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
11190713|NCT03448744|Experimental|combiantion therapy group|thymosin alpha 1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
11190714|NCT03448744|Placebo Comparator|entecavir group|ETV (0.5 mg orally, daily) at least for 72 weeks
11190715|NCT03448731|Experimental|Doxycycline|Doxycycline 50 mg p.o. daily during 6 weeks
11190716|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
11190717|NCT03448705|Experimental|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
11190718|NCT03448705|Experimental|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
11190719|NCT03448705|Active Comparator|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
11190720|NCT03448692|Experimental|PF-06730512 Cohort 1|Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
11190721|NCT03448692|Experimental|PF-06730512 Cohort 2|Subjects in cohort 2 will receive dose 2 IV infusion.
11190722|NCT03448666|Experimental|pembrolizumab and elettrochemiotherapy|drug: Pembrolizumab 200 mg flat dose every three weeks procedure: elettrochemiotherapy once after first pembrolizumab dose
11190723|NCT03448653|Experimental|Colonoscopy with NBI|
11190724|NCT03448627||Group 1: HSCT recipients|Pulmonary functions [spirometry], maximal exercise capacity [Modified-Incremental Shuttle Walk Test (ISWT)], inspiratory and expiratory muscle strength (MIP and MEP, respectively) [mouth pressure device] and peripheral muscle strength [hand-held dynamometer] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of Modified-ISWT.
11190725|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
11190726|NCT03448601|Active Comparator|Non-tailored intervention group|
11190727|NCT03448601|Experimental|Culturally tailored intervention group|
11190728|NCT03448588||group with normal T4 level or T4/T3|participants with T4 within 4.3-12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ≤7.52, which are considered to be normal T4 level and T4/T3.
11190729|NCT03448588||group with elevated T4 level or T4/T3|participants with T4 more than 12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) > 7.52, which are considered to be elevated T4 level and T4/T3.
11190730|NCT03448575|Sham Comparator|Control - Medication Alert Only|The control arm medication alert is a simple text pop-up in the EMR that will inform the prescriber of Choosing Wisely® recommendations developed the American Psychiatric Association regarding antipsychotic medication use in children and adolescents.
11190731|NCT03448575|Experimental|Intervention - Alert + CAP Review AND Enhanced BH Access|"The intervention alert prompts the prescriber to keep/remove the antipsychotic order, and/or order any study services: behavioral health navigation, expedited psychotherapy access, virtual consult with a child and adolescent psychiatrist (CAP). Passive case review by the study CAP will occur for all intervention arm cases. A virtual consult will be scheduled if the prescriber ordered it or the CAP needs to discuss the case. The CAP will provide the prescriber with a written summary of his/her review.
~Following review by the CAP, a navigator reaches out to the eligible intervention arm patient/family to offer extra support. The navigator's role is to (a) provide extra support to facilitate access and engagement in appropriate psychosocial therapies; (b) coordinate short-duration bridging therapy sessions for teens/families not engaged in psychotherapy, when appropriate; and (c) keep the prescriber informed of any clinically relevant updates."
11190732|NCT03448562|Experimental|Study Group|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR)
11190733|NCT03448562|Active Comparator|Control Group|CPVI alone
11190734|NCT03448549|Experimental|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
11190735|NCT03448549|Active Comparator|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
11190736|NCT03448536|Experimental|Naproxen Sodium : Acetaminophen|Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2
11190737|NCT03448536|Experimental|Acetaminophen : Naproxen Sodium|Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2
11190943|NCT03447093||Control group|30 healthy volunteers were included in the healthy control group
11190738|NCT03448523|Experimental|Right To Play's Positive Child and Youth Development program|Behavioural intervention
11190739|NCT03448523|No Intervention|Control|No intervention; intervention to be offered after end line assessment
11190740|NCT03448510|Experimental|Irreversible electroporation treatment|Subjects will receive irreversible electroporation of the prostate
11190741|NCT03448510|Active Comparator|standard medication group|Subjects will receive either α-blocker or 5α reductase monotherapy or combination therapy.
11190742|NCT03448497||Advanced Melanoma patients who intiated first-line therapy|patients who initiated any first-line therapy for advanced melanoma and had not previously received treatment for their advanced disease
11190743|NCT03448484|Experimental|Intervention|Intervention (agriculture-focused package + nutrition-sensitive and nutrition-specific interventions=integrated package)
11190744|NCT03448484|Other|Control|Control (agriculture-focused package)
11190745|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
11190746|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
11190747|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
11190748|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
11190749|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
11190750|NCT03448419|Experimental|Empagliflozin|
11190751|NCT03448419|Placebo Comparator|Placebo|
11190752|NCT03448406|Experimental|Empagliflozin|
11190753|NCT03448406|Active Comparator|Placebo|
11190754|NCT03448393|Experimental|Dose escalation|CD19/CD22-CARtransduced T cells at escalating doses
11190755|NCT03448393|Experimental|Dose expansion|CD19/CD22-CARtransduced T cells at MTD or highest dose administered
11190756|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
11190757|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
11190758|NCT03448354|Experimental|NAC-IDS-HIPEC|Under the clinicians' decision, HIPEC procedures will be performed at the time of IDS.
11190759|NCT03448354|No Intervention|NAC-IDS|Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS.
11190760|NCT03448328|Experimental|Pea Protein|NUTRALYS pea protein supplement
11190761|NCT03448328|Experimental|Whey Protein|Whey protein supplement
11190762|NCT03448328|Active Comparator|Apple juice|Apple juice
11190763|NCT03448315|Active Comparator|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
11190764|NCT03448315|Sham Comparator|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
11190765|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
11190766|NCT03448289|No Intervention|Control|This group will not receive the RLPT.
11190767|NCT03448289|Experimental|Intervention|This group will receive the RLPT.
11190768|NCT03448276|Experimental|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
11190769|NCT03448276|Active Comparator|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
11190770|NCT03448263|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
11190771|NCT03448263|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
11190772|NCT03448263|Experimental|Reciproc instruments|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
11190773|NCT03448250|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
11190774|NCT03448250|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
11190775|NCT03448237|Active Comparator|Speech therapy|Speech therapy adapted to the child,
11190776|NCT03448237|Experimental|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
11190777|NCT03448224|Experimental|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
11190778|NCT03448224|Active Comparator|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
11190779|NCT03448211|Experimental|Para-toluenesulfonamide Injection (PTS)|Investigational product
11190780|NCT03448198|Other|Knee arthritis|Total knee replacement
11190781|NCT03448185|Placebo Comparator|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
11190782|NCT03448185|Experimental|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
11190783|NCT03448185|Active Comparator|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
11190784|NCT03448185|Active Comparator|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
11190785|NCT03448172|Experimental|Investigational Product|[14C]PF-05221304
11190786|NCT03448159|Experimental|Fluoxetine Hydrochloride|Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).
11190787|NCT03448159|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks)."
11190788|NCT03448146|Experimental|Para-Toluenesulfonamide|".The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.
~. In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.
~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
11190789|NCT03448133|Experimental|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
11190790|NCT03448133|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
11190791|NCT03448120|No Intervention|Control Group|The volunteers who will remain in prolonged rest (10 minutes for homeostasis plus 30 minutes of no intervention).
11190792|NCT03448120|Experimental|Acupuncture Group|The volunteers will receive six needles in six acupoints in the non-dominant upper limb for 30 minutes.
11190793|NCT03448120|Experimental|Dry needling Group|The volunteers will receive application of six needles arranged in the non-dominant biceps brachialis for 30 minutes.
11190794|NCT03448107|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
11190795|NCT03448107|Active Comparator|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
11190796|NCT03448094|Experimental|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
11190797|NCT03448094|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
11190798|NCT03448081|Active Comparator|SNA-120 + Calcipotriene|
11190799|NCT03448081|Placebo Comparator|Placebo + Calcipotriene|
11190800|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.
~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.
~Ketamine infusion will not be titrated.
~Remaining care will be identical to standard therapy group."
11190801|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)
~Pre-op dexamethasone
~Pre-op midazolam at discretion of anesthesiologist
~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.
~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.
~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.
~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac
~Other post-op care as per usual surgical routine"
11190802|NCT03448055|Other|Interventional|Immunocal 20gm daily
11190803|NCT03448042|Experimental|Dose Escalation|Participants will be assigned sequentially to escalating doses of BTRC4017A, up to the maximum tolerated dose (MTD).
11190804|NCT03448042|Experimental|Dose Expansion|Participants will receive BTRC4017A based on the MTD or maximum allowed dose (MAD) identified during dose escalation.
11190805|NCT03448029||Endovascular Patients|Patients undergoing endovascular interventions for symptomatic PAD
11190806|NCT03448016|Experimental|Alcohol use disorders|[C-11]NOP-1A PET Scan
11190807|NCT03448016|Experimental|Controls|[C-11]NOP-1A PET Scan
11190808|NCT03448003|Experimental|Group I (IO prevention program)|Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
11190809|NCT03448003|Active Comparator|Group II (no intervention)|Patients receive no intervention. After 26 weeks, patients may crossover to Group I.
11190810|NCT03447990|Other|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo
~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
11190811|NCT03447990|Other|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo
~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
11190812|NCT03447977|Experimental|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
11212768|NCT03295968|Experimental|Ibuprofen and High Intensity Exercise|
11190813|NCT03447977|Experimental|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
11190814|NCT03447977|Experimental|exercise group|exercises, 2 session for 6 weeks
11190815|NCT03447964||Type 1 diabetes|dosing of sphingolipids
11190816|NCT03447964||Type 2 diabetes|Dosing of sphingolipids
11190817|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 20%TTV|Group 1: total dose = 20% total tumor volume
11190818|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 30%TTV|Group 2: total dose = 30% total tumor volume
11190819|NCT03447938|Active Comparator|CABG with sternotomy|Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).
11190820|NCT03447938|Experimental|Minimally-invasive CABG|Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.
11190821|NCT03447925|Experimental|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
11190822|NCT03447925|Experimental|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
11190823|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
11190824|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
11190825|NCT03447899|Experimental|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
11190826|NCT03447899|No Intervention|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
11190827|NCT03447886||Quality Of Life|"This study uses qualitative research methods, specifically semi-structured interviews.
~This will include moderator guide development,
~Phone interviews with breast cancer survivors will be conducted
~Qualitative data analysis of the phone interviews will be conducted"
11190828|NCT03447873|Active Comparator|Triple therapy|To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
11190829|NCT03447873|Experimental|Switch to dual therapy A|Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
11190830|NCT03447873|Experimental|Switch to dual therapy B|Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
11190831|NCT03447860|Active Comparator|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress.
11190832|NCT03447860|Experimental|PAACC|A mindfulness-based multi-component caregiver intervention to reduce caregiver stress.
11190833|NCT03447847|Experimental|Phase 1|A=oligomineral water, B=oligomineral water
11190834|NCT03447847|Experimental|Phase 2|A=oligomineral water, B=bicarbonate-rich water
11190835|NCT03447847|Experimental|Phase 3|A=bicarbonate-rich water, B=oligomineral water
11190836|NCT03447847|Experimental|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
11190837|NCT03447834|Experimental|Selective intracoronary hypothermia + PPCI|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation myocardial infarction with total ST-segment deviation of at least 5 mm. If the patient has TIMI grade flow 0 or 1, the experimental arm will be treated by selective intracoronary hypothermia just before and after reperfusion, in addition to routine PPCI.
11190838|NCT03447834|Other|Standard PPCI|The control group will receive routine PPCI.
11190839|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
11190840|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
11190841|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
11190842|NCT03447808|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11190843|NCT03447795|Experimental|autogenous tooth grafted sites|
11190844|NCT03447795|Active Comparator|autogenous demineralised dentin grafted sites|
11190845|NCT03447782|Experimental|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).
~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
11190846|NCT03447769|Experimental|canakinumab|Participants will be administered receive canakinumab for 18 cycles (approximately 54 weeks).
11190847|NCT03447769|Placebo Comparator|Placebo|Participants will be administered receive canakinumab placebo for 18 cycles (approximately 54 weeks).
11190877|NCT03447587|Placebo Comparator|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
11190944|NCT03447093||Drug treatment group|30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill
11190848|NCT03447756|Experimental|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
11190849|NCT03447756|Placebo Comparator|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
11190850|NCT03447743|Experimental|XR-NTX P&P office|30 participants will receive on-going XR-NTX injections in the local rural P&P office
11190851|NCT03447743|Active Comparator|XR-NTX services as usual|30 participants will receive on-going XR-NTX injections in a local community clinic
11190852|NCT03447730|Experimental|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
11190853|NCT03447730|Experimental|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10^11 CFU TID given immediately after meals from Days 1 through 6.
11190854|NCT03447730|Placebo Comparator|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
11190855|NCT03447717|Experimental|ActiGait|Patients who get the ActiGait implant
11190856|NCT03447704|Experimental|BCD-085|
11190857|NCT03447704|Placebo Comparator|Placebo|
11190858|NCT03447691|Experimental|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min
~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
11190859|NCT03447691|Active Comparator|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.
~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
11190860|NCT03447678|Experimental|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
11190861|NCT03447665|No Intervention|Control|Infant sleep monitoring and parental surveys only
11190862|NCT03447665|Experimental|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
11190863|NCT03447665|Experimental|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
11190864|NCT03447652|No Intervention|Control Group|Each patient in the control group did not perform any rehabilitation exercises. Over the intervention time frame, the patient was required to check in with a member of the research team each week to discuss any changes in their ankle or report any injury incidence.
11190865|NCT03447652|Experimental|Resistance Band Group|Each session, patients completed resistance training using a resistance band in 4 directions of ankle motion (plantarflexion, dorsiflexion, inversion and eversion). Patients would complete 3 sets of 10 repetitions during each session. Every 3 sessions, the band resistance would increase.
11190866|NCT03447652|Experimental|Biomechanical Ankle Platform System|The Biomechanical Ankle Platform System board is an oval shaped board that utilizes a half-sphere on the bottom of the board to allow the patient to train on an unstable surface. A one legged stance on their involved limb was performed on the Biomechanical Ankle Platform System board while clockwise and counterclockwise circles were completed. The initial rotation of direction was selected by the patient and changed every 10 seconds of the 40-second trial. Five 40-second trials were completed with 1-minute rest intervals in between the trials. Progression was determined by the supervising clinician and was based on the patient's ability to make smooth transitions between direction changes and completion of smooth circular rotations in both directions.
11190867|NCT03447652|Experimental|Combination Group|Patients completing the combination protocol completed both the resistance band and Biomechanical Ankle Platform System board protocols during each session. The order of exercise completion was counterbalanced for each session.
11190868|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
11190869|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
11190870|NCT03447626||Prospective Group- Robotic UKA Arm|Robotic UKA with the MAKO machine.
11190871|NCT03447626||Control- Fixed and Mobile UKA Arm|Patients who have received fixed or mobile bearing UKA
11190872|NCT03447626||Control-Total Knee Arthroplasty|Patients who have had cemented or cementless total knee arthroplasty
11190873|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
11190874|NCT03447600|Experimental|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at >/=5% weight loss which is an average of 12 weeks.
11190875|NCT03447600|Active Comparator|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at >/=5% weight loss which is an average of 12 weeks.
11190876|NCT03447587|Experimental|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
11190940|NCT03447106|Experimental|Open|
11190941|NCT03447106|Experimental|Laparoscopic|
11190878|NCT03447574|Experimental|Aim 1|The ethanol dilution is, in essence, a non-invasive dilution method. It is of interest because of how ethanol readily dissolves itself exclusively into the water space of the body[4], is non-toxic in reasonable concentrations, is metabolized in a 0th order reaction above concentrations of 0.015 g/dL[4], and there are non-invasive methods for determining blood alcohol concentration[5, 6]. Thus, by drinking a known amount of ethanol, total body water can be calculated after a few hours of periodic breathalyzer analyses. Ethanol has been validated against deuterium oxide, the invasive gold standard for determining total body water[4]. The ethanol dose will be 0.5g/kg body weight.
11190879|NCT03447574|Active Comparator|Aim 2|30mL/kg body weight of saline will be rapidly infused after the baseline measurements completed in Aim 1. Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated. To determine if non-invasive fluid volume techniques can accurately determine fluid changes in healthy participants.Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated.
11190880|NCT03447561|Experimental|Anticipatory + consummatory food reward|PET-MR scan session with a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (viewing neutral images and drinking sips of water) and the fourth block the 'food reward condition' (viewing high-calorie food images and drinking sips of chocolate milkshake).
11190881|NCT03447561|Experimental|Consummatory food reward|PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
11190882|NCT03447548|Experimental|Processing speed training|Neurofeedback processing speed training
11190883|NCT03447548|Active Comparator|Active control|Computer games
11190884|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder
~SDQ total difficulties score and the parents report SDQ total difficulties score:
~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
11190885|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder
~SDQ total difficulties score and the parents report SDQ total difficulties score:
~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (<12), parents report SDQ total difficulties score abnormal (>16)"
11190886|NCT03447509|Active Comparator|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
11190887|NCT03447509|Active Comparator|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
11190888|NCT03447509|Active Comparator|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
11190889|NCT03447496||Closed reduction|The children were treated with closed reduction.
11190890|NCT03447496||Open reduction|The children were treated with open reduction.
11190891|NCT03447483|Other|Cohort of patients starting a treatment by ICI|
11190892|NCT03447470|Other|Module 1, Part A|Patients will be given RXC004 at a specified dose level and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD
11190893|NCT03447457|Other|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
11190894|NCT03447457|Other|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
11190895|NCT03447444|Other|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
11190896|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
11190897|NCT03447418|Other|no treatment, open label|
11190898|NCT03447405|Experimental|Dino Egg Safety and useability|Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.
11190899|NCT03447405|No Intervention|Standard of Care|
11190900|NCT03447392|Experimental|patient education and Chinese medicine|1-hour, one-on-one teaching session with a educator to the standard discharge education of Integrated Traditional and Western Medicine
11190901|NCT03447392|No Intervention|patient education|no discharge education
11190902|NCT03447379|Active Comparator|P2Y12 monotherapy after 3 months of DAPT|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)
11190942|NCT03447106|Experimental|Robotic|
11190903|NCT03447379|Active Comparator|Dual-antiplatelet therapy for a year|DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year
11190904|NCT03447366|Experimental|Mitral doppler|Mitral doppler before and after vascular filling
11190905|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
11190906|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
11190907|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
11190908|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
11190909|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
11190910|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
11190911|NCT03447327|Other|operated group|patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia
11190912|NCT03447314|Experimental|Part 1a: GSK3174998 24 mg|In Part 1, subjects with advanced solid tumors will be enrolled. Part 1a will have up to five dose escalation cohorts to investigate the safety and tolerability of escalating doses of GSK1795091 in combination with GSK3174998 24 mg.
11190913|NCT03447314|Experimental|Part 1b: GSK3359609 80 mg|In Part 1, subjects with advanced solid tumors will be enrolled. Part 1b will have up to five dose escalation cohorts to investigate the safety and tolerability of escalating doses of GSK1795091 in combination with GSK3359609 80 mg.
11190914|NCT03447314|Experimental|Part 1c: pembrolizumab 200 mg|In Part 1, subjects with advanced solid tumors will be enrolled. Part 1c will have up to five dose escalation cohorts to investigate the safety and tolerability of escalating doses of GSK1795091 in combination with pembrolizumab 200 mg.
11190915|NCT03447314|Experimental|Part 1: PK/Pharmacodynamic cohort|Subjects will be enrolled into PK/PD cohort to collect additional data on safety, PK, and pharmacodynamic endpoints. Subjects will be enrolled at previously completed dose levels following dose escalation.
11190916|NCT03447314|Experimental|Part 2a: GSK3174998 24 mg|In Part 2, subjects with recurrent, locally advanced or metastatic SCCHN will be included. Subjects will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
11190917|NCT03447314|Experimental|Part 2b: GSK3359609 80 mg|In Part 2, subjects with recurrent, locally advanced or metastatic SCCHN will be included. Subjects will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
11190918|NCT03447314|Experimental|Part 2c: pembrolizumab 200 mg|In Part 2, subjects with recurrent, locally advanced or metastatic SCCHN will be included. Subjects will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
11190919|NCT03447301|Experimental|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
11190920|NCT03447301|No Intervention|Control|No consumption of extra virgin olive oil
11190921|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
11190922|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
11190923|NCT03447262|Experimental|Open-label triple combination|"Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.
~Parent studies are Phase 3 Vertex studies investigating VX-659 in combination with TEZ and IVA. This includes Studies VX17-659-102 and VX17-659-103."
11190924|NCT03447249|Placebo Comparator|Placebo|Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
11190925|NCT03447249|Experimental|VX-659/TEZ/IVA TC|Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
11190926|NCT03447236|Experimental|Feuerstein Program|All subjects participating in the Feuerstein Program will be evaluated by anatomical and functional MRI as well as computerized cognitive assessment prior to and following intervention as outlined in the protocol.
11190927|NCT03447223||ADHD-patients|The children 3-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
11190928|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 3-15 years old children.
11190929|NCT03447210|Experimental|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
11190930|NCT03447197|Active Comparator|On-Pump|Use of extracorporeal circulation
11190931|NCT03447197|No Intervention|Off-Pump|
11190932|NCT03447184||Androgen priming|Eight weeks prior to stimulation for IVF - at the onset of menses, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor will commence, concomitantly with GnRHa down-regulation with a depot GnRHa (28days). After 8 weeks, a standard rFSH stimulation with either 300 IU rFSH or 300 IU rFSH+rLH will start. The androgen priming (hCG and aromatase inhibitor) will stop on the first day of stimulation.
11190933|NCT03447171||Refractive Error|
11190934|NCT03447158|Experimental|15% Dextrose group|4.5cc 15% dextrose and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
11190935|NCT03447158|Placebo Comparator|control group|4.5cc normal saline and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
11190936|NCT03447145|Experimental|TQ-B3203|
11190937|NCT03447132|Active Comparator|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
11190938|NCT03447132|Placebo Comparator|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
11190939|NCT03447119|Experimental|Living Well with a Disability|The parents will work together with the project directors to deliver the adapted curriculum to participating families. With bi-weekly meetings for 10 weeks between parent facilitators and family participants in the home or another desired location. The project directors have already participated in the facilitator training and will serve as mentors to newly trained facilitators. At the end of the online training session, the parent facilitators will be equipped to successfully implement the Living Well curriculum.
11190949|NCT03447080|Experimental|Rice bran soybean milk|White Bread with 195ml of rice bran soybean mil
11190950|NCT03447080|Experimental|Soybean milk|White Bread with 195ml of soybean milk
11190951|NCT03447067|Experimental|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.
~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
11190952|NCT03447067|Experimental|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.
~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
11190953|NCT03447054|Experimental|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
11190954|NCT03447054|Active Comparator|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
11190955|NCT03447054|Active Comparator|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
11190956|NCT03447054|Sham Comparator|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
11190957|NCT03447041||the keratoplasty group|Patients who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
11190958|NCT03447015|Experimental|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
11190959|NCT03447015|No Intervention|Standard Maternity care|women will receive usual maternity care.
11190960|NCT03446989|Experimental|Case management|
11190961|NCT03446976|Experimental|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
11190962|NCT03446976|Experimental|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
11190963|NCT03446963|Experimental|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
11190964|NCT03446950|Active Comparator|Candy Cane|Participants in this arm will be positioned with their legs in candy cane stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
11190965|NCT03446950|Active Comparator|Boot Stirrups|Participants in this arm will have their feet placed in boot stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
11190966|NCT03446937|Experimental|Dexamethasone sodium phosphate injection|Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
11190967|NCT03446937|Experimental|Betamethasone sodium phosphate injection|Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
11190968|NCT03446937|Placebo Comparator|Water for injection|Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.
11190969|NCT03446924|Placebo Comparator|Control|The control group will be given a single dose of 1.5 g rice flour in capsule form (250 mg / capsule). The gelatine capsules (MyProtein, Northwich, UK) used are identical to those used in the treatment group. Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
11190970|NCT03446924|Active Comparator|Treatment|"The treatment group will be given a single dose of 1.5g phosphatidic acid in capsule form (250 mg / capsule). Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
~PA is considered a dietary supplement ingredient according to the US FDA. The source of PA will be a commercial available soy-derived PA (Mediator®, Chemi Nutra, White Bear Lake, MN). The safety of Mediator® Soy-PA has been thoroughly demonstrated in humans. Mediator® Soy-PA does not contain any compounds with narcotic, psychotropic or pharmaceutical effects and is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Mediator® Soy-PA is not a medicinal product."
11190971|NCT03446911|Active Comparator|SABR|Patients receive prior to surgery (lobectomy) SABR.
11190972|NCT03446911|Active Comparator|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
11190973|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
11190974|NCT03446872||All Study Participants|Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE
11190975|NCT03446859|Experimental|TENS|It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
11191102|NCT03445949|Other|6 months DAPT|extended postimplantation dual antiplatelet therapy
11190976|NCT03446859|No Intervention|Control|These are 25 subjects which were not in any intervention. These were subjects that were not placed on TENS and were not used to drug taken for the amelioration of the dysmenorrhea. They were educated on the purpose of research and their inform consent was obtained. Their pain intensity was measured firs, third and 5th days
11190977|NCT03446846|Experimental|5.0 mg MIN-117|
11190978|NCT03446846|Experimental|2.5 mg MIN-117|
11190979|NCT03446846|Placebo Comparator|Placebo|
11190980|NCT03446833|Experimental|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
11190981|NCT03446820|Other|Sleep participants|Crossover from standard sheets to hygro cotton sheets
11190982|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
11190983|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
11190984|NCT03446794||patients with NVAF and ESCKD on HD|
11190985|NCT03446781|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
11190986|NCT03446781|Placebo Comparator|Placebo|Placebo
11190987|NCT03446768|Active Comparator|Reactive Care (RC)|Participants in the RC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support.
11190988|NCT03446768|Active Comparator|Proactive Care (PC)|Participants in the PC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support. Additionally, the PC group will also receive access to an online study portal which houses an educational health curriculum covering topics related to COPD and OSA. The portal allows participants to send online messages to peer coaches and respiratory therapist coaches. PC group will also receive weekly updates.
11190989|NCT03446755|Experimental|Intra uterine Cook balloon|
11190990|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
11190991|NCT03446729|Experimental|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
11190992|NCT03446729|Active Comparator|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
11190993|NCT03446716|Experimental|EXTENSION|During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.
11190994|NCT03446716|No Intervention|CONTROL|Children followed their normal bedtime routine for five consecutive nights.
11190995|NCT03446703|Experimental|SCIT Social cognition interactive|Psychosocial intervention based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs & Penn; Lahera & Benito, in press).
11190996|NCT03446703|Active Comparator|TAR Training in affect recognition|Training in Affect Recognition it is a 12-session training on facial affect recognition over a period of 6 weeks.
11190997|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
11190998|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
11190999|NCT03446677|Experimental|Asymptomatic persons with HIV|
11191000|NCT03446664|Experimental|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
11191001|NCT03446651|Experimental|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
11191002|NCT03446651|Placebo Comparator|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
11191035|NCT03446391||Kinematic alignment with GMK Sphere®|Patients enrolled prospectively with surgeries planned to get kinematic alignment
11191036|NCT03446391||Mechanical alignment with GMK Sphere®|Historical group who had mechanical alignment, match-paired with the prospective group
11191068|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
11191003|NCT03446638|Experimental|Computational Biology-Informed Treatment|Patients randomized to this arm will receive an FDA-approved drug or combination of drugs predicted to have a therapeutic effect based on their individual MDS disease genetic profile by a computational biology simulation software program. The specific drug or combination of drugs that a patient on this arm will receive will be decided jointly by a molecular oncology board comprised of physicians, pharmacists, and nurse coordinators and the treating physician. Patients will receive a minimum of 2 months and a maximum of 4 months of treatment with the selected drug or combination of drugs.
11191004|NCT03446638|Active Comparator|Standard of Care Treatment|Patients randomized to this arm will receive either one of three standard of care treatment regimens of the treating physician's choice (low-dose cytarabine, 7 + 3 induction, or FLAG induction) or supportive care alone. Patients will receive a minimum of 2 months and a maximum of 4 months of the selected treatment regimen or of supportive care alone.
11191005|NCT03446625|Experimental|Resveratrol|Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
11191006|NCT03446625|Placebo Comparator|Control|Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
11191007|NCT03446612|Experimental|Participants receiving Daprodustat|Participants will receive 2 milligram (mg) daprodustat tablets once daily via oral route for a period of 41 days.
11191008|NCT03446612|Active Comparator|Participants receiving Darbepoetin alfa|Participants will receive Darbepoetin alfa solution for injection, administered as a single subcutaneous injection, once every two weeks (Days 1, 14 and 28).
11191009|NCT03446599|Experimental|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
11191010|NCT03446599|Experimental|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
11191011|NCT03446599|Placebo Comparator|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
11191012|NCT03446573|Experimental|DTG + 3TC 50 mg/300 mg|Subjects will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 200 (Early and Late Switch Phase).
11191013|NCT03446573|Active Comparator|TAF based regimen (TBR)|Subjects will continue their TBR from Day 1 to Week 148 (Early Switch Phase), and eligible subjects will switch to DTG + 3TC once daily from Week 148 to 200 (Late Switch Phase).
11191014|NCT03446560|Active Comparator|CPAP, conventional follow up|Follow up of patients after initiation of treatment according to clinical routine at the study site.
11191015|NCT03446560|Active Comparator|CPAP, telemedicine based follow up|Follow up of patients after initiation of treatment according to a telemedicine based routine.
11191016|NCT03446547|No Intervention|Arm A|SBRT and follow-up
11191017|NCT03446547|Experimental|Arm B|SBRT followed by Durvalumab
11191018|NCT03446534|Experimental|Amoxicillin|Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.
11191019|NCT03446534|Placebo Comparator|Placebo|Placebo mixture 0.25ml/kg every 8 hours for 7 days
11191020|NCT03446521||Test group|Patients undergoing liver transplantation, no intervention (study-specific) is planed
11191021|NCT03446521||Control Group|Respective organ donors of the included liver recipients, no intervention (study-specific) is planed
11191022|NCT03446508|Experimental|Active frontal|Active HD-tDCS
11191023|NCT03446508|Experimental|Active parietal|Active HD-tDCS
11191024|NCT03446508|Sham Comparator|Sham control|Sham HD-tDCS
11191025|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
11191026|NCT03446469|Experimental|Individuals with Chronic Ankle instability|Individuals with history of ankle sprains will be screened using the inclusion criteria before being included in the study
11191027|NCT03446456|Placebo Comparator|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.
~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
11191028|NCT03446456|Experimental|Arginine vasopressin|"Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).
~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment. Participants will be first stratified for sex and then randomized to saline (0.4 mL) or vasopressin (40 IU) group, respectively."
11191029|NCT03446443|Experimental|Honghe Fujie lotion group|
11191030|NCT03446443|Active Comparator|Metronidazole Suppositories group|
11191031|NCT03446430|Experimental|Hypertensives|PWV measurement by LDV
11191032|NCT03446417|Experimental|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
11191033|NCT03446417|Experimental|Phase 2|"MTD/RP2D in subjects:
~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.
~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
11191034|NCT03446404|Other|MOST Cohort|"One portion of the cohort will be age 62-92 years, average age approximately 71 years, at the start of this study. This cohort will consist of participants who already have symptomatic knee OA, in many cases advanced disease, or who had risk factors at the start of the Multicenter Osteoarthritis Study but have not developed symptomatic knee OA. All of the existing cohort who have 1 or 2 native knees will be approached providing native knees are not considered to be Kellgren-Lawrence grade 4 (bone on bone). The other portion of the cohort will consist of subjects with knee pain, aching or stiffness at baseline and participants without any knee symptoms in the previous 30 days. Both knees with Kellgren-Lawrence grades of radiographic OA of 0, 1, or 2 in the tibiofemoral (TF) and patellofemoral (PF) compartments."
11191037|NCT03446378|Experimental|Anodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
11191038|NCT03446378|Experimental|Cathodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where cathodal electrode will be on the affected hemisphere and the anodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
11191039|NCT03446378|Sham Comparator|Sham tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
11191040|NCT03446365|Experimental|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
11191041|NCT03446365|Active Comparator|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
11191042|NCT03446365|No Intervention|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
11191043|NCT03446352|Experimental|Psychomotor exercise program|The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
11191044|NCT03446352|Experimental|Combined exercise program|The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
11191045|NCT03446352|No Intervention|Control Group|Usual care. After the study, control group (CG) participants will be offered the opportunity to integrate a similar fall prevention program.
11191046|NCT03446326|Experimental|Stroke volume and cardiac output|"Pacing runs will occur at the following rates:
~50 beats per minute (bpm)
~60 bpm
~70 bpm
~80 bpm
~90 bpm
~100 bpm
~110 bpm
~120 bpm
~130 bpm
~The finger blood pressure cuff will be calibrated between pacing runs.
~Following the final pacing run while supine, the patient will be given 10 minutes to rest prior to the upright portion of the study. They will then be strapped into the table (so they will not fall) and then they will be tilted up to >70 degrees (almost standing up). They will stand for ~10 minutes prior to commencing the next pacing trains."
11191047|NCT03446313|Experimental|MVN Group|Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
11191048|NCT03446313|No Intervention|Usual Care|Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
11191049|NCT03446300||college student population|
11191050|NCT03446300||working population|
11191051|NCT03446300||aged more than 50 years old population|
11191052|NCT03446261|Experimental|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
11191053|NCT03446261|Active Comparator|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
11191054|NCT03446248|Active Comparator|Fetal Acoustic Stimulator|Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
11191055|NCT03446248|Experimental|Mobile Phone Application|Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.
11191056|NCT03446235|Experimental|Connected Health|This group will get 2 interviews about physical exercise (exercise instruction with motivational interview) and 6 communications with individualized instruction and counseling of their physical exercise (investigators can access activity data and exercise log) including the usage of the monitoring device.
11191057|NCT03446235|Active Comparator|Self-Monitoring|This group will do physical exercise following the initial instruction and self-monitor them. Investigators can access activity data and exercise log but will not discuss with the subjects about the data.
11191058|NCT03446222|Active Comparator|Catheter Ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
11191059|NCT03446222|Active Comparator|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
11191060|NCT03446209|Experimental|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
11191061|NCT03446209|Placebo Comparator|Placebo|0,9% physiological Saline
11191062|NCT03446196|Experimental|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
11191063|NCT03446196|No Intervention|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
11191064|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
11191065|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
11191066|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
11191067|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
11191069|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
11191070|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
11191071|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
11191072|NCT03446144|Experimental|IONIS-FB-Lrx|
11191073|NCT03446144|Placebo Comparator|Placebo (sterile saline 0.9%)|
11191074|NCT03446118|Experimental|MRI to detect inflammation and fibrosis in EoE patients|To assess through MRI the existence of an inflammatory and fibrotic component in strictures of eosinophilic esophagitis patients and to determine if this component is responsive to a therapeutic course of budesonide.
11191075|NCT03446105|Experimental|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
11191076|NCT03446105|Active Comparator|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
11191077|NCT03446092|Experimental|Mindfulness group|Group will receive mindfulness intervention
11191078|NCT03446079|Experimental|Primary Subjects|Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
11191079|NCT03446066||case group|20 cases suffering from excessive daytime sleepiness (4 females and 16 males) with their age range 32-58yrs and BMI range is 24.97-39.06 kg/m2
11191080|NCT03446066||control group|20 healthy subjects (5 females and 15 males) with their age range 31-55yrs and BMI range is 23.40-43.0 kg/m2
11191081|NCT03446053|Experimental|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
11191082|NCT03446053|Placebo Comparator|INT200-Placebo|Saline
11191083|NCT03446040|Experimental|Part A Dose Escalation: BMS-986258|
11191084|NCT03446040|Experimental|Part A1: BMS-986258 + Recombinant human hyaluronidase PH20 (rHuPH20)|
11191085|NCT03446040|Experimental|Part B Dose Escalation: BMS-986258 + nivolumab|
11191086|NCT03446040|Experimental|Part C Cohort Expansion: BMS-986258 + nivolumab|
11191087|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
11191088|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
11191089|NCT03446014||Control Group for Fitbit Sub-Study|Patient will be given Fitbit device, but will have no access to Fitbit website or interface. The coordinator will set up the patient's Fitbit on the office computer and will have access to the fitbit's associated username and password (this will be generated by the coordinator). The patient will be instructed to walk as much as they can each day, and to check the Fitbit wrist band periodically throughout the day to view their walking progress. At the end of the three month intervention, the patient will complete questionnaires and undergo a repeat 6 minute walk test.
11191090|NCT03446014||Intervention Group for Fitbit Sub-Study|Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
11191091|NCT03446001|Experimental|TRx0237 16 mg/day|
11191092|NCT03446001|Placebo Comparator|Placebo|
11191093|NCT03446001|Experimental|TRx0237 8 mg/day|
11191094|NCT03445988|Active Comparator|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
11191095|NCT03445988|Active Comparator|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Peers are people with chronic pain who live in the communities in which they teach. For this project, at least one peer facilitator per workshop will have had experience with prescription opioid use. Intervention fidelity is determined by having a trained observer with a checklist attend random workshop sessions. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session.
11191096|NCT03445988|Placebo Comparator|Taper Only (Usual Care)|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
11191097|NCT03445988|No Intervention|Observational Arm|Participants that do not wish to reduce their opioid medications but are otherwise eligible and interested in the research study will be offered participation in the observational arm. The observational arm of the study will not include interventions of any kind and will only collect survey data for the year following consent.
11191098|NCT03445975|Experimental|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
11191099|NCT03445975|No Intervention|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
11191100|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
11191101|NCT03445949|Other|30 days DAPT|short postimplantation dual antiplatelet therapy
11191103|NCT03445936|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
11191104|NCT03445936|Active Comparator|Permacol|Permacol is a acellular porcine dermal implant used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
11191105|NCT03445923|No Intervention|Morphology|Embryos for transfer will be selected based on standard morphological evaluation.
11191106|NCT03445923|Active Comparator|TLM|Embryos for transfer will be selected base on standard morphological evaluation and information from time-lapse monitoring.
11191107|NCT03445910|Experimental|Human chorionic gonadotrophin|The hCG Group included 50 patients who had an intrauterine injected of 500 IU of hCG on the day of ovum pick-up
11191108|NCT03445910|No Intervention|control|The Control Group included 50 patients who went through the ICSI conventional protocol without intrauterine injection.
11191109|NCT03445897|Experimental|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
11191110|NCT03445884|Experimental|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
11191111|NCT03445884|Active Comparator|Control group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.
11191112|NCT03445871|Active Comparator|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
11191113|NCT03445871|Active Comparator|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
11191114|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
11191115|NCT03445845|Experimental|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.
~Blood specimen at each visits"
11191116|NCT03445845|Active Comparator|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:
~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:
~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,
~etanercept: 50mg per week in subcutaneous injection,
~adalimumab: 40mg every other week in subcutaneous injection,
~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,
~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.
~Blood specimen at each visits"
11191117|NCT03445819|Other|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
11191118|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
11191119|NCT03445780|Experimental|First Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection
11191120|NCT03445780|Experimental|Second Group|The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection
11191121|NCT03445780|Experimental|Third Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease
11191122|NCT03445780|Experimental|Fourth Group|Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.
11191123|NCT03445767|No Intervention|Standard Care|All patients will receive perioperative care per the standards of TOH. Standard care relevant to our study consists of a history by a nurse or physician; a best possible medication history performed by a pharmacy technician; and standardized perioperative-specific medication recommendations (e.g., anticoagulant, diabetes agent, and ACE-inhibitor management) based on medical directives. Medication recommendations beyond these medical directives do not occur as standard care in our clinics. Participants will be informed that their medical care will proceed as usual and that they are being recruited for a study to evaluate medication recommendations before surgery
11191124|NCT03445767|Experimental|Intervention|In addition to standard care, the intervention will include a structured preoperative polypharmacy management strategy that consists of: a) input of best possible medication history and comorbidities into our polypharmacy management tool (MedSafer); b) communication of the prioritized deprescribing plan (if indicated) to the patient's active treating physicians (automatically via fax), to the perioperative team (surgeon, anesthesiologist), and to the electronic medical record. During the pre-operative visit, the patient will receive a generalized information flyer about deprescribing. As in the usual care phase, patients will continue to receive usual recommendations from the perioperative team based on medical directives relevant to the perioperative period.
11191125|NCT03445754|Experimental|Interventional Arm|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
11191126|NCT03445754|Sham Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
11191127|NCT03445741|Active Comparator|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
11191171|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
11191128|NCT03445741|Experimental|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
11191129|NCT03445741|Experimental|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
11191130|NCT03445728|Experimental|Treatment arm|Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
11191131|NCT03445728|Placebo Comparator|Placebo arm|Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.
11191132|NCT03445715|Experimental|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
11191133|NCT03445715|Experimental|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
11191134|NCT03445715|Experimental|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
11191135|NCT03445702|Experimental|Metformin intolerant & metformin|Metformin 1000mg once
11191136|NCT03445702|Placebo Comparator|Metformin intolerant & placebo|Placebo 1000mg once
11191137|NCT03445702|Active Comparator|Metformin tolerant & metformin|Metformin 1000mg once
11191138|NCT03445702|Placebo Comparator|Metformin tolerant and placebo|Placebo 1000mg once
11191139|NCT03445676|No Intervention|Usual Care|Study personnel silently observe and record what the healthcare worker does at each hand hygiene opportunity without direction to the healthcare worker
11191140|NCT03445676|Experimental|ABHR directly on gloves|Healthcare worker will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
11191141|NCT03445676|Placebo Comparator|Ideal Standard|Healthcare worker will be directed by study personnel to remove gloves, perform hand hygiene and replace gloves at each hand hygiene opportunity
11191142|NCT03445663|Experimental|AMG 424|Comparison of different dosages of AMG 424
11191143|NCT03445650|Experimental|ADX-102 1% Topical Dermal Cream (reproxalap)|
11191144|NCT03445650|Placebo Comparator|Vehicle of ADX-102 Topical Dermal Cream|
11191145|NCT03445624||patient on traditional therapy|Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
11191146|NCT03445624||patient on infliximab|drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
11191147|NCT03445611|Experimental|Group 1|These patients will receive a corticosteroid solution with lidocaine containing parabens.
11191148|NCT03445611|Active Comparator|Group 2|These patients will receive corticosteroid solution with paraben free lidocaine.
11191149|NCT03445598|Experimental|Interactive CCBT group|This group receives Interactive and Personalized CCBT
11191150|NCT03445598|Active Comparator|Limited CCBT control group|This group receives Feature-limited CCBT
11191151|NCT03445598|Other|Waitlist control group|This group receives waitlist control
11191152|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
11191153|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
11191154|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
11191155|NCT03445585||Control group 2|Patients without liver disease.
11191156|NCT03445572|Experimental|Group I (MSB)|Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.
11191157|NCT03445572|Experimental|Group II (IK meditation)|Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.
11191158|NCT03445572|Active Comparator|Group III (waitlist)|Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.
11191159|NCT03445559|No Intervention|Control|No intervention
11191160|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
11191161|NCT03445546||oral P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)
11191162|NCT03445546||intravenous P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)
11191163|NCT03445533|Experimental|Arm A: ipilimumab|ipilimumab 3 mg/kg intravenous
11191164|NCT03445533|Experimental|Arm B: IMO-2125 plus ipilimumab|IMO-2125 by intratumoral injection plus ipilimumab 3 mg/kg intravenous
11191165|NCT03445520|No Intervention|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
11191166|NCT03445520|Experimental|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
11191167|NCT03445507|Experimental|Intervention|Use of an evidence-based chat bot for smoking cessation
11191168|NCT03445507|Active Comparator|Control|Usual care (Madrid Health System Portfolio).
11191169|NCT03445494|Experimental|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
11191170|NCT03445494|Experimental|Normal sling|After surgery the patient must wear the normal sling for two weeks
11191172|NCT03445468|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The vaccine contains both B strain (Yamagata, Victoria)
11191173|NCT03445468|Active Comparator|IL-YANG Flu Vaccine Pre-filled Syringe|The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
11191174|NCT03445455||De novo AHRF|"Acute hypoxemic non hypercapnic respiratory failure with a PaO2/FiO2 ratio < 200.
~The following oxygenation devices are used and assessed during routine care:
~High concentration mask, High flow nasal canula, NIV using buco-nasal mask or Helmet.
~Electro impedence tomography signal will be recorded throughout this assessement for tidal volume measurement"
11191175|NCT03445442||Group 1|Sacrocolpopexy (SCP)
11191176|NCT03445442||Group 2|Native tissue repair surgery (NTR)
11191177|NCT03445442||Group 3|Vaginal mesh repair surgery (VMR)
11191178|NCT03445429|Experimental|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
11191179|NCT03445429|Experimental|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
11191180|NCT03445416|Experimental|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
11191181|NCT03445416|Active Comparator|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
11191182|NCT03445403|Experimental|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
11191183|NCT03445403|Active Comparator|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
11191184|NCT03445390|Experimental|Acetaminophen First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive acetaminophen first.
11191185|NCT03445390|Experimental|Placebo First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive placebo first.
11191186|NCT03445377|Active Comparator|Real-time continuous glucose monitoring|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
11191187|NCT03445377|Placebo Comparator|Self-monitoring of blood glucose|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. During the Control Period, masked CGM will be applied for one week, during Week 1, 4 and 8. At the end of this, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
11191188|NCT03445364|Active Comparator|Low coronary injection-pressure, 200 psi|"Patients with STEMI who undergo Primary PCI with the use of low intracoronary dye injection pressure (of 200 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.
~Use of different injection pressure during primary PCI"
11191189|NCT03445364|Active Comparator|High coronary injection-pressure,550 psi|"Patients with STEMI who undergo Primary PCI with the use of higher intracoronary dye injection pressure (of 500 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.
~Use of different injection pressure during primary PCI"
11191190|NCT03445351|Experimental|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
11191191|NCT03445338|Experimental|Cohort 1|
11191192|NCT03445338|Experimental|Cohort 2|
11191193|NCT03445338|Experimental|Cohort 3|
11191194|NCT03445325|Experimental|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
11191195|NCT03445312||study cohort|All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered
11191196|NCT03445299|Experimental|Music|Daily music listening for 30 minutes at bedtime
11191197|NCT03445286|Experimental|Silver Diamine Fluordie Application|This group will receive Silver Diamine Fluoride (SDF) application once every week within three weeks period
11191198|NCT03445286|Placebo Comparator|Normal Saline|This control group will receive normal saline application once a week within a a three-week period
11191199|NCT03445260|Placebo Comparator|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
11191200|NCT03445260|Experimental|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
11191201|NCT03445247|Sham Comparator|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
11191202|NCT03445247|Experimental|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
11191203|NCT03445234|Experimental|Blueberry|Freeze-dried blueberry powder
11191204|NCT03445234|Placebo Comparator|Placebo|Placebo powder
11191207|NCT03445221|Active Comparator|Group I|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 5 days before surgery.
11191208|NCT03445221|Active Comparator|Group II|patients will continue preoperative oral conventional diet.
11191209|NCT03445208|Experimental|Cohort 1|BMI 18.0 to ≤ 25.0
11191210|NCT03445208|Experimental|Cohort 2|BMI >25.0 to ≤ 30.0
11191211|NCT03445208|Experimental|Cohort 3|BMI >30.0 ≤ 40.0
11191212|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
11191213|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
11191214|NCT03445182|Active Comparator|Control group|Local anaesthesia with conventional syringe
11191215|NCT03445182|Active Comparator|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
11191216|NCT03445169|Experimental|Fasting|Belzutifan tablets taken after fasting
11191217|NCT03445169|Experimental|Non-Fasting|Belzutifan taken after eating a high calorie meal
11191218|NCT03445156|Experimental|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
11191219|NCT03445156|Experimental|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
11191220|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
11191221|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
11191222|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
11191223|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
11191224|NCT03445117|Experimental|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
11191225|NCT03445117|No Intervention|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
11191226|NCT03445104|Experimental|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
11191227|NCT03445104|Placebo Comparator|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
11191228|NCT03445091|Experimental|Patients using investigational product|Open-label use of SANKOM Patent Socks
11191229|NCT03445078|Active Comparator|A|Participants will be administered firstly selenium-rich corn powder 20g/d for 1 month and ordinary corn powder 20g/d for another month subsequently with a month washout period.
11191230|NCT03445078|Placebo Comparator|B|Participants will be administered firstly ordinary corn powder 20g/d for 1 month and selenium-rich corn powder 20g/d for another month subsequently with a month washout period.
11191231|NCT03445065|Experimental|Cohort 1|Patients with HbA1c > 8% will be randomized into two groups: enabled group using subcutaneously implanted sensor (CGM) and a control group with usual SMBG or FGM with CGM in autolog mode.
11191232|NCT03445065|Experimental|Cohort 2|Patients with T1D (time in hypoglycemia) spending >1.5 hour with sensor glucose <70 mg/dl per day will be randomized into two groups: enabled group using subcutaneously implanted sensor (CGM) and a control group with usual SMBG or FGM with CGM in autolog mode.
11191233|NCT03445052|Experimental|2018 XPAND Intervention Arm|This group will receive the personalised adherence intervention in 2018 in addition to routine clinical care.
11191234|NCT03445052|No Intervention|2018 XPAND Control Arm|This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
11191235|NCT03445039|Experimental|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
11191236|NCT03445039|Experimental|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
11191237|NCT03445039|Experimental|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
11191238|NCT03445039|Experimental|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
11191239|NCT03445013|Experimental|SB414 6%|SB414 6% topically twice daily
11191240|NCT03445013|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
11191241|NCT03445000|Experimental|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.
~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
11191311|NCT03444493|No Intervention|Control|Control group was informed about protecting for biomechanics of lumbar spine.
11191391|NCT03443960|Experimental|Treatment A (TNX-102 SL)|2 x TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg once daily for 20 consecutive days
11191242|NCT03444987||patients group|"include 40 premenopausal women (age ˂ 45 year) with uterine fibroids who are diagnosed through clinical gynecological, ultrasound and other auxiliary examinations.
~The protein expression of the followings markers will be estimated in tumor tissue samples:
~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.
~Phosphorylated protein kinase B (pAKT) level will be measured by western blot analysis.
~Circulating (cFAP) will be measured using ELISA in blood of UF patients."
11191243|NCT03444987||Control group|"include 40 (age, BMI) matched healthy females
~The protein expression followings markers will be estimated in normal myometrial tissue samples( 1cm from UF lesions):
~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.
~Phosphorylated protein kinase B (pAKT) level will be measured by western blot analysis.
~Circulating (cFAP) will be measured using ELISA in blood of healthy controls"
11191244|NCT03444974|Active Comparator|Patient therapy group|"Adolescents with substance use disorders
~Receiving an adapted treatment according to the MATRIX-A therapy"
11191245|NCT03444974|Active Comparator|Parental therapy group|"Parents of adolescents with substance use disorders
~Receiving an adapted treatment according to the MATRIX-A therapy"
11191246|NCT03444974|No Intervention|Patient waiting list group|"Adolescents with substance use disorders
~On the waiting list for receiving a MATRIX-A therapy"
11191247|NCT03444974|No Intervention|Parental waiting list group|"Parents of adolescents with substance use disorders
~On the waiting list for receiving a MATRIX-A therapy"
11191248|NCT03444974|No Intervention|control group|"Adolescents with no history of substance use disorders
~no other intake of psychotropic substances such as psychotropic medication"
11191249|NCT03444961|Experimental|CAREN system training|CAREN training
11191250|NCT03444948|Experimental|3 radiofrequency ablation procedures|Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
11191251|NCT03444948|Active Comparator|standard medical care|Subject will receive standard medical care, including pain relief drugs
11191252|NCT03444935|Experimental|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
11191253|NCT03444935|Other|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
11191254|NCT03444922|Placebo Comparator|Placebo|Participants consume Vanilla Wafer cookie
11191255|NCT03444922|Experimental|BPA 4 ug/kg BW|Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
11191256|NCT03444922|Experimental|BPA 50 ug/kg BW|Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
11191257|NCT03444909|Experimental|cardiotocograph and Toconaute|monitoring with cardiotocograph and next with the Toconaute of Bioserenity
11191258|NCT03444909|Experimental|Cardiotocograph and Toconaute and Electrophysiological device|monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
11191259|NCT03444909|Experimental|Cardiotocograph and electrophysiological device|monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
11191260|NCT03444896|Experimental|Acupuncture group|
11191261|NCT03444896|Placebo Comparator|Sham acupuncture group|
11191262|NCT03444883|Active Comparator|Treatment Group|10mg Ilaprazole x 2 tablets
11191263|NCT03444883|Placebo Comparator|Control Group|10mg placebo of Ilaprazole x 2 tablets
11191264|NCT03444870|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
11191265|NCT03444870|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
11191266|NCT03444857|Experimental|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
11191267|NCT03444857|No Intervention|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
11191268|NCT03444844|Experimental|Biochemical recurrent prostate cancer|"IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by whole body PET/CT scanning (pelvis to shoulders) for ~ 60 min (~150 min for first 10 patients/dosimetry) starting immediately after injection.
~A contrast CT scan follows PET scan."
11191269|NCT03444844|Experimental|Intermediate/High Risk primary prostate cancer|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by list mode PET/CT scanning using a fixed FOV including the pelvis area for ~ 50 min.
11191270|NCT03444831|Experimental|Buspirone plus Omeprazole|
11191271|NCT03444831|Placebo Comparator|Placebo plus Omeprazole|
11191272|NCT03444818|Experimental|[14C]-E6007|Participants will receive a single oral dose of 60 milligrams (mg) of [14C]-E6007.
11191273|NCT03444805||NISSC-2|SSC patients treated with AHSCT
11191274|NCT03444792|Experimental|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
11191275|NCT03444792|No Intervention|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
11191312|NCT03444480|Experimental|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
11191276|NCT03444779|Active Comparator|Control group|The patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.
11191277|NCT03444779|Experimental|Experimental group|"The patients will be treated with the Tibial Tuberoplasty technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique."
11191278|NCT03444766|Experimental|Monotherapy|administering nivolumab only
11191279|NCT03444753|Experimental|Arm A|BMS-986299
11191280|NCT03444753|Experimental|Arm B|BMS-986299 in combination with nivolumab and ipilimumab
11191281|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
11191282|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
11191283|NCT03444714|Experimental|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
11191284|NCT03444701|Experimental|E7130 (2-Week Regimen)|Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity excluding clinically insignificant events is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) will be determined, additional participants will be enrolled to explore participant's optimal biologic dose (OBD). Part 2: Participants with Her2-negative breast cancer and other solid tumors will be evaluated at the dose level determined in Part 1 in a 2-week or in a 3-week regimen based on the evaluations in Part 1.
11191285|NCT03444701|Experimental|E7130 (3-Week Regimen)|Part 1 (Cycle 1; 21 days): On Day 1, participants will receive E7130 at (-1) a lower dose than the dose at which the first DLT was observed in the 2-week regimen. Once the MTD will be determined, additional participants will be enrolled to explore participant's OBD. Part 2: Participants with Her2-negative breast cancer and other solid tumors will be evaluated at the dose level determined in Part 1 in a 3-week or in a 2-week regimen based on the evaluations in Part 1.
11191286|NCT03444688|Active Comparator|CT, Control Group|Conventional Gait Training
11191287|NCT03444688|Experimental|WT, Experimental Group|Gait rehabilitation with walker
11191288|NCT03444662|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
11191289|NCT03444662|Experimental|Cognizin and Omega-3|Intervention: Dietary Supplement: Citicoline and Omega-3 supplement
11191290|NCT03444662|Experimental|Omega-3|Intervention: Dietary Supplement: Omega-3 supplement
11191291|NCT03444649|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
11191292|NCT03444636|Experimental|Ropivacaine/Fentanyl|
11191293|NCT03444636|Active Comparator|Bupivacaine/Fentanyl|
11191294|NCT03444610|Other|Arm (blood transfusion escalation rate)|The intervention for the arm (blood transfusion escalation rate) will be about giving blood transfusion with escalating rate as described in intervention part to Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases.
11191295|NCT03444584|Experimental|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
11191296|NCT03444584|Placebo Comparator|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
11191297|NCT03444571|No Intervention|Control|
11191298|NCT03444571|Experimental|DNA based diagnosis|
11191299|NCT03444558|Experimental|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
11191300|NCT03444558|Placebo Comparator|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
11191301|NCT03444532|Experimental|12-week aerobic exercise and cognitive-behavioral therapy|12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions
11191302|NCT03444532|No Intervention|Control group|Patients assigned to the control group will receive usual care
11191303|NCT03444519|Experimental|Mannitol A|in this group, Mannitol (1.0g/kg) is given just after the induction of general anesthesia
11191304|NCT03444519|Active Comparator|Mannitol B|in this group, Mannitol (1.0g/kg) is given at the time of skin incision
11191305|NCT03444506|Placebo Comparator|Placebo nasal spray|Placebo nasal spray - 2 sprays per nostril, BID
11191306|NCT03444506|Experimental|Molo 1 (also referred as GSP 301-2 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
11191307|NCT03444506|Experimental|Molo 2 (also referred as GSP 301-1 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
11191308|NCT03444506|Active Comparator|DYMISTA nasal spray|Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
11191309|NCT03444506|Active Comparator|PATANASE nasal spray|Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID
11191310|NCT03444493|Experimental|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
11191355|NCT03444220|Placebo Comparator|Placebo|Anaerobically Cultivated medium
11191313|NCT03444480|Experimental|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
11191314|NCT03444467|Experimental|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
11191315|NCT03444467|Active Comparator|Glucagon|Participants will receive a single fixed dose of glucagon.
11191316|NCT03444454|Experimental|VRRS Khymeia|"The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).
~The exercise program will be remotely charged by therapist on the patient's computer.
~Each patient's performed session will be reviewed remotely by the therapist."
11191317|NCT03444454|Active Comparator|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
11191318|NCT03444428||Non Invasive Ventilation|"Age, height, weight
~History and Physical Examination
~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)
~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
~24h Blood Pressure monitor
~Spirometry - FEV1 and FVC
~Respiratory muscle strength - MIP, MEP, and SNIP
~Arterial Blood Gases
~Carotid-femoral pulse wave velocity
~Breath CO exhale"
11191319|NCT03444428||Without Non Invasive Ventilation|"Age, height, weight
~History and Physical Examination
~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)
~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)
~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)
~24h Blood Pressure monitor
~Spirometry - FEV1 and FVC
~Respiratory muscle strength - MIP, MEP, and SNIP
~Arterial Blood Gases
~Carotid-femoral pulse wave velocity
~Breath CO exhale"
11191320|NCT03444415|Experimental|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
11191321|NCT03444415|Other|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.
~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
11191322|NCT03444402|Experimental|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
11191323|NCT03444402|Experimental|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
11191324|NCT03444402|Experimental|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
11191325|NCT03444389||Study group|Patients with hemorrhoids
11191326|NCT03444389||Control group|Healthy participants without hemorrhoids
11191327|NCT03444376|Experimental|GX-188E, Keytruda|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
11191328|NCT03444363|Experimental|Study group|SRP plus diode laser (810 nm wavelength, 1 W power)
11191329|NCT03444363|Active Comparator|Control group|SRP plus placebo
11191330|NCT03444350|Active Comparator|Control group|SRP plus placebo
11191331|NCT03444350|Experimental|Gaseous ozone group|SRP plus gaseous ozone [1 W (100 mJ, 10 Hz)]
11191332|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
11191333|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
11191334|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)|Standard of Care
11191335|NCT03444311|Active Comparator|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
11191336|NCT03444311|Active Comparator|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
11191337|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Safflower Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
11191338|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
11191339|NCT03444285|Active Comparator|Warm Up|
11191340|NCT03444285|Active Comparator|Hot Pack|
11191341|NCT03444272|Experimental|Hepatitis C Treatment|HCV Treatment (Sofosbuvir and Daklatasuvir)
11191342|NCT03444272|No Intervention|Supportive treatment|supportive liver therapy
11191343|NCT03444259||Atrial fibrillation|Patients with atrial fibrillation
11191344|NCT03444259||Coronary bypass|Patients undergoing coronary bypass
11191345|NCT03444259||Aortic valve replacement|Patients undergoing aortic valve replacement
11191346|NCT03444259||Mitral valve repair|Patients undergoing mitral valve repair
11191347|NCT03444259||Other|Patients undergoing cardiac surgery for indication other than above
11191348|NCT03444246|Experimental|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
11191349|NCT03444246|Active Comparator|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
11191350|NCT03444233|Experimental|low f1 diet|low fructose diet week 1
11191351|NCT03444233|Experimental|fruit rich diet|fruit rich diet week 2
11191352|NCT03444233|Experimental|low f2 diet|low fructose diet week 3
11191353|NCT03444233|Experimental|HFCS rich diet|HFCS rich diet week 4
11191354|NCT03444220|Active Comparator|ACHIM|Anaerobically Cultivated Human Intestinal Microbiota
11191362|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
11191363|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
11191364|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
11191365|NCT03444155|Active Comparator|Panmol-B-Complex|B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
11191366|NCT03444155|Active Comparator|Synthetic Vitamin B-complex|B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
11191367|NCT03444142|Active Comparator|Drug: Exenatide LAR|Exenatide LAR 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
11191368|NCT03444142|Active Comparator|Drug: Dulaglutide|Dulaglutide .75 mg, once weekly subcutaneously Before breakfast during 4 weeks.
11191369|NCT03444129|Active Comparator|Control|This group will participate in a health education workshop with weekly sessions (control group)
11191370|NCT03444129|Experimental|Game|This group will participate in the health education workshop plus the interactive health game (intervention group).
11191371|NCT03444116||Cases (+FDO)|Patients who underwent an FDO
11191372|NCT03444116||Controls (-FDO)|Same as cases but did not undergo an FDO
11191373|NCT03444103|Active Comparator|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
11191374|NCT03444103|Placebo Comparator|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
11191375|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
11191376|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
11191377|NCT03444077|Active Comparator|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
11191378|NCT03444077|Experimental|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.
~TICCS < 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.
~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
11191379|NCT03444064|No Intervention|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
11191380|NCT03444064|Experimental|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
11191381|NCT03444051||20-gauge Procore®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:
~34 punctures were performed with a 20-gauge Procore® during the period study"
11191382|NCT03444051||22-gauge Acquire®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:
~34 punctures were performed with a 22-gauge Acquire® during the period study"
11191383|NCT03444038|Experimental|NBI-98854|NBI-98854 administered once daily for up to 24 weeks
11191384|NCT03444025|Experimental|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
11191385|NCT03444025|No Intervention|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
11191386|NCT03443986|Experimental|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes.
11191387|NCT03443986|Sham Comparator|Resistance training associated with sham|"The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment."
11191388|NCT03443986|No Intervention|Control group|Will not be submitted to any physical intervention. It continues in your daily life with only monitoring via phone callings. Guidelines about foot care.
11191389|NCT03443973|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
11191390|NCT03443973|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
11191392|NCT03443960|Active Comparator|Treatment B (AMRIX)|1 x AMRIX ER capsule 30 mg once daily for 20 consecutive days
11191393|NCT03443947|Experimental|D group|
11191394|NCT03443921|Experimental|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
11191395|NCT03443921|Active Comparator|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
11191396|NCT03443908||CPAP therapy|CPAP therapy (minimum of 3-4 weeks)
11191397|NCT03443895|Active Comparator|Experimental: AEF0117|Subjects in cohorts 1 through 3 receive active treatments. Subjects in Cohorts 1 through 3 will receive a single dose of 0.6, 2 and 6mg respectively of AEF0117 on Day 1 to Day 7.
11191398|NCT03443895|Placebo Comparator|Placebo|Subjects in Cohorts1 through 3 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
11191399|NCT03443882|Active Comparator|Astaxanthin formulation #1|capsules
11191400|NCT03443882|Active Comparator|Astaxanthin formulation #2|tablets
11191401|NCT03443882|Active Comparator|Astaxanthin formulation #3|powder
11191402|NCT03443882|Experimental|Astaxanthin formulations|fast condition
11191403|NCT03443869|Experimental|Letermovir|Letermovir (LET) 480mg (or 240 mg when co-administered with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
11191404|NCT03443869|Active Comparator|Valganciclovir|900 mg Valganciclovir (VGCV) tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
11191405|NCT03443856|Other|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
11191406|NCT03443856|Experimental|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
11191407|NCT03443843|Experimental|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
11191408|NCT03443843|Experimental|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
11191409|NCT03443843|Experimental|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
11191410|NCT03443843|Experimental|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
11191411|NCT03443830|Experimental|0.2 mg/kg|Subject will be administered with 0.2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11191412|NCT03443830|Experimental|0.5 mg/kg|Subject will be administered with 0.5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11191413|NCT03443830|Experimental|1 mg/kg|Subject will be administered with 1 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11191414|NCT03443830|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11191415|NCT03443830|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11191416|NCT03443830|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
11191417|NCT03443817|No Intervention|Control group|There is no conventional rehabilitation follow up program, but all patients are encouraged to continue training
11191418|NCT03443817|Experimental|Intervention group|The intervention group will obtain telerehabilitation
11191419|NCT03443804|Experimental|Test(DW1401)|tid PO, DW1401+Placebo of Stillen tab.
11191420|NCT03443804|Active Comparator|Reference(Stillen tab.)|tid PO, Stillen tab.+Placebo of DW1401
11191421|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
11191422|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
11191423|NCT03443778|Active Comparator|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
11191424|NCT03443778|Active Comparator|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
11191425|NCT03443778|Active Comparator|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
11191426|NCT03443765||Patients with Pityriasis alba|
11191427|NCT03443765||Healthy participants (control group)|
11191428|NCT03443752|Experimental|Shotokan-Karate|The protocol for Shotokan-karate training will involve a one hour training session which will be broken down into 3 major components. The training program will consist of warm-up exercises, katas (choreographed karate movements), and cool-down exercise.
11191429|NCT03443752|Experimental|Tai-Chi|The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre.The following program will be held three times per week.
11191430|NCT03443726|Experimental|Infiltrative technique|Patients in this arm will have buccal and lingual infiltrative anesthesia with 4% articaine 1:100.000 epinephrine for third molar extraction.
11191431|NCT03443726|Active Comparator|Nerve block technique|Patients in this arm will have inferior alveolar nerve and buccal nerve block with 4% articaine 1:100.000 epinephrine for third molar extraction.
11191432|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
11191433|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
11191434|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
11191435|NCT03443700|Active Comparator|sLT|Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
11191436|NCT03443700|Experimental|sLT + EX-T|Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
11191437|NCT03443687|Active Comparator|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo the intervention of 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
11191438|NCT03443687|Experimental|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months and their intervention will be to perform daily exercises with the device in place. At 3 months they will return for a follow up visit and complete questionnaires.
11191439|NCT03443674|Experimental|SCB-313|Dose escalation cohorts--10mg, 20mg, 40mg, 80mg, 160mg. For each cohort: administered twice weekly (eg.. Monday and Thursday or Tuesday and Friday) for 2 weeks (Days 1, 4, 8, and 11) by IP bolus injection.
11191440|NCT03443661|Experimental|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
11191441|NCT03443635|Experimental|Treatment|Subjects receiving hands-on cooking and nutrition education classes
11191442|NCT03443635|No Intervention|Control|Subjects not receiving any additional nutrition education aside from that contained in their curricula (for trainees) or medical care (for patients)
11191443|NCT03443622|Experimental|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
11191444|NCT03443622|Experimental|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
11191445|NCT03443622|Experimental|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
11191446|NCT03443622|Experimental|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
11191447|NCT03443622|Experimental|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
11191448|NCT03443622|Experimental|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
11191449|NCT03443609|Other|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
11191450|NCT03443596|Active Comparator|Early intensive BP control|BP in participants in this arm is treated aggressively, lowered and maintained at systolic blood pressure between 140-160mmHg, within 6 hours of stroke onset and maintained in this range for first 72 hours.
11191451|NCT03443596|No Intervention|Guidelined based BP control|Participants are treated according to the current international guidelines in thrombolysed acute ischemic stroke patients, i.e., less than 180/105mmHg
11191452|NCT03443570|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rituximab in combination with bortezomib at the indicated dose
11191453|NCT03443570|Active Comparator|control group|100 enrolled patients are randomly picked up to take rituximabalone at the indicated dose
11191454|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
11191455|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
11191456|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
11191457|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
11191458|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
11191459|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
11191460|NCT03443531|Experimental|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
11191461|NCT03443531|Placebo Comparator|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
11191462|NCT03443518|Experimental|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical land mark for psoas plexus, also normal saline 0.9% IV infusion will be in the same rate of the Remifentanil infusion for the other group.
11191463|NCT03443518|Experimental|L.A infiltration /Remifentanil infusion|L.A infiltration (lidocaine) 5 ml of 2% will be injected subcutaneous as L.A infiltration then Remifentanil infusion with rate 0.03-0.1 μg / kg / min to achieve Visual Analog Scale 3 or less.
11191464|NCT03443492|Experimental|SLOG|800 mg/m2 gemcitabine at a fixed rate of 10 mg/m2/min followed by a 2-hour intravenous infusion of oxaliplatin on day 1 plus twice daily oral S-1 80-120 mg/day (based on BSA) and oral leucovorin 30 mg twice a day on day 1 to day 7, every 14 days as a cycle
11191465|NCT03443492|Experimental|mFOLFIRINOX|oxaliplatin at a dose of 85 mg/m2, given as a 2-hour infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute infusion. The treatment was immediately followed by a continuous intravenous infusion via central venous catheter of leucovorin 400 mg/m2 given as a 2-hour infusion and 5-FU 2400 mg/m2 over a 46-hour period on day 1 every 14 days/cycle.
11191466|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
11191467|NCT03443466|Experimental|Epidural electrical stimulation (EES)|n=20
11191468|NCT03443466|Active Comparator|Loss of resistance (LOR)|n=20
11191537|NCT03442972|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
11191469|NCT03443453|Experimental|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
11191470|NCT03443453|Experimental|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
11191471|NCT03443427|Experimental|Schedule 0-2-6 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).
11191472|NCT03443427|Experimental|Schedule 0-2-12 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).
11191473|NCT03443414|Experimental|0.75 mg RPL554|
11191474|NCT03443414|Experimental|1.5 mg RPL554|
11191475|NCT03443414|Experimental|3 mg RPL554|
11191476|NCT03443414|Experimental|6 mg RPL554|
11191477|NCT03443414|Placebo Comparator|Placebo|
11191478|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
11191479|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
11191480|NCT03443388|Active Comparator|Part 2: Helmet|"After a screening period, 10 patients with drug resistant epilepsy will first be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. After experiencing a seizure resulting in a fall or any helmet deployment, patients will crossover to the no helmet group. If no seizure resulting in fall occurs in 3 months, participation will end."
11191481|NCT03443388|No Intervention|Part 2: No Helmet|"After a screening period, 10 subjects with drug resistant epilepsy will first be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. After approximately 3 months, patients will crossover to the helmet group."
11191482|NCT03443375|Experimental|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
11191483|NCT03443375|Experimental|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
11191484|NCT03443375|No Intervention|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
11191485|NCT03443362||Chronic urticaria|50 consecutive chronic urticaria patients receiving medical care within the CHU Brugmann Hospital. Diagnose according to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
11191486|NCT03443362||Control|20 healthy control patients, without chronic urticaria. Patients coming to the CHU Brugmann hospital for the excision of atypical naevi.
11191487|NCT03443349|Other|Use of the medical Device: Vibwife One|"The medical device will be used according to its market authorization.
~Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:
~First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.
~Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.
~All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.
~During the intervention period, position and module might be changed once if required."
11191488|NCT03443323|Experimental|OST-S Intervention group|
11191489|NCT03443323|No Intervention|Treatment as usual control group|
11191490|NCT03443310|Other|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
11191491|NCT03443297|Experimental|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight <1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
11191492|NCT03443297|No Intervention|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
11191493|NCT03443284|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of an iPhone or iPod Touch Operating System (iOS) mobile application (app) and a health care provider (HCP) portal.
11191494|NCT03443284|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
11191495|NCT03443271|Experimental|Group T (TAP Block with Bupivicaine)|Ultrasound guided TAP block will be performed in this group. Bupivicaine 0.25 % 20 ml will be administered in the block on either side.
11191496|NCT03443271|Placebo Comparator|Group C (TAP Block with Placebo drug)|Ultrasound guided TAP block will be performed in this group. 0.9 % Saline 20 ml will be administered in the block on either side.
11191538|NCT03442972|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
11191539|NCT03442959||patient with primary resection of the Small Intestinal TNE|
11191540|NCT03442959||patient without primary resection of the Small Intestinal TNE|
11191696|NCT03441919||Healthy subjects|"Absence of disease, no use of medication
~Matched for age, gender and BMI
~HbA1c <42 mmol/mol"
11191697|NCT03441893|Experimental|Patients with ulcerative colitis|
11191497|NCT03443258|Experimental|Intervention Group (IG)|Patients receive needs assessment tool integrated in nursing consultation in accordance with requirements by Danish Health and Medicine Board follow-up program for HNC patients. The consultation consists of 6 steps 1. Welcoming patient; 2. Introducing patient to assessment tool; 3. Discuss symptoms and concerns patient wishes to discuss; 4. Follow up on patients symptoms, concerns and emotional reactions/problems; 5. Accompany/support patient during appointment with surgeon and in cooperation with patient and surgeon ensure that problems arising from the tool needing medical attention are focused on; 6. Continue the consultation after appointment with surgeon; refer patient to multi-disciplinary team members when needed
11191498|NCT03443258|No Intervention|Control Group (CG)|CG will receive standard care according to the Danish Health and Medicine Board's follow-up program for HNC patients. At present this is done by a staff nurse interviewing the patient, who is a member of the rehabilitation team who perform nursing consultations. The interview takes place after the appointment with the surgeon. The nurse refers the patient to physical rehabilitation if needed
11191499|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
11191500|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
11191501|NCT03443232|Experimental|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
11191502|NCT03443232|Other|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
11191503|NCT03443219|Experimental|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
11191504|NCT03443219|Active Comparator|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
11191505|NCT03443206|Experimental|Intervention|This condition will include access to a website that includes a social component, in addition to psychoeducation and access to resources.
11191506|NCT03443206|Active Comparator|Control|This condition will include access to a website that includes psychoeducation and access to resources.
11191507|NCT03443193|Experimental|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
11191508|NCT03443193|Experimental|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
11191509|NCT03443180|Other|Dietary intervention|Participants will be asked to remove food containing gluten and ATI from their diets for 4 weeks.
11191510|NCT03443167|Active Comparator|Intervention group|Training on emergency telephone numbers and mnemonics
11191511|NCT03443167|Sham Comparator|Control group|Sham generic formation on the cardiopulmonary arrest.
11191512|NCT03443141|Experimental|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
11191513|NCT03443141|Sham Comparator|Standard dressing|Patients will receive a standard dressing over the wound
11191514|NCT03443128|Experimental|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
11191515|NCT03443102||SARS survivors|First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results.
11191516|NCT03443102||Controls|"Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results.
~Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus."
11191517|NCT03443089|Experimental|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
11191518|NCT03443089|Active Comparator|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
11191519|NCT03443076|Experimental|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
11191520|NCT03443076|Active Comparator|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
11191521|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
11191522|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
11191523|NCT03443050|Experimental|Experimental|Balance training on unstable surfaces
11191524|NCT03443050|Active Comparator|Control|Balance training on stable surface
11191525|NCT03443037||Amantadine group|Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
11191526|NCT03443037||Control group|Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
11191527|NCT03443024|Experimental|Group 1|Lebrikizumab, 125 mg every 4 weeks
11191528|NCT03443024|Experimental|Group 2|Lebrikizumab, 250 mg every 4 weeks
11191529|NCT03443024|Experimental|Group 3|Lebrikizumab, 250 mg every 2 weeks
11191530|NCT03443024|Placebo Comparator|Group 4|Placebos, every 2 weeks
11191531|NCT03443011|Experimental|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
11191532|NCT03442998|Other|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
11191533|NCT03442998|Other|Nature|Study participants will wall on a nature path setting for 50 minutes.
11191534|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
11191535|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
11191536|NCT03442985|Placebo Comparator|Placebo regimen|
11191541|NCT03442946||INS|Patients in need of a cardiovascular surgery will be included in this observational study. The focus is on the nutrition therapies provided to these critically ill patients according to institutional or international nutrition guidelines, what ever applies for the participating sites.
11191542|NCT03442933|Active Comparator|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
11191543|NCT03442933|Active Comparator|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
11191544|NCT03442920|Experimental|Obese women|Obese women who participated exercise programme.
11191545|NCT03442920|No Intervention|Normal weighted|Normal weighted women with non-periodontitis
11191546|NCT03442907|Experimental|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.
~To achieve the blood pressure target, fluid or vasoactive substances will be used."
11191547|NCT03442907|Active Comparator|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
11191548|NCT03442894|Active Comparator|Standard PT Treatment|"This group will receive manual therapy and exercise interventions provided by their physical therapist. The treatment will occur for 10 sessions over 6 weeks.
~Interventions: Manual therapy interventions including mobilization and manipulation of the shoulder girdle spine and ribcage. Exercise interventions will include strengthening and flexibility exercises for rotator cuff and shoulder girdle musculature."
11191549|NCT03442894|Experimental|Standard PT Treatment plus DN|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits.
11191550|NCT03442894|Sham Comparator|Standard PT Treatment plus Sham DN|In addition to the standard PT treatment, patients in the sham DN group will receive 6 sessions of sham DN intervention.
11191551|NCT03442881||benign adnexal mass|pathological examination of the specimen after excision reveals benign criteria
11191552|NCT03442881||Malignant adnexal mass|pathological examination of the specimen after excision reveals malignant criteria
11191553|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
11191554|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
11191555|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
11191556|NCT03442816|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
11191557|NCT03442803|Experimental|Propofol TCI|Delivery of Propofol via a Target-controlled infusion pump for procedural sedation.
11191558|NCT03442790|Experimental|Agitated Saline Method|The proper placement of the central venous line will be confirmed using agitated saline under ultrasound vision
11191559|NCT03442790|Active Comparator|Chest X-Ray Confirmation|The proper placement of the central venous line will be compared with chest x-ray obtained in supine position after central line placement
11191560|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings
~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
11191561|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings
~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
11191562|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.
~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
11191563|NCT03442764|Experimental|Group 1|Active Treatment for participants with base target trough concentration
11191564|NCT03442764|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
11191565|NCT03442764|Placebo Comparator|Placebo|Placebo Group
11191566|NCT03442751|Active Comparator|CXL Treatment Group|Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)
11191567|NCT03442751|Sham Comparator|Sham Treatment/Control Group|Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)
11191568|NCT03442738||Group I Endocuff group|Group I Endocuff cap use
11191569|NCT03442738||Group II standard colonoscope|Group II standard colonoscope, no further device used
11191570|NCT03442725|Experimental|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
11191571|NCT03442725|Active Comparator|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
11191572|NCT03442725|Experimental|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
11191573|NCT03442725|Experimental|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
11191574|NCT03442712|Active Comparator|Treatment arm 1|"Auricular acupressure (AA) plus smartphone App:
~Semen Vaccaria laccaria will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear. Subjects will be requested to apply pressure on the acupoints thrice per day. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. The total treatment period will be 8 weeks."
11191575|NCT03442712|Active Comparator|Treatment arm 2|The participants will only receive AA treatment and are required to perform daily self-administered seeds pressing.
11191576|NCT03442712|No Intervention|Treatment arm 3|The participants in the waitlist control group will maintain their usual dietary and exercising patterns.
11191577|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
11191578|NCT03442686|Experimental|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
11191579|NCT03442686|No Intervention|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
11191580|NCT03442673|Active Comparator|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
11191581|NCT03442673|Experimental|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
11191582|NCT03442660|Other|Data collection|An electronic data capture (EDC) system will be used to collect data in electronic format. Data will be collected at the enrolment visit, at the follow-up visit (8 weeks +/-2 weeks) and 1 to 4 days after the follow-up visit.
11191583|NCT03442647|Active Comparator|Living donors|sinistrin clearance dynamic measurement
11191584|NCT03442647|Active Comparator|ADPKD patients|sinistrin clearance dynamic measurement
11191585|NCT03442647|Active Comparator|Patients with primary renal tumor|sinistrin clearance dynamic measurement
11191586|NCT03442634|Experimental|Early Hydration Group|this study group will get 200 ml of sugar free water within 1 hour after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Early Oral Hydration
11191587|NCT03442634|Active Comparator|Traditional Hydration Group|this study group will get 200 ml of sugar free water after 6 hours after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Traditional Oral Hydration
11191588|NCT03442621|Experimental|Relacorilant Fasted|Relacorilant Fasted
11191589|NCT03442621|Experimental|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
11191590|NCT03442621|Experimental|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
11191591|NCT03442608|Experimental|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
11191592|NCT03442608|Placebo Comparator|northermia|normal physical cooling methods,like ice bag, conditionally required.
11191593|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
11191594|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
11191595|NCT03442582||Afluria|Afluria exposure in pregnancy
11191596|NCT03442569|Experimental|Open-label, single arm, Phase II|Nivolumab and ipilimumab with panitumumab
11191597|NCT03442556|Experimental|Treatment (docetaxel, carboplatin, rucaparib camsylate)|"INDUCTION: Patients receive docetaxel IV and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive rucaparib camsylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11191598|NCT03442543|Experimental|charcoal|
11191599|NCT03442543|Experimental|silver wire|
11191600|NCT03442530|Active Comparator|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
11191601|NCT03442530|Experimental|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
11191602|NCT03442517|Experimental|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
11191603|NCT03442517|Active Comparator|Usual prenatal care|Participants will continue their usual prenatal care.
11191671|NCT03442023|Active Comparator|Chlorhexidine 0.12%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 0.12% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 0.12%
11191672|NCT03442010||People with adverse drug event|People with adverse drug event
11191604|NCT03442504|Other|FES PET/CT|"The images will be made immediately after the injection of the FES in a dynamic acquisition, of 30 minutes, centered on a positive FDG lesion. The imaging will then be completed 1 hour after the injection, after obtaining a urination, by an acquisition whole body (from the top of the skull to the root of the thighs or more if element on FDG or conventional imaging) which will be performed in the supine position with arms around the body. During the PET / CT scan, patients will breathe spontaneously. The acquisition will last 30 minutes."
11191605|NCT03442491||Hayman's Haemostatic Suture|Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.
11191606|NCT03442478|Experimental|2D/3D Tomosynthesis|2D/3D Tomosynthesis images will be obtained in addition to standard mammographic images.
11191607|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone sarcoma
11191608|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone sarcoma
11191609|NCT03442452|Other|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
11191610|NCT03442439|Active Comparator|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
11191611|NCT03442439|Experimental|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
11191612|NCT03442426|Experimental|Intervention Cohort|Integrated model of primary care
11191613|NCT03442413|Experimental|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
11191614|NCT03442400|Experimental|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
11191615|NCT03442387|Experimental|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
11191616|NCT03442387|Experimental|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
11191617|NCT03442374|Experimental|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
11191618|NCT03442374|No Intervention|Non-exercise|No exercise intervention.
11191619|NCT03442361||Intralipid|Standard soybean oil-based therapy
11191620|NCT03442361||Clinoleic|Olive oil based therapy
11191621|NCT03442348|Experimental|Omega 3 fatty acid supplements|Participants in this arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
11191622|NCT03442348|Active Comparator|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (inulin fibre) per day for a period of 6 weeks.
11191623|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
11191624|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
11191625|NCT03442322|Active Comparator|transdisciplinary approach|The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
11191626|NCT03442322|Active Comparator|multidisciplinary approach|The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
11191627|NCT03442309|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
11191628|NCT03442309|Active Comparator|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.
~Dosage frequency will be twice-yearly."
11191629|NCT03442296|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
11191630|NCT03442296|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
11191631|NCT03442283||Supplementation|
11191632|NCT03442283||No Supplementation|
11191633|NCT03442257|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
11191634|NCT03442257|No Intervention|Control|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
11191635|NCT03442244|Experimental|LEO 90100 foam|Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g
11191636|NCT03442244|Placebo Comparator|Vehicle foam|"Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner.
~Foam vehicle does not contain active ingredients"
11191637|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
11191638|NCT03442218|Experimental|Clorhexidine|Vaginal wash with clorhexidine solution
11191639|NCT03442218|Placebo Comparator|Saline solution|Vaginal wash with saline solution
11191640|NCT03442205|Experimental|Group A|
11191641|NCT03442205|Experimental|Group B|
11191642|NCT03442205|Experimental|Group C|
11191643|NCT03442192|Other|PrEP Care Anywhere Services|The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.
11191644|NCT03442179|Active Comparator|Treatment Group|Anesthesiologists in the treatment group use the unprocessed EEG waveforms and EEG spectrogram to maintain appropriate levels of unconsciousness for general anesthesia while avoiding burst suppression.
11191645|NCT03442179|No Intervention|Control Group|Anesthesiologists managing patients assigned to the control group will manage each anesthetic based on their clinical judgment, using standard monitoring required by American Society of Anesthesiologists (ASA), which include cardiac and respiratory monitoring, but not EEG monitoring.
11191646|NCT03442166|Active Comparator|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
11191647|NCT03442166|Sham Comparator|Sham group|Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
11191648|NCT03442153|Experimental|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
11191649|NCT03442153|Placebo Comparator|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
11191650|NCT03442140|Experimental|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
11191651|NCT03442127|Other|Patient Group|Program users
11191652|NCT03442114|Experimental|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients & Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
11191653|NCT03442114|Active Comparator|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
11191654|NCT03442101|Experimental|Treatment group|These participants are newly diagnosed with psychosis.
11191655|NCT03442088|Experimental|Apremilast for Treatment of Psoriasis with the AM-endotype|Psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 5 monthly individual blood draws will be enrolled.
11191656|NCT03442088|No Intervention|Untreated healthy control|Untreated healthy controls will also be enrolled and will provide two blood draws. These are needed to maintain quality control of the normal levels of the biomarkers being tested.
11191657|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
11191658|NCT03442075||Group 2|Group 2 was administered analgesic orally
11191659|NCT03442075||Group 3|Group 3 was given trans rectal gel
11191660|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
11191661|NCT03442075||Group 5|Group was performed by placebo oral
11191662|NCT03442062|Experimental|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes ~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
11191663|NCT03442062|Experimental|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
11191664|NCT03442062|Experimental|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
11191665|NCT03442062|Other|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
11191666|NCT03442049|Experimental|Study group|Spinal stabilization exercises in addition to home exercise program
11191667|NCT03442049|Active Comparator|Control Group|Home exercise program
11191668|NCT03442036|Active Comparator|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.
~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
11191669|NCT03442036|Experimental|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.
~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
11191670|NCT03442023|Experimental|Chlorhexidine 2%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 2% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 2%
11191673|NCT03442010||People without adverse drug event|People without adverse drug event
11191698|NCT03441893|Experimental|Participants (control group)|
11191674|NCT03441997|Experimental|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
11191675|NCT03441997|Active Comparator|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
11191676|NCT03441997|No Intervention|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
11191677|NCT03441984|Experimental|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191678|NCT03441984|Experimental|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191679|NCT03441984|Experimental|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191680|NCT03441984|Experimental|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191681|NCT03441984|Experimental|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191682|NCT03441984|Experimental|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191683|NCT03441984|Experimental|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191684|NCT03441984|Experimental|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191685|NCT03441984|Experimental|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191686|NCT03441984|Experimental|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191687|NCT03441984|Experimental|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191688|NCT03441984|Experimental|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
11191689|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.
~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.
~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
11191690|NCT03441945|No Intervention|control|"The patients swallowed the capsule with water in the lying position.After finishing the stomach examination, the operation of the capsule is adjusted to small bowel mode without magnetic control. Capsule entered the duodenum under physiological peristalsis. The position of the capsule was established using a real-time viewer. If the capsule failed to enter the duodenum after one hour, domperidone (10 mg) was orally administered."
11191691|NCT03441945|Experimental|magnetic steering|"After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis. After reaching the duodenal bulb, capsule was held to the maximum position of Z, then the capsule would scan the duodenal bulb automatically with the mode 360° automatic scanning."
11191692|NCT03441932|Active Comparator|Dysphagia screening failed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
11191693|NCT03441932|Active Comparator|Dysphagia screening passed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
11191694|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"Diagnosis based on clinical criteria
~Duration of diabetes ≥10 years
~Age ≥20 years, ≤ 60 years
~HbA1c >64 mmol/mol"
11191695|NCT03441919||Patients with type 1 diabetes, good glycemic control|"Diagnosis based on clinical criteria
~Duration of diabetes ≥10 years
~Age ≥20 years, ≤ 60 years
~HbA1c <64 mmol/mol"
11191702|NCT03441867|Experimental|(CBT-Sz) - PNES|Participants with history of a head injury and confirmed PNES will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
11191703|NCT03441867|Experimental|(CBT-Sz) - PTE|Participants with history of a head injury and confirmed post-traumatic epilepsy (PTE) will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
11191704|NCT03441867|Active Comparator|TBI Control|Participants with TBI will complete 2 brain fMRI scans.
11191705|NCT03441854||HFNC group|The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.
11191706|NCT03441854||Control Group|For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.
11191707|NCT03441841|Experimental|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
11191708|NCT03441841|Active Comparator|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
11191709|NCT03441841|Active Comparator|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
11191710|NCT03441828|Experimental|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.
~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
11191711|NCT03441828|Active Comparator|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.
~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
11191712|NCT03441815|Experimental|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
11191713|NCT03441815|Experimental|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
11191714|NCT03441815|Experimental|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
11191715|NCT03441815|Experimental|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
11191716|NCT03441815|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
11191717|NCT03441802|Active Comparator|Cases|
11191718|NCT03441802|Other|Controls|
11191719|NCT03441789|Experimental|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
11191720|NCT03441789|Placebo Comparator|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
11191721|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
11191722|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
11191723|NCT03441763|Experimental|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
11191724|NCT03441763|Experimental|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
11191725|NCT03441763|Experimental|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
11191726|NCT03441750|Experimental|metformin plus standard lifestyle intervention|Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
11191727|NCT03441750|Other|Standard lifestyle intervention|Standard lifestyle advice will be united for all subjects by providing special booklet.
11191728|NCT03441737|Experimental|Exercise|Aerobic exercise intervention
11191729|NCT03441737|Active Comparator|Non-Exercise|Non-aerobic exercise intervention
11191730|NCT03441724||STEMI before PCI|ST-segment elevation, recording acquired before coronary intervention
11191731|NCT03441724||STEMI after PCI|ST-segment elevation, recording acquired from the same patients after coronary intervention
11191732|NCT03441711||Group 1|elevated sFlt-1/PlGF ratio
11191733|NCT03441711||Group 2|normal sFlt-1/PlGF ratio
11191734|NCT03441698|Experimental|Genuine acupuncture (A)|Genuine acupuncture (A) with neutral communication (A1) or positive communication (A2)
11191735|NCT03441698|Placebo Comparator|Sham Acupuncture (B)|Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
11191736|NCT03441698|Active Comparator|Rest (C)|Rest (C) with neutral communication (C1) or positive communication (C2)
11191737|NCT03441685|Experimental|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
11191738|NCT03441672|Experimental|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
11192000|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
11191739|NCT03441672|No Intervention|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
11191740|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.
~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~1b. patients who previously have been treated with VKA in the 12 months before index date."
11191741|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.
~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~2b. patients who previously have been treated with VKA in the 12 months before index date."
11191742|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.
~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~3b. patients who previously have been treated with VKA in the 12 months before index date."
11191743|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.
~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
~4b. patients who previously have been treated with VKA in the 12 months before index date."
11191744|NCT03441620|Placebo Comparator|Control|Calorie and fiber-matched control powder
11191745|NCT03441620|Experimental|Strawberry one serving|Freeze-dried powder equivalent to one serving fresh strawberries per day.
11191746|NCT03441620|Experimental|Strawberry two-half servings|Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
11191747|NCT03441607|Active Comparator|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
11191748|NCT03441607|Placebo Comparator|Placebo|Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
11191749|NCT03441581|Experimental|Cohort 1|IBS-D participants with evidence of BAM treated with Eluxadoline 100 mg oral tablets twice daily (BID) with food.
11191750|NCT03441581|Experimental|Cohort 2|IBS-D participants without evidence of BAM treated with Eluxadoline 100 mg oral tablets BID with food.
11191751|NCT03441568|Experimental|BAY987534|Infants and children with quiescent atopic dermatitis
11191752|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
11191753|NCT03441542|Experimental|Data-assisted Case Navigation|Patients are recruited and consented into the study by the patient navigator after which the navigator provides assistance with scheduling, reminders, and transportation. The navigator is also charged with responding to patient questions, and monitoring and documenting if and when patients achieve HCV care milestones. Each month, the project will update the Grady Liver Clinic HCV patient registry, to generate information about the patient's HCV care progress and use this information to develop instructions sheets regarding the expected care milestones to be achieved that month for each patient. During the month, the navigator will participate in project meetings and report on milestone achievement and barriers for patients assigned to the experimental arm of the study.
11191754|NCT03441542|Active Comparator|Standard of Care|Patients are recruited and consented into the study by the patient navigator at which time they will be reminded of their infection, consequences of untreated disease, and the availability of study sponsored antiviral treatment should they seek it. Patients will not be subsequently contacted by the study. Patients who seek treatment without patient navigation services will receive the same study provided HCV pre-treatment care and study provided treatment drugs when indicated. Self-referral to care and antiviral therapy when indicated are known to be effective in curing HCV among some patients, this arm is classified as an active comparator.
11191755|NCT03441529|Experimental|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
11191756|NCT03441529|Experimental|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
11191757|NCT03441516|Experimental|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
11191758|NCT03441516|Active Comparator|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
11191759|NCT03441503|Experimental|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey
~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:
~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.
~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
11191760|NCT03441503|No Intervention|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
11191761|NCT03441490|Active Comparator|ICBT standard|Internet-based cognitive behavioural therapy with therapeutic guidance through mail
11191762|NCT03441490|Experimental|ICBT chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat
11191763|NCT03441490|Experimental|ICBT learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail
11191764|NCT03441490|Experimental|ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat
11191765|NCT03441464|Experimental|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
11191766|NCT03441464|Experimental|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
11191767|NCT03441464|Experimental|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
11191768|NCT03441464|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
11191769|NCT03441438|Active Comparator|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
11191770|NCT03441438|Active Comparator|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
11191771|NCT03441438|Active Comparator|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
11191772|NCT03441425|No Intervention|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
11191773|NCT03441425|Experimental|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
11191774|NCT03441412|Experimental|Ticagrelor/Epinephrine/Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.
~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
11191775|NCT03441399|Experimental|Escalating Incentives|Participants assigned to the escalating financial incentives will receive an increasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
11191776|NCT03441399|Experimental|De-escalating Incentives|Participants assigned to the de-escalating financial incentives will receive a decreasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
11191777|NCT03441399|No Intervention|Control|Participants in this condition will receive usual care.
11191778|NCT03441386|Experimental|Cognitive Study|Cognitive Responses was analyzed after different intensities physical exercise sessions.
11191779|NCT03441373|Experimental|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
11191780|NCT03441373|Experimental|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.
~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
11191781|NCT03441373|Experimental|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
11191782|NCT03441373|Placebo Comparator|Placebo (Group D)|Placebo orally.
11191783|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: RMS|Pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS) will receive eribulin mesylate administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 milligrams per meters squared (mg/m^2). Participants will continue study therapy until progression of disease (per Response Evaluation Criteria In Solid Tumors [RECIST] 1.1), intolerable toxicity, or withdrawal of consent.
11191784|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: NRSTS|Pediatric participants with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
11191785|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: EWS|Pediatric participants with Ewing sarcoma (EWS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
11191786|NCT03441347|Experimental|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
11191787|NCT03441347|Other|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
11191788|NCT03441334|Experimental|High Frequency rTMS|The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
11191789|NCT03441334|Sham Comparator|Sham rTMS|The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.
11191790|NCT03441321|Experimental|Group I (focusing on indoor tanning and healthy body image)|Participants periodically read the content on the study-specific secret Facebook group related to living a healthy lifestyle including avoiding indoor tanning and excessive ultraviolet exposure, managing stress, healthy eating, promoting physically active lifestyles, and promoting a healthy body image, and participate in the group by providing reactions, commenting on the posts, or by sharing study relevant information within the group for 8 weeks.
11191791|NCT03441321|Active Comparator|Group II (focusing on other health topics)|Participants participate in secret Facebook groups that utilize content from the intervention content library related to other health topics of interest (e.g., physical activity, healthy eating, alcohol misuse prevention, stress reduction, sleep) for 8 weeks.
11191792|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
11191793|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
11191794|NCT03441295|Experimental|Study 1 Ligamys|Repair Surgery.
11191795|NCT03441295|Experimental|Study 1 Internal Bracing|Repair Surgery.
11191796|NCT03441295|Experimental|Study 2 Internal Bracing|Repair Surgery.
11191797|NCT03441295|Active Comparator|Study 2 Reconstruction|Reconstructive Surgery.
11191798|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.
~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
11191799|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.
~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents."
11191800|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
11191801|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
11191802|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
11191803|NCT03441256|Experimental|Intervention|All participant in the intervention group will undergo the LION procedure and subsequent neurostimulation.
11191804|NCT03441256|Active Comparator|Control|All participants in the control group will be issued with a device for neuromuscular electrical stimulation.
11191805|NCT03441243||Case group:Cesarean section urgently|- 43 patients had an emergency caesarean section between 01/01/2015 and 31/12/2016.
11191806|NCT03441243||Case group:Hemorrhage of deliverance|- 85 patients had haemorrhage of the delivery with need for a transfusion between 01/01/2015 and 31/12/2017.
11191807|NCT03441243||Control group: delivery physiological low path|- A control group will consist of 128 patients who had a physiological low birth delivery over the same period.
11191808|NCT03441230|Active Comparator|Circumference of 13 cm, sphere form (diameter of 4 cm)|
11191809|NCT03441230|Active Comparator|Circumference of 13 cm, cylinder form, length 11 cm|
11191810|NCT03441230|Active Comparator|Circumference of 16 cm, sphere form (diameter of 5 cm)|
11191811|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 11 cm|
11191812|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 18 cm|
11191813|NCT03441230|Active Comparator|Circumference of 19 cm, sphere form (diameter of 6 cm)|
11191814|NCT03441230|Active Comparator|Circumference of 19 cm, cylinder form, length 11 cm|
11191815|NCT03441230|Active Comparator|Circumference of 22 cm, sphere form (diameter of 7 cm)|
11191816|NCT03441230|Active Comparator|Circumference of 25 cm, sphere form (diameter of 8 cm)|
11191817|NCT03441230|Active Comparator|Circumference of 28 cm, sphere form (diameter of 9 cm)|
11191818|NCT03441217|Experimental|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
11191819|NCT03441217|Placebo Comparator|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
11191820|NCT03441204|Active Comparator|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
11191821|NCT03441204|Active Comparator|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
11191822|NCT03441191|Experimental|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
11191823|NCT03441191|Placebo Comparator|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
11191824|NCT03441178|Experimental|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
11191825|NCT03441152|Experimental|tDCS+CT|application of tDCS in combination with CT
11191826|NCT03441152|Sham Comparator|Sham tDCS|application of sham tDCS in combination with CT
11191827|NCT03441152|Active Comparator|CT|application of CT
11191828|NCT03441139|Experimental|Cryotherapy + medical analgesics|Percutaneous Cryotherapy and medical analgesics according to the investigator's discretion
11191829|NCT03441139|Active Comparator|Medical analgesics|Medical analgesics alone according to the investigator's discretion
11191830|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
11191831|NCT03441113|Other|Cohort 1: Study GS-US-352-0101|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
11191832|NCT03441113|Other|Cohort 2: Study GS-US-352-1214|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
11191995|NCT03440034|Experimental|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
11191833|NCT03441113|Other|Cohort 3: Study GS-US-352-1154|Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases..
11191834|NCT03441113|Other|Cohort 4: Study SRA-MMB-301|Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.
11191835|NCT03441100|Experimental|Experimental: IMA202 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.
~Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
11191836|NCT03441087|Other|Transvaginal ultrasound|Transvaginal ultrasound was applied 216 women with abnormal uterine bleeding.The transvaginal ultrasound diagnoses were compared with the received endometrial samples.
11191837|NCT03441087|Other|Hysteroscopy|Hysteroscopy was also performed under general anesthesia.Hysteroscopy was performed by a single operator (NNY).The operator and two supervising endoscopists were blinded to the ultrasound results.After the hysteroscopy, endometrial sampling was also done. The diagnoses were compared with the received endometrial samples.
11191838|NCT03441074|Experimental|Intervention Group|Patients randomly assigned to intervention group will get enhanced olfactory stimuli during the perioperative period
11191839|NCT03441074|No Intervention|Non-intervention Group|Patients randomly assigned to non-intervention group will not get any olfactory stimuli during the perioperative period
11191840|NCT03441061|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15 of cycle 1 and days 1 and 8 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11191841|NCT03441048|Experimental|IV infusion of Lintuzumab AC225 following CLAG-M chemotherapy|CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m2/day IV over two hours on days 2-6; cytarabine 2 gm/m2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy. Dose-escalation will be conducted according to a 3+3 design. The initial dose of Lintuzumab-Ac225 will be 0.25 uCi/kg (Dose level 1), and the highest dose administered will be 0.75uCi/kg.
11191842|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
11191843|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
11191844|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
11191845|NCT03441022|Experimental|Cardioversion|Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
11191846|NCT03440996|Experimental|Clinpro™ 5000|Participants will use Clinpro™ 5000 to brush their teeth for two minutes twice daily for 4 months.
11191847|NCT03440996|Experimental|Clinpro™ Tooth Crème|Participants will use Clinpro™ Tooth Crème to brush their teeth for two minutes twice daily for 4 months.
11191848|NCT03440996|Active Comparator|MI-Paste Plus|Participants will use MI-Paste Plus to brush their teeth for two minutes twice daily for 4 months.
11191849|NCT03440983|Experimental|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
11191850|NCT03440970|Experimental|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
11191851|NCT03440970|Placebo Comparator|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
11191852|NCT03440957|Other|Osteopathy treatment|
11191853|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
11191854|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
11191855|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
11191856|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
11191857|NCT03440892||1|
11191858|NCT03440879|Experimental|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
11191859|NCT03440879|No Intervention|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
11191860|NCT03440866|Experimental|Intervention|Administration of drugs concomitantly.
11191861|NCT03440866|No Intervention|Control|Administration of oral Mifepristone 600 mg and after interval of 48 hours administration of oral Misoprostol 400 mcg.
11191996|NCT03440021|Experimental|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
11216302|NCT03271437|Experimental|PC-trained therapists|
11191862|NCT03440853|Experimental|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
11191863|NCT03440853|Other|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
11191864|NCT03440840|Experimental|Computer Training with active tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with active transcranial direct current stimulation (tDCS).
11191865|NCT03440840|Active Comparator|Computer Training with sham tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with sham transcranial direct current stimulation (tDCS).
11191866|NCT03440840|Placebo Comparator|Computer Training with or without tDCS|Participants in this arm will watch educational videos as a comparator to computer training with the car racing game (watching educational videos).
11191867|NCT03440827|Other|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.
~Phase 2 : Administration of the scale of life's quality for validation."
11191868|NCT03440814|Experimental|DCCR|75 - 450 mg DCCR
11191869|NCT03440814|Placebo Comparator|Placebo|75 - 450 mg placebo for DCCR
11191870|NCT03440801|Experimental|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
11191871|NCT03440801|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
11191872|NCT03440775|Experimental|Experimental|
11191873|NCT03440775|Sham Comparator|Comparator|
11191874|NCT03440762|Other|AF awareness education|AF awareness education face to face
11191875|NCT03440749|Experimental|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
11191876|NCT03440749|Active Comparator|Control Group|Serial reaction time task: of movements according to the luminous stimuli
11191877|NCT03440736|Active Comparator|Secukinumab 300 mg s.c.|Patients in arm A receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
11191878|NCT03440736|Experimental|Secukinumab 300 mg s.c. and lifestyle intervention|Arm B: Patients in arm B receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24). In addition they participate in a lifestyle intervention program.
11191879|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
11191880|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
11191881|NCT03440710|Experimental|with BET|with BET and Tympanoplast
11191882|NCT03440710|Other|without BET|with Tympanoplast only
11191883|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
11191884|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)
~•positive genetic testing and/or a previous cardiac study required to be eligible"
11191885|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
11191886|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
11191887|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects
~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
11191888|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
11191889|NCT03440684|Experimental|Healthy individuals|Forty-one healthy individuals were volunteer to participate in the study and 39 of them had no neurological disease, were from 18 to 65 years old, and had no upper extremity injuries. And they have joined to exercise training during 6 weeks.
11191890|NCT03440671|Experimental|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
11191891|NCT03440671|Active Comparator|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
11191892|NCT03440645|Experimental|Family or Household Members|
11191893|NCT03440632|Other|FES start|"Start: 4 weeks 'adaptation phase' and 8 weeks 'FES phase'. Adaption phase: the stimulus (in Volt) will gradually be increased up to an effective level and the wear time has to be increased from 30 minutes to 6 hours a day. FES phase: the participants have to wear the FES device for minimal 6 hours a day during walking. Usual physiotherapy can be continued during the FES phase.
~Second: after the FES phase, this group will enter the 'wash-out' period of 6 weeks for fading of the therapeutic effects, in which they return to their conventional therapy. Afterwards, 12 weeks of conventional therapy (orthoses/shoes and usual physiotherapy) with measurements at start and end will follow."
11191894|NCT03440632|Other|Conventional start|"Start: wearing usual orthoses/shoes on a daily basis for the first 12 weeks of the study. Usual physiotherapy can be continued.
~Second: after 12 weeks this group will enter a 6 week watch out phase, and next be switched to FES treatment for 12 weeks, consisting of: 4 weeks 'adaptation phase' with gradual increase of the treatment and 8 weeks 'FES phase'."
11191895|NCT03440619|Experimental|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
11191997|NCT03440021|Experimental|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
11216303|NCT03271437|Experimental|EMDR-trained therapists|
11191896|NCT03440606|Experimental|MCAT Supervision Group|The 6-week 3-hour Mindful-Compassion Art Therapy (MCAT) supervision will include intervention elements of brief psycho-education, weekly mindfulness mediation that serve as a foundation to foster creative art making, reflective writing, group sharing and discussion.
11191897|NCT03440606|Experimental|Waitlist Control Group|Those assigned to the waitlist control group will not receive Mindful-Compassion Art Therapy (MCAT) supervision until approximately 1.5 month later; equivalent intervention and assessment procedures will be administered.
11191898|NCT03440593|Experimental|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
11191899|NCT03440593|No Intervention|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
11191900|NCT03440580|Active Comparator|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
11191901|NCT03440580|No Intervention|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
11191902|NCT03440567|Experimental|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
11191903|NCT03440567|Experimental|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. (Closed as of 12/12/2019)
11191904|NCT03440554|Experimental|Whole Body Non-Contrast MRI|
11191905|NCT03440541|Experimental|treated|Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
11191906|NCT03440515|Experimental|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop
11191907|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
11191908|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
11191909|NCT03440489|Other|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
11191910|NCT03440476|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
11191911|NCT03440476|Active Comparator|Intervention plus feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-only booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The content is clearly automatically generated.
11191912|NCT03440476|Active Comparator|Intervention plus feedback and personal contact booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-plus-personal-contact booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The email is sent from a member of the research staff.
11191913|NCT03440463|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
11191914|NCT03440463|Experimental|Intervention plus Norms-only booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use.
11191915|NCT03440463|Experimental|Intervention plus Norms-plus-Strategies booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use. It also includes reported harm reduction strategies, and other strategies they might consider.
11191916|NCT03440450|Experimental|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11191917|NCT03440450|Experimental|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11191918|NCT03440450|Experimental|Cohort 3: Treatment at 4.8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11191919|NCT03440450|Experimental|Cohort 4: Treatment at 8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
11191920|NCT03440437|Experimental|FS118 weekly|The initial cohorts will enroll sequentially as single-patient cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design.
11191921|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
11191998|NCT03440021|Placebo Comparator|Placebo|6 x placebo capsules in a single dose
11191922|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
11191923|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index [BMI]) will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
11191924|NCT03440411|Active Comparator|ARM A|Treatment with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
11191925|NCT03440411|Experimental|ARM B|Treatment with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
11191926|NCT03440411|Experimental|ARM I|Early treatment patients will receive treatment at biochemical relapse with pomalidomide-dexamethasone (Arm A) or pomalidomide-cyclophosphamide-dexamethasone (Arm B) according to randomization. The randomization between Arm A and B will be disclosed at biochemical relapse.
11191927|NCT03440411|Active Comparator|ARM II|Late treatment patients will be randomized at biochemical relapse and they will start treatment with pomalidomide-dexamethasone (Arm A) or pomalidomide-cyclophosphamide-dexamethasone (Arm B) at the onset of CRAB symptoms/significant paraprotein increase. The randomization between Arm A and B will be disclosed at the onset of CRAB symptoms/significant paraprotein increase.
11191928|NCT03440398|Active Comparator|Open NSM|Conventional Nipple Sparing Mastectomy
11191929|NCT03440398|Experimental|Robotic NSM|Robotic Nipple-Sparing Mastectomy
11191930|NCT03440385|Experimental|Administration of oral Ozanimod|Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation
11191931|NCT03440385|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally starting with a 7-day dose escalation
11191932|NCT03440372|Experimental|Administration of oral Ozanimod|Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation
11191933|NCT03440372|Placebo Comparator|Administration of Placebo|Subjects will receive placebo capsule orally starting with a 7-day dose escalation
11191934|NCT03440359|Other|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
11191935|NCT03440359|Active Comparator|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
11191936|NCT03440346|Experimental|Few-foods diet intervention|
11191937|NCT03440320|Experimental|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
11191938|NCT03440320|Active Comparator|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approxmiately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
11191939|NCT03440307|Placebo Comparator|Email Only|Participants received weekly email about health and fitness education. No face-to-face intervention, and not provided any other information about bisphenol exposure.
11191940|NCT03440307|Experimental|Face-to-Face Meetings|Participants met with a counselor once per week for 3-weeks to reduce bisphenol exposure. Intervention included same weekly email about health and fitness education as Email only group, and a weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Women provided with bisphenol-free cosmetics, hygiene, and glass food/water containers.
11191941|NCT03440294|Other|with neoprene suit and life jacket|"Realization of the following examinations WITH neoprene suit and life jacket :
~resting standard spirometry
~maximum exercise testing. No drug and no placebo will be used in this arm."
11191942|NCT03440294|Other|without neoprene suit and life jacket|"Realization of the following examinations WITHOUT neoprene suit and life jacket :
~resting standard spirometry
~maximum exercise testing. No drug and no placebo will be used in this arm."
11191943|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
11191944|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
11191945|NCT03440268|Experimental|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
11191946|NCT03440268|Placebo Comparator|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
11191947|NCT03440255|Experimental|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
11191948|NCT03440242||JJVC Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
11191949|NCT03440242||JJVC Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
11191950|NCT03440242||Marketed Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
11191999|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
11191951|NCT03440242||Marketed Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
11191952|NCT03440229|No Intervention|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
11191953|NCT03440229|Experimental|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
11191954|NCT03440216|Experimental|Sampling if GFR = or > 30 mL/min|"Note: GFR = Glomerular Filtration Rate
~Patients with a normal of moderately decreased renal function
~Temocillin: 6 g in continuous infusion over 24 h;
~Ceftriaxone: bolus 2 g (in 30 min) every 12h
~Meropenem: prolonged infusion (3 h) of 2 g every 8h
~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content when possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration when possible"
11191955|NCT03440216|Experimental|Sampling if GFR < 30 mL/min|"Patients with severe renal insufficiency or hemodialysis:
~Temocillin: 6 g in continuous infusion over 24 h;
~Ceftriaxone: bolus 2 g (in 30 min) every 12h
~Meropenem: prolonged infusion (3 h) of 2 g every 8h
~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content if possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration if possible"
11191956|NCT03440203||no Diabetic neuropathy|
11191957|NCT03440203||Diabetic peripheral neuropathy|
11191958|NCT03440203||Diabetic peripheral neuropathic pain|
11191959|NCT03440151|Experimental|contralateral submental flap for tongue cancer defect|
11191960|NCT03440151|Active Comparator|primary closure for tongue cancer defect|
11191961|NCT03440138||University Hospital Zurich|
11191962|NCT03440138||St Pierre University Hospital, Brussels, Belgium|
11191963|NCT03440138||Sana Klinikum, Offenbach, Germany|
11191964|NCT03440138||Complutense University of Madrid, Spain|
11191965|NCT03440138||Musgrove Park Hospital, Taunton, UK|
11191966|NCT03440138||University of Gothenburg, Sweden|
11191967|NCT03440138||AZ Sint-Jan Hospital in Bruges, Belgium|
11191968|NCT03440138||Bristol|
11191969|NCT03440138||Cleveland Clinic, Weston, Florida, USA|
11191970|NCT03440138||Oswaldo Cruz German Hospital, Sao Paolo, Brazil|
11191971|NCT03440138||Clínica Las Condes, Santiago, Chile|
11191972|NCT03440138||Brown University, Providence Rhode Island|
11191973|NCT03440138||Fresno Bariatric, CA, USA|
11191974|NCT03440138||Rijnstate Hospital, Arnhem, The Netherlands|
11191975|NCT03440138||CHU Nice, France|
11191976|NCT03440138||Claraspital Basel, Switzerland|
11191977|NCT03440138||Gastro-Obeso-Center Advanced Med Inst, Brazil|
11191978|NCT03440138||Hospital Dipreca Santiago Región Metropolitana , Chile|
11191979|NCT03440138||Medical University Wien, Austria|
11191980|NCT03440125|Experimental|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
11191981|NCT03440125|Experimental|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
11191982|NCT03440125|Experimental|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
11191983|NCT03440112|Active Comparator|Clarithromycin (Not used anymore as of 4/2020)|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
11191984|NCT03440112|Placebo Comparator|Placebo (Not used anymore as of 4/2020)|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
11191985|NCT03440112|Active Comparator|Transdermal flumazenil (added 4/2020)|Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
11191986|NCT03440112|Placebo Comparator|Placebo cream (added 4/2020)|Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
11191987|NCT03440099|Other|Training|All participants will participate in the 16-week resistance exercise training program.
11191988|NCT03440086|Experimental|Abdominal Jackson-Pratt drain|Patients in this arm will undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
11191989|NCT03440086|No Intervention|Controls|Patients in this arm will not undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
11191990|NCT03440073|Experimental|Mulligan Concept Intervention|Mulligan Concept Intervention, including Mobilizations with Movement intervention is administered. Up to 30 minutes total treatment time.
11191991|NCT03440073|Sham Comparator|Sham Mulligan Concept Treatment|Assessment procedures of the Mulligan Concept are followed, but no manual pressure is applied to the participant during treatment to provide a sham Mulligan Concept Treatment.
11191992|NCT03440060|No Intervention|standard group|participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy
11191993|NCT03440060|Active Comparator|Procalcitonin group|participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml
11191994|NCT03440047|Experimental|Fuji Flim Processor VP-7000|Screening or surveillance colonoscopy using Fuji Flim Processor VP-7000, Light Source BL-7000
11192001|NCT03439995|Experimental|Open Lung Protective Ventilation|Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
11192002|NCT03439995|Active Comparator|Conventional Ventilation|Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect
11192003|NCT03439982|Experimental|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
11192004|NCT03439969|No Intervention|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
11192005|NCT03439969|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
11192006|NCT03439969|Experimental|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
11192007|NCT03439969|Experimental|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
11192008|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
11192009|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
11192010|NCT03439943|Experimental|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
11192011|NCT03439943|Placebo Comparator|Placebo|Placebo: once daily subcutaneous injection
11192012|NCT03439930|Active Comparator|Uni-axial|Subjects in this group perform exercises on an uni-axial balance board
11192013|NCT03439930|Active Comparator|Multidirectional|Subjects in this group perform exercises on a multidirectional balance board
11192014|NCT03439917|Experimental|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
11192015|NCT03439917|Placebo Comparator|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
11192016|NCT03439904|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care
11192017|NCT03439904|No Intervention|control group|Patients will receive usual medical care
11192018|NCT03439891|Experimental|Lead-in Arm I (Part 2: nivolumab, sorafenib)|After determination of MTD [Part 1] participants receive nivolumab IV over 30 minutes on days 1 and 15, and sorafenib PO beginning on day 15 of course 1, then on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11192019|NCT03439891|Experimental|Lead-in Arm II (Part 2: sorafenib, nivolumab)|After determination of MTD [Part 1] participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11192020|NCT03439878|Experimental|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
11192021|NCT03439878|Active Comparator|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
11192022|NCT03439865|Experimental|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
11192023|NCT03439865|Placebo Comparator|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
11192024|NCT03439852|Experimental|Light to Moderate Physical Activity/Sedentary Time|The telephone counseling plus group cohesion intervention is designed to increase Light-to-Moderate intensity physical activity (LMPA) and reduce Sedentary time (ST). The 12-wk intervention includes group discussions during 3 regular monthly club meetings when clubs' accumulated milestones for LMPA/ST min/wk will be identified and future cumulative club goals for PA/ST set. In addition, each member will receive 12 weekly personalized phone calls from health coaches who will use motivational interviewing to set individualized LMPA/ST goals setting, reduce barriers, and facilitate social support for LMPA/ST change.
11192025|NCT03439852|No Intervention|Delayed Treatment/Healthy Aging|Delayed Treatment (DT) / Healthy Aging materials Condition is for 12 weeks and participants receive 12 phone calls using a previously developed contact-matched protocol that uses mailed healthy aging information and telephone calls to assess symptom ratings. After the initial 12 weeks they then receive the LMPA/ST intervention
11192026|NCT03439839|Experimental|Arm 1|10 patients receiving LNP023 high dose daily over up to approximately 3 years
11192027|NCT03439839|Experimental|Arm 2|5 patients receiving LNP023 low dose daily over up to approximately 3 years
11192059|NCT03439618|Other|time-restricted feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 6h (7:00-9:00,11:00-13:00,17:00-19:00).
11192028|NCT03439813|Experimental|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
11192029|NCT03439813|Active Comparator|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
11192030|NCT03439800|Experimental|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.
~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.
~Physical Practice: is the execution of the motor action."
11192031|NCT03439800|Active Comparator|Physical Practice|Physical Practice: is the execution of the motor action.
11192032|NCT03439787|Active Comparator|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
11192033|NCT03439787|Placebo Comparator|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
11192034|NCT03439774|Other|Adults 18 years old or older|
11192035|NCT03439761|Experimental|PT-112 Injection|PT-112 Injection alone
11192036|NCT03439748|Experimental|Positive Affect Treatment|Sessions 1-7: Planning for engagement in pleasurable activities and reinforcement of positive mood effects of those activities Sessions 8-10: Exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention
11192037|NCT03439748|Active Comparator|Negative Affect Treatment|Sessions 1-7: Exposures to avoided scenarios Sessions 8-10: Cognitive restructuring Sessions 11-14: Normalization of arousal response to exposure Session 15: Relapse prevention
11192038|NCT03439735|Experimental|Palbociclib and Aromatase Inhibitor|Participants will undergo blood collection (intervention) at time of initiating treatment with an aromatase inhibitor and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
11192039|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
11192040|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
11192041|NCT03439709|Experimental|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
11192042|NCT03439709|Active Comparator|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
11192043|NCT03439696|Experimental|Needlescopic-assisted|Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
11192044|NCT03439696|Active Comparator|Uniportal|Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
11192045|NCT03439683||Physicians|"Definition: Physicians working in the ICU for at least 50% of their time in the hospital
~Intervention: Survey about patient-ventilator asynchrony"
11192046|NCT03439683||Nurses|"Definition: Nurses working in the ICU for at least 20 hours/week
~Intervention: Survey about patient-ventilator asynchrony"
11192047|NCT03439683||Respiratory Therapists|"Definition: Respiratory Therapists working in the ICU for at least 20 hours/week
~Intervention: Survey about patient-ventilator asynchrony"
11192048|NCT03439670|Experimental|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
11192049|NCT03439670|Experimental|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
11192050|NCT03439670|Active Comparator|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
11192051|NCT03439670|Active Comparator|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
11192052|NCT03439670|Placebo Comparator|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
11192053|NCT03439670|Placebo Comparator|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
11192054|NCT03439657|Experimental|Co-Ad Group|Subjects at least 50 years of age at the time of the first vaccination, who will receive the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines will be administered intramuscularly, GSK1437173A will be administered in the deltoid muscle of the non-dominant arm, while Prevenar13 will be administered in the deltoid muscle of the dominant arm.
11192055|NCT03439657|Active Comparator|Control Group|Subjects at least 50 years of age at the time of the first vaccination, who will receive one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines will be administered intramuscularly, GSK1437173A will be administered in the deltoid muscle of the non-dominant arm, while Prevenar13 will be administered in the deltoid muscle of the dominant arm.
11192056|NCT03439631|Active Comparator|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
11192057|NCT03439631|Other|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
11192058|NCT03439618|Other|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
11192210|NCT03438513||Standard medical care|Occupational Therapy Assessment Psychological assessment
11192060|NCT03439592||hyperglycemic patients|diabetic patients admitted for STEMI and with hyperglycemia at hospital admission.
11192061|NCT03439592||normoglycemic patients|diabetic patients admitted for STEMI and with normoglycemia at hospital admission.
11192062|NCT03439579|Experimental|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
11192063|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
11192064|NCT03439553|Experimental|Intervention|People shown ads with referral to target websites.
11192065|NCT03439553|Active Comparator|Intervention with control websites|People shown ads with referral to control websites.
11192066|NCT03439553|No Intervention|Control|People who make target queries, but are not shown the ads.
11192067|NCT03439540|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 12 weeks.
11192068|NCT03439540|Experimental|Plantago major|Individuals receive Plantago major daily, for 12 weeks.
11192069|NCT03439527|Experimental|MPC-group|All patients are treated by the same product: Autologous MPCs
11192070|NCT03439527|Other|NMES+MPC-group|After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy (Neuromuscular Electromagnetic Stimulation, NMES)
11192071|NCT03439514|Experimental|Part 1 Double-blind Treatment|ARRY-371797 tablet orally OR matching placebo tablet orally
11192072|NCT03439514|Experimental|Part 2 Open-label Treatment|ARRY-371797 tablet orally
11192073|NCT03439501|Other|avelumab|"1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)
~Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
11192074|NCT03439488|Experimental|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ-440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
11192075|NCT03439488|Experimental|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily or twice daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
11192076|NCT03439488|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ-440/placebo once daily or twice daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
11192077|NCT03439436|Experimental|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
11192078|NCT03439436|Active Comparator|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
11192079|NCT03439423||Patients who underwent EVAR|
11192080|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
11192081|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
11192082|NCT03439397|Experimental|Ballon Technique group|Intervention：Ballon Technique
11192083|NCT03439397|Active Comparator|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
11192084|NCT03439384|Experimental|Experimental: Home Telemonitoring|Patients will receive home telemonitoring equipment and monitor their health for 60 days post-enrollment. A monitoring nurse will receive and review the patients health data on a daily basis for the 60 day duration and provide remote care, counseling and education.
11192085|NCT03439384|No Intervention|Control: No Home Telemonitoring|The patient will not receive any home telemonitoring once enrolled and will continue to receive the usual care he/she can expect as part of his/her care plan.
11192086|NCT03439371|Experimental|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
11192087|NCT03439358|Experimental|Magnesium sulfate|Magnesium sulfate (MgSO4) infusion will be commenced prior to epidural top-up.
11192088|NCT03439358|Placebo Comparator|Normal saline|Normal saline infusion will be commenced prior to epidural top-up.
11192089|NCT03439345|Experimental|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
11192090|NCT03439345|Placebo Comparator|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
11192091|NCT03439319|Active Comparator|MyndMove® therapy|Non-invasive Functional Electrical Stimulation (FES) technique with surface electrodes to stimulate from 3 to 8 muscles to create purposeful movements in one or both hands/arms
11192092|NCT03439319|Active Comparator|Intensive Conventional therapy|Using Conventional therapy which focuses exclusively on the purposeful movements in one or both hands/arms
11192211|NCT03438500|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
11192093|NCT03439306||healthy adult volunteer|"Subject is 18 to 50 years of age.
~Subject is a non-smoker or who has not smoked within 2 days prior to the study."
11192094|NCT03439293|Experimental|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 milligram per kilogram (mg/kg), intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), have an unacceptable toxicity, or withdraw consent, or when the study has completed or until the sponsor terminates the study.
11192095|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: TAK-079|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. Dose escalation of TAK-079 will range from 45 milligram (mg) to 1800 mg and may be done using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
11192096|NCT03439280|Experimental|Phase 1 Dose Confirmation Cohort: TAK-079|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD. TAK-079 dose will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the previous cohort of Phase 1.
11192097|NCT03439280|Experimental|Phase 1 Combination Cohort: TAK-079 + PomDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, orally, once daily on Days 1 to 21 and dexamethasone, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD. TAK-079 dose will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1.
11192098|NCT03439280|Experimental|Phase 2a: TAK-079 TBD|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study.
11192099|NCT03439267|Active Comparator|Proactive Current National Guidelines Group|Standard Interventional Control Group. Will receive treatment recommendation according to the current National guidelines for statin initiation and follow-up.
11192100|NCT03439267|Experimental|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin recommendation based on the cardiovascular risk algorithm.
11192101|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
11192102|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
11192103|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 18 months
11192104|NCT03439241|Experimental|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
11192105|NCT03439241|Experimental|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
11192106|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
11192107|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
11192108|NCT03439215|Experimental|Lorlatinb Arm|Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.
11192109|NCT03439202|Other|No arm used|No drug use for this study. No arm used in this study. Subjects are exposed to hypoxic conditions (clinical study).
11192110|NCT03439176|Experimental|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:
~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
11192111|NCT03439163||PD patients|the entire group underwent MRI scan
11192112|NCT03439150|Other|Study arm|The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery
11192113|NCT03439137|Experimental|MT-6548|
11192114|NCT03439137|Active Comparator|Darbepoetin alfa|
11192115|NCT03439124|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
11192116|NCT03439124|Active Comparator|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.
~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.
~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
11192117|NCT03439111|Placebo Comparator|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
11192118|NCT03439111|Experimental|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
11192119|NCT03439098|Experimental|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
11192120|NCT03439098|Experimental|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
11192121|NCT03439098|Placebo Comparator|Placebo|Placebo
11192212|NCT03438487||Flucelvax Trivalent or Quadrivalent Influenza Vaccine|Flucelvax Trivalent or Quadrivalent exposure in pregnancy
11192122|NCT03439085|Experimental|Treatment (INO-3112, durvalumab)|Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
11192123|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
11192124|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
11192125|NCT03439059|Experimental|intervention- reducing SB|prompted to do 10min of light physical activity 3x/day
11192126|NCT03439059|No Intervention|Control|go about their normal daily living
11192127|NCT03439046|Experimental|ribociclib+letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
11192128|NCT03439046|Experimental|alpelisib+fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
11192129|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
11192130|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
11192131|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
11192132|NCT03439020|Experimental|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.
~(Plastic stent anchoring)"
11192133|NCT03439020|Active Comparator|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
11192134|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
11192135|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
11192136|NCT03438994|Active Comparator|Participants diagnosed with ASD|
11192137|NCT03438994|Experimental|Participants diagnosed with OND|
11192138|NCT03438994|Active Comparator|Typically developing participants|
11192139|NCT03438968|Experimental|High-Intensity aerobic training|Individuals will exercise using a high-intensity interval exercise training protocol
11192140|NCT03438968|Active Comparator|Standard Moderate continuous training|Individuals will exercise using a standard moderate intensity continuous exercise training protocol
11192141|NCT03438955|Experimental|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
11192142|NCT03438955|Experimental|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
11192143|NCT03438942|Experimental|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
11192144|NCT03438942|Active Comparator|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
11192145|NCT03438903||Normal group|Healthy subjects without any ocular problems Repeat exams of OCT device (SD and SS-OCT)
11192146|NCT03438903||Retinal diseases group|Patients with various macular diseases Repeat exams of OCT device (SD and SS-OCT)
11192147|NCT03438890|Experimental|Warm saline group|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
11192148|NCT03438890|Experimental|anti-fog agent group|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
11192149|NCT03438890|Experimental|chlorhexidine group|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
11192150|NCT03438890|No Intervention|control group|In the control group, the lens was not wiped gauze or applied any solution before use of the laparoscope. When occurred the event of each laparoscopic lens fogging (LLF) that splatter of irrigation fluid, blood, and body fluids affected visual clearance, the laparoscopic lens was manually rubbed with clean gauze by a scrub nurse.
11192151|NCT03438877|Experimental|Intervention group|Intervention group is intensive dosage of PD.
11192152|NCT03438877|Active Comparator|Control group|Control group is regular dosage of PD.
11192153|NCT03438864|Experimental|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
11192154|NCT03438864|Experimental|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
11192155|NCT03438864|Sham Comparator|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
11192156|NCT03438851|Experimental|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
11192157|NCT03438851|Experimental|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
11192158|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
11192159|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
11192160|NCT03438812|Experimental|Poor ovarian responders with DHEA|Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.
11192161|NCT03438812|No Intervention|Poor ovarian responders|Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA
11192162|NCT03438812|No Intervention|Normal ovarian responders|Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.
11192163|NCT03438799||Cordio|Cordio R&D database to develop the Cordio System
11192164|NCT03438786|Experimental|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
11192165|NCT03438786|Experimental|group B|Patients undergoing lichtnestein's hernioplasty
11192166|NCT03438773|Other|Envarsus|Study group - Envarsus once daily in addition to standard of care.
11192167|NCT03438773|Other|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
11192168|NCT03438760|Placebo Comparator|Science + Phonological Awareness|In all conditions, science is taught via the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) Journal/Reflection, and 4) dialogic reading centered around a given theme such as plant life. In the control condition, a minimum of six phoneme identifications and five rhymes will be incorporated into each lesson of this curriculum. While these activities are likely to improve the children's awareness of the sounds of the language (a foundational skill for learning to read), they are not likely to improve their access to the science being taught. Therefore, this intervention constitutes a placebo.
11192169|NCT03438760|Experimental|Science + Grammar Intervention|In the science + grammar condition, focused stimulation, an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities. The approach is incidental, rather than explicit. The active ingredients are models and recasts of the target structure. Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Recasts and/or models will be provided at an average rate of one per minute, an accepted therapeutic dose.
11192170|NCT03438760|Experimental|Science + Vocabulary Intervention|This arm involves Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 20 words that pertain to scientific practices applicable to the FOSS lessons. The children receive a cumulative exposure of at least 20 times per word (a minimum of 5 times per each of four lessons) and at least 4 chances to produce the word (a minimum of 1 chance per each of four lessons).
11192171|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
11192172|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
11192173|NCT03438734|Active Comparator|Low flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 0.75 L/min. Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
11192174|NCT03438734|Sham Comparator|Normal flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 1.5 L/min.Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
11192175|NCT03438721|Experimental|Infant Obesity Prevention|The infant obesity prevention arm will provide parents with education on optimal infant feeding, sleep, and screen time practices.
11192176|NCT03438721|Experimental|Financial Coaching|The financial coaching arm will provide parents with education on basic financial literacy topics and coaching to help parents achieve financial goals.
11192177|NCT03438708|Experimental|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
11192178|NCT03438695|Experimental|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
11192179|NCT03438682||Essure Hysteroscopic Sterilization|Women who have undergone Essure hysteroscopic sterilization
11192180|NCT03438682||Laparoscopic Sterilization|Women who have undergone laparoscopic sterilization
11192181|NCT03438682||Intrauterine device (IUD) placement|Women who have undergone IUD placement
11192182|NCT03438656|Experimental|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
11192183|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
11192208|NCT03438513||Problem Solving Therapy|This program is intended for caregivers to acquire techniques to manage stressful situations encountered in everyday life.
11192209|NCT03438513||Speaking group|The group will be led by a psychologist.
11192184|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
11192185|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
11192186|NCT03438617|Experimental|First Cohort|The first cohort of 3 CHCs will receive the peer support intervention for the full duration of the study period (12 months).
11192187|NCT03438617|Other|Second Cohort|The second cohort of 3 CHCs will serve as a control group for the first 3 months of the study. After 3 months, the second cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 9 months.
11192188|NCT03438617|Other|Third Cohort|The third cohort of 4 CHCs will serve as a control group for the first 6 months of the study. After 6 months, the third cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 6 months.
11192189|NCT03438604|Other|Donepezil TDS with Heat Applied|Corplex Donepezil TDS 5 mg/day with heat applied
11192190|NCT03438604|Other|Donepezil TDS without Heat|Corplex Donepezil TDS 5 mg/day with no heat applied
11192191|NCT03438604|Other|Donepezil TDS Extension Study with Heat|Corplex Donepezil TDS 5 mg/day with heat. Two skin sensors will be placed underneath the TDS and adjacent to the TDS.
11192192|NCT03438591|Experimental|Cerclage-CRT (medtronic 4196 lead)|trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing'
11192193|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
11192194|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
11192195|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
11192196|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
11192197|NCT03438552|Experimental|SBRT at a total dose of 30 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
11192198|NCT03438552|Experimental|SBRT at a total dose of 25 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
11192199|NCT03438552|Experimental|SBRT at a total dose of 36 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
11192200|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
11192201|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
11192202|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
11192203|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
11192204|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
11192205|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
11192206|NCT03438526|Experimental|Melatonin (Circadin ®)|
11192207|NCT03438526|Placebo Comparator|Placebo|
11192213|NCT03438474|Active Comparator|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:
~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
11192214|NCT03438474|Experimental|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:
~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
11192215|NCT03438461|Experimental|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
11192216|NCT03438461|Experimental|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
11192217|NCT03438435|Experimental|QRH-882260 Heptapeptide|Five mL of reconstituted (with sterile 0.9% NaCl) QRH-882260 Cy-5-labeled heptapeptide
11192218|NCT03438422|Experimental|GROUP A|1 tablet a day of pollen A extract containing (140 mg aqueous extract and 8mg lipid purified pollen, aqueous extract pumpkin seed 300mg, 10mg Vitamin E)
11192219|NCT03438422|Active Comparator|GROUP B|1 tablet a day of pollen B extract containing (140 mg aqueous extract and lipid 8 mg of purified pollen)
11192220|NCT03438422|Active Comparator|GROUP C|1 tablet a day of pollen extract C containing (Pollen extract 160 mg, pumpkin seed extract, 300 mg and Vitamin E 10 mg)
11192221|NCT03438422|Placebo Comparator|PLACEBO|1 tablet a day of placebo
11192222|NCT03438409|Experimental|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
11192223|NCT03438396|Experimental|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
11192224|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
11192225|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
11192226|NCT03438370|No Intervention|Three monthly ART supply at facilities|Sites at which patients will be provided three monthly ART supply at health facilities.
11192227|NCT03438370|Experimental|Three monthly ART supply at CAGs|Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
11192228|NCT03438370|Experimental|Six monthly ART supply at outreaches|Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
11192229|NCT03438357||Patients with multiple sclerosis|
11192230|NCT03438344|Experimental|Arm I (CMV-MVA triplex vaccine)|Patients receive multi-antigen CMV-modified vaccinia Ankara vaccine via injection on days 28 and 56 post-HCT.
11192231|NCT03438344|Placebo Comparator|Arm II (placebo)|Patients receive placebo via injection on days 28 and 56 post-HCT.
11192232|NCT03438331|Experimental|CBT-I|
11192233|NCT03438331|Active Comparator|CBT-D|
11192234|NCT03438331|No Intervention|Waiting-list control|
11192235|NCT03438318|Experimental|Part A (CMP-001, Atezolizumab and Optional Radiation Therapy)|Participants will receive CMP-001 5 milligrams (mg) SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by every 3 weeks thereafter until discontinuation of treatment in combination with atezolizumab SC every 3 weeks starting at Week 2. Route of administration (IT/SC) for CMP-001 beyond Week 5 will be determined by Investigator. Participants enrolled in Part A who progressed per RECIST v1.1 on combination of CMP-001 and atezolizumab have opportunity to enroll in Part A optional radiation therapy add-on after documented disease progression per CT/MRI or PET scan. After CMP-001 washout period of 10 days, participants will be treated with radiation consisting of 20 grays in 5 fractions for 5 days then resume CMP-001 treatment.
11192236|NCT03438318|Experimental|Part B (Radiation Therapy, CMP-001 and Atezolizumab)|Participants will be treated with radiation therapy consisting of 20 grays in 5 fractions for 5 days, then participants will receive CMP-001 5 mg SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by dosing every 3 weeks thereafter until discontinuation of treatment. The route of administration (that is, IT or SC) for CMP-001 beyond Week 5 will be determined by the Investigator. First dose of CMP-001 will be administered within 2 days of radiation therapy. Atezolizumab will be administered SC in combination with CMP-001 every 3 weeks starting at Week 2.
11192237|NCT03438305||Group D|
11192238|NCT03438305||Group N|
11192239|NCT03438292|Experimental|Group A - TPGS emulsified with berberine|After an 8-10 hour overnight fast, Group A will receive two soft capsules of TPGS (400mg) emulsified berberine. Following a 7 day wash out period, Group A participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Following another 7 day wash out period, Group A participants will then receive two hard shell capsules of the berberine reference powder 400mg. Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
11192272|NCT03438032||SSc-ILD|SSc-ILD subjects will be defined by those who fulfill 2013 American College of Rheumatology SSc criteria and have forearm modified Rodnan skin scores (mRSS) ≥1 (a validated, semi-quantitative scoring system for dermal fibrosis) and clinically relevant SSc-interstitial lung disease (ILD). A subject will be defined as having ILD if they have radiographic evidence for ILD and a forced vital capacity <70% on pulmonary function test (PFT).
11193106|NCT03432299|Experimental|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
11192240|NCT03438292|Experimental|Group B - Quillaja extract emulsified with Berberine|After an 8-10 hour overnight fast, Group B will receive four soft capsules of Quillaja extract emulsified berberine (400mg). Following a 7 day wash out period, Group B participants will then receive two hard shell capsules of the berberine reference powder (400mg). Following another 7 day wash out period, Group B participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
11192241|NCT03438292|Experimental|Group C - Berberine reference powder|After an 8-10 hour overnight fast, Group C will receive two hard shell capsules of the berberine reference powder (400mg). Following a 7 day wash out period, Group C participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Following another 7 day wash out period, Group C participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
11192242|NCT03438279||First-Line Ipilimumab|patients who received ipilimumab as their first-line treatment
11192243|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
11192244|NCT03438266|Other|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
11192245|NCT03438240|Active Comparator|Group BF|Bupivacaine plus Fentanyl
11192246|NCT03438240|Active Comparator|Group BD|Bupivacaine plus Dexmedetomidine
11192247|NCT03438227|Experimental|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
11192248|NCT03438227|Active Comparator|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
11192249|NCT03438214|Active Comparator|Vancomycin continuous infusion|Continuous infusion of vancomycin
11192250|NCT03438214|Active Comparator|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
11192251|NCT03438201|Active Comparator|High-protein diet|High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol
11192252|NCT03438201|Active Comparator|Normoproteic diet|Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol
11192253|NCT03438188|Experimental|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
11192254|NCT03438188|No Intervention|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
11192255|NCT03438175|No Intervention|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
11192256|NCT03438175|Experimental|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
11192257|NCT03438162|No Intervention|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
11192258|NCT03438162|Experimental|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
11192259|NCT03438136|Experimental|Intervention arm|This arm will be enrolled in the intervention.
11192260|NCT03438136|No Intervention|No intervention arm|This arm will be enrolled in a no contact control group.
11192261|NCT03438123|Experimental|CZT SPECT|CZT SPECT imaging with/without the addition of CT on the Spectrum Dynamics camera
11192262|NCT03438084|Experimental|Interesterified|Commercially available interesterifed fat spread. 50g fat.
11192263|NCT03438084|Active Comparator|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
11192264|NCT03438084|Active Comparator|Control|Rapeseed oil. 50 g fat.
11192265|NCT03438084|Active Comparator|Saturated fat control|Butter. 50g fat
11192266|NCT03438071||Control group|
11192267|NCT03438071||Videoconference group|
11192268|NCT03438058||With complement-activating anti-HLA DSAs|Patients with complement-activating anti-HLA DSAs either C1q, C3d, C4d and IgG subclass
11192269|NCT03438058||Without complement-activating anti-HLA DSAs|Patients with anti-HLA DSAs but without the ability to activate the complement (either C1q, C3d, C4d and IgG subclass)
11192270|NCT03438058||Without DSAs and without complement-activating DSAs|Matching group of patients without DSAs and without complement-activating DSAs
11192271|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
11192273|NCT03438032||Control|Healthy control subjects recruited from the Northwestern community will complete demographic and basic medical forms to ensure health
11192274|NCT03438019|Experimental|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
11192275|NCT03438019|Experimental|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
11192276|NCT03438019|Sham Comparator|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
11192277|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 45 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
11192278|NCT03437993|Experimental|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
11192279|NCT03437993|Sham Comparator|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
11192280|NCT03437980|Experimental|propofol spinal acceptance|"The surgeon and the anesthetist will discuss the exclusion criteria. Then they will discuss the information's about spinal and general anesthesia with the illegible patients, also reply the patient's questions in a preoperative visit. The primary decision for the patient; either spinal or general anesthesia will be recorded.
~The patients refusing spinal anesthesia will be discussed again to detect the rate of acceptance of spinal anesthesia if propofol sedation is ensured during the procedure to provide a painless spinal injection. The final decision will be applied; either spinal with procedural sedation, or general anesthesia."
11192281|NCT03437967|Other|ABAB|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).
~ABAB initial period is active treatment - LASER.
~Active Treatment:
~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation."
11192282|NCT03437967|Other|BABA|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).
~BABA initial period is sham treatment - LOW LEVEL LASER.
~LOW LEVEL LASER treatment:
~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels."
11192283|NCT03437954|Other|Standard soft diet|
11192284|NCT03437954|Other|Non-restricted diet|
11192285|NCT03437941|Experimental|Dose Determination Segment 1|Patients will be treated with enzalutamide monotherapy once daily for 28 days followed by combination treatment with CORT125281 at escalating dose levels and enzalutamide once daily in 28-day dosing cycles.
11192286|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort|Patients who have progressed during treatment with abiraterone and no other AR-blocking therapies will be treated with CORT125281 and enzalutamide.
11192287|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort Food Effect|Sub-Cohort (first 10 patients enrolled into Cohort A). Patients enrolled into this subcohort will receive a single dose of CORT125281 at Cycle 1 Day -7 and a single dose of CORT125281 at Cycle 1 Day 1 30 minutes after a standard breakfast to assess the effect of food on PK parameters. Patients will then begin CORT125281 in combination with enzalutamide on Cycle 1 Day 2 and continue in 28-day dosing cycles.
11192288|NCT03437941|Experimental|Dose Expansion - ARant-Resistant Cohort|Patients who progressed during treatment with enzalutamide or second-generation AR-blocking therapies will be treated with a daily dose of CORT125281 and enzalutamide.
11192289|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm A|Patients randomized to this cohort will receive enzalutamide and a titrated dose of CORT125281. Enzalutamide will be continued at the dose currently tolerated by the patient at screening.
11192290|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm B|Patients randomized to this cohort will receive enzalutamide, placebo, and CORT125281.
11192291|NCT03437928|Experimental|Directional Deep Brain Stimulation|
11192292|NCT03437915|Experimental|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
11192293|NCT03437902|Experimental|Rutin C group|patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
11192294|NCT03437902|Experimental|Vitamin C group|patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
11192295|NCT03437902|No Intervention|Control group|patients will receive their usual antidiabetic treatment only for 8 weeks.
11192296|NCT03437889|Experimental|Epidural analgesia/anesthesia for childbirth|
11192297|NCT03437876|Experimental|patients with HBV induced cirrhosis|patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times intestinal microbiota transplant and the time interval is generally 2 weeks.
11192298|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
11192299|NCT03437850||South African cohort|
11192300|NCT03437850||Swedish Cohort|
11192301|NCT03437824|Experimental|Cyanocobalamin|Vitamin B12, 1,000 mg, Once
11192302|NCT03437824|Placebo Comparator|Placebo|Normal Saline Solution (0.9% Sodium Chloride), Once
11192303|NCT03437811||Active Treatment|Active arm, Electro Flo Percussor, Model 5000 airway clearance system for daily basis as needed (pro re nata).
11193153|NCT03431961|Placebo Comparator|Placebo|0.9% normal saline administered twice daily for 14 days
11192304|NCT03437785|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
11192305|NCT03437785|Experimental|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
11192306|NCT03437785|Placebo Comparator|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
11192307|NCT03437785|Active Comparator|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
11192308|NCT03437785|Active Comparator|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
11192309|NCT03437772||CBT with mindfulness|
11192310|NCT03437772||Treatment as Usual: Barkley therapy|
11192311|NCT03437759|Experimental|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
11192312|NCT03437759|No Intervention|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
11192313|NCT03437733|Experimental|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
11192314|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
11192315|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
11192316|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
11192317|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
11192318|NCT03437707|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
11192319|NCT03437707|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
11192320|NCT03437707|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
11192321|NCT03437694|Experimental|Medication Optimization Intervention|This group will represent those participants whose medical records have been provided to the pharmacist.
11192322|NCT03437694|Active Comparator|Medication Optimization Control|This group will represent those participants whose medical records have not been provided to the pharmacist.
11192323|NCT03437681|Experimental|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
11192324|NCT03437668|Experimental|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
11192325|NCT03437668|Placebo Comparator|Placebo tablets|Placebo oral tablet bid for 12 weeks
11192326|NCT03437655|Active Comparator|Zinc oxide and eugenol|Temporary direct restoration with zinc oxide and eugenol.
11192327|NCT03437655|Active Comparator|Mineral trioxide aggregate|Temporary direct restoration with Mineral trioxide aggregate.
11192328|NCT03437642||Tako-Tsubo - STP|Short term psychotherapy + Classic cardiological therapy
11192329|NCT03437642||Tako-Tsubo - Control|Classic cardiological therapy only
11192330|NCT03437642||Oncologic - STP|Short term psychotherapy + Classic oncological therapy
11192331|NCT03437642||Oncologic - Control|Classic oncological therapy only
11192332|NCT03437642||AMI - STP|Short term psychotherapy + Classic cardiological therapy
11192333|NCT03437642||AMI - Control|Classic cardiological therapy only
11192334|NCT03437642||Healthy Subjects|No therapy
11192335|NCT03437629|Active Comparator|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
11192336|NCT03437629|Active Comparator|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
11192337|NCT03437616|Experimental|Tulppa rehabilitation|8-10 weekly 3-hour group sessions and two follow-up sessions (6 and 12 months).
11192338|NCT03437616|No Intervention|Control group|Control group does not receive Tulppa rehabilitation during the study.
11192339|NCT03437603|Experimental|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
11192377|NCT03437317|Experimental|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
11193246|NCT03431246|Experimental|Gardasil and Gardasil-9|
11192340|NCT03437590|Experimental|Part 1: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with [18F]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram [mg]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of [18F]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.
11192341|NCT03437590|Experimental|Part 2: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline PET/MR scan with [18F]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
11192342|NCT03437577|Active Comparator|immediate-release tacrolimus|This is standard of care
11192343|NCT03437577|Experimental|extended release tacrolimus|replace standard of care
11192344|NCT03437564|Experimental|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
11192345|NCT03437564|Experimental|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
11192346|NCT03437551||no intervention|Cross-sectional Observation study
11192347|NCT03437538|Active Comparator|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
11192348|NCT03437538|Active Comparator|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
11192349|NCT03437525|Experimental|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
11192350|NCT03437525|No Intervention|Control|Usual care
11192351|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
11192352|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
11192353|NCT03437499|Active Comparator|Positive Pressure Ventilation|Positive Pressure Ventilation ( peak pressure set at 25 cmH20 and PEEP set at 5 cmH2O, with 40 inflations per minute)
11192354|NCT03437499|Experimental|Sustained Inflation|Prolonged inflation ( 25 cmH20 for 15 seconds) followed by PEEP set at 5 cmH2O
11192355|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
11192356|NCT03437473|Active Comparator|Active stimulation QD|
11192357|NCT03437473|Active Comparator|Active stimulation QID|
11192358|NCT03437473|Sham Comparator|No stimulation|
11192359|NCT03437460|Active Comparator|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
11192360|NCT03437460|Placebo Comparator|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
11192361|NCT03437460|No Intervention|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
11192362|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
11192363|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
11192364|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
11192365|NCT03437434||BunnyLens and Gore-Tex suture|All patients Underwent 4 point PC-IOL scleral fixation with Gore-Tex sutures
11192366|NCT03437421|Experimental|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
11192367|NCT03437421|Experimental|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
11192368|NCT03437408|Experimental|Mapping and ablation|Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
11192369|NCT03437395|Other|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
11192370|NCT03437382|Other|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
11192371|NCT03437369|Experimental|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
11192372|NCT03437369|Other|Standard of Care|The study drug will be compared with standard of Care treatment
11192373|NCT03437356|Active Comparator|ADT ON Group|'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.
11192374|NCT03437356|Active Comparator|ADT OFF Group|'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation
11192375|NCT03437330|Experimental|Empagliflozin (Jardiance®)|Dose/frequency: 25 mg once daily for 12 weeks Route of administration: oral
11192376|NCT03437330|Active Comparator|Insulin Glargine (Lantus®)|"Thus, insulin glargine doses should be adapted as follows:
~FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +4 IU FBG > 8 mmol/L: +6 IU"
11192378|NCT03437317|Sham Comparator|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
11192379|NCT03437317|Experimental|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
11192380|NCT03437317|Experimental|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
11192381|NCT03437317|Sham Comparator|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
11192382|NCT03437304|Experimental|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
11192383|NCT03437304|Experimental|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
11192384|NCT03437304|Experimental|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
11192385|NCT03437304|Experimental|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
11192386|NCT03437304|Placebo Comparator|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
11192387|NCT03437304|Experimental|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
11192388|NCT03437304|Active Comparator|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
11192389|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
11192390|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
11192391|NCT03437278|Experimental|A. Ligelizumab high dose|1 injection of ligelizumab (high dose) every 4 weeks from Day 1 to Week 20 (inclusive)
11192392|NCT03437278|Experimental|B.Ligelizumab low dose|1 injection of ligelizumab (low dose)every 4 weeks from Day 1 to Week 20 (inclusive)
11192393|NCT03437278|Placebo Comparator|C. Placebo|1 injection of placebo at Day 1, Week 4, Week 8; followed by the same treatment as in Arm A from week 12 onwards to week 20 (inclusive)
11192394|NCT03437265|Experimental|NER1006 powder for oral solution|"Oral administration of 1 sachet (115.96 g) NER1006 Dose 1 (containing PEG 3350, sodium sulfate and electrolytes), to be reconstituted with water and made up to 500 mL, consumed over approximately 30 min, followed by 500 mL water, consumed over approximately 30 min. Additional water may be drunk ad libitum after the dose.
~Following 1 hour rest period, oral administration of 2 sachets (101.91 g) NER1006 Dose 2 (containing sodium ascorbate, PEG 3350, ascorbic acid and electrolytes), to be reconstituted with water and made up to 500 mL, consumed over approximately 30 min, followed by 500 mL water, consumed over approximately 30 min. Additional water may be drunk ad libitum after the dose."
11192395|NCT03437239|Experimental|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
11192396|NCT03437239|No Intervention|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
11192397|NCT03437226|Experimental|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
11192398|NCT03437226|Placebo Comparator|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
11192399|NCT03437213|Experimental|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
11192400|NCT03437213|Active Comparator|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
11192401|NCT03437200|Experimental|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.
~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
11192402|NCT03437200|Experimental|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
11192403|NCT03437187|Other|Cholecystectomy without nerve blocks|Cholecystectomy, enteral and parenteral analgesics
11192404|NCT03437187|Placebo Comparator|Cholecystectomy with placebo nerve block|Cholecystectomy, NaCl as a placebo Quadratus lumborum block
11192405|NCT03437187|Active Comparator|Cholecystectomy with naropin nerve block|Cholecystectomy, Quadratus lumborum block with naropin
11192406|NCT03437161|Experimental|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
11192407|NCT03437148|Experimental|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
11192408|NCT03437135||Witness patients|Healthy Volunteers
11192413|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
11192414|NCT03437070|Experimental|TDO Dose Level|Trabectedin [T], Doxorubicin [D], and Olaratumab [O]
11192415|NCT03437057|Experimental|Patients treated with KARDEGIC 75mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with KARDEGIC 75mg No suspended.
11192416|NCT03437044|Experimental|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
11192417|NCT03437044|Active Comparator|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
11192418|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
11192419|NCT03437031|Experimental|Latent-VR|Patients in the latent phase of labor who will receive the VR intervention.
11192420|NCT03437031|No Intervention|Active-Control|Patients in the active phase of labor who will receive no intervention.
11192421|NCT03437031|Experimental|Active-VR|Patients in the active phase of labor who will receive the VR intervention.
11192422|NCT03437005|Experimental|Desonide 0.05%|Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
11192423|NCT03437005|Experimental|Ketoconazole 2%|Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
11192424|NCT03436992|Experimental|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
11192425|NCT03436992|No Intervention|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
11192426|NCT03436992|Experimental|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
11192427|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
11192428|NCT03436953|Experimental|CX-8998 T-type calcium channel blocker|
11192429|NCT03436953|Placebo Comparator|Comparator|
11192430|NCT03436940|Active Comparator|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
11192431|NCT03436940|Experimental|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
11192432|NCT03436927|Experimental|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
11192433|NCT03436927|Experimental|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
11192434|NCT03436927|No Intervention|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
11192435|NCT03436914|Experimental|PPI|Esomezol®
11192436|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
11192437|NCT03436875||FH+|FH+ = having at least 1 parent with type 2 diabetes
11192438|NCT03436875||FH-|FH- = having no history of type 2 diabetes for two generations (parents and grandparents)
11192439|NCT03436862|Experimental|Nivolumab|Patients will receive Nivolumab 240 mg by intravenous infusion (IV) starting Day 45-120 post-transplant (±10 days) every 2 weeks for up to a maximum of 6 months of treatment.
11192440|NCT03436849|Experimental|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
11192441|NCT03436849|Experimental|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
11192442|NCT03436849|Placebo Comparator|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
11192443|NCT03436849|Experimental|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
11192444|NCT03436849|Experimental|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
11192445|NCT03436849|Experimental|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
11192446|NCT03436849|Placebo Comparator|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
11192447|NCT03436849|Placebo Comparator|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
11192448|NCT03436849|Placebo Comparator|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
11192449|NCT03436836|Experimental|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.
~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
11192450|NCT03436836|Active Comparator|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
11193247|NCT03431233|Experimental|Group 1|protein enriched bar->commercial cereal bar->water
11192451|NCT03436823|Experimental|R.TMS + nurse semi-structured interview|Repeated Transcranial Magnetic Stimulation sessions associated with nurse semi-structured interview
11192452|NCT03436823|Sham Comparator|R.TMS + Music & Relaxation|Repeated Transcranial Magnetic Stimulation sessions associated with music listening & relaxation with eyes closed
11192453|NCT03436810|Experimental|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
11192454|NCT03436810|Active Comparator|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
11192455|NCT03436784|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
11192456|NCT03436784|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
11192457|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
11192458|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
11192459|NCT03436745|Active Comparator|Female|Single 5 mg oral dose of zolpidem
11192460|NCT03436745|Experimental|Zolpidem pre and post castration|5 mg oral dose of zolpidem prior to undergoing ADT followed by 5 mg oral dose of zolpidem after ADT and testosterone reaches castrate levels
11192461|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
11192462|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
11192463|NCT03436719|Experimental|Oral with Intravenous|Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
11192464|NCT03436719|Active Comparator|Intravenous|Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
11192465|NCT03436706||Participants|The cohort will consist of male and female children ages 11-12 accompanied by a participating parent over the age of 18 years. The family income of participants in this cohort cannot exceed 200% of the federal poverty level established in 2018.
11192466|NCT03436693|Experimental|Canagliflozin 100mg|
11192467|NCT03436693|Placebo Comparator|Placebo|
11192468|NCT03436680|Experimental|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
11192469|NCT03436680|Active Comparator|Group II (standard of care)|Participants receive standard of care.
11192470|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
11192471|NCT03436654|Experimental|ADT + Apalutamide|
11192472|NCT03436654|Experimental|ADT + Apalutamide + Abiraterone Acetate + Prednisone|
11192473|NCT03436628|Experimental|App Use|Kids (10-15 years old) with type 1 diabetes and one of their parents will receive the MyT1DHero app to use for a 3-month period. Participants are urged to use the app four times each day.
11192474|NCT03436615|Experimental|SB206 4%|SB206 4% topically twice daily
11192475|NCT03436615|Experimental|SB206 8%|SB206 8% topically twice daily
11192476|NCT03436615|Experimental|SB206 12%|SB206 12% topically once or twice daily
11192477|NCT03436615|Placebo Comparator|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
11192478|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
11192479|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
11192480|NCT03436589|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
11192481|NCT03436589|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
11192482|NCT03436576|Active Comparator|Autologous Serum 20%|Treatment with Autologous Serum 20% for 2 months
11192483|NCT03436576|Active Comparator|Autologous Serum 50%|Treatment with Autologous Serum 50% for 2 months
11192484|NCT03436563|Experimental|Treatment (M7824)|Patients receive M7824 IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity (Cohorts A,B, and C) or for six doses in patients with detectable circulating tumor DNA (ctDNA) following resection of all known liver metastases (Cohort D).
11192485|NCT03436550||Patients with Chronic Liver Disease|
11192486|NCT03436550||Control Group|
11192487|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
11192488|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
11192489|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
11192490|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
11192491|NCT03436524||Validation cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
11192492|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
11192493|NCT03436498|Experimental|SAR341402/NovoLog|SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.
11192494|NCT03436498|Experimental|NovoLog/SAR341402|Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.
11192495|NCT03436485|Experimental|ODM-208 Part 1 Dose escalation|
11192496|NCT03436485|Experimental|ODM-208 Part 2 Dose expansion|
11192497|NCT03436472|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
11192498|NCT03436472|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
11192499|NCT03436459|Active Comparator|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
11192500|NCT03436459|Active Comparator|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
11192501|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
11192502|NCT03436433|Active Comparator|Lacosamide|Enrolled subjects will be randomized to receive Lacosamide.
11192503|NCT03436433|Active Comparator|Levetiracetam|Enrolled subjects will be randomized to receive Levetiracetam.
11192504|NCT03436433|No Intervention|No anti-epileptic|Enrolled subjects will be randomized to not receive anti-epileptic drugs.
11192505|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
11192506|NCT03436407||PrEP Group|Subject offered to start PrEP treatment in routine clinical practice
11192507|NCT03436407||Control Group|"Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study.
~Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2)
~Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort."
11192508|NCT03436394|Experimental|Evobrutinib: Normal Renal Function|Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) will receive a single oral dose of evobrutinib under fasting conditions.
11192509|NCT03436394|Experimental|Evobrutinib: Severe Renal Impairment|Subjects with eGFR less than (<) 30 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
11192510|NCT03436394|Experimental|Evobrutinib: Moderate Renal Impairment|Subjects with eGFR >= to 30 mL/min/1.73 m^2 and < 60 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
11192511|NCT03436394|Experimental|Evobrutinib: Mild Renal Impairment|Subjects with eGFR >= to 60 mL/min/1.73 m^2 and < 90 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
11192512|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
11192513|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
11192514|NCT03436368|Active Comparator|GA group|General Anesthesia
11192515|NCT03436355|Experimental|Physical activity|60 minutes of daily physical activity (see intervention)
11192516|NCT03436342|Experimental|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
11192517|NCT03436329|Experimental|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
11192518|NCT03436329|Active Comparator|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
11192519|NCT03436316|Experimental|SAD Cohort 1 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 1) and 2 participants will receive placebo.
11192520|NCT03436316|Experimental|SAD Cohort 2 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 2) and 2 participants will receive placebo.
11192521|NCT03436316|Experimental|SAD Cohort 3 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 3) and 2 participants will receive placebo.
11192522|NCT03436316|Experimental|SAD Cohort 4 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 4) and 2 participants will receive placebo.
11192570|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
11192523|NCT03436316|Experimental|SAD Cohort 5 (Part 1)|"6 Participants will receive AZD8154 (single inhaled small particle dose 5) and 2 participants will receive placebo.
~Participants in this Cohort will return for a second Treatment Period after a minimum washout period of 7 to 14 days. All 6 subjects will receive an inhaled dose of AZD8154 (large particle size)."
11192524|NCT03436316|Experimental|SAD Cohort 6 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 6) and 2 participants will receive placebo.
11192525|NCT03436316|Experimental|Cohort 1 (Part 2)|All participants in this cohort will receive single IV dose of AZD8154 in Treatment Period 1 and then after washout period, will receive inhaled AZD8154 (small particle size) in Treatment Period 2.
11192526|NCT03436316|Experimental|MAD Cohort 1 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 8) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 8) or placebo once daily from Day 4 to Day 12.
11192527|NCT03436316|Experimental|MAD Cohort 2 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 9) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (Inhaled dose 9) or placebo once daily from Day 4 to Day 12.
11192528|NCT03436316|Experimental|MAD Cohort 3 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 10) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 10) or placebo once daily from Day 4 to Day 12.
11192529|NCT03436303|Experimental|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
11192530|NCT03436303|Experimental|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
11192531|NCT03436303|Experimental|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
11192532|NCT03436290|Experimental|Palliative Care Intervention|
11192533|NCT03436290|No Intervention|Standard of Care|
11192534|NCT03436277|Placebo Comparator|Placebo|Sucralose 1,5 g
11192535|NCT03436277|Experimental|L-Carnitine|L- Carnitine 1,5 g
11192536|NCT03436264||high sensitivity to pain|
11192537|NCT03436264||low sensitivity to pain|
11192538|NCT03436251|Experimental|Local Hyperthermia at 44℃ for HPV+/CIN-1|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18. HPV+ and normal cytology or HPV+/CIN-1
11192539|NCT03436251|Sham Comparator|local hyperthermia at 37℃ for 30 mins|HPV+/CIN-1
11192540|NCT03436251|Active Comparator|coniztion of the cervix treatment|coniztion of cervix for HPV+/CIN2, including LEEP or cold knife coniztion
11192541|NCT03436251|Experimental|Local Hyperthermia at 44℃ for CIN2/HPV+|Local hyperthermia at 44℃ for 30 mins at days of 1,2,3 and 17, 18. HPV+ and CIN2.
11192542|NCT03436238||MINSS cohort|"Adult patients >= 50 years old undergoing elective, major, abdominal surgery requiring at least one overnight stay in hospital.
~Major abdominal surgery is defined as those classified as major OR major/complex by the Surgical Outcome Risk Tool (SORT) (www.sortsurgery.com)."
11192543|NCT03436225|Other|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
11192544|NCT03436225|Other|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
11192545|NCT03436225|Other|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
11192546|NCT03436225|Other|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
11192547|NCT03436212|Other|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
11192548|NCT03436199|Experimental|ADS-5102 137 mg|
11192549|NCT03436199|Experimental|ADS-5102 274 mg|
11192550|NCT03436199|Other|Placebo|placebo capsules
11192551|NCT03436186||no arm|no arm
11192552|NCT03436173|Experimental|Fluoxetine|Fluoxetine 10 mg/2.5 ml
11192553|NCT03436173|Placebo Comparator|Placebo|Peppermint syrup measured to equivalent volume
11192554|NCT03436160|Experimental|WR826647|100 mcg Carbon-14 radio labeled WR826647 administered via IV
11192555|NCT03436160|Experimental|WR909388|100 mcg Carbon-14 radio labeled WR909388 administered via IV
11192556|NCT03436160|Experimental|WR909390|100 mcg Carbon-14 radio labeled WR909390 administered via IV
11192557|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
11192558|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
11192559|NCT03436134|Active Comparator|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
11192560|NCT03436134|Experimental|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
11192561|NCT03436121|Experimental|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
11192562|NCT03436121|Active Comparator|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
11192563|NCT03436108||PCOS group|patients who have PCOS
11192564|NCT03436108||control group|patients who donnot have PCOS
11192565|NCT03436095||research group|bundle measures to help patient to weaning ventilator
11192566|NCT03436095||historical control group|retrospect the patients who were difficult to wean from ventilator and collect some materials to compare.
11192567|NCT03436095||External control group|contrast other same level hospitals measures to patients who are difficult to wean ventilator.
11192568|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
11192569|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
11192612|NCT03435809|Active Comparator|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
11220082|NCT03244956|Experimental|patients with RAS mutation|
11192571|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
11192572|NCT03436056|Other|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
11192573|NCT03436043|Experimental|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
11192574|NCT03436043|No Intervention|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
11192575|NCT03436030|Experimental|Single arm, breathing manuevers|All subjects perform/undergo Valsalva, Muller, CPAP, hand grip, and passive leg raise, with ultrasound examination of heart recorded before and during the manoeuvre.
11192576|NCT03436017||ADHD|Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach
11192577|NCT03436017||non ADHD|"Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.
~The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach."
11192578|NCT03436004|Experimental|Experimental|Colonoscopy with specific device with CE marking (Endocuff Vision)
11192579|NCT03436004|Active Comparator|Active Comparator|Colonoscopy with standard device of the center
11192580|NCT03435991||OAB patients|
11192581|NCT03435991||Healthy volunteers|
11192582|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
11192583|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
11192584|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
11192585|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
11192586|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
11192587|NCT03435952|Experimental|Pembrolizumab + Clostridium novyi-NT|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months.
~Clostridium novyi-NT injected into the tumor on Day 8.
~Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT"
11192588|NCT03435939|Experimental|losartan|a daily dose of 50 mg losartan for 7 days (for tolerability). Then, the losartan dose will be increased to 100 mg daily for 12 weeks.
11192589|NCT03435913|Experimental|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
11192590|NCT03435913|Experimental|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).
~1 mmHg = 1,36 cmH20.
~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
11192591|NCT03435900|Experimental|Intervention group|
11192592|NCT03435900|Active Comparator|Control group|
11192593|NCT03435887|Active Comparator|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
11192594|NCT03435887|Active Comparator|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
11192595|NCT03435874|Experimental|Group 1 Active|n=6. Age 18-35 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 at D56.
11192596|NCT03435874|Placebo Comparator|Group 1 Comparator|n=3. Age 18-35 years. Rabies vaccine at D0 and D56.
11192597|NCT03435874|Experimental|Group 2a Active|n=6. Age 1-6 years. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
11192598|NCT03435874|Placebo Comparator|Group 2a Comparator|n=3. Age 1-6 years. Rabies vaccine at D0 and D56.
11192599|NCT03435874|Experimental|Group 2b Active|n=12. Age 1-6 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
11192600|NCT03435874|Placebo Comparator|Group 2b Comparator|n=6. Age 1-6 years. Rabies vaccine at D0 and D56.
11192601|NCT03435874|Experimental|Group 3a Active|n=6. Age 6-11 months. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
11192602|NCT03435874|Placebo Comparator|Group 3a Comparator|n=3. Age 6-11 months. Rabies vaccine at D0 and D56.
11192603|NCT03435874|Experimental|Group 3b Active|n=12. Age 6-11 months. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
11192604|NCT03435874|Placebo Comparator|Group 3b Comparator|n=6. Age 6-11 months. Rabies vaccine at D0 and D56.
11192605|NCT03435861|Experimental|VX-745|In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
11192606|NCT03435861|Placebo Comparator|placebo|In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
11192607|NCT03435848|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
11192608|NCT03435835|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 33ºC will be circulated through the pants for 80 minutes.
11192609|NCT03435835|Active Comparator|Heat Therapy|Participants will be dressed in water circulating trousers that are connected to. Warm water (42-43ºC) will be circulated through the pants for 80 minutes.
11192610|NCT03435822|Other|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
11192611|NCT03435822|Other|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
11192613|NCT03435809|Active Comparator|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
11192614|NCT03435796|Other|Subjects exposed to Gene-modified (GM) T cell therapy|Subjects will be followed for 15 years from the last GM T cells infusion until withdrawal of consent, lost to follow-up, or death, whichever occurs first. Annual safety assessments will be conducted every 6 months during the first 5 years from the date of last GM T cell infusion. Laboratory evaluations and safety assessments will be conducted during this period. After 5 years, subjects will continue to be followed yearly. During the trial, pediatric subjects will be monitored for growth, development and sexual maturity. Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.
11192615|NCT03435783|Experimental|Intervention|
11192616|NCT03435783|Active Comparator|Attention-matched control|
11192617|NCT03435770|Experimental|EUSRA RFA needle|This procedure is very similar to the standard technique of EUS-guided fine needle aspiration. All patients would undergo EUS with a linear array or therapeutic echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the EUSRA RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue.
11192618|NCT03435757|Experimental|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
11192619|NCT03435757|Active Comparator|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
11192620|NCT03435744|Experimental|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
11192621|NCT03435744|Placebo Comparator|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
11192622|NCT03435731|Experimental|Treatment Group|This group will undergo 1 month Dual Therapy.
11192623|NCT03435718|Experimental|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
11192624|NCT03435718|Experimental|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
11192625|NCT03435718|Experimental|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
11192626|NCT03435718|Experimental|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
11192627|NCT03435718|Active Comparator|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
11192628|NCT03435705|Experimental|intervention arm|maintaining of occupational therapy for a 4 months period
11192629|NCT03435705|No Intervention|control arm|usual care after the end of the recommended initial program
11192630|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.
~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
11192631|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.
~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
11192632|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.
~An intraoperative pain protocol will dictate if the patient will receive IV fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with PRN morphine and oxycodone as well as scheduled acetaminophen."
11192633|NCT03435679|Experimental|one-stage|one-stage surgical treatment of the infected knee arthroplasty
11192634|NCT03435679|Active Comparator|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
11192635|NCT03435666|Experimental|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
11192636|NCT03435666|Active Comparator|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
11192637|NCT03435653|Active Comparator|Control group|Control group OFD with DFDBA
11192638|NCT03435653|Experimental|Test group|Test group OFD with decortication and DFDBA
11192639|NCT03435640|Experimental|Doublet: NKTR-262 + bempegaldesleukin|"Phase 1 Doublet: NKTR-262 in escalating doses, will be combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a safe and tolerable RP2D for NKTR-262 in combination with bempegaldesleukin (Every Three Week [Q3W] fixed dose) in select tumor indications.
~Phase 2 Doublet: NKTR-262 RP2D will be combined with a Q3W dose of bempegaldesleukin in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.
~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
11192640|NCT03435640|Experimental|Triplet: NKTR-262 + bempegaldesleukin + Nivolumab|"Phase 1 Triplet: The RP2D of NKTR-262 RP2D will be combined with a Q3W dose regimen of bempegaldesleukin plus nivolumab. The goal is to establish the safety and tolerability of the triplet regimen.
~Phase 2 Triplet: The RP2D of NKTR-262 will be combined with a Q3W dose regimen of bempegaldesleukin plus nivolumab in select tumor indications to evaluate anti-tumor activity and to obtain additional safety data.
~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
11192641|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
11192642|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
11192643|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
11192644|NCT03435601|Experimental|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
11192645|NCT03435601|Placebo Comparator|Placebo|Placebo IV administration Q4W, a total of 6 doses
11192646|NCT03435588|Active Comparator|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
11192647|NCT03435588|Experimental|EUS-FNB alone|EUS-FNB is performed with a 22 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
11192648|NCT03435575|Active Comparator|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
11192649|NCT03435575|No Intervention|Control group|Standard care
11192650|NCT03435562|Experimental|electronic cigarette vs own brand use|Participants will come in for three session. During one session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (the session will be approximately 3 hours). The order of the sessions will be determined randomly and data about session will not be recorded or used in the analysis.
11192651|NCT03435549|No Intervention|Arm 1: Control Arm (Usual care)|If Patient is randomized to Arm 1, no contact will occur, patient will receive standard and routine clinical care
11192652|NCT03435549|Experimental|Arm 2a: Remote monitoring|If Patient is randomized to Arm 2a they will remote monitoring for 6 weeks post-surgery
11192653|NCT03435549|Experimental|Arm 2b: Remote monitoring plus goal setting and social support|If Patient is randomized to Arm 2b, they will receive a remote monitoring plus social support and nudge messaging for 6 weeks post-surgery
11192654|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
11192655|NCT03435523|Experimental|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
11192656|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
11192657|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
11192658|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
11192659|NCT03435484|Active Comparator|Arm A|Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
11192660|NCT03435484|Active Comparator|Arm B|Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
11192661|NCT03435471|Experimental|G1 - Clinician-Directed Therapy|"Clinician-Directed Weekly Swallowing Therapy: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises and review the home swallowing exercise program. Each session will last 30 minutes +/- ten minutes. Other assessments include:
~Clinician-Directed Prophylactic Swallowing Exercises
~Prophylactic Swallowing Home Exercise Program
~Penetration/Aspiration Scale (PAS)
~Functional Oral Intake Scale (FOIS)
~Eating Assessment Tool-10 (EAT-10)
~University of Washington Quality of Life (UW-QOL)
~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)
~DIGEST Safety Grade"
11192662|NCT03435471|Active Comparator|G2 - Patient-Directed Home Therapy|"Patient-Directed Home Swallowing Therapy: One face-to-face meeting with a study speech pathologist prior to initiation of treatment. During that session, they will be encouraged to practice the given exercises independently on a specific daily schedule regime throughout their treatment. Other assessments include:
~Prophylactic Swallowing Home Exercise Program
~Penetration/Aspiration Scale (PAS)
~Functional Oral Intake Scale (FOIS)
~Eating Assessment Tool-10 (EAT-10)
~University of Washington Quality of Life (UW-QOL)
~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)
~DIGEST Safety Grade"
11192663|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
11192664|NCT03435458|Active Comparator|Oral misoprostol alone|
11192665|NCT03435445|Experimental|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
11192666|NCT03435445|Experimental|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
11192667|NCT03435445|Active Comparator|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
11192668|NCT03435432|Active Comparator|Glucose|50 grams of glucose in 50 ml water
11192669|NCT03435432|Placebo Comparator|Water|50 ml water
11192792|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
11220083|NCT03244956|Experimental|patients with BRAFV600E mutation|
11192670|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria & Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.
~These will be tested by diagnostic tests under evaluation:
~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
11192671|NCT03435406||cirrhosis with HPS|Diagnosed as HPS
11192672|NCT03435406||cirrhosis without HPS|Not Diagnosed as HPS
11192673|NCT03435380|Experimental|Control (C)|Targeted mailed educational materials (C).
11192674|NCT03435380|Experimental|Patient activation (PA)|C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.
11192675|NCT03435380|Active Comparator|Patient activation + primary care provider activation (PA+PCP)|C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.
11192676|NCT03435367|Experimental|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for ~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
11192677|NCT03435367|Active Comparator|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for ~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
11192678|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
11192679|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
11192680|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
11192681|NCT03435328|Experimental|TENS intervention|"one group receiving TENS:
~- The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area."
11192682|NCT03435315|Active Comparator|Treadmill exercise|
11192683|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
11192684|NCT03435302|Experimental|Temozolomide Plus Cisplatin|per os 200 mg/m^2/d temozolomide on days 1 to 5 plus i.v. 75 mg/m^2 cisplatin divided into 3 days,which was repeated every 3 weeks for six cycles
11192685|NCT03435302|Active Comparator|High-Dose IFN-a2b|Participants will be treated with i.v. 15×10^6U/m^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10^6U IFN- a2b three times per week for 48 weeks.
11192686|NCT03435289|Other|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
11192687|NCT03435276|Experimental|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
11192688|NCT03435276|Experimental|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
11192689|NCT03435276|Experimental|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
11192690|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
11192691|NCT03435263||home management group A|home management
11192692|NCT03435250|Experimental|AG-270|AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
11192693|NCT03435250|Experimental|AG-270/docetaxel|AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion [IV]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.
11192694|NCT03435250|Experimental|AG-270/nab-paclitaxel/gemcitabine|AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.
11192695|NCT03435185|Active Comparator|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
11192696|NCT03435185|Placebo Comparator|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
11192697|NCT03435172|Experimental|Treatment Group|Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness meshed skin graft (STSG) will be used.
11192698|NCT03435172|No Intervention|Usual Care|Standard care of split thickness meshed skin graft (STSG) will be used.
11192722|NCT03434990|Experimental|Spinal manipulation/myofascial release|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. Myofascial release will be done on paravertebral muscle (Erector spinae, quadratus lumborum) and on gluteus maximus and piriform muscles, the pressure will depend of pain tolerance of each subject. After this procedure, the spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
11192855|NCT03434054|Experimental|Losartan|single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally
11192699|NCT03435159|Experimental|Manual Chiropractic Spinal Manipulation|Demographic informations, pain, previous trauma, diseases, current medicine, past surgical operations, pregnancy, smoking use and cervical artery dissection history in family are questioned. Cervical flexion, extension, right and left rotations, right and left lateral flexions are measured by physiotherapist, in sitting position and with goniometer.Upper extremity muscle strength was measured with manual muscle testing in sitting position by physical therapist. The muscles innervated by C4, C5, C6, C7, C8 and T1 cervical nerves were examined bilaterally. Cervical foraminal compression test was used to eliminate cervical root compression.Vertebrobasilar artery was assessed by premanipulative vertebrobasilar insufficiency test.Neck Disability Index was used to evaluate the functional neck status of the participants. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after manual manipulative intervention.
11192700|NCT03435159|Experimental|Instrumental Chiropractic Spinal Manipulation|The same assessments were applied to determine the eligibility of participants for this study. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after instrumental manipulative intervention.
11192701|NCT03435146|Experimental|Groups 1,2,3 and 4|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.
~3HP plus DTG +2NRTIs
~Group 2: The next 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.
~3HP plus DTG +2NRTIs
~Group 3: The next 25 (Group 3) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.
~IPT plus DTG +2NRTIs
~Group 4: The next 50 (Group 4) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.
~3HP plus DTG +2NRTIs"
11192702|NCT03435133|Active Comparator|Prasugrel|
11192703|NCT03435133|Active Comparator|Ticagrelor|
11192704|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
11192705|NCT03435107|Experimental|Durvalumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were refractory to fluoropyrimidines, irinotecan and oxaliplatin with or without targeted agents will be accrued.
~After checking the eligibility for the study entry, patients will be entered into the study treatment with durvalumab monotherapy."
11192706|NCT03435094||Fosamax®|1 group will be treated with alendronate 70 mg tablets (Fosamax®)
11192707|NCT03435094||Binosto®|1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)
11192708|NCT03435081|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11192709|NCT03435081|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11192710|NCT03435081|Placebo Comparator|Placebo|Placebo administered orally.
11192711|NCT03435068|Experimental|Ceramic rotary bur|For the ceramic bur group(Meisenger gingivectomies, ceramic rotary burs were used with 400-rpm rotary systems and with no serum irrigation, per the manufacturer's recommendation.
11192712|NCT03435068|Experimental|Diode laser|In the laser group (LG), a diode laser was applied to the operation sites in accordance with the manufacturer's guidelines (2.8 W continuous wave mode, wavelength 980 nm). The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power. The laser never made contact with the gingival tissue. The practice distance did not affect the laser spot size, which was 0.5 cm-1 cm. Smoke associated with the laser application was aspirated from the surgical site.
11192713|NCT03435068|Active Comparator|Scalpel|In the scalpel group following the local anesthetic administration, the gingivectomy was performed with a #15 scalpel. Subsequent to the operation, the borderline of gingiva was determined via the use of a pointer dental tweezers, and excessive gingival tissue was then removed with Gracey curettes
11192714|NCT03435055|Experimental|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous fMRI/EEG data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
11192715|NCT03435042|Experimental|Children with cancer + their siblings|
11192716|NCT03435042|Experimental|Parents of children with cancer|
11192717|NCT03435029|Experimental|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
11192718|NCT03435029|Active Comparator|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
11192719|NCT03435016|Other|Diagnosis|
11192720|NCT03435003|Experimental|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.
~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.
~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
11192721|NCT03435003|Active Comparator|Control Arm|"A) Pre-operatively: No intervention
~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.
~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
11192723|NCT03434990|Active Comparator|Spinal manipulation|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. The spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
11192724|NCT03434977|Experimental|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligram (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
11192725|NCT03434977|Experimental|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
11192726|NCT03434951|Experimental|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
11192727|NCT03434951|Active Comparator|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
11192728|NCT03434938|Experimental|MI Intervention|Standard geriatric rehabilitation combined with 4 MI sessions (within 72 hours from admission, within 6 days, at 1 week from the second session and pre-discharge, respectively). MI will be delivered by nurses trained through a certified MI course and additional group coaching sessions will be offered them throughout the study. Quality control of the MI sessions will be carried out using Motivational Interviewing Treatment Integrity (MITI) Code 3.1.1 through random video recording.
11192729|NCT03434938|No Intervention|Standard rehabilitation|Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
11192730|NCT03434899|Experimental|Intervention group|Health care plan including physical exercise and online support during the entire study
11192731|NCT03434899|Active Comparator|Control Group|Health care plan including physical exercise
11192732|NCT03434886|Experimental|CF View|
11192733|NCT03434886|Active Comparator|CF Educational videos|
11192734|NCT03434886|Active Comparator|CF View and videos|
11192735|NCT03434886|No Intervention|Usual standard of care|
11192736|NCT03434873|Active Comparator|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
11192737|NCT03434873|Active Comparator|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
11192738|NCT03434860|Active Comparator|probiotic|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
11192739|NCT03434860|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
11192740|NCT03434847|No Intervention|Control|Standard preoperative assessment
11192741|NCT03434847|Active Comparator|Education|Pre-operative education regarding post-operative pain expectations
11192742|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
11192743|NCT03434782|Experimental|G1- Negative Control|Group with no desensitizing treatment. Prior to bleaching therapy, a water-soluble placebo gel, with non-active agent will be applied to dental vestibular surfaces. After bleaching therapy, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
11192744|NCT03434782|Experimental|G2- LASER (Positive Control)|Group treated with placebo gel before bleaching and with LLLT after in-office bleaching.
11192745|NCT03434782|Experimental|G3- KNO3 (Positive Control)|Group treated with desensitizing gel before bleaching and after in-office bleaching, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
11192746|NCT03434782|Experimental|G4- KNO3 + LASER|Group treated with desensitizing gel before bleaching and with LLLT after in-office bleaching.
11192747|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
11192748|NCT03434756|Experimental|Propioceptive Training|
11192749|NCT03434743|Experimental|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
11192750|NCT03434743|Active Comparator|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
11192751|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
11192752|NCT03434717|Experimental|Control (high distress)|Control group receiving care as usual
11192753|NCT03434717|Experimental|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
11192754|NCT03434717|Experimental|Control group (low distress)|Control group receiving care as usual
11192755|NCT03434704|Experimental|Single Arm Treatment|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis."
11192756|NCT03434691|Experimental|DEX group|continuous infusion of Dexmedetomidine at 0.4 μg/kg per hour and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
11192790|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
11192791|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
11193248|NCT03431233|Experimental|Group 2|protein enriched bar->water->commercial cereal bar
11192757|NCT03434691|Active Comparator|MDZ group|continuous infusion of a Midazolam at 0,1 mg/kg/h and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
11192758|NCT03434678|Experimental|Epidural-General Anesthesia|
11192759|NCT03434678|Active Comparator|General Anesthesia|
11192760|NCT03434665|Other|Recruited patients|Transradial celiac artery angiography
11192761|NCT03434652|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
11192762|NCT03434652|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
11192763|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
11192764|NCT03434639||2a - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
11192765|NCT03434639||2b - Healthy subjects (gastric emptying)|A subset of healthy volunteers will be recruited to take part in experiments to help in understanding the impact of gastric emptying rate as a confounding factor in measurements of gut permeability.
11192766|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
11192767|NCT03434626|Experimental|ACP Education|Eligible patients in the experimental group will receive an educational intervention from an advance care planning navigator consisting of a 4-item values tool, a Goals of Care Designation form and, if applicable, watch a cardiopulmonary resuscitation video.
11192768|NCT03434626|Active Comparator|Usual care|Patients in the usual care group will complete a Goals of Care Designation form with the family physician.
11192769|NCT03434613|Active Comparator|Rosuvastatin monotherapy|Rosuvastatin 5mg 1T daily for 6 months
11192770|NCT03434613|Experimental|Rosuvastatin + ezetimibe combination therapy|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
11192771|NCT03434600|Active Comparator|Oxford|Patients receiving an Oxford UKA, which is the standard treatment for patients with medial osteoarthritis of the knee at our department.
11192772|NCT03434600|Experimental|Sigma|Patients receiving a Sigma UKA, which is the experimental treatment.
11192773|NCT03434587|Experimental|Syndactyly|Syndactyly
11192774|NCT03434587|Active Comparator|Reduction and inmobilization|Closed reduction and splint inmobilization
11192775|NCT03434574|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
11192776|NCT03434574|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
11192777|NCT03434548||Cohort 1|Healthy Controls
11192778|NCT03434548||Cohort 2|Huntington's Disease Gene Expansion Carriers (HDGECs: premanifest near-onset, peri-manifest, and manifest), and Healthy Controls
11192779|NCT03434535|Experimental|Intervention|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months. They will also receive an activity sensor and weight scale. Health state data from this group will be generated over a 3-6 month period and remotely monitored. These data will be used to provide personalized feedback regarding the participant's progress towards established goals.
11192780|NCT03434535|No Intervention|Control|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months.
11192781|NCT03434509|Experimental|Tai Chi|Ongoing, continuous Tai Chi and mindful movement instruction, 1 hour, twice per week
11192782|NCT03434496|Experimental|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
11192783|NCT03434496|Active Comparator|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
11192784|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
11192785|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.
~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .
~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
11192786|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
11192787|NCT03434457||Prenatal and 3 to 72 months|
11192788|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
11192789|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
11226368|NCT03201510||Observational|Observational study
11192793|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
11192794|NCT03434418|Experimental|osimertinib|
11192795|NCT03434405|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
11192796|NCT03434392|Active Comparator|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
11192797|NCT03434392|Active Comparator|Suspected CP|"Suspected Chronic Pancreatitis patients.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
11192798|NCT03434392|Active Comparator|Definite CP|"Definite Chronic Pancreatitis patients.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires.
~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3 and questionnaires."
11192799|NCT03434392|Active Comparator|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.
~Subjects will undergo the following Interventions:
~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
11192800|NCT03434379|Experimental|Atezolizumab + Bevacizumab|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator
11192801|NCT03434379|Active Comparator|Sorafenib|Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator
11192802|NCT03434366|Experimental|ketamine and dexmedetomidine group|intranasal ketamine and dexmedetomidine was treated in the children
11192803|NCT03434366|Experimental|ketamine group|intranasal ketamine was treated in the children
11192804|NCT03434366|Placebo Comparator|control group|intranasal insaline was used in the children
11192805|NCT03434353|Experimental|Group 1 (Inarigivir Soproxil 50 mg + TAF)|Inarigivir Soproxil 50 mg (2 x 25 mg capsule) plus TAF for 12 weeks, followed by TAF for 36 weeks
11192806|NCT03434353|Experimental|Group 2 (TAF)|TAF for 48 weeks
11192807|NCT03434353|Experimental|Group 3 (Inarigivir Soproxil 200 mg + TAF)|Inarigivir Soproxil 200 mg (2 x 100 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks
11192808|NCT03434353|Experimental|Group 4 (Inarigivir Soproxil 100 mg)|Inarigivir Soproxil 100 mg tablet for 12 weeks in virally suppressed participants currently being treated with a commercially available NUC
11192809|NCT03434353|Experimental|Group 5 (Inarigivir Soproxil 200 mg + TAF)|Inarigivir Soproxil 400 mg (2 x 200 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks (Group 5 applies to Hong Kong only)
11192810|NCT03434340|Experimental|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
11192811|NCT03434340|Active Comparator|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
11192812|NCT03434327|Experimental|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
11192813|NCT03434327|Experimental|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
11192814|NCT03434314|Experimental|MISACE arm|"Minimally-Invasive Segmental Artery Coil-Embolization
~MISACE procedure prior to aneurysm repair
~segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)"
11192815|NCT03434314|No Intervention|control arm|receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
11192816|NCT03434301|Active Comparator|Mesh with absorbable tack fixation|Mesh with absorbable tack (ReliaTack™) fixation
11192817|NCT03434301|Active Comparator|Mesh with non-absorbable fixation|Mesh with non-absorbable (Protack™) fixation
11192818|NCT03434288||Diabetic patients with foot osteomyelitis|Biological and MRI signs of foot osteomyelitis
11192819|NCT03434275|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
11192820|NCT03434275|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
11192821|NCT03434262|Experimental|A: ribociclib + gemcitabine|Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.
11192856|NCT03434054|Placebo Comparator|Placebo|single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally
11226958|NCT03198078|Placebo Comparator|Placebo|Matching placebo, daily
11192822|NCT03434262|Experimental|B: ribociclib + trametinib|Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.
11192823|NCT03434262|Experimental|C: ribociclib + sonidegib|Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.
11192824|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
11192825|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
11192826|NCT03434236|Placebo Comparator|Placebo|Patients will be taking placebo twice daily for 5 days prior to surgery. The placebo has a similar taste and smell as the active supplement.
11192827|NCT03434236|Experimental|low dose Lipinova (30mL)|Patients will take 15 mL Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
11192828|NCT03434236|Experimental|high dose Lipinova (60mL)|Patients will take 30mL of Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
11192829|NCT03434223||Single Cohort|
11192830|NCT03434210|Experimental|LAT-treated Community Model|The subjects in experimental group are on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
11192831|NCT03434210|Other|Care as usual|"The subjects in control group are on  cared as usual Which means Patients will be managed follow the request of National Continuing Management and Intervention Program for Psychoses. Patients will managed by community mental health professionals, get education information and rehablitation guidence from them."
11192832|NCT03434197|Experimental|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
11192833|NCT03434197|Active Comparator|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
11192834|NCT03434171|Active Comparator|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
11192835|NCT03434171|Active Comparator|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
11192836|NCT03434158|Experimental|Olaparib|600 mg/day
11192837|NCT03434145||patients with chronic kidney diseases|patients with end stage retinal disease undergoing hemodialysis underwent various ophthalmologic exams before and after hemodialysis.
11192838|NCT03434132|Active Comparator|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
11192839|NCT03434132|Experimental|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
11192840|NCT03434119|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine/lixisenatide) once daily in the morning within 1 hour before breakfast, on top of oral anti-diabetic drug (OAD) therapy for 26 weeks.
11192841|NCT03434119|Active Comparator|Lantus|Lantus (Insulin glargine) once daily at any time of the day but at about the same time every day on top of OAD therapy for 26 weeks.
11192842|NCT03434106|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
11192843|NCT03434106|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
11192844|NCT03434106|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
11192845|NCT03434106|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
11192846|NCT03434093|Active Comparator|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
11192847|NCT03434093|Active Comparator|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
11192848|NCT03434080||Autism Spectrum Disorder|The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)
11192849|NCT03434080||Cerebral Palsy|The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)
11192850|NCT03434080||Typical Development toddlers infants|The control group will consist of 50 healthy volunteers with TD
11192851|NCT03434067||Primary hyperthyroidism|Patients diagnosed with primary hyperparathyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
11192852|NCT03434067||Secondary hyperthyroidism|Patients diagnosed with Secondary hyperthyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
11192853|NCT03434067||Unilateral thyroidectomy|Patients diagnosed with unilateral thyroid benign tumor were prepared for unilateral thyroidectomy. PTH test paper is used addtional at postoperation
11192854|NCT03434067||thyroidectomy and bilateral CCD|Patients diagnosed with bilateral thyroid carcinoma were prepared to undergo total thyroidectomy and bilateral central clearing.PTH test paper is used addtional at postoperation
11193249|NCT03431233|Experimental|Group 3|commercial cereal bar->protein enriched bar->water
11192857|NCT03434041|Experimental|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
11192858|NCT03434041|Active Comparator|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
11192859|NCT03434028|Other|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
11192860|NCT03434028|Other|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
11192861|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.
~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
11192862|NCT03434002|Experimental|Arm-A|Randomized 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation
11192863|NCT03434002|Experimental|Arm-B|Randomized other 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation
11192864|NCT03433989|Experimental|Diagnosis and follow up arm|
11192865|NCT03433976|Other|Hyperbaric Bupivacaine|spinal anesthesia for planned cesarean sections control group
11192866|NCT03433976|Active Comparator|Hyperbaric Prilocaïne|spinal anesthesia for planned cesarean sections
11192867|NCT03433963|Experimental|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
11192868|NCT03433963|Placebo Comparator|Control group|Study participants in the group will take placebo during the trial.
11192869|NCT03433950||Fluctuator|Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
11192870|NCT03433937|Experimental|Negative pressure wound therapy|
11192871|NCT03433937|Active Comparator|Control|Micropore tape
11192872|NCT03433911|Experimental|FemBloc|Investigational device and procedure
11192873|NCT03433911|Active Comparator|Control|Laparoscopic bilateral tubal sterilization
11192874|NCT03433898|Experimental|Part 1|
11192875|NCT03433898|Experimental|Part 2|
11192876|NCT03433898|Experimental|Part 3|
11192877|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
11192878|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
11192879|NCT03433872|Other|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
11192880|NCT03433859|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
11192881|NCT03433859|Active Comparator|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
11192882|NCT03433846||Preterm Infants|Blood and stool samples will be obtained from preterm and former preterm infants at birth and then monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period. .
11192883|NCT03433846||Term Infants|Blood and stool samples will be obtained from term control infants admitted to the NICU with non-immune or infectious problems monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
11192884|NCT03433846||Healthy Adults|A 3-5ml blood sample and a small volume 0.5ml sample will be obtained.
11192885|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
11192886|NCT03433820|Experimental|randomized repeated biopsy|"The study will entail 1 cohort with a randomized repeated biopsy collection time. Three skin punch biopsies (3 mm) of the lower back will be taken from each volunteer on day 0. One biopsy sample taken on day 0 will serve as a baseline measurement for the repeated samples regarding the histology, immunohistochemistry, and RNA sequencing (RNA-seq) or real-time reverse transcription polymerase chain reaction (qRT-PCR) assessments.
~Repeated biopsies of the same location as on day 0 will be taken on day 7, 14 or 21 (biopsy lesion and day randomized), and day 28, 42 or 56 (biopsy lesion and day randomized) for all subjects. The observation biopsy (biopsy lesion randomized) will serve as primary biopsy and followed for all measurements."
11192913|NCT03433625|No Intervention|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
11192887|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
11192888|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
11192889|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
11192890|NCT03433781|Experimental|Absorbic Acid|All patients will receive at least 1 cycle of treatment (4 weeks). Patients with clinical benefit (CR,PR, or SD) then will undergo a second 4-week cycle of treatment.
11192891|NCT03433768||poor responders|
11192892|NCT03433768||normal responders|
11192893|NCT03433755|Active Comparator|Evolocumab 140 mg SC Q2W|Approximately 150 Subjects
11192894|NCT03433755|Active Comparator|Evolocumab 420 mg SC QM|Approximately 150 Subjects
11192895|NCT03433755|Placebo Comparator|Placebo SC Q2W|Approximately 75 Subjects
11192896|NCT03433755|Placebo Comparator|Placebo SC QM|Approximately 75 Subjects
11192897|NCT03433742|Other|Preoperative Group|This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
11192898|NCT03433742|Other|1 year Postoperative Group|This is the same group of 30 patients who are now one year post op after having a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at their one year visit.
11192899|NCT03433729|Experimental|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
11192900|NCT03433729|No Intervention|Usual care|Patients' appointment continues as usual.
11192901|NCT03433716|Experimental|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
11192902|NCT03433716|No Intervention|Control group|the subects of the control group received no any treatment
11192903|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
11192904|NCT03433690|Experimental|High Intensity Interval Training|Twelve weeks of High Intensity Interval Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
11192905|NCT03433690|Active Comparator|Moderate training|Twelve weeks of Moderate Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
11192906|NCT03433677|Experimental|LY900014|100 units per milliliter (U/mL) LY900014 administered by individualized, continuous, subcutaneous insulin infusion (CSII)
11192907|NCT03433677|Experimental|Insulin Lispro|100 U/mL insulin lispro (Humalog®) administered by individualized CSII
11192908|NCT03433664|Experimental|Treatment|Each treatment half of the scar received three standardised CO2 laser treatments using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping. Post-operatively all laser treatment and control zones had emollient applied and silicone dressings which were removed at 48 hours. Further emollient was applied twice daily for 2 weeks to all areas of the scar. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
11192909|NCT03433664|No Intervention|Control|Each control half of the scar received emollient applied twice daily for 2 weeks to all areas of the scar after each treatment. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
11192910|NCT03433651|Experimental|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
11192911|NCT03433651|Placebo Comparator|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
11192912|NCT03433625|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
11192914|NCT03433612|Other|All Patients|"Estimates of the location of the L4-L5 intervertebral space will be done by the classic intercristal line technique and novel SAIL technique. Each technique will be performed by different randomly assigned investigators.
~* Both techiques will be assessed on all patients"
11192915|NCT03433599|Experimental|dAIH + Rapael Glove|Participants will receive daily acute Intermittent Hypoxia (dAIH) and training with an Exoskeleton Rapael glove.
11192916|NCT03433599|Active Comparator|dAIH + training by research staff|Participants will receive daily acute Intermittent Hypoxia (dAIH) and training by research staff.
11192917|NCT03433599|Active Comparator|dAIH + no training|Participants will receive daily acute Intermittent Hypoxia (dAIH) and no training.
11192918|NCT03433599|Sham Comparator|Room Air + Rapael Glove|Participants will receive normal room air and training with an Exoskeleton Rapael glove.
11192919|NCT03433599|Sham Comparator|Room Air + training by staff|Participants will receive normal room air and training by research staff.
11192920|NCT03433599|Sham Comparator|Room air + no training|Participants will receive normal room air and no training.
11192921|NCT03433586|Placebo Comparator|Placebo|Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days
11192922|NCT03433586|Active Comparator|Aspirin|Aspirin (81mg) will be taken orally daily for 10-14 days.
11192923|NCT03433573|Experimental|Intervention|Abbott Sensor Based Glucose Monitoring System
11192924|NCT03433560||Korean female breast cancer patients|
11192925|NCT03433547|Experimental|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
11192926|NCT03433547|Active Comparator|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
11192927|NCT03433534||Pharmacokinetic of Nivolumab|Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
11192928|NCT03433508|Experimental|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
11192929|NCT03433508|Active Comparator|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
11192930|NCT03433495|Active Comparator|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
11192931|NCT03433495|No Intervention|Waiting list|No intervention
11192932|NCT03433482|Experimental|GSK3536820A ACWY_Liq24 Group|Approximately 417 healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
11192933|NCT03433482|Active Comparator|ACWY_1 Group|Approximately 417 healthy subjects receiving a single dose of the licensed GSK' MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
11192934|NCT03433482|Experimental|GSK3536820A ACWY_Liq30 Group|Approximately 417 healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
11192935|NCT03433482|Active Comparator|ACWY_2 Group|Approximately 417 healthy subjects receiving a single dose of the licensed GSK' MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
11192936|NCT03433469|Experimental|Treatment (osimertinib)|Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.
11192937|NCT03433456|Experimental|Home visitation + HABITS Program|The HABITS module will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children. Participants will receive the HABITS module in addition to their standard home visitation services.
11192938|NCT03433456|Active Comparator|Standard home visitation program|Participants will receive the standard of care home visitation regularly delivered through the existing home visitation program without the HABITS module.
11192939|NCT03433443|Active Comparator|Control group|Usual physical rehabilitation group
11192940|NCT03433443|Experimental|Intervention group|Case manager assisted rehabilitation
11192941|NCT03433430|Other|truSculpt|truSculpt treatment
11192942|NCT03433417|Other|Cutera truSculpt|One truSculpt treatment
11192943|NCT03433404|Experimental|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
11192944|NCT03433404|Active Comparator|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
11192945|NCT03433404|No Intervention|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
11192946|NCT03433391|Other|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
11192947|NCT03433391|Other|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
11192948|NCT03433378|Active Comparator|Tretinoin cream, 0.05%|Apply once a day application, under at-home use conditions.
11192949|NCT03433378|Active Comparator|RETIN-A® (tretinoin) cream, 0.05%|Apply once a day application, under at-home use conditions.
11192950|NCT03433378|Placebo Comparator|Vehicle of the test product|Apply once a day application, under at-home use conditions.
11192951|NCT03433365||1|Potential study subjects will sign an informed consent prior undergoing any study related procedure. Patients enrolled in this study will receive Lenalidomide-based regimen as maintenance therapy according to their previous decided therapeutic schedule. All consecutive patients treated with Lenalidomide-based regimen as maintenance therapy and with inclusion criteria will be asked to participate to this study.
11192952|NCT03433352||Control group|30 healthy volunteers were included in the healthy control group
11192953|NCT03433352||Recrudescence group|30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
11192954|NCT03433352||No recrudescence group|30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
11192955|NCT03433339|Experimental|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5mA for 20 min/ three times per week for 8 weeks.
11192956|NCT03433339|Sham Comparator|Sham Treatment|Thoracic anodal transcutaneous spinal direct current sham stimulation session of 20min/ three times per week for 8 weeks.
11192957|NCT03433313|Experimental|EG12014|Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
11192958|NCT03433313|Active Comparator|Herceptin|Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
11192959|NCT03433300|Experimental|Microprocessor Knee|Ottobock Kenevo/Ottobock C-Leg
11192960|NCT03433300|Active Comparator|Nonmicroprocessor knee|Ottobock 3R60 for K3 participants, Ottobock 3R62 for K2 participants.
11192961|NCT03433287|Experimental|18F-NaF-PET/MRI|Eligible patients who give informed consent will be offered a NaF -PET/MRI scan
11192962|NCT03433274|Experimental|Randomized Cohort - Treatment Group|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
11192963|NCT03433274|Active Comparator|Randomized Cohort - Control Group|Treatment of mitral regurgitation within commercially approved MitraClip system indications
11192964|NCT03433274|Experimental|Non-Randomized Cohort|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
11192965|NCT03433274|Experimental|Mitral Annular Calcification (MAC) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Mitral Valve System
11192966|NCT03433261|No Intervention|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
11192967|NCT03433261|Experimental|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
11192968|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
11192969|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
11192970|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
11192971|NCT03433235|Experimental|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
11192972|NCT03433235|Active Comparator|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
11192973|NCT03433222|Experimental|HF-LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
11192974|NCT03433222|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
11192975|NCT03433209|Active Comparator|Ligasure device|This group of women undergoing hysterectomy were randomized to the Ligasure energy device
11192976|NCT03433209|Active Comparator|Articulating Enseal|This group of women undergoing hysterectomy were randomized to the articulating Enseal energy device
11192977|NCT03433196|Experimental|HS-25 and Atorvastatin|HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
11192978|NCT03433196|Active Comparator|Atorvastatin|Atorvastatin 20mg, Placebo of HS-25 2 tablets
11192979|NCT03433183|Experimental|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
11192980|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
11192981|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
11192982|NCT03433157|Experimental|Hall technique|SSCs placed on primary teeth using Hall technique
11192983|NCT03433157|Active Comparator|Traditional technique|SSCs placed on primary teeth using Traditional technique
11192984|NCT03433144|Experimental|Intervention TXA|patients receiving TXA10mg/kg IV pre-operatively
11192985|NCT03433144|Placebo Comparator|Placebo|patients will receive an equivalent amount of normal saline 0.9% IV pre-operatively
11192986|NCT03433118|Experimental|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers to patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
11192987|NCT03433118|No Intervention|Standard care|Standard care for patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
11192988|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
11192999|NCT03433079||Acute Kidney Injury|Patients > 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
11193000|NCT03433066|Experimental|group I (Test)|Advanced platelet-rich fibrin mixed with biphasic alloplast
11193001|NCT03433066|Active Comparator|Group II (control)|Biphasic alloplast mixed with saline
11193002|NCT03433053|Placebo Comparator|Control|Participants will be exposed to a generic HIV testing message.
11193003|NCT03433053|Experimental|Experiment|Participants will be exposed to a targeted HIV testing message, developed specifically for African American women.
11193004|NCT03433040|Other|non obese|250mg 17 OHP-C
11193005|NCT03433040|Other|obese - control|250mg 17 OHP-C
11193006|NCT03433040|Experimental|obese|500mg 17 OHP-C
11193007|NCT03433027|Experimental|BB-401|BB-401 Intratumoral injection
11193008|NCT03433014|Active Comparator|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
11193009|NCT03433014|Other|Control|The control group will not receive any local infiltrative agent.
11193010|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants will take ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone will not be defined by the protocol but according to the package insert of each drug.
11193011|NCT03432988|Experimental|nurses in the hemodialysis service|Nursing Solution-Focused: Two two-hour training modules were designed by two recognized solution-focused therapy experts. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays.
11193012|NCT03432975|Experimental|Povidone Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine.
11193013|NCT03432975|Placebo Comparator|Sterile saline solution|The other side of the mouth will be irrigated with a sterile saline solution.
11193014|NCT03432962||Food code group|The participants freely selected foods from the online dietary assessment tool to record what they had eaten over the last 24h. They then provided information on brand details. The recalls were recoded to take into account all branded items and then recoded again to take represent all generic (ie. no brands) foods.
11193015|NCT03432949|No Intervention|Standard of Care Radium-223|Radium-223 treatment will be administered as per standard of care.
11193016|NCT03432949|Experimental|Radium-223 with oral Dexamethasone 0.5 mg|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
11193017|NCT03432936|Experimental|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
11193018|NCT03432923|Experimental|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
11193019|NCT03432923|Placebo Comparator|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
11193020|NCT03432910|Other|treatment group|Participants of the study undergo the standard stages of the clinical routine within a PAP therapy setting: a diagnostic night followed by one or two treatment nights.
11193021|NCT03432897|Experimental|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.
~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
11193022|NCT03432884|Experimental|Part A: BGB-3111|
11193023|NCT03432884|Placebo Comparator|Part A: Placebo|
11193024|NCT03432884|Experimental|Part B: BGB-3111, Placebo, and Moxifloxicin|
11193025|NCT03432871|Experimental|Nicotinamide Riboside|"This is an open-label experimental medicine study.
~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
11193026|NCT03432858|Active Comparator|Vancomycin|
11193027|NCT03432858|Active Comparator|Cefazolin|
11193028|NCT03432858|Placebo Comparator|Saline|
11193029|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
11193030|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
11193031|NCT03432832|Experimental|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions focused on mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement and practice sessions in the youth's community. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community."
11193032|NCT03432832|Active Comparator|Supportive Therapy|Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The intervention will not involve mindfulness or other emotion regulation strategies used in EASE. The therapy will be tailored to the individual's needs and will include aspects common in supportive therapy such as reflective listening, antecedent management, and problem-solving. This program does not have an online component.
11193033|NCT03432819|Experimental|Siempre Seguiré|We will conduct a small RCT, testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
11193034|NCT03432819|No Intervention|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
11193035|NCT03432806||presumptive Stage II or III colon cancer|
11193036|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
11193037|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
11193038|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
11193039|NCT03432793|Experimental|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
11193040|NCT03432793|Experimental|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
11193041|NCT03432780|Experimental|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
11193042|NCT03432780|Active Comparator|Hormone and radiation therapy|Radiation therapy and hormone therapy
11193043|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
11193044|NCT03432754|Experimental|Mindfulness-Based Attention Training|Four weekly group mindfulness attention training sessions of a 1.5-hour duration. Participants provided with audio recordings, readings, and homework assignments consisting of various mindfulness practices.
11193045|NCT03432754|Active Comparator|Lifestyle Education Group|Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
11193046|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal disease undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging FDG-PET, photography, and biopsy.
11193047|NCT03432728||S-ECC|Children in their fifth year of life with severe early childhood caries Children selected will require complete dental rehabilitation under general anesthesia All enrolled children will receive treatment of all dental carious lesions under general anesthesia
11193048|NCT03432728||Control|Children age and sex matched with the S-ECC group who are free of dental caries
11193049|NCT03432715|Experimental|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
11193050|NCT03432715|Experimental|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
11193051|NCT03432715|No Intervention|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
11193052|NCT03432702|Active Comparator|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
11193053|NCT03432702|Experimental|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
11193054|NCT03432689|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
11193055|NCT03432689|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
11193056|NCT03432676|Experimental|Treatment (pembrolizumab, epacadostat)|Participants receive pembrolizumab IV over 30 minutes on day 1 and epacadostat PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unaccepted toxicity.
11193057|NCT03432663|Experimental|24h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)
11193058|NCT03432663|Experimental|72h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)
11193059|NCT03432650|Experimental|QLB Block + Standard of Care|"Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
~Patients will receive a single shot anterior QLB (30cc 0.5% Bupivacaine with 2mg preservative free dexamethasone)."
11193060|NCT03432650|No Intervention|Standard of Care|Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
11193061|NCT03432637|Experimental|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
11193062|NCT03432637|Active Comparator|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
11193063|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
11193064|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
11193250|NCT03431233|Experimental|Group 4|commercial cereal bar->water->protein enriched bar
11193065|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
11193066|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
11193067|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
11193068|NCT03432611|Experimental|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
11193069|NCT03432611|Active Comparator|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
11193070|NCT03432611|Active Comparator|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
11193071|NCT03432598|Experimental|Non-squamous NSCLC|"Day 1 of each 21-day (3 weeks) cycle: Tislelizumab + pemetrexed + cisplatin 75 mg/m²/day IV (or carboplatin AUC 5).
~Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted."
11193072|NCT03432598|Experimental|Squamous NSCLC Cohort A|"Tislelizumab every 3 weeks (Q3W) + paclitaxel + cisplatin (or carboplatin), Q3W.
~Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
11193073|NCT03432598|Experimental|Squamous NSCLC Cohort B|"Tislelizumab Q3W on Day 1 + gemcitabine on Day 1 and Day 8 + cisplatin IV (or carboplatin) on Day 1.
~Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
11193074|NCT03432598|Experimental|SCLC|"Tislelizumab Q3W on Day 1, etoposide on Days 1, 2, and 3 + cisplatin (or carboplatin) on Day 1.
~Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles.
~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
11193075|NCT03432585||Family Support Grant applicants|Participants include applicants for the Family Support Grants that will be provided for the American Society for Nutrition annual meeting who are willing to complete the applicant survey.
11193076|NCT03432572|Experimental|pyridium|Group A will take 200 mg of oral Pyridium 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
11193077|NCT03432572|Active Comparator|riboflavin|Group B will take 400 mg of riboflavin 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
11193078|NCT03432572|Placebo Comparator|thiamine|Group C will take the placebo (50 mg of thiamine) 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
11193079|NCT03432559|Other|endoscopy|endoscopy of the upper GI tract
11193080|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
11193081|NCT03432533|Active Comparator|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
11193082|NCT03432533|Active Comparator|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
11193083|NCT03432507||disc herniation|patients suffering from disc herniation
11193084|NCT03432507||spinal stenosis|patients suffering from spinal stenosis
11193085|NCT03432494|Experimental|Study Arm 1|Subjects undergoing transcaval access for TAVR
11193086|NCT03432481|Experimental|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
11193087|NCT03432468|Active Comparator|postmenopausal hypertensive women|
11193088|NCT03432468|Placebo Comparator|age-matched hypertensive male patients|
11193089|NCT03432442|Experimental|Group 1 (6 dengue patients)|Volunteers weighed > 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
11193090|NCT03432442|Experimental|Group 2 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
11193091|NCT03432442|Experimental|Group 3 (6 dengue patients)|Volunteers weighed > 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
11193092|NCT03432442|Experimental|Group 4 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
11193093|NCT03432416|Experimental|Regimen 1: Continuous Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.
11193094|NCT03432416|Experimental|Regimen 2: Cyclical Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).
11193095|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
11193096|NCT03432390|Experimental|CPAP|
11193097|NCT03432390|Active Comparator|Control|
11193098|NCT03432364|Experimental|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
11193099|NCT03432351||Children: 0-36mo|EEG sensor will be placed on the subject's forehead to observe and record EEG activity. No other applicable intervention.
11193100|NCT03432338||idiopathic parkinson|Classical Parkinson´s disease, idiopathic
11193101|NCT03432338||secondary parkinsonism|parkinsonism due to other reasons than idiopathic
11193102|NCT03432338||controls|persona matched by age and gender, non parkinsonism
11193103|NCT03432325|Experimental|Neural Enabled Prosthesis|Neural Enabled Prosthesis Treatment Group
11193107|NCT03432286|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.
~Participants may be eligible for optional open-label extension at the end of the double-blind period."
11193108|NCT03432286|Placebo Comparator|Placebo|"Placebo administered by SQ injection.
~Participants may be eligible for optional open-label extension at the end of the double-blind period."
11193109|NCT03432273|Experimental|Nicotine 2 mg mint lozenges|
11193110|NCT03432273|Active Comparator|NiQuitin 2 mg mint lozenges|
11193111|NCT03432260|Experimental|DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
11193112|NCT03432260|Experimental|DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
11193113|NCT03432260|Experimental|DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
11193114|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
11193115|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
11193116|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
11193117|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
11193118|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
11193119|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
11193120|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
11193121|NCT03432208|Active Comparator|ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)|GI consult Procedure performed is EGD
11193122|NCT03432208|Experimental|ENDOSCOPIC ULTRASOUND (EUS)|GI consult Procedure performed is EUS
11193123|NCT03432195|Experimental|Donepezil TDS Back|Corplex Donepezil TDS 10 mg/day applied to the Back for 1 week (7 days)
11193124|NCT03432195|Experimental|Donepezil TDS Buttock|Corplex Donepezil TDS 10 mg/day applied to the Buttock for 1 week (7 days)
11193125|NCT03432195|Experimental|Donepezil TDS Leg|Corplex Donepezil TDS 10 mg/day applied to the Leg for 1 week (7 days)
11193126|NCT03432182|Other|very premature infants|Electroencephalography allowing sleep observation
11193127|NCT03432169|Active Comparator|Yoga|Stretching with mindfulness
11193128|NCT03432169|Active Comparator|Stretching|Stretching exercises without mindfulness
11193129|NCT03432156|Experimental|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
11193130|NCT03432156|No Intervention|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
11193131|NCT03432143|Experimental|Community Reviewers|24 community members will receive training and mentoring in reviewing manuscripts. Approximately 284 manuscripts will be randomized into the intervention group over the duration of the study. Manuscripts will be reviewed by both a community member and scientific reviewers.
11193132|NCT03432143|No Intervention|Scientific Reviewers Only|Approximately 284 manuscripts will be randomized into the control group over the duration of the study. Manuscripts will be reviewed by multiple scientific reviewers. Community reviewers will not be involved in reviewing these manuscripts.
11193133|NCT03432130|Experimental|Experimental group|Performing a structural training program twice a week, 30 minutes each.
11193134|NCT03432130|No Intervention|Control group|
11193135|NCT03432117|Experimental|Fixed respiratory rehabilitation program(A)|respiratory rehabilitation program for 12 weeks
11193136|NCT03432117|Experimental|Mixed respiratory rehabilitation program(B)|Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks
11193137|NCT03432117|No Intervention|Control(C)|Ordinary rehabilitation service of the site for 12 weeks
11193138|NCT03432104|Experimental|Verum|This arm receives 1 x 450 mg-capsule of Oxxynea®, a blend of polyphenol-rich fruit and vegetable extracts
11193139|NCT03432104|Placebo Comparator|Placebo|This arms receives 1 x 450 mg-capsule of Placebo, containing maltodextrin only
11193140|NCT03432078|Active Comparator|Individual hypnotherapy|Treatment given on a individual basis, face to face.
11193141|NCT03432078|Active Comparator|Group hypnotherapy|Treatment given in a group setting, face to face.
11193142|NCT03432065|Experimental|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
11193143|NCT03432039|Placebo Comparator|Psychoeducation arm|This arm will provide information about admission procedures, story telling and a follow-up phone call
11193144|NCT03432039|Experimental|Behavioral intervention|This arm will provide information about what invasive procedures maybe given to the child, the emotional and behavioral reactions of the child while on the ward, games and stories that the child can engage with the mother and a follow-up phone call
11193145|NCT03432026||Non-smoker COPD patients|stable non-smoker COPD patients diagnosed by a previous spiromtery to have FEV1/FVC less than 70
11193146|NCT03432013|Active Comparator|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
11193147|NCT03432013|Experimental|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
11193148|NCT03432000|Experimental|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
11193149|NCT03432000|Sham Comparator|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
11193150|NCT03431987||Marijuana Users|
11193151|NCT03431974|Experimental|Aminopterin oral capsule|LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
11193152|NCT03431974|Placebo Comparator|Placebo oral capsule|Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
11193154|NCT03431961|Experimental|Intranasal Corticosteroid|Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
11193155|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
11193156|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
11193157|NCT03431922|Experimental|endovascular denervation|endovascular denervation
11193158|NCT03431909|Experimental|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
11193159|NCT03431909|Sham Comparator|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
11193160|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.
~Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development
~Describe the levels longitudinally
~Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
11193161|NCT03431870|Other|Aorta dilated|Patients with aorta of 40mm or more who undergo a cardiac surgery. The intervention include: Trans-Esophageal Echocardiography
11193162|NCT03431857||Anatomic TESS V2 shoulder|Subjects who meet the inclusion/exclusion criteria and who received the Anatomic TESS V2 shoulder prosthesis .
11193163|NCT03431857||Reverse TESS V2 shoulder|Subjects who meet the inclusion/exclusion criteria and who received the ReverseTESS V2 shoulder prosthesis .
11193164|NCT03431831|Active Comparator|Intervention Control|All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
11193165|NCT03431831|Experimental|Counselling|These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
11193166|NCT03431831|Experimental|Contrave|These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
11193167|NCT03431831|Experimental|Contrave and counseling|These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
11193168|NCT03431805|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
11193169|NCT03431805|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
11193170|NCT03431792|Experimental|Long-Tail-FETO|"Fetus with severe CDH and o/e TFLV Ratio of < 25% or < 35% with liver herniation. The Long tail FETO will performed between 26 and 30 weeks of gestation.
~The MRI control will be perfirmed ar 32-34 weeks of gestation. Long Tail FETO: fetal i.m. application of 0.1 mg/kg Pancuronium, 1 µg/kg Fentanyl® and 0.01 mg/kg atropine. (Long-Tail Goldbal 5, 2,5 ml, BALT Extrusion, Montmorency, France). The fetoscope (Karl Storz, Tuttlingen, Germany) with a diameter of 1.3 mm, will be percutaneously inserted through a sheath into the uterus and then into the fetal trachea. The fetoscope will be removed and the balloon will be inserted under 4-D ultrasound guidance into the fetal trachea. The position of the balloon and suture will be visualized using the fetoscopy.
~The Long tail ballon will be removed by a second FETO after 34 weeks' gestation or bei the fetus itself with or without of the long tail balloon puncture with 22 gauge needle. The EXIT procedure is also possible."
11193171|NCT03431779|Experimental|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
11193172|NCT03431779|Active Comparator|Surgical excision|Excision of painful areas
11193173|NCT03431766|Placebo Comparator|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
11193174|NCT03431766|Experimental|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
11193175|NCT03431753|Experimental|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
11193176|NCT03431714|Experimental|single arm|Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight
11193177|NCT03431701|Experimental|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
11193178|NCT03431701|Active Comparator|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
11193179|NCT03431688|Active Comparator|PAM|treatment with PPI, metonidazole, amoxicillin
11193180|NCT03431688|Active Comparator|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
11193181|NCT03431675|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
11193182|NCT03431675|Active Comparator|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
11193251|NCT03431233|Experimental|Group 5|water->protein enriched bar->commercial cereal bar
11193252|NCT03431233|Experimental|Group 6|water->commercial cereal bar->protein enriched bar
11193253|NCT03431220|Experimental|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
11193183|NCT03431675|Active Comparator|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
11193184|NCT03431662|Experimental|Ellipse IM HTO Nail|In this arm, the subjects varus malalignment is corrected with Ellipse Intramedullary High Tibial Osteotomy Intramedullary Nail, which is a CE device. The device achieves the correction via progressive distraction osteogenesis.
11193185|NCT03431662|Active Comparator|TomoFix|In this arm, the subjects varus malalignment is corrected with Synthes TomoFix system, which is a CE device. The device achieves the correction via fixating an accute intraoperative correction of the varus malalignment.
11193186|NCT03431649|Experimental|Beraprost Sodium|"Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.
~22 patients"
11193187|NCT03431649|Active Comparator|Sildenafil citrate|"Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.
~20 patients"
11193188|NCT03431636|Experimental|Immersion in cold water|"The athlete will remain submerged in a Cryo Control - Ice Bath Systems® bathtub, which allows filtration and maintenance of constant water temperature, and shoulder blade water (Getto and Golden, 2013) for 15 minutes in the 15 degrees Celsius (Machado et al, 2016)."
11193189|NCT03431636|Active Comparator|Ice pack|The athlete will remain for 20 minutes with plastic packets of 500 grams of ice each, in the region of the evaluated muscles.
11193190|NCT03431636|Sham Comparator|Control|Group in which the athlete will be instructed to remain seated in a comfortable position, at rest, for 20 minutes.
11193191|NCT03431623|Experimental|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
11193192|NCT03431623|Active Comparator|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
11193193|NCT03431610|Experimental|SB414 2%|SB414 2% topically twice daily
11193194|NCT03431610|Experimental|SB414 6%|SB414 6% topically twice daily
11193195|NCT03431610|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
11193196|NCT03431597|Experimental|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
11193197|NCT03431597|Active Comparator|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
11193198|NCT03431597|No Intervention|control|no treatment will be given to this group observation only (no placebo)
11193199|NCT03431584|Active Comparator|Infiltration of corticosteroids|
11193200|NCT03431584|Experimental|Infiltration of corticosteroids and hyaluronic acid|
11193201|NCT03431571|Other|Single arm|ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group
11193202|NCT03431558|Experimental|Group 1|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).
~Duration: 1 month"
11193203|NCT03431558|Experimental|Group 2|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 300mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).
~Duration: 1 month"
11193204|NCT03431558|Placebo Comparator|Group 3|"Placebo: Only Glucan-D (99.4% glucoseDose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).
~Duration: 1 month"
11193205|NCT03431545|Experimental|PALS and BEECH|Play and Learning Strategies (PALS) and Beginning Education: Early Childcare at Home (BEECH) include web-based parent and teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.
11193206|NCT03431545|Active Comparator|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
11193207|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
11193208|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
11193209|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
11193210|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
11193211|NCT03431506|Active Comparator|non-training group|
11193212|NCT03431506|Experimental|training group|
11193213|NCT03431493|Experimental|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
11193214|NCT03431493|No Intervention|Usual Care Control|Usual Care Control
11193215|NCT03431480|Experimental|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
11193216|NCT03431467|No Intervention|Control|VA-ECMO alone per standard clinical protocol.
11193217|NCT03431467|Experimental|Experimental|VA-ECMO with early institution of Impella CP LV venting
11193218|NCT03431454|Active Comparator|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
11193219|NCT03431454|Active Comparator|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
11227351|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
11193220|NCT03431454|Active Comparator|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
11193221|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
11193222|NCT03431428|Experimental|transanal surgery|"To ensure the complete cutting edge with no residual tumor, the tumor with corresponding mesorectal excision was removed by the distance edge of 1cm.
~The intestinal wall was sutured to ensure the integrity of the bowel."
11193223|NCT03431428|Placebo Comparator|Miles surgery|According to the total mesorectal excision(TME) principle, complete mesorectum, lymph node and the anus was excised. A sigmoid colostomy was finally performed.
11193224|NCT03431415|Active Comparator|Surgery|Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
11193225|NCT03431415|Active Comparator|SBRT (Stereotactic Body Radiation Therapy)|Patients that will undergo SBRT as primary lung cancer treatment
11193226|NCT03431402|Other|Acute stroke receive hyperbaric oxygen|
11193227|NCT03431402|No Intervention|Acute stroke receive only conventional treatment|
11193228|NCT03431389|Active Comparator|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
11193229|NCT03431389|Active Comparator|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
11193230|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
11193231|NCT03431350|Experimental|Combination 1:Dose Selection: Niraparib + cetrelimab(Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2.
11193232|NCT03431350|Experimental|Combination 1:Dose Expansion: Niraparib + cetrelimab(Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol.
11193233|NCT03431350|Experimental|Combination 3: Niraparib + AA + prednisone|Participants will be assigned to one of the three cohorts to receive niraparib plus AA and prednisone as oral tablets.
11193234|NCT03431337|Experimental|High dose|Amoxicillin/clavulanate 875mg/125mg & amoxicillin 875 mg twice a day x 7 days
11193235|NCT03431337|Active Comparator|Standard dose|Amoxicillin/clavulanate 875 mg/125mg & placebo (lactase) twice a day x 7 days.
11193236|NCT03431324|Experimental|Mating-EFT Intervention Effectiveness|"Study 1: 90 participants will attend an initial session, at which point they will provide demographic information as well as their relationship status. They will then be randomly assigned to complete either the Episodic Future Thinking about Mating Opportunities intervention, a general-EFT intervention, or an unrelated questionnaire (yoked control condition).
~All participants will submit daily reports of the number of cigarettes smoked for a period of one week. Participants will then complete a series of questionnaires measuring individual differences in fundamental social motives (including mate-seeking motives), self-efficacy, and nicotine dependence."
11193237|NCT03431324|Experimental|Message Tailoring for Smoking Cessation|Study 2: A quasi-experimental design will be employed in order to determine whether targeting individuals who are single and highly motivated to seek a mate with a Targeted Mating-EFT Intervention is a more effective means of reducing cigarette consumption than presenting all individuals with a general-EFT intervention. A total of 180 smokers who intend to quit or reduce smoking will be recruited as participants. These individuals will be selected from a larger pool of participants based upon responses to screening questions. The screening questions will measure relationship status and mate seeking motivation.
11193238|NCT03431311|Experimental|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.
~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
11193239|NCT03431298|Experimental|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.
~Individualized functional movement control training is 60 min/week
~Aerobic exercise is 60 min/week"
11193240|NCT03431298|Active Comparator|Aerobic exercise|"The duration of intervention is 8 weeks.
~Frequency: 2 times/ week
~Duration: 60min/ time"
11193241|NCT03431285|Active Comparator|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
11193242|NCT03431285|Active Comparator|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
11193243|NCT03431272|Experimental|Treatment|lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day
11193244|NCT03431259|Experimental|Enrollment group|
11193245|NCT03431259|No Intervention|Information group|
11193254|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.
~The referenced range could be found in the following publication:
~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
11193255|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
11193256|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
11193257|NCT03431194|Active Comparator|midodrine group|Patients will receive midodrine tablets
11193258|NCT03431194|Placebo Comparator|placebo group|Patients receive sugary oral tablets therapy
11193259|NCT03431181|Experimental|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
11193260|NCT03431181|Active Comparator|Usual Care|Patients in the control arm will receive usual care (as per local practices).
11193261|NCT03431168|Active Comparator|Azithromycin/TMPS|"Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.
~TMPS double strength 1 tablet po daily."
11193262|NCT03431168|Placebo Comparator|Placebo/TMPS|"Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.
~TMPS double strength 1 tablet po daily."
11193263|NCT03431155|Experimental|Experimental group|Nursing intervention
11193264|NCT03431155|No Intervention|Control Group|- Receive routine nursing care
11193265|NCT03431142|Experimental|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
11193266|NCT03431142|Active Comparator|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
11193267|NCT03431116||Low implanted placenta group|
11193268|NCT03431103|Other|After home exercise program|"Patients will be instructed to use the Wii Fit for 20 minutes at least twice a week for 12 weeks using specific Wii Fit exercises while on the Wii pressure sensor floor mat. The Wii Fit exercises will be as follows: 1. Basic Run (warm-up exercise by walking in place); 2.Bird's Eye, Bull's-Eye (mostly arms, requires arm flipping); 3.Free Step (lower extremity exercise); 4.Hula Hoop (gyration exercise)"
11193269|NCT03431090|Experimental|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
11193270|NCT03431077|Experimental|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
11193271|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
11193272|NCT03431051|Active Comparator|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
11193273|NCT03431051|No Intervention|Control Arm|No change in beverages or education at two hospital campuses.
11193274|NCT03431025|No Intervention|Control|Participants in the Control Arm will wear sensors to monitor their upper limb movement but will not receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
11193275|NCT03431025|Experimental|Intervention|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
11193276|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
11193277|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
11193278|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
11193279|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
11193280|NCT03430999|Experimental|Group 1 (Japanese) Calmangafodipir|
11193281|NCT03430999|Placebo Comparator|Group 1 (Japanese) Placebo|
11193282|NCT03430999|Experimental|Group 2 (Caucasian) Calmangafodipir|
11193283|NCT03430999|Placebo Comparator|Group 2 (Caucasian) Placebo|
11193284|NCT03430986|Experimental|VOLUMA with Lidocaine|Participants will be treated with Voluma with Lidocaine injectable gel during the control period. Participants are eligible for touch-up treatment at day 57.
11193285|NCT03430986|Experimental|No-treatment control|No treatment during the control period. Optional treatment with VOLUMA with Lidocaine during the Post-Control period.
11193307|NCT03430843|Active Comparator|Investigator chosen chemotherapy|"Paclitaxel will be administered on Day 1, given every 21 days or on a weekly schedule.
~OR docetaxel will be administered on Day 1, given 21 days. OR irinotecan will be administered on Days 1, 8, given 21 days."
11194227|NCT03424538|Experimental|MStp|The MStp Group performs a traditional physiotherapy for 5 weeks.
11193286|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
11193287|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
11193288|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
11193289|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
11193290|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=60) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) case of beer on passenger seat, or (2) case of water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
11193291|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
11193292|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
11193293|NCT03430960|Other|Group A - Standard of Care|
11193294|NCT03430960|Experimental|Group B - mCare group|
11193295|NCT03430947|Experimental|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
11193296|NCT03430934|Experimental|NAVI mapping with Indocyanine green|Participants will undergo their scheduled Mohs surgery with the addition of the NAVI mapping with ICG dye
11193297|NCT03430921|Other|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
11193298|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
11193299|NCT03430895|Experimental|combination of durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting at Week 16 for 9 doses (total treatment duration of 12 months).
11193300|NCT03430882|Experimental|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11193301|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
11193302|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
11193303|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
11193304|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
11193305|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
11193306|NCT03430843|Experimental|Tislelizumab|Tislelzumab on Day 1, given every 21 days
11193497|NCT03429595|Experimental|Group 1: ATx201 GEL 2%|
11193308|NCT03430830|Experimental|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
11193309|NCT03430830|Experimental|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
11193310|NCT03430830|Experimental|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
11193311|NCT03430830|Experimental|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
11193312|NCT03430830|Experimental|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
11193313|NCT03430830|Experimental|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
11193314|NCT03430817|Experimental|Group C|Citicholine Drug
11193315|NCT03430817|Experimental|Group A|Amantadine Drug
11193316|NCT03430817|Experimental|Group D|Both Citocholine and Amantadine
11193317|NCT03430804||Single gruop320 parturients|Measurement of cervical length and digital examination of Bishop score in 320 women undergoing induction of labour will be carried out in ain shams university maternity hospital.
11193318|NCT03430791|Experimental|Nivolumab Monotherapy|Nivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months
11193319|NCT03430791|Experimental|Nivolumab+Ipilimumab|"Nivolumab 3 mg/kg IV with ipilimumab then 240 mg every 2 weeks for maximum of 24 months.
~Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. NovoTTF200A (Optune) TTF for maximum 24 months"
11193320|NCT03430778|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
11193321|NCT03430778|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
11193322|NCT03430765|Experimental|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
11193323|NCT03430765|No Intervention|Treatment as Usual|Standard breast cancer treatment.
11193324|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
11193325|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
11193326|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
11193327|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
11193328|NCT03430726|Experimental|Healthy Kids Probiotic Yogurt Drink Group|Healthy children will be given a commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.
11193329|NCT03430713|Experimental|Dental colour measurement|Comparison of dental colour measurement between two shade guides VITA Classical and VITA Toothguide 3D-Master and two spectrophotometers VITA Easyshade and Spectroshade Micro
11193330|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
11193331|NCT03430687|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
11193332|NCT03430674|Experimental|Exercise Intervention|Clinic and at home exercise sessions.
11193333|NCT03430661|Experimental|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
11193334|NCT03430661|Experimental|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
11193335|NCT03430661|Experimental|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
11193336|NCT03430661|Experimental|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
11193337|NCT03430661|Experimental|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
11193338|NCT03430661|Experimental|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
11193339|NCT03430661|Experimental|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
11193340|NCT03430661|Experimental|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
11193341|NCT03430661|Experimental|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
11193342|NCT03430648||Cognitively and metabolically normal|This group has been defined as being cognitively and metabolically normal.
11193343|NCT03430648||Cognitively normal with prediabetes|This group has been defined as being cognitively normal but showing signs of prediabetes.
11193344|NCT03430648||Persons with Mild Cognitive Impairment|This group has been defined as being mildly cognitively impaired.
11193345|NCT03430648||Persons with early Alzheimer's disase|This group has been defined as having early Alzheimer's disease.
11193498|NCT03429595|Experimental|Group 2: ATx201 GEL 4%|
11193499|NCT03429595|Experimental|Group 3: ATx201 GEL 4% plus vehicle|
11193346|NCT03430622|Experimental|LTP Plus|LTP Plus group participants will receive intervention over the telephone for 3 months one session per week for 2 months and rest of the sessions fortnightly by trained graduates, expert in delivering LTP plus intervention.
11193347|NCT03430622|Active Comparator|Treatment as Usual (TAU)|TAU group will receive routine care and their follow up will be done after completion of the intervention and then at 6-month post randomization.
11193348|NCT03430609|Active Comparator|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
11193349|NCT03430609|Active Comparator|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
11193350|NCT03430609|Active Comparator|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
11193351|NCT03430596|Experimental|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
11193352|NCT03430596|Active Comparator|Antan|Antan,flexible dose (2-4mg/d)
11193353|NCT03430583||MZ101|Dosing per treatment regimen
11193354|NCT03430570|Experimental|Tablet TRAC Emotion Regulation Intervention|
11193355|NCT03430570|No Intervention|Waitlist Control|Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 3-month follow-up
11193356|NCT03430557|Experimental|Periapical surgery with PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and PRP will be filled in the lesion before closure of flap
11193357|NCT03430557|Active Comparator|Periapical surgery without PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and flap will be closed without placement of PRP
11193358|NCT03430544|Placebo Comparator|Placebo|
11193359|NCT03430544|Experimental|1.5 mg/d cariprazine|
11193360|NCT03430544|Experimental|3.0 mg/d cariprazine|
11193361|NCT03430531|Experimental|Sphenopalatine ganglion block|Sphenopalatine ganglion block: this block will be performed by inserting swabs, with lidocaine squirted on them, into each nostril and reaching the nasopharyngeal wall.
11193362|NCT03430518|Experimental|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
11193363|NCT03430505|Active Comparator|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
11193364|NCT03430505|Active Comparator|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
11193365|NCT03430479|Experimental|Cohort A|
11193366|NCT03430479|Experimental|Cohort B|
11193367|NCT03430466|Experimental|Durvalmab&Tremelimumab&Fulvestrant|Durvalmab&Tremelimumab&Fulvestrant
11193368|NCT03430453|Experimental|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
11193369|NCT03430440|Experimental|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
11193370|NCT03430440|Active Comparator|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
11193371|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
11193372|NCT03430414||Therapy Responders|
11193373|NCT03430414||Non-Responders|
11193374|NCT03430401|Experimental|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
11193375|NCT03430401|Experimental|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
11193376|NCT03430401|Active Comparator|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, & Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
11193377|NCT03430388|Active Comparator|Rheumatic diseases patients|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
11193378|NCT03430388|Active Comparator|Healthy controls|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
11193500|NCT03429595|Experimental|Group 4: ATx201 GEL 4% plus vehicle|
11193501|NCT03429595|Placebo Comparator|Group 5: Vehicle|
11227352|NCT03195257|Experimental|Hypoglycemia-GIP|
11193379|NCT03430375|Active Comparator|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
11193380|NCT03430375|Active Comparator|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted.
11193381|NCT03430362|Active Comparator|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
11193382|NCT03430362|Placebo Comparator|Control group|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after
11193383|NCT03430349|Experimental|group 1|vaccination with novel OPV2 candidate vaccine 2 - 15 subjects
11193384|NCT03430349|Experimental|group 2|vaccination with novel OPV2 candidate vaccine 1 - 15 subjects
11193385|NCT03430336|Experimental|Computer-assisted medication management|"Family physician adds, modifies and optimizes medication in patient's with polypharmacy assisted by an user-initiated computerized decision support system (CDSS) which provides drug-therapy relevant information about patients (e.g. diagnoses and treatments) and alerts in case of drug-drug, drug-disease, drug-age interactions to systematically assess the appropriateness of medication:
~CDSS provides drug-therapy relevant information
~modification of medication
~assessment of medication appropriateness
~medication plan
~Guidance in medication process"
11193386|NCT03430336|No Intervention|Control arm|Patients will receive the usual clinical care based on current clinical practice guidelines during intervention period. After completion of trial, the patients in the control group will be invited to participate after written informed consent to receive the intervention.
11193387|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
11193388|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
11193389|NCT03430297|Experimental|JS001 240mg Q2W|
11193390|NCT03430297|Active Comparator|Dacarbazine 1000mg/m2 Q3W|
11193391|NCT03430284|Experimental|Integrated Treatment|
11193392|NCT03430284|Other|General Treatment|
11193393|NCT03430271|Active Comparator|Physical Activity (PA) Intervention|
11193394|NCT03430271|Placebo Comparator|Health Education (HE) Intervention|
11193395|NCT03430258|Placebo Comparator|conventional oxygen therapy|oxygen was delivered by a nasal cannula or nonrebreather mask
11193396|NCT03430258|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
11193397|NCT03430245|Experimental|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
11193398|NCT03430232|Experimental|Part I (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
11193399|NCT03430232|Experimental|Part I (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
11193400|NCT03430232|Experimental|Part II (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
11193401|NCT03430232|Experimental|Part II (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
11193402|NCT03430232|Experimental|Part II (Panel 3): STR-324 or placebo|Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
11193403|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
11193404|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
11193502|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
11193503|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
11227353|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
11193405|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
11193406|NCT03430193|Experimental|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
11193407|NCT03430193|Active Comparator|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
11193408|NCT03430193|No Intervention|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
11193409|NCT03430180|Placebo Comparator|placebo nasal spray|Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
11193410|NCT03430180|Active Comparator|Naloxone hydrochloride 40mg/ml nasal spray|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
11193411|NCT03430167|Other|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
11193412|NCT03430167|Other|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
11193413|NCT03430154||Adults with hemophilia and obesity/overweight|Adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
11193414|NCT03430154||Caregivers identified with obesity/overweight|Caregivers of children (any gender) currently aged <18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight
11193415|NCT03430154||Spouses or partners self-identified with obesity/overweight|Spouses or partners of adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
11193416|NCT03430154||Healthcare profs. managing hemophilia and obesity/overweight|Healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight.
11193417|NCT03430141|Experimental|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
11193418|NCT03430128|Experimental|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
11193419|NCT03430128|Active Comparator|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
11193420|NCT03430115||Weight loss plus exercise (WL+EX)|This group was randomized and previously assigned to weight loss plus exercise.
11193421|NCT03430115||Exercise alone (EX)|This group was randomized and previously assigned to exercise alone.
11193422|NCT03430115||Weight loss alone (WL)|This group was randomized and previously assigned to weight loss alone.
11193423|NCT03430115||Control|This group was randomized and previously assigned to control.
11193424|NCT03430102||LeftHeartCath|Patients scheduled for LV catheterization for direct measurement of LVEDP
11193425|NCT03430089|Experimental|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
11193426|NCT03430089|Experimental|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
11193427|NCT03430089|Experimental|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
11193428|NCT03430089|Experimental|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
11193429|NCT03430089|Experimental|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
11193430|NCT03430076|Experimental|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
11193431|NCT03430076|Active Comparator|Revascularization by Crude PTFE|
11193432|NCT03430063|Experimental|SDREGN2810|
11193433|NCT03430063|Experimental|SDREGN2810/ipi|
11193434|NCT03430063|Experimental|HDREGN2810|
11193435|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
11193436|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
11193437|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
11193438|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
11227354|NCT03195257|Experimental|Hyperglycemia-GIP|
11193439|NCT03430024||Cases|"We will enrol 100 women who have been newly diagnosed with T2 (>2cm) palpable invasive breast cancer having primary surgical treatment at Maidstone Hospital. We will exclude all patients with a metabolic disorder, significant co-morbidities and locally advanced or metastatic disease as well as those with a previous history of cancer treatment. We will collect data on tumour size, grade and phenotype as well as ER, progesterone receptor (PR) and Her-2 expression status and patient demographic information.
~We will investigate the Association of Myosin VI with oestrogen receptor."
11193440|NCT03430024||Controls|A cohort of control breast tissue will be obtained from 20 patients undergoing benign surgical breast procedures. For those control patients having reduction mammoplasties the excised tissue will be core biopsied but patients having other types of benign surgery will have an extra core biopsy taken from breast tissue surrounding the lesion being excised.
11193441|NCT03430011|Experimental|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
11193442|NCT03430011|Experimental|JCARH125 + anakinra|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
11193443|NCT03429998|Placebo Comparator|LDL apheresis|LDL apheresis during at least one year
11193444|NCT03429998|Active Comparator|Evolocumab|140 mg evolocumab biweekly
11193445|NCT03429998|Active Comparator|LDL apheresis and evolocumab|LDL-apheresis monthly evolocumab 140 mg biweekly
11193446|NCT03429985|Experimental|FRRM Intervention|The experimental arm will receive the FRRM intervention.
11193447|NCT03429985|No Intervention|Control|The control arm will not receive the FRRM intervention.
11193448|NCT03429972|Experimental|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
11193449|NCT03429972|Other|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
11193450|NCT03429959|Experimental|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
11193451|NCT03429959|Active Comparator|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
11193452|NCT03429946|Active Comparator|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
11193453|NCT03429946|Active Comparator|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
11193454|NCT03429946|Placebo Comparator|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
11193455|NCT03429933|Experimental|Single Ascending Dose|BMS-986278 or placebo
11193456|NCT03429933|Experimental|Multiple Ascending Dose|BMS-986278 or placebo
11193457|NCT03429920|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER:2 pouches per day, each pouch contains(12-15gms of fermented soy powder)
11193458|NCT03429920|Placebo Comparator|placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
11193459|NCT03429907|Experimental|Mind-Body Exercises|"Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are presented on an online application (app) that runs on participant's personal electronic device (such as a mobile phone or tablet).
~Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy."
11193460|NCT03429907|Other|Standard of Care|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
11193461|NCT03429894|Experimental|Treatment|All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.
11193462|NCT03429881|Active Comparator|Laparoscopic stripping ovarian endometriomas|
11193463|NCT03429881|Active Comparator|Laser CO2 treatment ovarian endometriomas|
11193464|NCT03429868|Experimental|integrated PET/MRI|The enrolled subjects receive an integrated 18F-FDG PET/MRI during tumor staging.
11193465|NCT03429855|Experimental|study group|Bobath based trunk exercises
11193466|NCT03429855|Other|control group|conventional physiotherapy approaches
11193467|NCT03429829|Experimental|Flairesse varnish|"All children in this group will recieve a dental examination (DMFS/dmfs) index at baseline as well as after 12, 24 and 36 months. Directly after the baseline examination Flairesse varnish (40ml) will be applied on all teeth using a soft brush according to manufacturares instructions, including flossing to spread the vanish to proximal areas.
~In addition to the intervention, all children will receive supervised toothbrushing throughout the study (treatment as usual) using fluoridated toothpaste (Colgate, fluoride ions 1100 ppm)."
11193504|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
11193468|NCT03429829|No Intervention|Control|"All children in this group will recieve a dental examination (DMFS/dmfs) index at baseline as well as after 12, 24 and 36 months, but they will not receive a sham or placebo treatment.
~However, all children will receive supervised toothbrushing throughout the study (treatment as usual) using fluoridated toothpaste (Colgate, fluoride ions 1100 ppm)."
11193469|NCT03429816|Experimental|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.
~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
11193470|NCT03429803|Experimental|TAK-580 (MLN2480) BSA </= 1.5m^2|"Phase I Part B BSA </= 1.5m^2
~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1
~Study treatment cycle lasts 28 days, oral, once a week"
11193471|NCT03429803|Experimental|TAK-580 (MLN2480) BSA > 1.5m^2|"Phase I Part B BSA > 1.5m^2
~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1
~Study treatment cycle lasts 28 days, oral, once a week"
11193472|NCT03429790|Experimental|group intra-operative cell salvage|"The theoretical amount of blood transfusion should be based on the following formula:
~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether the experimental group or the no intervention group."
11193473|NCT03429790|Active Comparator|group allogeneic blood transfusion|"The theoretical amount of blood transfusion should be based on the following formula:
~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether group intra-operative cell salvage or group allogeneic blood transfusion."
11193474|NCT03429777|Experimental|Hearing Loss Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in patients with hearing loss.
11193475|NCT03429777|Active Comparator|Control Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in control subjects without any prior or current hearing loss.
11193476|NCT03429764|Active Comparator|Control group (CG),CISS|continuous independent sling sutures (CISS) will be placed with minimum two intact contact points at the surgical site,
11193477|NCT03429764|Experimental|Test group (TG),VIMS|internal mattress suture (VIMS) will be placed with minimum two intact contact points at the surgical site,
11193478|NCT03429751|Experimental|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
11193479|NCT03429751|Active Comparator|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
11193480|NCT03429738|Experimental|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
11193481|NCT03429738|Active Comparator|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
11193482|NCT03429725|Experimental|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
11193483|NCT03429725|Experimental|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
11193484|NCT03429712|Experimental|Dose Split CT|
11193485|NCT03429699|Experimental|Intervention group|
11193486|NCT03429699|Other|Control group|
11193487|NCT03429686|Experimental|DRT Intervention|Intervention: Individual digital reminiscence therapy programme.
11193488|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
11193489|NCT03429660||Cohort|"Data to be collected are :
~- Medical information on Immune Thrombocytopenia treatment"
11193490|NCT03429647|Other|Sigmoid perfusion|Measured by visible light spectroscopy
11193491|NCT03429634|Experimental|Balloon-Stent Kissing technique|randomly, patients with bifurcation lesion treated by Balloon-Stent Kissing intervention technique in this group.For procedure,stent in main vessel and balloon protect of side branch,final kiss-balloon was performed.
11193492|NCT03429634|Sham Comparator|Jailed Wire technique|randomly,patients with bifurcation lesion treated by Jailed Wire intervention technique in this group.For procedure,stent in main vessel and only wire protect of side branch.If need,post-stent rewire of branch,and balloon dilation of side branch was performed.
11193493|NCT03429621|Experimental|Simethicone|Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
11193494|NCT03429621|No Intervention|No simethicone|The women will not be given Simethicone.
11193495|NCT03429608||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
11193496|NCT03429608||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
11193505|NCT03429569|Sham Comparator|accelerated conventional technique|"Pachymetry greater than 400μm
~Topographic criteria for keratoconus evolution:
~Variation over a 6-month period of the following changes:
~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
11193506|NCT03429569|Sham Comparator|iontophoresis|"Pachymetry greater than 400μm
~Topographic criteria for keratoconus evolution:
~Variation over a 6-month period of the following changes:
~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
11193507|NCT03429556|Placebo Comparator|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
11193508|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
11193509|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
11193510|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
11193511|NCT03429543|Experimental|Linagliptin|Linagliptin arm. Oral route. Linagliptin tablets administered once daily for 52 weeks
11193512|NCT03429543|Experimental|Empagliflozin|Empagliflozin arm. Oral route. Start with a low dose of empagliflozin administered once daily and randomly up titrate to the high dose of empagliflozin administered once daily if HbA1c ≥ 7% at week 12
11193513|NCT03429543|Placebo Comparator|Placebo|Placebo arm. Oral route. Placebo tablets administered once daily up to 26 weeks and then linagliptin or low dose of empagliflozin or high dose of empagliflozin administered once daily up to 52 weeks
11193514|NCT03429530||Group1|20 patients with chronic HCV
11193515|NCT03429530||GroupII|20 patient with chronic HCV related liver cirrhosis
11193516|NCT03429530||GroupIII|40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
11193517|NCT03429530||group IV|20 healthy blood donors will also be included as a control group
11193518|NCT03429517||Patients|ACS Lipogram
11193519|NCT03429517||Controls|Normal LDL-C level Lipogram
11193520|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
11193521|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
11193522|NCT03429491|Placebo Comparator|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
11193523|NCT03429491|Experimental|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
11193524|NCT03429491|Experimental|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
11193525|NCT03429478|Experimental|Music|Preoperative application of a Bluetooth enabled headphones with standard music played for atleast 2 hours preoperatively.
11193526|NCT03429478|Active Comparator|No Music|Preoperative application of a Bluetooth enabled headphones with no music played and headphones will just mask the surrounding noise.
11193527|NCT03429465|Experimental|EVO|All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
11193528|NCT03429439|Experimental|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.
~Interventions:
~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
11193529|NCT03429439|Other|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.
~Interventions:
~Procedure: antiviral therapy"
11193530|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.
~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
11193531|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
11193532|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
11193533|NCT03429413|Active Comparator|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
11193534|NCT03429413|Active Comparator|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
11193535|NCT03429413|No Intervention|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
11193536|NCT03429413|No Intervention|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
11193537|NCT03429413|No Intervention|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
11193538|NCT03429400|Other|Morphine Sulfate|oral morphine sulfate tablets oral morphine sulfate oral solution
11193539|NCT03429387|Experimental|FDG-PET/CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
11193608|NCT03428841||Patients with dural puncture at epidural|Patients who sustained an accidental dural puncture during the epidural procedure.
11193540|NCT03429387|Active Comparator|Conventional CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
11193541|NCT03429374|Active Comparator|Liquiband Fix8 glue mesh fixation|
11193542|NCT03429374|Active Comparator|Mesh fixation with absorbable tacks|
11193543|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
11193544|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
11193545|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
11193546|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
11193547|NCT03429322|Experimental|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
11193548|NCT03429322|Active Comparator|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
11193549|NCT03429309|Other|Anesthesia-induction with propofol|
11193550|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
11193551|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
11193552|NCT03429270|Experimental|Urodynamics Arm|
11193553|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
11193554|NCT03429244|Experimental|Low and intermediate risk prostate cancer|
11193555|NCT03429231||Active Group|Women who are taking coenzyme Q and who will continue taking it for 3 months
11193556|NCT03429231||Control Group|Women who are not taking coenzyme Q and who will not take it in the next 3 months
11193557|NCT03429218|Experimental|Single Arm TP-0184|Weekly dose of TP-0184 by oral administration
11193558|NCT03429205|Experimental|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
11193559|NCT03429205|Other|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
11193560|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
11193561|NCT03429179|Experimental|High anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were >10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
11193562|NCT03429179|Placebo Comparator|High anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were >10, and received an infusion of the same volume of 0.9% saline
11193563|NCT03429179|Experimental|Low anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
11193564|NCT03429179|Placebo Comparator|Low anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline
11193565|NCT03429166|Experimental|STAIR|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
11193566|NCT03429166|Active Comparator|PCT|PCT stands for Present Centered Therapy, a non-trauma-focused treatment
11193567|NCT03429140|Experimental|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
11193568|NCT03429140|Placebo Comparator|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
11193569|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
11193570|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
11193571|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
11193572|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
11193573|NCT03429101|Experimental|Poziotinib|"Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.
~Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
11193574|NCT03429088|Experimental|Telephone counseling|Participants were provided with approximately 7 telephone-based motivational interviewing over a 24-week period to increase their physical activity.
11193575|NCT03429088|No Intervention|Usual care|Participants in the usual care arm received a packet of places near their home in which they could engage in physical activity if they chose.
11193576|NCT03429075|Experimental|Psilocybin|Patients receive Psilocybin
11193577|NCT03429075|Active Comparator|Escitalopram|Patients receive Escitalopram
11193607|NCT03428880|Active Comparator|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.
~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
11193984|NCT03426241||smoking healthy|
11193578|NCT03429062||personal training|Individuals with a diagnosis of MS and any level of function will be recruited to participate in exercise two times per week with trained personal trainers. Exercise consists of strengthening, stretching, balance, endurance and gait when able. Equipment to be used include treadmill, stationary bike, weight equipment.
11193579|NCT03429062||Whole Body Platform|Individuals with a diagnosis of MS and able to walk with or without an assistive device will be recruited to participate in whole body platform training two times per week with a physical therapist. The exercise on the whole body platform includes strengthening, balance, stretching, and endurance for 30 second bouts. The whole body platform is on for 30 seconds then off. Each exercise will use the 30 seconds to complete.
11193580|NCT03429049|Placebo Comparator|Placebo|Single intra-articular 1.0 mg Placebo Injection
11193581|NCT03429049|Experimental|CNTX-4975-05|Single intra-articular 1.0 mg CNTX-4975-05 (trans-capsaicin) injection
11193582|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
11193583|NCT03429010|Experimental|"New guideline"|"New guideline anesthesia strategy team (Group A)"
11193584|NCT03429010|No Intervention|Current strategy|Current anesthesia strategy team (Group B)
11193585|NCT03428997|Experimental|Lotion|Test sites were patched with the lotion F #13451-131.
11193586|NCT03428997|Other|Negative Control|Test sites were patched with undosed occlusive patch.
11193587|NCT03428984|Experimental|EXPAREL 20 + 20|20 mL EXPAREL with 20 mL normal saline
11193588|NCT03428984|Experimental|EXPAREL 20 + 10|20 mL EXPAREL with 10 mL normal saline
11193589|NCT03428958|Experimental|NUC-3373+ leucovorin|Cohort 1a: NUC-3373 administered intravenously (IV) followed by a 2-week washout period. Then, LV 400 mg/m2 IV over 2 hours prior to each NUC-3373 infusion and NUC-3373 administered IV every 2 weeks.
11193590|NCT03428958|Experimental|NUC-3373|Cohort 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks.
11193591|NCT03428958|Experimental|NUC-3373 + oxaliplatin|Cohort 2a: NUC-3373 administered every 2 weeks in combination with oxaliplatin (85 mg/m2). Leucovorin may also be administered with this combination, depending on data from Part 1.
11193592|NCT03428958|Experimental|NUC-3373 + oxaliplatin + bevacizumab|Cohort 2b: NUC-3373 administered every 2 weeks in combination with oxaliplatin (85 mg/m2) and bevacizumab (5 mg/kg). Leucovorin may also be administered with this combination, depending on data from Part 1.
11193593|NCT03428958|Experimental|NUC-3373 + oxaliplatin + panitumumab|Cohort 2c: NUC-3373 administered every 2 weeks in combination with oxaliplatin (85 mg/m2) and panitumumab (6 mg/kg). Leucovorin may also be administered with this combination, depending on data from Part 1.
11193594|NCT03428958|Experimental|NUC-3373 + irinotecan|Cohort 3a: NUC-3373 administered every 2 weeks in combination with irinotecan (180 mg/m2). Leucovorin may also be administered with this combination, depending on data from Part 1.
11193595|NCT03428958|Experimental|NUC-3373 + irinotecan + cetuximab|Cohort 3b: NUC-3373 administered every 2 weeks in combination with irinotecan (180 mg/m2) and cetuximab 400 mg/m2 (first dose) and 250 mg/m2 (subsequent doses). Cetuximab is administered weekly. Leucovorin may also be administered with this combination, depending on data from Part 1.
11193596|NCT03428945|Experimental|Hydroxychloroquine|Hydroxychloroquine compound for oral use
11193597|NCT03428945|Placebo Comparator|Placebo|Placebo tablet matching active drug
11193598|NCT03428932|Active Comparator|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
11193599|NCT03428932|Active Comparator|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
11193600|NCT03428919|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.
~Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
11193601|NCT03428919|Active Comparator|In Vitro Fertilization (IVF)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.
~Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium.
~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen."
11193602|NCT03428906|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .
11193603|NCT03428906|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.
11193604|NCT03428893|Experimental|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
11193605|NCT03428893|No Intervention|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
11193606|NCT03428880|Active Comparator|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
11193609|NCT03428841||Patients with no dural puncture|Patients with no dural puncture during epidural procedure, to serve as a control group.
11193610|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
11193611|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
11193612|NCT03428815|Experimental|PCM liner|Willowwood Smart Temp Liner
11193613|NCT03428815|Active Comparator|regular liner|User's regular prescribed liner
11193614|NCT03428802|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
11193615|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
11193616|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
11193617|NCT03428776|Sham Comparator|Controls|Self returns
11193618|NCT03428776|Active Comparator|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives
11193619|NCT03428776|Active Comparator|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives
11193620|NCT03428763|Experimental|Homebased disease monitoring (eHealth)|Participants allocated to the intervention group will be trained in self-monitoring of their RA
11193621|NCT03428763|Active Comparator|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
11193622|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
11193623|NCT03428750|Placebo Comparator|Placebo|
11193624|NCT03428737|Other|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
11193625|NCT03428737|Other|Nocturnal pressure support ventilation|Use of a pressure support level identical during the night to the pressure support level at the end of the day.
11193626|NCT03428724|Active Comparator|standard group|standard polyethylene glycol preparation for colonoscopy
11193627|NCT03428724|Experimental|individualized group|either a low or a high volume bowel preparation according to patient characteristics
11193628|NCT03428711|Placebo Comparator|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
11193629|NCT03428711|Experimental|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.
~50 mg, twice-a-day, for 12 months"
11193630|NCT03428698|Experimental|experimental device|The extraction was completed, the socket was filled with a topical amino acid + sodium hyaluronate gel (Aminogam®, sterile syringe 2 ml).
11193631|NCT03428698|Placebo Comparator|control no device|The extraction was completed, socket was flushed, using a 2ml sterile syringe similar to one utilized to apply the gel, with sterile physiological solution.
11193632|NCT03428685|Active Comparator|Intervention group|
11193633|NCT03428685|Placebo Comparator|Placebo group|
11193634|NCT03428672|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
11193635|NCT03428672|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
11193636|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
11193637|NCT03428633|Active Comparator|Group A|Thoracic paravertebral block using ropivacaine
11193638|NCT03428633|Active Comparator|Group B|Morphine IV
11193639|NCT03428620|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints that will be manipulated include proximal tibiofibular, the distal tibiofibular, and talocrural joints and will be mobilized the first three sessions prior to the participants performing the exercise protocol.
11193640|NCT03428620|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
11193641|NCT03428607|Experimental|AZD6738+Olaparib|AZD6738 160mg QD per os administered for 7 days and olaparib 300mg BID per os administered daily. One cycle is considered of 28 days.
11193642|NCT03428594|Experimental|CKD-11101|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
11193643|NCT03428594|Active Comparator|NESP|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
11193644|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
11193645|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
11193646|NCT03428568|Experimental|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
11193647|NCT03428568|Active Comparator|Nexium|omeprazole 40 mg once per day for one month.
11193985|NCT03426241||non-smoking healthy|
11193648|NCT03428568|Experimental|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
11193649|NCT03428568|Active Comparator|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.
~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
11193650|NCT03428568|Experimental|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
11193651|NCT03428568|Experimental|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
11193652|NCT03428555|Experimental|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.
~Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.
~Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.
~Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
11193653|NCT03428555|Active Comparator|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
11193654|NCT03428542|No Intervention|Control arm|Instructed not to practice any yoga or mindfulness during the five-week study period.
11193655|NCT03428542|Active Comparator|Yin yoga intervention arm|"The Yin yoga intervention arm will receive Yin yoga, a calm-paced practice that uses seated and lying down positions.
~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
11193656|NCT03428542|Active Comparator|YOMI program intervention arm|"The YOMI intervention arm will receive stress education + yoga, and bring together education about stress, mindfulness and yoga practice. It will involve weekly group meetings, homework, and yoga postures. Stress education and mindfulness will make up one portion of the intervention. This will take place in a group lecture format and shall be conducted by a mental health professional(s). Yoga practice in a group format will make up the second portion of the intervention.
~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
11193657|NCT03428529|Experimental|Capecitabine|Neoadjuvant capecitabine plus RT
11193658|NCT03428529|Active Comparator|5-Flourouracil|Neoadjuvant 5-Fluorouracil plus RT
11193659|NCT03428516|Experimental|Fixed CPAP|CPAP always deliver air with the same pressure
11193660|NCT03428516|Active Comparator|Auto-adjusting CPAP|Auto-CPAP changes the pressure delivered depending on events detected at any time (apnea, hypopnea …) and applies the lowest pressure required to eliminate events.
11193661|NCT03428503|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
11193662|NCT03428503|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
11193663|NCT03428490|Experimental|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
11193664|NCT03428490|Active Comparator|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
11193665|NCT03428477|Experimental|Icosapent Ethyl (EPA-EE)|Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
11193666|NCT03428477|Placebo Comparator|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
11193667|NCT03428464|Experimental|Sodium bicarbonate|During the treatment period, participants will receive 0.5 mEq/kg-lean body weight (LBW)/day of oral sodium bicarbonate for 8 weeks.
11193668|NCT03428464|Placebo Comparator|Placebo|During the control period, participants will take the same number of placebo capsules as if they were assigned 0.5 mEq/kg-LBW/day of sodium bicarbonate.
11193669|NCT03428451|Active Comparator|Group A (Hypertonic saline )|patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.
11193670|NCT03428451|Active Comparator|Group B (Hypertonic saline)|patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.
11193671|NCT03428451|Active Comparator|Group C (Normal saline)|patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.
11193672|NCT03428438|Other|Study group SMS to home phone|A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E.
11193673|NCT03428438|Other|Controlled group hospital based|Physical rehabilitation in the ward physiotherapist
11193674|NCT03428425|Experimental|apatinib paclitaxel S-1|
11193675|NCT03428412|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
11193676|NCT03428412|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
11193677|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
11193678|NCT03428386|Experimental|Gastric plication ileal bypass|single-anastomosis plication ileal bypass
11193679|NCT03428373|Experimental|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
11193680|NCT03428373|Active Comparator|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
11193681|NCT03428360|Experimental|Subjects with Epilepsy|male or female pediatric, adolescent and adult subjects with a clinical diagnosis of epilepsy and with bouts of increased seizure activity, Acute Repetitive Seizures (ARS), frequent breakthrough seizures, seizure clusters or cluster seizures.Subjects with epilepsy self-administer Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15, or 17.5 mg or with the caregiver's assistance if applicable to treat seizures, in response to the occurrence of the same characteristic events as they previously would with their usual rescue medication, e.g. Diastat® AcuDial™ or usual rescue therapy.
11193682|NCT03428347|Experimental|Group 1|1.4 mg/kg body weight
11193683|NCT03428347|Experimental|Group 2|7 mg/kg body weight
11193684|NCT03428347|Experimental|Group 3|14 mg/kg body weight
11193685|NCT03428334|Experimental|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
11193686|NCT03428308|Experimental|Individualized treatment of detected somatic disease(s)|
11193687|NCT03428295|Experimental|Experimental: Single Cohort in CRC|This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
11193688|NCT03428282|Experimental|VR Box|Inferior alveolar nerve block will be performed with the aid of VR box as a means of distracting patients' attention.
11193689|NCT03428282|Experimental|Tablet device|Inferior alveolar nerve block will be performed with the aid of a tablet device as a means of distracting patients' attention.
11193690|NCT03428282|Active Comparator|Anesthesia|Inferior alveolar nerve block will be performed in the normal manner without any specific intervention to distract patients' attention. Classic anesthesia will be applied.
11193691|NCT03428269|Experimental|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
11193692|NCT03428269|Active Comparator|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
11193693|NCT03428256|Active Comparator|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
11193694|NCT03428256|Experimental|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
11193695|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
11193696|NCT03428230|Experimental|D1|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
11193697|NCT03428230|Experimental|D2|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
11193698|NCT03428230|Experimental|D3|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
11193699|NCT03428230|Placebo Comparator|P|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
11193700|NCT03428217|Experimental|CB-Cabo|CB-839 orally twice daily + cabozantinib orally once daily
11193701|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo orally twice daily + cabozantinib orally once daily
11193702|NCT03428204|Other|180 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 180 seconds for percutaneous treatment of femoropopliteal artery stenosis
11193703|NCT03428204|Other|300 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 300 seconds for percutaneous treatment of femoropopliteal artery stenosis
11193704|NCT03428178|Experimental|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
11193705|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
11193706|NCT03428165|No Intervention|spontaneous|
11193707|NCT03428152||Hypo|The participants with a superior hypogastric block
11193708|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
11193709|NCT03428139|Active Comparator|Group I|Each patient in this group was treated with pulsed radiofrequency on the affected dorsal root ganglion at 42°C for 120 seconds
11193710|NCT03428139|Active Comparator|Group II|Each patient in this group was treated with pulsed radiofrequency as in group I plus oral alpha lipoic acid (ALA) 600 mg.
11193711|NCT03428126|Experimental|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.
~Participants receive Durvalumab by vein every 4 weeks.
~Each cycle is 28 days."
11193712|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
11193713|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
11193714|NCT03428100|Experimental|Baricitinib High Dose|Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
11193715|NCT03428100|Experimental|Baricitinib Mid Dose|Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally in combination with topical corticosteroids to maintain the blind.
11193716|NCT03428100|Experimental|Baricitinib Low Dose|Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally in combination with topical corticosteroids to maintain the blind.
11193717|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally in combination with topical corticosteroids.
11193718|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
11193719|NCT03428074||Patients with the surgery of Ivor-Lewis|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Ivor-Lewis
11193720|NCT03428074||Patients with the surgery of Mckeown|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Mckeown
11193721|NCT03428061||Intervention group|The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
11193722|NCT03428061||Control group|Usual care will be based on the Dutch CVRM guideline, describing how to calculate the CVR and advices to lower this risk by lifestyle intervention and/or medication. However systematic identification of patients eligible for CVRM, actively inviting patients for a visit, regular follow-up and standardized collaboration with other disciplines in the health care chain are not necessarily part of usual care.
11193723|NCT03428048||Adults diagnosed with paroxysmal and persistent Afib|Adults diagnosed with paroxysmal and persistent Afib who are identified as candidates for an intervention either surgical (epicardial) known as the hybrid approach or an endocardial ablation with either laser, radio frequency or cryoablation energy source.
11193724|NCT03428035|Experimental|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
11193725|NCT03428035|No Intervention|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
11193726|NCT03428035|Active Comparator|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
11193727|NCT03428022|Experimental|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
11193728|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
11193729|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
11193730|NCT03427996||Coronary disease|
11193731|NCT03427983|Other|US-guided regular injection|US in-plane injection with corticosteroid and 1cc of lidocaine. Total of 2cc.
11193732|NCT03427983|Other|US-guided hydrodissection|US in-plane injection with corticosteroid and 1cc of lidocaine, and 3cc of saline. Total of 5cc.
11193733|NCT03427970|Active Comparator|control group|Control subjects will receive observation for 6 months.
11193734|NCT03427970|Experimental|experimental group|Experimental group will perform three-dimensionally integrated exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 20-min period per day under the supervision of the parents at home.The treatment regimens lasted for 6 months.
11193735|NCT03427957|Experimental|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
11193736|NCT03427957|Active Comparator|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
11193737|NCT03427957|Active Comparator|Classic alligator grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic alligator grasper.
11193738|NCT03427944|Active Comparator|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
11193739|NCT03427944|Placebo Comparator|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
11193740|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
11193741|NCT03427918|Experimental|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
11193742|NCT03427918|Experimental|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
11193743|NCT03427918|No Intervention|Control group|The control group will receive a routine counseling
11193744|NCT03427905|Active Comparator|GROUP I|lipoaspiration and transplantation of ADSVCs (for adipose-derived stromal vascular cells/primary fresh cells without culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
11193745|NCT03427905|Active Comparator|GROUP II|lipoaspiration and transplantation of ADSCs (for adipose-derived mesynchymal stem cells/after culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
11193746|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
11193747|NCT03427879|Placebo Comparator|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
11193748|NCT03427879|Active Comparator|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
11193749|NCT03427866|Experimental|Ruxolitinib Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day
~Dosing will be continuous, with a new cycle scheduled to start every 28 days.
~There will be no break in dosing between cycles
~Ruxolitinib can be administered with or without food."
11193750|NCT03427866|Experimental|Ruxolitinib Not Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day after transplant
~Dosing will be continuous, with a new cycle scheduled to start every 28 days.
~There will be no break in dosing between cycles
~Ruxolitinib can be administered with or without food."
11193751|NCT03427853|Experimental|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
11193752|NCT03427853|Placebo Comparator|Placebo|Placebo subcutaneous injection
11193753|NCT03427840||Hypo|The participants with a superior hypogastric block
11193754|NCT03427840||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)
11193755|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
11193756|NCT03427827|No Intervention|Observation arm|Patients randomized to this arm will receive no aditional treatment after chemoradiation
11193757|NCT03427814|Experimental|Pamiparib|Approximately 270 participants to receive pamiparib orally.
11193758|NCT03427814|Placebo Comparator|Placebo|Approximately 270 participants to receive placebo orally.
11193759|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
11193760|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
11193761|NCT03427788|Experimental|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
11193762|NCT03427788|Placebo Comparator|Placebo|Study group 1-11 of Placebo
11193763|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
11193764|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
11193765|NCT03427762|Experimental|Healthy cycling group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then there is a bicycle every 1 hour.
11193766|NCT03427762|Experimental|Healthy xbox group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then they will train 1 hour every day on an xbox program.
11193767|NCT03427762|No Intervention|Healthy controll group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
11193768|NCT03427762|Experimental|PD groupe|"Patients with PD have already been evaluated and compared to the results of a healthy group within a separate experiment.
~The study and the results have been completed. Clinical trial number:NCT03193268"
11193769|NCT03427736||Drug of Interest|Individuals receiving anesthetics or analgesics per standard of care
11193770|NCT03427723|Active Comparator|Standard care|visualization and palpation
11193771|NCT03427723|Experimental|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
11193772|NCT03427710|Experimental|Cohort A1|CiVi007 dose 1
11193773|NCT03427710|Experimental|Cohort A2|CiVi007 dose 2
11193774|NCT03427710|Experimental|Cohort A3|CiVi007 dose 3
11193775|NCT03427710|Experimental|Cohort A4|CiVi007 dose 4
11193776|NCT03427710|Experimental|Cohort A5|CiVi007 dose 5
11193777|NCT03427710|Placebo Comparator|Combined placebo group|group response from placebo subsets of dosing cohorts
11193778|NCT03427697|Experimental|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
11193779|NCT03427697|No Intervention|Control group|No intervention will be performed in the control group
11193780|NCT03427684|Experimental|Hypo-fractionated radiotherapy|Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer
11193781|NCT03427671|Experimental|Occlusin 500 microspheres|Uterine fibroid embolization
11193782|NCT03427658|Experimental|Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and additional sweet food consumption recommended.
11193783|NCT03427658|Active Comparator|Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and substitutions for sweet food consumption will be recommended.
11193784|NCT03427645|No Intervention|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
11193785|NCT03427645|Experimental|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
11193786|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
11193787|NCT03427619|Experimental|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive .1mg-.2mg 6-12 weeks apart up to 4 injections total.
11193788|NCT03427606|Experimental|Continuous Suture|
11193789|NCT03427606|Active Comparator|Single 5-points Suture|
11193790|NCT03427593|Experimental|Patients|Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
11193791|NCT03427593|Other|relatives (parents)|
11193792|NCT03427593|Sham Comparator|Controls|
11193793|NCT03427580|Experimental|treatment group|
11193794|NCT03427580|Experimental|delayed treatment control group|
11193795|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
11193796|NCT03427554|Experimental|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
11193797|NCT03427554|Active Comparator|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
11193798|NCT03427554|Placebo Comparator|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
11193799|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
11193800|NCT03427528|Experimental|FAB Pilot Study (Male Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.
~Male partners will receive Fathers and Babies (FAB Intervention) while his female partner will receive MB 1-on-1 plus MB-TXT."
11193801|NCT03427528|Experimental|MB 1-on-1 Plus TEXT (Female Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.
~Female clients will receive the Mothers and Babies with -Text Messages intervention (i.e., MB 1-on-1 plus MB-TXT) while her male partner will receive FAB."
11193802|NCT03427515|Experimental|Lactobacillus|Lactobacillus rhamnosus GG (ATCC 53103) - encapsulated
11193803|NCT03427515|Placebo Comparator|Placebo|Placebo - encapsulated mixture of maltodextrins
11193804|NCT03427515|Experimental|Saccharomyces|Saccharomyces boulardii (CNCM I-1079) - encapsulated
11193805|NCT03427502|Experimental|Study Group|"Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve.
~Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose.
~Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel."
11193806|NCT03427502|Placebo Comparator|Control Group|"At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron.
~Injection technique remains the same as in Study group."
11193807|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
11193808|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
11193809|NCT03427476|Experimental|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
11193810|NCT03427476|Experimental|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions > 7 cm (may also have metastatic disease) (N = 5)
11193811|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
11193812|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
11193813|NCT03427450||Healthy Volunteers (Controls)|A control population of healthy volunteers (HVs) consisting of women with no prior/current history of cancer and no known history of breast disease (the information obtained from the HVs may be 'self-reports', as complete medical records may not be available at the enrolling site for these control subjects), and with a broadly similar age range to the cancer patient study population. All eligible and consenting subjects will have blood draw.
11193814|NCT03427450||MBC Patients (Cancers)|Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrollment into the cancer population. All eligible and consenting subjects will have blood draw.
11193815|NCT03427437|Active Comparator|Conventional Group|Caudal block was performed by conventional method with %0,25 bupivacaine plus 1/200.000 adrenalin
11193816|NCT03427437|Active Comparator|Ultrasound Group|Caudal block was performed by ultrasound method with %0,25 bupivacaine plus 1/200.000 adrenalin
11193817|NCT03427424||AUD-E (Longitudinal-Alcohol)|Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHPs within about 2 month of starting treatment (AUD-E)
11193818|NCT03427424||AUD-L (Cross-sectional Alcohol)|Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (AUD-L)
11193819|NCT03427424||CON|healthy, non-drug using control participants (CON)
11193820|NCT03427424||POAUD-E (Longitudinal-Dual) (|Early-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHPs within 2 month of starting treatment (POUD-E)
11193821|NCT03427424||POAUD-L (Cross-sectional-Dual)|Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHPs more than 2 months and less than 5 years (POAUD-L)
11193822|NCT03427424||POUD-E (Longitudinal- Opiate)|Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health programs (PHP) within about 2 month of starting treatment (POUD-E)
11193823|NCT03427424||POUD-L (Cross-sectional-Opiate)|Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHPs more than 2 months and less than 5 years (POAUD-L)
11193824|NCT03427411|Experimental|1/Arm 1|M7824 at a flat dose of 1,200 mg IV once every 2 weeks
11193825|NCT03427385|Experimental|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
11193826|NCT03427372||group 1: patients with headache|the patients who have post spinal puncture headache after spinal anesthesia
11193827|NCT03427372||group 2: patients without headache|the patients who do not have post spinal puncture headache after spinal anesthesia
11193828|NCT03427372||group 3: patients with backache|the patients who have post spinal puncture backache after spinal anesthesia
11193829|NCT03427372||group 4: patients without backache|the patients who do not have post spinal puncture backache after spinal anesthesia
11194300|NCT03424031|No Intervention|Passive mobilization|Passive mobilization of the lower limb deficit
11193830|NCT03427359|Experimental|experimental arm|Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
11193831|NCT03427346|Active Comparator|EMR|Endoscopic mucosal resection
11193832|NCT03427346|Active Comparator|ESD|Endoscopic submucosal dissection
11193833|NCT03427333|Experimental|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
11193834|NCT03427320|Experimental|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
11193835|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
11193836|NCT03427281|Experimental|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
11193837|NCT03427268|Experimental|PM060184|PM060184
11193838|NCT03427255|Active Comparator|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
11193839|NCT03427255|Other|Waiting list|Six months waiting-list control condition.
11193840|NCT03427242|Experimental|treatment arm|oral apatinib
11193841|NCT03427229|Experimental|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
11193842|NCT03427229|Active Comparator|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
11193843|NCT03427216|Active Comparator|Vaginal Baclofen/diazepam supp|Insert vaginal suppository once daily
11193844|NCT03427216|Placebo Comparator|Vaginal Placebo supp|Insert vaginal suppository once daily
11193845|NCT03427203|Experimental|Arm 1|"The subjects test the products in the following order
~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 2 Coloplast Ostomy device 3"
11193846|NCT03427203|Experimental|Arm 2|"The subjects test the products in the following order
~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 3 Coloplast Ostomy device2"
11193847|NCT03427190|Active Comparator|Control|Phone contact with patient will be made by a professional psychologist within 21 days of hospital discharge. If contact cannot be made after 9 attempts, post-cards will be sent monthly at M2, M3, M4 and M5, asking the participant to establish contact with the designated psychologist. The phone call will determine whether or not the participant is in a state of suicidal crisis. If yes, steps will be taken to attend the crisis within 24 hours.
11193848|NCT03427190|Other|APSOM|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
11193849|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
11193850|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
11193851|NCT03427164|Experimental|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
11193852|NCT03427151|Experimental|IPP-201101|every 4 weeks
11193853|NCT03427138|Experimental|Jasper|JASPER (Joint Attention Symbolic Play Engagement Regulation) is a targeted intervention that focusses on early communication skills.
11193854|NCT03427138|Experimental|Parent Education|Parent education intervention focusses on parenting a child with autism.
11193855|NCT03427125|Experimental|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
11193856|NCT03427125|Placebo Comparator|Placebo|Placebo
11193857|NCT03427125|Active Comparator|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
11193858|NCT03427099|Active Comparator|Control group|usual care
11193859|NCT03427099|Experimental|Intervention group|Rehabilitation with a biopsychosocial focus
11193860|NCT03427086|Active Comparator|Interventional|Patient will received high dose of biotin (300 mg/day)
11193861|NCT03427086|Placebo Comparator|Placebo|Patients will receive placebo
11193862|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours
~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
11193863|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer
~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
11193864|NCT03427060|Experimental|Coversin treatment|Coversin - 22.5mg followed by 45mg for 6 months.
11193865|NCT03427047|Active Comparator|MyKnee with single use Efficiency Instrument|Patients randomized in this group will undergo Total Knee Arthroplasty utilizing patient matched cutting blocks and single use instruments. Customization will be by a CT scan of patients knee.
11193866|NCT03427047|Active Comparator|Stryker Navigational with conventional metal instruments|Patients randomized in this group will undergo Total Knee Arthroplasty with conventional metal instruments. CT scan are not utilized with this arm.
11193867|NCT03427034|Experimental|Cystoscopic surveillance|Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
11193986|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
11193868|NCT03427034|Experimental|Haematuria group|Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
11193869|NCT03427034|No Intervention|Longitudinal group|Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.
11193870|NCT03427021|Experimental|Arm A|will be treated with consistent exposure to oral ice
11193871|NCT03427021|Active Comparator|Arm B|Will not be treated with consistent exposure to oral ice.
11193872|NCT03427008|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
11193873|NCT03427008|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
11193874|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
11193875|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
11193876|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
11193877|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
11193878|NCT03426995|Experimental|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
11193879|NCT03426995|Experimental|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
11193880|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
11193881|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
11193987|NCT03426202|Experimental|modafinil group|a single dose of p.o. modafinil (200mg)
11193882|NCT03426982|Experimental|Anti-Xa group|- Heparin was monitored by Anti-Xa activity, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 0.30 and 0.70 IU/mL
11193883|NCT03426982|Experimental|APTT group|- Heparin was monitored by APTT, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 1.5 and 2.5 time the basiline.
11193884|NCT03426969|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on days -5, fludarabine phosphate IV over 1 hour on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously for approximately 2 weeks, then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 100, and filgrastim SC daily from day 7 until continued until ANC > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
11193885|NCT03426956|Experimental|Glucose|
11193886|NCT03426956|Experimental|Glucose + Canagliflozin|
11193887|NCT03426943|Experimental|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.
~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
11193888|NCT03426943|Active Comparator|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).
~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
11193889|NCT03426930|Active Comparator|The reference treatment of dysmorphophobia used|
11193890|NCT03426930|Experimental|The reference treatment with the virtual reality|
11193891|NCT03426904|Experimental|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
11193892|NCT03426904|Active Comparator|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
11193893|NCT03426891|Experimental|Combination Therapy|Pembrolizumab and Vorinostat Combined with Temozolomide and Radiotherapy. There are two parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). Dose Expansion: Twenty participants will be treated with vorinostat at the maximum tolerated dose (MTD) from dose escalation phase, pembrolizumab, temozolomide and radiation. During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months).
11193894|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
11193895|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
11193896|NCT03426865||Axumin PET scan|Only one arm is being evaluated--the arm receiving PET scan
11193897|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
11193898|NCT03426852||Control Group|Individuals with lumbar back pain
11193899|NCT03426839|Active Comparator|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
11193900|NCT03426839|Active Comparator|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
11193901|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
11193902|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
11193903|NCT03426813|Other|Early mobilization|Historical control group for early mobilization
11193904|NCT03426800|Experimental|Migraine_acupuncture and training|Migraine acupuncture and training
11193905|NCT03426800|Experimental|Migraine training|Migraine training
11193906|NCT03426800|Experimental|Tension_acupuncture and training|Tension headache acupuncture and training
11193907|NCT03426800|Experimental|Tension headache training|Tension headache training
11193908|NCT03426787|Experimental|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
11193909|NCT03426774|Experimental|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193910|NCT03426774|Experimental|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193911|NCT03426774|Experimental|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193912|NCT03426774|Experimental|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193913|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193914|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193915|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193916|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
11193917|NCT03426761|Experimental|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
11193988|NCT03426202|Experimental|placebo group|a single dose of p.o. placebo (200mg)
11193918|NCT03426761|Active Comparator|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
11193919|NCT03426748|Active Comparator|Low dose rate brachytherapy|Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
11193920|NCT03426748|Experimental|High dose rate brachytherapy|"Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.
~HDR brachytherapy is also accomplished as an out-patient."
11193921|NCT03426735|Experimental|Dry heat|Dry heat application with a termal bag
11193922|NCT03426735|Active Comparator|Dry cold|Dry cold application with a termal bag
11193923|NCT03426722|Active Comparator|L-carnitine|L-carnitine 500mg three times daily (per oral)
11193924|NCT03426722|Placebo Comparator|Placebo|Placebo 500mg three times daily (per oral)
11193925|NCT03426709|Experimental|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies) in groups of 8-12 people.
11193926|NCT03426709|No Intervention|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
11193927|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
11193928|NCT03426683|Experimental|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
11193929|NCT03426683|No Intervention|traditional drugs|The patients will receive traditional medicine treatment as usual.
11193930|NCT03426670|Active Comparator|OraQuick HIV Self-Test|Sex workers in the intervention arm will be instructed to self-test before starting each monthly course of PrEP. HIV Self-testing will be performed during the months between scheduled quarterly visits.
11193931|NCT03426670|No Intervention|In-clinic testing|All study participants will receive quarterly in-clinic HIV testing as standard-of-care.
11193932|NCT03426657|Experimental|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W / since Amendment 3: 300 mg absolute dose d5) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
11193933|NCT03426644|Active Comparator|Group A|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.
11193934|NCT03426644|Experimental|Group B|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
11193935|NCT03426644|Experimental|Group C|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
11193936|NCT03426644|Experimental|Group D|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group D.
11193937|NCT03426631|Placebo Comparator|Placebo|Placebo before sleep
11193938|NCT03426631|Experimental|DAW1033B2 oral capsule|DAW1033B2 before sleep
11193939|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
11193940|NCT03426605|Experimental|LAM-003|Open label LAM-003 at three increasing dose levels of 200, 300 and 450 mg.
11193941|NCT03426592|Active Comparator|Vitamin D3, 10000 Intl Units Oral Capsule|Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months
11193942|NCT03426592|Placebo Comparator|Placebo oral capsule|Oleic acid capsule by mouth, daily for 6 months
11193943|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
11193944|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
11193945|NCT03426553|Experimental|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
11193946|NCT03426553|Active Comparator|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
11193947|NCT03426540|Experimental|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
11193948|NCT03426540|No Intervention|control group|Pars plana vitrectomy alone
11193949|NCT03426527|Placebo Comparator|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
11193950|NCT03426527|Active Comparator|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
11193951|NCT03426514|Experimental|Three-port Laparoscopic Surgery|Patients with colorectal cancer undergo three-port laparoscopic surgery.
11193952|NCT03426514|Experimental|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（4 or more ports）.
11193989|NCT03426189||HIV infected individuals on long term ART|"Leukapheresis
~Lymph node biopsy"
11193990|NCT03426176|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
11194301|NCT03424018|Experimental|BMN 111|
11193953|NCT03426488||Västerbotten Intervention Programme|"The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.
~The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.
~The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.
~A large part is fasting samples.
~Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300"
11193954|NCT03426488||Mammography Screening Project|"Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).
~Survey data can be linked to the blood samples.
~Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000"
11193955|NCT03426488||The Northern Swedish MONICA Project|"The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.
~Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)"
11193956|NCT03426475|No Intervention|Control Group|Care of nursing home residents as usual.
11193957|NCT03426475|Experimental|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
11193958|NCT03426462|Experimental|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.
~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
11193959|NCT03426462|Experimental|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.
~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
11193960|NCT03426449|Active Comparator|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
11193961|NCT03426449|Active Comparator|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
11193962|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
11193963|NCT03426423|Experimental|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
11193964|NCT03426423|Active Comparator|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
11193965|NCT03426397||Study population|
11193966|NCT03426384|Active Comparator|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.
~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
11193967|NCT03426384|No Intervention|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
11193968|NCT03426371|Experimental|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
11193969|NCT03426371|Placebo Comparator|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
11193970|NCT03426358|Experimental|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
11193971|NCT03426345|Experimental|Relamorelin 10μg|Relamorelin 10μg injected subcutaneously twice daily for 12 weeks.
11193972|NCT03426345|Placebo Comparator|Placebo|Placebo injected twice daily for 12 weeks.
11193973|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
11193974|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
11193975|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
11193976|NCT03426280|Experimental|Apple Watch|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
11193977|NCT03426280|No Intervention|Usual Care|Usual care.
11193978|NCT03426267|Experimental|SDN-037|
11193979|NCT03426267|Placebo Comparator|vehicle|
11193980|NCT03426254|Experimental|Injections Subcutaneously Talazoparib|"Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Auto-Injector delivers a single dose of 1 mg Talazoparib injection (subcutaneous)"
11193981|NCT03426254|Active Comparator|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11193982|NCT03426241||smoking chronic periodontitis|
11193983|NCT03426241||non-smoking periodontitis|
11193991|NCT03426176|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
11193992|NCT03426176|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
11193993|NCT03426176|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
11193994|NCT03426163|Experimental|VR group|Application of virtual reality 12 hours before arthroscopic surgery
11193995|NCT03426163|No Intervention|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
11193996|NCT03426150|Experimental|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
11193997|NCT03426150|Placebo Comparator|Deionized water|Deionized water application on the specimen surface for 3 min
11193998|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
11193999|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
11194000|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
11194001|NCT03426124||Retrospective|Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
11194002|NCT03426124||Prospective|Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
11194003|NCT03426111|Placebo Comparator|Placebo|Diagnostic upper endoscopy plus lifestyle modification.
11194004|NCT03426111|Active Comparator|Treatment|Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
11194005|NCT03426098|Experimental|Treatment|After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
11194006|NCT03426085|Placebo Comparator|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
11194007|NCT03426085|Experimental|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
11194008|NCT03426072|Experimental|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
11194009|NCT03426072|No Intervention|Control|The control units (propensity matched) have no intervention and form a naturalistic control
11194010|NCT03426059||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
11194011|NCT03426046|Experimental|Biodentine|Partial pulpotomy treatment with Biodentine
11194012|NCT03426046|Active Comparator|Calcium Hydroxide|Partial pulpotomy treatment with Calcium Hydroxide
11194013|NCT03426046|Experimental|Mineral Trioxide Aggregate|Partial pulpotomy treatment with Mineral Trioxide Aggregate
11194014|NCT03426033|Experimental|Single dose of warfarin|Single dose of warfarin administered to obtain pharmacokinetic information.
11194015|NCT03426033|Experimental|Warfarin in combination with ISIS 681257|ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.
11194016|NCT03426020|Active Comparator|Oral midazolam (Demizolam®)|To prevent emergence agitation patient premedicated by 0.5 mg oral midazolam At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
11194017|NCT03426020|Active Comparator|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|To prevent emergence agitation patient premedicated by watching a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
11194018|NCT03426020|Active Comparator|Play game (PC fishing game)|To prevent emergence agitation patient premedicated by playing a simple PC game (fishing game) At the end of sugery patients postoperatif emergence agitation evaluated PAED(pediatric anesthesia emergence delirium scale).
11194019|NCT03426007|Experimental|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
11194020|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
11194021|NCT03425981|Experimental|WB-EMS-SRT|Training with basic global electrostimulation
11194022|NCT03425981|Experimental|WB-EMS-WT|Training with specific global electrostimulation for runners
11194023|NCT03425981|Placebo Comparator|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
11194024|NCT03425968||Knee hyperextension group|athletes who has knee hyperextension
11194025|NCT03425968||Control group|athletes who doesn't have knee hyperextension
11194026|NCT03425955|Experimental|GROUP 1|Normotypic or overweight subjects with rounded, oval or squared face (aged 35-50 years)
11194027|NCT03425955|Experimental|GROUP 2|"Thin subjects with oval or triangular face and sagging skin (aged 45-60 years)"
11194053|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
11194028|NCT03425942|Experimental|Internet CBT for insomnia|The intervention consists of Internet-based Cognitive Behavioral Therapy for insomnia (ICBT-i) (the main components are sleep restriction and stimulus control) for five consecutive weeks.
11194029|NCT03425942|Active Comparator|Internet ART for insomnia|The intervention consists of internet-based applied relaxation exercises/techniques (ART) (different and commonly used) for five consecutive weeks.The acronyme for this intervention is (IART-i).
11194030|NCT03425929|Active Comparator|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
11194031|NCT03425929|Active Comparator|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
11194032|NCT03425929|Placebo Comparator|Placebo|Placebo nasal spray for six days
11194033|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
11194034|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
11194035|NCT03425903|Active Comparator|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
11194036|NCT03425903|No Intervention|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
11194037|NCT03425890|Experimental|SURE Program Group|The intervention group will receive a SURE program booklet and will perform individualized daily self-exercise and functional use of the arm and hand on their own outside of therapy for 60 minutes/day, 6 days/week for 4 weeks. These self-exercises and upper limb functional use will be performed in addition to usual care. Three SURE program booklets have been developed which relate to the affected upper limb motor capability using individual Fugl Meyer (ULFM) score. Each SURE program booklet consists of warm-up exercises, strengthening exercises and motor tasks. The SURE program booklet also includes selected functional motor tasks to be performed by the participants using their affected upper limb. The performance of the exercises and functional motor tasks will be reviewed three times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.
11194038|NCT03425890|Experimental|Education Group|The control group will receive an education booklet with 10 modules. The education booklet will contain information on stroke, recovery and management strategies after stroke. Participants are to complete 2-3 modules per week and answer 1-2 simple questions after each module. Each module including answering questions takes approximately 5-10 minutes to complete. CPI will review the information with the participants 3 times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.The participants in the control group will continue with their usual care in the hospital.
11194039|NCT03425877|Experimental|Parkinson's disease Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.
~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
11194040|NCT03425877|Experimental|Stroke Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.
~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
11194041|NCT03425877|Experimental|Healthy Subjects Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.
~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
11194042|NCT03425864|Other|immediate implant|patient will receive immediate implant alone.
11194043|NCT03425864|Active Comparator|immediate implant with connective tissue graft|patient will receive immediate implant and connective tissue gaft
11194044|NCT03425851|Experimental|Intervention Group|Receive 600 diapers.
11194045|NCT03425851|Active Comparator|Control Group|Receive resources of diaper banks as requested.
11194046|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
11194047|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
11194048|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
11194049|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
11194050|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
11194051|NCT03425812|Experimental|Non- NSAIDS group|To withdraw NSAIDS therapy
11194052|NCT03425812|Active Comparator|NSAIDS group|To continue NSAIDS therapy
11194417|NCT03423303|No Intervention|Control arm|Registry-based follow-up and a questionnaire.
11194054|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
11194055|NCT03425786|Experimental|Early BPPV Management|Diagnostic and treatment training for BPPV.
11194056|NCT03425786|Active Comparator|Late BPPV Management|Diagnostic training for BPPV. Sports Medicine providers will refer patients positive for BPPV to an Otolaryngologist at our institution for treatment.
11194057|NCT03425773|Experimental|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
11194058|NCT03425747|Active Comparator|Calcium Carbonate|Calcium Carbonate
11194059|NCT03425747|Active Comparator|calcium Citrate|Calcium Citrate
11194060|NCT03425734|Experimental|D group|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
11194061|NCT03425734|Experimental|S group|50 ml saline
11194062|NCT03425721||All Participants|Subjects who present with late occurring nodules, occurring more than 4 weeks but less than 2 years after the latest injection of any HA soft tissue filler. This population will only include subjects who, before receiving the HA soft tissue filer were naïve to soft tissue fillers or had previously received only HA-based soft tissue fillers.
11194063|NCT03425708|Active Comparator|Treatment group1|Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
11194064|NCT03425708|Active Comparator|Treatment group2|Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
11194065|NCT03425708|No Intervention|Control group|Treatment of CKD patients with hyperuricaemia with conventional methods.
11194066|NCT03425695|Experimental|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination
~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
11194067|NCT03425695|Placebo Comparator|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination
~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
11194068|NCT03425682||Cervical Fusion - ACDF|Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
11194069|NCT03425682||Lumbar Interbody Fusion|Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
11194070|NCT03425669|Active Comparator|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
11194071|NCT03425669|Active Comparator|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
11194072|NCT03425669|Sham Comparator|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
11194073|NCT03425669|Active Comparator|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
11194074|NCT03425669|Sham Comparator|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
11194075|NCT03425656|Experimental|Trastuzumab (AryoTrust)|Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
11194076|NCT03425656|Active Comparator|Trastuzumab (Herceptin)|Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
11194077|NCT03425643|Experimental|NAC + Neoadjuvant/Adjuvant Pembrolizumab|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, intravenous (IV); given on cycle day 1] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].
~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab [200 mg, IV; given on cycle day 1]. Participants who receive radiotherapy without undergoing surgery will not receive adjuvant therapy."
11194078|NCT03425643|Placebo Comparator|NAC + Neoadjuvant/Adjuvant Placebo|"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1] in combination with platinum doublet NAC, consisting of cisplatin [75 mg/m^2, IV; given on cycle day 1] and either Gemcitabine [1000 mg/m^2, IV; given on cycle days 1 and 8] or Pemetrexed [500 mg/m^2, IV; given on cycle day 1].
~Adjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo [normal saline, IV; given on cycle day 1]. Participants who receive radiotherapy without undergoing surgery will not receive adjuvant therapy."
11194079|NCT03425630|Experimental|Argicolina (cross-over vs Normolip)|Argicolina is a dietary supplement containing monacolin (sachets)
11194080|NCT03425630|Active Comparator|Normolip (cross-over vs Argicolina)|Normolip is a dietary supplement containing monacolin (tablets)
11194081|NCT03425617|Experimental|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
11194082|NCT03425617|Experimental|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
11194083|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
11194084|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
11194299|NCT03424031|Experimental|Verticalization|the patient will be placed in the most vertical position possible.
11194085|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
11194086|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
11194087|NCT03425578|Experimental|MSG + CHO|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
11194088|NCT03425578|Active Comparator|MSG + placebo B|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
11194089|NCT03425578|Active Comparator|Placebo A + CHO|Participants will ingest placebo capsules followed by 75 g dextrose.
11194090|NCT03425565|Experimental|Pembrolizumab|
11194091|NCT03425552|Experimental|Test treatment|Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)
11194092|NCT03425552|Active Comparator|Reference treatment|Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension
11194093|NCT03425539|Experimental|Lucerastat|
11194094|NCT03425539|Placebo Comparator|Placebo|
11194095|NCT03425526|Experimental|Treatment (allogeneic adenovirus-specific CTLs)|Within two weeks of enrollment, patients receive allogeneic adenovirus-specific CTLs IV over 30 minutes. Patients may receive additional allogeneic adenovirus-specific CTL infusions at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.
11194096|NCT03425513||Hepatitis B group|
11194097|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
11194098|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
11194099|NCT03425487|Experimental|MBSR+TAU|Mindfulness based Intervention (MBSR) + Usual specialized treatment in mental health. MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
11194100|NCT03425487|Experimental|ABCT+TAU|Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
11194101|NCT03425487|Active Comparator|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
11194102|NCT03425474|Experimental|Remimazolam Tosilate|Remimazolam Tosilate at 5mg for initial dose
11194103|NCT03425474|Active Comparator|Propofol|Propofol at 1.5mg/kg for initial dose
11194104|NCT03425461|Experimental|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
11194105|NCT03425461|Experimental|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
11194106|NCT03425448|Active Comparator|Heparin group|
11194107|NCT03425448|Experimental|Neotrolin Group|
11194108|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
11194109|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
11194110|NCT03425409|Other|Continuous Flow|Oxygen delivery at 4 liters per minute is the standard method
11194111|NCT03425409|Other|Pneumatic Pulsed Flow|Oxygen delivery using test method
11194112|NCT03425396|Experimental|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
11194113|NCT03425396|Experimental|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
11194114|NCT03425396|Experimental|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
11194115|NCT03425396|Experimental|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
11194116|NCT03425396|Active Comparator|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
11194117|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
11194118|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
11194154|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
11194119|NCT03425370|Experimental|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
11194120|NCT03425370|Experimental|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
11194121|NCT03425357|Experimental|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
11194122|NCT03425344|Other|Diagnostic|All participants will be exposed to shoulder- MRI, ultrasound and sonoelastography.
11194123|NCT03425331|Experimental|Nivolumab+Ipilimumab|Nivolumab will be administered once every 2 weeks intravenously Ipilimumab will be administered once every 6 weeks intravenously
11194124|NCT03425318|Experimental|Single arm|
11194125|NCT03425292|Active Comparator|1 SOC|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
11194126|NCT03425292|Experimental|2 Nivo|Nivolumab
11194127|NCT03425292|Experimental|3 Nivo-Ipi|Nivolumab plus Ipilimumab
11194128|NCT03425292|Experimental|4 Nivo-Ipi-Bev|Nivolumab plus Ipilimumab plus Bevacizumab
11194129|NCT03425292|Experimental|5 Nivo-Ipi-TMZ|Nivolumab plus Ipilimumab plus metronomic Temozolomide
11194130|NCT03425292|Experimental|6 Nivo-Ipi-Bev-TMZ|Nivolumab plus Ipilimumab plus Bevacizumab plus metronomic Temozolomide
11194131|NCT03425279|Experimental|BA3011|Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with nivolumab.
11194132|NCT03425266|Experimental|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
11194133|NCT03425266|No Intervention|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
11194134|NCT03425253|Experimental|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® is injected into preplaytsmal fat tissue in the submental area. When the Investigator and subject agree that no further intervention is required to achieve the desired result, subjects will be eligible to receive VOLUMA™ treatment. VOLUMA™ is injected along the mandibular border.
11194135|NCT03425240|Experimental|Nerve Stimulation|Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.
11194136|NCT03425227|Experimental|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.
~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
11194137|NCT03425214|Experimental|NC with RBD|fMRI and video polysmnography
11194138|NCT03425214|Experimental|NC without RBD|fMRI and video polysomnography
11194139|NCT03425214|Experimental|control group (healthy subjects)|fMRI
11194140|NCT03425201|Experimental|Niraparib plus Cabozantinib|"Patients will receive niraparib and cabozantinib p.o. once daily in 28-day cycles.
~In phase I, patients will be accrued to each dose level in cohorts of 6 patients. Escalation will continue until a dose-limiting toxicity (DLT) is observed or the highest dose-level is reached.
~In phase II study patients will receive niraparib p.o. once daily and cabozantinib p.o. once daily in 28-day cycles at doses recommended in the phase I study.
~If niraparib or cabozantinib need to be interrupted due to toxicity, patient can continue only with the other drug."
11194141|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
11194142|NCT03425175|No Intervention|Control group|Standard care with recording of video but no audio-recording
11194143|NCT03425175|Experimental|Intervention group|Standard care with the addition of simultaneous audio-recording during the operation.
11194144|NCT03425162|Active Comparator|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+PCA (morphine)
11194145|NCT03425162|Sham Comparator|Group P|Group P:PCA (morphine)
11194146|NCT03425149|Experimental|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
11194147|NCT03425149|Experimental|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
11194148|NCT03425149|Experimental|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
11194149|NCT03425149|Experimental|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
11194150|NCT03425149|Placebo Comparator|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
11194151|NCT03425136|Experimental|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
11194152|NCT03425136|No Intervention|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
11194153|NCT03425123|Experimental|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
11194155|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
11194156|NCT03425084|Experimental|Morphine|Intravenous morphine (0,15 mg/kg) will be given as a single dosis at the end of the surgery followed by morphine administrated by patient-controlled analgesia (PCA) as single boluses (0,04mg/kg)
11194157|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
11194158|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
11194159|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
11194160|NCT03425045|Experimental|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
11194161|NCT03425045|Sham Comparator|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
11194162|NCT03425045|Active Comparator|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
11194163|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
11194164|NCT03425006|Experimental|Itacitinib and Pembrolizumab|
11194165|NCT03424993|Experimental|Dietary Sodium Restriction|Daily habitual dietary sodium intake < 2000mg
11194166|NCT03424993|Sham Comparator|Control|Routine habitual dietary sodium intake >3400mg
11194167|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
11194168|NCT03424967|Experimental|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
11194169|NCT03424954|Experimental|EpxOstomy|Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.
11194170|NCT03424941|Experimental|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
11194171|NCT03424941|Active Comparator|CABG and SAVR|CABG and SAVR
11194172|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
11194173|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
11194174|NCT03424915||Regular exercisers and non-exercising groups who have been diagnosed with breast cancer|There is no treatment on this study, it is a onetime assessment. exercisers: ≥120 minutes of vigorous-intensity aerobic exercise;There is no treatment on this study, it is a onetime assessment. non-exercisers: ≤ 30 minutes of moderate-intensity exercise per week.
11194175|NCT03424915||Regular exercisers who are at high risk of developing breast cancer|≥120 minutes of vigorous-intensity aerobic exercise;
11194176|NCT03424902||group1|patients with no or mild paravalular leakage
11194177|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
11194178|NCT03424889|Experimental|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
11194179|NCT03424889|Placebo Comparator|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
11194180|NCT03424876||Arm A|Imatinib 400 mg/day or 600mg/day, and within 6 weeks after surgery, continuous treatment was not tolerated until tumor progression, recurrence or adverse reactions were not tolerated.
11194181|NCT03424876||Arm B|Sunitinib 37.5 mg/day, continuous taking, or 50 mg/day (4/2), began within 6 weeks after surgery, and was continuously administered until tumor progression, recurrence or adverse reactions were not tolerated
11194182|NCT03424863|Experimental|Aortic stent graft patients|Patients who have received an aortic stent graft who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
11194183|NCT03424863|Experimental|Healthy volunteers|Healthy volunteers in general good health with no history of heart disease who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
11194184|NCT03424850|Experimental|HDR brachytherapy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
11194185|NCT03424837|Experimental|Intervention Arm: SoC (standard of care) and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
11194186|NCT03424837|No Intervention|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise & diet, and lived experiences modules.
11194187|NCT03424824|Experimental|BP1.3656 low dose|
11194188|NCT03424824|Experimental|BP1.3656 intermediate dose|
11194189|NCT03424824|Placebo Comparator|Placebo|
11194190|NCT03424811|Experimental|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
11194191|NCT03424811|No Intervention|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
11194192|NCT03424772||Patients with unexplained DD/ID|Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.
11194193|NCT03424759|Experimental|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
11194194|NCT03424746|Experimental|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
11194195|NCT03424733|Active Comparator|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
11194196|NCT03424733|Experimental|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
11194197|NCT03424720|Experimental|Comparison of PLE and BIS|Investigators assess PLE and BIS values as indicators of the depth of anesthesia during induction and emergence of anesthesia and facial nerve integrity monitoring
11194198|NCT03424707|Experimental|combination|
11194199|NCT03424707|Active Comparator|single|
11194200|NCT03424707|Placebo Comparator|placebo|
11194201|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.
~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
11194202|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.
~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
11194203|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
11194204|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
11194205|NCT03424655|Experimental|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
11194206|NCT03424655|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
11194207|NCT03424655|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
11194208|NCT03424655|Experimental|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
11194209|NCT03424642|Experimental|Interactive 4D-ultrasound examination|Pregnant women who are randomized to 4D-ultrasound intervention group will receive additional 4D-ultrasound examinations 2-3 times between gestational weeks 25-32. Patients in this group will also receive psychologist's interview twice and fill out questionaries.
11194210|NCT03424642|No Intervention|Control group|Pregnant women who are randomized to control group will receive psychologist's interview twice twice and fill out questionaires.
11194211|NCT03424629|Experimental|Low-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection
11194212|NCT03424629|Experimental|High-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection
11194213|NCT03424629|Active Comparator|Methotrexate|5-25mg Methotrexate orally
11194214|NCT03424616|Experimental|Postoperative immediate Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.
11194215|NCT03424616|Sham Comparator|Postoperative delayed Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.
11194216|NCT03424603|Experimental|STRO-001|intravenous
11194217|NCT03424590|Active Comparator|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
11194218|NCT03424590|No Intervention|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
11194219|NCT03424577|Experimental|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
11194220|NCT03424564|Experimental|Perampanel single-dose Part: 2 mg group|Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
11194221|NCT03424564|Experimental|Perampanel single-dose Part: 4 mg group|Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
11194222|NCT03424564|Experimental|Perampanel single-dose Part: 8 mg group|Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
11194223|NCT03424564|Experimental|Perampanel multiple-dose Part|Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
11194224|NCT03424551|Experimental|Vibrator|Local or Whole body vibration was applied at six different frequencies to Healthy control and spastic spinal cord injury. For local vibration, vibration frequencies were 50, 85, 140, 185, 235 and 265 Hz . For whole body vibration, vibration frequencies were 35, 37, 39, 41, 43 and 45 Hz
11194225|NCT03424538|Experimental|MSt|The MSt group that received 5 weeks of intensive therapy.
11194226|NCT03424538|No Intervention|MSc|The MS controll group that did not receive treatment.
11227355|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
11194228|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
11194229|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
11194230|NCT03424512|Experimental|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
11194231|NCT03424499|Active Comparator|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.
~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.
~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
11194232|NCT03424499|Experimental|Reused catheter|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.
~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soup after each catheterization and stored in a container with 0.5% benzalkonium chloride.
~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
11194233|NCT03424486||Adolescents (14 to 17 years old)|Patients with CF
11194234|NCT03424486||Parents|Parents of adolescents (14 to 17 years old with CF (father, mother and other)
11194235|NCT03424460|Experimental|population 1-A1 : DM1 with VTE|Myotonic dystrophy type 1 patients with a history of venous thromboembolism (pulmonary embolism and/or deep vein thrombosis)
11194236|NCT03424460|Active Comparator|population 1-B1 : DM1 without VTE|Myotonic dystrophy type 1 patients without a history of venous thromboembolism
11194237|NCT03424460|Active Comparator|population 1-C1 : Healthy volunteers|Healthy volunteers without any medical history or treatment
11194238|NCT03424460|Experimental|population 2-A2 : DM1 liver samples|Liver samples of patients with myotonic dystrophy type 1
11194239|NCT03424460|Active Comparator|population 2-B2 : Healthy liver samples|Liver samples from patients without any medical history
11194240|NCT03424447|No Intervention|Non stimulated|Prospective data obtained from non stimulated patients
11194241|NCT03424447|Experimental|Stimulated|Prospective data obtaied from stimulated patients
11194242|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
11194243|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
11194244|NCT03424408|Other|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
11194245|NCT03424395|Other|Personalized dietary and wellness program|An integrated personalized nutrition program which includes a combination of dietary and wellness advice/counseling on wellness and meals, or dietary and wellness advice/counseling alone, each for 10 weeks.
11194246|NCT03424382||Phase I|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
11194247|NCT03424382||Phase II|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
11194248|NCT03424369||Eustachian tube unobstructed|
11194249|NCT03424369||Eustachian tube dysfunction|
11194250|NCT03424356|Experimental|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
11194251|NCT03424356|Active Comparator|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
11194252|NCT03424343||cancer survivor, parents, sibling|
11194253|NCT03424330|Experimental|Arm1 - ReX first|Subjects begin with the ReX-C Intervention stage followed by Standard of Care stage.
11194254|NCT03424330|Experimental|Arm 2- Standard of Care first|Subjects start with Standard of Care stage followed by ReX-C Intervention.
11194255|NCT03424317|Active Comparator|Sodium intake reduction and exercise|education of sodium intake reduction and regular exercise
11194256|NCT03424317|Placebo Comparator|Exercise|education of regular exercise only
11194257|NCT03424304|Other|Excel V™ Laser With Green Genesis|Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
11194258|NCT03424291|Experimental|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
11194259|NCT03424278|Active Comparator|Motor Control|
11194260|NCT03424278|Experimental|Resistance Training|
11194261|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
11194262|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
11194263|NCT03424252|Experimental|FDL169 Dose Level 1,sublingual to oral|Dose level 1 sublingual first and oral second.
11194264|NCT03424252|Experimental|FDL169 Dose Level 1 dosing,oral to sublingual|Dose level 1 oral first and sublingual second.
11194265|NCT03424252|Experimental|FDL169 Dose Level 2 sublingual to oral,Optional|Dose level 2 sublingual first and oral second.
11194266|NCT03424252|Experimental|FDL169 Dose Level 2 oral to sublingual,Optional|Dose level 2 oral first and sublingual second.
11227356|NCT03195244|No Intervention|Observation|
11194267|NCT03424239|Experimental|Drug: Zoledronic Acid, Calcium+Vitamin D|Subjects will receive a single intravenous infusion of zoledronic acid (5 mg). Supplemental calcium citrate + vitamin D (500mg+500IU) and vitamin D3 (1000 IU) will be dispensed throughout the study to fit individual needs.
11194268|NCT03424226|Experimental|day of acetazolamide|acetazolamide 125mg twice a day, started morning of ascent
11194269|NCT03424226|Active Comparator|night before acetazolamide|acetazolamide 125mg twice a day, started evening before ascent
11194270|NCT03424213||white low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
11194271|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
11194272|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
11194273|NCT03424213||AA low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
11194274|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
11194275|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
11194276|NCT03424200|Other|Coaching plus Routine Care|Participants will receive coaching plus routine care
11194277|NCT03424200|Other|Routine Care|Participants will receive the routine care
11194278|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
11194279|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
11194280|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
11194281|NCT03424174|Experimental|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
11194282|NCT03424174|Active Comparator|Standard Total Knee Arthroplasty|Implantation Standard Total Knee Arthroplasty
11194283|NCT03424161|Other|Secret RF|Treatment with Secret RF for skin quality
11194284|NCT03424148|Other|Excel V™ Laser & Micro-Lens Array Attach|Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
11194285|NCT03424135|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
11194286|NCT03424135|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
11194287|NCT03424122|Experimental|Treatment A|Parsaclisib + Rituximab
11194288|NCT03424122|Experimental|Treatment B|Parsaclisib + Bendamustine + Rituximab
11194289|NCT03424122|Experimental|Treatment C|Parsaclisib + Ibrutinib
11194290|NCT03424109||Beneficiaries with a one-year mortality of at least 30%|The patient cohort will be extracted via the Centers for Medicare and Medicaid Services (CMS) Research Data Assistance Center (ResDAC) using a two-step process to maximize diversity, and minimize intentional or unintentional exclusions based on risk, age, health literacy, demographics, or expected adherence.
11194291|NCT03424083||1 cohort|adult patients of both sexes (>18 and <80 years) with no previous diagnosis or follow up by a pulmonologist, send by a general practitioner to the lung function lab
11194292|NCT03424070|Active Comparator|Laryngoscopy view with a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy with and then without the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
11194293|NCT03424070|Placebo Comparator|Laryngoscopy without a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy without and then with the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
11194294|NCT03424057|Experimental|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).
~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
11194295|NCT03424057|Active Comparator|Group 2|Group 2 were treated with the standard Karydakis technique.
11194296|NCT03424044|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
11194297|NCT03424044|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
11194298|NCT03424044|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
11194302|NCT03424005|Active Comparator|Atezolizumab + Nab-Paclitaxel|1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab + nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11194303|NCT03424005|Experimental|Atezolizumab + Nab-Paclitaxel + Tocilizumab|1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11194304|NCT03424005|Experimental|Atezolizumab + Sacituzumab Govitecan|1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11194305|NCT03424005|Active Comparator|Capecitabine|"2L CIT-naive participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria."
11194306|NCT03424005|Experimental|Atezolizumab + Ipatasertib|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab + ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria."
11194307|NCT03424005|Experimental|Atezolizumab + SGN-LIV1A|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria."
11194308|NCT03424005|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"2L-CIT-naive participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria."
11194309|NCT03424005|Experimental|Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)|2L CIT-naive participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naive participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemotherapy (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11194310|NCT03423992|Experimental|Biological: Chimeric antigen receptor T cells|
11194311|NCT03423979|Experimental|Optilume™ BPH Prostatic DCB Dilation Catheter|Optilume™ BPH Prostatic DCB treatment procedure
11194312|NCT03423966|Experimental|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
11194313|NCT03423966|No Intervention|Usual Care (UC)|Usual Care of obesity
11194314|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
11194315|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
11194316|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
11194317|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
11194318|NCT03423927|Experimental|Intervention group : hypnosis + self-care|Groupal intervention combining self-care techniques and self-hypnosis exercises
11194319|NCT03423927|No Intervention|Control group : no intervention|Control group receiving usual care but not the intervention
11194320|NCT03423914|Experimental|Writing Intervention Group|Expressive writing The participant will write four days about her deepest thoughts and feelings in relation to the experience of hospitalization of the premature newborn and how this experience is related to your current life and to your future.
11194321|NCT03423914|Active Comparator|Control Group|Only Writing The participants will write about situations not related to the subjective human experience of their preterm birth, but about general aspects.
11194322|NCT03423901|Experimental|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
11194323|NCT03423901|Experimental|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
11194324|NCT03423901|Experimental|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
11194325|NCT03423888|Experimental|High-flow nasal oxygen|
11194326|NCT03423875|No Intervention|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
11194327|NCT03423875|Experimental|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
11194328|NCT03423849|Experimental|The original program (NG/NP)|Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）
11194329|NCT03423849|Experimental|One of the original program (N)|Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.
11194330|NCT03423849|Experimental|Capecitabine monotherapy|Capecitabine oral 1250mg/m2,bid,for 6 cycles
11194331|NCT03423836||High Risk Infants|Motor infants born prior to 35 weeks gestational age, or, infants small (<10th percentile) for gestational age.
11194332|NCT03423836||Low Risk Infants|Motor infants born after the completion of the 37th week of gestation and appropriate for gestational age.
11194333|NCT03423823|Experimental|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
11194334|NCT03423823|Other|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
11194335|NCT03423810|Experimental|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
11194336|NCT03423797|Active Comparator|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
11194337|NCT03423797|Experimental|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
11194338|NCT03423784|Experimental|HA BPX V3.3|A HMWHA gel available in a formulation specificaly designed for use in infants
11194339|NCT03423784|Active Comparator|Dentinox-Gel N|Gold standard for teething symptoms
11194340|NCT03423771|Experimental|NPF-08 Low dose （1-day treatment）|
11194341|NCT03423771|Experimental|NPF-08 Medium dose （2-day split dose）|
11194342|NCT03423771|Experimental|NPF-08 High dose （2-day split dose）|
11194343|NCT03423771|Experimental|NPF-08 Medium dose （1-day treatment）|
11194344|NCT03423771|Experimental|NPF-08 High dose （1-day treatment）|
11194345|NCT03423771|Experimental|NPF-08 Low～High dose （1-day treatment）|
11194346|NCT03423771|Experimental|NPF-08 Medium～High dose （2-day split dose）|
11194347|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
11194348|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
11194349|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
11194350|NCT03423732|Active Comparator|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
11194351|NCT03423732|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
11194352|NCT03423719|Experimental|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
11194353|NCT03423719|Placebo Comparator|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
11194354|NCT03423706|Experimental|new model of haplo-HSCT|use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
11194355|NCT03423693||Asthma with SAO+|Asthmatic patients with RV/TLC > or = 40
11194356|NCT03423693||Asthma with SAO-|Asthmatic patients with RV/TLC < 40
11194357|NCT03423693||ACO|Asthmatic patients with smoking > or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC < 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 > or = 200 ml and FEV1% > or =12% after BD)
11194358|NCT03423693||COPD|Patients with history of smoking > or = 10 pack year with post-BD FEV1/FVC < 0.7 and negative BD reversibility (absolute increase in FEV1 < 200 ml and FEV1% <12% after BD)
11194359|NCT03423680|Experimental|Abilify (Tablet)|
11194360|NCT03423680|Placebo Comparator|Placebo of Abilify (Tablet)|
11194361|NCT03423667|Experimental|N-acetylcysteine|
11194362|NCT03423667|Placebo Comparator|Lactose powder|
11194363|NCT03423654|Experimental|Training Group|Spatial training
11194364|NCT03423654|Other|Control Group|Letter number matching
11194365|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
11194366|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
11194367|NCT03423628|Experimental|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
11194368|NCT03423615|Experimental|CHHIP Arm|"All enrolled students in schools in the CHHIP Arm were eligible to receive the CHHIP intervention. The CHHIP intervention was delivered by lay fieldworkers (SHAs). Intervention activities included:
~Health Education: activity-based curriculum with lessons delivered once per week. Units include hygiene, nutrition, safety, disease prevention& management, and social, emotional, and behavior development.
~Basic Primary Health Services: school-based treatment including deworming and iron supplementation; screening and referral programs including growth monitoring, well-child exam, vision screening, epilepsy screening, and oral health; psychosocial and counseling support for students with atypical behaviors.
~Health School Environment: improvements to physical infrastructure including latrines and water systems; modeling of positive behavior reinforcement, inclusive learning environment, and avoidance of corporal punishment."
11194369|NCT03423615|No Intervention|Comparison Arm|All enrolled students in schools in the Comparison Arm received school health activities as were routinely available in their school, through their curriculum, or through special events.
11194370|NCT03423602|Experimental|Investigational device|PerQseal® closure system
11194371|NCT03423589|Experimental|VSL#3|Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
11194759|NCT03421158|No Intervention|Control|Newborns received no pain interventions during the procedure
11194372|NCT03423576|Experimental|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
11194373|NCT03423576|No Intervention|Control|Standard care
11194374|NCT03423563|Experimental|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
11194375|NCT03423563|Experimental|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
11194376|NCT03423550||Participants who are suspected with TB|
11194377|NCT03423537|Experimental|Group 1 [HCG (+) group]|"Group 1 will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH"
11194378|NCT03423537|Placebo Comparator|Group 2 [placebo]|"Group 2 will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead"
11194379|NCT03423524|Experimental|Arm: Investigational Device|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. consisting of hydrophobic material"
11194380|NCT03423511|Experimental|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
11194381|NCT03423511|Active Comparator|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
11194382|NCT03423498|Experimental|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
11194383|NCT03423498|No Intervention|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
11194384|NCT03423485|Experimental|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
11194385|NCT03423472|Experimental|Full intervention|Healthy Baby Toolkit (HBT) in addition to Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
11194386|NCT03423472|Active Comparator|Partial intervention|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
11194387|NCT03423472|Other|Control|Government standard of care for nutrition education through the Health Development Army
11194388|NCT03423459||CT Cohort|"Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.
~Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.
~Determine how the Evolut PRO conforms to LVOT calcification.
~Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.
~Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.
~Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
11194389|NCT03423459||Non-CT Cohort|"Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.
~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.
~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
11194390|NCT03423446|Experimental|Severe Hepatic Impairment|Up to 8 subjects with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15 points)
11194391|NCT03423446|Experimental|Healthy Control|Up to 8 healthy control subjects with normal hepatic function
11194392|NCT03423433|No Intervention|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.
~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.
~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
11194418|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
11194419|NCT03423264|Experimental|Gabapentin|Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
11194532|NCT03422588|Experimental|Intracorporeal|Totally laparoscopic right colectomy with intracorporeal anastomosis
11194393|NCT03423433|Experimental|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.
~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
11194394|NCT03423407||PET/MR|"Participants will be scanned on a PET-MRI scanner which is FDA-approved and will operate within FDA-approved guidelines.
~Participants will be asked to lie still within the scanner for up to 90 minutes"
11194395|NCT03423394|Experimental|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment.
11194396|NCT03423394|Active Comparator|Treatment as Usual|The treatment as usual (TAU) condition was selected to mirror the existing process in the military for identifying and encouraging treatment for personnel who screen positive for PTSD.
11194397|NCT03423381|Experimental|Cereal product 1|Cereal based müsli no. 1, made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df). The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
11194398|NCT03423381|Experimental|Cereal product 2|Cereal based muesli no. 2 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
11194399|NCT03423381|Experimental|Cereal product 3|Cereal based muesli no.3 made from typical Swedish cereals. All experimental products have different types and amounts of df.The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
11194400|NCT03423381|Experimental|Cereal product 4|Cereal based muesli no. 4 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
11194401|NCT03423381|Experimental|Cereal product 5|Cereal based muesli no. 5 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
11194402|NCT03423381|Placebo Comparator|Control product|A cereal based product with low concentrations of df. The control portion is consumed as a single evening meal prior to determinations of test variables in the morning.
11194403|NCT03423368|Experimental|Libramed|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of Libramed for 30 days
11194404|NCT03423368|Placebo Comparator|Placebo|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of placebo for 30 days
11194405|NCT03423355|Active Comparator|Dapagliflozin|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. The study will be performed under double-blinded conditions with respect to treatment with dapagliflozin or matching placebo.
~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
11194406|NCT03423355|Placebo Comparator|Placebo dapagliflozin|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. The study will be performed under double-blinded conditions with respect to treatment with dapagliflozin or matching placebo.
~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
11194407|NCT03423355|Other|Hydrochlorothiazide|"Treatment with the SGLT2 inhibitor dapagliflozin will be compared to matching placebo and the reference HCT in a parallel design. However, treatment in the reference group will not be blinded.
~In this study, the effect of dapagliflozin on EPO levels, physical fitness and biomarkers for erythropoiesis and hemodynamic regulation are evaluated and compared to that of matching placebo and the diuretic and anti-hypertensive drug HCT."
11194408|NCT03423342|Experimental|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
11194409|NCT03423342|Placebo Comparator|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
11194410|NCT03423329|Experimental|Group A|"Intervention:Drug: Brufen & Placebo
~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
11194411|NCT03423329|Experimental|Group B|"Intervention: Drug: Cital and Placebo
~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
11194412|NCT03423329|Placebo Comparator|Group C|"Intervention: Drug: Placebo
~Other names:
~(Placebo for Brufen) (Placebo for Cital)
~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
11194413|NCT03423316|No Intervention|Healthy Controls|
11194414|NCT03423316|No Intervention|Age-Matched Controls|Subjects without PAD who have the same average age as the PAD patients
11194415|NCT03423316|Experimental|PAD Patients|Patients with PAD. Approximately 75% of PAD patients will be enrolled in the 12-week exercise therapy program.
11194416|NCT03423303|Experimental|Screening arm|Invitation to prostate cancer screening and questionnaires.
11194420|NCT03423264|No Intervention|Supportive Care Only|Participants will receive standard best supportive care medications as per their treating physician's recommendation.
11194421|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
11194422|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
11194423|NCT03423225|Experimental|ADVAGRAF®|One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
11194424|NCT03423212|Experimental|Experimental Condition|Participants assigned to the experimental arm will be enrolled in the 2-session Just Do You intervention described elsewhere.
11194425|NCT03423212|No Intervention|Treatment as Usual Condition|Participants assigned to treatment as usual will receive the PROS program that is standard in the agencies without any additional intervention.
11194426|NCT03423212|Active Comparator|Active Control Condition|Participants assigned to the active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
11194427|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
11194428|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
11194429|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
11194430|NCT03423186|Experimental|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
11194431|NCT03423186|Experimental|Dose group 3|SOBI003 dose to be decided once weekly for 24 weeks
11194432|NCT03423173|Placebo Comparator|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
11194433|NCT03423173|Experimental|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
11194434|NCT03423173|Experimental|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
11194435|NCT03423173|Experimental|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
11194436|NCT03423160||Autism|Right-handed children, ages 8.0-12.9, diagnosed with high-functioning ASD (and no co-morbid conditions, excluding anxiety disorders)
11194437|NCT03423160||Control|Right-handed children, ages 8.0-12.9, with no neurological or psychiatric diagnoses, currently or by history
11194438|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
11194439|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
11194440|NCT03423134|Experimental|Test of new adhesive strip|A new adhesive strip will be tested in this investigation
11194441|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
11194442|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
11194443|NCT03423108|No Intervention|Control|Participants randomized to this group will perform monthly cohabitation meetings.
11194444|NCT03423108|Experimental|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
11194445|NCT03423108|Experimental|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
11194446|NCT03423095|Placebo Comparator|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
11194447|NCT03423095|Active Comparator|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
11194448|NCT03423095|Experimental|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
11194449|NCT03423095|Experimental|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
11194450|NCT03423082|Experimental|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
11194451|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
11194452|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
11194760|NCT03421158|Experimental|Breastfeeding|Newborns were breastfed during the procedure
11194453|NCT03423056|Experimental|Preoperative exercise program|"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks.
~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:
~Week 1: heart rate target: 50% of maximum heart rate Week 2: heart rate target: 60% of maximum heart rate Week 3: heart rate target: 70% of maximum heart rate Week 4: heart rate target: 60% of maximum heart rate The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist."
11194454|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
11194455|NCT03423030|Experimental|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
11194456|NCT03423030|Placebo Comparator|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
11194457|NCT03423030|Experimental|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
11194458|NCT03423030|Placebo Comparator|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
11194459|NCT03423030|Experimental|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
11194460|NCT03423030|Active Comparator|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
11194461|NCT03423030|Experimental|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
11194462|NCT03423030|Active Comparator|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
11194463|NCT03423017|Other|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate
~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
11194464|NCT03423017|Other|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
11194465|NCT03423017|Other|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
11194466|NCT03423004|Experimental|Patient with lesional skin|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
11194467|NCT03423004|No Intervention|Patients with healthy skin|the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed
11194468|NCT03422991|Other|Congestive Heart Failure patients Cohort|Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) > 500 ng/l. Will be followed during 18 months.
11194469|NCT03422978|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
11194470|NCT03422978|Experimental|Dexmedetomidine 0.25 mcg/kg|0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
11194471|NCT03422978|Experimental|Dexmedetomidine 0.50 mcg/kg|0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
11194472|NCT03422978|Experimental|Dexmedetomidine 1.00 mcg/kg|1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
11194473|NCT03422965|Active Comparator|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
11194474|NCT03422965|Sham Comparator|Healthy controls|Cohort of Healthy controls
11194475|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
11194476|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
11194477|NCT03422926|Experimental|Intervention|Social marketing messaging campaign
11194478|NCT03422926|No Intervention|Control|No messaging campaign
11194479|NCT03422913|Experimental|CLCVP Group|Controlled low central venous pressure(CLCVP) will be performed combined with intraoperative combined hilar intermittent (Pringle method)
11194480|NCT03422913|No Intervention|Control Group|Only intraoperative combined hilar intermittent (Pringle method) will be performed
11194481|NCT03422900|Experimental|Specific Diabetes Formula|"Diabetes-Specific Enteral Formula:
~Caloric density: 1,0 kcal/ml
~Energy: 100 kcal
~Carbohydrates: 10,1 g/100 ml;
~Fat: 4,5 g/100 ml
~Prot: 3,8 g/100 ml
~Osmolarity: 345 mOsm/l
~Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble)."
11194482|NCT03422900|Active Comparator|Standard Formula|"Standard Enteral Formula:
~Caloric density: 1,0 kcal/ml
~Energy: 100 kcal
~Carbohydrates: 13,8 g/100 ml;
~Fat: 3,4 g/100 ml
~Prot: 3,8 g/100 ml
~Osmolarity: 220 mOsm/l
~Fiber: 0 g/100 ml"
11194483|NCT03422887|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
11194484|NCT03422887|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
11194485|NCT03422887|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
11194486|NCT03422874|Experimental|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.
~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts [1250mg, 1875mg, 2500mg, 3125mg]) will be administered orally twice daily in the dose cohorts listed."
11194487|NCT03422861|Active Comparator|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
11194488|NCT03422861|Placebo Comparator|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
11194489|NCT03422848|Active Comparator|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
11194490|NCT03422848|Other|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
11194491|NCT03422835|Active Comparator|R-TME|Robotic total mesentery excision surgery for rectal cancer.
11194492|NCT03422835|Experimental|R-TaTME|Robotic transanal total mesentery excision surgery for rectal cancer.
11194493|NCT03422822|Experimental|Abrocitinib 100 mg|Abrocitinib 100 mg QD PO
11194494|NCT03422822|Experimental|Abrocitinib 200 mg|Abrocitinib 200 mg QD PO
11194495|NCT03422796|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
11194496|NCT03422796|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
11194497|NCT03422783|Experimental|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
11194498|NCT03422770|Other|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
11194499|NCT03422770|Other|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
11194500|NCT03422770|Other|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
11194501|NCT03422770|Other|Controls|100 subjects, all undergoing echocardiography and blood test, 30 undergoing MRI.
11194502|NCT03422757|Experimental|adaptive DBS|adaptive Deep Brain Stimulation, by AlphaDBSvext.
11194503|NCT03422757|Active Comparator|conventional DBS|conventional Deep Brain Stimulation, by AlphaDBSvext.
11194504|NCT03422744|Experimental|patient with peripheral lung lesion|"Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.
~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.
~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control"
11194505|NCT03422731||Cohort I (TMLI+FLT/TMLI)|COHORT I (TLMI+FLT/TMLI): Patients may undergo optional fluorothymidine F-18 PET scan over 2 hours at baseline, on days 30 and 100, at 1 year, and at time of relapse. Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline, on days 30 and 100, at year 1, and at time of relapse. Patients also undergo collection of bone marrow and blood samples at baseline, on days 30 and 100, and at 1 year. Patients undergo fluorothymidine F-18 PET, DECT, and water-fat MRI as in TMLI+FLT.
11194506|NCT03422731||Cohort II (TBI)|Patients undergo collection of bone marrow at baseline, day 30, time of relapse, and at 1 year.
11194507|NCT03422718|Experimental|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
11194508|NCT03422718|Experimental|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
11194509|NCT03422718|Experimental|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
11194510|NCT03422718|Experimental|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
11194511|NCT03422718|Experimental|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
11194512|NCT03422718|Experimental|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
11194513|NCT03422718|Experimental|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
11194514|NCT03422718|Experimental|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
11194515|NCT03422705|Sham Comparator|Standard of care|No intervention - no programming, no medical intervention.
11194516|NCT03422705|Experimental|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
11194517|NCT03422705|Experimental|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
11194518|NCT03422692|Experimental|BioXlude memebrane|Subjects in this arm will receive demineralized freeze dried bone allograft covered with BioXclude amnion-chorion membrane following tooth extraction
11194519|NCT03422692|Active Comparator|Mem-Lok|subjects in this arm will receive demineralized freeze dried bone allograft covered with Mem-Lok collagenous membrane following tooth extraction
11194520|NCT03422679|Experimental|CB-103|CB-103 capsules will be administered orally as a continuous once daily (QD) dosing during the treatment period of Part A (escalation) and Part B (expansion).
11194521|NCT03422666|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
11194522|NCT03422666|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
11194523|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
11194524|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
11194525|NCT03422640|Experimental|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
11194526|NCT03422627|Experimental|Phase 1b|The phase 1b portion of this study will be conducted as a multiple ascending dose study. Each dosing cohort will consist of 3 subjects who will receive either weekly or biweekly AMG 592 plus protocol permitted background therapy for up to 52 weeks.
11194527|NCT03422627|Experimental|Phase 2|The phase 2 portion of this study will be conducted as a single arm, multi-center, open-label trial in subjects with steroid refractory cGVHD. All subjects will receive the recommended phase 2 dose of AMG 592 for up to 52 plus protocol permitted background therapy for cGVHD.
11194528|NCT03422614||Patient|Patients with Primary Immunodeficiency
11194529|NCT03422614||Control|Healthy Controls
11194530|NCT03422601||3 months treatment|FOLFOX or CAPOX
11194531|NCT03422601||6 months treatment|FOLFOX or CAPOX
11194533|NCT03422588|Active Comparator|Extracorporeal|Laparoscopic assisted right colectomy with extracorporeal anastomosis
11194534|NCT03422575|Experimental|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
11194535|NCT03422575|Active Comparator|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
11194536|NCT03422562|Active Comparator|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
11194537|NCT03422562|No Intervention|Control|Standard of care arm
11194538|NCT03422549|Active Comparator|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
~Intervention: Device: Drager VN500 Ventilator"
11194539|NCT03422549|Active Comparator|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.
~Intervention: Device: Drager VN500 Ventilator"
11194540|NCT03422536|Experimental|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11194541|NCT03422536|Experimental|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11194542|NCT03422523|Active Comparator|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
11194543|NCT03422523|Experimental|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.
~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
11194544|NCT03422510|Experimental|Regimen 1 - CXA-10 75 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.
11194545|NCT03422510|Experimental|Regimen 1 - CXA-10 150 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.
11194546|NCT03422510|Experimental|Regimen 2 - CXA-10 150 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
11194547|NCT03422510|Experimental|Regimen 2 - CXA-10 300 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.
11194548|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
11194549|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
11194550|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
11194551|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
11194552|NCT03422471|Experimental|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
11194553|NCT03422458|No Intervention|natural healing|no treatment and the coagulum within the socket is left open for spontaneous healing
11194554|NCT03422458|Experimental|Alveolar Ridge Preservation|A bone substitute material (BioOss Collagen) is placed within the bony envelope at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mucograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
11194555|NCT03422458|Experimental|Immediate Implant + Alveolar Ridge Preservation|An immediate implant (Winsix) placement is performed. After implant insertion, a bone substitute material (BioOss Collagen) is placed in the gap occurred between the implant surface and the hard tissue walls of the extraction socket at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mugograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
11194556|NCT03422445|Experimental|Apatinib plus Temozolomide|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.
11194557|NCT03422432|Experimental|Group 1|Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
11194558|NCT03422432|Experimental|Group 2|Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
11194559|NCT03422419|Experimental|TIPS+Anticoagulation|
11194560|NCT03422419|Active Comparator|Anticoagulation|
11194561|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
11194562|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
11194563|NCT03422393|Experimental|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
11194564|NCT03422380||Weight Loss Maintainers (WLM)|Individuals maintaining ≥13.6 kg (30 lb) weight loss for ≥1 year
11194565|NCT03422380||Normal Weight Controls (NC)|Individuals with normal weight whose BMI was matched to the current BMI of the WLM. NC had to be weight stable and not maintaining a weight loss of ≥13.6kg
11194566|NCT03422380||Controls with Overweight/Obesity (OC)|Individuals with overweight/obesity whose BMI was matched to the pre-weight loss maximum BMI of WLM. OC had to be weight stable and not maintaining a weight loss of ≥13.6kg
11194567|NCT03422367|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
11194568|NCT03422367|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
11194569|NCT03422367|No Intervention|Control|Participants who are unable to complete JASPER due to age or time/distance commitment can enroll for single-time point participation
11194570|NCT03422354|Active Comparator|Paravertebral block Group|Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
11194571|NCT03422354|Active Comparator|General anesthesia Group|"Patients will receive only GA All patients in the study will receive GA in the form of propofol 2mg/kg , atracurium 0.5ml/kg ,fentanyl 100 microgram in induction with ETT and mechanical ventilation , full monitoring with ECG , NIBP and puls oximetry will be applied.
~To control intraoperative BP,fentanyl will be used as well as,hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
~To achieve post operative analgesia, intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed"
11194572|NCT03422341|Experimental|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.
~Intervention will be the Comparison between GenePOC CR and Reference Method."
11194573|NCT03422341|Active Comparator|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.
~Intervention will be the Comparison between GenePOC CR and Reference Method."
11194574|NCT03422328|Experimental|Open-label macitentan 10 mg|10 mg macitentan film coated tablet, administered orally once daily
11194575|NCT03422315|Experimental|External control|propofol;injection;2mg/kg;single-dose
11194576|NCT03422302|Experimental|Treatment (CT simulation, CPAP, DIBH, SBRT, BiPAP)|Patients undergo free-breathing, DIBH, and CPAP CT simulation scans. If patient has difficulty exhaling on CPAP, then patient undergo BiPAP CT simulation. The attending physician then compares all 3 simulation treatment plans (free-breathing, DIBH, and CPAP/BiPAP) and determines which method to use during SBRT. If CPAP/BiPAP is chosen as preferred method, patients wear CPAP/BiPAP over 1 hour prior to SBRT, then again during SBRT over 30-60 minutes. All other patients complete free-breathing or DIBH during SBRT over 30-60 minutes.
11194577|NCT03422289|Experimental|Myo-inositol + folic acid|2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation.
11194578|NCT03422289|Experimental|Myo-inositol + folic a. + α-lactalbumin|2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation
11194579|NCT03422276|Active Comparator|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
11194580|NCT03422276|Active Comparator|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
11194581|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
11194582|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
11194583|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
11194584|NCT03422250|Experimental|Arm 1|Anodal tDCS of disconnected networks
11194585|NCT03422250|Experimental|Arm 2|Cathodal tDCS of hyper-connected networks
11194586|NCT03422237|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
11194587|NCT03422237|Experimental|RSV 276 vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
11194588|NCT03422237|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11194589|NCT03422224||Good transplant function|
11194590|NCT03422224||Transplant Rejection|
11194591|NCT03422211||Sports orthopaedic surgery|Patients that recently underwent orthopaedic sports surgery performed by two separate surgeons
11194592|NCT03422198|Experimental|Short course vaginal cuff brachytherapy|Patients undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
11194593|NCT03422198|Active Comparator|Vaginal cuff brachytherapy|Patients undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
11194594|NCT03422172|Experimental|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
11194595|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
11194630|NCT03421938|Experimental|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
11194596|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
11194597|NCT03422146|Experimental|Cliradex® eyelid hygiene|Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.
11194598|NCT03422146|Other|I-Lid 'n Lash® Hygiene|Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,
11194599|NCT03422133||Pre-Implementation Phase|"Participants in this group (before the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
~Patients will be recruited using standardized procedures, and process and outcome measures will be recorded using the same tools and methods in both study phases to decrease the risk of measurement and selection bias."
11194600|NCT03422133||Post-Implementation Phase|Participants in this group (after the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
11194601|NCT03422120||Healthy Donors|Healthy patients, without a diagnosis of cancer and age>40. The Natural Killer Cell Activity Assay (NKA) will be measured with a blood test.
11194602|NCT03422120||Colorectal Cancer Surgery Patients|Patients >40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
11194603|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
11194604|NCT03422107||cAVR|Conventional Valve Replacement
11194605|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
11194606|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
11194607|NCT03422094|Experimental|Cohort A: NeoVax+Nivolumab (start at time of progression)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)
~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression"
11194608|NCT03422094|Experimental|Cohort B: NeoVax+Nivolumab (start with Cycle 2)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)
~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)"
11194609|NCT03422094|Experimental|Cohort C: NeoVax + Nivolumab (start with Cycle 1)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)
~Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)"
11194610|NCT03422094|Experimental|Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)
~Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase)
~Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle"
11194611|NCT03422094|Experimental|Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&15 each cycle)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)
~Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 …)
~Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1"
11194612|NCT03422081||growth hormone deficiency|
11194613|NCT03422081||small for gestational age|
11194614|NCT03422081||matched controls|
11194615|NCT03422068|Experimental|BI 1015550|
11194616|NCT03422068|Placebo Comparator|Placebo|
11194617|NCT03422055|Experimental|99mTc-Fucoidan SPECT|
11194618|NCT03422042|Active Comparator|Short duration of antibiotic|group A: will received intravenous antibiotic until the temperature is less than 37.8 c for 72 hours, then antibiotic is discontinued
11194619|NCT03422042|Active Comparator|Standard treatment of antibiotic|group B: will received intravenous antibiotic for 7 days, and followed by oral antibiotic for 7 days, regardless of body temperature
11194620|NCT03422029|Experimental|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
11194621|NCT03422016||autistic spectrum disorder|intelligence quotient IQ>85 age 4-25yrs
11194622|NCT03422016||control|age 4-25yrs no eye disorder
11194623|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
11194624|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
11194625|NCT03421990||Group A|General anesthesia technique
11194626|NCT03421990||Group B|Regional anesthesia technique
11194627|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
11194628|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
11194629|NCT03421938|Experimental|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
11194631|NCT03421925|Other|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
11194632|NCT03421925|Other|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
11194633|NCT03421912|Experimental|Arm A : Cicaplast balm B5|Use of Cicaplast balm B5, 2 to 3 applications per day, since the first day of iEGFR treatment initiation for 30 days to avoid or limit appearance of cutaneous toxicities related to iEGFR treatment.
11194634|NCT03421912|Active Comparator|Arm B : Dexeryl|Use of Dexeryl, 2 to 3 applications per day, since de first day of iEGFR treatment initiation for 30 days to avoid or limit appearence of cutaneous toxicities related to iEGFR treatment.
11194635|NCT03421899||Genetic Parkinson's group|Those participants with Parkinson's disease and a genetic mutation known to cause or increase risk of Parkinson's disease (e.g. Parkin, PINK1, GBA or LRRK2)
11194636|NCT03421899||Idiopathic Parkinson's group|Those participants with Parkinson's disease but without a known genetic mutation known to cause or increase risk of Parkinson's disease
11194637|NCT03421899||Healthy control group|Those participants unaffected by Parkinson's disease
11194638|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
11194639|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
11194640|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
11194641|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
11194642|NCT03421860|Active Comparator|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
11194643|NCT03421860|Active Comparator|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
11194644|NCT03421860|Active Comparator|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
11194645|NCT03421860|Active Comparator|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
11194646|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
11194647|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
11194648|NCT03421834|Experimental|Prophylactic VT ablation prior to ICD implantation|
11194649|NCT03421834|Active Comparator|ICD implantation and optimal medical treatment|ICD implantation and optimal medical care until at least 2 appropriate ICD shock occurs or an arrhythmic storm and catheter ablation thereafter.
11194650|NCT03421821|Experimental|Subfascial Injection Group|30 ml of 0.33% ropivacaine was injected to subfascial.
11194651|NCT03421821|Active Comparator|Extrafascial Injection Group|30 ml of 0.33% ropivacaine was injected to extrafascial.
11194652|NCT03421808|Experimental|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
11194653|NCT03421808|Active Comparator|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
11194654|NCT03421795|Experimental|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
11194655|NCT03421795|Sham Comparator|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum & Gorter, 2012) .
11194656|NCT03421782|Experimental|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
11194657|NCT03421782|Experimental|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
11194658|NCT03421769|Experimental|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
11194659|NCT03421769|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
11194660|NCT03421756|Experimental|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
11194661|NCT03421743|Experimental|Inhaled molgramostim/antimycobacterials|Inhaled molgramostim administered in subjects who remain sputum culture positive while currently on a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen, which has been ongoing for at least 6 months prior to the Baseline Visit
11194662|NCT03421743|Experimental|Inhaled molgramostim|Inhaled molgramostim administered in subjects who remain sputum culture positive but have stopped a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance, or who never started such treatment
11194663|NCT03421730|Experimental|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194664|NCT03421730|Experimental|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194665|NCT03421730|Experimental|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
11194666|NCT03421730|Experimental|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194667|NCT03421730|Experimental|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194668|NCT03421730|Experimental|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
11194669|NCT03421730|Experimental|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194670|NCT03421730|Experimental|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194671|NCT03421730|Experimental|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
11194672|NCT03421730|Experimental|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194673|NCT03421730|Experimental|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194674|NCT03421730|Experimental|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
11194675|NCT03421717|Experimental|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
11194676|NCT03421717|Active Comparator|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
11194677|NCT03421691|Other|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
11194678|NCT03421678||Japanese American|Two parents of Japanese descent
11194679|NCT03421678||Non-Hispanic Whites|Two parents of non-Hispanic white descent
11194680|NCT03421678||Native Hawaiians|At least one parent of Hawaiian descent
11194681|NCT03421665||Titan 3-D Wedge System|Subjects who receive one or more Titan 3D wedge(s).
11194682|NCT03421652|Experimental|Treatment (nivolumab, radiation therapy)|Given IV
11194683|NCT03421639|Active Comparator|Ulipristal acetate|control group treated with Ulipristal acetate as control
11194684|NCT03421639|Experimental|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
11194685|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
11194686|NCT03421613|Experimental|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
11194687|NCT03421613|Placebo Comparator|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
11194688|NCT03421600|Active Comparator|Blue laser imaging|Blue laser imaging
11194689|NCT03421600|Experimental|White light imaging|White light imaging
11194690|NCT03421587||Individuals exposed to an intentional/non-intentional trauma|
11194691|NCT03421587||Healthy controls without trauma-exposure|
11194692|NCT03421574|Experimental|MR-Guided Focused Ultrasound|
11194693|NCT03421561|Experimental|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
~Basic Catheter Specifications
~Guidewire: 0.035
~Balloon Length: 40/80/120 mm
~Sheath Compatibility: greater than or equal to 6 French
~Balloon Diameter: 4/5/6 mm
~Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
11194722|NCT03421353|Experimental|Arm A4|"Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:
~For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or
~For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks).
~There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing."
11194761|NCT03421158|Experimental|Oral Sucrose|Newborns were given oral sucrose during the procedure
11194694|NCT03421561|Placebo Comparator|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
~Basic Catheter Specifications
~Guidewire: 0.035
~Balloon Length: 40/80/120 mm
~Sheath Compatibility: greater to or equal to 6 French
~Balloon Diameter: 4/5/6 mm
~Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
11194695|NCT03421548|Experimental|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
11194696|NCT03421548|No Intervention|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
11194697|NCT03421535|Active Comparator|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
11194698|NCT03421535|Experimental|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
11194699|NCT03421522|Experimental|Intervention - ICBN preservation|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved.
11194700|NCT03421522|No Intervention|Control - Usual Care|For participants allocated to the usual surgical care arm, attending surgeons will perform a standard Level 1 and 2 axillary node dissection (sacrifice of the ICBN), either alone or with mastectomy or breast conserving surgery.
11194701|NCT03421496|Experimental|Cannabidiol Oral Solution (CBD)|"Cannabidiol Oral Solution, up to 40 milligrams per kilogram per day (mg/kg/day), participants will be dosed approximately every 12 hours with food.
~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
11194702|NCT03421496|Placebo Comparator|Placebo|"Matching CBD placebo, up to 40 mg/kg/day, participants will be dosed approximately every 12 hours with food.
~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
11194703|NCT03421483|Active Comparator|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
11194704|NCT03421483|Placebo Comparator|No supplementation|Participants only receive an adult multivitamin supplement
11194705|NCT03421457|Experimental|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
11194706|NCT03421457|Experimental|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
11194707|NCT03421431|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
11194708|NCT03421431|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
11194709|NCT03421431|Placebo Comparator|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
11194710|NCT03421418|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
11194711|NCT03421418|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
11194712|NCT03421405|Experimental|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
11194713|NCT03421392||Idiopathic thrombocytopenic purpura|
11194714|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
11194715|NCT03421392||without thrombocytopenia|
11194716|NCT03421379|Experimental|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
11194717|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
11194718|NCT03421366||Cystic Fibrosis on Posaconazole|"Able to provide written informed consent
~Greater than 18 years of age or older
~Have a diagnosis of cystic fibrosis
~No known azole hypersensitivity
~To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus
~Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care
~Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily."
11194719|NCT03421353|Experimental|Arm A1|Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every four weeks (Q4W). There will be a 1 week AZD9150 lead-in prior to durvalumab dosing.
11194720|NCT03421353|Experimental|Arm A2|Patients will receive AZD9150 once weekly (QW) + durvalumab every three weeks (Q3W) + Cisplatin on Day 1 + 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
11194721|NCT03421353|Experimental|Arm A3|Depending on the results of Arm A2, Arm A3 may not be conducted. If Arm A3 is conducted, patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + cisplatin on Day 1 + 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
11194757|NCT03421184|Active Comparator|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
11227357|NCT03195244|Active Comparator|One-on-one Aquatic Therapy|
11194723|NCT03421353|Experimental|Arm A5|Patients will receive AZD9150 every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks). There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
11194724|NCT03421353|Experimental|Arm D: AZD9150 SC|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
11194725|NCT03421353|Experimental|Arm D: AZD9150 IV|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
11194726|NCT03421340|Other|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
11194727|NCT03421340|Other|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
11194728|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
11194729|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
11194730|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
11194731|NCT03421314|Experimental|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
11194732|NCT03421314|Experimental|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
11194733|NCT03421314|Experimental|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
11194734|NCT03421314|No Intervention|Control|Participants in this arm will not take supplementation as a control.
11194735|NCT03421301|Experimental|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
11194736|NCT03421301|Placebo Comparator|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
11194737|NCT03421288|Experimental|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
11194738|NCT03421288|Active Comparator|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
11194739|NCT03421275|Experimental|Esketamine|intravenous anaesthetic and analgetic
11194740|NCT03421275|Active Comparator|Fentanyl Citrate|intravenous opioid analgetic
11194741|NCT03421275|Placebo Comparator|Saline Nasal|"intravenous Natriumklorid b. Braun 9 mg/ml"
11194742|NCT03421262|Experimental|One-step:IADPSG Criteria|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gr oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
11194743|NCT03421262|Active Comparator|Two-step:NDDG Criteria|"Step 1: Perform a 1h 50-g glucose load test (nonfasting. If the plasma glucose level measured 1 h after the load is 140 mg/dL, proceed to a 100-g OGTT.
~Step 2: 100-g OGTT. The diagnosis of GDM is made if at least two of the following four plasma glucose levels(measured fasting and 1 h, 2 h, 3 h after the OGTT) are met or exceeded: 105mg/dl, 190mg/dl, 165mg/dl and 145mg/dl respectively"
11194744|NCT03421249|Active Comparator|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
11194745|NCT03421249|Active Comparator|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
11194746|NCT03421249|Placebo Comparator|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
11194747|NCT03421249|Active Comparator|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
11194748|NCT03421236|Experimental|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
11194749|NCT03421223||Case|Individuals diagnosed with chronic pain
11194750|NCT03421223||Control|Individuals without chronic pain
11194751|NCT03421210|Other|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
11194752|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
11194753|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
11194754|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
11194755|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
11194756|NCT03421184|Experimental|Patient with Systemic Lupus Erythematosus|30 women with SLE
11194758|NCT03421184|Active Comparator|Healthy control|30 healthy control women
11194762|NCT03421158|Experimental|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
11194763|NCT03421158|Experimental|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
11194764|NCT03421119|Experimental|CinnaGen-liraglutide|CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
11194765|NCT03421119|Active Comparator|Victoza®|Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
11194766|NCT03421106|Experimental|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
11194767|NCT03421106|Active Comparator|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
11194768|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
11194769|NCT03421080|Active Comparator|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
11194770|NCT03421080|Experimental|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
11194771|NCT03421054|Other|nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
11194772|NCT03421041|Experimental|Dexamethasone group|
11194773|NCT03421041|No Intervention|control group|
11194774|NCT03421028|Active Comparator|Control group|Patients with masticatory muscle pain treated with occlusal splint, physiotherapy and counseling
11194775|NCT03421028|Experimental|Experimental group 1|Patients diagnosed with masticatory muscle pain treated with 4 meetings of EMG-biofeedback assisted training
11194776|NCT03421028|Experimental|Experimental group 2|Patients diagnosed with masticatory muscle pain treated with 8 meetings of EMG-biofeedback
11194777|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
11194778|NCT03421015||Control Group|patients without biochemical recurrence (control group)
11194779|NCT03421002|Experimental|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour. Micafungin will be administered for a minimum of 14 days until 1 of the following conditions applied: •Negative results (absence of Candida growth) from at least 2 consecutive blood cultures and/or resolution of clinical and laboratory symptoms and reduction of mannan antigen blood level (< 125 pg/mL) are obtained. •In case of meningitis, hydrocephalus and external ventricular derivation, negative results (absence of Candida growth) from at least 2 consecutive cerebral spinal fluid (CSF) cultures associated with resolution of clinical and laboratory symptoms. •Interruption (including addition or switch to another antifungal agent or dosage change of micafungin) due to demonstration of therapy failure.
11194780|NCT03420989|Active Comparator|Active snack food|snack food with carob and seaweeds 50 gr per day
11194781|NCT03420989|Placebo Comparator|Control snack food|snack food without carob and seaweeds 50 gr per day
11194782|NCT03420976|Experimental|Novel Supplement-based Therapy|"Low FODMAP diet + supplements outlined below:
~Product Name: Liver-G.I. Detox Active Ingredients: Alpha lipoic acid, n-acetyl-l-cystine, turmeric root extract, milk thistle seed extract, broccoli sprout concentrate, artichoke leaf extract, taurine, glycine, l-glutamine, l-methionine, and chlorella.
~Product Name: l-Glutamine Active Ingredients: l-glutamine
~Product Name: MicroDefense Active Ingredients: berberine sulfate, olive leaf extract, sweet wormwood, clove bud powder, and grapefruit seed and fruit extract.
~Product Name: A.C. Formulla II Active Ingredients: calcium and magnesium undecylenate, calcium and magnesium caprylate, bromelain, grapefruit seed and fruit extract, and berberine sulfate
~Product Name: Probiotic-5 (Pure Encapsulations) Active Ingredients: Probiotic blend
~Product Name: Digestive Enzymes Ultra with Betaine HCl Active Ingredients: Digestive enzyme blend and betaine HCl"
11194783|NCT03420963|Experimental|Treatment (cyclophosphamide, etoposide, NK cells)|Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
11194784|NCT03420950|Other|Sedative first|Rapid sequence intubation: sedative first
11194785|NCT03420950|Other|Paralytic agent first|Rapid sequence intubation: paralytic first
11194786|NCT03420937|Experimental|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.
~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).
~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.
~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
11194892|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
11194893|NCT03420261|Active Comparator|Crystalloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of 0.9% saline (up to a maximum of 30 ml/kg)
11194787|NCT03420937|Experimental|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
11194788|NCT03420924|Experimental|Thermal suit|
11194789|NCT03420924|Active Comparator|Conventional hospital clothes|
11194790|NCT03420911|Active Comparator|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
11194791|NCT03420911|Active Comparator|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
11194792|NCT03420898||1|General Medicine in Hospital Unit 70 Bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
11194793|NCT03420898||2|General Medicine in Hospital 38 Bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
11194794|NCT03420898||3|Cardiovascular Surgery in Hospital Unit 36 bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
11194795|NCT03420898||4|General Surgery in Hospital 24 bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
11194796|NCT03420898||5|Cardiac 36-bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
11194797|NCT03420898||6|General Medicine 26 Bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
11194798|NCT03420885|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
11194799|NCT03420885|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
11194800|NCT03420872||Subset from PROGRESS cohort|Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City
11194801|NCT03420846|Experimental|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
11194802|NCT03420846|No Intervention|Control arm|Standard MMS is performed
11194803|NCT03420833|Experimental|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
11194804|NCT03420833|Experimental|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
11194805|NCT03420820|Experimental|5% Betadine, Ocular Surface only|Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
11194806|NCT03420820|Experimental|10% Betadine, Ocular Surface only|Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
11194807|NCT03420820|Experimental|10% Betadine, Ocular Surface and Adnexa|Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
11194808|NCT03420807|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
11194809|NCT03420794|Active Comparator|Control Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once just prior to surgery.
11194810|NCT03420794|Experimental|Study Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once 3-4 hours prior to surgery.
11194811|NCT03420781|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 46 weeks.
11194812|NCT03420781|Experimental|Relamorelin 10 μg, followed by Placebo|Relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo injected twice daily for 6 weeks.
11194813|NCT03420781|Experimental|Placebo, followed by Relamorelin 10 μg|Placebo injected subcutaneously twice daily for 40 weeks, followed by Relamorelin 10 μg injected twice daily for 6 weeks.
11194814|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
11194815|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
11194816|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
11194817|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
11194818|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
11194819|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
11194820|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
11194821|NCT03420755|Experimental|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
11194822|NCT03420755|Experimental|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
11195292|NCT03417518|Active Comparator|Desflurane Inhalant Product Group|general anesthesia with desflurane
11194823|NCT03420742|Experimental|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
11194824|NCT03420729|Experimental|magnetic assisted capsule endoscopy|All participants will undergo magnetic assisted capsule endoscopy at the sloan medical centre
11194825|NCT03420729|Active Comparator|gastroscopy|All participants will undergo gastroscopy as standard of care at sheffield teaching hospitals
11194826|NCT03420716|Experimental|functional yogurt|Participants are given the symbiotic yogurt daily (180 ml)
11194827|NCT03420716|Experimental|control yogurt|Participants are given the control yogurt daily (180 ml)
11194828|NCT03420703|Active Comparator|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
11194829|NCT03420703|Sham Comparator|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
11194830|NCT03420690||Family of patient|
11194831|NCT03420677|Active Comparator|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
11194832|NCT03420677|Sham Comparator|No application of tones|During NREM sleep no short tones will be played
11194833|NCT03420664|Experimental|Cast immobilisation|A below knee cast is applied in order to achieve ankle immobilisation for one hour
11194834|NCT03420664|Experimental|Orthosis (VACOped) immobilisation|A below knee orthosis which allows for ankle movement is applied for one hour.
11194835|NCT03420651|Experimental|PEFR Guided Management|Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
11194836|NCT03420651|Experimental|Non-PEFR Guided Management|Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
11194837|NCT03420638|Experimental|Adjunct Exparel|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL], i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension on each side.
11194838|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
11194839|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
11194840|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
11194841|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
11194842|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
11194843|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
11194844|NCT03420612||validation|The validation cohort was used to verify the IDS
11194845|NCT03420599||health control|healthy controls are all from normal volunteers
11194846|NCT03420599||splenectomy|Traumatic patients after total splenectomy
11194847|NCT03420586|Active Comparator|Nitrous oxide Group|The nitrous oxide group (GN2O) will receive air in 30% O2 during general anesthesia until the last 30 min of surgery, when 70% N2O in 30% O2 will be administered.
11194848|NCT03420586|No Intervention|Oxygen Group|The Oxygen group will receive gas carrier mixture consisting of air in 30% O2 during general anesthesia.
11194849|NCT03420560|Experimental|warmer temperature|To compare the incidence and intensity of pain on injection that is caused by propofol in warm temperature（27℃） versus normal temperature(23℃).
11194850|NCT03420560|Placebo Comparator|normal temperature|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol in different room temperature(27 VS 23).
11194851|NCT03420547|Experimental|Intervention group|Group of participants receiving the RISE intervention
11194852|NCT03420547|No Intervention|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
11194853|NCT03420534|Experimental|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
11194854|NCT03420534|Active Comparator|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
11194855|NCT03420534|Active Comparator|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
11194856|NCT03420534|Experimental|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
11194857|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab-240 mg IV over 60 minutes Q2W Ipilimumab 1mg/kg IV over 30 minutes Q6W
11194894|NCT03420261|Experimental|Colloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of HES 130/0.4 (up to a maximum of 30 ml/kg, VOLUVEN ®, Fresenius Kabi)
11195293|NCT03417518|Experimental|Propofol Group|general anesthesia with propofol
11194858|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
11194859|NCT03420495|Experimental|OCD Group|Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for principal OCD. These participants will complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
11194860|NCT03420495|Experimental|Non-psychiatric Control Group|No current DSM-5 diagnosis. These participants will also complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
11194861|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
11194862|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
11194863|NCT03420469|Experimental|Baseline CYP2D6 activity|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
11194864|NCT03420469|Experimental|CYP2D6 activity with single dose of bupropion|The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
11194865|NCT03420469|Experimental|CYP2D6 activity after treatment with bupropion to steady sate|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
11194866|NCT03420456|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
11194867|NCT03420443|Experimental|Oat bran|45 g oat bran
11194868|NCT03420443|Experimental|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
11194869|NCT03420443|Other|No oral supplementation|No oral supplementation.
11194870|NCT03420417|Experimental|Assessement of respiratory mechanics|Measurement of respiratory mechanics characteristics
11194871|NCT03420404|Experimental|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
11194872|NCT03420404|No Intervention|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
11194873|NCT03420391|Placebo Comparator|Placebo PBMT|Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
11194874|NCT03420391|Active Comparator|5 Minutes|"Participants will be performed the eccentric exercise protocol 5 minutes after PBMT.
~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
11194875|NCT03420391|Active Comparator|3 Hours|"3 hours: Participants will be performed the eccentric exercise protocol 3 hours after PBMT.
~Assessments will be performed before at baseline, 1 minute, 1 hour and 24, 48 hours after the end of exercise protocol."
11194876|NCT03420391|Active Comparator|6 Hours|"6 hours: Participants will be performed the eccentric exercise protocol 6 hours after PBMT.
~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
11194877|NCT03420391|Active Comparator|24 hours|24 hours: Participants will be performed the eccentric exercise protocol 24 hours after PBMT. Assessments will be performed before at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
11194878|NCT03420391|No Intervention|Control|Participants will not receive intervention. Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
11194879|NCT03420378|Experimental|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
11194880|NCT03420365|Experimental|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
11194881|NCT03420352|Other|butterfly needle with valve|thromboelastography
11194882|NCT03420352|Other|Standard hypodermic needle|thromboelastography
11194883|NCT03420339|Experimental|Subjects on stimulant medication|All participants: Children and adolescents diagnosed with AD/HD, displaying disruptive behavior, and taking stimulant medication.
11194884|NCT03420326||Atria fibrillation (AF) group|"Detection of AF during 30 seconds ECG assessment
~Once diagnosed with atrial fibrillation before
~Undergo the frailty status assessment"
11194885|NCT03420326||Non-AF group|"No detection of AF during 30 seconds ECG assessment
~Undergo the frailty status assessment"
11194886|NCT03420313|Experimental|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).
~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad. (e) monthly follow-up assessments"
11194887|NCT03420313|No Intervention|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same monthly assessments.
11194888|NCT03420300|Experimental|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
11194889|NCT03420287|Experimental|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
11194890|NCT03420287|Active Comparator|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
11194891|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
11194895|NCT03420248|Experimental|Non-spherical polyvinyl alcohol particle|For embolic material, non-spherical polyvinyl alcohol particle is used.
11194896|NCT03420248|Experimental|Tris-acryl gelatin microsphere|For embolic material, Tris-acryl gelatin microsphere is used.
11194897|NCT03420235|No Intervention|Control group|Control group will receive standard care alone.
11194898|NCT03420235|Experimental|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
11194899|NCT03420222|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
11194900|NCT03420222|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
11194901|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
11194902|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
11194903|NCT03420196|Experimental|Supervised Rehabilitation program|It will be consist in a supervised exercise program by physical therapist, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility
11194904|NCT03420196|Active Comparator|Nonsupervised rehabilitation program|It will consist in an exercise program for home, nonsupervised, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility. The patients will perform an exercise program at home.
11194905|NCT03420170|Experimental|Graded Exercise Integrated Education|"The graded exercise (8 weeks)
~Strengthening exercise
~Aerobic Exercise
~Educational session to increase exercise self-efficacy and physical activity level (16 weeks)"
11194906|NCT03420170|Active Comparator|Conventional physical therapy|Normal routine of physical therapy (8 weeks)
11194907|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
11194908|NCT03420144|Active Comparator|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
11194909|NCT03420144|Active Comparator|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
11194910|NCT03420131||FFR-iFR-QFR group|
11194911|NCT03420118|Experimental|Tumor tissue and blood samples collection|
11194912|NCT03420105|Other|Group A|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
11194913|NCT03420105|Other|Group B|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
11194914|NCT03420105|Other|Healthy volunteers|Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
11194915|NCT03420092|Experimental|Treatment A|The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
11194916|NCT03420092|Experimental|Treatment B|The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
11194917|NCT03420092|Experimental|Treatment C|The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
11194918|NCT03420092|Experimental|Treatment D|The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
11194919|NCT03420092|Experimental|Treatment E|The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
11194920|NCT03420092|Experimental|Treatment F|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
11194921|NCT03420079|Experimental|Dose escalation cohort of FCN-411|"FCN-411 will be orally administrated at five sequential dose levels, which are 4 mg, 8 mg, 16 mg, 24 mg, and 32 mg.
~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
11194922|NCT03420079|Experimental|Dose expansion cohort of FCN-411|"FCN-411 will be orally administrated at MTD.
~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
11194923|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
11194924|NCT03420053|Experimental|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.
~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
11194925|NCT03420053|Placebo Comparator|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.
~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
11194926|NCT03420053|Experimental|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
11194958|NCT03419793|Sham Comparator|physical therapy intervention|physical therapy intervention alone
11194927|NCT03420053|Experimental|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.
~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
11194928|NCT03420053|Placebo Comparator|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.
~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
11194929|NCT03420040|Experimental|QS-M Needle Free Injector group|To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.
11194930|NCT03420040|Active Comparator|Glargine pen group|To observe the amount of insulin used by the Glargine pen group under good blood glucose control.
11194931|NCT03420014|Active Comparator|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
11194932|NCT03420014|Experimental|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.
~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
11194933|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
11194934|NCT03420001||controls|women after one vaginal delivery
11194935|NCT03419988|Experimental|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
11194936|NCT03419988|No Intervention|Control|8-weeks control: asked not to change anything or start exercising.
11194937|NCT03419975|Experimental|TJO-002|
11194938|NCT03419975|Active Comparator|latanoprost|
11194939|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
11194940|NCT03419936||Helicobacter pylori(HP) positive|Participants who are diagnosed with gastric cancer and Helicobacter Pylori infection will be treated with subtotal gastrectomy.
11194941|NCT03419923|Placebo Comparator|saline flushes|saline flushes with 250 mL were carried out every 30 min.
11194942|NCT03419923|Active Comparator|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
11194943|NCT03419923|Experimental|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
11194944|NCT03419910|Experimental|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
11194945|NCT03419897|Experimental|Tislelizumab|200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
11194946|NCT03419871||monitoring sleep effects on toddlers|Monitoring the sleep characteristics of toddlers living in economically stressed communities.
11194947|NCT03419858|Experimental|Mindfulness Meditation Group|"Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are momentary and fleeting and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and simply let go of discursive thoughts."
11194948|NCT03419858|Active Comparator|Placebo Meditation Group|The purpose of this intervention was to lead subjects to attend to one's breathing in a non-evaluative manner. Subjects were instructed to sit with a straight posture, closed eyes, and to take a deep, slow breaths every 2-3 minutes.
11194949|NCT03419858|Active Comparator|Slow-Breathing Group|A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
11194950|NCT03419845|Experimental|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
11194951|NCT03419832|Experimental|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
11194952|NCT03419832|Active Comparator|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
11194953|NCT03419819|Experimental|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.
~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
11194954|NCT03419806|Experimental|Infudopa i.v.|"Infudopa i.v. in 75% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion.
~From patient 6 and onwards:
~Infudopa i.v. in 81% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion."
11194955|NCT03419806|Experimental|Infudopa s.c.|"Infudopa s.c. in the same dosage as the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion.
~From patient 6 and onwards:
~Infudopa s.c. in 86% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion."
11194956|NCT03419806|Active Comparator|LCIG (Duodopa)|Individually optimized dosing of LCIG (Duodopa) (delivered directly to the proximal small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable infusion pump) will be delivered over a 16-h period, administered as a morning rapid constant rate administration followed by continuous infusion.
11194957|NCT03419793|Experimental|physical therapy intervention and segmental muscle vibration|physiotherapy intervention and segmental muscle vibration device
11194959|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
11194960|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
11194961|NCT03419767|Active Comparator|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
11194962|NCT03419767|Sham Comparator|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
11194963|NCT03419754|Experimental|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
11194964|NCT03419754|Placebo Comparator|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
11194965|NCT03419741|Active Comparator|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
11194966|NCT03419741|Sham Comparator|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
11194967|NCT03419728|Experimental|Healthy Families, Healthy Futures|Family coaches meet with participating pregnant and parenting females, the woman's partner, and the child. Visit frequency varies from once per week to once per month, depending on the length of time in the program, the client's needs, and the accomplishment of program milestones. In the short term, the program seeks to increase the use of Long-Acting Reversible Contraception (LARC), enhance family functioning including improving father involvement, and to meet the baby's child development needs. In the long term, the program aims to delay subsequent pregnancies, ensure positive child development, and increase parents' self-sufficiency.
11194968|NCT03419728|No Intervention|Control group|"No active treatment for control group. Control group has access to business as usual services in community."
11194969|NCT03419715|Experimental|Bimatoprost Topical Solution|0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
11194970|NCT03419715|Placebo Comparator|Control|Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks
11194971|NCT03419702|No Intervention|Control|No almonds
11194972|NCT03419702|Experimental|Experimental|Almonds
11194973|NCT03419689|Experimental|Sample Collection|"The following samples may be collected during the study:
~Tumour tissue samples
~Blood samples
~Ascites samples
~Other fluids requiring drainage"
11194974|NCT03419676|No Intervention|Control|No reinforcement.
11194975|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
11194976|NCT03419663||gastric cancer|
11194977|NCT03419650|Other|Treatment arm|treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
11194978|NCT03419637|No Intervention|Control - Standard of Care|The standard of care consists of in-clinic counseling, informational handouts, and access to patient medical records
11194979|NCT03419637|Experimental|Intervention - Mobile app|The mobile app, or app, is used to document before and after photos of the excised skin areas and to document related diagnoses. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
11194980|NCT03419624|Experimental|Dapagliflozin plus Exenatide|Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
11194981|NCT03419624|Placebo Comparator|Placebo plus Placebo|Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
11194982|NCT03419624|Active Comparator|Placebo plus Exenatide|Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
11194983|NCT03419611|Experimental|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
11194984|NCT03419611|Experimental|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
11194985|NCT03419611|Placebo Comparator|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
11194986|NCT03419611|Experimental|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
11194987|NCT03419611|Experimental|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
11194988|NCT03419598|Experimental|ToKa HTO|"Opening wedge high tibial osteotomy
~ToKa subject specific custom HTO plate"
11194989|NCT03419598|Active Comparator|Generic HTO|"Opening wedge high tibial osteotomy
~Generic HTO plate"
11194990|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
11194991|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
11194992|NCT03419572||Second line therapy|Data collection
11194993|NCT03419572||Third and later line therapy|Data collection
11194994|NCT03419559|Experimental|LN-145 in combination with durvalumab|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
11195348|NCT03417154|Experimental|Stage 1 Arms 1&2: Nivolumab and Cyclophosphamide|
11194995|NCT03419546||Bronchoscopic procedures|Bronchoscopies performed in different sites to evaluate the level of satisfaction of the operators with the device Ambu® aScope™ 4
11194996|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
11194997|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
11194998|NCT03419520|Experimental|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
11194999|NCT03419520|No Intervention|Control group|Schools monitored along the study but won't receive any healthy action.
11195000|NCT03419507|Active Comparator|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
11195001|NCT03419507|Active Comparator|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
11195002|NCT03419494||VDCLD regimen containing PLD|PLD 36mg/㎡.d d1、d15，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
11195003|NCT03419494||VDCLD regimen containing DNR|DNR 45mg/㎡.d d1～3，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
11195004|NCT03419481|Experimental|pembrolizumab|
11195005|NCT03419468|Experimental|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
11195006|NCT03419468|Active Comparator|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
11195007|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
11195008|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
11195009|NCT03419429|Experimental|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
11195010|NCT03419429|Experimental|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
11195011|NCT03419429|Experimental|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
11195012|NCT03419429|Experimental|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
11195013|NCT03419403|Experimental|Arm B: Standard Steroids + Vasoconstrictor + Cold Compress|Arm B: Steroid eye drop plus vasoconstrictor eye drop and cold compress plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy [TMZ] periods of this study.
11195014|NCT03419403|Experimental|Arm A: Standard Steroid (SS)|Arm A: Steroid Eye Drops plus depatuxizumab mafodotin during both the chemoradiation therapy (radiation [RT] and temozolomide [TMZ]) and the adjuvant therapy [TMZ] periods of this study.
11195015|NCT03419403|Experimental|Arm C: Enhanced Steroids+Vasoconstrictor+Cold Compress (ES/VC)|Arm C: Steroid Eye Drop plus ophthalmic steroid ointment plus vasoconstrictor eye drop and cold compresses plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy [TMZ] periods of this study.
11195016|NCT03419390|Other|Healthy subjects|One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
11195017|NCT03419390|Other|Diseased groups|lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
11195018|NCT03419390|Other|Diseased subgroups|"Every second subject will be allocated to the subgroup.
~Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
~Thickness measurement with reference medical device."
11195019|NCT03419377|Experimental|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
11195020|NCT03419377|No Intervention|Standard care|Standard care including gynecological examination.
11195021|NCT03419364|Experimental|Nicotinamide|All participants will receive study agent
11195022|NCT03419351|Other|Main group|Main study group including all individuals that underwent the study procedures
11195023|NCT03419338|Experimental|Test group|Surgical alveolus + maxillary sinus lift with inorganic bovine bone + newly forming bone + collagen membrane
11195024|NCT03419338|Active Comparator|Control group|Maxillary sinus lift with inorganic bovine bone + collagen membrane
11195025|NCT03419325|Experimental|HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:
~An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
11195026|NCT03419325|Experimental|HTPR/no-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Presence of HTPR, but no CYP2C19 LOF allele found:
~An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
11195027|NCT03419325|Experimental|no-HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Presence of a CYP2C19 LOF allele, but no HTPR:
~An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
11195028|NCT03419325|Experimental|No-HTPR/No-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.
~Absence of both HTPR and CYP2C19 LOF alleles:
~Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
11195029|NCT03419312|Experimental|Study sequence A|"Proclaim™ Elite 5: Burst - Washout - Sham
~14 days of burst stimulation.
~7 days washout.
~14 days of sham stimulation."
11195030|NCT03419312|Experimental|Study sequence B|"Proclaim™ Elite 5: Sham - Washout - Burst
~14 days of sham stimulation.
~7 days washout.
~14 days of burst stimulation."
11195031|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
11195032|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
11195033|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
11195034|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
11195035|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
11195036|NCT03419247|Experimental|Tumor tissue and blood sample collection|
11195037|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
11195038|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
11195039|NCT03419221|Active Comparator|A: Patients with PET/CT performs at day 14 after the drawing|Arm A: Patients with PET/CT performs at day 14 after the drawing of the first blood culture
11195040|NCT03419221|Placebo Comparator|B : Patients' routine care with performance of explorations|Arm B : Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
11195041|NCT03419208|Experimental|SPIN-HAND Program|Offered the SPIN-HAND program
11195042|NCT03419208|No Intervention|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
11195043|NCT03419195|Experimental|Type 2 diabetes|Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C <9%).
11195044|NCT03419195|Experimental|Healthy overweight controls|Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.
11195045|NCT03419182|Active Comparator|RCT - ORIF|A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
11195046|NCT03419182|Active Comparator|RCT - (THA) + ORIF|A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
11195047|NCT03419182|No Intervention|OBS - ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
11195048|NCT03419182|No Intervention|OBS (THA) + ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
11195049|NCT03419169|Experimental|Light load BFR resistance training|This arm of the clinical trial will involve eight weeks of twice weekly light load resistance training with BFR. Patients in this arm will complete four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press exercise at 30% of predicted one repetition maximum. BFR will be applied at 80% of total limb arterial occlusive pressure. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum. Both legs will be trained with BFR.
11195050|NCT03419169|Active Comparator|Heavy load resistance training|This arm of the clinical trial will involve eight weeks of twice weekly heavy load resistance training. Patients in this arm will complete three sets of ten repetitions of unilateral leg press exercise at 70% of predicted one repetition maximum. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum.
11195051|NCT03419156|Experimental|Text Message Arm|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
11195052|NCT03419143||Cohort 1|naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)
11195053|NCT03419143||Cohort 2|"naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs"
11195054|NCT03419143||Cohort 3|naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents** other than a single TNFi
11195055|NCT03419130|Experimental|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
11195056|NCT03419130|Experimental|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
11195057|NCT03419117|Experimental|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
11195058|NCT03419117|Placebo Comparator|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
11195349|NCT03417154|Experimental|Stage 2: Nivolumab and Cyclophosphamide|
11195059|NCT03419104|Experimental|Preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
11195060|NCT03419091|Active Comparator|Reusable Ureteroscope|Standard ureteroscope.
11195061|NCT03419091|Experimental|single-use flexible digital ureteroscope (LithoVue)|Disposable ureteroscope being tested.
11195062|NCT03419065|Other|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
11195063|NCT03419052|Experimental|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
11195064|NCT03419052|Active Comparator|MIND food and training control|Consumption of foods high in polyphenols (i.e., MIND foods) AND online (inert) games
11195065|NCT03419052|Active Comparator|Control foods and speed of processing training|Consumption of low polyphenol foods AND speed of processing training
11195066|NCT03419052|Sham Comparator|Double Control|Consumption of low polyphenol foods AND online (inert) games
11195067|NCT03419039|Experimental|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
11195068|NCT03419039|Placebo Comparator|Placebo|2 identically appearing placebo capsules daily
11195069|NCT03419026||breast cancer|
11195070|NCT03419026||control|
11195071|NCT03419013|Experimental|Test of new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation
11195072|NCT03419000|Experimental|Patient|Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
11195073|NCT03419000|Active Comparator|healthy volunteers|Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
11195074|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
11195075|NCT03418974|Experimental|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
11195076|NCT03418974|Experimental|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
11195077|NCT03418974|Experimental|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
11195078|NCT03418961|Experimental|Arm I (carvedilol)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive carvedilol PO BID. Courses repeat every 12 weeks for 108 weeks in the absence of disease progression or unacceptable toxicity.
11195079|NCT03418961|Active Comparator|Arm II (no intervention)|Patients not taking beta blocker, ARB, or ACE inhibitor at registration receive no study intervention for up to 108 weeks.
11195080|NCT03418961|Active Comparator|Arm III (observation)|Patients undergo observation for up to 108 weeks.
11195081|NCT03418948|Active Comparator|2 x CC|2 x conventional colonoscopy (CC), back-to-back design
11195082|NCT03418948|Active Comparator|CC followed by EC|Conventional colonoscopy followed by Endocuff Vision- assisted colonoscopy, back-to-back design
11195083|NCT03418948|Active Comparator|EC followed by CC|Endocuff Vision-assisted colonoscopy followed by conventional colonoscopy, back-to-back design
11195084|NCT03418948|Active Comparator|2 x EC|2 x Endocuff Vision-assisted colonoscopy
11195085|NCT03418935|Experimental|Remaxol 400 ml|Group I: treatment with Remaxol 400 ml IV + Ringer solution 400 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
11195086|NCT03418935|Experimental|Remaxol 800 ml|Group II: treatment with Remaxol 800 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
11195087|NCT03418935|Placebo Comparator|Control|Group III: Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
11195088|NCT03418922|Experimental|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
11195089|NCT03418922|Experimental|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
11195090|NCT03418909||Oropharyngeal carcinoma (excluding M+ stage)|"Eligible patients with histologically verified early stage squamous cell carcinoma of the oropharynx.
~Patients will be treated in accordance with current hospital protocols with transoral robotic surgery (T1-2, N1, M0) or radio(chemo)therapy (any T-stage, any N-stage, M0)."
11195091|NCT03418896|Experimental|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
11195092|NCT03418883|Experimental|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
11195093|NCT03418883|Sham Comparator|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
11195094|NCT03418870|Experimental|Family Integrated Care (mFI-Care)|Parents of infants assigned to the Family Integrated Care (mFI-Care) intervention will be treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches. Parent training on the Canadian FI-Care Parent Curriculum will be provided during small group sessions facilitated by the study team. Parents will receive peer support from mFI-Care-trained alumni parents and can interact with other mFI-Care parents through the We3Health App secure online parent forum. mFI-Care parents will be expected to track time spent with their infant; record infant activity, feeds and output; track learning and skills acquisition; and keep a journal of the NICU experience using the We3Health app.
11195168|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
11195169|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
11195095|NCT03418870|No Intervention|Family-Centered Care (FCC)|Infants assigned to usual FCC will have NICU nurses as primary caregivers per standard NICU protocol. FCC provides parents with orientation to the NICU; individualized teaching and support; and encouragement to participate in infant care under nursing supervision. Individualized support from social workers, lactation consultants and other specialists will be offered. As part of the study, parents will be asked to use the We3Health mobile app track their time in the NICU, time learning and time spent in infant caregiving activities and to keep of a journal of their NICU experience.
11195096|NCT03418857|Experimental|Experimental|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains 3.16 × 109 colony forming units (CFU) bifidobacterium animalis subsp. lactis BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
11195097|NCT03418857|Placebo Comparator|Control|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains no BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
11195098|NCT03418844|Other|Interest group (patients treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
11195099|NCT03418844|Other|Patient control group (patients not treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
11195100|NCT03418844|Other|Healthy volunteers|Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.
11195101|NCT03418831|Active Comparator|Raloxifene|Raloxifene Hydrochloride
11195102|NCT03418831|Placebo Comparator|Placebo|placebo tablet
11195103|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
11195104|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
11195105|NCT03418805|Active Comparator|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
11195106|NCT03418805|Active Comparator|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
11195107|NCT03418792|Experimental|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head & neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
11195108|NCT03418779|Experimental|Control Group|Optimized supportive care, YQF placebo (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
11195109|NCT03418779|Experimental|YQF Group|Optimized supportive care, YQF (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
11195110|NCT03418766||Normal|Normal healthy individual without migraine.
11195111|NCT03418766||Magraine|Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.
11195112|NCT03418753||single|subjects with abnormal intracranial pressure
11195113|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
11195114|NCT03418727|Experimental|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
11195115|NCT03418727|Experimental|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
11195116|NCT03418727|Placebo Comparator|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
11195117|NCT03418714|Experimental|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
11195118|NCT03418701|Active Comparator|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
11195119|NCT03418701|Active Comparator|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
11195120|NCT03418688|Active Comparator|COR388|Increasing doses of COR388 will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
11195121|NCT03418688|Placebo Comparator|Placebo|Matching placebo capsules will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
11195122|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
11195123|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
11195124|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
11195125|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
11195126|NCT03418649|Experimental|Experimental|Eplerenone 50 Mg Tab
11195127|NCT03418649|Placebo Comparator|Control|Placebo Oral Tablet
11195128|NCT03418636|Experimental|Staying Safe (Ssafe)|"Ssafe is delivered in a small group format (consisting of approximately 10-12 participants) by a trained facilitator over 4 2.5-hour sessions (10 hours total). To help promote the maintenance of risk reduction over the trial's 12-month follow-up period, Ssafe participants will be provided with a novel interactive, smartphone-delivered booster application based on core Ssafe principles and risk reduction strategies."
11195129|NCT03418636|Active Comparator|Healthy Living|Healthy Living is a time- and attention-matched control intervention of equivalent session structure and duration as Ssafe (4 2.5-hour sessions; 10 hours total), also delivered in a small group format (10-12 participants). Healthy Living participants will be provided with a publicly available, sleep hygiene-focused smartphone app to promote healthy sleep habits over the trial's follow-up period.
11195130|NCT03418623|Experimental|GET73|GET73 is administered at the dose of 300 mg t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of GET73: 3 capsules of GET73 on the first day of the related phase, according to randomization, and 2 capsules on the second day of each phase.
11195131|NCT03418623|Placebo Comparator|Placebo|Placebo is administered t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of Placebo: 3 capsules of Placebo on the first day of the related phase, according to randomization, and 2 capsules on the second day.
11195132|NCT03418610|Other|Open Label Single Arm|Azelaic Acid Foam 15% applied twice daily
11195133|NCT03418597|Experimental|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
11195134|NCT03418597|Active Comparator|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
11195135|NCT03418584|Experimental|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
11195136|NCT03418571|Experimental|ALX-0171 1.5 mg/kg|
11195137|NCT03418571|Placebo Comparator|Placebo|
11195138|NCT03418558|Experimental|HERACLES RESCUE|Patients will receive trastuzumab-emtansine, iv 3,6 mg/kg every 21 days. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first
11195139|NCT03418532|Experimental|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
11195140|NCT03418519|Experimental|CIMT group|"Two-hour mCIMT per day for 15 days (dosage = 30 hours)
~24-hour restraint for 3 weeks"
11195141|NCT03418519|No Intervention|Control group|no CIMT
11195142|NCT03418506|Experimental|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
11195143|NCT03418506|No Intervention|Control|No specific education will be given to the control group.
11195144|NCT03418493|Experimental|LY3316531 (Part A)|LY3316531 administered IV and/or SC.
11195145|NCT03418493|Placebo Comparator|Placebo (Part A)|Placebo matching LY3316531 administered IV.
11195146|NCT03418493|Experimental|LY3316531 (Part B)|LY3316531 administered IV and/or SC.
11195147|NCT03418493|Placebo Comparator|Placebo (Part B)|Placebo matching LY3316531 administered IV and/or SC.
11195148|NCT03418493|Experimental|LY3316531 (Part C)|LY3316531 administered IV and/or SC.
11195149|NCT03418480|Experimental|RNA Vaccine A|Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.
11195150|NCT03418480|Experimental|RAN Vaccine B|Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.
11195151|NCT03418467||tachycardiomyopathy|Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.
11195152|NCT03418467||dilated cardiomyopathy|Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.
11195153|NCT03418454||Oral Squamous Cell Carcinoma|Buccal mucosa samples for Extraction of BACTERIAL DNA
11195154|NCT03418454||Oral Epithelial Dysplasia|Buccal mucosa samples for Extraction of BACTERIAL DNA
11195155|NCT03418454||Control: Healthy age matched patients|Buccal mucosa samples for Extraction of BACTERIAL DNA
11195156|NCT03418454||Osteonecrosis of the Jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
11195157|NCT03418454||Underlying disease, no necrosis of the jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
11195158|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
11195159|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
11195160|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
11195161|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
11195162|NCT03418415|Experimental|Renal denervation|Procedure: Renal denervation
11195163|NCT03418402|Experimental|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
11195164|NCT03418402|Active Comparator|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
11195165|NCT03418389||Pediatric-onset Hypophosphatasia|
11195166|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
11195167|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
11195170|NCT03418363|Active Comparator|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
11195171|NCT03418363|Placebo Comparator|Placebo Oral Capsule|
11195172|NCT03418337|Experimental|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
11195173|NCT03418337|Active Comparator|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
11195174|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
11195175|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
11195176|NCT03418311|No Intervention|Control-Group|Control-group-women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications.
11195177|NCT03418311|Experimental|Cervical Pessary-Group|placement of the cervical pessary (non-invasive) at enrollment; removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37.
11195178|NCT03418298|Experimental|Prehabilitation group|Subjects will carry out a preoperative internet-based program including aerobic and resistance training three sessions per week
11195179|NCT03418272||Ventilated Pediatric Intensive Care Unit patient Group|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
11195180|NCT03418272||Intubated OR patient Control Group|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
11195181|NCT03418259|Experimental|Active KCS Medical Device|
11195182|NCT03418259|Placebo Comparator|Inactive KCS Medical Device|
11195183|NCT03418246|Sham Comparator|GIC filling|"Intervention/treatment One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer).
~Placebo Comparator: GIC
~Participants will have a restoration placed with GIC in the lesion near the gum line. Device: GIC Application of a tooth colored filling in the cavitated dental lesion. Other Name: Resin modified glass ionomer"
11195184|NCT03418246|Experimental|Biodentine filling|"Intervention/treatment The second group will be treated with Biodentine that will be placed near the gum line.Experimental: Biodentine
~Participants will have a restoration placed with Biodentine in the lesion near the gum line. Device: Biodentine Application of a white colored filling in dental lesion."
11195185|NCT03418233|Active Comparator|Active Group|"Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.
~The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
11195186|NCT03418233|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
11195187|NCT03418220|Other|AMD early / intermediate|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD early / intermediate
11195188|NCT03418220|Other|AMD exudative|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD exudative
11195189|NCT03418220|Other|AMD atrophic|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD atrophic
11195190|NCT03418220|Other|control group|A blood and aqueous humor sample will be taken during cataract surgery in patients with cataract (control group)
11195191|NCT03418207|Other|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
11195192|NCT03418194|Experimental|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
11195193|NCT03418194|Placebo Comparator|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
11195194|NCT03418181|Other|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
11195195|NCT03418181|Experimental|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.
~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
11195196|NCT03418168|Experimental|Molidustat (BAY85-3934)|Molidustat group
11195197|NCT03418155|Experimental|Treatment of TongBi Capsule|
11195198|NCT03418155|Placebo Comparator|Treatment of TongBi Placebo|
11195199|NCT03418142|Experimental|Priovi|Priovi is an Internet-administered intervention for people with BPD.
11195200|NCT03418142|Active Comparator|Care-as-Usual (CAU) / wait list|Additionaly, they will be informed about helpful and free available online self-help-proposals for BPD patients immediately after randomization.
11195323|NCT03417323|Experimental|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
11195201|NCT03418129|Experimental|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
11195202|NCT03418129|Experimental|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
11195203|NCT03418129|Experimental|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
11195204|NCT03418116|Experimental|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
11195205|NCT03418090|Active Comparator|Arm 1|Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy
11195206|NCT03418090|Active Comparator|Arm 2|Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI
11195207|NCT03418077|Experimental|energy drink|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
11195208|NCT03418077|Placebo Comparator|Placebo-control|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
11195209|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
11195210|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
11195211|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
11195212|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
11195213|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
11195214|NCT03418038|Experimental|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 courses may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11195215|NCT03418038|Active Comparator|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 courses may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11195216|NCT03418038|Experimental|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17 and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according standard regimen schedule. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 courses may switch to an alternative chemotherapy regimen.
11195217|NCT03418025|Experimental|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
11195218|NCT03418025|Active Comparator|Group II (pre and post testing)|Questionnaire Administration & Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
11195219|NCT03418012|Experimental|Cervical Pessary-Group|Cervical Pessary Group: placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37
11195220|NCT03418012|Other|Control-Group|Control-Group women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
11195221|NCT03417999|Experimental|Cohort 1|"Cohort 1A:
~Dexmedetomidine 2 μg/kg
~Under general oral endotracheal anesthesia
~7 subjects age >2 yo and ≤ 6 yo
~7 subjects age ≥1 mo and ≤2 yo
~Cohort 1B:
~Dexmedetomidine 2 μg/kg
~Under sedation with a natural airway
~7 subjects age >2 yo and ≤ 6 yo
~7 subjects age ≥1 mo and ≤2 yo"
11195222|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg
~Under general oral endotracheal anesthesia
~7 subjects age >2 yo and ≤ 6 yo"
11195223|NCT03417999|Experimental|Cohort 3|Currently analyzing data. May perform a 3 μg/kg pending review.
11195224|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
11195225|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
11195226|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
11195324|NCT03417323|No Intervention|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
11195227|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
11195228|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
11195229|NCT03417960|Experimental|iTBS|accelerated iTBS to Left DLPFC
11195230|NCT03417947|Placebo Comparator|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
11195231|NCT03417947|Experimental|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
11195232|NCT03417921|Experimental|ARM A|ABTL0812 (starting 1,300 mg tid orally) in combination with gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer
11195233|NCT03417921|Active Comparator|ARM B|Gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer as standard pattern
11195234|NCT03417908|Active Comparator|COPD - PNF|COPD - PNF
11195235|NCT03417908|Sham Comparator|COPD - sham|COPD - sham
11195236|NCT03417908|Active Comparator|Individuals Without COPD - PNF|Individuals Without COPD - PNF
11195237|NCT03417908|Sham Comparator|Individuals Without COPD - sham|Individuals Without COPD - sham
11195238|NCT03417895|Experimental|A(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
11195239|NCT03417895|Experimental|B(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（5 Days on, 2 Days off）
11195240|NCT03417895|Experimental|C(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（7 Days on, 7 Days off）
11195241|NCT03417882|Experimental|Cohort 1|All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
11195242|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
11195243|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
11195244|NCT03417843|Experimental|EUSRA RF electrode|new ablation catheter RFA (RADIOFREQUENCY under EUS), developed by TAEWOONG company for the treatment of pancreatic premalignant and early malignant cystic lesion.
11195245|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
11195246|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
11195247|NCT03417817|Other|Healthy subjects|Bravo wireless pH monitoring over 96 hours
11195248|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
11195249|NCT03417778|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
11195250|NCT03417778|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
11195251|NCT03417778|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
11195252|NCT03417765|Experimental|Cohort A: 5 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
11195253|NCT03417765|Experimental|Cohort B: 10 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
11195254|NCT03417765|Experimental|Cohort C: 25 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
11195255|NCT03417752|Experimental|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
11195256|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
11195257|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
11195258|NCT03417739|Experimental|BVD-523|BVD-523 is to be taken twice daily orally for 28 consecutive days
11195259|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
11195260|NCT03417700|Experimental|Training NW|exercise and supplementation
11195261|NCT03417700|Experimental|Training HICT and vitamin D|Training HICT plus vitamin D
11195262|NCT03417700|Experimental|Placebo|placebo Vitamin D
11195263|NCT03417687|Active Comparator|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
11195264|NCT03417687|Active Comparator|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
11195265|NCT03417674|Experimental|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
11195266|NCT03417674|No Intervention|Control group|Routine care.
11195291|NCT03417531|Sham Comparator|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
11195267|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
11195268|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
11195269|NCT03417661|Experimental|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
11195270|NCT03417648|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
11195271|NCT03417648|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
11195272|NCT03417635|Experimental|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.
~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
11195273|NCT03417635|Active Comparator|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.
~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
11195274|NCT03417622|Experimental|Post-treatment volume-resection margin|Lumpectomy is performed with resection margin of the clinically / radiologically identifiable post-treatment tumor.
11195275|NCT03417622|Active Comparator|Pre-treatment volume-resection margin|Lumpectomy is performed with resection margin of the bracketed tissue.
11195276|NCT03417609||Sarcopenia|Elderly patients with sarcopenia
11195277|NCT03417609||Control|Elderly patients without sarcopenia
11195278|NCT03417596|Experimental|Vestibular Rehabilitation|"Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day.
~Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around.
~Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides.
~The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit."
11195279|NCT03417596|Experimental|Vestibular Rehabilitation+Pharmacological Therapy|"Same exercises that were applied in first group were also applied to this group.
~For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated."
11195280|NCT03417596|Other|Pharmacological Therapy only|Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.
11195281|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
11195282|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
11195283|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap.
11195284|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap
11195285|NCT03417557|Experimental|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
11195286|NCT03417557|Active Comparator|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
11195287|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:
~Atezolizumab (IV) every 3 weeks (q3w)]
~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)
~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
11195288|NCT03417531|Active Comparator|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
11195289|NCT03417531|Active Comparator|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
11195290|NCT03417531|Active Comparator|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
11227358|NCT03195244|Experimental|Group Aquatic Therapy|
11195294|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
11195295|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
11195296|NCT03417492|Experimental|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
11195297|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
11195298|NCT03417466|Experimental|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
11195299|NCT03417453|Active Comparator|Eye Drop Dispenser TYPE Opticare|subject will assess TYPE 1 dispenser
11195300|NCT03417453|Active Comparator|Eye Drop Dispenser Autodrop|subject will assess Autodrop dispenser
11195301|NCT03417440|Other|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
11195302|NCT03417440|Other|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
11195303|NCT03417440|Other|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
11195304|NCT03417440|Other|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
11195305|NCT03417440|Other|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
11195306|NCT03417440|Other|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
11195307|NCT03417440|Other|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
11195308|NCT03417440|Other|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
11195309|NCT03417427|Active Comparator|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
11195310|NCT03417427|Placebo Comparator|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
11195311|NCT03417414||B-CLL|Patients with B-Cell CLL
11195312|NCT03417414||B-NHL|Patients with B-Cell NHL
11195313|NCT03417401|Experimental|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
11195314|NCT03417388|Experimental|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
11195315|NCT03417388|Active Comparator|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
11195316|NCT03417375|Experimental|Osteocel Plus|Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
11195317|NCT03417375|Active Comparator|alloOss|The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
11195318|NCT03417362|Other|Animation|Animation describing process of early medical abortion, what to expect, how to take medicines. This is prior to consultation.
11195319|NCT03417362|No Intervention|Standard|Standard of Care - no animation ,standard consultation only.
11195320|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
11195321|NCT03417336|Experimental|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
11195322|NCT03417336|Active Comparator|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
11195325|NCT03417310|Experimental|"H joystick"|"Patients are treated with the H joystick on a traction table"
11195326|NCT03417310|Active Comparator|Common reduction methods|Patients are treated with common reduction methods on a traction table
11195327|NCT03417297|Experimental|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
11195328|NCT03417284|Experimental|Group 1 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.
~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
11195329|NCT03417284|Experimental|Group 2 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.
~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
11195330|NCT03417271|Active Comparator|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
11195331|NCT03417271|Active Comparator|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
11195332|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
11195333|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
11195334|NCT03417245|Experimental|fitusiran|Fitusiran administered subcutaneously (SC) as prophylaxis once monthly, with use of on-demand factor concentrates for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months
11195335|NCT03417245|Experimental|On demand factor concentrates|On-demand factor concentrates for treatment of breakthrough bleeding episodes. On-demand use of factor concentrates is defined as the use of these agents, as needed, for episodic bleeding, and not on a regular regimen intended to prevent spontaneous bleeding. All patients will be treated for a total of 9 months.
11195336|NCT03417232|Experimental|Split Full Split Elevation of CAF|The central portion of the flap apical to the recession was elevated full thickness by the use of a small periostium elevator inserted into the probable sulcus
11195337|NCT03417232|Sham Comparator|Split Elevation of CAF|The flap was fully elevated with a split thickness approach: the blade of the knife was inserted into the sulcus
11195338|NCT03417219|Experimental|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
11195339|NCT03417219|Active Comparator|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
11195340|NCT03417206|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE between 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
11195341|NCT03417206|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
11195342|NCT03417206|Experimental|TIVA USING PROPOROL|Infusion of propofol will be adjusted at target of SE 40,remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
11195343|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
11195344|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
11195345|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
11195346|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
11195347|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
11195350|NCT03417141|Experimental|Valchor treatment of Lichen Planopilaris|Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
11195351|NCT03417128|No Intervention|Control|Participants in the control group will receive a one-time personalised nutrition and lifestyle advised based from the Malaysian Dietary Guideline 2010. They will be assured to be followed up twice for the next six month.
11195352|NCT03417128|Experimental|Peer support|This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering.
11195353|NCT03417115||Her2 positive|Patients with Her2 positive tumors
11195354|NCT03417115||triple negative|Patients with triple negative tumors
11195355|NCT03417115||HR positive, Her2 negative|Patients with HR positive, Her2 negative tumors
11195356|NCT03417102|Experimental|Fitusiran|Fitusiran administered subcutaneously (SC) as prophylaxis once monthly, with use of on-demand BPAs for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months
11195357|NCT03417102|Active Comparator|On demand bypassing agents|On-demand bypassing agents (BPAs) for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months.
11195358|NCT03417089|Experimental|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
11195359|NCT03417089|Active Comparator|No suspension|working without suspension of the falciform ligament
11195360|NCT03417076|Experimental|Bexagliflozin|Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of < 30 ug 14C-bexagliflozin in 0.9% saline solution).
11195361|NCT03417050||Randomized CABG patients|Patients which were randomized to undergo CABG.
11195362|NCT03417050||Randomized PCI patients|Patients which were randomized to undergo PCI.
11195363|NCT03417050||Registry CABG|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
11195364|NCT03417050||Registry PCI|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
11195365|NCT03417037|Experimental|Arm A|BMS-986205 and Nivolumab administered in combination
11195366|NCT03417037|Experimental|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
11195367|NCT03417037|Active Comparator|Arm C|Chemotherapy administered alone
11195368|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
11195369|NCT03416998|Active Comparator|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
11195370|NCT03416998|Placebo Comparator|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
11195371|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
11195372|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
11195373|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
11195374|NCT03416972||Stage I-III NSCLC patients|Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
11195375|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
11195376|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
11195377|NCT03416933|Experimental|Biological|
11195378|NCT03416920|Experimental|Wellframe|Subjects in this arm will use the Wellframe application for 90 days
11195379|NCT03416907|Active Comparator|Original|Participants will review the full-length, original consent form for the clinical trial.
11195380|NCT03416907|Experimental|Shortened|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
11195381|NCT03416907|Experimental|Reordered|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
11195382|NCT03416907|Experimental|Highlighted|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
11195383|NCT03416907|Experimental|Interactive|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
11195384|NCT03416894|Experimental|Deep Brain Stimulation|
11195385|NCT03416868|Experimental|Week 3 start|"For the first two weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In the following 3 weeks of voice therapy (weeks 3 through 5), patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
11230694|NCT03172637||Group B|50 normal female patients
11195386|NCT03416868|Experimental|Week 4 start|"For the first three weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy weeks 4 and 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
11195387|NCT03416868|Experimental|Week 5 start|"For the first four weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy week 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
11195388|NCT03416855||Overall population|Participants will be decided to be treated with Ryzodeg® FlexTouch® by physicians before the enrolment in the study based on clinical judgement in the diabetes management.
11195389|NCT03416842|Experimental|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
11195390|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
11195391|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
11195392|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
11195393|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
11195394|NCT03416803|Experimental|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
11195395|NCT03416803|No Intervention|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
11195396|NCT03416777|Active Comparator|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
11195397|NCT03416777|Experimental|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
11195398|NCT03416777|Experimental|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
11195399|NCT03416764|Experimental|EFP-NF (participants without steady menstrual cycle).|EFP-NF training, twice a week for a total of 10 sessions .
11195400|NCT03416764|No Intervention|TAU|Participant will receive no EFP-NF training, and continue their treatment as usual (TAU).
11195401|NCT03416764|Experimental|EFP-NF during HIGH estrogen phase|EFP-NF training, twice a week, during high-estrogen phases only (days 7-21 of a 28-day cycle), for a total of 10 sessions.
11195402|NCT03416764|Experimental|EFP-NF during LOW estrogen phase|EFP-NF training, twice a week, during low-estrogen phases only (days 21-28 of a cycle and days 1-7 of the following cycle,based on a 28-day cycle), for a total of 10 sessions.
11195403|NCT03416751|Experimental|Fecal Microbial transplantation|Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor
11195404|NCT03416751|Placebo Comparator|Placebo|Patients will get one-dose of 90ml of saline enema on day 1
11195405|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
11195406|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
11195407|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
11195468|NCT03416335|Experimental|Monotherapy Arm - Part A|Dose Escalation Drug DSP-0509
11195469|NCT03416335|Experimental|Combination arm - Part B|Dose Escalation Drug DSP-0509, Pembrolizumab
11195408|NCT03416712|No Intervention|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).
~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
11195409|NCT03416712|Experimental|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
11195410|NCT03416686|Experimental|Radiofrequency|
11195411|NCT03416673|Active Comparator|CTG+CAF|The surgical procedure will include a connective tissue graft harvested from the palate and used under a coronally advanced flap
11195412|NCT03416673|Experimental|peCTG+CAF|A papillary extended connective tissue graft reshaped after harvested from the palate will be used under a coronally advanced flap
11195413|NCT03416660|Active Comparator|Low density|Fractional carbon dioxide laser: Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).
11195414|NCT03416660|Active Comparator|Medium density|Fractional carbon dioxide laser : Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).
11195415|NCT03416660|Active Comparator|High density|Fractional carbon dioxide laser : Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).
11195416|NCT03416647|Experimental|SMAS patients|
11195417|NCT03416634|Active Comparator|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
11195418|NCT03416634|Experimental|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
11195419|NCT03416634|Experimental|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
11195420|NCT03416634|Active Comparator|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
11195421|NCT03416634|Experimental|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
11195422|NCT03416634|Experimental|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
11195423|NCT03416621|Experimental|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
11195424|NCT03416621|Placebo Comparator|Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
11195425|NCT03416621|Active Comparator|Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
11195426|NCT03416595|Active Comparator|N1115 Probiotic Supplement|A probiotic supplement containing Lactobacillus paracasei N1115 [Junlebao Lp. N1115] Participators, who met inclusion criteria, will receive following product during 8 weeks: N1115 Probiotic Supplement in the form of powder packaged in sachet (one sachet containing 10^9 CFU Lp. N1115).
11195427|NCT03416595|Placebo Comparator|Placebo control|Dietary Supplement: Placebo Participators, who met inclusion criteria, will receive an identical N1115 Probiotic Supplement looking and tasting placebo.
11195428|NCT03416582|Experimental|SMENC Group|"The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.
~During the telephone call, the patient will report the use of the Drinks Diary."
11195429|NCT03416569|Experimental|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
11195430|NCT03416556|Experimental|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
11195431|NCT03416556|Sham Comparator|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
11195432|NCT03416556|No Intervention|No-contact condition|There was no manual contact between the therapist and the participant
11195433|NCT03416543||Puncture|Patient with RA or gout or osteoarthritis and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.
11195434|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
11195435|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
11195436|NCT03416530|Experimental|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
11195437|NCT03416530|Experimental|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
11195438|NCT03416530|Experimental|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
11195439|NCT03416530|Experimental|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
11195440|NCT03416530|Experimental|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
11195441|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 1b)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11195442|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 2)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15 mg/m^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. The final dose of anlotinib and irinotecan depends on the result from previous phase Ib study. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11195443|NCT03416504|Experimental|Gradual Exposure Group|The gradual exposure group received the Gradual Exposure (EXP-G) Intervention.
11195444|NCT03416504|Experimental|Variable Exposure Group|The variable exposure group received the Variable Exposure (EXP-V) Intervention.
11195445|NCT03416491|Experimental|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
11195446|NCT03416491|Experimental|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
11195447|NCT03416491|Experimental|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
11195448|NCT03416478||ctDNA test group|
11195449|NCT03416452|Experimental|PD patients no|PD patients without freezing of gait
11195450|NCT03416452|Placebo Comparator|Healthy|HV using Mobile Gait Trainer
11195451|NCT03416452|Experimental|PD patients|pd patients using vibratory cueing device
11195452|NCT03416452|Experimental|PD patients 1|PD patients with freezing of gait
11195453|NCT03416452|Experimental|Healthy Volunteers|Age and gender matched healthy volunteers.
11195454|NCT03416439|Experimental|intervention arm|lifestyle intervention program carried out by trained professionals
11195455|NCT03416439|No Intervention|control arm|standard, unstructured information given by the family physicians
11195456|NCT03416426||patients undergone PFO closure|patients with ischemic stroke and PFO documented by bubble contrast TEE with no other identifiable cause of the ischemic event who undergone PFO closure using Amplatzer® PFO occluder or Gore® Septal Occluder
11195457|NCT03416413|Active Comparator|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
11195458|NCT03416413|Active Comparator|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
11195459|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
11195460|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
11195461|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
11195462|NCT03416387|Other|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
11195463|NCT03416374|Experimental|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
11195464|NCT03416361|Experimental|Vitamin D|4000IU Vitamin D3 as two 50mcg tablets per day
11195465|NCT03416361|Placebo Comparator|Control|Placebo - two chewable blackcurrant flavoured tablets per day
11195466|NCT03416348|Placebo Comparator|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
11195467|NCT03416348|Active Comparator|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
11195470|NCT03416322|No Intervention|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
11195471|NCT03416322|Experimental|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
11195472|NCT03416296||normal placenta|TA , TV ,TP us
11195473|NCT03416296||placenta previa and MAP|TA,TV.TP us
11195474|NCT03416283|Experimental|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
11195475|NCT03416283|Experimental|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
11195476|NCT03416283|No Intervention|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
11195477|NCT03416270|Experimental|Ertuglifozin Treatment Arm|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
11195478|NCT03416270|Placebo Comparator|Placebo Arm|Placebo Matching Ertugliflozin Tablet for 12 weeks
11195479|NCT03416257||WIHS|Women's Interagency HIV Study
11195480|NCT03416257||MACS|Multicenter AIDS Cohort Study
11195481|NCT03416244|Experimental|A: Nivolumab / Ipilimumab combination treatment|Nivolumab 240 mg fixed dose IV every 2 weeks; Additionally, after 7 week safety assessment Ipilimumab 1mg/kg IV every 6 weeks
11195482|NCT03416244|Experimental|B. Nivolumab monotherapy|Nivolumab 240 mg fixed dose IV every 2 weeks
11195483|NCT03416231|Experimental|apatinib plus docetaxel|apatinib combine with docetaxel， 4~6 cycles
11195484|NCT03416218|Experimental|Intervention|All participants enrolled in the study will play Prognosis, the intervention being assessed in this study.
11195485|NCT03416205|Experimental|EST|EST is an operation using the Erbao electric knife and Three-cavity incision knife to make a large incision to the duodenal nipples，and the incision scope is the nipple mouth uplift length of 4/5. It has been used since 1974. The technique is intuitive and intact. However, EST cut too small to achieve the purpose of treatment and will affect the next step, and if the incision is too large it may be easier to occur gastrointestinal perforation and bleeding.The EST will also damage the anatomy of the Oddi sphincter structure,which causes bacterial reflux to the bile duct, the recurrence of CBD.Some surgeons prefer it because it's postoperative pancreatitis rate is lower and it may be easier to find the lesion position if bleeding or perforation occurs.
11195486|NCT03416205|Experimental|EPBD|EPBD is an operation using the Columnar expansion balloon to expand duodenal to achieve the purpose of using the basket and other instruments to take stone out. Balloon expansion may retain part of the sphincter not destroyed, and basically retain the normal physiological function of the nipple sphincter.Thus it may reduce the risk of recurrence of stones and bacterial reflux. However,the postoperative pancreatitis rate is high(4.8% -19.5% ), and nipple sphincter tear is uncontrollable in EPBD.If the digestive tract perforation or bleeding occur after EPBD,it is hard to accurately find the lesion position.Some surgeons prefer it for it's lower bleeding and perforation rate.
11195487|NCT03416205|Experimental|sEST+EPBD|sEST+EPBD is an operation combining EST and EPBD. Investigators use the Erbao electric knife and Three-cavity incision knife to make a small incision to the duodenal nipples, and the incision length is less than 5mm while the incision scope is less than the nipple mouth uplift length of 1/2. Then, Investigators match the appropriate Columnar expansion balloon according to the diameter of the common bile duct and gradually expand the duodenal nipples.This method allows the nipple sphincter to be cut in a small range, then the balloon can guide the direction of the nipple sphincter tearing after the expansion , so that the digestive tract bleeding, perforation may be smaller and more controllable. Besides,it may reduce postoperative pancreatitis rate and the recurrence rate of stones.
11195488|NCT03416192|Experimental|MCO-HD|Hemodialysis with Medium Cut-Off filter
11195489|NCT03416192|Active Comparator|High-flux HDF|Hemodiafiltration with standard high-flux filter
11195490|NCT03416179|Experimental|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
11195491|NCT03416179|Placebo Comparator|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
11195492|NCT03416179|Experimental|Arm A (Non-intensive study)|Glasdegib + azacitidine
11195493|NCT03416179|Placebo Comparator|Arm B (Non-intensive study)|Placebo + azacitidine
11195494|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
11195495|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
11195496|NCT03416140|Experimental|Therapeutic exercise|
11195497|NCT03416140|No Intervention|Control|
11195498|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
11195499|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
11195500|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
11195501|NCT03416088|Experimental|Liquid volume|Drink 300ml wine (alcohol concentration:13%) or 300ml coffee (caffeine concentration 1.2%).
11195502|NCT03416062|Experimental|Remaxol® 400 ml + Placebo 400 ml|Treatment with Remaxol® 400 ml IV + Ringer solution 400 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
11195503|NCT03416062|Experimental|Remaxol® 800 ml|Treatment with Remaxol® 800 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
11195504|NCT03416062|Placebo Comparator|Control|Treatment with Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
11195505|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
11195506|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
11195507|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
11195508|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
11195509|NCT03416036|Experimental|Arm 1: TV003 + rDEN2Δ30-7169|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
11195510|NCT03416036|Experimental|Arm 2: TV003 + rDEN3Δ30|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN3Δ30 on Day 28.
11195511|NCT03416036|Placebo Comparator|Arm 3: Placebo + rDEN2Δ30-7169|Participants will receive placebo at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
11195512|NCT03416036|Placebo Comparator|Arm 4: Placebo + rDEN3Δ30|Participants will receive placebo at study entry (Day 0) and rDEN3Δ30 on Day 28.
11195513|NCT03416023|Experimental|Single|
11195514|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
11195515|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
11195516|NCT03415997|Active Comparator|Total Body Weight|
11195517|NCT03415997|Active Comparator|Lean Body Weight|
11195518|NCT03415984||Exposed patients|Patients with Parkinson's disease treated with L-DOPA
11195519|NCT03415984||Non exposed patients|Patients with Parkinson's disease not treated with L-DOPA
11195520|NCT03415971|Active Comparator|ASTRA TECH implants|implant restoration(replace of a missing tooth) - 35 patients
11195521|NCT03415971|Active Comparator|CROWN|to fixed denture restorations in own teeth - 32 patients
11195522|NCT03415971|Placebo Comparator|non-edontulos|control group will consist 38 non-edotulos patients
11195523|NCT03415958||Open reduction internal fixation|Patients with displaced midshaft clavicle fractures will be offered operative treatment which involves open reduction and internal fixation.
11195524|NCT03415958||Conservative care|Patients will be treated in a sling for the acute phase of two weeks with progressive physiotherapy.
11195525|NCT03415945|Experimental|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
11195526|NCT03415932|Experimental|Health education|Assessment of healt care Contacts Before and after intervention
11195527|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
11195528|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
11195529|NCT03415919||Control patients|Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
11195530|NCT03415906|Experimental|sacubitril+valsartan|Combined angiotensin receptor and neprilysin inhibition
11195531|NCT03415906|Active Comparator|valsartan|Angiotensin receptor inhibition alone
11195532|NCT03415880|Other|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
11195533|NCT03415880|Experimental|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
11195534|NCT03415867|Experimental|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
11195535|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
11195536|NCT03415841|Experimental|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
11195537|NCT03415841|No Intervention|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
11195538|NCT03415828|Experimental|Ethanol gel|CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
11195539|NCT03415828|Active Comparator|Steroid infiltration|Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
11195540|NCT03415815||T1-T3 esophageal cancer|Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries
11195541|NCT03415802|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
11195600|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
11195601|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
11198496|NCT03394989|Active Comparator|Comparator|Fluticasone propionate/salmeterol 100/50 µg
11195542|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.
~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.
~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
11195543|NCT03415776|Experimental|Twice weekly|Two sessions of hemodialysis per week
11195544|NCT03415776|Experimental|Thrice weekly|Three sessions of hemodialysis per week
11195545|NCT03415763|No Intervention|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
11195546|NCT03415763|Experimental|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
11195547|NCT03415763|Experimental|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
11195548|NCT03415763|Experimental|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
11195549|NCT03415750|Experimental|Everolimus arm|Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'
11195550|NCT03415750|Active Comparator|Mycophenolate arm|Patients will remain in Tacrolimus + Mycophenolate mofetil combination
11195551|NCT03415724|Active Comparator|1.8 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
11195552|NCT03415724|Active Comparator|3.6 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
11195553|NCT03415724|Active Comparator|1.8 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
11195554|NCT03415724|Active Comparator|3.6 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
11195555|NCT03415711|Experimental|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
11195556|NCT03415711|Experimental|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
11195557|NCT03415711|Active Comparator|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
11195558|NCT03415698|Active Comparator|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
11195559|NCT03415698|Active Comparator|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
11195560|NCT03415685|Active Comparator|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
11195561|NCT03415685|Active Comparator|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
11195562|NCT03415672|Active Comparator|Group 1|Subjects included in Group 1 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine. They will receive three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
11195563|NCT03415672|Experimental|Group 2|"Subjects included in Group 2 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine). They will receive three doses of HBAI20 at 0, 1, and 2 months.
~The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly."
11195564|NCT03415659|Experimental|HWH340 monotherapy|HWH340 tablet, oral administration
11195565|NCT03415646|Active Comparator|Block Group|Erector Spinae Plane Block administered group
11195566|NCT03415646|Sham Comparator|Control Group|Control group
11195567|NCT03415633|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
11195568|NCT03415633|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
11195602|NCT03415412|Experimental|Group CU (Clearfil Universal)|Clearfil Univesal Bond (Kuraray Dental, New York, United States of America), adhesive system
11195603|NCT03415412|Experimental|Group IU (Ibond Universal)|IBond Universal (Heraeus Kulzer GmbH, Hanau, Germany), adhesive system
11195604|NCT03415412|Experimental|Group GP (G-Premio)|G-Premio Bond (GC Coorporation, Tokyo, Japan), adhesive system
11195569|NCT03415620|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres. Patient will choose the desired playlist and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.
~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
11195570|NCT03415594|Experimental|FE203799 5 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
11195571|NCT03415594|Placebo Comparator|Placebo|Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration
11195572|NCT03415594|Other|FE203799 10 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
11195573|NCT03415581|Placebo Comparator|Doxazosin 0 mg (Placebo)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
11195574|NCT03415581|Active Comparator|Doxazosin 16 mg|Maintenance on a daily dose of oral doxazosin (16 mg) for 4 weeks. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
11195575|NCT03415568|Placebo Comparator|LCT consumption|Muffin that contains 15g of long-chain triglyceride (LCT) oils were provided to conduct 6-h meal tolerance test.
11195576|NCT03415568|Experimental|MCDG consumption|Muffin that contains 15g of the mixture of medium-chain triglyceride and diacylglycerol (MCDG) oils were provided to conduct 6-h meal tolerance test.
11195577|NCT03415555|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
11195578|NCT03415555|Experimental|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
11195579|NCT03415542|Other|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
11195580|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
11195581|NCT03415516|Experimental|Gluma Universal, self-etch mode (GSE)|
11195582|NCT03415516|Experimental|Gluma Universal, selective etching (GSL)|
11195583|NCT03415516|Experimental|Gluma Universal, etch&rinse (GER)|
11195584|NCT03415516|Experimental|All Bond Universal, self-etch (ASE)|
11195585|NCT03415516|Experimental|All Bond Universal, selective etching (ASL)|
11195586|NCT03415516|Experimental|All Bond Universal, etch&rinse (AER)|
11195587|NCT03415516|Experimental|Single Bond2, etch&rinse (SBU)|
11195588|NCT03415503|Placebo Comparator|placebo|The placebo capsules only contained pullulan and maltodextrin.During the trial period, the participants were instructed to consume 2 Medox® placebo capsules twice daily (30 min after breakfast or supper).
11195589|NCT03415503|Experimental|40mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (40 mg anthocyanins per capsule) will provid a total daily intake of 40 mg anthocyanins.
11195590|NCT03415503|Experimental|80mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule) will provid a total daily intake of 80 mg anthocyanins.
11195591|NCT03415503|Experimental|320mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,4 per day) will provid a total daily intake of 320 mg anthocyanins.
11195592|NCT03415490|Active Comparator|Classic technique of self-adherent wrap|"over 16 years old
~free of any symptoms in the eyes
~classic technique of self-adherent wrap after surgery"
11195593|NCT03415490|Experimental|Folded technique of self-adherent wrap|"over 16 years old
~free of any symptoms in the eyes
~folded technique of self-adherent wrap after surgery"
11195594|NCT03415477|Experimental|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
11195595|NCT03415464|Experimental|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
11195596|NCT03415464|No Intervention|Regular army training|Regular military training.
11195597|NCT03415451|Experimental|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
11195598|NCT03415438||Group 1|Assessments will be done for 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of Baskent University.
11195599|NCT03415438||Group 2|Assessments will be done for 30 healthy volunteers
11198497|NCT03394989|Other|Placebo|Test Placebo
11195605|NCT03415399|Experimental|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
11195606|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
11195607|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
11195608|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
11195609|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
11195610|NCT03415373|Experimental|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
11195611|NCT03415360|Other|cryoablation|peripheral nerve cryoablation
11195612|NCT03415347|Active Comparator|Abscess de-roofing and curettage|Abscess de-roofing and curettage. The patient will be placed in the lateral position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. A spindle-shaped (elliptical) excision will be performed to the lateral aspect of the abscess formation with a scalpel staying away from the midline. Once the pus has been drained through this lateral incision the wound cavity will then be curetted and washed out with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
11195613|NCT03415347|Active Comparator|Abscess wide local excision|Wide local excision. Patients will be placed in the prone position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. Diluted methylene blue will be injected in all visible pits and a wide spindle-shaped (elliptical) midline excision of the skin and the underlying subcutaneous tissue down to the coccygeal (pre-sacral) fascia including all sinuses will be performed with electrocautery. The specimen will be sent for histology as per routine surgical practice. The wound will be washed with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
11195614|NCT03415334|Other|behavioral change|two approaches for behavior changes : social marketing and behavioral development
11195615|NCT03415321|Experimental|Intervention group|Postpartum Mobile Support Application
11195616|NCT03415321|No Intervention|Control Group|Routine care
11195617|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
11195618|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
11195619|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
11195620|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
11195621|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
11195622|NCT03415282|Experimental|Open-label treatment arm|Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
11195623|NCT03415269|Experimental|20 mg ambroxol|20 mg ambroxol lozenge delivered once on one day
11195624|NCT03415256|Experimental|passive vibration group|The passive vibration group patients will receive passive vibration (50 Hz, one cycle= 60 seconds working time with 2 seconds rest time) on their calf in supine position for ten minutes. The total number of sessions will be nine. Passive vibration will be given to the treatment group twice a week for four weeks (eight sessions) and the ninth session will be the follow up. At every session, the skin blood flow will be measured before, immediately, and 15 minutes after passive vibration.
11195625|NCT03415256|Active Comparator|no passive vibration group|The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
11195626|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
11195627|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
11195628|NCT03415230|Experimental|Therapeutic massage|Women will undertake sessions of therapeutic massage
11195629|NCT03415230|Sham Comparator|Sham massage|Women will undertake sessions of sham massage
11195630|NCT03415217|Other|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
11195631|NCT03415204|Experimental|acupuncture|
11195632|NCT03415204|No Intervention|no acupuncture|
11195633|NCT03415191|Experimental|Ketamine Group|Five minutes before thoracotomy incision, Ketamine Group received a bolus dose of ketamine 1 mg/kg intravenously
11195634|NCT03415191|Placebo Comparator|Placebo Group|Five minutes before thoracotomy incision, Placebo Group received a bolus dose of normal saline 1 mg/kg intravenously
11195667|NCT03414957||Malay women without PCOS|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who did not fulfill these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria.
11195635|NCT03415178|Experimental|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
11195636|NCT03415178|Experimental|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
11195637|NCT03415165|Active Comparator|green tea buccal tablet|buccal tablet 3 times aday
11195638|NCT03415165|Sham Comparator|corticosteroids topical|topical steroids 3 times aday
11195639|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
11195640|NCT03415139||Arm 1 for MRD HCT Recipients|Patients undergo an Oral Glucose Tolerance Test (OGTT) and 1 hyperglycemic clamp will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
11195641|NCT03415139||Arm 2 for MRD HCT Recipients|Patients undergo 2 Oral Glucose Tolerance Test (OGTTs) (with and without GLP-1 infusion) will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
11195642|NCT03415126|Experimental|ASN007 ascending doses|Patients will receive escalating doses of ASN007 to identify the best dose.
11195643|NCT03415126|Experimental|ASN007 RD: KRAS mutant Melanoma|Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
11195644|NCT03415126|Experimental|ASN007 RD: NRAS mutant Melanoma|Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
11195645|NCT03415126|Experimental|ASN007 RD: KRAS mutant metastatic CRC|Patients with KRAS mutant CRC will receive the recommended dose from Part A
11195646|NCT03415126|Experimental|ASN007 RD: KRAS mutant NSCLC|Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
11195647|NCT03415126|Experimental|ASN007 RD: Metastatic Pancreatic Cancer|Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
11195648|NCT03415126|Experimental|ASN007 RD: MEK, All BRAF, BRAF-fusion cancers|Patients with solid tumors will receive the recommended dose from Part A
11195649|NCT03415100|Experimental|CAR-NK cells targeting NKG2D ligands|
11195650|NCT03415087|Active Comparator|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
11195651|NCT03415087|Experimental|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
11195652|NCT03415074|Active Comparator|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
11195653|NCT03415074|Active Comparator|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
11195654|NCT03415061|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7
11195655|NCT03415061|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7
11195656|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
11195657|NCT03415022|Experimental|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
11195658|NCT03415022|Experimental|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
11195659|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
11195660|NCT03414996|Experimental|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
11195661|NCT03414996|Active Comparator|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
11195662|NCT03414983|Experimental|Arm A|Nivo + SOC
11195663|NCT03414983|Active Comparator|Arm B|SOC
11195664|NCT03414970|Active Comparator|Group I (radiation therapy)|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
11195665|NCT03414970|Experimental|Group II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
11195666|NCT03414957||Malay PCOS women|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who fulfilled these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria
11195668|NCT03414944|Experimental|SMART-Brain|selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.
11195669|NCT03414931|Experimental|NMDAE|An NMDA enhancer
11195670|NCT03414931|Active Comparator|SSRI|Sertraline
11195672|NCT03414918|Experimental|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
11195673|NCT03414905|Experimental|Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1
~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
11195674|NCT03414892|Experimental|Globalagliatin Hydrochloride (SY-004)|If subjects tolerate 20mg of Globalagliatin Hydrochloride (SY-004) for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
11195675|NCT03414892|Placebo Comparator|Placebo|If subjects tolerate 20mg of Placebo for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
11195676|NCT03414879|Active Comparator|Ketamine group|Nebulization with ketamine
11195677|NCT03414879|Active Comparator|Lidocaine group|Nebulization with with lidocaine
11195678|NCT03414866||Acute thoracic aortic syndrome|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
11195679|NCT03414866||Subacute/chronic dissection of the aorta|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
11195680|NCT03414866||Aortic aneurysm|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
11195681|NCT03414853||With algorithm use|
11195682|NCT03414853||No algorithm use|
11195683|NCT03414814|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
11195684|NCT03414801|Active Comparator|Cohort 1|Cat Allergic Subjects
11195685|NCT03414801|Active Comparator|Cohort 2|Non-Allergic Subjects will
11195686|NCT03414788|Experimental|Treatment Arm - PF 06687234 and [124I]IB PF 06687234|PF 06687234 and [124I]IB PF 06687234
11195687|NCT03414775|Active Comparator|Pediasure|Patients assigned to this arm will receive Pediasure
11195688|NCT03414775|Active Comparator|Nourish|Patients assigned to this arm will receive Nourish
11195689|NCT03414762|Experimental|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
11195690|NCT03414762|Active Comparator|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
11195691|NCT03414749|Experimental|Lower Extremity First (LEF)|The treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
11195692|NCT03414749|Experimental|Upper Extremity First (UEF)|The treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
11195693|NCT03414736|Experimental|Cohort 1|Daily dose escalation (click-by-click): Starting at dose 1 in the morning with daily increments to dose 2. During the escalation phase, the dose will only be increased if the patient is feeling fine.
11195694|NCT03414736|Experimental|Cohort 2|Weekly dose escalation in 6 escalation steps (7 dose levels): Starting at dose 1 injected in the morning with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
11195695|NCT03414736|Experimental|Cohort 3|Weekly dose escalation in 4 escalation steps (5 dose levels): Starting at dose 3 with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
11195696|NCT03414723|Experimental|SAR439954 with or without ramipril|"On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing.
~On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing."
11195697|NCT03414710|Experimental|Intervention group|"Health education booklet plus video plus brief counseling
~In addition to the educational booklet received by the control group, the intervention group will receive the following health promotion:
~Watch a 10-minute video promoting VMMC
~Receive a brief counseling promoting VMMC If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
11195698|NCT03414710|Active Comparator|Control group|"Health education booklet only After randomization took place, the control group will receive an education booklet introducing voluntary medical male circumcision.
~If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
11195699|NCT03414697|Other|Control group|Routine rehabilitation treatments
11195700|NCT03414697|Experimental|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
11195701|NCT03414697|Experimental|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
11195702|NCT03414697|Experimental|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
11195703|NCT03414684|Experimental|Carboplatin + Nivolumab|"Nivolumab is administered every three weeks intravenously
~Nivolumab dosage is 360mg
~Carboplatin is administered every three weeks intravenously
~Carboplatin dosage is pre-determined by the PI"
11195704|NCT03414684|Experimental|Carboplatin|"Carboplatin is administered every three weeks intravenously
~Carboplatin dosage is pre-determined by the PI"
11195705|NCT03414671||historical control|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
11195706|NCT03414671||Standardized|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
11195707|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle
~Vinorelbine is administered intravenously 3 times per cycle"
11195708|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle
~Vinorelbine is administered intravenously 3 times per cycle
~Avelumab is administered intravenously twice per cycle
~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
11195709|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle
~Vinorelbine is administered intravenously 3 times per cycle
~Avelumab is administered intravenously twice per cycle
~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab
~Utomilumab is administered intravenously once per cycle"
11195710|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm
~Avelumab is administered intravenously twice per cycle
~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab
~Utomilumab is administered intravenously once per cycle
~Trastuzumab is administered intravenously twice per cycle"
11195711|NCT03414645|Experimental|CAM-101 10%|FD hPL 10 vol/vol %
11195712|NCT03414645|Experimental|CAM-101 30%|FD hPL 30 vol/vol %
11195713|NCT03414645|Placebo Comparator|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
11195714|NCT03414632|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
11195715|NCT03414619|Experimental|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
11195716|NCT03414619|Experimental|Non-psychiatric Control Group|A score 1 SD below the community mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
11195717|NCT03414593|Experimental|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
11195718|NCT03414593|Active Comparator|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
11195719|NCT03414580||Ulcerative colitis|Patients with ulcerative colitis whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
11195720|NCT03414580||Crohn's disease|Patients with crohn's disease whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
11195721|NCT03414580||Healthy control|Subject with no intestinal symptoms or no known gastrointestinal disorders. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
11195722|NCT03414567||Control Group|Non-smoker
11195723|NCT03414567||Study Group|Smoker
11195724|NCT03414554||HCV patients receiving DAAs|Patients with HCV-related liver cirrhosis (eligible for treatment) who will recieve DAAs therapy with one year follow up.markers: miR121, miR122, miR124will be assessed in both groups before and after DAAs
11195725|NCT03414541|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
11195726|NCT03414541|Experimental|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
11195727|NCT03414541|Experimental|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
11195728|NCT03414528||Patients with PID|
11195729|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
11195730|NCT03414502|Other|Single arm Methotrexate|"This study is a 16-week, open-label study designed to identify the subset of RA patients that respond to methotrexate monotherapy. All patients will receive methotrexate at a starting dose of 15 mg once weekly plus folic acid 1 mg daily. If a patient is not in remission by 8 weeks, then the dose will be escalated as tolerated to 20 mg once weekly. Both oral and injectable methotrexate are acceptable.
~If the patient is unable to tolerate the Methotrexate at 15 mg, it is allowed to titrate the dose as tolerated as long as patient remains on Methotrexate."
11195731|NCT03414476|Experimental|ET group|Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium
11195732|NCT03414476|Experimental|Control group|Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium
11195733|NCT03414463|Experimental|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
11195734|NCT03414463|Experimental|Waitlist Control|After Time 1 testing in Week 1, participants randomized to WLC will not receive any treatment during Weeks 2-5. The only staff interaction during this no treatment time period will be to schedule Time 2 testing appointment for week 6. After Time 2 testing, WLC will receive TREAT (weeks 14-17), followed up with testing.
11195735|NCT03414450|Experimental|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
11195736|NCT03414450|Experimental|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
11195737|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
11195738|NCT03414398||Experimental|Qualitative interview
11195739|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
11195740|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
11195741|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
11195742|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
11195743|NCT03414359|Active Comparator|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
11195744|NCT03414359|Experimental|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
11195745|NCT03414346|Experimental|Exclusively ice pack:|Ice pack application: 500 grams of crushed ice.
11195746|NCT03414346|Experimental|Ice pack added 10% of water:|Wetted ice pack application: 500 grams of crushed ice added to 50 mL of water at room temperature.
11195747|NCT03414346|Experimental|Ice pack added 100% of water:|Wetted ice pack application: 500 grams of crushed ice added to 500 mL of water at room temperature.
11195748|NCT03414333|Experimental|Roux-en- Y gastric bypass (RYGB)|Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
11195749|NCT03414333|Active Comparator|GLP-1|GLP-1 is an intestinal hormone secreted in response to nutrients.
11195750|NCT03414320|Experimental|Study Arm|We will gather data from this group of patients.
11195751|NCT03414307|Experimental|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
11195752|NCT03414294|Experimental|K-755 Part A (SAD)|
11195753|NCT03414294|Placebo Comparator|Placebo Part A (SAD)|
11195754|NCT03414294|Experimental|K-755 Part B (MAD)|
11195755|NCT03414294|Placebo Comparator|Placebo Part B (MAD)|
11195756|NCT03414294|Experimental|K-755 Part C (FE)|
11195757|NCT03414294|Experimental|K-755 Part D (FE)|
11195758|NCT03414294|Experimental|K-755 Part E (MAD)|
11195759|NCT03414294|Placebo Comparator|Placebo Part E (MAD)|
11195760|NCT03414281|Experimental|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
11195761|NCT03414281|Experimental|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
11195762|NCT03414281|Active Comparator|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
11195763|NCT03414268|Experimental|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
11195764|NCT03414268|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
11195765|NCT03414255|Experimental|Micronized DHACM|1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
11195766|NCT03414255|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
11195767|NCT03414242|Experimental|Cervical spine musculature|
11195768|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
11195769|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
11195770|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
11195771|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
11195772|NCT03414216|Experimental|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:
~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.
~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
11195773|NCT03414216|Active Comparator|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.
~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
11195774|NCT03414203|Active Comparator|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
11195775|NCT03414203|Experimental|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
11195776|NCT03414203|Sham Comparator|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
11195777|NCT03414190|Experimental|Experimental|Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
11195778|NCT03414190|No Intervention|No Intervention|Usual Care
11195827|NCT03413930|Active Comparator|LaTME|Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
11195828|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
11231706|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
11195779|NCT03414177|Active Comparator|Telemedicine Group|Telemedicine participants will have asthma subspecialty follow-up visits conducted via real-time audio and video conferencing in conjunction with electronic examination peripherals and remote pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
11195780|NCT03414177|Active Comparator|In-Person Group|In-Person participants will have asthma subspecialty follow-up visits at a subspecialty clinic. They will receive pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
11195781|NCT03414164|Experimental|procyanidine group|
11195782|NCT03414164|No Intervention|control group|
11195783|NCT03414151||Observational - Case Arm|All participants will be placed in this arm or group if they have an eligible psychiatric diagnosis as a case (there is no randomization procedure)
11195784|NCT03414151||Observational - Healthy Control Arm|All participants will be placed in this arm if they are healthy controls (there is no randomization procedure)
11195785|NCT03414138|Experimental|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
11195786|NCT03414138|Active Comparator|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
11195787|NCT03414125|Active Comparator|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).
~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.
~Centralized processes to promote guideline-based follow-up."
11195788|NCT03414125|Experimental|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.
~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.
~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).
~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.
~Centralized processes to promote guideline-based follow-up."
11195789|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
11195790|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
11195791|NCT03414099|Experimental|Ketum|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
11195792|NCT03414099|Placebo Comparator|Placebo|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
11195793|NCT03414086||Myositis in Remission|Subjects who are in remission with their myositis diagnosis.
11195794|NCT03414086||Healthy Controls|Subjects who do not have a myositis diagnosis.
11195795|NCT03414073|Sham Comparator|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
11195796|NCT03414073|Active Comparator|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
11195797|NCT03414073|Sham Comparator|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
11195798|NCT03414073|Active Comparator|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
11195799|NCT03414073|Sham Comparator|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
11195800|NCT03414073|Sham Comparator|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
11195801|NCT03414073|Sham Comparator|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
11195802|NCT03414073|Sham Comparator|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
11195803|NCT03414073|Active Comparator|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
11195804|NCT03414060|Experimental|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
11195805|NCT03414047|Experimental|Prexasertib Cohort 1|Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
11195806|NCT03414047|Experimental|Prexasertib Cohort 2|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received <3 lines of prior therapy.
11195807|NCT03414047|Experimental|Prexasertib Cohort 3|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
11195808|NCT03414047|Experimental|Prexasertib Cohort 4|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
11195809|NCT03414034|Experimental|Arm A: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.
11195810|NCT03414034|Experimental|Arm B: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
11195811|NCT03414034|Experimental|Arm C: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
11195812|NCT03414021||Thyroid Diseases|SPECT-CT Scan
11195813|NCT03414021||Heart Diseases|SPECT-CT Scan
11195814|NCT03414021||Bone Diseases|SPECT-CT Scan
11195815|NCT03414021||Brain Diseases|SPECT-CT Scan
11195816|NCT03414021||Kidney Diseases|SPECT-CT Scan
11195817|NCT03414008|Experimental|Active Drug Group|Single dose
11195818|NCT03414008|Placebo Comparator|Placebo Group|
11195819|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
11195820|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
11195821|NCT03413969|Experimental|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
11195822|NCT03413956||NSCLC patients with lymph metastases|Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
11195823|NCT03413943|Experimental|explicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
11195824|NCT03413943|Experimental|implicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
11195825|NCT03413943|Sham Comparator|sham gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
11195826|NCT03413930|Experimental|TaTME|Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
11195829|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
11195830|NCT03413904|Experimental|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
11195831|NCT03413904|Active Comparator|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
11195832|NCT03413891|Placebo Comparator|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
11195833|NCT03413891|Experimental|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
11195834|NCT03413878|Experimental|Wet snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a small air pocket
11195835|NCT03413878|Experimental|Dry snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a small air pocket
11195836|NCT03413878|Experimental|Wet snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a large air pocket
11195837|NCT03413878|Experimental|Dry snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a large air pocket
11195838|NCT03413865|Experimental|OTN virtual clinic|Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
11195839|NCT03413865|No Intervention|In person Visits|Patients are followed in person at the cancer clinic based on standard of care guidelines
11195840|NCT03413839|Experimental|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
11195841|NCT03413839|Other|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
11195842|NCT03413826|Experimental|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
11195843|NCT03413826|Experimental|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
11195844|NCT03413826|No Intervention|control|This group will remain sedentary for 12 weeks
11195845|NCT03413800|Experimental|Lenalidomide-Dexamethasone-DLI|"Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each
~For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg
~In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg
~If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg
~Patient will be followed for 5 years post relapse."
11195846|NCT03413774||Abortion group|910 women attended Fayoum University hospital outpatient gynecology clinic with recent first trimesteric spontaneous miscarriage
11195847|NCT03413774||Control group|940 women attended Fayoum University hospitalpresented for any other gynecological complaint
11195848|NCT03413748|Active Comparator|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
11195849|NCT03413748|Active Comparator|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
11195850|NCT03413735|Placebo Comparator|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
11195851|NCT03413735|Experimental|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
11195852|NCT03413722||Conversion Group|Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
11195853|NCT03413722||Control Group|Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
11195854|NCT03413709|Active Comparator|Treatment Group (n=350)|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour Family Formation Program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships,and economic stability and mobility. In addition, participants will receive case management and a variety of employment, legal and support services for up to one year following the completion of the curriculum.
11195895|NCT03413423|Experimental|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
11195855|NCT03413709|No Intervention|Comparison Group (n=350)|The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
11195856|NCT03413696||Not referred for HCV therapy|
11195857|NCT03413696||Referred for HCV therapy,did not show up|
11195858|NCT03413696||Referred,attended HCV therapy evaluation|
11195859|NCT03413657|Other|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
11195860|NCT03413657|Other|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
11195861|NCT03413631|Experimental|Prenatal mentalization intervention|The intervention group participants were offered three mentalization-focused 4D interactive ultrasounds at 24, 30 and 34 gestational weeks and a mentalization-focused week-by-week pregnancy diary combined with three prenatal sessions and option for one session after delivery in addition to obstetric care as usual (see Prenatal obstetric treatment as usual).
11195862|NCT03413631|Active Comparator|Prenatal obstetric treatment as usual|The control group received obstetric care as usual in a tertiary setting. The comprehensive treatment as usual was conducted at the hospital antenatal outpatient clinic, including regular obstetric ultrasounds. The multidisciplinary treatment team, consisting of an obstetrician, a midwife, a social worker and a psychiatric nurse, assess and support health and psychosocial situation of the pregnant woman. The pregnant woman was referred to addiction and psychiatric treatment when needed.
11195863|NCT03413618|Experimental|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
11195864|NCT03413618|Active Comparator|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
11195865|NCT03413605|Experimental|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
11195866|NCT03413605|No Intervention|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
11195867|NCT03413592|Other|Driving test|
11195868|NCT03413579|Experimental|Nimotuzumab|Injection of 200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8
11195869|NCT03413579|Placebo Comparator|Placebo|Injection of the Placebo in the same procedures (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8
11195870|NCT03413566||Children with clinical diagnosis of CP|All children residing in Norway with a validated diagnosis of cerebral palsy.
11195871|NCT03413566||Children without CP|All children residing in Norway without a diagnosis of cerebral palsy.
11195872|NCT03413553|Active Comparator|control group|patient will receive immediate implant alone.
11195873|NCT03413553|Other|intervention group|"immediate implant combined with connective tissue graft and platelet rich fibrin .
~."
11195874|NCT03413540|Experimental|Group 1|10-cm step, 10 reps
11195875|NCT03413540|Experimental|Group 2|10-cm step, 50 reps
11195876|NCT03413540|Experimental|Group 3|10-cm step, 100 reps
11195877|NCT03413540|Experimental|Group 4|20-cm step, 10 reps
11195878|NCT03413540|Experimental|Group 5|20-cm step, 50 reps
11195879|NCT03413540|Experimental|Group 6|20-cm step, 100 reps
11195880|NCT03413540|Experimental|Group 7|30-cm step, 10 reps
11195881|NCT03413540|Experimental|Group 8|30-cm step, 50 reps
11195882|NCT03413540|Experimental|Group 9|30-cm step, 100 reps
11195883|NCT03413540|No Intervention|Group 10|Control
11195884|NCT03413527|Experimental|rTMS Treatment|
11195885|NCT03413514|Experimental|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
11195886|NCT03413501|No Intervention|Treatment as usual|Receives treatment as usual at the clinic
11195887|NCT03413501|Experimental|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
11195888|NCT03413488|Experimental|Kinesio taping|subject with shoulder impingement syndrome
11195889|NCT03413488|Active Comparator|Exercise|subject with shoulder impingement syndrome
11195890|NCT03413462|Active Comparator|HS-25|20mg, QD, 12 weeks
11195891|NCT03413462|Placebo Comparator|Placebo of HS-25|20mg, QD, 12 weeks
11195892|NCT03413449||Resections|Frailty model for patients undergoing esophagectomy and pneumonectomy/lobectomy for cancer
11195893|NCT03413436|Experimental|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
11195894|NCT03413436|Active Comparator|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
11199320|NCT03388892|Experimental|Drug-Eluting Balloon|PTA with DEB at venous anastomotic stenosis of AVG
11195896|NCT03413423|Active Comparator|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
11195897|NCT03413410|Experimental|Metoprolol interventional group|"This is a multi-center, prospective, open label, single-arm interventional study.
~Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study."
11195898|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone
~Dosage form: crystalline powder for intramuscular injection
~Dose(s): 1 g
~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
11195899|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
11195900|NCT03413371|Experimental|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
11195901|NCT03413371|Experimental|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
11195902|NCT03413371|Experimental|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
11195903|NCT03413371|Experimental|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
11195904|NCT03413371|Experimental|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
11195905|NCT03413358|Experimental|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
11195906|NCT03413358|Experimental|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
11195907|NCT03413345||subjects without a history of cardiac disease|
11195908|NCT03413345||subjects with a history of cardiac disease|
11195909|NCT03413332|Experimental|E-Talkcare Group|use the web-based patient education tool
11195910|NCT03413332|Placebo Comparator|Usual Care Group|receive usual care
11195911|NCT03413319|Experimental|ABBV-8E12|ABBV-8E12 administered by intravenous (IV) infusion.
11195912|NCT03413306|Experimental|Eltrombopag + IST (ATG + CsA)|
11195913|NCT03413306|Active Comparator|IST (ATG + CsA)|
11195914|NCT03413293||Nosocomial infected cirrhotic patients|
11195915|NCT03413280|Experimental|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml Before surgical incision
11195916|NCT03413280|Active Comparator|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml After surgical incision
11195917|NCT03413267|Experimental|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
11195918|NCT03413267|Experimental|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
11195919|NCT03413267|Experimental|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
11195920|NCT03413267|Experimental|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
11195921|NCT03413254|Active Comparator|2nd look DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up according to the Dutch colorectal cancer guideline until 5 years.
11195922|NCT03413254|Experimental|2nd and 3rd DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up and third look DLS after negative CT abdomen at 18 months and normal CEA. Third look DLS is not performed in patients with evidence of disease that is not curable, or in those already diagnosed with PM in the preceding period.
11195923|NCT03413228||Influenza-like illness group|
11195924|NCT03413215|No Intervention|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
11195925|NCT03413215|Experimental|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
11195926|NCT03413202|Experimental|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
11195927|NCT03413202|Placebo Comparator|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
11195928|NCT03413189||PREDICT participants|This cohort is obtained from the PREDICT study enrolment (approx. 500) and a review of their medical records will be conducted
11195929|NCT03413189||PREDITCABLE participants|This is a nested cohort of patients recruited into PREDICT (approx. 40) that consent for a physiotherapist home visit to assess their physical and cognitive function and perform and interview to obtain themes regarding recovery
11195930|NCT03413163|Sham Comparator|control|"Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
~Intervention: Other: Standard Pain Followup and Monitorization"
11195931|NCT03413163|Experimental|ESP block|"In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
~Interventions:
~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
11195932|NCT03413150||severely ill patients receiving amiodarone for ATs|cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital.Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent atrial tachycardia during their hospitalization in the ICU.
11195933|NCT03413137|Active Comparator|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
11195934|NCT03413137|Active Comparator|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
11195935|NCT03413124|Active Comparator|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
11195936|NCT03413124|Active Comparator|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
11195937|NCT03413111|Experimental|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
11195938|NCT03413111|No Intervention|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
11195939|NCT03413098|Experimental|Trial nasal Continuous Positive Airway Pressure (CPAP) mask|Trial nasal CPAP mask
11195940|NCT03413085|Other|Group A|"Intervention name: multifocal soft contact lens/single vision soft contact lens
~Left eye: multifocal soft contact lens Right eye: single vision soft contact lens"
11195941|NCT03413085|Other|Group B|"Intervention name: multifocal soft contact lens/single vision soft contact lens
~Left eye: single vision soft contact lens Right eye: multifocal soft contact lens"
11195942|NCT03413059|Active Comparator|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
11195943|NCT03413059|Active Comparator|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
11195944|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
11195945|NCT03413046||Control|30 healthy children
11195946|NCT03413033||Group 1|43 participants will produce the vowel /a:/ three times as baseline during 5 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce series of a semi-occluded vocal tract exercises (resonance tube or lip trill). Afterwards, subjects will produce the vowel /a:/ three times once again. Electroglottographic signals will be captured before and after each exercise. A 15 minutes voice rest will be taken between exercises by all subjects.
11195947|NCT03413020|Experimental|Tailored Therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
11195948|NCT03412994|Experimental|Apatinib group|"Apatinib combined with second-line chemotherapy (5-Fu combined with irinotecan or oxaliplatin standard regimen ) Apatinib tablets: 500 mg po qd . Continuous medication, the cycle is consistent with the chemotherapy cycle.
~Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）"
11195949|NCT03412994|Placebo Comparator|Control group|Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）
11195950|NCT03412968|Experimental|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
11195951|NCT03412968|Active Comparator|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
11195952|NCT03412955|Experimental|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
11195953|NCT03412942|Other|Treatment with FISH device|Vascular closure to be performed with FISH device.
11195954|NCT03412929|Experimental|Honey Impregnated Dressing|Honey Impregnated Dressing
11195955|NCT03412916|Experimental|GetActive|The GetActive program uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The GetActive sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is a 10-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions.
11195956|NCT03412916|Experimental|GetActive with Fitbit|The GetActive with Fitbit is identical to that of the p3RP with the addition of a digital monitoring device (i.e., Fitbit) for recording of physical activity.
11195957|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
11195958|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
11195959|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
11195960|NCT03412890|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 28 weeks.
11195961|NCT03412877|Experimental|1/iTCR|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high or low-dose aldesleukin
11195962|NCT03412877|Experimental|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
11195963|NCT03412851||A Direct Aspiration First Pass Technique|
11195964|NCT03412851||Stentriever Thrombectomy|
11195965|NCT03412838|Active Comparator|Cortico-Cancellous|Graft surgery with cortico-cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
11195966|NCT03412838|Active Comparator|Cancellous|Graft surgery with cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
11195967|NCT03412825|Experimental|Nutrition Supplementation|
11195968|NCT03412825|No Intervention|Control|
11195969|NCT03412812|Experimental|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
11195970|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
11195971|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
11195972|NCT03412773|Experimental|Arm A: Tislelizumab & Safety Run-In Substudy [Japan Only]|
11195973|NCT03412773|Active Comparator|Arm B: Sorafenib|
11195974|NCT03412760|Experimental|Trio exome sequencing|There is only one arm of this study. All enrolled participants will be offered trio exome sequencing (or duo where necessary). Please refer to the Study Design section for further details.
11195975|NCT03412747|Experimental|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
11195976|NCT03412747|Experimental|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
11195977|NCT03412747|Active Comparator|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
11195978|NCT03412734|Experimental|Chlorhexidine group|
11195979|NCT03412734|Active Comparator|Iodine group|
11195980|NCT03412721|Experimental|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
11195981|NCT03412721|Placebo Comparator|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
11195982|NCT03412708|Active Comparator|Vestibular Rehabilitation|"Vestibular Rehabilitation Program Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking
~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
11195983|NCT03412708|Experimental|Vestibular Rehabilitation supported with Virtual Reality|"Patients will perform the exercises in a virtual reality environment using a virtual reality goggle and a smartphone.The virtual environments consist of 2 media provided by the videos taken with a 360 camera . 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full. Exercises conducted while sitting and standing on a soft ground will happen in the 1st environment, and the ones on the treadmill will happen in the 2nd environment.
~Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking
~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
11195984|NCT03412695|Experimental|Arm A|Use of the MyFood tool among patients and nurses (intervention group)
11195985|NCT03412695|No Intervention|Arm B|No intervention. Regular hospital routines
11195986|NCT03412682|Experimental|Budesonide (6 mg)|
11195987|NCT03412682|Experimental|Budesonide (9 mg)|
11195988|NCT03412682|Active Comparator|Mesalazine (3,600 mg)|
11195989|NCT03412669|Experimental|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
11195990|NCT03412669|Active Comparator|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
11195991|NCT03412656|Experimental|Patient|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing the subjects' own prosthetic sockets. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
11195992|NCT03412656|Other|Control|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing an adapter simulating a prosthetic socket. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
11195993|NCT03412643|Experimental|Arm 1|"Celcuity CELx HSF Test on tumor material obtained from research core biopsy to select patients with abnormal HER2 signaling tumors
~Doxorubicin + cyclophosphamide followed by Weekly Paclitaxel +Trastuzumab+Pertuzumab"
11195994|NCT03412630|Experimental|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
11195995|NCT03412604|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
11195996|NCT03412591|Other|Open label trial of suvorexant in SUDs|It is an open label trial to study the efficacy of suvorexant in a group of opioid use and alcohol use disorder subjects.
11195997|NCT03412578|No Intervention|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
11195998|NCT03412578|Active Comparator|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
11195999|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
11196000|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
11196001|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
11196002|NCT03412565|Experimental|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
11196003|NCT03412552||severe preeclampsia without HELLP syndrome|severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure >160 mm/ Hg or diastolic blood pressure >110 mm/Hg, headache, epigastric or right-upper-quadrant pain, visual disturbances,pulmonary edema, and proteinuria (urinary protein level >5 g/24 h).Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/ mm3, serum lactate dehydrogenase <600 IU /dL, serum total bilirubin <1.2 mg/dL and serum aspartate aminotransferase <70IU/L
11196004|NCT03412552||eclampsia without HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded
11196058|NCT03412058|Experimental|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
11231707|NCT03165929|Placebo Comparator|placebo-free gingival graft|
11196005|NCT03412552||eclampsia with HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded.HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
11196006|NCT03412552||HELLP syndrome without eclampsia|HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
11196007|NCT03412526|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day
~Preparation and administration of unselected or 4-1BB enriched TIL
~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
11196008|NCT03412513|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
11196009|NCT03412513|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
11196010|NCT03412500|Active Comparator|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
11196011|NCT03412500|Experimental|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
11196012|NCT03412487|Active Comparator|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level >20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
11196013|NCT03412487|Active Comparator|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
11196014|NCT03412474|Active Comparator|Bupivacaine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
11196015|NCT03412474|Active Comparator|Dexmedetomidine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
11196016|NCT03412461|Experimental|Thought Spot Application|Participants randomly assigned to the experimental arm will have access to the Thought Spot application. The Thought Spot application is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area. This group will continue to have access to usual care.
11196017|NCT03412461|Active Comparator|Resource pamphlet|Participants randomly assigned to the active comparator will receive a pamphlet that outlines mental health services and wellness services across the Greater Toronto Area. This group will continue to have access to usual care.
11196018|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
11196019|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
11196020|NCT03412409|Experimental|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.
~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
11196021|NCT03412396|Experimental|Treatment (apalutamide, radical prostatectomy)|Patients receive apalutamide PO daily for 24 weeks in the absence of disease progression or unacceptable toxicity. Within 2 weeks of completing apalutamide, patients undergo radical prostatectomy.
11196022|NCT03412370||Observational (questionnaires, cognitive assessment)|Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.
11196023|NCT03412357|Experimental|pleurectomy/decortication|
11196024|NCT03412357|Experimental|indwelling pleural catheter|
11196025|NCT03412331|Active Comparator|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
11196026|NCT03412331|Experimental|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
11196027|NCT03412318|Experimental|Twisted file|Use of twisted file during cleaning and shaping of root canals
11196028|NCT03412318|Active Comparator|Mpro|Use of Mpro file during cleaning and shaping of root canals
11196029|NCT03412305|Active Comparator|Amoxicillin oral tablets|2 g amoxicillin tablets orally 1 hour before implant placement
11196030|NCT03412305|Placebo Comparator|Placebo|Placebo tablets orally 1 hour before implant placement
11196031|NCT03412292|Experimental|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).
~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
11196059|NCT03412058|Experimental|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
11196032|NCT03412266|Other|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.
~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
11196033|NCT03412240|Experimental|Anti tachycardia pacing|
11196034|NCT03412227|Other|Principal Anxiety Disorder|Youth with a principal anxiety disorder
11196035|NCT03412227|Other|Principal Depressive Disorder|Youth with a principal unipolar depressive disorder
11196036|NCT03412201|Active Comparator|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
11196037|NCT03412201|Experimental|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
11196038|NCT03412188|Experimental|group 1 Eltrombopag arm|"Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count with an increment of 25mg once per day at 2 weeks intervals (Maximum dose: 75 mg orally once a day).
~Patients, who responded poorly to eltrombopag in 6 months or developed adverse effects, were asked to discontinue the medication. Those who responded were followed for further 6 month period."
11196039|NCT03412188|Active Comparator|group 2 conventional Treatment|"Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab).
~patients will continue on the conventional line of treatment"
11196040|NCT03412175|Experimental|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
11196041|NCT03412175|No Intervention|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
11196042|NCT03412162|Experimental|Ethnic and Racial Identity Promotion|Students will participate in 8, 1 hour and 15 minute classroom based intervention sessions at their local high school, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to promote a positive ethnic and racial identity (positive feelings about ones' ethnic and racial heritage and ethnic and racial group membership).
11196043|NCT03412162|Active Comparator|Academic Skills Promotion|Students in this active comparison group will participate in an 8-week, 1 hour and 15 minute classroom based intervention, during which a facilitator will lead them through a series of lectures, group activities, and individual homework activities designed to provide information regarding college and career planning, and promote college and career planning as well as study skills and strategies. This condition receives the same amount of facilitator time and attention as the Experimental condition.
11196044|NCT03412149|Active Comparator|Mini Gastric Bypass|Mini Gastric Bypass: The gastric pouch will be performed starting below the incisura angularis (transverse resection 4 cm) on the lesser curvature (18).Then the stomach will be transected against a 36 Fr bougie up to the gastro-esophageal junction Then 1/3 of the small bowel will be excluded (approximately 200cms) and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler.
11196045|NCT03412149|Active Comparator|Roux en Y Gastric Bypass|Roux en Y Gastric Bypass: The steps of the standard double loop RYGB technique will be followed (17). The gastric pouch will be created 7 cm from the gastro-esophageal junction to obtain a volume of 30-40 ml, and the length of the alimentary limb will be 150 cm and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler. The length of the biliopancreatic limb will be from 65 to 75 cm beyond the ligament of Treitz. The lengths of both limbs should carefully measured with a graduated instrument. The mesenteric defects will be closed.
11196046|NCT03412136|Experimental|Control|
11196047|NCT03412136|Experimental|Glucose|
11196048|NCT03412136|Experimental|Protein|
11196049|NCT03412123|Experimental|gLiFE pilot group|
11196050|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
11196051|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
11196052|NCT03412071|No Intervention|Control group|25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.
11196053|NCT03412071|Active Comparator|Oral tinidazole group|25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.
11196054|NCT03412071|Active Comparator|Topical metronidazole (0.75%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.
11196055|NCT03412071|Active Comparator|Topical clindamycin (2%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.
11196056|NCT03412071|Active Comparator|Topical hydrogen peroxide (1%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.
11196057|NCT03412058|Experimental|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
11196159|NCT03411239|Other|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
11196060|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
11196061|NCT03412032|Other|ERC|Assessment as used by the European Resuscitation Council
11196062|NCT03412032|Other|AHA|Assessment as used by the American Heart Association
11196063|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
11196064|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
11196065|NCT03412006|Experimental|Fulacimstat (BAY1142524)|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
11196066|NCT03412006|Placebo Comparator|Placebo|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
11196067|NCT03411980|Experimental|Subjects with moderately decreased renal function|Subjects with moderate renal impairment with an estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m*2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
11196068|NCT03411980|Experimental|Subjects with severely decreased renal function|Subjects with severe renal impairment not on dialysis with an eGFR <30 mL/min/1.73 m*2 (CKD-EPI formula).
11196069|NCT03411980|Experimental|Control subjects with normal renal function|Subjects with an eGFR ≥90 mL/min/1.73 m*2 (CKD-EPI formula) who are matched based on sex, age, race and weight.
11196070|NCT03411967|Experimental|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
11196071|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
11196072|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
11196073|NCT03411928|Experimental|Tracheolator|Tracheal dilatation using the study device as per the protocol.
11196074|NCT03411915|Experimental|XmAb18087|XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles
11196075|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
11196076|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
11196077|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
11196078|NCT03411876|Experimental|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
11196079|NCT03411876|Experimental|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
11196080|NCT03411863|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
11196081|NCT03411850|Active Comparator|Orencia (Abatacept)|Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
11196082|NCT03411850|Placebo Comparator|Placebo|Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
11196083|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
11196084|NCT03411811|Active Comparator|Usual Care|
11196085|NCT03411811|Experimental|Dextrose|
11196086|NCT03411798|Experimental|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
11196087|NCT03411785|Experimental|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
11196088|NCT03411785|No Intervention|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
11196089|NCT03411772|Active Comparator|TAP block|Patients undergoing bariatric surgery having TAP block upon completion of the procedure
11196090|NCT03411772|Sham Comparator|Non TAP block|Patients undergoing bariatric surgery without having TAP block
11196091|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
11196092|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
11196093|NCT03411720|Experimental|FES-row-training|Subjects will perform 4 months of FES-row-raining
11196094|NCT03411720|Other|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
11196095|NCT03411720|Active Comparator|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
11196096|NCT03411707||Mutiple screening test group|
11196097|NCT03411681|Active Comparator|Normal Weight|
11196098|NCT03411681|Experimental|Obese|
11196099|NCT03411668|Experimental|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
11196100|NCT03411668|No Intervention|Usual Educational Programme|Without intervention. The participants in this group will be maintain usual educational programme.
11196101|NCT03411655|Active Comparator|Ambu® Aura-ITM|
11196102|NCT03411655|Active Comparator|Ambu Aura GainTM|
11196103|NCT03411603||INCA2 2006-07|"French National Dietary Intake Survey, conducted in 2006-2007 by the French Agency for Food, Environmental and Occupational Health Safety.
~Adults aged 18y and over, n=1918 included in the analyses."
11196104|NCT03411603||NHANES 2011-12|Wave 2011-12 of the National Health and Nutrition Examination Survey, the US national dietary intake Survey, conducted by the Centers for Disease Control and Prevention (CDC) Adults aged 18y and over, n=5073 included in the analyses.
11196105|NCT03411590|Other|200ml|Toddlers will be allocated to the 200 ml group
11196106|NCT03411590|Other|400ml|Toddlers will be allocated to the 400 ml group
11196107|NCT03411590|Other|600ml|Toddlers will be allocated to the 600 ml
11196108|NCT03411577|Experimental|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
11196109|NCT03411577|No Intervention|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
11196110|NCT03411564|Experimental|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
11196111|NCT03411564|No Intervention|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
11196112|NCT03411551|Active Comparator|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
11196113|NCT03411551|Experimental|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
11196114|NCT03411538||Hospital-acquired bacterial infection|
11196115|NCT03411525|Experimental|Commitment invitation at time 1|In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
11196116|NCT03411525|Experimental|Commitment invitation at time 2|In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
11196117|NCT03411525|Experimental|Commitment invitation at time 3|In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
11196118|NCT03411525|Experimental|Commitment invitation at time 4|In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
11196119|NCT03411525|Experimental|Commitment invitation at time 5|In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
11196120|NCT03411525|Experimental|Commitment invitation at time 6|In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
11196121|NCT03411525|Experimental|Commitment invitation at time 7|In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
11196122|NCT03411525|Experimental|Commitment invitation at time 8|In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
11196123|NCT03411512||CHD|Newborns with structural congenital heart defects. The exclusion criteria were pulmonary or neurological disease, perinatal asphyxia, acute illness, prematurity and congenital abnormality other than CHD.
11196124|NCT03411512||Healthy controls|The control group comprised of healthy matched newborns without a diagnosed CHD.
11196125|NCT03411499|Experimental|Early surgery|Surgery within 72 hours from endocarditis diagnosis
11196126|NCT03411499|Active Comparator|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
11196127|NCT03411473|Experimental|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
11196128|NCT03411460|Experimental|Interstitial glucose|Glucose level tested by continuous monitoring device
11196129|NCT03411460|Active Comparator|Blood glucose|Glucose level tested on glucose monitor using standard finger prick
11196130|NCT03411447|Active Comparator|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
11196131|NCT03411447|Active Comparator|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
11196132|NCT03411434|Experimental|ADHD patients|90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
11196158|NCT03411252|Placebo Comparator|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
11196216|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
11196133|NCT03411421|Experimental|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
11196134|NCT03411421|Experimental|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
11196135|NCT03411408|Experimental|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
11196136|NCT03411395|Placebo Comparator|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
11196137|NCT03411395|Experimental|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
11196138|NCT03411395|Experimental|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
11196139|NCT03411395|Experimental|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
11196140|NCT03411382|Experimental|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
11196141|NCT03411382|Experimental|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
11196142|NCT03411382|Experimental|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
11196143|NCT03411382|Placebo Comparator|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
11196144|NCT03411369|Experimental|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
11196145|NCT03411369|Placebo Comparator|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
11196146|NCT03411356|Active Comparator|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
11196147|NCT03411356|Experimental|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
11196148|NCT03411343|Active Comparator|Interscalene Block|Patients randomized to receive an intesrcalene block.
11196149|NCT03411343|Experimental|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
11196150|NCT03411330|Active Comparator|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.
~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
11196151|NCT03411330|Active Comparator|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.
~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
11196152|NCT03411291||Diet: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.
11196153|NCT03411291||Statin: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.
11196154|NCT03411278|Experimental|Deep Oscillation (DO) self treatment|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2). The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
11196155|NCT03411278|No Intervention|No intervention, control|No intervention
11196156|NCT03411265|Experimental|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
11196157|NCT03411252|Experimental|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
11196217|NCT03410771||ICU patients on piperacillin/tazobactam|
11196160|NCT03411226||re-TREPP|Patients who presented with a recurrent inguinal hernia after previous TREPP repair.
11196161|NCT03411213|Experimental|Vascular function|Diffuse optical tomography detection of differences in vascular function between healthy volunteers and patients with proven heart disease or diabetes.
11196162|NCT03411213|Experimental|Coronary artery disease|Diffuse optical tomography prediction of presence or severity of coronary artery disease on angiography.
11196163|NCT03411200|Experimental|Intervention group (n=50)|Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.
11196164|NCT03411200|No Intervention|Control group (n=50)|Participants in the control group will receive usual care.
11196165|NCT03411187|Active Comparator|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
11196166|NCT03411187|Placebo Comparator|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
11196167|NCT03411174|Experimental|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
11196168|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously every two weeks at different doses on D1 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
11196169|NCT03411161|Active Comparator|paclitaxel phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.
~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m² during a 28-day cycle."
11196170|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.
~S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
11196171|NCT03411148|Experimental|Exercise Group A|Weekly exercise sessions with physical therapist and psychologist
11196172|NCT03411148|Placebo Comparator|Exercise Group B|Home-based exercises
11196173|NCT03411122|Experimental|Single-sequence 3-period|Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9
11196174|NCT03411109||Opioid Only Intrathecal|
11196175|NCT03411109||Opioid + Local Anesthetic Intrathecal|
11196176|NCT03411096|Experimental|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
11196177|NCT03411096|Placebo Comparator|Placebo|Quadratus lumborum block with normal saline
11196178|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
11196179|NCT03411070|Experimental|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
11196180|NCT03411057||Mindfulness Based Stress Reduction (MBSR)|Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) and scleroderma participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
11196181|NCT03411057||Control|Rheumatoid Arthritis, Psoriatic Arthritis, and scleroderma participants in this group will watch an educational stress reduction video (10 minutes).
11196182|NCT03411044||Subjects with a Fitmore Hip Stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem
11196183|NCT03411031|Active Comparator|A: Elotuzumab + Lenalidomide at 25 mg|"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.
~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule."
11196184|NCT03411031|Active Comparator|B: Elotuzumab + Lenalidomide at 10 mg|"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.
~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule."
11196185|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
11196186|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
11196187|NCT03411005|Experimental|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.
~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
11196188|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
11196189|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
11196218|NCT03410771||ICU patients on meropenem|
11196219|NCT03410771||ICU patients on vancomycin|
11196190|NCT03410979|Experimental|GLPG2737 single dose|Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
11196191|NCT03410979|Placebo Comparator|Placebo single dose|Single doses of Placebo oral suspension
11196192|NCT03410979|Experimental|GLP2737 multiple dose|Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
11196193|NCT03410979|Placebo Comparator|GLPG2737 multiple dose|Multiple doses of Placebo oral suspension
11196194|NCT03410966|Experimental|Intervention group|All patients affected by paroxysmal symptomatic atrial fibrillation, and anti-arrhythmic drug refractory atrial fibrillation will receive a trans catheter ablation therapy (intervention).
11196195|NCT03410953|Experimental|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:
~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
11196196|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
11196197|NCT03410927|Experimental|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
11196198|NCT03410914|Experimental|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
11196199|NCT03410901|Experimental|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
11196200|NCT03410888|Experimental|popliteal approach|Blockade of the sciatic nerve at the level of the popliteal fossa.
11196201|NCT03410888|Active Comparator|infragluteal approach|Blocking the sciatic nerve at the subgluteal level.
11196202|NCT03410875|Experimental|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
11196203|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
11196204|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
11196205|NCT03410849|Active Comparator|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
11196206|NCT03410849|Active Comparator|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
11196207|NCT03410836|Experimental|intravenous lidocaine (IVL)|Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
11196208|NCT03410836|Placebo Comparator|Placebo|Will receive the same volume of normal saline for the entire duration of anesthesia.
11196209|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
11196210|NCT03410810||Infant Control Group|The control arm (term born Infants) will receive an MRI at neonatal age and neurodevelopmental follow-up assessments, investigators will then compare significant morphological and diffusion properties within the brain to those of a Preterm brain.
11196211|NCT03410810||Infant Preterm Group|The experimental group will consist of preterm infants, who will receive an MRI at neonatal age and neurodevelopmental assessments. This groups scans will then be compared to those of the control arm. Significant biomarkers will then be identified.
11196212|NCT03410810||Childhood Control Group|The experimental group will consist of preterm born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children control arm. Significant biomarkers will then be identified.
11196213|NCT03410810||Childhood Preterm Group|The experimental group will consist of term born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children preterm group. Significant biomarkers will then be identified.
11196214|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
11196215|NCT03410784|Other|First-line chemotherapy with pembrolizumab|"Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles
~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
11196222|NCT03410732|Experimental|Radical surgery plus activated DCs|In 21 days after a radical surgery, activated DCs are iv infused
11196223|NCT03410732|Active Comparator|Radical surgery only|Radical surgery only group as a control group
11196224|NCT03410719|Experimental|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
11196225|NCT03410719|Experimental|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
11196226|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
11196227|NCT03410693|Experimental|Rogaratinib|"Rogaratinib treatment study arm, comprising
~Pre-treatment period, including FGFR testing and screening,
~Treatment period, and
~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
11196228|NCT03410693|Active Comparator|Chemotherapy|"Chemotherapy treatment study arm, comprising
~Pre-treatment period, including FGFR testing and screening,
~Treatment period, and
~Follow-up period, including active follow-up and long-term follow-up. Patients will be considered on study during the pre-treatment, treatment and active followup periods. During the long-term follow-up period the patients will be considered off study."
11196229|NCT03410680|No Intervention|Control arm|Patients will receive the standard of care at the clinic. Questionnaires will be applied 4 times in a period of 10 months
11196230|NCT03410680|Experimental|Intervention arm|"Each participant will receive FUERTES for a period of 4 months. It consists of receiving a habit-formation kit, which include an information and habit-formation tool that can be accessed through a web platform, a mobile app and a booklet; b) pill cases; c) a fidget cube; and f) a notebook. Patients will have the option of contacting a MD though WhatsApp regarding questions related to their treatment.
~After completing baseline a questionnaire, patients with a score of 2 for barriers that might affect their ART adherence will be assigned a coach. The coach will have 7 one-on-one sessions with the patient in a period of 4 months in order to catalyze ART adherence. MSM living with HIV who have been taking ART for >3 years will provide a one-time one-on-one peer support session"
11196231|NCT03410667|Other|Standard Care|Standard of care arm
11196232|NCT03410667|Experimental|Intervention Arm|Intervention arm
11196233|NCT03410654|Experimental|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
11196234|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
11196235|NCT03410641||Control|No intervention
11196236|NCT03410628|Experimental|gammaCore Active Device|open label
11196237|NCT03410615|Active Comparator|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
11196238|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).
~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
11196239|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|ARM CLOSED TO ACCRUAL WITH AMENDMENT #1
11196240|NCT03410602|Placebo Comparator|Supragingival and subgingival scaling|Supragingival and subgingival scaling group comprised of 15 orthodontic patients treated with routine full-mouth supragingival scaling and subgingival scaling only around all banded first molars. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
11196241|NCT03410602|Active Comparator|Subgingival irrigation|Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
11196242|NCT03410589||Single arm|
11196243|NCT03410576||Carotid artery stenting|Patients undergo carotid artery stenting.
11196244|NCT03410576||Carotid endarterectomy|Patients receive elective carotid endarterectomy.
11196245|NCT03410563||Healthy participants|
11196246|NCT03410550|Experimental|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
11196247|NCT03410537|Experimental|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
11196248|NCT03410537|Placebo Comparator|Placebo|Placebo 2.4mg/d for 12 weeks
11196249|NCT03410524|Active Comparator|Simethicone with PEG-3350 bisacodyl preparation|"Treatment arm:
~200 mg Simethicone in 3 mL of liquid formulation mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
11196250|NCT03410524|Placebo Comparator|Placebo with PEG-3350 bisacodyl preparation|"Placebo arm:
~3 mL of water mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
11196251|NCT03410511|Experimental|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
11196252|NCT03410511|Experimental|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake.
11196253|NCT03410511|Experimental|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
11196254|NCT03410498|Other|MS group|This group will perform walking trials in various conditions, i.e. normal walking, walking whilst performing an attention demanding task and walking while being physically tired.
11196255|NCT03410485|Active Comparator|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
11196256|NCT03410485|Experimental|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
11196257|NCT03410472|Experimental|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
11196258|NCT03410472|No Intervention|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
11196259|NCT03410459|Active Comparator|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
11196260|NCT03410459|Active Comparator|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
11196261|NCT03410446|Experimental|Ketamine|"Three doses of ketamine will be given intranasal:
~Dose 1 will be 50 mg on Day 1
~Dose 2 will be between 50-100 mg on Day 4
~Dose 3 will be between 50-150 mg on Day 7"
11196262|NCT03410433|Active Comparator|Silk 4.0|Silk suture
11196263|NCT03410433|Active Comparator|PG910 4.0|Vicryl Rapid suture
11196264|NCT03410433|Experimental|PP 4.0|Non-absorbable polypropylene monofilament
11196265|NCT03410433|Active Comparator|Silk 5.0|Silk suture
11196266|NCT03410433|Active Comparator|PG910 5.0|Vicryl suture
11196267|NCT03410433|Experimental|PP 5.0|Non-absorbable polypropylene monofilament
11196268|NCT03410433|Experimental|APG 5.0|Antibacterial Vicryl suture
11196269|NCT03410433|Experimental|ePTFE 5.0|expanded polytetrafluoroethylene
11196270|NCT03410420|Active Comparator|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
11196271|NCT03410420|Experimental|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
11196272|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
11196273|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.
~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23
~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24
~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
11196274|NCT03410381|Experimental|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
11196275|NCT03410368|Experimental|autologous natural killer cells|Infusion of 1-2×10^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.
11196276|NCT03410368|No Intervention|routine follow-up|According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.
11196277|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
11196278|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
11196279|NCT03410342|Placebo Comparator|Low Fruits and Vegetables (LFV)|"1 portion of fruits plus 1 portion of vegetables, of commonly consumed types per day.
~Intakes are at 25th percentile of UK consumption (NDNS) and will exclude citrus fruits, cruciferous and allium vegetables."
11196280|NCT03410342|Experimental|High Fruits and Vegetables (HFV)|4 portions of fruits plus 4 portions of vegetables, of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
11196281|NCT03410342|Experimental|High Citrus fruits and Cruciferous vegetables (CC)|4 portions of citrus fruits plus 4 portions of cruciferous vegetables per day excluding any other types of fruits and vegetables including allium vegetables.
11196282|NCT03410329|Experimental|High weekly training frequency|three sessions a week of resistance training
11196283|NCT03410329|Experimental|Low weekly training frequency|one workouts per week
11196284|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
11231708|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
11196285|NCT03410303|Other|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
11196286|NCT03410290||Group 1|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
11196287|NCT03410277|Experimental|All Subjects|Experimental hypoglycemia
11196288|NCT03410264|Experimental|CR-EXP|Cognitive restructuring before exposure with response prevention (45 minute intervention).
11196289|NCT03410264|Experimental|EXP-CR|Exposure with response prevention before cognitive restructuring (45 minute intervention).
11196290|NCT03410264|Active Comparator|Stress Management|Stress management skills.
11196291|NCT03410238|Experimental|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
11196292|NCT03410238|No Intervention|Control|Participants receive a brochure containing psycho-education and resources only.
11196293|NCT03410225|Experimental|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
11196294|NCT03410225|Active Comparator|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
11196295|NCT03410212|Active Comparator|Ketorolac Tromethanine|In the experimental group, 30mg/mL, ketorolac tromethamine will be injected as same as the first IANB and 5 minutes following it.
11196296|NCT03410212|Sham Comparator|No injection|In the control group, 5 minutes following the IANB, the sham injection will be provided at the same place of the first injection.
11196297|NCT03410173|Experimental|Taurine|2.4mg/d for 12 weeks
11196298|NCT03410173|Placebo Comparator|Placebo|2.4mg/d for 12 weeks
11196299|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
11196300|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
11196301|NCT03410147|Other|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
11196302|NCT03410147|Other|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
11196303|NCT03410147|Other|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
11196304|NCT03410134|Experimental|NeoMTA|Vital pulp therapy with NeoMTA
11196305|NCT03410121|Other|Standard 1 : Thoracic location|The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location
11196306|NCT03410121|Other|Standard 2 : Humeral location|The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location
11196307|NCT03410108|Experimental|Brigatinib 90 mg + Brigatinib 180 mg|90 mg of Brigatinib tablets, once daily for 7 days, followed by 180 mg of Brigatinib tablets, once daily in a 28-days cycle.
11196308|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
11196309|NCT03410082|Active Comparator|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
11196310|NCT03410082|Active Comparator|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
11196311|NCT03410069|Experimental|IKORUS UP|
11196312|NCT03410056|Experimental|AMG 592|The phase 1b part of the study is a double-blind, placebo controlled, MAD study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AMG 592 in subjects with active RA. The phase 2a part of the study will commence after a RP2D is identified in the phase 1b part of the study.
11196313|NCT03410056|Placebo Comparator|Placebo|The phase 1b part of the study is a double-blind, placebo controlled, MAD study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AMG 592 in subjects with active RA. The phase 2a part of the study will commence after a RP2D is identified in the phase 1b part of the study.
11196314|NCT03410043|Experimental|Group I (LCT)|Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11196315|NCT03410043|Experimental|Group II (no LCT)|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11196316|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
11196317|NCT03410017||Normally-hearing|Children with normal hearing
11196318|NCT03410004|Experimental|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
11196319|NCT03409991|Experimental|Experimental|Receives the 12-week Opening Doors group sessions, and up to 8 individual career counseling sessions.
11196320|NCT03409991|No Intervention|Waitlist Control|Offered non-vocational classes at the Boston University Center for Psychiatric Rehabilitation, and offered the chance to attend the Opening Doors program at the end of their enrolled 12-month study period.
11196352|NCT03409770|Experimental|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
11196353|NCT03409757||hemodialysis patients with hyperphosphatemia|"dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
~Velphoro® medication"
11196354|NCT03409757||control group|- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
11196355|NCT03409744|Experimental|evinacumab|
11196321|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
11196322|NCT03409965|Experimental|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
11196323|NCT03409952|Active Comparator|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
11196324|NCT03409952|Active Comparator|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
11196325|NCT03409939|Experimental|Aromatic Amino Acid Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
11196326|NCT03409926|Active Comparator|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
11196327|NCT03409926|Experimental|Acacia Gum 5 grams/day|fermentable dietary fiber
11196328|NCT03409926|Experimental|Acacia Gum 10 grams/day|fermentable dietary fiber
11196329|NCT03409913||GCA cases|In a cohort of patients suspected of GCA based on the following inclusion criteria were 1) age ≥50 years, 2) CRP>15mg/l or ESR>40mm/h, 3) either a) cranial symptoms, b) new-onset extremity claudication or c) weight loss >5 kilograms or fever>38oC for >3 weeks, patients with a clinical diagnosis of GCA is identified.
11196330|NCT03409913||controls|Age-(+/- 3 years) and sex-matched malignant melanoma (MM) patients who had a follow-up metastatic-disease-free FDG PET/CT ≥6 months after MM resection
11196331|NCT03409900|Experimental|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
11196332|NCT03409900|Experimental|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
11196333|NCT03409887|Experimental|Intraorifice Group|Intraorifice barrier of GIC.
11196334|NCT03409887|Experimental|Base Group|Base of GIC
11196335|NCT03409887|Active Comparator|Control Group|Direct composite restoration
11196336|NCT03409874|Experimental|Dry Needling and Spinal Manipulation|
11196337|NCT03409874|Active Comparator|Interocclusal Appliance, NSAIDs and TMJ Mobs|
11196338|NCT03409848|Experimental|A: Chemo-free immunotherapy|Week 1-12 Trastuzumab 6mg/kg d1 every 3 weeks (loading dose 8mg/kg) Nivolumab 1mg/kg i.v. d1 every 3 weeks Ipilimumab 3mg/kg i.v. d1 every 3 weeks Week 13 till EOT (max treatment period 12 months) Trastuzumab 4mg/kg d1 every 2 weeks Nivolumab 240mg i.v. d1 every 2 weeks
11196339|NCT03409848|Experimental|B: Chemo- / immunotherapy|"Trastuzumab 4mg/kg d1 every 2 weeks (loading dose 6mg/kg) Nivolumab 240mg i.v. d1 every 2 weeks mFOLFOX6 every 2 weeks Oxaliplatin at a dose of 85 mg/m2 IV over two hours (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv over two hours (day 1) 5-FU at a dose of 2400 mg/m2 IV over 46 hours (day 1-3)
~Max Treatment period 12 months"
11196340|NCT03409835|Experimental|Ramosetron|
11196341|NCT03409835|Placebo Comparator|Control|
11196342|NCT03409822|Other|Placenta previa|
11196343|NCT03409809|Experimental|Training Alone|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website.
11196344|NCT03409809|Experimental|Training and Technical Assistance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies, and communication.
11196345|NCT03409809|Experimental|Training, Tech. Assist., Qual. Assurance|This condition involves an intensive 2-day initial train-the-trainer workshop that simultaneously trains peer educators to deliver the intervention and campus supervisors to train and support future peer educators, plus the facilitator guide and facilitator support website. This condition additionally contains a 1/2 day implementation training to articulate goals, needs, leadership structure, adoption options, recruitment strategies and communication. Furthermore, this condition will have 1 year of technical assistance, coaching, and quality assurance to enhance implementation skills and sustainability.
11196346|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
11196347|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
11196348|NCT03409783|Active Comparator|Active or ENSO Group|Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
11196349|NCT03409783|Sham Comparator|Sham Group|Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
11196350|NCT03409770|No Intervention|Usual care|Usual care (normothermia) arm
11196351|NCT03409770|Experimental|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
11196356|NCT03409731|Other|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
11196357|NCT03409718||Biomet Comprehensive Shoulder System|Subjects in need of a total shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Shoulder System.
11196358|NCT03409705|Experimental|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
11196359|NCT03409705|Placebo Comparator|Control group|2,000 mg of placebo was orally administered per day for 12 weeks.
11196360|NCT03409679|Experimental|Murepavadin|Murepavadin IV + one anti-pseudomonal antibiotic
11196361|NCT03409679|Active Comparator|Two anti-pseudomonal antibiotics|Association of 2 anti-pseudomonal antibiotics
11196362|NCT03409666|Experimental|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
11196363|NCT03409666|Active Comparator|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
11196364|NCT03409627|Experimental|Group 1|Single infusion of INXN-4001, Dose 1
11196365|NCT03409627|Experimental|Group 2|Single infusion of INXN-4001, Dose 2
11196366|NCT03409614|Other|Chemo|Part 1: Chemotherapy
11196367|NCT03409614|Experimental|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
11196368|NCT03409614|Experimental|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
11196369|NCT03409614|Experimental|Placebo+Chemo|Part 2: Placebo plus chemo
11196370|NCT03409614|Experimental|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
11196371|NCT03409601|Experimental|100% Portion Size|Test meal consists of baseline (100%) portion size of meal.
11196372|NCT03409601|Experimental|125% Portion Size|Test meal consists of food portion size that is 125% the size of baseline portion.
11196373|NCT03409601|Experimental|150% Portion Size|Test meal consists of food portion size that is 150% the size of baseline portion.
11196374|NCT03409601|Experimental|175% Portion Size|Test meal consists of food portion size that is 175% the size of baseline portion.
11196375|NCT03409588|Experimental|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
11196376|NCT03409575|Other|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
11196377|NCT03409575|Other|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
11196378|NCT03409562|Experimental|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
11196379|NCT03409562|Active Comparator|motor control training alone|This group will only perform motor control training.
11196380|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
11196381|NCT03409510|Experimental|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
11196382|NCT03409497|Active Comparator|Concord Grape Juice|Concord Grape Juice
11196383|NCT03409497|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
11196384|NCT03409497|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
11196385|NCT03409484|Active Comparator|Concord Grape Juice|100% Concord Grape Juice
11196386|NCT03409484|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
11196387|NCT03409484|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
11196388|NCT03409458|Experimental|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion
~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study."
11196389|NCT03409432|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
11196390|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
11196391|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
11196392|NCT03409406|Experimental|Caregiver Intervention + ST Intervention|Parents/caregivers receive web-based tablet protocol containing sequenced communication information for working with their child at home in addition to the Standard of Care Intervention.
11196393|NCT03409406|Active Comparator|ST Intervention|This intervention is the once monthly standard of care intervention 30-minutes speech therapy (ST) session that the child receives at the hospital.
11196394|NCT03409393|Experimental|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
11196395|NCT03409393|Other|Control Group|Usual care (OPUS treatment).
11196396|NCT03409380|Experimental|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
11196397|NCT03409380|Placebo Comparator|Placebo|Placebo drink provided 1 time.
11196398|NCT03409367|Experimental|Daily Emollient|Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
11196399|NCT03409367|No Intervention|Natural Skin|Parents assigned to the control arm will receive educational materials promoting general infant skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
11196400|NCT03409354|Experimental|Tele-rehabilitation|Tele-rehabilitation via iPad.
11196401|NCT03409354|Active Comparator|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
11196402|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
11196403|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
11196404|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
11196405|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
11196406|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
11196407|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
11196408|NCT03409302|Experimental|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla & Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
11196409|NCT03409302|Active Comparator|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
11196410|NCT03409289||ROSC RUSH Exam|The study population will include out of hospital cardiac arrest (both traumatic and non-traumatic causes) with return of spontaneous circulation after the cardiac arrest while in the emergency department .
11196411|NCT03409276|Experimental|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
11196412|NCT03409276|Placebo Comparator|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
11196413|NCT03409276|Experimental|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
11196414|NCT03409276|Placebo Comparator|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
11196415|NCT03409276|Experimental|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
11196416|NCT03409276|Placebo Comparator|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
11196417|NCT03409250|Other|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
11196418|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
11196419|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
11196420|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
11196421|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
11196422|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
11196423|NCT03409211|Active Comparator|Pso|with or without PsA
11196424|NCT03409211|Active Comparator|Healthy Subjects|Without PsA
11196425|NCT03409198|Active Comparator|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
11196426|NCT03409198|Experimental|Arm B|Chemo + ipilimumab + nivolumab
11196427|NCT03409185|Experimental|Alcon lens group|Alcon 1 piece SA60AT lens
11196428|NCT03409185|Active Comparator|AMO lens group|AMO 1 piece Sensar AABOO lens
11196429|NCT03409172|Experimental|Control group (CTr)|No counseling or nutritional therapy and no exercise
11196430|NCT03409172|Experimental|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).
~MICT:
~3 sessions per week
~intensity at 65-75% HRmax
~time-effort per session: 50 min"
11196431|NCT03409172|Experimental|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).
~HIIT:
~3 sessions per week
~10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax
~time-effort per session: 25 min"
11196432|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton >37 week pregnancy.
~Subjects will be recruited for the study in the following groups :
~At least 10 patients with Body Mass Index (BMI) < 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
11196433|NCT03409133|Experimental|Multi contact electrode implant|"Ten subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.
~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
11196434|NCT03409120|Experimental|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
11196435|NCT03409107|Experimental|Daprodustat receivers|Participants will receive oral daprodustat once daily
11196436|NCT03409107|Placebo Comparator|Placebo receivers|Participants will receive oral placebo once daily
11196473|NCT03408782||No drainage|Those patients that underwent surgery and no drain was inserted at the end of the procedure
11196437|NCT03409068|Experimental|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
11196438|NCT03409068|Active Comparator|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
11196439|NCT03409055||Group 0|patients without pleural effusion
11196440|NCT03409055||Group 1|patients with pleural effusion
11196441|NCT03409055||Group 2|patients with pleural Effusion and need of drainage
11196442|NCT03409029|Experimental|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
11196443|NCT03409016||Immune Checkpoint Inhibitor Therapy|Patients starting treatment with ipilimumab, nivolumab, pembrolizumab, or atezolizumab, alone or in combination, for treatment of a metastatic solid tumor cancer will be enrolled. Patients will receive checkpoint inhibitor therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
11196444|NCT03409016||Control|An additional 18 patients starting standard chemotherapy will be enrolled as a control population. Patients will receive chemotherapy per standard protocol
11196445|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
11196446|NCT03408990||Healthy|Healthy children, no relevant pathologies
11196447|NCT03408977|Experimental|Men|
11196448|NCT03408977|Experimental|Women|
11196449|NCT03408964||Group 0 (set-up)|Patients with known diagnosis of CSPC (Group 0a) and CRPC (Group 0b) irrespective of the PC treatment (not first diagnosis)
11196450|NCT03408964||Group 1a (control)|Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer
11196451|NCT03408964||Group 1|Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery and / or radical radiotherapy
11196452|NCT03408964||Group 2|Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy
11196453|NCT03408964||Group 3|Patients with recurrent/progressive/metastatic CRPC planned to receive chemotherapy
11196454|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
11196455|NCT03408938||Continuous Hb monitoring with Masimo Radical|"Plethysmography Variability Index (PVI) is a measure of the dynamic changes in the perfusion index (PI) that occur during the respiratory cycle . PVI = ﴾PI Max - PI Min﴿ ÷ PI Maxx 100 %.
~PVI has the potential to provide useful information concerning changes in the balance between intrathoracic airway pressure and intravascular fluid volume. Trending of PVI may be useful in monitoring surgical patients, both intraoperatively and postoperatively, for appropriate hydration states. For example, a rising PVI may indicate developing hypovolemia and gives an alarm for the need of appropriate fluid and or blood products transfusion supported by the patient hemoglobin level"
11196456|NCT03408925|Experimental|Intervention|The intervention consists of an exercise program developed by the medical team of the National Federation of Orienteering. Specifically, it consists of four exercises targeting strength, flexibility and coordination of the lower extremity. The orienteerers are asked to perform the exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function (online supplement). Each second week the exercises' difficulty level is increased.
11196457|NCT03408925|No Intervention|Control|Normal training, no intervention
11196458|NCT03408912|Other|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
11196459|NCT03408899|Experimental|PC-1005|All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
11196460|NCT03408886|Experimental|Group A|Group A receives treatment in Part 1 and Part 2
11196461|NCT03408886|Other|Group B|Group B receives no treatment in Part 1, but does receive treatment in Part 2
11196462|NCT03408873|Experimental|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
11196463|NCT03408860|Other|2-week baseline|Patients complete assessment only for a duration of 2-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
11196464|NCT03408860|Other|4-week baseline|Patient complete assessment only for a duration of 4-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
11196465|NCT03408847|Active Comparator|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
11196466|NCT03408847|Placebo Comparator|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
11196467|NCT03408834|Active Comparator|pulse variability index|fluid management performed by pulse variability index
11196468|NCT03408834|Placebo Comparator|conventional fluid management|fluid management performed by conventional fluid management
11196469|NCT03408821|Experimental|Problem Solving Therapy|All participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.
11196470|NCT03408808|Active Comparator|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
11196471|NCT03408808|Experimental|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
11196472|NCT03408795|Other|GOALS-DG Group|Participants in GOALS-DG Group score the performance of procedure after LDG.
11196474|NCT03408782||Drainage|Those patients that underwent surgery and one or several drains were inserted at the end of the procedure.
11196475|NCT03408756|Active Comparator|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
11196476|NCT03408756|Active Comparator|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
11196477|NCT03408743|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
11196478|NCT03408743|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
11196479|NCT03408743|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks. *Also referred to as 'benefits' in other arm descriptions**
11196480|NCT03408743|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus perceived benefits and self-efficacy modules for a period up to 3 weeks.
11196481|NCT03408743|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
11196482|NCT03408743|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus injunctive norms and self-efficacy modules for a period up to 3 weeks.
11196483|NCT03408743|Experimental|Injunctive norms and benefits|Participants will have access to the knowledge module plus injunctive norms and perceived benefits modules for a period up to 3 weeks.
11196484|NCT03408743|Experimental|Injunctive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196485|NCT03408743|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms modules for a period up to 3 weeks.
11196486|NCT03408743|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
11196487|NCT03408743|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
11196488|NCT03408743|Experimental|Descriptive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196489|NCT03408743|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
11196490|NCT03408743|Experimental|Descriptive and injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
11196491|NCT03408743|Experimental|Descriptive and injunctive norms, and benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
11196492|NCT03408743|Experimental|Descriptive & injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196493|NCT03408743|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
11196494|NCT03408743|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
11196495|NCT03408743|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
11196496|NCT03408743|Experimental|Expectancies, benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196497|NCT03408743|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
11196498|NCT03408743|Experimental|Expectancies, injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
11196499|NCT03408743|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
11196500|NCT03408743|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196501|NCT03408743|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
11196502|NCT03408743|Experimental|Expectancies, descriptive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
11196503|NCT03408743|Experimental|Expectancies, descriptive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
11196504|NCT03408743|Experimental|Expectancies, descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196505|NCT03408743|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies , descriptive norms, and injunctive norms modules for a period up to 3 weeks.
11196506|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, efficacy|Participants will have access to the knowledge module plus the expectancies , descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
11196507|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
11196508|NCT03408743|Experimental|Expectancies, descriptive & injunctive, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11196509|NCT03408730|Experimental|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
11196510|NCT03408730|Experimental|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
11196511|NCT03408730|Experimental|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
11196512|NCT03408730|Active Comparator|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
11196513|NCT03408717||Control|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Patients will be assigned to this group when no significant pain is noted during the follow-up evaluations at 4 and 6 months.
11196514|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Patients will be assigned to this group when high pain score is recorded during the follow-up evaluations at 4 and 6 months.
11196515|NCT03408704|Experimental|ASP-arm|This group of primary health care centers get the internal education (ASP).
11196516|NCT03408704|No Intervention|Control-arm|No intervention at all.
11196517|NCT03408691|Active Comparator|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
11196518|NCT03408691|Placebo Comparator|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
11196519|NCT03408691|No Intervention|No product|no product
11196520|NCT03408665|Experimental|SBRT|Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.
11196521|NCT03408652|Experimental|Arm A|bone targeted treatment (denosumab or zoledronic acid)
11196522|NCT03408652|No Intervention|Arm B|no specific treatment
11196523|NCT03408639|Experimental|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
11196524|NCT03408639|Active Comparator|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
11196525|NCT03408626|Experimental|papain chemomechenical caries removal agent (brix 3000)|papain chemomechenical caries removal agent (Birx 3000) and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action
11196526|NCT03408626|Placebo Comparator|conventional|conventional 330 bur
11196527|NCT03408613|Experimental|Positive Airway Pressure (PAP)|A registered polysomnographic technologist will perform a titration starting at 4 cm water (H2O) and adjust this value as needed to identify the optimal pressure to achieve an Apnea Hypopnea Index (AHI) <5 (including rapid eye movement sleep in the supine position). After PAP titration, subjects will be instructed to use the machine at the optimal pressure every night for 3 months. Compliance will be defined as: ≥4 hours use on 70% of nights and average use ≥6 hours per night.
11196528|NCT03408613|Experimental|Supplemental Oxygen (O2)|Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
11196529|NCT03408613|Sham Comparator|Sham|Subjects in the sham treatment group will complete the oxygen titration protocol described for the night-time supplemental oxygen group, except that their oxygen concentrator will have been covertly modified to deliver room air at a rate of 0.5 l/min.
11196530|NCT03408613|No Intervention|Controls|Subjects without OSA will be recruited and complete all testing for primary outcome measures, but will not undergo any intervention.
11196531|NCT03408587|Experimental|CVA21 / Ipilimumab|Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
11196532|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
11196533|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
11196534|NCT03408561|Experimental|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
11196535|NCT03408548|Placebo Comparator|Placebo|Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.
11196536|NCT03408548|Experimental|Probiotic|Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.
11196537|NCT03408535|Other|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
11196538|NCT03408509|Experimental|Cognitive training|
11196588|NCT03408158|Experimental|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
11196539|NCT03408496|Experimental|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
11196540|NCT03408496|Experimental|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
11196541|NCT03408496|Active Comparator|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
11196542|NCT03408483|Experimental|quadratus lumborum block (QLB)|"Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.
~Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.
~After QLB is placed, patients will have THA under spinal anesthesia."
11196543|NCT03408483|Active Comparator|Standard of Care|"Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.
~Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
11196544|NCT03408470|Experimental|TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus|Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
11196545|NCT03408470|Experimental|[14C]-TD-1473 Oral Capsule|Cohort 2 - One oral dose
11196546|NCT03408431|Experimental|Group E|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neck extension positioning.
11196547|NCT03408431|Active Comparator|Group C|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neutral head and neck position.
11196548|NCT03408418|Experimental|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
11196549|NCT03408418|No Intervention|Control|Conventional tooth extraction without any bone substitute.
11196550|NCT03408405|Experimental|Acthar Gel treatment group|Participants will be treated with 'Acthar Gel 80 UNT/ML Injectable Solution'. Initial dose for week 1 will be 50% of 80 units, injected twice per week. Week 2 is 75% of 80 units, week 3 and throughout treatment period (6 months in total) will be 80 units/ml twice per week.
11196551|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
11196552|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
11196553|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
11196554|NCT03408353||Observational (mammography, questionnaires, blood collection)|Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
11196555|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
11196556|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
11196557|NCT03408327|Experimental|Experimental group|"Wearable technology (fitness wristband & App)
~4 times group activities (2 hr / each times)
~LINE group interaction
~Reminder and feedback form researcher"
11196558|NCT03408327|Active Comparator|Control group|"Wearable technology (fitness wristband + App)
~Health promotion manual"
11196589|NCT03408145|Placebo Comparator|Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml and 1ml of Saline) comprising a total volume of 8.5ml fluid during one procedure.
11196590|NCT03408145|Active Comparator|Hyaluronic Acid & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Saline) comprising a total of 8.5mL fluid during one procedure.
11196559|NCT03408314|Experimental|PediQUEST Response|"Weekly PediQUEST surveys are automatically assigned to parents and children (if 5 years old or older) and sent 48 hours prior to participant's usual clinic day
~Once a PediQUEST survey is assigned, automated email reminders/app notifications are sent daily for two days
~After 48 hours, unanswered or incomplete surveys are auto-submitted
~PQ-feedback report generated automatically after a PQ Survey is answered
~A pdf of the report is automatically emailed/available on mobile App to designated recipients
~Will also receive oncology-PC integrated care through the Response team
~Duration of follow-up: 18 weeks (2-week run-in period, followed by a 16-week post-randomization follow-up)"
11196560|NCT03408314|Other|Usual Cancer Care|"Will receive the usual cancer care provided at the participating sites
~Will complete weekly PQ-Surveys (no feedback reports will be generated)
~Can receive regular palliative care consultations following the site's usual referral procedures
~Same follow-up (18 weeks)"
11196561|NCT03408301||Tourniquet deflation|Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia
11196562|NCT03408288||Nurses|
11196563|NCT03408288||Urologists|
11196564|NCT03408275||Pregnant women|Pregnant women enrolled in ALSPAC
11196565|NCT03408262|Active Comparator|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
11196566|NCT03408262|Experimental|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
11196567|NCT03408262|Experimental|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
11196568|NCT03408262|Experimental|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
11196569|NCT03408262|Active Comparator|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
11196570|NCT03408262|Experimental|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
11196571|NCT03408262|Experimental|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
11196572|NCT03408262|Experimental|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
11196573|NCT03408249|Experimental|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
11196574|NCT03408236|Experimental|Botulax|Single dose
11196575|NCT03408236|Active Comparator|Botox|Single dose
11196576|NCT03408223|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
11196577|NCT03408223|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12-20 Gy on Days -8 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
11196578|NCT03408210|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
11196579|NCT03408210|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
11196580|NCT03408197|Experimental|EasyWarm|
11196581|NCT03408197|Active Comparator|BairHugger|
11196582|NCT03408184|Active Comparator|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
11196583|NCT03408184|Active Comparator|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
11196584|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
11196585|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
11196586|NCT03408158|No Intervention|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
11196587|NCT03408158|No Intervention|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
11196668|NCT03407560|Experimental|SintLife|Use of SintLife putty as bone substitute for spinal fusion in lumbar spine surgery for degenerative diseases.
11231709|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
11196591|NCT03408145|Active Comparator|Amniotic Tissue & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Saline and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
11196592|NCT03408145|Experimental|Amniotic Tissue & Hyaluronic Acid|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
11196593|NCT03408132|Experimental|FE203799 5 mg|FE203799 5 mg subcutaneous injection
11196594|NCT03408119|Experimental|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
11196595|NCT03408119|Experimental|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
11196596|NCT03408119|Placebo Comparator|Group C|800 IU vitamin D and 450 mg elemental calcium
11196597|NCT03408093||Interferon beta-1b|Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
11196598|NCT03408080|Experimental|Open Arm|All subjects will receive the same dosage throughout the study.
11196599|NCT03408054|No Intervention|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
11196600|NCT03408054|Active Comparator|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
11196601|NCT03408054|Active Comparator|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
11196602|NCT03408054|Active Comparator|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
11196603|NCT03408041||Alzheimer Disease|Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
11196604|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
11196605|NCT03408015|Experimental|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
11196606|NCT03408015|Experimental|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
11196607|NCT03408015|Experimental|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
11196608|NCT03408002|No Intervention|control group|no intervention
11196609|NCT03408002|Experimental|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
11196610|NCT03407976|Experimental|Apatinib and Pembrolizumab, all patients|
11196611|NCT03407963|Experimental|Prostate cancer patients|
11196612|NCT03407950|Other|Group IPT+|2 sessions of IPT+ by week during 6 months
11196613|NCT03407950|Other|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
11196614|NCT03407937|Other|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
11196615|NCT03407924|Experimental|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
11196616|NCT03407924|Active Comparator|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
11196617|NCT03407924|No Intervention|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
11196618|NCT03407911||Peri-implant microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
11196619|NCT03407911||Periodontal pocket microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
11196620|NCT03407911||healthy teeth|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
11196621|NCT03407898||C-mac D blade used for intubation|
11196622|NCT03407898||mcgrath X blade used for intubation|
11196623|NCT03407885|Experimental|Experimental|Bundled payments for knee and hip replacement
11196624|NCT03407885|No Intervention|Control|No intervention
11196625|NCT03407872|Experimental|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
11196626|NCT03407872|Experimental|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
11196627|NCT03407872|Experimental|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
11196628|NCT03407872|Placebo Comparator|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
11196629|NCT03407859|Experimental|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.
11196630|NCT03407846|Active Comparator|Total laparscopic hystrectomy|
11196631|NCT03407846|Experimental|Total abdominal hystrectomy|
11196632|NCT03407833||Obese, surgery|Obese subjects recruited from the Center for Surgical Weight loss who are undergoing weight loss surgery as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at surgical visits.
11196633|NCT03407833||Obese, nonsurgery|Obese subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
11196812|NCT03406507|Experimental|ALXN1210|
11196634|NCT03407833||Lean control|Lean control subjects recruited from the Vanderbilt Endoscopy Clinic who are undergoing upper endoscopy or colonoscopy as part of their standard of care. Tissue biopsies, blood, and fecal swabs will be collected at day of procedure.
11196635|NCT03407833||Liver transplant|Lean or obese subjects who are undergoing liver transplantation as part of their standard of care. Excised liver tissue will be collected the day of procedure.
11196636|NCT03407820|Active Comparator|1st random 50% of cohort|Absorbable Chromic gut sutures
11196637|NCT03407820|Active Comparator|2nd random 50% of cohort|Non-absorbable Nylon sutures
11196638|NCT03407794|No Intervention|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
11196639|NCT03407794|Experimental|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
11196640|NCT03407794|Active Comparator|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
11196641|NCT03407781|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
11196642|NCT03407768|Other|Individualized interventions|Exercise, Yoga, massage therapy, acupuncture, and others
11196643|NCT03407755|Active Comparator|Air|Intraocular 100% atmospheric air (anterior chamber).
11196644|NCT03407755|Experimental|SF6|Intraocular 20% sulphur hexaflouride (anterior chamber).
11196645|NCT03407742|Experimental|Intervention|CAPAS Youth Parenting Intervention
11196646|NCT03407742|No Intervention|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
11196647|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=20).Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
11196648|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
11196649|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11196650|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
11196651|NCT03407690||PIN2 study participants|All those giving swabs for the study
11196652|NCT03407677|Other|ROTO Track|The individual patient will serve as his/her own control before intervention with ROTO Track
11196653|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
11196654|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
11196655|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
11196656|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
11196657|NCT03407638|Active Comparator|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems-not investigators-implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
11196658|NCT03407638|No Intervention|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
11196659|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
11196660|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
11196661|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
11196662|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
11196663|NCT03407599|Experimental|Faster aspart followed by insulin aspart (NovoRapid®)|Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
11196664|NCT03407599|Experimental|Insulin aspart (NovoRapid®) followed by faster aspart|Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
11196665|NCT03407586|Other|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
11196666|NCT03407573|Active Comparator|Restrictive|Restrictive transfused when Hb at or below 70
11196667|NCT03407573|Active Comparator|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
11231814|NCT03165227|Placebo Comparator|Placebo|
11196669|NCT03407521|Active Comparator|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
11196670|NCT03407521|Placebo Comparator|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
11196671|NCT03407508|Placebo Comparator|Baseline|No dietary changes.
11196672|NCT03407508|Placebo Comparator|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
11196673|NCT03407495|Experimental|single arm: IOP injection (MPB-1523)|single group treatment
11196674|NCT03407482|Experimental|GDC-0853|Participants will receive GDC-0853 twice daily (BID) for 48 weeks, followed by a safety follow-up period of 8 weeks.
11196675|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
11196676|NCT03407443|Experimental|Exposure to Make the Connection messages|
11196677|NCT03407443|Active Comparator|Active Control group|
11196678|NCT03407443|No Intervention|No exposure control group|
11196679|NCT03407430|Experimental|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.
~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
11196680|NCT03407430|Experimental|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.
~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
11196681|NCT03407417|Experimental|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
11196682|NCT03407417|Active Comparator|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
11196683|NCT03407404|Experimental|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
11196684|NCT03407404|Active Comparator|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
11196685|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
11196686|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
11196687|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
11196688|NCT03407378|Experimental|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
11196689|NCT03407378|Experimental|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
11196690|NCT03407365|Experimental|Home Exercises|Patients will be given a set of home exercises to perform as part of their rehabilitation home exercise program. They will be initially trained by a research team member and will be given a DVD home exercise video with instructions on how to perform the exercises.
11196691|NCT03407365|Active Comparator|DVD Program|Weeks 1-10, subjects will not be prescribed exercise at home. If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
11196692|NCT03407352|Active Comparator|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
11196693|NCT03407352|Experimental|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
11196694|NCT03407339|Active Comparator|Shared Oral Care Intervention|
11196695|NCT03407339|No Intervention|Control|
11196696|NCT03407326|Experimental|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
11196697|NCT03407326|Active Comparator|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
11196698|NCT03407313|Experimental|Rotational fractional resection|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
11196699|NCT03407300|Active Comparator|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
11196700|NCT03407300|Active Comparator|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
11196701|NCT03407287||Cardiac Catheterization|
11196702|NCT03407287||Distributive shock|
11196703|NCT03407287||Vasoactive and inotropic agents|
11196704|NCT03407287||Congestive heart failure|
11196705|NCT03407287||Atrial fibrillation|Patients with atrial fibrillation undergoing elective direct current cardioversion
11196706|NCT03407287||Patients undergoing surgery|Patients undergoing surgery requiring positive pressure ventilation and arterial line placement
11196707|NCT03407261|Experimental|Micro-osteoperforations|Minimally invasive micro-osteoperforations procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice
11196708|NCT03407261|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (sliding mechanics)
11196709|NCT03407235|Other|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.
~Time to completion is recorded."
11196710|NCT03407222|Active Comparator|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
11196711|NCT03407222|No Intervention|Control group|Control group does not receive text message
11196712|NCT03407209|Sham Comparator|PEIB - Use of local levobupivacaine anesthetics: 0.625 mg / ml|"automatic hourly bolus: 8ml (5mg) on 3 min
~patient controlled bolus: 8ml (5mg) on 3 min
~refractory period: 8min
~continuous infusion: 0
~maximum dose: 65mg/4h"
11196713|NCT03407209|Experimental|FREE programming - levobupivacaine anesthetics: 0.625 mg / ml|"Epidural analgesia totally controlled by the patient
~automatic hourly bolus: 0
~patient controlled bolus: 8ml (5mg) on 3 min
~refractory period: 8min
~continuous infusion: 0
~maximum dose: 65mg/4h"
11196714|NCT03407183||spastic neurogenic bladder|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.
11196715|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
11196716|NCT03407157|Experimental|Intervention|Probiotic supplementation
11196717|NCT03407157|Placebo Comparator|Control|Placebo
11196718|NCT03407144|Experimental|Pembrolizumab + AVD (Group 1)|After receiving two 4-week cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) induction therapy, SER participants in Group 1 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) on Day 1 of each 3-week cycle (Q3W) in combination with two cycles of AVD chemotherapy (doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2 and dacarbazine 375 mg/m^2 on Days 1 and 15; cycle frequency every 4 weeks [Q4W]). All SERs in Group 1 will receive radiotherapy (RT) after completing AVD chemotherapy.
11196719|NCT03407144|Experimental|Pembrolizumab + COPDAC-28 (Group 2)|After receiving two 4-week cycles of OEPA (vincristine, etoposide/etopophos, prednisone/prednisolone and doxorubicin) induction therapy, SER participants in Group 2 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) Q3W, in combination with 4 cycles of COPDAC-28 chemotherapy (cyclophosphamide 500 mg/m^2 on Days 1 and 8, vincristine 1.5 mg/m^2 with maximum single dose 2 mg on Days 1 and 8, prednisone/prednisolone 40 mg/m^2/day divided in 3 doses on Days 1 to 15, dacarbazine 250 mg/m^2 on Days 1 to 3; cycle frequency Q4W). SERs in Group 2 will receive RT if they have a positive Positron Emission Tomography (PET) response after completing COPDAC-28 chemotherapy.
11196720|NCT03407131|Experimental|Joint replacement|Intertrochanteric fracture patients were treated with joint replacement surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
11196721|NCT03407131|Active Comparator|Intramedullary nail fixation|Intertrochanteric fracture patients were treated with intramedullary nail fixation surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
11196722|NCT03407118|Experimental|LY900014|Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).
11196723|NCT03407118|Active Comparator|Insulin Lispro (Humalog)|Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.
11196724|NCT03407105|Experimental|Arm 2|Specified dose on specified days
11196725|NCT03407092||Stentriever Cohort|
11196726|NCT03407092||ADAPT cohort|
11196727|NCT03407079|Experimental|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
11196728|NCT03407079|Placebo Comparator|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
11196729|NCT03407066||In-person|200 in-person healthy volunteers.
11196730|NCT03407066||On-line|10,000 online healthy volunteers
11196731|NCT03407053|Active Comparator|1/Ultra-processed diet|Patients assigned to this arm will consume ultra-processed diet
11196732|NCT03407053|Active Comparator|2/Unprocessed diet|Patients assigned to this arm will consume unprocessed diet
11196733|NCT03407040||1/Cancer Patients|Patients with a cancer diagnosis enrolled on protocol 03-C-0277
11196734|NCT03407027|Experimental|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
11196735|NCT03407027|Experimental|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
11196736|NCT03407027|Active Comparator|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
11196737|NCT03407001|Experimental|Screening (US, CEUS, Lumason)|Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.
11196738|NCT03406988|Experimental|Autologous fat grafting|Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
11196739|NCT03406988|Placebo Comparator|Sham procedure|False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
11196740|NCT03406975|Placebo Comparator|Control Group|Participants randomized to the control group (lifestyle intervention only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. Control group participants who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI >30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program for 12 months.
11196741|NCT03406975|Active Comparator|Treatment Group|Participants randomized to the treatment group will proceed to have the Overstitch ESG at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved >25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
11231815|NCT03165214|Active Comparator|coil group|micro coils
11196742|NCT03406962|Experimental|MGTA-456|MGTA-456 is an expanded CD34+ cell therapy investigational product used in replacement of single umbilical cord blood transplantation.
11196743|NCT03406949|Experimental|MGD009 + MGA012|B7-H3 x CD3 DART protein + anti-PD-1 antibody
11196744|NCT03406936|Active Comparator|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
11196745|NCT03406936|No Intervention|No Sedation|No sedation will be given after initiation of mechanical ventilation
11196746|NCT03406923|No Intervention|Usual care|Receive usual care only.
11196747|NCT03406923|Experimental|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
11196748|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
11196749|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
11196750|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
11196751|NCT03406884|Experimental|Open label C-kit+ cells Group A|Group A is an open-label treatment group determining safety and feasibility. Participants enrolled in this group will be receiving previously harvested c-kit+ cells during their BDCPA/GLENN operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
11196752|NCT03406884|Active Comparator|C-kit+ cells Group B|Participants randomized to Group B Treatment Group will receive previously harvested c-kit+ cells during their BDCPA/GLENN operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
11196753|NCT03406884|No Intervention|No Intervention Group|Participants randomized to Group B Control Group will receive only their standard of care (SOC) BDCPA/GLENN procedure without the injection of harvested c-kit+ cells.
11196754|NCT03406871|Experimental|Nivolumab + Regorafenib|Nivolumab and Regorafenib
11196755|NCT03406858|Experimental|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
11196756|NCT03406845|Experimental|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
11196757|NCT03406845|Active Comparator|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
11196758|NCT03406832|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
11196759|NCT03406832|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
11196760|NCT03406832|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
11196761|NCT03406819|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
11196762|NCT03406819|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
11196763|NCT03406819|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
11196764|NCT03406806|Experimental|GaitBox|
11196765|NCT03406806|Active Comparator|Sprint System device|
11196766|NCT03406806|Active Comparator|NIH Toolbox 4 meter test|
11196767|NCT03406793|Experimental|1. Standard MNP|
11196768|NCT03406793|Experimental|2. High zinc, low iron MNP|
11196769|NCT03406793|Experimental|3. High zinc, low/no iron|
11196770|NCT03406793|Active Comparator|4. Dispersible zinc supplement|
11196771|NCT03406793|Experimental|5. Intermittent zinc supplement|
11196772|NCT03406793|Placebo Comparator|6. Placebo powder|
11196773|NCT03406780|Experimental|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
11196774|NCT03406780|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
11196775|NCT03406767|Experimental|GLA:D Canada Program|GROUP 1: GLA:DTM CANADA GROUP (STANDARDIZED EXERCISE PROGRAM)
11196776|NCT03406767|Experimental|JointEffort Program|GROUP 2: JOINTEFFORT GROUP (INDIVIDUALIZED EXERCISE PROGRAM)
11196777|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
11196778|NCT03406741|Experimental|Child with Hirschsprung's disease|Neuropsychological assessment at elementary school
11196779|NCT03406728|Active Comparator|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
11196780|NCT03406728|Active Comparator|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
11196781|NCT03406728|Experimental|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
11196782|NCT03406715|Experimental|Combination Immunotherapy Plus Vaccine|Combination immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC). Induction Immunotherapy, followed by Maintenance Immunotherapy and potentially Retreatment. During retreatment, participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone every three weeks for a maximum of one additional year.
11196783|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
11196784|NCT03406689|Active Comparator|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
11196785|NCT03406689|Active Comparator|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
11196786|NCT03406689|Placebo Comparator|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
11196787|NCT03406676|Experimental|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
11196788|NCT03406676|No Intervention|saline|50ml of saline is administrated I.V before anesthesia induction.
11196789|NCT03406663|Experimental|Group 1|"In group 1, the dose of Gla-300 will be titrated by the patients by 1 unit per day until achieving a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (INSIGHT algorithm).
~Titration algorithms:
~Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.
~Fasting SMPG in the range of
~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose
~> 4.4 and ≤ 5.6 mmol/L, no change
~< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
11196790|NCT03406663|Active Comparator|Group 2|"In group 2, the dose of Gla-300 will be titrated by the patients based on the SMPG values of the last 3 days at least weekly, but no more often than every 3 days to achieve a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (EDITION algorithm).
~Fasting SMPG (median of the last 3 days including current day) in the range of
~≥ 7.8 mmol/L, increase 6 units of Gla-300 dose
~> 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose
~> 4.4 and ≤ 5.6 mmol/L, no change
~≥ 3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose
~< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
11196791|NCT03406650|Experimental|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
11196792|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
11196793|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
11196794|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
11196795|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
11196796|NCT03406611|Active Comparator|Active drug|
11196797|NCT03406611|Placebo Comparator|Placebo|
11196798|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
11196799|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 1)|
11196800|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 2)|
11196801|NCT03406585|Placebo Comparator|Sham transplantation (placebo)|
11196802|NCT03406572|Experimental|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
11196803|NCT03406572|Active Comparator|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
11196804|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
11196805|NCT03406546|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
11196806|NCT03406546|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
11196807|NCT03406533|Experimental|Group F|Sedated with midazolam and fentanyl
11196808|NCT03406533|Experimental|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
11196809|NCT03406533|Experimental|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
11196810|NCT03406533|Experimental|Group PR|Sedated with midazolam, propofol and remifentanil
11196811|NCT03406520|Experimental|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
11196813|NCT03406494|Experimental|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
11196814|NCT03406494|No Intervention|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
11196815|NCT03406468|Experimental|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
11196816|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
11196817|NCT03406442|Other|patients|The patient who have lesions affecting pterygopalatine fossa, lateral recess of the sphenoid sinus, petrous apex, Meckel's cave, cavernous sinus, infratemporal fossa and lateral nasopharynx and can be treated by endonasal endoscopic transptergoid approaches
11196818|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
11196819|NCT03406416|Experimental|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
11196820|NCT03406403|Active Comparator|Laryngeal mask airway group|20 slips of papers will be taken and labeled as group L (LMA) These slips will be placed in an envelope and one slip will be raised for each patient.
11196821|NCT03406403|Active Comparator|Magensium sulphate group|20 slips of papers will be taken and labeled as group M (Mgso4) These slips will be placed in an envelope and one slip will be raised for each patient
11196822|NCT03406403|Active Comparator|Control group (closure of anesthetics)|20 slips of papers will be taken and labeled as group C (Control) These slips will be placed in an envelope and one slip will be raised for each patient.
11196823|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
11196824|NCT03406377|Placebo Comparator|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
11196825|NCT03406377|Experimental|OPK-88003|70 mg/vial (extractable volume 1 mL)
11196826|NCT03406364|Experimental|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours); 8:00 PM (±2 hours)]
11196827|NCT03406351||Asthma|
11196828|NCT03406351||Healthy|Matched controls
11196829|NCT03406338|Active Comparator|Surgical fasciectomy|Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures
11196830|NCT03406338|Experimental|Collagenase Clostridium Histolyticum|Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures
11196831|NCT03406325||urticaria|Patients with this condition
11196832|NCT03406325||asthma|Patients with this condition
11196833|NCT03406325||eczema|Patients with this condition
11196834|NCT03406325||food allergy|Patients with this condition
11196835|NCT03406325||anaphylaxis|Patients with this condition
11196836|NCT03406325||mastocytosis|Patients with this condition
11196837|NCT03406325||mast cell activating syndrome|Patients with this condition
11196838|NCT03406312||Gastric Bypass Surgery population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
11196839|NCT03406312||Control population|liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
11196840|NCT03406299|Experimental|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
11196841|NCT03406299|Active Comparator|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
11196842|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
11196843|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
11196844|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
11196845|NCT03406260|Experimental|Lasmiditan 200 mg (milligrams)|Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
11196846|NCT03406260|Experimental|Lasmiditan 100 mg|Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
11196847|NCT03406260|Placebo Comparator|Placebo|Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
11196848|NCT03406247|Experimental|Nivolumab|Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months
11196849|NCT03406247|Experimental|Nivolumab + Ipilimumab|"Patients in cohorts 2 and 2bis will be administered
~nivolumab 240 mg every 2 weeks during 6 months
~ipilimumab 1mg/kg IV every 6 weeks during 6 months"
11196850|NCT03406234||A group of participants|
11196851|NCT03406221|Experimental|Intervention arm|
11196852|NCT03406221|Active Comparator|Control Arm|
11196853|NCT03406208|Experimental|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
11196854|NCT03406208|Experimental|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
11196855|NCT03406195|Experimental|healthy older adults|Healthy older adults who will receive TMS
11196856|NCT03406169|Active Comparator|Sildenafil 25mg Oral Tablet|25mg sildenafil citrate twice daily
11196857|NCT03406169|Active Comparator|Pentoxifylline|400mg pentoxifylline twice daily
11196858|NCT03406169|Placebo Comparator|Placebo|placebo twice daily
11196859|NCT03406156|Experimental|Obinutuzumab +/- bendamustine then obinutuzumab + venetoclax|"Debulking Period: Obinutuzumab with or without bendamustine (bendamustine administered in participants with high tumor load as described in the protocol) during the debulking period (up to 6 cycles).
~Treatment Period: Venetoclax + obinutuzumab regimen initiated when participant achieves low tumor burden during debulking period, or if the participant has not achieved low tumor burden status after 6 cycles of debulking, the participant may proceed to venetoclax per the discretion of the treating provider after discussion with the study physician. During this regimen period, participants to receive obinutuzumab in combination with venetoclax for 5 months then venetoclax therapy alone to continue for a total duration of up to 53 weeks."
11196860|NCT03406143|Experimental|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
11196861|NCT03406143|Sham Comparator|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
11196862|NCT03406130|Active Comparator|Insignia orthodontic treatment|
11196863|NCT03406130|Experimental|Piezocision-assisted Insignia orthodontic treatment|
11196864|NCT03406117|Experimental|HAT1-EPBF2|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.
~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.
~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
11196865|NCT03406117|Experimental|HAT1-HMF3|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.
~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.
~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
11196866|NCT03406117|Active Comparator|Saline Solution: Sodium Chloride|Saline, Sodium Chlorine (NaCl; 0.9%), was used as the negative irritant control in the CIT portion of the study
11196867|NCT03406104|Experimental|GS010|Lenadogene nolparvovec Intravitreal occular unilateral Injection
11196868|NCT03406104|Sham Comparator|Sham|Sham Intravitreal occular unilateral Injection
11196869|NCT03406091||Poor Mobilizer (PM) in Multiple Myeloma (MM) patients|
11196870|NCT03406078|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
11196871|NCT03406078|Placebo Comparator|Placebo|Placebo subcutaneous injection
11196872|NCT03406065|Experimental|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
11196873|NCT03406065|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
11196874|NCT03406052|Experimental|Smartphone-Assisted MB-CBT|Online intervention accessed through smartphone or online accessed computer comprised of Mindfulness-Based Cognitive Behaviour content
11196875|NCT03406052|No Intervention|Control|Standard psychiatric care
11196876|NCT03406039|Experimental|Integrated Online CBT and MI|Participants in this arm will be given access to the online integrated treatment.
11196877|NCT03406039|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about alcohol and mental illness.
11196878|NCT03406026|Experimental|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
11196949|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
11196953|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
11196879|NCT03406026|Active Comparator|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
11196880|NCT03406013|Active Comparator|Group I|Written Information
11196881|NCT03406013|Experimental|Group II|Written Information Prescription
11196882|NCT03406013|Experimental|Group III|Written Information Prescription Technology
11196883|NCT03406013|Experimental|Group IV|Written Information Prescription Technology Coaching
11196884|NCT03406000|Experimental|Insulin glargine (U300)|Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
11196885|NCT03405987||ECV < median|
11196886|NCT03405987||ECV ≥ median|
11196887|NCT03405974|Experimental|Aspirin|"Aspirin 100 mg
~1 tablet/ day for 2 years"
11196888|NCT03405974|Placebo Comparator|Placebo|"Placebo
~1 tablet/ day for 2 years"
11196889|NCT03405961||Manual PAR score|Patient will receive upper and lower impressions, which will be cast to produce plaster models. A calibrated individual will PAR score the casts in the traditional manner (regular care pathway)
11196890|NCT03405961||Direct digital PAR score|Patient will receive upper and lower intra-oral scans which will be PAR scored directly by the computer
11196891|NCT03405961||Indirect digital PAR score|Patient will receive upper and lower impressions which will be cast to produce plater models (regular care pathway). The casts will be scanned with Carestream 3600 intra oral scanner and scored digitally by the computer.
11196892|NCT03405948|Experimental|botulinum toxin|injection of Botulinum toxin
11196893|NCT03405948|Placebo Comparator|placebo|Injection of saline serum (placebo)
11196894|NCT03405935|Experimental|B/F/TAF|B/F/TAF FDC for at least 96 weeks. At the Week 96 Visit, participants in a country where B/F/TAF FDC is not yet commercially available, will be given the option to receive B/F/TAF FDC for up to an additional 48 weeks (up to Week 144) or until Gilead Sciences elected to discontinue the study in that country, whichever occurs first.
11196895|NCT03405922|Placebo Comparator|Placebo|Placebo 40 mL Saline 0.9%
11196896|NCT03405922|Active Comparator|Ropivacain|40 mL Ropivacain 0.5%
11196897|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:
~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis
~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
11196898|NCT03405896|Experimental|Normal subjects|
11196899|NCT03405883||RIF (women with repeated implantation failure)|Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy
11196900|NCT03405883||NF (normal fertile women)|Spontaneous conception or conception after max 9 IUI cycles
11196901|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
11196902|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
11196903|NCT03405857|Experimental|Group 1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
11196904|NCT03405857|No Intervention|Group 2|No intervention will be administered
11196905|NCT03405831|Active Comparator|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
11196906|NCT03405831|Placebo Comparator|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
11196907|NCT03405818|Experimental|Tavaborole 5% Topical Solution|All study participants apply study drug
11196908|NCT03405805||3+1|Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
11196909|NCT03405805||3+0|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
11196910|NCT03405805||2+1|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
11196911|NCT03405792|Experimental|Optune System combined with Temozolomide (TMZ) + Pembrolizumab|Patients with newly-diagnosed GBM who undergo maximal safe resection (biopsy alone is eligible) followed by chemoradiation consisting of concomitant TMZ daily and radiation therapy (RT) with minimal RT will be eligible for this trial. Four to six weeks after finishing chemoradiation, patients will start monthly cycles of adjuvant TMZ. Treatment with Optune will start at approximately the same time as the first cycle of adjuvant TMZ and continue until second disease progression or a maximum of 2 years. Within one week after starting Cycle 2 of adjuvant TMZ and Optune therapy, patients will begin open-label treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
11196912|NCT03405792|Other|Historical Control|Historical control data of patients treated with Optune System combined with Temozolomide alone will be compared with the Optune System combined with Temozolomide (TMZ) + Pembrolizumab arm.
11196913|NCT03405753|Active Comparator|Aroia|
11196914|NCT03405753|Placebo Comparator|Placebo|
11196915|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
11196916|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
11196917|NCT03405727|No Intervention|Standard treatment|
11196918|NCT03405727|Experimental|Oral dietary supplements|
11196950|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
11196951|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
11196952|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
11231816|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
11196919|NCT03405714|Experimental|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects >=12 to <16 years; Cohort 2: Subjects >=6 to <12 years; Cohort 3: Subjects >=2 to <6 years; Cohort 4: Subjects 1 month to <2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
11196920|NCT03405701|Active Comparator|IVM (in vitro maturation)|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
11196921|NCT03405701|Active Comparator|IVF (in vitro fertilization)|Undergoing controlled ovarian hyperstimulation for in vitro Fertilization (IVF) with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist triggering will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
11196922|NCT03405688|Experimental|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
11196923|NCT03405688|Other|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
11196924|NCT03405688|Experimental|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
11196925|NCT03405688|Other|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
11196926|NCT03405688|Experimental|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
11196927|NCT03405688|Other|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
11196928|NCT03405675||SLAS 1|The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).
11196929|NCT03405675||SLAS 2|An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).
11196930|NCT03405662|Active Comparator|Acitve PBM|This arm will receive active photobiomodulation (PBM), delivered with the Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
11196931|NCT03405662|Sham Comparator|Sham PBM|This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
11196932|NCT03405649|Experimental|Group A|Participants train 60 min per session for 10 weeks on non-consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and weights, elastic bands and balls will be used. Babies less than 20 weeks of age will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
11196933|NCT03405649|Experimental|Group B|Participants train 60 min per session for 10 weeks on non consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and different equipment such as weights, elastic bands and balls will be used. Babies older than 20 weeks will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
11196934|NCT03405636|Experimental|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
11196935|NCT03405623|Active Comparator|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
11196936|NCT03405623|Active Comparator|Conventional long-axis|
11196937|NCT03405610|Experimental|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
11196938|NCT03405610|No Intervention|Usual Care|The Usual Care (UC) group will continue with their current medical care.
11196939|NCT03405597|Experimental|Healthy control|Commercial Hepatitis B vaccine
11196940|NCT03405597|Experimental|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
11196941|NCT03405597|Active Comparator|Chronic hepatitis B without vaccination|Standard treatment
11196942|NCT03405584|Experimental|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
11196943|NCT03405584|Active Comparator|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
11196944|NCT03405545|Experimental|HIIT+carbohydrate-rich beverage|This group of subjects will perform High Intensity Interval training while consuming a insulinogenic, carbohydrate-rich beverage
11196945|NCT03405545|Experimental|HIIT+water|This group of subjects will perform High Intensity Interval training while consuming water.
11196946|NCT03405519|Other|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
11196947|NCT03405493|Experimental|Wake and Light Therapy|This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Light Therapy is given daily
11196948|NCT03405493|Active Comparator|Sleep and Light Therapy|Participants will be given information on sleep hygiene and getting a good night's sleep. They are then given Light Therapy daily for 1 week.
11234550|NCT03145883|No Intervention|Control group|Control group
11196954|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
11196955|NCT03405454|Active Comparator|standard chemotherapy|Patients on physician's choice of chemotherapy are allowed to receive any systemic chemotherapy either as a single agent or in combination. However, biologics( including bevacizumab) and oral tyrosine kinase inhibitors will not be allowed for patients on this arm
11196956|NCT03405454|Experimental|durvalumab|Patients on durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months
11196957|NCT03405441|Experimental|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
11196958|NCT03405441|Experimental|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
11196959|NCT03405441|Experimental|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
11196960|NCT03405428|Other|All patients|
11196961|NCT03405402|Experimental|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
11196962|NCT03405402|Other|Control group|Allo-immunization not detected
11196963|NCT03405389||Patients|Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks
11196964|NCT03405376|Experimental|Branch retinal vein occlusion|Aflibercept 2mg is injected into the vitreous cavity. Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
11196965|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
11196966|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
11196967|NCT03405350|Active Comparator|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
11196968|NCT03405350|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
11196969|NCT03405337||FVIII products (prospective)|"Qualitative patient/caregiver study:
~Hemophilia A patients/caregivers (N=30) having initiated a FVIII products with improved half-life"
11196970|NCT03405337||Conventional FVIII replacement therapies|"Qualitative patient/caregiver study:
~Hemophilia A patients/caregivers (N=30) receiving conventional FVIII replacement therapy for at least 6 months who are considering switching to a FVIII product with improved half-life within the next 1 year"
11196971|NCT03405337||FVIII products (retrospective)|"Quantitative physician interview/ chart review study:
~Hemophilia A patients (N=100) who have switched from conventional FVIII replacement therapy to FVIII products with improved half-life."
11196972|NCT03405324|Active Comparator|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
11196973|NCT03405324|Sham Comparator|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
11196974|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
11196975|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
11196976|NCT03405298|Active Comparator|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
11197074|NCT03404674|Experimental|Group B|3 intramuscular injections of 5ug CssBA + 100ng dmLT (10 participants)
11196977|NCT03405298|Active Comparator|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
11196978|NCT03405285|Experimental|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
11196979|NCT03405272|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
11196980|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
11196981|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
11196982|NCT03405246|Active Comparator|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
11196983|NCT03405246|Experimental|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
11196984|NCT03405233|Experimental|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
11196985|NCT03405233|Active Comparator|Group B|Single vein cuffed PTFE graft at the outflow end
11196986|NCT03405233|Active Comparator|Group C|PTFE graft without vein cuff will be used
11196987|NCT03405220|Experimental|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
11196988|NCT03405220|Active Comparator|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
11196989|NCT03405220|Experimental|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
11196990|NCT03405220|No Intervention|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
11196991|NCT03405220|No Intervention|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
11196992|NCT03405220|No Intervention|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
11196993|NCT03405220|Experimental|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
11196994|NCT03405220|Experimental|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
11196995|NCT03405220|Experimental|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
11196996|NCT03405220|Active Comparator|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
11196997|NCT03405220|Experimental|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
11196998|NCT03405220|Experimental|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
11196999|NCT03405220|Experimental|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
11197000|NCT03405220|Experimental|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
11197001|NCT03405220|Experimental|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
11197002|NCT03405207|Active Comparator|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
11197003|NCT03405207|Placebo Comparator|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
11197004|NCT03405194|Experimental|Elvitegravir-Cobicistat-TAF-FTC|Elvitegravir 150mg po QD Cobicistat 150 mg po QD TAF 10 mg po QD FTC 200 mg QD
11197005|NCT03405194|Active Comparator|EFV-TDF-3TC|EFV 600 mg po QD TDF 300 mg po QD 3TC 300 mg po QD
11197006|NCT03405181|Experimental|Training with additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet with an additional weight characterized by 20% of the total mass of the upper limb placed on both wrists. This training will be adopted for the adequate weight intervention group and low weight intervention group.
11197007|NCT03405181|Placebo Comparator|Training without additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet without additional weight, placed on both wrists. This training will be adopted for the adequate weight placebo group and low weight placebo group.
11197008|NCT03405168|Experimental|routine therapy plus moxifloxacin|Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.
11197009|NCT03405155|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11197010|NCT03405142|Experimental|T1 or T2 stage and node negative|T1 or T2 stage primary tumor and node negative (i.e., cN0)
11197011|NCT03405142|Experimental|Any T stage and node positive|Any T stage tumor and node positive (i.e., cN+)
11197012|NCT03405129|Active Comparator|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
11197013|NCT03405129|Experimental|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
11197075|NCT03404674|Experimental|Group C|3 intramuscular injections of 5ug CssBA + 500ng dmLT (10 participants)
11197014|NCT03405129|Experimental|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
11197015|NCT03405103|Experimental|Striving|Striving vs Boning-up & Personal Choice
11197016|NCT03405103|Active Comparator|Boning-up Standard Education|Boning-up vs Striving and Personal Choice
11197017|NCT03405103|Sham Comparator|Personal Choice|Personal Choice vs Striving & Boning-up
11197018|NCT03405090|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
11197019|NCT03405090|Active Comparator|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
11197020|NCT03405077|Experimental|IPT Online Training|"Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from gold-standard training."
11197021|NCT03405064|Experimental|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
11197022|NCT03405064|Active Comparator|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
11197023|NCT03405025|Other|Safety and Feasibility|All patients will undergo endoscopic US guided radiofrequency ablation, to assess safety and feasibility.
11197024|NCT03404999|Experimental|clinical decision support activated|"TWO MED ASSIST ALERTS
~Enter height (when missing)
~Repeat BP (when high)
~ONE PROVIDER ALERT
~BP high & prior BP/BP%s
~Defines elev. BP, HTN stage 1-2 with button to enter diagnosis
~Link to tailored ordersets
~TAILORED ORDERSETS
~Elevated BP
~Button to schedule f-up <6 m
~Button for diet/lifestyle counseling/check-out instructions
~HTN stage 1
~Buttons to order labs/studies pre-checked for stage 1 recs
~Button for nephrology referral
~Button to schedule f-up in 1-2 wk/<1 m
~Button for diet/lifestyle counseling/check-out instructions
~HTN stage 2
~Buttons to order labs/studies for stage 2
~Button for nephrology referral (pre-checked)
~Button to f-up 1 wk
~Button for diet/lifestyle counseling/check-out instruction"
11197025|NCT03404986|Other|Standardized ureteroscopy group|
11197026|NCT03404986|Other|Ultrasonography ureteroscopy group|
11197027|NCT03404960|Experimental|Arm A|Niraparib + Nivolumab
11197028|NCT03404960|Experimental|Arm B|Niraparib + Ipilimumab
11197029|NCT03404947|Experimental|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
11197030|NCT03404947|No Intervention|No Ethanol|Participants will ingest a volume matched beverage of water only.
11197031|NCT03404934|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
11197032|NCT03404921|Experimental|ESTD group|Use tunnelling method during ESD operation
11197033|NCT03404921|Other|ESD group|Use traditional method during ESD operation
11197034|NCT03404908|Experimental|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
11197035|NCT03404908|Experimental|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
11197036|NCT03404895|Sham Comparator|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
11197037|NCT03404895|Active Comparator|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
11197038|NCT03404882|Experimental|text messaging plus peer support arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. In addition to peer support, participants in this arm of the study will receive daily supportive text messages from an automated online application and reminder text messages for their community clinic/program appointments.
11197039|NCT03404882|Active Comparator|supportive/reminder text message only arm|Patients in the supportive/reminder text message only arm of the study will receive daily supportive text messages from the automated online application and reminder text messages for their community clinic/program appointments.
11197040|NCT03404882|No Intervention|Control arm|Patients in the control arm of the study will receive the usual follow-up appointment offered to all patients who are discharged from acute care. However, they will not receive peer support or supportive/reminder text messages.
11197041|NCT03404882|Active Comparator|peer support only arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. Patients will not receive daily supportive/reminder text messages
11197042|NCT03404869|Other|Treatment with ORL-1M - D-mannose|
11197043|NCT03404856|Other|Treatment with ORL-1G - D-galactose|
11197044|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
11197045|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
11197046|NCT03404830|Experimental|HIIT group|This group receives physical training based on HIIT
11197047|NCT03404830|Experimental|MICT group|This group receives physical training based on MICT
11197048|NCT03404830|No Intervention|No intervention group|This group does not receive any treatment.
11197049|NCT03404817|Active Comparator|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
11197050|NCT03404817|Active Comparator|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
11197051|NCT03404817|Active Comparator|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:
~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
11197052|NCT03404804|Experimental|Oral Challenge|Patients getting amoxicillin
11197053|NCT03404791|Experimental|Participants Ineligible for Radical Cystectomy|Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.
11197054|NCT03404778||Biomet Comprehensive Reverse Shoulder|Subjects in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Shoulder System.
11197055|NCT03404765|Experimental|Tai Chi group|The Tai Chi group (i.e. the intervention group) received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long.
11197056|NCT03404765|No Intervention|Ususal care group|The control group received the usual care offered by the respective centers. No intervention had been arranged for the control group during the study period. Participants in the control group were advised to attend different kinds of recreational activities provided by their community centers and to continue with their daily activities, including their usual general physical mobility and social activities.
11197057|NCT03404752|Experimental|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
11197058|NCT03404752|Active Comparator|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
11197059|NCT03404739|Experimental|Single-dose group|Ceftazidime 2g at the start of POEM
11197060|NCT03404739|Active Comparator|Multiple-dose group|Ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure
11197061|NCT03404726|Experimental|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
11197062|NCT03404726|Experimental|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
11197063|NCT03404726|Experimental|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
11197064|NCT03404713|Active Comparator|Standard Behavioral Weight Loss (BWL) Treatment|All participants will participate in 4 weeks of group based behavioral weight lost treatment in the intervention called Pathways to Health. Based on early treatment response (improvement in binge eating), participants will be assigned to either continue in this arm for the remaining 12 weeks of treatment (early strong responders) or be assigned to the 2nd arm of this study.
11197065|NCT03404713|Experimental|Acceptance-Based Binge Eating Treatment|After 4 weeks of standard BWL treatment, early weak responders will be assigned to individual acceptance-based treatment for the remaining 12 weeks of treatment.
11197066|NCT03404700|Experimental|Group 1:Test breakfast A and B|"*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.
~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
11197067|NCT03404700|Experimental|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
11197068|NCT03404700|Experimental|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
11197069|NCT03404700|Experimental|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
11197070|NCT03404700|Experimental|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
11197071|NCT03404700|Experimental|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
11197072|NCT03404687||Patients with adnexal masses|
11197073|NCT03404674|Experimental|Group A|3 intramuscular injections of 5ug CssBA (5 participants) or 100ng dmLT (5 participants)
11197076|NCT03404674|Experimental|Group D|3 intramuscular injections of 15ug CssBA + 100/500ng dmLT (10 participants) (dose of dmLT dependent upon previous groups)
11197077|NCT03404674|Experimental|Group E|3 intramuscular injections of 45ug CssBA + 100/500ng dmLT (10 participants) (dose of dmLT dependent upon previous groups)
11197078|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
11197079|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
11197080|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
11197081|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
11197082|NCT03404635||Apixaban for VTE|
11197083|NCT03404635||Rivaroxaban for VTE|
11197084|NCT03404622|Active Comparator|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
11197085|NCT03404622|Active Comparator|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
11197086|NCT03404609|Experimental|rTMS|Participants in the rTMS group will receive MagPro X100 by MagVenture (Active) cortical stimulation condition.
11197087|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
11197088|NCT03404583|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform
11197089|NCT03404583|No Intervention|Usual Care|Evidence-based care
11197090|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
11197091|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
11197092|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
11197093|NCT03404557||Crohn's Disease patients group|44 patients
11197094|NCT03404557||Ulcerative Colitis patients group|22 patients
11197095|NCT03404557||Healthy volunteers group|22 patients
11197096|NCT03404544|Active Comparator|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
11197097|NCT03404544|Experimental|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
11197098|NCT03404531|Experimental|Social Media Messages Intervention Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
11197099|NCT03404531|Active Comparator|Website Only Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.
11197100|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.
~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
11197101|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.
~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
11197102|NCT03404505|Experimental|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
11197103|NCT03404505|Experimental|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
11197104|NCT03404492|Other|Patients with pulmonary hypertension|
11197105|NCT03404479|Experimental|Co-administration group|Co-administration of Diacerein 50mg, Celecoxib 100mg.
11197106|NCT03404479|Active Comparator|Single administration group 1|Single administration of Diacerein 50mg and placebo.
11197107|NCT03404479|Active Comparator|Single administration group 2|Single administration of Celecoxib 100mg and placebo.
11197108|NCT03404466|Experimental|experimental group one|10 mg of Hypidone Hydrochloride tablets
11197109|NCT03404466|Experimental|experimental group two|20 mg of Hypidone Hydrochloride tablets
11197110|NCT03404453||Paediatric patients at preanaesthetic visi|Difficult airway incidence and prediction:Paediatric patients at preanaesthetic visit scheduled for surgery under general anaesthesia
11197111|NCT03404440|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
11197112|NCT03404440|Placebo Comparator|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
11197113|NCT03404427|Sham Comparator|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
11197114|NCT03404427|Experimental|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
11197115|NCT03404414|Experimental|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
11197116|NCT03404401|Experimental|BLI4700 Bowel Preparation|
11197119|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
11197120|NCT03404362|Active Comparator|MRgFUS|"The treatment process begins with the physician acquiring a set of MR images, identifying target volume(s) of tissue to ablate, and then drawing the treatment contours.
~The therapy planning software computes the type and number of sonications required to treat the defined region while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment"
11197121|NCT03404362|Active Comparator|EBRT|Patient would undergo single fraction of external beam radiation to a dose of 8Gy or a session of 10 fractions of external beam radiations at 3Gy per fraction for two weeks.
11197122|NCT03404349|Experimental|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
11197123|NCT03404336|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
11197124|NCT03404336|Placebo Comparator|Control condition|The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.
11197125|NCT03404310|Experimental|Treatment|Zinc Sulfate 220mg twice daily for three months.
11197126|NCT03404310|Placebo Comparator|Placebo|Gelatin Placebo tablet twice daily for three months.
11197127|NCT03404297|Experimental|Immediate Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
11197128|NCT03404297|Placebo Comparator|Delayed Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy after completing ~ 14 weeks of chemotherapy.
11197129|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
11197130|NCT03404271|Placebo Comparator|Normal Diet|Participants in the normal diet (ND) group will follow a traditional dietary pattern, consisting of eating breakfast and continuing to eat throughout the day until the evening. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
11197131|NCT03404271|Experimental|Time-Restricted Feeding|Participants in the time-restricted feeding (TRF) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
11197132|NCT03404271|Experimental|Time-Restricted Feeding plus HMB|Participants in the time-restricted feeding plus HMB (TRF+HMB) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive HMB capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
11197133|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
11197134|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
11197135|NCT03404245|Active Comparator|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered PT, and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
11197136|NCT03404245|Placebo Comparator|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a PT. In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
11197137|NCT03404232|Active Comparator|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
11197138|NCT03404232|Active Comparator|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
11197139|NCT03404232|Active Comparator|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
11197140|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
11197141|NCT03404206|Active Comparator|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
11197142|NCT03404206|Placebo Comparator|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
11197287|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
11197143|NCT03404193|Experimental|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11197144|NCT03404180|Experimental|Peripheral nerve block|"Prospectively evaluate peripheral nerve blocks as a primary anesthetic in the setting of above-the-knee amputations.
~All enrollees will be administered Intravenous sedatives using propofol or dexmedetomidine and have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator nerve blocks and lateral femoral cutaneous nerve blocks will also be performed."
11197145|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
11197146|NCT03404141|Experimental|Experimental group|The intervention administered to the experimental group will be a cognitive-behavior therapy applied by two specifically trained psychologists
11197147|NCT03404141|Active Comparator|Control group|The intervention administered to the control group will consist on a regular parent craft classes offered by the community midwife
11197148|NCT03404128||Questionnaires|Questionnaire for patient Questionnaire for neurologist
11197149|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
11197150|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
11197151|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
11197152|NCT03404102||university clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion
~Informed Consent: All participants will give their informed consent prior to enrollment.
~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).
~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
11197153|NCT03404102||primary healthcare unit clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion
~Informed Consent: All participants will give their informed consent prior to enrollment.
~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).
~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
11197154|NCT03404089|Experimental|pharmacokinetic device|MON4STRAT system
11197155|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
11197156|NCT03404063|Experimental|Active Group|Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
11197157|NCT03404063|Placebo Comparator|Control Group|Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.
11197158|NCT03404050|Experimental|Music and dance movement therapy group|Music and dance movement therapy group
11197159|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
11197160|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
11197161|NCT03404024|Experimental|Stage 1-Low dose VM202RY|Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)
11197162|NCT03404024|Experimental|Stage 1-Middle dose VM202RY|Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)
11197163|NCT03404024|Experimental|Stage 1-High dose VM202RY|Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)
11197164|NCT03404024|Placebo Comparator|Stage 2-Placebo|Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)
11197165|NCT03404024|Experimental|Stage 2-Low dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)
11197166|NCT03404024|Experimental|Stage 2-High dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)
11197167|NCT03404011|Experimental|Propylene glycol and Glycerol intake|One gram intake of a Propylene glycol/Glycerol mix (50:50)
11197168|NCT03404011|Placebo Comparator|Mimicking intake|Mimicking Propylene glycol/Glycerol intake with the device turns off
11197169|NCT03403998|Experimental|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
11197170|NCT03403998|Placebo Comparator|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
11197171|NCT03403985|Experimental|calcium hydroxide direct pulp capping|calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group
11197172|NCT03403985|Experimental|MTA direct pulp capping|Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group
11197173|NCT03403972|Experimental|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
11197288|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
11197174|NCT03403959|Experimental|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
11197175|NCT03403959|No Intervention|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
11197176|NCT03403946|Experimental|Intervention|"All patients received the same treatment.
~Laryngscopy with C-MAC PM + Macintosh blade
~Laryngscopy with C-MAC PM + D-Blade
~Intubation with C-MAC PM + D-Blade"
11197177|NCT03403933|Experimental|cardiopathic patients in hypovitaminosis|Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D > 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study
11197178|NCT03403907|Experimental|Probiotic|Probiotic administration
11197179|NCT03403881|Active Comparator|Physical activity promotion + TAU|"Physical activity promotion based on:
~Pedometers use;
~Weekly contact (telephone or face-to-face);
~Contact based on a self-determination theory.
~TAU:
~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
11197180|NCT03403881|Placebo Comparator|Control|"Weekly calls with general health content.
~TAU:
~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
11197181|NCT03403868|Other|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
11197182|NCT03403855|Experimental|Rocket® IPC- Long External Length|"Intervention Rocket® IPC- Long External Length: a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.
~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.
~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate their product."
11197183|NCT03403855|Experimental|Rocket® IPC- Short External Length|"Intervention Rocket® IPC- Short External Length : a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.
~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.
~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate Rocket's product."
11197184|NCT03403842|Active Comparator|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
11197185|NCT03403842|Active Comparator|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
11197186|NCT03403842|Experimental|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
11197187|NCT03403829|Experimental|maintenance arm|Gemcitabine maintenance treatment
11197188|NCT03403829|Sham Comparator|control arm|observe and follow-up
11197189|NCT03403816|Active Comparator|Intervention|"Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.
~."
11197190|NCT03403816|No Intervention|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
11197191|NCT03403803||Control Group|
11197192|NCT03403803||Optune Only|
11197193|NCT03403803||Optune and TMZ|
11197194|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
11197195|NCT03403777|Experimental|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
11197196|NCT03403764|Experimental|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.
~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
11197197|NCT03403764|No Intervention|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
11197198|NCT03403751|Experimental|Reltecimod|Single dose
11197199|NCT03403751|Placebo Comparator|0.9% Sodium Chloride Injection|Single dose
11197200|NCT03403738|Active Comparator|Enhanced usual Care|usual care plus comprehensive resource list
11197201|NCT03403738|Experimental|BBN|Bounce Back Now intervention
11197202|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.
~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
11197203|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.
~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
11197204|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
11197205|NCT03403699||nondiabetics|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must be a healthy control and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
11197206|NCT03403699||Diabetic|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) carry the diagnosis of diabetes and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
11197207|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
11197208|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
11197209|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
11197210|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
11197211|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
11197212|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
11197213|NCT03403660|Experimental|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
11197214|NCT03403660|Placebo Comparator|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
11197215|NCT03403647|Experimental|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
11197216|NCT03403647|No Intervention|No vitamin D deficiency|Regular and routine monitoring
11197217|NCT03403634|Experimental|Treatment (celecoxib, interferon alfa-2b, rintatolimod)|Patients receive celecoxib orally PO BID, recombinant interferon alfa-2b IV QD over 20 minutes, and rintatolimod IV QD on days 1, 2, 3, 8, 9, 10, 15, 16 and 17 in the absence of disease progression or unacceptable toxicity.
11197218|NCT03403621|Experimental|Topical agent A|Topical Pentamidine Isethionate will be randomized to be applied to either the proximal or distal end of the incision. The patient is his/her own control.
11197219|NCT03403621|Placebo Comparator|Topical agent B|Silicone Gels base will be randomized to be applied either to the proximal or distal end of the incision. The patient is his/her own control
11197220|NCT03403595|Experimental|177Lu-EB-PSMA-617 dosimetry calculation|All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
11197221|NCT03403582|No Intervention|Control arm|A high-fat break fast meal with no raspberries.
11197222|NCT03403582|Experimental|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
11197223|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
11197224|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
11197225|NCT03403556|Experimental|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
11197226|NCT03403556|Active Comparator|Monorova ® Tab.|Rosuvastatin 20mg
11197227|NCT03403543||1|This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.）
11197228|NCT03403530|Active Comparator|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
11197229|NCT03403530|Placebo Comparator|control group|antibiotics only
11197230|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
11197231|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
11197232|NCT03403504|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
11197233|NCT03403504|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
11197234|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
11197235|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
11197236|NCT03403478|No Intervention|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
11197237|NCT03403478|Experimental|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
11197289|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
11197728|NCT03400176|Experimental|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
11197238|NCT03403478|Experimental|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
11197239|NCT03403478|Experimental|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
11197240|NCT03403478|Experimental|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
11197241|NCT03403465|Other|Single arm interventional study|Research FDG-PET scan obtained before radiation therapy; a second research FDG-PET scan is obtained at about 3-5 weeks after treatment has started.
11197242|NCT03403452|Experimental|arm for Apatinib|500 mg,p.o.,qd
11197243|NCT03403439|Experimental|All Subjects|Reference Treatment - BI 1015550 alone followed by Test Treatment (itraconazole + BI 1015550)
11197244|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
11197245|NCT03403413|Experimental|Muscle Vibration|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
11197246|NCT03403400|Experimental|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
11197247|NCT03403400|Active Comparator|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
11197248|NCT03403400|No Intervention|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
11197249|NCT03403387|Experimental|GlutenShield|3 capsules of GlutenShield supplement/day for 28 days
11197250|NCT03403387|Placebo Comparator|Placebo|3 capsules of the placebo (Avicel and bentonite powder (for color))/ day for 28 days
11197251|NCT03403374|Experimental|Evolocumab|Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).
11197252|NCT03403361|Active Comparator|Arm A: Conventional SECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine single-energy computed tomography (SECT) or DECT scans
~In Arm A, patients are treated with treatment plans optimized and calculated on the SECT data. Plan dose is re-calculated for every patient with the clinical plan in a Monte Carlo dose calculation engine for better accuracy. The investigators will use TOPAS, an extension of Geant4 simulation toolkit, as the dose calculation engine.
~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy or early in their course and up to 2nd week of treatment. Additionally at approximately 4 weeks after initiating therapy as well as at conclusion of therapy
~Scans can be performed on the Phillips or Siemens scanners"
11197253|NCT03403361|Experimental|Arm B1: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans
~In Arm B1, DECT data is used to estimate the actual dose delivered using the clinical plan based on SECT data.
~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy or early in their course and up to 2nd week of treatment. Additionally at approximately 4 weeks after initiating therapy as well as at conclusion of therapy
~Scans can be performed on the Phillips or Siemens scanners"
11197254|NCT03403361|Experimental|Arm B2: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans
~In Arm B2, the plan is re-optimized on DECT data with the conventional uncertainty margin of 3.5% of proton range.
~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy or early in their course and up to 2nd week of treatment. Additionally at approximately 4 weeks after initiating therapy as well as at conclusion of therapy
~Scans can be performed on the Phillips or Siemens scanners"
11197255|NCT03403361|Experimental|Arm B3: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans
~In Arm B3, the plan is re-optimized on DECT data with the SPR uncertainties derived from the patient-specific uncertainty model developed.
~An additional 2 or 3 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating proton therapy or early in their course and up to 2nd week of treatment. Additionally at approximately 4 weeks after initiating therapy as well as at conclusion of therapy
~Scans can be performed on the Phillips or Siemens scanners"
11197256|NCT03403348|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 7 cohorts and receive one of the 7 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
11197257|NCT03403348|Experimental|Part 2A: Food Effect|Participants enrolled in cohort 4 of part 1 will roll-over in Part 2A and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
11197258|NCT03403348|Experimental|Part 2B: Relative Bioavailability (Optional)|Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
11197501|NCT03401684|Experimental|Resilient Minds|Four comprehensive, skill-building learning modules in the areas of psychological trauma, mental health problems, resiliency and workplace stress.
11197259|NCT03403348|Experimental|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. There will be 3 optional cohorts and participants in these cohorts will follow 7- to 14-day dosing schedule. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
11197260|NCT03403348|Experimental|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging PK and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
11197261|NCT03403348|Experimental|Part 5: SAD/Japanese|Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
11197262|NCT03403348|Experimental|Part 6: MAD/Japanese (Optional)|Participants of Japanese descent may be enrolled in 3 cohorts and will receive one of the corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 to 14 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (Parts 1, 2, 3, and 5) cohorts.
11197263|NCT03403335|Experimental|Mindfulness Based Practices for Health Care Professionals|
11197264|NCT03403335|No Intervention|Control Group|
11197265|NCT03403322|Other|First test|All measures were evaluated
11197266|NCT03403322|Other|Second test|All measures were evaluated
11197267|NCT03403309|Experimental|Inosine 5'-monophosphate arm|Subjects are treated with inosine 5'-monophosphate to increase serum uric acid level.
11197268|NCT03403309|Placebo Comparator|Placebo arm|Subjects are treated with placebo not to increase serum uric acid level.
11197269|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
11197270|NCT03403283||Group 1|Diabetic
11197271|NCT03403283||Group 2|Healthy Controls
11197272|NCT03403270|Experimental|ENCOURAGE App Intervention|Users will download the ENCOURAGE mobile app. The App uses a time management technique (i.e. Pomodoro technique) as a strategy to provide prompts for users to engage in an activity. The App can be customized by the users to set prompts at intervals that fit into their schedule. For example, these activities can range from a stretching activity (e.g., a neck stretch), a standing activity (e.g., stand and read), or a physical activity (e.g., fill up the printer with paper, do a squat). Additionally, the App will use Behaviour Change Techniques as a strategy to support participants as they reduce their sedentary behaviour and improve their physical activity levels. The App uses a series of Behavior Change Techniques shown to be effective in promoting a more active lifestyle.
11197273|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
11197274|NCT03403257||Caregivers|Primary caregivers of subjects
11197275|NCT03403244|Experimental|US-MR image fusion-guided PTED|US-MR image fusion-guided PTED: the puncture procedure during PTED was performed under the guidance of ultrasound-MR fusion technique.
11197276|NCT03403244|Active Comparator|fluoroscopy-guided PTED|fluoroscopy-guided PTED: the puncture procedure during PTED was performed under the guidance of fluoroscopy.
11197277|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
11197278|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
11197279|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
11197280|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
11197281|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
11197282|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
11197283|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
11197284|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
11197285|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
11197286|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
11197290|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
11197291|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
11197292|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
11197293|NCT03403218|Experimental|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
11197294|NCT03403205|Experimental|ALXN1840 15-60 mg|
11197295|NCT03403205|Active Comparator|Standard of Care (SoC) Medication|
11197296|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
11197297|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
11197298|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
11197299|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
11197300|NCT03403179|Experimental|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
11197301|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
11197302|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
11197303|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
11197304|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
11197305|NCT03403140|Experimental|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes
~Source: GEMABIOTECH S. A. Formulation per unit:
~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
11197306|NCT03403101|Experimental|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
11197307|NCT03403088|Experimental|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
11197308|NCT03403088|Placebo Comparator|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
11197309|NCT03403088|Experimental|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
11197310|NCT03403088|Placebo Comparator|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
11197311|NCT03403088|Experimental|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
11197312|NCT03403088|Experimental|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
11197313|NCT03403075|Active Comparator|Usual Care|"Control Group will be offered usual care (UC), plus two sessions of therapeutic education delivered in small groups. In these educational sessions, patients are provided with useful information on communication strategies, problem solving strategies, recognition and management of symptoms and the management of any aids/orthoses provided in everyday life, etc. In the meetings, it will be emphasized the importance of maintaining an active lifestyle as much as possible by encouraging involvement in physical activity even during the cancer treatment period.
~Written information material that summarizes the concepts addressed during group meetings will be provided."
11197314|NCT03403075|Experimental|ETAF: Therapeutic Education Physical Activity|"Intervention group will perform UC, and the two sessions of therapeutic education delivered in small group, as for the Control Group. The Intervention group will also provided for 6 individual sessions of therapeutic education and physical activity held by physiotherapists dedicated to the study, according to the patients' needs and objectives.
~In these sessions, the topics discussed in group will be deepened, personalizing them according to the patient's characteristics. Furthermore, personalized physical activity is planned, taking into account the context of execution, the clinical condition and the patient's preferences. The patient will be trained to build an action plan aimed at self-plan physical activities and a diary will be provided to monitor the physical activity carried out autonomously.
~Written information material that summarizes the concepts addressed during group and individual sessions will be provided."
11197315|NCT03403049|Experimental|Arm 1|Dose-escalation phase I clinical study. In the initial dose levels, 'dose-escalation' refers to an increase in the radiotherapy dose delivered using carbon ion radiotherapy along with a corresponding decrease in the dose delivered using photons.
11197316|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
11197317|NCT03403023|Experimental|DES treated patients|This single group of patients is imaged by the Tear Film Imager (TFI) device before and after treatment with Restasis, the treatment indicated for their condition.
11197318|NCT03403010|No Intervention|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
11197319|NCT03403010|Active Comparator|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
11197320|NCT03403010|No Intervention|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
11197321|NCT03402997||Resistivity measurements|The resistivity measurements will be done by introducing the needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues
11197322|NCT03402984|Experimental|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
11197323|NCT03402984|Placebo Comparator|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
11197324|NCT03402971||healthy pregnant+healthy fetus|healthy pregnant women with suspected healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
11197325|NCT03402971||non healthy pregnant|non healthy women with suspected healthy or unhealthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
11197326|NCT03402971||non healthy fetus|healthy or non healthy pregnant women with suspected non healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
11197327|NCT03402945|Active Comparator|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.
~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
11197328|NCT03402945|Active Comparator|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.
~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
11197329|NCT03402945|Active Comparator|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.
~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
11197330|NCT03402945|Active Comparator|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.
~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
11197331|NCT03402932|Experimental|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
11197332|NCT03402932|Experimental|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
11197333|NCT03402932|Experimental|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
11197334|NCT03402932|Other|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
11197335|NCT03402919||Normal healthy elderly|participants with no subjective or objective cognitive deficits or decline.
11197336|NCT03402919||Subjective Cognitive Decline|Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
11197337|NCT03402919||Mild Cognitive Impairment (MCI)|Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
11197338|NCT03402919||Vascular MCI|Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
11197339|NCT03402919||Alzheimer's Disease|Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
11197340|NCT03402919||Dementia of Mixed Etiology|Participants with dementia and evidence of more than one etiology.
11197341|NCT03402919||Lewy Body/Parkinson's spectrum|Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
11197342|NCT03402919||Frontotemporal dementia (FTD) spectrum|Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
11197771|NCT03399903|Active Comparator|Align|40 participants will be randomized to take Align tablets, once daily for 8 weeks
11197343|NCT03402906|Experimental|Family-Clinician Collaboration|"Experimental group which will be performing the Family-Clinician Collaboration Program. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the patient.
~Intervention: Behavioral - Family-Clinician Collaboration Program; Behavioral - Standard Care at KIR"
11197344|NCT03402906|Sham Comparator|Control|"Control group in which patient will receive the standard treatment provided at Kessler Institute for Rehabilitation (KIR).
~Intervention: Behavioral - Standard Care at KIR"
11197345|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
11197346|NCT03402880|Experimental|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
11197347|NCT03402867|Experimental|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
11197348|NCT03402854|Experimental|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
11197349|NCT03402854|Experimental|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
11197350|NCT03402841|Experimental|Olaparib|"Olaparib will be supplied as film-coated tablets containing 150 mg or 100 mg of olaparib.
~Patients will be administered olaparib orally twice daily (bid) at 300 mg."
11197351|NCT03402815|Experimental|A|Patients received Maraviroc 300 mg/day in addition to current ART for 24 weeks. At the end of the first 24-week period patients were switched to ART with no additional treatment.
11197352|NCT03402815|Experimental|B|Patients received ART with no additional treatment for 24 weeks. At the end of the first 24-week period patients were switched to Maraviroc 300 mg/day in addition to current ART.
11197353|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
11197354|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
11197355|NCT03402776|No Intervention|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
11197356|NCT03402776|Experimental|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
11197357|NCT03402776|No Intervention|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
11197358|NCT03402763|No Intervention|Control Arm|Participants receive a short informational handout on the process and choices involved in advance care planning.
11197359|NCT03402763|Experimental|Intervention|Participants are shown a 6-minute video that describe CPR, breathing tube placement, and mechanical breathing support in addition to the general process of advance care planning.
11197360|NCT03402750|Experimental|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
11197361|NCT03402750|Active Comparator|Standard Care|Electronic prescription with patient pickup at the pharmacy
11197362|NCT03402737|Experimental|Stereotactic body radiotherapy + IM|Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.
11197363|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
11197364|NCT03402698|Experimental|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
11197365|NCT03402685|No Intervention|NIBP-Group|NIBP will be shown, ClearSight will be covered.
11197366|NCT03402685|Experimental|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
11197367|NCT03402672|Experimental|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
11197368|NCT03402659|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
11197369|NCT03402659|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
11197370|NCT03402646|Experimental|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
11197371|NCT03402646|Experimental|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
11197372|NCT03402646|No Intervention|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
11197373|NCT03402620|Active Comparator|four ampoules group|gonadotropin starting dose is 4 ampoules daily
11197374|NCT03402620|Active Comparator|six ampoules group|gonadotropin starting dose is 6 ampoules daily
11197502|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
11199321|NCT03388892|Active Comparator|Plain Balloon|PTA with PCB at venous anastomotic stenosis of AVG
11197375|NCT03402607|Active Comparator|Percutaneous Local Abalation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
11197376|NCT03402607|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
11197377|NCT03402594|No Intervention|No oxygen|No oxygen supplementation given
11197378|NCT03402594|Active Comparator|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
11197379|NCT03402594|Experimental|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
11197380|NCT03402581||c-mac used for intubation|obese patients intubated with c-mac videolaryngoscope
11197381|NCT03402581||mc-grath used for intubation|obese patients intubated with mc-grath videolaryngoscope
11197382|NCT03402542||Cholecystectomy|Patients with a symptomatic vesicular lithiasis, having undergone cholecystectomy during a scheduled hospitalization in the CHU Brugmann Hospital between May 2016 and November 2017.
11197383|NCT03402529|Other|CESM|
11197384|NCT03402516|Experimental|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
11197385|NCT03402516|Active Comparator|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
11197386|NCT03402503|Experimental|Group A|Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.
11197387|NCT03402503|Placebo Comparator|Group B|Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.
11197388|NCT03402490|Experimental|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
11197389|NCT03402490|No Intervention|Usual care|Participants who served as controls received usual care.
11197390|NCT03402464|Experimental|Icotinib combined dihydroaremisinin|
11197391|NCT03402438|Experimental|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
11197392|NCT03402438|Experimental|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m*2
11197393|NCT03402438|Experimental|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m*2
11197394|NCT03402438|Experimental|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m*2
11197395|NCT03402425|Experimental|All included patients|A 18F-FET PET scan is performed
11197396|NCT03402412|Experimental|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
11197397|NCT03402399|Other|Primary Myelofibrosis|Blood test
11197398|NCT03402399|Other|Secondary Myelofibrosis|Blood test
11197399|NCT03402386|Experimental|MT-6548|
11197400|NCT03402373|Experimental|Lycoderm|soft gel contains nutritional supplement
11197401|NCT03402373|Placebo Comparator|Placebo|Soft gel without active ingredients
11197402|NCT03402360|Experimental|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
11197403|NCT03402360|Active Comparator|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
11197404|NCT03402347|Experimental|Laser irradiation regimes|Non-ionising radiation intervention will be applied to skin explants
11197405|NCT03402334|Experimental|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.
~Cardiovascular risk factor counseling will include:
~Increased risk for atherosclerosis with chronic HCV infection
~Increased risk of heart attack and stroke
~Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
11197406|NCT03402334|No Intervention|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:
~HCV infection poses an increased risk for hepatocellular carcinoma
~Hepatitis C is a curable disease
~Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles
~HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)
~HCV+ individuals should reduce alcohol intake and shellfish consumption"
11197407|NCT03402321|Active Comparator|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
11197408|NCT03402321|Experimental|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
11197409|NCT03402308|Experimental|Schisandra chinensis extract group|This group takes Schisandra chinensis extract for 12 weeks
11197410|NCT03402308|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
11197411|NCT03402295|Active Comparator|Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)|"Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.
~Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles"
11234783|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
11197412|NCT03402295|Active Comparator|Ctd- Cyclophosphamide, thalidomide and dexamethasone|"Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)
~28 days each cycles- total of four cycles"
11197413|NCT03402282|Experimental|embolization|upper rectal artery embolization
11197414|NCT03402282|Active Comparator|surgical treatment|surgical repair through the classic technique (Milligan and Morgan technique)
11197415|NCT03402269||Adolescents with displaced clavicle fractures|Adolescents (11 to 17 years old) with displaced clavicle fractures will be enrolled in this study.
11197416|NCT03402256|Experimental|Text Message (TM)|"Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. 1). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. high, med, low), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval."
11197417|NCT03402256|No Intervention|Standard Care (SC)|"Participants will receive only standard care provided by the liver transplantation team. No additional behavioral or psychosocial interventions will be provided. All aspects of care received by SC participants will also provided to the TM condition participants. Medical care will be managed by medical specialty providers. SC condition participants will receive behavioral treatment within the liver transplantation clinic by psychology fellows and/or psychologists/psychiatrists. Treatment schedules and session topics will be determined by individual providers, per usual practice.
~These participants will receive only study-specific assessments. Participants in this condition will complete assessments at baseline, 4-weeks and 8-weeks that measure self- reported substance use, stress, and coping skills. At each in-person assessment, participants will provide urine for EtG analysis and will be compensated."
11197418|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
11197419|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
11197420|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
11197421|NCT03402230|Experimental|Arm I (Avmacol lower dose, Avmacol higher dose)|Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
11197422|NCT03402230|Experimental|Arm II (Avmacol higher dose, Avmacol lower dose)|Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
11197423|NCT03402204|Experimental|Simvastatin 10 mg|Simvastatin 10 mg
11197424|NCT03402204|Experimental|Simvastatin 40 mg|Simvastatin 40 mg
11197425|NCT03402191|Active Comparator|L-arginine|l-arginine for pulmonary hypertension in patients with thalassemia.
11197426|NCT03402191|Active Comparator|Sildenafil|Sildenafil for pulmonary hypertension in patients with thalassemia.
11197427|NCT03402191|No Intervention|Control|No pulmonary hypertension
11197428|NCT03402178|Experimental|E2082|E2082 will be administered as a solution (0.2 milligram [mg]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
11197429|NCT03402178|Placebo Comparator|E2082-matched placebo|Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
11197430|NCT03402165|Experimental|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
11197431|NCT03402165|Experimental|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
11197432|NCT03402165|Experimental|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
11197503|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
11197727|NCT03400189|Other|Single arm|"Single oral dose of sulthiame (Ospolot® tablets)
~Period I: 50 mg
~Period II: 100 mg
~Period III: 200 mg given 3 weeks apart"
11197433|NCT03402152|Experimental|NRX-101 vs. Placebo|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral placebo and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
11197434|NCT03402152|Experimental|NRX-101 vs. lurasidone HCl|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral lurasidone and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
11197435|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
11197436|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
11197437|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
11197438|NCT03402113|Experimental|Dexmedetomidine group|Dexmedetomidine consistent infusion as sedative.
11197439|NCT03402113|Active Comparator|Midazolam group|Midazolam consistent infusion as sedative.
11197440|NCT03402100|Experimental|0.01% atropine|children who received 0.01% atropine for myopia
11197441|NCT03402100|Experimental|0.005% atropine|children who received 0.005% atropine for myopia
11197442|NCT03402100|Experimental|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
11197443|NCT03402100|Experimental|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
11197444|NCT03402100|Experimental|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
11197445|NCT03402087|Experimental|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
11197446|NCT03402074|Experimental|Group Hypnosis|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home
11197447|NCT03402061||Community living seniors|Approximately 50 seniors will taste test each nutrient enhanced recipe and determine acceptability and palatability.
11197448|NCT03402061||LTC cognitively well|Approximately 15 seniors living in long term care who do not have cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
11197449|NCT03402061||LTC persons living with dementia|Approximately 15 seniors living in long term care with cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
11197450|NCT03402048|Active Comparator|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:
~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.
~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.
~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
11197451|NCT03402048|Experimental|experimental arm|"Treatment prescriptions will be based on gene analysis:
~Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.
~Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.
~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.
~Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.
~Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.
~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
11197452|NCT03402035||Whole Blood|Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
11197453|NCT03402035||Component Therapy|Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
11197454|NCT03402009|Experimental|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
11197455|NCT03402009|Active Comparator|Active Control|independent meditation using web-based tools and apps
11197456|NCT03401996|Experimental|Real tDCS|
11197457|NCT03401996|Sham Comparator|Sham tDCS|
11197458|NCT03401983|Experimental|PFMT + AT|Pelvic Floor Muscle Training and Abdominal Training
11197459|NCT03401983|Active Comparator|PFMT|Pelvic Floor Muscle Training
11197460|NCT03401970|Active Comparator|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
11197461|NCT03401970|Experimental|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
11197462|NCT03401970|Experimental|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
11197463|NCT03401957||RAS wild-type colorectal cancer|RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
11197464|NCT03401944|Active Comparator|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
11197465|NCT03401944|Placebo Comparator|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
11197587|NCT03401086|Active Comparator|Study group|Kinesio Taping
11197588|NCT03401086|No Intervention|Control group|No intervention
11197466|NCT03401918|Experimental|Comparing the microbiome and ERA in RPL and infertility|"In this arm we will assess the uterine environment at the time of implantation in recurrent pregnancy loss patients and unexplained infertility patients and compare the environment in these patient populations to healthy parous controls.
~We will test the uterine endometrial gene expression using the ERA test and the uterine micro biome."
11197467|NCT03401918|Experimental|The impact of progesterone and antibiotics/probiotics|In this arm, recurrent pregnancy loss and unexplained infertility patients who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome.
11197468|NCT03401905|Experimental|Low frequency|Percutaneous electrical nerve stimulation with frequency of 2 Hz and 120 microseconds of pulse width will be applied.
11197469|NCT03401905|Active Comparator|High frequency|Percutaneous electrical nerve stimulation with frequency of 120 Hz and 200 microseconds of pulse width will be applied.
11197470|NCT03401892|Experimental|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
11197471|NCT03401892|Experimental|Healthy control subjects|healthy age-and sex- matched control subjects
11197472|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
11197473|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
11197474|NCT03401866|Other|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
11197475|NCT03401853|Experimental|Treatment (pembrolizumab, rituximab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive rituximab or obinutuzumab IV on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab Iv on day 1 of cycles 5, 9, 13, 17, 21, and 25 only."
11197476|NCT03401840|Experimental|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
11197477|NCT03401827|Experimental|Gemcitabine + nab-paclitaxel|Case with chemotherapy (Gemcitabine + nab-paclitaxel)
11197478|NCT03401801|Active Comparator|4 ml of 1% lidocaine|Procedure: 4 ml of 1% lidocaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
11197479|NCT03401801|Active Comparator|6 ml of 1% lidocaine|Procedure: 6 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
11197480|NCT03401801|Active Comparator|8 ml of 1% lidocaine|Procedure: 8 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
11197481|NCT03401788|Experimental|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
11197482|NCT03401775|Experimental|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
11197483|NCT03401775|No Intervention|Group2|No intervention will be administered
11197484|NCT03401762|Experimental|Chronic stroke MCI Electromyogram (EMG) pairs|Decoupling 2 muscles at a time with MCI
11197485|NCT03401762|Experimental|Chronic stroke MCI EMG triplets|Decoupling 3 muscles at a time with MCI
11197486|NCT03401762|Experimental|Chronic stroke MCI while reaching|Decoupling muscles with MCI while reaching to targets
11197487|NCT03401762|Sham Comparator|Chronic stroke Sham MCI|Sham control group
11197488|NCT03401762|Experimental|Acute stroke MCI|Decoupling muscles with MCI in acute stroke subjects
11197489|NCT03401762|Sham Comparator|Acute stroke Sham MCI|Acute stroke subjects sham comparator
11197490|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
11197491|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
11197492|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
11197493|NCT03401736|Experimental|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
11197494|NCT03401736|Active Comparator|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65~85 and the Ramsay score was 3 to 4.
11197495|NCT03401723|Other|Novices|"Any physician who has no experience of endoscopies or has done no more than 50 colonoscopies.
~Each subject included are to perform on the Endoscopy Training System (ETS) during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
11197496|NCT03401723|Other|Experienced|"Includes any physician who have succeeded more than 140 colonoscopies. Professional backgrounds include surgeons and gastroenterologists.
~Each subject included are to perform on the ETS during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
11197497|NCT03401710|Experimental|Group 1|Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
11197498|NCT03401710|No Intervention|Group 2|No recombinant human erythropoietin will be administered to this group
11197499|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
11197500|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
11197657|NCT03400644|No Intervention|Without Collar|Subjects do not need to wear any cervical collar postoperatively
11197504|NCT03401645|Experimental|Treatment (Alarm Active)|"Participants will be wearing the wrist device with an alarm timer that sends out signals every 5 minutes. The alarm is a buzzing noise and a vibration. Participants must turn off the alarm then perform a series of visuomotor tasks. This will be done for one hour, twice a day for two weeks.
~Intervention: Device - Wrist Alarm; Behavioral - Home-based Arm and Hand Exercise"
11197505|NCT03401645|Sham Comparator|Control (Sham Control)|"Participants will perform the same tasks as the Alarm/Treatment group, but without the alarm timer. This is a series of visuomotor tasks for one hour, twice per day for two weeks.
~Intervention: Behavioral - Home-based Arm and Hand Exercise"
11197506|NCT03401619||Osteoporosis With Cognitive impairment|
11197507|NCT03401619||Osteoporosis With Arterial stiffness|
11197508|NCT03401619||Osteoporosis|
11197509|NCT03401619||Normal|
11197510|NCT03401606|Active Comparator|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
11197511|NCT03401606|Active Comparator|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
11197512|NCT03401593|Active Comparator|ablation|Patients in this group are treated with radio-frequency catheter ablation.
11197513|NCT03401593|No Intervention|non-ablation|Patients in this group are treated with rate control medications (e.g., beta blocker, calcium channel blocker, and digitalis) and anti-arrhythmic drugs. They also can be treated with DC cardio-version.
11197514|NCT03401580|Experimental|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
11197515|NCT03401580|Experimental|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
11197516|NCT03401580|Experimental|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
11197517|NCT03401580|Experimental|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
11197518|NCT03401567|Experimental|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
11197519|NCT03401567|No Intervention|Control group|Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.
11197520|NCT03401554|Active Comparator|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
11197521|NCT03401554|Experimental|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
11197522|NCT03401541|Experimental|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
11197523|NCT03401541|Experimental|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
11197524|NCT03401541|Experimental|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
11197525|NCT03401541|Experimental|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
11197526|NCT03401528|Experimental|Single Ascending Dose - AVB-S6-500|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
11197527|NCT03401528|Placebo Comparator|Single Ascending Dose - placebo|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
11197528|NCT03401528|Experimental|Repeat Dose - AVB-S6-500|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
11197529|NCT03401528|Placebo Comparator|Repeat Dose - placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
11197530|NCT03401515|Active Comparator|Intervention|Adminstration of propranolol hydrochloride ( 1 MG /ml) 1 mg every 6 hrs .
11197531|NCT03401515|Placebo Comparator|Control|Adminstration of normal saline 1 mg every 6 hrs
11197532|NCT03401502|Experimental|Treatment groups|Ranolazine 1000 mg
11197533|NCT03401502|Placebo Comparator|Control group|Placebos
11197534|NCT03401489|Experimental|PACESETTER|
11197535|NCT03401489|No Intervention|Healthy Lifestyle Intervention Group|
11197536|NCT03401476|Active Comparator|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
11197537|NCT03401476|Active Comparator|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
11197538|NCT03401463|Active Comparator|once a day|Cuff pressure checks once a day.
11197539|NCT03401463|Active Comparator|three times a day|Cuff pressure checks three times a day
11197540|NCT03401450|Active Comparator|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
11197541|NCT03401450|Active Comparator|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
11197542|NCT03401437||Retrospective cohorte|Patients seen in consultation between January 2017 and August 2017, who have already completed the SF-36 questionnaire (pre-operative, M1 and M3), the HAD and ANSM questionnaires (pre-operative and M3)
11197543|NCT03401437||Prospective cohorte|Patients seen in consultation between August 2017
11197544|NCT03401424|Experimental|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
11197545|NCT03401424|Active Comparator|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
11197546|NCT03401411|Experimental|Standard SCCMP|Health care provider completes triage survey of 15 fictional patient case scenarios using the standard SCCMP to prioritize each for admission.
11237464|NCT03125928|Experimental|Investigational Arm|
11197547|NCT03401411|Experimental|SCCMP + Algorithm-based Triage Tool|Health care provider completes triage survey of 15 fictional patient case scenarios using SCCMP in addition to a newly designed flowchart-based triage guide to prioritize each for admission.
11197548|NCT03401398|Active Comparator|Treatment|Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
11197549|NCT03401398|Placebo Comparator|Placebo|Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
11197550|NCT03401385|Experimental|Dose Escalation - All Participants|All participants enrolled in the dose escalation part
11197551|NCT03401385|Experimental|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
11197552|NCT03401372|Experimental|Doxycycline/BCD chemotherapy|Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy
11197553|NCT03401372|Active Comparator|BCD chemotherapy|Bortezomib-cyclophosphamide-dexamethasone chemotherapy
11197554|NCT03401346|Experimental|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
11197555|NCT03401346|Active Comparator|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
11197556|NCT03401346|Active Comparator|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
11197557|NCT03401333|Experimental|Text messaging and brief intervention|Brief motivational interview and 4-weeks of text messaging.
11197558|NCT03401320|Experimental|Cohort 1: Letrozole ISM 50 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 50 mg Letrozole ISM
11197559|NCT03401320|Experimental|Cohort 2: Letrozole ISM 100 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 100 mg Letrozole ISM
11197560|NCT03401320|Experimental|Cohort 3: Letrozole ISM 200 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 200 mg Letrozole ISM
11197561|NCT03401320|Experimental|Cohort 4: Letrozole ISM 400 mg|14 oral doses of 2.5 mg Femara (once daily) + single IM injection of 400 mg Letrozole ISM
11197562|NCT03401307||Responders to Fampridine Treatment|Participants, who are classified as responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify responders to Fampridine. Participants who improve with ≥20% on the T25FW are categorized as responders.
11197563|NCT03401307||Non-Responders to Fampridine Treatment|Participants, who are classified as non-responders to Fampridine treatment, have already been identified in the MS-centers in the Region of Southern Denmark, where they undergo outpatient treatment and clinical controls. A 2-week Fampridine treatment phase, as described in the trial outline section, has been used to identify non-responders to Fampridine. Participants who do not improve with ≥20% on the T25FW are categorized as non-responders.
11197564|NCT03401294|Other|Single arm|FOLFOXIRI and Bevacizumab
11197565|NCT03401281|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
11197566|NCT03401281|Active Comparator|Butter|50g Butter to be consumed daily for four weeks
11197567|NCT03401281|Active Comparator|Olive oil|50g extra virgin olive oil to be consumed daily for four weeks
11197568|NCT03401268|Experimental|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
11197569|NCT03401229|Experimental|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
11197570|NCT03401229|Placebo Comparator|Placebo SC + MF|
11197571|NCT03401216|Experimental|SYNERGY 48 PCI + 3 month OCT follow-up|Synergy 48 mm stent implantation followed by 3 month OCT imaging
11197572|NCT03401216|Experimental|SYNERGY 48 PCI + 6 month OCT follow-up|Synergy 48 mm stent implantation followed by 6 month OCT imaging
11197573|NCT03401203|Experimental|rotational atherectomy followed by balloon angioplasty|
11197574|NCT03401203|Active Comparator|balloon angioplasty|
11197575|NCT03401190|Experimental|Low Dose Female|Cohort 1 will consist of 4 female patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
11197576|NCT03401190|Experimental|Low Dose Male|Cohort 2 will consist of 4 male patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
11197577|NCT03401190|Experimental|High Dose Female|Cohort 3 will consist of 8 female patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
11197578|NCT03401190|Experimental|High Dose Male|Cohort 4 will consist of 8 male patients who will be randomized 3:1 to receive CM4620-IE plus supportive care versus supportive care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
11197579|NCT03401177|Experimental|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
11197580|NCT03401177|Placebo Comparator|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
11197581|NCT03401125||Sickle cell disease patients (SS genotype)|Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
11197582|NCT03401112|Placebo Comparator|Placebo|
11197583|NCT03401112|Experimental|Dose 1|IMR-687
11197584|NCT03401112|Experimental|Dose 2|IMR-687
11197585|NCT03401099|Active Comparator|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
11197586|NCT03401099|Active Comparator|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
11197589|NCT03401073|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
11197590|NCT03401073|Experimental|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
11197591|NCT03401060|Experimental|Experimental medication 1|Denosumab 60 mg subcutaneously injection with prefilled syringe
11197592|NCT03401060|Placebo Comparator|Experimental medication 2|NaCl 0.9%, 20ml phial, solution for injection
11197593|NCT03401047|Experimental|Transdermal Estradiol|Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
11197594|NCT03401021||Crrent Male smokers|"Male smokers met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).
~be aged 18 or above,
~have a history of smoking at least one cigarette per day before their partners became pregnant,
~be involved with partners whose pregnancies could be confirmed,
~able to read Chinese and communicate in the Mandarin dialect."
11197595|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
11197596|NCT03400995|Experimental|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
11197597|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
11197598|NCT03400969|Active Comparator|Glycerol 17 %|Oral moisturizer
11197599|NCT03400969|Active Comparator|Aequasyal (OGT)|Oral moisturizer
11197600|NCT03400969|Active Comparator|Salient (new product)|Oral moisturizer
11197601|NCT03400956|Experimental|Vilaprisan|Vilaprisan: 2 treatment periods of 12 weeks, separated by 1 bleeding episode.
11197602|NCT03400956|Experimental|Placebo+Vilaprisan|Placebo: 1 treatment period of 12 weeks; and Vilaprisan: 1 treatment period of 12 weeks; separated by 1 bleeding episode.
11197603|NCT03400956|Experimental|Vilaprisan+Placebo|Vilaprisan: 1 treatment period of 12 weeks; and Placebo: 1 treatment period of 12 weeks; separated by 1 bleeding episode.
11197604|NCT03400943|Experimental|Vilaprisan_A1|vilaprisan (2 mg), 2 treatment periods of 12 weeks, separated by 1 bleeding episode
11197605|NCT03400943|Experimental|Vilaprisan_A2|vilaprisan (2 mg), 2 treatment periods of 12 weeks without a break
11197606|NCT03400943|Experimental|Vilaprisan_B1|placebo, 1 treatment period of 12 weeks, and vilaprisan (2 mg), 1 treatment period of 12 weeks, separated by 1 bleeding episode
11197607|NCT03400943|Experimental|Vilaprisan_B2|vilaprisan (2 mg), 1 treatment period of 12 weeks, and placebo, 1 treatment period of 12 weeks, separated by 1 bleeding episode
11197608|NCT03400930||OptiDiag-Cohort, Liberia|A respresentative population of 275 Liberian children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
11197609|NCT03400930||OptiDiag/MANGO-Cohort, Burkina Faso|A respresentative population of 275 Burkinabé children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
11197610|NCT03400930||OptiDiag-cohort, Bangladesh|A respresentative population of 275 Bangladeshi children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
11197611|NCT03400917|Experimental|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
11197612|NCT03400891|Experimental|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
11197613|NCT03400891|No Intervention|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
11197614|NCT03400878|Active Comparator|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
11197615|NCT03400878|Active Comparator|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
11197616|NCT03400865|Experimental|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.
11197617|NCT03400852|Experimental|Treatment A, MNK1411 High Dose|Cosyntropin suspension 0.5/0.4 mL for up to 48 weeks
11197618|NCT03400852|Experimental|Treatment B, MNK1411 Low Dose|Cosyntropin suspension 0.25/0.2 mL for up to 48 weeks
11197619|NCT03400852|Placebo Comparator|Treatment C, Placebo High Dose|Placebo suspension 0.4/0.5 mL for up to 24 weeks
11197620|NCT03400852|Placebo Comparator|Treatment D, Placebo Low Dose|Placebo suspension 0.25/0.2 mL for up to 24 weeks
11197621|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.
~Patients will be submitted to the assessment of:
~Daily physical activity levels;
~6-minute walk test;
~Cardiopulmonary exercise testing;
~Muscle Function;
~Lung Function;
~Body composition;
~HRQoL - SGRQ-I;
~HRQoL - SF36;
~Anxiety and depression;
~Symptoms - mMRC
~Symptoms - UCSD/SOBQ;
~Sleep quality;
~Sleepiness;
~Inflammatory markers and oxidative stress."
11197658|NCT03400631|Experimental|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
11197622|NCT03400839||Control Group|"Age-matched peers without lung diseases.
~Participants will be submitted to the assessment of:
~Daily physical activity levels;
~6-minute walk test;
~Cardiopulmonary exercise testing;
~Muscle Function;
~Lung Function;
~Body composition;
~HRQoL - SF36;
~Anxiety and depression;
~Sleep quality;
~Sleepiness;
~Inflammatory markers and oxidative stress."
11197623|NCT03400826|Experimental|Treatment Group|The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
11197624|NCT03400826|Placebo Comparator|Placebo Group|The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
11197625|NCT03400813|No Intervention|Control|Patients in this group continue their usual care without intervention.
11197626|NCT03400813|Experimental|R-TEP EMDR|Patients in R-TEP EMDR group will receive the intervention.
11197627|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
11197628|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
11197629|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.
~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
11197630|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
11197631|NCT03400774|Other|Control|Oral glucose tolerance test with no stair-climbing
11197632|NCT03400774|Experimental|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
11197633|NCT03400774|Experimental|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
11197634|NCT03400774|Active Comparator|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
11197635|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
11197636|NCT03400735|Experimental|Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets|
11197637|NCT03400735|Active Comparator|Cefdinir 300 mg Capsules|
11197638|NCT03400722|Experimental|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
11197639|NCT03400722|Experimental|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
11197640|NCT03400709|Experimental|N-acetylcisteine group|
11197641|NCT03400709|Placebo Comparator|Control group|
11197642|NCT03400696|Experimental|Randomized- Lower carbohydrate diet|
11197643|NCT03400696|Experimental|Randomized- Higher fiber diet|
11197644|NCT03400696|Experimental|Randomized- Exercise focused|
11197645|NCT03400696|Experimental|Participant chooses- Lower carbohydrate diet|
11197646|NCT03400696|Experimental|Participant chooses- Higher fiber diet|
11197647|NCT03400696|Experimental|Participant chooses- Exercise focused|
11197648|NCT03400683|Active Comparator|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
11197649|NCT03400683|Active Comparator|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
11197650|NCT03400683|Active Comparator|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
11197651|NCT03400670|Active Comparator|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
11197652|NCT03400670|Active Comparator|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
11197653|NCT03400657||fully implemented to the MDT decision|group of patients fully implemented to the MDT decision
11197654|NCT03400657||not completly implemented to the MDT-decision|group of patients not completly implemented to the MDT decision
11197655|NCT03400657||not implemented to the MDT decision|group of patients not implemented to the MDT decision
11197656|NCT03400644|Active Comparator|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
11197659|NCT03400631|Experimental|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
11197660|NCT03400618|Experimental|Moderate carbohydrate diet|A healthy diet containing 30 E % carbohydrates
11197661|NCT03400618|Experimental|Higher carbohydrate diet|A healthy diet containing 50 E % carbohydrates
11197662|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
11197663|NCT03400592|Experimental|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
11197664|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
11197665|NCT03400566|Experimental|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
11197666|NCT03400566|Experimental|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
11197667|NCT03400566|Active Comparator|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
11197668|NCT03400566|Active Comparator|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
11197669|NCT03400553|Experimental|non-traumatic thoracic pain|Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.
11197670|NCT03400540|Experimental|Group A|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~squeeze the pelvic floor muscles
~squeeze and lift the pelvic floor muscles as if stopping the flow of urine
~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.
~contract all of the above together"
11197671|NCT03400540|Experimental|Group B|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:
~squeeze the pelvic floor muscles
~squeeze the anus
~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.
~contract all of the above together"
11197672|NCT03400527|Experimental|Exercise|Participant will be pedaling a stationary exercise bicycle
11197673|NCT03400501|Experimental|subjects receiving insulin degludec|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin degludec injections.
11197674|NCT03400501|Active Comparator|Subjects receiving insulin glargine|Youth aged 8-18 years with T1D whose diabetes is poorly-controlled (A1c ≥8.5%) will receive insulin glargine injections.
11197675|NCT03400488|Experimental|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
11197676|NCT03400488|Placebo Comparator|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
11197677|NCT03400475|Experimental|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
11197678|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
11197679|NCT03400462|Experimental|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
11197680|NCT03400462|Experimental|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:
~Nimesulide 2*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
11197681|NCT03400462|Active Comparator|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.
~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
11197682|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
11197683|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
11197684|NCT03400423|Experimental|Non-caffeine exercise|Exercise cognition score
11197685|NCT03400423|Active Comparator|Non-caffeine cognition|Caffeine cognition score
11197686|NCT03400423|Experimental|Caffeine consumption exercise|Exercise cognition score
11197687|NCT03400423|Active Comparator|Caffeine consumption cognition|Caffeine cognition score
11197688|NCT03400423|Experimental|Deprived Caffeine consumers exercise|Exercise cognition score
11197689|NCT03400423|Active Comparator|Deprived caffeine consumers cognition|Caffeine administration cognition score
11197690|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.
~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
11197726|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
11197691|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.
~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
11197692|NCT03400397||Intervention|Treatment with the Cool Kids programme. The Cool Kids programme is a manualised cognitive behavioural treatment programme for children with anxiety disorders.
11197693|NCT03400384|Experimental|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
11197694|NCT03400384|No Intervention|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
11197695|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
11197696|NCT03400371||Controls|People without a lifetime history of seizures.
11197697|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
11197698|NCT03400332|Experimental|Dose Finding|BMS-986253 administered in combination with Nivolumab
11197699|NCT03400332|Experimental|Dose Expansion|BMS-986253 administered in combination with Nivolumab
11197700|NCT03400319||Thoracic Aortic Aneurysm|Patients with Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm.
11197701|NCT03400319||No Thoracic Aortic Aneurysm|Patients without Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva <39mm, or ascending aorta <42mm. Men: at the level of the sinus of valsalva <44mm, or ascending aorta <46mm.
11197702|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
11197703|NCT03400306|Experimental|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
11197704|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
11197705|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
11197706|NCT03400280|Experimental|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
11197707|NCT03400280|No Intervention|Current practice|Postoperative care according to current usual practice.
11197708|NCT03400267|Active Comparator|paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
11197709|NCT03400267|Active Comparator|fentanyl|
11197710|NCT03400254|Experimental|Phase II: Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
11197711|NCT03400254|Experimental|Phase II: Arm B|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
11197712|NCT03400254|Experimental|Phase II: Arm C|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
11197713|NCT03400254|Experimental|Phase II: Arm D|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
11197714|NCT03400254|Experimental|Phase Ib Arm|Patients will receive HCQ, 600 mg BID, and GED, administered weekly as an intravenous dose of 150 mg, for 6 weeks.
11197715|NCT03400241|Experimental|Tiotropium Easyhaler Product A|tiotropium bromide monohydrate 2 inhalations as a single dose
11197716|NCT03400241|Experimental|Tiotropium Easyhaler Product B|tiotropium bromide monohydrate 2 inhalations as a single dose
11197717|NCT03400241|Experimental|Tiotropium Easyhaler Product C|tiotropium bromide monohydrate 2 inhalations as a single dose
11197718|NCT03400241|Active Comparator|Spiriva HandiHaler|tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler
11197719|NCT03400228|Experimental|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
11197720|NCT03400228|Placebo Comparator|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
11197721|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
11197722|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
11197723|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
11197724|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
11197725|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
11199729|NCT03386188|Experimental|Healthy arm|posterior parietal cortex (PPC) transitory inactivation
11197729|NCT03400176|Experimental|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
11197730|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
11197731|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
11197732|NCT03400150|Experimental|ProSpace group|Marking + ProSpace implantation + IMRT
11197733|NCT03400150|Sham Comparator|Control group|Marking + IMRT
11197734|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
11197735|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
11197736|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
11197737|NCT03400124|Active Comparator|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
11197738|NCT03400124|Active Comparator|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
11197739|NCT03400111|Experimental|Low-level laser therapy|Patients upper and lower jaws will be irradiated with low-level laser therapy at specific points on the alveolus around the teeth from the vestibular and lingual sides. This group of patients will be followed up till the end of treatment.
11197740|NCT03400111|Experimental|Panadol-extra|Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
11197741|NCT03400111|No Intervention|Traditional Treatment|Patients will not undergo any actual irradiation therapy or take any active tablets during orthodontic treatment.
11197742|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
11197743|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
11197744|NCT03400072|Experimental|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
11197745|NCT03400072|Experimental|Supervised APA program|usual care plus a 6-month supervised APA program
11197746|NCT03400072|No Intervention|Usual care|Usual care
11197747|NCT03400059|Experimental|Active Treatment|
11197748|NCT03400059|Sham Comparator|Sham Treatment|
11197749|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
11197750|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
11197751|NCT03400020|Experimental|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
11197752|NCT03400020|Placebo Comparator|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
11197753|NCT03400007||Prolapse surgery|
11197754|NCT03399994|Experimental|ABLUMINUS DES+|device implantation during coronary angioplasty
11197755|NCT03399994|Active Comparator|Everolimus-eluting DES|device implantation during coronary angioplasty
11197756|NCT03399981||Tysabri (TOUCH Cohort)|Patients from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
11197757|NCT03399981||Tysabri (EU MS Cohort)|Patients from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
11197758|NCT03399968|Experimental|ESWT|Application of shockwaves non-invasively at the level of injury
11197759|NCT03399968|Placebo Comparator|Placebo ESWT|Positioning of the therapy head at the injury level without application of shockwaves
11197760|NCT03399955|Experimental|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
11197761|NCT03399955|Experimental|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
11197762|NCT03399942|Experimental|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
11197763|NCT03399942|Experimental|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
11197764|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
11197765|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
11197766|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
11197767|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
11197768|NCT03399916|Experimental|Prompt|"An email based prompt was sent- containing either a stand or move message. Exploratory variations of the prompt were designed to include the addition of a goal e.g., stand for the next 5-minutes, and/or employer support e.g., PTS says stand for the next 5 minutes."
11197769|NCT03399916|No Intervention|No Prompt|Prompt delivery was sequentially randomized to be sent (ST) or not sent (NST) to all participants (probability of 0.5), at eight decision points per day (between 9am and 5pm), to achieve a total of 3200 randomizations across participants (160 per participant). Therefore 50% of the time, no prompt was sent.
11197770|NCT03399903|Experimental|Pentasa|40 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks
11199800|NCT03385655|Experimental|Durvalumab and Tremelimumab immunotherapy|
11197772|NCT03399890||Group S|Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent. Neurological physical exam time was recorded.
11197773|NCT03399890||Group N|"Group N: Group Neostigmine
~Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded."
11197774|NCT03399877|Active Comparator|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
11197775|NCT03399877|Active Comparator|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
11197776|NCT03399877|Experimental|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
11197777|NCT03399864|Experimental|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
11197778|NCT03399864|Other|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
11197779|NCT03399851|Active Comparator|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
11197780|NCT03399851|Active Comparator|Watchman/FLX|Left atrial appendage closure (LAAC) with Watchman/FLX implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
11197781|NCT03399838|Experimental|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
11197782|NCT03399838|Active Comparator|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
11197783|NCT03399825||Healthy controls|Children without eye disease
11197784|NCT03399825||Retinopathy of prematurity (ROP)|Previously preterm children with a history of ROP
11197785|NCT03399825||Diabetic retinopathy|Children with diabetes
11197786|NCT03399812|Experimental|Whey protein isolate|
11197787|NCT03399812|Active Comparator|Pea protein isolate|
11197788|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Intravenous (IV)|Participants will receive IV infusion of Talquetamab at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
11197789|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Subcutaneous (SC)|Participants will receive Talquetamab SC. The dose levels will be selected to identify safe and tolerable putative RP2D(s).
11197790|NCT03399799|Experimental|Part 2: Dose Expansion (Talquetamab)|Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D[s]) as determined in Part 1.
11197791|NCT03399786|Experimental|evinacumab|
11197792|NCT03399786|Experimental|Placebo|
11197793|NCT03399773|Experimental|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A (High Dose TBI) or regimen B (Intermediate Dose).
~REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.
~REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 and -4, and TBI on days -2 and -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0."
11197794|NCT03399760|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
11197795|NCT03399760|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
11197796|NCT03399747|Experimental|Abb-R-CHOP|
11197797|NCT03399734|Experimental|Treatment A|4 milligrams (mg) perampanel tablet
11197798|NCT03399734|Experimental|Treatment B|4 mg perampanel fine granules
11197799|NCT03399721|Active Comparator|Chordate S101 Active|Active treatment With Device Chordate S101
11197800|NCT03399721|Placebo Comparator|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
11197801|NCT03399695|Active Comparator|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
11197802|NCT03399695|Experimental|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
11197803|NCT03399682||Incidence of Post Cystography Urinary Tract Infections|all children less than 16 years having cystography
11197804|NCT03399669|Experimental|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
11197805|NCT03399656|Placebo Comparator|Placebo|4 placebo tablets
11197806|NCT03399656|Active Comparator|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
11197807|NCT03399656|Active Comparator|High Dose Avmacol|4 Avmacol tablets
11197808|NCT03399630|Active Comparator|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
11199801|NCT03385655|Experimental|Carboplatin platinum based chemotherapy|
11197809|NCT03399630|Placebo Comparator|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
11197810|NCT03399617|Active Comparator|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
11197811|NCT03399617|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
11197812|NCT03399617|Experimental|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
11197813|NCT03399604|Experimental|LIQ861 Inhaled Treprostinil|"LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.
~LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients."
11197814|NCT03399578|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 MERS, 5 x 10^9 vp through intramuscular route.
11197815|NCT03399578|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp through intramuscular route.
11197816|NCT03399578|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 MERS, 5 x 10^10 vp through intramuscular route.
11197817|NCT03399578|Experimental|Group 4|Group 4 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10^10 vp at week 26. Both administrations will be given through intramuscular route.
11197818|NCT03399578|Experimental|Group 5|Group 5 volunteers (n=6-12) will be administered ChAdOx1 MERS, 2.5 x 10^10 vp at week 0, followed by ChAdOx1 MERS, 2.5 x 10^10 vp at week 4. Both administrations will be given through intramuscular route.
11197819|NCT03399552|Experimental|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
11197820|NCT03399539|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11197821|NCT03399526|Experimental|Mapracorat|10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
11197822|NCT03399526|Active Comparator|Prednicarbate|10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
11197823|NCT03399526|Active Comparator|Clobetasol|10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
11197824|NCT03399526|Active Comparator|Calcipotriene|10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
11197825|NCT03399526|Active Comparator|Calcipotriene/Betamethasone dipropionate|10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
11197826|NCT03399513|Experimental|Ibrutinib and R-CHOEP chemotherapy|"All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (dose capped at 2 mg), etoposide 300 mg/m², prednisolone 500 mg.
~In addition, ibrutinib capsules will be administered orally once daily at a dose of 560 mg (4 x 140 mg hard capsules) for 112 days."
11197827|NCT03399500|Active Comparator|Usual Case Management (UCM)|Group receives standard case management at the shelter
11197828|NCT03399500|Experimental|UCM + Smartphone|Group receives standard case management and an unlimited smartphone
11197829|NCT03399500|Experimental|Smartphone Based Case Management (SPCM)|Group receives standard case management and an unlimited smartphone with the SPCM app
11197866|NCT03399266|No Intervention|Expectant management|Women in the expectant management group will be transferred to the Ob/Gyn ward for hospitalization and conservative management until spontaneous labor ensues.
11197867|NCT03399253|Active Comparator|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
11197830|NCT03399487|Experimental|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.
~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.
~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
11197831|NCT03399474|Active Comparator|Lidocaine only|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.
11197832|NCT03399474|Experimental|0.5 ug/kg dexmedetomidine|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
11197833|NCT03399474|Experimental|0.25 ug/kg dexmedetomidine|1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.25 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min. for intravenous regional anesthesia.
11197834|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
11197835|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
11197836|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
11197837|NCT03399448|Experimental|Multiple Myeloma (MM)|
11197838|NCT03399448|Experimental|Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL)|
11197839|NCT03399448|Experimental|Melanoma|Not Recruiting at the UPenn Site
11197840|NCT03399435|Experimental|Part A|8 cohorts are planned to be treated.
11197841|NCT03399435|Experimental|Part B|Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.
11197842|NCT03399435|Experimental|Part C|Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
11197843|NCT03399422|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
11197844|NCT03399422|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
11197845|NCT03399409|Experimental|Motivational Interviewing|
11197846|NCT03399409|Active Comparator|Anti-inflammatory information program|
11197847|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
11197848|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
11197849|NCT03399383|Other|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
11197850|NCT03399370|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
11197851|NCT03399370|Placebo Comparator|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
11197852|NCT03399357||≥ 65 Years old|Healthy community-dwelling elderly (men and women) age 65 and above who are eligible for influenza vaccine and fulfil inclusion and exclusion criteria
11197853|NCT03399344|Other|DW-MRI|Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
11197854|NCT03399331|Experimental|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
11197855|NCT03399331|Experimental|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
11197856|NCT03399331|Placebo Comparator|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
11197857|NCT03399318|Experimental|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30mg/kg load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
11197858|NCT03399318|Placebo Comparator|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
11197859|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
11197860|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
11197861|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
11197862|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
11197863|NCT03399279|Experimental|Open flap debridement & perforated&Nano|Perforated collagen membrane and nano-hydroxyapatite and open flap debridement
11197864|NCT03399279|Active Comparator|Open flap debridment &Occlusive&Nano|Occlusive membrane and nano-hydroxyapatite and open flap debridement
11197865|NCT03399266|Experimental|Double balloon catheter for induction of labor|in this group a trans-cervical double balloon catheter will be inserted. Following device insertion, 20 minutes of external monitoring is performed. The patient will be transferred to the Ob/Gyn ward for hospitalization. 12 hours after insertion of the device the balloons are deflated and the device removed. At this stage the patient is assessed for a second Bishop score and expectant management is resuming.
11197868|NCT03399253|Experimental|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
11197869|NCT03399240|Experimental|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
11197870|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
11197871|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
11197872|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 1|IV injection, 0.27 mg/kg
11197873|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 2|IV injection, 0.54 mg/kg
11197874|NCT03399201|Active Comparator|General Anesthesia|Standard General Anesthesia will be applied.The change of the pulmonary functions will be evaluated via spirometer.
11197875|NCT03399201|Active Comparator|Neuraxial Anesthesia|Neuraxial anesthesia will be applied. The change of the pulmonary functions will be evaluated via spirometer.
11197876|NCT03399188|Experimental|FMT group|Group who received fecal microbiome transplantation
11197877|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
11197878|NCT03399162|Experimental|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
11197879|NCT03399162|Active Comparator|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
11197880|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
11197881|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.
~Time period: From March 2017 to end of study"
11197882|NCT03399136|Experimental|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
11197883|NCT03399136|Experimental|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
11197884|NCT03399123|Experimental|Low tidal volume group|Use a low tidal volume(6'8ml/kg) ventilation mode during liver segmentation。
11197885|NCT03399123|Active Comparator|Standard tidal volume group|Use a standard tidal volume(10'12ml/kg) ventilation mode during operation.
11197886|NCT03399110|Experimental|XELOX for 4 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease
11197887|NCT03399110|Active Comparator|XELOX for 6 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
11197888|NCT03399097||non-obese|non-obese
11197889|NCT03399097||obese|obese
11197890|NCT03399097||previously obese|previously obese
11197891|NCT03399084|Experimental|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
11197892|NCT03399084|Active Comparator|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
11197893|NCT03399071|Experimental|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.
~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
11197894|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
11197895|NCT03399058|Other|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2). The Hearth messages are contextualized messages on child feeding practices that women in the community have found helpful to successfully prevent child malnutrition. This program will be delivered through in person community meetings.
11197896|NCT03399058|Other|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a similar program as group 2 with contextualized child feeding messages (PDH lite program) and receive follow-up through mobile support phone calls (Group 3).
11197897|NCT03399045|Experimental|9-minute withdrawal group|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.
11198108|NCT03397732||Aorta stentgraft|Patients scheduled for elective aorta stentgraft implantation by vascular surgeons and consented to participate in the study.
11197898|NCT03399045|Active Comparator|6-minute withdrawal group|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.
11197899|NCT03399032||Caspofungin|Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
11197900|NCT03399019|Experimental|Dexmedetomidine|"Dexmedetomidine
~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr
~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
11197901|NCT03399019|Active Comparator|Propofol|"Propofol
~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
11197902|NCT03399019|Active Comparator|Midazolam|"Midazolam
~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr
~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
11197903|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
11197904|NCT03399006||Normal pregnancy|women with normal blood presure
11197905|NCT03398993|Active Comparator|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.
~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
11197906|NCT03398993|Active Comparator|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
11197907|NCT03398980||survivors treated with CRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with convention radiotherapy (CRT).
11197908|NCT03398980||survivors treated with IMRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with intensity-modulated radiotherapy (IMRT).
11197909|NCT03398941|Experimental|Combined group|
11197910|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
11197911|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
11197912|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
11197913|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
11197914|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
11197915|NCT03398902|Experimental|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
11197916|NCT03398902|Active Comparator|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
11197917|NCT03398889||Unexplained Atherosclerosis phenotype|Residual score in linear regression >2
11197918|NCT03398889||Explained Atherosclerosis phenotype|Residual score in linear regression <-2, <2
11197919|NCT03398889||Protected Atherosclerosis phenotype|Residual score <-2
11197920|NCT03398876|Experimental|Part 1; Treatment Sequence ABDC|Participants will receive Treatment A (one spray of oromucosal nicotine spray [ONS]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette [10 puffs]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
11197921|NCT03398876|Experimental|Part 1; Treatment Sequence BCAD|Participants will receive Treatment B at Visit 1, then Treatment C at Visit 2, then Treatment A at Visit 3 followed by Treatment D at Visit 4. The visits will be separated by a period of at least 7 calendar days.
11197922|NCT03398876|Experimental|Part 1; Treatment Sequence CDBA|Participants will receive Treatment C at Visit 1, then Treatment D at Visit 2, then Treatment B at Visit 3 followed by Treatment A at Visit 4. The visits will be separated by a period of at least 7 calendar days. The visits will be separated by a period of at least 7 calendar days.
11197923|NCT03398876|Experimental|Part 1; Treatment Sequence DACB|Participants will receive Treatment D at Visit 1, then Treatment A at Visit 2, then Treatment C at Visit 3 followed by Treatment B at Visit 4. The visits will be separated by a period of at least 7 calendar days.
11197924|NCT03398876|Experimental|Part 2; Treatment Sequence EF|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment E (two consecutive sprays of ONS once every 30 minutes until 11.5 hours) at Visit 5, followed by Treatment F (two consecutive sprays of ONS once every 1 hour until 11 hours) at Visit 6. The visits will be separated by a period of at least 7 calendar days.
11197925|NCT03398876|Experimental|Part 2; Treatment Sequence FE|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment F at Visit 5 followed by Treatment E at Visit 6. The visits will be separated by a period of at least 7 calendar days.
11197926|NCT03398863|Active Comparator|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
11241238|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (82mg)|
11197927|NCT03398863|No Intervention|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
11197928|NCT03398837|Experimental|Cohort 1|Lenabasum 5 mg BID
11197929|NCT03398837|Experimental|Cohort 2|Lenabasum 20 mg BID
11197930|NCT03398837|Placebo Comparator|Cohort 3|Placebo BID
11197931|NCT03398824|Experimental|Treatment arm|Receive metformin HCl
11197932|NCT03398811|Other|"Group I the depot medroxy-progesterone acetate group"|where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
11197933|NCT03398811|Other|"Group II Implanon group"|where they will have Implanon (etonogestrel implant) 68 mg implant
11197934|NCT03398811|Other|group III (Microlut group)|where they are using Microlut pills (0.5 mg levonorgestrel) one pill every day for 35 days without pill-free interval.
11197935|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
11197936|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
11197937|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
11197938|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
11197939|NCT03398785|Experimental|Intevention|Adrenal Artery Ablation
11197940|NCT03398785|No Intervention|Control|No intervention, but treated with standard anti-hypertensive drigs
11197941|NCT03398772|Experimental|Experiment|Comprehensive Health Coaching Program
11197942|NCT03398772|No Intervention|Control|Guideline-based usual care
11197943|NCT03398759|Experimental|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
11197944|NCT03398759|Placebo Comparator|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
11197945|NCT03398746|Experimental|LOOP Technique|Placement of subcutaneous loop drain
11197946|NCT03398746|Active Comparator|Incision and Drainage|Standard Incision and Drainage Technique
11197947|NCT03398733|Other|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively.
11197948|NCT03398720|Experimental|Cohort 1|One participant will receive HTI-1066 at the starting dose.
11197949|NCT03398720|Experimental|Cohort 2|Participants will receive HTI-1066 at dose level 2.
11197950|NCT03398720|Experimental|Cohort 3|Participants will receive HTI-1066 at dose level 3.
11197951|NCT03398720|Experimental|Cohort 4|Participants will receive HTI-1066 at dose level 4.
11197952|NCT03398694|Experimental|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-3 days prior to surgical resection.
11197953|NCT03398681|Active Comparator|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
11197954|NCT03398681|Placebo Comparator|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
11197955|NCT03398668|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
11197956|NCT03398668|Sham Comparator|Sham Comparator: Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
11197957|NCT03398655|Experimental|Arm 1|VB-111 + Paclitaxel
11197958|NCT03398655|Active Comparator|Arm 2|Placebo + Paclitaxel
11197959|NCT03398642|Experimental|French Lifestyle Redesign|16 older adults, 10 without and 6 with disabilities, participated to weekly 2-hour group sessions, including outings, and monthly 1-hour individual sessions led by a occupational therapist over 6-month period and promoting healthy lifestyle and involvement in meaningful activities.
11197960|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)>95th percentile).
11197961|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
11197962|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
11197963|NCT03398603||Group 1|25 women with age of 18-25 years
11197964|NCT03398603||Group 2|25 women with age of 26-40 years
11197965|NCT03398590|Experimental|mHealth Intervention for Older Adults|"Pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.
~This is a one Group Pretest-Posttest Designed study. Ten participants will be recruited from Joslin Diabetes Center, Boston, MA. They will receive a 2-month, self-regulation theory-based weight loss intervention (five 60-minute, biweekly group sessions) and will be provided with a technology toolkit for self-monitoring including an (1) iPhone Plus, (2) the Lose It! app for self-monitoring of dietary intake, (3) Fitbit for self-monitoring of physical activity, (4) Bluetooth-enabled scale for daily weight, and (5) Bluetooth-enabled blood glucose monitor for testing blood glucose levels."
11197966|NCT03398577|Experimental|Intervention group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Intervention group will receive Dapagliflozin 10 mg in addition to oral anti-diabetic medication administered prior to study enrollment.
11197967|NCT03398577|Placebo Comparator|Control group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Control group will receive placebo in addition to oral anti-diabetic medication administered prior to study enrollment.
11197968|NCT03398564|Placebo Comparator|Group I (Control)|ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline
11197969|NCT03398564|Active Comparator|Group II (ESP)|ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%
11197970|NCT03398564|Active Comparator|Group III(OSTAP)|Ultrasound-guided bilateral oblique subcostal TAP block
11197971|NCT03398538|Experimental|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
11197972|NCT03398538|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
11197973|NCT03398525|Active Comparator|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
11197974|NCT03398525|Experimental|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
11197975|NCT03398512|Experimental|Experimental|HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
11197976|NCT03398499|Experimental|Magnetoledotherapy|Active ELF EMF Participants will receive active transcranial low frequency elec-tromagnetic field and magnetic induction (ELF EMF) and high energy LED light were used stimulation,Using the Viofor JPS device (Med & Live)
11197977|NCT03398486|Experimental|Kinesiotaping|Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.
11197978|NCT03398486|Experimental|inactivation of trigger points (TrP)|Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break
11197979|NCT03398473|Experimental|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
11197980|NCT03398473|Experimental|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
11197981|NCT03398460|Other|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
11197982|NCT03398434|Experimental|MAA868 low dose regimen|patients receive dose monthly.
11197983|NCT03398434|Experimental|MAA868 middle dose regimen|patients receive dose monthly.
11197984|NCT03398434|Experimental|MAA868 high dose regimen|patients receive dose monthly.
11197985|NCT03398434|Active Comparator|Apixaban|Apixaban 5 mg b.i.d
11197986|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
11197987|NCT03398408|Experimental|Intervention|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.
~Participants in the intervention group will then be provided with the Lumosity cognitive flexibility training module and complete daily training for a total of five weeks. 1-3 days after completion of their training, all patients will be invited to complete the computerized versions of the TMT A and B, Color Match, and NCPT tests again on their personal computers."
11197988|NCT03398408|No Intervention|Control|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.
~Patients in the control group will complete all tests upon enrollment and approximately five weeks after their initial testing, but will not participate in training."
11197989|NCT03398395|Active Comparator|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
11197990|NCT03398395|Active Comparator|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
11197991|NCT03398382|Placebo Comparator|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
11197992|NCT03398382|Placebo Comparator|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
11197993|NCT03398382|Placebo Comparator|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
11197994|NCT03398382|Placebo Comparator|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.
~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
11197995|NCT03398369|Experimental|Intervention|CMR-Guided CRT
11197996|NCT03398369|No Intervention|Control|Standard CRT
11197997|NCT03398356|Other|group A|metformin dose 3 x 500 mg
11197998|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
11197999|NCT03398356|No Intervention|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
11198000|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
11198001|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
11198002|NCT03398317|Experimental|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
11198003|NCT03398317|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
11198004|NCT03398304|Experimental|Graded Exercise|Volunteers will participate in 3 study visits. The study visits will consist either of 20 minutes of walking, 20 minutes of running or 20 minutes of sitting. At the beginning of each study visit, prior to any exercise, a 4.5mL blood sample will be collected. The participant will then complete either 20 minutes of walking, running or sitting and will then have a 4.5mL blood draw taken from a new site.
11198005|NCT03398304|Experimental|Marathon Participation|On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
11198006|NCT03398291|Active Comparator|Standard treatment|Patients continue to receive standard chemotherapy.
11198007|NCT03398291|Experimental|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
11198008|NCT03398278|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
11198009|NCT03398278|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
11198010|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
11198011|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
11198012|NCT03398252|Experimental|Doxazosin XL|Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
11198013|NCT03398252|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
11198014|NCT03398239|Active Comparator|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
11198015|NCT03398239|Experimental|AVAPS|Non-invasive Ventilation with AVAPS mode
11198016|NCT03398226||Control group|
11198017|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
11198018|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
11198019|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
11198020|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
11198021|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
11198022|NCT03398200|Experimental|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
11198023|NCT03398200|Active Comparator|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
11198024|NCT03398174|Experimental|Motor Control Exercise Plus Patient Education|"Participants will receive a total of 12 sessions (2 sessions per week) of exercise program consisting of motor control training and group patient education session once a week (6 sessions) all over 6-weeks.
~The motor control training will be aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.
~The patient education program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.
~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
11198025|NCT03398174|Experimental|Motor Control Exercise|"Participants will receive the same motor control exercise program described in the patient education and motor control exercise group.
~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
11198026|NCT03398174|Experimental|Patient Education|"Participants will receive the same patient education program described in the motor control exercise plus patient education group.
~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
11198027|NCT03398161|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
11198028|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
11198029|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
11198030|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 3|Participants randomized to receive risankizumab dose 3 administered by intravenous (IV) infusion.
11198031|NCT03398148|Placebo Comparator|Substudy 1, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
11198032|NCT03398148|Experimental|Substudy 1, Induction 1: Open-label Risankizumab Dose 1|Participants receive risankizumab dose 1 administered by intravenous (IV) infusion.
11198033|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
11198034|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
11198211|NCT03396965|Experimental|Mini-c-arm|Fluoroscopically aided reductions
11198212|NCT03396965|No Intervention|Standard|
11198035|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
11198036|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
11198037|NCT03398148|Experimental|Substudy 2, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
11198038|NCT03398148|Placebo Comparator|Substudy 2, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
11198039|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
11198040|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
11198041|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
11198042|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
11198043|NCT03398135|Placebo Comparator|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
11198044|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
11198045|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
11198046|NCT03398135|Experimental|Substudy 2: Open-label (OL) Clinical Assessment Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
11198047|NCT03398135|Experimental|Substudy 2: OL Therapeutic Drug Monitoring Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
11198048|NCT03398135|Experimental|Substudy 3: OL Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
11198049|NCT03398122|Experimental|Apatinib combined with TACE|patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
11198050|NCT03398122|Placebo Comparator|chemoemtranscatherer arterial bolization|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
11198051|NCT03398109|Experimental|Customized toric IOL|Customized toric IOL for post-Dalk atigmatism in cataract patients
11198052|NCT03398096|Experimental|Cardiac shock wave therapy (CSWT) group|The CWST group were performed with a CSWT equipment (Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan with respect to the shockwave output and the number of shots implemented to each spot and the protocol developed by the University of Essen, Germany.
11198053|NCT03398096|No Intervention|Control group|No CWST treatment.
11198054|NCT03398083|Active Comparator|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
11198055|NCT03398083|Active Comparator|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
11198056|NCT03398083|Active Comparator|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
11198057|NCT03398083|Active Comparator|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
11198058|NCT03398083|Active Comparator|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
11198059|NCT03398083|Placebo Comparator|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
11198060|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.
~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.
~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:
~Delivery of a positive rule-in diagnosis of functional neurological disorder
~Individuals are provided with educational materials on functional neurological disorders
~Referred to physical therapy and/or occupational therapy as clinically indicated
~FND related cognitive behavioral therapy (CBT) referral when appropriate
~Psychotropic medication management based on standard psychiatric care"
11198061|NCT03398057|Experimental|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
11198062|NCT03398057|Placebo Comparator|Control group|Placebo health education.
11198063|NCT03398044|Experimental|Dexamethasone|Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
11198064|NCT03398044|Placebo Comparator|Placebo|Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
11198065|NCT03398031|Active Comparator|Magnesium supplement|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
11198066|NCT03398031|Placebo Comparator|placebo|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
11198067|NCT03398018|Experimental|Treatment|Treated with repository corticotropin injection
11198068|NCT03398005|Experimental|CaPre|
11198069|NCT03398005|Placebo Comparator|Placebo|
11198070|NCT03397992|Active Comparator|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
11198071|NCT03397992|Active Comparator|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
11198072|NCT03397979|Active Comparator|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
11198073|NCT03397979|Active Comparator|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
11198074|NCT03397966|Experimental|BNP infusion|Subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32)) for 240 minutes.
11198075|NCT03397966|Placebo Comparator|saline infusion (control)|Subjects will receive an IV infusion of normal saline for 240 minutes. The volume of saline delivered will be equivalent to the volume of saline that the subject receives during the BNP infusion visit.
11198076|NCT03397953|Experimental|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
11198077|NCT03397940||Year Round School|Children attending year round school
11198078|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
11198079|NCT03397927|Experimental|orthosis|
11198080|NCT03397914|Experimental|Group A Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 2.5 mg/kg of colistimethate sodium intravenous as loading dose followed by 1.25 mg/kg every 12 hours as maintenance dose
11198081|NCT03397914|Experimental|Group B Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 5 mg/kg of colistimethate sodium intravenous as loading dose followed by 2.5 mg/kg every 12 hours as maintenance dose
11198082|NCT03397901|Experimental|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
11198083|NCT03397888|Experimental|Cohort 1|Mild Impairment, Child-Pugh Category A
11198084|NCT03397888|Experimental|Cohort 2|Moderate Impairment, Child-Pugh Category B
11198085|NCT03397888|Experimental|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 & 2 for age, sex and weight.
11198086|NCT03397875|Active Comparator|Zinc oxide based sealer|After root canal treatment obturation with gutta percha will be done using zinc oxide based sealer.
11198087|NCT03397875|Experimental|Epoxy resin based sealer|After root canal treatment obturation with gutta percha will be done using epoxy resin based sealer.
11198088|NCT03397875|Experimental|Bioactive silicone based sealer|After root canal treatment obturation with gutta percha will be done using bioactive silicone based sealer.
11198089|NCT03397862|Experimental|Corplex Donepezil TDS 5 mg/day|Subjects will receive Corplex Donepezil TDS 5 mg/day during Induction, Challenge, and Re-Challenge phase.
11198090|NCT03397862|Placebo Comparator|Vehicle TDS|Subjects will receive Vehicle TDS during Induction, Challenge, and Re-Challenge phase.
11198091|NCT03397849|Active Comparator|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
11198092|NCT03397849|No Intervention|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
11198093|NCT03397836|Experimental|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
11198094|NCT03397836|Active Comparator|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
11198095|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
11198096|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
11198097|NCT03397823||healthy control|subjects matched in gender and age without cancer
11198098|NCT03397810|Experimental|Singe arm|Subjects will receive a low dose radiotherapy focused to the heart
11198099|NCT03397797||Group with muscle relaxant|Rocuronium is used during the operation to maintain moderate relaxation.
11198100|NCT03397797||Group without muscle relaxant|Rocuronium is not used during the operation for the eletrophysiological monitoring.
11198101|NCT03397784||fluid responders|Patients whose stroke volume index increase by ≥15% in response to a 500-ml fluid bolus was defined as fluid responders.
11198102|NCT03397784||fluid non-responders|Patients whose stroke volume index increase by <15% in response to a 500-ml fluid bolus was defined as fluid non-responders.
11198103|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
11198104|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
11198105|NCT03397758|Experimental|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
11198106|NCT03397745|Other|BIS group|Patients who received the esophageal surgery
11198107|NCT03397732||Aorto-bifemoral bypass|Patients scheduled for elective aorto-bifemoral bypass surgery by vascular surgeons and consented to participate in the study.
11198109|NCT03397719|Active Comparator|Control Group|This group will receive treatment as usual. Each participant will receive three hours of in-vivo parent coaching per week for 6 months.
11198110|NCT03397719|Experimental|Treatment Condition|This group will receive an additional component which will involve videotaping parent/child interactions at home for thirty minutes a week. Each week, the therapist will select sections of the video to review with the parent during one of the parent coaching sessions.
11198111|NCT03397706|Experimental|Phase 1b Dose Escalation|"VRx-3996 (cohort 1) and valganciclovir
~VRx-3996 (cohort 2) and valganciclovir
~VRx-3996 (cohort 3) and valganciclovir
~VRx-3996 (cohort 4) and valganciclovir
~VRx-3996 (cohort 5) and valganciclovir"
11198112|NCT03397706|Experimental|Phase 2 Dose Expansion|VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
11198113|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
11198114|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
11198115|NCT03397693||3|Control fertile women with no treatment given.
11198116|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
11198117|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
11198118|NCT03397667|Other|Control|Primary Care
11198119|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
11198120|NCT03397654|Experimental|TACE followed by pembrolizumab|Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year
11198121|NCT03397641|Active Comparator|Active|x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion. Doses of HBI-3000 (Cohorts A to G) may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 µg.h/mL and Cmax of 20 µg/mL (based on the NOAEL) in both 14-day repeat-dose toxicology species rat and minipig) and the expected therapeutic dose.
11198122|NCT03397641|Placebo Comparator|Placebo|Matching placebo for x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion.
11198123|NCT03397628|No Intervention|Control|
11198124|NCT03397628|Experimental|Intervention|
11198125|NCT03397615|Active Comparator|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
11198126|NCT03397615|No Intervention|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
11198127|NCT03397602|No Intervention|standard care|Participants do not participate in a on site structured exercise training program.
11198128|NCT03397602|Experimental|standard care + MICE|standard care + moderate-intensity continuous exercise training (MICE)
11198129|NCT03397602|Experimental|standard care + HIIT|standard care + high-intensity interval training (HIIT)
11198130|NCT03397589|Experimental|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
11198131|NCT03397589|No Intervention|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
11198132|NCT03397576|Experimental|ATHENA|Subjects in the experimental arm will participate in monthly group medication adherence counseling sessions within prison led by a nurse and peer educator. After prison release, subjects in the experimental group will participate in four home visits during which intervention staff (nurses and peer educators working in teams) will deliver individualized medication adherence counseling based on the Freirian educational model.
11198133|NCT03397576|No Intervention|Control|Subjects in the control group will receive standard care, which includes a referral for HIV care and ART if prescribed ART within prison.
11198134|NCT03397563|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)
11198135|NCT03397563|Sham Comparator|Sham-CPAP treatment|sham Continuous Positive Airway Pressure (sham-CPAP)
11198136|NCT03397537|Other|the postmenopausal|2.5 mg letrozole every day for six months
11198137|NCT03397537|Experimental|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
11198138|NCT03397524|Experimental|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
11198139|NCT03397524|No Intervention|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
11198140|NCT03397511|Experimental|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
11198141|NCT03397498|Experimental|Computerized cognitive training|Received the Computerized cognitive training program, CogniFit™
11198142|NCT03397498|Active Comparator|Control-games|Received the Computerized games program
11198143|NCT03397485|Experimental|Growing Milk|"Experimental Fortified milk has energy from fatty acids, protein and carbohydrates. This milk has probiotics and essential micronutrients such as Zn, Fe, vitamins ( A, D, E, K, C and B complex), selenium and Copper among others.
~Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend."
11198144|NCT03397485|Active Comparator|Fortified Milk|Fortified milk has no energy from fatty acids nor micronutrients such as vitamin B12, Selenium and Copper. This milk was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend.
11198145|NCT03397472|Experimental|treatment group|use the sleep pillow with the magnetic field modulation treatment
11198146|NCT03397472|Placebo Comparator|placebo group|use the sleep pillow without magnetic field modulation treatment
11198147|NCT03397446|Experimental|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
11198148|NCT03397433|Experimental|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.
~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
11198149|NCT03397433|No Intervention|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
11198150|NCT03397420|Experimental|FAM-CARE|"Two facility clusters (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring"
11198151|NCT03397420|Active Comparator|Control Standard of Care|"Two clusters (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family."
11198152|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
11198153|NCT03397342|No Intervention|standard breath hold|
11198154|NCT03397342|Experimental|CPAP intervention|
11198155|NCT03397329|Active Comparator|Sequence A|
11198156|NCT03397329|Active Comparator|Sequence B|
11198157|NCT03397316|No Intervention|Marginal bone loss without grafting.|immediate implant placement in upper esthetic zone.
11198158|NCT03397316|Active Comparator|marginal bone loss with xenograft.|xenograft placement (Geistlich Bio-Oss) in immediate implant placement in upper esthetic zone between the residual labial bone and implant surface.
11198159|NCT03397303|Experimental|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
11198160|NCT03397303|Other|controls|
11198161|NCT03397290|Experimental|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
11198162|NCT03397277|Experimental|Screened positive intervention video|Safety behaviour promoting video
11198163|NCT03397277|Sham Comparator|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
11198164|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)
11198165|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)
11198166|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
11198167|NCT03397264|Experimental|Ph 2a: 2.0 mg aflibercept with highest tested or MTD OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed highest tested or MTD from Phase 1b OPT-302 intravitreal injection (0.05 mL)
11198168|NCT03397264|Sham Comparator|Ph 2a: 2.0 mg aflibercept with sham|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection
11198169|NCT03397251|Experimental|Ascyrus Medical Dissection Stent|Ascyrus Medical Dissection Stent placement
11198170|NCT03397238||Non-metastatic TC|
11198171|NCT03397238||Metastatic TC|
11198172|NCT03397238||MNG surgery|
11198173|NCT03397238||MNG RAI treatment|
11198174|NCT03397238||Healthy volunteers|
11198175|NCT03397225|Experimental|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
11198176|NCT03397225|Active Comparator|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
11198177|NCT03397225|No Intervention|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
11198178|NCT03397212|Experimental|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
11198179|NCT03397212|Sham Comparator|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
11198180|NCT03397199|Experimental|Apatinib + S-1|Apatinib + S-1
11198181|NCT03397186|Other|Basic science (trabectedin, biopsy)|Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 cycles. Beginning 1 week after completion of cycle 2 and prior to cycle 3, patients undergo a second biopsy. Patients who achieve clinical benefit (CR, PR, SD) after the first post-treatment scan and who continue trabectedin for 4 cycles undergo a third biopsy after cycle 4.
11198182|NCT03397173|Experimental|Azacitidine + Ascorbic acid|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, (allowing for weekends, and holidays) of each 28-day cycle. Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle.
11198183|NCT03397160|No Intervention|Usual care|Participants assigned to the control arm will receive usual care, including whatever information materials are provided to them by their urologist.
11198184|NCT03397160|Active Comparator|Decision Support Intervention (DSI)|"Participants assigned to the intervention will receive Decision Support Intervention in the form of a decision aid plus health coaching. The decision aid (delivered by internet and as a Portable Document Format (PDF) document) provides participants with a report on options and outcomes as described in the literature; along with more tailored risk information. The tailored risk information will include their estimated risk of harboring more aggressive prostate cancer based on their clinical/pathologic features (i.e., My Clinical Risk). The DSI was developed and piloted at UCSF according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332), and incorporates tailored risk models developed and validated."
11198185|NCT03397147|No Intervention|Usual Care|Usual Care
11198186|NCT03397147|Experimental|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
11198187|NCT03397134|Experimental|Roluperidone 64 mg|Roluperidone 64 mg for entire study
11198188|NCT03397134|Experimental|Roluperidone 32 mg|Roluperidone mg for entire study
11198189|NCT03397134|Placebo Comparator|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
11198190|NCT03397134|Placebo Comparator|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
11198191|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
11198192|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
11198193|NCT03397108||Women with IBD|This group is composed of breastfeeding women aged over 18 years and in their first 4-month postpartum period, who are diagnosed with Crohn's disease or Ulcerative Colitis.
11198194|NCT03397108||Healthy breastfeeding women|This group is composed of healthy breastfeeding women aged over 18 years and in their first 4-month postpartum period.
11198195|NCT03397095|Experimental|CSWT+BMMSCs|Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.
11198196|NCT03397095|Sham Comparator|CSWT+Sham operation|Placebo group will receive a 3-month CSWT and a sham procedure.
11198197|NCT03397082|Experimental|Lidocaine + Paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
11198198|NCT03397082|Placebo Comparator|Placebo + paracervical blockade|5 minutes previous to endouterine manual aspiration, standard paracervical blockade was applied plus placebo gel (KY).
11198199|NCT03397069|Placebo Comparator|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
11198200|NCT03397069|Experimental|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
11198201|NCT03397069|Experimental|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
11198202|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.
~Intervention: Questionnaire"
11198203|NCT03397043|Experimental|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
11198204|NCT03397030|Experimental|Home-Based Exercise Program|Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.
11198205|NCT03397030|No Intervention|Waitlist-Control Group|Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.
11198206|NCT03397004|Active Comparator|doxycycline Hyclate|subjects will be treated with a 6-month course of doxycycline oral capsule at a dose of 100mg twice daily
11198207|NCT03397004|Placebo Comparator|Placebo|subjects will be given a placebo oral capsule twice daily for 6-months
11198208|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
11198209|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
11198210|NCT03396978|Experimental|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
11198213|NCT03396952|Experimental|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11198214|NCT03396939|Experimental|Orthosis|The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
11198215|NCT03396939|No Intervention|Control|The group will receive the same amount of a study-specific training program without the orthotic device.
11198216|NCT03396926|Experimental|Treatment (pembrolizumab, bevacizumab, capecitabine)|Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11198217|NCT03396913|Experimental|IPL followed by MGX|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
11198218|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
11198219|NCT03396900|Active Comparator|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
11198220|NCT03396900|Experimental|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
11198221|NCT03396887|Experimental|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
11198222|NCT03396887|Active Comparator|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
11198223|NCT03396874|Experimental|68Ga-PSMA|PET/CT imaging
11198224|NCT03396861|Experimental|Subconjunctival aflibercept|Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.
11198225|NCT03396848|Experimental|SHAReClinic|All participants will have access to the online clinic
11198226|NCT03396835|Experimental|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
11198227|NCT03396809|Experimental|Punctal Plugs|This arm of the study receives punctal plug intervention.
11198228|NCT03396796|Experimental|Vagus nerve-preserving group|Every patient of vagus nerve-preserving group will receive the modified vagus nerve-preserving laparoscopic azygoportal disconnection procedure.
11198229|NCT03396796|No Intervention|Conventional group|Every patient of conventional group will receive the conventional laparoscopic azygoportal disconnection procedure.
11198230|NCT03396783|Experimental|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
11198231|NCT03396783|Other|Control|during the visit, nurse will make a blood test for biological and immunological analysis
11198232|NCT03396770|Active Comparator|Control group|Standard clinical routine
11198233|NCT03396770|Experimental|Nephrocheck group|Nephrocheck test
11198234|NCT03396757|Active Comparator|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
11198235|NCT03396757|Experimental|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
11198236|NCT03396744|Active Comparator|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
11198237|NCT03396744|Active Comparator|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
11198238|NCT03396731|No Intervention|Standard care alone (control)|Multilayer/multi component compression bandaging treatment
11198239|NCT03396731|Active Comparator|6 hours geko™|geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
11198240|NCT03396731|Active Comparator|12 hours geko™|geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
11198241|NCT03396718|Experimental|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
11198242|NCT03396718|Experimental|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
11198243|NCT03396718|Active Comparator|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
11198244|NCT03396718|Active Comparator|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
11198245|NCT03396692|Active Comparator|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
11198246|NCT03396692|Experimental|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
11198247|NCT03396692|Experimental|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
11198498|NCT03394976||Study population|Participants will be enrolled passively at health centres. Passive enrolment will include patients referred to or presenting directly at the health facilities.
11198248|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
11198249|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
11198250|NCT03396666|Experimental|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
11198251|NCT03396666|No Intervention|No intervention|Regular follow-up with advice on physical activity and nutrition
11198252|NCT03396653|Active Comparator|Peer-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
11198253|NCT03396653|Active Comparator|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
11198254|NCT03396640|Experimental|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
11198255|NCT03396640|Active Comparator|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
11198256|NCT03396627||muller muscle|muller muscle and conjunctiva excised during muller muscle conjunctival resection
11198257|NCT03396614||EEG, ECG, CT, MRI|
11198258|NCT03396601|Experimental|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
11198259|NCT03396601|Experimental|Saline (placebo) infusion|Infusion of IV Saline
11198260|NCT03396588|Active Comparator|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
11198261|NCT03396588|Active Comparator|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
11198262|NCT03396575|Experimental|Group A|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) during cycles of Dose-intensified TMZ
11198263|NCT03396575|Experimental|Group B|TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs) with Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
11198264|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.
~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
11198265|NCT03396549|Experimental|real tDCS|20 min of 2 mA tDCS over the right and left dorsolateral prefrontal cortex
11198266|NCT03396549|Sham Comparator|new sham tDCS|20 min 2 mA tDCS over the left and right sensorimotor cortex
11198267|NCT03396536||Group 1|Group 1 will be implants with keratinized mucosa (KM).
11198268|NCT03396536||Group 2|Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
11198269|NCT03396523|Experimental|Losartan group|
11198270|NCT03396523|Placebo Comparator|Placebo group|
11198271|NCT03396510|Experimental|IMPROVED intervention|Patients randomized to the IMPROVED intervention will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the study team will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the study team will not provide guidance about what actions to take in response to patients' symptoms.
11198272|NCT03396510|No Intervention|Usual Care|Usual Care per hospital standard will be administered. Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports.
11198273|NCT03396497|Experimental|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
11198274|NCT03396484|Experimental|Methyldopa|"Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day
~Children: methyldopa dose based on weight twice daily for one week then increased to three times a day"
11198275|NCT03396484|Placebo Comparator|Placebo|Inactive agent to match active drug in appearance and dose frequency.
11198276|NCT03396471|Experimental|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
11198277|NCT03396458||Hepatitis B group|Hepatitis B serology and questionnaire
11198278|NCT03396445|Experimental|Arm 1: MK-5890|Participants receive escalating doses of MK-5890 via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
11198279|NCT03396445|Experimental|Arm 2: MK-5890 + Pembrolizumab|Participants receive escalating doses of MK-5890 via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
11198280|NCT03396445|Experimental|Arm 3: MK-5890 + Pembrolizumab + Pemetrexed + Carboplatin|Participants receive MK-5890 at the selected dose via IV infusion PLUS pembrolizumab 200 mg via IV infusion PLUS pemetrexed 500 mg/m^2 via IV infusion PLUS carboplatin Area Under the Curve (AUC) 5 mg/mL/min via IV infusion, all given on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
11198281|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:
~Storz C-MAC Video Laryngoscope"
11198282|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:
~Miller Laryngoscope"
11198315|NCT03396185|Experimental|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
11241239|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (164mg)|
11198283|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.
~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.
~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.
~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
11198284|NCT03396406|Experimental|PCRF group|received Pulsed radiofrequency (PRF) at 42°C for 8 minutes followed by CRF at 60°C for 270s
11198285|NCT03396406|Experimental|CRF group|received sole thermocoagulation at 70°C for 270 s
11198286|NCT03396393|Experimental|Dihydroartemisinin 40mg|Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
11198287|NCT03396393|Experimental|Dihydroartemisinin 80mg|Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
11198288|NCT03396393|Experimental|Dihydroartemisinin 120mg|Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
11198289|NCT03396393|Placebo Comparator|placebo|Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
11198290|NCT03396380|Active Comparator|vitamin D|93 women who will receive clomiphene citrate for induction of ovulation with vitamin D and calcium supplement
11198291|NCT03396380|Placebo Comparator|placebo|93 women who will receive clomiphene citrate for induction of ovulation with placebo and calcium supplement
11198292|NCT03396367|Experimental|PARTNER Intervention|This intervention is a four-session intervention designed to increase PrEP uptake, increase PrEP adherence, and reduce drug use and HIV transmission risk behaviors of individuals in relationships.
11198293|NCT03396367|Active Comparator|Education Intervention|This intervention is a four-session intervention that discussed drug use and its effect on physiological social functioning.
11198294|NCT03396354|Experimental|Integrated robotic surgery|
11198295|NCT03396354|Active Comparator|Conventional laparoscopic surgery|
11198296|NCT03396341||patients receiving a positive BRCA1/2 mutation result|All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
11198297|NCT03396328|Active Comparator|Conventional education|
11198298|NCT03396328|Experimental|Low salt dietary education by smartphone application|
11198299|NCT03396315|Active Comparator|alendronate|Subjects will receive oral alendronate
11198300|NCT03396315|Active Comparator|zoledronic acid|Subjects will receive zoledronic acid
11198301|NCT03396302|Experimental|Experimental|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education).
11198302|NCT03396302|No Intervention|Control|The control group will receive Hospital treatment as usual.
11198303|NCT03396289|Active Comparator|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
11198304|NCT03396289|Experimental|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
11198305|NCT03396276|Experimental|Suboxone induction into MAT in the ED|Suboxone induction into medication-assisted treatment (MAT) in the emergency department (ED)
11198306|NCT03396263|Experimental|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
11198307|NCT03396263|Experimental|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
11198308|NCT03396263|Placebo Comparator|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
11198309|NCT03396250|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
11198310|NCT03396250|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
11198311|NCT03396237||Group A|Case group contain cases of unexplained infertility women
11198312|NCT03396237||Group B|Control group contain fertile pregnant women
11198313|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
11198314|NCT03396211|Experimental|Apatinib (also known as rivoceranib) with Nivolumab|Oral daily doses of apatinib (as its mesylate salt) with a fixed dose of nivolumab given intravenously every 2 weeks
11200432|NCT03381573||Roflumilast unexposed|Patients with COPD never exposed to Roflumilast
11198316|NCT03396172|Other|Control|The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
11198317|NCT03396172|Active Comparator|FreeDom|"FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation):
~-initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met.
~After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,"
11198318|NCT03396159|Experimental|mini fluid challenge|mini fluid will be given and stroke volume will be assessed before and after
11198319|NCT03396146|Experimental|Type1diabetes with exocrine pancreatic function insufficiency|12 ml total blood tubes volume Fecal sample
11198320|NCT03396146|Experimental|Type1diabetes without exocrine pancreatic function insuficienc|12 ml total blood tubes volume Fecal sample
11198321|NCT03396146|Active Comparator|Type 3c diabetes|12 ml total blood tubes volume Fecal sample
11198322|NCT03396133|Experimental|Snap group|individuals in this arm used Snap according to the instruction on time and screened at the symptomatic
11198323|NCT03396133|No Intervention|RC group|patients in the RC arm accepted normal methods
11198324|NCT03396107|Active Comparator|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
11198325|NCT03396107|Placebo Comparator|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
11198326|NCT03396094|Experimental|Intervention|High-flow nasal cannula oxygenation at 60L/min for pre-oxygenation and apnoeic oxygenation
11198327|NCT03396094|Active Comparator|Control|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
11198328|NCT03396081|Experimental|PRADO-IC|
11198329|NCT03396081|Other|Usual care|
11198330|NCT03396068|Experimental|NRX-101|Subjects will be treated with oral NRX-101 (fixed dose combination of D-Cycloserine/lurasidone) that will be titrated to a combined dose of 950mg/66mg per day.
11198331|NCT03396068|Active Comparator|Lurasidone comparator|Subjects will be treated with oral lurasidone in a matched placebo capsule that will be titrated to a dose of 66 mg per day
11198332|NCT03396055|Experimental|Treatment group|Specific rehabilitation exercise
11198333|NCT03396055|No Intervention|Control|No intervention
11198334|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to <=20/200
11198335|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity >20/200 to <=20/50
11198336|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to <=20/200
11198337|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity >20/200 to <=20/50
11198338|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to <=20/200
11198339|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity >20/200 to <=20/50
11198340|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to <=20/200
11198341|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity >20/200 to <=20/50
11198342|NCT03396029|Experimental|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
11198343|NCT03396029|Experimental|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
11198344|NCT03396029|No Intervention|Control|No contact with the participant.
11198345|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
11198346|NCT03396003|Experimental|GALILEI G6 Lens Professional|The GALILEI G6 Lens Professional will measure anterior segment geometry and axial intra-ocular distances of the eye.
11198347|NCT03396003|Active Comparator|Oculus Pentacam AXL|The Oculus Pentacam AXL will measure anterior segment geometry and axial intra-ocular distances of the eye.
11198348|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
11198349|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
11198350|NCT03395977|Placebo Comparator|Placebos PO and IV|PO : per os IV : intraveinously
11198351|NCT03395977|Experimental|Febuxostat PO and Placebo IV|240 mg a day for 3 days
11198352|NCT03395977|Experimental|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
11198353|NCT03395977|Experimental|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
11198354|NCT03395964|Active Comparator|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo GIA II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
11198355|NCT03395964|Experimental|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
11198356|NCT03395938|Placebo Comparator|Current practice|"Intervention A depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation."
11241240|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (246mg)|
11198357|NCT03395938|Active Comparator|Proactive engagement|"Intervention B involves a series of proactive engagements in hope to spur patients into contacting their siblings and improve their receptiveness towards colorectal cancer screening."
11198358|NCT03395925|Experimental|Celon Pro Surge|Ablation of thyroid tissue
11198359|NCT03395912|Experimental|Intervention|Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
11198360|NCT03395912|No Intervention|control|Abdominal layers will be closed without Infiltration .
11198361|NCT03395899|Active Comparator|Atezolizumab alone|1200mg of Atezolizumab D1 C1
11198362|NCT03395899|Experimental|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
11198363|NCT03395899|Experimental|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
11198364|NCT03395899|Experimental|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
11198365|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
11198366|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
11198367|NCT03395873|Experimental|Single arm|"Decitabine 20mg/m2 IV day 1-5, every 28 days
~Avelumab 10mg/kg IV, day 1, every 14 days"
11198368|NCT03395860|Experimental|group A|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
11198369|NCT03395860|Experimental|group B|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
11198370|NCT03395847|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11198371|NCT03395834|Experimental|O3 monitor|tissue oxygenation comparison of O3 & INVOS
11198372|NCT03395821|Active Comparator|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
11198373|NCT03395821|Experimental|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
11198374|NCT03395808|Other|AVE-901 50mg|IV Tramadol
11198375|NCT03395795|Other|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
11198376|NCT03395782||Age group 40-49|30 patients will be stratified to this age group.
11198377|NCT03395782||Age group 50-59|30 patients will be stratified to this age group.
11198378|NCT03395782||Age group 60-69|30 patients will be stratified to this age group.
11198379|NCT03395782||Age group 70-79|30 patients will be stratified to this age group.
11198380|NCT03395756|Active Comparator|12-14 mm follicle size group|Once the participant's leading follicle reaches 12-14mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
11198381|NCT03395756|Active Comparator|15-17 mm follicle size group|Once the participant's leading follicle reaches 15-17mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
11198382|NCT03395756|Active Comparator|18 mm or greater follicle size group|Once the participant's leading follicle reaches 18mm or greater, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
11198383|NCT03395730|Experimental|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):
~Clamping and cutting the placental cord after delivery of the baby.
~Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
11198384|NCT03395730|Experimental|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):
~Clamping and cutting the placental cord after delivery of the baby.
~Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
11198385|NCT03395730|Active Comparator|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):
~Clamping and cutting the placental cord after 2 minutes of delivery of the baby.
~Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
11198453|NCT03395249|Other|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.
~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
11198386|NCT03395717|Experimental|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
11198387|NCT03395717|No Intervention|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.
~Traditional Over ground Gait Trainings include:
~Sit-to-Stand tasks
~Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.
~CG patients will not use any other robots or treadmill for gait training."
11198388|NCT03395704|Active Comparator|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
11198389|NCT03395704|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
11198390|NCT03395691|Active Comparator|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach.
11198391|NCT03395691|Active Comparator|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
11198392|NCT03395678|Experimental|Microneedling|Participants in this arm will receive 5 treatments of microneedling.
11198393|NCT03395678|Active Comparator|Fractional non-ablative 1,540nm laser|Participants in this arm will receive 5 treatments of fractional non-ablative1,540nm laser.
11198394|NCT03395639|Experimental|Edoxaban|Two out of three participants will be randomized for treatment with edoxaban solution or tablets
11198395|NCT03395639|Active Comparator|Standard of Care (SOC)|One out of three participants will be randomized for treatment with the institution's SOC regimen
11198396|NCT03395626|Experimental|ID-JPL934|probiotics 20%, corn starch 80%
11198397|NCT03395626|Placebo Comparator|placebo|corn starch 100%
11198398|NCT03395613|No Intervention|Standard management|Standard sterile gauze dressing on surgical groin wound.
11198399|NCT03395613|Experimental|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
11198400|NCT03395600|Active Comparator|0.1%bupivacaine+10µg sufentanyl|Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
11198401|NCT03395600|Active Comparator|0.125%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
11198402|NCT03395600|Active Comparator|0.1%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
11198403|NCT03395587|Experimental|Experimental intervention|Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
11198404|NCT03395587|Other|Control intervention|"Standard therapy:
~Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)"
11198405|NCT03395574|Experimental|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
11198406|NCT03395574|Placebo Comparator|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
11198407|NCT03395561|Active Comparator|green coffe|2 capsuls of green coffe
11198408|NCT03395561|Placebo Comparator|control|2 capsuls
11198409|NCT03395548|Active Comparator|Inflammatory bowel disease|"The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.
~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
11198410|NCT03395548|Active Comparator|Irritable bowel syndrome|"The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.
~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
11198411|NCT03395548|Active Comparator|Healthy|"The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.
~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
11198412|NCT03395535|Experimental|'Laser-1st'|"Initial Selective Laser Trabeculoplasty (SLT) [PROCEDURE] followed by conventional medical therapy (eye-drops) as required.
~All participants in this arm start their treatment pathway with SLT. If this does not reach the predefined, patient-specific target IOP then repeat laser (once only) is given. If the IOP target is then not reached additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed."
11198452|NCT03395249|Placebo Comparator|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.
~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
11198454|NCT03395236|Experimental|Treatment|StellarexTM 0.014 OTW Drug-coated Angioplasty Balloon (Stellarex Balloon)
11198413|NCT03395535|Active Comparator|Medicine-1st|"Conventional medical therapy [DRUG] without laser. All participants in this arm start their treatment pathway medical treatment. If the IOP target is then not reached, additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed.
~During this pathway of treatment all commercially available medical treatments (eye-drops) are permitted according to a pre-specified step-wise intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
11198414|NCT03395522|Experimental|Device|ITind device implant
11198415|NCT03395496|Experimental|Biodentine|Dental materials
11198416|NCT03395496|Experimental|ProRoot MTA|Dental Materials
11198417|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
11198418|NCT03395470|Experimental|Group A1|Dose 1 or placebo
11198419|NCT03395470|Experimental|Group A2|Dose 2 or placebo
11198420|NCT03395470|Experimental|Group A3|Dose 3 or placebo
11198421|NCT03395470|Experimental|Group A4|Dose 4 or placebo
11198422|NCT03395470|Experimental|Group A5|Dose 5 or placebo
11198423|NCT03395470|Experimental|Group B|Dose + Rosuvastatin
11198424|NCT03395457|Active Comparator|Care as usual|This is the care provided by the neurologist for chronic migraine.
11198425|NCT03395457|Experimental|Care as usual plus manual therapy|Other
11198426|NCT03395444|Active Comparator|Study Group|Pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
11198427|NCT03395444|Sham Comparator|Control Group|Sham pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
11198428|NCT03395431|Active Comparator|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
11198429|NCT03395431|No Intervention|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
11198430|NCT03395405|Experimental|Nitazoxanide Arm|500 mg (one tablet) nitazoxanide by mouth twice daily with food for 56 consecutive doses. N=80
11198431|NCT03395405|Placebo Comparator|Placebo Arm|Placebo (one tablet) by mouth twice daily with food for 56 consecutive doses. N=80
11198432|NCT03395392|Experimental|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
11198433|NCT03395392|Active Comparator|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
11198434|NCT03395379||Group 1|RFA without air dissection protection
11198435|NCT03395379||Group 2|RFA with air dissection protection
11198436|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
11198437|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
11198438|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
11198439|NCT03395340|Experimental|Ruxolitinib Cream|Investigational cream to 1 location; vehicle cream to 2nd location
11198440|NCT03395340|Placebo Comparator|Vehicle cream|Investigational cream to 1 location; vehicle cream to 2nd location
11198441|NCT03395314|Placebo Comparator|midazolam|Midazolam IV; 0.04mg/kg over 40 minutes
11198442|NCT03395314|Active Comparator|low dose ketamine|ketamine IV; 0.5 mg/kg over 40 minutes
11198443|NCT03395301|Experimental|tubal occlusion|Fiber coils were inserted into the interstitial part of fallopian tubes, and IVF-ET was taken out in the following.
11198444|NCT03395288|Experimental|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
11198445|NCT03395288|No Intervention|RCT control arm|Participants in this arm will not use any additional intervention.
11198446|NCT03395288|Experimental|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
11198447|NCT03395275|Experimental|Intrathecal Pump Therapy Participants|Patients eligible for intrathecal pump therapy will undergo quantitative sensory tests and surveys during various stages of the treatment process.
11198448|NCT03395262|Experimental|Active with caffeine|Novel formula with caffeine
11198449|NCT03395262|Active Comparator|Active without caffeine|Novel formula without caffeine
11198450|NCT03395262|Placebo Comparator|Placebo|Dextrose
11198451|NCT03395249|Experimental|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.
~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
11241241|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-111 (175mg)|
11198455|NCT03395223|Experimental|ProvayBlue (Methylene Blue) arm|"Methylene Blue 0.5% will be administered.
~1 mg/kg will be administered intravenously over 5-30 minutes. If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose."
11198456|NCT03395210|Experimental|PRN1008 Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.
~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
11198457|NCT03395197|Experimental|Combination arm|Talazoparib plus enzalutamide
11198458|NCT03395197|Active Comparator|Monotherapy arm|Ezalutamide plus placebo
11198459|NCT03395184|Experimental|PF-06700841 or placebo|
11198460|NCT03395184|Experimental|PF-06651600 or placebo|
11198461|NCT03395171|Experimental|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
11198462|NCT03395171|No Intervention|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
11198463|NCT03395158||Prior alert criteria|Patients who activated full, limited or no alert criteria according to the prior alert criteria
11198464|NCT03395158||Present alert criteria|Patients who activated full, limited or no alert criteria according to the present alert criteria
11198465|NCT03395145|Experimental|Bio-Oss Collagen and Mucograft Seal|Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
11198466|NCT03395145|No Intervention|Natural healing|Evaluation of Bone volume Changes after tooth extraction (natural healing)
11198467|NCT03395132|Experimental|Fucicort® Lipid cream|Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
11198468|NCT03395132|Active Comparator|Fucidin cream +betamethasone cream|The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.
11198469|NCT03395132|Placebo Comparator|Vehicle cream|The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.
11198470|NCT03395119|Sham Comparator|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
11198471|NCT03395119|Experimental|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
11198472|NCT03395119|Experimental|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
11198473|NCT03395106|Experimental|Parent source + intuitive story content|
11198474|NCT03395106|Experimental|Doctor source + intuitive story content|
11198475|NCT03395106|Experimental|Parent source + deliberative content|
11198476|NCT03395106|Experimental|Doctor source + deliberative content|
11198477|NCT03395093|Experimental|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
11198478|NCT03395093|Active Comparator|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
11198479|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EEC|300mg DKN-01 monotherapy in recurrent EEC
11198480|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EEC|300mg DKN-01+paclitaxel in recurrent EEC
11198481|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EOC|300mg DKN-01 monotherapy in recurrent EOC
11198482|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EOC|300mg DKN-01+paclitaxel in recurrent EOC
11198483|NCT03395080|Experimental|DKN-01 monotherapy in carcinosarcoma|600mg DKN-01 monotherapy in carcinosarcoma
11198484|NCT03395080|Experimental|DKN-01 +paclitaxel in carcinosarcoma|600mg DKN-01 +paclitaxel in carcinosarcoma
11198485|NCT03395067|Active Comparator|Lifestyle counseling|
11198486|NCT03395067|No Intervention|Control group|
11198487|NCT03395054|Other|the stabilization group|the stabilization group performed cervical stabilization exercises in lying, sitting, standing and on a swisball 3times a week during 8 weeks.
11198488|NCT03395054|Other|the control group|the control group performed conventional exercises including neck isometric, isotonic and posture exercises 3 times a week during 8 weeks.
11198489|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.
~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
11198490|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.
~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
11198491|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
11198492|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
11198493|NCT03395002|Experimental|Tiotropium/Salmeterol/Fluticasone|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Discair®
11198494|NCT03395002|Active Comparator|Tiotropium + Salmeterol/Fluticasone|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® + Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus®
11198495|NCT03394989|Experimental|Test|Fluticasone propionate/salmeterol 100/50 µg
11198499|NCT03394950|Experimental|rtPA combined with Butyphthalide|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
11198500|NCT03394950|Active Comparator|rtPA compared with placebo|Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
11198501|NCT03394937|Experimental|Cohort 1 600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
11198502|NCT03394937|Experimental|Cohort 1 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
11198503|NCT03394937|Experimental|Cohort 2 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
11198504|NCT03394937|Experimental|Cohort 2 3600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
11198505|NCT03394924|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
11198506|NCT03394924|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
11198507|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
11198508|NCT03394911|Experimental|Experimental Group|250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
11198509|NCT03394911|Placebo Comparator|Placebo Group|Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
11198510|NCT03394885|Experimental|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by
~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by
~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).
~(Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
11198511|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
11198512|NCT03394846|Experimental|Pilot Test of MI Prototype|We will pilot test a Movement Integration product prototype with 60 elementary classroom teachers.
11198513|NCT03394833|Experimental|Preoperative fluids|40 individuals receiving preoperative colloid fluid bolus at 6 ml/kg LBW, (Gelofusine™, Fresenius Kabi AB, Sweden) before anesthesia induction by TCI (n = 20) or RSI (n =20).
11198514|NCT03394833|No Intervention|No preoperative fluids|40 individuals anesthetized by TCI (n = 20) or RSI (n =20) without preoperative fluids.
11198515|NCT03394820|Active Comparator|dexamethasone 1 hour prior to block|The patient will receive dexamethasone through IV one hour prior to receiving their block. During the patient's block, 1 hour after and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
11198516|NCT03394820|Experimental|dexamethasone during the block|The patient will receive dexamethasone through IV at the same time the patient has the SCB done. One hour prior to the block, one hour after the block and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
11198517|NCT03394820|Active Comparator|dexamethasone 1 hour after block|The patient will receive dexamethasone through IV one hour after the block has been administered. One hour prior to block, during the block and two hours after the block the patient will receive normal saline to maintain the blind.
11198518|NCT03394820|Active Comparator|dexamethasone 2 hours after block|The patient will receive dexamethasone 2 hours after the block has been administered. One hour prior to the block, during the block and one hour after the block the patient will receive normal saline to maintain the blind.
11198519|NCT03394807|Experimental|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
11198520|NCT03394807|Placebo Comparator|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
11198521|NCT03394794|Active Comparator|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
11198522|NCT03394794|Experimental|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
11198523|NCT03394794|Experimental|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
11198524|NCT03394794|Experimental|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
11198525|NCT03394781|Experimental|DUR-928 10 mg|10 mg oral suspension
11198526|NCT03394781|Experimental|DUR-928 50 mg|50 mg oral suspension
11198527|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
11198565|NCT03394495|No Intervention|Exercise group|"16-week programme with health talks and exercise training.
~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
11198528|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
11198529|NCT03394755|Experimental|Thrombosomes|
11198530|NCT03394742|Experimental|Intervention group|Peer support group received, in addition to usual care, peer support via telephone 1-5 times according to their own preference. Peer support was started at the time between diagnosis and the beginning of treatments.
11198531|NCT03394742|No Intervention|Control group|The control group received usual care only. For ethical reasons, participants in the control group were not discouraged from seeking peer support by themselves if they felt a need for it.
11198532|NCT03394729|Experimental|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
11198533|NCT03394729|Active Comparator|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
11198534|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
11198535|NCT03394690|Active Comparator|green coffe|green coffe 2 capsuls of green coffe
11198536|NCT03394690|Placebo Comparator|control|2 capsuls of placebo
11198537|NCT03394677|Experimental|RVT-501 0.5% ointment|Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
11198538|NCT03394677|Placebo Comparator|RVT-501 vehicle ointment|Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
11198539|NCT03394664|Experimental|Very-Low Carbohydrate Diet|Feeding study. Dietary composition (approximately): 75% fat
11198540|NCT03394664|Experimental|High-Carbohydrate Low-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
11198541|NCT03394664|Experimental|High-Carbohydrate High-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
11198542|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
11198543|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
11198544|NCT03394638|Active Comparator|Conventional group|"Treatment includes:
~10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.
~Additional visits if necessary
~No further access to the BePATIENT website"
11198545|NCT03394638|Experimental|Online group|"Treatment includes:
~Added to conventional group: Continuation of access to the BePATIENT website with:
~eLearning programs
~Informative videos
~Patient network
~Video consulting"
11198546|NCT03394638|Experimental|Device group|"Added to Online group:Four wireless devices, which are
~Weight Scale
~Blood Pressure
~Oximeter
~Activity Tracker"
11198547|NCT03394625|Experimental|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
11198548|NCT03394625|Active Comparator|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
11198549|NCT03394612|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
11198550|NCT03394599|Active Comparator|TheraTrainer Only|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer only for the duration of their participation at the Geriatric program. Their carers will also be recruited.
11198551|NCT03394599|Experimental|TheraTrainer + Motiview|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer with the addition of Motiview (engaging videos to watching while cycling). Their carers will also be recruited.
11198552|NCT03394586||UC patients with golimumab|We will retrospectively analyze all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
11198553|NCT03394573||OCT guided treatment arm|OCT guided aflibercept injection
11198554|NCT03394573||VA guided treatment arm|VA guided aflibercept injection
11198555|NCT03394560|Experimental|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
11198556|NCT03394560|Sham Comparator|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
11198557|NCT03394547|Active Comparator|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
11198558|NCT03394547|Placebo Comparator|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
11198559|NCT03394547|No Intervention|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
11198560|NCT03394534|Experimental|CGA group|
11198561|NCT03394534|No Intervention|Treatment as Usual|
11198562|NCT03394508|Placebo Comparator|Placebo|ALK diluent 0,3% human albumin'
11198563|NCT03394508|Experimental|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension
11198564|NCT03394495|Experimental|BCE Combination group|"16-week BCE programme with exercise training.
~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
11241242|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-112 (145mg)|
11198566|NCT03394495|No Intervention|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
11198567|NCT03394482|Experimental|Lu AF35700 5 mg clinical formulation|
11198568|NCT03394482|Experimental|Lu AF35700 5 mg commercial formulation|
11198569|NCT03394482|Experimental|Lu AF35700 10 mg clinical formulation|
11198570|NCT03394482|Experimental|Lu AF35700 10 mg commercial formulation|
11198571|NCT03394482|Experimental|Lu AF35700 20 mg clinical formulation|
11198572|NCT03394482|Experimental|Lu AF35700 20 mg commercial formulation|
11198573|NCT03394469|Other|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
11198574|NCT03394456|Experimental|Intervention|Receive diabetes group visits
11198575|NCT03394456|No Intervention|Control|Receive usual care in the clinic, followed by group visits (wait list control)
11198576|NCT03394430|Placebo Comparator|Group A|
11198577|NCT03394430|Experimental|Group B|
11198578|NCT03394430|Experimental|Group C|
11198579|NCT03394417|No Intervention|standard clinical practice (control)|aqueous cream
11198580|NCT03394417|Active Comparator|StrataXRT (intervention)|silicon-based gel
11198581|NCT03394404|Experimental|ECG-I mapping and PVI|ECG-I mapping and PVI
11198582|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
11198583|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
11198584|NCT03394365|Experimental|SOT cohort -Subgroup A|Participants who have failed rituximab will receive IV tabelecleucel.
11198585|NCT03394365|Experimental|SOT cohort -Subgroup B|Participants who have failed both rituximab and chemotherapy will receive IV tabelecleucel.
11198586|NCT03394365|Experimental|HCT cohort|Participants who have failed rituximab will receive IV tabelecleucel.
11198587|NCT03394352|Experimental|Activity on Board|Blinded CGM data will be collected prior to the Experimental Admission to determine the insulin bolus that will be determined by the activity on board calculator. Subjects will wear a continuous glucose monitor during the study admission.
11198588|NCT03394352|Placebo Comparator|Usual Diabetes Care|Subjects will use their usual diabetes care, including basal rate, correction factor and carbohydrate-insulin ratio. Subjects will determine their own insulin usage during the Control Admission. Subjects will wear a continuous glucose monitor during the study admission.
11198589|NCT03394326|Experimental|LOW-ED|In the LOW-ED condition each participant will consume at least 10 low-ED foods/day (ED ≤1.0 kcal/g) and no more than 2 high ED foods/day (ED ≥3.0 kcal/g). Foods with an ED >1.0 kcal/g and <3.0 kcal/g will be unlimited; however, lowering the overall ED of the diet will be encouraged.
11198590|NCT03394326|Active Comparator|STANDARD|In the STANDARD condition participants will consume the recommendations for calories, fruits, vegetables and whole grains based on age and sex corresponding with MyPlate. The daily caloric recommendations from MyPlate are for weight maintenance.
11198591|NCT03394287|Experimental|SHR-1210 +Apatinib daily dosing|SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
11198592|NCT03394287|Experimental|SHR-1210+Apatinib intermittent dosing|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)
11198593|NCT03394274||Transfusion|Patients (n:892) were enrolled who underwent elective major surgery between the 01/01/2016-31/12/2016, and over the age of 18 years. They separated subgroups as restrictive and liberal blood transfusion groups
11198594|NCT03394261|Experimental|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
11198595|NCT03394261|No Intervention|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
11198596|NCT03394235|Experimental|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
11198597|NCT03394222|Experimental|Budesonide inhalation group|This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
11198598|NCT03394222|Placebo Comparator|Normal saline inhalation group|This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
11198599|NCT03394209|Experimental|Favipiravir+oseltamivir|Favipiravir+oseltamivir will be given twice daily for a 10-day period.
11198600|NCT03394196|Experimental|No HIV-2 resistance|
11198601|NCT03394196|Experimental|HIV-2 NRTI resistance only|
11198602|NCT03394196|Experimental|HIV-2 NRTI and PI resistance|
11198603|NCT03394183|Experimental|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
11198604|NCT03394183|Active Comparator|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
11198605|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
11198606|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
11198607|NCT03394157|Other|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
11198608|NCT03394144|Experimental|C1:AZD9150, C2:AZD9150+Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open
11198609|NCT03394131|Experimental|Hyalase|injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided
11198610|NCT03394131|Placebo Comparator|Placebo|injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided
11198611|NCT03394131|Active Comparator|Insilin|injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided
11198612|NCT03394118|Experimental|Group_TAGRISSO|Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period.
11198613|NCT03394105|Experimental|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
11198614|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
11198615|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
11198616|NCT03394079|Experimental|OCT-guided|
11198617|NCT03394079|Active Comparator|IVUS-guided|
11198618|NCT03394066|Experimental|TMS|All participants will receive TMS to investigate acute modulations of brain activity by TMS
11198619|NCT03394053||1|Affected Patient
11198620|NCT03394053||2|Relative of Patient
11198621|NCT03394053||3|Normal Volunteer
11198622|NCT03394040||1|The study seeks individuals of all ages experiencing diarrhea from the Washington Metropolitan area
11198623|NCT03394027|Experimental|Arm 1|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: ER + breast cancer, triple negative breast cancer, and endometrial cancer
11198624|NCT03394014|Active Comparator|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
11198625|NCT03394014|Active Comparator|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
11198626|NCT03394001|Active Comparator|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
11198627|NCT03394001|Active Comparator|Ketorolac tromethamine|Wound infiltration with Ketorolac
11198628|NCT03393988|Active Comparator|Group F|Fentanyl infusion (0.5 µg/kg/hr)
11198629|NCT03393988|Active Comparator|Group (TAP-Dex)|"Ultrasound guided TAP block and Dexmedetomidine
~Ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine
~Dexmedetomidine infusion(200 µg in 2 ml diluted in 48 ml of saline)
~Fentanyl infusion (0.5 µg/kg/hr)."
11198630|NCT03393975|Experimental|Prophylaxis Cohort I|Participants randomized to SOC arm in prophylactic cohort will receive PK dose of their current SoC product followed by a single dose intravenous (IV) infusions of 40 International units per kilogram (IU/kg) BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
11198631|NCT03393975|Experimental|Prophylaxis Cohort II|Participants randomized to BAX-930 arm in prophylactic cohort will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by a PK dose of their current SoC product at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
11198632|NCT03393975|Experimental|On Demand Cohort I|Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
11198633|NCT03393975|Experimental|On Demand Cohort II|Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
11198634|NCT03393962|Experimental|OC-EIEs|Autologous ovarian cancer antigen-specific cytotoxic lymphocytes
11198635|NCT03393949|Experimental|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
11198636|NCT03393949|Experimental|Group C|Patients in Group C received methylprednisolone 0.5mg•kg-1
11198701|NCT03393442|Active Comparator|2. Healthy subjects|Diagnostic Test: Brain MRI scan Age-matched female control subjects that never received Gd-based contrast agents.
11198637|NCT03393936|Experimental|CCT301-59|The safety and efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
11198638|NCT03393936|Experimental|CCT301-38|The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
11198639|NCT03393923|No Intervention|Control Group|Patient will undergo gait analysis
11198640|NCT03393923|Experimental|Experimental group|Patient will undergo gait analysis with use of anterior wedge
11198641|NCT03393910|No Intervention|Observational|Normal pelvic exam exposures: External exam followed by speculum exam, followed by bimanual exam
11198642|NCT03393910|Active Comparator|Experimental Pelvic Exam|Changing the order of the pelvic exam Intervention: External exam, bimanual exam,speculum exam
11198643|NCT03393897||Hemodynamic instability with hypotension|
11198644|NCT03393884|Experimental|NACT + GEN-1|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
11198645|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
11198646|NCT03393858|Experimental|Immunotherapy plus Hyperthermia|
11198647|NCT03393845|Experimental|Pembrolizumab + Fulvestrant|Pembrolizumab 200m IV q3W + Fulvestrant. Loading dose 500mg IV IM q2W x3 followed by 500mg IM q4W
11198648|NCT03393832||Oral Care with Mother's Milk|All infants admitted to the Texas Children's Hospital NICUs who have mother's milk available will receive oral care with mother's milk.
11198649|NCT03393832||Oral Care with Sterile Water|Infants will receive oral care with sterile water when mother's milk is not available.
11198650|NCT03393819|Experimental|Duraprep Surgical Solution|Surgical site (hip) is prepared with Duraprep (iodine-alcohol) prior to surgery according to package instructions.
11198651|NCT03393819|Experimental|Chloraprep Surgical Solution|Surgical site (hip) is prepared with Chloraprep (chlorhexidine-alcohol) prior to surgery according to package instructions.
11198652|NCT03393806|Experimental|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
11198653|NCT03393806|Placebo Comparator|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
11198654|NCT03393767|Other|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
11198655|NCT03393754|Experimental|Sci-B-Vac® Hepatitis B Vaccination|Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
11198656|NCT03393754|Active Comparator|Engerix-B® Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
11198657|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
11198658|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
11198659|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
11198660|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
11198700|NCT03393442|Experimental|1. Gd-exposed subjects|Diagnostic Test: Brain MRI scan Female subjects at high risk for breast cancer that previously underwent more than 6 Gd-based contrast enhanced MRI exams of the breast.
11198702|NCT03393429|Active Comparator|DAVID assisted training|Group I: Training assisted by DAVID devices
11198661|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.
~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.
~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
11198662|NCT03393728|Experimental|Intervention|72-hour propanolol before specific treatment of hyperthyroidism
11198663|NCT03393715|Experimental|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
11198664|NCT03393715|Active Comparator|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
11198665|NCT03393702|Experimental|Gabapentin|"Single dose preoperative gabapentin.
~After surgery gabapentin 2 times per day for 3 days."
11198666|NCT03393702|Placebo Comparator|Placebo Control|"Single dose preoperative placebo control.
~After surgery placebo 2 times per day for 3 days."
11198667|NCT03393689|Experimental|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR
11198668|NCT03393650|Active Comparator|Exercise + Placebo group|50 subjects will receive a placebo supplementation with an exercise intervention (EX group)
11198669|NCT03393650|Active Comparator|Exercise + Protein group|50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)
11198670|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
11198671|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
11198672|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
11198673|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
11198674|NCT03393611|Experimental|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
11198675|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
11198676|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
11198677|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
11198678|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
11198679|NCT03393572|Active Comparator|Group BM|bupivacaine 0.25% plus magnesium sulphate.
11198680|NCT03393572|Active Comparator|Group BN|bupivacaine 0.25% plus nalbuphine
11198681|NCT03393559|Experimental|Group L|leg elevation during the beach chair position
11198682|NCT03393559|No Intervention|Group C|Patients' leg will be straightened without any intervention.
11198683|NCT03393546|Experimental|Auricular Point Acupressure - Interventionist|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day). The treatment will be administered by the research team's trained acupressure interventionist.
~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
11198684|NCT03393546|Experimental|Auricular Point Acupressure - Caregiver Training|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).
~If participants live more than 15 miles away from the research team's office, the caregiver will receive in-person training by the interventionist on how to administer the treatment to their patient for the 4 weeks of treatment.
~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
11198685|NCT03393533|Other|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
11198686|NCT03393533|Active Comparator|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
11198687|NCT03393520|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
11198688|NCT03393520|Experimental|AVP-786; Dose 1|Participants will receive AVP-786 (Dose 1) capsules administered twice a day over a 12-week period.
11198689|NCT03393520|Experimental|AVP-786; Dose 2|Participants will receive AVP-786 (Dose 2) capsules administered twice a day over a 12-week period.
11198690|NCT03393507|Experimental|apatinib combine with chemotherapy|
11198691|NCT03393507|Active Comparator|chemotherapy|
11198692|NCT03393494|Experimental|Perrigo active|Test product
11198693|NCT03393494|Active Comparator|Reference active|RLD product
11198694|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
11198695|NCT03393481|Experimental|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
11198696|NCT03393481|Experimental|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
11198697|NCT03393481|Active Comparator|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
11198698|NCT03393468|Experimental|Sequence A: Dapivirine gel|Participants will receive 2.5 g of dapivirine gel administered rectally via an applicator, followed by a 2- to 4-week washout period. Participants will then receive a second dose of up to 10 g of dapivirine gel administered rectally via a coital simulation device.
11198699|NCT03393468|Experimental|Sequence B: Dapivirine gel|Participants will receive up to 10 g of dapivirine gel administered rectally via a coital simulation device, followed by a 2- to 4-week washout period. Participants will then receive a second dose of 2.5 g of dapivirine gel administered rectally via an applicator.
11198703|NCT03393429|Placebo Comparator|training recommendation|"Group II: Training based on stay active recommendations"
11198704|NCT03393416|Experimental|MASCT-I or MASCT-I +PD1 antibody|"This study is divided into three stages:
~The first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The first stage is MASCT-I, using 3+3 design. The second stage is divided into two groups: MASCT-I+PD1 antibody in low dose group and MASCT-I+PD1 antibody in high dose group, using 3+3 design. The third stage is the dose expansion stage , 10 patients in the low or high dose group were treated with the corresponding dose group."
11198705|NCT03393403|Experimental|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
11198706|NCT03393403|Experimental|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
11198707|NCT03393403|Active Comparator|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
11198708|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
11198709|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
11198710|NCT03393377|Experimental|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
11198711|NCT03393377|Placebo Comparator|control group|received placebo for 30 days
11198712|NCT03393364|Experimental|Opioid arm|Patients receive opioid medication, oxycodone, after outpatient urologic surgery.
11198713|NCT03393364|Experimental|Non-opioid arm|Patients receive a non-opioid medication, ketorolac, after outpatient urologic surgery.
11198714|NCT03393351|Experimental|Shared decision-making program|
11198715|NCT03393351|Active Comparator|Usual care|
11198716|NCT03393338|Experimental|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
11198717|NCT03393338|No Intervention|Usual Medical Care|Usual medical care
11198718|NCT03393312|Experimental|Bifrontal tDCS|20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).
11198719|NCT03393312|Sham Comparator|Sham tDCS|Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.
11198720|NCT03393299|Experimental|STOPP/START|Use of STOPP/START criteria during medication reconciliation
11198721|NCT03393299|No Intervention|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
11198722|NCT03393273|Experimental|Elotuzumab|This is a single arm phase II trial to assess the Very Good Partial Response rate of a strategy involving autologous hematopoietic stem cell transplantation, after intensive treatment and followed by consolidation phase, with elotuzumab, dexamethasone, velcade, and thalidomide in elderly patients.
11198723|NCT03393247|Active Comparator|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
11198724|NCT03393247|Active Comparator|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
11198725|NCT03393234|Experimental|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
11198726|NCT03393234|No Intervention|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
11198727|NCT03393221|Experimental|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
11198728|NCT03393221|Active Comparator|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
11198729|NCT03393208|Experimental|First Test GIR (Fasting), Then Reference GIR (Fasting)|Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
11198730|NCT03393208|Experimental|First Reference GIR (Fasting), Then Test GIR (Fasting)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
11198731|NCT03393208|Experimental|First Test GIR (Fed), Then Reference GIR (Fed)|Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
11198732|NCT03393208|Experimental|First Reference GIR (Fed), Then Test GIR (Fed)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
11198733|NCT03393195|Experimental|Time-restricted eating plan|Participants in this group will be instructed to fast every day from 8pm until 12pm the following day. From 12pm until 8pm, participants can eat and drink whatever they want. During fasting hours, participants can drink water and black coffee.
11198734|NCT03393195|Active Comparator|Consistent Meal Timing Plan|Participants in this group will be instructed to eat three daily meals during specified eating times. Their first meal will be between 7am-11am. Second meal between 11am and 3pm, and third meal between 4pm-10pm. Participants will be encouraged to eat small snacks if needed so that they can eat their next meal during the specified window.
11198735|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)
~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
11198736|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)
~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
11198737|NCT03393156|Experimental|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
11198738|NCT03393156|No Intervention|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
11198739|NCT03393143||Oregon patients|Adult Medicaid patients with back pain who get their care in community health clinics in Oregon
11198740|NCT03393143||California patients|Adult Medicaid patients with back pain who get their care in community health clinics in California
11198741|NCT03393130||Participants possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who possess at least one copy of the APOE-ε4 allele.
11198742|NCT03393130||Participants not possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who do not possess a copy of the APOE-ε4 allele.
11198743|NCT03393117|Experimental|Liposomal Bupivacaine + Bupivacaine|This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
11198744|NCT03393117|Active Comparator|Bupivacaine|This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
11198745|NCT03393104|Experimental|Motor Control Exercise and Patient Education|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise and 4 sessions (1 session per week) of patient education program as described in respective protocol.
~In addition, they will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
11198746|NCT03393104|Experimental|Motor Control Exercise|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.
~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
11198747|NCT03393104|Experimental|Patient Education|"Participants will receive patient education session once a week at interval of 1-week over 8-weeks (4 sessions). The program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
11198748|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
11198749|NCT03393078|Active Comparator|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
11198750|NCT03393078|Sham Comparator|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
11198751|NCT03393065|Experimental|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
11198752|NCT03393065|No Intervention|Control group|control group the fluid management will not be LUS guided
11198753|NCT03393052|Active Comparator|Left Radial access|Left Radial approach for coronary angiography in patients with prior history of CABG surgery
11198754|NCT03393052|Active Comparator|Femoral access|Femoral approach for coronary angiography in patients with prior history of CABG surgery
11198755|NCT03393039|Experimental|Behavioral|Negative Affect Task
11198756|NCT03393026|Experimental|Lurasidone 40-160 mg|Lurasidone 40-160 mg
11198757|NCT03393013|Experimental|KZR-616 60 mg + standard therapy (Phase 2)|60 mg dose level of KZR-616 selected based on data from the Phase 1 dose escalation and administered to patients with active Lupus Nephritis in combination with standard therapy.
11241243|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-119 (233mg)|
11198758|NCT03393013|Experimental|KZR-616 45 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
11198759|NCT03393013|Experimental|KZR-616 60 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
11198760|NCT03393013|Experimental|KZR-616 75 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
11198761|NCT03393000|Experimental|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
11198762|NCT03393000|Active Comparator|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
11198763|NCT03392987|Experimental|OTL-200 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.
11198764|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
11198765|NCT03392961|Experimental|IN-105 (Insulin Tregopil)|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.
~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.
~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
11198766|NCT03392961|Placebo Comparator|Placebo tablet|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.
~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.
~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
11198767|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
11198768|NCT03392922|Experimental|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
11198769|NCT03392922|Experimental|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
11198770|NCT03392909|Experimental|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
11198771|NCT03392896|Experimental|Group A Active (DCR-PHXC)|HVs, single ascending doses of DCR-PHXC.
11198772|NCT03392896|Placebo Comparator|Group A Placebo|HVs, normal saline 0.9% injection to match active doses.
11198773|NCT03392896|Experimental|Group B Active (DCR-PHXC)|PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.
11198774|NCT03392883|Experimental|Digital Health Assisted Mental Healthcare|This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).
11198775|NCT03392870|Experimental|TAVA-ACTIVE|Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient>70, verbal communication and no behavioural alterations.
11198776|NCT03392870|Active Comparator|CONTROL|As usual
11198777|NCT03392844|Experimental|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
11198778|NCT03392844|Experimental|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
11198779|NCT03392831|Experimental|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
11198780|NCT03392831|Active Comparator|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
11198781|NCT03392818|Experimental|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
11198782|NCT03392818|Experimental|Fiberoptic bronchoscope|intubation of Uniblocker under the Under the guidance of Fiberoptic bronchoscope
11198783|NCT03392818|Experimental|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of FOB.
11198784|NCT03392805|Experimental|sedentary life style|
11198785|NCT03392805|No Intervention|physically active life style|
11198786|NCT03392792|Active Comparator|tissue plasmnogen activator|
11198787|NCT03392792|Active Comparator|thrombectoy|
11198788|NCT03392779|Experimental|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
11198789|NCT03392779|Experimental|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo
~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
11198790|NCT03392779|Experimental|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo
~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
11198791|NCT03392779|Experimental|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo
~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
11198792|NCT03392779|Experimental|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo
~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
11198793|NCT03392779|Experimental|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo
~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
11198794|NCT03392779|Experimental|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.
~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
11198795|NCT03392779|Experimental|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE
~ZSP1601 50 mg/Placebo for 14 Days."
11198796|NCT03392779|Experimental|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.
~ZSP1601 100 mg/Placebo for 14 Days."
11198797|NCT03392766|Experimental|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
11198798|NCT03392766|Experimental|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
11198799|NCT03392753|Active Comparator|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
11198800|NCT03392753|Active Comparator|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
11198801|NCT03392740|Experimental|Lisinopril treatment|These patients will be initiated at 5mg lisinopril daily by the research nurse at the time of enrollment. The drug will then be titrated up by the research nurse in a stepwise fashion from 5mg, to 10mg, and then to 20mg once a day every 1 to 3 weeks according to their regular/scheduled next office visits. Blood pressure will be monitored at every visit by the research nurse if it is less than or equal to 90 mmHg
11198802|NCT03392740|Placebo Comparator|Placebo Oral Tablet|These patients will be started on the placebo medication at the time of enrollment. According to their regular scheduled visits every 1 to 3 weeks, they will meet with the research nurse and be given a new placebo medication to take once a day.
11198803|NCT03392727|Experimental|Study Box & Education Session|Parents are provided a baby box and infant health and safety products and participate in a face to face educational session
11198804|NCT03392727|Active Comparator|Community Box & Online Education|Parents are informed how to receive a free box from a community site and are provided a guide to online resources for prenatal and infant health promotion
11198805|NCT03392714|Experimental|R-B(O)AD|Intravenous R-B(O)AD every 4 weeks for up to 4 cycles
11198806|NCT03392701|Experimental|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
11198807|NCT03392701|Placebo Comparator|Placebo|NaCl
11198808|NCT03392688|Experimental|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.
~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
11198809|NCT03392688|Active Comparator|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.
~Surface EMG, Q angle measurement were administered to the control group."
11198810|NCT03392675|Experimental|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
11198811|NCT03392675|No Intervention|Control|Usual care and asked to complete measures at follow-up time points.
11198812|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
11198813|NCT03392662||Hemopatch Sealant Use with General Surgery|
11198814|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
11198815|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
11198816|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
11198817|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
11198818|NCT03392649|No Intervention|Sham Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, but the Parasym will not be turned on and the subject will not receive any stimulation. The clip will be switched to the other ear every 4 hours for a total of 48 hours.
11198819|NCT03392649|Experimental|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, and the subject will receive continuous stimulation for 48 hours. The clip will be switched to the other ear every 4 hours.
11198820|NCT03392636|Experimental|Group A|Mitchell Banks Herniotomy
11198821|NCT03392636|Experimental|Group B|Fergusson Gross Herniotomy
11198822|NCT03392623|Other|Control group|Macules of melasma without any treatment
11198823|NCT03392623|Experimental|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
11198824|NCT03392623|Experimental|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
11198825|NCT03392623|Placebo Comparator|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
11198826|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
11198827|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
11198828|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
11198829|NCT03392597|Experimental|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
11198830|NCT03392597|Active Comparator|Programming-as-Usual|Usual programming implemented in afterschool programs.
11198831|NCT03392584||APR|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR)
11198832|NCT03392584||APR with VRAM|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) and subsequent reconstruction of the perineum with a vertical rectus abdominis myocutaneous flap (VRAM)
11198833|NCT03392571|Experimental|Resectable and borderline restable|"Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.
~Patients receive 3 cycles of preoperative chemotherapy (NGC-triple regimen). The regimen consists of gemcitabine 800 mg/m2, Nab-paclitaxel 100 mg/m2and Cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).
~Patients will be evaluated for adjuvant therapy within 12 weeks of surgery which will consist of Nab-paclitaxel, gemcitabine, and Cisplatin IV weekly x 2, every 3 weeks (one cycle) x 3 cycles."
11198834|NCT03392558|Experimental|Nature-Based Sensitive Skin Regimen|"Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):
~Burt's Bees Sensitive Facial Cleanser (to be used day and night)
~Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)
~Burt's Bees Sensitive Night Cream (to be used at night)"
11198835|NCT03392558|Active Comparator|Control Regimen|"Control Skin Care Regimen (Control Regimen, CR):
~Cetaphil Gentle Skin Cleanser (to be used day and night)
~Cetaphil Moisturizing Lotion (to be used day and night)"
11198836|NCT03392545|Experimental|Combined immune adjuvants and radiation|Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
11198837|NCT03392532|Other|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
11198838|NCT03392532|Other|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
11198839|NCT03392519||Chronic stroke|More than 3 months post-stroke Ischemic or hemorrhagic stroke
11198840|NCT03392506|Experimental|EBUS-TBNA-RTE|Patients do CT、 PETCT examination and EBUS-TBNA-RTE
11198841|NCT03392493|Experimental|Group A|In the phase 1 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week); In the phase 2 :12 training sessions of Standard treatment only. (60 minutes a time, 2 times a week)
11198842|NCT03392493|Active Comparator|Group B|In the phase 1 :12 training sessions of Standard treatment only(60 minutes a time, 2 times a week) ; In the phase 2 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
11198843|NCT03392480||Adult non-haptoglobin 2-2 group|Patients are 45 to 65 years old.
11198844|NCT03392480||Adult haptoglobin 2-2 group|Patients are 45 to 65 years old.
11198845|NCT03392480||Elder non-haptoglobin 2-2 group|Patients are elder than 65 years.
11198846|NCT03392480||Elder haptoglobin 2-2 group|Patients are elder than 65 years.
11198847|NCT03392467|Experimental|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
11198848|NCT03392467|Placebo Comparator|Placebo|normal saline
11198849|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
11198850|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
11198851|NCT03392441|Experimental|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
11198852|NCT03392428|Experimental|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.
~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
11198853|NCT03392428|Active Comparator|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.
~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
11198854|NCT03392415|Active Comparator|Initial conservative treatment|Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
11198855|NCT03392415|Experimental|initial interventional treatment|CTO PCI attempt as initial strategy with medical optimization simultaneously
11198856|NCT03392389|Experimental|mRNA-1653|
11198857|NCT03392389|Placebo Comparator|Placebo|
11198858|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.
~Other name: Serenase"
11198859|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
11198860|NCT03392350|Active Comparator|Behavioral Intervention arm|"A behavioral intervention consisting of a physician body scan consultation with a radiologist which included viewing self imagery followed by an 18 month behavioral intervention which included educational modules covering:
~Responding to Stress More Effectively Enhancing the effects of Relaxation Nourishing your immune system Energizing your Body Welcoming Others and Strengthening Relationships"
11198861|NCT03392350|Active Comparator|Control Group|No Intervention
11241244|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-125 (233mg)|
11198862|NCT03392337|Experimental|Open Label Narrowband UVB phototherapy|Open Label Narrowband UVB phototherapy for 12 weeks.
11198863|NCT03392324|Experimental|PRIMA|Implantation of PRIMA device
11198864|NCT03392311|Experimental|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
11198865|NCT03392298|Experimental|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
11198866|NCT03392298|No Intervention|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
11198867|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
11198868|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
11198869|NCT03392272|Experimental|Tisseel|Müller's Muscle-Conjunctival Resection (MMCR) using glue instead of sutures
11198870|NCT03392272|Active Comparator|Sutures|Müller's Muscle-Conjunctival Resection (MMCR) using the usual procedure
11198871|NCT03392259|No Intervention|Control group|conventional treatment
11198872|NCT03392259|Experimental|App group|conventional treatment + use of smartphone app.
11198873|NCT03392246|Experimental|Osimertinib + Selumetinib|"Selumetinib are to be administered orally intermittently (4 days on, 3 days off)
~Osimertinib are to be administered orally on a daily basis"
11198874|NCT03392233|Experimental|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
11198875|NCT03392220|Experimental|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
11198876|NCT03392220|Experimental|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
11198877|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
11198878|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
11198879|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
11198880|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
11198881|NCT03392181|Experimental|18F-DCFPyL|
11198882|NCT03392168|Experimental|Cohort 1 - PK and Safety|Open Label ARQ-151 cream 0.5%
11198883|NCT03392168|Active Comparator|Cohort 2 - ARQ-151 cream 0.5%|Blinded
11198884|NCT03392168|Active Comparator|Cohort 2 - ARQ-151 cream 0.15%|Blinded
11198885|NCT03392168|Placebo Comparator|Cohort 2 - ARQ-151 cream placebo|Blinded
11198886|NCT03392155|Experimental|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
11198887|NCT03392142|Experimental|tabelecleucel|Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2 x 10^6 cells/kg on Days 1, 8 and 15, followed by observation through Day 35. Treatment will continue until maximal response, unacceptable toxicity, initiation of non-protocol therapy, or failure of multiple tabelecleucel cell products.
11198888|NCT03392129|Experimental|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
11198889|NCT03392129|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
11198890|NCT03392116|Experimental|Part A: NGM120|Single Dose
11198891|NCT03392116|Placebo Comparator|Part A: Placebo|Single Dose
11198892|NCT03392116|Experimental|Part B: NGM120|Multiple Dose
11198893|NCT03392116|Placebo Comparator|Part B: Placebo|Multiple Dose
11198894|NCT03392103|Experimental|postoperative CRT|postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
11198895|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care
~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.
~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences
~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
11198896|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
11198897|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
11198898|NCT03392064|Experimental|AMG 119 Treatment|AMG 119 administered as a one-time intravenous infusion at different cell dose levels
11198899|NCT03392051|Experimental|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
11198900|NCT03392051|Experimental|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
11198901|NCT03392038|Experimental|Thin ADM|Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR)
11198902|NCT03392038|Active Comparator|Thick ADM|Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM)
11198903|NCT03392025|Active Comparator|Flaxseed|Daily consumption of 30 grams flaxseed for 3 months
11198904|NCT03392025|Active Comparator|Flaxseed and the Mediterranean-like diet|Daily consumption of 30 grams flaxseed in adjunct to the Mediterranean-like diet for 3 months
11198905|NCT03392025|Placebo Comparator|Placebo|Daily consumption of Placebo for 3 months
11198906|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
11198907|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
11198908|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
11198909|NCT03391973|Experimental|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
11198910|NCT03391947|Experimental|semilunar coronally positioned flap|A semilunar incision will be done following the curvature of the gingival margin and ending about 2 to 3 mm short of the tip of the papillae. The most apical distance of this incision to the gingival margin will be obtained by adding the bone sounding measurement to the recession height. Perform a split-thickness dissection coronally from the incision, and connect it to an intrasulcular incision. The tissue will be collapsed coronally, covering the denuded root. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite. Finally, the area will be covered with a periodontal dressing. This is called semilunar coronally positioned flap.
11198911|NCT03391947|Active Comparator|coronally advanced flap|Coronally positioned flap will be initiated with two vertical incisions, extending from a mesial and distal linear angle at the cementoenamel junction (CEJ) and go beyond the mucogingival junction. A split thickness flap will be prepared by sharp dissection mesial and distal to the recession and connected with an intra crevicular incision. On the facial aspect of the tooth, a full thickness flap, approximately 3-4 mm apical to crest of alveolar bone. Then, the flap will be returned and sutured it at 1 mm coronal to the CEJ after de-epithelize the papillae. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite and sutured in the papilla region and releasing incision. Finally, the area will be covered with a periodontal dressing.
11198912|NCT03391934|Experimental|Cetuximab+ FOLFIRI|Cetuximab (Produced by CinnaGen Co.): 400 mg/m2 weekly in the first dose and 250 mg/m2 in the next doses Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
11198913|NCT03391934|Active Comparator|Cetuximab + FOLFIRI|Erbitux® (Produced by Merk Co.): 400 mg/m2 weekly Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
11198914|NCT03391921|Active Comparator|ARM B: 3 doses (0, 2 and 6 months)|ARM B: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
11198915|NCT03391921|Experimental|ARM A: 2 doses (0 and 6 months )|ARM A: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 2 doses at 0 and 6 months intramuscularly. A third facultative dose will be given if antibodies measured at month 7 are insufficent.
11198916|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
11198917|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
11198918|NCT03391895|Active Comparator|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
11198919|NCT03391895|Experimental|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
11198920|NCT03391882|Experimental|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
11198921|NCT03391882|Active Comparator|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
11198922|NCT03391869|Experimental|Arm A (ipilimumab, nivolumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients receive nivolumab IV over 60 minutes on days 1, 15, and 29 and ipilimumab IV over 90 minutes on day 1. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
11198923|NCT03391869|Experimental|Arm B (ipilimumab, nivolumab, LCT)|"INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients receive LCT consisting of surgery and/or radiation 14 days after completion of Induction Phase. Patients then receive nivolumab and ipilimumab as in arm A beginning within 4 weeks after LCT. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
11198924|NCT03391856|Experimental|intervention arm|NAC 400mg p.o tid from day 60 to day 90 post transplant
11198969|NCT03391544|Experimental|V4c toric ICL implantation Group|V4c toric ICL implantation Group
11198925|NCT03391856|Other|controlled arm|Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count <20000/ul
11198926|NCT03391843|Experimental|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
11198927|NCT03391830|Active Comparator|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
11198928|NCT03391830|Placebo Comparator|Placebo|Placebo
11198929|NCT03391817|Active Comparator|Intervention arm|Fecal transplant from a thin donor
11198930|NCT03391817|Placebo Comparator|Placebo arm|Fecal transplant made from patients own feces
11198931|NCT03391804|Experimental|ALLN-177|ALLN-177 7,500 units (2 capsules)
11198932|NCT03391791||Genetically engineered T Cell Receptor- treated|Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial
11198933|NCT03391778|Experimental|GSK3377794|Long term follow-up of subjects with solid or hematological malignancies who have received NY-ESO-1ᶜ²⁵⁹T in a previous trial
11198934|NCT03391765|Experimental|Group 2|Dose 2 ABBV-8E12
11198935|NCT03391765|Experimental|Group 1|Dose 1 ABBV-8E12
11198936|NCT03391752||Royal Alexandria|Administrative records
11198937|NCT03391752||Pasqua Regional hospital|Administrative records
11198938|NCT03391752||Concordia Hospital|Administrative records
11198939|NCT03391752||Niagara General Hospital|Administrative records
11198940|NCT03391752||Hospital 6|Administrative Records
11198941|NCT03391752||Hospital 7|Administrative Records
11198942|NCT03391752||Hospital 8|Administrative Records
11198943|NCT03391752||Hospital 9|Administrative Records
11198944|NCT03391752||Hospital 10|Administrative records
11198945|NCT03391739|Experimental|Arm 1|CART-19 cells treat
11198946|NCT03391726|Experimental|Arm 1|CART-19 cells treat
11198947|NCT03391713|No Intervention|Control|No exposure to waiting room posters
11198948|NCT03391713|Active Comparator|Intervention|During the second half of the study (two weeks), there will be an education poster in the waiting room of the clinic, fashioned after the Face, Arms, Speech, Time (FAST) poster developed by the American Heart Association (AHA), but in Malay.
11198949|NCT03391700|Active Comparator|Moderate muscle relaxation|Rocuronium is administered to maintain moderate relaxation during operation. This is conventional muscle relaxation level of this institute.
11198950|NCT03391700|Experimental|Deep muscle relaxation|Rocuronium is administered to maintain deep relaxation during operation.
11198951|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
11198952|NCT03391674|Experimental|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
11198953|NCT03391674|No Intervention|Observational|Observational
11198954|NCT03391661|Experimental|Chronic Pain and the Brain|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
11198955|NCT03391661|Placebo Comparator|Health Behavior Control|This 15 to 20-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
11198956|NCT03391648||Cesarean|
11198957|NCT03391635|Experimental|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.
~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
11198958|NCT03391635|Active Comparator|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.
~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
11198959|NCT03391609|Placebo Comparator|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
11198960|NCT03391609|Active Comparator|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
11198961|NCT03391596|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
11198962|NCT03391596|Active Comparator|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
11198963|NCT03391596|Other|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
11198964|NCT03391583|Experimental|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
11198965|NCT03391583|No Intervention|Standard of Care|Current standard of care provided in tertiary health care setting
11198966|NCT03391570|Active Comparator|COX-2 inhibitor (Celecoxib)|Celebrex; COX-2 inhibitor
11198967|NCT03391570|Placebo Comparator|Placebo drug (Ramnos)|Ramnos; Lactobacillus casei variety rhamnosus
11198968|NCT03391557|Experimental|Patients with the UE examination|Patients with enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max > 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction were finally selected.
11198970|NCT03391531|Active Comparator|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine [Chirocaine®] 0.375% Epi 1/200000.
11198971|NCT03391531|Placebo Comparator|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
11198972|NCT03391505|Experimental|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
11198973|NCT03391505|Experimental|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
11198974|NCT03391505|Placebo Comparator|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
11198975|NCT03391492||influenza group|All consecutive patients older than 18 years ,admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
11198976|NCT03391492||control group|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza,
11198977|NCT03391479|Experimental|Avelumab and Best Supportive Care|"Avelumab will be given intravenously (by vein) at a dose of 10 mg/kg, once every 2 weeks
~Best supportive care will be provided as required."
11198978|NCT03391466|Experimental|Axicabtagene Ciloleucel Treatment|
11198979|NCT03391466|Active Comparator|Standard of Care Therapy|
11198980|NCT03391440|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
11198981|NCT03391427|Experimental|Lidocaine|This group will receive lidocaine infusion perioperatively
11198982|NCT03391427|Experimental|Ketamine|This group will receive ketamine infusion perioperatively
11198983|NCT03391427|Experimental|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
11198984|NCT03391427|Placebo Comparator|placebo|This group will receive saline infusion as placebo perioperatively
11198985|NCT03391414|Experimental|hypertonic bicarbonate|subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer
11198986|NCT03391414|Active Comparator|hypertonic saline|subjects will be administered a solution of 7% sodium chloride by nebulizer
11198987|NCT03391401||Adip1|Patients with morbid obesity (i.e. BMI >35 kg/sqm) and age >18 scheduled for bariatric surgery (all standard procedures included)
11198988|NCT03391388|Experimental|Cohort I (3D-CRT APBI)|Patients undergo 3D-CRT APBI for 3-5 days.
11198989|NCT03391388|Experimental|Cohort II (proton APBI)|Patients undergo proton beam radiation therapy APBI for 3-5 days.
11198990|NCT03391388|Experimental|Cohort III (brachytherapy APBI)|Patients undergo brachytherapy ABPI for 3-5 days.
11198991|NCT03391375|Experimental|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
11198992|NCT03391362|Experimental|Stereotactic Radiation|"Stereotactic radiation will begin within 14 days of the MRI used for radiation planning
~Lesions <2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction
~Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction
~Lesions >3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
11198993|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
11198994|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
11198995|NCT03391323|Other|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
11198996|NCT03391323|Other|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
11198997|NCT03391310|Experimental|Honey dressing group|In this group, the wound will be cleaned with normal saline and then honey (medicated ) will be applied to cover the wound surface. The dressing will be changed once soiled (alternate day in most cases). The dressing will be applied for a maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
11198998|NCT03391310|No Intervention|Standard treatment group|In this group, the wound will be first cleaned with 'povidone iodine' and then covered with hydrocolloid dressing changed alternate day for maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
11198999|NCT03391297|Experimental|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
11199000|NCT03391297|Active Comparator|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
11199001|NCT03391284|Experimental|Oral|1000 mg acetominophen oral
11199002|NCT03391284|Active Comparator|Intravenous|1000 mg acetominophen intravenous
11199003|NCT03391271|Experimental|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
11199004|NCT03391271|Placebo Comparator|Placebo group|No PBMT
11199005|NCT03391258|Experimental|Bone Regeneration with GLAM technique|At the beginning of each surgery, a venipuncture will be performed, to obtain the L-PRF membranes. Also, two white topped tubes will be centrifuged for 3 minutes to obtain PRP. After implant placement, achieving a primary stability of at least 45 Ncm, the stiff bone-block (L-PRF membranes and PRP combined with bovine xenograft) will be used in the buccal plate of the pre-maxilla, to enhance bone volume in the esthetic area.
11199006|NCT03391245||Cirrhotic patients with or without infection|"We will include admitted patients with liver cirrhosis irrespective of the underlying etiology during 6 months in Al Rajhi Tertiary Liver Hospital, Assiut, Egypt. They will be divided into 2 Groups. Group I: Cirrhotic patients with evidence of infections at any site and Group II: Cirrhotic patients without evidence of infections.
~Diagnosis of infection will based on related clinical symptoms and signs with laboratory and radiological findings."
11242560|NCT03091166|No Intervention|No Dexmedetomidine|
11199007|NCT03391232|Experimental|PolyPEPI1018 CRC Vaccine|The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses.
11199008|NCT03391219|Active Comparator|intravitreal Bevacizumab|
11199009|NCT03391219|Active Comparator|intravitreal Bavacizumab and Fasudil|
11199010|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
11199011|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
11199012|NCT03391193|Experimental|Multi-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal containing) in multi-dose presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
11199013|NCT03391193|Active Comparator|Single-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free) in single-dose syringe presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
11199014|NCT03391180|Experimental|ICON Remineralization|Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.
11199015|NCT03391180|Active Comparator|CPP-ACPF|Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.
11199016|NCT03391167|Sham Comparator|Control|Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
11199017|NCT03391167|Experimental|ESP Block|In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
11199018|NCT03391154|Active Comparator|levothyroxine|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy
11199019|NCT03391154|Placebo Comparator|placebo|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive placebo throughout the pregnancy
11199020|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:
~Heart Failure
~COPD
~Cancer"
11199021|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:
~Heart Failure
~COPD
~Cancer"
11199022|NCT03391089|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
11199023|NCT03391076|Experimental|FilmArray group|Patients in this group will use FilmArray Respiratory Panel to test potential viral pathogens.
11199024|NCT03391076|No Intervention|Routine test group|Patients in this group will use clinical routine methods to test potential viral pathogens.
11199025|NCT03391063|Experimental|reinforced polyamide denture base|metal reinforced polyamide denture base
11199026|NCT03391063|Active Comparator|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
11199027|NCT03391050|Experimental|APR-246 + Dabrafenib|
11199028|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
11199029|NCT03391024|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
11199030|NCT03391011|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
11199031|NCT03390998||Peripartum SCAD|Female patients who experienced any SCAD event that occurred during pregnancy or up to 1 year post-delivery
11199032|NCT03390998||Non-peripartum SCAD|Female patients who experienced any SCAD with event onset outside of the pregnancy period
11199033|NCT03390972|Experimental|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
11199034|NCT03390972|Placebo Comparator|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
11199035|NCT03390959|Experimental|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
11199036|NCT03390959|Other|Control Group|The group continues in their daily lives with phone monitoring.
11199037|NCT03390946|Experimental|four-drug interval-compressed regimen|"Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.
~Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.
~Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.
~After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.
~Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'."
11199038|NCT03390933|Experimental|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
11199039|NCT03390920|Experimental|Amniotic|The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the amniotic product utilized will be either 0.5 cc's or 1.0cc's.
11199040|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
11199041|NCT03390881|Experimental|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
11199042|NCT03390881|Active Comparator|Sugar condition|Effects of sugar consumption on breath acetone changes
11199043|NCT03390881|Active Comparator|Fat condition|Effects of fat consumption on breath acetone changes
11199044|NCT03390868|Experimental|Intervention arm|Phase 1, participants in the intervention group will take part in an web-based training for staff working with people with intellectual disabilities and challenging behaviour aiming to in a more effective way communicate to prevent challenging behaviour. The participants (staff) will by their own, go through the web-based training program during working hours. Measurement are conducted before intervention, at intervention completion an average of 12 weeks, and for a 3 month follow up after completed intervention
11199045|NCT03390868|Other|control arm|Control arm: participants in the control-group will maintain regular care and have the opportunity to receive the web-based training for staff working with people with intellectual disabilities and challenging behaviour in phase 2.
11199046|NCT03390855|Experimental|Broccoli sprout and follow up|Daily consumption of 30 g of raw, fresh, broccoli sprouts, not cooked, during 10 weeks (70 days), followed by other 90 days of no ingestion of broccoli sprouts
11199047|NCT03390842|Experimental|TRC101|Administered once daily (QD) for 40 weeks
11199048|NCT03390842|Placebo Comparator|Placebo|Administered once daily (QD) for 40 weeks
11199049|NCT03390829||Patients|
11199050|NCT03390829||Doctors|
11199051|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
11199052|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
11199053|NCT03390803||patients with hemifacial spasm|
11199054|NCT03390803||healthy control subjects|
11199055|NCT03390790|Experimental|Lidocaine gel|If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.
11199056|NCT03390790|Placebo Comparator|Lubricant gel|If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.
11199057|NCT03390777|Active Comparator|surgery only|Surgery consisting in debridement/removal of affected tissue/s will be performed.
11199058|NCT03390777|Active Comparator|surgery and PRGF|Surgery consisting in debridement/removal of affected tissue/s will be performed. Platelet Rich Growth Factor (device) will be produced by a venous blood sampling of the patient and applied to the treated area
11199059|NCT03390764|Active Comparator|4:1 closure group|Patients randomized to and receiving the intervention small stitch 4:1 technique for closure of the abdominal wall.
11199060|NCT03390764|Active Comparator|RTL plus 4:1 closure group|Patients randomized to and receiving the intervention reinforced tension-line suture plus small stitch 4:1 technique for closure of the abdominal wall.
11199061|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
11199062|NCT03390738|Experimental|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
11199063|NCT03390725|Experimental|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
11199064|NCT03390725|Active Comparator|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
11199065|NCT03390712||Paliperidone Palmitate|Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
11199066|NCT03390712||Risperidone Long-acting injection.|Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.
11199067|NCT03390699|Experimental|before and after partial maxillectomy|Microbial profile among patients before and after partial maxillectomy
11199068|NCT03390686|Experimental|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
11199069|NCT03390686|Active Comparator|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
11199070|NCT03390673|Experimental|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
11199071|NCT03390673|Active Comparator|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
11199072|NCT03390673|Active Comparator|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
11199073|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
11199074|NCT03390647|Experimental|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
11199075|NCT03390647|Experimental|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
11199076|NCT03390647|Experimental|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
11199077|NCT03390608||Women with T1ab breast cancer.|
11199234|NCT03389594|No Intervention|Surgical guide designed from voxel size 0.2mm|Surgical guide will be designed based on CBCT voxel size 0.2mm
11199078|NCT03390595|Experimental|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
11199079|NCT03390595|Active Comparator|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
11199080|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
11199081|NCT03390582||healthy controls|healthy controls are all from normal volunteers
11199082|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
11199083|NCT03390582||treated GD|GD patients treated by Methimazole Pill
11199084|NCT03390569|Experimental|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
11199085|NCT03390556|Experimental|Asthma education|
11199086|NCT03390543|Experimental|Device group (Group D)|Arm Description: Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound and simple needle guide device.
11199087|NCT03390543|Placebo Comparator|sono only group (Group S)|Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound without simple needle guide device.
11199088|NCT03390530|Active Comparator|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
11199089|NCT03390530|Placebo Comparator|Placebo treatment|Intravenous placebo treatment every 12 hours.
11199090|NCT03390517|Experimental|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
11199091|NCT03390517|No Intervention|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
11199092|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]).
11199093|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
11199094|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs).
11199095|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
11199096|NCT03390491|Experimental|OnTrack>TheGame (OTG)|Participants randomized to the OTG group (n=100) will have the option to play the online role-playing game for a period of 2 months. They will receive weekly email reminders that the game remains available to them.
11199097|NCT03390491|Other|Recovery Videos (RV)|Participants randomized to the RV group (n=100) will have the option to visit a website that will contain the recovery videos and the static information that is contained in the game. The RV group will also have 2 months to view the materials on the website and will receive weekly email reminders that the website/videos remain available to them. At the end of the study (after the follow-up assessment), the RV participants will be provided access to the game.
11199098|NCT03390478|No Intervention|Control Group|The participants that will be assign to the control group will receive institutional usual care.
11199099|NCT03390478|Experimental|Combined Intervention Group|The participants that will be assigned to the experimental group will receive the Combined Intervention Program
11199100|NCT03390465|Other|Arm1(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
11199101|NCT03390465|Other|Arm2(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
11199102|NCT03390465|Other|Arm3(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
11199103|NCT03390465|Other|Arm4(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
11199104|NCT03390465|Other|Arm5(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
11199105|NCT03390465|Other|Arm6(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
11199235|NCT03389594|Active Comparator|Surgical guide designed from voxel size 0.4m|Surgical guide will be designed based on CBCT voxel size 0.4 mm
11199236|NCT03389568|Experimental|Intervention for caregivers of ICU patients|
11199106|NCT03390452|Experimental|Intervention|"The parents will receive Mobile phone messages about oral hygiene and healthy dieting of their children through teachers.
~The message format will be text and images, depending upon the education/ literacy level of the parents. Parents will be reminded and information reinforced, at frequent intervals for a period of six months.
~Oral hygiene of School children will be assessed before intervention, after 6 months interval"
11199107|NCT03390452|No Intervention|Control|The primary school children in the control group will not receive any intervention via their parents or teachers (in-active controls) but will be observed on selected outcome measures for baseline data, then at six month interval to compare for differences (if any) with intervention group.
11199108|NCT03390439|Active Comparator|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
11199109|NCT03390439|Experimental|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
11199110|NCT03390426|Experimental|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
11199111|NCT03390426|Placebo Comparator|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
11199112|NCT03390413|Active Comparator|Robot|
11199113|NCT03390413|Experimental|Cryo|
11199114|NCT03390400|Active Comparator|Anterior Capsulotomy before Lens Fragmentation|Anterior capsulotomy will be performed by femtosecond laser before lens fragmentation
11199115|NCT03390400|Active Comparator|Lens Fragmentation before Anterior Capsulotomy|Lens fragmentation will be performed by femtosecond laser before anterior capsulotomy
11199116|NCT03390387|Experimental|Dexa intermittent|Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).
11199117|NCT03390387|Active Comparator|Dexa constant|Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).
11199118|NCT03390387|Active Comparator|Dexa|Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.
11199119|NCT03390387|Experimental|Medrol|Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.
11199120|NCT03390387|Experimental|IDA|Induction and consolidation therapy with Idarubicin
11199121|NCT03390387|Active Comparator|DNR|Induction and consolidation therapy with Daunorubicin
11199122|NCT03390387|Experimental|Protocol Ib+|Two-phase induction therapy (additional second phase of induction - protocol Ib)
11199123|NCT03390387|Active Comparator|Protocol Ib-|Standard induction therapy (without second phase)
11199124|NCT03390387|Active Comparator|Bortezomib-|Consolidation therapy without Bortezomib
11199125|NCT03390387|Experimental|Bortezomib+|Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)
11199126|NCT03390374|Experimental|Nystatin group|Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day
11199127|NCT03390374|No Intervention|Control group|Sterile water 1 mL three times a day for oral hygiene
11199128|NCT03390361|Active Comparator|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
11199129|NCT03390361|Placebo Comparator|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
11199130|NCT03390335|Experimental|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
11199131|NCT03390322|Experimental|Duodenal Glycemic Control™|
11199132|NCT03390309|Other|Partially Hydrolyzed Formula|Infant was identified and got 1 or more scores by using infant feeding & stool pattern questionnaire at Visit 1 will be assigned into experimental group randomly
11199133|NCT03390309|Placebo Comparator|Normal Formula|Normal Formula
11199134|NCT03390296|Experimental|Arm A (anti-OX40 antibody PF-04518600)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11199135|NCT03390296|Experimental|Arm B (azacitidine, venetoclax, GO)|Patients receive azacitidine IV over 10-40 minutes or via injection SC on days 1-7 or 1-5 and 8-9. Patients also receive venetoclax PO on days 1-28 and GO IV over 2 hours on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11199136|NCT03390296|Experimental|Arm C (azacitidine, GO, avelumab)|Patients receive azacitidine and GO as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11199137|NCT03390296|Experimental|Arm D (azacitidine, venetoclax, avelumab)|Patients receive azacitidine and venetoclax as in Arm A and avelumab as in Arm C. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11199138|NCT03390296|Experimental|Arm E (azacitidine, avelumab, anti-OX40 antibody PF-04518600)|Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11199139|NCT03390296|Experimental|Arm F (GO, glasdegib)|Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11199140|NCT03390283||Observational (Online survey)|Participants complete online survey on an iPad over 20 minutes.
11199141|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
11199142|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
11199143|NCT03390244|Experimental|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
11199165|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.
~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
11244025|NCT03081208|Placebo Comparator|Placebo|
11199144|NCT03390231|Experimental|Stem Cell Educator|"The Stem Cell Educator (SCE) technology involves a closed-loop system that circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns only the educated immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have been conducted to demonstrate the proof of concept and clinical safety of SCE therapy. They suggest that SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages that are encountered through the action of the autoimmune regulator (AIRE) and other molecular mechanisms. Following induction of immune tolerance in the immune cells, the immune balance and homeostasis may be restored when treated cells are returned in vivo."
11199145|NCT03390218|Experimental|TAO (Therapy Assisted Online)|TAO participants will attend a once weekly group in a computer lab. Each participant will complete an interactive educational module using an evidence based protocoled treatment for anxiety and/or depression, and have a brief session with the group leader to discuss application of the content. Participants will have access to a companion app they may use between sessions to practice skills and reinforce learning.
11199146|NCT03390218|Active Comparator|Treatment as usual|After the completion of a psychosocial assessment, and development of a treatment plan, clients are offered individual and group therapy sessions, case management services, and medication management services depending on the diagnoses. Individual and group therapy is often generic in nature as well, although some structured, evidence-based treatments are offered such as Psycho-Education Multi-Family Group and Illness Management Recovery.
11199147|NCT03390205||Patients|
11199148|NCT03390205||Controls|
11199149|NCT03390192|Experimental|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
11199150|NCT03390192|Active Comparator|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
11199151|NCT03390179||diabetes|Patient with non insulin diabetes
11199152|NCT03390179||control|Patient without diabete
11199153|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
11199154|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
11199155|NCT03390153|Experimental|semi flexible socket group|A new form of residuum containment is the semi-flexible carbon fiber prosthetic socket. A semi-flexible carbon fiber socket is constructed with the same security for the subject in mind, and is even more lightweight than a rigid socket. The carbon fiber and resin used in a semi-flexible socket may provide the same durability and stability as previous designs, but will deform, intentionally, without failing (breaking). This distinct feature of semi-flexible sockets makes them a potential option for people living with limb loss. By moving slightly with the residual limb, the socket-user-interface should experience fewer forces/stresses, and yield greater comfort for the prosthetic user.
11199156|NCT03390153|Active Comparator|rigid fiber socket group|A rigid carbon fiber socket is constructed for security and is mechanically lightweight to ensure stability and efficient build height. Carbon is used for its durability and stability. It proves to be a detriment in comfort and flexibility. The standard for carbon fiber weaves come in two forms: Unidirectional (UD) and Bidirectional (BD). UD carbon fiber has a zero-degree alignment, which is highly durable when compressed, but has low torsional durability. The BD carbon fibers are aligned in a 90 degree angle allowing for moderate compression and torsional strength. When oriented at 45 degrees to the line of progression, fibers become more flexible and exhibit greater torsional strength. Resins and glass composites are added to ensure security and sturdiness.
11199157|NCT03390140|Experimental|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
11199158|NCT03390140|Active Comparator|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
11199159|NCT03390140|No Intervention|Control|No group sessions, no YouTube videos, no workbook
11199160|NCT03390127|Experimental|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
11199161|NCT03390127|No Intervention|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
11199162|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
11199163|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
11199164|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.
~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
11199166|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.
~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
11199167|NCT03390075||ResearchNow NuVal shoppers|a convenience sample of 665 shoppers at two NuVal chains.
11199168|NCT03390062|Experimental|apatinib|apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death
11199169|NCT03390049|Active Comparator|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
11199170|NCT03390049|Sham Comparator|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
11199171|NCT03390036|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
11199172|NCT03390036|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
11199173|NCT03390036|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
11199174|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
11199175|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
11199176|NCT03390010|Active Comparator|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon and methergibe drugs during CS
~this group in which prevention of uterine atony is made by intrauterine misotac plus the usual syntocinon and methergine during cesarean section"
11199177|NCT03390010|Active Comparator|Active management of labour group|"Procedure: Giving syntocinon and methergine drugs during cesarean section
~this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and methergine during cesarean section"
11199178|NCT03389984|Experimental|Adalimumab|
11199179|NCT03389971|Active Comparator|multi-sidehole catheter|
11199180|NCT03389971|Experimental|USAT catheter|
11199181|NCT03389945|Active Comparator|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
11199182|NCT03389945|Experimental|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
11199183|NCT03389932|No Intervention|Standard of Care (Control)|For patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
11199184|NCT03389932|Experimental|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
11199185|NCT03389906|Experimental|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
11199186|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).
~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.
~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
11199187|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).
~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.
~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
11199188|NCT03389880|Active Comparator|Patellar denervation|
11199189|NCT03389880|Experimental|Non-patellar denervation|
11199190|NCT03389867|Experimental|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
11199191|NCT03389854|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
11199192|NCT03389854|Experimental|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
11199193|NCT03389854|Experimental|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
11199194|NCT03389854|Experimental|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
11199195|NCT03389841|Active Comparator|Intervention|Education of the caregiver
11199196|NCT03389841|No Intervention|No intervention|Usual care
11199197|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
11199198|NCT03389815|Experimental|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
11199199|NCT03389802|Experimental|Stratum 1|The recurrent, progressive, or refractory primary malignant non-brainstem CNS tumor patients will be treated with APX005M.
11199200|NCT03389802|Experimental|Stratum 2|The newly diagnosed diffuse intrinsic pontine gliomas (DIPGs) patients will be treated with APX005M.
11199201|NCT03389789|Experimental|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
11199202|NCT03389789|Experimental|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
11199203|NCT03389789|Active Comparator|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
11199204|NCT03389789|Active Comparator|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
11199205|NCT03389763|Experimental|SPI-guided remifentanyl|remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50%
11199206|NCT03389763|Experimental|PRD-guided remifentanyl|solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50%
11199207|NCT03389763|Experimental|BBS-guided remifentanyl|BBS assessment every 5 minutes, solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute; when BBS>2, infusion speed of remifentanyl will be increased by 50%
11199208|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxymorphone|Intravenous (IV) Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
11199209|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxycodone|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
11199210|NCT03389750|Active Comparator|Intravenous Challege Drug: Morphine|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
11199211|NCT03389750|Active Comparator|Intravenous Challege Drug: Hydromorphone|IV Dose Range: 0, 5.6, 10, 18 mg/70kg of the participant's body weight
11199212|NCT03389750|Placebo Comparator|Intravenous Challege Drug: Placebo|IV saline
11199213|NCT03389737|Experimental|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
11199214|NCT03389737|Active Comparator|Control|Control group will not have monthly contact with the physicians.
11199215|NCT03389724|Experimental|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
11199216|NCT03389724|No Intervention|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
11199217|NCT03389698|Active Comparator|Heatlthy Control Group|cognitively normal (CN) subjects in two age groups: young(20-40) and old (65-85)
11199218|NCT03389698|Active Comparator|Amnestic mild cognitive impairment (aMCI)|32 participants who have aMCI.
11199219|NCT03389685|Experimental|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
11199220|NCT03389685|Placebo Comparator|Saline Placebo|Unmarked syringe with 5 ml of saline
11199221|NCT03389672||spinal anesthesia|The anesthesia technique were applied with modified approach and conventional approach
11199222|NCT03389672||epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
11199223|NCT03389672||combined spinal-epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
11199224|NCT03389659|Experimental|Vitamin D3 group|vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
11199225|NCT03389659|Placebo Comparator|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
11199226|NCT03389646|Active Comparator|Treated with Device: Including sham|"Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
11199227|NCT03389646|No Intervention|Control|Control without CERAMENT device
11199228|NCT03389633|Experimental|Rehabilitation group|this group follows a 3 months rehab program
11199229|NCT03389633|No Intervention|No rehabilitation|This group does not follow a rehab program
11199230|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
11199231|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
11199232|NCT03389607||diabetic|the patients must have diabetic disease
11199237|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :
~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days
~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days
~Hydrocortisone 50mg every 6 hours x 4-days"
11199238|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
11199239|NCT03389542|Experimental|Early mitral valve repair|Surgery will be performed within 3 months after randomization. Clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. Echocardiography will be performed at discharge, at 6 months and at the end of follow-up.
11199240|NCT03389542|Active Comparator|Conservative management|Patients will be followed up by clinical interview and echocardiography every 6 months.
11199241|NCT03389516|Active Comparator|Polymem breast pads|
11199242|NCT03389516|Active Comparator|Lanolin|
11199243|NCT03389503|Active Comparator|Right radial approach|Right radial approach for coronary angiography and coronary intervention
11199244|NCT03389503|Active Comparator|Left radial approach|Left radial approach for coronary angiography and coronary intervention
11199245|NCT03389490|Experimental|Active|Insulin glargine 300U/ml
11199246|NCT03389490|Active Comparator|Control|Neutral Protamine Hagedorn insulin
11199247|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cisplatin & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)
~Step 2: Cisplatin 100 mg/m^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks
~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin & IMRT"
11199248|NCT03389477|Experimental|Cohort 1: 1: palbociclib, 2: Cetuximab & IMRT, 3: palbociclib|"Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)
~Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks
~Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab & IMRT"
11199249|NCT03389464|Experimental|confrontation group|computer-based confrontation with dysfunctional beliefs
11199250|NCT03389464|No Intervention|control group|no computer-based confrontation with dysfunctional beliefs
11199251|NCT03389451|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
11199252|NCT03389438|Experimental|Experimental arm|Participants who were treated with autologous Tcm cells immunotherapy.
11199253|NCT03389438|No Intervention|No intervention arm|Participants who were treated with no autologous Tcm cells immunotherapy.
11199254|NCT03389425|Experimental|SIMPLE weightloss group|
11199255|NCT03389412|Experimental|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
11199256|NCT03389412|Experimental|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
11199257|NCT03389412|Active Comparator|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
11199258|NCT03389412|Active Comparator|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
11199259|NCT03389412|Active Comparator|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
11199260|NCT03389412|Active Comparator|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
11199261|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
11199262|NCT03389386||Congestive Heart Failure (NYHA II-IV)|"N=90
~Patients with a clinically documented diagnosis of congestive heart failure (CHF), as assessed per New York Heart Association (NYHA) functional classification will be prospectively and consecutively enrolled in this group. Patients will be of both sexes, enrolled in 1:1 ratio.
~All subjects in this group will undergo blood withdrawal for laboratory analysis, transthoracic echocardiography (TTE) examination and will be treated with the Standard-of-care treatment according to their current clinical condition at admission."
11199263|NCT03389386||Healthy Control Group|"N=30
~Healthy volunteers (both sexes, enrolled in 1:1 ratio) with a negative history of cardiovascular diseases will be enrolled in this group that will serve as a study control.
~All subjects in this group will undergo blood withdrawal for laboratory analysis and transthoracic echocardiography (TTE) examination."
11199264|NCT03389373|Other|Child with full primary dentition|All children who match inclusion criteria are eligible to have a saliva sample obtained which will act as a proxy for bacterial levels. High bacteria levels are correlated with a higher risk of developing cavities.
11199265|NCT03389347|Experimental|Device feasibility (high-throughput assay, sequencing)|Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.
11199317|NCT03388918|Experimental|Intervention group|"The intervention group has three steps:
~Step I: Titration of medicine ( 0-3 months)
~Step II: Telerehabilitation program at healthcare center or by call center ( 3 months)
~Step III: Rehabilitation in everyday life ( 6 months)
~The patients is monitoring vital signs such as blood pressure, pulse, weight, steps, respiration, and sleep. Have access to a Heart Portal that is an information cite on heart failure. Via the portal patients can see measured values & communicate with staff. Every other week the patients fill in an online questionnaires on symptoms, sleep and well being."
11199266|NCT03389334|Experimental|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
11199267|NCT03389321|Experimental|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
11199268|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.
~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.
~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
11199269|NCT03389295|Experimental|Reduced Target Delineation and Radiation Doses|All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation. The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
11199270|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI > 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
11199271|NCT03389269||Matched controls|Healthy, obese with BMI > 27, the postprandial glucose metabolism will be tested with a meal test
11199272|NCT03389256|Experimental|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
11199273|NCT03389256|Active Comparator|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
11199274|NCT03389243|Experimental|metamizol|analgesic drug
11199275|NCT03389243|Experimental|paracetamol|analgesic drug
11199276|NCT03389243|Experimental|metamizole & paracetamol|analgesic drugs
11199277|NCT03389230|Experimental|Arm I (intratumoral/intracavitary delivery)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
11199278|NCT03389230|Experimental|Arm II (dual delivery Tcm enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
11199279|NCT03389230|Experimental|ARM III (dual delivery Tn/mem enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tn/mem cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
11199280|NCT03389217|Experimental|Real-tDCS + rehabilitation programme|The real transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 minutes over the the left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
11199281|NCT03389217|Active Comparator|Sham-tDCS + rehabilitation programme|The sham transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
11199282|NCT03389204|Active Comparator|Breast surgery and exercise|Patient that underwent breast surgery only without other intervention with exercise of the upper limb and instruction to continue after discharge.
11199283|NCT03389204|Active Comparator|Breast surgery and no exercise|Patient after breast surgery alone are discharged without exercise and instructions.
11199284|NCT03389204|Active Comparator|Breast, axilar surgery with exercise|Patients that underwent surgery of the breast and axilar lymph node surgery with exercise of the upper limb and instruction to continue after discharge.
11199285|NCT03389204|Active Comparator|Breast, axillar surgery without exercise|The patients that underwent surgery of the breast and axilar nodes samples or dissection are discharged without exercise and instructions.
11199286|NCT03389191|Experimental|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
11199556|NCT03387280||left circumflex coronary artery stenosis|The stenosis site is located at the left circumflex coronary artery according to the coronary angiograms.
11199287|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.
~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
11199288|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control.
~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
11199289|NCT03389165|Experimental|Elderly adults|Stair climbing with and without a wearable hip assist robot
11199290|NCT03389139|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia. (Near infrared spectroscopy (spinal anesthesia))
11199291|NCT03389139|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia. (Near infrared spectroscopy (general anesthesia)).
11199292|NCT03389126|Experimental|Avelumab|Avelumab 10 mg/kg every 2 wks until disease progression or unacceptable toxicity
11199293|NCT03389113|Experimental|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
11199294|NCT03389113|Active Comparator|Exercise only group|The control group performed the same session without vibration.
11199295|NCT03389100|Experimental|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
11199296|NCT03389087|Experimental|Apatinib and Etoposide Capsule|Apatinib and Etoposide Capsule
11199297|NCT03389061|Active Comparator|sofosbuvir/velpatasvir tablet|Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
11199298|NCT03389061|Experimental|sofosbuvir/velpatasvir crushed|Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
11199299|NCT03389048|Experimental|degenerative lumbar spine disease|patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200
11199300|NCT03389035|Experimental|CARCIK-CD19|
11199301|NCT03389022|Active Comparator|Treatment|0,15mg/kg (LBM) of intravenous single pre-incisional injection of ketamine given for bariatric patients in the operating room.
11199302|NCT03389022|Placebo Comparator|Control|The same amount of intravenous single pre-incisional injection of saline for bariatric patients in the operating room.
11199303|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.
~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
11199304|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.
~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
11199305|NCT03388996||Benign ovarian disease|The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.
11199306|NCT03388996||Malignant ovarian disease|The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.
11199307|NCT03388983|Experimental|6-week prehabilitation group|6-week prehabilitation
11199308|NCT03388983|No Intervention|Control group|Patients will receive standard preoperative care (including information about the surgery from an orthopedic surgeon, and a pamphlet summarizing tips of maintaining proper posture and staying active). The usual postoperative care does not include routine rehabilitation program though a short course of rehabilitation may be given based on orthopedic surgeons' discretion.
11199309|NCT03388970|Experimental|research group|normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。
11199310|NCT03388970|Placebo Comparator|placebo group|normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1
11199311|NCT03388957|Experimental|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
11199312|NCT03388957|Experimental|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
11199313|NCT03388957|Experimental|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
11199314|NCT03388944|Experimental|PCT group|PCT group
11199315|NCT03388944|No Intervention|Standard practice group|No intervention
11199316|NCT03388931|Experimental|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
11199318|NCT03388918|No Intervention|Traditional rehabilitation group|"This group follows the International Cardiac Guidelines. There are three steps in this arm:
~Step I: Titration of medicine (3 months).
~Step II: Traditional rehabilitation at the healthcare center ( 3 months).
~Step III: Everyday life with HF ( 6 months)
~The participants do not have access to the Heart Portal and is not monitoring any vital signs."
11199319|NCT03388905|Experimental|Wearable Cardioverter Defibrillator group|
11245459|NCT03070951|Experimental|OBE2109 dose 1 + Placebo Add-back|
11199322|NCT03388879|Experimental|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
11199323|NCT03388879|Active Comparator|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
11199324|NCT03388866|Active Comparator|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mite Dermatophagoides pteronyssinus, as represented below:
~Weekly dose schedule Monday Wednesday Friday
~st week 1 drop 2 drops 4 drops
~nd week 6 drops 8 drops 8 drops
~Monthly Dilution Schedule Dilution of mite extract
~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v
~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v
~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
11199325|NCT03388866|Placebo Comparator|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:
~Weekly dose schedule Monday Wednesday Friday
~st week 1 drop 2 drops 4 drops
~nd week 6 drops 8 drops 8 drops
~Intervention: Placebo - Immunotherapy allergen diluent"
11199326|NCT03388853|Experimental|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
11199327|NCT03388853|Placebo Comparator|Placebo|Placebo once daily for four weeks
11199328|NCT03388840|Experimental|Adipose derived stem cells suspention|suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
11199329|NCT03388840|Active Comparator|Platelet rich plasma|platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
11199330|NCT03388827|Experimental|Laminaria|Laminaria tent was introduced in the cervical canal
11199331|NCT03388827|Active Comparator|Laminaria plus Misoprostol|Laminaria and Misoprostol were introduced
11199332|NCT03388814|Active Comparator|Bupivacaine Group|Those patients randomized to surgeon infiltration will have a skin wheal performed with lidocaine at the site where an actual pectoralis nerve block would be performed as visualized using ultrasound. Surgeons performing infiltration techniques will be blinded to the contents of the injectate and those patients randomized to surgeon infiltration will receive pharmacy study drug labeled bupivacaine injected in the same fashion and volume as the saline group for oncologic and plastic surgery.
11199333|NCT03388814|Experimental|Pectoralis Nerve block Group|Those patients who are randomized to pectoralis nerve block will have randomization immediately preoperatively and will undergo the nerve block procedure using local anesthetic in the standard fashion. Those patients randomized to pectoralis block will have a standard volume of normal saline injected for oncologic and plastic surgery.
11199334|NCT03388801|Experimental|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
11199335|NCT03388788|Experimental|Normal Weight|Healthy lean controls [18.5<BMI<25 kg/m2 and WC <94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
11199336|NCT03388788|Experimental|Overweight|Healthy obese [30≤BMI<40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
11199337|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.
~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
11199338|NCT03388762|Active Comparator|GlucoSupreme™ Herbal|Each daily serving of four GlucoSupreme™ Herbal tablets includes extracts from: cinnamon bark (Cinnamomum cassia) 500 mg, banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid) 200 mg, kudzu root (Pueraria lobata standardized to 40% isoflavones) 200 mg, fenugreek seed (Trigonella foenum-graceum standardized to contain 60% saponins) 200 mg, and gymnema leaf (Gymnema sylvestre standardized to contain 25% gymnemic acid). Additionally, American ginseng root (Panax quinquefolius standardized to contain 5% ginsenosides) 200 mg, and berberine HCl derived from bark (Berberis aristata) 500 mg. Other ingredients include Cellulose (capsule), microcrystalline cellulose, silicon dioxide, and vegetable stearate.
11199339|NCT03388762|Placebo Comparator|Control|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
11199340|NCT03388749|Experimental|Liposomal annamycin|
11199341|NCT03388736|No Intervention|No lavender|No mist will be diffused into the environment.
11199342|NCT03388736|Active Comparator|0,1 lavender|0,1 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
11199343|NCT03388736|Active Comparator|0,3 lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
11199344|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:
~Identification of epigenetic signatures
~Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood
~Glucose, insulin and lipids in mothers during pregnancy
~Anthropometry and blood pressure"
11199345|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
11199346|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:
~Stability of epigenetic signatures in offspring through childhood and adolescence
~Relation of these signatures with phenotype"
11199347|NCT03388671|Active Comparator|TAB Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Transversus abdominis plane block.
11199348|NCT03388671|Active Comparator|Psoas Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided psoas block.
11199349|NCT03388645|Experimental|High Dose RSV A2|"The remaining volunteers receive one 107 PFU of RSV A2. This will be followed by daily clinical assessments and collection of nasal fluid and blood samples for virologic and immunologic assays. Subjects will have 2 follow-up outpatient visits at Day 28 and 56."
11199350|NCT03388645|Experimental|Low Dose RSV A2|The first four volunteers receive a single dose of 1Q^6.3 PFU of RSV A2. This is followed by daily clinical assessments and collection of nasal fluid and blood samples for virologic and immunologic assays. Subjects have 2 follow-up outpatient visits at Day 28 and 56.
11199351|NCT03388632|Experimental|Lead-in doublet A|Lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + ipilimumab (anti- CTLA-4) given IV on day 8 (IL-15 doses are limited to first 4 cycles only)
11199352|NCT03388632|Experimental|Lead-in doublet B|Lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + nivolumab (anti-PD1) given IV on days 8, 22, and 36 (IL-15 doses are limited to first 4 cycles only)
11199353|NCT03388632|Experimental|Triplet|Triplet combination
11199354|NCT03388619|Experimental|1/Prostate bed with integrated boost|Dose to prostate bed with integrated boost
11199355|NCT03388619|Experimental|2/Prostate bed irradiation only|Dose to prostate bed irradiation only
11199356|NCT03388606||Adolescents with Major Depression|Adolescents with a current or past history of meeting full critieria for major depressive disorder
11199357|NCT03388606||Adolescents with sub-threshold Major Depression|Adolescents with no past or current history of major depression who meet criteria at initialenrollment of sub-threshold major depression as defined in the protocol
11199358|NCT03388606||Health volunteer adolescents|Adolescents with no history of significant psychiatric or medical disorders (as defined in the protocol) currently or in the past.
11199359|NCT03388593|Placebo Comparator|Placebo|Placebo in addition to standard therapy
11199360|NCT03388593|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
11199361|NCT03388580||BAL|patients undergoing elective bronchoalveolar lavage
11199362|NCT03388567|Experimental|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
11199363|NCT03388567|No Intervention|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
11199364|NCT03388554|Active Comparator|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
11199365|NCT03388554|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
11199366|NCT03388541|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
11199367|NCT03388541|Placebo Comparator|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
11199368|NCT03388528|Experimental|Treatment Group|This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
11199369|NCT03388515|Experimental|SSS11, 1.5mg|SSS11, 1.5mg, iv, single dose at Day 1;
11199370|NCT03388515|Experimental|SSS11, 3.0mg|SSS11, 3.0mg, iv, single dose at Day 1;
11199371|NCT03388515|Experimental|SSS11, 6.0mg|SSS11, 6.0mg, iv, single dose at Day 1;
11199372|NCT03388515|Experimental|SSS11, 12.0mg|SSS11, 12.0mg, iv, single dose at Day 1;
11199373|NCT03388515|Experimental|SSS11, 24.0mg|SSS11, 24.0mg, iv, single dose at Day 1;
11199374|NCT03388502|Experimental|Text Messaging (SMS) Bot|Patients undergoing total joint (hip & knee) arthroplasty will be enrolled in their physician's automated 'Text Messaging (SMS) Bot' in addition to receiving the routine perioperative education and instructions.
11199375|NCT03388502|Active Comparator|Routine Perioperative Instructions|Patients undergoing total joint (hip & knee) arthroplasty will receive only their 'Routine Perioperative Instructions'.
11199376|NCT03388489|Experimental|Mind-Body Walking|breathing, walking and meditation
11199377|NCT03388489|No Intervention|Usual care|maintain their daily activity
11199378|NCT03388476|Other|Suspicion of pulmonary hypertension|At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
11199379|NCT03388463|Active Comparator|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
11199380|NCT03388463|Placebo Comparator|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
11199381|NCT03388450|Active Comparator|Omega 3|Patients received enteral nutrition supplemented with 1000 mg omega-3.
11199382|NCT03388450|Placebo Comparator|Placebo|Patients received enteral nutrition supplemented without 1000 mg omega-3.
11245460|NCT03070951|Experimental|OBE2109 dose 1 + Add-back|
11199383|NCT03388437|Experimental|NI-NAVA|Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation
11199384|NCT03388437|Active Comparator|NIPPV|Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
11199385|NCT03388424||Control|Healthy people of both sex
11199386|NCT03388424||quantification of microbiota in Brain|Patients of both sex with neural disorders and diseases
11199387|NCT03388424||quantification of microbiota in GI|Patients of both sex with gastrointestinal diseases
11199388|NCT03388424||quantification of microbiota in Lung|Patients of both sex with Respiratory diseases
11199389|NCT03388424||quantification of microbiota Metabolic|Patients of both sex with Metabolic Diseases
11199390|NCT03388424||quantification of microbiota in UG|Patients of both sex with Uro-genital Diseases
11199391|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
11199392|NCT03388411||Non-obese children|5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
11199393|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
11199394|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
11199395|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
11199396|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
11199397|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
11199398|NCT03388385|Placebo Comparator|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
11199399|NCT03388385|Active Comparator|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
11199400|NCT03388372|Experimental|Nimotuzumab plus RT and temozolomide.|Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
11199401|NCT03388359|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment.
11199402|NCT03388359|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).
~Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment."
11199403|NCT03388346|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
11199404|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
11199405|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
11199406|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
11199407|NCT03388320|Experimental|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
11199408|NCT03388307|Experimental|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
11199409|NCT03388307|Experimental|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
11199410|NCT03388294|Experimental|PC followed by SR|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention pre-linguistic (PC) domain to identify their child's pre-linguistic communication bids during daily routines and respond to those bids in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on sensory reactivity bids.
11199411|NCT03388294|Experimental|SR followed by PC|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention sensory reactions (SR) domain to identify their child's sensory reactions to daily activities and respond to those reactions or modify the environment in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on pre-linguistic communication bids.
11199412|NCT03388281||Patients with implanted pacemaker|Patients with implanted cardiac pacemaker registered in pacemaker database of the Department of Cardiology at the Medical University Vienna were included.
11199413|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
11199414|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
11199415|NCT03388255|Experimental|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.
~The study period consists of the following phases:
~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).
~Follow up period: 3 months after end of active treatment, without study medication."
11199416|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
11199417|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
11199418|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
11199419|NCT03388216|Experimental|Stage I - Drug: INM004 Dose 1|
11199420|NCT03388216|Placebo Comparator|Stage I - Placebo Dose 1|
11199421|NCT03388216|Experimental|Stage I- Drug: INM004 Dose 2|
11199422|NCT03388216|Placebo Comparator|Stage I- Placebo Dose 2|
11199423|NCT03388216|Experimental|Stage II- Drug: INM004 Repeated Dose|
11199424|NCT03388216|Placebo Comparator|Stage II- Placebo Repeated Dose|
11200478|NCT03381209|Experimental|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
11199425|NCT03388190|Active Comparator|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
11199426|NCT03388190|Experimental|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
11199427|NCT03388177|Experimental|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
11199428|NCT03388177|Other|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy [CBT], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
11199429|NCT03388164|Active Comparator|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
11199430|NCT03388164|Placebo Comparator|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
11199431|NCT03388151|Active Comparator|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
11199432|NCT03388151|Active Comparator|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
11199433|NCT03388125|Active Comparator|Injection Sclerotherapy|5% ethano lamine oleate
11199434|NCT03388125|Active Comparator|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
11199435|NCT03388112|No Intervention|antibiotics|the patients in this arm will not receive probiotics.
11199436|NCT03388112|Experimental|probiotics concurrent with antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks concurrent with antibiotic.
11199437|NCT03388112|Experimental|probiotics after antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks after antibiotic.
11199438|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
11199439|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
11199440|NCT03388086||Onabotulinum 300 units|
11199441|NCT03388086||Onabotulinum 200 units|
11199442|NCT03388073|Experimental|Berry extract I|Plant-based antioxidant-rich berry-based extract.
11199443|NCT03388073|Experimental|Berry extract II|Plant-based antioxidant-rich berry-based extract.
11199444|NCT03388073|Experimental|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
11199445|NCT03388073|Placebo Comparator|Placebo|
11199446|NCT03388060|Active Comparator|Ultrasound guided SWL|ultrasound guided SWL for Radiolucent stone
11199447|NCT03388060|Active Comparator|Dissolution therapy|Dissolution therapy for Radiolucent stone
11199448|NCT03388060|Active Comparator|Combined ultrasound guided SWL and dissolution therapy|Combined treatment for Radiolucent stone.
11199449|NCT03388047|Experimental|Barrett's Esophagus patients|Multi-Spectral Endoscopic Imaging
11199450|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by swabbing"
11199451|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by swabbing
~Blood sampling:
~A blood sample collected by fingerprick"
11199452|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis
~Blood sampling:
~A blood sample collected by fingerprick"
11199453|NCT03388021|Experimental|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:
~Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire
~Balloon angioplasty and/or stenting
~Intraarterial thrombolysis
~Aiming to correct any residual angiographic lesion as:
~Residual thrombus
~Retained embolus
~Atheromatous plaque"
11199454|NCT03388021|Active Comparator|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
11199455|NCT03388008|Active Comparator|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
11199456|NCT03388008|Experimental|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
11199457|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
11199458|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
11199459|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
11199460|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
11199461|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
11199462|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
11199463|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
11199464|NCT03387969||meningitic group|Children suffering from fever , disturbed consciousnessand convulsion admitted in emergency department attending to assiut University Children Hospital aged between 2-18 years old
11199465|NCT03387956|Active Comparator|Atropine group|Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.
11199466|NCT03387956|Active Comparator|Dexamethasone group|Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).
11199467|NCT03387956|Active Comparator|Dexamethasone and Atropine group|Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.
11199468|NCT03387943|Experimental|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
11199469|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
11199470|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
11199471|NCT03387917|Experimental|TLD-1|"Duration of treatment
~1 cycle: 21 days,
~until progression or occurrence of unacceptable toxicity or withdrawal, but
~maximum 9 cycles for patients previously not treated with anthracyclines
~maximum 6 cycles for patients previously treated with anthracyclines.
~Dose: i.v., according to DL on day 1 of each cycle"
11199472|NCT03387904|Experimental|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11199473|NCT03387904|Active Comparator|Irinotecan|Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11199474|NCT03387891||Cancer patients|Cancer patients admitted to hospital for treatment or monitoring of health condition
11199475|NCT03387878|Other|Single Arm Study|This is a single arm study with no comparator
11199476|NCT03387852|Experimental|SAR440340/REGN3500 Monotherapy|SAR440340/REGN3500 administered by subcutaneous (SC) injections every 2 weeks for 12 weeks and coadministration of dupilumab placebo by SC injection every 2 weeks for 12 weeks
11199477|NCT03387852|Active Comparator|Dupilumab Monotherapy|Dupilumab administered by SC injection every 2 weeks for 12 weeks and coadministration of SAR440340/REGN3500 placebo by SC injections every 2 weeks for 12 weeks
11199478|NCT03387852|Experimental|SAR440340/REGN3500 and Dupilumab Coadministration|SAR440340/REGN3500 administered by SC injections every 2 weeks for 12 weeks and coadministration of dupilumab administered by SC injection every 2 weeks for 12 weeks
11199479|NCT03387852|Placebo Comparator|Placebo|Coadministration of matching placebos for SAR440340/REGN3500 and dupilumab administered by SC injections, respectively, every 2 weeks for 12 weeks
11199480|NCT03387839||Medial-Pivot Knee Prosthesis|
11199481|NCT03387839||Posterior-Stabilized Knee Prosthesis|
11199482|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
11199483|NCT03387826|Experimental|Ticagrelor|Ticagrelor 60mg twice daily followed by Prasugrel 5mg once daily
11199484|NCT03387826|Active Comparator|Prasugrel|Prasugrel 5m once daily followed by Ticagrelor 60mg twice daily
11199485|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.
~All subjects will receive a CardioMEMS™ HF System."
11199486|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.
~All subjects will receive a CardioMEMS™ HF System."
11199487|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.
~All subjects will receive a CardioMEMS™ HF System."
11199488|NCT03387800|Experimental|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
11199489|NCT03387800|Active Comparator|Basic health education messages|Members of the control group will receive health education messages that will also be sent to the intervention group through WeChat. The messages include topics on physical and psychological aspects of perceived severity of smoking and perceived benefits of smoking cessation, and tips/skills on resisting situational temptations that may lead to relapse.
11199490|NCT03387787|Experimental|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
11199491|NCT03387774|Experimental|Concurrent chemoradiotherapy and ulinastatin|"Concurrent chemoradiotherapy (CCRT) and intravenous drip of ulinastatin, the details are as follows:
~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT;
~Ulinastatin through intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline, 3 times every radiation day, until the end of radiotherapy."
11199492|NCT03387774|Active Comparator|Concurrent chemoradiotherapy|"Concurrent chemoradiotherapy (CCRT) alone:
~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT."
11199493|NCT03387761|Experimental|Cohort 1: Ipi + Nivo|"Day 1: Ipilimumab 3 mg/kg i.v.
~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.
~Day 43: Nivolumab 3 mg/kg i.v."
11199494|NCT03387761|Experimental|Cohort 2a: high-Ipi + low-Nivo|"Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.
~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.
~Day 43: Nivolumab 3 mg/kg i.v.
~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
11199495|NCT03387761|Experimental|Cohort 2b: low-Ipi + high-Nivo|"Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.
~Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.
~Day 43: Nivolumab 3 mg/kg i.v.
~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
11199496|NCT03387748|Experimental|Gesture elicitation|Observation: hand gesture elicitation task
11199497|NCT03387735|Placebo Comparator|Treatment as usual (TAU) + Internet|Patients will be given access to helpful websites such as National Institute on Aging.
11199498|NCT03387735|Experimental|Treatment as usual (TAU) + ElderTree|Patients will be given access to the ElderTree website for 12 months which provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.
11199499|NCT03387709|Experimental|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
11199500|NCT03387709|Active Comparator|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
11199501|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
11199502|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
11199503|NCT03387670|Active Comparator|Simvastatin|
11199504|NCT03387670|Placebo Comparator|Placebo|
11199505|NCT03387657|Experimental|Sotagliflozin + Hydrochlorothiazide (HCTZ)|Sotagliflozin to be administered alone in Period 1. HCTZ to be given in Period 2 for 4 days followed immediately by HCTZ and sotagliflozin for 5 days.
11199506|NCT03387644|Active Comparator|Pregabalin (PG)|Patients received 150 mg pregabalin one hour before the procedure.
11199507|NCT03387644|Placebo Comparator|Control placebo (C)|Patients received placebo tablet one hour before surgery.
11199508|NCT03387618|Experimental|Investigational Scan|new-generation digital PET/CT imaging technology
11199509|NCT03387605|Active Comparator|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
11199510|NCT03387605|Placebo Comparator|Placebo|Matching placebo given PO twice per day
11199511|NCT03387592|Active Comparator|FOLFIRI regimen|CPT-11 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks followed by 5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a 48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of 12 cycles
11199512|NCT03387592|Experimental|CAPTEM regimen|Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with Temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum of 6 cycles
11199513|NCT03387579|Active Comparator|Composite fish oil lipid (Smoflipid)|Patients randomized to this arm will receive the composite fish oil lipid, Smoflipid, at standard dosing up to 3 g/kg/day. Patients will be started on a dose of 1 g/kg/day and titrated up to maximum dose. As enteral nutrition is advanced the lipid dose will be weaned per study protocol and dietary recommendations.
11199514|NCT03387579|Active Comparator|Soy-based lipid reduction|Patients randomized to this arm will receive soy-based lipid (Intralipid) at a dose of 1 g/kg/day throughout their enrollment in the study.
11199515|NCT03387566|Experimental|HB002.1M 0.3mg|Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.
11199516|NCT03387566|Experimental|HB002.1M 0.5mg|Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.
11199517|NCT03387566|Experimental|HB002.1M 1.0mg|Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.
11199518|NCT03387566|Experimental|HB002.1M 2.0mg|Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.
11199519|NCT03387566|Experimental|HB002.1M 3.0mg|Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.
11199520|NCT03387553|Active Comparator|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
11199521|NCT03387553|Active Comparator|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
11199522|NCT03387553|Experimental|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
11199523|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
11199557|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
11199558|NCT03387254|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
11199524|NCT03387527|Experimental|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
11199525|NCT03387514|Experimental|18F-DCFPyL whole body PET/CT scan|18F-DCFPyL whole body PET/CT scan at three time-points
11199526|NCT03387501|Experimental|PRGF|Plasma rich in growth factors (PRGF) administration
11199527|NCT03387488|Experimental|Treatment|StingrayTM, Medtronic®
11199528|NCT03387475|Experimental|Deferasirox|efficacy of 3.5mg/kg/day
11199529|NCT03387462|Experimental|DOT Diary Optimization Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
11199530|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
11199531|NCT03387436|No Intervention|1.) Treatment as usual (TAU)|Patients assigned to this arm will receive palliative treatment as usual.
11199532|NCT03387436|Sham Comparator|2.) Sham-Intervention|Patients assigned to this arm will receive an sham intervention with unspecific supportive therapy (i.e. listening, empathy etc., but no specific intervention rationale) and palliative treatment as usual.
11199533|NCT03387436|Experimental|3.) Study-Intervention|Patients assigned to this arm will receive the study-intervention and palliative treatment as usual.
11199534|NCT03387410|Experimental|Intravenous IRDye 800BK|Patients undergoing laparoscopic bowel resection & laparoscopic donor nephrectomy
11199535|NCT03387397||Lower Medications (LM) cohort|Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period.
11199536|NCT03387397||Higher Medications (HM) cohort|Patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
11199537|NCT03387371|Active Comparator|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
11199538|NCT03387371|Experimental|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
11199539|NCT03387358||Historical Comparison Group|This group includes patients who were admitted to St. Paul's Hospital ICU (Vancouver BC, Canada) from September 2014 to September 2015, and had a small bore feeding tube in place at some point during their ICU admission, and were matched to key variables to the prospective observational treated group.
11199540|NCT03387358||Prospective Observational Treated Group|This group includes all patients who were admitted to St. Paul's Hospital ICU from Nov. 2017 to Dec. 2018, and nasal bridle securement device for small bore feeding tubes at some point during their ICU admission. The clinical indicators for a nasal bridle securement device outlined in our nursing practice standards include one or more of the following: recurrent nasoenteric tube dislodgement; confused and/or agitated patients; fluoroscopically or endoscopically placed nasoenteric tube; history of difficult tube placement; facial burn victims with nasoenteric tube; and/or oily skin causing decreased adhesion of traditional securement.
11199541|NCT03387345|Experimental|bread-50/50-steelcut-80/20-flake-rice|25 g of available carbohydrate was delivered to participants via (1) white bread, followed by (2) 50/50 rice-barley mix, followed by (3) 100% steel cut barley, followed by (4) 80/20 rice-barley mix, followed by (5) 100% barley flakes, followed by (6) 100% rice
11199542|NCT03387345|Experimental|50/50-steelcut-80/20-flake-rice-bread|25 g of available carbohydrate was delivered to participants via (1) 50/50 rice-barley mix, followed by (2) 100% steel cut barley, followed by (3) 80/20 rice-barley mix, followed by (4) 100% barley flakes, followed by (5) 100% rice, followed by (6) white bread
11199543|NCT03387345|Experimental|steelcut-80/20-flake-rice-bread-50/50|25 g of available carbohydrate was delivered to participants via (1) 100% steel cut barley, followed by (2) 80/20 rice-barley mix, followed by (3) 100% barley flakes, followed by (4) 100% rice, followed by (5) white bread, followed by (6) 50/50 rice-barley mix
11199544|NCT03387345|Experimental|80/20-flake-rice-bread-50/50-steelcut|25 g of available carbohydrate was delivered to participants via (1) 80/20 rice-barley mix, followed by (2) 100% barley flakes, followed by (3) 100% rice, followed by (4) white bread, followed by (5) 50/50 rice-barley mix, followed by (6) 100% steel cut barley
11199545|NCT03387345|Experimental|flake-rice-bread-50/50-steelcut-80/20|25 g of available carbohydrate was delivered to participants via (1) 100% barley flakes, followed by (2) 100% rice, followed by (3) white bread, followed by (4) 50/50 rice-barley mix, followed by (5) 100% steel cut barley, followed by (6) 80/20 rice-barley mix
11199546|NCT03387345|Experimental|rice-bread-50/50-steelcut-80/20-flake|25 g of available carbohydrate was delivered to participants via (1) 100% rice, followed by (2) white bread, followed by (3) 50/50 rice-barley mix, followed by (4) 100% steel cut barley, followed by (5) 80/20 rice-barley mix, followed by (6) 100% barley flakes
11199547|NCT03387332|Experimental|APG-1252|The starting dose for this study was 40 mg and 1 patient would be enrolled at this dose level. The dose escalation will convert to a standard 3+3 design following the occurrence of DLT or two ≥ Grade 2 adverse event or at doses 80 mg.
11199548|NCT03387319|Experimental|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
11199549|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
11199550|NCT03387306||Patient group|This grup included 38 patients with NTG.
11199551|NCT03387306||Control group|This group included 38 healthy controls.
11199552|NCT03387293|Experimental|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
11199553|NCT03387293|Experimental|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
11199554|NCT03387280||proximal RCA stenosis|The stenosis site is before the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
11199555|NCT03387280||distal RCA stenosis|The stenosis site is after the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
11200479|NCT03381209|Experimental|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
11199559|NCT03387254|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
11199560|NCT03387241|Experimental|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs
~Unit Strength:
~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
11199561|NCT03387241|Active Comparator|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs
~Unit Strength:
~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
11199562|NCT03387228|Experimental|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
11199563|NCT03387228|Active Comparator|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
11199564|NCT03387215|Experimental|10 mg ITI-214|Single oral dose
11199565|NCT03387215|Experimental|30 mg ITI-214|Single oral dose
11199566|NCT03387215|Experimental|75 mg - 150 mg ITI-214|Single oral dose
11199567|NCT03387215|Placebo Comparator|Placebo|Single oral dose
11199568|NCT03387202||pelvic organ prolapse|"Participants received Laparoscopic lateral suspension with mesh as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success."
11199569|NCT03387189||Quality Improvement Project|Quality Improvement Project: Regions Hospital
11199570|NCT03387189||No Quality Improvement Project|No Quality Improvement Project: The comparison group is Methodist Hospital, where the Quality Improvement project is not occurring.
11199571|NCT03387176||zonulin ≤17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
11199572|NCT03387176||zonulin >17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
11199573|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
11199574|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
11199575|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
11199576|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
11199577|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
11199578|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
11199579|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
11199580|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
11199581|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
11199582|NCT03387137|Experimental|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
11199583|NCT03387137|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
11199584|NCT03387137|Experimental|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
11199585|NCT03387137|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
11199586|NCT03387111|Experimental|NANT Squamous Cell Carcinoma (SCC) Vaccine|Combination of agents will be administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
11199587|NCT03387098|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ehtyl esters, oxaliplatin, SBRT.
11199588|NCT03387085|Experimental|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, SBRT.
11199589|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
11199590|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
11199591|NCT03387059|Experimental|Forielle Endometrial Washing|
11199592|NCT03387059|No Intervention|No Endometrial Washing|
11199593|NCT03387046|Experimental|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
11199594|NCT03387046|Placebo Comparator|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
11245461|NCT03070951|Experimental|OBE2109 dose 2 + Placebo Add-back|
11199595|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
11199596|NCT03387020|Experimental|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
11199597|NCT03387007|Experimental|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
11199598|NCT03387007|No Intervention|Control|The teachers from the schools in this arm did not receive training on psycho-social support
11199599|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
11199600|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
11199601|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
11199602|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
11199603|NCT03386955|Experimental|BPI-7711 treatment|"Phase I: Patients in dose escalation group will receive single dose of BPI-7711 on day -7 and start receive the 21 days/cycle continuous treatment once a day after 7 day washout period. Patients in the extension group will receive BPI-7711 once a day with the selected doses.
~Phase IIa: Patients will receive BPI-7711 capsule(recommend phase 2 dose) as the first line treatment."
11199604|NCT03386942|Experimental|MORAb-202|"Part 1 (Dose-escalation): The initial dose level of MORAb-202 will be 0.3 milligrams per kilogram (mg/kg) every 3 weeks in the first cohort with 1 participant for dose-limiting toxicity (DLT) evaluation. DLTs will be evaluated in successive dose level cohorts with a single participant until a drug-related Grade 2 or higher toxicity is observed. If such a toxicity is observed, the cohort will be expanded to enroll a total of 3 participants.
~Part 2 (Treatment Phase): MORAb-202 will be administered every 3 weeks during the treatment phase at the dose determined in Part 1 until participants meet any of the criteria for discontinuation. Criteria for discontinuation include: withdrawal of consent, major protocol violations, unable to continue due to adverse events, pregnancy, progressive disease, Investigator decision, or infusion reactions."
11199605|NCT03386929|Experimental|Avelumab, Axitinib, Palbociclib|"For the Phase 1:
~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).
~For the Phase 2:
~Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study."
11199606|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
11199607|NCT03386903|Experimental|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
11199608|NCT03386903|Placebo Comparator|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
11199609|NCT03386903|No Intervention|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
11199610|NCT03386877|Experimental|Dental pulp stem cells|Test sites (n=15) Periodontal regeneration using micro-grafts of Dental pulp stem cells seeded onto collagen sponge
11199611|NCT03386877|Active Comparator|coagulum|control sites (n=14) Periodontal regeneration using coagulum and collagen sponge alone
11199612|NCT03386864||Control|
11199613|NCT03386864||Insulin Resistant|
11199614|NCT03386864||Type 2 Diabetes|
11199615|NCT03386838|Experimental|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
11199616|NCT03386838|Active Comparator|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
11199617|NCT03386825||Regorafenib_DoT<4 months|DoT < 4 months
11199618|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT < 12 months
11199619|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
11199620|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
11199621|NCT03386786|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of a mobile application (app) and a web-based portal.
11199622|NCT03386786|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
11199623|NCT03386773|Experimental|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
11199624|NCT03386773|Active Comparator|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
11199625|NCT03386760|Experimental|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
11199626|NCT03386760|Active Comparator|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
11199627|NCT03386747|Experimental|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
11199628|NCT03386747|Experimental|Center based parenting group|Intervention: Center based parenting groups
11199629|NCT03386747|No Intervention|control group|The rest of pregnant women and their children who will not receive the intervention
11199630|NCT03386734|Experimental|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
11199631|NCT03386734|Active Comparator|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
11199632|NCT03386721|Experimental|Cohort A in Part I- arm is now closed to recruitment|Checkpoint Inhibitor (CPI)-Naïve Participants with non-small-cell lung cancer (NSCLC) who have not received CPI therapy previously will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.
11199633|NCT03386721|Experimental|Cohort B in Part I- arm is now closed to recruitment|CPI-Experienced Participants (NSCLC) who have received CPI therapy previously will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
11199634|NCT03386721|Experimental|Cohort C in Part I- arm has not been opened to recruitment|"This is a mandatory biopsy cohort based on the treatment's safety and preliminary activity analysis to enroll CPI-Naive Participants. Participants (NSCLC) will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199635|NCT03386721|Experimental|Cohort D Arm I in Part I- arm is now closed to recruitment|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.
~Participants will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199636|NCT03386721|Experimental|Cohort D Arm 2 in Part I- arm is now closed to recruitment|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel.
~Participants will receive RO6874281 intravenous (IV) infusion once in 3 weeks (Q3W) up to maximum 36 months. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q3W at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199637|NCT03386721|Experimental|Cohort D Arm 3 in Part I- arm is now closed to recruitment|"CPI Experienced Participants (NSCLC) who were previously treated with platinum and docetaxel will receive a single-agent gemcitabine or vinorelbine as per approved protocol.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199638|NCT03386721|Experimental|Cohort E Arm I in Part II- arm is now closed to recruitment|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 5 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 36 months. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199639|NCT03386721|Experimental|Cohort E Arm 2 in Part II- arm is now closed to recruitment|"This cohort will enroll participants (NSCLC) with High-Tumor PD-L1 Expression who have not received any prior systemic therapy. Participants will receive RO6874281 IV infusion in combination with atezolizumab Q3W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199640|NCT03386721|Experimental|Cohort G in Part III|"CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort G Part III will receive RO6874281 Q3W in combination with atezolizumab Q3W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
~Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion."
11199641|NCT03386721|Experimental|Cohort H in Part III|"Previously treated, CPI-experienced squamous cell carcinoma head and heck cancer (20 response evaluable participants), mandatory biopsies.
~Participants in cohort H Part III will receive RO6874281 Q3W in combination with atezolizumab Q3W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
~Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion."
11199666|NCT03386591|Experimental|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
11199667|NCT03386591|Experimental|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
11200592|NCT03380468|No Intervention|Observation|Observation and follow up only
11199642|NCT03386721|Experimental|Cohort I in Part III|"Previously treated, CPI-naïve squamous esophageal cancer (20 response evaluable participants), mandatory biopsies. Participants in cohort I Part III will receive RO6874281 Q3W in combination with atezolizumab Q3W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199643|NCT03386721|Experimental|Cohort J in Part III|"Previously treated, CPI-naïve squamous cervical cancer (20 response evaluable participants): mandatory biopsy. Participants in cohort J Part III will receive RO6874281 Q3W in combination with atezolizumab Q3W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199644|NCT03386721|Experimental|Cohort F in Part I- this arm is now closed to recruitment|"CPI-experienced, docetaxel naive participants (NSCLC) who experienced disease progression during or following treatment with a platinum - containing regimen. Participants will receive combination of RO6874281 and atezolizumab in a Q3W schedule. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 1200 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional."
11199645|NCT03386721|Experimental|Cohort K in Part III|"CPI-naïve SCC of the head and neck (SCCHN) (20 response-evaluable participants), mandatory biopsies. Participants in cohort K Part III will receive RO6874281 QW in combination with atezolizumab Q2W for 4 weeks followed by RO6874281 in combination with atezolizumab Q2W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional. Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion."
11199646|NCT03386721|Experimental|Cohort L in Part III|"Previously treated, CPI-experienced squamous cell carcinoma head and neck cancer (20 response evaluable participants), mandatory biopsies.
~Participants in cohort L Part III will receive RO6874281 QW in combination with atezolizumab Q2W for 4 weeks followed by RO6874281 in combination with atezolizumab Q2W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.
~Biopsies are not applicable to participants presenting with a single target lesion and absence of any non-target lesion."
11199647|NCT03386721|Experimental|Cohort M in Part III|"Esophageal SCC participants will receive RO6874281 QW in combination with atezolizumab Q2W for 4 weeks followed by RO6874281 in combination with atezolizumab Q2W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional"
11199648|NCT03386721|Experimental|Cohort N in Part III|"Cervical SCC participants will receive RO6874281 QW in combination with atezolizumab Q2W for 4 weeks followed by RO6874281 in combination with atezolizumab Q2W. RO6874281 will be administered at a 10 mg flat dose. Atezolizumab IV infusion will be administered at a dose of 840 mg.
~Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional"
11199649|NCT03386708|Experimental|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
11199650|NCT03386708|Placebo Comparator|NS intrauterine injection group|Normal saline (NS) (2ml)
11199651|NCT03386708|Experimental|hUC-MSC intravenous injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
11199652|NCT03386708|Placebo Comparator|NS intravenous injection group|Normal saline (NS) (30ml)
11199653|NCT03386695|Other|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
11199654|NCT03386695|Other|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
11199655|NCT03386682|Experimental|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
11199656|NCT03386669|Experimental|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
11199657|NCT03386656|Experimental|Amchafibrin|Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
11199658|NCT03386656|Placebo Comparator|Saline Solution 0,9%.|Comparator of tranexamic acid
11199659|NCT03386643|Experimental|Bifidobacterium animalis subsp. lactis|"Intervention:
~Bifidobacterium animalis subsp. lactis HN019"
11199660|NCT03386643|Active Comparator|Clobetasol propionate 0.05%|"Intervention:
~Clobetasol propionate 0.05%"
11199661|NCT03386630|Experimental|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
11199662|NCT03386630|Experimental|Hyperbaric bupivacaine+morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
11199663|NCT03386617|Experimental|NEPA|"Day 1 of each chemotherapy cycle:
~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
11199664|NCT03386604|Experimental|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
11199665|NCT03386604|Placebo Comparator|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
11199668|NCT03386591|Experimental|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
11199669|NCT03386591|Experimental|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
11199670|NCT03386591|Experimental|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
11199671|NCT03386578|Experimental|Pharmacokinetics Component: Group 1|Participants will be enrolled during singleton pregnancy at 14-24 weeks' gestation. Participants will receive a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) once daily under direct observation from Day 0 through Week 12.
11199672|NCT03386578|Experimental|Pharmacokinetics Component: Group 2|Participants will be enrolled postpartum within 6-12 weeks after delivery. Participants will receive a fixed-dose combination of FTC/TDF once daily under direct observation from Day 0 through Week 12.
11199673|NCT03386578|Experimental|PrEP Comparison Component: Cohort 1|Participants will receive daily oral PrEP (FTC/TDF) from Day 0 through Week 26. Participants will also receive behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
11199674|NCT03386578|Active Comparator|PrEP Comparison Component: Cohort 2|Participants will receive a behavioral HIV risk reduction package, including cohort-appropriate SMS messages, from Day 0 through Week 26.
11199675|NCT03386565|Active Comparator|control group|"Sodium chloride solution 10 mL IV just before induction of anesthesia
~IV infusion during the surgery"
11199676|NCT03386565|Active Comparator|lidocaine group|"lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia
~IV infusion during the surgery"
11199677|NCT03386552|Experimental|Isifera+|Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml
11199678|NCT03386552|Placebo Comparator|Buffer|Subjects are pertubated with a buffer solution without lidocaine
11199679|NCT03386539|Experimental|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.
~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
11199680|NCT03386539|Active Comparator|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)
~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
11199681|NCT03386526|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
11199682|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 will be administered by IV on two different schedules for patients with relapsed/refractory AML or BPDCN:
~Schedule A: Day 1 of each cycle, with cycles repeating every 21 days
~Schedule B: Days 1, 4 and 8 of each cycle, with cycles repeating every 21 days
~Expansion: IMGN632 will be administered based on the recommended phase 2 dose (RP2D) and schedule as determined in the Escalation Phase, across five expansion cohorts, for patients with 1) relapsed, refractory OR selected untreated BPDCN; 2) relapsed AML; 3) relapsed or refractory ALL; 4) other relapsed or refractory CD123+ hematologic malignancies; 5) other relapsed or refractory AML."
11199683|NCT03386500|Other|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
11199684|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
11199685|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
11199686|NCT03386474|Experimental|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
11199687|NCT03386474|Other|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16 to maintain the masking of the extension trial only.
11199688|NCT03386461|Experimental|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
11199689|NCT03386461|Placebo Comparator|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
11199690|NCT03386448|Placebo Comparator|control|Participants will receive placebo medication
11199691|NCT03386448|Experimental|Active|participants will receive active medications scopolamine and naltrexone
11199692|NCT03386435|Experimental|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
11199693|NCT03386435|No Intervention|Control|In the control group, the same maneuver was applied but without cuff inflation.
11199694|NCT03386422|Experimental|Mindfulness Self-Compassion Intervention MSC|"Mindfulness Self-Compassion (MSC) is a standardized program to increase self-compassion. It has been developed by Neff and Germer. The structure of the program is similar to de Mindfulness-Based Stress Reduction program (MBSR), with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with practical and experiential exercices in sessions and between sessions.
~The MSC program focuses primary on helping patients to develop self-compassion, and it includes Mindfulness just as a secondary component.
~The MSC program will be conducted by a clinician trained in this specific program."
11199727|NCT03386214|Experimental|Arm 3: Dose Level 3 - 20 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.
~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
11199728|NCT03386201|Experimental|Intravenous methylene blue|
11200624|NCT03380195|Active Comparator|Sport drink|
11199695|NCT03386422|Active Comparator|Cognitive-Behavioural Intervention CBT|"It has been adapted a Cognitive-Behavioural Intervention for Chronic Pain by Moix and Kovacs. Our program will have 8 sessions, with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with homework between sessions.
~During these 8 sessions we will train the following techniques: psychoeducation about pain, relaxation training, cognitive restructuring training, solving problem training, psychoeducation about emotions, interpersonal skills and time organization."
11199696|NCT03386409|No Intervention|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
11199697|NCT03386409|Experimental|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
11199698|NCT03386409|Experimental|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
11199699|NCT03386396|Experimental|High protein/low carbohydrate|A breakfast shake will be made with high protein/low carbohydrate mixture.
11199700|NCT03386396|Experimental|High carbohydrate/low protein|A breakfast shake will be made with high carbohydrate/low protein mixture.
11199701|NCT03386383|Experimental|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
11199702|NCT03386383|No Intervention|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
11199703|NCT03386370|Other|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo
11199704|NCT03386357|Experimental|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases.
11199705|NCT03386357|Active Comparator|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w) without radiotherapy
11199706|NCT03386344|Experimental|Dose 1|Sotagliflozin dose 1 given as two (2) dose 2 sotagliflozin tablets on top of baseline antidiabetic therapy
11199707|NCT03386344|Experimental|Dose 2|Sotagliflozin dose 2 given as one (1) dose 2 sotagliflozin tablet and one (1) sotagliflozin matching placebo tablet on top of baseline antidiabetic therapy
11199708|NCT03386344|Placebo Comparator|Placebo|Placebo, given as two (2) sotagliflozin matching placebo tablets on top of baseline antidiabetic therapy
11199709|NCT03386331|Other|Diet and Exercise|
11199710|NCT03386318||day surgery patients|20 patients female 30-60 years of age
11199711|NCT03386305|Experimental|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
11199712|NCT03386305|Active Comparator|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
11199713|NCT03386279|Other|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
11199714|NCT03386279|Other|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
11199715|NCT03386279|Other|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
11199716|NCT03386279|Other|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
11199717|NCT03386279|Other|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
11199718|NCT03386279|Other|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
11199719|NCT03386253|Experimental|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
11199720|NCT03386253|Sham Comparator|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
11199721|NCT03386240|Experimental|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
11199722|NCT03386240|Placebo Comparator|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
11199723|NCT03386227|No Intervention|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
11199724|NCT03386227|Experimental|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
11199725|NCT03386214|Experimental|Arm 1: Starting Dose - 5 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.
~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
11199726|NCT03386214|Experimental|Arm 2: Dose Level 2 - 10 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.
~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
11199730|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
11199731|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
11199732|NCT03386149|Experimental|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
11199733|NCT03386149|Active Comparator|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
11199734|NCT03386136|Experimental|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction [clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm] provided with 100% oxygen via non-rebreather face mask, for 6 hours
11199735|NCT03386123|Experimental|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.
~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
11199736|NCT03386123|Active Comparator|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.
~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
11199737|NCT03386123|Placebo Comparator|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.
~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
11199738|NCT03386110|Experimental|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
11199739|NCT03386110|Active Comparator|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
11199740|NCT03386097||Type 2 diabetes patients|
11199741|NCT03386097||Healthy controls|
11199742|NCT03386084|Experimental|direct application of microwave diathermy and motor control|
11199743|NCT03386084|Placebo Comparator|application of microwave diathermy without therapeutic effects|
11199744|NCT03386058|Experimental|Intervention|Temporary device deactivation
11199745|NCT03386045|Active Comparator|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
11199746|NCT03386045|Active Comparator|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
11199747|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
11199748|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
11199749|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.
~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
11199750|NCT03386019|Experimental|Sprinters|Sprinters will be recruited from the track and field team of National Taiwan Normal University (NTNU) in this study. After individuals' enrollments and baseline data collections, all subjects will receive all three different treatments (massage, cold water immersion and static stretching) in randomized orders a week apart, respectively. Outcome measures are: visual analogue scale (VAS) score, lower leg volume, pressure pain threshold and horizontal jump distance. All measurements will be recorded at baseline, immediately after exercise, immediately after treatment, and 10 minutes after treatment as the follow up.
11199802|NCT03385642||Chondromimetic|Treatment of osteochondral defect in the knee with Chondromimetic device(s) in previous study 0MCM0107
11199751|NCT03386006|Experimental|Noom Coach for Bariatric Health|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app.
11199752|NCT03386006|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period."
11199753|NCT03385993|Experimental|Mediation and Relaxation Intervention|Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.
11199754|NCT03385980||Post-mortem patients|Post-mortem oncological patients (within 2-6 hrs from death, maximum time for tissue preservation).
11199755|NCT03385967|Active Comparator|ropivacaine only|0.5% ropivacaine
11199756|NCT03385967|Active Comparator|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
11199757|NCT03385954|Experimental|Intervention|distance education curse with 8 hours to be accomplished in 2 weeks,
11199758|NCT03385954|Experimental|Control|Wiil receive a lecture of 30 minutes
11199759|NCT03385941||Osteoporotic|Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
11199760|NCT03385941||Non-osteoporotic|Female, 27-40 years of age, no established history of osteoporosis
11199761|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
11199762|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
11199763|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
11199764|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
11199765|NCT03385902|Experimental|optimal start group|The DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE reaching to 30-35, which defined as the optimal start time.
11199766|NCT03385902|Active Comparator|late start group|the DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE less than 30, which defined as late start time.
11199767|NCT03385889|Experimental|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
11199768|NCT03385889|Experimental|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
11199769|NCT03385889|No Intervention|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
11199770|NCT03385876|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
11199771|NCT03385863||early preterm infants with RDS|gestational age<34 weeks
11199772|NCT03385863||near term infants with RDS|34 weeks≤gestational age< 37 weeks
11199773|NCT03385863||term infants with RDS|Gestational age ≥ 37 weeks
11199774|NCT03385850|Experimental|early enteral nutrition|
11199775|NCT03385850|Active Comparator|delayed enteral nutrition|
11199776|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
11199777|NCT03385824|Experimental|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
11199778|NCT03385824|No Intervention|Control|SAIL workbook provided at the conclusion of the study.
11199779|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
11199780|NCT03385798|Active Comparator|Endo-GIA|
11199781|NCT03385798|Experimental|Endo-wrist|
11199782|NCT03385759|Active Comparator|UKA|Medial unicompartmental knee arthroplasty
11199783|NCT03385759|Active Comparator|TKA|Total knee arthroplasty
11199784|NCT03385746|Experimental|polyamide|metal reinforced polyamide denture base material
11199785|NCT03385746|Active Comparator|heat cured acrylic resin|conventional heat cured acrylic resin denture base
11199786|NCT03385733|Experimental|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
11199787|NCT03385733|No Intervention|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
11199788|NCT03385720|Experimental|Experimental group|
11199789|NCT03385720|Active Comparator|Control group|
11199790|NCT03385707|Experimental|CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
11199791|NCT03385694||Assessment|All the patients operated on Van Nes Rotationplasty for bone tumors at IOR and long term surviving
11199792|NCT03385681|Experimental|Intervention Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
11199793|NCT03385681|No Intervention|Control Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate in the study.
11199794|NCT03385668|Experimental|Pirfenidone|All patients will receive Pirfenidone
11199795|NCT03385655|Experimental|WEE-1 inhibitor|
11199796|NCT03385655|Experimental|cMET inhibitor|
11199797|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
11199798|NCT03385655|Experimental|CFI400945 PLK4 inhibitor|
11199799|NCT03385655|Experimental|Ipatasertib AKT inhibitor|
11199803|NCT03385629|Experimental|CSM theory-based Arm|CSM theory-based didactic education and skills training Practice EMR changes
11199804|NCT03385629|Active Comparator|AAP-based Arm|AAP-based didactic education
11199805|NCT03385616|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS)
11199806|NCT03385603|Experimental|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
11199807|NCT03385603|Active Comparator|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
11199808|NCT03385590|Experimental|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
11199809|NCT03385590|Active Comparator|Maize|Complementary food composed of maize flour.
11199810|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
11199811|NCT03385564|Experimental|BI 655064|
11199812|NCT03385564|Placebo Comparator|Placebo|
11199813|NCT03385551||ARM 1|Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments
11199814|NCT03385551||ARM 2|Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments
11199815|NCT03385538|Experimental|Clopidogrel non-responders|Increasing doses og Clopidogrel depending on PRU values measured on VerifyNow
11199816|NCT03385525|Experimental|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
11199817|NCT03385512|Experimental|OPEN High Touch|Participants in this arm will experience the OPEN High Touch intervention.
11199818|NCT03385512|Experimental|OPEN High Tech|Participants in this arm will experience the OPEN High Tech intervention.
11199819|NCT03385512|Experimental|ASK|Participants in this arm will experience the ASK intervention.
11199820|NCT03385499|Other|negative control group|blood additional samples on negative control group
11199821|NCT03385499|Other|positive control group|blood additional samples on positive control group
11199822|NCT03385499|Other|seroconversion group|blood additional samples on seroconversion group
11199823|NCT03385486|Experimental|TBX-3400|TBX-3400 by intravenous infusion
11199824|NCT03385473|Active Comparator|Pharmacological Adequation (PA)|Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug monitoring results.
11199825|NCT03385473|No Intervention|Standard of Care (SOC)|Without pharmacological adequation
11199826|NCT03385460|Experimental|ESWL BOTOX|Each patient will be subjected to Low Energy Shock Waves.The target dose of low energy shock waves will be 3000 shock delivered into SP region in 3 horizontal points at SP transverse crease . all patients will be catheterized using nylaton catheter 16 ch, the study group will be injected with 100 IU botulinium toxin A. vial will be dissolved in saline half of the estimated bladder capacity. All patients will be kept for 2 hours without micturation giving a chance of BOTOX absorption .
11199827|NCT03385447|Experimental|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
11199828|NCT03385434|Experimental|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
11199829|NCT03385434|No Intervention|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
11199830|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
11199831|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
11199832|NCT03385395|Experimental|OctaAlpha1|
11199833|NCT03385395|Active Comparator|Glassia®|
11199834|NCT03385382||Dexamethasone group|Patients with diabetic macular edema receiving dexamethasone
11199835|NCT03385382||ranibizumab|Patients with diabetic macular edema receiving ranibizumab
11199836|NCT03385369|Placebo Comparator|Placebo Japanese Descent|Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
11199837|NCT03385369|Experimental|MEDI0382 50 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.
11199838|NCT03385369|Experimental|MEDI0382 100 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
11199839|NCT03385369|Experimental|MEDI0382 150 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.
11199840|NCT03385369|Experimental|Placebo Chinese Descent|Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
11199841|NCT03385369|Experimental|MEDI0382 100 mcg Chinese Descent|Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
11199842|NCT03385356|Active Comparator|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
11199843|NCT03385356|Active Comparator|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
11199844|NCT03385343|Experimental|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
11199941|NCT03384771||Raters|experience mindfulness teachers, recruited by invitation, who will participate in MBI-TAC training
11199845|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
11199846|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
11199847|NCT03385317|Experimental|Mindfulness|
11199848|NCT03385304|Experimental|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
11199849|NCT03385304|Experimental|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
11199850|NCT03385291|Experimental|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
11199851|NCT03385291|Experimental|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
11199852|NCT03385278|Experimental|real-sham|the group first received real rTMS,then sham one.
11199853|NCT03385278|Experimental|sham-real|the group first received sham rTMS,then real one.
11199854|NCT03385265|Experimental|DIPPer Academy|Families randomized to this group will participate in the DIPPer Academy curriculum.
11199855|NCT03385265|Active Comparator|Standard of Care Control|
11199856|NCT03385252|Experimental|Egg Group|Egg Intervention: Provision of eggs to caregivers of enrolled infants, with instructions to prepare and feed one egg to the infant each day for 6 months time. Households will be visited twice weekly to provide eggs and monitor intake.
11199857|NCT03385252|Active Comparator|Control Group|Control Group: Caregivers will receive a food basket at the end of the study. Throughout the trial, households will be visited twice weekly and asked about food intake.
11199858|NCT03385239|Placebo Comparator|Pooled Placebo|Participants in each cohort (A,B,C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
11199859|NCT03385239|Experimental|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
11199860|NCT03385239|Experimental|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
11199861|NCT03385239|Experimental|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
11199862|NCT03385239|Placebo Comparator|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
11199863|NCT03385226|Experimental|Pembrolizumab with radiotherapy|"All patients will receive
~single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity
~radiotherapy, 12Gy in 3 fractions"
11199864|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
11199865|NCT03385213||Remission|Patients who get remission after curative surgery
11199866|NCT03385200|Active Comparator|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
11199867|NCT03385200|No Intervention|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
11199868|NCT03385187|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
11199869|NCT03385174|Other|Carbon monoxide|Each participant receives CO inhalation
11199870|NCT03385161|Active Comparator|botulinum toxin A|"Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.
~One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.
~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate."
11199871|NCT03385161|Active Comparator|Ethanol|"Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.
~An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.
~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate."
11199872|NCT03385148|Experimental|colorectal patients|the colorectal patients undergo 68Ga-Sgc8 PET/CT
11199873|NCT03385135|Active Comparator|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
11199874|NCT03385135|No Intervention|No Allopurinol group|Optimal medical therapy alone
11199875|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
11199876|NCT03385096|Experimental|BUCY+VP-16|For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
11199877|NCT03385096|Active Comparator|Melphalan|For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
11199878|NCT03385083|Experimental|ACTIVITY TRACKER|Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
11199879|NCT03385083|Placebo Comparator|Control|Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.
11199880|NCT03385070||Salt-sensitive group|"Patients (n:163)with HT who presented at the emergency service at least once with a minimum increase in their systolic and diastolic blood pressure of 10% after consuming salty foods were included in the SSH group.
~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
11199881|NCT03385070||Salt resistance group|"Patients(n:142) who did not exhibit this increase were included in the SRH group
~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
11199882|NCT03385070||Control group|"Sex- and age-matched patients(n:124) without a HT diagnosis were included in the control group.
~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
11199883|NCT03385057|Active Comparator|Ibuprofen Arm|
11199884|NCT03385057|Active Comparator|Acetaminophen|
11199885|NCT03385044|Active Comparator|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
11199886|NCT03385044|Active Comparator|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
11199887|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
11199888|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
11199889|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
11199890|NCT03385018|Experimental|Laparoscopic group|Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
11199891|NCT03385018|Active Comparator|Open group|Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
11199892|NCT03385005|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
11199893|NCT03385005|Active Comparator|Spinal Cord Injury Participants|This arm consists of spinal cord injury participants receiving electrical stimulation of the muscles within the forearm via an investigational (not FDA approved) neuromuscular stimulator.
11199894|NCT03384992|Experimental|Group 1|Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
11199895|NCT03384992|Experimental|Group 2|Participants were exposed to the one of the following usual care conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3.
11199896|NCT03384992|Experimental|Group 3|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
11199897|NCT03384992|Experimental|Group 4|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
11199898|NCT03384992|Experimental|Group 5|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
11199899|NCT03384992|Experimental|Group 6|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
11199900|NCT03384992|Experimental|Group 7|Participants were exposed to the following conditions: cognitive restructuring for week 1, worry practice for week 2, and General Health and Diet (General and BCSS) for week 3. Telephone coaching was given.
11199901|NCT03384992|Experimental|Group 8|Participants were exposed to the following conditions: cognitive restructuring for week 1, scheduled worry practice for week 2, and General Health and Diet (General and BCSS) for week 3.
11199902|NCT03384992|Experimental|Group 9|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
11199903|NCT03384992|Experimental|Group 10|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3.
11199904|NCT03384992|Experimental|Group 11|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
11199905|NCT03384992|Experimental|Group 12|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3.
11199906|NCT03384992|Experimental|Group 13|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
11199907|NCT03384992|Experimental|Group 14|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and General health and Diet (General and BCSS) for week 3.
11199942|NCT03384758|Active Comparator|mild to moderate PAD|
11199908|NCT03384992|Experimental|Group 15|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and cognitive restructuring for week 3. Telephone coaching was given.
11199909|NCT03384992|Experimental|Group 16|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and cognitive restructuring for week 3.
11199910|NCT03384979|Placebo Comparator|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
11199911|NCT03384979|Experimental|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
11199912|NCT03384966|Experimental|Selatogrel 8 mg|ACT-246475 is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
11199913|NCT03384966|Experimental|Selatogrel 16 mg|ACT-246475 is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
11199914|NCT03384966|Placebo Comparator|Placebo|Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
11199915|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
11199916|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
11199917|NCT03384940|Experimental|DS-8201a Cohort A|"Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
~Enrollment to this cohort was closed and this cohort is active until study completion."
11199918|NCT03384940|Experimental|DS-8201a Cohort B|"Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
~This cohort is active."
11199919|NCT03384940|Experimental|DS-8201a Cohort C|"Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks
~Enrollment to this cohort was closed and this cohort is active until study completion."
11199920|NCT03384914|Active Comparator|Dendritic Cell (DC1) Vaccine|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.
~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
11199921|NCT03384914|Active Comparator|pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.
~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
11199922|NCT03384888|Experimental|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
11199923|NCT03384888|Experimental|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
11199924|NCT03384888|Sham Comparator|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
11199925|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
11199926|NCT03384875|Placebo Comparator|Control|Standard of care
11199927|NCT03384862|Experimental|Nutritional Intervention Arm|5 μg vitamin B12 plus 400 μg folic acid
11199928|NCT03384862|Placebo Comparator|Control Arm|Placebo
11199929|NCT03384849||MRI patients|Up to 200 patients of different age, weight and sex, which undergo MRI examinations.
11199930|NCT03384836|Experimental|Treatment (propranolol hydrochloride, pembrolizumab)|Patients receive propranolol hydrochloride PO BID and pembrolizumab IV over 30 minutes of day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11199931|NCT03384823|Experimental|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
11199932|NCT03384823|Experimental|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
11199933|NCT03384823|Placebo Comparator|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
11199934|NCT03384823|Placebo Comparator|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
11199935|NCT03384797||Healthy Volunteers|
11199936|NCT03384797||Parkinson's Disease|
11199937|NCT03384784|Experimental|Galantamine|"This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day).
~The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures."
11199938|NCT03384784|Placebo Comparator|Placebo|"12-week placebo-controlled medication period
~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical.
~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period."
11199939|NCT03384771||MBSR Students|community-dwelling adults who register for relevant MBSR courses at UMass CFM, UCSF, or participating community sites
11199940|NCT03384771||MBSR Teachers|those teaching MBSR courses at UMass CFM, UCSF, or participating community sites
11199945|NCT03384745|Experimental|M1095 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
11199946|NCT03384745|Experimental|M1095 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
11199947|NCT03384745|Experimental|M1095 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
11199948|NCT03384745|Experimental|M1095 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
11199949|NCT03384745|Placebo Comparator|Placebo / M1095 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
11199950|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
11199951|NCT03384719|Experimental|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
11199952|NCT03384719|Experimental|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
11199953|NCT03384719|Active Comparator|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
11199954|NCT03384706|Active Comparator|Cognitive Processing Therapy (CPT)|PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
11199955|NCT03384706|Experimental|Accelerated Resolution Therapy (ART)|PTSD Psychotherapy
11199956|NCT03384706|No Intervention|Wait List Control|Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
11199957|NCT03384693|Experimental|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
11199958|NCT03384667|Experimental|MMDT group|
11199959|NCT03384667|Placebo Comparator|Placebo group|
11199960|NCT03384654|Experimental|Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL|Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
11199961|NCT03384654|Experimental|Cohort 2: T-Cell ALL/LL|Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
11199962|NCT03384641|Experimental|Bedaquiline|Participants will receive bedaquiline 200 (milligram) mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet three times a week (tiw) for 6 weeks with at least 48 hours between doses.
11199963|NCT03384628|Active Comparator|First Pair Senofilcon A contact lens|The first pair of Senofilcon A contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the first pair Senofilcon A contact lens and subsequent removal.
11199964|NCT03384628|Active Comparator|Second pair Senofilcon A contact lens|The second pair of contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the second pair Senofilcon A contact lens and subsequent removal.
11199965|NCT03384628|Active Comparator|Third pair Senofilcon A contact lens|The third pair of Senofilcon A contact lens is applied (according to the fitting schedule), allowed to settle before assessment of the third pair Senofilcon A contact lens and subsequent removal.
11199966|NCT03384615|Experimental|Compassion-focused therapy|
11199967|NCT03384615|No Intervention|Waitlist control group|
11199968|NCT03384602|Active Comparator|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
11199969|NCT03384602|Active Comparator|home exercise strength program|simple strength training program to perform individually at home
11199970|NCT03384602|No Intervention|Control group|no change in the daily activities, no exercise intervention
11199971|NCT03384589|Active Comparator|Group 1: 3 doses of PCV13|PCV13, 0.5ml intramuscular at 2, 4 and 12 months of age
11199972|NCT03384589|Experimental|Group 2: 2 doses of PCV13|PCV13, 0.5ml intramuscular at 2 and 12 months of age
11199973|NCT03384576|Experimental|Music intervention|Participants listen to music in the waiting room
11199974|NCT03384576|Active Comparator|No music|Participants will not have music in the waiting room
11199975|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-6 months|
11199976|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-6 months|
11199977|NCT03384563|Placebo Comparator|Placebo 1-6 months|
11199978|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 6-12 months|
11199979|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 6-12 months|
11199980|NCT03384563|Placebo Comparator|Placebo 6-12 months|
11199981|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-3 years|
11199982|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-3 years|
11199983|NCT03384563|Placebo Comparator|Placebo 1-3 years|
11199984|NCT03384550|Active Comparator|Control|"Participants in this arm receive no incentives.
~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.
~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
11199985|NCT03384550|Experimental|Financial Incentives|"Participants in this arm receive financial incentives.
~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.
~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
11199986|NCT03384550|Experimental|Charity Incentives|"Participants in this receive charity incentives.
~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.
~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
11199987|NCT03384537|Experimental|Listerine total care zero|Listerine total care zero
11199988|NCT03384537|Active Comparator|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
11199989|NCT03384524|Active Comparator|Combination regiment|A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)
11199990|NCT03384524|Placebo Comparator|Placebo|Three placebo pills, matching the external appearance of active drugs
11199991|NCT03384511|Experimental|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
11199992|NCT03384485|Other|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
11199993|NCT03384459|Experimental|Experimental group|"For a total period of 12 months, perform the 308-nm excimer laser treatment once a month.
~At this time, the dose of the 308-nm excimer laser is based on the 50% of the maximum dose that the patient received for the treatment.
~Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
11199994|NCT03384459|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
11199995|NCT03384446|Active Comparator|Tooth-borne treatment|A cleaning aid that resembles tooth cleaning instruments and is empirically used for implant surface cleaning.
11199996|NCT03384446|Experimental|Implant-specific treatment|A cleaning aid that has been specifically designed for implant surface cleaning.
11199997|NCT03384433|Experimental|exosome or vesicle|CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
11199998|NCT03384420|Experimental|Intervention CD34+ cells enriched with MNV-BLD|Intervention CD34+ cells enriched with MNV-BLD
11199999|NCT03384407|Experimental|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
11200000|NCT03384394|Placebo Comparator|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
11200001|NCT03384394|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
11200002|NCT03384368|Placebo Comparator|Screw-Distraction (SD) group|six pedicle screws were implanted firstly, then distraction was achieved.
11200003|NCT03384368|Experimental|Distraction-Screw (DS) group|four pedicle screws were implanted firstly, then distraction was achieved, two additional screws were introduced at the fracture level at last.
11200004|NCT03384355||Class 0|no visible or palpable varicose veins
11200005|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
11200006|NCT03384355||Class 2|varicose veins
11200007|NCT03384355||Class 3|edema
11200008|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
11200009|NCT03384355||Class 5|healed venous ulcer
11200010|NCT03384355||Class 6|active venous ulcer
11200011|NCT03384342|Experimental|Experimental group|"For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.
~At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
11200012|NCT03384342|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.
~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
11200013|NCT03384329|Experimental|Resveratrol Pill|
11200014|NCT03384329|Placebo Comparator|Placebo|
11200015|NCT03384316|Experimental|1/Arm 1-Dose De-Escalation|Dose De-Escalation
11200016|NCT03384316|Experimental|2/Arm 2 - Dose Expansion|Dose Expansion
11200017|NCT03384303|Other|LBPL-RYGB|
11200018|NCT03384303|Other|S-RYGB|
11200019|NCT03384290|Placebo Comparator|Placebo|
11200020|NCT03384290|Experimental|PRS-060|
11200021|NCT03384277|Experimental|Steroid+Rituximab|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
11200022|NCT03384277|Active Comparator|Steroid +Cyclophosphamide|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
11200023|NCT03384264|Experimental|TG|
11200024|NCT03384264|No Intervention|CG|the CG maintained their normal physical activity habits over the study
11200025|NCT03384251|Experimental|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
11200026|NCT03384251|No Intervention|Control group|This group will not be given any form of education.
11200027|NCT03384238|Experimental|Cohort 1a|A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
11200028|NCT03384238|Experimental|Cohort 1b|Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
11200029|NCT03384238|Experimental|Cohort 1c|Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
11200030|NCT03384238|Experimental|Cohort 1d|Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
11200031|NCT03384238|Experimental|Cohort 2- Dose Expansion|Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1
11200032|NCT03384225|Experimental|CBA group|"CBA as HSCT conditioning:
~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
11200033|NCT03384225|Active Comparator|FBA group|"FBA as HSCT conditioning:
~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
11200034|NCT03384212|Experimental|CBA group|"CBA as HSCT conditioning:
~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
11200035|NCT03384212|Active Comparator|FBA group|"FBA as HSCT conditioning:
~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
11200036|NCT03384199|Experimental|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
11200037|NCT03384186|Experimental|ACH-0144471 Modified Release Prototypes|
11200038|NCT03384173|Experimental|NIRS monitoring|These infants will be monitored with NIRS
11200039|NCT03384160|Active Comparator|Group 1-Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction
11200040|NCT03384160|Active Comparator|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction
11200041|NCT03384147|Experimental|Drinking|"Occasional drinkers assigned to start with a 3week drinking period (women 1 u/day - men 2 u/day)
~Followed by crossover without washout to 3 week abstaining period"
11200042|NCT03384147|Experimental|Abstaining|"Habitual drinkers assigned to start 2 weeks of abstaining from alcohol
~Followed by crossover without washout to 3 weeks drinking (women 1 u/day - men 2 u/day)"
11200043|NCT03384134|Experimental|Pain Buddy|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
11200044|NCT03384134|No Intervention|Control|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
11200045|NCT03384121|Experimental|Rifampin|All subjects
11200046|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
11200047|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
11200048|NCT03384095|Experimental|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
11200049|NCT03384095|Placebo Comparator|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
11200050|NCT03384082|Experimental|Hysteroscopic treatment|Hysteroscopic surgery
11200051|NCT03384082|No Intervention|Control group|No treatment
11200052|NCT03384069|Experimental|Group-based Cognitive Behavioral Therapy (CBT)|The Group-based CBT will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
11200053|NCT03384069|Experimental|Phone-based Cognitive Behavioral Therapy (CBT)|This intervention will follow the same protocol as the group-based CBT, but without the opportunity for group-interaction. It will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
11200054|NCT03384069|No Intervention|Standard of care|Participants will continue to receive care and follow up from their primary care providers, that incorporates general education regarding lifestyle activities and AD prevention.
11200055|NCT03384056||Self Pressurized Airway Device with Blocker|
11200056|NCT03384056||Proseal Laryngeal Mask Airway|
11200090|NCT03383809|Experimental|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
11200091|NCT03383796|Experimental|3D approach|Three dimensional laparoscopic resection for pCCA
11200092|NCT03383796|Experimental|open approach|Open resection for pCCA
11200057|NCT03384043|Experimental|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time--based tasks (...take my medicine at 7pm) and event--based tasks (pick-up milk at the grocery store)."
11200058|NCT03384043|Active Comparator|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When…then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
11200059|NCT03384030|Experimental|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
11200060|NCT03384017|Experimental|TSCS and gait training|
11200061|NCT03384004|Experimental|Irrigation Technique 1|Patients randomized into this group will be treated using EndoVac Pure followed by Ultrasonic Irrigation.
11200062|NCT03384004|Experimental|Irrigation Technique 2|Patients randomized into this group will be treated using EndoVac Pure only.
11200063|NCT03383991|Experimental|Reverse Total Shoulder Arthroplasty|
11200064|NCT03383991|Active Comparator|Hemiarthroplasty|
11200065|NCT03383978|Experimental|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
11200066|NCT03383965|Experimental|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
11200067|NCT03383952|Experimental|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
11200068|NCT03383939|Experimental|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.
~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
11200069|NCT03383939|Placebo Comparator|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.
~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
11200070|NCT03383939|No Intervention|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
11200071|NCT03383926|Experimental|Group 1|Suture confection of theTobacco-pouch of 4.5cm from the anal margin.
11200072|NCT03383926|Experimental|Group 2|Suture confection of theTobacco-pouch of 6cm from the anal margin.
11200073|NCT03383913|Experimental|Intervention|The intervention arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure baseline and outcome assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firsbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. Participants placed in the intervention arm will receive 4-6 weeks of Heart Rate Variability Biofeedback training. All measures will be repeated at the end of the six week period.
11200074|NCT03383913|No Intervention|Control|The control arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firstbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. The control group will receive their usual care for SCD and complete baseline and post-baseline outcome assessments without any HRV-B training. All measures will be repeated at the end of the six week period.
11200075|NCT03383900|Experimental|G-IMT|The experimental group will first carry out a diaphragmatic reeducation program, followed a posteriori by an inspiratory muscle training program use progressive resistance loads up to 80% of the PImax during the 12 weeks
11200076|NCT03383900|Placebo Comparator|Gn-IMT|The Gn-IMT will use by an inspiratory muscle training program use resistance loads up to 10% PImax during the 12 weeks.
11200077|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
11200078|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
11200079|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
11200080|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
11200081|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
11200082|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
11200083|NCT03383848|Experimental|Experimental Software Group|Subjects in the experimental group will be provided with free access to the medication management software online, which will be able to be accessed on the SmartPhone/SmartDevice and home tablet(s) or computer(s) of their choice, through any browser. They will also be provided with links to the surveys to be filled out in the REDCap secure web application throughout the study.
11200084|NCT03383848|No Intervention|Control Group|Subjects in the control group will receive standard of care, and will receive emails with links to the surveys to be filled out in the REDCap secure web application throughout the study.
11200085|NCT03383835|Experimental|Omega-3 Supplementation|Participants will take the dose of omega-3 supplementation (600mg DHA and 300mg EPA) daily for 6 months.
11200086|NCT03383822|Experimental|Intranasal insulin|40 IU of intranasal insulin
11200087|NCT03383822|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
11200088|NCT03383809|Experimental|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
11200089|NCT03383809|Experimental|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
11200093|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
11200094|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
11200095|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
11200096|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
11200097|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).
~A tuohy needle is used."
11200098|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).
~A facet needle is used."
11200099|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
11200100|NCT03383744|Experimental|Vitamin A supplementation 1|Vitamin A status assessed at Baseline and one month after the administration of 200,000 IU of vitamin A
11200101|NCT03383744|Experimental|Vitamin A supplementation 3|Vitamin A status assessed at Baseline and three months after the administration of 200,000 IU of vitamin A
11200102|NCT03383731|Active Comparator|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
11200103|NCT03383731|Experimental|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
11200104|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
11200105|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve
~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve
~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve
~Optimal Medical Treatment/OMT"
11200106|NCT03383705|Experimental|Treatment arm|
11200107|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
11200108|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 until Day 21 of Cycle 3
11200109|NCT03383679|Experimental|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
11200110|NCT03383679|Other|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).
~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
11200111|NCT03383666|Experimental|Treatment Group|PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.
11200112|NCT03383640|No Intervention|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
11200113|NCT03383640|Other|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
11200114|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.
~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.
~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.
~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
11200115|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
11200116|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
11200117|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
11200118|NCT03383601||Users of IQOS with HeatStick|Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (>70%) use Heated Tobacco product IQOS/heatstick
11200162|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
11200119|NCT03383601||Smokers of combustible cigarettes|Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
11200120|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
11200121|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
11200122|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
11200123|NCT03383575|Experimental|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11200124|NCT03383575|Experimental|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11200125|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
11200126|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
11200127|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
11200128|NCT03383549|Experimental|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
11200129|NCT03383549|No Intervention|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
11200130|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
11200131|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
11200132|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
11200133|NCT03383536||Phase 2: HC|healthy controls
11200134|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
11200135|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
11200136|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
11200137|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
11200138|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
11200139|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
11200140|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
11200141|NCT03383510|Experimental|Climate friendly group|The climate friendly group will receive instructions to eat according to a climate friendly diet, i.e., to replace the majority of their intake of animal based products with plant based food.
11200142|NCT03383510|Experimental|Organic group|The organic group will receive instructions to eat an organic diet, i.e., to replace at least 50% of their normally consumed food with organic equivalents.
11200143|NCT03383510|Experimental|Climate friendly and organic group|The climate friendly and organic group will receive instructions to consume a climate friendly and organic diet, i.e, to replace the majority of their intake of animal based products with plant based food AND to consume at least 50% organic food products.
11200144|NCT03383510|Placebo Comparator|Control group|The control group will receive instructions to eat according to the Nordic Nutrition Recommendations.
11200145|NCT03383497||Idiopathic Parkinson Disease|
11200146|NCT03383497||Other Parkinsonian syndromes|
11200147|NCT03383484|No Intervention|No intervention|No OMT, yoga, acupuncture, or other interventions.
11200148|NCT03383484|Experimental|OMT intervention|Weekly OMT for 3 months
11200149|NCT03383484|Experimental|Yoga intervention|Yoga 3 times per week for 3 months
11200150|NCT03383471|Experimental|Invossa K Inj.|Invossa K Inj.
11200151|NCT03383471|Placebo Comparator|Placebo|Placebo control
11200152|NCT03383458|Experimental|Arm A|
11200153|NCT03383458|Placebo Comparator|Arm B|
11200154|NCT03383445|Other|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
11200155|NCT03383445|Other|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
11200156|NCT03383432|Other|Trans-abdominal ultrasound intrauterine device group.|Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.
11200157|NCT03383432|Other|Uterine Sounding Sparing intrauterine device group|The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.
11200158|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
11200159|NCT03383406|Experimental|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
11200160|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
11200161|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
11200163|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
11200164|NCT03383367|Experimental|Tempo Colo|
11200165|NCT03383341|Experimental|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
11200166|NCT03383341|Placebo Comparator|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
11200167|NCT03383328|Active Comparator|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
11200168|NCT03383328|Active Comparator|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
11200169|NCT03383328|Experimental|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
11200170|NCT03383328|Experimental|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.
~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
11200171|NCT03383328|Experimental|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.
~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
11200172|NCT03383315|Experimental|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
11200173|NCT03383315|Active Comparator|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
11200174|NCT03383302|Experimental|Arm 1 Tolerabilty|This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status < 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
11200175|NCT03383289|Experimental|R-REM training|3 module training for frontline staff in assisted living facilities related to recognizing and management of resident-to-resident elder mistreatment
11200176|NCT03383289|No Intervention|Control condition|Usual care
11200177|NCT03383276|Experimental|IL-1Ra|
11200178|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
11200179|NCT03383250|Experimental|Meal ingestion|
11200180|NCT03383237|Experimental|Apatinib|Apatinib 500mg/d,q.d.,p.o.
11200181|NCT03383224|Experimental|Genotype-guided (A allele carriers)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (A allele carriers will be given pharmacologic therapy (nicotine replacement therapy --NRT; nicotine patch used according to FDA labelling).)
11200182|NCT03383224|Experimental|Genotype-guided (GG homozygotes)|CHRNA5 rs16969968 genotype will be determined. Genotype-guided therapy will be given (GG homozygotes will be given smoking cessation counseling)
11200183|NCT03383224|Active Comparator|Standard (non-genotype guided) - NRT|1/2 of patients in this arm will be given nicotine replacement therapy (NRT; nicotine patch used according to FDA labeling) but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
11200184|NCT03383224|Active Comparator|Standard (non-genotype guided)- counseling|1/2 of patients in this arm will be given smoking cessation counseling but this will NOT be based on the patient's genotype. Note that both nicotine replacement therapy and counseling are accepted treatments for smoking cessation in patients with coronary artery disease.
11200185|NCT03383211||HIV+|Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.
11200186|NCT03383211||LTBI|Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.
11200187|NCT03383211||HV+/LTBI|Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.
11200188|NCT03383211||Healthy Control|Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.
11200189|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
11200190|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
11200191|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
11200192|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
11200229|NCT03383016||Men at high-rik of prostate cancer|Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
11200625|NCT03380195|Active Comparator|Sugar water|
11200193|NCT03383172|Experimental|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
11200194|NCT03383172|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
11200195|NCT03383172|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
11200196|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
11200197|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
11200198|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
11200199|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
11200200|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 52 weeks.
11200201|NCT03383146|Placebo Comparator|Placebo|Placebo injected twice daily for 52 weeks.
11200202|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
11200203|NCT03383120|Experimental|Laser|Mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette. Adjunctive sub-mucosal diode laser application according to the instructions of the manufacturer (settings: 810 nm, 2.5 W, 50 Hz, 10 ms), 3x for 30 seconds, using a 400-µm thick fiber (Doctor Smile Wiser diode laser, Orcos Medical AG, Küsnacht, Switzerland), will be performed three times at one week intervals (days 0, 7, and 14).
11200204|NCT03383120|Active Comparator|Surgery|Active control includes mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette at day 1. An open flap debridement procedure is performed at day 14 using normal saline for implant decontamination. Adjunctive systemic antimicrobials will be prescribed; Amoxi-mepha 500mg 3x/day and Metronidazole 500mg 3x/day, for 1 week. A chlorhexidine 0.2% mouth rinse will also be prescribed 2x/day for one week. Suture removal and prophylaxis are performed 7-10 days post-operatively.
11200205|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
11200206|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
11200207|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
11200208|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
11200209|NCT03383094|Active Comparator|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)
11200210|NCT03383094|Experimental|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
11200211|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
11200212|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
11200213|NCT03383081|No Intervention|Control groups|No intervention
11200214|NCT03383068|Other|control|metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance
11200215|NCT03383068|Experimental|acarbose|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months
11200216|NCT03383068|Experimental|Exenatide|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months
11200217|NCT03383068|Experimental|Orlistat|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months
11200218|NCT03383055|Experimental|CMV-MVA Triplex|
11200219|NCT03383042|Experimental|Cohort 1|Single-ascending cohort 1
11200220|NCT03383042|Experimental|Cohort 2|Single-ascending cohort 2
11200221|NCT03383042|Experimental|Cohort 3|Single-ascending cohort 3
11200222|NCT03383042|Experimental|Cohort 4|Single-ascending cohort 4
11200223|NCT03383042|Experimental|Cohort 5|Single-ascending cohort 5
11200224|NCT03383042|Experimental|Cohort 6|Multiple-ascending cohort 1
11200225|NCT03383042|Experimental|Cohort 7|Multiple-ascending cohort 2
11200226|NCT03383042|Experimental|Cohort 8|Multiple-ascending cohort 3
11200227|NCT03383042|Experimental|Cohort 9|Multiple-ascending cohort 4
11200228|NCT03383029|Experimental|iEAT|Children with food refusal will participate in the iEAT program.
11200265|NCT03382795|Experimental|EGFR retreat group|
11200230|NCT03383003|Experimental|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
11200231|NCT03383003|Active Comparator|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
11200232|NCT03382990||STEMI|Patients with STEMI treated with PCI and stent placement (DES or BMS)
11200233|NCT03382990||NSTEMI|Patients with NSTEMI treated with PCI and stent placement (DES or BMS)
11200234|NCT03382977|Experimental|Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
11200235|NCT03382977|Experimental|Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
11200236|NCT03382977|Experimental|Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
11200237|NCT03382977|Experimental|Dose Level 4|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
11200238|NCT03382977|Experimental|Dose Level 5|VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
11200239|NCT03382964|Active Comparator|VLA1553 low dose|VLA1553 with 3.2x10^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL (milliliter)
11200240|NCT03382964|Active Comparator|VLA1553 medium dose|VLA1553 with 3.2x10^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
11200241|NCT03382964|Active Comparator|VLA1553 high dose|VLA1553 with 3.2x10^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
11200242|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
11200243|NCT03382938|Active Comparator|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
11200244|NCT03382938|Active Comparator|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
11200245|NCT03382938|Active Comparator|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
11200246|NCT03382938|Placebo Comparator|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
11200247|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
11200248|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
11200249|NCT03382912|Experimental|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.
~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
11200250|NCT03382912|Active Comparator|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
11200251|NCT03382899|Experimental|1|Pegilodecakin self-administered as a SQ injection QD (≤ 80kg body weight = 0.8mg or [0.2mL] > 80kg body weight = 1.6mg [0.4mL]). Pembrolizumab will be administered as intravenous (IV) infusion on Day 1 of a 21-day cycle (200mg over 30 minutes (± 10min))
11200252|NCT03382899|Active Comparator|2|Pembrolizumab will be administered as an intravenous (IV) infusion on Day 1 of a 21-day cycle (200mg over 30 minutes (± 10min))
11200253|NCT03382886|Experimental|Nivolumab and bevacizumab, all patients|
11200254|NCT03382873|Active Comparator|Group Lifestyle Balance (GLB)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who achieve >2.5% weight loss at week 5 will remain in the GLB arm.
11200255|NCT03382873|Experimental|Group Lifestyle Balance Plus (GLB+)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who fail to achieve >2.5% weight loss at week 5 will transfer to the GLB+ arm.
11200256|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
11200257|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
11200258|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
11200259|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
11200260|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
11200261|NCT03382821|Active Comparator|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
11200262|NCT03382821|Active Comparator|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
11200263|NCT03382808|Experimental|SEE Training|The training sequence comprises four weekly sessions using a modified dote-probe paradigm (fearful vs. neutral expression).
11200264|NCT03382808|Active Comparator|GAZE Training|The GAZE training sequence comprises four weekly sessions using a modified dote-probe paradigm (averted vs. directed gaze).
11200266|NCT03382782|Active Comparator|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 12 months. BWLI consists of a 8-month initial intervention phase followed by 4-month maintenance phase. The initial intervention phase comprises four types of contact:
~1-hour to 1-hour, 30 minute group weight-management class led by facilitator (once per week; 26 classes followed by a one week break and an additional 8 weight management review classes)
~45 minute, physical activity led by facilitator (one-two times per week);
~20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and
~weigh-in during weight management group and individual visits (once each week)."
11200267|NCT03382782|Experimental|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:
~partnering with participant on BWLI homework;
~meeting with participant and BWLI facilitator individually;
~attending all other health care appointments; and
~partnering on tasks that arise out of those appointments."
11200268|NCT03382782|Active Comparator|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
11200269|NCT03382769|Experimental|Group A|Group A will consist of 30 individuals who are candidates for cochlear implantation. They will be unilaterally implanted immediately after initial study testing has been completed and then be followed for 12 months after device activation.
11200270|NCT03382769|Active Comparator|Group B|Group B will consist of 30 individuals who are candidates for cochlear implantation. They will continue to wear hearing aids after enrolling in the study and then be unilaterally implanted and followed for 6 more months after device activation.
11200271|NCT03382756|Experimental|Group A|"Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition
~Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition"
11200272|NCT03382756|Experimental|Group B|"Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition
~Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition"
11200273|NCT03382743|Active Comparator|Group A (Lidocaine group)|5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy
11200274|NCT03382743|No Intervention|Group B (control group)|office hysteroscopy is done without analgesia
11200275|NCT03382730|Other|Oral Chlorhexidine Mouth Rinse|Application of chlorhexidine gluconate mouth rinse per unit protocol.
11200276|NCT03382730|Experimental|De-Adoption of Oral Chlorhexidine Mouth Rinse|No application of chlorhexidine gluconate mouth rinse. Oral care bundle.
11200277|NCT03382717|Experimental|Excilor Forte|
11200278|NCT03382717|Active Comparator|Loceryl 5%|
11200279|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
11200280|NCT03382691|Experimental|EXPERIMENTAL|Blood pressure check using mobile device and control device
11200281|NCT03382652||Patients who received the Continuum Metal on Metal System|Patients requiring total hip arthroplasty, who meet the inclusion/exclusion criteria and received the Continuum Metal on Metal System
11200282|NCT03382639|Experimental|Double-blind: TAK-831 50 mg|TAK-831 50 milligram (mg), tablets, orally, once daily up to 14 weeks.
11200283|NCT03382639|Experimental|Double-blind: TAK-831 125 mg|TAK-831 125 mg, tablets, orally, once daily up to 14 weeks.
11200284|NCT03382639|Experimental|Double-blind: TAK-831 500 mg|TAK-831 500 mg, tablets, orally, once daily up to 14 weeks.
11200285|NCT03382639|Placebo Comparator|Double-blind: Placebo|TAK-831 placebo-matching tablets, orally, once daily up to 14 weeks.
11200286|NCT03382626|Active Comparator|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve working memory, attention, and executive function).
11200287|NCT03382626|Sham Comparator|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve working memory, attention and executive function).
11200288|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
11200289|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
11200290|NCT03382600|Experimental|Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)|Participants receive Pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
11200291|NCT03382600|Experimental|Pembrolizumab + Cisplatin +TS-1 (Cohort 2)|Participants receive Pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
11200292|NCT03382587||Aflibercept|Treatment-naive wet age-related macular degeneration patients under routine intravitreal aflibercept treatment in a treat-and-extend scheme
11200336|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
11200337|NCT03382236|Experimental|Real osteopathy|
11200293|NCT03382574|Experimental|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
11200294|NCT03382574|Active Comparator|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.
11200295|NCT03382561|Experimental|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
11200296|NCT03382561|Active Comparator|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11200297|NCT03382548|Active Comparator|Short antibiotic treatment duration for VAP (7 days or less)|
11200298|NCT03382548|Active Comparator|Long antibiotic treatment duration for VAP ( 8 days or more)|
11200299|NCT03382535|Active Comparator|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
11200300|NCT03382535|Experimental|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
11200301|NCT03382535|Other|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
11200302|NCT03382509|Experimental|Single Dose Group|
11200303|NCT03382509|Experimental|Multiple Dose Group|
11200304|NCT03382496||Lung Cancer patients in France|Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
11200305|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
11200306|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
11200307|NCT03382457|Experimental|Treatment|Treatment with the Edwards Cardioband Tricuspid Valve Reconstruction System
11200308|NCT03382431|Experimental|PC786|Repeat dose
11200309|NCT03382431|Placebo Comparator|Placebo/vehicle|Repeat dose
11200310|NCT03382418|Experimental|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
11200311|NCT03382418|Experimental|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
11200312|NCT03382418|Placebo Comparator|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
11200313|NCT03382405|Experimental|mRNA-1647|
11200314|NCT03382405|Experimental|mRNA-1443|
11200315|NCT03382405|Placebo Comparator|Placebo|
11200316|NCT03382392||ALS|
11200317|NCT03382392||control 1|
11200318|NCT03382392||control 2|
11200319|NCT03382379|Experimental|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
11200320|NCT03382379|Placebo Comparator|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
11200321|NCT03382366|Other|Sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as sarcopenic by the DXA.
~This group will undergo the same evaluations/intervention of the second group."
11200322|NCT03382366|Other|Non-sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as non-sarcopenic by the DXA.
~This group will undergo the same evaluations/intervention of the first group."
11200323|NCT03382353|Active Comparator|No Treatment (NT)|Educational training
11200324|NCT03382353|Experimental|Partial Treatment (PT)|Nutritional supplementation & Counselling on a brain-healthy diet
11200325|NCT03382353|Experimental|Full Treatment (FT)|Nutritional supplementation & Counselling on a brain-healthy diet & Physical exercise training & Computerized cognitive training
11200326|NCT03382340|Experimental|Imx-110|
11200327|NCT03382327|Experimental|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
11200328|NCT03382314|Experimental|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
11200329|NCT03382314|Active Comparator|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
11200330|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
11200331|NCT03382301|Placebo Comparator|NaCl preconditioning|
11200332|NCT03382288|Experimental|Examination of participants|Examination of participants by means of the investigational device, Eyestar 900 as well as the comparative devices.
11200333|NCT03382262|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
11200334|NCT03382262|Active Comparator|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
11200335|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
11200339|NCT03382210||ERP group|A prospective series of patients (N=100) undergoing elective colorectal resection and completing a standardized enhanced recovery protocol in 2013-2015 (ERP group) at the S. Anna University Hospital in Ferrara (Italy).
11200340|NCT03382210||Pre-ERP group|A retrospective series of patients (N=100) operated on at the the S. Anna University Hospital in Ferrara (Italy) in 2009-2011 (Pre-ERP group), before the introduction of ERP methodology.
11200341|NCT03382197|Experimental|Nebulization|control intervention, will only perform nebulization;
11200342|NCT03382197|Experimental|Positive expiratory pressure valve|Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP)
11200343|NCT03382197|Experimental|Nonivasive ventilation|intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;
11200344|NCT03382184|Experimental|Fraxel DUAL 1550 nm|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group.
11200345|NCT03382184|Experimental|Halo Hybrid Laser 1550 nm|The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group.
11200346|NCT03382171|Experimental|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
11200347|NCT03382171|No Intervention|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
11200348|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
11200349|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
11200350|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
11200351|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
11200352|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
11200353|NCT03382132|Experimental|momHealth|Participants will receive support and information via the momHealth program.
11200354|NCT03382132|Active Comparator|Control|Participants will receive the normal support they would normally receive if they were not in a study.
11200355|NCT03382119||Patients having Fontan cardiac surgery|"This group includes pediatric patients, aged 2-5 years, who have had a Fontan operation. This surgery corrects a heart defect found at birth in which the heart has only one ventricle.
~Patients will have an Ultrasound with ARFI imaging."
11200356|NCT03382119||Patients with Liver disease|"This group includes pediatric patients, aged 2-5 years, who have chronic liver disease caused by biliary atresia.
~Patients will have an Ultrasound with ARFI imaging."
11200357|NCT03382106|Experimental|Smoking Cessation Group 1|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 25 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
11200358|NCT03382106|Placebo Comparator|Smoking Cessation Group 2|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 25 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day placebo oral tablet for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
11200359|NCT03382106|Experimental|Non-Smokers Group 1|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 25 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. We will provide 10 females and 10 males three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months.
11200360|NCT03382106|No Intervention|Non-Smokers Group 2|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 25 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. 10 females and 10 males will not receive any medication for the full 3 months.
11200433|NCT03381547|Active Comparator|A|Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
11200361|NCT03382093|Active Comparator|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
11200362|NCT03382093|Active Comparator|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
11200363|NCT03382080|Experimental|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
11200364|NCT03382080|Experimental|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through
~Co-location of services and staff working in services
~One open door to increase accessibility to the services and staff for students
~Focus on the transition from lower to upper secondary school
~Close follow-up of students at risk to ensure tailored help to each student
~Early intervention and follow up when students starts being absent from school"
11200365|NCT03382080|No Intervention|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
11200366|NCT03382067|Active Comparator|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
11200367|NCT03382067|Placebo Comparator|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing < 0,0009 mg (-)-Epicatechin/100g
11200368|NCT03382054||Older surgical patients|Male and female patients with age 65 years and above scheduled for surgery
11200369|NCT03382041|Experimental|Carbon Fiber Implant|There is an alternative to the standard treatment, which is carbon fiber implants (tibial nails), especially in the prophylactic reinforcement of bones susceptible to pathological fractures following metastatic tumors. The new carbon fiber has also been used in the treatment of tibial non-union (non- healing bone); which has shown satisfactory outcomes.
11200370|NCT03382041|Active Comparator|Titanium Implant|The standard of practice in the treatment of fractures of the tibial shaft and other long bones has been the intramedullary nailing using titanium or stainless steel implants.
11200371|NCT03382015|Active Comparator|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
11200372|NCT03382015|Placebo Comparator|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
11200373|NCT03381989|Experimental|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
11200374|NCT03381976|Active Comparator|Intervention 2X/week (G2X)|This group performed resistance training twice a week (Tuesdays and Thursdays)
11200375|NCT03381976|Active Comparator|Intervention 3X/week (G3X)|This group performed resistance training three sessions a week (Mondays, Wednesdays, and Fridays).
11200376|NCT03381976|No Intervention|Control group (GC)|This group did not perform any type of organized physical exercise during the study period.
11200377|NCT03381963||Aromatase inhibitors|
11200378|NCT03381963||Tamoxifen|
11200379|NCT03381937|No Intervention|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
11200380|NCT03381937|Experimental|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
11200381|NCT03381937|Experimental|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
11200382|NCT03381924|Experimental|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
11200383|NCT03381924|Placebo Comparator|Control group|Routine clinical practice
11200384|NCT03381911|No Intervention|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
11200385|NCT03381911|Experimental|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
11200386|NCT03381898|Experimental|Telehealth Coordinated Allied Health|rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
11200387|NCT03381885|Experimental|Intervention Group|"A nudge grounded in behavioral economic theory (nudge=gentle incentive, preserving freedom of choice)"
11200388|NCT03381885|Placebo Comparator|Control|"No nudge"
11200389|NCT03381872|Active Comparator|Intravascular imaging arm|The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.
11200428|NCT03381599|Experimental|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
11200429|NCT03381586|Experimental|Group A|1.0 mg/ml ALT-803
11200430|NCT03381586|Experimental|Group B|2.0 mg/ml ALT-803
11200390|NCT03381872|Active Comparator|Angiography arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
11200391|NCT03381859|Experimental|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
11200392|NCT03381846|Experimental|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
11200393|NCT03381833|Active Comparator|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
11200394|NCT03381833|Active Comparator|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
11200395|NCT03381820|Experimental|music listening|Participants who were randomized into intervention group were assigned to listen to the music everyday (day 1st to day 30th), at anytime of day that was suitable with their lifestyles but not at the time of BP measurement. During day 31st -120th, participants did not listen to the music. Other treatment was the same as the control arm.
11200396|NCT03381820|No Intervention|control|control arm received conventional hypertension treatment.
11200397|NCT03381807|Experimental|TCRA and intrauterine infusion of hAESCs|hAESCs is infused into uterine cavity after TCRA.
11200398|NCT03381794||Patients with corneal transplantation|Aim is to include all patients in Germany treated with the different types of corneal transplantation with an interim-assessment of the period between 2001 and 2016.
11200399|NCT03381781|Experimental|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
11200400|NCT03381768|Experimental|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
11200401|NCT03381755|Experimental|half-dose ticagrelor|
11200402|NCT03381755|Active Comparator|standard-dose ticagrelor|
11200403|NCT03381742|Experimental|ticagrelor 45mg bidpo.|To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
11200404|NCT03381742|Experimental|ticagrelor 90mg qdpo.|To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
11200405|NCT03381742|Active Comparator|ticagrelor 90mg bidpo.|To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
11200406|NCT03381742|Active Comparator|clopidogrel 75mg qdpo.|To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
11200407|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of onasemnogene abeparvovec-xioi
11200408|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of onasemnogene abeparvovec-xioi
11200409|NCT03381729|Experimental|Dose C|Intrathecal administration 2.4 X 10^14 vg of onasemnogene abeparvovec-xioi
11200410|NCT03381716||male|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
11200411|NCT03381716||female|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
11200412|NCT03381703|Experimental|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
11200413|NCT03381703|Experimental|Part 2|Investigate the absolute bioavailability of YH12852
11200414|NCT03381690||Epidural (ED) emergent C-sec|
11200415|NCT03381690||Non-ED emergent C-sec|
11200416|NCT03381690||Non-ED elective C-sec|
11200417|NCT03381677|Experimental|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
11200418|NCT03381677|Active Comparator|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):
~DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and
~DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
11200419|NCT03381664|Experimental|AVP-923-20/10 capsule|Participants will receive a single AVP-923-20/10 (dextromethorphan hydrobromide [DM] 20 milligram [mg]/quinidine sulfate [Q] 10 mg) capsule administered orally.
11200420|NCT03381664|Experimental|AVP-923-20/10 via applesauce|Participants will receive the contents from a single AVP-923-20/10 capsule mixed and consumed in 1 tablespoon of applesauce.
11200421|NCT03381664|Experimental|AVP-923-20/10 via nasogastric feeding tube|Participants will receive the contents from a single AVP-923-20/10 capsule solubilized in feeding solution and administered through a nasogastric feeding tube.
11200422|NCT03381651|Active Comparator|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
11200423|NCT03381651|Active Comparator|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
11200424|NCT03381638||Normal Volunteer|Volunteers who report to have never had a concussion and are not at high risk of getting a concussion are scanned to obtain a baseline of all ages, sex, race, etc. All patients will be scanned with the Blink Reflexometer.
11200425|NCT03381638||Concussion Protocol|Athletes who had a potential concussion and will go through any stage of the approved protocol, are scanned by the Blink Reflexometer device. Results are then analyzed prior to unblinding the clinical diagnosis from an Athletic Trainer and/or Neurologist.
11200426|NCT03381625|Experimental|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
11200427|NCT03381625|Placebo Comparator|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
11200431|NCT03381573||Roflumilast exposed|Patients with COPD ever exposed to Roflumilast
11200626|NCT03380195|Placebo Comparator|Water|
11200434|NCT03381547|Active Comparator|B|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
11200435|NCT03381547|Active Comparator|C|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
11200436|NCT03381534|Placebo Comparator|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
11200437|NCT03381534|Experimental|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
11200438|NCT03381521|Experimental|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
11200439|NCT03381521|Active Comparator|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
11200440|NCT03381508||The study population|"The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.
~Intervention: Brizzy continuous positive pressure device"
11200441|NCT03381495|Experimental|Epidural analgesia during labor|The epidural analgesia technique was used to maintain analgesia for parturients who request labor analgesia.First, we injected a test dose of 5ml 1% lidocaine . If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the epidural catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h until the delivery of neonates.
11200442|NCT03381495|No Intervention|Non-epidural analgesia during labor|Women who refused epidural labor analgesia were included in the non-epidural analgesia group, and they don't receive epidural analgesia during labor
11200443|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
11200444|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
11200445|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
11200446|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
11200447|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
11200448|NCT03381469|Experimental|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
11200449|NCT03381469|Active Comparator|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
11200450|NCT03381469|Active Comparator|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
11200451|NCT03381456|Experimental|Healthy subject|LICI
11200452|NCT03381456|Experimental|Dystonic subject|LICI
11200453|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
11200454|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
11200455|NCT03381430|Experimental|Gefitinib + Radiotherapy|Experimental: Gefitinib Gefitinib 250 mg/day oral daily Radiotherapy Total dose 50-54Gy, divided dose 1.8-2Gy
11200456|NCT03381417|Experimental|Pegcyte (Nanogen pegfilgrastim)|6 mg in each cycle
11200457|NCT03381417|Active Comparator|Neulastim (Roche pegfilgrastim)|6 mg in each cycle
11200458|NCT03381404|Experimental|[14C] MT-8554|
11200459|NCT03381391|Experimental|Feedback intervention condition|
11200460|NCT03381391|No Intervention|Assessment-only control condition|
11200461|NCT03381365|Experimental|investigational arm|
11200462|NCT03381352|Experimental|Chemo-radiotherapy with IMRT technique|Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
11200463|NCT03381339|Experimental|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
11200464|NCT03381339|No Intervention|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
11200465|NCT03381313|Experimental|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
11200466|NCT03381300|Other|Single cohort|
11200467|NCT03381287|Experimental|500mg HTD1801|
11200468|NCT03381287|Experimental|1000mg HTD1801|
11200469|NCT03381287|Experimental|2000mg HTD1801|
11200470|NCT03381274|Experimental|Arm A|MEDI9447 and osimertinib
11200471|NCT03381274|Experimental|Arm B|MEDI9447 and AZD4635
11200472|NCT03381261|Experimental|Botulinum toxin type A injection arm|All patients will be injected with Botulinum toxin on one side of the back of the head.
11200473|NCT03381248|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
11200474|NCT03381248|Active Comparator|Hyaluronic Acid Injection|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain
11200475|NCT03381235|Experimental|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
11200476|NCT03381235|No Intervention|Mild exercise|Sessions will be focused on balance and stretching.
11200477|NCT03381209|Experimental|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
11200698|NCT03379701||allergic rhinitis|Patients with allergic rhinitis
11200480|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
11200481|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
11200482|NCT03381183|Experimental|Phase 1 - Dose Escalation|Six patients will be enrolled at Dose Level 1 with IRX-2 230 units/day in combination with cyclophosphamide and durvalumab and treated sequentially at least 1 week apart. If less than 2 out of 6 patients have DLTs in Dose Level 1, the dose will be escalated to administration of IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab as Dose Level 2. If 2 of 6 patients have DLTs, stop accrual and re-evaluate. In the next safety phase, six patients at IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab will be enrolled and treated sequentially (at least 1 week apart). If DLT occurs in less than 2 of 6 patients during the first 6 weeks of treatment, enrollment can continue in the dose expansion phase at Dose Level 2. If DLT is observed in 2 of 6 patients, accrual will be stopped and Dose Level 1 will resume in the dose expansion phase.
11200483|NCT03381183|Experimental|Phase 2 - Dose Expansion|14 patients will be enrolled at the recommended dose level from the dose finding phase for a total enrollment of 20 patients; however, investigators will replace patients with any missing tumor sample collection and continue enrollment until there are at least 20 pre- and post-treatment paired tumors (i.e. minimum 2 of 3 tumors per patient). The 6 patients treated at the recommended dose in the dose finding phase of the study will be counted as a part of the dose expansion patient population,
11200484|NCT03381170|Experimental|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
11200485|NCT03381157||Cystic Fibrosis Group|
11200486|NCT03381157||Control Group|
11200487|NCT03381144|Experimental|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
11200488|NCT03381144|Placebo Comparator|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
11200489|NCT03381144|Experimental|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
11200490|NCT03381144|Placebo Comparator|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
11200491|NCT03381144|Experimental|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
11200492|NCT03381144|Placebo Comparator|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
11200493|NCT03381118|Experimental|Ara-C+HaploLymphocyte+Nivo|"Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:
~[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0
~+ Nivolumab 40 mg D+5] х 2-3 cycles"
11200494|NCT03381118|Experimental|Ara-C+ Nivo|"Patients treated with nivolumab and intermediate dose cytarabine:
~[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1] х 2-3 cycles"
11200495|NCT03381092||invasive breast cancer|Patients with invasive breast cancer who have clinically negative axilla and receive neoadjuvant treatment followed by sentinel lymph node biopsy are eligible for this study.
11200496|NCT03381079|Experimental|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
11200497|NCT03381079|No Intervention|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
11200498|NCT03381066|Experimental|Intercalating arm|gefitinib, pemetrexed,cisplatin
11200499|NCT03381066|Active Comparator|chemotherapy alone arm|Vinorelbine, cisplatin
11200500|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
11200501|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
11200502|NCT03381040|Active Comparator|Group A|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
11200503|NCT03381040|Active Comparator|Group B|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
11200504|NCT03381027|Experimental|Interventional Arm- Baby Massage|Interventional Arm= Baby Massage
11200505|NCT03381027|No Intervention|Control Arm- no Baby Massage|Control Arm= no Baby Massage
11200506|NCT03381001|Active Comparator|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
11200507|NCT03381001|Experimental|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
11200508|NCT03380988|Experimental|Fiber-enriched buckwheat pasta|Acute test meal
11200509|NCT03380988|Active Comparator|Corn pasta|Acute test meal
11200510|NCT03380975|Experimental|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
11200511|NCT03380962|Experimental|Clazakizumab|All twenty patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
11200512|NCT03380949|Experimental|PPI (Pain Pupillary Index)|Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
11200513|NCT03380949|Experimental|SPI (Surgical Pleth Index)|Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
11200514|NCT03380949|Experimental|NOL (Nociception Level)|Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
11200515|NCT03380949|Active Comparator|Control|Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
11200516|NCT03380936|Active Comparator|Arm 1 - conversion to Envarsus XR|Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet [Envarsus]) with goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
11200517|NCT03380936|Active Comparator|Arm 2 - plasma exchange and IVIG|Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
11200518|NCT03380923|Experimental|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.
~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with ~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.
~HR is monitored throughout each session and stored for analysis."
11200519|NCT03380923|Experimental|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.
~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.
~HR is monitored throughout each session and stored for analysis."
11200520|NCT03380910|Experimental|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
11200521|NCT03380910|Other|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
11200522|NCT03380897|Active Comparator|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with visual analogy scale at home. The intervention is to go home.
~Intervention for outpatient group was to go home."
11200523|NCT03380897|Placebo Comparator|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with visual analogy scale in the ward. The intervention is to stay at ward.
~Intervention for inpatient group was to stay at ward."
11200699|NCT03379701||Control|Healthy subjects.
11200524|NCT03380884|No Intervention|Control|Control group will remain in their habitual life style and no vibration used
11200525|NCT03380884|Experimental|Vibration Group|The intervention group will undergo Low-magnitude high-frequency vibration (LMHFV) at 35Hz, 0.3g (peak to peak magnitude), displacement of <0.1mm, 20 min/day, at least 3 times per week, for 6 months in community centres
11200526|NCT03380871|Experimental|NEO-PV-01/Adjuvant + pembrolizumab + chemotherapy|Pembrolizumab at a dose of 200 mg administered by intravenous infusion (IV) plus chemotherapy with carboplatin (AUC 5) + pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with pembrolizumab.
11200527|NCT03380845|Active Comparator|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face
~Fraxel Restore: acne scar correction
~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
11200528|NCT03380845|Active Comparator|Fractora on the other side of the face|"Fractora on the other side of the face
~Fractora: acne scar correction
~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
11200529|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
11200530|NCT03380819|Experimental|Genome sequencing|Patients undergo exome or whole-genome sequencing, and their patients receive an interpreted clinical report.
11200531|NCT03380806|Active Comparator|Arm 1|Conventional Radiotherapy (CRT) Prostate Boost Pelvic Radiation LHRH agonist
11200532|NCT03380806|Experimental|Arm 2|Stereotactic Body Radiotherapy (SBRT) Prostate Boost Pelvic Radiation LHRH agonist
11200533|NCT03380793|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
11200534|NCT03380780|Experimental|Emicizumab|
11200535|NCT03380767|Experimental|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
11200536|NCT03380767|Experimental|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
11200537|NCT03380754|Experimental|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
11200538|NCT03380754|Placebo Comparator|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
11200539|NCT03380754|No Intervention|No Drink|Group C will not receive any drink. This group will follow normal protocol.
11200540|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
11200541|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
11200542|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
11200543|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
11200544|NCT03380741||Group 5|Normal cervix at colposcopy
11200545|NCT03380728|Experimental|Group 1|Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
11200546|NCT03380728|Experimental|Group 2|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, placebo on day 7
11200547|NCT03380728|Experimental|Group 3|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, Ibogaine Hydrochloride 400 mg on day 7
11200548|NCT03380715|Active Comparator|right nostril in patients with rhinitis|Intervention : Administration of either 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity or
11200549|NCT03380715|No Intervention|Left nostril in patients with rhinitis|No nasal decongestion administration into the left nostril
11200550|NCT03380715|Active Comparator|Right nostril in patients with rhinitis|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
11200551|NCT03380702|Active Comparator|whitening photoactivation gel|exposure to hydrogen gel and photoactivation for teeth whitening
11200552|NCT03380702|Placebo Comparator|placebo|exposure to gel without active whitening substance and the same photoactivation source as active comparator
11200553|NCT03380689|Experimental|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
11200554|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
11200555|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
11200556|NCT03380663|Active Comparator|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
11200557|NCT03380663|Active Comparator|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
11200558|NCT03380663|Active Comparator|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
11245462|NCT03070951|Experimental|OBE2109 dose 2 + Add-back|
11200559|NCT03380663|Active Comparator|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
11200560|NCT03380663|Active Comparator|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
11200561|NCT03380663|No Intervention|Control - Healthy|No intervention.
11200562|NCT03380663|No Intervention|Control - HF|No intervention.
11200563|NCT03380650|Other|durg-coated balloon dilation|The drug-coated balloon will be used to treat the femoropopliteal occlusion.
11200564|NCT03380650|Other|directional atherectomy and LDD|The directional atherectomy and local drug delivery will be used to treat the femoropopliteal occlusion.
11200565|NCT03380637||Pregnant and non-pregnant females|The pregnant females posted for elective lower segment cesarean section and non-pregnant females posted for elective surgeries are scanned by ultrasound in the pre recovery room. The visibility of the gastric antrum is assessed. The qualitative and quantitative assessment is made and is compared.
11200566|NCT03380624|Experimental|Refresh Optive|The subjects are randomly assigned to Arm one or Arm two such as in the first arm, subjects are assigned to be treated with one drop of Refresh Optive at 15 minutes, 1, 2 and four hours After which there is a washout period before proceeding to the second arm
11200567|NCT03380624|Experimental|Refresh Optima OMEGA 3|The subjects are randomly assigned to Arm one or Arm two such as in the first arm, subjects are assigned to be treated with one drop of Refresh Optima OMEGA 3 at 15 minutes, 1, 2 and four hours After which there is a washout period before proceeding to the second arm
11200568|NCT03380611|Experimental|Wakame|Subjects will receive capsules containing wakame
11200569|NCT03380611|Experimental|Spirulina|Subjects will receive capsules containing spirulina
11200570|NCT03380611|Placebo Comparator|Control|Subjects will receive capsules containing microcrystalline cellulose
11200571|NCT03380598|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
11200572|NCT03380598|Active Comparator|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
11200573|NCT03380585|Experimental|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
11200574|NCT03380585|Active Comparator|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
11200575|NCT03380572|Experimental|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
11200576|NCT03380572|Active Comparator|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
11200577|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
11200578|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
11200579|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
11200580|NCT03380546|Experimental|acarbose|The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
11200581|NCT03380546|Active Comparator|prandial insulin|The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.
11200582|NCT03380533|Active Comparator|Buprenorphine Patch|"Buprenorphine 10mg Patch + Placebo Tablet + Multimodal Oral Scheme
~Multimodal Oral Scheme:
~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
11200583|NCT03380533|Active Comparator|Tramadol Tablet|"Placebo Patch + Tramadol 50mg Tablet + Multimodal Oral Scheme
~Multimodal Oral Scheme:
~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
11200584|NCT03380520|Experimental|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
11200585|NCT03380520|Placebo Comparator|Placebo|Normal saline (0.9%)
11200586|NCT03380507|Experimental|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.
~Triple therapy regimen:
~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
11200587|NCT03380507|No Intervention|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
11200588|NCT03380494|Experimental|Overhead perturbation training technique|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
11200589|NCT03380494|Active Comparator|Non-perturbed exercise|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied via a weight held in the hand- such that the glenohumeral joint is exposed to a load but without a perturbation of joint position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
11200590|NCT03380481||SECRETS-TCM|Stroke patients who treated by western medicine and/or traditional Chinese medicine in southern China
11200591|NCT03380468|Experimental|Cisplatin plus pemetrexed|Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
11200593|NCT03380455|Experimental|Treatment period A & B|"Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.
~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10)."
11200594|NCT03380442|Experimental|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
11200595|NCT03380442|Active Comparator|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
11200596|NCT03380442|No Intervention|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
11200597|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
11200598|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
11200599|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
11200600|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
11200601|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
11200602|NCT03380416|Experimental|Portfolio Diet|The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
11200603|NCT03380416|Active Comparator|MUFA Diet|The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
11200604|NCT03380403|Active Comparator|PDT|Methylene blue and Photon Irradiation , every each week, until total ulcer healing.
11200605|NCT03380403|Active Comparator|Ciprofloxacin|Diabetic foot patients were treated on conventional way, using antibiotics and surgery.
11200606|NCT03380390|Experimental|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
11200607|NCT03380377|Experimental|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
11200608|NCT03380364|Experimental|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
11200609|NCT03380351||SCDIC interventions|Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
11200610|NCT03380351||SCDIC control groups|Careful detail the control conditions of each of the SCDIC sites for each of the interventions being developed.
11200611|NCT03380338|Experimental|Exercise program|Twice weekly exercise program, combined aerobic and strenght training
11200612|NCT03380325|Experimental|Iloprost first|Cross-over starts with iloprost intervention, then second clamp without iloprost.
11200613|NCT03380325|Experimental|Iloprost second|Cross-over starts without iloprost intervention, then second clamp with iloprost.
11200614|NCT03380286||Coronary Stenosis|
11200615|NCT03380273|No Intervention|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
11200616|NCT03380273|Other|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
11200617|NCT03380260|Experimental|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
11200618|NCT03380260|No Intervention|Control Condition|No manipulation of paranoid ideation
11200619|NCT03380234|Experimental|Intervention|8 worksheets and around 15 online quizzes and 30 WhatsApp messages.
11200620|NCT03380234|Other|Control|Control students will receive the following minimal intervention to reduce their intention to smoke and SHS - a leaflet on smoking and SHS published by the Department of Health.
11200621|NCT03380221|Experimental|Watermelon|
11200622|NCT03380221|Active Comparator|Low fat cookies|
11200623|NCT03380195|Experimental|Watermelon juice|
11200627|NCT03380182|Experimental|Acupuncture/Acupressure Group|Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
11200628|NCT03380182|Sham Comparator|Control Group|Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
11200629|NCT03380169|Experimental|Advance dressing|Prophylactic advance wound dressing
11200630|NCT03380169|Active Comparator|Conventional gauze dressing|Prophylactic conventional wound dressing
11200631|NCT03380156|Experimental|Interventional|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
11200632|NCT03380156|Placebo Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
11200633|NCT03380143|Experimental|Wellscapes Intervention|The wellness landscape intervention (Wellscapes) will establish a multi-level system infrastructure (Community Hub, Organization Wellness Teams, Activity Setting/Leaders) and provide training and support for population health quality improvement cycle processes targeting two evidence-based practices (EBPs): (1) stacking time segments of PA episodes within an organization's daily routine, and (2) improving the quality of PA episodes (% time in PA).
11200634|NCT03380143|Active Comparator|Standard Practice|The standard collective impact public health practice intervention will establish a multi-level system infrastructure and provide training on community development.
11200635|NCT03380130|Experimental|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
11200636|NCT03380117|Experimental|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
11200637|NCT03380117|No Intervention|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
11200638|NCT03380104|Experimental|Single Arm|Intradural Spinal Cord Stimulation; Administration of Questionnaires
11200639|NCT03380091|Experimental|Metformin|Metformin 1000 mg PO bid
11200640|NCT03380091|Experimental|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
11200641|NCT03380078|Active Comparator|Standard|Programs assigned to the Standard condition will receive standard EBI training only
11200642|NCT03380078|Experimental|TEAMS Leadership Institute (TLI) ONLY|Programs assigned to the TLI ONLY condition will receive standard EBI training for providers and leaders will participate in TLI.
11200643|NCT03380078|Experimental|Motivational Enhancement (TIPS for Training) ONLY|Programs assigned to the TIPS ONLY condition will receive enhanced TIPS EBI training for providers.
11200644|NCT03380078|Experimental|TIPS + TLI|Programs assigned to the TIPS + TLI condition will receive TIPS EBI training for providers and leaders will participate in TLI
11200645|NCT03380065|Active Comparator|Late deflation of TR band|"first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.
~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
11200646|NCT03380065|Active Comparator|Early deflation of TR band|"First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.
~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
11200647|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
11200648|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
11200649|NCT03380039|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
11200650|NCT03380026|Experimental|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
11200651|NCT03380026|Active Comparator|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
11200652|NCT03380013|Experimental|OMT group|Osteopathic Manipulative Therapy (OMT); two treatments between day 4 and 7 of life
11200653|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
11200654|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
11200655|NCT03379987|Experimental|PVB morphine|
11200656|NCT03379987|Active Comparator|PVB bupivacaine|
11200657|NCT03379974|Experimental|ARM A: DDAVP followed by exercise|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: Exercise intervention"
11200700|NCT03379688||Cardiac surgery patients|Patients undergoing cardiac surgery at Charité Campus Mitte
11201212|NCT03376048|Active Comparator|Wound infiltration|Wound infiltration placed by surgeon
11200658|NCT03379974|Active Comparator|ARM B: DDAVP alone|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: no further intervention (rest)"
11200659|NCT03379974|Experimental|ARM C: Exercise intervention|"Intervention #1: Exercise intervention
~Intervention #2: no further intervention (rest)"
11200660|NCT03379974|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise intervention
~Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
11200661|NCT03379948||Group 1 with central venous line|lab investigation Complete blood count blood culture
11200662|NCT03379948||Group 2 with only peripheral line|lab investigation Complete blood count blood culture
11200663|NCT03379935||Bipolar radial head arthroplasty|Patients treated with bipolar head arthroplasty due to radial head fracture
11200664|NCT03379935||Unipolar radial head arthroplasty|Patients treated with unipolar head arthroplasty due to radial head fracture
11200665|NCT03379922|Experimental|Stress balls|The first arm will be given stress balls to squeeze during their treatment and will also receive standard care (the offer of oral analgesia)
11200666|NCT03379922|Experimental|Headphones|The second arm will be given headphones to listen to music during their treatment and will also receive standard care.
11200667|NCT03379922|No Intervention|Control|The control group will receive standard care (the offer of oral analgesia)
11200668|NCT03379909|Experimental|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
11200669|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
11200670|NCT03379896||Control|Age-matched healthy control
11200671|NCT03379883|Placebo Comparator|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
11200672|NCT03379883|Experimental|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
11200673|NCT03379870|Experimental|Arm 1|"Subjects who receive a CI and present with a post-operative LFPTA of ≤ 75 dB HL.
~Electric Acoustic Speech Processor: EAS fitting. They will be evaluated in the EAS condition and the hearing aid (HA) alone condition."
11200674|NCT03379870|Experimental|Arm 2|"Subjects with pre-operative low frequency hearing who receive a CI and present with a post-operative LFPTA of > 75 dB HL.
~Electric Acoustic Speech Processor: Electric only fitting They will be evaluated in the traditional fully electric condition only."
11200675|NCT03379857|Other|Cannabis User|
11200676|NCT03379844|Experimental|Holmium-166 radioembolization|
11200677|NCT03379818|Experimental|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
11200678|NCT03379818|Experimental|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
11200679|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
11200680|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
11200681|NCT03379792|Active Comparator|Lean T1D|
11200682|NCT03379792|Active Comparator|Obese T1D|
11200683|NCT03379792|Active Comparator|Non-diabetic|
11200684|NCT03379779||Pneumonia patient with respiratory failure|Sputum and stool sampling day 1, 3 and 7 after enrolling into study
11200685|NCT03379766|Experimental|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
11200686|NCT03379766|Active Comparator|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
11200687|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
11200688|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
11200689|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :
~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
11200690|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :
~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
11200691|NCT03379727|Experimental|Midostaurin|Induction phase - D8 to D28 in combination with standard of care (7+3 or 5+2 chemotherapy) up to 2 cycles Consolidation phase - D8 to D28 in combination with cytarabine up to 4 cycles Maintenance phase - D1 to D28 up to 12 cycles
11200692|NCT03379714||Patients with ruptured or unruptured intracranial aneurysms|
11200693|NCT03379701||CRSwPolyps with no Eosonophilia|CRS patients with nasal polyposis, and no eosonophilia.
11200694|NCT03379701||CRSwPolyps with Eosonopholia|CRS patients with nasal polyposis and eosonophilia.
11200695|NCT03379701||CRS without Polyps|Patients with chronic rhinosinusitis and no nasalpolyposis.
11200696|NCT03379701||PCD|Patients with Primrary ciliary dyskinesia .
11200697|NCT03379701||AFRS|Patients with allergic fungal rhinosinusitis.
11200701|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
11200702|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
11200703|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
11200704|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
11200705|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
11200706|NCT03379649|Experimental|PRP|Receives intrauterine infusion of platelet rich plasma
11200707|NCT03379649|Placebo Comparator|Placebo|Receives intrauterine infusion of embryo culture media
11200708|NCT03379636|No Intervention|no tape|tests are realised without any shoulder tape
11200709|NCT03379636|Experimental|kinesiotape|tests are realised with a kinesiotape applied according to Dr Kase model, over the deltoid muscle and over the acromioclavicular joint
11200710|NCT03379636|Sham Comparator|sham tape|tests are realised with a sham tape, applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area
11200711|NCT03379623|Experimental|Intervention group|
11200712|NCT03379623|No Intervention|Usual care group|
11200713|NCT03379597|Experimental|Probiotics Group|"Probiotics add-on treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0*10^7 CFU.
~Bifico: 840mg Bid."
11200714|NCT03379597|No Intervention|Control Group|No probiotics or dietary fiber group.
11200715|NCT03379597|Experimental|Dietary fiber Group|Prebiotics add-on treatment: dietary fibers compound powder, 30g bid
11200716|NCT03379597|Experimental|Dietary fiber Probiotics group|Dietary fiber and probiotics group: receiving both Bifico 840mg Bid and dietary fiber 30g bid.
11200717|NCT03379584|Experimental|SGN-CD48A|SGN-CD48A
11200718|NCT03379558||Cohort 1 : alirocumab exposed|Pregnant women diagnosed with primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and exposed to alirocumab during the current pregnancy.
11200719|NCT03379558||Cohort 2 : disease matched comparison|Pregnant women diagnosed of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and unexposed to alirocumab during the current pregnancy.
11200720|NCT03379558||Cohort 3 : non disease comparison|Healthy pregnant women who do not have a known diagnosis of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and have no known exposure to a known human teratogen.
11200721|NCT03379545|Other|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
11200722|NCT03379532|Active Comparator|BCI-NMES|Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.
11200723|NCT03379532|Sham Comparator|Sham-NMES|Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.
11200724|NCT03379519|Experimental|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
11200725|NCT03379519|Active Comparator|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
11200726|NCT03379506|Experimental|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
11200727|NCT03379493|Experimental|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
11200728|NCT03379480|Active Comparator|Yoga arm|Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.
11200729|NCT03379480|No Intervention|Control arm|Healthy volunteers who will not receive yoga.
11200730|NCT03379467|Experimental|SMS Reminder|"Single SMS at each of the following times:
~3 days before immunization
~1 day before immunization
~Day of immunization"
11200731|NCT03379467|Experimental|Interactive Reminder|"Single SMS at each of the following times:
~3 days before immunization
~1 day before immunization
~Day of immunization On the day of immunization, study participants are required to respond back through SMS notifying us that child got vaccinated or if not, the reason for delay in immunization. In case of no response, 2 additional reminders will be sent at:
~1 day after scheduled immunization date
~1 week after scheduled immunization date"
11200732|NCT03379467|No Intervention|Control|Subjects in this arm will not receive any intervention
11200733|NCT03379441|Experimental|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:
~PD,
~unacceptable toxicity,
~investigator choice,
~patients IC withdrawal,
~up to a maximum of 24 months (35 administrations) Experimental"
11200734|NCT03379441|No Intervention|Observation|
11200735|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
11200736|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
11200737|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
11201427|NCT03374618|Experimental|systemic lupus erythematosus|adult with systemic lupus erythematosus
11200738|NCT03379428|Experimental|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
11200739|NCT03379415|Experimental|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
11200740|NCT03379415|Experimental|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
11200741|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
11200742|NCT03379389|Experimental|Methenamine + Methylthioninium|Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
11200743|NCT03379389|Active Comparator|Methenamine+Methylthioninium+Acriflavine+Atropa belladona|Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
11200744|NCT03379376|Experimental|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
11200745|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
11200746|NCT03379350|Experimental|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
11200747|NCT03379350|No Intervention|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
11200748|NCT03379337|Experimental|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
11200749|NCT03379324|Active Comparator|Superiority of augmented repairs|Assess pain, function, and structural integrity of the rotator cuff at 3 months, 6 months, 1 year, and 2 years post-operation
11200750|NCT03379324|Active Comparator|Fat degeneration of supraspinatus muscle|MRI assessment the quantity and disposition of fat within the supraspinatus muscle body compared to pre-operation MRI, at 1 year and 2 years post-operation
11200751|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
11200752|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
11200753|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
11200754|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
11200755|NCT03379233|Active Comparator|Usual Care|Concept2 inhaler
11200756|NCT03379233|Experimental|Telehealth|Concept2 inhaler with patient application
11200757|NCT03379220||Subdural ECoG (Group 1)|For patients who require craniotomy to treat TBI, a subdural electrode strip will be placed intraoperatively following evacuation of a hematoma or contusion, as required. Electrode strips will be used for subsequent electrocorticography (ECoG) during intensive care. Patients will also undergo continuous scalp EEG monitoring.
11200758|NCT03379220||Burr Hole ECoG (Group 2)|For patients who do not require surgery but do require invasive monitoring, an intraparenchymal ECoG electrode array will be placed through a cranial burr hole. Depending on other monitoring needs, the location of injuries, and other clinical considerations, the burr hole may be the same as used for placement of other probes or may be separate. In cases of focal injury, the burr hole will be placed to allow electrode targeting to a lobe with significant primary lesion(s). Patients will also undergo continuous scalp EEG monitoring.
11200759|NCT03379220||EEG (Groups 1-3)|Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
11200760|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.
~Interventions:
~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 3, 8, and 15 during ICU stay
~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
11200761|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.
~Interventions:
~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,
~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
11200762|NCT03379194|Experimental|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
11200763|NCT03379194|No Intervention|Control|No intervention
11200764|NCT03379181|Experimental|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
11200765|NCT03379168|Placebo Comparator|Placebo Injection|Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.
11200766|NCT03379168|Active Comparator|Corticosteroid Injection|Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.
11200767|NCT03379168|Experimental|Lipogems Injection|Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste.
11200768|NCT03379155|Experimental|Active Group|Internet-based self-help
11200769|NCT03379155|No Intervention|Waiting List Group|
11200770|NCT03379142|Other|Behavioral: Faith-Based messages|We will send faith-based messages one week prior to Ramadan and twice a day during Ramadan.
11200771|NCT03379103|Active Comparator|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
11200772|NCT03379103|Placebo Comparator|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
11200773|NCT03379077|Experimental|LTP Plus Supported Implementation|LTP Plus Supported Implementation group participants will receive intervention by trained LHWs of HANDS, co-facilitated and supervised by senior trained PILL researchers, expert in delivering LTP plus intervention
11200774|NCT03379077|Active Comparator|LTP Plus|Participants in LTP Plus arm will receive LTP plus intervention by trained LHWs of Health and Nutrition Development Society (HANDS).
11200775|NCT03379064|Experimental|culturally adapted Cognitive Behavior Therapy|We will use The STreSS CBT manual developed by Schroder and his colleagues
11200776|NCT03379064|No Intervention|Treatment As Usual|The Treatment As Usual (TAU) group will receive regular treatment they have been receiving already as prescribed by the physician.
11200777|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
11200778|NCT03379038|Experimental|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.
~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
11200779|NCT03379038|Placebo Comparator|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).
~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
11200780|NCT03379025|Experimental|Early Intervention Group|JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
11200781|NCT03379025|Other|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
11200782|NCT03379012|Experimental|Testosterone and Targeted therapy|Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)
11200783|NCT03379012|Active Comparator|Control|Targeted therapy (sunitinib or pazopanib) only
11200784|NCT03378999|Placebo Comparator|Control|Placebo capsules containing microcrystalline cellulose
11200785|NCT03378999|Experimental|Rhodospirillum rubrum 0.25 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day
11200786|NCT03378999|Experimental|Rhodospirillum rubrum 0.5 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day
11200787|NCT03378999|Experimental|Rhodospirillum rubrum 1.0 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day
11200788|NCT03378986||Unilateral THA|Patients who underwent to unilateral total hip arthroplasty
11200789|NCT03378986||Bilateral THA|Patients who underwent to simultaneous bilateral total hip arthroplasty
11200790|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
11200791|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
11200792|NCT03378960|Other|omeprazole|omeprazole 20 mg
11200793|NCT03378934|Experimental|Berberine Arm|In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
11200794|NCT03378934|Active Comparator|Control Arm|In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
11200795|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation is performed by experienced endoscopists through flexible sigmoideoscopy into the afferent limb. The second FMT is installed via catheter into the pouch 4 weeks after the first FMT.
11200796|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation is performed by experienced endoscopists through flexible sigmoideoscopy into the afferent limb. The second FMT is installed via catheter into the pouch 4 weeks after the first FMT.
11200797|NCT03378908|No Intervention|Conventional Treatment 6 meals|Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
11200971|NCT03377634|No Intervention|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
11200798|NCT03378908|Experimental|Intervention Treatment 3 meals|Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
11200799|NCT03378895|Experimental|adults aged 35 to 55 years|
11200800|NCT03378817|Active Comparator|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
11200801|NCT03378817|Experimental|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
11200802|NCT03378804|Experimental|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:
~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
11200803|NCT03378804|Active Comparator|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:
~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
11200804|NCT03378791|Experimental|Group A|Iron bisglycinate (27mg of elemental iron)
11200805|NCT03378791|Active Comparator|Group B|Ferrous fumarate (115mg of elemental iron)
11200806|NCT03378778||Less than 33% Tooth Structure remaining|Root canal treatment followed by CAD CAM restoration
11200807|NCT03378778||33%-50% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
11200808|NCT03378778||50% -66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
11200809|NCT03378778||More than 66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
11200810|NCT03378765||African origin adults|African origin adults from Ghana, Jamaica, Seychelles, South Africa and USA between the ages of 30- 50.
11200811|NCT03378752||Atelectasis formation using HFJV|Computed tomography scans are performed every 15 minute during the first 45 minutes during general anaesthesia using high frequency jet ventilation.
11200812|NCT03378726|Experimental|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
11200813|NCT03378726|Experimental|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
11200814|NCT03378726|Experimental|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
11200815|NCT03378713|Experimental|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
11200816|NCT03378713|Active Comparator|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
11200817|NCT03378713|Active Comparator|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
11200818|NCT03378700|Experimental|Brief Hope Intervention Group|In addition to the pre-dialysis educational programme on self-care and treatment options for ESRF patients as per the control group, brief hope intervention will be offered: a four-weeks individual intervention. Two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between. A booklet modified from the goal worksheet in Lopez et al. (2000) will be prepared for the participants for reviewing their planned goals, recording achieved targets and successful experiences.
11200819|NCT03378700|Active Comparator|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
11200820|NCT03378687||status epileptius|Cases were patients 29 days to 18 years who were diagnosed with status epileptius in 35 hospitals in China between January 1， 2013 and December 31，2015.
11200821|NCT03378674|Experimental|Group A|remifentanil infusion of 0,15 mcg/Kg/min
11200822|NCT03378674|Active Comparator|Group B|remifentanil infusion of 0,3 mcg/Kg/min
11200823|NCT03378661|Experimental|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
11200824|NCT03378661|Experimental|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
11200825|NCT03378661|Experimental|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
11201146|NCT03376594|Placebo Comparator|Loratadine|Loratadine 10 mg capsule by mouth 3 times a day for 42 days
11200826|NCT03378661|Experimental|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
11200827|NCT03378661|Experimental|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:
~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.
~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
11200828|NCT03378661|Experimental|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks
~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
11200829|NCT03378661|Placebo Comparator|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.
~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
11200830|NCT03378648|Experimental|CHF6366 active|
11200831|NCT03378648|Placebo Comparator|CHF6366|
11200832|NCT03378648|Active Comparator|Comparator|
11200833|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
11200834|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
11200835|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
11200836|NCT03378622|Experimental|Anchor|Anchor used for mesh attachment
11200837|NCT03378622|Active Comparator|Suture|Suture used for mesh attachment
11200838|NCT03378609|Other|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
11200839|NCT03378596|Experimental|L-citrulline & L-arginine|L-citrulline (6 grams) L-arginine (8 grams)
11200840|NCT03378596|Active Comparator|L-citrulline & Placebo|L-citrulline (6 grams) Placebo (6 grams)
11200841|NCT03378596|Active Comparator|L-arginine & Placebo|L-arginine (8 grams) Placebo (6 grams)
11200842|NCT03378596|Active Comparator|Placebo|Placebo (6 grams)
11200843|NCT03378583||control,|control normal ventilation
11200844|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
11200845|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
11200846|NCT03378570|Active Comparator|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
11200847|NCT03378570|Active Comparator|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
11200848|NCT03378544|Experimental|Experimental arm|Patients with suicidal ideation and depression will receive psychosocial interventions adapted from the WHO mental health Global Action Programme Intervention Guide (mhGAP-IG). The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity.
11200849|NCT03378544|No Intervention|Control group|Patients with suicidal ideation and depression will be trained on how to refer patients suffering from depression, using a referral note to the nearest health centre for further treatment
11200850|NCT03378531|Experimental|AEB1102|Each patient may receive AEB1102 administered IV for up to approximately 3 years.
11200851|NCT03378505|Experimental|Mobile App|Half of the students randomly assigned
11200852|NCT03378505|Experimental|Reflection|Half of the students randomly assigned
11200853|NCT03378492|Active Comparator|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
11200854|NCT03378492|Experimental|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
11200855|NCT03378479|Other|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
11200856|NCT03378479|Other|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
11200857|NCT03378466|Experimental|Unfractionated Heparin (UFH)|UFH initiated at 18 IU/kg/hr
11200858|NCT03378466|Other|Venous thromboprophylaxis (VTE)|as per local standard
11200859|NCT03378453|Other|NarCo|Narcolepsy type 1 over 65 years old
11200860|NCT03378453|Other|CoS|Cognitevement healthy controls
11200861|NCT03378427|Experimental|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (>= 6 weeks) tedizolid treatment given orally.
11200862|NCT03378414|Experimental|Intravenous infusion group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
11200863|NCT03378414|Experimental|Intrathecal injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
11200864|NCT03378414|No Intervention|Control groups|No intervention
11200865|NCT03378401|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
11200866|NCT03378401|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
11200867|NCT03378388||Vedolizumab|Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments without exclusion except participant refusal, and were potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.
11200868|NCT03378362|Experimental|Partial denervation of the wrist joint|Patients will be operated with a partial denervation of the wrist through a single dorsal approach.
11201147|NCT03376581|Experimental|Prospective treatment|
11245464|NCT03070899|Experimental|OBE2109 dose 1 + Placebo Add-back|
11200869|NCT03378349|Experimental|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
11200870|NCT03378349|Placebo Comparator|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
11200871|NCT03378336||Observational Group|This is an observational study with only one group/cohort with no intervention
11200872|NCT03378323|Active Comparator|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
11200873|NCT03378323|Experimental|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
11200874|NCT03378310|Experimental|Reference tablet followed by BMS-986205 tablet with free base|BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2).
11200875|NCT03378310|Experimental|BMS-986205 tablet with free base followed by reference tablet|BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2).
11200876|NCT03378297|No Intervention|Feasibility study cohort|
11200877|NCT03378297|Experimental|Metformin|850 mg
11200878|NCT03378297|Experimental|Acetylsalicylic acid|160 mg
11200879|NCT03378297|Experimental|Olaparib|300 mg x 2
11200880|NCT03378297|Experimental|Letrozol|2.5 mg
11200881|NCT03378284|Experimental|Tegoprazan(Test drug)|Tegoprazan drug QD for 7 days
11200882|NCT03378284|Active Comparator|Active comparator drug|Active comparator drug QD for 7 days
11200883|NCT03378271|Experimental|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.
~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
11200884|NCT03378245|Experimental|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
11200885|NCT03378232|Placebo Comparator|Placebo Olive Oil|Placebo supplement with olive oil
11200886|NCT03378232|Experimental|High EPA Supplement|Supplements providing up to 3g per day of Omega-3, with increased EPA
11200887|NCT03378232|Experimental|High DHA Supplement|Supplements providing up to 3g per day of Omega-3, with increased DHA
11200888|NCT03378219||Cohort 1|Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
11200889|NCT03378219||Cohort 2|Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
11200890|NCT03378219||Cohort 3|Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
11200891|NCT03378206|Experimental|Hinged 8-figure plate|Hinged 8-figure plate is a novel devise that has modifications in order to improve the treatment effect of conventional 8-figure plate. This arm will be used to verify the effectiveness and feasibility of the modification.
11200892|NCT03378206|Active Comparator|conventional 8-figure plate|Conventional 8-figure plate is widespread method to treat genu varum and valgus. This arm, as a comparator, will be the control group to verify the feasibility of the novel hinged 8-figure plate.
11200893|NCT03378167|Experimental|MICROBIOTA|Patients randomized to the INTERVENTION arm will receive a baseline fecal microbiota transplant (FMT) colonoscopic infusion at Week 0, followed by twice-weekly oral microbiota capsule (OMC) therapy for 6 weeks (including Week 0). (n = 30)
11200894|NCT03378167|Placebo Comparator|PLACEBO|Patients randomized to the CONTROL arm will receive a baseline normal saline (NS) colonoscopic infusion at Week 0, followed by twice-weekly dextrose-containing oral placebo capsule (OPC) therapy for 6 weeks (including Week 0). (n = 15)
11200895|NCT03378154|Experimental|Tracheal Intubation in infants using Macintosh laryngoscopes|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the Macintosh laryngoscope
11200896|NCT03378154|Experimental|Tracheal Intubation in infants using King vision|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the King vision videolaryngoscope
11200897|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
11200898|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive arm only receives standard MNCH services
11200899|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
11200900|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.
~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10^3- 2 x 10^5 per kg of recipient weight."
11200901|NCT03378089|Experimental|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
11200902|NCT03378089|Active Comparator|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
11200903|NCT03378076|Experimental|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
11200904|NCT03378076|Active Comparator|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
11200905|NCT03378063|Experimental|transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be given to the infants with BPD.
11200906|NCT03378063|Active Comparator|no transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be not given to the infants with BPD.
11200907|NCT03378050|Experimental|Intervention group|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages."
11200908|NCT03378050|Active Comparator|Control group|"Participants is the control group will be placed on a waiting list for 12 weeks. They will receive the intervention, after they complete the 12-week follow-up assessment. Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
11200909|NCT03378037|Experimental|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
11200910|NCT03378037|Sham Comparator|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
11200911|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).
~And follow up for 3 years to identify of the correlation with PAD outcome."
11200912|NCT03378011|Active Comparator|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
11200913|NCT03378011|Active Comparator|Topical PUVA|Topical PUVA in acral vitiligo
11200914|NCT03377998|Experimental|vitiligo patients|lesional skin biopsy to measure ERDR1 level
11200915|NCT03377998|Experimental|controls|normal skin biopsy to measure ERDR1 level
11200916|NCT03377985|Active Comparator|axillary brachial plexus block group|Patients placed in the supine position with arm to be blocked abducted and externally rotated. After sterilization of the axilla ultrasound device with high frequency of 8-12 MHZ, linear transducer was put parallel to the anterior axillary fold at axilla to identify the axillary artery, lateral, medial and posterior cords of the brachial plexus in relation to the axillary artery. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, 7-10 ml of bupivacaine 0.5% was injected around each cord of the brachial plexus
11200917|NCT03377985|Active Comparator|supraclavicular brachial plexus block group|patients placed in the supine position with the head of the bed elevated 30 degrees and patient's head turned away from the side to be blocked after skin disinfection, ultrasound device was put transversely parallel to and above the middle third of the clavicle, the probe was tilted till identification of the subclavian artery, 1st rib, pleura and brachial plexus lateral to the subclavian artery and above the 1st rib. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the lateral side of the probe. A needle was inserted in plane 1 cm lateral to the probe when adjacent to brachial plexus 25 ml of bubivacaine 0.5% was injected around the brachial plexus
11200918|NCT03377972||WHO diagnostic standard|
11200919|NCT03377972||Japan diagnostic standard|
11200920|NCT03377959|Experimental|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
11200921|NCT03377959|Other|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
11200922|NCT03377946|Experimental|probiotics on type 2 diabetes|take probiotics
11200923|NCT03377946|Experimental|probiotics on pre-diabetes|take probiotics
11200924|NCT03377946|Placebo Comparator|placebo on type 2 diabetes|take placebo
11200925|NCT03377946|Placebo Comparator|placebo on pre-diabetes|take placebo
11200926|NCT03377933|Experimental|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
11200927|NCT03377920|Experimental|Severe asthma patients; COPD patients|Cross sectional study Lung function measurement
11200928|NCT03377907|Active Comparator|Ketamine in hematoma block|Ketamine used in hematoma block
11200929|NCT03377907|Active Comparator|ketamine intravenous anesthesia|ketamine used in local intravenous anesthesia
11200930|NCT03377907|Active Comparator|lidocaine intravenous anesthesia|2.5 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
11200972|NCT03377621|Experimental|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
11200973|NCT03377608||Depo-Provera|
11200931|NCT03377894|Active Comparator|• Group (A) blunt incision|"100 primigravidas at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy.
~undergoing blunt uterine incision expansion"
11200932|NCT03377894|Active Comparator|• Group (B) sharp incision|100 primigravidas, at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy undergoing sharp uterine incision expansion
11200933|NCT03377881|Other|Traditional|The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed.
11200934|NCT03377881|Experimental|STHLM3+MRI/Fusion|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.
11200935|NCT03377868|Other|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
11200936|NCT03377868|Other|Control|Parallel cohort of healthy age and sex matched subjects
11200937|NCT03377855|Experimental|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
11200938|NCT03377842|Active Comparator|FOLFOX regimen|FOLFOX regime alone.
11200939|NCT03377842|Experimental|Apatinib and FOLFOX regimen|Apatinib combine with FOLFOX regimen.
11200940|NCT03377829|Experimental|Percutaneous laser ablation(PLA)|Eligible participants with PTMC will be randomly assigned to this group and undergo percutaneous laser ablation(PLA). All the process is under the detection of real-time ultrasound.After surgery, all the patients will accept contrast-enhanced ultrasound(CEUS), regular ultrasound follow-up, thyroid functional detection, fine-needle aspiration biopsy(FNAB), neck CT.Per and post-operative complications, need of drug treatment, length of hospital admission and customer satisfaction will be registered.
11200941|NCT03377829|Active Comparator|Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/subtotal thyroid surgery.
11200942|NCT03377816|Experimental|Art Therapy|The AT intervention is an 8-week group intervention comprised of 8 1.5 hour weekly sessions conducted by an experienced Art Therapist who received special training in conducting the treatment protocol as designed.
11200943|NCT03377816|Sham Comparator|Mandala group|The comparison group will color prefabricated shapes. The same art materials as in the intervention group will be on the table as will the same instrumental music.
11200944|NCT03377803|Active Comparator|VP-102|VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
11200945|NCT03377803|Placebo Comparator|Placebo|Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
11200946|NCT03377790|Active Comparator|VP-102|VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days
11200947|NCT03377790|Placebo Comparator|Placebo|Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days
11200948|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
11200949|NCT03377764||Landmark Technique|Control group
11200950|NCT03377764||Ultrasound guided technique|Neuroaxial block using Ultrasound guidance
11200951|NCT03377751|Experimental|Additional posterior wall isolation|Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
11200952|NCT03377751|Experimental|Voltage-guided substrate homogenization|Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
11200953|NCT03377751|Active Comparator|PVI only group|Operator will perform PVI only
11200954|NCT03377738|No Intervention|anti-smoking therapy|All patients will be given only an intervention for tobacco cessation which will depend on the individual's cessation phase
11200955|NCT03377738|Experimental|anti-smoking therapy + spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase. In addition, in this group will be given a spirometry test as a motivational element for dishabituation.
11200956|NCT03377725|Experimental|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
11200957|NCT03377725|Active Comparator|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
11200958|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
11200959|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
11200960|NCT03377699|Experimental|Insulin Degludec|Insulin Degludec once daily and Insulin Aspart 2-4 times daily
11200961|NCT03377699|Active Comparator|Insulin Determir|Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily
11200962|NCT03377686||Asthma|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with doctor's diagnosed asthma
11200963|NCT03377686||Cystic fibrosis|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with CF
11200964|NCT03377686||Healthy|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years old without respiratory diseases
11200965|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
11200966|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
11200967|NCT03377647|Active Comparator|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
11200968|NCT03377647|Active Comparator|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
11200969|NCT03377647|Active Comparator|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
11200970|NCT03377634|Experimental|Intervention|Participants receive the MORPH intervention.
11200975|NCT03377595|Experimental|TAP (Transversus Abdominis Plane) block|20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.
11200976|NCT03377595|Experimental|Wound infiltration|20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.
11200977|NCT03377582|Active Comparator|Conventional therapy|Exercise-based cardiac rehabilitation
11200978|NCT03377582|Experimental|Virtual reality based therapy|Exercise-based virtual reality
11200979|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
11200980|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
11200981|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
11200982|NCT03377556|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11200983|NCT03377543|Experimental|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
11200984|NCT03377543|Experimental|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
11200985|NCT03377543|Experimental|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
11200986|NCT03377530||Premature neonates infected with bacillus Species|The investigators studied retrospectively eleven cases of these infections in our NICU and reviewed series and report cases in literature.
11200987|NCT03377517|Experimental|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
11200988|NCT03377504|Experimental|mirror group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. Mirror therapy will be applied to the mirror group for 30 minutes per day in addition to this routine treatment.
11200989|NCT03377504|Active Comparator|control group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. A total of 20 sessions of treatment will be given to each patient.
11200990|NCT03377491|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with gemcitabine and nab-Paclitaxel
11200991|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
11200992|NCT03377478|Experimental|Lung Transplant|Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
11200993|NCT03377465|Experimental|Experimental Group|Patients with stroke of undetermined cause age 18-65
11200994|NCT03377465|Active Comparator|Comparative group|Healthy patients age 18-65
11200995|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
11200996|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
11200997|NCT03377439||Group A|Participants with platelet counts <32×10^9/L.
11200998|NCT03377439||Group B|Participants with platelet counts between 32×10^9/L and 132×10^9/L.
11200999|NCT03377439||Group C|Participants with platelet counts >132×10^9/L.
11201000|NCT03377426|Experimental|LYS228|IV infusion
11201001|NCT03377426|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
11201002|NCT03377400|Experimental|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
11201003|NCT03377387|Experimental|capecitabine 7/7 with neratinib|"In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).
~The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine."
11201004|NCT03377374|Experimental|Probiotic|L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10^8 Colony Forming Units (CFU)
11201005|NCT03377374|Placebo Comparator|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
11201006|NCT03377361|Experimental|Previously Treated Metastatic Colorectal Cancer Doublet|Treatment of mCRC participants
11201007|NCT03377361|Experimental|Previously Treated Metastatic Colorectal Cancer Triplet|Treatment of mCRC participants
11201008|NCT03377348|Other|subconjunctival injection of triamcinolone acetonide|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
11201009|NCT03377335|Experimental|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).
~The total duration of treatment is 6 months."
11201010|NCT03377335|Placebo Comparator|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).
~The total duration of treatment is 6 months."
11201011|NCT03377322|Active Comparator|Treatment|Probiotics capsules
11201012|NCT03377322|Placebo Comparator|Placebo|Placebo capsules containing maltodextrin
11201013|NCT03377309|Experimental|Fycompa|
11201148|NCT03376568||Narcolepsy with RBD & Control|Narcolepsy with REM sleep disorder lable(20) and Control subjects lable(20)
11201014|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
11201015|NCT03377283|Active Comparator|AP-KTx/LTx|Transplant recipients receiving an rATG-perfused kidney or liver
11201016|NCT03377283|Placebo Comparator|CP-KTx/LTx|Transplant recipients receiving a control-perfused kidney or liver.
11201017|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
11201018|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
11201019|NCT03377270|Other|Home Practice Arm|RST + Home Practice Arm
11201020|NCT03377257|Active Comparator|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
11201021|NCT03377257|Experimental|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
11201022|NCT03377244|Other|Healthy Bodies, Healthy Souls intervention|Participants in Diabetes Prevention Program Lifestyle Intervention (DPP-LI) with Healthy Bodies Healthy Souls (HBHS) intervention which includes the enhancement of working with Marshallese churches to implement organizational/institutional level changes to support the individual behavioral intervention of the DPP-LI.
11201023|NCT03377231|Experimental|Prevention|
11201024|NCT03377231|Experimental|Treatment|
11201025|NCT03377218|No Intervention|Control|Without additional iodine supplementation.
11201026|NCT03377218|Experimental|Iodine|Receiving iodine.
11201027|NCT03377218|Experimental|Iodine + Selenium|Receiving iodine and selenium.
11201028|NCT03377205|Active Comparator|Plate|Compression screws and neutralization plate.
11201029|NCT03377205|Experimental|Intramedullary nail|Acumed Fibular Rod System
11201030|NCT03377179|Experimental|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
11201031|NCT03377166|Active Comparator|Vertigo|Participants with vestibular disorder
11201032|NCT03377166|Active Comparator|Control|Participants without vestibular disorder
11201033|NCT03377153|Active Comparator|Hesperidin and Flaxseed|
11201034|NCT03377153|Placebo Comparator|control|
11201035|NCT03377140|Active Comparator|Hesperidin|2 capsuls of Hesperidin
11201036|NCT03377140|Placebo Comparator|control|2 capsuls of placebo
11201037|NCT03377127|Active Comparator|SOC|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
11201038|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
11201039|NCT03377114|Active Comparator|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
11201040|NCT03377114|Experimental|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
11201041|NCT03377101|Active Comparator|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
11201042|NCT03377101|Experimental|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
11201043|NCT03377088|Placebo Comparator|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
11201044|NCT03377088|Experimental|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
11201045|NCT03377075||Healthy subjects|
11201046|NCT03377062||EEG monitoring|Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness
11201047|NCT03377049||Acetazolamide Challenge|Subjects entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
11201048|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
11201049|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
11201072|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
11201050|NCT03377023|Experimental|Phase 1 - Dose Escalation|"Nivolumab + Ipilimumab + Nintedanib dose escalation.
~Nivolumab: 3 mg/kg IV Q2 weeks.
~Ipilimumab: 1 mg/kg Q6 weeks.
~Nintedanib Level -1: 100 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =100 mg).
~Nintedanib Level 0:150 mg by mouth (PO) once a day (QD) Days 1-14 (Daily dose =150 mg)
~Nintedanib Level 1: 100 mg PO twice daily (BID) Days 2-28 (Daily dose = 200 mg).
~Nintedanib Level 2: 150 mg PO BID Days 1-14 (Daily dose = 300 mg).
~Nintedanib Level 3: 200 mg PO BID Days 1-14 (Daily dose = 400 mg)."
11201051|NCT03377023|Active Comparator|Phase 2 - Arm A|"Arm A: Newly diagnosed or treatment-naïve patients, with a target overall response rate (ORR) of 50%.
~Nivolumab + Ipilimumab + Nintedanib at RP2D."
11201052|NCT03377023|Active Comparator|Phase 2 - Arm B|"Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.
~Nivolumab + Ipilimumab + Nintedanib at RP2D."
11201053|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
11201054|NCT03376997|Experimental|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
11201055|NCT03376997|Experimental|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
11201056|NCT03376997|Experimental|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
11201057|NCT03376984|Active Comparator|Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. For all the patients into the control arm of the study, the root canals will be filled with gutta percha (current standard of care), using the vertical condensation obturation technique (standard of care RCT technique).
11201058|NCT03376984|Experimental|ND and Amox modified Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, gutta percha modified with nanodiamonds and amoxicillin (NDGX) will be used for the middle and coronal thirds.
11201059|NCT03376971|Experimental|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
11201060|NCT03376958|Experimental|Apatinib|Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
11201061|NCT03376945||trail cohort|n-3 FAs
11201062|NCT03376945||control cohort|Structolipid
11201063|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
11201064|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
11201065|NCT03376932|Active Comparator|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
11201066|NCT03376932|Active Comparator|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
11201067|NCT03376919|Experimental|CLs++|CLs ++ gait training
11201068|NCT03376906|Experimental|Obese Subjetcs|The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions (HIIE 1, HIIE 3 and Control) in a random order, which were performed with a 96 h interval between them.
11201069|NCT03376893||SCA with overt stroke|Participants have sickle cell disease and a history of overt stroke.
11201070|NCT03376893||SCA with silent stroke|Participants have sickle cell disease and a history of silent stroke.
11201071|NCT03376893||SCA with no stroke|Participants have sickle cell disease and no history of stroke.
11201073|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
11201074|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
11201075|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
11201076|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
11201077|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
11201078|NCT03376867||Healthy volunteers|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
11201079|NCT03376867||Volunteers with chronic pain|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
11201080|NCT03376854|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
11201081|NCT03376854|Active Comparator|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
11201082|NCT03376841|Experimental|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
11201083|NCT03376841|Experimental|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
11201084|NCT03376828|Active Comparator|Hypertensive T group|Hypertensive T group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) Macintosh laryngoscopy using intubated
11201085|NCT03376828|Active Comparator|Hypertensive VL group|Hypertensive VL group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) C-Mac Videolaryngoscope using intubated
11201086|NCT03376828|Sham Comparator|Non-hypertensive T group|Non-hypertensive T group: (Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg) Macintosh laryngoscopy using intubated
11201087|NCT03376828|Sham Comparator|Non-hypertensive VL group|Non-hypertensive VL group: Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg C-Mac Videolaryngoscope using intubated
11201088|NCT03376815||prostate ,traditional sample method|Samples from 100 patients with prostate carcinoma were obtained by traditional sampling method
11201089|NCT03376815||prostate ,landscape sample method|Samples from 100 patients with prostate carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201090|NCT03376815||liver, traditional sample method|Samples from 100 patients with liver cancer were obtained by traditional sampling method.
11201091|NCT03376815||liver,landscape sample method|Samples from 100 patients with liver cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201092|NCT03376815||esophageal ,traditional sample method|Samples from 100 patients with esophageal carcinoma were obtained by traditional sampling method.
11201093|NCT03376815||esophageal ,landscape sample method|Samples from 100 patients with esophageal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201094|NCT03376815||GIST,traditional sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by traditional sampling method.
11201095|NCT03376815||GIST,landscape sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201096|NCT03376815||colorectal ,traditional sample method|Samples from 100 patients with colorectal carcinoma were obtained by traditional sampling method.
11201097|NCT03376815||colorectal ,landscape sample method|Samples from 100 patients with colorectal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201098|NCT03376815||pancreatic ,traditional sample method|Samples from 100 patients with pancreatic carcinoma were obtained by traditional sampling method.
11201099|NCT03376815||pancreatic,landscape sample method|Samples from 100 patients with pancreatic carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201100|NCT03376815||lung cancer,traditional sample method|Samples from 100 patients with lung cancer were obtained by traditional sampling method.
11201101|NCT03376815||lung cancer,landscape sample method|Samples from 100 patients with lung cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201102|NCT03376815||Renal ,traditional sample method|Samples from 100 patients with renal carcinoma were obtained by traditional sampling method.
11201103|NCT03376815||Renal carcinoma,landscape sample method|Samples from 100 patients with renal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201104|NCT03376815||Breast cancer,traditional sample method|Samples from 100 patients with breast cancer were obtained by traditional sampling method.
11201428|NCT03374618|Experimental|systemic sclerosis|adult with systemic sclerosis
11201105|NCT03376815||Breast cancer,landscape sample method|Samples from 100 patients with breast cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201106|NCT03376815||cervical ,traditional sample method|Samples from 100 patients with cervical carcinoma were obtained by traditional sampling method.
11201107|NCT03376815||cervical ,landscape sample method|Samples from 100 patients with cervical carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
11201108|NCT03376802|Experimental|SAR425899|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 19 days
11201109|NCT03376802|Placebo Comparator|Placebo|Repeated once daily SC doses of placebo administered over 19 days
11201110|NCT03376789|Active Comparator|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
11201111|NCT03376789|Active Comparator|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
11201112|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
11201113|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
11201114|NCT03376763|Experimental|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
11201115|NCT03376763|Experimental|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
11201116|NCT03376750|Experimental|CO - OP via telerehabilitation + standard care|10 CO-OP videoconferencing sessions from an occupational therapist . Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
11201117|NCT03376750|Experimental|CO - OP via face to face + standard care|10 CO - OP face to face sessions from an occupational therapist. Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
11201118|NCT03376750|No Intervention|control group - standard care|standard care as given from public health service
11201119|NCT03376737|Experimental|Apatinib + Pemetrexed|Apatinib + Pemetrexed
11201120|NCT03376724|Experimental|Functional exercise|
11201121|NCT03376724|Active Comparator|Control Group|
11201122|NCT03376711|No Intervention|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
11201123|NCT03376711|Experimental|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
11201124|NCT03376698|Active Comparator|Colchicine 0.5 mg|
11201125|NCT03376698|Active Comparator|Colchicine 0.25 mg|
11201126|NCT03376698|Placebo Comparator|Placebo|
11201127|NCT03376685|Experimental|Endurance Exercise Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
11201128|NCT03376685|Experimental|Sprint Exercise Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
11201129|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
11201130|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
11201131|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
11201132|NCT03376659|Experimental|Phase I - Safety|"MVA-BN-CV301 (prime) - Day 1 and Day 29.
~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.
~Durvalumab - q2 weeks
~Capecitabine - twice a day, Monday - Friday Weekly
~Bevacizumab - q2weeks (colorectal cancer patients only)"
11201133|NCT03376659|Experimental|Phase II - Colorectal Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.
~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.
~Durvalumab - q2 weeks
~Capecitabine - twice a day, Monday - Friday Weekly
~Bevacizumab - q2weeks"
11201134|NCT03376659|Experimental|Phase II - Pancreatic Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.
~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.
~Durvalumab - q2 weeks
~Capecitabine - twice a day, Monday - Friday Weekly"
11201135|NCT03376646|Experimental|Cohort A: Dissolve™|
11201136|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
11201137|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
11201138|NCT03376633|No Intervention|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
11201139|NCT03376633|Experimental|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
11201140|NCT03376620|Sham Comparator|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
11201141|NCT03376620|Active Comparator|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
11201142|NCT03376607|Experimental|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
11201143|NCT03376607|Experimental|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
11201144|NCT03376607|No Intervention|Control group|The control group will receive routine practice.
11201145|NCT03376594|Active Comparator|Benjakul Extract|Benjakul Extract 100 mg capsule by mouth 3 times a day for 42 days
11201149|NCT03376568||Narcolepsy with /without RBD|Narcolepsy with REM sleep disorder lable(20) and Narcolepsy without REM sleep disorderlable (20)
11201150|NCT03376555|Active Comparator|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
11201151|NCT03376555|Experimental|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
11201152|NCT03376555|Experimental|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
11201153|NCT03376555|Experimental|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
11201154|NCT03376555|Experimental|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day
~After 8 days on diet:
~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
11201155|NCT03376542|Experimental|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
11201156|NCT03376529|Experimental|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
11201157|NCT03376529|Experimental|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
11201158|NCT03376529|Experimental|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
11201159|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
11201160|NCT03376503|Experimental|Pegcyte (Nanogen pegfilgrastim)|pegcyte 6 mg in the first cycle
11201161|NCT03376503|Active Comparator|Neulastim (Roche pegfilgrastim)|Neulastim 6 mg in the first cycle
11201162|NCT03376477|Experimental|Lenalidomide plus GM-CSF Vaccine plus Prevnar13|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.
~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration."
11201163|NCT03376477|Placebo Comparator|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
11201164|NCT03376477|Placebo Comparator|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.
~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline."
11201165|NCT03376464|Experimental|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
11201166|NCT03376464|Experimental|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
11201167|NCT03376451|Other|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
11201168|NCT03376438||Prospective observational cohorts|1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
11201169|NCT03376412|Experimental|Single Arm Treatment.|All patients will be unilaterally implanted in the non-dominant eye with the Raindrop Near Vision Inlay for the compensation of presbyopia.
11201170|NCT03376386|Other|HNSCC receiving (chemo)radiotherapy|Imaging
11201171|NCT03376373|Experimental|active|Neurofeedback for FER
11201172|NCT03376373|No Intervention|control|waiting list
11201173|NCT03376347|No Intervention|Conventional arm|Institutional Standard of Care with intention to keep MAP> 65 mmHg. The FlotracIQ will be connected, but fully covered.
11201174|NCT03376347|Active Comparator|Treatment arm|FlotracIQ with HPI algorithm.
11201175|NCT03376334|Experimental|Motor Imagery (MI)|Those meeting the inclusion criteria were selected (n=22). Each participant was necessary to complete the Movement Imagery Questionnaire in a quiet room. Finally, each participant assigned a score by using a 7-point scale regarding the ease/difficulty associated with representing each movement mentally. Next their baseline balance measurement was performed using the SEBT. Later this group had 9 motor imagery sessions, each session for 15 minutes, 3 sessions (alternate days) per week for a total of 3 weeks. Reassessment of balance was done after every 3 sessions.
11201176|NCT03376334|No Intervention|Control (C)|Those meeting the inclusion criteria were selected (n=10). Baseline measurement of SEBT was done on day 1, end of week 1, end of week 2 and end of week 3.
11201211|NCT03376048|Experimental|Wound infiltration plus TAP|Wound infiltration placed by surgeon + TAP-LAP placed laparoscopically guided by surgeon
11201177|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
11201178|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
11201179|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.
~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
11201180|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter >2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.
~Pain score, withdrawal movement score and hemodynamic response was recorded."
11201181|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
11201182|NCT03376282|Other|HBOT treatment|HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
11201183|NCT03376282|No Intervention|Standard treatment|follow up with the standard recommended treatment
11201184|NCT03376269|Active Comparator|Combined HBOT/psychotherapy|combined concurrent intervention of HBOT and creative art psychotherapy.
11201185|NCT03376269|Other|psychotherapy|single intervention with creative art psychotherapy
11201186|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
11201187|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
11201188|NCT03376243|Experimental|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
11201189|NCT03376243|No Intervention|Control|Only structured parent education
11201190|NCT03376230||Control patients|
11201191|NCT03376230||Crohn's disease patients|
11201192|NCT03376230||Ulcerative colitis patients|
11201193|NCT03376217|No Intervention|Control|IPTp delivered at antenatal clinic
11201194|NCT03376217|Experimental|Intervention|IPTp delivered by HSAs
11201195|NCT03376204||Adult subjets|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
11201196|NCT03376178|Experimental|six-hole group|lidocaine and ropivacaine injection through catheters
11201197|NCT03376178|Active Comparator|end-hole group|lidocaine and ropivacaine injection through catheters
11201198|NCT03376152|Active Comparator|Treatment Arm|"Poverty households invited to attend cluster-level electric kettle promotion events and offered free kettles, information, and promotional materials 450 households in 15 clusters (30 households per cluster)"
11201199|NCT03376152|No Intervention|Control Arm|450 households in 15 clusters (30 households per cluster)
11201200|NCT03376139|Experimental|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
11201201|NCT03376139|Placebo Comparator|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
11201202|NCT03376126||MI-ILP|
11201203|NCT03376113|Experimental|VHS group|Patients will be asked to make links between critical situations and appropriate solutions in the volitional help sheet (VHS).
11201204|NCT03376113|No Intervention|Control group|Patients will be asked to read the VHS. This is an active control group. That means all patients in this study will be exposed to situations and solutions in the VHS.
11201205|NCT03376100|Active Comparator|Control Group|Patients with distal forearm fractures randomized to Hematoma Block.
11201206|NCT03376100|Active Comparator|Intervention Group|Patients with distal forearm fractures randomized to Ultrasound guided nerve block
11201207|NCT03376074|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
11201208|NCT03376074|Active Comparator|Conventional cold storage|
11201209|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
11201210|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
11201429|NCT03374618|Other|healthy volunteers|healthy volunteer (adult)
11201213|NCT03376035|Active Comparator|Unilateral breast reconstruction|Temperature measurements are obtained from the reconstructed breast and compared to the non-reconstructed breast.
11201214|NCT03376035|Experimental|Bilateral breast reconstruction|Temperature measurements are obtained from both reconstructed breasts and the core temperature is measured as well for comparison.
11201215|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.
~Interventions:
~Blood sample for serum and plasma biomarkers:
~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
11201216|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
11201217|NCT03375983|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
11201218|NCT03375970|Experimental|Collaborative Care of TCM and Western Medicine|
11201219|NCT03375970|Active Comparator|Western Medicine|
11201220|NCT03375957|Experimental|ATx201 2% Gel|
11201221|NCT03375957|Experimental|ATx201 4% Gel|
11201222|NCT03375957|Placebo Comparator|ATx201 Gel Placebo|
11201223|NCT03375944|No Intervention|control group|Cardiac supervision
11201224|NCT03375944|Other|study group|Cardiac supervision and rehabilitation
11201225|NCT03375931|Experimental|prayer group|
11201226|NCT03375931|Active Comparator|non-prayer group|
11201227|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
11201228|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
11201229|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
11201230|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
11201231|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
11201232|NCT03375905|Experimental|cNEP|cNEP treatment
11201233|NCT03375892|Experimental|Prone Position and Supine Position|
11201234|NCT03375879|Active Comparator|Bandage contact lens|Placing a bandage contact lens in one eye.
11201235|NCT03375879|No Intervention|Sham contact lens (immediate removal)|Sham contact lens will be placed on other eye, placing it and immediately removing it so patient does not know which eye will have a bandage contact lens.
11201236|NCT03375866|Active Comparator|Pretzels|
11201237|NCT03375866|Experimental|Mixed nuts|
11201238|NCT03375853|Active Comparator|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
11201239|NCT03375853|Experimental|Experimental Condition|Participants will complete computer based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention.
11201240|NCT03375840|Experimental|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
11201241|NCT03375840|Experimental|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
11201242|NCT03375840|Experimental|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
11201243|NCT03375840|Experimental|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
11201244|NCT03375840|Experimental|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
11201245|NCT03375840|Experimental|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion
~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
11201281|NCT03375580|Active Comparator|TLC + simvastatin group|transform life custom (TLC) combined with 20mg simvastatin, PO qn
11201246|NCT03375827|Experimental|Survey QOL|"Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.
~Participants will be asked to complete the IGCDG questionnaire prior to their next visit.
~Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
11201247|NCT03375814|Experimental|Experimental group|The group that takes the main drug. They received the conventional treatment group and crocin.
11201248|NCT03375814|Placebo Comparator|Placebo group|The group that takes the Placebo.
11201249|NCT03375801|No Intervention|control group/pre intervention|the first 164 patients will receive care as usual and will make the decision together with their clinician without support of the decision aid. They will be asked to fill out the questionnaires.
11201250|NCT03375801|Experimental|intervention arm|another 164 patients will receive the decision aid as support for the decision making process with their clinician.
11201251|NCT03375788|Experimental|Tesamorelin|tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
11201252|NCT03375788|Placebo Comparator|Placebo|identical placebo given subcutaneously daily
11201253|NCT03375775|Experimental|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
11201254|NCT03375775|Active Comparator|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
11201255|NCT03375762|Experimental|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
11201256|NCT03375762|Sham Comparator|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
11201257|NCT03375749|Experimental|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
11201258|NCT03375749|Other|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
11201259|NCT03375736|Experimental|Intervention arm|Whole body vibration will be provided by an equipment, GalileoTM Med L Plus (Novotech Medical GmbH). The study participant will stand still on the vibration platform with both knees slightly flexed.
11201260|NCT03375723|Experimental|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique
~Information about anatomy
~Information about physiology
~Breathing technique"
11201261|NCT03375723|Active Comparator|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
11201262|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
11201263|NCT03375697|Experimental|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
11201264|NCT03375697|Experimental|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
11201265|NCT03375684|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
11201266|NCT03375684|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
11201267|NCT03375671|Experimental|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
11201268|NCT03375671|Active Comparator|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
11201269|NCT03375658|Experimental|Intervention arm|All vital signs registered as part of usual care are used for modelling patients state and trajectories and made available to clinicans via the Patient Deterioration Warning System in nursing and physician offices.
11201270|NCT03375658|No Intervention|Control arm|Usual care
11201271|NCT03375632|Experimental|Uric acid-overproduction Type|
11201272|NCT03375632|Experimental|Uric acid-underexcretion Type|
11201273|NCT03375619||Participants who received CAR-20/19-T cells.|Participants who received CAR-20/19-T cells in study NCT03019055.
11201274|NCT03375606|Experimental|CSL730|
11201275|NCT03375606|Placebo Comparator|Placebo|
11201276|NCT03375593|Experimental|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
11201277|NCT03375593|Experimental|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
11201278|NCT03375580|Placebo Comparator|TLC group|transform life custom (TLC) group
11201279|NCT03375580|Active Comparator|TLC + metformin group|transform life custom (TLC) combined with 0.5g metformin, PO tid
11201280|NCT03375580|Experimental|TLC + CZT capsules group|transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid
11201430|NCT03374605|Experimental|Active tDCS|
11201282|NCT03375567|Experimental|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
11201283|NCT03375567|Active Comparator|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
11201284|NCT03375541|No Intervention|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
11201285|NCT03375541|Experimental|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
11201286|NCT03375528|Experimental|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
11201287|NCT03375515|Experimental|PCA IV Hydromorphone titration|PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient hiself/herself) in 24hrs.
11201288|NCT03375515|Active Comparator|non-PCA IV Hydromorphone titration|Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titrationn. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. Increasal dose of hydromorphone by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
11201289|NCT03375502|Experimental|MG1111(Varicella vaccine)|A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1
11201290|NCT03375502|Active Comparator|Comparator(Varicella vaccine)|A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1
11201291|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment
~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks
~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
11201292|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic
~PC visits will be scheduled on the same day as an oncology visit if possible"
11201293|NCT03375476||Vascular surgical patients|Patients undergoing elective vascular non-cardiac surgery in general anesthesia
11201294|NCT03375463|Experimental|Tirzepatide Test Part A|SC dose of tirzepatide solution formulation
11201295|NCT03375463|Experimental|Tirzepatide Reference Part A|SC dose of tirzepatide lyophilized formulation
11201296|NCT03375463|Experimental|Tirzepatide Formulation Part B|IV dose of tirzepatide formulation
11201297|NCT03375463|Experimental|Tirzepatide Part C|Titrated SC doses of tirzepatide solution formulation
11201298|NCT03375463|Placebo Comparator|Placebo Part C|SC dose of placebo matching tirzepatide dose
11201299|NCT03375450||Observation|Cohort of patients with COPD
11201300|NCT03375437|Experimental|NTRK, ROS and ALK molecular screening|
11201301|NCT03375424||1st subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced Vedolizumab (VDZ) therapy (n=1.800). A former therapy with other biologics is allowed. More than 30% of these Vedolizumab patients will be biologics-naiv.
11201302|NCT03375424||2nd subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti-TNF-alpha therapy other than VDZ (n=350) in biologics-naiv patients.
11201303|NCT03375424||3rd subpopulation|IBD patients (age at enrollment: 18-80 years) with an early disease (n=350), who were first diagnosed <2 years before the start of documentation in the Investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future.
11201304|NCT03375411|Experimental|INC1-Bare metal stent|Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
11201305|NCT03375398|Experimental|3 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™
11201306|NCT03375398|Placebo Comparator|Rice only|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice
11201307|NCT03375398|Experimental|6 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™
11201308|NCT03375385|Other|Hemodynamic parameters|
11201309|NCT03375385|Other|Ramsay sedation score|
11201310|NCT03375385|Other|Intraoperative side effects|
11201311|NCT03375385|Other|recovery of sedation|
11201312|NCT03375372|Active Comparator|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
11201313|NCT03375372|No Intervention|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
11201314|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
11201315|NCT03375346|Experimental|Whole body vibration group|Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
11201316|NCT03375346|Active Comparator|Exercise only group|The control group performed the same session without vibration.
11201317|NCT03375333||20GPs|20 general practitioners, who use ultrasound in the examination of patients.
11201426|NCT03374631|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing
11201318|NCT03375320|Experimental|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11201319|NCT03375320|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11201320|NCT03375307|Experimental|Cohort I (olaparib)|Patients that have cancer-associated DNA-repair gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11201321|NCT03375307|Experimental|Cohort II (biospecimen collection)|Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline.
11201322|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
11201323|NCT03375281|Experimental|No touch group|RFA for small HCC would be done by using no touch technique
11201324|NCT03375255|Experimental|SRP-5051|"Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051 on Day 1.
~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
11201325|NCT03375242||crizotinib|
11201326|NCT03375229|Active Comparator|Group On|This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
11201327|NCT03375229|Active Comparator|Group Off|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
11201328|NCT03375229|Placebo Comparator|Placebo group|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
11201329|NCT03375216|Active Comparator|taper|participants undergoing a taper as directed by their pain physician. Interventions include sensory testing ( heat, cold, and pressure) and PROMIS surveys.
11201330|NCT03375216|Placebo Comparator|non taper systemic <90|participants on systemic opioids < 90 MEDD (morphine equivalent daily dose) and no taper
11201331|NCT03375216|Placebo Comparator|non taper systemic >90|participants on systemic opioids > 90 MEDD and no taper
11201332|NCT03375216|Placebo Comparator|non taper intrathecal|Participants on intrathecal therapy and no taper
11201333|NCT03375216|Sham Comparator|non opioids|Participants on non-opioid therapy will undergo behavioral tests and PROMIS surveys
11201334|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
11201335|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
11201336|NCT03375203|Experimental|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
11201337|NCT03375203|Experimental|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
11201338|NCT03375203|Experimental|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
11201339|NCT03375190|Experimental|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
11201340|NCT03375190|Experimental|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM, Devon, UK) at insertion site
11201341|NCT03375190|Experimental|Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
11201342|NCT03375190|Experimental|Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
11201343|NCT03375190|Experimental|Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
11201344|NCT03375190|Experimental|Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
11201345|NCT03375164|Experimental|Cohort A|Patients between 3 months to 3 years of age, will receive intravenous SRP-9001.
11201346|NCT03375164|Experimental|Cohort B|Patients between 4 to 7 years of age, will receive intravenous SRP-9001.
11201347|NCT03375151|Experimental|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
11201348|NCT03375151|Other|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
11201349|NCT03375151|Other|No feedback|The participants will perform the exercise without feedback during practice.
11201350|NCT03375138|Experimental|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
11201351|NCT03375138|Experimental|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
11201352|NCT03375125|Experimental|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
11201353|NCT03375125|Placebo Comparator|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
11201354|NCT03375112|Experimental|Fascia Iliaca Compartment Block|A Fascia Iliaca Compartment Block will be administered in the block room.
11201355|NCT03375112|Placebo Comparator|Control|The patients will be brought back to the block room, prepped, and a blunt needle will be touched to the skin. A band aid will be applied over the site.
11201356|NCT03375099|Experimental|Lethal Means Counseling|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners.
11201357|NCT03375099|Active Comparator|Lethal Means Counseling plus Gun Locks|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners. Individuals in this condition will also receive a free gun (cable) lock for each of their personal firearms.
11201358|NCT03375099|Active Comparator|Health and Stress Reduction|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework.
11201359|NCT03375099|Active Comparator|Health + Stress Reduction plus Gun Locks|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
11201360|NCT03375086|Experimental|Single arm|Patients will receive APX3330 orally, twice per day until disease progression
11201361|NCT03375073|Experimental|Positive communication|Positive communication during medical transmission
11201362|NCT03375073|No Intervention|Non-optimized communication|Medical transmission with non-optimized communication.
11201363|NCT03375047|Experimental|Low Dose|8 mg MRT5005
11201364|NCT03375047|Experimental|Low/Mid Dose|12 mg MRT5005
11201365|NCT03375047|Experimental|Mid Dose|16 mg MRT5005
11201366|NCT03375047|Experimental|Mid/High Dose|20 mg MRT5005
11201367|NCT03375047|Experimental|High Dose|24 mg MRT5005
11201368|NCT03375047|Placebo Comparator|Placebo Comparator|Normal Saline 0.9% USP
11201369|NCT03375047|Experimental|Daily Dose|20 mg MRT5005 delivered in 5 consecutive daily doses of 4mg
11201370|NCT03375034|Experimental|NDMC 20mg|oral single dose
11201371|NCT03375034|Experimental|NDMC 60mg|oral single dose
11201372|NCT03375034|Active Comparator|Clonazepam 1.5mg|oral single dose
11201373|NCT03375034|Placebo Comparator|Placebo|oral single dose
11201374|NCT03375021|Experimental|Sequence 1 PL|Eligible subjects were randomized to Sequence 1 PL in which they received placebo (P) followed by crossover to CX717 200 mg low dose (L) of active treatment
11201375|NCT03375021|Experimental|Sequence 2 PH|Eligible subjects were randomized to Sequence 2 PH in which they received placebo (P) followed by crossover to CX717 800 mg High dose (H) of active treatment
11201376|NCT03375021|Experimental|Sequence 3 LP|Eligible subjects were randomized to Sequence 3 LP in which they received CX717 200 mg Low dose (L) of active treatment followed by crossover to placebo (P)
11201377|NCT03375021|Experimental|Sequence 4 HP|Eligible subjects were randomized to Sequence 2 PH in which they received CX717 800 mg High dose (H) of active treatment followed by crossover to placebo (P)
11201378|NCT03375008|Experimental|Imaging diagnostic and biopsy|47 subjects who are suspected NASH from June 2016 to December 2017.
11201379|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
11201380|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
11201381|NCT03374982|Experimental|DentalVibe On|DentalVibe will be turned on during local anesthetic injection at one appointment.
11201382|NCT03374982|No Intervention|DentalVibe Off|DentalVibe will be be turned off during local anesthetic injection at one appointment.
11201383|NCT03374969|Experimental|Attachment and Biobehavioral Catch-Up|
11201384|NCT03374969|Active Comparator|Developmental Education for Families|
11201385|NCT03374956|Experimental|Intervention group|Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
11201386|NCT03374956|Active Comparator|Control Group|Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
11201387|NCT03374943|Experimental|KB004 dose escalation|Patients will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned in this study (3.5mg/kg, 5.25 mg/kg, 7.9 mg/kg) Additional dose levels may be explored based on the emerging data in the study.
11201388|NCT03374930|Other|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
11201389|NCT03374917|Experimental|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
11201390|NCT03374904|Active Comparator|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
11201391|NCT03374904|Experimental|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
11201392|NCT03374891|No Intervention|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
11201393|NCT03374891|Active Comparator|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
11201394|NCT03374878|Experimental|oral contraceptive and training|Users of oral contraceptive training for 10 weeks
11201395|NCT03374878|Placebo Comparator|no oral contraceptive and training|Non-users of oral contraceptive training for 10 weeks
11201396|NCT03374865||Video-mediated consultation|Consultations using Facetalk videocommunication software
11201397|NCT03374865||Face-to-face consultation|Traditional face-to-face consultations
11201398|NCT03374852|Experimental|CPI-613 + mFOLFIRNOX|"CPI-613: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port mFOLFIRNOX (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port
~Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).
~Irniotecan at 140 mg/m2 given as a 90-min IV infusion via a central venous port via a Yconnector.
~Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan"
11201399|NCT03374839|Experimental|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.
~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
11201400|NCT03374826|Experimental|Dedicated axillary hybrid PET-MRI axilla|
11201401|NCT03374813|Experimental|MimetikOss|Ridge preservation bone grafting after tooth extraction
11201402|NCT03374813|Active Comparator|Bio-Oss|Ridge preservation bone grafting after tooth extraction
11201403|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
11201404|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
11201405|NCT03374787|Experimental|Fusion sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
11201406|NCT03374774||Participants with Type 2 Diabetes Mellitus|Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.
11201407|NCT03374761|Experimental|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
11201408|NCT03374761|No Intervention|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
11201409|NCT03374735|Experimental|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
11201410|NCT03374722||Mechanically ventilated critically ill patients|Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours
11201411|NCT03374709|Experimental|Treatment Group|This arm includes subjects who have been prescribed Oxtellar XR 150Mg Extended Release Tablets.
11201412|NCT03374696|Experimental|Intervention group|The intervention SAFETY was performed in school facilities by professional actors and staff from the municipality's youth guidance center within the county. The actors first enacted a play portraying youths and problems with condom use. Next, a value exercise was held by the youth guidance center staff. The class continued with chlamydia games held by the youth guidance center staff, providing information on symptoms, protection, how to get tested, treatment and consequences. The youth guidance center staff and the actors, playing students, then held a condom school. Lastly, the students came up with new endings to the play. All replays were enacted and the students gave feedback on the new endings. The class ended with condoms being handed out.
11201413|NCT03374696|Active Comparator|Control group|The intervention in the control group contained standard education from school staff, based on the sex education guidelines of the Swedish National Agency for Education. Students got education on human sexuality, reproduction, menstruation, love, sex, pregnancy and how STIs and unwanted pregnancy are prevented.
11201414|NCT03374683|Experimental|Risk Reframing (RR) Digital Tool|
11201415|NCT03374683|Active Comparator|RR In-Person Workshop|
11201416|NCT03374683|Sham Comparator|Position Statement Active Outdoor Play|
11201417|NCT03374670|Experimental|Cohort 1|Zimura dosage 1 + Eylea 2 mg
11201418|NCT03374670|Experimental|Cohort 2|Zimura dosage 2 + Eylea 2 mg
11201419|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
11201420|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
11201421|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
11201422|NCT03374657|Experimental|CPK Dose 4 (next to highest dose)|CPK850, one subretinal injection to the study eye
11201423|NCT03374657|Experimental|CPK Dose 5 (highest dose)|CPK850, one subretinal injection to the study eye
11201424|NCT03374644|Experimental|ETCO2 monitoring with nasal cannula|SentriTM ETCO2 adult nasal cannula (Intersurgical ® code 1144002) will be placed into patient's nostril following radial artery catheter insertion. A baseline (without oxygen flow) ETCO2, PaO2, SPO2, RR and PaCO2 will be recorded. Oxygen will then be administered at 2,4, and 6 liters per minute for a period of five minutes.ETCO2, PaCO2 and PaO2 will be recorded for each level of oxygen administration.Sedation will be given during intra-operative period with the target of Observer Assessment of alertness/sedation scale (OAA/S) score of 3. During intraoperative period, oxygen will be administered at 2 and 4 liters per minute for a period of five minutes. ETCO2, PaCO2 and PaO2 level will be recorded during each level of oxygen administration.
11201425|NCT03374631|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing
11201432|NCT03374592|Active Comparator|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
11201433|NCT03374592|Experimental|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
11201434|NCT03374579|Experimental|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
11201435|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
11201436|NCT03374553|Experimental|MINIject 636 implant|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.
~The intervention is to be performed as stand-alone surgery."
11201437|NCT03374540||Rivaroxaban|Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
11201438|NCT03374540||Vitamin K antagonist (VKA)|Patients who initiated OAC treatment with VKA
11201439|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
11201440|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
11201441|NCT03374527||Control group|Healthy subjects
11201442|NCT03374514|Experimental|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
11201443|NCT03374514|Placebo Comparator|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
11201444|NCT03374501|Experimental|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
11201445|NCT03374501|Experimental|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
11201446|NCT03374501|Placebo Comparator|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
11201447|NCT03374488|Experimental|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
11201448|NCT03374488|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
11201449|NCT03374475|Placebo Comparator|Lead-in period: Placebo|Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
11201450|NCT03374475|Experimental|Treatment period: JNJ-42847922 or Placebo|Placebo lead-in period responders and non-responders will be randomized to receive either placebo or 20 milligram (mg) JNJ-42847922 or 40 mg JNJ-42847922 for 5 Weeks. Participants will swallow JNJ-42847922 20 mg (2*10-mg capsules) or JNJ-42847922 40 mg (2*20-mg capsules) or 2 matching placebo capsules once daily for 5 Weeks.
11201451|NCT03374475|Placebo Comparator|Withdrawal period: Placebo|Participants who will complete the treatment period prior to the end of Week 8 will enter the withdrawal period where they will be treated with placebo (2 capsules taken orally) for the remaining time of the double-blind phase of the study. Investigators and participants will be blinded to exact duration of each participant-specific withdrawal period.
11201452|NCT03374462|Experimental|Telemedicine Intervention|All participants will receive the study intervention, which consists of home-based telemedicine visits with a diabetes specialist, at a frequency determined by the patient's degree of glycemic control (every 4, 6, or 8 weeks).
11201453|NCT03374449|Experimental|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
11201454|NCT03374449|Active Comparator|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
11201455|NCT03374436|Experimental|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
11201456|NCT03374436|Experimental|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each)."
11201457|NCT03374436|Active Comparator|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
11201458|NCT03374423|Active Comparator|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
11201459|NCT03374423|Active Comparator|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
11201460|NCT03374397|Active Comparator|SurgiGuard|Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
11201461|NCT03374397|No Intervention|Bipolar electrocauterization|Bipolar electrocauterization during surgery Drug(-)
11201462|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
11201463|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
11201464|NCT03374358|No Intervention|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
11201465|NCT03374358|Experimental|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
11201466|NCT03374345|Experimental|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
11201467|NCT03374345|Placebo Comparator|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
11245465|NCT03070899|Experimental|OBE2109 dose 1 + Add-back|
11201468|NCT03374332|Experimental|Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)
~Patients < 70 years old: GO 9mg/m2 (3mg/m2 each dose)
~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^7 CD3+ cells and maximum of 2x10^7 CD3+ cells/kg irrespective of the number of CD34+ cells.
~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
11201469|NCT03374332|Experimental|Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)
~Patients: < 70 years old: GO 9mg/m2 (3mg/m2 each dose)
~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^8 CD3+ cells and maximum of 2x10^8 CD3+ cells/kg irrespective of the number of CD34+ cells.
~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
11201470|NCT03374319|Experimental|Intervention group|Modified amputation procedure
11201471|NCT03374319|Active Comparator|Control group|Standard amputation procedure
11201472|NCT03374306|Experimental|Atropine 0.01%|Group receiving atropine treatment for 18 months
11201473|NCT03374306|Placebo Comparator|Artifical tear|Group receiving placebo for 18 months
11201474|NCT03374293|Experimental|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
11201475|NCT03374280|Experimental|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.
~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
11201476|NCT03374280|Active Comparator|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
11201477|NCT03374254|Experimental|Pembrolizumab + Binimetinib (Cohort A)|During Part 1, participants in Cohort A will receive a standard dose (DL1) of pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at a starting dose of 30 mg twice a day (BID). Based on dose-limiting toxicities (DLT) assessed during the initial 21 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (Dose Level 2 [DL2]). Once a preliminary RP2D for binimetinib is identified in Part 1 for Cohort A, participants will receive pembrolizumab 200 mg IV Q3W plus binimetinib orally at the preliminary RP2D during Part 2.
11201478|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 (Cohort B)|During Part 1, participants in Cohort B will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2 over 46-48 hours) IV every 2 weeks (Q2W). Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of mFOLFOX7 may be de-escalated to oxaliplatin 70 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours] IV Q2W. Once a preliminary RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D during Part 2.
11201479|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 + Binimetinib (Cohort C)|After an RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants may enroll in Cohort C and receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the RP2D determined for Cohort B Q2W plus binimetinib orally at the RP2D determined for Cohort C in Part 1.
11201480|NCT03374254|Experimental|Pembrolizumab + FOLFIRI (Cohort D)|During Part 1, participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) IV Q2W. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of FOLFIRI may be de-escalated to irinotecan 150 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours) IV Q2W. Once a preliminary RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D during Part 2.
11201481|NCT03374254|Experimental|Pembrolizumab + FOLFIRI + Binimetinib (Cohort E)|After an RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants may enroll in Cohort E and receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the RP2D determined for Cohort D Q2W plus binimetinib orally at the RP2D determined for Cohort E in Part 1.
11201482|NCT03374241|Experimental|Cohort 1|HM15211 or Placebo (single dose, subcutaneous injection)
11201483|NCT03374241|Experimental|Cohort 2|HM15211 or Placebo (single dose, subcutaneous injection)
11201484|NCT03374241|Experimental|Cohort 3|HM15211 or Placebo (single dose, subcutaneous injection)
11201485|NCT03374241|Experimental|Cohort 4|HM15211 or Placebo (single dose, subcutaneous injection)
11201486|NCT03374241|Experimental|Cohort 5|HM15211 or Placebo (single dose, subcutaneous injection)
11201487|NCT03374228|Experimental|BMS-986205|Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of [13C]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration
11201488|NCT03374215||Adult AA with primary aldosteronism|Adult invdiviuals (age 18 or older) with HTN and discrete adrenal masses or bilateral hyperplasia of the adrenal glands, with outpatient positive ARR or string clinical suspicion for PA
11201489|NCT03374215||Family members age >= 7 of participants|DNA from relatives of patients (age 7 or older)
11201490|NCT03374202|Experimental|Group 1|5x10(10)vg/kg dose of AAV8-VRC07
11201491|NCT03374202|Experimental|Group 2|5x10(11)vg/kg dose of AAV8-VRC07
11201492|NCT03374202|Experimental|Group3|2.5x10(12) vg/kg dose of AAV8-VRC07
11201493|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
11201494|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
11201495|NCT03374176|Active Comparator|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.
~1 capsule tid during 7 days."
11201496|NCT03374176|Experimental|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.
~1 capsule tid during 7 days."
11201497|NCT03374163|Experimental|treatment group who recived intralipid|71 patients who recived intralipid on day of embryo transfer day, pregnancy day.
11201498|NCT03374163|No Intervention|control group|71 patient not recived intralipid
11201499|NCT03374150|Experimental|high protein|High protein (HP) group were given counseling about weight loss program by applying low calorie-high protein diet with diet menu composition of 22-30% protein, along with instructions for allowed cooking method.
11201500|NCT03374150|Active Comparator|standard protein|Active comparator receiving standard protein (SP) proportion were counseled about weight loss program by means of low calorie-balanced composition diet with menu comprised of 12-20% protein.
11201501|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
11201502|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
11201503|NCT03374111|Experimental|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
11201504|NCT03374111|Placebo Comparator|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
11201505|NCT03374098|Experimental|Education|Attend an hour-long classes once per week for three weeks
11201506|NCT03374098|Experimental|Home Visitation|Receive home visits that focus on the social determinants of health and attend hour-long classes once per week for three weeks
11201507|NCT03374085|Experimental|Administration of CC-92480 and Dexamethasone|Escalating doses of CC-92480 in combination with a fixed dose of dexamethasone administered according to two different dosing schedules
11201508|NCT03374072|Experimental|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in videoteleconference sessions with an Arc community provider. The content and format of the program is still being finalized. In the initial conception of the program, we proposed 6 sessions: Session 1 will focus on assessment and motivation (Sibling and adult with ASD). In Session 2, the sibling will learn family communication strategies. Session 3 will provide the sibling with information about adult services and how to navigate the service system. Session 5 will be a joint session with the family members with ASD. In the final session, the sibling will develop a plan of action outlining their involvement in family future planning.
11201509|NCT03374072|Active Comparator|Information Only Condition|We will create an information packet for siblings in the control condition. Siblings in the control condition will receive the same tip sheets and packet of information about resources for adults with ASD as those distributed in Session 3 of the Siblings FORWARD program.
11201510|NCT03374059|Experimental|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
11201511|NCT03374059|Experimental|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
11201512|NCT03374059|No Intervention|Control Group|Control group did not receive any treatments
11201513|NCT03374046|No Intervention|Control Group|Standard care
11201514|NCT03374046|Experimental|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula
~If 0-2 years: 3L/min NC of 100% FiO2
~If > or = to 2 through17 years: 5L/min NC of 100% FiO2"
11201515|NCT03374033|No Intervention|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
11201516|NCT03374033|Experimental|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
11201517|NCT03374033|Experimental|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
11201518|NCT03374033|Experimental|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
11201519|NCT03374020||Intermediate AMD|
11201520|NCT03374020||Advanced AMD|
11201521|NCT03374020||DR without macular edema|
11201522|NCT03374020||DR with macular edema|
11201523|NCT03374007|Experimental|GB226 1mg/kg single-dose|Geptanolimab, 1mg/kg, i.v., single-dose
11201524|NCT03374007|Experimental|GB226 3 mg/kg single-dose|Geptanolimab, 3mg/kg, i.v., single-dose
11201525|NCT03374007|Experimental|GB226 10mg/kg single-dose|Geptanolimab 10mg/kg, i.v., single-dose
11201526|NCT03374007|Experimental|GB226 1mg/kg multiple dosing, every 2 weeks|Geptanolimab, 1mg/kg, i.v., q2w*6
11201527|NCT03374007|Experimental|GB226 3mg/kg multiple dosing,every 2 weeks|Geptanolimab, 3mg/kg, i.v., q2w*6
11201528|NCT03374007|Experimental|GB226 10mg/kg multiple dosing, every 2 weeks|Geptanolimab,10mg/kg, i.v., q2w*6
11201529|NCT03374007|Experimental|GB226 280mg multiple dosing|Geptanolimab, 280mg, i.v., q3w
11201530|NCT03374007|Experimental|GB226 3mg/kg multiple dosing|Geptanolimab, 3mg/kg, i.v., q2w
11201531|NCT03373994||18F-FDG PET/CT initial-time imaging|PET/CT imaging was underwent 5min after 18F-FDG injection.
11201532|NCT03373994||18F-FDG PET/CT balanced-time imaging|PET/CT imaging was underwent 60min after 18F-FDG injection.
11201533|NCT03373981|Experimental|intervention|rTMS
11201534|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
11201535|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
11201536|NCT03373942||Primary Open Angle Glaucoma (POAG)|The study included 30 eyes of 30 patients diagnosed with POAG who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
11201537|NCT03373942||Pseudoexfoliation Syndrome (PEX)|The study included 30 eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
11201538|NCT03373942||Control|The control group included 30 eyes of 30 healthy individuals with similar age distribution with POAG and PEX group
11201539|NCT03373929|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO
11201540|NCT03373929|Other|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.
11201541|NCT03373916|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
11201542|NCT03373916|Active Comparator|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
11201543|NCT03373903|Placebo Comparator|Placebo once daily for 16 weeks|
11201544|NCT03373903|Experimental|BEZ235 once daily for 16 weeks|
11201545|NCT03373903|Experimental|BEZ235 twice daily for 16 weeks|
11201546|NCT03373903|Experimental|BEZ235 plus RAD001 once daily for 16 weeks|
11201547|NCT03373890|Experimental|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
11201548|NCT03373890|Active Comparator|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
11201549|NCT03373877|Experimental|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
11201550|NCT03373877|Experimental|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
11201551|NCT03373877|Experimental|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
11201552|NCT03373877|Experimental|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
11201553|NCT03373864|Experimental|Unilateral spinal anesthesia|In this arm, the patients will have a hypobaric lateral spinal anesthesia. Sedation can be added for the patients comfort.
11201554|NCT03373864|Active Comparator|General anesthesia|In this arm, the patients will have a general anesthesia.
11201555|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
11201556|NCT03373838||Census|Epidemiological study. Sociodemographic and medical survey.
11201557|NCT03373838||Qualitative interview|Individual qualitative interview.
11201558|NCT03373825|Experimental|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
11201559|NCT03373825|Experimental|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
11201560|NCT03373812|Active Comparator|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
11201561|NCT03373812|Active Comparator|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
11201562|NCT03373799|Experimental|Group 1|Video-Based Rehabilitation Group
11201563|NCT03373799|Active Comparator|Group 2|Physiotherapist-Supervised Rehabilitation Group
11201564|NCT03373786|Experimental|RG-012 Single Dose|1.5 mg/kg RG012 subcutaneous injection
11201565|NCT03373786|Experimental|RG012 Every Other Week|1.5 mg/kg RG012 subcutaneous injections every other week
11201566|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.
~Subjects in this arm will remove the Foley catheter at home."
11201567|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.
~Subjects in this arm will remove the Foley catheter in a medical office."
11201568|NCT03373760|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11201569|NCT03373747|Experimental|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
11201643|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
11201778|NCT03372265|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
11201570|NCT03373747|Experimental|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
11201571|NCT03373708|Experimental|EC follow T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
11201572|NCT03373708|Experimental|TC follow endocrine|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for four cycles followed by goserelin acetate+tamoxifen for young patients/ letrozole for postmenopausal patients
11201573|NCT03373695|Experimental|Dissolve™|
11201574|NCT03373695|Active Comparator|SeQuent®Please|
11201575|NCT03373669|Active Comparator|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
11201576|NCT03373669|Experimental|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
11201577|NCT03373656|Experimental|low antibody titers|Antibody titers lower than protection level
11201578|NCT03373656|Other|high antibody titers|Antibody titers higher than protection level
11201579|NCT03373643|Experimental|Patient suspected for NAFLD|
11201580|NCT03373630|Experimental|Midline catheter|
11201581|NCT03373617||General anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under general anesthesia.
11201582|NCT03373617||Spinal anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under spinal anesthesia without sedation.
11201583|NCT03373617||Spinal anesthesia with sedation group|Patients in general anesthesia group are scheduled to undergo RIRS under spinal anesthesia with sedation.
11201584|NCT03373604|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
11201585|NCT03373604|Active Comparator|No cognitive impairment|Healthy controls
11201586|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
11201587|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
11201588|NCT03373591|No Intervention|No TAP block|Patients will be randomized to receive no TAP block as a control group.
11201589|NCT03373578|Active Comparator|earmuffs|Preterm newborns with earmuffs during the Quiet time
11201590|NCT03373578|No Intervention|control|Preterm newborns without earmuffs during de Quiet time
11201591|NCT03373565|Active Comparator|Radial|Coronary angiography using radial approach
11201592|NCT03373565|Experimental|palmar|Coronary angiography using palmar approach
11201593|NCT03373552||non responder Group|"Platelet function assay:
~High platelet reactivity: PRU>230"
11201594|NCT03373552||responder Group|"Platelet function assay:
~PRU<230"
11201595|NCT03373526|Active Comparator|Aerobic Physical Training|Aerobic Training
11201596|NCT03373526|Experimental|Combined Physical Training|Inspiratory Muscle Training Aerobic Training
11201597|NCT03373513|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
11201598|NCT03373513|Active Comparator|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
11201599|NCT03373500|Experimental|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
11201600|NCT03373500|No Intervention|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
11201601|NCT03373487|Experimental|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
11201602|NCT03373487|Other|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
11201603|NCT03373474|Experimental|local distribution points association|Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
11201604|NCT03373474|Experimental|local-distal points association|Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
11201605|NCT03373474|No Intervention|waiting-list|Patients in the waiting-list group will not receive any acupuncture treatment during the study. However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
11201606|NCT03373461|Placebo Comparator|Placebo|Placebo to LNP023
11201607|NCT03373461|Experimental|LNP023 dose 1|Dose 1 of LNP023
11201608|NCT03373461|Experimental|LNP023 dose 2|Dose 2 of LNP023
11201609|NCT03373461|Experimental|LNP023 dose 3|Dose 3 of LNP023
11201644|NCT03373240|Experimental|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
11201679|NCT03373032|Other|Finished|All finished, of the 3 groups Stiper / Acupuncture / Control. 1session with a Peridell Massager ( hotflowers)
11201880|NCT03371563||controls|
11201610|NCT03373448|Active Comparator|Labrida BioClean|Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
11201611|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided with titanium curettes.
11201612|NCT03373435|Experimental|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
11201613|NCT03373435|Experimental|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
11201614|NCT03373422|Experimental|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
11201615|NCT03373422|Experimental|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
11201616|NCT03373422|Experimental|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
11201617|NCT03373422|Experimental|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
11201618|NCT03373422|Experimental|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
11201619|NCT03373422|Placebo Comparator|Placebo|One placebo tablet in the morning and one in the evening
11201620|NCT03373409|Experimental|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
11201621|NCT03373409|Experimental|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
11201622|NCT03373409|Active Comparator|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
11201623|NCT03373396|Other|Case group with Metavir score between F1 and F4|Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
11201624|NCT03373396|Other|Control group with Metavir score of between F0|Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed.
11201625|NCT03373383|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
11201626|NCT03373383|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
11201627|NCT03373383|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
11201628|NCT03373383|Experimental|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
11201629|NCT03373383|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
11201630|NCT03373357|Other|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
11201631|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
11201632|NCT03373344|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
11201633|NCT03373344|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.
~They will receive placebo control exercises administered on a laptop computer."
11201634|NCT03373331|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
11201635|NCT03373331|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.
~They will receive placebo control exercises administered on a laptop computer.
~."
11201636|NCT03373318|Experimental|Experimental|Human Albumin
11201637|NCT03373318|Active Comparator|Control|Plasmalyte
11201638|NCT03373305|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11201639|NCT03373292|Experimental|Venous stenting (Group-1)|Patients in this group will undergo venous stenting treatment at once after enrollment.
11201640|NCT03373292|Experimental|Stenting one-month after routine medical treatment (Group-2)|Patients in this group will undergo routine medical treatment for one month, followed by venous stenting intervention.
11201641|NCT03373266|Active Comparator|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
11201642|NCT03373266|Active Comparator|isoflurane|anesthesia was maintained with isoflurane 1-2%.
11201645|NCT03373240|Placebo Comparator|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
11201881|NCT03371563||young patients|
11201646|NCT03373227|Experimental|Prospective|25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care.
11201647|NCT03373227|No Intervention|Retrospective|25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.
11201648|NCT03373214|Experimental|30 µg Na-GST-1 + CPG 10104|
11201649|NCT03373214|Experimental|100 µg Na-GST-1 + CPG 10104|
11201650|NCT03373214|Experimental|100 µg Na-GST-1|
11201651|NCT03373201|Experimental|Tasimelteon|
11201652|NCT03373201|Placebo Comparator|Placebo|
11201653|NCT03373188|Active Comparator|Arm I (surgery)|Patients undergo surgery.
11201654|NCT03373188|Experimental|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
11201655|NCT03373188|Experimental|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
11201656|NCT03373188|Experimental|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
11201657|NCT03373175|Experimental|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record Pressure Support 10 (PS 10)record Pressure Support 15 (PS 15) record Pressure Support 20 (PS 20) record
11201658|NCT03373175|Experimental|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
11201659|NCT03373175|Experimental|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
11201660|NCT03373175|Experimental|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
11201661|NCT03373162|Experimental|MRI Scans Pre and Post-Botox Injection|Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.
11201662|NCT03373149|Experimental|Growth hormone/HPuFSH/GnRH antagonist|The patients receive growth hormone
11201663|NCT03373149|Active Comparator|HPuFSH/GnRH antagonist|Growth hormone is not used
11201664|NCT03373136|Experimental|Cold snaring|Polypectomy will be done without electrocautery
11201665|NCT03373136|Active Comparator|Hot snaring|Polypectomy will be performed with electrocautery
11201666|NCT03373123|Experimental|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
11201667|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
11201668|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
11201669|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
11201670|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
11201671|NCT03373084||hamstring muscle lesions|Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire
11201672|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
11201673|NCT03373058|Experimental|Experimental group|"Cytoreductive surgery
~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available.)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
11201674|NCT03373058|Active Comparator|Control group|"Cytoreductive surgery
~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
11201675|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
11201676|NCT03373032|Active Comparator|Stiper|Stiper,patients with breast cancer diagnosis during chemotherapy cycles, 1 a week, 10 weeks
11201677|NCT03373032|Active Comparator|Acupuncture|Acupuncture with needles, patients with breast cancer diagnosis during chemotherapy cycles, 1 a week, 10 weeks
11201678|NCT03373032|Placebo Comparator|Control|Control Exercise,patients with breast cancer diagnosis during chemotherapy cycles, 1 a week, 10 weeks
11245466|NCT03070899|Experimental|OBE2109 dose 2 + Placebo Add-back|
11201680|NCT03373019|Experimental|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
11201681|NCT03373006|Experimental|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
11201682|NCT03372980||Case|
11201683|NCT03372980||Control|
11201684|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
11201685|NCT03372954|Experimental|Bone marrow autologous cells concentrate (BMAC)|retrograde administration on non-selected BMAC via coronary sinus
11201686|NCT03372954|Placebo Comparator|Control|standard treatment o heart failure
11201687|NCT03372941|Active Comparator|Alternative treatment strategy|Patient will receive a single dose of dalbavancin administered in the BJH ED or ED observation unit for ABSSSI followed by discharge w/ close Infectious Disease outpatient clinic follow-up.
11201688|NCT03372941|No Intervention|Usual care|"Patients will receive usual care (i.e., hospital admission for intravenous antibiotics - typically, vancomycin) - antibiotic and doses to be determined at the discretion of the treating clinician (both in the BJH ED and on the BJH inpatient ward)."
11201689|NCT03372928|Experimental|Standard EAA Dose|EAA dose provided at 0.10 g/kg body mass
11201690|NCT03372928|Experimental|High EAA Dose|EAA dose provided at 0.30 g/kg body mass
11201691|NCT03372915|Active Comparator|Standard Exposure|This arm will receive exposure therapy conducted according to standard care practices.
11201692|NCT03372915|Experimental|Exposure + Inhibitory Learning|This arm will receive exposure therapy conducted according to principles of inhibitory learning.
11201693|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
11201694|NCT03372902||suspicious lesion group (BI-RADS 4)|
11201695|NCT03372889|Active Comparator|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
11201696|NCT03372889|Active Comparator|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
11201697|NCT03372876|Experimental|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
11201698|NCT03372876|Placebo Comparator|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
11201699|NCT03372863||Cardiac surgery patients|
11201700|NCT03372850|Experimental|Sequence Group 1|Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)
11201701|NCT03372850|Experimental|Sequence Group 2|Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)
11201702|NCT03372837|Experimental|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.
~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
11201703|NCT03372824||Pregnant women|Primiparas above 25 years of age, singleton pregnancy
11201704|NCT03372811|Active Comparator|TC cream (10%)|
11201705|NCT03372811|Placebo Comparator|Vehicle|
11201706|NCT03372785||Complete revascularization group|Complete Revascularization of CTO and non-CTO lesions
11201707|NCT03372785||Non-CTO revascularization group|Non-CTO vessel revascularization
11201708|NCT03372772|No Intervention|Control group|Control group - patients with only levothyroxine therapy
11201709|NCT03372772|Experimental|Intervention group|Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
11201710|NCT03372759|Active Comparator|study group air|airtamponade
11201711|NCT03372759|Sham Comparator|study group saline|saline
11201712|NCT03372746||1|Participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2
11201713|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil
11201714|NCT03372733|Experimental|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
11201715|NCT03372720|Experimental|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
11201716|NCT03372720|Sham Comparator|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
11201717|NCT03372707|Experimental|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
11201718|NCT03372707|No Intervention|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
11201739|NCT03372564|No Intervention|No Hip Capsule Repair (Control)|Patients in the control group (no hip capsule repair) have the same portals utilized and will have the same interportal capsulotomy performed. They will have all central and peripheral compartment pathologies addressed in the same way that the study group does. At the conclusion of the case, the hip capsule will be left open and not repaired.
11201719|NCT03372694|Experimental|Chemotherapy+Training+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Rehabilitation training is mainly composed of gymnastic qigong, which will be started in one month after operation.
~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
11201720|NCT03372694|Experimental|Chemotherapy+Education+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.
~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
11201721|NCT03372694|Placebo Comparator|Chemotherapy+Education+Placebo|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.
~Patients who received rehabilitation education will not accept rehabilitation training.
~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages. The patient will take placebo granules for 3 months."
11201722|NCT03372681|Experimental|Antiperistaltic|In this group patients undergo the distal gestrectomy with antiperistaltic Billroth II + Braun anastomosis
11201723|NCT03372681|Active Comparator|Isoperistaltic|In this group patients undergo the distal gestrectomy with isoperistaltic Billroth II + Braun anastomosis
11201724|NCT03372668|Other|All Participants|Each study participant will progress through the three, 4-week study periods in the ABA withdrawal design in the same, designated order. The first and third 4-week study periods (or the A periods) have no intervention and only consist of twice weekly data collection. The second 4-week study period (or the B period) will include the twice weekly delivered massage therapy combined with components of mirror therapy intervention.
11201725|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
11201726|NCT03372629|Experimental|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
11201727|NCT03372629|Placebo Comparator|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
11201728|NCT03372629|Experimental|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
11201729|NCT03372629|Placebo Comparator|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
11201730|NCT03372616||All participants|Aortic blood pressure, LV filling pressrue, and LV volume will be measured in all participants. Meanwhile, echocardiography and non-invasive aortic blood presure measurement will be performed. Three devices will be used in non-invasive aortic blood presure measurement, including Sphygmocor (AtCor Medical, Australia), PulsePen (DiaTecne SRL, Italy), and Mobil-O-Graph (IEM, Germany). In conclusion, all participants will receive invasive and non-invasive left ventricular diastolic function assessment, together with invasive and non-invasive aortic blood pressure assessment.
11201731|NCT03372603|Experimental|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
11201732|NCT03372603|Experimental|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
11201733|NCT03372590|Experimental|NICU-based rehabilitation bundle|Patients identified to be at high risk for cerebral palsy will be enrolled after parental consent is obtained to the NICU rehabilitation program. This program consists of maternal-driven evidence based intervention that include: vocal soothing, scent exchange, comforting touch, kangaroo care, and infant massage. These intervention will be provided at GA-appropriate intervals.
11201734|NCT03372590|Other|Standard of care|Infants not participating in the intervention study will be provided with standard or care. Interventions include kangaroo care, physical therapy and infant massage provided by NICU staff.
11201735|NCT03372577|Experimental|patient and partner|
11201736|NCT03372577|Experimental|patient ,partner and cardiac rehabilitation team|
11201737|NCT03372577|Active Comparator|Treatment as usual|
11201738|NCT03372564|Experimental|Hip Capsule Repair|Patients in the intervention group (Hip capsule repair) will undergo initial diagnostic arthroscopy of the hip. Two to three standard portals (anterolateral, mid anterior, distal antero-lateral, posterolateral) will be used during the entire procedure to assess and treat the patient. After establishing standard portals, an interportal capsulotomy is completed to allow for complete evaluation of the central compartment of the hip. In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl). Three to four simples sutures will be placed and tied using arthroscopic technique.
11201740|NCT03372551|Experimental|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
11201741|NCT03372551|Active Comparator|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
11201742|NCT03372538||multidisciplinary team group|500 patients of placenta accreta managed by obstetricans and urologists
11201743|NCT03372538||obstetricians only group|500 patients of placenta accreta managed by obstetricans only
11201744|NCT03372525|Experimental|HFOV|Ventilated infants were randomized to HFOV.
11201745|NCT03372525|Active Comparator|CMV|Ventilated infants were randomized to CMV.
11201746|NCT03372512||Fluid overload (Liters) ≥ median|
11201747|NCT03372512||Fluid overload (Liters) < median|
11201748|NCT03372499|Experimental|nutritional management group|diet management strategy for encephalopathy
11201749|NCT03372499|No Intervention|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
11201750|NCT03372486|Active Comparator|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
11201751|NCT03372486|Placebo Comparator|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
11201752|NCT03372473|Experimental|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
11201753|NCT03372473|Active Comparator|Montelukast|Montelukast 5mg one dose per day
11201754|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
11201755|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS will include a 30-second ramp up to 1mA, 30 seconds of stimulation at 1mA, followed by a 30-second ramp down to off. The device will remain off for the remainder of the session. This process will be used for each of the 6 sessions during a 2 week period.
11201756|NCT03372447|Experimental|Megadose multivitamin complex|Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
11201757|NCT03372421|Experimental|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
11201758|NCT03372421|Active Comparator|Standard Information|Participants will read standard information about what to expect from the assessment.
11201759|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
11201760|NCT03372395|Other|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
11201761|NCT03372395|Experimental|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
11201762|NCT03372382|Active Comparator|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
11201763|NCT03372382|Experimental|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
11201764|NCT03372369|Active Comparator|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
11201765|NCT03372369|Experimental|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
11201766|NCT03372356||Neuroendocrine tumors|Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.
11201767|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index < 0.9 or vascular Duplex confirmed peripheral artery disease.
~* Standard care for sepsis and PAD"
11201768|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index >= 0.9 or vascular Duplex found no evidence of peripheral artery disease.
~* Standard care for sepsis"
11201769|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
11201770|NCT03372304|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 10 mL, every 8th hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
11201771|NCT03372304|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
11201772|NCT03372304|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
11201773|NCT03372291|Experimental|Psychological app|"Psychological intervention consist of four components
~Supportive psychotherapy interventions to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance;
~Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social supports;
~Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty;
~Self-care to promote positive health behaviors and enhance patients' sense of control especially as they transition from the hospital to outpatient care.
~The psychological intervention will consist of five sessions (20-25 minutes each) that patients will start during their first week of admission for intensive chemotherapy and continue weekly for five weeks after diagnosis"
11201774|NCT03372291|Active Comparator|Usual Care|"Participants receiving usual care will not have access to the psychological intervention app. -They will receive usual leukemia care with all the supportive care measures instituted by the leukemia team.
~Patients in usual care will also meet with the leukemia social worker based on their request or at the discretion of the treating leukemia team"
11201775|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
11201776|NCT03372265|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
11201777|NCT03372265|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
11201779|NCT03372252|Experimental|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
11201780|NCT03372252|Experimental|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
11201781|NCT03372239|Experimental|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:
~Single dose of Indoximod base formulation under fasting conditions
~Single dose of Indoximod HCL (salt) formulation under fed conditions
~Single dose of Indoximod HCL (salt) formulation under fasting conditions"
11201782|NCT03372239|Experimental|Part 2: Single Ascending Dose|
11201783|NCT03372226|Experimental|Online self-help program|"The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 10 modules with many interactional exercises and homework-sheets.
~Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse."
11201784|NCT03372226|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
11201785|NCT03372213||2003-2004|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
11201786|NCT03372213||2005-2006|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
11201787|NCT03372213||2011-2012|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
11201788|NCT03372213||2013-2014|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
11201789|NCT03372200|Experimental|FYU-981|
11201790|NCT03372200|Active Comparator|Febuxostat|
11201791|NCT03372187|Experimental|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
11201792|NCT03372174|Experimental|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
11201793|NCT03372174|Active Comparator|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
11201794|NCT03372161|Experimental|SP-102|SP-102
11201795|NCT03372161|Placebo Comparator|Placebo|Placebo
11201796|NCT03372148|Experimental|pHRMi in evaluation of swallowing function|Pharyngeal High Resolution Manometry and Impedance (pHRMi) evaluation of swallowing function at baseline, 3 months post radiation, then at 9 months
11201797|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
11201798|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
11201799|NCT03372122|Active Comparator|SAGE Chlorhexidine Gluconate Cloth|Ready to use disinfectant cloth
11201800|NCT03372122|Active Comparator|HUBS with Hibiclens|Dry cloths to be used with water and disinfectant
11201801|NCT03372109|Active Comparator|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
11201802|NCT03372109|Placebo Comparator|Placebo|Multivitamin tablet administered daily for 52 days
11201803|NCT03372096|Experimental|All patients|Patients will receive the Prostatic Artery Embolization procedure.
11201804|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
11201805|NCT03372070|Experimental|cNEP|silicone collar applied to anterior neck
11201806|NCT03372057|Experimental|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
11201807|NCT03372057|Experimental|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
11201808|NCT03372057|Experimental|Expansion Phase|Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)
11201809|NCT03372044|Experimental|PF-06865571|Treatment
11201810|NCT03372031|Experimental|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
11201811|NCT03372031|Experimental|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
11201812|NCT03372018|Experimental|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
11201813|NCT03372018|Active Comparator|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
11201814|NCT03372005|Experimental|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
11201815|NCT03372005|No Intervention|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
11201816|NCT03371992|Other|Lung Cancer Patients|Lung cancer patients receiving one of three standard of care immunotherapy drugs including nivolumab, pembrolizumab or atezolizumab. 3D-EX will be performed on biopsies from patients enrolled in the study to correlate with the patient's evaluation of response by RECIST.
11201817|NCT03371979|Experimental|Pegzilarginase plus Pembrolizumab|Phase 1 & 2
11201818|NCT03371966|Active Comparator|High Nitrate Beetroot Juice|Beetroot juice high in nitrate will contain approximately 10.0 mmole nitrate per 120 ml.
11201819|NCT03371966|Placebo Comparator|Low Nitrate Beetroot Juice|Beetroot juice low in nitrate will contain approximately 0.5 mmole nitrate per 120 ml.
11201820|NCT03371953|Active Comparator|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
11201821|NCT03371953|Active Comparator|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
11201822|NCT03371953|Active Comparator|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
11201823|NCT03371940|Experimental|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.
~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:
~Education about depression and the cognitive-behavioral therapy model;
~A safe relationship for participants to explore their symptom patterns and try to new tools to address them;
~Coaching as participants fully engage emotional and behavioral strategies."
11201824|NCT03371940|Experimental|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
11201825|NCT03371940|Experimental|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise as detailed above.
11201826|NCT03371940|Placebo Comparator|Usual care (UC)|Participants randomized to usual care received no study intervention.
11201827|NCT03371927|No Intervention|Standard Feeding Method|The control group consisted of prescribed volumes of oral and/or gavage feedings at two or three hour intervals per feeding.
11201828|NCT03371927|Experimental|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
11201829|NCT03371914|Experimental|Treatment: Management + data training|"The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.
~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis."
11201830|NCT03371914|No Intervention|Control: data training only|The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
11201831|NCT03371901|Experimental|Physical therapy with BFR-LLST|
11201832|NCT03371888|Experimental|PRP injections|Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle
11201833|NCT03371888|Placebo Comparator|0,9% NaCl injections|Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle
11201834|NCT03371875|Experimental|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
11201835|NCT03371875|No Intervention|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
11201836|NCT03371862|Experimental|Test group|
11201837|NCT03371849|Experimental|Group 1|Reference Drug → Test Drug
11201838|NCT03371849|Experimental|Group 2|Test Drug → Reference Drug
11201839|NCT03371836|Other|open label single treatment arm|open label
11201840|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
11201841|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
11201842|NCT03371810|Experimental|Bright light therapy|"Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total.
~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
11245467|NCT03070899|Experimental|OBE2109 dose 2 + Add-back|
11201843|NCT03371810|Experimental|Physical exercise|"Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total.
~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
11201844|NCT03371810|No Intervention|Treatment as usual|Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
11201845|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
11201846|NCT03371784|Active Comparator|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
11201847|NCT03371784|Placebo Comparator|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
11201848|NCT03371771|Experimental|Volunteer-delivered Behavioral Activation|
11201849|NCT03371771|Active Comparator|MSW-delivered Behavioral Activation|
11201850|NCT03371758|Experimental|vitiligo patients|
11201851|NCT03371758|Experimental|healthy controls|
11201852|NCT03371745|Active Comparator|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
11201853|NCT03371745|Active Comparator|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
11201854|NCT03371745|Active Comparator|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
11201855|NCT03371732|Other|Groupe 1|G1 : Motivational Intervention group
11201856|NCT03371732|Other|Groupe 2|G2 : Educational advises group
11201857|NCT03371719|Placebo Comparator|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
11201858|NCT03371719|Experimental|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
11201859|NCT03371706|Experimental|Evidence-Based Treatment 1|
11201860|NCT03371706|Active Comparator|Evidence-Based Treatment 2|
11201861|NCT03371693|Experimental|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.
~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
11201862|NCT03371693|Other|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
11201863|NCT03371680|Experimental|Injection of stable isotopes|Injection of 1-13 Carbon Leucine and deuterated water: all patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
11201864|NCT03371667|Experimental|Methotrexate|"5mg/Kg/day methotrexate for 4 weeks then 3 mg/m2 every two weeks for 12 weeks
~2mg/kg/day PO prednisone prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.
~10 mg po or iv lederfolin after each MTX administration"
11201865|NCT03371667|Placebo Comparator|Placebo|"Once a week placebo for 4 weeks then every two weeks for 12 weeks
~2 mg/kg/day PO prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.
~10 mg po or iv lederfolin after each placebo administration"
11201866|NCT03371641|Other|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
11201867|NCT03371641|Other|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
11201868|NCT03371628|Experimental|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
11201869|NCT03371628|No Intervention|Group O2|Oxygen therapy
11201870|NCT03371615|Active Comparator|Fermented IF + LBG + Gos Fos|Fermented infant formula with Locust bean gum and Gos Fos
11201871|NCT03371615|Placebo Comparator|Fermented IF +LBG|Fermented infant formula with Locust bean gum
11201872|NCT03371602|Experimental|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
11201873|NCT03371602|Experimental|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
11201874|NCT03371602|Experimental|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
11201875|NCT03371602|Experimental|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
11201876|NCT03371589|Experimental|no P.O corticosteroids|Steroids injection
11201877|NCT03371576||2 different torical intraocular lenses|
11201878|NCT03371563||elderly patients|
11201879|NCT03371563||middle-aged patients|
11201882|NCT03371550|Experimental|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
11201883|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
11201884|NCT03371524||Native valves_30 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.
11201885|NCT03371524||Native valves_30 and 60 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.
11201886|NCT03371524||Bioprosthesis_30 seconds loops|Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.
11201887|NCT03371511||MiLC Cohort|"Participants donated HM from two consecutive pumping sessions at home. Women pumped once with their own pump and milk collection kit, and once with a sterile and sterile collection kit. Both pumping sessions occurred at participants' homes between 0700 and 1100 hours. The second pumping session occurred within 3 hr (+/- 30 min) after the beginning of the first. Randomization was used to determine which pump was used first. Women elected from which breast they donated their HM and were asked not to nurse on that side 2 hr before the first pumping session and not until after the second. Before women pumped with their own pump, swabs were taken of the breast from which HM was donated, the women's dominant hand, their own bottle/flange, their own pumps (port of pump and tubing), and their babies' mouths.
~There was only one group but stratified enrollment was used to ensure equal numbers of women whose infants consumed HM only and women whose infants consumed HM and complementary foods."
11201888|NCT03371498|Experimental|Methylprednisolone Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
11201889|NCT03371498|Placebo Comparator|Control Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo
11201890|NCT03371485|Active Comparator|Arm A|Patients with advanced NSCLC, to receive AST-VAC2.
11201891|NCT03371485|No Intervention|Arm B|Patients with advanced NSCLC, receiving no AST-VAC2 treatment and serving as a control for Arm A.
11201892|NCT03371485|Active Comparator|Arm C:|Patients with previously treated NSCLC, currently disease free, to receive AST-VAC2 in the adjuvant setting.
11201893|NCT03371485|No Intervention|Arm D:|Patients with previously treated NSCLC, currently disease free, receiving no AST-VAC2 treatment and serving as a control for Arm C.
11201894|NCT03371472|Other|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
11201895|NCT03371472|Other|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
11201896|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
11201897|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
11201898|NCT03371446||Smokers/Non-smokers|It was an experimental study with parallel controls, comparing two groups, a group with patients who smoked for more than 10 years, consuming 10 more cigarettes per day and diagnosing chronic periodontitis (case) and another group (control) were non-smokers with chronic periodontitis, according to the standard of World Health Organization (WHO) definition of the smoking population
11201899|NCT03371420|Experimental|124I-PU-AD|A single dose of 124I-PU-AD will be administered by intravenous (IV) injection
11201900|NCT03371407||Parkinsonian patient under dopaminergic medication|
11201901|NCT03371407||Parkinsonian patient without dopaminergic medication|
11201902|NCT03371407||Control participants|
11201903|NCT03371394||median 1|
11201904|NCT03371394||median 2|
11201905|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
11201906|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
11201907|NCT03371368|Active Comparator|Gastric Bypass Diabetic and Non-diabetic|Roux-en-Y gastric bypass surgery
11201908|NCT03371368|Active Comparator|Sleeve Gastrectomy Diabetic and Non-diabetic|sleeve gastrectomy surgery
11201909|NCT03371368|Active Comparator|Very Low Calorie Diet Diabetic and Non-diabetic|very low calorie diet
11201910|NCT03371368|No Intervention|Obese Control|Non-diabetic obese subjects
11201911|NCT03371368|No Intervention|Lean Control Group|Non-diabetic lean subjects
11201912|NCT03371355|Placebo Comparator|Pooled Placebo|Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
11201913|NCT03371355|Experimental|Cohort B: ISIS 703802, 40 mg Q4W|Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
11201914|NCT03371355|Experimental|Cohort C: ISIS 703802, 80 mg Q4W|Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
11201915|NCT03371355|Experimental|Cohort A: ISIS 703802, 20 mg QW|Participants received ISIS 703802, 20 mg once every week for 26 doses.
11201916|NCT03371342|Experimental|MEDITOXIN|
11201917|NCT03371342|Active Comparator|BOTOX|
11201918|NCT03371329|Experimental|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.
11201919|NCT03371329|Experimental|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.
11201920|NCT03371329|Experimental|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.
11201921|NCT03371329|Experimental|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.
11201922|NCT03371316|Experimental|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
11201923|NCT03371303||diabetology|
11201924|NCT03371303||cardiology|
11201925|NCT03371303||rheumatology|
11201926|NCT03371303||geriatrics|
11201927|NCT03371290|Experimental|Mirror Therapy Intervention|
11201928|NCT03371290|Active Comparator|Control Intervention|
11201929|NCT03371277|Experimental|Arm1|patients with Parkinson's disease treated with deep brain stimulation.
11201930|NCT03371277|Experimental|Arm2|patients with Parkinson's disease treated without deep brain stimulation.
11201931|NCT03371264||Cohort R1 and Cohort T1|Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
11201932|NCT03371264||Cohort R2 and Cohort T2|Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)
11201933|NCT03371251|Experimental|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
11201934|NCT03371251|Placebo Comparator|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
11201935|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
11201936|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
11201937|NCT03371238|Experimental|Floorball|
11201938|NCT03371238|No Intervention|Control|
11201939|NCT03371225|Experimental|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
11201940|NCT03371225|Active Comparator|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
11201941|NCT03371225|Active Comparator|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
11201942|NCT03371225|Sham Comparator|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
11201943|NCT03371212|Active Comparator|Conventional Cohort|Patients in this group will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
11201944|NCT03371212|Experimental|Modular Dual Mobility Cohort|Patients in this group will receive a Taperloc femoral stem, inner ceramic femoral head (28mm), mobile polyethylene bearing, cobalt alloy liner, and G7 acetabular shell.
11201945|NCT03371199|Active Comparator|Sodium arm|Sodium tablets
11201946|NCT03371199|Placebo Comparator|Placebo arm|Placebo tablets
11201947|NCT03371186|Experimental|Bundled RMNCH Intervention|Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
11201948|NCT03371173|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
11201949|NCT03371147|Experimental|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
11201950|NCT03371147|No Intervention|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
11201951|NCT03371134||Sarcopenic group|Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
11201952|NCT03371134||Control group|Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
11201953|NCT03371121|Other|Chondro-gide - Geistlich|Arthroscopic use of chondro-gide to treat symptomatic osteochondral talar lesion
11201954|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
11201955|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
11201956|NCT03371095|Experimental|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
11201957|NCT03371095|Active Comparator|Cyclophosphamide|Cyclophosphamide 0.7g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
11201958|NCT03371082|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
11201959|NCT03371082|Active Comparator|Lantus®|Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
11201960|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
11201961|NCT03371056|Experimental|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
11201962|NCT03371056|Experimental|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (> 12 hours before labor) but > 37 SA will be included.
11201963|NCT03371056|Experimental|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection <37SA
11201964|NCT03371056|Experimental|Women with premature delivery or premature delivery threat|Woman with high risk of infection <37SA and Women with premature delivery or premature delivery threat
11201965|NCT03371043||users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
11201966|NCT03371030|Experimental|Pronator quadratus reparation|Surgical Intervention: Radius fracture teated with plate and pronator quadratus muscle repair.
11201967|NCT03371030|Active Comparator|No pronator quadratus reparation|Surgical Intervention: Radius fracture with plate without pronator quadratus muscle repair.
11201968|NCT03371017|Experimental|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
11201969|NCT03371017|Placebo Comparator|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
11201970|NCT03371004|Experimental|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
11201971|NCT03370991|Experimental|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
11201972|NCT03370991|Placebo Comparator|Control|22 g/day placebo powder for 12 weeks
11201973|NCT03370978|Experimental|Text Messaging|Receives text messages to remind of upcoming follow-up appointment with primary care doctor. Also provides opportunity for subjects to text ED staff for follow-up care concerns or to reschedule primary care appointment.
11201974|NCT03370978|No Intervention|Usual Care|Received usual care including follow-up phone calls if clinically indicated.
11201975|NCT03370965|Experimental|Patients with optic neuritis|
11201976|NCT03370952|Active Comparator|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).
~Aspiration of the cyst:
~Delivery of affected ovary outside the abdominal cavity:
~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.
~Ovarian cystectomy:
~Re-introduction of the ovary to inside the abdominal cavity:"
11201977|NCT03370952|Active Comparator|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
11201978|NCT03370913|Experimental|valoctocogene roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg
11201979|NCT03370900|No Intervention|Learning and Assessment at 12 months|Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
11201980|NCT03370900|Experimental|Testing Every Two Months|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests without any feedback at 2, 4, 6, 8, 10, 12 months.
11201981|NCT03370900|Experimental|Low Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 6 months, the 20-case post-test will be delivered with feedback.
11201982|NCT03370900|Experimental|High Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 4, 8, and 12 months, the 20-case post-test will be delivered with feedback.
11201983|NCT03370887|Experimental|Low dose AZD8601 (3 mg)|8 patients will be randomised to receive 3 mg AZD8601
11201984|NCT03370887|Experimental|High dose AZD8601 (30 mg)|8 patients will be randomised to receive 30 mg AZD8601
11201985|NCT03370887|Placebo Comparator|Placebo|8 patients will be randomised to receive placebo injections
11201986|NCT03370874|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
11201987|NCT03370874|Placebo Comparator|Vehicle Sheet|Hydrogel sheet without Allogenic mesenchymal stem cell
11201988|NCT03370848|Experimental|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.
~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER
~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
11201989|NCT03370848|Active Comparator|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.
~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
11201990|NCT03370835|Experimental|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10
~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
11201991|NCT03370835|Active Comparator|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10
~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
11201992|NCT03370822||Study Participants|Women who have continuous fetal monitoring using the MONICA AN24 device. The MONICA AN24 is a wearable monitor with five adhesive electrodes placed on the mother's abdomen. This records the fetal heart rate, maternal heart rate and uterine contractions.
11202173|NCT03369535|Active Comparator|MUFA rich diet|MUFA rich diet for 6 weeks
11201993|NCT03370809|Experimental|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
11201994|NCT03370796|Experimental|Reminiscence Therapy|The Reminiscence program will consist of a set of sessions thematically sequenced topics that address the life course of the participant. Each session will integrate a group of activities that will be developed in group and will have a didactic character, privileging subjective interests and interpersonal communication.
11201995|NCT03370796|No Intervention|Control Group|The control group shall participate in the institutional care provided by the professionals of each RSE.
11201996|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
11201997|NCT03370757|Active Comparator|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
11201998|NCT03370757|Active Comparator|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
11201999|NCT03370744||Subjective cognitive decline, SCD|The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) failure to meet the following criteria for MCI.
11202000|NCT03370744||Normal control, NC|NC are individuals who have no self-report persistent decline in cognitive capacity, and with neither worry nor concern about their cognition. Without measurable cognitive impairment according to results of standard assessments.
11202001|NCT03370744||Mild cognitive impairment, MCI|MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9.
11202002|NCT03370744||Alzheimer's disease, AD|The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) with a total CDR score of 1.
11202003|NCT03370744||Subjective Cognitive Decline plus, SCD-plus|The inclusion criteria for SCD-plus are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI.
11202004|NCT03370731|Experimental|Adenotonsillectomy|Surgical management, i.e. adenotonsillectomy, including adenoidectomy, tonsillectomy or adenoidectomy combined tonsillectomy
11202005|NCT03370731|Other|Nonsurgical management|Nonsurgical management, including nasal irrigation, inhaled corticosteroids etc.
11202006|NCT03370718|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
11202007|NCT03370705|Active Comparator|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l
11202008|NCT03370705|Experimental|Sulodexide + CT group|"78 patients will be treated by :
~Sulodexide (250ULS, twice daily , oral administration)
~Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l"
11202009|NCT03370666|Experimental|HFNT|HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.
11202010|NCT03370666|Active Comparator|NIV|NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.
11202011|NCT03370653|Experimental|Double-blind - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
11202012|NCT03370653|Experimental|Double-blind - odiparcil 500 mg per day|1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
11202013|NCT03370653|Placebo Comparator|Double-blind - placebo|2 tablets of placebo per os, twice daily (BID)
11202014|NCT03370653|Experimental|Open Label - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
11202015|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 1|An oral 25 mg dose of SEP 363856 once daily for 3 days, then 50 mg dose of SEP-363856 once daily for 7 days.
11202016|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 2|An oral 50 mg dose of SEP 363856 once daily for 3 days, then 75 mg dose of SEP-363856 once daily for 7 days.
11202017|NCT03370640|Experimental|SEP-363856 Part 2 Cohort 3|An oral 25 mg dose of SEP 363856 once daily for 3 days, 50 mg dose of SEP 363856 once daily for 4 days, and then 75 mg dose of SEP-363856 once daily for 7 days.
11202018|NCT03370627|Experimental|Patient|
11202019|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
11202020|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
11202021|NCT03370601|Other|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
11202022|NCT03370601|Other|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
11202023|NCT03370588|Experimental|dexmedetomidine infusion group|
11202024|NCT03370588|Active Comparator|normal saline infusion group|
11202025|NCT03370575|Experimental|ethiodized poppyseed oil|
11202026|NCT03370575|Active Comparator|the second-generation non-ionic monomer contrast|
11202027|NCT03370562|Active Comparator|Dexmedetomidine|Patient will receive 10 mcg of dexmedetomidine in 5 ml of normal saline, administered by slow intravenous injection
11202028|NCT03370562|Placebo Comparator|Placebo|Patient will receive 5 ml of normal saline, administered by slow intravenous injection
11202029|NCT03370549|Experimental|AWARE intervention|Group psychotherapy intervention for Asian-American women
11202030|NCT03370549|Other|Waitlist control|Delayed AWARE intervention for Asian-American women
11202031|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
11202032|NCT03370510|Experimental|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
11202033|NCT03370510|Placebo Comparator|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
11202034|NCT03370497|Active Comparator|Whey protein hydrolysate|Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
11202035|NCT03370497|Experimental|Whey protein hydrolysate plus milk mineral supplement|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
11202036|NCT03370484|Placebo Comparator|Control|Water with artificial sweetener
11202037|NCT03370484|Experimental|Milk mineral supplement|Milk Minerals containing 1000 mg calcium with artificial sweetener and water
11202038|NCT03370471|Active Comparator|Study Only|Subject uses their own strategy for learning words; no active retrieval during learning.
11202039|NCT03370471|Active Comparator|Retrieval Practice|Subject actively retrieves words as prompted during learning.
11202040|NCT03370458|Experimental|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.
~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
11202041|NCT03370458|Placebo Comparator|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
~Intervention: Dietary Supplement: Placebo"
11202042|NCT03370432||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
11202043|NCT03370432||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
11202044|NCT03370419|Experimental|The Pick Two to Stick To|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
11202045|NCT03370419|Other|Usual Care|Participants receive usual care only.
11202046|NCT03370406|No Intervention|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
11202047|NCT03370406|Experimental|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
11202048|NCT03370406|Experimental|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
11202049|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
11202050|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
11202051|NCT03370367|Experimental|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
11202052|NCT03370367|Placebo Comparator|Arm B|Take 2 placebo pills once a day for up to 2 years.
11202053|NCT03370354||Control group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is > 18, the patient will be in the control group.
11202054|NCT03370354||troubled sleeping patterns group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is < 18, the patient will be in the troubled patterns group.
11202055|NCT03370341|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
11202056|NCT03370341|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
11202057|NCT03370328|Experimental|Peppermint oil|post-op surgical patients
11202058|NCT03370328|Experimental|Ginger oil|post-op surgical patients
11202059|NCT03370328|Experimental|Peppermint and ginger oil|post-op surgical patients
11202060|NCT03370315|Experimental|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.
~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
11202061|NCT03370315|Experimental|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.
~Intervention administered: Walking program with 3 different moments."
11202092|NCT03370094||patients with suspected stroke|patients with suspected stroke due to paramedic's initial evaluation of face, arm, and speech function will be diagnosed with audio-video-streaming of suspected stroke symptoms and signs
11202093|NCT03370081|Experimental|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
11202062|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
11202063|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
11202064|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
11202065|NCT03370276|Experimental|Phase I - Affiliate Sites Only|"Nivolumab and dose escalation of Cetuximab.
~Dose Level 1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.
~Dose Level -1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
11202066|NCT03370276|Experimental|Phase I - Moffitt Site Only|"Nivolumab and dose escalation of Cetuximab.
~Dose Level 1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.
~Dose Level -1:
~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
11202067|NCT03370276|Experimental|Phase II - Affiliate Sites Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
11202068|NCT03370276|Experimental|Phase II - Moffitt Site Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
11202069|NCT03370263||Benlysta intravenous (IV)|This arm will include subjects who will receive Benlysta IV. Observation period per subject will be for 52 weeks from start of Benlysta administration.
11202070|NCT03370263||Benlysta subcutaneous (SC)|This arm will include subjects who will receive BENLYSTA SC. Observation period per subject will be for 52 weeks from start of Benlysta administration.
11202071|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11202072|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11202073|NCT03370211|Experimental|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
11202074|NCT03370211|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
11202075|NCT03370198|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
11202076|NCT03370198|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
11202077|NCT03370198|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
11202078|NCT03370185|Experimental|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
11202079|NCT03370172|Experimental|Cohort 1|Cohort 1 participants will receive a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0 x 10^12 capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).
11202080|NCT03370172|Experimental|Cohort 2|Cohort 2 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 6.0 x 10^12 cp/kg on the day of dosing (Day 0).
11202081|NCT03370172|Experimental|Cohort 3|Cohort 3 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 1.2 x 10^13 cp/kg on the day of dosing (Day 0).
11202082|NCT03370159|Experimental|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11202083|NCT03370146||TKA patients - Experimental Group|
11202084|NCT03370146||TKA patients - Control Group 1|
11202085|NCT03370146||Healthy subjects - Control Group 2|
11202086|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
11202087|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
11202088|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
11202089|NCT03370120|Experimental|Padsevonil|"Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study.
~Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available."
11202090|NCT03370107|Active Comparator|Active rTMS and H coil|
11202091|NCT03370107|Placebo Comparator|sham rTMS and Hcoil|
11202094|NCT03370081|No Intervention|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
11202095|NCT03370068|Experimental|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
11202096|NCT03370068|Active Comparator|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
11202097|NCT03370055|Active Comparator|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
11202098|NCT03370055|Placebo Comparator|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
11202099|NCT03370042|Active Comparator|Semilunar Coronally Positiones Flap + Free Gingival Graft|semilunar coronally positioned flap with free gingival graft for root coverage
11202100|NCT03370042|Sham Comparator|Semilunar Coronally Positioned Flap|semilunar coronally positioned flap alone without free gingival graft for root coverage
11202101|NCT03370029||Primary ciliary dyskinesia patients|Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
11202102|NCT03370029||Healthy individuals|Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.
11202103|NCT03370016|Experimental|Reduction in pressure|This group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
11202104|NCT03370016|Active Comparator|Stand Amount of Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
11202105|NCT03369990|Experimental|Botulinum toxin type A|DWP450
11202106|NCT03369990|Placebo Comparator|Placebo|Normal Saline
11202107|NCT03369977|Experimental|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
11202108|NCT03369977|Other|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
11202109|NCT03369964|Experimental|Atezolizumab + Emactuzumab|Participants will receive Atezolizumab and Emactuzumab on Day 1 of each 21- day cycle
11202110|NCT03369964|Active Comparator|Atezolizumab + Emactuzumab + Obinutuzumab|"Participants will receive Atezolizumab, Emactuzumab, and Obinutuzumab on Day 1 of each- 21 day cycle (starting in cycle 2)
~(Atezolizumab starting in cycle 2); and Obinutuzumab on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2-8."
11202111|NCT03369951|Experimental|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
11202112|NCT03369938|Experimental|exercise training intervention|
11202113|NCT03369938|No Intervention|usual care|
11202114|NCT03369925|Placebo Comparator|Placebo|
11202115|NCT03369925|Experimental|Cognizin|
11202116|NCT03369912|Experimental|Active|CSJ148
11202117|NCT03369912|Placebo Comparator|Placebo|5% dextrose
11202118|NCT03369886|Other|Early glaucoma group|Patients whose visual field mean deviation is > -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
11202119|NCT03369886|Other|Advanced glaucoma group|Patients whose visual field mean deviation is < -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
11202120|NCT03369873|Experimental|Nursing Orientation with guidance manual|The patients received the nursing orientation with validated guidance manual of cardiac catheterization.
11202121|NCT03369873|No Intervention|Routine Nursing Orientation|The patients received the routine nursing orientation about cardiac catheterization.
11202122|NCT03369860|Experimental|Healthy Subjects|Healthy Subjects take part in the experimental manipulation
11202123|NCT03369847|Experimental|Inhaled Corticosteroids|"Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.
~Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
11202124|NCT03369847|No Intervention|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
11202125|NCT03369834|No Intervention|Control Group|the volunteers of this group will not be submitted to the intervention.
11202126|NCT03369834|Experimental|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
11202127|NCT03369834|Active Comparator|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
11202128|NCT03369834|Active Comparator|LED group mixed|in the volunteers of this group will be applied Infrared and Red Light-emitting diode device with the wavelength of 940nm and 620nm throughout the tibialis anterior muscle and bilateral sural triceps.
11202129|NCT03369834|Placebo Comparator|Sham Group|LED device off.
11202130|NCT03369821||Study 1: Existing EET1D (Case)|"Aged 0 to 70 years
~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)
~Negative genetic test for mutations causing non-autoimmune neonatal diabetes if diagnosed <12 months
~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)."
11202131|NCT03369821||Study 1: T1D (Control)|"Age 0-70 years (matched to above)
~Clinical diagnosis of T1D (diagnosed age 1-20 years)
~Insulin treated from diagnosis."
11202132|NCT03369821||Study 2: Newly diagnosed EET1D (Case)|"Aged 0 to 24 months at recruitment
~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)
~Negative genetic test for mutations causing non-autoimmune neonatal diabetes
~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)"
11202133|NCT03369821||Study 2: NDM (Control)|"Diagnosis of diabetes <24 months
~Age 0 to 24 months at recruitment
~Diagnosis of NDM (confirmed by Exeter Molecular Genetics Laboratory)."
11202134|NCT03369808|Experimental|7.5μg H7N9 Vaccine|Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
11202135|NCT03369808|Experimental|15μg H7N9 Vaccine|Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
11202136|NCT03369808|Experimental|30μg H7N9 vaccine|Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
11202137|NCT03369808|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
11202138|NCT03369808|Placebo Comparator|Phosphate buffer solution|Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
11202139|NCT03369795|Experimental|Study Drug|Methotrexate 10mg
11202140|NCT03369795|Placebo Comparator|Placebo|Pills equivalent to other study arm (10 mg)
11202141|NCT03369782|Placebo Comparator|Placebo|Placebo alternative for rocuronium and for sugammadex
11202142|NCT03369782|Active Comparator|Rocuronium|Rocuronium as bolus and in syringe pump Sugammadex just before reduction of the joint
11202143|NCT03369769|Experimental|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine & handler
11202144|NCT03369769|Active Comparator|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy & handler
11202145|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
11202146|NCT03369717|Experimental|Antibiotics|To receive postoperative antibiotics
11202147|NCT03369717|No Intervention|No antibiotics|Will not receive any postoperative antibiotics
11202148|NCT03369704|Experimental|Omalizumab|Eligible patients randomized to this arm received omalizumab subcutaneously for 12 weeks
11202149|NCT03369704|Placebo Comparator|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 12 weeks
11202150|NCT03369665|Experimental|Mavenclad®|
11202151|NCT03369652|Experimental|Intervention|Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
11202152|NCT03369652|No Intervention|Control|Medication history by pharmaconomist. Usual care by physicians.
11202153|NCT03369626|Other|FareWell Program|All participants receive the FareWell Program intervention in this evaluation study
11202154|NCT03369613|Active Comparator|MRI - HC tDCS|Healthy controls in Phase 1 transcranial electrical stimulation set to direct current
11202155|NCT03369613|Active Comparator|MRI - HC tACS|Healthy controls in Phase 1- transcranial electrical stimulation set to alternating current
11202156|NCT03369613|Active Comparator|MRI - CD tCDS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to direct current
11202157|NCT03369613|Active Comparator|MRI - CD tACS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to alternating current
11202158|NCT03369613|Active Comparator|Phase II - Stim|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is active
11202159|NCT03369613|Sham Comparator|Phase II - Sham|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is sham
11202160|NCT03369600|Experimental|Healthy Controls|Women Supersonic Imagine Aixplorer SWE Ultrasound Imaging on two separate occasions.
11202161|NCT03369600|Experimental|FIB-Sx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to elective hysterectomy for treatment of symptomatic uterine fibroids.
11202162|NCT03369600|Experimental|FIB-Mx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to and at two points during elective medical therapy for treatment of symptomatic uterine fibroids.
11202163|NCT03369587|Experimental|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
11202164|NCT03369587|Active Comparator|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
11202165|NCT03369574||chronic rhinosinusitis and eosinophilic asthma|Adults over the age of 18, diagnosed with poorly controlled moderate to severe asthma with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment) who are initiating/undergoing reslizumab therapy and also carry a physician diagnosis of chronic rhinosinusitis with nasal polyposis
11202166|NCT03369561||normal cardiac patient|"Full history and clinical examination ECG on the left and right side Echocardiography and measurement of both left and right ventricular functions Laboratory investigation including cardiac enzymes, CK, CK MB, and cardiac troponin I.
~Serum urea and creatinine and the calculated e GFR"
11202167|NCT03369548|Experimental|Apple/ Polyphenol|Participants will be asked to consume 2 Renetta Canada apples (with skin) and 2 placebo capsules every day for 8 weeks.
11202168|NCT03369548|Experimental|Oats / Prebiotic|Participants will be asked to consume 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
11202169|NCT03369548|Experimental|Lactobacillus reuteri NCIMB 30242 / Probiotic|Participants will be asked to consume 2 probiotic capsules and 40g cornflakes with semi-skimmed milk every day for 8 weeks.
11202170|NCT03369548|Placebo Comparator|Placebo / cornflakes|Participants will be asked to consume 40g cornflakes with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
11202171|NCT03369535|Placebo Comparator|Baseline|Baseline corresponds to typical American diet
11202172|NCT03369535|Active Comparator|PROT rich diet|Protein rich diet for 6 weeks
11202174|NCT03369535|Active Comparator|CARB rich diet|CARB rich diet for 6 weeks
11202175|NCT03369522||Construction|100 recordings that will be used for the algorithm development
11202176|NCT03369522||Validation|100 recordings for the validation of the algorithm
11202177|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
11202178|NCT03369496||MoNNET-HA Panel|Adults 25 years and older residing in the Montreal Metropolitan Area
11202179|NCT03369483||CPAP|At the end of the abdominal surgical procedure, mechanical ventilation withdrawal and extubation, patients will receive Continuous Positive Airway Pressure CPAP). CPAP will be be delivered using any commercially available CPAP equipment. CPAP will be started as soon as possible after the end of surgery. The starting airway pressure (PEEP) will be 5 cmH2O. PEEP may be changed at the discretion of the responsible physician. The maximum permissible PEEP during the trial intervention period will be 10 cmH2O. CPAP may be continued after the four-hour trial intervention period has finished, at the discretion of the responsible physician.
11202180|NCT03369470|Experimental|App Dexterity|
11202181|NCT03369470|Active Comparator|Theraband|
11202182|NCT03369444|Experimental|FLT180a Treatment|Participants receiving gene therapy vector
11202183|NCT03369431|Other|Group A|Group A starts with Vivomixx probiotic for the first 12 weeks then crosses over to have the placebo after a 4-week washout.
11202184|NCT03369431|Other|Group B|Group B starts with the placebo for the first 12 weeks then crosses over to have Vivomixx probiotic after a 4-week washout.
11202185|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
11202186|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
11202187|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
11202188|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
11202189|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
11202190|NCT03369392|Experimental|Feasibility Cycle 1|Participants use the initial PANDA application.
11202191|NCT03369392|Experimental|Feasibility Cycle 2|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1.
11202192|NCT03369392|Experimental|Feasibility Cycle 3|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1 and 2.
11202193|NCT03369379|Active Comparator|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
11202194|NCT03369379|Placebo Comparator|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
11202195|NCT03369366|Experimental|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
11202196|NCT03369340|Active Comparator|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
11202197|NCT03369340|Active Comparator|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
11202198|NCT03369340|Active Comparator|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
11202199|NCT03369340|Active Comparator|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
11202200|NCT03369340|Active Comparator|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
11202201|NCT03369340|Active Comparator|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:
~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
11202202|NCT03369327|Experimental|sofosbuvir/daclatasvir|Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic
11202203|NCT03369314||Patients Receiving octaplasLG®|The data will be collected in all patients who have received at least one infusion of octaplasLG®
11202204|NCT03369301||Gammanorm|Patients on Gammanorm per standard of care
11202205|NCT03369301||Other Subcutaneous Immunoglobulin|Patients on subcutaneous immunoglobulin treatments other than Gammanorm
11202206|NCT03369275|Experimental|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
11246000|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
11202207|NCT03369275|Placebo Comparator|Placebo|Intravenous infusion of Placebo, with excipients
11202208|NCT03369262|Experimental|Active|"OBE022 plus atosiban:
~OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start.
~Loading dose: 1 000 mg on Day 1.
~Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2.
~Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7)
~Atosiban will be administered over 48h as per label."
11202209|NCT03369262|Active Comparator|Placebo|"OBE022 matching placebo plus atosiban:
~OBE022 matching placebo administration will follow the same regimen as the active group.
~Atosiban will be administered over 48h as per label."
11202210|NCT03369249|Experimental|Link2CARE|This arm is comprised of participants randomized to the 4-session Link2CARE intervention.
11202211|NCT03369249|No Intervention|Standard of Care|This arm is comprised of participants who will not receive the 4-session Link2CARE intervention.
11202212|NCT03369236|Placebo Comparator|Placebo|Placebo tablets 3 times daily (TID) for the first 2 weeks (Dose Adjustment Period) with the opportunity for dose adjustment, then continued for an additional 6 months (Treatment Period). At the time of treatment completion, drug will be tapered as appropriate.
11202213|NCT03369236|Experimental|ACH-0144471|ACH-0144471 tablets at a starting dose of 100 mg TID for the first 2 weeks (Dose Adjustment Period) with the opportunity for dose adjustment, then continued for an additional 6 months (Treatment Period). At the time of treatment completion, drug will be tapered as appropriate.
11202214|NCT03369223|Experimental|Part 1A: BMS-986249|
11202215|NCT03369223|Experimental|Part 1B: BMS-986249+nivolumab (nivo)|
11202216|NCT03369223|Experimental|Part 2A Arm A: BMS-986249+nivo then nivo|
11202217|NCT03369223|Experimental|Part 2A Arm B: BMS-986249+nivo|
11202218|NCT03369223|Experimental|Part 2A Arm C: BMS-986249+nivo|
11202219|NCT03369223|Experimental|Part 2A Arm D: ipilimumab+nivo then nivo|
11202220|NCT03369223|Experimental|Part 2A Arm E: Nivo|
11202221|NCT03369210|Experimental|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
11202222|NCT03369210|Active Comparator|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
11202223|NCT03369197|Experimental|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
11202224|NCT03369197|Active Comparator|Control: Nasal cannula|Nasal Cannula with standard care
11202225|NCT03369184|Experimental|Supplemental oxygen|Inhalation of oxygen 6 L/min through an open face mask
11202226|NCT03369184|Sham Comparator|Ambient air|Breathing ambient air through an open face mask
11202227|NCT03369171|Experimental|patients with MYO armband|
11202228|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
11202229|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
11202230|NCT03369145|Experimental|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
11202231|NCT03369145|No Intervention|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
11202232|NCT03369132|Experimental|Angiflash|
11202233|NCT03369132|Placebo Comparator|Placebo|
11202234|NCT03369119|Active Comparator|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
11202235|NCT03369119|Placebo Comparator|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
11202236|NCT03369106||Multiple Sclerosis siblings|Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects
11202237|NCT03369093|Active Comparator|Ampicillin arm|Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days
11202238|NCT03369093|Experimental|Amoxicillin arm|Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days
11202239|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
11202240|NCT03369067|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
11202241|NCT03369067|Placebo Comparator|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
11202242|NCT03369054|Experimental|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
11202378|NCT03368066|Experimental|Hospitalized cirrhosis patients|Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency
11202243|NCT03369054|Active Comparator|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
11202244|NCT03369028||2d and 3D image|A 2D and 3D image of the participants' face will be taken. It will at least last 2-3 sec.
11202245|NCT03369015|Experimental|Placebo, then 10 mg d-amphetamine, then 20mg d-amphetamine|
11202246|NCT03369015|Experimental|Placebo, then 20 mg d-amphetamine, then 10mg d-amphetamine|
11202247|NCT03369015|Experimental|10 mg d-amphetamine, then placebo, then 20mg d-amphetamine|
11202248|NCT03369015|Experimental|10 mg d-amphetamine, then 20mg d-amphetamine, then placebo|
11202249|NCT03369015|Experimental|20 mg d-amphetamine, then 10mg d-amphetamine, then placebo|
11202250|NCT03369015|Experimental|20 mg d-amphetamine, then placebo, then 10mg d-amphetamine|
11202251|NCT03369002|Experimental|Normal|"Child-Pugh Score: N/A
~Subjects will receive a single 10 mg oral dose of seladelpar"
11202252|NCT03369002|Experimental|Mild Impairment|"Child-Pugh Score: A (5 to 6 points)
~Subjects will receive a single 10 mg oral dose of seladelpar"
11202253|NCT03369002|Experimental|Moderate Impairment|"Child-Pugh Score: B (7 to 9 points)
~Subjects will receive a single 10 mg oral dose of seladelpar"
11202254|NCT03369002|Experimental|Severe Impairment|"Child-Pugh Score: C (10 to 15 points)
~Subjects will receive a single 10 mg oral dose of seladelpar"
11202255|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
11202256|NCT03368976||Interscalene|
11202257|NCT03368976||Supraclavicular|
11202258|NCT03368976||Infraclavicular|
11202259|NCT03368976||Transversus Abdominus Plane|
11202260|NCT03368976||Paravertebral Space|
11202261|NCT03368976||Fascia Iliaca|
11202262|NCT03368976||Femoral Nerve|
11202263|NCT03368976||Saphenous Nerve via Adductor Canal|
11202264|NCT03368976||Popliteal Sciatic Nerve|
11202265|NCT03368963|Experimental|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Cycles repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11202266|NCT03368950|Experimental|Intervention|Participants in this arm are invited to undertake an 8-week online mindfulness course
11202267|NCT03368950|Active Comparator|Wait list|Participants in this arm are informed they are on a wait list and are required to wait 8 weeks, before being invited to take part in the intervention itself (an 8-week online mindfulness course).
11202268|NCT03368937|Experimental|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
11202269|NCT03368924|Other|SCA patients (SS genotype)|"To compare the level of anti band 3 antibodies in steady state and during vaso-occlusive crises in SCA patients.
~To assess the relationship between level of biomarkers of oxidation of SS RBCs, altered hemorheological parameters, biomarkers of cellular activation (microparticles) and anti band 3 antibodies rate, taking into account the alpha-globin genes status.
~To study the relationship between level of anti band 3 antibodies and severity of these VOC using an index of clinical severity (IS2) calculated at the end of SCA patients hospitalization for VOC.
~To study early clinical (including the activity of the autonomic nervous system activity) and biological items to evaluate the relationship between these items and severity of VOC."
11202270|NCT03368911|Experimental|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
11202271|NCT03368911|Active Comparator|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
11202272|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
11202273|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
11202274|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
11202275|NCT03368885|Experimental|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:
~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
11202276|NCT03368885|No Intervention|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
11202277|NCT03368872|Experimental|Astaxanthin and exercise|Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
11202278|NCT03368872|Placebo Comparator|Placebo and exercise|Placebo intake for one month followed by 3-month exercise training with placebo intake.
11202279|NCT03368859|Experimental|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
11202280|NCT03368859|Active Comparator|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
11202281|NCT03368846|Experimental|[14C]-Varlitinib|
11202282|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
11202283|NCT03368833||Control|Patients who do not receive a caudal block.
11202284|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
11202285|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
11202286|NCT03368794|Experimental|Intervention|Telephone alert signal from ambulance staff to out-patient substance use disorder treatment facility, for active outreach aiming to locate and include the patient in long-term evidence-based treatment for the substance use disorder.
11202287|NCT03368794|Active Comparator|Control|Information-only. Ambulance staff hand over written information to the individual about how to seek treatment for the substance use disorder.
11202288|NCT03368781|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
11202289|NCT03368768||Contact group email of Mahidol-Oxford Research Unit (MORU)|The investigator aims to have at least 100 adult people who could provide information for the total of one year. This expects that at least 20 of those 100 people would have common cold or diarrhea at least one time over one year period. This should provide more than 80% power to detect whether the proportion of having antibiotics when they have common cold or diarrhea was lower than 50% or not. The hypothesized proportion was 20% as stated by the national strategy against AMR in Thailand
11202290|NCT03368755|Experimental|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
11202291|NCT03368755|Active Comparator|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with cases.
~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
11202292|NCT03368742|Experimental|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
11202293|NCT03368742|Experimental|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
11202294|NCT03368742|No Intervention|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
11202295|NCT03368729|Experimental|Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
11202296|NCT03368729|Experimental|Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
11202297|NCT03368729|Experimental|Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
11202298|NCT03368716|Experimental|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
11202299|NCT03368703|Experimental|COPD patients|COPD patients group
11202300|NCT03368703|Active Comparator|Healthy subjects|Healthy subject group, matched with COPD patients group on age, weight and BMI
11202301|NCT03368690|Experimental|Oligopin®|"Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.
~Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; > 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; > 60 kg body weight: 150 mg Oligopin®/day"
11202302|NCT03368690|Placebo Comparator|Placebo|Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )
11202303|NCT03368677||Teriflunomide group|20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.
11202304|NCT03368677||No disease modifying treatment|10 MS-patients who do not use any regular disease modifying MS treatment of their own volition
11202305|NCT03368664|Experimental|alemtuzumab|- alemtuzumab - Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, prednisolone, H1 antagonist [antihistamine], H2 antagonist, paracetamol, acyclovir) will be administered prior alemtuzumab administration. - Type: Experimental
11202306|NCT03368651|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
11202307|NCT03368651|No Intervention|control group|no neo-adjuvant treatment before operation
11202308|NCT03368638|Experimental|Intervention|
11202309|NCT03368625|Other|Arm 1|Neoadjuvant SRS
11202310|NCT03368599|Experimental|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
11202311|NCT03368599|Active Comparator|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
11202312|NCT03368573|No Intervention|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
11202313|NCT03368573|Experimental|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
11202314|NCT03368560|Active Comparator|Sudarshan Kriya Yoga|Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
11202315|NCT03368560|No Intervention|Control|The seven recruited age-matched controls will complete a screening appointment and an MRI only for comparison. Demographic information will also be collected from the control participants. These individuals will not undergo the study intervention.
11202316|NCT03368547|Experimental|Diagnostic (68Ga-PSMA-11, PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo a single PET/CT scan over 45-60 minutes at week 1
11202317|NCT03368534|Experimental|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
11202318|NCT03368521|Other|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
11202319|NCT03368521|No Intervention|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
11202320|NCT03368508|Experimental|Experimental group|the real-object rotatable 3D images were used in demonstrating these three techniques. The photogrammetry technique was used to produce the 3D images.
11202321|NCT03368508|Active Comparator|Control group|The control group received similar materials, but the only difference was that all the images were two-dimensional.
11202322|NCT03368495|Experimental|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
11202323|NCT03368495|Active Comparator|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
11202324|NCT03368495|Active Comparator|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
11202325|NCT03368482|Experimental|Brain Gym Exercises|Brain Gym® (BG) is a movement-based program originally designed to improve learning capabilities through the performance of mind-body exercises. BG can be considered as an interesting field of research due to the need of identifying novel therapies which might be more pleasant for older adults who tend not to be prone to participating in conventional exercise programs and might have a positive effect on their cognitive function. In spite of this, scientific evidence regarding the effects of BG on people with cognitive impairment is scarce.
11202326|NCT03368482|Active Comparator|Standard Exercises|A traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
11202327|NCT03368469|Experimental|transcranial direct current stimulation|Transcranial direct current stimulation (35 sq cm anode over left dorsolateral prefrontal cortex, 35 sq cm cathode over right supraorbital area, 1 mA current, 20 min per treatment session, 1 session per day, 10 treatment sessions over two weeks)
11202328|NCT03368456|Experimental|S4E App Intervention|Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles
11202329|NCT03368456|Placebo Comparator|Usual Care Condition|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
11202330|NCT03368443|Active Comparator|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
11202331|NCT03368443|Experimental|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
11202332|NCT03368430|Experimental|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
11202333|NCT03368430|Placebo Comparator|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
11202334|NCT03368417|Active Comparator|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
11202335|NCT03368417|Experimental|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
11202336|NCT03368417|Experimental|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
11202337|NCT03368404|Experimental|CBL-102 eye drops|CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides
11202338|NCT03368404|Active Comparator|Vismed Multi eye drops|CE marked medical device, tear substitute containing 0.18% sodium hyaluronate
11202339|NCT03368391|Other|Sequence 1|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.
~Sequence 1 participants will receive the drugs in the following sequence: 1) tetracaine HCl and oxymetazoline HCl 2) 3% mepivacaine 3) 2% lidocaine with 1:100,000 epi"
11202340|NCT03368391|Other|Sequence 2|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.
~Sequence 2 participant will receive the drugs in the following sequence: 1) 2% lidocaine with 1:100,000 epi 2) tetracaine HCl and oxymetazoline HCl 3) 3% mepivacaine"
11202341|NCT03368391|Other|Sequence 3|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.
~Sequence 3 participants will receive the drugs in the following sequence: 1) 3% mepivacaine 2) 2% lidocaine with 1:100,000 epi 3) tetracaine HCl and oxymetazoline HCl"
11202342|NCT03368378|Experimental|Group 1|During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
11202379|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
11202380|NCT03368027|Experimental|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
11202343|NCT03368378|Active Comparator|Group 2|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
11202344|NCT03368365|Other|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
11202345|NCT03368352|No Intervention|Normoxia|Sleep in normal room air with no drug
11202346|NCT03368352|Placebo Comparator|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
11202347|NCT03368352|Experimental|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
11202348|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.045%)|topical Ophthalmic Drops (0.045%)
11202349|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.06%)|topical Ophthalmic Drops (0.06%)
11202350|NCT03368339|Placebo Comparator|Vehicle|Placebo
11202351|NCT03368313|Experimental|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
11202352|NCT03368313|No Intervention|Control arm|No compression
11202353|NCT03368300|Other|Patients|Parkinson's patient
11202354|NCT03368300|Other|witnesses: without parkinson's disease|Subjects without parkinson's disease
11202355|NCT03368287|Experimental|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
11202356|NCT03368274|Experimental|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
11202357|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
11202358|NCT03368248||All neonatal resuscitation services.|All professionals in contact with children were interviewed: doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical.
11202359|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
11202360|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
11202361|NCT03368209|Experimental|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:
~Optical Coherence Tomography (OCT)
~Optical screening on measuring site with WM3.4.
~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
11202362|NCT03368209|Experimental|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.
~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
11202363|NCT03368209|Experimental|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.
~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
11202364|NCT03368196|Experimental|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
11202365|NCT03368183|Experimental|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
11202366|NCT03368183|Active Comparator|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
11202367|NCT03368170|Experimental|Mesdopetam (IRL790)|Capsule 2.5 mg, oral administration
11202368|NCT03368170|Placebo Comparator|Placebo|Identical capsule, oral administration
11202369|NCT03368144|Experimental|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
11202370|NCT03368131|Experimental|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
11202371|NCT03368131|Active Comparator|XELOX and radiotherapy|Capecitabine：825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
11202372|NCT03368118|Experimental|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 12 months.
11202373|NCT03368105|Experimental|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
11202374|NCT03368105|Placebo Comparator|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
11202375|NCT03368092|Experimental|Dornase alfa|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
11202376|NCT03368092|Placebo Comparator|Placebo|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
11202377|NCT03368079|Experimental|Negative Pressure Suction Device|
11246226|NCT03065491|Placebo Comparator|Placebo|Placebo
11202381|NCT03368027|Active Comparator|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
11202382|NCT03368014|Experimental|Lyrics-writing and singing show|The one-hour lyrics-writing and singing workshop was conducted first at the beginning of the programme for the intervention group, followed by two small workshops teaching lyrics-writing skills and the lyrics-writing competition after the workshop. A lyrics writing and singing show and an award ceremony will be held at the end.
11202383|NCT03368014|No Intervention|Waitlist control|The workshops will not be provided to the control schools during the evaluation period and will be provided after the evaluation period.
11202384|NCT03368001|Experimental|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
11202385|NCT03368001|Active Comparator|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
11202386|NCT03367988|Experimental|Opioid-free Anesthesia|Patients will receive no intraoperative narcotics as part of their anesthesia regimen
11202387|NCT03367988|Active Comparator|Opioid Anesthesia|Patients will receive intraoperative narcotics as part of their anesthesia regimen
11202388|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
11202389|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
11202390|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
11202391|NCT03367949|No Intervention|Accuracy of surgical guide from Model optical scan|
11202392|NCT03367949|Active Comparator|Accuracy of surgical guide from Impression inversion Technique|
11202393|NCT03367936|Active Comparator|Self-monitoring group|All subjects will use a smartphone to self-monitor diet and monitor physical activity (Fitbit Charge 2), and a Withings or Fitibit digital scale for weight. Following randomization, participants will be oriented to Self-monitoring and provided a tutorial with images shown on the laptop and devices as well as printed materials showing the screen shots. At baseline, each participant will have a one-on-one session with the project interventionist, which covers the core principles of behavioral weight loss. The participant also will be given personalized fat, calorie, and PA goals for weight loss and information about how to access the intervention materials from the Diabetes Prevention Program (DPP) online which is publicly available (https://www.diabetesprevention.pitt.edu/).
11202394|NCT03367936|Experimental|Self-monitoring+Feedback group|All subjects will be asked to do everything the self-monitoring group is asked to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. Messages will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
11202395|NCT03367923|Experimental|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
11202396|NCT03367923|Experimental|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
11202397|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
11202398|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
11202399|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
11202400|NCT03367884|Experimental|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
11202401|NCT03367884|Active Comparator|Radiotherapy group|Definitive radiotherapy (70Gy)
11202402|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).
11202403|NCT03367858|Experimental|Motivational Interviewing (MI)|
11202404|NCT03367858|Active Comparator|Brief Adolescent Mindfulness (BAM)|
11202405|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
11202406|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
11202407|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
11202408|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
11202409|NCT03367832||Paediatric surgical patients|All patients < 16 years, admitted to participating centres during the study period who undergo elective and non-elective surgery
11247149|NCT03059212|Sham Comparator|Sham rTMS|Sham stimulation
11202410|NCT03367819|Experimental|Phase 1: mCRPC/NSCLC|Isatuximab dose 1 and REGN2810 predefined dose
11202411|NCT03367819|Experimental|Cohort A-1: mCRPC, isatuximab and REGN2810 combination|Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
11202412|NCT03367819|Experimental|Cohort A-2: mCRPC, isatuximab monotherapy|Patients with mCRPC will be given isatuximab dose 2
11202413|NCT03367819|Experimental|Phase 2 Cohort B: NSCLC|Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
11202414|NCT03367819|Experimental|Phase 2 Cohort C: mCRPC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC
11202415|NCT03367819|Experimental|Phase 2 Cohort D: NSCLC|Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
11202416|NCT03367793|Experimental|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
11202417|NCT03367793|Experimental|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
11202418|NCT03367793|Experimental|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
11202419|NCT03367793|Experimental|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
11202420|NCT03367793|Experimental|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
11202421|NCT03367793|Experimental|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
11202422|NCT03367780||RT with curative intent for HNSCC|several schemes for radical (chemo)radiotherapy, administered in 30-35 fractions over 6-7 weeks
11202423|NCT03367767||1|Former AREDS2 and AREDS2 Follow-On participants
11202424|NCT03367754|Experimental|1|Single dose of 200 mg (IV infusion)
11202425|NCT03367754|Placebo Comparator|2|Single dose (IV infusion)
11202426|NCT03367741|Experimental|Arm A (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15, then on day 1 beginning cycle 5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11202427|NCT03367741|Experimental|Arm B (nivolumab)|Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11202428|NCT03367728|Placebo Comparator|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
11202429|NCT03367728|Experimental|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
11202430|NCT03367715|Experimental|Nivolumab + Ipilimumab + Short-course radiation therapy|within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1
11202431|NCT03367702|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
11202432|NCT03367702|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
11202433|NCT03367689|Experimental|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
11202434|NCT03367676|Experimental|Experimental Arm|12 weeks adjuvant docetaxel plus trastuzumab
11202435|NCT03367663|Experimental|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
11202519|NCT03366961|Other|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
11202591|NCT03366441|No Intervention|Control group|No intervention will be giving to this group.
11202436|NCT03367663|Experimental|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
11202437|NCT03367650|Other|ALS's patients in Guadeloupe and Martinique|"We shall determine:
~Impact of ALS in Guadeloupe and Martinique
~Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study
~The distribution of ALS various phenotypes in our population of patients.
~We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.
~Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease
~Search for possible environmental factors"
11202438|NCT03367637|Active Comparator|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).
~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
11202439|NCT03367637|Experimental|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
11202440|NCT03367611|Experimental|Immunochemical faecal occult blood test|All participants will collect a single faecal sample for haemoglobin measurement (immunochemical faecal occult blood test, iFOBT), and be examined by colonoscopy.
11202441|NCT03367598||Normal weight|nondiabetic and nonobese individuals (18.5 kg/m2 ≤ BMI < 25 kg/m2, n=349)
11202442|NCT03367598||Overweight|nondiabetic and nonobese individuals (25 kg/m2 ≤ BMI < 30 kg/m2, n=154)
11202443|NCT03367585|Experimental|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
11202444|NCT03367585|Placebo Comparator|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
11202445|NCT03367572|Experimental|Group I (netupitant/palonosetron hydrochloride, dexamethasone|Within 1 hour prior to chemotherapy, patients receive netupitant/palonosetron hydrochloride PO on day 1. Within 30 minutes prior to chemotherapy, patients also receive dexamethasone PO on days 1-4. Patients also receive placebo PO with chemotherapy Q8H on days 1-4.
11202446|NCT03367572|Experimental|Group II (net/pal hydro, dexa, prochlorperazine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive prochlorperazine PO Q8H and placebo PO with chemotherapy on days 1-4.
11202447|NCT03367572|Experimental|Group III (net/pal hydro, dexa, olanzapine, placebo)|Patients receive netupitant/palonosetron hydrochloride and dexamethasone as in Group I. Patients also receive olanzapine PO and placebo PO Q8H with chemotherapy on days 1-4.
11202448|NCT03367559|Experimental|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
11202449|NCT03367546|Experimental|rATG, FLU/CY/TBI, & Thiotepa|Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), & Thiotepa
11202450|NCT03367533|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
11202451|NCT03367533|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
11202452|NCT03367520|Experimental|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
11202453|NCT03367507|Experimental|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
11202454|NCT03367507|Active Comparator|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
11202455|NCT03367494|Other|Subjects with Cystic Fibrosis|Diagnostic
11202456|NCT03367494|Other|Healthy Volunteers|Diagnostic
11202457|NCT03367481|Active Comparator|Control - Toothbrush type: soft|The participants will use a toothbrush with soft bristles.
11202458|NCT03367481|Experimental|Test - Toothbrush type: medium|The participants will use a toothbrush with medium bristles.
11202459|NCT03367468|Active Comparator|Physiotherapy group|Strengthening and stretching exercises,cross friction massage (supervised by physiotherapist) Mobilization techniques Daily usage of prescribed orthotic insole
11202460|NCT03367468|Active Comparator|Home exercise group|Strenthening and stretching exercises Daily usage of prescribed orthotic insole
11202461|NCT03367468|No Intervention|Control group|Follow ups Daily usage of prescribed orthotic insole
11202462|NCT03367455||ARIC and JHS participants|A combined cohort of Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) participants
11202463|NCT03367429|Experimental|Exp 2 & 3 - Arm 1|"If within-subject design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM and one standard BT injection of of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic MGM.
~If between-subjects design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM."
11202464|NCT03367429|Experimental|Exp 2 & 3 - Arm 2|"If within-subject study design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM and one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic MGM.
~If between-subjects design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM."
11202465|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
11202466|NCT03367403|Experimental|LY3002813|LY3002813 administered intravenously (IV).
11202467|NCT03367403|Placebo Comparator|Placebo|Placebo administered IV.
11202468|NCT03367390|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
11202469|NCT03367377|Experimental|LY3209590|Escalating doses of LY3209590 administered by subcutaneous (SC) injection
11202470|NCT03367377|Active Comparator|Insulin glargine|Insulin glargine administered by SC injection
11202471|NCT03367364|Active Comparator|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
11202472|NCT03367364|Placebo Comparator|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
11202473|NCT03367351|Experimental|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
11202474|NCT03367351|Placebo Comparator|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
11202475|NCT03367338|Active Comparator|Group A|Participants in group A consumed a 2-day very low-phosphate diet with PPR of 8 mg/g, followed by a 5-day washout period in which they adhered to usual diets, and then consumed a 2-day low-phosphate diet with PPR of 10 mg/g.
11202476|NCT03367338|Active Comparator|Group B|Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.
11202477|NCT03367325|Experimental|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
11202478|NCT03367325|No Intervention|CDS-NVAF not-benefiting group|
11202479|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
11202480|NCT03367299|Experimental|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
11202481|NCT03367286||Computed Tomography Perfusion (CTP)|
11202482|NCT03367286||Magnetic Resonance Perfusion (MRP)|
11202483|NCT03367273|Experimental|vitiligo patients|
11202484|NCT03367273|Experimental|controls|
11202518|NCT03366974|Experimental|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2
~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9
~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
11202485|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,
~A smartphone-based symptom management app,
~A print and web-based symptom management toolkit,
~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences
~BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks
~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
11202486|NCT03367247|Other|Enhanced Discharge Planning (EDP)|"Medication education,
~Self-management strategies for symptoms,
~Skills training,
~A list of red flag symptoms and numbers for who to call"
11202487|NCT03367234|Experimental|Personalized Addiction-to-Health (PATH)|Cognitive Behavioral Therapy (CBT) sessions with a behavioral health consultant twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed weeks 27-52; Contingency management rewards for specified recovery behaviors which could include medication adherence, attendance at CB/RP sessions and/or CB/RP exercise participation; Medication-assisted treatment, either extended-release naltrexone once monthly or buprenorphine once daily; Peer recovery specialist support twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed for weeks 27-52; Psychiatric consultation as needed.
11202488|NCT03367234|Active Comparator|Standard Care|Treatment may differ slightly by treatment program, but addiction specialty Intensive Outpatient Treatment (ASAM Level 2.1) will generally include individual therapy sessions with a counselor 1 hour per week for week; Medication-assisted treatment, either extended-release naltrexone once monthly or suboxone once daily; Group therapy sessions 9 hours per week then decreasing to 3 hours per week; Psychiatric consultation as needed.
11202489|NCT03367221|Experimental|NAVA group|NAVA ventilation
11202490|NCT03367195|Active Comparator|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
11202491|NCT03367195|Experimental|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
11202492|NCT03367182||Weekly paclitaxel + bevacizumab|
11202493|NCT03367182||Topotecan + bevacizumab|
11202494|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
11202495|NCT03367169|Active Comparator|minimally invasive method|The patients are treated with minimally invasive method
11202496|NCT03367169|Active Comparator|open reduction method|The patients are treated with open reduction method
11202497|NCT03367156|Experimental|Group I (dexamethasone)|Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
11202498|NCT03367156|Active Comparator|Group II (placebo, dexamethasone)|Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
11202499|NCT03367143|Experimental|L-ICE|Lenalidomide 25mg/d po d1-10, Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3, Frequency every 21 days, Total cycles 4
11202500|NCT03367130|Experimental|Intervention|HIV-positive individuals will receive the standard HIV care following the national ART guidelines. In addition, the intervention group will receive mobile phone calls. A mobile phone reminder will be made two days prior to their scheduled appointment for pills pick up. Trained research assistants will remind them of their scheduled clinic appointment of pills pick up. If the first call is missed, the second call will be made within the same day, if the second call is also missed, the final call will be made next day. The intervention will be delivered over the period of six months. Outcome assessors will not be involved in the phone calls.
11202501|NCT03367130|Placebo Comparator|Control|Control group will also receive the standard HIV care following the national ART guidelines and phone calls educating them on healthy living. Phone calls will be made once a month.
11202502|NCT03367104||Normal healthy controls|
11202503|NCT03367104||Heart failure patients|
11202504|NCT03367091|Experimental|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:
~20-minute Ekso GT gait training with high swing assistance
~20-minute Ekso GT gait training with neutral swing assistance
~20-minute Ekso GT gait training with high swing resistance.
~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
11202505|NCT03367078||tDCS cohort|DOC patients treated according to usual care, plus anodal tDCS (prospective cohort)
11202506|NCT03367078||Historical control cohort|DOC patients treated according to usual care only (retrospective cohort of patients matched for demographic and clinical characteristics, admitted at the Montecatone Rehabilitation Institute no more than 3 years before the introduction of tDCS)
11202507|NCT03367065|Experimental|Dynamic contrast enhanced computerised tomography|
11202508|NCT03367052|Experimental|Two level Prodisc-C vivo|Two level Prodisc-C vivo cervical artificial disc replacement.
11202509|NCT03367052|Active Comparator|Hybrid|This group of patients will be treated with hybrid construct, i.e., one level of Prodisc-C vivo and one level of anterior cervical discectomy fusion (ACDF).
11202510|NCT03367039|Experimental|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
11202511|NCT03367039|Active Comparator|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
11202512|NCT03367026|Active Comparator|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
11202513|NCT03367026|No Intervention|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
11202514|NCT03367013|Experimental|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
11202515|NCT03367013|Sham Comparator|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
11202516|NCT03367000|Experimental|Ceprolac|Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months
11202517|NCT03367000|Placebo Comparator|Dietary counseling (DC)|Received standard diet counselling only for 6 months.
11202520|NCT03366935|Experimental|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
11202521|NCT03366935|Active Comparator|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
11202522|NCT03366935|Active Comparator|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
11202523|NCT03366922|Active Comparator|Control Arm|Participants will be on routine HAART only. No Artemisia Annua, Moringa oleifera will be given.
11202524|NCT03366922|Experimental|Intervention Arm 1|Participants will be given HAART and Artemisia annua leaf powder 4 g per day. They will only receive Artemisia Annua, Moringa oleifera will not be given.
11202525|NCT03366922|Experimental|Intervention Arm 2|Participants will be given HAART with Artemisia annua leaf powder of 4 grams per day and Moringa oleifera leaf powder of 10 grams per day. Both Artemisia Annua, Moringa oleifera will be given.
11202526|NCT03366909|Experimental|MBRP group|20 patients 2 groups of 10 patients
11202527|NCT03366909|Active Comparator|classic care in addictology center|20 patients
11202528|NCT03366896|Experimental|Delirium|Diagnosis of delirium according to 5th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by Psychiatrist.
11202529|NCT03366883|Experimental|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
11202530|NCT03366883|Experimental|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
11202531|NCT03366870|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
11202532|NCT03366870|Experimental|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
11202533|NCT03366857|Active Comparator|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
11202534|NCT03366857|Active Comparator|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
11202535|NCT03366844|Experimental|Pembrolizumab with RT Boost|"Study drug plus tumor boost before standard of care treatment"
11202536|NCT03366831|Active Comparator|15 minute version without questions|15 minute version of the TMW-Newborn intervention video without questions interspersed
11202537|NCT03366831|Active Comparator|15 minute version with questions|15 minute version of the TMW-Newborn intervention video with questions interspersed
11202538|NCT03366831|Active Comparator|7 minute version without questions|7 minute version of the TMW-Newborn intervention video without questions interspersed
11202539|NCT03366831|Active Comparator|7 minute version with questions|7 minute version of the TMW-Newborn intervention video with questions interspersed.
11202540|NCT03366818|Experimental|thrombectomy|thrombectomy by Versi system
11202541|NCT03366805|Active Comparator|Wound Care Video|Wound Care Patient Education Video
11202542|NCT03366805|Experimental|Pain Management Video Group|Pain Management Patient Education Video
11202543|NCT03366792|Experimental|MRI Targeted Biopsy|
11202544|NCT03366779|Other|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
11202545|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
11202546|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
11202547|NCT03366753|Experimental|Acute normovolemic hemodilution|acute normovolemic hemodilution by using hydroxyethyl starch
11202548|NCT03366753|Experimental|In-vitro hemodilution|adding additional hydroxyethyl starch for achieving further 30% dilution of whole blood sample which already underwent ANH of 4-6 ml/kg.
11202549|NCT03366740|Experimental|GB mixed full strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the GB mixed full strength rice suji.
~The allocated diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
11202550|NCT03366740|Experimental|Full strength rice suji alone|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.
11202551|NCT03366740|Active Comparator|3/4th strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.
11202552|NCT03366727|Experimental|DCB group|this group treated with drug coated balloon catheter, Orchid
11202553|NCT03366727|Experimental|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
11202554|NCT03366714|Experimental|RAM cannula|nasal CPAP support with RAM cannula
11202555|NCT03366714|Active Comparator|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
11202556|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
11202557|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
11202558|NCT03366688|Active Comparator|IBI306|Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
11202559|NCT03366688|Placebo Comparator|placebo|Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design
11202560|NCT03366675|Experimental|AZD2811|AZD2811 200mg IV QD CnD1 & D4 every 4weeks
11202561|NCT03366649|Other|UMA (Group 1)|Participants in the UMA group will receive an undersizing mitral annuloplasty (UMA).
11202562|NCT03366649|Other|UMA + PMA (Group 2)|Participants in the UMA + PMA group will receive an undersizing mitral annuloplasty (UMA) with papillary muscle approximation (PMA).
11202563|NCT03366649|No Intervention|Retrospectively identified patients|Retrospectively identified patients, who already underwent the standard of care surgery for the lesion of interest at Emory, within 6 months (± 1 month) after the date of their surgery, and are suitable for recruitment to the study for their post-operative research.
11202564|NCT03366636|No Intervention|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
11202565|NCT03366636|Experimental|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
11202566|NCT03366623|Other|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.
~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
11202567|NCT03366623|Other|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
11202568|NCT03366610||Patients Previously Treated with Daclatasvir-Based Regimens|Patients in China Previously Treated with Daclatasvir-Based Regimens
11202569|NCT03366597|Experimental|Sevoflurane|Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
11202570|NCT03366584|Experimental|Intervention|"beta carotene 25,000 IU
~vitamin D3 50,000 IU
~zinc 50 mg
~dexamethasone 6 mg"
11202571|NCT03366584|Active Comparator|Control|dexamethasone 6 mg
11202572|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
11202573|NCT03366571||Non anti-viral therapy group|History study from literature
11202574|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
11202575|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
11202576|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
11202577|NCT03366532||Nurses' Health Study|The NHS began in 1976 when 121,700 female nurses aged 33-55 years and residing in the United States responded to a baseline questionnaire.
11202578|NCT03366532||Nurses' Health Study II|The NHSII was initiated in 1989 with the recruitment of 116,671 younger female registered nurses, 24 to 44 years of age, from 14 states
11202579|NCT03366532||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was established in 1986 and was comprised of 51,529 US male health professionals ranging in age from 40 to 75 years at enrollment from 50 states
11202580|NCT03366519||patients with pulmonary embolism|patients with pulmonary embolism confirmed by tomography scan in emergency department
11202581|NCT03366506||ALS patients|"ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).
~Observation"
11202582|NCT03366493|Experimental|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
11202583|NCT03366493|Experimental|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
11202584|NCT03366493|Experimental|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
11202585|NCT03366480|Experimental|Endometrial cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
11202586|NCT03366480|Experimental|Squamous non-small cell lung cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
11202587|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
11202588|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
11202589|NCT03366441|Experimental|Telephone group|The telephone group received telephone calls. All non-response and refusing donors were included for further follow-up. Donors who answered the phone call and agreed to be interviewed were asked the reasons why they had stopped donating according to a pre-designed questionnaire. All of the responsed donors were re-recruited by altruistic appeal.
11202590|NCT03366441|Experimental|SMS group|"The SMS intervention group received the following text message:Dear donors, Thank you for your donation through which your love brought hope to those helpless patients and your donated blood reignited the fire in their lives. If you can, please consider donating blood again to save a life. Thank you again for your support! . All donors either receiving or not receiving the message were included for further follow-up."
11202592|NCT03366428|Experimental|All Participants|All participants will receive DS-8201a by intravenous infusion
11202593|NCT03366415|Experimental|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
11202594|NCT03366415|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
11202595|NCT03366402||Influenza A|
11202596|NCT03366402||Influenza B|
11202597|NCT03366389||Case|patients with irritable bowel syndrome
11202598|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
11202599|NCT03366376|Experimental|Experimental|WBRT with hippocampus-sparing and SIB
11202600|NCT03366363|Experimental|Electro-acupuncture|"5 compulsory acupoints (ST35、EX-LE5、LR8、GB33 and Ashi) and 3 optional matching acupoints (stomach meridian syndrome：ST34、ST36、ST32、ST40、EX-LE2；gallbladder meridian syndrome：GB31、GB36、GB34、GB39、GB41；bladder meridian syndrome：BL39、BL40、BL57、BL60；San Yin meridian syndrome：LR7、SP9、SP10、KI10、SP4、SP6、LR3、KI3) will be chosen. Needles will be stimulated manually to achieve De Qi sensation and an electrical apparatus (Nanjing Jisheng Medical Co., Ltd., wave of 2/100Hz) will be then connected to the needles with alligator clips in pairs LR8-GB33 and two other matching acupoints. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity. Patients will receive 30-minute, 24 sessions intervention over eight weeks."
11202601|NCT03366363|Experimental|manual acupuncture|Participants in the manual acupuncture group have the same schedule as the Electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
11202602|NCT03366363|Sham Comparator|sham acupuncture|Those in the sham acupuncture group receive shallow acupuncture at non-acupoints without manipulation，Deqi or actual current output.
11202603|NCT03366350|Experimental|Consolidative allo-HSCT following CAR-T therapy|Patients who had achieved MRD-negative complete remissions through CAR-T therapy (NCT02965092) will, on their own accord, receive allo-HSCT if there are no previous HSCT, contraindications, and other restrictions.
11202604|NCT03366337|Experimental|Patients with baseline ACR > 300 mg/g but ≤ 2,500 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, 20 mg at week 4, and then to 30 mg at Week 6.
11202605|NCT03366337|Experimental|Patients with baseline ACR ≤ 300 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2 and 20 mg at week 4.
11202606|NCT03366324|Experimental|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
11202607|NCT03366311|Active Comparator|holding position|different holding position of endotracheal tube
11202608|NCT03366311|Active Comparator|stylet shapes|banana shape versus straight-to-cuff shape
11202609|NCT03366311|Active Comparator|epiglottis lift|with epiglottis lift or without
11202610|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
11202611|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
11202612|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
11202613|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
11202614|NCT03366285||Fullterm infants|Quality of bonding is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from the local elementary school.
11202615|NCT03366285||Moderate to late preterm infants|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the trauma and depression in late preterm parents study (TraDelPP) conducted 2010 to 2011."
11202616|NCT03366285||Preterm infants with skin to skin contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the skin to skin contact group. The study was conducted from 2012 to 2015."
11202617|NCT03366285||Preterm infants with visual contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the visual contact group. The study was conducted from 2012 to 2015."
11202618|NCT03366272|Active Comparator|(R)-GemOx|eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)
11202619|NCT03366272|Experimental|Nivo-(R)-GemOx|eight cycles of nivolumab (3 mg/kg) plus (R)-GemOx in 2-wk intervals followed by additional 18 infusions of Nivolumab (3 mg/kg) in 2-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
11202620|NCT03366259|Active Comparator|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
11202621|NCT03366259|Placebo Comparator|Group B (control group)|No prostaglandins administration before cesarean section
11202622|NCT03366246|Active Comparator|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
11202623|NCT03366246|Placebo Comparator|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
11202624|NCT03366233|Experimental|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
11202709|NCT03365622|Active Comparator|IV acetaminophen and placebo pills|
11202625|NCT03366233|Placebo Comparator|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
11202626|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
11202627|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
11202628|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
11202629|NCT03366181||heart failure patients|
11202630|NCT03366168||Group 1|Ages 18-39 years
11202631|NCT03366168||Group 2|Ages 40-59 years
11202632|NCT03366168||Group 3|Ages 60 years and older
11202633|NCT03366155|Experimental|1/Arm 1|HAIP chemotherapy + Systemic chemotherapy
11202634|NCT03366142|Experimental|Single Arm|treatment with ustekinumab based on weight
11202635|NCT03366129||Cohort|Stroke patients with white matter hyperintensities (WMH)
11202636|NCT03366116|Experimental|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
11202637|NCT03366103|Experimental|Treatment (navitoclax, vistusertib)|Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11202638|NCT03366090||IBD patients|Biopsies for immunological analyses
11202639|NCT03366090||healthy controls|Biopsies for immunological analyses
11202640|NCT03366077|Active Comparator|Active|
11202641|NCT03366077|Placebo Comparator|Placebo|
11202642|NCT03366064|Experimental|Pemetrexed and donor NK cell infusion|Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion
11202643|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
11202644|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
11202645|NCT03366038||Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy is performed following pancreaticoduodenectomy.
11202646|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
11202647|NCT03366012|Other|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
11202648|NCT03365999|Active Comparator|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.
~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
11202649|NCT03365999|Experimental|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.
~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.
~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
11202650|NCT03365973||Spinal metastases of breast cancer|Patients with potentially unstable spinal metastases of breast cancer
11202651|NCT03365960|Active Comparator|Active1|watermelon rind
11202652|NCT03365960|Active Comparator|Active2|watermelon flesh
11202653|NCT03365960|Active Comparator|Active3|watermelon seeds
11202654|NCT03365960|Placebo Comparator|Control Comparator|placebo
11202655|NCT03365947|Active Comparator|ARO-HBV Injection|
11202656|NCT03365947|Placebo Comparator|Placebo|
11202657|NCT03365934|Experimental|ADHESIVE BANDAGE #1|bandage applied to wounded site.
11202658|NCT03365934|Experimental|ADHESIVE BANDAGE #2|bandage applied to wounded site.
11202659|NCT03365934|Experimental|ADHESIVE BANDAGE #3|bandage applied to wounded site
11202660|NCT03365934|Experimental|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
11202661|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
11202662|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
11202663|NCT03365921|Experimental|Hepatitis E vaccine lot 1|
11202664|NCT03365921|Experimental|Hepatitis E vaccine lot 2|
11202665|NCT03365921|Experimental|Hepatitis E vaccine lot 3|
11202666|NCT03365908|Experimental|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
11202667|NCT03365908|No Intervention|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
11202668|NCT03365895|Experimental|Diagnostic (non-enhanced MRI using MRN and DTI)|Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.
11247218|NCT03058757|No Intervention|Control arm|No intervention applied.
11202669|NCT03365882|Experimental|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11202670|NCT03365882|Experimental|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
11202671|NCT03365869|Active Comparator|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
11202672|NCT03365869|Placebo Comparator|placebo|sirolimus placebo: 2mg po. QD
11202673|NCT03365856||RA patients|As routinary clinical practice and observational study
11202674|NCT03365843|Experimental|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
11202675|NCT03365843|Active Comparator|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
11202676|NCT03365817|Experimental|Taper off|Decrease of opioid daily dose until discontinuation for up to six months.
11202677|NCT03365817|Active Comparator|Control Group|No changes on opioids and adjuvant medication for up to six months.
11202678|NCT03365804|Experimental|3D Printed Brace|This group will receive 3D printed brace
11202679|NCT03365804|No Intervention|Traditional Brace|This group will receive the traditional brace
11202680|NCT03365791|Experimental|PDR001+LAG525|"Patients with select solid tumors or hematological malignancies: Small cell lung cancer, Gastric adenocarcinoma, Esophageal adenocarcinoma, Castration resistant prostate adenocarcinoma, Soft tissue sarcoma, Ovarian adenocarcinoma, Advanced well-differentiated neuroendocrine tumors or Diffuse large B cell lymphoma
~PDR001 will be supplied as powder for solution for infusion. LAG525 will be supplied as a liquid formulation. PDR001 and LAG525 will be administered via i.v. infusion over 30 minutes once every 3 weeks. LAG525 will be given first followed by PDR001."
11202681|NCT03365778|Active Comparator|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
11202682|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
11202683|NCT03365778|Other|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
11202684|NCT03365765|Experimental|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
11202685|NCT03365765|Active Comparator|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
11202686|NCT03365752|Experimental|Chloroprocaine|
11202687|NCT03365752|Active Comparator|Mepivacaine|
11202688|NCT03365752|Active Comparator|General Anesthesia|
11202689|NCT03365739|Active Comparator|Active Comparator 1|Treatment - Mango (pulp/flesh-500 g)
11202690|NCT03365739|Active Comparator|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
11202691|NCT03365739|Placebo Comparator|Control Comparator|Vitamin C (100 mg)
11202692|NCT03365726|Experimental|DST (dobutamine-stress-test)|dobutamine stress echocardiography performed to patients undergoing major surgery
11202693|NCT03365726|No Intervention|NDST (no-dobutamine-stress-test)|patients refused the dobutamine stress test and transesophageal echocardiography measured the troponin level in first 24 hours after surgery
11202694|NCT03365700|Active Comparator|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
11202695|NCT03365700|Active Comparator|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
11202696|NCT03365687|Active Comparator|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
11202697|NCT03365687|Placebo Comparator|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
11202698|NCT03365674|Experimental|Vibration group|Vibrator head was applied (100Hz) on the popliteal fossa, during the trigger point injection
11202699|NCT03365674|Placebo Comparator|Placebo group|In placebo group, vibrator head was applied with switch-off sate, during the trigger point injection
11202700|NCT03365661|Experimental|ALT-803|
11202701|NCT03365648|Experimental|Lertal® + standard therapy|Lertal® double-layer tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
11202702|NCT03365648|Placebo Comparator|Placebo + standard therapy|Placebo tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
11202703|NCT03365635|Experimental|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
11202704|NCT03365635|Experimental|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
11202705|NCT03365635|Experimental|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
11202706|NCT03365635|Experimental|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
11202707|NCT03365635|Experimental|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
11202708|NCT03365635|Experimental|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
11202710|NCT03365622|Placebo Comparator|placebo IV (normal saline) + oral acetaminophen|
11202711|NCT03365609|Experimental|T-group|T-group(triple therapy)
11202712|NCT03365609|Experimental|S-group|S-group( sequential therapy)
11202713|NCT03365609|Experimental|B-group|B-group( bismuth quadruple therapy )
11202714|NCT03365609|Experimental|C-group|C-group( concomitant therapy)
11202715|NCT03365596||Subacute stroke|
11202716|NCT03365583||Vitamin B12 deficiency|"No intervention will be administered for this study. Serum vitamin B12 <203 pg/mL is considered as vitamin B12 deficiency.
~Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual"
11202717|NCT03365583||Vitamin B12 sufficient|Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
11202718|NCT03365557|Experimental|Intracuff pressure set by airway peak pressure|
11202719|NCT03365557|Other|Intracuff pressure set at 60 mmHg|
11202720|NCT03365544|Experimental|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
11202721|NCT03365544|Experimental|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
11202722|NCT03365531|Experimental|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
11202723|NCT03365531|Active Comparator|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
11202724|NCT03365518|Experimental|Cognitive Behavioural Therapy (CBT)|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
11202725|NCT03365518|Experimental|Mindfulness-Based Therapy|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
11202726|NCT03365518|No Intervention|Control - Usual Care|"Participants who are randomized to the control group will not receive mindfulness or CBT treatment. They will proceed with the course of treatment they were receiving prior to enrollment in the study. As resources for couples dealing with changes to their sexual lives after prostate cancer are limited, it is anticipated that the majority of these patients will have no treatment targeting sexual intimacy during the 6-week period between completing the first and second questionnaire.
~Those randomized to the control group will have the opportunity to be randomized to one of the treatment groups following their third and final questionnaire if they wish. In this case, they will be issued an additional participant ID within one of the treatment groups."
11202727|NCT03365492|Experimental|Treatment Arm|Patients with CAD who receive the BioFreedom™ Biolimus A9™ stent.
11202728|NCT03365479|Experimental|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
11202729|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
11202730|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
11202731|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
11202732|NCT03365466||Group D|Patients who did not receive any treatment.
11202733|NCT03365453|Experimental|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
11202734|NCT03365440||EP study with transseptal passage|"15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
~Focal pacing maneuvers"
11202735|NCT03365440||EP study without transseptal passage|- 15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
11202736|NCT03365440||Healthy participants|- 60 minute esophageal ECG (using esoECG-3D catheter) & respiration recording
11202737|NCT03365427|Experimental|Application Group|People in this arm will be introduced to an APP on smart phone, and receive lessons on how to use it on their own phones. The APP will be installed and prepare to use before surgery. People will be asked and monitored on-line to regularly use the APP.
11202738|NCT03365427|No Intervention|Convention Group|People in this arm receive exactly the same treatment and lessons on post-operative rehabilitation except the reach of the APP.
11202739|NCT03365414|Other|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
11202740|NCT03365414|Other|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
11202741|NCT03365401|Experimental|grade 1|Decompression surgery
11202742|NCT03365401|Active Comparator|grade 2|nonsurgical treatment
11202743|NCT03365388|Experimental|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
11202744|NCT03365388|Active Comparator|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
11202745|NCT03365375|Active Comparator|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
11202746|NCT03365375|Experimental|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
11202747|NCT03365362|Experimental|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
11202970|NCT03363763|Active Comparator|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
11202748|NCT03365362|Active Comparator|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
11202749|NCT03365362|Experimental|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
11202750|NCT03365362|Active Comparator|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
11202751|NCT03365349|Experimental|living theatre|One session consisting for the patient of telling a story about his/her own life with diabetes , which is first written and then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a little play.
11202752|NCT03365349|Active Comparator|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
11202753|NCT03365336|Experimental|Intervention Group|Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
11202754|NCT03365336|Active Comparator|Standard Care Group|Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
11202755|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
11202756|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
11202757|NCT03365310|Experimental|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
11202758|NCT03365310|Active Comparator|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
11202759|NCT03365297|Experimental|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
11202760|NCT03365284|Experimental|Smart Kneebrace|Smart Kneebrace with a smart phone app will be used during the rehabilitation after surgery for three months
11202761|NCT03365284|Placebo Comparator|without Smart Kneebrace|regular rehabilitation procedure will be applied after surgery
11202762|NCT03365271|Experimental|drainage|A drainage will be applied in this group.
11202763|NCT03365271|Active Comparator|without drainage|Non-drainage will be applied in this group.
11202764|NCT03365258|Other|High Nutritional Risk|modified NUTRIC score ≥ 5
11202765|NCT03365258|Other|Low Nutritional Risk|modified NUTRIC score < 5
11202766|NCT03365245|Other|study arm|Microperimetry and automated visual field are performed at three different days
11202767|NCT03365232|Experimental|non custom base attachment|
11202768|NCT03365232|Active Comparator|custom base attachment|
11202769|NCT03365219|Experimental|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
11202770|NCT03365219|Active Comparator|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
11202771|NCT03365180|Experimental|The Starter Kit Algorithm|Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
11202772|NCT03365167|Active Comparator|LANAP|LANAP (Laser Assisted New Attachment Procedure)
11202773|NCT03365167|Placebo Comparator|LANAP off|laser therapy in off mode
11202774|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
11202775|NCT03365141|Experimental|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
11202776|NCT03365141|Active Comparator|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
11202777|NCT03365115|Active Comparator|intrathecal fentanyl|
11202778|NCT03365115|Active Comparator|intrathecal morphine|
11202779|NCT03365115|Experimental|intrathecal morphine and fentantyl|
11202780|NCT03365102|Experimental|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
11202781|NCT03365102|Experimental|anodal tDCS over the lOFC|anodal tDCS over the lOFC
11202782|NCT03365102|Placebo Comparator|sham tDCS stimulation|sham tDCS stimulation
11202783|NCT03365089|Experimental|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
11202784|NCT03365089|No Intervention|Control|No collateral vein ligation.
11202785|NCT03365076|Experimental|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
11202786|NCT03365076|No Intervention|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
11202787|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
11202788|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
11202789|NCT03365037|Experimental|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
11202790|NCT03365037|Active Comparator|Fracture healing film|Patients with acute soft tissue injury treated with fracture healing film
11202791|NCT03365024|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
11202792|NCT03365024|Active Comparator|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
11202793|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.
~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
11202794|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.
~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
11202795|NCT03364998|Experimental|BAY94-9027 and Elocta|Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
11202796|NCT03364998|Experimental|Elocta and BAY94-9027|Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment
11202797|NCT03364985|Experimental|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
11202798|NCT03364985|Experimental|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
11202799|NCT03364985|Experimental|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
11202800|NCT03364985|Experimental|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
11202801|NCT03364985|Experimental|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
11202802|NCT03364985|Experimental|Cohort 6: DWP16001 Fmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
11202803|NCT03364985|Experimental|Cohort 7: DWP16001 Gmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
11202804|NCT03364985|Experimental|Cohort 8: DWP16001 Hmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
11202805|NCT03364985|Experimental|Cohort 9: DWP16001 Img|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
11202806|NCT03364985|Experimental|Cohort 10: DWP16001 Jmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
11202807|NCT03364972|Experimental|Experimental intraocular lens implant|'Alcon Clareon' : New monofocal, hydrophobic acrylic intraocular lens implant
11202808|NCT03364972|Active Comparator|Standard intraocular lens implant|Abbott Tecnis PCB00- Standard monofocal,hydrophobic acrylic intraocular lens implant
11202809|NCT03364959|Experimental|Flixotide|Patients inhale first Flixotide and then Qvar
11202810|NCT03364959|Experimental|Qvar|Patients inhale first Qvar and then Flixotide
11202811|NCT03364946||High Nasal Flow Therapy|Every patient in the ICU that requires High Nasal Flow Therapy
11202812|NCT03364933|Experimental|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
11202813|NCT03364933|No Intervention|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
11202814|NCT03364920||normal level of serum maresin-1|
11202815|NCT03364920||abnormal level of serum maresin-1|
11202816|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
11202817|NCT03364868|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
11202818|NCT03364868|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
11202819|NCT03364855|Active Comparator|SEBT exercise group|Star Excursion Balance Test will be used
11202820|NCT03364855|Active Comparator|KAT 2000 exercise group|Kinesthetic ability trainer will be used
11202821|NCT03364855|Active Comparator|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
11202822|NCT03364842|Experimental|F group|Furosemide group
11202823|NCT03364842|No Intervention|C group|Control group
11202824|NCT03364829|Experimental|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
11202825|NCT03364816||TDR with Prodisc-C|participant underwent total disc replacement with Prodisc-C artificial disc
11202826|NCT03364816||TDR with Mobi-C|participant underwent total disc replacement with Mobi-C artificial disc
11202827|NCT03364816||TDR with Prestige-LP|participant underwent total disc replacement with Prestige-LP artificial disc
11202828|NCT03364803||Participants with Cushing's Syndrome|
11202829|NCT03364790|Experimental|group1|participant with posterior lumbar interbody fusion(PLIF or PLF)
11202830|NCT03364790|Experimental|group2|participant with total knee arthroplasty (TKA)
11202831|NCT03364790|Experimental|group3|participant with PLIF and TKA on one stage
11202832|NCT03364790|No Intervention|group4|participant without operation
11202833|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
11202971|NCT03363763|Placebo Comparator|Arm 3|Placebo ointment applied topically hs x 12 weeks
11202834|NCT03364764|Experimental|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
11202835|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
11202836|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
11202837|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
11202838|NCT03364725|Experimental|Open Label Treatment Arm|Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients
11202839|NCT03364712||pregnant|Pregnant women receiving routine medical care, including venipuncture.
11202840|NCT03364712||non-pregnant|Women not pregnant receiving routine medical care, including venipuncture.
11202841|NCT03364699|Active Comparator|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
11202842|NCT03364699|Experimental|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
11202843|NCT03364686|Experimental|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
11202844|NCT03364673|Experimental|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
11202845|NCT03364660|Experimental|Voluntary Movement Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for voluntary movement.
11202846|NCT03364660|Experimental|Cardiovascular Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function.
11202847|NCT03364660|Experimental|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
11202848|NCT03364660|Experimental|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
11202849|NCT03364647|Experimental|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
11202850|NCT03364647|Sham Comparator|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
11202851|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
11202852|NCT03364608|Experimental|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
11202853|NCT03364608|Experimental|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
11202854|NCT03364608|Placebo Comparator|• Placebo MDI|(2 actuations)
11202855|NCT03364608|Active Comparator|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
11202856|NCT03364608|Active Comparator|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
11202857|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
11202858|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
11202859|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
11202860|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
11202861|NCT03364569||Participant with tranexamic acid.|The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
11202862|NCT03364569||Participant without tranexamic acid.|This group concerns participants followed without acid tranexamic treatment. Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
11202863|NCT03364543||Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
11202864|NCT03364543||Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
11202865|NCT03364530|Other|Gemcitabine-Oxaliplatin Regimen|
11202866|NCT03364517|Experimental|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
11202867|NCT03364517|No Intervention|Control group|The classic care will be made according to the usual practices of the doctor and the center.
11202868|NCT03364504|Experimental|PXE patients|urine collection and culture of renal cells
11202869|NCT03364491|Experimental|Tranexamic Acid|Tranexamic Acid for intravenous administration
11202870|NCT03364491|Placebo Comparator|Placebo|Normal saline for intravenous administration
11202972|NCT03363750|Experimental|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
11202871|NCT03364478|Experimental|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach. In DML group, the dissecting based on CME is performed with dorsal approach and medial approach hybridized.
11202872|NCT03364478|Active Comparator|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach. In MLA group,the dissecting based on CME is performed with meidial-to-lateral approach.
11202873|NCT03364465|No Intervention|GruopFix|one-lung ventilation with constant tidal volume
11202874|NCT03364465|Active Comparator|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
11202875|NCT03364439|Experimental|One arm for all patients|Patients eligible for the study will receive 6 courses of R-CHOP14 or R-CHOP21.
11202876|NCT03364413||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
11202877|NCT03364400|Experimental|VT1021|Escalating doses of VT1021 to determine RP2D
11202878|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
11202879|NCT03364374||Controls|Healthy controls with no history of stroke
11202880|NCT03364361|Other|Acupuncture|Feasibility Study
11202881|NCT03364348|Experimental|Cohort 1 (Ado-trastuzumab emtansine + utomilumab)|Utomilumab at escalating doses of 20 mg and 100 mg will be given intravenously in combination with the FDA-approved dose and schedule of ado-trastuzumab emtansine (3.6 mg/kg IV) every 3 weeks.
11202882|NCT03364348|Experimental|Cohort 2 (trastuzumab + utomilumab)|Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 2).
11202883|NCT03364335|Placebo Comparator|Placebo|Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
11202884|NCT03364335|Experimental|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
11202885|NCT03364335|Experimental|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
11202886|NCT03364335|Experimental|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
11202887|NCT03364335|Experimental|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
11202888|NCT03364322||Dry eye syndrome|
11202889|NCT03364309|Experimental|Ixekizumab Dose Schedule 1|Ixekizumab given subcutaneously (SC).
11202890|NCT03364309|Experimental|Ixekizumab Dose Schedule 2|Ixekizumab given SC. Placebo given SC to maintain blind.
11202891|NCT03364309|Placebo Comparator|Placebo|Placebo given SC
11202892|NCT03364296|Other|Patients hospitalized for stroke|
11202893|NCT03364283||Sitting Position|Sitting and semi-sitting
11202894|NCT03364283||Horizontal Position|Prone, lateral and park bench.
11202895|NCT03364270|Experimental|[F-18] RDG-K5|PET/CT Imaging with administration of [F-18] RGD-K5
11202896|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
11202897|NCT03364231|Experimental|Umbralisib|Umbralisib oral daily dose
11202898|NCT03364218|Experimental|Treatment Group|Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.
11202899|NCT03364218|No Intervention|Control Group|Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.
11202900|NCT03364205|Experimental|intervention|solution-focused interview techniques
11202901|NCT03364205|No Intervention|control|This group did not apply solution-focused interview techniques.
11202902|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
11202903|NCT03364179||young onset dementia|
11202904|NCT03364179||late onset dementia|
11202905|NCT03364166|Active Comparator|buccinator muscle excision with skin|surgical excision of the buccinator muscle with the skin in buccal squamous cell carcinoma and neck dissection also done
11202906|NCT03364166|Active Comparator|buccinator muscle excision without skin|surgical excision the buccinator muscle without the skin in buccal squamous cell carcinoma and neck dissection also done.
11202907|NCT03364153|Experimental|Cohort 1|Zimura dose group
11202908|NCT03364153|Sham Comparator|Cohort 2|Sham dose group
11202909|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
11202910|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
11202911|NCT03364114|Experimental|EndoRotor Resection|For the purpose of this study the EndoRotor System is investigationally indicated for use during endoscopic procedures to resect and remove refractory Barrett's esophagus tissue in conjunction with a submucosal saline injection mix using adrenaline and dye. Subjects randomized to the EndoRotor arm will be treated up to 3 times through the 9 month follow-up period to remove gross visible Barrett's.
11202912|NCT03364114|Active Comparator|Continued Ablation (Control)|The investigator shall exercise standard of care for subjects undergoing continued ablative therapies (RFA and/or Cryotherapy). These will constitute the control devices. The investigator will choose the system in this arm. Operation of each system will be done according to the manufacturer's IFU. Subjects randomized to the control arm may be treated up to 3 time through the 9 month follow-up period to remove gross visible Barrett's.
11202913|NCT03364101|Experimental|PowerOff|PowerOff is a nutraceutical and a blend of nine ingredients for sleep, including: melatonin; California Poppy; L-Cystine; Glycine; and Magnolia Officinalis
11202973|NCT03363737|Active Comparator|Static|
11202974|NCT03363737|Experimental|Dynamic|
11202978|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
11202914|NCT03364101|Placebo Comparator|Placebo|The placebo pill will be manufactured at the same facility and appear identical in all aspects. However, the control agent will feature non-active ingredients with regards to sleep.Capsules will be instructed to commence on day 7 of the study after baseline appointment
11202915|NCT03364088|Active Comparator|Spinal anesthesia with tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.
~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
11202916|NCT03364088|Active Comparator|Spinal anesthesia without tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation.
~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
11202917|NCT03364088|Active Comparator|General anesthesia with tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.
~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
11202918|NCT03364088|Active Comparator|General anesthesia without tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet.
~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.
~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
11202919|NCT03364075|Active Comparator|Duloxetine Treatment|patients treated with Duloxetine
11202920|NCT03364075|Active Comparator|Propranolol Treatment|patients treated with Propranolol
11202921|NCT03364075|Placebo Comparator|Placebo Treatment|patients treated with placebo
11202922|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
11202923|NCT03364049|Experimental|MK-7162+Pembrolizumab|Cycle 1: Participants receive MK-7162 (at a daily dose of between 25 mg and 400 mg) via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 (at a daily dose of between 25 mg and 400 mg) via oral tablets QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
11202924|NCT03364036|Experimental|Mavenclad®|
11202925|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
11202926|NCT03364010|Experimental|Dyslexic and non dyslexic Children|Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language
11202927|NCT03363997|Experimental|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
11202928|NCT03363997|Experimental|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
11202929|NCT03363997|Experimental|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
11202930|NCT03363984|Experimental|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
11202931|NCT03363971|Experimental|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
11202932|NCT03363971|Placebo Comparator|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
11202933|NCT03363958|Experimental|RIC Group|Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
11202934|NCT03363958|Sham Comparator|Control Group|Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
11202935|NCT03363945|Active Comparator|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
11202936|NCT03363945|No Intervention|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
11202975|NCT03363724||HaGuide version 1.0 software module|Patients diagnosed with Parkinson's Disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinson's Disease, using the Neuro-Omega device for navigation and procedure's MER digital recorded data is available.
11202976|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
11202977|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
11202937|NCT03363932||Perimembranous VSD with high pulmonary flow rate|"It is an observational study, no intervention or examination will be realized for the sole purpose of the study. Patient management will be at the discretion of referral cardiologists according to the practices of the centers.
~As part of the usual follow-up of these patients, the participating centers collect the clinical and echocardiography data from inclusion and the following year, as well as data from a functional assessment at baseline and at one year. and the collection of cardiovascular events at 5 years and 10 years of follow-up.
~Data from a possible percutaneous or surgical closure procedure will be collected. The indication of VSD closure will be left to the discretion of participating centers. There will be no recommendation for percutaneous or surgical closure of VSD for the sole purpose of this observatory."
11202938|NCT03363919|Active Comparator|1 Hz left prefrontal rTMS|36 sessions of 1 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 continuous pulses.
11202939|NCT03363919|Active Comparator|10 Hz left prefrontal rTMS|36 sessions of 10 Hz rTMS at 120% motor threshold applied to the left prefrontal cortex. Each session is 2400 pulses with 4 seconds on and 36 seconds off.
11202940|NCT03363906|Experimental|Dulaglutide (Reference)|Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
11202941|NCT03363906|Experimental|Dulaglutide (Test)|Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
11202942|NCT03363893|Experimental|Module 1 Part A|Participants with advanced solid tumours receive CT7001 as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D). This module includes a cohort expansion of participants with breast cancer who provide paired biopsy samples.
11202943|NCT03363893|Experimental|Module 1 Part B|"Participants with advanced solid tumours that may include, but is not limited to, triple negative breast cancer (TNBC), castrate-resistant prostate cancer (CRPC), small cell lung cancer (SCLC) or ovarian cancer, will receive CT7001 as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
~To date Module 1 Part B Arm has recruited a cohort of CRPC participants."
11202944|NCT03363893|Experimental|Module 1 Part B-1 TNBC Expansion|Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001 as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
11202945|NCT03363893|Experimental|Module 2 Part A|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 oral monotherapy in combination with fulvestrant.
11202946|NCT03363893|Experimental|Module 2 Part B|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will be randomized to receive CT7001 or matching placebo as oral monotherapy at the dose determined in Module 2 Part A, in combination with fulvestrant.
11202947|NCT03363893|Experimental|Module 2 Part C|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer who were enrolled to the placebo arm in Module 2 Part B will, on progression of disease, receive CT7001 oral monotherapy in combination with fulvestrant.
11202948|NCT03363893|Experimental|Module 4|Participants with advanced solid tumours will receive CT7001 oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
11202949|NCT03363880|Experimental|experimental group|The trauma treatment team will be established in the experimental group
11202950|NCT03363880|Active Comparator|control group|The trauma treatment team will not be established in this group，just establish the basic experimental settings
11202951|NCT03363867|Experimental|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
11202952|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):
~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen A."
11202953|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):
~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen B."
11202954|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):
~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen A."
11202955|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):
~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.
~Week 16 to 32 (continuation period):
~Tralokinumab continuation SC injection regimen A."
11202956|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):
~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.
~Week 16 to 32 (continuation period):
~Placebo continuation SC injection regimen A."
11202957|NCT03363841|Experimental|SCY-078|SCY-078
11202958|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
11202959|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
11202960|NCT03363815|Experimental|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
11202961|NCT03363815|Experimental|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
11202962|NCT03363815|Experimental|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
11202963|NCT03363815|Experimental|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
11202964|NCT03363789|Active Comparator|Brisement|Patients will receive a series of brisement injections for treatment of non insertional Achilles tendinosis.
11202965|NCT03363789|Active Comparator|Physical Therapy|Patients will undergo physical therapy for treatment of non insertional Achilles tendinosis.
11202966|NCT03363776|Experimental|Monotherapy|BMS-986277 administered alone
11202967|NCT03363776|Experimental|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
11202968|NCT03363776|Experimental|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
11202969|NCT03363763|Active Comparator|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
11202979|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
11202980|NCT03363659|Experimental|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
11202981|NCT03363633|No Intervention|Observation|
11202982|NCT03363633|Experimental|Injection + Compression|
11202983|NCT03363633|Active Comparator|Compression|
11202984|NCT03363620|Experimental|self ligation brackets damon ormco®|the self ligation bracket (damon system) in the orthodontic treatment, was used in the experimental group with the recommended protocol damon arches sequence.
11202985|NCT03363620|Active Comparator|conventional brackets orthos ormco®|the conventional bracket (orthos system) in the orthodontic treatment, was used in the active comparator group with the recommended protocol damon arches sequence as used in the experimental group.
11202986|NCT03363607|Experimental|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
11202987|NCT03363607|Active Comparator|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
11202988|NCT03363594||1|Diabetes Mellitus
11202989|NCT03363581||Control|Normal Weight Healthy Controls
11202990|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
11202991|NCT03363568|Experimental|Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
11202992|NCT03363568|Active Comparator|Non-Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
11202993|NCT03363555|Experimental|SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
11202994|NCT03363542|Active Comparator|Fruits and vegetables rich diet|dietary education to increase fruits and vegetable consumption
11202995|NCT03363542|Active Comparator|Whole grain fiber rich diet|dietary education to increase whole grain fiber consumption
11202996|NCT03363542|Active Comparator|Fruits and vegetables and whole grain fiber rich diet|dietary education to increase fruits and vegetable and whole grain fiber consumption
11202997|NCT03363542|No Intervention|Control group|Routine care
11202998|NCT03363529|Placebo Comparator|Standard|This study arm utilizes a standard lighting condition in the patient room
11202999|NCT03363529|Experimental|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
11203000|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
11203001|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
11203002|NCT03363503|Experimental|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
11203003|NCT03363503|Active Comparator|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
11203004|NCT03363490|Other|Control|The patients in this group will only receive health education intervention.
11203005|NCT03363490|Other|Neuromuscular exercise therapy|The patients in this group will receive exercise therapy intervention.Besides, health education will be performed for every group.
11203006|NCT03363490|Other|Self-management program|The patients in this group will receive self-management intervention.Besides, health education will be performed for every group.
11203007|NCT03363490|Other|Exercise therapy+self-management|The patients in this group will receive exercise therapy and self-management intervention.Besides, health education will be performed for every group.
11203008|NCT03363477|Experimental|AB treatment sequence|Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
11203009|NCT03363477|Active Comparator|BA treatment sequence|Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
11203010|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
11203011|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
11203012|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
11203013|NCT03363451||Infection Group|Patients with end stage liver disease with infection
11203014|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
11203015|NCT03363438||martinique|
11203016|NCT03363438||guadeloupe|
11203017|NCT03363425|Active Comparator|Lidocaine|
11203018|NCT03363425|Active Comparator|Dexmedetomidine|
11203019|NCT03363425|Placebo Comparator|Normal Saline 0,9%|
11203020|NCT03363412|Experimental|Underdilated TIPS|Patients will be treated with PTFE-covered stent grafts balloon-dilated to less than 8 mm.
11203021|NCT03363386|Experimental|Proprioceptive Exercise Group (PG)|Aerobic Exercise Proprioceptive Exercises
11203022|NCT03363386|Active Comparator|Resistive Exercise Group (RG)|Aerobic Exercise Resistive Exercises
11203073|NCT03363009|Experimental|Connected device with close following|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be analyzed every day and used for coaching
11203105|NCT03362801|Other|Sarcopenic|sarcopenic status the day before cystectomy.
11203106|NCT03362801|Other|not sarcopenic|sarcopenic status the day before cystectomy.
11203023|NCT03363373|Experimental|GM-CSF + Naxitamab|Each investigational cycle is started with 5 days of GM-CSF administered at 250 µg/m2/day in advance of the start of Naxitamab administration. GM-CSF is thereafter administered at 500 µg/m2/day on days 1 to 5. As standard treatment, Naxitamab is administered at 3 mg/kg/day on days 1, 3, and 5 totalling 9 mg/kg per cycle. Treatment cycles are repeated every 4 weeks until CR or PR followed by 5 additional cycles every 4 weeks (±1 week). Subsequent cycles are repeated every 8 weeks (±2 weeks) through 101 weeks from first infusion at the discretion of the investigator. After end of treatment patients will enter a long-term follow up for up to 3 years after end of treatment visit.
11203024|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
11203025|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
11203026|NCT03363321|Experimental|PF-06741086 (Cohort 1)|
11203027|NCT03363321|Experimental|PF-06741086 (Cohort 2)|
11203028|NCT03363321|Experimental|PF-06741086 (Cohort 3)|
11203029|NCT03363321|Experimental|PF-06741086 (Cohort 4)|
11203030|NCT03363321|Experimental|PF-06741086 (Cohort 5)|
11203031|NCT03363321|Experimental|PF-06741086 (Cohort 6)|
11203032|NCT03363308|Experimental|Phase 1|training for health care workers supplemented by QI teams
11203033|NCT03363308|No Intervention|Phase 2|
11203034|NCT03363295|Experimental|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
11203035|NCT03363295|No Intervention|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
11203036|NCT03363282|Experimental|Mini-SLET|Simple Limbal Epithelial Transplantation
11203037|NCT03363282|Experimental|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
11203038|NCT03363269|Experimental|ID1201 100mg|
11203039|NCT03363269|Experimental|ID1201 200mg|
11203040|NCT03363269|Experimental|ID1201 400mg|
11203041|NCT03363269|Placebo Comparator|Placebo|
11203042|NCT03363256|Experimental|TAU+TES-NAV|Standard outpatient addiction treatment plus Therapeutic Education System adapted for AI/AN
11203043|NCT03363256|Active Comparator|TAU|Standard outpatient addiction treatment
11203044|NCT03363243|Experimental|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
11203045|NCT03363243|Active Comparator|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
11203046|NCT03363230|Experimental|Mindfulness skills|
11203047|NCT03363230|Active Comparator|Interpersonal effectiveness skills|
11203048|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
11203049|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
11203050|NCT03363217|Experimental|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
11203051|NCT03363217|Experimental|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
11203052|NCT03363204|Experimental|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
11203053|NCT03363191|Experimental|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
11203054|NCT03363191|Active Comparator|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
11203055|NCT03363178|Experimental|GC3107|BCG Vaccine, 0.1mL
11203056|NCT03363165|Active Comparator|VM202|Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
11203057|NCT03363165|Placebo Comparator|Placebo|Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.
11203058|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
11203059|NCT03363100|Experimental|Intervention|
11203060|NCT03363100|No Intervention|Control|
11203061|NCT03363087|Experimental|Mapping and ablation|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation
11203062|NCT03363074|Experimental|Orthotic Insole|Device: Orthotic Insole 8-week follow-up with Orthotic Insole
11203063|NCT03363074|Experimental|Low-level Laser Therapy|Low-Level Laser 5-week follow-up
11203064|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
11203065|NCT03363048|Experimental|Restricted|
11203066|NCT03363048|Experimental|Restriction plus Incentive|
11203067|NCT03363048|No Intervention|Control|
11203068|NCT03363035|Experimental|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily
11203069|NCT03363035|Experimental|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily
11203070|NCT03363035|Active Comparator|enoxaparin|Enoxaparin 1mg/kg twice daily SC twice daily
11203071|NCT03363022|Experimental|Standard Medical Treatment+Fecal Microbiota Transplant|
11203072|NCT03363022|Active Comparator|Standard Medical Treatment+Placebo|
11203074|NCT03363009|Other|Connected device with standard coaching|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be saved but not used for coaching
11203075|NCT03362996|Experimental|Experimental Group|"50 patients Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.
~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
11203076|NCT03362996|Placebo Comparator|Control group 1|50 patients Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
11203077|NCT03362996|Other|Control Group 2|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
11203078|NCT03362983|Experimental|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
11203079|NCT03362983|No Intervention|Standard care|Standard care at separate specialty clinics and primary care as needed.
11203080|NCT03362970|Active Comparator|Standard of Care|For children randomized to the standard of care arm, the treating physician will be informed to proceed as per their usual practice and treatment patterns. If stool is unavailable a rectal swab will be collected and sent to Calgary Laboratory Services (CLS) for routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care. Home stool collection will be performed for those unable to provide a sample at enrolment and will be achieved by providing families with collection kits.
11203081|NCT03362970|Experimental|BioFire Gastrointestinal Panel FilmArray|For children randomized to the BioFire FilmArray arm, stool, if available, will be sent STAT to Calgary Laboratory Services (CLS) for the performance of the BioFire FilmArray test and routine culture. If stool is unavailable, a rectal swab will be performed and sent to CLS for the performance of the BioFire FilmArray test and routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care once it is available. Treatment decisions will be at the sole discretion of the ED treating physician who receives the result.
11203082|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
11203083|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
11203084|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
11203085|NCT03362944|Experimental|Active Music Therapy|
11203086|NCT03362944|Experimental|Passive Music Therapy|
11203087|NCT03362931|Experimental|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
11203088|NCT03362918|No Intervention|Control Group|"Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.
~Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study."
11203089|NCT03362918|Experimental|High-Intensity Interval Training|Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
11203090|NCT03362918|Experimental|Continuous Aerobic Exercise Training|Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
11203091|NCT03362905|Experimental|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
11203092|NCT03362905|Active Comparator|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
11203093|NCT03362905|Active Comparator|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
11203094|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
11203095|NCT03362853|Experimental|Nemonoxacin 500Mg Capsule|
11203096|NCT03362853|Experimental|Nemonoxacin 750Mg Capsule|
11203097|NCT03362853|Placebo Comparator|Placebo oral capsule|
11203098|NCT03362853|Active Comparator|Moxifloxacin 400Mg Tablet|
11203099|NCT03362840|Experimental|Early Start Denver Model (ESDM) group|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition.
11203100|NCT03362840|Active Comparator|Eclectic preschool intervention group|The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.
11203101|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
11203102|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
11203103|NCT03362814|Experimental|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
11203104|NCT03362814|Placebo Comparator|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
11203107|NCT03362788||VKA|"Patients receiving VKA as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
11203108|NCT03362788||NOAC|"Patients receiving a NOAC as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
11203109|NCT03362775|Other|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
11203110|NCT03362723|Experimental|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
11203111|NCT03362723|Experimental|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
11203112|NCT03362723|Experimental|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
11203113|NCT03362723|Experimental|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
11203114|NCT03362723|Experimental|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade </=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
11203115|NCT03362710|Experimental|PAD patients|"Patients referred for an arterial doppler assessment of lower limbs will be included.
~Intervention is a series of examination, followed by the measurement of the ABI and an arterial echo-doppler of the lower limbs +/- transcutaneous oxygen pressure measurements in case of suspected critical limb ischemia.
~A technician will perform the evaluation with simplified tools blinded to the results of vascular specialised investigations"
11203116|NCT03362697|Experimental|Probiotic|5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, PAC-A and Zinc
11203117|NCT03362697|Active Comparator|Antibiotic|Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick
11203118|NCT03362684|Experimental|FOLFOX-4 plus Cetuximab|
11203119|NCT03362684|Active Comparator|FOLFOX-4|
11203120|NCT03362671|Experimental|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
11203121|NCT03362658||Patients|ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
11203122|NCT03362658||Controls|Healthy controls who are age and gender matched to patients.
11203123|NCT03362645||Fabry cardiomyopathy|
11203124|NCT03362645||Hypertrophic cardiomyopathy|
11203125|NCT03362632||Infection Group|Patients with end stage liver disease with SBP
11203126|NCT03362632||Non-infection Group|Patients with end stage liver disease without SBP
11203127|NCT03362619|Experimental|CC-EIEs|Autologous cervical cancer specific engineered immune effectors (EIEs)
11203128|NCT03362606|Experimental|OC-CTLs|Autologous ovarian cancer specific cytotoxic lymphocytes
11203129|NCT03362593|Experimental|MEDI7219|Experimental Drug
11203130|NCT03362593|Placebo Comparator|Placebo|Placebo
11203131|NCT03362593|Placebo Comparator|Formulation without Active Drug|Formulation without Active Drug
11203132|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
11203133|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
11205079|NCT03348839|Experimental|Cluster 3|NeLLY service is implemented after 16 months.
11203134|NCT03362567|Experimental|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
11203135|NCT03362567|Experimental|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
11203136|NCT03362554|Experimental|Intervention|
11203137|NCT03362554|No Intervention|Control|
11203138|NCT03362541|Experimental|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
11203139|NCT03362541|Active Comparator|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
11203140|NCT03362528|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
11203141|NCT03362528|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for the initial 30 days, distributed over a time period of 60 days. Subjects will for the remaining 60 days of measurements, distributed over 120 days collect spectral data twice a day. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
11203142|NCT03362515|Experimental|Furosemide|
11203143|NCT03362515|Placebo Comparator|Placebo|
11203144|NCT03362502|Experimental|PF-06939926|
11203145|NCT03362489|Other|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
11203146|NCT03362489|Other|IUI|Intrauterine insemination
11203147|NCT03362476|Experimental|Computer-based alcohol reduction intervention.|Brief, computer-based, alcohol reduction intervention based on cognitive behavioral therapy (CBT) tailored for HIV/HCV co-infected women in conjunction with standard clinical care for current substance users.
11203148|NCT03362476|Other|Standard-of-care.|Routine counseling to avoid alcohol and drugs.
11203149|NCT03362463||Acute Coronary Syndrom|acute coronary syndrome in a real-life setting for patients hospitalized with an ACS (i.e. STEMI, NSTEMI, unstable angina)
11203150|NCT03362450||Pregnant patients seen for second or third trimester|Foetus with diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings
11203151|NCT03362437|Experimental|Treatment A|Receive 200 mg BMS-986177 Form A without food
11203152|NCT03362437|Experimental|Treatment B|Receive 200 mg BMS-986177 Form B without food
11203153|NCT03362437|Experimental|Treatment C|Receive 200 mg BMS-986177 Form B with food
11203154|NCT03362424|Experimental|Mesenchymal stem cell group|rotator cuff repair stem cells
11203155|NCT03362424|Active Comparator|Control group|rotator cuff repair
11203156|NCT03362411|Experimental|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
11203157|NCT03362411|Experimental|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
11203158|NCT03362411|Experimental|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
11203159|NCT03362411|Experimental|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
11203160|NCT03362398|Active Comparator|Omarigliptin|Drug: Omarigliptin 25 mg
11203161|NCT03362398|Active Comparator|Trelagliptin|Drug: Trelagliptin 100 mg
11203162|NCT03362385||OSA|
11203163|NCT03362385||Non-OSA|
11203164|NCT03362372|Experimental|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
11203165|NCT03362372|No Intervention|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
11203166|NCT03362359|Experimental|Ga-68-PSMA-11|
11203167|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
11203168|NCT03362333|Experimental|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
11203169|NCT03362333|Active Comparator|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
11203170|NCT03362320|Experimental|double layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with double layer fixation
11203171|NCT03362320|Experimental|single layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with single layer fixation
11203172|NCT03362307|Active Comparator|Laser Emitting group|subjects received Low-Level Laser and Light-Emitting Diodes after implant placement
11203173|NCT03362307|Placebo Comparator|Non Emitting group|In laser emitiiing group, subjects received Low-Level Laser and Light-Emitting Diodes after implant placement and in Non-emitting group,the same device was used while device was off.
11203174|NCT03362294|Experimental|GA Depot 40mg once monthly|Monthly IM injection
11203175|NCT03362281|Experimental|Ilaprazole|
11203176|NCT03362281|Active Comparator|omeprazole|
11203177|NCT03362268|Experimental|Ilaprazole|
11203178|NCT03362268|Active Comparator|omeprazole|
11203179|NCT03362255|Active Comparator|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
11203180|NCT03362255|Active Comparator|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
11203181|NCT03362242|Active Comparator|ARO-AAT|
11203182|NCT03362242|Placebo Comparator|Placebo|
11203183|NCT03362229|Active Comparator|FIXATION|Medial malleolus fixation, with the method of fixation left to the surgeons discretion.
11203184|NCT03362229|Active Comparator|NON-FIXATION|A well reduced medial malleolus fracture is then left without fixation ie, non-operative management.
11203185|NCT03362216|Experimental|experimental group|Treated with Compound Methyl Salicylate Liniment group
11203186|NCT03362216|Active Comparator|Control group|Treated with Diclofenac Sodium Liniment group
11203187|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
11203188|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
11203189|NCT03362190|Experimental|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
11203190|NCT03362190|Experimental|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
11203191|NCT03362190|Experimental|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
11203192|NCT03362190|Experimental|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
11203193|NCT03362177|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
11203194|NCT03362177|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
11203195|NCT03362151|Experimental|Regular pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
11203196|NCT03362151|Experimental|High protein pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
11203197|NCT03362151|Experimental|White rice|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
11203198|NCT03362138||Dermoscopy|Dermoscopic imaging of a lesion decided to be biopsied
11203199|NCT03362099|No Intervention|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
11203200|NCT03362099|Active Comparator|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.
~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
11203201|NCT03362073|Experimental|Ketamine|continuous intravenous infusion of ketamine
11203202|NCT03362060|Experimental|PVX-410|"PVX-410 vaccine at W0, 1, 2, 3, 4, and 5 followed by booster PVX-410 vaccine doses at W10 and 28
~Pembrolizumab will be administered every 3 weeks intravenously starting with week 1"
11203203|NCT03362047|Experimental|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
11203204|NCT03362047|Experimental|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
11203205|NCT03362034|Active Comparator|single transfer tray|
11203206|NCT03362034|Experimental|double transfer trays|
11203207|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
11203208|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
11203209|NCT03362008|Experimental|Group I|Period I: administration of Zeropix Period II: administration of Champix®
11203210|NCT03362008|Experimental|Group II|Period I: administration of Champix® Period II: administration of Zeropix
11203211|NCT03361995|Experimental|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after PCI.
11203212|NCT03361995|Active Comparator|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
11203213|NCT03361982|No Intervention|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
11203214|NCT03361982|Experimental|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
11203215|NCT03361969|Active Comparator|estetrol|
11203216|NCT03361969|Placebo Comparator|placebo|
11203217|NCT03361956|Experimental|Part A: Arm 1 (JNJ-56136379 or NA) (open label)|Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]), and enter the 24 week post treatment follow-up phase.
11203218|NCT03361956|Placebo Comparator|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203219|NCT03361956|Experimental|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11251327|NCT03030989|Placebo Comparator|Placebo wipe|
11203220|NCT03361956|Placebo Comparator|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203221|NCT03361956|Experimental|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203222|NCT03361956|Experimental|Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
11203223|NCT03361956|Placebo Comparator|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203224|NCT03361956|Experimental|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203225|NCT03361956|Placebo Comparator|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203226|NCT03361956|Experimental|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
11203227|NCT03361930|Experimental|CP participants|Single-day data collection for walking conditions; barefoot, with plain ankle-foot orthosis (flat foot plate) on involved side, with tone-reducing ankle-foot orthosis on involved side.
11203228|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
11203229|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
11203230|NCT03361891|No Intervention|Control|Patients receive no intervention
11203231|NCT03361891|Experimental|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
11203232|NCT03361878|Active Comparator|Metformin Tolerant|
11203233|NCT03361878|Active Comparator|Metformin Intolerant|
11203234|NCT03361865|Experimental|Pembrolizumab 200 mg + epacadostat 100 mg BID|Pembrolizumab + epacadostat
11203235|NCT03361865|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
11203236|NCT03361852|Experimental|Neo Vax|"Neo Vax is injected into up to 4 different anatomic site.
~NeoVax may be administered within +/- 1 day of the scheduled administration date for days 4 and 8,
~Within +/-3 days of the scheduled administration date for days 15 and 22
~Within +/-7 days of days 78 and 134.
~Participants will receive Rituximab weekly x 4 weeks per institutional standard"
11203237|NCT03361839|Active Comparator|1|patients with RIF
11203238|NCT03361839|Placebo Comparator|2|fertile arm as r reference for result
11203239|NCT03361826|Other|DBT Only|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder.
11203240|NCT03361826|Experimental|MagPro MST with Cool TwinCoil + DBT|MST treatments will be administered using the MagPro MST with Cool TwinCoil. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
11203241|NCT03361813|Active Comparator|trans-cutaneous ultrasound guided peritonsillar infiltration|
11203242|NCT03361813|Placebo Comparator|trans-oral ultrasound guided peritonsillar infiltration|
11203243|NCT03361800|Experimental|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
11203244|NCT03361787|Experimental|Parentship coaching intervention|
11203245|NCT03361774|Experimental|Test dentifrice|Participants in this arm will receive experimental dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 parts per million [ppm] fluoride).
11203246|NCT03361774|Active Comparator|Control dentifrice|Participants in this arm will receive comparator dentifrice containing 0.454% SnF2 (1100ppm fluoride).
11203247|NCT03361761||experimental|therapeutic coordination apartments with formalized/official Health education program
11203248|NCT03361761||active comparator|therapeutic coordination apartments without formalized/official Health education program
11203249|NCT03361748|Experimental|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 45 x 10^7 CAR+ T cells after receiving lymphodepleting chemotherapy.
11203250|NCT03361735|Experimental|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
11203251|NCT03361709|Active Comparator|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
11203252|NCT03361709|Placebo Comparator|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
11203253|NCT03361683|Experimental|High-flow nasal oxygen|Randomized patients will receive oxygen through a high flow nasal device capable of delivering humidified, heated air at an output rate of 40 L/min
11203254|NCT03361683|Active Comparator|Conventional oxygen|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
11203255|NCT03361670||Specimens that meet inclusion criteria|
11203458|NCT03360266|Active Comparator|Profluorid group|5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
11203256|NCT03361657||One sample|Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10-12mmHg
11203257|NCT03361644|Experimental|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
11203258|NCT03361644|Active Comparator|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
11203259|NCT03361631|Experimental|arm treated with MSC|"Type 1 diabetic man
~Aged from 18 to 50 years
~Having a diabetes evolving for at least 10 years
~Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot
~Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)
~IIEF-5 score less than or equal to 10"
11203260|NCT03361618|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
11203261|NCT03361618|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
11203262|NCT03361605|Experimental|Propofol Administration|
11203263|NCT03361592|Experimental|Spinal Manipulative Therapy|The participants assigned to the intervention group received the procedure Lumbar (SMT) was performed after baseline measurements, using Diversified techniques, aiming to correct vertebral dysfunctional segments after clinical assessment. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was performed in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
11203264|NCT03361592|Sham Comparator|Sham pre-load positioning SMT|"The participants assigned to the control group received the procedure Sham (pre-load positioning MVT). The Sham (SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained for approximately 1 minute in total, 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
11203265|NCT03361579|Other|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
11203266|NCT03361579|Other|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
11203267|NCT03361566|Experimental|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
11203268|NCT03361566|Experimental|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
11203269|NCT03361566|Experimental|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
11203270|NCT03361566|Experimental|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
11203271|NCT03361566|Experimental|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
11203272|NCT03361566|Experimental|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
11203273|NCT03361566|Experimental|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
11203274|NCT03361566|Experimental|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
11203275|NCT03361566|Experimental|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
11203276|NCT03361566|Experimental|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
11203277|NCT03361566|Experimental|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
11203278|NCT03361566|Experimental|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
11203279|NCT03361540|Experimental|Single dose of ASP8302 dose-1|Subjects will receive a single dose of ASP8302.
11203280|NCT03361540|Experimental|Single dose of ASP8302 dose-2|Subjects will receive a single dose of ASP8302.
11203281|NCT03361540|Experimental|Single dose of ASP8302 dose-3|Subjects will receive a single dose of ASP8302.
11203282|NCT03361540|Experimental|Single dose of ASP8302 dose-4|Subjects will receive a single dose of ASP8302.
11203283|NCT03361540|Placebo Comparator|Single dose of Placebo|Subjects will receive a single dose of Placebo.
11203284|NCT03361540|Experimental|Multiple dose of ASP8302 dose-5|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
11203285|NCT03361540|Experimental|Multiple dose of ASP8302 dose-6|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
11203286|NCT03361540|Placebo Comparator|Multiple dose of Placebo|Subjects will receive once daily dosing of Placebo for 14 consecutive days.
11203287|NCT03361514|Active Comparator|Supported Protocolized Discontinuation|Supported Protocolized Discontinuation (SPD) Patients will receive guidance of their GP and can have supportive meetings with the mental health assistant.
11203288|NCT03361514|Experimental|SPD + Mindfulness (MBCT)|In addition to the SPD (as mentioned above) patients are offered Mindfulness Based Cognitive Therapy (MBCT)
11203289|NCT03361501|Experimental|CaPre|
11203290|NCT03361501|Placebo Comparator|Placebo|
11203291|NCT03361488|Experimental|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
11203292|NCT03361488|No Intervention|Control anesthesiologist|Patient interview by control anesthesiologists
11251504|NCT03029715|Other|Inhalation anaesthesia|Desflurane Remifentanil
11203293|NCT03361475|Experimental|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
11203294|NCT03361475|No Intervention|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
11203295|NCT03361462|Experimental|Intervention group|Two joyful adventure days in the form of physical activities and competitions with adventure games and short interactive talk on SME.
11203296|NCT03361462|No Intervention|Waitlist control group|The intervention won't be provided during evaluation period and will be provided after the evaluation period
11203297|NCT03361449|Active Comparator|Group 1|training with kinesthetic ability trainer.
11203298|NCT03361449|Active Comparator|Group 2|Flamingo exercise
11203299|NCT03361449|Active Comparator|Group 3|training with kinesthetic ability trainer and Flamingo exercise
11203300|NCT03361436|Experimental|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of cycle 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
11203301|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
11203302|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
11203303|NCT03361410|Experimental|Grape Powder|
11203304|NCT03361410|Placebo Comparator|Placebo Powder|
11203305|NCT03361397|Active Comparator|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
11203306|NCT03361397|Placebo Comparator|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
11203307|NCT03361384|Experimental|Alcohol condition|The amount of alcohol received in the alcohol condition will be determined by an algorithm developed by Curtin (Curtin, 2000). Participants in the alcohol condition will receive a dose of alcohol (target BAC = .08%), administered in a chilled beverage of 80-proof vodka mixed with tonic water and lime juice in a 1:4 ratio.
11203308|NCT03361384|Placebo Comparator|Placebo condition|Placebo participants will receive tonic water and lime juice served to enhance alcohol cues in an amount comparable to the amount that they would have received if assigned to the alcohol condition.
11203309|NCT03361384|No Intervention|Control (water)|Participants in the water control condition will receive a glass of chilled water in volume of liquid comparable to the amount that they would have received if assigned to the alcohol or placebo condition.
11203310|NCT03361371|Experimental|Interventional group|"Intervention Group: in addition to receiving the aforementioned bronchiolitis discharge instructions, this group will undergo nasal suctioning prior to each feeding as needed for 72 hours post discharge home, using exclusively the Zo-Li study device (see above under study device), with saline nose drops. Families in this group will be given the Zo-Li device at no cost and instructed in the appropriate technique and importance of using this tool.
~We shall not reveal the identity of the study devices to the ED physicians in order to minimize contamination of the control group. The ED treating physicians will also be blinded to which device the infant had been randomized to. We shall also ask the ED treating physicians not to recommend specific suctioning devices to the study patients."
11203311|NCT03361371|Placebo Comparator|Control group|Control Group: this group will receive standardized routine discharge instructions describing information about bronchiolitis, expected course of illness, recommended management strategies such as fever control, augmented air humidification, need for frequent feeding and warning signs prompting return for care. This group will be suctioned prior to feeds via bulb suction (with saline drops) which is expected to provide minimal effect, due to non-sustained negative pressures generated during bulb release. Since the benefit of nasal suction in bronchiolitis is unknown, this design is ethically reasonable. However, the use of no suction would likely meet with parental resistance and enrollment would be difficult. Families in the control group will be given the bulb device at no cost and instructed in the appropriate technique of using this tool prior to feeds.
11203312|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
11203313|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
11203314|NCT03361332||Healthy subjects|
11203315|NCT03361332||Patients with Gilles de la Tourette Syndrome|
11203316|NCT03361319|Experimental|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:
~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
11203317|NCT03361319|Experimental|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
11203318|NCT03361319|Placebo Comparator|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.
~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
11203319|NCT03361306|Experimental|KRd-Elotuzumab|Carfilzomib, Revlimid, Dexamethasone, Elotuzumab
11203320|NCT03361293|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
11203321|NCT03361293|Sham Comparator|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
11203322|NCT03361280|Experimental|Atenolol|Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
11203323|NCT03361280|Experimental|Bisoprolol|Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
11203324|NCT03361280|Experimental|Metoprolol|Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
11203325|NCT03361280|Experimental|Carvedilol|Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
11203326|NCT03361267|Active Comparator|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
11203327|NCT03361267|Experimental|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
11203328|NCT03361241|Experimental|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
11203329|NCT03361241|Active Comparator|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
11203330|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
11203331|NCT03361228|Experimental|INCB001158 + Epacadostat|
11203332|NCT03361202||Atrial fibrillation group|blood sampling
11203333|NCT03361202||control group|blood sampling
11203334|NCT03361189|Experimental|CLS-On|Subjects in this arm will programmed to CLS-on to received closed loop stimulation-based pacing.
11203335|NCT03361189|No Intervention|CLS-Off|Subjects in this arm, will be placed in a standard pacing mode (i.e. AAIR or DDDR).
11203336|NCT03361176|Active Comparator|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
11203337|NCT03361176|Experimental|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
11203338|NCT03361163|Experimental|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)
~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10^4 to 1-3x10^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
11203339|NCT03361150|Experimental|HIT|Preoperative nutrition, relaxation strategies + high intensity interval training (HIT). HIT alternates a series of high-intensity bouts with relief period. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
11203340|NCT03361150|Active Comparator|MCT|Preoperative nutrition, relaxation strategies + high intensity interval training (MCT). MCT is continuous exercise with a constant intensity below anaerobic threshold. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
11203341|NCT03361137|Experimental|Cohort 1 - PwHA With Inhibitors: Emicizumab Prophylaxis|All eligible participants with Hemophilia A (PwHA) with inhibitors will receive emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continue to derive sufficient benefit. Participants must have received all loading doses prior to surgery and plan to continue emicizumab for a minimum of 1 month after surgery. Dosing should be adjusted if the participant has a significant change in body weight.
11203342|NCT03361137|Experimental|Cohort 2 - PwHA Without Inhibitors: Emicizumab Prophylaxis|All eligible participants with Hemophilia A (PwHA) without inhibitors will receive emicizumab via SC injection at a loading dose of 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continue to derive sufficient benefit. Participants must have received all loading doses prior to surgery and plan to continue emicizumab for a minimum of 1 month after surgery. Dosing should be adjusted if the participant has a significant change in body weight.
11203343|NCT03361124|Placebo Comparator|Control|Patient will receive standard post-partum Oxytocin (20 mU in 1 L LR) and 1 L LR over 8 hours following delivery.
11203344|NCT03361124|Experimental|Treatment|Patient will receive standard post-partum Oxytocin(20 mU in 1 L LR) an additional 20 mU Oxytocin in 1 L LR over 8 hours following delivery.
11203345|NCT03361098|Experimental|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
11203346|NCT03361098|Active Comparator|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
11203347|NCT03361098|Active Comparator|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
11203348|NCT03361098|Placebo Comparator|double placebo|placebo dapagliflozin and placebo exenatide twice daily
11203349|NCT03361085|Experimental|Intervention|nvHAP-Prevention Bundle
11203350|NCT03361072|Experimental|Milk allergy|Milk oral immunotherapy intervention for milk allergy
11203351|NCT03361072|Experimental|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
11203352|NCT03361072|Experimental|Egg allergy|Egg oral immunotherapy intervention for egg allergy
11203353|NCT03361046||Transcatheter Aortic Valve-in-Valve Implantation Cohort|
11203423|NCT03360487|Sham Comparator|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
11203459|NCT03360266|Experimental|Enamel Pro|Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
11203354|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
11203355|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
11203356|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
11203357|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
11203358|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
11203359|NCT03360994|Experimental|WATChmAN|Patients randomized to the WATChmAN Active Surveillance arm will receive their active surveillance testicular cancer care via an online virtual clinic. Importantly, patients will follow the same surveillance schedule as patients in the standard of care arm. However, patients in the WATChmAN arm will be able to see their upcoming tests and virtual appointments online, request requisitions to perform their required testing at outside institutions, and indicate any concerns for physicians to review during the virtual visit.
11203360|NCT03360994|Active Comparator|Standard of Care|Patients randomized to the standard of care arm (in-person active surveillance) will follow the current active surveillance protocol in place at Princess Margaret Cancer Centre's Multidisciplinary Testicular Cancer Clinic. This protocol involves the same schedule of testing as the WATChmAN arm, but will require patients to come into the clinic to receive their test results (as in current practice).
11203361|NCT03360981|Active Comparator|diabetics incretin-users (arm 1)|epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy.
11203362|NCT03360981|Placebo Comparator|diabetics never-incretin-users (arm 2)|epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.
11203363|NCT03360981|No Intervention|non diabetics (arm 3)|non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy.
11203364|NCT03360968|Experimental|Treatment A-B|Patient is treated with 1 hour SPN-CPAP/PS followed by 1 hour of Variable-PS ventilation mode
11203365|NCT03360968|Experimental|Treatment B-A|Patient is treated with 1 hour Variable-PS followed by 1 hour of SPN-CPAP/PS ventilation mode
11203366|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
11203367|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
11203368|NCT03360942||DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
11203369|NCT03360929|Experimental|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. two dose cohorts are planned for dose escalation, including: 150 and 250 mg twice daily.
~RP2D in dose expansion."
11203370|NCT03360916|Placebo Comparator|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
11203371|NCT03360916|Experimental|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
11203372|NCT03360916|Experimental|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
11203373|NCT03360903|Experimental|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
11203374|NCT03360903|Experimental|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
11203375|NCT03360890|Experimental|Cohort 1: salivary gland tumors without SOC treatment option|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
11203376|NCT03360890|Experimental|Cohort 2: 'aggressive' thyroid cancer without SOC treatment op|All patients will receive pembrolizumab and docetaxel. First pembrolizumab and docetaxel will be given together. After which patients will receive pembrolizumab alone until disease progression or up to 35 cycles (about 2 years).
11203377|NCT03360877|Other|Health-care associated infection|
11203378|NCT03360864|Experimental|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.
~This program will take place within 6 months after biologic treatment initiation."
11203379|NCT03360864|No Intervention|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
11203424|NCT03360487|Active Comparator|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
11203425|NCT03360487|Sham Comparator|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
11203519|NCT03359772|No Intervention|Group 1|Exercise Only Group
11203380|NCT03360851|Experimental|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose <0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
11203381|NCT03360851|Experimental|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
11203382|NCT03360851|No Intervention|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
11203383|NCT03360838||CogCheck application|Performance in the application
11203384|NCT03360812|Experimental|Intervention group|The intervention is an online training resource to improve the recognition of imminent death in palliative care patients. The intervention should take approximately 15 minutes to complete. During this time, the participants who are in the intervention arm will be shown the results of a previous study which identified how expert palliative care doctors recognise imminently dying palliative care patients. The intervention will be implemented via the website, immediately after participants have completed the first set of vignettes.
11203385|NCT03360812|No Intervention|Control group|The participants assigned to the control group will not receive this additional information and will simply be informed that they are approximately half way through the task and will be asked to continue on to the next set of vignettes.
11203386|NCT03360799||Observational (questionnaire)|Participants complete 5 questionnaires.
11203387|NCT03360786|Experimental|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
11203388|NCT03360786|Active Comparator|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
11203389|NCT03360760|Experimental|Pre surgical Chemotherapy|Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).
11203390|NCT03360760|Other|Immediate Surgery|Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.
11203391|NCT03360747|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
11203392|NCT03360734|Experimental|Combination|"First part: Combination of Gatipotuzumab (GAT) and Tomuzotuximab (TOM) Treatment: 5 weeks monotherapy with TOM (Day 1: 60mg, Day 2: 660mg, Week 2: 1200mg, Week 4: 1200mg). Then combination of 1200mg TOM with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity.
~Second part: Combination of GAT and TOM or an approved anti-EGFR antibody, i.e. Cetuximab, Panitumumab, or Necitumumab Treatment: One week monotherapy with TOM (Week 1, Day 1: 60mg, Day 2: 660mg). Then 1200mg TOM in combination with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity or commercial anti-EGFR antibody (dosage according to local practices) in combination with 1400mg of GAT every two weeks until disease progression or until unacceptable toxicity"
11203393|NCT03360721|Experimental|Treatment (abiraterone acetate, apalutamide, prednisone)|Participants receive abiraterone acetate PO once daily QD, apalutamide PO QD, and prednisone PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11203394|NCT03360708|Experimental|Treatment (vaccine therapy)|Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11203395|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - PILOT|"Proactive Psychiatry Consultation and Case Management is:
~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.
~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.
~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.
~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
11203426|NCT03360487|Active Comparator|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
11203396|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - Randomized Trial|"Proactive Psychiatry Consultation and Case Management is:
~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.
~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.
~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.
~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
11203397|NCT03360695|Active Comparator|Enhanced Usual Care (EUC) - Randomized Trial|Study staff will send a templated email to the treating oncologist at enrollment informing the oncologists of the psychiatric diagnosis and available psychosocial services. Study staff will also inform the patient and caregiver of available psychosocial services.
11203398|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 1|"The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.
~treatment 48 weeks"
11203399|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 2|"The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.
~treatment 48 weeks"
11203400|NCT03360669|Experimental|Sequence: Clinical/Research|Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
11203401|NCT03360669|Active Comparator|Sequence: Research/Clinical|Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
11203402|NCT03360656|Experimental|Transnasal Thermal Regulating Device|Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours
11203403|NCT03360643|Active Comparator|Point-of-care ultrasound prior to radiology ultrasound|
11203404|NCT03360643|Active Comparator|Radiology-performed ultrasound|
11203405|NCT03360630|Experimental|Anti-PD-1 plus DC-CIK|
11203406|NCT03360630|Active Comparator|Anti-PD-1 alone|
11203407|NCT03360617|Experimental|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
11203408|NCT03360617|Sham Comparator|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
11203409|NCT03360604|Experimental|Low GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a low glycaemic index. This is the Low Glycaemic Diet intervention.
11203410|NCT03360604|Experimental|High GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a high glycaemic index. This is the High Glycaemic Diet intervention.
11203411|NCT03360591|Experimental|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.
~Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.
~Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.
~Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.
~In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
11203412|NCT03360591|Other|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
11203413|NCT03360552|Experimental|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
11203414|NCT03360552|Placebo Comparator|Usual care|support for patients without multidimensional evaluation (RAI-CA)
11203415|NCT03360539|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
11203416|NCT03360539|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
11203417|NCT03360526|Active Comparator|PICSI|Physiological ICSI
11203418|NCT03360526|Experimental|TESA|Testicular sperm aspiration
11203419|NCT03360513||general group|Comprised 70 caucasian Brazilian individuals with normal occlusion and at least four of Andrew's six keys.
11203420|NCT03360500|Experimental|EXERCISE PROTOCOL + CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
11203421|NCT03360500|Experimental|EXERCISE PROTOCOL|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
11203422|NCT03360500|Placebo Comparator|EXERCISE PROTOCOL + PLACEBO|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
11203457|NCT03360279|Active Comparator|DCB (paclitaxel-coated balloon)|Use DCB (paclitaxel-coated balloon) to perform additional balloon angioplasty.
11203427|NCT03360487|Sham Comparator|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
11203428|NCT03360487|Active Comparator|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
11203429|NCT03360474|Experimental|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
11203430|NCT03360461|Experimental|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
11203431|NCT03360448|Experimental|Experimental|Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
11203432|NCT03360448|Placebo Comparator|Placebo Comparator|Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
11203433|NCT03360435||Participants with transdermal patches|All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch
11203434|NCT03360422|Active Comparator|Survey group|Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
11203435|NCT03360422|Active Comparator|Focus Group|30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
11203436|NCT03360422|Active Comparator|Usability Study|10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
11203437|NCT03360409|Experimental|grade 1|ACD
11203438|NCT03360409|Active Comparator|grade 2|ACDF
11203439|NCT03360409|Active Comparator|grade 3|ACDA
11203440|NCT03360396|Experimental|Endobronchial Coils|Treatment with PneumRx Endobronchial Coil System
11203441|NCT03360396|No Intervention|Control|Medically-managed control group
11203442|NCT03360383|Experimental|grade 1|percutaneous vertebroplasty
11203443|NCT03360383|Active Comparator|grade 2|conservative treatment
11203444|NCT03360370||6 to 66 months children with significant CHD|"Children with significant congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages & Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays."
11203445|NCT03360357|Experimental|guided drills|These people will be going through all the guided drills before being evaluated.
11203446|NCT03360357|No Intervention|Self-trained|These people will watch a video and be able to practice by themselves without having any direction regarding how and what to practice.
11203447|NCT03360344|Experimental|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.
~A tape removal form will be provided should the participants want to remove it prior to the next visit."
11203448|NCT03360344|Sham Comparator|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
11203449|NCT03360344|Active Comparator|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
11203450|NCT03360318|Active Comparator|Elbow cast|Device: Elbow cast
11203451|NCT03360318|Experimental|Removable elbow brace|Device: Removable elbow brace
11203452|NCT03360305|No Intervention|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
11203453|NCT03360305|Experimental|Intervention|"ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.
~PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.
~Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.
~Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
11203454|NCT03360292|Experimental|Higher target range|Infants will be targeted to 92-97% oxygen saturation
11203455|NCT03360292|No Intervention|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
11203456|NCT03360279|Active Comparator|Regular balloon|Use the regular balloon to perform standard balloon angioplasty.
11203460|NCT03360266|Experimental|MI varnish|Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth
11203461|NCT03360253|Experimental|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
11203462|NCT03360253|Placebo Comparator|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
11203463|NCT03360253|Experimental|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
11203464|NCT03360253|Placebo Comparator|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
11203465|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
11203466|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
11203467|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride).
11203468|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
11203469|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride).
11203470|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
11203471|NCT03360201|Experimental|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted in both content and implementation model based on formative research in this context. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection.
11203472|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.
~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
11203473|NCT03360136|Other|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
11203474|NCT03360123|Active Comparator|Midazolam Hydrochloride 2Mg/mL Syrup|"The participants in this arm will receive midazolam+nitrous oxide at the 1st dental appointment.
~Dosage: Midazolam: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment."
11203475|NCT03360123|Active Comparator|Triazolam 0.125 MG|The participants in this arm will receive triazolam+nitrous oxide at the 1st dental appointment. Dosage: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
11203476|NCT03360110|Active Comparator|Test lens|Subjects randomized to wear pair of test lens either first or second
11203477|NCT03360110|Active Comparator|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
11203478|NCT03360097|No Intervention|Fresh ET|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
11203479|NCT03360097|Experimental|Frozen Embryo Transfer|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
11203480|NCT03360071|Experimental|Allergen Immunotherapy Group|
11203481|NCT03360071|Placebo Comparator|Control Group|
11203482|NCT03360058|Experimental|Immediate access to STBD training|Immediate access to training materials and print pieces to support implementation
11203483|NCT03360058|Placebo Comparator|Delayed access to STBD training|Delayed access to training materials and print pieces
11203484|NCT03360045|Active Comparator|Tranexamic acid group|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
11203485|NCT03360045|Placebo Comparator|Placebo group|5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
11203486|NCT03360045|Active Comparator|Merocel Group|Merocel packing is applied.
11203487|NCT03360032||All participants|All patients will be asked to undertake an incremental shuttle walk test and a cardiopulmonary exercise test and the results will be compared.
11203488|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
11203489|NCT03360019|Active Comparator|Resident in independent living setting|
11203490|NCT03360019|Other|Care Partners|
11203491|NCT03360006|Experimental|ABBV-744 Dose Escalation|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
11203492|NCT03360006|Experimental|ABBV-744 Dose Expansion|ABBV-744 will be administered at the recommended Phase 2 dose determined during the Dose Escalation phase.
11203520|NCT03359772|Active Comparator|Group 2|Kinesthetic Ability Trainer Group
11203493|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
11203494|NCT03359980|Experimental|treated patients|Treated with Fecal Microbiota Transfer (FMT)
11203495|NCT03359954|Experimental|Treatment (radiation therapy, surgery)|Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
11203496|NCT03359941|Experimental|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
11203497|NCT03359928|Experimental|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
11203498|NCT03359928|Experimental|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
11203499|NCT03359928|Experimental|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).
~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
11203500|NCT03359915|Experimental|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
11203501|NCT03359915|No Intervention|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
11203502|NCT03359902|Experimental|Initial tVNS|This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
11203503|NCT03359902|Experimental|Initial Sham|This group will receive sham stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
11203504|NCT03359889||patients administered with PraxbindTM|
11203505|NCT03359876||Rivaroxaban|NVAF patients with renal dysfunction newly initiated on rivaroxaban 15 mg for stroke prevention
11203506|NCT03359876||Warfarin|NVAF patients with renal dysfunction newly initiated on vitamin K antagonist (warfarin) for stroke prevention
11203507|NCT03359863|Experimental|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
11203508|NCT03359850|Experimental|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
11203509|NCT03359850|Experimental|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
11203510|NCT03359837|Experimental|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
11203511|NCT03359837|Active Comparator|Premixed insulin|Twice daily premixed insulin
11203512|NCT03359824|Other|Exercise|Arm: Exercise: Combination of moderate intensity continuous training, high intensity interval training and endurance training 5 times per week for a total of 6 weeks. Out of 5 sessions three were supervised by trainer and two sessions were performed by subjects on their own.The duration of the exercise was increased progressively. The first two weeks was 30 minutes that increased to 45 minutes in the third and fourth week. It was 60 minutes for the last two weeks.
11203513|NCT03359811|Experimental|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
11203514|NCT03359811|Active Comparator|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
11203515|NCT03359798|Experimental|Narcotic counseling script|Study participants will be read a script regarding post-cesarean section narcotic use.
11203516|NCT03359798|Sham Comparator|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
11203517|NCT03359785|Experimental|TAK-831 500 mg + TAK-831 50 mg|TAK-831 500 milligrams (mg) or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by TAK-831 50 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
11203518|NCT03359785|Experimental|TAK-831 50 mg + TAK-831 500 mg|TAK-831 50 mg or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by TAK-831 500 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
11203521|NCT03359746|Experimental|Treatment Group|This is a prospective, interventional, case-control study at King Faisal Specialist Hospital & Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir combination. Data will be compared with matched historical controls, which will be selected according to the following matching criteria: age, time from transplant to initiation of therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any patient who received at least one dose of Grazoprevir/Elbasvir combination will be included in the safety analysis.
11203522|NCT03359733|Experimental|TAK-659 100 mg Fasted + TAK-659 100 mg Fed|TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.
11203523|NCT03359733|Experimental|TAK-659 100 mg Fed + TAK-659 100 mg Fasted|TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.
11203524|NCT03359720||guyane|
11203525|NCT03359720||martinique|
11203526|NCT03359720||guadeloupe|
11203527|NCT03359694|Experimental|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
11203528|NCT03359694|Active Comparator|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
11203529|NCT03359694|Experimental|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
11203530|NCT03359694|No Intervention|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.
~No drugs treatment in this group."
11203531|NCT03359681|Active Comparator|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
11203532|NCT03359681|Placebo Comparator|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
11203533|NCT03359668|Experimental|Non-contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
11203534|NCT03359668|Active Comparator|Contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
11203535|NCT03359655|Active Comparator|Rectal misoprostol|200 mcg of misoprostol will be administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
11203536|NCT03359655|Active Comparator|Rectal hyoscine butyl bromide|10 mg hyoscine butyl bromide administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
11203537|NCT03359655|No Intervention|Sham administration|A rectal examination will be performed by a third party health professional who will be blinded to the procedure. No drug will be administered
11203538|NCT03359642|Experimental|Patients with anti-TNF alpha|12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which a first anti-TNF alpha treatment is indicated.
11203539|NCT03359642|Active Comparator|mirror group|"A mirror group of 12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which an all but anti-TNF alpha or biotherapy treatment is indicated will be included to distinguish the specific effects on microbiota of anti-TNF alpha."
11203540|NCT03359616|Experimental|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
11203541|NCT03359616|Active Comparator|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
11203542|NCT03359603|Experimental|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
11203543|NCT03359603|Experimental|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
11203544|NCT03359590|Experimental|Sitagliptin arm|Drug: Sitagliptin
11203545|NCT03359590|Experimental|Placebo arm|Placebo comparator
11203546|NCT03359577|Experimental|Psorax35|Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
11203547|NCT03359577|Placebo Comparator|MCT oil|Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil). Dose: 10 capsules of 590 mg: Route of administration: oral.
11203548|NCT03359564||micro endoscopic discectomy|the patients with lumbar disc herniation
11203549|NCT03359538|Placebo Comparator|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
11203550|NCT03359538|Active Comparator|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
11203551|NCT03359538|Active Comparator|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
11203552|NCT03359525|Experimental|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
11203553|NCT03359525|Experimental|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
11203742|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
11203554|NCT03359525|Experimental|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
11203555|NCT03359512|Experimental|qCON monitor|Simultaneous measurement of BIS and qCON
11203556|NCT03359499|Experimental|Bacillus clausii|Bacillus clausii administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
11203557|NCT03359499|Other|Antispasmodic|Trimebutine administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
11203558|NCT03359486|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
11203559|NCT03359486|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
11203560|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
11203561|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
11203562|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
11203563|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
11203564|NCT03359460|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11203565|NCT03359447|Experimental|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
11203566|NCT03359447|Active Comparator|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
11203567|NCT03359434|Experimental|Two measuring methods of blood pressure|
11203568|NCT03359421||Aeromedical transport|Patients transported to trauma center by helicopter
11203569|NCT03359421||Ground transport|Patients transported to trauma center by ground ambulance
11203570|NCT03359408|No Intervention|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
11203571|NCT03359408|Experimental|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
11203572|NCT03359395|Active Comparator|Alfentanil|
11203573|NCT03359395|Placebo Comparator|placebo|
11203574|NCT03359382|No Intervention|control|
11203575|NCT03359382|Experimental|exercise|
11203576|NCT03359369||Septic Patients|
11203577|NCT03359369||Non Septic Patients|
11203578|NCT03359356|Experimental|Dupilumab|An initial dose of 600 mg (two 300 mg subcutaneous injections), followed by 300 mg given every other week
11203579|NCT03359356|Placebo Comparator|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
11203580|NCT03359343||experts|In this group, two experts distinguish a set of polyps on LCI images as adenoma or non-adenoma.
11203581|NCT03359343||non-experts|In this group, two non-experts distinguish the set of polyps(the same to experts group) on LCI images as adenoma or non-adenoma.
11203582|NCT03359343||Computer-aided diagnosis system|In this group, a newly developed computer-aided diagnosis system will be used to distinguish a set of polyps as adenoma or non-adenoma.
11203583|NCT03359330||Degradable conduit small gap tublization|patients with fresh peripheral nerve injury in the upper extremities,repaired with degradable conduit small gap tublization
11203584|NCT03359317|Experimental|jogging|At least 5 times/week
11203585|NCT03359291|Experimental|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
11203586|NCT03359278||open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
11203587|NCT03359265|Active Comparator|Test|The test group used underpants made of precious metal fibers (germanium, titanium and phosphorus), developed by Green Energy Nano Technology Co., Ltd.
11203588|NCT03359265|Placebo Comparator|Control|The control group used commercially available underpants.
11203589|NCT03359252|Active Comparator|non-stent assisted coiling|patients treated with non-stent assisted coiling of unruptured intracranial aneurysms
11203590|NCT03359252|Experimental|stent assisted coiling|patients treated with stent assisted coiling of unruptured intracranial aneurysm
11203591|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
11203592|NCT03359226|Experimental|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
11203593|NCT03359213|Experimental|JR-141 1.0 mg/kg/week|
11203594|NCT03359213|Experimental|JR-141 2.0 mg/kg/week|
11203595|NCT03359213|Experimental|JR-141 4.0 mg/kg/week|
11203596|NCT03359187|Active Comparator|Normal saline with salt/Soda|Normal saline with salt/soda rinse 4 times a day/everyday and for each time 15 ml.
11203597|NCT03359187|Experimental|Clinacanthus nutans|Clinacanthus nutans in form of mouth wash rinse 4 times a day/everyday and for each time 15 ml.
11203598|NCT03359187|Experimental|Boesenbergia rotunda|Boesenbergia rotunda in form of mouth wash 4 times a day/everyday and for each time 15 ml.
11203599|NCT03359174|Experimental|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
11203743|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
11203744|NCT03358134|Experimental|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
11203600|NCT03359161|Experimental|In-Home Subcutaneous Furosemide Treatment ARm|Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
11203601|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
11203602|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
11203603|NCT03359135||group1|hEDS treated with rehabilitation only
11203604|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
11203605|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
11203606|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
11203607|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
11203608|NCT03359096|Experimental|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
11203609|NCT03359096|Sham Comparator|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
11203610|NCT03359070|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
11203611|NCT03359070|Active Comparator|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
11203612|NCT03359057|Experimental|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
11203613|NCT03359057|Placebo Comparator|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
11203614|NCT03359044||Sedation + topical anesthesia|midazolam 0.1～0.2 mg/kg for sedation, 2%lidocaine for topical anesthesia
11203615|NCT03359044||General anesthesia+ topical anesthesia|propofol 4～5mg/kg、Remifentanil2～3μg/kg for induction ,insert Laryngeal Mask Airway(LMA) , 2%lidocaine for topical anesthesia
11203616|NCT03359031|No Intervention|No patient education|This group of patients will not receive any additional information beyond standard of care educational pamphlets provided by the hospital.
11203617|NCT03359031|Other|Patient education|This group of patients will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
11203618|NCT03359018|Experimental|apatinib plus anti-PD1 therapy arm|Every patients will received apatinib 250mg or 500mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
11203619|NCT03359005|Experimental|5d VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 50mg/m2/d IV over 60 minutes on days 1-5.
~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
11203620|NCT03359005|Active Comparator|5d x 2 VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 20mg/m2/d IV over 60 minutes on days 1-5 and 8-12.
~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
11203621|NCT03358979||Severe eye dryness|
11203622|NCT03358979||absence of eye dryness|
11203623|NCT03358966||Early to moderate CKD (stage 1-3)|40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
11203624|NCT03358966||Advanced CKD (stage 4-5)|40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
11203625|NCT03358953|Other|Electronic Cigarettes|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the electronic cigarette arm. They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
11203626|NCT03358953|Other|Nicotine replacement patches|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the nicotine replacement patch arm (standard care). They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
11203627|NCT03358940|Other|patient with miscarriage complications or not|The day of inclusion, for patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
11203628|NCT03358927|Active Comparator|Standard Group|Deferred fast-track care
11203629|NCT03358927|Experimental|Immediate Fast-Track Group|Immediate fast-track care
11203630|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
11203631|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
11203632|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
11205080|NCT03348839|Experimental|Cluster 4|NeLLY service is implemented after 20 months.
11203633|NCT03358901|Experimental|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
11203634|NCT03358901|Placebo Comparator|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
11203635|NCT03358888|Active Comparator|Standard of Care|
11203636|NCT03358888|Active Comparator|Multi-modal with as needed opioids|
11203637|NCT03358888|Active Comparator|Multi-modal with one week of opioids offered|
11203638|NCT03358875|Experimental|BGB-A317|100 mg per vial, 200mg intravenous (IV), Q3W
11203639|NCT03358875|Experimental|Docetaxel|75 mg/m2 IV Q3W
11203640|NCT03358862||Myopes|Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
11203641|NCT03358849|Experimental|experimental group|
11203642|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
11203643|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
11203644|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of >10%
11203645|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
11203646|NCT03358810|Active Comparator|Active group|patients randomized to receive active PES
11203647|NCT03358810|Sham Comparator|Sham treatmment|Patients randomized to sham will not receive any PES.
11203648|NCT03358797|Experimental|intervention-HPP|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
11203649|NCT03358797|Experimental|CBLI+RT|based on randomization, group that will be assigned to CBLI+RT will receive the CBLI curriculum (as described in the intervention-HPP arm) in addition to the resiliency training
11203650|NCT03358797|Experimental|Attention control (CBLI-)|The attention control group will receive the core curriculum of the CBLI (as described in the intervention-HPP arm) only without the resiliency training. The sessions of the resiliency training will be replaced with sessions on health topics that do not contribute to our outcome (increased resiliency) (i.e. breast cancer, osteoporosis)
11203651|NCT03358797|Experimental|Pilot|This group will not be randomized. The group will receive the CBLI content (as described in the intervention-HPP arm) in addition to the resiliency training. The aim of this pilot is to create a resiliency training manual to be implemented in the following groups that will be assigned to receive the CBLI+RT
11203652|NCT03358784||PHILOS Plate|three or four-part fractures of proximal humerus treated with internal fixation
11203653|NCT03358784||Hemi-shoulder arthroplasty|three or four-part fractures of proximal humerus treated with hemi-shoulder arthroplasty
11203654|NCT03358771|No Intervention|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
11203655|NCT03358771|Active Comparator|COPD discharge care bundle|"COPD discharge care bundle:
~Ensure patient has demonstrated adequate inhaler technique
~Send discharge summary to family physician office and arrange follow-up
~Optimize and reconcile prescription of respiratory medications
~Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions
~Refer to pulmonary rehabilitation
~Screen for frailty and comorbid condition(s)
~Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
11203656|NCT03358771|Experimental|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
11203657|NCT03358745|Experimental|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
11203658|NCT03358745|Experimental|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
11203659|NCT03358745|Experimental|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
11203660|NCT03358745|Experimental|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
11203661|NCT03358732|Experimental|Mock embryo transfer|The patients underwent a mock embryo transfer one day before the scheduled actual transfer
11203662|NCT03358732|No Intervention|No mock embryo transfer|The patients did not undergo mock embryo transfer one day before the scheduled actual transfer
11204008|NCT03356106|Experimental|CPAP|Nocturnal administration of continuous positive airway pressure treatment (CPAP) until delivery
11203663|NCT03358719|Experimental|Treatment (CDX-1401, poly ICLC, decitabine, nivolumab)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.
11203664|NCT03358706|Experimental|Crohn's Disease or Ulcerative Colitis Participants: Ustekinumab + Probe Cocktail|Participants will receive a single Intravenous (IV) infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8 and a ustekinumab 90 milligram (mg) maintenance dose via subcutaneous (SC) route on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator. The probe cocktail (2 milligram [mg] of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) will be administered orally on Days 1, 22, and 113.
11203665|NCT03358706|Experimental|Healthy Participants: Probe Cocktail|Participants will receive the probe cocktail (2 mg of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) orally on Day 1.
11203666|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
11203667|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
11203668|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
11203669|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
11203670|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
11203671|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
11203672|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
11203673|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
11203674|NCT03358654|Experimental|mesenchymal stem cells|Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection
11203675|NCT03358641||Wuchuan residents|All residents that meet the criteria can be enrolled in this group, receiving a home interview (including IPA-Q to assess the level of physical activity) and a weight-bearing posteroanterior semiflexed view of radiographs at tibiofemoral (TF) joints at baseline and 3 years later.
11203676|NCT03358628||Osteosarcoma|Osteosarcoma patients with metastatic relapsed or unresectable progressive disease (total n= up to 20) following resection of the primary lesion and adjuvant chemotherapy.
11203677|NCT03358602|Experimental|Radiotherapy|Radiotherapy & open partial supraglottic laryngectomy(primary tumor)
11203678|NCT03358602|Active Comparator|Elective neck dissection|Elective neck dissection & open partial supraglottic laryngectomy(primary tumor)
11203679|NCT03358589|Other|MESTAR|All patients will have the same scans performed
11203680|NCT03358576|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
11203681|NCT03358576|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
11203682|NCT03358563|Experimental|Degarelix SC + bicalutamide + docetaxel|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3
11203683|NCT03358563|Experimental|DegarelixSC+bicalutamide+docetaxel+Ferumoxytol enhanced MRI|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3 + Ferumoxytol enhanced MRI within 21 days prior to start of hormonal therapy and second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
11203684|NCT03358550|Experimental|Accommodation in scotopic luminance|
11203685|NCT03358537|Active Comparator|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
11203686|NCT03358537|Active Comparator|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
11203687|NCT03358524|Experimental|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
11203688|NCT03358524|Placebo Comparator|Placebo|Placebo capsule once per day orally for 8 weeks
11203689|NCT03358511|Experimental|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
11203690|NCT03358498||β-thalassemia group|"SICT It is a questionnaire to assess patient satisfaction with ICT regimens. It comprises 19 items assessing four domains: perceived effectiveness of ICT (PE), burden of ICT (BD), acceptance of ICT (AC), and side effects of ICT (SE). Patients rate all items on scale from 1 very dissatisfied to 5 very satisfied.
~Lab methods :
~full history and thorough clinical evaluation.
~. Complete blood count. .3- Serum ferritin .
~4-Renal function tests. 5-liver function tests."
11203691|NCT03358485|Experimental|Aolanti Weikang tablets|3，6 or 8 Aolanti Weikang tablets each time,tid
11203692|NCT03358485|Placebo Comparator|Placebo|3,6 or 8 tablets each time,tid
11203693|NCT03358472|Experimental|Pembrolizumab + Epacadostat|
11203694|NCT03358472|Experimental|Pembrolizumab|
11203695|NCT03358472|Active Comparator|EXTREME|EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.
11203696|NCT03358459||EP|For diagnosis non-acquired epilepsy;
11203697|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.
~A group is the patients with non-overlapping range"
11203698|NCT03358446||S group|S group is the patients without non-overlapping range
11203699|NCT03358433|Experimental|Exercise|
11203700|NCT03358433|Active Comparator|Antidepressants|
11203701|NCT03358407|Experimental|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
11203702|NCT03358407|Experimental|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
11203703|NCT03358407|Experimental|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
11203704|NCT03358407|Experimental|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
11203705|NCT03358394|Experimental|Intervention group|The intervention group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention time period(i.e., after five weeks).
11203706|NCT03358394|Experimental|Control group|"The control group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention after six weeks.
~At the end of the pilot trial, control group will receive the full intervention. They would be sent the materials week by week as same as the intervention group."
11203707|NCT03358381|Experimental|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
11203708|NCT03358381|Active Comparator|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
11203709|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
11203710|NCT03358342||ED Patients treated using ePneumonia CDS|ED patients with community-acquired pneumonia treated in ED's after roll out of ePneumonia
11203711|NCT03358342||Usual care|ED patients with pneumonia receiving usual care without electronic CDS
11203712|NCT03358329|Experimental|S8 Sinus Implant|corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
11203713|NCT03358316||cuff tear patients|Patients with cuff tear
11203714|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
11203715|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
11203716|NCT03358290|Experimental|JTE-051 Dose 1|JTE-051 dose 1 for 12 weeks
11203717|NCT03358290|Experimental|JTE-051 Dose 2|JTE-051 dose 2 for 12 weeks
11203718|NCT03358290|Experimental|JTE-051 Dose 3|JTE-051 dose 3 for 12 weeks
11203719|NCT03358290|Experimental|JTE-051 Dose 4|JTE-051 dose 4 for 12 weeks
11203720|NCT03358290|Experimental|Placebo|Placebo for 12 weeks
11203721|NCT03358277|Experimental|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
11203722|NCT03358264|Experimental|Type 2 diabetic patients|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c>6
11203723|NCT03358264|Experimental|Healthy volunteers|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers
11203724|NCT03358251|Other|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
11203725|NCT03358238|Placebo Comparator|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
11203726|NCT03358238|Experimental|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
11203727|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
11203728|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
11203729|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
11203730|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
11203731|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
11203732|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
11203733|NCT03358186||revision of periprosthetic fracture|patients with surgically treated periprosthetic femur fracture
11203734|NCT03358173||Conservative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
11203735|NCT03358173||Operative Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the humeral shaft fracture will be carried out
11203736|NCT03358160||TKA|Orthopaedic patients who underwent surgical operation for total knee arthroprothesis.
11203737|NCT03358160||Rizoarthrosis|Orthopaedic patients who underwent surgical operation to treat chronic arthrosis of the thumb.
11203738|NCT03358160||Healthy Controls|Healthy age-matched controls.
11203739|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
11203740|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
11203741|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
11203745|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
11203746|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
11203747|NCT03358108||Group A: interferon group|formerly interferon group (including interferon alone or interferon combined with other drugs)
11203748|NCT03358108||Group B:nucleoside analogue group|formerly nucleoside analogue treatment group. Each group was followed for five years
11203749|NCT03358095|No Intervention|Early surgery|Patients in this group proceed to pancreatic resection within 2 week of recruitment.
11203750|NCT03358095|Active Comparator|Preoperative biliary drainage|Endoscopic retrograde cholangiopancreatography (ERCP) is used to place an endoprosthesis to the biliary ducts to drain biliary stasis, and the patients proceed to pancreatic resection within 6 weeks of recruitment.
11203751|NCT03358082|Active Comparator|Tacrolimus group|Tacrolimus 0.03% ointment twice daily for 6 months
11203752|NCT03358082|Active Comparator|Hydrocortisone group|hydrocortisone acetate 1% ointment twice daily for 6 months
11203753|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
11203754|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
11203755|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
11203756|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
11203757|NCT03358056|Experimental|Mindfulness-based Cognitive Therapy|
11203758|NCT03358030|Placebo Comparator|Placebo|Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
11203759|NCT03358030|Experimental|Cohort A: ISIS 416858, 200 mg|Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
11203760|NCT03358030|Experimental|Cohort B: ISIS 416858, 250 mg|Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
11203761|NCT03358030|Experimental|Cohort C: ISIS 416858, 300 mg|Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
11203762|NCT03358017|Active Comparator|ARM A - standard NACT|Standard anthracyclines/taxanes based neoadjuvant chemotherapy chosen by the investigator and administered according to clinical practice, for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
11203763|NCT03358017|Experimental|ARM B - standard NACT + Zol + atorvastatin|Standard anthracyclines/taxanes based neoadjuvant CT chosen by the investigator and administered according to clinical practice + Zoledronate 4 mg i.v. every 3-4 weeks and Atorvastatin 80 mg/die administered for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
11203764|NCT03358004|Experimental|ARM A|Vinorelbine 50 mg, thrice a week
11203765|NCT03358004|Experimental|ARM B|Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day
11203766|NCT03357978|Other|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution
~bioelectrical impedance Analysis
~blood draw
~transient elastography (FibroScan)
~ataxia score
~Five-Times-Sit-to-Stand Test"
11203767|NCT03357952|Experimental|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
11203768|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
11203769|NCT03357939|Experimental|HLX03|There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
11203770|NCT03357939|Active Comparator|Humira|There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
11203771|NCT03357926||Observation Group|
11203772|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
11203773|NCT03357900|Experimental|Orthotopic liver transplantation|
11203774|NCT03357874|Experimental|Clopidogrel group|
11203775|NCT03357874|Experimental|Ticagrelor group|
11203776|NCT03357848||Study group|Surgical patients receiving nutritional support (enteral and/or parenteral nutrition) pre and/or after surgery
11203777|NCT03357848||Control group|Surgical patients without nutritional support during the perioperative period
11203778|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
11203812|NCT03357627|Experimental|Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
11204009|NCT03356106|No Intervention|Control|Usual antenatal care for high risk pregnancy
11205081|NCT03348839|Experimental|Cluster 5|NeLLY service is implemented after 24 months.
11203779|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
11203780|NCT03357822|Experimental|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
11203781|NCT03357822|Active Comparator|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
11203782|NCT03357809|Experimental|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
11203783|NCT03357796|Experimental|Group A: LY03005 cross-over to Pristiq®|Subjects in Group A will receive an 80 mg oral dose of LY03005 and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator followed by a 4-day stay in the CRU (Period 2).
11203784|NCT03357796|Experimental|Group B: Pristiq® cross-over to LY03005|Subjects in Group B will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005 followed by a 4-day stay in the CRU (Period 2).
11203785|NCT03357770|Experimental|low dose of mesenchymal stem cells|Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 × 10^7cells / 3mL
11203786|NCT03357770|Experimental|medium dose of mesenchymal stem cells|the medium-dose is 5 × 10^7cells / 3mL
11203787|NCT03357770|Experimental|high dose of mesenchymal stem cells|the high dose is 1 × 10^8cells / 3mL
11203788|NCT03357757|Experimental|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
11203789|NCT03357731|Experimental|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
11203790|NCT03357731|Experimental|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
11203791|NCT03357731|Experimental|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
11203792|NCT03357731|Experimental|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
11203793|NCT03357731|Experimental|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
11203794|NCT03357731|Experimental|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
11203795|NCT03357718|Experimental|Dexmedetomidine|2 µg/kg Precedex
11203796|NCT03357718|Active Comparator|Midazolam|0.5 mg/kg dormicum
11203797|NCT03357705|Experimental|synthetic|alveolar ridge preservation with synthetic bone
11203798|NCT03357705|Active Comparator|collagen|alveolar ridge preservation with bovine collagen
11203799|NCT03357692|Experimental|maxillary total edentulism|all on four implant rehabilitation with trans-sinusal implants
11203800|NCT03357679|Active Comparator|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
11203801|NCT03357679|Active Comparator|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
11203802|NCT03357666|Experimental|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
11203803|NCT03357666|Experimental|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
11203804|NCT03357666|Experimental|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
11203805|NCT03357666|Experimental|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
11203806|NCT03357666|Placebo Comparator|Placebo|Placebo, once a day, two tablets at a time for 7 days
11203807|NCT03357653|Experimental|Losartan group|Losartan 50 mg daily
11203808|NCT03357653|Placebo Comparator|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
11203809|NCT03357640|Placebo Comparator|no intervention|The women will receive one package of placebo. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
11203810|NCT03357640|Active Comparator|combined oral contraception pills|The women will receive intervention of one package of combined oral contraception pills and will be counseled about how to take oral contraception and informed of possible side effects. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
11203811|NCT03357627|Experimental|Dose Escalation: TAK-659 + Venetoclax|TAK-659 40, 60, 80, or 100 milligram (mg) (tablet, orally, once daily, up to 35 days in Cycle 1 or in different intermittent schedules [7 days dosing followed by 7 days off or 14 days dosing followed by 7 days off or other intermittent dosing schedules]) along with venetoclax 200, 400, 800 or 1200 mg (tablet, orally, once daily, up to 35 days in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.
11203813|NCT03357627|Experimental|Safety Expansion: Follicular Lymphoma (FL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
11203814|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
11203815|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
11203816|NCT03357601|Experimental|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
11203817|NCT03357601|Experimental|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
11203818|NCT03357588|Active Comparator|Control|Standard of Care monitoring
11203819|NCT03357588|Experimental|Intervention|Intensified monitoring
11203820|NCT03357575|Experimental|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
11203821|NCT03357575|Active Comparator|hyaluronic acid|Hyaluronic acid will be injectied.
11203822|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
11203823|NCT03357549|Experimental|Brief Motivational Intervention|The women of this group will receive a Brief Motivational Intervention during 20 or 30 minutes.
11203824|NCT03357549|Active Comparator|Breastfeeding education|The women of this group will receive a standard education about breastfeeding during 20-30 minutes
11203825|NCT03357536|Experimental|Patients with Listeriosis|"Patients with Listeriosis.
~Human biological samples :
~Blood sample
~Skin biopsy
~Saliva"
11203826|NCT03357536|Experimental|Volunteers related with patients with Listeriosis|"Volunteers related with patients with Listeriosis.
~Human biological samples :
~Blood sample
~Skin biopsy
~Saliva"
11203827|NCT03357523|Experimental|Red LED|Light emitting diodes, 633 nm, 70 mW/cm2, Omnilux new-U (Red LED) (Photomedex, Horsham, PA, USA); RESPeRATE; Heating bag
11203828|NCT03357523|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/ cm2, Omnilux new-U (Near infrared LED) (Photomedex, Horsham, PA, USA); RESPeRATE metronome; Heating bag
11203829|NCT03357497|Experimental|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
11203830|NCT03357497|No Intervention|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
11203831|NCT03357484|Experimental|L-PRF|Third molar extraction sockets were filled with two leukocyte- and platelet rich fibrin (L-PRF) clots
11203832|NCT03357484|Active Comparator|Blood clot|Third molar extraction sockets allowed to form a natural blood clot and undergo natural healing
11203833|NCT03357471|Experimental|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
11203834|NCT03357471|Experimental|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
11203835|NCT03357458|Experimental|Family Integrated Care|Study participants receive FICare, a dynamic psycho-educational intervention, while their infant(s) was/were admitted to a Level II NICU.
11203836|NCT03357458|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
11203837|NCT03357445|Other|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
11203838|NCT03357445|Other|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
11203839|NCT03357432|Experimental|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
11203840|NCT03357419|Active Comparator|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.
~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
11203841|NCT03357419|Placebo Comparator|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
11203842|NCT03357406|Experimental|edentulism side 1|ultrasound implant site preparation
11203843|NCT03357406|Active Comparator|edentulism side 2|conventional implant site preparation
11203844|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
11203845|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
11203846|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
11203847|NCT03357380|Experimental|Semaglutide|Semaglutide will be initiated with a starting dose of 0.05 mg/day for the first 4 weeks. The dose will be increased every 4 weeks until the target dose of 0.4 mg/day has been reached.
11203848|NCT03357380|Placebo Comparator|Placebo|Placebo will be initiated with a starting volume corresponding to 0.05 mg/day of semaglutide for the first 4 weeks. The volume will then be increased every 4 weeks until the target volume corresponding to 0.4 mg/day of semaglutide has been reached.
11203849|NCT03357367|Experimental|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).
~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
11203850|NCT03357354|Experimental|Obese Children in precarious situations|
11203851|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
11203852|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
11203853|NCT03357328|Active Comparator|Therapy light room|This group (4 NH units, about 35 patients) will receive light therapy administered via LED technology. The light will vary in intensity and colour temperature throughout the day. Ceiling-mounted LED-lights are installed in the living rooms of participating nursing home units. Between 07:00 and 10:00 light of 400 lux at eye level, with 4000 K, will be provided. Between 10:00 and 15:00 the light will comprise 1000 lux at eye level, with 6000 K. From 15:00 to 18:00 the light will comprise 400 lux at eye level and 4000 K. When light is on from 18:00 to 07:00, standard light (about 100 lux at eye level, 3000K) will be administered.
11203854|NCT03357328|Placebo Comparator|Standard light|"This group (4 NH units, about 35 patients) will receive standard light (100 lux at eye level, 3000K). The light will be administered between 07:00 and 18:00; and the same when light is on between 18:00 to 07:00. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."
11203855|NCT03357315|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11203856|NCT03357315|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11203857|NCT03357289|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11203858|NCT03357289|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11203859|NCT03357276|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11203860|NCT03357276|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11203861|NCT03357263|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
11203862|NCT03357263|Active Comparator|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
11203863|NCT03357237|Experimental|XYLOGLUCAN|treatment regimen with oral rehydration solution and xyloglucan
11203864|NCT03357237|Placebo Comparator|PLACEBO|rehydration solution and placebo.
11203865|NCT03357224|Experimental|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
11203866|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
11203867|NCT03357172|Experimental|Recipient|
11203868|NCT03357172|Experimental|Donor|
11203869|NCT03357159|Experimental|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
11203870|NCT03357146||CRA|Patients with chronic retinal artery occlusion
11203871|NCT03357146||Control|Healthy
11203872|NCT03357133|Experimental|Tirofiban and alteplase|
11203873|NCT03357133|Placebo Comparator|Alteplase|
11203874|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
11203875|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
11203876|NCT03357068|Active Comparator|Control|Autogenous bone block surgery without treatment of bone surfaces.
11203877|NCT03357068|Experimental|Acid|Autogenous bone block surgery with citric acid treatment of bone block and recipient site
11203878|NCT03357055|Experimental|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
11203879|NCT03357055|Placebo Comparator|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
11203880|NCT03357042|Experimental|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
11203881|NCT03357042|Active Comparator|Healthy control|Persons without post-concussive symptoms. No intervention.
11203882|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
11203883|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
11203884|NCT03357016|Experimental|High Intensity Interval Training program (HIIT)|Subjects perform three sessions of training during 12 weeks: 35 min at 50% maximal aerobic power on bicycle.
11203885|NCT03357016|Experimental|Moderate Intensity Continuous Training program (MICT)|Subjects perform three sessions of training during 12 weeks: repeated cycles of sprinting for 8s and pedaling slowly for 12s (between 20 and 30 rpm) for a maximum of 60 repeats per session.
11203886|NCT03357016|Experimental|HIIT + Resistance Training program (RT)|Subjects perform three sessions of training during 12 weeks: Each subject performed HIIT protocol and then a single set of 8 exercises with 1 ou 2min resting period between exercises. Each set consisted of 8-12 repetitions at about 80% maximum repetition.
11203887|NCT03356990|Experimental|Resistant Starch|"Intervention:
~Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose in the evening
~Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).
~Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).
~Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks)."
11203888|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
11203889|NCT03356964|Active Comparator|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
11203890|NCT03356964|Experimental|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
11203891|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
11203892|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
11203893|NCT03356938|No Intervention|Baseline recording|
11203894|NCT03356938|Experimental|Sleep restriction|
11203895|NCT03356938|Experimental|Sleep deprivation|
11203896|NCT03356925|No Intervention|Centralised Xpert®Ultra testing|Patients are selected to receive the standard of care for TB diagnosis at a centralised laboratory facility
11203897|NCT03356925|Active Comparator|Xpert Ultra Point of Care testing|Patients are selected to receive the point of care for TB diagnosis at the clinic facility they are visiting
11203898|NCT03356912|Active Comparator|Cabazitaxel plus prednisone|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks, plus prednisone 10 mg orally given daily. Premedication must be administered according to Cabazitaxel Package Insert.
11203899|NCT03356912|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks. Premedication must be administered according to Cabazitaxel Package Insert.
11203900|NCT03356899|Active Comparator|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
11203901|NCT03356899|Active Comparator|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
11203902|NCT03356886|Experimental|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
11203903|NCT03356886|Active Comparator|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
11203904|NCT03356873|Experimental|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
11203905|NCT03356873|Placebo Comparator|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
11203906|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
11203907|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
11203908|NCT03356847|Experimental|SISA implant|
11203909|NCT03356834|Experimental|TDF switch to TAF|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
11203910|NCT03356834|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
11204006|NCT03356132||Polyurethane Group|Women undergoing primary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
11203911|NCT03356821|Experimental|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
11203912|NCT03356808|Experimental|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
11203913|NCT03356795|Experimental|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
11203914|NCT03356782|Experimental|Sarcoma-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.
11203915|NCT03356769|Experimental|experimental：asprin & AEDS|Aspirin 5mg/kg，maximum 300mg; once a day plus AEDS
11203916|NCT03356769|Placebo Comparator|control: placebo & AEDS|placebo 5mg/kg，maximum 300mg; once a day plus AEDS
11203917|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
11203918|NCT03356743|Experimental|Ex-Vivo|
11203919|NCT03356730|Experimental|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
11203920|NCT03356730|Placebo Comparator|Arm placebo|Placebo for 2 months (10 drops after lunch)
11203921|NCT03356717|Experimental|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.
~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
11203922|NCT03356717|Active Comparator|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
11203923|NCT03356704||General anaesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had general anesthesia
11203924|NCT03356704||continued spinal anesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had continued spinal anesthesia
11203925|NCT03356704||peripheral nerve blocks|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had peripheral nerve blocks
11203926|NCT03356691|No Intervention|Control group|No intervention.
11203927|NCT03356691|Experimental|Complementary Spiritist Therapy|"Prayer, Spirit education, Spiritist passe and magnetized water"
11203928|NCT03356691|Other|Prayer|Prayer during 1-2 minutes
11203929|NCT03356691|Other|"Spiritist passe"|"Spiritist passe during 5-10 minutes."
11203930|NCT03356691|Placebo Comparator|Laying on of hands with intent to heal|laying on of hands with intent to heal during 5-10 minutes.
11203931|NCT03356691|Other|Fluid water or magnetized water|Spiritist healers laying on of hands hands on the glass of water and desire health, restoration of balance and health for the patient.
11203932|NCT03356691|Other|Non-fluidic water|individuals receive water without fluidification (no laying on of hands hands on the glass of water).
11203933|NCT03356665|Experimental|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
11203934|NCT03356652|Experimental|Tailor-made CRT delivery|Patient undergoes acute noninvasive electrical dyssynchrony study with various CRT configurations. CRT device is then implanted with optimal configuration.
11203935|NCT03356639|Experimental|ASP6981 50 mg, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
11203936|NCT03356639|Experimental|Matching Placebo, then ASP6981 50 mg|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
11203937|NCT03356639|Experimental|ASP6981 135 mg, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
11203938|NCT03356639|Experimental|Matching Placebo, then ASP6981 135 mg|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
11203939|NCT03356626|Experimental|ULTRACISION Harmonic Scalpel|Patients group randomized to use ULTRACISION Harmonic Scalpel when receives laparoscopic gastrectomy
11203940|NCT03356626|Experimental|Ligasure Maryland|Patients group randomized to use Ligasure Maryland when receives laparoscopic gastrectomy
11203941|NCT03356626|Experimental|Thunderbeat|Patients group randomized to use Thunderbeat when receives laparoscopic gastrectomy
11203942|NCT03356613||focus group of paramedical staff from Nancy|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
11204037|NCT03355976|Experimental|Arm 1 Nivolumab Extra-renal|Nivolumab 240 mg Day 1 Cycle = 2 weeks
11203943|NCT03356613||focus group of paramedical staff from Metz|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
11203944|NCT03356613||focus group of paramedical staff from Dijon|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
11203945|NCT03356613||focus group of paramedical staff from Bar-le-Duc|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
11203946|NCT03356613||Test of the tool by paramedical staff center 1|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
11203947|NCT03356613||Test of the tool by paramedical staff center 2|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
11203948|NCT03356600|Experimental|Apatinib plus radiotherapy|"Apatinib:
~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.
~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.
~Radiotherapy:
~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy."
11203949|NCT03356587|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
11203950|NCT03356561|Experimental|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5*10^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
11203951|NCT03356561|Experimental|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5*10^10 vp on Day 1 and placebo on Day 57 via IM route.
11203952|NCT03356561|Experimental|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1*10^11 vp via IM route on Days 1 and 57.
11203953|NCT03356561|Experimental|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1*10^11 vp on Day 1 and placebo on Day 57 via IM route.
11203954|NCT03356561|Placebo Comparator|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
11203955|NCT03356509|Experimental|Exercise|They will do a 26-min bout of high intensity interval exercise.
11203956|NCT03356509|No Intervention|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
11203957|NCT03356496|Experimental|Intervention|Patient provided with instructions and video for the use of an incentive spirometry device. Patient instructed to use incentive spirometry device as frequently as every hour while awake but at least 4 times daily for at least 10 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
11203958|NCT03356496|No Intervention|Control|Patient receives only usual care as provided by perioperative healthcare providers.
11203959|NCT03356483|Experimental|Psilocybin|Psilocybin (0.25mg/kg)
11203960|NCT03356483|Placebo Comparator|Niacin|Niacin (250mg)
11203961|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
11203962|NCT03356457|Active Comparator|DCA in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
11203963|NCT03356457|Placebo Comparator|Placebo in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a placebo oral capsule.
11203964|NCT03356457|Active Comparator|DCA in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study. Each subject will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
11203965|NCT03356457|Placebo Comparator|Placebo in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study will receive a placebo oral capsule.
11203966|NCT03356444|Experimental|Abiraterone group|Abiraterone acetate is administered in this arm.
11203967|NCT03356444|Active Comparator|Docetaxel group|Docetaxel is administered in this arm.
11203968|NCT03356431|Experimental|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
11203969|NCT03356431|Experimental|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.
~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).
~The exercise program are the same as the supervised group exercise."
11203970|NCT03356418|Experimental|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
11204007|NCT03356119|Experimental|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
11256625|NCT02995057||Nickel allergic|Participants have proven nickel allergy
11203971|NCT03356418|Sham Comparator|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
11203972|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention: telephone call on day 90 to assess the primary outcome (mRs d90)
11203973|NCT03356379|Experimental|Patients|Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing
11203974|NCT03356379|Sham Comparator|Controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing
11203975|NCT03356366|Experimental|Principal study|Patients pathological process will be assessed using MRI 3T
11203976|NCT03356366|Experimental|Ancillary study 1|Patients pathological process will be assessed using MRI 1,5T
11203977|NCT03356366|Experimental|Ancillary study 2|Patients pathological process will be assessed using MRI 7T
11203978|NCT03356353|Experimental|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
11203979|NCT03356327|Experimental|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
11203980|NCT03356327|Active Comparator|Group 2|Group 2 consisting of 30 children who received only SOR.
11203981|NCT03356301|Experimental|Triathletes|Every triathlete will realize three cardiac MRI exams.The second of those will be done at the fitness peak, 2-3 weeks before the main objective of the sports season. Training will be increased between the study beginning and the first MRI, and the second exam. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
11203982|NCT03356301|Experimental|Controls|Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
11203983|NCT03356288||Asthma|20 Participants with moderate to severe asthma, as defined by British Thoracic Society (BTS) guidelines
11203984|NCT03356288||Chronic heart failure|10 Participants with a diagnosis of chronic heart failure
11203985|NCT03356288||Breathing Pattern Disorder|10 Participants with a diagnosis of Breathing Pattern Disorder
11203986|NCT03356288||Pneumonia|10 participants with a radiologically confirmed diagnosis of pneumonia
11203987|NCT03356288||Motor Neurone Disease|10 participants with a diagnosis of motor neurone disease with known hypercapnic failure.
11203988|NCT03356288||Healthy|10 Participants who have no known lung, cardiac or neuromuscular condition.
11203989|NCT03356275|Experimental|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
11203990|NCT03356249||Sepsis Group|Patients (n=500) with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions).
11203991|NCT03356236||Observation group 1|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1
11203992|NCT03356236||Observation group 2|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2
11203993|NCT03356223|Experimental|Abemaciclib|
11203994|NCT03356210|No Intervention|Treatment as usual (TAU)|This control group will receive treatment as usual; conventional counseling
11203995|NCT03356210|Experimental|Neurofeedback + TAU|20 sessions of symptom-based NF training in conjunction with traditional therapy
11203996|NCT03356184|Experimental|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11203997|NCT03356184|Active Comparator|The Earlysense System Device Group|The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11203998|NCT03356171|Experimental|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
11203999|NCT03356171|Active Comparator|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
11204000|NCT03356158|Experimental|CPGJ 602 low dose|Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
11204001|NCT03356158|Experimental|CPGJ 602 normal dose|Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
11204002|NCT03356158|Active Comparator|Cetuximab normal dose|Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.
11204003|NCT03356145|Experimental|12 mL arm|"Intervention:
~Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle
~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix
~The tenaculum is immediately placed at the previously injected site
~The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)
~No wait time between injection and dilator insertion"
11204004|NCT03356145|Active Comparator|20 mL arm|"Intervention:
~Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle
~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix
~The tenaculum is immediately placed at the previously injected site
~The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)
~No wait time between injection and dilator insertion"
11204005|NCT03356132||Textured Group|Women undergoing primary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
11205082|NCT03348839|Experimental|Cluster 6|NeLLY service is implemented after 28 months.
11204010|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
11204011|NCT03356080|Experimental|DLAAG|"All patients receive 1-2 cycles of induction chemotherapy,that is DLAAG,which is expected to be 6 weeks/cycle,including decitabine,cytarabine, all-transretinoic acid,and Granulocyte Colony-Stimulating Factor(G-CSF).
~patients with CR after the first course of induction therapy (DLAAG) will continue to receive 1 cycle of consolidation therapy, while those with therapy failure will continue the second course of induction therapy. If CR is not achieved, quit the study.
~Patients who achieve CR after induction therapy will be in accordance with the guidelines, such as the proposed active treatment of allogeneic hematopoietic stem cell transplantation"
11204012|NCT03356067|Sham Comparator|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope.
11204013|NCT03356067|Experimental|Gastric endoscopic peroral pyloromyotomy|Experimental per-oral endoscopic myotomy of the pyloric sphincter
11204014|NCT03356054|Experimental|Brentuximab vedotin-R-DHAP|Brentuximab vedotin added to R-DHAP
11204015|NCT03356041|Active Comparator|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
11204016|NCT03356041|No Intervention|Usual care Group|The usual care group will be provided the standard medical services
11204017|NCT03356028|Other|impacted by the attack of 14 July 2016|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire following the mass trauma of 14 July 2016 in Nice on a sample of exposed pediatric population
11204018|NCT03356028|Other|control group|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire of children controls
11204019|NCT03356015|Experimental|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
11204020|NCT03356015|Active Comparator|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
11204021|NCT03356002|Active Comparator|High risk subjects|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.
~Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:
~c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms:"
11204022|NCT03356002|Experimental|Average risk|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.
~Average risk based on their age and demographics referred for screening for polyps."
11204023|NCT03355989|Experimental|Low Flat Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.80 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204024|NCT03355989|Experimental|Low Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204025|NCT03355989|Experimental|Low Sharp Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.75 on the BCG/Penta-1/Penta-2 vaccine and $1.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204026|NCT03355989|Experimental|Low Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $3.75 on the BCG/Penta-1/Penta-2 vaccine and $5.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204027|NCT03355989|Experimental|High Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204028|NCT03355989|Experimental|High Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204029|NCT03355989|Experimental|High Sharp Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.25 on the BCG/Penta-1/Penta-2 vaccine and $3.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204030|NCT03355989|Experimental|High Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $11.25 on the BCG/Penta-1/Penta-2 vaccine and $15.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
11204031|NCT03355989|Experimental|Easypaisa Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
11204032|NCT03355989|Experimental|Easypaisa Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
11204033|NCT03355989|Experimental|SMS Reminder Only|The intervention consists of only sending 3 SMS reminders before, at and after the due date.
11204034|NCT03355989|No Intervention|Control|No intervention will be provided either in the form of cash incentive or reminder SMS. Vaccination facilities will be provided as per usual.
11204035|NCT03355976|Experimental|Arm 1 Nivolumab Ovarian|Nivolumab 240 mg Day 1 Cycle = 2 weeks
11204036|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Ovarian|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
11204038|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Extra-renal|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
11204039|NCT03355963|Placebo Comparator|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
11204040|NCT03355963|Active Comparator|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
11204041|NCT03355963|Active Comparator|Group C|"The treatment group C:
~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
11204042|NCT03355950|Active Comparator|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
11204043|NCT03355950|Active Comparator|Lichtenstein group|Patients who undergo Lichtenstein repair.
11204044|NCT03355937|Active Comparator|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
11204045|NCT03355937|Experimental|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
11204046|NCT03355937|Active Comparator|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
11204047|NCT03355937|Experimental|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
11204048|NCT03355872|Experimental|HLX01|
11204049|NCT03355872|Active Comparator|Rituximab|
11204050|NCT03355859|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
11204051|NCT03355846|Experimental|AAF treated with Centella® Complex|Centella® Complex 1 cps 60 mg per os
11204052|NCT03355846|Experimental|AAF treated with Proctocella® cream|Proctocella® Complex cream to be applied in anal area and anal canal
11204053|NCT03355846|Experimental|AAF treated with Flavonil® cps|Flavonil® 1 cps 300 mg per os
11204054|NCT03355846|Experimental|AAF treated with Flavonil® Cream|Flavonil® Cream Cream to be applied in anal region and anal canal
11204055|NCT03355846|Experimental|AAF treated with Rectalgan Mousse|Rectalgan Mousse cleansing cleanser for anal and perineal region
11204056|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
11204057|NCT03355807|Experimental|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
11204058|NCT03355807|No Intervention|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
11204059|NCT03355794|Experimental|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 300mg daily (DIPG only); </=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (>21yrs 2.5mg/day (DIPG only); </=21yr 1.2 mg/m2/day) BSA >/=0.75m2
11204060|NCT03355794|Experimental|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA >/=0.45m2
11204061|NCT03355794|Experimental|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA >/=0.45m2
11204062|NCT03355794|Experimental|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
11204063|NCT03355781||Schizophrenic patients|Patients will have clinical psychiatric evaluation, brain imaging and blood sample
11204064|NCT03355781||Related volunteers (first degree relative of patient)|Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
11204065|NCT03355781||Healthy volunteers|Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
11204066|NCT03355768|Experimental|Romidepsin Arm|Control Arm: Subjects will receive Romidepsin 14 mg/m2 on Days 1, 8, 15.
11204067|NCT03355768|Experimental|Romidepsin + Pralatrexate Combination Arm|Combination Arm: Subjects will receive Romidepsin 12 mg/m2 and Pralatrexate 25 mg/m2.
11204068|NCT03355755|Experimental|Interventional Group|All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
11204069|NCT03355742|Experimental|XIENCE|XIENCE + Short duration (1 month) of DAPT
11204070|NCT03355716|Placebo Comparator|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
11204071|NCT03355716|Active Comparator|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
11204072|NCT03355716|Active Comparator|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
11204073|NCT03355716|Active Comparator|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
11204074|NCT03355690||Stroke patients|Stroke patients are treated according to the clinical practice which can be divided into: anti-aggregation, thrombectomy and/or thrombolysis
11204075|NCT03355677|Active Comparator|Case finding clinics|The visit will be a minimum 90 minutes long at the participants own GP surgery. This will include a respiratory assessment including spirometry will performed by a RT Respiratory Nurse Specialist (RNS) and where possible a Practice Nurse or Nurse Practitioner will attend. The visit will consist of objective measurements, investigations and questionnaires
11204076|NCT03355677|Placebo Comparator|Case finding Usual care|In the control arm of the study, practices will continue with usual care according to national guidance for case finding for COPD (NICE, 2010). Matched practices will have their eligible population identified through electronic searches based on data routinely recorded in primary care run in the HHRa. Case finding yield will be measured as the percentage of patients from the eligible population identified with a respiratory diagnosis in the 12 months from study beginning to study end.
11204144|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
11204215|NCT03354767||Non-wasting patients|Patients with <10% loss of skeletal muscle one week after major aortic surgery
11204077|NCT03355677|Active Comparator|At Risk Case clinics|The complex case clinic will be a minimum 120 minute appointment at the participants own GP surgery. The intervention will include an initial assessment by a RT Respiratory Nurse Specialist (RNS) and followed by a joint assessment by a respiratory physician (RP) working alongside a practice clinician (GP and/or Practice Nurse/Nurse Practitioner). The visit will consist of objective measurements, investigations and questionnaires as outlined in section 3 below. A personalised disease management and action plan will be agreed jointly between the RT, practice clinician and participant. The practice clinician will undertake the necessary tasks required for the agreed management plan. The clinical responsibility for the participant will remain with the GP practice.
11204078|NCT03355677|Placebo Comparator|At Risk Usual Care|In the control arm of the study, practices will continue with usual care according to national guidance for the management of COPD and asthma . A cohort of patients matched for practice and for age, sex, disease condition and, where possible, disease control will be identified. This cohort will be monitored against markers of sub-optimal disease (medication usage, exacerbations, unscheduled visits to the practice, attendance or admission to hospital).
11204079|NCT03355664|Active Comparator|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
11204080|NCT03355664|Experimental|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
11204081|NCT03355651|Active Comparator|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
11204082|NCT03355651|No Intervention|Control Group|Standard Rehabilitation + ACL reconstruction
11204083|NCT03355638|Active Comparator|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
11204084|NCT03355638|Experimental|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
11204085|NCT03355638|Experimental|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
11204086|NCT03355612|Experimental|experimental group|Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
11204087|NCT03355612|Active Comparator|active comparator|Drug:XELOX(Capecitabine and Oxaliplatin)
11204088|NCT03355599|Other|3d camera|3d camera
11204089|NCT03355586||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.
~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.
~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.
~These will be subjected to a combined approach of modalities with the main intervention being electromagnetic navigation."
11204090|NCT03355573|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 4 years.
11204091|NCT03355560|Experimental|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 6 doses.
11204092|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
11204093|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
11204094|NCT03355534|Experimental|nasal dexmedetomidine|dexmedetomidine is given nasally, saline is given intravenously
11204095|NCT03355534|Experimental|intravenous dexmedetomidine|saline is given nasally, dexmedetomidine is given intravenously
11204096|NCT03355534|Placebo Comparator|normal saline|saline is given nasally and intravenously
11204097|NCT03355521|Experimental|Nordic walking Experimental|Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.
11204098|NCT03355521|Active Comparator|Free walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
11204099|NCT03355508|Other|puncture bevel up|
11204100|NCT03355508|Other|puncture bevel domn|
11204101|NCT03355495|No Intervention|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
11204102|NCT03355495|Active Comparator|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
11204103|NCT03355482|Active Comparator|Depomedrol arm|Patients are treated with new or ascending doses of subcutaneous methotrexate, and receive a single intramuscular dose of Depomedrol (160mg) at baseline.
11204104|NCT03355482|Sham Comparator|Placebo arm|Patients are treated with new or ascending doses methotrexate, and receive a single intramuscular placebo injection at baseline.
11204105|NCT03355469|Placebo Comparator|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
11204106|NCT03355469|Placebo Comparator|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
11204145|NCT03355222|No Intervention|No Intervention|No intervention: The community receives no chickens and no special education is provided.
11204216|NCT03354754|Experimental|LYS228|IV infusion every 6 hours for at least 5 days
11204217|NCT03354754|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
11204107|NCT03355469|Active Comparator|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
11204108|NCT03355469|Active Comparator|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
11204109|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
11204110|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
11204111|NCT03355456|Active Comparator|PVI + Posterior wall ablation|PVI radiofrequency ablation along with ablation of the posterior wall.
11204112|NCT03355443|Active Comparator|Re-examination Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined in the same fashion. After that, the rest of the colon is examined in routine method.
11204113|NCT03355443|Experimental|Retroflexion Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined with the colonoscope tip in reverse direction (retroflexion fashion). After that, the rest of the colon is examined in routine method.
11204114|NCT03355430||moderate keratoconus group|moderate keratoconus group underwent combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
11204115|NCT03355417|Experimental|OT-SI|Occupational therapy using a sensory integration approach
11204116|NCT03355404|Experimental|"Standing Patient"|
11204117|NCT03355404|No Intervention|"Standardized management in stretcher"|
11204118|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
11204119|NCT03355378|Experimental|study group|gum chewing during spinal anesthesia and early ambulation
11204120|NCT03355378|No Intervention|Control group|no gum chewing
11204121|NCT03355365|Experimental|Intrathecal MSC-NP injection|Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.
11204122|NCT03355365|Placebo Comparator|Intrathecal saline injection|Patients will receive six placebo injections through spinal taps every 2 months over a year.
11204123|NCT03355352||Patients treated with conventional i.v. PCA|
11204124|NCT03355352||Patients treated with Zalviso|
11204125|NCT03355339|Experimental|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
11204126|NCT03355339|Active Comparator|No binasal occlusion|Participants will be fitted with non-occluded glasses.
11204127|NCT03355326|Experimental|Glycerin Suppository Group|
11204128|NCT03355326|No Intervention|Non-suppository Group|
11204129|NCT03355313|Experimental|Low level light therapy 1|
11204130|NCT03355313|Experimental|Low level light therapy 2|
11204131|NCT03355313|Experimental|Low level light therapy 3|
11204132|NCT03355300|Experimental|Cannabidiol Oral Solution|Cannabidiol Oral solution, dose as assigned in INS-17-103.
11204133|NCT03355287|Placebo Comparator|Traditionally Threshed Teff (TTT)|The control group will consume injera based on teff threshed under the hooves of cattle. We plan to have a certain number of teff flour suppliers, where the teff is traditionally threshed and contains at least 50 mg Fe per 100 g flour.
11204134|NCT03355287|Experimental|Lab Threshed Teff (LTT)|The intervention group will consume injera based on teff flour that has been lab threshed using a modern teff threshing machine.
11204135|NCT03355287|Active Comparator|Fortified Lab Threshed Teff (FTT)|This arm will be the positive control group consuming Ferrous Sulphate drops ( with injera that consist of lab-threshed teff. The Fe drops have to be consumed with the meal and will provide an additional 6 mg of Ferrous sulfate to the diet of the children.
11204136|NCT03355274|Experimental|Patients|Patients suspected of thoracic outlet syndrome Transcutaneous oximetry during upper arm manoeuvers
11204137|NCT03355274|Sham Comparator|controls|healthy asymptomatic subjects Transcutaneous oximetry during upper arm manoeuvers
11204138|NCT03355261|Experimental|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
11204139|NCT03355261|Experimental|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
11204140|NCT03355261|Experimental|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
11204141|NCT03355261|Experimental|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
11204142|NCT03355248|Active Comparator|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
11204143|NCT03355248|Experimental|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
11205083|NCT03348839|Experimental|Cluster 7|NeLLY service is implemented after 32 months.
11204146|NCT03355222|Experimental|Experimental: providing chickens and egg shell|"Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers.
~The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens."
11204147|NCT03355209|Experimental|ZX008 0.2 or 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 (0.2 mg/kg/day or 0.8 mg/kg/day) or placebo.
11204148|NCT03355209|Placebo Comparator|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
11204149|NCT03355209|Placebo Comparator|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
11204150|NCT03355196|Experimental|LRX712|LRX712 given intra-articularly
11204151|NCT03355196|Placebo Comparator|Placebo|Placebo given intra-articularly
11204152|NCT03355183|Experimental|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
11204153|NCT03355170|Experimental|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
11204154|NCT03355170|Active Comparator|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
11204155|NCT03355157|Experimental|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
11204156|NCT03355157|Active Comparator|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
11204157|NCT03355144|Experimental|Internal Medicine residents at NYU|effect of supplying Internal Medicine residents at NYU with free coffee on self reported features of psychological health, energy and burnout
11204158|NCT03355131|Experimental|Adapted NASA's Mission X program|Adapted NASA's Mission X program for the intervention group
11204159|NCT03355131|No Intervention|Mission X Control|no intervention
11204160|NCT03355105|Experimental|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
11204161|NCT03355105|Active Comparator|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
11204162|NCT03355092|Experimental|vBloc Therapy + Usual Care for Type 2 Diabetes|
11204163|NCT03355092|No Intervention|Usual Care for Type 2 Diabetes|
11204164|NCT03355079|Experimental|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
11204165|NCT03355079|No Intervention|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake. Standard of care tube feeding or parenteral nutrition is allowed to start earliest 3 weeks after baseline visit, if required.
11204166|NCT03355066|Experimental|Cohort 1|SM08502 10 mg
11204167|NCT03355066|Experimental|Cohort 2|SM08502 20 mg
11204168|NCT03355066|Experimental|Cohort 3|SM08502 40 mg
11204169|NCT03355066|Experimental|Cohort 4|SM08502 60 mg
11204170|NCT03355066|Experimental|Cohort 5|SM08502 80 mg
11204171|NCT03355066|Experimental|Cohort 6|SM08502 120 mg
11204172|NCT03355066|Experimental|Cohort 7|SM08502 160 mg
11204173|NCT03355066|Experimental|Cohort 8|SM08502 200 mg
11204174|NCT03355053|Active Comparator|Dexmedetomidine (Dex) slow-bolus group|"Study drug will be administered by the patient's nurse. Two 60 mL syringes will be supplied for each patient, containing 50 mL of Dex HCl at 4 ug/ ml Dex HCl or 50 ml normal saline (NS)), depending on randomized assignment. An initial bolus dose will be given over 45 min at 0.33 ml/kg/h (provides 1 mcg/kg/h for Dex patients) at 8PM, followed by continuous overnight infusion at 0.025 ml/kg/h (for Dex patients, provides 0.1 mcg/kg/h), for 7 consecutive nights (or until leaving the ICU), as follows:
~1) Dex slow-bolus group: Dex slow bolus at 8PM over 45 min, then overnight NS until 8AM"
11204175|NCT03355053|Active Comparator|Dexmedetomidine (Dex) continuous infusion group|"Study drug will be administered by the patient's nurse. Two 60 mL syringes will be supplied for each patient, containing 50 mL of Dex HCl at 4 ug/ ml Dex HCl or 50 ml normal saline (NS)), depending on randomized assignment. An initial bolus dose will be given over 45 min at 0.33 ml/kg/h (provides 1 mcg/kg/h for Dex patients) at 8PM, followed by continuous overnight infusion at 0.025 ml/kg/h (for Dex patients, provides 0.1 mcg/kg/h), for 7 consecutive nights (or until leaving the ICU), as follows:
~2) Dex continuous infusion group: NS slow bolus at 8PM over 45 min, then overnight Dex until 8AM"
11204176|NCT03355053|Placebo Comparator|Usual care + placebo group|"Study drug will be administered by the patient's nurse. Two 60 mL syringes will be supplied for each patient, containing 50 mL of Dex HCl at 4 ug/ ml Dex HCl or 50 ml normal saline (NS)), depending on randomized assignment. An initial bolus dose will be given over 45 min at 0.33 ml/kg/h (provides 1 mcg/kg/h for Dex patients) at 8PM, followed by continuous overnight infusion at 0.025 ml/kg/h (for Dex patients, provides 0.1 mcg/kg/h), for 7 consecutive nights (or until leaving the ICU), as follows:
~3) NS slow bolus at 8PM over 45 min, then overnight NS until 8AM"
11204177|NCT03355027|Experimental|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
11204178|NCT03355027|Active Comparator|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
11204179|NCT03355014|Experimental|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day
~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
11257191|NCT02991222|Active Comparator|Reference001 type I|Treatment type I
11204180|NCT03355014|Experimental|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg
~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
11204181|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
11204182|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
11204183|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
11204184|NCT03354988|Active Comparator|physical exercise group|For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
11204185|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
11204186|NCT03354975|Experimental|Experiential Training|
11204187|NCT03354975|Active Comparator|Training-as-usual|
11204188|NCT03354962|Active Comparator|ARM A|
11204189|NCT03354962|Experimental|ARM B|
11204190|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.
~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).
~Propulsion speed of a wheelchair."
11204191|NCT03354923|Experimental|immediate intervention group|Immediate PEERS intervention
11204192|NCT03354923|Other|delayed intervention|delayed PEERS intervention to begin after experimental group
11204193|NCT03354910|No Intervention|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
11204194|NCT03354910|Active Comparator|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
11204195|NCT03354910|Experimental|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
11204196|NCT03354897|Other|Treatment|16 weeks treatment 5mg/day
11204197|NCT03354884|Experimental|Cabozantinib|All subjects will receive open label Cabozantinib 60 mg orally once daily
11204198|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
11204199|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
11204200|NCT03354845|No Intervention|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
11204201|NCT03354845|Other|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
11204202|NCT03354832||Foetal death|In-utero dead foetus weighting at least 500 g or 22-amenorrhea weeks old. In utero death means that death occurs during delivery or per partum
11204203|NCT03354832||New-born death|New-born dead during post-birth hospital stay and at least 23-amenorrhea weeks old.
11204204|NCT03354832||Birth control for foetal death|Same gender child born, and alive, in the same hospital, and born on time (37-41 amenorrhea weeks old).
11204205|NCT03354832||Birth control for new-born death|"Same gender infant born, and alive, in the same hospital, and:
~for 23-amenorrhea weeks old new-born death: control new-born are born on time (37-41 amenorrhea weeks old).
~for 24 to 31-amenorrhea weeks old new-born death: control new-born are premature infant (24-31 amenorrhea weeks old), and are included when their hospital stay ends.
~for 32 and more-amenorrhea weeks old new-born death: control new-born are 32 and more-amenorrhea weeks old infant"
11204206|NCT03354819|Experimental|Modified MBCT|A group-based, 10-week, 7-session modified Mindfulness Based Cognitive Therapy (MBCT) will be adopted in the MBCT intervention group with a group size of 15-20. The program includes different mindfulness activities (such as mindful eating and mindful walking) and peer sharing.
11204207|NCT03354819|Active Comparator|SIRE on dementia|The frequency of the Social Interactions and Routine Education (SIRE) program is the same as that of modified MBCT which consists of seven sessions (weekly for the first four sessions and bi-weekly for the last three sessions) and each session will last about two hours for 10 weeks with group size 15-20.
11204208|NCT03354806|Experimental|Continuous peripheral nerve blocks|Ropivacaine-continous treatment using catheters for continous sciatic nerve blocks
11204209|NCT03354806|Active Comparator|Analgesic treatment|Pharmacological pain management in accordance with WHO's pain relief ladder
11204210|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
11204211|NCT03354793||non endometriosis|Survey on first pregnancy
11204212|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
11204213|NCT03354780||non endometriosis|Survey on first pregnancy
11204214|NCT03354767||Wasting patients|Patients with >10% loss of skeletal muscle one week after major aortic surgery
11257192|NCT02991222|Active Comparator|Reference type II|Treatment type II
11204218|NCT03354741|Other|Laser then Sham therapy|2nd cycle of chemotherapy : administration of laser therapy 3th cycle of chemotherapy : administration of a sham laser according to the same modalities
11204219|NCT03354741|Other|Sham therapy then laser|2nd cycle of chemotherapy : administration of a sham laser 3th cycle of chemotherapy : administration of laser therapy according to the same modalities
11204220|NCT03354728|Experimental|Supportive Care (multi-antigen CMV-modified vaccinia ankara)|Patients receive multi-antigen CMV-modified vaccinia ankara vaccine IM on days 28 and 56 post-HCT.
11204221|NCT03354715|Sham Comparator|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
11204222|NCT03354715|Sham Comparator|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
11204223|NCT03354702|Experimental|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
11204224|NCT03354702|Active Comparator|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
11204225|NCT03354676||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
11204226|NCT03354676||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
11204227|NCT03354663|Experimental|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
11204228|NCT03354650||complete blood count|blood sample is collected from infant to detect presence of sepsis
11204229|NCT03354650||c reactive protein|measuring c reactive protein in blood sample to determine neonatal sepsis
11204230|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
11204231|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
11204232|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
11204233|NCT03354624|Experimental|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
11204234|NCT03354624|Experimental|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
11204235|NCT03354611|Experimental|Diagnostic Workup|The subjects will first have a pre-contrast CBBCT scan. Iodinated contrast will be injected intravenously, and then another CBBCT scans will be performed to capture the tumor vasculature enhancement.
11204236|NCT03354598|Experimental|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
11204237|NCT03354598|Active Comparator|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
11204238|NCT03354585|Experimental|Meditation Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
11204239|NCT03354585|Active Comparator|Meditatin Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
11204240|NCT03354585|Active Comparator|Book Listening Control Group|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 12 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
11204241|NCT03354572|Active Comparator|NAC|receive 150 mg/kg acetylcysteïne in 200 ml saline (NaCl0,9%) prior to surgery
11204242|NCT03354572|Placebo Comparator|placebo|receive only NaCl 0.9% prior to surgery (volume identical to active comparator)
11204243|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count > 100.000 x 10 9/L
11204244|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
11204245|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
11204246|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
11204247|NCT03354533|Other|Treatment with ORL-1F - L-fucose|
11204248|NCT03354520|Active Comparator|Tailored Videos|
11204249|NCT03354520|Active Comparator|Standard Videos|
11204250|NCT03354520|Active Comparator|OSA Treatment|
11204251|NCT03354507|Experimental|Sodium Bicarbonate|"Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.
~< 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. > 42kg : 3/4 teaspoon bid."
11204252|NCT03354507|No Intervention|Control|Patients will not receive treatment if they do not have metabolic acidosis at baseline.
11204253|NCT03354494||DSG-CTP|
11204254|NCT03354481|Experimental|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
11204255|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
11204256|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
11204257|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
11204258|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
11204259|NCT03354455|Experimental|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
11204260|NCT03354455|Sham Comparator|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
11204261|NCT03354442|Experimental|Modified Fixed Mandibular Retractor|All patients in this group will be treated using Modified Fixed Mandibular Retractor Appliance. This appliance will be used full-time.
11204262|NCT03354442|No Intervention|Untreated control group|All patients in this group will be observed during the period of treating the patients in the other group to assess the growth changes.
11204263|NCT03354429|Experimental|TICAGRELOR|
11204264|NCT03354429|Placebo Comparator|TICAGRELOR PLACEBO|
11204265|NCT03354416||1/ Cohort 1|Subjects with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
11204266|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
11204267|NCT03354390|Experimental|1|This is a single-arm, phase 1 trial of HERV-E TCRtransduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study isplanned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six hasexperienced a dose limiting toxicity (DLT).
11204268|NCT03354377|Experimental|Vegan Diet|"Participants in this group will follow a plant-based vegan diet. The vegan group diet will be based on investigators' pilot work, which instructs participants to favor a diet built around whole grains, fruits, vegetables, and legumes. This group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course.
~Interventions include intervention meetings, physical activity, and podcasts/mailings."
11204269|NCT03354377|Experimental|Omnivorous (Omni) Diet|"Participants in this group will follow a low-fat omni diet. The diet intervention for the omni group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide, A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course).
~Interventions include intervention meetings, physical activity, and podcasts/mailings."
11204270|NCT03354364|Active Comparator|Group 1|Receives pea hull fiber snack for the first 4 weeks and then control snack for the last 4 weeks of the study with 4-week washout between them.
11204271|NCT03354364|Active Comparator|Group 2|Receives control snack for the first 4 weeks and then pea hull fiber snack for the last 4 weeks of the study with 4-week washout between them
11204272|NCT03354351||NB-Group|Stepped-care model comprising a hierarchy of interventions, from the least to the most intensive, matched to the cardiac man's needs. The model involves three steps: Step 1 (therapist-guided and self-guided 3-session psychoeducational program), Step 2 (Group sessions involving care partners), and Step 3 (individual or dyadic (patient and care Partner) sessions. As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
11204273|NCT03354351||ON-Group|Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
11204274|NCT03354351||QC-Group|Standard Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
11204275|NCT03354338|Experimental|Experimental Group|Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
11204276|NCT03354338|Placebo Comparator|PLACEBO|Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
11204277|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
11204278|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
11204279|NCT03354312|Experimental|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
11204280|NCT03354312|Experimental|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
11204281|NCT03354299|Experimental|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
11204282|NCT03354299|Active Comparator|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
11204311|NCT03354130|Experimental|Non-processed pork diet|Volunteers will consume a diet containing non-processed pork during 3 days for 5 meals in total
11204283|NCT03354286|Experimental|Developmental & Technological Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.
11204284|NCT03354286|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
11204285|NCT03354286|Experimental|Nutrition, Set Point, & C:I Ratio|Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.
11204286|NCT03354286|Experimental|Hypoglycemia management|Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia
11204287|NCT03354286|Placebo Comparator|Minimal Intervention|A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.
11204288|NCT03354273|Experimental|1|Flurpiridaz PET MPI (following off-study SPECT MPI)
11204289|NCT03354260|Experimental|intervention|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
11204290|NCT03354260|No Intervention|Control|
11204291|NCT03354247|No Intervention|Healthy Control|Participants in this group will attend small group sessions providing basic education about NAFLD/NASH, and about principles of healthy eating, physical activity and weight control. These sessions occur every 12 weeks and are conducted by a Master's level nutritionist or health educator. Providing basic education about diet and exercise has produced minimal weight loss in other clinical trials. The educational sessions will be included in this study in order to provide standard care to these patients and to maximize subject retention.
11204292|NCT03354247|Experimental|NAFLD Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants who are able to lose more than 10% of their body weight will be encouraged to do so. Participants will be seen weekly for the first 6 months and then biweekly for months 7-12. The lifestyle intervention focused on diet, exercise, and behavior modification.
11204293|NCT03354234|Experimental|Stimuli of slowly increasing intensities|"300-s check before the stimuli
~LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s
~180-second phase of rest between stimuli
~75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)
~180-second phase of rest between stimuli
~75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT
~120-s check after the stimuli"
11204294|NCT03354234|Experimental|Stimuli of rapidly increasing intensities|"120-s check before the stimuli
~75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)
~180-second phase of rest between stimuli
~LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.
~180 second phase of rest between stimuli
~push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT
~120-s check after the stimuli"
11204295|NCT03354221|Experimental|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
11204296|NCT03354208||Group 1|patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
11204297|NCT03354208||Group 2|patients with suspected HIE, non-confirmed
11204298|NCT03354208||Group 3|healthy, retrospectively classified as such
11204299|NCT03354195|Active Comparator|Group 1|"Group 1 - intact ACL ligament will be accepted as functionally intact
~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
11204300|NCT03354195|Active Comparator|Group 2|"Group 2 - intact but fibrillated (frayed) ligament) will be accepted as functionally intact
~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
11204301|NCT03354195|Active Comparator|Group 3|"Group 3 - nearly completely torn ligament (>50% and disrupted) will be deemed as having functionally absent ACLs
~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
11204302|NCT03354182|Active Comparator|Control group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen + Bio-gide
11204303|NCT03354182|Active Comparator|Test group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen alone
11204304|NCT03354169|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
11204305|NCT03354169|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
11204306|NCT03354156||High-LDL|patients with LDL cholesterol levels of >4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
11204307|NCT03354156||Control|control subjects with an LDL cholesterol level of <3.5 mmol/l
11204308|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
11204309|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
11204310|NCT03354130|Active Comparator|Tofu control|Volunteers will consume a vegetarian diet containing tofu during 3 days for 5 meals in total
11259075|NCT02978053|Experimental|Bright light|10 000 lux
11204312|NCT03354130|Experimental|Bacon diet|Volunteers will consume a diet containing bacon during 3 days for 5 meals in total
11204313|NCT03354130|Experimental|Sausage diet|Volunteers will consume a diet containing sausage during 3 days for 5 meals in total
11204314|NCT03354130|Experimental|Dry-cured sausage diet|Volunteers will consume a diet containing dry-cured sausage during 3 days for 5 meals in total
11204315|NCT03354117|Experimental|Ulipristal 30mg plus Meloxicam 15mg|Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.
11204316|NCT03354104|Experimental|Recession coverage with connective tissue graft + Emdogain®|A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with 24% EDTA (PrefGel®, Straumann, Basel, Switzerland) for 2 minutes and then washed with saline. Subsequently, EMD (Emdogain®, Straumann, Basel, Switzerland) is applied on root surfaces. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
11204317|NCT03354104|Active Comparator|Recession coverage with connective tissue graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
11204318|NCT03354091|Experimental|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
11204319|NCT03354091|No Intervention|Control|Patient education program only.
11204320|NCT03354078|Active Comparator|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
11204321|NCT03354078|Active Comparator|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
11204322|NCT03354065|Active Comparator|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
11204323|NCT03354065|Experimental|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
11204324|NCT03354052|Experimental|Real-rTMS + Gloreha device|
11204325|NCT03354052|Active Comparator|Sham-rTMS + Gloreha device|
11204326|NCT03354039|Experimental|Tamoxifen 20 mg once daily|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.
11204327|NCT03354039|Placebo Comparator|Matching placebo once daily|Patients randomised to placebo will be administered matching placebo.
11204328|NCT03354026|Experimental|Experimental: AICH-PXZY|Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
11204329|NCT03354026|Experimental|Experimental: AICH-without PXZY|Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
11204330|NCT03354026|Placebo Comparator|Placebo: AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
11204331|NCT03354013|Experimental|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo 100% ICSI-AOA if less than 6 mature oocytes are collected upon oocyte retrieval. If 6 or more mature oocytes are retrieved, 50%ICSI and 50%ICSI-AOA will be applied.
~Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.
~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
11204332|NCT03354000|Placebo Comparator|Take-home online training|Participants received a link to access the online tutorial videos on their own.
11204333|NCT03354000|Active Comparator|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
11204334|NCT03353987|No Intervention|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
11204335|NCT03353987|Experimental|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
11204336|NCT03353974|Experimental|Video game therapy|Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 18 sessions of treatment within 6 weeks (3 sessions per week); each session will last 1 hour. Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
11204337|NCT03353974|Active Comparator|Balance platform therapy|"Subjects belonging to the control group will receive the same amount of therapy (18 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an entry level, and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback."
11204371|NCT03353714|Placebo Comparator|Pudendal block with saline|Pudendal block with normal saline
11204372|NCT03353714|Active Comparator|Pudendal block with bupivacaine|Pudendal block with bupivacaine
11204338|NCT03353961|Experimental|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
11204339|NCT03353961|Active Comparator|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
11204340|NCT03353948|Active Comparator|Metfrormin group (MET)|Drug: Metformin
11204341|NCT03353948|Active Comparator|COMBI group (COMBI)|Drug: liraglutide
11204342|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
11204343|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
11204344|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
11204345|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
11204346|NCT03353909|Experimental|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
11204347|NCT03353909|No Intervention|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
11204348|NCT03353896|Experimental|Treatment (medical device)|Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
11204349|NCT03353883|Active Comparator|(Group A) Midluteal Triptorelin depot|infertile women with impaired ovulation who will be subjected to Triptorelin sustained release(Decapeptyl depot 375 mg one injection )at D-21 of previous menstrual cycle Hormon Replacement Therapy (HRT)Cyclo-Progynova (estradiol, norgestrel)(Group A). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-HCG level and was confirmed 2-weeks later by TVU.
11204350|NCT03353883|Active Comparator|(Group B)first day Triptorelin depot|infertile women with impaired ovulation who will be subjected toTriptorelin sustained release(Decapeptyl depot 375 mg one injection) at D-1 of menses then Cyclo-Progynova (estradiol, norgestrel) (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-Human Chorionic Gonadotropin level and was confirmed 2-weeks later by TVU.
11204351|NCT03353870||qualitative interview|This study has only one arm
11204352|NCT03353857|Experimental|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
11204353|NCT03353857|Experimental|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
11204354|NCT03353857|Experimental|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
11204355|NCT03353857|Experimental|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
11204356|NCT03353857|Experimental|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.
~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
11204357|NCT03353844|Experimental|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
11204358|NCT03353844|No Intervention|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
11204359|NCT03353831|Placebo Comparator|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
11204360|NCT03353831|Experimental|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
11204361|NCT03353818|Active Comparator|Golf|In three different golf clubs patients will be introduced how to play golf. They will be taught techniques and recieve basic golf equipment. A total of 1 year membership free membership in the golf clubs will be given.
11204362|NCT03353818|Placebo Comparator|Placebo|No intervention given. No restrictions on physical activity.
11204363|NCT03353792|Active Comparator|CL/AP system|To improved glycemic control and strict avoidance of hypoglycemia via 8-week use of a CL/AP system (closed-loop/artificial pancreas) reverses brain metabolic adaptations in older adult T1DM patients.
11204364|NCT03353792|Placebo Comparator|usual care|Subjects in this control group will continue their usual diabetic care (insulin pump therapy) along with CGM recording.
11204365|NCT03353766|Experimental|Early crossbite correction|Early crossbite correction with Q-H Device
11204366|NCT03353766|No Intervention|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
11204367|NCT03353753|Active Comparator|Arm 1|150 mg QD DCC-2618
11204368|NCT03353753|Placebo Comparator|Arm 2|Placebo
11204369|NCT03353740|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
11204370|NCT03353727|Experimental|Orthoptic rehabilitation|
11204373|NCT03353701|Other|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
11204374|NCT03353688|Active Comparator|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
11204375|NCT03353688|Placebo Comparator|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
11204376|NCT03353688|Active Comparator|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
11204377|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
11204378|NCT03353662||Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years
11204379|NCT03353662||Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6 - 59 months
11204380|NCT03353662||Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years
11204381|NCT03353662||Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between 6 - 59 months
11204382|NCT03353662||Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years
11204383|NCT03353662||Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6 - 59 months
11204384|NCT03353649|Experimental|Binge Eating Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (images of highly palatable foods for obese individuals), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets. Specifically, participants in this sample will be exposed to images of food and control non-food images. In different trials, subjects will be given a now cue instructing them to engage with the immediate hedonic properties of the stimulus or a later cue instructing them to imagine the long-term consequences of using the stimulus.
~This arm includes fMRI and the now vs. later cue intervention"
11204385|NCT03353649|Experimental|Smoking Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (tobacco-related images or smokers), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets.
~A similar approach to the Binge Eating sample will be used for the smoking sample using two stimulus sets. Instead of foods and non-food control images, smokers will see smoking-related images and the same control non-food non-smoking images as the Binge Eating sample.
~This Arm includes fMRI and the now vs. later cue intervention"
11204386|NCT03353636|Experimental|Natural Calm Magnesium|150mg elemental magnesium in a single oral dose
11204387|NCT03353636|Active Comparator|Magnesium Bis-glycinate|150mg elemental magnesium in a single oral dose
11204388|NCT03353636|Active Comparator|MAGSmart|150mg elemental magnesium in a single oral dose
11204389|NCT03353636|Active Comparator|Magnesium citrate|150mg elemental magnesium in a single oral dose
11204390|NCT03353636|Placebo Comparator|Placebo|
11204391|NCT03353623|Experimental|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
11204392|NCT03353623|Experimental|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
11204393|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
11204394|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
11204395|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
11204396|NCT03353597|Experimental|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
11204397|NCT03353584|No Intervention|Standard Care|Participants receive standard care treatment for their vaso-occlusive crisis. Participants will be randomized by age.
11204398|NCT03353584|Active Comparator|Virtual Reality|Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
11204399|NCT03353571|Other|C3 PATIENT PARTICIPANTS|This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the C3 in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days in patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.
11204400|NCT03353558||Study Group (CML group)|"This group will be CML patients. In this group each participant will be asked to wear a watch Actigraph for one week.
~He will be asked to fill the appropriate questionnaires, and a daily sleep diary."
11204401|NCT03353558||Control Group|"The control group will be non-CML patients, also without any known malignancy or known sleep disturbances.
~They will be asked to wear the watch Actigraph for one week, and to fill the appropriate questionnaires and a daily sleep diary."
11204402|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
11204403|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria
~Type of procedure
~Age
~ASA score
~BMI
~Duration of procedure (as percentile for this procedure)
~Diabetes
~Sex"
11204442|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
11204443|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
11204471|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-<2500g but with a gestation age >37 weeks.
11204404|NCT03353519|Experimental|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
11204405|NCT03353519|No Intervention|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
11204406|NCT03353506|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
11204407|NCT03353506|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
11204408|NCT03353493|Experimental|MBCT + TAU|Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.
11204409|NCT03353493|Other|TAU|Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.
11204410|NCT03353480|Other|Reference|250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US
11204411|NCT03353480|Experimental|Experimental|250mg Azithromycin tablet manufactured at Pfizer Dalian, China
11204412|NCT03353467|Experimental|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
11204413|NCT03353467|Active Comparator|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
11204414|NCT03353454|Experimental|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
11204415|NCT03353454|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
11204416|NCT03353441|Active Comparator|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
11204417|NCT03353441|Placebo Comparator|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
11204418|NCT03353441|No Intervention|No treatment|
11204419|NCT03353428|Experimental|LC-CTLs|Autologous lung cancer specific cytotoxic lymphocytes
11204420|NCT03353415|Experimental|CGM Use|Each participant will wear the DexCom continuous glucose monitor for four weeks. During the first two weeks, participants will not be able to read the sensor glucose levels. In the second two weeks, participants will be able to read the sensor glucose levels. Frequency of hypoglycemia will be compared between the two phases of the study.
11204421|NCT03353402|Experimental|Fecal Microbiota Transplant (FMT)|FMT includes a colonoscopy conducted by a gastroenterologist followed by stool capsules which will be swallowed by the patient.
11204422|NCT03353389||No AKI|Adult admissions without Acute Kidney Injury during their stay
11204423|NCT03353389||CA-AKI|Adult admissions with Acute Kidney Injury diagnosed within 48 hours during their stay (Community-acquired Acute Kidney Injury)
11204424|NCT03353389||HA-AKI|Adult admissions with Acute Kidney Injury diagnosed after 48 hours during their stay (Hospital-acquired Acute Kidney Injury)
11204425|NCT03353376|Experimental|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
11204426|NCT03353376|Active Comparator|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
11204427|NCT03353363|Placebo Comparator|Normal Saline|Subject will receive 20ml of normal saline infiltration
11204428|NCT03353363|Experimental|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
11204429|NCT03353363|Experimental|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
11204430|NCT03353350|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
11204431|NCT03353350|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
11204432|NCT03353350|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
11204433|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
11204434|NCT03353337|Experimental|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 month.
11204435|NCT03353337|Placebo Comparator|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
11204436|NCT03353324|Active Comparator|intravitreal injection of bevacizumab|
11204437|NCT03353324|Active Comparator|intravitreal injection of bevacizumab+ targeted laser|Intervention intravitreal bevacizumab injection + targeted laser photocoagulation of retinal non perfused areas
11204438|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.
~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
11204439|NCT03353298|Active Comparator|Arm A|Allopurinol 300 mg
11204440|NCT03353298|Placebo Comparator|Arm B|Placebo Oral tablets
11204441|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
11204444|NCT03353272|No Intervention|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
11204445|NCT03353272|Experimental|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
11204446|NCT03353259|No Intervention|SS-TG|Standard surgery using burr-hole procedure, irrigation and drainage.
11204447|NCT03353259|Active Comparator|SS-TXA-TG|Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
11204448|NCT03353259|Active Comparator|SS-TXA-RoA|Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.
11204449|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
11204450|NCT03353233|Experimental|iPACK Block Group|A nerve block technique using a numbing medication called ropivacaine.
11204451|NCT03353233|Placebo Comparator|Sham Group|The same nerve block technique as above, however using an inactive solution of salt water.
11204452|NCT03353220|Experimental|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
11204453|NCT03353220|Experimental|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
11204454|NCT03353207||health Control|"No family history of RBD;
~Age- and sex- matched with isolated RSWA subjects
~Absence of dream enactment behaviors;
~A score of RBDQ-HK less than 19;
~Absence of RSWA as measured by v-PSG;
~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
11204455|NCT03353207||Case with isolated RSWA|"First degree relatives of patients with iRBD;
~Age 45 years or above;
~Absence of dream enactment behaviors;
~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;
~Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.
~for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
11204456|NCT03353207||Case without isolated RSWA|"First degree relatives of patients with iRBD;
~Age- and sex- matched with isolated RSWA subjects;
~Absence of dream enactment behaviors;
~A score of RBDQ-HK less than 19;
~Absence of RSWA as measured by v-PSG;
~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
11204457|NCT03353181|Experimental|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
11204458|NCT03353181|Active Comparator|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
11204459|NCT03353155|Active Comparator|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
11204460|NCT03353155|Active Comparator|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
11204461|NCT03353142|Experimental|Equal Breathing|
11204462|NCT03353116|Active Comparator|maxilla first group|the maxillary osteotomy is going to be done and fixed first
11204463|NCT03353116|Experimental|mandible first group|the mandibular osteotomy is going to be done and fixed first
11204464|NCT03353103|Active Comparator|symptomatic|
11204465|NCT03353103|Active Comparator|asymptomatic|
11204466|NCT03353077|Experimental|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
11204467|NCT03353064|Active Comparator|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
11204468|NCT03353064|Active Comparator|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.
~No EMS home visits will be set up"
11204469|NCT03353051||Group A: other - observational study|neonates ≥2000-<2500g and born with a gestation age <37 weeks.
11204470|NCT03353051||Group B: other- observational study|Group B will contain neonates >2500g and born with a gestation age <37 weeks.
11204550|NCT03352557|Placebo Comparator|Placebo|Intravenous (IV) infusion once every 4 weeks.
11204472|NCT03353051||Group D1:other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
11204473|NCT03353051||Group D2: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
11204474|NCT03353051||Group D3: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
11204475|NCT03353038|Active Comparator|Off-The-Shelf Pillbox vs 3D Printed Pillbox|Participants in the study were pillbox users at baseline. Participants described their experiences and preferences with their own pillbox. Then participants will be given a 3D printed pillbox. Researchers will compare participants' experiences and preferences between their off-the-shelf pillbox used at baseline and the customized 3D printed pillbox delivered to participants as part of the study.
11204476|NCT03353025|Experimental|transsphenoidal surgery treatment|Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
11204477|NCT03353025|Experimental|dopamine agonist treatment|Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
11204478|NCT03353012|Experimental|Levonorgestrel immediate post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 48-72 hr after child delivery
11204479|NCT03353012|Experimental|Etonogestrel immediate post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 48-72 hr after child delivery
11204480|NCT03353012|Active Comparator|Levonorgestrel delayed post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 5-7 weeks after child delivery
11204481|NCT03353012|Active Comparator|Etonogestrel delayed post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 5-7 weeks after child delivery
11204482|NCT03352999|Other|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
11204483|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
11204484|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
11204485|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
11204486|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
11204487|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
11204488|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
11204489|NCT03352973|Experimental|active tDCS on the dlPFC|tDCS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an active transcranial direct current stimulation (tDCS) intervention on this DLPFC region (1.5 mA for 20 minutes).
11204490|NCT03352973|Sham Comparator|sham tDCS on the dlPFC|Each participant will also receive a sham tDCS intervention as a controlled condition. The sham tDCS only include a 30-s ramp up and a 30-s ramp down.
11204491|NCT03352947|Active Comparator|Continuous (Standard)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle
11204492|NCT03352947|Experimental|Intermittent (experimental)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle
11204493|NCT03352934|Experimental|Avelumab|10 mg/kg Avelumab every 2 weeks
11204494|NCT03352921|Experimental|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
11204495|NCT03352921|Active Comparator|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
11204496|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
11204497|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
11204498|NCT03352895|Placebo Comparator|control|Control group will receive placebo medication therapy
11204499|NCT03352895|Experimental|test group|resveratrol group will receive oral resveratrol (100 mg per day)
11204500|NCT03352882|Other|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
11204501|NCT03352869|Experimental|Exenatide|Drug: Byetta Generic name: Exenatide Dosage form: 5ug and 10ug Dosage: 10-20ug/day Frequency: twice a day Duration: 3 months
11204502|NCT03352869|Active Comparator|Metformin|Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
11204503|NCT03352869|Experimental|Combination|Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
11204504|NCT03352856|Active Comparator|Active|Highly purified barley starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
11204505|NCT03352856|Placebo Comparator|Placebo|Maize starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
11204506|NCT03352843|Experimental|Single arm|
11204507|NCT03352830|No Intervention|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. Participants in the control arm will, however, receive no other intervention.
11204508|NCT03352830|Experimental|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
11204509|NCT03352830|Experimental|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
11204510|NCT03352830|Experimental|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. Participants in this arm also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
11204511|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
11204512|NCT03352804||Patients hospitalized in internal medicine ward|Patients included are patients hospitalized in internal medicine ward.
11204513|NCT03352791|Active Comparator|DSM-H Hospice Edition|training, assigning of champions to serve as mentors and performance improvement leads, and workflow changes including caregiver education pamphlets, interdisciplinary care plans, treatment algorithms, and assessment instruments.
11204514|NCT03352791|Active Comparator|Control Arm|Usual Care
11204515|NCT03352778||IMRT|
11204516|NCT03352778||2DRT|
11204517|NCT03352765|Experimental|rituximab, bendamustine & melphalan and ASCT|This is a phase I study of rituximab, bendamustine and melphalan (RBM) conditioning followed by ASCT in elderly patients with B-cell NHL. Conditioning regimen consist of rituximab 375 mg/m2 on days -11 and -4, bendamustine 160 mg/m2 intravenously on days -3 and -2; melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0. The conditioning timeline can be modified if there are patient scheduling conflicts.
11204518|NCT03352752|Experimental|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
11204519|NCT03352752|Experimental|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
11204520|NCT03352739|Experimental|DBS of the fornix, power on|
11204521|NCT03352739|Experimental|DBS of the NbM, power on|
11204522|NCT03352739|Sham Comparator|DBS of the fornix, power off|
11204523|NCT03352739|Sham Comparator|DBS of the NbM, power off|
11204524|NCT03352739|No Intervention|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
11204525|NCT03352726|Experimental|DBV712 Solution for Skin Prick Test|DBV712 In-House Reference Skin Prick Test preparation
11204526|NCT03352713|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
11204527|NCT03352700|Placebo Comparator|3L PEG|only used 3L PEG
11204528|NCT03352700|Experimental|3L PEG+Dyclonine Hydrochloride Mucilage|used 3L PEG+Dyclonine Hydrochloride Mucilage
11204529|NCT03352687|Experimental|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
11204530|NCT03352687|Experimental|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
11204531|NCT03352674|Experimental|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
11204532|NCT03352674|Active Comparator|Insulin Glargine Lantus|Insulin Glargine Pen Injector [Lantus]
11204533|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
11204534|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
11204535|NCT03352635||Native Hawaiians|One parent of Hawaiian descent.
11204536|NCT03352635||Japanese Americans|Two parents of Japanese descent.
11204537|NCT03352635||Non-Hispanic Whites|Two parents of non-Hispanic white descent.
11204538|NCT03352622|Active Comparator|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness
11204539|NCT03352622|Active Comparator|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
11204540|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
11204541|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
11204542|NCT03352596|Experimental|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
11204543|NCT03352596|No Intervention|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
11204544|NCT03352583|Active Comparator|Day|Group receives casein protein during the day (greater than 6 hours before bed).
11204545|NCT03352583|Experimental|Night|Group receives casein protein immediately before going to bed.
11204546|NCT03352570|Experimental|COLOVAC device|colorectal surgery performed per standard of care with deployment of the Colovac device to protect the anastomosis site
11204547|NCT03352557|Experimental|Low-dose BIIB092|Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.
11204548|NCT03352557|Experimental|Medium-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
11204549|NCT03352557|Experimental|High-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
11204551|NCT03352544|Experimental|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week).
11204552|NCT03352544|No Intervention|Usual treatment|Usual treatment during 12 weeks, coinciding with exercise intervention time frame.
11204553|NCT03352531|Experimental|AK-105|Single-arm
11204554|NCT03352518|Experimental|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
11204555|NCT03352505||control|healthy walking control participants
11204556|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
11204557|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
11204558|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
11204559|NCT03352492|Experimental|Bilateral iridotomy: Superior|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
11204560|NCT03352492|Experimental|Bilateral iridotomy: Temporal|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
11204561|NCT03352479|Other|Opioids Prescribed|Each participant in the study will be given an envelope for return of unused opioids. The percentage of returned number of opioids will be calculated based on the number prescribed
11204562|NCT03352466|Experimental|NasoShield very low dose|Single intranasal spray (Part A)
11204563|NCT03352466|Experimental|NasoShield low dose|Single intranasal spray (Part A)
11204564|NCT03352466|Experimental|NasoShield medium dose|Single intranasal spray (Part A)
11204565|NCT03352466|Experimental|NasoShield high dose|Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
11204566|NCT03352466|Placebo Comparator|Placebo|Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
11204567|NCT03352466|Active Comparator|BioThrax|Three intramuscular injections 15 days apart (Part A)
11204568|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
11204569|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
11204570|NCT03352440|Experimental|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
11204571|NCT03352440|Experimental|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
11204572|NCT03352440|Active Comparator|Control Group - Kinect|Group with typical development that will perform the task on Kinect
11204573|NCT03352440|Active Comparator|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
11204574|NCT03352427|Experimental|Dasatinib+Everolimus|"Dasatinib = 60 mg/m2 orally twice daily
~Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml
~Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles."
11204575|NCT03352414|Experimental|Alvimopan|
11204576|NCT03352414|Placebo Comparator|Placebo|
11204577|NCT03352388|Experimental|Snack|Dairy- and berry-based snacks
11204578|NCT03352388|No Intervention|Reference|No snacks
11204579|NCT03352375|Active Comparator|Orotracheally Intubation|Intervention:orotracheally intubation
11204580|NCT03352375|Active Comparator|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
11204581|NCT03352362|Experimental|caldolor|intravenous caldolor injection during intraoperative period
11204582|NCT03352362|Active Comparator|denogan|intravenous denogan injection during intraoperative period
11204583|NCT03352362|Experimental|combination|intravenous denogan and caldolor injection during intraoperative period
11204584|NCT03352349|Experimental|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
11204585|NCT03352323|Experimental|oxymetazoline cream|
11204586|NCT03352310|Experimental|Study Group|autologous UCB transfusion
11204587|NCT03352310|Other|Control Group|standard care
11204588|NCT03352284|Experimental|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
11204589|NCT03352271|Experimental|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
11204590|NCT03352271|Active Comparator|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
11204591|NCT03352258|No Intervention|Observation|Subjects in this arm will only be followed and not treated (observational arm)
11204592|NCT03352258|Experimental|Treatment arm|Subjects will receive a low dose brain radiotherapy
11204593|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
11204594|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
11204595|NCT03352232|Experimental|Subacute Ischemic Stroke|Subacute stroke patients post stroke within 3 months of enrollment, have persistent neurological deficits despite conventional rehabilitation
11204596|NCT03352232|Experimental|Chronic Ischemic Stroke|Chronic stroke patients more than 6 months from stroke with persistent neurological deficits despite conventional rehabilitation
11204638|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
11204639|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
11204709|NCT03351517|Experimental|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
11204597|NCT03352219|Experimental|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
11204598|NCT03352219|Placebo Comparator|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
11204599|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
11204600|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
11204601|NCT03352193||SOTI group|Wheat spaghetti
11204602|NCT03352193||Historical control group|No intervention
11204603|NCT03352180|Active Comparator|subscapularis tendon repair|arthroscopic reapir of subscapularis tendon
11204604|NCT03352180|Active Comparator|subscapularis tendon debridement|arthroscopic debredement of subscapularis tendon
11204605|NCT03352167||ED Hjoerring|
11204606|NCT03352167||ED Aalborg|
11204607|NCT03352167||ED Aarhus|
11204608|NCT03352167||ED Herning|
11204609|NCT03352167||ED Aabenraa|
11204610|NCT03352167||ED Odense|
11204611|NCT03352167||ED Slagelse|
11204612|NCT03352167||ED Koege|
11204613|NCT03352154|Experimental|patients with unilateral cochlear implants submitted to P300|Patients with unilateral cochlear implants, using the speech processor at least 6 months, submitted to P300 exam before CI surgery, on speech processor activation and after 06 months.
11204614|NCT03352141|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
11204615|NCT03352128|Experimental|Creatine supplementation|7-day creatine supplementation
11204616|NCT03352128|Placebo Comparator|Placebo supplementation|7-day calcium lactate supplementation
11204617|NCT03352115|Experimental|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
11204618|NCT03352115|Placebo Comparator|Control|Will receive placebo syrup for 5 days post-operatively
11204619|NCT03352102|Experimental|Diaphragm Group (DG)|"subjects who received conventional physical therapy once a day, plus a daily session of electrical stimulation in the diaphragm.
~Intervention: Electrical stimulation of the diaphragm."
11204620|NCT03352102|Active Comparator|Quadriceps Group (QG)|"subjects who also received conventional physical therapy once a day, plus a daily session of electrical stimulation in the quadriceps.
~Intervention: Electrical stimulation of the quadriceps."
11204621|NCT03352102|No Intervention|Control Group (CG)|subjects who received regular treatment, i.e., conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day, including weekend, during their stay in the ICU.
11204622|NCT03352089||Aortic stenosis group|Patients with severe aortic stenosis >70 years of age referred for aortic valve intervention
11204623|NCT03352089||Healthy volunteer group|Patients with no history of symptoms to suggest current cardiovascular disease >70 years of age
11204624|NCT03352076|Active Comparator|Oral Danatrol|200 mg orally TDS (600 mg daily) for 5-7 days
11204625|NCT03352076|Experimental|Vaginal Danazol|100 mg of Danazol Cream to be applied vaginally for 5-7 days on a single daily dose
11204626|NCT03352063|Active Comparator|Sitting with Exercise|Subjects will complete a short term training protocol while sitting >11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
11204627|NCT03352063|Active Comparator|Walking with exercise|Subjects will complete a short term training protocol while sitting <5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
11204628|NCT03352050|Active Comparator|ground beef|ground beef instead of mushrooms
11204629|NCT03352050|Active Comparator|Mushroom|2 servings of mushrooms
11204630|NCT03352037|Other|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
11204631|NCT03352024|Other|Standard Care|Relational care used to help the patient by reducing the fear and anxiety
11204632|NCT03352024|Other|Hypnosis|Hypno-analgesia is used to help the patient by reducing the fear and anxiety
11204633|NCT03352011|Experimental|Primary Care Brief Mindfulness Training|
11204634|NCT03352011|Active Comparator|PTSD Psychoeducational Class|
11204635|NCT03351998|Placebo Comparator|Placebo|Participants receiving matching placebo oral tablet.
11204636|NCT03351998|Active Comparator|Low dose statin|Participants will receive Lipitor 20Mg Tablet to take daily.
11204637|NCT03351998|Active Comparator|High dose statin|Participants will receive Lipitor 80Mg Tablet to take daily.
11204640|NCT03351972|Active Comparator|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
11204641|NCT03351972|Active Comparator|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
11204642|NCT03351972|Experimental|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
11204643|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
11204644|NCT03351946|Active Comparator|ZEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) until start of emergence preoxygenation.
~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
~First CT scan after completion of surgery, before emergence. After the first CT scan and immediately before start of emergence preoxygenation, this group will have the PEEP exchanged for zero PEEP (ZEEP). ZEEP will remain until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
11204645|NCT03351946|Active Comparator|PEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) even after start of emergence preoxygenation.
~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
~First CT scan after completion of surgery, before emergence. After the first CT scan, this group will have PEEP remained until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
11204646|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
11204647|NCT03351894|Placebo Comparator|Conventional|Conventional phacoemulsification surgery
11204648|NCT03351894|Active Comparator|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
11204649|NCT03351881|Active Comparator|Opt Out|
11204650|NCT03351881|Active Comparator|Opt In|
11204651|NCT03351881|Active Comparator|Opt Neutral|
11204652|NCT03351868|Experimental|Gene-modified autologous stem cells|Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo
11204653|NCT03351855|Experimental|HPV-CTLs|Autologous or allogenic HPV specific cytotoxic lymphocytes
11204654|NCT03351842|Active Comparator|Arm I|Undergo surgery, followed by observation. Patients receive no further therapy
11204655|NCT03351842|Experimental|Arm II|Undergo surgery, followed by chemotherapy (cis Platinum/Carboplatin, Pemetrexed Disodium). Patients receive chemotherapy comprising cisplatin 75mg/m2 or Carboplatin AUC=5mg/ml/min, and pemetrexed 500mg/m2 in day 1. Treatment continues every 3 weeks for 4 courses.
11204656|NCT03351829|Experimental|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
11204657|NCT03351816|Experimental|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
11204658|NCT03351816|Experimental|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
11204659|NCT03351803||Participants with Ashkenazi ancestry|
11204660|NCT03351790||All included participants|Patients that complete study questionnaire and have endoscopy recorded.
11204661|NCT03351777|Experimental|PR022 topical gel, 0.05%|Applied twice daily for 28 days
11204662|NCT03351777|Experimental|PR022 topical gel, 0.1%|Applied twice daily for 28 days
11204663|NCT03351777|Placebo Comparator|PR022 topical gel vehicle|Applied twice daily for 28 days
11204664|NCT03351764|Experimental|Arm 1|these are within subject repeated measures studies across number of conditions
11204665|NCT03351764|Placebo Comparator|Arm 2|Placebo Comparator
11204666|NCT03351751|Placebo Comparator|Placebo|Subjects receiving placebo
11204667|NCT03351751|Experimental|PF-06372865|Subjects receiving PF-06372865
11204668|NCT03351738|Placebo Comparator|Placebo|Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
11204669|NCT03351738|Experimental|MEDI5884 50 mg|Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
11204670|NCT03351738|Experimental|MEDI5884 100 mg|Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
11204671|NCT03351738|Experimental|MEDI5884 200 mg|Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
11204672|NCT03351738|Experimental|MEDI5884 350 mg|Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
11204673|NCT03351738|Experimental|MEDI5884 500 mg|Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
11204674|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
11204675|NCT03351712|Active Comparator|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Gold Standard Intervention + Activity Tracker WITHOUT Feedback (Medical Rehabilitation, Motivational Support and Psycho-Education) During the in-patient phase, participants will participate in the intensive four-week hospital-based and medically-managed rehabilitation program for weight reduction. All patients will be placed on a hypocaloric nutritionally balanced diet tailored to the individual after consultation with a dietitian. Furthermore, they will receive nutritional counseling provided by dietitians, have physical activity training provided by physiotherapists and motivational support with elements of psycho-education provided by physicians trained and informed by psychologists-psychotherapists.
11204701|NCT03351556|Experimental|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.
11204676|NCT03351712|Experimental|Gold Standard Intervention and Activity Tracker WITH Feedback|In this experimental condition, will be provided the same rehabilitation program for the 4-weeks in-patient phase. In addition, for these subjects will be implemented a Stepped Protocol using wearable devices / activity trackers to collect information about daily physical activity and providing meaningful and informative feedbacks. The additional procedure starts during the in-patients phase, delivering and explaining the use of the wearable devices. In this meeting, longer than the one previously described for the control condition, experimenters provide information, set individualized goals and explain feedbacks which will be delivered after ending in-patients phase by the electronic wearable devices.
11204677|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|In this experimental condition, the subjects followed the normal medical rehabilitation program described above for the first experimental condition. For the out-patient phase the ACT intervention includes monthly 30 minutes skype-telephone sessions. The ACT-based interventions includes different processes: 1) Acceptance, that involves the active awareness of difficult private experiences without attempts to control or avoid unpleasant emotions. 2) Mindfulness, refers to engaging in present moment experience and adopting an open and curious attitude. 3) Defusion: Participants will be encouraged to defuse from thoughts and feelings by turning attention toward the 'noticing-self', instead of becoming attached to thoughts and 'run' through life on 'auto-pilot'. 4) Values and Commitment: encouraging participants to live in accordance with their values, participants can engage in meaningful activities despite experiencing unwanted emotions/ sensations.
11204678|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITH Feedback|ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
11204679|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
11204680|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
11204681|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
11204682|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
11204683|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
11204684|NCT03351686|Experimental|tranexamic acid group|
11204685|NCT03351686|No Intervention|non tranexamic (control) group|
11204686|NCT03351673|Experimental|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
11204687|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
11204688|NCT03351634|Experimental|Children with neurogenic incontinence with spinal dysraphism|
11204689|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
11204690|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
11204691|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
11204692|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
11204693|NCT03351608|Active Comparator|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
11204694|NCT03351582|Experimental|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
11204695|NCT03351582|Experimental|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
11204696|NCT03351582|No Intervention|Control|Group three will be the control group and will not receive the grief and communication family intervention.
11204697|NCT03351569|Experimental|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
11204698|NCT03351569|Placebo Comparator|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
11204699|NCT03351556|No Intervention|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
11204700|NCT03351556|Experimental|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.
11204702|NCT03351543|Experimental|Exposed group|these volunteers receive microbial inoculate
11204703|NCT03351543|No Intervention|control|these volunteers do not receive microbial inoculate
11204710|NCT03351517|Placebo Comparator|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
11204711|NCT03351504|No Intervention|Control (usual lighting)|Participants will continue to use their usual lighting sources.
11204712|NCT03351504|Experimental|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
11204713|NCT03351478|Experimental|Sotagliflozin|Sotagliflozin will be given as two tablets and one placebo capsule (identical to empagliflozin capsule in appearance), once daily before the first meal of the day.
11204714|NCT03351478|Active Comparator|Empagliflozin|Empagliflozin will be given as two placebo tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin, once daily before the first meal of the day.
11204715|NCT03351478|Placebo Comparator|Placebo|Placebo given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day.
11204716|NCT03351465|Experimental|CALM|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive-behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living that directly incorporates our previously optional modules for depression into the main program. The computerized/internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed. Participants in the intervention group will be visited by the calm specialist weekly between 6 and 8 times prenatally;postpartum visits will vary based on continuing assessment of symptoms.
11204717|NCT03351465|No Intervention|Treatment as Usual|Participants will receive pre-natal care as usual, and will be visited at 4 time points by the graduate student researchers: baseline, 12 weeks post baseline, and 10 weeks postpartum.
11204718|NCT03351452|Experimental|Real tDCS|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the VLPFC (current density: 0.057 mA/cm2) and cathodal 10x10 rubber electrode over supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11204719|NCT03351452|Experimental|Real tACS|20 min of 2 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
11204720|NCT03351452|Sham Comparator|Sham tES|30 s of 2 mA sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase of the memory task.
11204721|NCT03351439|Active Comparator|Group 1|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily x 3 weeks
11204722|NCT03351439|Experimental|Group 2|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Zopiclone 7.5 mg nightly for 7 days
11204723|NCT03351439|Experimental|Group 3|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Gabapentin 600 mg pre-operatively for one dose and 600 mg post-operatively for one dose
11204724|NCT03351439|Experimental|Group 4|Oxycodone-acetaminophen 5 mg/325 mg, 1-2 tabs every 6 hours as needed for 60 tabs Naprosyn 500 mg twice daily for 3 weeks Celebrex 400 mg pre-operatively for one dose
11204725|NCT03351426|Active Comparator|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
11204726|NCT03351426|Sham Comparator|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
11204727|NCT03351413|Experimental|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:
~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls
~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk
~Medication review and feedback concerning medications with increased fall risk"
11204728|NCT03351413|No Intervention|Control|- An individualized fall risk assessment provided to participant and their primary care provider
11204729|NCT03351400|Experimental|Treatment group|Stem cells administered to participants
11204730|NCT03351387||SPY Intra-operative Angiography|The SPY Fluorescent Imaging System
11204731|NCT03351374||Temple Physicians Incorporated|A community-based provider, operating 32 primary care sites
11204732|NCT03351374||WhiteBark|For profit entity created by the Indiana Rural Health Association
11204733|NCT03351374||Drexel Family Intervention Science|Academic center that developed and deployed Attachment Based Family Therapy (ABFT) assessment, treatment, and prevention models with an interest in adolescents struggling with substance abuse, depression, trauma, and suicidality.
11204734|NCT03351374||Bon Secours Health System|A primary care clinic in Baltimore that provides care services to a population in a lower socioeconomic status in downtown Baltimore.
11204735|NCT03351374||Howard University Hospital CARES|A project provides free outpatient medical, dental, mental health, nutrition and social services for HIV positive uninsured and underinsured residents of the District of Columbia.
11204736|NCT03351361|Experimental|Nivolumab + Ipilimumab|
11204737|NCT03351361|Active Comparator|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
11204738|NCT03351348|Placebo Comparator|Placebo|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
11204739|NCT03351348|Experimental|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
11204740|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
11204741|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
11204742|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
11204743|NCT03351322|Experimental|ENERGI-F701|ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
11204744|NCT03351322|Active Comparator|Regaine|Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
11204745|NCT03351309|Experimental|Telephone-based cognitive behavioral therapy|Telephone-based cognitive behavioral therapy (CBT) intervention - Four session protocol plus routine perioperative management.
11204746|NCT03351309|No Intervention|Treatment as Usual|Treatment as Usual (TAU) - Routine perioperative management.
11204747|NCT03351296|Experimental|LV5FU2 + streptozotocin +/- Bevacizumab|
11204748|NCT03351296|Experimental|Capecitabine + temozolomide +/- Bevacizumab|
11204749|NCT03351283|Experimental|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.
~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
11204750|NCT03351283|Active Comparator|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
11204751|NCT03351244|Experimental|BI 409306 high dose|
11204752|NCT03351244|Experimental|BI 409306 low dose|
11204753|NCT03351244|Placebo Comparator|Placebo|
11204754|NCT03351231|Experimental|Dose Escalation|BMS-986242 administered in combination with Nivolumab
11204755|NCT03351231|Experimental|Dose Expansion|BMS-986242 administered in combination with Nivolumab
11204756|NCT03351218|Other|Patients|25 patients with cervical and 25 patients with myoclonus dystonia
11204757|NCT03351218|Other|Controls|50 healthy volunteers matched to patents ( age, sex)
11204758|NCT03351205|Experimental|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
11204759|NCT03351205|Experimental|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
11204760|NCT03351179||AMI patients with HFpEF|
11204761|NCT03351179||AMI patients without HF|
11204762|NCT03351166|Experimental|Molidustat (BAY85-3934)|Molidustat group
11204763|NCT03351153|Other|X-ray group|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week.
11204764|NCT03351153|Other|CT group|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week.
11204765|NCT03351153|Other|Specimen group|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
11204766|NCT03351140||Subjects with breast cancer|Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
11204767|NCT03351140||Subjects with prostate cancer|Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
11204768|NCT03351140||Subjects with NSCLC|Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
11204769|NCT03351140||Subjects with multiple myeloma|Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
11204770|NCT03351140||Subjects with DLBCL or follicular lymphoma|Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
11204771|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
11204772|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
11204773|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
11204774|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
11204775|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
11204776|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
11204777|NCT03351114|Experimental|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
11204778|NCT03351101|Experimental|Senofilcon C|Senofilcon C Contact Lens
11204779|NCT03351101|Experimental|Samfilcon A|Samfilcon A Contact Lens
11204812|NCT03350867|Experimental|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
11204813|NCT03350867|Placebo Comparator|Placebo Group|The participants will use plane insoles.
11204780|NCT03351088|Other|Preventive ligation|Preventive ligation of DVC is done after the opening of endopelvic fascia and before bladder neck dissection. DVC is ligated at the level of the apex with a 8-fashion single stich (1-0 Monocryl® CT-1 stich) trying to preserve puboprostatic ligaments and the muscle fibres of the rabdosphincter. DVC is then dissected at the end of prostatectomy before the section of the urethra.
11204781|NCT03351088|Other|Delayed ligation|Delayed ligation is done after the section of the urethra and once the prostatectomy is completed with a single stich (3-0 Monocryl® UR-6).
11204782|NCT03351075|Experimental|Intervention group|Standard physical therapy program + Modern educational program
11204783|NCT03351075|Active Comparator|Control group|Standard physical therapy program + Traditional biomedical educational program
11204784|NCT03351062|Active Comparator|Tamoxifen treatment group|Patients in this group will receive tamoxifen treatment.
11204785|NCT03351062|Active Comparator|Toremifene treatment group|Patients in this group will receive Toremifene treatment.
11204786|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
11204787|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
11204788|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
11204789|NCT03351010|Experimental|Mindfulness|Receiving education program and mindfulness training
11204790|NCT03351010|Active Comparator|Control|Receiving education program
11204791|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
11204792|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
11204793|NCT03350984|Experimental|NPH insulin group|Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
11204794|NCT03350984|Active Comparator|Glargine and Lispro insulin group|"Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro.
~Intervention drug: Glargine and Lispro"
11204795|NCT03350971|Experimental|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
11204796|NCT03350971|Active Comparator|Control|chest physical therapy
11204797|NCT03350958|Experimental|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
11204798|NCT03350958|Placebo Comparator|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
11204799|NCT03350945|Active Comparator|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
11204800|NCT03350945|Active Comparator|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
11204801|NCT03350945|Experimental|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
11204802|NCT03350932|No Intervention|Control|This group of children, will have to perform a sensory imagination task about neutral facts before choosing the portion size of a food.
11204803|NCT03350932|Experimental|Food sensory imagination|"This group, the food sensory imagination group, will have to perform a sensory imagination task foods (being the intervention) before choosing the portion size of a food."
11204804|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
11204805|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
11204806|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The DHA/EPA soft gels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. The duration of the intervention will be 6 months.
11204807|NCT03350906|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
11204808|NCT03350893|Placebo Comparator|Control Group|Emulsion base without probiotics
11204809|NCT03350893|Experimental|Active Group|Emulsion base with probiotics
11204810|NCT03350880|Experimental|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
11204811|NCT03350880|Active Comparator|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
11204814|NCT03350854|No Intervention|The non-intervention control group|In the non-intervention control group, providers are blind to the patient's preferred decision making role.
11204815|NCT03350854|Experimental|The intervention group|The provider will be informed of the patient preference in treatment decision making (preferred role) and have a discussion about this with the patient in the intervention group.
11204816|NCT03350841|Experimental|Revascularization|platelet rich plasma injected in the canals
11204817|NCT03350841|Active Comparator|root canal treatment|endodontic treatment obturated with gutta percha
11204818|NCT03350815|Active Comparator|Responders|Patients achieving an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (total score <1.3) at both Week 12 and Week 16.
11204819|NCT03350815|Active Comparator|Inadequate responders|Patients who have active disease, defined as an Ankylosing Spondylitis Disease Activity Score (ASDAS) total score of >1.3 at both Week 12 and Week 16, and who do achieve a decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.
11204820|NCT03350815|Active Comparator|Non-responders|"Patients who exhibit no change or an increase (worsening) from baseline in total Ankylosing Spondylitis Disease Activity Score (ASDAS) score at either Week 12 or Week 16.
~Non-responders will not enter Treatment Period 2. Non-responders will be discontinued from the study at Week 16."
11204821|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
11204822|NCT03350789|Experimental|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
11204823|NCT03350789|Sham Comparator|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
11204824|NCT03350763|Experimental|Plastic biliary stent|A plastic (ie Tannenbaum 10 Fr) biliary stent is used to achieve biliary decompression
11204825|NCT03350763|Experimental|Self-expandable metallic biliary stent|A self-expandable metallic biliary stent is used to achieve biliary decompression
11204826|NCT03350750|Active Comparator|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
11204827|NCT03350750|Sham Comparator|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) four months after the procedure.
11204828|NCT03350737|Experimental|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
11204829|NCT03350737|Placebo Comparator|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
11204830|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
11204831|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
11204832|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
11204833|NCT03350698|Experimental|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
11204834|NCT03350685||Classic Whipple's disease (CWD)|"Classic Whipple's disease (CWD), defined as
~duodenal biopsy positive by PAS/immunohistochemistry
~or blood positive by PCR"
11204835|NCT03350685||Focal Whipple's disease (FWD)|"Focal Whipple's disease (FWD), defined as
~joint fluid positive by PCR
~but duodenal biopsy negative by PAS/immunohistochemistry"
11204836|NCT03350685||Chronic T. whipplei-associated arthritis (CTWA)|"Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and
~duodenal biopsy, stool, or saliva positive by PCR
~duodenal biopsy negative by PAS/immunohistochemistry
~joint fluid negative by PCR"
11204837|NCT03350672|Experimental|Cohort 1a|"Age 18 or older at the time of signed informed consent
~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP
~Willing and able to independently provide written informed consent
~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
11204838|NCT03350672|Experimental|Cohort 1b|"Age 18 or older at the time of signed informed consent
~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP
~Willing and able to independently provide written informed consent
~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
11204839|NCT03350672|Active Comparator|Cohort 2|"Age 18 or older at the time of signed informed consent
~Willing and able to independently provide written informed consent
~Last viral load < 20 copies/mL within the last four weeks of screening
~Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months
~Undetectable viral load, as defined by < 50 copies/ml, for at least 6 months"
11204840|NCT03350659|Experimental|Atomoxetine|Atomoxetine 18mg once a day.
11204841|NCT03350659|Active Comparator|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
11204842|NCT03350646|Other|Low volume (20-25 μl)|Low volume (20-25 μl)
11204843|NCT03350646|Other|High volume (40-45 μl)|High volume (40-45 μl)
11204844|NCT03350633|Experimental|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
11204845|NCT03350633|Active Comparator|Azathioprine|Imuran
11204846|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1
~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
11204847|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2
~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
11204848|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)
~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
11259076|NCT02978053|Placebo Comparator|Red light|400 lux
11204849|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.
~There will be free exchanges along the lines between therapist and family, within the family and between therapists.
~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
11204850|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
11204851|NCT03350581|Active Comparator|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
11204852|NCT03350581|Experimental|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
11204853|NCT03350555|Experimental|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
11204854|NCT03350555|No Intervention|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
11204855|NCT03350542|Experimental|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
11204856|NCT03350529|Experimental|Localised PC prior to RP|MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, index lesion(s) within prostate and if possible with 5mm angular extension (imaging based healthy tissue marginal) to both sides from the tumour boundary in transverse plane and 5 mm in coronal plane. The ablative effect is aimed to reach prostate capsule by heating the control boundary (3 mm from capsule) to temperature 57 °C. The focal approach is intended to be radical as for index lesion.
11204857|NCT03350529|Experimental|Symptomatic locally advanced PC|MRI guided transurethral HIFU ablation is targeted to main prostatic malignant tumour squeezing and/or invading the prostatic urethra and/or bladder neck. The approach is intended to be palliative.
11204858|NCT03350529|Experimental|Locally recurrent PC after EBRT|"MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, local recurrent index lesion(s) within and/or surrounding prostate and if possible with 5 mm angular extension to either side from the tumour boundary in transverse plane and 5 mm in coronal plane. The approach is intended to be focal and salvage.
~The whole-gland HIFU ablation approach will be considered in case of extensive organ confined recurrent prostate cancer (positive biopsies for malignancy from extensive/multiple area in prostate and/or extensive/multiple lesion(s) at baseline MRI) to cover whole prostate."
11204859|NCT03350529|Experimental|Symptomatic BPH|MRI guided transurethral HIFU ablation is targeted to adenomas of the prostate. The HIFU sector encompasses bilateral (anterolateral) transitional zones between bladder neck and verumontanum (colliculus seminalis).
11204860|NCT03350516|Experimental|Daily 500 mg Calcium|
11204861|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
11204862|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
11204863|NCT03350490|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11204864|NCT03350490|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11204865|NCT03350490|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11204866|NCT03350490|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11204867|NCT03350477|Active Comparator|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11204868|NCT03350477|Active Comparator|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11204869|NCT03350477|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11204870|NCT03350477|No Intervention|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11204871|NCT03350464|Experimental|Pain in PD Arm|This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.
11204872|NCT03350451|Experimental|Lumasiran (ALN-GO1)|
11204873|NCT03350438||PTSD Patients|patients ranging 18-60, diagnosed with PTSD following a trauma that occured over one year before the current study and do not have other health problems that may affect their everyday participation.
11204874|NCT03350438||healthy adults|healthy adults, ranging 18-60, without any health problems that may affect their everyday participation.
11204875|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
11204876|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
11204877|NCT03350399||level of placenta growth factor in IUGR|
11204878|NCT03350386|Experimental|Single dose|Single administration of FYU-981
11204879|NCT03350386|Experimental|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
11204880|NCT03350373|Experimental|Fasted dosing followed by fed dosing|Dosing of FYU-981 in the fasted state followed by fed dosing
11204881|NCT03350373|Experimental|Fed dosing followed by fasted dosing|Dosing of FYU-981 in the fed state followed by fasted dosing
11204882|NCT03350360|Experimental|Attention Control Training Clinic|"Attention Control Training Clinic will consist of:
~6 sessions in the clinic lasting approximately 10 minutes each.
~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
11204883|NCT03350360|Experimental|Attention Control Training Web-delivery|"Attention Control Training Web-delivery will consist of:
~6 sessions lasting approximately 10 minutes each logged into via the internet from the participants' home.
~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).
~Ideally participants will complete 2 sessions per week, allowing them to complete the trial in less than one month's time"
11204884|NCT03350360|Placebo Comparator|Comparison Task Clinic|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.
~Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).
~(Note that those receiving this arm, are invited to repeat the attention control training web-delivery arm at the end of their participation)."
11204885|NCT03350347|Experimental|Molidustat (BAY85-3934)|Molidustat group
11204886|NCT03350347|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
11204887|NCT03350334|Active Comparator|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
11204888|NCT03350334|Placebo Comparator|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
11204889|NCT03350321|Experimental|Molidustat (BAY85-3934)|Molidustat group
11204890|NCT03350321|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
11204891|NCT03350308||Patients with chronic end-stage renal failure|
11204892|NCT03350295|Experimental|GRP1 - Assess relative bioavailability(3-way cross-over)|"GROUP 1 (Treatments A, B, C) All 3 treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets). Participants received the 3 treatments in one of six treatment sequences under fed condition.
~Treatment A, dose administration with fast in vitro dissolution characteristics Treatment B, dose administration with medium in vitro dissolution characteristics Treatment C, dose administration with slow in vitro dissolution characteristics"
11204893|NCT03350295|Experimental|GRP2 - Assess relative bioavailability (2-way cross-over)|"GROUP 2 (Treatments D and E) Participants received the 2 treatments in one of two treatment sequences under fed condition.
~Treatment D, a single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics Treatment E, a single dose of 120 mg nifurtimox"
11204894|NCT03350282|Experimental|Mixture GAA-creatine|Mixture of guanidinoacetic acid and creatine monohydrate
11204895|NCT03350282|Active Comparator|Creatine|Creatine monohydrate
11204896|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
11204897|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
11204898|NCT03350256|Experimental|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
11204899|NCT03350243|Experimental|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves a primary care provider and/or neonatal follow-up at routine times.
11204900|NCT03350243|No Intervention|Control group|Participants will receive the standard medical care at their institution, which involves a primary care provider and/or neonatal follow-up at routine times.
11204901|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
11204902|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
11204903|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
11204904|NCT03350204|Experimental|Meniscus Injured|These participants will come in pre and post operation
11204905|NCT03350204|Experimental|Healthy|These participants will be used as a standardised comparison for the patient group
11204906|NCT03350191|Experimental|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
11204907|NCT03350191|Experimental|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
11204908|NCT03350178|Experimental|treated patients|Treated wit FMT
11204909|NCT03350165|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
11204910|NCT03350165|Placebo Comparator|Control Group|placebo tablet twice daily.
11204911|NCT03350152||LAM group|Have a diagnosis of AML according to World Health Organization (WHO) classification Are at least 70 years of age
11204943|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
11204912|NCT03350139||Patients treated with gamma knife radiosurgery|Collection of non-genetic, chronobiological, therapeutic and co-morbidities
11204913|NCT03350126|Experimental|Experimental arm|Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months
11204914|NCT03350113|Experimental|HemoSpec|Blood Sampling for analysis in the HemoSpec device
11204915|NCT03350100|Experimental|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
11204916|NCT03350100|Experimental|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
11204917|NCT03350100|Placebo Comparator|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
11204918|NCT03350087|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
11204919|NCT03350087|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
11204920|NCT03350087|Experimental|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
11204921|NCT03350087|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
11204922|NCT03350087|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
11204923|NCT03350087|Experimental|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
11204924|NCT03350061|Experimental|SENSY benefit|Sensory feedback elicited by intraneural stimulation will be provided by SENSY with and without the leg prosthesis to improve walking ability, increase embodiment, and reduce metabolic cost, cognitive load and phantom pain.
11204925|NCT03350048||Training Set|"First 500 participants recruited for the Training Set:
~Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory
~Blood, sputum, saliva and urine collection for secondary objectives and repository"
11204926|NCT03350048||Test Set|"Subsequent 300 participants to be used for the Test Set:
~Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR
~Blood, sputum, saliva and urine collection for secondary objectives and repository"
11204927|NCT03350035|Experimental|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
11204928|NCT03350035|Placebo Comparator|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
11204929|NCT03350022|Experimental|Sham Feeding|
11204930|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
11204931|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
11204932|NCT03349996|Experimental|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
11204933|NCT03349983|Experimental|MVA-BN-Brachyury/ FPV-Brachyury|
11204934|NCT03349970||TEE vs PAC|we will compare the SV measurements obtained by PAC thermodilution technique to those obtained by different TEE methods in 60 patients undergoing coronary artery bypass grafting (CABG) and/or aortic valve (AV) or aortic surgery with cardiopulmonary bypass (CPB) in 2 different cardiac centres. The LV cardiac deformation, expressed as global longitudinal strain (GLS) will be calculated off-line from the acquired images. We will also determine the intra and inter-observer reproducibility of each TEE method.
11204935|NCT03349944|Active Comparator|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
11204936|NCT03349944|Experimental|High intensity training|High intensity interval training three times pr. week for 15 min.
11204937|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
11204938|NCT03349918|Experimental|Mobile Health Monitoring|Participants will monitor their blood pressure using a wireless-enabled blood pressure cuff or mood using a mobile health application once per week at baseline. The investigators will monitor their medical records to determine if a medication change has occurred. After this, the investigators will increase the frequency of notifications to monitor the participant's specific health condition to once daily for 1 month. This monitoring will continue for a study duration of 6 months.
11204939|NCT03349905|Active Comparator|Fresh transfer|"Women randomized in the non experimental group will have:
~Antagonist stimulation protocol
~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)
~All of their embryo kept in prolonged culture
~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)
~Supernumerary blastocysts cryopreserved"
11204940|NCT03349905|Experimental|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:
~Antagonist stimulation protocol
~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)
~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.
~A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
11204941|NCT03349892|Experimental|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
11204942|NCT03349879||Vitamin D deficiency|serum 25(OH)D < 30 nmol/L
11204945|NCT03349866|Experimental|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
11204946|NCT03349866|Active Comparator|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
11204947|NCT03349840|Active Comparator|Insulin glargine U100|Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
11204948|NCT03349840|Active Comparator|insulin degludec U100|Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening
11204949|NCT03349827|Experimental|Experimental|HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
11204950|NCT03349814||Appendicitis group|"Patients, who undergo a diagnostic laparoscopy, which because of the operative findings leads to an appendectomy, and the appendix is found to be inflamed in the pathology report.
~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed."
11204951|NCT03349814||Normal appendix group|"Patients, who undergo a diagnostic laparoscopy, that either because of the operative findings (mesenteric lymphadenitis or normal diagnostic laparoscopy) does not lead to appendectomy, or leads to appendectomy, but the appendix is not found to be inflamed in the pathology report.
~A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
~OR
~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed, but is not found to be inflamed in the pathology report."
11204952|NCT03349801||no AMD|No interventions
11204953|NCT03349801||early AMD|No interventions.
11204954|NCT03349801||intermediate AMD|No interventions.
11204955|NCT03349801||late AMD|No interventions.
11204956|NCT03349788|Experimental|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
11204957|NCT03349788|Active Comparator|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
11204958|NCT03349775|Active Comparator|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
11204959|NCT03349775|Placebo Comparator|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
11204960|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
11204961|NCT03349762||Observational 2|Huaier Granule & Radiotherapy or chemotherapy
11204962|NCT03349762||Observational 3|Huaier Granules
11204963|NCT03349749||Patients undergoing fluid resuscitation|Adult patients in the intensive care unit (ICU) undergoing fluid resuscitation guided by the LiDCOplus haemodynamic monitor.
11204964|NCT03349736|Other|Pelvic Floor Muscle Training|"Women visiting antenatal (up to16 weeks of gestation) will be enrolled for the study. The women will be follow up 4 times during the antenatal visit until 37 weeks of gestation. Questionnaire data and clinical measurements(strength of PFM by Electromyograph biofeedback) will be registered at baseline and and follow-up at week 37 of pregnancy.
~The treatment program will include
~1) Information, educational material (leaflets, posters, and video) and individual/group exercise on PFM exercise on the 1st day of the visit. Counseling about the importance of performing PFM exercise will be provided. Women are advised to perform home PFM exercise and record in the exercise diary."
11204965|NCT03349723|Experimental|BI 1265162|BI 1265162
11204966|NCT03349723|Placebo Comparator|Placebo|Placebo
11204967|NCT03349710|Experimental|Arm A|Cohort 1
11204968|NCT03349710|Experimental|Arm B|Cohort 1
11204969|NCT03349710|Experimental|Arm C|Cohort 2
11204970|NCT03349710|Experimental|Arm D|Cohort 2
11204971|NCT03349697|Experimental|Active Product then Placebo|
11204972|NCT03349697|Experimental|Placebo then Active Product|
11204973|NCT03349684|Experimental|Acarbose plus metformin arm|Participants received loose combination of acarbose and metformin 3 times daily.
11204974|NCT03349684|Active Comparator|Metformin plus placebo arm|Participants received loose combination of placebo and metformin 3 times daily.
11204975|NCT03349658|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia.
11204976|NCT03349658|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia.
11204977|NCT03349645|Experimental|Ampion|4 mL Ampion (<5 kilodatlon (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution
11204978|NCT03349632|Other|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
11204979|NCT03349632|Other|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
11204980|NCT03349632|Other|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
11204981|NCT03349619|Experimental|Resveratrol plus Carboxymethyl-β-Glucan|
11204982|NCT03349619|Placebo Comparator|Placebo|
11204983|NCT03349606|Experimental|Cocaine dependence|[C-11]FLB 457 PET at baseline and post d-amphetamine
11204984|NCT03349606|Experimental|Controls|[C-11]FLB 457 PET at baseline and post d-amphetamine
11205033|NCT03349125||Collar On|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) on.
11205034|NCT03349125||Collar Off|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) off.
11204985|NCT03349580|Experimental|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
11204986|NCT03349580|No Intervention|The control group|The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
11204987|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
11204988|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
11204989|NCT03349554|Experimental|"standardized meditation technique body-scan"|
11204990|NCT03349541|Experimental|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
11204991|NCT03349541|No Intervention|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
11204992|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
11204993|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
11204994|NCT03349515|Active Comparator|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
11204995|NCT03349515|Active Comparator|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
11204996|NCT03349502|Experimental|MG4101|"MG4101 administration (Not yet commercialized)
~Dosage Bwt<50 : 2.0 x109 cells (2 bags) 50≤Bwt<70 : 3.0 x109 cells (3 bags) 70≤Bwt<100 : 4.0 x109 cells (4 bags) Bwt≥100 : 5.0 x109 cells (5 bags)
~Duration and frequency
~Intravenous over 1 hour
~Day 4, Day 11, Day 18 of each cycle"
11204997|NCT03349489|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
11204998|NCT03349489|Active Comparator|Reduction of insulin basal rate 90 minutes prior to exercise|
11204999|NCT03349476|Experimental|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.
~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
11205000|NCT03349463|Experimental|18F-Fluciclovine|
11205001|NCT03349450|Experimental|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.
~Pembrolizumab 200mg Intravenously.
~Cyclophosphamide 50mg Twice daily orally."
11205002|NCT03349437|Experimental|Vitabreath Device|The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
11205003|NCT03349437|Active Comparator|Pursed Lip Breathing|Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.
11205004|NCT03349424|Experimental|Stilamin group|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
11205005|NCT03349424|No Intervention|Control group|Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.
11205006|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
11205007|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
11205008|NCT03349398|Active Comparator|the group of Roux-en-Y|
11205009|NCT03349398|Experimental|the group of Uncut Roux-en-Y|
11205032|NCT03349138|Experimental|Electrical Stimulation and Robotic Glove|Electrical Stimulation & Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy or 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. Half of the sessions are allocated to the electrical stimulation system, and half are allocated to the robotic glove system. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11205078|NCT03348839|Experimental|Cluster 2|NeLLY service is implemented after 12 months.
11205010|NCT03349346|Experimental|Cohort 1- Participants 12 to less than 18 years of age|"Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m^2 twice daily (BID), Dose level 2 = 85 mg/m^2 BID, Dose level 3 = 125 mg/m^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.
~Day 1: single dose of idelalisib
~Day 2 up to Day 21: initiate and continue idelalisib BID dosing
~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
11205011|NCT03349346|Experimental|Cohort 2- Participants 1 to less than 12 years of age|"Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.
~Day 1: single dose of idelalisib
~Day 2 up to Day 21: initiate and continue idelalisib BID
~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
11205012|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
11205013|NCT03349307|Experimental|No Intervention|
11205014|NCT03349281|Experimental|Dose Level 1: Pevonedistat 15 + VXLD|"Pevonedistat: 15 mg/m2 intravenously (IV)
~Vincristine: 1.5 mg/m2/dose IV push
~Dexamethasone: 10 mg/m2/day divided twice daily
~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.
~Doxorubicin: 60 mg/m2/day IV
~Intrathecal (IT) chemotherapy via injection per protocol:
~All subjects: Cytarabine 70 mg ;
~For central nervous system (CNS) negative subjects: Methotrexate 15 mg;
~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
11205015|NCT03349281|Active Comparator|Dose Level -1: Pevonedistat 10 + VXLD|"Pevonedistat: 10 mg/m2 IV
~Vincristine: 1.5 mg/m2/dose IV push
~Dexamethasone: 10 mg/m2/day divided twice daily
~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.
~Doxorubicin: 60 mg/m2/day IV
~Intrathecal (IT) chemotherapy via injection per protocol:
~All subjects: Cytarabine 70 mg ;
~For CNS negative subjects: Methotrexate 15 mg;
~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
11205016|NCT03349281|Active Comparator|Dose Level 2: Pevonedistat 20 + VXLD|"Pevonedistat: 20 mg/m2 IV
~Vincristine: 1.5 mg/m2/dose IV push
~Dexamethasone: 10 mg/m2/day divided twice daily
~PEG-asparaginase: 2000 IU's/m2/day, capped at maximal dose of 3750 IU's.
~Doxorubicin: 60 mg/m2/day IV
~Intrathecal (IT) chemotherapy via injection per protocol:
~All subjects: Cytarabine 70 mg ;
~For CNS negative subjects: Methotrexate 15 mg;
~For CNS positive subjects (Triple IT Therapy): Cytarabine 30 mg, Methotrexate 15 mg, and Hydrocortisone 15 mg."
11205017|NCT03349268|Active Comparator|Pulsed UV Device Emitting Germicidal UV|Pulsed UV Device to be used to disinfect rooms following post-discharge terminal cleaning
11205018|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
11205019|NCT03349255|Experimental|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
11205020|NCT03349255|Experimental|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
11205021|NCT03349216|Experimental|Intravenous regional Analgesia|in this arm patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes will be deflated (hence named Rapid MiniBier's block).
11205022|NCT03349216|Experimental|Systemic Analgesia|In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
11205023|NCT03349203|Experimental|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks before surgery and 2 years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity.
11205024|NCT03349177|Experimental|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
11205025|NCT03349177|Experimental|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
11205026|NCT03349177|Experimental|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
11205027|NCT03349151|Active Comparator|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
11205028|NCT03349151|Placebo Comparator|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
11205029|NCT03349138|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different standard motor training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11205030|NCT03349138|Experimental|Robotic Glove|Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11205031|NCT03349138|Experimental|Electrical Stimulation|Electrical Stimulation & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11205035|NCT03349112|Active Comparator|Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter, Participants in this group will additionally receive .8 mL of a 4% Lidocaine spray to both nares prior to HRPM.
11205036|NCT03349112|Placebo Comparator|Non-Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. Randomized participants in this group will not receive .8 mL of a 4% Lidocaine spray prior to HRPM .
11205037|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
11205038|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
11205039|NCT03349086|Active Comparator|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
11205040|NCT03349086|No Intervention|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
11205041|NCT03349073|Experimental|T-1101 (Tosylate)|
11205042|NCT03349060|Experimental|PF-04965842 100 mg|
11205043|NCT03349060|Experimental|PF-04965842 200 mg|
11205044|NCT03349060|Placebo Comparator|Placebo|
11205045|NCT03349047|Active Comparator|Behavioral Intervention|Behavioral Intervention Group - Education regarding nut allergy and will also have contact with nut.
11205046|NCT03349047|Placebo Comparator|Control|Education regarding nut allergy
11205047|NCT03349034|Experimental|Test Group|Local Ropivicaine Infusion
11205048|NCT03349034|Placebo Comparator|Control Group|Local Saline Infusion
11205049|NCT03349021|Experimental|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
11205050|NCT03349008|Placebo Comparator|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
11205051|NCT03349008|Experimental|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
11205052|NCT03348995|Experimental|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing an absorbable implant (the BEAR Implant) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into
11205053|NCT03348982|Experimental|Intervention group|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.
11205054|NCT03348982|No Intervention|Control group|Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).
11205055|NCT03348969|Experimental|Intervention|Neoadjuvant Mitomycin C
11205056|NCT03348969|Active Comparator|Control|Adjuvant Mitomycin C
11205057|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
11205058|NCT03348943|Active Comparator|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
11205059|NCT03348943|Experimental|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
11205060|NCT03348943|Active Comparator|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
11205061|NCT03348943|Experimental|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
11205062|NCT03348930|Experimental|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
11205063|NCT03348930|Placebo Comparator|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
11205064|NCT03348917|Active Comparator|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C
~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)
~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)
~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
11205065|NCT03348917|Active Comparator|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A
~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)
~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)
~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
11205066|NCT03348917|Active Comparator|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -> A ->B
~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)
~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)
~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
11205067|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
11205068|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
11205069|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
11205070|NCT03348891|Other|Subgroup 1|Patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
11205071|NCT03348891|Other|Subgroup 2|Patients treated with the combined treatment anti-PD-1+anti-CTLA-4 (nivolumab + ipilimumab)
11205072|NCT03348878|Other|cohort of uncontrolled hypertensive patients|
11205073|NCT03348865|Experimental|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.
~Each session is expected lasts 30 mins to 1 hour."
11205074|NCT03348865|No Intervention|Control|Patients are to undergo treatment as usual.
11205075|NCT03348852|Active Comparator|Active tDCS|Active transcranial direct current stimulation
11205076|NCT03348852|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
11205077|NCT03348839|Experimental|Cluster 1|NeLLY service is implemented after 8 months.
11205084|NCT03348826|Experimental|Alteplase then Sodium Bicarbonate|Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.
11205085|NCT03348826|Experimental|Sodium Bicarbonate then Alteplase|Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.
11205086|NCT03348813|Experimental|HIV/STI Prevention Intervention|Two-session, small group HIV/STI prevention intervention.
11205087|NCT03348813|Active Comparator|General Health Control Intervention|Two-session, small group general health promotion intervention.
11205088|NCT03348800|Experimental|Test Side|The side in which computer controlled anesthetic delivery system will be used as dental anesthesia before dental surgery
11205089|NCT03348800|Active Comparator|Control Side|The side in which conventional syringe will be used as dental anesthesia before dental surgery
11205090|NCT03348787|Experimental|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
11205091|NCT03348761|Experimental|rTMS Group|"Twenty sessions of neurostimulation at the left DLPFC.
~Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses).
~Phase II: A Neuro-MS/D Advanced Therapeutic Transcranial Magnetic Stimulator (Neurosoft, Russia) with a 100-mm cooled figure-of-eight coil and Neural Navigator navigation (Brain Science Tools, the Netherlands) are used. Stimulation parameters: triplet 50 hertz, repeated at 5 hertz, 120% resting motor threshold, 20 trains of 2 seconds with 8 seconds between trains, 600 pulses per day delivered 5 days per week (total: 12000 pulses)."
11205092|NCT03348748|Experimental|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
11205093|NCT03348748|Experimental|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
11205094|NCT03348748|Experimental|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
11205095|NCT03348735|Experimental|Lidocaine patch 5%|Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.
11205096|NCT03348735|Experimental|Capsaicin 8% patch|Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).
11205097|NCT03348735|Active Comparator|Pregabaline|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.
11205098|NCT03348722||Active surveillance|Newly diagnosed low risk prostate cancer patients managed according to an active surveillance program
11205099|NCT03348722||Radical prostatectomy|Newly diagnosed low risk prostate cancer patients undergoing radical prostatectomy
11205100|NCT03348722||Radiotherapy|Newly diagnosed low risk prostate cancer patients undergoing radiotherapy (external or brachitherapy)
11205101|NCT03348722||Other radical treatment|Newly diagnosed low risk prostate cancer patients undergoing other radical treatments (HIFU, cryotherapy, others)
11205102|NCT03348709|Experimental|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
11205103|NCT03348709|Active Comparator|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
11205104|NCT03348696|Active Comparator|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
11205105|NCT03348696|Active Comparator|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
11205106|NCT03348683|Experimental|Propranolol|2mg of IV push
11205107|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
11205108|NCT03348670|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein
~0.5 ml Lactated Ringer's Injection, USP"
11205109|NCT03348657|Other|Music intervention Group|Patients who participated to at least one music session provided by volunteers while being admitted to the geriatric assessment unit. Participation to the music sessions was voluntary.
11205110|NCT03348657|No Intervention|Control Group|Patients who did not want to participate to the music sessions provided by volunteers while being admitted to the geriatric assessment unit
11205111|NCT03348644|Experimental|Phosphate tablets.|800 mg oral phosphor supplement distributed over five times a day independently of any prior treatment dose.
11205112|NCT03348644|Active Comparator|High cheese intake.|Cheese with an estimated phosphate content of 800 mg distributed over 5 meals.
11205113|NCT03348644|Active Comparator|High milk intake.|800 ml of milk daily corresponding to approximately 800 mg phosphor per day.
11205114|NCT03348631|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11205115|NCT03348618|Experimental|IVIG|IVIG dose at 1 g/Kg/body weight
11205116|NCT03348605|Other|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
11205117|NCT03348605|Other|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
11205118|NCT03348592|Experimental|Oligofructose-enriched inulin (p-inulin)|Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
11205119|NCT03348579||The before period|The before period (control phase) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning hospital-acquired pneumonia.
11205120|NCT03348579||The second period|"Intensive care units are randomized in two groups:
~Standard training: The centers will receive the text of the recommendation electronically. The principal investigator of each center will then train doctors, interns, nurses and physiotherapists to the use of these recommendations (team leader). A computer presentation common to all the centers will be used and a communication strategy vis-à-vis the other caregivers of the investigative services will be put in place. All doctors, interns and nurses must have attended this theoretical training during the awareness phase."
11205121|NCT03348579||The third and final period|The third and final period will consist of all consecutive patients admitted to the participating ICUs after the formal training.
11205122|NCT03348553|Sham Comparator|control group|20 subjects do not receive any supplementation
11205123|NCT03348553|Active Comparator|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
11205124|NCT03348553|Active Comparator|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
11205125|NCT03348553|Active Comparator|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
11205126|NCT03348540|Experimental|Attention Control Training|"6 sessions in the clinic lasting approximately 10 minutes each.
~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
11205127|NCT03348540|Placebo Comparator|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.
~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
11205128|NCT03348527|Experimental|Stage I: Dose = 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
11205129|NCT03348527|Experimental|Stage I: Dose = 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
11205130|NCT03348527|Experimental|Stage II: Dose = 16mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 16mL
11205131|NCT03348527|Experimental|Stage II: Dose = 20mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 20mL
11205132|NCT03348514|Experimental|Accelerated Escalation Design|
11205133|NCT03348514|Experimental|"3+3 Dose Escalation Design"|
11205134|NCT03348488|No Intervention|Standard ultrafiltration|standard ultrafiltration (fluid removal from the body by dialysis at the prescribed volume and rate) during a conventional treatment
11205135|NCT03348488|Active Comparator|High dose ultrafiltration|Intervention= Fixed rate high dose ultrafiltration (fluid removed from the body by dialysis) of 1 litre per hour over 1 hr instaed of standard ultrafiltration rate and volume.
11205136|NCT03348475|Experimental|Experimental Group|Binge Focused Therapy (BFT) Intervention
11205137|NCT03348462|Experimental|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
11205138|NCT03348462|Active Comparator|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
11205139|NCT03348436|Experimental|patients with atrioventricular nodal reentrant tachycardia|radiofrequency catheter ablation therapy
11205140|NCT03348436|Experimental|patients with atrioventricular tachycardia|radiofrequency catheter ablation therapy
11205141|NCT03348423|Experimental|DEX-IN 50 µg|Dexmedetomidine Intranasal Spray
11205142|NCT03348423|Active Comparator|Fentanyl 50 µg|Intravenous Fentanyl
11205143|NCT03348423|Placebo Comparator|Placebo|Placebo
11205144|NCT03348410|Experimental|Intervention|Motivational interviewing
11205145|NCT03348410|No Intervention|Control|Control group
11205146|NCT03348397||Contegra patients|
11205147|NCT03348397||Pulmonary homograft patients|
11205148|NCT03348384|Experimental|Cocaine use disorders|PET scan
11205149|NCT03348384|Experimental|Controls|PET scan
11205150|NCT03348371|Experimental|Oral day|Participant receive ethanol orally
11205151|NCT03348371|Experimental|i.v. infusion day|Participant receive ethanol in an i.v. infusion
11205152|NCT03348358|Placebo Comparator|control|No music during labor
11205153|NCT03348358|Experimental|Quiet music|Women hearing quiet music during labor
11205154|NCT03348358|Experimental|Rhythmic music|Women hearing rhythmic music during labor
11205155|NCT03348345|Experimental|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
11205156|NCT03348345|No Intervention|Wait-List|Participants are placed on a wait-list receiving no intervention.
11205157|NCT03348332|No Intervention|Sedentary pregnant women|Pregnant women who do not exercise regularly during pregnancy
11205158|NCT03348332|Experimental|Exercise pregnant women|Pregnant women who participate in a supervised exercise program
11205159|NCT03348319||Cadaver organs|
11205160|NCT03348306|Experimental|All patients|
11205161|NCT03348293|Experimental|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
11205162|NCT03348280||Vitamin D Deficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of <20 ng/ml
11205163|NCT03348280||Vitamin D Sufficient|Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of >30 ng/ml
11205201|NCT03347968|Experimental|MEDI0382|All participants will receive MEDI0382.
11205202|NCT03347968|Active Comparator|Warfarin|All participants will receive Warfarin
11205164|NCT03348267|Experimental|Protein|On the match day, 25g of protein consumed immediately after the match and then 30g at 3h (+3h) and 25g at 6h (+6h). On each day of the remaining days, 20 g of protein consumed with breakfast.
11205165|NCT03348267|Active Comparator|Placebo|On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
11205166|NCT03348254||1|Group one will consist of patients receiving a single shot antibiotic prophylaxis preoperatively before primary arthroplasty of hip or knee
11205167|NCT03348254||2|Group two will consist of patients receiving multiple shot antibiotic prophylaxis perioperatively before and after primary arthroplasty of hip or knee
11205168|NCT03348241|Experimental|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
11205169|NCT03348241|Other|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
11205170|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
11205171|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
11205172|NCT03348215|Other|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
11205173|NCT03348202||Focus Group Participants|Approximately 24 groups (6 per country; Finland, Norway, Spain, Italy) consisting participants aged 80+ recruited from: senior community centres, adult day care centres, nursing homes. Each focus group will comprise from 4 to 8 people. Attempts would be made to create gender-balanced groups.
11205174|NCT03348189||Observational|Healthy males and females
11205175|NCT03348176|Experimental|Vegetable exposure|Repeated exposure to a variety of vegetables from the start of complementary feeding
11205176|NCT03348176|Experimental|VIPP-Feeding Infants|Promotion of responsive feeding practices from the start of complementary feeding
11205177|NCT03348176|Experimental|Exposure + VIPP-FI|Combination of repeated exposure to vegetables and promotion of responsive feeding practices
11205178|NCT03348176|Sham Comparator|Control|Phone calls on development child with no information on complementary feeding
11205179|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to B/FTC/TAF bfor 48 weeks
11205180|NCT03348163|Active Comparator|Continue Current ART|Continue current (ART) therapy (emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks
11205181|NCT03348150|Experimental|Gastrecomy + Cytoreductive surgery + HIPEC|
11205182|NCT03348150|No Intervention|palliative systemic chemotherapy|
11205183|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
11205184|NCT03348124|Experimental|Intervention|"Educational lessons based on the conversational material Toolkit Children - what does it involve?, will be delivered in the classroom at school and caring for the RCB simulator during three days and nights."
11205185|NCT03348124|No Intervention|Control|Education as usual.
11205186|NCT03348111|Experimental|Air-polishing device|Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®
11205187|NCT03348098|Experimental|single arm|Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC
11205188|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
11205189|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
11205190|NCT03348033|Experimental|Chronic Myeloid Leukemia + NK cell|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total.
~NK Cell infusion on Days 0 to 14 for 6 doses total."
11205191|NCT03348020|Experimental|Baseline Clinical Trial|Before blood donation, subjects will participate in a baseline clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
11205192|NCT03348020|Experimental|Post-Blood Donation Clinical Trial|1 month after blood donation, subjects will participate in post-blood donation clinical trial where the research team will perform a series of metabolic tests as described in the detailed study description.
11205193|NCT03348007|Experimental|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
11205194|NCT03348007|Active Comparator|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
11205195|NCT03347994|Experimental|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level
~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
11205196|NCT03347994|Experimental|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:
~0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
11205197|NCT03347994|Experimental|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1
~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
11205198|NCT03347994|Experimental|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2
~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
11205199|NCT03347981|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
11205200|NCT03347981|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
11205203|NCT03347968|Active Comparator|Esmolol|All participants will receive Esmolol
11205204|NCT03347955|Experimental|Neural implantation group|Human embryonic dopamine neurons were implanted into brains of half the randomized participants (n = 20). Participants were evaluated at baseline, 4, 8, and 12 months after surgery.
11205205|NCT03347955|Sham Comparator|Sham Surgery group|This group (n = 20) received sham surgery with a steel frame affixed to their heads and four burr holes drilled into their foreheads without crossing the blood/brain barrier. Participants were assessed at baseline, 4, 8, and 12 months after surgery.
11205206|NCT03347942|Experimental|Intervention|During a period of 30 days the research participant in the intervention group will be instructed to wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before being served again if he or she feels the need.
11205207|NCT03347942|Other|Control|The control group will also serve the dish the same way, but you can serve additional portion without waiting.
11205208|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
11205209|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
11205210|NCT03347916|Placebo Comparator|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
11205211|NCT03347916|Active Comparator|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
11205212|NCT03347890|Experimental|Liraglutide 3.0 mg|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
11205213|NCT03347890|Placebo Comparator|Placebo|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
11205214|NCT03347877|Experimental|autologous bone-periosteal graft|The patients in experimental group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteo-periosteal cylinder graft transplantation.
11205215|NCT03347877|Active Comparator|autologous osteochondral graft|The patients in control group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteochondral graft transplantation.
11205216|NCT03347864|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 30-45 min later
11205217|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
11205218|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
11205219|NCT03347838|Experimental|Nivolumab Injection [Opdivo]|240 mg IV every 2 weeks for 4 doses
11205220|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
11205221|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
11205222|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
11205223|NCT03347812||Endovascular Aortic Repair|Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.
11205224|NCT03347812||Total Arch Replacement|Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.
11205225|NCT03347773|Experimental|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
11205226|NCT03347773|No Intervention|Control|The subjects will be assigned to receive standard care alone.
11205227|NCT03347760|Experimental|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
11205228|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
11205229|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
11205230|NCT03347734|Experimental|Eye Exercises Group (EEG)|For the individuals in the group of eye exercises (GEG), 10 repetitive eye exercises protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
11205231|NCT03347734|Experimental|Convergence Exercise Group (CEG)|For the individuals in the group of convergence exercise, 5 minutes convergence exercise protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
11205232|NCT03347734|Experimental|Oculomotor Exercise Group (OMEG)|For the individuals in the group of oculomotor exercise, 10 repetitive, four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
11205233|NCT03347721|Active Comparator|Lidocaine gel|
11205234|NCT03347721|Placebo Comparator|Lubricant Gel|
11205235|NCT03347708|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells).
11205236|NCT03347708|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
11205237|NCT03347708|Placebo Comparator|Saline|Single intradiscal injection with saline solution.
11205238|NCT03347708|Placebo Comparator|Sodium Hyaluronate Vehicle|Single intradiscal injection with Sodium Hyaluronate Vehicle.
11205239|NCT03347695|Experimental|A modified Cox-Maze operation|Two circular incisions were performed in the left atrial wall between the pulmonary veins and the mitral annulus. with those two incisions , Circumferential resection of a strip for the left atrial was obtained . Then, the resected margin around the mitral annulus was directly anastomosed to the remnant posterior left atrium wall including the pulmonary veins. Right atrium cox-Maze procedure was performed as per usual standard.
11205240|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
11205241|NCT03347669|Experimental|FM patients|50 fibromyalgia patients/50 healthy subjects
11205242|NCT03347669|Active Comparator|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
11205243|NCT03347643|Active Comparator|tDCS with real stimulation|A total of 25 patients will be allocated into active comparator with real stimulation with tDCS.
11205244|NCT03347643|Sham Comparator|tDCS with sham stimulation|A total of 25 patients will be allocated into sham comparator with sham stimulation with tDCS.
11205245|NCT03347630|Other|oesophagus cancer MRI|Diagnostic test
11205246|NCT03347617|Experimental|Diagnostic (Ferumoxytol MRI, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 years or 35 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI scans at baseline, 4 weeks after the last day of standard of care stereotactic radiosurgery or chemoradiotherapy, every 9 weeks thereafter until suspected radiographic progression, and then within 4 weeks from suspected radiographic progression.
11205247|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of > 0.85 in women, or > 0.9 in men.
11205248|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
11205249|NCT03347578||Lung cancer surgery|All patients undergoing thoracic surgery for lung cancer either with thoracoscopy or thoracotomy will receive diaphragmatic Ultrasonography 2 and 24 hours after surgery
11205250|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
11205251|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
11205252|NCT03347552|Experimental|Active Treatment|Participants in the active arm will be enrolled in the HOME Program.
11205253|NCT03347552|No Intervention|E-CARE|"Receiving enhanced care as usual. Participants at these sites are described as receiving enhanced care as usual or E-CARE because they will be recruited, enrolled and complete baseline and follow-up assessments in addition to care as usual."
11205254|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
11205255|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
11205256|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
11205257|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1 mg/mL|
11205258|NCT03347526|Active Comparator|Vigabatrin|
11205259|NCT03347513|Experimental|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).
~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.
~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
11205260|NCT03347513|Active Comparator|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
11205261|NCT03347500||obese OA patients|"Use of patient-derived biological samples
~Inclusion Criteria:
~Subscription of informed consent
~BMI ≥ 30
~age between 60-80 years included
~Kelgrenn-Lawrence equal or superior to grade III
~presence of synovitis
~patients undergoing knee replacement
~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice
~Exclusion criteria:
~- HCV, HIV, HBV, TPHA infection"
11205262|NCT03347500||Non-obese OA patients|"Use of patient-derived biological samples
~Inclusion criteria:
~Subscription of informed consent
~BMI ≤ 28
~age between 60-80 years included
~Kelgrenn-Lawrence equal or superior to grade III
~presence of synovitis
~patients undergoing knee replacement
~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice
~Exclusion criteria:
~- HCV, HIV, HBV, TPHA infection"
11205263|NCT03347487|Experimental|Deep Brain Stimulation of Bilateral Habenula|
11205264|NCT03347474|Experimental|Bilateral surgical implantation of DBS system to NAc|
11205265|NCT03347461|Experimental|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
11205266|NCT03347461|Active Comparator|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
11205303|NCT03347175|Experimental|Volume controlled ventilation|Intervention1: Ventilation with Volume controlled ventilation
11205304|NCT03347175|Active Comparator|Pressure controlled ventilation|Intervention2: Ventilation with Pressure controlled ventilation
11205267|NCT03347461|Active Comparator|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
11205268|NCT03347435|Experimental|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
11205269|NCT03347435|Active Comparator|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
11205270|NCT03347422|Experimental|Part A: sutimlimab or Placebo|In Part A, participants will be randomized 1:1 to receive an intravenous (IV) infusion of sutimlimab or placebo.
11205271|NCT03347422|Experimental|Part B: Response Extension Phase (sutimlimab)|In Part B, all participants will undergo blinded cross-over loading doses to allow all participants to receive sutimlimab while maintaining Part A blinding.
11205272|NCT03347409|No Intervention|Standard Perioperative (SP) care|
11205273|NCT03347409|Experimental|ERAS protocol|
11205274|NCT03347396|Experimental|Sutimlimab|Participants will receive an intravenous (IV) infusion of sutimlimab. Participants who complete Part A per protocol through the end of treatment visit (Day 182) will participate in Part B, and continue to receive sutimlimab up to 1 year after last patient out (LPO) in Part A.
11205275|NCT03347383|Experimental|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
11205276|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
11205277|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
11205278|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
11205279|NCT03347357|Experimental|tacrolimus|
11205280|NCT03347344|Experimental|RILUZOLE|Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.
11205281|NCT03347344|Placebo Comparator|PLACEBO|The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study
11205282|NCT03347331|Experimental|Input function group|Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling
11205283|NCT03347331|Experimental|Test-retest group|Each subject underwent 2 PET scans distant from 1 to 3 weeks
11205284|NCT03347305|Experimental|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
11205285|NCT03347305|Experimental|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
11205286|NCT03347292|Experimental|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
11205287|NCT03347292|Experimental|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
11205288|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
11205289|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
11205290|NCT03347266|Experimental|VVZ-149 injections|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.
11205291|NCT03347266|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
11205292|NCT03347240|Active Comparator|Brain lesioning group|Stereotactic lesioning of the thalamus or gloves pallidus
11205293|NCT03347240|Active Comparator|Combined rhizotomy group|Combined anterior and posterior lumbosacral rhizotomy
11205294|NCT03347240|Active Comparator|Deep brain stimulation group|Bilateral globus pallidus internus deep brain stimulation
11205295|NCT03347240|Active Comparator|Intra-thecal Baclofen infusion therapy|Intra-thecal infusion pump
11205296|NCT03347227|Active Comparator|Pulmonary Vein Isolation|Wide area circumferential catheter ablation for pulmonary vein isolation
11205297|NCT03347227|Experimental|Pulmonary Vein Isolation and scar ablation|Wide area circumferential catheter ablation for pulmonary vein isolation and scar ablation
11205298|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
11205299|NCT03347201|Experimental|Intervention Group|"Initial heparin bolus before CPB to be calculated using HMS Plus.
~Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.
~Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
11205300|NCT03347201|No Intervention|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of >480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
11205301|NCT03347188|Experimental|Fremanezumab|675 mg of fremanezumab administered as 3 sc injections (225 mg/1.5 mL each ) at week 0, week 4, and week 8.
11205302|NCT03347188|Placebo Comparator|Placebo|4.5 mL of placebo administered as 3 sc injections (1.5 mL each ) at week 0,week 4, and week 8.
11205305|NCT03347175|Active Comparator|CPAP mode|Intervention3: Ventilation with Continuous Positive Airway Pressure mode only
11205306|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
11205307|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
11205308|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
11205309|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
11205310|NCT03347136|Active Comparator|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
11205311|NCT03347136|Experimental|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
11205312|NCT03347123|Experimental|Treatment Group A|Epacadostat + nivolumab + ipilimumab
11205313|NCT03347123|Experimental|Treatment Group B|Epacadostat + nivolumab + lirilumab
11205314|NCT03347110|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 2 years.
11205315|NCT03347097|Experimental|TIL cells|10 days after the end of concurrent chemoradiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
11205316|NCT03347097|Experimental|PD1-TIL cells|10 days after the end of concurrent chemoradiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
11205317|NCT03347084|Active Comparator|Excitation|Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
11205318|NCT03347084|Active Comparator|Inhibition|Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
11205319|NCT03347071||Prevention Course Group|The Prevention Course Group is composed of female student-athletes enrolled in the 7-week prevention course. The course occurs once a week (1 hour, 40 minute sessions) for a total of 7-weeks during the academic semester. Approximately 1 hour of each class session is lecture based, leaving 40 minutes for yoga practice administered by a certified yoga instructor. The course instructor is certified in Eat Breathe Thrive Program delivery. The course teaching assistant is certified in yoga instruction.
11205320|NCT03347071||Control Group|The Control Group is composed of female student-athletes not enrolled in the 7-week prevention course. Female student-athletes in this group will not be enrolled in the course during the period of data collection, nor will they have previously completed the course.
11205321|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
11205322|NCT03347045|Experimental|Trimodal Prehab & ERP|"Trimodal prehab includes:
~Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.
~Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.
~Anxiety reduction workshop and take-home anxiety reduction program."
11205323|NCT03347045|Active Comparator|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
11205324|NCT03347032|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
11205325|NCT03347032|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
11205326|NCT03347019|Experimental|accelerated rehabilitation after surgery|patients were included progressive rehabilitation programme first week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
11205327|NCT03347019|Experimental|delayed rehabilitation after surgery|Patients were not allowed to start passive shoulder exercises first three weeks after surgery. Patients were included progressive rehabilitation programme third week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
11205328|NCT03347006|Placebo Comparator|Placebo|Placebo control
11205329|NCT03347006|Experimental|Dose 1|1.5 g of omega-3 supplement
11205330|NCT03347006|Experimental|Dose 2|3.0 g of omega-3 supplement
11205331|NCT03347006|Experimental|Dose 3|4.5 g of omega-3 supplement
11205332|NCT03346993|Experimental|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
11205333|NCT03346993|Experimental|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
11205334|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
11205335|NCT03346967|Experimental|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
11205336|NCT03346967|Experimental|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
11205337|NCT03346954|Experimental|Patients with Cushing's disease|Implementation of [11C]-Methionine PET/MRI
11205452|NCT03346083|Experimental|Cohort 2 Bertrixaban/Placebo|Single oral dose 80 mg
11205338|NCT03346915|Experimental|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
11205339|NCT03346902|Placebo Comparator|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection
~Injection of Placebo into area of scarring (forehead)"
11205340|NCT03346902|Active Comparator|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
11205341|NCT03346876||Study group|patients with pectus excavatum
11205342|NCT03346876||Control group|healthy subjects without pectus excavatum
11205343|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
11205344|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
11205345|NCT03346837|Experimental|Inhibition (Cohort 1)|Single oral dose BMS-986205
11205346|NCT03346837|Experimental|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
11205347|NCT03346837|Experimental|Induction (Cohort 3)|Single oral dose BMS-986205
11205348|NCT03346837|Experimental|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
11205349|NCT03346811|Experimental|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
11205350|NCT03346798|Experimental|Food Photography|On the first visit, participants will engage in food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
11205351|NCT03346798|Experimental|Non-Food Photography|On the first visit, participants will engage in non-food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
11205352|NCT03346785|Experimental|Food Photography|Participants will engage in food photography on their smart phones while eating
11205353|NCT03346785|Experimental|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
11205354|NCT03346785|Experimental|No Phone Use|Participants will not use their smart phones while eating
11205355|NCT03346772|Experimental|Influenza vaccination cohort|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
11205356|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
11205357|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
11205358|NCT03346746|Experimental|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
11205359|NCT03346746|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
11205360|NCT03346720||Participants recruited into biomedical research|Participants recruited into biomedical research where data collected may be shared with the wider research community.
11205361|NCT03346720||Frontline research staff|Frontline research staff directly involved in obtaining consent from participants in the above studies e.g. study nurses, investigators
11205362|NCT03346720||Research related staff and other stakeholders|Research related staff and other stakeholders involved in the implementation of the data sharing policy e.g. study managers, data access committee members, ethics committee members, study nurses, investigators, research collaborators, data managers and other clinical trials support staff.
11205363|NCT03346720||Community advisory board members|Community advisory board members and other community members
11205364|NCT03346707||10.5 Tesla|
11205365|NCT03346694|Active Comparator|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
11205366|NCT03346694|Active Comparator|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
11205367|NCT03346694|Active Comparator|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
11205368|NCT03346681|Experimental|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
11205369|NCT03346681|No Intervention|Albuterol|Albuterol will be administered via nebulization every six hours.
11205370|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
11205371|NCT03346642|Experimental|GVD and SHR-1210 with or without Decitabine|This is a two stage study. For the first stage, the participants will receive the combination of GVD chemotherapy and PD-1 antibody SHR-1210. The patients enrolled into the second stage will received the combination of GVD and SHR-1210 with low-dose decitabine primed.
11205372|NCT03346629|Experimental|Mifepristone + Misoprostol|Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
11205424|NCT03346213||Major surgery|"Adult patients undergoing elective surgery
~Having a CPET as part of routine care
~Patients with a Hb value of < 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.
~Able to provide written informed consent."
11205425|NCT03346200|Active Comparator|20 mg tamoxifen|
11205373|NCT03346616|Experimental|Texting Group|"The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2 pm and 3 pm."
11205374|NCT03346616|Active Comparator|Non Texting Group|The non-texting group received access to the journal articles from which the text message content was derived, but did not receive any text messages or any of the online material or question stems.
11205375|NCT03346590|Active Comparator|16 patients with active RA|"Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.
~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
11205376|NCT03346590|Sham Comparator|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).
11205377|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
11205378|NCT03346564|Experimental|Ritual training program|ritual training program for 8 weeks, biweekly
11205379|NCT03346564|Placebo Comparator|Routine care|Routine care following hospital
11205380|NCT03346551|Experimental|women with postnatal depression|
11205381|NCT03346551|Other|women without postnatal depression|
11205382|NCT03346538|Experimental|Continuous infusion high-dose group (Group H)|High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
11205383|NCT03346538|Experimental|Continuous infusion low-dose group (Group L)|Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
11205384|NCT03346538|Experimental|Approved dosing regimen group (control group)|A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
11205385|NCT03346525|Experimental|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
11205386|NCT03346525|No Intervention|Control Arm|No prophylaxis
11205387|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
11205388|NCT03346499|Experimental|NK cells and IL-2|
11205389|NCT03346486|Placebo Comparator|Control diet|Regular diet
11205390|NCT03346486|Active Comparator|Intervention diet|Brainfood diet
11205391|NCT03346473||Adolescents aged 12-15 years in LMICs|No interventions administered
11205392|NCT03346460|Experimental|Tongue scraper group (Group 1)|Fifteen patients will be included in this group. Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
11205393|NCT03346460|Experimental|aPDT group (Group 2)|Fifteen patients will be included in this group. One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
11205394|NCT03346460|Experimental|Tongue scraper and aPDT (Group 3)|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
11205395|NCT03346434|Experimental|Part A (Open label Dupilumab): Age cohorts 1 & 2|"Age cohort 1: ≥2 years old to <6 years old
~Age cohort 2: ≥6 months to <2 years old"
11205396|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 1|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
11205397|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 2|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
11205398|NCT03346434|Experimental|Part B (Double-Blind): Placebo|
11205399|NCT03346421||diet and physical activity|
11205400|NCT03346408||Patients|data collection obtained from patient (self-questionnaire) and algologist physician (questionnaire).
11205426|NCT03346200|Experimental|10 mg tamoxifen|
11205427|NCT03346200|Experimental|5 mg tamoxifen|
11205428|NCT03346200|Experimental|2.5 mg tamoxifen|
11205429|NCT03346200|Experimental|1 mg tamoxifen|
11205430|NCT03346200|Placebo Comparator|0 mg tamoxifen|
11205483|NCT03345914|Experimental|Group 2|Participants will receive dupilumab, dosing regimen 2
11205484|NCT03345914|Experimental|Group 3|Participants will receive matching placebo
11205401|NCT03346395|Experimental|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
11205402|NCT03346395|Active Comparator|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
11205403|NCT03346369|Experimental|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
11205404|NCT03346356|Experimental|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
11205405|NCT03346356|No Intervention|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
11205406|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.
~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
11205407|NCT03346330|Experimental|TRK-750, single and multiple doses|
11205408|NCT03346330|Placebo Comparator|Placebo, single and multiple doses|
11205409|NCT03346317|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
11205410|NCT03346317|Experimental|estrogen|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
11205411|NCT03346304|Experimental|PDT treatment (Intervention Arm)|Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
11205412|NCT03346304|No Intervention|Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
11205413|NCT03346291|Experimental|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
11205414|NCT03346278|No Intervention|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
11205415|NCT03346278|Experimental|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
11205416|NCT03346265|Experimental|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.
~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
11205417|NCT03346265|Experimental|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
11205418|NCT03346252|Experimental|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
11205419|NCT03346239|Experimental|Gaze Contingent Music Reward Therapy|Participants will receive gaze-contingent feedback according to their viewing patterns, over a course of 12 weeks.
11205420|NCT03346239|Active Comparator|Selective Serotonin Reuptake Inhibitors|Participants will receive 10-20 mg of Escitalopram over a course of 12 weeks.
11205421|NCT03346239|Placebo Comparator|Waitlist Control|Participants will wait for treatment for 12 weeks, then receive GC-MRT for 12 weeks.
11205422|NCT03346226|Experimental|Dexmedetomidine Hydrochloride|Dex Group: 0.5 μg/kg of Dex is given 10 minutes before operation through injection pump during 15 minutes. After the operation starts, the initial pumping ratio of Dex is 0.5ug/kg/h and adjusted under BIS surveillance to keep BIS between 70-80 until 30 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
11205423|NCT03346226|Active Comparator|Propofol|Prop Group: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts. Under BIS surveillance, dripping rate is adjusted to keep BIS between 70-80 until 5 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
11205431|NCT03346187|Experimental|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.
~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
11205432|NCT03346187|Experimental|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.
~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
11205433|NCT03346174|Experimental|AAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage. By modulating manually the functional breathing level within the vital capacity, optimal airflow will be obtained at the targeted airway generations, where secretions have been identified. A gentle increase of manual pressure on the chest during each inspiration is performed to guide the breathing of the patient towards the desired lung volume level. During expiration the breathing movement of the patient is followed gently.
11205434|NCT03346174|Experimental|BAAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage .AAD sometimes leads to crying or resistance against therapy.Bouncing (at low amplitude:6-8 cm) in a stable upright position is a gentle up-and-down movement on a physio ball. It is not an ACT, but used to maximize the relaxation of the infant, avoiding resistance against or crying during treatment. Due to the relaxing effect of bouncing, infants appear to tolerate better AAD, increasing the effectiveness of the treatment.
11205435|NCT03346161|Experimental|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
11205436|NCT03346161|Active Comparator|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
11205437|NCT03346135|Experimental|Treatment (ASCT, melphalan, daratumumab)|Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
11205438|NCT03346122|Experimental|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
11205439|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
11205440|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
11205441|NCT03346122|Experimental|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
11205442|NCT03346122|Experimental|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
11205443|NCT03346122|Experimental|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
11205444|NCT03346122|Experimental|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
11205445|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
11205446|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
11205447|NCT03346122|Experimental|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
11205448|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
11205449|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
11205450|NCT03346096|Experimental|Thiotepa|Thiotepa for reduce toxicity and improve outcome following transplantation
11205451|NCT03346083|Experimental|Cohort 1 Bertrixaban/Andexanet|Single oral dose 40 mg
11205453|NCT03346070|Experimental|Sugammadex 2 mg/kg ABW|Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
11205454|NCT03346070|Experimental|Sugammadex 2 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
11205455|NCT03346070|Experimental|Sugammadex 4 mg/kg ABW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
11205456|NCT03346070|Experimental|Sugammadex 4 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
11205457|NCT03346070|Active Comparator|Neostigmine/Glycopyrrolate|Following administration of NMBA, participants received a single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW. Neostigmine/Glycopyrrolate was used for reversal of moderate NMB. Active comparator treatment for reversal for deep NMB was not available.
11205458|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
11205459|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
11205460|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
11205461|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
11205462|NCT03346044|Active Comparator|Carpentier-Edwards SAV bioprostheses|
11205463|NCT03346044|Active Comparator|Medtronic Mosaic bioprostheses|
11205464|NCT03346031|No Intervention|Group 1|Group 1 is control group that does not listen to music
11205465|NCT03346031|Active Comparator|Music Therapy Group 2|Group 2 is the group listening to preoperative music
11205466|NCT03346031|Active Comparator|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
11205467|NCT03346018||uveitis of tuberculous etiology|Analysis of aqueous humor and plasma samples: The patients with diagnosis of uveitis of tuberculous etiology, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
11205468|NCT03346018||uveitis of suspect sarcoidosis|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of suspect sarcoidosis, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
11205469|NCT03346018||uveitis of undifferentiated origin|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis), undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
11205470|NCT03346005|Experimental|Adult patients with positive FIT test|Adult patients with a positive FIT-test will breath into an e-nose device for 5 minutes.
11205471|NCT03345992|Placebo Comparator|Placebo|After enrollment, the placebo arm will receive water for injection at a volume of 20ml diluted to a final volume of 250 ml dextrose in water 5%, infused once daily through intravenous route, within 1 hour, for a duration of four consecutive days.
11205472|NCT03345992|Active Comparator|Clarithromycin|After enrollment, the active drug arm will receive 1g of clarithromycin (500 mg powder for concentrate for solution for infusion per vial), dissolved into 20 ml water for injection and then diluted to a final volume of 250 ml dextrose in water 5%. This will be infused through intravenous route, once daily within 1 hour, for a duration of four consecutive days.
11205473|NCT03345979|Experimental|Treatment Group 1|Regular injections
11205474|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
11205475|NCT03345966|Experimental|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.
~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
11205476|NCT03345966|Experimental|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):
~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:
~Finally, RQ was calculated according to the following equation:
~∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene
~∆∆ Ct = ∆ Ct sample - Ct control gene
~RQ = 2-(∆∆Ct)"
11205477|NCT03345953|Experimental|BP 1.4979|15 mg tablet BID
11205478|NCT03345953|Placebo Comparator|Placebo|Matching placebo tablet
11205479|NCT03345940|Active Comparator|Fingolimod 0.5 mg/day|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.
~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
11205480|NCT03345940|Active Comparator|Dimethyl Fumarate 240 mg twice daily|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.
~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
11205481|NCT03345927||high cardiovascular risk group|no intervention
11205482|NCT03345914|Experimental|Group 1|Participants will receive dupilumab, dosing regimen 1
11205487|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
11205488|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
11205489|NCT03345875|Other|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
11205490|NCT03345862|Experimental|Intervention|Non-pharmacological multicomponent intervention
11205491|NCT03345862|No Intervention|Control|Not intervention, usual attention
11205492|NCT03345849|Experimental|Arm A: Upadacitinib|Participants will receive Upadacitinib dose A for 12 weeks. Non-responders will receive Upadacitinib dose B for 12 weeks
11205493|NCT03345849|Experimental|Arm B: Placebo and Upadacitinib|Participants will receive placebo for 12 weeks. Non-responders will receive Upadacitinib dose A for 12 weeks.
11205494|NCT03345836|Experimental|Arm A|Participants will receive upadacitinib dose A for 12 weeks.
11205495|NCT03345836|Experimental|Arm B|Participants will receive placebo for 12 weeks.
11205496|NCT03345836|Other|Arm C|Participants will receive open-label upadacitinib dose A for 12 weeks.
11205497|NCT03345823|Experimental|Group A - Arm A|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose B.
11205498|NCT03345823|Experimental|Group A - Arm B|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose C.
11205499|NCT03345823|Experimental|Group A- Arm C|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive placebo.
11205500|NCT03345823|Experimental|Group B - Arm A|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose B.
11205501|NCT03345823|Experimental|Group B - Arm B|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose C.
11205502|NCT03345823|Experimental|Group B - Arm C|This is a long-term extension group with 240 weeks which includes participants who complete group A.
11205503|NCT03345810|Active Comparator|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
11205504|NCT03345810|Experimental|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3
~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W"
11205505|NCT03345810|Experimental|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3
~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)"
11205506|NCT03345810|Active Comparator|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3
~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
11205507|NCT03345797|Experimental|Naive patients - ARM 1|TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
11205508|NCT03345797|Experimental|Non-naive patients - ARM 2|TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage >/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
11205509|NCT03345784|Experimental|Treatment (radiation therapy, adavosertib, cisplatin)|Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.
11205510|NCT03345771|Active Comparator|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
11205511|NCT03345771|Active Comparator|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
11205512|NCT03345758||ECMO mode,outcome|ECMO mode includes VV-ECMO and VA-ECMO, outcome includes survive condition , physical and mental health, cognitive function and social adaptation
11205513|NCT03345745||Periodontally healthy subjects|Salivary samples
11205514|NCT03345745||Chronic periodontitis patients|Salivary samples
11205515|NCT03345745||Gingivitis patients|Salivary samples
11205516|NCT03345706|Experimental|Selective cerebral hypothermia|Selective cerebral hypothermia
11205517|NCT03345706|Active Comparator|Regular hypothermia|Regular hypothermia
11205518|NCT03345693|Experimental|Treated with MoTrack Therapy|Patients receive the MoTrack Therapy device to assist them in their at-home therapy exercises. The patient is instructed to use the MoTrack Therapy device when they want to do their at-home therapy exercises. The patients therapy in the clinic is not affected.
11205519|NCT03345680|No Intervention|Control Group|Children will be screened, both parents and children will be informed of any abnormalities in the mouth.
11205520|NCT03345680|Experimental|Interventional Group|Interventional (Dental Screening) Children will be screened for dental caries and referred to a specific hospital for treatment, namely King Saud University Dental College, treatment will be provided free of charge to the referred participants.
11205521|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
11205522|NCT03345654|Placebo Comparator|Standard-of-care hearing aid fit|
11205523|NCT03345654|Experimental|Toolset-directed hearing aid fit|
11205524|NCT03345641||dyads|dyads with babies and their mothers
11205525|NCT03345628||sedated|infants requiring intubation and ventilation who received sedatives for at least 3 days
11205526|NCT03345628||non-sedated|infants who received respiratory support by non-invasive ventilation and were not sedated
11205527|NCT03345615|Experimental|Intensive Monitoring|30-day ambulatory cardiac event monitoir
11205528|NCT03345615|No Intervention|Standard Care|Standard Care (no supplemental monitoring)
11205529|NCT03345589|Experimental|18-22mg/kg/d Ursodeoxycholic group|
11205531|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
11205532|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
11205533|NCT03345563|Experimental|Body Mind Training (BMT)|Body mind training
11205534|NCT03345563|Active Comparator|Body Training (BT)|Body training only
11205535|NCT03345563|Other|Usual care (UC):|Control
11205536|NCT03345550|Experimental|Omega-3 Polyunsaturated Fatty Acid Treatment Arm|Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
11205537|NCT03345550|Placebo Comparator|Placebo Arm|Participants randomized to this study arm will receive placebo drug for 3 months.
11205538|NCT03345524|Experimental|Peer-buddy system|Will meet with peer-buddy who will help with them with CPAP usage. Also will receive standard of care CPAP educational training
11205539|NCT03345524|Active Comparator|Usual Care|Will receive educational material at the same frequency that those in the experimental arm. Will also receive standard of care CPAP educational training.
11205540|NCT03345511|Experimental|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
11205541|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
11205542|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
11205543|NCT03345485|Experimental|Tinostamustine (EDO-S101)|"Phase 1:
~Schedule A: Tinostamustine (EDO-S101), IV, 60mg/m2 up to 100mg/m2 Day 1 and 15 of each 28 day cycle
~Phase 2:
~The RP2D and selected schedule will be further investigated in patients with specific types of solid tumors: relapsed/refractory SCLC, soft tissue sarcoma, triple negative breast cancer, ovarian cancer and endometrial cancer."
11205544|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
11205545|NCT03345459|Experimental|Internet-Based Treatment (ICare)|ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
11205546|NCT03345459|No Intervention|Usual Care|Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
11205547|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF < 55% per the protocol).
11205548|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF > 55% per the protocol).
11205549|NCT03345433|Experimental|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
11205550|NCT03345420|Experimental|Treatment (hypofractionated radiation therapy)|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
11205551|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
11205552|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
11205553|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
11205554|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
11205555|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
11205556|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
11205557|NCT03345394|Active Comparator|Standard Treatment|12 weeks of standard treatment offered by the 2 treatment facilities where the study is being conducted
11205558|NCT03345394|Experimental|Contingency Management|12 weeks of standard treatment offered by these same facilities associated with Contingency Management
11205559|NCT03345381|Experimental|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) plus usual care
11205560|NCT03345381|Active Comparator|Usual Care|Treatment as usual
11205561|NCT03345368|Experimental|rTMS treated group|A Magstim Rapid2 Stimulator equipped with a double 70mm alpha coil P/N 3191-00 (Magstim, Wales, UK) will be used to stimulate the motor cortex. Transcranial magnetic stimulation will be applied through a coil at 10 Hz, a field intensity of 90% of the motor threshold. Stimuli will be provided in 10 trains of 100 pulses, followed by a 28 s rest period.
11205562|NCT03345368|Sham Comparator|sham rTMS group|Sham rTMS will be administered with the coil held in contact with the head but a 180 degrees from scalp, and the power parameter will be reduced by half to avoid stimulation.b
11205563|NCT03345355||patient with axial spondyloarthritis|
11205564|NCT03345342|Experimental|PP1M: Transition Phase|Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
11205565|NCT03345342|Experimental|PP1M/PP3M: Maintenance Phase|All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
11205566|NCT03345342|Experimental|PP6M or Placebo: Double-Blind Phase|Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
11205567|NCT03345342|Experimental|PP3M: Double-Blind Phase|Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
11205568|NCT03345329||Periodontal patient|
11205569|NCT03345329||Healthy person|
11205570|NCT03345329||Peri-implantitis patient|
11205571|NCT03345316|Experimental|FFI-1010|
11205572|NCT03345303|Experimental|Bortezomib treatment|'Bortezomib Injectable Solution
11205573|NCT03345303|No Intervention|supportive care|supportive care
11205574|NCT03345290|Experimental|Subjects|Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
11205575|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
11205576|NCT03345264|Experimental|Cancer patients, survivors, and partners|
11205577|NCT03345251|Experimental|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
11205578|NCT03345251|Placebo Comparator|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
11205579|NCT03345238|Experimental|Active MTP|
11205580|NCT03345238|Experimental|Latent MTP|
11205581|NCT03345238|Experimental|Out of MTP|
11205582|NCT03345225|Active Comparator|Control Group|Participants will be randomized to receive DEB-TACE utilizing a standard endhole microcatheter
11205583|NCT03345225|Experimental|Surefire Group|Participants will be randomized to receive DEB-TACE utilizing the Surefire Infusion System
11205584|NCT03345212|No Intervention|Control group|Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
11205585|NCT03345212|Experimental|Training group|"Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.
~Patients will be informed about group allocation."
11205586|NCT03345199|Experimental|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
11205587|NCT03345186|Experimental|Nurse led plus standard of care|Nurse Led Patient Management Programme to Improve Outcomes in Gout and Standard of care for gout patients, including nurse delivered patient education and follow up
11205588|NCT03345186|No Intervention|Standard of care|Standard of care for gout patients
11205589|NCT03345173|Experimental|CI-581a|"CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.
~(0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)"
11205590|NCT03345173|Placebo Comparator|CI-581b|"CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.
~(2-min saline bolus followed by 0.0125 mg/kg over 90 min)"
11205591|NCT03345160|Experimental|Peanut Flour: Open label peanut OIT|This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study
11205592|NCT03345147||Normal Vitamin A intake|Normal Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to Normal Vit. A consumption if daily Vit. A is between 250 and 600 micrograms per day.
11205593|NCT03345147||High Vitamin A intake|High Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to High Vit. A consumption if daily Vit. A is above 900 micrograms per day.
11205594|NCT03345134|Experimental|MK-3475 and BCG|Single treatment group of high risk superficial upper urinary tract transitional cell carcinoma; combination treatment with MK-3475 and BCG
11205595|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
11205596|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
11205597|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
11205598|NCT03345095|Experimental|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
11205599|NCT03345095|Active Comparator|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
11205600|NCT03345082|Experimental|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
11205601|NCT03345082|Experimental|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
11205602|NCT03345082|Sham Comparator|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
11205603|NCT03345056|Other|included cases|vitrectomy done with planned foveal separation and followed for the result
11205604|NCT03345043|Experimental|VAL-339851|
11205605|NCT03345043|Placebo Comparator|Placebo|
11205606|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
11205607|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
11205608|NCT03345004|Active Comparator|Active arm|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
11205609|NCT03345004|Placebo Comparator|Placebo arm|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)
11205610|NCT03344991|Active Comparator|Cardboard Cot Care|Stable infant will be transferred to cardboard cot, lined with reflective film for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
11205611|NCT03344991|Placebo Comparator|Open Crib|Stable infant will be transferred to standard of care open crib for duration of hospital stay following weaning from radiant warmer. Infant's axillary temperature will be taken at 1 hour, 6 hours, 24 hours after being placed in the cot or crib, and then once every 24 hours until discharge.
11205612|NCT03344978|Active Comparator|Cardboard Cot Care|Stable infant will be nursed in a cardboard cot, lined with reflective film for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Incubator Care), and back for a total of 2 24-hour periods in each arm.
11205613|NCT03344978|Placebo Comparator|Incubator Care|Stable infant will be nursed in an incubator for 24 hour period of time. Infant's axillary temperature will be taken at 1 hour after randomization, at 6 hours after randomization, and 24 hours after randomization. After 24 hours, infant will be swapped to the other arm (Cardboard Cot Care), and back for a total of 2 24-hour periods in each arm.
11205614|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
11205615|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
11205616|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
11205617|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:
~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.
~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
11205618|NCT03344926|Experimental|ACTsmart|ACT treatment via a smart phone application
11205619|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
11205620|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
11205621|NCT03344900||Phase I|It is estimated that 100 participants with SCD will be enrolled for the Phase I portion which will identify barriers to hydroxyurea utilization.
11205622|NCT03344900||Phase II|It is estimated that 72 participants with SCD will be enrolled for the Phase II portion of the study which will evaluate the degree of feasibility and acceptance of mHealth intervention on hydroxyurea adherence.
11205623|NCT03344887|Active Comparator|RBC Transfusion from male donor|For the treatment of anemia
11205624|NCT03344887|Active Comparator|RBC Transfusion from female donor|For the treatment of anemia
11205625|NCT03344874|Experimental|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.
~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
11205626|NCT03344874|Active Comparator|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.
~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
11205627|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
11205628|NCT03344848|Experimental|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
11205629|NCT03344835||Prostate Cancer|Patients diagnosed with prostate cancer
11205630|NCT03344822|Experimental|68Ga-PSMA PET-CT|
11205660|NCT03344614|Experimental|raltitrexed combined with apatinib|therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.
11205731|NCT03344120|Active Comparator|Vortek double-J stent|Vortek double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
11205631|NCT03344796||Focus Group|"32 subjects
~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days. The analysis will determine enablers and barriers to sun protected outdoor activities and determine strategies for achieving sun protected outdoor activities."
11205632|NCT03344796||Usability testing|"10 subjects
~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week."
11205633|NCT03344796||Cohort Study 1|"60 subjects
~First cohort study: It is expected that each of 60 melanoma survivors will wear the sensor and transmit data for 21 days in the warm weather months of June-Aug 2019. It will take about 2 months to enroll the subjects. Subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized to receive a survey item inviting selection of strategies to achieve sun-protected outdoor activities (structured goal attainment) or submit a free text description of their strategy (unstructured goal attainment)."
11205634|NCT03344796||Structured Interviews|50 young adults, ages 18-39 will participate in structured interviews to determine their barriers and enablers of sun exposure and sun protection. Eligible subjects will have at least one hour a day outdoors with 30 minutes of the hour being consecutive. It will take about 3 months to enroll the subjects. The audio files will be transcribed and analysis completed in 60 days.
11205635|NCT03344796||Cohort Study 2|Second cohort study: 40 young adults will wear the sensor and transmit data for 28 days in summer 2020.
11205636|NCT03344783||mother-children pairs|
11205637|NCT03344770|Experimental|Active rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
11205638|NCT03344770|Sham Comparator|Sham rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
11205639|NCT03344757|Experimental|C-CBSM|Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
11205640|NCT03344757|Active Comparator|CBSM|Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
11205641|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
11205642|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
11205643|NCT03344744||Control|Healthy volunteers
11205644|NCT03344731|Experimental|Experimental Group|Patient with any form ob brain damage
11205645|NCT03344731|Other|Control Group|Healthy volounteers
11205646|NCT03344705|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
11205647|NCT03344692|Experimental|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
11205648|NCT03344692|Placebo Comparator|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.
~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
11205649|NCT03344679|Other|Control group|Bupivacaine 0.25% for pectoral nerve block.
11205650|NCT03344679|Other|Adenosine|Bupivacaine 0.25% with added Adenosine 12mg for pectoral nerve block.
11205651|NCT03344679|Other|Magnesium sulphate|Bupivacaine 0.25% with Magnesium sulphate 500 mg for pectoral nerve block.
11205652|NCT03344666|Experimental|First Treatment|Participants will be randomized to first treatment to compare Brief Intervention + Health Coach (Step 1 Treatment BI+HC) to Brief Intervention + Text Messages (Step 1 Treatment BI+TM). Participants in the BI+HC will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks. Participants in the BI+TM will receive a BI in the ED, followed by daily TMs for 4 weeks.
11205653|NCT03344666|Experimental|Second Treatment for Responders and Non-Responders|"Beginning in week 5, all participants will be classified as Responders or Non-Responders (based on weekly assessments) and re-randomized.
~Step 2 Treatment Responders: Responders will be randomized to either stay the course or be stepped down. Specifically, participants in the BI+HC will either continue to receive the HC or stepped down to receive a control brochure; participants in the BI+TM will either continue to receive the TM or stepped down to receive a control brochure.
~Step 2 Treatment Non-Responders: Non-Responders will be randomized to either stay the course or be stepped up. Specifically, participants in the BI+HC will either continue to receive the HC or stepped up to receive a HC+; participants in the BI+TM will either continue to receive the TM or stepped up to receive HC."
11205654|NCT03344653|Active Comparator|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
11205655|NCT03344653|Active Comparator|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
11205656|NCT03344640|Experimental|secukinumab|AIN457 subcutaneously for 12 weeks
11205657|NCT03344640|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
11205658|NCT03344627|Active Comparator|Meropenem standard dose|Meropenem 1 g every 8 hours
11205659|NCT03344627|Active Comparator|Meropenem high dose|Meropenem 2 g every 8 hours
11205817|NCT03343522|No Intervention|Sedentarism|Patients assigned to this arm shall not perform regular exercise training.
11205661|NCT03344601|No Intervention|Reference Cohort|A 12-month longitudinal evaluation of physical fitness and physical activity assessments in a cohort of individuals with HD (n=60) recruited from the Enroll-HD platform study.
11205662|NCT03344601|Experimental|Physcial Activity Intervention|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to a 12-month physical activity and coaching intervention.
11205663|NCT03344601|No Intervention|Activity as usual control|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to continue with physical activity as usual for 12 months
11205664|NCT03344588|Active Comparator|artery preserving varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group A (APV), testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
11205665|NCT03344588|Active Comparator|artery ligation varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group B (ALV), all vascular channels will be ligated without identifying or sparing the internal spermatic arteries
11205666|NCT03344575|Active Comparator|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
11205667|NCT03344575|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
11205668|NCT03344562|Experimental|CES Active|Active cranial electrical stimulation device
11205669|NCT03344562|Sham Comparator|CES Sham|Inactive device identical to the active device.
11205670|NCT03344549|Experimental|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
11205671|NCT03344549|Other|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
11205672|NCT03344536|Experimental|fulvestrant and Debio 1347|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter. Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated. The dosage in the phase 2 portion will be the MTD/RP2D determined in the phase 1b portion.
11205673|NCT03344523|Experimental|standard treatment + Iron succinylate|1 bottle orally, twice daily, take orally before meals
11205674|NCT03344523|Placebo Comparator|standard treatment + placebo|1 bottle orally, twice daily, take orally before meals
11205675|NCT03344510|Experimental|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
11205676|NCT03344510|Experimental|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
11205677|NCT03344497|Other|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
11205678|NCT03344497|No Intervention|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
11205679|NCT03344484|Experimental|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
11205680|NCT03344484|Experimental|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
11205681|NCT03344471|Other|women with PTSD after preterm deliver|
11205682|NCT03344471|Other|women without PTSD after preterm deliver|
11205683|NCT03344458|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
11205684|NCT03344445|No Intervention|traditional vist|Patients receive traditional anesthesiologist visit
11205685|NCT03344445|Experimental|video-assisted|Patients watch the video, then an anesthesiologist visit
11205686|NCT03344432||With intraocular pressure high|Intracranial pressure equal or more than 20 mmHg
11205687|NCT03344432||Without intraocular pressure high|Intracranial pressure smaller than 20 mmHg
11205688|NCT03344419|Experimental|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
11205689|NCT03344419|Active Comparator|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
11205690|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
11205691|NCT03344393|Active Comparator|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
11205692|NCT03344393|Active Comparator|normal saline|intravenous normal saline infusion in the intraoperative period
11205693|NCT03344380||Prospective cohort|Adult patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. The GWAS will be performed with the blood obtained from enrolled patients.
11205694|NCT03344380||Retrospective cohort|In previous study performed in adult patients undergoing liver transplantation (NCT02489474, 4-2015-0411), we enrolled patients and collected data regarding the development of acute kidney injury during the first 72 hours post-liver transplantation. Among these patients enrolled in this previous study, only patients who agreed to additional use of the blood sample for research purposes will be included in the present study. The GWAS will be performed with the blood obtained from enrolled patients.
11205695|NCT03344367|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.
11205696|NCT03344354|Active Comparator|Biogel 1|Biogel 1 (overglove) sterile surgical glove
11205697|NCT03344354|Active Comparator|Ansell|Ansell sterile surgical glove
11205698|NCT03344354|Active Comparator|Cardinal|Cardinal sterile surgical glove
11205699|NCT03344354|Active Comparator|Biogel 2|Biogel 2 (underglove) sterile surgical glove
11205700|NCT03344354|Active Comparator|Medline|Medline sterile sergical glove
11205701|NCT03344341|Experimental|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
11205702|NCT03344341|Active Comparator|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
11205703|NCT03344315|Active Comparator|autologous connective tissue graft|Soft tissue harvesting from patient palate
11205704|NCT03344315|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
11205705|NCT03344302|Experimental|study group|100 women were assigned to receive an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour minutes diluted into 500 mL of normal 0.9% sodium chloride) immediately after opening the visceral peritoneum just before incising the uterine wall during Cesarean section
11205706|NCT03344302|Active Comparator|Control group|100 women were assigned to an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour diluted into 500 mL of normal 0.9% sodium chloride) immediately after clamping the umbilical cord during cesarean section
11205707|NCT03344289|Experimental|Linked color imaging|When the patient is randomized for LCI, the imaging mode is switched to LCI and colonoscopic inspection will take place during withdrawal of the endoscope
11205708|NCT03344289|Active Comparator|High definition white light|When the patient is randomized for HD-WLE, the imaging mode is switched to HD-WLE and colonoscopic inspection will take place during withdrawal of the endoscope.
11205709|NCT03344276|Active Comparator|Control Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months). The two preoperative time points will serve as the control group.
11205710|NCT03344276|Experimental|Intervention Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points after invention (1 month and 2 months). The two postoperative time points will serve as the intervention group.
11205711|NCT03344263|Experimental|tests of attentional performance|
11205712|NCT03344250|Experimental|Main Study|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
11205713|NCT03344250|Experimental|Subcohort for MGMT unmethylated patients|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. About 4 weeks after completion of RT/TMZ, participants will receive 8 weekly doses of EGFR BATs.
11205714|NCT03344224||normal blood lipid/protein group|
11205715|NCT03344224||abnormal blood lipid/protein group|
11205716|NCT03344211|Experimental|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11205717|NCT03344211|Experimental|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11205718|NCT03344198|Experimental|Firefighter (Veteran) Group|Firefighters with >10yrs experience. Circuit Training exercise & Modified Mediterranean diet
11205719|NCT03344198|Experimental|Firefighter (Novice) Group|Firefighters with <10yrs experience. Circuit Training exercise & Modified Mediterranean diet
11205720|NCT03344198|Experimental|Control Non-Firefighter Group|Non-Firefighter adults. Circuit Training exercise & Modified Mediterranean diet
11205721|NCT03344185|Experimental|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
11205722|NCT03344185|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
11205723|NCT03344172|Experimental|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
11205724|NCT03344172|Experimental|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
11205725|NCT03344159|Experimental|Spironolactone|Participants with chronic right-sided heart failure will receive spironolactone 12.5mg daily up to a maximum dose of 50 mg daily for a total duration of 12 weeks.
11205726|NCT03344159|Placebo Comparator|Placebo|Participants with chronic right-sided heart failure will receive placebo daily for a total duration of 12 weeks.
11205727|NCT03344146|Other|Group 1|Intake reminders followed by crossover to no intake reminders
11205728|NCT03344146|Other|Group 2|No intake reminders followed by crossover to intake reminders
11205729|NCT03344133|Experimental|Exercise|4-week moderate intensity exercise programme
11205730|NCT03344133|No Intervention|Control|4 weeks of habitual life style
11205895|NCT03343002|Experimental|fentanyl at 10-15 min before end of surgery|
11205732|NCT03344120|Active Comparator|Silicone double-J stent|Silicone double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
11205733|NCT03344107|Active Comparator|Vortek double-J stent after RIRS|Vortek double-J stent positioning after RIRS. USSQ questionnaire administration.
11205734|NCT03344107|Active Comparator|Polaris Loop stent after RIRS|Polaris Loop ureteral stent positioning after RIRS. USSQ questionnaire administration.
11205735|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
11205736|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
11205737|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
11205738|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
11205739|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
11205740|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
11205741|NCT03344068|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radical radiotherapy with or without chemotherapy plus Nutren® Optimum of 7 scoops tid at begin of radiotherapy.
11205742|NCT03344068|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radical radiotherapy with or without chemotherapy plus routine diet guidance at begin of radiotherapy.
11205743|NCT03344055|Active Comparator|Colonoscopy with Endocuff Vision (ECV)|ECV-assisted colonoscopy ( with the use of Endocuff Vision (ECV) Second generation)
11205744|NCT03344055|No Intervention|Standard colonoscopy|Standard colonoscopy (without the use of Endocuff Vision (ECV) Second generation)
11205745|NCT03344042|Active Comparator|Fentanyl|100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation
11205746|NCT03344042|Active Comparator|Sufentanyl|10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation
11205747|NCT03344042|No Intervention|Control|No epidural analgesia
11205748|NCT03344029|Experimental|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
11205749|NCT03344029|Active Comparator|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
11205750|NCT03344016|No Intervention|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
11205751|NCT03344016|Active Comparator|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
11205752|NCT03344003||Wilate or Nuwiq prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
11205753|NCT03344003||Wilate or Nuwiq retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
11205754|NCT03343990||group A|Interlocking multi-twisted wires techniqe in sternal closure
11205755|NCT03343990||group B|Eight Figure techniqe in sternal closure
11205756|NCT03343977|Experimental|Every two weeks docetaxel|50 mg/m2 of docetaxel will be given on day 1 every 14 days over one hour IV infusion for up to 9 cycles (1 cycle = 14 days)
11205757|NCT03343977|Active Comparator|Every three weeks docetaxel|75 mg/m2 of docetaxel will be given on day 1 every 21 days over one hour IV infusion for up to 6 cycles (1 cycle = 21 days)
11205758|NCT03343964||Children with moderate to severe TBI|
11205759|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
11205760|NCT03343938|Experimental|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
11205761|NCT03343938|No Intervention|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
11205762|NCT03343912|Experimental|Test 1 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
11205763|NCT03343912|Experimental|Test 2 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
11205764|NCT03343912|Experimental|Test 3 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days
11205765|NCT03343873|Experimental|Midarolam|midarolam sensation group
11205766|NCT03343873|Experimental|Propofol|propofol sensation group
11205767|NCT03343873|Experimental|dexmedetomidine|dexmedetomidine sensation group
11205768|NCT03343860|Active Comparator|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
11205769|NCT03343860|Active Comparator|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
11205770|NCT03343847|Experimental|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
11205771|NCT03343847|Placebo Comparator|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
11205813|NCT03343561|Experimental|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
11205814|NCT03343548|Active Comparator|Group I|magnesium group (Mg)
11205815|NCT03343548|Placebo Comparator|Group II|control group (C)
11205816|NCT03343535|Experimental|OCS|OCS Lung Preservation
11205772|NCT03343834|Other|EBV+ allograft population|"Retrospective study (n=80) : Patient who underwent HSCT, in Saint-Antoine hospital, between 2010-2015, treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).
~Prospective study (n=58) : Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière, in 2016-2017, treated by rituximab for high level EBV-DNAemia (above 10 000c/mL), And/or having post-transplant lymphoproliferative diseases(PTLD) Concerned population Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with a high Epstein-Barr virus (EBV) viral load"
11205773|NCT03343821||Frail elderly patient|
11205774|NCT03343795|Experimental|study group 1|oral progesterone
11205775|NCT03343795|Active Comparator|study group 2|intramuscular progesterone
11205776|NCT03343782|Experimental|Stem cell transplantation|Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
11205777|NCT03343769||Patient|
11205778|NCT03343769||Control|
11205779|NCT03343743|Other|Hydration|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
11205780|NCT03343730|Experimental|Non-mydriatic color fundus photography|All participants will receive Non-mydriatic color fundus photography with the RetinaVue camera at an already scheduled annual physical exam or follow up clinic visit with their primary care provider (PCP).
11205781|NCT03343730|Active Comparator|Standard of Care (Control)|All patients will also receive a referral for a dilated eye exam with an eye care professional. A yearly dilated exam as referred by the PCP.
11205782|NCT03343717|Experimental|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.
~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.
~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
11205783|NCT03343717|Active Comparator|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
11205784|NCT03343704|Experimental|Idarucizumab|
11205785|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.
~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
11205786|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
11205787|NCT03343678|Experimental|Venetoclax + BI 836826|
11205788|NCT03343665|Experimental|Nivolumab 40 mg|Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11205789|NCT03343652|Experimental|NB|Nivolumab 3 mg/kg IV infusion on day 1,14 + Bendamustine hydrochloride 90 mg/kg IV infusion on day 1,2 up to 3 cycles. Duration of cycle 28 days
11205790|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
11205791|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
11205792|NCT03343626|Placebo Comparator|Placebo|TAK-426 placebo-matching injection, intramuscular, once on Days 1 and 29.
11205793|NCT03343626|Experimental|Low Dose: PIZV 2 microgram (mcg)|PIZV 0.5 milliliter (mL), 2 mcg antigen, injection, intramuscular, once on Days 1 and 29.
11205794|NCT03343626|Experimental|Medium Dose: PIZV 5 mcg|PIZV 0.5 mL, 5 mcg antigen, injection, intramuscular, once on Days 1 and 29.
11205795|NCT03343626|Experimental|High Dose: PIZV 10 mcg|PIZV 0.5 mL, 10 mcg antigen, injection, intramuscular, once on Days 1 and 29.
11205796|NCT03343613|Experimental|LY3381916 Escalation|LY3381916 administered orally.
11205797|NCT03343613|Experimental|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
11205798|NCT03343613|Experimental|LY3381916 Expansion|LY3381916 administered orally.
11205799|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B1|"Metastatic triple negative breast cancer (TNBC)
~LY3381916 administered orally and LY3300054 administered IV."
11205800|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B2|"Metastatic non-small cell lung cancer (NSCLC)
~LY3381916 administered orally and LY3300054 administered IV."
11205801|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B3|"Metastatic clear cell carcinoma renal cell carcinoma (RCC)
~LY3381916 administered orally and LY3300054 administered IV."
11205802|NCT03343600|Experimental|Imatinib|Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
11205803|NCT03343600|Placebo Comparator|Placebo|Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.
11205804|NCT03343587|Experimental|LY3375880 Single Dose|Single dose of LY3375880 administered IV or SC
11205805|NCT03343587|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered IV or SC
11205806|NCT03343587|Experimental|LY3375880 Multiple Dose|Multiple doses of LY3375880 administered IV or SC
11205807|NCT03343587|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered IV or SC
11205808|NCT03343574|Experimental|Abdominal Strengthening Exercise|All participants in this arm shall perform exercises for the strengthening of abdominal muscles for a period of three months in addition to the routine care provided to them for the management of Parkinson's Disease. The exercises are structured and need to be performed on a routine basis.
11205809|NCT03343574|No Intervention|Routine Care|All participants in this group shall continue to obtain routine care for the management of Parkinson's Disease.
11205810|NCT03343561|No Intervention|Control|Subjects would have subjects' own diet as usual
11205811|NCT03343561|Experimental|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
11205812|NCT03343561|Experimental|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
11205818|NCT03343522|Experimental|Exercise Training|Patients assigned to this arm will be enrolled in exercise training program.
11205819|NCT03343509|Experimental|Group A - Oral|Oral metronidazole 400mg 3 times a day for 7 days Placebo ointment applied 3 time times a day for 7 days to affected region
11205820|NCT03343509|Experimental|Group B - Topical|Topical metronidazole ointment 10% 3 times a day for 7 days Oral placebo tablets 3 times a day for 7 days
11205821|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
11205822|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
11205823|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
11205824|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
11205825|NCT03343457|Experimental|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
11205826|NCT03343457|Experimental|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
11205827|NCT03343457|No Intervention|Control|Control group
11205828|NCT03343444|Active Comparator|Arm 1|Treatment-naïve is defined as having never received treatment for HCV with any interferon (IFN), ribavirin , or other approved or experimental HCV specific direct acting antivirals.
11205829|NCT03343444|Active Comparator|Arm 2|"Treatment-experienced is defined as:
~IFN Intolerant
~Non-response
~Relapse/Breakthrough"
11205830|NCT03343444|Experimental|Short Track|Treatment-naïve or Treatment-experienced who achived very rapid virological responce - Negative HCV PCR after treatment with (Sofosbuvir 400mg/Ledipasvir 90mg) for 1 week
11205831|NCT03343418|Active Comparator|desmopressin|Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.
11205832|NCT03343418|Placebo Comparator|Placebo|Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).
11205833|NCT03343405|Experimental|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
11205834|NCT03343405|No Intervention|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
11205835|NCT03343392|Experimental|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
11205836|NCT03343392|Placebo Comparator|Placebo group|One hour before in-office bleaching patients received either placebo.
11205837|NCT03343379|Other|Healthy cohort|Core stability test
11205838|NCT03343366|Experimental|Test Group 1|The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
11205839|NCT03343366|Active Comparator|Test Group 2|The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1
11205840|NCT03343366|Other|Control Group 3|The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.
11205841|NCT03343353|Experimental|LED red group (630nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
11205842|NCT03343353|Experimental|LED infrared group (940nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
11205843|NCT03343353|Sham Comparator|Group Sham|This group will not receive irradiation by led light. You will only receive the routine care of the hospital unit to which you are hospitalized. These patients will be evaluated in the same way as the other two intervention groups, and also by a blind evaluator.
11205844|NCT03343340|Experimental|Early CRRT|Early Continous Renal Replacement Therapy within 6 hours + Standard Medical Therapy
11205845|NCT03343340|Active Comparator|Late CRRT|Late Continous Renal Replacement Therapy + Standard Medical Therapy
11205846|NCT03343327|Experimental|Chronocort®, then Cortef®|Single dose of 20mg Chronocort® (oral administration), followed by a single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration).
11205847|NCT03343327|Active Comparator|Cortef®, then Chronocort®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration), followed by a single dose of 20mg Chronocort® (oral administration).
11205848|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
11205896|NCT03343002|Active Comparator|fentanyl at end of surgery|
11205982|NCT03342352|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
11205849|NCT03343301|Other|Phase 1 Study of FPA144 + mFOLFOX6|"Phase 1 dose escalation of FPA144 administered intravenously over approximately 30 minutes in cohorts of 3-6 patients to evaluate for the recommended dose (RD) of FPA144 for phase 3. mFOLFOX6 administered 30 minutes after the end of the FPA144 infusion as follows:
~Oxaliplatin 85 mg/m2 intravenously over 2 hours on day 1
~Leucovorin 400 mg/m2 intravenously over 2 hours. Can be administered concurrently with oxaliplatin using a Y-connector on day 1
~Immediately after completion of oxaliplatin and leucovorin, administer 5-fluorouracil (5-FU) 400 mg/m2 intravenously over 5 minutes
~Immediately after the 5-FU bolus, 5-FU 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
~Treatment is repeated every 2 weeks."
11205850|NCT03343288|Experimental|Silver HA coated implants|Silver doped hydroxyapatite coated implants
11205851|NCT03343275|Experimental|Experimental|"Dietary supplement : Lit-Control® pH Down
~Pharmaceutical form: capsules
~Administration : oral
~Dose: 3 capsules/day.
~• Sanitary product : Lit-Control® pH Meter
~In vitro diagnosis sanitary product
~Use:Urinary pH evaluation"
11205852|NCT03343275|Placebo Comparator|Placebo|"Placebo:
~Pharmaceutical form: capsules
~Administration : oral
~Dose: 3 capsules/day.
~• Sanitary product : Lit-Control® pH Meter
~In vitro diagnosis sanitary product
~Use:Urinary pH evaluation"
11205853|NCT03343262|Experimental|"ta-VNS yidan-pi"|"Device:ta-VNS & Electro-acupuncture(yidan-pi auricular acupoints):2 times per day,2 days per week for 12 weeks"
11205854|NCT03343262|Placebo Comparator|"ta-VNS jian"|"Device:ta-VNS & Electro-acupuncture(jian auricular acupoints):2 times per day,2 days per week for 12 weeks"
11205855|NCT03343249|Experimental|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.
~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
11205856|NCT03343236||Patients with head and neck cancer|All patients with newly diagnosed and untreated head and neck cancer. Exclusion criteria: previous treatment for malignant disorder except for skin cancer, severe alcohol abuse, psychiatric disorder, inability to understand Swedish
11205857|NCT03343223|Experimental|Intervention Group|"Public health personnel identify PrEP-eligible clients.
~PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.
~Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.
~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.
~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).
~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).
~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
11205858|NCT03343223|No Intervention|Control Group|"Public health personnel identify PrEP-eligible.
~Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.
~The client initiates contact with a PrEP provider in Iowa and schedules an appointment.
~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.
~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).
~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).
~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
11205859|NCT03343210|Experimental|cancer patient|cancer patient
11205860|NCT03343210|Active Comparator|no cancer patient|no cancer patient
11205861|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
11205862|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
11205863|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
11205864|NCT03343184|Active Comparator|SEE and incremental restoration|50 teeth will receive restorations using SEE Strategy and Incremental Restoration
11205865|NCT03343184|Experimental|SEE and bulk restoration|50 teeth will receive restorations using SEE Strategy and Bulk Fill Restoration
11205866|NCT03343184|Experimental|SET and incremental restoration|50 teeth will receive restorations using SET Strategy and Incremental Restoration
11205867|NCT03343184|Experimental|SET and bulk restoration|50 teeth will receive restorations using SET Strategy and Bulk Fill Restoration
11205868|NCT03343145|Experimental|Test Drug Group|Leucostim 5µg/kg/day
11205869|NCT03343145|Active Comparator|Reference Drug Group|Neupogen 5µg/kg/day
11205870|NCT03343132||Subacute SCI|
11205871|NCT03343132||Chronic SCI|
11205872|NCT03343132||Controls|
11205873|NCT03343119||Hospitalised patients|No intervention
11205874|NCT03343119||Healthy volunteers|No intervention
11205875|NCT03343119||Dog owners (healthy volunteers)|No intervention
11205876|NCT03343119||Veterinarians (healthy volunteers)|No intervention
11205877|NCT03343119||Pig farmers (healthy volunteers)|No intervention
11205929|NCT03342781|Active Comparator|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) > 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
11205983|NCT03342352|Active Comparator|Arm B|EXTREME regimen.
11205878|NCT03343106|Experimental|ACT plus ERP|Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
11205879|NCT03343106|Experimental|ERP alone|ERP followed Kozak and Foa's treatment manual. Sessions 1 and 2 included information-gathering, psychoeducation about the cognitive-behavioral model of OCD and rationale for ERP, and introduction to self-monitoring of rituals. Session 3 was dedicated to developing the treatment plan (exposure hierarchy, response prevention plan). Sessions 4-16 included in-session prolonged and repeated gradual exposure therapy (in vivo and imaginal as needed), the assignment of daily exposure practices for between-sessions, and instructions to refrain from rituals (response prevention in session and between sessions), along with self monitoring of any rituals that were performed. Session 16 also addressed discontinuation and relapse prevention.
11205880|NCT03343093|Experimental|Intervention Evaluation Control Group|Surveys at 3 month intervals
11205881|NCT03343093|Experimental|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
11205882|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.
~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.
~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
11205883|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.
~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.
~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
11205884|NCT03343067|Experimental|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
11205885|NCT03343067|Experimental|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
11205886|NCT03343067|Experimental|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group
~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
11205887|NCT03343067|Experimental|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD
~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group
~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
11205888|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
11205889|NCT03343041|Active Comparator|low carbohydrate nutrition|"We will use a low-carbohydrate nutrition (LCN) formulated by the MICU registered dietitian and pharmacy staff, who routinely prepare enteral and parenteral nutrition which will provide:
~5% carb, 41% protein, 54% lipid."
11205890|NCT03343041|Active Comparator|standard enteral nutrition|"The standard enteral nutrition (SEN) and per cent contribution of carbohydrates used in the Yale MICU is as follows:
~Jevity 1.2 56% carb, 29.5% lipid, 18.5% protein Diabetisource 33% carb, 44% lipid, 20% protein Promote 55% carb, 25% lipid, 25% protein Vital AF 37% carb, 40% lipid, 25% protein Peptamin Intense 29% carb, 34% lipid, 37% protein Osmolite 1.5 54% carb, 29.5% lipid, 16.5% protein"
11205891|NCT03343028||Psychotherapy|The investigators will assess and acquire data on these Veterans across the course of the project prior to and after receiving Prolonged Exposure (PE) or Cognitive Processing Theory (CPT) treatment at VA Palo Alto (VAPAHCS) and the Albuquerque VA. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva at baseline on these Veterans and again 3 months after treatment to assess prediction and durability of the clinical and brain/behavioral metrics. All study assessments will take place at Stanford University/VAPAHCS. Subjects will be recruited through VAPAHCS and Albuquerque VA. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
11205892|NCT03343028||Healthy Controls|The investigators will assess and acquire data on these Veterans who do not have history of PTSD and have no history of any Axis I psychiatric disorder, are taking psychotropic medication, or use illicit drugs. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva once. All study assessments will take place at Stanford University. Subjects will be recruited through public flying, online ads and VAPAHCS. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
11205893|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
11205894|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
11205897|NCT03342989|Experimental|Speed of Processing Training|Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
11205898|NCT03342989|Active Comparator|Internet-Based Contact Control|Training involves mentally stimulating activity and consists of three levels: (1) using a computer (e.g., mouse training, pull-down menus, selecting options), (2) internet search engine training, and (3) search engine proficiency tasks. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
11205899|NCT03342976|Active Comparator|Cases|"Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities.
~Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
11205900|NCT03342976|Placebo Comparator|Controls|"Pre-frail subjects will be followed according to best standard of care protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
11205901|NCT03342963|Experimental|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.
~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
11205902|NCT03342963|Experimental|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.
~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
11205903|NCT03342963|Experimental|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.
~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
11205904|NCT03342963|Experimental|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.
~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
11205905|NCT03342950|Active Comparator|Active drug group|Treatment with the topical solution of clonidine + pentoxifylline (0.1%/5%)
11205906|NCT03342950|Placebo Comparator|Placebo group|Treatment with placebo solution with out active drug ingredients
11205907|NCT03342937|Experimental|Oxaliplatin+Capecitabine+Pembrolizumab|
11205908|NCT03342924|Experimental|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
11205909|NCT03342911|Experimental|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11205910|NCT03342898|Experimental|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
11205911|NCT03342898|Experimental|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
11205912|NCT03342898|Experimental|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
11205913|NCT03342885|Experimental|Intervention group|Participants enrolled into the intervention group receive specific sleep ergonomics guidance
11205914|NCT03342885|Active Comparator|Control group|Participants enrolled into the control group will receive general sleep ergonomics guidance
11205915|NCT03342872|Experimental|Core Training|
11205916|NCT03342872|Experimental|Core Training & Facilitation|
11205917|NCT03342872|No Intervention|Control|
11205918|NCT03342859|Experimental|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
11205919|NCT03342859|Active Comparator|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
11205920|NCT03342859|No Intervention|Control group|Patients undergoing surgery without any prior treatment, as control group
11205921|NCT03342846|Active Comparator|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
11205922|NCT03342846|Active Comparator|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
11205923|NCT03342833|Active Comparator|Blood flow restriction|
11205924|NCT03342833|Sham Comparator|Usual training|
11205925|NCT03342820|Experimental|Quadriceps muscle fatigue|Quadriceps muscle fatigue
11205926|NCT03342807|Experimental|Group Insulin|
11205927|NCT03342807|Experimental|Group Aphesis|
11205928|NCT03342794|Other|preexisting posterior capsule defects|congenital cataracts with a preexisting posterior capsule defect
11205978|NCT03342404|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
11205930|NCT03342781|Active Comparator|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
11205931|NCT03342768|Experimental|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
11205932|NCT03342768|Other|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
11205933|NCT03342742|Experimental|Daily Caloric Restriction|The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.
11205934|NCT03342742|Experimental|Intermittent Fasting|Participants in the intermittent fasting group will be instructed to reduce energy intake to ~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~34% (similar to the daily caloric restriction group).
11205935|NCT03342729|Experimental|Intervention Group|Immediate exposure to the 10-week Aging Mastery Program (AMP)
11205936|NCT03342729|Placebo Comparator|Wait-list Group|Class to start 3 months after the Intervention Group
11205937|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
11205938|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
11205939|NCT03342703||Patients with Liver Fibrosis Measurement|Group1: Patients will undergo an Ultrasound to correlate fibrosis measurements obtained using standard-of-care MRI.
11205940|NCT03342703||Patients with Liver Steatosis Measurement|Group 2: Patients will undergo an Ultrasound to correlate steatosis measurements obtained using standard-of-care MRI.
11205941|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
11205942|NCT03342677|Other|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
11205943|NCT03342664|Experimental|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
11205944|NCT03342664|Active Comparator|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
11205945|NCT03342651|Other|Observational research|Vitamin D levels and respiratory complications; observational research.
11205946|NCT03342638|Experimental|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
11205947|NCT03342638|Experimental|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
11205948|NCT03342625|Experimental|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
11205949|NCT03342612|Experimental|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
11205950|NCT03342599|Experimental|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
11205951|NCT03342599|Placebo Comparator|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
11205952|NCT03342586||Central Nervous System Lymphoma|Participants will have non-Hodgkins lymphoma involving the brain (primary or secondary)
11205953|NCT03342573|Experimental|Single Arm|Patients with a biopsy proven diagnosis of PRP
11205954|NCT03342560|Experimental|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
11205955|NCT03342547|Experimental|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
11205956|NCT03342534|Active Comparator|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
11205957|NCT03342534|Active Comparator|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
11205958|NCT03342534|Active Comparator|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
11205959|NCT03342534|Sham Comparator|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
11205960|NCT03342508|Experimental|Fetal Pillow Inflated (FPI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow. The obstetrician will not be aware to inflation of Fetal Pillow
~Cesarean delivery will then be performed
~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
11205979|NCT03342404|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
11205980|NCT03342391|Other|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
11205981|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
11205961|NCT03342508|No Intervention|Fetal Pillow Not Inflated (FPNI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The Fetal Pillow will not be inflated.
~Cesarean delivery will then be performed. The obstetrician will continue to be able to use conventional methods for delivery of a second stage arrest including hand from below and reverse breech extraction.
~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
11205962|NCT03342495|Experimental|Patient Navigator Arm|"Patient Navigator (Social Worker) will assist youth adapt and attach to adult delivered healthcare for up to 24 months.
~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.
~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.
~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.
~Participants will be provided the opportunity to journal online about their experiences.
~Up to 100 participants will be provided the opportunity to be interviewed at baseline and end of study about their transition experience."
11205963|NCT03342495|Other|Usual Care Arm|"Youth will receive usual care from their pediatric clinics in preparation and transfer to adult care.
~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.
~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.
~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.
~Participants will be provided the opportunity to journal online about their experiences."
11205964|NCT03342482|Placebo Comparator|Placebo|5 g of placebo (sugar and salt) will be administered in veggie capsules
11205965|NCT03342482|Experimental|MSG|5 grams of MSG will be administered in veggie capsules
11205966|NCT03342469|Experimental|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
11205967|NCT03342469|Experimental|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
11205968|NCT03342469|Experimental|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
11205969|NCT03342469|Experimental|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
11205970|NCT03342456|Experimental|group 1|week1 to week2：Doxycycline Hyclate Enteric-Coated Capsules 0.1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily
11205971|NCT03342456|Active Comparator|group 2|"Amoxicillin Capsules 1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily.
~week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily"
11205972|NCT03342443|Experimental|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
11205973|NCT03342443|Placebo Comparator|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
11205974|NCT03342430||Early Dieting in Girls cohort|A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years
11205975|NCT03342417|Experimental|Neoadjuvant Breast Cancer|"Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy.
~Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab."
11205976|NCT03342417|Experimental|Platinum-resistant ovarian cancer|Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.
11205977|NCT03342417|Experimental|Advanced gastric cancer patients|"Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin.
~Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab."
11205984|NCT03342352|Experimental|Arm C|Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
11205985|NCT03342339|Other|patients with Parkinson's disease|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
~viewing of video : scale of differential emotions and Positive and Negative Affect Scale
~Test of Iowa Gambling Task"
11205986|NCT03342339|Other|witnesses|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
~viewing of video : scale of differential emotions and Positive and Negative Affect Scale
~Test of Iowa Gambling Task"
11205987|NCT03342326|Other|patient with Alzheimer's Disease|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
~Music Experience Questionnaire : questions about the past music training
~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
11205988|NCT03342326|Other|healthy volunteer|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
~Music Experience Questionnaire : questions about the past music training
~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.
~For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test"
11205989|NCT03342313|Experimental|healthy weight|BMI (kg/m2) ≥ 18.5 and < 23
11205990|NCT03342313|Experimental|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
11205991|NCT03342300|Experimental|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
11205992|NCT03342300|Placebo Comparator|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
11205993|NCT03342274|Experimental|Lifestyle Program Intervention|Participants receive usual care and group weight loss sessions adapted from the Diabetes Prevention Program delivered by Community Health Workers.
11205994|NCT03342274|Other|Wait list|Participants receive usual care and after 1 year receive the Lifestyle Program intervention
11205995|NCT03342261||HCV patients with mixed cryoglobulinemia|HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
11205996|NCT03342248|Experimental|access to the social network|This group is made up of carers who have access to the social network via a digital platform developed during step 1. This network will offer features from step 1 (sharing experiences on a forum, monitoring health status )
11205997|NCT03342248|No Intervention|no access to the network|"This group consists of caregivers who do not have access to the social network via a digital platform developed during step 1.
~Access to the social network will be offered to all carers at the end of the study, especially those assigned in the control group to limit their refusal to participate."
11205998|NCT03342235|Experimental|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
11205999|NCT03342235|Active Comparator|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
11206000|NCT03342222|Experimental|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
11206001|NCT03342222|Active Comparator|Biosure PK interference screw|Biosure PK interference screw from Smith & Nephew plc.
11206002|NCT03342209|Experimental|HFNC therapy|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
11206003|NCT03342196|Experimental|Thiotepa + Fludarabine + Melphalan + KGF|Melphalan 100 mg/m2 on day -8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days -6, -5, -4 and -3. Keratinocyte Growth Factor (KGF) 60mcg/kg IV on day -11, -10, and -9 and 0, +1, and +2.
11206004|NCT03342183|Experimental|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation). To be administered on a monthly basis from the baseline visit to the year 1 visit.
11206005|NCT03342183|Sham Comparator|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
11206006|NCT03342170||CIRRAL|alcoholic cirrhosis
11206007|NCT03342170||CIRVIR|Viral cirrhosis
11206008|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
11206009|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
11206010|NCT03342144||Participants Receiving Venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
11206011|NCT03342144||Participants Receiving Venetoclax + Rituximab|Participants with CLL receiving venetoclax in combination with rituximab.
11206012|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
11262696|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
11206013|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
11206014|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
11206015|NCT03342118|Experimental|Phloroglucin group|patients taken Phloroglucin(Flospan®)
11206016|NCT03342118|Placebo Comparator|Normal saline placebo group|patients taken normal saline placebo
11206017|NCT03342105|Experimental|Cettum (Electrical moxibustion)|The patients in this group will receive Cettum (Electrical moxibustion) treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
11206018|NCT03342105|Active Comparator|Acupuncture|The patients in this group will receive acupuncture treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
11206019|NCT03342092||Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation
11206020|NCT03342079|Experimental|Group 1|local anesthetic + placebo
11206021|NCT03342079|Experimental|Group 2|local anesthetic + nitrous oxide
11206022|NCT03342079|Placebo Comparator|Group 3|Placebo + nitrous oxide
11206023|NCT03342066||A|Cariogram
11206024|NCT03342066||B|CAMBRA
11206025|NCT03342053|Experimental|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
11206026|NCT03342053|Experimental|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
11206027|NCT03342040|Experimental|TAP block|Patients undergoing laparoscopic ventral hernia repair with TAP block with 0.2% ropivacaine under ultrasound guidance
11206028|NCT03342040|Active Comparator|No TAP block|Patients undergoing laparoscopic ventral hernia repair without TAP block
11206029|NCT03342027|Experimental|Bupropion + Positively Smoke Free|Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation bupropion--used for smoking cessation
11206030|NCT03342027|Experimental|Bupropion + Standard of Care|Standard of Care--brief advice to quit provided in a standardized format bupropion--used for smoking cessation
11206031|NCT03342027|Experimental|Placebo + Positively Smoke Free|Placebo--matched to bupropion Positively smoke free-- an 8 session tailored behavioral treatment for smoking cessation
11206032|NCT03342027|Placebo Comparator|Placebo + Standard of Care.|Placebo--matched to bupropion Standard of Care--brief advice to quit provided in a standardized format
11206033|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
11206034|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
11206035|NCT03341988|Other|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
11206036|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
11206037|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
11206038|NCT03341962|Experimental|10 mg IMU-838 (Induction)|"Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.
~Patients will receive only half of their assigned full dose during the first week of treatment."
11206039|NCT03341962|Experimental|30 mg IMU-838 (Induction)|"Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.
~Patients will receive only half of their assigned full dose during the first week of treatment."
11206040|NCT03341962|Experimental|45 mg IMU-838 (Induction)|"Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.
~Patients will receive only half of their assigned full dose during the first week of treatment."
11206041|NCT03341962|Placebo Comparator|placebo (during induction)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.
11206042|NCT03341962|Experimental|10 mg IMU-838 (Maintenance)|Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
11206043|NCT03341962|Experimental|30 mg IMU-838 (Maintenance)|Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
11206044|NCT03341962|Placebo Comparator|placebo (during maintenance)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).
11206045|NCT03341962|Experimental|30 mg IMU-838 (Open-label)|Two 15 mg tablets once daily of IMU-838 for up to 10 years and up to 3 years in UK sites
11206046|NCT03341949|Experimental|Patient with chronic kidney disease|Determination of the Cluster of Differentiation 146 (CD146)
11206144|NCT03341260|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
11206047|NCT03341936|Experimental|Nivolumab+Lirilumab|"The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection.
~In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle
~In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle."
11206048|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
11206049|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
11206050|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
11206051|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
11206052|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
11206053|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
11206054|NCT03341897|Experimental|Surgical varicocelectomy|
11206055|NCT03341884|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
11206056|NCT03341884|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
11206057|NCT03341884|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
11206058|NCT03341884|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
11206059|NCT03341871||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.
11206060|NCT03341845|Experimental|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
11206061|NCT03341832|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
11206062|NCT03341832|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
11206063|NCT03341832|Placebo Comparator|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
11206064|NCT03341819|Active Comparator|Retained Urinary Catheter|
11206065|NCT03341819|Experimental|Non-retained Urinary Catheter|
11206066|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
11206067|NCT03341793|Experimental|Muscle secretion|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
11206068|NCT03341767|Experimental|Clofazimine|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
11206069|NCT03341767|Placebo Comparator|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
11206070|NCT03341767|Experimental|Clofazimine, no diarrhea|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
11206071|NCT03341754|Experimental|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.
~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
11206072|NCT03341754|Experimental|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.
~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
11206073|NCT03341754|Active Comparator|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
~Week 28 = Controlled Human Malaria Infection (CHMI)"
11206074|NCT03341741|Experimental|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
11206075|NCT03341741|Active Comparator|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
11206076|NCT03341728|Experimental|Intervention, then Control|Older adults will walk during exposure to optical flow perturbations
11206077|NCT03341728|Experimental|Control, then Intervention|Older adults will walk normally (without optical flow perturbations)
11206078|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
11206079|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
11206080|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
11265803|NCT02933450|No Intervention|Standard of Care group|Standard of Care
11206081|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
11206082|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
11206083|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
11206084|NCT03341676|Experimental|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
11206085|NCT03341676|Placebo Comparator|Placebo|8ml IV 0.9% w/v saline
11206086|NCT03341650|Experimental|High Pasta|Habitual pasta consumption equal or higher than 5 times/week.
11206087|NCT03341650|Experimental|Low Pasta|Habitual pasta consumption equal or lower than 3 times/week.
11206088|NCT03341637|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
11206089|NCT03341637|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
11206090|NCT03341624|Experimental|cataract surgery cataract extraction and intraocular implanta|
11206091|NCT03341611||Adults 55 and younger|
11206092|NCT03341611||Adults 55 and older|
11206093|NCT03341598|Active Comparator|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
11206094|NCT03341598|Experimental|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
11206095|NCT03341585|Experimental|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
11206096|NCT03341572|Experimental|high response group|patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
11206097|NCT03341572|Placebo Comparator|low response group|the change of CVP is less than 2.5cmH2O
11206098|NCT03341559||With Existing Diabetic Ulcers|Current DFU
11206099|NCT03341559||Diabetic Ulcers in remission|DFU in remission
11206100|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
11206101|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
11206102|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
11206103|NCT03341520|Experimental|interventional arm|Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
11206104|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a Mc Coy laryngoscope will be performed.
11206105|NCT03341494|Experimental|Gefitinib 250mg qd thalidomide 200mg qn|
11206106|NCT03341494|Active Comparator|Gefitinib 250mg qd|
11206107|NCT03341481|Experimental|Femaltiker|7.7 g of Femaltiker twice a day for 14 days of the trial.
11206108|NCT03341481|Placebo Comparator|placebo|7.7 g placebo 14 days of the trial.
11206109|NCT03341468|Experimental|Urethral catheter immobilization|Subjects randomized to the intervention group will undergo radical prostatectomy with placement of the urethral catheter per the standard of care. The urethral catheter immobilization device will be applied in the operating room prior to the patient being transported to the recovery room. Subjects will be informed on safe use of the device and must demonstrate competency in removing and replacing the device prior to discharge. Subjects will also be given an elastic leg strap, which they may use concurrently with the device. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care, at which the device will no longer be needed.
11206110|NCT03341468|No Intervention|No urethral catheter immobilization|Subjects randomized to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care.
11206145|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
11206146|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
11206147|NCT03341234|Active Comparator|Group SPB|Ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
11206111|NCT03341455|Other|Intervention preschools|"Capacity building to support families affected by IPV & substance misuse will be provided to the intervention preschools.
~Specifically, capacity building, training and support will be provided to
~selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.
~selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.
~intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
11206112|NCT03341455|No Intervention|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
11206113|NCT03341442|Experimental|No hip precautions|No hip precautions practiced after THA surgery
11206114|NCT03341442|No Intervention|Hip precautions|Hip precautions practiced per standard of care after THA surgery
11206115|NCT03341429|Experimental|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg
~Study dosing of liraglutide:
~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily
~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
11206116|NCT03341429|Placebo Comparator|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.
~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
11206117|NCT03341416|Experimental|Device - deep brain stimulation ON|"Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.
~The stimulation will remained turned ON during 3 months - phase 1 - blinded and continuous during the open-label phase"
11206118|NCT03341416|Sham Comparator|Device - deep brain stimulation Sham|"Sham stimulation: device (deep brain stimulation of the dentate nucleus in cerebellum). Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.
~During the sham stimulation the intervention will remained turned OFF during 3 months"
11206119|NCT03341403|Active Comparator|Synbiotic group|"severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive Probiotical ® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
11206120|NCT03341403|Placebo Comparator|Placebo group|severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
11206121|NCT03341390|Active Comparator|Aspirin|325 mg tablet, once daily for 5 days (Day -5 to -1)
11206122|NCT03341390|Experimental|BMS-986177 plus aspirin|200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
11206123|NCT03341390|Placebo Comparator|Placebo plus aspirin|200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)
11206124|NCT03341377||Lung cancer surgical patients|Patient-reported symptom assessments in patients undergoing lung cancer surgery.
11206125|NCT03341364|Experimental|ACT group treatment|Participants receiving the ACT-based group therapy.
11206126|NCT03341364|Active Comparator|ACT individual|Participants receiving individual ACT-based therapy.
11206127|NCT03341351|Active Comparator|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
11206128|NCT03341351|Active Comparator|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
11206129|NCT03341325|Experimental|animal-assisted intervention|the intervention is a real animal is presented in different forms to the participants
11206130|NCT03341325|Active Comparator|control intervention|the control intervention is a stuffed toy animal is presented in different forms to the participants
11206131|NCT03341312|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
11206132|NCT03341312|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
11206133|NCT03341312|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
11206134|NCT03341312|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
11206135|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
11206136|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
11206137|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
11206138|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
11206139|NCT03341286|Experimental|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
11206140|NCT03341286|Placebo Comparator|Placebo|Placebo orally, to be taken three times a day
11206141|NCT03341273|Experimental|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
11206142|NCT03341273|Placebo Comparator|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
11206143|NCT03341260|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg tablet to be administered one hour before treatment.
11206148|NCT03341234|Active Comparator|Group Control|Ultrasound guided sham block with 2 ml saline subcutaneously
11206149|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
11206150|NCT03341195|Active Comparator|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
11206151|NCT03341195|Active Comparator|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
11206152|NCT03341195|Active Comparator|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
11206153|NCT03341195|Active Comparator|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
11206154|NCT03341195|No Intervention|5. Control Arm|One time counseling at the baseline survey.
11206155|NCT03341182|Active Comparator|normal method group (group A)|A mirror is not used in tunnel view technique (conventional manner)
11206156|NCT03341182|Experimental|mirror use group (group B)|A mirror is used in tunnel view technique
11206157|NCT03341169|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
11206158|NCT03341169|Placebo Comparator|Placebo|
11206159|NCT03341156|Experimental|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
11206160|NCT03341156|Active Comparator|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
11206161|NCT03341143|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy. FMT will be performed on Cycle 1 Day 1 and will take 15 to 30 minutes.
~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT), and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
11206162|NCT03341130|Experimental|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
11206163|NCT03341130|Experimental|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
11206164|NCT03341130|No Intervention|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
11206165|NCT03341117|Active Comparator|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
11206166|NCT03341117|Placebo Comparator|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),
~1 capsule 300 mg before each meal for a period of 90 days."
11206167|NCT03341091|Experimental|Tai-chi group|"16-week 10-step simplified Tai-chi programme.
~Two 1-hour sessions of centre-based Tai-chi training and a minimum of three 30-minute Tai-chi sessions at home on a weekly basis."
11206168|NCT03341091|No Intervention|Control group|"Group recreational activities and continue their usual lifestyles and levels of physical activity as usual for 16 weeks.
~Two 1-hour sessions of group recreational activities on a weekly basis."
11206169|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
11206170|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
11206171|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
11206172|NCT03341065|Experimental|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
11206173|NCT03341065|Experimental|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
11206174|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
11206175|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
11206176|NCT03341026|Other|Induction day 1, 4, 7, 14|Patient will come to the hospital on day 1, 4, 7 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
11206177|NCT03341026|Other|Induction day 1, 7, 10, 14|Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
11206178|NCT03341013|Experimental|Sequence 1|formulation 2 on Day 1 and formulation 3 on Day 10
11206179|NCT03341013|Experimental|Sequence 2|formulation 3 on Day 1 and formulation 2 on Day 10
11206180|NCT03341000|Experimental|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
11206181|NCT03340987|Experimental|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
11206182|NCT03340987|Active Comparator|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
11206183|NCT03340974|Experimental|Arm A: SBRT + GC4419|
11206184|NCT03340974|Placebo Comparator|Arm B: SBRT + Placebo|
11206185|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
11206186|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
11206187|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
11206188|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
11206189|NCT03340948|Experimental|MBSR participation|Participation in the 8 week Mindfulness Based Stress Reduction (MBSR) course.
11206190|NCT03340935|Experimental|Fasting mimicking diet|Fasting mimicking diet (FMD)
11206191|NCT03340922|Experimental|Automatic annotation of LAT (WF-method)|The annotation of LAT in each acquired point will be automatically performed using the LAT annotation tool integrated into CARTO navigation system, called Wavefront (WF). Automatic annotation of LAT performed by the CARTO system uses the maximum negative slope of the distal U-EGM to set the timing of the mapping annotation, displayed on the corresponding B-EGM. Additionally, the automatic annotation of LAT will be aided by an ECG recognition pattern algorithm (included in the last version of CARTO), which is intended to avoid wrong annotation of ventricular complexes other than the clinical PVC.
11206192|NCT03340922|Active Comparator|Manual annotation of LAT (M-method)|A detailed electrocardiogram (ECG)-gated activation map of the chamber of interest will be acquired using the CARTO navigation system. An experienced electrophysiologist will perform the annotation of LAT in each acquired point. The LAT will be measured from the onset of B-EGM (earliest positive or negative deflection) of the distal dipole of the mapping catheter to the defined reference. The use of the U-EGM as a guidance to identify the real onset of B-EGM will be decided under electrophysiologist criteria.
11206193|NCT03340909|Experimental|Prednisolone|Prednisolone tablets 5 mg
11206194|NCT03340909|Placebo Comparator|Placebo|Placebo tablets with identical appearance to the experimental drug.
11206195|NCT03340896|Active Comparator|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy
~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
11206196|NCT03340896|Experimental|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy
~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
11206197|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
11206198|NCT03340870|Experimental|Sonazoid™ 0.12 microliter (µl)|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.
11206199|NCT03340870|Experimental|Sonazoid™ 0.60 µl|Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.
11206200|NCT03340857|Experimental|Intelligent electric bicycle (VELIS) sessions|Intelligent electric bicycle (VELIS) sessions with an instructor, twice a week for 6 weeks
11206201|NCT03340844|Experimental|No Touch (NT)|Pancreatic and Periampullary Tumors resection by no-touch technique
11206202|NCT03340844|Active Comparator|Superior Mesenteric Artery First (SMA)|Pancreatic and Periampullary Tumors resection by superior Mesenteric Artery First technique
11206203|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
11206204|NCT03340818|Experimental|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
11206205|NCT03340818|Sham Comparator|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
11206206|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
11206207|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
11206208|NCT03340792|Experimental|Exoskeleton robot ambulation training|Ambulation training utilizing an exoskeleton robot
11206209|NCT03340779|Experimental|Norepinephrine alone|Administration of norepinephrine with increasing dose
11206210|NCT03340779|Active Comparator|Norepinephrine plus Dobutamine|Administration of norepinephrine and dobutamine
11206211|NCT03340766|Experimental|COHORT Ia|Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 15).
11206212|NCT03340766|Experimental|COHORT IIa|Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 19).
11206213|NCT03340766|Experimental|COHORT IIIa|Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 19).
11206214|NCT03340766|Experimental|Expansion Cohort|This cohort will test the Maximum Tolerated Dose of Blinatumomab in combination with Pembrolizumab identified using cohort design from cohorts Ia, IIa, and IIIa tested in Part 1 of the study.
11206215|NCT03340753|Active Comparator|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) in capsule formulation in a 2-period crossover design with a 2-week washout/follow-up period
11265940|NCT02932514|Experimental|Eversense (Senseonics) CGM System|
11206216|NCT03340753|Experimental|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) in tablet formulation in a 2-period crossover design with a 2-week washout/follow-up period
11206217|NCT03340740|Experimental|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
11206218|NCT03340740|Placebo Comparator|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
11206219|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
11206220|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
11206221|NCT03340714|Experimental|Device Feasibility (ADAMM)|Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
11206222|NCT03340701|Other|Vaginal Progesterone|micronized progesterone vaginal suppository 200mg
11206223|NCT03340688|Active Comparator|Cervical cerclage + vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤15mm and Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
11206224|NCT03340688|No Intervention|Vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
11206225|NCT03340675|Experimental|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
11206226|NCT03340675|Experimental|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
11206227|NCT03340675|Placebo Comparator|Placebos|Matching Placebo
11206228|NCT03340662|Experimental|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
11206229|NCT03340662|Experimental|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
11206230|NCT03340662|Experimental|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
11206231|NCT03340662|Experimental|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
11206232|NCT03340623||Mammary reconstruction by DIEP with venous coupler|
11206233|NCT03340623||Mammary reconstruction by DIEP without venous coupler|
11206234|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
11206235|NCT03340597|Experimental|A1; F901318 (10 days)|F901318 : 10 days dosing orally
11206236|NCT03340597|Experimental|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
11206237|NCT03340597|Experimental|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
11206238|NCT03340597|Experimental|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
11206239|NCT03340584|Experimental|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
11206240|NCT03340584|Other|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
11206241|NCT03340571||Alzheimer's Patients|
11206242|NCT03340571||Healthy Volunteers|
11206243|NCT03340558|Experimental|Monotherapy Cohort|The first 10 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No study treatment is administered while subjects are healing after surgery.
11206244|NCT03340558|Experimental|Combination Cohort|The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
11206245|NCT03340545|Other|Healthy Individuals|Healthy individuals will be imaged for comparison purposes
11206246|NCT03340545|Other|Disc Herniation|Subjects diagnosed with Intervertebral Disc Herniation will be imaged to evaluate sensitivity of the proposed method.
11206247|NCT03340532|Placebo Comparator|Sleep hygiene video|Participants will watch a sleep hygiene video
11206248|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
11206249|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
11206250|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
11206251|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
11206252|NCT03340506|Experimental|dabrafenib monotherapy|"Patients in this study may receive:
~- monotherapy of dabrafenib"
11206253|NCT03340506|Experimental|trametinib monotherapy|"Patients in this study may receive:
~- monotherapy of trametinib"
11206254|NCT03340506|Experimental|Combination therapy (dabrafenib & trametinib)|"Patients in this study may receive:
~- the combination of dabrafenib and trametinib"
11206255|NCT03340493|Active Comparator|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
11206256|NCT03340493|Experimental|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over ~10 seconds).
11206257|NCT03340480|Experimental|NVP-1402-1|NVP-1402 was administered once a day for 24 hours
11206258|NCT03340480|Experimental|NVP-1402-2|NVP-1402 was administered once a day for 24 hours
11206259|NCT03340467|Experimental|CGM patch|Patient receives four models of CGM patches. Adhesion sites are randomly allocated (1 on each upper arm, 2 on the abdomen).
11206260|NCT03340454|Active Comparator|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
11206261|NCT03340454|Active Comparator|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
11206262|NCT03340428|Experimental|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
11206263|NCT03340428|No Intervention|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
11206264|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
11206265|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
11206266|NCT03340402|Experimental|Accelerated Partial Breast Irradiation|"Accelerated partial breast irradiation using proton beam scanning will consist of;
~5 daily treatments using custom prone patient immobilization, contrast-enhanced CT planning, and daily image guidance
~Radiation therapy may be delivered with photons if proton treatments cannot be delivered
~Dose will be prescribed such that the gross tumor (GTV) receives the prescription dose per institutional policy and standard of care
~Daily target localization will also be confirmed using AlignRTTM"
11206267|NCT03340389|Experimental|cataract surgery|cataract extraction and intraocular implantation
11206268|NCT03340376|Experimental|atezolizumab monotherapy|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease
11206269|NCT03340376|Experimental|atezolizumab combined with doxorubicin|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
11206270|NCT03340376|Active Comparator|doxorubicin monotherapy|Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
11206271|NCT03340363|Experimental|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
11206272|NCT03340363|Experimental|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
11206273|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
11206274|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|The subjects will receive Neo-Russian electrical stimulation.
11206275|NCT03340337|Experimental|Aussie Electrical Stimulation|The subjects will receive Aussie electrical stimulation.
11206276|NCT03340337|Experimental|RBS Electrical Stimulation|The subjects will receive RBS electrical stimulation.
11206277|NCT03340337|Experimental|Fatigue Test|The subjects will receive, randomly, a fatigue test with the three types of current.
11206278|NCT03340324|Experimental|One arm open label V-Endo recepients|This is single arm open label trial wherein active drug is V-Endo
11206279|NCT03340311|Other|Pre-Post|"(Phase one): Each participant will receive usual care (four weeks). Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.
~(Phase two): Each participant will receive a BG5 wireless glucose meter with supplies enough for four weeks. Each participant will download the iGluco application to their smartphone. Education will be given on the monitor and iGluco application use. Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.
~At the conclusion of phase 2, the participants will be asked to complete a satisfaction survey about the care received and their preference of monitors."
11206280|NCT03340298|Experimental|grain|25 gram fiber from whole grain products and 10 gram fiber from fruits and vegetables
11206281|NCT03340298|Experimental|fruits and vegetables|25 gram fiber from fruits and vegetables as main supplier and the remaining 10 grams from whole grain sources
11206282|NCT03340298|Experimental|grain-fruits and vegetables|17.5 gram fiber from whole grain and 17.5 gram fiber from fruits and vegetables
11206283|NCT03340285|Experimental|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
11206284|NCT03340285|Placebo Comparator|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
11206285|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
11206286|NCT03340246|Active Comparator|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
11206287|NCT03340246|Experimental|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
11206288|NCT03340233|Experimental|Group 1|Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
11206289|NCT03340233|Experimental|Group 2|Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
11206290|NCT03340233|Experimental|Group 3|Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
11206291|NCT03340220|Experimental|XPF-008|"Single ascending dose: Single oral dose for each cohort
~Multiple ascending dose: 7 days of single oral dose daily for each cohort"
11206292|NCT03340220|Placebo Comparator|Placebo - Microcrystalline cellulose|"Single Ascending Dose: Single oral dose for each cohort
~Multiple Ascending Dose: 7 days of single oral dose daily for each cohort"
11206293|NCT03340207|Experimental|Pneumaglide|After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
11206294|NCT03340207|No Intervention|non-pneumaglide|The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.
11206295|NCT03340194||Systemic sclerosis patients|
11206296|NCT03340181|Experimental|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
11206297|NCT03340181|Sham Comparator|control|patient in control group using a blood pressure cuff on an upper limb without inflating
11206298|NCT03340168|Experimental|Bisphenol-S kinetics - oral exposure|Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.
11206299|NCT03340168|Experimental|Bisphenol-S kinetics - dermal exposure|volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).
11206300|NCT03340142|Experimental|Single Arm|All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.
11206301|NCT03340129|Active Comparator|Nivolumab + ipilimumab|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.
~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
11206302|NCT03340129|Active Comparator|Nivolumab + ipilimumab,concurrent SRS|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.
~Stereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.
~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
11206303|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
11206304|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
11206305|NCT03340103|Experimental|Experimental group A|Group A (18 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
11206306|NCT03340103|Placebo Comparator|Control group B|Group B (18 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
11206307|NCT03340090|Experimental|Intervention|First group of patients will undergo standard CABG procedure in CPB. In addition, two pieces of Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of left internal mammary artery (LIMA) harvesting and second piece of Hemopatch will be placed beneath the sternum.
11206308|NCT03340090|No Intervention|Control|Second group of patients will undergo standard CABG procedure in CPB only.
11206309|NCT03340077|Experimental|MOR Toolkit|Medicines Optimisation Review consultation + My clinical companion (patient questionnaire about their medications)
11206310|NCT03340077|Active Comparator|Standard of Care|Current standard of care for patients with HIV receiving antiretroviral therapy, which consists of a phamacists review of ART prescriptions.
11206311|NCT03340064|Experimental|Levetiracetam|"Subjects aged 1 month to <6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.
~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months or by LEV 20 mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0 mg/kg/day."
11206312|NCT03340051|Active Comparator|EFT group|Episodic Future Thinking (EFT) is the intervention in this arm. EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
11206313|NCT03340051|Placebo Comparator|ERT group|Episodic Recent Thinking (ERT) is the intervention in this arm. ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
11206314|NCT03340038|Active Comparator|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
11206315|NCT03340038|No Intervention|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
11206316|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
11206317|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
11206382|NCT03339544|Placebo Comparator|Placebo tablets|placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
11206318|NCT03340012|Experimental|GTR + radiation-sterilize allogenic bone graft (TEST)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of radiation-sterilized allogenic bone graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
11206319|NCT03340012|Active Comparator|GTR + xenogenic graft (CONTROL)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of xenogenic graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
11206320|NCT03339999|Placebo Comparator|Placebo|Placebo, oral administration, once-daily for 16 weeks.
11206321|NCT03339999|Experimental|AGN-242428 Higher Dose|AGN-242428, oral administration, once-daily for 16 weeks.
11206322|NCT03339999|Experimental|AGN-242428 Medium Dose|AGN-242428, oral administration, once-daily for 16 weeks.
11206323|NCT03339999|Experimental|AGN-242428 Lower Dose|AGN-242428 and placebo, oral administration, once-daily for 16 weeks.
11206324|NCT03339986|Experimental|Reduction|Participants will be instructed to reduce all high energy dense snacks that they serve to thier children by 50%
11206325|NCT03339986|Experimental|Replacement|Participants will be instructed to replace all high energy dense snacks with fresh fruit and vegetables
11206326|NCT03339973|Experimental|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)
11206327|NCT03339973|Placebo Comparator|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
11206328|NCT03339960|Active Comparator|Robotic camera controlled|
11206329|NCT03339960|Active Comparator|Human camera controlled|
11206330|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
11206331|NCT03339921|Experimental|Botulinum toxin injections|Botulinum toxin injections for chronic compartment syndrome
11206332|NCT03339921|Active Comparator|surgical fasciotomy|surgical fasciotomy for chronic compartment syndrome
11206333|NCT03339908|Experimental|patients with Multiple Sclerosis|Patients will benefit from unilateral thalamotomy by Gamma Knife radiosurgery
11206334|NCT03339895|Experimental|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
11206335|NCT03339895|Experimental|traditional-guided|4-8 ml/kg/h infusion during surgery
11206336|NCT03339882|Experimental|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
11206337|NCT03339882|No Intervention|Control|No intervention during LHRH-a treatment in breast cancer
11206338|NCT03339869|Experimental|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
11206339|NCT03339856|Experimental|Treatment arm|Patients received selective retina therapy
11206340|NCT03339843|Experimental|Abemaciclib|"This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage.
~Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment.
~A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1."
11206341|NCT03339817|Other|Patients with severe MS|polysomnography and functional pulmonary testings.
11206342|NCT03339804|Experimental|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
11206343|NCT03339791|Active Comparator|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
11206344|NCT03339791|Active Comparator|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
11206345|NCT03339765|Experimental|Serious game intervention|Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
11206346|NCT03339765|No Intervention|Enhanced care as usual|If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
11206347|NCT03339752|Active Comparator|Treatment A|Rosuvastatin Day 1
11206348|NCT03339752|Experimental|Treatment B1|ACT-541468 Day 5 to Day 7
11206349|NCT03339752|Other|Treatment B2|Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
11206350|NCT03339739|Experimental|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
11206351|NCT03339739|Active Comparator|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
11206352|NCT03339739|Placebo Comparator|Counseling Group|Group of participants which receive education brochure and no further interventions.
11206353|NCT03339726|Experimental|New Formulation Phenylephrine HCl|
11206354|NCT03339726|Active Comparator|Marketed Phenylephrine HCl|
11206355|NCT03339726|Placebo Comparator|Placebo|
11206383|NCT03339531|Experimental|2D radiotherapy|Patients with prostate cancer were treated with 2D-radiotherapy
11206384|NCT03339518|Experimental|BRIM3 Educational intervention|Individuals will receive a booklet and counseling about risk.
11206385|NCT03339518|Other|Wait list Control|At the completion of the study, individuals in the wait list condition will receive a booklet.
11206356|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
11206357|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
11206358|NCT03339700|Experimental|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY 2) conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then patients will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.
11206359|NCT03339687|Experimental|Induction of Open Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
11206360|NCT03339687|Experimental|Induction of a Closed Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
11206361|NCT03339674|Experimental|Intervention|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress: Psychological group intervention with 3 sessions of 60 min (Odenwald & Semrau, 2012). Contains psychoeducation on alcohol drinking related to stress and PTSD.
11206362|NCT03339674|Active Comparator|Control|Cognitive Training: Psychological group intervention with 3 sessions of 60 min. The content is paper-and-pencil based cognitive training of memory and attention functions.
11206363|NCT03339661|Experimental|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
11206364|NCT03339661|Experimental|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
11206365|NCT03339661|Experimental|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
11206366|NCT03339648|Experimental|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:
~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:
~E-Content Clinics- Content Clinics are offered online using digital video technology.
~Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.
~Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
11206367|NCT03339648|Active Comparator|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
11206368|NCT03339635|Experimental|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
11206369|NCT03339635|Placebo Comparator|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
11206370|NCT03339622|Experimental|smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
11206371|NCT03339622|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
11206372|NCT03339609||Immediate uroflow/EMG testing|Participants performed two direct repetitions of uroflowmetry in combination with EMG.
11206373|NCT03339609||uroflow measurement beforehand|Participants performed a preceding measurement of isolated uroflowmetry, followed by two randomized measurements of either isolated uroflowmetry or uroflowmetry with EMG.
11206374|NCT03339596|Experimental|Erythropoietin|4 intravenous infusions of recombinant human erythropoietin (EPO)
11206375|NCT03339596|Placebo Comparator|Saline|4 intravenous infusions of saline (1 ml NaCl)
11206376|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
11206377|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
11206378|NCT03339557|Active Comparator|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
11206379|NCT03339557|Active Comparator|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
11206380|NCT03339557|Active Comparator|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
11206381|NCT03339544|Experimental|Celebrex premedication|Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
11206435|NCT03339128|Experimental|Eluxadoline 25mg|Eluxadoline 25mg, oral administration, twice daily
11206386|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
11206387|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
11206388|NCT03339492|Active Comparator|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
11206389|NCT03339492|Sham Comparator|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
11206390|NCT03339479|Experimental|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
11206391|NCT03339479|Placebo Comparator|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
11206392|NCT03339479|Other|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
11206393|NCT03339453|Experimental|Nasal Glucagon|Single dose of Nasal Glucagon.
11206394|NCT03339453|Active Comparator|Intramuscular Glucagon|Single intramuscular (IM) dose of Glucagon.
11206395|NCT03339440|Experimental|Intervention Group|Patients in this group will be receiving the Hearts and Parks intervention.
11206396|NCT03339440|No Intervention|Control Group|Patients in this group will continue receiving standard of care.
11206397|NCT03339427|Active Comparator|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
11206398|NCT03339427|Other|control|A total of 150 subjects were recruited in the control group.
11206399|NCT03339401|Experimental|Brincidofovir (BCV)|BCV
11206400|NCT03339401|Other|Standard of Care (SOC)|SOC
11206401|NCT03339375||control|Monitoring arterial pressure, central venous pressure and pulse pressure variation
11206402|NCT03339375||esophagela Doppler|Monitoring arterial pressure, central venous pressure Insertion of esophageal Doppler probe to patient Monitoring stroke volume, cardiac output, corrected flow time from esophageal Doppler Use stroke volume optimization goal directed therapy protocol
11206403|NCT03339362|Active Comparator|Active Procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.
~4 X-ray guided intra-articular facet-joint injections via a spinal needle at 2 bilateral lumbar levels, using 0.5ml 0.5% bupivacaine + 20mg methylprednisolone per joint"
11206404|NCT03339362|Sham Comparator|Sham procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.
~4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml normal saline per injection"
11206405|NCT03339349|Experimental|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
11206406|NCT03339336|Experimental|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
11206407|NCT03339336|Experimental|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
11206408|NCT03339336|Placebo Comparator|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
11206409|NCT03339323|No Intervention|Control|Standard rehabilitation procedure
11206410|NCT03339323|Experimental|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
11206411|NCT03339310|Experimental|Optimizer Smart System with 2-leads|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
11206412|NCT03339297|Experimental|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
11206413|NCT03339297|Active Comparator|Standard of Care|Standard of Care Immunoprophylaxis Alone
11206414|NCT03339284|Active Comparator|QLB with dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and dexamethasone 5 mg/ml 0,4 ml
11206415|NCT03339284|Active Comparator|QLB without dexamethasone|Single sided US-guided QLB using ropivacaine 3,75 mg/ml 20 ml and isotonic natriumchloride solution (NaCl 0,9%) 0,4 ml
11206416|NCT03339284|Placebo Comparator|Placebo|Single sided US-guided QLB using isotonic natriumchloride solution (NaCl 0,9%) 20,4 ml
11206417|NCT03339271|Active Comparator|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
11206418|NCT03339271|Active Comparator|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
11206434|NCT03339141|Active Comparator|25° head-up position|Patients are placed in the 25° head-up position (half-seat or whole body proclive) from arrival in the room until intubation.
11206534|NCT03338413|Experimental|Goal Management Training|
11206419|NCT03339258|Experimental|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
11206420|NCT03339258|Placebo Comparator|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
11206421|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
11206422|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
11206423|NCT03339232|No Intervention|Usual Care|Participants will receive standardized information about a healthy diet, including the potential benefit of small, frequent meals and nighttime snacking . In addition, the treating hepatologist will counsel participants on the benefits of increased physical activity. These recommendations will be provided at the beginning of the study. The usual care arm reflects current clinical practice. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
11206424|NCT03339232|Other|BCAA Supplement|BCAA powder (Bulk Supplements®) will be provided as the powder was found to be easier to swallow. Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio. BCAA will be provided by the study investigators and half will be provided at baseline study visit and the second half at the week 6 visit. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
11206425|NCT03339232|Other|BCAA supplement plus supervised physical activity|BCAA supplement will be as described for group 2, above. Study coordinators will supervise the physical activity program for study participants at the Loyola Fitness Center. Participants will attend the fitness center one hour each week; the fitness session will consist of low-impact aerobic physical activity, beginning with walking on the indoor track and possibly building to a recumbent exercise bicycle and light resistance training. Participants will be given a list of exercises to perform at home at least two times during the week with a goal of >90 minutes of physical activity per week. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity which they will return during the weekly fitness center sessions. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study.
11206426|NCT03339219|Experimental|Cabozantinib|Cabozantinib 60 mg, tablet, orally, once daily in the fasted state.
11206427|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
11206428|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
11206429|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
11206430|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
11206431|NCT03339167|Experimental|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.
~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
11206432|NCT03339154|Experimental|Methionine bioavailability in chickpeas|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).
~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or chickpeas with or without rice, which will be provided by the investigators"
11206433|NCT03339141|Placebo Comparator|supine position|Patients are placed in the supine position at 0° from arrival in the room until intubation
11206436|NCT03339128|Experimental|Eluxadoline 50mg|Eluxadoline 50mg, oral administration, twice daily
11206437|NCT03339128|Experimental|Eluxadoline 100mg|Eluxadoline 100mg, oral administration, twice daily
11206438|NCT03339128|Experimental|Placebo|Dose-matched placebo, oral administration, twice daily
11206439|NCT03339115|Experimental|Cardiovalve Transfemoral Mitral Valve|Mitral replacement valve delivered through a transfemoral access and transseptal approach
11206440|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
11206441|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
11206442|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
11206443|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
11206444|NCT03339076|Other|For a single-arm trial|"Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 Mini Catheter
~Males > 50 years of age
~Signed subject informed consent
~Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter
~Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.
~Exclusion Criteria
~Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)
~Gross hematuria
~Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction)."
11206445|NCT03339050|Experimental|Health for Hearts United|Health for Hearts United (HHU) is a 18-month church-based intervention to reduce CVD risk in mid-life and older African Americans.
11206446|NCT03339037|Active Comparator|Hyperbaric oxygen therapy|"60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour.
~1 meter per minute compression and decompression."
11206447|NCT03339037|Sham Comparator|Normobaric air SHAM|"60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour.
~1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment"
11206448|NCT03339024|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.
~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
11206449|NCT03339024|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.
~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
11206450|NCT03339011|Experimental|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.
~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
11206451|NCT03339011|No Intervention|No intervention|No attention from the study
11206452|NCT03338998|Experimental|BAF312|"Days 1 - 7, IV uptitration; days 8 - 14, final daily dose administered orally"
11206453|NCT03338998|Placebo Comparator|Placebo|Days 1 through 7: i.v. matching placebo Days 8 through 14: p.o. matching placebo QD
11206454|NCT03338985|Experimental|"Group cases patients"|patients with endometrial hyperplasia or endometrial cancers
11206455|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells)|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).
11206456|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
11206457|NCT03338946||CIED subjects|CIED interrogation
11206458|NCT03338933||Control Group|No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
11206459|NCT03338933||Nicotine Group|Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance
11206460|NCT03338933||Nicotine and Alcohol Group|DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling.
11206461|NCT03338933||Alcohol Group|DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
11206462|NCT03338920|Experimental|Sumatriptan nasal powder|Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
11206463|NCT03338920|Placebo Comparator|Placebo|Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.
11206464|NCT03338907|Experimental|Oxycarbon (5% CO2 + 95% O2)|Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.
11206465|NCT03338907|Placebo Comparator|Control (95% O2)|"Same procedure as arm active comparator"
11206466|NCT03338894|Other|Yoga group|Each subject will serve as their own control
11206467|NCT03338881|Experimental|[14C]-TAK-659 100 mg|[14C]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
11206535|NCT03338413|Experimental|Computerized Cognitive Training|
11266446|NCT02929160|Experimental|JJ Stent|Retrograde ureteric JJ stent
11206468|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
11206469|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
11206470|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.
~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
11206471|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.
~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
11206472|NCT03338842|Experimental|Distractor and Lower limb VR|The training sessions consist of Phase 1 (Distractor VR) in which patients will explore VR environments and Phase 2 (Lower limb VR) in which they will play games using their VR lower-limbs.
11206473|NCT03338829|No Intervention|Control|The control arm will received compensation at time of enrollment for agreeing to participate.
11206474|NCT03338829|Experimental|Positive Incentive|The positive incentive arm will receive compensation per prescribed test, payable every month based on testing adherence.
11206475|NCT03338829|Experimental|Loss Aversion|"The loss aversion arm will have compensation deposited into a University of Iowa Women's Health account. The participant will then lose compensation depending on actual adherence to recommended testing"
11206476|NCT03338816|Experimental|Givosiran/Givosiran|Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
11206477|NCT03338816|Placebo Comparator|Placebo/Givosiran|Matching placebo (normal saline [0.9% NaCl]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.
11206478|NCT03338803||Patients with a written prescription for linagliptin|
11206479|NCT03338790|Experimental|nivolumab + rucaparib|Specified dose on specified days
11206480|NCT03338790|Experimental|nivolumab + docetaxel + prednisone|Specified dose on specified days
11206481|NCT03338790|Experimental|nivolumab + enzalutamide|Specified dose on specified days
11206482|NCT03338777|Experimental|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
11206483|NCT03338764|Experimental|Experimental (SM-1)|Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
11206484|NCT03338764|Placebo Comparator|Placebo|Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
11206485|NCT03338751|Active Comparator|Hearing Assistance Device (HAD) First|Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.
11206486|NCT03338751|Active Comparator|No Hearing Assistance Device (HAD) First|Sham hearing aid device
11206487|NCT03338738|Experimental|Patients with ESBL, antibiotic pressure|Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.
11206488|NCT03338725|Active Comparator|Patients without intervention|Patients without follow-up by clinical pharmacy model
11206489|NCT03338725|Experimental|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
11206490|NCT03338699|Experimental|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
11206491|NCT03338699|Active Comparator|Mogen clamp|Mogen clamp circumcision.
11206492|NCT03338686|Active Comparator|Free Gingival Graft|Free Gingival Graft (FGG)
11206493|NCT03338686|Experimental|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
11206494|NCT03338673|Experimental|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
11206495|NCT03338673|Experimental|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
11206496|NCT03338660|Placebo Comparator|Control (Placebo)|Subjects will receive infusion of placebo (saline).
11206497|NCT03338660|Active Comparator|Platelet storage routine|Subjects will receive infusion of platelets stored by routine method.
11206498|NCT03338660|Experimental|Platelet storage experimental|Subjects will receive infusion of platelets stored by a novel methodology.
11206499|NCT03338647|Active Comparator|TACE|Transarterial chemoembolization with drug eluted beads or doxorubicin/lipoidol
11206500|NCT03338647|Experimental|SBRT|Stereotactic radiation therapy with risk adapted dose prescription
11206501|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
11206502|NCT03338621|Experimental|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
11206503|NCT03338621|Active Comparator|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
11206504|NCT03338621|Experimental|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
11206505|NCT03338608|Experimental|Vertical Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the vertical platysma incision.
11206506|NCT03338608|Experimental|Transverse Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the transverse platysma incision.
11206507|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
11206508|NCT03338569|Active Comparator|Intervention|Vitamin C
11206509|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
11206510|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
11206511|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
11206512|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
11206513|NCT03338543|Experimental|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
11206514|NCT03338543|Experimental|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
11206515|NCT03338543|No Intervention|Control|Conventional analgesic medication is offered.
11206516|NCT03338530|Experimental|Comprehensive School-Based Intervention|Children with HFASD assigned to the CSBI received social skills groups, computer instruction in emotion recognition, therapeutic activities, and a behavioral reinforcement system (individual daily note) during the school year and their parents participated in monthly parent training. School staff received training prior to the school year and demonstrated fidelity with the protocol. Fidelity was also monitored during the school year by research assistants.
11206517|NCT03338530|No Intervention|Business-As-Usual (BAU) Control|Children with HFASD in the BAU schools received their typical special education programming as legally-mandated. The programming received by each was carefully monitored per the following: 1) Each student's IEP was reviewed to document the legally mandated services received; 2) For those receiving counseling or speech-language services, the related-service provider completed a survey indicating specific treatment targets and the protocol for service provision; 3) Parents completed a monthly survey of any external therapeutic programming their child may have received; and 4) Fidelity measures designed for the intervention group (with sequencing requirements removed) were completed for the control condition during two 60-minute classroom observations per week by research assistants.
11206518|NCT03338517|Active Comparator|Study group|Helium Neon Laser
11206519|NCT03338517|No Intervention|Control group|No intervention
11206520|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value >99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
11206521|NCT03338491|Experimental|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
11206522|NCT03338491|Experimental|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
11206523|NCT03338491|No Intervention|Control|Participants will revive no induction of any mindset.
11206524|NCT03338478|Experimental|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
11206525|NCT03338478|Experimental|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
11206526|NCT03338465|Active Comparator|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
11206527|NCT03338465|Active Comparator|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
11206528|NCT03338452|Experimental|participants|The participants will be subjected to low energy ketogenic diet.
11206529|NCT03338439||CSII|CSII: patients with continuous subcutaneous insulin infusion
11206530|NCT03338439||MDI|MDI: patients with multi-daily injections
11206531|NCT03338426|Experimental|Experimental|Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
11206532|NCT03338426|Active Comparator|Active Comparator 1|Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
11206533|NCT03338426|Active Comparator|Active Comparator 2|Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
11206536|NCT03338400|Active Comparator|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
11206537|NCT03338400|Placebo Comparator|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
11206538|NCT03338387|Experimental|Acipimox|Other Names: Olbetam
11206539|NCT03338387|Placebo Comparator|Placebo|"Other Names:
~Placebo (for Olbetam)"
11206540|NCT03338374|Experimental|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
11206541|NCT03338361|Experimental|AAT active - VPT sham|Approach avoidance training active intervention and visual probe training sham intervention
11206542|NCT03338361|Experimental|VPT active - AAT sham|Visual probe training active condition and approach avoidance training sham condition
11206543|NCT03338361|Experimental|AAT active - VPT active|Approach avoidance training active condition and visual probe training active condition
11206544|NCT03338361|Sham Comparator|AAT sham - VPT sham|Approach avoidance training sham condition and visual probe training sham condition
11206545|NCT03338348|Other|Azacitidine + Vosaroxin|"Cycle 1-8:
~Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
~Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
11206546|NCT03338322|Experimental|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
11206547|NCT03338322|Active Comparator|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
11206548|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
11206549|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
11206550|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
11206551|NCT03338283|Experimental|Electromassage|"Electromassage and conservatory treatment. All subjects will be received a conservatory treatment (1h and 40 min) and electro-massage (10min).
~The protocol will consist of six sessions, twice a week for three weeks. The duration will be 1 hour and 40 min for the conservatory treatment and 10 min for the electro-massage."
11206552|NCT03338283|Active Comparator|Conservatory Treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
11206553|NCT03338257|Experimental|Husky Reads Intervention|The Husky Reads curriculum includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and sometimes food tasting to complement the learning objectives. Undergraduate students enrolled in the Husky Reads service-learning course at UCONN or college students participating in a paid summer internship deliver the program. Each team of 2-3 students is assigned 2-3 early care classrooms to visit and deliver Husky Reads on a weekly basis.
11206554|NCT03338257|No Intervention|Wait list Control|Programs on the wait list for Husky Reads, participate in the pre and post intervention testing but do not receive the program.
11206555|NCT03338244|Active Comparator|Azithro|Communities will receive four rounds of biannual mass azithromycin.
11206556|NCT03338244|Placebo Comparator|Placebo|Communities will receive four rounds of biannual mass placebo.
11206557|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
11206558|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
11206559|NCT03338205|Experimental|Ketamine Treatment|"Everyone enrolled in study presenting in status asthmaticus to pediatric emergency department at Augusta University will receive a ketamine treatment, who include:
~Patients with a Clinical Asthma SCore (CAS) of greater than or equal to 10 on presentation and have received at least two (appropriately dosed based on weight) albuterol treatments prior to arrival
~OR
~Patients with a CAS of ≥ greater than or equal to 10 that have not received treatment prior to arrival and after receiving 1 hour of treatment per the severe asthma pathway do not have a decrease in CAS of greater than 2
~OR
~Patients with a CAS above > 6 but less than < 10 when as measured 1 hour after initiation of standard treatment per Augusta University's moderate asthma pathway"
11206560|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
11206561|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
11206562|NCT03338179|Experimental|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
11206563|NCT03338179|Experimental|Aged Patients|Schizophrenia patients aged 59.5 years and above
11206564|NCT03338179|Active Comparator|Adult Controls|Controls aged between 18 and 45 years old
11206565|NCT03338179|Active Comparator|Aged Controls|Controls aged 59.5 years and above
11206566|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
11206567|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
11206568|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
11206569|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
11206570|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
11206571|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
11206572|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
11206573|NCT03338127||Participants|all patients recruited in the trial will be investigated for renal function test
11206574|NCT03338114|Experimental|FLX-787-ODT (orally disintigrating tablet)|FLX-787-ODT (orally disintigrating tablet)
11206575|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
11206576|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
11206577|NCT03338062|Experimental|HIDA and MRI Scan|Two imaging scans will be added to the standard radiation planning, treatment and follow up process; a Hepatobiliary Iminodiacetic Acid (HIDA) scan and an MRI scan with Eovist contrast
11206578|NCT03338049|Other|Veran System|Staged biopsy sampling methodology. If lymph node staging is negative, EMN-bronchoscopy will be performed. If EMN-bronchoscopy is negative, EMN-TTNA will be performed
11206579|NCT03338036|Experimental|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
11206580|NCT03338036|No Intervention|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
11206581|NCT03338036|No Intervention|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
11206582|NCT03338023|Experimental|LY2963016 + Insulin Lispro|LY2963016 administered subcutaneously (SC) with insulin lispro administered SC.
11206583|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Lantus® administered SC with insulin lispro administered SC.
11206584|NCT03338010|Experimental|LY2963016|LY2963016 administered subcutaneously (SC). Participants will continue their pre-study oral antihyperglycemic medication (OAMs) throughout the study.
11206585|NCT03338010|Active Comparator|Lantus®|Lantus® administered SC. Participants will continue their pre-study OAMs throughout the study.
11206586|NCT03337997|Experimental|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
11206587|NCT03337971|Placebo Comparator|PLACEBO|"Intervention: Dietary Supplement: PLACEBO A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.
~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
11206588|NCT03337971|Active Comparator|Milk-based protein matrix|"Intervention: Dietary Supplement: MBPM A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.
~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
11206589|NCT03337958|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
11206590|NCT03337958|Experimental|INTERVENTION GROUP|The group received the standard medical and pharmacological care provided by the hospital. In addition, an educational program on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program, furthermore, the technique of inhaler use was trained.
11206591|NCT03337945|Experimental|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
11206592|NCT03337932|Active Comparator|MEM-7 days doxycycline|
11206593|NCT03337932|Active Comparator|MEM-14 days doxycycline|
11206594|NCT03337932|Placebo Comparator|Controls|
11206595|NCT03337919|Experimental|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
11206596|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
11206597|NCT03337893||Breastfed|The kids who breastfed
11206598|NCT03337893||non-breastfed|The kids who did not breastfed
11206599|NCT03337880||Cases|newborns who were delivered with an extractor
11206600|NCT03337880||Controls|newborns who were not delivered with an extractor
11206601|NCT03337867|Active Comparator|Real-iTBS|
11206602|NCT03337867|Sham Comparator|Sham-iTBS|
11206603|NCT03337841|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
11206604|NCT03337828|Active Comparator|Alcohol-free beer with regular composition|Two cans (33 cl.) per day of an alcohol-free beer with regular carbohydrates composition.
11206605|NCT03337828|Experimental|Alcohol-free beer with modified composition|Two cans (33 cl.) per day of alcohol-free beer with modified carbohydrates composition. This include the substitution of regular maltose by isomaltulose and the addition of maltodextrin (fiber).
11206606|NCT03337815|Active Comparator|Treatment of MTX and TwHF placebo|Patients were treated with Methotrexate (MTX) and Tripterygium wilfordii Hook F（TwHF）placebo.
11206607|NCT03337815|Experimental|Treatment of TwHF and MTX placebo|Patients were treated with Tripterygium wilfordii Hook F（TwHF）and Methotrexate (MTX) placebo.
11206608|NCT03337802|No Intervention|Pregnant women at standard diet|obstetrical and gynecological follow-up
11206609|NCT03337802|Experimental|Pregnant women at mediterranean diet|obstetrical and gynecological follow-up + nutritional counseling
11206610|NCT03337789|Experimental|Polygonatum sibiricum|
11206611|NCT03337789|Placebo Comparator|Placebo|
11206612|NCT03337776|Active Comparator|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
11206613|NCT03337776|Active Comparator|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
11206614|NCT03337750|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
11206615|NCT03337737|Placebo Comparator|Placebo|Placebo will be composed of microcrystalline cellulose in a gel capsule
11206616|NCT03337737|Active Comparator|Extreme Endurance|Dietary Supplement manufactured by LifeSpan International LLC
11206617|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
11206619|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
11206620|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206621|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206622|NCT03337698|Active Comparator|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206623|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206624|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206625|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206626|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206627|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206628|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
11206629|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
11206630|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
11206631|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
11206632|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
11206633|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
11206634|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
11206635|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
11206636|NCT03337672|Experimental|Dexmedetomidine group|Subjects who receive dexmedetomidine for prevention of emergence delirium
11206637|NCT03337672|Active Comparator|Midazolam group|Subjects who receive midazolam for prevention of emergence delirium
11206638|NCT03337659|Experimental|FICare Intervention Group|Study participants received Family Integrated Care (intervention) while their infant(s) was/were admitted to a Level II NICU.
11206639|NCT03337659|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
11206640|NCT03337646|Other|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
11206641|NCT03337633|Active Comparator|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
11206642|NCT03337633|Active Comparator|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
11206643|NCT03337633|Active Comparator|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
11206644|NCT03337633|Active Comparator|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
11206645|NCT03337620|Active Comparator|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
11206646|NCT03337620|Placebo Comparator|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
11206647|NCT03337607|Active Comparator|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
11206648|NCT03337607|Active Comparator|rESWT alone|Patients will receive rESWT
11206649|NCT03337607|Active Comparator|C-E drugs alone|Patients will receive Celecoxib and Eperisone
11206650|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
11206651|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
11206652|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
11206653|NCT03337581|Sham Comparator|group 1.1|Normal saline group
11206654|NCT03337581|Experimental|group 1.2|0.25μg/kg dexmedetomidine group
11206655|NCT03337581|Experimental|group 1.3|0.5μg/kg dexmedetomidine group
11206656|NCT03337581|Experimental|group 1.4|0.75μg/kg dexmedetomidine group
11206657|NCT03337581|Experimental|group 1.5|1.0μg/kg dexmedetomidine group
11206658|NCT03337555|Active Comparator|Macintosh|intubation using Macintosh direct laryngoscope
11206659|NCT03337555|Experimental|McGrath|intubation using McGrath MAC®
11206660|NCT03337555|Experimental|Pentax|intubation using Pentax-airway scope®
11206661|NCT03337542|Other|Treatment arm description|Subjects will receive maintenance dosing with AR101.
11206662|NCT03337529|Experimental|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
11206663|NCT03337529|Placebo Comparator|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
11206664|NCT03337516|Experimental|Patients treated with Cytarabine|
11206665|NCT03337503|Experimental|THC and CDB in a 1 to 1 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.
~2.5 mg THC with 2.5 mg CBD capsule"
11206666|NCT03337503|Experimental|THC and CBD in a 1 to 2 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.
~2.5 mg THC with 5 mg CBD capsule"
11206667|NCT03337503|Experimental|high CBD with trace THC|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.
~20 mg CBD with traces of THC"
11206668|NCT03337503|Placebo Comparator|placebo|"Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.
~carrier oil capsule"
11206669|NCT03337490|Experimental|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
11206670|NCT03337490|Active Comparator|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
11206671|NCT03337490|Placebo Comparator|Placebo 0% Lotion|0% lotion, 117g, single dose
11206672|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
11206673|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
11206674|NCT03337464|Experimental|Parkinson's disease|Subjects with Parkinson's disease
11206675|NCT03337464|Active Comparator|Control|Subjects without Parkinson's disease
11206676|NCT03337451|Experimental|OPN-305|
11206677|NCT03337438|Other|Values-PFI|
11206678|NCT03337438|Other|Traditional-PFI with values assessment|
11206679|NCT03337438|Other|Traditional PFI no values assessment|
11206680|NCT03337425|Experimental|psychoeducational groups|Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
11206681|NCT03337425|Active Comparator|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
11206682|NCT03337412|Experimental|Patients|initial assessment of physical capacities, determination of personalized objectives on the occasion of 1 to 2 workshops during the hospital checkup. Telephone Contact by the APA educator at 6 months. One-year medical visit.
11206683|NCT03337412|Experimental|Employees|"initial assessment of physical capacities, participation in 10 to 20 physical activity workshops over 6 months on working time, then employees oriented towards autonomous activities over the following 6 months.
~Evaluation by computer-filled questionnaires."
11206684|NCT03337399|Experimental|Stepped PC|"Patients will receive Stepped PC
~During step 1, patients will be scheduled to meet with the outpatient PC clinician within four weeks of study enrollment and after they are admitted to the hospital or have a change in their cancer treatment
~Patients will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) to monitor their quality of life every six weeks and if their quality of life deteriorates substantially, they will step up to step 2 of the protocol
~Patients who transition to step 2 will then meet with the PC clinician at least every four weeks for the remainder of their illness"
11206741|NCT03337022|Experimental|CC-90006; Dose level 1|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
11266575|NCT02928302|No Intervention|no screening|no TVU CL screening
11206685|NCT03337399|Experimental|Early Integrated PC|"Patients will receive Early Integrated PC
~Patients will meet with the PC clinician within four weeks of enrollment and at least every four weeks throughout their course of illness"
11206686|NCT03337386|Experimental|Inferior Vena Cava Collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
11206687|NCT03337386|Experimental|Subclavian Vein Collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
11206688|NCT03337386|Active Comparator|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
11206689|NCT03337373|Experimental|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
11206690|NCT03337360|Active Comparator|Impryl|One tablet daily for 6 months
11206691|NCT03337360|Placebo Comparator|Placebo|One tablet daily for 6 months
11206692|NCT03337334|Other|Non-Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable). One 5*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10*10 cm2 over the ankle. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation. By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
11206693|NCT03337334|Other|Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation. By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
11206694|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
11206695|NCT03337308|Experimental|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
11206696|NCT03337308|Experimental|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
11206697|NCT03337308|Active Comparator|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
11206698|NCT03337308|Placebo Comparator|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
11206699|NCT03337295||Low-MGD|
11206700|NCT03337295||High-MGD|
11206701|NCT03337282||Observational cohort|Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia
11206702|NCT03337269|Other|Control|Subject does not receive an educational intervention
11206703|NCT03337269|Other|Educational video|Subject watches an educational video
11206704|NCT03337269|Other|Educational handout|Subject reads an educational handout
11206705|NCT03337256|Experimental|GI bleeding score|Early endoscopy in emergency department + other clinical parameters
11206706|NCT03337243|Experimental|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
11206707|NCT03337243|No Intervention|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
11206708|NCT03337230|Experimental|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
11206709|NCT03337217|Experimental|Prone Position|Position during colonoscopy
11206710|NCT03337217|Active Comparator|Left lateral decubitus position|Position during colonoscopy
11206711|NCT03337204|Experimental|Engaged4Life|"Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later); and 2) a one-time, 3hr workshop and peer mentoring (via phone 2X/week for 3 weeks). The workshop includes psychoeducation on the relationship between active engagement and health and well-being and a goal setting activity focused on carefully assessing and then make improvements upon existing activity portfolios. Peer mentors provide support as participants implement their goals."
11206742|NCT03337022|Experimental|CC-90006; Dose level 2|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
11206743|NCT03337022|Experimental|CC-90006; Dose level 3|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
11206744|NCT03337022|Experimental|CC-90006; Dose level 4|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
11206712|NCT03337204|Active Comparator|Technology-assisted self-monitoring only|Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
11206713|NCT03337191|Active Comparator|ultrasound guided caudal block|Caudal block was performed by ultrasound guided with %0,125 levobupivacaine + 10 mq/kg morphine
11206714|NCT03337191|Active Comparator|conventional caudal block|Caudal block was performed by conventional method with %0,125 levobupivacaine + 10 mq/kg morphine
11206715|NCT03337178|No Intervention|Control|Standard of care
11206716|NCT03337178|Experimental|Blinded Fitbit|Blinded Fitbit, no step goal, and no activity feedback
11206717|NCT03337178|Experimental|Fitbit|Fitbit plus step goal and activity feedback
11206718|NCT03337165|Experimental|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
11206719|NCT03337152|Other|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
11206720|NCT03337152|Other|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
11206721|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
11206722|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
11206723|NCT03337126|Active Comparator|Fasting Condition|Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
11206724|NCT03337126|Active Comparator|Fed Condition|Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
11206725|NCT03337113|Experimental|WMT + rTMS|WMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
11206726|NCT03337113|Active Comparator|Sham WMT + rTMS|Sham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
11206727|NCT03337113|Active Comparator|WMT + sham rTMS|WMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
11206728|NCT03337113|Sham Comparator|Sham WMT + sham rTMS|sham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
11206729|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
11206730|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:
~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
11206731|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11206732|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
11206733|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
11206734|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
11206735|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
11206736|NCT03337061|Experimental|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
11206737|NCT03337061|No Intervention|Control (Sleep Advice)|This is the control arm that will receive usual care
11206738|NCT03337048|Experimental|Measurement of endpoints|"In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter (SpeediCath).
~In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter."
11206739|NCT03337035|Active Comparator|oral probiotics and oxytocin spray|Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
11206740|NCT03337035|Placebo Comparator|oral placebo and oxytocin spray|Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
11206745|NCT03337022|Placebo Comparator|Placebo|Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29.
11206746|NCT03337009|Experimental|Naloxone Navigator|"Targeted, web-based animated video (Naloxone Navigator [NN]):
~This arm is a web-based intervention targeted to patients receiving chronic opioid therapy identified in the electronic health record. Participants in this arm have access to naloxone under standing orders from the pharmacy or with a prescription from their providers."
11206747|NCT03337009|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and clinicians. As part of usual care, participants can access naloxone through physician prescription or standing orders.
11206748|NCT03336996|Experimental|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
11206749|NCT03336996|Experimental|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
11206750|NCT03336996|Experimental|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
11206751|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
11206752|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
11206753|NCT03336970|Active Comparator|Single visit root canal treatment|The teeth were treated in single-visit (SV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
11206754|NCT03336970|Active Comparator|Multiple visit root canal treatment|The teeth were treated in multiple visit (MV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
11206755|NCT03336957|Experimental|Pregnant group|Test group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
11206756|NCT03336957|Active Comparator|Non-Pregnant|Control group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
11206757|NCT03336931||High-risk childhood cancers|Expected survival < 30%
11206758|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
11206759|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
11206760|NCT03336905|Experimental|Physical Activity and Prevention|"co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer
~balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation
~meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
11206761|NCT03336892|Experimental|Intervention|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
11206762|NCT03336892|No Intervention|Control|Enhanced usual care with written mental health resources and system navigation information.
11206763|NCT03336879|Experimental|Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
11206764|NCT03336866|Placebo Comparator|Placebo|Normal saline
11206765|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
11206766|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
11206767|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
11206768|NCT03336840|Experimental|Metformin|
11206769|NCT03336840|Experimental|Probiotics|
11206770|NCT03336840|Experimental|Metformin and Probiotics|
11206771|NCT03336827|Other|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
11206772|NCT03336827|Other|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
11206773|NCT03336814|Experimental|terlipressin associated with norepinephrine|
11206774|NCT03336814|Placebo Comparator|placebo (physiologic serum) associated with norepinephrine|
11206775|NCT03336801|Active Comparator|Sevoflurane|Intervention Back surgery and sevoflurane.
11206776|NCT03336801|Active Comparator|Propofol|Intervention Back surgery and propofol.
11206777|NCT03336788|Placebo Comparator|TMS|
11206778|NCT03336788|Active Comparator|TMS with virtual reali|
11206878|NCT03336125|Placebo Comparator|Control group|Placebo capsule contains olive oil
11207600|NCT03332017|Experimental|Arm B|Approximately 70 subjects to receive obinutuzumab
11206779|NCT03336775|Experimental|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
11206780|NCT03336775|No Intervention|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
11206781|NCT03336749|Experimental|Sensory group|Sensory re-learning in combination with task-specific training
11206782|NCT03336749|Active Comparator|Control group|Traditional task-specific training
11206783|NCT03336736||Pulmonary Sarcoidosis|"Self-reported and self-referred self-reported medically diagnosed pulmonary sarcoidosis.
~Exercise capacity and function will be assessed."
11206784|NCT03336736||Control|Healthy age-matched control group with no known lung disease. Exercise capacity and function will be assessed.
11206785|NCT03336723|Experimental|Experimental Group|Two piece zirconia dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
11206786|NCT03336723|Active Comparator|Control Group|Two piece titanium dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
11206787|NCT03336710||Primary sample|Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.
11206788|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
11206789|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
11206790|NCT03336684|Experimental|Patient Education Group|Patients will be provided with disease education literature
11206791|NCT03336684|No Intervention|Normal Group|Patients will not be provided with disease education literature
11206792|NCT03336671|Active Comparator|Adenoidectomy|Current standard of care for pediatric chronic rhino sinusitis.
11206793|NCT03336671|Experimental|Adenoidectomy plus Endoscopic Sinus Surgery|endoscopic sinus surgery in addition to adenoidectomy
11206794|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
11206795|NCT03336632|Experimental|Chidamide|Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5~D+100
11206796|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
11206797|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
11206798|NCT03336606|Active Comparator|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
11206799|NCT03336606|Active Comparator|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
11206800|NCT03336593|Experimental|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
11206801|NCT03336593|Experimental|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
11206802|NCT03336593|Experimental|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
11206803|NCT03336593|Active Comparator|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
11206804|NCT03336593|Experimental|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
11206805|NCT03336593|Experimental|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
11206806|NCT03336580|Experimental|PRX004|"Dose escalation in up to 6 dose levels
~Expansion of previously studied cohort(s) from Dose Escalation
~Extended dosing at RP2D"
11206807|NCT03336567||Subjects with hematological malignancies|It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
11206808|NCT03336567||Subjects with NSCLC or soft-tissue sarcoma|It will Include subjects with NSCLC on second or later-line therapy or soft-tissue sarcoma on second or later line therapy. Subjects will undergo a telephonic interview for up to 90 minutes.
11206809|NCT03336567||Oncologists from academic centers with CGT experience|It will include oncologists using TCR therapies, CAR-T or participating in CAR-T or TCR therapy clinical trials. Oncologists will undergo a telephonic interview for up to 60 minutes.
11206810|NCT03336567||Oncologists from community clinics|It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.
11206811|NCT03336554||observation group|One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
11206812|NCT03336541|Experimental|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
11206813|NCT03336541|Placebo Comparator|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
11206814|NCT03336528|Experimental|Degludec inpatient|Study participants treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals. Degludec insulin 100 Units/mL, average dose: 30-45 U/day. aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day.
11206815|NCT03336528|Active Comparator|Glargine U100 inpatient|"Study participants treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals. Glargine (U-100) insulin 100 Units/mL, average dose: 30-45 U/day.
~Aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day."
11207361|NCT03333343|Experimental|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
11206816|NCT03336528|Experimental|Degludec post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in the degludec inpatient arm will be invited to participate in the prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus degludec once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with degludec and aspart insulin before meals.
11206817|NCT03336528|Active Comparator|Glargine U100 post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in glargine inpatient arm will be invited to participate in this open label prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus glargine once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with glargine and aspart insulin before meals.
11206818|NCT03336515|Other|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
11206819|NCT03336515|Placebo Comparator|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
11206820|NCT03336515|Experimental|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
11206821|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
11206822|NCT03336476|Experimental|Videolaryngoscopy|Videolaryngoscopy the trachea will be intubated using a videolaringoscope
11206823|NCT03336476|Active Comparator|Direct laryngoscopy|Direct laringoscopy the trachea will be intubated using a laringoscope
11206824|NCT03336463||Controls|No intervention
11206825|NCT03336463||Cases|No intervention
11206826|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
11206827|NCT03336437|Active Comparator|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
11206828|NCT03336437|Placebo Comparator|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
11206829|NCT03336424|Experimental|Non-invasive investigations group|Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
11206830|NCT03336424|Experimental|Invasive investigations group|urodynamic study including: cystomanometry, pressure flow study, EMG
11206831|NCT03336411|Active Comparator|mHealth|
11206832|NCT03336411|Experimental|Personalized mHealth|
11206833|NCT03336398|Experimental|Tinnitus Distressed Patients|Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
11206834|NCT03336398|Experimental|Tinnitus Patients|Tinnitus patients are patients who do not experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
11206835|NCT03336385|Placebo Comparator|Placebo|Maltodextrin 12 gram used as placebo
11206836|NCT03336385|Active Comparator|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
11206837|NCT03336385|Active Comparator|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
11206838|NCT03336372|Experimental|Picato topical gel|
11206839|NCT03336359|Active Comparator|LCI|Tandem colonoscopy with Linked Color Imaging system
11206840|NCT03336359|Active Comparator|NBI|Tandem colonoscopy with Narrow band imaging system
11206841|NCT03336346||DTG group|Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
11206842|NCT03336346||No ART group|Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
11206843|NCT03336346||EFV group|Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
11206844|NCT03336333|Experimental|Cohort 1: Zanubrutinib|Participants without del[17p] will receive zanubrutinib for up to six 28-day cycles
11206845|NCT03336333|Experimental|Cohort 1: B+R|Participants without del[17p] will receive bendamustine plus rituximab for up to six 28-day cycles
11206846|NCT03336333|Experimental|Cohort 1a (China only): Zanubrutinib|Participants without del[17p] will receive zanubrutinib for up to six 28-day cycles
11206847|NCT03336333|Experimental|Cohort 1a (China only): B+R|Participants without del[17p] will receive bendamustine plus rituximab for up to six 28-day cycles
11206848|NCT03336333|Experimental|Cohort 2: Zanubrutinib|Participants with del[17p] will receive zanubrutinib for up to six 28-day cycles
11206849|NCT03336333|Experimental|Cohort 3: Venetoclax + zanubrutinib|Participants with del[17p] will receive venetoclax and zanubrutinib for up to six 28-day cycles
11206850|NCT03336320|Experimental|Multidomain Intervention Group|Home-based multidomain intervention composed of nutritional counselling, exercise (balance, gait, , and cognitive training provided using ICT solutions. A web platform, containing information, questionnaires, videos, games, and tests related to each one of the three components of the multidomain intervention will be made available to participants in this group.
11206874|NCT03336151|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.
~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
11206875|NCT03336138|Active Comparator|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
11206851|NCT03336320|Active Comparator|Control Group|"Participants from CG will also be equipped with wrist worn accelerometers (that will record daily activity data continuously) but contrary to MIG, participants won't have access to the password encrypted application, and therefore, to the multidomain intervention. However, they will be able to access the study website with overall information on the eMIND study and links to the website of health authorities (such as http://www.mangerbouger.fr/PNNS or the World Health Organization http://www.who.int/topics/ageing/fr/) regarding healthy ageing topics. Plus, in order to control for the social aspect of MIG, participants in CG will receive monthly phone calls from the research team."
11206852|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.
~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.
~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
11206853|NCT03336294|Other|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
11206854|NCT03336294|Other|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
11206855|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug [bDMARD] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
11206856|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
11206857|NCT03336268|Experimental|POINT|This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
11206858|NCT03336268|No Intervention|Standard Care|This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
11206859|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
11206860|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
11206861|NCT03336242|Experimental|Cohort 1: Cannabidiol Oral Solution 20 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.
11206862|NCT03336242|Experimental|Cohort 2: Cannabidiol Oral Solution 30 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.
~Treatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks."
11206863|NCT03336242|Experimental|Cohort 3: Cannabidiol Oral Solution 40 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days, followed by 30 mg/kg/day divided BID for 5 days.
~Treatment Period: Cannabidiol Oral Solution 40 mg/kg/day divided BID for 4 weeks."
11206864|NCT03336229|Active Comparator|Intervention|
11206865|NCT03336229|No Intervention|Control|
11206866|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy:
~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
11206867|NCT03336216|Experimental|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
11206868|NCT03336216|Experimental|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
11206869|NCT03336216|Experimental|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
11206870|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
11206871|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
11206872|NCT03336190|Experimental|Intervention|Receives the full program, including the toolkit training and avatar interaction
11206873|NCT03336164|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage sold in the same campus university restaurant after the control period without food labelling.
~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
11206876|NCT03336138|No Intervention|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
11206877|NCT03336125|Experimental|Vitamin D group|Intervention is vitamin D supplement
11206879|NCT03336112|Experimental|Intervention group|5 weeks guided internet-delivered cognitive behavioral therapy program The program consists of psychoeducation, exposure to physical activity, and awareness (mindfulness) training.
11206880|NCT03336112|Active Comparator|Control group|Information program delivered by the Internet during 5 weeks.
11206881|NCT03336099|Experimental|Spa Treatment|Bicarbonate and sulfurated water cares in Vals-les-Bains thermal cure center, massage, cataplasm.
11206882|NCT03336086|Other|experimental|This group underwent a weight loss program
11206883|NCT03336086|No Intervention|control|This group underwent adlibitum diet + physical activity
11206884|NCT03336073|Experimental|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
11206885|NCT03336073|Active Comparator|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
11206886|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
11206887|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
11206888|NCT03336047|Active Comparator|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
11206889|NCT03336047|Experimental|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
11206890|NCT03336034||IBS-C|Constipation-predominant irritable bowel syndrome
11206891|NCT03336021|Experimental|Intervention|FAS program
11206892|NCT03336021|No Intervention|Comparison|Comparison group
11206893|NCT03335982|Other|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
11206894|NCT03335969|Experimental|pre colon irrigation diaries followed by post diaries|4 week bowel movement and rescue medication diaries will be compared to same diaries used 4 weeks after the colon irrigation procedure
11206895|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 1|
11206896|NCT03335956|Experimental|SAD Part 1 Active Cohort Period 1|
11206897|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 2|
11206898|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 2|
11206899|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 3|
11206900|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 3|
11206901|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 4|
11206902|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 4|
11206903|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 5|
11206904|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 5|
11206905|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 6|
11206906|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 6|
11206907|NCT03335956|Placebo Comparator|MAD Placebo Cohort 1|
11206908|NCT03335956|Experimental|MAD Active Cohort 1|
11206909|NCT03335956|Placebo Comparator|MAD Placebo Cohort 2|
11206910|NCT03335956|Experimental|MAD Active Cohort 2|
11206911|NCT03335956|Placebo Comparator|MAD Placebo Cohort 3|
11206912|NCT03335956|Experimental|MAD Active Cohort 3|
11206913|NCT03335956|Placebo Comparator|MAD Placebo Cohort 4|
11206914|NCT03335956|Experimental|MAD Active Cohort 4|
11206915|NCT03335943|Experimental|CDA-2 (Cell Differentiation Agent 2)|Patients will be given CDA-2 therapy.
11206916|NCT03335930|Experimental|Morning exercise|To exercise at morning (08:00-10:00)
11206917|NCT03335930|Active Comparator|Afternoon exercise|To exercise at afternoon (14:00-16:00)
11206918|NCT03335930|Active Comparator|Evening exercise|To exercise at evening (18:00-20:00)
11206919|NCT03335917|Placebo Comparator|Normobaric Normoxia|This will serve as the exercise only control trial
11206920|NCT03335917|Experimental|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
11206921|NCT03335917|Experimental|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
11206922|NCT03335904|Placebo Comparator|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
11206923|NCT03335904|Experimental|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
11206924|NCT03335891|Experimental|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
11206925|NCT03335891|Active Comparator|Control Group|Asthma Education Program Breathing Exercises
11206985|NCT03335462|Experimental|Paravertebral injections|Lumbar paravertebral injections containing contrast will be performed. The needles are kept in their position and afterwards followed by CT scan.
11206926|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
11206927|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
11206928|NCT03335852|Experimental|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
11206929|NCT03335839|Experimental|Intracoronary tPA 10 mg|
11206930|NCT03335839|Experimental|Intracoronary tPA 20 mg|
11206931|NCT03335839|Placebo Comparator|Placebo|saline
11206932|NCT03335826|Experimental|Combined epidural-general anesthesia|Patients assigned to this group receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
11206933|NCT03335826|Active Comparator|General anesthesia|Patients assigned to this group receive general anesthesia and postoperative patient-controlled intravenous analgesia.
11206934|NCT03335813|Experimental|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
11206935|NCT03335800|Experimental|Apple Heart Study App|
11206936|NCT03335787|Experimental|Intervention|Taping will be applied three times and will be reapplied one and two weeks later prior to first application for two weeks.
11206937|NCT03335787|Other|Control|Control group would not receive any taping in order to prevent sham taping sensory stimulation effect.
11206938|NCT03335774|Active Comparator|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
11206939|NCT03335774|Placebo Comparator|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
11206940|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
11206941|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
11206942|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
11206943|NCT03335748|Active Comparator|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
11206944|NCT03335748|Experimental|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
11206945|NCT03335735|Experimental|Loss-Framed Text Messages|Loss-framed text message
11206946|NCT03335735|No Intervention|Control|Participants in this arm will not receive any intervention.
11206947|NCT03335735|Experimental|Gain-Framed Messaging Group|Gain-framed text message
11206948|NCT03335722|Active Comparator|Active TDCS and Fluency Intervention|Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
11206949|NCT03335722|Sham Comparator|Sham TDCS and Fluency Intervention|Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
11206950|NCT03335709|Experimental|ADL intervention|The participants are assigned to an eight-week intervention program aiming at enhancing ADL ability. The program consists of a minimum of five and a maximum of eight sessions; Session one - First meeting and occupational therapy evaluation (mandatory), Session two - Goal setting and clarifying reasons for problems related to ADL (mandatory), Session three- seven - Interventions aiming at enhancing ADL ability (Number of sessions can vary. However, a minimum of two sessions are mandatory), Session eight - Re-evaluation (Mandatory)
11206951|NCT03335683|Experimental|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
11206952|NCT03335683|Placebo Comparator|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
11206953|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
11206954|NCT03335657|Experimental|CBPT Treatment|The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
11206986|NCT03335449|Experimental|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
11206987|NCT03335449|No Intervention|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
11206955|NCT03335657|Placebo Comparator|Education Treatment|The education program provides a postoperative recovery and is based on education that would typically be provided by a treating physician or a physical therapist in an outpatient setting. The education program is matched to the CBPT treatment in terms of session frequency and contact with the study therapist. The therapist will call weekly to check in with the patient and encourage him/her to read the manual. Manuals contain educational information on injury patterns and symptoms, stress and recovery, benefits of physical therapy, and importance of daily exercise, and ways to promote healing. Education on sleep hygiene, energy management, healthy eating, and preventing future injury are also provided.
11206956|NCT03335631|Experimental|Group-supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
11206957|NCT03335631|Experimental|Home-based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
11206958|NCT03335618|Experimental|Active Coaching and Monitoring|
11206959|NCT03335618|Sham Comparator|Passive Monitoring|
11206960|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
11206961|NCT03335605||Healthy controls|Age and gender-matched control subjects
11206962|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
11206963|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
11206964|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
11206965|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
11206966|NCT03335553|Experimental|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
11206967|NCT03335553|Experimental|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
11206968|NCT03335540|Experimental|Arm B|Combination therapy determined by biomarker assessment
11206969|NCT03335540|Experimental|Arm C|Combination therapy determined by biomarker assessment
11206970|NCT03335540|Experimental|Arm D|Combination therapy determined by biomarker assessment
11206971|NCT03335540|Experimental|Arm F|Combination therapy determined by biomarker assessment
11206972|NCT03335540|Experimental|Arm G|Combination therapy determined by biomarker assessment
11206973|NCT03335527|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
11206974|NCT03335527|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
11206975|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
11206976|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
11206977|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
11206978|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
11206979|NCT03335501|Active Comparator|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
11206980|NCT03335501|Active Comparator|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
11206981|NCT03335488|Experimental|Arm 1, RAVICTI|Used for Baseline, Treatment, Transition, Maintenance, and Safety. Dosing will be based on participants disease and treatment status at entry to the study. RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose.
11206982|NCT03335488|Active Comparator|Arm 2, NaPBA (sodium phenylbutyrate)|"Used for Baseline and Treatment. Sodium Phenylbutyrate (NaPBA). Dosing will be based on participants disease and treatment status at entry to the study.
~NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose
~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
11206983|NCT03335475|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
11206984|NCT03335475|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
11206988|NCT03335436|Experimental|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
11206989|NCT03335436|Placebo Comparator|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
11206990|NCT03335423|Experimental|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
11206991|NCT03335423|Experimental|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
11206992|NCT03335423|Experimental|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
11206993|NCT03335423|Experimental|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
11206994|NCT03335410||shoulder surgery|18-85 years, undergoing day case shoulder surgery during 15th Sept- 15th Oct 2017, possibility to e-mail and an internet connection, understands Finnish,
11206995|NCT03335397|Experimental|M-learning group|Participants receive mobile app (m-learning application) with interactive content (quiz).
11206996|NCT03335397|Other|Control group|Participants receive traditional learning process (books, journals available in the University library).
11206997|NCT03335384|Experimental|Measurement of Pdi|Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
11206998|NCT03335384|Experimental|Measurement of SNIPs|While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
11206999|NCT03335371|Experimental|TTP399 400 mg|
11207000|NCT03335371|Placebo Comparator|Placebo|
11207001|NCT03335358|Experimental|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
11207002|NCT03335358|Other|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
11207003|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
11207004|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
11207005|NCT03335332|Experimental|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
11207006|NCT03335332|Active Comparator|Moderate intensity exercise|
11207007|NCT03335319|Experimental|Periodized Exercise Training Regime|The ET program will be carried out 3 times a week (60 minutes per session) on non-consecutive days for 48 weeks and supervised for both groups. Exercise prescription will be gradually progressed through various combinations of duration, frequency and/or intensity of training. Over the 1st-15th exercise sessions: MCT and anatomical resistance training; from the 16th-30th session: combined ET with HIIT and hypertrophy; from the 31st-45th exercise session, after the adjustments of the respectively time point assessments: MCT and maximal strength; from the 46th-60th exercise sessions: HIIT with hypertrophy; at the end of the 60th session until the end (6 months has passed): the same exercise prescription will repeat all over again at the same order.
11207008|NCT03335319|Active Comparator|Non Periodized Exercise Training Regime|participants will do a combined ET regime (aerobic and RT). Aerobic component: combine moderate to vigorous exercises 3 d.wk-1 on nonconsecutive days, for 20 min per session, involving major muscle groups using the available ergometers to perform continuous and rhythmic activities in nature. Resistance component: RT should be performed after the aerobic component of the exercise session to allow for adequate warm-up. Initial load should be trained initially with one set of 10-15 repetitions that can be lifted without straining (~30%-40% 1RM for the upper body; ~50%-60% 1 RM for the lower body). Each major muscle group should be trained initially with one set; multiple set regimens may be introduced later as tolerated. It will be performed 8-10 exercises of the major muscle groups.
11207009|NCT03335306||Healthy subjects in Hong Kong|
11207010|NCT03335293|Placebo Comparator|Placebo|normal saline vehicle added to subarachnoid block
11207011|NCT03335293|Experimental|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
11207012|NCT03335293|Experimental|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
11207013|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
11207014|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
11207015|NCT03335267|Experimental|CPX-351 (Cytarabine:Daunorubicin) Injection|"Dosing for first induction: CPX-351
~• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5
~Dosing for second induction:
~• CPX-351 at 100 u/m2 will be administered on days 1 and 3
~Dosing for consolidation:
~• CPX-351 at 65 u/m2 will be administered on days 1 and 3"
11207016|NCT03335254|Experimental|Dose-Escalating Arm 1|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207017|NCT03335254|Experimental|Dose-Escalating Arm 2|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 633 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207018|NCT03335254|Experimental|Dose-Escalating Arm 3|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207019|NCT03335254|Experimental|Dose-Escalating Arm 4|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease to 507 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207020|NCT03335254|Experimental|Dose-Escalating Arm 5|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207021|NCT03335254|Experimental|Dose-Escalating Arm 6|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 507 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207022|NCT03335254|Experimental|Dose-Escalating Arm 7|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207023|NCT03335254|Experimental|Dose-Escalating Arm 8|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207024|NCT03335254|Experimental|Dose-Escalating Arm 9|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207025|NCT03335254|Experimental|Dose-Escalating Arm 10|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 443 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207038|NCT03335228|Experimental|Eclipse Easy Spin for PRP Treatment|Assessing the safety and efficacy of platelet rich plasma for treating frontal fibrosing alopecia. This will be accomplished by the production of platelet rich plasma by the Eclipse Easy Spin centrifuge. Subjects will receive treatment once a month for 6 months. Platelet rich plasma will be administered via injections into the affected areas of the scalp.
11207067|NCT03335020|Placebo Comparator|Normal|Healthy volunteers. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
11207026|NCT03335254|Experimental|Dose-Escalating Arm 11|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207027|NCT03335254|Experimental|Dose-Escalating Arm 12|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207028|NCT03335254|Experimental|Dose-Escalating Arm 13|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207029|NCT03335254|Experimental|Dose-Escalating Arm 14|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 380 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207030|NCT03335254|Experimental|Dose-Escalating Arm 15|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207031|NCT03335254|Experimental|Dose-Escalating Arm 16|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.
~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 253 mg TU twice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207032|NCT03335254|Experimental|Dose-Escalating Arm 17|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207033|NCT03335254|Experimental|Dose-Escalating Arm 18|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207034|NCT03335254|Experimental|Dose-Escalating Arm 19|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207035|NCT03335254|Experimental|Dose-Escalating Arm 20|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).
~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.
~Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU daily.
~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
11207036|NCT03335241|Experimental|Arm 1: Fludarabine and Pegylated liposomal doxorubicin|
11207037|NCT03335241|Active Comparator|Arm 2: Pegylated liposomal doxorubicin|
11207066|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
11207039|NCT03335215|Experimental|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
11207040|NCT03335215|No Intervention|usual care|
11207041|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
11207042|NCT03335189|Experimental|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
11207043|NCT03335189|No Intervention|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
11207044|NCT03335176|Experimental|Endurance and Resistance Training Exercise|
11207045|NCT03335176|No Intervention|Control group|Usual care
11207046|NCT03335163|Experimental|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
11207047|NCT03335150|Active Comparator|Supportive Care|Support Group for PD-MCI
11207048|NCT03335150|Experimental|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
11207049|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
11207050|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
11207051|NCT03335124|Experimental|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.
~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.
~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
11207052|NCT03335124|Placebo Comparator|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
11207053|NCT03335111|Experimental|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
11207054|NCT03335111|Sham Comparator|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
11207055|NCT03335098|Experimental|Study arm|Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)
11207056|NCT03335085|Active Comparator|Oxytocin|Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)
11207057|NCT03335085|Placebo Comparator|Placebo|All ingredients except for oxytocin.
11207058|NCT03335072|Active Comparator|WHO-recommended|Annual mass azithromycin distribution of all residents
11207059|NCT03335072|Experimental|Age-based core group|Annual mass azithromycin treatment of everyone plus quarterly treatment of children
11207060|NCT03335072|Experimental|PCR infection-based core group|Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
11207061|NCT03335072|Experimental|TI-based core group|Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
11207062|NCT03335059|Experimental|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
11207063|NCT03335046|Experimental|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
11207064|NCT03335046|Other|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
11207065|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
11207068|NCT03335020|Active Comparator|Fibromuscular Dysplasia (FMD)|Subjects with diagnosis of FMD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
11207069|NCT03335020|Active Comparator|Atherosclerosis|Subjects with diagnosis of atherosclerosis. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
11207070|NCT03335020|Active Comparator|Spontaneous Coronary Artery Dissection (SCAD)|Subjects with diagnosis of SCAD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
11207071|NCT03335020|Active Comparator|Segmental Arterial Mediolysis (SAM)|Subjects with diagnosis of SAM. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
11207072|NCT03335007|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
11207073|NCT03335007|Placebo Comparator|Placebo|Placebo
11207074|NCT03334994|Active Comparator|Control group: immediate implant alone|Patient will be treated with immediate implant alone.
11207075|NCT03334994|Active Comparator|(Group A) immediate implant alone|Patient will be treated with immediate implant alone.
11207076|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
11207077|NCT03334968||Patient group|Acute ischemic stroke patients
11207078|NCT03334968||Control group|Those served as control group
11207079|NCT03334955|Experimental|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
11207080|NCT03334942|Experimental|CFTSI|Youth and caregivers randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 5 to 8 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
11207081|NCT03334942|No Intervention|Violence Intervention Program|Youth and caregivers randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
11207082|NCT03334929|Experimental|Virtual Reality intervention|Participants will be wearing Virtual Reality headset called Oculus gear equipped with Samsung galaxy S7 during the trigger point injections. The VR app chosen is called Relax VR - Rest, Relaxation & Meditation, which will provide a calm beach scene with waves and soothing musics.
11207083|NCT03334929|No Intervention|control|Participants in this group will receive trigger point injections without any intervention. The trigger point injections will be performed in daily manner.
11207084|NCT03334916|Experimental|YMC026|108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
11207085|NCT03334916|Placebo Comparator|Placebo|108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
11207086|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
11207087|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
11207088|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
11207089|NCT03334864||I Retrospective cohort|Diagnosis of advanced non-small cell lung cancer from 2012-2016
11207090|NCT03334864||II Prospective cohort|Advanced non-small cell lung cancer with driver gene mutations
11207091|NCT03334864||III Prospective cohort|Non-small cell lung cancer in immuno-therapy;
11207092|NCT03334864||IV Prospective cohort|Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
11207093|NCT03334864||V Prospective cohort|Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
11207094|NCT03334851|Experimental|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
11207095|NCT03334851|Experimental|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207096|NCT03334851|Experimental|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207097|NCT03334851|Experimental|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207098|NCT03334851|Experimental|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207099|NCT03334851|Experimental|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207100|NCT03334851|Experimental|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207101|NCT03334851|Experimental|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
11207102|NCT03334851|Experimental|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous administration.
11207103|NCT03334851|Experimental|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
11207104|NCT03334851|Experimental|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
11207105|NCT03334851|Experimental|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
11207488|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
11207106|NCT03334851|Experimental|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
11207107|NCT03334851|Experimental|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
11207108|NCT03334838|Experimental|GRP 1 - Assess relative bioavailability (4-way crossover)|"GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets).
~In Treatment A, dose administration will be in a fasted state.
~For the other treatments, dose administration will be in a fed state:
~Treatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast."
11207109|NCT03334838|Experimental|GRP 2 - Assess relative bioavailability (2-way crossover)|"All subjects in Group 2 will receive a single dose of nifurtimox in each of the Treatments D and E.
~In Treatment D, subjects will receive 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects will receive 240 mg nifurtimox (8 x 30 mg tablets). Both treatments will be administered in a fed state, after a high-calorie and high-fat breakfast."
11207110|NCT03334825|Experimental|Enhanced housing placement assistance|
11207111|NCT03334825|Active Comparator|Standard housing placement assistance|
11207112|NCT03334812|Experimental|LNA043 20mg/ml|LNA043 20mg/ml single dose
11207113|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
11207114|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/ml single dose
11207115|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
11207116|NCT03334799|Other|Sacroiliac belt on and off|Belt on and belt off
11207117|NCT03334786|Experimental|FLX-787-ODT (orally disintegrating tablet)|Single dose
11207118|NCT03334773|Experimental|Intervention group|Nutrition education (group inclusive of education materials)
11207119|NCT03334773|No Intervention|Control group|Only receives education materials
11207120|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
11207121|NCT03334747|Experimental|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
11207122|NCT03334747|Experimental|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
11207123|NCT03334747|Experimental|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
11207124|NCT03334747|Experimental|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
11207125|NCT03334747|Experimental|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
11207126|NCT03334747|Experimental|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
11207127|NCT03334747|Experimental|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
11207128|NCT03334747|Active Comparator|Treatment arm 9: Coartem Control|Coartem® control
11207129|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
11207130|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
11207131|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
11207132|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
11207133|NCT03334721|Experimental|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
11207134|NCT03334721|Experimental|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
11207135|NCT03334708||Locally Advanced or Metastatic Pancreatic Cancer Cohort|For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.
11207136|NCT03334708||Acute Benign Pancreatic Pathology Control Cohort|For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter
11207137|NCT03334708||Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl|For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.
11207138|NCT03334708||Healthy Control|For normal controls, blood specimens will be drawn once at study baseline.
11207139|NCT03334695|Experimental|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1*10^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
11207140|NCT03334695|Placebo Comparator|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
11207141|NCT03334682|Experimental|spironolactone|Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial (12 months: 6 months on double-blinded spironolactone then 6 months on open-label spironolactone), + topical therapy during all the trial (benzoyl peroxide 5%)
11207142|NCT03334682|Active Comparator|doxycycline|(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months, on double-blinded + topical therapy during all the trial (benzoyl peroxide 5%
11207143|NCT03334669|Experimental|Intervention|"Sites randomized to the intervention group will receive the following:
~Parents Connect for Healthy Living (PConnect)
~Enhanced Nutrition Support
~Media Resources"
11207144|NCT03334669|No Intervention|Control|Control sites will not receive any intervention components (i.e., standard practice).
11207489|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
11207145|NCT03334656|Experimental|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:
~Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.
~The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
11207146|NCT03334656|Active Comparator|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.
~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.
~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
11207147|NCT03334643|Experimental|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
11207148|NCT03334643|Experimental|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
11207149|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using temperature-controlled ablation catheter
11207150|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat atrial fibrillation using contact-force sensing ablation catheter
11207151|NCT03334617|Experimental|Durvalumab + olaparib|Durvalumab given in combination with olaparib .
11207152|NCT03334617|Experimental|Durvalumab + AZD9150|Durvalumab given in combination with AZD9150.
11207153|NCT03334617|Experimental|Durvalumab + AZD6738|Durvalumab given in combination with AZD6738.
11207154|NCT03334617|Experimental|Durvalumab + vistusertib|Durvalumab given in combination with Vistusertib (AZD2014).
11207155|NCT03334617|Experimental|Durvalumab + Oleclumab|Durvalumab given in combination with Oleclumab
11207156|NCT03334617|Experimental|durvalumab + trastuzumab deruxtecan|durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)
11207157|NCT03334617|Experimental|durvalumab + cediranib|durvalumab given in combination with cediranib (AZD2171)
11207158|NCT03334617|Experimental|AZD6738 (ceralasertib) monotherapy|AZD6738 (ceralasertib) given as monotherapy
11207159|NCT03334617|Experimental|durvalumab & AZD6738 (ceralasertib)|durvalumab given in combination with AZD6738 (D15-D28)
11207160|NCT03334604|Experimental|Multispecies probiotic group|175 participants.
11207161|NCT03334604|Placebo Comparator|Control group|175 participants.
11207162|NCT03334591|Experimental|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
11207163|NCT03334591|Active Comparator|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
11207164|NCT03334578|Experimental|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.
~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
11207165|NCT03334578|No Intervention|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
11207166|NCT03334565|Sham Comparator|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
11207167|NCT03334565|Active Comparator|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
11207168|NCT03334565|Active Comparator|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
11207169|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|0.10% HL036 Ophthalmic Solution, BID for 8weeks
11207170|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|0.25% HL036 Ophthalmic Solution, BID for 8weeks
11207171|NCT03334539|Placebo Comparator|Placebo|Placebo vehicle Solution, BID for 8weeks
11207172|NCT03334526|Experimental|healthy volunteers|
11207173|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
11207174|NCT03334500|Experimental|Cohort 1|Gleason 6 (n=10)
11207175|NCT03334500|Experimental|Cohort 2|Gleason 7-8 (n=10)
11207176|NCT03334500|Experimental|Cohort 3|Gleason 9 or oligometastic disease (n=10)
11207177|NCT03334487|Experimental|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
11207178|NCT03334474||young|18-35 years old
11207179|NCT03334474||middle|35-65 years old
11207180|NCT03334474||aged|65-85 years old
11207272|NCT03333902|Experimental|QLB type 2|"Ultrasound-guided, Inject at the point posterior to quadratus lumborum muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
11207181|NCT03334461|Experimental|high concentration enamel remineralisation agent|first month brushing teeth three times per day: twice per day with high-fluorides gel (Mirafluor K gel cola 6150 ppm F pH 5.1) and once per day without toothpaste and fluoride gel next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
11207182|NCT03334461|Experimental|oral antiseptic|first month brushing teeth without toothpaste three times per day and using oral antiseptic chlorhexidine mouthwash (Curasept ADS 212 a 200ml 0,12%) twice per day next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
11207183|NCT03334461|No Intervention|Control|regular oral hygiene without exposure to oral antiseptic or high concentration enamel remineralisation agent three months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
11207184|NCT03334448|Experimental|LY900014-U200|Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
11207185|NCT03334448|Experimental|LY900014-U100|Single SC dose of 15 U LY900014 U-100 in two of four study periods
11207186|NCT03334435|Experimental|Baricitinib High Dose Nonresponders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11207187|NCT03334435|Experimental|Baricitinib High Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11207188|NCT03334435|Experimental|Baricitinib Mid Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11207189|NCT03334435|Experimental|Baricitinib High Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11207190|NCT03334435|Experimental|Baricitinib Mid Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11207191|NCT03334435|Experimental|Baricitinib Low Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
11207192|NCT03334435|Placebo Comparator|Placebo Responders|Placebo administered orally.
11207193|NCT03334435|Experimental|Baricitinib Open Label Extension|Baricitinib administered orally.
11207194|NCT03334422|Experimental|4 Milligram (mg) Baricitinib|4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
11207195|NCT03334422|Experimental|2mg Baricitinib|2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
11207196|NCT03334422|Experimental|1mg Baricitinib|1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
11207197|NCT03334422|Placebo Comparator|Placebo|Placebo administered orally once daily.
11207198|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
11207199|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
11207200|NCT03334396|Experimental|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
11207201|NCT03334396|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
11207202|NCT03334396|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
11207203|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally once daily.
11207204|NCT03334396|Experimental|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
11207205|NCT03334396|Experimental|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
11207206|NCT03334396|Experimental|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
11207207|NCT03334396|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
11207208|NCT03334383|Experimental|Sponge group|Patients offered surgery with the retractor sponge
11207209|NCT03334383|No Intervention|Control group|Patients receiving standard care: surgery in Trendelenburg position
11207210|NCT03334370||DM subjects in Hong Kong|
11207211|NCT03334357|No Intervention|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
11207212|NCT03334357|Experimental|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).
~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.
~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.
~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).
~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
11207236|NCT03334188|Other|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
11207352|NCT03333343|Experimental|Arm 1|EGF816+ trametinib in escalation phase
11207353|NCT03333343|Experimental|Arm 2|EGF816 + ribociclib in escalation phase
11207213|NCT03334357|Experimental|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be >95% VO2max and HIIT with short intervals (Type B session), >120% VO2max.
~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.
~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
11207214|NCT03334357|Experimental|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.
~Electrical parameters:
~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.
~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).
~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.
~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
11207215|NCT03334344|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
11207216|NCT03334344|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
11207217|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
11207218|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
11207219|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
11207220|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
11207221|NCT03334279||non smokers|
11207222|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
11207223|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
11207224|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
11207225|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
11207226|NCT03334253|Experimental|Atropine Group|0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops
11207227|NCT03334253|Placebo Comparator|Placebo Group|Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops
11207228|NCT03334240|Experimental|CLS003|Digoxin and Furosemide topical formulation
11207229|NCT03334240|Placebo Comparator|Vehicle|Inactive vehicle
11207230|NCT03334227|Experimental|High-Flow nasal cannula (HFNC)|"Treatment with HFNC will be adjusted for SpO2 >92%, even with FiO2 of 0.21, if needed.
~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow >50 L/min is uncomfortable for many patients.
~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat."
11207231|NCT03334227|No Intervention|Conventional therapy|"Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 < 92% by pulse oximetry.
~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 >95% without oxygen supply is acceptable. On the contrary, SpO2 <92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients."
11207232|NCT03334214|Experimental|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
11207233|NCT03334214|Placebo Comparator|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
11207234|NCT03334201|Other|Western diet first|To receive Western diet controlled feeding first, followed by non-Western diet controlled feeding
11207235|NCT03334201|Other|Non-Western diet first|To receive non-Western diet controlled feeding first, followed by Western diet controlled feeding
11207271|NCT03333915|Experimental|High-grade ovarian cancer and triple negative breast cancer|
11207354|NCT03333343|Experimental|Arm 3|EGF816 + LXH254 in escalation phase
11207237|NCT03334188|Active Comparator|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
11207238|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
11207239|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
11207240|NCT03334162|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for 12 weeks in addition to usual care.
11207241|NCT03334162|No Intervention|Control group|Children in the control group will receive treatment as usual. The control group will be given the opportunity to participate in the intervention after study completion
11207242|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
11207243|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
11207244|NCT03334136|Active Comparator|Vitamin D|25-hydroxyvitamin D 20.000 IU capsule given orally. Five capsules the first day and thereafter one capsule every week for 4 months.
11207245|NCT03334136|Placebo Comparator|Placebo|Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
11207246|NCT03334123|Experimental|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
11207247|NCT03334123|Active Comparator|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
11207248|NCT03334110|Experimental|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
11207249|NCT03334110|Other|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
11207250|NCT03334097|Experimental|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
11207251|NCT03334084|Experimental|1|Scheme 1
11207252|NCT03334084|Experimental|2|Scheme 2
11207253|NCT03334084|Experimental|3|Scheme 3
11207254|NCT03334071|Active Comparator|Exercise Intervention|Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
11207255|NCT03334071|No Intervention|Negative Control|Patients in the control arm will not undergo an exercise training program.
11207256|NCT03334071|No Intervention|Observational|Patients who do not enrol in RCT will be enrolled in the observational arm
11207257|NCT03334058|Experimental|ARGX-113|
11207258|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
11207259|NCT03334045||Controls|Healthy controls
11207260|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed
~at baseline: on admission to inpatient treatment
~at follow-up: 6 months after admission on outpatient basis"
11207261|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
11207262|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
11207263|NCT03334006|No Intervention|A: Control group|Standard of Care
11207264|NCT03334006|Active Comparator|B: Pentaglobin®|Standard of Care + Pentaglobin®
11207265|NCT03333993|Experimental|Intervention Group|Patients in this group will be submitted to 10 sessions of Mat Pilates exercises, performed twice a week, lasting 60 minutes, for a period of 5 weeks (from the beginning to the end of radiotherapy). The program will consist of group sessions of up to 4 patients, supervised by a specialized physiotherapist. In addition, they will be guided to follow with the home exercises, according to the institutional routine.
11207266|NCT03333993|Active Comparator|Control Group|Patients assigned to this group will not participate in the Mat Pilates exercises and will be instructed to maintain the home exercises for upper limbs, guided by physiotherapists in the postoperative period, according to the institutional routine.
11207267|NCT03333941||RES (Regenerative Epithelial Suspension)|
11207268|NCT03333928|Active Comparator|500mg HTD1801, bid|
11207269|NCT03333928|Active Comparator|1000mg HTD1801, bid|
11207270|NCT03333928|Placebo Comparator|placebo, bid|
11207273|NCT03333902|Experimental|QLB type 3|"Ultrasound-guided, Inject at the point between the quadratus lumborum and the psoas major muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
11207274|NCT03333902|Experimental|QLB type 2+3|"Ultrasound-guided, conduct both QLB type 2 and 3, 0.2% ropivacaine 15mL in each point of injection, for a total of 60mL.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
11207275|NCT03333902|Active Comparator|epidural anesthesia group (EA)|"Epidural catheter placement was conducted when finishing spinal anesthesia. After surgery, 30 mL saline (placebo) was Injected at the point posterior to the quadratus lumborum in each side for a total of 60mL. We used a single bolus of 0.15% ropivacaine + 2 mg morphine (diluted in 6 ml saline) via epidural cathether.
~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
11207276|NCT03333889|Active Comparator|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
11207277|NCT03333889|Experimental|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
11207278|NCT03333876|Active Comparator|Nasal Dilator|Nasal dilators have been used to treat snoring and sleep apnea. Many studies focus on external nasal dilators like Breathe Right Strips. These interventions largely were not effective in treating OSA. However, there is some evidence to suggest internal to the nose dilators (like Mute) may work to reduce snoring
11207279|NCT03333876|Active Comparator|Mandibular Advancement|Mandibular advancement devices have shown to be effective, but not necessarily acceptable to primary snorers.
11207280|NCT03333876|Active Comparator|Positional Therapy|Studies have shown mixed results for positional therapy as a whole. Braver and Block reported that foam wedges used to keep patients in a lateral position were not effective in reducing snoring in 20 individuals.
11207281|NCT03333850|Experimental|Visual feedback of physical activity|Participants in the exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing and walking. This information will be visible to the health personnel, the patients and their relatives.
11207282|NCT03333850|Active Comparator|No feedback of physical activity|The participants in the non-exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation. No visual feedback is provided.
11207283|NCT03333837|Active Comparator|Dance Group|The Dance Group will participate in 1-hour group improvisational dance lessons 2x/week for 12 weeks. Improvisational dance classes are grounded in 4 principles that shape the tone of the class and result in a sense of social belonging: non-judgment, non-competitiveness, curiosity, and playfulness. The following training strategies are used to maintain: active imagination, variability, and pacing.
11207284|NCT03333837|Active Comparator|Non-group Dance|The Non-group dance intervention is designed to capture the same dance movement and auditory stimuli as the group class without social interaction. Recordings of the dance instructor teaching a dance class will be played. This will ensure participants hear comparable music and receive comparable verbal auditory cues to prompt dance movements that students in the group class will hear, without interacting with other people. Improvisational dance is particularly suited for this means of delivery because the primary method of instruction is verbal auditory cueing. Participants will be asked to follow the same schedule as participants in the Dance Group arm and complete 2 one-hour dance sessions each week.
11207285|NCT03333837|Active Comparator|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
11207286|NCT03333837|Sham Comparator|No Contact|A No Contact condition captures the condition of no added social contact and no added dance movement. Participants randomized to the No Contact condition will be asked to continue their current disease management and lifestyle for 12 weeks
11207287|NCT03333824|Experimental|Wee-1 kinase inhibitor AZD1775|To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval
11207288|NCT03333798|Experimental|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
11207289|NCT03333798|Active Comparator|Standard psychosocial care|Standard psychosocial care delivered by health services.
11207290|NCT03333785|Experimental|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
11207291|NCT03333785|No Intervention|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
11207292|NCT03333772|Experimental|REAL-T Intervention|The current feasibility study will evaluate the feasibility of implementing the REAL-T RCT by enrolling 10 participants who are 18-30 years of age, conducting the REAL-T intervention with all participants over a 3-month period, evaluating pre-to-post changes in their health and quality of life, and assessing the process of implementing the study (feasibility and participant satisfaction).
11207355|NCT03333343|Experimental|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
11207356|NCT03333343|Experimental|Arm B|EGF816 + trametinib in expansion phase
11207357|NCT03333343|Experimental|Arm C|EGF816 + ribociclib in expansion phase
11207293|NCT03333759|Experimental|Laser Treatment|"Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.
~Laser parameters are as follows:
~iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap"
11207294|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11207295|NCT03333733|Experimental|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
11207296|NCT03333733|No Intervention|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
11207297|NCT03333720|Experimental|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
11207298|NCT03333707|Experimental|Active|Participants will be provided will full access to the Pacifica app.
11207299|NCT03333707|No Intervention|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
11207300|NCT03333694|Experimental|CLL442|Cutaneous Cream application twice daily
11207301|NCT03333694|Placebo Comparator|Placebo|Placebo Cutaneous Cream application twice daily
11207302|NCT03333681|Experimental|Refractory rheumatoid arthritis patients|Autologous mesenchymal stem cells
11207303|NCT03333668|Active Comparator|Lisdexamfetamine - Placebo|
11207304|NCT03333668|Active Comparator|Guanfacine - Placebo|
11207305|NCT03333668|Experimental|Lisdexamfetamine - Guanfacine|
11207306|NCT03333655|Other|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
11207307|NCT03333642|Experimental|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
11207308|NCT03333629|Experimental|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
11207309|NCT03333629|No Intervention|Usual care|Providers will not change their early detection strategies, but will be monitored.
11207310|NCT03333616|Experimental|Nivolumab+Ipilimumab|"Nivolumab and Ipilimumab are administered intravenously every 3 weeks for a total of 4 maximum doses. After combination therapy, nivolumab will be administered as monotherapy every 4 weeks.
~Doses are determined per protocol."
11207311|NCT03333603|Experimental|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
11207312|NCT03333590|Experimental|Cohort 1 (Minimal Efficacious Dose) rAAVrh74.MCK.GALGT2|N = 3 [2.5 x E13 vg/kg per leg, delivered bilaterally (total 5.0 x E13 vg/kg)]
11207313|NCT03333590|Experimental|Cohort 2 (Dose Escalation) rAAVrh74.MCK.GALGT2|N=3 [5 x E13 vg/kg per leg, delivered bilaterally (total 1.0 x E14 vg/kg)]
11207314|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
11207315|NCT03333564|Experimental|VD3 group|treated with 50,000 IU VD3 / week
11207316|NCT03333564|Experimental|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
11207317|NCT03333564|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
11207318|NCT03333564|Other|Control group|No intervention was given
11207319|NCT03333551|Experimental|Patients with AL cardiac amyloid|Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
11207320|NCT03333538|Experimental|Stage 1 (component A)|a single administration of component A (VSV) of vaccine
11207321|NCT03333538|Experimental|Stage 1 (component B)|a single administration of component B (Ad5) of vaccine
11207322|NCT03333538|Experimental|Stage 2 (Primary Group)|150 people who will receive the vaccine in the therapeutic scheme: the sequential introduction of components A and B with an interval of 21 days
11207323|NCT03333538|Placebo Comparator|Stage 2 (Controll Group)|50 people who will receive placebo in the therapeutic scheme: the sequential introduction of components A (placebo) and B (placebo) with an interval of 21 days
11207324|NCT03333525|Experimental|Insulin dose-CARB counting HPM group|HPM (high protein meal), contained 36 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
11207358|NCT03333343|Experimental|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
11207359|NCT03333343|Experimental|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
11207360|NCT03333343|Experimental|Arm F|EGF816 + gefitinib in expansion phase
11207325|NCT03333525|Experimental|Insulin dose-CARB counting HPFM group|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
11207326|NCT03333525|Experimental|Insulin dose-CARB+FPU counting-HPFM|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting plus fat-protein counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
11207327|NCT03333525|Active Comparator|Insulin dose-CARB counting SM group|SM (standart meal), contained 24 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
11207328|NCT03333512|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
11207329|NCT03333512|No Intervention|No nap|After each night with a 6.5-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead watch documentaries.
11207330|NCT03333499|Placebo Comparator|the control group|YanXinShi placebo pills
11207331|NCT03333499|Experimental|YanXinShi group|YanXinShi pills
11207332|NCT03333499|Active Comparator|Trimetazidine group|Trimetazidine pills
11207333|NCT03333499|Other|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
11207334|NCT03333486|Experimental|Treatment (fludarabine, cyclophosphamide, TBI, PBSCT)|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
11207335|NCT03333473|Experimental|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
11207336|NCT03333473|No Intervention|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
11207337|NCT03333460|Experimental|Active Comparator: Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
11207338|NCT03333460|Placebo Comparator|Sham Comparator: Sham rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with the software necessary for the operator to remain blind to the stimulation condition. Also, the software will be pre-programmed by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the individual resting motor threshold so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
11207339|NCT03333447||Study Population|Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, treated with VPRIV® at the beginning of the study. Patients should have one MRI data in the 5 previous years before starting VPRIV® treatment (up to 3 months after initiation of VPRIV®.
11207340|NCT03333434|Other|AFO - Ankle_7 group|AFO is active comparator, ANKLE7 is the experimental treatment
11207341|NCT03333434|Other|Ankle-7 - AFO group|AFO is active comparator, ANKLE7 is the experimental treatment
11207342|NCT03333408|Active Comparator|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
11207343|NCT03333408|No Intervention|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
11207344|NCT03333395|Active Comparator|HS Group (study group)|
11207345|NCT03333395|Active Comparator|S Group (control group)|
11207346|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
11207347|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
11207348|NCT03333369|Active Comparator|Madopar Arm|A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide
11207349|NCT03333369|Placebo Comparator|Placebo Arm|A single dose of a cachet filled with Dextrose
11207350|NCT03333356|Experimental|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
11207351|NCT03333356|No Intervention|Standard Arm|Surveillance
11207362|NCT03333330|Experimental|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.
~Intervention is related to the administration of contrast agents:
~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
11207363|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
11207364|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
11207365|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
11207366|NCT03333304|Experimental|PCT group|Procalcitonin measurement and Discontinuation of antimicrobials according to Procalcitonin kinetics
11207367|NCT03333304|No Intervention|Standard of care|Standard practice
11207368|NCT03333291|Experimental|Fecal transplantation|Duodenal transfer of healthy donor fecal suspension
11207369|NCT03333278|Active Comparator|Vitamins|intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)
11207370|NCT03333278|Other|Control|Hydrocortisone (50mg every 6 hours)
11207371|NCT03333265|Experimental|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
11207372|NCT03333265|Experimental|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
11207373|NCT03333265|Placebo Comparator|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
11207374|NCT03333252|Experimental|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
11207375|NCT03333252|Placebo Comparator|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
11207376|NCT03333239|Experimental|psychodynamic psychotherapy|
11207377|NCT03333239|Experimental|cognitive behavioral psychotherapy|
11207378|NCT03333239|Active Comparator|psychodynamic family intervention|
11207379|NCT03333226|Experimental|ARM lymph node preservation|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.
11207380|NCT03333226|Active Comparator|ARM lymph node removal|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed.
11207381|NCT03333213|Experimental|Gua Sha therapy|Patients' backs were first covered with Tumarol N Balsam. The study physician then applied a round-edged instrument (the inside smooth edged lip of a metal cap) to patients' skin in downward strokes. Patients were treated twice with a 7-day interval.
11207382|NCT03333213|No Intervention|Waitlist control group|Treatments in the control group were not regulated but patients were asked to continue their self-directed medical care. They were offered the Gua Sha therapy once the trial was concluded.
11207383|NCT03333187|Experimental|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
11207384|NCT03333187|Active Comparator|Arm B|Treatment with Ruxolitinib continuous therapy
11207385|NCT03333174|Experimental|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
11207386|NCT03333174|Active Comparator|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
11207387|NCT03333161|Experimental|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is >7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
11207388|NCT03333161|Active Comparator|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is <7.45."
11207389|NCT03333148|Experimental|Arm A - Nestle IMPACT Immunonutrition|Treatment Arm A (n=146) - Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
11207390|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
11207391|NCT03333135|Experimental|HK100 Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
11207490|NCT03332693|Active Comparator|No exercise|Volunteers will not participate in exercise
11207491|NCT03332693|Active Comparator|Light exercise|Volunteers will participate in one short exercise
11207392|NCT03333135|Sham Comparator|HK100 Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
11207393|NCT03333135|Experimental|UTMB Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
11207394|NCT03333135|Sham Comparator|UTMB Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
11207395|NCT03333122||Breast Conserving Therapy|Patient who undergo breast conserving therapy or breast conserving therapy with oncoplastic therapies will complete the BREAST-Q Lumpectomy survey module.
11207396|NCT03333122||Mastectomy|Patients who undergo mastectomy will complete the BREAST-Q Mastectomy survey module.
11207397|NCT03333122||Mastectomy with Reconstruction|Patient who undergo breast reconstruction will complete the BREAST-Q Reconstruction survey module. This group will be further subdivided based on implant or autologous tissue reconstruction.
11207398|NCT03333109|Experimental|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
11207399|NCT03333109|Experimental|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
11207400|NCT03333109|Placebo Comparator|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
11207401|NCT03333096|Other|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery
~Ocusweep system compared to neuropsychological testing"
11207402|NCT03333083|Experimental|Raltegravir + Lamivudine|
11207403|NCT03333070|Active Comparator|Treatment Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.
~After 12 weeks of treatment they will be randomized: treated arm will receive probiotic containing Lactobacillus reuteri for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
11207404|NCT03333070|Placebo Comparator|Placebo Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.
~After 12 weeks of treatment they will be randomized: control arm will receive placebo for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
11207405|NCT03333057|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
11207406|NCT03333057|Experimental|NOV03 2 times daily (BID)|100%Perfluorohexyloctance solution 2 times daily (BID)
11207407|NCT03333057|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
11207408|NCT03333057|Placebo Comparator|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
11207409|NCT03333044|Experimental|CHW-led health coaching|Group sessions
11207410|NCT03333044|Experimental|HIT-enabled & CHW led|Supportive care enabled by mobile devices.
11207411|NCT03333044|Experimental|CHW & Physician Feedback|Patient setting progress communicated to physician via PHI
11207412|NCT03333031|Experimental|HS-196|HS-196 will be administered intravenously as a single dose
11207413|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
11207414|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
11207415|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
11207416|NCT03333005|Experimental|APX001 with Standard of Care Anti-fungal agent|
11207417|NCT03332992|Experimental|Viral changes + General intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
11207418|NCT03332992|Experimental|Viral changes + Behavioral intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
11207419|NCT03332992|Experimental|Viral changes + Accountability|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
11207420|NCT03332992|Experimental|Protect others + General intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
11207421|NCT03332992|Experimental|Protect others + Behavioral intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
11207422|NCT03332992|Experimental|Protect others + Accountability|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
11207492|NCT03332693|Active Comparator|Heavy exercise|Volunteers will participate in heavy exercise
11207423|NCT03332966||Participants|"The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.
~The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission."
11207424|NCT03332953|Other|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
11207425|NCT03332940|Experimental|Tc99m-sulfur colloid + Tc99m-tilmanocept|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
11207426|NCT03332927|Experimental|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
11207427|NCT03332927|Active Comparator|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
11207428|NCT03332914|Active Comparator|First group|control group fisrt and after washing out Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
11207429|NCT03332914|Active Comparator|Second group|"Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
~after washing out control group"
11207430|NCT03332888|Experimental|Interventional Group|For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.
11207431|NCT03332875|Experimental|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
11207432|NCT03332875|Experimental|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
11207433|NCT03332862|Experimental|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
11207434|NCT03332862|Active Comparator|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
11207435|NCT03332849|Experimental|Cohort 1|T1DM: Multiple dose subcutaneous administration
11207436|NCT03332849|Experimental|Cohort 2|T1DM: Multiple dose subcutaneous administration
11207437|NCT03332849|Experimental|Cohort 3|T2DM: Multiple dose subcutaneous administration
11207438|NCT03332849|Experimental|Cohort 4|T2DM: Multiple dose subcutaneous administration
11207439|NCT03332836|Experimental|Cohort 1|Single dose subcutaneous administration (Dose A)
11207440|NCT03332836|Experimental|Cohort 2|Single dose subcutaneous administration (Dose B)
11207441|NCT03332836|Experimental|Cohort 3|Single dose subcutaneous administration (Dose C)
11207442|NCT03332823|Experimental|SME Ambassadors training & program|- SME Ambassadors will participate in train-the-ambassador workshops and provide voluntary services and promote mental well-being activities to vulnerable groups.
11207443|NCT03332810|Experimental|SME family based physical activity|Adults and family members will participate into one core session and one booster session
11207444|NCT03332810|Active Comparator|Gathering activity|Adults and family members will participate into two gathering activities
11207445|NCT03332797|Experimental|Dose Escalation: GDC-9545|During dose escalation, postmenopausal participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).
11207446|NCT03332797|Experimental|Dose Escalation: Cohort B0: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose lower than the MTD or MAD determined in single-agent dose escalation, in combination with the label-recommended dose of palbociclib.
11207447|NCT03332797|Experimental|Dose Expansion: Cohort A1: GDC-9545 Dose 1|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 1).
11207448|NCT03332797|Experimental|Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 1) in combination with an approved LHRH agonist.
11207449|NCT03332797|Experimental|Dose Expansion: Cohort A3: GDC-9545 Dose 2|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 2).
11207450|NCT03332797|Experimental|Dose Expansion: Cohort A4: GDC-9545 Dose 2 + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants at a dose that is less than or equal to the MTD/MAD (Dose 2) in combination with an LHRH agonist.
11207451|NCT03332797|Experimental|Dose Expansion: Cohort A5: GDC-9545 Dose 3|GDC-9545 will be administered to postmenopausal participants as a single-agent at a dose that is less than or equal to the MTD/MAD (Dose 3).
11207452|NCT03332797|Experimental|Dose Expansion: Cohort B1: GDC-9545 + Palbociclib|GDC-9545 will be administered to postmenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib.
11207453|NCT03332797|Experimental|Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH|GDC-9545 will be administered to pre- or perimenopausal participants, at a dose that is less than or equal to the MTD/MAD, in combination with the label-recommended dose of palbociclib and an approved LHRH agonist.
11207454|NCT03332797|Experimental|Dose Expansion: Cohort C1: GDC-9545 Dose 2 +/- Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2) as a single agent for 14 days, followed by treatment with either GDC-9545 (Dose 2) plus palbociclib or GDC-9545 (Dose 2) alone for the duration of the study, as determined by the investigator.
11207455|NCT03332797|Experimental|Dose Expansion: Cohort C2: GDC-9545 Dose 2 + Palbociclib|GDC-9545 will be administered to postmenopausal participants at a pre-defined dose level (Dose 2), in combination with the label-recommended dose of palbociclib.
11207456|NCT03332797|Experimental|Dose Expansion: Cohort X: GDC-9545 Dose 3|GDC-9545 will be administered at a pre-defined dose level (Dose 3) to postmenopausal participants currently receiving clinical benefit with GDC-0927 or GDC-0810 on Studies GO29656 (NCT02316509) or GO29642 (NCT01823835), respectively, upon completion of their studies.
11207457|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
11207458|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
11207459|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
11207460|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
11207461|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
11207462|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
11207463|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
11207464|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
11207465|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
11207466|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
11207467|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
11207468|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
11207469|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
11207470|NCT03332784|Placebo Comparator|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
11207471|NCT03332771|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two tablets, and two glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day
11207472|NCT03332771|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as one tablet and one sotagliflozin-matching placebo tablet, and two glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day
11207473|NCT03332771|Active Comparator|Glimepiride|Two sotagliflozin-matching placebo tablets, and combination of 2 glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day
11207474|NCT03332771|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets and two glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day
11207475|NCT03332758||RD treated with vitrectomy|Vitreous fluid from retinal detachment treated with pars plana vitrectomy
11207476|NCT03332758||RD treated with external drainage|Subretinal fluid from retinal detachment treated with external drainage.
11207477|NCT03332758||Macular holes treated with vitrectomy|Vitreous fluid from patients treated for macular hole
11207478|NCT03332758||ERM treated with vitrectomy|Vitreous fluid from patients treated for epiretinal membrane
11207479|NCT03332745||Severe aortic stenosis|Patients with severe aortic stenosis who are scheduled to undergo aortic valve replacement surgery
11207480|NCT03332745||Control group|Patients scheduled to undergo non-aortic valve cardiac or elective ascending aortic surgery
11207481|NCT03332732|Experimental|Part 1A|In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..
11207482|NCT03332732|Experimental|Part 1B|In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.
11207483|NCT03332732|Experimental|Part 2 - 2A|Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022
11207484|NCT03332732|Experimental|Part 2 - 2B|Multiple dose administration of High Dose VNRX-5133 + VNRX-5022
11207485|NCT03332732|Placebo Comparator|Part 2 - 2C|Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)
11207486|NCT03332719|Active Comparator|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
11207487|NCT03332719|Experimental|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
11207493|NCT03332680|Experimental|EmbryoGlue® (laboratory culture medium)|"laboratory culture medium
~laboratory embryo culture medium, embryos are placed in this media prior to transfer into uterus via embryo transfer procedure to facilitate IVF. EmbryoGlue contains Hyaluronic acid."
11207494|NCT03332680|Active Comparator|Standard control medium|"laboratory culture medium
~In standard procedure embryos are placed in a media prior to transfer into uterus via embryo transfer procedure to facilitate IVF."
11207495|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
11207496|NCT03332654||Multiple sclerosis|Prevalence and risk factor of stress urinary incontinence in women with multiple sclerosis and included in the database over 15 years from December 1999 to June 2014, who had undergone a urodynamic test
11207497|NCT03332641|Experimental|Citron peel Extract|Citron peel extract for 12 weeks
11207498|NCT03332641|Placebo Comparator|Placebo|Placebo for 12 weeks
11207499|NCT03332628|Other|Microneedle application|This is the only arm of the study. Nine sites on the upper arm will be identified, and baseline measurements of trans-epidermal water loss, electrical resistance, hydration, color, and pH of the skin will be made at every site. At three of the sites a small microneedle patch will be applied to the skin. Microneedle application will only occur once on the first day of the study, and the microneedle patches will then be discarded. The sites will be covered with a small patch secured in place with medical tape; three of the other sites that did not receive microneedle application will also be covered with patches. The last three sites will not have any microneedle application and will not be covered with patches. Measurements will be repeated daily at all nine sites for four consecutive days after the day of microneedle application (trans-epidermal water loss measurements will only be made on day 1).
11207500|NCT03332615|Active Comparator|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
11207501|NCT03332615|Placebo Comparator|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
11207502|NCT03332602|Experimental|free FeSO4|wheat bread fortified with free FeSO4
11207503|NCT03332602|Experimental|free FeSO4 and empty microspheres|wheat bread fortified with free FeSO4, and empty microspheres
11207504|NCT03332602|Experimental|free FeSO4 with eudragit polymer|wheat bread fortified with free FeSO4, and eudragit polymer
11207505|NCT03332602|Experimental|free FeSO4 with Hyaluronic Acid|wheat bread fortified with free FeSO4, and hyaluronic acid
11207506|NCT03332602|Experimental|encapsulated FeSO4 3.2%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading
11207507|NCT03332602|Experimental|encapsulated FeSO4 20%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 20% Fe loading
11207508|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading, and encapsulated Vitamin A as microspheres
11207509|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A, free folicacid|wheat bread fortified with encapsulated FeSO4 as microsphere with 3.2% Fe loading, encapsulated Vitamin A as microspheres and free folic acid
11207510|NCT03332602|Experimental|FeSO4 embedded in Hyaluronic Acid|wheat bread fortified with FeSO4 that is embedded in hyaluronic acid.
11207511|NCT03332589|Experimental|Monotherapy Safety Run-in: E6201|"E6201 320 mg/m^2 administered IV over 2 hours twice weekly on Days 1, 4, 8, 11, 15 and 18, repeated every 28 days (=1 cycle).
~Dose reductions for toxicity are 240 mg/m^2 (Dose Level -1) and 160 mg/m^2 (Dose Level -2) twice weekly."
11207512|NCT03332589|Experimental|Combination Safety Run-in: E6201 Plus Dabrafenib|Dose Level 1: E6201 320 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -1: E6201 240 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -2: E6201 240 mg/m^2 twice weekly plus dabrafenib 100 mg BID. Dose Level -3: E6201 160 mg/m^2 twice weekly plus dabrafenib 100 mg BID Dose Level -4: E6201 160 mg/m^2 twice weekly plus dabrafenib 75 mg BID. Dose Level -5: E6201 160 mg/m^2 twice weekly plus dabrafenib 50 mg BID.
11207513|NCT03332589|Experimental|Expansion: E6201 Plus Dabrafenib|A total of up to N=18 will be treated at the E6201 plus dabrafenib combined MTD.
11207514|NCT03332576|Experimental|Cohort 1|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)
~Low dose cyclophosphamide"
11207515|NCT03332576|Experimental|Cohort 2|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)
~Low dose cyclophosphamide"
11207516|NCT03332576|Experimental|Cohort 3|"3 Doses DPX-Survivac (1 prime, 2 boost q8w)
~Low dose cyclophosphamide"
11207517|NCT03332576|Experimental|Cohort 4|"5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)
~Low dose cyclophosphamide"
11207518|NCT03332576|Experimental|Cohort 5|"5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)
~Low dose cyclophosphamide"
11207519|NCT03332563|Experimental|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
11207520|NCT03332563|No Intervention|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
11207521|NCT03332550||purulent peritonitis|Hinchey 3
11207522|NCT03332550||faecal peritonitis|Hinchey 4
11207523|NCT03332537|No Intervention|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
11207559|NCT03332303|Placebo Comparator|Placebo Comparator: Placebo (Test vehicle cream) Vaginal Cream|"Placebo (Test vehicle cream) Vaginal Cream, administered once daily for 7 days.
~Intervention: Drug: Placebo (Test vehicle cream) Vaginal Cream"
11207560|NCT03332290|Active Comparator|sport training|training course lasting 10 days. It included 10 days of multisports practice once (2h) per day.
11207561|NCT03332290|Experimental|diving|diving course lasting 10 days. It included 10 days of diving once (2h) per day. Diving will be carried out using air at a maximum depth of 30-meters
11207524|NCT03332537|Experimental|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
11207525|NCT03332524|Experimental|Arm 1 Product SP160412|oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.
11207526|NCT03332524|Placebo Comparator|capsules Ibuprofen&placebo|2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,
11207527|NCT03332524|Placebo Comparator|Capsule Chlorpheniramin&placebo|capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route
11207528|NCT03332511|Experimental|Investigational arm|Oral nilotinib 300mg twice daily with a 12-hour interval
11207529|NCT03332498|Experimental|Pembrolizumab and Ibrutinib|"Pembrolizumab intravenously (IV): 200 mg every 3 weeks (Q3W).
~Ibrutinib by mouth (PO): Phase I Dose Escalation at doses of 420 mg daily (cohort 0) and 560 mg daily (cohort 1);. Phase II treatment at Recommended Phase II dose."
11207530|NCT03332485|Experimental|ECP Colon Prep Kit|
11207531|NCT03332485|Active Comparator|MoviPrep®|
11207532|NCT03332472|Experimental|Telemedicine group|Telematics visit in front of the conventional visit face to face
11207533|NCT03332472|Placebo Comparator|Conventional group|Group with conventional medical visit
11207534|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
11207535|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
11207536|NCT03332446|Experimental|cooling|strength training and cold water immersion
11207537|NCT03332446|No Intervention|control|strength training and no cold water immersion
11207538|NCT03332433|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
11207539|NCT03332433|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
11207540|NCT03332420||Observational 1|Huaiqihuang Granule
11207541|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
11207542|NCT03332420||Observational 3|Standard treatment
11207543|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
11207544|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
11207545|NCT03332381|Active Comparator|Attention training technique|
11207546|NCT03332381|Active Comparator|Mindful self-compassion|
11207547|NCT03332368||TCM exposure group|TCM exposure group were treated with traditional Chinese medicine while the other do not treated with that
11207548|NCT03332355|Experimental|PAC-1 in combination with temozolomide|Temozolomide (PO) will be dosed at 150 mg (adjusted for body size area [m2]) daily for 5 days starting on day 8 at cycle 1, and then for each successive cycle. In Component 2, the first PAC-1 dose will be 1 dose level lower than the PAC-1 MTD established in Component 1, and the maximum dose will not exceed 450 mg. PAC-1 will be taken in the morning on days 1-21 in each 28-day cycle.
11207549|NCT03332342|Experimental|Daily rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.
11207550|NCT03332342|Active Comparator|Weekly rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.
11207551|NCT03332342|Experimental|Occasional rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions
11207552|NCT03332329|Experimental|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
11207553|NCT03332316|Placebo Comparator|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
11207554|NCT03332316|Experimental|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
11207555|NCT03332316|Experimental|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
11207556|NCT03332316|Experimental|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
11207557|NCT03332303|Experimental|Experimental: Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC)|"Estradiol Vaginal Cream, USP, 0.01%, administered once daily for 7 days.
~Intervention: Drug: Estradiol Vaginal Cream, USP, 0.01%"
11207558|NCT03332303|Active Comparator|Active Comparator: Estrace® Cream|"Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%), administered once daily for 7 days.
~Intervention: Drug: Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%)"
11207599|NCT03332017|Experimental|Arm A|Approximately 140 subjects to receive BGB-3111 and obinutuzumab
11207562|NCT03332264|Experimental|Drug coated balloon catheter|"PTA with paclitaxel coated SeQuent Please OTW"
11207563|NCT03332264|Active Comparator|Drug coated stent|"PTA with paclitaxel coated Eluvia Vascular Stent System"
11207564|NCT03332264|Active Comparator|Uncoated stent|PTA with bare nitinol stent (as commonly used in site)
11207565|NCT03332251|Experimental|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
11207566|NCT03332251|No Intervention|Control|No treatment will be provided for control participants.
11207567|NCT03332238|Placebo Comparator|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
11207568|NCT03332238|Active Comparator|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
11207569|NCT03332225|Experimental|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
11207570|NCT03332225|Placebo Comparator|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
11207571|NCT03332225|Experimental|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
11207572|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
11207573|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
11207574|NCT03332199|No Intervention|Control|Participants in the control group received standard treatment from oncologists and nurses at Hanoi Medical University Hospital.
11207575|NCT03332199|Experimental|Intervention|In addition to standard care provided by oncologists and nurses at Hanoi Medical University Hospital as described above, participants assigned to the intervention group received the psychoeducational intervention delivered by the nurse researcher.
11207576|NCT03332186|Experimental|Mild Renal Impairment|Mild renal impairment defined as eGFR 60 to <90 mL/min/1.73 m^2
11207577|NCT03332186|Experimental|Moderate renal impairment|Moderate renal impairment defined as eGFR 30 to <60 mL/min/1.73 m^2
11207578|NCT03332186|Experimental|Severe renal impairment|Severe renal impairment defined as eGFR <30 mL/min/1.73 m^2, not requiring dialysis
11207579|NCT03332186|Experimental|Normal renal function|Normal renal function defined as eGFR ≥90 mL/min/1.73 m^2
11207580|NCT03332173|Experimental|BGB-3111|
11207581|NCT03332160|Active Comparator|Standard of Care|Standard home lymphedema care
11207582|NCT03332160|Experimental|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
11207583|NCT03332147|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11207584|NCT03332147|Active Comparator|reference group-Earlysense system|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11207585|NCT03332134|Experimental|Married Couple Dyad|Husband-wife dyads will receive the intimate partner violence (IPV) intervention program over the course of six weeks.
11207586|NCT03332134|No Intervention|Control Group|Husband-wife dyads in the control group will not receive an intervention.
11207587|NCT03332121|Experimental|B001,B001 dose escalation|5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
11207588|NCT03332108|Experimental|Intervention|Those allocated to the intervention arm will be enrolled in the mHealth intervention (EpxBreastfeeding) for six months, and will also be asked about breastfeeding status at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
11207589|NCT03332108|Other|Control|Those in the control arm will be asked about breastfeeding status (exclusive, supplementing, or formula only) at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
11207590|NCT03332095|Experimental|Cohort 1: DOR|Participants will receive a single dose of DOR at study entry (Day 0).
11207591|NCT03332095|Experimental|Cohort 2: DOR/3TC/TDF|Participants will receive DOR/3TC/TDF from Day 0 through Week 96.
11207592|NCT03332082|Experimental|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
11207593|NCT03332069|Experimental|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
11207594|NCT03332069|Active Comparator|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
11207595|NCT03332056|Active Comparator|Belladonna and Opium (B&O) suppository|A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation. The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine. Opium is compound drug that is composed of 20 alkaloids. The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
11207596|NCT03332056|Placebo Comparator|Placebo Suppository|placebo suppository
11207597|NCT03332043|Experimental|HIRREM|Subjects in the experimental arm will receive an in-office, open-label course of acoustic stimulation linked to brain activity (High-resolution, relational, resonance-based, electroencephalic mirroring, HIRREM).
11207598|NCT03332043|Active Comparator|Ambient Nature Sounds|Subjects in the active comparator arm will receive an in-office, open-label course of acoustic stimulation not linked to brain activity (ambient natures sounds).
11207601|NCT03332004|Experimental|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
11207602|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
11207603|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
11207604|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
11207605|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
11207606|NCT03331952||Invasive pneumococcal disease study (PCV-D)|"Prospective study of children with invasive pneumococcal disease / probable bacterial meningitis (PCV-D)
~Clinical procedures
~At study enrolment:
~Admission clinical findings / laboratory results will be recorded.
~A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status, household structure, environmental exposures, and recent antimicrobial use.
~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) may be performed as part of a child's diagnostic work up. CXRs will be read and interpreted primarily by the AHC radiologists. All CXR will subsequently be re-read by two study clinicians and interpreted according to the WHO paediatric radiologic pneumonia criteria.
~Laboratory procedures
~• Residual routine clinical specimens further analysed as part of the study protocol:
~Blood and cerebrospinal fluid culture specimens.
~EDTA / serum specimens.
~Urine."
11207607|NCT03331952||Pneumonia study (PCV-P)|"Prospective study of children hospitalised with clinical and/or radiologic pneumonia (PCV-P)
~Clinical procedures As described for PCV-D.
~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) is performed on all children with an admission diagnosis of pneumonia. CXRs will be handled as described for PCV-D.
~Laboratory procedures
~Study specific specimens:
~o Nasopharyngeal swab at enrolment.
~Residual routine clinical specimens further analysed as part of the study protocol:
~As described for PCV-D."
11207608|NCT03331952||Pneumococcal colonisation study (PCV-C)|"Cross-sectional pneumococcal colonisation surveys in children attending the AHC out-patient department (PCV-C)
~Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees.
~Clinical procedures
~• Subjects will be recruited from the OPD waiting area after nurse triage. A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status (by review of the handheld immunisation card where possible), household structure, environmental exposures, and recent antimicrobial use.
~Laboratory procedures • Study specific specimens:
~o Nasopharyngeal swab at enrolment. A nasopharyngeal swab will be collected from each participant and these will be processed as described for PCV-P."
11207609|NCT03331939|Experimental|No stimulation|All patients will receive three different stimulations
11207610|NCT03331939|Other|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
11207611|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
11207612|NCT03331913|Active Comparator|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
11207613|NCT03331913|Experimental|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
11207614|NCT03331900|Placebo Comparator|Placebo|
11207615|NCT03331900|Active Comparator|COR388 TBD mg|
11207616|NCT03331887|Active Comparator|E-max CAD crowns retained with Fiber Reinforced Composite Post|"The modulus of elasticity of FRC post is (18-22 GPa) resembling that of dentin. Ideally the remaining tooth, the fiber post and the composite cement create a monoblock in which the loads are uniformly dissipated, ensuring a behavior similar to healthy teeth with a lower risk of root fracture. Using lithium disilicate e.max restorations is documented in literature as a successful restoration."
11207617|NCT03331887|Experimental|E-max CAD Endocrowns|Endocrowns have several advantages over conventional crowns like adequate function and esthetic with less chair time reduced number of interfaces in the restorative system. Stress concentration is less because of the reduction in the nonhomogenous material present. The preparation design is conservative compared to the traditional crown. Supragingival margin prevents interferences with periodontal tissues so involvement of the biological width is minimal. The application and polymerization of resins is also better controlled. Emax ceramic material have a high mechanical strength and are capable of being acid etched, with the adhesive capacity of adhesive systems and resinous cements, made it possible to restore endodontically treated teeth, without cores and intraradicular posts.
11207618|NCT03331874||Basal Cell Carcinoma|Diagnosis of Basal Cell Carcinoma by Reflectance confocal microscopy
11207619|NCT03331861|Experimental|Metformin|Metformin for 6 months
11207620|NCT03331861|Placebo Comparator|Placebo|Matched placebo for 6 months
11207623|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
11207624|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>
~> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
11207625|NCT03331822|Experimental|Light|High illuminance ,white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux.
11207626|NCT03331822|No Intervention|No Light|Ambient, standard white fluorescent environmental light will serve as control.
11207627|NCT03331809|Active Comparator|Control|
11207628|NCT03331809|Experimental|Two-hand|
11207629|NCT03331796|Experimental|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
11207630|NCT03331796|Experimental|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
11207631|NCT03331796|Placebo Comparator|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
11207632|NCT03331783|Experimental|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.
~The difference between the four patches is that they are made of four different adhesives.
~The primary endpoint is measured after 8 hours and 24 hours."
11207633|NCT03331770|Experimental|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
11207634|NCT03331757|Experimental|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207635|NCT03331757|Experimental|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207636|NCT03331757|Experimental|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207637|NCT03331757|Experimental|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207638|NCT03331757|Experimental|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207639|NCT03331757|Experimental|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207640|NCT03331757|Experimental|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
11207641|NCT03331731|Experimental|Single arm|Single Arm
11207642|NCT03331718|No Intervention|Control|Pancreaticojejunostomy with duct-to-mucosa anastomosis is performed as usual.
11207643|NCT03331718|Active Comparator|PGA felt reinforcement|In addition to usual pancreaticojejunostomy, PGA felt is used in duplicate.
11207644|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
11207645|NCT03331692|Other|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.
~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
11207646|NCT03331692|Other|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
11207647|NCT03331679|Experimental|2 Wk HIIT|2 weeks of High Intensity Interval Training
11207648|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
11207649|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
11207650|NCT03331653|Experimental|Dry Needling and Ischemic Compression at the Trigger Point|Dry Needling and Ischemic Compression at the Trigger Point
11207651|NCT03331653|Active Comparator|Intervention at 1.5 cm from the Trigger Point|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
11207652|NCT03331640|Experimental|OFF|
11207653|NCT03331640|Experimental|FOLFIRI|
11207654|NCT03331627|Active Comparator|STR001-IT/STR001-ER|
11207655|NCT03331627|Active Comparator|STR001-IT/STR001-ER Placebo|
11207657|NCT03331614|No Intervention|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
11207658|NCT03331614|Active Comparator|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
11207659|NCT03331588|Active Comparator|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted thoracic surgery, no use of rib-spreader.
11207660|NCT03331588|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted thoracic surgery, no use of rib-spreader.
11207661|NCT03331575|Experimental|Arm1(Hypofractionated Radiotherapy)|Hypofractionated Radiotherap（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
11207662|NCT03331575|Placebo Comparator|Arms2（Conventional Radiotherapy）|Conventional Radiotherapy（PTV-G60Gy/30Fx,2Gy/Fx; PTV-C 50.4Gy/30Fx, 1.8Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
11207663|NCT03331562|Active Comparator|pembrolizumab & paricalcitol|pembrolizumab 200 mg IV q 3 weeks and paricalcitol 25 mcg IV 3 xs per week
11207664|NCT03331562|Placebo Comparator|pembrolizumab & placebo|pembrolizumab 200 mg IV q 3 weeks & placebo- normal saline IV 3 xs per week
11207665|NCT03331549||Myocardial infarction|
11207666|NCT03331549||Control group|
11207667|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
11207668|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
11207669|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
11207670|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
11207671|NCT03331523|Experimental|Calcipotriene/betamethasone dipropionate|
11207672|NCT03331523|Active Comparator|Taclonex®|
11207673|NCT03331523|Placebo Comparator|Placebo|
11207674|NCT03331497|Experimental|Tonsillotomy|The patients diagnosed with PFAPA will have tonsillotomy performed in one month from randomisation.
11207675|NCT03331497|No Intervention|Follow up|The patients diagnosed with PFAPA will be monitored for 3 months time. If the symptoms still persist, tonsillectomy will be performed
11207676|NCT03331484|Other|Ticagrelor and Rivaroxaban|All participants will be prescribed ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily for a year.
11207677|NCT03331471|Active Comparator|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
11207678|NCT03331471|Experimental|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
11207679|NCT03331458|Experimental|subjects with prostate cancer|
11207680|NCT03331445|Experimental|160 ppm Nitric Oxide|
11207681|NCT03331432|Placebo Comparator|Placebo|Taking daily placebo capsules for 4 weeks
11207682|NCT03331432|Experimental|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
11207683|NCT03331419||Males with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
11207684|NCT03331419||Females with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
11207685|NCT03331406|Experimental|12-week physical activity program|"The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.
~At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.
~Exercise Trainer --A exercise trainer will be assigned to design a physical activity program."
11207686|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
11207687|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
11207688|NCT03331380|Other|Group A|Group A includes 600 healthy adult volunteers of both sexes with-out known cardiovascular disease
11207689|NCT03331380|Other|Group B|Group B includes 500 adult subjects of both sexes with known sta-ble cardiovascular disease including adults with stable coronary ar-tery disease after myocardial infarction; adults with heart failure and reduced left ventricular systolic function; adults with pulmonary artery hypertension; adults with congenital heart disease including cardiac shunts; adults with valvular heart disease including aortic stenosis, mitral regurgitation, and tricuspid regurgitation; and adults with metallic cardiovascular implants (such as coronary and periph- eral artery stents) known to be safe for CMR at 1.5T
11207690|NCT03331380|Other|Group C|Group C includes 500 adult subjects of both sexes with known non-cardiovascular disease
11207691|NCT03331367|Active Comparator|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
11207692|NCT03331367|Active Comparator|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
11207693|NCT03331367|Active Comparator|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
11207694|NCT03331367|Active Comparator|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
11207695|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
11207696|NCT03331354|Experimental|Compass|a distant learning vocational program
11207697|NCT03331341|Experimental|Treatment (APVD)|Patients receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
11207698|NCT03331328|Sham Comparator|Control/sham|The CO2 laser will not be activated but the same procedure of moving the probe inside the vagina in a systematic manner including depressing the foot pedal at similar frequency will be performed. The smoke evacuator will also be activated, laser eye glasses and masks worn by the laser team and the subject. However, the laser will remain in the standby mode.
11207699|NCT03331328|Active Comparator|Treated|Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
11207700|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
11207701|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
11207702|NCT03331302|Active Comparator|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
11207703|NCT03331302|Experimental|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
11207704|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
11207705|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
11207706|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
11207707|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
11207708|NCT03331276|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with high Sn-2 Palmitate, Alpha Lactalbumin and Osteopontin to better mimic human milk.
11207709|NCT03331276|Active Comparator|Brand|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
11207710|NCT03331263|Experimental|Abdominal application of 2% CHG|
11207711|NCT03331263|Experimental|Groin application of 2% CHG|
11207712|NCT03331263|No Intervention|Control treatment with no application|
11207713|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously
~Each cycle contains 21 days
~Dosing is per the FDA label for other cancers"
11207714|NCT03331237|Active Comparator|LVS group|interscalene injection
11207715|NCT03331237|Active Comparator|ISO group|in this group all patients will receive ISO block.
11207716|NCT03331224|Experimental|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
11207717|NCT03331224|Active Comparator|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
11207718|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
11207719|NCT03331198|Experimental|Phase 1 JCAR017 monotherapy|Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
11207720|NCT03331198|Experimental|Phase 1 JCAR017 + ibrutinib|Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose + ibrutinib
11207721|NCT03331198|Experimental|Phase 2 JCAR017 monotherapy|Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
11207722|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
11207723|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
11207724|NCT03331172|Experimental|High Intensity Focused Ultrasound|
11207725|NCT03331159|Experimental|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
11207726|NCT03331159|Active Comparator|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
11207727|NCT03331146|Placebo Comparator|Control group|saline infusion will be administered after induction of general anesthesia
11207728|NCT03331146|Active Comparator|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
11207729|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
11207730|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
11207731|NCT03331120|Active Comparator|Control Group|"1--Control group
~. Conventional treatment:
~moist hot pack.
~manual therapy.
~Therapeutic Exercise.
~Home program routine."
11207732|NCT03331120|Experimental|Study or Experimental Group|"2--Experimental or study group:
~moist hot pack.
~manual therapy.
~Therapeutic Exercise.
~Home program routine.
~ambulatory mirror image functional re-training through wearing 3D adjustable cervical thoracic Posture Corrective orthosis (CTPCO) For 10 weeks(3Times/week for 20 minutes)."
11207733|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
11208230|NCT03327987||181-365 days|181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
11207734|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
11207735|NCT03331081|Experimental|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
11207736|NCT03331081|Active Comparator|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
11207737|NCT03331081|Active Comparator|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
11207738|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
11207739|NCT03331055|Experimental|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
11207740|NCT03331055|Experimental|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
11207741|NCT03331055|No Intervention|Control|Conventional analgesic medication is offered.
11207742|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
11207743|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
11207744|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
11207745|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
11207746|NCT03331029|Other|transesophageal echocardiography|Comparison of 3D Ultrasound with transesophageal echokardiography
11207747|NCT03331016|Other|Waitlist Control Group|Waitlist Control Group will serve as control group for 6 months, receiving no intervention during that time but completing periodic surveys to assess outcomes among controls (knowledge, attitudes, behaviors). They will also later receive the intervention (training program) and be followed for 6 more months.
11207748|NCT03331016|Experimental|Intervention Group|Intervention Group will receive the intervention (training program) right away, then will be followed for 6 months.
11207749|NCT03331003|Experimental|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
11207750|NCT03331003|Placebo Comparator|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
11207751|NCT03330990|Other|Entrectinib / Midazolam|
11207752|NCT03330977|Other|Before and after use of pressure garments|"At inclusion, patients will only have medication prescription as usual but without pressure garments, and thus, for 4 months.
~4 months after inclusion, patients will continue medication but will also be prescribed pressure garments Then every 6 months, until 26 months, patients will come back to have new pressure garments (as usual practice)"
11207753|NCT03330964|Experimental|electroacupuncture group|The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
11207754|NCT03330964|No Intervention|control group|The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
11207755|NCT03330938|Experimental|CBI and Resilience|8 sessions total, once a week, 2 hours long each, consistent of 6 sessions of Cognitive-behavioral Intervention (CBI) plus 2 sessions to improve resilience strengths.
11207756|NCT03330938|Active Comparator|Cognitive-behavioral Intervention|8 sessions total, once a week, 2 hours long each. Cognitive-behavioral Intervention (CBI) without resilience strengthening.
11207757|NCT03330925|Experimental|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
11207758|NCT03330912|Experimental|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
11207759|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
11207760|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
11207761|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
11207762|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
11207763|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
11207764|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.
~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
11207765|NCT03330899|Active Comparator|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.
~Each dose = 0,5 ml"
11207766|NCT03330899|Placebo Comparator|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.
~Each dose = 0,5 ml"
11207767|NCT03330873|Experimental|Foley catheter|After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.
11207768|NCT03330873|Experimental|Disposable balloon uterine stent|After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.
11207769|NCT03330860|Experimental|Neuromarketing strategy|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
11207770|NCT03330860|Active Comparator|No-capsule group|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
11207771|NCT03330847|Active Comparator|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
11207772|NCT03330847|Active Comparator|Olaparib+Ceralasertib|All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
11207773|NCT03330847|Active Comparator|Olaparib+adavosertib|All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
11207774|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
11207775|NCT03330821|Experimental|Treatment (idarubicin, cytarabine, pevonedistat)|"INDUCTION: Patients receive idarubicin IV over 10-15 minutes on days 1-3, cytarabine IV over 1-3 hours on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Patients with gross residual disease on day 14 bone marrow may receive a second course of induction chemotherapy.
~CONSOLIDATION: Patients who achieve CR and will not undergo bone marrow transplant receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28-35 days for 4 courses in the absence of disease progression or unaccepted toxicity."
11207776|NCT03330808|Experimental|Epidural with general anesthesia|Epidural anesthesia with 0.2% ropivacaine 10 ml
11207777|NCT03330808|No Intervention|General anesthesia alone|Sevoflurane and nitrous oxide.
11207778|NCT03330795|Experimental|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
11207779|NCT03330782|Experimental|Elderly|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.
11207780|NCT03330782|Active Comparator|Adult|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.
11207781|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
11207782|NCT03330756|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
11207783|NCT03330756|Experimental|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
11207784|NCT03330743|No Intervention|Usual care|
11207785|NCT03330743|Placebo Comparator|Parent Mentor|
11207786|NCT03330743|Active Comparator|Parent Mentor with Positive Deviance|
11207787|NCT03330730|Experimental|Experimental|"Patients with oncological follow up and home-care service package IsereADOM:
~Objects connected to patients' home (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer) with graduated protocol for medical platform support.
~Digital linkbook (different from the medical file) accessible to the patient and the standard care actors.
~Referent sentinel: a field actor to coordinate the care. Preferred contact of the patient outside the center Motivational coaching: 1 to 2 axes to be defined by the investigator among the following axes (physical activity, nutrition and hydration, drug compliance, medical follow-up, chronic and moral pain, acceptance of the disease and treatments)."
11207788|NCT03330730|No Intervention|Control|Patients with oncological follow up only
11207789|NCT03330717|Placebo Comparator|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
11207790|NCT03330717|Experimental|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
11207791|NCT03330717|Experimental|General anesthesia with preoperative session of hypnosis|Patients interested in hypnosis but too anxious to have surgery while on hypnosis sedation will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation using technology of virtual reality
11207792|NCT03330704|Active Comparator|Standard Therapy|This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.
11207793|NCT03330704|Experimental|Balanced Therapy|This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach
11207794|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v1|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
11207795|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v2|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
11207796|NCT03330678|Experimental|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
11207797|NCT03330665|No Intervention|Control|No meditation
11207798|NCT03330665|Experimental|Intervention|Meditate using headspace app 3 times a week
11207799|NCT03330639|Experimental|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
11266717|NCT02927353|Experimental|DMB-3113|adalimumab biosimilar
11207800|NCT03330639|Placebo Comparator|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
11207801|NCT03330626|Active Comparator|IO group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the intake-output balance.
11207802|NCT03330626|Experimental|InBody group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the bioimpedance analysis (InBody S10).
11207803|NCT03330613|Other|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
11207804|NCT03330613|Active Comparator|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
11207805|NCT03330600|Experimental|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
11207806|NCT03330600|Placebo Comparator|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
11207807|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
11207808|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
11207809|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
11207810|NCT03330561|Experimental|PRS-343|
11207811|NCT03330548|Active Comparator|TeleMOVE!|Veterans randomized to the control arm will participate in TeleMOVE!, an arm of the Management of Overweight Veterans (MOVE!) program. TeleMOVE! is telehealth treatment program within the VA designed to improve the lives of Veterans by assisting with weight management and health promotion. This program includes daily interaction with in-home messaging technologies and clinician contact as needed
11207812|NCT03330548|Experimental|Culinary Rx|Veterans randomized to the experimental arm will participate in Culinary Rx. Culinary Rx is an online instructional cooking and nutrition course that healthcare professionals can prescribe to patients who need to transition away from a Standard American Diet to a more health-supportive, whole foods, plant-based lifestyle. In partnership with The Plantrician Project, this course will focus on teaching the foundational cooking skills needed for long-term behavioral change, coupled with lifestyle education around nutrition and resources that will help users successfully face the many challenges inherent to dietary change.
11207813|NCT03330535|Active Comparator|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
11207814|NCT03330535|Experimental|Reminders once a week|Participants will receive active reminders once a week.
11207815|NCT03330535|Experimental|Reminders three times a week|Participants will receive active reminders three times a week.
11207816|NCT03330535|Experimental|Daily reminders|Participants will receive active reminders daily.
11207817|NCT03330522|Experimental|Intervention|"The active intervention is Love, Sex, & Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
11207818|NCT03330522|Active Comparator|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
11207819|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
11207820|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
11207821|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
11207822|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
11207823|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=15)
11207824|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=15)
11207825|NCT03330496||Small infants|1-3 month-old infants (n=15)
11207826|NCT03330496||Older infants|3-6 month-old infants (n=15)
11207827|NCT03330483||Female Speedicath nelathon|Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
11207828|NCT03330483||Female nelathon|Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
11207829|NCT03330483||Male Speedicath tiemann|Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
11207830|NCT03330483||Male tiemann|Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion
11207831|NCT03330470|Experimental|exercise and carnosine supplementation|exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
11207832|NCT03330470|Experimental|exercise and supplementation with placebo|exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
11207833|NCT03330470|Experimental|stretching controls and carnosine supplementation|stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
11207834|NCT03330470|Experimental|stretching controls and supplementation with placebo|stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
11207835|NCT03330457|Experimental|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
11207836|NCT03330457|Experimental|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
11207837|NCT03330457|Experimental|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
11207838|NCT03330457|Experimental|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
11207839|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
11207840|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
11207841|NCT03330431|Experimental|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
11207842|NCT03330431|Experimental|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
11207843|NCT03330431|Active Comparator|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
11207844|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
11207845|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
11207846|NCT03330405|Experimental|Dose Level 0 Phase 1b|"Drug: Avelumab
~Drug: Talazoparib"
11207847|NCT03330405|Experimental|Dose Level -1 Phase 1b|"Drug: Avelumab
~Drug: Talazoparib"
11207848|NCT03330405|Experimental|Dose Level -2 Phase 1b|"Drug: Avelumab
~Drug: Talazoparib"
11207849|NCT03330405|Experimental|A1. NSCLC Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207850|NCT03330405|Experimental|A2. NSCLC PD-L1 Resistant DDR+ Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207851|NCT03330405|Experimental|B1. TNBC Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207852|NCT03330405|Experimental|B2. HR+BC DDR Defect +Assay Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207853|NCT03330405|Experimental|C1. Ovarian CA Recurrent Plat-Sensitive Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207854|NCT03330405|Experimental|C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207855|NCT03330405|Experimental|D.Urothelial CA Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207856|NCT03330405|Experimental|E1. CRPC Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207857|NCT03330405|Experimental|E2. CRPC DDR Defect +Assay Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207858|NCT03330405|Experimental|F: Advanced Solid Tumors with BRCA or ATM defect Phase 2|"Drug: Avelumab
~Drug: Talazoparib"
11207859|NCT03330392|Experimental|AGP|take two tablets per day (500 mg/day) for 8 weeks.
11207860|NCT03330392|Placebo Comparator|Placebo|take two tablets per day for 8 weeks.
11207861|NCT03330379|Experimental|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
11207862|NCT03330379|No Intervention|usual care|patients with usual care
11207863|NCT03330366|Experimental|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
11207864|NCT03330366|Placebo Comparator|Placebo|take two capsules per day for 8 weeks
11207865|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
11207866|NCT03330340||Percutaneous vertebroplasty|All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
11207867|NCT03330340||Conservative treatment|In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.
11207868|NCT03330327|Experimental|Part 1|Intravenous (IV) infusion of HM12470
11207869|NCT03330327|Experimental|Part 2: Sequence 1|Intravenous (IV) infusion of HM12470
11207870|NCT03330327|Experimental|Part 2: Sequence 2|Intravenous (IV) infusion of HM12470
11207871|NCT03330314|Experimental|Part 1|Intravenous (IV) infusion
11207872|NCT03330314|Experimental|Part 2: Cohort A|Intravenous (IV) infusion (Dose A)
11207873|NCT03330314|Experimental|Part 2: Cohort B|Intravenous (IV) infusion (Dose B)
11207874|NCT03330314|Experimental|Part 2: Cohort C|Intravenous (IV) infusion (Dose C)
11207875|NCT03330301||Exposed|"Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.
~Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
11207926|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
11207876|NCT03330301||Non-exposed|"Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.
~Controls: cohort of matched disease-free individuals"
11207877|NCT03330288||Patients with Hip OA stage I to III|Male and female patients from 45 to 75 of age with Hip osteoarthritis stage I to III
11207878|NCT03330288||Patients with Knee OA stage I to III|Male and female patients from 45 to 75 of age with knee osteoarthritis stage I to III
11207879|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
11207880|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
11207881|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
11207882|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
11207883|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
11207884|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
11207885|NCT03330262|Experimental|BALCAP prosthesis|Participants will be asked to perform a series of appropriate exercises daily at home wearing the BALCAP prosthesis for a period of 6 weeks. The training exercises will include: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, incorporating turns and movements other than straight forward walking, eyes open.
11207886|NCT03330262|No Intervention|Control|Participants will be asked to perform a series of appropriate exercises daily at home for a period of 6 weeks. The training exercises will include: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, incorporating turns and movements other than straight forward walking, eyes open.
11207887|NCT03330249|Experimental|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
11207888|NCT03330249|Active Comparator|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
11207889|NCT03330236|Experimental|Study arm|"All patients in the study arm will receive the anesthetic care guided by the SedLine EEG Brain Function Monitor in addition to the conventional monitors. In addition to the conventional/standard interventions of anesthetic care, an additional intervention related to this trial is the anesthetic depth management via the titration of the propofol and remifentanil infusion rates to maintain SEF and PSI in the targeted ranges based on the SedLine EEG monitoring."
11207890|NCT03330236|No Intervention|Control arm|All patients in the control arm will receive the anesthetic care guided by the conventional monitors only. Patients in the control arm will be monitored using the SedLine EEG Brain Function Monitor; however, the screen of this monitor will be covered by an opaque cloth and blinded to the anesthesia team.
11207891|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
11207892|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
11207893|NCT03330197|Experimental|Arm 1 - Closed|Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
11207894|NCT03330197|Experimental|Arm 2 - Open|Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
11207895|NCT03330184|Experimental|Berberine Hydrochloride group|2/day, 16 weeks
11207896|NCT03330184|Experimental|Bifidobacterium group|2/day, 16 weeks
11207897|NCT03330184|Experimental|Berberine Hydrochloride and Bifidobacterium group|2/day, 16 weeks
11207898|NCT03330184|Placebo Comparator|placebo|bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks
11207899|NCT03330171|Other|HIV-unexposed children|HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
11207927|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
11207928|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
11207900|NCT03330171|Other|HIV-exposed children|A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
11207901|NCT03330158|Experimental|ASTS device|Implantation of device ASTS (for ACTIVE TREATMENT SCOLIOSIS SYSTEM ) in children between 4 and 10
11207902|NCT03330145|Experimental|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
11207903|NCT03330145|Active Comparator|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
11207904|NCT03330132|Active Comparator|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207905|NCT03330132|Experimental|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207906|NCT03330132|Experimental|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207907|NCT03330132|Experimental|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207908|NCT03330132|Experimental|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207909|NCT03330132|Experimental|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207910|NCT03330132|Experimental|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207911|NCT03330132|Experimental|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207912|NCT03330132|Experimental|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207913|NCT03330132|Experimental|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207914|NCT03330132|Experimental|Alternating recombinant vaccine and adjuvanted vaccine|Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
11207915|NCT03330119|Experimental|Alternate Management|
11207916|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
11207917|NCT03330106|Experimental|Part A: Pevonedistat 25 mg/m^2 + Pevonedistat 50 mg/m^2|Pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
11207918|NCT03330106|Experimental|Part A: Pevonedistat 50 mg/m^2 + Pevonedistat 25 mg/m^2|Pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
11207919|NCT03330106|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or pevonedistat 20 mg/m^2 in combination with carboplatin plus paclitaxel 175 mg/m^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m^2 or 20 mg/m^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.
11207920|NCT03330093|Experimental|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
11207921|NCT03330093|Active Comparator|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
11207922|NCT03330080||Ecological momentary assessment (EMA)|The ecological momentary assessment (EMA) will be used for participants to complete surveys from home on two occasions each day over seven days.
11207923|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
11207924|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
11207925|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
11207929|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
11207930|NCT03330028|Experimental|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
11207931|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
11207932|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
11207933|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
11207934|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
11207935|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
11207936|NCT03329950|Experimental|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
11207937|NCT03329950|Experimental|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
11207938|NCT03329950|Experimental|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
11207939|NCT03329950|Experimental|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
11207940|NCT03329937|Experimental|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor >=1 cm) will receive niraparib (200 mg PO).
11207941|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
11207942|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
11207943|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.
~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles
~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
11207944|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.
~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles
~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
11207945|NCT03329898|Experimental|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
11207946|NCT03329898|Sham Comparator|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
11207947|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
11207948|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
11207949|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
11207950|NCT03329872||Patients group|Patients follow-up in hospital will have data collection
11207951|NCT03329859|Experimental|Interventional arm|"High resolution standardized laparoscopic cholecystectomy Patients in which laparoscopic cholecystectomy was performed after high Resolution standardization and Training of the OR Team according to the Standard."
11207952|NCT03329859|Active Comparator|Control arm|No 'High resolution standardized laparoscopic cholecystectomy' Patients in which laparoscopic cholecystectomy was performed in the conventional way without prior standardization
11207953|NCT03329846|Active Comparator|Nivolumab + Placebo|"Specified dose on specified day
~Participants will no longer receive BMS-986205 Placebo"
11207954|NCT03329846|Experimental|Nivolumab + BMS-986205|"Specified dose on specified day.
~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
11207955|NCT03329833|Experimental|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
11207956|NCT03329833|Experimental|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
11207957|NCT03329833|Experimental|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
11207958|NCT03329833|No Intervention|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
11207959|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
11207960|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
11207961|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
11207962|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
11207963|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
11207964|NCT03329807|Experimental|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
11207965|NCT03329807|Sham Comparator|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.
~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
11207966|NCT03329781|Experimental|Trial|350 mg of BCM-95, 1 capsule per day, for 21 days.
11207967|NCT03329781|Placebo Comparator|Control|350 mg of starch, 1 capsule per day, for 21 days
11207968|NCT03329755|Experimental|Experimental|
11207969|NCT03329755|Other|Standard|
11207970|NCT03329742|Placebo Comparator|Control protein diet arm|20% protein content
11207971|NCT03329742|Experimental|Low protein diet arm|10% protein content
11207972|NCT03329729||Hyperlipidemic patients|
11207973|NCT03329716|Other|Immediate Brace Weaning|Immediate weaning of brace
11207974|NCT03329716|Other|Gradual Brace Weaning|Nocturnal brace wearing for 6 months prior to stopping brace
11207975|NCT03329703|Experimental|Immediate-Treatment|This group will receive Project UPLIFT immediately after completing surveys.
11207976|NCT03329703|Active Comparator|Waitlist Control|This group will receive Project UPLIFT after waiting approximately 3 months to begin the intervention.
11207977|NCT03329690|Experimental|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
11207978|NCT03329690|Active Comparator|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
11207979|NCT03329690|Other|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
11207980|NCT03329690|Other|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
11207981|NCT03329677|Experimental|Transference-focused Psychotherapy (TFP)|Transference-focused psychotherapy is a psychodynamic talk therapy utilized in treating borderline personality disorder in men and women.
11207982|NCT03329664|Experimental|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
11207983|NCT03329664|Active Comparator|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
11207984|NCT03329651|Experimental|Metformin treatment|
11207985|NCT03329651|Placebo Comparator|Placebo treatment|
11207986|NCT03329638|Experimental|DE-127 Ophthalmic Solution low dose|
11207987|NCT03329638|Experimental|DE-127 Ophthalmic Solution medium dose|
11207988|NCT03329638|Experimental|DE-127 Ophthalmic Solution high dose|
11207989|NCT03329638|Placebo Comparator|Placebo Ophthalmic Solution|
11207990|NCT03329625|Experimental|Pathways Triple P|Families randomized to the Pathways Triple P received a 14 week home based intervention.
11207991|NCT03329625|Active Comparator|Services as Usual|Families randomized to the services as usual condition received services as usual through the Missouri Children's Division
11207992|NCT03329612|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
11207993|NCT03329612|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
11207994|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
11207995|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
11207996|NCT03329586|Experimental|Training|
11207997|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
11207998|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
11207999|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
11208000|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
11208001|NCT03329560|Experimental|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
11208002|NCT03329547|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= SKF101804 cefixime 400 mg test capsules and B= cefixime 400 mg reference capsules. Subjects will receive single oral dose of treatment A in treatment period 1 on Day 1 and treatment B in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
11208003|NCT03329547|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B= cefixime 400 mg reference capsules and A= SKF101804 cefixime 400 mg test capsules. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days. Subjects will receive single oral dose of treatment B in treatment period 1 on Day 1 and A in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
11208004|NCT03329534|Experimental|Subjects with GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.
11208005|NCT03329534|Active Comparator|Subjects without GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.
11208006|NCT03329521|Experimental|Multicomponent Initiative|A number of quality improvement initiatives will be provided at the CKD programs.
11208007|NCT03329521|No Intervention|Routine Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
11208008|NCT03329508|Experimental|P2B001|Fixed dose combination once daily capsule of pramipexole and rasagiline
11208009|NCT03329508|Experimental|rasagiline capsule|rasagiline Once daily capsule
11208010|NCT03329508|Experimental|Pramipexole capsule|Pramipexole once daily capsule
11208011|NCT03329508|Active Comparator|Pramipexole Extended Release|pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg
11208012|NCT03329495|Active Comparator|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
11208013|NCT03329495|Experimental|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
11208014|NCT03329482|Experimental|Pulse Ultrasound Group A|This is the Pulse Ultrasound group. Twenty five patients will be in this group.
11208015|NCT03329482|Experimental|Kneading Massage Group B|This is kneading massage group . Also 25 patients will be in this group.
11208016|NCT03329469||Experimental: 1: Toshiba CT-FFR Arm|All patients who consent will receive Toshiba CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
11208017|NCT03329456|Other|Ropivacaine|Single arm intervention
11208018|NCT03329443|Placebo Comparator|placebo|
11208019|NCT03329443|Active Comparator|Spironolactone|
11208020|NCT03329430|Experimental|Foot orthoses|Customize foot orthoses
11208021|NCT03329417|Active Comparator|Traditional occupational therapy|The program includes 30 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
11208022|NCT03329417|Active Comparator|Mirror therapy using a mirror box|The program includes 30 minutes of mirror therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
11208023|NCT03329417|Experimental|Virtual reality based mirror therapy|The program includes 30 minutes treatment session of virtual reality mirror therapy, followed by 20 minutes of motor task specific training in each treatment session.
11208024|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1 6°C
11208025|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
11208026|NCT03329391|Experimental|Intervention Group|The intervention group will receive a 8-week nurse-led psychosocial care group,which involve 90 minutes session every week.
11208027|NCT03329391|No Intervention|Control Group|The control group will receive usual care, which refers to the pharmacological therapy provided by psychiatrists in the Psychiatric Department.
11208028|NCT03329378|Active Comparator|ddACTHP|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Pegfilgrastim 6mg SC, day 2 of AC
~Cycled every 14 days for 4 cycles, followed by, Paclitaxel 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15 Trastuzumab 8 mg/kg IV day 1, followed by 6mg/kg Pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks
~Cycled every 21 days for 4 cycles, followed by, Trastuzumab 6mg/kg every 21 days to complete 1 year"
11208029|NCT03329378|Active Comparator|TCHP|TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
11208030|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
11208031|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
11208032|NCT03329352|Experimental|F&P Vitera Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
11208033|NCT03329339|No Intervention|2 L PEG with ascorbic acid group|
11208034|NCT03329339|Experimental|1 L PEG with ascorbic acid with PLD|
11208035|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
11208036|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
11208037|NCT03329300|Other|All participants|Family-based Behavioral Treatment (FBT)
11208038|NCT03329287|Experimental|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
11208039|NCT03329287|Active Comparator|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
11208040|NCT03329287|Active Comparator|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
11208041|NCT03329274||Patients with Erdheim-Chester Disease|
11208042|NCT03329261|Active Comparator|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
11208043|NCT03329261|Active Comparator|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
11208044|NCT03329248|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, oxaliplatin, SBRT
11208045|NCT03329235|Experimental|Intraosseous and intra-articular|injection of PRP 2 ml
11208046|NCT03329235|Active Comparator|intra-articular PRP|injection PRP 2 ml
11208047|NCT03329235|Active Comparator|Intra-articular injection of HA|injection of HA 2 ml
11208048|NCT03329222|Experimental|Intervention group|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
11208049|NCT03329222|Active Comparator|Control group|Standard cow's milk with prebiotics mixture
11208050|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
11208051|NCT03329196|Experimental|MT-6548|
11208052|NCT03329196|Active Comparator|Darbepoetin alfa|
11208053|NCT03329183|Experimental|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
11208054|NCT03329183|No Intervention|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
11208055|NCT03329183|No Intervention|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
11208056|NCT03329170|Experimental|CHD intervention|educational intervention using motivational interviewing
11208057|NCT03329170|No Intervention|CHD control|At 24 and 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
11208058|NCT03329170|No Intervention|Healthy control|At 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
11208059|NCT03329157|Other|Rebuilding Bridges|This is a one-group study and the group will receive the Rebuilding Bridges intervention
11208060|NCT03329144|Experimental|Cognitive Behavioural Therapy|The women in this arm will receive a 9-week CBT-based curriculum delivered by Public Health Nurses to help build resilience and optimize mood, anxiety, and emotion regulation while attending a supported school program in Niagara Region.
11208061|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
11208062|NCT03329118|Experimental|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
11208063|NCT03329105|Experimental|Sea Salt Mouth Rinse|
11208064|NCT03329105|Active Comparator|Standardized Oral Health Practices|
11208065|NCT03329092|Experimental|Aztreonam-Avibactam ± Metronidazole|All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
11208066|NCT03329092|Active Comparator|Meropenem ± Colistin|All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
11208067|NCT03329079|Experimental|Mobile Technology Plus (MT+)|Experimental arm will receive a 3-month MT+ intervention using the premium mobile phone app version with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
11208068|NCT03329079|Active Comparator|Mobile Technology (MT)|Comparison group will receive the basic version of the mobile phone app only.
11208069|NCT03329066|Experimental|MAST - Managing Asthma & Sleep in Teens|This is an eight week intervention consisting of 4 group and 4 individual tailored coaching sessions that focuses on both asthma and sleep. In this behavioral medicine intervention, teenagers learn ways to better care for their asthma and sleep hygiene. Teen sessions are delivered in school. Their caregivers will receive four educational booklets that correspond to each group session; topics mirror the objectives of each group and the booklets are sent at the time of each group.
11208100|NCT03328936|Experimental|Arm II (melphalan hydrochloride or 5-day severe neutropenia))|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for predicted 5-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
11208101|NCT03328923|Experimental|500mg brown seaweed powder|2 x 250mg capsules InSea2® (brown seaweed powder)
11208102|NCT03328923|Placebo Comparator|Placebo|2 x capsules microcrystalline cellulose (bulking agent) (0mg InSea2®)
11208311|NCT03327545|Experimental|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
11208070|NCT03329066|Active Comparator|ASMA - Asthma Self-Management for Adol|ASMA is an evidence-based intervention for students, caregiver education, and education for students' medical providers. The student intervention consists of 3 group sessions & 5 individual tailored coaching sessions. All sessions are held at school. The caregiver intervention includes 3 educational booklets that correspond to the timing of the student group and 4 brief telephone-counseling sessions to review the booklets, answer questions, and provide strategies to support adolescents' steps to care for their asthma. With caregiver permission, we mail students' healthcare providers a toolkit consisting of (1) a letter informing them their patient is participating in ASMA and is being directed to them for clinical evaluation and (2) summaries of key NHLBI guidelines for treating asthma.
11208071|NCT03329066|Placebo Comparator|Information & Referral Control Group|The information-and-referral control intervention is a student-only intervention that consists of 3 group sessions and 5 individual sessions. Sessions are held once a week at school, where students will receive guideline-based information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
11208072|NCT03329053|Experimental|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
11208073|NCT03329053|Active Comparator|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
11208074|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
11208075|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
11208076|NCT03329027|Experimental|Vibrating Mode 1|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
11208077|NCT03329027|Experimental|Vibrating Mode 2|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
11208078|NCT03329027|Sham Comparator|Sham|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week)
11208079|NCT03329014|Experimental|Intravenous Remimazolam|4 mg intravenous remimazolam as an intravenous control
11208080|NCT03329014|Experimental|10 mg Powder Remimazolam|Powder containing 10 mg remimazolam for intranasal administration
11208081|NCT03329014|Experimental|10 mg Solution Remimazolam|Solution containing 10 mg remimazolam for intranasal administration
11208082|NCT03329014|Experimental|20 mg Powder Remimazolam|Powder containing 20 mg remimazolam for intranasal administration
11208083|NCT03329014|Experimental|20 mg solution Remimazolam|Solution containing 20 mg remimazolam for intranasal administration
11208084|NCT03329014|Experimental|40 mg Powder Remimazolam|Powder containing 40 mg remimazolam for intranasal administration
11208085|NCT03329014|Experimental|40 mg Solution Remimazolam|Solution containing 40 mg remimazolam for intranasal administration
11208086|NCT03329014|Placebo Comparator|Placebo Powder|Powder containing 20 mg placebo for intranasal administration
11208087|NCT03329014|Placebo Comparator|Placebo solution|Solution containing 20 mg placebo for intranasal administration
11208088|NCT03329001|Experimental|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet (1x300mg) followed by single dose niraparib capsule (3x100mg) followed by optional daily dosing extension phase
11208089|NCT03329001|Experimental|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule (3x100mg) followed by single dose niraparib tablet (1x300mg) followed by optional daily dosing extension phase
11208090|NCT03329001|Experimental|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet (1x300 mg) followed by single dose niraparib capsule (3x100 mg) followed by optional daily dosing extension phase.
11208091|NCT03329001|Experimental|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule (3x100 mg) followed by single dose niraparib tablet (1x300 mg) followed by optional daily dosing extension phase.
11208092|NCT03328988|Experimental|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
11208093|NCT03328988|No Intervention|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.
~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
11208094|NCT03328975|Active Comparator|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
11208095|NCT03328975|Placebo Comparator|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
11208096|NCT03328962|No Intervention|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
11208097|NCT03328962|Experimental|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
11208098|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
11208099|NCT03328936|Experimental|Arm I (melphalan hydrochloride for 3-day severe neutropenia)|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for for predicted 3-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
11208165|NCT03328468|Experimental|Breathing Exercise|
11208271|NCT03327740||Subjects that start any other DTG based ARV regimen|These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
11208103|NCT03328910||Analgesia monitoring|After anesthesia induction, all participants received standard anesthesia monitoring, SPI monitor (GE Healthcare, Helsinki, Finland) and bispectral index (BIS). BIS was kept between 40-60, whereas no specific target was determined for SPI. At the end of surgery, anesthesia was terminated and the patients were stimulated to wake up. After the participants were able to breathe spontaneously and obey verbal commands, extubation was carefully performed, and the monitoring of SPI was stopped.
11208104|NCT03328897|Experimental|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
11208105|NCT03328897|Experimental|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
11208106|NCT03328897|Placebo Comparator|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
11208107|NCT03328884|Other|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
11208108|NCT03328871|Experimental|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
11208109|NCT03328871|Experimental|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
11208110|NCT03328858|Other|Ketogenic Diet|Participants will be provided a consultation with a ketogenic dietitian, and test the tolerance to the diet in an inpatient mode
11208111|NCT03328845|Other|Tresiba & NovoRapid|Patients treated with Tresiba insulin and NovoRapid insulin
11208112|NCT03328845|Other|Toujeo SoloStar & NovoRapid|Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
11208113|NCT03328845|Other|Tresiba & Humalog Kwikpen|Patients treated with Tresiba insulin and Humalog kwikpen insulin
11208114|NCT03328845|Other|Toujeo SoloStar & Humalog Kwikpen|Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
11208115|NCT03328845|Other|Tresiba & Apidra|Patients treated with Tresiba insulin and Apidra insulin
11208116|NCT03328845|Other|Toujeo SoloStar & Apidra|Patients treated with Toujeo SoloStar insulin and Apidra insulin
11208117|NCT03328832|Active Comparator|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
11208118|NCT03328832|Active Comparator|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
11208119|NCT03328819|Experimental|Acupuncture for Depression/Acupuncture for pain|
11208120|NCT03328819|Experimental|Acupuncture for pain/Acupuncture for Depression|
11208121|NCT03328793|Experimental|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:
~mood assessment
~emotion assessment
~mobility assessment
~communication assessment"
11208122|NCT03328793|Active Comparator|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:
~mood assessment
~emotion assessment
~mobility assessment
~communication assessment"
11208123|NCT03328780||Hemoglobin determination|In this study classical laboratory determination, determination with HemoCue® and Rad-67™ will be performed to compare precision of those three methods as well as their correlation.
11208124|NCT03328767|Experimental|Early activity and Mobilisation intervention|Patients will be randomised within 48 hrs of commencing ECMO. Patients unable to initially receive active physical training will receive passive physical training for a minimum of 20 minutes and a maximum of one hour per day to maintain joint and muscle activity until active physical training is commenced. The intervention involves a progression of exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 minutes) at each session, based on our published ICU mobility scale now used internationally in ICU trials. This is performed with or without IMV (including both endotracheal tubes or tracheostomies).
11208125|NCT03328767|No Intervention|Standard Care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
11208126|NCT03328754|Experimental|Group 1 Powerscope|Powerscope placed bilaterally for class II correction
11208127|NCT03328754|Experimental|Group 2 Forsus|Forsus placed bilaterally for class II correction
11208128|NCT03328741|Experimental|Joint Academy|Online osteoarthritis treatment
11208129|NCT03328741|Active Comparator|The BOA program|Face-to-face osteoarthritis treatment
11208130|NCT03328728|Experimental|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
11208131|NCT03328728|Active Comparator|Synvisc-One|One intra-articular injection of a crosslinked HA
11208132|NCT03328715|Active Comparator|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
11208133|NCT03328715|Sham Comparator|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
11208134|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
11208135|NCT03328689|Experimental|Physical activity in the community|The physical activity program will include an individualized exercise program delivered in community exercise facility plus education..
11208136|NCT03328689|Active Comparator|Control group standard care|Participants from the control group will receive no additional intervention other than being encouraged to continue with their physiotherapists or chiropractor recommendation which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
11208202|NCT03328169|Experimental|Mindfulness|Mindfulness-Based Therapy
11208312|NCT03327545|Placebo Comparator|Control group|Control group
11208137|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
11208138|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
11208139|NCT03328663|Experimental|CARE intervention|"Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist
~The CARE intervention contain 3 component
~a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills
~a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty
~a self-care component to promote caregiver health and well-being"
11208140|NCT03328663|Active Comparator|Standard transplant care|"Standard Transplant Care
~Social work consults to help caregivers only upon request"
11208141|NCT03328650|Experimental|Reference Point Indentation|Participants who have elected to participate in the optional, interventional arm of this study will undergo routine proximal humeral plate fixation for their proximal humerus fracture. Once the participant has been anesthetized prior to stabilizing the fracture with a ALPS proximal humerus plate, the participant's arm will be secured and the orthopaedic surgeon will indent the proximal humeral metaphysis, distal to the site of the fracture, at 10 to 15 locations ((~2 mm apart) using the OsteoProbe-RPI. The indent size is approximately ~300 μm in diameter and ~300 μm in depth.
11208142|NCT03328637|Experimental|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman & Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
11208143|NCT03328637|No Intervention|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
11208144|NCT03328624|Experimental|DVT Cuff users|Current or previous DVT cuff users
11208145|NCT03328598|Experimental|Positive psychology therapy group|This arm will be given a positive psychological group intervention developed from an foreign psychotherapy.
11208146|NCT03328598|Experimental|Resilience promotion therapy group|This arm will be given a resilience group intervention developed from our pervious research results.
11208147|NCT03328598|Active Comparator|Controlled routine activity group|This arm will continue to participate in conventional community activities.
11208148|NCT03328585|Active Comparator|CBT-I in person|
11208149|NCT03328585|Experimental|CBT-I via telemedicine|
11208150|NCT03328585|Other|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
11208151|NCT03328572|Active Comparator|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
11208152|NCT03328572|Experimental|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
11208153|NCT03328559|Other|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
11208154|NCT03328559|Other|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
11208155|NCT03328533|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
11208156|NCT03328533|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine bitartrate infusion by a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min). The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
11208157|NCT03328520|Experimental|First Year Students in Wellness FYIs|
11208158|NCT03328507|Experimental|BLI4900|BLI4900 Bowel Preparation
11208159|NCT03328507|Active Comparator|PEG Control|Polyethylene glycol-based bowel preparation
11208160|NCT03328494|Experimental|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
11208161|NCT03328494|Experimental|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. During dose escalation, further exploration of the treatment schedule for the BOS172722-paclitaxel combination will be initiated. In such combination cohorts, BOS172722 will be administered with paclitaxel on Days 1, 8, and 15 only of each treatment cycle (except for Cycle 2 Day1), and will not be administered on Day 2, 9, and 16. These alternative schedules will be explored to further characterize the pharmacokinetics and tolerability of such a dosing regimen.
11208162|NCT03328494|Experimental|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
11208163|NCT03328481|Experimental|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
11208164|NCT03328481|Active Comparator|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
11208166|NCT03328455|Experimental|Active training|Adaptive training tailored to each individual's thresholds will be used. Specifically, a two-alternative forced-choice TOJ task will be used, where participants will be asked to judge the temporal order of the stimulus pair (an auditory beep and a visual flash) with varying SOAs. On each training day, the range of SOAs will be established for individuals based on their thresholds determined from the pre-training TOJ assessment given on the same day. The maximum SOA will be 0.2 log units greater than their estimated threshold and will be used for both visual leading (positive SOA) and auditory leading (negative SOA) stimuli. Feedback will be provided after each response.
11208167|NCT03328455|Sham Comparator|Passive training|To control for pure practice or exposure effects, a second group of elderly participants will undergo passive training. Participants will be exposed to the stimulus pair with varying SOAs, similarly as in the active training group. The maximum SOA for each individual will be likewise determined by his or her threshold from the TOJ assessment. However participants will not be asked to perform the TOJ task and no feedback will be provided. Instead, participants will perform an oddball task in which they are asked to detect a stimulus that occurs less frequently than the standard one. Having an oddball task in both auditory and visual modalities will ensure that participant's attention is divided between the two modalities as required in the active training task.
11208168|NCT03328442|Experimental|Vista technique|The vista technique with PRF membrane uses a Vestibular incision subperiosteal tunnel access in combination with Platelet rich fibrin membrane to treat gingival recession defects.
11208169|NCT03328442|Active Comparator|modified coronally advanced flap|A modified coronally advanced flap utilising Platelet rich fibrin membrane to treat gingival recession defects.
11208170|NCT03328429|Other|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
11208171|NCT03328429|Other|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
11208172|NCT03328416|Experimental|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
11208173|NCT03328403|Experimental|Aspiration First|Aspiration thrombectomy with large bore catheters
11208174|NCT03328403|Experimental|Stent retriever first|Thrombectomy with a licensed stent retriever device
11208175|NCT03328390|Experimental|Quadratus lumborum block Group|ultrasound guided
11208176|NCT03328390|Active Comparator|Transversus abdominis plane block Group|ultrasound guided
11208177|NCT03328364||enzalutamide (mCRPC pre-chemo)|Patients treated with enzalutamide prior to chemotherapy
11208178|NCT03328364||enzalutamide and chemotherapy (mCRPC post chemo)|Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
11208179|NCT03328351|Experimental|manual group|"The Manual therapy (Mobilization):
~Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set
~Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.
~Strengthening Exercises for deep neck flexor muscle"
11208180|NCT03328351|Sham Comparator|sham group|"Superficial soft tissue massage
~Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
11208181|NCT03328325|Experimental|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
11208182|NCT03328312|Active Comparator|Sugammadex|For reversal of rocuronium neuromuscular- block we will use Sugammadex
11208183|NCT03328312|Placebo Comparator|neostigmine+atropine|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
11208184|NCT03328312|Experimental|neostigmine+atropine+sugammadex|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.
11208185|NCT03328299|Active Comparator|Dexmedetomidine group|patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
11208186|NCT03328299|Placebo Comparator|bupivacaine group|patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
11208187|NCT03328286|Experimental|Weekly group meeting w/psychotherapist|All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or Problems the Group members have
11208188|NCT03328273|Other|Arm A Part 1 and 2|DISCONTINUED (ceralasertib monotherapy)
11208189|NCT03328273|Experimental|Arm B Part 1 and 2|ceralasertib + acalabrutinib in combination
11208190|NCT03328260|Experimental|Treatment|
11208191|NCT03328247|No Intervention|Control|Control group will attend their routine melanoma follow-ups
11208192|NCT03328247|Experimental|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
11208193|NCT03328234|Experimental|SIB-IMRT combined chemotherapy with IFI|
11208194|NCT03328234|Experimental|SIB-IMRT with IFI|
11208195|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
11208196|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
11208197|NCT03328195|Active Comparator|Neuro RX Gamma synchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
11208198|NCT03328195|Sham Comparator|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
11208199|NCT03328195|Active Comparator|Neuro RX Gamma asynchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril. The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
11208200|NCT03328182|Experimental|New oral endotracheal tube holder|Single Study Product Arm
11208201|NCT03328169|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia
11208203|NCT03328156||patient with STEMI will treated by PPCI|Primary angioplasty procedure The procedure will be performed using a standard angioplasty technique. A bolus of100 IU kg of heparin will be administered intra-arterially after insertion of the vascular catheter. The target lesions will initially treated with appropriate balloon predilatation as necessary, followed by intracoronary stenting. After stent implantation, heparin will be routinely administered. The sheaths will be removed the same day.
11208204|NCT03328156||patient with STEMI will treated by Thrombolytic therapy|oral clopidogrel (300 mg), Low-flow nasal oxygen, oral acetylsalicylic acid (325 mg), Will be given to each patient. Streptokinase will be given intravenously at 1.5 million units over approximately 60 min. Reperfusion afterTT will be assessed according to clinical criteria .
11208205|NCT03328143|Experimental|Treatment with Lavender|Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.
11208206|NCT03328130|Experimental|Cohort 1 - Low Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.
11208207|NCT03328130|Experimental|Cohort 2a - Medium Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the medium dose. Confirmatory dose will be determined after DSMC assessment.
11208208|NCT03328130|Experimental|Cohort 2b - High Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.
11208209|NCT03328130|Experimental|Cohort 3 - Confirmatory Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
11208210|NCT03328117|Active Comparator|Intervention|
11208211|NCT03328117|Placebo Comparator|Placebo|
11208212|NCT03328104|Experimental|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
11208213|NCT03328091|Active Comparator|Traditional pre-test genetic counseling|"In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing
~Participant is given a pamphlet introducing prostate cancer genes, genetic testing
~Participant is sent electronic family history tool
~Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
11208214|NCT03328091|Experimental|Pre-test video education|"Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing
~Participant is sent electronic family history tool
~Participant is approached in clinic by research staff at a pre-planned time
~The patient is given the Genetic Testing Information for Decision Making packet
~The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
11208215|NCT03328078|Experimental|CA-4948 dose escalation|Part A1: Dose-level cohorts with up to 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for CA-4948.
11208216|NCT03328078|Experimental|CA-4948 and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral CA-4948 in combination with 560 mg daily (QD) of oral ibrutinib (or 420 mg QD for WM/LPL and CLL/SLL). Separate escalation will be performed for each of these ibrutinib doses. The starting dose of CA-4948 to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 18 patients will be required to establish optimal combination dosing.
11208217|NCT03328078|Experimental|CA-4948 and ibrutinib dose expansion|"In expansion phase, the CA-4948 recommended Phase 2 dose (RP2D) in combination with ibrutinib will be administered in Non-Hodgkin Lymphoma (NHL) disease-specific cohorts. Up to 46 NHL patients will be enrolled in each of the following 4 NHL disease-specific cohorts:
~Cohort 1 - Marginal zone lymphoma (MZL)
~Cohort 2 - ABC diffuse large B-cell lymphoma (DLBCL) or extranodal subtypes: Leg-, testicular-, or NOS-type
~Cohort 3 - Primary central nervous system lymphoma (PCNSL)
~Cohort 4 - Patients receiving ibrutinib monotherapy who have developed adaptive, secondary resistance. Indications include:
~Mantle Cell Lymphoma (MCL), MZL, CLL/SLL, or WM/LPL
~Indications for which ibrutinib is National Comprehensive Cancer Network (NCCN)-listed (e.g., PCNSL)
~Patients with NHL and known myddosome mutations
~Patients may be candidates for maintaining ibrutinib while CA-4948 will be added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks is acceptable."
11208218|NCT03328065||Stable patients, early responders to treatment and caregivers|
11208219|NCT03328065||Stable patients and intermediate responders and c|Stable patients and intermediate responders to treatments and caregivers
11208220|NCT03328065||Doctors|
11208221|NCT03328065||Patients in therapeutic escape and their caregivers|
11208222|NCT03328052|Experimental|MYnd Analytics PEER Online directed therapy|Patients in this arm will receive anti-depressants as recommended by the PEER Online algorithm as described below.
11208223|NCT03328052|Sham Comparator|Conventional therapy|Patients in this arm will receive anti-depressants as chosen by the physician without guidance by the PEER Online algorithm.
11208224|NCT03328026|Experimental|INCMGA00012, SV-BR-1-GM combination|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 with cycles every 3 weeks
11208225|NCT03328026|Experimental|INCMGA00012, Epacadostat 600 mg BID, SV-BR-1-GM combination|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 and epacadostat 600 mg BID with cycles every 3 weeks
11208226|NCT03328026|Experimental|INCMGA00012, Epacadostat, SV-BR-1-GM combination expansion|Patients will be treated with the SV-BR-1-GM regimen (including pre-treatment with low dose cyclophosphamide and post-treatment Interferon inoculation) in combination with INCMGA00012 and epacadostat (dose to be determined) with cycles every 3 weeks
11208227|NCT03328013||Women aged 25 to 33 years in 2017|"Women aged 25 to 33 years in 2017 and having performed an analyzed smear at the Brest University Hospital.
~They are invited to fill out an online questionnaire asking them about :
~vaccine status against HPV
~if vaccinated, the name of the vaccine and the number of injection
~age of first sexual intercourse
~do they have a gynecological pathology"
11208228|NCT03327987||31-90 days|Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
11208229|NCT03327987||91-180 days|91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
11208231|NCT03327974|Other|depressed patients|"All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.
~All patients are depressed patients."
11208232|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
11208233|NCT03327948|Experimental|Treatment group|Urinary Urgency Incontinence
11208234|NCT03327935|Experimental|Nutrition|Oral nutritional supplements and dietetic advice
11208235|NCT03327935|Experimental|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
11208236|NCT03327935|No Intervention|Control|Standard Hospital Procedure
11208237|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
11208238|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
11208239|NCT03327909|Experimental|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
11208240|NCT03327909|Experimental|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
11208241|NCT03327896||OCHIN EHR|"Patients who were established patients at OCHIN Primary Care Clinics in 2015 and had a face to face visit at the clinic in 2015.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
11208242|NCT03327896||OneFlorida EHR|"Patients who were established patients at OneFlorida Primary Care clinics in 2015 and had a face to fact visit at the clinic in 2015.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
11208243|NCT03327896||Oregon Medicaid|"Clients who were continuously insured through Oregon Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
11208244|NCT03327896||Florida Medicaid|"Clients who were continuously insured through Florida Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider. Florida Medicaid data is limited to clients who were 22 years or younger.
~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
11208245|NCT03327883||1/Patients medical records|Medical records of patients with metastatic bladder cancer
11208246|NCT03327870||1|Sjogren's Syndrome
11208247|NCT03327870||2|Sicca
11208248|NCT03327870||3|Incomplete Sjogren's Syndrome
11208249|NCT03327870||4|Healthy Volunteers
11208250|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
11208251|NCT03327857|Experimental|Neihulizumab (AbGn-168H)|Intravenous doses of Neihulizumab (AbGn-168H)
11208252|NCT03327844|Active Comparator|RET using bi-Antibiotics|Interventions: Bi-antibiotics (Ciprofloxacin and Metronidazole) placed into the root canal during first treatment stage (disinfection stage)
11208253|NCT03327844|Active Comparator|RET using non-setting Calcium Hydroxide|Interventions: non-setting calcium hydroxide placed into the root canal during first treatment stage (disinfection stage)
11208254|NCT03327831|Experimental|Open Label Treatment Arm|This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
11208255|NCT03327818||conservative surgery group|
11208256|NCT03327818||hysterectomy group|
11208257|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 2 weeks prior to and during the testing period.
11208258|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 2 weeks prior to and during the testing period.
11208259|NCT03327805|Experimental|Acute Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate 8 hours prior to the third testing session at baseline testing.
11208260|NCT03327805|Placebo Comparator|Acute Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo 8 hours prior to the third testing session at baseline testing.
11208261|NCT03327792|Experimental|200 mg Mavoglurant|200 mg mavoglurant once daily for 7-10 days
11208262|NCT03327792|Placebo Comparator|Placebo|Placebo once daily for 7-10 days
11208263|NCT03327766||RPL group|history of unexplained recurrent pregnancy loss (defined as two or more consecutive missed miscarriage before 14 weeks of gestation).
11208264|NCT03327766||Control group|womens coming for contraception after normal pregnancy outcome.
11208265|NCT03327753|Experimental|Motor control exercises|A primary goal of the motor control exercise program is to regain control and coordination of the spine and pelvis using principles of motor learning such as segmentation and simplification. The whole intervention is based on assessment of the individual patient's motor control impairments and the patient's individual treatment goals (set collaboratively with the therapist).
11208266|NCT03327753|Experimental|Graded activity|A primary goal of the graded activity program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. The intervention uses cognitive behavioral approaches to deal with fear of movement and self efficacy.
11208267|NCT03327740||Subjects on DTG based ARV with ABC|These are subjects who begin a DTG based ARV regimen that includes ABC
11208268|NCT03327740||Subjects that start DTG based ARV regimen but without ABC|These are subjects who begin a DTG-based ARV regimen that does not contain ABC
11208269|NCT03327740||Subjects on other integrase inhibitor based regimen with ABC|These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
11208270|NCT03327740||Subjects on other integrase inhibitor based regimen but no ABC|These are subjects that start non-ABC containing RAL or EGV based regimens
11208272|NCT03327727|Experimental|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
11208273|NCT03327727|Active Comparator|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
11208274|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
11208275|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
11208276|NCT03327701|Active Comparator|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
11208277|NCT03327701|Placebo Comparator|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
11208278|NCT03327688|Active Comparator|POCUS group|Point-of-care ultrasound
11208279|NCT03327688|No Intervention|Radiologist group|Traditional diagnostic way
11208280|NCT03327688|Active Comparator|DVT POCUS group|DVT group after POCUS education
11208281|NCT03327688|No Intervention|DVT traditional group|DVT group traditional diagnostic way before educational intervention
11208282|NCT03327675|Experimental|68Ga-PSMA PET/MR|Hybrid 68Ga-PSMA PET/MR scan
11208283|NCT03327662|Experimental|Interventional|Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
11208284|NCT03327662|No Intervention|Control|Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.
11208285|NCT03327649|Sham Comparator|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
11208286|NCT03327649|Experimental|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
11208287|NCT03327636|Experimental|High Intensity Focused Ultrasound|Apply the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the papillary thyroid microcarcinoma.
11208288|NCT03327636|No Intervention|Active surveillance|The participants will be monitored by the doctors actively, like more frequent in follow-up to observe their current situation.
11208289|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
11208290|NCT03327623||Control|Subjects who are healthy volunteers
11208291|NCT03327610|No Intervention|BASELINE|The subjects were kept in their current ventilatory mode.
11208292|NCT03327610|Experimental|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
11208293|NCT03327610|Experimental|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
11208294|NCT03327610|Experimental|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
11208295|NCT03327610|Experimental|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
11208296|NCT03327610|Experimental|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
11208297|NCT03327610|Experimental|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
11208298|NCT03327597|Active Comparator|Abnormal Non-MGUS|Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
11208299|NCT03327597|Experimental|MGUS group arm 1|Participants diagnosed with MGUS, randomized to group 1.
11208300|NCT03327597|Experimental|MGUS group arm 2|Participants diagnosed with MGUS, randomized to group 2.
11208301|NCT03327597|Experimental|MGUS group arm 3|Participants diagnosed with MGUS, randomized to group 3.
11208302|NCT03327597|Active Comparator|Normal group|Participants without MGUS.
11208303|NCT03327597|Active Comparator|Controls|Participants without MGUS, matched to MGUS participants by age and gender.
11208304|NCT03327584|Active Comparator|Ultrasound Guided Arthrocentesis|The patients in this group will have ultrasound guided arthrocentesis.
11208305|NCT03327584|Active Comparator|Landmark Guided Arthrocentesis|The patients in this group will have landmark guided arthrocentesis.
11208306|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
11208307|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
11208308|NCT03327558|Experimental|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
11208309|NCT03327558|Active Comparator|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
11208310|NCT03327545|Experimental|Experimental Group 1|Neural mobilization for a total of 12 minutes
11266718|NCT02927353|Active Comparator|adalimumab|adalimumab
11208313|NCT03327532|Experimental|Patients hospitalized for acute heart failure|"One arm study.
~Patients hospitalized for acute heart failure will undergo the following evaluations:
~Clinical examination centered on congestion
~Cardiopulmonary and peritoneal ultrasound
~Blood sample retrieved for biological assessment and biobanking
~Telephone interview"
11208314|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
11208315|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
11208316|NCT03327506|Experimental|hypnosis group|Intervention: hypnosis session the eve of the surgery
11208317|NCT03327506|Active Comparator|premedication|alprazolam 0,5 mg the eve and the morning of the surgery
11208318|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
11208319|NCT03327480|Experimental|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
11208320|NCT03327480|Experimental|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
11208321|NCT03327454||Benepali|Treatment of participants with the Benepali pre-filled pen takes place in accordance with the prescribing information and standard medical practice.
11208322|NCT03327441|Experimental|Almonds|
11208323|NCT03327441|Active Comparator|Omelette|
11208324|NCT03327428||Patients with Sickle Cell Disease|Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.
11208325|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
11208326|NCT03327402|Experimental|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
11208327|NCT03327389|Experimental|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
11208328|NCT03327389|Placebo Comparator|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
11208329|NCT03327376||Characteristic and regularity of CRT|The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT).
11208330|NCT03327363|Experimental|ICT base monitoring group|In the ICT-based centralized monitoring group, both subjects and medical staff receive feedback regarding decreased lung function and exacerbation in asthma symptoms in the form of text messages
11208331|NCT03327363|Placebo Comparator|control group|Use standard asthma treatment
11208332|NCT03327350||WATCHMAN transplantation|This group will receive WATCHMAN device implantation.Device implantation included concomitant antithrombotic medication to facilitate device endothelialization: warfarin and aspirin for 45 days. To assess for device stability, peridevice leaks, and device-related thrombus, transesophageal echo (TEE) imaging was performed at 45 days, 6 months, and 12 months. When the 45-day TEE revealed minimal residual peridevice flow (jet width ≤5 mm) and no device-related thrombus, warfarin will be stopped and replaced by clopidogrel, 75 mg daily, until the 6-month visit, after which only aspirin was continued. If an adequate seal is not obtained or a thrombus is detected, patients continue taking warfarin until an adequate seal is attained or thrombus is resolved before transitioning to aspirin.
11208333|NCT03327350||Oral anticoagulant therapy|"This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).
~For patients taking warfarin, international normalized ratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Follow-up visits occurred twice annually after the first year, with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected."
11208334|NCT03327337|Experimental|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
11208335|NCT03327337|Other|control group|operate with open reduction and internal fixation on this group patients
11208336|NCT03327324|Other|Resident of the Skilled Nursing Facility|
11208337|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
11208338|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
11208339|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
11208340|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
11208341|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
11208342|NCT03327298|Other|accuracy of pedicle screw insertion|postoperative CT lumbar spine axial and sagittal views.
11208343|NCT03327285|Experimental|C-CAR011|The amount of cells received：1.0-5.0×10^6 CAR+T cells/kg
11208344|NCT03327272|Active Comparator|Local injection of methylprednisolone|Drug: methylprednisolone Injection of 80mg methylprednisolone injectable suspension at surgical site prior to incision closure
11208345|NCT03327272|Placebo Comparator|Local injection of saline|Administration of saline at surgical site prior to incision closure.
11208346|NCT03327259|Active Comparator|Activity Planning Only|
11208347|NCT03327259|Experimental|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
11208348|NCT03327246|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
11208349|NCT03327246|No Intervention|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
11208380|NCT03327012|Experimental|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
11208350|NCT03327233|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
11208351|NCT03327233|No Intervention|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
11208352|NCT03327220|Experimental|iovera° Treatment Group|Subjects are treated with the iovera° device 3-7 days prior to Total Knee Arthroplasty
11208353|NCT03327220|No Intervention|Standard of Care Total Knee Arthroplasty|Subjects undergo the standard Total Knee Arthroplasty
11208354|NCT03327207||Study group|Children who receive Growth hormone treatment. Non Interventional
11208355|NCT03327207||Control group|Healthy children . Non Interventional
11208356|NCT03327194|Experimental|ADHEAR Audio processor|
11208357|NCT03327181|Experimental|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
11208358|NCT03327181|Active Comparator|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
11208359|NCT03327168|Active Comparator|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
11208360|NCT03327168|No Intervention|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
11208361|NCT03327168|Experimental|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
11208362|NCT03327155|Experimental|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
11208363|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
11208364|NCT03327129||Patients with SI and low acquired capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
11208365|NCT03327129||Patients with SI and high acquired capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
11208366|NCT03327116|Experimental|Methotrexate|
11208367|NCT03327103|No Intervention|Enhanced Usual Care|Receive standard care
11208368|NCT03327103|Experimental|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
11208369|NCT03327090|Experimental|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):
~Gluteal maximus muscle.
~Quadriceps muscle.
~Gastrocnemius muscle and soleus muscle (triceps surae).
~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
11208370|NCT03327090|Sham Comparator|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.
~Gluteal maximus muscle.
~Quadriceps muscle.
~Gastrocnemius muscle and soleus muscle (triceps surae).
~There were no tension on the tape and no muscle stretching during the application."
11208371|NCT03327077|No Intervention|Control Group|
11208372|NCT03327077|Experimental|Intervention Group|Music group
11208373|NCT03327064|Active Comparator|Renal Transplant subjects receiving UAB30|Generally healthy renal transplant subjects receive UAB30 for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
11208374|NCT03327064|Placebo Comparator|Renal Transplant subjects receiving placebo|Generally healthy renal transplant subjects receive placebo for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
11208375|NCT03327051|Active Comparator|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
11208376|NCT03327051|Placebo Comparator|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
11208377|NCT03327038|Experimental|Psychological Intervention|Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
11208378|NCT03327038|Active Comparator|Control|Patients will be randomized to the control group after they have completed the study screening form. Patients randomized to the control group will receive the usual standard of care that is available to patients with moderate anxiety or depression. Additionally, control patients will completed detailed questionnaires for assessment of primary and secondary outcomes.
11208379|NCT03327025|Experimental|Intervention|
11208575|NCT03325712|Experimental|Dose Group 1|
11208381|NCT03327012|Placebo Comparator|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
11208382|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
11208383|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
11208384|NCT03326986|Experimental|Panel A|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
11208385|NCT03326986|Experimental|Panel B|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
11208386|NCT03326986|Experimental|Panel C|Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
11208387|NCT03326973||online or telephone survey|This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.
11208388|NCT03326960||Sevoflurane|Patients in Sevoflurane group are maintained with sevoflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
11208389|NCT03326960||Propofol|Patients in Propofol group are maintained with propofol through intravenous administration guided by Narcrotrend index monitoring.
11208390|NCT03326960||Desflurane|Patients in Desflurane group are maintained with desflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
11208391|NCT03326947|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.
~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
11208392|NCT03326947|No Intervention|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
11208393|NCT03326934|Sham Comparator|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
11208394|NCT03326934|Experimental|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
11208395|NCT03326921|Experimental|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine for 1-3 doses 3-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
11208396|NCT03326908|Other|Normal conditions of light exposure|"Spectral Domain Optical Coherence Tomography (SD-OCT):
~Five SD-OCTs will be produced under the same lighting conditions (photopic).
~At baseline
~20 minutes after baseline
~25 minutes after baseline
~45 minutes after baseline
~60 minutes after baseline"
11208397|NCT03326908|Other|Light variations|"Spectral Domain Optical Coherence Tomography (SD-OCT):
~Five SD-OCT will be performed:
~at baseline, in a room with photopic artificial lighting (400 lux)
~after a period of adaptation to the dark (20 minutes in the dark: 0 lux)
~after 5 min of retinal glare, obtained by means of a projection of light of 1000 lux on the fundus of eye
~15 minutes after this period of retinal glare, in photopic artificial lighting
~30 minutes after the period of retinal glare, in photopic artificial lighting"
11208398|NCT03326895|Experimental|Group 1|Powered circular stapler used to complete anastomosis of colon
11208399|NCT03326882|Active Comparator|Glidescope|A device for endotracheal intubation
11208400|NCT03326882|Active Comparator|Macintosh laringoscope|A device for endotracheal intubation
11208401|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay
~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
11208402|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay
~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
11208403|NCT03326856|Placebo Comparator|Vehicle|Vehicle
11208404|NCT03326856|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
11208405|NCT03326856|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
11208406|NCT03326856|Experimental|Dose 3|botulinum toxin, Type A, Dose 3
11208407|NCT03326856|Experimental|Dose 4|botulinum toxin, Type A, Dose 4
11208408|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
11208409|NCT03326830|Active Comparator|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
11208410|NCT03326830|Experimental|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
11208411|NCT03326817|Active Comparator|Control Group|This group will receive standard care.
11208412|NCT03326817|Experimental|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
11208413|NCT03326804||Cohort 1 - Safety|"Cohort 1 will consist of the first 20 participants recruited into the study for H1 Hip Resurfacing Arthroplasty. These patients will receive additional CT scans preoperatively and then post-operatively at these time points: immediately postoperatively (2days), at 6 weeks, 3 months, 6 months, 1 year and 2 years. They will have metal-ion measurements for safety analysis. Blood samples will be taken preoperatively and postoperatively at 3 months, 6 months, 1 year and 2 years.
~A safety analysis of Cohort 1 will be performed at the 6 week, 3 month and 6 month post-operative stage by independent assessors. Yearly clinical evaluations will be performed until 10 years, and radiographs at 3,5,10 years. If the investigation supports the safety of the implant, the study will proceed with recruitment into Cohort 2."
11208414|NCT03326804||Cohort 2 - Efficacy|Cohort 2 will consist of the remaining target size population of 230 patients for H1 Hip Resurfacing Arthroplasty. They will undergo the same intervention as previously described for Cohort 1, but will not undergo metal-ion testing and reduced frequency CT-scans.
11208415|NCT03326791|Experimental|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
11208416|NCT03326791|Placebo Comparator|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
11208417|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
11208418|NCT03326765|Other|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
11208419|NCT03326765|Other|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
11208420|NCT03326752|Experimental|Dose Escalation Cohort 1-5|"Cohort 1-4
~DV281 - Dose Level 1-5
~DV281 in combination with nivolumab
~DV281 is administered via a breath actuated nebulizer"
11208421|NCT03326752|Experimental|Dose Expansion (RP2D)|"4 Cohorts
~Preliminary Recommended Phase 2 dosing of DV281 in combination with nivolumab
~Cohort 1: Non-squamous and non-EGFR/ ALK mutation and progressed on anti-PD-1/L1 therapy
~Cohort 2: Non-squamous and EGFR/ ALK mutation and progressed on targeted therapy
~Cohort 3: Squamous and anti-PD-1/ L1 therapy experienced
~Cohort 4: Squamous and anti-PD-1/L1 therapy naive
~DV281 is administered via a breath actuated nebulizer."
11208422|NCT03326739|Active Comparator|Ultrasound Guided A-Line Placement|Patients in this group will have ultrasound guided arterial line placement.
11208423|NCT03326739|Active Comparator|Landmark Guided A-line Placement|Patients in this group will have landmark guided arterial line placement.
11208424|NCT03326726|Experimental|Chlorhexidine Gluconate|2% CHG
11208425|NCT03326713|Experimental|Telephone Counseling & Navigation (TCN)|Telephone Counseling
11208426|NCT03326713|Active Comparator|Mailed Targeted Print (TP)|Mailed Targeted Print
11208427|NCT03326713|Other|Usual Care (UC)|Control
11208428|NCT03326700|Active Comparator|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
11208429|NCT03326700|Active Comparator|Open hernia repair.|Intervention: inguinal hernia repair.
11208430|NCT03326687|Experimental|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
11208431|NCT03326687|Experimental|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
11208432|NCT03326674|Experimental|Arm A: Tesetaxel (oral) and capecitabine (oral)|Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
11208433|NCT03326674|Active Comparator|Arm B: Capecitabine (oral)|Capecitabine (1,250 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
11208434|NCT03326661|Active Comparator|Needle aspiration|Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
11208435|NCT03326661|Active Comparator|Tonsillectomy a chaud|Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
11208436|NCT03326648|Experimental|Strength training + protein supplement|Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
11208437|NCT03326648|Experimental|Protein supplement|Daily protein supplementation for 10 weeks.
11208438|NCT03326635||frailty group|frailty score ≤ 3
11208439|NCT03326635||non-frailty group|frailty score >3
11208440|NCT03326622|Experimental|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
11208441|NCT03326622|Active Comparator|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
11208442|NCT03326609|Experimental|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
11208443|NCT03326609|Experimental|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
11208444|NCT03326609|Experimental|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
11208445|NCT03326609|Experimental|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
11208446|NCT03326609|Experimental|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
11208447|NCT03326596|Experimental|ProphylacticTranexamic Acid|Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.
11208448|NCT03326583|No Intervention|No Intervention: Pre-Treatment|This arm is the 2 week observation period before the start of the Patiromer treatment phase.
11208449|NCT03326583|Experimental|Intervention: Treatment|This arm is the 12 week treatment phase. Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks.
11208450|NCT03326583|No Intervention|No Intervention: Post-Treatment|This arm is the 2 week observation period after the Patiromer treatment phase.
11208451|NCT03326570||Bronchoscopy Data Collection|Medical information collected after bronchoscopy for up to 2 years.
11208452|NCT03326557|Active Comparator|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
11208453|NCT03326557|Active Comparator|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
11208454|NCT03326544|Experimental|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
11208455|NCT03326544|Experimental|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
11208456|NCT03326518|Experimental|Lumentin® 44|Contrast agent
11208457|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
11208458|NCT03326518|Active Comparator|Movprep®|Contrast agent
11208459|NCT03326505|Active Comparator|Injection of Umbilical cord derived UC- MSCs|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients
11208460|NCT03326505|Active Comparator|injection of UC- MSCs and SPT|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program
11208461|NCT03326505|Active Comparator|Supervised Physical Therapy (SPT)|Supervised physical therapy program without stem cells
11208462|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.
~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
11208463|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
11208464|NCT03326466||Patients with SAP|
11208465|NCT03326466||Healthy Controls|
11208466|NCT03326453|Experimental|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
11208467|NCT03326453|No Intervention|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
11208468|NCT03326440|Other|Study Arm|Patients with a histological diagnosis of prostate cancer are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system prior to the start of Radiotherapy.
11208469|NCT03326440|Other|Control Arm|Patients with a histological diagnosis of prostate cancer who are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system following completion of Radiotherapy.
11208470|NCT03326427|Experimental|Skill Training Group|A twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
11208471|NCT03326427|Active Comparator|Treatment as Usual|Patients will have one psychiatric session to control their medication adherence.
11208472|NCT03326414|Other|Constant PEEP - low tidal volume|PEEP is 10mbar, tidal volume is set to 4-5ml/kg IBW
11208473|NCT03326414|Other|Constant PEEP - high tidal volume|PEEP is 10mbar, tidal volume is set to 8-10ml/kg IBW
11208474|NCT03326414|Other|constant tidal volume - low PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 3mbar
11208475|NCT03326414|Other|constant tidal volume - high PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 12mbar
11208476|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
11208477|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
11208478|NCT03326388|Experimental|Selumetinib Intermittent Dosing|Phase 1 of the study to evaluate Intermittent Dosing (Selumetinib given twice daily on 5 out of 7 days) in children with NF1 and inoperable plexiform neurofibromas. The Maximum tolerated dose will define the Recommended phase 2 dose of selumetinib.
11208576|NCT03325712|Experimental|Dose Group 2|
11208577|NCT03325712|Experimental|Dose Group 3|
11208479|NCT03326375|Experimental|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
11208480|NCT03326375|No Intervention|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
11208481|NCT03326362|Experimental|High intensity resistance training (HIRT)|"12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions. The HIRT performed the squat, deadlift and lunge exercises, as these exercises induce high core muscles activity. HIRT started with two weeks of low intensity exercises emphasizing the activation of core muscles (pelvic elevation with feet on the floor, superman, static supine bridge on bosu), and the technique of the selected resistance exercises (e.g. squat, deadlift, and lunges). Participants performed 3 sets of 10 repetitions per exercise. In the third and forth weeks, participants performed the exercises from the previous weeks and also static unipedal forward flexion on bosu and dynamic unipedal forward flexion and the main exercises with a load corresponding to (50% of the 1 RM load (Brzycki, 1993).
~From the 5th to the 12th week, participants performed only the selected resistance exercises with progressive higher intensities (from 12RM to 8RM)."
11208482|NCT03326362|Active Comparator|Low intensity resistance training (LIRT)|12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions.The LIRT group performed very low intensity and volume exercises (i.e. 1 set per exercise). Exercises started with participants lying on a firm surface, with the back supported, knees bent and feet flat on the floor. Then, participants performed the following exercises: 1) inhaling and exhaling and then isometrically contract in gluteal and abdominal muscles for 20 seconds and relax; 2) raising the head, lifting the chin and shoulders toward the chest for 20 seconds and relax; 3) raising one knee towards the chest and raising the head and shoulders likewise in the second exercise for 20s, relaxing, and changing the leg.; 4) raising both knees towards the chest in the same time that raise the head and shoulder off the floor during 20 seconds and relax.
11208483|NCT03326349|Experimental|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) 5 days per week over 6 weeks.
11208484|NCT03326349|Sham Comparator|Ictus.online|Itus.online 5 days per week over 6 weeks
11208485|NCT03326336|Other|Cohort|3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
11208486|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
11208487|NCT03326310|Experimental|Azacitidine and selumetinib|Subjects will receive azacitidine subcutaneously on days 1-7. Selumetinib will be administered on days 8-21. Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
11208488|NCT03326297|Experimental|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
11208489|NCT03326297|Active Comparator|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
11208490|NCT03326297|No Intervention|No specific intervention|No specific intervention, prescriptions by pediatrician
11208491|NCT03326284|Experimental|15g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 15g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
11208492|NCT03326284|Experimental|35g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
11208493|NCT03326284|Experimental|60g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 60g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
11208494|NCT03326284|Experimental|35g protein energy balanced diet|Following a 5-day energy balanced diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
11208495|NCT03326271||Lubinus SP2 stem|Patients treated with a cemented Lubinus SP2 stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
11208496|NCT03326271||Exeter stem|Patients treated with a cemented Exeter stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
11208497|NCT03326258|Experimental|Treatment (glembatumumab vedotin, nivolumab, ipilimumab)|Patients receive glembatumumab vedotin IV over 90 minutes and nivolumab IV over 60 minutes on day 8 of course 1 and on day 1 of subsequent courses. Patients in melanoma expanded cohort also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 21 days for 4 courses in the absence of disease progression or unaccepted toxicity and courses with glembatumumab vedotin and nivolumab repeat every 21 days in the absence of disease progression or unaccepted toxicity.
11208498|NCT03326245|Active Comparator|1:Oral MP- IV PL|Oral Methylphenidate /IV Placebo
11208499|NCT03326245|Active Comparator|2 Oral PL/IV MP|Oral Placebo/IV Methylphenidate
11208500|NCT03326245|Placebo Comparator|3: Oral PL/IV PL|Oral Placebo/IV Placebo
11208501|NCT03326232|Experimental|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
11208502|NCT03326232|Experimental|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
11208503|NCT03326219|Other|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
11208504|NCT03326206||COPE participants|Individuals living with diabetes seen at a study site who were enrolled in the COPE programmatic intervention during the study period. Participation in COPE consists of receiving home visits by a Navajo Community Health Representative (CHR) once or twice a month for a period of at least 12 months. CHRs use structured patient coaching materials to support behavior change. CHRs also check vital signs, monitor blood glucose levels through finger sticks, and facilitate access to appointments and medical refills. CHRs communicate regularly with providers through electronic health record documentation and case management rounds. In-person or telephone communication is be used to address acute issues that may arise.
11208578|NCT03325712|Experimental|Dose Group 4|
11208579|NCT03325712|Experimental|Dose Group 5|
11208505|NCT03326206||Non-COPE participants|Individuals living with diabetes seen at a study site, did not participate in the COPE programmatic intervention, and had comparable baseline characteristics.
11208506|NCT03326193|Experimental|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle. On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
11208507|NCT03326180|Experimental|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
11208508|NCT03326180|Active Comparator|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.
~Administered as a single dose intra-operatively by periarticular infiltration."
11208509|NCT03326167||Patients with or suspected coronary heart disease|
11208510|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:
~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
11208511|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:
~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
11208512|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:
~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
11208513|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:
~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
11208514|NCT03326128|Active Comparator|BUP-300|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
11208515|NCT03326128|Experimental|BUP-450|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
11208516|NCT03326115|Experimental|Peer Visitation Program (PVP)|Participants in this group will begin participation in the Peer Visitation Program (PVP) beginning at amputation date with the initiation window ranging from immediately pre-operative to 7 days post operative.
11208517|NCT03326115|No Intervention|Delayed Peer Visitation (NoPVP)|Not participating in a Peer Visitation Program for 60 days post-operatively, followed by participation and completion in a PVP 60 days later than the PVP group for a total of 120 days.
11208518|NCT03326102|Experimental|DHP107|"The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.
~Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days."
11208519|NCT03326102|Experimental|IV paclitaxel|Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)
11208520|NCT03326089|Active Comparator|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
11208521|NCT03326089|Placebo Comparator|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
11208522|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
11208523|NCT03326076||Control|A matched control cohort of 1000 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) or KidneyCare will be retrospectively selected
11208524|NCT03326076||Secondary donor-derived cell-free DNA|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
11208525|NCT03326076||Primary KidneyCare®|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
11208526|NCT03326076||Secondary KidneyCare®|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
11208527|NCT03326063|Active Comparator|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
11208528|NCT03326063|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
11208529|NCT03326050|Placebo Comparator|gemifloxacin and Rifampicin|first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..
11208530|NCT03326050|Placebo Comparator|gemifloxacin and ciprofloxacin|. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily
11208531|NCT03326050|Placebo Comparator|gemifloxacin and placipo|.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily
11208532|NCT03326024||A|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years.
11208533|NCT03326024||B|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling
11208534|NCT03326011|Experimental|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
11208535|NCT03325998|Experimental|Gait training group|"Gait training with Samsung Hip Assist v1
~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
11208580|NCT03325712|Placebo Comparator|Placebo|
11208581|NCT03325712|Experimental|Dose Group 8|
11208536|NCT03325985|Experimental|Nurse-led telephonic case management|"Telephonic nurses will contact patients within 72 hours of enrollment
~Patients will speak with the telephonic nurse over the phone once a week (or as often as needed) for a duration of 6 months."
11208537|NCT03325985|Active Comparator|Facilitated, outpatient specialty palliative care|"Patients will be scheduled for their first in-person palliative care visit within two weeks of enrollment and then once a month for 6 months.
~Clinic visits will be scheduled the same day as other specialty appointments if possible"
11208538|NCT03325972|Experimental|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
11208539|NCT03325972|Placebo Comparator|Placebo|saline placebo
11208540|NCT03325959|Active Comparator|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
11208541|NCT03325959|Active Comparator|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.
~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
11208542|NCT03325946||Children and Adults with Cerebral Palsy|
11208543|NCT03325946||Children and Adults with Microcephaly|
11208544|NCT03325946||Children and Adults with other Neuromotor Impairments|
11208545|NCT03325933|Experimental|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
11208546|NCT03325933|Experimental|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
11208547|NCT03325933|No Intervention|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
11208548|NCT03325920|Experimental|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
11208549|NCT03325920|Experimental|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
11208550|NCT03325907|Experimental|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
11208551|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
11208552|NCT03325881|Experimental|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
11208553|NCT03325881|Placebo Comparator|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
11208554|NCT03325868|Experimental|Ulipristal|Ulipristal acetate 5mg daily for 12 weeks
11208555|NCT03325842||Cerebral palsy|ASKp will be submitted to children of 5 to 15 years with hemiplegia or diplegia due to Cerebral Palsy, with normal or slightly impaired cognitive level.
11208556|NCT03325842||Healthy individuals|ASKp will be submitted to children of 5 to 15 years with typical development
11208557|NCT03325829||Patients with colonic diverticula|No interventional study
11208558|NCT03325816|Experimental|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.
~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
11208559|NCT03325816|Experimental|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.
~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
11208560|NCT03325816|Experimental|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.
~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
11208561|NCT03325816|No Intervention|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
11208562|NCT03325803|Experimental|150μm-AFL-PDT|
11208563|NCT03325803|Experimental|350μm-AFL-PDT|
11208564|NCT03325803|Experimental|500μm-AFL-PDT|
11208565|NCT03325790|Placebo Comparator|Placebo|Placebo
11208566|NCT03325790|Experimental|200mg SPI-1005 twice daily (BID)|200mg SPI-1005 BID
11208567|NCT03325790|Experimental|400mg SPI-1005 BID|400mg SPI-1005 BID
11208568|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
11208569|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
11208570|NCT03325764|Other|PRE group|candidates seeking sleeve gastrectomy
11208571|NCT03325764|Other|POST group|patients 6 months after sleeve gastrectomy
11208572|NCT03325751||Healthy subjects|
11208573|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
11208574|NCT03325725|Experimental|NewBreez LD Intra-laryngeal implant|
11208582|NCT03325699|Experimental|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
11208583|NCT03325699|No Intervention|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
11208584|NCT03325686|Experimental|vitamin D supplement|D
11208585|NCT03325686|Placebo Comparator|control|P
11208586|NCT03325673|Experimental|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
11208587|NCT03325673|Sham Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
11208588|NCT03325660|Active Comparator|study group|whole body vibration
11208589|NCT03325660|No Intervention|control group|No intervention
11208590|NCT03325647|Experimental|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
11208591|NCT03325647|Experimental|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
11208592|NCT03325634|Experimental|Treatment (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) every other day for 3 fractions.
11208593|NCT03325621|Active Comparator|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
11208594|NCT03325621|Placebo Comparator|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
11208595|NCT03325608|Experimental|Intervention|The POISED care management team consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) will conduct a biopsychosocial/environmental needs assessment by phone within 48 hours of emergency room discharge if not possible during the ED stay.
11208596|NCT03325608|Placebo Comparator|Usual Care|will receive referrals to services at the time of enrollment.
11208597|NCT03325595|Active Comparator|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
11208598|NCT03325595|Placebo Comparator|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
11208599|NCT03325569|Active Comparator|NGT|NGT - normal glucose tolerance. Women with PCOS and normal glucose tolerance
11208600|NCT03325569|Active Comparator|IGH|IGH - impaired glucose homeostasis Women with PCOS and impaired glucose homeostasis - that means impaired fasting glucose or impaired glucose tolerance.
11208601|NCT03325556|Placebo Comparator|Placebo|
11208602|NCT03325556|Experimental|Drug - Pimavanserin|
11208603|NCT03325543|Experimental|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
11208604|NCT03325543|Active Comparator|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
11208605|NCT03325530||Focus Group|
11208606|NCT03325504|Experimental|hBM-MSCs-Low Dose|Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells
11208607|NCT03325504|Experimental|hBM-MSCs-High Dose|Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells
11208608|NCT03325504|Active Comparator|Autologous Illiac crest graft|Autologous Iliac Crest Grafting
11208609|NCT03325491|Experimental|Acipimox plus exercise training|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
11208610|NCT03325491|Placebo Comparator|Placebo plus exercise training|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
11208611|NCT03325465|Experimental|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.
~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
11208612|NCT03325452|Experimental|cardio-respiratory arrest|
11208613|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
11208614|NCT03325426|No Intervention|Usual care|
11208615|NCT03325426|Experimental|Physical activity tracker|
11208616|NCT03325413|No Intervention|Control|Usual care with assessment only (no study-related intervention)
11208617|NCT03325413|Other|Implementation|Implementation of intervention measures
11208618|NCT03325413|Other|Full-scale intervention|
11208619|NCT03325400|Other|Non-fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
11208718|NCT03324581|Active Comparator|Atomoxetine|40 mg capsule titrated up to 80 mg, daily, oral
11208719|NCT03324581|Placebo Comparator|Placebo|tablet/capsule, daily, oral
11208620|NCT03325400|Active Comparator|Fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
11208621|NCT03325387|Experimental|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
11208622|NCT03325387|Placebo Comparator|Placebo|Saline solution administered by SC injection
11208623|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
11208624|NCT03325361|Experimental|TD|
11208625|NCT03325361|No Intervention|NTD|
11208626|NCT03325348|Experimental|Oral Nifedipine|Nifedipine 10mg oral tablet & 1ml 0.9%N/Saline will be given every 15 minutes up till one hour
11208627|NCT03325348|Active Comparator|IV Labetalol|IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour
11208628|NCT03325335|Active Comparator|Midazolam premedication group (Group P)|Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery.
11208629|NCT03325335|Other|Control group (Group N)|Patients of group N were not premedicated with midazolam (Do not use placebo). [Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-> removed from interventions)]
11208630|NCT03325322|Experimental|Treatment|Fisetin 20 mg/kg/day, orally for 2 consecutive days
11208631|NCT03325322|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
11208632|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
11208633|NCT03325296|Experimental|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
11208634|NCT03325296|Placebo Comparator|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
11208635|NCT03325283|Experimental|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
11208636|NCT03325270|Experimental|ferrous fumarate|labeled iron as Ferrous Fumarate
11208637|NCT03325270|Experimental|ferrous fumarate and GOS|labeled ferrous fumarate + prebiotics
11208638|NCT03325270|Experimental|ferrous sulfate and GOS|labeled ferrous sulfate + prebiotics
11208639|NCT03325244||All participants|All participants will use a portable EEG monitor and FITBIT to monitor sleep and activity before and after night call
11208640|NCT03325231||Bladder Cancer Patients|Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
11208641|NCT03325218||Questionnaire Set A|
11208642|NCT03325218||Questionnaire Set B|
11208643|NCT03325205|Experimental|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
11208644|NCT03325205|Sham Comparator|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
11208645|NCT03325192|Placebo Comparator|Standard of care|Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
11208646|NCT03325192|Experimental|Rapid pleurodesis protocol|Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter
11208647|NCT03325179|Experimental|participants received treatment|100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial. Each will receive Thread-embedding therapy.
11208648|NCT03325166|Experimental|Treatment (pembrolizumab, ferumoxytol MRI)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (or up to 32 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI at baseline, 12 weeks after radiation, at suspected radiographic progression, and 6 weeks after suspected radiographic progression.
11208649|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
11208650|NCT03325114|Other|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
11208651|NCT03325101|Experimental|Treatment (apheresis, pembrolizumab, cryosurgery, mDCs)|Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
11208652|NCT03325088|Other|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
11208653|NCT03325088|Other|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
11208654|NCT03325088|Other|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
11208655|NCT03325075|Experimental|VAL-181388|
11208656|NCT03325075|Placebo Comparator|Placebo|
11208657|NCT03325062|Experimental|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
11208658|NCT03325062|Active Comparator|CONTROL|Contemporary progressive rehabilitation
11208695|NCT03324789|Experimental|Single Implant Partial Over-denture|The design will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
11208720|NCT03324568|Other|Educational handout|
11208659|NCT03325049|Experimental|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
11208660|NCT03325049|Active Comparator|Control Arm|Usual Care
11208661|NCT03325023|Active Comparator|Active Comparator:|Dietary modification + Probiotic supplementation (Sanprobi Super Formula)
11208662|NCT03325023|Placebo Comparator|Placebo Comparator|Dietary modification + placebo.
11208663|NCT03325010|Placebo Comparator|Placebo|Capsule, administered once daily for 12 weeks.
11208664|NCT03325010|Experimental|Valbenazine|Capsule, administered once daily for 12 weeks.
11208665|NCT03324997|Experimental|Restylane|half the chest to be treated with Restylane Silk
11208666|NCT03324997|Placebo Comparator|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
11208667|NCT03324984|Experimental|1% Chloroprocaine (PF)|1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
11208668|NCT03324984|Active Comparator|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
11208669|NCT03324971|Experimental|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
11208670|NCT03324958|Experimental|Virtual Reality Helmet|Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
11208671|NCT03324958|Active Comparator|No Virtual Reality Helmet|Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.
11208672|NCT03324945|Experimental|Neurocognitive Assessment +/- FMRI|All participants receive pre- and post-chemotherapy neurocognitive assessments. A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
11208673|NCT03324932|Other|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
11208674|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
11208675|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
11208676|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
11208677|NCT03324906|Active Comparator|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
11208678|NCT03324906|Active Comparator|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
11208679|NCT03324893|Experimental|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
11208680|NCT03324880|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) 50 microgram (mcg) subcutaneous (SC) injection once daily (QD), titrated within the dose range of 25-100 mcg QD as an adjunctive treatment with active vitamin D and calcium supplements based on metabolic response.
11208681|NCT03324880|Placebo Comparator|Placebo|Participants will receive placebo matched to rhPTH(1-84) as SC injection QD with active vitamin D and calcium supplements.
11208682|NCT03324867|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7
11208683|NCT03324867|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to POD 7
11208684|NCT03324854|Experimental|mosquito net mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the mosquito net mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
11208685|NCT03324854|Active Comparator|prolene mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the prolene mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
11208686|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
11208687|NCT03324828|Active Comparator|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
11208688|NCT03324828|Experimental|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
11208689|NCT03324828|Active Comparator|Placebo+clowns|Patients will receive placebo solution and clowns intervention
11208690|NCT03324828|No Intervention|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
11208691|NCT03324815|Active Comparator|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
11208692|NCT03324815|Active Comparator|Morphine|Morphine: 5mg/6h
11208693|NCT03324802|Experimental|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
11208694|NCT03324802|Experimental|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
11208696|NCT03324789|Active Comparator|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
11208697|NCT03324776|Other|Afrezza Inhalant Product|Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
11208698|NCT03324763||stool sampling|
11208699|NCT03324737|No Intervention|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
11208700|NCT03324737|Active Comparator|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.
~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
11208701|NCT03324724|Experimental|Adolescents with Eating Disorder|Adolescents with bulimia nervosa or binge eating disorder, with one or more of their parents, will receive integrative cognitive-affective therapy for adolescents (ICAT-A).
11208702|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
11208703|NCT03324685|Experimental|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
11208704|NCT03324672|Active Comparator|TRIGGER|
11208705|NCT03324672|Experimental|TRIGGER+CURETAPE|
11208706|NCT03324659|Experimental|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
11208707|NCT03324659|Sham Comparator|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
11208708|NCT03324646||controls|healthy subjects
11208709|NCT03324620|Experimental|pre active HSCT|"Candidates for transplantation of hematopoietic progenitors since May 12, 2012, regardless of sex and age, who agree to participate in the study and sign informed consent.
~In the pre-transplantation visit with the physiotherapist: Measures of muscle mass and strength, quality of life questionnaires, program presentation, fitness assessment and lifestyle determination. The exercises will be personalized, stimulating your practice before admission and involving the family. During admission, the team will encourage the patient to remain active by adapting to the symptoms. At discharge, measures of resistance, exercise tolerance and quality of life at discharge, in the month after discharge, 3 months after discharge, 6 months after discharge and 12 months after discharge."
11208710|NCT03324620|No Intervention|control group|"Patients' candidates for transplantation of hematopoietic progenitors prior to May 12, 2012, regardless of gender and age, who meet the inclusion criteria and are collected correlatively until completing 104 subjects.
~Clinical history review to calculate the days of hospitalization in the different hospitalization units during the transplant. As well as the number and type of complications and the use of health resources. Status vitae. Baseline review of functional tests and exercise tolerance."
11208711|NCT03324594|Active Comparator|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
11208712|NCT03324594|Active Comparator|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
11208713|NCT03324594|Active Comparator|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
11208714|NCT03324594|Active Comparator|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
11208715|NCT03324594|Active Comparator|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
11208716|NCT03324594|Active Comparator|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
11208717|NCT03324581|Experimental|OPC-64005|20 mg tablet dose, titrated up to a max of 30 mg, daily, oral
11208723|NCT03324529|Experimental|Participants in the NYU takotsubo registry|"10 patients with a confirmed history of takotsubo syndrome
~10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness"
11208724|NCT03324516|Experimental|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
11208725|NCT03324516|Active Comparator|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
11208726|NCT03324503|Experimental|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
11208727|NCT03324490|Active Comparator|TSA group|Thoracic Spinal Anesthesia; Bupivacaine 0.5% (hyperbaric) 7.5mg, Fentanyl 25 µg & Dexmedetomidine 5 µg by intrathecal injection
11208728|NCT03324490|Active Comparator|TEA group|Thoracic Epidural Anesthesia; Bupivacaine 0.5% (isobaric) 25-50 mg & Fentanyl 10-20 µg by epidural injection
11208729|NCT03324477|Experimental|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
11208730|NCT03324477|Experimental|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
11208731|NCT03324464|Experimental|CET-Working Memory (WM)|Central Executive Training: Working Memory
11208732|NCT03324464|Active Comparator|CET-Behavioral Inhibition (BI)|Central Executive Training: Inhibitory Control
11208733|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
11208734|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
11208735|NCT03324438|Active Comparator|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
11208736|NCT03324438|Experimental|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
11208737|NCT03324438|Experimental|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
11208738|NCT03324438|Experimental|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
11208739|NCT03324425|Experimental|Simvastatin|Simvastatin 80 mg in combination with anti-HER2 therapy regimen
11208740|NCT03324412|Active Comparator|Treatment of MTX|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.
11208741|NCT03324412|Experimental|Treatment of MTX and TwHF|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF).
11208742|NCT03324399|Experimental|High Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.
~Patients taking proprietary probiotic"
11208743|NCT03324399|Experimental|Low Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.
~Patients taking proprietary probiotic"
11208744|NCT03324386|Experimental|Individual Orientation|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients: Experimental: individual orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);The ntervention is composed by relational strategies characterized by interpersonal relationships
11208745|NCT03324386|Experimental|VLE for Distance Learning|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients:Experimental: a technological education strategy for distance learning (DL), using a technological education strategy (E-Care of Hypertension) for Distance Learning (DL) characterized by 7 nursing visits at 20-day intervals, for 4 months). The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in educational environments remotely accessed for health education specifically for hypertensive patients
11208746|NCT03324386|Experimental|E-blended Learning|This was a prospective randomized clinical study with the patient received experimental intervention: a technological education strategy with E-blended Learning modality with E-Care of Hypertension, associated with face-to-face consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months. The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in presential educational environments intended for health education specifically for hypertensive patients
11208747|NCT03324386|No Intervention|No intervention|No type of intervention was performed making 2 nursing visits at baseline and 1 after 120 days (No intervention)
11208748|NCT03324373|Experimental|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
11208749|NCT03324360|Experimental|Control Participants Part I|A MRI with injection of hyperpolarized 13C pyruvate.
11208750|NCT03324360|Experimental|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
11208751|NCT03324360|Experimental|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
11208752|NCT03324347|Experimental|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
11208753|NCT03324347|No Intervention|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
11208754|NCT03324334||Study group|Patients with ulcerative colitis Interventions to be administered: Thyroid antibodies and Thyroid sonography
11267475|NCT02922699|Active Comparator|Omeprazole 80 mg|Omez 80mg OD
11208755|NCT03324334||Control group|normal control subjects selected from general population at random Interventions to be administered: Thyroid antibodies and Thyroid sonography
11208756|NCT03324321|Experimental|Hyperventilation Protocol|This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
11208757|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.
~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
11208758|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
11208759|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
11208760|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
11208761|NCT03324282|Experimental|Arm A: GC + avelumab group|
11208762|NCT03324282|Active Comparator|Arm B: GC group|
11208763|NCT03324269|Other|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).
~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 10 or decrement of 1 ng/ml if NOL gradient < 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision and sternotomy. NOL and hemodynamic responses will be recorded during the entire duration of thyroid surgery and until the cardiopulmonary bypass during cardiac surgery."
11208764|NCT03324256|Active Comparator|Energy drink and placebo gum|Commercially-available energy drink (16oz) + 2 pieces of placebo gum
11208765|NCT03324256|Active Comparator|Caffeinated drink and placebo gum|Commercially-available caffeinated drink (16oz) + 2 pieces of placebo gum
11208766|NCT03324256|Active Comparator|Control drink and energy gum|Control drink (16oz) + 2 pieces of energy gum
11208767|NCT03324256|Placebo Comparator|Control drink and placebo gum|Control drink (16oz) + 2 pieces of placebo gum
11208768|NCT03324256|Active Comparator|Energy drink and total sleep deprivation|Commercially-available energy drink (16oz) + 2 pieces of placebo gum following total sleep deprivation
11208769|NCT03324243|Experimental|Crenolanib|
11208770|NCT03324217|Experimental|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
11208771|NCT03324217|Experimental|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
11208772|NCT03324217|Active Comparator|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
11208773|NCT03324204|Experimental|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
11208774|NCT03324204|Active Comparator|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
11208775|NCT03324191|Placebo Comparator|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
11208776|NCT03324191|Experimental|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
11208834|NCT03323749|Experimental|Part 1: Elamipretide|Subjects will be randomized to receive either elamipretide or placebo for 24 weeks. For the elamipretide arm, subjects will administer daily 40 mg (0.5mL) subcutaneous injections of elamipretide.
11208777|NCT03324191|Experimental|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
11208778|NCT03324191|Experimental|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.
~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.
~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
11208779|NCT03324178|Experimental|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training performed once a day over the course of four weeks (four sessions each week)
11208780|NCT03324178|Active Comparator|Video game control group|Sixteen 30-minute sessions of playing video games once a day over the course of four weeks (four sessions each week)
11208781|NCT03324165|No Intervention|Usual Care Arm|Patients randomized to Usual Care Arm will be managed as per current best practice that is based on the individual doctor's discretion.
11208782|NCT03324165|Experimental|Intervention Arm|Patients randomized to Intervention Arm will be managed as per the proposed algorithm, which is based on the computation of Alvarado Score.
11208783|NCT03324152|Experimental|High-intensity interval training (HIIT) - myositis|12-week, 3d/w, HIIT
11208784|NCT03324152|Active Comparator|Standard low-intensity home exercise control (CG)|12-week, 5 d/w, home exercise.
11208785|NCT03324152|Active Comparator|High-intensity interval training (HIIT) - healthy|12-week, 3d/w, HIIT.
11208786|NCT03324139|Experimental|Study Group|Treatment with low molecular weight Heparin.
11208787|NCT03324139|Placebo Comparator|Control Group|Treatment with Placebo.
11208788|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
11208789|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
11208790|NCT03324113|Experimental|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
11208791|NCT03324100||Allergic Rhinitis Patients|
11208792|NCT03324100||Healthy Controls|
11208793|NCT03324087||Adult patients with ITP|The investigators are undertaking a multi-center, prospective trail of 1000 adult ITP patients and use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
11208794|NCT03324061|Experimental|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
11208795|NCT03324061|Active Comparator|Faslodex (R)|Faslodex (250 mg/mL)
11208796|NCT03324048|Other|Patients anxious|Patients anxious will be perform relaxation session.
11208797|NCT03324035|Experimental|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
11208798|NCT03324035|Placebo Comparator|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
11208799|NCT03324009|Experimental|2-stage screen|All patients will be enrolled in the two-stage cervical cancer screening protocol
11208800|NCT03323996||Health Professionals|Health Professionals attending a training in therapeutic education
11208801|NCT03323996||Patients|Patients of the health Professionals recruited for the study
11208802|NCT03323983||Normal lung clearance index|
11208803|NCT03323983||Elevated lung clearance index|
11208804|NCT03323970||Physicians|
11208805|NCT03323957||Patients|all infants admitted for care
11208806|NCT03323944|Experimental|Cohort 1: huCART-meso cells without lymphodepletion|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells without any conditioning chemotherapeutic regimen.
11208807|NCT03323944|Experimental|Cohort 2: huCART-meso cells following lymphodepletion|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells following a flat dose of 1 gram/m^2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (approximately day -4 to day -2).
11208808|NCT03323944|Experimental|Cohort -1: low-dose huCART-meso cells without lymphodepletion|Subjects will receive a single dose of 1-3x10^6 cells/m^2 lentiviral transduced huCART-meso cells on day 0 without any conditioning chemotherapeutic regimen.
11208809|NCT03323931|Active Comparator|(1) standard therapy|Standard therapy based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the therapist reinforces the adaptive behavior of the child.
11208835|NCT03323749|Placebo Comparator|Part 1: Placebo|Subjects will be randomized to receive either elamipretide or placebo for 24 weeks. For the placebo arm, subjects will administer daily 40 mg (0.5 mL) subcutaneous injections of placebo for 24 weeks.
11208810|NCT03323931|Experimental|(2) robot--enhanced intervention|A treatment developed on the same principles as standard therapy, based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the robotic agent reinforces the adaptive behaviors of the child, under the supervision of the therapist.
11208811|NCT03323918|Experimental|ImPACT|Project ImPACT will be provided in 18 weekly intervention sessions, during which parents will learn how to stimulate their children's social imitation, social engagement, language and play skills. First, parents are taught techniques that promote interaction with the child (one technique per session, through demonstration and coaching). In the second half of the intervention, parents are taught direct teaching techniques, e.g., to promote language or play, again by means of demonstration and coaching. After completion of the program, families will receive guidance every 2-3 weeks for an additional 12 weeks, during which the support will generally not focus on social-communicative abilities, although ImPACT follow-up sessions might be given if necessary.
11208812|NCT03323918|Active Comparator|TAU|Treatment as usual (TAU) will be provided at the typical frequency, which is every 2-3 weeks. TAU can include targeting eating and sleeping problems, adaptive skills, or other goals. TAU will not include forms of intervention explicitly targeting social communicative skills. However, limited guidance on social communication development can be given if explicitly asked by parents.
11208813|NCT03323905|Experimental|MR Guided High Intensity Focused Ultrasound|
11208814|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
11208815|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.
~Intervention = second sperm sample"
11208816|NCT03323879|Experimental|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
11208817|NCT03323866|Active Comparator|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
11208818|NCT03323866|Experimental|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
11208819|NCT03323853|Experimental|CARS Report|
11208820|NCT03323853|No Intervention|No CARS report|
11208821|NCT03323840|Experimental|Incentivized Care|Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement.
11208822|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.
~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) nondiabetics 20 subjects will be enrolled"
11208823|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.
~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 32 subjects will be enrolled"
11208824|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.
~Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 20 subjects will be enrolled."
11208825|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
11208826|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
11208827|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
11208828|NCT03323801|Experimental|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
11208829|NCT03323788||Aim 1|Aim 1. To determine whether the transcription factor expression response to exercise is dysregulated in muscle from type 2 diabetic patients. We will test the hypothesis that MZF1, NFKB1, RELA, SP1/KLF and EGR1 responses to an acute exercise bout are reduced in insulin resistant patients with type 2 diabetes.
11208830|NCT03323788||Aim 2|"Aim 2. To determine how insulin resistance changes the response of post-translational modifications of SP1/KLF family and MZF1 transcription factors to acute exercise in muscle from type 2 diabetic patients. We will test the hypothesis that:
~SP1/KLF2, 4, and 6 and phosphorylation/acetylation and MZF1 phosphorylation is altered in response to acute exercise.
~The response of SP1/KLF2, 4, and 6 phosphorylation and acetylation and MZF1 phosphorylation to acute exercise is abnormal in patients with type 2 diabetes."
11208831|NCT03323788||Aim 3|"Aim 3. To define the response of miRNAs to acute exercise in healthy and insulin resistant muscle from obese and type 2 diabetic patients. We will test the hypotheses that:
~The exercise-induced increases in expression of miR-378 members and miR-128 are lower in obese and type 2 diabetic muscle than in lean healthy controls.
~FOXO1 expression, a target of miR-378 and miR-128, is higher in obese and type 2 diabetic muscle and this is accompanied by decreased FOXO1 phosphorylation.
~The exercise-induced increases in expression of miR-30 family members, miR-10a, miR-422a, and miR-532 are lower in obese and type 2 diabetic muscle.
~There are novel miRNAs that regulate the transcriptional program induced by acute exercise and are dysregulated in insulin resistance."
11208832|NCT03323788||Aim 4|Aim 4. To determine whether treatment with PPAR-Alpha agonist fibrate derivatives suppresses the normal gene expression response to acute exercise. We will test the hypothesis that Gemfibrozil treatment inhibits the normal transcriptional response to exercise.
11208833|NCT03323762|Experimental|RIC|"RIC treatment arm The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes.
~The treatment will be carried out on the morning of day 2 to day 7 by the participants themselves at their home."
11208901|NCT03323255|Sham Comparator|SHAM stimulation (placebo)|SHAM stimulation
11208836|NCT03323749|Experimental|Part 2: Elamipretide open label|Once subjects complete part 1, and meet continuation criteria, they will have the option to continue into an open-label treatment extension. Subjects will receive 40 mg (0.5 mL) subcutaneous injections of elamipretide for up to 144 weeks.
11208837|NCT03323736|Other|Pivotal Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office.
11208838|NCT03323736|Other|Office Lead-In Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office. Physician initial in-office iontophoresis and tube insertion procedures (minimum of 2 subjects per investigator).
11208839|NCT03323736|Other|OR Lead-In Cohort|Tubes insertion using the Tube Delivery System in the operating room (OR). Physician initial tube insertion procedures in the OR (minimum of 2 subjects per investigator).
11208840|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
11208841|NCT03323710|Experimental|Propranolol plus Sunitinib|
11208842|NCT03323697|Experimental|Herbal|SZ-05 (2.5 gr; 3 capsules twice a day)
11208843|NCT03323697|Active Comparator|Selective serotonin reuptake inhibitor|Escitalopram (10 mg capsule plus 5 placebo capsules)
11208844|NCT03323684|Experimental|Quadratus lumborum block Group (QL)|Quadratus lumborum block will be performed
11208845|NCT03323684|Experimental|Transversus abdominis plane Group (TAP)|Subcostal transversus abdominis plane will be performed
11208846|NCT03323684|Experimental|Control group (C)|Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac
11208847|NCT03323671|Experimental|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
11208848|NCT03323671|Experimental|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
11208849|NCT03323658|Experimental|Prevention (bexarotene)|Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.
11208850|NCT03323645||Patients with penile prostheses|
11208851|NCT03323632|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
11208852|NCT03323619||GA|No intervention. General anesthesia is decided by the physicien according to his usual practice
11208853|NCT03323619||LASed|No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice
11208854|NCT03323606|Active Comparator|Gambling Internet Intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
11208855|NCT03323606|Experimental|Gambling Internet Intervention + CYD|The G+A intervention condition will consist of the G-only intervention and an online intervention for drinking. The online drinking intervention chosen is Check Your Drinking, a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
11208856|NCT03323593|Active Comparator|iv|
11208857|NCT03323593|Active Comparator|drip|
11208858|NCT03323593|Active Comparator|atomizer|
11208859|NCT03323580|Experimental|SVV-based GDFT group|The patients will receive fluid therapy under SVV-directed goal.
11208860|NCT03323580|Sham Comparator|non-SVV-based GDFT group|The patients will receive fluid therapy without SVV-directed goal.
11208861|NCT03323567|Experimental|MD Muscle Collagen group|Group with collagen intramuscular injections
11208862|NCT03323567|Experimental|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
11208863|NCT03323567|Placebo Comparator|Saline|Group with 0,9% NaCl intramuscular injections
11208864|NCT03323554|Experimental|Ustrap®|Ustrap is a new adjustable-pressure 4-arm device
11208865|NCT03323554|Active Comparator|AMS 800®|Artificial sphincter currently considered the gold standard device in this field
11208866|NCT03323541||Group of patients treated with Zarxio|All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
11208867|NCT03323528|Active Comparator|Dorithricin|"Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.
~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
11208868|NCT03323528|Placebo Comparator|Placebo|"Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.
~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
11208869|NCT03323502|Experimental|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
11208870|NCT03323502|No Intervention|Usual Care|Facility will followed usual ACP procedures.
11208871|NCT03323489|Experimental|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
11208872|NCT03323476|Experimental|Discontinuation of maintenance treatment|
11208873|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
11208874|NCT03323463|Experimental|Arm A: HPV associated oropharyngeal carcinoma|HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia
11208875|NCT03323463|Experimental|Arm B: HPV associated oropharyngeal carcinoma|"HPV associated oropharyngeal carcinoma subjects who also have no evidence of hypoxia.
~Given the restrictions of surgery during the COVID19 pandemic, we will start enrolling patients on Cohort B where surgery is not required. Once the COVI19 pandemic is over, we will resume and complete enrollment on Cohort A where surgery is required, prior to continuing enrolling patients on Cohort B."
11208876|NCT03323450|Experimental|High grade gliomas(WHO grade III or IV; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
11208877|NCT03323450|Experimental|Low grade gliomas(WHO grade II; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
11208878|NCT03323437|Experimental|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
11208879|NCT03323437|No Intervention|Control|Healthy, psychosis-free controls who will not receive risperidone
11208880|NCT03323424|Experimental|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
11208881|NCT03323424|Active Comparator|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
11208882|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
11208883|NCT03323398|Experimental|Arm A: mRNA-2416 alone|mRNA-2416 escalating dose levels; expansion cohort
11208884|NCT03323398|Experimental|Arm B: mRNA-2416 in combination with durvalumab|mRNA-2416 in combination with durvalumab escalating dose levels; expansion cohort
11208885|NCT03323385|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
11208886|NCT03323385|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
11208887|NCT03323372|Active Comparator|control group|In group 1 (G1-control), the operator applied a desensitizing gel based on 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2% ®, FGM , Joinville, Santa Catarina, Brazil) with the aid of a custom silicone tray, which was made from a model obtained from the patient, with a vacuum plasticizer. A small layer of the gel was placed on the surface of the tray that was in contact with the vestibular face of the upper anterior teeth of the participants. The tray remained in position in the mouth for 10 minutes, according to the manufacturer's specifications.
11208888|NCT03323372|Experimental|experimental group|In group 2 (G2-intervention group), the operator applied a desensitizing gel containing 3% potassium nitrate and 0.25% sodium fluoride (Ultra EZ®, Ultradent Products Inc, South Jordan, UT, Estados Unidos) with the help of a tray in which the material is stored on the vestibular surfaces of the upper anterior teeth of the participants. The tray remained in position in the mouth for 15 minutes, according to the manufacturer's specifications.
11208889|NCT03323359|Experimental|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
11208890|NCT03323359|Other|Standard Surgery Technique|Common surgical techniques
11208891|NCT03323346|Experimental|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.
~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.
~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
11208892|NCT03323333|Experimental|Intervention|
11208893|NCT03323307|Experimental|OCT imaging|OCT device images retina
11208894|NCT03323294||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
11208895|NCT03323294||Healthy Obese|Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
11208896|NCT03323294||Obese Insulin Resistant|Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
11208897|NCT03323294||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance (n=20)
11208898|NCT03323281||Diabetic Type 1 or Type 2 with foot wound|Type 1 or type 2 diabetic patients with hospitalization for foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
11208899|NCT03323281||Diabetic Type 1 or Type 2 without a foot wound or antecedent|Type 1 or Type 2 diabetic patients with no foot wounds or history of foot wounds having an interview with a neuropsychologist or a physician trained in neuropsychological assessments
11208900|NCT03323255|Active Comparator|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
11208902|NCT03323242|No Intervention|Control group|Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
11208903|NCT03323242|Experimental|LS group|Recipient hepatectomy applying LigaSure.
11208904|NCT03323242|Experimental|USD group|Recipient hepatectomy applying Harmonic Ultrasonic dissector.
11208905|NCT03323229|No Intervention|Usual care (control group)|Patient receives care as usual.
11208906|NCT03323229|Experimental|Enhanced communications & ultrasound|The paramedic will record a brief video summary of the patient's condition, then remotely supported point of care ultrasound scans will be performed, and both file types sent to the hospital for review and feedback from the consultant.
11208907|NCT03323216||No diabetes|Patients without diabetes
11208908|NCT03323216||Type 2 diabetes|Patients with diagnosis of type 2 diabetes (new/established)
11208909|NCT03323216||Prediabetes|Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.
11208910|NCT03323190|Experimental|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
11208911|NCT03323177|Experimental|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
11208912|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
11208913|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
11208914|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
11208915|NCT03323151|Experimental|Phase I: Ixazomib & Ibrutinib|Ixazomib and Ibrutinib will be given by mouth until progression or unacceptable toxicity.
11208916|NCT03323151|Experimental|Phase II: Ixazomib & BTK-Naive|Patients who are BTK-Naive will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
11208917|NCT03323151|Experimental|Phase II: Ixazomib & BTK Pre-Treated (Closed 8/7/2020)|Patients previously treated with a BTK will receive Ixazomib and Ibrutinib by mouth until progression or unacceptable toxicity.
11208918|NCT03323138|Experimental|Ex-PRESS and phacoemulsification|A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).
11208919|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
11208920|NCT03323099|Experimental|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
11208921|NCT03323099|Placebo Comparator|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
11208922|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
11208923|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
11208924|NCT03323073|Active Comparator|Bipolar disorder type I or II|a single resting state fMR for patients with bipolar disorder type I or II with acute depressive state
11208925|NCT03323073|Active Comparator|Unipolar disorder|a single resting state fMR for patients with monopolar disorder with acute depressive state
11208926|NCT03323073|Other|Healthy volunteers|a single resting state fMRI for subjects without psychiatric disorders assessed by the SCID
11208927|NCT03323060||Male and/or females ≥ 22 yrs old|≥ 22 years of age requiring transanal procedures in the areas of the anus, rectum, and distal colon Transanal endoscopic surgical procedure
11208928|NCT03323047|Experimental|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
11208929|NCT03323047|Active Comparator|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
11208930|NCT03323047|Placebo Comparator|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
11208931|NCT03323034|Experimental|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1. Beginning cycle 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan IV over 90 minutes on days 1-5. Treatment repeats every 28 days for cycle 1 and 21 days for subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
11208932|NCT03323021|Experimental|Treatment with DHACM|Partial nephrectomy patched with DHACM
11208933|NCT03323021|Active Comparator|Control without DHACM|Partial nephrectomy without DHACM.
11208934|NCT03323008|Experimental|Training Prototype|Testing of 3 modules
11208935|NCT03322995|Experimental|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
11209062|NCT03322098|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
11208936|NCT03322995|Experimental|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
11208937|NCT03322995|Experimental|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
11208938|NCT03322982|Experimental|MS Diet|34 people with MS following low-fat diet
11208939|NCT03322982|No Intervention|MS Wait-List|34 people with MS following usual diet
11208940|NCT03322982|No Intervention|Diet Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Diet group
11208941|NCT03322982|No Intervention|Wait-List Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Wait-List group
11208942|NCT03322969|Experimental|receiving modified chemotherapy|Paclitaxel/DDP
11208943|NCT03322969|Active Comparator|receiving the original chemotherapy|XELOX/SOX
11208944|NCT03322956|Experimental|experimental group (EGR)|"Physical therapy intervention.
~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
11208945|NCT03322956|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.
~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
11208946|NCT03322930||Retinitis Pigmentosa|patients with a diagnosis of retinitis pigmentosa and reduced rod function on baseline testing
11208947|NCT03322930||Age-related Macular Degeneration|patients with a diagnosis of intermediate AMD and reduced rod function on baseline testing
11208948|NCT03322891|Experimental|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
11208949|NCT03322878|Experimental|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
11208950|NCT03322878|Active Comparator|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
11208951|NCT03322878|Placebo Comparator|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
11208952|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
11208953|NCT03322839|Experimental|Multifaceted implementation strategies|The school-management will participate in a one-day training. In addition each intervention school will form an implementation team that is responsible for the implementation of the guideline within their school. The implementation teams will participate in 4-5 workshops in order to support the implementation process.
11208954|NCT03322839|Active Comparator|Single implementation strategy|The control-schools will only receive training to the school-management.
11208955|NCT03322826|Active Comparator|Lymphadenectomy|systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
11208956|NCT03322826|Experimental|systematic sampling of the lymph nodes|systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
11208957|NCT03322813|Experimental|ExAblate 4000 - Type 2|ExAblate BBBD
11208958|NCT03322800|Experimental|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
11208959|NCT03322800|Experimental|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
11208960|NCT03322800|Experimental|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
11208961|NCT03322800|Experimental|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
11208962|NCT03322800|Experimental|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
11208963|NCT03322800|Other|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
11208964|NCT03322787|No Intervention|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
11208965|NCT03322787|Experimental|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
11208966|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
11208967|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
11209025|NCT03322371|Other|ICU patients, sedated and ventilated|Adult ICU patients (> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited electroencephalography recording
11208968|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
11208969|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
11208970|NCT03322761|Experimental|Systematic exercise training|Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
11208971|NCT03322761|Active Comparator|Educational program|Educational program on physical activity and health, consisting of four educational sessions in the intervention period.
11208972|NCT03322761|No Intervention|Standard treatment alone|Data from The Danish MS Registry will serve as control-data for standard treatment alone.
11208973|NCT03322748|Experimental|Experimental group|Usual physical therapy+ strengthening of lower limbs muscles
11208974|NCT03322748|Other|Control group|Usual physical therapy
11208975|NCT03322735|Experimental|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.
~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
11208976|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
11208977|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
11208978|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
11208979|NCT03322696||Cirr-PVT|Cirrhotic patients developing over 1 yr period thrombosis of portal vein or collaterals
11208980|NCT03322683|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 5 massage sessions with the PHYSIUM device for a month.
11208981|NCT03322683|Experimental|CONTROL GROUP|"The multimodal physical therapy program includes 10 sessions of:
~ultrasound pulsatil therapy (US) for 10 minutes.
~transcutaneous electric nerve stimulation (TENS) for 20 minutes.
~massage for 20 minutes."
11208982|NCT03322670||Signs of CAP and a positive chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
11208983|NCT03322670||Patients directly hospitalized|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and who are directly hospitalized before complementary examinations
11208984|NCT03322670||Control patients|Healthy Patients (age-matched with a radiologically confirmed CAP patient)
11208985|NCT03322670||Patients with partial participation|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and who can not or do not want to perform all the complementary examinations of the study
11208986|NCT03322670||Signs of CAP and a negative Chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
11208987|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
11208988|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
11208989|NCT03322644|Experimental|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
11208990|NCT03322644|No Intervention|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
11208991|NCT03322631|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
11208992|NCT03322631|Placebo Comparator|Placebo|Placebo administered SC.
11208993|NCT03322618|Experimental|SpA HLA-B27 +,|
11208994|NCT03322618|Experimental|SpA HLA-B27-|
11208995|NCT03322618|Active Comparator|healthy subject|
11208996|NCT03322592|Active Comparator|EUS-FNB with ROSE|Intervention: Rapid on-site evaluation (ROSE) In the EUS-FNB with ROSE arm, the material obtained with the first pass will be processed for ROSE using the touch imprint technique. The biopsy specimen is carefully pressed onto the slide, allowing the superficial cells to adhere, and then gently lifted with forceps thereby creating a touch imprint of the specimen on the slide. In case of inadequate sample, a second pass will be done and the touch imprint technique will be repeated up to a maximum of 3 passes. In case of adequate ROSE at the first or the second pass, the additional passes will be performed as EUS-FNB and the material obtained placed directly into formalin or other fixative for subsequent histopathological evaluation.
11208997|NCT03322592|Active Comparator|EUS-FNB without ROSE|Intervention: histologic evaluation In the FNB alone arm, 3 needle passes will be performed and the samples obtained will be placed directly in a vial containing formalin (or other fixative according to the local individual protocol). Macroscopic on-site evaluation (MOSE) of acquired sample will be then performed by the endoscopist.
11208998|NCT03322579|Experimental|Patients with Eustachian tube dysfunction|
11209026|NCT03322358|No Intervention|Control|No changes to normal sleep habits.
11209027|NCT03322358|Experimental|Naps only|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
11209059|NCT03322124|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
11208999|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
11209000|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
11209001|NCT03322566|Experimental|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
11209002|NCT03322553|Experimental|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
11209003|NCT03322553|Sham Comparator|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
11209004|NCT03322540|Experimental|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
11209005|NCT03322540|Active Comparator|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
11209006|NCT03322514|Experimental|experimental group|10 g of Inulin-Propionate Esters will be administered per day
11209007|NCT03322514|Active Comparator|Inulin|10 g of Inulin will be administered per day
11209008|NCT03322501|Experimental|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
11209009|NCT03322488|Experimental|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
11209010|NCT03322488|Experimental|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
11209011|NCT03322475|Experimental|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
11209012|NCT03322462|Experimental|Flortaucipir PET Scan|
11209013|NCT03322449|Experimental|Animal Diet|during this Arm, the participants will receive a diet enriched in animal products
11209014|NCT03322449|Experimental|Plant Diet|during this Arm, the participants will receive a diet enriched in plant products
11209015|NCT03322436||AMI patients treated by PCI|AMI patient treated by PCI at risk to develop Heart Failure
11209016|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
11209017|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
11209018|NCT03322410|Experimental|Patients|
11209019|NCT03322397|Experimental|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
11209020|NCT03322397|Active Comparator|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
11209021|NCT03322397|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
11209022|NCT03322384|Experimental|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
11209023|NCT03322371|Other|Health Subjects in Sleep Lab|Adult patients (> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device. 2-lead limited electroencephalography recording
11209024|NCT03322371|Other|ICU patients, not sedated or ventilated|Adult ICU patients (> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited electroencephalography recording
11268504|NCT02916121|Placebo Comparator|placebo|placebo
11209028|NCT03322358|Experimental|Home sleep aids only|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
11209029|NCT03322358|Experimental|Home sleep aids + Sleep incentives|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful. In addition, they will be given a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
11209030|NCT03322358|Experimental|Naps + Home sleep aids|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
11209031|NCT03322358|Experimental|Naps + Home sleep aids + Sleep incentives|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish, and 3) a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period. The sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
11209032|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
11209033|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
11209034|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (> 50%) in the coronary arteries
11209035|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
11209036|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
11209037|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
11209038|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
11209039|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
11209040|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
11209041|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
11209042|NCT03322319|Experimental|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
11209043|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.
~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
11209044|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.
~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
11209045|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.
~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
11209046|NCT03322280|Experimental|TACE+I-125 seeds|TACE combined with iodine-125 seeds implantation
11209047|NCT03322280|Active Comparator|TACE alone|TACE alone
11209048|NCT03322267|Experimental|Pembrolizumab|Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab
11209049|NCT03322228|Experimental|Music Therapy|1 music therapy session, lasting approximately 45 min-1 hr
11209050|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant
~Palbociclib:
~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.
~Fulvestrant:
~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
11209051|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
11209052|NCT03322202|Experimental|Motivational Interviewing|Physical and Occupational Therapists will have 16 hours of training in Motivational Interviewing and use these techniques during sessions with patients.
11209053|NCT03322202|No Intervention|Control|Therapists will not participate in additional training.
11209054|NCT03322150|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
11209055|NCT03322150|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
11209056|NCT03322137|Active Comparator|SNA-120 (0.05% )|Pegcantratinib Ointment
11209057|NCT03322137|Active Comparator|SNA-120 (0.5%)|Pegcantratinib Ointment
11209058|NCT03322137|Placebo Comparator|Vehicle|
11209060|NCT03322124|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
11209063|NCT03322098|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
11209064|NCT03322085|Experimental|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
11209065|NCT03322085|Experimental|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
11209066|NCT03322085|Experimental|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
11209067|NCT03322072|Experimental|Real-Time Position Transponder Beacons|Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)
11209068|NCT03322059|Active Comparator|Control|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
~Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values."
11209069|NCT03322059|Experimental|Intervention|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit. Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values.
~Participants will be in the form of a charitable donation in their name to a cancer charity."
11209070|NCT03322046||Therapeutic Lifestyle Change (TLC) Intervention Group|TLC group received CVD risk lecture, enrolled in lifestyle program, received follow-up visits from team practitioner after each blood draw, access to food journaling portal for 12 month period, telephonic coaching
11209071|NCT03322046||Control Group|Control group received CVD risk lecture, then baseline, 3, 6, 12 month blood draws and 3 day food journals prior to each blood draw.
11209072|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
11209073|NCT03322020|Experimental|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
11209074|NCT03322020|Experimental|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
11209075|NCT03321994|Experimental|Stereotaxic unit, navigation|
11209076|NCT03321994|Active Comparator|Conventional biopsy technique|
11209077|NCT03321981|Experimental|Cohort 1 doublet|
11209078|NCT03321981|Experimental|Cohort 1 triplet|
11209079|NCT03321981|Experimental|Cohort 2|
11209080|NCT03321968|Experimental|Lot 1|Quadrivalent VLP Influenza Vaccine
11209081|NCT03321968|Experimental|Lot 2|Quadrivalent VLP Influenza Vaccine
11209082|NCT03321968|Experimental|Lot 3|Quadrivalent VLP Influenza Vaccine
11209083|NCT03321955|Experimental|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
11209084|NCT03321942|Active Comparator|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
11209085|NCT03321942|Placebo Comparator|Control group|Treatment of chronic renal failure patients with conventional methods.
11209086|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects will have intraoperative imaging using the LUM Imaging Device
11209087|NCT03321916|Experimental|Subthreshold Photothermal Therapy|
11209088|NCT03321916|Sham Comparator|Sham|
11209089|NCT03321903||1: Intraoral Squamous Cell Carcinomas|Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
11209090|NCT03321903||2: Cutaneous Malignant Tumors|Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
11209091|NCT03321903||3: Breast Cancers|Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
11209092|NCT03321903||4: Other tumors|Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
11209093|NCT03321890|Experimental|Combination therapy regimen|Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate
11209094|NCT03321877|Experimental|Study group|All included patients underwent dose reduction.
11209095|NCT03321864|Experimental|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
11209096|NCT03321851|Other|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
11270083|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
11209097|NCT03321838|Experimental|Accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
11209098|NCT03321825|Experimental|Belotero® Volume Lidocaine|Subdermal injection
11209099|NCT03321825|No Intervention|No treatment|
11209100|NCT03321812|Experimental|decalcification bone scaffold|Decalcification bone scaffold is a novel tissue engineered acellular matrix scaffold with the closest biomechanics and structure to normal cartilage.
11209101|NCT03321812|Active Comparator|Microfracture|Microfracture is a conventional treatment for cartilage lesions of the knee.
11209102|NCT03321799|Active Comparator|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
11209103|NCT03321799|Experimental|NPWT|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.
~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
11209104|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
11209105|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
11209106|NCT03321773|Experimental|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
11209107|NCT03321773|Active Comparator|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
11209108|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
11209109|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
11209110|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
11209111|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
11209112|NCT03321747|Experimental|Phase 1/Dose Level 1|11 Gy will be given in 5 fractions for a total dose of 55 Gy
11209113|NCT03321747|Experimental|Phase 1/Dose Level 2|12 Gy will be given in 5 fractions for a total dose of 60 Gy
11209114|NCT03321747|Experimental|Phase 1/Dose Level 3|13 Gy will be given in 5 fractions for a total dose of 65 Gy
11209115|NCT03321747|Experimental|Phase 1/Dose Level 4|14 Gy will be given in 5 fractions for a total dose of 70 Gy
11209116|NCT03321747|Experimental|Phase 2|The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.
11209117|NCT03321734|Experimental|Extended Caffeine Treatment|Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
11209118|NCT03321734|Placebo Comparator|Placebo|Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.
11209119|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
11209120|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
11209121|NCT03321682|Experimental|Functional Training|Patients in the functional training group, in addition to maintaining their usual care, will perform functional training including exercises for core strength, power training, knee dominance, hip dominance, horizontal pressure, vertical pressure, horizontal pull and vertical pull, using unstable surfaces.
11209122|NCT03321682|Active Comparator|Strength Training|These group, in addition to maintaining their usual care, will perform the exercise protocol as recommended by the American Heart Association.
11209123|NCT03321669|Active Comparator|Increased Fat Diet|
11209124|NCT03321669|Sham Comparator|Low Fat Diet|
11209125|NCT03321656|Active Comparator|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
11209126|NCT03321656|Experimental|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
11209127|NCT03321643|Experimental|Treatment (rituximab, gemcitabine, oxaliplatin, atezolizumab)|"INDUCTION PHASE: Patients receive rituximab IV, gemcitabine IV, and oxaliplatin IV every 2 weeks. Starting course 2, patients also receive atezolizumab IV over 30-60 minutes every 2 weeks. Treatment repeats every 14 days of course 1 and every 28 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
~MAINTENANCE PHASE: Patients receive rituximab IV and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unaccepted toxicity."
11209128|NCT03321630|Other|Lenvatinib & Pembrolizumab|
11209129|NCT03321617|Experimental|POMA 40mg BID (80mg)|Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.
11209130|NCT03321617|Experimental|POMA 80mg BID (160 mg)|Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days
11209131|NCT03321617|Experimental|POMA 120mg BID (240mg)|Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days
11209132|NCT03321617|Experimental|POMA 160 mg BID (320 mg)|Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days
11209133|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
11209134|NCT03321539|Experimental|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
11209421|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
11209135|NCT03321539|Active Comparator|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
11209136|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
11209137|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
11209138|NCT03321513|Active Comparator|Aflibercept Group|2.0 mg intravitreous aflibercept
11209139|NCT03321513|Experimental|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
11209140|NCT03321500|Experimental|Versacyl soft liner|Versacryl soft liner are flexible biocompatible materials with a reported predictable long term performance, durable bonding to acrylic denture bases, high fatigue endurance, excellent wear characteristics and solvent resistance with almost no free monomer in the processed material
11209141|NCT03321500|Active Comparator|Silicone-based soft liner|Resilient liners were introduced in the1950s and have been used since then as a gold standard material to increase the tolerance, retention and comfort of complete dentures. Resilient liners also known as 'soft liners' can be classified as temporary or permanent, cold-cured or heat-cured.Resilient liners can be divided into two main types: plasticized acrylic resins and silicone elastomers.
11209142|NCT03321487|Experimental|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
11209143|NCT03321487|Experimental|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
11209144|NCT03321474|Experimental|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
11209145|NCT03321474|Active Comparator|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts
~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.
~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
11209146|NCT03321461|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
11209147|NCT03321461|Active Comparator|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
11209148|NCT03321448|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
11209149|NCT03321448|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
11209150|NCT03321435||placenta previa group|
11209151|NCT03321435||Normal control group|
11209152|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
11209153|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
11209154|NCT03321396|Experimental|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
11209155|NCT03321344|Experimental|Test Arm|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
11209190|NCT03321123|Experimental|CRA treatment|"The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 ~2x10e7 MB-CART19.1/kg.
~A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells."
11209156|NCT03321331|Experimental|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
11209157|NCT03321331|Active Comparator|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
11209158|NCT03321318|Experimental|A group|AK-R215, test drug
11209159|NCT03321318|Active Comparator|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
11209160|NCT03321292|Experimental|L-arginine and Acetylesalicylic acid|L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
11209161|NCT03321292|Active Comparator|Acetylesalicylic acid75mg|acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
11209162|NCT03321279|No Intervention|Control|Participants' daily step counts will be for weeks 2-13 after hospital discharge. Participants will be asked to complete surveys at 5, 9 and 13 weeks post-discharge.
11209163|NCT03321279|Experimental|Intervention|Participants' daily step counts will be monitored for weeks 2-13 after hospital discharge. Participants will have a weekly step goal that increases from baseline by 10% each week of the intervention (12 weeks). Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
11209164|NCT03321266||Patients treated for a anorectal fistula|Patients who were treated for a anorectal fistula with a Biodesign Fistula plug
11209165|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
11209166|NCT03321240||The SEEG group|Group with the SEEG analysis
11209167|NCT03321240||The direct surgery group|Group with a direct surgery
11209168|NCT03321227|Experimental|Snack skipping|No snack provided
11209169|NCT03321227|Experimental|Whole eggs|2 whole large eggs as a snack
11209170|NCT03321227|Experimental|Egg whites|2 egg whites as a snack
11209171|NCT03321227|Experimental|Egg yolks|2 egg yolks as a snack
11209172|NCT03321227|Active Comparator|Yogurt|Full fat yogurt as a snack
11209173|NCT03321214|Experimental|Light use of Nima|Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).
11209174|NCT03321214|Experimental|Moderate use of Nima|Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).
11209175|NCT03321214|Experimental|Heavy use of Nima|Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).
11209176|NCT03321201|Experimental|Cauterization|
11209177|NCT03321201|Active Comparator|Fibrin glue|
11209178|NCT03321188|Experimental|HIPEC + adjuvant IV chemotherapy|"HIPEC
~HIPEC will be administered intraoperatively one time only.
~*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)
~Administration of HIPEC will have a duration of 90 minutes.
~Adjuvant IV chemotherapy
~IV Paclitaxel
~Dose: 80mg/m2 IV over 1 hour
~Schedule: Days 1, 8 and 15
~Cycle Length: 3 weeks (21 days)
~IV Carboplatin
~Dose: Area under the curve (AUC) 6 IV
~Schedule: Day 1
~Cycle Length: 3 weeks (21 days)"
11209179|NCT03321175|Experimental|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
11209180|NCT03321175|No Intervention|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
11209181|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
11209182|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
11209183|NCT03321149|Experimental|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
11209184|NCT03321136|Placebo Comparator|Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11209185|NCT03321136|Placebo Comparator|LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11209186|NCT03321136|Placebo Comparator|LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11209187|NCT03321136|Placebo Comparator|LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11209188|NCT03321136|Placebo Comparator|LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11209189|NCT03321136|Placebo Comparator|LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
11209194|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
11209195|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
11209196|NCT03321084|Experimental|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
11209197|NCT03321084|Other|Control|It continues in your daily life with phone monitoring.
11209198|NCT03321071|Experimental|Healthy Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (~45min-1hr time blocks).
11209199|NCT03321071|Active Comparator|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
11209200|NCT03321071|No Intervention|Passive control|Children in this condition will not attend a summer program.
11209201|NCT03321045|Experimental|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab [89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
11209202|NCT03321032|Experimental|Amphilimus-eluting stents|Polymer-free Amphilimus-eluting stents
11209203|NCT03321032|Active Comparator|Zotarolimus-eluting stents|Biolinx Polymer-based zotarolimus-eluting stents
11209204|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
11209205|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
11209206|NCT03321006|Active Comparator|Antidepressant (AD) + full amplification hearing aids|Participant will be randomized to active comparator and will receive escitalopram or duloxetine + active hearing aid for 12 weeks.
11209207|NCT03321006|Sham Comparator|Antidepressant (AD) + Low amplification (sham) hearing aids|Participant will be randomized to sham comparator and will receive escitalopram or duloxetine + sham hearing aid for 12 weeks.
11209208|NCT03320993|Active Comparator|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
11209209|NCT03320993|Experimental|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
11209210|NCT03320993|Experimental|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
11209211|NCT03320980||RALPPS|Patients with initial volume of FLR < 40% which underwent RALPPS and major liver resection (as the second stage of RALPPS) for hilar and intrahepatic cholangiocarcinoma
11209212|NCT03320980||Portal vein embolization (PVE)|Patients with initial volume of FLR < 40% undergoing PVE and major liver resection for hilar and intrahepatic cholangiocarcinoma
11209213|NCT03320954|Experimental|Anomia treatment|Phase 2 portion of the research during which participants with acquired brain injury will perform intervention activities.
11209214|NCT03320941|Experimental|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
11209215|NCT03320941|Experimental|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
11209216|NCT03320941|Experimental|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
11209217|NCT03320941|Experimental|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
11209218|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
11209219|NCT03320915|Experimental|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
11209220|NCT03320915|No Intervention|Usual care|Usual care
11209221|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
11209222|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
11209223|NCT03320889|Other|Pamphlets plus Review with Expert Educator|Educational Intervention includes Pamphlets plus Review with Expert Educator
11209224|NCT03320889|Other|Pamphlets only|Educational Intervention includes Pamphlets only
11209225|NCT03320876|Experimental|filgotinib|
11209226|NCT03320863|Active Comparator|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
11209227|NCT03320863|No Intervention|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
11209228|NCT03320850|Experimental|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209229|NCT03320850|Placebo Comparator|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209230|NCT03320850|Experimental|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209231|NCT03320850|Placebo Comparator|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209232|NCT03320850|Experimental|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209233|NCT03320850|Placebo Comparator|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209234|NCT03320850|Experimental|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209235|NCT03320850|Placebo Comparator|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
11209236|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
11209237|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
11209238|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
11209239|NCT03320824|Experimental|New Dermal Filler|hyaluronic acid
11209240|NCT03320824|Active Comparator|Dermal Filler|hyaluronic acid
11209241|NCT03320811||"group celiac disease"|
11209242|NCT03320811||"group no celiac disease"|
11209243|NCT03320798||"group Bullous pemphigoid"|Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
11209244|NCT03320772|Experimental|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
11209245|NCT03320772|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
11209246|NCT03320759|No Intervention|No rehabilitation|
11209247|NCT03320759|Experimental|Rehabilitation|
11209248|NCT03320746|Experimental|Activity trackers|The participants were requested to wear a commercial wrist-worn activity tracker (Polar Loop 2, Polar, Kempele, Finland) every day and night for 12 months.
11209249|NCT03320746|No Intervention|No activity trackers|Control group members were requested to abstain from the use of any type of activity trackers and they were informed that they will receive the activity trackers and guidance for using them after the follow-up.
11209250|NCT03320733|Experimental|Surgical|"Includes patients who will undergo surgery for their pancreatic cysts.
~In addition to the routine pre-operative CT abdomen performed for surgical planning purposes, these patients will receive Dual Energy CT scan with subtraction imaging before surgery."
11209251|NCT03320733|Experimental|Surveillance|"Includes patients who are undergoing surveillance for their pancreatic cysts.
~Dual Energy CT scan with subtraction imaging will be performed in addition to the standard-of-care surveillance method of MRI scans."
11209252|NCT03320720|Experimental|Home Treatment|Patients with acute mental illness are treated at their houses by a mobile and multiprofessional care team instead of being treated as inpatients if their medical condition permits.
11209253|NCT03320720|Active Comparator|Treatment-as-usual|Patients with acute mental illness are treated as inpatients in a psychiatric clinic.
11209254|NCT03320707|Experimental|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort. Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
11209255|NCT03320707|Placebo Comparator|Placebo|Participants will receive placebo as a single SC dose in each of first 7 cohorts.
11209256|NCT03320694|Experimental|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
11209257|NCT03320694|Active Comparator|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
11209258|NCT03320681|Active Comparator|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
11209259|NCT03320681|Other|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
11209260|NCT03320668|No Intervention|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
11209261|NCT03320668|Experimental|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
11209262|NCT03320655|Active Comparator|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
11209283|NCT03320525|Experimental|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
11209284|NCT03320512|Experimental|P3|Participants will use P3
11209285|NCT03320512|Experimental|P3+|Participants will use P3+
11209286|NCT03320512|Placebo Comparator|Control|Participants will receive the standard of care
11209287|NCT03320499||echo doppler at the bed|
11209263|NCT03320655|Experimental|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
11209264|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
11209265|NCT03320629|Experimental|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
11209266|NCT03320629|Active Comparator|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
11209267|NCT03320616|Experimental|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
11209268|NCT03320616|Experimental|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
11209269|NCT03320616|Experimental|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
11209270|NCT03320616|Experimental|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
11209271|NCT03320603|Other|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
11209272|NCT03320603|Other|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
11209273|NCT03320590||Couple|Couple with female aged under 37 years
11209274|NCT03320577|Active Comparator|Class instruction of breathing exercises|Class participation/instruction weekly for 6 weeks and requested to practice Pranayama breathing exercises of 15 minute duration for an additional 4x during the week; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
11209275|NCT03320577|Active Comparator|DVD instruction of breathing exercises|Received DVD with instructions and 15 minute Pranayama breathing exercises of 15 minute duration. Participants requested to practice breathing exercises 5x during the week for 6 week intervention; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
11209276|NCT03320577|Placebo Comparator|Control|Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
11209277|NCT03320564|Experimental|Infiltration|Repeat F-18 FDG PET
11209278|NCT03320551|Experimental|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
11209279|NCT03320538|Experimental|Hou Gu Mi Xi|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
11209280|NCT03320538|Experimental|Hou Gu Mi Xi + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
11209281|NCT03320538|Placebo Comparator|Placebo + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
11209282|NCT03320538|Placebo Comparator|Placebo|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).
~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Hou Gu Mi Xi (once 10 g, twice a day).
~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).
~Extensional observational period (53 to 104 weeks): no intervention."
11209288|NCT03320499||echo doppler in the vascular exploration platform|
11209289|NCT03320486|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, once daily, during 42 days.
11209290|NCT03320486|Active Comparator|Group 2 - ketoconazole cream 2%|Topical application of ketoconazole cream 2%, once daily, during 42 days.
11209291|NCT03320473|Experimental|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
11209292|NCT03320460|Experimental|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
11209293|NCT03320460|Active Comparator|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
11209294|NCT03320447|Experimental|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
11209295|NCT03320447|Experimental|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
11209296|NCT03320434|Experimental|PRT-2761 0.5%|
11209297|NCT03320434|Experimental|PRT-2761 1%|
11209298|NCT03320434|Active Comparator|Patanol|
11209299|NCT03320434|Active Comparator|Pred-forte|
11209300|NCT03320434|Placebo Comparator|PRT-2761 0%|
11209301|NCT03320421|Experimental|SIB group|"Radiation therapy:
~daily 5 days per week for 3 weeks. 43.5 Gy in 15 fractions to the whole breast 49.5 Gy in 15 fractions to the tumor bed boost"
11209302|NCT03320408||Asymptomatic AAA|These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.
11209303|NCT03320408||Acute AAA|These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.
11209304|NCT03320408||Repaired AAA|These patients are included while they already had had AAA repair (both elective and emergency repair).
11209305|NCT03320395|Experimental|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
11209306|NCT03320369|Other|Treatment|Elemental formula Intervention: Elemental Diet Therapy
11209307|NCT03320356||shoulder pain|Patients presenting inflammatory, degenerative, or post-traumatic shoulder pain and consulting at Orthopaedic Department, Reims Teaching Hospital.
11209308|NCT03320343||Patients recruited for pelvic imaging examination|
11209309|NCT03320330|Experimental|Treatment (pepinemab)|Patients receive pepinemab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
11209310|NCT03320317||Colorectal cancer|
11209311|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
11209312|NCT03320291|Experimental|Regjoint|
11209313|NCT03320278||SPIDS,TMH|There will be two tests in this study for evaluation. Both of them will be measured in same group.
11209314|NCT03320265|Experimental|PC-mAb|Phosphorylcholine human monoclonal antibody, i.v. infusions
11209315|NCT03320265|Placebo Comparator|Placebo|Placebo to PC-mAb, i.v. infusions
11209316|NCT03320239|Experimental|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
11209317|NCT03320239|Experimental|intervention group 2|HIV risk behavior investigation and routine education
11209318|NCT03320239|Placebo Comparator|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
11209319|NCT03320226|Other|Probiotic 10 (Nature's Bounty)|The suggested dose will be two (2) pills of Probiotic 10 (Nature's Bounty) after dinner daily. Subjects will be asked to take probiotics for six (6) days after providing baseline fecal specimen. Subjects will self-report their daily GI function including the frequency of nausea, vomiting, and bowel movement(s). Then, the subjects will stop taking probiotics for two (2) days and resume taking probiotics for another six (6) days. This six (6)-day on and two (2)- day off cycle is repeated two (2) times.
11209320|NCT03320200|Experimental|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
11209321|NCT03320200|Experimental|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
11209322|NCT03320187|Experimental|Group A|Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
11209323|NCT03320187|Placebo Comparator|Group B|Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
11209324|NCT03320174|Active Comparator|Tafenoquine 200 mg (2 x 100 mg tablets)|Tafenoquine 200 mg (2 x 100 mg tablets) daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
11209325|NCT03320174|Placebo Comparator|Placebo|Placebo daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
11209384|NCT03319654|Experimental|Spontaneous cycle IUI|"DNA fragmentation by TUNEL assay
~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination."
11209385|NCT03319641|Experimental|PSMA-PET/CT scan|PSMA-PET/CT imaging in advanced ACC/SDC
11209326|NCT03320148|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
11209327|NCT03320148|Active Comparator|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
11209328|NCT03320135|Active Comparator|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
11209329|NCT03320135|Active Comparator|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
11209330|NCT03320122|Experimental|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
11209331|NCT03320122|Active Comparator|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
11209332|NCT03320122|Active Comparator|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
11209333|NCT03320096|Experimental|Microfocused ultrasound with visualization|
11209334|NCT03320083|Active Comparator|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
11209335|NCT03320083|No Intervention|Usual Care|General anticipatory guidance given
11209336|NCT03320070|Experimental|Acthar Gel|Participants receive Acthar Gel as a 1 mL injection under the skin twice weekly
11209337|NCT03320070|Placebo Comparator|Placebo|Participants receive Placebo as a 1 mL injection under the skin twice weekly
11209338|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
11209339|NCT03320031|Experimental|combined group|Drug: linagliptin&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.
11209340|NCT03320031|Active Comparator|linsulin group|Drug: premixed insulin Treated with premixed insulin for 12 weeks.
11209341|NCT03320018|Experimental|Hydrogen/Minocycliine|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, q 8 hours for 3 days.
~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
11209342|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
11209343|NCT03320005|Active Comparator|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
11209344|NCT03320005|No Intervention|Non training group|sedentary elderly
11209345|NCT03319992|No Intervention|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
11209346|NCT03319992|Experimental|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
11209347|NCT03319966||Oculomotor Dysfunction|This group consists of subjects with mTBI who have been diagnosed with OMD by objective OD measurements. These subjects will undergo neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury per usual clinical standard of care at the HCMC TBI Clinic.
11209348|NCT03319953|Experimental|TAK-041 40 mg + Placebo|TAK-041 40 milligram (mg), suspension, orally on Day 1 of treatment period 1, followed by 35 days wash-out period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of treatment period 2. All participants will take a stable dose of antipsychotics throughout the duration of the treatment period.
11209349|NCT03319953|Experimental|Placebo + TAK-041 40 mg|TAK-041 placebo-matching, suspension, orally on Day 1 of treatment period 1, followed by 35 days wash-out period, followed by TAK-041 40 mg, suspension, orally on Day 1 of treatment period 2. All participants will take a stable dose of antipsychotics throughout the duration of the treatment period.
11209350|NCT03319940|Experimental|Part A or Part B|AMG 757 Monotherapy
11209351|NCT03319940|Experimental|Part C|AMG 757 with Pembrolizumab
11209352|NCT03319940|Experimental|Part D|AMG 757 with additional cytokine release syndrome (CRS) mitigation strategies
11209386|NCT03319628|Experimental|Dose Escalation and Confirmation|XMT-1536 treatment is administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1536 at this fixed-dose.
11209387|NCT03319615|No Intervention|Habitual dietary intake|Habitual dietary intake
11209388|NCT03319615|Experimental|Energy Restriction|Match period (to comparator) of dietary energy restriction
11209353|NCT03319927|Experimental|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
11209354|NCT03319927|Active Comparator|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
11209355|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
11209356|NCT03319901|Experimental|Venetoclax + Chemotherapy|"Venetoclax is administered orally once daily for 21 days in each cycle
~Standard Chemotherapy will be administered every 28 days"
11209357|NCT03319888|Experimental|cpap group|CPAP treatment plus conservative treatment with lifestyle modifications.
11209358|NCT03319888|Active Comparator|control group|Conservative treatment with lifestyle modifications.
11209359|NCT03319849|Experimental|Renexus®|
11209360|NCT03319849|Sham Comparator|Sham|
11209361|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula [2015].
11209362|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula [2016].
11209363|NCT03319823|Experimental|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg
11209364|NCT03319823|Experimental|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
11209365|NCT03319810|Experimental|infusion of IVIG|
11209366|NCT03319797|Other|Treatment with NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte transplantation)
11209367|NCT03319784|Active Comparator|Ketorolac (Toradol) Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
11209368|NCT03319784|Active Comparator|Steroid Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Steroid group will receive a single dose of 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
11209369|NCT03319771|Experimental|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
11209370|NCT03319771|Active Comparator|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
11209371|NCT03319758|Experimental|thin or dehiscences buccal plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with thin or dehiscences buccal plate.
11209372|NCT03319745|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
11209373|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
11209374|NCT03319719|Experimental|Belotero® Balance with integral lidocaine|Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
11209375|NCT03319719|Active Comparator|Belotero Balance without lidocaine|Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
11209376|NCT03319706|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
11209377|NCT03319706|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
11209378|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
11209379|NCT03319680|Active Comparator|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
11209380|NCT03319680|No Intervention|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
11209381|NCT03319667|Experimental|Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm|"Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone
~Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone"
11209382|NCT03319667|Active Comparator|Bortezomib/Lenalidomide/Dexamethasone = VRd arm|"Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone
~Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone"
11209383|NCT03319667|Other|Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm|4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone
11209389|NCT03319602|Active Comparator|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
11209390|NCT03319602|Experimental|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
11209391|NCT03319589|Experimental|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
11209392|NCT03319589|No Intervention|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
11209393|NCT03319576|Experimental|Early feeding|Patients randomized to early feeding will be fed 4 hours following gastrostomy tube placement
11209394|NCT03319576|No Intervention|Standard feeding|Patients randomized to standard feeding will be fed 24 hours following gastrostomy tube placement
11209395|NCT03319563|Experimental|local anesthetic-epinephrine group|"after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels:
~Subcutaneous: before incision at a volume 20 ml/10 cm/side.
~Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume.
~Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration."
11209396|NCT03319563|Placebo Comparator|saline group|after general anesthesia, the same infiltration volume and technique using normal saline.
11209397|NCT03319550|Experimental|Casein|"LPS + 36 hour fast and bedrest + Casein (9% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping."
11209398|NCT03319550|Experimental|Whey|"LPS + 36 hour fast and bedrest + Whey (11% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
11209399|NCT03319550|Experimental|Leucine-enriched whey|"LPS + 36 hour fast and bedrest + Leucine-enriched whey (16% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
11209400|NCT03319537|Experimental|Pevonedistat|
11209401|NCT03319537|Experimental|pevonedistat in combination with pemetrexed and cisplatin|
11209402|NCT03319511|Active Comparator|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
11209403|NCT03319511|Experimental|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
11209404|NCT03319498|Active Comparator|Peppermint Oil Vapor|Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.
11209405|NCT03319498|Placebo Comparator|Mineral Oil Vapor|Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.
11209406|NCT03319485|Experimental|ExAblate Pallidotomy|ExAblate treatment for Advanced Idiopathic Parkinson's Disease
11209407|NCT03319485|Sham Comparator|Sham ExAblate Pallidotomy|Sham (fake) treatment
11209408|NCT03319472||Benign Pleural Effusion|Patients that will be diagnosed within a month from admission with any non-malignant cause of pleural effusion, including but not limited to effusions caused by common or tuberculous or fungal infection, heart failure, etc. Documentation of the etiology will be required for inclusion in this group, including but not limited to bacteriology, virology, PCR, radiology, heart echocardiogram or catheterization, as appropriate.
11209409|NCT03319472||Malignant Pleural Effusion|Patients that will be diagnosed within a month from admission with any malignant cause of pleural effusion, including but not limited to effusions caused by lung, breast, colon, ovary, mesothelial, hematopoietic, prostate, or any other cancer. Diagnosis will be based on verification of the presence of malignant cells in the pleural fluid or tissues. Patients with cancer and an effusion without such documentation will be assigned to the benign group if an alternative diagnosis is made. In any other case, they will be excluded.
11209410|NCT03319459|Experimental|Regimen A|FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies.
11209411|NCT03319459|Experimental|Regimen B|FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
11209412|NCT03319459|Experimental|Regimen C|Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
11209413|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index <3.5 when baseline monitors are attached while the patient is being prepared for surgery.
11209414|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index >3.5 when baseline monitors are attached while the patient is being prepared for surgery.
11209415|NCT03319420|Experimental|LO2A|1 drop of sodium hyaluronate instilled into each eye 4 times daily
11209416|NCT03319420|Active Comparator|Systane Ultra UD|1 drop of Systane Ultra UD instilled into each eye 4 times daily
11209417|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
11209418|NCT03319394|Experimental|The First Twenty|TF20 group completed a structured exercise program. Once a week a trained firefighter with current CPR and First Aid certifications met with the group to assess progress and answer questions about the workouts or the program. The rest of the time, the participants completed the workouts on their own time. Workouts contained a combination of aerobic (e.g., running, rowing, jumping), body weight (e.g., air squats, pushups, situps), and weight lifting (e.g., presses, back squats, lunges) exercises with workouts designed to use equipment available in an exercise/gym facility (e.g., weight racks, benches). Sixty-minute TF20 sessions included a warm-up, workout and cool down. All sessions were able to be logged online in TF20 program.
11209419|NCT03319394|Active Comparator|Comparison|The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
11209420|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
11209422|NCT03319368|Experimental|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
11209423|NCT03319342|Experimental|Group I (acts of kindness to others)|Participants perform small acts of kindness or generosity for others 3 times per week for 4 weeks and complete weekly online questionnaires.
11209424|NCT03319342|Experimental|Group II (acts of kindness to self)|Participants perform small acts of kindness for themselves 3 times per week for 4 weeks and complete weekly online questionnaires.
11209425|NCT03319342|Experimental|Group III (self-kindness meditation)|Participants direct kind, loving thoughts to themselves, via guided meditation, 3 times per week for 4 weeks and complete weekly online questionnaires.
11209426|NCT03319342|Active Comparator|Group IV (track daily activities)|Participants keep track of their daily activities, focusing on factual information rather than thoughts and feelings, on 3 separate days each week. At the end of the week, participants report on their activities and complete several online questionnaires.
11209427|NCT03319329||critically ill adult patients|"Part I: A cross-sectional study to compare validity of several predictive equations used to predict REE in critically ill adult patients for staying ≤ 5 days, 6 - 10 days and > 10 days by using indirect calorimetry (IC) as the reference standard.
~Part II: To develop predictive equation for the estimation of energy requirement by identifying variables that might influence REE of mechanically ventilated critically ill patients.
~Part III: To validate the newly developed predictive equation for the estimation of energy requirement by using Ten fold cross-validation approach"
11209428|NCT03319316|Experimental|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
11209429|NCT03319316|No Intervention|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
11209430|NCT03319316|Experimental|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
11209431|NCT03319316|No Intervention|Cohort 2 - Squamous - Arm B|Patients will have observation
11209432|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
11209433|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
11209434|NCT03319264|Experimental|Patients with SpA|"Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :
~dynamometry exam
~walking test
~Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia & Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire."
11209435|NCT03319238||Patient cohort|Neuropathic pain patient taking ketamine
11209436|NCT03319225||Tetraplegia|Persons with Tetraplegia
11209437|NCT03319225||Paraplegia|Persons with Paraplegia
11209438|NCT03319225||Neurologically-intact|Neurologically-intact controls
11209439|NCT03319212|Other|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
11209440|NCT03319199|Active Comparator|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
11209441|NCT03319199|Placebo Comparator|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
11209442|NCT03319186|Experimental|EDIT Management|
11209443|NCT03319186|Active Comparator|Standard Care|
11209444|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.
~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
11209445|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.
~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
11209446|NCT03319160||Retrospective|Patients who have already completed use of LifeVest before start of the study
11209447|NCT03319160||Prospective|Patients receiving a LifeVest prescription in clinical routine
11209448|NCT03319147|Placebo Comparator|Placebo|4g of maltodextrin
11209449|NCT03319147|Active Comparator|Active|4g of essential amino acids
11209450|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
11209451|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
11209452|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
11209453|NCT03319121|Experimental|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
11209454|NCT03319121|Experimental|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
11209455|NCT03319108|Other|Low Comorbidity Index Score|CCI; 1-3 as Group 1
11209456|NCT03319108|Other|High Comorbidity Index Score|CCI; 4 and above as Group 2
11209457|NCT03319095|No Intervention|Control|Control group: participants will receive only verbal instructions on PFM anatomy and function during the first assessment when women will be required to contract their pelvic floor muscle. The participants will have no contact with the service until the second assessment
11209458|NCT03319095|Active Comparator|Intervention|Intravaginal Electrical Nerve Stimulation: participants will be submitted to Intravaginal Electrical Nerve Stimulation
11209459|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
11209460|NCT03319069|Experimental|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
11209461|NCT03319069|Active Comparator|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
11209462|NCT03319056|Active Comparator|Real purification|Air purifier turned on
11209463|NCT03319056|Sham Comparator|Sham purification|Air purifier turned off
11209464|NCT03319043|Experimental|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
11209465|NCT03319043|Placebo Comparator|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
11209466|NCT03319030||Duchenne Muscular Dystrophy (DMD)|Enrolls boys with a genetically confirmed diagnosis of DMD.
11209467|NCT03319017||Multiple-trauma patients|The patients who are diagnosed with multiple-trauma and have blood test in an emergency room. The patients with multiple-trauma are defined as the patients who have trauma in more than two regions.
11209468|NCT03319004|Experimental|Compare bispectral index and phase lag entropy|
11209469|NCT03318991|Active Comparator|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
11209470|NCT03318991|Active Comparator|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
11209471|NCT03318978|Experimental|25 ng dose|Capsule containing 25 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
11209472|NCT03318978|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
11209473|NCT03318978|Experimental|100 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
11209474|NCT03318978|Experimental|250 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
11209475|NCT03318952|Experimental|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
11209476|NCT03318952|Experimental|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
11209477|NCT03318939|Experimental|Poziotinib|"Cohort 1: Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)
~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)
~Cohort 3: Treatment naïve patients with EGFR exon 20 insertion-mutant positive NSCLC (fully enrolled)
~Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutant positive NSCLC
~Cohort 5: Patients who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed
~Cohort 6: Patients with acquired EGFR mutation who progressed while on treatment with first-line osimertinib
~Cohort 7: Patients with EGFR or HER2 activating mutations"
11209478|NCT03318913|No Intervention|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
11209479|NCT03318913|Placebo Comparator|DM Placebo|Sucralose
11209480|NCT03318913|Active Comparator|DM FHP|Fish protein hydrolysates
11209481|NCT03318900|Experimental|Treatment (T-cell infusion, aldesleukin, utomilumab)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV on day -2, CD8-positive T-lymphocyte via infusion on day 0, and aldesleukin SC every 12 hours for 14 days. Beginning 24 hours after CD8-positive T-lymphocyte, patients also receive utomilumab IV over 90 minutes on days 1, 29, 57, 85, 113, and 141 in the absence of disease progression or unacceptable toxicity.
11209482|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
11209483|NCT03318874|Experimental|Blephasteam|Heat delivery device, to be used according to guidelines from manufacturer.
11209484|NCT03318874|Active Comparator|THERA°PEARL Eye Mask|Heat delivery device, to be used according to guidelines from manufacturer.
11209485|NCT03318861|Experimental|Dose Escalation: 3 x 10^7 KITE-585|Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 autologous anti-B-cell maturation antigen (BCMA) CAR T cells at a dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
11209486|NCT03318861|Experimental|Dose Escalation: 1 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
11209522|NCT03318575|Experimental|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
11209523|NCT03318575|Sham Comparator|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
11270084|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
11209487|NCT03318861|Experimental|Dose Escalation: 3 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 3 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
11209488|NCT03318861|Experimental|Dose Escalation: 1 x 10^9 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^9 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
11209489|NCT03318861|Experimental|Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585|RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min [Grade 2 chronic kidney disease]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 24 mg/m^2/day IV infusion for 3 days followed by a single intravenous infusion of KITE-585 anti-autologous BCMA CAR T cells at a tolerable dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
11209490|NCT03318848|Experimental|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
11209491|NCT03318848|No Intervention|Simulation without video|The students of the control group performed the simulation of the bed bath procedure, with the aid of a tutor.
11209492|NCT03318835|Experimental|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
11209493|NCT03318835|Active Comparator|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
11209494|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
11209495|NCT03318809|Experimental|AMG 986 Treatment|Group 1: Severely Renal Impaired subjects; Group 2: Healthy Subjects
11209496|NCT03318796|Other|Interventional|Coronary artery stenting of De novo bifurcation lesions MB & SB
11209497|NCT03318783|Active Comparator|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
11209498|NCT03318783|Placebo Comparator|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
11209499|NCT03318770||All patients|All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
11209500|NCT03318757|Experimental|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
11209501|NCT03318757|Active Comparator|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
11209502|NCT03318744|Experimental|aspirin 100mg|Participants will be given aspirin 100mg once per day.
11209503|NCT03318744|Placebo Comparator|placebo|Participants will be given placebo oral tablets once per day.
11209504|NCT03318731|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
11209505|NCT03318731|Experimental|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
11209506|NCT03318731|Experimental|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
11209507|NCT03318718|Experimental|TOF measurement|TOF and MEP measurement after Anesthesia with non-depolarizing NMBA Rocuronium
11209508|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
11209509|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
11209510|NCT03318666|Active Comparator|Enhanced Usual Care (EUC)|Both arms will receive this intervention
11209511|NCT03318666|Experimental|Supporting Our Valued Adolescents (SOVA)|This arm will receive the SOVA intervention in addition to Enhanced Usual Care
11209512|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
11209513|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
11209514|NCT03318640|Experimental|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
11209515|NCT03318640|No Intervention|Control|Patient will have usual medical care.
11209516|NCT03318627|Other|Tension Measuring|Measuring intraoperative tension of rotator cuff tendon with sterile spring Balance.
11209517|NCT03318614|Experimental|Probiotics M-63 group|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (Morinaga Milk Industry Co., Ltd., Japan) to consume daily in addition to advice of good hygiene and sanitation practices.
11209518|NCT03318614|Placebo Comparator|Control group|No probiotic intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.
11209519|NCT03318601|Experimental|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
11209520|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
11209521|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
11209524|NCT03318562|Experimental|TNBC Cohort|female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received >=1 prior cancer therapy regimen for metastatic disease
11209525|NCT03318562|Experimental|HCC Cohort|male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed >=1 systemic therapy, which must include sorafenib, or are intolerant to multikinase inhibitor therapies
11209526|NCT03318549||Glaucoma|Patients with diagnosed glaucoma
11209527|NCT03318549||Suspicious of having glaucoma|Patients with suspicious of having glaucoma based on intra-ocular pressure or optic nerve photographs with glaucoma appearance
11209528|NCT03318549||Non-glaucomatous optic neuropathies;|Patients with optic neuropathies that do not look glaucomatous-like
11209529|NCT03318549||Age-related macular degeneration (AMD)|Patients with diagnosed age-related macular degeneration
11209530|NCT03318549||Retinal degenerations|Patients with other retinal degenerations excluding AMD
11209531|NCT03318549||Other diseases of visual pathways|Other diseases of the visual pathway not included in the previous groups
11209532|NCT03318549||Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups
11209533|NCT03318536||No Granisetron|120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
11209534|NCT03318536||With Granisetron|120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
11209535|NCT03318523|Placebo Comparator|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.
~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
11209536|NCT03318523|Experimental|BIIB054 250 mg|Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
11209537|NCT03318523|Experimental|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
11209538|NCT03318523|Experimental|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
11209539|NCT03318497|Experimental|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
~Procedure: Computed Tomography
~Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
~Other: Laboratory Biomarker Analysis
~Procedure: Positron Emission Tomography"
11209540|NCT03318484|Active Comparator|Optimal Medical Care|Optimal medical care (OMC) only is administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
11209541|NCT03318484|Experimental|Optimal Medical Care and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
11209542|NCT03318471|Active Comparator|Group M|received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes
11209543|NCT03318471|Placebo Comparator|Group S|received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.
11209544|NCT03318458|Experimental|Pilates group|
11209545|NCT03318458|No Intervention|No intervention group|
11209546|NCT03318445|Experimental|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.
~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.
~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
11209547|NCT03318445|Experimental|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
11209548|NCT03318419|Experimental|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
11209549|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
11209550|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
11209551|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
11209552|NCT03318380|Experimental|Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)|Patients receive sulfur hexafluoride IV and undergo CEUS imaging over 10 minutes.
11209553|NCT03318367|Experimental|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
11209554|NCT03318354|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
11209555|NCT03318354|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
11209556|NCT03318341|Other|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
11209557|NCT03318341|Other|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
11209558|NCT03318315|Experimental|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
11209559|NCT03318315|Experimental|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
11209560|NCT03318315|Active Comparator|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
11209561|NCT03318289|Experimental|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
11209562|NCT03318289|No Intervention|Control group|No intervention but can continue daily activities.
11209563|NCT03318276|Experimental|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
11209564|NCT03318276|Active Comparator|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
11209565|NCT03318263|Other|experimental|
11209566|NCT03318250|Active Comparator|Burst3D|"This is a device progamme setting which is being compared against DR6-LF.
~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant. Once device is implanted participants are assigned progammes in a randomized manner."
11209567|NCT03318250|Active Comparator|DRG-LF|"This is a device progamme setting which is being compared against Burst3D.
~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant.Once device is implanted participants are assigned progammes in a randomized manner."
11209568|NCT03318237||Patients with focal epilepsy|Patients undergoing ultra high field MRI of the brain
11209569|NCT03318211|Active Comparator|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
11209570|NCT03318211|Active Comparator|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
11209571|NCT03318198|Active Comparator|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
11209572|NCT03318198|Placebo Comparator|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
11209573|NCT03318185|Experimental|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
11209574|NCT03318185|Sham Comparator|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
11209575|NCT03318172|Experimental|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
11209576|NCT03318172|Active Comparator|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
11209577|NCT03318159|Other|posaconazole prophylaxis group|aplastic anemia / hypoplastic myelodysplastic syndrome patients undergoing antithymocyte globulin treatment and receiving posaconazole as prophylaxis antifungal agent
11209578|NCT03318146|Experimental|EXP-LP punctum plug|EXP-LP is a novel and innovative drug delivery system aiming to improve patient compliance and outcomes. EXP-LP punctum plug, is a non-invasive insert that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other major eye diseases. EXP-LP is a combination of an ophthalmic prostaglandin drug (Latanoprost). The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye
11209579|NCT03318146|Active Comparator|XALATAN®|XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension. XALATAN is administrated once a day
11209580|NCT03318133|Experimental|GA group|"general anesthesia(GA) group:
~Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring
~Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2
~Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed
~Transfer to ICU after surgery"
11209581|NCT03318133|Experimental|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:
~Open peripheral vein fluid infusion
~In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)
~Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block
~After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed
~Transfer to ICU after surgery"
11209582|NCT03318120|Experimental|Progressive Resistance Training|Participants assigned to this arm will receive progressive resistance training under the supervision of a personal trainer at a gym facility close to their home. They will be required to perform these exercises twice a week for the first six months. They will be monitored with an activity monitor.
11209583|NCT03318120|No Intervention|Control Arm|The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
11209613|NCT03317886|Active Comparator|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
11209584|NCT03318107|Experimental|Transvaginal probe (Photoacoustic + ultrasound imaging)|"A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images
~This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
11209585|NCT03318094|Placebo Comparator|Intact Day|Saline
11209586|NCT03318094|Experimental|Blocked Day|Phentolamine
11209587|NCT03318081|Active Comparator|cognitive function rehabilitation group|The main content of cognitive function rehabilitation esecutive function,including working memory,sustained attention, response inhibition function and cognitive flexibility, 45 minutes a day over 6 weeks period.
11209588|NCT03318081|Active Comparator|cognitive bias modification group|The main content of cognitive bias modification groups were changing ATS related attention bias, 45 minutes a day over 6 weeks period.
11209589|NCT03318081|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center
11209590|NCT03318068|Experimental|Yoga intervention arm|The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
11209591|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.
~Inclusion Criteria:
~> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
11209592|NCT03318042|Experimental|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
11209593|NCT03318029|Placebo Comparator|Placebo UK trial|Placebo and living in the UK
11209594|NCT03318029|Active Comparator|Vitamin D UK trial|Vitamin D supplementation and living in the UK
11209595|NCT03318029|Placebo Comparator|Placebo Brazil Trial|Placebo and living in the Brazil
11209596|NCT03318029|Active Comparator|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
11209597|NCT03318016|Experimental|Cyclophosphamide|"Cohort -1: Cyclophosphamide 500 mg/m2
~Cohort 1: Cyclophosphamide 1000 mg/m2
~Cohort 2: Cyclophosphamide 2000 mg/m2
~Cohort 3: Cyclophosphamide 3000 mg/m2
~Cohort 4: Cyclophosphamide 4000 mg/m2"
11209598|NCT03318003|Experimental|Auto-PAP Therapy|
11209599|NCT03318003|No Intervention|No Therapy|
11209600|NCT03317990|Experimental|NeuroSAFE procedure|These patients will undergo robotic radical prostatectomy with bilateral nerve spare.The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade.The tissue sample will be snap frozen and embedded in OCT.Using a cryostat, 10 micron thick slices will be placed on slides.The entire length of the area of interest will be sampled in this way generating ≈10 frozen sections per side.The slides will be stained with H&E and will be examined by a consultant pathologist.As soon as examination is complete the pathologist will telephone the operating surgeon to give the result.Presence of cancer cells at the margin of resection constitutes a positive margin and the neurovascular bundle on that side will be resected
11209601|NCT03317990|No Intervention|Control|These patients will undergo robotic radical prostatectomy with a nerve sparing procedure based on surgical planning performed by a consultant radiologist. The mp-MRI will be reviewed by a consultant radiologist along with the details of the prostate biopsy and DRE a decision to perform unilateral, bilateral or non-nerve sparing will be established and recorded in the clinical record form (CRF) for each patient.
11209602|NCT03317977|Experimental|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
11209603|NCT03317977|Active Comparator|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
11209604|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
11209605|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
11209606|NCT03317951|Experimental|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
11209607|NCT03317951|Active Comparator|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
11209608|NCT03317938|Experimental|Fecobionics studies|
11209609|NCT03317912|Active Comparator|Lidocaïne 2%|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
11209610|NCT03317912|Placebo Comparator|Placebo (for Lidocaïne)|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
11209611|NCT03317899|Experimental|Group I (auto HSCT tbo-filgrastim)|Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.
11209612|NCT03317899|Experimental|Group II (auto HSCT)|Patients undergo auto Hematopoietic Cell Transplantation (HSCT).
11209763|NCT03316781|Experimental|HLX03 group|
11209764|NCT03316781|Active Comparator|adalimumab group|
11209614|NCT03317886|Active Comparator|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
11209615|NCT03317873|Experimental|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
11209616|NCT03317873|Experimental|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
11209617|NCT03317860|Sham Comparator|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
11209618|NCT03317860|Active Comparator|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
11209619|NCT03317847|Experimental|Bromfenac|Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
11209620|NCT03317847|Active Comparator|Dexamethasone|Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
11209621|NCT03317834||Study Population|Total Knee Replacement with Navio Surgical Systems
11209622|NCT03317808|Active Comparator|Heavy slow resistance exercise|
11209623|NCT03317808|Placebo Comparator|Traditional supervised exercise|
11209624|NCT03317795|Active Comparator|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
11209625|NCT03317795|Active Comparator|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
11209626|NCT03317769|Experimental|Experimental Treatment|Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
11209627|NCT03317769|Active Comparator|Active Comparator|Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
11209628|NCT03317756|Experimental|Patient Variation 1|Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
11209629|NCT03317756|Experimental|Patient Variation 2|Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
11209630|NCT03317743|Experimental|NOV140101 (IDX-1197)|
11209631|NCT03317730|Experimental|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
11209632|NCT03317717|Experimental|botulinum toxin 2U|
11209633|NCT03317717|Experimental|botulinum toxin 5U|
11209634|NCT03317717|Experimental|botulinum toxin 10U|
11209635|NCT03317717|Experimental|botulinum toxin 20U|
11209636|NCT03317717|Experimental|botulinum toxin 30U|
11209637|NCT03317704|Active Comparator|speed endurance training (SET)|Training 6 weeks 3 times pr. week
11209638|NCT03317704|No Intervention|Controls|Asked to continue their usual life style
11209639|NCT03317704|Active Comparator|speed endurance training (SET) II|Training 6 weeks 3 times pr. week
11209640|NCT03317691||ST segment Elevation Myocardial Infarction|ST segment Elevation Myocardial Infarction patients' diagnosis was confirmed by coronary artery angiography. The prior surgery electrocardiogram need to be collected.
11209641|NCT03317678|Experimental|BioKefir (BKP)|BioKefir™ (Lifeway Foods) is a lactose-free fermented milk drink containing 12 different species of bacteria within the lactobacillus, bifidobacterium, and streptococcus generas totaling approximately 20 CFU per 3.5 ounce serving. The product also contains 2 g of fiber, including pectin and inulin. These fibers, especially inulin, are prebiotics that may function along with the probiotic species to support gastrointestinal health. The product is available commercially. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The probiotic will be provided in individual 3.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
11209642|NCT03317678|Placebo Comparator|Non-fermented Milk (NFM)|The NFM is dairy-based product ultra-filtered to remove lactose. In addition to being matched to lactose, the NFM contains similar energy, fat, and protein content as the probiotic. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The NFM control will be provided in 11.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
11209643|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
11209644|NCT03317652|Experimental|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.
~Interventions are:
~Hyperventilation
~6% CO2 breathing
~Infusion of sodium nitroprusside"
11209645|NCT03317639|Experimental|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
11209646|NCT03317639|No Intervention|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
11209765|NCT03316755|No Intervention|without pamphlet|a group not exposed to pamphlet
11209766|NCT03316755|Experimental|With pamphlets|a group exposed to pamphlet
11209647|NCT03317626|Experimental|Cold Stimulus|The study procedure will beto use a coldstimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted
11209648|NCT03317613|Experimental|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
11209649|NCT03317600|Active Comparator|Lidocaine block|
11209650|NCT03317600|Placebo Comparator|Isotonic saline block|
11209651|NCT03317587|Experimental|INSPIRE|
11209652|NCT03317574|Experimental|MEDITOXIN|
11209653|NCT03317574|Active Comparator|BOTOX|
11209654|NCT03317561||Myocardial injury|Subjects who have had an increase in troponin T level (> 99 percentile) in the perioperative period shall form the cases.
11209655|NCT03317561||Control|Subjects who do not have an increase in troponin T level (< 99 percentile) in the perioperative period shall form the controls.
11209656|NCT03317548||fresh embryo transfer|patients with fresh day 3 embryo transfer after oocyte pick up, the hormone including FSH, LH, E2 and progesterone was test before embryo transfer for analysis. The clinical outcomes including implantation and pregnancy were checked and recorded.
11209657|NCT03317548||frozen embryo transfer|"freeze-all embryo was performed after oocyte fertilization, the hormone including FSH, LH, E2 and progesterone was test before oocyte pick up and embryo transfer for analysis.
~vitrification of pronuclear stage embryo (zygote) and frozen embryo transfer"
11209658|NCT03317535|Other|Local anesthesia/conscious sedation|Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
11209659|NCT03317535|Other|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol (1-2mg/kg) and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60 with propofol and remifentanil. After tracheal intubation, patients will be kept with controlled ventilation.
11209660|NCT03317522||Belfast HAPO|"All pregnant women who attended the Royal Victoria Maternity Hospital, Belfast were eligible to participate unless they met one or more exclusion criteria.
~All eligible women from the Belfast centre were invited to take part in a prospective observational study involving an additional fasting serum sample for lipids at 28 weeks gestation and long term follow up of their HAPO offspring. Only those women who had remained blinded to oral glucose tolerance test (OGTT) results during pregnancy were included (fasting plasma glucose ≤5·8 mmol/L and 2-hour glucose ≤11·1 mmol/L). Offspring from these pregnancies had anthropometric measurements performed within 72 hours of birth and at age 5-7 years."
11209661|NCT03317509|Active Comparator|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
11209662|NCT03317509|Sham Comparator|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
11209663|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
11209664|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
11209665|NCT03317496|Experimental|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
11209666|NCT03317496|Experimental|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
11209667|NCT03317470|Active Comparator|Phase I:|"In Phase 1 of the study (first five months), the investigators will enroll new patients when they call them to remind them of their first colposcopy appointment. If patients consent, the investigators also will assess their basic needs during the call. Those who screen positive for at least one unmet basic need, will be referred to the 2-1-1 helpline at their clinic visit (or this information will be sent to them if they miss their clinic visit).
~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.
~For patients in phase 1, the follow-up survey will only assess acceptability of the basic needs survey (five questions)"
11209668|NCT03317470|Experimental|Phase 2:|"-In Phase 2 of the study (second five months), new colposcopy patients will be approached and consented in a similar fashion as in Phase 1 and asked to complete the basic needs survey. However, this time, patients who screen positive with at least one unmet basic need will be offered assistance by a life navigator (a trained case manager) who will contact the patients by phone within 2 business days of completing the survey.
~The life navigator will connect patients with community resources in each area to help with their unmet basic needs.
~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.
~Patients enrolled in phase 2 will be asked the same five questions in addition to seven more assessing perceived effectiveness of the life navigator"
11209669|NCT03317457|Experimental|Durvalumab and Tremelimumab|"Cycles/courses 1-3:
~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks
~Cycles/courses ≥4:
~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
11209670|NCT03317457|Active Comparator|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
11209671|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
11209672|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
11209673|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
11209674|NCT03317405|Experimental|Cohort I (Z-endoxifen hydrochloride)|Participants apply Z-endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
11209675|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
11209676|NCT03317392|Experimental|Arm I (radium Ra 223 dichloride, olaparib)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11210030|NCT03315000|Placebo Comparator|Placebo|Lactose powder inhaled through Ellipta® inhaler
11209677|NCT03317392|Experimental|Arm II (radium Ra 223 dichloride)|Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib.
11209678|NCT03317379|Experimental|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
11209679|NCT03317379|Active Comparator|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
11209680|NCT03317379|No Intervention|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
11209681|NCT03317353|Experimental|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
11209682|NCT03317353|Experimental|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
11209683|NCT03317353|Experimental|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
11209684|NCT03317353|No Intervention|Control group|Group D. No vestibular rehabilitation is developed.
11209685|NCT03317340||Patient Undergoing Urodynamics|
11209686|NCT03317327|Experimental|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
11209687|NCT03317301|Experimental|Experimental|Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
11209688|NCT03317301|Active Comparator|Active comparator|Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
11209689|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
11209690|NCT03317275|Experimental|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
11209691|NCT03317275|Active Comparator|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
11209692|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
11209693|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
11209694|NCT03317236|Experimental|Reference - Test|A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).
11209695|NCT03317236|Experimental|Test - Reference|A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).
11209696|NCT03317223|Experimental|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g
11209697|NCT03317223|Active Comparator|Lansoprazole/Clarithromycin/Amoxicillin|Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g
11209698|NCT03317210|Other|iron therapy with good response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. The maximum total iron dose was 1,600 mg, therefore therapy was stopped if the maximal iron sucrose dose was administered, or target Hb > 10.5 g/dL was achieved.
11209699|NCT03317210|Other|iron therapy with poor response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. If response to therapy with iron sucrose was poor (i.e. Hb increase <0.7 g/dl after 2 weeks), patients additionally received recombinant human erythropoietin (10,000 U EPREX®, Janssen-Cilag, Baar, Switzerland).
11209700|NCT03317210|Other|iron therapy and erythropoietin|Patients with an Hb between 8.0 and 8.9 g/dl received 200mg iron sucrose and recombinant human erythropoietin intravenously twice weekly.
11209701|NCT03317197|Placebo Comparator|Control Group|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
~Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Saline solution
~Syringe No. 2 : Saline solution"
11209795|NCT03316560|Experimental|Group 5|Subjects at least 18 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug.
11209702|NCT03317197|Active Comparator|Experimental Group 1|"Using Vasopressin [20 IU/CPR cycle] injection until the 5th cycle
~Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Vasopressin
~Syringe No. 2 : Saline solution"
11209703|NCT03317197|Active Comparator|Experimental Group 2|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
~Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Saline solution
~Syringe No. 2 : Steroid"
11209704|NCT03317197|Experimental|Experimental Group 3|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
~Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.
~Syringe No. 1 : Vasopressin
~Syringe No. 2 : Steroid"
11209705|NCT03317184|Experimental|Periumbilical incisions|
11209706|NCT03317184|Experimental|Pfannenstiel incision|
11209707|NCT03317171|Experimental|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
11209708|NCT03317171|Placebo Comparator|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
11209709|NCT03317158|Experimental|Phase 1: (cohort 1):|Durvalumab monotherapy (cohort 1)
11209710|NCT03317158|Experimental|Phase 1: (cohort 2a) & (cohort 2b):|"(cohort 2a) - Durvalumab plus BCG
~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)"
11209711|NCT03317158|Experimental|Phase 2: (cohort 2a), (cohort 2b), & (BCG re-treatment)|"(cohort 2a) - Durvalumab plus BCG
~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)
~(BCG re-treatment) - Cross-over to Durvalumab Monotherapy"
11209712|NCT03317145|Active Comparator|Arm A (NMES followed by IPC)|Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
11209713|NCT03317145|Active Comparator|Arm B (IPC followed by NMES)|Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
11209714|NCT03317132|Experimental|Individual Placement and Support|One year of IPS Support
11209715|NCT03317132|No Intervention|Treatment as usual|Treatment as usual
11209716|NCT03317119|Experimental|Treatment (TAS-102, trametinib)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11209717|NCT03317080||patients with lung cancer|patients with stages I-IV lung cancer eligible for surgery
11209718|NCT03317067|Experimental|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
11209719|NCT03317067|Placebo Comparator|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
11209720|NCT03317041|Experimental|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
11209721|NCT03317041|No Intervention|Control group|Participants will test passively in a sitting position for 30-min period
11209722|NCT03317028|Experimental|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
11209723|NCT03317028|Experimental|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
11209724|NCT03317028|Experimental|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
11209725|NCT03317028|Placebo Comparator|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
11209726|NCT03317015|Experimental|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
11209727|NCT03317015|Active Comparator|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
11209728|NCT03317002|Experimental|AZD5718 Dose A|AZD5718 Dose A once daily
11209729|NCT03317002|Experimental|AZD5718 Dose B|AZD5718 Dose B once daily
11209730|NCT03317002|Placebo Comparator|Placebo|Matching placebo once daily
11209731|NCT03316989||obese children|Children and adolescents with BMI according to the CDC greater that 95%ile
11209732|NCT03316989||normal weight|Children and adolescents with BMI according to the CDC less than the 85%ile
11209733|NCT03316989||obese with the MetS|obese children with metabolic syndrome compared to obese children with out the MetS and normal weight children
11209734|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
11209735|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
11209736|NCT03316963|Experimental|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
11209796|NCT03316560|Experimental|Group 6|Subjects at least 18 y/o treated with Dose 6 of rAAV2tYF-GRK1-RPGR study drug.
11209737|NCT03316950|Experimental|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
11209738|NCT03316950|Sham Comparator|IntraGen Sham|Patients will undergo all acts of receiving radiofrequency treatment, but no direct energy will be applied. Patients will have 3 sham treatments space one month apart. Each treatment session will be a total of 20 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
11209739|NCT03316950|Experimental|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
11209740|NCT03316950|Sham Comparator|DiVA Sham|Patients randomized into the DiVA sham group will undergo all acts of receiving DiVA treatment, but not direct energy will be applied. Patients will have a total of 3 treatments, spaced 1 month apart. Each treatment will last approximately 10 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
11209741|NCT03316950|Experimental|Dual Treatment|Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
11209742|NCT03316937|Experimental|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
11209743|NCT03316937|Experimental|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
11209744|NCT03316911|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
11209745|NCT03316911|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
11209746|NCT03316898|Placebo Comparator|Placebo|Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
11209747|NCT03316898|Experimental|AGN-242071 5 mg|One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
11209748|NCT03316898|Experimental|AGN-242071 15 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
11209749|NCT03316898|Experimental|AGN-242071 25 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
11209750|NCT03316885|Experimental|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted as a replacement of the human crystalline lens during cataract surgery
11209751|NCT03316872|Experimental|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks
~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
11209752|NCT03316859|Experimental|Naloxegol|naloxegol 25 mg pill
11209753|NCT03316859|Placebo Comparator|Placebo|placebo pill
11209754|NCT03316846|Experimental|Internet-delivered therapy|10 week, guided and individually tailored internet-delivered cognitive behavioral therapy.
11209755|NCT03316846|No Intervention|Wait list control group|Wait list control group, receives treatment at later point.
11209756|NCT03316820|Experimental|Treatment A|K0706 tablet
11209757|NCT03316820|Experimental|Treatment B|K0706 tablet
11209758|NCT03316820|Experimental|Treatment C|K0706 tablet
11209759|NCT03316820|Experimental|Treatment D|K0706 capsule
11209760|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11209761|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11209762|NCT03316794|Experimental|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
11209767|NCT03316742|Experimental|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
11209768|NCT03316742|Experimental|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
11209769|NCT03316729|Experimental|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
11209770|NCT03316729|Placebo Comparator|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
11209771|NCT03316716|No Intervention|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
11209772|NCT03316716|Experimental|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
11209773|NCT03316703|Active Comparator|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
11209774|NCT03316703|Experimental|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
11209775|NCT03316690|Experimental|Metformin treatment|
11209776|NCT03316690|Placebo Comparator|Placebo treatment|
11209777|NCT03316677|Other|colorectal resection and anastamosis|"Intraoperative testing of colorectal anastomoses
~Insert a Foley catheter through the anus into the rectum.
~Insufflate the Foley balloon with 5 cc of air.
~fill the pelvic space with 500 CC of warm saline
~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer
~Remove the saline from the pelvic space.
~Inject methylene blue in to the rectum up to a pressure of 35 mmH2o measured by external manometer
~Remove the methylene blue from rectum.
~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.
~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
11209778|NCT03316664|Experimental|INT|Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min.
11209779|NCT03316664|Active Comparator|IPT|Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min.
11209780|NCT03316664|Other|CoC|COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.
11209781|NCT03316651|Experimental|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:
~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.
~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
11209782|NCT03316638|Experimental|W0101 - Cohort A1|This is a 14 days treatment cycle cohort in a 2 weeks schedule
11209783|NCT03316638|Experimental|W0101 - Cohort A2|This is a 21 days treatment cycle cohort in a 3 weeks schedule
11209784|NCT03316638|Experimental|W0101 - Expansion Phase|Will be initiated after completion of cohorts A1 and A2
11209785|NCT03316625|Experimental|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
11209786|NCT03316612|Experimental|Intervention group|"Ingredients: Vaccinium Myrtillus L. extracts, and excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)
~Brown oval tablet, 650mg per tablet with 150mg Vaccinium Myrtillus L. extracts, twice a day, 2 tablets each time.
~The intervention period is about 3 months."
11209787|NCT03316612|Placebo Comparator|Placebo group|"Ingredients: excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)
~Brown oval tablet without Vaccinium Myrtillus L. extracts, 650mg per tablet, twice a day, 2 tablets each time.
~The intervention period is about 3 months."
11209788|NCT03316599|Experimental|Ficlatuzumab + Gemcitabine and Nab-Paclitaxel|"Ficlatuzumab will be administered intravenously days 1 and 15 of a 28 day cycle
~Gemcitabine 1000 mg/m2 and Nab-Paclitaxel 125mg/m2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
~Dosage of Ficlatuzumab is determined by dose level to which the patient is assigned at time of enrollment."
11209789|NCT03316586|Experimental|Nivolumab + Cabozantinib|"Nivolumab given every 4 weeks intravenously
~Cabozantinib given orally once daily"
11209790|NCT03316573|Experimental|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks for 35 cycles
11209791|NCT03316560|Experimental|Group 1|Subjects at least 18 y/o treated with Dose 1 of rAAV2tYF-GRK1-RPGR study drug.
11209792|NCT03316560|Experimental|Group 2|Subjects at least 18 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug.
11209793|NCT03316560|Experimental|Group 3|Subjects at least 18 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
11209794|NCT03316560|Experimental|Group 4|Subjects at least 6 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
11209823|NCT03316339|Experimental|Dexmedetomidine|
11209797|NCT03316560|Experimental|Group 7|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-GRK1-RPGR study drug determined by Groups 1-6.
11209798|NCT03316547|No Intervention|Control|The control group will receive standard hosptial care.
11209799|NCT03316547|Experimental|Intervention|The sensory-based intervention group will be provided daily support to engage families in sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program).
11209800|NCT03316534|Placebo Comparator|Placebo|Placebo
11209801|NCT03316534|Active Comparator|Aspirin|Aspirin (100 mg/daily)
11209802|NCT03316521|Experimental|Single Ascending Dose (SAD)|"In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). All cohorts will include at least four subjects each. Additional subjects may be added in any cohort if necessary.
~AMY-101 will be administered as a SQ or IV injection. Subjects in each cohort will be dosed sequentially, to allow for close safety monitoring. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee. Subsequent dose levels will be administered until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) is reached based on specified dose escalation criteria."
11209803|NCT03316521|Experimental|Multiple Dose (MD)|Depending on the results of the SAD, multiple doses of AMY-101 will be administered at the dose which has been identified as the dose which saturates target C3, for a duration that results to an exposure level equivalent to the maximum exposure achieved in the SAD. The dose and dosing interval will be determined based on the PK data obtained in the SAD part of the study. Each MD cohort will include at least four subjects and may be expanded with additional subjects if necessary. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee.
11209804|NCT03316495|No Intervention|without pamphlet|NOT EXPOSED TO PAMPHLETS
11209805|NCT03316495|Experimental|with pamphlet|EXPOSED TO PAMPHLETS
11209806|NCT03316482|Experimental|Leuplin DPS 11.25mg s.c. every 12 weeks|Open
11209807|NCT03316469|Experimental|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
11209808|NCT03316469|Experimental|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
11209809|NCT03316456||AL Patients Undergoing Induction Chemotherapy|Adults undergoing inpatient induction chemotherapy for newly diagnosed/relapsed acute leukemia.
11209810|NCT03316443|Active Comparator|(Group G)|Glidescope group: 45 patients will be intubated by Glidescope (Group G). For endotracheal intubation with glidoscope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
11209811|NCT03316443|Experimental|(Group M)|Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first, the laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced
11209812|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
11209813|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
11209814|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
11209815|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
11209816|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
11209817|NCT03316378|Experimental|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
11209818|NCT03316378|No Intervention|Group without Achilles Tendinopathy|The control group did not receive an injection between test repetitions
11209819|NCT03316365|Experimental|Continuous RAS|The experimental group (continuous treatment) trained daily with RAS for 24 weeks.
11209820|NCT03316365|Active Comparator|Intermittent RAS|The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks.
11209821|NCT03316352|Experimental|Ultrasound-assisted|Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
11209822|NCT03316352|Active Comparator|Landmark-guided|In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.
11209825|NCT03316326|Experimental|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
11209826|NCT03316313||Date of birth|Those people born within the years 1945-1965
11209827|NCT03316300|Experimental|Renexus|
11209828|NCT03316300|Sham Comparator|Sham|
11209829|NCT03316287|Experimental|Hearing aid + mobile phone|
11209830|NCT03316287|Experimental|Hearing aid + mobile phone + biosensor|
11209831|NCT03316274|Experimental|Nivolumab (Cohort A-Safety)|All participants will receive 10mg in 1 mL injection into a single KS lesion in the skin, every 2 weeks for 4 doses.
11209832|NCT03316274|Experimental|Nivolumab (Cohort B-Expansion)|All participants will receive injection into up to two KS lesion in the skin, every 2 weeks for 4 doses. For participants in the expansion cohort whose injected lesion is improving as of week 26 and they also did not experience any serious adverse events (SAE), they can receive additional intra-lesional injections of nivolumab into up to 4 lesions every 2 weeks for up to 4 doses (for total up to 8 doses). The injected volume will not exceed 10 mg (or 1 mL) each time
11209833|NCT03316248|Experimental|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
11209834|NCT03316248|Active Comparator|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
11209835|NCT03316222|Experimental|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
11209836|NCT03316222|Experimental|Dose Expansion|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
11209837|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
11209838|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
11209839|NCT03316183|Experimental|Intervention Group|"Maintain rSO2 values at or above 75% of the baseline
~Midline position
~Target CO2 of ≥40 mmHg, target MAP >60 mm Hg
~Maintain cerebral perfusion pressure >50 mm Hg
~Target pump flow 2.5 L/m2/min
~If rSO2 persistently below treatment threshold:
~FiO2 is increased
~or propofol 50-100 mg bolus is administered
~If Hct below 20% packed red blood cells will be transfused
~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
11209840|NCT03316183|No Intervention|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
11209841|NCT03316170|Experimental|Social Support + NRT Sampling|"The treatment group will receive:
~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,
~a written directory of a range of social support resources delivered via mail,
~a brief phone consult (10-15 minutes via phone) germane to smoking cessation,
~a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and
~a free, 2-week supply of nicotine patches and lozenges delivered via mail."
11209842|NCT03316170|Active Comparator|Social Support|"The control group will receive:
~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,
~a written directory of a range of social support resources delivered via mail,"
11209843|NCT03316157|Experimental|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
11209844|NCT03316157|No Intervention|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
11209845|NCT03316144|Experimental|1 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs
11209846|NCT03316144|Experimental|3 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
11209847|NCT03316144|Experimental|10 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs
11209848|NCT03316131|Experimental|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:
~verinurad + febuxostat + dapagliflozin;"
11209849|NCT03316131|Experimental|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:
~verinurad + febuxostat + dapagliflozin matched placebo"
11209850|NCT03316118|Active Comparator|Group 1|Patient will receive genicular nerve block with bupivacaine
11209851|NCT03316118|Placebo Comparator|Group 2|Patient will receive normal saline as the nerve block
11209852|NCT03316105|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
11209881|NCT03315910|Experimental|NRT Lozenge (Yes vs. No)|Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
11210031|NCT03314987|Active Comparator|intervention group|Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks
11209853|NCT03316105|Sham Comparator|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
11209854|NCT03316079|Active Comparator|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
11209855|NCT03316079|Experimental|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
11209856|NCT03316066|Experimental|Group 5|stellate ganglion block with ropivacaine 0.2% 5 mL
11209857|NCT03316066|Active Comparator|Group 2|stellate ganglion block wit ropivacaine 0.2% 2 mL
11209858|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
11209859|NCT03316040|No Intervention|Control 1|This arm represent control schools. No JIC will be implemented.
11209860|NCT03316040|Experimental|Treatment 1|This arm implements the JIC among a random subset of students within the pre-defined grade.
11209861|NCT03316040|Experimental|Treatment 2|This arm implements the JIC among indegree central students within the pre-defined grade.
11209862|NCT03316040|Experimental|Treatment 3|This arm implements the JIC among edge betweeness central students within the pre-defined grade.
11209863|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
11209864|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
11209865|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
11209866|NCT03315988|Experimental|Vegan diet|"Intervention Description and Definition The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.
~The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly."
11209867|NCT03315975|Experimental|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
11209868|NCT03315962|Experimental|Aim 1: DHO Intervention Arm|A selection of DHO or TB district supervisors that are randomized to the multicomponent SPIRIT intervention.
11209869|NCT03315962|No Intervention|Aim 1: DHO Control Arm|A selection of DHO or TB district supervisors that are randomized to the country standard of care, but not to receive the study intervention.
11209870|NCT03315962|Experimental|Aim 2: SPC Intervention Arm|Individuals randomized to receive the Single Pill Combination (SPC) for IPT who reside in districts where the SPIRIT intervention is being implemented.
11209871|NCT03315962|No Intervention|Aim 2: Non-SPC Control Arm|Individuals randomized to receive the non-Single Pill Combination (SPC) for IPT who reside in districts where the SPIRIT intervention is being implemented.
11209872|NCT03315962|No Intervention|Aim 2: Adherence Sub-Study Observation|Individuals who are prescribed INH and reside in districts where the DHO has been enrolled in the SEARCH-IPT study will undergo observation for adherence to their INH regimen through testing hair samples, questionnaires, and clinic chart review.
11209873|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
11209874|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
11209875|NCT03315936|Experimental|Single rising dose part|
11209876|NCT03315936|Experimental|Relative bioavailability (rel BA) part|
11209877|NCT03315923|Experimental|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
11209878|NCT03315923|Experimental|Glatiramer acetate|Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
11209879|NCT03315910|Experimental|Motivational Interviewing( MI) (Yes vs. No)|Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.
11209880|NCT03315910|Experimental|Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)|Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
11209916|NCT03315585|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
11210032|NCT03314987|Placebo Comparator|placebo group|Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks
11209882|NCT03315910|Experimental|Message Framing (Gain vs. Loss)|Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).
11209883|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
11209884|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
11209885|NCT03315884|Experimental|Iliac segment recanalization and stenting Iliac segment CFA|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
11209886|NCT03315884|Active Comparator|Iliac segment recanalization, stenting and plastic CFA patch|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
11209887|NCT03315871|Experimental|1/combination therapy|Combination Immunotherapy
11209888|NCT03315871|Experimental|2/combination therapy + surveillance|surveillance then combination immunotherapy
11209889|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
11209890|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
11209891|NCT03315819|Experimental|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique. The procedure must be performed within 15 days of dislocation.
11209892|NCT03315819|Active Comparator|Immobilization interne rotation|Immobilization of the shoulder during 3 weeks
11209893|NCT03315806|Active Comparator|Beetroot Juice|Beetroot juice containing 9 mmol of nitrate per dose
11209894|NCT03315806|Placebo Comparator|Placebo juice (nitrate depleted)|Beetroot juice nitrate-depleted
11209895|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
11209896|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
11209897|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
11209898|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
11209899|NCT03315767|Other|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.
~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.
~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
11209900|NCT03315754|Experimental|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
11209901|NCT03315741|Experimental|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
11209902|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
11209903|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
11209904|NCT03315689|Placebo Comparator|Vehicle|Vehicle
11209905|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
11209906|NCT03315676|Active Comparator|Oral Bonoprazan|Daily intake of Bonoprazan
11209907|NCT03315676|Active Comparator|Oral Esomeprazol|Daily intake of Esomeprazol
11209908|NCT03315663|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
11209909|NCT03315663|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
11209910|NCT03315637|Experimental|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
11209911|NCT03315624|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
11209912|NCT03315611|Active Comparator|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
11209913|NCT03315611|Experimental|AD, not sensitized, not treated|Allergen challenge chamber
11209914|NCT03315611|Experimental|AD, sensitized, not treated|Allergen challenge chamber
11209915|NCT03315598|Experimental|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
11209917|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
11209918|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
11209919|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
11209920|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
11209921|NCT03315533|Experimental|Duloxetine 30 milligrams (mg)|
11209922|NCT03315533|Placebo Comparator|Placebo|
11209923|NCT03315533|Experimental|Duloxetine 60 milligrams (mg)|
11209924|NCT03315520|Experimental|Relapsed/refractory malignant lymphomas|Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen
11209925|NCT03315507|Experimental|PB1046 Injection|PB1046 Subcutaneous Injection
11209926|NCT03315494|Experimental|SKI-O-703 200 mg (once daily)|SKI-O-703 capsule (1 x 200 mg)
11209927|NCT03315494|Experimental|SKI-O-703 400 mg (once daily)|SKI-O-703 capsule (2 x 200 mg, once daily)
11209928|NCT03315494|Experimental|SKI-O-703 200 mg (twice daily)|SKI-O-703 capsule (1 x 200 mg twice daily)
11209929|NCT03315494|Placebo Comparator|Placebo|Placebo capsule
11209930|NCT03315481|Active Comparator|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
11209931|NCT03315481|Active Comparator|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
11209932|NCT03315455|Experimental|Arm A: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm A will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
11209933|NCT03315455|Experimental|Arm B: Emicizumab Prophylaxis at 6 mg/kg Q4W|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm B will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 6 mg/kg via SC injection Q4W for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
11209934|NCT03315455|Other|Arm C: No Prophylaxis (Control Arm)|Participants ≥12 years old with hemophilia A (with or without FVIII inhibitors) who are randomized to Arm C will not receive any prophylactic treatment for at least 24 weeks. After 24 weeks, participants will have the opportunity to switch to receive emicizumab prophylaxis at 3 mg/kg QW via SC injection for 4 weeks, followed by 6 mg/kg Q4W until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
11209935|NCT03315455|Experimental|Arm D: Emicizumab Prophylaxis at 1.5 mg/kg QW|Participants <12 years old with hemophilia A and FVIII inhibitors who are enrolled to Arm D will receive prophylactic emicizumab at a dose of 3 mg/kg via SC injection QW for first 4 weeks, followed by 1.5 mg/kg via SC injection QW for at least 24 weeks. After 24 weeks treatment, participants will be allowed to continue emicizumab until marketing authorization as part of this study or a separate extension study, as long as they derive clinical benefit. Participants will continue to receive standard-of-care treatments on an episodic basis for the treatment of breakthrough bleeds during the study.
11209936|NCT03315442|Sham Comparator|Caffeine Group|Caffeine group consumed 200mg of caffeine one time.
11209937|NCT03315442|Experimental|Energy Drink Group|The energy drink group consumed 1 16 ounces energy drink one time.
11209938|NCT03315429|Other|Stress testing arm|Stress testing of patients with functional mitral regurgitation.
11209939|NCT03315416||NHS Sample|Children diagnosed with speech sound disorder aged 2-5 years
11209940|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
11209941|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
11209942|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.
~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
11209943|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
11210028|NCT03315000|Experimental|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
11209944|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.
~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
11209945|NCT03315390|Experimental|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
11209946|NCT03315390|Active Comparator|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
11209947|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
11209948|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
11209949|NCT03315364|Experimental|Liporaxel® (oral paclitaxel)|"28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.
~Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration."
11209950|NCT03315364|Active Comparator|Taxol® (IV paclitaxel)|"28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.
~Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL."
11209951|NCT03315351|Experimental|Study Procedure|Brachytherapy. PET-scan.
11209952|NCT03315338|Experimental|SAD Part 1 Active Cohort A|CORT118335, 25 mg
11209953|NCT03315338|Placebo Comparator|SAD Part 1 Placebo oral capsule Cohort A|
11209954|NCT03315338|Experimental|SAD Part 1 Active Cohort B|CORT118335, 75mg
11209955|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort B|
11209956|NCT03315338|Experimental|SAD Part 1 Active Cohort C|CORT118335, 225mg
11209957|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort C|
11209958|NCT03315338|Experimental|SAD Part 1 Active Cohort D|CORT118335, 675mg
11209959|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort D|
11209960|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fasting|CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast
11209961|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fed|CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast
11209962|NCT03315338|Placebo Comparator|SAD Part 2 Placebo PD Effect Cohort B|
11209963|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335|
11209964|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335|
11209965|NCT03315338|Experimental|MAD Part 3 Active Cohort A|CORT118335, 375mg qd for 14 days
11209966|NCT03315338|Placebo Comparator|MAD Part 3 Placebo Cohort A|Placebo qd for 14 days
11209967|NCT03315338|Experimental|SAD Part 4 Active Cohort A|CORT118335, 100mg
11209968|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort A|
11209969|NCT03315338|Experimental|SAD Part 4 Active Cohort B|CORT118335, 300mg
11209970|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort B|
11209971|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fasting|CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast
11209972|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fed|CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast
11209973|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fasting|Supplied as suspension for oral dosing given after an overnight fast
11209974|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fed|Supplied as suspension for oral dosing given after a high-fat breakfast
11209975|NCT03315338|Experimental|SAD Part 4 Active Cohort Part D|CORT118335, 1500mg
11209976|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort D|
11209977|NCT03315338|Experimental|MAD Part 5 Active Cohort A|CORT118335, 150mg
11209978|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort A|
11209979|NCT03315338|Experimental|MAD Part 5 Active Cohort B|CORT118335, dose to be determined
11209980|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort B|
11209981|NCT03315338|Experimental|MAD Part 5 Active Cohort C|CORT118335, dose to be determined
11209982|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort C|
11209983|NCT03315325|Experimental|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
11209984|NCT03315325|Experimental|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
11209985|NCT03315325|Experimental|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
11209986|NCT03315312|Active Comparator|Fissure sealant|
11209987|NCT03315312|Experimental|Fluoride varnish|
11209988|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
11209989|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
11209990|NCT03315273|Experimental|Traumatic brain injury|"Patients who have suffered a traumatic brain injury will be assessed with a test battery including
~a motor imagery ability questionnaire (MIQ-rs)
~a mental rotation test
~a chronometry test (TDMI)"
11210029|NCT03315000|Experimental|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
11210033|NCT03314974|Experimental|TBI Regimen|
11209991|NCT03315273|Active Comparator|Control|"Healthy volunteers matched for age, sex and educational level will be assessed with the same test battery including
~a motor imagery ability questionnaire (MIQ-RS)
~a mental rotation test
~a chronometry test (TDMI)"
11209992|NCT03315260||Bone metastatic CRPC patients|Japanese patients who are designated to undertake Ra-223/Xofigo therapy based on physician judgement
11209993|NCT03315247|No Intervention|Treatment as Usual|Participants assigned to the Treatment as Usual group will attend routine clinic visits at the Toronto Western Hospital Bariatrics Surgery Program (TWH-BSP). These visits generally include education on bariatric surgery and nutrition. Patients meet with select members of the multidisciplinary team at 1, 2, and 3 years post-surgery, and may attend an optional monthly support group. Participants' service utilization (i.e., attendance at optional sessions) will be documented and compared across groups.
11209994|NCT03315247|Experimental|Telephone-Based CBT|"The Tele-CBT intervention will be delivered 1 year following bariatric surgery. Participants will receive 6 weekly Telephone-based Cognitive Behavioural Therapy sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration and scheduled at a time convenient for the participants."
11209995|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
11209996|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
11209997|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
11209998|NCT03315221|Experimental|Test product|Human Milk Fortifier (HMF) with added lipids.
11209999|NCT03315221|Active Comparator|Control product|Commercially available HMF (without lipids).
11210000|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
11210001|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
11210002|NCT03315195|Experimental|Preoperative oral nutritional supplement|Oral nutritional supplement 500 kcal/day for 14 days and dietary advice
11210003|NCT03315195|No Intervention|Conventional treatment|Dietary advice
11210004|NCT03315182|Experimental|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:
~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)"
11210005|NCT03315182|Experimental|Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:
~• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)"
11210006|NCT03315182|Experimental|Cohort 3 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:
~• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)"
11210007|NCT03315169|Active Comparator|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
11210008|NCT03315169|Experimental|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
11210009|NCT03315156||Patients|patients with AOM
11210010|NCT03315143|Experimental|Sotagliflozin|Sotagliflozin dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
11210011|NCT03315143|Placebo Comparator|Placebo|Placebo dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
11210012|NCT03315130|Experimental|0.1 mg/kg zilucoplan (RA101495)|
11210013|NCT03315130|Experimental|0.3 mg/kg zilucoplan (RA101495)|
11210014|NCT03315130|Placebo Comparator|Placebo|
11210015|NCT03315104|Experimental|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.
~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
11210016|NCT03315104|Experimental|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.
~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
11210017|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.
~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
11210018|NCT03315091|Experimental|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
11210019|NCT03315091|Experimental|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
11210020|NCT03315078|Experimental|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
11210021|NCT03315065|Other|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
11210022|NCT03315052|Experimental|Budesonide treatment arm|Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen
11210023|NCT03315052|Active Comparator|Standard immunosuppression arm|Patients treated with standard immunosuppression after liver transplant
11210024|NCT03315039|Experimental|Liposomal annamycin|
11210025|NCT03315026|Experimental|Siltuximab|Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
11210026|NCT03315013|Experimental|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
11210027|NCT03315013|No Intervention|Standard|The standard arm will be referred to standard care after study enrollment.
11210034|NCT03314974|Experimental|Non-TBI Regimen|
11210036|NCT03314935|Experimental|Treatment Group B|INCB001158 + gemcitabine/cisplatin
11210037|NCT03314935|Experimental|Treatment Group C|INCB001158 + paclitaxel
11210038|NCT03314922|Experimental|Parsaclisib|
11210039|NCT03314909|Experimental|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
11210040|NCT03314909|Experimental|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
11210041|NCT03314909|Experimental|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
11210042|NCT03314909|No Intervention|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
11210043|NCT03314896|Experimental|Laparoscopic surgery for T4 colon tumor|Laparoscopic surgery for T4 colon cancers
11210044|NCT03314896|No Intervention|Open surgery for T4 colon tumor|Conventional open surgery for T4 colon cancers
11210045|NCT03314883|Experimental|D-US ARF|Diaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
11210046|NCT03314870|Other|Retrospective study|Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
11210047|NCT03314870|Other|Prospective study|Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
11210048|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
11210049|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
11210050|NCT03314831||Systemic Inflammatory Response Syndrome|Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
11210051|NCT03314831||No inflammation|Patients without systemic inflammation.
11210052|NCT03314818||Ultrasound 3D Imaging|To investigate natural history of subclinical atherosclerosis as determined by 3D carotid ultrasound.
11210053|NCT03314805|Placebo Comparator|Control|Placebo
11210054|NCT03314805|Experimental|Treatment|Astragalus polysaccharides 500 mg
11210055|NCT03314792|Active Comparator|Oxycodone|Active comparator drug administrated.
11210056|NCT03314792|Experimental|Tapentadol|Experimental drug administrated.
11210057|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
11210058|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.
~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).
~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.
~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
11210059|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.
~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).
~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).
~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
11210060|NCT03314740|Active Comparator|Arm A|Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.
11210061|NCT03314740|Experimental|Arm B|"Oral administration of two experimental drugs:
~Cediranib 20 mg/day given 7 days per week
~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
11210062|NCT03314740|Experimental|Arm C|"Oral administration of two experimental drugs:
~Cediranib 20 mg/day given 5 days per week
~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
11210063|NCT03314727|No Intervention|Control group|Drink 200 ml soup with no added salt
11210064|NCT03314727|Experimental|High salt (NaCl) intake|Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water
11210065|NCT03314714|Experimental|Acute bout of endurance exercise|Intramyocellular lipid metabolism will be assessed in insulin resistant and healthy, sedentary individuals after an acute bout of endurance exercise.
11210066|NCT03314701|Active Comparator|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:
~Following endotracheal intubation BIPAP mode will be started with:
~Inspiratory positive airway pressure [IPAP] at 20 cmH2O
~Expiratory positive airway pressure [EPAP] at 5 cmH2O
~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]
~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
11210067|NCT03314701|Active Comparator|Group 2|"Airway Pressure Release Ventilation (APRV) group:
~high airway pressure (Phigh) will be set at 20 cmH2O
~low airway pressure ( Plow) will be set at 5 cmH2O
~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min
~T high at 4.5-6 seconds
~T low at 0.5 to 0.8 second"
11210068|NCT03314688|Active Comparator|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).
~Lifestyle intervention books for breast cancer survivors at the end of the 2-year study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
11210101|NCT03314441|Experimental|Yoga|Patients receiving Yoga lessons for 3 months
11210069|NCT03314688|Experimental|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
11210070|NCT03314675|Other|CRT-D Measurements|Pre-specified measurements and additional follow-ups
11210071|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
11210072|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
11210073|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
11210074|NCT03314649||Observational study|Patients with gastric cancer and non-cancerous disease planned to have laparotomy
11210075|NCT03314636|Experimental|PET-CT-positive patients|Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles
11210076|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
11210077|NCT03314597|Active Comparator|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
11210078|NCT03314597|Experimental|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
11210079|NCT03314584|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
11210080|NCT03314584|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex.
11210081|NCT03314571||non applicable|
11210082|NCT03314558||COPD patients following a pulmonary rehabilitation program|COPD patients following a pulmonary rehabilitation program
11210083|NCT03314545|Other|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
11210084|NCT03314545|Other|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
11210085|NCT03314532|No Intervention|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
11210086|NCT03314532|Experimental|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
11210087|NCT03314519|Experimental|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
11210088|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
11210089|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
11210090|NCT03314493|Experimental|Spironolactone group|Spironolactone oral tablet 25mg/day, for 12 months
11210091|NCT03314493|No Intervention|Control group|No spironolactone use
11210092|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
11210093|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
11210094|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
11210095|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
11210096|NCT03314467||Control|diabetic patients without ocular abnormalities
11210097|NCT03314454|Active Comparator|Elevated Mental Status|Elevated score on Patient Health Questionnaire
11210098|NCT03314454|Active Comparator|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
11210099|NCT03314454|Active Comparator|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
11210100|NCT03314454|Active Comparator|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
11210102|NCT03314428|Experimental|Gait retraining|Runners will be taught how to modify their running gait through multiple laboratory sessions and in-field training.
11210103|NCT03314415|Experimental|Early robotic intervention|Participants randomized to the early robotic intervention will attend robotic assistance sessions for a two-week period earlier in the study (during the first half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
11210104|NCT03314415|Experimental|Late robotic intervention|Participants randomized to the late robotic intervention will attend robotic assistance sessions for a two-week period later in the study (during the latter half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
11210105|NCT03314402|Experimental|group 1|Jaktinib Dihydrochloride Monohydrate
11210106|NCT03314402|Placebo Comparator|group 2|Placebo
11210107|NCT03314389|Experimental|Cochet bonnet esthesiometer|To examine sensation
11210108|NCT03314376|Experimental|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
11210109|NCT03314376|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
11210110|NCT03314363|Other|all patients|Classic CRRT with citrate predilution
11210111|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
11210112|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
11210113|NCT03314324|Experimental|ODM-201|
11210114|NCT03314324|Active Comparator|Enzalutamide|
11210115|NCT03314311|Experimental|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
11210116|NCT03314311|No Intervention|Control|Usual care control arm
11210117|NCT03314298|Experimental|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
11210118|NCT03314285|Other|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
11210119|NCT03314285|Other|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
11210120|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:
~<150 mg/dl: 0 units of insulin
~150-220 mg/dl: 2 units of insulin
~201-250 mg/dl: 4 units
~251-300 mg/dl: 6 units
~301-350 mg/dl: 8 units
~351-400 mg/dl: 10 units
~> 400 mg/dl: inform the MD on call"
11210121|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.
~Intervention:
~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.
~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
11210122|NCT03314259|Experimental|Tamsulosin|Patients will then consume oral tamsulosin 0.4mg every morning daily for 5 days prior to elective surgery
11210123|NCT03314259|Placebo Comparator|Placebo|Patients will then consume placebo every morning daily for 5 days prior to elective surgery
11210124|NCT03314246|Other|Intervention|FAST user
11210125|NCT03314246|Other|Control|Standard of care
11210126|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
11210127|NCT03314220|Experimental|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
11210128|NCT03314220|No Intervention|standard care|
11210129|NCT03314194|Experimental|Plant Based Diet Group|Study is one cohort being tested over 6 days in two conditions: habitual diet versus plant based diet.
11210130|NCT03314181|Experimental|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
11210131|NCT03314181|Experimental|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
11210132|NCT03314181|Experimental|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
11210133|NCT03314181|Experimental|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
11210134|NCT03314181|Experimental|Arm F: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
11210157|NCT03314064|Experimental|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
11210135|NCT03314181|Experimental|Arm G: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
11210136|NCT03314181|Active Comparator|Arm H: DVd Dose|Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1
11210137|NCT03314168|Active Comparator|Control group|Patients who are randomized in control group will receive the usual care in their respective hospital.
11210138|NCT03314168|Experimental|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
11210139|NCT03314168|Experimental|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
11210140|NCT03314155|Experimental|Cerebral neuroinflammation evaluation|The density of TSPO (which is an inflammation maker) is evaluated by the tracer's brain distribution volume ([18F] DPA-714).
11210141|NCT03314142|Experimental|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11210142|NCT03314142|Experimental|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11210143|NCT03314142|Experimental|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11210144|NCT03314142|Experimental|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11210145|NCT03314142|Experimental|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11210146|NCT03314129|Experimental|Contrast sensitivity|UltimEyes
11210147|NCT03314129|Experimental|Perceptual organization|Contour Integration Training
11210148|NCT03314129|Experimental|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
11210149|NCT03314129|Active Comparator|Cognitive remediation|MyBrainSolutions
11210150|NCT03314116|Experimental|video group|guided by a 7-minute video that explains the importance of using ear plugs and correct installation.
11210151|NCT03314116|No Intervention|control group|instructed to use earplugs properly, including practical exercises by a medic
11210152|NCT03314103|Experimental|Vaccine|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
11210153|NCT03314103|Placebo Comparator|Placebo|Placebo with no live virus
11210154|NCT03314090|Experimental|Silicone Gel Group|Intervention: Silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day (BID). The amount being similar in size to a grain of rice.
11210155|NCT03314077||Standard managed subjects|COPD patients accepted standard COPD management.
11210156|NCT03314077||Controls|COPD patients didn't accepted standard COPD management or quality control, who are from hospital subjects with a retrospective cohort study.
11210190|NCT03313791|Experimental|50%whey-50% casein (Alternative)|portion size that contains 25 g of protein, oral, single administration
11210536|NCT03311412|Experimental|Sym021 Dose Level 1|Part 1, Sym021 monotherapy dose level 1
11210158|NCT03314025|Experimental|Tamsulosin|The patients in the Experimental group will receive Tamsulosin Hydrochloride 0.4 MG (milligrams) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
11210159|NCT03314025|Placebo Comparator|Placebo|The patients in the Placebo group will receive a placebo oral capsule (sugar) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
11210160|NCT03314012|Experimental|Catheter-Based Carotid Body Ablation|All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
11210161|NCT03313999|Other|Durometer Measurement|All patients participating in the study will receive standard of care treatment for their lymphedema. As part of the study they will be measured by the durometer in addition to other, standard diagnostics to further characterize their lymphedema progression.
11210162|NCT03313973|Experimental|with self stretching same muscle|
11210163|NCT03313973|Sham Comparator|with self stretching forearm muscle|
11210164|NCT03313960|Active Comparator|"One Drop | Premium with Afrezza"|
11210165|NCT03313960|Other|"One Drop | Premium without Afrezza"|
11210166|NCT03313947|Other|Difficult Airway|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
11210167|NCT03313947|Other|Obstructive Sleep Apnea|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
11210168|NCT03313947|Other|Predictive Obstructive Sleep Apnea|"The following 6 questions will be asked during the preoperative visit:
~While sleeping, does your child snore more than half the time?
~While sleeping, does your child always snore?
~Have you ever seen your child stop breathing during the night?
~Does your child occasionally wet the bed?
~Did your child stop growing at a normal rate at any time since birth?
~Is your child overweight"
11210169|NCT03313934|Placebo Comparator|Hyaluronic Acid Filler with Saline|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.
11210170|NCT03313934|Experimental|Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.
11210171|NCT03313921|Experimental|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
11210172|NCT03313908|Experimental|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
11210173|NCT03313895|Active Comparator|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
11210174|NCT03313895|Active Comparator|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
11210175|NCT03313895|Experimental|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
11210176|NCT03313895|Sham Comparator|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
11210177|NCT03313882||donor|donor: normal heart samples from donor
11210178|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
11210179|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
11210180|NCT03313869|Experimental|Control|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol No cocktail during the protocol
~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
11210181|NCT03313869|Experimental|Cocktail intervention|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol + Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
11210182|NCT03313856|Placebo Comparator|Placebo|The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
11210183|NCT03313856|Experimental|Guazuma ulmifolia plus Tecoma stans|The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.
11210184|NCT03313830|Experimental|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
11210185|NCT03313830|Experimental|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
11210186|NCT03313804|Experimental|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
11210187|NCT03313791|Experimental|Whey protein concentrate|portion size that contains 25 g of protein, oral, single administration
11210188|NCT03313791|Experimental|Yoghurt|portion size that contains 25 g of protein, oral, single administration
11210189|NCT03313791|Experimental|50%whey-50% casein (Standard)|portion size that contains 25 g of protein, oral, single administration
11276869|NCT02856425|Experimental|NSCLC of adenocarcinoma tumor hist|
11210191|NCT03313791|Experimental|Micellar Casein Isolate- WPH|portion size that contains 25 g of protein, oral, single administration
11210192|NCT03313791|Experimental|Micellar Casein Isolate - Na-caseinate|portion size that contains 25 g of protein, oral, single administration
11210193|NCT03313791|Experimental|Micellar Casein Isolate|portion size that contains 25 g of protein, oral, single administration
11210194|NCT03313791|Experimental|UHT milk|portion size that contains 25 g of protein, oral, single administration
11210195|NCT03313791|Experimental|Recombined milk|portion size that contains 25 g of protein, oral, single administration
11210196|NCT03313791|Experimental|Recombined 50% whey milk|portion size that contains 25 g of protein, oral, single administration
11210197|NCT03313791|Experimental|Ca-caseinate|portion size that contains 25 g of protein, oral, single administration
11210198|NCT03313791|Experimental|Milk protein isolate|portion size that contains 25 g of protein, oral, single administration
11210199|NCT03313778|Experimental|Part A: Dose Escalation|mRNA-4157
11210200|NCT03313778|Experimental|Part B: Dose Escalation|mRNA-4157 + pembrolizumab
11210201|NCT03313778|Experimental|Part B: Dose Expansion|mRNA-4157 + pembrolizumab
11210202|NCT03313778|Experimental|Part B, C, and D: Dose Expansion|mRNA-4157 + pembrolizumab
11210203|NCT03313765|Experimental|Intervention|
11210204|NCT03313765|Active Comparator|Standard-of-care|
11210205|NCT03313752|Placebo Comparator|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
11210206|NCT03313752|Experimental|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
11210207|NCT03313739|Experimental|Intervention group|An Educational Program
11210208|NCT03313739|No Intervention|Control group|This group(n=30) received no intervention.
11210209|NCT03313726|Experimental|GnRh-antagonist A|
11210210|NCT03313726|Experimental|GnRh-antagonist B|
11210211|NCT03313713|Active Comparator|Beta-glucans|Beta-glucans, 3 g per day, per 8 weeks, at breakfast
11210212|NCT03313713|Placebo Comparator|Placebo|Placebo, 3 g per day, per 8 weeks, at breakfast
11210213|NCT03313700|Experimental|Robotic Distal Gastrectomy|Robotic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
11210214|NCT03313700|Active Comparator|Laparoscopic Distal Gastrectomy|Laparoscopic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
11210215|NCT03313674|Experimental|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
11210216|NCT03313674|No Intervention|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
11210217|NCT03313674|No Intervention|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
11210218|NCT03313661|Experimental|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
11210219|NCT03313661|Active Comparator|Gliclazide|gliclazide (60-120 mg) once daily
11210220|NCT03313661|No Intervention|Placebo|Placebo
11210221|NCT03313648|Experimental|Laparoscopic Hepatectomy|Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
11210222|NCT03313648|Active Comparator|Radiofrequency Ablation|With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
11210223|NCT03313635||Men presenting with low-T|Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.
11210224|NCT03313622||OCD group|"Day 1: Questionnaires/Assessments
~Day 2: Tasks"
11210225|NCT03313596|Active Comparator|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
11210226|NCT03313596|Experimental|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
11210227|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
11210228|NCT03313557|Experimental|Wee-1 kinase inhibitor AZD1775|To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.
11210229|NCT03313544|Experimental|NIVOLUMAB PATIENTS|
11210230|NCT03313531||Study group 1|Patients with severe hemophilia A
11210231|NCT03313531||Study group 2|Healthy volunteers
11210232|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population.
11210233|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
11210234|NCT03313518|Active Comparator|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
11210235|NCT03313518|Sham Comparator|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
11210236|NCT03313505||Patients who had been tested for S100B protein|
11210237|NCT03313505||Patients who have benefited from another strategy|
11210238|NCT03313492|Active Comparator|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
11210274|NCT03313232|Experimental|Healty controls|Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.
11210537|NCT03311412|Experimental|Sym021 Dose Level 2|Part 1, Sym021 monotherapy dose level 2
11210239|NCT03313492|Active Comparator|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
11210240|NCT03313492|Experimental|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
11210241|NCT03313479||Group 1|GA and Dexmedetomidine
11210242|NCT03313479||group 2|GA and peribulbar
11210243|NCT03313479||group3|GA and xylocaine gel
11210244|NCT03313466|Experimental|iCBTI|Intervention: An internet-based cognitive behavioral therapy program for insomnia (iCBTI) that is tailored to the individual's needs based on responses to questions.
11210245|NCT03313466|Active Comparator|Usual care|Intervention: A group class on insomnia provided at each Kaiser Permanente Southern California medical center.
11210246|NCT03313453|Experimental|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
11210247|NCT03313453|Placebo Comparator|Control comparator|Mock device of PuriCare in active mode
11210248|NCT03313440|Experimental|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
11210249|NCT03313440|Experimental|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
11210250|NCT03313427|Experimental|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
11210251|NCT03313427|Other|Control|Usual care
11210252|NCT03313414|Experimental|Treatment with Sofosbuvir/Velpatasvir|14 days of treatment with Sofosbuvir/Velpatasvir tablet
11210253|NCT03313388|Experimental|Tart Cherry Juice|290 mL per day of Tart Cherry juice for 7 days
11210254|NCT03313388|Active Comparator|Gatorade|290 mL per day of Gatorade for 7 days
11210255|NCT03313375|No Intervention|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
11210256|NCT03313375|Active Comparator|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
11210257|NCT03313375|Experimental|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
11210258|NCT03313362|Experimental|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
11210259|NCT03313349|Other|Usual Provision (UP)|"Usual Provision
~Psychotherapy: 1. cognitive therapy 2.family intervention"
11210260|NCT03313349|Other|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision
~Psychotherapy: 1.cognitive therapy 2.family intervention"
11210261|NCT03313336|Active Comparator|Cohort 1|EMLA Test Patch.
11210262|NCT03313336|Active Comparator|Cohort 2|EMLA Reference Patch.
11210263|NCT03313336|Placebo Comparator|Cohort 3|Placebo patch.
11210264|NCT03313323|Experimental|Zirconium-ipilimumab|Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
11210265|NCT03313310|Experimental|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
11210266|NCT03313297|Active Comparator|AZD4017|400mg oral AZD4017 twice daily for 35 days
11210267|NCT03313297|Placebo Comparator|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
11210268|NCT03313284|Experimental|Study Group|
11210269|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
11210270|NCT03313258|Active Comparator|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
11210271|NCT03313258|Experimental|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
11210272|NCT03313232|Experimental|Fragrance allergic patients|Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
11210273|NCT03313232|Experimental|Possible fragrance allergic patients|Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
11210427|NCT03312231|Experimental|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
11276870|NCT02856425|Experimental|NSCLC of squamous cell tumor histo|
11210275|NCT03313219|Experimental|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
11210276|NCT03313206|Experimental|Patients with Resectable head and neck mucosal melanomas|
11210277|NCT03313193|Experimental|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
11210278|NCT03313193|No Intervention|Arm B|Usual care alone
11210279|NCT03313180|Experimental|All patients|
11210280|NCT03313167||Atrial Fibrillation-potential Patients|individuals 65 years of age or older with moderate-to-high risk of stroke
11210281|NCT03313154||Neuropsychiatric screening (treatment+)|Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
11210282|NCT03313154||Neuropsychiatric screening (treatment-)|Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
11210283|NCT03313141|Experimental|Subjects|Only one arm is considered
11210284|NCT03313128||Historic intervention|Infants born into the historic intervention arm of sanitation trial (NCT02362932)
11210285|NCT03313128||Historic control|Infants born into the historic control arm of sanitation trial (NCT02362932)
11210286|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
11210287|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
11210288|NCT03313102|Experimental|Horton disease|
11210289|NCT03313102|Experimental|control|
11210290|NCT03313089||PSAN + MNP|"PSAN (Papas más nutritivas project) + MNP (micronutrients powders):
~Children of the families beneficiaries of Community Schools of Family Agriculture of the municipalities of Cumbal, Carlosama Guachucal and Túquerres, who are part of the project Papas más nutritivas and exposed to project activities in which they work on topics related to food and nutritional security, equity and gender, production and entrepreneurship, Additionally, the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses (specified in the MNP only group). After the delivery of MNP, advising, measurements of weight and height, clarification of doubts regarding fortification with MNP, nutrition education, and accompaniment by the project staff will take place."
11210291|NCT03313089||MNP only|"Cohort of exposed to MNP (micronutrients powders):
~Children who will receive MNP delivered through the hospital or institutional health service providers of the municipalities of Guachucal and Carlosama, following the protocol for the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses: the first period consists of the taking of MNP for 2 months, followed by a rest period of 4 months and continues again by another MNP intake for 2 months and rest for 4 months, and exposed to dissemination of basic information with regard to MNP and monitoring by growth and development that is routinely performed by health staff."
11210292|NCT03313076|Experimental|n-3 PUFA (O3FA) + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule
11210293|NCT03313076|Experimental|n-3 PUFA (O3FA) Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
11210294|NCT03313076|Experimental|n-3 PUFAs (O3FA) + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
11210295|NCT03313076|Placebo Comparator|n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo|4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
11210296|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
11210297|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
11210298|NCT03313050|Experimental|Stage 1 multivalent (ages 50-64 years)|multivalent
11210299|NCT03313050|Active Comparator|Stage 1 Tdap (ages 50-64 years)|Tdap
11210300|NCT03313050|Experimental|Stage 2 multivalent (ages 65-85 years)|multivalent
11210301|NCT03313050|Active Comparator|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
11210302|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
11210303|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
11210304|NCT03313011||Progressive Apraxia of Speech|
11210305|NCT03312998|Experimental|Xrays|
11210306|NCT03312985|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
11210307|NCT03312985|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
11210308|NCT03312972|Experimental|HDR Brachytherapy|HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion in one to two fractions.
11210309|NCT03312959|Experimental|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
11210310|NCT03312959|Active Comparator|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
11210311|NCT03312946|Experimental|Treatment oscillating vibro|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks. Being performed twice a week, with a total duration of 50 minutes to the session, being 10 sessions total to end the treatment.
11210428|NCT03312231|Experimental|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
11210312|NCT03312933||Duration of boot >2 weeks|All patients who were placed into a CAM walker boot for >2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
11210313|NCT03312920|Experimental|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
11210314|NCT03312920|Sham Comparator|Sham tDCS|sham tDCS with Face Name associate Memory task
11210315|NCT03312920|Experimental|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
11210316|NCT03312907|Placebo Comparator|Arm A (Control) 0-52 Weeks|Eligible subjects will receive belimumab plus rituximab-placebo. No immunosuppressant medications are allowed after week 4. Subjects may receive standard of care therapy which may include anti-malarials, Non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day through Week 52. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study. Subjects will stop receiving Belimumab injections after week 52.
11210317|NCT03312907|Placebo Comparator|Arm A (Control) 53-104 Weeks|Eligible subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day in Week 53 through 104. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
11210318|NCT03312907|Experimental|Arm B (Combination) 0-52 Weeks|Eligible subjects will receive belimumab plus rituximab. No immunosuppressant medications are allowed after week 4 (Other than Rituximab at Week 6). Subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day through Week 52. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study. Subjects will stop receiving Belimumab injections after week 52.
11210319|NCT03312907|Experimental|Arm B (Combination) 53-104 Weeks|Eligible subjects may receive standard of care therapy which may include anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day in Week 53 through 104. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
11210320|NCT03312907|Experimental|Arm C (Reference) 0-52 Weeks|Eligible subjects will receive belimumab plus standard therapy including immunosuppressant which may be continued throughout the study. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
11210321|NCT03312907|Experimental|Arm C (Reference) 53-104 Weeks|Eligible subjects will receive belimumab plus standard therapy which may be continued throughout the study. Doses of corticosteroids taper shall be reduced at Week 12 and reach a prednisone equivalent dose of =< 5 mg/day by Week 26 which may be maintained throughout the study.
11210322|NCT03312894|Experimental|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
11210323|NCT03312894|Placebo Comparator|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
11210324|NCT03312894|Experimental|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
11210325|NCT03312894|Placebo Comparator|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
11210326|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
11210327|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
11210328|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
11210329|NCT03312855|Experimental|Revacept 80 mg|single dose, intravenous
11210330|NCT03312855|Experimental|Revacept 160 mg|single dose, intravenous
11210331|NCT03312855|Placebo Comparator|Placebo|single dose, intravenous
11210332|NCT03312842|Experimental|CS1001|
11210333|NCT03312816|Placebo Comparator|Placebo|0 mg/d added POP
11210334|NCT03312816|Active Comparator|low dosage|low added POP
11210335|NCT03312816|Active Comparator|Medium dose|medium added POP
11210336|NCT03312816|Active Comparator|Hige dose|high added POP
11210337|NCT03312803|Active Comparator|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
11210338|NCT03312803|Active Comparator|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
11210339|NCT03312790|Experimental|augmented reality device|Tasks realized using augmented reality device
11210340|NCT03312790|Other|Real condition|Same tasks than augmented reality realized in normal/real condition
11210341|NCT03312777|Experimental|Omnitram|Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
11210342|NCT03312777|Active Comparator|Tramadol|Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
11210343|NCT03312777|Placebo Comparator|Placebo|Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
11210344|NCT03312764|Experimental|Online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants in the online program receive paced curriculum, access to a live health coach, interactive group message forums, and connected weight scale and activity monitoring devices.
11210345|NCT03312764|Active Comparator|Enhanced Standard Care|All participants randomized to the standard-care/control group (SC) will be offered the opportunity to attend a single 90-minute diabetes prevention class with a trained health professional (MPH, RD, or related advanced degree). The class will focus on healthful eating based on the current MyPlate recommendations, guidance on gradual increases in moderate intensity physical activity, and action planning to be shared with friends and/or family. Control participants will also be given the opportunity to participate in the online digital intervention upon completion of the 12-month follow-up assessment.
11210346|NCT03312751|Experimental|Emapalumab|
11210347|NCT03312738|Experimental|Everolimus + Exemestane|Everolimus 10mg/Day + Exemestane 25mg/Day
11210348|NCT03312738|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
11210349|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
11210350|NCT03312712||Participants with sarcoidosis|"Bronchoscopy, BAL collection, and PFTs* [SoC] *if required
~Screening, research and safety bloods
~Dynamic 18F-FDG PET/CT scan"
11210351|NCT03312712||Healthy volunteers|"Part A:
~PFTs
~Screening, research and safety bloods
~Dynamic 18F-FDG PET/CT scan
~Part B:
~PFTs
~Screening, research and safety bloods
~Baseline and post challenge Dynamic 18F-FDG PET/CT scans
~LPS/saline challenge"
11210352|NCT03312699|Experimental|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210353|NCT03312699|Experimental|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210354|NCT03312699|Experimental|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210355|NCT03312699|Experimental|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210356|NCT03312699|Experimental|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210357|NCT03312699|Experimental|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210358|NCT03312699|Experimental|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210359|NCT03312699|Experimental|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11210360|NCT03312686||Eosinophilic Esophagitis patients|PPI treatment
11210361|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
11210362|NCT03312660|Experimental|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
11210363|NCT03312660|Placebo Comparator|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
11210364|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
11210365|NCT03312634|Experimental|Palovarotene Chronic/Flare-Up Regimen|Subjects will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing will be adjusted for weight in skeletally immature subjects.)
11210429|NCT03312218|Experimental|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
11210538|NCT03311412|Experimental|Sym021 Dose Level 3|Part 1, Sym021 monotherapy dose level 3
11210366|NCT03312621|Experimental|Intervention|The intervention group received all aspects of enhanced usual care but was also assigned a healthcare transition nurse who coordinated the delivery of specific intervention services. These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
11210367|NCT03312621|No Intervention|Control|The control group received enhanced usual care which provides standardized healthcare transition-specific written information including a written transition policy, as well as insurance and guardianship information. Participants were also provided with a transition readiness assessment and entered into a healthcare transition registry to facilitate tracking and communication.
11210368|NCT03312608||mild myelopathy (JOA>12)|40 patients (JOA>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
11210369|NCT03312608||moderate myelopathy|40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
11210370|NCT03312608||healthy control|As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
11210371|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
11210372|NCT03312582|Experimental|Manual debridement and 1% metformin gel|
11210373|NCT03312582|Placebo Comparator|Manual debridement and placebo|
11210374|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
11210375|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
11210376|NCT03312556|Placebo Comparator|Placebo pill or patch or sham CPAP|Placebo pill or patch or sham CPAP
11210377|NCT03312556|Active Comparator|CPAP (continuous positive airway pressure)|Continuous positive airway pressure during the night
11210378|NCT03312543|Experimental|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
11210379|NCT03312543|Sham Comparator|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
11210380|NCT03312530|Experimental|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
11210381|NCT03312530|Experimental|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
11210382|NCT03312530|Experimental|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
11210383|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
11210384|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
11210385|NCT03312517|Active Comparator|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
11210386|NCT03312517|Active Comparator|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
11210387|NCT03312517|Sham Comparator|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
11210388|NCT03312504|Experimental|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
11210389|NCT03312504|Placebo Comparator|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
11210390|NCT03312478|Other|Case|Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
11210391|NCT03312478|Other|Control|Age-matched non-diabetic controls as described in the inclusion criteria for controls
11210392|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
11210393|NCT03312452|Experimental|Infusion pump group|Study subjects assigned to this group will receive intravenous fluid via an infusion pump (Hospira plum pump) during their surgery.
11210394|NCT03312452|Active Comparator|Gravity drip group|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
11210395|NCT03312439|Active Comparator|Intervention group|Will be given advice as described above
11210396|NCT03312439|No Intervention|Control group|Consisting of subjects from the general Swedish population.
11210397|NCT03312426|Experimental|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
11210398|NCT03312426|Experimental|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
11210399|NCT03312426|Experimental|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
11210400|NCT03312426|Experimental|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
11210401|NCT03312413|Experimental|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
11210402|NCT03312413|Experimental|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
11210403|NCT03312413|Experimental|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
11210404|NCT03312413|Placebo Comparator|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
11210405|NCT03312400|Active Comparator|200 mg Arm|100 mg twice a day
11210406|NCT03312400|Active Comparator|400 mg Arm|200 mg twice a day
11210407|NCT03312387|Experimental|Essential Amino Acid and Exercise|Participants will be provided with essential amino acids during exercise training.
11210408|NCT03312387|Placebo Comparator|Placebo and Exercise|Participants will be provided with placebo supplement during exercise training.
11210409|NCT03312374||stage II CRC|Patients with stage II colorectal cancer
11210410|NCT03312374||stage III CRC|Patients with stage III colorectal cancer
11210411|NCT03312361|Experimental|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
11210412|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
11210413|NCT03312335|Experimental|Low-dose Aldesleukin (Proleukin®)|
11210414|NCT03312322|Experimental|CWT with high-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
11210415|NCT03312322|Experimental|CWT with low-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
11210416|NCT03312322|Experimental|CWT with sham electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
11210417|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .
~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .
~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
11210418|NCT03312283|Experimental|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
11210419|NCT03312283|Active Comparator|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
11210420|NCT03312270|Experimental|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
11210421|NCT03312257|Experimental|Multifocal D +2.50 add & 0.01% atropine|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine."
11210422|NCT03312244|Experimental|Pyridostigmine|Pyridostigmine 180mg/d slow-release formulation
11210423|NCT03312244|Placebo Comparator|Placebo|Placebo
11210424|NCT03312231|Experimental|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
11210425|NCT03312231|Experimental|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
11210426|NCT03312231|Experimental|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
11210430|NCT03312218|No Intervention|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
11210431|NCT03312205|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
11210432|NCT03312192|Active Comparator|Plate and Cage|ACDF with interbody cage and anterior plating.
11210433|NCT03312192|Active Comparator|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
11210434|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
11210435|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
11210436|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
11210437|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
11210438|NCT03312166|Experimental|Compression device|
11210439|NCT03312153|Experimental|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
11210440|NCT03312153|Active Comparator|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
11210441|NCT03312140|Other|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
11210442|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
11210443|NCT03312114|Experimental|Single arm|Avelumab and SABR
11210444|NCT03312101|Experimental|Experimental|exercise program
11210445|NCT03312101|No Intervention|Control|observation
11210446|NCT03312075||cystic fibrosis patients|Sputum and blood samples
11210447|NCT03312062|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
11210448|NCT03312062|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
11210449|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
11210450|NCT03312023|Experimental|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
11210451|NCT03312023|Experimental|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
11210452|NCT03312023|Experimental|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.
~Randomized 1:1 with Group D."
11210453|NCT03312023|Experimental|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.
~Randomized 1:1 with Group C."
11210454|NCT03312010|Experimental|High Frequency|Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
11210455|NCT03312010|Sham Comparator|Sham|Subjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
11210456|NCT03311997|No Intervention|Non-operative treatment|Active rehabilitation program
11210457|NCT03311997|Active Comparator|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
11210458|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
11210459|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
11210460|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
11210461|NCT03311971|Experimental|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
11210462|NCT03311958|Experimental|Nivolumab|
11210463|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
11210464|NCT03311932|Active Comparator|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
11210465|NCT03311932|Experimental|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
11210466|NCT03311932|Active Comparator|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
11210467|NCT03311932|Experimental|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
11210468|NCT03311906|Experimental|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
11210469|NCT03311906|Active Comparator|Control Side|Scaling and Root Planing
11210470|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
11210471|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
11210472|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
11210473|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
11210474|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
11210475|NCT03311854|Experimental|NI-0501|
11210476|NCT03311841|Experimental|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
11210477|NCT03311841|Experimental|Severe Impairment|Participants with <30 mL/min/1.73m^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
11210478|NCT03311841|Experimental|Moderate Impairment|Participants with 30 to <60 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
11210479|NCT03311841|Experimental|Mild Impairment|Participants with 60 to <90 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
11210480|NCT03311841|Active Comparator|Healthy Control|Participants with ≥90 mL/min creatinine clearance. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
11210481|NCT03311828|Experimental|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
11210482|NCT03311802||1|
11210483|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
11210484|NCT03311763|Active Comparator|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
11210485|NCT03311763|Experimental|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
11210486|NCT03311750|Experimental|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
11210487|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
11210488|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
11210489|NCT03311724|Experimental|Tirzepatide Group 1|Tirzepatide administered subcutaneously (SC)
11210490|NCT03311724|Experimental|Tirzepatide Group 2|Tirzepatide administered SC
11210491|NCT03311724|Experimental|Tirzepatide Group 3|Tirzepatide administered SC
11210492|NCT03311724|Placebo Comparator|Placebo|Placebo administered SC
11210493|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
11210494|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
11210495|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
11210496|NCT03311698|Experimental|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
11210497|NCT03311698|No Intervention|Control|Households receive the standard of care in the area for agricultural and health services.
11210498|NCT03311685|Experimental|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.
~vaginal tactile imager"
11210499|NCT03311685|Experimental|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
11210535|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
11210500|NCT03311672|Experimental|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
11210501|NCT03311672|Experimental|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
11210502|NCT03311659|Experimental|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
11210503|NCT03311646|Experimental|Nicotine Content Manipulation|All participants receive normal nicotine content (NNC) cigarettes during Baseline and all participants receive very low nicotine content (VLNC) cigarettes during the very low nicotine content condition.
11210504|NCT03311633|Experimental|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
11210505|NCT03311633|Active Comparator|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
11210506|NCT03311620|Other|Endobronchial ultrasound transbronchial needle aspirate|
11210507|NCT03311607|Other|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
11210508|NCT03311594|Experimental|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
11210509|NCT03311594|Experimental|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
11210510|NCT03311594|Experimental|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
11210511|NCT03311594|Experimental|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
11210512|NCT03311594|Placebo Comparator|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
11210513|NCT03311594|Experimental|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
11210514|NCT03311594|Placebo Comparator|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
11210515|NCT03311594|Experimental|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
11210516|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
11210517|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
11210518|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
11210519|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
11210520|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
11210521|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
11210522|NCT03311555|Experimental|Recurrent PSA-only non-metastatic prostate cancer|Subjects with recurrent PSA-only prostate cancer within 4 years of prostatectomy, and a PSA of greater than 0.2 ng/mL and less than 4 ng/mL in the absence of metastatic disease on CT and bone scans.
11210523|NCT03311529|Experimental|Applied Relaxation|
11210524|NCT03311529|No Intervention|usual care|
11210525|NCT03311516|Experimental|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
11210526|NCT03311516|Other|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
11210527|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
11210528|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
11210529|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
11210530|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
11210531|NCT03311464|Experimental|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
11210532|NCT03311451|Other|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
11210533|NCT03311438|Other|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
11210534|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
11210539|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 1|Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022
11210540|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 2|Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022
11210541|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 3|Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022
11210542|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 4|Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022
11210543|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 1|Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023
11210544|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 2|Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023
11210545|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 3|Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023
11210546|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 4|Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023
11210547|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 5|Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023
11210548|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 6|Part 2, Arm B: Sym021 RP2D in combination with dose level 6 of Sym023
11210549|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 7|Part 2, Arm B: Sym021 RP2D in combination with dose level 7 of Sym023
11210550|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 1|Part 3, Sym021 in combination with Sym022 and Sym023
11210551|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 2|Part 3, Sym021 in combination with Sym022 and Sym023
11210552|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 3|Part 3, Sym021 in combination with Sym022 and Sym023
11210553|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 4|Part 3, Sym021 in combination with Sym022 and Sym023
11210554|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 5|Part 3, Sym021 in combination with Sym022 and Sym023
11210555|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 6|Part 3, Sym021 in combination with Sym022 and Sym023
11210556|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
11210557|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
11210558|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
11210559|NCT03311386|Other|Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
11210560|NCT03311373|Experimental|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
11210561|NCT03311373|Experimental|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
11210562|NCT03311373|Experimental|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
11210563|NCT03311373|Experimental|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
11210564|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
11210565|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
11210566|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
11210567|NCT03311347|Experimental|Air breathing|Primary aim, item 1
11210568|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Nivolumab|
11210569|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Pembrolizumab|
11210570|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
11210571|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
11210572|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
11210573|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
11210574|NCT03311295|Experimental|ARTO System|
11210575|NCT03311282|Experimental|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
11210576|NCT03311282|Experimental|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
11210577|NCT03311282|Experimental|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
11210578|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
11210579|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
11210580|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
11210581|NCT03311269|Active Comparator|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
11210582|NCT03311269|Active Comparator|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
11210583|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
11210584|NCT03311243|Active Comparator|Systemically healthy controls|
11210585|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
11276871|NCT02856425|Experimental|Urothelial cancer|
11210586|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
11210587|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
11210588|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
11210589|NCT03311217|Experimental|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
11210590|NCT03311217|No Intervention|Control group|No intervention will be implemented in the stores in the control communities.
11210591|NCT03311204|Experimental|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
11210592|NCT03311204|Experimental|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
11210593|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
11210594|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
11210595|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
11210596|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
11210597|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
11210598|NCT03311152|Experimental|HCC-free cirrhotic patients|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
11210599|NCT03311152|Experimental|HCC-positive cirrhotic patients|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
11210600|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
11210601|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
11210602|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
11210603|NCT03311126|Experimental|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):
~Bendamustine 90 mg/m2 IV days 1 & 2 every 28 days X 4-6 cycles
~Obinutuzumab:
~Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 & 15
~Cycles 2-6: 1000 mg IV day 1
~Consolidation phase:
~Obinutuzumab 1000 mg IV weekly X 4 doses
~Maintenance phase (8 week cycles):
~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
11210604|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
11210605|NCT03311100||Lung cancer|
11210606|NCT03311100||Central Nervous System Cancers|
11210607|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
11210608|NCT03311100||Skin cancers|
11210609|NCT03311100||Sarcomas|
11210610|NCT03311100||Urothelial cancer|
11210611|NCT03311100||Hepatocarcinoma|
11210612|NCT03311074|Experimental|Strimvelis treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received Strimvelis will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
11210613|NCT03311061|Experimental|DREAMS|"The experimental group will be exposed to the DREAMS curriculum including the supplemental technology based application.It is composed of 10 modules: Introduction; Self Exploration; Healthy Relationships; Adolescent Sexuality; Attitudes and Adolescent Sexual Activity; Consequences of Sex - HIV/STI; Consequences of Sex - Pregnancy; Managing Pressure to Engage in Sexual Activity through the Lens of Social Media; Financial Literacy; Careers; Post secondary Education; Wrap up and Close Out.
~The technology app will include curriculum support and additional resources.
~Students will have access to the mobile app after the in school programming ends. The intent is for students to have access to portions of the app that deal with self developed goals and progress monitoring for goals, and resource material. This is similar to a student having continued access to a textbook/other class materials."
11210614|NCT03311061|Active Comparator|Non DREAMS|The control group experience will include health curriculum already adopted by the school district. Continued services as usual. The control group schools, for the most part, lack any formal pregnancy prevention services. All schools claim that lessons developed by the teachers meet the Texas Essential Knowledge Standards (TEKS). No outside services are provided to students and school based services are limited. The services offered at the schools is predominately abstinence based. Students attending the schools would need to initiate any services that are available within the community. The control group will not have access to the DREAMS curriculum or the technology-based application to enhance the DREAMS curriculum. The technology-based application will be a closed, password protected, system during the research trial.
11210615|NCT03311048|Experimental|Hospital|Hospital cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
11210647|NCT03310853|Experimental|Probiotic|Combination of two probiotic strains in one capsule
11210648|NCT03310853|Placebo Comparator|Placebo|Non active ingredients in a capsule
11210649|NCT03310827|Experimental|Personalized Nutrition|Participant receives gene test results with diet plan (personalized nutrition)
11276872|NCT02856425|Experimental|Renal Cell cancer (RCC)|
11210616|NCT03311048|Experimental|University|Campus (university) cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
11210617|NCT03311048|Experimental|Housekeeper|Housemaid (cleaning workers) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
11210618|NCT03311048|Experimental|Control|Office workers (no relationship to cleaning) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
11210619|NCT03311035|Experimental|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
11210620|NCT03311035|Experimental|Group B|patients undergoing Seton method
11210621|NCT03311022|Experimental|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
11210622|NCT03311022|Active Comparator|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
11210623|NCT03311009|Experimental|GLPG1972|
11210624|NCT03311009|Placebo Comparator|Placebo|
11210625|NCT03310996|Experimental|tDCS Active arm|The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
11210626|NCT03310996|Placebo Comparator|tDCS Sham arm|The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
11210627|NCT03310983||ADORE Participants|Participants enrolled in the ADORE study are invited to participate in this study.
11210628|NCT03310970|Active Comparator|Lidocaine Patch|Each of the 24 subjects will complete three study arms in a crossover design, with adequate washout in between arms. Lidocaine will be administered to subjects in three ways (one route per study arm): a single intravenous dose of 0.5 mg/kg lidocaine hydrochloride, wearing three Lidoderm® topical patches for 12 hours, and wearing three generic lidocaine patches for 12 hours. Twelve subjects will be randomized to Group 1 (generic lidocaine patch first, then intravenous lidocaine hydrochloride followed by the Lidoderm® topical patch), and 12 subjects will be randomized to Group 2 (Lidoderm® topical patch first, then intravenous lidocaine hydrochloride followed by a generic lidocaine patch).
11210629|NCT03310970|Active Comparator|Lidoderm® Topical Patch|Each of the 24 subjects will complete three study arms in a crossover design, with adequate washout in between arms. Lidocaine will be administered to subjects in three ways (one route per study arm): a single intravenous dose of 0.5 mg/kg lidocaine hydrochloride, wearing three Lidoderm® topical patches for 12 hours, and wearing three generic lidocaine patches for 12 hours. Twelve subjects will be randomized to Group 1 (generic lidocaine patch first, then intravenous lidocaine hydrochloride followed by the Lidoderm® topical patch), and 12 subjects will be randomized to Group 2 (Lidoderm® topical patch first, then intravenous lidocaine hydrochloride followed by a generic lidocaine patch).
11210630|NCT03310957|Experimental|SGN-LIV1A plus pembrolizumab|SGN-LIV1A + pembrolizumab
11210631|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
11210632|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
11210633|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
11210634|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
11210635|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
11210636|NCT03310918|Experimental|Collaborative palliative and oncology care|"1st palliative care visit within 96 hours of randomization in the outpatient or hospital
~In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone
~During hospital admissions to MGH: At least twice weekly palliative care visits"
11210637|NCT03310918|Active Comparator|Standard leukemia care|"Palliative care consults only upon request
~Standard Leukemia care"
11210638|NCT03310905|Experimental|Abdominal Wall Transplant with Belatacept|
11210639|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
11210640|NCT03310892|No Intervention|Usual Care|Participants in this arm will Usual scheduling process without any intervention
11210641|NCT03310892|Experimental|Generic Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a generic message encouraging colonoscopy scheduling."
11210642|NCT03310892|Experimental|Tailored Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a tailored message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions."
11210643|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis
~Dosage will be determine by the PI"
11210644|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis
~Dosage will be determine by the PI"
11210645|NCT03310866|Active Comparator|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
11210646|NCT03310866|Experimental|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
11210650|NCT03310827|Placebo Comparator|Gene Test Report Only|Participant receives standard diet plan
11210651|NCT03310814|Experimental|Personalized nutrition intervention|Participant receives gene-test results plus personalized nutrition information from a registered dietician
11210652|NCT03310814|Placebo Comparator|Usual nutrigenomics intervention|Participant receives usual nutrigenomics intervention (direct-to-consumer)
11210653|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
11210654|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
11210655|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
11210656|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.
~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
11210657|NCT03310762|Experimental|Alma Sana Bracelet Arm|Subjects in this arm will receive a vaccine reminder and tracker bracelet developed by Alma Sana Inc. This bracelet uses a combination of symbols and numbers to denote the entire vaccine schedule a child is supposed to receive before the age of 2 years. Shapes indicate vaccines, and numbers signify the child's age.
11210658|NCT03310762|Experimental|Simple Silicon Bracelet Arm|Subjects in this arm will receive a simple silicon bracelet. This bracelet has six symbols to remind parents that their child needs to get at least six vaccination visits before he reaches 2 years of age. The first five symbols are represented by a crescent shape and the sixth symbol is represented by a star shape to denote that the child is fully immunized.
11210659|NCT03310762|No Intervention|Control Arm|Subjects in this arm will not receive any bracelet/intervention.
11210660|NCT03310749|Other|Treatment sequence A|Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
11210661|NCT03310749|Other|Treatment sequence B|Gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days
11210662|NCT03310749|Other|Treatment sequence C|Metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days
11210663|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
11210664|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
11210665|NCT03310710|Experimental|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
11210666|NCT03310697|Experimental|Children with afebrile seizure|"For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
~Intervention : Collection of blood and urine samples, and Clinical examination"
11210667|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
11210668|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.
~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
11210669|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
11210670|NCT03310671||CASES|"Cases:
~Age ≥ 65 years at the time of cardiac ultrasound
~Genetically diagnosed HFH or in a first-degree relative
~History of hypercholesterolemia with LDLc levels> 220 mg / dL without lipid-lowering treatment"
11210671|NCT03310671||Controls|"Genetically Similar
~Siblings of the normocholesterolemic case, defined by LDLc <190 mg / dl without lipid-lowering treatment.
~In the absence of available siblings, first cousins may be included.
~In the presence of several siblings available, the same sex will be included,
~Environmentally similar
~Stable partner of the case with cohabitation> 25 years"
11210672|NCT03310658|Experimental|Single Study Site: UANL|As the only study arm, 10 enrolled subjects received vaginal cuff closure with the Zip-Stitch Soft Tissue Closure System as part of Total Laparoscopic Hysterectomy.
11210673|NCT03310645|Experimental|Dose 1 of BAY1817080|"Study Part 1:
~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
11210674|NCT03310645|Experimental|Dose 2 of BAY1817080|"Study Part 1:
~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
11210675|NCT03310645|Experimental|Dose 3 of BAY1817080|"Study Part 1:
~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
11210676|NCT03310645|Experimental|Dose 4 of BAY1817080|"Study Part 1:
~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
11210677|NCT03310645|Placebo Comparator|Placebo|"Study Part 1:
~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
11210678|NCT03310645|Experimental|Placebo+BAY1817080|"Study Part 2:
~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
11276873|NCT02856425|Experimental|Colo Rectal Cancer|
11210679|NCT03310645|Experimental|BAY1817080+Placebo|"Study Part 2:
~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
11210680|NCT03310632|Experimental|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.
~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
11210681|NCT03310619|Experimental|Arm A: JCAR017 in combination with Durvalumab|JCAR017 will be administered at a single flat dose of 50 x 10^6 CAR+T cells or 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules.
11210682|NCT03310619|Experimental|Arm B: JCAR017 in combination with CC-122|This arm will test JCAR017 in combination with the CC-122. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
11210683|NCT03310619|Experimental|Arm C: JCAR017 in combination with CC-220|This arm will test JCAR017 in combination with the CC-220. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
11210684|NCT03310619|Experimental|Arm D: JCAR017 in combination with Ibrutinib|This arm will test JCAR017 in combination with the Ibrutinib. In adult subjects with R/R aggressive B-cell NHL. JCAR017 will be administered at a dose of 100 x 10^6 CAR+T cells. The combination agent will be administered at different doses
11210685|NCT03310606|Other|Peritonitis|"Patient received for antibiotic treatment a B lactam according to French recommendation :
~type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem
~dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g"
11210686|NCT03310593|Experimental|Cannabidiol|Cannabidiol 150-300mg per day for 12 weeks.
11210687|NCT03310593|Placebo Comparator|Placebo|Cannabidiol comparator for 12 weeks.
11210688|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
11210689|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
11210690|NCT03310580|Placebo Comparator|Placebo Comparator|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
11210691|NCT03310567|Experimental|Epacadostat + pembrolizumab|
11210692|NCT03310554|Experimental|26cm suspended overlength biliary stents group|
11210693|NCT03310554|Experimental|30cm suspended overlength biliary stents group|
11210694|NCT03310554|Other|ordinary plastic biliary stents group|
11210695|NCT03310541|Experimental|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
11210696|NCT03310541|Experimental|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
11210697|NCT03310541|Experimental|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
11210698|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
11210699|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
11210700|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
11210701|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
11210702|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
11210703|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
11210704|NCT03310489|Active Comparator|Psychoeducation about anxiety|
11210705|NCT03310476|Experimental|Baked, consumed chilled potatoes|
11210706|NCT03310476|Experimental|Boiled, consumed hot potatoes|
11210707|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
11210708|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
11210709|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
11210710|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
11210711|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
11210792|NCT03309982|Placebo Comparator|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
11210712|NCT03310450||Group 140kms cycling|"Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.
~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
11210713|NCT03310450||Group 100kms cycling|"Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.
~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
11210714|NCT03310450||Group 240kms cycling|"Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.
~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
11210715|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
11210716|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
11210717|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
11210718|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
11210719|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
11210720|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
11210721|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
11210722|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
11210723|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
11210724|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
11210725|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
11210726|NCT03310372|Experimental|ultrafractionated brain irradiation - temozolomide|
11210727|NCT03310359|Active Comparator|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
11210728|NCT03310359|Placebo Comparator|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
11210729|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
11210730|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
11210731|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
11210732|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
11210733|NCT03310307|Active Comparator|vitamin D3|50,000 IU
11210734|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
11210735|NCT03310294|Placebo Comparator|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
11210736|NCT03310294|Active Comparator|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
11210737|NCT03310281|Active Comparator|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
11210738|NCT03310281|Active Comparator|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
11210739|NCT03310268|Experimental|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total).
11210740|NCT03310268|Active Comparator|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
11210741|NCT03310268|Active Comparator|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
11210742|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
11210743|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
11210744|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
11210745|NCT03310216|Experimental|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
11210746|NCT03310216|Active Comparator|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
11210747|NCT03310203|Experimental|Obese women: central obesity|OGTT with iron
11210748|NCT03310203|Experimental|Obese women: peripheral obesity|OGTT with iron
11210749|NCT03310203|Experimental|Lean women|OGTT with iron
11210750|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
11210751|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
11210752|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
11210753|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
11210754|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
11210755|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
11210756|NCT03310151|No Intervention|control|Follows usual care
11210757|NCT03310138|Active Comparator|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation
~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
11210758|NCT03310138|Active Comparator|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation
~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
11210759|NCT03310138|Placebo Comparator|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation
~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
11210760|NCT03310125|Experimental|Colchicine|Oral colchicine 0.5mg
11210761|NCT03310125|Placebo Comparator|Placebo|Placebo oral tablet
11210762|NCT03310112|Experimental|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
11210763|NCT03310112|Active Comparator|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
11210764|NCT03310112|No Intervention|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
11210765|NCT03310099|Experimental|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated [MUFA] and polyunsaturated fatty acids [PUFA]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
11210766|NCT03310086|Experimental|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
11210767|NCT03310086|Experimental|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
11210768|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.
~The subject received bOPV, Pentabio and IPV according to the study schedule."
11210769|NCT03310060|Active Comparator|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.
~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
11210770|NCT03310060|Placebo Comparator|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
11210771|NCT03310047|Experimental|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.
~This will be repeated after 24 hours."
11210772|NCT03310047|Experimental|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.
~This will be repeated after 24 hours."
11210773|NCT03310034|Active Comparator|Intervention|
11210774|NCT03310034|Placebo Comparator|Control|
11210775|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
11210776|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
11210777|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
11210778|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
11210779|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
11210780|NCT03310021|Experimental|Cohort 6|Apixaban + high dose andexanet
11210781|NCT03310021|Experimental|Cohort 7|Edoxaban + low dose andexanet
11210782|NCT03310021|Experimental|Cohort 8|Apixaban + low dose andexanet
11210783|NCT03310021|Experimental|Cohort 9|Rivaroxaban + low dose andexanet
11210784|NCT03310021|Experimental|Cohort 10|Edoxaban + low dose andexanet
11210785|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
11210786|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
11210787|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
11210788|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
11210789|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
11210790|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
11210791|NCT03309982|Experimental|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
11210793|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
11210794|NCT03309956|Other|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
11210795|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
11210796|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
11210797|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
11210798|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:
~MAP set at 80-85 mmHg for 5 min.
~MAP set at 70-75 mmHg for 5 min.
~MAP set at 60-65 mmHg for 5 min.
~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
11210799|NCT03309904|Experimental|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
11210800|NCT03309904|No Intervention|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
11210801|NCT03309891|Experimental|Cohort 1|GX-H9 subcutaneous injections (weekly)
11210802|NCT03309891|Experimental|Cohort 2|GX-H9 subcutaneous injections (weekly)
11210803|NCT03309891|Experimental|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
11210804|NCT03309891|Active Comparator|Cohort 4|Genotropin subcutaneous injections (daily)
11210805|NCT03309878|Experimental|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11210806|NCT03309878|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11210807|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
11210808|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
11210809|NCT03309826|Experimental|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
11210810|NCT03309826|Active Comparator|Nasal Dilator Strip|Nightly use of nasal dilator strip
11210811|NCT03309813|Experimental|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
11210812|NCT03309813|Sham Comparator|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
11210813|NCT03309800|Experimental|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
11210814|NCT03309800|Placebo Comparator|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
11210815|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
11210816|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
11210817|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
11210818|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.
~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
11210819|NCT03309761||Patients aged 55-60|
11210820|NCT03309748|Active Comparator|Dental Prophylaxis|Standard dental prophylaxis
11210821|NCT03309748|Active Comparator|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
11210822|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
11210823|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
11210824|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
11210825|NCT03309722||early stage|
11210826|NCT03309722||advanced|
11210827|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
11210828|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
11210829|NCT03309696|Experimental|tDCS and 1 Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC. .
11210830|NCT03309696|Experimental|tDCS and 10Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
11210831|NCT03309696|Experimental|tDCS over DLFC and 1 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
11210832|NCT03309696|Experimental|tDCS over DLFC and 10 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
11210833|NCT03309683|Experimental|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
11210834|NCT03309683|No Intervention|Control group|Standard treatment after EMR (as described in the detailed study description above)
11210835|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
11210836|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
11210837|NCT03309644||Peripheral nerve block|Peripheral nerve block
11210838|NCT03309644||No peripheral nerve block|No peripheral nerve block
11210839|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
11210840|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
11210841|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
11210842|NCT03309605|Experimental|ELX-02|ELX-02
11210843|NCT03309592|Other|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
11210844|NCT03309579|Experimental|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
11210845|NCT03309579|Active Comparator|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
11210846|NCT03309566|Experimental|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
11210847|NCT03309566|Experimental|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
11210848|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
11210849|NCT03309553|Experimental|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
11210850|NCT03309540|Experimental|experimental group (EGR)|"Physical therapy intervention.
~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
11210851|NCT03309540|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.
~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
11210852|NCT03309527|Experimental|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
11210853|NCT03309527|Active Comparator|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
11210854|NCT03309514|Experimental|Treatment|
11210855|NCT03309501|Experimental|Tong-Luo-Qu-Tong Plaster group|Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
11210856|NCT03309501|Active Comparator|Qi-Zheng-Xiao-Tong Plaster group|Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
11210857|NCT03309488||Food allergic|Patients with a positive oral challenge to the food being studied.
11210858|NCT03309488||Non food allergic|Patients with a negative oral challenge to the food being studied.
11210859|NCT03309475|Experimental|SocialMIND|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
11210860|NCT03309475|Active Comparator|Psychoeducational Multicomponent Intervention|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
11210861|NCT03309462|Experimental|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
11210862|NCT03309462|Experimental|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
11210863|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
11210864|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
11210865|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
11210866|NCT03309436|Experimental|Use Clomiphene Citrate protocol|Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
11210867|NCT03309436|Active Comparator|Procedure|Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
11210868|NCT03309423||Respiratory disease|Patients with acute respiratory insufficiency admitted to the ICU and with pH <7,35 or >7,45
11210869|NCT03309423||Metabolic disease|Patients with acute metabolic disease admitted to the ICU and with pH <7,35 or >7,45
11210870|NCT03309423||Sepsis|Patients with acute sepsis admitted to the ICU and with pH <7,35 or >7,45
11210871|NCT03309410||Pre-study|In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
11210872|NCT03309410||Main study|In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission. The clinical indication for ABG analysis was decided by the responsible physician in the ED upon patient admission and based on national guidelines and criteria.
11210873|NCT03309358|Experimental|Inhaled SNSP113|
11210874|NCT03309358|Placebo Comparator|Inhaled Placebo|
11210875|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
11210876|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
11210877|NCT03309332|Experimental|Device|Subjects implanted with the AMPLATZER™ PFO Occluder.
11210878|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
11210879|NCT03309306|No Intervention|Phase 1: Lab Testing (Visit 1, Day 0)|Participants will test the FoodImage App and Pen-and-paper Records with in a Laboratory Kitchen. Participants will use the FoodImage app and food records to measure food waste during simulated shopping trip and kitchen clean-out. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
11210880|NCT03309306|Active Comparator|Phase 2: RCT Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
11210881|NCT03309306|Experimental|Phase 2: RCT Food Waste Reduction|"Phase 2 will occur in participants' natural environment (free-living conditions). Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:
~Feedback on the amount of food waste their household created during the first week,
~A goal to reduce the next week's food waste by 20% or more, and
~Tips on how to reduce household food waste adapted from current consumer campaigns"
11210882|NCT03309293|Other|controls|biological samples bank
11210883|NCT03309293|Experimental|cases|
11210884|NCT03309280||Patient at risk for OSA scheduled for Cardiac surgery|Patients with a positive STOP-Bang and DES-OSA score (that means patients at risk for OSA)
11210885|NCT03309280||Patient not at risk for OSA scheduled for Cardiac surgery|Patients with a negative STOP-Bang and DES-OSA score (that means patients not at risk for OSA)
11211013|NCT03308331|No Intervention|Healthy control nonsmokers|
11211014|NCT03308331|Active Comparator|HIV-1 nonsmokers using nicotine patch|
11210886|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
11210887|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
11210888|NCT03309254|Experimental|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
11210889|NCT03309254|Experimental|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
11210890|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
11210891|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
11210892|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
11210893|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
11210894|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
11210895|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
11210896|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
11210897|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
11210898|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
11210899|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
11210900|NCT03309176|Active Comparator|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
11210901|NCT03309176|Experimental|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
11210902|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
11210903|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
11210904|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
11210905|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
11210906|NCT03309137|Experimental|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
11210907|NCT03309137|No Intervention|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
11210908|NCT03309124|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
11210909|NCT03309124|Experimental|Baked potato with skin|Baked russet potato
11210910|NCT03309124|Experimental|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
11210911|NCT03309124|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
11210912|NCT03309124|Experimental|Meal skipping|No food given
11210913|NCT03309111|Experimental|ISB 1342|Open-label dose escalation of ISB 1342
11210914|NCT03309098||Ankle Injury|Person who injures their ankle
11210915|NCT03309085|Experimental|Single arm|Repeated CT scan
11210916|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
11210917|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
11210918|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
11210919|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
11211015|NCT03308331|No Intervention|HIV-1 nonsmokers using placebo patch|
11211016|NCT03308331|Active Comparator|Healthy control nonsmokers using nicotine patch|
11210920|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
11210921|NCT03309046|Experimental|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
11210922|NCT03309046|Active Comparator|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
11210923|NCT03309033||Observational (questionnaire, biospecimen collection)|Patients complete a short questionnaire regarding risk factors for HPV infection and undergo collection of blood samples for testing HPV16 and HPV18 levels at years 13 and 15 after receiving initial vaccination.
11210924|NCT03309020|Active Comparator|Control|Control with clinical need for cataract surgery
11210925|NCT03309020|Experimental|EVD Survivors|EVD survivors with need for cataract surgery
11210926|NCT03309007|Experimental|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
11210927|NCT03309007|Placebo Comparator|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
11210928|NCT03308994||Oral first line disease modifying treatments|
11210929|NCT03308994||Injectable first line disease modifying treatments|
11210930|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
11210931|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
11210932|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
11210933|NCT03308968|Placebo Comparator|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
11210934|NCT03308968|Experimental|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
11210935|NCT03308968|Experimental|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
11210936|NCT03308955|Active Comparator|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
11210937|NCT03308955|Sham Comparator|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
11210938|NCT03308942|Experimental|Stage 1 (Cohort 1): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/programmed death-ligand 1 (PD-L1) inhibitor treatment and whose tumors have high PD-L1 expression (tumor proportion score [TPS]: >= 50%) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
11210939|NCT03308942|Experimental|Stage 1 (Cohort 2): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
11210940|NCT03308942|Experimental|Stage 1 (Cohort 3): Niraparib|Participants with locally advanced and metastatic squamous NSCLC who have been previously treated with both platinum and either PD-1 or PD-L1 inhibitor will receive single agent niraparib.
11210941|NCT03308942|Experimental|Stage 2 (Cohort 1A): Niraparib plus Dostarlimab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have high PD-L1 expression (TPS: >= 50%) will receive combination of niraparib and a PD-1 inhibitor; Dostarlimab.
11211017|NCT03308331|No Intervention|Healthy control nonsmokers using placebo patch|
11210942|NCT03308942|Experimental|Stage 2 (Cohort 2A): Niraparib plus Dostarlimab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; Dostarlimab.
11210943|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
11210944|NCT03308890|Active Comparator|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
11210945|NCT03308890|Active Comparator|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
11210946|NCT03308890|No Intervention|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
11210947|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
11210948|NCT03308877|Active Comparator|Standard Care (SC)|
11210949|NCT03308864|Experimental|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
11210950|NCT03308864|Active Comparator|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
11210951|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
11210952|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
11210953|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
11210954|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
11210955|NCT03308825|Experimental|Group 1: 6 to < 36 Months|Children aged 6 to < 36 months received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
11210956|NCT03308825|Experimental|Group 2: 3 to < 9 Years|Children aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
11210957|NCT03308825|Experimental|Group 3: 18 to < 65 Years|Adults aged 18 to < 65 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
11210958|NCT03308825|Experimental|Group 4: >= 65 Years|Adults aged >= 65 years received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
11210959|NCT03308812|Active Comparator|Health360x|Participants will use the Health360x application for 6 months.
11210960|NCT03308812|Experimental|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
11210961|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
11210962|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
11210963|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
11210964|NCT03308786|Experimental|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks, in addition to combination antiretroviral therapy.
11210965|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
11210966|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
11210967|NCT03308734|Experimental|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
11210968|NCT03308734|No Intervention|Control Group|Following baseline testing, participants will receive usual care only.
11210969|NCT03308721|Experimental|NNC9204-1177|Dose trial with a sequential trial design
11210970|NCT03308721|Placebo Comparator|Placebo|
11210971|NCT03308708|No Intervention|Control group|
11210972|NCT03308708|Experimental|NE group|
11210973|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
11210974|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
11210975|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
11210976|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
11210977|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
11210978|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
11210979|NCT03308643|Experimental|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
11210980|NCT03308643|Placebo Comparator|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
11210981|NCT03308630|Experimental|Energy Alignment and Mantra|
11210982|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
11211018|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
11210983|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
11210984|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
11210985|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
11210986|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
11210987|NCT03308565|Experimental|Phase I|Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
11210988|NCT03308552|Active Comparator|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
11210989|NCT03308552|Placebo Comparator|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
11210990|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
11210991|NCT03308500|Experimental|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
11210992|NCT03308500|Active Comparator|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
11210993|NCT03308487|Active Comparator|vitamin D3 (1000 IU)|group 1
11210994|NCT03308487|Active Comparator|vitamin D3 (2000 IU)|group 2
11210995|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
11210996|NCT03308448|Active Comparator|Group 1|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
11210997|NCT03308448|Active Comparator|Group 2|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
11210998|NCT03308448|Active Comparator|Group 3|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
11210999|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
11211000|NCT03308409|Active Comparator|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
11211001|NCT03308409|Experimental|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
11211002|NCT03308409|Experimental|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
11211003|NCT03308396|Experimental|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.
~Phase Ib:
~Days 1-5
~Guadecitabine:
~Dose 0: 60 mg/m^2
~Dose -1: 45 mg/m^2
~Phase II:
~Days 1-5 Guadecitabine (at Ph II dose)
~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
11211004|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
11211005|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
11211006|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
11211007|NCT03308344|Experimental|Spouse Trainers (MT-ST)|Participants will engage in a short-form mindfulness training delivered by their peers who underwent an extensive training practicum.
11211008|NCT03308344|No Intervention|Wait-list control|Participants will be tested before and after a no-training interval and may receive training at a later time.
11211009|NCT03308344|Experimental|Mindfulness Expert (MT-ME)|Participants will engage in a short-form mindfulness training delivered by an expert mindfulness trainer.
11211010|NCT03308331|Experimental|HIV-1 smokers|
11211011|NCT03308331|No Intervention|HIV-1 nonsmokers|
11211012|NCT03308331|Active Comparator|Healthy control smokers|
11211020|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
11211021|NCT03308279||Asinthomatic|The only group evaluated
11211022|NCT03308266||CLP children with pain-related TMD|
11211023|NCT03308266||CLP children with no TMD|
11211024|NCT03308266||CLP children with painfree TMD|
11211025|NCT03308253|Other|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
11211026|NCT03308253|Experimental|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
11211027|NCT03308240|Experimental|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.
~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
11211028|NCT03308240|No Intervention|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
11211029|NCT03308227||Experimental Group|septic shock patients;
11211030|NCT03308227||Conrol Group|non-septic shock patients;
11211031|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
11211032|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
11211033|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.
~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
11211034|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
11211035|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
11211036|NCT03308175|Experimental|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.
~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .
~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.
~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
11211037|NCT03308175|Experimental|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.
~Functional bite will be taken to position the mandible in the proper position forward.
~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
11211038|NCT03308162|Experimental|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
11211039|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
11211040|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
11211041|NCT03308123||Health Care Professionals|Health care professionals
11211042|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
11211043|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
11211044|NCT03308110|Other|Relative Bioavailability Cohort|Relative Bioavailability cohort
11211045|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
11211046|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
11211047|NCT03308084|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
11211048|NCT03308084|Placebo Comparator|IV dexamethasone|Standard systemic (IV) dexamethasone only
11211049|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
11211050|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
11211051|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
11211052|NCT03308058|No Intervention|Printed Educational material|Printed educational material
11211053|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
11211330|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
11211054|NCT03308032|Experimental|Intervention|Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course. Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons. For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both
11211055|NCT03308032|Active Comparator|Control|"Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course.
~Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons (see below). For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both"
11211056|NCT03308019|Experimental|Adjunctive photodynamic therapy|This arm will be given scaling and root planing (SRP) with adjunctive photodynamic therapy (aPDT)
11211057|NCT03308019|Active Comparator|Dental scaling|This arm will be given scaling and root planing (SRP) only
11211058|NCT03308006|Experimental|Stem cells therapy|
11211059|NCT03307993|Experimental|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)
~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
11211060|NCT03307967|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
11211061|NCT03307967|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
11211062|NCT03307954|Experimental|Ekso Therapy|Up to 12 weeks of Ekso Therapy. Three sessions per week. One hour per session
11211063|NCT03307954|Active Comparator|Control|Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.
11211064|NCT03307941|Other|Single arm (classic 3+3 design)|
11211065|NCT03307928|Experimental|Cardiopulmonary Exercise Test Protocol|All subjects performed an incremental cardiopulmonary exercise test (CPET) to maximum exercise tolerance. All the procedures were performed in agreement with the American Thoracic Society/American College of Chest Physicians guidelines for cycle ergometer tests.
11211066|NCT03307928|Experimental|Polysomnography Assessment|All hypertensive subjects were submitted to a polysomnography exam to diagnose OSA. The OSA diagnose was confirmed by the apnea/hypopnea index (AHI) and classified as follows: AHI < 5 events/h, absence of OSA; 5 ≤ AHI ≤ 15 events/h, low OSA; 15 ≤ AHI ≤ 30 events/h, moderate OSA; AHI > 30 events/h, severe OSA.
11211067|NCT03307915|Experimental|Group 1: Ad26.Mos4.HIV + MVA-Mosaic/Placebo|Participants will receive adenovirus serotype 26-Mosaic 4 -Human Immunodeficiency Virus (Ad26.Mos4.HIV) 5*10^10 virus particles (vp) as intramuscular (IM) injection at Weeks 0 and 12 (1 injection) followed by modified Vaccinia Ankara-Mosaic (MVA-Mosaic) 10^8 Plaque-forming unit (pfu) and placebo as IM injection at Weeks 24 and 36 (2 injections).
11211068|NCT03307915|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV, 5*10^10 vp as IM injection at Weeks 0 and 12 (1 injection) followed by both Ad26.Mos4.HIV 5*10^10 vp plus Clade C gp140 (125 microgram [mcg]) plus Mosaic gp140 (125 mcg) with aluminum phosphate adjuvant or an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36 (2 injections).
11211069|NCT03307915|Placebo Comparator|Group 3: Placebo|Participants will receive 0.9 percent (%) saline as IM injection at Weeks 0, 12 (one injection) and at Week 24, 36 (two injections).
11211070|NCT03307902|Experimental|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
11211071|NCT03307902|Active Comparator|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
11211072|NCT03307902|Active Comparator|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
11211073|NCT03307876||groups that are fac + and -|autologous PPP injection is given to all patients. Prior to injection, a lavage of the disc space is taken to test for FAC.
11211074|NCT03307863|Experimental|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
11211075|NCT03307863|Experimental|Topiramate-Implant|Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted
11211076|NCT03307863|Active Comparator|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
11211077|NCT03307850|Experimental|Observation of Exercise|Observation During Exercise and Stress
11211078|NCT03307837|Experimental|CA-008|
11211079|NCT03307837|Placebo Comparator|CA-008 Placebo|
11211080|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
11211082|NCT03307811|Experimental|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
11211083|NCT03307785|Experimental|Part A: Dose Finding|Test safety and tolerability of combination therapy of Niraparib with TSR-042. To establish a Phase 2 dose (RP2D).
11211084|NCT03307785|Experimental|Part B: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Pacitaxel with TSR-042. To establish a Phase 2 dose (RP2D).
11211085|NCT03307785|Experimental|Part C: Dose Finding|Test safety and tolerability of combination therapy of Niraparib and Bevacizumab with TSR-042. To establish a Phase 2 dose (RP2D).
11211086|NCT03307785|Experimental|Part D: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Paclitaxel and Bevacizumab with TSR-042. To establish a Phase 2 dose (RP2D).
11211087|NCT03307785|Experimental|Part E:Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Pemetrexed with TSR-042. To establish a Phase 2 dose (RP2D).
11211088|NCT03307785|Experimental|Part F: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Pemetrexed and TSR-022 with TSR-042. To establish a Phase 2 dose (RP2D).
11211089|NCT03307785|Experimental|Part G: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-nab-Paclitaxel with TSR-042. To establish a Phase 2 dose (RP2D).
11211090|NCT03307785|Experimental|Part H: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-nab-Paclitaxel, TSR-022 with TSR-042. To establish a Phase 2 dose (RP2D).
11211091|NCT03307785|Experimental|Part I: Safety and Tolerability Evaluation|Test the safety and tolerability of combination therapy of Carboplatin-Paclitaxel, TSR-022 with TSR-042. To establish a Phase 2 dose (RP2D).
11211092|NCT03307772|Placebo Comparator|placebo drink|The placebo drink consists of fermented low-fat milk with no added Lactobacillus GG.(placebo)
11211093|NCT03307772|Active Comparator|LGG Drink (|The probiotic drink consists of fermented low-fat milk with added Lactobacillus GG. (probiotics)
11211094|NCT03307772|Active Comparator|FOS Drink|The prebiotics drink consists of fermented low-fat milk with fructooligosaccharides. (prebiotics)
11211095|NCT03307772|Active Comparator|LGG e FOS Drink|The probiotics and prebiotics drink consists of acidified low-fat milk with added Lactobacillus GG and fructooligosaccharides (prebiotics and probiotics)
11211096|NCT03307759|Active Comparator|SABR plus pembrolizumab|SABR followed by pembrolizumab
11211097|NCT03307759|Active Comparator|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
11211098|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
11211099|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
11211100|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
11211101|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
11211102|NCT03307720|Active Comparator|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
11211103|NCT03307720|Experimental|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
11211104|NCT03307720|Active Comparator|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
11211105|NCT03307720|Experimental|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
11211106|NCT03307720|Active Comparator|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
11211107|NCT03307720|Experimental|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
11211108|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) <50% or LVEF >50% and E/e'>10.
11211109|NCT03307707||No Heart Failure (NHF)|subjects with LVEF>50%
11211110|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
11211111|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
11211112|NCT03307681|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
11211113|NCT03307681|Experimental|Baked potato with skin|Baked russet potato
11211114|NCT03307681|Experimental|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
11211115|NCT03307681|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
11211119|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
11211120|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
11211121|NCT03307642|No Intervention|SLIV + usual communication|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV
11211122|NCT03307642|Active Comparator|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
11211123|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.
~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.
~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
11211124|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.
~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The Safety Steering Committee will inform on dose for cohort expansion.
~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
11211125|NCT03307616|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
11211126|NCT03307616|Experimental|Arm B (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
11211127|NCT03307616|Experimental|Arm C (nivolumab, RT)|Patients receive nivolumab IV over 1 hour on days 1, 15, 29, and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
11211128|NCT03307616|Experimental|Arm D (nivolumab, ipilimumab, RT)|Patients receive nivolumab as in Arm C, ipilimumab as in Arm B, and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
11211129|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
11211130|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
11211131|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
11211132|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
11211133|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
11211134|NCT03307564|Experimental|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
11211135|NCT03307551|Active Comparator|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
11211136|NCT03307551|Active Comparator|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
11211137|NCT03307538|Experimental|Stereotactic body radiation therapy|
11211138|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
11211139|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
11211140|NCT03307499|Experimental|Treatment|NeoPatch
11211141|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
11211142|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
11211143|NCT03307460|Experimental|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
11211144|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
11211145|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
11211146|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
11211147|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
11211182|NCT03307187|No Intervention|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
11211255|NCT03306706|Experimental|split yellow pea|2 muffins containing 25g available carbohydrate from split yellow peas. Intervention: Split pea muffins
11211148|NCT03307421|Other|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .
~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
11211149|NCT03307395|Experimental|Middle Meningeal Artery Embolization|
11211150|NCT03307382|Experimental|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
11211151|NCT03307356|Experimental|Uterine Transplantation|Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a deceased donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 12 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
11211152|NCT03307343|Experimental|Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
11211153|NCT03307343|No Intervention|Control|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
11211154|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
11211155|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
11211156|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
11211157|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
11211158|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
11211159|NCT03307304||Family members|Unaffected family members of individuals diagnosed with CLN3-Batten
11211160|NCT03307304||Proband/Affected Individuals|Individuals diagnosed with CLN3-Batten
11211161|NCT03307278|Experimental|Steroid resistance in HDM allergic patients|
11211162|NCT03307278|Experimental|Steroid resistance in non HDM allergic subjects|
11211163|NCT03307265|Experimental|Imbalance correction|
11211164|NCT03307265|Active Comparator|Control|
11211165|NCT03307252|Experimental|Treatment Reference 1|
11211166|NCT03307252|Experimental|Treatment Reference 2|
11211167|NCT03307252|Experimental|Treatment Reference 3|
11211168|NCT03307252|Experimental|Treatment 1|
11211169|NCT03307252|Experimental|Treatment 2|
11211170|NCT03307252|Experimental|Treatment 3|
11211171|NCT03307252|Experimental|Treatment 4|
11211172|NCT03307252|Experimental|Treatment 5|
11211173|NCT03307252|Experimental|Treatment 6|
11211174|NCT03307239|Experimental|cold application (experimental group)|subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before CTR
11211175|NCT03307239|Sham Comparator|tap water packs application (sham group)|subjects in the sham group (n = 30) received tap water packs.
11211176|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)
~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development
~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
11211177|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)
~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development
~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)
~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
11211178|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
11211179|NCT03307213|Experimental|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
11211180|NCT03307213|Active Comparator|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
11211181|NCT03307187|Experimental|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
11211218|NCT03306940|Placebo Comparator|unilateral injection group|Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.
11211183|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:
~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.
~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
11211184|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:
~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.
~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
11211185|NCT03307161|Active Comparator|Parkinsons fwd posture manual treatment|Subject will receive the intervention, osteopathic manual treatment protocol.
11211186|NCT03307161|No Intervention|Parkinsons forward posture|Subjects will receive counseling.
11211187|NCT03307161|No Intervention|Parkinsons without forward posture|Subjects will receive counseling.
11211188|NCT03307148|Experimental|ATRA in combination with Gemcitabine and Nab-Paclitaxel|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
11211189|NCT03307135|Experimental|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
11211190|NCT03307135|Experimental|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
11211191|NCT03307135|Experimental|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
11211192|NCT03307122|Active Comparator|Routine Infant Formula 1|Routine infant formula with probiotic
11211193|NCT03307122|Active Comparator|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
11211194|NCT03307109||Patients having prosthetic joint infection|The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
11211195|NCT03307096|Experimental|Microperc surgery|Patient is turned into prone position and the desired calyx is punctured by 4.8F microperc under fluoroscopic or sonographic guidance. No tract dilation is needed. A 200um holmium laser fiber will be used to break stone into less than 2mm. Pull out microperc without drainage tube left.
11211196|NCT03307096|Active Comparator|FURS|Patient is placed in the lithotomy position, pull out the pre-inserted double J, and place guidewire into the renal pelvis. A 12/14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and flexible ureteroscope is passed through the UAS. The stones are fragmented smeller than 2mm using a 200um holmium laser fiber. Fragments are removed using a stone basket for stone analysis if necessary, a double J stent is placed at the conclusion of the procedure and removed post-operative 4 weeks.
11211197|NCT03307070|Active Comparator|Active Group|Participants who are randomized to begin the Cognitive Behavioral Therapy for individuals with TBI immediately after screening. This treatment is a version of Cognitive Behavioral Therapy (CBT) adapted specifically for patients who have experienced a moderate to severe Traumatic Brain Injury (TBI).
11211198|NCT03307070|Other|Waitlist Control|Participants who are randomized to be put on a waitlist after screening. After 12 weeks of being on the waitlist, participants will be offered the Cognitive Behavioral Therapy for individuals with TBI
11211199|NCT03307057|Experimental|Social Communication Growth Charts (SCGC)|Infants with a sibling who is diagnosed with ASD, who are randomized to receive the Social Communication Growth Charts (SCGC) intervention.
11211200|NCT03307057|No Intervention|Usual care|Infants with a sibling who is diagnosed with ASD, who are randomized to receive usual care.
11211201|NCT03307057|Experimental|Parent-Implemented (P-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) based on the Early Social Interaction model.
11211202|NCT03307057|Experimental|Clinician-Implemented (C-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model.
11211203|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
11211204|NCT03307031|Experimental|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
11211205|NCT03307031|Experimental|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
11211206|NCT03307031|Placebo Comparator|Control Group|Did not exercise, during 10 weeks.
11211207|NCT03307018|Experimental|Bronch|Postoperative systematic bronchial aspiration.
11211208|NCT03307018|No Intervention|Control|In this arm bronchial aspiration with bronchoscope will not be done.
11211209|NCT03307005|Experimental|Intervention|
11211210|NCT03307005|Placebo Comparator|Control|
11211211|NCT03306992|Experimental|Personalized Exercise Program|
11211212|NCT03306992|No Intervention|Standard of Care - No Exercise|
11211213|NCT03306979|Active Comparator|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
11211214|NCT03306979|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
11211215|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
11211216|NCT03306953|Active Comparator|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
11211217|NCT03306953|No Intervention|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
11211219|NCT03306940|Experimental|bilateral injection group|Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.
11211220|NCT03306927|Experimental|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
11211221|NCT03306927|Experimental|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
11211222|NCT03306927|Placebo Comparator|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
11211223|NCT03306927|Placebo Comparator|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
11211224|NCT03306914|Active Comparator|Albumin group|Albumin resuscitation Albumin 5%
11211225|NCT03306914|Experimental|Hydroxyethylstarch group|Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
11211226|NCT03306901|Experimental|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 ~ 4,000mg/m2) intravenously for 4 to 5 days.
~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
11211227|NCT03306901|Active Comparator|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
11211228|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
11211229|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
11211230|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
11211231|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
11211232|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
11211233|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
11211234|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
11211235|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
11211236|NCT03306836|Experimental|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
11211237|NCT03306836|Active Comparator|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
11211238|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
11211239|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
11211240|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
11211241|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
11211242|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
11211243|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
11211244|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
11211245|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
11211246|NCT03306758|Experimental|Experimental: sodium bicarbonate|
11211247|NCT03306758|No Intervention|No Intervention|
11211248|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids
~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
11211249|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
11211250|NCT03306732|Active Comparator|Thiamine group|
11211251|NCT03306732|Placebo Comparator|Placebo group|
11211252|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
11211253|NCT03306719||Control Group|Pregnant women without IAI
11211254|NCT03306706|Experimental|whole yellow pea|2 muffins containing 25g available carbohydrate from whole yellow peas. Intervention: Whole pea muffins
11211256|NCT03306706|Placebo Comparator|wheat-PPGR|2 muffins containing 25g available carbohydrate from wheat flour. Intervention: Wheat muffins
11211257|NCT03306706|Placebo Comparator|wheat-satiety|"2 muffins containing wheat flour to match the calories in the whole and split pea muffins.
~Intervention: Wheat muffins"
11211258|NCT03306693|Experimental|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
11211259|NCT03306693|Sham Comparator|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
11211260|NCT03306680|Experimental|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy
~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy
~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy"
11211261|NCT03306667|Experimental|Normal group|Healthy control subjects
11211262|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
11211263|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
11211264|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
11211265|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
11211266|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11211267|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11211268|NCT03306641|Active Comparator|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
11211269|NCT03306641|Active Comparator|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
11211270|NCT03306628|Experimental|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
11211271|NCT03306628|Experimental|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
11211272|NCT03306615|Experimental|Treatment Arm|Hyaluronidase plus saline
11211273|NCT03306615|Placebo Comparator|Control Arm|Normal Saline
11211274|NCT03306602|Experimental|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
11211275|NCT03306602|Active Comparator|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
11211276|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
11211277|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
11211278|NCT03306576|Experimental|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
11211279|NCT03306576|Active Comparator|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
11211280|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
11211281|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
11211282|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
11211283|NCT03306550|Active Comparator|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
11211284|NCT03306550|Active Comparator|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
11211285|NCT03306550|Experimental|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
11211286|NCT03306524|Experimental|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
11211287|NCT03306524|Experimental|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
11211288|NCT03306524|Experimental|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
11211289|NCT03306524|Experimental|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
11211290|NCT03306524|Experimental|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
11211291|NCT03306524|Experimental|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
11211292|NCT03306524|Experimental|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
11211293|NCT03306524|Experimental|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
11211294|NCT03306524|Experimental|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
11211295|NCT03306524|Experimental|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
11211296|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
11211297|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
11211298|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
11211299|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
11211300|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure > 5% on pH monitoring performed off PPI).
~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
11211301|NCT03306472|Active Comparator|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
11211302|NCT03306472|Experimental|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
11211303|NCT03306472|Experimental|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
11211304|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting >35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
11211305|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
11211306|NCT03306446|Experimental|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
11211307|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
11211308|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
11211309|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
11211310|NCT03306420|Experimental|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
11211311|NCT03306420|Experimental|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
11211312|NCT03306420|Experimental|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
11211313|NCT03306420|Experimental|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
11211314|NCT03306420|Experimental|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
11211315|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
11211316|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
11211317|NCT03306394|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
11211318|NCT03306381|Experimental|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
11211319|NCT03306381|No Intervention|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
11211320|NCT03306368|No Intervention|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
11211321|NCT03306368|Experimental|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:
~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
11211322|NCT03306355|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
11211323|NCT03306355|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
11211324|NCT03306342|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
11211331|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
11211332|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
11211333|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
11211334|NCT03306290|Other|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
11211335|NCT03306277|Experimental|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
11211336|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
11211337|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
11211338|NCT03306238|Active Comparator|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
11211339|NCT03306238|Active Comparator|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
11211340|NCT03306212|Experimental|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
11211341|NCT03306212|Active Comparator|Control Group|Patients treated by botulinum toxin A and occupational therapy
11211342|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
11211343|NCT03306173|Experimental|Ventilated cigarettes|Participants in this ARM will be assigned to ~25% filter ventilation commercially available cigarettes.
11211344|NCT03306173|Experimental|Unventilated cigarettes|Participants in this ARM will be assigned to ~0% filter ventilation commercially available cigarettes.
11211345|NCT03306147|Experimental|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
11211346|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
11211347|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
11211348|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
11211349|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
11211350|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
11211351|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
11211352|NCT03306082|Experimental|Image-guided Cochlear Implant Programming (IGCIP)|Cochlear implant programming using IGCIP.
11211353|NCT03306069|Experimental|Control|Nutritional therapy / no exercise
11211354|NCT03306069|Experimental|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
11211355|NCT03306069|Experimental|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
11211356|NCT03306069|Experimental|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding ~70-75% HRmax) combined with Nutritional therapy
11211357|NCT03306056|Experimental|Control|Nutritional therapy / no exercise
11211358|NCT03306056|Experimental|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
11211359|NCT03306056|Experimental|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
11211360|NCT03306056|Experimental|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
11211361|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
11211362|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
11211363|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
11211364|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
11211365|NCT03306004||Health Care Providers|Providers answer questionaires
11211366|NCT03306004||Mothers|Mothers answer questionaires
11211367|NCT03305978|Experimental|Ultra low dose chest CT|
11211368|NCT03305978|Active Comparator|Low dose chest CT|
11211369|NCT03305965|Experimental|Patient navigation|
11211370|NCT03305965|No Intervention|Care as usual|
11211371|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
11211450|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
11211555|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
11211372|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
11211373|NCT03305939|Experimental|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
11211374|NCT03305939|No Intervention|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
11211375|NCT03305926|Active Comparator|Conventional CVR|
11211376|NCT03305926|Experimental|eCVR|
11211377|NCT03305913|Experimental|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
11211378|NCT03305913|Experimental|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
11211379|NCT03305913|Experimental|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
11211380|NCT03305913|Experimental|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
11211381|NCT03305913|Experimental|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
11211382|NCT03305913|Experimental|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
11211383|NCT03305887|Experimental|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
11211384|NCT03305887|Active Comparator|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
11211385|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
11211386|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
11211387|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
11211388|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
11211389|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
11211390|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
11211391|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
11211392|NCT03305809|Experimental|LY3154207 High Dose|LY3154207 administered orally.
11211393|NCT03305809|Experimental|LY3154207 Mid Dose|LY3154207 administered orally.
11211394|NCT03305809|Experimental|LY3154207 Low Dose|LY3154207 administered orally.
11211395|NCT03305809|Placebo Comparator|Placebo|Placebo administered orally.
11211396|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
11211397|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
11211398|NCT03305770|Experimental|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
11211399|NCT03305770|Active Comparator|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
11211400|NCT03305757|Active Comparator|conventional wound closure|The skin flaps will not undergo further treatment in this group.
11211401|NCT03305757|Experimental|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
11211402|NCT03305757|Experimental|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
11211403|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
11211404|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
11211405|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
11211451|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
11211452|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
11211453|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
11211655|NCT03304054|Placebo Comparator|placebo tablets|
11211406|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
11211407|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
11211408|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
11211409|NCT03305718|Experimental|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
11211410|NCT03305718|Experimental|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
11211411|NCT03305718|Experimental|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
11211412|NCT03305718|Experimental|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
11211413|NCT03305718|Experimental|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
11211414|NCT03305718|Experimental|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
11211415|NCT03305718|Experimental|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
11211486|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
11211416|NCT03305718|Experimental|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
11211417|NCT03305718|Experimental|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.
~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
11211418|NCT03305705|Experimental|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
11211419|NCT03305705|Experimental|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
11211420|NCT03305692|Experimental|ECG Belt|Use ECG Belt body surface mapping system to optimize CRT programming.
11211421|NCT03305692|Experimental|Echocardiography|Use mitral inflow echocardiography to optimize CRT programming.
11211422|NCT03305679|Experimental|Direct provisional technique|Patients here will be subjected to the direct provisional technique
11211423|NCT03305679|Active Comparator|Indirect Provisional technique|Patients here will be subjected to the indirect provisional technique
11211424|NCT03305666|Active Comparator|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
11211425|NCT03305666|Active Comparator|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
11211426|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
11211427|NCT03305627|Experimental|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
11211428|NCT03305627|Active Comparator|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
11211429|NCT03305614|Active Comparator|Aphasia therapy and tDCS|
11211430|NCT03305614|Sham Comparator|Aphasia therapy and sham-tDCS|
11211431|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
11211432|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
11211433|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
11211434|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
11211435|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
11211436|NCT03305549|Active Comparator|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
11211437|NCT03305549|Experimental|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
11211438|NCT03305536|Active Comparator|Interventional|1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve
11211439|NCT03305536|Active Comparator|interventional|5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study
11211440|NCT03305523|Experimental|Thermocautery|Circumcision with thermocautery technique was applied all participants
11211441|NCT03305510||Vitamin D deficiency|The level of vitamin D is below 20ng/ml.
11211442|NCT03305510||Vitamin D insufficient|The level of vitamin D is between 20ng/ml and 30ng/ml.
11211443|NCT03305510||Vitamin D sufficient|The level of vitamin D is above 30ng/ml.
11211444|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
11211445|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
11211446|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
11211447|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
11211448|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
11211449|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
11211454|NCT03305445|Experimental|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
11211455|NCT03305432|Experimental|PPI group|take preoperative PPI for 10 days
11211456|NCT03305432|Active Comparator|Control group|take placebo for for 10 days preoperative
11211457|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
11211458|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
11211459|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
11211460|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
11211461|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
11211462|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
11211463|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
11211464|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
11211465|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
11211466|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
11211467|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
11211468|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
11211469|NCT03305406||Focus Group Participants|Semi-structured focus groups
11211470|NCT03305406||Interview Participants|One-on-one interviews
11211471|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
11211472|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
11211473|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
11211474|NCT03305367|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
11211475|NCT03305367|Experimental|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
11211476|NCT03305367|Experimental|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
11211477|NCT03305354|Experimental|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
11211478|NCT03305354|Active Comparator|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
11211479|NCT03305341|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein
~0.5 ml Lactated Ringer's Injection, USP"
11211480|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
11211481|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
11211482|NCT03305315||Cases|Diseases of the temporomandibular joint
11211483|NCT03305315||Controls|Asymptomatic subjects
11211484|NCT03305289|Active Comparator|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
11211485|NCT03305289|Active Comparator|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
11211550|NCT03304808|Active Comparator|behavioral|
11211551|NCT03304808|No Intervention|waiting list|
11211487|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
11211488|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
11211489|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
11211490|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
11211491|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
11211492|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
11211493|NCT03305224|Other|Ra-223 + Enzalutamide|
11211494|NCT03305211|Other|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
11211495|NCT03305198|Experimental|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
11211496|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
11211497|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
11211498|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
11211499|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
11211500|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
11211501|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
11211502|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
11211503|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
11211504|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
11211505|NCT03305146|Experimental|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.
~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
11211506|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.
~Children will then drink 240mL of chocolate milk"
11211507|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.
~Children will then drink 240mL of water"
11211508|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
11211509|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
11211510|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
11211552|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
11211553|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
11211554|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
11211511|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
11211512|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
11211513|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
11211514|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
11211515|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
11211516|NCT03305055|Experimental|Fentanyl Plus Ketamine|"Study drug group
~Ketamine Loading Dose (Low Dose, Slow Infusion) =
~• 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, … Then,
~Fentanyl Loading Dose (UC, injection) =
~• 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated < 1 minute prior to wound care.
~Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.
~Fentanyl PRN dose* = 1 mcg / kg. Provided when participant requires additional pain medication."
11211517|NCT03305055|Active Comparator|Fentanyl Plus Saline|"Usual care group
~Saline Loading Dose (Low Dose, Slow Infusion) =
~• An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), … Then, ...
~Fentanyl Loading Dose (UC, injection) =
~• 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated <1 minute prior to wound care.
~Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.
~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
11211518|NCT03305042||21-54 y|Ages 21-54 y
11211519|NCT03305042||55-74 y|Ages 55-74 y
11211520|NCT03305042||>75 y|Age >75 y
11211521|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
11211522|NCT03305016|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
11211523|NCT03305003|Active Comparator|Communication modality: spiral notebook|
11211524|NCT03305003|Experimental|Communication modality: mobile application|
11211525|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
11211526|NCT03304990||Risk Factors for CA|No dx of CA
11211527|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
11211528|NCT03304964|Experimental|100 mg FP-025 (b.i.d)|
11211529|NCT03304964|Experimental|200 mg FP-025 (b.i.d.)|
11211530|NCT03304964|Experimental|400 mg FP-025 (b.i.d)|
11211531|NCT03304964|Experimental|200 mg FP-025 (single dose; fasted)|
11211532|NCT03304964|Experimental|200 mg FP-025 (single dose; fed condition)|
11211533|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
11211534|NCT03304938|Active Comparator|Lavender oil|
11211535|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
11211536|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
11211537|NCT03304912||Cohort|The cohort will be comprised of women who inject drugs who are eligible for PrEP.
11211538|NCT03304899|Experimental|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:
~Airway control & breathing.
~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).
~Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.
~Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
11211539|NCT03304899|Active Comparator|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:
~Airway control & breathing.
~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
11211540|NCT03304886||Migraineurs|with a migraine
11211541|NCT03304886||Control|Participants without migraine
11211542|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
11211543|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
11211544|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
11211545|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
11211546|NCT03304834|Experimental|ECHOPULSE|Arm of patient treated by HIFU
11211547|NCT03304821|Experimental|GM-CSF|Participants receiving 500µg of granulocyte-macrophage colony stimulating factor (GM-CSF), administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
11211548|NCT03304821|Placebo Comparator|Placebo|Participants receiving 500µg of a placebo, administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
11211549|NCT03304808|Experimental|device|
11211556|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
11211557|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
11211558|NCT03304756|Experimental|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
11211559|NCT03304743||Post-menopausal women|A cohort of 124 consecutive post-menopausal women that performed a DXA scan within the previous 12 months
11211560|NCT03304730||facet inflammatory signs|patients with facet inflammatory signs identified on MRI
11211561|NCT03304730||no facet inflammatory signs|patients without facet inflammatory signs identified on MRI
11211562|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
11211563|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
11211564|NCT03304704||DSF Cohort|Accrual/Screening up to 1800 will include volunteers between the ages of 5 and 17 years and will be enrolled for genotyping and monthly blood sampling
11211565|NCT03304704||Genotype Cohort|Accrual/Screening up to 1500 will complete a single visit with blood draw for genotyping for future fidelity assessments with blood-fed, spray wild-caught mosquitoes.
11211566|NCT03304704||Parasite Surveillance Cohort|Accrual/Screening up to 1500 will be enrolled for genotyping and a minimum of six monthly blood sampling and mosquito wild catches wild-caught mosquitoes within their compound
11211567|NCT03304691||Bandiagara, Mali|Children of both sexes between 6 months and 10 years of age.
11211568|NCT03304691||Yirimadio, Bamako, Mali|Children and adults of both sexes 6 months and older.
11211569|NCT03304678||taking sirolimus|Subjects will come to the NIH and begin taking sirolimus
11211570|NCT03304665||Healthy Volunteers|Healthy Volunteers
11211571|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11211572|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
11211573|NCT03304626|Experimental|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows
~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
11211574|NCT03304613|Active Comparator|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
11211575|NCT03304613|Experimental|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
11211576|NCT03304613|No Intervention|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
11211577|NCT03304600|Experimental|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
11211578|NCT03304600|Sham Comparator|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
11211579|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.
~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.
~Light therapy will be self-administered using a light visor cap
~Each participant will make (3) overnight visits to the sleep laboratory
~On 2 randomly selected days, the participants will wear a light meter during wake time"
11211580|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.
~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.
~Light therapy will be self-administered using a light visor cap
~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
11211581|NCT03304574|No Intervention|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
11276874|NCT02856425|Experimental|Ovarian cancer (OC)|
11211582|NCT03304574|Experimental|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
11211583|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
11211584|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
11211585|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
11211586|NCT03304522|Experimental|VX-150|
11211587|NCT03304522|Active Comparator|Placebo|
11211588|NCT03304509|No Intervention|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
11211589|NCT03304509|Experimental|Telematic follow-up|Telematic follow-up after hospital discharge
11211590|NCT03304496|Experimental|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
11211591|NCT03304496|Placebo Comparator|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
11211592|NCT03304483|Experimental|Athletes|246-km running
11211593|NCT03304470|Experimental|ATx201 2% CREAM|
11211594|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
11211595|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
11211596|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
11211597|NCT03304444|Active Comparator|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).
~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
11211598|NCT03304444|Experimental|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
11211599|NCT03304431|No Intervention|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
11211600|NCT03304431|Other|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
11211601|NCT03304418|Experimental|Radium Ra 223 dichloride and radiation, all patients|
11211602|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
11211603|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
11211604|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
11211605|NCT03304379|Experimental|Dosing regimen 1|
11211606|NCT03304379|Experimental|Dosing regimen 2|
11211607|NCT03304379|Experimental|Dosing regimen 3|
11211608|NCT03304379|Experimental|Dosing regimen 4|
11211609|NCT03304366||Patients with primary pterygium|"All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.
~All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
11211610|NCT03304353|Experimental|Self-managed protocol|
11211611|NCT03304353|Active Comparator|Predetermined protocol|
11211612|NCT03304340|Experimental|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device & Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
11211656|NCT03304041|Experimental|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.
~low-FODMAPs diet therapy for 3 weeks"
11276875|NCT02856425|Experimental|Hepatocellular (HCC)|
11211613|NCT03304340|Experimental|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
11211614|NCT03304340|Active Comparator|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
11211615|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
11211616|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
11211617|NCT03304314|Experimental|Control|
11211618|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
11211619|NCT03304301|No Intervention|control group|Participants will receive routine care.
11211620|NCT03304288|Experimental|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m^2 qd for 12 weeks.
11211621|NCT03304288|Active Comparator|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
11211622|NCT03304275|Experimental|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
11211623|NCT03304275|Experimental|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
11211624|NCT03304262|Active Comparator|Cathodal tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
11211625|NCT03304262|Active Comparator|Anodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
11211626|NCT03304262|Sham Comparator|Sham tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
11211627|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
11211628|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
11211629|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
11211630|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
11211631|NCT03304210|Experimental|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
11211632|NCT03304210|Experimental|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
11211633|NCT03304210|Experimental|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
11211634|NCT03304210|Experimental|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
11211635|NCT03304210|Experimental|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
11211636|NCT03304197|Experimental|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
11211637|NCT03304197|Experimental|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
11211638|NCT03304197|Experimental|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
11211639|NCT03304197|Experimental|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
11211640|NCT03304184|Placebo Comparator|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
11211641|NCT03304184|Experimental|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
11211642|NCT03304158|Experimental|FCHV visit-diabetes|
11211643|NCT03304158|No Intervention|FCHV no visit-diabetes|
11211644|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
11211645|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
11211646|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
11211647|NCT03304119||Control group control|Group that has not been checked for patellar instability.
11211648|NCT03304106|Experimental|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
11211649|NCT03304106|Experimental|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
11211650|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
11211651|NCT03304080|Experimental|HR-positive, Her2-positive Metastatic Breast Cancer|Women with HR-positive, Her2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
11211652|NCT03304067|Experimental|Intervention|
11211653|NCT03304067|No Intervention|Control|
11211654|NCT03304054|Experimental|amifamapridine phosphate tablets|
11211657|NCT03304041|Placebo Comparator|Traditional dietary advice|"Traditional dietary advice (TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period
~Traditional dietary advice for 3 weeks"
11211658|NCT03304028|Other|Refusal Group|"Refusal Questionnaires Intervention:
~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
11211659|NCT03304028|Other|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
11211660|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
11211661|NCT03304015|No Intervention|Control: No intervention|
11211662|NCT03303989|Experimental|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
11211663|NCT03303989|Placebo Comparator|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
11211664|NCT03303976|Experimental|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
11211665|NCT03303976|Experimental|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
11211666|NCT03303976|Experimental|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
11211667|NCT03303976|Active Comparator|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
11211668|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
11211669|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
11211670|NCT03303950|Experimental|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Patients receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Patients undergo HSCT on day 0. Patients then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
11211671|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
11211672|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:
~Days 1-3 (6 times daily)
~Days 4-12 (5 times daily)
~Days 13-16 (4 times daily)
~Days 17-20 (3 times daily)
~Days 21-24 (2 times daily)
~Day 25 (Once daily)"
11211673|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:
~Days 1-3 (6 times daily)
~Days 4-12 (5 times daily)
~Days 13-16 (4 times daily)
~Days 17-20 (3 times daily)
~Days 21-24 (2 times daily)
~Day 25 (Once daily)"
11211674|NCT03303898|Other|asymptomatic carriers|
11211675|NCT03303898|Other|uninfected patient|
11211676|NCT03303872||AF-pacemaker registry|
11211677|NCT03303846|Experimental|Treatment (breast MRI, biopsy)|Participants undergo standard of care high risk breast cancer screening MRIs at baseline and follow-up and blood sample collection at baseline. Participants also undergo collection of breast tissue samples at any breast biopsy or breast surgery.
11211678|NCT03303833||Persons with Lynch syndrome|
11211679|NCT03303807|Other|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
11211680|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
11211681|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
11211682|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
11211683|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
11211684|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
11211685|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
11211686|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
11211687|NCT03303742|Experimental|feather edge finish line marginal design|intervention
11211688|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
11211689|NCT03303729|Experimental|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
11211690|NCT03303729|Active Comparator|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
11211691|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
11211692|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
11211693|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
11211694|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
11211695|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
11211777|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
11211778|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
11211696|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
11211697|NCT03303664|Experimental|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
11211698|NCT03303664|No Intervention|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
11211699|NCT03303651|Experimental|PPI (Pain Pupillary Index)|Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
11211700|NCT03303651|Experimental|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electrics) Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide analgesics (15 - 17). 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
11211701|NCT03303651|Experimental|NOL (Nociception Level)|Opioid administration (sufentanil) guided by Nociception Level (NOL) derived from finger photoplethysmography performed with the analgesia monitoring device PMD200 manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature and finger motion. The composite algorithm of the device analyses the data and the numerical index NOL is presented on a scale from 0 (no pain) to 100 (extreme pain) (18). A NOL score between 10 and 25 has been proposed as the target range to guide analgesics. 5 µg Sufentanil will be administered every 5 minutes if NOL score is calculated more than 25.
11211702|NCT03303651|Active Comparator|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
11211703|NCT03303638|Other|Multi-sensory Environment during bathing|The MSE intervention will be provided by an interactive waterproof fiber optic kit that includes: a light-emitting diode (LED) wall-washer light, a waterproof fiber optic cable that can be controlled by a waterproof switch held by the participant while bathing, showering, and or tub bathing, and a mobile MSE cart. The wall-washer LED light creates the illusion that the room is painted a variety of bright colors that can be changed by the veteran being bathed. The mobile MSE cart includes an LED solar projector providing visual sensory stimulation by projecting scenes on the wall, an aroma therapy diffuser and a portable bubble tube to create positive distraction during the bathing process.
11211704|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
11211705|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
11211706|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
11211707|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
11211708|NCT03303612|Other|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.
~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
11211709|NCT03303612|Other|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
11211710|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
11211711|NCT03303586|Active Comparator|Asthma group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
11211779|NCT03303066|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
11211780|NCT03303066|Placebo Comparator|Placebo (Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
11211712|NCT03303586|Active Comparator|Healthy group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
11211713|NCT03303573||recombinant human erythropoietin group|cerebral palsy patients who had received erythropoietin from January 2013 to November 2016
11211714|NCT03303547|Experimental|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
11211715|NCT03303534|Experimental|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
11211716|NCT03303534|No Intervention|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
11211717|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
11211718|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
11211719|NCT03303508|Other|anti-ds DNA|anti-ds DNA
11211720|NCT03303495|Experimental|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1; l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1; 5-FU - bolus 400 mg/m2 IV bolus Day 1; 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
11211721|NCT03303495|Experimental|CPT-11 +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1
11211722|NCT03303482|Experimental|Intervention Group|
11211723|NCT03303482|No Intervention|Waitlist Control Group|
11211724|NCT03303469|Experimental|FMISO PET imaging post TACE and SBRT|FMISO imaging at baseline, post-TACE and post-SBRT
11211725|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
11211726|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
11211727|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
11211728|NCT03303443||Younger|20-40 years old patients
11211729|NCT03303443||Elderly|over 60 years old patients
11211730|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
11211731|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
11211732|NCT03303417|Experimental|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
11211733|NCT03303417|Placebo Comparator|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
11211734|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
11211735|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
11211736|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
11211737|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
11211738|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
11211739|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
11211740|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
11211741|NCT03303352|Experimental|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.
~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.
~For each patient, the passes order with be either done as fast pass first, slow pass second."
11211781|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
11211782|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
11211742|NCT03303352|Experimental|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.
~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.
~For each patient, the passes order with be either done as slow pass first, fast pass second."
11211743|NCT03303339|Experimental|Phase 1b: Onvansertib + low-dose cytarabine|Onvansertib, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m^2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). Onvansertib administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days. Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
11211744|NCT03303339|Experimental|Phase 1b: Onvansertib + decitabine|Onvansertib will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). Onvansertib administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days (Day 1 through Day 5). Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
11211745|NCT03303339|Experimental|Phase 2: Onvansertib + decitabine|Onvansertib recommended phase 2 dose, orally Day 1 through Day 5 every 28 days (1 cycle) and decitabine, administered consistently as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
11211746|NCT03303326|Experimental|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
11211747|NCT03303326|No Intervention|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
11211748|NCT03303313|Experimental|Cemdisiran|
11211749|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
11211750|NCT03303287|No Intervention|control|usual
11211751|NCT03303274|Experimental|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
11211752|NCT03303274|No Intervention|Supine|Catheterization of right subclavian vein in supine position.
11211753|NCT03303248|Experimental|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
11211754|NCT03303248|No Intervention|Standard of Care|This group will be given only the standard of care during their clinic visit.
11211755|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group
~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
11211756|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group
~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
11211757|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
11211758|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
11211759|NCT03303196|Experimental|Bihormonal bionic pancreas admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
11211760|NCT03303196|No Intervention|Standard care admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
11211761|NCT03303183|Active Comparator|Direct Ear Scanner|Digitale impression via direct ear scanner
11211762|NCT03303183|Active Comparator|Silicone Ear impression|Impression via silicone
11211763|NCT03303170|Experimental|Sebacia Microparticles|
11211764|NCT03303170|Active Comparator|Nd:Yag Laser|
11211765|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
11211766|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
11211767|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
11211768|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
11211769|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
11211770|NCT03303118|Other|Left|No product administration will be done in this study.
11211771|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly [except for a loading dose of 675 mg in subjects with CM]).
11211772|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
11211773|NCT03303092|Experimental|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
11211774|NCT03303092|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
11211775|NCT03303092|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
11211776|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
11211939|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
11211783|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
11211784|NCT03303040|Experimental|Stimulation|Electrical stimulation of hemidiaphragm
11211785|NCT03303040|No Intervention|Control|No stimulation of hemidiaphragm
11211786|NCT03303027|Experimental|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
11211787|NCT03303027|Experimental|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
11211788|NCT03303014|Experimental|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
11211789|NCT03303014|Experimental|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
11211790|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
11211791|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
11211792|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
11211793|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
11211794|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
11211795|NCT03302962|Experimental|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
11211796|NCT03302962|No Intervention|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
11211797|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
11211798|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
11211799|NCT03302936|Experimental|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
11211800|NCT03302936|No Intervention|Control arm|No intervention in this group. Routine perioperative care.
11211801|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
11211802|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
11211803|NCT03302923|No Intervention|Control group|No brisk walking session
11211804|NCT03302910|Experimental|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
11211805|NCT03302910|Active Comparator|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
11211806|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
11211807|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
11211808|NCT03302884|Experimental|Biological sampling in ovarian carcinoma|Blood and tumor samples
11211809|NCT03302871|Experimental|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
11211810|NCT03302871|Active Comparator|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
11211811|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
11211812|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
11211813|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
11211814|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
11211815|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
11211816|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
11211817|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
11211818|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
11211819|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
11211902|NCT03302156|Other|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
11211820|NCT03302780|Experimental|Sham tDCS and then BreEStim|This study has a single-blinded, single-center, sham-controlled, crossover design. It included a 20-min sham tDCS to the current dominant primary motor cortex(M1), followed by a 20-min BreEStim to the median nerve(160 times) transcutaneously on the current dominant side.
11211821|NCT03302780|Experimental|active tDCS (M1) and then BreEStim|This study has a single-blinded, single-center, sham-controlled, crossover design. It included a 20-min active tDCS to the current dominant primary motor cortex(M1), followed by a 20-min BreEStim to the median nerve(160 times) transcutaneously on the current dominant side.
11211822|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
11211823|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).
~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).
~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
11211824|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
11211825|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
11211826|NCT03302728|Experimental|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
11211827|NCT03302715|Experimental|Mucosal biopsies|Only blood samples and mucosal biopsies
11211828|NCT03302702|Other|Exercise program|Treatment group
11211829|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
11211830|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
11211831|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.
~Daily registrations in a patient dairy."
11211832|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
11211833|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
11211834|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
11211835|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
11211836|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
11211837|NCT03302650|Experimental|Angiotensin group|Patients will receive Angiotensin II at a starting dose of 20 ng/Kg/min. During the first 30 minutes after randomization, the angiotensin II infusion will be titrated to achieve a mean arterial pressure of 65-75 mmHg while the norepinephrine infusion will be withdrawn and stopped. Following a stabilization of 60 minutes, the angiotensin II infusion is titrated to achieve a mean arterial pressure of 85-95 mmHg. Following a 30 minutes wash-in period and a 60 minutes stabilization period, a third set of measurements will be taken. Then, the angiotensin II infusion will be withdrawn in small steps and replaced by a norepinephrine infusion which will then be titrated to achieve a mean arterial pressure of 65-75 mmHg. Then, the final set of measurements will be taken.
11211838|NCT03302650|Placebo Comparator|Normal saline group|Patients will receive normal saline infusion in addition to norepinephrine infusion. The same mean arterial pressure levels (65-75 mmHg > 85-95 mmHg > 65-75 mmHg) will be achieved by titration of the norepinephrine infusion. Identical wash-in and stabilization periods will be kept as in the study group. Measurements will be taken at the same time points as in the study group. The maximum dose of norepinephrine applied will be 0.7 mcg/kg/min.
11211839|NCT03302637||Cases|subjects with histology-confirmed incident pancreatic cancer, with no prior history of cancer (except non-melanoma skin cancer), a valid consent, and pre-diagnostic oral wash samples.
11211840|NCT03302637||Control|selected by incidence density sampling63 among cohort members who had no cancer prior to selection, provided a valid consent and an oral wash. Controls were frequency matched to cases by cohort, age at cohort entry (5 year), sex, race, and calendar year of cohort entry.
11211841|NCT03302624||Patients who were included in ELVIS study|
11211842|NCT03302611|Experimental|Surf Therapy|Participants receive a physical activity-based intervention, which in this arm is surf therapy. Each service member is paired with a surf instructor who typically works with them each week for the length of the program.
11211843|NCT03302611|Active Comparator|Hike Therapy|Participants receive a physical activity-based intervention, which in this arm is hike therapy. During hike therapy, service members may hike together or at a self-selected pace.
11211844|NCT03302598|Other|patients with enterocutaneous fistula|
11211845|NCT03302585|Experimental|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:
~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
11211903|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
11211846|NCT03302585|Placebo Comparator|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:
~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
11211847|NCT03302572|Experimental|Brief information group|Patients will be given brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
11211848|NCT03302572|No Intervention|Control group|"Patients who fall into a control group will only be attended to their reason for visiting and will be asked for the necessary data to obtain the independent variables if they do not appear in their history. If the patient in this group wants the information, he will be excluded from the study because he refuses to participate."
11211849|NCT03302559|Experimental|Retinol Complex 0.5|During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
11211850|NCT03302546|Active Comparator|Incremental Hemodialysis|Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.
11211851|NCT03302546|Active Comparator|Conventional hemodialysis|Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.
11211852|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
11211853|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
11211854|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
11211855|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
11211856|NCT03302507|Experimental|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
11211857|NCT03302507|Active Comparator|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
11211858|NCT03302494|Experimental|WaveCrest|WaveCrest left atrial appendage occluder
11211859|NCT03302494|Active Comparator|Watchman (control)|Watchman left atrial appendage closure device
11211860|NCT03302481|Experimental|Experimental Group|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
11211861|NCT03302455|Experimental|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
11211862|NCT03302455|No Intervention|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
11211863|NCT03302429|Experimental|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
11211864|NCT03302429|Active Comparator|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
11211865|NCT03302416|Experimental|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
11211866|NCT03302403|Experimental|CAR T cell|"In this study, autologous T cells transduced with a chimeric antigen receptor are used to treat patients with malignant tumors:
~CAR-CD19 T cell is for the treatment of B-cell Leukaemia/Lymphoma; CAR-BCMA T cell is for the treatment of Myeloma; CAR-GPC3 T cell is for the treatment of Hepatocellular Carcinoma; CAR-CLD18 T cell is for the treatment of Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction.
~Route of administration: Intravenous injection.
~Lymphodepletion conditioning:
~Lymphodepletion will be conducted several days prior to CAR T cell infusion, which may improve in vivo cell count and survival of T cells.
~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
11211867|NCT03302390||Biopsy of Skin with Psoriasis|Shave biopsy of psoriasis lesion
11211868|NCT03302377|Experimental|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
11211869|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
11211870|NCT03302351|Experimental|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
11211871|NCT03302351|Experimental|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
11211872|NCT03302351|Experimental|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
11211873|NCT03302338|Experimental|SAFE group|SAFE group: simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
11211874|NCT03302338|Placebo Comparator|Placebo|Placebo group: distilled water 2.5 ml/kg every 3 hours enterally given.
11211875|NCT03302325||Stage IV solid tumors|adult patients with stage IV cancer that are starting a new line of treatment
11211904|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
11211940|NCT03301870|Active Comparator|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
11211876|NCT03302312||Participants|Service members who received at least one SGB study procedure as part of the clinical effectiveness trial during the three months prior to qualitative data collection or service members who received at least one SGB for PTSD symptoms at a study site in the three months prior to qualitative data collection.
11211877|NCT03302312||Providers|Behavioral Health or other (e.g., Family Medicine) clinicians who have referred or could potentially have referred service members for SGB for PTSD symptoms, as well as physicians who provide SGBs.
11211878|NCT03302299|Experimental|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
11211879|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
11211880|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
11211881|NCT03302273|Experimental|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
11211882|NCT03302260|No Intervention|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
11211883|NCT03302260|Experimental|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
11211884|NCT03302247|Experimental|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
11211885|NCT03302234|Experimental|pembrolizumab + ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
11211886|NCT03302234|Active Comparator|pembrolizumab + placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
11211887|NCT03302221|Other|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
11211888|NCT03302221|Experimental|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
11211889|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
11211890|NCT03302208|Active Comparator|pregabalin group|
11211891|NCT03302208|Placebo Comparator|placebo group|
11211892|NCT03302195|Active Comparator|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
11211893|NCT03302195|Experimental|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
11211894|NCT03302195|Experimental|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
11211895|NCT03302195|Experimental|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.
~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
11211896|NCT03302182|Experimental|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.
~For group1:
~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
~For group2:
~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
11211897|NCT03302182|Experimental|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.
~For group3:
~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
~For group4:
~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
11211898|NCT03302169|Experimental|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
11211899|NCT03302169|Active Comparator|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
11211900|NCT03302156|Other|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
11211901|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
11211905|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
11211906|NCT03302091|Experimental|All Subjects|
11211907|NCT03302078|Experimental|Treatment T|Fed state
11211908|NCT03302078|Experimental|Treatment R|Fasted state
11211909|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
11211910|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
11211911|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
11211912|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
11211913|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
11211914|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
11211915|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
11211916|NCT03302026|Experimental|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
11211917|NCT03302026|No Intervention|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
11211918|NCT03302013|Experimental|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
11211919|NCT03302013|Active Comparator|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
11211920|NCT03302000|Experimental|Visual stimulation|"Early visual stimulation (EVS) will be implemented by caregivers.
~Three phases:
~the caregiver will establish eye-to-eye contact with the infant. The caregiver will communicate with the infant talking, singing, changing facial expressions, touching his/her face. Total duration of this part of stimulation is between 2 and 3 minutes
~the caregivers will present visual contrast cards at a distance of 15-20 centimetres
~the caregiver will present two toys to the infant
~Stimulation will last for 28 days (4 weeks) in total, one time a day for 10-15 minutes, all days week."
11211921|NCT03302000|Other|standard care|Caregivers will receive an Illustrated Handbook, according to the age range of birth to three months. Assessors will explain all information contained in the handbook after the first assessment and randomisation.
11211922|NCT03301987|Experimental|Therapeutic exercise|
11211923|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
11211924|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
11211925|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
11211926|NCT03301948|Experimental|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
11211927|NCT03301948|Experimental|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
11211928|NCT03301922|Experimental|Work-focused metacognitive therapy|Work-focused metacognitive therapy
11211929|NCT03301922|Other|Waiting list|Waiting list
11211930|NCT03301909|Experimental|PillCam™ Endoscopy System|"PillCam™ Endoscopy System consists of the following subunits:
~PillCam™ Capsule products' family:
~PillCam™ COLON 2
~PillCam™ UGI (upper gastrointestinal)
~PillCam™ SB3 (small bowel 3)
~PillCam™ Crohn's capsule
~Patency capsule: PillCam™ Patency capsule
~All the bellow system subunits are part of the Pillcam™ systems:
~PillCam™ Recorder
~PillCam™ Sensor Arrays & Sensor Belt
~PillCam™ Software v. 9
~Workstation unit"
11211931|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
11211932|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
11211933|NCT03301883|Experimental|Tocilizumab|Participants weighing greater than or equal to (>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from <30 to >/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
11211934|NCT03301870|Experimental|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
11211935|NCT03301870|Experimental|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
11211936|NCT03301870|Experimental|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
11211937|NCT03301870|Experimental|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
11211938|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
11211941|NCT03301870|Active Comparator|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
11211942|NCT03301870|Active Comparator|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
11211943|NCT03301857|Experimental|Denosumab|"Cohort A (subjects who are still being treated with denosumab when 20062004 completes): 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
~For subjects undergoing retreatment with denosumab: 120 mg administered SC on Days 1, 8, 15 and 28 then every 4 weeks subsequently."
11211944|NCT03301857|No Intervention|Safety Follow up|"Subjects still receiving treatment will have follow-up study visits in the clinic every 6 months while receiving denosumab (Cohort A).
~Subjects who completed denosumab treatment and were in safety follow-up at the conclusion of 20062004 will have follow-up visits performed every 6 months via telephone or in-person clinic visit (Cohort B)."
11211945|NCT03301844|Experimental|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
11211946|NCT03301844|Other|Standard treatment|Wet, warm gauze twice daily for one month.
11211947|NCT03301831|Experimental|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
11211948|NCT03301831|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
11211949|NCT03301818|Experimental|Patients undergoing USI repair|
11211950|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
11211951|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
11211952|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
11211953|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
11211954|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
11211955|NCT03301766|Experimental|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
11211956|NCT03301766|Active Comparator|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
11211957|NCT03301740|Experimental|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.
~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
11211958|NCT03301740|Experimental|Conventional HD Phase First|"First treatment phase begins with conventional HD.
~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
11211959|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
11211960|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
11211961|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
11211962|NCT03301714|No Intervention|Control: Standard of Care|Regular dental care under the standard clinic operation
11211963|NCT03301714|Experimental|Intervention 1: Group-based oral health education|Group based oral health education
11211964|NCT03301714|Experimental|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
11211965|NCT03301701|Experimental|Arm 1|Radical prostatectomy
11211966|NCT03301701|Active Comparator|Arm 2|Radiotherapy
11211967|NCT03301688|Experimental|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
11211968|NCT03301688|Experimental|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
11211969|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
11211970|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
11211971|NCT03301649|Experimental|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
11211972|NCT03301649|Active Comparator|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
11211973|NCT03301649|Placebo Comparator|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
11211974|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
11211975|NCT03301636|Experimental|Nivolumab + Indoximiod|
11211976|NCT03301623|Experimental|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
11211977|NCT03301623|Experimental|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.
11211978|NCT03301610|Experimental|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
11211979|NCT03301610|Placebo Comparator|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
11211980|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
11211981|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
11211982|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
11211983|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
11211984|NCT03301584|Active Comparator|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.
~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.
~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.
~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.
~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
11211985|NCT03301584|Active Comparator|Usual Care Treatment|Standard rehabilitation
11211986|NCT03301571|Other|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:
~Change in preload and afterload
~Change in inspired oxygen
~Change in pacemaker modes"
11211987|NCT03301558|Active Comparator|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
11211988|NCT03301558|Active Comparator|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
11212022|NCT03301337|Experimental|Beef|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
11211989|NCT03301545|Active Comparator|Fast-Track to Bariatric Surgery|Patients will undergo standard of care for bariatric surgery patients in Manitoba and receive preoperative evaluation by the Centre for Metabolic and Bariatric Surgery (CMBS) team of nurses, dietitians, psychologist, and kinesiologist. Patients must attend the standard appointments and achieve the personalized program goals to be approved for laparoscopic Roux-En-Y gastric bypass surgery. Once approved, one of four surgeons performs surgery (within 12 months of randomization). Patients are followed post-operatively (by surgeon) at 6 weeks, and at 6 and 12 months. Pharmacologic glycemic control will be determined by an endocrinologist as per a standardized post-operative protocol. Post-procedural multidisciplinary follow-up occurs based on established CMBS guidelines (phone call 1 week post-operatively and an appointment at 3 and 12 months). Patients receive surgery within the current publically funded bariatric surgery program; no additional direct costs incurred by the patients.
11211990|NCT03301545|No Intervention|Best Diabetic Care Group|Patients will receive the best available medical practice for the treatment, education, and follow-up T2DM based on Manitoba Diabetes Care Recommendations and Diabetes Canada's clinical practice guidelines. Patients will have access to a general physician, endocrinologist, and a diabetes education nurse. An Endocrinologist will deliver the program to patients. Diabetes care, education and self-management support services will be provided by the Victoria General Hospital (VGH) Diabetes Education Centre; led by a registered nurse and dietitian. Patients will undergo individual diabetes management instruction which may include counseling on topics such as diet, exercise, smoking cessation, medications, diabetic complications, and blood sugar testing. Medical therapies, including pharmaceutical agents, will be determined on an individual basis as per standard protocol. There will be no direct patient-related medication costs (publicly funded).
11211991|NCT03301545|No Intervention|Retrospective Cohort|A retrospective cohort of non-Indigenous bariatric surgery patients from the Centre for Metabolic and Bariatric Surgery Program will allow comparison with the intervention group. The cohort will be age and gender matched.
11211992|NCT03301532|Experimental|Patients on a ketogenic diet|This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
11211993|NCT03301506|Experimental|Seladelpar 5 mg Capsules|
11211994|NCT03301506|Experimental|Seladelpar 10 mg Capsule|
11211995|NCT03301480||No contraception/18-19 years old|
11211996|NCT03301480||Use of ENG-I/18 - 19 years old|
11211997|NCT03301480||LNG-IUS/18-19 years old|
11211998|NCT03301480||No Contraception/ 25 - 45 years old|
11211999|NCT03301480||Use of ENG-I/25 - 45 years old|
11212000|NCT03301480||LNG-IUS/25-45 years old|
11212001|NCT03301467|Experimental|Avacopan|Avacopan (formerly CCX168) 10 mg capsules x 3 administered twice daily during the blinded 26 week blinded treatment period
11212002|NCT03301467|Placebo Comparator|Avacopan Matching Placebo|Matching placebo capsules x 3 administered twice daily during the 26 week blinded treatment period period
11212003|NCT03301454|Experimental|Arm A|Pursuit of chemotherapy.
11212004|NCT03301454|No Intervention|Arm B|Interruption of chemotherapy, best supportive care
11212005|NCT03301441||Migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine (Classification into migraine without or with aura)
11212006|NCT03301441||Non migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine A short questionnaire validating the absence of migraine
11212007|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
11212008|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
11212009|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
11212010|NCT03301415|Experimental|Confirmed congenital CMV without baseline SNHL|Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229
11212011|NCT03301402|Active Comparator|Filter|
11212012|NCT03301402|No Intervention|No filter|
11212013|NCT03301389||Control group|
11212014|NCT03301389||Pretreatment group|Patients in pretreatment state
11212015|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
11212016|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
11212017|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
11212018|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
11212019|NCT03301350|Experimental|Neoadjuvant Chemotherapy|"Regimen A (cycles 1-4):
~Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks)
~Regimen B (cycles 5-8):
~Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)
~There is a one week break between the end of cycle 4 and the beginning of cycle 5.
~Regimen C:
~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
11212020|NCT03301337|Experimental|Hydrolyzed meat protein|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
11212021|NCT03301337|Experimental|Minced Meat|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
11212049|NCT03301155|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Anaferon for children scheme.
11212023|NCT03301311|Experimental|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
11212024|NCT03301311|Experimental|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
11212025|NCT03301298|Experimental|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
11212026|NCT03301298|Experimental|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
11212027|NCT03301298|Experimental|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
11212028|NCT03301298|Experimental|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
11212029|NCT03301298|Experimental|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
11212030|NCT03301298|Experimental|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
11212031|NCT03301298|Placebo Comparator|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
11212032|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
11212033|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
11212034|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
11212035|NCT03301259|Experimental|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.
~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
11212036|NCT03301259|Experimental|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
11212037|NCT03301246|Experimental|Artimes Pro Low Profile Dilatation Catheter|Subjects who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional PTCA catheters and stents, according to standard of care will be enrolled in this study.
11212038|NCT03301233|Active Comparator|estradiol valerate|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma). One tablet every 12 hour from 2nd day of the cycle till the day of trigger of ovulation).
11212039|NCT03301233|Experimental|estradiol valerate and sildenafil|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25 mg, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
11212040|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
11212041|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
11212042|NCT03301207|Experimental|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
11212043|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
11212044|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
11212045|NCT03301181|Experimental|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
11212046|NCT03301181|Experimental|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
11212047|NCT03301168|Experimental|BPX-501 T cells and Rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.
~Rimiducid: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment."
11212048|NCT03301155|Experimental|Anaferon for children|"Tablet for oral use. One tablet per intake, once daily (approximately at the same time).
~The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature."
11212050|NCT03301142|Experimental|Device laser|treatment with application of Erbium Laser: YAG 2940nm, SMOOTH mode, one session per month for three months (n=20
11212051|NCT03301142|Active Comparator|kinesiotherapy|with supervision twice a week for three months (n=20)
11212052|NCT03301129|Experimental|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
11212053|NCT03301129|Experimental|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
11212054|NCT03301129|Experimental|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
11212055|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
11212056|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
11212057|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.
~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
11212058|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.
~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
11212059|NCT03301090|Experimental|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
11212060|NCT03301090|Experimental|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
11212061|NCT03301090|Experimental|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
11212062|NCT03301090|Experimental|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
11212063|NCT03301090|Experimental|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
11212064|NCT03301090|Experimental|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
11212065|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
11212066|NCT03301064|Experimental|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
11212067|NCT03301064|Active Comparator|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
11212068|NCT03301051|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
11212069|NCT03301051|Placebo Comparator|Placebo|Single dose - Placebo
11212070|NCT03301038|Experimental|All Subjects|
11212071|NCT03301025|Active Comparator|Pregabalin group|(n=53):
11212072|NCT03301025|Placebo Comparator|placebo group|(n=53):
11212073|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
11212074|NCT03301012|Experimental|Smartphone Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-A mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
11212075|NCT03300999|Experimental|Ginger Tea|"End of the second menstruation cycle - Start of the third menstruation cycle: Subjects will take ginger tea daily, avoid home remedies, refrain from taking pain medications and supplements, and keep track of ginger tea intake by placing a check mark each day in the daily log checklist.
~Start of the third menstruation cycle - End of the third menstruation cycle: Subjects will drink ginger tea daily. Subjects will rate discomfort using the visual analog pain scales and the symptom checklist at the end of each day during menstruation.
~After the third menstruation cycle ends: Subjects will meet with student investigators at a location convenient to the subject to turn in daily logs, visual analog pain scales, and symptom checklists."
11212076|NCT03300999|No Intervention|No Ginger Tea|"End of the first menstruation cycle - Start of the second menstruation cycle: Subjects will not take ginger tea, avoid home remedies, and refrain from taking pain medications or supplements.
~Start of the second menstruation cycle - End of the second menstruation cycle: Subjects will rate discomfort using the visual analog pain scales and symptom checklist during menstruation. Subjects will meet with student investigators at a convenient location to the subject and will complete surveys and questionnaires. Subjects will be given daily logs, visual analog pain scales, symptom checklists, and supplies for the ginger tea."
11212077|NCT03300986||Functional Electrical Stimulation (FES) users|
11212078|NCT03300973|Active Comparator|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
11212079|NCT03300973|Active Comparator|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
11212080|NCT03300960|Experimental|Provera|
11212081|NCT03300960|Active Comparator|Orgalutrán Ganirelix (GnRH antagonist)|
11212082|NCT03300947|Experimental|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
11212083|NCT03300947|Experimental|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
11212084|NCT03300947|Placebo Comparator|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
11212085|NCT03300934|Experimental|closed loop glucose control system|Closed loop glucose control system
11212086|NCT03300934|No Intervention|CSII Pump treatment|CSII Pump treatment without the integrated algorithm and glucose sensor
11212087|NCT03300921|Experimental|Arm A|Arm A: 50mcg IV weekly
11212088|NCT03300921|Experimental|Arm B|Arm B: 12mcg PO daily
11212089|NCT03300908|Experimental|Project ADHERE|Participants will receive a 3-session antiretroviral medication adherence and risk reduction intervention called Project ADHERE.
11212090|NCT03300908|Active Comparator|Control MACE|Participants will receive a one-session antiretroviral medication adherence intervention called MACE.
11212091|NCT03300895|Experimental|High-intensity interval training|
11212092|NCT03300895|Active Comparator|Moderate-intensity continuous exercise|
11212093|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
11212094|NCT03300856||Chart Review|Existing records of patients within the NINDS database who have had TMS performed to measure central motor conduction time (CMCT).
11212095|NCT03300843|Experimental|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
11212096|NCT03300830||Group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease.
11212097|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
11212098|NCT03300804|Active Comparator|20-herb formulation|Active herb
11212099|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
11212100|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
11212101|NCT03300778|Experimental|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
11212102|NCT03300778|Placebo Comparator|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
11212103|NCT03300765|Experimental|Apatinib with IMRT|Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)
11212104|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
11212105|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
11212106|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
11212107|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
11212108|NCT03300713|Experimental|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
11212109|NCT03300713|Sham Comparator|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
11212110|NCT03300687|Active Comparator|Active|Subjects will receive FX-322 as an intratympanic injection
11212111|NCT03300687|Placebo Comparator|Placebo|Subjects will receive Placebo as an intratympanic injection
11212112|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
11212113|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
11212114|NCT03300661|Experimental|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
11212115|NCT03300648|No Intervention|Unual care|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees
11212116|NCT03300648|Experimental|Mechanical ventilation|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days
11212117|NCT03300648|Experimental|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
11212118|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
11212119|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
11212120|NCT03300609|Experimental|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE:
~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
11212121|NCT03300609|Active Comparator|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE:
~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11212122|NCT03300596|Experimental|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
11212123|NCT03300596|Other|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
11212124|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
11212125|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
11212126|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
11212127|NCT03300570|Experimental|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
11212128|NCT03300570|Placebo Comparator|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
11212129|NCT03300557|Experimental|Treatment (exemestane)|Patients receive exemestane PO QD over 21-42 days in the absence of disease progression or unaccepted toxicity. Patients undergo standard of care surgery between days 22-43.
11212130|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
11212131|NCT03300531|Experimental|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
11212132|NCT03300531|Experimental|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
11212133|NCT03300531|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
11212134|NCT03300518|Other|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
11212135|NCT03300518|Other|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
11212136|NCT03300505|Experimental|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.
~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
11212137|NCT03300492|Experimental|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days
~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
11212138|NCT03300479|Experimental|Clevidipine|The treatment starts at admission to the ICU for 24 hours with 2 mg to a maximum of 16 mg Clevidipine per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
11212279|NCT03299439|Experimental|acupuncture at highly sensitive points|
11212139|NCT03300479|Active Comparator|Urapidil|The treatment starts at admission to the ICU for 24 hours with 5 mg to a maximum of 40 mg Urapidil per hour infused intravenously and continuously to reach the systolic target pressure < 160 mmHg (>120 mmHg).
11212140|NCT03300466|Experimental|GP0045|Treatment with GP0045
11212141|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
11212142|NCT03300453|Experimental|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
11212143|NCT03300440|Experimental|Intervention group|Probiotics and vitamin B7
11212144|NCT03300440|Placebo Comparator|Control group|Placebo and vitamin B7
11212145|NCT03300427|Experimental|sacubitril/valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. Two strengths of sacubitril/valsartan will be available for use after randomization, 49 mg sacubitril/51 mg valsartan and 97 mg sacubitril/103 mg valsartan. After randomization, subjects in this arm will receive sacubitril/valsartan 100 mg orally twice daily (BID). The dose will be then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration is not possible). Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate the 100 mg BID dose at the minimum. In total, participants will be on sacubitril/valsartan for a minimum of 8 weeks and a maximum of 10 weeks.
11212146|NCT03300427|Active Comparator|valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. In this arm, Valsartan 80 mg and 160 mg will be used as comparative drug, taken orally BID at home. Depending on the screening/run-in dose the subjects in this arm will get either valsartan 80 mg BID or valsartan 160 mg BID. During the treatment period the dose of valsartan will be up-titrated to the highest tolerated dose (160 mg BID) or maintained at 80 mg BID if up-titration is not possible. Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate at least 80 mg BID dose of valsartan. The treatment phase will be a minimum of 8 weeks, and a maximum of 10 weeks.
11212147|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
11212148|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
11212149|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
11212150|NCT03300388|Placebo Comparator|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
11212151|NCT03300388|Experimental|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
11212152|NCT03300388|Experimental|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
11212153|NCT03300388|Experimental|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
11212154|NCT03300375|Active Comparator|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
11212155|NCT03300375|Experimental|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
11212156|NCT03300362|Experimental|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1
11212157|NCT03300362|Placebo Comparator|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride
11212158|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
11212159|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
11212160|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
11212161|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
11212162|NCT03300336|Experimental|Intervention|Implementation of STRIDE program
11212163|NCT03300336|No Intervention|Usual Care|Pre-implementation before STRIDE program
11212164|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
11212165|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
11212166|NCT03300310|Experimental|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
11212167|NCT03300310|Experimental|without nursing visit|no nursing visit
11212168|NCT03300297|Active Comparator|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
11212169|NCT03300297|Sham Comparator|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
11212170|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
11212171|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
11212172|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
11212173|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
11212174|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
11212175|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
11212176|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
11212177|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
11212178|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
11212179|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
11212180|NCT03300232|No Intervention|Treatment as Usual|Participants randomized to the treatment as usual control condition will not undergo the CBT therapy.
11212181|NCT03300219|Experimental|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
11212182|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
11212183|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
11212184|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
11212185|NCT03300180|No Intervention|Control|The patients in this group will receive no AD screening
11212186|NCT03300180|Active Comparator|Screening Only|The patients in this group will receive screening for AD. Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic and some information about local clinical resources for them to peruse regarding follow-up care. The patient's PCP is also be notified of the screening results via EHR message.
11212187|NCT03300180|Experimental|Collaborative Dementia Care Program|The patients in this group will receive screening for AD, Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic. Also, the family member will receive two follow-up phone calls. One from the COADS Study Coordinator and one from a care coordinator at the Aging Brain Care Program (ABC). This phone call will include an opportunity for the family to ask questions and a conversation about the program and diagnostic evaluation and management. Dyads have the option to refuse the follow-up visit. The patient's PCP is also be notified of the screening results via EHR message,
11212188|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
11212189|NCT03300154|Experimental|Financial incentives|
11212190|NCT03300154|Experimental|Framing (SMS)|
11212191|NCT03300154|No Intervention|Usual care|
11212192|NCT03300141|Active Comparator|Healthy|Healthy participants will participate in reaching activity using the Looking Glass and Leap motion tracking system
11212193|NCT03300141|Experimental|Chronic Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
11212194|NCT03300141|Experimental|Chronic Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
11212195|NCT03300141|Experimental|Acute Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
11212196|NCT03300141|Experimental|Acute Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
11212197|NCT03300128|Experimental|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
11212280|NCT03299439|Active Comparator|acupuncture at lowly/non-sensitive points|
11212198|NCT03300128|Active Comparator|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
11212199|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
11212200|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
11212201|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
11212202|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
11212203|NCT03300063|No Intervention|control|Standard Medical care
11212204|NCT03300063|Active Comparator|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
11212205|NCT03300050|Experimental|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants will receive 0.5mL cH8/1N1 LAIV administered as 0.25mL per nostril on D1 followed by 0.5mL cH5/1N1 IIV + AS03A administered as an injection on D85.
11212206|NCT03300050|Experimental|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants will receive 0.5mL cH8/1N1 LAIV administered as 0.25mL per nostril on D1 followed by 0.5mL cH5/1N1 IIV administered as an injection on D85.
11212207|NCT03300050|Placebo Comparator|Group 3: Placebo|Participants will receive 0.5mL of normal saline administered as 0.25mL per nostril on D1 followed by 0.5mL phosphate buffered saline administered as an injection on D85.
11212208|NCT03300050|Experimental|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants will receive 0.5mL of cH8/1N1 IIV + AS03A administered as an injection on D1 followed by 0.5mL cH5/1N1 IIV + AS03A administered as an injection on D85.
11212209|NCT03300050|Placebo Comparator|Group 5: Placebo|Participants will receive 0.5mL phosphate buffered saline administered as an injection on D1 followed by 0.5mL phosphate buffered saline administered as an injection on D85.
11212210|NCT03300024|Active Comparator|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
11212211|NCT03300024|Experimental|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
11212212|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
11212213|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
11212214|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
11212215|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
11212216|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
11212217|NCT03299985|Experimental|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
11212218|NCT03299985|Sham Comparator|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
11212219|NCT03299972|Placebo Comparator|Control|
11212220|NCT03299972|Experimental|Whey Protein|
11212221|NCT03299972|Experimental|Resistance Exercise + Control|
11212222|NCT03299972|Experimental|Resistance Exercise + Whey Protein|
11212223|NCT03299959|Experimental|Agili-C|
11212224|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
11212225|NCT03299946|Experimental|Arm 1|
11212226|NCT03299920|Active Comparator|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
11212227|NCT03299920|Other|Control|Patient will receive conventional instructions on postoperative pain management.
11212228|NCT03299907||COPD|Subject with FEV1/FVC post BD < 0.7 or LLN
11212229|NCT03299907||Non COPD|Subject with FEV1/FVC post BD >= 0.7 or LLN
11212230|NCT03299894|Experimental|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
11212231|NCT03299894|No Intervention|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
11212232|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
11212233|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
11212234|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
11212235|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
11212236|NCT03299842|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
11212281|NCT03299439|No Intervention|no acupuncture (waiting-list)|
11212237|NCT03299816|Active Comparator|Self-Shopping DASH group (S-DASH)|The Self-Shopping DASH group will receive printed patient-centered materials on the DASH diet and chronic kidney disease. Participants will also receive $30/week allowance for the purchase of food and drinks of their choosing from a local grocer (Klein's ShopRite stores of Maryland) during the first four months. During the remainder of the study (months 5-12), the participants in this group will be asked to continue to follow the dietary advice provided but will not receive the food allowance.
11212238|NCT03299816|Experimental|Coaching DASH group (C-DASH)|The C-DASH group intervention will be a patient-tailored program, delivered by a study coach that is trained by a dietitian, which emphasizes key self-management behaviors - diet and self-monitoring. This group will receive advice from the study coach and purchase $30 worth of fresh fruits, vegetables, nuts and beans that are high in potassium on a weekly basis for the first four months.
11212239|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
11212240|NCT03299803|No Intervention|Control group|Telephone contact only
11212241|NCT03299790|Active Comparator|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
11212242|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
11212243|NCT03299790|No Intervention|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
11212244|NCT03299790|No Intervention|Healthy controls|
11212245|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
11212246|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
11212247|NCT03299764|Experimental|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
11212248|NCT03299764|Active Comparator|Control|Non-invasive ventilation with standard non-invasive ventilation device
11212249|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
11212250|NCT03299738|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
11212251|NCT03299725|Experimental|Treatment arm|
11212252|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
11212253|NCT03299686|Experimental|CJM112|Study treatment
11212254|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
11212255|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
11212256|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
11212257|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
11212258|NCT03299621|Experimental|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
11212259|NCT03299621|Experimental|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
11212260|NCT03299582|Experimental|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
11212261|NCT03299582|Experimental|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
11212262|NCT03299582|Experimental|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
11212263|NCT03299582|Experimental|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
11212264|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
11212265|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
11212266|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
11212267|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
11212268|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
11212269|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
11212270|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
11212271|NCT03299517|Experimental|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).
~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
11212272|NCT03299517|Experimental|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)
~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
11212273|NCT03299491|Experimental|MWA+IEC intervention|
11212274|NCT03299491|Experimental|IEC intervention|
11212275|NCT03299491|No Intervention|Control|
11212276|NCT03299478||NSCLC patients|
11212277|NCT03299465|Experimental|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
11212278|NCT03299452|Experimental|Alphacait-guided therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
11212282|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
11212283|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
11212284|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
11212285|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
11212286|NCT03299387|Active Comparator|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
11212287|NCT03299387|Active Comparator|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
11212288|NCT03299374|Active Comparator|Falls Group|Falls prevention intervention
11212289|NCT03299374|Experimental|Pilates Group|Pilates intervention
11212290|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
11212291|NCT03299348|Placebo Comparator|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
11212292|NCT03299335|Other|Early-stage sIMB patients|
11212293|NCT03299335|Other|Late-stage sIMB patients|
11212294|NCT03299335|Other|Control subjects|
11212295|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
11212296|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
11212297|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
11212298|NCT03299309|Experimental|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
11212299|NCT03299296|Experimental|Rivaroxaban arm|Rivaroxaban 10 Milligrams
11212300|NCT03299296|Active Comparator|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
11212301|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
11212302|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
11212303|NCT03299270||Group 1|Elderly patiences with solid malignancy
11212304|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
11212305|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
11212306|NCT03299244|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may be titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
11212307|NCT03299244|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may be titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
11212308|NCT03299231|Active Comparator|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
11212309|NCT03299231|Sham Comparator|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
11212310|NCT03299218|No Intervention|Control|Receiving current Government of Punjab health services
11212311|NCT03299218|Experimental|Cash-based transfers|Cash-based transfers only by BISP
11212312|NCT03299218|Experimental|Cash with SBCC|Cash-based transfers and Social & behaviour change communication (SBCC)
11212313|NCT03299218|Experimental|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
11212314|NCT03299218|Experimental|Cash,SNF (Wawamum) & SBCC|Cash-based transfers, SNF (Wawamum) and SBCC
11212315|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
11212316|NCT03299192|Experimental|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
11212317|NCT03299192|Active Comparator|Health Education|twice weekly classes for 12 weeks
11212318|NCT03299192|Active Comparator|Usual Medical Care|the usual care to which participants are entitled by their health insurance
11212346|NCT03298971||Healthy Subjects|Healthy Subjects were invited to fill in a set of questionnaires.
11212319|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
11212320|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
11212321|NCT03299166|Experimental|BHV-4157|
11212322|NCT03299166|Placebo Comparator|Placebo|
11212323|NCT03299153|Experimental|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
11212324|NCT03299153|No Intervention|control group|patients in this group received no intervention
11212325|NCT03299140|Other|Family Focused Therapy|Only 1 arm
11212326|NCT03299127|Experimental|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
11212327|NCT03299127|No Intervention|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
11212328|NCT03299114|Active Comparator|Intervention Group|Treated with warm whirlpool
11212329|NCT03299114|Placebo Comparator|Placebo group|Treated with sham whirlpool
11212330|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
11212331|NCT03299088|Experimental|Arm A (trametinib, pembrolizumab)|Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11212332|NCT03299088|Experimental|Arm B (pembrolizumab, trametinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Beginning on day 1 of course 2, patients also receive trametinib PO daily. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11212333|NCT03299062|Active Comparator|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
11212334|NCT03299062|Active Comparator|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
11212335|NCT03299062|Placebo Comparator|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
11212336|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
11212337|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
11212338|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
11212339|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
11212340|NCT03299036|Experimental|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
11212341|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
11212342|NCT03298997|Experimental|Ligation and Hemorrhoidopexy|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Introduction of a proctoscope. Identification of the hemorrhoidal nodules (3rd, 7th, 11th hour). Confirmation of the hemorrhoidal artery location, through palpation. Ligation of the hemorrhoidal nodules using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).
~Placement of a fixative suture in the hemorrhoidal nodule and then performance of hemorrhoidopexy Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to pudendal nerve block. Using an atraumatic 25 Gauge (G) needle, a 20ml lidocaine solution (diluted with saline in a 1:1 rate) will be administered bilaterally, medially to the ischial tuberosity.
~10 minutes before the operation, the patient will receive 1-2.5mg midazolam and 0.1-0.2 mg fentanyl."
11212343|NCT03298997|Active Comparator|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Use of a proctoscope combined with a Doppler sensor. After the hemorrhoidal artery localization, Z ligations will be placed, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).
~The proper artery ligation will be confirmed by the absence of the Doppler signal.
~In the presence of residual hemorrhoidal tissue hemorrhoidopexy will be performed, by applying a continuous suture.
~Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to spinal anesthesia. Using an atraumatic 25 Gauge (G) needle, a levobupivacaine 5mg/ml and fentanyl 25mg solution, will be administered at the height of lumbar (L)2-L3 or L3-L4."
11212344|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
11212345|NCT03298971||Survivors of Childhood Osteosarcoma|Survivors of Childhood Osteosarcoma were invited to fill in a set of questionnaires.
11212483|NCT03297918|No Intervention|Control group|no intervention
11212347|NCT03298958|Placebo Comparator|Placebo Oral Tablet|Subject will be randomized to take the Placebo once daily for 2 years or until disease recurrence
11212348|NCT03298958|Active Comparator|Sirolimus (Rapamycin) 0.5 mg/day for 2 years|Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence
11212349|NCT03298945|Active Comparator|Golytely|4-L split-dose Golytely bowel prep
11212350|NCT03298945|Experimental|Miralax-Gatorade prep|2-L split-dose Miralax-Gatorade bowel prep
11212351|NCT03298919|Experimental|Exercise Videogames|Exercise videogames 3 times weekly for 12 weeks followed by 6 months of home practice
11212352|NCT03298919|Active Comparator|Standard Exercise|Exercise using aerobic equipment such as stationary bikes and treadmills 3 times weekly for 12 weeks followed by home practice
11212353|NCT03298919|No Intervention|Wellness Control|Weekly mailings on general health and wellness topics for 12 weeks followed by monthly mailings for 6 months.
11212354|NCT03298906|Experimental|Esketamine + Ticlopidine|Participants will self-administer one 14 milligram (mg) spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg (Treatment A) in Treatment Period 1. After that participants will receive 250 mg of ticlopidine tablets orally twice daily on Day -9 through Day 1, and will self-administer one 14 mg spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later in the morning of Day 1, a total dose of 56 mg (Treatment B) in Treatment Period 2. A washout period of greater than or equal to (>=)10 days will separate the esketamine self-administrations between 2 treatment periods.
11212355|NCT03298893|Experimental|Nivolumab + radiochemotherapy|5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone
11212356|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
11212357|NCT03298867|Active Comparator|Teprotumumab 20 mg/kg|Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
11212358|NCT03298867|Placebo Comparator|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
11212359|NCT03298828|Experimental|CD19 CAR|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR T-cells.
11212360|NCT03298828|Experimental|CD19 CAR and PD-1 knock out|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR and PD-1 knock out engineered T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR and PD-1 knock out engineered T-cells.
11212361|NCT03298815|Active Comparator|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
11212362|NCT03298815|Placebo Comparator|Saline Solution - All participants, One eye|
11212363|NCT03298802|Active Comparator|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
11212364|NCT03298802|Placebo Comparator|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
11212365|NCT03298789|Experimental|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
11212366|NCT03298789|Other|Control|7 series of static stretching will be conducted in the control condition.
11212367|NCT03298776|Active Comparator|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
11212368|NCT03298776|Experimental|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
11212369|NCT03298763|Experimental|Phase 1 - RP2D finding study|Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients
11212370|NCT03298763|Active Comparator|Phase 2 Intervention Arm|"Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.
~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
11212371|NCT03298763|Placebo Comparator|Phase 2 Control Arm|"cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.
~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
11212372|NCT03298750|Experimental|Mechanical stimulation|Mechanical stimulation of ovarian tissue
11212373|NCT03298737||Correct to normal vision population|
11212374|NCT03298724|Experimental|TAPP Intervention|The Teachers and Partners intervention will be provided
11212375|NCT03298698|Experimental|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
11212376|NCT03298698|Active Comparator|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
11212377|NCT03298685||CF patient and parents cohort in 3 CF center|All adolescents for whom the transition to the adult center is scheduled within six months and their parent will be interviewed before and after transition.
11212378|NCT03298672|Experimental|NDX-1017|NDX-1017 will be administered via subcutaneous injection
11212379|NCT03298672|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection
11212380|NCT03298659|Experimental|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
11212381|NCT03298659|Active Comparator|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
11212769|NCT03295955|Active Comparator|Postop antibiotics group|Prescribe Amoxicillin Clavulanate
11212382|NCT03298646|Experimental|Lidacaine hydrochloride|"Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.
~22 women."
11212383|NCT03298646|Active Comparator|Diclofenac|"100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.
~22 women."
11212384|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
11212385|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
11212386|NCT03298620|Experimental|Intervention|Electric toothbrush
11212387|NCT03298620|Active Comparator|Control|New standard manual toothbrush
11212388|NCT03298607|Placebo Comparator|Placebo|2 capsules daily for 2 months containing inactive substances
11212389|NCT03298607|Active Comparator|Serelys PMS|2 capsules daily for 2 months containing pollen extract
11212390|NCT03298594|Experimental|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
11212391|NCT03298594|No Intervention|Usual cervicograph|The usual cervicograph in our unit is not having lines
11212392|NCT03298581|Experimental|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
11212393|NCT03298568|Experimental|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
11212394|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
11212395|NCT03298555|No Intervention|Control|This group will only receive standard care.
11212396|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
11212397|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
11212398|NCT03298529|Experimental|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
11212399|NCT03298529|Experimental|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
11212400|NCT03298529|Experimental|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
11212401|NCT03298529|Experimental|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
11212402|NCT03298529|Experimental|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
11212403|NCT03298516|Experimental|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11212404|NCT03298516|Experimental|Arm B: DCLL9718S and Azacitidine|Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
11212405|NCT03298503|Active Comparator|early stage or non-freezers PD|"early stage defined as modified Hoehn and Yahr scale 1, 1.5 and 2, means that symptoms involved unilateral or bilateral without impairment of balance.
~non-freezers defined as without freezing of gait, means that patients without transient inability to generate effective stepping."
11212406|NCT03298503|Experimental|moderate stage or freezers PD|"moderate stage defined as modified Hoehn and Yahr scale 2.5 and 3, means that symptoms involved unilateral or bilateral without impairment of balance.
~freezers defined as with freezing of gait, means that patients have transient inability to generate effective stepping."
11212407|NCT03298477|Other|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
11212408|NCT03298464|Experimental|NGM313|
11212409|NCT03298464|Active Comparator|Pioglitazone|
11212410|NCT03298451|Experimental|Arm 1|Durvalumab
11212411|NCT03298451|Experimental|Arm 2|Durvalumab in combination with tremelimumab (Regimen 1)
11212412|NCT03298451|Experimental|Arm 3|Durvalumab in combination with tremelimumab (Regimen 2)
11212413|NCT03298451|Active Comparator|Arm 4|Sorafenib
11212486|NCT03297879|Experimental|exenatide group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
11212414|NCT03298425|Active Comparator|Treatment NMES|Patients allocated to the NMES group will be given an information booklet on NMES machines. The Cefar Compex three electrical stimulator will be used. Participants are expected to use the NMES machine for half an hour and complete bed exercises twice daily. Patients should relax during the NMES as completing both does not demonstrate better results, due to unsynchronised activation of the NMES (Gregory & Bickel, 2005). Using the machine once daily will allow for the recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
11212415|NCT03298425|Placebo Comparator|Placebo NMES|The placebo group will act as the control group. They will be expected to complete the same regime as previously described above, however these machines will be on TENS setting (80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is designed as a sensory stimulus therefore will have no effects on muscle strength however the patient will feel a small twitch sensation. This setting is not painful and will have no effect on muscle fatigue. The patient will not be expected to complete the bed exercises and the TENS session together.
11212416|NCT03298412|Experimental|Blinatumomab|"After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1).
~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval."
11212417|NCT03298399|Experimental|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
11212418|NCT03298399|Experimental|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
11212419|NCT03298399|Experimental|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
11212420|NCT03298386|Experimental|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
11212421|NCT03298386|No Intervention|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
11212422|NCT03298373|Placebo Comparator|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
11212423|NCT03298373|Experimental|11β-MNTDC|11β-MNTDC capsules administered orally (200 mg or 400 mg).
11212424|NCT03298347|Experimental|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP.
11212425|NCT03298347|Active Comparator|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP.
11212426|NCT03298334|Active Comparator|Receives Vaginal Seeding|
11212427|NCT03298334|Sham Comparator|No Vaginal Seeding|
11212428|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
11212429|NCT03298308|Experimental|Brainwave|Brainwave analysis after cranial electric stimulation
11212430|NCT03298295|Experimental|Insertion of Insulin Infusion Catheters|Non-diabetic patients scheduled for abdominoplasty will be inserted continuous subcutaneous insulin infusion (CSII) catheters of two different materials into the part of the abdomen which will be removed during surgery.
11212431|NCT03298282||Imaging Registry|Imaging cohort: Patients with intermediate lesions
11212432|NCT03298269|Experimental|Mindfulness-Oriented Recovery Enhancement|
11212433|NCT03298269|Active Comparator|Supportive Counseling|
11212434|NCT03298256||Lenke type 1 AIS|Patients will be given a new prescription for a custom made Boston type thoracic-lumbo- sacral-orthosis (TLSO) braces. All patients will undergo low dose biplanar X-rays using the EOS ® machine system.
11212435|NCT03298243|Experimental|Stroke Cohort - Optimize Delivery|Aim 1 intervention: Vibrotactile stimulation. An optimal location and style of vibrotactile feedback for reach and stabilization behaviors will be determined.
11212436|NCT03298243|Experimental|Stroke Cohort - Extended Training|Aim2 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching and stabilizing tasks using vibrotactile feedback to guide performance
11212437|NCT03298230|Experimental|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
11212438|NCT03298230|Active Comparator|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
11212439|NCT03298217|Other|Bronchiolitis patients sverity|In patients with bronchiolitis mWCAS / 3-5 : Measurement of the peak tidal inspiratory flow (PTIF)
11212440|NCT03298204||Chemoradiotherapy|
11212441|NCT03298204||Chemoradiotherapy following chemotherapy|
11212442|NCT03298204||Chemoradiotherapy followed by chemotherapy|
11212443|NCT03298191|Experimental|Magnesium sulphate|
11212444|NCT03298191|Experimental|Ritodrine|
11212445|NCT03298191|Experimental|Calcium channel blocker|
11212446|NCT03298178||all aortic stenosis|
11212447|NCT03298165|Experimental|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
11212448|NCT03298165|Placebo Comparator|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
11212449|NCT03298152|Active Comparator|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
11212484|NCT03297905|Experimental|Complementary and Integrative Therapies|Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
11212485|NCT03297905|Active Comparator|Standard Rehabilitative Care|Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
11212450|NCT03298152|Experimental|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
11212451|NCT03298139|Experimental|parabolic flights|parabolic flights in normogravity (1g), hypergravity (1.8g) and microgravity (0g).
11212452|NCT03298126|Active Comparator|TR BAND Protocol A|In this group, air removal from TR band was initiated after 2 hours of TR band application. 3 ml of air was removed periodically at an interval of 15 minutes until all the air is eliminated from the band. In case of bleeding or hematoma while deflating air, 4 ml of air was re-injected and observed for 30 minutes until next attempt was made to deflate the band. The data including the attempts made at deflating TR band, time and amount of air injected along with the response to each deflation i.e. occurrence of bleeding or hematoma was noted down in the proforma
11212453|NCT03298126|Active Comparator|TR BAND PROTOCOL B|In this group deflation was initiated after 2 hours of TR band application as described by Cohen and Alfonso. [6] 5 ml of air was deflated at first attempt. Next attempt was carried out after 15 minutes in which further 5 ml was removed. After 15 minutes, the remaining 2 ml of air was released from the band. In case of bleeding or hematoma at any attempt, 6 ml air was re-injected and interval for 15 minutes taken to attempt further air deflation. All the attempts and its response were recorded in the proforma filled out by the assessor.
11212454|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
11212455|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
11212456|NCT03298100||Postmenopausal women|
11212457|NCT03298087|Experimental|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
11212458|NCT03298074|Experimental|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
11212459|NCT03298074|Active Comparator|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
11212460|NCT03298061|Experimental|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
11212461|NCT03298048|Active Comparator|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
11212462|NCT03298048|Active Comparator|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
11212463|NCT03298048|Active Comparator|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
11212464|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
11212465|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
11212466|NCT03298022|Experimental|AbGn-168H|intravenous doses of AbGn-168H
11212467|NCT03298009|Placebo Comparator|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
11212468|NCT03298009|Experimental|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
11212469|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
11212470|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
11212471|NCT03297983|Experimental|First M7583 Tablet:Fasted, Then PiC:Fasted, Then Tablet:Fed|
11212472|NCT03297983|Experimental|First M7583 PiC:Fasted, Then Tablet:Fasted, Then Tablet:Fed|
11212473|NCT03297970||Bogota School Children Cohort|"Children are classified according to exposure levels of:
~Micronutrient biomarker indicators:
~Ferritin
~Hemoglobin
~Mean corpuscular volume
~Zinc
~Vitamin A
~Vitamin B12
~Folate
~Vitamin D
~Serum fatty acids
~Inflammatory biomarkers:
~C-reactive protein
~Diet
~Socioeconomic status indicators
~Anthropometric indicators
~Incidence of infectious morbidity symptoms
~DNA biomarkers"
11212474|NCT03297957|Experimental|Arm 1: Goggle Imaging|-Patient will then be taken to the operating room for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room. Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce. Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this). The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization. After this is performed, the goggle system will be removed and the procedure will be completed per normal.
11212475|NCT03297944|Experimental|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
11212476|NCT03297931|Active Comparator|Commercial corn chips + Onion dip|Corn chips + onion dip
11212477|NCT03297931|Experimental|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
11212478|NCT03297931|Experimental|Novel pulse chip + pulse spread|Yellow pea chip + hummus
11212479|NCT03297931|Experimental|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
11212480|NCT03297931|Experimental|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
11212481|NCT03297931|Experimental|Non-pulse chip + pulse spread|Corn chips + hummus
11212482|NCT03297918|Active Comparator|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
11212487|NCT03297879|Active Comparator|metformin group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
11212488|NCT03297866||Incentive schemes 1|No incentive will be given after completing the follow-up survey
11212489|NCT03297866||Incentive schemes 2|Receiving $100 supermarket coupon after completing the follow-up survey
11212490|NCT03297866||Incentive schemes 3|Receiving $200 supermarket coupon after completing the follow-up survey
11212491|NCT03297866||Incentive schemes 4|Receiving $100 supermarket coupon before completing the follow-up survey and another $100 supermarket coupon after completing the follow-up survey
11212492|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
11212493|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
11212494|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
11212495|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
11212496|NCT03297814|Active Comparator|Platelet lysate|A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval
11212497|NCT03297814|Placebo Comparator|placebo|A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval
11212498|NCT03297801||Fish oil group|Women who chose to supplement with fish oil, rich in omega-3 polyunsaturated fatty acids, during gestation or lactation.
11212499|NCT03297801||No fish oil group|Women who chose not to supplement with fish oil during gestation or lactation.
11212500|NCT03297788|Experimental|Arm A: SRS|Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases
11212501|NCT03297788|Active Comparator|Arm B: WBRT|Patients receive whole brain radiotherapy (WBRT)
11212502|NCT03297775||Evidence of interstitial lung disease|"Subjects who screen positive for ILD will be followed annually until study closure.
~Assessments are as follows:
~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic - Assessment for airways disease, interstitial lung abnormalities
~Genetic - DNA, RNA
~Biologic - Serum, Plasma, Sputum"
11212503|NCT03297775||No evidence of interstitial lung disease|"Subjects who screen negative for ILD will be followed five years after the initial screen and re-screened with a chest CT scan to check for evidence of new lung disease.
~Assessments are as follows:
~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)
~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance
~Radiologic - Assessment for airways disease, interstitial lung abnormalities
~Genetic - DNA, RNA
~Biologic - Serum, Plasma, Sputum"
11212504|NCT03297762|Experimental|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
11212505|NCT03297762|Active Comparator|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
11212506|NCT03297736|Active Comparator|Control|Subjects receive the control device.
11212507|NCT03297736|Experimental|Investigational device|Subject receives the 3D CAD/CAM autograft prosthesis implant.
11212508|NCT03297723||Experimental arm|The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.
11212509|NCT03297723||Controle arm|The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.
11212510|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
11212511|NCT03297697||Arm 1: Lymphotrack|-Patients will be treated with frontline chemotherapy per the treating physician's discretion. Collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay. The results of these studies will be performed in batches and therefore will not be available to patients and clinicians to make clinical decisions.
11212512|NCT03297671||Pregnant Women|2000 pregnant women from the communities in the catchment area of THQ Johi and DHQ Dadu. Rh negative women will receive two RhIg prophylaxis injections.
11212513|NCT03297671||Lady Health Visitors (LHVs)|3-5 LHVs who are full time employees at THQ Johi and DHQ Dadu. LHVs will perform ELDONCARD test and provide RhIg prophylaxis injections.
11212514|NCT03297658|Active Comparator|electro-acupuncture (EA) intervention|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects will receive electro-acupuncture (EA) (treatment) mixed frequency( continuous plus dense disperse) will be at 2Hz and 100 Hz the amplitude will be 1000 microA.
11212515|NCT03297658|Sham Comparator|sham electro acupuncture|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
11212516|NCT03297645|Experimental|Arm 1|school + asthma education + home environment remediation
11212517|NCT03297645|Experimental|Arm 2|asthma education + home environment remediation
11212519|NCT03297632|Experimental|Intervention Group|Receives instructor-based functional resistance exercise. 45 minutes per session. 3 times per week, during 10 weeks in total.
11212520|NCT03297632|No Intervention|Control group|Asked to normally active according to their current lifestyle
11212521|NCT03297632|Active Comparator|Home-based group|Receives home-based exercises with written instructions and digital video support. 45 minutes per session. 3 times per week, during 10 weeks in total.
11212522|NCT03297619|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
11212523|NCT03297619|Active Comparator|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
11212524|NCT03297606|Experimental|Group 1|VEGFR1, VEGFR2, VEGFR3
11212525|NCT03297606|Experimental|Group 2|BCR-ABL, SRC
11212526|NCT03297606|Experimental|Group 3|ALK, ROS1, MET
11212527|NCT03297606|Experimental|Group 4|KIT, PDGFRA, PDGFRB, ABL1
11212528|NCT03297606|Experimental|Group 5|EGFR
11212529|NCT03297606|Experimental|Group 6|high mutation burden, POLE, POLD1
11212530|NCT03297606|Experimental|Group 7|BRCA1, BRCA2, mutations in HRD
11212531|NCT03297606|Experimental|Group 8|CDKN2A, CDK4, CCND1, SMARCA4
11212532|NCT03297606|Experimental|Group 9|CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
11212533|NCT03297606|Experimental|Group 10|AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
11212534|NCT03297606|Experimental|Group 11|ERBB2
11212535|NCT03297606|Experimental|Group 12|BRAFV600
11212536|NCT03297606|Experimental|Group 13|PTCH1, SMO
11212537|NCT03297593|Experimental|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).
~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
11212538|NCT03297567|Experimental|verbal guidance and booklet|verbal guidance and a booklet on the importance and benefits of movement during hospital stay, as well as what the patients should do to increase the level of physical activity.
11212539|NCT03297567|No Intervention|No Intervention|The control group will not receive any type of intervention
11212540|NCT03297554|Experimental|m-health approach|See intervention description
11212541|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
11212542|NCT03297528|Experimental|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
11212543|NCT03297528|No Intervention|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
11212544|NCT03297515|Experimental|Omega 3 fatty acids|Omega 3 fatty acids
11212545|NCT03297515|Placebo Comparator|Placebo|Placebo (sunflower oil)
11212546|NCT03297502|Experimental|Pimecrolimus cream, 1%|
11212547|NCT03297502|Active Comparator|Elidel (pimecrolimus) cream 1%|
11212548|NCT03297502|Placebo Comparator|placebo|
11212549|NCT03297489|Experimental|Diagnostic (intravital microscopy)|Patients receive fluorescein sodium injection IV. Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery.
11212550|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
11212551|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
11212552|NCT03297463|Experimental|Phase Ib (Dose Escalation)|
11212553|NCT03297463|Experimental|Phase II (Dose Expansion)|
11212554|NCT03297450|Active Comparator|Aphasia therapy and tDCS|
11212555|NCT03297450|Sham Comparator|Aphasia therapy and sham-tDCS|
11212556|NCT03297450|Sham Comparator|Standard of care and sham-tDCS|
11212557|NCT03297424|Experimental|PLX2853|"Phase 1b (Dose Escalation): Approximately 45 subjects with advanced malignancies to establish the MTD/RP2D. Up to 6 additional subjects may be enrolled at the MTD/RP2D as a dose confirmation.
~Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL."
11212558|NCT03297411|Active Comparator|Brief Temporoparietal ECT|Brief Pulse Temporoparietal ECT
11212559|NCT03297411|Active Comparator|Ultrabrief Temporoparietal ECT|Ultrabrief Pulse Temporoparietal ECT
11212560|NCT03297411|Active Comparator|Brief Frontoparietal ECT|Brief Pulse Frontoparietal ECT
11212561|NCT03297411|Active Comparator|Ultrabrief Frontoparietal ECT|Ultrabrief Pulse Frontoparietal ECT
11212562|NCT03297398|Placebo Comparator|Other|Placebo Group
11212563|NCT03297398|Experimental|Drug Group 1|15mg, OPK-88004
11212564|NCT03297398|Experimental|Drug Group 2|25,mg OPK-88004
11212565|NCT03297385|Experimental|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.
~After 3 months they will have a prostatectomy."
11212566|NCT03297372|Experimental|IOL Implantation experimental|Implantation of Micropure 1.2.3. in one of the eyes of the study subject
11212590|NCT03297190|Active Comparator|SMS|Participants will receive SMS messages on nutrition and health related topics
11212591|NCT03297190|Active Comparator|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
11212592|NCT03297190|Active Comparator|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
11212567|NCT03297359|Experimental|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.
~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)
~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
11212568|NCT03297346|Other|Breast cancer patients treated with RT|"Cardiac imaging and circulating biomarkers measurements to evaluate:
~myocardial dysfunction and deformation (ECHO-ST)
~coronary artery lesions and coronary artery calcium score (CT)
~myocardium including tissue abnormalities, cardiac morphology and function (MRI)
~blood-based biomarkers of cardiovascular changes (BLOOD)"
11212569|NCT03297333|Experimental|Resistance training group|Resistance training will consist of a supervised circuit training 3 sessions/week for approximately 45-50 min/session. The circuit will include 7 strength exercises engaging the major muscle groups (leg press, rows, back squats, weighted crunches, deadlifts, bench press, and squat jumps with weights). The participants will perform 3 sets of 10 repetitions with resting periods of 30 seconds between exercises, and 2 minutes between sets. The overall OMNI-Resistance Exercise Scale per set will range between 8-10. Heart rate and exercise energy expenditure during the workout will be monitored. The load will be changed depending on the participants' perception when needed. In addition, the intensity will be monitored assessing Lactate concentrations at baseline and at the end of each session. Circuit will be repeated until meeting the targeted exercise energy expenditure of 450-500 kcal/session.
11212570|NCT03297333|Experimental|Aerobic interval training group|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure. Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity, and the second period the intensity will be reduced for 2 minutes. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion as needed. Heart rate and exercise energy expenditure during the workout will be monitored. Intensity will be monitored assessing Lactate concentrations at the end of each session. Intervals will be repeated until meeting the targeted exercise energy expenditure (450-500 kcal/session).
11212571|NCT03297333|No Intervention|Control group|Participants in the control group will not participate in the training programs.
11212572|NCT03297320|Active Comparator|Team Referrals|In-depth conversations about Goals of Care and ACP (the intervention) will be held for the patients referred to the research team by the three healthcare teams in Internal Medicine at London Health Sciences Centre (University Campus)
11212573|NCT03297320|Active Comparator|Random selection|A random selection of patients (not referred to the research team by the healthcare team) in Internal Medicine at London Health Sciences Centre (University Campus) will be selected to have in-depth conversations about Goals of Care and ACP (the intervention)
11212574|NCT03297307|Experimental|Mother-Child with Intervention|Children will attend presurgical visits with their mother
11212575|NCT03297307|No Intervention|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
11212576|NCT03297294|Experimental|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
11212577|NCT03297294|Placebo Comparator|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
11212578|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
11212579|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
11212580|NCT03297268||Phase 1-Controlled Validation & Study Planning|Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.
11212581|NCT03297268||Phase 2 - In-situ Validation and Ethnographic Analysis|Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.
11212582|NCT03297268||Phase 3 - Intervention with Home-Based Caregivers|Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.
11212583|NCT03297229|Experimental|Peer mentoring|Peers will be patients with hypertension that have already been adequately controlled within the last six months. They will be selected within each center by the staff of the center and invited to participate in the study.
11212584|NCT03297229|Experimental|Self-monitoring|Each participant will receive a blood pressure monitor. The study nurse will teach the participant on how to use the device.
11212585|NCT03297229|No Intervention|Control|Usual care
11212586|NCT03297216|Active Comparator|250 mg 17P|weekly intramuscular injection of 250mg 17P
11212587|NCT03297216|Placebo Comparator|Placebo|weekly intramuscular injection of indistinguishable placebo
11212588|NCT03297203|Experimental|groupe1|patients in septic shock (group 1) in the medical intensive care unit of the Timone Hospital.
11212589|NCT03297203|Active Comparator|groupe 2|patients with a bacterial sepsis alone, during a 6 months period.
11212594|NCT03297177|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF Via Closed Syringe Microcannula
11212595|NCT03297177|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation & concentration in Centricyte 1000 closed system to create AD-cSVF
11212596|NCT03297177|Experimental|Sterile Normal Saline Infusion|Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
11212597|NCT03297164||optimized group|the patients in this group have been given the suggestive treatment from guideline.
11212598|NCT03297164||un-optimized group|the patients in this group have not been given the suggestive treatment from guideline.
11212599|NCT03297151|Sham Comparator|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.
~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.
~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
11212600|NCT03297151|Active Comparator|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.
~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
11212601|NCT03297151|Active Comparator|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.
~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
11212602|NCT03297125|Experimental|Imaging: Standard MRI|Anticipated Results/Interpretation Standard anatomic imaging will prove not to be reliable for evaluation of progression free survival, but may show some ability to predict overall survival.
11212603|NCT03297125|Experimental|Imaging: Advanced MRI|Anticipated Results/Interpretation Advanced MRI methods will demonstrate the ability to predict response earlier than with standard MRI methods.
11212604|NCT03297112|Experimental|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
11212605|NCT03297099|Experimental|Robot-assisted Laparoscopic operation|Da Vinci surgical robot can overcome limitations of conventional laparoscopic surgery in terms of vision and instrumentation flexibility, making the minimally invasive treatment of complex hepatolithiasis possible.
11212606|NCT03297099|Active Comparator|Open surgery|The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
11212607|NCT03297086|Active Comparator|Bi-Flex|Medicontur Bi-Flex 677MY IOL was implanted into 24 eyes of 12 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
11212608|NCT03297086|Active Comparator|ReStor|and Alcon Acrysof Restor SN6AD1 IOL was implanted into 36 eyes of 18 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
11212609|NCT03297073|Experimental|major hepatic surgery|resection greater than or equal to three hepatic segments
11212610|NCT03297073|Experimental|hepatic surgery|resection less than three hepatic segments
11212611|NCT03297073|Experimental|hepatic surgery recovery|
11212612|NCT03297060|Experimental|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
11212613|NCT03297060|No Intervention|Standard Care|Standard Care SBIRT services
11212614|NCT03297047|Active Comparator|upper arm combi cast|standardized treatment
11212615|NCT03297047|Experimental|forearm combi cast|Treatment with a forearm combi cast should be a sufficient immobilization
11212616|NCT03297021|Placebo Comparator|Ondansetron 4mg Pre-emergence|
11212617|NCT03297021|Experimental|Ondansetron 8mg Pre-emergence|
11212618|NCT03297021|Experimental|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
11212619|NCT03296995|Experimental|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
11212620|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
11212621|NCT03296969|Active Comparator|rectus muscle approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
11212622|NCT03296969|Active Comparator|rectus muscle non approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
11212623|NCT03296956|Active Comparator|Day-5 postpartum - Active dietary supplement|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.
~Intervention: Full dose dietary supplement Motherwell"
11212624|NCT03296956|Placebo Comparator|Day-5 postpartum - Placebo|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.
~Intervention: Placebo"
11212625|NCT03296943|Experimental|Essential oil|Essential oil is prepared from the product of Thailada with manufacture standard ID 1087/2548 by Thailand Ministry of Industry. Essential oil is extracted by a cold compressed method from the lavandula angustifolia (lavender) grown in Australia.
11212626|NCT03296943|Sham Comparator|Perfume|Perfume is the synthetic perfume of lavender flavor without essential oil.
11212627|NCT03296930|Active Comparator|first drug group|Sofosbuvir 400 MG Oral Tablet
11212628|NCT03296930|Active Comparator|second drug group|Ombitasvir/paritaprevir/ritonavir
11212629|NCT03296917|Experimental|IMP - PrEP-001|"In Viral Challenge arm cohort:
~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).
~In the Safety arm's first dose cohort:
~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).
~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:
~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
11212630|NCT03296917|Placebo Comparator|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:
~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
11212631|NCT03296904|Experimental|CLs++|Baseline assessment, intervention, final assessment
11212632|NCT03296891|Active Comparator|PoCUS Guided Resuscitation of Shock|Participants randomized to this arm of the study will undergo PoCUS guided resuscitation of shock.
11212633|NCT03296891|No Intervention|Usual Care|Participants randomized to the 'usual care' arm of the study will be suggested to have the following guide resuscitation: 1) Pulse pressure variation (PPV), stroke volume variation (SVV) and/or systolic pressure variation (SPV) on their arterial line, 2) central venous pressure (CVP) and oxygen saturation(ScvO2) measurement, 3) Passive leg raise (PLR) maneuver.
11212634|NCT03296878|Other|Own-Price Elasticity|"The price of eggs will vary (own-price elasticity) while the price of other foods in the mock grocery store will remain constant."
11212635|NCT03296878|Other|Cross-Price Elasticity|"The eggs will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
11212636|NCT03296865|No Intervention|Without taping|Evaluations without taping
11212637|NCT03296865|Experimental|Kinesio taping|Kinesio taping was apllied only one time. It was removed after intervention.
11212638|NCT03296865|Placebo Comparator|Placebo|Placebo was apllied only one time. It was removed after intervention.
11212639|NCT03296852|Experimental|Healthy Volunteers|
11212640|NCT03296826||BRCA1/2 variant carriers|Japanese women who carry BRCA 1/2 variants.
11212641|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
11212642|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:
~1 mg oral torsemide = 2-4 mg oral furosemide
~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
11212643|NCT03296800|Experimental|Bexagliflozin/probenecid|
11212644|NCT03296800|Experimental|Bexagliflozin/rifampin|
11212645|NCT03296800|Experimental|Bexagliflozin/verapamil|
11212646|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
11212647|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
11212648|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
11212649|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
11212650|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
11212651|NCT03296774|Placebo Comparator|Usual Care|Usual postpartum care
11212652|NCT03296774|Experimental|Healthy Beyond Pregnancy|Web-based program for postpartum care and education and scheduling. Incentive for committing and returning for postpartum care.
11212653|NCT03296761||ESM-1<5ng/ml|
11212654|NCT03296761||ESM-1≥5ng/ml|
11212655|NCT03296748|Active Comparator|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
11212656|NCT03296748|Active Comparator|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
11212657|NCT03296735|Experimental|Ipsilateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
11212658|NCT03296735|No Intervention|Supine|Measuring the cross-sectional area of right subclavian vein in supine position.
11212659|NCT03296735|Active Comparator|Contralateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
11212660|NCT03296722|No Intervention|Control group|The control group comprised 41 patients, which was to go once a month to receive nutritional intervention with the prescription of a hypocaloric diet on the part of the nutritionist. The control group had a monthly monitoring for 3 months.
11212661|NCT03296722|Experimental|Intervention group|The intervention group made up of 42 patients using the transtheoretical model and MI through sessions group and sessions individual with topics of healthy eating habits taught by a nutritionist, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy and confrontation of barriers given by a psychologist. The intervention group had a monthly monitoring for 3 months. The diet that was prescribed to the intervention group was with the characteristics of the DASH diet.
11212662|NCT03296709|Active Comparator|PPC m|
11212664|NCT03296696|Experimental|Dose exploration|Dose exploration of the intervention, AMG 596 alone or in combination with AMG 404
11212665|NCT03296696|Experimental|Dose expansion|Dose expansion of the intervention, AMG 596 alone or in combination with AMG 404
11212666|NCT03296683|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
11212667|NCT03296670|Experimental|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
11212668|NCT03296670|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
11212669|NCT03296657|Experimental|stannous fluoride toothpaste|0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
11212670|NCT03296644|Active Comparator|PowerScope2 group (G1)|Class II correction using PowerScope2
11212671|NCT03296644|Active Comparator|Forsus group (G2)|Class II correction using Forsus
11212672|NCT03296631||children|"Enrollment of 15 to 20 children (< 9 months old) at the early beginning of their entry in nursery (crèche) between August and November 2017.
~This cohort will be followed during a maximum period of 36 months . Diapers with fresh stools will be collected once a week per child and then frozen.
~Spontaneous personal day care informations given by the parents to the nurses and recorded in each child's daily logbook will be collected for the research. No specific interviews will be conducted."
11212673|NCT03296618|Experimental|NSI-566 neural stem cell implantation|
11212674|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
11212675|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
11212676|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.
~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI
~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.
~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment
~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.
~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
11212677|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
11212678|NCT03296579|Active Comparator|Conventional asthma therapy.|Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
11212679|NCT03296579|Experimental|Non-invasive ventilation (CPAP).|Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
11212680|NCT03296579|Experimental|Non-invasive ventilation (BiPAP)|Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
11212681|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
11212682|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
11212683|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
11212684|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
11212685|NCT03296540|Active Comparator|Uncrushed|6 Integral tablets Prasugrel as loading dose
11212686|NCT03296540|Experimental|Crushed|6 Crushed tablets Prasugrel as loading dose
11212687|NCT03296527|Experimental|Follitropin delta|rFSH. Follitropin delta for subcutaneous injection
11212688|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
11212689|NCT03296514|No Intervention|Wait List Control|Will receive voucher for MBSR after study is concluded
11212690|NCT03296514|Other|Intervention|These people will receive the MBSR
11212691|NCT03296501|Experimental|Autologous ADRC injection|
11212692|NCT03296488|Experimental|Nalbuphine Sebacate|receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.
11212693|NCT03296488|Active Comparator|Fentanyl Citrate|receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
11212694|NCT03296475|Experimental|Midline Ventral Hernia|"Main inclusion criteria:
~Patients with midline hernia defects.
~Patients with either a maximal ventral hernia axial width of greater than 5cm or a loss of domain of greater then 20%.
~Patients aged ≥ 18 years old.
~Midline hernias closed in the midline with primary fascial closure with or without mesh augmentation.
~Midline ventral hernias of VHWG grade 2 or 3."
11212695|NCT03296462|Experimental|Hip external rotation exercise (alone)|Standardised hip external rotation exercise training - over 12 week period
11212696|NCT03296462|Experimental|Hip external rotation + PFM exercises|Standardised hip external rotation plus pelvic floor muscle exercises - over 12 week period
11212697|NCT03296462|Active Comparator|pelvic floor muscle exercises (alone)|Standardised pelvic floor muscle exercises - over 12 week period (usual care)
11212770|NCT03295955|No Intervention|No postop antibiotics|Do not prescribe Amoxicillin Clavulanate
11212698|NCT03296449|No Intervention|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
11212699|NCT03296449|Active Comparator|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
11212700|NCT03296449|Experimental|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
11212701|NCT03296436|Experimental|Treatment Group|Group that will be receiving the investigational product
11212702|NCT03296423|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
11212703|NCT03296423|Active Comparator|Vaccination|One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)
11212704|NCT03296410|Experimental|EV71 and two measles attenuated live vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and two measles attenuated live vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
11212705|NCT03296410|Experimental|EV71 and attenuated Japanese encephalitis vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and live attenuated Japanese encephalitis vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
11212706|NCT03296410|Active Comparator|two measles attenuated live vaccine|infants vaccinated with two measles attenuated live vaccine at 8 months old
11212707|NCT03296410|Active Comparator|live attenuated Japanese encephalitis vaccine|infants vaccinated with live attenuated Japanese encephalitis vaccine at 8 months old
11212708|NCT03296410|Active Comparator|EV71 vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
11212709|NCT03296397|Active Comparator|HPV Quadrivalent vaccine (QHV)|Gardasil
11212710|NCT03296397|Placebo Comparator|Placebo|Normal Saline
11212711|NCT03296384|Other|Patients with schizophrenia|
11212712|NCT03296384|Other|Relatives|
11212713|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
11212714|NCT03296358|No Intervention|Control group|Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
11212715|NCT03296358|Experimental|Experiment 1|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
11212716|NCT03296358|Experimental|Experiment 2|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
11212717|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment will be to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores will be collected using the FACES scale currently in place. In consenting patients, chart review will be performed with the following data being collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, whether or not the patient was discharged, and if re-presentation occurred in the subsequent 3 months.
~In addition, a survey, which is attached, will be given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
11212718|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up to as many as are available within the last year will be summed and compared to their visit where they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients act as their own controls in the above manner. Patients are allowed to re-enroll 4 weeks after presentation, which is typically considered a second vaso-occlusive crisis in the literature."
11212719|NCT03296319|Active Comparator|echocardiography guided fluid resuscitation|
11212720|NCT03296319|Experimental|clinically guided fluid resuscitation|
11212721|NCT03296306|Active Comparator|6 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional two to four cycles of chemotherapy (totally six cycles)
11212722|NCT03296306|Experimental|4 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional zero to two cycles of chemotherapy (totally four cycles)
11212723|NCT03296293|Other|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
11212724|NCT03296293|Other|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg
11212725|NCT03296293|Other|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD>6mmHg
11212726|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
11212727|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
11212728|NCT03296267|Other|gastroduodenoscopy|all participants undergo a gastroduodenoscopy to use the biopsies in an Ussing chamber experiment.
11212729|NCT03296254|Experimental|Course A|Body Mindfulness Exercised followed by Sitting Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
11212730|NCT03296254|Experimental|Course B|Sitting Mindfulness Exercises followed by Body Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
11212731|NCT03296241|Experimental|Laser|One session of non-ablative Er:YAG laser (2940 nm) treatment of the vaginal wall, introitus and vestibule.
11212732|NCT03296241|Sham Comparator|Sham control|The sham control group was treated with the same procedure but with zero intensity settings - without receiving therapeutic irradiation (placebo).
11212733|NCT03296228||Hong Kong|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)
~supine side-bending and fulcrum bending films"
11212734|NCT03296228||Turkey|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)
~Radiation: Flexibility Radiographs (awake traction)
~Radiation: Flexibility Radiographs (STUGA)
~supine side-bending, fulcrum bending films, awake traction and supine traction under GA"
11212735|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
11212736|NCT03296202||HIV patients|4500 patients infected with HIV-1
11212737|NCT03296189|Active Comparator|Local anaesthetic|Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
11212738|NCT03296189|Active Comparator|Local anaesthetic + steroid|Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
11212739|NCT03296189|Placebo Comparator|Placebo|Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
11212740|NCT03296176|Experimental|presymptomatic|
11212741|NCT03296176|Experimental|symptomatic|
11212742|NCT03296176|Other|controls|
11212743|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
11212744|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
11212745|NCT03296150|No Intervention|Control arm : Information|Patients will receive the usual standard information delivered to patients
11212746|NCT03296150|Experimental|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
11212747|NCT03296137|Experimental|All participants|
11212748|NCT03296098|Experimental|ulipristal acetate|Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
11212749|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
11212750|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
11212751|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
11212752|NCT03296059|Experimental|RBC transfusion with conventional treatment|Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
11212753|NCT03296059|Active Comparator|conventional treatment|neonates diagnosed with ARDS is treated with conventional treatment.
11212754|NCT03296046||PPBL patients|
11212755|NCT03296033|Active Comparator|24 Hours group|Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
11212756|NCT03296033|Experimental|36 Hours Group|Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.
11212757|NCT03296020|No Intervention|control group|"After the surgery, during the hospitalization ,the control group would get as is customary in our ENT department :acetaminophen syrup+ syrup oxycode( as necessary).
~After the discharge from the hospital - the patients would take( as is customary in our ENT department): acetaminophen syrup ( as necessary) and other painkillers ( as necessary).
~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
11212758|NCT03296020|Experimental|"case group-HONEY"|"After the surgery, during the hospitalization ,the case group would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup + syrup oxycode( as necessary).
~After the discharge from the hospital - the patients would take:acetaminophen syrup ( as necessary) and other painkillers+honey twice a day( 5 ml- one tea spoon each time) .
~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
11212759|NCT03296007|Experimental|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
11212760|NCT03296007|Active Comparator|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
11212761|NCT03295994|Active Comparator|Operative|surgery + post-operative physical therapy
11212762|NCT03295994|Active Comparator|Non-Operative|non-operative physical therapy
11212763|NCT03295981|No Intervention|Control group|The surgical procedure for all patients will include extensive curettage of the lesion to remove macroscopic tumor, high-speed burring of the residual cavity, adjuvant treatment to the residual cavity, followed by packing of the cavity with either polymethylmethacrylate (PMMA) bone cement (Simplex P; Stryker, Mahwah, New Jersey) alone or bone cement with subchondral allograft bone graft. The choice of cavity reconstruction will be at the discretion of the treating surgeon. Traditional local adjuvants (argon beam coagulation, phenol, ethanol, or cryotherapy) will be used depending on surgeon preference. In addition to the above standard treatment, the patients will be randomized into one of two study arms. In Arm 1, the control group, no additional local therapy will be utilized.
11212764|NCT03295981|Experimental|Bisphosphonate group|In Arm 2, the bisphosphonate group, 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement.
11212765|NCT03295968|No Intervention|Water and Rest|
11212771|NCT03295942|Experimental|OMP-336B11|Intravenous (in the vein) infusions of OMP-336B11
11212772|NCT03295916|Experimental|Systemic therapy plus SBRT to OM|Stereotactic Body Radiotherapy (SBRT) up to 5 OM sites
11212773|NCT03295903|Placebo Comparator|Placebo|Sugar pill that will have no effect.
11212774|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
11212775|NCT03295903|Active Comparator|Cannabidiol (1 dose)|Only cannabidiol supplement.
11212776|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
11212777|NCT03295903|Active Comparator|Cannabidiol only (2 dose)|Only cannabidiol supplement.
11212778|NCT03295890|Sham Comparator|Sham Needling|Intervention = Sham Needling
11212779|NCT03295890|Active Comparator|Active Needling|Intervention = Active Needling
11212780|NCT03295877|Experimental|RO7171009: SAD|Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
11212781|NCT03295877|Experimental|RO7171009: MD|Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
11212782|NCT03295864|Experimental|Patients with Chiari type 1 malformation|Tympanometry measurement at inclusion and 6 months after surgery
11212783|NCT03295864|Experimental|Healthy volunteers|Tympanometry measurement at inclusion. Every healthy volunteer will be match with a patient for his age and his BMI (body mass index).
11212784|NCT03295851|Experimental|IV Ferric Carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
11212785|NCT03295851|Active Comparator|Oral Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily
11212786|NCT03295838|Experimental|Mentalization-based Treatment|MBT was conducted according to the treatment manual developed by Bateman & Fonagy. Patients were offered individual sessions with a psychotherapist and group sessions with 6-8 participants and 1-2 group therapists for 18 months. An introductory psycho-educational component (9-12 sessions) was also offered focusing on explicit mentalising skills (i.e. understanding one's own or others' intentions). Group and individual MBT focused on implicit mentalising towards self and others.
11212787|NCT03295825|Other|Biomarker|Blood sampling
11212788|NCT03295799|Experimental|Patient Self-Management|Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
11212789|NCT03295799|No Intervention|Anticoagulation Clinic Care|Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
11212790|NCT03295786|Placebo Comparator|Placebo|Patients randomized to this group will receive 6 monthly infusions of placebo/vehicle
11212791|NCT03295786|Experimental|CDNF mid-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to mid-dose
11212792|NCT03295786|Experimental|CDNF high-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to high-dose
11212793|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
11212794|NCT03295760||Children with cyclic vomiting syndrome|Children followed at Children's Hospital of Nancy treated with Q10 coenzyme for cyclic vomiting syndrome
11212795|NCT03295747|Experimental|Peppermint oil soft gel|Children will be randomized to receive either 180 mg, 360 mg, or 540 mg of peppermint oil.
11212796|NCT03295734|Active Comparator|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
11212797|NCT03295734|Active Comparator|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
11212798|NCT03295734|Active Comparator|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
11212799|NCT03295721|Experimental|Treatment Group 1|HTX-011
11212800|NCT03295721|Placebo Comparator|Treatment Group 2|Saline placebo
11212801|NCT03295721|Active Comparator|Treatment Group 3|Bupivacaine HCl
11212802|NCT03295708|Experimental|experimental group|the experimental group will be given 4 fish oil capsules (1g/one capsule)twice daily after two meals at roughly the same time each day,lasting for the first 6 months.fish oil capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.
11212803|NCT03295708|Placebo Comparator|control group|the control group will be given 4 soybean oil capsules ( placebo capsule,1g/one capsule) twice daily after two meals at roughly the same time each day,lasting for the first 6 months.placebo capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.The placebo capsule's appearance and flavor are made the exactly the same as the fish oil capsules .
11212804|NCT03295695|Experimental|Cardiac Imaging - All Participants|Study agent: 2-deoxy-2-[18F]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
11212805|NCT03295656|Experimental|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
11212806|NCT03295643|Other|Mobile smoking cessation program|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
11212807|NCT03295630|Other|Actigraph GT3X accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
11212808|NCT03295617||spinal thoracic herniation|
11212809|NCT03295604|Experimental|test group|Miller class I-II gingival recession defects operated with sub epithelial connective tissue graft (SCTG) in addition with enamel matrix derivatives (EMD) (Emdogain ®, Switzerland ) in SCTG+EMD group.
11212810|NCT03295604|Experimental|control group|Miller class I-II gingival recession defects operated with only sub epithelial connective tissue graft (SCTG). No drug or something else were used
11212811|NCT03295578|Experimental|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
11212812|NCT03295578|Placebo Comparator|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
11212813|NCT03295565|Active Comparator|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
11212814|NCT03295565|Active Comparator|B: Abiraterone OR Enzalutamide|"At physician's discretion:
~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
11212815|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
11212816|NCT03295539|Other|Acute or Chronic clot|If chronic clot, no intervention given via Indigo
11212817|NCT03295526|No Intervention|Control group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and systematic pelvic lymphadenectomy
11212818|NCT03295526|Experimental|Experimental group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and selective enlarged lymph node dissection.
11212819|NCT03295513|Active Comparator|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
11212820|NCT03295513|Experimental|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
11212821|NCT03295500||Experimental Group One|In this group ,the participants receive the dose fraction of 49Gy/7f (BED 83.3Gy) by cyberknife.
11212822|NCT03295500||Experimental Group Two|In this group ,the participants receive the dose fraction of 54Gy/6f(BED 102.6Gy) by cyberknife.
11212823|NCT03295500||Control Group|In this group ,the participants receive the dose fraction of 55Gy/5f(115.5Gy) by cyberknife.
11212824|NCT03295487|Active Comparator|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
11212825|NCT03295487|Active Comparator|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
11212826|NCT03295474||Rehabilitation using telehealth technology|
11212827|NCT03295461|Active Comparator|test group|SRP+ 10% Emblica officinalis irrigation
11212828|NCT03295461|Active Comparator|positive control group|SRP + 0.2% Chlorhexidine irrigation
11212829|NCT03295461|Active Comparator|negative control group|SRP + 0.9% Saline irrigation
11212830|NCT03295461|Active Comparator|test gropup|SRP +10% E. officinalis gel application
11212831|NCT03295461|Placebo Comparator|control group|received SRP+ placebo gel application.
11212832|NCT03295448|Active Comparator|Fat - Sugar - Fiber|Intervention: consuming diets rich in fat, rich in sugar, and rich in fibers during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
11212833|NCT03295448|Active Comparator|Fat - Fiber - Sugar|Intervention: consuming diets rich in fat, rich in fiber, and rich sugar during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
11212834|NCT03295448|Active Comparator|Sugar - Fiber - Fat|Intervention: Consuming diets rich in sugar, rich in fiber, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
11212835|NCT03295448|Active Comparator|Sugar - Fat - Fiber|Intervention: Consuming diets rich in sugar, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
11212836|NCT03295448|Active Comparator|Fiber - Sugar - Fat|Intervention: Consuming diets rich in fiber, rich in sugar, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
11212837|NCT03295448|Active Comparator|Fiber - Fat - Sugar|Intervention: consuming diets rich in fiber, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
11212838|NCT03295422|Active Comparator|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
11212839|NCT03295422|Experimental|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
11212840|NCT03295409|Experimental|Experimental: Standard self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:
~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.
~If I feel threatened or anxious, then I will…
~think about the things I value about myself
~remember things that I have succeeded in
~think about what I stand for
~think about things that are important to me
~If…___________________________________________________________________"
11212841|NCT03295409|Experimental|Experimental: Familial self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:
~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.
~If I feel threatened or anxious, then I will…
~think about the things my family and I value about ourselves
~remember things that my family and I have succeeded in
~think about what my family and I stand for
~think about things that are important to my family and me
~If…__________________________________________________________________"
11212842|NCT03295409|No Intervention|Control|Participants are asked to complete a questionnaire.
11212843|NCT03295396|Experimental|Arm A|ONC201 in relapsed H3 K27M glioma
11212881|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
11276876|NCT02856425|Experimental|Mesothelioma (MPM)|
11212844|NCT03295396|Experimental|Arm B|"ONC201 in relapsed H3 K27M glioma, excluding:
~Primary malignant lesion located in the pons or spinal cord.
~Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).
~Prior bevacizumab treatment of >4 doses of >7.5 mg/Kg
~Tumors with known 1p/19q co-deletion."
11212845|NCT03295383|Experimental|Rituximab treatment|"Rituximab at a dose of 1000 mg (or matching placebo) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
~cyclophosphamide placebo will be administered orally once daily"
11212846|NCT03295383|Active Comparator|Cyclophosphamide treatment|"cyclophosphamide will be administered orally once daily at the following initial doses:
~patients younger than 75 years: 1.5 mg/kg/day, orally. patients older than 75 years: 1 mg/kg/day, orally.
~Rituximab placebo (NaCl 0.9 %) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197"
11212847|NCT03295370|Experimental|Active Group|Needle electrical stimulation of accessory spinal nerve
11212848|NCT03295370|Sham Comparator|Sham Group|Needle of accessory spinal nerve without electrical stimulation
11212849|NCT03295357||Patients with extubation while on ECLS|
11212850|NCT03295357||Patients without extubation|
11212851|NCT03295344||Patients|
11212852|NCT03295344||Healthy volunteers|
11212853|NCT03295331||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above
11212854|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.
~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
11212855|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.
~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
11212856|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.
~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
11212857|NCT03295305|Experimental|Action Based Cognitive Remediation|
11212858|NCT03295305|Active Comparator|Unstructured support group|
11212859|NCT03295292|Sham Comparator|Standard Surgery with Vehicle|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL Fibrin Sealant (sham) without cells.
11212860|NCT03295292|Experimental|Standard Surgery with Stem Cells|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL of a mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in the thrombin component of Fibrin Sealant (TISEEL, Baxter).
11212861|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate [eGFR] of ≤60mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
11212862|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
11212863|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
11212864|NCT03295253|Experimental|Female patients with Stress Incontinence|Female patients who will undergo autologous adipose tissue harvesting/grafting using Lipogems and grafting in urethra/bladder neck
11212865|NCT03295240|Experimental|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
11212866|NCT03295227|Experimental|Pembrolizumab|"Part 1: Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of every 21 day Cycle.
~Part 2: Participants received Pembrolizumab at the maximum tolerated dose from Part 1."
11212867|NCT03295214|Active Comparator|Acetaminophen 975mg Per Os|975mg of Acetaminophen given by mouth
11212868|NCT03295214|Active Comparator|Acetaminophen 1000mg Intravenous|1000mg of Acetaminophen given intravenously
11212869|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
11212870|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
11212871|NCT03295188|Experimental|Intervention Group|Two 0.5 mg plasmalogen capsules per day
11212872|NCT03295188|Placebo Comparator|Placebo Group|Two placebo capsules containing no plasmalogen per day
11212873|NCT03295175||Congenital Megaprepuce|Congenital Megaprepuce Hematoxylin-eosin and smooth muscle actin markers
11212874|NCT03295175||Hypospadias|Hypospadias Hematoxylin-eosin and smooth muscle actin markers
11212875|NCT03295175||Control|Circumcision for non-medical reasons. Hematoxylin-eosin and smooth muscle actin markers
11212876|NCT03295162|Experimental|Sepsis A Group|neonates diagnosed with Sepsis and will receive melatonin. 10 mg product as a total dose of 20 mg .together with conventional treatment of Neonatal sepsis
11212877|NCT03295162|Sham Comparator|Sepsis B Group|neonates diagnosed with Sepsis and willnot receive melatonin., they will recieve only the conventional treatment of Neonatal Sepsis
11212878|NCT03295162|No Intervention|Control|healthy neonates, in whom sepsis will be ruled-out on the basis of absence of any clinical or laboratory evidence suggestive of infection.
11212879|NCT03295136|Experimental|Health Promotion Training for Women Employees|Groups of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
11212880|NCT03295110|Experimental|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
11277026|NCT02855372||Lung transplanted patients|
11212882|NCT03295097|Other|Clinical Decision Support System|The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
11212883|NCT03295084|Experimental|Irinotecan|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily for 14 days within 3 week treatment cycle
11212884|NCT03295084|Experimental|Irinotecan with Capecitabine|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily in combination with Capecitabine tablet taken twice daily for 14 days within 3 week treatment cycle
11212885|NCT03295071||Single-group study|This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
11212886|NCT03295058|Experimental|Non ATG regimen|the first 50% of patients will receive Fludarabine + cyclophosphamide prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
11212887|NCT03295058|Experimental|ATG regimen|the other 50% will receive Cyclophosphamide + ATG prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
11212888|NCT03295032|Experimental|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
11212889|NCT03295032|No Intervention|Waiting list control|Waiting list control - received treatment as usual.
11212890|NCT03295019|Experimental|Test Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
11212891|NCT03295019|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their placebo mouth spray, 2 times daily (morning and evening), for the 4 week duration of the study.
11212892|NCT03295006||Previous Therasphere treatment|Patients who had received TheraSphere yttrium-90 microspheres
11212893|NCT03294993|Experimental|Ultrasound assess group|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
11212894|NCT03294967|Active Comparator|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
11212895|NCT03294967|Placebo Comparator|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
11212896|NCT03294954|Experimental|GINAKIT cells + cytoxan + fludara|"Cyclophosphamide and fludarabine will be administered prior to the GINAKIT cells.
~Day -4: Cyclophosphamide and Fludarabine
~Day -3: Cyclophosphamide and Fludarabine
~Day -2: Fludarabine
~Day -1: Rest
~Day 0: GINAKIT cells"
11212897|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
11212898|NCT03294928|Experimental|progressive increasing of PEEP level|four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level.
11212899|NCT03294915|Active Comparator|Resistant Starch|Green banana flour
11212900|NCT03294915|Placebo Comparator|Placebo|Maltodextrin, cellulose and guar gum
11212901|NCT03294902||Critical Limb Ischaemia (CLI) Group with tibial arterial dis|Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
11212902|NCT03294902||Peripheral Artery Disease (PAD) Group with SFA disease|Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
11212903|NCT03294902||PAD-free group (Healthy Volunteer Group)|Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
11212904|NCT03294863|Experimental|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound
11212905|NCT03294863|Placebo Comparator|Standard of Care|Another 1/2 of cutaneous wound will be treated per standard of care
11212906|NCT03294850|Experimental|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
11212907|NCT03294850|Active Comparator|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
11212908|NCT03294824||patients who reactivate CMV or AdV after allogeneic HSCT|allotransplanted patients who reactivated respectively CMV (n=30) and AdV (n=10)
11212909|NCT03294824||Control group: allogeneic HSC transplanted patients|allotransplanted patients who didn't reactivate CMV
11212910|NCT03294824||Healthy donors group|healthy donors serologically + for CMV
11212911|NCT03294811|Experimental|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
11212912|NCT03294811|No Intervention|Control group|Control group (usual care, without telemonitoring)
11212913|NCT03294798|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
11212914|NCT03294798|Active Comparator|Pegasys|Pegasys 180 mcg, once per week
11212969|NCT03294421|Experimental|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
11212970|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
11213255|NCT03292432|Active Comparator|Standard of Care|Standard of Care for adherence support at Site
11212915|NCT03294785|Experimental|Chuna manual therapy|The Chuna manual therapy group will receive Chuna manual therapy alone. Chuna manual therapy will employ a semi-standardized treatment plan of Chuna manual therapy through Chuna technique selection based on physician judgement of techniques from Chuna Medicine (Korean Society of Chuna Manual Medicine for Spine & Nerves: Chuna Medicine: Seoul: Korean Society of Chuna Manual Medicine for Spine & Nerves; 2017) and osteopathic manipulative medicine. The Chuna techniques employed in this study are divided into cervical, thoracic and rib cage, lumbar, pelvic, sacral, pubic, and hip joint area techniques. Chuna manual therapy sessions will be administered 2 sessions/week over a period of 5 weeks (total 10 sessions). The time duration of 1 Chuna manual therapy session will consist of approximately 10-20 minutes of diagnosis and approximately 10 minutes of treatment.
11212916|NCT03294785|Active Comparator|Usual care|The usual care group will receive usual care alone. Usual care will be limited to physical therapy and conventional medication in this study. Usual care will be provided with reference to a list of most frequently used treatments in neck pain-related patients from Korean Health Insurance Review and Assessment (HIRA) 2014 statistics. Frequency and types of physical therapy used will be recorded in a separate electronic case report form for outcome assessor blinding purposes.
11212917|NCT03294772|Experimental|Hand sanitizer group|DCCs received alcohol-based hand sanitizer and a program educational. Characteristics of the hydroalcoholic gel (Alco aloe gel): chlorhexidine digluconate at 0.2% solution, phenoxyethanol 1%, benzalkonium chloride 0.1%. aloe barbadensis 5%, ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 70%, ph = 7-7,5.
11212918|NCT03294772|Experimental|Liquid soap group|DCCs received soap and program educational. The liquid soaps used for handwashing in this study did not contain specific antibacterial component, ph= 5.5.
11212919|NCT03294772|No Intervention|Control group|No hand sanitizer or educational program were used.
11212920|NCT03294759|Experimental|Bio-ACL (Amion)|Intervention: ACL Autograft Reconstruction with Amion Collagen Scaffold. Stem Cells isolated from bone marrow aspirate from distal femur will be injected inside the Amion Collagen Scaffold.
11212921|NCT03294759|Active Comparator|Control|Intervention: Normal ACL Autograft Reconstruction with either patella or hamstring autograft will be performed in the control group.
11212922|NCT03294746|Other|Clinical evaluations and Thoracic CT scan scoring of DIILD|
11212923|NCT03294733|Other|Ultrasound|Ultrasound wrists to determine carpal tunnel size
11212924|NCT03294720|Experimental|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
11212925|NCT03294707|Experimental|AG10 single oral dose|AG10 oral tablet, administered by mouth, once
11212926|NCT03294707|Placebo Comparator|Placebo single oral dose|Placebo Oral Tablet, administered by mouth, once
11212927|NCT03294694|Experimental|Ribociclib and PDR001 (Cohort A)|"The treatment regimen is defined as ribociclib + PDR001.
~Treatment will be administered on an outpatient basis.
~The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.
~Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.
~Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.
~Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer."
11212928|NCT03294694|Experimental|Ribociclib, PDR001 and Fulvestrant (Cohort B)|"The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .
~Treatment will be administered on an outpatient basis.
~There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.
~Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.
~Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC)."
11212929|NCT03294681||Cochlear Implant Recipients|
11212930|NCT03294668|Experimental|KONTAKT Australia|A social skills group training
11212931|NCT03294668|Active Comparator|Super Chef|A social cooking group
11212932|NCT03294655|No Intervention|No contact control|the no contact control group will do nothing
11212933|NCT03294655|Experimental|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
11212934|NCT03294642|Experimental|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
11212935|NCT03294642|Experimental|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
11212936|NCT03294642|Experimental|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
11212937|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
11212938|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.
~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
11212971|NCT03294395|Active Comparator|Ceftriaxone im|Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
11212972|NCT03294395|Experimental|Ertapenem im|Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
11213756|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
11212939|NCT03294616|Experimental|scleroderma patients-0|for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
11212940|NCT03294616|Experimental|scleroderma patient-1|for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
11212941|NCT03294616|Experimental|scleroderma patients-2|for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
11212942|NCT03294603|Experimental|[14C]-CC-220 solution|A single oral dose of 1 mg [14C]-CC-220 solution, containing approximately 1.4 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
11212943|NCT03294590|Experimental|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
11212944|NCT03294590|Active Comparator|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
11212945|NCT03294577|Active Comparator|TAC + Pegfilgrastim|"Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo
~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
11212946|NCT03294577|Experimental|TAC + Pegfilgrastim + Plinabulin|Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)
11212947|NCT03294564|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
11212948|NCT03294564|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
11212949|NCT03294551|No Intervention|Standard of Care Control|Usual source of care
11212950|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Autodialer|HPV Vaccine Reminder Recall - Autodialer: Receive up to 4 reminders via telephone (live call or voicemail) - includes brief educational message + providers name + providers telephone number
11212951|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Texting|HPV Vaccine Reminder Recall - Texting: Receive up to 4 reminders via text message - includes brief educational message + providers name + providers telephone number
11212952|NCT03294538|Experimental|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
11212953|NCT03294538|Active Comparator|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
11212954|NCT03294538|Placebo Comparator|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
11212955|NCT03294525||Escitalopram-for MDD|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
11212956|NCT03294525||Duloxetine-for MDD|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
11212957|NCT03294525||Mirtazepine-for MDD|Eligible patients were assigned to mirtazepine treatment based on investigators' clinical practice.
11212958|NCT03294525||other antidepressant-for MDD|Eligible patients were assigned to other antidepressant treatment (including sertraline, paroxetine, fluoxetine, venlafaxine, etc) based on investigators' clinical practice.
11212959|NCT03294512|Experimental|Heart Failure Patients|Patients who are seen at Intermountain Medical Center with heart failure, based on the Intermountain-specific Heart Failure Identification and Risk Stratification, will be screened for this study. The Principal Investigator and/or his delegate will confirm the presence of heart failure, based on established standard of care criteria for diagnosis.
11212960|NCT03294486|Experimental|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
11212961|NCT03294473|Experimental|Autodial R/R|R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
11212962|NCT03294473|Experimental|Text Message R/R|R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
11212963|NCT03294473|Experimental|Postcard R/R|R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
11212964|NCT03294473|No Intervention|Standard of Care Control|Participants in this group will not receive any influenza vaccination reminders
11212965|NCT03294460|Experimental|1|Alcohol self-administration (IV ethanol for sessions 1 and 3, oral for session 2)
11212966|NCT03294447|Experimental|Fall Prevention Intervention by OT|Fall prevention interventions implemented by an OT in a geriatric primary care setting for a client immediately following the provider visit within the office.
11212967|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
11212968|NCT03294421|Active Comparator|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
11213096|NCT03293615|No Intervention|No myopathy|Patients without myopathy on muscle biopsy
11212973|NCT03294395|Experimental|Fosfomycin po|Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
11212974|NCT03294395|Experimental|Gentamicin im|Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
11212975|NCT03294382|Experimental|Botulinum toxin|5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus
11212976|NCT03294382|Placebo Comparator|Normal Saline|0.1 mL normal saline, administered in the other intercanthus
11212977|NCT03294369||Cohort of the study|A sample from the general population aged 18 years or older, randomly selected from a database of sanitary cards stratified by age and gender.
11212978|NCT03294356|Experimental|FT210771 Group|7 day at-home use of electronic cigarette FT210771 followed by a 2 day in-clinic period.
11212979|NCT03294356|Experimental|FT210751 Group|7 day at-home use of electronic cigarette FT210751 followed by a 2 day in-clinic period.
11212980|NCT03294356|Experimental|6T30134157764 Group|7 day at-home use of electronic cigarette 6T30134157764 followed by a 2 day in-clinic period.
11212981|NCT03294356|Experimental|G41A7C071 Group|7 day at-home use of electronic cigarette G41A7C071 followed by a 2 day in-clinic period.
11212982|NCT03294356|Experimental|M011161212 Group|7 day at-home use of electronic cigarette M011161212 followed by a 2 day in-clinic period.
11212983|NCT03294356|Experimental|FT21002 Group|7 day at-home use of combustible cigarette FT21002 followed by a 2 day in-clinic period.
11212984|NCT03294343|Experimental|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
11212985|NCT03294343|Experimental|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
11212986|NCT03294343|Other|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
11212987|NCT03294330|Experimental|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
11212988|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
11212989|NCT03294304|Experimental|Nivolumab, Cisplatin, & Gemcitabine|
11212990|NCT03294291|Active Comparator|Quadratus Lumborum block group|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.7 ml/kg bupivacaine 0.25 % injected unilaterally at the posterior border of the quadratus lumborum muscle.
11212991|NCT03294291|Active Comparator|Caudal block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory caudal block wil performe with bupivacaine 0.7 ml/kg as 0.25%.
11212992|NCT03294278|Active Comparator|Ablation plus ICD|Epicardial ablation by radio-frequency
11212993|NCT03294278|Active Comparator|ICD alone|Implantation of ICD
11212994|NCT03294265|Experimental|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.
~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
11212995|NCT03294265|Active Comparator|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.
~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
11212996|NCT03294252|Experimental|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the CIPPA procedure (injection and nebulisation in intraperitoneal).
11212997|NCT03294239|Experimental|Group A (Transurethal group)|Patients will have trans urethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone disintegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
11212998|NCT03294239|Experimental|Group B (Percutaneous group)|Patients will have per cutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the mid line 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
11212999|NCT03294226|Experimental|AuraGain|After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
11215522|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E|or matching placebo - HV
11213000|NCT03294226|Active Comparator|I-gel|After anesthetic induction, I-gel is inserted for airway management. Size of the device is selected according to the patient's weight; size 1.5 for 5-10kg, size 2 for 10-20kg.
11213001|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
11213002|NCT03294200|Experimental|Tricinch Coil System treatment|
11213003|NCT03294187|Experimental|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
11213004|NCT03294187|Placebo Comparator|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will *not* receive multimodal feedback.
11213005|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
11213006|NCT03294174||Opioid exposure|Patients who have been exposed to(> 6months), but not currently taking opioids, but will receive ropicacaine injection
11213007|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
11213008|NCT03294161|Experimental|Immucillin DI4G|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .
11213009|NCT03294161|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.
11213010|NCT03294148|Experimental|Placebo|The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
11213011|NCT03294148|Experimental|Psychotherapy|Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.
11213012|NCT03294148|No Intervention|Waitlist|Wait-listed patients will be asked not to change their treatment regime for the 4 weeks in between their two fMRI sessions. Wait-listed patients in the placebo injection arm will be offered the opportunity to receive the placebo treatment (optional). Waitlisted participants in the psychotherapy arm will be given a copy of Dr. Schubiner's book and free access to his online self-help program (optional to accept these).
11213013|NCT03294135|Experimental|Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 28 (+10) and 300 (+21), booster vaccination of 55 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
11213014|NCT03294135|Experimental|Accelerated/Rapid Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 7 (+3) and 21 (+7), booster vaccination of 9 subjects in study V48P7E1 (NCT00387634) 40 subjects received their booster vaccination before enrolment in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
11213015|NCT03294135|Experimental|Accelerated Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 133 subjects in study V48P7 on Days 0, 14 (+3) and 300 (+21), booster vaccination of 109 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
11213016|NCT03294122||PCa patients - Discovery cohort|External beam radiotherapy for prostate cancer
11213017|NCT03294122||HNCa patients - Discovery cohort|External beam radiotherapy for head and neck cancer
11213018|NCT03294122||PCa patients - Validation cohort|External beam radiotherapy for prostate cancer
11213019|NCT03294122||HNCa patients - Validation cohort|External beam radiotherapy for head and neck cancer
11213020|NCT03294109|Experimental|study|liposomal bupivacain
11213021|NCT03294109|No Intervention|control|no intervention
11213022|NCT03294096|Experimental|experimental group|
11213023|NCT03294096|Active Comparator|control group|
11213024|NCT03294083|Experimental|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.
~REGN2810 will be administered via IV infusion every 3 weeks."
11213025|NCT03294083|Experimental|Part 2, Pexa-Vec (IT) and REGN2810|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.
~REGN2810 will be administered via IV infusion every 3 weeks."
11213026|NCT03294083|Experimental|Part 2, REGN2810|"REGN2810 will be administered via IV infusion every 3 weeks.
~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. REGN2810 will continue every 3 weeks."
11213027|NCT03294083|Experimental|Part 2, Pexa-Vec (IV) and REGN2810|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.
~REGN2810 will be administered via IV infusion every 3 weeks."
11279979|NCT02834325||failure|HFNC with need for mechanical ventilation
11213028|NCT03294070|Experimental|Fimasartan 60 mg + amlodipine besylate 5 mg|Fimasartan 60 mg + amlodipine besylate 5 mg. In subjects with a DBP equal to or greater than 90 mmHg and / or SBP equal to or greater than 140 mmHg at week 8, the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD (in these cases, the subject will receive one 60 mg Fimasartan tablet plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate tablet.
11213029|NCT03294057|Experimental|ICT programs + Tele-coaching programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. And a trained nurse provides tele-coaching programs to subjects. After that, subjects will conduct self-management health care and tele-coaching programs for 12 weeks. After 3 months, they finish self-management ICT + coaching programs, and then they fill out the questionnaire.
11213030|NCT03294057|Experimental|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
11213031|NCT03294057|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
11213032|NCT03294044|Experimental|ICT programs|ICT programs that include health information learning by disease, and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
11213033|NCT03294044|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
11213034|NCT03294031|Experimental|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
11213035|NCT03294031|Active Comparator|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
11213036|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
11213037|NCT03294005||Subjects with nodular goiter|Enrolled subjects with nodular goiter had thyroid sonography and thyroidectomy from 2002 January to 2016 December in CMUH. Total enrolled subject about 2000. These subjects were confirmed by pathology. Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients. Gray scale ultrasonography was routinely performed in every subject. Color Doppler ultrasonography for blood flow and thyroid fine needle aspiration was not absolute done in routine procedure. All data at least was interpreted by 3 endocrinologists under the blind method. Each subject was analyzed under thyroid echogenicity, margin, calcification, inclusion, grooving change and size & ratio size of tall and transverse.
11213038|NCT03293992|Experimental|0.01% RO7058584 or Matching Placebo|
11213039|NCT03293992|Experimental|0.1% RO7058584 or Matching Placebo|
11213040|NCT03293992|Experimental|1% RO7058584 or Matching Placebo|
11213041|NCT03293992|Experimental|RO7058584 and Latanoprost 0.005%|
11213042|NCT03293940|Experimental|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.
~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
11213043|NCT03293940|Active Comparator|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.
~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
11213044|NCT03293927|Experimental|Fentanyl + Dexmedetomidine|
11213045|NCT03293927|Experimental|Dexmedetomidine + Fentanyl|
11213046|NCT03293927|Experimental|Fentanyl only|
11213047|NCT03293927|Experimental|Dexmedetomidine only|
11213048|NCT03293914|Experimental|Intervention|Participants will be invited to enroll in an occupational therapy (OT) lifestyle redesign intervention focused on diabetes management. The intervention includes approximately 8 one-hour OT sessions over 4 months.
11213049|NCT03293914|No Intervention|Usual Care Control|Participants will not be contacted; outcome data will be extracted from medical records.
11213050|NCT03293901|No Intervention|Rest|
11213051|NCT03293901|Active Comparator|Exercise|Militarily relevant exercise
11213052|NCT03293875|Other|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
11213053|NCT03293875|Other|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
11213054|NCT03293862|Active Comparator|Suture group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
11213055|NCT03293862|Experimental|Prophylactic mesh group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
11213056|NCT03293849|Experimental|Patient Navigation Arm|After an assessment of supportive care needs, a patient navigator will present assessment results and develop and implement a personalized supportive care intervention plan based on the findings in collaboration with a multidisciplinary supportive care team, formed by oncologists and pain and palliative care specialists. The developed plan will be sent to the treating oncologist and oncology team.
11213057|NCT03293849|No Intervention|Control Arm|Assessment results will be provided in printed and electronic form to the treating oncologist for their review. Referrals or interventions for patients allocated to the control arm will be coordinated by the treating oncologist without involvement from the patient navigator or the study team.
11213058|NCT03293836|Experimental|Radiofrequency treatment|Radiofrequency ablation of insufficient saphenous and perforating veins plus multilayer compressive bandage treatment
11213059|NCT03293836|Active Comparator|Multilayer Compressive Bandage only|Receive only compressive treatment
11213060|NCT03293823|Experimental|vision-based speed of processing (VSOP) cognitive training|use the INSIGHT online program (Posit Science), which includes five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
11213061|NCT03293823|Active Comparator|active control|The standardized computerized leisure activities program - MLA, including crossword puzzle, Sudoku, etc. will be used
11213062|NCT03293797|Experimental|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
11213063|NCT03293784|Other|COHORT 1|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
11213064|NCT03293784|Other|COHORT 2|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
11213065|NCT03293771||Stage 1 Focus Groups|The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.
11213066|NCT03293771||Stage 2 Questionnaire Groups|Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.
11213067|NCT03293745|Active Comparator|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
11213068|NCT03293745|Experimental|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
11213069|NCT03293732|Active Comparator|HA antigen only|All subjects in this group received 2 doses of 22.2 μg HA antigens
11213070|NCT03293732|Experimental|7.5 μg of DCB07010|All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.
11213071|NCT03293732|Experimental|15 μg of DCB07010|All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.
11213072|NCT03293732|Experimental|30 μg of DCB07010|All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.
11213073|NCT03293732|Experimental|45 μg of DCB07010|All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.
11213074|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
11213075|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
11213076|NCT03293706|Active Comparator|CHO Control 1 Glucose|25 g glucose
11213077|NCT03293706|Active Comparator|CHO Control 2 Glucose|25 g glucose
11213078|NCT03293706|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
11213079|NCT03293706|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
11213080|NCT03293706|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
11213081|NCT03293706|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
11213082|NCT03293693|Experimental|Test meal 1|Test meal with 0.5 g beta-glucan
11213083|NCT03293693|Experimental|Test meal 2|Test meal with 3.5 g beta-glucan
11213084|NCT03293693|Experimental|Test meal 3|Test meal with 8 g beta-glucan
11213085|NCT03293680|Experimental|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
11213086|NCT03293667|Other|Exploratory arm|
11213087|NCT03293654|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11213088|NCT03293654|Active Comparator|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11213089|NCT03293654|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
11213090|NCT03293641|Experimental|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
11213091|NCT03293641|Placebo Comparator|Control Arm|Standard of Care for 6 months
11213092|NCT03293628|Experimental|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
11213093|NCT03293628|Active Comparator|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
11213094|NCT03293615|Experimental|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
11213095|NCT03293615|Active Comparator|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
11213097|NCT03293602|Experimental|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
11213098|NCT03293589||OR|patients treated with open revascularization
11213099|NCT03293589||EVT|patients treated with endovascular revascularization
11213100|NCT03293576|Experimental|Intervention|Volitional help sheet
11213101|NCT03293576|No Intervention|Control|Short Zimbardo's time perspective inventory (Orosz et al. 2017)
11213102|NCT03293563||Patients|Adult patients with kidney cancer
11213103|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
11213104|NCT03293537|Experimental|Patients with dementia|The subject will be informed of the procedure and their task before the sensors are attached. Electrodermal activity (EDA) and heart rate (HR) will be continuously monitored while the subject views the image sequence on a PC monitor. EDA will be measured using electrodes attached to the middle (D3) and ring finger (D4). Heart rate will be measured using an infrared pulseoximeter attached to one of the free digits of the hand. A pulseoximeter is a non-invasive sensor, using tissue absorption of infrared light to determine blood-oxygen saturation (SaO2). EDA and HR will be recorded concurrently using commercial software. Data analysis will involve both commercial and in-house software.
11213105|NCT03293524|Experimental|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
11213106|NCT03293524|Placebo Comparator|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
11213107|NCT03293511|Experimental|Order of administration: oxytocin - placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
11213108|NCT03293511|Experimental|Order of administration: placebo - oxytocin|Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
11213109|NCT03293498|Experimental|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
11213110|NCT03293498|Experimental|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
11213111|NCT03293498|Active Comparator|Group C|Fluzone HD - Day 0; Saline - Day 21
11213112|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
11213113|NCT03293472|Experimental|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm.
~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
11213114|NCT03293472|Active Comparator|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients < 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml > 180 cm.
~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
11213115|NCT03293459|Experimental|Shunt Occlusion +SMT|Shunt Occlusion +SMT
11213116|NCT03293459|Active Comparator|Standard Medical Treatment (SMT)|
11213117|NCT03293446|Experimental|Patients with chronic kidney disease|
11213118|NCT03293446|Active Comparator|Healthy controls|
11213119|NCT03293433||Patient with lung cancer|Patient with pulmonary nodule showed in scanner (defined as a rounded picture higher than 5 mm and less than 30 mm in the lung parenchyma) presenting at one of the 3 participant services and meeting the inclusion criteria and exclusion. A blood punction will be performed in order to extract micro RNA.
11213120|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
11213121|NCT03293394|Experimental|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
11213122|NCT03293394|Placebo Comparator|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
11213123|NCT03293368|Experimental|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
11213124|NCT03293368|Active Comparator|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
11213125|NCT03293355|No Intervention|Control|Standard of care
11213126|NCT03293355|Experimental|Intervention|"The VPN intervention has 2 in-person sessions:
~1) Providing training on service integration and team building for CHW and tools for them to network more effectively with OPC and MMT treatment providers as well as reach out to their patients; and 2) Learning to use effective communication tools such as motivational ruler and decision balance sheet to work more effectively with their patients and use Facebook group to facilitate collaboration among providers and e-chat for patient engagements. Sessions will occur once a week for two weeks, with each session featuring a different set of themes and relevant activities."
11213127|NCT03293342|Experimental|D CBT|Dentist administered cognitive behaviioral treatment
11213128|NCT03293342|Active Comparator|Control|Treatment as usual
11213129|NCT03293329|Experimental|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
11213130|NCT03293329|Experimental|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
11213223|NCT03292679|No Intervention|Control|Subjects that are randomized into Arm A will have their fractures repaired in the usual fashion i.e. using plates that are bent by free hand.
11213131|NCT03293329|Active Comparator|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
11213132|NCT03293316|Sham Comparator|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
11213133|NCT03293316|Experimental|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
11213134|NCT03293316|Experimental|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
11213135|NCT03293303|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
11213136|NCT03293303|No Intervention|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
11213137|NCT03293290|Experimental|PrEP|For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
11213138|NCT03293277|Experimental|A1|20µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
11213139|NCT03293277|Experimental|A2|20µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intranasally on Day 8
11213140|NCT03293277|Experimental|B1|40µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
11213141|NCT03293277|Experimental|B2|40µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intranasally on Day 8
11213142|NCT03293277|Experimental|C|80µg Dexmedetomidine or Placebo is administered intranasally on Day 1
11213143|NCT03293264|Experimental|Exercise training group|The intervention group will be encouraged to perform 150 min of exercise training per week for 6 months. Subjects will be provided with individual feedback and exercise Training prescriptions. After month 6 subjects will be randomized to three different groups for follow-up observation.
11213144|NCT03293264|No Intervention|Waiting-control group|The control group will be provided with general informations on a healthy lifestyle. After 6 months wait-list-control months subjects will receive the guided exercise training intervention for 6 months.
11213145|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
11213146|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
11213147|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
11213148|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
11213149|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
11213150|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
11213151|NCT03293225||add H2RA|Add antihistamines to standard drug therapy
11213152|NCT03293225||change ns-H1RA|Change to ns-H1RA in standard medication
11213153|NCT03293225||ns-H1RA(3-4 tabs)|Standard treatment with ns-H1RA 4X dose
11213154|NCT03293225||ns-H1RA(3-4kinds)|Use of NS 4 kinds for standard treatment
11213155|NCT03293199|Active Comparator|Chest tube drainage|This group will undergo chest tube drainage as an intervention for spontaneous pneumothorax treatment.
11213156|NCT03293199|Active Comparator|Needle aspiration|This group will undergo repetitive needle aspiration as an intervention for spontaneous pneumothorax treatment.
11213157|NCT03293186|Experimental|Use MEDICLORE|use mediclore at the end of surgery
11213158|NCT03293186|No Intervention|No antiadhesive product|use no antiadhesive product at the end of surgery
11213159|NCT03293173|Experimental|Group A|Biologically low risk group, R-CHOEP-14
11213160|NCT03293173|Experimental|Group B|Biologically high risk group, DA-EPOCH-R
11213161|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
11213162|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
11213163|NCT03293147|Experimental|Arm A|Intervention group: Non-adherent hypertensive patients randomised in Arm A will receive standard clinical care plus HPLC-MS/MS-guided intervention.
11213164|NCT03293147|Active Comparator|Arm B|Control group: Non-adherent hypertensive patients randomised in Arm B will receive clinical standard care.
11213165|NCT03293147|Active Comparator|Arm C|Control group: Adherent hypertensive patients randomised in Arm C will receive clinical standard care.
11213166|NCT03293121|Experimental|Strength and Coordination Training|The strength and coordination group will perform a progression of exercises utilizing body weight and resistance bands as resistance. Exercises include squats, lunges, jumps etc. typical of a normal strength training program.
11213167|NCT03293121|Active Comparator|Walking|The walking group will be instructed to walk 3x/week, progressing from 30 to 45 min over 8 weeks.
11213220|NCT03292705|Active Comparator|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
11213168|NCT03293108|Experimental|AryoGen Pharmed Denosumab|"Arylia (Denosumab Prefilled Syringe produced by AryoGen Pharmed) 60 mg/1 ml in a prefilled syringe.
~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
11213169|NCT03293108|Active Comparator|Amgen Denosumab|"Prolia® (Denosumab Prefilled Syringe produced by Amgen) 60 mg/1 ml in a prefilled syringe.
~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
11213170|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
11213171|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
11213172|NCT03293069|Experimental|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
11213173|NCT03293069|Placebo Comparator|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
11213174|NCT03293056|Experimental|High-intensity Interval Hydrogynmastics|High-intensity Interval training Hydrogynmastics, 2x/week, for 3 months.
11213175|NCT03293056|Active Comparator|Hydrogynmastics Continuous Moderate|Hydrogynmastics Continuous Moderate training (HCM), 2x/week, for 3 months.
11213176|NCT03293043|Experimental|Experimental Group|After initial screening, appropriately obtained informed consent and confirmation of eligibility at time of transplant, those recipients (a total of 12 subjects) who agree to continue as participants will receive reconditioned marginal lungs should the lungs on the device meet acceptable criteria to proceed with clinical transplantation.
11213177|NCT03293030|Experimental|Dupilumab treatment|15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.
11213178|NCT03293017|Experimental|Baclofen 30 mg/day|baclofen 30 mg/day
11213179|NCT03293017|Experimental|Baclofen 60 mg/day|
11213180|NCT03293017|Placebo Comparator|Placebo|
11213181|NCT03293004|Experimental|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
11213182|NCT03293004|Experimental|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
11213183|NCT03293004|Experimental|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
11213184|NCT03293004|Placebo Comparator|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
11213185|NCT03292978|Experimental|probiotics intervention|"The probiotic is provided in sachets as a 2g powder dried with corn starch.
~The powder is orally taken once daily for 4 weeks.
~The powder contains totally 11 log 10 colony forming units(CFU) of probiotics.
~The types of probiotics are Lactobacillus.rhamnosus, Lactobacillus.acidophilus, Bifidobacteria.animalis and Bifidobacteria.longum."
11213186|NCT03292978|Placebo Comparator|non-probiotic control|The placebo is corn starch alone provided and the shape, color, weight,flavor and taste are same with the powder of probiotics intervention.
11213187|NCT03292965|Active Comparator|Neostigmine|"At the end of surgery, administrating neostigmine to participants according to the protocol below:
~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
11213188|NCT03292965|Active Comparator|Sugammadex|"At the end of surgery, administrating sugammadex to participants according to the protocol below:
~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
11213189|NCT03292952|Experimental|Active Treatment|KP415 oral capsule 20, 30 or 40 mg
11213190|NCT03292952|Placebo Comparator|Placebo Treatment|Placebo oral capsule
11213191|NCT03292939|Other|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
11213221|NCT03292692|Experimental|OurRelationship|Online Intervention
11213192|NCT03292926|Active Comparator|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
11213193|NCT03292926|Active Comparator|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
11213194|NCT03292913|Experimental|Intervention Group|Receives the Positive Health Check intervention plus standard of care
11213195|NCT03292913|Other|Control Group|Receives standard of care
11213196|NCT03292887||Elaprase Treated|Participants with Hunters Syndrome received or receiving treatment with Elaprase as prescribed by their physician following locally approved prescribing information.
11213197|NCT03292887||Elaprase Non-Treated|Participants received no treatment for Hunters Syndrome.
11213198|NCT03292874|Other|Paired imaging|Single arm, paired imaging of high resolution MRI (hrMRI) and stand MRI (sMRI)
11213199|NCT03292861|Active Comparator|Thymoglobulin®|"Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.
~In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation"
11213200|NCT03292861|No Intervention|No induction therapy|Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.
11213201|NCT03292848|Experimental|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
11213202|NCT03292848|Experimental|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
11213203|NCT03292822|Experimental|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.
11213204|NCT03292822|Active Comparator|Paclitaxel|chemotherapeutic drug
11213205|NCT03292809|Experimental|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
11213206|NCT03292809|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle only
11213207|NCT03292796|Other|Stop prostaglandin eye drops post op|Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
11213208|NCT03292796|Other|Continue prostaglandin eye drops post op|Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
11213209|NCT03292783|Experimental|NOV150101 (ABL001)|
11213210|NCT03292770|No Intervention|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
11213211|NCT03292770|Experimental|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.
~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
11213212|NCT03292757|Experimental|Mesenteric ICG|Indocyanine green injected into the small bowel mesentery during oesophagectomy.
11213213|NCT03292757|Experimental|Feeding jejunostomy ICG (cream)|Indocyanine green mixed with cream infiltrated into the feeding jejunostomy.
11213214|NCT03292744|Experimental|Alfacalcidol|Alfacalcidol 0,5 mcg once daily for 90 days
11213215|NCT03292744|Placebo Comparator|Placebo|Amylum same capsule form, weight and colour with treatment arm
11213216|NCT03292731|Active Comparator|hydroxyprogesterone caproate 250 mg|Pregnant subject will receive 250mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
11213217|NCT03292731|Experimental|hydroxyprogesterone caproate 500 mg|Pregnant subject will receive 500mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
11213218|NCT03292718|Experimental|use of MyCyFAPP|use of MyCyFAPP during 6 months
11213219|NCT03292705|Experimental|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.
~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.
~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
11213222|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
11213224|NCT03292679|Experimental|3D template|Subjects that are randomized into Arm B will have custom models of relevant portions of their facial skeleton printed and used as templates for bending and shaping plates for stabilizing the fracture(s).
11213225|NCT03292666||Extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for > 3 months
11213226|NCT03292666||No extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for no longer than 3 months
11213227|NCT03292653|Experimental|Sotagliflozin Cohort 1|Cohort 1 will receive sotagliflozin (SAR439954) dose 1 administered as one dose 1 tablet plus one placebo sotagliflozin tablet once daily (OD) prior to the first meal of the day for 14 days.
11213228|NCT03292653|Experimental|Sotagliflozin Cohort 2|Cohort 2 will receive sotagliflozin (SAR439954) dose 2 administered as two dose 1 tablets OD prior to the first meal of the day for 14 days.
11213229|NCT03292653|Experimental|Sotagliflozin Cohort 3|Cohort 3 will be allocated to sotagliflozin (SAR439954) dose 1 or dose 2 administered as two tablets OD prior to the first meal of the day for 14 days.
11213230|NCT03292653|Placebo Comparator|Placebo|Placebo sotagliflozin administered as two placebo tablets (identical to sotagliflozin dose 1 tablets in appearance) OD prior to the first meal of the day for 14 days.
11213231|NCT03292640|Experimental|DFD-03 Lotion (0.1% tazarotene)|DFD-03 Lotion (0.1% tazarotene)
11213232|NCT03292640|Placebo Comparator|DFD-03 Vehicle (0% tazarotene)|DFD-03 Vehicle Lotion (0% tazarotene)
11213233|NCT03292627||mid age|mid age: 50-70 years old
11213234|NCT03292627||old age|old age: age older than 70 years old
11213235|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
11213236|NCT03292601|Experimental|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
11213237|NCT03292588|Experimental|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
11213238|NCT03292588|Placebo Comparator|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
11213239|NCT03292575||Stroke related to CAAF|
11213240|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
11213241|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
11213242|NCT03292549||Patients|Robotic partial surgery
11213243|NCT03292536|Experimental|Merestinib, all patients|
11213244|NCT03292523||Hyperventilation syndrome|
11213245|NCT03292510|Experimental|GO-OUT Group|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes.
11213246|NCT03292510|Active Comparator|Workshop Group|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
11213247|NCT03292497|Experimental|Treatment algorithm|"Mitral valve will be replaced if posterior leaflet tethering angle >=25 degrees.
~Mitral valve will be repaired if posterior leaflet tethering angle <25 degrees"
11213248|NCT03292497|Active Comparator|No treatment algorithm|Mitral valve will be repaired or replaced at surgeon's discretion.
11213249|NCT03292484|Experimental|Treatment Pathway 1, 2, 3, 4, 5|Subjects will be assigned to one of five treatment pathways when first enrolled into ARC008, which is dependent on the treatment received (AR101 or placebo) during the parent study and their tolerance of this treatment regimen (e.g., daily or non-daily schedule).
11213250|NCT03292471|Experimental|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
11213251|NCT03292471|Experimental|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
11213252|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
11213253|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
11213254|NCT03292445|Experimental|Immune tolerance after kidney transplant|Immune tolerance after kidney transplant will be induced by transfusion of enriched donor blood stem cells and T cells to initiate blood cell mixed chimerism in patients conditioned with total lymphoid irradiation and rabbit anti-thymocyte globulin after kidney transplant. Patients will receive corticosteroids for 14 weeks with gradual dose reduction. They will also receive 12 months of mycophenolate mofetil and 18 months of tacrolimus with dose tapering beginning 9 months post-transplant and continuing as long as mixed chimerism is maintained and there is no evidence of graft versus host disease and no kidney rejection evident. Patients losing chimerism will continue on low dose immunosuppressive drug doses unless additional kidney rejection therapy is needed.
11213256|NCT03292432|Experimental|TERA Intervention|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
11213257|NCT03292419|Other|Topography guided LASI|
11213258|NCT03292406|Experimental|Group 1|Placebo followed by CD11301 (0.03%) Topical Gel
11213259|NCT03292406|Experimental|Group 2|CD11301 (0.03%) Topical Gel
11213260|NCT03292406|Experimental|Group 3|CD11301 (0.06%) Topical Gel
11213261|NCT03292393|Active Comparator|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
11213262|NCT03292393|Active Comparator|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
11213263|NCT03292393|Placebo Comparator|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
11213264|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
11213265|NCT03292367||ldTRA|Patients who are planned to perform coronary angiography will be enrolled via left distal radial artery
11213266|NCT03292354|Active Comparator|Body Weight (BW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on body weight.
11213267|NCT03292354|Active Comparator|Cardiac output (CO)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on cardiac output.
11213268|NCT03292354|Active Comparator|Lean Body weight (LBW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on Lean Body Weight.
11213269|NCT03292354|No Intervention|Control group|Patients in this group will be included retrospectively and have received the standard CM injection protocol previously used in our department.
11213270|NCT03292341|Experimental|Patients|"Patients diagnosed with larynx cancer and ex-larynx cancer patients:
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
11213271|NCT03292341|Experimental|Clinicians|"2.Clinicians Radiotherapy-oncologists, ENT(Ear-Nose-Throat)-specialists, General practitioners, Nurses
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
11213272|NCT03292341|Experimental|Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
11213273|NCT03292328|Experimental|Yoga Arm|After randomization, participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
11213274|NCT03292328|Active Comparator|Wait List Control Arm (WLC)|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
11213275|NCT03292315|Experimental|Exenatide 2 MG Injection [Bydureon]|20 subjects will be randomized to receive once weekly injection of Exenatide (Bydureon 2mg) for 26 weeks.
11213276|NCT03292315|Other|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
11213277|NCT03292302|Placebo Comparator|Placebo Comparator Arm|
11213278|NCT03292302|Active Comparator|Active treatment|ELX-02
11213279|NCT03292289|Experimental|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
11213280|NCT03292276|Experimental|Amadeo training|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The robotic exercises will be carried in passive modality (15 minutes), passive/plus (15 minutes), assisted modality (15 minutes).
11213281|NCT03292276|Active Comparator|occupational therapy|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The control group will receive the same amount of training by physiotherapist skilled in occupational tharapy.
11213282|NCT03292263|Experimental|Mel+Nivo|Autologous Stem Cell Transplant Drug: Melphalan 140-200 mg/m^2, Nivolumab100 mg iv days -3, +17
11213283|NCT03292250|Experimental|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
11213284|NCT03292250|Experimental|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
11213285|NCT03292250|Experimental|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
11213541|NCT03290274|Experimental|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
11213286|NCT03292250|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
11213287|NCT03292250|Experimental|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)
~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
11213288|NCT03292237|No Intervention|Standard Nutrition Arm|"In ICU:
~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.
~PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.
~Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.
~After ICU:
~Nutrition management will be as per usual site management at that hospital.
~Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
11213289|NCT03292237|Experimental|Intensive Arm|"Intervention
~In ICU:
~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation
~The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge
~If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.
~After ICU:
~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
11213290|NCT03292211|Experimental|early mobilization|early mobilization group will commence rehabilitation consisting of out-of-bed mobilization (including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.)
11213291|NCT03292211|Other|early standard intervention|early standard intervention included bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and the facilitation techniques during the period in a stroke center.
11213292|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.
~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
11213293|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.
~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
11213294|NCT03292185|Experimental|IDeglira-IDeg-Liraglutide|Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide
11213295|NCT03292185|Experimental|IDeglira-Liraglutide-IDeg|Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec
11213296|NCT03292185|Experimental|IDeg-Liraglutide-IDeglira|Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide
11213297|NCT03292185|Experimental|IDeg-IDeglira-Liraglutide|Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide
11213298|NCT03292185|Experimental|Liraglutide-IDeg-IDeglira|Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide
11213299|NCT03292185|Experimental|Liraglutide-IDeglira-IDeg|Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec
11213300|NCT03292172|Experimental|Group 1 - Escalation Dose: RO6870810 + Atezolizumab|Participants will be administered escalating doses of RO6870810 (0.3 milligram per kilogram [mg/kg], 0.45 mg/kg, and 0.65 mg/kg) subcutaneously (SC) once daily (QD) along with fixed dose of atezolizumab 1200 mg intravenously (IV) on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
11213301|NCT03292172|Experimental|Group 2 - Sequential Dose: RO6870810 + Atezolizumab|Participants will be administered RO6870810 monotherapy (starting dose 0.30 mg/kg) during the first 14 days of 21-day Run-in period. Following the Run-in period, participants will continue to receive RO6870810 at the same dose in combination with fixed dose of atezolizumab 1200 mg IV every 3 weeks in 21-day cycles.
11213302|NCT03292172|Experimental|Group 3 - Expansion in TNBC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
11213303|NCT03292172|Experimental|Group 4 - Expansion in OC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
11213304|NCT03292159|Experimental|RAVANS|
11213305|NCT03292159|Sham Comparator|Sham stimulation|
11213306|NCT03292146|Experimental|Active Denosumab 60mg Injection|Denosumab 60mg injection at baseline study visit and 6 month study visit.
11213307|NCT03292146|Placebo Comparator|Placebo|Placebo injection at baseline study visit and 6 month study visit.
11213362|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
11213308|NCT03292133|Experimental|EGF816 + Gefitinib|"All patients will receive gefitinib orally once daily
~EGF816 will be administered orally once daily
~Participant will be requested to maintain a medication diary of each dose of medication"
11213309|NCT03292120|Experimental|patients with septic shock|
11213310|NCT03292094||Black men|294 young healthy men were included (clinic normotensive, non-HIV)
11213311|NCT03292094||White men|284 young healthy men were included (clinic normotensive, non-HIV)
11213312|NCT03292094||Black women|312 young healthy women were included (clinic normotensive, non-HIV)
11213313|NCT03292094||White women|312 young healthy women were included (clinic normotensive, non-HIV)
11213314|NCT03292081|Experimental|OFDI-guided PCI|
11213315|NCT03292081|Active Comparator|IVUS-guided PCI|
11213316|NCT03292068|Experimental|Acupuncture, acupressure|"Intervention with Pyonex-needles & Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.
~Intervention Acupressure & Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
11213317|NCT03292068|Experimental|Timbal diet|"Timbal diet including ice cream & Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
11213318|NCT03292068|Other|Extended telephone counseling|Extended telephone counseling & Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
11213319|NCT03292042|Experimental|Experimental Group|"This group will carry out the lifestyle intervention (Physical health promotion program) during 6 months.
~The group will attend a session per week."
11213320|NCT03292042|No Intervention|Control group|usual care
11213321|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
11213322|NCT03292016|Experimental|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
11213323|NCT03292016|Active Comparator|Subcutaneous APO-go|Subcutaneous APO-go, once daily
11213324|NCT03292016|Active Comparator|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
11213325|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
11213326|NCT03291990|Experimental|5 fraction radiotherapy with standard temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
11213327|NCT03291977|Experimental|Fluorescein sodique FAURE|Fluorescein (Fluorescéine sodique FAURE) will be given intravenously during the induction of the anesthesia
11213328|NCT03291977|Active Comparator|White-light surgery|"In the control arm, the surgery will be performed under classical conditions (so-called  white-light  surgery)."
11213329|NCT03291951|Experimental|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
11213330|NCT03291951|No Intervention|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
11213331|NCT03291938|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7 of cycle 1 in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of cycle 1 and then on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11213332|NCT03291925|Experimental|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
11213333|NCT03291925|Active Comparator|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
11213334|NCT03291912|Experimental|Chuna Manual Therapy (CMT)|"Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)
~Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)
~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.
~CMT and UC group will receive the same UC regimen."
11213363|NCT03291678|Experimental|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
11213542|NCT03290261|Experimental|Patients with reccurent cystitis|Patient perform 3 hypnosis sessions
11279980|NCT02834312|Experimental|2.5 mg estetrol|
11213335|NCT03291912|Active Comparator|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)
~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).
~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.
~CMT and UC group will receive the same UC regimen."
11213336|NCT03291899|Experimental|Experimental single arm|"Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:
~Oxaliplatin-85 mg/m2 IV Day 1
~Leucovorin-400 mg/m2 IV Day 1
~Irinotecan-180 mg/m2 IV Day 1
~Fluorouracil (FU)-400 mg/m2 IV bolus Day 1
~Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1"
11213337|NCT03291886|Experimental|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.
~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
11213338|NCT03291886|Placebo Comparator|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.
~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
11213339|NCT03291873|Active Comparator|topography guided PRK in one eye|Topography-guided (placido disk- based) using T-CAT Contoura treatment.
11213340|NCT03291873|Active Comparator|Q-value adjusted ( custom Q) PRK in the other eye|The target Q will be estimated according to a nomogram considering the patient's age
11213341|NCT03291847|Experimental|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
11213342|NCT03291847|Active Comparator|Methadone treated|Participants receiving methadone treatment for opioid use disorder during pregnancy
11213343|NCT03291821|Experimental|DuoStim|Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
11213344|NCT03291821|Active Comparator|Conventional Stimulation|Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
11213345|NCT03291808|Experimental|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
11213346|NCT03291795|Experimental|Exercise Intervention|
11213347|NCT03291782|Experimental|D-0120 Dose 1|D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation
11213348|NCT03291782|Experimental|D-0120 Dose 2|D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation
11213349|NCT03291782|Experimental|D-0120 Dose 3|D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation
11213350|NCT03291782|Experimental|D-0120 Dose 4|D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation
11213351|NCT03291782|Experimental|D-0120 Dose 5|D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.
11213352|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
11213353|NCT03291743|Experimental|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
11213354|NCT03291743|Active Comparator|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
11213355|NCT03291730|Experimental|Hand Lettering|"The participant will engage in art-therapy by tracing and coloring a detailed letter or word
~Participants will also be guided through a relaxation breathing and journaling exercise that can be incorporated into the art activity."
11213356|NCT03291717|Experimental|Bridging Community Gaps Photovoice (BCGP)|The BCGP program is a 6-month photovoice-based intervention to help individuals with psychiatric disabilities enhance their community participation.
11213357|NCT03291717|No Intervention|Services as Usual|Individuals in this group continue with their regular mental health services with no additional intervention.
11213358|NCT03291704|Experimental|Thermal Therapy|Heat application using at home thermal therapy device
11213359|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
11213360|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
11213361|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
11213543|NCT03290248|Placebo Comparator|Vehicle|"Intranasal application:
~1 pump (140ul) per nostril BID for 14 days"
11213364|NCT03291678|Active Comparator|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
11213365|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.
~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.
~Diagnosis procedure: DSA/3DRA"
11213366|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.
~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.
~Diagnosis procedure: DSA/3DRA"
11213367|NCT03291613|Experimental|Pinpoint App|Tablet application.
11213368|NCT03291600|Experimental|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
11213369|NCT03291600|No Intervention|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
11213370|NCT03291587|Experimental|Intervention - Key Informant|NCORP site coordinator will call each participant to administer a 5 minute telephone survey within 14 days of the lung cancer screening clinic visit. A participant contact log is appended. This assessment focuses on exposure to the intervention and subsequent quit attempts.
11213371|NCT03291587|No Intervention|Usual Care|Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)
11213372|NCT03291574|Experimental|Electroacupuncture group|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
11213373|NCT03291574|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
11213374|NCT03291561|Experimental|Electroacupuncture group|Electroacupuncture Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
11213375|NCT03291561|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu, sanli and bilateral Tian shu.
11213376|NCT03291548|Experimental|Quinoa Biscuit|The quinoa-enriched biscuits containing 7.11g quinoa flour.
11213377|NCT03291548|Placebo Comparator|Control biscuit|The placebo control biscuit: an iso-energetic, matched product in terms of appearance, taste, texture and smell.
11213378|NCT03291535|Placebo Comparator|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
11213379|NCT03291535|Active Comparator|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
11213380|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
11213381|NCT03291509|Active Comparator|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
11213382|NCT03291509|Experimental|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
11213383|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
11213384|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
11213385|NCT03291496||Healthy Adult|One-time whole blood draw of 1ml collection
11213386|NCT03291483|Experimental|whole body vibration group|basketball players had done exercises on whole body vibration platform.
11213387|NCT03291483|Sham Comparator|plyometric training|Basketball players had done same plyometric exercises
11213388|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
11213389|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
11213390|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
11213391|NCT03291444|Experimental|CAR-T cells combined with peptide specific dendritic cell|CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell
11213392|NCT03291444|Active Comparator|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
11213393|NCT03291431|Active Comparator|Active iTBS|
11213394|NCT03291431|Sham Comparator|Sham iTBS|
11213395|NCT03291418|Experimental|ATB-346 OR Placebo|Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
11213396|NCT03291418|Active Comparator|Naproxen sodium|Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
11213397|NCT03291405||Body Mass Index less than 30|
11213398|NCT03291405||Body Mass Index more than 30|
11213399|NCT03291392||Atherosclerosis|"Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking.
~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
11213400|NCT03291392||Family members|"The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection.
~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
11213401|NCT03291392||Normal subjects|"Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking.
~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
11213402|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
11213403|NCT03291366|Experimental|MSC|infusion of aUCMSC and conventional therapy
11213404|NCT03291366|Active Comparator|conventional|conventional therapy
11213405|NCT03291353|Experimental|AML Patients|pembrolizumab 200 mg given IV once every three weeks
11213406|NCT03291340||Cognitively normal elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
11213407|NCT03291340||Cognitive impaired elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
11213408|NCT03291327|Active Comparator|Investigational product (Lactobacillus A)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.
~Lactobacillus (A) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
11213409|NCT03291327|Active Comparator|Investigational product (Lactobacillus B)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.
~Lactobacillus (B) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
11213410|NCT03291327|Placebo Comparator|Placebo Product (P)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.
~Placebo (P) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The placebo will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
11213411|NCT03291314|Experimental|Axitinib + Avelumab|On day 1 of the treatment phase, patients recruited to this arm will initiate concomitant continuous daily treatment with axitinib (InlytaTM, 5 mg comp BID) in combination with avelumab (10 mg/kg IV Q2 weeks)
11213412|NCT03291314|Experimental|Axitinib (+Avelumab)|"On day 1 of the treatment phase, patients recruited to this arm will initiate treatment with continuous daily axitinib (InlytaTM, 5 mg comp BID).
~Patients who tolerate treatment with axitinib and are able to taper the dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone (or an equivalent dose of another oral corticosteroid) will initiate combination therapy with avelumab (10 mg/kg IV Q2 weeks) on day 43, following the the first MRI-based tumor response evaluation in week 6.
~Patients who do not tolerate monotherapy with axitinib, or cannot decrease their daily dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone will not be allowed to initiate avelumab treatment."
11213413|NCT03291301|Experimental|CBT Group|Cognitive Behavioral Therapy for Insomnia
11213414|NCT03291301|Experimental|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
11213415|NCT03291301|No Intervention|Wait-list Control Group|
11213416|NCT03291288|Experimental|Pexidartinib|"Part 1 (Drug-drug Interaction Phase):
~On Day 1, all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg). On Day 3, pexidartinib (800 mg/d) in twice daily (400 mg BID) dosing will be initiated and continue throughout the remainder of Part 1 and into Part 2. On the first day of pexidartinib treatment (Day 3), a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning pexidartinib dose (400 mg). On Day 13, a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning dose of pexidartinib (400 mg).
~Part 2 (Efficacy and Safety Phase):
~All participants will continue to receive pexidartinib 400 mg BID."
11213417|NCT03291249|Placebo Comparator|Group A|Group A will receive placebo solution for 30 consecutive days
11213418|NCT03291249|Experimental|Group B|Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
11213419|NCT03291249|Experimental|Group C|Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
11213420|NCT03291249|Experimental|Group D|Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
11213421|NCT03291223||GOS Participants|GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment
11213422|NCT03291210|Experimental|Normoxemia|Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.
11213678|NCT03289338|Placebo Comparator|Placebos|Placebo normal saline
11213423|NCT03291210|Active Comparator|Hyperoxemia|Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.
11213424|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
11213425|NCT03291171|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
11213426|NCT03291171|No Intervention|Waiting-list control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
11213427|NCT03291158|Experimental|Minocycline IV|Open label Minocin IV
11213428|NCT03291145|Experimental|Beta Blockers|With and without Beta Blockers
11213429|NCT03291145|Experimental|Spironolactone|With and without Spironolactone
11213430|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.
~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
11213431|NCT03291093|Experimental|18F-Flutemetamol PET/MRI dynamic|"All included patients will be patients with a recent stroke and a significant carotid plaque.
~The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging."
11213432|NCT03291093|Experimental|18F-Flutemetamol PET/MRI CEA|10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
11213433|NCT03291093|Experimental|18F-Flutemetamol PET/MRI|The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.
11213434|NCT03291080|Experimental|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
11213435|NCT03291080|Experimental|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
11213436|NCT03291067|Experimental|MT-8554 Low dose|
11213437|NCT03291067|Experimental|MT-8554 Medium dose|
11213438|NCT03291067|Experimental|MT-8554 High dose|
11213439|NCT03291067|Placebo Comparator|Placebo|
11213440|NCT03291054|Experimental|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
11213441|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
11213442|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
11213443|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
11213444|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
11213445|NCT03291015|Other|radiographic guided treatment|radiographic guided treatment of kienbock disease using plain x ray for determine treatment plan
11213446|NCT03291015|Other|arthroscopic guided treatment|arthroscopic guided treatment of kienbock disease using wrist arthroscopy for determine treatment plan (Wrist arthroscopy)
11213447|NCT03291002|Experimental|Cohort A|Dose escalation of CV8102
11213448|NCT03291002|Experimental|Cohort B|Optional expansion cohorts of CV8102
11213449|NCT03291002|Experimental|Cohort C|Dose escalation of CV8102 + anti-PD-1 therapy
11213450|NCT03291002|Experimental|Cohort D|Optional expansion of CV8102 + anti-PD-1 therapy
11213451|NCT03290976|No Intervention|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
11213452|NCT03290976|Active Comparator|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
11213453|NCT03290976|Active Comparator|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
11213454|NCT03290963|Active Comparator|Ketamine plus Lithium|Lithium will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of lithium treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and lithium treatment .
11213455|NCT03290963|Placebo Comparator|Ketamine plus Placebo|Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
11213488|NCT03290703|Experimental|Part 2: GDC-0853 (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of one GDC-0853 formulations selected from Part 1 of this study. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
11213456|NCT03290950|Experimental|Cohort 1|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
11213457|NCT03290950|Experimental|Cohort 2|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
11213458|NCT03290937|Experimental|Treatment (irinotecan hydrochloride, cetuximab, utomilumab)|Patients receive irinotecan hydrochloride IV over 90 minutes and cetuximab IV over 1-2 hours on days 1 and 15, and utomilumab IV over 1 hour on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11213459|NCT03290924|Experimental|Intervention|Low-dose high-frequency health worker training approach to update skilled birth attendants in key evidence-based intrapartum and immediate newborn care practices
11213460|NCT03290924|Active Comparator|Comparison|Training on data collection and reporting
11213461|NCT03290898|Active Comparator|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.
~Training session:
~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
11213462|NCT03290898|No Intervention|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
11213463|NCT03290885|Experimental|Combined use of contact aspiration and stent retriever|Combined use of contact aspiration and stent retriever mechanical thrombectomy for recanalization
11213464|NCT03290885|Active Comparator|Stent retriever mechanical thrombectomy alone|Stent retriever mechanical thrombectomy alone for recanalisation
11213465|NCT03290872|Active Comparator|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral Valve Annuloplasty Ring Repair using Carpentier Edwards Physio 2 Complete flexible mitral ring
11213466|NCT03290872|Active Comparator|Simplici T Partial flexible mitral annuloplasty ring|Mitral Valve Annuloplasty Ring Repair using Simplici T Partial flexible mitral annuloplasty ring
11213467|NCT03290859||Training intervention|Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol.
11213468|NCT03290859||Effectiveness of training intervention|Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times.
11213469|NCT03290846|Experimental|Secretin study|PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo cold exposure PET scanning once.
11213470|NCT03290833|Experimental|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
11213471|NCT03290833|Active Comparator|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
11213472|NCT03290820|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
11213473|NCT03290820|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
11213474|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
11213475|NCT03290781|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
11213476|NCT03290781|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
11213477|NCT03290781|Placebo Comparator|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
11213478|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
11213479|NCT03290755||MSM co-infected HIV-HCV|
11213480|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
11213481|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
11213482|NCT03290729|Experimental|narrow ridge|edentulous site with crestal bone width comprised between 3,5 and 5 millimeters wedge shape implants insertion
11213483|NCT03290716|Experimental|SS+SSSC|Salt substitute plus stepwise salt supply control
11213484|NCT03290716|Experimental|SS only|Salt substitute only
11213485|NCT03290716|Experimental|SSSC only|Stepwise salt supply control only
11213486|NCT03290716|No Intervention|control|No salt substitute and no stepwise salt supply control
11213487|NCT03290703|Experimental|Part 1: GDC-0853 (Effect of Formulation)|Participants will receive five single oral doses of test formulations of GDC-0853 co-administered with rabeprazole in the fasted state.
11213489|NCT03290703|Experimental|Part 3: GDC-0853 Optimized (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of an optimized tablet formulations of GDC-0853. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
11213490|NCT03290690||All Subjects|"All subjects in this study will have their wounds imaged and assessed in the following manner:
~Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form"
11213491|NCT03290677|Experimental|CT-guided Percutaneous Cryoablation of Lung Tumor|"Image-guided core needle biopsy to confirm cancer will be perform
~Patients will undergo cryoablation as a standard procedure
~cryoablation will be performed with a three-cycle freeze-thaw phase protocol
~Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
11213492|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
11213493|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
11213494|NCT03290638|Experimental|Dehydrated Human Amnion Chorion Membrane|This membrane was investigated to evaluate its use as an open barrier for guided bone regeneration (GBR) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.
11213495|NCT03290638|Active Comparator|Type I Bovine Collagen Membrane|This membrane has been tested as an open barrier for GBR after tooth extraction. The intentional use of this membrane to the oral environment did not compromise ridge dimensions and bone vitality for implant placement.
11213496|NCT03290625|Experimental|DexKet|Intranasal DEXMEDETOMIDINE (2.0 mcg/kg, maximum 100 mcg) + KETAMINE (1.0 mg/kg, maximum 100 mg)
11213497|NCT03290625|Active Comparator|Dex|DEXMEDETOMIDINE (2.5 mcg/kg, maximum 100 mcg)
11213498|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
11213499|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
11213500|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
11213501|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
11213502|NCT03290573|Active Comparator|Dorsum of hand group|short peripheral venous catheter place in the dorsum of the hand
11213503|NCT03290573|Experimental|Forearm group|short peripheral venous catheter place in the forearm
11213504|NCT03290560|Experimental|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
11213505|NCT03290560|Placebo Comparator|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
11213506|NCT03290547|Other|arm-1|Cutera enLighten laser treatments that allows the user to choose a wavelength between 640nm to 800nm.
11213507|NCT03290534|Experimental|CivaSheet Directional LDR Brachytherapy|FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
11213508|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
11213509|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
11213510|NCT03290508||Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
11213511|NCT03290508||No Prolaris Testing|Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing
11213512|NCT03290495|Active Comparator|isonly|This arm will receive spinal anesthesia. then this arm will receive saline during isoflurane anesthesia. this arm will serve as a control group.
11213513|NCT03290495|Active Comparator|isoket|this arm will receive spinal anesthesia. then will receive isoflurane inhalation. during isoflurane inhalation, this arm will receive single injection of ketamine. at end of anesthesia, effect of ketamine on recovery will be monitored.
11213514|NCT03290482||EE Study Patients 2000-2008|"All patients with the diagnosis of EE from the study period 2000 to 2008. Sixty patients participated in the 10 year follow up phone interview and questionnaire. These are the subjects we will contact to see if they are interested in participating in this study.
~If interested in participating, subjects will complete:
~Evaluation by the PI physical examination
~Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) questionnaires
~Barium Esophagram with maximal and minimal esophageal diameter measurement
~EsophaCap cytology"
11213515|NCT03290469|Experimental|15 day cWGS and Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 15 days of the sample receipt while still undergoing standard of care (SOC).
11213516|NCT03290469|No Intervention|Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 60 days of the sample receipt while still undergoing standard of care (SOC).
11213517|NCT03290456|Experimental|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day will be administered from Day 1 to Month 12
11213518|NCT03290456|Placebo Comparator|Placebo 5mg/day extended of 12 additional months|Placebo 5mg/day will be administered from Day 1 to Month 12
11213519|NCT03290443|Experimental|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
11213520|NCT03290430|Experimental|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
11213521|NCT03290430|Experimental|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
11213522|NCT03290430|Experimental|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
11213523|NCT03290430|Experimental|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.
~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
11213524|NCT03290417|No Intervention|Unmodified Diet|Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
11213525|NCT03290417|Experimental|Diet modification|Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
11213526|NCT03290391|Experimental|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
11213527|NCT03290391|No Intervention|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
11213528|NCT03290378|Active Comparator|AVE-901 50 mg|
11213529|NCT03290378|Active Comparator|AVE-901 25 mg|
11213530|NCT03290378|Placebo Comparator|Placebo|
11213531|NCT03290365|Active Comparator|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
11213532|NCT03290365|Placebo Comparator|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
11213533|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
11213534|NCT03290326|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
11213535|NCT03290313|Experimental|shu gan yi yang capsule|4 capsules / time, 3 times / day, taking 8 weeks
11213536|NCT03290313|Placebo Comparator|shu gan yi yang capsule capsule simulation agent|4 capsules / time, 3 times / day, taking 8 weeks
11213537|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
11213538|NCT03290287||New users of aclidinium bromide|This nested cohort will be composed of patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of aclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and aclidinium/formoterol)
11213539|NCT03290287||New users of other COPD medication|This nested cohort will include patients aged 40 years or older who have previously been diagnosed with COPD and who are new users of other COPD medication: tiotropium, other LAMAs, LABA, LABA/ICS and LAMA/LABA.
11213540|NCT03290274|Experimental|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
11279981|NCT02834312|Experimental|5 mg estetrol|
11213544|NCT03290248|Active Comparator|B 244 1x (low dose)|"Intranasal application:
~1 pump (140ul) per nostril BID for 14 days"
11213545|NCT03290248|Active Comparator|B244 4x (mid dose)|"Intranasal application:
~1 pump (140ul) per nostril BID for 14 days"
11213546|NCT03290235|Experimental|PEG-somatropin-1|Dosage 0.2mg/kg/w
11213547|NCT03290235|Experimental|PEG-somatropin-2|Dosage 0.1-0.2mg/kg/w
11213548|NCT03290222||TRACK|Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
11213549|NCT03290209|Experimental|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
11213550|NCT03290209|Active Comparator|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
11213551|NCT03290196|Other|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:
~size of surgical site
~volume required to cover the area
~individual patient factors that may impact the safety of an amide local anesthetic
~maximum doe of 266 mg (20 mL)"
11213552|NCT03290183||Intrathoracic malignancy|Patients with (strong suspicion of) intrathoracic malignancy and an indication for tissue collection by CT-guided, transthoracic or thoracoscopic approach undergo additional imaging with confocal laser endomicroscopy (CLE).
11213553|NCT03290170|Experimental|Measured resection technique|Measured resection surgical technique
11213554|NCT03290170|Experimental|Gap Balancing Technique|Gap Balancing surgical technique
11213555|NCT03290157|No Intervention|Control group|Regular colonoscopy preparation paper based information provided
11213556|NCT03290157|Other|ColoprAPP group|Regular colonoscopy preparation paper based information provided plus usage of a downloaded SPA (ColoprAPP) as a reminder system for colonoscopy preparation
11213557|NCT03290144||with diabetes|
11213558|NCT03290144||without diabetes|
11213559|NCT03290131|Active Comparator|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
11213560|NCT03290131|Active Comparator|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
11213561|NCT03290131|Placebo Comparator|Placebo|Placebo
11213562|NCT03290118|Experimental|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.
~Intervention is the Nutrition Rating System - Traffic Light"
11213563|NCT03290118|Experimental|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.
~Intervention is the Nutrition Rating System - Health Star Rating"
11213564|NCT03290118|Experimental|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.
~Intervention is the Nutrition Rating System - Warning Labels"
11213565|NCT03290118|No Intervention|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
11213566|NCT03290105||study population|Consecutive critically-ill patients admitted to the ICU and receiving invasive mechanical ventilation for more than 48 hours
11213567|NCT03290092|Experimental|Treatment|
11213568|NCT03290079|Experimental|Pembrolizumab Treatment|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks. Estimated average length of treatment per participant: 4 months.
~Second Course Study Treatment: Participants may be eligible for up to one year of additional pembrolizumab therapy if they progress after stopping study treatment. If they meet the criteria to be eligible for the Second Course, participants will restart treatment at the same dose and dose interval as when they last received pembrolizumab."
11213569|NCT03290066|Active Comparator|Kinesiotape|"Kinesiotape will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).
~Patients will be taped for four days , ıt will start at the beginning of the menstruation."
11213570|NCT03290066|Active Comparator|Usual care|"Participants will use the usual self-care for primary dysmenorrhea. It will start at the beginning of the menstruation.
~They will note the treatment indicating the dosage in a calendar."
11213571|NCT03290053|Experimental|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
11213572|NCT03290053|Sham Comparator|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
11213573|NCT03290053|Experimental|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
11213574|NCT03290053|Sham Comparator|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
11213575|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
11213576|NCT03290027|Placebo Comparator|Vehicle|Vehicle (0% tazarotene) Lotion
11213577|NCT03290014||Good sleepers|COPD patients with good sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
11213578|NCT03290014||Bad sleepers|COPD patients with poor sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
11213579|NCT03289988||Normal group|Normal group(control group): patients with negative colonoscopy findings (n= 238).
11213580|NCT03289988||Low risk adenoma group|Low risk adenoma group: patients having at least one low risk adenoma (n=250).
11213581|NCT03289988||High-risk adenoma group|High-risk adenoma group: patients having at least one of following criteria (more than 1 cm in size, villous or tubulovillous histologic type, high-grade dysplasia findings) (n=316).
11213582|NCT03289988||Colon cancer|Colon cancer: histologically confirmed colon cancer patients (n=160).
11213583|NCT03289962|Experimental|Phase 1a Flat Dose Escalation: RO7198457|Participants will receive RO7198457 at escalated dosages.
11213757|NCT03288766||PICC Placement with Study Device|PICC Placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
11213584|NCT03289962|Experimental|Phase 1b Flat Dose Escalation: RO7198457 +Atezolizumab|Participants will receive RO7198457 at escalated dosages along with atezolizumab at a fixed dose of 1200 milligrams (mg)
11213585|NCT03289962|Experimental|Phase Ib: Dose Exploration: RO7198457 + Atezolizumab|Non-small cell lung cancer (NSCLC) or melanoma cancer immunotherapy (CIT)-treated participants will receive RO7198457 (at dosage lower than maximum tolerated dose [MTD] based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
11213586|NCT03289962|Experimental|Phase 1b Expansion: RO7198457 + Atezolizumab|Participants with different indications as per inclusion criteria will receive RO7198457 (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a fixed dose of 1200 mg.
11213587|NCT03289962|Experimental|Phase 1b Expansion: RO7198457 + Atezolizumab (Serial Biopsy)|CIT-naive patients with selected tumor types who consent to optional serial biopsies will receive RO7198457 (at multiple dose levels below MTD based on available safety data) along with atezolizumab at a dixed dose of 1200 mg.
11213588|NCT03289949|Other|Project 1: Occupancy of psilocybin/ketanserin|After baseline MRI & 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
11213589|NCT03289949|Other|Project 2: Long term effects of psilocybin|After baseline MRI & CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.
11213590|NCT03289949|Other|Project 3: Functional connectivity and synaptic plasticity|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.
11213591|NCT03289936|Experimental|Start ventilation with NIPPV|Alternatively vented with NIPPV and SNIPPV
11213592|NCT03289936|Experimental|Start ventilation with SNIPPV|Alternatively vented with SNIPPV and NIPPV
11213593|NCT03289923|Sham Comparator|Sham TMS + active psychological placebo|inactive
11213594|NCT03289923|Experimental|TMS+SST|active
11213595|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11213596|NCT03289910|Active Comparator|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11213597|NCT03289897|Experimental|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
11213598|NCT03289897|No Intervention|Control Arm|Standard of care as per guidelines of the local centre
11213599|NCT03289884||Control Group (CE1)|"All patients must have cystic lesions which must exceed 30mm in diameter.
~All patients must be aged 16 or over and able to provide informed consent.
~Patients will have an MRI scan (not involving ionising radiation)
~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'
~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
11213600|NCT03289884||CE group (CE2-4)|"All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.
~All patients must be aged 16 or over and able to provide informed consent.
~All patients will have an MRI scan (not involving ionising radiation)
~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'
~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.
~Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
11213601|NCT03289871|Experimental|Excilor|2 applications per day for 6 months
11213602|NCT03289871|Active Comparator|Loceryl 5%|1 application per week for 6 months
11213603|NCT03289858|Experimental|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
11213604|NCT03289858|Placebo Comparator|Saline Control|Saline Solution (Sodium Chloride)
11213605|NCT03289845|Other|BHX implant|All patients implanted with BHX implant
11213606|NCT03289832|Active Comparator|Crucera-SGS®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) per day.
~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third days of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
11213607|NCT03289832|Active Comparator|Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.
~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks, for a total of 8 skin-punch biopsies per individual."
11213679|NCT03289325|Experimental|DEX group|The active drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
11213680|NCT03289325|Placebo Comparator|CTRL group|The placebo drug (normal saline, or 0.9% sodium chloride for injection) will be administered in the same rate and volume for a same duration as that in the DEX group.
11279982|NCT02834312|Experimental|10 mg estetrol|
11213608|NCT03289832|Active Comparator|Crucera-SGS® and Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a cruciferous vegetable-free diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) and Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.
~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
11213609|NCT03289819|Experimental|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.
~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
~After the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.
~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
11213610|NCT03289806||Cases|Glaucoma surgery
11213611|NCT03289806||Controls|Strabismus surgery
11213612|NCT03289793|Experimental|Group A|"Children will be assigned to this group in a random fashion according to a ratio 2:1 with respect to group B (see below).
~20 subjects will be included in this group."
11213613|NCT03289793|Active Comparator|Group B|Children will be assigned in this group in a random fashion. 10 subjects will be included in this group.
11213614|NCT03289793|Active Comparator|Group C|"Will be included in this group children who meet the inclusion criteria and who, with their families, are motivated to participate in the study but cannot claim to be part of groups A or B (because of logistical constraints: living too far away to comply with the frequency of the visits required by the training).
~Group C allows to follow the natural evolution of children with ADHD with no intervention."
11213615|NCT03289767|Experimental|Curved-tube|Giving additional curve to the endotracheal tube by simple preparation.
11213616|NCT03289767|No Intervention|Control|No other manipulation of the endotracheal tube is done.
11213617|NCT03289754|Experimental|ConforMIS iTotal Knee with iPoly Insert|The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.
11213618|NCT03289741|Experimental|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
11213619|NCT03289741|Experimental|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
11213620|NCT03289728|Experimental|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.
~- Low or intermediate risk patients will receive optimal medical treatment."
11213621|NCT03289728|Active Comparator|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
11213622|NCT03289715|Experimental|arm 1|on demand humidification
11213623|NCT03289702|Experimental|CORETOX®|
11213624|NCT03289702|Active Comparator|BOTOX®|
11213625|NCT03289689|Experimental|Whole body vibration|"The subjects in the WBV group performed one series of five consecutive repetitions of 60 sec unsynchronised multidimensional WBV (Zeptoring, Scisen GmbH, Germany; 4 Hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. The construction of this device is designed to perform a nonharmonious generation of oscillating movements in vertical and horizontal planes in order to prevent occurrences of resonance and habituation of receptors.
~During the intervention, subjects wore thin-soled gymnastic-type shoes, carrying out in a squatting standing position, with slight flexion at the hips, knees and ankle joint, on the vibration platform."
11213626|NCT03289689|No Intervention|Control|The controls did not receive any training.
11213627|NCT03289676|Experimental|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
11213628|NCT03289676|Active Comparator|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
11213629|NCT03289663|Active Comparator|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
11213630|NCT03289663|Experimental|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
11213631|NCT03289650|Active Comparator|Standard of care tacrolimus twice-daily|
11213632|NCT03289650|Active Comparator|Extended-release tacrolimus once-daily|
11213633|NCT03289637|Experimental|Active intervention|"In the group randomised to active treatment and with a screening level of 25-OH-vitamin D 25-50nmol/L an intervention with 1600IE daily of vitamin D will be given.
~In those randomised to active treatment and with a screening level of 25-OH-vitamin D of <25nmol/L, an intervention of 2400IE of vitamin D will be given."
11213634|NCT03289637|Placebo Comparator|Placebo|In the group randomised to placebo and with a screening level of 25-OH-vitamin D <50 mol/L, the participants will be given placebo.
11213681|NCT03289312||Sepsis|Diagnosis of new onset sepsis within 24h without history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.
11213682|NCT03289312||Health control|Health vonlunteers
11213828|NCT03288402|Experimental|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
11213635|NCT03289624|Experimental|SHARE for Chronic Conditions|"Six weekly SHARE for Chronic Conditions (SHARE-CC) sessions will be conducted in the dyad's home or another location preferred by the participants. A care plan (the SHARE plan) is created that reflects the mutual decisions made by the dyad as a result of their participation in the SHARE-CC program. The SHARE plan is intended to help the caregiver (CG) ensure the PWCC's values and preferences are supported when decisions have to be made in an emergency or in the end stages of the disease. SHARE plans will be documented in a notebook that also contains information on key topics and provides links to local and online resources and services."
11213636|NCT03289624|No Intervention|Health Coaching|Six 30-minute weekly telephone calls to provide information and education related to the PWCC's conditions and information about services and care options will be conducted.
11213637|NCT03289611|No Intervention|Control|Usual management
11213638|NCT03289611|Experimental|Experimental|Ambulatory management if sFlt-1 / PlGF ratio is below 38 Usual management if sFlt-1/PlGF is between 38 and 85. If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued
11213639|NCT03289598|Experimental|Interventionsgroup|
11213640|NCT03289598|No Intervention|Controlgroup|
11213641|NCT03289585||Hidradenitis Suppurativa Cohort|Patients with Hidradenitis Suppurativa (ages 18-99 years old) will be asked to complete a series of questionnaires on how Hidradenitis Suppurativa impacts quality of life.
11213642|NCT03289559|No Intervention|Control|
11213643|NCT03289559|Placebo Comparator|GnRH antagonist + Placebo Gel|
11213644|NCT03289559|Active Comparator|GnRH antagonist + Testosterone Gel|
11213645|NCT03289546|Experimental|Mindfulness training only|1 mindfulness training class (1 hour) every week for 8 weeks.
11213646|NCT03289546|Experimental|Aerobic training only|3 aerobic training sessions (1 hour) per week for 12 weeks.
11213647|NCT03289546|Experimental|mindfulness + aerobic training|2 aerobic training sessions + 1 mindfulness training class every week for 8 weeks, then continue with 3 aerobic training sessions/ week for 4 additional weeks.
11213648|NCT03289546|No Intervention|Usual care|
11213649|NCT03289533|Experimental|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
11213650|NCT03289520|Experimental|Clopidogrel|
11213651|NCT03289520|Placebo Comparator|Placebo|
11213652|NCT03289507|Active Comparator|Treatment1|Longvida Capsule formulation A
11213653|NCT03289507|Active Comparator|Treatment 2|Longvida Capsule formulation B
11213654|NCT03289507|Experimental|Treatment3|Curcuma longa extract of Rhizomes
11213655|NCT03289494|Active Comparator|Diet A|Balanced diet high in Slowly Digestible Starch
11213656|NCT03289494|Placebo Comparator|Diet B|Balanced diet low in Slowly Digestible Starch
11213657|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
11213658|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge for one week and perform cardiac testing.
11213659|NCT03289468||Group1|Endometrial Benign Disease
11213660|NCT03289468||Group2|Endometrial Cancer and Precancerous Lesions
11213661|NCT03289455|Experimental|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
11213662|NCT03289442|Experimental|supine position group|
11213663|NCT03289442|No Intervention|left lateral position|
11213664|NCT03289429|Experimental|Atorvastatin|Atorvastatin and intravenous placebo
11213665|NCT03289429|Experimental|Magnesium sulfate|Magnesium sulfate and tablets placebo
11213666|NCT03289429|Placebo Comparator|Control|intravenous placebo and tablet placebo
11213667|NCT03289416|Other|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
11213668|NCT03289416|Other|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
11213669|NCT03289403|Experimental|Study group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins)
11213670|NCT03289403|Active Comparator|Control group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
11213671|NCT03289390||Acetaminophen to close PDA|Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen
11213672|NCT03289377|Experimental|RDAD training to APNs|Half-day workshop to provide APNs with all skills necessary to conduct RDAD in their clinical settings. A subset of the trained APNs will implement RDAD as part of their ongoing care of persons with ADRD.
11213673|NCT03289364|Experimental|Penguin Cold Caps|Penguin Cold-cap therapy will commence at least 50 minutes prior to chemotherapy infusion, and will continue for 4 hours following completion of chemotherapy.
11213674|NCT03289351|No Intervention|2-drug Therapy|ceftriaxone/metronidazole
11213675|NCT03289351|Experimental|1-drug Therapy|piperacillin-tazobactam
11213676|NCT03289338|Experimental|Zoledronic acid|Bisphosphonate Zoledronic acid
11213677|NCT03289338|Active Comparator|Methylprednisolone|Glucocorticoid Methylprednisolone
11213683|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
11213684|NCT03289286|Other|Patients with breast cancer operated in ambulatory|
11213685|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
11213686|NCT03289260|Experimental|Interventional Arm|Imiquimod 5% cream therapy Fulguration
11213687|NCT03289260|Placebo Comparator|Placebo Arm|Placebo cream therapy Fulguration
11213688|NCT03289247|No Intervention|Regular|"Regular closure:
~The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure."
11213689|NCT03289247|Experimental|Additional tissue adhaesive|The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
11213690|NCT03289234|Experimental|mild hepatic impairment|
11213691|NCT03289234|Experimental|moderate hepatic impairment|
11213692|NCT03289234|Experimental|normal hepatic function|
11213693|NCT03289221|Experimental|Experimental Group|Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
11213694|NCT03289208|Experimental|mild renal impairment|
11213695|NCT03289208|Experimental|moderated renal impairment|
11213696|NCT03289208|Experimental|normal renal function|
11213697|NCT03289195|Experimental|MRI biopsy|All patients enrolled will have had complete MR imaging response post Neoadjuvant Chemotherapy (NAC) and will undergo percutaneous MR guided biopsy.
11213698|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
11213699|NCT03289169|Experimental|MEDITOXIN|Meditoxin(Botulinum toxin type A)
11213700|NCT03289156|Active Comparator|Arousal Reappraisal|Brief educational intervention about the stress response and arousal reappraisal
11213701|NCT03289156|Active Comparator|Exercise|Three 5-minute bouts of aerobic exercise at increasing intensities
11213702|NCT03289156|Experimental|Arousal Reappraisal + Exercise|Brief educational intervention about the stress response and arousal reappraisal followed by three 5-minute bouts of aerobic exercise at increasing intensities with practice applying the arousal reappraisal learned earlier.
11213703|NCT03289156|No Intervention|Control|Time-matched rest
11213704|NCT03289143|Experimental|Dose 1 Semorinemab|
11213705|NCT03289143|Experimental|Dose 2 Semorinemab|
11213706|NCT03289143|Experimental|Dose 3 Semorinemab|
11213707|NCT03289143|Placebo Comparator|Placebo|
11213708|NCT03289117|Experimental|Novel gel installation device procedure|"Catheter change with novel device.
~Each subject will undergo catheter change with novel gel instillation device procedure"
11213709|NCT03289117|Active Comparator|Standard procedure|"Catheter change with standard procedure.
~Each subject will undergo catheter change with standard procedure"
11213710|NCT03289104|Active Comparator|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
11213711|NCT03289104|Experimental|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
11213712|NCT03289091|Experimental|water-based continuous aerobic training|Participants who will be randomized for the intervention in the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
11213713|NCT03289091|Experimental|water-based interval aerobic training|Participants who will be randomized for the intervention in the interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
11213714|NCT03289078|Experimental|Thermal care|Spa Treatment realised daily 6 days a week during 18 days
11213715|NCT03289078|No Intervention|Standard Care|Usual care
11213716|NCT03289065||FOS Participant|FOS is a disease registry open to all Fabry participants irrespective of treatment status or type of treatment.
11213717|NCT03289052|Experimental|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
11213718|NCT03289052|No Intervention|No intervention arm|No treatment
11213719|NCT03289039|Experimental|Neratinib|"Neratinib will be administered orally once daily
~Neratinib is dosed at 240mg (six 40mg tablets)"
11213755|NCT03288792|Experimental|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
11213720|NCT03289039|Experimental|Neratinib + Fulvestrant|"Neratinib will be administered orally once daily
~Neratinib is dosed at 240mg (six 40mg tablets)
~Fulvestrant will be administered intramuscular as an injection (shot) on day 1 and 15 of cycle 1, day 1 of cycle 2, and then on day 1 of each subsequent cycle.
~Fulvestrant is dosed as 250 mg/5mL (x2) for a total of 500 mg via intramuscular injection (two injections)."
11213721|NCT03289026|Experimental|aripiprazole group|Patients receive aripiprazole treatment
11213722|NCT03289013|Experimental|Testing of new adhesive strips|"Each subject will test six adhesive strips on pre-stripped skin.
~Standard adhesive 1
~Standard adhesive 2
~LT-2
~LT-21
~LT-25
~33-20
~The six strips are applied on the abdominal skin. The order of the adhesive strips on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of adhesive strips will be measured at 5 visits."
11213723|NCT03289000||ConforMIS PS Group|Patients who have undergone a total knee replacement with the ConforMIS iTotal PS Knee Replacement System
11213724|NCT03288987|Experimental|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
11213725|NCT03288987|Active Comparator|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
11213726|NCT03288974||Post Marketing Survey of MM patients treated with POMALYST®|As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline [standard for Re-examination of New Drugs, etc.] as a post approval commitment.
11213727|NCT03288948|Active Comparator|Standard Contrast Increment|
11213728|NCT03288948|Experimental|Reduced Contrast Increment|
11213729|NCT03288948|Experimental|No Contrast Increment|
11213730|NCT03288935|Active Comparator|Group 1 (TICM only)|Assigned to TICM group after reception & placement.
11213731|NCT03288935|Active Comparator|Group 2 (TICO only)|Assigned to TICO group after reception & placement.
11213732|NCT03288935|Active Comparator|Group 3 (TICM & TICO)|Assigned to both TICM and TICO group after reception & placement.
11213733|NCT03288935|No Intervention|Group 4 (None)|No additional intervention after reception & placement
11213734|NCT03288922|Experimental|Limited BF OL-HDF with SHF|Limited blood flow pre-dilution online hemodiafiltration using super high-flux dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of protein-bound toxin removals with the control period.
11213735|NCT03288922|Active Comparator|High-efficiency OL-HDF|High-efficiency post-dilution online hemodiafiltration using standard high-flux dialyzer was assigned as the control period.
11213736|NCT03288909||Early onset Parkinson's disease|Idiopathic Parkinson's disease within 1 year of symptom onset
11213737|NCT03288909||Idiopathic REM Sleep Behavior Disorder|Idiopathic REM Sleep Behavior Disorder
11213738|NCT03288909||Age-matched healthy controls|Age-matched healthy controls
11213739|NCT03288896|Experimental|Alerta Alcohol|Intervention Group: The Experimental Group receives the Alerta Alcohol intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. Evaluation takes place after four months.
11213740|NCT03288896|No Intervention|Control Group|Control Group: The Control Group just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition). Evaluation takes place after four months from baseline
11213741|NCT03288883|Active Comparator|Fractional Microablative CO2-laser|
11213742|NCT03288883|Active Comparator|Photothermal Non-ablative Erbium:YAG-laser|
11213743|NCT03288870|Experimental|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
11213744|NCT03288870|Active Comparator|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
11213745|NCT03288857|No Intervention|Bulb Aspirator|If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
11213746|NCT03288857|Experimental|Nasal Oral Aspirator (NeilMed Naspira)|If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
11213747|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
11213748|NCT03288831|Active Comparator|Normal Subjects, Gluten Drink|Normal subjects will drink a solution containing 6 grams of gluten one time.
11213749|NCT03288831|Placebo Comparator|Normal Subjects, Placebo Drink|Normal subjects will drink a solution without gluten one time.
11213750|NCT03288831|Active Comparator|Celiac Subjects, Gluten Drink|Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
11213751|NCT03288831|Placebo Comparator|Celiac Subjects, Placebo Drink|Subjects with celiac disease will drink a solution without gluten one time.
11213752|NCT03288831|Active Comparator|Gluten Sensitivity, Gluten Drink|Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
11213753|NCT03288831|Placebo Comparator|Gluten Sensitivity, Placebo Drink|Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
11213754|NCT03288818|Experimental|low dose TSEBT, mechlorethamine hydrochloride gel|Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
11213758|NCT03288753|Experimental|Adults and children above 14 years old|"Visit 1:
~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1
~Visit 2 (15 days after V1):
~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2
~Visit 3 (3 months after V2):
~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
11213759|NCT03288753|Experimental|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1
~Visit 2 (15 days after V1):
~Satisfaction questionnaire on Neuro 2
~Visit 3 (3 months after V2):
~Satisfaction questionnaire on Neuro 2
~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
11213760|NCT03288740|Experimental|Semaglutide 0.5 mg|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
11213761|NCT03288740|Placebo Comparator|Semaglutide 0.5 mg placebo|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
11213762|NCT03288740|Experimental|Semaglutide 1.0 mg|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
11213763|NCT03288740|Placebo Comparator|Semaglutide 1.0 mg placebo|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.
11213764|NCT03288727|Experimental|Negative IF result|
11213765|NCT03288727|Experimental|Positive IF result|
11213766|NCT03288714|Experimental|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
11213767|NCT03288714|Sham Comparator|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
11213768|NCT03288701|Experimental|Body Composition Analysis|Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
11213769|NCT03288688|Experimental|Exercise program and education|An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
11213770|NCT03288688|No Intervention|No intervention|Participants in this group will be asked to continue their usual activities.
11213771|NCT03288675|Active Comparator|Active aiTBS - active CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive active CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
11213772|NCT03288675|Experimental|Active aiTBS - sham CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive a control training for a period of 4 weeks in combination with an antidepressant (SSRI)
11213773|NCT03288675|Experimental|Sham aiTBS - aiTBS - active CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week receive CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
11213774|NCT03288675|Experimental|Sham aiTBS - aiTBS - sham CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week control training for a period of 4 weeks in combination with an antidepressant (SSRI)
11213775|NCT03288662|Experimental|CT and histopathological classification|With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .
11213776|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
11213777|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
11213778|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
11213779|NCT03288636|Experimental|Experimental|"PKGroup:
~Ravidasvir + Danoprevir/ Ritonavir"
11213780|NCT03288636|Placebo Comparator|Placebo|"Placebo Group:
~Placebo"
11213781|NCT03288623|Experimental|Dark Chocolate|Dark chocolate (85% cocoa) 40 mg per day for 30 days
11213782|NCT03288623|Placebo Comparator|White/Milk Chocolate|White chocolate or Milk chocolate administration in tablet (<35% cocoa) per day for 30 days
11213783|NCT03288610||With inflammatory response|"Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome.
~Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.
~Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2.
~Patients without postoperative severe SIRS and without postoperative vasodilation syndrome"
11213784|NCT03288597||A: advanced and metastatic neuroendocrine tumors|Advanced and metastatic neuroendocrine tumors receive syestematic treatment
11213785|NCT03288597||A: advanced and metastatic neuroendocrine carcinomas|Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment
11213786|NCT03288584||Tocilizumab|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
11213787|NCT03288584||Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
11213788|NCT03288584||Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
11213824|NCT03288441||anticoagulant-based|"Patients receiving only anticoagulants or both anticoagulant and antiplatelet medication combined. This includes any class, dose or duration of any antiplatelet or anticoagulant drug.
~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
11213789|NCT03288571|Experimental|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.
~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
11213790|NCT03288558|Experimental|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
11213791|NCT03288558|No Intervention|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
11213792|NCT03288545|Experimental|EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L|Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
11213793|NCT03288545|Experimental|Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
11213794|NCT03288545|Experimental|Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
11213795|NCT03288545|Experimental|Cohort D: Enfortumab Vedotin + Cisplatin in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
11213796|NCT03288545|Experimental|Cohort E: Enfortumab Vedotin + Carboplatin in 1L|Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
11213797|NCT03288545|Experimental|Optional Cohort F: Enfortumab Vedotin + Gemcitabine in 1L|Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
11213798|NCT03288545|Experimental|Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
11213799|NCT03288545|Experimental|Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 every 21 days
11213800|NCT03288545|Experimental|Cohort J: EV + Pembrolizumab in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
11213801|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin Monotherapy|Enfortumab vedotin on days 1 and 8 every 21 days
11213802|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
11213803|NCT03288532|No Intervention|Arm A (active monitoring)|Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse
11213804|NCT03288532|Experimental|Arm B (durvalumab monotherapy)|Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)
11213805|NCT03288532|Experimental|Arm C (durvalumab + tremelimumab)|Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)
11213806|NCT03288506|Experimental|Google Hangout (VC) group|This group receive peer led support for depression via Google Hangouts for 8-weeks
11213807|NCT03288506|No Intervention|Waiting list control group|Waiting list
11213808|NCT03288493|Experimental|Phase 1: P-BCMA-101 CAR-T cells|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
11213809|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort A)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
11213810|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort B)|Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
11213811|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells (Cohort C)|Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
11213812|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
11213813|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
11213814|NCT03288493|Experimental|Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT)|Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
11213815|NCT03288493|Experimental|Phase 2: P-BCMA-101 CAR-T Cells|CAR-T cells administered via intravenous infusion as a total dose
11213816|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
11213817|NCT03288467|Active Comparator|Root canal treatment with 5% NaOCl|Root canal treatment with 5% NaOCl: 5 ml of 5% sodium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 5% sodium hypochlorite.
11213818|NCT03288467|Active Comparator|Root canal treatment with 1% NaOCl|5 ml of 1% soium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 1% sodium hypochlorite.
11213819|NCT03288454|Experimental|Cohort 1|ciraparantag (60 mg)
11213820|NCT03288454|Experimental|Cohort 2|ciraparantag (120 mg)
11213821|NCT03288454|Experimental|Cohort 3|ciraparantag (30 mg)
11213822|NCT03288454|Placebo Comparator|Placebo|placebo (saline for injection)
11213823|NCT03288441||antiplatelet only|"Patients receiving antiplatelet medication, but not anticoagulation. Antiplatelet drugs include any class, dose or duration of any platelet aggregation inhibitor.
~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
11213825|NCT03288428|Experimental|nalbuphine|using nalbuphine for patient controlled analgesia
11213826|NCT03288428|Active Comparator|morphine|using morphine for patient controlled analgesia
11213827|NCT03288402|Experimental|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
11213829|NCT03288402|Experimental|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
11213830|NCT03288389|Placebo Comparator|Placebo|Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
11213831|NCT03288389|Active Comparator|NTFactor Lipids®|Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
11213832|NCT03288363|Experimental|tDCS|20 sessions tDCS (DC-Stimulator Plus -Neuroconn) during 2 Weeks on temporal cortex - each session : 30 minutes - 2 mA - 2 sessions per day - evaluation at 12 weeks post-treatment
11213833|NCT03288363|Sham Comparator|sham stimulation|the same parameters of stimulation as with real current stimulation (time, parameters to be seen on the apparatus screen) 20 sessions during 2 Weeks on temporal cortex - each session : 30 minutes - 2 sessions per day.
11213834|NCT03288350|Experimental|mDCF + Avelumab|"Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.
~Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen."
11213835|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
11213836|NCT03288324|Experimental|Tofacitinib Arm|open-label study
11213837|NCT03288311|Active Comparator|Protocolized Post-extubation Respiratory Support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
11213838|NCT03288311|Active Comparator|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
11213839|NCT03288298|Experimental|luteolin|a natural extract derived flavinoids
11213840|NCT03288298|Active Comparator|nano-luteolin|nano-particles derived from a natural extract luteolin
11213841|NCT03288272|Active Comparator|Arm 1 - WBRT 10 x 2 Gy|Arm 1 - WBRT 10 x 2 Gy Whole brain radiotherapy with a total dose of 20 Gy in single fractions of 2 Gy
11213842|NCT03288272|Active Comparator|Arm 2 - WBRT 15 x 2 Gy|Arm 2 - WBRT 15 x 2 Gy Whole brain radiotherapy with a total dose of 30 Gy in single fractions of 2 Gy
11213843|NCT03288272|Active Comparator|Arm 3 - Best Supportive Care|Symptomatic treatment includes steroids, pain medication, nutritional support etc.
11213844|NCT03288259|Experimental|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
11213845|NCT03288246|No Intervention|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
11213846|NCT03288246|Experimental|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
11213847|NCT03288233||Primary Group|
11213848|NCT03288220||Healthy older adults|Healthy older adults-Age 50 and over
11213849|NCT03288220||Stroke patients|Age 18 and over; Mild to moderate unilateral or bilateral upper limb hemiparesis; Stroke onset > 6 months prior to participation
11213850|NCT03288207||Mobile Health|African-American female; age of 25-75 years oldMust be overweight or obese (Body Mass Index (BMI) greater than or equal to 25 kg/m^2)Must live in Washington DC Wards (5, 7, or 8)
11213851|NCT03288194|Experimental|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
11213852|NCT03288194|Active Comparator|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
11213853|NCT03288181|Experimental|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
11213854|NCT03288181|No Intervention|Control Arm|This is the group who has undergone no splint for 4 weeks.
11213855|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
11213856|NCT03288155|Experimental|Flavonoid rich cocoa|Dark cocoa beverage rich in flavonoids
11213857|NCT03288155|Placebo Comparator|Low flavonoid cocoa|A control cocoa beverage low inn flavonoids
11213858|NCT03288142|Experimental|Intervention|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
11213900|NCT03287882|No Intervention|Standard of care|"Preconception period: none
~Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy
~Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
11214040|NCT03286894||1264 healthy schoolchildren|There is only one study group consisting of 1264 children recruited at school.
11214041|NCT03286881|Experimental|Group 1|
11213859|NCT03288142|No Intervention|Control|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
11213860|NCT03288129|Experimental|Perampanel|Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
11213861|NCT03288116||patient|Scheimplug imaging and contrast and sensitivity test
11213862|NCT03288116||early disease|Scheimplug imaging and contrast and sensitivity test
11213863|NCT03288116||normal|Scheimplug imaging and contrast and sensitivity test
11213864|NCT03288103|Experimental|Growth Hormone Treatment for Participants with ACAN Deficiency|Pre-pubertal children with ACAN deficiency on daily growth hormone (Norditropin) regimen for 12 month period.
11213865|NCT03288090||Treated|
11213866|NCT03288090||Non-treated|
11213867|NCT03288077|Experimental|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
11213868|NCT03288064|Experimental|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
11213869|NCT03288064|Experimental|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
11213870|NCT03288064|Placebo Comparator|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
11213871|NCT03288051|Active Comparator|Crystalloid group|
11213872|NCT03288051|Active Comparator|Colloid group|
11213873|NCT03288038|Experimental|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
11213874|NCT03288038|Active Comparator|RSV5mg|Rosuvastatin 5mg
11213875|NCT03288038|Experimental|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
11213876|NCT03288038|Active Comparator|RSV10mg|Rosuvastatin 10mg
11213877|NCT03288038|Experimental|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
11213878|NCT03288038|Active Comparator|RSV20mg|Rosuvastatin 20mg
11213879|NCT03288025|Experimental|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
11213880|NCT03288025|No Intervention|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
11213881|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
11213882|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
11213883|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
11213884|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
11213885|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
11213886|NCT03287973|Active Comparator|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
11213887|NCT03287973|Other|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
11213888|NCT03287960|Experimental|setmelanotide|setmelanotide subcutaneous injection once daily
11213889|NCT03287960|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
11213890|NCT03287947|Experimental|A|Nintedanib
11213891|NCT03287934|Experimental|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
11213892|NCT03287934|Active Comparator|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
11213893|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
11213894|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
11213895|NCT03287908|Experimental|AMG 701|
11213896|NCT03287908|Experimental|AMG 701 + Pomalidomide|
11213897|NCT03287908|Experimental|AMG 701 + Pomalidomide + Dexamethasone|
11213898|NCT03287895|Experimental|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
11213899|NCT03287895|No Intervention|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
11214042|NCT03286881|Experimental|Group 2|
11214043|NCT03286881|Experimental|Group 3|
11214044|NCT03286881|Experimental|Group 4|
11213901|NCT03287882|Experimental|MMN supplementation and life skills education|"Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials
~Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy
~Postpartum period: daily MMN supplementation to 6 months postpartum"
11213902|NCT03287869|Experimental|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
11213903|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
11213904|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
11213905|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
11213906|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
11213907|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message
~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
11213908|NCT03287817|Experimental|AUTO3|Patient with relapsed or refractory DLBCL
11213909|NCT03287804|Experimental|AUTO2|Relapsed or refractory Myeloma patients
11213910|NCT03287791|Experimental|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
11213911|NCT03287791|Active Comparator|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
11213912|NCT03287791|Placebo Comparator|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
11213913|NCT03287778|Active Comparator|Pyridoxine|Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.
11213914|NCT03287778|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
11213915|NCT03287765|Experimental|Experimental 18F-AV-1451|
11213916|NCT03287752|Active Comparator|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant.
11213917|NCT03287752|Active Comparator|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube ETT.
11213918|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
11213919|NCT03287726|Experimental|probiotics|
11213920|NCT03287726|Placebo Comparator|placebo|
11213921|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
11213922|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
11213923|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
11213924|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
11213925|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
11213926|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
11213927|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
11213928|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
11213929|NCT03287687|Active Comparator|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
11213930|NCT03287687|Experimental|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
11214045|NCT03286881|Active Comparator|Group 5|
11214799|NCT03281499|Experimental|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
11213931|NCT03287674|Experimental|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.
~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.
~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.
~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
11213932|NCT03287661|Experimental|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
11213933|NCT03287661|No Intervention|Wait-list Control Condition|Wait-list Control group (8-weeks)
11213934|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
11213935|NCT03287622|Experimental|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
11213936|NCT03287622|Experimental|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
11213937|NCT03287622|Experimental|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
11213938|NCT03287622|No Intervention|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
11213939|NCT03287609|Active Comparator|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
11213940|NCT03287609|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
11213941|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium"
11213942|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium
~3D Sequence ZTE2 DP with gadolinium
~3D sequence UTE with gadolinium"
11213943|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium
~3D Sequence ZTE2 DP with gadolinium
~3D sequence UTE with gadolinium"
11213944|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium
~3D Sequence UTE without gadolinium
~3D Sequence ZTE2 DP with gadolinium
~3D sequence UTE with gadolinium"
11213945|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
11213946|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
11213947|NCT03287570|Experimental|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
11213948|NCT03287570|Active Comparator|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
11213949|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
11213950|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
11213951|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
11213952|NCT03287531|Experimental|conventional therapy (group I)|"Exercise therapy.
~For muscles around TMJ :
~Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric
~Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
11213953|NCT03287531|Experimental|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
11213954|NCT03287518|Active Comparator|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
11213955|NCT03287518|Placebo Comparator|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.
~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
11213956|NCT03287505|Experimental|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
11213957|NCT03287505|Experimental|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
11213958|NCT03287492|Experimental|Group I (QPS)|Participants receive QPS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
11213959|NCT03287492|Active Comparator|Group II (GIS)|Participants receive GIS and answer questions from physician. At follow up visit, participants receive both QPS and GIS.
11213960|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
11213961|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
11213962|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
11213963|NCT03287466|Active Comparator|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
11214005|NCT03287180|Active Comparator|Control group|Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
11214046|NCT03286868|Placebo Comparator|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
11213964|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
11213965|NCT03287440|Active Comparator|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
11213966|NCT03287440|Active Comparator|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
11213967|NCT03287427|Experimental|TetMYB Vaccine & BGB-A317|
11213968|NCT03287414|Experimental|VAY736|VAY736 administered subcutaneously (s.c.) every 4 weeks
11213969|NCT03287414|Placebo Comparator|Placebo|Placebo administered subcutaneously (s.c.) every 4 weeks
11213970|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
11213971|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
11213972|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
11213973|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
11213974|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 5 weeks interval.
11213975|NCT03287362|Experimental|ST-arm|one-third of the patients is randomized to schema therapy
11213976|NCT03287362|Active Comparator|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
11213977|NCT03287362|Placebo Comparator|IST-arm|one-third of the patients is randomized to individualized supportive therapy
11213978|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
11213979|NCT03287336|Experimental|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
11213980|NCT03287336|Experimental|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
11213981|NCT03287336|Experimental|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
11213982|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
11213983|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
11213984|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
11213985|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
11213986|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
11213987|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
11213988|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
11213989|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
11213990|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
11213991|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
11213992|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
11213993|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
11213994|NCT03287284|Active Comparator|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
11213995|NCT03287284|Placebo Comparator|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
11213996|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
11213997|NCT03287258|Active Comparator|three program|200 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
11213998|NCT03287258|Active Comparator|one program|200 patients are subjected to educational Pelvic floor dysfunction prevention program
11213999|NCT03287245|Experimental|Idasanutlin|Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).
11214000|NCT03287232|Placebo Comparator|Placebo|
11214001|NCT03287232|Experimental|Prasterone|
11214002|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
11214003|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
11214004|NCT03287180|Experimental|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
11279983|NCT02834312|Experimental|15 mg estetrol|
11214006|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
11214007|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
11214008|NCT03287154|Experimental|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
11214009|NCT03287154|Sham Comparator|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).
~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
11214010|NCT03287141|Sham Comparator|First intervention|The subjects did a shuttle walk test without any previous intervention.
11214011|NCT03287141|Experimental|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
11214012|NCT03287141|Experimental|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
11214013|NCT03287115|Experimental|Broccoli|Subjects will consume a dose of broccoli on day 11
11214014|NCT03287102|Other|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
11214015|NCT03287102|Other|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
11214016|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
11214017|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
11214018|NCT03287076|Experimental|active|Patients will receive exenatide injections
11214019|NCT03287076|No Intervention|standard care/no intervention|standard care for stroke as per hospital protocol
11214020|NCT03287050|Experimental|Pembrolizumab + SBRT|
11214021|NCT03287037|Experimental|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
11214022|NCT03287024|Experimental|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
11214023|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
11214024|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
11214025|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
11214026|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay >72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
11214027|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.
~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
11214028|NCT03286959|Active Comparator|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
11214029|NCT03286959|Active Comparator|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
11214030|NCT03286959|Active Comparator|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
11214031|NCT03286946|Experimental|Blunt-type block needle|block with Blunt-type block needle.
11214032|NCT03286946|Active Comparator|Sharp-type block needle|block with Sharp-type block needle.
11214033|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
11214034|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
11214035|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
11214036|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
11214037|NCT03286907|Experimental|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 & 8
11214038|NCT03286907|Experimental|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 & 8
11214039|NCT03286907|Active Comparator|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
11214047|NCT03286868|Experimental|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
11214048|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
11214049|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
11214050|NCT03286842|Experimental|Olaparib|Olaparib 150mg tablets administered orally twice daily continuously
11214051|NCT03286829|Experimental|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
11214052|NCT03286829|Experimental|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
11214053|NCT03286829|Active Comparator|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
11214054|NCT03286829|Experimental|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
11214055|NCT03286816|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
11214056|NCT03286816|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
11214057|NCT03286803|Experimental|Arm A|Inactivated Poliovirus vaccine
11214058|NCT03286803|Active Comparator|Arm B|fractional dose inactivated poliovirus vaccine
11214059|NCT03286803|Experimental|Arm C|inactivated poliovirus vaccine
11214060|NCT03286803|Active Comparator|Arm D|fractional dose inactivated poliovirus vaccine
11214061|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
11214062|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
11214063|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
11214064|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
11214065|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
11214066|NCT03286751|Experimental|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
11214067|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
11214068|NCT03286725|No Intervention|Control Group|The Control Group will be asked to continue with their normal PE lessons.
11214069|NCT03286725|Experimental|Intervention Group|'Physical Education (PE) Programme'
11214070|NCT03286712|Experimental|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
11214071|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
11214072|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
11214073|NCT03286686|Experimental|Experience 1|
11214074|NCT03286686|Experimental|Experience 2|
11214075|NCT03286686|Experimental|Experience 3|
11214076|NCT03286686|Experimental|Experience 4|
11214077|NCT03286686|Experimental|Experience 5|
11214078|NCT03286686|Experimental|Experience 6|
11214079|NCT03286673|Experimental|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
11214080|NCT03286673|Experimental|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
11214081|NCT03286673|Experimental|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
11214082|NCT03286673|Active Comparator|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
11214083|NCT03286660|Other|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.
~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
11214084|NCT03286647|Experimental|NORMALGRIEF|Oral hygiene instruction
11214085|NCT03286647|Experimental|COMPLICATEDGRIEF|Oral hygiene instruction
11214086|NCT03286647|Active Comparator|CONTROLS|Oral hygiene instruction
11214117|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
11214118|NCT03286426|Experimental|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
11215523|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F|or matching placebo - HV
11214087|NCT03286634|Experimental|SR|"Standard Risk (SR) :
~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD <0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%
~SR strategy:
~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.
~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
11214088|NCT03286634|Experimental|LR|"Low Risk (LR):
~Time-point #1 (Day 15 induction) Flow MRD <1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) <0.01% AND CNS 1 only
~LR strategy:
~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.
~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
11214089|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
11214090|NCT03286621||Typically Developing Children|Typically developing children
11214091|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
11214092|NCT03286595|Experimental|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
11214093|NCT03286595|Experimental|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
11214094|NCT03286582|Experimental|AC-203|
11214095|NCT03286582|Active Comparator|Clobetasol|
11214096|NCT03286569|Active Comparator|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
11214097|NCT03286569|Placebo Comparator|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
11214098|NCT03286556|Experimental|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.
~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.
~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19
~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
11214099|NCT03286556|Active Comparator|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
11214100|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
11214101|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
11214102|NCT03286530|Experimental|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
11214103|NCT03286517|Experimental|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
11214104|NCT03286517|Experimental|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
11214105|NCT03286517|Experimental|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
11214106|NCT03286517|Experimental|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
11214107|NCT03286517|Experimental|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
11214108|NCT03286517|Experimental|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
11214109|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
11214110|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take ~ 2 hours.
11214111|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
11214112|NCT03286478|Experimental|Mindfulness|Mindfulness-based body image intervention
11214113|NCT03286478|Experimental|Dissonance|Cognitive dissonance-based body image intervention
11214114|NCT03286478|Experimental|Confident Me|Dove Confident Me body image intervention
11214115|NCT03286478|No Intervention|Control|Classes as usual, assessment-only control group.
11214116|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
11214119|NCT03286413|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
11214120|NCT03286413|Active Comparator|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
11214121|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
11214122|NCT03286387|Experimental|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
11214123|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
11214124|NCT03286361|Experimental|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
11214125|NCT03286335|Experimental|Proton Radiation|"Radiation therapy will be delivered typically five (5) days per week on weekdays
~Proton Radiation dose be determine by histology"
11214126|NCT03286322|Experimental|manual therapy cervical spine|
11214127|NCT03286322|Sham Comparator|control group|
11214128|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
11214129|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
11214130|NCT03286296|Experimental|LZM009|
11214131|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
11214132|NCT03286257|Experimental|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
11214133|NCT03286244|Experimental|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:
~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
11214134|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
11214135|NCT03286218|Placebo Comparator|Placebo|Placebo was administered orally in one of five treatment periods
11214136|NCT03286218|Active Comparator|Alprazolam 2 milligram (mg)|2 mg of alprazolam was administered orally in one of five treatment periods
11214137|NCT03286218|Experimental|Lasmiditan 100 mg|100 mg of lasmiditan was administered orally in one of five treatment periods
11214138|NCT03286218|Experimental|Lasmiditan 200 mg|200 mg of lasmiditan was administered orally in one of five treatment periods
11214139|NCT03286218|Experimental|Lasmiditan 400 mg|400 mg of lasmiditan was administered orally in one of five treatment periods
11214140|NCT03286205|Active Comparator|Weekly Dosage|weekly dose of 100mg
11214141|NCT03286205|Active Comparator|3 week dosage|every 3 week dosage.
11214142|NCT03286192|Experimental|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
11214143|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.
~• Subjects will utilize autologous tears twice daily in the study eye."
11214144|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
11214145|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
11214146|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
11214147|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
11214148|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
11214149|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
11214150|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.
~(inpatient palliative care consultation team)"
11214151|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
11214152|NCT03286114|Experimental|Pembrolizumab|
11214153|NCT03286101|Experimental|0.5% Ivermectin Lotion|
11214154|NCT03286101|Placebo Comparator|Vehicle control|
11214155|NCT03286088|Other|Group A|TransEsophageal Echocardiography + TransThoracic Echocardiography
11214156|NCT03286088|Other|Group B|TransEsophageal Echocardiography + TransThoracic Echocardiography + cardiac Magnetic Resonance
11214157|NCT03286088|Other|Group C|TransEsophageal Echocardiography + TransThoracic Echocardiography + MitraClip
11214191|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
11215524|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A - MAD|or matching placebo - HV
11214158|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).
~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
11214159|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).
~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
11214160|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).
~Subjects will receive a 30-minutes SHAM session of tDCS."
11214161|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
11214162|NCT03286049||Healthy children (HC)|10 healthy children
11214163|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
11214164|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
11214165|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
11214166|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
11214167|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
11214168|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
11214169|NCT03286010|Experimental|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
11214170|NCT03286010|No Intervention|Control|Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.
11214171|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
11214172|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
11214173|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
11214174|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
11214175|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
11214176|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
11214177|NCT03285971|Experimental|CPP Alert Group|Device: Electronic CPP pager alert anesthesia providers will receive a pager alert when CPP decreases below 60 mmHg (median value over 5-minute epochs)
11214178|NCT03285971|No Intervention|Control|This arm will not receive the automated pager alerts.
11214179|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
11214180|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
11214181|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
11214182|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
11214183|NCT03285932|Experimental|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)
~Resection cavity:
~7 x 5 Gy @ 95%-isodose
~Potential additional brain metastases:
~20 Gy @ 70%-isodose (lesions < 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions > 3 cm max. diameter)"
11214184|NCT03285932|Other|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
11214185|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
11214186|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
11214187|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
11214188|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
11214189|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
11214190|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
11214192|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
11214193|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
11214194|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
11214195|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
11214196|NCT03285854||Healthy age and gender matched children|"All children <18 years
~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)
~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
11214197|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
11214198|NCT03285841||Vulvar sites|Imaging vulvar lesions
11214199|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
11214200|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
11214201|NCT03285815|Experimental|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
11214202|NCT03285815|Experimental|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
11214203|NCT03285802|Experimental|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
11214204|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
11214205|NCT03285789|Experimental|Dyslexics with normal visual attention span|
11214206|NCT03285789|Active Comparator|controls|
11214207|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
11214208|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
11214209|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
11214210|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
11214211|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
11214212|NCT03285737|Experimental|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
11214213|NCT03285737|Active Comparator|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
11214214|NCT03285724|Experimental|Harpoon Medical Transapical device TSD-5|This is a prospective, single arm, nonrandomized, early feasibility study to evaluate the safety and performance of the Harpoon Medical Device.
11214215|NCT03285711|Experimental|Lanraplenib 30 mg|"Participants receive lanraplenib 30 mg tablet + filgotinib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.
~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
11214216|NCT03285711|Experimental|Filgotinib 200 mg|"Participants receive filgotinib 200 mg tablet + lanraplenib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.
~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
11214217|NCT03285711|Experimental|Lanraplenib 30 mg to Filgotinib 200 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive filgotinib 200 mg + lanraplenib placebo for additional 16 weeks.
~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
11214218|NCT03285711|Experimental|Filgotinib 200 mg to Lanraplenib 30 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive lanraplenib 30 mg + filgotinib placebo for additional 16 weeks.
~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
11214219|NCT03285698|Other|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
11214220|NCT03285698|Experimental|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
11214221|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
11214222|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
11214223|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
11214224|NCT03285672|Experimental|Arm 1|FP-101
11214225|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
11214226|NCT03285659|Experimental|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
11214275|NCT03285282|No Intervention|Control|
11214227|NCT03285659|No Intervention|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
11214228|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
11214229|NCT03285646|Placebo Comparator|Placebo|SC every 4 weeks
11214230|NCT03285633|Other|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
11214231|NCT03285620|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram [mg]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
11214232|NCT03285620|Experimental|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
11214233|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.
~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:
~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)
~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)
~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)
~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
11214234|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.
~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:
~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)
~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)
~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)
~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
11214235|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.
~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:
~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)
~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)
~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)
~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
11214236|NCT03285594|Placebo Comparator|Placebo|Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
11214237|NCT03285594|Experimental|Sotagliflozin 200 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
11214238|NCT03285594|Experimental|Sotagliflozin 400 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
11214239|NCT03285581|Other|Arm-1|Device:Treatment Subject(s) will receive 2 RF treatments
11214240|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
11214241|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
11214242|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
11214243|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
11215525|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B MAD|or matching placebo - HV
11214244|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
11214245|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
11214246|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
11214247|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
11214248|NCT03285503|Experimental|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
11214249|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment will be applied once daily for X consecutive days on the face or scalp
11214250|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment will be applied once daily for X consecutive days on the face or scalp
11214251|NCT03285477|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment will be applied once daily for X consecutive days on the face or scalp
11214252|NCT03285477|Placebo Comparator|Placebo|The Vehicle Ointment will be applied once daily for X consecutive days on the face or scalp
11214253|NCT03285464|Active Comparator|Hip|This group will perform a known hip strengthening program
11214254|NCT03285464|Experimental|Trunk|This group will use the trunk as a lever to strengthen the hip
11214255|NCT03285438|Experimental|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 24 months (12 to 48 months)
11214256|NCT03285438|Active Comparator|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 24 months (12 to 48 months).
11214257|NCT03285412|Experimental|Ribociclib + Endocrine Rx|Ribociclib will be administered. Endocrine therapy will be administered.
11214258|NCT03285412|Active Comparator|Endocrine Rx|Endocrine therapy will be administered.
11214259|NCT03285386|Experimental|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
11214260|NCT03285386|Active Comparator|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
11214261|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
11214262|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.
~Steps:
~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.
~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.
~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.
~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
11214263|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.
~Steps:
~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.
~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.
~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.
~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
11214264|NCT03285347|Experimental|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.
~Computer-based cognitive training."
11214265|NCT03285347|Experimental|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.
~Computer-based cognitive training."
11214266|NCT03285347|No Intervention|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
11214267|NCT03285334|Experimental|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
11214268|NCT03285334|Active Comparator|iRace|rotary files
11214269|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
11214270|NCT03285321|Experimental|Arm 2|Nivolumab 3mg/kg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
11214271|NCT03285308|Experimental|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily for 12 weeks.
11214272|NCT03285308|Placebo Comparator|Placebo|Placebo injected twice daily for 12 weeks.
11214273|NCT03285295|Experimental|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
11214274|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
11214276|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
11214277|NCT03285256|Experimental|Experimental Memory Training|Experimental memory training program
11214278|NCT03285256|Active Comparator|Comparator Memory Training 1|Comparator memory training program
11214279|NCT03285256|Active Comparator|Comparator Memory Training 2|Alternative comparator memory training program
11214280|NCT03285243|Sham Comparator|Blue light - non monochromatic|
11214281|NCT03285243|Experimental|Monochromatic blue light|
11214282|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
11214283|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
11214284|NCT03285204||ALS patients|
11214285|NCT03285204||Friedreich Ataxia patients|
11214286|NCT03285204||Healthy control|
11214287|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
11214288|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
11214289|NCT03285178|Experimental|IW-1701 (Olinciguat) Low Dose|
11214290|NCT03285178|Experimental|IW-1701 (Olinciguat) Medium Dose|
11214291|NCT03285178|Experimental|IW-1701 (Olinciguat) High Dose|
11214292|NCT03285178|Experimental|IW-1701 (Olinciguat) Higher Dose|
11214293|NCT03285178|Placebo Comparator|Placebo|
11214294|NCT03285165|Active Comparator|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
11214295|NCT03285165|Active Comparator|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
11214296|NCT03285165|Active Comparator|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
11214297|NCT03285165|Active Comparator|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
11214298|NCT03285152|Experimental|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
11214299|NCT03285152|Active Comparator|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
11214300|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
11214301|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
11214302|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
11214303|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
11214304|NCT03285087|Experimental|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
11214305|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
11214306|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
11214307|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
11214308|NCT03285035||Non-operable esophageal cancer|Cryotherapy treatment
11214309|NCT03285022|Experimental|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
11214310|NCT03285022|Active Comparator|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
11214311|NCT03285009|Other|Training intervention|See information elsewhere
11214312|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
11214313|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
11214314|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
11214315|NCT03284957|Experimental|Part A Dose escalation: SAR439859 monotherapy|SAR439859 will be administered orally once (QD) or twice a day (BID). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent patients is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in 28-day cycle.
11214316|NCT03284957|Experimental|Part B Dose expansion: SAR439859 monotherapy|Patients will be administered the determined monotherapy recommended dose (RD) of SAR439859. Drug will be administered in 28-day cycle.
11214317|NCT03284957|Experimental|Part C Dose escalation: SAR439859/palbociclib combination|SAR439859 will be administered in combination with palbociclib: SAR439859 starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of SAR439859 (with standard palbociclib dose) to subsequent patients will be based on occurrence of DLTs at initial and subsequent doses, until MAD of SAR439859 is reached. Drugs will be administered in 28-day cycle (palbociclib will be administered for 21 days of cycle). If results from Part A BID indicate a benefit of BID regimen, an additional BID dose regimen could be tested in Part C.
11214318|NCT03284957|Experimental|Part D Dose expansion: SAR439859/palbociclib combination|"Based on the results in Part C, patients will be administered either: 1) a determined SAR439859 dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of SAR439859 with standard dose of palbociclib in combination therapy.
~Drugs will be administered in 28-day cycle (palbociclib will be administered for 21 days of cycle)."
11214319|NCT03284957|Experimental|Part E Midazolam Drug-Drug Interaction Sub-Study|Midazolam will be administered as a single oral dose two times within Cycle 1 (Day 1 and Day 15). SAR439859 will be administered at two sequential dose levels.The PK evaluation will be done in the first 8 patients treated at the first dose level. Each dose level will be completed depending on the PK analysis of the first dose level.
11214320|NCT03284957|Experimental|Part F Dose escalation: SAR439859/alpelisib combination|SAR439859 will be administered at 2 dose levels in combination with alpelisib. SAR439859 starting oral daily dose will be one dose level below monotherapy RD, and alpelisib will be dosed at fixed standard dose. Administration of higher dose of SAR439859 (with standard aleplisib dose) to subsequent patients will be based on occurrence of DLTs at initial and subsequent dose, until MAD of SAR439859 is reached. Both SAR439859 and alpelisib will be administered in 28-day cycle.
11214321|NCT03284957|Experimental|Part G Dose expansion: SAR439859/alpelisib combination|Based on the results in Part F, patients will be administered either: 1) a determined SAR439859 dose (RD) with standard dose of alpelisib in combination therapy, or 2) one of two randomized dose levels of SAR439859 with standard dose of alpelisib in combination therapy. Both study drugs will be administered in 28-day cycle.
11214322|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
11214323|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
11214324|NCT03284931|Experimental|SAGE-217 high dose|SAGE-217
11214325|NCT03284931|Experimental|SAGE-217 low dose|SAGE-217
11214326|NCT03284931|Placebo Comparator|Placebo|Placebo
11214327|NCT03284918|Experimental|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
11214328|NCT03284918|Placebo Comparator|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
11214329|NCT03284905|Active Comparator|Probiotics|
11214330|NCT03284905|Placebo Comparator|Placebo|
11214331|NCT03284892|Experimental|PED Care group|Received PED care addition to usual care
11214332|NCT03284892|Active Comparator|Control group|Received usual care only
11214333|NCT03284879||Patients with PsV and PsA treated with OTEZLA Tablets|Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
11214334|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
11214335|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
11214336|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
11214337|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
11214338|NCT03284840||Adults (18-65 years)|
11214339|NCT03284840||Elderly (65-74 years)|
11214340|NCT03284827|Experimental|NOAC|60 mg once daily
11214341|NCT03284827|Active Comparator|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD)
11214342|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
11214343|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
11214344|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
11214345|NCT03284788|Experimental|ABT Weight Loss Intervention|Adolescent girls will attend healthy lifestyle sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
11214346|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation
11215526|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C MAD|or matching placebo - HV
11214347|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
11214348|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
11214349|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
11214350|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
11214351|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.
~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
11214352|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
11214353|NCT03284723|Experimental|PF-06804103|Study Treatment
11214354|NCT03284723|Experimental|PF-06804103+Combination Regimen|Study Treatment
11214355|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
11214356|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
11214357|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
11214358|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
11214359|NCT03284697|Active Comparator|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
11214360|NCT03284697|Active Comparator|DPC with MTA|Direct pulp capping with MTA
11214361|NCT03284684||circulating DNA plasma level test|
11214362|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
11214363|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
11214364|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
11214365|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
11214366|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
11214367|NCT03284632||Smokers|
11214368|NCT03284632||E-cigarette users|
11214369|NCT03284632||Non-smokers|
11214370|NCT03284619|Experimental|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
11214371|NCT03284606|Experimental|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
11214372|NCT03284606|Placebo Comparator|NO TAPING|Common rehabilitation for hemiplegic patients without taping
11214373|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
11214374|NCT03284593||Azacitidine group|patients treated with azacitidine
11214375|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
11214376|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
11214377|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
11214378|NCT03284567|Active Comparator|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.
~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
11214379|NCT03284567|No Intervention|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
11214380|NCT03284554|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).
~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
11214381|NCT03284554|Sham Comparator|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.
~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
11214382|NCT03284554|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).
~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
11214419|NCT03284255|Active Comparator|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
11214469|NCT03283930|Experimental|Active ABMT|Active attention bias modification will be provided in addition to individual cognitive behavioral therapy
11215527|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D MAD|or matching placebo - HV
11214383|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
11214384|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
11214385|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
11214386|NCT03284502|Experimental|Stage 1|Dose escalation
11214387|NCT03284502|Experimental|Stage 2|Expansion
11214388|NCT03284489||ICU patients|Patients with pancreatitis
11214389|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
11214390|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
11214391|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
11214392|NCT03284450|Experimental|Dance performance fitness test (DPFT)|
11214393|NCT03284450|Active Comparator|Sport specific repeated sprints (SSRS)|
11214394|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
11214395|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
11214396|NCT03284424|Experimental|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
11214397|NCT03284424|Experimental|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
11214398|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
11214399|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
11214400|NCT03284385|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11214401|NCT03284372|Experimental|Intervention 1|Text Message Only
11214402|NCT03284372|Experimental|Intervention 2, Incentive 1|Text message + Incentive 1
11214403|NCT03284372|Experimental|Intervention 2, Incentive 2|Text message + Incentive 2
11214404|NCT03284372|No Intervention|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
11214405|NCT03284372|No Intervention|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
11214406|NCT03284372|No Intervention|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
11214407|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
11214408|NCT03284359|No Intervention|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
11214409|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
11214410|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
11214411|NCT03284333|Experimental|other|no arm
11214412|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
11214413|NCT03284294|Placebo Comparator|Placebo|Oral placebo daily for 8 weeks
11214414|NCT03284294|Active Comparator|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
11214415|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
11214416|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
11214417|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
11214418|NCT03284255|Experimental|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
11214586|NCT03283033|Experimental|Experimental 1|Introduction of a new salad bar during second semester of school year
11214420|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
11214421|NCT03284229|Experimental|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
11214422|NCT03284216|Other|Normal glycemia + exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
11214423|NCT03284216|Experimental|Steady-state hyperglycemia + exercise|Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
11214424|NCT03284216|Experimental|Fluctuating hyperglycemia + exercise|Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
11214425|NCT03284216|No Intervention|Normal glycemia, no exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
11214426|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
11214427|NCT03284190||ASDH Copenhagen, Denmark|
11214428|NCT03284190||ASDH Odense, Denmark|
11214429|NCT03284190||ASDH Århus, Denmark|
11214430|NCT03284190||ASDH Ålborg, Denmark|
11214431|NCT03284190||ASDH Lund, Sweden|
11214432|NCT03284190||ASDH Linköping, Sweden|
11214433|NCT03284190||ASDH Gothenburg, Sweden|
11214434|NCT03284190||ASDH Stockholm, Sweden|
11214435|NCT03284190||ASDH Uppsala, Sweden|
11214436|NCT03284190||ASDH Umeå, Sweden|
11214437|NCT03284177|Experimental|C13-CAC|
11214438|NCT03284164|Experimental|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
11214439|NCT03284164|Experimental|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
11214440|NCT03284138|Active Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
11214441|NCT03284138|Sham Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
11214442|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
11214443|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
11214444|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
11214445|NCT03284099|Experimental|intervention|ACEIs or ARBs will be switch to be taken before bedtime
11214446|NCT03284099|Active Comparator|control|ACEIs or ARBs will be taken in the morning as usual
11214447|NCT03284086|Other|paraplegic|Well-trained participants with a spinal cord injury (<Th1) were included in this group.
11214448|NCT03284086|Other|able bodied|Upper-body trained, able-bodied participants were included in this group.
11214449|NCT03284073|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
11214450|NCT03284060|Experimental|Cognitive remediation program|
11214451|NCT03284047|Experimental|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
~2.5 U
~5 U
~7.5 U"
11214452|NCT03284047|Experimental|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
~2.5 U
~5 U
~7.5 U"
11214453|NCT03284047|Experimental|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
~2.5 U
~5 U
~7.5 U"
11214454|NCT03284034|Active Comparator|Cyrolipolysis|
11214455|NCT03284034|Experimental|Deoxycholic Acid|
11214456|NCT03284021|Other|Fraxel laser|
11214457|NCT03284008|Experimental|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
11214458|NCT03284008|Active Comparator|stretching exercise|Patients will receive education to perform stretching exercises at home.
11214459|NCT03283995||cardiogenic shock without SCA|
11214460|NCT03283995||cardiogenic shock with SCA|
11214461|NCT03283995||SCA,|
11214462|NCT03283995||acute left heart failure with severe alteration of LVEF|
11214463|NCT03283982|Active Comparator|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
11214464|NCT03283982|Active Comparator|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
11214465|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
11214466|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
11214467|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
11214468|NCT03283943|Experimental|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
11214470|NCT03283930|Placebo Comparator|Placebo|Placebo attention bias modification will be provided in addition to individual cognitive behavioral therapy
11214471|NCT03283917|Experimental|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
11214472|NCT03283904|Experimental|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
11214473|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
11214474|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
11214475|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.
~< 120 kg - patients will receive 2 grams of cefazolin
~≥ 120 kg - patient will receive 3 grams of cefazolin
~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
11214476|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.
~< 120 kg - patients will receive 2 grams of cefazolin
~≥ 120 kg - patient will receive 3 grams of cefazolin
~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
11214477|NCT03283865|Experimental|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.
~All study participants will have ultrasound used for caudal block."
11214478|NCT03283839|Other|Temporomandibular disorder|
11214479|NCT03283839|Other|Without temporomandibular disorder|
11214480|NCT03283826|Experimental|ATA188|Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description.
11214481|NCT03283826|Placebo Comparator|Placebo|Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).
11214482|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
11214483|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
11214484|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
11214485|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
11214486|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
11214487|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
11214488|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
11214489|NCT03283761|Experimental|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A every 14 days of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m^2 and leucovorin IV 400 mg/m^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every 8 weeks to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
11214490|NCT03283748|Experimental|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
11214491|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
11214492|NCT03283735|No Intervention|Control|This will be the control group.
11214493|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
11214494|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
11214495|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
11214496|NCT03283670|Experimental|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, in known N-methyl-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
11214497|NCT03283670|Experimental|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, in known N-methyl-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
11214498|NCT03283670|Placebo Comparator|Placebo Gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen
11214499|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
11214500|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
11214501|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
11214502|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
11214503|NCT03283631|Experimental|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
11214504|NCT03283618|No Intervention|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
11214505|NCT03283618|Experimental|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
11214506|NCT03283605|Experimental|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
11214507|NCT03283592|Experimental|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
11214508|NCT03283592|Active Comparator|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
11214509|NCT03283579||Pregnant women|
11214510|NCT03283566|Active Comparator|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
11214511|NCT03283566|Placebo Comparator|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
11214512|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
11214513|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
11214514|NCT03283540||TaTME|Trans-anal Total Mesorectal Excision (TaTME) is the visualization and dissection of the rectum located deep in the pelvis. In it, a trans-anal port is inserted for the duration of the surgery. Multiple surgical tools are then introduced through the port and the rectum is resected from down-to-up under direct visualization.
11214515|NCT03283540||abdominal TME|"Total Mesorectal Excision involves resecting the rectum along with its surrounding Mesorectal plane. If the anal sphincter is spared, this surgery is named Low Anterior resection (LAR) for rectal cancer. Traditionally, TME dissection in LAR is performed through open or laparoscopic incisions(s) made in the abdominal wall. Mobilization of the splenic flexure along with sigmoid dissection follows. Lastly, the rectum is dissected in accordance with TME principles from above. This up-to-down approach is known as abdominal TME."
11214516|NCT03283488|Experimental|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
11214517|NCT03283488|Active Comparator|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
11214518|NCT03283475|No Intervention|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.
~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
11214519|NCT03283475|Active Comparator|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.
~After assessment, one of the following techniques will be selected:-
~Liposuction only.
~thigh lift.
~Liposuction assisted thigh lift."
11214520|NCT03283462|Active Comparator|AMAZ-02|
11214521|NCT03283462|Placebo Comparator|Placebo|
11214587|NCT03283033|No Intervention|Control|No introduction of a new salad bar and no introduction of marketing conditions
11214522|NCT03283449|Experimental|AV-1451 Recipients|Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
11214523|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
11214524|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
11214525|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
11214526|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
11214527|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
11214528|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
11214529|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
11214530|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
11214531|NCT03283371|Experimental|Natalizumab 300 mg|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
11214532|NCT03283371|Placebo Comparator|Placebo|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
11214533|NCT03283358|Experimental|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
11214534|NCT03283358|No Intervention|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
11214535|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
11214536|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
11214537|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
11214538|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
11214539|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
11214540|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
11214541|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
11214542|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
11214543|NCT03283293|Experimental|Target volume delineation after NACT|
11214544|NCT03283280|Experimental|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
11214545|NCT03283280|Active Comparator|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
11214546|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
11214547|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
11214548|NCT03283254|Experimental|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
11214549|NCT03283254|Active Comparator|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
11214550|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
11214551|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
11214552|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
11214553|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
11214554|NCT03283202|Experimental|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
11214555|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
11214556|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
11214557|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
11214558|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
11214559|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
11214560|NCT03283189||Group 6|Liberal follow-up of pregnancy
11214561|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
11214562|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
11214563|NCT03283163|Experimental|Chronic Pain//PTSD group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
11214564|NCT03283163|Active Comparator|Trauma-exposed healthy control group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
11214565|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
11214566|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
11214567|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
11214568|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
11214569|NCT03283124|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
11214570|NCT03283124|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
11214571|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
11214572|NCT03283098|Placebo Comparator|Placebo|Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
11214573|NCT03283098|Experimental|Etelcalcetide|5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
11214574|NCT03283085|Experimental|25 mg Ontamalimab|Participants will be receiving 25 milligram (mg) of ontamalimab solution for injection subcutaneously (SC) every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
11214575|NCT03283085|Experimental|75 mg Ontamalimab|Participants will be receiving 75 mg of ontamalimab solution for injection SC every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
11214576|NCT03283072|Sham Comparator|Sham|normoxia for 2 minutes, normoxia 1 minute x 8 using hypoxicator
11214577|NCT03283072|Experimental|Trubower|15 bouts of hypoxia for 1 minute, normoxic 1 minute using hypoxicator
11214578|NCT03283072|Experimental|Hayes|15 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
11214579|NCT03283072|Experimental|Tester|8 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
11214580|NCT03283059|Experimental|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
11214581|NCT03283059|Active Comparator|Aricept|Aricept 5mg/day P.O.
11214582|NCT03283059|Placebo Comparator|Placebo|Placebo P.O. tid
11214583|NCT03283046|Experimental|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.
~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.
~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.
~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:
~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
11214584|NCT03283033|Experimental|Experimental 3|Introduction of a new salad bar and marketing conditions during second semester of school year
11214585|NCT03283033|Experimental|Experimental 2|Introduction of marketing conditions during second semester of school year
11214588|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
11214589|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
11214590|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
11214591|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
11214592|NCT03282994|Experimental|Treatment with cryotherapy|Dermal Cooling System
11214593|NCT03282981|Experimental|Timolol|Timoptic-XE plus standard of care (SOC)
11214594|NCT03282981|Placebo Comparator|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
11214595|NCT03282968|Experimental|Experimental|Regular neurophysiotherapy plus REWIRE exercises
11214596|NCT03282968|Active Comparator|Control|Regular neurophysiotherapy plus standing balance exercises
11214597|NCT03282955|Experimental|Lipidem|i.v. lipid emulsion containing fractionated fish oil (n-3 fatty acid triglycerides)
11214598|NCT03282955|Active Comparator|Lipofundin MCT|i.v. lipid emulsion
11214599|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
11214600|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
11214601|NCT03282929|Experimental|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
11214602|NCT03282929|Experimental|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
11214603|NCT03282929|Experimental|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
11214604|NCT03282929|Experimental|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
11214605|NCT03282929|Experimental|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
11214606|NCT03282916|Active Comparator|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day.
11214607|NCT03282916|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day.
11214608|NCT03282903||Crohn's disease patients|1550 Crohn's disease patients who are symptomatically controlled.
11214609|NCT03282903||Ulcerative Colitis patients|1550 Ulcerative Colitis patients who are symptomatically controlled.
11214610|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
11214611|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
11214612|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
11214613|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
11214614|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
11214615|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
11214616|NCT03282851|Experimental|MSB11456|
11214617|NCT03282851|Active Comparator|US-licensed Actemra|
11214618|NCT03282851|Active Comparator|EU-approved RoActemra|
11214619|NCT03282838|Experimental|DFN-15 (fasted)|
11214620|NCT03282838|Experimental|DFN-15 (fed)|
11214621|NCT03282838|Experimental|Comparator (fed)|
11214622|NCT03282825|Experimental|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.
~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.
~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
11214623|NCT03282812||cases|
11214624|NCT03282812||controls|
11214625|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
11214626|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
11214731|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
11214627|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
11214628|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
11214629|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
11214630|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
11214631|NCT03282773|Experimental|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
11214632|NCT03282773|Active Comparator|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
11214633|NCT03282760|Experimental|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
11214634|NCT03282734|Experimental|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
11214635|NCT03282734|Active Comparator|The control group|Conventional home rehabilitation exercise education for 4 weeks
11214636|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
11214637|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
11214638|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).
~Data collection with self-administered questionnaire"
11214639|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
11214640|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.
~These patients will receive standard pain treatment until the planned surgery."
11214641|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.
~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.
~These patients will receive standard pain treatment until the planned surgery."
11214642|NCT03282682|Experimental|hypogonadal males without TRT|Strength training
11214643|NCT03282682|Experimental|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
11214644|NCT03282682|Active Comparator|healthy eugonadal males|Strength training
11214645|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
11214646|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
11214647|NCT03282656|Experimental|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
11214648|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
11214649|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
11214650|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
11214651|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
11214652|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
11214653|NCT03282617|Experimental|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
11214654|NCT03282617|Experimental|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
11214655|NCT03282604||male|
11214656|NCT03282604||female|
11214657|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
11214658|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
11214659|NCT03282578|Active Comparator|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
11214660|NCT03282578|Active Comparator|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
11214798|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
11214661|NCT03282565|Experimental|Functional Resistance Training|Participants will receive functional resistance training while walking on a treadmill 2-3 times a week for about 8 weeks.
11214662|NCT03282565|Sham Comparator|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
11214663|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.
~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
11214664|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.
~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
11214665|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.
~In this group all patients will receive the usual standard of care, with no other interventions included"
11214666|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
11214667|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
11214668|NCT03282526|Experimental|Whole body plethysmography|
11214669|NCT03282526|Active Comparator|spirometery|
11214670|NCT03282513|Experimental|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
11214671|NCT03282513|Active Comparator|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
11214672|NCT03282513|Experimental|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
11214673|NCT03282513|Active Comparator|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)
~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
11214674|NCT03282500|Experimental|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
11214675|NCT03282500|No Intervention|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
11214676|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
11214677|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
11214678|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
11214679|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
11214680|NCT03282461|Experimental|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
11214681|NCT03282448|Experimental|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
11214682|NCT03282448|No Intervention|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
11214683|NCT03282435|Experimental|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
11214684|NCT03282435|Active Comparator|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
11214685|NCT03282422|Experimental|Intervention group|Upper-limb splint and home-based protocol in specific tasks
11214686|NCT03282422|Active Comparator|Control group|Home-based protocol in specific tasks
11214687|NCT03282396|Experimental|Treatment (ibrutinib)|Participants receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for 5 years in the absence of disease progression or unacceptable toxicity.
11214688|NCT03282370|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
11214689|NCT03282370|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
11214690|NCT03282357|Experimental|Radiesse®|Patients are randomized as to which of the two nasolabial folds is treated with Radiesse®.
11214691|NCT03282357|Active Comparator|Restylane®|Patients are randomized as to which of the two nasolabial folds is treated with Restylane®.
11214692|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
11214693|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
11214694|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
11214695|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
11214696|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
11215528|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E MAD|or matching placebo - HV
11214697|NCT03282318|Experimental|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
11214698|NCT03282318|Placebo Comparator|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
11214699|NCT03282292|Experimental|Jugular|CVC insertion in the left or right internal jugular vein
11214700|NCT03282292|Active Comparator|Femoral|CVC insertion in the right or left femoral vein
11214701|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
11214702|NCT03282266|Experimental|PADN + 5-phosphodiesterase|A total of 64 patients are assigned to PADN + 5-phosphodiesterase group after randomization schedule.
11214703|NCT03282266|Sham Comparator|Sham operation + 5-phosphodiesterase|A total of 64 patients are assigned to sham operation + 5-phosphodiesterase group after randomization schedule.
11214704|NCT03282240|Experimental|QIV-HD|Participants randomized to receive a single injection of 0.7 mL QIV-HD by intramuscular (IM) route at Day 0.
11214705|NCT03282240|Active Comparator|TIV-HD1 (Licensed TIV-HD1)|Participants randomized to receive a single injection of 0.5 mL licensed TIV-HD1 by IM route at Day 0.
11214706|NCT03282240|Active Comparator|TIV-HD2 (Investigational TIV-HD2)|Participants randomized to receive a single injection of 0.5 mL investigational TIV-HD2 by IM route at Day 0.
11214707|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
11214708|NCT03282214|Experimental|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
11214709|NCT03282214|No Intervention|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
11214710|NCT03282201||Transfused|Patients in whom blood transfusion is used
11214711|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
11214712|NCT03282188|Experimental|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
11214713|NCT03282188|Experimental|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
11214714|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
11214715|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
11214716|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
11214717|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
11214718|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
11214719|NCT03282149|Experimental|Dose 1|Lowest trial dose of XT-150
11214720|NCT03282149|Experimental|Dose 2|Second, escalating dose of XT-150
11214721|NCT03282149|Experimental|Dose 3|Third, escalating dose of XT-150
11214722|NCT03282149|Placebo Comparator|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
11214723|NCT03282136|Active Comparator|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
11214724|NCT03282136|Placebo Comparator|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
11214725|NCT03282123|Experimental|MDMA-assisted psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
11214726|NCT03282110|Experimental|ta-VNS & Electro-acupuncture|"Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months
~Other:Electro-acupuncture:3 times per week, once every other day for two months"
11214727|NCT03282110|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
11214728|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
11214729|NCT03282097|Active Comparator|Home safety guide|The home safety guide is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group away from talking about mammography with the patient's PCP.
11214730|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
11214732|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
11214733|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
11214734|NCT03282058|Experimental|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
11214735|NCT03282058|No Intervention|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
11214736|NCT03282045|Experimental|Lysobact Complete Sprey|"Lysobact Complete Sprey
~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open
~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
11214737|NCT03282045|Active Comparator|Tantum Verde® Spray|"Tantum Verde® Spray
~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.
~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
11214738|NCT03282045|Active Comparator|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray
~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.
~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
11214739|NCT03282045|Placebo Comparator|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.
~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
11214740|NCT03282032|Experimental|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
11214741|NCT03282032|No Intervention|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
11214742|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
11214743|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
11214744|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
11214745|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
11214746|NCT03281980|Experimental|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
11214747|NCT03281980|Sham Comparator|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
11214748|NCT03281980|No Intervention|Comparison|
11214749|NCT03281967|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
11214750|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
11214751|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
11214752|NCT03281941|Other|Patients without BT|
11214753|NCT03281941|Other|Post BT|
11214754|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
11214755|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
11214756|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
11214757|NCT03281928|Placebo Comparator|High Sodium plus placebo|
11214758|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
11214759|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
11214760|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patients undergo collection of blood at baseline and on day 1 of each treatment cycle. Patients also undergo tumor biopsy at baseline and 2 months. Biopsy samples are analyzed for genetic profile via next generation sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model. Patients are followed up for 3 years.
11214761|NCT03281889|Experimental|Proton Radiotherapy|"Patients will be treated with Proton Beam once daily 5 days per week.
~Doses will be prescribed such that maximum possible coverage is achieved"
11214762|NCT03281876|Experimental|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
11214763|NCT03281876|Placebo Comparator|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
11214764|NCT03281837|Experimental|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
11214765|NCT03281837|Other|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
11214766|NCT03281837|Other|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
11279984|NCT02834312|Placebo Comparator|placebo|
11214767|NCT03281824|Experimental|ALT-P7|"8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,
~Administration: Day 1 of each 3-week cycle"
11214768|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
11214769|NCT03281798|Experimental|Fetuses with LUTO|Performance of ultrasound-guided, percutaneous fetal cystoscopy with the Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set
11214770|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
11214771|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
11214772|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
11214773|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
11214774|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
11214775|NCT03281759|Active Comparator|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
11214776|NCT03281759|Placebo Comparator|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
11214777|NCT03281746|Active Comparator|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
11214778|NCT03281746|Experimental|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
11214779|NCT03281720|Experimental|Targeted Axillary Dissection|"After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes.
~The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an axillary dissection."
11214780|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
11214781|NCT03281681|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
11214782|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
11214783|NCT03281655|Experimental|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
11214784|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
11214785|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
11214786|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
11214787|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
11214788|NCT03281603|Experimental|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.
~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
11214789|NCT03281603|Active Comparator|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
11214790|NCT03281590||Patients with stroke|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
11214791|NCT03281590||Patients without stroke|Control subject who have the risk factors but never had stroke.
11214792|NCT03281577|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
11214793|NCT03281577|Experimental|TAK-954 0.1 mg|TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
11214794|NCT03281577|Experimental|TAK-954 0.3 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
11214795|NCT03281577|Experimental|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
11214796|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
11214797|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
11280366|NCT02831712|Other|Iron supplement|Ferrous Fumarate tablet 200 mg
11214800|NCT03281486|Experimental|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
11214801|NCT03281486|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
11214802|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
11214803|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
11214804|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
11214805|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
11214806|NCT03281447|Experimental|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
11214807|NCT03281447|Active Comparator|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
11214808|NCT03281434|Active Comparator|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
11214809|NCT03281434|Experimental|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
11214810|NCT03281421|Experimental|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
11214811|NCT03281421|Active Comparator|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
11214812|NCT03281421|Active Comparator|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
11214813|NCT03281408||Suspected OSA Patients Undergoing Knee or Hip Arthroplasty|These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.
11214814|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
11214815|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
11214816|NCT03281382|Experimental|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
11214817|NCT03281369|Active Comparator|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
11214818|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
11214819|NCT03281369|Experimental|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
11214891|NCT03280901|Experimental|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
11214892|NCT03280875|Experimental|healthy volunteers|
11280367|NCT02831699||Febrile Rash|
11214820|NCT03281369|Experimental|1L-B: mFOLFOX6 + Atezo (Gastric Cancer)|Participants in the 1L-B Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
11214821|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
11214822|NCT03281369|Experimental|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
11214823|NCT03281369|Experimental|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
11214824|NCT03281369|Experimental|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
11214825|NCT03281369|Experimental|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
11214826|NCT03281369|Experimental|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
11214827|NCT03281369|Experimental|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
11214828|NCT03281369|Active Comparator|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
11214829|NCT03281369|Experimental|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
11214830|NCT03281356|Experimental|Intervention Group|
11214831|NCT03281343|Experimental|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
11214832|NCT03281343|Active Comparator|Standard of Care (SOC)|Approximates care currently provided at the prison.
11214833|NCT03281330||persons with Multiple Sclerosis|
11214834|NCT03281330||Healthy controls|
11214835|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
11214836|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
11214837|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
11214838|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
11214839|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
11214840|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
11214841|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
11214842|NCT03281239|Experimental|welder/airport agent|No drug and no placebo were used in this study.
11214843|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
11214844|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
11214845|NCT03281213||Female|
11214846|NCT03281213||Male|
11214847|NCT03281200||Anatomical main group:|
11214848|NCT03281200||Therapeutic subgroup|
11214849|NCT03281200||Pharmacological subgroup|
11214850|NCT03281200||Chemical subgroup|
11214851|NCT03281200||Chemical substance|
11214852|NCT03281187|Experimental|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
11214853|NCT03281187|Active Comparator|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
11214854|NCT03281187|Placebo Comparator|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
11214855|NCT03281187|Placebo Comparator|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
11214856|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
11214857|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
11280368|NCT02831699||Household|
11214858|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
11214859|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
11214860|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
11214861|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
11214862|NCT03281135|Other|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
11214863|NCT03281135|No Intervention|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
11214864|NCT03281122|Experimental|Arm A|Specified dose on specified days
11214865|NCT03281122|Placebo Comparator|Arm B|Specified dose on specified days
11214866|NCT03281096|Experimental|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
11214867|NCT03281096|Placebo Comparator|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
11214868|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
11214869|NCT03281057|Experimental|Individual CRAFT|Individual CRAFT is offered to 135 participants and each participants are going to get 6 sessions.
11214870|NCT03281057|Experimental|Group CRAFT|Open group CRAFT is offered to 135 participants in 6 sessions.
11214871|NCT03281057|Experimental|Self-help materials|Self-help materials (control group) are going to be offered a self-help book, because it is unethically not to offer any intervention, as the CRAFT intervention in early studies have shown to be very effectful
11214872|NCT03281044|Experimental|FMT group|Patient group receiving active FMT capsules
11214873|NCT03281044|Placebo Comparator|Placebo group|Patient group receiving placebo capsules
11214874|NCT03281031|Other|Additional MRI Examination|Single arm, all patient will undergo CT followed by additional MRI examination
11214875|NCT03281018|Experimental|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
11214876|NCT03281018|No Intervention|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
11214877|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
11214878|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
11214879|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
11214880|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
11214881|NCT03280979|Experimental|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
11214882|NCT03280979|Experimental|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
11214883|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
11214884|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
11214885|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
11214886|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
11214887|NCT03280927|Experimental|Jublia®|
11214888|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
11214889|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
11214890|NCT03280901|Experimental|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
11280369|NCT02831699||Guillain-Barré prospective|
11214893|NCT03280862|Active Comparator|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
11214894|NCT03280862|Experimental|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
11214895|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
11214896|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
11214897|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.
~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
11214898|NCT03280810|Experimental|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
11214899|NCT03280810|No Intervention|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
11214900|NCT03280797|Other|Control|
11214901|NCT03280797|Other|Rheumatoid arthritis patients|
11214902|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
11214903|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
11214904|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
11214905|NCT03280758|No Intervention|Control group|No exercise training.
11214906|NCT03280745|Active Comparator|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
11214907|NCT03280745|Active Comparator|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
11214908|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
11214909|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:
~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
11214910|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:
~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
11214911|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:
~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
11214912|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:
~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
11214913|NCT03280706|Experimental|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
11214914|NCT03280706|Active Comparator|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
11214915|NCT03280706|Active Comparator|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
11214916|NCT03280680|Experimental|Female+male group sessions|
11214917|NCT03280680|Experimental|Female group sessions|
11214918|NCT03280680|Other|No group sessions|
11214919|NCT03280667|Experimental|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
11214920|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels <7,55
11214921|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels >=7,55
11214922|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
11214923|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
11214924|NCT03280628|Active Comparator|Absorbable Sutures|30 patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
11214925|NCT03280628|Experimental|Steri-Strips|"30 patients will have their laceration closed with a special medical tape called Steri-Strips."
11214926|NCT03280628|Experimental|Dermabond|"30 patients will have their laceration closed with a special skin glue called Steri-Strips."
11214927|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
11214928|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
11280370|NCT02831699||Prior Guillain-Barré|
11214929|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
11214930|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
11214931|NCT03280589|Active Comparator|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
11214932|NCT03280589|Experimental|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
11214933|NCT03280589|Experimental|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
11214934|NCT03280589|Experimental|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
11214935|NCT03280589|Experimental|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
11214936|NCT03280576||Sepsis|Patients with sepsis
11214937|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
11214938|NCT03280576||Healthy controls|Normal individuals
11214939|NCT03280563|Active Comparator|Stage 1: Fulvestrant|Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.
11214940|NCT03280563|Experimental|Stage 1: Atezolizumab + Entinostat|Participants will receive doublet combination treatment with atezolizumab plus entinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11214941|NCT03280563|Experimental|Stage 1: Atezolizumab + Fulvestrant|Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11214942|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib|Participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
11214943|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus ipatasertib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
11214944|NCT03280563|Experimental|Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy|Those who progress or experience unacceptable toxicity during treatment in Stage 1 may be eligible to enter Stage 2. Participants will receive triplet combination therapy with atezolizumab plus bevacizumab plus one of three endocrine therapies (fulvestrant, exemestane, or tamoxifen) selected by the physician. Treatment in Stage 2 will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11214945|NCT03280563|Experimental|Stage 1: Mandatory On-Treatment Biopsy|For experimental combination arms that demonstrate clinical activity during the preliminary phase, the Sponsor may open enrollment into a separate mandatory on-treatment biopsy cohort for that combination.
11214946|NCT03280563|Experimental|Stage 1: Atezolizumab + Abemaciclib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus abemaciclib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
11214977|NCT03280316|Experimental|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
11283029|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
11214947|NCT03280550|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
11214948|NCT03280550|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
11214949|NCT03280537|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
11214950|NCT03280537|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
11214951|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
11214952|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
11214953|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
11214954|NCT03280498|Other|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
11214955|NCT03280472|Experimental|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
11214956|NCT03280472|Other|Symptom Tracking|Participants will track their symptoms.
11214957|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
11214958|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
11214959|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
11214960|NCT03280420|Active Comparator|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
11214961|NCT03280420|Active Comparator|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
11214962|NCT03280407|Active Comparator|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
11214963|NCT03280407|Experimental|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
11214964|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
11214965|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
11214966|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
11214967|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
11214968|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.
~Inclusion before initiation of anticoagulation."
11214969|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
11214970|NCT03280355|Experimental|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
11214971|NCT03280355|Active Comparator|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
11214972|NCT03280342|Active Comparator|IR-TPM (Topamax)|IR-TPM (Topamax)
11214973|NCT03280342|Active Comparator|XR-TPM (Trokendi XR)|
11214974|NCT03280329|No Intervention|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
11214975|NCT03280329|Active Comparator|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
11214976|NCT03280329|Active Comparator|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:
~Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;
~Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);
~Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, …);
~Mixing tracks so that there is continuity and fluidity of listening"
11214978|NCT03280316|Experimental|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
11214979|NCT03280316|Experimental|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
11214980|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
11214981|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)
~In a complete remission rate of leucocytes with ≥ 2G / L
~Affiliated to social security person or beneficiary of such a scheme."
11214982|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ
~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)
~Having a rate of circulating lymphocytes ≥ 1 G / L
~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population
~The statutes CMV and EBV are known (positive or negative).
~Affiliated to social security person or beneficiary"
11214983|NCT03280277|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
11214984|NCT03280264|Experimental|KHK7580|oral administration
11214985|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
11214986|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
11214987|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
11214988|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
11214989|NCT03280238|Experimental|Experiment|"Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode
~Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)
~Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
11214990|NCT03280225||VISNs requesting implementation support|VA has divided the country into regions of care and these are called Veteran Integrated Service Networks (VISNs). This group consists of VISNs with facilities that need additional implementation support to fully implement REACH VET and that agree to participate.
11214991|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)
~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
11214992|NCT03280212|No Intervention|Control Arm|"No intervention
~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
11214993|NCT03280199|Other|Type of simulator - 1|"VR simulator with physical mannequin and probe.
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
11214994|NCT03280199|Other|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
11214995|NCT03280199|Other|Type of image acquisition - 3|"US images are acquired through real US volumes from patients
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
11214996|NCT03280199|Other|Type of image acquisition - 4|"US images are acquired through computer-generated images.
~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
11214997|NCT03280186|Experimental|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
11214998|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
11214999|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
11215000|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
11215001|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
11215002|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
11215003|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
11215004|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
11215005|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
11215006|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
11215007|NCT03280108|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
11215008|NCT03280108|Active Comparator|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
11215099|NCT03279471|Placebo Comparator|Pill Placebo|These individuals will receive a pill placebo.
11215009|NCT03280095|Experimental|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
11215010|NCT03280095|Experimental|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
11215011|NCT03280095|Active Comparator|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
11215012|NCT03280082|Other|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.
~The criteria for admission include:
~MUAC <120 mm
~Bilateral edema of grade + or ++
~The criteria for release of care include:
~MUAC ≥ 125 mm at 2 consecutive visits
~Minimum stay 3 weeks in the program
~Absence of acute medical complications
~Absence of edema"
11215013|NCT03280082|Other|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC<125 mm will be referred to Nutrition Centers for admission.
~The criteria for admission include:
~MUAC<115 mm and/or
~Z score <-3 and /or
~Bilateral edema of grade + or ++
~The criteria for release of care include:
~MUAC ≥ 125 mm at 2 consecutive visits
~Minimum stay 3 weeks in the program
~Absence of acute medical complications
~Absence of edema"
11215014|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
11215015|NCT03280056|Active Comparator|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
11215016|NCT03280056|Placebo Comparator|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
11215017|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
11215018|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
11215019|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
11215020|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
11215021|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
11215022|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
11215023|NCT03280004||Moxifloxacin group|
11215024|NCT03280004||β-lactams group|
11215025|NCT03279978|Experimental|BI 730357|
11215026|NCT03279978|Placebo Comparator|Placebo|
11215027|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
11215028|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
11215029|NCT03279952|Other|medication arm|CNS Stimulant
11215030|NCT03279939|Experimental|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
11215031|NCT03279939|Experimental|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
11215032|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
11215033|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
11215034|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
11215035|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
11215036|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass
~ARF was defined as one of the following conditions:
~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,
~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
11215037|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
11215038|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
11215039|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
11215040|NCT03279835||Absence of cognitive disorder|
11215041|NCT03279835||Asymptomatic cognitive disorder|
11215042|NCT03279835||Symptomatic cognitive impairment|
11215043|NCT03279835||HIV associated dementia|
11215044|NCT03279822||Group|
11215045|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
11215046|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
11215165|NCT03279081|Experimental|Cx601|Cx601 eASCs 120 million cells (5 million cells per milliliter [mL]) will be administered once by intralesional injection.
11285417|NCT02796443||Delayed LC (DLC)|Operation after 6-12 weeks
11215047|NCT03279796|Experimental|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
11215048|NCT03279796|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
11215049|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
11215050|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
11215051|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
11215052|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
11215053|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
11215054|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
11215055|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
11215056|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
11215057|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
11215058|NCT03279744|Experimental|Single-Arm|Radion™-pdt
11215059|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
11215060|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
11215061|NCT03279718|Experimental|periodontal treatment|
11215062|NCT03279718|No Intervention|only oral hygiene instruction, no treatment|
11215063|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
11215064|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
11215065|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks
~Pembrolizumab will be administered through IV infusion"
11215066|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
11215067|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
11215068|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
11215069|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
11215070|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
11215071|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
11215072|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
11215166|NCT03279081|Placebo Comparator|Placebo|CX601 placebo-matching eASCs cells will be administered once by intralesional administration.
11215073|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1
~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
11215074|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1
~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.
~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
11215075|NCT03279627||Hypoglycemia|This group will be those who experience a BG < 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
11215076|NCT03279627||Hyperglycemia|This group will be those who experience a BG > 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
11215077|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
11215078|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
11215079|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
11215080|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
11215081|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
11215082|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
11215083|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
11215084|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
11215085|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
11215086|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
11215087|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
11215088|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
11215089|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
11215090|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
11215091|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
11215092|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
11215093|NCT03279510|Experimental|Hearing aids|All study participants will be fit with hearing aids.
11215094|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
11215095|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
11215096|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
11215097|NCT03279471|Experimental|CBT/BIACA|These participants will receive CBT treatment using Behavioral Interventions for Anxiety in Children with Autism (BIACA). BIACA is an anxiety treatment package designed for children with ASD that includes elements of CBT and social skills training.
11215098|NCT03279471|Active Comparator|Sertraline|These participants will receive sertraline
11215100|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
11215101|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
11215102|NCT03279445||African American|Patient of African American race
11215103|NCT03279445||Caucasian|Patient of Caucasian race
11215104|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.
~Patient may or may not be receiving terlipressin therapy."
11215105|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.
~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
11215106|NCT03279393|Active Comparator|PTSD Subjects|
11215107|NCT03279393|Active Comparator|Trauma Control Subjects|
11215108|NCT03279393|Placebo Comparator|Healthy Control Subjects|
11215109|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
11215110|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).
~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
11215111|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).
~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
11215112|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
11215113|NCT03279354|Experimental|Intervention group|Family Move app intervention
11215114|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
11215115|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
11215116|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
11215117|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
11215118|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
11215119|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
11215120|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
11215121|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
11215122|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
11215123|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
11215124|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
11215125|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
11215126|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
11215127|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
11215128|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
11215129|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
11215130|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
11215131|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
11215132|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
11215133|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
11215134|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
11215135|NCT03279250|Experimental|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
11215196|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
11215197|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
11215136|NCT03279250|Experimental|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
11215137|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle
~Oxaliplatin is administered intravenously
~Leucovorin is administered intravenously
~Irinotecan is administered intravenously
~5-Fluorouracil is administered intravenously
~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
11215138|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
11215139|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
11215140|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
11215141|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
11215142|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
11215143|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
11215144|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
11215145|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
11215146|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
11215147|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
11215148|NCT03279172|Experimental|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
11215149|NCT03279172|Experimental|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
11215150|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
11215151|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
11215152|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
11215153|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
11215154|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
11215155|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
11215156|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
11215157|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
11215158|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
11215159|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
11215160|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
11215161|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
11215162|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
11215163|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
11215164|NCT03279094|Experimental|Haploidentical stem cell transplantation|
11215270|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
11215167|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
11215168|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.
~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.
~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
11215169|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi
~SHUTi is delivered over 6 sessions, each taking 20-30 minutes
~SHUTi is delivered by a virtual therapist
~Participants will learn about the etiology and maintenance of their insomnia
~Participants will learn how to maintain their sleep log
~Participants will learn how to address lifestyle barriers that impact their sleep
~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom
~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior
~Participants will be taught how to gradually expand their restricted sleep"
11215170|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
11215171|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
11215172|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
11215173|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
11215174|NCT03279003|Experimental|Light-emitting diode therapy|Exposure to LED light
11215175|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
11215176|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
11215177|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
11215178|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
11215179|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
11215180|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
11215181|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
11215182|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
11215183|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
11215184|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
11215185|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
11215186|NCT03278925|Experimental|Prevention (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
11215187|NCT03278912||IBD|-Patients with IBD without a diagnosed PIDD.-First- or second-degree relatives of patients with a PIDD of interest who do not have a PIDD themselves, but have diagnosed or suspected IBD.
11215188|NCT03278912||Non-PIDD/non-IBD (healthy volunteers)|healthy volunteers
11215189|NCT03278912||PIDD|CGD cohort; IPEX syndrome cohort; CTLA4 haploinsufficiency cohort; LRBA deficiency and hypomorphic RAG deficiency cohorts
11215190|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
11215191|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
11215192|NCT03278873|Experimental|Biological-Low dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single low dose of either AAV - CNGB3 or AAV - CNGA3
11215193|NCT03278873|Experimental|Biological-medium dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single medium dose of either AAV - CNGB3 or AAV - CNGA3
11215194|NCT03278873|Experimental|Biological-high dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single high dose of either AAV - CNGB3 or AAV - CNGA3
11215195|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
11215529|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F MAD|or matching placebo - HV
11215198|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
11215199|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.
~Twice per day for 45 minutes.
~Exercise - Home exercises programme once per day with 10 exercises."
11215200|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.
~Exercise - Home exercises programme once per day with 10 exercises."
11215201|NCT03278821|Experimental|Self Match|The patient must choose between the five possible treatment options.
11215202|NCT03278821|Active Comparator|Expert Match|The Patient is referred to treatment by standard procedure which is Expert Match based on patient data.
11215203|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
11215204|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
11215205|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
11215206|NCT03278795|Active Comparator|PSV mode|PSV weaning group
11215207|NCT03278795|Experimental|VSV mode|VSV weaning group
11215208|NCT03278782|Experimental|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
11215209|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
11215210|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
11215211|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
11215212|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
11215213|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
11215214|NCT03278730|Active Comparator|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.
~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.
~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
11215215|NCT03278730|Placebo Comparator|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.
~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.
~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
11215216|NCT03278717|Experimental|Olaparib and Cediranib|"Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD.
~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
11215217|NCT03278717|Active Comparator|Olaparib|"Patients will receive oral olaparib 300mg BD.
~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
11215218|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
11215219|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
11215220|NCT03278691|Placebo Comparator|Placebo|Drug: Placebo Saline 1 ml IV Q6H
11215221|NCT03278691|Experimental|Intervention|Ketorolac 15 mg (15mg/ml) IV Q6H
11215222|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
11215223|NCT03278652||Patient with renal colic|
11215224|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
11215225|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
11215226|NCT03278626|Other|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
11215271|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
11215272|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
11215724|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
11215227|NCT03278613|Experimental|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 36 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
11215228|NCT03278613|Sham Comparator|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation.
11215229|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
11215230|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
11215231|NCT03278587|Active Comparator|Community-based screening|
11215232|NCT03278587|Active Comparator|Cataract camp program|
11215233|NCT03278587|Active Comparator|Community health worker program|
11215234|NCT03278587|No Intervention|No intervention|
11215235|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
11215236|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
11215237|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
11215238|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
11215239|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
11215240|NCT03278548|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
11215241|NCT03278548|Active Comparator|Ionolyte|Ionolyte solution for infusion
11215242|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 10 men and 10 women aged between 18-29 years
11215243|NCT03278535||age group 30-39years|CAREN-based gait analysis: 10 men and 10 women aged between 30-39years
11215244|NCT03278535||age group 40-49years|CAREN-based gait analysis: 10 men and 10 women aged between 40-49years
11215245|NCT03278535||age group 50-59years|CAREN-based gait analysis: 10 men and 10 women aged between 50-59years
11215246|NCT03278535||age group 60-69years|CAREN-based gait analysis: 10 men and 10 women aged between 60-69years
11215247|NCT03278535||age group 70-79years|CAREN-based gait analysis: 10 men and 10 women aged between 70-79years
11215248|NCT03278535||age group 80+|CAREN-based gait analysis: 10 men and 10 women aged 80 years and older
11215249|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
11215250|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
11215251|NCT03278509|Experimental|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
11215252|NCT03278509|No Intervention|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
11215253|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
11215254|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
11215255|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
11215256|NCT03278483|Active Comparator|Isoniazid|Diabetic patients with a positive TST of >10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
11215257|NCT03278483|Active Comparator|Rifampin|Diabetic patients with a positive TST of >10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
11215258|NCT03278470|Experimental|HL237 50mg|take oral tablet once
11215259|NCT03278470|Experimental|HL237 100mg|take oral tablet once
11215260|NCT03278470|Experimental|HL237 200mg|take oral tablet once
11215261|NCT03278470|Experimental|HL237 400mg|take oral tablet once
11215262|NCT03278470|Experimental|HL237 800mg|take oral tablet once
11215263|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
11215264|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
11215265|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
11215266|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
11215267|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
11215268|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
11215269|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
11215273|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
11215274|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
11215275|NCT03278392|Experimental|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
11215276|NCT03278392|Sham Comparator|Placebo challenge task|Participants will be assigned to complete the placebo non-stress task immediately after consuming a standardized breakfast drink
11215277|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
11215278|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
11215279|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
11215280|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
11215281|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
11215282|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
11215283|NCT03278327|Other|Endoscopic resection|
11215284|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
11215285|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
11215286|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
11215287|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
11215288|NCT03278262||36-69 letters|Baseline VA 36-69 letters
11215289|NCT03278262||<=35 letters|Baseline VA <=35 letters
11215290|NCT03278249|Experimental|Modified Atkins Ketogenic Diet|Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
11215291|NCT03278236|Experimental|TRF|
11215292|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
11215293|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
11215294|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
11215295|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
11215296|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
11215297|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses
~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
~Questionnaires"
11215298|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
11215299|NCT03278184|Sham Comparator|tDCS sham motor cortex|25 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
11215300|NCT03278184|Active Comparator|Active motor cortex stimulation|25 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
11215301|NCT03278184|Active Comparator|active prefrontal cortex stimulation|25 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
11215302|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
11215303|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
11215304|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
11215305|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
11215306|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
11215307|NCT03278158|Experimental|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
11215308|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
11215309|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
11215367|NCT03277742|Active Comparator|Control|This arm will receive the standard of care for patients with TB and DM2
11215310|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
11215311|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
11215312|NCT03278119||Sleep Apnea|"Overall 56
~both male and female
~age group 55 to 75 years, having mild to severe obstructive sleep apnea
~in good general health with no significant comorbidities
~Located for the most part in boroughs of New York City"
11215313|NCT03278119||No Sleep Apnea|"Overall 56
~both male and female
~age group 55 to 75 years, without OSA
~in good general health with no significant comorbidities
~Located for the most part in boroughs of New York City"
11215314|NCT03278106|Experimental|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11215315|NCT03278080|Other|driving test|
11215316|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
11215317|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
11215318|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
11215319|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
11215320|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
11215321|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
11215322|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
11215323|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
11215324|NCT03278028|Experimental|Active|A-101 Topical Solutions
11215325|NCT03278028|Placebo Comparator|Vehicle|Vehicle
11215326|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
11215327|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
11215328|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
11215329|NCT03278002||Group/Cohort Information|This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
11215330|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
11215331|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
11215332|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
11215333|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
11215334|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
11215335|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
11215336|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
11215337|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
11215338|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
11215339|NCT03277937|Experimental|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
11215368|NCT03277742|Experimental|Intervention|This arm will receive the community intervention
11215369|NCT03277729|Experimental|Treatment (CD20-specific CAR T cell, chemotherapy)|Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion.
11215370|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
11215371|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
11215340|NCT03277924|Experimental|Sunitinib+Nivolumab|"Adult patients will receive an initial induction phase from day 1 to day 14 of sunitinib 37.5 mg/day followed by a maintenance phase of sunitinib 25mg/day orally continuously + nivolumab 240mg intravenous every 2 weeks infused over 1 hour. Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
~Pediatric patients will receive an initial induction phase from day 1 to day 14 of sunitinib 25 mg/day, or 37.5 mg/day if BSA > 1.7, followed by a maintenance phase of sunitinib 25mg/day orally continuously + nivolumab 240mg intravenous every 2 weeks infused over 1 hour. Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
~Sunitinib (Sutent): Hard Capsule (12.5, 25 mg). Oral use.
~Nivolumab (Opdivo) 10 mg/mL concentrate for solution for infusion. Intravenous use"
11215341|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
11215342|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
11215343|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
11215344|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
11215345|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
11215346|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
11215347|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
11215348|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
11215349|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
11215350|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
11215351|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
11215352|NCT03277833|Placebo Comparator|Placebo|Placebo
11215353|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
11215354|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
11215355|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
11215356|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
11215357|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
11215358|NCT03277794|Active Comparator|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
11215359|NCT03277794|Experimental|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
11215360|NCT03277781||Current smokers|
11215361|NCT03277781||Ex-smokers|
11215362|NCT03277781||Coronary heart disease|
11215363|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
11215364|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
11215365|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
11215366|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
11215372|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
11215373|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
11215374|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
11215375|NCT03277677|Active Comparator|normal saline|
11215376|NCT03277677|Active Comparator|balanced solution|
11215377|NCT03277664|Experimental|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
11215378|NCT03277664|No Intervention|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
11215379|NCT03277651||liver fibrosis|liver biopsy proved
11215380|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
11215381|NCT03277638|Experimental|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
11215382|NCT03277638|Experimental|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
11215383|NCT03277638|Experimental|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
11215384|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
11215385|NCT03277612||C-Section|Infants delivered by C-section
11215386|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
11215387|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
11215388|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
11215389|NCT03277586|Experimental|Probio'Stick|
11215390|NCT03277586|Placebo Comparator|Placebo|
11215391|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
11215392|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
11215393|NCT03277534|Experimental|Electrical stimulation|
11215394|NCT03277534|Sham Comparator|Control|
11215395|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
11215396|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
11215397|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
11215398|NCT03277508|Experimental|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
11215399|NCT03277508|Active Comparator|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
11215400|NCT03277495|Active Comparator|nicotine SREC|The liquid in the e-cigarette refills contains nicotine
11215401|NCT03277495|Placebo Comparator|placebo SREC|The liquid in the e-cigarette refills does not contain nicotine
11215402|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy
~*q4 weeks durvalumab for 13 cycles or until progression"
11215403|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab
~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
11215404|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained
~MRI Tracker is used during catheter positioning with serial MR imaging during implant
~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice
~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
11215437|NCT03277261|Active Comparator|Teriflunomide + IV Placebo|Oral daily Administration
11215438|NCT03277248|Experimental|Ublituximab + Oral Placebo|IV infusion
11215439|NCT03277248|Active Comparator|Teriflunomide + IV Placebo|Oral daily administration
11215405|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained
~Standard process is used with serial MR imaging to evaluate catheter position during implant
~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice
~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
11215406|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
11215407|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.
~Modified model surgical tecnique:
~Obtain wax bite registration.
~Record face-bow transfer.
~Duplication of articulating model for surgical simulation.
~Measure all casts and bases in standard model surgery fashion.
~Fabricate intermediate splint & Final splint.
~Condylar repositional splint."
11215408|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.
~Computer-aided planning for study group:
~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.
~Pre-operative Fabrication of computer aided surgical splint:
~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.
~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
11215409|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
11215410|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
11215411|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
11215412|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
11215413|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
11215414|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
11215415|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
11215416|NCT03277391|Active Comparator|Serratus anterior plane block|Deep serratus anterior plane block
11215417|NCT03277391|Active Comparator|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
11215418|NCT03277378||Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
11215419|NCT03277378||Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
11215420|NCT03277352|Experimental|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
11215421|NCT03277339|Experimental|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
11215422|NCT03277339|Other|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
11215423|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
11215424|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
11215425|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
11215426|NCT03277313|Experimental|Epoch 1|Pediatric patients with primary immunodeficiency disease (PIDD) who are on intravenous (IV) or non-HYQVIA subcutaneous (SC) treatment with immunoglobulin (IV-pre-treated, SC-pre-treated) will be enrolled and treated with HYQVIA subcutaneously with a dose or interval ramp-up period of up to six weeks.
11215427|NCT03277313|Experimental|Epoch 2|"HYQVIA treatment at following intervals:
~For intravenous (IV)-pre-treated participants: every 3 or 4 weeks, depending on participant's previous IV schedule.
~For subcutaneous (SC)-pre-treated participants: every 3 or 4 weeks, at discretion of investigator and participant.
~After one year in Epoch 2, anti-rHuPH20 binding antibody assay results during year will decide next steps in study:
~Participants with anti-rHuPH20 antibody titer <160 at all time-points during study will complete the study completion visit at next possible occasion following 12-month visit.
~Participants with anti-rHuPH20 antibody titer ≥160 during study and/or at last measurement will continue in Epoch 2 for additional 2 years of HYQVIA treatment and observation, and complete study completion visits at next possible occasion following 36-month visit.
~Alternative treatment intervals, such as infusion every 2 weeks, may be considered for tolerability reasons, at discretion of investigator after informing sponsor"
11215428|NCT03277313|Active Comparator|Epoch 3|Approximately one year safety follow-up, if needed: for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a study drug related serious adverse event (SAE) or a related severe adverse event (AE) will be followed accordingly.
11215429|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
11215430|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
11215431|NCT03277287|No Intervention|Group C|No intervention
11215432|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
11215433|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
11215434|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
11215435|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
11215436|NCT03277261|Experimental|Ublituximab + Oral Placebo|IV Infusion
11215440|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
11215441|NCT03277235|No Intervention|Control|Usual care
11215442|NCT03277222|Active Comparator|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
11215443|NCT03277222|Placebo Comparator|IN Sterile Saline|Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
11215444|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
11215445|NCT03277196|Experimental|Ivacaftor Arm|
11215446|NCT03277196|No Intervention|Observational Arm|
11215447|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
11215448|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
11215449|NCT03277170|Experimental|High-dose Montelukast Oral Granules|30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
11215450|NCT03277170|Placebo Comparator|Placebo|Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
11215451|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
11215452|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
11215453|NCT03277144|Experimental|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
11215454|NCT03277144|Active Comparator|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
11215455|NCT03277131|Experimental|1|Antimicrobial Dressing
11215456|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
11215457|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
11215458|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
11215459|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
11215460|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
11215461|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
11215462|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
11215463|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 1|Diclofenac sodium 1 topical patches will be compared against placebo patches.
11215464|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 2|Diclofenac sodium 2 topical patches will be compared against placebo patches.
11215465|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
11215466|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
11215467|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
11215468|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
11215469|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
11215470|NCT03277001|Active Comparator|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
11215471|NCT03277001|Experimental|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
11215472|NCT03276988|Other|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
11215473|NCT03276988|Other|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
11215474|NCT03276975|Experimental|Patching of CSF Leaks with Autologous Blood and Fibrin|
11215475|NCT03276975|No Intervention|Simulated Patching Procedure|
11215476|NCT03276962|Experimental|R012-20 Group|Subjects will receive full doses of RTS,S/AS01E at Month 0, Month 1, Month 2 and a full dose at Month 20.
11215477|NCT03276962|Experimental|R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26, Month 38.
11215478|NCT03276962|Experimental|Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38.
11215479|NCT03276962|Experimental|Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32.
11215480|NCT03276962|Experimental|Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2.
11215725|NCT03275350|Active Comparator|TAU|Treatment as usual
11215481|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
11215482|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
11215483|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
11215484|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
11215485|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
11215486|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
11215487|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
11215488|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
11215489|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
11215490|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
11215491|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
11215492|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
11215493|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
11215494|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
11215495|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
11215496|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
11215497|NCT03276845|Other|1|
11215498|NCT03276832|Experimental|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Courses repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity.
11215499|NCT03276819|Experimental|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:
~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
11215500|NCT03276819|Experimental|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.
~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.
~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
11215501|NCT03276819|Experimental|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
11215502|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
11215503|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
11215504|NCT03276793|Experimental|MRI and behavioral assessment|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
11215505|NCT03276780|Experimental|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
11215506|NCT03276780|Active Comparator|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
11215507|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
11215508|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
11215509|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
11215510|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
11215511|NCT03276728|Active Comparator|AMG 986 IV Dose Level A|or matching placebo
11215512|NCT03276728|Active Comparator|AMG 986 IV Dose Level B|or matching placebo
11215513|NCT03276728|Active Comparator|AMG 986 IV Dose Level C|or matching placebo
11215514|NCT03276728|Active Comparator|AMG 986 IV Dose Level D|or matching placebo
11215515|NCT03276728|Active Comparator|AMG 986 IV Dose Level E|or matching placebo
11215516|NCT03276728|Active Comparator|AMG 986 IV Dose Level F|or matching placebo
11215517|NCT03276728|Active Comparator|AMG 986 IV Dose Level G|or matching placebo
11215518|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A|or matching placebo - HV
11215519|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B|or matching placebo - HV
11215520|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C|or matching placebo - HV
11215521|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D|or matching placebo - HV
11215530|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-HEF|Heart failure patients with reduced ejection fraction
11215531|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-REF|Heart failure patients with preserved ejection fraction
11215532|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
11215533|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
11215534|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
11215535|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
11215536|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
11215537|NCT03276663|Other|Formula fed group|Formula feeding regimen
11215538|NCT03276663|No Intervention|Human milk-fed group|
11215539|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
11215540|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
11215541|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
11215542|NCT03276598|Active Comparator|Amlodipine|One of the four monotherapy treatment periods.
11215543|NCT03276598|Active Comparator|Bisoprolol|One of the four monotherapy treatment periods.
11215544|NCT03276598|Active Comparator|Hydrochlorothiazide|One of the four monotherapy treatment periods.
11215545|NCT03276598|Active Comparator|Losartan|One of the four monotherapy treatment periods.
11215546|NCT03276598|Placebo Comparator|Placebo|Placebo treatment period.
11215547|NCT03276572|Experimental|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
11215548|NCT03276559|Experimental|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.
~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
11215549|NCT03276559|Placebo Comparator|Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.
~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
11215550|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
11215551|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
11215552|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
11215553|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
11215554|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
11215555|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
11215556|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
11215557|NCT03276494|Other|Intraosseous|Administration of intraosseous hypertonic saline
11215558|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
11215559|NCT03276468|Experimental|Experimental|Combination of venetoclax, atezolizumab and obinutuzumab
11215560|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
11215561|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
11215562|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
11215563|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
11215564|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
11215565|NCT03276390|Active Comparator|Intervention study site|"Exposure to the intervention, which is the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.
~The intervention study site will provide the intervention to its Hispanic patients.
~The intervention study will will also provide the routine care (control arm) to all other patients.
~For the purposes of this study, Hispanic potential recipients recruited into the study will be exposed to this intervention. Non-Hispanic Whites recruited into the study will not be exposed to this intervention."
11215566|NCT03276390|No Intervention|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
11215567|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
11215568|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
11215569|NCT03276364||Shock|
11215570|NCT03276351|Active Comparator|Long-Stemmed with Hybrid Fixation|Participants will receive the Long-Stemmed revision implant with Hybrid Fixation during their surgery.
11215571|NCT03276351|Experimental|Short-Stemmed with Augmented Fixation|Participants will receive the Short-Stemmed primary implant with Augmented Fixation during their surgery.
11215572|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
11215573|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
11215574|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
11215575|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
11215576|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
11215577|NCT03276312|No Intervention|Control|Routine clinical practice
11215578|NCT03276299|Active Comparator|test 1|six minute walking test
11215579|NCT03276299|Experimental|test 2|six minute walking test
11215580|NCT03276299|Experimental|test with encouragement|six minute walking test
11215581|NCT03276299|Active Comparator|test without encouragement|six minute walking test
11215582|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
11215583|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
11215584|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
11215585|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
11215586|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
11215587|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
11215588|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
11215589|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
11215590|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
11215591|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
11215592|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
11215593|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
11215594|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
11215595|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
11215596|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
11215597|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
11215598|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
11215599|NCT03276169|Experimental|Left atrial appendage closure group|
11215600|NCT03276169|Other|Radiofrequency ablation group|
11215601|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
11215602|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
11215603|NCT03276143|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
11215604|NCT03276143|Active Comparator|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
11215605|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
11215606|NCT03276143|Experimental|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
11215607|NCT03276143|Experimental|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
11215608|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
11215609|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
11215610|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
11215611|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
11215612|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
11215613|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
11215614|NCT03276104|Active Comparator|IOL repositioning group|
11215615|NCT03276104|Active Comparator|IOL exchange group|
11215616|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
11215617|NCT03276078|Experimental|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
11215618|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
11215619|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
11215620|NCT03276052|Experimental|Aclidinium Bromide 200 μg|One inhalation from the 200 μg Aclidinium Bromide inhaler.
11215621|NCT03276052|Experimental|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
11215622|NCT03276052|Experimental|Aclidinium Bromide 800 μg|Two inhalations from the 400 μg Aclidinium Bromide inhaler.
11215623|NCT03276039||25 patients with non-alcoholic fatty liver disease|
11215624|NCT03276039||25 patients with NAFLD and chronic HCV|
11215625|NCT03276039||20 healthy controls|
11215626|NCT03276026|Active Comparator|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
11215627|NCT03276026|Active Comparator|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
11215628|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
11215629|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
11215630|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
11215631|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
11215632|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
11215633|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
11215634|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
11215635|NCT03275974|Experimental|Treatment|Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
11215636|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
11215637|NCT03275948|Experimental|whole grain|
11215638|NCT03275948|Other|refrence|white wheat based product
11215639|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
11215640|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
11215641|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
11215642|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
11215643|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
11215644|NCT03275896|Experimental|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
11215645|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
11215646|NCT03275857|Other|Cisplatin|
11215647|NCT03275844||Group 1|Children with congenital heart disease
11215648|NCT03275844||Group 2|Control healthy subjects
11215649|NCT03275831|Active Comparator|Intrasite Gel|Intrasite Gel is an effective method for hydrating dry necrotic and sloughy wounds. It is an amorphous gel that contains 85% water, and gently increases the moisture level within the wound, encouraging moist wound healing through autolytic debridement.
11215650|NCT03275831|Experimental|PluroGel Burn and Wound Dressing|PluroGel contains a surfactant-based cleanser to assist wound debridement and cleansing
11215651|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:
~Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days
~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing > 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
11215652|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will begin the 12-week regiment around 6 weeks of age.
11216044|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
11215653|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive 6 weeks of full-time Pavlik treatment. Patients will begin the 6-week regiment around 6 weeks of age. Patients will not be eligible for this arm, or study inclusion if they do not have acceptable findings at 6-week follow up.
11215654|NCT03275792|Experimental|Admission/Intravascular Volume Expansion|"Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes
~0.9% NS with 5% dextrose at 150% of standard maintenance volume
~If urine output is <0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload
~Oral fluids ad lib along with strict input/output documentation
~Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload
~Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:
~A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child
~Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
11215655|NCT03275792|Active Comparator|Outpatient Observation|"Following standard emergency department (ED) care [volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).
~Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge
~Additional health assessments as required
~Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child"
11215656|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
11215657|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
11215658|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC
~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
11215659|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA
~should inhibit overactive premotor cortices"
11215660|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA
~should facilitate neural activity within premotor cortices"
11215661|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex
~should have no effect at all (no transcranial magnetic stimulation, only sound)"
11215662|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
11215663|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
11215664|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
11215665|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
11215666|NCT03275740|Experimental|PF-06755347 intravenous|intravenous administration
11215667|NCT03275740|Placebo Comparator|Placebo intravenous|intravenous administration
11215668|NCT03275740|Experimental|PF-06755347 subcutaneous|subcutaneous administration
11215669|NCT03275740|Placebo Comparator|Placebo subcutaneous|subcutaneous administration
11215670|NCT03275727|Experimental|A - iACT-BC experimental group|
11215671|NCT03275727|Other|B - Waiting list control group|
11215672|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
11215673|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
11215674|NCT03275701|Other|Triumeq|Single Arm, Open Label
11215675|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
11215676|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
11215677|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
11215678|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
11215679|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
11215680|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
11215681|NCT03275636|Experimental|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
11215682|NCT03275636|Active Comparator|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
11215683|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
11215684|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
11215685|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.
~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 75 mg via infusion Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients >30 kg Weight-based dosing utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 1 mg/kg Q4W"
11215686|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
11215687|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
11215688|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
11215689|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
11215690|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
11215691|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
11215692|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
11215693|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
11215694|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
11215695|NCT03275506|Experimental|Pembrolizumab + Chemo|"Pembrolizumab (ketruda) 200 mg then carboplatin (AUC 5 or 6) and paclitaxel (175mg/m²), q3 weeks.
~6 cyles 15 month total"
11215696|NCT03275506|Active Comparator|CHEMO alone|carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks. 6 cyles 15 month total
11215697|NCT03275493|Experimental|Experimental: Cohort 1|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
11215698|NCT03275493|Experimental|Experimental: Cohort 2|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
11215699|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
11215700|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
11215701|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
11215702|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
11215703|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
11215704|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
11215705|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
11215706|NCT03275402|Experimental|131I-omburtamab|"One treatment cycle of 131I-omburtamab consists of 1 dose at 50mCi at week 1. For Japan only one treatment cycle of 131I-omburtamab consists of 2 doses: 2mCi at week 1 and 50mCi at week 2. First cycle is initiated right after confirmation of eligibility at week 1. At week 5 (week 6 for Japan) the participant will be evaluated for safety and if eligible, receive a second cycle of 131I-omburtamab.
~Secondary efficacy endpoints will be evaluated at week 26 and primary efficacy endpoint will be evaluated at week 156."
11215707|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects will receive one dose of D-SUIV Formulation 1 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 2 at Month 14
11215708|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects will receive one dose of D-SUIV Formulation 2 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 1 at Month 14
11215709|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects will receive one dose of D-SUIV Formulation 1 at Day 1, one dose of D-SUIV Formulation 2 at Day 57 and one booster dose of D-SUIV Formulation 3 at Month 14
11215710|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects will receive one dose of D-SUIV Formulation 4 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 5 at Month 14
11215711|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects will receive one dose of D-SUIV Formulation 5 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 4 at Month 14
11215712|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects will receive one dose of D-SUIV Formulation 4 at Day 1, one dose D-SUIV Formulation 5 at Day 57 and one booster dose of D-SUIV Formulation 6 at Month 14
11215713|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects will receive one dose of D-SUIV Formulation 7 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 8 at Month 14
11215714|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects will receive one dose of D-SUIV Formulation 8 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 7 at Month 14
11215715|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects will receive one dose of D-SUIV Formulation 7 at Day 1, one dose D-SUIV Formulation 8 at Day 57 and one booster dose of D-SUIV Formulation 9 at Month 14
11215716|NCT03275389|Active Comparator|IIV4 Group|Subjects will receive one dose of Fluarix Quadrivalent at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent at Month 14
11215717|NCT03275376|Experimental|Statin treated group|
11215718|NCT03275376|Placebo Comparator|Control group|
11215719|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
11215720|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
11215721|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
11215722|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
11215723|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
11215726|NCT03275337|Experimental|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
11215727|NCT03275337|Experimental|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
11215728|NCT03275337|Active Comparator|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
11215729|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
11215730|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
11215731|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
11215732|NCT03275272|Other|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
11215733|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
11215734|NCT03275246|Experimental|Total knee arthroplasty|Patients undergoing total knee arthroplasty
11215735|NCT03275207|Placebo Comparator|control group|an equal volume of saline
11215736|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
11215737|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
11215738|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
11215739|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
11215740|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
11215741|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
11215742|NCT03275168|Active Comparator|Control|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention
11215743|NCT03275168|Experimental|Intervention|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention plus dyadic counseling and negotiation practice with partner
11215744|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
11215745|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
11215746|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
11215747|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
11215748|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
11215749|NCT03275129|Experimental|Ultrasound assessment of heart and lungs|Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
11215750|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
11215751|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
11215752|NCT03275103|Experimental|Arm A: Single Step Dose Escalation for BFCR4350A|Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
11215753|NCT03275103|Experimental|Arm B: Multistep Dose Escalation for BFCR4350A|In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
11215754|NCT03275103|Experimental|Arm C: Single Step Dose Expansion for BFCR4350A|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
11215755|NCT03275103|Experimental|Arm D: Multistep Dose Expansion for BFCR4350A|The multistep dose expansion stage of the study may use the dosing and assessment schedule from the multistep dose escalation arm in Cycle 1, based on data from Arm B.
11215756|NCT03275103|Experimental|Arm E: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of BFCR4350A and Cycle 1 BFCR4350A doses for other treatment arms.
11215757|NCT03275103|Experimental|Arm F: Single Step Dose Expansion for BFCR4350A|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
11215758|NCT03275103|Experimental|Arm G: Multistep Dose Expansion for BFCR4350A|The multistep dose expansion stage of the study may use the dosing and assessment schedule from the multistep dose escalation arm in Cycle 1, based on data from Arm B.
11215759|NCT03275090|Active Comparator|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
11215760|NCT03275090|No Intervention|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
11215761|NCT03275077||Controls|Normal Healthy Volunteers
11215762|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
11215763|NCT03275064|Experimental|LNA043 - lower dose (Part A)|Single i.a. injection of 20 mg [LNA043], once-weekly injections from Week 1 to Week 4 (Part A)
11215764|NCT03275064|Placebo Comparator|Placebo (Part A)|Single i.a. injection of placebo to 20 mg [LNA043], once-weekly injections from Week 1 to Week 4 (Part A)
11215765|NCT03275064|Experimental|LNA043 - higher dose (Part B)|Single i.a. injection of 40 mg [LNA043], once-monthly injection from week 1 to week 13 (Part B)
11215766|NCT03275064|Experimental|LNA043 - Lower Dose (Part B)|Single i.a. injection of 20 mg [LNA043], once-monthly injection from week 1 to week 13 (Part B)
11215767|NCT03275064|Placebo Comparator|Placebo (Part B)|Single i.a. injection placebo, once-monthly injection from week 1 to week 13 (Part B)
11215768|NCT03275051|Experimental|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
11215769|NCT03275038|No Intervention|Control group|Maintain the original life style
11215770|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
11215771|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
11215772|NCT03275025|Experimental|YRA-1909 low dose|
11215773|NCT03275025|Experimental|YRA-1909 medium does|
11215774|NCT03275025|Experimental|YRA-1909 high dose|
11215775|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
11215776|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
11215777|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
11215778|NCT03274999|Experimental|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
11215779|NCT03274999|Experimental|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
11215780|NCT03274986|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
11215781|NCT03274986|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
11215782|NCT03274973||Zomacton|
11215783|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
11215784|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
11215785|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
11215786|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
11215787|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
11215788|NCT03274947|Active Comparator|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
11215789|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
11215790|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
11215791|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
11215792|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
11215793|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
11215794|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
11215795|NCT03274908||Group|
11215796|NCT03274895|Experimental|PHMB 0.08% plus placebo|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
11215797|NCT03274895|Active Comparator|PPHMB 0.02% plus propamidine 0.1%|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
11215798|NCT03274882|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
11215799|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
11215800|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
11215801|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
11215802|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
11215803|NCT03274843|Experimental|Patient with stroke|
11215804|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
11215805|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
11215806|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
11215807|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
11215808|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
11215809|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.
~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
11215810|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.
~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
11215811|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.
~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.
~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
11215812|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
11215813|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
11215814|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
11215815|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
11215816|NCT03274739||Pregnant women|
11215817|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
11215818|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
11215819|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:
~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.
~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.
~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
11215849|NCT03274505||Stroke patients|Patients seen by a rehabilitation physician at a routine 3 months' post-stroke examination
11215850|NCT03274505||TIA patients|"Patients seen by a stroke specialist at the SOS TIA examination"
11216164|NCT03272178||Depuy knee total knee arthroplasty|50 Patients who are assigned to Depuy knee, half cemented/half cementless
11215820|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:
~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.
~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.
~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
11215821|NCT03274687|Experimental|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy for 37 fractions over 7 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
11215822|NCT03274687|Experimental|Arm II (hypofractionated radiation therapy|Patients undergo hypofractionated radiation therapy for 25 fractions over 5 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
11215823|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
11215824|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
11215825|NCT03274661|Experimental|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
11215826|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
11215827|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
11215828|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
11215829|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
11215830|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
11215831|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
11215832|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
11215833|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
11215834|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
11215835|NCT03274622|Experimental|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
11215836|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
11215837|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.
~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.
~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.
~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
11215838|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
11215839|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
11215840|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
11215841|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
11215842|NCT03274557|Active Comparator|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
11215843|NCT03274557|Active Comparator|Phusical therapy|Supervised eccentric training
11215844|NCT03274544|Experimental|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
11215845|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
11215846|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
11215847|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.
~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
11215848|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
11215851|NCT03274492|Experimental|R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin|Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m^2) IV, cyclophosphamide 750 mg/m^2 IV, and doxorubicin 50 mg/m^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
11215852|NCT03274492|Placebo Comparator|R-CHOP plus Polatuzumab Vedotin Placebo|Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m^2 IV, cyclophosphamide 750 mg/m^2 IV, doxorubicin 50 mg/m^2 IV, and vincristine 1.4 mg/m^2 IV (maximum 2 milligrams per dose [mg/dose]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m^2 IV will be administered as monotherapy in Cycles 7 and 8.
11215853|NCT03274479|Experimental|PBF-1129_40mg|
11215854|NCT03274479|Experimental|PBF-1129_80mg|
11215855|NCT03274479|Experimental|PBF-1129_160mg|
11215856|NCT03274479|Experimental|PBF-1129_320mg|
11215857|NCT03274466|Experimental|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel & Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
11215858|NCT03274466|Active Comparator|Standard of Care Dressing|Silver impregnated dressing
11215859|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.
~Infusion will be maintained for 24 hours."
11215860|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
11215861|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
11215862|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.
~Infusion will be maintained for 24 hours."
11215863|NCT03274440|Experimental|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (<1%) content.
11215864|NCT03274440|Experimental|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (<1%) and high CBD (>10%) content.
11215865|NCT03274440|Placebo Comparator|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
11215866|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
11215867|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
11215868|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
11215869|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
11215870|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
11215871|NCT03274401|No Intervention|Control Arm|Standard of care
11215872|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
11215873|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
11215874|NCT03274375|Experimental|IA session|"4 Rituximab injections
~10 IA sessions"
11215875|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
11215876|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
11215877|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
11215878|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
11215879|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
11215880|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
11215881|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
11215882|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
11215883|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
11215884|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
11215885|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
11215886|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
11215887|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
11215888|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
11215889|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
11216045|NCT03273088|Experimental|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
11215890|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
11215891|NCT03274271|Experimental|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215892|NCT03274271|Experimental|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215893|NCT03274271|Experimental|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215894|NCT03274271|Experimental|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215895|NCT03274271|Experimental|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215896|NCT03274271|Experimental|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215897|NCT03274271|Experimental|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).
~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
11215898|NCT03274271|Active Comparator|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
11215899|NCT03274258|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11215900|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
11215901|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
11215902|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
11215903|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
11215904|NCT03274219|Experimental|bb21217 Experimental Arm|
11215905|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg
~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
11215906|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo
~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
11215907|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
11215908|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
11215909|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
11215910|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
11215911|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
11215912|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
11215913|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
11215914|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
11215915|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
11215916|NCT03274141||RC Patients|RA patients managed with routine care(RC)
11215917|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
11215957|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
11216165|NCT03272165|Experimental|MEDI1341|
11215918|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
11215919|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
11215920|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
11215921|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
11215922|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
11215923|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
11215924|NCT03274089|Experimental|Kiosk intervention group|
11215925|NCT03274089|No Intervention|Nurse clinician control group|
11215926|NCT03274076|Active Comparator|Tofacitinib|5mg Tofacitinib twice a day
11215927|NCT03274076|Placebo Comparator|Placebo|5mg Placebo twice a day
11215928|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
11215929|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
11215930|NCT03274050||patient group|Surgery with robot - all patients operated in pediatric surgery department with indication of robot in the routine care (all specialities).
11215931|NCT03274050||control group|Open surgery or coelioscopy - patient operated for pyeloplasty
11215932|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
11215933|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
11215934|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
11215935|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
11215936|NCT03273985|Experimental|Dry needling|
11215937|NCT03273985|Experimental|Ischemic compression|
11215938|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
11215939|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
11215940|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
11215941|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
11215942|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
11215943|NCT03273933|Active Comparator|10 children with DragONE only|
11215944|NCT03273933|Experimental|10 children with DragONE and SmartOne|
11215945|NCT03273920|Experimental|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
11215946|NCT03273920|Active Comparator|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
11215947|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
11215948|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
11215949|NCT03273881|Active Comparator|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
11215950|NCT03273881|Active Comparator|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
11215951|NCT03273868|Experimental|High velocity low amplitude manipulation|
11215952|NCT03273868|Sham Comparator|Sham manipulation|
11215953|NCT03273855|Active Comparator|Intervention|Active Comparator. Transplant from either Donor A or Donor B, one transplant consist of 50-80g of feacal matter.
11215954|NCT03273855|Placebo Comparator|Placebo|Placebo. Patient will recieve an autologous fecal microbiota transplantation.
11215955|NCT03273842|Experimental|PF-06881894|PF-06881894 6 mg SC
11215956|NCT03273842|Active Comparator|US-approved Neulasta|US-approved Neulasta 6 mg SC
11216166|NCT03272165|Placebo Comparator|Placebo|
11215958|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
11215959|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
11215960|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
11215961|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
11215962|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
11215963|NCT03273751|Experimental|Remote Ischemic Preconditioning (RIPC)|Four cycles of upper arm ischemia/reperfusion
11215964|NCT03273751|Sham Comparator|Sham control|Placement of a blood pressure cuff around upper arm without inflation.
11215965|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
11215966|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
11215967|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
11215968|NCT03273699|Experimental|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
11215969|NCT03273699|No Intervention|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
11215970|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
11215971|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
11215972|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
11215973|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
11215974|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
11215975|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
11215976|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
11215977|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
11215978|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
11215979|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
11215980|NCT03273595|Placebo Comparator|Control|
11215981|NCT03273595|Experimental|Experimental group|
11215982|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
11215983|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
11215984|NCT03273543|Experimental|Nasal Tip Projection|
11215985|NCT03273543|Experimental|Upper Lip Position|
11215986|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
11215987|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
11215988|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
11215989|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.
~The placebo product will be applied in the same way, on the controlateral leg."
11215990|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.
~Height and weight will be measured using standard procedures
~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.
~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
11215991|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.
~Height and weight will be measured using standard procedures
~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.
~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
11215992|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
11215993|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
11215994|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
11215995|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
11215996|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
11215997|NCT03273426|Experimental|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
11215998|NCT03273426|Experimental|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
11215999|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
11216000|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
11216001|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
11216002|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
11216003|NCT03273387|Placebo Comparator|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
11216004|NCT03273387|Experimental|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
11216005|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
11216006|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
11216007|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
11216008|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
11216009|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
11216010|NCT03273335||Surgical patients|Surgical patients will undergo CSF biomarker assays, cognitive testing and fMRI scans.
11216011|NCT03273322|Experimental|1: Rivaroxaban 10 mg qd|Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
11216012|NCT03273322|Experimental|2: Rivaroxaban 15 mg qd|"Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90
~should be taken between 8 and 10 AM"
11216013|NCT03273322|Active Comparator|3: DAPT|Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
11216014|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
11216042|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
11216043|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
11216015|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
11216016|NCT03273296|Active Comparator|Amoxicillin|
11216017|NCT03273296|Active Comparator|Azithromycin|
11216018|NCT03273296|Active Comparator|Vancomycin|
11216019|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
11216020|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
11216021|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
11216022|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
11216023|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
11216024|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
11216025|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
11216026|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
11216027|NCT03273231|Placebo Comparator|control group|0.9% saline solution
11216028|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
11216029|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
11216030|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:
~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
11216031|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:
~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
11216032|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
11216033|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
11216034|NCT03273166|Experimental|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
11216035|NCT03273153|Experimental|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
11216036|NCT03273153|Active Comparator|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
11216037|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).
~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
11216038|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
11216039|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
11216040|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
11216041|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
11216046|NCT03273088|Active Comparator|Pfizer etanercept|Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.
11216047|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
11216048|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
11216049|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.
~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
11216050|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.
~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
11216051|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID
~OR
~Placebo Comparator 15 days of Placebo pill TID"
11216052|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID
~OR
~Active Comparator 15 days of Tolcapone 200mg TID"
11216053|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
11216054|NCT03273036|Placebo Comparator|placebo injection|no injection agent
11216055|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
11216056|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
11216057|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
11216058|NCT03272984|Other|SC group|Patients will undergo the SC group.
11216059|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
11216060|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
11216061|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
11216062|NCT03272919|Experimental|Arm 1: Investigational INF|Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow.
11216063|NCT03272919|Other|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
11216064|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
11216065|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
11216066|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
11216067|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
11216068|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
11216069|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
11216070|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
11216071|NCT03272828|Active Comparator|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible. Outcomes between the groups will be compared
11216072|NCT03272828|Active Comparator|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible. Outcomes between the groups will be compared.
11216073|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
11216074|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
11216075|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:
~Tab. Rilutek 50 mg PO q12hr on empty stomach.
~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.
~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
11216076|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.
~Instructions:
~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
11216077|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
11216078|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
11216079|NCT03272763|Experimental|F&P Jupiter|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
11216080|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
11216081|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
11216082|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
11216083|NCT03272737|Active Comparator|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.
~Interventions:
~Plethysmography;
~Protocols of isometric exercise;
~Pulse wave Velocity (PWV);
~Flow-mediated dilatation (FMD);
~Arterial pressure and blood pressure;
~Quality of life (Euro Qol);
~1RM test
~Speed gait test
~Anthropometric Assessment"
11216084|NCT03272737|Active Comparator|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.
~Interventions:
~Plethysmography;
~Protocols of isometric exercise;
~Pulse wave Velocity (PWV);
~Flow-mediated dilatation (FMD);
~Arterial pressure and blood pressure;
~Quality of life (Euro Qol);
~1RM test
~Speed gait test
~Anthropometric Assessment"
11216085|NCT03272711|Experimental|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
11216086|NCT03272711|Placebo Comparator|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
11216087|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
11216088|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
11216089|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.4 mg/g nicotine; 9 mg of tar)
11216090|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg/g nicotine; 9 mg of tar)
11216091|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
11216092|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
11216093|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.
~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
11216094|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
11216095|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
11216096|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
11216097|NCT03272633|Experimental|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
11216098|NCT03272633|Experimental|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
11216099|NCT03272607|No Intervention|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
11216100|NCT03272607|Experimental|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
11216101|NCT03272594|Experimental|Breastfeeding|
11216102|NCT03272594|Active Comparator|24% oral sucrose|
11216103|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
11216104|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
11216105|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.
~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
11216162|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
11216106|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.
~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
11216107|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
11216108|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
11216109|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
11216110|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
11216111|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
11216112|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
11216113|NCT03272516|Active Comparator|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
11216114|NCT03272516|Experimental|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
11216115|NCT03272503|Experimental|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
11216116|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
11216117|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
11216118|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
11216119|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.
~Adjuvant Therapy: Standard of care"
11216120|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.
~Adjuvant Therapy: Standard of care"
11216121|NCT03272464|Experimental|Trametinib + Dabrafenib + INCB039110|"Dabrafenib is administered orally every 12 hours
~Trametinib is administered orally once a day
~INCB039110 is administered orally once a day"
11216122|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
11216123|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
11216124|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
11216125|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
11216126|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
11216127|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
11216128|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
11216129|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
11216130|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
11216131|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
11216163|NCT03272178||Triathlon knee total knee arthroplasty|50 Patients who are assigned to Triathlon knee, half cemented/half cementless
11216132|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
11216133|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
11216134|NCT03272373|Other|Monoblock|Subjects that receive the NexGen TM Monoblock Tibia
11216135|NCT03272373|Other|Modular|Subjects that receive the NexGen TM Modular Tibia
11216136|NCT03272360||Chronic Pelvic Pain|
11216137|NCT03272360||Elective Tubal Ligation|
11216138|NCT03272347|Experimental|Islatravir 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
11216139|NCT03272347|Experimental|Islatravir 0.75 mg|Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
11216140|NCT03272347|Experimental|Islatravir 2.25 mg|Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to MK- 1439A for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to MK-1439A may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
11216141|NCT03272347|Active Comparator|MK-1439A|Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and MK-1439A consisting of 100 mg DOR + 300 mg 3TC + 300 mg tenofovir disoproxil fumarate (TDF) for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only MK-1439A QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
11216142|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
11216143|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
11216144|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
11216145|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
11216146|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
11216147|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
11216148|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
11216149|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
11216150|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
11216151|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
11216152|NCT03272256|Experimental|IM156, Dose escalation|
11216153|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
11216154|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
11216155|NCT03272230|Experimental|bvFTD|"Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
11216156|NCT03272230|Experimental|Healthy control|"Healthy age, sex and education matched controls
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
11216157|NCT03272230|Experimental|Parkinson's disease without Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
11216158|NCT03272230|Experimental|Depression|"Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV).
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
11216159|NCT03272230|Experimental|Parkinson's disease with Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ICDs are closely related to use of dopaminergic medications.
~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
11216160|NCT03272217|Experimental|Arm A - Atezolizumab + Bevacizumab|Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
11216161|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
11216167|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
11216168|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
11216169|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
11216170|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
11216171|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
11216172|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
11216173|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
11216174|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
11216175|NCT03272113|No Intervention|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.
~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
11216176|NCT03272113|Experimental|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
11216177|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
11216178|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
11216179|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
11216180|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
11216181|NCT03272074|Experimental|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
11216182|NCT03272074|Active Comparator|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
11216183|NCT03272061|Experimental|Aerobic-based exercise program|
11216184|NCT03272061|No Intervention|Control program|Maintenance of habitual physical activity levels
11216185|NCT03272048|Experimental|Low-Fear/Not-Temporary|
11216186|NCT03272048|Experimental|Low-Fear/Temporary|
11216187|NCT03272048|Experimental|High-Fear/Not-Temporary|
11216188|NCT03272048|Experimental|High-Fear/Temporary|
11216189|NCT03272022||women|never-pregnant women
11216190|NCT03272022||pregnant women|pregnant
11216191|NCT03272009|Experimental|Treatment A|oral EYP001a
11216192|NCT03272009|Experimental|Treatment B|oral EYP001a
11216193|NCT03272009|Experimental|Treatment C|oral EYP001a
11216194|NCT03272009|Experimental|Treatment D|oral EYP001a
11216195|NCT03272009|Placebo Comparator|Treatment E|oral placebo
11216196|NCT03272009|Active Comparator|Treatment F|oral Entecavir
11216197|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
11216198|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
11216199|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
11216200|NCT03271996|Experimental|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
11216201|NCT03271996|Experimental|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
11216202|NCT03271983|Other|metronidazole gel 1|RLD gel
11216203|NCT03271983|Other|metronidazole gel 2|generic gel
11216204|NCT03271983|Other|metronidazole cream|generic cream
11216205|NCT03271970||Patients with conductive hearing loss|
11216206|NCT03271944|Other|Single group 30 post menopause females.|
11216207|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
11216208|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
11216209|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
11216210|NCT03271918|Experimental|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
11216211|NCT03271918|No Intervention|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
11216212|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
11216300|NCT03271450||Discontinuer at 180 Days: Warfarin|
11216213|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
11216214|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
11216215|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
11216216|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
11216217|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
11216218|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
11216219|NCT03271866|Other|metformin treatment|
11216220|NCT03271866|No Intervention|non-metformin treatment|
11216221|NCT03271853||SBS II|
11216222|NCT03271827|Experimental|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
11216223|NCT03271827|No Intervention|Standard care group|Standard airway management
11216224|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
11216225|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
11216226|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
11216227|NCT03271801|Active Comparator|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
11216228|NCT03271801|Experimental|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
11216229|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
11216230|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
11216231|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
11216232|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
11216233|NCT03271762|Experimental|MITRACLIP NT Device / MITRACLIP NTR/XTR Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
11216234|NCT03271762|Active Comparator|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
11216235|NCT03271749|No Intervention|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
11216236|NCT03271749|Experimental|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
11216237|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
11216238|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
11216239|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
11216301|NCT03271450||Discontinuer at 270 Days: Warfarin|
11216240|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
11216241|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
11216242|NCT03271684|Experimental|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
11216243|NCT03271684|Other|control group|Will receive booklet consist of home exercises and education besides the usual care
11216244|NCT03271671|Active Comparator|PSV|Pressure support ventilation
11216245|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
11216246|NCT03271658|Experimental|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or usual care comparison.
11216247|NCT03271658|No Intervention|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
11216248|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
11216249|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
11216250|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
11216251|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
11216252|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
11216253|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
11216254|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
11216255|NCT03271606|Experimental|ERAS group|The patients in this group receive enhanced measures perioperatively
11216256|NCT03271606|Active Comparator|Traditional group|The patients in this group receive traditional measures perioperatively
11216257|NCT03271593||All children admitted|All children admitted to hospital
11216258|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:
~Finger prick test for HbA1c measurement
~Punch biopsy
~VAC sponge collection
~Ankle brachial index"
11216259|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:
~Finger prick test for HbA1c measurement
~Punch biopsy
~VAC sponge collection
~Ankle brachial index"
11216260|NCT03271554||Alectinib|Participants with ALK-positive, locally advanced or metastatic non-small cell lung cancer, who are treated with alectinib in accordance with local clinical practice and local labeling, are observed in this study.
11216261|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:
~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.
~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:
~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.
~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
11216262|NCT03271528|Experimental|lacosamide|
11216263|NCT03271528|Placebo Comparator|Placebo oral capsule|
11216264|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
11216265|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
11216266|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
11216267|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
11216268|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
11216269|NCT03271489|Placebo Comparator|Placebo|Placebo
11216270|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
11216271|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
11216272|NCT03271450||Continuer at 90 Days: Dabigatran|
11216273|NCT03271450||Continuer at 180 Days: Dabigatran|
11216274|NCT03271450||Continuer at 270 Days: Dabigatran|
11216275|NCT03271450||Continuer at 90 Days: Apixaban|
11216276|NCT03271450||Continuer at 180 Days: Apixaban|
11216277|NCT03271450||Continuer at 270 Days: Apixaban|
11216278|NCT03271450||Continuer at 90 Days: Rivaroxaban|
11216279|NCT03271450||Continuer at 180 Days: Rivaroxaban|
11216280|NCT03271450||Continuer at 270 Days: Rivaroxaban|
11216281|NCT03271450||Continuer at 90 Days: Edoxaban|
11216282|NCT03271450||Continuer at 180 Days: Edoxaban|
11216283|NCT03271450||Continuer at 270 Days: Edoxaban|
11216284|NCT03271450||Continuer at 90 Days: Warfarin|
11216285|NCT03271450||Continuer at 180 Days: Warfarin|
11216286|NCT03271450||Continuer at 270 Days: Warfarin|
11216287|NCT03271450||Discontinuer at 90 Days: Dabigatran|
11216288|NCT03271450||Discontinuer at 180 Days: Dabigatran|
11216289|NCT03271450||Discontinuer at 270 Days: Dabigatran|
11216290|NCT03271450||Discontinuer at 90 Days: Apixaban|
11216291|NCT03271450||Discontinuer at 180 Days: Apixaban|
11216292|NCT03271450||Discontinuer at 270 Days: Apixaban|
11216293|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
11216294|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
11216295|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
11216296|NCT03271450||Discontinuer at 90 Days: Edoxaban|
11216297|NCT03271450||Discontinuer at 180 Days: Edoxaban|
11216298|NCT03271450||Discontinuer at 270 Days: Edoxaban|
11216299|NCT03271450||Discontinuer at 90 Days: Warfarin|
11216304|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
11216305|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
11216306|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
11216307|NCT03271411|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
11216308|NCT03271411|Experimental|Progressive counting (PC) arm|
11216309|NCT03271398||Adult victims of sexual assault|
11216310|NCT03271398||Children who have been exposed to domestic abuse|
11216311|NCT03271398||Women with perinatal emotional complications|
11216312|NCT03271398||Teens with behavior problems and histories of abuse|
11216313|NCT03271398||Veterans with military-related trauma|
11216314|NCT03271398||Survivors of intimate partner violence|
11216315|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
11216316|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
11216317|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
11216318|NCT03271372|Experimental|Arm I (avelumab)|Patients receive avelumab IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
11216319|NCT03271372|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 1 hour once every 15 days for the first 120 days (Induction Phase 1), once every 30 days for the next 120 days (Induction Phase 2), and then once every 120 days (Maintenance Phase) for a maximum of 720 days (approximately 24 months or 2 years total) in the absence of disease progression or unacceptable toxicity.
11216320|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
11216321|NCT03271359|Experimental|Progressive counting (PC) arm|
11216322|NCT03271333||patients with systemic sclerosis|
11216323|NCT03271320||systemic sclerosis|patients with systemic sclerosis
11216324|NCT03271320||control|Healthy subjects
11216325|NCT03271307|No Intervention|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
11216326|NCT03271307|Experimental|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
11216327|NCT03271307|Experimental|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
11216328|NCT03271307|No Intervention|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
11216329|NCT03271307|Experimental|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
11216330|NCT03271294|Other|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
11216331|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
11216332|NCT03271255|Experimental|Arm Apatinib|"Apatinib-FOLFIRI:
~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
11216333|NCT03271255|Active Comparator|Arm Bevacizumab|"Bevacizumab-FOLFIRI:
~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
11216334|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
11216335|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
11216336|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
11216337|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
11216338|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
11216339|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
11216340|NCT03271190|Experimental|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
11216341|NCT03271190|Active Comparator|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
11216342|NCT03271177|Experimental|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
11216343|NCT03271177|Placebo Comparator|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
11216344|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
11216345|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
11216346|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
11216347|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
11216348|NCT03271138|Active Comparator|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
11216349|NCT03271138|Placebo Comparator|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
11216350|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
11216351|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
11216352|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
11216353|NCT03271099|No Intervention|Usual Care|Usual care
11216354|NCT03271099|Experimental|Navigator|Patient navigator services provided as part of survivorship care plan
11216355|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
11216356|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
11216357|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
11216358|NCT03271060|Active Comparator|Lumbar spondylolisthesis1|
11216359|NCT03271060|Active Comparator|Lumbar spondylolisthesis 2|
11216360|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
11216361|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
11216362|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
11216363|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
11216364|NCT03271034|Experimental|Baseline Lipedema characterization|Body composition and Fat distribution, adipose tissue biology, metabolic and immune function in women with Lipedema. Participants will receive a low-calorie diet therapy in the form of low calorie meals or shakes.
11216365|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
11216366|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
11216367|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
11216368|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
11216369|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
11216370|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
11216371|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
11216372|NCT03270982||Comprehensive SRS Replacement|
11216373|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
11216374|NCT03270956|Experimental|Neo-Kidney Augment|Neo-Kidney Augment (NKA) Treatment - Patients will receive their first treatment of 2 injections of NKA as soon as NKA product is made available.
11216375|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
11216376|NCT03270943|Active Comparator|Healthy Lifestyles (TCY)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
11216377|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
11216378|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
11216379|NCT03270917|Other|Open|Open liver surgery
11216380|NCT03270917|Other|Laparoscopy|Laparoscopic liver surgery
11216381|NCT03270904|Experimental|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
11216382|NCT03270904|No Intervention|Group 2 - Usual care|This group receive routine care and no additional intervention.
11216383|NCT03270891|Active Comparator|Delayed intervention (control arm)|Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
11216384|NCT03270891|Experimental|PGx Test|Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
11216385|NCT03270878|Experimental|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
11216386|NCT03270878|Experimental|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
11216387|NCT03270865|Experimental|Usability and Ergonomic Evaluation of Self-Positioning System|
11216388|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
11216389|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
11216390|NCT03270839|Active Comparator|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
11216391|NCT03270839|Placebo Comparator|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
11216392|NCT03270839|Active Comparator|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
11216393|NCT03270839|Placebo Comparator|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
11216394|NCT03270839|Active Comparator|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
11216395|NCT03270839|Placebo Comparator|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
11216396|NCT03270839|Active Comparator|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
11216397|NCT03270839|Placebo Comparator|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
11216398|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
11216399|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
11216400|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
11216401|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
11216402|NCT03270787|Placebo Comparator|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
11216403|NCT03270787|Experimental|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
11216439|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
11216440|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
11216441|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
11216404|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
11216405|NCT03270735|Experimental|Treatment|Snake venom thrombin
11216406|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
11216407|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
11216408|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
11216409|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
11216410|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 450,000 IU orally
11216411|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 450,000 IU orally
11216412|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 450,000 IU orally
11216413|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 450,000 IU orally
11216414|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.
~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
11216415|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.
~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
11216416|NCT03270657|Other|Intraoperative Recording During DBS Implant Surgery|Participants will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who already are scheduled to undergo the planned deep brain electrode placement for treatment of their movement disorder. Intraoperative recordings of participants' neural signals will be made through the implanted deep brain electrode(s).
11216417|NCT03270644|Experimental|Lasmiditan Reference|Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
11216418|NCT03270644|Active Comparator|Propranolol Reference|Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
11216419|NCT03270644|Experimental|Lasmiditan + Propranolol Test|Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
11216420|NCT03270631|No Intervention|Control|Multidisciplinary rehabilitation, no interventions
11216421|NCT03270631|Experimental|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
11216422|NCT03270631|Other|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
11216423|NCT03270631|Other|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
11216424|NCT03270631|Sham Comparator|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
11216425|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
11216426|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
11216427|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
11216428|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
11216429|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ-64511070 in the human brain with the appropriate arterial IF.
11216430|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
11216431|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
11216432|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
11216433|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
11216434|NCT03270527|Experimental|High SFA diet to low SFA diet|Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each. Study visits will occur before and after each dietary intervention period. To comply with current UK dietary recommendations, Diets 1 and 2 will both contain ~35% energy from total fat. These diets will be consumed within the homes of free-living participants, by the substitution of ~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre). This will be achieved using a dietary exchange model developed for the 'DIVAS' study (Vafeiadou K et al (2015) Am J Clin Nut 102, 40-8).
11216435|NCT03270514|Experimental|Exparel Injectable Product|Liposomal Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the LB group (~30).
11216436|NCT03270514|Active Comparator|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~30).
11216437|NCT03270501|Experimental|Arm 1: Golimumab|
11216438|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
11216442|NCT03270449|Experimental|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
11216443|NCT03270449|No Intervention|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
11216444|NCT03270436|Experimental|WORD DPP|The WORD DPP-LI is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. The first 8 modules are intended to be delivered weekly. The last 8 modules are intended to be delivered every other week. Participants in the WORD DPP-LI will be encouraged to maintain a daily weight, nutrition, physical activity and prayer log.
11216445|NCT03270436|Experimental|PILI DPP|The PILI DPP-LI is a family and community based diabetes prevention curriculum that teaches participants to engage their social support (family and community) to have a healthy weight, eat healthy, and be physically active. The PILI DPP-LI includes 14 modules that are intended to be delivered over a 24 week period and each module approximately 90 minutes in length. The first 4 modules are intended to be delivered weekly. The last 10 modules are intended to be delivered every other week. Participants will be encouraged to track their weight, physical activity, and their nutrition in a log on a daily basis.
11216446|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
11216447|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
11216448|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
11216449|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
11216450|NCT03270410||Neonates|Babies born in Rennes University Hospital
11216451|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
11216452|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
11216453|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
11216454|NCT03270371|Experimental|MCO Dialysis|Theranova Dialyzer
11216455|NCT03270371|Active Comparator|Standard High Flux Dialysis|Standard High Flux Dialyzer
11216456|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
11216457|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
11216458|NCT03270332|Experimental|albuterol first then placebo|For albuterol first then placebo, echocardiographic measurements will be made before and at 15, 30, 60, and 120 min after inhaled albuterol (270ug) at visit 2, and echocardiographic measurements before and at 15, 30, 60, and 120 min after inhaled placebo at visit 3
11216459|NCT03270332|Experimental|placebo first then albuterol|For placebo first then albuterol, echocardiographic measurements will be made before and at 15, 30, 60, and 120 min after inhaled placebo at visit 2 and inhaled albuterol (270ug) at visit 3
11216460|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:
~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter
~intubated or tracheostomy in place
~echocardiography requested by the treating physician
~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
11216461|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:
~zygomatic protuberance
~nostril's angle
~inferior margin of tragus
~lip marionette lines
~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
11216462|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
11216463|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
11216464|NCT03270267||Patients with IBD|
11216465|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
11216466|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
11216467|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
11216529|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
11216530|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
11216468|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
11216469|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
11216470|NCT03270189|Experimental|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
11216471|NCT03270189|No Intervention|Controls|Patients without cervical dystonia.
11216472|NCT03270176|Experimental|Debio 1143 and Avelumab|"Part A: Participants will receive Debio 1143 100 to 250 milligram (mg) capsule orally at an escalating dose levels for 10 days every 2 weeks along with avelumab 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion every 2 weeks.
~Part B: Participants will receive Debio 1143 capsules orally at a recommended phase 2 dose (RP2D) of 200 mg/day (days 1-10 and 15-24 every 28 days ([q4w]) in combination with avelumab IV infusion at the standard dose unless disease progression or unacceptable toxicity occurs, as judged by investigators up to 26 cycles (each cycle is of 28 days)."
11216473|NCT03270163|Experimental|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
11216474|NCT03270150|Experimental|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
11216475|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).
~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.
~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
11216476|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).
~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.
~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
11216477|NCT03270124|Active Comparator|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
11216478|NCT03270124|Experimental|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (steps per day) and resistance exercises
11216479|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
11216480|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
11216481|NCT03270098|Experimental|Aerobic Exercise|using traditional exercise equipment (i.e., treadmill, stationary bike) along with active-play video games (Xbox Kinect).
11216482|NCT03270098|Active Comparator|Stretching and Toning Exercise|
11216483|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.
~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.
~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.
~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
11216484|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.
~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
11216485|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
11216486|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
11216487|NCT03270059|Experimental|Group I (gadolinium, ferumoxytol, MRI)|Patients receive gadolinium IV and then ferumoxytol IV and undergo MRI over 60 minutes on day 1.
11216488|NCT03270059|Experimental|Group II (ferumoxytol, gadolinium, MRI)|Patients receive ferumoxytol IV and then gadolinium IV and undergo MRI over 60 minutes on day 1.
11216489|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.
~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
11217144|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
11216490|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.
~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
11216491|NCT03270033|Active Comparator|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11216492|NCT03270033|Active Comparator|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11216493|NCT03270033|Active Comparator|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11216494|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
11216495|NCT03270007|Experimental|Chemotherapy|
11216496|NCT03270007|No Intervention|Control|
11216497|NCT03269994|Active Comparator|Cefoxitin|
11216498|NCT03269994|Experimental|Piperacillin-tazobactam|
11216499|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
11216500|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
11216501|NCT03269968|Experimental|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
11216502|NCT03269968|Placebo Comparator|Standard dressing|Standard dressing
11216503|NCT03269955|Experimental|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
11216504|NCT03269955|No Intervention|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
11216505|NCT03269942|Active Comparator|Endovascular Flow-Diversion|Implantation of flow-diversion device
11216506|NCT03269942|Active Comparator|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
11216507|NCT03269929|Experimental|Music therapy|
11216508|NCT03269929|Active Comparator|Midazolam|
11216509|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
11216510|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
11216511|NCT03269903|Experimental|Patients|Patients with malignant dysphagia treated with the HILZO stent
11216512|NCT03269890|Experimental|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
11216513|NCT03269890|Active Comparator|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
11216514|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
11216515|NCT03269864|Active Comparator|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.
~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.
~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.
~Careful and meticulous dissection is done in a blunt way isolating the perforator.
~After deflation of the tourniquet, hemostasis is performed."
11216516|NCT03269864|Active Comparator|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.
~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
11216517|NCT03269812|Experimental|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
11216518|NCT03269812|Experimental|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
11216519|NCT03269799|Active Comparator|test group|vitamin C 500 mg oral capsule
11216520|NCT03269799|Placebo Comparator|control group|placebo
11216521|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
11216522|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
11216523|NCT03269773|Placebo Comparator|Placebo|
11216524|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
11216525|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
11216526|NCT03269747|Active Comparator|Prednisone|Prednisone 40 mg daily for 7 days
11216527|NCT03269747|Placebo Comparator|Placebo|Placebo daily for 7 days
11216528|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
11217145|NCT03265119|Experimental|AEVI-001|
11216531|NCT03269708|No Intervention|Control|Participants receive standard care in cardiac rehabilitation program
11216532|NCT03269708|Experimental|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
11216533|NCT03269695|Experimental|PF-06687234|PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
11216534|NCT03269695|Placebo Comparator|Placebo|PF-06687234 matched Placebo SC QW x 12 doses
11216535|NCT03269669|Experimental|Arm I (obinutuzumab, umbralisib)|Patients receive obinutuzumab IV on day 1 and umbralisib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11216536|NCT03269669|Experimental|Arm II (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11216537|NCT03269669|Active Comparator|Arm III (obinutuzumab, combination chemotherapy)|"PRIOR BENDAMUSTINE-BASED CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with combination chemotherapy repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~PRIOR CHOP CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, and bendamustine IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 or 12 cycles (bendamustine and obinutuzumab, respectively) in the absence of disease progression or unacceptable toxicity."
11216538|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
11216539|NCT03269643|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11216540|NCT03269643|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11216541|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"Pulmonary hypertension patients (WHO group 1-5)
~Systemic sclerosis patients without pulmonary hypertension
~Mixed connective tissue disease patients without pulmonary hypertension"
11216542|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
11216543|NCT03269630||Healthy controls|"Age>18
~Not actively smoking
~No chronic medical conditions"
11216544|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
11216545|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
11216546|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
11216547|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
11216548|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
11216549|NCT03269591|Active Comparator|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
11216550|NCT03269591|Experimental|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
11216551|NCT03269591|Other|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
11216552|NCT03269591|Other|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
11216553|NCT03269591|Other|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
11216554|NCT03269578||1|Patients with advanced, refractory cancers being treated on NCI/DTC studies
11216555|NCT03269565|Experimental|Arm 1|BCD-100 1 mg/kg Q2W;
11216556|NCT03269565|Experimental|Arm 2|BCD-100 3 mg/kg Q3W.
11216557|NCT03269552|Experimental|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
11216558|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
11216559|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
11216560|NCT03269526|Experimental|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.
11216561|NCT03269513|Experimental|Intervention group|"Adolescent Obesity
~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).
~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
11216562|NCT03269513|No Intervention|Control group|
11216563|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
11216564|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
11216565|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EB diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
11217146|NCT03265119|Placebo Comparator|Placebo|
11216566|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EB. Tissue specimen will be collected from an inconspicuous skin area.
11216567|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
11216568|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
11216569|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
11216570|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%
~+ Normal saline IV"
11216571|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV
~+ Bilateral greater occipital nerve block with normal saline"
11216572|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
11216573|NCT03269409|Sham Comparator|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
11216574|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
11216575|NCT03269396|Experimental|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
11216576|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
11216577|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
11216578|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
11216579|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
11216580|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
11216581|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
11216582|NCT03269357|Other|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
11216583|NCT03269357|No Intervention|Routine counselling|Clinics randomized to routine counselling
11216584|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
11216585|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
11216586|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
11216587|NCT03269331||Control Group|No CTEP EBP Immersion Course
11216588|NCT03269318|Experimental|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
11216589|NCT03269318|No Intervention|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
11216590|NCT03269279|Experimental|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
11216591|NCT03269240|Experimental|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
11216592|NCT03269240|Active Comparator|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
11216593|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.
~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.
~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
11216594|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
11216595|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
11216596|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
11216597|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
11216598|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
11216599|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
11216600|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia
~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
11216601|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
11216602|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
11216603|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
11216604|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
11216605|NCT03269175|Other|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
11216606|NCT03269175|Other|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
11216607|NCT03269162|Experimental|Jinfukang + Chemotherapy Group|
11216608|NCT03269162|Placebo Comparator|Chemotherapy Group|
11216609|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
11216610|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
11216611|NCT03269136|Experimental|PF-06863135|BCMA-CD3 bispecific antibody
11216612|NCT03269136|Experimental|PF-06863135 + PF-06801591|BCMA-CD3 bispecific antibody + anti-PD-1
11216613|NCT03269136|Experimental|PF-06863135 + lenalidomide|BCMA-CD3 bispecific antibody + lenalidomide
11216614|NCT03269123|Other|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
11216615|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
11216616|NCT03269084||Children at HLA-conferred risk for T1D|
11216617|NCT03269071|Experimental|Treatment Cohort A|"See Study Description
~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
11216618|NCT03269071|Experimental|Treatment Cohort B|"See Study Description
~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
11216619|NCT03269071|Experimental|Treatment Cohort C|"See Study Description
~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
11216620|NCT03269071|Experimental|Treatment Cohort D|"See Study Description
~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
11216621|NCT03269058|Experimental|Patients not treated with statins|
11216622|NCT03269058|Experimental|Patients treated with statins|
11216623|NCT03269045|Other|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
11216624|NCT03269032|Experimental|Phase 1 Healthy Volunteers|Healthy volunteers will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks.
11216625|NCT03269032|Experimental|Phase 2 IBS Patients|Participants with IBS will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks
11216626|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
11216627|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
11216628|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
11216629|NCT03269006|Experimental|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
11216630|NCT03269006|Experimental|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
11216631|NCT03269006|Experimental|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
11216632|NCT03269006|Experimental|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
11216633|NCT03269006|No Intervention|Control|without any study interventions
11216721|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
11216722|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
11216634|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
11216635|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
11216636|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
11216637|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
11216638|NCT03268967|Active Comparator|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
11216639|NCT03268967|No Intervention|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
11216640|NCT03268954|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 milligram per square meter (mg/m^2), intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+/-10) infusion, intravenous, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity.
11216641|NCT03268954|Experimental|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles until disease progression or unacceptable toxicity.
11216642|NCT03268941|Placebo Comparator|Part 1: Placebo|TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
11216643|NCT03268941|Experimental|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
11216644|NCT03268941|Experimental|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
11216645|NCT03268941|Experimental|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
11216646|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fed Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
11216647|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fasted Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
11216648|NCT03268941|Active Comparator|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
11216649|NCT03268928|Experimental|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.
~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
11216650|NCT03268928|Other|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.
~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
11216651|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
11216652|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
11216653|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
11216654|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
11216655|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
11216656|NCT03268889|Experimental|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
11216657|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (> stage IIa) at the participating institutions will be asked to participate.
11216658|NCT03268863|Experimental|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
11216659|NCT03268863|Sham Comparator|Control|Powered down Google Cardboard Virtual Reality headset
11216660|NCT03268850|Experimental|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
11216661|NCT03268850|Experimental|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
11216662|NCT03268837|Experimental|Programmed Intermittent Bolus|
11216663|NCT03268837|Active Comparator|Continuous Infusion|
11216664|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
11216665|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
11216767|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
11216768|NCT03267966|Experimental|Group A|Leeds Pathology Protocol (LEEPP)
11216666|NCT03268811|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.
11216667|NCT03268798|Experimental|Wrist extension training|
11216668|NCT03268785|No Intervention|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
11216669|NCT03268785|Experimental|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
11216670|NCT03268772|Experimental|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
11216671|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
11216672|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
11216673|NCT03268746|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
11216674|NCT03268733|Experimental|Treatment group|45 PCOS patients will receive 5 mg folic acid
11216675|NCT03268733|No Intervention|control group|45 PCOS patients will receive no folic acid
11216676|NCT03268720|Other|healthy controls|FODMAP low diet gluten-free diet
11216677|NCT03268720|Other|NCGS patients|FODMAP low diet gluten-free diet
11216678|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
11216679|NCT03268707|Experimental|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
11216680|NCT03268694|Experimental|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
11216681|NCT03268655|Experimental|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
11216682|NCT03268655|Experimental|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
11216683|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:
~intravenous immune globulin;
~large dose of glucocorticoids;
~mechanical ventilation;
~hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);
~continuous renal replacement therapy."
11216684|NCT03268642||conventional therapy group|"meet one of the following conditions:
~without/insufficient intravenous immune globulin;
~without/with various doses of glucocorticoid ;
~vasoactive drug;
~without/delayed mechanical ventilation;
~without/delayed hemodynamic support;
~without/delayed continuous renal replacement therapy."
11216685|NCT03268629|Experimental|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
11216686|NCT03268629|Active Comparator|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
11216687|NCT03268616|Experimental|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
11216688|NCT03268616|Experimental|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
11216689|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 1 x 10^8 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 5 x 10^7, based on Dose Modification Rules. One further dose reduction to 1 x 10^7 may occur in later injections.
11216690|NCT03268590|Experimental|All Study Participants|Breathing 21% oxygen via non-rebreather face mask followed by breathing 100% oxygen via non-rebreather face mask
11216691|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
11216692|NCT03268564|Experimental|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):
~Viewing a promotion video and a demonstration video
~Brief motivational interviewing through telephone
~Visiting the HIVST-online webpage
~Receiving a free self-testing kit and follow-up reminders
~Health promotion for re-testers:
~Viewing a promotion video and a demonstration video
~Visiting the HIVST-online webpage
~Receiving a free self-testing kit and follow-up reminders"
11216769|NCT03267966|No Intervention|Group B|"Conventional method of pathological evaluation"
11216693|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
11216694|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
11216695|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
11216696|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
11216697|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
11216698|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
11216699|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
11216700|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
11216701|NCT03268473|Experimental|Experimental: Non-surgical periodontal therapy|"Non-surgical periodontal therapy consisted of scaling and root planing and supportive periodontal therapy during 3 months
~Intervention: Procedure: Non-surgical periodontal therapy"
11216702|NCT03268473|Active Comparator|Delayed non-surgical periodontal therapy|No periodontal treatment for 3 months
11216703|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
11216704|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
11216705|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
11216706|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
11216707|NCT03268421|Experimental|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
11216708|NCT03268421|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
11216709|NCT03268421|Active Comparator|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
11216710|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
11216711|NCT03268408||Control|Usual care
11216712|NCT03268395|Other|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
11216713|NCT03268382|Experimental|APR-246 + PLD|
11216714|NCT03268369|Active Comparator|Control group|
11216715|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
11216716|NCT03268369|Experimental|Idiopathic generalized epilepsy|
11216717|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
11216718|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
11216719|NCT03268343|Experimental|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):
~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).
~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
11216720|NCT03268343|Experimental|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):
~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).
~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
11216858|NCT03267303|Placebo Comparator|Placebo|
11216723|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:
~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;
~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;
~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
11216724|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
11216725|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
11216726|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
11216727|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
11216728|NCT03268239|Other|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.
~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
11216729|NCT03268226|Experimental|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
11216730|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
11216731|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
11216732|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
11216733|NCT03268187|Experimental|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
11216734|NCT03268187|Active Comparator|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
11216735|NCT03268174|Active Comparator|AO+Mist|AO+Mist
11216736|NCT03268174|Placebo Comparator|Placebo|Placebo
11216737|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
11216738|NCT03268148|Experimental|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
11216739|NCT03268148|No Intervention|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
11216740|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
11216741|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
11216742|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
11216743|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
11216744|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
11216745|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
11216746|NCT03268109||people living with HIV|subjects infected with HIV and with cognitive complaints
11216747|NCT03268109||control subjects|subjects not infected with HIV and with cognitive complaints
11216748|NCT03268083|Experimental|Group A1|3 to 6 years
11216749|NCT03268083|Experimental|Group A2|3 to 6 years
11216750|NCT03268083|Experimental|Group A3|3 to 6 years
11216751|NCT03268083|Experimental|Group B1|2 to 35 months
11216752|NCT03268083|Experimental|Group B2|2 to 35 months
11216753|NCT03268083|Experimental|Group B3|2 to 35 months
11216754|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
11216755|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
11216756|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
11216757|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
11216758|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
11216759|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
11216760|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
11216761|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
11216762|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
11216763|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
11216764|NCT03268018|Other|Single arm|
11216765|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
11216766|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
11216770|NCT03267953|Experimental|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
11216771|NCT03267953|Experimental|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
11216772|NCT03267953|Experimental|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
11216773|NCT03267940|Experimental|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m^2) of CIS plus 1000 mg/m^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
11216774|NCT03267940|Experimental|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
11216775|NCT03267940|Experimental|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
11216776|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
11216777|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
11216778|NCT03267940|Active Comparator|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
11216779|NCT03267927|Experimental|Patient with OSA|
11216780|NCT03267914|Experimental|Tray group|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
11216781|NCT03267914|Active Comparator|Brush group|Patients will brush with the fluoride for 2 minutes each day.
11216782|NCT03267901|Experimental|Walnut-Control|
11216783|NCT03267901|Experimental|Control-Walnut|
11216784|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11216785|NCT03267875|Experimental|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
11216786|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
11216787|NCT03267836|Experimental|Avelumab + Proton Therapy|"Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months
~Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays
~After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care
~If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.
~After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
11216788|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
11216789|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
11216790|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
11216791|NCT03267797|Experimental|Treatment group|Peripheral blood mononuclear cells (PBMCs) were administered into the uterine cavity of RIF patients in this group.
11216792|NCT03267797|Placebo Comparator|Control group|Phosphate buffer saline (PBS) as placebo was injected into the uterine cavity of RIF patients in this group.
11216793|NCT03267784|Experimental|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
11216794|NCT03267771|Active Comparator|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
11216795|NCT03267771|Experimental|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
11216796|NCT03267758|Experimental|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
11216797|NCT03267758|Placebo Comparator|Placebo|Subjects in this arm will consume 1 serving of heat-killed placebo daily for first 6 weeks.
11216798|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
11216799|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
11216800|NCT03267732|Active Comparator|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
11216801|NCT03267732|Active Comparator|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
11216802|NCT03267719|Experimental|laser therapy|Erbium-laser therapy will be applied
11216803|NCT03267706|Active Comparator|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
11216804|NCT03267706|No Intervention|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
11216805|NCT03267680|Experimental|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
11216806|NCT03267680|Active Comparator|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
11216807|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
11216808|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
11216809|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
11216810|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
11216811|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
11216812|NCT03267628|Sham Comparator|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
11216813|NCT03267628|Active Comparator|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
11216814|NCT03267628|Active Comparator|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
11216815|NCT03267628|Active Comparator|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
11216816|NCT03267602|Experimental|Continuous Positive Airway Pressure (CPAP) Therapy|
11216817|NCT03267589|Experimental|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
11216818|NCT03267589|Experimental|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
11216819|NCT03267589|Experimental|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
11216820|NCT03267576|Experimental|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to [>=] 1500 milligram per day [mg/day]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin >=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
11216821|NCT03267576|Experimental|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
11216822|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
11216823|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
11216859|NCT03267290|Experimental|Sonazoid- CEUS+CEMRI or CECT+CEMRI|Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
11216824|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
11216825|NCT03267550|Experimental|remote programming system|
11216826|NCT03267537|Active Comparator|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
11216827|NCT03267537|Experimental|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
11216828|NCT03267524|Experimental|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
11216829|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
11216830|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
11216831|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
11216832|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
11216833|NCT03267498|Experimental|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11216834|NCT03267446|Experimental|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
11216835|NCT03267433|Experimental|Group I (auto-HCT, rituximab)|Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 60-120 days after transplant, patients receive rituximab IV once every 8 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11216836|NCT03267433|Experimental|Group II (rituximab alone)|Patients receive standard of care induction chemotherapy. Beginning 40-120 days after completion of chemotherapy, patients receive rituximab as in Group I.
11216837|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
11216838|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
11216839|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
11216840|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
11216841|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
11216842|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
11216843|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
11216844|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
11216845|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
11216846|NCT03267368|Experimental|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
11216847|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
11216848|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
11216849|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
11216850|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
11216851|NCT03267316|Experimental|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. [Completed December 2018]
11216852|NCT03267316|Experimental|Monotherapy (Q1W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).
11216853|NCT03267316|Experimental|Monotherapy (Q1W/Q2W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).
11216854|NCT03267316|Experimental|Combination - NSCLC|Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).
11216855|NCT03267316|Experimental|Combination - PDAC|Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).
11216856|NCT03267303|Experimental|TS-091 5mg|
11216857|NCT03267303|Experimental|TS-091 10mg|
11216860|NCT03267277|Experimental|Treatment|Patient will be assessed for 10 weeks off treatment and then will receive 10 weeks of treatment. They will return at weeks 24 and 62 for safety and sustainability of efficacy assessments.
11216861|NCT03267264|Experimental|Group 1|
11216862|NCT03267264|Experimental|Group 2|
11216863|NCT03267264|Experimental|Group 3|
11216864|NCT03267264|Experimental|Group 4|
11216865|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
11216866|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
11216867|NCT03267238|Experimental|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
11216868|NCT03267212|Active Comparator|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
11216869|NCT03267212|Sham Comparator|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
11216870|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
11216871|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
11216872|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
11216873|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
11216874|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
11216875|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
11216876|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis
~no intervention is given"
11216877|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
11216878|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
11216879|NCT03267108|Active Comparator|Inhaled Nitric Oxide (iNO)|Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
11216880|NCT03267108|Placebo Comparator|Placebo|Pulsed inhaled N2, 99.999% gas
11216881|NCT03267108|Other|Open Label Extension|Pulsed inhaled iNO 45 mcg/kg IBW/hr
11216882|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
11216883|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
11216884|NCT03267082|Experimental|Evaluation the role of Laparoscopic management of perforated a|
11216885|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
11216886|NCT03267056||DCB arm|drug eluting balloon catheter
11216887|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
11216888|NCT03267043|Experimental|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
11216889|NCT03267043|Active Comparator|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
11216890|NCT03267043|Experimental|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
11216891|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
11216892|NCT03267017||Patient scheduled for surgery under general anesthesia|
11216893|NCT03267004|Experimental|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
11216894|NCT03267004|Experimental|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
11216895|NCT03266991|Experimental|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
11216896|NCT03266991|Active Comparator|control|Participants treated with daily isoniazid for six months
11216897|NCT03266965|Experimental|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
11216898|NCT03266939|Placebo Comparator|Placebo|
11216899|NCT03266939|Active Comparator|Active Medication|
11216972|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
11216900|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
11216901|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
11216902|NCT03266913|Active Comparator|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
11216903|NCT03266913|No Intervention|No probiotic|Routine phototherapy
11216904|NCT03266900|Experimental|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
11216905|NCT03266900|Active Comparator|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
11216906|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
11216907|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
11216908|NCT03266835|Other|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
11216909|NCT03266822||Healthy control|
11216910|NCT03266822||RA patients on anti-TNF therapy|
11216911|NCT03266822||RA patients on anti-IL-6R therapy|
11216912|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:
~Early invasive breast cancer (stage I-III)
~Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)
~WHO performance status 0-2."
11216913|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
11216914|NCT03266783|Active Comparator|Apixaban group|10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment
11216915|NCT03266783|Active Comparator|Rivaroxaban group|15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment
11216916|NCT03266770|Other|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
11216917|NCT03266744|Other|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.
~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
11216918|NCT03266744|Other|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
11216919|NCT03266731|Experimental|use of aspirin and clopidogrel|
11216920|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
11216921|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
11216922|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
11216923|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
11216924|NCT03266692|Experimental|ACTR087 in combination with SEA-BCMA|
11216925|NCT03266679|Other|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker & Klion) - weekly for a period of 12 months. No control/comparison group.
11216926|NCT03266666|Other|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
11216927|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
11216928|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
11216929|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
11216930|NCT03266614|Experimental|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
11216931|NCT03266614|No Intervention|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
11216932|NCT03266601|Experimental|Recombinant Human Interferon α-2b Spray|
11216933|NCT03266601|Active Comparator|Ribavirin|
11216934|NCT03266588|Experimental|Rimegepant|
11216935|NCT03266575|Active Comparator|Pulmonary Rehabilitation|Participants will participate in formal Pulmonary Rehabilitation Exercise program
11216936|NCT03266575|Active Comparator|Home based program|Participants will participate in a Home based Exercise program
11216973|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
11216937|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
11216938|NCT03266549|Experimental|Botulinum toxin augmented surgery group|bilateral 7.0-mm medial rectus muscle recessions, with augmentation with 1.25units of botulinum toxin in 1 muscle for patients with deviations of 65 to 70 PD, and 2.5 units (either 1.25 units in both muscles or 2.5 units in 1 muscle) for patients with deviations greater than 70 PD
11216939|NCT03266549|Active Comparator|conventional surgery group|bilateral MR muscle recessions combined with unilateral or bilateral LR muscle resections (according to the standard correction tables)
11216940|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
11216941|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
11216942|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
11216943|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
11216944|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
11216945|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
11216946|NCT03266510|Experimental|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
11216947|NCT03266510|Sham Comparator|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
11216948|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.
~The probiotics sachets will be taken twice a day for 12 weeks."
11216949|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo
~The identical placebo sachets will be taken twice a day for 12 weeks."
11216950|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
11216951|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
11216952|NCT03266445|Active Comparator|FULL-BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
11216953|NCT03266445|No Intervention|LOW-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone reduced to 8mg on the day of surgery
11216954|NCT03266432|Other|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
11216955|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
11216956|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
11216957|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
11216958|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
11216959|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
11216960|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
11216961|NCT03266367||Healthy Group|control group
11216962|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
11216963|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
11216964|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
11216965|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
11216966|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
11216967|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
11216968|NCT03266276|No Intervention|Treatment as Usual Control Group|Treatment as usual.
11216969|NCT03266276|Experimental|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
11216970|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
11216971|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
11216974|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
11216975|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
11216976|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
11216977|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
11216978|NCT03266224||Wryneck|those with a condition
11216979|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
11216980|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
11216981|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
11216982|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
11216983|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
11216984|NCT03266172|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
11216985|NCT03266172|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
11216986|NCT03266172|Experimental|Subjects in Part C|Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
11216987|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
11216988|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
11216989|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
11216990|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
11216991|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
11216992|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
11216993|NCT03266146|Experimental|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
11216994|NCT03266146|Experimental|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
11216995|NCT03266133|Experimental|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
11216996|NCT03266133|No Intervention|Routine Care|Usual care
11216997|NCT03266120|Active Comparator|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
11216998|NCT03266120|Experimental|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
11216999|NCT03266107|Experimental|Treatment|Intracept System ablation
11217000|NCT03266094|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs Radio frequency (RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
11217001|NCT03266081|Experimental|0.75% bupivacaine|
11217002|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
11217036|NCT03265808|Placebo Comparator|Placebo|Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
11217341|NCT03263650|No Intervention|Observation Only|Participants randomized to observation only beginning cycle 7.
11217003|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
11217004|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
11217005|NCT03266055|Experimental|Blueberry powder|
11217006|NCT03266055|Placebo Comparator|Blueberry placebo powder|
11217007|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
11217008|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
11217009|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
11217010|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
11217011|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
11217012|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
11217013|NCT03265990|Experimental|Group A|Conventional haemrrhoidectomy,Ferguson technique
11217014|NCT03265990|Experimental|Group B|Ligasure haemorrhoidectomy
11217015|NCT03265977|Experimental|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
11217016|NCT03265977|Placebo Comparator|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
11217017|NCT03265964|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
11217018|NCT03265964|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
11217019|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
11217020|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
11217021|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
11217022|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
11217023|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
11217024|NCT03265925||Healthy|Healthy controls
11217025|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
11217026|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
11217027|NCT03265899|Experimental|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
11217028|NCT03265899|Placebo Comparator|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
11217029|NCT03265886|Experimental|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
11217030|NCT03265886|Active Comparator|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
11217031|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
11217032|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
11217033|NCT03265834|Experimental|Long course antibiotic therapy (28 days)|Antibiotic therapy for a duration of 28 days
11217034|NCT03265834|Active Comparator|Short course antibiotic therapy (≤10 days)|Antibiotic therapy for a duration of ≤10 days
11217035|NCT03265808|Experimental|allogeneic human mesenchymal stem cells (allo-hMSCs)|Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
11217037|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
11217038|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
11217039|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
11217040|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
11217041|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
11217042|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
11217043|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
11217044|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
11217045|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
11217046|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
11217047|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
11217048|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
11217049|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
11217050|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
11217051|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
11217052|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
11217053|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
11217054|NCT03265665|Experimental|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants. Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
11217055|NCT03265665|Other|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
11217056|NCT03265652|Experimental|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
11217057|NCT03265652|Placebo Comparator|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
11217058|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
11217059|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
11217060|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
11217061|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
11217097|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
11217098|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
11217062|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
11217063|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.
~-No intervention package but standard service will be maintained"
11217064|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
11217065|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
11217066|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
11217067|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
11217068|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
11217069|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
11217070|NCT03265574|Experimental|Intervention|
11217071|NCT03265574|No Intervention|Standard care|
11217072|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
11217073|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
11217074|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
11217075|NCT03265548|Experimental|Intervention|Video laryngoscopy
11217076|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
11217077|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
11217078|NCT03265522|Experimental|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
11217079|NCT03265522|Experimental|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
11217080|NCT03265522|Placebo Comparator|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
11217081|NCT03265509|Active Comparator|Glutamine|30 g/day Glutamine supplementation for three months
11217082|NCT03265509|Placebo Comparator|Fantomalt|30 g/day Fantomalt supplementation for three months
11217083|NCT03265496|Experimental|study procedure|Clinical exam. Liquid biopsy. Diagnostic exam (biopsy and imagery). 1st line treatment. tumor evaluation. Biopsy
11217084|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
11217085|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
11217086|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
11217087|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
11217088|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
11217089|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
11217090|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
11217091|NCT03265457||Normal people at same age|
11217092|NCT03265444|Experimental|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
11217093|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
11217094|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
11217095|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
11217096|NCT03265418|Experimental|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
11217143|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
11217099|NCT03265405|No Intervention|Observation|The subjects with sarcoidosis who do not have any indication for immunosuppressive treatment will be observed and monitored. If any treatment requiring indication arises during the observed period, the subjects will be randomized to one of the above study groups
11217100|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
11217101|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
11217102|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
11217103|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
11217104|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
11217105|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
11217106|NCT03265379||patients with an isolated recurrence in the chest wall|
11217107|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
11217108|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
11217109|NCT03265379||patients refusing to undergo surgery|
11217110|NCT03265366|Experimental|ABPA|15 patients with ABPA
11217111|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
11217112|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
11217113|NCT03265353|Other|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
11217114|NCT03265353|Other|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
11217115|NCT03265340|Active Comparator|A|dTMS standard protocol 10 min session
11217116|NCT03265340|Active Comparator|B|dTMS standard protocol 20 min session
11217117|NCT03265340|Active Comparator|C|dTMS standard protocol 40 min session
11217118|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
11217119|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
11217120|NCT03265314|Experimental|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
11217121|NCT03265314|Placebo Comparator|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
11217122|NCT03265301|Other|Office hysteroscopy|
11217123|NCT03265301|Other|Conventional hysteroscopy|
11217124|NCT03265288|Experimental|LAU-7b|Active drug fenretinide (as LAU-7b capsules)
11217125|NCT03265288|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
11217126|NCT03265262|Experimental|Children receiving OFC during a diagnost|paediatric patients attending food allergy
11217127|NCT03265249|Experimental|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
11217128|NCT03265249|No Intervention|Group 2|Subjects will receive the standard of care pain control analgesia
11217129|NCT03265236||Group1|Patients with early rheamatoid arthritis
11217130|NCT03265236||Group 2|patients with late rheamatoid arthritis
11217131|NCT03265236||Group 3|Healthy control
11217132|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
11217133|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
11217134|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
11217135|NCT03265210|Experimental|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
11217136|NCT03265210|No Intervention|Referral|Referral for mental health based on clinical indication.
11217137|NCT03265197|Experimental|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
11217138|NCT03265197|Active Comparator|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
11217139|NCT03265184|Experimental|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
11217140|NCT03265184|Placebo Comparator|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
11217141|NCT03265145|Experimental|Stiolto Respimat|
11217142|NCT03265145|Active Comparator|ICS plus LABA plus LAMA (triple therapy)|ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)
11217147|NCT03265106|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10^6/kg / 1x10^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
11217148|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
11217149|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
11217150|NCT03265080|Experimental|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.
~Two dose levels of ADXS-NEO will be explored: 1 x 10 to the 9th power and 1 x 10 to the 8th power colony forming unit (CFU)."
11217151|NCT03265080|Experimental|Part B|Two dose levels of ADXS-NEO will be explored [i.e., 1 x 10 to the 8th power and 5 x 10 to the 8th power colony forming unit (CFU)] in combination with 200mg of pembrolizumab.
11217152|NCT03265080|Experimental|Part C|ADXS-NEO will be explored at 1 x 10 to the 8th power colony forming unit (CFU) in combination with 200mg of pembrolizumab in an expansion cohort.
11217153|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
11217154|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
11217155|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
11217156|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
11217157|NCT03265028||Intervention|Invited to take the TRACE e-learning.
11217158|NCT03265028||Control|Not (yet) invited to take the TRACE e-learning.
11217159|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
11217160|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
11217161|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
11217162|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
11217163|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
11217164|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
11217165|NCT03264989|Experimental|crizanlizumab 5 mg/kg|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.
11217166|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
11217167|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
11217168|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
11217169|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
11217170|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.
~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
11217171|NCT03264963|Active Comparator|Control|
11217172|NCT03264963|Experimental|Intervention|
11217173|NCT03264950|Other|SIngle Arm|All patients undergo Elastography. This is a single arm study
11217174|NCT03264937|Experimental|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
11217175|NCT03264937|No Intervention|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
11217176|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
11217177|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
11217178|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
11217179|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
11217180|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
11217181|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
11217182|NCT03264898||FIT Group|Fecal immunochemical tests will be completed.
11217183|NCT03264885|No Intervention|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
11217184|NCT03264885|Other|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
11217185|NCT03264872|Experimental|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
11217186|NCT03264872|Other|Waitlist Control|Delayed Treatment.
11217187|NCT03264846||Group 1|PCOS participants with periodontitis
11217188|NCT03264846||Group 2|PCOS participants with periodontally healthy
11217189|NCT03264846||Group 3|systemically healthy participants with periodontitis
11217190|NCT03264846||Group 4|systemically and periodontally healthy participants
11217191|NCT03264820|Experimental|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.
~Then will be performed :
~Visit 1 :
~Biology report * (* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))
~Laser measurements at the forearm (with laser speckle)
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature
~Visit 2 :
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature"
11217192|NCT03264820|Experimental|Healthy volunteers|"The healthy volunteers (11) will undergo :
~Visit 1 :
~Biology report (+ urinary pregnancy test (if applicable))
~Laser measurements at the forearm (with laser speckle)
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature
~Visit 2 :
~Laser measurements at the level of each finger
~Pain evaluation (EVA)
~Measurement of blood pressure and heart rate
~Environmental measures and skin temperature"
11217193|NCT03264807|Active Comparator|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
11217194|NCT03264807|Experimental|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
11217195|NCT03264794|Experimental|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
11217196|NCT03264794|Active Comparator|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
11217197|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
11217198|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
11217199|NCT03264768|Other|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
11217200|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
11217201|NCT03264755|Active Comparator|cortical excitability in smokers|
11217202|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
11217203|NCT03264729|Experimental|Isometric exercise|
11217204|NCT03264729|Active Comparator|Isotonic exercise|
11217205|NCT03264729|Active Comparator|Walking|
11217206|NCT03264716|Experimental|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
11217207|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
11217208|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
11217209|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
11217210|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
11217211|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
11217212|NCT03264664|Experimental|E7386 BID|E7386 will be administered as a single agent orally as capsule or tablet, initially twice daily (BID) continuously in 28 days treatment cycle at a starting dose of 5 milligrams (mg). The dose will be escalated in cohorts of participants subject to safety data and the absence of dose-limiting toxicities (DLTs). Based on the emerging data after completion of Dose Escalation Part, identifying MTD or RP2D, or after a decision is made to evaluate more than one potential RP2D level, a Dose Expansion Part will be initiated. Participants will continue to receive study treatment in extension phase until disease progression, development of unacceptable toxicity, withdrawal of consent, or discontinuation of E7386 development by the sponsor.
11217213|NCT03264651|Experimental|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
11217214|NCT03264638|Experimental|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
11217342|NCT03263637|Experimental|Arm A: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory haematological malignancies excluding AML/ALL/high-risk MDS/CMML/CLL.
11217215|NCT03264638|Experimental|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
11217216|NCT03264638|Active Comparator|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
11217217|NCT03264625|Experimental|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
11217218|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
11217219|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.
~The exercise included three stages: warming up, swimming and cooling down."
11217220|NCT03264612|No Intervention|Non swimming group|no intervention
11217221|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
11217222|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
11217223|NCT03264586|Active Comparator|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum
~EMLA cream was applied, 1 hour before the expected time of birth.
~With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.
~No additional anesthetic was applied if episiotomy was necessary.
~Before commancement of perineal repair any residual cream was wiped off."
11217224|NCT03264586|Active Comparator|mepivacaine infiltration group|"In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.
~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.
~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
11217225|NCT03264573|Active Comparator|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
11217226|NCT03264573|Active Comparator|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
11217227|NCT03264560|Active Comparator|Synchronous Telepsychiatry (STP) group|
11217228|NCT03264560|Experimental|Asynchronous Telepsychiatry (ATP) group|
11217229|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*
~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
11217230|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
11217231|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
11217232|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
11217233|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
11217234|NCT03264508|Experimental|Heat therapy|Hot water immersion 3-4x per week for 8-10 weeks
11217235|NCT03264508|Sham Comparator|Thermoneutral water immersion|Thermoneutral water immersion 3-4x per week for 8-10 weeks
11217236|NCT03264482|Active Comparator|THUVAP|thulium vaporization
11217237|NCT03264482|Active Comparator|M-TURP|monopolar transurethral resection
11217238|NCT03264456|Experimental|[18F] Fluciclovine PET/MRI|[18F] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
11217239|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
11217240|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
11217241|NCT03264430|Active Comparator|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
11217242|NCT03264430|Placebo Comparator|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
11217243|NCT03264404|Experimental|Pembrolizumab|Patients with advanced pancreatic cancer will receive pembrolizumab with the hypomethylating agent azacitidine.
11217244|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
11217245|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
11217246|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
11217247|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
11217343|NCT03263637|Experimental|Arm B: (Cohort 1-3)|dose level 1-3 in subjects with relapsed or refractory AML, ALL, high-risk MDS, CMML, CLL and Richter's syndrome.
11217248|NCT03264352|Active Comparator|active-treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP both by at least 10 mm Hg and lower than 130 mm Hg. In the active-treatment group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication); scored tablets with hydrochlorothiazide 25 mg (third-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) and afterwards hydrochlorothiazide (first 12.5 mg or then 25 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line or similarly, second-line medication may be replaced by third-line medication.
11217249|NCT03264352|Placebo Comparator|placebo group|This arm receives identical agents to the active study drugs (Allisartan Isoproxil placebo, Amlodipine placebo and hydrochlorothiazide placebo) also to decrease systolic BP both by at least 10 mm Hg and lower than 130 mm Hg, with a similar schedule of administration to the parallel arm.
11217250|NCT03264339|Experimental|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
11217251|NCT03264326|Experimental|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
11217252|NCT03264326|Sham Comparator|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
11217253|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
11217254|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
11217255|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
11217256|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
11217257|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.
~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.
~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.
~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).
~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
11217258|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.
~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.
~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.
~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).
~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
11217259|NCT03264274|Other|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
11217260|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
11217261|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
11217262|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
11217263|NCT03264235|Experimental|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
11217264|NCT03264235|Active Comparator|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
11217265|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
11217266|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
11217267|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
11217268|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
11217269|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
11217270|NCT03264170|Active Comparator|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
11217271|NCT03264170|No Intervention|Control|Women will not receive the prediction score
11217272|NCT03264157|Experimental|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
11217273|NCT03264157|Active Comparator|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
11217274|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
11217275|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
11217300|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
11217344|NCT03263624|Experimental|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
11217345|NCT03263624|Active Comparator|Group (B)|Tazarotene Cream 0.1%
11217276|NCT03264131|Experimental|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP [(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m^2 on D1; doxorubicin 50 mg/m^2 on D1, etoposide 100 mg/m^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)] for 4 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
11217277|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
11217278|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
11217279|NCT03264105|Experimental|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
11217280|NCT03264105|Active Comparator|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
11217281|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
11217282|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
11217283|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
11217284|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
11217285|NCT03264066|Experimental|Cohort 3 - RCC - treatment naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
11217286|NCT03264066|Experimental|Cohort 1 - SCCHN - treatment naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
11217287|NCT03264066|Experimental|Cohort 2 - UC - treatment naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
11217288|NCT03264066|Experimental|Cohort 4 - SCCHN - previous treatment exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
11217289|NCT03264066|Experimental|Cohort 5 - UC - previous treatment exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
11217290|NCT03264066|Experimental|Cohort 6 - RCC - previous treatment exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
11217291|NCT03264066|Experimental|Cohort 7 - biopsy cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles
11217292|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
11217293|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
11217294|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
11217295|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
11217296|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
11217297|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
11217298|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
11217299|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
11217340|NCT03263650|Experimental|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
11217301|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
11217302|NCT03263962||With canrenone|Patients with canrenone
11217303|NCT03263962||Without canrenone|Patients without canrenone
11217304|NCT03263936|Other|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
11217305|NCT03263923|Experimental|Intervention group|Online intervention is cognitive behavioral skills' training and 4 weeks of online journaling. Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they have learned/used.
11217306|NCT03263923|Active Comparator|Comparison group|Comparator intervention is Reflective journaling training and 4 weeks of online journaling. Participants watch a reflective journaling video with specific instructions, and then the participants complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations.
11217307|NCT03263910|Experimental|NPO-11|
11217308|NCT03263910|Placebo Comparator|Placebo|
11217309|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
11217310|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
11217311|NCT03263884|Experimental|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.
~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
11217312|NCT03263884|Sham Comparator|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
11217313|NCT03263871|Experimental|Intervention|PTM202 and micro-nutrient sprinkles
11217314|NCT03263871|Other|Control|micro-nutrient sprinkles
11217315|NCT03263858|Experimental|Cohort 1 and 2|
11217316|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).
~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
11217317|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).
~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
11217318|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
11217319|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
11217320|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
11217321|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
11217322|NCT03263793|Experimental|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
11217323|NCT03263780|Experimental|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
11217324|NCT03263767|Experimental|LYMPHOID HEMOPATHY|patients with lymphoid hemopathy
11217325|NCT03263767|Experimental|MYELOID HEMOPATHY|patients with myeloid hemopathy
11217326|NCT03263754|Experimental|Intervention|
11217327|NCT03263754|Active Comparator|Control|
11217328|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
11217329|NCT03263728|Experimental|Stress Cardiac MR|
11217330|NCT03263715|Experimental|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe [Actemra] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid [Glucocorticoids]
11217331|NCT03263715|Placebo Comparator|Placebo|Placebo [Placebos] and rapidly tapered Glucocorticoid [Glucocorticoids] treatment
11217332|NCT03263702|Experimental|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
11217333|NCT03263689|Experimental|Intervention|"ITM group were given
~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
~100 micrograms of preservative-free morphine."
11217334|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
11217335|NCT03263676|Experimental|Icon reusable underwear|
11217336|NCT03263676|Placebo Comparator|Disposable pad|
11217337|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
11217338|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
11217339|NCT03263650|Experimental|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
11217346|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
11217347|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
11217348|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
11217349|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
11217350|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
11217351|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
11217352|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
11217353|NCT03263572|Experimental|Treatment (blinatumomab, chemotherapy, ponatinib)|Patients receive blinatumomab IV nonstop on days 1-28 of cycles 1-5, and methotrexate and cytarabine intrathecally (by spinal tap) on days 1, 15, and 29 of cycles 1-4. Patients also receive ponatinib PO daily. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11217354|NCT03263559|Experimental|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
11217355|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
11217356|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
11217357|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:
~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
11217358|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:
~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
11217359|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
11217360|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
11217361|NCT03263507|Experimental|IONIS-PKK-LRx|Ascending single and multiple doses of IONIS-PKK-LRx administered subcutaneously
11217362|NCT03263507|Placebo Comparator|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
11217363|NCT03263494|Active Comparator|CGM|
11217364|NCT03263494|No Intervention|BGM|
11217365|NCT03263481|Experimental|ERCP with intraductal secretin test|Subjects undergoing ERCP for biliary indication in which inadvertent pancreatic cannulation occurs will receive intraductal secretin testing using a one-time intravenous injection of 16 mcg of human secretin for injection administered over one minute.
11217366|NCT03263468|Experimental|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm).
11217367|NCT03263468|Active Comparator|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
11217368|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
11217369|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
11217370|NCT03263442|Experimental|Intervention|Thiamine 200 mg IV
11217371|NCT03263442|Placebo Comparator|Control|Normal saline IV
11217372|NCT03263429|Experimental|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11217373|NCT03263416|Experimental|Arm A|
11217374|NCT03263416|Other|Arm B|Standard
11217375|NCT03263403|Experimental|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
11217376|NCT03263403|Active Comparator|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
11217377|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
11217378|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
11217379|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
11217412|NCT03263156|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
11217413|NCT03263143|No Intervention|Standard of Care|
11217414|NCT03263143|Other|Early Palliative Care Consultation|
11217415|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
11217380|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
11217381|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
11217382|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
11217383|NCT03263338|Active Comparator|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
11217384|NCT03263338|Experimental|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
11217385|NCT03263338|Experimental|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
11217386|NCT03263325||AKI Group|Patients developing AKI after surgery
11217387|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
11217388|NCT03263312|Experimental|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
11217389|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
11217390|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
11217391|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
11217392|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
11217393|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
11217394|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
11217395|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
11217396|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
11217397|NCT03263247|Experimental|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.
~Intervention: Visual Imaging Training in individual sessions"
11217398|NCT03263247|Active Comparator|Psychoeducation|"Participants will receive information about memory functioning and aging.
~Intervention: behavioral: Psychoeducation in individual sessions"
11217399|NCT03263247|Experimental|Alphabet Search|"Participants will receive alphabet search training.
~Intervention: Alphabet Search in individual sessions"
11217400|NCT03263234|Active Comparator|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
11217401|NCT03263234|Active Comparator|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
11217402|NCT03263234|No Intervention|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.
~This group serves as a control for:
~Physiological or mental decline in participants during the study period
~Seasonal variation"
11217403|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
11217404|NCT03263195||HIV-infected women|Pregnant women infected with HIV only and their infants.
11217405|NCT03263195||ZIKV-infected women|Pregnant women infected with ZIKV only and their infants.
11217406|NCT03263195||HIV- and ZIKV-infected women|Pregnant women infected with HIV and ZIKV and their infants.
11217407|NCT03263195||Not HIV- or ZIKV- infected women|Pregnant women not infected with either HIV or ZIKV and their infants.
11217408|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
11217409|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
11217410|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
11217411|NCT03263156|Experimental|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
11217416|NCT03263117|Active Comparator|Sedation|The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.
11217417|NCT03263117|Active Comparator|General Anesthesia|The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.
11217418|NCT03263104|Experimental|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
11217419|NCT03263104|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
11217420|NCT03263091|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
11217421|NCT03263091|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
11217422|NCT03263078|Experimental|TIVA with Propofol in major surgery|Total intravenous anesthesia(TIVA) with Propofol
11217423|NCT03263078|Active Comparator|Sevoflurane in major surgery|Inhalation anesthesia with Sevoflurane
11217424|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
11217425|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
11217426|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
11217427|NCT03263052||Tacrolimus XR|
11217428|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
11217429|NCT03263026|Active Comparator|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
11217430|NCT03263026|Placebo Comparator|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
11217431|NCT03263013||FMD patients|patients with a diagnosis of clinically definite FMD who have been assessed at the HMCS clinic, and who have completed protocol 07-N-0190.
11217432|NCT03263000||Healthy|24 healthy volunteers (HVs)
11217433|NCT03263000||Patients|24 patients with blepharospasm
11217434|NCT03263000||Patients 2|24 patients with increased blinking alone.
11217435|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
11217436|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
11217437|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
11217438|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
11217439|NCT03262948|Experimental|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
11217440|NCT03262948|Active Comparator|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
11217441|NCT03262935|Experimental|(vic-)trastuzumab duocarmazine|SYD985, every 3 weeks (Q3W)
11217442|NCT03262935|Active Comparator|Physician's choice|"Lap/Cap
~T/Cap
~T/Vino
~T/Eri"
11217443|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
11217444|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
11217445|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
11217446|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:
~Prolonged mechanical ventilation (longer than 96 hours)
~Tracheostomy
~Sepsis
~Serious injury (burn)
~Stroke (hemorhagic or ischemic)
~Traumatic brain injury"
11217447|NCT03262857|Experimental|time of start of anesthesia|
11217448|NCT03262857|Experimental|intensity of anesthesia|
11217449|NCT03262844|Placebo Comparator|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
11217450|NCT03262844|Experimental|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
11217478|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **
~+ 11 weeks of post-TQD varenicline
~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.
~Brief individual counseling at clinic visits"
11217479|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
11217480|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
11217557|NCT03262090|Active Comparator|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
11217451|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga
~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.
~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel
~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
11217452|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
11217453|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery
~Immediately after the transvaginal US, US/PAI imaging will be performed
~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
11217454|NCT03262805|Placebo Comparator|Placebo|Placebo
11217455|NCT03262805|Active Comparator|Active|Lanconone(R)
11217456|NCT03262792|Placebo Comparator|Placebo|Microcrystalline cellulose
11217457|NCT03262792|Active Comparator|ParActin 150|ParActin 150 mg
11217458|NCT03262792|Active Comparator|ParActin 300|ParActin 300 mg
11217459|NCT03262779|Experimental|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks.
11217460|NCT03262766|Active Comparator|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
11217461|NCT03262766|Experimental|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).
~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
11217462|NCT03262766|Active Comparator|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).
~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
11217463|NCT03262766|Sham Comparator|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.
~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
11217464|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
11217465|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
11217466|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
11217467|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
11217468|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
11217469|NCT03262714|Experimental|Dancing|Elderly women randomized to the dance intervention programme.
11217470|NCT03262714|Experimental|Walking|Elderly women randomized to the walking intervention programme.
11217471|NCT03262714|Active Comparator|Stretching|Elderly women randomized to the stretching intervention programme.
11217472|NCT03262701|Experimental|Hydrogen Peroxide gel for 13weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 13 weeks.
11217473|NCT03262701|Experimental|Hydrogen Peroxide gel for 26weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 26 weeks.
11217474|NCT03262701|Other|Scaling and Root Planing|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without any interventional hydrogen peroxide application in one or two visits.
11217475|NCT03262688|Experimental|INL-001|Bupivacaine HCl collagen-matrix implant
11217476|NCT03262688|Active Comparator|Infiltration|Bupivacaine HCl infiltration
11217477|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **
~+ 11 weeks of post-TQD varenicline
~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.
~Brief individual counseling at clinic visits"
11217555|NCT03262090|Active Comparator|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
11217556|NCT03262090|Active Comparator|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
11217481|NCT03262636|Other|Diagnostic value of Second Window ICG|"The primary study objective is to determine the diagnostic value of Second Window ICG (delayed, high dose IV administration of ICG) in the surgical resection of nervous system tumors.
~The first objective is to determine safety/efficacy of high dose, delayed indocyanine green (second window ICG) during surgery of nervous system tumors."
11217482|NCT03262636|Other|Optimal timing and dose of SWG|"The second study objective is to calculate diagnostic test characteristics (sensitivity/specificity) of delayed, high dose indocyanine green (second window ICG) as a diagnostic aid during surgery of nervous system tumors.
~The third study objective is to optimize timing and dose of second window Indocyanine Green during surgery of nervous system tumors, based on sensitivity/specificity."
11217483|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
11217484|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
11217485|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
11217486|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
11217487|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
11217488|NCT03262558||Patients with ECC|No intervention
11217489|NCT03262545|Experimental|experimental group|apatinib 500 mg p.o. once daily
11217490|NCT03262545|Placebo Comparator|control group|placebo p.o. once daily
11217491|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
11217492|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
11217493|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
11217494|NCT03262506|Experimental|Cognitive Training|
11217495|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
11217496|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
11217497|NCT03262480|Active Comparator|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
11217498|NCT03262480|Sham Comparator|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
11217499|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
11217500|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
11217501|NCT03262454|Experimental|Interventions|Atezolizumab
11217502|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
11217503|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
11217504|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
11217505|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
11217506|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
11217507|NCT03262402|Experimental|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
11217508|NCT03262402|Active Comparator|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
11217509|NCT03262389|Experimental|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
11217510|NCT03262376|Experimental|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
11217511|NCT03262376|Experimental|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
11217512|NCT03262376|Experimental|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
11217513|NCT03262376|Placebo Comparator|Placebo|Cellulose crystalline placebo
11217514|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
11217515|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
11217516|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
11217517|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
11217518|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
11217519|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
11217520|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
11217521|NCT03262311|Experimental|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
11217522|NCT03262298|Experimental|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
11217523|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
11217524|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
11217525|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
11217526|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
11217527|NCT03262259|Experimental|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
11217528|NCT03262259|No Intervention|Comparison|Comparison cities receiving no evidence-based interventions.
11217529|NCT03262233|Experimental|Active Deprived|"21 mg nicotine patches and 2 mg nicotine lozenges
~+ First NPU task takes place 24 hours after start of quit attempt"
11217530|NCT03262233|Experimental|Active Non-deprived|"21 mg nicotine patches and 2 mg nicotine lozenges
~+ First NPU task takes place during normal smoking prior to quit attempt"
11217531|NCT03262233|Active Comparator|Placebo Deprived|"Placebo patches and placebo lozenges
~+ First NPU task takes place 24 hours after start of quit attempt"
11217532|NCT03262233|Active Comparator|Placebo Non-deprived|"Placebo patches and placebo lozenges
~+ First NPU task takes place during normal smoking prior to quit attempt"
11217533|NCT03262207||testicular tumours|
11217534|NCT03262207||fertile|
11217535|NCT03262207||infertile|
11217536|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
11217537|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
11217538|NCT03262168|Other|Study Group One|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
11217539|NCT03262168|Other|Study Group Two|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
11217540|NCT03262168|Other|Study Group One - phase 2|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
11217541|NCT03262168|Other|Study Group Two - phase 2|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
11217542|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
11217543|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
11217544|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
11217545|NCT03262142|No Intervention|Antibiotic-free treatment|
11217546|NCT03262116|Experimental|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
11217547|NCT03262116|Experimental|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
11217548|NCT03262116|Experimental|Bionic Pancreas - BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
11217549|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
11217550|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
11217551|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
11217552|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
11217553|NCT03262090|No Intervention|control group|Subjects were randomly assigned to receive saline before skin incision
11217554|NCT03262090|Active Comparator|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
11217806|NCT03260361|Other|usual practice|physiopathology and treatments
11217558|NCT03262090|Active Comparator|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
11217559|NCT03262077|Experimental|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
11217560|NCT03262077|Experimental|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
11217561|NCT03262077|Experimental|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
11217562|NCT03262077|Experimental|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
11217563|NCT03262077|Experimental|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
11217564|NCT03262077|Experimental|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
11217565|NCT03262051||Patient with acute inflammation|patients undergoing hip surgery
11217566|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
11217567|NCT03262038|Experimental|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
11217568|NCT03262038|Placebo Comparator|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
11217569|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
11217570|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
11217571|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
11217572|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
11217573|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
11217574|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
11217575|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
11217576|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
11217577|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.
~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
11217578|NCT03261986|Other|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
11217579|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
11217580|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
11217581|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
11217582|NCT03261947|Experimental|TAK-931|TAK-931 50 milligram (mg), capsules, orally, once daily for 14 days, followed by 7-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 1 year).
11217583|NCT03261921|Active Comparator|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
11217584|NCT03261921|Active Comparator|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
11217585|NCT03261921|Active Comparator|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
11217586|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
11217587|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
11217588|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
11217589|NCT03261895|No Intervention|control group|usual diabetes care
11217590|NCT03261882||Foreign-born Mexican-Americans|
11217591|NCT03261882||US-born Mexican-Americans|
11217592|NCT03261882||non-Hispanic Whites|
11217593|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
11217594|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
11217595|NCT03261856||small intetsinal bacterial overgrowth|Glucose breath test, 75 g glucose in 250 ml water. Breath samples collected at baseline and every 15 min for 2 hours
11217596|NCT03261856||Fructose breath Test|Fructose breath test, 25 g fructose in 250 ml water. Breath samples collected at baseline and every 30 min for 3 hours
11217597|NCT03261856||Lactose Breath test|Lactose breath test, 25 g lactose in 250 ml water. Breath samples collected at baseline and every 30 min for 5 hours
11217598|NCT03261843|Active Comparator|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
11217599|NCT03261843|Active Comparator|posterior lumbar interbody fusion|bone graft alone
11217600|NCT03261830|Active Comparator|Pre-operative Antibiotics|Patients randomized to preoperative antibiotics will receive 25mg/kg cefazolin IV up to 1g or clindamycin 10mg/kg up to 600mg IV in cases of documented allergy to cefazolin.
11217601|NCT03261830|Placebo Comparator|Saline Placebo|Patients randomized to the no-antibiotic group will receive a saline placebo. This placebo will consist of a 10 mL pre-filled syringe of normal saline.
11217602|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
11217603|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
11217604|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
11217605|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
11217606|NCT03261804||Group I:internal vaginal douching users|
11217607|NCT03261804||Group II: none internal vaginal douching users|
11217608|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
11217609|NCT03261778|Experimental|Acromion 2.0 Brace|
11217610|NCT03261778|Active Comparator|Mitella Sling|
11217611|NCT03261765||Multiple repeat cesarean (four or more)|
11217612|NCT03261765||Fewer repeat cesarean (two-three)|
11217613|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
11217614|NCT03261752||healthy people|blood sample will be collected for comparison
11217615|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
11217616|NCT03261739|Placebo Comparator|Placebo|vehicle control
11217617|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
11217618|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
11217619|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
11217620|NCT03261700|Experimental|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
11217621|NCT03261700|Active Comparator|Information and referral condition|This brochure-based intervention includes education about IPV, health effects of IPV, resources and referral options to address a wide-array of health and social issues associated with IPV, and safety planning. Participants randomized to this arm are offered resources and referrals to VA and community resources.
11217622|NCT03261687|Experimental|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
11217623|NCT03261687|Experimental|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
11217624|NCT03261674|Experimental|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBT-I)
11217625|NCT03261674|Experimental|ABTI|Arousal-Based Therapy for Insomnia (ABT-I)
11217626|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
11217627|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
11217628|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
11217629|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
11217630|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
11217631|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
11217632|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
11217633|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
11217634|NCT03261622|Active Comparator|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
11217635|NCT03261622|Sham Comparator|Intervention arm|"Alternation of stimulation amplitude
~Period - Stimulation amplitude 0.05 Volts (lowest possible)
~Period - Stimulation amplitude - 50% of sensory threshold.
~Period - Stimulation amplitude - 90% of sensory threshold."
11217636|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.
~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).
~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
11217637|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.
~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
11217638|NCT03261596|Experimental|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
11217639|NCT03261596|Experimental|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
11217640|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
11217641|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
11217642|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
11217643|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
11217644|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
11217645|NCT03261544||Proximal Femur Replacement|The proximal femur is a common site for primary bone sarcomas and metastatic disease. The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
11217646|NCT03261531|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
11217647|NCT03261505|Experimental|VGAIT|
11217648|NCT03261505|Sham Comparator|VGAIT Control|
11217649|NCT03261505|Active Comparator|Real Acupuncture|
11217650|NCT03261505|Placebo Comparator|Sham Acupuncture|
11217651|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
11217652|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
11217653|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
11217654|NCT03261466|Active Comparator|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
11217655|NCT03261466|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
11217656|NCT03261453|Experimental|Treatment|Patients randomized to treatment will receive the Elipse device.
11217657|NCT03261453|Sham Comparator|Control|Patients randomized to the control arm will receive the sham device.
11217658|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
11217659|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
11217660|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
11217661|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
11217662|NCT03261401|Experimental|Part A: M5717|
11217663|NCT03261401|Placebo Comparator|Part A: Placebo|
11217664|NCT03261401|Experimental|Part B: M5717|
11217665|NCT03261401|Placebo Comparator|Part B: Placebo|
11217666|NCT03261401|Experimental|Part C: M5717|
11217667|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
11217668|NCT03261375|Experimental|Renal denervation (RDN) Group|
11217669|NCT03261375|Sham Comparator|Control Group|
11217670|NCT03261362|Placebo Comparator|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
11217671|NCT03261362|Active Comparator|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
11217672|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
11217673|NCT03261336|Experimental|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
11217674|NCT03261323|Active Comparator|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
11217807|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
11217675|NCT03261323|Experimental|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
11217676|NCT03261310|Experimental|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
11217677|NCT03261310|Placebo Comparator|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
11217678|NCT03261310|Experimental|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
11217679|NCT03261310|Placebo Comparator|Placebo & Laminectomy|Placebo administered during laminectomy.
11217680|NCT03261284|Experimental|DOAC group|Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).
11217681|NCT03261284|Experimental|Higher-INR group|Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.
11217682|NCT03261284|No Intervention|Control group|Patients continue previous strategy without change.
11217683|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
11217684|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
11217685|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
11217686|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
11217687|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
11217688|NCT03261245||Controls|No hypertension disorder during pregnancy
11217689|NCT03261219|Experimental|Intrapulmonary Percussive ventilation|
11217690|NCT03261219|Active Comparator|Chest Physiotherapy vest|
11217691|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
11217692|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
11217693|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
11217694|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
11217695|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
11217696|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
11217697|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
11217698|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
11217699|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
11217700|NCT03261141||study group sixty three children|"severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.
~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).
~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
11217701|NCT03261141||control group sixty three children|"severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.
~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).
~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
11217702|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
11217703|NCT03261115|No Intervention|Control group|Topical Anesthesia
11217704|NCT03261115|Experimental|Study group|No topical anesthesia
11217705|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:
~Week 0: 160 mg SC
~Week 2: 80 mg SC
~Followed by 40 mg SC every 2 weeks' maintenance therapy"
11217706|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:
~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week
~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
11217707|NCT03261076|Experimental|SERIOUS Intervention|All youth will be juveniles in a residential facility for post-adjudicated youth. They will be recruited into the study as they are being placed in the facility post-adjudication, to ensure that they meet criteria and will be in the facility long enough to complete the program. All qualified youth will be invited to participate in the SERIOUS intervention; once a group of youth are recruited to complete the multiple baseline design and interventionists are free (from running interventions with other participants) to work with the youth, an intervention cycle will begin.
11217708|NCT03261063|Experimental|Evera Implanted Group|
11217873|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg|
11217709|NCT03261050||R61 (Phase 1)|In R61, participants are randomly assigned to either the treatment group or the wait-list condition. Participants assigned to the treatment group receive Counter Attitudinal Therapy (CAT). Participants in the treatment group are compared with participants in the wait-list condition. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. Additionally, at pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Electrocardiography (ECG) data will be collected at pre and post.
11217710|NCT03261050||R33 (Phase 2)|In R33, participants from wait-list condition are assigned to receive either Counter Attitudinal Therapy or Interpersonal Therapy. Participants will complete target and outcome measures at pretest and posttest, including a 6-month follow-up, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. At pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Additionally, thin-ideal valuation will be accessed outside the scanner at pre, post and follow-up. Similarly, binge food valuation will be accessed outside the scanner at pre, post, and follow-up and weeks 2, 4, and 6 during treatment for dose-response analysis. Electrocardiography (ECG) data will be collected at pre and post.
11217711|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
11217712|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.
~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.
~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.
~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.
~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
11217713|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.
~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.
~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.
~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
11217714|NCT03261011|Experimental|AK-104|Single-arm
11217715|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
11217716|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
11217717|NCT03260985|Experimental|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
11217718|NCT03260985|No Intervention|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
11217719|NCT03260972|Active Comparator|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
11217720|NCT03260972|Placebo Comparator|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
11217721|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
11217722|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
11217723|NCT03260920|Experimental|Low Dose|
11217724|NCT03260920|Experimental|Medium Dose|
11217725|NCT03260920|Experimental|High Dose|
11217726|NCT03260907|Experimental|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
11217727|NCT03260907|Experimental|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
11217728|NCT03260894|Experimental|Pembrolizumab + Epacadostat|
11217729|NCT03260894|Active Comparator|SoC (Sunitinib or Pazopanib)|Standard of care (SoC) (sunitinib or pazopanib monotherapy).
11217730|NCT03260881|Active Comparator|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
11217731|NCT03260881|Placebo Comparator|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after 12 weeks.
11217874|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo|
11217732|NCT03260868|Experimental|Virtual|Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.
11217733|NCT03260868|Active Comparator|Traditional|Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.
11217734|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
11217735|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
11217736|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
11217737|NCT03260829|Active Comparator|vitamin C injection|orthodontic traction with vitamin C injection
11217738|NCT03260829|Placebo Comparator|orthodontic traction|orthodontic traction without vitamin C injection
11217739|NCT03260816|Experimental|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
11217740|NCT03260816|Active Comparator|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
11217741|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
11217742|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
11217743|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13
11217744|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
11217745|NCT03260777||children with Alopecia Areata|
11217746|NCT03260777||children with tinea capitis|
11217747|NCT03260777||children with trichotillomania|
11217748|NCT03260777||children with tractional alopecia|
11217749|NCT03260764|Experimental|group A|
11217750|NCT03260764|Placebo Comparator|group B|
11217751|NCT03260764|Experimental|group C|
11217752|NCT03260764|Placebo Comparator|group D|
11217753|NCT03260751|Experimental|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
11217754|NCT03260751|Placebo Comparator|Placebo|Placebo for 12 weeks
11217755|NCT03260738|Experimental|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 3 weeks included in a 3hours daily (5 days a week) rehabilitation program.
11217756|NCT03260738|Active Comparator|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 3 weeks
11217757|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
11217758|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
11217759|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
11217760|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
11217761|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
11217762|NCT03260686|Experimental|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
11217763|NCT03260686|No Intervention|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
11217764|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
11217765|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
11217766|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.
~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
11217767|NCT03260621|Other|echocardiographic increase in left atrial pressure|
11217768|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
11217875|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
11218785|NCT03253705||Research Subjects|Research Subjects already enrolled on other NIH protocols
11217769|NCT03260608|Experimental|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
11217770|NCT03260608|No Intervention|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
11217771|NCT03260595|Experimental|Crisaborole ointment 2%|
11217772|NCT03260595|Placebo Comparator|Vehicle|
11217773|NCT03260582|No Intervention|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
11217774|NCT03260582|Experimental|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
11217775|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
11217776|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
11217777|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
11217778|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
11217779|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
11217780|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
11217781|NCT03260517|Experimental|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
11217782|NCT03260504|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
11217783|NCT03260491|Experimental|Dose Escalation: Cohort 1, 3.2 mg/kg|Participants in the Dose Escalation Cohort 1 will receive U3-1402 intravenously (IV) once every three weeks at 3.2 mg/kg.
11217784|NCT03260491|Experimental|Dose Escalation: Cohort 2, 6.4 mg/kg|Participants in Dose Escalation Cohort 2 will receive U3-1402 intravenously (IV) once every three weeks at 6.4 mg/kg.
11217785|NCT03260491|Experimental|Dose Escalation: Cohort 3, 9.6 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 9.6 mg/kg.
11217786|NCT03260491|Experimental|Dose Escalation: Cohort 4, 12.8 mg/kg|Participants in Dose Escalation Cohort 3 will receive U3-1402 intravenously (IV) once every three weeks at 12.8 mg/kg.
11217787|NCT03260491|Experimental|Dose Expansion: Cohort 1, EGFR mutant|Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
11217788|NCT03260491|Experimental|Dose Expansion: Cohort 2, EGFR wild-type|Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE).
11217789|NCT03260491|Experimental|Dose Expansion: Cohort 3a, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive U3-1402 IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
11217790|NCT03260491|Experimental|Dose Expansion: Cohort 3b, EGFR mutant|Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive U3-1402 IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
11217791|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
11217792|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
11217793|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
11217794|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
11217795|NCT03260452|Experimental|Patients|'Abdominal subcutaneous biopsies and Blood test'
11217796|NCT03260439|Other|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
11217797|NCT03260439|Other|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
11217798|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
11217799|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
11217800|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
11217801|NCT03260400|Experimental|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
11217802|NCT03260400|Experimental|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
11217803|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
11217804|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-
~Electric compound action potential
~Electric stapedial reflex threshold
~Electric auditory brain stem response"
11217805|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
11217808|NCT03260322|Experimental|ASP8374|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 (monotherapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 8 dose strengths).
11217809|NCT03260322|Experimental|ASP8374 and pembrolizumab|Participants will be enrolled in the escalation cohorts or expansion cohorts and receive ASP8374 and pembrolizumab (combination therapy) intravenously on Day 1 of every 3-week cycle (up to a maximum of 5 dose strengths of ASP8374 and one fixed dose strength of pembrolizumab).
11217810|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
11217811|NCT03260309|Experimental|control group|Routine infusion therapy tactic
11217812|NCT03260296||University students|university students who use smartphones
11217813|NCT03260283|Experimental|Group I|0.4 mgkg-1 of pethidine hydrochloride
11217814|NCT03260283|Experimental|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
11217815|NCT03260257|Experimental|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
11217816|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
11217817|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
11217818|NCT03260205|Placebo Comparator|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
11217819|NCT03260205|Experimental|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
11217820|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
11217821|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
11217822|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
11217823|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
11217824|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
11217825|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
11217826|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
11217827|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
11217828|NCT03260127|Experimental|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
11217829|NCT03260127|Active Comparator|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
11217830|NCT03260114|No Intervention|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
11217831|NCT03260114|Active Comparator|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
11217832|NCT03260114|Active Comparator|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
11217833|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
11217834|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
11217835|NCT03260075||ward cat|Patients and staff at wards that have a cat present
11217836|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
11217837|NCT03260062|Experimental|PEARLS|Participants in this arm will receive 10 1-hour weekly sessions of the PEARLS intervention
11217838|NCT03260062|Active Comparator|Control|Participants in this arm will receive 10 1-hour weekly sessions of the standard of care LSL Speech Therapy
11217839|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
11217840|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
11217841|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
11217842|NCT03260023|Experimental|TG4001/Avelumab|
11217843|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
11217844|NCT03259997|Active Comparator|Probiotic supplement|
11217845|NCT03259997|Placebo Comparator|Placebo|
11217876|NCT03259763|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
11217915|NCT03259490|Experimental|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
11217846|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
11217847|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
11217848|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
11217849|NCT03259971|Placebo Comparator|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
11217850|NCT03259971|Active Comparator|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
11217851|NCT03259971|Placebo Comparator|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
11217852|NCT03259971|Active Comparator|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
11217853|NCT03259958|Experimental|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
11217854|NCT03259958|Active Comparator|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
11217855|NCT03259932|Other|usual management|
11217856|NCT03259932|Experimental|physical training|
11217857|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
11217858|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
11217859|NCT03259906|Active Comparator|Osteosynthesis using a posterior plate|
11217860|NCT03259906|Active Comparator|Osteosynthesis using an anterior plate|
11217861|NCT03259893|Active Comparator|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
11217862|NCT03259893|Experimental|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
11217863|NCT03259867|Experimental|Hepatocellular carcinoma|"PD-1 inhibitor (either Opdivo 240 mg Q2W IV or Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
11217864|NCT03259867|Experimental|Colorectal cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
11217865|NCT03259867|Experimental|Gastric cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
11217866|NCT03259867|Experimental|NSCLC|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.
~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
11217867|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
11217868|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
11217869|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
11217870|NCT03259828|Experimental|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
11217871|NCT03259815|Experimental|PIOS Intervention Group|"Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is <0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).
~The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result."
11217872|NCT03259815|Active Comparator|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
11217877|NCT03259763|Active Comparator|Enteral Stenting (ES)|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
11217878|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
11217879|NCT03259698|Experimental|ARM 1 = NURSE-LED nPEP, TEXT MESSAGING SUPPORT|"PEP will be delivered by a sexual health clinic nurse operating under a medical directive, and participants will receive weekly text message check-ins and optional automated text appointment reminders via the WelTel system."
11217880|NCT03259698|Experimental|ARM 2 = ID PHYSICIAN-LED nPEP, TEXT MESSAGING SUPPORT|"PEP will be delivered according to the standard of care by an infectious diseases physician, and participants will receive weekly text message check-ins and optional automated text appointment reminders via the WelTel system."
11217881|NCT03259698|Experimental|ARM 3 = NURSE-LED nPEP, NO TEXT MESSAGING SUPPORT|PEP will be delivered by a sexual health clinic nurse operating under a medical directive, and participants will not receive any additional outreach beyond the usual standard of care.
11217882|NCT03259698|Active Comparator|ARM 4 = ID PHYSICIAN-LED nPEP, NO TEXT MESSAGING SUPPORT|PEP will be delivered according to the standard of care by an infectious diseases physician, and participants will not receive any additional outreach beyond the usual standard of care.
11217883|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
11217884|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
11217885|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
11217886|NCT03259672|Active Comparator|Sevoflurane|
11217887|NCT03259672|Experimental|Desflurane|
11217888|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
11217889|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
11217890|NCT03259646|Experimental|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
11217891|NCT03259646|No Intervention|Standard Practice|Standard clinical practice
11217892|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
11217893|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
11217894|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
11217895|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
11217896|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
11217897|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
11217898|NCT03259594|Experimental|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
11217899|NCT03259594|Sham Comparator|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
11217900|NCT03259581|Experimental|Transarterial chemoembolization|Transarterial chemoembolization
11217901|NCT03259568|Active Comparator|Active rTMS|
11217902|NCT03259568|Sham Comparator|Sham rTMS|
11217903|NCT03259555|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
11217904|NCT03259555|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
11217905|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
11217906|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.
~Duration of cycle 28 days"
11217907|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.
~Duration of cycle 28 days"
11217908|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.
~Duration of cycle 28 days"
11217909|NCT03259516|Experimental|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
11217910|NCT03259516|Experimental|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
11217911|NCT03259516|Experimental|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
11217912|NCT03259516|Experimental|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
11217913|NCT03259516|Experimental|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
11217914|NCT03259503|Experimental|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
11217916|NCT03259490|Experimental|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
11217917|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
11217918|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
11217919|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
11217920|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
11217921|NCT03259438|Experimental|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
11217922|NCT03259438|Active Comparator|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
11217923|NCT03259425|Experimental|Nivolumab and HF10, all patients|
11217924|NCT03259412|Experimental|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
11217925|NCT03259412|Placebo Comparator|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
11217926|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
11217927|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
11217928|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
11217929|NCT03259373|Experimental|Early Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
11217930|NCT03259373|Experimental|Delayed Intervention|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
11217931|NCT03259360|Experimental|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
11217932|NCT03259360|Experimental|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
11217933|NCT03259347|Experimental|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
11217934|NCT03259347|Active Comparator|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
11217935|NCT03259334|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligrams (mg) of ontamalimab (SHP647) subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
11217936|NCT03259334|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
11217937|NCT03259334|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
11217938|NCT03259308|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
11217939|NCT03259308|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.
11217940|NCT03259308|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.
11217941|NCT03259295|Experimental|Skin tag removal initial|Removal of skin tags 1 cm or less using Digiclamp
11217942|NCT03259295|Experimental|Skin tag removal follow-up|Follow-up 2-3 months after skin tag removal.
11217943|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
11217944|NCT03259269||Delamanid and companion WHO Group 5 drugs|
11217945|NCT03259256|Experimental|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
11217946|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
11217947|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
11217948|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
11217990|NCT03258879|Experimental|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
11217949|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
11217950|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
11217951|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
11217952|NCT03259217|Experimental|stem cell product|stem cell transplant
11217953|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
11217954|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
11217955|NCT03259191|Other|completely circumferential ARMS|
11217956|NCT03259191|Other|semi-circumferential ARMS|
11217957|NCT03259165|Experimental|Nitrate Intense Strategy|Patients randomized to the Nitrate intense strategy will be treated according to protocol with nitrates in combination with IV loop diuretics. This protocol only involves therapies used in everyday AHF clinical practice.
11217958|NCT03259165|Experimental|Diuretic Intense Strategy|Patients randomized to the Diuretic intense strategy will be treated according to protocol with IV loop diuretics in combination with nitrates. This protocol only involves therapies used in everyday AHF clinical practice.
11217959|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
11217960|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
11217961|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
11217962|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
11217963|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
11217964|NCT03259126|Experimental|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
11217965|NCT03259126|No Intervention|Control|Control Group without the SCUT
11217966|NCT03259113|Other|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
11217967|NCT03259087|Experimental|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
11217968|NCT03259087|Experimental|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
11217969|NCT03259087|Experimental|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
11217970|NCT03259087|Experimental|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
11217971|NCT03259087|Experimental|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
11217972|NCT03259074|Experimental|Secukinumab 150 mg s.c.|Secukinumab 150 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
11217973|NCT03259074|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
11217974|NCT03259074|Experimental|GP2017 (adalimumab biosimilar) 40mg s.c.|GP2017 (adalimumab biosimilar) 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 102
11217975|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
11217976|NCT03259035|Experimental|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
11217977|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
11217978|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
11217979|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
11217980|NCT03258983||The Diet, Cancer and Health cohort|
11217981|NCT03258957|Experimental|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
11217982|NCT03258944|Experimental|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
11217983|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
11217984|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
11217985|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
11217986|NCT03258905|Experimental|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
11217987|NCT03258905|Active Comparator|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
11217988|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
11217989|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
11218129|NCT03257995|Experimental|Sequence 5|B-A-C
11217991|NCT03258879|Active Comparator|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
11217992|NCT03258866|Experimental|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
11217993|NCT03258866|Experimental|group B|In group B, Rituximab was given with a single dose of 375mg/m2
11217994|NCT03258853|Active Comparator|Usual Care|Usual Care diabetes management: Patients will manage their diabetes using standard of care for diabetes as per their typical regimen including use of an insulin pump or injectable insulin. Usual care arm for 7 days. Patients will wear a continuous glucose monitor (CGM) during this arm
11217995|NCT03258853|Experimental|Bi-hormonal bionic pancreas (insulin + glucagon)|Bi-hormonal Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 7 days.
11217996|NCT03258853|Experimental|Insulin only bionic pancreas|Insulin Only Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin only using a continuous glucose monitoring (CGM) device, for 7 days.
11217997|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
11217998|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
11217999|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
11218000|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
11218001|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
11218002|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
11218003|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
11218004|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
11218005|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
11218006|NCT03258775|Active Comparator|250ml|
11218007|NCT03258775|Active Comparator|500ml|
11218008|NCT03258762|Experimental|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
11218009|NCT03258762|Experimental|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
11218010|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
11218011|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
11218012|NCT03258736|Other|Caudal block|Caudal block Marcaine
11218013|NCT03258736|Other|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
11218014|NCT03258723|Experimental|Intervention|Highest risk pre-diabetic patients
11218015|NCT03258723|No Intervention|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
11218016|NCT03258710|Experimental|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
11218017|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
11218018|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
11218019|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
11218020|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
11218021|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
11218022|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
11218023|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
11218130|NCT03257995|Experimental|Sequence 6|C-B-A
11218131|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
11218132|NCT03257969|Experimental|The DROP program|
11218133|NCT03257969|Other|Standard of care|
11218024|NCT03258658|Experimental|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
11218025|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
11218026|NCT03258632|No Intervention|Usual Care|Under usual care, when a patient screens positive on the AUDIT-C administered at intake, a provider (social worker, nurse) provides Brief Intervention (BI), i.e., tells the patient that problems are associated with alcohol use, and about recommended drinking limits; notes the patient as ready to change drinking or not, and as agreeing to treatment or not. If the patient agrees to treatment, specialty addiction services are notified.
11218027|NCT03258632|Experimental|Intervention|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
11218028|NCT03258606||Individuals with affected capacity to consent|Individuals with who were unable to consent and were allowed by protocol to give surrogate consent.
11218029|NCT03258593|Experimental|1/Run In|Durvalumab + Vicinium, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 subjects
11218030|NCT03258593|Experimental|2/Expansion|Durvalumab + Vicinium, at the MTD. Up to 24 subjects
11218031|NCT03258580|Experimental|Substudy 1: All participants|Measuring facial response to painful stimulation.
11218032|NCT03258580|No Intervention|Substudy 2: Healthy volunteers|Measuring pain assessment accuracy
11218033|NCT03258580|No Intervention|Substudy 2: Medical providers|Measuring pain assessment accuracy
11218034|NCT03258580|No Intervention|Substudy 3: Control|Subjects will judge stimuli with the same instructions as Sub-Study 2 (which provides a test of replication).
11218035|NCT03258580|Experimental|Substudy 3: Feedback Group|Subjects will receive feedback about assessment accuracy after every trial.
11218036|NCT03258580|Experimental|Substudy 3: Instructed Group|Subjects will be informed at the beginning of the taskwhich facial regions are the most predictive of pain.
11218037|NCT03258567|Experimental|Nivolumab (A)|Nivolumab, 3mg/kg IV every 2 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment (closed effective with activation of Amendment C)
11218038|NCT03258567|Experimental|Nivolumab (B)|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
11218039|NCT03258554|Active Comparator|Arm I (cetuximab, radiation therapy)|Patients receive cetuximab IV weekly over 60-120 minutes. Treatment repeats every week for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo IMRT 5 fractions per week for up to 7 weeks.
11218040|NCT03258554|Experimental|Arm II (durvalumab, radiation therapy)|Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every 4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.
11218041|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
11218042|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.
~Infants were fed while in their positions via feeding tube."
11218043|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
11218044|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
11218045|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
11218046|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
11218047|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
11218048|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.
~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
11218049|NCT03258502|Experimental|RV521|RV521 drug substance in capsule for oral administration
11218050|NCT03258502|Placebo Comparator|Placebo|Micro-crystalline cellulose in capsule for oral administration
11218051|NCT03258489|Active Comparator|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
11218052|NCT03258489|Active Comparator|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
11218053|NCT03258489|Placebo Comparator|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
11218134|NCT03257956|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11218231|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
11218054|NCT03258476|Experimental|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
11218055|NCT03258476|Active Comparator|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
11218056|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
11218057|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
11218058|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
11218059|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
11218060|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
11218061|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
11218062|NCT03258424|Active Comparator|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
11218063|NCT03258424|Placebo Comparator|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
11218064|NCT03258411|Active Comparator|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
11218065|NCT03258411|Active Comparator|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
11218066|NCT03258411|Active Comparator|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
11218067|NCT03258398|Experimental|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
11218068|NCT03258398|Experimental|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
11218069|NCT03258398|Experimental|Part 2: eFT508 alone|subjects will receive eFT508 alone
11218070|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
11218071|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
11218072|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
11218073|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
11218074|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
11218075|NCT03258346|Experimental|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
11218076|NCT03258346|Placebo Comparator|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
11218077|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
11218078|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
11218079|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
~Procedure: radical prostatectomy surgery."
11218080|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
11218081|NCT03258307|Active Comparator|omentectomy|Preoperative
11218082|NCT03258307|Other|Omentectomy|Postoperative
11218083|NCT03258307|Other|No omentectomy|Preoperative post operative
11218084|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
11218085|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
11218086|NCT03258281|Active Comparator|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
11218087|NCT03258281|Placebo Comparator|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
11218294|NCT03256760|Placebo Comparator|Placebo|Placebo
11218088|NCT03258268|Experimental|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.
~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
11218089|NCT03258268|Active Comparator|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.
~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
11218090|NCT03258255|Active Comparator|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
11218091|NCT03258255|Active Comparator|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
11218092|NCT03258242|Experimental|Experimental: Keluo Xin Capsule|
11218093|NCT03258242|Placebo Comparator|Placebo Comparator: Placebo|
11218094|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
11218095|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
11218096|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
11218097|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
11218098|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
11218099|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
11218100|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
11218101|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
11218102|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
11218103|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
11218104|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
11218105|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
11218106|NCT03258164|Experimental|ASC|
11218107|NCT03258164|Active Comparator|Control|
11218108|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
11218109|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
11218110|NCT03258138|Experimental|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
11218111|NCT03258138|Experimental|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
11218112|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
11218113|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
11218114|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
11218115|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
11218116|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
11218117|NCT03258086|Experimental|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
11218118|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
11218119|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
11218120|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
11218121|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
11218122|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
11218123|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
11218124|NCT03258008|Experimental|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.
~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
11218125|NCT03257995|Experimental|Sequence 1|A-B-C
11218126|NCT03257995|Experimental|Sequence 2|B-C-A
11218127|NCT03257995|Experimental|Sequence 3|C-A-B
11218128|NCT03257995|Experimental|Sequence 4|A-C-B
11218135|NCT03257956|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
11218136|NCT03257943|Experimental|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
11218137|NCT03257943|Active Comparator|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
11218138|NCT03257943|Placebo Comparator|Vehicle of the Test product|One 10 minute application, under at-home use conditions
11218139|NCT03257930|Experimental|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
11218140|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
11218141|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
11218142|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
11218143|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
11218144|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
11218145|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
11218146|NCT03257865|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
11218147|NCT03257865|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind
11218148|NCT03257852|Experimental|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
11218149|NCT03257852|Placebo Comparator|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
11218150|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
11218151|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
11218152|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
11218153|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
11218154|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.
~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
11218155|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.
~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
11218156|NCT03257787|Experimental|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
11218157|NCT03257774|Experimental|Test of three new adhesive strips|"The subjects test three new adhesive strips
~adhesive strip A
~adhesive strip B
~adhesive strip C"
11218158|NCT03257761|Experimental|Treatment (guadecitabine, durvalumab)|Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11218159|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
11218160|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
11218161|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
11218162|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
11218163|NCT03257709|Active Comparator|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
11218164|NCT03257709|Active Comparator|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
11218195|NCT03257462|Experimental|Cohort C|Cohort C will begin enrollment after Cohort B has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
11218196|NCT03257436|Other|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
11218165|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
11218166|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
11218167|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
11218168|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
11218169|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.
~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
11218170|NCT03257644|Experimental|Cohort 1|Ruxolitinib phosphate cream 0.5%.
11218171|NCT03257644|Experimental|Cohort 2|Ruxolitinib phosphate cream 1.5%.
11218172|NCT03257644|Experimental|Cohort 3|Ruxolitinib phosphate cream 0.75%.
11218173|NCT03257644|Experimental|Cohort 4|Ruxolitinib phosphate cream 1.5%.
11218174|NCT03257644|Experimental|Cohort 5|Ruxolitinib phosphate cream 0.75%.
11218175|NCT03257644|Experimental|Cohort 6|Ruxolitinib phosphate cream 1.5%.
11218176|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
11218177|NCT03257618|Experimental|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.
~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
11218178|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
11218179|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
11218180|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
11218181|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
11218182|NCT03257579|Experimental|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
11218183|NCT03257579|Experimental|Education Alone|At St. Joseph's Hospital and Niagara Health System education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
11218184|NCT03257579|No Intervention|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
11218185|NCT03257553|Experimental|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
11218186|NCT03257540||Small Bone Intramedullary Nail|All study participants
11218187|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
11218188|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
11218189|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
11218190|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
11218191|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
11218192|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
11218193|NCT03257462|Experimental|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
11218194|NCT03257462|Experimental|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
11218230|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
11218398|NCT03255993|Experimental|SPH3127 100mg|A single dose of SPH3127 50 mg*2 qd *7 days
11218197|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
11218198|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
11218199|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
11218200|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
11218201|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
11218202|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
11218203|NCT03257397|Experimental|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
11218204|NCT03257397|Active Comparator|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
11218205|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
11218206|NCT03257358|Other|Cohort 1|RMS patients who were newly prescribed commercially available fingolimod 0.5mg per day
11218207|NCT03257358|Other|Cohort 2|RMS patients who had been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
11218208|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
11218209|NCT03257319|Experimental|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
11218210|NCT03257319|Placebo Comparator|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
11218211|NCT03257306|Active Comparator|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
11218212|NCT03257306|Active Comparator|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
11218213|NCT03257293|Active Comparator|Routine Cystoscopy|
11218214|NCT03257293|Experimental|Modified Cystoscopy|
11218215|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
11218216|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
11218217|NCT03257267|Experimental|Experimental Therapy|Cemiplimab
11218218|NCT03257267|Active Comparator|Control Therapy|Investigator choice (IC) chemotherapy
11218219|NCT03257241|Active Comparator|A arm (DA-90)|"Induction I:
~DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion
~Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
11218220|NCT03257241|Active Comparator|B arm (DAC)|"Induction I:
~DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion
~cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C
~Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
11218221|NCT03257241|Active Comparator|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
11218222|NCT03257241|Active Comparator|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
11218223|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
11218224|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
11218225|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
11218226|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
11218227|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
11218228|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
11218229|NCT03257202|No Intervention|Control|No topical treatment
11218232|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
11218233|NCT03257189|Other|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.
~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
11218234|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
11218235|NCT03257163|Experimental|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
11218236|NCT03257150|Experimental|Study Treatment|Single arm trial of irreversible electroporation using the NanoKnife system for locally advanced pancreatic ductal adenocarcinoma.
11218237|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
11218238|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
11218239|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)
~Leptomeningeal metastasis cohort (LM cohort)"
11218240|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
11218241|NCT03257085|Experimental|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
11218242|NCT03257085|Experimental|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
11218243|NCT03257072|Experimental|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
11218244|NCT03257072|Experimental|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
11218245|NCT03257072|Experimental|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
11218246|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
11218247|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
11218248|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
11218249|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
11218250|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
11218251|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
11218252|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
11218253|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
11218254|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
11218255|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
11218256|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
11218257|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
11218258|NCT03257007|No Intervention|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
11218259|NCT03257007|Active Comparator|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
11218260|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.
~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.
~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3."
11218261|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
11218262|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
11218263|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
11218264|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.
~Single injection session, injections into the lips."
11218265|NCT03256942|No Intervention|No Treatment|
11218266|NCT03256929|Experimental|depression participants - intervention|personalized diet intervention based on microbiota analysis and health status
11218267|NCT03256929|Experimental|depression participants - control|General information on nutrition and health
11218268|NCT03256929|Experimental|pre-depression participants - control|General information on nutrition and health for pre-depression participants
11218269|NCT03256929|Experimental|pre-depression participants - intervention|personalized diet intervention based on microbiota analysis and health status for pre-depression participants
11218270|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.
~Then Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
11218271|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).
~In this patient will receive Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
11218272|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
11218273|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
11218274|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
11218275|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
11218276|NCT03256877||All participants|Patients with haematuria.
11218277|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)
~Other Names:
~Prograf
~Advagraf
~Zortress
~Certican"
11218278|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)
~Other Names:
~Prograf
~Advagraf
~Zortress
~Certican"
11218279|NCT03256851|Active Comparator|In-Person Delivered Exercise|"Participants in the in-person training group will:
~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.
~complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
11218280|NCT03256851|Experimental|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:
~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.
~receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
11218281|NCT03256838|Experimental|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
11218282|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
11218283|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
11218284|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
11218285|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
11218286|NCT03256799|Experimental|Ivacaftor/Ataluren|
11218287|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
11218288|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
11218289|NCT03256773||Notmal|No lung Disease
11218290|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
11218291|NCT03256773||PCD|Primary Ciliary Dyskinesia
11218292|NCT03256773||COPD|Chronic Obstructive Lung Disease
11218293|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
11218295|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
11218296|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
11218297|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
11218298|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
11218299|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
11218300|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
11218301|NCT03256695|Experimental|ABS eMDPI|Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.
11218302|NCT03256682|Experimental|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
11218303|NCT03256682|Active Comparator|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
11218304|NCT03256682|No Intervention|Selfcare|Use stress management materials to manage yourself.
11218305|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
11218306|NCT03256656|Experimental|Healthy subjects|
11218307|NCT03256656|Active Comparator|Patients with SCI|
11218308|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
11218309|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
11218310|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
11218311|NCT03256617|Experimental|Provider training|
11218312|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
11218313|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
11218314|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
11218315|NCT03256578|Experimental|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
11218316|NCT03256578|No Intervention|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
11218317|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
11218318|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
11218319|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
11218320|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
11218321|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
11218322|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
11218323|NCT03256526|Placebo Comparator|Placebo|
11218324|NCT03256526|Experimental|PF-06835919 Low Dose|75 mg once daily
11218325|NCT03256526|Experimental|PF-06835919 High Dose|300 mg once daily
11218326|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
11218327|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
11218328|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
11218329|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
11218330|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
11218331|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
11218332|NCT03256461|Experimental|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
11218333|NCT03256461|Experimental|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
11218334|NCT03256461|Placebo Comparator|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
11218335|NCT03256435|Experimental|Treatment Arm|RAMP PrEP initiation, adherence, and retention intervention package as well as standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
11218336|NCT03256435|No Intervention|Control Arm|Standard of care (access to a financial advocate and clinical staff to support, facilitate, and assist in linkage to the established PrEP clinic at Open Arms and to facilitate initiation of, and obtaining, PrEP medications)
11218337|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
11218338|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
11218339|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
11218340|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
11218341|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
11218342|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
11218343|NCT03256383||Adult|Patients aged 18+ years
11218344|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
11218345|NCT03256383||Children <7|Patients aged under 7 years
11218346|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
11218347|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
11218348|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
11218349|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
11218350|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
11218351|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab|Talimogene laherparepvec given by intralesional injection on Day one and every 21 days per protocol for a maximum on 12 cycles. Atezolizumab given by intravenous injection on Day one and every 21 days per protocol
11218352|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
11218353|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
11218354|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
11218355|NCT03256305|Experimental|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
11218356|NCT03256305|Active Comparator|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
11218357|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
11218358|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
11218359|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
11218360|NCT03256266||healthy controls|healthy controls
11218361|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
11218362|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
11218363|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
11218364|NCT03256240|Active Comparator|side-to-side functional end anastomosis|side-to-side functional end anastomosis creation
11218365|NCT03256240|Active Comparator|Kono-S|antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis
11218366|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
11218367|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
11218368|NCT03256214|Experimental|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
11218369|NCT03256214|Active Comparator|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
11218370|NCT03256201|Experimental|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
11218371|NCT03256201|Experimental|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
11218372|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
11218373|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
11218374|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
11218375|NCT03256162|Experimental|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
11218376|NCT03256162|Active Comparator|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
11218377|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
11218378|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
11218379|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
11218380|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
11218381|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
11218382|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
11218383|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
11218384|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
11218385|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
11218386|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
11218387|NCT03256097|Experimental|XDP sound processing strategy|XDP sound processing strategy is cochlear implant sound processing strategy. It is non adaptive and does not alter its functioning according to the listening environment.
11218388|NCT03256097|Experimental|Voice Guard sound processing strategy|Voice Guard sound processing strategy is cochlear implant sound processing strategy. It is adaptive and alters its functioning according to the listening environment.
11218389|NCT03256097|Experimental|Voice Track noise cancellation|Voice Track in a cochlear implant noise cancellation technique
11218390|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).
~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
11218391|NCT03256071|Experimental|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
11218392|NCT03256071|Active Comparator|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
11218393|NCT03256058|Active Comparator|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
11218394|NCT03256058|Placebo Comparator|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
11218395|NCT03256045|Experimental|Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
11218396|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
11218397|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
11218399|NCT03255993|Placebo Comparator|Placebo to SPH3127 100mg|A single dose of placebo matching to SPH3127 50mg*2 qd *7 days
11218400|NCT03255993|Experimental|SPH3127 200mg|A single dose of SPH3127 100 mg*2 qd *7 days
11218401|NCT03255993|Placebo Comparator|Placebo to SPH3127 200mg|A single dose of placebo matching to SPH3127 100mg*2 qd *7 days
11218402|NCT03255993|Experimental|SPH3127 400mg|A single dose of SPH3127 100 mg*4 qd *7 days
11218403|NCT03255993|Placebo Comparator|Placebo to SPH3127 400mg|A single dose of placebo matching to SPH3127 100mg*4 qd *7 days
11218404|NCT03255980|Experimental|Xonrid®|Xonrid® is a medical device for radiation dermatitis
11218405|NCT03255980|Active Comparator|Standard of Care|Standard of care suggested by MASCC guidelines
11218406|NCT03255967|Experimental|QI program care|DSM-H performance improvement program Patients in the performance improvement group will receive care from a care team who has received the DSM-H performance improvement program
11218407|NCT03255967|Active Comparator|Control|provide usual carereceive usual care from a care team who has not received the performance improvement program
11218408|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
11218409|NCT03255941|Active Comparator|Lay provider & DMPA|Lay provider providing DMPA
11218410|NCT03255941|Active Comparator|Lay provider & Sayana Press|Lay Provider providing Sayana Press
11218411|NCT03255941|Active Comparator|Clinic provider & DMPA|Clinic provider providing DMPA
11218412|NCT03255941|Active Comparator|Clinic provider and Sayana Press|Clinic provider providing Sayana Press
11218413|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
11218414|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
11218415|NCT03255915|Experimental|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
11218416|NCT03255915|Experimental|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
11218417|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
11218418|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
11218419|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
11218420|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
11218421|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
11218422|NCT03255863|Other|Questionnaire|Auto and hetero questionnaire
11218423|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
11218424|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
11218425|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
11218426|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
11218427|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
11218428|NCT03255837|Sham Comparator|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
11218429|NCT03255824|Active Comparator|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
11218430|NCT03255824|Experimental|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
11218431|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
11218432|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
11218433|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
11218434|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
11218435|NCT03255759|Active Comparator|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
11218436|NCT03255759|No Intervention|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
11218437|NCT03255746|Experimental|Sleep Enhancement|
11218438|NCT03255746|Placebo Comparator|Health Education|
11218439|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
11218440|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.
~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
11218441|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
11218442|NCT03255707|Experimental|Group A|50 patients will receive the gold standard occlusion therapy
11218443|NCT03255707|Experimental|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
11218444|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
11218445|NCT03255681|Experimental|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
11218446|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
11218447|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
11218448|NCT03255642|Active Comparator|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
11218449|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
11218450|NCT03255629|Experimental|Treatment Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
11218451|NCT03255629|Placebo Comparator|Control Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
11218452|NCT03255616|Experimental|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
11218453|NCT03255616|Experimental|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
11218454|NCT03255603|Experimental|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
11218455|NCT03255603|Experimental|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
11218456|NCT03255603|Experimental|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
11218457|NCT03255603|Placebo Comparator|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
11218458|NCT03255590|Experimental|Real tDCS & Configuration task|Real-stimulation: Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved. Participants will receive REAL anodal tDCS stimulation during the training.
11218459|NCT03255590|Sham Comparator|Sham tDCS & Configuration task|Sham-stimulation: Chronic stroke patients (i.e. great than 6 months) with ischemic stroke confirmed by CT or MRI, residual unilateral upper extremity weakness, able to give informed consent, and able to understand the tasks involved. Participants will receive sham SHAM tDCS stimulation during the training.
11218460|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
11218461|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
11218462|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
11218463|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
11218464|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
11218465|NCT03255525|Active Comparator|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
11218466|NCT03255525|Experimental|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
11218467|NCT03255525|Experimental|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
11218468|NCT03255512|Experimental|Vericiguat + isosorbite mononitrate|Co-administration of vericiguat and isosorbite mononitrate.
11218469|NCT03255512|Placebo Comparator|Placebo + isosorbite mononitrate|Administration of (vericiguat) matching placebo and isosorbite mononitrate.
11218470|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
11218471|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
11218472|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
11218473|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
11218566|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
11218474|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.
~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
11218475|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
11218476|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
11218477|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
11218478|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
11218479|NCT03255447|Experimental|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
11218480|NCT03255434|Active Comparator|Folfox 4|Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²
11218481|NCT03255434|Experimental|Folfox 4 LBM|Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)
11218482|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.
~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
11218483|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
11218484|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
11218485|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
11218486|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
11218487|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
11218488|NCT03255382|Experimental|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
11218489|NCT03255382|Active Comparator|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
11218490|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
11218491|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
11218492|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
11218493|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
11218494|NCT03255343|Experimental|IMDENDRIM|
11218495|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
11218496|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
11218497|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
11218498|NCT03255304|Experimental|health prime|
11218499|NCT03255304|Experimental|palatability prime|
11218500|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
11218501|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
11218527|NCT03255122|Experimental|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
11218528|NCT03255122|Other|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
11218502|NCT03255291|Experimental|Risk Display Format:Table:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
11218503|NCT03255291|Experimental|Risk Display Format:Table: Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
11218504|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
11218505|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.
~Participants take Baseline Survey 1.
~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.
~Participants take Baseline Survey 2.
~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).
~Participants take surveys via text at the end of each week for 4 weeks.
~90 days post-baseline, participants complete a survey sent through the mail.
~Participants may be contacted for another survey 1 year later."
11218506|NCT03255278|Experimental|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
11218507|NCT03255278|Placebo Comparator|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
11218508|NCT03255278|Experimental|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
11218509|NCT03255278|Experimental|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
11218510|NCT03255278|Experimental|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.
~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
11218511|NCT03255265||Acute rejection|
11218512|NCT03255265||No acute rejection|
11218513|NCT03255252|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
11218514|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
11218515|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
11218516|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
11218517|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
11218518|NCT03255213|Experimental|Late Onset Pompe Disease who have tongue weakness|
11218519|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
11218520|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
11218521|NCT03255174|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
11218522|NCT03255161|Experimental|Immediate communication education and support group|
11218523|NCT03255161|No Intervention|Waitlist|
11218524|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
11218525|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
11218526|NCT03255135|Experimental|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
11218529|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
11218530|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
11218531|NCT03255083|Experimental|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 80 mg oral dose of osimertinib
11218532|NCT03255070|Experimental|Phase 1a: Cohort 1|Cohort 1 will administer Dose Level 1 of ARX788 every 4 weeks (Q4W) via intravenous infusion.
11218533|NCT03255070|Experimental|Phase 1a: Cohort 2|Cohort 1 will administer Dose Level 1 of ARX788 every 3 weeks (Q3W) via intravenous infusion.
11218534|NCT03255070|Experimental|Phase 1a: Cohort 3|Cohort 3 will administer Dose Level 2 of ARX788 every 4 weeks (Q4W) via intravenous infusion.
11218535|NCT03255070|Experimental|Phase 1a: Cohort 4|Cohort 4 will administer Dose Level 2 of ARX788 every 3 weeks (Q3W) via intravenous infusion.
11218536|NCT03255070|Experimental|Phase 1a: Cohort 5 Q4W|Cohort 5 will administer Dose Level 3 of ARX788 every 4 weeks (Q4W) via intravenous infusion.
11218537|NCT03255070|Experimental|Phase 1a: Cohort 6 Q4W|Cohort 5 will administer Dose Level 3 of ARX788 every 4 weeks (Q4W) via intravenous infusion.
11218538|NCT03255057|Experimental|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
11218539|NCT03255057|Active Comparator|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
11218540|NCT03255044|Active Comparator|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
11218541|NCT03255044|Active Comparator|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
11218542|NCT03255031|Experimental|Diet Randomization-KD|Diet consists of a ketogenic diet (KD) snacks and shakes 3x p/day (high in fat).
11218543|NCT03255031|Placebo Comparator|Diet Randomization-SA|Standard American (SA) diet consists of shakes 3x p/day in the proportions of carbohydrates, protein and fat of traditional western diet. SA will receive the same KD solid snacks, in order to keep the diets blind to participants.
11218544|NCT03255018|Experimental|1|Subjects with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
11218545|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
11218546|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
11218547|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
11218548|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
11218549|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
11218550|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
11218551|NCT03254979|Experimental|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
11218552|NCT03254979|Active Comparator|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
11218553|NCT03254966|Experimental|SHR0302 dose level 1|
11218554|NCT03254966|Experimental|SHR0302 dose level 2|
11218555|NCT03254966|Experimental|SHR0302 dose level 3|
11218556|NCT03254966|Experimental|SHR0302 dose level 4|
11218557|NCT03254966|Placebo Comparator|Placebo|
11218558|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet
~participants are asked to use the MyFitnessPal app for self-monitoring
~given goal to lose 5% weight by end of intervention (3 months)
~weekly personalized feedback via email
~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email
~weekly action plans via email"
11218559|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months
~participants are asked to use the MyFitnessPal app for self-monitoring
~given goal to lose 5% weight by end of intervention (3 months)
~weekly personalized feedback via email
~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email
~weekly action plans via email"
11218560|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months
~participants are asked to use the MyFitnessPal app for self-monitoring
~given goal to lose 5% weight by end of intervention (3 months)"
11218561|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
11218562|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
11218563|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
11218564|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
11218565|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
11218567|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
11218568|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
11218569|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
11218570|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
11218571|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
11218572|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
11218573|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
11218574|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
11218575|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
11218576|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
11218577|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
11218578|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
11218579|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
11218580|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
11218581|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
11218582|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
11218583|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
11218584|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
11218585|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
11218586|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
11218587|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
11218588|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
11218589|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
11218590|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
11218591|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
11218592|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
11218593|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
11218594|NCT03254914||Control Site|Measure Clinic Blood Pressure
11218595|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
11218596|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
11218597|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
11218598|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
11218599|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
11218634|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
11218670|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
11218600|NCT03254888||Control group|"• 50 (age and sex matched )control
~The followings markers must be estimated :
~Autophagy markers:
~( Atg7) level using (quantitative real time polymerase chain reaction).
~(LC3A)level using immunohistochemistry .
~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)
~Oxidative stress Marker:(MDA)using chemical method
~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
11218601|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
11218602|NCT03254875|No Intervention|Control|Usual care
11218603|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:
~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
11218604|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:
~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
11218605|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
11218606|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
11218607|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.
~Patients will recieve treatment as per standard of care."
11218608|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
11218609|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
11218610|NCT03254810|Experimental|SYN060|a single 0.57 mg/kg dose of SYN060
11218611|NCT03254810|Active Comparator|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
11218612|NCT03254810|Active Comparator|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
11218613|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.
~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
11218614|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.
~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
11218615|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
11218616|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
11218617|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
11218618|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
11218619|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
11218620|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
11218621|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
11218622|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
11218623|NCT03254758|Experimental|Mesenchymal stem cell|Single dose of ADR-001 (Mesenchymal stem cell)
11218624|NCT03254745|Experimental|Pharmacist intervention|"Disease education (General education about rheumatoid arthritis in a verbal and written manner)
~Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)
~Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)
~Advice on medication use (General counseling on medication use as well as patient centered counseling)."
11218625|NCT03254745|No Intervention|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
11218626|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
11218627|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
11218628|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
11218629|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
11218630|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
11218631|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
11218632|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
11218633|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
11218635|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
11218636|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
11218637|NCT03254667||Brodalumad exposed|1500 subjects exposes to brodalumab
11218638|NCT03254667||Comparator Subjects|2000 comparator subjects
11218639|NCT03254654|Experimental|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20
~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
11218640|NCT03254654|Active Comparator|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
11218641|NCT03254641||hypogondal men|men referred for hCG stimulation test
11218642|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
11218643|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
11218644|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
11218645|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
11218646|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
11218647|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
11218648|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
11218649|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
11218650|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
11218651|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
11218652|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
11218653|NCT03254576||Children at high-risk for obesity|Healthy-weight children (30th-75thBMI%) with two overweight/obese parents (BMI>25)
11218654|NCT03254576||Children at low-risk for obesity|Healthy-weight children (30th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
11218655|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
11218656|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
11218657|NCT03254550|No Intervention|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
11218658|NCT03254550|Experimental|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
11218659|NCT03254537|Experimental|Mediterranean Organic|
11218660|NCT03254537|Experimental|Mediterranean conventional|
11218661|NCT03254524||Patients visiting an emergency department in New York State|
11218662|NCT03254511|Experimental|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
11218663|NCT03254511|Active Comparator|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) alone.
11218664|NCT03254498|Active Comparator|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
11218665|NCT03254498|Placebo Comparator|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
11218666|NCT03254485|Experimental|IW-1973 High Dose|
11218667|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
11218668|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
11218669|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
11218671|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
11218672|NCT03254433|Experimental|BAS+|As part of the main study, participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
11218673|NCT03254433|Placebo Comparator|SC|As part of the main study, participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
11218674|NCT03254420|Active Comparator|Image-guided radiation therapy (IGRT) with standard margins|Standard IMRT during 8 weeks
11218675|NCT03254420|Experimental|Calypso tracking system with margin reduction|Standard IMRT during 8 weeks after calypso beacon implant 10 days before
11218676|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
11218677|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.
~FOLFOX:
~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
11218678|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.
~FOLFOX:
~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
11218679|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
11218680|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
11218681|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
11218682|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
11218683|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
11218684|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
11218685|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
11218686|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
11218687|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
11218688|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
11218689|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
11218690|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
11218691|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
11218692|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
11218693|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
11218694|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
11218695|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
11218696|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
11218697|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
11218698|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
11218699|NCT03254277|Experimental|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
11218700|NCT03254277|Experimental|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
11218701|NCT03254277|Experimental|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
11218702|NCT03254277|Experimental|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
11218703|NCT03254277|Experimental|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
11218704|NCT03254277|Experimental|Group 1D|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
11218705|NCT03254277|Experimental|Group 2D|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
11218706|NCT03254277|Experimental|Group 1E|HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
11218707|NCT03254277|Experimental|Group 1F|HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
11218708|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
11218709|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
11218710|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
11218711|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
11218712|NCT03254225|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
11218713|NCT03254225|No Intervention|Control|in this arm, the group will remain sedentary for the same period of the experimental group, and they will be invited to engage on the raining program after the sedentary period
11218714|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
11218715|NCT03254199|Experimental|Experimental|
11218716|NCT03254199|Placebo Comparator|Placebo Comparator|
11218717|NCT03254186|Experimental|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
11218718|NCT03254186|Placebo Comparator|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
11218719|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
11218720|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
11218721|NCT03254160|Experimental|DNS-3379 (0.5mg)|
11218722|NCT03254160|Experimental|DNS-3379 (2.5mg)|
11218723|NCT03254160|Placebo Comparator|Placebo|
11218724|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
11218725|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
11218726|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
11218727|NCT03254108|Experimental|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
11218728|NCT03254108|Experimental|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
11218729|NCT03254108|Experimental|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
11218730|NCT03254108|Experimental|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
11218731|NCT03254108|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
11218732|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
11218733|NCT03254082|Experimental|Sumac|Sumac sorghum flour
11218734|NCT03254082|Experimental|Wheat|Wheat flour
11218735|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
11218736|NCT03254082|Active Comparator|Sucrose|Table sugar
11218737|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
11218738|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
11218739|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
11218740|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
11218741|NCT03254043|Active Comparator|Treatment-as-Usual|Participants will routine methadone clinic care.
11218742|NCT03254043|Experimental|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
11218743|NCT03254043|Other|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
11218744|NCT03254030|Placebo Comparator|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
11218745|NCT03254030|Active Comparator|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
11218746|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
11218747|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
11218748|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
11218749|NCT03253978|Experimental|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
11218750|NCT03253978|Active Comparator|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
11218751|NCT03253965|Experimental|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
11218752|NCT03253965|Experimental|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
11218753|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
11218754|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
11218755|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
11218756|NCT03253939||Control group|Cytoreductive surgery alone
11218757|NCT03253926|Experimental|Lorcaserin + Marijuana|
11218758|NCT03253926|Placebo Comparator|Placebo + Marijuana|
11218759|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.
~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
11218760|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
11218761|NCT03253887|Experimental|Ethanol-lock therapy (ELT) Group|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
11218762|NCT03253887|No Intervention|Control Group|This group did not receive the ethanol-lock, being only followed daily and treated according to the standard protocol in operation at this healthcare unit.
11218763|NCT03253874|Experimental|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
11218764|NCT03253874|No Intervention|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
11218765|NCT03253861||control patients|patients without an infected pancreatic necrosis
11218766|NCT03253861||Case patients|patients with an infected pancreatic necrosis
11218767|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
11218768|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
11218769|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
11218770|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.
~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
11218771|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
11218772|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
11218773|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.
~ECG signals will be saved digitally for analysis"
11218774|NCT03253796|Experimental|Open-label (OL) GLM SC QM ---> PBO SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with placebo (PBO) SC QM
11218775|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with double-blinded (DB) GLM SC QM
11218776|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC Q2M|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with DB GLM SC Q2M
11218777|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
11218778|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
11218779|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.
~Intervention : paper cognitive aid in the hand of the leader during crises management."
11218780|NCT03253744|Experimental|1/Tumor Irradiation|SBRT will be delivered to areas of recurrent prostatecancer identified on imaging and biopsy
11218781|NCT03253744|Experimental|2/Prostate and Tumor Irradiation|SBRT will be delivered to areas of recurrent prostatecancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
11218782|NCT03253731||Healthy Volunteers|15 healthy volunteers
11218783|NCT03253718||Healthy Volunteers|Healthy Volunteers between 18 and 68 years of age
11218784|NCT03253705||Controls|Healthy Controls
11218786|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
11218787|NCT03253679|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11218788|NCT03253666||Nurses' Health Study|"See Detailed Description"
11218789|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
11218790|NCT03253653|Experimental|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
11218791|NCT03253653|No Intervention|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
11218792|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
11218793|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
11218794|NCT03253627|Experimental|MBSR|Mindfulness-Based Stress Reduction
11218795|NCT03253627|Active Comparator|HEP|Health Enhancement Program
11218796|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
11218797|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
11218798|NCT03253601|Experimental|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
11218799|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
11218800|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced
~2nd line metastatic/locally advanced"
11218801|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
11218802|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
11218803|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
11218804|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
11218805|NCT03253562|No Intervention|Healthy control|healthy volunteers not suffering from diabetes or hypertension
11218806|NCT03253562|No Intervention|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
11218807|NCT03253562|Other|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
11218808|NCT03253562|Other|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
11218809|NCT03253549|Experimental|SMArTVIEW|
11218810|NCT03253549|No Intervention|Standard Care|
11218811|NCT03253536||entire cohort|none (observational study)
11218812|NCT03253523|No Intervention|Continued maximal medical management|
11218813|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
11218814|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
11218815|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
11218816|NCT03253497|Active Comparator|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
11218817|NCT03253497|No Intervention|Control|before 15 minute normal salin will be administrated to oropharynx
11218818|NCT03253484|Experimental|NAFL-treated wounds|NAFL treated wounds
11218819|NCT03253484|No Intervention|Control|untreated control wound
11218820|NCT03253471|Experimental|AL-611|
11218821|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
11218822|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
11218823|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
11218824|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
11218825|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
11218826|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
11218827|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
11218828|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
11218829|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
11218830|NCT03253419|Other|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
11218831|NCT03253406|Experimental|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
11218832|NCT03253406|Active Comparator|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
11218833|NCT03253393|Experimental|Smart Touch Technology Contact Lens|
11218834|NCT03253393|Active Comparator|Contact Lens in Conventional Packaging|
11218835|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
11218836|NCT03253367||Current/former clozapine users|This group has only one visit.
11218837|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
11218838|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
11218839|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
11218840|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
11218841|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
11218842|NCT03253341|Experimental|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
11218843|NCT03253341|Active Comparator|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
11218844|NCT03253328|Active Comparator|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
11218845|NCT03253328|Placebo Comparator|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
11218846|NCT03253289|Experimental|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
11218847|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
11218848|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
11218849|NCT03253263|Experimental|SHP607 250 mcg/kg/24 hours|Participants will receive continuous intravenous (IV) infusion of SHP607 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) from birth up to postmenstrual age (PMA) 29 weeks +6 days.
11218850|NCT03253263|Experimental|SHP607 400 mcg/kg/24 hours|Participants will receive continuous IV infusion of SHP607 400 mcg/kg/24 hours through from birth up to PMA 29 weeks +6 days.
11218851|NCT03253263|No Intervention|Standard Neonatal Care|Standard neonatal care alone will be provided.
11218852|NCT03253250|Active Comparator|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
11218853|NCT03253250|Experimental|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\TDF\ADV) for 96 weeks.
11218854|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
11218855|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
11218856|NCT03253211||State|North Carolina
11218857|NCT03253211||SCD Patients|
11218858|NCT03253211||Providers|Primary care and emergency department clinicians
11218859|NCT03253211||Year|Baseline, year 2, year 3
11218860|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
11218861|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
11218862|NCT03253185|Experimental|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
11218863|NCT03253172|Placebo Comparator|Placebo|Placebo
11218864|NCT03253172|Experimental|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
11218865|NCT03253172|Experimental|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
11218866|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
11218867|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
11218868|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.
~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.
~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.
~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
11218869|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
11218902|NCT03252938|Experimental|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
11218903|NCT03252938|Experimental|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
11218870|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:
~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.
~Intravenous chemotherapy protocol:
~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
11218871|NCT03253120|Other|Patient|Patients will drink 5dl of water.
11218872|NCT03253120|Other|Healthy volunteer|Healthy volunteers will drink 5dl of water.
11218873|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
11218874|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
11218875|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
11218876|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
11218877|NCT03253094|Active Comparator|Fluconazole|150 mg/day for 1 day
11218878|NCT03253094|Experimental|SCY-078|5 different active dosing groups with 2 different treatment regiments of either 1 or 3 days
11218879|NCT03253081|Active Comparator|PARENT focused intervention|The PF condition will consist of a 90-minute parent group session twice per week. The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent.
11218880|NCT03253081|Active Comparator|CHILD focused intervention|In the CF condition both parent and child will attend the 90-minute session twice weekly. The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist.
11218881|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
11218882|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
11218883|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
11218884|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
11218885|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
11218886|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
11218887|NCT03253029|Experimental|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
11218888|NCT03253029|Placebo Comparator|Control|(arm 2): control group (no BCAAs provided)
11218889|NCT03253016|Experimental|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
11218890|NCT03253016|Experimental|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
11218891|NCT03253016|No Intervention|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
11218892|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
11218893|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
11218894|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
11218895|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
11218896|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
11218897|NCT03252964|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
11218898|NCT03252951|Experimental|Eccentric Training|
11218899|NCT03252951|Experimental|Concentric Training|
11218900|NCT03252951|Experimental|Isometric Training|
11218901|NCT03252951|Active Comparator|Biofeedback|
11218904|NCT03252938|Experimental|Solid tumors + chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
11218905|NCT03252938|Experimental|Solid tumors + Avelumab/IMP321 therapy|"Avelumab and IMP321 as follows:
~800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles [48 weeks])
~6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles [24 weeks])"
11218906|NCT03252925|Experimental|Experimental Group|N-Acetylcysteine
11218907|NCT03252925|Placebo Comparator|Control Group|Placebo Oral Tablet
11218908|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
11218909|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
11218910|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
11218911|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
11218912|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
11218913|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
11218914|NCT03252847|Experimental|Low dose AAV2/5-RPGR|Single, subretinal administration of low dose AAV2/5-RPGR
11218915|NCT03252847|Experimental|Intermediate dose AAV2/5-RPGR|Single, subretinal administration of intermediate dose AAV2/5-RPGR
11218916|NCT03252847|Experimental|High dose AAV2/5-RPGR|Single, subretinal administration of high dose AAV2/5-RPGR
11218917|NCT03252834||Patients with endometrial or ovarian cancer|
11218918|NCT03252834||Patients with colorectal cancer|
11218919|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
11218920|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
11218921|NCT03252821|No Intervention|Control group|Usual care
11218922|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
11218923|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
11218924|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
11218925|NCT03252795|Experimental|Uterus transplantation|
11218926|NCT03252782|Active Comparator|Functional Treatment|Acrylic Splint Herbst Appliance
11218927|NCT03252782|Active Comparator|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
11218928|NCT03252769|Other|Self-sampling|Invitation to self-sample
11218929|NCT03252756|Placebo Comparator|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
11218930|NCT03252756|Experimental|Phytocannabinoid cannabidiol (CBD)|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
11218931|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
11218932|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
11218933|NCT03252717|Experimental|blood sample|Pre-treatment blood samples will be collected: 8 samples
11218934|NCT03252704|Experimental|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
11218935|NCT03252704|Experimental|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
11218936|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
11218937|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
11218938|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
11218939|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
11218940|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
11218941|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
11218942|NCT03252626|Active Comparator|Alprostadil|Based on the standard medical care, 2ml of Alprostadil
11218943|NCT03252626|Placebo Comparator|Normal saline|Based on the standard medical care, 2ml of 0.9% saline as the placebo
11218944|NCT03252600|Experimental|Arm I (lenalidomide, dexamethasone, elotuzumab)|"Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
11218945|NCT03252600|Experimental|Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)|"Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
11218946|NCT03252587|Experimental|BMS-986165 Dose 1 oral administration|
11218947|NCT03252587|Experimental|BMS-986165 Dose 2 oral administration|
11218948|NCT03252587|Experimental|BMS-986165 Dose 3 oral administration|
11218949|NCT03252587|Placebo Comparator|Placebo oral administration|
11218950|NCT03252574|Other|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
11218951|NCT03252574|Other|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
11218952|NCT03252561|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
11218953|NCT03252561|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
11218954|NCT03252535|Experimental|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
11218955|NCT03252535|Experimental|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
11218956|NCT03252535|Placebo Comparator|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
11218957|NCT03252522|Experimental|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
11218958|NCT03252522|Placebo Comparator|Placebo|Capsules of inactive placebo.
11218959|NCT03252522|Experimental|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
11218960|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
11218961|NCT03252496|Experimental|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
11218962|NCT03252496|Active Comparator|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
11218963|NCT03252483|Active Comparator|HIV Only|Those randomized to the control group were offered only an HIV test.
11218964|NCT03252483|Experimental|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
11218965|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
11218966|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
11218967|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
11218968|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
11218969|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
11218970|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
11218971|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
11218972|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
11218973|NCT03252418|Experimental|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
11218974|NCT03252418|Experimental|diode laser|photothermolysis by diode laser in one session
11218975|NCT03252405|Active Comparator|mask ventilation|induction is made with mask ventilation
11218976|NCT03252405|Experimental|intravenous induction|induction is made with intravenous cannulation
11218977|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
11218978|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
11218979|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
11218980|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
11218981|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
11218982|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.
~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
11218983|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
11218984|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
11218985|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
11218986|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
11218987|NCT03252327|No Intervention|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
11218988|NCT03252327|Experimental|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
11218989|NCT03252327|Experimental|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
11218990|NCT03252327|Experimental|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
11218991|NCT03252314||Subjects with ruptured aneurysms|
11218992|NCT03252288|No Intervention|No intervention|No intervention
11218993|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
11218994|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
11218995|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
11218996|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
11218997|NCT03252262|Active Comparator|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
11218998|NCT03252262|Active Comparator|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
11218999|NCT03252262|Active Comparator|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
11219000|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy is the intervention.
11219001|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy is the intervention.
11219002|NCT03252236|Experimental|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
11219003|NCT03252236|Active Comparator|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
11219004|NCT03252236|No Intervention|Control|No training was given to the subjects in this group
11219005|NCT03252223|Active Comparator|Women with normal menses|
11219006|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
11219007|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.
~Post Hoc Multiple Comparisons"
11219008|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
11219009|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
11219010|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G1)|Low level laser therapy with energy dose of 18J will be applied on left brachial artery of the subject.
11219011|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G2)|Low level laser therapy with energy dose of 36J will be applied on left brachial artery of the subject.
11219012|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G3)|Low level laser therapy with energy dose of 54J will be applied on left brachial artery of the subject.
11219013|NCT03252184|Placebo Comparator|Phase 1 - Placebo low level laser therapy - 1 (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
11219014|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
11219061|NCT03251872|Experimental|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
11219015|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
11219016|NCT03252184|Placebo Comparator|Phase 2 - Placebo low level laser therapy - 2 (G3)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
11219017|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
11219018|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3(G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
11219019|NCT03252171|Experimental|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
11219020|NCT03252171|No Intervention|No Intervention|
11219021|NCT03252158|Experimental|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods
~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
11219022|NCT03252158|Experimental|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods
~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
11219023|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
11219024|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
11219025|NCT03252132|Active Comparator|12-week resistance training|
11219026|NCT03252132|No Intervention|No training|
11219027|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
11219028|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
11219029|NCT03252106|Experimental|Contour augmentation|
11219030|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
11219031|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
11219032|NCT03252080|Active Comparator|Education (Group A)|short-intensive education for one month
11219033|NCT03252080|Experimental|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
11219034|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
11219035|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
11219036|NCT03252015|Experimental|Probe Drug Cocktail (Cohort 1a)|Probe Drug Cocktail administered orally on Day -3.
11219037|NCT03252015|Experimental|200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)|200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
11219038|NCT03252015|Placebo Comparator|Placebo+Probe Drug Cocktail (Cohort 1b)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
11219039|NCT03252015|Experimental|400 mg Lasmiditan (Cohort 2a)|400 mg lasmiditan administered orally for 7 days.
11219040|NCT03252015|Experimental|Placebo (Cohort 2b)|Placebo administered orally for 7 days.
11219041|NCT03252002|Experimental|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
11219042|NCT03252002|Experimental|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
11219043|NCT03252002|Experimental|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
11219044|NCT03252002|Experimental|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
11219045|NCT03252002|Experimental|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
11219046|NCT03252002|Experimental|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
11219047|NCT03251989||1/Patient with a rare CNS diagnosis|A diagnosis of rare CNS Tumors
11219048|NCT03251976|Experimental|Intervention|video decision aid
11219049|NCT03251976|Active Comparator|Usual care|
11219050|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
11219051|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
11219052|NCT03251950|Experimental|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
11219053|NCT03251950|Other|Control group|Wait list control -- to receive intervention after serving as wait list group
11219054|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
11219055|NCT03251924|Experimental|BMS-986226|administered intravenously
11219056|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
11219057|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
11219058|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
11219059|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
11219060|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
11219062|NCT03251859|Active Comparator|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
11219063|NCT03251859|Experimental|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
11219064|NCT03251833||obese|Body mass index >30 Kilogram/m2
11219065|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
11219066|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
11219067|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
11219068|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
11219069|NCT03251781|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation
11219070|NCT03251768|Experimental|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
11219071|NCT03251768|Active Comparator|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
11219072|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
11219073|NCT03251755|No Intervention|Control|Usually clinical practice
11219074|NCT03251742|Active Comparator|Fontan patient population|
11219075|NCT03251742|Sham Comparator|Healthy volunteers|
11219076|NCT03251729|Experimental|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
11219077|NCT03251729|Other|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
11219078|NCT03251716|Experimental|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
11219079|NCT03251690|Experimental|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
11219080|NCT03251690|Active Comparator|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
11219081|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
11219082|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
11219083|NCT03251664||Anemic|Hemoglobin <11 g/l
11219084|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
11219085|NCT03251651|Experimental|PPF|Patient who received propofol during the operation
11219086|NCT03251651|Experimental|DEX|Patient who received dexmedetomidine during the operation
11219087|NCT03251625|Placebo Comparator|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
11219088|NCT03251625|Placebo Comparator|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
11219089|NCT03251612|Other|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
11219090|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
11219091|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
11219092|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219093|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219094|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219095|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219096|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219097|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219098|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219099|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
11219100|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
11219101|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
11219102|NCT03251560|Experimental|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
11219103|NCT03251560|Placebo Comparator|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
11219104|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
11219105|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
11219106|NCT03251508|Experimental|Peanut OIT/food equivalent|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months followed by an equivalent amount of peanut food for an additional 6 months.
11219107|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
11219108|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
11219109|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
11219110|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
11219111|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
11219112|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
11219113|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
11219114|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
11219115|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
11219116|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
11219117|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
11219118|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
11219119|NCT03251469|Active Comparator|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
11219120|NCT03251469|Placebo Comparator|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
11219121|NCT03251456|Experimental|Tertiary care|
11219122|NCT03251456|Active Comparator|Usual care|
11219123|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
11219124|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
11219125|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
11219126|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
11219127|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
11219128|NCT03251404|Active Comparator|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
11219129|NCT03251404|Experimental|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
11219130|NCT03251391|Experimental|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
11219131|NCT03251391|Active Comparator|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
11219132|NCT03251378|Experimental|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
11219133|NCT03251378|Experimental|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
11219134|NCT03251378|Experimental|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
11219135|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort B|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
11219136|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort C|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
11219137|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort D|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
11219138|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort E|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
11219139|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
11219140|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
11219141|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
11219142|NCT03251339|Experimental|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
11219143|NCT03251339|Experimental|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
11219144|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
11219145|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
11219146|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
11219147|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
11219148|NCT03251313|Experimental|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
11219149|NCT03251313|Experimental|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
11219150|NCT03251313|Experimental|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
11219151|NCT03251313|Experimental|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
11219152|NCT03251300|Experimental|group A|daytime dosing of mirabegron
11219153|NCT03251300|Active Comparator|group B|nighttime dosing of mirabegron
11219154|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
11219155|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
11219156|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
11219157|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
11219158|NCT03251261||Specimen collection|
11219159|NCT03251248|Experimental|First MSB11455 Then Neulasta|
11219160|NCT03251248|Experimental|First Neulasta Then MSB11455|
11219161|NCT03251235|Experimental|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
11219162|NCT03251235|No Intervention|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
11219163|NCT03251222|Experimental|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
11219164|NCT03251222|Placebo Comparator|Placebo Concentrate|Patients will recive 0.9% NaCl
11219165|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
11219269|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
11219166|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
11219167|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
11219168|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
11219169|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
11219170|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
11219171|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
11219172|NCT03251170|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
11219173|NCT03251170|Active Comparator|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
11219174|NCT03251144|Experimental|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be
~If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.
~If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
11219175|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
11219176|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
11219177|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
11219178|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
11219179|NCT03251092|Active Comparator|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
11219180|NCT03251092|Placebo Comparator|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
11219181|NCT03251092|Active Comparator|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
11219182|NCT03251092|Placebo Comparator|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
11219183|NCT03251092|Active Comparator|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
11219184|NCT03251092|Placebo Comparator|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
11219185|NCT03251092|Experimental|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
11219186|NCT03251092|Placebo Comparator|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
11219187|NCT03251092|Experimental|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
11219188|NCT03251092|Active Comparator|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
11219189|NCT03251092|Active Comparator|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
11219190|NCT03251092|Placebo Comparator|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
11219191|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428|In cohorts 3 & 4 subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
11219192|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
11219193|NCT03251092|Placebo Comparator|Part 4 CF PTI-808 placebo + PTI-801 placebo + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
11219194|NCT03251066|Other|Test group|Proponent Nasal Spray Medical device
11219195|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
11219196|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
11219197|NCT03251040|Other|Fibrin sealant|Single arm pilot study
11219198|NCT03251027|Experimental|Intensity-Modulated Radiation Therapy|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
11219199|NCT03251014|Experimental|YSS/salmon group|YSS followed by salmon
11219200|NCT03251014|Experimental|Salmon/YSS group|Salmon followed by YSS
11219201|NCT03251001|Active Comparator|Control|Sites receiving a free gingival graft
11219202|NCT03251001|Experimental|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
11219203|NCT03250975|Experimental|Medical Therapy|medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days
11219204|NCT03250975|Placebo Comparator|Placebo Control|Placebo control medication for 14 days
11219205|NCT03250962|Experimental|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
11219206|NCT03250962|Experimental|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
11219207|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
11219208|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
11219209|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
11219210|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
11219211|NCT03250923|Experimental|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
11219212|NCT03250910|Experimental|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
11219213|NCT03250910|Experimental|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
11219214|NCT03250910|Active Comparator|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
11219215|NCT03250910|Active Comparator|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
11219216|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
11219217|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.
~It is divided into three phases:
~induction: attention of the patient fixed on an object or a part of the body,
~the dissociation where the patient cuts off auditory, visual and tactile perceptions,
~and finally the opening towards a hypnotic experience thanks to the imaginary."
11219218|NCT03250858|Placebo Comparator|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.
~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
11219219|NCT03250858|Experimental|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
11219220|NCT03250832|Experimental|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams [mg], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
11219221|NCT03250832|Experimental|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
11219222|NCT03250832|Experimental|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
11219223|NCT03250832|Experimental|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
11219224|NCT03250832|Experimental|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care [SOC]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
11219225|NCT03250832|Experimental|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
11219226|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
11219227|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
11219228|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
11219229|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
11219230|NCT03250780|Experimental|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
11219231|NCT03250767||Integra Titan Modular Shoulder System 2.5|
11219232|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
11219233|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
11219234|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
11219235|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
11219236|NCT03250728|Other|CDG with stroke-like history|
11219237|NCT03250728|Other|CDG without stroke-like history|
11219238|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
11219239|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
11219240|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
11219241|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
11219242|NCT03250676|Experimental|H3B-6545 Arm 1: Dose escalation|
11219243|NCT03250676|Experimental|H3B-6545 Arm 2: Phase 2|
11219244|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
11219245|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
11219246|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
11219247|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
11219248|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
11219249|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
11219250|NCT03250624|Experimental|CD5024 0.3% cream|Active drug
11219251|NCT03250624|Experimental|CD5024 cream placebo|Placebo of active drug
11219252|NCT03250611|Experimental|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
11219253|NCT03250598|Experimental|Cohort A|
11219254|NCT03250598|Experimental|Cohort B|
11219255|NCT03250598|Experimental|Cohort C|
11219256|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
11219257|NCT03250572||control group|
11219258|NCT03250572||NAFLD patients without hepatic fibrosis|
11219259|NCT03250572||NAFLD patients with hepatic fibrosis|
11219260|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.
~Intervention: percutaneous nephrolithotomy."
11219261|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.
~Intervention: percutaneous nephrolithotomy."
11219262|NCT03250546|Experimental|Haplo-identical group|
11219263|NCT03250546|Active Comparator|HLA-9/10 MMUD group|
11219264|NCT03250533|Experimental|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
11219265|NCT03250533|Experimental|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
11219266|NCT03250533|Experimental|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
11219267|NCT03250533|No Intervention|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
11219268|NCT03250520|Experimental|glioma brain stem|
11219270|NCT03250507|Active Comparator|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
11219271|NCT03250507|Active Comparator|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.
~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
11219272|NCT03250507|Experimental|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.
~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
11219273|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
11219274|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
11219275|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
11219276|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
11219277|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
11219278|NCT03250468|Experimental|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
11219279|NCT03250468|No Intervention|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
11219280|NCT03250455||CTA+CTP|
11219281|NCT03250455||CTA only|
11219282|NCT03250442|Other|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
11219283|NCT03250442|Active Comparator|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
11219284|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
11219285|NCT03250403|Experimental|PRP injection|
11219286|NCT03250403|Active Comparator|medical treatment|
11219287|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
11219288|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
11219289|NCT03250377|Experimental|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
11219290|NCT03250364|Experimental|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure (Emulsified Latex FoamTM 8mm, Thuasne, France); and the third layer of inelastic bandages (6, 8 and/or 10 cm Rosidal K Short Stretch Bandage, Germany). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
11219291|NCT03250364|Experimental|Simplified multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm Bande coton Short Stretch; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
11219292|NCT03250364|Experimental|Cohesive bandage group|Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject.
11219293|NCT03250364|Experimental|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
11219294|NCT03250364|Experimental|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
11219327|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
11219328|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
11219329|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
11219295|NCT03250351|Experimental|Neurodynamic group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
11219296|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program consisting of physical therapy aimed at reducing postoperative edema, treatment of the scar, the muscle pain and / or joint and recovery and integration of the upper limb functional motor patterns plus instructions with printed material about lymphatic system, lymphedema, pain, movement & pain; etc…. (educational strategy). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
11219297|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
11219298|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
11219299|NCT03250325|Experimental|Split dose of 5x10^9 TBI-1301|Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
11219300|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
11219301|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.
~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
11219302|NCT03250299|Experimental|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
11219303|NCT03250299|Experimental|Expansion Cohort|BAL101553 at the MTD / highest dose considered safe (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
11219304|NCT03250286|Experimental|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
11219305|NCT03250286|Active Comparator|ERCP group|ERCP without EUS is performed in all patients.
11219306|NCT03250273|Experimental|Arm A - Cholangiocarcinoma|
11219307|NCT03250273|Experimental|ARM B - Pancreatic Cancer|
11219308|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
11219309|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
11219310|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
11219311|NCT03250247|Experimental|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.
~Subjects randomized to EVT will receive the following:
~imaging-guided iliac vein stent placement, and
~endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.
~optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
11219312|NCT03250247|No Intervention|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
11219313|NCT03250234|Other|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
11219314|NCT03250234|Other|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
11219315|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
11219316|NCT03250208|Placebo Comparator|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
11219317|NCT03250208|Experimental|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
11219318|NCT03250195|Other|PET/MRI|All participants will have a PET/MRI performed
11219319|NCT03250182|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
11219320|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
11219321|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
11219322|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
11219323|NCT03250143|Active Comparator|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
11219324|NCT03250143|Active Comparator|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
11219325|NCT03250130|Experimental|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
11219326|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
11219330|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
11219331|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
11219332|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
11219333|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
11219334|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
11219335|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
11219336|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
11219337|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
11219338|NCT03250065|Experimental|ETT Study Group|The Sensing ET Tube study Group
11219339|NCT03250052|Experimental|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
11219340|NCT03250052|Experimental|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
11219341|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
11219342|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
11219343|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
11219344|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
11219345|NCT03250013|Experimental|Children and adolescents with ADHD|Children and adolescents medicating for ADHD of any subtype (presentation) with comorbidities
11219346|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
11219347|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
11219348|NCT03249987|Other|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
11219349|NCT03249987|Other|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
11219350|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
11219351|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
11219352|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
11219353|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
11219354|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
11219355|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
11219356|NCT03249935|Experimental|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
11219357|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
11219358|NCT03249909|Other|Exufiber Ag +|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
11219359|NCT03249909|Other|Exufiber|Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
11219360|NCT03249909|Other|Aquacel® Ag Extra|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
11219361|NCT03249896|Experimental|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
11219362|NCT03249896|No Intervention|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.
~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
11219789|NCT03247101|Active Comparator|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
11219363|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
11219364|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
11219365|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
11219366|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
11219367|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
11219368|NCT03249844|Experimental|experimental group|Children will be treated by methylprednisolone + prednisolone and standard of care
11219369|NCT03249844|No Intervention|control group|Children will be treated by standard of care alone
11219370|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.
~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.
~The minimally manipulated transplant product is manufactured using the CliniMACS device."
11219371|NCT03249818|Other|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
11219372|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
11219373|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
11219374|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
11219375|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
11219376|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
11219377|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
11219378|NCT03249779|Experimental|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
11219379|NCT03249753|Experimental|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
11219380|NCT03249753|Experimental|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
11219381|NCT03249740|Experimental|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
11219382|NCT03249740|Experimental|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
11219383|NCT03249740|Active Comparator|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
11219384|NCT03249714|Experimental|Ofatumumab arm|Ofatumumab 20 mg subcutaneous injections every 4 weeks for 24 weeks
11219385|NCT03249714|Placebo Comparator|Placebo arm|Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks
11219386|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
11219387|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
11219388|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
11219389|NCT03249688|Other|Control|Regular health advice
11219390|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
11219391|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
11219392|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
11219393|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:
~Acute: within 2 weeks of injury
~PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
11219394|NCT03249662|Experimental|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
11219395|NCT03249662|Active Comparator|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
11219396|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
11219397|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
11219398|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
11219399|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
11219400|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
11219401|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
11219402|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
11219403|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
11219404|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
11219405|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
11219406|NCT03249597||2. Control|Adult (>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
11219407|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
11219408|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
11219409|NCT03249571|Placebo Comparator|Placebo|Placebo
11219410|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
11219411|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
11219412|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
11219413|NCT03249532|Active Comparator|standard hemodialysis|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
11219414|NCT03249532|Active Comparator|cool hemodialysis|prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
11219415|NCT03249532|Active Comparator|low volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
11219416|NCT03249532|Active Comparator|high volume hemodiafiltration|prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
11219417|NCT03249519|Experimental|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m^2 (6 cycles) Hyperthermia: 10 times
11219418|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
11219419|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs >= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
11219420|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
11219421|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
11219422|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
11219423|NCT03249454|Experimental|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219887|NCT03246360|Experimental|continuous administration of cloxacillin|
11219424|NCT03249454|Experimental|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219425|NCT03249454|Experimental|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219426|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219427|NCT03249454|Experimental|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219428|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219429|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219430|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219431|NCT03249454|Experimental|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219432|NCT03249454|Experimental|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219433|NCT03249454|Experimental|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
11219434|NCT03249441|Experimental|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
11219435|NCT03249441|No Intervention|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
11219436|NCT03249428|Active Comparator|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
11219437|NCT03249428|Active Comparator|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
11219438|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
11219439|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
11219440|NCT03249376|Experimental|Lumateperone|Lumateperone (ITI-007 60 mg) administered once daily every evening for 6 weeks
11219441|NCT03249376|Placebo Comparator|Placebo|Placebo administered once daily every evening for 6 weeks
11219442|NCT03249363|Experimental|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
11219443|NCT03249363|Active Comparator|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
11219444|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
11219445|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
11219446|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
11219447|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
11219448|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
11219449|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
11219450|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
11219451|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
11219452|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
11219453|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids
~Bolus of 250 ml crystaloids will be infused regarding the measures"
11219454|NCT03249298|Active Comparator|Colloids|"Bolus of colloids
~Bolus of 250 ml colloids will be infused regarding the measures"
11219455|NCT03249285|Experimental|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
11219456|NCT03249285|Experimental|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
11219457|NCT03249285|Active Comparator|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
11219458|NCT03249285|Active Comparator|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
11219459|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
11219460|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
11219461|NCT03249272|Active Comparator|Control|
11219462|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
11219463|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
11219464|NCT03249246||Infection only|The patients have only infection
11219465|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
11219466|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
11219467|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
11219468|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
11219469|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
11219470|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
11219471|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
11219472|NCT03249220|Experimental|CBMS|
11219473|NCT03249207|Active Comparator|IL-1Ra twice daily|
11219474|NCT03249207|Placebo Comparator|Placebo twice daily|
11219475|NCT03249194|Experimental|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.
~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
11219476|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.
~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
11219477|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
11219478|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
11219479|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
11219480|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
11219481|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
11219482|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
11219483|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
11219484|NCT03249116|Active Comparator|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
11219485|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
11219486|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
11219487|NCT03249103|Placebo Comparator|Placebo|Up to 24 subjects will receive Placebo, NYX-2925 Low Dose, and NYX-2925 High Dose
11219488|NCT03249103|Experimental|NYX-2925 High Dose|Up to 24 subjects will receive High Dose of NYX-2925
11219489|NCT03249103|Experimental|NYX-2925 Low Dose|Up to 24 subjects will receive Low Dose of NYX-2925
11219490|NCT03249090|Experimental|Patient Self-Reporting of Symptoms|Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
11219491|NCT03249090|Active Comparator|Usual Care Delivery|Evidence-based symptom management pathways provided to patients and clinicians
11219492|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
11219493|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
11219494|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
11219495|NCT03249064||Vitiligo untreated patients|
11219496|NCT03249064||Control. Patients without vitiligo|
11219497|NCT03249051|Experimental|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
11219498|NCT03249051|No Intervention|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
11219499|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
11219500|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
11219501|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
11219502|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
11219503|NCT03248960|Experimental|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:
~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
11219504|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
11219505|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
11219506|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
11219507|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
11219508|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
11219509|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
11219510|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
11219511|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
11219512|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
11219513|NCT03248895|Active Comparator|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
11219514|NCT03248895|Active Comparator|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
11219515|NCT03248882|Placebo Comparator|Placebo|Double-Blind, PF-05221304-matching Placebo
11219516|NCT03248882|Active Comparator|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
11219517|NCT03248882|Active Comparator|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
11219518|NCT03248882|Active Comparator|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
11219519|NCT03248882|Active Comparator|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
11219520|NCT03248869|Active Comparator|Current Daily Survey|need description
11219521|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
11219522|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
11219523|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
11219524|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
11219525|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
11219526|NCT03248843|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
11219888|NCT03246347|Experimental|Single Arm|Docetaxel + Enzalutamide + Androgen Deprivation Therapy
11219527|NCT03248817|Experimental|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
11219528|NCT03248817|Active Comparator|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
11219529|NCT03248817|Active Comparator|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
11219530|NCT03248804|Experimental|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
11219531|NCT03248804|Other|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
11219532|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
11219533|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
11219534|NCT03248778|Experimental|disclosure-support counseling|
11219535|NCT03248778|No Intervention|Treatment as Usual|
11219536|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
11219537|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
11219538|NCT03248752|Active Comparator|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
11219539|NCT03248752|Experimental|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
11219540|NCT03248739|Active Comparator|Clear Bactiseal 'large' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
11219541|NCT03248739|Active Comparator|Orange Bactiseal 'small' catheter (EVD)|All EVDs will be placed by neurological surgeons in either the major operating suite or in an ICU setting using a previously published protocol. This protocol includes using a burr hole entry point 1 cm anterior to the coronal suture in the mid-pupillary line, prep and sterile drape, pre-procedural antibiotic administration, and tunneling the catheter to an exit site at least 5 cm from the incision. In general, physicians are instructed to first attempt distal irrigation of the drainage chamber using sterile techniques (rarely effective), followed by gentle aspiration of the proximal system and catheter if distal flushing is not effective. If these do not restore patency, a small volume of sterile saline, 3 ml or less, is flushed proximally into the catheter. Patency is checked by lowering the EVD drainage system and evaluating for spontaneous flow through the EVD.
11219542|NCT03248726|Experimental|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
11219543|NCT03248726|Active Comparator|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
11219544|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
11219545|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
11219546|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
11219547|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
11219548|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
11219549|NCT03248661|Experimental|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
11219550|NCT03248661|No Intervention|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
11219551|NCT03248648|Active Comparator|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
11219552|NCT03248648|Active Comparator|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
11219553|NCT03248635||Focus group|Male and female adults age 40-75
11219554|NCT03248622||Anti-HBc positive|Anti-HBc positive
11219555|NCT03248622||HCV positive Cohort|HCV positive Cohort
11219556|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
11219557|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
11220599|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
11219558|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
11219559|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
11219560|NCT03248583|Experimental|Default|
11219561|NCT03248583|Active Comparator|Psychoeducation|
11219562|NCT03248583|Active Comparator|Incentive|
11219563|NCT03248570|Experimental|DNA damage repair proficient group|Twenty-five subjects with mismatch repair (MMR) intact
11219564|NCT03248570|Experimental|DNA damage repair defective group|Twenty-five subjects with defective DNA repair
11219565|NCT03248557||Study|Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.
11219566|NCT03248557||Control|Patients who are conscious (GCS=15) and whose neurological status is known and good at admission.
11219567|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
11219568|NCT03248544|Other|control|Control patients will not be received any intervention
11219569|NCT03248531|Experimental|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
11219570|NCT03248531|Active Comparator|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
11219571|NCT03248531|Placebo Comparator|Placebo|Subjects will receive several placebo applications to keep the blinding.
11219572|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
11219573|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
11219574|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
11219575|NCT03248505|Placebo Comparator|Placebo TENS|TENS unit turned on, but with zero amplitude.
11219576|NCT03248505|Experimental|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
11219577|NCT03248505|Experimental|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
11219578|NCT03248505|Experimental|Cryotherapy|1,5 Kg crushed ice pack
11219579|NCT03248505|Experimental|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
11219580|NCT03248505|Experimental|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
11219581|NCT03248492|Experimental|DS-8201a Low Dose|T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
11219582|NCT03248492|Experimental|DS-8201a Medium Dose|T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
11219583|NCT03248492|Experimental|DS-8201a High Dose|T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
11219584|NCT03248492|Other|Exploratory Arm|In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
11219585|NCT03248479|Experimental|R/R Safety Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; and 30 mg/kg weekly thereafter starting Cycle 3 up to end of the study.
11219586|NCT03248479|Experimental|R/R Expansion Cohort:|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1 Week 1 (Day 1 and Day 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Days 11 and 15; 30 mg/kg weekly on Cycle 1 Day 22 through end of Cycle 2, then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
11219587|NCT03248479|Experimental|R/R MDS Magrolimab Monotherapy Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, weekly on Cycle 2, and then biweekly starting Cycle 3 up to end of the study.
11219588|NCT03248479|Experimental|Treatment-naive Unfit (TNU) Dose Evaluation Cohort|Participants will receive 1 mg/kg magrolimab on Cycle 1 (Days 1, 4); 15 mg/kg on Cycle 1 Day 8; 30 mg/kg on Cycle 1 Day 11, 15, 22, and then weekly starting Cycle 2 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
11219589|NCT03248479|Experimental|Treatment-naive Unfit (TNU) Dose Expansion Cohort|Participants will receive 1 mg/kg magrolimab twice weekly for Cycle 1; 15 mg/kg weekly for Cycle 1 Day 8; 30 mg/kg weekly through end of cycle 2; and then 30 mg/kg every 2 weeks starting Cycle 3 up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 7 of each cycle.
11219590|NCT03248479|Experimental|RBC transfusion-dependent low-risk MDS, Safety Run-in Phase|Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 weeks starting on Cycle 2 Day 1 and thereafter up to end of the study. For participants who do not respond after Cycle 2, azacitidine 75 mg/m^2 may be added on subsequent cycles (ie starting at Cycle 3) on Days 1 to 5 of each cycle.
11219591|NCT03248479|Experimental|RBC transfusion-dependent low-risk MDS, Expansion Phase|"Participants will receive 1 mg/kg magrolimab on Cycle 1 Day 1; at 30 mg/kg on Cycle 1 Days 8, 15, and 22; and 60 mg/kg every 4 starting on Cycle 2 Day 1 and thereafter up to end of the study + azacitidine 75 mg/m^2 on Days 1 to 5 of each cycle.
~Based on Clinical Trial Steering Committee (CTSC) evaluation of the safety cohort, the expansion cohort may be treated with magrolimab monotherapy or magrolimab+azacitidine and the magrolimab 60 mg/kg may be changed to a lower dosing regimen along with a change in dose interval."
11219891|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
11219592|NCT03248479|Experimental|Rollover|Participants on a previous AML Phase 1 trial (SCI-CD47-002; NCT02678338) with clinical benefit on magrolimab treatment will receive the same dose level (0.1 mg/kg up to 30.0mg/kg based on the cohort to which the participant was assigned) twice weekly or may transition to once weekly dosing at the discretion of the Investigator and approval from Gilead.
11219593|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
11219594|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
11219595|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
11219596|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
11219597|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
11219598|NCT03248440|Experimental|SUN-131 1.5% TDS|
11219599|NCT03248440|Placebo Comparator|Placebo TDS|
11219600|NCT03248427|Experimental|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
11219601|NCT03248427|Other|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
11219602|NCT03248414|Experimental|Lactobacillus sakei|2 packs per day
11219603|NCT03248414|Placebo Comparator|Control|2 packs per day
11219604|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
11219605|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
11219606|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
11219607|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
11219608|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
11219609|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
11219610|NCT03248349||1|Pharmacokinetics
11219611|NCT03248336|Experimental|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
11219612|NCT03248323||pre-con|
11219613|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
11219614|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
11219615|NCT03248297|Experimental|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
11219616|NCT03248297|Experimental|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
11219617|NCT03248297|Placebo Comparator|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
11219618|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
11219619|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
11219620|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
11219621|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
11219622|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
11219623|NCT03248193|Experimental|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
11219624|NCT03248193|Experimental|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
11219625|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce < 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
11219626|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
11219627|NCT03248167|Experimental|Cannabidiol (CBD 600 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
11219628|NCT03248167|Placebo Comparator|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
11219629|NCT03248154|No Intervention|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
11219630|NCT03248154|Experimental|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn >=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
11219631|NCT03248154|No Intervention|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
11219632|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
11219633|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
11219634|NCT03248128|Experimental|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
11219635|NCT03248128|Active Comparator|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
11219636|NCT03248128|Experimental|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
11219637|NCT03248128|Active Comparator|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
11219638|NCT03248102|Experimental|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A&E
11219639|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
11219640|NCT03248063|Active Comparator|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion.
11219641|NCT03248063|Experimental|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
11219642|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
11219643|NCT03248050|No Intervention|Control pharmacy|
11219644|NCT03248037|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
11219645|NCT03248037|Placebo Comparator|Placebo|Placebo eye drop, dosed topically once a day for 9 months
11219646|NCT03248011|Experimental|Flexibility|Stretching exercise
11219647|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
11219648|NCT03248011|Experimental|Neuromuscular|Balance exercise
11219649|NCT03248011|No Intervention|Control|No exercise
11219650|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.
~See Detailed Description for additional details and description of follow-up procedures."
11219651|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.
~See Detailed Description for additional details and description of follow-up procedures."
11219652|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
11219653|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
11219654|NCT03247972||Patients with PAD|
11219655|NCT03247959|Experimental|Group A|Group A: Videogame distraction during extraction procedure
11219656|NCT03247959|Experimental|Group B|Group B: Video distraction during extraction procedure
11219657|NCT03247959|Active Comparator|Group C|group C: Verbatim during extraction procedure
11219658|NCT03247946|Active Comparator|Intervention group|intervention: upright head position
11219659|NCT03247946|No Intervention|Control group|no feeding position instructions
11219694|NCT03247712|Experimental|Treatment Cohort 2|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
11219695|NCT03247712|Experimental|Treatment Cohort 3|Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
11219660|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).
~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.
~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
11219661|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.
~Clinical practice."
11219662|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.
~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
11219663|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
11219664|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
11219665|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
11219666|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
11219667|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
11219668|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
11219669|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
11219670|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
11219671|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
11219672|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
11219673|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
11219674|NCT03247881|Active Comparator|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
11219675|NCT03247868|Experimental|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
11219676|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
11219677|NCT03247842|Active Comparator|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
11219678|NCT03247842|Active Comparator|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
11219679|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
11219680|NCT03247803|Experimental|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
11219681|NCT03247803|Experimental|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
11219682|NCT03247790|Experimental|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
11219683|NCT03247790|Experimental|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
11219684|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
11219685|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
11219686|NCT03247764||patients with epilepsy and depression|Patients with comorbidity of epilepsy and depression will be asked to use antidepressants such as selective serotonin reuptake inhibitor(SSRIs) or xylaria nigripes and followed up
11219687|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
11219688|NCT03247738|Experimental|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
11219689|NCT03247738|Placebo Comparator|Placebo|Normal saline bolus and infusion for 2 hours
11219690|NCT03247725|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
11219691|NCT03247725|Experimental|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
11219692|NCT03247725|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
11219693|NCT03247712|Experimental|Treatment Cohort 1|Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
11219696|NCT03247712|Experimental|Treatment Cohort 4|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
11219697|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
11219698|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
11219699|NCT03247686|Placebo Comparator|Placebo|Placebo
11219700|NCT03247686|Active Comparator|RSLV-132|Experimental drug
11219701|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
11219702|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
11219703|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
11219704|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
11219705|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.
~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
11219706|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
11219707|NCT03247647|Experimental|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
11219708|NCT03247647|Placebo Comparator|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
11219709|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
11219710|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
11219711|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
11219712|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
11219713|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
11219714|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
11219715|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
11219716|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
11219717|NCT03247569||Edoxaban|Patients treated with Edoxaban
11219718|NCT03247556|Placebo Comparator|Placebo|Placebo qd
11219719|NCT03247556|Experimental|400mg SPN-812 ER|400mg SPN-812 ER qd
11219720|NCT03247556|Experimental|600mg SPN-812 ER|600mg SPN-812 ER qd
11219721|NCT03247543|Placebo Comparator|Placebo|Placebo qd
11219722|NCT03247543|Active Comparator|200mg SPN-812 ER|200mg SPN-812 ER qd
11219723|NCT03247543|Active Comparator|400mg SPN-812 ER|400mg SPN-812 ER qd
11219724|NCT03247530|Placebo Comparator|Placebo|Placebo qd, oral capsule
11219725|NCT03247530|Experimental|100mg SPN-812 ER|SPN-812 ER Low Dose A, oral capsule
11219726|NCT03247530|Experimental|200mg SPN-812 ER|SPN-812 ER Low Dose B, oral capsule
11219727|NCT03247517|Placebo Comparator|Placebo|Placebo qd
11219728|NCT03247517|Experimental|200mg SPN-812 ER|200mg SPN-812 ER qd
11219729|NCT03247517|Experimental|400mg SPN-812 ER|400mg SPN-812 ER qd
11219730|NCT03247491|Experimental|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
11219731|NCT03247491|No Intervention|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
11219732|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
11219733|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
11219734|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
11219735|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.
~2 liters of polyethylene glycol plus ascorbic acid will be administered"
11219736|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.
~2 liters of polyethylene glycol plus ascorbic acid will be administered"
11219737|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
11219738|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
11219739|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
11219740|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
11219741|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
11219742|NCT03247400|Active Comparator|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
11219743|NCT03247400|Active Comparator|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
11219744|NCT03247400|Placebo Comparator|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
11219745|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
11219746|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
11219747|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise
~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.
~Exercise: see group Combined aerobic/resistance exercise"
11219748|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise
~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.
~Exercise: see group Combined aerobic/resistance exercise"
11219749|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise
~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
11219750|NCT03247322|Experimental|Intervention Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
11219751|NCT03247322|No Intervention|Control Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
11219752|NCT03247309|Experimental|IMA201 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~One dose of IMA201 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.
~Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2"
11219753|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
11219754|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
11219755|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
11219756|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
11219757|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
11219758|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
11219759|NCT03247257|Active Comparator|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
11219760|NCT03247257|Active Comparator|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
11219761|NCT03247244|Other|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
11219762|NCT03247244|Other|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
11219763|NCT03247244|Other|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
11219764|NCT03247244|Other|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
11219765|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).
~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.
~The study drug will be taken once a day per os, during one year."
11219766|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
11219767|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.
~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
11219768|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.
~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
11219769|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.
~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
11219770|NCT03247179|Experimental|PTSD Coach Condition|PTSD Coach App
11219771|NCT03247179|No Intervention|Treatment as Usual Condition|Treatment as Usual
11219772|NCT03247166|Experimental|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
11219773|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
11219774|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
11219775|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
11219776|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
11219777|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
11219778|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
11219779|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
11219780|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
11219781|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
11219782|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
11219783|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
11219784|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
11219785|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
11219786|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
11219787|NCT03247101|Experimental|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
11219788|NCT03247101|Active Comparator|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
11219892|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
11219790|NCT03247088|Experimental|Treatment (sorafenib, busulfan, fludarabine, HSCT)|"PRE-STEM CELL INFUSION: Patients receive sorafenib orally PO QD or BID on days -24 to -5, busulfan IV over 3 hours on days -20 and -13 and -6 and -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.
~STEM CELL INFUSION: Patients receive allogeneic HSCT IV in the absence of disease progression or unacceptable toxicity.
~POST-STEM CELL INFUSION: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus PO BID beginning day 5 for about 50 days, filgrastim SC on day 7 and sorafenib PO BID beginning between days +30 and +120 for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with matched unrelated donor receive mycophenolate mofetil PO TID or IV over 2 hours TID beginning on day 5 for up to 90 days for longer."
11219791|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
11219792|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
11219793|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.
~The entire ICU population will be observed before and after intervention."
11219794|NCT03247023||Integra Cadence Total Ankle System|
11219795|NCT03246997|Other|Autumn Group|Intervention Group
11219796|NCT03246997|Other|Spring Group|Delayed Intervention
11219797|NCT03246984|Experimental|VasQ device implantation|
11219798|NCT03246971|Experimental|Wafermine™|
11219799|NCT03246971|Placebo Comparator|Placebo|
11219800|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
11219801|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
11219802|NCT03246945|Experimental|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
11219803|NCT03246945|No Intervention|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
11219804|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
11219805|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
11219806|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
11219807|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
11219808|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
11219809|NCT03246906|Experimental|Arm I (mycophenolate mofetil, cyclosporine, sirolimus)|Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.
11219810|NCT03246906|Experimental|Arm II (cyclosporine, sirolimus, cyclophosphamide)|Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.
11219811|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
11219812|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
11219813|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
11219814|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
11219815|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
11219816|NCT03246867|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
11219817|NCT03246867|Experimental|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
11219818|NCT03246867|Active Comparator|Control group|The participants in this group will receive no stretching. They will only be evaluated.
11219819|NCT03246854|Experimental|DBPR112|
11219820|NCT03246841|Other|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
11219821|NCT03246828|Experimental|Omission of gliclazide|
11219822|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
11219823|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
11220944|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
11219824|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
11219825|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
11219826|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
11219827|NCT03246776|Experimental|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
11219828|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
11219829|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
11219830|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
11219831|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
11219832|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
11219833|NCT03246737||pregnant women|
11219834|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:
~• Cataracts
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
11219835|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:
~Pars plana vitrectomy
~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
11219836|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:
~Descemet Stripping Endothelial Keratoplasty (DSEK)
~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)
~Descemet Membrane Endothelial Keratoplasty (DMEK)
~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)
~Conjunctival and/or corneal lesion excisions
~Pterygium
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
11219889|NCT03246334||Cohort|Case group: critically ill patients admitted >12 hours to the ICU. Control group: critically ill patients to the ICU <12 hrs, or to Post Anaesthesia Care Unit (PACU), or Medium Care or High Dependency Unit.
11219890|NCT03246321|Experimental|repetitive ePIPAC-OX|
11219837|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:
~Ahmed valve
~Ahmed valve with cataracts
~Trabeculectomy
~Trabeculectomy with cataracts
~Baerveldt
~Baerveldt with cataracts
~Endocyclophotocoagulation
~Endocyclophotocoagulation with cataracts
~Istent
~Cataracts with istent
~Kahook
~Cataracts with kahook
~Cypass
~Cypass with cataracts
~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:
~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo
~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
11219838|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
11219839|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
11219840|NCT03246711||Non fasting|women who did not fast at all
11219841|NCT03246698|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
11219842|NCT03246698|Experimental|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.
~Additionally they will receive standard physiotherapy."
11219843|NCT03246698|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
11219844|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
11219845|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
11219846|NCT03246672|Experimental|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
11219847|NCT03246659|Experimental|arm 1|111In-CP04
11219848|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
11219849|NCT03246646|Experimental|Coaching|Telephone coaching along with web-based CRAFT course
11219850|NCT03246633|Other|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
11219851|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
11219852|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
11219853|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
11219854|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
11219855|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.
~Placement of oesophageal probe for temperature measurement"
11219856|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.
~Intervention: Power limitation of RF generator"
11219857|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
11219858|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
11219859|NCT03246568|Active Comparator|Pulmonary vein isolation alone|PVI by cryo-balloon ablation without linear ablation
11219860|NCT03246568|Experimental|Renal nerve denervation|PVI by cryo-balloon ablation without linear ablation plus bilateral RND using a multi-electrode renal denervation catheter.
11219861|NCT03246555|Experimental|Fimasartan or Fimasartan/Hydrochlorothiazide|
11219862|NCT03246555|Active Comparator|Perindopril or Perindopril/Indapamide|
11219863|NCT03246529|Experimental|BL-8040 1.25mg/kg + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
11219864|NCT03246529|Active Comparator|Placebo + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
11219865|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
11219866|NCT03246490|Other|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
11219867|NCT03246464|Placebo Comparator|Single-vision spectacles|
11219868|NCT03246464|Active Comparator|Orthokeratology lenses|
11219869|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
11219870|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
11219871|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
11219872|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
11219873|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
11219874|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
11219875|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
11219876|NCT03246425|Active Comparator|1. Volume control- Pressure control- APRV- VPA group|
11219877|NCT03246425|Active Comparator|2. Pressure control- APRV- Volume control- PAV group|
11219878|NCT03246425|Active Comparator|3. APRV- Volume control- pressure control- AVP group|
11219879|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
11219880|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
11219881|NCT03246399|Experimental|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
11219882|NCT03246399|Experimental|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
11219883|NCT03246399|Experimental|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
11219884|NCT03246386|Experimental|Obese subjects|Subjects with a BMI>35 kg/m2
11219885|NCT03246386|Active Comparator|Non-obese subjects|Subjects with a BMI>18.5 and <25 kg/m2
11219886|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
11219893|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.
~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
11219894|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
11219895|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
11219896|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
11219897|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
11219898|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
11219899|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
11219900|NCT03246243||Preterm infants|Group A will consist of preterm infants born < 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
11219901|NCT03246243||Term infants with HIE or at risk of brain injury|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia who are at risk of HIE; admitted with concern for neonatal stroke; seizures of unknown etiology; and those admitted who are at risk of abnormal neurodevelopment such as those with hypoglycemia or NAS. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
11219902|NCT03246243||Term infants healthy at birth|Group C will consist of healthy term infants from the community and term infants admitted to who had an initial uncomplicated postnatal course that will serve as the control group. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
11219903|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
11219904|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
11219905|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
11219906|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
11219907|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
11219908|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
11219909|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
11219910|NCT03246178|Other|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
11219911|NCT03246178|Experimental|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
11219912|NCT03246152|Experimental|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
11219913|NCT03246139|Experimental|Action observation, imagery & execution|
11219914|NCT03246139|Active Comparator|Action observation|
11219915|NCT03246139|Active Comparator|Control treatment|
11220175|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
11219916|NCT03246126|Experimental|Valiant™Thoracoabdominal Stent Graft System|The implantation of the Valiant™ Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance
11219917|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
11219918|NCT03246100|No Intervention|Control|These patients will receive no reminders from the health department and will receive usual care.
11219919|NCT03246100|Experimental|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
11219920|NCT03246100|Experimental|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
11219921|NCT03246087|Active Comparator|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
11219922|NCT03246087|Experimental|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
11219923|NCT03246087|Experimental|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
11219924|NCT03246074|Experimental|Fostamatinib and Paclitaxel|Participants will receive paclitaxel on Days 1, 8 and 15 of each cycle and fostamatinib at a fixed oral dose twice daily throughout each 28-day cycle. The dose of fostamatinib will be determined by the enrollment dose level. Given the mTPI design, dose-escalation decisions will be made based on the three dosing intervals, where the underdosing interval corresponds to dose escalation (E), overdosing interval corresponds to dose de-escalation (D), and proper dosing corresponds to staying at the current dose (S). The initial dose level will be Level 1 of Table 1. Participants will be individually continually assessed for DLT. The associated dose-escalation decisions are presented in Table 2. For illustration, suppose a cohort of 3 patients is at the current dose.
11219925|NCT03246061|Experimental|RF Ablation|RF ablation with non-surgical management therapies
11219926|NCT03246061|Active Comparator|Control|Continue with non-surgical management therapies
11219927|NCT03246035|Active Comparator|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
11219928|NCT03246035|Experimental|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
11219929|NCT03246022||Group l|SBP index was less than 30% of AHI
11219930|NCT03246022||Group 2|SBP index was less than 60% but more than 30%
11219931|NCT03246009|Experimental|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
11219932|NCT03246009|Experimental|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
11219933|NCT03246009|Experimental|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
11219934|NCT03246009|Experimental|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
11219935|NCT03246009|Experimental|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
11219936|NCT03246009|Experimental|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
11219937|NCT03245996|Experimental|Subjects|Subjects with a cardiac pacemaker
11219938|NCT03245983|Experimental|Patient willing to participate|
11219939|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.
~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
11219940|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
11219941|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
11219942|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
11219943|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
11219944|NCT03245944|Active Comparator|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
11219945|NCT03245944|Experimental|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
11219946|NCT03245918|Other|Aprepitant Capsule Study Period #1|
11219947|NCT03245918|Other|Aprepitant Oral Suspension Study Period#1|
11219948|NCT03245905|Experimental|Chidamide|
11219949|NCT03245892|Experimental|Carboplatin and Paclitaxel Chemotherapy With Nivolumab|Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
11219950|NCT03245892|Experimental|Nivolumab plus Ipilimumab plus Paclitaxel & Carboplatin|Patients will be treated with nivolumab plus ipilimumab plus standard of care dose dense paclitaxel & carboplatin chemotherapy for 3 cycles (up to a maximum of six), each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen. Paclitaxel 80mg/m2 IV will be administered over approx 1 hour on Days 1,8, & 15 of each 21 day cycle. Carboplatin AUC6 will be administered as an approx 30 minute IV infusion, following paclitaxel admin on Day 1 of each 21 day cycle. Nivolumab 360mg will be infused IV over approx 30 min on Day 1 of Cycles 1-6 (to 9) of each 21 day cycle. Ipilimumab 1mg/kg will be infused IV over approx 30 min on Day 1 of Cycles 1 & 3, as well as Cycle 4 & Cycle 6. Of note, if patients receive more than 3 cycles in the pre-operative setting, then ipilimumab will be administered with the first & third cycle in the post-operative setting. Nivolumab will then be infused Day 1 of each 28 day maintenance phase cycle.
11219951|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
11219952|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
11219953|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
11219954|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
11219955|NCT03245853|Other|Treatment|Treatment as per protocol, there is no placebo arm.
11219956|NCT03245840|Experimental|Budesonide Oral Suspension|Participants will be initiated on 10 milliliter (mL) of Budesonide oral suspension (0.2 milligram/mL) twice daily up to 72 months (Visit 12) or early termination (ET).
11219957|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
11219958|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
11219959|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
11219960|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
11219961|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
11219962|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
11219963|NCT03245788|Experimental|Lay Navigation|Patients with even MRN.
11219964|NCT03245788|No Intervention|Usual Care|Patients with odd MRN.
11219965|NCT03245775|Experimental|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
11219966|NCT03245775|Experimental|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
11219967|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
11219968|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
11219969|NCT03245736|Experimental|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
11219970|NCT03245723|Active Comparator|National Lung Project Cohort|Individuals born premature that are registered on the National Lung Project. Individuals are in their late twenties. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
11219971|NCT03245723|Placebo Comparator|Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
11219972|NCT03245723|Active Comparator|Non-National Lung Project Preterm Adults|Individuals that were born premature, but are not a part of the National Lung Project Cohort. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
11219973|NCT03245710|Experimental|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
11219974|NCT03245710|Placebo Comparator|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
11219975|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
11219976|NCT03245684|Experimental|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.
~assessment of inflammatory response during PSV"
11219977|NCT03245684|Active Comparator|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
11219978|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
11219979|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
11219980|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
11219981|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
11219982|NCT03245645|Experimental|100% Fructose|The fructose group will help to determine whether an absolute amount of fructose will lead to IBS symptoms.
11219983|NCT03245645|Placebo Comparator|100% Glucose|The glucose group will serve as a control since glucose is not a FODMAP and as a result is not expected to lead to recurrent symptoms.
11219984|NCT03245645|Active Comparator|Fructose and Glucose|The glucose/fructose mixture group is a cross comparison group that will determine whether the relative excess fructose concentration is an important cause of IBS symptoms.
11219985|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
11219986|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
11219987|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
11219988|NCT03245619|Experimental|Subjects receiving Placebo (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
11219989|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
11219990|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
11219991|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
11219992|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
11219993|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
11219994|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
11219995|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.
~Then will be performed:
~a liver biopsy
~an abdominal MRI
~a transient elastography"
11219996|NCT03245593||Shared Decision making for care|
11219997|NCT03245593||Standard decision making for care|
11219998|NCT03245580|Other|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
11219999|NCT03245580|Other|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
11220000|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
11220001|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
11220002|NCT03245554|Experimental|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
11220003|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
11220004|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
11220005|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
11220006|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
11220007|NCT03245489|Experimental|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
11220008|NCT03245489|Experimental|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
11220009|NCT03245476|Active Comparator|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
11220010|NCT03245476|Active Comparator|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
11220011|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
11220012|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
11220013|NCT03245450|Experimental|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m^2 or 40 mg/m^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m^2 or 125 mg/m^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
11220014|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
11220015|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
11220016|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
11220017|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
11220018|NCT03245411|No Intervention|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
11220051|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
11220019|NCT03245411|Experimental|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care
~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
11220020|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
11220021|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
11220022|NCT03245385|Experimental|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
11220023|NCT03245372|Active Comparator|Standard care|Basic intraoperative hemodynamic objectives
11220024|NCT03245372|Experimental|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
11220025|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
11220026|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
11220027|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
11220028|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
11220029|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
11220030|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
11220031|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
11220032|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
11220033|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
11220034|NCT03245307|Experimental|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
11220035|NCT03245294|Active Comparator|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
11220036|NCT03245294|Active Comparator|Lumbar ESI with midline approach|Lumbar ESI with midline approach
11220037|NCT03245281|Experimental|Diuretic Suspension (DS)|
11220038|NCT03245281|Experimental|Diuretic Increase (DI)|
11220039|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
11220040|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
11220041|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
11220042|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
11220043|NCT03245229|Experimental|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
11220044|NCT03245229|Experimental|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
11220045|NCT03245229|Experimental|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.
~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
11220046|NCT03245216|Experimental|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
11220047|NCT03245216|Active Comparator|rest + motor skill practice|seated rest before motor learning
11220048|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
11220049|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
11220050|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
11220052|NCT03245164|Experimental|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
11220053|NCT03245164|Experimental|Basketball program|Basketball educaiton was presented for 12 weeks.
11220054|NCT03245164|No Intervention|Control group|This group did not continue any physical activity regularly.
11220945|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
11220055|NCT03245151|Experimental|Phase 1: Phase 1; Recurrent or refractory solid tumors|During Phase 1 (Treatment Phase: 1 cycle; 28 days of treatment), utilizing a rolling 6 design, participants with recurrent or refractory solid tumors will receive escalating doses of lenvatinib in combination with everolimus for determination of the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Participants who complete 1 cycle of treatment will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
11220056|NCT03245151|Experimental|Phase 2: Cohort 1, Ewing sarcoma/pPNET|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor (pPNET) (Cohort 1) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1. Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
11220057|NCT03245151|Experimental|Phase 2: Cohort 2, Rhabdomyosarcoma|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory rhabdomyosarcoma (Cohort 2) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks of treatment). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
11220058|NCT03245151|Experimental|Phase 2: Cohort 3, High Grade Glioma (HGG)|During Phase 2 (four 28-day cycles [up to 16 weeks of treatment]), utilizing Simon's optimal 2-stage design, participants with recurrent or refractory HGG (Cohort 3) will receive the RP2D of lenvatinib in combination with everolimus determined in Phase 1 (1 cycle; 4 weeks). Participants who discontinue study treatment before completing 4 cycles will transition to the Off-treatment Visit. Participants who complete 4 cycles will transition to the Extension Phase, in which they will continue to receive the same study treatment in 28-day cycles.
11220059|NCT03245138|Experimental|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
11220060|NCT03245138|Active Comparator|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
11220061|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
11220062|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
11220063|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
11220064|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
11220065|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
11220066|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
11220067|NCT03245073|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
11220068|NCT03245073|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
11220069|NCT03245060|Experimental|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
11220070|NCT03245060|Other|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
11220071|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
11220072|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
11220073|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
11220074|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
11220075|NCT03245008|Experimental|MT-5547 dosing regimen 1|MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.
11220076|NCT03245008|Experimental|MT-5547 dosing regimen 2|MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.
11220077|NCT03245008|Placebo Comparator|MT-5547-matching placebo|MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.
11220078|NCT03244995|Experimental|Group I (CBMB program)|Patients undergo CBMB program consisting of 4-5 deep-breathing and meditation exercise sessions over 60 minutes and 2 weekly telephone calls over 15 minutes for 6 weeks. Patients also complete questionnaires regarding health, mood, sleeping habits, relationship, health care, work productivity, and quality of life.
11220079|NCT03244995|Active Comparator|Group II (waitlist control)|Patients complete questionnaires as in Group I. Patients may undergo CBMB program after completion of study.
11220080|NCT03244982|Active Comparator|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
11220081|NCT03244982|Experimental|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
11220084|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
11220085|NCT03244930|Experimental|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
11220086|NCT03244917|Experimental|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
11220087|NCT03244917|No Intervention|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
11220088|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:
~before fluid challenge
~after fluid challenge
~During each phase, the subjects will be studied at:
~baseline - spontaneously breathing
~head down position - spontaneously breathing
~baseline - positive pressure ventilation
~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
11220089|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
11220090|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
11220091|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.
~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
11220092|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
11220093|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.
~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.
~Shared Care include the following
~Formal Care Coordination Plan
~Patient Engagement and Education
~Local Oncologist Engagement and Education
~Patient/Local Oncologist/Transplant Oncologist Web Portal"
11220094|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.
~Majority of routine visits in first 180 days will be at DFCI."
11220095|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
11220096|NCT03244813|Experimental|Adapted physical activity|
11220097|NCT03244813|No Intervention|Standard care|
11220098|NCT03244800|Placebo Comparator|Placebo Cohort 1|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
11220099|NCT03244800|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 7 days, followed by Dose 2 for 7 days, Dose 3 for 7 days, and Dose 4 for 28 days
11220100|NCT03244800|Placebo Comparator|PLacebo Cohort 2|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
11220101|NCT03244800|Experimental|MEDI0382 Cohort 2|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 14 days, followed by Dose 2 for 14 days, Dose 3 for 14 days, and Dose 4 for 7 days.
11220102|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
11220103|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
11220104|NCT03244774|Experimental|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.
~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:
~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);
~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)
~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
11220105|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
11220106|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
11220107|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
11220108|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
11220109|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
11220110|NCT03244722|Other|Obese - Very low calorie diet (VLCD)|Participants will adopt a very-low calorie diet
11220111|NCT03244722|Other|Obese - Standard of care (SOC)|Participants will receive the standard of care for obese women looking to become pregnant.
11220112|NCT03244722|Other|Lean - Standard of care (SOC)|Participants will receive the standard of care for lean women looking to become pregnant.
11220138|NCT03244527|Placebo Comparator|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
11220176|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
11221065|NCT03238261|Active Comparator|Radiotherapy|
11220113|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.
~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.
~Week 24. TCZ tapering every 8 weeks as follows:
~1 injection every 2 weeks
~1 injection every 3 weeks
~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
11220114|NCT03244696|Experimental|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
11220115|NCT03244696|Active Comparator|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
11220116|NCT03244683|Other|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
11220117|NCT03244683|Other|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
11220118|NCT03244657|Experimental|Q12W group|
11220119|NCT03244657|Experimental|TAE group|
11220120|NCT03244644|Placebo Comparator|Group A|Placebo is an enema of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
11220121|NCT03244644|Experimental|Group B|RBX2660 is an enema of a microbiota suspension in a 0.9% sodium chloride irrigation USP solution and cryoprotectant
11220122|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
11220123|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
11220124|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
11220125|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
11220126|NCT03244605|Experimental|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.
~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
11220127|NCT03244605|Placebo Comparator|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.
~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
~The patient will take placebo granules for 3 months."
11220128|NCT03244592|Active Comparator|Minocycline|200 mg/day
11220129|NCT03244592|Placebo Comparator|Sugar Pill|Matched placebo
11220130|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
11220131|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
11220132|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
11220133|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
11220134|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
11220135|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.
~PCA with morphine in the PACU"
11220136|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.
~PCA with morphine in the PACU"
11220137|NCT03244527|Experimental|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
11220174|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
11220139|NCT03244514|Experimental|Intervention group|"Implementation of the cardiovascular surgery AKI bundle
~discontinuation of all nephrotoxic agents when possible
~optimization of volume status and hemodynamic parameters
~close monitoring of serum creatinine, fluid balance and urinary output
~avoidance of hyperglycemia
~considerations of alternatives to radiocontrast agents
~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period
~avoidance of HES, gelatin, and chlorid-rich solutions"
11220140|NCT03244514|No Intervention|Control group|The patients will receive standard of care (according to each center)
11220141|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
11220142|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
11220143|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
11220144|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
11220145|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
11220146|NCT03244475|Experimental|Neurofeedback|mTBI Veterans blindly assigned to a 6 week IASIS neurofeedback treatment with two sessions per week.
11220147|NCT03244475|Placebo Comparator|Sham Treatment|mTBI Veterans blindly assigned to a sham treatment for 6 weeks with two sessions per week.
11220148|NCT03244475|No Intervention|Control|Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.
11220149|NCT03244475|Experimental|Nexalin|After IASIS treatment is complete and participants in the mTBI group may have remaining PCS, additional Nexalin treatment will be offered.
11220150|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:
~single oral dose of BAY1834845
~single oral dose of BAY1834845 + i.v. BAY1834845
~single oral dose of BAY1834845 under fed conditions"
11220151|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:
~single oral dose of BAY1834845+ i.v. BAY1834845
~single oral dose of BAY1834845
~single oral dose of BAY1834845 under fed conditions"
11220152|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:
~single oral dose of methotrexate (MTX)
~single oral dose of MTX + single oral dose of BAY1834845"
11220153|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:
~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845
~single oral dose of MTX"
11220154|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
11220155|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
11220156|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
11220157|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
11220158|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.
~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
11220159|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
11220160|NCT03244384|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
11220161|NCT03244384|Active Comparator|Arm B (observation)|Patients undergo observation.
11220162|NCT03244371|Experimental|Co infected HIV and HCV patients|
11220163|NCT03244358|Experimental|Epalrestat|Epalrestat added to standard treatment
11220164|NCT03244345|Experimental|Epileptic patient|
11220165|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
11220166|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
11220167|NCT03244319|Experimental|Edoxaban|
11220168|NCT03244319|Active Comparator|Warfarin|
11220169|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
11220170|NCT03244280|Other|MOB015B|
11220171|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
11220172|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
11220173|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
11220177|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
11220178|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
11220179|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
11220180|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
11220181|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
11220182|NCT03244215|Experimental|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.
~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.
~No drugs will be administered to the patients for the purpose of our study."
11220183|NCT03244215|Other|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
11220184|NCT03244202|Experimental|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
11220185|NCT03244202|Active Comparator|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
11220186|NCT03244189|Experimental|Intervention|"Participants in the intervention arm will receive an individualized fluid prescription, which will be the additional volume of fluid intake needed to maintain a study-specified urine output. This fluid will be consumed from and measured by a smart water bottle. The intervention arm also includes a behavioral program that consists of financial incentives and structured problem solving (SPS) to maintain the recommended fluid intake."
11220187|NCT03244189|No Intervention|Control|"Participants in the control arm will receive standard care instructions according to American Urological Association (AUA) guidelines to increase overall fluid consumption to achieve study-specified urine output. They will also receive a smart water bottle with capability to self-monitor their fluid intake."
11220188|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
11220189|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
11220190|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
11220191|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
11220192|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
11220193|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
11220194|NCT03244124|Active Comparator|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
11220195|NCT03244124|Experimental|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
11220196|NCT03244124|Experimental|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
11220197|NCT03244124|Experimental|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch&Rinse Wet Application Strategy, leaving dentin wet
11220198|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
11220199|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
11220200|NCT03244098|Experimental|Transition Assistance Program (TAP)|
11220201|NCT03244098|No Intervention|Standard of Care|
11220202|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
11220203|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
11220204|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
11220205|NCT03244072|Active Comparator|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
11220206|NCT03244072|Placebo Comparator|Placebo group|Intracameral injection of placebo after cataract surgery
11220207|NCT03244059|Experimental|Belimumab|"Subjects randomized to the experimental treatment arm will receive i.v. administrations of belimumab (10 mg/kg), consisting of three loading doses, two weeks apart, followed by five (5) more monthly infusions. The final assessment will be performed at month 8."
11220208|NCT03244059|Placebo Comparator|Placebo|"These subjects will be treated with identically appearing placebo i.v. on the same schedule as the experimental arm subjects (i.e., three loading doses, two weeks apart, followed by five more monthly infusions. Again, the final assessment will be performed at month 7 (210+10 days after treatment start)."
11220209|NCT03244046|Active Comparator|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
11220210|NCT03244046|Experimental|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
11220211|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
11220212|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
11220213|NCT03244020|Experimental|LMWH for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
11220214|NCT03244020|Experimental|ASA for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to aspirin 325 mg po daily for VTE prophylaxis
11220215|NCT03244020|Experimental|LMWH for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
11220216|NCT03244020|Experimental|ASA for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to aspirin 325 mg po daily for VTE prophylaxis
11220217|NCT03244020|Experimental|LMWH for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
11220218|NCT03244020|Experimental|ASA for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to aspirin 325 mg po daily for VTE prophylaxis
11220219|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
11220220|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
11220221|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
11220222|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
11220223|NCT03243981|Experimental|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
11220224|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
11220225|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
11220226|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
11220227|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
11220228|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
11220229|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
11220230|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
11220231|NCT03243916|Experimental|combination|TACE plus cyber knife
11220232|NCT03243903|Experimental|needle-free insulin injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
11220233|NCT03243903|Active Comparator|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
11220234|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
11220235|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
11220236|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.
~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
11220237|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.
~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
11220238|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
11220705|NCT03240614|Active Comparator|BMI >35 with no lung disease|Patients with a BMI> 35 with no lung disease
11220239|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :
~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks
~Metformin :
~1st cycle (4 weeks)
~1 week(1st~7th day) = 1,000mg/day
~1 week(8th~14th day) = 1,500mg/day
~2 weeks(15th ~28th day) = 2,000mg/day
~2nd to 6th cycle (20 weeks) = 2,000mg/day"
11220240|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :
~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks
~Placebo:
~1st cycle (4 weeks)
~1 week(1st~7th day) = 1,000mg/day
~1 week(8th~14th day) = 1,500mg/day
~2 weeks(15th~28th day) = 2,000mg/day
~2nd to 6th cycle (20 weeks) = 2,000mg/day"
11220241|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
11220242|NCT03243825|Experimental|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
11220243|NCT03243825|Active Comparator|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
11220244|NCT03243812|Active Comparator|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :
~Blood sample
~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test
~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
11220245|NCT03243812|Active Comparator|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :
~Blood sample
~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test
~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
11220246|NCT03243812|Active Comparator|control group|"Healthy subjects. Each subject will undergo the following :
~Blood sample
~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test
~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
11220247|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.
~Group psychoeducation."
11220248|NCT03243799|No Intervention|Control Group|Usual clinical care
11220249|NCT03243786|Active Comparator|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
11220250|NCT03243786|Active Comparator|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
11220251|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220252|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220253|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220254|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
11220255|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220256|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220257|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220258|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220259|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
11220260|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
11220261|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
11220262|NCT03243734|Experimental|trūFreeze® System spray cryotherapy|trūFreeze® System spray cryotherapy as clinically indicated for symptom relief
11220263|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
11220264|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
11220265|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
11220266|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
11220267|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
11220268|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
11220269|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
11220270|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
11220271|NCT03243669|Active Comparator|Fujinon standard|
11220272|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
11220273|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
11220274|NCT03243669|Active Comparator|Olympus standard|
11220275|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
11220276|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
11220277|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
11220278|NCT03243669|Active Comparator|Pentax standard|
11220279|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
11220280|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
11220281|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
11220282|NCT03243656|No Intervention|control arm|standard immunosuppressive therapy (antilymphocyte globulin and cyclosporine),
11220283|NCT03243656|Active Comparator|case arm|standard immunosuppressive therapy plus an oral dose of Eltrombopag
11220284|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.
~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
11220285|NCT03243630|Placebo Comparator|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
11220286|NCT03243630|Active Comparator|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
11220287|NCT03243630|Active Comparator|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
11220288|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
11220289|NCT03243617|Placebo Comparator|Placebo|Placebo
11220290|NCT03243591|Active Comparator|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
11220291|NCT03243591|Active Comparator|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
11220292|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
11220293|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
11220294|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
11220295|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
11220296|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
11220297|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
11220298|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
11220299|NCT03243500|Sham Comparator|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml
~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
11220300|NCT03243500|Active Comparator|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml
~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
11220301|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).
~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
11220329|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
11220302|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
11220303|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
11220304|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
11220305|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
11220306|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
11220307|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
11220308|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
11220309|NCT03243461|Experimental|Temozolomide + Valproic acid|Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
11220310|NCT03243461|Experimental|Temozolomide + Chloroquine|Resochin junior® (Chloroquine), depending on patient weight and treatment scedule 1/2 to 3 tablets [25-150 mg] every day, p.o., in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
11220311|NCT03243448||The general public|people between 20-85 years old, without sympathetic hyperactivity disease
11220312|NCT03243448||Sympathetic hyperactivity diseases|Sympathetic hyperactivity diseases included: hypertension, heart failure atherosclerotic diseases, arrhythmias, cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, sleep apnea, pulmonary embolism, hepatitis, liver cirrhosis, hepatopulmonary syndrome, hepatorenal syndrome, renal failure, nephritis, irritable bowel syndrome.
11220313|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
11220314|NCT03243422|Active Comparator|Successful aging education intervention|Individual sessions on healthy aging topics
11220315|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
11220316|NCT03243396|Experimental|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
11220317|NCT03243396|Experimental|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
11220318|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
11220319|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
11220320|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
11220321|NCT03243357|Experimental|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha&epoxy resin sealer.
11220322|NCT03243357|Other|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
11220323|NCT03243344|Experimental|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
11220324|NCT03243344|Experimental|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
11220325|NCT03243344|Experimental|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
11220326|NCT03243344|No Intervention|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
11220327|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
11220328|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
11220330|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
11220331|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
11220332|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
11220333|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
11220334|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
11220335|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
11220336|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
11220337|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
11220338|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
11220339|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
11220340|NCT03243201|Experimental|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
11220341|NCT03243201|Placebo Comparator|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
11220342|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
11220343|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
11220344|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
11220345|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
11220346|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
11220347|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
11220348|NCT03243149|Sham Comparator|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
11220349|NCT03243149|Active Comparator|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
11220350|NCT03243149|Experimental|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
11220351|NCT03243123|Experimental|Passive mobilization|Upper limb passive mobilization assisted with robotic device
11220352|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.
~Participants must be 1 to 85 years old."
11220353|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
11220354|NCT03243084|Sham Comparator|Sham tACS|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
11220355|NCT03243084|Active Comparator|Active 10 Hz tACS|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
11220356|NCT03243071|Experimental|Intervention Group|The intervention group (n=50) will have access to culturally tailored website.
11220357|NCT03243071|Active Comparator|Control Group|Participants in the control group (n=50) will have access to NYU 's standard trial participation website.
11220358|NCT03243058|Active Comparator|Treatment Arm|ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
11220359|NCT03243058|Experimental|Treatment-Placebo Arm|Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
11220360|NCT03243058|Placebo Comparator|Placebo|Participants in this group will receive a placebo injection for two years.
11220361|NCT03243032|Experimental|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
11220433|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
11220706|NCT03240614|Active Comparator|BMI >35 with lung disease|Patients with a BMI> 35 with lung disease
11220362|NCT03243032|Placebo Comparator|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
11220363|NCT03243019|Experimental|SIROLIMUS|
11220364|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
11220365|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
11220366|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
11220367|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:
~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
11220368|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
11220369|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
11220370|NCT03242967|Experimental|Vadadustat|Oral tablet
11220371|NCT03242967|Active Comparator|Darbepoetin alfa|subcutaneous or intravenous
11220372|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Parental permission required
11220373|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
11220374|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Autonomous consent
11220375|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Parental permission required and Adult permission required and Autonomous consent
11220376|NCT03242941|Experimental|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
11220377|NCT03242928|Placebo Comparator|Placebo|
11220378|NCT03242928|Experimental|AFQ056|
11220379|NCT03242915|Experimental|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
11220380|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
11220381|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
11220382|NCT03242889|Experimental|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram [mg] with Recombinant Human Hyaluronidase [rHuPH20] 30,000 units [U] that is 2000 U/milliliter [U/mL]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 [Day 1]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
11220383|NCT03242876|Placebo Comparator|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
11220384|NCT03242876|Experimental|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
11220385|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
11220386|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
11220387|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
11220388|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
11220389|NCT03242850|Experimental|Intervention group|
11220390|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
11220391|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
11220392|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
11220393|NCT03242811|Experimental|Examination by MRI|MRI scan of knee, ankle and wrist
11220394|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
11220395|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
11220501|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
11220396|NCT03242772|Active Comparator|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
11220397|NCT03242772|Placebo Comparator|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
11220398|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
11220399|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.
~a 3-years follow-up for pregnancy outcome
~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
11220400|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.
~a 3-years follow-up for pregnancy outcome
~Transvaginal ultrasound for pretreatment cervical dimensions/volume
~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit
~Estimation of cone dimensions/volume
~Calculation of the proportion of volume/length excised"
11220401|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
11220402|NCT03242720|Active Comparator|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
11220403|NCT03242720|Sham Comparator|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
11220404|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
11220405|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
11220406|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
11220407|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
11220408|NCT03242681|Active Comparator|Simple Probing|Simple Probing
11220409|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
11220410|NCT03242655|Experimental|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
11220411|NCT03242655|No Intervention|Control|Individual onsite HCV treatment at a primary care center
11220412|NCT03242642|Experimental|Primary Cohort- TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
11220413|NCT03242642|Experimental|Mitral Annular Calcification -TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
11220414|NCT03242629|Active Comparator|oral group|
11220415|NCT03242629|Experimental|enema group|
11220416|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)
~Pemetrexed (500 mg/m2, day 1)
~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)
~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose
~Dexa 4mg po bid on D0-2"
11220417|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
11220418|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
11220419|NCT03242590|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
11220420|NCT03242564|Experimental|Active Device|"Active Device: Vevazz LED red light therapy system
~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
11220421|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
11220422|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
11220423|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
11220424|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
11220425|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
11220426|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
11220427|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
11220428|NCT03242499|Experimental|Active|Lovastatin 80mg per day for 48 weeks.
11220429|NCT03242499|Placebo Comparator|Placebo|Placebo 80mg per day for 48 weeks.
11220430|NCT03242486|Experimental|toric intraocular lens|toric intraocular lens is implanted to all subjects
11220431|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
11220432|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
11220434|NCT03242447|Experimental|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
11220435|NCT03242447|Active Comparator|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
11220436|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
11220437|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
11220438|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
11220439|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
11220440|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
11220441|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
11220442|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
11220443|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
11220444|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
11220445|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
11220446|NCT03242343|Experimental|VasQ device implantation|"Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints.
~Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints."
11220447|NCT03242330|Experimental|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
11220448|NCT03242330|Active Comparator|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
11220449|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
11220450|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
11220451|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
11220452|NCT03242291|Active Comparator|conventional resin-based flowable composite|
11220453|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
11220454|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
11220455|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
11220456|NCT03242252|Placebo Comparator|Placebo|2 placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily before the first meal of the day - Type: Placebo Comparator
11220457|NCT03242252|Experimental|Dose 1|2 tablets: 1 sotagliflozin tablet and 1 placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily before the first meal of the day
11220458|NCT03242252|Experimental|Dose 2|2 sotagliflozin tablets, once daily before the first meal of the day
11220459|NCT03242239|Experimental|ALT02|
11220460|NCT03242239|Active Comparator|EU-licensed Herceptin|
11220461|NCT03242239|Active Comparator|US-licensed Herceptin|
11220462|NCT03242226|Experimental|two spectacles|
11220463|NCT03242226|Active Comparator|single vision spectacles|
11220464|NCT03242213|No Intervention|Usual Care|Standard of Care
11220465|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
11220466|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
11220467|NCT03242187|Experimental|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
11220468|NCT03242187|Active Comparator|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
11220469|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
11220502|NCT03241927|No Intervention|Healthy Donors|
11220470|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
11220471|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
11220472|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
11220473|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
11220474|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
11220475|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
11220476|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
11220477|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
11220478|NCT03242096|Experimental|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
11220479|NCT03242096|Active Comparator|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
11220480|NCT03242083||Primary atrophic AMD|
11220481|NCT03242083||Secondary atrophic AMD|
11220482|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
11220483|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
11220484|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age
~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion
~Randomize to either NIPPV or NI-NAVA, 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.
~ABG or CBG to be obtained at 4 hrs. post extubation
~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
11220485|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age
~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion
~Randomize to either NIPPV or NI-NAVA, 1:1 randomization
~PI will not be blinded to the intervention (not feasible)
~ABG or CBG to be obtained at 4 hrs. post extubation
~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
11220486|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
11220487|NCT03242031|Experimental|1 session|
11220488|NCT03242031|Active Comparator|4 sessions|
11220489|NCT03242018|Placebo Comparator|Placebo|Given as two placebo tablets (identical to sotagliflozin dose 2 in appearance) orally once daily
11220490|NCT03242018|Experimental|Dose 1|Given as two sotagliflozin dose 2 tablets orally once daily
11220491|NCT03242018|Experimental|Dose 2|Given as two tablets: one sotagliflozin dose 2 tablet and one placebo tablet (identical to sotagliflozin dose 2 in appearance) orally once daily
11220492|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
11220493|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
11220494|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
11220495|NCT03241979||laryngeal microsurgery|
11220496|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
11220497|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
11220498|NCT03241953|Experimental|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
11220499|NCT03241953|Active Comparator|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
11220500|NCT03241940|Experimental|Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and cyclophosphamide IV over 60 minutes on day -2. Patients then receive CD19/CD22-CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22-CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
11220503|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11220504|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11220505|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):
~tablet for 5-14kg;
~tablets for 15-24 kg;
~tables for 25 - 34kg and
~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.
~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
11220506|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.
~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
11220507|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11220508|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11220509|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11220510|NCT03241875|Placebo Comparator|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
11220511|NCT03241875|Experimental|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
11220512|NCT03241875|Experimental|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
11220513|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
11220514|NCT03241849|Other|Modified surgical technique for placenta accreta|
11220515|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
11220516|NCT03241810|Experimental|Arm A|"Seribantumab
~Fulvestrant"
11220517|NCT03241810|Active Comparator|Arm B|"Placebo
~Fulvestrant"
11220518|NCT03241797|Experimental|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
11220519|NCT03241784|Experimental|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
11220520|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
11220521|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
11220522|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
11220523|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
11220524|NCT03241732|Active Comparator|Dietary (AID) Cohort|Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
11220525|NCT03241732|Active Comparator|Intravenous/Oral NAC Cohort|N-acetyl Cysteine: This arm provide patients with a natural supplement, n-acetyl cysteine (NAC) which is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, that supports antioxidants to reduce oxidative damage in the body. NAC is a common over-the-counter supplement. It is used as an injectable pharmaceutical to protect the liver in cases of acetaminophen overdose. Laboratory studies have suggested that NAC might have a beneficial effect in neurodegenerative disorders such as TBI. Patients in this arm will receive IV NAC once a week plus oral NAC supplement 500 mg twice per day for approximately 3 months until the follow up evaluation.
11220526|NCT03241732|No Intervention|Control Cohort|Control Group: Standard of Care Treatment for at least 3 months. After the first 3 month, participants in this arm may crossover to the NAC study arm.
11220527|NCT03241719|Experimental|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
11220528|NCT03241706|Placebo Comparator|Controls-saline|Each subject from Group 1 will undergo a metabolic study where saline is infused so as to not stimulate liver glucose uptake and glycogen deposition.
11220529|NCT03241706|Active Comparator|Controls-high fructose|A second group of control subjects will undergo a single metabolic study using a higher dose of fructose (6.5 mg/kg/min).
11220530|NCT03241706|Active Comparator|Controls-low fructose|Each subject from Group 1 will undergo another metabolic study where fructose (1.3 mg/kg/min) is infused so as to stimulate liver glucose uptake and glycogen deposition.
11220531|NCT03241693|Other|control group|Physiotherapy students
11220532|NCT03241693|Experimental|experimental group|Physiotherapy students
11220533|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
11220534|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
11220535|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
11220536|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
11220537|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
11220538|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
11220539|NCT03241641|Experimental|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
11220540|NCT03241641|Active Comparator|Switching from TDF to TAF|"Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks
~Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
11220541|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.
~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
11220542|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
11220543|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
11220544|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
11220545|NCT03241602|Active Comparator|Group of pulmonary recruitment|
11220546|NCT03241602|No Intervention|group receive passive exsufflation through port|
11220547|NCT03241589|Experimental|Direct to Patient Facing Apps Use|VA sites who have received the direct to patient facing apps from OCC
11220548|NCT03241589|Experimental|Control Direct to Patient Facing apps|VA sites to eventually receive the direct to patient facing apps but at present have not
11220549|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
11220550|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
11220551|NCT03241563|Active Comparator|without triamcinolone|sodium Deoxycholate without triamcinolone
11220552|NCT03241563|Active Comparator|with triamcinolone|sodium Deoxycholate with triamcinolone
11220553|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
11220554|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
11220555|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
11220556|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
11220557|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
11220558|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
11220559|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
11220560|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
11220561|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
11220562|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
11220596|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
11220597|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
11220598|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
11220563|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
11220564|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
11220565|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
11220566|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
11220567|NCT03241472|Experimental|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
11220568|NCT03241472|Active Comparator|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
11220569|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
11220570|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|
11220571|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
11220572|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
11220573|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
11220574|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
11220575|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
11220576|NCT03241433|Active Comparator|No exercise|No excercise training will be done
11220577|NCT03241420|Active Comparator|Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
11220578|NCT03241420|Active Comparator|Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
11220579|NCT03241407|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
11220580|NCT03241407|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
11220581|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
11220582|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
11220583|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
11220584|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
11220585|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
11220586|NCT03241368|Other|MRE, Patency Capsule (if needed), CE, and IC|Single-arm study, which includes MRE procedure, Patency Capsule Procedure (if needed), PillCam Crohn's Capsule Endoscopy Procedure and Ileocolonoscopy procedure.
11220587|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
11220588|NCT03241355|Placebo Comparator|placebo maltodextrin|
11220589|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
11220590|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
11220591|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
11220592|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
11220593|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
11220594|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
11220595|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
11220600|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
11220601|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
11220602|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
11220603|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
11220604|NCT03241264|Experimental|Module A|Lyophilized Formulation
11220605|NCT03241264|Experimental|Module B|Frozen Formulation
11220606|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
11220607|NCT03241238|Other|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
11220608|NCT03241238|Other|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
11220609|NCT03241238|Other|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
11220610|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
11220611|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
11220612|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.
~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
11220613|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.
~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
11220614|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
11220615|NCT03241186|Experimental|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days
~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
11220616|NCT03241173|Experimental|INCAGN01949 + Nivolumab|INCAGN01949 combined with nivolumab.
11220617|NCT03241173|Experimental|INCAGN01949 + Ipilimumab|INCAGN01949 combined with ipilimumab.
11220618|NCT03241173|Experimental|INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab and ipilimumab.
11220619|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
11220620|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
11220621|NCT03241147|Experimental|Healthy subjects (Group B)|
11220622|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
11220623|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
11220624|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
11220625|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
11220626|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
11220627|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
11220628|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
11220629|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
11220630|NCT03241095|No Intervention|Control|
11220631|NCT03241095|Sham Comparator|Sham OMT|
11220632|NCT03241095|Active Comparator|OMT|
11220633|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.
~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
11220634|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
11220635|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
11220636|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
11220637|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
11220638|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
11220639|NCT03241043|Experimental|Envarsus - Advagraf|
11220640|NCT03241043|Active Comparator|Advagraf - Envarsus|
11220641|NCT03241030|Experimental|Experimental Group|Subjects will receive sucralfate
11220642|NCT03241030|Placebo Comparator|Placebo Group|Subjects will receive a placebo
11220643|NCT03241017|Experimental|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
11220644|NCT03241004|Experimental|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.
~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
11220645|NCT03241004|Experimental|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.
~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
11220646|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
11220647|NCT03240978|Experimental|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart rate maximum for 12 weeks.
11220648|NCT03240978|Experimental|Moderate intensity intervention|Exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
11220649|NCT03240978|No Intervention|non-exercise group|Participants will not receive any type of exercise training.
11220650|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
11220651|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
11220652|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
11220653|NCT03240939|Active Comparator|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
11220654|NCT03240939|Experimental|YY-201|YY-201 capsule, singe dose
11220655|NCT03240926|Experimental|Loop Band|Measure accuracy of vital sign measurements
11220656|NCT03240913|Experimental|Treatment Group|
11220657|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
11220658|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
11220659|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
11220660|NCT03240887|Experimental|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
11220661|NCT03240887|No Intervention|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
11220662|NCT03240874|Experimental|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups
~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
11220663|NCT03240874|Experimental|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing
~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
11220664|NCT03240874|Experimental|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm
~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
11220665|NCT03240874|No Intervention|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm
~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
11220666|NCT03240861|Experimental|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.
~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.
~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
11220876|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
11220877|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
11220667|NCT03240848|Experimental|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
11220668|NCT03240848|Active Comparator|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
11220669|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
11220670|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
11220671|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
11220672|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
11220673|NCT03240796|Experimental|minimal invasive surgery and secondary IOL implantation|
11220674|NCT03240796|Active Comparator|traditional cataract surgery and secondary IOL implantation|
11220675|NCT03240783|Experimental|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
11220676|NCT03240783|Experimental|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
11220677|NCT03240783|Experimental|Arm 3|"Dexamethasone Oral Tablet:
~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
11220678|NCT03240783|Other|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
11220679|NCT03240770|No Intervention|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
11220680|NCT03240770|Experimental|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ Sham"
11220681|NCT03240770|Experimental|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ Sham"
11220682|NCT03240770|Experimental|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ HFV with the VPro5 device at 5 min/day"
11220683|NCT03240770|Experimental|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))
~+ HFV with the VPro5 device at 5 min/day"
11220684|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
11220685|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
11220686|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
11220687|NCT03240731|Experimental|bone marrow transplant|"All the included patient will receive an haploidentical bone marrow transplant with the following protocol concerning the conditioning and GvHD prevention
~Conditioning
~THYMOGLOBULINE : 0.5mg/kg at D-9 and 2 mg/kg at D-8 and D-7
~THIOTEPA: 10mg/kg/j at D-7
~CYCLOPHOSPHAMIDE (Endoxan®):14.5mg/kg/j at D-6 and D-5
~FLUDARABINE (Fludara®): 30mg/m2 per Day from D-6 to D-2
~TBI : 2GY : D -1 Graft : Injection at D0 of G-CSF-stimulated bone marrow transplant.
~Prophylaxis of GvHD
~CYCLOPHOSPHAMIDE (Endoxan®): 50mg/Kg per Day from D+3 to D+4
~Sirolimus and MycophénolateMofétil (MMP) from D+5. In the absence of acute GvHD (aGvHD), stop of MMP to D35 and pursuit of sirolimus 1 year after the graft."
11220688|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
11220689|NCT03240718|No Intervention|Control scar|Standard care
11220690|NCT03240705|Experimental|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
11220691|NCT03240705|No Intervention|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
11220692|NCT03240692|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
11220693|NCT03240679|Active Comparator|EMR with Extracelluar Matrix|Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive Extracellular Matrix to the defect site
11220694|NCT03240679|No Intervention|EMR|assess baseline dysphagia (Mellow-Pinkas scale and Mayo Dysphagia Questionnaire). Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive standard of care.
11220695|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
11220696|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
11220697|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
11220698|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
11220699|NCT03240627|Experimental|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
11220700|NCT03240627|Placebo Comparator|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
11220701|NCT03240614|Active Comparator|BMI <30 no lung disease|Patients with a BMI <30 with no lung disease
11220702|NCT03240614|Active Comparator|BMI <30 with lung disease|Patients with a BMI <30 with lung disease
11220703|NCT03240614|Active Comparator|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
11220704|NCT03240614|Active Comparator|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
11220707|NCT03240601|Sham Comparator|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
11220708|NCT03240601|Experimental|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
11220709|NCT03240588|Active Comparator|De Novo Cohort|Study subjects who have not previously attempted a Neurostimulator trial will be followed up to 36 months post-Neurostimulation trial procedure or IPG Activation on the use of their Neurostimulation system.
11220710|NCT03240588|Active Comparator|Existing Cohort|Study subjects who have completed permanent neurostimulator IPG implant and are in various stages of follow-up will be followed up to 36 months post-Neurostimulation trial or IPG Activation procedure on the use of their Neurostimulation system.
11220711|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
11220712|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
11220713|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
11220714|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
11220715|NCT03240549|No Intervention|conventional therapy group|Treatment with previous regimen of combined chemotherapy
11220716|NCT03240549|Experimental|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
11220717|NCT03240536|Experimental|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
11220718|NCT03240536|No Intervention|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
11220719|NCT03240523|Experimental|Group A1: Vilaprisan (3/1 regimen)|Orally, 2 mg, once daily, 3 months treatment followed by 1 menstrual bleeding episode
11220720|NCT03240523|Experimental|Group A2: Vilaprisan (6/2 regimen)|Orally, 2 mg, once daily, 6 months treatment followed by 2 menstrual bleeding episodes
11220721|NCT03240523|Experimental|Group A3/B (3/2 regimen)|"Orally, 2 mg, once daily, 3 months treatment followed by 2 menstrual bleeding episodes
~With protocol version 5.0 the blinded study arms A3 and B were converted to one open-label study arm called A3/B."
11220722|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
11220723|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
11220724|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
11220725|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
11220726|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
11220727|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
11220728|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
11220729|NCT03240471|Experimental|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
11220730|NCT03240471|Other|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
11220731|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
11220732|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
11220733|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
11220734|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
11220735|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
11220736|NCT03240419|Experimental|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
11220737|NCT03240419|Placebo Comparator|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
11220738|NCT03240406|Active Comparator|Anti-inflammatory dietary intervention|18 month intervention of dietary counseling to adhere to the Multicultural Healthy Diet or the anti-inflammatory diet,
11220739|NCT03240406|Placebo Comparator|Usual Diet plus Self-Care|18 month intervention of usual diet plus self-care modules
11220740|NCT03240393|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
11220741|NCT03240393|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
11220742|NCT03240393|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
11220743|NCT03240380|Experimental|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
11220744|NCT03240380|Active Comparator|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
11220745|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
11220746|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
11220747|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
11220748|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
11220749|NCT03240341|Experimental|Patient Activation Measure (PAM)|completion of the PAM questionnaire
11220750|NCT03240328|Experimental|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
11220751|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
11220752|NCT03240302|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
11220753|NCT03240302|Active Comparator|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
11220754|NCT03240289|Other|Texting|Texting group
11220755|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
11220756|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
11220757|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
11220758|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
11220759|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
11220760|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
11220761|NCT03240237|Experimental|CCM therapy|Optimizer SMART
11220762|NCT03240224|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220763|NCT03240224|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220764|NCT03240224|Experimental|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220765|NCT03240224|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220766|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate|Subjects will receive pembrolizumab 200 mg IV day 1 with pralatrexate 30 mg/m2 IV day 1, 8, and 15.
11220767|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate plus Decitabine|Subjects will receive pembrolizumab 200 mg IV day 8 with pralatrexate 20 mg/m2 IV day 1, 8, and 15 and decitabine 10 mg/m2 from day 1 to 5.
11220768|NCT03240211|Experimental|Pembrolizumab plus Decitabine|Subjects will receive pembrolizumab 200 mg IV and decitabine 20 mg/m2 from day 1 to 5.
11220769|NCT03240198||COPD|
11220770|NCT03240198||Controls|
11220771|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
11220772|NCT03240159|Active Comparator|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.
~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.
~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
11220872|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
11220773|NCT03240159|Active Comparator|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.
~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.
~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
11220774|NCT03240159|Active Comparator|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.
~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.
~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.
~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
11220775|NCT03240146|Active Comparator|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
11220776|NCT03240146|Placebo Comparator|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
11220777|NCT03240133|Experimental|Part1: BCX7353 750 mg|
11220778|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
11220779|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
11220780|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
11220781|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
11220782|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
11220783|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
11220784|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
11220785|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
11220786|NCT03240081|Active Comparator|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
11220787|NCT03240081|Active Comparator|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
11220788|NCT03240068|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
11220789|NCT03240068|Placebo Comparator|Saline|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
11220790|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
11220791|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
11220792|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
11220793|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
11220794|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
11220795|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
11220796|NCT03240016|Experimental|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
11220797|NCT03240003|Experimental|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
11220798|NCT03240003|Active Comparator|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
11220799|NCT03240003|Experimental|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
11220800|NCT03239990|Experimental|Incredible Years, Parent support|Incredible Years, Parent group supported by home visiting includes the Incredible Years Parent Training Program, Preschool Basic version, with 18-20 group meetings. Four home visits are added to the program to support parents in practicing new skills and to provide individual practical consultation.
11220801|NCT03239990|No Intervention|Treatment as usual|The control group will receive treatment as usual
11220802|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
11220803|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
11220804|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.
~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
11220805|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.
~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
11220806|NCT03239951|Experimental|Device|Temporary implant (iTind)
11220807|NCT03239938|Experimental|Modern pain neuroscience approach|Modern pain neuroscience approach
11220808|NCT03239938|Active Comparator|Usual care evidence-based physiotherapy|Usual care physiotherapy
11220809|NCT03239925|Experimental|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
11220810|NCT03239925|Placebo Comparator|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
11220811|NCT03239912|Experimental|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
11220812|NCT03239912|Experimental|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
11220813|NCT03239899|Experimental|Pembrolizumab arm|Pembrolizumab 200mg will be administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
11220814|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
11220815|NCT03239873|Experimental|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
11220816|NCT03239873|Active Comparator|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
11220817|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
11220818|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
11220819|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
11220820|NCT03239847|Experimental|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
11220821|NCT03239847|Experimental|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
11220822|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
11220823|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
11220824|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
11220825|NCT03239821|Sham Comparator|Placebo - deflated balloon|
11220826|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
11220827|NCT03239821|Active Comparator|Codeine - delfated balloon|
11220828|NCT03239821|Active Comparator|Codeine - inflated balloon|
11220829|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
11220830|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
11220831|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
11220832|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
11220833|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.
~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.
~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
11220834|NCT03239769|Active Comparator|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
11220835|NCT03239769|Experimental|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
11220873|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
11220836|NCT03239769|Experimental|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
11220837|NCT03239756|Experimental|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
11220838|NCT03239756|Experimental|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
11220839|NCT03239756|Experimental|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
11220840|NCT03239756|Experimental|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
11220841|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
11220842|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
11220843|NCT03239717|Placebo Comparator|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
11220844|NCT03239717|Experimental|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
11220845|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
11220846|NCT03239704|Active Comparator|Minimal Intervention|
11220847|NCT03239691|Experimental|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
11220848|NCT03239691|Placebo Comparator|Placebo|Placebo will be administered on two study days
11220849|NCT03239678|Active Comparator|group A|100% Oxygen
11220850|NCT03239678|Experimental|group B|30% Oxygen.
11220851|NCT03239678|Experimental|group C|21% Oxygen
11220852|NCT03239678|Experimental|group D|40% Oxygen
11220853|NCT03239678|Experimental|group E|60% Oxygen
11220854|NCT03239678|Experimental|group F|80% Oxygen
11220855|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
11220856|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
11220857|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
11220858|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
11220859|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
11220860|NCT03239626|Experimental|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
11220861|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
11220862|NCT03239600|Experimental|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
11220863|NCT03239600|Placebo Comparator|Part II: Placebo|Placebo will be administered IV with MTX
11220864|NCT03239587||No Musical Intervention - Control Group|"Participants wait for 30 minutes in a standard pre-surgery waiting area without music.
~Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.
~Participants complete 2 questionnaires about anxiety and stress levels."
11220865|NCT03239587||Musical Intervention Group|"Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
~Blood drawn before, and about 30 minutes after participant in the waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
~Participants complete 2 questionnaires about anxiety and stress levels."
11220866|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
11220867|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
11220868|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
11220869|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
11220870|NCT03239535|Experimental|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
11220871|NCT03239535|Placebo Comparator|Normal saline|Normal saline, Intramuscular injection
11220874|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
11220875|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
11220878|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
11220879|NCT03239483|Experimental|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
11220880|NCT03239483|Placebo Comparator|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
11220881|NCT03239470|Experimental|Cohort 1: 1.0 x 10^8 PolyTregs|A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.
11220882|NCT03239470|Experimental|Cohort 2: 2.5x10^8 PolyTregs|A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.
11220883|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
11220884|NCT03239444|Other|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
11220885|NCT03239431||Asthma group|Patients with asthma
11220886|NCT03239418|Experimental|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
11220887|NCT03239418|Sham Comparator|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
11220888|NCT03239405||SCS|Treated via suction callibrated system
11220889|NCT03239405||Bougie|Treated with multiple tubes & bougie
11220890|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
11220891|NCT03239379|Placebo Comparator|Placebo|Normal saline
11220892|NCT03239379|Experimental|BNZ132-1-40|PEGylated BNZ-1 for Injection
11220893|NCT03239366|Active Comparator|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
11220894|NCT03239366|Placebo Comparator|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
11220895|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
11220896|NCT03239353|Active Comparator|3 mg ETV XR tablet|
11220897|NCT03239353|Active Comparator|6 mg ETV XR tablet|
11220898|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
11220899|NCT03239353|Other|0.5 mg ETV IR tablet|
11220900|NCT03239340|Experimental|Osimertinib|An oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer
11220901|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
11220902|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
11220903|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
11220904|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
11220905|NCT03239301|Active Comparator|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
11220906|NCT03239301|Active Comparator|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
11220907|NCT03239288|Placebo Comparator|Control digestible carbohydrate|Control baked breakfast bar
11220908|NCT03239288|Experimental|Test resistant starch type 4|Test baked breakfast bar
11220909|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.
~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
11220910|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
11220911|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
11220912|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
11220913|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
11220914|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
11220915|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
11220916|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
11220917|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
11220918|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.
~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.
~Arterial blood gas samples will be taken at different time points."
11220919|NCT03239223|Experimental|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
11220920|NCT03239223|Experimental|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
11220921|NCT03239210|Active Comparator|Ondansetron (OND)|24 mg/day for 4 weeks
11220922|NCT03239210|Placebo Comparator|Placebo (PL)|Placebo pill
11220923|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
11220924|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220925|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220926|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220927|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220928|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220929|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220930|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220931|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220932|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220933|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220934|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
11220935|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11220936|NCT03239145|Experimental|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
11220937|NCT03239145|Experimental|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
11220938|NCT03239145|Experimental|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
11220939|NCT03239145|Experimental|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
11220940|NCT03239145|Experimental|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
11220941|NCT03239132|Experimental|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
11220942|NCT03239132|Active Comparator|Control|The control will receive meditation educational materials.
11220943|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
11220946|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
11220947|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
11220948|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
11220949|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
11220950|NCT03239067||ticagrelor group|patients prescribed with ticagrelor
11220951|NCT03239067||clopidogrel group|patients prescribed with clopidogrel
11220952|NCT03239054|Experimental|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
11220953|NCT03239054|Other|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
11220954|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.
~The social navigation team will function as follows:
~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
11220955|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
11220956|NCT03239028||Danish National Birth Cohort|
11220957|NCT03239015|Experimental|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib.
11220958|NCT03238976|Experimental|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.
~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.
~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
11220959|NCT03238976|No Intervention|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.
~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
11220960|NCT03238963|Experimental|BI 1467335|
11220961|NCT03238963|Placebo Comparator|Placebo|
11220962|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
11220963|NCT03238950|Other|Synthetic|Training conducted on synthetic model
11220964|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
11220965|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
11220966|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
11220967|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
11220968|NCT03238911|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
11220969|NCT03238911|Active Comparator|Ferric carboxymaltose|Administered IV
11220970|NCT03238898|Active Comparator|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
11220971|NCT03238898|Placebo Comparator|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
11220972|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
11220973|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
11220974|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
11220975|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
11220976|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
11220977|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
11220978|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
11220979|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
11220980|NCT03238833|Experimental|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
11220981|NCT03238833|Active Comparator|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
11220982|NCT03238820|Experimental|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
11220983|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
11220984|NCT03238807|No Intervention|Control Group|Control Group
11220985|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
11220986|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
11220987|NCT03238781|Placebo Comparator|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
11220988|NCT03238781|Experimental|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
11220989|NCT03238781|Experimental|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
11220990|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
11220991|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
11220992|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
11220993|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
11220994|NCT03238742|Experimental|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
11220995|NCT03238742|Placebo Comparator|Placebo group|normal saline 200 mL every 12 hours for 5 days
11220996|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
11220997|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
11220998|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
11220999|NCT03238716|Active Comparator|NM Re-ed and Exercise|
11221000|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
11221001|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
11221002|NCT03238677|Experimental|Biofeedback, Massed->Distributed|Sequenced biofeedback Mass Practice--> Distributed Scheduling
11221003|NCT03238677|Active Comparator|No Biofeedback, Distributed|Speech Motor Chaining with no biofeedback. 2 sessions/wk for 10 weeks
11221004|NCT03238677|Experimental|Biofeedback, Distributed|Sequenced biofeedback, 2 sessions/wk for 10 weeks
11221005|NCT03238677|Experimental|No Biofeedback, Massed-> Distributed|Speech Motor Chaining with no biofeedback. Mass Practice--> Distributed Scheduling
11221006|NCT03238664|Experimental|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
11221007|NCT03238664|Active Comparator|Arm B (RARC)|Patients undergo standard of care RARC.
11221008|NCT03238651|Experimental|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
11221009|NCT03238651|Experimental|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
11221010|NCT03238651|Experimental|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
11221011|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.
~Cohort 1: Acquired Resistance Cohort
~Treat upon emergence of acquire resistance
~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease
~Progressive disease on recent scans
~Intercurrent therapy is allowed
~Cohort 2: Suboptimal Benefit Cohort
~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance
~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)
~Ongoing stable disease on recent scans
~Both cohorts will receive pembrolizumab and epacadostat."
11221066|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.
~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
11221012|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.
~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
11221013|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.
~Intervention: Every individual receives two injections:
~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
11221014|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
11221015|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
11221016|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
11221017|NCT03238586|Experimental|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
11221018|NCT03238586|No Intervention|Standard of Care|Five-week standard of care program.
11221019|NCT03238573||optical enhancment endoscopy|
11221020|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
11221021|NCT03238534|Active Comparator|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole [30' before meal] and Neobianacid® placebo [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.
~Treatment regimen:
~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo Lunch: Neobianacid® placebo Midafternoon: Neobianacid® placebo Dinner: Neobianacid® placebo Before going to bed: Neobianacid® placebo
~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo (both on demand) Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed
~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
11221022|NCT03238534|Experimental|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo [30' before meal] and Neobianacid® [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.
~Treatment regimen:
~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®
~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® (both on demand) Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed
~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
11221023|NCT03238521|Active Comparator|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
11221024|NCT03238521|Experimental|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
11221025|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
11221026|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
11221027|NCT03238495|Active Comparator|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
11221028|NCT03238495|Experimental|Chemotherapy plus Metformin|TCH+P plus metformin
11221029|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
11221030|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
11221031|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
11221032|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
11221033|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
11221034|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
11221035|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
11221067|NCT03238235|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
11221068|NCT03238235|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
11221143|NCT03237780|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11221036|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
11221037|NCT03238430|Experimental|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
11221038|NCT03238430|Experimental|intrathecal morphine|Rachianalgesia + PCA morphine
11221039|NCT03238430|Active Comparator|morphine PCA|PCA morphine alone
11221040|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
11221041|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
11221042|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
11221043|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
11221044|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
11221045|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
11221046|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
11221047|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
11221048|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
11221049|NCT03238352|Experimental|Test Product|Participants will rinse twice daily (morning and evening) with 10 milliliters (mL) of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
11221050|NCT03238352|Other|Negative Control|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
11221051|NCT03238352|Placebo Comparator|Placebo|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
11221052|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
11221053|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
11221054|NCT03238326|Experimental|Rollover & De-Novo|1-4 mg/day; Start at 0.5 mg/day, titrate and maintain between 1mg/day to max of 4 mg/day
11221055|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
11221056|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
11221057|NCT03238300|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg capsules by mouth, two pills twice daily for 10 days.
11221058|NCT03238300|Placebo Comparator|Placebo Oral Capsule|Placebo capsules by mouth, two pills twice daily for 10 days.
11221059|NCT03238287|Active Comparator|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
11221060|NCT03238287|Active Comparator|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
11221061|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
11221062|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
11221063|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
11221064|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
11221069|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
11221070|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
11221071|NCT03238209|Experimental|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
11221072|NCT03238196|Experimental|Escalation|"Fulvestrant - injection into muscle 1 time per month
~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)
~Erdafitinib tablet taken by mouth 1 time per day"
11221073|NCT03238196|Experimental|Expansion|"Fulvestrant - injection into muscle 1 time per month
~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)
~Erdafitinib tablet taken by mouth 1 time per day"
11221074|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
11221075|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
11221076|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
11221077|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
11221078|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
11221079|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
11221080|NCT03238131|Active Comparator|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
11221081|NCT03238131|Experimental|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
11221082|NCT03238131|Active Comparator|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
11221083|NCT03238131|Active Comparator|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
11221084|NCT03238118|Experimental|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
11221085|NCT03238118|Placebo Comparator|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
11221086|NCT03238118|Placebo Comparator|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
11221087|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
11221088|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
11221089|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
11221090|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
11221091|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
11221220|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
11221092|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.
~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
11221093|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.
~If HDR BT is chosen:
~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT
~If PDR BT is chosen:
~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
11221094|NCT03238053|Active Comparator|Menopausal Laser|20 women with vaginal laser treatment
11221095|NCT03238053|Sham Comparator|Menopausal sham|20 women with probe, no active laser ray
11221096|NCT03238053|Active Comparator|breast cancer laser|20 women with breast cancer with vaginal laser treatment
11221097|NCT03238053|Sham Comparator|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
11221098|NCT03238053|Active Comparator|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
11221099|NCT03238053|Sham Comparator|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
11221100|NCT03238053|Active Comparator|overactive bladder laser|20 women with overactive bladder with vaginal laser treatment
11221101|NCT03238053|Sham Comparator|Overactive bladder sham|20 women with overactive bladder with vaginal probe, no active laser rays
11221102|NCT03238027|Experimental|Ph1a D1: 1 mg/kg SNDX-6352|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
11221103|NCT03238027|Experimental|Ph1a D2: 3 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
11221104|NCT03238027|Experimental|Ph1a D3: 6 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
11221105|NCT03238027|Experimental|Ph1a D4: 10 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 10 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
11221106|NCT03238027|Experimental|Ph1b D1: 1 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg SNDX-6352 dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
11221107|NCT03238027|Experimental|Ph1b D2: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
11221108|NCT03238027|Experimental|Ph1b D3: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
11221109|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
11221110|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
11221111|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
11221112|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
11221113|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
11221114|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
11221115|NCT03237975|Experimental|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
11221116|NCT03237975|Active Comparator|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
11221117|NCT03237962|Experimental|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
11221118|NCT03237962|Experimental|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
11221119|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
11221120|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
11221121|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
11221122|NCT03237910|Experimental|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
11221123|NCT03237910|Active Comparator|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
11221124|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
11221125|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
11221126|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
11221127|NCT03237858|Active Comparator|HeartLogic ON|ICD and CRT-D devices with HeartLogic alerts turned ON
11221128|NCT03237858|Placebo Comparator|HeartLogic OFF|ICD and CRT-D devices with HeartLogic alerts turned OFF
11221129|NCT03237845|Experimental|BHV-3000|rimegepant 75 mg tablet QD
11221130|NCT03237845|Placebo Comparator|Placebo|Matching 75mg placebo tablet QD
11221131|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
11221132|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
11221133|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
11221134|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
11221135|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
11221136|NCT03237819|Placebo Comparator|Placebo|Glucose serum (3 ampoules)
11221137|NCT03237819|Experimental|Magnesium Sulfate|20/5000 magnesium sulfate (4 ampoules, 1,5g each)
11221138|NCT03237806|No Intervention|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
11221139|NCT03237806|Experimental|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
11221140|NCT03237806|Experimental|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
11221141|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
11221142|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
11221221|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
11221144|NCT03237780|Experimental|Arm II (atezolizumab, eribulin mesylate)|Patients receive atezolizumab IV over 30-60 minutes on day 1 and eribulin mesylate IV over 2-3 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11221145|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
11221146|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
11221147|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
11221148|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
11221149|NCT03237741|Experimental|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
11221150|NCT03237741|Experimental|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
11221151|NCT03237741|Experimental|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
11221152|NCT03237741|Experimental|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
11221153|NCT03237728|Experimental|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
11221154|NCT03237728|Experimental|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
11221155|NCT03237728|Experimental|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
11221156|NCT03237728|Experimental|Placebos|Group D:Placebos,Q8h,Day1-Day7
11221157|NCT03237715||Breast fed cohort|
11221158|NCT03237715||Formula fed cohort|
11221159|NCT03237702|Experimental|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
11221160|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
11221161|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
11221162|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
11221163|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
11221164|NCT03237663|Experimental|One enteric capsule|
11221165|NCT03237663|Experimental|Two enteric capsule|
11221166|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
11221167|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
11221168|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
11221169|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
11221170|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
11221171|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
11221172|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
11221173|NCT03237585|Experimental|i) Intervention arm- Receive Gender Centre's RRS package|
11221174|NCT03237585|No Intervention|No intervention|
11221278|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
11221175|NCT03237572|Experimental|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
11221176|NCT03237572|Experimental|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
11221177|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
11221178|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
11221179|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
11221180|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
11221181|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
11221182|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
11221183|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
11221184|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
11221185|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
11221186|NCT03237494||Participants with polyneuropathy or cardiomyopathy|Participants with polyneuropathy or cardiomyopathy of no obvious etiology aged between 18 and 85 years
11221187|NCT03237481|Experimental|Treatment Group 1|HTX 011
11221188|NCT03237481|Active Comparator|Treatment Group 2|Bupivacaine HCl
11221189|NCT03237481|Placebo Comparator|Treatment Group 3|Saline placebo
11221190|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
11221191|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
11221192|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
11221193|NCT03237442|Experimental|group 1|
11221194|NCT03237442|Active Comparator|group 2|
11221195|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
11221196|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
11221197|NCT03237416|Experimental|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
11221198|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11221199|NCT03237377|Experimental|Durvalumab with Radiation|
11221200|NCT03237377|Experimental|Durvalumab and Trememlimumab with Radiation|
11221201|NCT03237351|Active Comparator|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
11221202|NCT03237351|Experimental|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV < 5%) .
11221203|NCT03237351|Experimental|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV < 8%) .
11221204|NCT03237338|Experimental|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
11221205|NCT03237338|Sham Comparator|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
11221206|NCT03237325|Experimental|SGX942|Patients are randomized 1:1 active/placebo.
11221207|NCT03237325|Placebo Comparator|Placebo|Patients are randomized 1:1 active/placebo.
11221208|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
11221209|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
11221210|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
11221211|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
11221212|NCT03237286|Experimental|Ketamine + Cognitive Training|
11221213|NCT03237286|Sham Comparator|Ketamine + Sham Training|
11221214|NCT03237286|Placebo Comparator|Saline + Cognitive Training|
11221215|NCT03237273|Experimental|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
11221216|NCT03237260|Experimental|Vedolizumab 300mg|vedolizumab open label
11221217|NCT03237247||Benign|cases with benign biliary stricture
11221218|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
11221219|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
11221222|NCT03237234|Sham Comparator|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
11221223|NCT03237234|Experimental|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
11221224|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
11221225|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
11221226|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
11221227|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
11221228|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
11221229|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
11221230|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
11221231|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
11221232|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
11221233|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
11221234|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
11221235|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
11221236|NCT03237117|Experimental|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
11221237|NCT03237117|Active Comparator|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
11221238|NCT03237117|No Intervention|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
11221239|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
11221240|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
11221241|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
11221242|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
11221243|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
11221244|NCT03237091|Active Comparator|sham-control|
11221245|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
11221246|NCT03237065|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
11221247|NCT03237065|Active Comparator|Ferric carboxymaltose|Administered IV
11221248|NCT03237052|Experimental|model|model aided decision
11221249|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
11221250|NCT03237039|Other|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
11221251|NCT03237026||Cohort A|Cohort A will be recruited in the first 12 months of the study period to generate the first batch of urine metabolite profiles as predictive and prognostic markers.
11221252|NCT03237026||Cohort B|Cohort B will be recruited in the next 12 months of the study period to validate the first batch of newly developed urine metabolite profiles.
11221279|NCT03236805|Experimental|Ketamine IV|
11221280|NCT03236805|Active Comparator|Morphine IV|
11221281|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
11221451|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
11221253|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
11221254|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
11221255|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
11221256|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.
~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
11221257|NCT03236987|Active Comparator|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :
~Rifampicin (10mg/kg once daily)
~Ethambutol (15 to 20 mg/kg once daily)
~Clarithromycin (500 mg twice daily)"
11221258|NCT03236987|Experimental|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :
~Rifampicin (10mg/kg once daily)
~Ethambutol (15 to 20 mg/kg once daily)
~Azithromycin (250 mg once daily)"
11221259|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
11221260|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
11221261|NCT03236961|Active Comparator|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
11221262|NCT03236961|Active Comparator|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
11221263|NCT03236948|Experimental|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
11221264|NCT03236948|No Intervention|Control|
11221265|NCT03236935|Experimental|L-NMMA Plus Pembrolizumab|L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1-5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 20 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
11221266|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
11221267|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
11221268|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
11221269|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
11221270|NCT03236883|Experimental|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)*10^8/kg
11221271|NCT03236883|Other|Gemcitabine|
11221272|NCT03236883|Other|GPBSC|
11221273|NCT03236870||Participants with moderate to severe plaque psoriasis in China|Participants with moderate to severe plaque psoriasis in China receiving adalimumab in daily clinical practice.
11221274|NCT03236857|Experimental|Venetoclax with or without chemotherapy|Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
11221275|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
11221276|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
11221277|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
11221282|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
11221283|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
11221284|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
11221285|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
11221286|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
11221287|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
11221288|NCT03236727|No Intervention|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
11221289|NCT03236727|Active Comparator|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
11221290|NCT03236701|No Intervention|Control|usual diet
11221291|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
11221292|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
11221293|NCT03236675||EML4-ALK|ALK positive patients
11221294|NCT03236675||T790M EGFR|T790M positive patients
11221295|NCT03236662|Experimental|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
11221296|NCT03236649|Experimental|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
11221297|NCT03236649|Active Comparator|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
11221298|NCT03236636|Experimental|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
11221299|NCT03236636|Active Comparator|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
11221300|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
11221301|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
11221302|NCT03236610|Experimental|tenofovir|
11221303|NCT03236610|Active Comparator|tenofovir plus entecavir|
11221304|NCT03236597|No Intervention|Usual Desk|participants will work at their usual desk for four weeks.
11221305|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
11221306|NCT03236584|Active Comparator|lamivudine adefovir|
11221307|NCT03236584|Experimental|tenofovir|
11221308|NCT03236571|Experimental|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
11221309|NCT03236558|Experimental|Patients with diabetes|T1D patients with blood collection
11221310|NCT03236545|Experimental|No to Low Endogenous Estrogen|PMW and young women (YW) will receive medical study clearance after a detailed physical examination. YW will self-administer subcutaneous injections of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix acetate (Antagon, 0.25 mg/day in 0.5 ml of normal saline, Organon, Inc., West Orange, New Jersey,) daily to suppress endogenous ovarian hormone production (16, 17, 18). This will begin following a separate medical screening at Reproductive Associates of Delaware 48 hours prior to initiating the hormone intervention to rule out other contraindications prior to beginning the treatment. YW will begin using the antagonist on days 26-28 of their menstrual cycle, and continue daily for 10-12 days. The experimental protocol will be conducted in YW after 3-4 days of using the GnRH antagonist. PMW will complete the experimental protocol prior to use of the 17β-estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch).
11221311|NCT03236545|Experimental|Estrogen Add-Back|Estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch) will be administered for 7 days to both young and PMW. Young women will use the E2 over the last 7 days of Antagon administration.
11221312|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
11221313|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
11221314|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
11221315|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
11221316|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
11221317|NCT03236493|Experimental|PF-06700841|Multiple ascending doses of PF-06700841
11221318|NCT03236493|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
11221319|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
11221320|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
11221321|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
11221322|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
11221323|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
11221324|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
11221325|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
11221326|NCT03236428|Experimental|Daratumumab|Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20
11221327|NCT03236415|Active Comparator|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
11221328|NCT03236415|Active Comparator|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
11221329|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
11221330|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
11221331|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
11221332|NCT03236402||>65 years|Adults who were in the age group of >65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of >65 years.
11221333|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
11221334|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
11221335|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
11221336|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
11221337|NCT03236363|No Intervention|Control|No intervention
11221338|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
11221339|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
11221340|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
11221341|NCT03236337|No Intervention|Control|No intervention
11221342|NCT03236337|Experimental|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
11221343|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
11221344|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
11221345|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks.
11221346|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
11221347|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
11221348|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
11221349|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
11221350|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
11221351|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
11221352|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
11221353|NCT03236272||case group|patients with ARDS
11221354|NCT03236272||control group|patients Without ARDS
11221355|NCT03236259|Active Comparator|Brainport high dose|
11221356|NCT03236259|Active Comparator|Brainport low dose|
11221357|NCT03236259|Placebo Comparator|Placebo|Maltodextrin
11221358|NCT03236246|Experimental|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
11221359|NCT03236246|Experimental|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
11221360|NCT03236233|Experimental|Single dose - healthy subjects|
11221361|NCT03236233|Experimental|Repeat dose - healthy subjects|
11221362|NCT03236233|Experimental|Single dose - subjects with asthma|
11221363|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
11221364|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
11221365|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
11221366|NCT03236181|Other|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
11221367|NCT03236181|Other|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
11221368|NCT03236181|Other|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
11221369|NCT03236181|Other|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
11221370|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
11221371|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
11221372|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
11221373|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
11221374|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
11221375|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
11221376|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
11221377|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
11221378|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
11221379|NCT03236103|Other|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
11221380|NCT03236090|Active Comparator|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
11221448|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
11221381|NCT03236090|Active Comparator|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
11221382|NCT03236077|No Intervention|Control|
11221383|NCT03236077|Experimental|Intervention|
11221384|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
11221385|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
11221386|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
11221387|NCT03236025|Experimental|Experimental group|Video+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group.
11221388|NCT03236025|Active Comparator|Conditional control group|Text-message+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. Text-message contains the same content with videos and will be sent in the same frequency with the videos through the smart phone to the participants in the Conditional control group.
11221389|NCT03236025|Placebo Comparator|Placebo control group|Participants in the control group will be given a one-sentence smoking cessation advice during the baseline assessment. A leaflet showed the information related to the smoking cessation will be allocated to them at the same time.
11221390|NCT03236012|Experimental|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.
~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
11221391|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
11221392|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
11221393|NCT03235986|Experimental|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
11221394|NCT03235986|Other|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
11221395|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
11221396|NCT03235947|Experimental|Fosfomycin disodium|"Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.
~Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
11221397|NCT03235947|Active Comparator|Trimethoprim / Sulfamethoxazole|"Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.
~Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
11221398|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
11221399|NCT03235921|Other|control group|no drug given to the patients in control group
11221400|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
11221401|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.
~Followed by one day face to face CME activity"
11221402|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
11221403|NCT03235895|No Intervention|Wait listed|No CME activity will be given
11221404|NCT03235882||observational group|"Infants born 24-32 weeks.
~Inclusion criteria:
~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:
~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or
~a nasogastric tube inserted as part of routine management of preterm infants.
~Written informed consent has been obtained"
11221405|NCT03235869|Experimental|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
11221406|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
11221407|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
11221408|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
11221409|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
11221410|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
11221411|NCT03235817|Experimental|Spontaneous ventilation|
11221412|NCT03235817|Experimental|Pressure support ventilation|
11221413|NCT03235817|Active Comparator|Pressure control ventilation|
11221414|NCT03235804|No Intervention|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat).
11221449|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
11221450|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
11221415|NCT03235804|Experimental|High-Protein Group|Those assigned to the High-Protein group will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
11221416|NCT03235778|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
11221417|NCT03235778|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
11221418|NCT03235778|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
11221419|NCT03235778|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
11221420|NCT03235778|Experimental|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
11221421|NCT03235778|Experimental|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
11221422|NCT03235778|Experimental|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
11221423|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
11221424|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
11221425|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
11221426|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
11221427|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
11221428|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
11221429|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
11221430|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
11221431|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
11221432|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
11221433|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
11221434|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
11221435|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
11221436|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
11221437|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
11221438|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
11221439|NCT03235700|Experimental|Adenosine followed by nicorandil|
11221440|NCT03235700|Experimental|Nicorandil followed by adenosine|
11221441|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
11221442|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
11221443|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
11221444|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
11221445|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
11221446|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
11221447|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
11221452|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
11221453|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
11221454|NCT03235583|Other|MotionPod Validation|Medical device validation
11221455|NCT03235570|Experimental|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
11221456|NCT03235544|Experimental|Cohort 1- Parsaclisib|Participants who have previously received ibrutinib.
11221457|NCT03235544|Experimental|Cohort 2 - Parsaclisib|Participants who have not previously received a BTK inhibitor.
11221458|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.
~CIWA Score 9-14: 1 mg IV push lorazepam
~CIWA Score >15: 2 mg IV push lorazepam
~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.
~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
11221459|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool
~CIWA Score 9-14: 1 mg IV push lorazepam
~CIWA Score >15: 2 mg IV push lorazepam
~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
11221460|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
11221461|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
11221462|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
11221463|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
11221464|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
11221465|NCT03235505|Experimental|Nicotine containing e-cigarettes|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
11221466|NCT03235505|Active Comparator|Nicotine-free e-cigarettes|Nicotine-free e-cigarettes + varenicline tartrate+ MI
11221467|NCT03235505|Placebo Comparator|Motivational Interview (MI)|Placebo-varenicline + nicotine -free e-cigarettes + MI
11221468|NCT03235492|Experimental|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
11221469|NCT03235479|Experimental|BHV-3000|
11221470|NCT03235479|Placebo Comparator|Placebo|
11221606|NCT03234608|No Intervention|Control|Patients will receive usual care.
11221607|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
11221608|NCT03234569|Experimental|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
11221471|NCT03235466|Active Comparator|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
11221472|NCT03235466|Active Comparator|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
11221473|NCT03235466|Active Comparator|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
11221474|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
11221475|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
11221476|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
11221477|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
11221478|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
11221479|NCT03235414|Experimental|Normals|Will receive an MRI and a blood draw
11221480|NCT03235401||Pulmonary Arterial Hypertension patients|
11221481|NCT03235388|Experimental|Intervention|Audit filter implementation in hospital
11221482|NCT03235388|No Intervention|Control|Routine care
11221483|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
11221484|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
11221485|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
11221486|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
11221487|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
11221488|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
11221489|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
11221490|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.
~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
11221491|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
11221492|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.
~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.
~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
11221493|NCT03235349|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
11221609|NCT03234556|Active Comparator|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
11221494|NCT03235323|Experimental|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
11221495|NCT03235323|No Intervention|Control group|Patients of Control group received routine medicine treatment postoperatively
11221496|NCT03235297||Healthy subjects|Healthy subjects
11221497|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
11221498|NCT03235284|Active Comparator|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
11221499|NCT03235284|Active Comparator|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.
~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
11221500|NCT03235284|Experimental|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
11221501|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
11221502|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
11221503|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
11221504|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
11221505|NCT03235245|Active Comparator|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
11221506|NCT03235245|Experimental|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
11221507|NCT03235232|Experimental|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
11221508|NCT03235232|Active Comparator|Combigan®|1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
11221509|NCT03235219|Experimental|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
11221510|NCT03235219|Experimental|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
11221511|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
11221512|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
11221906|NCT03232541|Placebo Comparator|Sham acupuncture (B)|Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
11221513|NCT03235180|Experimental|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.
~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
11221514|NCT03235167|Experimental|CpG DNA|CpG DNA concentrate
11221515|NCT03235167|Placebo Comparator|placebo|placebo concentrate
11221516|NCT03235154|Other|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
11221517|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
11221518|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
11221519|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
11221520|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
11221521|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
11221522|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
11221523|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
11221524|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
11221525|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
11221526|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
11221527|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
11221528|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
11221529|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
11221530|NCT03235089|Active Comparator|Test lens|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
11221531|NCT03235089|Active Comparator|nelfilcon A lens (control)|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
11221532|NCT03235076|Experimental|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
11221533|NCT03235076|Experimental|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
11221534|NCT03235076|Experimental|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
11221535|NCT03235076|Experimental|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
11221536|NCT03235050|Experimental|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
11221537|NCT03235050|Experimental|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
11221538|NCT03235050|Experimental|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
11221539|NCT03235050|Placebo Comparator|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
11221540|NCT03235050|Active Comparator|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
11221541|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
11221542|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle
~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
11221543|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle
~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
11221544|NCT03234998|Experimental|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
11221545|NCT03234998|Active Comparator|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
11221546|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
11221547|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
11221672|NCT03234114|Experimental|12-month DT-1|Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg qd for 12 months after PCI
11221548|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death [each cycle is 28 days]), if recommended by the site investigator.
11221549|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
11221550|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
11221551|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
11221552|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
11221553|NCT03234933|Experimental|Mobility Tracker|"Each patient will be provided by the research team staff with a new mobility tracker
~The standard pre-operative assessment, surgical procedure and post-operative care will still be done
~Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
11221554|NCT03234920|Placebo Comparator|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
11221555|NCT03234920|Experimental|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
11221556|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase.
11221557|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV, infusion, at Weeks 0, 2, and 6 in the induction phase.
11221558|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q8W + Placebo Q8W|Vedolizumab 300 mg, IV, infusion, every 8 Weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching IV, infusion Q8W at Weeks 18, 26, 34, 42, 50 and 58 in the maintenance phase in participants who receive vedolizumab in the induction phase and achieve clinical response at Week 10.
11221559|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q4W|Vedolizumab 300 mg, IV, infusion, every 4 weeks (Q4W), from Week 14 to Week 58 in the maintenance phase in participants who receive vedolizumab or placebo in the induction phase and do not achieve clinical response at Week 10.
11221560|NCT03234907|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching IV, infusion, every 4 weeks, Week 14 to Week 58 in the maintenance phase in participants who receive placebo in the induction phase and achieve clinical response at Week 10.
11221561|NCT03234894|Other|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.
~There is a secondary metric as to patient reported pain on a 1-10scale."
11221562|NCT03234881|Active Comparator|MOVE!|Weight management delivered as Treatment-as-Usual
11221563|NCT03234881|Experimental|MOVE!+gshCBT|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
11221564|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
11221565|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
11221566|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
11221610|NCT03234556|Experimental|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.
~If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.
~If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
11221671|NCT03234114|Experimental|6-month TT|Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 6 months (180 days）then quit aspirin till 12 months after PCI
11221567|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.
~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:
~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
11221568|NCT03234855||LMD|Physician uses LMD during procedure.
11221569|NCT03234842|Experimental|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
11221570|NCT03234842|Active Comparator|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
11221571|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
11221572|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
11221573|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
11221574|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
11221575|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
11221576|NCT03234790|Active Comparator|Filtered Air Exposure|Exposure for 4 hours to filtered air
11221577|NCT03234790|Experimental|Diesel Exhaust Exposure|Volunteers exposed to different concentrations of diesel exhaust
11221578|NCT03234777|Experimental|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
11221579|NCT03234777|Sham Comparator|Regular video|3 minute video on hand washing for infection control
11221580|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
11221581|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
11221582|NCT03234738|Active Comparator|Cohort A|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11221583|NCT03234738|Active Comparator|Cohort B|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11221584|NCT03234738|Active Comparator|Cohort C|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11221585|NCT03234738|Active Comparator|Cohort D|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11221586|NCT03234738|Active Comparator|Cohort E|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11221587|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
11221588|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
11221589|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
11221590|NCT03234699|Experimental|Single Group|
11221591|NCT03234686|Experimental|Deferiprone|Patients will orally receive the equivalent 15 mg/kg of 600mg delayed release Deferiprone tablets twice daily.
11221592|NCT03234686|Placebo Comparator|Placebo|Patients will receive matching placebo tablets designed to mimic the experimental treatment, twice daily
11221593|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
11221594|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
11221595|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
11221596|NCT03234660|Experimental|Dexmedetomidine|dexmedetomidine infusion
11221597|NCT03234660|Placebo Comparator|control|placebo infusion
11221598|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
11221599|NCT03234634|No Intervention|Group 1: patients with good collateral|
11221600|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
11221601|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
11221602|NCT03234621|Experimental|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
11221603|NCT03234621|Experimental|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
11221604|NCT03234621|Experimental|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
11221605|NCT03234608|Experimental|Intervention|Patients will use the AASPIRE Healthcare Toolkit and will share a copy of their Autism Healthcare Accommodations Report with their primary care provider.
11221611|NCT03234543|Experimental|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
11221612|NCT03234543|Sham Comparator|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
11221613|NCT03234530||WTC responders|WTC Health Program participants
11221614|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
11221615|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
11221616|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
11221617|NCT03234504||Normal healthy volunteers|
11221618|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
11221619|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
11221620|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
11221621|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
11221622|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
11221623|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
11221624|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
11221625|NCT03234465|Experimental|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
11221626|NCT03234465|Placebo Comparator|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
11221627|NCT03234452|Experimental|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
11221628|NCT03234452|Placebo Comparator|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
11221629|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
11221630|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
11221631|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
11221632|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
11221633|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
11221634|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
11221635|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
11221666|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).
~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
11221667|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
11221668|NCT03234127|Other|Control|FH patient with atheroclerosis
11221669|NCT03234127|Other|the related population without familial hypercholesterolemia|No FH patient
11221636|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes
~Inclusion criteria:
~Males and females ≥ 12 years of age
~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat) and, where possible, diagnostic genotyping
~Established CFRD in accordance with the most recent American Diabetes Association positional statement]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:
~2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)
~Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)
~Glycated hemoglobin ≥ 48 mmol/mol
~No contraindications to performing exhaustive exercise
~Can understand and cooperate with the study protocol
~No increase in symptoms or weight loss in the preceding 2 weeks"
11221637|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes
~Inclusion criteria:
~Males and females ≥ 12 years of age
~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired
~No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; [110]).
~No contraindications to performing exhaustive exercise
~Can understand and cooperate with the study protocol
~No increase in symptoms or weight loss in the preceding 2 weeks"
11221638|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
11221639|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
11221640|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
11221641|NCT03234361|Experimental|High Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.
11221642|NCT03234361|Placebo Comparator|Low Phosphate Phase|All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.
11221643|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
11221644|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
11221645|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
11221646|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
11221647|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
11221648|NCT03234309|Experimental|Diagnostic (ferumoxytol, MRI)|Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
11221649|NCT03234296|Active Comparator|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
11221650|NCT03234296|Active Comparator|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
11221651|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
11221652|NCT03234270|Experimental|F35 pilots|
11221653|NCT03234270|Active Comparator|F15 pilots|
11221654|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
11221655|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
11221656|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
11221657|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
11221658|NCT03234231|No Intervention|Control Group|This group receive nothing during the study period.
11221659|NCT03234231|Experimental|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
11221660|NCT03234205|Experimental|MRI scan during free respiration|
11221661|NCT03234192|Active Comparator|Therapeutic ultra sound|
11221662|NCT03234192|Active Comparator|Astym Treatment Technique|
11221663|NCT03234192|Active Comparator|Graston Treatment Technique|
11221664|NCT03234153|Experimental|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
11221665|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :
~PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396
~RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441
~FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229
~MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178
~MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321
~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
11221670|NCT03234114|Experimental|1-month TT|Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 1 month (30 days) then quit aspirin till 12 months after PCI
11222182|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
11221673|NCT03234114|Experimental|12-month DT-2|Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI
11221674|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
11221675|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
11221676|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
11221677|NCT03234062|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11221678|NCT03234062|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11221679|NCT03234062|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11221680|NCT03234062|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11221681|NCT03234062|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11221682|NCT03234062|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
11221683|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
11221684|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
11221685|NCT03234036|Experimental|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.
~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.
~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.
~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
~There will be a wash out of 15 days between Part 1A and Part 1B."
11221686|NCT03234036|Experimental|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.
~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.
~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.
~There will be a wash out of 15 days between Part 1A and Part 1B."
11221687|NCT03234036|Experimental|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
11221688|NCT03234036|Placebo Comparator|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
11221689|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
11221690|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
11221691|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
11221692|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
11221693|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
11221694|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
11221695|NCT03233997|Experimental|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
11221696|NCT03233997|Experimental|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
11221697|NCT03233997|Experimental|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
11221698|NCT03233997|Experimental|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
11221699|NCT03233984|No Intervention|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
11221700|NCT03233984|Active Comparator|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
11221701|NCT03233984|Experimental|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
11221702|NCT03233971||Older adults|
11221703|NCT03233971||Caregivers|
11221704|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
11221705|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
11221706|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
11221729|NCT03233737|Experimental|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
11221707|NCT03233919|Experimental|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:
~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.
~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.
~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
11221708|NCT03233919|No Intervention|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
11221709|NCT03233906|Active Comparator|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
11221710|NCT03233906|No Intervention|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
11221711|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
11221712|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
11221713|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
11221714|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
11221715|NCT03233854|Experimental|Treatment (CD19/CD22 CAR T cells, chemotherapy)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
11221716|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
11221717|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
11221718|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
11221719|NCT03233828|Experimental|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
11221720|NCT03233828|Placebo Comparator|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
11221721|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
11221722|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
11221723|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
11221724|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
11221725|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
11221726|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
11221727|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.
~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.
~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
11221728|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
11222273|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<10gm/dl
11221730|NCT03233737|Active Comparator|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
11221731|NCT03233737|Experimental|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
11221732|NCT03233737|Active Comparator|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
11221733|NCT03233737|Placebo Comparator|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
11221734|NCT03233724|Experimental|1/Dose Escalation|DAC-THU + pembrolizumab at escalating doses
11221735|NCT03233724|Experimental|2/Dose Expansion|DAC-THU + pembrolizumab at the dose established in Arm 1
11221736|NCT03233711|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11221737|NCT03233711|Other|Arm B (clinical observation)|Patients undergo observation for up to 6 months.
11221738|NCT03233685|Experimental|Experimental Group|Subjects will perform a visual training for 12 weeks
11221739|NCT03233685|Active Comparator|Control Group|Subjects will perform the normal training routine for 12 weeks
11221740|NCT03233672|Other|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
11221741|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
11221742|NCT03233646|Experimental|Case|500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease
11221743|NCT03233646|Active Comparator|Controls|Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease.
11221744|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
11221745|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
11221746|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
11221747|NCT03233594||Chiropractic Group|Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
11221748|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
11221749|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
11221750|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
11221751|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
11221752|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
11221753|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
11221754|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
11221755|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
11221756|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
11221757|NCT03233542|Experimental|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
11221758|NCT03233542|No Intervention|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
11221759|NCT03233542|Other|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
11221760|NCT03233529|Experimental|Crisaborole ointment|
11221761|NCT03233529|Placebo Comparator|Placebo ointment (vehicle)|
11221762|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
11221763|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
11221764|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
11221765|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
11221766|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
11221767|NCT03233490|Experimental|CPR training intervention|CPR training without web course
11221768|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：
~Clinical diagnosis of Posner-Schlossman Syndrome
~Able to communicate with doctor and understand this study
~Exclusion criteria:
~Not be able to communicate with doctor and understand this study
~One or more authorized investigators think he or she will suffer from any severe risks from the study"
11221769|NCT03233477||cataract|"Inclusion criteria：
~Clinical diagnosis of age-related cataract
~Prepare for cataract operation
~Open angle and intraocular pressure is normally at anytime
~No family history of glaucoma
~Exclusion criteria:
~Patients above 65 years old
~With Secondary ocular hypertension
~Have the history of receiving any ophthalmologic operation or anti-viral therapy
~With diabetes mellitus
~With autoimmune disease
~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
11221770|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：
~Both eyes involved
~Open angle
~Progressive glaucomatous optic neuropathy
~Specific visual field loss of glaucoma
~Intraocular pressure above the up limit of normal people
~Exclusion criteria:
~Patients above 65 years old
~With Secondary ocular hypertension
~Have the history of receiving any ophthalmologic operation or anti-viral therapy
~With diabetes mellitus
~With autoimmune disease
~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
11221771|NCT03233451|Experimental|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
11221772|NCT03233451|No Intervention|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
11221773|NCT03233438|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
11221774|NCT03233438|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
11221775|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
11221776|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
11221777|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
11221778|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
11221779|NCT03233386||Condition 1|Mexico City Cohort
11221780|NCT03233386||Condition 2|Monterrey Cohort
11221781|NCT03233386||Condition 3|Guadalajara Cohort
11221782|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
11221783|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
11221784|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
11221785|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
11221786|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
11221787|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
11221788|NCT03233308|Placebo Comparator|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
11221789|NCT03233295|Experimental|Vitamin D deficiency|
11221790|NCT03233282|Other|Cognitive Fatigability|
11221791|NCT03233282|Other|Physical Fatigability|
11221904|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
11221792|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
11221793|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
11221794|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
11221795|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
11221796|NCT03233230|Placebo Comparator|Placebo|
11221797|NCT03233230|Experimental|M2951 25 mg QD|
11221798|NCT03233230|Experimental|M2951 75 mg QD|
11221799|NCT03233230|Experimental|M2951 50 mg BID|
11221800|NCT03233217|Experimental|Cohort 1: QIV-HD by IM|Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
11221801|NCT03233217|Experimental|Cohort 1: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
11221802|NCT03233217|Experimental|Cohort 2: QIV-HD by IM|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
11221803|NCT03233217|Experimental|Cohort 2: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
11221804|NCT03233217|Active Comparator|Cohort 2: QIV-SD by SC|Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
11221805|NCT03233204|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11221806|NCT03233191|Experimental|Arm A (digital mammography)|Patients undergo bilateral screening DM with standard CC and MLO views at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
11221807|NCT03233191|Experimental|Arm B (digital tomosynthesis mammography)|Patients undergo manufacturer-defined screening TM at baseline, 12, 24, 36, and 48 months if pre-menopausal or at baseline, 24, and 48 months if post-menopausal.
11221808|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
11221809|NCT03233178||Liraglutide|Patients initiation liraglutide
11221810|NCT03233178||Sitagliptin|Patients initiating sitagliptin
11221811|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
11221812|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.
~Intervention using Er:YAG laser"
11221813|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.
~Intervention using Er,Cr:YSGG laser"
11221814|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.
~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).
~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
11221815|NCT03233139|Experimental|REGN2810|Part 1
11221816|NCT03233139|Experimental|Cohort A|Part 2
11221817|NCT03233139|Experimental|Cohort B|Part 2
11221818|NCT03233126|Experimental|KRN23|
11221819|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
11221820|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
11221821|NCT03233100|Experimental|FMT group|
11221822|NCT03233087||Top third of subjects based levels of selected biomarker.|
11221823|NCT03233087||Middle third of subjects based levels of selected biomarker.|
11221824|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
11221825|NCT03233074||Acute Myeloid Leukemia patients|For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
11221826|NCT03233074||Healthy donors|Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
11221827|NCT03233061|Active Comparator|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
11221828|NCT03233061|Experimental|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
11221829|NCT03233048|Experimental|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
11221830|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
11221831|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
11221832|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
11221833|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
11221834|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11221835|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11221836|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
11221837|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
11221838|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
11221839|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
11221840|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
11221841|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
11221842|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
11221843|NCT03232983|Experimental|LY900014 (SC Abdomen)|Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
11221844|NCT03232983|Experimental|LY900014 (SC Thigh)|Single dose of 15-U of LY900014 administered SC into the thigh in one period
11221845|NCT03232983|Experimental|LY900014 (SC Arm)|Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
11221846|NCT03232983|Active Comparator|LY900014 (IV)|Single dose of 15-U of LY900014 administered intravenously (IV) in one period
11221847|NCT03232970|Experimental|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
11221848|NCT03232970|No Intervention|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
11221849|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
11221850|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
11221851|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
11221852|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
11221853|NCT03232931|Experimental|Intervention|The Multisensory intervention will be carried out in addition to standard care and will include 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking for the first 20 minutes of holding. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
11221854|NCT03232931|Other|Control (standard of care)|The standard care of infant currently follows 2 medical protocols, one for parental Skin-to-Skin holding and one for exposure to parent's voice.
11221855|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
11221856|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
11221857|NCT03232905|Experimental|PF-06651600|Multiple ascending doses of PF-06651600
11221858|NCT03232905|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
11221859|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
11221860|NCT03232879|Experimental|Experimental 1|Motor Imagery
11221861|NCT03232879|Experimental|Experimental 2|Action Observation
11221862|NCT03232879|No Intervention|Control Group|No intervention
11221863|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
11221864|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
11221905|NCT03232541|Other|Standard care (A)|Standard care (A) with neutral communication (A1) or positive communication (A2)
11221865|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
11221866|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
11221867|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
11221868|NCT03232827|Active Comparator|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
11221869|NCT03232814|Experimental|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
11221870|NCT03232801|Experimental|mindfulness group|A multicomponent group-based intervention rooted in mindfulness, administered in 3 sessions over 6 weeks
11221871|NCT03232801|Active Comparator|educational group|A general midlife health and aging educational group, administered in 3 sessions over 6 weeks
11221872|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
11221873|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
11221874|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
11221875|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
11221876|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
11221877|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
11221878|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
11221879|NCT03232736|No Intervention|Healthy Control|
11221880|NCT03232736|Experimental|LVAD Group w/Pacemaker|Pacemaker adjustments will be made to this group in blinded manner.
11221881|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
11221882|NCT03232710|Experimental|pilot study group|
11221883|NCT03232710|Experimental|group 1 (under fasting condition)|
11221884|NCT03232710|Experimental|group 2 (under fasting condition)|
11221885|NCT03232710|Experimental|group 3 (under fed condition)|
11221886|NCT03232710|Experimental|group 4 (under fed condition)|
11221887|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
11221888|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
11221889|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
11221890|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
11221891|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.
~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
11221892|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
11221893|NCT03232619|Experimental|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
11221894|NCT03232619|Experimental|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
11221895|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
11221896|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
11221897|NCT03232580|Experimental|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
11221898|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
11221899|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
11221900|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
11221901|NCT03232567|Placebo Comparator|Placebo|Normal saline administered by intranasal spray at a single dose
11221902|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
11221903|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
11221907|NCT03232541|Experimental|Genuine acupuncture (C)|Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
11221908|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
11221909|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
11221910|NCT03232515|Experimental|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
11221911|NCT03232502|No Intervention|Control|
11221912|NCT03232502|Experimental|Intervention|
11221913|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
11221914|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
11221915|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
11221916|NCT03232424|Experimental|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
11221917|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
11221918|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
11221919|NCT03232385|Experimental|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
11221920|NCT03232385|Active Comparator|EM Fusion or No Fusion Arm|
11221921|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
11221922|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
11221923|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
11221924|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
11221925|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
11221926|NCT03232359||Control group|This group included 20 pregnant women (gestational age of >20 weeks) having normal pregnancy with normal blood pressure and platelet count.
11221927|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
11221928|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
11221929|NCT03232333||MIRODERM|Biologic wound graft
11221930|NCT03232320|Experimental|MEDITOXIN|
11221931|NCT03232320|Placebo Comparator|Placebo|
11221932|NCT03232307|Experimental|Treatment (ibrutinib, rituximab, lenalidomide, dexamethasone)|Participants receive ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also receive rituximab IV on days 1, 8, 15 and 22 in course 1 and 2, on day 1 of course 3-8, and then on day 1 of every other 28-day course, lenalidomide PO on days 1-21, and dexamethasone PO weekly. Treatment with rituximab repeats every 28 days for 2 years, with lenalidomide for 1 year, and with dexamethasone for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11221933|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
11221934|NCT03232281|Experimental|triptorelin pamoate PR 3-month|
11221935|NCT03232281|Active Comparator|triptorelin acetate PR 1-month|
11221936|NCT03232268|Experimental|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
11221937|NCT03232255|Experimental|Treatment Group|
11221938|NCT03232229||Tennis players|
11221939|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
11221940|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
11221941|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
11221942|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
11221943|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
11222046|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
11221944|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
11221945|NCT03232190|Experimental|INTNIC|NICU Intervention Group Web Application Infants < 32 weeks
11221946|NCT03232190|No Intervention|CNIC|NICU Control Group No Web Application Infants < 32 weeks
11221947|NCT03232190|No Intervention|CMAT|Maternity Unit Control Group No Web Application Infants > 37 weeks
11221948|NCT03232177|Experimental|Anagre Cap.|twice a day
11221949|NCT03232164|Experimental|18F-DCFPyL PET|We will have three separate sub-studies evaluating 18F-DCFPyL PET imaging of prostate cancer in three prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, and (3) androgen-resistant metastatic disease.
11221950|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
11221951|NCT03232138|Experimental|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
11221952|NCT03232138|Placebo Comparator|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
11221953|NCT03232125|Experimental|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
11221954|NCT03232125|Placebo Comparator|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
11221955|NCT03232112|Active Comparator|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
11221956|NCT03232112|Placebo Comparator|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
11221957|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
11221958|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
11221959|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11221960|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11221961|NCT03232073|Experimental|Ponesimod|20 mg administered orally once daily
11221962|NCT03232047|Experimental|Combined cognitive training|The training is combined executive function and memory training. The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
11221963|NCT03232047|No Intervention|Waiting-list group|Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period. During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
11221964|NCT03232034|Placebo Comparator|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
11221965|NCT03232034|Active Comparator|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
11221966|NCT03232034|Experimental|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
11221967|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
11221968|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
11221969|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
11221970|NCT03232008|Experimental|Experiment A- experimental|3g Canderel in 250ml water
11221971|NCT03232008|No Intervention|Experiment A- control|3g of maltodextrin in 250 ml of water
11221972|NCT03232008|Experimental|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
11221973|NCT03232008|No Intervention|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
11221974|NCT03231995|Experimental|Respiratory microbiome biomarkers|
11221975|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
11221976|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
11221977|NCT03231969|Experimental|Bilastine 0.2%|
11221978|NCT03231969|Experimental|Bilastine 0.4%|
11221979|NCT03231969|Experimental|Bilastine 0.6%|
11221980|NCT03231969|Placebo Comparator|Bilastine 0%|
11221981|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
11221982|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
11221983|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
11221984|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
11223241|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
11221985|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
11221986|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
11221987|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
11221988|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
11221989|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
11221990|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
11221991|NCT03231878|Active Comparator|Active|
11221992|NCT03231878|Placebo Comparator|Placebo|
11221993|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
11221994|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
11221995|NCT03231839|Placebo Comparator|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
11221996|NCT03231839|Active Comparator|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
11221997|NCT03231839|Active Comparator|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
11221998|NCT03231813|Experimental|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
11221999|NCT03231813|Placebo Comparator|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
11222000|NCT03231813|Sham Comparator|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
11222001|NCT03231813|No Intervention|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
11222002|NCT03231800|Experimental|Dasotraline|Dasotraline capsule 2mg/day
11222003|NCT03231800|Placebo Comparator|Placebo|Placebo capsule
11222004|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.
~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.
~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
11222005|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
11222006|NCT03231761|Experimental|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
11222007|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
11222008|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
11222009|NCT03231735|Other|Mid frequency ventilation|Mid frequency ventilation delivered at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
11222010|NCT03231735|Other|Standard frequency ventilation|Standard frequency ventilation delivered at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
11222011|NCT03231722|Active Comparator|mFOLFOX6 + Panitumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by
~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by
~5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
11222041|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
11222042|NCT03231501|Experimental|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
11222043|NCT03231488|Experimental|Mindfulness intervention|
11222044|NCT03231488|Active Comparator|Control intervention (unfocused attention)|
11222045|NCT03231475|Experimental|SPH1188-11|SPH1188-11 dose escalation, 50mg/100mg/200mg/300mg/450mg/600mg
11222012|NCT03231722|Experimental|mFOLFOXIRI + Panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by
~Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by
~Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
11222013|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
11222014|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
11222015|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
11222016|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
11222017|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
11222018|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
11222019|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:
~sFlt1/PlGF ratio >38: pre-eclampsia risk
~sFlt1/PlGF ratio >85: pre-eclampsia
~ISSHP pre-eclampsia definition + ratio >210: severe PE
~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
11222020|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
11222021|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
11222022|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.
~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
11222023|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.
~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
11222024|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
11222025|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
11222026|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
11222027|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
11222028|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
11222029|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
11222030|NCT03231566|Active Comparator|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
11222031|NCT03231566|Experimental|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
11222032|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
~Receive MiQuit text message cessation programme."
11222033|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
11222034|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
11222035|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
11222036|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
11222037|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
11222038|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
11222039|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
11222040|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
11222047|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
11222048|NCT03231423|Experimental|DRAIN PLACEMENT|Effects of drainage
11222049|NCT03231423|No Intervention|DRAIN NOT PLACED|Effects of not using drain
11222050|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
11222051|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
11222052|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
11222053|NCT03231397|Other|AAA's undergoing treatment|"Six subjects (three males, AAA >5.5cm and three females, AAA >5.0cm) with AAAs that are indicated for treatment.
~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
11222054|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
11222055|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
11222056|NCT03231371|Experimental|Study Arm|
11222057|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
11222058|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
11222059|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
11222060|NCT03231332|Experimental|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
11222061|NCT03231332|No Intervention|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
11222062|NCT03231332|Active Comparator|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
11222063|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
11222064|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
11222065|NCT03231319|Placebo Comparator|IV PCA only|
11222066|NCT03231306|Experimental|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.
~Recruitment of subjects 1 - 17 years of age (Stratum B) is currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) was established by a phase 1 study (NCT022)."
11222067|NCT03231280|Experimental|SB-061|SB-061
11222068|NCT03231280|Placebo Comparator|Placebo|Placebo
11222069|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
11222070|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
11222071|NCT03231254||Chinese patients with OSA|
11222072|NCT03231254||Canada patients with OSA|
11222073|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
11222074|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
11222075|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
11222076|NCT03231228|Active Comparator|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
11222077|NCT03231228|Active Comparator|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
11222078|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
11222079|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
11222306|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
11222080|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.
~Additional peripheral embolization is left to the discretion of the interventional radiologist.
~The study does not interfere with local diagnostic work-up and treatment protocols."
11222081|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
11222082|NCT03231176|Experimental|Varlitinib and Capecitabine|
11222083|NCT03231163|Placebo Comparator|No Music|
11222084|NCT03231163|Experimental|Relaxing Classical Music|
11222085|NCT03231163|Experimental|Self-Selected Relaxing Music|
11222086|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
11222087|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
11222088|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
11222089|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
11222090|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
11222091|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
11222092|NCT03231137|No Intervention|Control|Spontaneously healed socket
11222093|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.
~Days 1 - 3: 10 mg dose twice a day for three days
~Days 4 - 6: 20 mg dose twice a day for three days
~Days 7 - 11: 30 mg dose twice a day for five days
~Days 12: 30 mg dose once in the morning"
11222094|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.
~Days 1 - 3: 10 mg dose twice a day for three days
~Days 4 - 6: 20 mg dose twice a day for three days
~Days 7 - 11: 30 mg dose twice a day for five days
~Days 12: 30 mg dose once in the morning"
11222095|NCT03231111|No Intervention|traditional group|
11222096|NCT03231111|Experimental|Multimedia group|
11222097|NCT03231085|Active Comparator|Ferrous fumarate or ferrostrane|"The oral treatment should begin 21 days before surgery.
~Recommended Dosage ferrous fumarate according to the SPC in force:
~5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate
~8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate
~10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate
~Ferrostrane ® (syrup) Laboratory TEOFARMA SRL Either 34mg of iron per teaspoon
~Recommended dosage according to the SPC in force:
~Infant 5 to 8 kg (about 1 to 6 months): 2 teaspoons a day,
~Infant from 8 to 12 kg (about 6 to 30 months): 3 teaspoons a day."
11222098|NCT03231085|Experimental|Ferric carboxymaltose|The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.
11222099|NCT03231072|Experimental|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
11222100|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
11222101|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.
~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
11222102|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
11222103|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
11222104|NCT03231033|Experimental|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
11222105|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
11222106|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
11222107|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
11222108|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
11222109|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
11222110|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
11222180|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
11222111|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
11222112|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
11222113|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
11222114|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
11222115|NCT03230955|Experimental|Psychological and psycho-educational support|The intervention group (IG) [that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process]
11222116|NCT03230955|Active Comparator|Control Group|The control group (CG) [that will receive only a brief counselling session after discharge]
11222117|NCT03230942|Experimental|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
11222118|NCT03230942|Active Comparator|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
11222119|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
11222120|NCT03230916|Experimental|IMI/REL FDC|Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
11222121|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
11222122|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
11222123|NCT03230890|Experimental|HIRREM|This is the intervention, treatment arm that all participants receive in this open label, single arm trial. The intervention is High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM).
11222124|NCT03230864|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
11222125|NCT03230864|Experimental|Double-blind treatment (DBT) period, Lu AF35700 10 mg|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
11222126|NCT03230864|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period
11222127|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
11222128|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
11222129|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
11222130|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
11222131|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
11222132|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
11222133|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
11222134|NCT03230838|Experimental|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose) administered intravenously (IV) every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
11222135|NCT03230838|Active Comparator|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.
11222136|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
11222137|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
11222138|NCT03230812|Experimental|Low carnitine status|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
11222181|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
11223242|NCT03223519|Placebo Comparator|Placebo|
11222139|NCT03230812|Experimental|High carnitine status|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
11222140|NCT03230799|Active Comparator|traditional cataract surgery|
11222141|NCT03230799|Experimental|minimal invasive lens surgery|
11222142|NCT03230786|Placebo Comparator|Placebo|Placebo QD for 12 weeks as add-on to metformin
11222143|NCT03230786|Experimental|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
11222144|NCT03230786|Experimental|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
11222145|NCT03230786|Experimental|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
11222146|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
11222147|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
11222148|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
11222149|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
11222150|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
11222151|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
11222152|NCT03230760|Experimental|treatment|
11222153|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
11222154|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
11222155|NCT03230721|Active Comparator|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
11222156|NCT03230721|Active Comparator|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
11222157|NCT03230721|Active Comparator|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
11222158|NCT03230708|Experimental|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
11222159|NCT03230708|Active Comparator|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
11222160|NCT03230695|Active Comparator|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.
~Number of interventions sessions: 1"
11222161|NCT03230695|Sham Comparator|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.
~Number of interventions sessions: 1"
11222162|NCT03230682||major depressive disorder|
11222163|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
11222164|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
11222165|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:
~working memory strategies
~executive function program
~divided attention program
~environmental changes
~identification of problematic cognitive-communication situations"
11222166|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:
~- Same cognitive-communication therapy is administered"
11222167|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
11222168|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
11222169|NCT03230604|Active Comparator|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
11222170|NCT03230604|Active Comparator|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
11222171|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
11222172|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
11222173|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
11222174|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
11222175|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
11222176|NCT03230552|Experimental|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
11222177|NCT03230552|No Intervention|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
11222178|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
11222179|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
11223243|NCT03223519|Active Comparator|Ibuprofen|
11222183|NCT03230500|Experimental|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
11222184|NCT03230500|Active Comparator|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
11222185|NCT03230487|Experimental|BI 1015550|
11222186|NCT03230487|Placebo Comparator|Placebo|
11222187|NCT03230474|Active Comparator|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
11222188|NCT03230474|Active Comparator|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
11222189|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
11222190|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
11222191|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
11222192|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
11222193|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
11222194|NCT03230435||Anorexia nervosa|Treatment settings as usual.
11222195|NCT03230435||Healthy controls|No interventions.
11222196|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
11222197|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
11222198|NCT03230409|No Intervention|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
11222199|NCT03230409|Experimental|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:
~Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
~Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.
~Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.
~Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
11222200|NCT03230396|Placebo Comparator|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.
~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
11222201|NCT03230396|Experimental|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).
~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
11222202|NCT03230396|Experimental|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).
~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
11222203|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
11222204|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
11222205|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
11222206|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
11222207|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
11222208|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
11222209|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
11222210|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.
~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.
~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.
~Accordingly, one group can be used as the control group of the other one."
11222211|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.
~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.
~Accordingly,one group can be used as the control group of the other one."
11222373|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
11222212|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
11222213|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
11222214|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
11222215|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
11222216|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
11222217|NCT03230318|Experimental|derazantinib|Oral administration
11222218|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over
~With solid cancer irrespective of the stage
~Pre-screened or screened for at least one ongoing clinical trial in the center
~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)
~Social security affiliation"
11222219|NCT03230292|Experimental|Cohort 1|Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is >=50% to <75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
11222220|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
11222221|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
11222222|NCT03230266|Other|collection|collection of biological and device samples
11222223|NCT03230253|Experimental|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
11222224|NCT03230253|Experimental|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
11222225|NCT03230253|Active Comparator|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
11222226|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
11222227|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
11222228|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
11222229|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
11222230|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
11222231|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
11222232|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
11222233|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
11222234|NCT03230175|Experimental|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
11222235|NCT03230162|Experimental|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
11222236|NCT03230162|Experimental|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow < 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily > 170 kg 75 u/kg/day
11222237|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
11222238|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
11222239|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
11222240|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
11222241|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
11222242|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
11222243|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
11222244|NCT03230097|Experimental|BI 409306|
11222245|NCT03230097|Placebo Comparator|Placebo|
11222246|NCT03230084|Experimental|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
11222247|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
11222248|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
11222249|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
11222250|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
11222251|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
~Patients will be followed up every week after being discharged until complete resolution is noted."
11222252|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
~Patients will be followed up every week after being discharged until complete resolution is noted."
11222253|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
11222254|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
11222255|NCT03230032|Experimental|Intervention Group|Sessions will use a pacifier-activated device (PAL) system. The device sensor attaches to a routinely-used pacifier and measures timing and pressure of the sucks. If the infant reaches the preset suck pressure, he receives 10 seconds of mother's voice. The receiver/speaker box controls the volume to < 65dB on scale C. PAM will be set to the lowest settings for the first session. Using sensor measurements, the therapist will increase the threshold for number of sucks and strength once the infant produces three consecutive sucks above current level and continue per protocol.
11222256|NCT03230032|No Intervention|Control Group|Infants will receive 2 daily 15-min listening sessions of mother's voice recording, contiguous but not simultaneous with PAM NNS sessions without suck-contingent reinforcement (no voice).
11222257|NCT03230019|Active Comparator|chest tube|VATS with chest tube placement
11222258|NCT03230019|Experimental|two-lumen catheter|VATS with two-lumen catheterization
11222259|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
11222260|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
11222261|NCT03229993|Experimental|OCT guided PCI|
11222262|NCT03229993|Experimental|OCT guided medicine|
11222263|NCT03229993|No Intervention|SPECT guided PCI|
11222264|NCT03229993|No Intervention|SPECT guided medicine|
11222265|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
11222266|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
11222267|NCT03229967||Exploration Cohort|Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
11222268|NCT03229967||Validation Cohort|Up to 10 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
11222269|NCT03229967||Well Baby Cohort|40 Well Baby Infants have been enrolled and may be used for secondary analysis of microbial community composition of the meconium.
11222270|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
11222271|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
11222272|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<7gm/dl
11222274|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
11222275|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
11222276|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
11222277|NCT03229915|Active Comparator|PTSD|Will receive Cognitive Processing Therapy
11222278|NCT03229915|Active Comparator|Trauma-exponsed control|Will receive Cognitive Processing Therapy
11222279|NCT03229915|No Intervention|no trauma healthy control|Scanned twice (13 weeks apart) without any intervention
11222280|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
11222281|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
11222282|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
11222283|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
11222284|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
11222285|NCT03229876|Experimental|CD19-UCART|All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (0.5-1x10^6/kgBW, 1.5-3x10^6/kgBW, 4-5x10^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.
11222286|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
11222287|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
11222288|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
11222289|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
11222290|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
11222291|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
11222292|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
11222293|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
11222294|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
11222295|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
11222296|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
11222297|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
11222298|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
11222299|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
11222300|NCT03229785|Experimental|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
11222301|NCT03229772|Other|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
11222302|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
11222303|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
11222304|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
11222305|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
11223244|NCT03223519|Active Comparator|Magnesium|
11222307|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
11222308|NCT03229733|Experimental|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
11222309|NCT03229733|Active Comparator|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
11222310|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
11222311|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
11222312|NCT03229707|Active Comparator|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :
~Modified (USPHS) criteria"
11222313|NCT03229707|Experimental|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)
~Software:
~0 to 1: no difference in perception
~1 to 2: only perceptible to a trained observer
~2 to 3.5: perceptible difference
~3.5 to 5: marked difference"
11222314|NCT03229694|Experimental|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
11222315|NCT03229694|Placebo Comparator|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
11222316|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
11222317|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
11222318|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
11222319|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
11222320|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
11222321|NCT03229655|Experimental|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
11222322|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
11222323|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
11222324|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
11222325|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
11222326|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC
~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
11222327|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)
~Within household, recipient of voucher (mother or father) will be randomly selected.
~Food voucher"
11222328|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC
~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)
~Within household, recipient of voucher (mother or father) will be randomly selected.
~BCC: Behavior Change Communication"
11222329|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC
~Husband/partner of the enrolled mother will receive BCC
~Enrolled participants will receive monthly voucher worth 200 birr(~$10)
~Within household, recipient of voucher (mother or father) will be randomly selected.
~BCC: Behavior Change Communication"
11222330|NCT03229629|No Intervention|Control|Control group
11222331|NCT03229616|Experimental|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
11222332|NCT03229616|Active Comparator|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
11222333|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
11222334|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
11222335|NCT03229577|Experimental|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
11222336|NCT03229577|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
11222337|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
11222338|NCT03229577|No Intervention|Control|The control group will receive no intervention.
11222502|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only
~concomitant administration"
11222339|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
11222340|NCT03229551|Experimental|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
11222341|NCT03229551|Active Comparator|Control|This arm is the standard of care saline irrigation solution.
11222342|NCT03229538|Experimental|Methylprednisolone Arm|IV Methylprednisolone
11222343|NCT03229538|Placebo Comparator|Placebo Arm|IV Isotonic Saline
11222344|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
11222345|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
11222346|NCT03229512|Experimental|Intervention|Topical 1% Sildenafil Cream
11222347|NCT03229499|Experimental|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
11222348|NCT03229499|Placebo Comparator|Placebo|1 tablet taken by mouth once a day for one year
11222349|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
11222350|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
11222351|NCT03229460|Active Comparator|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
11222352|NCT03229460|Experimental|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
11222353|NCT03229460|Placebo Comparator|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
11222354|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
11222355|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
11222356|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
11222357|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).
~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
11222358|NCT03229408|Experimental|Salsalate-Treated Lean PCOS without IR|n=15
11222359|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS without IR|n=15
11222360|NCT03229408|Experimental|Salsalate-Treated Lean PCOS with IR|n=15
11222361|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS with IR|n=15
11222362|NCT03229408|Experimental|Salsalate-Treated Obese PCOS|n=15
11222363|NCT03229408|Placebo Comparator|Placebo-Treated Obese PCOS|n=15
11222364|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
11222365|NCT03229395||control patients|Selected patients are matched for age and sex.
11222366|NCT03229382|Experimental|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|
11222367|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
11222368|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
11222369|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
11222370|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
11222371|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
11222372|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
11222374|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
11222375|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
11222376|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
11222377|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
11222378|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
11222379|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
11222380|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
11222381|NCT03229265|Experimental|Patiromer|
11222382|NCT03229252|Placebo Comparator|Placebo|Placebo Inhalation solution twice daily for 28 days.
11222383|NCT03229252|Experimental|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
11222384|NCT03229252|Experimental|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
11222385|NCT03229239|Experimental|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
11222386|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
11222387|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
11222388|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
11222389|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
11222390|NCT03229187||neoadjuvant chemotherapy|
11222391|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
11222392|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
11222393|NCT03229161|Experimental|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
11222394|NCT03229161|No Intervention|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
11222395|NCT03229148|Active Comparator|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
11222396|NCT03229148|Active Comparator|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
11222397|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
11222398|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
11222399|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
11222400|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
11222401|NCT03229109|Experimental|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
11222402|NCT03229109|Experimental|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
11222403|NCT03229109|Experimental|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
11222404|NCT03229109|Experimental|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
11222405|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
11222503|NCT03228485||MyBPH Care|All patients enrolled in this study.
11222406|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
11222407|NCT03229070|No Intervention|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
11222408|NCT03229070|Experimental|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
11222409|NCT03229070|Experimental|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
11222410|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
11222411|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
11222412|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
11222413|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
11222414|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
11222415|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
11222416|NCT03229031|Experimental|ES135|
11222417|NCT03229031|Placebo Comparator|Placebo|
11222418|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
11222419|NCT03229005|Active Comparator|A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
11222420|NCT03229005|Experimental|A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
11222421|NCT03229005|Active Comparator|B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
11222422|NCT03229005|Experimental|B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
11222423|NCT03228992|Active Comparator|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
11222424|NCT03228992|Placebo Comparator|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
11222425|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
11222426|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
11222427|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
11222428|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
11222429|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
11222430|NCT03228927||twin A|Sampling of the facial and fecal microbiome
11222431|NCT03228927||twin B|Sampling of the facial and fecal microbiome
11222432|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
11222433|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
11222434|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
11222435|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
11222460|NCT03228732|Active Comparator|DHEA|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA
~Visit 2:
~same as visit 1"
11222461|NCT03228732|Active Comparator|Fluoxetine and DHEA|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA
~Visit 2:
~same as visit 1"
11222436|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.
~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
11222437|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.
~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
11222438|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
11222439|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
11222440|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
11222441|NCT03228849|Active Comparator|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
11222442|NCT03228849|Active Comparator|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
11222443|NCT03228836|Experimental|IBI308|
11222444|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
11222445|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
11222446|NCT03228810||Men >18 years old with metastatic prostate cancer|
11222447|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
11222448|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
11222449|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
11222450|NCT03228771|Active Comparator|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
11222451|NCT03228771|Active Comparator|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
11222452|NCT03228771|No Intervention|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
11222453|NCT03228758|Active Comparator|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.
~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
11222454|NCT03228758|Active Comparator|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.
~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
11222455|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
11222456|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
11222457|NCT03228732|Placebo Comparator|Placebo 1|"Visit 1:
~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo
~Visit 2:
~same as visit 1"
11222458|NCT03228732|Placebo Comparator|Placebo 2|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo
~Visit 2:
~same as visit 1"
11222459|NCT03228732|Active Comparator|Fluoxetine|"Visit 1:
~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine
~Visit 2:
~same as visit 1"
11222462|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
11222463|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
11222464|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
11222465|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
11222466|NCT03228693|Active Comparator|Group 1|Baseline lesional and non-lesional biopsies and re-biopsy 6-8 weeks later with intralesional triamcinolone injections at 9-10, 12-16, and 24-32 weeks.
11222467|NCT03228693|Active Comparator|Group 2|Baseline lesional biopsy and re-biopsy at 6-8 weeks with intralesional triamcinolone injections at 3-4, 9-10, 12-16, and 24-32 weeks
11222468|NCT03228693|Active Comparator|Group 3|Baseline lesional and non-lesional biopsy and re-biopsy 3-4 months later with intralesional triamcinolone injections at 18-20 and 24-32 weeks.
11222469|NCT03228693|Active Comparator|Group 4|Baseline lesional biopsy and re-biopsy at 3-4 months with intralesional triamcinolone injections at 3-4, 6-8, 18-20 and 24-32 weeks.
11222470|NCT03228693|Active Comparator|Group 5|Normal patient skin (surgical or adjacent to other biopsy) from subjects with no self-reported history of keloids.
11222471|NCT03228693|Other|Earlobe Keloid|Complete excision of an earlobe keloid measuring > 10mm will be taken.
11222472|NCT03228680|Experimental|Follitropin delta|
11222473|NCT03228680|Active Comparator|Follitropin beta|
11222474|NCT03228667|Other|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.
~1a - Non-small cell lung cancer
~1b - Small cell lung cancer
~1c - Urothelial carcinoma
~1d - Head and neck squamous cell carcinoma
~1e - Merkel cell carcinoma
~1f - Melanoma
~1g - Renal cell carcinoma
~1h - Gastric cancer
~1i - Cervical cancer
~1j - Hepatocellular carcinoma
~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
11222475|NCT03228667|Other|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
11222476|NCT03228667|Other|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
11222477|NCT03228667|Experimental|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
11222478|NCT03228667|Experimental|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
11222479|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
11222480|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
11222481|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
11222482|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
11222483|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
11222484|NCT03228615|Experimental|Shared Decision Making Intervention|
11222485|NCT03228615|No Intervention|Usual Care Group|
11222486|NCT03228602|Active Comparator|healthy subjects|
11222487|NCT03228602|Experimental|obese|
11222488|NCT03228602|Experimental|obese diabetic|
11222489|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
11222490|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
11222491|NCT03228576||TREVISE|
11222492|NCT03228563|Experimental|Probiotics|Taking two capsules of probiotics twice daily for 6 months.
11222493|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
11222494|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
11222495|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
11222496|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
11222497|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.
~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.
~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
11222498|NCT03228524|Experimental|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
11222499|NCT03228524|Placebo Comparator|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
11222500|NCT03228511|Experimental|Formerly Arm Label|
11222501|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day
~concomitant administration"
11222504|NCT03228472|Experimental|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
11222505|NCT03228472|Placebo Comparator|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
11222506|NCT03228459|Experimental|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
11222507|NCT03228459|No Intervention|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
11222508|NCT03228446|Experimental|Young subjects|Working memory training & attentional filter training for participants (18-30 years)
11222509|NCT03228446|Experimental|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
11222510|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
11222511|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
11222512|NCT03228433|Experimental|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
11222513|NCT03228433|Experimental|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
11222514|NCT03228433|Experimental|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
11222515|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
11222516|NCT03228420|Active Comparator|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
11222517|NCT03228420|Other|CMM Alone|Conventional Medical Management
11222518|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
11222519|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
11222520|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
11222521|NCT03228394|Experimental|Ganaxolone|Intravenous
11222522|NCT03228394|Placebo Comparator|Placebo|Intravenous
11222523|NCT03228381|Experimental|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
11222524|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
11222525|NCT03228355|Active Comparator|Levcromakalim|
11222526|NCT03228355|Placebo Comparator|Saline|
11222527|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
11222528|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
11222529|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
11222530|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
11222531|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
11222532|NCT03228303|Active Comparator|Chronic phase CML treated by nilotinib|Newly diagnosed
11222533|NCT03228303|Active Comparator|Chronic phase CML treated by imatinib|Newly diagnosed
11222534|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
11222535|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
11222536|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
11222537|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
11222538|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
11222539|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
11223245|NCT03223519|Active Comparator|Vitamin C|
11222540|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
11222541|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
11222542|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
11222543|NCT03228225|Experimental|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
11222544|NCT03228212|Experimental|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
11222545|NCT03228212|Experimental|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
11222546|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
11222547|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
11222548|NCT03228186|Experimental|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
11222549|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
11222550|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
11222551|NCT03228147|Experimental|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
11222552|NCT03228134|Experimental|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
11222553|NCT03228134|Sham Comparator|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
11222554|NCT03228134|Experimental|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
11222555|NCT03228134|Sham Comparator|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
11222556|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
11222557|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
11222558|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:
~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or
~fosfomycin 3 g orally 2 hours before prostate biopsy, or
~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
11222559|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
11222560|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
11222561|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
11222562|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
11222563|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
11222582|NCT03228056|Active Comparator|two-ports VATS lobectomy|"two-ports VATS lobectomy
~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)
~ketoprofene 100 mg i.v every 12 hours
~paracetamol 1000 mg i.v every 8 hours
~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)
~pain intensity measured in VAS scale"
11222785|NCT03226652||Sleep Disordered Breathing assessment|Patients referred for Sleep disordered breathing assessment.
11222564|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
11222565|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
11222566|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
11222567|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
11222568|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
11222569|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
11222570|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
11222571|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
11222572|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
11222573|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
11222574|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
11222575|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
11222576|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
11222577|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.
~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
11222578|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
11222579|NCT03228069|Experimental|single visit 4-site ID vaccination|Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.
11222580|NCT03228069|Active Comparator|Conventional IM vaccination|Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.
11222581|NCT03228056|Experimental|uniportal VATS lobectomy|"uniportal VATS lobectomy
~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)
~ketoprofene 100 mg i.v every 12 hours
~paracetamol 1000 mg i.v every 8 hours
~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)
~pain intensity measured in VAS scale"
11222624|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
11223246|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
11222583|NCT03228056|Active Comparator|three-ports VATS lobectomy|"three-ports VATS lobectomy
~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)
~ketoprofene 100 mg i.v every 12 hours
~paracetamol 1000 mg i.v every 8 hours
~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)
~pain intensity measured in VAS scale"
11222584|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
11222585|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
11222586|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
11222587|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
11222588|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
11222589|NCT03228017|No Intervention|Healthy Control|
11222590|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
11222591|NCT03227991|Active Comparator|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
11222592|NCT03227991|Active Comparator|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
11222593|NCT03227978|Experimental|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
11222594|NCT03227965|Other|ELITE|
11222595|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
11222596|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
11222597|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
11222598|NCT03227939|Active Comparator|LSG Group|LSG only
11222599|NCT03227926|No Intervention|Molecular Screening|"Molecular Screening Phase will determine the molecular eligibility of the patients for 3rd line panitumumab re-challenge. Patients will be liquid biopsied (LB) at different check-points and their ctDNA tested by ddPCR to monitor the emergency, and subsequent decay, of RAS altered clones. The RAS Baseline Mutational Load (BML) will be defined within 15 days from last anti-EGFR dose prior documented 1st line PD. Only patients with a > 3% RAS fractional mutational abundance (RAS+) will move to the next step of the screening. RAS+ patients will receive a 2nd line anti-EGFR-free chemotherapy according to physician choice. RAS+ patients progressing during or after 2nd line therapy will be retested at the Rechallenge Mutational Load (RML) checkpoint. Patients showing a >50% drop in RAS mutational load at RML compared to BML will be declared molecularly eligible for the Trial Phase."
11222600|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
11222601|NCT03227913|Active Comparator|Good chewing ability|
11222602|NCT03227913|Experimental|Impaired chewing ability|
11222603|NCT03227900|Active Comparator|Lidocaine|LIdocaine dissolved in water for injections
11222604|NCT03227900|Placebo Comparator|Placebo|Water for injections
11222605|NCT03227887|Active Comparator|Good chewing ability|
11222606|NCT03227887|Experimental|Impaired chewing ability|
11222607|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
11222608|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
11222609|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
11222610|NCT03227822|Experimental|Short spot stenting|Short spot stenting
11222611|NCT03227822|Experimental|Long lesion stenting|Long lesion stenting
11222612|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
11222613|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
11222614|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
11222615|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
11222616|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
11222617|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
11222618|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
11222619|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
11222620|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
11222621|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
11222622|NCT03227796|Experimental|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
11222623|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
11222625|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
11222626|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
11222627|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
11222628|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
11222629|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
11222630|NCT03227796|Placebo Comparator|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
11222631|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.
~Current intensity: 2mA, 20min/day"
11222632|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects
~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
11222633|NCT03227770|Active Comparator|regular hemodialysis|Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.
11222634|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment once every two week
11222635|NCT03227757|Experimental|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm.
11222636|NCT03227744|Active Comparator|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
11222637|NCT03227744|Placebo Comparator|Not enrolled in group therapy|Patients in control arm will be issued surveys
11222638|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
11222639|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
11222640|NCT03227718||athletic background|ex-gymnasts
11222641|NCT03227718||control|age-matched non-gymnastics background
11222642|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
11222643|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
11222644|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
11222645|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
11222646|NCT03227679|Active Comparator|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
11222647|NCT03227679|Active Comparator|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
11222648|NCT03227666|Experimental|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
11222649|NCT03227666|No Intervention|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
11222650|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
11222651|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
11222652|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
11222653|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
11222654|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
11222655|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
11222656|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
11222657|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
11224735|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
11222658|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
11222659|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
11222660|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
11222661|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
11222662|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
11222663|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
11222664|NCT03227549|Active Comparator|Posterior Approach|
11222665|NCT03227523||subjects with copd|
11222666|NCT03227523||subjects without pulmonary disease|
11222667|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
11222668|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
11222669|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.
~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
11222670|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
~Treatment arm includes 56 g of whole walnuts daily."
11222671|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
11222672|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
11222673|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
11222674|NCT03227471|Experimental|Part A: VX-445 in Healthy Subjects (HS)|Part A includes single dose escalation.
11222675|NCT03227471|Placebo Comparator|Part A: Placebo|
11222676|NCT03227471|Experimental|Part B: VX-445 in HS|Part B includes multiple-dose escalation.
11222677|NCT03227471|Placebo Comparator|Part B: Placebo|
11222678|NCT03227471|Experimental|Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-445 in TC with TEZ/IVA
11222679|NCT03227471|Placebo Comparator|Part C: Placebo|
11222680|NCT03227471|Experimental|Part D1: F/MF genotypes TC|Subjects will receive 100 mg VX-445 qd in TC with TEZ and IVA for 4 weeks.
11222681|NCT03227471|Placebo Comparator|Part D1: Placebo|Subjects will receive placebo for 4 weeks.
11222682|NCT03227471|Experimental|Part D2: F/MF genotypes TC-High|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
11222683|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Mid|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
11222684|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Low|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
11222685|NCT03227471|Placebo Comparator|Part D2: Placebo|
11222686|NCT03227471|Experimental|Part E: F/F genotype - TC|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks
11222687|NCT03227471|Active Comparator|Part E: TEZ/IVA|Subjects will receive TEZ and IVA for 4 weeks.
11222688|NCT03227471|Experimental|Part F: F/MF genotypes - TC|Subjects will receive VX-445 in TC with TEZ and VX-561 for 4 weeks.
11222689|NCT03227471|Experimental|Part F: Placebo|
11222690|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
11222691|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
11222692|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
11222693|NCT03227445|Experimental|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
11222694|NCT03227445|Experimental|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
11222695|NCT03227445|Experimental|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
11222726|NCT03227224|Placebo Comparator|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
11222696|NCT03227445|Experimental|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
11222697|NCT03227432|Experimental|Nivolumab + Elotuzumab|"22 patients will be entered, If > 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.
~Nivolumab will be administered intravenously twice per cycle for cycle 1-4
~Nivolumab will be administered intravenously once per cycle for cycle 5
~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2
~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4
~Elotuzumab will be administered intravenously once per cycle for cycle 5"
11222698|NCT03227432|Experimental|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"Nivolumab will be administered intravenously twice per cycle for cycle 1-4
~Nivolumab will be administered intravenously once per cycle for cycle 5
~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2
~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4
~Elotuzumab will be administered intravenously once per cycle for cycle 5
~Pomalidomide will be administered for 21 days per cycle
~Dexamethasone will be administered weekly"
11222699|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.
~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
11222700|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.
~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
11222701|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
11222702|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
11222703|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
11222704|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
11222705|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
11222706|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
11222707|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
11222708|NCT03227367|Experimental|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
11222709|NCT03227367|Other|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
11222710|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
11222711|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
11222712|NCT03227328|Active Comparator|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
11222713|NCT03227328|Experimental|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
11222714|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
11222715|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
11222716|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
11222717|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
11222718|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
11222719|NCT03227276|Placebo Comparator|Placebo|
11222720|NCT03227276|Experimental|Litramine|
11222721|NCT03227263|Experimental|Bevacizumab|Intravenous infusion of Bevacizumab at a dose of 5 mg/kg
11222722|NCT03227263|Placebo Comparator|Placebo|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
11222723|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
11222724|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper & pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
11222725|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper & pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
11224811|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
11222727|NCT03227224|Experimental|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
11222728|NCT03227211||COPD exacerbated patients admitted|No specific intervention
11222729|NCT03227198|Experimental|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
11222730|NCT03227198|Placebo Comparator|Placebo|Placebo intramyocardial injection in patients with Heart Failure
11222731|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.
~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
11222732|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.
~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
11222733|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
11222734|NCT03227133|Experimental|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
11222735|NCT03227120|Experimental|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
11222736|NCT03227120|No Intervention|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
11222737|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
11222738|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
11222739|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
11222740|NCT03227081|No Intervention|Sleep|Sleep
11222741|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
11222742|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
11222743|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
11222744|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
11222745|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
11222746|NCT03227029|Experimental|RSV 276 vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
11222747|NCT03227029|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11222748|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
11222749|NCT03226977|Experimental|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
11222750|NCT03226977|Active Comparator|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
11222751|NCT03226964|Experimental|High flow nasal oxygen|(Optiflow; Fisher & Paykel, Auckland, New Zealand)
11222752|NCT03226964|Active Comparator|Nasal prongs|
11222753|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
11222754|NCT03226925|Experimental|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
11222755|NCT03226925|Experimental|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
11222756|NCT03226925|Experimental|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
11222757|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet once daily (QD) plus a stable, medically appropriate dose of an XOI
11222758|NCT03226899|Placebo Comparator|Placebo + XOI|lesinurad placebo matching tablet plus a stable, medically appropriate dose of an XOI
11222780|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
11222781|NCT03226704||1|Patients 3-39 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy.
11222782|NCT03226691|Experimental|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
11222783|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (CAD)|
11222784|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)|
11222759|NCT03226886||All patients|"In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.
~CAPTURE Sub-study:
~We plan to enrol patients/participants into three groups:
~Group A: patients with confirmed or suspected COVID-19 and a history of cancer Group B: patients without a history of COVID-19 infection and a history of cancer Group C: Hospital staff with or without a history of COVID-19"
11222760|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
11222761|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
11222762|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
11222763|NCT03226847|Experimental|Pulmonary Vein Isolation|ablation
11222764|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
11222765|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
11222766|NCT03226821|Experimental|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
11222767|NCT03226808|Other|Vivacit-E Liner|All subjects enrolled receive the study implant.
11222768|NCT03226795|Experimental|interventional arm|
11222769|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
11222770|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.
~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
11222771|NCT03226769|Active Comparator|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
11222772|NCT03226769|Experimental|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
11222773|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
11222774|NCT03226743|Experimental|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
11222775|NCT03226743|No Intervention|Control Group|treatment as usual in German health care system
11222776|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
11222777|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
11222778|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
11222779|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
11222786|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
11222787|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
11222788|NCT03226613|Experimental|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
11222789|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
11222790|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
11222791|NCT03226587|Experimental|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
11222792|NCT03226587|Placebo Comparator|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
11222793|NCT03226574|Experimental|RTX epidural injection|Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.
11222794|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
11222795|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
11222796|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
11222797|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
11222798|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
11222799|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
11222800|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
11222801|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
11222802|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
11222803|NCT03226496|Experimental|Intervention Group|This group receives a brief motivational interviewing session about PrEP
11222804|NCT03226496|No Intervention|Control Group|This group receives standard of care clinic based counseling about PrEP
11222805|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.
~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
11222806|NCT03226470|Experimental|T27 group|Subjects will receive suppository with T27 at 2 intervals for one month.
11222807|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
11222808|NCT03226470|No Intervention|Control group|Observation
11222809|NCT03226457|Active Comparator|Empagliflozin|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
11222810|NCT03226457|Placebo Comparator|Placebo|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator
11222811|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
11222812|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
11222813|NCT03226444|Placebo Comparator|placebo|placebo solution
11222814|NCT03226431|Experimental|ARINA-1|Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
11222815|NCT03226418|Experimental|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.
~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
11222816|NCT03226418|Experimental|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.
~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for >= 3 months orally. Glasdegib dose is 100 mg oral daily.
~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
11222817|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.
~The Patient Navigation Program include
~Education,
~Appointment reminders,
~Help with insurance,
~Transportation,
~Navigating the Cancer Center,
~Assisting in finding appropriate child care,
~Interpreting,
~Connecting the patient to psychosocial and/or palliative care teams,
~Physically escorting the patient to appointments"
11222849|NCT03226119|Experimental|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
11222818|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,
~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
11222819|NCT03226392|Active Comparator|QAW039|QAW039 once daily
11222820|NCT03226392|Placebo Comparator|Placebo|Placebo once daily
11222821|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
11222822|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
11222823|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
11222824|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
11222825|NCT03226353|Experimental|somofilcon A 1-day soft contact lenses|Habitual and refitted wearers of omafilcon A were refit into somofilcon A for a week
11222826|NCT03226340|Experimental|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
11222827|NCT03226340|Active Comparator|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
11222828|NCT03226327|Experimental|hypertension patients|
11222829|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
11222830|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.
~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
11222831|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.
~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
11222832|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.
~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.
~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:
~progression according to IWCLL criteria or
~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).
~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
11222833|NCT03226275|Experimental|Fasting: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
11222834|NCT03226275|Experimental|Fasting: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
11222835|NCT03226275|Experimental|Fed: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
11222836|NCT03226275|Experimental|Fed: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
11222837|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
11222838|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
11222839|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
11222840|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
11222841|NCT03226210|Experimental|NovoRapid group (group Asp)|
11222842|NCT03226210|Experimental|Prandilin group (group Lis)|
11222843|NCT03226197|Experimental|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
11222844|NCT03226171|Experimental|Dose-adjusted SK-1403|
11222845|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C
~Will have MRI Motility and High Resolution Manometry
~Then will have:
~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo
~Both agents will have their matched placebo dispensed alongside the active product of the other agent.
~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
11222846|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
11222847|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
11222848|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
11222966|NCT03225261|Experimental|Citrus extract|Citrus extract
11222850|NCT03226119|Experimental|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
11222851|NCT03226106|Experimental|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
11222852|NCT03226106|Active Comparator|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
11222853|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
11222854|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
11222855|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
11222856|NCT03226067|Experimental|GKT137831 400mg twice daily|"GKT137831 400mg twice daily
~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
11222857|NCT03226067|Experimental|GKT137831 400mg once daily|"GKT137831 400mg once daily
~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
11222858|NCT03226067|Placebo Comparator|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
11222859|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
11222860|NCT03226041|Experimental|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
11222861|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.
~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
11222862|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
11222863|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
11222864|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
11222865|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
11222866|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
11222867|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
11222868|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
11222869|NCT03225950||Chronic periodontitis donors|"Donors are medically healthy.
~Slow to moderate attachment loss and bone destruction.
~Good correlation between etiological factors and serverity of attachment loss."
11222870|NCT03225950||Aggressive periodontitis donors|"Donors are medically healthy.
~Rapid attachment loss and bone destruction.
~Familial aggregation.
~No correlation between etiological factors and serverity of attachment loss."
11222871|NCT03225950||Control donors|"Donors are medically healthy.
~No sign of inflammatory conditions."
11222872|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
11222873|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
11222874|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
11222875|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
11222876|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
11222967|NCT03225261|Placebo Comparator|Placebo|Maltodextrin
11222968|NCT03225248|Experimental|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
11222969|NCT03225248|Active Comparator|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
11222877|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
11222878|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
11222879|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
11222880|NCT03225885|Active Comparator|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
11222881|NCT03225885|Experimental|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
11222882|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
11222883|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
11222884|NCT03225846|Experimental|WVE-120102 (2 mg) or placebo|
11222885|NCT03225846|Experimental|WVE-120102 (4 mg) or placebo|
11222886|NCT03225846|Experimental|WVE-120102 (8 mg) or placebo|
11222887|NCT03225846|Experimental|WVE-120102 (16 mg) or placebo|
11222888|NCT03225846|Experimental|WVE-120102 (32 mg ) or placebo|
11222889|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
11222890|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
11222891|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
11222892|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
11222893|NCT03225833|Experimental|WVE-120101 (Dose E) or placebo|
11222894|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.
~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
11222895|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.
~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
11222896|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
11222897|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
11222898|NCT03225768|Experimental|Guided Training|
11222899|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
11222900|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
11222901|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
11222902|NCT03225729|Experimental|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.
~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
11222903|NCT03225729|Active Comparator|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
11222904|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily
~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
11222905|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
11222906|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
11222907|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
11222908|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
11222909|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
11222910|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
11222911|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
11223008|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
11223009|NCT03224949||Alcoholic cirrhosis with HCC|
11223010|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
11222912|NCT03225664|Experimental|Treatment (trametinib, pembrolizumab)|Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11222913|NCT03225651|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
11222914|NCT03225651|Experimental|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
11222915|NCT03225638|Other|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
11222916|NCT03225638|Other|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
11222917|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
11222918|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
~Exoskeleton or equivalent stimulation following this treatment."
11222919|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
~Virtual Reality or equivalent visualization following this treatment."
11222920|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
11222921|NCT03225599|Experimental|Procedure|
11222922|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
11222923|NCT03225560|Experimental|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
11222924|NCT03225560|Active Comparator|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
11222925|NCT03225547|Experimental|Cohort 1|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with hormone receptor positive, hormone refractory advanced breast cancer will be enrolled in cohort 1. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
11222926|NCT03225547|Experimental|Cohort 2|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with triple-negative advanced breast cancer will be enrolled in cohort 2. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
11222927|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.
~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
11222928|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.
~The following interventions will be carried out:
~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
11222929|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.
~Interventions:
~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.
~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.
~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.
~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
11222930|NCT03225495|Active Comparator|Standard Implant|
11222931|NCT03225495|Experimental|Ultra-narrow Implant|
11222932|NCT03225482|Experimental|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
11222933|NCT03225482|Active Comparator|SC|8-week Goal-focused Supportive Contact group
11222934|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
11222935|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
11222936|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
11222937|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
11222938|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
11225046|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
11222939|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
11222940|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.
~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
11222941|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
11222942|NCT03225417|Experimental|Experimental group|"Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.
~Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
~Starting Dose of Ixazomib according to phase I."
11222943|NCT03225417|Other|Control group|Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
11222944|NCT03225404|Experimental|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
11222945|NCT03225404|Experimental|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
11222946|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
11222947|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
11222948|NCT03225378||Acute circulatory failure|Mechanically ventilated patients displaying acute circulatory failure in whom the physician decides to perform a fluid challenge (fluid loading of 500 mL of crystalloid solution) and a passive leg raising test to predict fluid responsiveness.
11222949|NCT03225365|Other|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.
~30 patients will be included in the arm."
11222950|NCT03225365|Other|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.
~30 patients will be included in the arm."
11222951|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
11222952|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
11222953|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
11222954|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
11222955|NCT03225339|Experimental|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
11222956|NCT03225339|No Intervention|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
11222957|NCT03225326|Experimental|Computer controlled 4% articaine delivery by Anaeject|
11222958|NCT03225326|Active Comparator|Conventional 4% articaine delivery by carpule syringe|
11222959|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
11222960|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
11222961|NCT03225313|Experimental|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
11222962|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
11222963|NCT03225287|Experimental|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
11222964|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
11222965|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
11222970|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:
~tumor (RS) = 1.5
~Late rectal and bladder complications = 3.0
~early rectal and bladder complications = 10.0."
11222971|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
11222972|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
11222973|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
11222974|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
11222975|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:
~WK1-WK12 (5 MR/DAY)
~WK13-14 (4 MR/DAY)
~WK 15 (3 MR/DAY)
~WK 16 (2 MR/DAY)
~WK 17-18 (1 MR/DAY)
~WK 19-24 (No MR)"
11222976|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
11222977|NCT03225183||1|Framingham Heart Study participants
11222978|NCT03225170|Sham Comparator|Control|The control group will rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the 9th ranked item and why it might be important to someone else. The control condition is consistent with the control used in other SA intervention studies. The 9th ranked item is chosen to inhibit a reverse effect, where participants feel affirmed because they do not value something that is averse to them.
11222979|NCT03225170|Experimental|Intervention|Arm Description: Participants will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
11222980|NCT03225157||1|Adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tractwho will undergo cisplatin chemotherapy with concurrent radiation.
11222981|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
11222982|NCT03225131||0|participants without AMD meaning no large drusen (>= 125 microns) or advanced AMD in either eye
11222983|NCT03225131||1|participants with large drusen (>= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
11222984|NCT03225131||2|participants with bilateral large drusen (>= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
11222985|NCT03225131||3|participants with large drusen (>= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
11222986|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
11222987|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
11222988|NCT03225105|Experimental|M3541 + Palliative Radiotherapy (RT)|
11222989|NCT03225092|Experimental|PRP Injection|Ultrasound-guided platelet rich plasma injection
11222990|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
11222991|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
11222992|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
11222993|NCT03225027|Experimental|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
11222994|NCT03225027|Experimental|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
11222995|NCT03225027|Experimental|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
11222996|NCT03225014|Active Comparator|Physical Therapy|
11222997|NCT03225014|Active Comparator|ARP Wave Therapy|
11222998|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
11222999|NCT03224988||Normal Adults|
11223000|NCT03224988||MCI Adults|
11223001|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
11223002|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
11223003|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
11223004|NCT03224949||Healthy controls|
11223005|NCT03224949||Alcoholic hepatitis|
11223006|NCT03224949||Alcoholic steatosis|
11223007|NCT03224949||Alcoholic cirrhosis without HCC|
11223011|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:
~If score under 2, patients will receive only aspirin 81 mg once daily
~If DAPT score is ≥ 2
~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen
~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily
~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
11223012|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
11223013|NCT03224897|Active Comparator|Cathodal tDCS|
11223014|NCT03224897|Active Comparator|Anodal tDCS|
11223015|NCT03224897|Sham Comparator|Sham tDCS|
11223016|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
11223017|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
11223018|NCT03224871|Experimental|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
11223019|NCT03224871|Experimental|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
11223020|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
11223021|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
11223022|NCT03224845|Experimental|Cognitive behavioural skills training|
11223023|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
11223024|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
11223025|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
11223026|NCT03224819|Experimental|Exploration Phase|Dose finding phase of the study
11223027|NCT03224819|Experimental|Expansion Phase|Maximum Tolerated Dose identified by Exploration Phase administered to subjects
11223028|NCT03224806|Other|Wholegrain bread|
11223029|NCT03224806|Other|White bread|
11223030|NCT03224806|Other|15% fiber-rich bread|
11223031|NCT03224806|Other|30% fiber-rich bread|
11223032|NCT03224793|Experimental|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
11223033|NCT03224793|Experimental|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
11223034|NCT03224793|Experimental|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
11223035|NCT03224793|Experimental|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
11223036|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
11223037|NCT03224741|Placebo Comparator|Information|
11223038|NCT03224741|Active Comparator|Active Choice|
11223039|NCT03224741|Experimental|Monetary incentive|
11223040|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
11223041|NCT03224715|Experimental|Actinic Cheilitis patients|
11223042|NCT03224702|Experimental|M6495|
11223043|NCT03224702|Placebo Comparator|Placebo|
11223044|NCT03224689|Experimental|PEEK Femoral|
11223045|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
11223046|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
11223047|NCT03224650||Surgical|Patients treated surgically for spinal metastases
11223048|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
11223049|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
11223050|NCT03224637|Active Comparator|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
11223051|NCT03224637|Active Comparator|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
11223052|NCT03224624|Experimental|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
11223053|NCT03224624|No Intervention|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
11223054|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
11223055|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
11223056|NCT03224598|Experimental|No medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
11223057|NCT03224598|Experimental|Medically abrading|A-101 40% with the identified DPN lesions medically abraded prior to treatment
11223058|NCT03224598|Experimental|Initial cohort - no medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
11223059|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
11223060|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
11223061|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
11223062|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
11223063|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
11223064|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
11223065|NCT03224546|No Intervention|Control Group|This group will receive payment for providing urine samples throughout the trial.
11223066|NCT03224546|Experimental|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
11223067|NCT03224546|Experimental|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
11223068|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
11223069|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
11223070|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
11223071|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
11223072|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
11223073|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
11223074|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
11223075|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
11223076|NCT03224507|Experimental|KRdD followed by auto-HCT|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22 (KRd-Dara). Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Days 8 and 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, auto-HCT is done (consolidation 1), then up to two 4-cycle blocks of KRd-Dara consolidation (consolidations 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
11223077|NCT03224507|Experimental|KRdD only|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then @ 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22. Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Day 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, Following induction therapy, patients will receive up to three 4-cycle blocks of KRd-Dara consolidation (consolidations 1, 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
11223078|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.
~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
11223079|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.
~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
11223080|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
11223081|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
11223082|NCT03224468|Active Comparator|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
11223083|NCT03224468|No Intervention|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
11223084|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
11223085|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
11223086|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
11223087|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
11223088|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
11223089|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
11223090|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
11223091|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
11223092|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
11223093|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
11223094|NCT03224403|Placebo Comparator|Placebo|Placebo
11223095|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
11223096|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
11223097|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
11223098|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
11223099|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
11223100|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
11223101|NCT03224351|Experimental|Part 1: F/MF genotype -TC Low|Subjects will receive 80 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.
11223102|NCT03224351|Experimental|Part 1: F/MF genotype - TC Mid|Subjects will receive 240 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.
11223103|NCT03224351|Experimental|Part 1: F/MF genotype - TC High|Subjects will receive 400 mg VX-659 qd in TC with TEZ and IVA for 4 weeks.
11223104|NCT03224351|Placebo Comparator|Part 1: F/MF genotype - Placebo|Subjects will receive placebo for 4 weeks.
11223105|NCT03224351|Experimental|Part 2: F/F genotype - TC|Subjects will receive 400 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.
11223106|NCT03224351|Active Comparator|Part 2: F/F genotype - TEZ/IVA|Subjects will receive TEZ and IVA for 4 weeks.
11223107|NCT03224351|Experimental|Part 3: F/MF genotype - TC|Subjects will receive 400 mg of VX-659 qd in TC with TEZ and VX-561 for 4 weeks.
11223108|NCT03224351|Placebo Comparator|Part 3: F/MF genotype - Placebo|Subjects will receive placebo for 4 weeks.
11223109|NCT03224338|Experimental|: Dolutegravir (DTG)|
11223110|NCT03224325|Other|Placebo (Pooled)|TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.
11223111|NCT03224325|Experimental|TAK-831 100 mg|TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.
11223112|NCT03224325|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.
11223113|NCT03224325|Experimental|TAK-831 600 mg|TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.
11223114|NCT03224325|Experimental|TAK-831 15 mg|TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.
11223115|NCT03224325|Experimental|TAK-831 800 mg|TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
11223116|NCT03224325|Experimental|TAK-831 1200 mg|TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
11223117|NCT03224312||Primary aldosteronism|
11223118|NCT03224312||Essential hypertension|
11223119|NCT03224299|Experimental|Investigational Product #1 (IP1)|Antimicrobial agent in a single use applicator
11223120|NCT03224299|Experimental|Investigational Product #2 (IP2)|Antimicrobial agent in a single use applicator
11223121|NCT03224299|Active Comparator|Active Control|Active control
11223122|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
11223123|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
11223124|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
11223125|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
11223126|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
11223127|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
11223128|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
11223129|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
11223130|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
11223131|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
11223132|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
11223133|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
11223134|NCT03224247|Active Comparator|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
11223135|NCT03224247|Active Comparator|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
11223437|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
11223136|NCT03224234|Experimental|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
11223137|NCT03224234|Active Comparator|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
11223138|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
11223139|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
11223140|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.
~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
11223141|NCT03224182|Experimental|Qapzola|One dose of 8mg Qapzola on Day 1
11223142|NCT03224182|Placebo Comparator|Placebo|One dose of placebo on Day 1
11223143|NCT03224169|Experimental|Intervention|Directly observed hand hygiene
11223144|NCT03224169|No Intervention|Control|No directly observed hand hygiene
11223145|NCT03224156||Dilated Cardiomyopathy|
11223146|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:
~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.
~The nurse presents the object (doll or cube) to the patient.
~The nurse leaves the patient alone with the object.
~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.
~The nurse returns into the room and takes back the object."
11223147|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:
~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.
~The nurse presents the cube to the patient.
~The nurse leaves the patient alone with the cube.
~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.
~The nurse returns into the room and takes back the cube."
11223148|NCT03224130|Experimental|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
11223149|NCT03224130|Active Comparator|Standard of Care|This arm will receive standard of care.
11223150|NCT03224117|Placebo Comparator|Placebo|SQ injection
11223151|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
11223152|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
11223153|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
11223154|NCT03224104|Experimental|Group A - TG02 + RT|Elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and radiation therapy.
11223155|NCT03224104|Experimental|Group B - TG02 + TMZ|Elderly patients with IDH1R132H-non mutant and MGMT promoter-methylated anaplastic astrocytoma or glioblastoma who will receive TG02 and temozolomide.
11223156|NCT03224104|Experimental|Group C - TG02|Patients initially diagnosed with anaplastic astrocytoma or glioblastoma at first relapse post TMZ/RT --> TMZ therapy who will receive TG02.
11223157|NCT03224091||Patients at Psychiatric Center Ballerup|
11223158|NCT03224091||Healthy Controls|
11223159|NCT03224091||Healthy Controls recovered from an eating disorder|
11223160|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
11223161|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
11223162|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
11223163|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.
~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.
~The dosing of all antibiotics will be adjusted according to creatinine clearance."
11223164|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
11223165|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include
~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose
~Normal saline 1ml intravenous (IV) push x 1 dose"
11223166|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:
~Normal saline 0.3 mL IN x 1 dose
~Morphine 0.1 mg/kg IV push x 1 dose"
11223167|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
11223168|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
11223169|NCT03224013|Active Comparator|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
11223170|NCT03224013|Active Comparator|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
11223467|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
11223171|NCT03224000|Experimental|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
11223172|NCT03224000|Active Comparator|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
11223173|NCT03223974|Experimental|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
11223174|NCT03223974|Active Comparator|DES in MB|with regular techniques
11223175|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
11223176|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
11223177|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
11223178|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
11223179|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
11223180|NCT03223935|Active Comparator|Roasted snacks|Corn nuts
11223181|NCT03223935|Experimental|Roasted chickpeas|Chickpeas
11223182|NCT03223935|Experimental|Roasted yellow peas|Yellow peas
11223183|NCT03223935|Experimental|Roasted pinto beans|Pinto beans
11223184|NCT03223935|Experimental|Roasted soybeans|Soybeans
11223185|NCT03223935|Experimental|Roasted almonds|Almonds
11223186|NCT03223922|Experimental|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
11223187|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
11223188|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
~1 drop every 4 hours for 90 days."
11223189|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.
~1 drop every 4 hours for 90 days."
11223190|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
11223191|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
11223192|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
11223193|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
11223194|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
11223195|NCT03223844|Experimental|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
11223196|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
11223197|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
11223198|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
11223199|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
11223200|NCT03223805|Other|Control Arm|Usual Care
11223201|NCT03223805|Experimental|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
11223202|NCT03223792|Active Comparator|Control|
11223203|NCT03223792|Experimental|Investigational|
11223204|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator
~Photon SBRT will be given during TAS-102 dosing
~TAS-102 dosing occurs on days 1 through 5 and 8 through 12
~TAS-102 tablets should be taken twice a day orally"
11223205|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
11223206|NCT03223753|Active Comparator|Arm I (Sqord monitor, limited version of Sqord website|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear Sqord activity monitor daily and upload data at least once a week to the Sqord website. Patients also access the limited version of Sqord website to get basic information related to their physical activity for 6 months.
11223239|NCT03223532|Active Comparator|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.
~*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
11223240|NCT03223532|Experimental|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
11223207|NCT03223753|Experimental|Arm II (Sqord monitor, interactive-reward based Sqord website)|Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear Sqord activity monitor daily and upload data at least once a week to the Sqord website. Patients also access the full version of the interactive-reward based Sqord website to see their activity, earn activity points, see other Sqord player's activity, and interact with other Sqord members for 6 months.
11223208|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
11223209|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
11223210|NCT03223714|Experimental|Conbercept|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).
~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
11223211|NCT03223714|Sham Comparator|Conbercept or sham|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).
~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
11223212|NCT03223701|Other|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
11223213|NCT03223688|Experimental|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
11223214|NCT03223688|Experimental|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
11223215|NCT03223688|Active Comparator|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
11223216|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
11223217|NCT03223662|Other|Neoadjuvant Chemoradiotherapy and esophagectomy|Standard of care neoadjuvant chemoradiotherapy (nCRT) and esophagectomy
11223218|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
11223219|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory thresholdas determined during a V02max test.
11223220|NCT03223636|Experimental|Healthy Volunteers|Healthy Volunteers
11223221|NCT03223623|Active Comparator|FHD|adults with Focal Hand Dystonia
11223222|NCT03223623|Placebo Comparator|Healthy Volunteer|adult healthy volunteers
11223223|NCT03223610|Experimental|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
11223224|NCT03223610|Experimental|Arm 1 Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPO (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
11223225|NCT03223610|Experimental|Arm 2 Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
11223226|NCT03223610|Experimental|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab,lenalidomide) for cycles 2-6
11223227|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
11223228|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
11223229|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
11223230|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
11223231|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
11223232|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
11223233|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
11223234|NCT03223571||Controls|Healthy people with no history of neurological pathologies
11223235|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
11223236|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
11223237|NCT03223545|Experimental|Mindfulness-based cognitive therapy delivered by telephone|
11223238|NCT03223545|Placebo Comparator|Usual Care (UC)|
11223247|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
11223248|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
11223249|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
11223250|NCT03223480|Experimental|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated. A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
11223251|NCT03223467|Active Comparator|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
11223252|NCT03223467|Active Comparator|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
11223253|NCT03223467|Active Comparator|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
11223254|NCT03223467|No Intervention|No intervention|Study participants that do not want to undergo surgical treatment.
11223255|NCT03223454|Experimental|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
11223256|NCT03223454|Placebo Comparator|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
11223257|NCT03223454|Experimental|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
11223258|NCT03223454|Experimental|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
11223259|NCT03223454|Experimental|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
11223260|NCT03223428||Carcinoid Syndrome patients initiating Xermelo|Patients with Carcinoid Syndrome who are initiating treatment with XERMELO.
11223261|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
11223262|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
11223263|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
11223264|NCT03223389|Experimental|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
11223265|NCT03223389|Experimental|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
11223266|NCT03223376|Active Comparator|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/m2 day1, 8, 15 of 4 weeks cycle.
11223267|NCT03223376|Placebo Comparator|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/m2 day1, 8, 15 of 4 weeks cycle.
11223268|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
11223269|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
11223270|NCT03223350|Experimental|Capsaicin|0.1% capsaicin cream, one application
11223271|NCT03223350|Placebo Comparator|Placebo|Topical cream with no active drug
11223272|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
11223273|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
11223274|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
11223275|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
11223276|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
11223307|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
11223308|NCT03223064|Experimental|PSMA PET-CT and USPIO MRI|
11223468|NCT03221985|Other|Questionnaires|
11223277|NCT03223298|Experimental|Botulinum Toxin Type A|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive 100 units of reconstituted botulinum toxin A. 37.5 units will be injected into each masseter muscle and 12.5 units into each temporalis muscle. A written post-operative instruction sheet will be provided to all patients.
11223278|NCT03223298|Placebo Comparator|0.9% Sodium Chloride Injection|The intramuscular injections will be performed with the patient awake in the oral and maxillofacial surgery clinic. Three injection sites into bilateral masseter muscles and two injection sites into bilateral temporalis muscles will be identified by having the patient clench. The sites will be marked with a surgical pen prior to injections. The skin at the injection sites will be cleaned with an alcohol swab. Via a 1cc TB syringe and a 30-gauge needle, the subject will then receive unpreserved 0.9% sodium chloride. A written post-operative instruction sheet will be provided to all patients.
11223279|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
11223280|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
11223281|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
11223282|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
11223283|NCT03223246|No Intervention|Usual care|
11223284|NCT03223246|Experimental|Additional teaching|
11223285|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
11223286|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
11223287|NCT03223220|Experimental|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
11223288|NCT03223220|Placebo Comparator|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
11223289|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
11223290|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
11223291|NCT03223194|Experimental|Cohort 1|1.5 x 10^12 vg/kg of AT342 delivered intravenously one time
11223292|NCT03223194|Experimental|Cohort 2|6.0 x 10^12 vg/kg of AT342 delivered intravenously one time
11223293|NCT03223194|Experimental|Cohort 3|1.5 x 10^13 vg/kg of AT342 delivered intravenously one time
11223294|NCT03223194|No Intervention|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
11223295|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
11223296|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
11223297|NCT03223155|Experimental|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
11223298|NCT03223155|Experimental|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
11223299|NCT03223142|Experimental|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
11223300|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.
~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
11223301|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.
~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
11223302|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.
~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
11223303|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
11223304|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
11223305|NCT03223090|Experimental|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
11223306|NCT03223090|Active Comparator|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
11223392|NCT03222453|Experimental|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
11223309|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.
~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
11223310|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
11223311|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
11223312|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
11223313|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
11223314|NCT03222986||Sepsis with organ failure|Patients have organ failure
11223315|NCT03222986||Sepsis without organ failure|Patients have no organ failure
11223316|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
11223317|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
11223318|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
11223319|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
11223320|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
11223321|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
11223322|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
11223323|NCT03222908|No Intervention|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
11223324|NCT03222908|Experimental|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
11223325|NCT03222908|Experimental|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
11223326|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
11223327|NCT03222882|Experimental|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
11223328|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
11223329|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
11223330|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
11223331|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
11223332|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
11223333|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
11223334|NCT03222830|Experimental|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .
~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
11223335|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
11223336|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
11223393|NCT03222453|No Intervention|non-intervention Patient|No treatment
11223337|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
11223338|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
11223339|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
11223340|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
11223341|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
11223342|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
11223343|NCT03222765|Placebo Comparator|Placebo|"Placebo
~Lifestyle modification (diet and physical activity recommendations)"
11223344|NCT03222765|Experimental|Metformin|"Metformin
~Lifestyle modification (diet and physical activity recommendations)"
11223345|NCT03222765|Experimental|Linagliptin|"Linagliptin
~Lifestyle modification (diet and physical activity recommendations)"
11223346|NCT03222765|Experimental|Linagliptin and Metformin|"Fixed dose combination of Linagliptin and metformin
~Lifestyle modification (diet and physical activity recommendations)"
11223347|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
11223348|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
11223349|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
11223350|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
11223351|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
11223352|NCT03222700||robotic thyroidectomy group|
11223353|NCT03222700||open thyroidectomy group|
11223354|NCT03222687|Experimental|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
11223355|NCT03222674|Experimental|Single arm|CAR T cells to treat AML
11223356|NCT03222648|Experimental|Structured Responsive Exercise Training|8 week twice weekly supervised structured responsive static-cycle based exercise training. Training protocol used the same as Loughney et al. 2016
11223357|NCT03222648|Active Comparator|Standard of Care Arm|Completion of outcome measures only
11223358|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
11223359|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
11223360|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
11223361|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
11223362|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
11223363|NCT03222609|Experimental|Navitoclax + ruxolitinib|Participants will be administered navitoclax once daily (QD) at various doses and a dose greater than or equal to 10 mg of ruxolitinib twice daily (BID).
11223364|NCT03222609|Experimental|Navitoclax|Participants will be administered various doses of navitoclax once daily (QD)
11223365|NCT03222596|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
11223366|NCT03222596|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
11223367|NCT03222583|Experimental|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.
~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
11223368|NCT03222583|Experimental|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.
~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
11223369|NCT03222570|Experimental|IPT-A - possible augment with addl IPT-A|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, the dose of IPT-A will be increased by scheduling sessions twice per week for 4 weeks (16 sessions total).
11223435|NCT03222206|Experimental|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
11223436|NCT03222206|Placebo Comparator|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
11223370|NCT03222570|Experimental|IPT-A - possible augment with SSRI|Adolescents begin with an initial treatment plan of 12 weekly sessions of interpersonal psychotherapy for depressed adolescents (IPT-A). Depressive symptoms will be assessed systematically over the course of therapy. If an adolescent demonstrates an insufficient response to IPT-A at one of these assessments, treatment will be augmented by adding a selective serotonin reuptake inhibitor (SSRI).
11223371|NCT03222570|Active Comparator|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI.
11223372|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
11223373|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
11223374|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
11223375|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
11223376|NCT03222531|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"HCV seropositive non-viremic (HCV Ab+/NAT-) donor hearts to HCV seronegative recipients.
~Heart recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.
~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
~Intervention: Drug: sofosbuvir/velpatasvir"
11223377|NCT03222531|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|"HCV seropositive viremic (HCV Ab+/NAT+) donor hearts to HCV seronegative recipients.
~Starting post-operative day 1, heart recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
~Intervention: Drug: sofosbuvir/velpatasvir"
11223378|NCT03222518|Active Comparator|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
11223379|NCT03222518|Active Comparator|NSAID Group|The patient receives an envelope containing NSAID 20 mg piroxicam twice daily / day + follow-up sheet + appointment card.
11223380|NCT03222518|Active Comparator|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 20 mg piroxicam at a dose of 2 times/day + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
11223381|NCT03222505|Experimental|Treadmill|
11223382|NCT03222505|Experimental|Overground Walking|
11223383|NCT03222492|Experimental|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.
~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
11223384|NCT03222492|Placebo Comparator|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.
~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
11223385|NCT03222492|Experimental|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.
~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
11223386|NCT03222492|Placebo Comparator|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.
~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
11223387|NCT03222492|Experimental|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.
~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
11223388|NCT03222492|Placebo Comparator|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.
~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
11223389|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
11223390|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
11223391|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
11223394|NCT03222440|Experimental|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
11223395|NCT03222427|Experimental|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
11223396|NCT03222427|Experimental|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion.
11223397|NCT03222414|Experimental|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
11223398|NCT03222414|Active Comparator|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
11223399|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
11223400|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
11223401|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
11223402|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
11223403|NCT03222388||IIEF5 paper-electronic|
11223404|NCT03222388||IIEF5 electronic-paper|
11223405|NCT03222388||IIEF15 paper-electronic|
11223406|NCT03222388||IIEF15 electronic-paper|
11223407|NCT03222388||IIEF5 electronic-electronic|
11223408|NCT03222388||IIEF15 electronic-electronic|
11223409|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
11223410|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
11223411|NCT03222349|Other|Interictal State (Period A) of Epilepsy|Diazepam Buccal Soluble Film will be administered to epileptic patients during the icterictal state (Period A)
11223412|NCT03222349|Other|ictal/peri-ictal state (Period B)|Diazepam Buccal Soluble Film will be administered to epileptic patients during the ictal/peri-ictal state (Period B)
11223413|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
11223414|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
11223415|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
11223416|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
11223417|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
11223418|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
11223419|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
11223420|NCT03222284|Experimental|Group 1|"N=10 Device intervention
~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
11223421|NCT03222284|Experimental|Group 2|"N=20 Device intervention
~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
11223422|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:
~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).
~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.
~Respiratory rate (RR): 10-12 breath/minute."
11223423|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:
~Patient's height in cm..
~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).
~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O
~Minimum and maximum Pressure Support (PS) :8-16
~Respiratory rate :10-12 breath/min."
11223424|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
11223425|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
11223426|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
11223427|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
11223428|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
11223429|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
11223430|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
11223431|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
11223432|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
11223433|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
11223434|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
11226369|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
11223438|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
11223439|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
11223440|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
11223441|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
11223442|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
11223443|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
11223444|NCT03222141|Experimental|SAPIEN 3™ valve|
11223445|NCT03222128|Experimental|PIIS3i - SAPIEN 3|PIIS3i - SAPIEN 3 is Operable Group
11223446|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
11223447|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
11223448|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.
~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.
~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
11223449|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.
~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
11223450|NCT03222076|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11223451|NCT03222076|Experimental|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11223452|NCT03222076|Experimental|Arm C (ipilimumab, nivolumab)|Patients receive ipilimumab and nivolumab as in Arm B. Patients undergo post-treatment biopsy on day 1 of week 7, then receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks up to 2 years in the absence of disease progression or unacceptable toxicity.
11223453|NCT03222063|Experimental|Experimental group|"Experimental Group:
~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
11223454|NCT03222063|No Intervention|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
11223455|NCT03222050|Experimental|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
11223456|NCT03222050|Experimental|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
11223457|NCT03222050|Experimental|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
11223458|NCT03222050|No Intervention|control group|Routine care was given during immunization and no intervention was given
11223459|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
11223460|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
11223461|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
11223462|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
11223463|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
11223464|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
11223465|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
11223466|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
11223469|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
11223470|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
11223471|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
11223472|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
11223473|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
11223474|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
11223475|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
11223476|NCT03221907|Experimental|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
11223477|NCT03221907|Active Comparator|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
11223478|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
11223479|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
11223480|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
11223481|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
11223482|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
11223483|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
11223484|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
11223485|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
11223486|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
11223487|NCT03221816|Placebo Comparator|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.
~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.
~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
11223488|NCT03221816|Experimental|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.
~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
11223489|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
11223490|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
11223491|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
11223492|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
11223493|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
11223494|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
11223495|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.
~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
11223901|NCT03219008|Experimental|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
11223496|NCT03221764|Experimental|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
11223497|NCT03221751|Experimental|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
11223498|NCT03221751|Placebo Comparator|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
11223499|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
11223500|NCT03221725|Experimental|sacrospinosus fixation group|The group which sacrospinous fixation was performed
11223501|NCT03221699|Placebo Comparator|control|Formula without ZnO
11223502|NCT03221699|Active Comparator|intervention|Formula with ZnO
11223503|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
11223504|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
11223505|NCT03221660|Experimental|F-Composite 2 system|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the F-Composite 2 system.
11223506|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
11223507|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
11223508|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
11223509|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
11223510|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
11223511|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
11223512|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
11223513|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
11223514|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
11223515|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
11223516|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
11223517|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
11223518|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
11223519|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
11223520|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
11223521|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
11223522|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
11223523|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
11223524|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
11223525|NCT03221517|Experimental|Cohort 1|Shift workers receive a standardized meal with a glucose challenge test
11223526|NCT03221517|Experimental|Cohort 2|Matched healthy controls receive a standardized meal with a glucose challenge test
11223527|NCT03221504|Active Comparator|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
11223528|NCT03221504|Experimental|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
11223529|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
11223530|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
11223531|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
11223532|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
11223533|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
11223534|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
11223535|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
11223536|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
11223537|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
11223538|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
11223539|NCT03221439|Experimental|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
11223540|NCT03221439|Active Comparator|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
11223541|NCT03221426|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
~Adjuvant: 4 to 10 weeks post-surgery, participants receive pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 14 cycles."
11223542|NCT03221426|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle.
~Adjuvant: 4 to 10 weeks post-surgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU via continuous IV infusion on Days 1 to 5 of each 3-week cycle for up to 14 cycles."
11223543|NCT03221426|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.
~Adjuvant: 4 to 10 weeks postsurgery, participants receive pembrolizumab 200 mg via IV infusion Day 1 Q3W for up to 11 cycles PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
11223544|NCT03221426|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations.
~Adjuvant: 4 to 10 weeks postsurgery, participants receive placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3) for 4 administrations."
11223545|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
11223546|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
11223547|NCT03221400|Experimental|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
11223548|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
11223549|NCT03221400|Experimental|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
11223550|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
11223551|NCT03221374|Experimental|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
11223552|NCT03221374|No Intervention|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
11223553|NCT03221361|Active Comparator|Thermoplastic resin group|Thermoplastic complete denture placement is done
11223554|NCT03221361|Placebo Comparator|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
11223555|NCT03221348|Experimental|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
11223556|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
11223557|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
11223558|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
11223559|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening
~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
11223560|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).
~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
11223561|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
11223562|NCT03221283|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
11223563|NCT03221283|Experimental|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
11223564|NCT03221270|Experimental|tACS (alpha)|20 participants: 10 Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily during 5 consecutive days of stimulation, then 40 minutes once weekly for 8 weeks of maintenance stimulation.
11223565|NCT03221270|Sham Comparator|Sham tACS (alpha)|20 participants: Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation, then once weekly for 8 weeks of maintenance stimulation.
11223566|NCT03221257|Placebo Comparator|Placebo (Plac) + Mycophenolate (MMF)|Participants will receive Placebo (Plac) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
11223567|NCT03221257|Experimental|Pirfenidone (PFD) + Mycophenolate (MMF)|Participants will receive Pirfenidone (PFD) as add-on to a background therapy of Mycophenolate Mofetil (MMF).
11223568|NCT03221244|Experimental|VR Treatment|"The VR distractor condition is an adaptive training, experimental treatment. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context. Distractors will be presented intermittently throughout the test session. During training sessions, distractor saliency and frequency will increase or decrease based on performance on the tests.
~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.
~The investigators expect a decrease in distraction after adaptive distractor exposure in the VR classroom."
11223569|NCT03221244|Active Comparator|VR Active Control|"The VR classroom with no distractors presented is an active control group. This group will undergo the same training regimen, only their virtual classroom environment will not contain adaptive distractors. Participants will wear a headset VR system programmed to simulate a virtual classroom. They will be asked to perform computer tests of math, attention, or working memory in the virtual reality context.
~25 sessions should be completed in approximately 5-7 weeks. In-home VR training sessions will each be about 20-30 minutes in length.
~The investigators expect no change in response to distraction in the ADHD group after control exposure to the VR classroom."
11223570|NCT03221231|Experimental|N-acetylcysteine|
11223571|NCT03221231|Placebo Comparator|Placebo|
11223572|NCT03221231|Active Comparator|Healthy controls|
11223573|NCT03221218|Experimental|Enhanced screening-informed letter|Family physicians will receive a letter that includes their patient's screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines for MTBI (2013).
11223574|NCT03221218|No Intervention|Standard letter|Family physicians will receive a letter that includes generic recommendations for managing MTBI based on the Ontario Neurotrauma Foundation clinical practice guidelines (2013). Screening test results will not be provided.
11223575|NCT03221205|Sham Comparator|Sham CPAP|Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
11223576|NCT03221205|Experimental|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
11223577|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
11223578|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
11223579|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
11223580|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
11223581|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
11223582|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
11223583|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
11223584|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
11223585|NCT03221114|Experimental|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
11223586|NCT03221114|No Intervention|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
11223587|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
11223588|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings
~PS mode
~IPAP according to clinical and hemodynamic tolerance
~EPAP according to air trapping
~RR around 12/ min.
~LOT for SaO2 > 90%
~Monitoring with capnometry for settings validation"
11223589|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
11223590|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
11223591|NCT03221088|No Intervention|Negative control group|Untreated Control Group
11223592|NCT03221075||Invasive Aspergillosis|
11223593|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
11223594|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
11223595|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
11223596|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
11223597|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
11223598|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
11223599|NCT03221036|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
11223600|NCT03221036|Placebo Comparator|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
11223601|NCT03221036|Experimental|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
11223602|NCT03221036|Placebo Comparator|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
11223603|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
11223604|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
11223605|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
11223606|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
11223607|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
11223608|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:
~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.
~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
11223609|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
11223610|NCT03220971||proposed cross-section study|"100 subjects with NAFLD/NASH and negative anti-HCV Ab
~50 subjects with HCC and negative anti-HCV Ab
~50 subjects with HCC and positive for genotype-1 HCV
~50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV
~50 controls with all negative for NAFL, NASH and HCV"
11223681|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
11223611|NCT03220971||proposed longitudinal study|"50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR
~10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR
~10 HCC patients and positive for genotype-1 HCV with SVR
~10 HCC patients and positive for genotype-1 HCV without SVR
~50 chronic hepatitis C but not NAFLD patients with SVR
~10 chronic hepatitis C but not NAFLD patients without SVR"
11223612|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
11223613|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
11223614|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
11223615|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
11223616|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
11223617|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
11223618|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
11223619|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
11223620|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
11223621|NCT03220893||Women with Dense Breast Tissue|"Subjects will have had heterogeneously dense or extremely dense breasts on most recent prior mammographic examination (Breast Imaging Reporting and Data System (BI-RADS) c or d) and be asymptomatic for breast disease.
~Subjects will receive Molecular Breast Imaging (MBI) and Digital Breast Tomosynthesis (DBT) at Year 0 screening within a 24-hour period. All patients who did not receive a diagnosis of breast cancer during the Year 0 screening will undergo DBT and MBI at approximately one year (Year 1 screening), again within a 24-hour period."
11223622|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
11223623|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
11223624|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
11223625|NCT03220854|Experimental|SRT + PD-1 or PD-L1 inhibitor|Stereotactic radiotherapy (SRT), 3-5 fractions over 1-2 weeks plus programmed death receptor-1 (PD-1) or programmed death-ligand1 (PD-L1) inhibitor after last SRT fraction (on same day) and continuing per standard treatment schedule for 12 months
11223626|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
11223627|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
11223628|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
11223629|NCT03220828|Experimental|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
11223630|NCT03220815|Experimental|Biologic drilling drilling at low speed|
11223631|NCT03220815|Active Comparator|conventional drilling drilling at high speed|
11223632|NCT03220802|Experimental|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
11223633|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
11223634|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
11223635|NCT03220776|Experimental|N-Acetylcysteine|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
11223636|NCT03220776|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
11223637|NCT03220776|Placebo Comparator|Placebo Oral Tablet|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
11223638|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
11223639|NCT03220737|Experimental|Cohort 1 (active, 12-17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
11223640|NCT03220737|Placebo Comparator|Cohort 1 (placebo, 12 - 17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
11223641|NCT03220737|Experimental|Cohort 2 (active, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
11223642|NCT03220737|Placebo Comparator|Cohort 2 (placebo, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
11223643|NCT03220737|Experimental|Cohort 3 (active, 2 - 5 yrs)|Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
11223644|NCT03220737|Placebo Comparator|Cohort 3 (placebo, 2 - 5 yrs)|Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
11223645|NCT03220737|Other|Historical Control: Adult Bridging Population|This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
11223646|NCT03220724|Experimental|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
11223647|NCT03220724|Experimental|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
11223648|NCT03220724|Experimental|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
11223649|NCT03220724|Placebo Comparator|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
11223650|NCT03220724|Experimental|Part B: Group 5|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, 8, 12, and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
11223651|NCT03220724|Experimental|Part B: Group 6|Participants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8; CH505w78 at Months 12 and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
11223652|NCT03220724|Experimental|Part B: Group 7|Participants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, 8, 12, and 16.
11223653|NCT03220724|Placebo Comparator|Part B: Group 8|Participants will receive placebo at Months 0, 2, 4, 8, 12, and 16.
11223654|NCT03220711|Experimental|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
11223655|NCT03220685||1.normal persons|normal persons include 25 person
11223656|NCT03220685||2.CKD pt with anemia|includes 25 previously diagnosed CKD patients with or without treatment of anemia.
11223657|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
11223658|NCT03220659|Placebo Comparator|Standard settings|Usual pacing programming
11223659|NCT03220659|Experimental|Multi-point pacing|MPP programming
11223660|NCT03220646|Experimental|A:recurrent IDH wildtype RB1 intact grade II and III gliomas|The main study cohort will consist of patients with recurrent IDH wildtype, RB1 wildtype, WHO grade II and III gliomas that have failed previous therapy. This arm is currently on hold.
11223661|NCT03220646|Experimental|B:Recurrent glioma any grade|Ten patients who require standard of care cytoreductive surgery for recurrent astrocytoma, oligodendroglioma, or glioblastoma, will be offered pre-surgical abemaciclib and then resume the drug following recovery from surgery, continuing until disease progression or unacceptable toxicity analogous to the non-surgical patients in cohort A and C. This arm is closed to accrual.
11223662|NCT03220646|Experimental|C:All other recurrent brain tumors|This is an exploratory cohort including patients with recurrent IDH mutant glioma, meningioma, recurrent ependymoma, and recurrent PCNSL,and other primary brain tumors.
11223663|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
11223664|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
11223665|NCT03220620||GDT Group|receives goal-directed therapy
11223666|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
11223667|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
11223668|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
11223669|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
11223670|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
11223671|NCT03220581|Active Comparator|Referral for care|Referral for mental health issues and family support services
11223672|NCT03220581|Experimental|Behavioral therapy|8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors
11223673|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
11223674|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
11223675|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
11223676|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
11223677|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
11223678|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
11223679|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
11223680|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
11223682|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
11223683|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
11223684|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
11223685|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
11223686|NCT03220503|Experimental|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
11223687|NCT03220503|No Intervention|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
11223688|NCT03220490|Experimental|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.
~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.
~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
11223689|NCT03220490|Experimental|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.
~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.
~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
11223690|NCT03220490|Experimental|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.
~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
11223691|NCT03220490|Experimental|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.
~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
11223692|NCT03220477|Experimental|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
11223693|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
11223694|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
11223695|NCT03220438|Active Comparator|TMS|rTMS
11223696|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
11223697|NCT03220425|Experimental|Insulin detemir|
11223698|NCT03220425|Active Comparator|NPH insulin|
11223699|NCT03220412|Experimental|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
11223700|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
11223701|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1
~1capsule, oral dosing"
11223702|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2
~1Tablet, oral dosing"
11223703|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
11223704|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
11223705|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
11223706|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
11223707|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
11223744|NCT03220165|Experimental|Treatment|MGL-3196
11223902|NCT03218995|Experimental|Experimental: Treated Group|
11223708|NCT03220347|Experimental|CC-90010 in patients with solid tumors and NHL|Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
11223709|NCT03220334|Experimental|Apply platelet rich plasma to the artificial gastric ulcer|
11223710|NCT03220334|Placebo Comparator|Apply normal saline to the artificial gastric ulcer|
11223711|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
11223712|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
11223713|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
11223714|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
11223715|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
11223716|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
11223717|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
11223718|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
11223719|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
11223720|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
11223721|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
11223722|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
11223723|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
11223724|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
11223725|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
11223726|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
11223727|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
11223728|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
11223729|NCT03220282|Active Comparator|Donor milk|Pasteurized donor breast milk
11223730|NCT03220282|Placebo Comparator|Preterm infant formula|Preterm formula determined by clinical practice
11223731|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
11223732|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
11223733|NCT03220256|Experimental|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
11223734|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
11223735|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
11223736|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
11223737|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
11223738|NCT03220204|Experimental|PP-based health behavior intervention|Participants will undergo a 12-week, Positive Psychology (PP)-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
11223739|NCT03220204|Experimental|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. This Motivational Interviewing (MI)-based educational control condition will introduce these participants to motivational interviewing topics in concert with the health behavior education topics.
11223740|NCT03220204|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group will not receive any interventions between the baseline visit and follow-up visits.
11223741|NCT03220191|Experimental|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
11223742|NCT03220178|Experimental|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
11223743|NCT03220178|Other|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
11223745|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
11223746|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
11223747|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
11223748|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
11223749|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
11223750|NCT03220113|Experimental|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.
~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
11223751|NCT03220100|Experimental|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
11223752|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
11223753|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
11223754|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
11223755|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
11223756|NCT03220061|No Intervention|control|usual care was given to participant in control group
11223757|NCT03220048|Other|Cohort A: Sentinel Group|Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
11223758|NCT03220048|Experimental|Cohort B: PrEP-001|PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
11223759|NCT03220048|Experimental|Cohort B: Placebo|Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
11223760|NCT03220035|Experimental|Treatment (vemurafenib)|Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11223761|NCT03220022|Experimental|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
11223762|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.
~PART II: Patients undergo active surveillance for 1 year."
11223763|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.
~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
11223764|NCT03219996||non-survivor group|
11223765|NCT03219996||survivor group|
11223766|NCT03219983|Active Comparator|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
11223767|NCT03219983|Active Comparator|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
11223768|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
11223769|NCT03219957|Experimental|AT-527|
11223770|NCT03219957|Placebo Comparator|Placebo|
11223771|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
11223772|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
11223773|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
11223798|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
11223774|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
11223775|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
11223776|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
11223777|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
11223778|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
11223779|NCT03219905|Experimental|Kinesio-taping Group|Therapeutic Kinesio-taping
11223780|NCT03219905|Sham Comparator|Control Group|Sham Kinesio-taping
11223781|NCT03219892|Experimental|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
11223782|NCT03219892|Sham Comparator|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
11223783|NCT03219879|Experimental|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
11223784|NCT03219879|Active Comparator|Usual care|Treatment as usual
11223785|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
11223786|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
11223787|NCT03219853|Experimental|Lower selenium-status|
11223788|NCT03219853|Experimental|higher selenium|
11223789|NCT03219840|Experimental|CPC-Xylitol complex|Cetylpyridium Chloride (CPC) 0.09% + Xylitol chewing gum A All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
11223790|NCT03219840|Placebo Comparator|Placebo|Xylitol chewing gum B All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
11223791|NCT03219827|Experimental|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.
~Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)
~After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
11223792|NCT03219827|Experimental|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.
~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
11223793|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.
~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
11223794|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
11223795|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
11223796|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
11223797|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
11223799|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
11223800|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
11223801|NCT03219775|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy
~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
11223802|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
11223803|NCT03219749|Experimental|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
11223804|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
11223805|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
11223806|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
11223807|NCT03219710|Active Comparator|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:
~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;
~The patient on control group with weight category of > 40 kg will receive:
~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg
~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
11223808|NCT03219710|Experimental|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)
~Weight category of > 40 kg in study group will receive:
~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant & Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
11223809|NCT03219697|Experimental|Parenting education program|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits
11223810|NCT03219697|No Intervention|Control|Receive regular health care
11223811|NCT03219671|Experimental|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
11223812|NCT03219658|Experimental|Parenting education sessions|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits.
11223813|NCT03219658|No Intervention|Control|Attend one-on-one check-ins with the interdisciplinary team at STOMP; wait-listed control group.
11223814|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
11223815|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
11223816|NCT03219619|Experimental|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
11223817|NCT03219619|Active Comparator|Duo group: Duo|Undergoing side-viewing duodenoscope
11223818|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
11223819|NCT03219593|Experimental|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
11223820|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
11223821|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
11223822|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
11223823|NCT03219541|Active Comparator|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
11223824|NCT03219541|Placebo Comparator|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
11223825|NCT03219528|Active Comparator|Rifaximin|Rifaximin 550 mg three times daily for 14 days
11223826|NCT03219528|Active Comparator|Low FODMAP Group|Low FODMAP diet for 4 weeks
11223827|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
11223828|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
11223829|NCT03219502|Experimental|Group I (rTMS)|Patients undergo rTMS over 30 minutes for 10 sessions over 10 business days.
11223830|NCT03219502|Sham Comparator|Group II (sham rTMS)|Patients undergo sham rTMS over 30 minutes for 10 sessions over 10 business days.
11223831|NCT03219502|Active Comparator|Group III (standard of care)|Patients receive standard of care.
11223832|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
11223833|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
11223834|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
11223835|NCT03219463|Experimental|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
11223836|NCT03219463|Active Comparator|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
11223837|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.
~The priming shots will comprise days 1, 4, 8, 15, and 22.
~Booster shots will be given on days 78 and 134."
11223838|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.
~The priming shots will comprise days 1, 4, 8, 15, and 22.
~Booster shots will be given on days 78 and 134.
~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
11223839|NCT03219437|Active Comparator|Methotrexate|Participants to receive double-blind methotrexate.
11223840|NCT03219437|Experimental|Risankizumab|Participants to receive double-blind risankizumab.
11223841|NCT03219411|Active Comparator|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
11223842|NCT03219411|Placebo Comparator|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
11223843|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
11223844|NCT03219398|Active Comparator|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
11223845|NCT03219385|Experimental|Treatment with the Mirabilis System|
11223846|NCT03219372|Experimental|Pravastatin Pill|Daily pravastatin (40mg)
11223847|NCT03219372|Placebo Comparator|Placebo Oral Tablet|Placebo
11223848|NCT03219359|Experimental|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
11223849|NCT03219346|Experimental|Oral hygiene|
11223850|NCT03219333|Experimental|Enfortumab vedotin|Enfortumab vedotin on days 1, 8 and 15 every 28 days
11223851|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
11223852|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
11223853|NCT03219307|Experimental|NOVOCART 3D|Matrix associated autologous chondrocyte implant
11223854|NCT03219294|Active Comparator|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
11223855|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
11223856|NCT03219268|Experimental|MGD013|MGD013 administered IV once every 2 or 3 weeks for up to 96 weeks
11223857|NCT03219268|Experimental|MGD013 plus margetuximab|MGD013 administered in combination with margetuximab IV once every 3 weeks for up to 32 3-week cycles
11223858|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
11223859|NCT03219242|Experimental|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
11223860|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
11223861|NCT03219216|Experimental|Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
11223862|NCT03219216|Experimental|Arm B: GLE/PIB for 12 Weeks|Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.
11223863|NCT03219203|Experimental|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
11226959|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
11223864|NCT03219203|Active Comparator|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
11223865|NCT03219190|Experimental|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
11223866|NCT03219190|No Intervention|Treatment as Usual (Control)|Standard health education
11223867|NCT03219177|Experimental|Patient education group|
11223868|NCT03219177|Active Comparator|Control- Standard of care counseling|
11223869|NCT03219164|Experimental|AZLI|AZLI for 28 days
11223870|NCT03219164|Experimental|AZLI + Placebo|AZLI for 14 days followed by placebo for 14 days
11223871|NCT03219151|Experimental|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
11223872|NCT03219151|Active Comparator|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
11223873|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
11223874|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
11223875|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
11223876|NCT03219125||Group 2 (controls)|no history of fragility fracture
11223877|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
11223878|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
11223879|NCT03219086|Active Comparator|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
11223880|NCT03219086|Active Comparator|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
11223881|NCT03219073|Sham Comparator|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
11223882|NCT03219073|Active Comparator|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
11223883|NCT03219060|Experimental|Intervention group|MI based four individual sessions
11223884|NCT03219060|Active Comparator|Control group|Brief advice following 5As
11223885|NCT03219047|Experimental|Cohort 2 (Co-trial cohort)|Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. Patients who experience relapse after treatment with ibrutinib are moved to Cohort I if the PDX models are not ready.
11223886|NCT03219047|Experimental|Cohort I (Traditional cohort)|Patients who have previously received ibrutinib, acalabrutinib, PI3K inhibitor ACP-319, or BTK inhibitor BGB-3111 receive treatment through ongoing clinical trials at MD Anderson or standard of care. At the same time, previously collected tissue is used to develop PDX models and suitable drugs/regimens are tested in the PDX models. Patients then receive treatment based on the results of the PDX models through another clinical trial or standard of care.
11223887|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
11223888|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
11223889|NCT03219008|Experimental|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
11223890|NCT03219008|Experimental|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
11223891|NCT03219008|Experimental|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
11223892|NCT03219008|Experimental|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
11223893|NCT03219008|Experimental|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
11223894|NCT03219008|Experimental|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
11223895|NCT03219008|Experimental|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
11223896|NCT03219008|Experimental|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
11223897|NCT03219008|Experimental|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
11223898|NCT03219008|Experimental|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
11223899|NCT03219008|Experimental|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
11223900|NCT03219008|Experimental|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
11227797|NCT03192176|Experimental|Medium dose ESN364|ESN364 medium dose BID, oral, 12 weeks
11223903|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
11223904|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
11223905|NCT03218969|Experimental|Study period 1|"Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by
~Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by
~Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
11223906|NCT03218969|Experimental|Study period 2|"Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by
~Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by
~Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
11223907|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
11223908|NCT03218943|Active Comparator|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
11223909|NCT03218943|Active Comparator|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
11223910|NCT03218930|Other|Social marketing intervention|Participants will receive a total combination of four interventions.
11223911|NCT03218917|Experimental|INS1007 10 mg Oral Tablet|Once per day for 24 weeks.
11223912|NCT03218917|Experimental|INS1007 25 mg Oral Tablet|Once per day for 24 weeks.
11223913|NCT03218917|Placebo Comparator|Placebo Oral Tablet|Once per day for 24 weeks.
11223914|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
11223915|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
11223916|NCT03218891|Experimental|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.
~The intervention is the Cardiac Rehabilitation."
11223917|NCT03218891|No Intervention|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
11223918|NCT03218891|No Intervention|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
11223919|NCT03218891|No Intervention|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
11223920|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
11223921|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
11223922|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)
~cyclophosphamide(1g intravenous use,per 1 month*6months);
~supportive care,including ACE-I or ARBs and blood pressure control"
11223923|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);
~supportive care,including ACE-I or ARBs and blood pressure control"
11223924|NCT03218839|Experimental|HIV+ PrePex|PrePex male circumcision device
11223925|NCT03218826|Experimental|Treatment (docetaxel, PI3Kbeta inhibitor AZD8186)|Patients receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 PO BID for 5 days each week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11223926|NCT03218813|No Intervention|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
11223927|NCT03218813|Experimental|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
11223928|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
11223929|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
11223930|NCT03218787|Experimental|XIENCE + 3-month DAPT|
11223931|NCT03218774|Other|Home Group|
11223932|NCT03218774|Experimental|Center Group|
11223933|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.
~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
11223934|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.
~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
11223935|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.
~Fidelity to manual: rated by a research assistant who is present during the group session"
11223936|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
11223937|NCT03218735|Experimental|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
11223938|NCT03218735|Active Comparator|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
11223939|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
11223940|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
11223941|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
11223942|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
11223943|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
11223944|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
11223945|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
11223946|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
11223947|NCT03218683|Experimental|Monotherapy AZD5991|Dose escalation - multiple dose levels
11223948|NCT03218683|Experimental|Monotherapy AZD5991 expansion|Dose expansion
11223949|NCT03218683|Experimental|AZD5991 + venetoclax|Dose escalation - multiple dose levels
11223950|NCT03218657|Experimental|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
11223951|NCT03218657|Other|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
11223952|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
11223953|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
11223954|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
11223955|NCT03218605|Experimental|healthy active participants|
11223956|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
11223957|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
11223958|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
11223959|NCT03218579|No Intervention|No intervention|No intervention after antibiotic treatment.
11223960|NCT03218579|Active Comparator|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
11223961|NCT03218579|Active Comparator|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
11223962|NCT03218566|Other|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
11223963|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
11223964|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
11223965|NCT03218540|Experimental|SVV group|Fluid management protocol
11223966|NCT03218540|Active Comparator|CVP group|Fluid management protocol
11223967|NCT03218501|Active Comparator|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
11223968|NCT03218501|Active Comparator|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
11223969|NCT03218501|Placebo Comparator|Placebo|Placebo is to be administered orally once daily for 2 weeks
11223970|NCT03218488||Participants With Moderate to Severe Plaque Psoriasis|All Participants diagnosed with moderate to severe plaque psoriasis who will either start therapy with ustekinumab within 2 months after the first assessment within the study or have started therapy with ustekinumab in the 12-week period before the first assessment within the study as per routine clinical practice, will be monitored for the long-term safety of ustekinumab and long-term effects of ustekinumab on growth and development of pediatric participants. The primary data source for the study will be the medical records of participants and standardized questionnaires (completed by the physician and by the participant/parent).
11223971|NCT03218475|Experimental|MR Guided Focused Ultrasound|
11223972|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
11223973|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
11223974|NCT03218449||1/NC|noninfective complication
11223975|NCT03218449||2/IC|infective complication
11223976|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
11223977|NCT03218436|No Intervention|Control cohort|no intervention
11223978|NCT03218410|Active Comparator|surgical pulmonary embolectomy|
11223979|NCT03218410|Active Comparator|catheter-directed thrombolysis|
11223980|NCT03218397|Active Comparator|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
11223981|NCT03218397|Active Comparator|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
11223982|NCT03218384|Experimental|ferric carboxymaltose|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
11223983|NCT03218384|Active Comparator|Placebo|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
11223984|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
11223985|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
11223986|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
11223987|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
11223988|NCT03218332||Healthy controls|Active Comparator
11223989|NCT03218319|Experimental|All patients|
11223990|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
11223991|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
11223992|NCT03218293|Experimental|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
11223993|NCT03218293|No Intervention|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
11223994|NCT03218280|Active Comparator|Antioxidant Therapy|
11223995|NCT03218280|No Intervention|Antioxidant Free|
11223996|NCT03218267|Experimental|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
11223997|NCT03218267|Active Comparator|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
11223998|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
11223999|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
11224000|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
11224001|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
11224002|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
11224003|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
11224004|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
11224005|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
11224006|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
11224007|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
11224008|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
11224009|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
11224010|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
11224011|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
11224012|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
11224013|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
11224014|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
11224015|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
11224016|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
11224017|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
11224018|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
11224019|NCT03218137|Other|Adenosine/ Verapamil Arm|"Adenosine: 0.84 mg/kg IV (140 mcg/kg/minute IV for 6 minutes) Verapamil: 0.15 mg/kg IV
~Adenosine is known to terminate ventricular arrhythmias that are due to triggered activity (ref Lerman). To study the effects of adenosine on PVC, the investigators will administer Verapamil to slow down the heart initially and adenosine after catheters are introduced to patients who are being treated for symptomatic PVC and have consented to treatment with an invasive electrophysiology study and catheter ablation."
11224020|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
11224021|NCT03218111|Other|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
11224022|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
11224023|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
11224024|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
11224025|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
11224026|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
11224027|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
11224028|NCT03218033|No Intervention|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
11224029|NCT03218033|Active Comparator|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.
~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
11224030|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
11224031|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
11224032|NCT03218007|Experimental|acute coronary syndrome|
11224033|NCT03217994|Active Comparator|37.5% gel|37.5% gel to bleach teeth
11224034|NCT03217994|Experimental|6% gel|6% gel to bleach teeth
11224035|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
11224036|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
11224037|NCT03217968|Experimental|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
11224038|NCT03217955|Experimental|CBT-SA|"Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;
~Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
11224039|NCT03217955|Active Comparator|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
11224040|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
11224041|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
11224042|NCT03217929|Active Comparator|Active-taVNS|
11224043|NCT03217929|Sham Comparator|Sham-taVNS|
11224044|NCT03217916||normotensive groups|pregnant women with normal blood pressure
11224045|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
11224046|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
11224047|NCT03217877|Active Comparator|No Routine stress testing after PCI|
11224048|NCT03217877|Experimental|Routine stress testing at 9~15 months after PCI|
11224049|NCT03217851||Patients Presenting P. falciparum Malaria|
11224050|NCT03217838|Experimental|Part A - Arm 1 Dose Escalation|AZD2811 single agent on Days 1 and 4 of each 28 day cycle. Dose escalation
11224051|NCT03217838|Experimental|Part A - Arm 2 Dose Escalation|AZD2811 single agent on Days 1, 4, 15, and 18 of each 28 day cycle. Dose Escalation
11224052|NCT03217838|Experimental|Part A - AZD2811 plus Azacitidine Dose Escalation|AZD2811 plus azacitidine combination therapy. Escalating doses of AZD2811
11224053|NCT03217838|Experimental|Part A - AZD2811 plus Venetoclax Dose Escalation|AZD2811 plus venetoclax combination therapy. Escalating doses of AZD2811
11224054|NCT03217838|Experimental|Part B - Group 1 AZD2811 Monotherapy Dose Expansion|Monotherapy dose expansion. Additional patients will be enrolled at the AZD2811 MTD.
11224055|NCT03217838|Experimental|Part B - Group 2 AZD2811 plus Combination Drug Dose Expansion|Combination therapy (either azacitidine or venetoclax) dose expansion. Additional patients will be enrolled at the AZD2811 combination MTD.
11224056|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
11224057|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
11224058|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
11224059|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
11224102|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
11224103|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
11224060|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is greater than [>]2 milligram per deciliter [mg/dL] at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
11224061|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
11224062|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
11224063|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
11224064|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
11224065|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
11224066|NCT03217747|Experimental|Arm A (utomilumab, avelumab)|Patients receive utomilumab IV over 60 minutes on day 1 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224067|NCT03217747|Experimental|Arm B (PF-04518600, avelumab)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224068|NCT03217747|Experimental|Arm C (PF-04518600, utomilumab, avelumab)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 15 of each cycle, utomilumab over 60 minutes on day 1, and avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224069|NCT03217747|Experimental|Arm D (avelumab, utomilumab, radiation therapy)|Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 of beginning day 15 of cycle 1 and utomilumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224070|NCT03217747|Experimental|Arm E (avelumab, PF-04518600, radiation therapy)|Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1 and anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 15, and. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224071|NCT03217747|Experimental|Arm F (avelumab, PF-04518600, radiation therapy)|Patients undergo radiation therapy on days -14 to -1. Patients receive avelumab IV over 60 minutes on days 1 and 15 beginning day 15 of cycle 1, utomilumab IV over 60 minutes on day 1, and anti-OX40 antibody PF-04518600 IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224072|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
11224073|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
11224074|NCT03217708||Children without OSA|Children for AT due to chronic tonsillitis without OSA.
11224075|NCT03217708||Children with OSA|Children with OSA for AT as determined by PSG
11224076|NCT03217695|Experimental|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
11224077|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
11224078|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
11224104|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
11224105|NCT03217487|Experimental|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
11224106|NCT03217487|Active Comparator|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
11224107|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
11224108|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
11227798|NCT03192176|Experimental|High dose ESN364|ESN364 high dose BID, oral, 12 weeks
11224079|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.
~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.
~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
11224080|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).
~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
11224081|NCT03217656||Mother-child birth cohort|
11224082|NCT03217643|Experimental|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
11224083|NCT03217630||Diabetic patients|
11224084|NCT03217630||Non-diabetic patients|
11224085|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
11224086|NCT03217604|Placebo Comparator|Placebo|Placebo
11224087|NCT03217604|Experimental|PF-06852231|Single ascending doses of PF-06852231
11224088|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
11224089|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
11224090|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
11224091|NCT03217565|Experimental|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered intravenously (IV). For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
11224092|NCT03217565|Experimental|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension. For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
11224093|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.
~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:
~The Mologic Biomarker Panel
~PCT
~CRP
~Other inflammatory markers or pathogen detection that may augment the panels accuracy
~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
11224094|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:
~Patients being managed for potential infection
~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.
~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
11224095|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
11224096|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
11224097|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
11224098|NCT03217526|Active Comparator|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.
~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
11224099|NCT03217526|Experimental|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
11224100|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
11224101|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
11224201|NCT03216889|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
11224109|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
11224110|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
11224111|NCT03217448|Experimental|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
11224112|NCT03217448|Active Comparator|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
11224113|NCT03217435|Experimental|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
11224114|NCT03217435|Active Comparator|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
11224115|NCT03217422|Experimental|Arm 1|VAY736 Dose 1
11224116|NCT03217422|Experimental|Arm 2|VAY736 Dose 2
11224117|NCT03217422|Experimental|Arm 3|VAY736 Dose 3
11224118|NCT03217422|Placebo Comparator|Arm 4|Placebo
11224119|NCT03217409|Experimental|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
11224120|NCT03217409|Active Comparator|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
11224121|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
11224122|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
11224123|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
11224124|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
11224125|NCT03217370|Other|all haematologists|"There will be only one arm: the haematologists will all be included in the interventional phase.
~Interventions are: 1) rewriting guidelines to order blood components; 2) to show the last hemoglobin value on the orders for erytrocytes and the last platelet count on the orders dor thrombocytes and 3)implementation of a clinical decision support system in the electronic rodering of blood components to stimulate restrictive blood transfusion."
11224126|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
11224127|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
11224128|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
11224129|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
11224130|NCT03217331|Experimental|CRD-102 Treatment|CRD102 Treatment
11224131|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
11224132|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
11224133|NCT03217305|Other|NAVA vs Pressure Support|Control (pressure support) - NAVA - Control (Pressure Support) Intervention is NAVA
11224134|NCT03217292|Experimental|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
11224135|NCT03217292|Active Comparator|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
11224136|NCT03217266|Experimental|Treatment (MDM2 inhibitor KRT-232, radiation therapy)|Patients receive MDM2 inhibitor KRT-232 PO on day 2, days 2 and 4, days 2-4, days 2-5, or days 1-5 of weeks -1 to 5. Patients also undergo radiation therapy daily on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity.
11224137|NCT03217253|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224138|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
11224139|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
11224140|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:
~Cardiovascular Magnetic Resonance Imaging with Exercise Bike
~Blood Sampling
~Activity and Lifestyle Questionnaires
~Fat Mass Measurement"
11224141|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:
~Cardiovascular Magnetic Resonance Imaging with Exercise Bike
~Blood Sampling
~Cardiac Catheterization
~Activity, Lifestyle and Medication Compliance Questionnaires
~Fat Mass Measurement
~Retinal Photography (Optional)"
11224142|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)
~Passive Thermography (PT): 2 thermoscans of the following parts:
~Both carotid artery on left and right of the neck.
~Both superficial temporal artery on the left and right of forehead.
~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
11224202|NCT03216889|Active Comparator|Control|6 weeks of stretching and thinking games.
11224143|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)
~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
11224144|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
11224145|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
11224146|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
11224147|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
11224148|NCT03217188|Experimental|fractionated full dose re-irradiation|
11224149|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
11224150|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
11224151|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
11224152|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
11224153|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
11224154|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
11224155|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
11224156|NCT03217136|Experimental|Ceftolozane/Tazobactam + Metronidazole|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose); plus Metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.
11224157|NCT03217136|Active Comparator|Meropenem + Placebo for Metronidazole|Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.
11224158|NCT03217123|Experimental|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 [Nacc],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
11224159|NCT03217110|Experimental|patient active rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
11224160|NCT03217110|Sham Comparator|patient sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
11224161|NCT03217110|Active Comparator|Control active rTMS|
11224162|NCT03217110|Sham Comparator|Control sham rTMS|
11224163|NCT03217097|Experimental|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
11224164|NCT03217097|Active Comparator|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
11224165|NCT03217097|Experimental|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
11224166|NCT03217097|Active Comparator|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
11224167|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
11224203|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
11224168|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.
~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
11224169|NCT03217071|Experimental|Pembrolizumab|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
11224170|NCT03217071|Experimental|Pembrolizumab + Radiation|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
11224171|NCT03217058||Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
11224172|NCT03217058||Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
11224173|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
11224174|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
11224175|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
11224176|NCT03217019|Experimental|Guidewire|"Radial artery puncture with direct radial pulse palpation.
~24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
11224177|NCT03217019|Active Comparator|Direct|"Radial artery puncture with direct radial pulse palpation.
~24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
11224178|NCT03217006|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
11224179|NCT03217006|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
11224180|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
11224181|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
11224182|NCT03216980|Experimental|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
11224183|NCT03216980|Placebo Comparator|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
11224184|NCT03216980|Experimental|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
11224185|NCT03216980|Placebo Comparator|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
11224186|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
11224187|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
11224188|NCT03216954|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules two times daily.
11224189|NCT03216954|Experimental|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
11224190|NCT03216954|Experimental|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
11224191|NCT03216941|Active Comparator|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
11224192|NCT03216941|Active Comparator|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
11224193|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
11224194|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
11224195|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
11224196|NCT03216902|Experimental|Ultra-low dose 0.0005% DE-126|
11224197|NCT03216902|Experimental|Low dose 0.001% DE-126|
11224198|NCT03216902|Experimental|Medium dose 0.002% DE-126|
11224199|NCT03216902|Experimental|High dose 0.003% DE-126|
11224200|NCT03216902|Active Comparator|0.005% Latanoprost|
11224204|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
11224205|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
11224206|NCT03216863|Experimental|8 weeks Respiratory rehabilitation|
11224207|NCT03216850||Patients in ICU requiring parenteral nutrition|
11224208|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
11224209|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
11224210|NCT03216824|Active Comparator|Dressing|A dressing is maintained on the CVAD exit site.
11224211|NCT03216824|Experimental|No-Dressing|The CVAD exit site is not covered with a dressing.
11224212|NCT03216811|Experimental|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
11224213|NCT03216772|Experimental|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
11224214|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
11224215|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.
~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.
~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
11224216|NCT03216746|Experimental|Oral orientation and App for smartphone|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
11224217|NCT03216746|Experimental|Oral orientation|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
11224218|NCT03216746|Experimental|Video orientation and App for smartphone|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
11224219|NCT03216746|Experimental|Video orientation|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.
11224220|NCT03216733|Experimental|COMBO|PCI with COMBO stent
11224221|NCT03216733|Active Comparator|ORSIRO|PCI with ORSIRO stent
11224222|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
11224223|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
11224224|NCT03216707|Sham Comparator|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
11224225|NCT03216707|Active Comparator|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
11224226|NCT03216707|Active Comparator|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
11224227|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
11224228|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
11224229|NCT03216668|Experimental|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
11224230|NCT03216668|Active Comparator|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
11224231|NCT03216655|Experimental|traditional group|phone call
11224232|NCT03216655|Experimental|new device group|wechat group
11224233|NCT03216629|Experimental|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
11224234|NCT03216629|No Intervention|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
11224235|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
11224236|NCT03216603|Experimental|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
11224237|NCT03216603|No Intervention|Usual care group|Usual care group will receive usual follow up
11224238|NCT03216590|No Intervention|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
11224239|NCT03216590|Experimental|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
11224240|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
11224241|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
11224242|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
11224243|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
11224244|NCT03216551||The assumed selective lymph node dissection group|Patients with consolidation tumor ratios ≤ 0.5 tumors will be considered to have negative mediastinal metastasis. Patients with intraoperative lepidic predominant adenocarcinoma diagnosis will be considered to have negative mediastinal metastasis. Patients with an apical tumor will be considered to have negative inferior mediastinal lymph node metastasis. If both N1 nodes and visceral pleural invasion are negative, patients with peripheral non-apical-segment upper lobe tumors will be considered to have negative inferior medistinal lymph node metastasis. If N1 nodes are negative, patients with left superior segment tumors will be considered to have negative 4L lymph node metasis, and patients with left basal segment tumors will be considered to have negative superior mediastinal lymph node metastasis.
11224245|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
11224246|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
11224247|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
11224248|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
11224249|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
11224250|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
11224251|NCT03216499|Experimental|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study
~Laboratory Biomarker Analysis
~Pharmacogenomic Study"
11224252|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
11224253|NCT03216473|Experimental|Neuronox|Botulinum Toxin Type A for injection
11224254|NCT03216473|Active Comparator|Botox|Botulinum Toxin Type A for injection
11224255|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
11224256|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
11224257|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
11224258|NCT03216434|Experimental|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
11224259|NCT03216434|Experimental|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
11224260|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
11224261|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
11224262|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
11224263|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
11224264|NCT03216395|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
11224265|NCT03216395|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
11224266|NCT03216382|Experimental|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
11224267|NCT03216382|Placebo Comparator|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
11224520|NCT03214588|Experimental|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
11224268|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
11224269|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
11224270|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
11224271|NCT03216356|Active Comparator|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
11224272|NCT03216343|Experimental|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
11224273|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.
~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.
~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)
~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.
~At least 18 years old"
11224274|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.
~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.
~At least 18 years old"
11224275|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
11224276|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
11224277|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
11224278|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
11224279|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
11224280|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
11224281|NCT03216278|Experimental|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
11224282|NCT03216278|Active Comparator|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
11224283|NCT03216278|Experimental|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
11224284|NCT03216278|Active Comparator|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
11224285|NCT03216278|Experimental|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
11224286|NCT03216278|Active Comparator|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
11224287|NCT03216278|Experimental|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
11224288|NCT03216278|Active Comparator|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
11224289|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
11224290|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
11224291|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
11224292|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
11224293|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
11224294|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
11224295|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
11224296|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
11224297|NCT03216213|No Intervention|Control|Vignette contains no extra information
11224298|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
11224299|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
11224300|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
11224301|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
11224302|NCT03216187|Experimental|Pregabalin|Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
11224303|NCT03216187|Placebo Comparator|Placebo|Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.
11224304|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
11224400|NCT03215485|Experimental|Intervention Group|"All intervention youth participants will receive three components:
~Nutrition lessons
~Virtual World learning environment
~Newsletters"
11228632|NCT03186495|Experimental|Severe renal impairment|Subjects with severe renal impairment
11224305|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
11224306|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
11224307|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
11224308|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
11224309|NCT03216122|Active Comparator|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
11224310|NCT03216122|Active Comparator|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
11224311|NCT03216109|Experimental|Weekly telephone symptom assessment|"Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Symptom assessments will be documented into an encrypted, HIPAA compliant digital platform which provides longitudinal symptom data management and also provides symptom assessment tools for the clinical team in their intervention strategies.
~In addition, patients will complete symptom and quality of life surveys at 0, 3, 6 and 9 months."
11224312|NCT03216109|No Intervention|Control Arm|Patients randomized to usual clinical care will receive standard of care for thoracic malignancies as provided by the VA Palo Alto Health Care System. Patients will complete outcome surveys at 0, 3, 6, and 9 months.
11224313|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
11224314|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
11224315|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
11224316|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
11224317|NCT03216057|Experimental|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
11224318|NCT03216057|Placebo Comparator|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
11224319|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
11224320|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
11224321|NCT03216005|Experimental|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
11224322|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
11224323|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
11224324|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
11224325|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
11224326|NCT03215966|Experimental|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
11224327|NCT03215966|Experimental|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
11224328|NCT03215953|Active Comparator|Group A|cast shoe plus standard wound care
11224329|NCT03215953|Active Comparator|Group B|removable walker plus standard wound care
11224330|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
11224331|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
11224332|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
11224333|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
11224334|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
11224335|NCT03215914|Experimental|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
11224336|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
11224337|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
11224338|NCT03215901|No Intervention|Pure Control|Participants view no video.
11224339|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
11224340|NCT03215888||controls|matched non-obese controls
11224341|NCT03215875|Experimental|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
11224342|NCT03215875|Experimental|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
11224343|NCT03215862|Active Comparator|Control|
11224344|NCT03215862|Experimental|Experimental|
11224345|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
11224346|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
11224347|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
11224348|NCT03215836|Other|Obese Asthmatics|BMI >/= 30 and without metabolic syndrome
11224349|NCT03215836|Other|Obese Astmatics|BMI >/= 30 and with metabolic syndrome
11224350|NCT03215836|Other|Obese non-asthmatics|BMI >/= 30
11224351|NCT03215836|Other|Non - obese asthmatics|BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
11224352|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
11224353|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
11224354|NCT03215810|Experimental|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
11224355|NCT03215797|Active Comparator|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
11224356|NCT03215797|Other|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
11224357|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
11224358|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
11224359|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
11224360|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
11224361|NCT03215758|Active Comparator|QAW039|QAW039 once daily
11224362|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
11224363|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
11224364|NCT03215745|No Intervention|Control group|Usual care
11224365|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
11224366|NCT03215706|Experimental|Module A|Chemotherapy/Biologics combined
11224367|NCT03215706|Active Comparator|Module B|Chemotherapy Combination
11224368|NCT03215693|Experimental|X-396 capsule|225mg once daily
11224369|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
11224370|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
11224371|NCT03215667|Experimental|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
11224372|NCT03215654|Experimental|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
11224373|NCT03215654|Experimental|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
11224374|NCT03215654|Experimental|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
11224375|NCT03215654|No Intervention|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
11224376|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
11224401|NCT03215485|Active Comparator|Comparison|"All comparison youth participants will only receive one component:
~1) Newsletters"
11224521|NCT03214588|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
11224377|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
11224378|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
11224379|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
11224380|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
11224381|NCT03215615|Active Comparator|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
11224382|NCT03215615|Active Comparator|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
11224383|NCT03215615|Active Comparator|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
11224384|NCT03215615|Active Comparator|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
11224385|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).
~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
11224386|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.
~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
11224387|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
11224388|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
11224389|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
11224390|NCT03215537|No Intervention|observation|No Intervention
11224391|NCT03215537|Active Comparator|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
11224392|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
~Daratumumab, IV, at 16 mg/kg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.
~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.
~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.
~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
11224393|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
~Daratumumab, IV, at 16 mg/kg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.
~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.
~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.
~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
11224394|NCT03215511|Experimental|Phase 1: Cancer patients <12 years|Dose escalation cohorts with pediatric patients aged <12 years. Dose escalation starts with 43 mg of selitrectinib per m2 body surface twice daily.
11224395|NCT03215511|Experimental|Phase 1: Cancer patients ≥12 years|Dose escalation cohorts with patients aged 12 years or older. Dose escalation starts with 100 mg of selitrectinib twice daily.
11224396|NCT03215511|Experimental|Phase 2: Cancer patients_Cohort 1|Expansion cohort consisting of patients with NTRK fusion cancers showing disease progression despite treatment with a TRK inhibitor. Patients receive selitrectinib at recommended dose twice daily.
11224397|NCT03215511|Experimental|Phase 2: Cancer patients_Cohort 2|Expansion cohort consisting of patients with NTRK fusion cancers showing intolerance or unresponsiveness to previous treatment with a TRK inhibitor. Patients receive selitrectinib at recommended dose twice daily.
11224398|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
11224399|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
11224402|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
11224403|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
11224404|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
11224405|NCT03215446|Active Comparator|propofol|
11224406|NCT03215446|Experimental|sevoflurane|
11224407|NCT03215420|Experimental|Certain or probable Meniere's disease|
11224408|NCT03215407|Experimental|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
11224409|NCT03215407|Active Comparator|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
11224410|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
11224411|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
11224412|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
11224413|NCT03215381|Other|[11C]AZD1390 Microdose|[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
11224414|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
11224415|NCT03215342|Experimental|pGMT|Pediatric Goal Management Training
11224416|NCT03215342|Experimental|pBHW|Pediatric Brain Health Workshop
11224417|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
11224418|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
11224419|NCT03215303|Experimental|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
11224420|NCT03215303|Placebo Comparator|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
11224421|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
11224422|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
11224423|NCT03215277|Experimental|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
11224424|NCT03215277|Experimental|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
11224425|NCT03215264|Experimental|Single Arm|
11224426|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
11224427|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
11224428|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
11224429|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
11224430|NCT03215225||Root canal treatment|
11224431|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
11224432|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
11224433|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
11224434|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
11224435|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
11224436|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
11224437|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
11224438|NCT03215173|Experimental|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
11224439|NCT03215173|Active Comparator|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
11224440|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
11224441|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
11224442|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
11224443|NCT03215121|Active Comparator|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
11224444|NCT03215121|Active Comparator|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
11224445|NCT03215121|Active Comparator|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
11224446|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
11224447|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
11224448|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
11224449|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
11224450|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
11224451|NCT03215069|Experimental|Empagliflozin|Empagliflozin 10 mg PO daily
11224452|NCT03215069|Placebo Comparator|Placebo|Matched placebo PO daily
11224453|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.
~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.
~Dose of PENTHROX® should not exceed 6 mL in a single administration.
~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.
~The maximum dose administered will not exceed 6 mL of methoxyflurane."
11224454|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.
~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.
~Dose of normal saline should not exceed 10 mL in a single administration.
~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.
~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
11224455|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
11224456|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
11224457|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
11224458|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
11224459|NCT03215030|Experimental|Phase 1 Schedule A: TAK-573 0.001 to 14 mg/kg|TAK-573 0.001 to 14 milligram per kilogram (mg/kg), infusion, intravenously, once on Days 1, 8, 15 and 22 of each 28-day treatment cycle up to 2 cycles, followed by once on Days 1 and 15 of each 28-day treatment cycle up to 4 cycles, followed by once on Day 1 of each 28-day treatment cycle until treatment discontinuation.
11224460|NCT03215030|Experimental|Phase 1 Schedule B: TAK-573 TBD|TAK-573 TBD, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
11224461|NCT03215030|Experimental|Phase 1 Schedule C: TAK-573 TBD|TAK-573 TBD, infusion, intravenously, once on Day 1 of each 21-day treatment cycle u until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
11224462|NCT03215030|Experimental|Phase 1 Schedule D: TAK-573 TBD|TAK-573 TBD, infusion, intravenously, once on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
11224463|NCT03215030|Experimental|Phase 2: TAK-573 TBD|Dose for Phase 2 will be based on safety and tolerability results from the preceding Phase 1 dose escalation cohorts. Participants in Phase 2 cohorts will receive TAK-573 TBD as a single agent. Participants in at least 1 cohort will receive TAK-573 TBD and dexamethasone 40 mg, orally, once weekly of each 28-day treatment cycle until treatment discontinuation.
11224464|NCT03215017|Experimental|Transanal irrigation|Manual transanal irrigation to control bowel function.
11224465|NCT03215017|Active Comparator|Medication|Medication to control bowel function.
11224466|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
11224467|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
11224468|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
11224469|NCT03214939|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
11224470|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
11224471|NCT03214913|Other|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
11224472|NCT03214913|Other|Ruijin Group|"Ruijin Strategy therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.
~target： fulfillment of two or more of four criteria:1. HR（heart rate） <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%~35%."
11224473|NCT03214887|Experimental|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
11224474|NCT03214887|Experimental|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
11224475|NCT03214887|Experimental|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
11224476|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
11224477|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
11224478|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
11224479|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
11224480|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
11224481|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
11224482|NCT03214835|Experimental|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
11224483|NCT03214835|Experimental|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
11224484|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
11224485|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
11224486|NCT03214809|Experimental|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
11224487|NCT03214809|No Intervention|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
11224488|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
11224489|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
11224519|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
11224490|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
11224491|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
11224492|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
11224493|NCT03214757||group with dilated cardiomyopathy without anemia|
11224494|NCT03214757||group with dilated cardiomyopathy with anemia|
11224495|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
11224496|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
11224497|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
11224498|NCT03214718|Experimental|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
11224499|NCT03214718|Active Comparator|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
11224500|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
11224501|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
11224502|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
11224503|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
11224504|NCT03214679|Active Comparator|Usual Care|Usual care represents the current procedure after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
11224505|NCT03214666|Experimental|GTB-3550 TriKE™ (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE™ at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE™ followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
11224506|NCT03214666|Experimental|GTB-3550 TriKE™ Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
11224507|NCT03214653|Active Comparator|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
11224508|NCT03214653|Active Comparator|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
11224509|NCT03214640|Active Comparator|Palpation with spinal block (Group C-P)|insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest) for placement of spinal block for cesarean delivery
11224510|NCT03214640|Active Comparator|Palpation with neuraxial block (Group L-P)|the needle insertion site for the neuraxial block will be identified with palpation for labor analgesia
11224511|NCT03214640|Experimental|Rivanna Accuro Ultrasound Device with spinal block (Group C-R)|insertion will be identified with Rivanna Accuro U/S device for placement of spinal block for cesarean delivery
11224512|NCT03214640|Experimental|Rivanna Ultrasound Device with neuraxial block (Group L-R)|insertion will be identified with Rivanna Accuro U/S device for placement of neuraxial block (combined spinal epidural) for labor analgesia
11224513|NCT03214627|Experimental|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period
~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period
~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
11224514|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
11224515|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
11224516|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
11224517|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
11224518|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
11224522|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
11224523|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
11224524|NCT03214562|Experimental|Treatment (venetoclax, FLAG-IDA)|See detailed description.
11224525|NCT03214549|Active Comparator|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
11224526|NCT03214549|Active Comparator|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
11224527|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
11224528|NCT03214523|Experimental|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
11224529|NCT03214523|No Intervention|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
11224530|NCT03214510|Experimental|Arm I (TAE)|Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.
11224531|NCT03214510|Experimental|Arm II (TAP)|Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.
11224532|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
11224533|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
11224534|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.
~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
11224535|NCT03214484|Active Comparator|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.
~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
11224536|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
11224537|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
11224538|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
11224539|NCT03214445|Experimental|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
11224540|NCT03214445|Active Comparator|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
11224541|NCT03214445|No Intervention|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
11224542|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
11224543|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
11224544|NCT03214406|Experimental|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm & Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
11224545|NCT03214406|Active Comparator|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
11224546|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
11224547|NCT03214380|Experimental|LY900014|LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
11224548|NCT03214380|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
11224549|NCT03214380|Experimental|LY900014 Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
11224550|NCT03214380|Active Comparator|Insulin Lispro (Humalog) MEE|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
11224551|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
11224552|NCT03214367|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
11224553|NCT03214367|Experimental|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
11224554|NCT03214367|Experimental|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
11224555|NCT03214367|Active Comparator|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
11224556|NCT03214367|Experimental|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
11224557|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
11224558|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
11224559|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
11224560|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
11224561|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
11224562|NCT03214289|Experimental|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.
~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.
~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
11224563|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
11224564|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
11224565|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
11224566|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
11224567|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
11224568|NCT03214250|Experimental|Gem/NP/nivolumab|Gemcitabine+Nab-Paclitaxel+nivolumab
11224569|NCT03214250|Experimental|Gem/NP/APX005M|Gemcitabine+Nab-Paclitaxel+APX005M
11224570|NCT03214250|Experimental|Gem/NP/nivolumab/APX005M|Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M
11224571|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
11224572|NCT03214224|Experimental|remote PFT (rPFT) validation|Subjects in this arm perform both standard and remote PFT assessments in order to validate the procedure.
11224573|NCT03214198||Vonoprazan 10 mg|The usual adult dosage is 10 mg of Vonoprazan administered orally once daily. Participants will receive interventions as part of routine medical care.
11224574|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
11224575|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
11224576|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
11224577|NCT03214159|Experimental|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.
~Intervention:
~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
11224578|NCT03214159|Experimental|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.
~Intervention:
~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
11224579|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.
~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
11224580|NCT03214133|Experimental|Epicatechin Dose Response|This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
11224581|NCT03214133|Placebo Comparator|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
11224582|NCT03214107|Active Comparator|Full snack given before exercise|A snack containing ~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
11224583|NCT03214107|Active Comparator|Distributed snack over exercise period|A snack containing ~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
11224584|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
11224585|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
11224586|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
11224587|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
11224588|NCT03214016|Experimental|Pilates method group|The participants will do Mat Pilates.
11224589|NCT03214016|Active Comparator|Aerobic training group|The participants will do aerobic exercise on treadmill.
11224590|NCT03214003|Experimental|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
11224591|NCT03214003|Active Comparator|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
11224592|NCT03213990|Other|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
11224593|NCT03213990|Other|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
11224594|NCT03213977|Experimental|Arm I:R-DA-EPOCH|Protocol involves 8 cycles.
11224595|NCT03213977|Experimental|Arm II:R-DA-EPOCH + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
11224596|NCT03213977|Active Comparator|Arm III:R-CEOP90|Protocol involves 8 cycles.
11224597|NCT03213977|Active Comparator|Arm IV:R-CEOP90 + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
11224598|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.
~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).
~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.
~Lymphodepletion with Cyclophosphamide and Fludarabine."
11224599|NCT03213951||Prostate cancer|Gleason grade group 1-5 on prostate biopsy or prostate cancer recurrence.
11224600|NCT03213938|Experimental|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
11224730|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
11224601|NCT03213938|Sham Comparator|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
11224602|NCT03213925|Experimental|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.
~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
11224603|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
11224604|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
11224605|NCT03213873|Experimental|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
11224606|NCT03213873|Active Comparator|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
11224607|NCT03213860|Active Comparator|eye mask|
11224608|NCT03213860|No Intervention|Control|
11224609|NCT03213847|Other|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
11224610|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
11224611|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
11224612|NCT03213821|Experimental|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
11224613|NCT03213821|Active Comparator|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
11224614|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
11224615|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
11224616|NCT03213808||anaphylaxis|anaphylaxis
11224617|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
11224618|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
11224619|NCT03213782|Experimental|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
11224620|NCT03213782|No Intervention|Control group|Usual routine care was continued
11224621|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
11224622|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
11224623|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
11224624|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
11224625|NCT03213743|Other|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
11224626|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
11224627|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
11224628|NCT03213730|No Intervention|Control group|Standard care alone
11224629|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
11224630|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
11224631|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
11224632|NCT03213704|Experimental|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO or via NG- or G-tube twice per day (BID) on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11224633|NCT03213691|Experimental|Treatment (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11224731|NCT03212885|Experimental|1|STN Monopolar Stimulation
11224634|NCT03213678|Experimental|Treatment (PI3K/mTOR inhibitor LY3023414)|Patients receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unexpected toxicity.
11224635|NCT03213665|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11224636|NCT03213652|Experimental|Treatment (ensartinib)|Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11224637|NCT03213639|Experimental|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
11224638|NCT03213639|Placebo Comparator|control group|Patients will take an inert tablet similar in appearance, color and consistency
11224639|NCT03213626|Experimental|Cabozantinib + erlotinib|
11224640|NCT03213613|Experimental|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
11224641|NCT03213613|Placebo Comparator|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
11224642|NCT03213613|Placebo Comparator|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
11224643|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
11224644|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
11224645|NCT03213587|Experimental|apatinib|
11224646|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
11224647|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
11224648|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
11224649|NCT03213548|Experimental|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
11224650|NCT03213548|Active Comparator|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
11224651|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
11224652|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
11224653|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.
~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
11224654|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.
~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
11224655|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
11224656|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
11224657|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
11224658|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
11224659|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
11224660|NCT03213457|Experimental|Elagolix + Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix administered twice daily and Estradiol/Norethindrone Acetate (E2/NETA) administered once daily
11224661|NCT03213457|Experimental|Elagolix|It is administered twice daily.
11224662|NCT03213457|Placebo Comparator|Placebo|A matching placebo for Elagolix and E2/NETA are administered.
11224663|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
11224664|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
11224665|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of <90 and ≥40 and 30 of their parents.
11224732|NCT03212885|Experimental|2|rZI + STN stimulation
11224733|NCT03212872|Other|Endoscopy|
11224666|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
11224667|NCT03213418|Experimental|Contingency management|
11224668|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
11224669|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
11224670|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
11224671|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
11224672|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
11224673|NCT03213379|No Intervention|Referent group|"The patient of the referent group will have 2 measures of actimetry:
~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
11224674|NCT03213379|Experimental|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:
~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
11224675|NCT03213366|Experimental|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
11224676|NCT03213366|Active Comparator|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
11224677|NCT03213353|Experimental|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
11224678|NCT03213353|Experimental|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
11224679|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
11224680|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
11224681|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
11224682|NCT03213327|Other|Case management|Case management program Utilization of the StayOk web application
11224683|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
11224684|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
11224685|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
11224686|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
11224687|NCT03213301|Experimental|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
11224688|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
11224689|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
11224690|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
11224691|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
11224692|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
11224693|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision
~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists
~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling
~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
11224694|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision
~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists
~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling
~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
11224695|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
11224696|NCT03213210|Other|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
11224697|NCT03213197|Experimental|CPR video|Patient watches a short CPR video
11224698|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
11224734|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
11224699|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
11224700|NCT03213145|Experimental|Part 1|
11224701|NCT03213145|Experimental|Part 2|
11224702|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
11224703|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
11224704|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
11224705|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
11224706|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
11224707|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
11224708|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
11224709|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
11224710|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
11224711|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
11224712|NCT03213067||Mitochondrial Disease Patients|"Male and Females >18 years at the time of screening
~Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.
~Capacity to provide informed consent taken before any study related activities.
~Ability and willingness to adhere to the protocol, including all appointments.
~Ability to read and converse in English."
11224713|NCT03213067||Healthy Control Group|"Male and Females >18 years at the time of screening
~Capacity to provide informed consent taken before any study related activities.
~Ability and willingness to adhere to the protocol, including all appointments.
~Ability to read and converse in English."
11224714|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
11224715|NCT03213041|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
11224716|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
11224717|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
11224718|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
11224719|NCT03212989|Experimental|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:
~Step 2 - Single dose of Vorinostat (VOR) 400 mg PO
~Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions
~Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
11224720|NCT03212976|Other|Study Phase 1|Patients with an intracranial pressure monitor will undergo phase contrast magnetic resonance imaging to measure their ICP.
11224721|NCT03212976|Other|Study Phase 2|Patients with shunts or CSF access devices such as Ommaya reservoir, etc will undergo phase contrast magnetic resonance imaging
11224722|NCT03212963|Experimental|Halobetasol lotion treatment arm|All subjects will receive Halobetasol Topical Lotion, 0.05%.
11224723|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
11224724|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
11224725|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
11224726|NCT03212924|Experimental|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.
~Evaluation of speech comprehension in quiet
~Evaluation of speech comprehension in noise
~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)
~Auto evaluation of listening effort in quiet
~Auto evaluation of listening effort in noise"
11224727|NCT03212911|Active Comparator|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
11224728|NCT03212911|Active Comparator|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
11224729|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
11224736|NCT03212846|Experimental|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
11224737|NCT03212846|No Intervention|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
11224738|NCT03212820|Experimental|Biologic drilling|drilling at low speed
11224739|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
11224740|NCT03212807|Experimental|Investigational|Durvalumab + Lenalidomide
11224741|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
11224742|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
11224743|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
11224744|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
11224745|NCT03212755|Experimental|group 1|25 diabetic patients without diabetic nephropathy
11224746|NCT03212755|Experimental|group 2|25 type 2 diabetic patients with diabetic nephropathy
11224747|NCT03212755|Sham Comparator|group 3|25 healthy subjects
11224748|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:
~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.
~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.
~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
11224749|NCT03212729|Active Comparator|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
11224750|NCT03212729|Experimental|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
11224751|NCT03212716|Experimental|diltiazem|oseltamivir + diltiazem
11224752|NCT03212716|Placebo Comparator|oseltamivir + placebo|oseltamivir + placebo of diltiazem
11224753|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
11224754|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
11224755|NCT03212690|Experimental|Mechanically ventilated subjects|Subjects receiving invasive mechanical ventilation (Duration of ventilation <=48 hours) will be evaluated using standard care investigations.
11224756|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
11224757|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
11224758|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
11224759|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
11224760|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
11224761|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
11224762|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
11224763|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
11224764|NCT03212664|Other|Exercise|
11224765|NCT03212651|Experimental|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
11224766|NCT03212638|Experimental|Baricitinib T1 (Part A)|4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
11224767|NCT03212638|Experimental|Baricitinib T2 (Part A)|4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
11224768|NCT03212638|Experimental|Baricitinib R (Part A)|4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
11224769|NCT03212638|Experimental|Baricitinib TF Fasted (Part B)|4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
11224770|NCT03212638|Experimental|Baricitinib TF Fed (Part B)|4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
11224771|NCT03212625|Experimental|Urea cream 20%|144 patients spread urea cream (urea 20%)
11224772|NCT03212625|Placebo Comparator|Placebo|144 patients spread placebo cream (urea 0%)
11224812|NCT03212300|Active Comparator|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
11224813|NCT03212300|No Intervention|treatment as usual|standard treatment
11224773|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.
~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
11224774|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
11224775|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
11224776|NCT03212573|Experimental|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
11224777|NCT03212573|Active Comparator|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
11224778|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
11224779|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
11224780|NCT03212547|Experimental|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
11224781|NCT03212547|No Intervention|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
11224782|NCT03212534|Experimental|Prediction Algorithm|
11224783|NCT03212534|No Intervention|Control|
11224784|NCT03212521|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
11224785|NCT03212495|Active Comparator|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
11224786|NCT03212495|Active Comparator|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
11224787|NCT03212469|Experimental|Patients with head and neck squamous cell carcinoma|
11224788|NCT03212469|Experimental|Patients lung cancer|
11224789|NCT03212469|Experimental|Patients with oesophagus cancer|
11224790|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
11224791|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
11224792|NCT03212443|Sham Comparator|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
11224793|NCT03212443|Active Comparator|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
11224794|NCT03212417|Other|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
11224795|NCT03212404|Experimental|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
11224796|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
11224797|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
11224798|NCT03212378||CHIP 1 - low risk patients|
11224799|NCT03212378||CHIP 2 - medium risk patients|
11224800|NCT03212378||CHIP 3 - high risk patients|
11224801|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
11224802|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
11224803|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
11224804|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
11224805|NCT03212339|Experimental|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
11224806|NCT03212339|Experimental|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
11224807|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
11224808|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
11224809|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
11224810|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
11224905|NCT03211676|Sham Comparator|Elisio-21H|
11224814|NCT03212274|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11224815|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
11224816|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.
~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
11224817|NCT03212222|Experimental|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
11224818|NCT03212222|Active Comparator|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
11224819|NCT03212209|Experimental|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
11224820|NCT03212209|Experimental|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
11224821|NCT03212209|Active Comparator|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
11224822|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
11224823|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
11224824|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
11224825|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
11224826|NCT03212170|Experimental|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
11224827|NCT03212157|Experimental|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
11224828|NCT03212157|Experimental|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
11224829|NCT03212157|Experimental|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
11224830|NCT03212144|Experimental|High Intensity Interval Training then Peanut Consumption|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
11224831|NCT03212144|Experimental|Peanut Consumption then High Intensity Interval Training|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
11224832|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
11224833|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
11224834|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
11224835|NCT03212118|Other|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
11224836|NCT03212118|Active Comparator|Two talks|Two standard talks (not including elements from motivational interviewing)
11224837|NCT03212118|Experimental|Motivational interviewing|Two standard talks with a motivational interviewing content.
11224838|NCT03212105|Active Comparator|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
11224839|NCT03212105|Other|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
11224840|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
11224841|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
11224842|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
11224843|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
11224844|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
11224845|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
11224846|NCT03212066|No Intervention|Wait-List Control|Business as usual
11224847|NCT03212053|Other|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.
~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
11224848|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
11224849|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
11224850|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
11224851|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
11224852|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
11224853|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
11224854|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
11224855|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
11224856|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
11224857|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
11224858|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.
~Surveys conducted up to four times using validated survey tools."
11224859|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.
~Surveys conducted up to four times using validated survey tools."
11224860|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
11224861|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
11224862|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.
~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
11224863|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
11224864|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
11224865|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.
~PEEP 4 cmH2O
~Use ultrasound"
11224866|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.
~PEEP titrated
~Use ultrasound
~Impedance tomography
~Best PEEP for less collapse"
11224867|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
11224868|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
11224869|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
11224870|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
11224871|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
11224872|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
11224873|NCT03211910|Placebo Comparator|Standard Care of Treatment|Participants will be treated with standard of care treatment.
11224874|NCT03211910|Active Comparator|SacralSaver|SacralSaver
11224906|NCT03211663|Other|Interventional : MOTO Medial® UKA|Interventional : Patients who are planned to undergo a primary medial UKA using the MOTO Medial® will be enrolled.
11224875|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
11224876|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
11224877|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
11224878|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
11224879|NCT03211884|Experimental|Problem-solving therapy|"PST consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet & greet session, participants will receive written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7 steps to solve at least one problem together before ending the training. Participants will keep a record of their problem-solving efforts between sessions and questions they have related to the application of PST. These records will be used as a basis for discussion during the intervention."
11224880|NCT03211884|No Intervention|Usual Care|Potential participants will be told that by agreeing to be randomized to UC group, and completing the study surveys over 18 months, they will contribute to our knowledge about what it is like to provide care and assistance to a post-9/11 Veteran or Service Member with a TBI, what caregiver services they use, and to learn if education in problem solving improves mental health outcomes in these military family caregiver (compared to caregivers assigned to the UC group).
11224881|NCT03211871|Active Comparator|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
11224882|NCT03211871|Placebo Comparator|Croup C|group C (control) received normal saline infusion
11224883|NCT03211858|Experimental|SAR341402|SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
11224884|NCT03211858|Active Comparator|NovoLog/NovoRapid|NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.
11224885|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
11224886|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
11224887|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
11224888|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.
~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
11224889|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
11224890|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
11224891|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
11224892|NCT03211793|Experimental|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
11224893|NCT03211793|Placebo Comparator|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
11224894|NCT03211780|Experimental|Ultrasound|
11224895|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
11224896|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
11224897|NCT03211754|Experimental|Obese patients|Treatment for 8 weeks
11224898|NCT03211741|Other|open label|
11224899|NCT03211728|Experimental|experimental group|
11224900|NCT03211728|Placebo Comparator|placebo group|
11224901|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
11224902|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
11224903|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
11224904|NCT03211676|Active Comparator|Theranova-500|
11224907|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
11224908|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
11224909|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
11224910|NCT03211637|Experimental|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
11224911|NCT03211637|Active Comparator|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
11224912|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
11224913|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
11224914|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
11224915|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
11224916|NCT03211598|Other|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
11224917|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
11224918|NCT03211559|Active Comparator|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
11224919|NCT03211559|Experimental|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
11224920|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
11224921|NCT03211507||Case|Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
11224922|NCT03211507||Controls|Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
11224923|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
11224924|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
11224925|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
11224926|NCT03211468|No Intervention|Control Group|No participation in intervention program.
11224927|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.
~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
11224928|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
11224929|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
11224930|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
11224931|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
11224932|NCT03211416|Experimental|Treatment (sorafenib tosylate, pembrolizumab)|Patients receive sorafenib tosylate PO BID on days -28 to -1 and 1-21. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11224933|NCT03211403|Experimental|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
11224934|NCT03211403|Experimental|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
11224935|NCT03211403|Experimental|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
11224936|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
11224937|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
11224938|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
11224939|NCT03211364|Active Comparator|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
11225093|NCT03210233|Experimental|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
11224940|NCT03211364|Active Comparator|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
11224941|NCT03211364|Placebo Comparator|Scapular mobilization|Scapular mobilization without glenohumeral movement.
11224942|NCT03211351|Experimental|Liposic|Liposic was applied to one eye of patients in this group
11224943|NCT03211351|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
11224944|NCT03211338|Active Comparator|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224945|NCT03211338|Active Comparator|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224946|NCT03211338|Active Comparator|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224947|NCT03211338|Active Comparator|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224948|NCT03211338|Active Comparator|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
11224949|NCT03211338|Active Comparator|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
11224950|NCT03211338|Active Comparator|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
11224951|NCT03211338|Active Comparator|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
11224952|NCT03211338|Active Comparator|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224953|NCT03211338|Active Comparator|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224954|NCT03211338|Active Comparator|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224955|NCT03211338|Active Comparator|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
11224956|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :
~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.
~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
11224957|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :
~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.
~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
11224958|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :
~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.
~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
11224959|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
11224960|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
11224961|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
11224962|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
11224963|NCT03211286|Active Comparator|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
11224964|NCT03211286|Placebo Comparator|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
11224965|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
11224966|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
11224967|NCT03211247|Experimental|Viaskin Peanut 250 mcg|
11224968|NCT03211247|Experimental|Viaskin Peanut 100 mcg|
11224969|NCT03211247|Placebo Comparator|Placebo|
11224970|NCT03211234|Experimental|Low Dose DE-122|Low Dose DE-122 and Lucentis
11224971|NCT03211234|Experimental|High Dose DE-122|High Dose DE-122 and Lucentis
11224972|NCT03211234|Sham Comparator|Sham|Sham and Lucentis
11225006|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
11225007|NCT03210935||Merkel cell carcinoma|
11225008|NCT03210935||Advanced basal cell carcinoma|
11225009|NCT03210935||Cutaneous adnexal carcinomas|
11224973|NCT03211221|Active Comparator|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
11224974|NCT03211221|Placebo Comparator|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
11224975|NCT03211195|Experimental|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
11224976|NCT03211195|Active Comparator|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
11224977|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
11224978|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
11224979|NCT03211169|Experimental|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
11224980|NCT03211169|Active Comparator|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
11224981|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
11224982|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
11224983|NCT03211143|Experimental|A|"TR group
~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days
~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
11224984|NCT03211143|Experimental|B|"RT group
~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days
~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
11224985|NCT03211130|Experimental|SystemCHANGE™|
11224986|NCT03211130|Active Comparator|Attention-Control|
11224987|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
11224988|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
11224989|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.
~formulation : curcumin powder 240mg/capsule
~general name : Diferuloylmethane
~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
11224990|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
11224991|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
11224992|NCT03211065|Experimental|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
11224993|NCT03211052|Experimental|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
11224994|NCT03211052|Other|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
11224995|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
11224996|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
11224997|NCT03211013|Experimental|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
11224998|NCT03211013|Placebo Comparator|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
11224999|NCT03210987|Active Comparator|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
11225000|NCT03210987|Active Comparator|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
11225001|NCT03210961|Experimental|PF-06826647 tablet|
11225002|NCT03210961|Placebo Comparator|Placebo tablet|
11225003|NCT03210961|Experimental|PF-06826647 oral suspension|
11225004|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
11225005|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
11225010|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
11225011|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
11225012|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
11225013|NCT03210896|No Intervention|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
11225014|NCT03210896|Experimental|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 & 180 minutes.
11225015|NCT03210896|No Intervention|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
11225016|NCT03210870|Other|Intervention|In-person nutritional education classes
11225017|NCT03210870|No Intervention|Control|no in-person nutritional education classes
11225018|NCT03210857|Experimental|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.
~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
11225019|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
11225020|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
11225021|NCT03210805|Experimental|Supplementation|Omega-3 Polyunsaturated Fatty Acids
11225022|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
11225023|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
11225024|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
11225025|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
11225026|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
11225027|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
11225028|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
11225029|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
11225030|NCT03210727|Other|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
11225031|NCT03210714|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11225032|NCT03210701|Other|Patients requesting a HIV screening test|
11225033|NCT03210688|Active Comparator|High dose prednisolone|Prednisolone 1 mg/kg/day
11225034|NCT03210688|Experimental|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
11225035|NCT03210675|Other|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
11225036|NCT03210675|Other|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
11225037|NCT03210662|Experimental|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11225038|NCT03210649|Experimental|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
11225039|NCT03210649|Experimental|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
11225040|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
11225041|NCT03210623|Experimental|group A|subjects applying the stent retriever(TonbridgeMT)
11225042|NCT03210623|Active Comparator|group B|subjects applying Solitaire™
11225043|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
11225044|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
11225045|NCT03210597|Experimental|hydro-power|Resistance water exercise
11225047|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
11225048|NCT03210558|Active Comparator|Group A|Testosterone cream 1% (Andro-Feme® )
11225049|NCT03210558|Placebo Comparator|Group B|Placebo cream
11225050|NCT03210545|Active Comparator|dexamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of dexamethasone in an estimated physiological dose during one treatment period.
11225051|NCT03210545|Active Comparator|dexamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of dexamethasone in an estimated supra physiological dose during one treatment period.
11225052|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
11225053|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
11225054|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
11225055|NCT03210519|Experimental|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
11225056|NCT03210519|Placebo Comparator|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
11225057|NCT03210506|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
11225058|NCT03210506|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
11225059|NCT03210493|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
11225060|NCT03210493|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
11225061|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
11225062|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
11225063|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
11225064|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
11225065|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
11225066|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
11225067|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
11225068|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
11225069|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
11225070|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
11225071|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
11225072|NCT03210402|Active Comparator|Elevated night pacing on|
11225073|NCT03210402|Placebo Comparator|Elevated night pacing off|
11225074|NCT03210389|Experimental|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
11225075|NCT03210376|Experimental|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.
~Sugammadex intravenously as a single bolus injection after surgery.
~Pain assessment done at about 15, 45, and 90 minutes after surgery."
11225076|NCT03210376|Experimental|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.
~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.
~Pain assessment done at about 15, 45, and 90 minutes after surgery."
11225077|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :
~Two serum tubes of blood will be collected"
11225078|NCT03210337|Experimental|Active|A-101 Topical Solution
11225079|NCT03210337|Placebo Comparator|Vehicle|Vehicle
11225080|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
11225081|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
11225082|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
11225083|NCT03210311|No Intervention|control group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema
~Perform skin care
~Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
11225084|NCT03210311|Active Comparator|intervention group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema
~Perform skin care
~Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible
~Wear a compression sleeve"
11225085|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
11225086|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
11225087|NCT03210272|Experimental|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
11225088|NCT03210272|Experimental|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
11225089|NCT03210259|Experimental|BI 695501|
11225090|NCT03210259|Active Comparator|Humira®|
11225091|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
11225092|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
11225094|NCT03210233|Experimental|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
11225095|NCT03210233|Experimental|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
11225096|NCT03210220|Experimental|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
11225097|NCT03210220|No Intervention|control group|There is no block.
11225098|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.
~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.
~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
11225099|NCT03210194|Active Comparator|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
11225100|NCT03210194|Experimental|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
11225101|NCT03210181|Experimental|Block|Patients will receive superficial cervical plexus block
11225102|NCT03210181|Placebo Comparator|Placebo|Patients will receive normal saline
11225103|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
11225104|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
11225105|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
11225106|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
11225107|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
11225108|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
11225109|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
11225110|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
11225111|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
11225112|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
11225113|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
11225114|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
11225115|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
11225116|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
11225117|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
11225118|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
11225119|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
11225163|NCT03209661|Active Comparator|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
11225120|NCT03210025|Experimental|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
11225121|NCT03210025|Active Comparator|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
11225122|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
11225123|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
11225124|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
11225125|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
11225126|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
11225127|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
11225128|NCT03209973|Experimental|Tislelizumab|Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)
11225129|NCT03209947|Experimental|Ulnar nerve ultrasound|
11225130|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
11225131|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
11225132|NCT03209895|Experimental|Joint Health Product|
11225133|NCT03209895|Placebo Comparator|Placebo|
11225134|NCT03209895|Active Comparator|Glucosamine / Chondroitin|
11225135|NCT03209882|Experimental|TILS|Six weekly sessions of TILS. The TILS will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each session will consist of totally 8 minutes, with eight 1-min cycles alternating between two locations on the right forehead. The laser power will be 3.4 Watts.
11225136|NCT03209882|Sham Comparator|Sham|One weekly session of sham. The sham session will be randomly assigned into the first two intervention visits. The sham will consist of using the same CG-5000 laser for totally 8 minutes, with eight 1-min cycles alternating between two locations on the right forehead. However, the laser power will be turned to be 0 Watts. Therefore the sham session will generate same instrumental sound as TILS, but the subjects won't receive any actual laser illumination.
11225137|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
11225138|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
11225139|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
11225140|NCT03209843|Other|Successfully CTO recanalization|
11225141|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
11225142|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
11225143|NCT03209817|Experimental|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
11225144|NCT03209817|Experimental|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
11225145|NCT03209817|No Intervention|Control No tomato|No tomato products consumption
11225146|NCT03209804|Other|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
11225147|NCT03209804|Experimental|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
11225148|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
11225149|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
11225150|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
11225151|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
11225152|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
11225153|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
11225154|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
11225155|NCT03209765|No Intervention|No reminder|
11225156|NCT03209739|Active Comparator|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
11225157|NCT03209739|No Intervention|No reminder|No additional reminder will be given
11225158|NCT03209713|Active Comparator|Parental Education|Participants will receive parental education on HPV vaccine and the vaccine's benefits.
11225159|NCT03209713|Experimental|Parental Education + Text Messaging|Participants will receive parental education on HPV vaccine and the vaccine's benefits plus text messaging reminder.
11225160|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
11225161|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
11225162|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
11225164|NCT03209661|Placebo Comparator|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
11225165|NCT03209661|Placebo Comparator|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
11225166|NCT03209648|Experimental|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
11225167|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
11225168|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
11225169|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.
~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
11225170|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
11225171|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
11225172|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
11225173|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
11225174|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
11225175|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
11225176|NCT03209570|Experimental|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
11225177|NCT03209570|Active Comparator|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
11225178|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
11225179|NCT03209557|Experimental|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.
~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.
~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
11225180|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
11225181|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
11225182|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
11225183|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
11225184|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
11225185|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
11225186|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
11225187|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
11225188|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
11225189|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
11225190|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
11225191|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
11225192|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
11225193|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
11225194|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
11225195|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
11225196|NCT03209427|Active Comparator|Group I|intrathecal injection of 100 μg morphine
11225197|NCT03209427|Active Comparator|Group II|iIntrathecal injection of 200 μg morphine
11225198|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
11225199|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
11225200|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
11225201|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
11225202|NCT03209401|Experimental|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.
~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
11225203|NCT03209362|Experimental|SI-613|
11225204|NCT03209362|Placebo Comparator|Placebo|
11225205|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.
~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
11225206|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.
~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
11225207|NCT03209336|Experimental|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
11225208|NCT03209336|No Intervention|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
11225209|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
11225210|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
11225211|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
11225212|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
11225213|NCT03209310||Control Group|Children with typical development were included in this study
11225214|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
11225215|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
11225216|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
11225217|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
11225218|NCT03209271|Experimental|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
11225219|NCT03209271|Active Comparator|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
11225220|NCT03209258|Other|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
11225221|NCT03209258|Other|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
11225222|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.
~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
11225223|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
11225224|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
11225225|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
11225226|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
11225227|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
11225228|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
11225229|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
11225230|NCT03209193|Experimental|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
11225231|NCT03209193|Experimental|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
11225232|NCT03209180|Active Comparator|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
11225233|NCT03209180|Experimental|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
11225234|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
11225235|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
11225236|NCT03209154|Experimental|Study Group|Study Group intervention: Therapeutic drug monitoring.
11225237|NCT03209154|Active Comparator|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
11225238|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
11225239|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
11225240|NCT03209128||Irradiation prophyllactique cérébrale|
11225241|NCT03209115|Active Comparator|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
11225242|NCT03209115|Active Comparator|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
11225243|NCT03209102|Experimental|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
11225244|NCT03209102|Experimental|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
11225245|NCT03209076|Experimental|Robotic|Robotic low anterior resection
11225246|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
11225247|NCT03209063||Group 1|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy.
11225248|NCT03209063||Group 2|90 Patients having history of two or more miscarriages.
11225249|NCT03209050|Other|Central Venous Access Placement|Central venous access placement
11225250|NCT03209037|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
11225251|NCT03209037|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
11225252|NCT03209024|Other|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
11225253|NCT03209024|Experimental|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
11225254|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
11225255|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
11225256|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
11225257|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
11225258|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
11225300|NCT03208725||Hospitalized children with severe wasting or kwashiorkor (SWK)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
11225259|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
11225260|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
11225261|NCT03208959|Experimental|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
11225262|NCT03208959|Experimental|Dose level 2|100% Increment from dose level 1
11225263|NCT03208959|Experimental|Dose level 3|100% Increment from dose level 2
11225264|NCT03208959|Experimental|Dose level 4|100% Increment from dose level 3
11225265|NCT03208959|Experimental|Dose level 5|50% Increment from dose level 4
11225266|NCT03208946|Experimental|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
11225267|NCT03208946|Sham Comparator|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
11225268|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
11225269|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
11225270|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
11225271|NCT03208907|Active Comparator|CQ coadministered with PQ|Chloroquine will be administered for 3 days according to the brazilian protocol and Primaquine will be administered for 14 days (0.50mg/kg/day)
11225272|NCT03208907|Experimental|DHA-PQP coadministered with PQ|Dihydroartemisinin/Piperaquine will be administered according to the weight and Primaquine (0.50mg/kg/day)
11225273|NCT03208907|Experimental|CQ and PQ starting on Day 42|Chloroquine will be administered for 3 days according to the brazilian protocol and Primaquine starting on Day 42 for 14 days (0.50mg/kg/day)
11225274|NCT03208907|Experimental|DHA-PQP and PQ starting on Day 42|Dihydroartemisinin/Piperaquine will be administered for 3 days according to the weight and Primaquine will start on Day 42 for 14 days (0.50mg/kg/day)
11225275|NCT03208894|Experimental|with salbutamol|
11225276|NCT03208894|Experimental|with furosemide|
11225277|NCT03208894|Experimental|both furosemide and salbutamol|
11225278|NCT03208894|No Intervention|no inervention|
11225279|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
11225280|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
11225281|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
11225282|NCT03208855|Experimental|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
11225283|NCT03208855|No Intervention|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
11225284|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits
~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of
~---the site of the intrauterine gestational sac in relation to the endometrial cavity .
~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.
~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
11225285|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits
~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of
~---the site of the intrauterine gestational sac in relation to the endometrial cavity .
~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.
~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
11225286|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
11225287|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
11225288|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
11225289|NCT03208790|Experimental|Group A|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.
11225290|NCT03208790|Experimental|Group B|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.
11225291|NCT03208790|Placebo Comparator|Group 3|patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.
11225292|NCT03208777||control group|taking blood samples from apparently healthy people
11225293|NCT03208777||benign colorectal|taking blood samples from patients
11225294|NCT03208777||malignant colorectal|taking blood samples from patients
11225295|NCT03208764|Experimental|Nitric Oxide treatment|
11225296|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
11225297|NCT03208738|No Intervention|Assessment only|
11225298|NCT03208738|Experimental|VetChange mobile app|
11225299|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
11225301|NCT03208725||Community reference participants (CP)|Children recruited from the community who are seen a single appointment in the community.
11225302|NCT03208725||Hospitalized children with moderate wasting (MW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
11225303|NCT03208725||Hospitalized children without wasting (NW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
11225304|NCT03208712|Experimental|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
11225305|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
11225306|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
11225307|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
11225308|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
11225309|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
11225310|NCT03208634|Experimental|Robotic intervention|Robotic intervention.
11225311|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
11225312|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
11225313|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
11225314|NCT03208556|Experimental|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
11225315|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
11225316|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
11225317|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
11225318|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
11225319|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).
~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
11225320|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
11225321|NCT03208491|Experimental|serious games|
11225322|NCT03208491|Active Comparator|usual care|
11225323|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
11225324|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
11225325|NCT03208465|Experimental|Patients with Empagliflozin|
11225326|NCT03208465|Active Comparator|Patients with Sitagliptin|
11225327|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
11225328|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
11225329|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
11225330|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
11225331|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
11225332|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
11225333|NCT03208413|Experimental|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
11225334|NCT03208400|Other|virtual reality exposure|one-session exposure conveyed via virtual reality technology
11225335|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
11228734|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
11225336|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
11225337|NCT03208387||Age-Matched Healthy Children Controls|
11225338|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
11225339|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
11225340|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
11225341|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
11225342|NCT03208335|Experimental|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
11225343|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
11225344|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
11225345|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
11225346|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
11225347|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
11225348|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
11225349|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
11225350|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
11225351|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
11225352|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
11225353|NCT03208257|Experimental|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
11225354|NCT03208244|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
11225355|NCT03208231|Experimental|Arm 1: VRC01|Participants will receive VRC01 at Weeks 0, 2, 6, and 10.
11225356|NCT03208231|Placebo Comparator|Arm 2: No study treatment|Participants will not receive the study treatment.
11225357|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
11225358|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
11225359|NCT03208192|Experimental|ErbeJet|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
11225360|NCT03208192|Experimental|Misonix|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
11225361|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
11225362|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
11225363|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
11225364|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
11225365|NCT03208166|Other|Usual Care|Standard medical care.
11225366|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
11225367|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
11225368|NCT03208127|Experimental|Treatment with Direct Acting Antiviral Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
11225369|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
11225370|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
11225371|NCT03208101|Experimental|Test group|DTP-HepB-IPV-Hib vaccine
11225372|NCT03208101|Active Comparator|Control group|DTP-HepB-Hib vaccine & IPV
11225373|NCT03208088|Experimental|Sequence 1|etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental)
11225374|NCT03208088|Experimental|Sequence 2|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator)
11225375|NCT03208088|Experimental|Sequence 3|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental)
11225376|NCT03208088|Experimental|Sequence 4|etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental)
11225377|NCT03208088|Experimental|Sequence 5|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental)
11225378|NCT03208088|Experimental|Sequence 6|etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental / etafilcon A Test Lens 1 (experimental)
11225379|NCT03208088|Experimental|Sequence 7|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental)
11225380|NCT03208088|Experimental|Sequence 8|etafilcon A Test Lens 1 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental / etafilcon A Test Lens 3 (experimental)
11225381|NCT03208088|Experimental|Sequence 9|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental / etafilcon A Control Lens (Active Comparator) /etafilcon A Test Lens 4 (experimental)
11225382|NCT03208088|Experimental|Sequence 10|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental / etafilcon A Control Lens (Active Comparator)
11225383|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
11225384|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
11225385|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
11225386|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:
~patients with osteoarthritis of the hip or knee and rehabilitated in the institute
~patients with primary and secondary tumors of the skeleton
~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
11225387|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves very sleepy (not just tired, but actually sleepy) they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
11225388|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identification of dysfunctional sleep cognitions, 2) challenging their validity, and 3) replacing them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are given information about relevant elements of the science of sleep and healthy sleep practices.
11225389|NCT03208036|Experimental|TDCS|TDCS offered concurrent with working memory focused cognitive training
11225390|NCT03208036|Sham Comparator|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
11225391|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
11225392|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
11225393|NCT03208010|Experimental|Diabetes Prevention Intervention|The intervention is 12 weeks of education on diet and physical activity, followed by 14 bi-weekly support groups for problem solving, and 3 booster sessions. Further, motivational interviewing is integrated into all group sessions.
11225394|NCT03208010|Active Comparator|Enhanced Usual Care|"The comparator is an enhanced usual care control group that receives health care from personal physicians plus has access to: a) data collection sessions; b) individualized exit interviews with program staff after each data collection session to receive immediate feedback on lab results and trends in personal health indicators (e.g., BMI, A1C) and to ask questions; c) referral to a local physician or clinic, if needed; and d) Spanish-language materials on diabetes prevention."
11225395|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
11225396|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
11225397|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
11225398|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
11225399|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to treat multiple gingival recessions in aesthetic areas
11228771|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
11225400|NCT03207984|Experimental|Test MG|Root coverage surgery with Mucograft collagen matrix graft to treat multiple gingival recessions in aesthetic areas
11225401|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
11225402|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
11225403|NCT03207958|Experimental|Belimumab|"Subjects meeting eligibility criteria will start treatment between Day +3- and Day +60 after alloHCT
~Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 7 cycles (6 months)"
11225404|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
11225405|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
11225406|NCT03207932||ultrasound|CVC insertion using ultrasound
11225407|NCT03207932||landmark technique|CVC insertion using landmark technique
11225408|NCT03207919|Experimental|Lullaby Project|
11225409|NCT03207919|No Intervention|Control Group|
11225410|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
11225411|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
11225412|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
11225413|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
11225414|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
11225415|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
11225416|NCT03207867|Experimental|NIR178 + PDR001|Part 1: all patients will receive NIR178 continuously in combination with PDR001 400mg every 4 weeks. The part 1 will enroll 8 different tumor types.
11225417|NCT03207867|Experimental|NIR178 BID Intermittent + PDR001|Three different dosing schedules of NIR178 will be explored.
11225418|NCT03207867|Experimental|Part 3|Initiation of part 3 will depend on results from parts 1 and 2.
11225419|NCT03207867|Experimental|Japanese safety run-in part|Two different dosing schedules of NIR178 will be explored.
11225420|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
11225421|NCT03207841|Experimental|LC/HP group|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
11225422|NCT03207841|No Intervention|Control|Control group will not receive the experimental diet and will continue with their usual diets. Participants will complete three 24-hour food recalls (on 2 week days and one day in the weekend) three times (at weeks 1, 4 and 8) during the course of the study to gather dietary information including dietary intake and/or particular aspects of the diet. Participants will be asked to recall foods and beverages they consumed in the 24 hours prior to the interview. Three 24-hour food recalls appear optimal for estimating energy intake.
11225423|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
11225424|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.
~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
11225425|NCT03207815|Experimental|Filgotinib|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.
~All participants will receive filgotinib for up to 52 weeks."
11225426|NCT03207815|Placebo Comparator|Placebo|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.
~All participants will receive placebo to match filgotinib for up to 52 weeks."
11225427|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
11225428|NCT03207776|Other|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
11225429|NCT03207776|Other|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
11225454|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
11225455|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
11225456|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
11225457|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
11225430|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
11225431|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
11225432|NCT03207750|Experimental|HRV PCV-free Liq Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
11225433|NCT03207750|Active Comparator|HRV Lyo Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
11225434|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
11225435|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
11225436|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
11225437|NCT03207711|Active Comparator|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
11225438|NCT03207711|Experimental|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
11225439|NCT03207698|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
11225440|NCT03207698|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
11225441|NCT03207698|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
11225442|NCT03207685|Other|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
11225443|NCT03207672|Experimental|Schedule 1: E7389-LF|Participants will receive E7389-liposomal formulation (LF) at a starting dose of 1.0 to 2.5 milligrams per meters squared (mg/m^2), administered as an intravenous (IV) infusion on Day 1 of a 21-day cycle (tri-weekly).
11225444|NCT03207672|Experimental|Schedule 2: E7389-LF|Participants will receive E7389-LF at a starting dose of 1.0 to 1.5 mg/m^2, administered as an IV infusion on Day 1 and Day 15 of a 28-day cycle (bi-weekly).
11225445|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
11225446|NCT03207659|Experimental|Basketing|stones will be actively extracted.
11225447|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
11225448|NCT03207646|No Intervention|Control|Standard-of-care alone.
11225449|NCT03207633|Active Comparator|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
11225450|NCT03207633|Active Comparator|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
11225451|NCT03207633|Sham Comparator|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
11225452|NCT03207620|Active Comparator|smoker asthmatics|"Asthma control questionnaire (ACQ) score
~Spirometry
~Sputum cytology"
11225453|NCT03207620|Active Comparator|non-smoker asthmatics|"Asthma control questionnaire (ACQ) score
~Spirometry
~Sputum cytology"
11225559|NCT03206866||patients with hepatitis C Ab negative|
11225458|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
11225459|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
11225460|NCT03207594||Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
11225461|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
11225462|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
11225463|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
11225464|NCT03207555|Experimental|Ibrutinib|Participants take Ibrutinib by mouth 1 time every day for up to 2 years (24 cycles).
11225465|NCT03207542|Experimental|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.
~Each cycle is 28 days."
11225466|NCT03207542|Experimental|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.
~Each cycle is 28 days."
11225467|NCT03207529|Experimental|Treatment (alpelisib, enzalutamide)|Patients receive alpelisib PO and enzalutamide PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11225468|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast
~administration of two 100 g croissants prepared with sourdough after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.
~washout period: 7 days
~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
11225469|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough
~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.
~washout period: 7 days
~administration of two 100 g croissants prepared with sourdough after an overnight fast.
~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
11225470|NCT03207503||MDD patients|Participants ages 35-75 determined to be clinically depressed via structured clinical interview. No interventions will be administered as part of this study.
11225471|NCT03207503||non-MDD patients|Participants ages 35-75 determined to be lifetime free of psychiatric conditions as assessed by structured clinical interview. No interventions will be administered as part of this study.
11225472|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
11225473|NCT03207477|Experimental|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
11225474|NCT03207477|Active Comparator|Term born infants|Visual acuity measurement in term born control infants
11225475|NCT03207464|Experimental|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria19, with an Expanded Disability Status Scale (EDSS) less than 6.5.
11225476|NCT03207464|Experimental|Healthy Control|This group will serve as non disease population.
11225477|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
11225478|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
11225479|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
11225480|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
11225481|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
11225482|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
11225483|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
11225484|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
11225485|NCT03207425|Experimental|Mild hepatic impairment group|
11225486|NCT03207425|Experimental|Moderate hepatic impairment group|
11225487|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
11225488|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
11225489|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
11225490|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
11225491|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
11225492|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
11225493|NCT03207360|Experimental|Pain Coping Skills|
11225494|NCT03207347|Experimental|Cohort A|This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.
11225495|NCT03207347|Experimental|Cohort B (Closed to enrollment)|This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).
11225496|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
11225497|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
11225498|NCT03207321||Control|No supplement was provided in 14 control villages.
11225499|NCT03207308|Experimental|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
11225500|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
11225501|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
11225502|NCT03207282||Participants with Diagnosis of Depression|Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.
11225503|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
11225504|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
11225505|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
11225506|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
11225507|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
11225508|NCT03207243|Experimental|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
11225509|NCT03207243|Placebo Comparator|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
11225510|NCT03207230|Experimental|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
11225511|NCT03207217|Experimental|Phase I Knowledge Assessment|
11225512|NCT03207217|Experimental|Phase II Efficacy|
11225513|NCT03207217|Experimental|Phase II Acceptability|
11225514|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
11225515|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
11225516|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
11225517|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
11225518|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
11225519|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
11225520|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
11225521|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
11225522|NCT03207191|Experimental|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.
~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
11225523|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
11225524|NCT03207165|Active Comparator|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular [LV] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
11225643|NCT03206320|No Intervention|Control|
11225644|NCT03206320|Active Comparator|Reference|
11225525|NCT03207165|Active Comparator|Right ventricular [RV] dysfunction|Assessment of right ventricular [RV] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
11225526|NCT03207152|Experimental|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
11225527|NCT03207139|Experimental|Ga-68 PSMA ligand|Diagnostic performance of [Ga68] PSMA-11
11225528|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
11225529|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.
~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
11225530|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
11225531|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
11225532|NCT03207087|Experimental|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
11225533|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
11225534|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
11225535|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
11225536|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
11225537|NCT03207035|Active Comparator|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
11225538|NCT03207035|Experimental|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
11225539|NCT03207022|Active Comparator|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
11225540|NCT03207022|Experimental|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
11225541|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
11225542|NCT03206996|Experimental|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
11225543|NCT03206996|Experimental|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
11225544|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
11225545|NCT03206970|Experimental|zanubrutinib|160 mg administered orally twice daily (BID) for up to 3 years
11225546|NCT03206957|Other|Study group|Down Syndrome children
11225547|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
11225548|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
11225549|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
11225550|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
11225551|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
11225552|NCT03206918|Experimental|Zanubrutinib|
11225553|NCT03206905|Experimental|Endoscopic Sleeve Gastroplasty|
11225554|NCT03206905|Active Comparator|Diet and exercise only.|
11225555|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
11225556|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
11225557|NCT03206866||patients with HCC|
11225558|NCT03206866||patients with hepatitis C Ab positive|
11225560|NCT03206853|Experimental|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
11225561|NCT03206853|Other|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
11225562|NCT03206840|Experimental|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
11225563|NCT03206840|Experimental|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
11225564|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
11225565|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
11225566|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
11225567|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
11225568|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
11225569|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
11225570|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
11225571|NCT03206788|Experimental|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
11225572|NCT03206788|Placebo Comparator|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
11225573|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
11225574|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
11225575|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
11225576|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
11225577|NCT03206775||Healthy Controls (Phase 3)|Participants will complete the full Posit Science cognitive assessment battery and self-report questionnaires for credit in the Research Experience Program at the University of Minnesota.
11225578|NCT03206775||Healthy Controls, Battery D (Phase 2)|Participants will complete the Cognitive Battery E (Phase 2) developed by Posit Science while at the Minnesota State Fair.
11225579|NCT03206775||Healthy Controls, Battery E (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
11225580|NCT03206775||Adolescents with anxiety diagnosis (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
11225581|NCT03206775||Adolescents, healthy controls (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
11225582|NCT03206762|Experimental|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
11225583|NCT03206762|Active Comparator|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
11225584|NCT03206749|Experimental|VX-150|
11225585|NCT03206749|Experimental|Hydrocodone bitartrate/Acetominophen (HB/APAP)|
11225586|NCT03206749|Placebo Comparator|Placebo|
11225587|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
11225588|NCT03206723|Active Comparator|Group 1|1. Standard care
11225589|NCT03206723|Active Comparator|Group 2|"Standard care
~Bandage contact lens"
11225590|NCT03206710||smokers who received Vitamin C|
11225591|NCT03206710||smokers who received placebo|
11225592|NCT03206710||control group non-smokers|
11225593|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
11225594|NCT03206684|Experimental|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
11225595|NCT03206684|Active Comparator|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
11225596|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
11225597|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
11225598|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
11225599|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
11225600|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
11225601|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
11225645|NCT03206320|Experimental|New|
11225602|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
11225603|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; PTC596 PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
11225604|NCT03206632|Experimental|BI 690517 dose group 1|
11225605|NCT03206632|Experimental|BI 690517 dose group 2|
11225606|NCT03206632|Experimental|BI 690517 dose group 3|
11225607|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
11225608|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
11225609|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
11225610|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
11225611|NCT03206580|Experimental|Concentric training|Concentric training
11225612|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
11225613|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
11225614|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
11225615|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
11225616|NCT03206554|Sham Comparator|sham LIA|Saline injections
11225617|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
11225618|NCT03206541||Controls|"There are two age-matched control groups:
~Household controls that have lived with the case for at least three months before the onset of neurological symptoms.
~Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
11225619|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
11225620|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
11225621|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
11225622|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
11225623|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
11225624|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
11225625|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
11225626|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
11225627|NCT03206476|Active Comparator|Control group|Nutritional information
11225628|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
11225629|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
11225630|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
11225631|NCT03206450||Observational (questionnaire, biospecimen collection)|Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
11225632|NCT03206437|Experimental|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
11225633|NCT03206437|Other|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
11225634|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
11225635|NCT03206385||CK Boost pelvis|
11225636|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
11225637|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
11225638|NCT03206359||Patients|Patients with SLE
11225639|NCT03206359||Healthy subjects|
11225640|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
11225641|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
11225642|NCT03206333||Breast cancer patients treated with radiotherapy|
11225646|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
11225647|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
11225648|NCT03206294|Other|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
11225649|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
11225650|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
11225651|NCT03206268||healthy eyes|
11225652|NCT03206268||uveitis eyes|
11225653|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
11225654|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
11225655|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
11225656|NCT03206242||initial|0 month begin physiotherapy
11225657|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
11225658|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
11225659|NCT03206229|Experimental|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
11225660|NCT03206229|Active Comparator|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
11225661|NCT03206216|Experimental|Group A - Painful CIPN|Participants with painful chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
11225662|NCT03206216|Active Comparator|Group B - Painless CIPN|Participants with painless chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
11225663|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11225664|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
11225665|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
11225666|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
11225667|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
11225668|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
11225669|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
11225670|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
11225671|NCT03206151|Experimental|CMAB009 + FOLFIRI|"Drug: CMAB009(recombinant chimeric anti-EGFR monoclonal antibody injection), will be administered every 7 days at an initial dose of 400mg/m^2 and 250mg/m^2 for subsequent infusions until progression of disease , withdrawal of consent, or unacceptable toxicity.
~Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.
~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
11225672|NCT03206151|Active Comparator|FOLFIRI|"FOLFIRI Drug: Irinotecan bi-weekly irinotecan infusion of 180mg/m^2 on Day 1. Drug: Folinic Acid infusion 400mg/m^2 of folinic acid in on Day 1. Drug: 5-Fluorouracil bolus 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-48 h continuous infusion of 2400mg/m^2.
~every 2 weeks until progression of disease , withdrawal of consent, or unacceptable toxicity."
11225673|NCT03206138|Experimental|GX-188E, GX-I7|GX-188E + GX-I7
11225674|NCT03206138|Experimental|GX-188E, Imiquimod|GX-188E + Imiquimod
11225675|NCT03206125||Controls|Controls
11225676|NCT03206125||ESCC Cases|ESCC Cases
11225677|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
11225678|NCT03206112||Healthy Volunteers|Healthy Volunteers
11225679|NCT03206099||Biological Relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
11225680|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
11225681|NCT03206086|Experimental|Group|Eltrombopag
11225682|NCT03206073|Experimental|1/Arm A1|Pexa-Vec escalation dose levels + Durvalumab
11225683|NCT03206073|Experimental|2/Arm A2|MTD of Pexa-Vec after the MTD is established +Durvalumab
11225684|NCT03206073|Experimental|3/Arm B1|Pexa-Vec escalation dose levels + Durvalumab +Tremelimumab
11225685|NCT03206073|Experimental|4/Arm B2|MTD of Pexa-Vec after the MTD is established+Durvalumab + Tremelimumab
11228772|NCT03185663|Placebo Comparator|a pillow between the legs|
11225686|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
11225687|NCT03206047|Experimental|Cohort I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11225688|NCT03206047|Experimental|Cohort II (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11225689|NCT03206047|Experimental|Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)|Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11225690|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
11225691|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
11225692|NCT03206021|Experimental|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
11225693|NCT03206021|Experimental|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
11225694|NCT03206021|Experimental|Supratentorial Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 10 patients with recurrent/refractory supratentorial ependymoma.
11225695|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
11225696|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
11225697|NCT03205995|Experimental|OMS721|Administration of OMS721
11225698|NCT03205982|Sham Comparator|Control|WiseApp that delivers fitness reminders
11225699|NCT03205982|Experimental|Intervention|WiseApp that delivers medication adherence reminders
11225700|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
11225701|NCT03205956|Experimental|PD Group|A broad range of Parkinson's disease severity and disease duration. Some subjects will not be treated currently with levodopa, and thus likely will be early in the disease process.
11225702|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
11225703|NCT03205917|Experimental|Group 1A HIV-Uninfected|PGDM1400 low dose
11225704|NCT03205917|Experimental|Group 1B HIV-Uninfected|PGDM1400 mid dose
11225705|NCT03205917|Experimental|Group 1C HIV-Uninfected|PGDM1400 high dose
11225706|NCT03205917|Experimental|Group 2A HIV-Uninfected|PGDM1400 + PGT121 low dose
11225707|NCT03205917|Experimental|Group 2B HIV-Uninfected|PGDM1400 + PGT121 mid dose
11225708|NCT03205917|Experimental|Group 2C HIV-Uninfected|PGDM1400 + PGT121 high dose
11225709|NCT03205917|Experimental|Group 3A HIV-infected off ART|PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
11225710|NCT03205917|Experimental|Group 3B HIV-infected off ART|PGDM1400 + PGT121 at high dose; HIV + without ART
11225711|NCT03205904|Active Comparator|Intervention group|Group that will be receive the diet
11225712|NCT03205904|No Intervention|control|Group that will not receive the diet
11225713|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.
~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.
~Each cycle is 21 days.
~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
11225714|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
11225715|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
11225716|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
11225717|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
11225718|NCT03205839|Experimental|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.
~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
11225719|NCT03205839|No Intervention|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
11225720|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
11225721|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
11225722|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
11225723|NCT03205787|Experimental|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
11225784|NCT03205371|Active Comparator|South Korea (Group 3): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
11225724|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
11225725|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
11225726|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
11225727|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
11225728|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
11225729|NCT03205735||normal DPD result group|patients group with a normal DPD result
11225730|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
11225731|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
11225732|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
11225733|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
11225734|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
11225735|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
11225736|NCT03205683|Experimental|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
11225737|NCT03205683|Sham Comparator|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).
~Missing > 4 sessions will invalidate subject outcomes."
11225738|NCT03205670|Experimental|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
11225739|NCT03205631|Sham Comparator|Sham Natural Frequency Patch|
11225740|NCT03205631|Active Comparator|Active Natural Frequency Patch|
11225741|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
11225742|NCT03205605|Other|baseline patch|patch
11225743|NCT03205605|Other|baseline gel|gel
11225744|NCT03205605|Other|patch with heat|patch
11225745|NCT03205605|Other|gel with occlusion|gel
11225746|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
11225747|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
11225748|NCT03205566|Active Comparator|Arm A Raltegravir|Raltegravir 400mg tablet, taken twice a day for 7days.
11225749|NCT03205566|Active Comparator|Arm B Raltegravir Lamivudine|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days.
11225750|NCT03205553|Other|Standard of Care Treatment|Non-treatment group will be placed in silo at time of birth and subsequently serially reduced in silo with umbilical tape until the bowel contents are at the level of fascial and deemed suitable for closure. A drain will be placed at the top of the silo as described below to aspirate peritoneal fluid for sampling. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons and will not receive peritoneal dialysis fluid.
11225751|NCT03205553|Experimental|Investigational Treatment Group|The Investigational treatment group will be treated with direct peritoneal resuscitation (DPR). These subjects will undergo DPR during the entirety of silo placement which is usually four to five days. The silo and drain placement will be placed as described below. No additional incisions will be made. These subjects will also be serially reduced with umbilical tape and closed as staged procedure which is the same as the non-treatment group.
11225752|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
11225753|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
11225754|NCT03205527|Experimental|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
11226403|NCT03201302|Experimental|Martial arts|Children who participated in organized Martial arts training for the entire school year.
11225755|NCT03205527|No Intervention|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
11225756|NCT03205527|Experimental|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
11225757|NCT03205527|No Intervention|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
11225758|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (>0.80).
11225759|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.
~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
11225760|NCT03205488|Active Comparator|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
11225761|NCT03205488|Active Comparator|Cohort 2|Early/de novo Randomized 2:1
11225762|NCT03205475|Active Comparator|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
11225763|NCT03205475|Active Comparator|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
11225764|NCT03205475|Active Comparator|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
11225765|NCT03205475|Active Comparator|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
11225766|NCT03205475|Active Comparator|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
11225767|NCT03205475|Active Comparator|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
11225768|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
11225769|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
11225770|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
11225771|NCT03205449|Experimental|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
11225772|NCT03205449|Active Comparator|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
11225773|NCT03205436|Experimental|Graft|Affinity human amniotic membrane
11225774|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
11225775|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
11225776|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
11225777|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
11225778|NCT03205397|Experimental|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
11225779|NCT03205397|Other|Usual care|Consultation of anesthesia and the care of the child without parental presence
11225780|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
11225781|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
11225782|NCT03205371|Experimental|South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
11225783|NCT03205371|Experimental|South Korea (Group 2): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
11225956|NCT03204227|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
11225785|NCT03205371|Experimental|Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
11225786|NCT03205371|Experimental|Thailand (Group 11):MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
11225787|NCT03205371|Active Comparator|Thailand (Group 12): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
11225788|NCT03205371|Experimental|Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.
11225789|NCT03205371|Experimental|Mexico (Group 5): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
11225790|NCT03205371|Active Comparator|Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.
11225791|NCT03205371|Experimental|Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.
11225792|NCT03205371|Experimental|Russian Federation (Group 8): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
11225793|NCT03205371|Active Comparator|Russian Federation (Group 9): PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.
11225794|NCT03205358|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
11225795|NCT03205358|Active Comparator|Group 2: NIMENRIX®|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
11225796|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
11225797|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
11225798|NCT03205345|Placebo Comparator|Placebo|Matching placebo
11225799|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
11225800|NCT03205332|No Intervention|Control|Assessment only.
11225801|NCT03205319|Experimental|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
11225802|NCT03205319|No Intervention|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
11225803|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
11225804|NCT03205293|No Intervention|Control Group|Regular school curriculum
11225805|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
11225806|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
11225807|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
11225808|NCT03205241|Experimental|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
11225809|NCT03205241|Placebo Comparator|Placebo|Olive Oil - 6g/ day for 4 weeks
11225810|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
11225811|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
11225812|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
11225813|NCT03205215|Experimental|Immediate Treatment|This arm will receive hyperbaric oxygen therapy once consented.
11225814|NCT03205215|Experimental|Waitlist - to be treated|This arm will receive a hyperbaric oxygen therapy after waiting two months.
11225815|NCT03205202|Active Comparator|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)
~Dietary Supplement: Multivitamin"
11225816|NCT03205202|Active Comparator|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)
~Dietary Supplement: Multivitamin placebo"
11225817|NCT03205202|Active Comparator|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin
~Dietary Supplement: Cocoa extract placebo"
11225818|NCT03205202|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo
~Dietary Supplement: Multivitamin placebo"
11225819|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
11225820|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
11225821|NCT03205176|Experimental|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
11225822|NCT03205176|Experimental|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
11225891|NCT03204734|Experimental|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
11225823|NCT03205163|Experimental|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
11225824|NCT03205163|Experimental|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
11225825|NCT03205150|Experimental|LIK066 Dose 1|LIK066 Dose 1 was taken once daily before lunch for 12 weeks
11225826|NCT03205150|Experimental|LIK066 Dose 2|LIK066 Dose 2 was taken once daily before lunch for 12 weeks.
11225827|NCT03205150|Experimental|Placebo|Placebo was taken once daily before lunch for 12 weeks.
11225828|NCT03205137||Telmisartan and hydrochlorothiazide group|
11225829|NCT03205137||Telmisartan and amlodipine group|
11225830|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
11225831|NCT03205137||telmisartan+amlodipine double-pill combination group|
11225832|NCT03205124|Experimental|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
11225833|NCT03205124|Sham Comparator|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
11225834|NCT03205124|Experimental|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
11225835|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
11225836|NCT03205085|Experimental|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
11225837|NCT03205085|Experimental|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
11225838|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
11225839|NCT03205059|Experimental|LST MS curriculum+ Bullying/Cyberbullying serious game|
11225840|NCT03205059|Active Comparator|LST MS curriculum|
11225841|NCT03205046|Experimental|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
11225842|NCT03205046|Experimental|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
11225843|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
11225844|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
11225845|NCT03205020||women with preterm labor|
11225846|NCT03205020||women delivered at full term|
11225847|NCT03205007|Experimental|Health promotion nutrition program|Health promotion nutrition program
11225848|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
11225849|NCT03204981|Experimental|Intramural Needle Ablation|
11225850|NCT03204968|No Intervention|control|
11225851|NCT03204968|Active Comparator|Treated|
11225852|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
11225853|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
11225854|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
11225855|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
11225856|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
11225857|NCT03204929|Experimental|Cu(II)ATSM|Cu(II)ATSM dosed once daily
11225858|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.
~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.
~FOCUS GROUPS: Healthcare providers participate in focus groups over 2-3 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses which will be recorded on a flip-chart or white board, followed by discussion of the ideas for clarification"
11225859|NCT03204903|Experimental|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
11225860|NCT03204903|Sham Comparator|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
11225861|NCT03204890|Experimental|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
11225862|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
11225863|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
11225864|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
11225865|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
11225866|NCT03204851|Active Comparator|Venous Stasis Ulcer|Venous Stasis Ulcer
11225867|NCT03204851|Active Comparator|Pressure Ulcers|Pressure Ulcers
11225868|NCT03204851|Active Comparator|Diabetic Foot Ulcers|Diabetic Foot Ulcers
11225869|NCT03204851|Active Comparator|Wounds from a variety of etiologies|Wounds from a variety of etiologies
11225870|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
11225871|NCT03204825|Experimental|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
11225872|NCT03204825|Placebo Comparator|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
11225873|NCT03204825|Experimental|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
11225874|NCT03204825|Experimental|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
11225875|NCT03204812|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
11225876|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
11225877|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
11225878|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
11225879|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
11225880|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
11225881|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
11225882|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
11225883|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
11225884|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
11225885|NCT03204773||HSP patients|Patients with hereditary spastic paraplegia regardless of their genetic mutation
11225886|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
11225887|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
11225888|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
11225889|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.
~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
11225890|NCT03204734|Experimental|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
11225892|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
11225893|NCT03204721|No Intervention|Controll|No procedure
11225894|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
11225895|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
11225896|NCT03204695|Experimental|LAA Occlusion|
11225897|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
11225898|NCT03204643|Experimental|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
11225899|NCT03204643|No Intervention|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
11225900|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
11225901|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
11225902|NCT03204630|Placebo Comparator|Control|Standard infant formula
11225903|NCT03204617|Experimental|DDDMM + CCM|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20. At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
11225904|NCT03204617|Placebo Comparator|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since fifth placebo administration, administration of 0.9% sterile normal saline solution at weeks 0, 12 and 24.
11225905|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
11225906|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
11225907|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
11225908|NCT03204578|Experimental|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
11225909|NCT03204578|Experimental|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
11225910|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
11225911|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
11225912|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
11225913|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
11225914|NCT03204526|Experimental|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
11225915|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
11225916|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
11225917|NCT03204500|Experimental|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
11225918|NCT03204500|Placebo Comparator|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
11225919|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
11225920|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
11225921|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
11225922|NCT03204461||PCOS-NIH|
11225923|NCT03204461||PCOS-Rotterdam|
11225924|NCT03204461||Controls|
11225925|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
11226506|NCT03200717|Experimental|pazopanib 800 mg|administered after checkpoint inhibitor treatment
11225926|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
11225927|NCT03204435|Other|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
11225928|NCT03204435|Experimental|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
11225929|NCT03204422||Children's group|no intervention. participants, whose age was 8 to 18 years, were enrolled in Children's group.
11225930|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
11225931|NCT03204409||Symptomatic adults|adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h)
11225932|NCT03204396|Active Comparator|Intervention group|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via pen s.c. once weekly for 12 weeks.
11225933|NCT03204396|Placebo Comparator|Placebo group|0.5 ml normal saline (0.9% sodium chloride (NaCl)), injection s.c. via syringe once weekly for 12 weeks.
11225934|NCT03204370||MPS4A patients|
11225935|NCT03204357|Experimental|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
11225936|NCT03204357|Active Comparator|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
11225937|NCT03204344|Experimental|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.
~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
11225938|NCT03204344|Sham Comparator|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.
~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
11225939|NCT03204331|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
11225940|NCT03204331|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
11225941|NCT03204331|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
11225942|NCT03204318|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
11225943|NCT03204318|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
11225944|NCT03204318|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
11225945|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
11225946|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
11225947|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
11225948|NCT03204279|Experimental|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients < 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
11225949|NCT03204279|Experimental|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients < 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
11225950|NCT03204266|Experimental|Immunonutrition: ARS + Omega-3 Fatty Acids|"Participants take 1 ounce (30mls) of Arginine recovery supplement (ARS) four times daily 5 days preoperatively and 14 days postoperatively.
~Participants also given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively."
11225951|NCT03204266|No Intervention|No Immunonutrition|Participants receive regular enhanced recovery after surgery (ERAS)/Optimized Surgical Journey (OSJ) education and follow up.
11225952|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
11225953|NCT03204253|Active Comparator|rFSH alone|control group
11225954|NCT03204240|Experimental|Intervention|This group will receive electrical stimulation induced exercises in addition to their standard care during in-patient rehabilitation (IPR). Standard care will include respiration therapy, bed mobility, transfers, wheelchair mobility skills, bowel and bladder management, tone and spasticity management, and skills for performing other activities of daily living. Exercises will include neuromuscular electrical stimulation (NMES) induced-resistance exercise (RE) (1x/day) and NMES-aerobic exercise (1x/day) for 3 days/week.
11225955|NCT03204240|No Intervention|Control|This group will receive standard care plus passive dynamic exercise of the lower legs (sham treatment for NMES-RE, 1x/day) and transcutaneous electrical nerve stimulation (TENS, sham treatment for NMES-aerobic exercise, 1x/day) during IPR.
11225957|NCT03204227|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
11225958|NCT03204201|Experimental|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
11225959|NCT03204188|Experimental|Single Arm|IFP
11225960|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
11225961|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
11225962|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
11225963|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
11225964|NCT03204149|Experimental|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.
~Intervention: MC-8XL low level laser device and Standard wound care"
11225965|NCT03204149|Sham Comparator|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.
~Intervention: Sham laser device and Standard wound care"
11225966|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
11225967|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
11225968|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with CT or MRI|Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.
11225969|NCT03204123|Active Comparator|Ga-HBED-iPSMA PET with MRI|Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted. This arm will be closed to accrual and these patients will be analyzed separately.
11225970|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
11225971|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
11225972|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
11225973|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
11225974|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
11225975|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
11225976|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
11225977|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
11225978|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
11225979|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
11225980|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
11225981|NCT03204045|Active Comparator|fentanyl|fentanyl 1 ㎍/kg
11225982|NCT03204045|Active Comparator|oxycodone|oxycodone 0.08 mg/kg
11225983|NCT03204045|Placebo Comparator|control|isotonic saline
11225984|NCT03204032|Experimental|Tegafur and Temozolomide|
11225985|NCT03204032|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|
11225986|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11225987|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11225988|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
11225989|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
11225990|NCT03203967|Experimental|Epidural morphine|"Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
11225991|NCT03203967|Placebo Comparator|Epidural placebo|"Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.
~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
11225992|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
11225993|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
11225994|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
11225995|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
11225996|NCT03203928|No Intervention|Control|No treatment provided.
11225997|NCT03203915|Experimental|Group 1|"Order of treatments:
~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
11225998|NCT03203915|Experimental|Group 2|"Order of treatments:
~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
11225999|NCT03203915|Experimental|Group 3|"Order of treatments:
~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
11226000|NCT03203915|Experimental|Group 4|"Order of treatments:
~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
11226001|NCT03203915|Experimental|Group 5|"Order of treatments:
~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
11226002|NCT03203915|Experimental|Group 6|"Order of treatments:
~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
11226003|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:
~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)
~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
11226004|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:
~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)
~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
11226005|NCT03203902|No Intervention|Control|No intervention
11226006|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
11226007|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
11226008|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
11226009|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
11226010|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
11226011|NCT03203850|Experimental|Deferasirox FCT Arm|randomized in a 2:1 ratio: Deferasirox to surgery
11226012|NCT03203850|Experimental|phlebotomy|randomized in a 2:1 ratio: Deferasirox to surgery
11226013|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
11226014|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
11226015|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
11226016|NCT03203811|Experimental|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
11226017|NCT03203811|Experimental|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
11226018|NCT03203811|Experimental|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
11226019|NCT03203798|Active Comparator|Training of pelvic floor muscles|
11226020|NCT03203798|Experimental|Hipopressive abdominal gymnastics|
11226021|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
11226022|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
11226023|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
11226024|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
11226025|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
11226026|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
11226027|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
11226028|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
11226029|NCT03203733|Experimental|'Cooral™'|oral cooling with use of cooling device
11226030|NCT03203733|Active Comparator|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
11228773|NCT03185663|Experimental|traction-stuck|
11226031|NCT03203720|No Intervention|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
11226032|NCT03203720|Experimental|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
11226033|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
11226034|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
11226035|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
11226036|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
11226037|NCT03203694|Experimental|Lower body heating|This intervention consists of 45-60 minutes of lower body heating (40-42 degree C) 4 days per week for 8 weeks.
11226038|NCT03203681|Other|Natesto|Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.
11226039|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
11226040|NCT03203655|Experimental|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
11226041|NCT03203655|Other|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
11226042|NCT03203642|Experimental|Treatment Group|50mg tesevatinib administered once daily for up to 24 months.
11226043|NCT03203642|Placebo Comparator|Control Group|Matching placebo administered once daily for up to 24 months.
11226044|NCT03203616|Experimental|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
11226045|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
11226046|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
11226047|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
11226048|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
11226049|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
11226050|NCT03203577|Active Comparator|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
11226051|NCT03203577|Experimental|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
11226052|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
11226053|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
11226054|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
11226055|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
11226056|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
11226057|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:
~brushing the palate (3 times a day/ 2 minutes);
~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);
~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;
~the prostheses must be conditioned in a vessel with water during the whole night period.
~Periods of analysis (Baseline, 7 and 37 days):
~the prostheses will be evidenced and photographed.
~the biofilm present on the inner surface of the prostheses will be collected;
~photographe of the participants' palate;
~collected the palate biofilm."
11226058|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
11226059|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
11226060|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
11226061|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
11226062|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
11226063|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
11226064|NCT03203525|Experimental|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11226065|NCT03203525|Experimental|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11226066|NCT03203512|Active Comparator|Intervention|Fish oil capsules
11226067|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
11226068|NCT03203499|Experimental|ANS-6637|Single ascending doses of ANS-6637 administered orally
11226069|NCT03203499|Placebo Comparator|Placebo|Placebo administered orally
11226070|NCT03203486|Experimental|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
11226071|NCT03203473|Experimental|Initial Primary Treatment|"Therapy with nivolumab IV every 2 weeks
~Serial imaging assessments every 8 weeks
~After confirmatory scans, patients are assigned to Arm A or Arm B."
11226072|NCT03203473|Experimental|Arm A: Persistent (PR/CR)|"Serial imaging assessments every 8 weeks
~Therapy with nivolumab IV every 2 weeks
~If scans persistently show PR/CR, nivolumab is discontinued until progression.
~Nivolumab is re-initiated, and if there is subsequent progression, ipilimumab is added for x2 doses.
~Ipilimumab IV every 3 weeks (only in patients who progress after nivolumab re-initiation)
~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
11226073|NCT03203473|Experimental|Arm B: Persistent (PD/SD)|"Therapy with nivolumab IV every 2 weeks
~Ipilimumab IV every 3 weeks
~Serial imaging assessments every 8 week
~If scans show SD/PR/CR, nivolumab continued until progression. If progression, therapy discontinued."
11226074|NCT03203460|Experimental|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
11226075|NCT03203460|No Intervention|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
11226076|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
11226077|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
11226078|NCT03203434||Esophageal anastomotic leakage|
11226079|NCT03203434||Esophageal uncomplicated controls|
11226080|NCT03203434||Pancreatic anastomotic leakage|
11226081|NCT03203434||Pancreatic uncomplicated controls|
11226082|NCT03203421|Active Comparator|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10^9 vp) on day 0.
11226083|NCT03203421|Active Comparator|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10^10 vp) on day 0 and one dose of MVA LS2 (2 x 10^8 pfu) on day 56.
11226084|NCT03203421|No Intervention|Control Group A|No vaccinations will be administered.
11226085|NCT03203421|No Intervention|Control Group B|No vaccinations will be administered.
11226086|NCT03203408|Experimental|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
11226087|NCT03203408|Active Comparator|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
11226088|NCT03203395|Experimental|Heart patients|Screening and counselling
11226089|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
11226090|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
11226091|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
11226092|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
11226093|NCT03203343|Active Comparator|PIRS group|Patients operated laparoscopically - PIRS technique
11226094|NCT03203343|Active Comparator|Marcy group|Patients operated by open modified Marcy technique
11226095|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
11226096|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
11226097|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
11226098|NCT03203317|Experimental|Exercise|10 min of maximal exercise
11226099|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.
~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
11226138|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
11226100|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.
~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
11226101|NCT03203291|Experimental|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
11226102|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
11226103|NCT03203278|No Intervention|Control group|Usual care
11226104|NCT03203265|Other|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
11226105|NCT03203265|Other|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
11226106|NCT03203265|Other|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
11226107|NCT03203239|Experimental|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
11226108|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
11226109|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
11226110|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient
~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)
~A urine sample is taken if possible."
11226111|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
11226112|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
11226113|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
11226114|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
11226115|NCT03203174|Experimental|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
11226116|NCT03203174|Sham Comparator|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
11226117|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
11226118|NCT03203135|Experimental|Intervention Group|
11226119|NCT03203135|No Intervention|Control Group|
11226120|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
11226121|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
11226122|NCT03203096|Placebo Comparator|Placebo|identically tasting and looking Placebo
11226123|NCT03203096|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
11226124|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
11226125|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
11226126|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
11226127|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
11226128|NCT03203057||control group|10 individuals get randomised to control group.
11226129|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
11226130|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
11226131|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
11226132|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
11226133|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
11226134|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
11226135|NCT03203018|Experimental|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
11226136|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
11226137|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
11226139|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
11226140|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
11226141|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
11226142|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
11226143|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
11226144|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
11226145|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
11226146|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
11226147|NCT03202979|Experimental|Group 1|Trazodone 20 mg
11226148|NCT03202979|Experimental|Group 2|Trazodone 10 mg
11226149|NCT03202979|Placebo Comparator|Group 3|Placebo
11226150|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
11226151|NCT03202953|Experimental|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
11226152|NCT03202953|Active Comparator|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
11226153|NCT03202940|Experimental|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
11226154|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
11226155|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
11226156|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
11226157|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
11226158|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
11226159|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
11226160|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)
~Excipients:
~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
11226161|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
11226162|NCT03202875|Experimental|Test (T)|SAR341402: single dose injection
11226163|NCT03202875|Active Comparator|Reference 1 (R1)|NovoRapid®: single dose injection
11226164|NCT03202875|Active Comparator|Reference 2 (R2)|NovoLog®: single dose injection
11226165|NCT03202862|Experimental|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
11226166|NCT03202849|Experimental|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
11226167|NCT03202849|Active Comparator|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
11226168|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
11226169|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
11226170|NCT03202823||Diabetics|
11226171|NCT03202823||Non-diabetics|
11226172|NCT03202797||Patients|
11226173|NCT03202784|Experimental|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
11226174|NCT03202784|Experimental|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
11226175|NCT03202784|Experimental|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
11226176|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
11226401|NCT03201302|Experimental|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
11226177|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
11226178|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months
~Tremelimumab for up to 4 doses/cycles
~FOLFOX"
11226179|NCT03202745|No Intervention|Control|The control arm will not receive any communications as a result of this study.
11226180|NCT03202745|Experimental|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
11226181|NCT03202745|Experimental|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
11226182|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.
~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.
~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.
~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
11226183|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.
~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.
~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
11226184|NCT03202719|Active Comparator|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
11226185|NCT03202719|Active Comparator|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
11226186|NCT03202719|Active Comparator|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
11226187|NCT03202719|Active Comparator|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
11226188|NCT03202719|Active Comparator|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
11226189|NCT03202706||Patients|
11226190|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
11226191|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
11226192|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
11226193|NCT03202667|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
11226194|NCT03202667|Placebo Comparator|Placebo|Treatment with Placebo tablets once daily for 28 days
11226195|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
11226196|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
11226197|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).
~Interventions:
~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).
~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
11226198|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.
~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11226199|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
11226200|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
11226201|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
11226202|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
11226203|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
11226204|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
11226205|NCT03202563|Experimental|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.
~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
11226206|NCT03202563|Active Comparator|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.
~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
11226207|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
11226208|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
11226209|NCT03202537|Experimental|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
11226210|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
11226211|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
11226212|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
11226213|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
11226214|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
11226215|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
11226216|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
11226217|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
11226218|NCT03202485|Active Comparator|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
11226219|NCT03202485|Experimental|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
11226220|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
11226221|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
11226222|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
11226223|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
11226224|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
11226225|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
11226226|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
11226227|NCT03202433|Experimental|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
11226228|NCT03202433|No Intervention|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
11226229|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
11226230|NCT03202407|Placebo Comparator|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.
~all the following investigation will be done before and after consecutive 3 months of administration :
~Complete blood count
~Kidney function tests (serum urea and creatinine)
~Serum total calcium level.
~Serum phosphorus level.
~Calcium × phosphorus product.
~Serum parathormone level.
~Serum alkaline phosphatase level.
~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).
~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
11226231|NCT03202407|Experimental|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.
~all the following investigation will be done before and after consecutive 3 months of administration :
~Complete blood count
~Kidney function tests (serum urea and creatinine)
~Serum total calcium level.
~Serum phosphorus level.
~Calcium × phosphorus product.
~Serum parathormone level.
~Serum alkaline phosphatase level.
~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).
~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
11226232|NCT03202394|Active Comparator|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
11226233|NCT03202394|Placebo Comparator|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
11226234|NCT03202381|Experimental|Degarelix|
11226235|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
11226236|NCT03202355|Experimental|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
11226237|NCT03202355|Experimental|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
11226238|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
11226239|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
11226240|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
11226241|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
11226242|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
11226243|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
11226244|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
11226245|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
11226246|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
11226247|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
11226248|NCT03202329|Other|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
11226249|NCT03202329|Other|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
11226250|NCT03202316|Experimental|Treatment (atezolizumab, cobimetinib, eribulin)|Patients receive atezolizumab IV over about 30 minutes-1 hour every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30 minutes-1 hour every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over about 5 minutes on days 1 and 8 of courses 1-4. Courses 1-4 repeat every 21 days and subsequent courses with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11226251|NCT03202303|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
11226252|NCT03202303|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
11226253|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
11226254|NCT03202290|Other|Controls|healthy controls
11226255|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
11226256|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
11226257|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
11226258|NCT03202238|Active Comparator|Conventional|Venepuncture without the use of any venepuncture assistive device
11226259|NCT03202238|Active Comparator|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
11226260|NCT03202238|Experimental|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
11226261|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
11226262|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
11226263|NCT03202199|Experimental|PET/MRI|PET/MRI examination
11226264|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
11226265|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
11226266|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
11226267|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
11226268|NCT03202173|Active Comparator|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
11226269|NCT03202173|Experimental|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
11226329|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
11226270|NCT03202173|Experimental|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
11226271|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
11226272|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
11226273|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
11226274|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
11226275|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
11226276|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
11226277|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
11226278|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
11226279|NCT03202095|Experimental|Open Label Treatment with Creatine|
11226280|NCT03202082|Experimental|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
11226281|NCT03202082|No Intervention|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
11226282|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
11226283|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
11226284|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
11226285|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
11226286|NCT03202056|No Intervention|Control|Control group. No intervention.
11226287|NCT03202043|Experimental|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
11226288|NCT03202043|Experimental|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
11226289|NCT03202043|Experimental|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
11226290|NCT03202043|Other|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
11226291|NCT03202030|Experimental|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
11226292|NCT03202030|Active Comparator|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
11226293|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
11226294|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
11226295|NCT03202004|Experimental|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram [mg/g]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
11226296|NCT03202004|Placebo Comparator|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
11226297|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
11226298|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
11226299|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
11226300|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
11226330|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
11226331|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
11226332|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
11226402|NCT03201302|Experimental|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
11226301|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
11226302|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
11226303|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
11226304|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
11226305|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
11226306|NCT03201926|Experimental|mealworms|mealworms
11226307|NCT03201926|Placebo Comparator|grain powder|grain powder
11226308|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).
~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
11226309|NCT03201900|Experimental|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
11226310|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
11226311|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
11226312|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
11226313|NCT03201887|No Intervention|Chronic pain|optimal effort
11226314|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
11226315|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
11226316|NCT03201861|Experimental|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
11226317|NCT03201861|Active Comparator|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel
~Investigators will declare one of the following regimens:
~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.
~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
11226318|NCT03201848|Experimental|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
11226319|NCT03201848|Placebo Comparator|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
11226320|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
11226321|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
11226322|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
11226323|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
11226324|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
11226325|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
11226326|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
11226327|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
11226328|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
11226333|NCT03201783|Other|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
11226334|NCT03201783|Other|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
11226335|NCT03201770|Experimental|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
11226336|NCT03201757|Experimental|ALKS 3831|Coated bilayer tablet
11226337|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
11226338|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
11226339|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
11226340|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
11226341|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
11226342|NCT03201705|Experimental|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
11226343|NCT03201692|Active Comparator|Treadmill Training|40' treadmill training walking holding the handrail
11226344|NCT03201692|Experimental|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
11226345|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
11226346|NCT03201679||Patients without preoperative sepsis|
11226347|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
11226348|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
11226349|NCT03201640|Other|slideshow|Participant receives traditional slideshow presentation for preoperative preparation
11226350|NCT03201640|Other|virtual|Participant receives virtual reality presentation for preoperative preparation
11226351|NCT03201627|Experimental|treatment|
11226352|NCT03201614|Experimental|A-CP HA|Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.
11226353|NCT03201614|Active Comparator|ArthroVisc 40|Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.
11226354|NCT03201614|Placebo Comparator|Placebo|Patients randomized in this group will be treated with a saline solution.
11226355|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
11226356|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
11226357|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
11226358|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).
~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
11226359|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
11226360|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
11226361|NCT03201562|Experimental|PRX-100 Ophthalmic Solution|
11226362|NCT03201562|Active Comparator|PRX-100 Component #1 Ophthalmic Solution|
11226363|NCT03201562|Sham Comparator|PRX-100 Vehicle Ophthalmic Solution|
11226364|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
11226365|NCT03201536|Active Comparator|sutures|zipLine3 device verses conventional sutures
11226366|NCT03201536|Active Comparator|Zip3 Device|
11226367|NCT03201523|Experimental|Intervention|Community members will be exposed to multiple interventions designed through the participatory approach, integrating the socio-ecological model.
11226370|NCT03201471|Experimental|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
11226371|NCT03201458|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11226372|NCT03201458|Experimental|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11226373|NCT03201445|Experimental|Part A and Part B (Filgotinib or Placebo)|Participants will receive double-blind filgotinib or placebo for 13 weeks in Part A. Based on inflammatory bowel disease response status and sperm parameters, participants will continue on the blinded treatment for up to an additional 13 weeks in Part B or discontinue blinded study drug and commence open-label filgotinib.
11226374|NCT03201445|Experimental|Open-Label Filgotinib Phase|Participants will receive open-label filgotinib for up to 13 weeks.
11226375|NCT03201445|Experimental|Monitoring Phase|Participants whose sperm parameters meet a pre- specified decrease threshold at any time during the study, regardless of inflammatory bowel disease response status, will discontinue study drug and receive standard of care therapy in the Monitoring Phase.
11226376|NCT03201445|Experimental|Long Term Extension Phase|Participants qualifying to enter the Long Term Extension Phase will receive either open-label filgotinib or blinded study drug for up to 195 weeks based on the individual's response criteria.
11226377|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
11226378|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
11226379|NCT03201419|Placebo Comparator|Placebo|
11226380|NCT03201419|Active Comparator|Desmopressin|Desmopressin ODT (25 μg for females and 50 μg for males)
11226381|NCT03201419|Experimental|FE 201836 (1)|Dose 1
11226382|NCT03201419|Experimental|FE 201836 (2)|Dose 2
11226383|NCT03201419|Experimental|FE 201836 (3)|Dose 3
11226384|NCT03201419|Experimental|FE 201836 (4)|Dose 4
11226385|NCT03201419|Experimental|FE 201836 (5)|Dose 5
11226386|NCT03201419|Experimental|FE 201836 (6)|Dose 6
11226387|NCT03201393|Experimental|ALLOD-2 Capsules|Component A and Component B
11226388|NCT03201393|Placebo Comparator|Placebo Capsules|Placebo for Component A and Placebo for Component B
11226389|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis
~- treated with rivaroxaban"
11226390|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
11226391|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
11226392|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
11226393|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
11226394|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
11226395|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
11226396|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
11226397|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
11226398|NCT03201328|Active Comparator|healthy subjects|
11226399|NCT03201328|Experimental|patients with unilateral cochlear implants|
11226400|NCT03201328|Experimental|patients with bilateral cochlear implants|
11226404|NCT03201302|Experimental|Climbing|Children who participated in organized climbing training for the entire school year.
11226405|NCT03201302|Experimental|Volleyball|Children who participated in organized volleyball training for the entire school year.
11226406|NCT03201302|Experimental|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
11226407|NCT03201302|Experimental|Swimming|Children who participated in organized swimming training for the entire school year.
11226408|NCT03201302|Experimental|Dance|Children who participated in organized dance training for the entire school year.
11226409|NCT03201302|Experimental|Basketball|Children who participated in organized basketball training for the entire school year.
11226410|NCT03201302|Experimental|Wrestling|Children who participated in organized wrestling training for the entire school year.
11226411|NCT03201302|Experimental|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
11226412|NCT03201302|Experimental|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
11226413|NCT03201302|Experimental|Track and field|Children who participated in organized track and field training for the entire school year.
11226414|NCT03201302|Experimental|Tennis|Children who participated in organized tennis training for the entire school year.
11226415|NCT03201302|Experimental|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
11226416|NCT03201302|Experimental|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
11226417|NCT03201289||Cardiac surgery|
11226418|NCT03201276||Drug group|patients taking glucosamine
11226419|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
11226420|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
11226421|NCT03201250|Experimental|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone
~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.
~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.
~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
11226422|NCT03201237|Experimental|30 min AOT|
11226423|NCT03201237|Placebo Comparator|60 min AOT|
11226424|NCT03201224||Group without image transmission|"Before Group"
11226425|NCT03201224||Group with image transmission|"After Group"
11226426|NCT03201211|Experimental|Group A|Subjects who received two doses of formulation 1 of the NTHi-Mcat investigational vaccine during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development.
11226427|NCT03201211|Experimental|Group B|Subjects who received two doses of formulation 2 of the NTHi-Mcat investigational vaccine during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development.
11226428|NCT03201211|Placebo Comparator|Group C|Subjects who received placebo during STEP 2 of NTHi -Mcat-001 (201281 - NCT02547974) study and for whom blood sampling was taken at each planned visit during the NTHI Mcat-006 study, for antibody determination and assay validation/development
11226429|NCT03201198|Experimental|Active Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
11226430|NCT03201198|Sham Comparator|Chair exercises|The Chair exercise intervention includes chair exercises, behavioral relaxation and health education.
11226431|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
11226432|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
11226433|NCT03201172||Univation® X|
11226434|NCT03201172||iUni®|
11226435|NCT03201159|Experimental|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
11226436|NCT03201159|Experimental|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
11226437|NCT03201159|Experimental|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
11226438|NCT03201146|Experimental|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
11226439|NCT03201146|Experimental|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
11226440|NCT03201146|Experimental|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
11226441|NCT03201146|Experimental|Apatinib|Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
11226442|NCT03201146|Active Comparator|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.
11226443|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
11226444|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
11226445|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
11226533|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
11226446|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.
~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
11226447|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.
~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
11226448|NCT03201107|Experimental|Pilates group|This group receives physical training based on pilates exercises
11226449|NCT03201107|No Intervention|No intervention group|This group does not receive any treatment
11226450|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
11226451|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
11226452|NCT03201094|Experimental|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
11226453|NCT03201094|Experimental|HPRO only|Patients will receive HPRO three times daily during study period
11226454|NCT03201081|Experimental|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
11226455|NCT03201081|No Intervention|control group|The control group, did not participate in the motivational resistance-training program.
11226456|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
11226457|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
11226458|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
11226459|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
11226460|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
11226461|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
11226462|NCT03201003|Active Comparator|Biological/Vaccine: AR101|AR101 powder provided in capsules & sachets
11226463|NCT03201003|Placebo Comparator|Placebo|Placebo powder provided in capsules & sachets
11226464|NCT03200990|Experimental|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
11226465|NCT03200990|Active Comparator|Impella CP pVAD|Clinically indicated ventricular support for high-risk PCI with Impella CP.
11226466|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
11226467|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
11226468|NCT03200951|Experimental|Bolus group|
11226469|NCT03200951|Active Comparator|Infusion group|
11226470|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
11226471|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
11226472|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:
~their intention to practice skin to skin at the time of delivery
~if they participated in skin to skin in a previous pregnancy
~if they had any formal education about skin to skin
~if they did have formal education was it either
~a.) Provided at a prenatal appointment,
~b.) A formal class led by either a nurse or a lactation consultant.
~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
11226473|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.
~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.
~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
11226474|NCT03200912|Active Comparator|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
11226475|NCT03200912|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% [Test]
11226476|NCT03200912|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
11226602|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
11226603|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
11226477|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
11226478|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
11226479|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
11226480|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
11226481|NCT03200873|Active Comparator|high impulsivity|participants with high impulsivity (BIS >62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
11226482|NCT03200873|Active Comparator|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
11226483|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
11226484|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
11226485|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
11226486|NCT03200834|Active Comparator|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
11226487|NCT03200834|Experimental|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
11226488|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
11226489|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
11226490|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.
~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
11226491|NCT03200795|Experimental|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
11226492|NCT03200795|Experimental|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
11226493|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
11226494|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
11226495|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
11226496|NCT03200769|No Intervention|Group I|AHI/h < 15
11226497|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
11226498|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
11226499|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
11226500|NCT03200756|Experimental|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
11226501|NCT03200756|Active Comparator|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
11226502|NCT03200743||Hpertension|
11226503|NCT03200743||Health|
11226504|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
11226505|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
11226507|NCT03200704|Experimental|IC2000/SPY-PHI|Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.
11226508|NCT03200691|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.
~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.
~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
11226509|NCT03200678|Experimental|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
11226510|NCT03200678|Other|Control group|other Intervention: isokinetic assessment
11226511|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
11226512|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
11226513|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.
~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
11226514|NCT03200639|Active Comparator|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
11226515|NCT03200639|Active Comparator|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
11226516|NCT03200639|Experimental|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
11226517|NCT03200639|Experimental|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
11226518|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
11226519|NCT03200626||Routine plerixafor based mobilization|
11226520|NCT03200626||Chemomobilization|
11226521|NCT03200613|Experimental|Apixaban|Apixaban 2.5 mg orally twice daily
11226522|NCT03200613|Active Comparator|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
11226523|NCT03200600|Experimental|Dexamethasone and flurbiprofen axetil|"Dexamethasone 10 mg is administered before anesthesia induction.
~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
11226524|NCT03200600|Experimental|Dexamethasone and lipid microsphere|"Dexamethasone 10 mg is administered before anesthesia induction.
~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
11226525|NCT03200600|Experimental|Normal saline and flurbiprofen axetil|"Normal saline 2 ml is administered before anesthesia induction.
~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
11226526|NCT03200600|Experimental|Normal saline and lipid microsphere|"Normal saline 2 ml is administered before anesthesia induction.
~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
11226527|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
11226528|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
11226529|NCT03200561|Active Comparator|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
11226530|NCT03200561|Placebo Comparator|I group|IVIG (2g/Kg in 12 hours)
11226531|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
11226532|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
11226869|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
11226534|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
11226535|NCT03200535|No Intervention|Usual care|Usual care
11226536|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
11226537|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
11226538|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
11226539|NCT03200522|Active Comparator|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
11226540|NCT03200522|Active Comparator|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
11226541|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
11226542|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
11226543|NCT03200496|Experimental|TALION®|
11226544|NCT03200496|Experimental|DA-5206(Fasting)|
11226545|NCT03200496|Experimental|DA-5206(Fed)|
11226546|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
11226547|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
11226548|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
11226549|NCT03200470||Suspected PJI|
11226550|NCT03200457|Experimental|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla device and the other on a 3 Tesla device.
11226551|NCT03200444|Experimental|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.
~Standard adhesive 1
~standard adhesive 2
~Standard adhesive 3
~P-4
~P-15
~P-16
~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
11226552|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
11226553|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.
~The difference between the four patches is that they consist of different adhesives.
~One patch is made of a standard hydrocolloid adhesive
~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
11226554|NCT03200405|Experimental|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
11226555|NCT03200405|Active Comparator|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
11226556|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
11226557|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
11226558|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
11226559|NCT03200366|Active Comparator|DVD|Tailored digital video disc (DVD)
11226560|NCT03200366|Active Comparator|DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
11226561|NCT03200366|No Intervention|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
11226562|NCT03200353|Experimental|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
11226563|NCT03200340|Placebo Comparator|Placebo|Matching placebo
11226564|NCT03200340|Experimental|EC-18 500 mg|1 capsule of EC-18
11226565|NCT03200340|Experimental|EC-18 1000 mg|2 capsules of EC-18 500 mg
11226566|NCT03200340|Experimental|EC-18 2000 mg|4 capsules of EC-18 500 mg
11226567|NCT03200327|Active Comparator|laparoscopic promontofixation|
11226568|NCT03200327|Experimental|Anterior vaginal sacrospinofixation|
11226569|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
11226570|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
11226571|NCT03200288|Experimental|HL-01|Single 2 ml intra-articular injection of HL-01 (solution of high and low molecular weight hyaluronic acid (HA))
11226572|NCT03200288|Placebo Comparator|Placebo|Single 2 ml intra-articular injection of Placebo (physiological solution)
11226604|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
11226573|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.
~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
11226574|NCT03200249|Experimental|Treatment|"- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)
~Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy
~Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.
~- TME surgery (8 weeks after the end of treatment)"
11226575|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
11226576|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
11226577|NCT03200223|Experimental|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
11226578|NCT03200223|No Intervention|Conventional group|Patients with conventional care
11226579|NCT03200210|Experimental|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
11226580|NCT03200210|Placebo Comparator|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
11226581|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
11226582|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
11226583|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
11226584|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
11226585|NCT03200171||Group II|HCC patients who are naive to DAAs.
11226586|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
11226587|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
11226588|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
11226589|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
11226590|NCT03200093|Experimental|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.
~Taken by mouth once daily for:
~If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.
~If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
11226591|NCT03200093|Placebo Comparator|Placebo arm|"Ora-Sweet 5 mL
~Taken by mouth once daily for:
~If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.
~If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
11226592|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
11226593|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
11226594|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
11226595|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
11226596|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
11226597|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
11226598|NCT03200067|Experimental|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
11226599|NCT03200067|No Intervention|Conventional group|Breast cancer patients with conventional care
11226600|NCT03200054|No Intervention|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
11226601|NCT03200054|Experimental|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
11226870|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
11226605|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
11226606|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
11226607|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
11226608|NCT03199989|Active Comparator|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy[CapeOX（Capecitabine+Oxaliplatin）] by the current guidelines
11226609|NCT03199989|Experimental|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
11226610|NCT03199976|Experimental|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
11226611|NCT03199976|Active Comparator|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
11226612|NCT03199976|Active Comparator|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
11226613|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
11226614|NCT03199963|Placebo Comparator|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
11226615|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
11226616|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
11226617|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
11226618|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
11226619|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
11226620|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
11226621|NCT03199924|Active Comparator|diclofenac alone|diclofenac alone
11226622|NCT03199911|Experimental|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
11226623|NCT03199911|Placebo Comparator|Topical Non-Antibiotic Ointment|Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
11226624|NCT03199898||34-32 GA|premature infants born <34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
11226625|NCT03199898||32-28 GA|premature infants born <32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
11226626|NCT03199898||28-23 GA|premature infants born <28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
11226627|NCT03199885|Experimental|Arm I (pertuzumab, trastuzumab, paclitaxel, atezolizumab)|Patients receive pertuzumab IV over 30-60 minutes on days 1 and 22, trastuzumab IV over 30-90 minutes on days 1 and 22, paclitaxel IV over 60 minutes on days 1, 8, 15, 22, 29, and 36, and atezolizumab IV over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab and atezolizumab repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.
11226628|NCT03199885|Active Comparator|Arm II (pertuzumab, trastuzumab, paclitaxel, placebo)|Patients receive pertuzumab, trastuzumab, and paclitaxel as in Arm I. Patients also receive placebo IV over 60 minutes on days 1 and 22. Cycles for pertuzumab, trastuzumab, and placebo repeat every 6 weeks and treatment with paclitaxel repeats every 6 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional 3 cycles of paclitaxel in the absence of progression at the investigator's discretion.
11226629|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
11226630|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
11226631|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
11226632|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
11226633|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
11226634|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
11226635|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
11226636|NCT03199833|Experimental|Arms|RETRAINER-S2 & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11226637|NCT03199833|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11226638|NCT03199820|Active Comparator|Cook Cervical balloon|Cook cervical double balloon catheter
11226639|NCT03199820|Active Comparator|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
11226640|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
11226641|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
11226642|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
11226643|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
11226644|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
11226645|NCT03199755|Active Comparator|ACT|"Standard Artemisinin Combination Therapy (ACT) being used as currently approved antimalarial therapy at WHO and manufacturer recommended dosage. The specific ACT used is artemether-lumefantrine (Coartem). Form is scored tablets that each contain 20 mg artemether and 120 mg lumefantrine.
~Tablets per dose, are given BID for 3 days as shown below:
~Coartem tablets/dose by bodyweight; tablets/day morning and evening for total of 6 doses over 3 days
~Body weight (kg) and Tablets: 5 to <15 kg, 1 tab; 15 to <25 kg, 2 tabs; 25 to <35 kg, 3 tabs; 35 kg and over, 4 tabs."
11226646|NCT03199755|Experimental|DLA1|"Dried leaf Artemisia annua (DLA) from 0.25-1 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.
~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.
~Body weight (kg) and tablets/dose:
~For DLA1x: 5 to < 15 kg, 1/4 tab; 15-30 kg, 1/2 tab; 1/2>30 kg, 1 tab."
11226647|NCT03199755|Experimental|DLA2|"Dried leaf Artemisia annua (DLA) from 0.5-2 g total/day, BID. DLA is given as 500 mg tablets according to body weight (see below) for 5 days.
~DLA tablets/dose by bodyweight; tablets/day, morning and evening, for total of 10 doses over 5 days.
~Body weight (kg) and tablets/dose:
~For DLA2x: 5 to < 15 kg, 1/2 tab; 15-30 kg, 1 tab; >30 kg, 2 tabs."
11226648|NCT03199742|Active Comparator|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
11226649|NCT03199742|Experimental|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
11226650|NCT03199742|Experimental|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
11226651|NCT03199742|Experimental|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
11226652|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
11226653|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
11226654|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
11226655|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
11226656|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
11226657|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
11226658|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
11226659|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
11226730|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
11226660|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:
~Day 1 - 7
~- Dolutegravir 50 mg once daily with food
~Day 8 - 14 - Dolutegravir 100 mg once daily with food
~Day 15 - 28
~- Rifampicin 600 mg once daily
~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily
~Day 36 - 42
~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
11226661|NCT03199677|Experimental|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
11226662|NCT03199664|Active Comparator|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
11226663|NCT03199664|Active Comparator|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB & Tacrolimus 0.03 % ointment for 6 months
11226664|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
11226665|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
11226666|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
11226667|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
11226668|NCT03199638|No Intervention|control group|"in which we will use historic data from previous study (Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function) by choosing 12 children between 13-19 years with type 1 diabetes and meeting the very same inclusion/ exclusion criteria. We have readily available data for their HbA1C, CGM downloads, all labs and anthropometry for 3 months. We will select age, gender, and HbA1c-matched adolescents as these data were prospectively collected."
11226669|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
11226670|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
11226671|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
11226672|NCT03199612|Active Comparator|Sildenafil|Baseline blood samples and study measurements will be acquired. Then 20 mg of the study drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is < 5 mmHg after 2 hours and patient is asymptomatic), patient will proceed to take 20 mg of the study drug every 8 hours. The patient will return to clinic on day 8 and 20 mg of the study drug will be administered. After 2 hours blood samples and study measurements will be collected and the patient will resume 20 mg of the study for the next two doses. The patient will return for a third clinic visit on the next day and if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then the patient will continue taking 40 mg every 8 hours. The patient will return to clinic on day 15 for a final study visit and will be given the last 40 mg dose of the study drug and after 2 hours blood samples and study measurements will be taken.
11226673|NCT03199612|Placebo Comparator|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.
11226674|NCT03199586|Experimental|NP-G2-044|capsule
11226675|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
11226676|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
11226677|NCT03199547|Experimental|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
11226678|NCT03199547|Placebo Comparator|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
11226679|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
11226680|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
11226681|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
11226682|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
11226683|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
11226684|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
11226685|NCT03199508|Experimental|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
11226686|NCT03199508|Active Comparator|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
11226687|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
11226688|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
11226689|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
11226690|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
11226691|NCT03199469|Experimental|1.0 x 10^14 vg/kg|1.0 x 10^14 vg/kg of AT132 delivered intravenously one time
11226692|NCT03199469|Experimental|3.0 x 10^14 vg/kg|3.0 x 10^14 vg/kg of AT132 delivered intravenously one time
11226693|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.
11226694|NCT03199456|Experimental|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
11226695|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
11226696|NCT03199443||Overactive bladder patients|
11226697|NCT03199443||Non Obstructive Urinary Retention patients|
11226698|NCT03199430|Placebo Comparator|Placebo|1450mg Corn flour
11226699|NCT03199430|Active Comparator|Epigallocatechin gallate|1450mg Epigallocatechin gallate
11226700|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
11226701|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
11226702|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
11226703|NCT03199378||Caucasian|English speaking Caucasian individuals
11226704|NCT03199378||African American|English speaking African American individuals
11226705|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
11226706|NCT03199365|Experimental|Prevention (TSSC intervention)|Participants undergo two TSSC intervention sessions delivered at participants' homes by trained CHWs over 1.5 hours.
11226707|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
11226708|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
11226709|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
11226710|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
11226711|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
11226712|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
11226713|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
11226714|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
11226715|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
11226716|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
11226717|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
11226718|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
11226719|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
11226720|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
11226721|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
11226722|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
11226723|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
11226724|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
11226725|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
11226726|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
11226727|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
11226728|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
11226729|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
11226731|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
11226732|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
11226733|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
11226734|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
11226735|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
11226736|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
11226737|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
11226738|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
11226739|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
11226740|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
11226741|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
11226742|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
11226743|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
11226744|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
11226745|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
11226746|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
11226747|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
11226748|NCT03199274|Experimental|Group I (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours post radioembolization and at approximately 7 and 14 days after yttrium Y-90 radioembolization.
11226749|NCT03199274|Active Comparator|Group II (standard of care)|Patients undergo standard of care yttrium Y-90 radioembolization.
11226750|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
11226751|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
11226752|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
11226753|NCT03199248||the participant accepted aspiration for DMC only|
11226754|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
11226755|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
11226756|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
11226757|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
11226758|NCT03199209|Experimental|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
11226759|NCT03199209|Experimental|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
11226760|NCT03199196|Experimental|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.
~Participant emailed electronic newsletters to read that may help participant be more physically active.
~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).
~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.
~Participants invited to take part in a final focus group sometime after the 16-week visit."
11226761|NCT03199196|Other|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.
~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).
~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.
~Participants invited to take part in a final focus group sometime after the 16-week visit."
11226762|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
11226763|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
11226764|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
11226765|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
11226766|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
11226767|NCT03199157|No Intervention|Control group|
11226768|NCT03199144|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
11226769|NCT03199131|Experimental|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
11226770|NCT03199131|Other|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
11226771|NCT03199118|Experimental|CAF+SCTG+PRF|Intervention: surgical procedure : coronally advanced flap + SCTG Intervention: membrane: platelet rich fibrin Patients with class I or II gingival recession will receive treatment that consists of coronally advanced flap (CAF) with subepithelial connective tissue graft (SCTG) and platelet rich fibrin(PRF)
11226772|NCT03199118|Active Comparator|CAF+SCTG|Patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG Intervention: surgical procedure : coronally advanced flap + SCTG
11226773|NCT03199105|Experimental|preoperative education and tetracaine|
11226774|NCT03199105|Experimental|tetracaine|
11226775|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
11226776|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
11226777|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
11226778|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
11226779|NCT03199066||All NHL subtypes|no interventions
11226780|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
11226781|NCT03199066||FL|only patients with follicular lymphoma
11226782|NCT03199066||MCL|only patients with mantle cell lymphoma
11226783|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
11226784|NCT03199066||MZL|only patients with marginal zone lymphoma
11226785|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
11226786|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
11226787|NCT03199053|Experimental|Low dose Dapagliflozin|Oral route. Start with a low dose of dapagliflozin administered once daily and remain on the low dose regardless of your HbA1c at week 12.
11226788|NCT03199053|Experimental|Low dose/high dose Dapagliflozin|Oral route. Start with a low dose of Dapagliflozin administered once daily and up titrate to the high dose Dapagliflozin administered once daily if HbA1c >= 7% at week 12
11226789|NCT03199053|Experimental|Low dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and remain on the low dose regardless of your HbA1c at week 12
11226790|NCT03199053|Experimental|Low dose/high dose Saxagliptin|Oral route. Start with a low dose of saxagliptin administered once daily and up titrate to the high dose if HbA1c >= 7% at week 12
11226791|NCT03199053|Placebo Comparator|Placebo arm|Oral route. Placebo tablets administered for 52 weeks
11226792|NCT03199040|Experimental|Neoantigen DNA vaccine + Durvalumab|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1
~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days
~For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
11226793|NCT03199040|Experimental|Neoantigen DNA vaccine|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1
~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
11226794|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
11226795|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
11226796|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
11226797|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
11226798|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
11226827|NCT03198767|Experimental|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
11226828|NCT03198767|Experimental|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
11226829|NCT03198767|Experimental|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
11226799|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
11226800|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
11226801|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
11226802|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
11226803|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
11226804|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
11226805|NCT03198936|Experimental|Brain Pill|Dose - 2 capsules twice a day with meals
11226806|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
11226807|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
11226808|NCT03198910||Pulmonary arterial hypertension|
11226809|NCT03198910||Chronic thromboembolic pulmonary hypertension|
11226810|NCT03198897||Observation|Patients with a Homozygous familial Hypercholesterolemia or high-grade suspicion for Homozygous familial Hypercholesterolemia
11226811|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
11226812|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
11226813|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
11226814|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
11226815|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.
~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
11226816|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.
~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
11226817|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
11226818|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
11226819|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime
~For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days
~For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
11226820|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime
~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
11226821|NCT03198806|Active Comparator|Control group in supine position|"Intervention:
~- Only treadmill aerobic exercise with 60 min recovery in supine position"
11226822|NCT03198806|Experimental|Hydration group in supine position|"Interventions:
~Treadmill aerobic exercise with 60 min recovery in supine position
~Water intake"
11226823|NCT03198806|Active Comparator|Control group in orthostatic position|"Intervention:
~- Only treadmill aerobic exercise with 10 min recovery in orthostatic position"
11226824|NCT03198806|Experimental|Hydration group in orthostatic position|"Interventions:
~Treadmill aerobic exercise with 10 min recovery in orthostatic position
~Water intake"
11226825|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
11226826|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.
~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
11226830|NCT03198767|Experimental|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
11226831|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
11226832|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
11226833|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
11226834|NCT03198754|Experimental|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
11226835|NCT03198754|Active Comparator|Comparison Light|Ambient light fixture installed in the patient's hospital room
11226836|NCT03198741|Active Comparator|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.
~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
11226837|NCT03198741|Experimental|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
11226838|NCT03198741|Experimental|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
11226839|NCT03198728|Experimental|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
11226840|NCT03198728|Active Comparator|Andro-Gel treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 42.
11226841|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
11226842|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
11226843|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
11226844|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
11226845|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
11226846|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
11226847|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
11226848|NCT03198689|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
11226849|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
11226850|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
11226851|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
11226852|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
11226853|NCT03198663|Experimental|POSSE Intervention|
11226854|NCT03198663|Other|Control|Delayed intervention
11226855|NCT03198650|Experimental|Part 1 / Part 2|Acalabrutinib
11226856|NCT03198650|Experimental|Part 3|Acalabrutinib in combination with Obinutuzumab
11226857|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
11226858|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
11226859|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
11226860|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
11226861|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
11226862|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
11226863|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
11226864|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
11226865|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
11226866|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
11226867|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:
~Mitral lateral annulus e' in tissue Doppler < 10 cm/s
~American society of echocardiography (ASE) criteria 2009
~ASE criteria 2016"
11226868|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
11226871|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
11226872|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
11226873|NCT03198598|No Intervention|Healthy subjects|
11226874|NCT03198585|Active Comparator|Empagliflozin 10 mg|
11226875|NCT03198585|Placebo Comparator|Placebo|
11226876|NCT03198572|Experimental|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
11226877|NCT03198572|Placebo Comparator|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
11226878|NCT03198559|Experimental|Experimental|"Participants current ART regimen:
~2 grams disulfiram by mouth per day for a total of 28 days
~400mg vorinostat by mouth per day on days 8, 9,10 and days 22, 23, 24"
11226879|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 or or TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
11226880|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
11226881|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
11226882|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
11226883|NCT03198507|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
11226884|NCT03198507|Active Comparator|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
11226885|NCT03198494|Experimental|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
11226886|NCT03198494|Sham Comparator|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
11226887|NCT03198494|No Intervention|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
11226888|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
11226889|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
11226890|NCT03198468|Experimental|Vapor Ablation|
11226891|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
11226892|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
11226893|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
11226894|NCT03198429|Experimental|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:
~a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV
~access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV
~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,
~cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program
~clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
11226895|NCT03198429|Experimental|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:
~a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development
~access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues
~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,
~cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program
~clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
11226896|NCT03198429|Experimental|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
11226926|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
11226897|NCT03198429|No Intervention|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
11226898|NCT03198416|Experimental|Investigational Device|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) with the Solar GI High Resolution pharyngeal Manometry system.
11226899|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
11226900|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
11226901|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
11226902|NCT03198390||Healthy subjects|
11226903|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
11226904|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
11226905|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
11226906|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
11226907|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
11226908|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
11226909|NCT03198351||Cohort I|Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
11226910|NCT03198351||Cohort II|Pregnant women with MS not exposed to teriflunomide during the current pregnancy
11226911|NCT03198351||Cohort III|Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
11226912|NCT03198351||"Registry group (not eligible for cohorts)"|Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.
11226913|NCT03198338|Experimental|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
11226914|NCT03198338|Sham Comparator|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
11226915|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
11226916|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
11226917|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
11226918|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
11226919|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
11226920|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
11226921|NCT03198273|Experimental|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
11226922|NCT03198273|Experimental|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
11226923|NCT03198260|Experimental|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
11226924|NCT03198260|Active Comparator|Running kinematics|the change in a range of joint angles during different phases of running
11226925|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.
~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
11226927|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
11226928|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
11226929|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
11226930|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
11226931|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
11226932|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
11226933|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
11226934|NCT03198208||Reference group|No fentanyl dose administered during surgery
11226935|NCT03198208||Comparative group|Fentanyl dose administered during surgery
11226936|NCT03198182|Experimental|Module A|BMS-986036 Arm
11226937|NCT03198182|Placebo Comparator|Module B|Placebo Arm
11226938|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
11226939|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
11226940|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
11226941|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
11226942|NCT03198156|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
11226943|NCT03198156|Sham Comparator|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
11226944|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
11226945|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
11226946|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
11226947|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
11226948|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
11226949|NCT03198117|Experimental|Huaier Granule|Huaier Granule
11226950|NCT03198117|Placebo Comparator|placebo|placebo
11226951|NCT03198117|No Intervention|No-treatment Control|patients refused any treatment
11226952|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
11226953|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
11226954|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
11226955|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
11226956|NCT03198078|Experimental|Brexpiprazole (OPC-34712)|2-4 mg/day; Start at 0.5 mg/day, titrate to max of 4 mg/day
11226957|NCT03198078|Active Comparator|Aripiprazole|10-20 mg/day; Start at 2 mg per day, titrate up to max of 20 mg/day
11226960|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
11226961|NCT03198052|Experimental|CAR-T cell therapy group|Patients will receive 3 or more cycles of the CAR-T cells treatment via intra-tumor injection or vein, from 1x10e6/kg-10x10e6/kg weight.
11226962|NCT03198039|Experimental|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
11226963|NCT03198039|Experimental|Group 2|Meditation twice daily for four weeks after surgery
11226964|NCT03198039|No Intervention|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
11226965|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 months after course 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.
11226966|NCT03198013|Experimental|Module A|Single Ascending Dose
11226967|NCT03198013|Experimental|Module B|Multiple Ascending Dose
11226968|NCT03198000|Experimental|Formula # 13418-148|
11226969|NCT03198000|Experimental|Formula # 13418-158|
11226970|NCT03198000|Active Comparator|Control Formula # PF004390|
11226971|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
11226972|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
11226973|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
11226974|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
11226975|NCT03197961|Experimental|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
11226976|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
11226977|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants will receive atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will continue to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
11226978|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants will receive placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
11226979|NCT03197922|Experimental|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
11226980|NCT03197922|No Intervention|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
11226981|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
11226982|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
11226983|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
11226984|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
11226985|NCT03197883|Experimental|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
11227154|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
11226986|NCT03197883|Other|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
11226987|NCT03197870|Experimental|AKB-9778 15mg BID|
11226988|NCT03197870|Experimental|AKB-9778 15mg QD|
11226989|NCT03197870|Placebo Comparator|Placebo BID|
11226990|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
11226991|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
11226992|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
11226993|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
11226994|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
11226995|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.
~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:
~Control
~Control + protein supplementation
~Training in aquabike
~Training in aquabike + protein supplementation
~Bicycle training
~Bicycle training + protein supplementation"
11226996|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
11226997|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
11226998|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
11226999|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
11227000|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
11227001|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
11227002|NCT03197805|Experimental|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
11227003|NCT03197792|Experimental|Pulmonary endarterectomy patients|All patients
11227004|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
11227005|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
11227006|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
11227007|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
11227008|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
11227009|NCT03197766|Experimental|Active BMN 111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
11227010|NCT03197766|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
11227011|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
11227012|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
11227013|NCT03197740|Active Comparator|aricept Tab 5mg|
11227014|NCT03197740|Experimental|donepezil patch 25cm2|
11227015|NCT03197740|Active Comparator|aricept Tab 10mg|
11227016|NCT03197740|Experimental|donepezil patch 50cm2|
11227017|NCT03197727|Other|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
11227018|NCT03197714|Experimental|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
11227019|NCT03197688||Notapplicable|Not applicable as non-interventional study
11227076|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
11227020|NCT03197675|Sham Comparator|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
11227021|NCT03197675|Active Comparator|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
11227022|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
11227023|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
11227024|NCT03197649|No Intervention|Control|No laser phototherapy treatment
11227025|NCT03197649|Experimental|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
11227026|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
11227027|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
11227028|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
11227029|NCT03197623|Placebo Comparator|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
11227030|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
11227031|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
11227032|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
11227033|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
11227034|NCT03197571|Experimental|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
11227035|NCT03197558|Other|Tube insertion using Tube Delivery System (TDS)|Active Tymbion iontophoresis and tube insertion using the TDS
11227036|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
11227037|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
11227038|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
11227039|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
11227040|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
11227041|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
11227042|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
11227043|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
11227044|NCT03197506|Experimental|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.
~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.
~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.
~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
11227077|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
11227045|NCT03197506|Experimental|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.
~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
11227046|NCT03197493|Experimental|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
11227047|NCT03197493|Experimental|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
11227048|NCT03197480|Other|DME treatment group|"All patients will received 4 intravitreal injections of aflibercept.
~Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:
~Less than 20% reduction in CRT on OCT or <5 letter improvement of VA (if VA<6/6 and CRT>=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT"
11227049|NCT03197467|Experimental|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
11227050|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
11227051|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
11227052|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
11227053|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
11227054|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
11227055|NCT03197415|Experimental|PRP group|Intradisc injection of autologous platelet-rich plasma gel
11227056|NCT03197402|Active Comparator|Comparator group|Milk protein gel delivery system supplementation
11227057|NCT03197402|Experimental|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
11227058|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
11227059|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
11227060|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
11227061|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
11227062|NCT03197389|Other|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
11227063|NCT03197389|Other|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
11227064|NCT03197376|Experimental|Pneumosil Lot 1|Pneumosil Lot 1
11227065|NCT03197376|Experimental|Pneumosil Lot 2|Pneumosil Lot 2
11227066|NCT03197376|Experimental|Pneumosil Lot 3|Pneumosil Lot 3
11227067|NCT03197376|Active Comparator|Synflorix|Synflorix
11227068|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
11227069|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next 4 years. Eligible patients include those with age ≥50 years, LVEF ≥45%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) within the 60 days before inclusion.
~Intervention: cMR"
11227070|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.
~Intervention: cMR"
11227071|NCT03197337|Experimental|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
11227072|NCT03197337|Experimental|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
11227073|NCT03197324|Active Comparator|Digoxin Alone|
11227074|NCT03197324|Active Comparator|Digoxin with Bexagliflozin|
11227075|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
11227078|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
11227079|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
11227080|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.
~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
11227081|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
11227082|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
11227083|NCT03197246|Experimental|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
11227084|NCT03197246|Active Comparator|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
11227085|NCT03197220|Experimental|fish|
11227086|NCT03197220|Experimental|walnut|
11227087|NCT03197220|Experimental|fish-walnut|
11227088|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
11227089|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
11227090|NCT03197194|Experimental|A : Alteplase|Intravenous injection of Alteplase and one tablet of placebo
11227091|NCT03197194|Active Comparator|B : Acetylsalicylic Acid|one tablet of Acetylsalicylic Acid and one dose of IV placebo
11227092|NCT03197181|Experimental|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
11227093|NCT03197181|Sham Comparator|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
11227094|NCT03197168|Experimental|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
11227095|NCT03197168|Placebo Comparator|Control|Usual care
11227096|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
11227097|NCT03197129|Other|first sade|children that in the first appointment will wait in the SADE waiting room and in the traditional waiting room in the second visit
11227098|NCT03197129|Other|first traditional|children that in the first appointment will wait in the traditional waiting room and in the SADE waiting room in the second visit
11227099|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
11227100|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
11227101|NCT03197103|Experimental|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
11227102|NCT03197103|No Intervention|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
11227103|NCT03197090|Experimental|Zenicor ON|Patients allocated to the experimental group will undergo systematic short ECG monitoring
11227104|NCT03197090|No Intervention|Zenicor OFF|In patients allocated to the control group, usual diagnostic procedures for detection of atrial fibrillation will be employed according to ESC Guidlines.
11227105|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
11227106|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
11227107|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
11227108|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
11227109|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
11227110|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
11227111|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
11227112|NCT03197038|Experimental|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
11227151|NCT03196791|Experimental|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
11227152|NCT03196791|Experimental|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
11227153|NCT03196778|Experimental|Low Dose Radiation|
11227205|NCT03196375|Placebo Comparator|Placebo Comparator|
11227113|NCT03197038|Active Comparator|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
11227114|NCT03197025|Experimental|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
11227115|NCT03197025|Experimental|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
11227116|NCT03197012|Experimental|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
11227117|NCT03197012|Experimental|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
11227118|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
11227119|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
11227120|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
11227121|NCT03196986|Experimental|MIL60|MIL60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
11227122|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
11227123|NCT03196973|Experimental|DF289 plus DF277|Otic solution
11227124|NCT03196973|Active Comparator|DF289|Otic solution
11227125|NCT03196973|Active Comparator|DF277|Otic solution
11227126|NCT03196947|Experimental|Single arm, APO010 Dose escalation|
11227127|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
11227128|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
11227129|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
11227130|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
11227131|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
11227132|NCT03196895|Active Comparator|WR|Weight reduction training
11227133|NCT03196895|Active Comparator|GE|PPG training
11227134|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
11227135|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
11227136|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
11227137|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
11227138|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
11227139|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum
~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
11227140|NCT03196869|Experimental|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
11227141|NCT03196869|Other|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
11227142|NCT03196856|Experimental|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 12 weeks
11227143|NCT03196856|Placebo Comparator|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 12 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
11227144|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
11227145|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
11227146|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
11227147|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
11227148|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
11227149|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
11227150|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
11227155|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
11227156|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
11227157|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
11227158|NCT03196713|Other|Tailored supervision|
11227159|NCT03196713|Other|Regular supervision|
11227160|NCT03196700|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
11227161|NCT03196674|Active Comparator|manipulated feedback|
11227162|NCT03196674|Active Comparator|non-manipulated feedback|
11227163|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
11227164|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
11227165|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
11227166|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).
~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
11227167|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
11227168|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
11227169|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
11227170|NCT03196635|Experimental|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal [CC] and mediolateral oblique [MLO]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
11227171|NCT03196622|Experimental|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
11227172|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:
~15 patients with non-small cell lung cancer (NSCLC)
~10 patients with hepatocellular cancer:
~10 patients with colorectal cancer
~10 patients with breast cancer
~10 patients with prostate cancer
~10 patients with glioblastoma"
11227173|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
11227174|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
11227175|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
11227176|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
11227206|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
11227207|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
11227208|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
11227209|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
11229315|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
11227177|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
11227178|NCT03196557|Experimental|Arm A|Specified dose on specified days
11227179|NCT03196557|Placebo Comparator|Arm B|Specified dose on specified days
11227180|NCT03196544|Experimental|Social Approach Training (5 sessions)|
11227181|NCT03196544|Experimental|Social Approach Training (10 sessions)|
11227182|NCT03196544|No Intervention|Delayed Treatment (Waitlist)|
11227183|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
11227184|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
11227185|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
11227186|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
11227187|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
11227188|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
11227189|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
11227190|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
11227191|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
11227192|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
11227193|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
11227194|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
11227195|NCT03196466||antiepileptics titration and available blood samples|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
11227196|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
11227197|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
11227198|NCT03196453|Placebo Comparator|Placebo|Placebo
11227199|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous infusion, every 8 weeks for up to 5 years.
11227200|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive Vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive Vedolizumab 100 mg intravenous infusion, every 8 weeks for up to 5 years.
11227201|NCT03196414|Experimental|CART-138/BCMA/19/more|
11227202|NCT03196401|Experimental|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
11227203|NCT03196388|Experimental|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
11227204|NCT03196375|Experimental|Experimental|
11227210|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
11227211|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
11227212|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
11227213|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
11227214|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
11227215|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
11227216|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
11227217|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
11227218|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
11227219|NCT03196284|Experimental|Concizumab|Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
11227220|NCT03196284|Active Comparator|Eptacog alfa and concizumab|Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase
11227221|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
11227222|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
11227223|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
11227224|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
11227225|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
11227226|NCT03196219|Other|Arm 1|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
11227227|NCT03196219|Placebo Comparator|Arm 2|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
11227228|NCT03196219|Other|Arm 3|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
11227229|NCT03196206|Experimental|Group A|Normal Renal Function
11227230|NCT03196206|Experimental|Group B|Moderate Renal Impairment
11227231|NCT03196206|Experimental|Group C|Severe Renal Impairment
11227232|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.
~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
11227233|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
11227234|NCT03196180|Experimental|Treatment (topical fluorouracil, imiquimod)|Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.
11227235|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
11227236|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
11227237|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
11227238|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
11227264|NCT03195985|Active Comparator|"Age Well psycho-education course"|4-week active control condition
11227265|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
11229316|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
11227239|NCT03196141|Active Comparator|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously & pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.
~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.
~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.
~This will determine inter-day variability. (total time is 53 min)."
11227240|NCT03196141|Active Comparator|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.
~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.
~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).
~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.
~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
11227241|NCT03196141|Active Comparator|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.
~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.
~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).
~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.
~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.
~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
11227242|NCT03196128|Active Comparator|Digital|
11227243|NCT03196128|Active Comparator|Non Digital|
11227244|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
11227245|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|
11227246|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|
11227247|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|
11227248|NCT03196089|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
11227249|NCT03196089|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
11227250|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
11227251|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
11227252|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
11227253|NCT03196063|Active Comparator|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.
~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
11227254|NCT03196063|Experimental|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.
~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
11227255|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
11227256|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
11227257|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
11227258|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
11227259|NCT03196011|Active Comparator|TKR with mechanical alignment|TKR implanted using traditional alignment methods
11227260|NCT03196011|Experimental|TKR using alternative alignment method|TKR implanted using alternative alignment methods
11227261|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
11227262|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
11227263|NCT03195985|Experimental|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
11227266|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
11227267|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
11227268|NCT03195933|Experimental|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
11227269|NCT03195933|Experimental|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
11227270|NCT03195920|Experimental|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
11227271|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
11227272|NCT03195907||Control group|Those served as control group
11227273|NCT03195894|Experimental|Conventional treatment and TripleA|Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver
11227274|NCT03195894|No Intervention|Conventional treatment|Conventional treatment
11227275|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
11227276|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):
~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.
~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).
~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
11227277|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):
~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.
~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
11227278|NCT03195842|No Intervention|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
11227279|NCT03195842|Experimental|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
11227280|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
11227281|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
11227282|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
11227283|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
11227284|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
11227285|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
11227286|NCT03195790|Active Comparator|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
11227287|NCT03195790|Experimental|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
11227288|NCT03195777|Experimental|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
11227289|NCT03195764|Experimental|T-1101 (Tosylate)|
11227290|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
11227291|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
11227292|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
11227293|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
11227294|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
11227295|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
11227349|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
11227296|NCT03195699|Experimental|Dose escalation study|"In a 3 + 3 cohort design, three patients are initially enrolled into a given dose cohort. If there is no DLT observed in any of the first three subjects, the trial proceeds with enrolling additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in >1 of 6 subjects in a specific dose cohort will determine the MTD and no further dose escalation is done.
~Dose Level/TTI-101 (mg/kg/day) administered in divided doses every 12 hours 1/3.2 2/6.4 3/12.8 4/25.6 5/To be determined and approved through the amended protocol
~At the end of the dose escalation phase of the study, the investigators will determine the characteristics of the patients who will be enrolled at the expansion phase of the study."
11227297|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.
~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
~Procedure: Carotid Artery Stenting"
11227298|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
11227299|NCT03195660|Experimental|ASV Therapy|ASV Therapy
11227300|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
11227301|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
11227302|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.
~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
11227303|NCT03195621|Experimental|Interventional therapy group|
11227304|NCT03195621|No Intervention|Conservative treatment group|
11227305|NCT03195608|Experimental|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
11227306|NCT03195608|Active Comparator|Control|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, participants will drive the scenario and receive feedback from a trained evaluator regarding their live performance. No lane change assistance system will be utilized. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world.
11227307|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
11227308|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
11227309|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.
~Parallel radiograph will be taken after the surgery"
11227310|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.
~Parallel radiograph will be taken after the surgery"
11227311|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
11227312|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
11227313|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
11227314|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
11227315|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
11227316|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
11227317|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
11227350|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
11227318|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.
~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.
~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
11227319|NCT03195517|No Intervention|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
11227320|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
11227321|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
11227322|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
11227323|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|Specified Dose of Nivolumab and Ipilimumab on specified days
11227324|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
11227325|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
11227326|NCT03195478|Experimental|Nivo/Ipi Combination Arm D|Specified dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
11227327|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
11227328|NCT03195452|Experimental|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
11227329|NCT03195439|Experimental|patients in ICU|
11227330|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.
~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.
~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
11227331|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
11227332|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
11227333|NCT03195400||CC Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 obese CC adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20.
11227334|NCT03195400||TT Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 TT subjects will be enrolled in this group. An anticipated 50 obese TT adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will be enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20
11227335|NCT03195387|Experimental|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
11227336|NCT03195387|Experimental|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
11227337|NCT03195387|Experimental|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
11227338|NCT03195387|Placebo Comparator|Placebo|MMV390048 placebo
11227339|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
11227340|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
11227341|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
11227342|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
11227343|NCT03195322|Experimental|Pre-pectoral Tissue Expander|Pre-pectoral immediate tissue expander breast reconstruction with complete AlloDerm® coverage to reinforce breast tissues.
11227344|NCT03195309|Active Comparator|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
11227345|NCT03195309|Active Comparator|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
11227346|NCT03195309|Active Comparator|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
11227347|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
11227348|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
11227359|NCT03195231|Experimental|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
11227360|NCT03195231|Placebo Comparator|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
11227361|NCT03195218|Experimental|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
11227362|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
11227363|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
11227364|NCT03195179||Suprapubic tube placement|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will have a suprapubic tube placed to manage the acute urethral injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
11227365|NCT03195179||Urethral realignment|Standard of care management for men with complete urethral injuries where a Foley catheter fails to be placed will undergo urethral realignment with a combined antegrade / retrograde approach within 7 days of injury. This is a standard of care approach and a retrospective review will be done on the patient record to determine outcomes.
11227366|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
11227367|NCT03195153|Experimental|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
11227368|NCT03195153|Experimental|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
11227369|NCT03195153|Experimental|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
11227370|NCT03195140|Experimental|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
11227371|NCT03195140|No Intervention|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
11227372|NCT03195127|Experimental|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
11227373|NCT03195127|No Intervention|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
11227374|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
11227375|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
11227376|NCT03195088|Experimental|Active Treatment|Single rising doses of BI drug
11227377|NCT03195088|Placebo Comparator|Placebo|Matching volumes of drug-free solution
11227378|NCT03195075|Active Comparator|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
11227379|NCT03195075|Active Comparator|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
11227380|NCT03195062|Experimental|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
11227381|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
11227382|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
11227383|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
11227384|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
11227385|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
11227386|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
11227387|NCT03195010|Experimental|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
11227388|NCT03195010|Experimental|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
11227389|NCT03194997|Experimental|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
11227390|NCT03194997|Experimental|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
11227423|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
11227424|NCT03194789|Active Comparator|Traditional Pelvic Floor Therapy|up to six sessions, with one session every alternate week.
11227391|NCT03194997|No Intervention|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. Also, this group will be invited to three meeting during the 16 weeks of intervention, the first meeting will focus on stretching exercise to develop at home, a second meeting will be about self-esteem and the last meeting will be about prevented of lymphedema. The women in this group will not receive a dance or pilates intervention.
11227392|NCT03194984|Other|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
11227393|NCT03194984|Other|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
11227394|NCT03194971||TTField at Recurrence|
11227395|NCT03194971||TTField at New Diagnosis|
11227396|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
11227397|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
11227398|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
11227399|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
11227400|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
11227401|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
11227402|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
11227403|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
11227404|NCT03194932|Experimental|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.
~Note: Part 1 has been completed.
~Two expansion cohorts will be enrolled:
~Cohort A will be a group of 12 participants receiving the recommended phase 2 doses (RP2D) of venetoclax plus cytarabine.
~Cohort B will be a group of 12 participants receiving the RP2D of venetoclax plus cytarabine and idarubicin.
~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia.
~Cohort C: Participants will receive venetoclax PO on days 1-21, azacitidine IV on days 1-7, and cytarabine Q12H on days 8-11."
11227405|NCT03194919|Experimental|Negotiating quit date|Endre: a digital smoking cessation counsellor
11227406|NCT03194919|Active Comparator|Preset quit date|Endre: a digital smoking cessation counsellor
11227407|NCT03194906|Active Comparator|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
11227408|NCT03194906|Placebo Comparator|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
11227409|NCT03194893|Experimental|Alectinib|Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
11227410|NCT03194893|Experimental|Crizotinib|Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
11227411|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
11227412|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.
~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
11227413|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.
~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
11227414|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
11227415|NCT03194854|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
11227416|NCT03194854|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
11227417|NCT03194841|Experimental|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
11227418|NCT03194828|Active Comparator|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
11227419|NCT03194828|Experimental|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
11227420|NCT03194815|Active Comparator|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
11227421|NCT03194815|Placebo Comparator|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
11227422|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
11229317|NCT03181828|No Intervention|Non- AHA|
11227425|NCT03194789|Experimental|FGBMM plus Traditional pelvic floor therapy|Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
11227426|NCT03194776|Experimental|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
11227427|NCT03194776|Placebo Comparator|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
11227428|NCT03194750|Experimental|Share Data|
11227429|NCT03194750|Active Comparator|Do Not Share Data|
11227430|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
11227431|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
11227432|NCT03194724||High Vitamin A exposure|There was no intervention
11227433|NCT03194724||Low vitamin A exposure|No intervention
11227434|NCT03194711||Patients with stable CAD|
11227435|NCT03194698|Experimental|MGX and Intense Pulsed Light Treatment (IPL)|Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
11227436|NCT03194698|Active Comparator|Meibomian Gland Expression (MGX)|Treatment with 4 visits and 4 treatments of MGX only
11227437|NCT03194685|Experimental|Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227438|NCT03194685|Experimental|Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227439|NCT03194685|Experimental|Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227440|NCT03194685|Experimental|Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227441|NCT03194685|Experimental|Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227442|NCT03194685|Experimental|Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227443|NCT03194685|Experimental|Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227444|NCT03194685|Experimental|Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227445|NCT03194685|Experimental|Cohort 20: 50 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227446|NCT03194685|Experimental|Cohort 21: 75 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227447|NCT03194685|Experimental|Cohort 22: 100 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
11227448|NCT03194672|Experimental|Intervention Condition|"This experimental condition has three major components:
~Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.
~Transportation assistance for medical home appointments.
~Electronic Prompts/Reminders to Encourage Completion of Goals."
11227449|NCT03194672|No Intervention|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.
~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
11227450|NCT03194659|No Intervention|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
11227451|NCT03194659|Experimental|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the experimental arm of the trial, supplemental choline chloride will be added to the cocktail.
11227452|NCT03194646|Experimental|A1(3/1 regimen)|2.0 mg treatment of 12 weeks, each separated by 1 bleeding break
11227453|NCT03194646|Experimental|A2(6/2 regimen)|2.0 mg treatment period of 24 weeks, each separated by 2 bleeding break
11227454|NCT03194646|Experimental|A3(3/2 regimen)|2.0 mg treatment period of 12 weeks, each separated by 2 bleeding break
11227455|NCT03194646|Other|B(Standard of care)|Standard of care as determined by the investigators, this could be watch& wait or non-hormonal medical treatment
11227456|NCT03194633||Nifedipine controlled-release tablets(Adalat, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) will be enrolled.
11227457|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
11227458|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
11227459|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
11227460|NCT03194620|Experimental|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
11227461|NCT03194620|Experimental|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
11227462|NCT03194620|Active Comparator|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
11227463|NCT03194620|Experimental|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
11227464|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
11227465|NCT03194607||Patients|
11227466|NCT03194607||Controls|
11227467|NCT03194594|Active Comparator|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
11227799|NCT03192176|Experimental|Low dose ESN364 + Placebo|ESN364 low dose once daily (QD) + placebo QD, oral, 12 weeks
11227468|NCT03194594|Active Comparator|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
11227469|NCT03194594|Experimental|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
11227470|NCT03194568|Experimental|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
11227471|NCT03194555|Experimental|ALLOD-2 capsules|Component A and Component B
11227472|NCT03194555|Placebo Comparator|Placebo capsules|Placebo for Component A and Placebo for Component B
11227473|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
11227474|NCT03194529|Experimental|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
11227475|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
11227476|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
11227477|NCT03194490|Experimental|The combined intervention group|The combined intervention group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
11227478|NCT03194490|Active Comparator|The standard intervention|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
11227479|NCT03194477|Experimental|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
11227480|NCT03194477|No Intervention|Control - SOC Case Management|Standard of care (SOC) case management.
11227481|NCT03194464|Experimental|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
11227482|NCT03194438|Experimental|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
11227483|NCT03194425|Experimental|OAB|Patients with overactive bladder on sacral neuromodulation.
11227484|NCT03194425|Experimental|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
11227485|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
11227486|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
11227487|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
11227488|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
11227489|NCT03194412|No Intervention|Control group|Without intervention
11227490|NCT03194399|Experimental|Breast cancer patients|
11227491|NCT03194386|No Intervention|Control|usual care
11227492|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
11227493|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
11227494|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:
~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
11227495|NCT03194360||delirium group|
11227496|NCT03194360||nondelirium group|
11227497|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
11227498|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
11227499|NCT03194334|Experimental|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
11227500|NCT03194321|Experimental|Tacrolimus extended release arm|All patients will receive tacrolimus extended-release adjusted to target trough levels, mycophenolate mofetil or mycophenolate sodium, and prednisone per CSMC practice.
11227501|NCT03194308|Other|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
11227502|NCT03194295|Experimental|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
11227503|NCT03194295|Active Comparator|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
11227546|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
11227504|NCT03194282|Experimental|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
11227505|NCT03194282|Sham Comparator|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
11227506|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
11227507|NCT03194256|Active Comparator|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
11227508|NCT03194256|Experimental|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
11227509|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
11227510|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
11227511|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
11227512|NCT03194217|Experimental|BEN-2001, 0.5mg|Experimental treatment
11227513|NCT03194217|Placebo Comparator|Placebo|Placebo comparator
11227514|NCT03194217|Experimental|BEN-2001, 1.0mg|Experimental treatment
11227515|NCT03194217|Experimental|BEN-2001, 3.0mg|Experimental treatment
11227516|NCT03194204|Active Comparator|RA patients treated with methotrexate|"Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .
~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
11227517|NCT03194204|Active Comparator|RA patients treated with methotrexate plus doxycycline|"Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.
~Cardiac assessment :
~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
11227518|NCT03194191|Experimental|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
11227519|NCT03194191|Sham Comparator|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
11227520|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
11227521|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
11227522|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
11227523|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
11227524|NCT03194139|Experimental|Sentinel Cohort|
11227525|NCT03194139|Experimental|Crossover Design|
11227526|NCT03194126|Experimental|Mifepristone + Misoprostol OR oxytocine + laminaria|
11227527|NCT03194126|Other|Mifepristone + Misoprostol OR oxytocine|
11227528|NCT03194113|Active Comparator|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
11227529|NCT03194113|Active Comparator|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
11227530|NCT03194113|Active Comparator|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
11227531|NCT03194100||Diabetes Mellitus|
11227532|NCT03194100||Prediabetes|
11227533|NCT03194100||Normal glucose tolerance|
11227534|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
11227535|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
11227536|NCT03194061|Experimental|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
11227537|NCT03194048|Experimental|Functional Chewing Training|Children with CP and have tongue thrust included this group.
11227538|NCT03194048|Active Comparator|Control|Children with CP and have tongue thrust included this group.
11227539|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
11227540|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
11227541|NCT03193996|Other|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
11227542|NCT03193983|Experimental|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
11227543|NCT03193983|Experimental|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
11227544|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
11227545|NCT03193957|Experimental|SB4|SB4 (etanercept) 50 mg/mL
11227547|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
11227548|NCT03193931|Experimental|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
11227549|NCT03193931|Active Comparator|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
11227550|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
11227551|NCT03193905|Other|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
11227552|NCT03193905|Other|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
11227553|NCT03193879||COPD group|COPD patients
11227554|NCT03193879||Asthma group|Asthma patients
11227555|NCT03193879||Health group|Healthy volunteers
11227556|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
11227557|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
11227558|NCT03193827|Experimental|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
11227559|NCT03193827|Active Comparator|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
11227560|NCT03193814|Experimental|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
11227561|NCT03193801|Experimental|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
11227562|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment
~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
11227563|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
11227564|NCT03193775|Active Comparator|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.
~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
11227565|NCT03193775|No Intervention|control group|A control group (n=100) did not receive HBV vaccine
11227566|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
11227567|NCT03193749|Experimental|Amiodarone Hydrochloride|Oral treatment for at least 6 months
11227568|NCT03193749|Placebo Comparator|Placebo|Oral treatment for at least 6 months
11227569|NCT03193736|Experimental|implant|
11227570|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
11227571|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
11227572|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
11227573|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
11227574|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
11227575|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
11227576|NCT03193684|Experimental|Treatment|dapagliflozin 10 mg per day
11227577|NCT03193684|Placebo Comparator|control|matching placebo 1 pill per day
11227578|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
11227579|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
11227580|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
11227581|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
11227582|NCT03193658|Active Comparator|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
11227583|NCT03193658|Active Comparator|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid & acetaminophen) only.
11227584|NCT03193645||Degarelix|
11227585|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
11227586|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
11227587|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
11227588|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
11227589|NCT03193593|Placebo Comparator|Placebo Injections|"Intervention: Drug: Placebo
~Single Saline Injection into the Pectoralis Muscle"
11227590|NCT03193593|Active Comparator|EB-001 Dose 1|"Intervention: Drug: EB-001
~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
11227591|NCT03193593|Active Comparator|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001
~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
11227592|NCT03193593|Active Comparator|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001
~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
11227593|NCT03193593|Active Comparator|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001
~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
11227594|NCT03193593|Active Comparator|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001
~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
11227595|NCT03193593|Active Comparator|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001
~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
11227596|NCT03193580|Experimental|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
11227597|NCT03193580|Experimental|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
11227598|NCT03193580|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
11227599|NCT03193567|Experimental|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
11227600|NCT03193502|Experimental|Portal Vein thrombosis|rivaroxaban
11227601|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
11227602|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
11227603|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
11227604|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
11227605|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
11227606|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
11227607|NCT03193437|Experimental|Selinexor|Open Label Selinexor 40 mg
11227608|NCT03193424|Experimental|Apatinib|
11227609|NCT03193424|Active Comparator|docetaxel|
11227610|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
11227611|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
11227612|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
11227613|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
11227614|NCT03193385||Closed reduction|
11227615|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
11227616|NCT03193359|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
11227617|NCT03193346|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
11227618|NCT03193346|Placebo Comparator|Placebo|Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.
11229415|NCT03181178|Active Comparator|Nutrition Education Only|Nutrition Education
11227619|NCT03193333|Experimental|PRO-122 group|"To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.
~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.
~Pharmaceutical form: Ophthalmic solution
~Made by: Laboratorios Sophia, S.A. de C.V.
~Posology: 1 drop every 12 hours for 90 days
~Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free
~Package description: 5 m multidose dropper bottle.
~Placebo (for
~Two pieces of approved placebo. Administered in 2 multidose dropper bottles.
~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
11227620|NCT03193333|Active Comparator|Concomitant triple therapy group|"Imot Ofteno
~Drug substance: Timolol 5 mg/mL
~Pharmaceutical form: Ophthalmic solution
~Made by Laboratorios Sophia S.A. de C.V.
~Alphagan
~Drug substance Brimonidine 2 mg/mL
~Pharmaceutical form: Ophthalmic solution
~Made by: Allergan, Inc.
~Trusopt
~Drug substance: Dorzolamide 20 mg/mL
~Pharmaceutical form: Ophthalmic solution
~Made by: Merck Sharp and Dohme Corp.
~Posology: 1 drop every 12 hours for 90 days"
11227621|NCT03193333|Active Comparator|Krytantek Ofteno Group|"To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.
~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.
~Pharmaceutical form: Ophthalmic solution
~Made by: Laboratorios Sophia, S.A. de C.V.
~Posology: 1 drop every 12 hours for 90 days
~Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.
~Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.
~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
11227622|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
11227623|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
11227624|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
11227625|NCT03193307|Experimental|All subjects|Microgynon alone (run in period) then Microgynon & BI 409306 treatment period
11227626|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
11227627|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
11227628|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).
~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.
~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
11227629|NCT03193268|Experimental|High intensity agility group|Exercise therapy
11227630|NCT03193268|Experimental|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
11227631|NCT03193268|No Intervention|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
11227632|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
11227633|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
11227634|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
11227635|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
11227636|NCT03193242|Experimental|Intervention|"Electronic Asthma Management System: eAMS Intervention
~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
11227637|NCT03193242|No Intervention|Control|"Electronic Asthma Management System: eAMS - Control
~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
11227654|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab|Cohort 1: Participants will receive Tocilizumab 8 mg/kg IV infusion on Day 1 of each 28 day cycle; Atezolizumab 1680 mg IV infusion on Day 1 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
11227638|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
11227639|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
11227640|NCT03193216|Experimental|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
11227641|NCT03193203|Experimental|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
11227642|NCT03193203|Experimental|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
11227643|NCT03193190|Active Comparator|Cohort 1: Control (Nab-Paclitaxel and Gemcitabine)|"Cohort 1: Participants will receive Nab-Paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
~Participants in the Cohort 1 control arm who experience disease progression will be given the option of enrolling into Cohort 2 (if open for enrollment), provided they meet eligibility criteria."
11227644|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Selicrelumab 16 mg subcutaneous injection on Day 1 of Cycles 1-4 and every third cycle thereafter (i.e. Cycles 7, 10, 13 etc.) of each 28-day cycle.
11227645|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Bevacizumab 10 mg/kg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
11227646|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + AB928|Cohort 1: Participant will receive AB928 150 mg orally once daily on Days 1 to 28 of each 28 day cycle; Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
11227647|NCT03193190|Experimental|Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab|Cohort 1: Participants will receive Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28 day cycle; Tiragolumab 420 mg IV infusion on Days 1 and 15 of each 28 day cycle; Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
11227648|NCT03193190|Experimental|Cohort 2: Atezolizumab + Cobimetinib|"Cohort 2: Participants will receive Cobimetinib 60 milligrams (mg) once daily orally on Days 1-21 of each 28-day cycle; and Atezolizumab 840 mg IV infusion on Days 1 and 15 of each 28-day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arm is open for enrollment."
11227649|NCT03193190|Experimental|Cohort 2: Atezolizumab + PEGPH20|"Cohort 2: Participants will receive PEGPH20 3 micrograms per kilogram (mcg/kg) IV infusion on Days 1, 8 and 15 of each 21-day cycle; and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
11227650|NCT03193190|Experimental|Cohort 2: Atezolizumab + BL-8040|"Cohort 2: Participants will receive BL-8040 1.25 milligrams per kilogram (mg/kg) subcutaneously (SC) on Days 1-5 of the first week, followed by combination treatment consisting of BL-8040 1.25 mg/kg SC three times a week on non-consecutive days and Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
11227651|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 2 weeks|"Cohort 2: Participants will receive Atezolizumab 840 mg IV infusion on days 1 and 15 of each 28 day cycle; RO6874281 will be administered 10 mg by IV infusion on day 1 and 15 mg on days 8, 15, and 22 for cycle 1 (28 day cycle). RO6874281 will be administered 15 mg by IV infusion on days 1 and 15 of each subsequent 28 day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
11227652|NCT03193190|Experimental|Cohort 2: Atezolizumab + RO6874281 every 3 weeks|"Cohort 2: Participants will receive Atezolizumab 1200 mg IV infusion on Day 1 of each 21 day cycle; and RO6874281 10 mg by IV infusion on day 1 of each 21 day cycle.
~Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib, provided they meet the eligibility criteria and the arm is open for enrollment."
11227653|NCT03193190|Active Comparator|Cohort 2: Control (Nab-Paclitaxel and Gemcitabine or mFOLFOX6)|"Cohort 2: Participants who progressed on a prior fluoropyrimidine-based regimen will receive Nab-paclitaxel 125 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle; and Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28 day cycle.
~Participants who progressed on a prior gemcitabine-based regimen will receive 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Participants will receive Oxaliplatin 85 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Leucovorin 400 mg/m^2 IV on Days 1 and 15 of each 28 day cycle; Fluorouracil 400 mg/m^2 IV push on Days 1 and 15 of each 28 day cycle; and Fluorouracil 2400 mg/m^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28 day cycle.
~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Cobimetinib or Atezolizumab + RO6874281 treatment, provided they meet the eligibility criteria and the arms are open for enrollment."
11227655|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
11227656|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
11227657|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
11227658|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
11227659|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
11227660|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
11227661|NCT03193099|Other|Premanifest HTT mutation carriers|
11227662|NCT03193099|Other|non HTT mutation carriers|
11227663|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
11227664|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.
~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.
~Iron study at time of diagnosis and 3 months after treatment .
~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.
~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
11227665|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.
~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.
~Pre-transplant full blood count serial measures every / 3 months for 2 years.
~Pre transplant serum Iron study and annually for 2 years.
~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.
~Post-transplant serum FGF-23 (as independent risk factor) at 6months.
~Different immunosuppressive protocols.
~Pre-transplant panel reactive antibody,donor-specific antibody"
11227666|NCT03193047|Experimental|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
11227667|NCT03193047|Placebo Comparator|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
11227668|NCT03193034|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
11227669|NCT03193021|Experimental|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
11227670|NCT03193021|Active Comparator|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
11227671|NCT03192995|Active Comparator|lorcaserin|
11227672|NCT03192995|Placebo Comparator|Placebo|
11227673|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
11227674|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.
~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
11227675|NCT03192969|Experimental|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
11227676|NCT03192969|Placebo Comparator|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
11227677|NCT03192969|Placebo Comparator|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
11227678|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
11227679|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
11227680|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
11227681|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
11227682|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
11227683|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
11227684|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
11227685|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
11227686|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
11227687|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.
~Diaphragmatic paralysis will be defined using ultrasounds."
11227688|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
11227689|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
11227690|NCT03192852|Experimental|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
11227691|NCT03192852|Experimental|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
11227692|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
11227693|NCT03192839|Experimental|Low dose PUFA|
11227694|NCT03192839|Experimental|High dose PUFA|
11227695|NCT03192839|Placebo Comparator|Placebo|
11227696|NCT03192826|Active Comparator|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
11227697|NCT03192826|Active Comparator|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
11227698|NCT03192826|Placebo Comparator|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
11227699|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
11227700|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
11227701|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
11227702|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
11227703|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
11227704|NCT03192735|Experimental|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
11227705|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
11227706|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
11227707|NCT03192722|Other|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
11227708|NCT03192722|Other|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
11227709|NCT03192709|Experimental|A|Sildenafil vaginal suppositories users
11227710|NCT03192709|Placebo Comparator|B|Daily vaginal placebo users with HMG administration
11227711|NCT03192709|Placebo Comparator|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
11227712|NCT03192696|Experimental|Treatment Cohort|Atherectomy of in-stent restenosis
11227713|NCT03192683|Active Comparator|Regular sling|
11227714|NCT03192683|Experimental|Cast-sling|
11227715|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
11227716|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.
~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.
~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
11227717|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.
~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.
~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
11227718|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.
~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.
~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
11227719|NCT03192657|Experimental|Basiliximab group|"Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.
~Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.
~Steroids: 1mg/kg/d, calculated with prednisone."
11227720|NCT03192657|Active Comparator|control group|"Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.
~Steroids: 1mg/kg/d, calculated with prednisone."
11227721|NCT03192644|Experimental|Group A (TAI)|
11227722|NCT03192644|Active Comparator|Group B (TACE)|
11227723|NCT03192631|Experimental|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
11227724|NCT03192631|No Intervention|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
11227725|NCT03192618|Experimental|treatment group|
11227726|NCT03192618|No Intervention|control group|
11227727|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
11227728|NCT03192605|Placebo Comparator|Placebo|Placebo control
11227729|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
11227730|NCT03192579|Experimental|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
11227731|NCT03192579|Active Comparator|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
11227732|NCT03192566|Experimental|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:
~children < 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children > or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
11227733|NCT03192553|Experimental|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
11227734|NCT03192553|Experimental|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
11227735|NCT03192553|Experimental|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
11227736|NCT03192553|Other|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
11227737|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
11227738|NCT03192527|Experimental|Arm A|KN015, Triptorelin
11227739|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
11227740|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
11227741|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
11227742|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
11227743|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
11227744|NCT03192488|Experimental|Cetirizine/Hypoxia|Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
11227745|NCT03192488|Placebo Comparator|Placebo/Normoxia|Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
11227746|NCT03192488|Placebo Comparator|Placebo/Hypoxia|Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
11227747|NCT03192475|Active Comparator|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
11227748|NCT03192475|Placebo Comparator|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
11227749|NCT03192462|Experimental|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
11227750|NCT03192462|Experimental|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
11227751|NCT03192462|Experimental|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
11227752|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
11227753|NCT03192436|Active Comparator|Real Ultrasound|The subjects will receive real ultrasound intervention.
11227754|NCT03192436|Sham Comparator|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
11227755|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
11227756|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
11227757|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
11227758|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.
~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.
~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
11227759|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
11227760|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
11227761|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
11227762|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
11227763|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
11227764|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
11227765|NCT03192345|Experimental|Dose Escalation SAR439459 monotherapy|SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses
11227766|NCT03192345|Experimental|Dose Expansion SAR439459 monotherapy|SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses
11227767|NCT03192345|Experimental|Dose Escalation SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab
11227768|NCT03192345|Experimental|Dose Expansion SAR439459 + cemiplimab combination|SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab
11227769|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
11227770|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
11227771|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
11227772|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
11227773|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
11227774|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
11227775|NCT03192306|Active Comparator|Merlin|glycolic acid and ethanol mixture
11227776|NCT03192306|Placebo Comparator|Ethanol|
11227777|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:
~Metformin: 850mg (one tablet) twice a day
~Simvastatin: 20mg (one tablet) once every night
~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:
~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.
~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
11227778|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.
~Images of the treated area will be captured using multiple medical devices."
11227779|NCT03192267||No treatment|No treatment
11227780|NCT03192254|Active Comparator|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
11227781|NCT03192254|Experimental|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
11227782|NCT03192254|Experimental|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
11227783|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
11227784|NCT03192241|Active Comparator|book|Mothers provided with a children's book
11227785|NCT03192215|Experimental|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
11227786|NCT03192215|Active Comparator|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
11227787|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
11227788|NCT03192202|Experimental|Cohort 2|1.5 mg/kg of AFM13 three times per week for weeks 1-8.
11227789|NCT03192202|Experimental|Cohort 3|0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
11227790|NCT03192202|Experimental|Cohort 4|1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
11227791|NCT03192202|Experimental|Cohort 5|7.0 mg/kg of AFM13 once weekly for weeks 1-8.
11227792|NCT03192202|Experimental|Cohort 6|4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
11227793|NCT03192189||Patients with acute kidney injury|Requiring treatment with dialysis
11227794|NCT03192176|Experimental|Lowest dose ESN364|ESN364 lowest dose twice daily (BID), oral, 12 weeks
11227795|NCT03192176|Placebo Comparator|Placebo|Placebo BID, oral, 12 weeks
11227796|NCT03192176|Experimental|Low dose ESN364|ESN364 low dose BID, oral, 12 weeks
11227800|NCT03192176|Experimental|Medium dose ESN364 + Placebo|ESN364 medium dose QD + placebo QD, oral, 12 weeks
11227801|NCT03192176|Experimental|Highest dose ESN364 + Placebo|ESN364 highest dose QD + placebo QD, oral, 12 weeks
11227802|NCT03192163||ResearchMatch Group|
11227803|NCT03192163||Northwestern Center for Ethnic Skin Group|
11227804|NCT03192150|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
11227805|NCT03192150|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
11227806|NCT03192137|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
11227807|NCT03192137|Placebo Comparator|Vehicle|DuraSite® 2 Vehicle
11227808|NCT03192111|Experimental|Mild Renal Impairment|Subjects with mild renal impairment
11227809|NCT03192111|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment
11227810|NCT03192111|Experimental|Severe Renal Impairment|Subjects with severe renal impairment
11227811|NCT03192111|Experimental|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
11227812|NCT03192098|Experimental|Progressive|Patients will be dilated > 3mm and can be dilated up to 6mm in diameter
11227813|NCT03192098|Active Comparator|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
11227814|NCT03192085|Other|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
11227815|NCT03192085|Active Comparator|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
11227816|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
11227817|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
11227818|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
11227819|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
11227820|NCT03192033|Other|Arterial closure device used is Proglide® (Abbott)|
11227821|NCT03192033|Other|Arterial closure device used is Femoseal® (Terumo)|
11227822|NCT03192020|Active Comparator|Percutaneous needle fasciotomy|
11227823|NCT03192020|Active Comparator|Collagenase clostridium histolyticum|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times.
11227824|NCT03192020|Active Comparator|Limited fasciectomy|
11227825|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
11227826|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
11227827|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
11227828|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
11227829|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
11227830|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
11227831|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
11227832|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
11227833|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
11227834|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
11227835|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
11227836|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
11227837|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
11227838|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
11227839|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
11227840|NCT03191916|Experimental|Experimental group|The experimental group will receive 2 milliamps of anodal transcranial direct current stimulation for 20 minutes daily for 5 days.
11227841|NCT03191916|Sham Comparator|Sham group|The sham group will be connected to the anodal transcranial direct current stimulation device daily for 5 days. During the 20 minute sessions, the participant will only receive stimulation for a 30-second ramp up period, at which point the stimulation will be discontinued for the remainder of the time.
11227842|NCT03191903|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
11227843|NCT03191903|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
11227844|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
11227845|NCT03191877|Experimental|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
11227846|NCT03191877|Active Comparator|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.
~Women in this group will not receive either coffee."
11227847|NCT03191877|No Intervention|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
11227848|NCT03191864|Experimental|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
11227849|NCT03191864|Experimental|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
11227850|NCT03191864|Experimental|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
11227851|NCT03191864|Experimental|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
11227852|NCT03191864|Placebo Comparator|Placebo BID|Placebo 30 minutes after breakfast and HS
11227853|NCT03191851|Active Comparator|Standard Device|Standard device
11227854|NCT03191851|Experimental|Melody Device|Melody device without Pump
11227855|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
11227856|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
11227857|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
11227858|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
11227859|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
11227860|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
11227861|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
11227862|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
11227863|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
11227864|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
11227865|NCT03191799|Experimental|Emicizumab|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
11227866|NCT03191786|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
11227867|NCT03191786|Active Comparator|Single Agent Chemotherapy (Vinorelbine or Gemcitabine)|Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
11227868|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
11227869|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
11227870|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
11227871|NCT03191721|Experimental|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
11227872|NCT03191721|Placebo Comparator|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
11227873|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
11227874|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
11227875|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
11227876|NCT03191630|Experimental|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
11227877|NCT03191630|Experimental|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
11227878|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
11227879|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
11227880|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
11227881|NCT03191591|Experimental|First 1,000 Days Program|
11227882|NCT03191578|Experimental|RUTI® injection|
11227883|NCT03191578|Placebo Comparator|Sodium Chloride 0.9% injection|
11227884|NCT03191565|Experimental|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
11227885|NCT03191565|Active Comparator|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
11227886|NCT03191552|Experimental|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.
~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
11227887|NCT03191552|Experimental|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
11227888|NCT03191552|Active Comparator|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
11227889|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
11227890|NCT03191526|Experimental|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
11227891|NCT03191526|Placebo Comparator|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
11227892|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
11227893|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
11227894|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
11227895|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
11227896|NCT03191487|Experimental|ChimioPal|Systematic collection of clinical and laboratory toxicities.
11227897|NCT03191487|Active Comparator|Standard|The usual management and logistic pathways will be respected.
11227898|NCT03191474|No Intervention|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
11227899|NCT03191474|Experimental|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
11227900|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
11227901|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
11227902|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.
~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
11227903|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
11227904|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
11227905|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
11229416|NCT03181178|No Intervention|Growth Monitoring Only|Growth monitoring
11227906|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
11227907|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
11227908|NCT03191396|Experimental|Semaglutide|Half the study participants are randomised to receive semaglutide
11227909|NCT03191396|Active Comparator|Liraglutide|Half the study participants are randomised to receive liraglutide
11227910|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
11227911|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
11227912|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
11227913|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
11227914|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
11227915|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
11227916|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
11227917|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
11227918|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
11227919|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
11227920|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
11227921|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
11227922|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.
~no intervention/Observational"
11227923|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.
~no intervention/Observational"
11227924|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.
~no intervention/Observational"
11227925|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).
~no intervention/Observational"
11227926|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
11227927|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
11227928|NCT03191331|Experimental|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
11227929|NCT03191331|No Intervention|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
11227930|NCT03191318|Active Comparator|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
11227931|NCT03191318|Active Comparator|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
11227932|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
11227933|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
11227934|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
11227935|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
11227936|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
11227937|NCT03191266|Active Comparator|active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
11227938|NCT03191266|Sham Comparator|sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
11227939|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
11228047|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
11227940|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
11227941|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
11227942|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
11227943|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
11227944|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
11227945|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
11227946|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.
~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
11227947|NCT03191188|Experimental|Levothyroxine|
11227948|NCT03191188|Placebo Comparator|Placebo|
11227949|NCT03191175||HIV patients|
11227950|NCT03191175||Control patients|
11227951|NCT03191162|Active Comparator|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
11227952|NCT03191162|Experimental|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
11227953|NCT03191162|Experimental|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
11227954|NCT03191149|Experimental|Treatment (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11227955|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
11227956|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
11227957|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
11227958|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
11227959|NCT03191110||Colorectal cancer patients|
11227960|NCT03191097|Experimental|Ingavirin|
11227961|NCT03191097|Placebo Comparator|Placebo oral capsule|
11227962|NCT03191084|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
11227963|NCT03191084|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
11227964|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.
~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
11227965|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.
~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
11227966|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.
~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
11227967|NCT03191058|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
11227968|NCT03191058|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q.
11227969|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
11227970|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
11227971|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
11227972|NCT03191019|Experimental|Mobile-phone app for smoking cessation|"The intervention arm will receive a smoking cessation program based on a mobile-phone app. The program contains strategies to support smoking cessation, including motivational messages, tips on stress management, on how to ask support from friends and family, how to use distraction techniques and how to deal with cravings, lapses and early relapse. It also includes a saving calculator, a help button which provides extra messages in case of cravings and a lapse button, which provides advice about what to do if the participant presents lapses or relapse after being abstinent at least 24 hours."
11227973|NCT03191019|Placebo Comparator|Control mobile-phone app|The control arm will receive a mobile-phone app which will send 1 message every two weeks thanking participants for taking part in the study, and encouraging them to stay in the study for the 6 month follow-up period.
11227974|NCT03191006|Active Comparator|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
11227975|NCT03191006|No Intervention|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
11227976|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
11227977|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
11227978|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
11227979|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
11227980|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
11227981|NCT03190967|Experimental|1/Phase I|T-DM1 + TMZ in dose escalation
11227982|NCT03190967|Active Comparator|2A / Phase II / T- DMl alone|T-DM1
11227983|NCT03190967|Experimental|2B/Phase II/T- DMl + TMZ|T-DM1 + TMZ at RP2D
11227984|NCT03190954|Experimental|Methylphenidate/Placebo|Single-blind. Participants will undergo three scans with positron emission tomography (PET): one with [11C]NNC-112 to assess baseline D1R, another with [11C]raclopride after placebo to assess baseline D2R and a third one with [11C]raclopride after MP administration (60mg oral) to assess striatal DA release (assessed as the difference in specific binding of [11C]raclopride between baseline and MP). In addition, participants will undergo two imaging sessions with MRI to assess functional reactivity to drug-cues and to a measure of self-control (delayed discounting task), to assess RFC and to obtain structural brain measures (including diffusion tensor imaging, DTI). One of the sessions will be done under baseline conditions (no drug administered) and the other after MP (about one hour after the [11C]raclopride MP scan is completed). Neuropsychological tests (NP) and accelerometers will be used to assess cognitive performance and locomotor activity respectively
11227985|NCT03190954|Experimental|Placebo/Methylphenidate|Single-blind. Participants will undergo three scans with positron emission tomography (PET): one with [11C]NNC-112 to assess baseline D1R, another with [11C]raclopride after placebo to assess baseline D2R and a third one with [11C]raclopride after MP administration (60mg oral) to assess striatal DA release (assessed as the difference in specific binding of [11C]raclopride between baseline and MP). In addition, participants will undergo two imaging sessions with MRI to assess functional reactivity to drug-cues and to a measure of self-control (delayed discounting task), to assess RFC and to obtain structural brain measures (including diffusion tensor imaging, DTI). One of the sessions will be done under baseline conditions (no drug administered) and the other after MP (about one hour after the [11C]raclopride MP scan is completed). Neuropsychological tests (NP) and accelerometers will be used to assess cognitive performance and locomotor activity respectively
11227986|NCT03190941|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
11227987|NCT03190941|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
11227988|NCT03190928||1|Patients with grades 1-2 or 3a follicular lymphoma (FL)
11227989|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11227990|NCT03190902|Experimental|specific computer training (ST) - POMS|
11227991|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
11227992|NCT03190902|Experimental|specific computer training (ST) - ADHD|
11227993|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
11227994|NCT03190889|No Intervention|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
11227995|NCT03190889|Other|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
11227996|NCT03190889|Experimental|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
11227997|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
11227998|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
11227999|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
11228000|NCT03190863|Experimental|Motor imagery combined with neurofeedback (MINF)|
11228001|NCT03190863|Active Comparator|Motor imagery (MI)|
11228002|NCT03190863|Sham Comparator|Control (C)|
11228003|NCT03190850|Experimental|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
11228004|NCT03190850|Placebo Comparator|Control|Control: Exercises without load
11228005|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
11228006|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
11228007|NCT03190811|Active Comparator|Anti-PD-1 alone|
11228008|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
11228009|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
11228048|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
11229638|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
11228010|NCT03190785|Experimental|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
11228011|NCT03190772|Experimental|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
11228012|NCT03190772|Placebo Comparator|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
11228013|NCT03190772|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
11228014|NCT03190746||No SNP|Subjects have two copies of the wild type gene
11228015|NCT03190746||SNP present|Subjects have one or two copies of the SNP
11228016|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
11228017|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
11228018|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
11228019|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
11228020|NCT03190707|Experimental|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
11228021|NCT03190707|No Intervention|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
11228022|NCT03190694|Experimental|Dapagliflozin 10mg Tablet|10 mg Green, plain, diamond shaped, film coated tablet (orally)
11228023|NCT03190694|Placebo Comparator|Placebo Matching Dapagliflozin Tablet|Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient
11228024|NCT03190681|Experimental|methylphenidate|
11228025|NCT03190681|Placebo Comparator|inactive pill|
11228026|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
11228027|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
11228028|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
11228029|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
11228030|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
11228031|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
11228032|NCT03190629|Active Comparator|High-flux hemodialysis|3 times per week
11228033|NCT03190629|Experimental|On line-hemodiafiltration|3 times per week
11228034|NCT03190616|Experimental|drug,apatinib|apatinib 500mg/qd, 28d/cycle
11228035|NCT03190603|Experimental|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
11228036|NCT03190590|Active Comparator|Transcranial direct current stimulator (tDCS)|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
11228037|NCT03190590|Active Comparator|Transcranial magnetic stimulation (TMS)|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability.]
11228038|NCT03190590|Placebo Comparator|Sham-tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
11228039|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
11228040|NCT03190551|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
11228041|NCT03190551|Active Comparator|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
11228042|NCT03190525||Multiple Myeloma patients|
11228043|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
11228044|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.
~Intervention: The Psychological questionnaires were filled."
11228045|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
11228046|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
11229639|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
11228049|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
11228050|NCT03190473|Experimental|Svelte|
11228051|NCT03190473|Active Comparator|Control|
11228052|NCT03190460|Experimental|Intervention|
11228053|NCT03190460|Other|Education|
11228054|NCT03190447|Active Comparator|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
11228055|NCT03190447|Experimental|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
11228056|NCT03190447|Experimental|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
11228057|NCT03190447|Experimental|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
11228058|NCT03190447|Experimental|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
11228059|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
11228060|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
11228061|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
11228062|NCT03190408||Shock|
11228063|NCT03190395|Experimental|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
11228064|NCT03190395|Active Comparator|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
11228065|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
11228066|NCT03190369|Placebo Comparator|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
11228067|NCT03190369|Experimental|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
11228068|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
11228069|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
11228070|NCT03190330|Experimental|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
11228071|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
11228072|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
11228073|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
11228074|NCT03190304|Active Comparator|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
11228075|NCT03190304|Experimental|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
11228076|NCT03190278|Experimental|Part 1: Dose Escalation|"Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified
~Dose Expansion: UCART123 administered at the selected dose determined from the dose escalation phase"
11228077|NCT03190265|Experimental|CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
11228078|NCT03190265|Experimental|Nivolumab, Ipilimumab, CRS-207|
11228079|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
11228080|NCT03190239|Experimental|Apatinib|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
11228081|NCT03190226|Experimental|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.
~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
11228082|NCT03190213|Experimental|Pembrolizumab, all patients|
11228083|NCT03190200||MRI|Subjects with healthy knees
11228084|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
11228085|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
11228086|NCT03190174|Experimental|Arm 1|"This is an open label, dose-seeking phase 1b study using a defined dose of nivolumab and escalating doses of Nab-Rapamycin (ABI-009) given intravenously.
~I. Dose Escalation Phase 1 Part of Study: The study will employ the standard cohort of three design. No intra-patient dose escalation will take place.
~II. Expansion Phase 1b Part of Study: Following dose escalation, an additional 22-28 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs."
11228087|NCT03190161|Experimental|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
11228088|NCT03190148|Other|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
11228089|NCT03190148|Other|Normal weight pregnant women|Normal weight pregnant women were investigated.
11228090|NCT03190148|Other|Obese Pregnant women|Obese pregnant women were investigated.
11228091|NCT03190135|Experimental|BOKS: 2 day per week|
11228092|NCT03190135|Experimental|BOKS: 3 day per week|
11228093|NCT03190135|No Intervention|Non-BOKS|
11228094|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
11229640|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
11228095|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
11228096|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
11228097|NCT03190070|Experimental|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
11228098|NCT03190057||Consecutive percutaneous coronary intervention|
11228099|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
11228100|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
11228101|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
11228102|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
11228103|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
11228104|NCT03190005||group 1|placebo control without medication.
11228105|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
11228106|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
11228107|NCT03190005||group 4|normo-reactive responser after clopidogrel.
11228108|NCT03190005||group 5|reaction after OPC-13013
11228109|NCT03190005||group 6|reaction after AR-C
11228110|NCT03190005||group 7|reaction after simastatin
11228111|NCT03189992|Experimental|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
11228112|NCT03189992|Placebo Comparator|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
11228113|NCT03189992|Experimental|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
11228114|NCT03189992|Placebo Comparator|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
11228115|NCT03189979|Experimental|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
11228116|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(1ml/kg) after general anesthesia
11228117|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(1ml/kg).after general anesthesia.
11228118|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
11228119|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
11228120|NCT03189940|Active Comparator|App user group|
11228121|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
11228122|NCT03189927|Experimental|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
11228123|NCT03189914|Experimental|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.
~Abraxane: 75 - 125 mg/m^2, infused once per week for 3 weeks. 1 washout week/ cycle."
11228124|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
11228125|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
11228126|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
11228127|NCT03189875||Observation|Cohort of patients with moderate-to-severe SLE
11228128|NCT03189862|Experimental|CHAMP|CHAMP, is a mastery climate motor skills interventions, that provides children the opportunity to establish behaviors that reinforces decision-making while participating in a variety of challenging movement & physical activity tasks. Duration of CHAMP is 30 min/day 4 days/week for 30 weeks. CHAMP consist of a) a 2-3 min of motor skill introductory activity that includes a group motor activity, the teaches the lesson, includes a demonstration, and understanding of developmentally appropriate learning clues b) 25 min of motor skill instruction & practice where preschoolers engage in 3-4 motor activity stations that align with the TARGET structures c) & 2-3 min motor skill closure activity that involves a review of the lesson & critical elements.
11228129|NCT03189862|No Intervention|Control - Free Play|The control/free play condition will be the preschools typical activity programs (i.e., outdoor/indoor recess) and will be implemented according to the existing procedures within the preschool centers. The centers outdoor program consist of outdoor free-play activity on a large playground area with a variety of play structures (swings, slides, ladders) that promote gross movement and activity in preschoolers. For the control condition, there will be no planned instruction nor activities provided by the classroom teachers.
11228130|NCT03189836|Experimental|ACTR707 in combination with rituximab|
11228247|NCT03188991|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
11228131|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
11228132|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
11228133|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:
~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
11228134|NCT03189797|No Intervention|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
11228135|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
11228136|NCT03189784|No Intervention|Control group|The control group will receive no intervention
11228137|NCT03189771|Experimental|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
11228138|NCT03189771|Placebo Comparator|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
11228139|NCT03189758|Experimental|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
11228140|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
11228141|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
11228142|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
11228143|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
11228144|NCT03189719|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
11228145|NCT03189719|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
11228146|NCT03189706|Experimental|Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS)|Each cycle consists of four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.
11228147|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
11228148|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
11228149|NCT03189680|Experimental|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
11228150|NCT03189680|No Intervention|Control|Parkinson's disease control group that will not receive exercise treatment.
11228151|NCT03189680|No Intervention|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
11228152|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation
~Vessel treatment with Drug-coated balloon"
11228153|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation
~Vessel treatment with additional Plain balloon angioplasty:"
11228154|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
11228155|NCT03189654||Control group|Oxygen Administration via nasal tube
11228156|NCT03189641|Experimental|Cilostazol eluting stent system (CES-1)|
11228157|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
11228158|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
11228159|NCT03189615|Experimental|Patients with mild hepatic impairment (Group1)|
11228160|NCT03189615|Experimental|Patients with moderate hepatic impairment (Group 2)|
11228161|NCT03189615|Experimental|Healthy subjects (Group 3)|
11228162|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
11228163|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
11228164|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
11228165|NCT03189563|Placebo Comparator|Placebo|placebo, tid
11228166|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
11228167|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
11228168|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
11228169|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
11228280|NCT03188757|Experimental|hyperglycaemic clamp|
11228281|NCT03188744||Group 1|Patients with CC with PFMD.
11228170|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
11228171|NCT03189537|Experimental|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
11228172|NCT03189537|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 7 days
11228173|NCT03189524|Experimental|BGB-3111|"Two regimens of BGB-3111 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and 3+3 design is adopted for the study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary anti-tumor effects of BGB-3111 in Chinese subjects with follicular lymphoma (FL) or marginal zone lymphoma (MZL)"
11228174|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
11228175|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
11228176|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
11228177|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
11228178|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
11228179|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
11228180|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
11228181|NCT03189472|Experimental|active tDCS|
11228182|NCT03189472|Sham Comparator|sham tDCS|
11228183|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.
~Completion of Home Visit Program intervention."
11228184|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.
~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
11228185|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
11228186|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.
~Completion of Caregiver Mentorship Program intervention."
11228187|NCT03189446|Experimental|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
11228188|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
11228189|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
11228190|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
11228191|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
11228192|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
11228282|NCT03188744||Group 2|Patients with CC without PFMD.
11228283|NCT03188744||Group 3|Patients without CC with PFMD.
11228284|NCT03188744||Group 4|Patients without CC without PFMD.
11228193|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
11228194|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
11228195|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
11228196|NCT03189381|Experimental|Cohort A|Standard PCI dose
11228197|NCT03189381|Experimental|Cohort B|Low PCI dose
11228198|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.
~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
11228199|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
11228200|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
11228201|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
11228202|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
11228203|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
11228204|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
11228205|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
11228206|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
11228207|NCT03189290|Active Comparator|ropivacaine|"Active Comparator: ropivacaine group
~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
11228208|NCT03189290|Placebo Comparator|placebo|"Sham Comparator: saline group
~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
11228209|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
11228210|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
11228211|NCT03189238|Placebo Comparator|Placebo|
11228212|NCT03189238|Active Comparator|PRP|
11228213|NCT03189225|Other|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
11228214|NCT03189212|Active Comparator|Usual Care Visit|
11228215|NCT03189212|Experimental|Telemedicine Visit|
11228216|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
11228217|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.
~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:
~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
11228218|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
11228219|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
11228220|NCT03189160|No Intervention|Non-treatment control group|
11228221|NCT03189147|Experimental|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
11228222|NCT03189147|Active Comparator|Debridement|Patients in this group will received debridement intervention to address their labral lesion
11228223|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
11228224|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
11228225|NCT03189108||Cohort 1|Patients with a diagnosis of malignant solid tumors
11228226|NCT03189095|Experimental|Intervention|
11228227|NCT03189095|No Intervention|Wait-List Control|
11228228|NCT03189082|Experimental|Intervention group|
11228229|NCT03189069||Patients prescribed apixaban|
11228230|NCT03189069||Patients prescribed dabigatran|
11228231|NCT03189069||Patients prescribed rivaroxaban|
11228232|NCT03189069||Patients prescribed warfarin|
11228285|NCT03188731||Pregnant Women|
11228233|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography
~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
11228234|NCT03189043|Experimental|Test|Use of antimicrobial surface
11228235|NCT03189043|No Intervention|Control|No antimicrobial surface
11228236|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
11228237|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.
~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
11228238|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.
~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
11228239|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
11228240|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
11228241|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
11228242|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
11228243|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
11228244|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
11228245|NCT03188991|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
11228246|NCT03188991|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
11230248|NCT03175549|Placebo Comparator|Placebo|Placebo pill taken orally for 14 days
11228248|NCT03188991|Experimental|Second Phase: NanoPac® at Best Dose|Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.
11228249|NCT03188978|Experimental|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
11228250|NCT03188978|Placebo Comparator|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
11228251|NCT03188965|Experimental|Dose escalation of BAY1895344 in Part A|Single-agent dose-escalation part. Part A has the objective to define the MTD and / or RP2D.
11228252|NCT03188965|Experimental|J-arm of Part A|Single-agent dose-escalation part in Japanese patients. J-arm has the objective to confirm the MTD (or RP2D) dose is safe and tolerable in Japanese patients.
11228253|NCT03188965|Experimental|Dose expansion of BAY1895344 in Part B|Single-agent expansion part. Once the MTD has been defined, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study. Once the MTD dose has been confirmed is safe and tolerable in Japanese patients, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study.
11228254|NCT03188965|Experimental|Part A.1: Single-agent dose escalation part|Part A.1 - single-agent dose escalation part with alternative dosing schedule Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations will be included.
11228255|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
11228256|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
11228257|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
11228258|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
11228259|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
11228260|NCT03188900||preeclampsia|pregnancy with preeclampsia
11228261|NCT03188900||control|pregnancy without preeclampsia
11228262|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade.
11228263|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets
11228264|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
11228265|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
11228266|NCT03188835|Other|Isocaloric Diet|Two weeks of isocaloric diet
11228267|NCT03188835|Other|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
11228268|NCT03188835|Other|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
11228269|NCT03188822|Experimental|Bioabsorbable steroid releasing sinus implant|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
11228270|NCT03188822|Experimental|bioabsorbable nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
11228271|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
11228272|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
11228273|NCT03188796|Placebo Comparator|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
11228274|NCT03188796|Experimental|High Dose Vitamin D3|"oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000
~loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)
~followed by 4000 IU daily (10 drops) for the entire active study period (90 days)"
11228275|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
11228276|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
11228277|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
11228278|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
11228279|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
11228286|NCT03188718|Other|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
11228287|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
11228288|NCT03188692|Experimental|BK1310|
11228289|NCT03188679|Other|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
11228290|NCT03188666|Experimental|REGN2477|
11228291|NCT03188666|Experimental|Placebo|
11228292|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
11228293|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
11228294|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
11228295|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
11228296|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
11228297|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
11228298|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
11228299|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
11228300|NCT03188627|Experimental|Bronchial basal cells|Transplantation of autologous bronchial basal cells
11228301|NCT03188627|No Intervention|Control|Conventional treatment
11228302|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
11228303|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
11228304|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
11228305|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
11228306|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
11228307|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
11228308|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
11228309|NCT03188575|Active Comparator|Waiting List|Waiting list control
11228310|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT
~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
11228311|NCT03188562|Experimental|TEMLA|"PET/CT
~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
11228312|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
11228313|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
11228314|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
11228315|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
11228316|NCT03188523|Experimental|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
11228317|NCT03188523|Experimental|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
11228318|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
11228319|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
11228320|NCT03188510|Experimental|LY3074828 Reference|LY3074828 administered subcutaneously (SC) as 3 injections
11228321|NCT03188510|Experimental|LY3074828 Test 1|LY3074828 administered as SC injections in two prefilled syringes
11228322|NCT03188510|Experimental|LY3074828 Test 2|LY3074828 administered as SC injections in four prefilled syringes
11228323|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
11228324|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
11228325|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
11228326|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
11228327|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
11228328|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
11228329|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
11228330|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
11228331|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
11228332|NCT03188445|Experimental|IV administration|Iron isomaltoside (Monofer) Administered iv
11228333|NCT03188445|Active Comparator|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
11228633|NCT03186495|Experimental|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
11228334|NCT03188432|Experimental|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
11228335|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
11228336|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
11228337|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM >0
11228338|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
11228339|NCT03188393|Experimental|Diagnostic (biopsy of breast)|After completion of neoadjuvant therapy, patients undergo stereotactic biopsy of breast tumor any time prior to breast conserving surgery. Patients then undergo breast conserving surgery as per standard of care. Patients may also undergo postoperative radiation therapy per standard of care or adjuvant therapy at the investigator's discretion.
11228340|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
11228341|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
11228342|NCT03188367|Active Comparator|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228343|NCT03188367|Active Comparator|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228344|NCT03188367|Active Comparator|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228345|NCT03188367|Placebo Comparator|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228346|NCT03188367|Placebo Comparator|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228347|NCT03188367|Placebo Comparator|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228348|NCT03188367|Active Comparator|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228349|NCT03188367|Active Comparator|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228407|NCT03187964|No Intervention|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
11228350|NCT03188367|Active Comparator|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228351|NCT03188367|Placebo Comparator|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228352|NCT03188367|Placebo Comparator|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228353|NCT03188367|Placebo Comparator|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
11228354|NCT03188354|Experimental|CNS lymphoma patients|Patients included in the study will be examined with both 18F-FDG and 18F-Fluciclovine as well as standard MRI in the PET/MRI scanner on two consecutive days, both in primary staging and for therapy assessment
11228355|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure
~clinically disclosed cardiac complications during and after vascular surgery procedure"
11228356|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
11228357|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
11228358|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
11228359|NCT03188302|Other|Specimen collection|Collection of stool samples
11228360|NCT03188289|Placebo Comparator|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
11228361|NCT03188289|Active Comparator|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
11228362|NCT03188289|Active Comparator|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
11228363|NCT03188289|Active Comparator|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
11228364|NCT03188276|Active Comparator|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
11228365|NCT03188276|No Intervention|Healthy controls|20 Healthy controls without any treatment
11228366|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
11228367|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
11228368|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
11228369|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
11228370|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
11228371|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
11228372|NCT03188224|Experimental|Intervention|MyTransition app
11228373|NCT03188224|No Intervention|Control|Usual care
11228374|NCT03188211|Other|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
11228375|NCT03188211|Other|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
11228408|NCT03187964|Active Comparator|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
11228570|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
11228376|NCT03188198|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m^2 IV on Day 1.Doxorubicin 50 mg/m^2 IV on Day 1.Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.
~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
11228377|NCT03188198|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m^2/day CIVI on Days 1-4.Etoposide 50 mg/m^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.
~Interventions:
~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
11228378|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
11228379|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
11228380|NCT03188172|Experimental|Trial Treatment|"Induction:
~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11
~ASCT stem cell harvest:
~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly
~Consolidation part 1:
~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22
~Consolidation part 2:
~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1
~Maintenance:
~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
11228381|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
11228382|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
11228383|NCT03188133|Experimental|VH|schizophrenia patients with visual hallucinations
11228384|NCT03188133|Active Comparator|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
11228385|NCT03188133|Active Comparator|C|healthy controls
11228386|NCT03188120||Spiriva Respimat group|
11228387|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
11228388|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
11228389|NCT03188094||South Asians with Prediabetes|
11228390|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
11228391|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
11228392|NCT03188068|Active Comparator|Sirolimus plus propranolol|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
~Propranolol was initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2."
11228393|NCT03188068|Active Comparator|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
11228394|NCT03188055|Experimental|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
11228395|NCT03188055|No Intervention|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.
11228396|NCT03188042|Experimental|rtACS Stimulation Group|
11228397|NCT03188042|Sham Comparator|Sham Intervention Group|Sham stimulation looks like rtACS, but is not active rtACS.
11228398|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
11228399|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
11228400|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
11228401|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.
~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
11228402|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.
~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
11228403|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
11228404|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
11228405|NCT03187977|Active Comparator|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
11228406|NCT03187977|No Intervention|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
11228467|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
11228409|NCT03187964|No Intervention|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
11228410|NCT03187964|Active Comparator|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
11228411|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.
~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
11228412|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.
~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.
~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
11228413|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
11228414|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
11228415|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
11228416|NCT03187899|Sham Comparator|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
11228417|NCT03187899|Active Comparator|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
11228418|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
11228419|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
11228420|NCT03187860|Experimental|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.
~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
11228421|NCT03187860|Experimental|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))
~Intervention: Bronchial Biopsy + ALI culture"
11228422|NCT03187860|Experimental|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD
~Intervention: Bronchial Biopsy + ALI culture"
11228423|NCT03187860|Experimental|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.
~Intervention: Bronchial Biopsy + ALI culture"
11228424|NCT03187834|Active Comparator|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.
~Children will receive treatment everyday, once a day as is:
~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
11228425|NCT03187834|Active Comparator|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.
~Children will receive treatment everyday, twice a day as is:
~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
11228426|NCT03187834|Active Comparator|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.
~Children will receive treatment everyday, once a day as is:
~Co-trimoxazole: 240 mg daily for Days 1-5"
11228427|NCT03187834|Placebo Comparator|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.
~Children will receive Placebo everyday, once a day."
11228428|NCT03187821|Active Comparator|Superior|Laser peripheral iridotomy done at superior part of iris.
11228429|NCT03187821|Active Comparator|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
11228430|NCT03187808|Experimental|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
11228431|NCT03187808|Experimental|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
11228432|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
11228730|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
11228433|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
11228434|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
11228435|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
11228436|NCT03187756|Experimental|Cyclophosphamide|
11228437|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
11228438|NCT03187730|Active Comparator|Intervention Arm|
11228439|NCT03187730|Placebo Comparator|Waitlist Control|
11228440|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
11228441|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
11228442|NCT03187704|Active Comparator|filtration|Air filtration in homes
11228443|NCT03187704|Sham Comparator|no filtration|Sham air filtration
11228444|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
11228445|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
11228446|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
11228447|NCT03187678|Experimental|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
11228448|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
11228449|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
11228450|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
11228451|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
11228452|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
11228453|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
11228454|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
11228455|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
11228456|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
11228457|NCT03187587|Experimental|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
11228458|NCT03187587|Active Comparator|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
11228459|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
11228460|NCT03187574||Group B|group received Perigee™ transvaginal mesh
11228461|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
11228462|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
11228463|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
11228464|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
11228465|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
11228466|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
11228468|NCT03187509|Experimental|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
11228469|NCT03187509|Active Comparator|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
11228470|NCT03187496|Experimental|Single Arm|
11228471|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
11228472|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
11228473|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
11228474|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
11228475|NCT03187444|Experimental|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
11228476|NCT03187431|Experimental|IPF patients|autologous bone marrow mesenchymal stem cells
11228477|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
11228478|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
11228479|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
11228480|NCT03187392|Active Comparator|lidocaine injection|
11228481|NCT03187392|Experimental|lidocaine-prilocaine cream|
11228482|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
11228483|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
11228484|NCT03187366|No Intervention|Status quo|Status quo pesticide use
11228485|NCT03187366|Active Comparator|Low risk|Villages shifted to low risk pesticides that don't kill prawns
11228486|NCT03187366|Experimental|No agrochemcials|Villages that eliminate agrochemicals
11228487|NCT03187353|Active Comparator|Lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
11228488|NCT03187353|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
11228489|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
11228490|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
11228491|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
11228492|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
11228493|NCT03187301|Placebo Comparator|Placebo|Placebo
11228494|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
11228495|NCT03187288|Experimental|CFI-400945|CFI-400945 will be given by mouth at 64,96,128,160,192 or 224 mg/day, everyday until intolerable side effects or disease progression.
11228496|NCT03187275|Experimental|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
11228497|NCT03187275|Active Comparator|Light Touch Intervention|Participants in this arm will receive light touch only.
11228498|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance
~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day
~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle
~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
11228499|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
11228500|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
11228501|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
11228502|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
11228503|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
11228504|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
11228505|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
11228731|NCT03185897||Hemophilia A|Participants with hemophilia A
11228506|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:
~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
11228507|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1
~BeEAM Regimen:
~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
11228508|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
11228509|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
11228510|NCT03187184|Experimental|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
11228511|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
11228512|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
11228513|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
11228514|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
11228515|NCT03187145||diabetic patients|
11228516|NCT03187145||healthy control|
11228517|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
11228518|NCT03187132|Active Comparator|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
11228519|NCT03187119|Experimental|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
11228520|NCT03187119|Active Comparator|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
11228521|NCT03187106|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
11228522|NCT03187106|Placebo Comparator|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
11228523|NCT03187093|Active Comparator|Vortioxetine|
11228524|NCT03187093|Active Comparator|Escitalopram|
11228525|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
11228526|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
11228527|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
11228528|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
11228529|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
11228530|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
11228531|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
11228532|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
11228533|NCT03187067||Mozambique, cases|
11228534|NCT03187067||Mozambique, controls|
11228535|NCT03187067||Pakistan, cases|
11228536|NCT03187067||Pakistan, controls|
11228537|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
11228538|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
11228601|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
11228539|NCT03187041|Experimental|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.
~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
11228540|NCT03187028|Active Comparator|Diet only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
11228541|NCT03187028|Experimental|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling also receiving a fitness bracelet to facilitate counseling by the certified Cancer Exercise Trainer.
11228542|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
11228543|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
11228544|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
11228545|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
11228546|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
11228547|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
11228548|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
11228549|NCT03186963|Experimental|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
11228550|NCT03186963|Active Comparator|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
11228551|NCT03186950|Active Comparator|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
11228552|NCT03186950|Experimental|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
11228553|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.
~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.
~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
11228554|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
11228555|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
11228556|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
11228557|NCT03186898|Experimental|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
11228558|NCT03186898|Experimental|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
11228559|NCT03186885|Experimental|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
11228560|NCT03186885|Experimental|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
11228561|NCT03186885|Active Comparator|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
11228562|NCT03186872|No Intervention|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
11228563|NCT03186872|Experimental|Digital behavioral program app|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
11228564|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
11228565|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
11228566|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
11228567|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
11228568|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
11228569|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
11228571|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
11228572|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
11228573|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
11228574|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.
~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.
~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
11228575|NCT03186794|Experimental|SLE Exercise|We propose to enroll 20 sedentary, adult, women with negligible to mild SLE disease activity (SELENA-SLEDAI less than or equal to 4) in this pilot study. Subjects must also have a Fatigue Severity Scale (FSS) composite score less than or equal to 4.0. We will restrict our recruitment to women with SLE as this is a small pilot study and would like to eliminate possible gender-biased confounders of physical activity (approximately 90% of patients with SLE are women).
11228576|NCT03186781|Experimental|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
11228577|NCT03186781|Experimental|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
11228578|NCT03186781|Experimental|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
11228579|NCT03186781|Experimental|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
11228580|NCT03186781|Experimental|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
11228581|NCT03186781|Experimental|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
11228582|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
11228583|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
11228584|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
11228585|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
11228586|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
11228587|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
11228588|NCT03186729|Experimental|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
11228589|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
11228590|NCT03186716|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
11228591|NCT03186716|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
11228592|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
11228593|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
11228594|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
11228595|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
11228596|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
11228597|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
11228598|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
11228599|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
11228600|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
11228631|NCT03186495|Experimental|Moderate renal impairment|Subjects with moderate renal impairment
11228602|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
11228603|NCT03186651|Experimental|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
11228604|NCT03186651|No Intervention|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
11228605|NCT03186638|Experimental|Arm I (ibuprofen)|Patients receive ibuprofen PO BID for 6 weeks.
11228606|NCT03186638|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 weeks.
11228607|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
11228608|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
11228609|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
11228610|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
11228611|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
11228612|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
11228613|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.
~Patient with monthly feedback call
~Patients on continuous MEMS monitoring."
11228614|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
11228615|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
11228616|NCT03186573|No Intervention|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
11228617|NCT03186573|Active Comparator|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
11228618|NCT03186573|Placebo Comparator|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
11228619|NCT03186560|Active Comparator|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
11228620|NCT03186560|Active Comparator|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
11228621|NCT03186560|Active Comparator|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
11228622|NCT03186560|Active Comparator|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
11228623|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
11228624|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
11228625|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
11228626|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
11228627|NCT03186508|Active Comparator|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
11228628|NCT03186508|Active Comparator|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
11228629|NCT03186495|Experimental|Normal renal function|Subjects with normal renal function
11228630|NCT03186495|Experimental|Mild renal impairment|Subjects with mild renal impairment
11228634|NCT03186482|Active Comparator|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.
~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
11228635|NCT03186482|Active Comparator|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.
~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
11228636|NCT03186482|Active Comparator|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.
~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
11228637|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
11228638|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
11228639|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
11228640|NCT03186456|Experimental|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg
11228641|NCT03186456|Placebo Comparator|Group 2|Aspirin Tablet, 100mg/d; Placebo
11228642|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
11228643|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
11228644|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
11228645|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
11228646|NCT03186417|Experimental|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
11228647|NCT03186417|Experimental|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
11228648|NCT03186417|Experimental|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
11228649|NCT03186404|Placebo Comparator|Placebos|Placebos
11228650|NCT03186404|Experimental|Statin|Atorvastatin 40mg
11228651|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
11228652|NCT03186378|Experimental|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
11228653|NCT03186378|Experimental|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
11228654|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
11228655|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
11228656|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
11228657|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
11228658|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
11228659|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
11228660|NCT03186326|Active Comparator|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
11228661|NCT03186326|Experimental|Arm B - Immunotherapy (experimental arm)|Avelumab
11228662|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
11228663|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.
~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
11228664|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
11228665|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
11228666|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
11228667|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
11228668|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
11228669|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
11228670|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
11228671|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
11228672|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
11228673|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
11228674|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
11228675|NCT03186248|Experimental|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
11228676|NCT03186248|Active Comparator|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
11228677|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
11228678|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
11228679|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
11228680|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
11228681|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
11228682|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
11228683|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
11228684|NCT03186209|Experimental|Benralizumab|Benralizumab administered subcutaneously
11228685|NCT03186209|Placebo Comparator|Placebo|Placebo administered subcutaneously
11228686|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
11228687|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
11228688|NCT03186183|Experimental|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.
~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.
~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.
~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.
~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.
~1-2 supplemental sessions may be added as needed."
11228689|NCT03186170|Experimental|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.
~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
11228690|NCT03186170|Active Comparator|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.
~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
11228691|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
11228692|NCT03186144|Experimental|No arm : descriptive study|
11228693|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
11228694|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
11228695|NCT03186118|Experimental|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
11228696|NCT03186118|Experimental|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
11228732|NCT03185897||Hemophilia B|Participants with hemophilia B
11228697|NCT03186118|Experimental|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
11228698|NCT03186118|Experimental|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
11228699|NCT03186105|Experimental|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
11228700|NCT03186092|Active Comparator|Intervention Group|inspiratory muscle training with load
11228701|NCT03186092|Sham Comparator|Control Group|unloaded inspiratory muscle training
11228702|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
11228703|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
11228704|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
11228705|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
11228706|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
11228707|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
11228708|NCT03186040|Other|Lacosamide|
11228709|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.
~Active supplement based on Coenzyme Q10 plus NADH"
11228710|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.
~Placebo: phosphoserine plus vitamin C"
11228711|NCT03186014|Experimental|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
11228712|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
11228713|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
11228714|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
11228715|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA
11228716|NCT03185988|Experimental|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
11228717|NCT03185988|Experimental|Biliary tract cancer|HER2 positive Biliary tract cancer
11228718|NCT03185988|Experimental|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
11228719|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
11228720|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
11228721|NCT03185962||Successful extubation|extubated successfully
11228722|NCT03185962||Extubation failure|reintubated within 48 hours
11228723|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
11228724|NCT03185949|Sham Comparator|Sedation and subcutaneous lidocaine|Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
11228725|NCT03185949|Experimental|interventional: bariatric embolization|• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
11228726|NCT03185936|Experimental|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
11228727|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
11228728|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
11228729|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
11228733|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
11228735|NCT03185871|Experimental|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.
~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
11228736|NCT03185858|Experimental|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
11228737|NCT03185858|No Intervention|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
11228738|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
11228739|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
11228740|NCT03185832||CRT-D Cohort|Composite rate of first appropriately treated ventricular arrhythmia
11228741|NCT03185832||ICD Cohort|Composite rate of first appropriately treated ventricular arrhythmia
11228742|NCT03185832||PM / CRT-P Cohort|All cause mortality
11228743|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
11228744|NCT03185819|Placebo Comparator|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
11228745|NCT03185819|Experimental|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
11228746|NCT03185819|Experimental|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
11228747|NCT03185819|Experimental|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
11228748|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
11228749|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
11228750|NCT03185793|Placebo Comparator|Placebo|placebo for 5 weeks
11228751|NCT03185793|Experimental|2.5mg SHR4640|SHR4640 for 5 weeks
11228752|NCT03185793|Experimental|5mg SHR4640|SHR4640 for 5 weeks
11228753|NCT03185793|Experimental|10mg SHR4640|SHR4640 for 5 weeks
11228754|NCT03185793|Active Comparator|50mg benzbromarone|Benzbromarone for 5 weeks
11228755|NCT03185780|Experimental|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
11228756|NCT03185767|Other|SLE group|
11228757|NCT03185767|Other|control group|
11228758|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
11228759|NCT03185741|Experimental|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.
~Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.
~Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
11228760|NCT03185741|Experimental|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
11228761|NCT03185741|No Intervention|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
11228762|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
11228763|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
11228764|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
11228765|NCT03185715|Other|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
11228766|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
11228767|NCT03185702||Unaffected controls|Normal females and unaffected family members
11228768|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
11228769|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
11228770|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
11228774|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
11228775|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
11228776|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
11228777|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
11228778|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
11228779|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
11228780|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
11228781|NCT03185624|Experimental|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
11228782|NCT03185624|No Intervention|Blank control|No intervention after surgery
11228783|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
11228784|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
11228785|NCT03185598||non-MACE|no MACE occurred
11228786|NCT03185598||MACE|MACE occurred
11228787|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
11228788|NCT03185559|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
11228789|NCT03185559|Sham Comparator|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
11228790|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
11228791|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
11228792|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
11228793|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
11228794|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
11228795|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
11228796|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
11228797|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
11228798|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
11228799|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
11228800|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
11228801|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
11228802|NCT03185481|Experimental|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
11228803|NCT03185481|Experimental|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
11228804|NCT03185481|Experimental|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
11228805|NCT03185481|Experimental|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
11228806|NCT03185481|Experimental|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
11228807|NCT03185481|Experimental|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
11228808|NCT03185481|Experimental|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
11228809|NCT03185481|Experimental|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
11228863|NCT03185078|Experimental|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2.
11228810|NCT03185468|Experimental|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
11228811|NCT03185468|Experimental|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
11228812|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
11228813|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
11228814|NCT03185442|Experimental|PRF-fMRI|
11228815|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide
~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
11228816|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
11228817|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
11228818|NCT03185403|Active Comparator|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.
~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
11228819|NCT03185403|Active Comparator|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
11228820|NCT03185390|Other|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
11228821|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
11228822|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
11228823|NCT03185351|Active Comparator|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.
~."
11228824|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
11228825|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
11228826|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
11228827|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
11228828|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
11228860|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
11228861|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
11228829|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
11228830|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
11228831|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
11228832|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
11228833|NCT03185325||healthy voulnteers|venous blood samples
11228834|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
11228835|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
11228836|NCT03185312||control|"Skin biopsies will be taken from skin of controls.
~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
11228837|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
11228838|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
11228839|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
11228840|NCT03185247|Experimental|Group Intervention|10-week parent-child multi-family group
11228841|NCT03185234|Active Comparator|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
11228842|NCT03185234|Sham Comparator|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
11228843|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
11228844|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
11228845|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
11228846|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
11228847|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
11228848|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
11228849|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
11228850|NCT03185182|Experimental|experimental group|"185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.
~This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma."
11228851|NCT03185169|Other|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
11228852|NCT03185156|Experimental|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
11228853|NCT03185156|Placebo Comparator|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
11228854|NCT03185143|Experimental|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B
11228855|NCT03185143|Active Comparator|Sumatriptan 100 mg Capsules|One capsule contains Sumatriptan 100 mg and one capsule contains a sham comparator for component B.
11228856|NCT03185143|Placebo Comparator|Placebo Capsules|One capsule contains a sham comparator for component A and one capsule contains a sham comparator for component B .
11228857|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
11228858|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
11228859|NCT03185117||All patients|Adult patients scheduled to undergo a total knee arthroplasty or total hip arthroplasty, who give written informed consent to participate in the study.
11228862|NCT03185091|Other|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
11228864|NCT03185078|Experimental|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2.
11228865|NCT03185078|Sham Comparator|Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
11228866|NCT03185065|Experimental|Arm A|amantadine, placebo, modafinil, methylphenidate
11228867|NCT03185065|Experimental|Arm B|placebo, methylphenidate, amantadine, modafinil
11228868|NCT03185065|Experimental|Arm C|modafinil, amantadine, methylphenidate, placebo
11228869|NCT03185065|Experimental|Arm D|methylphenidate, modafinil, placebo and amantadine
11228870|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
11228871|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
11228872|NCT03185026|Active Comparator|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
11228873|NCT03185026|Experimental|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
11228874|NCT03185013|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
11228875|NCT03185013|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
11228876|NCT03185000|Experimental|Immediate ATIMP (AP)|Patients randomised to AP will receive Treg immunotherapy (TR004) infusion at Week 0 and Placebo infusion at Week 8.
11228877|NCT03185000|Experimental|Delayed ATIMP (PA)|Patients randomised to PA will receive Placebo infusion at Week 0 and Treg immunotherapy (TR004) infusion at Week 8.
11228878|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
11228879|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
11228880|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.
~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
11228881|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.
~*No individual participants are recruited for this study."
11228882|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.
~*No individual participants are recruited for this study."
11228883|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.
~*No individual participants are recruited for this study."
11228884|NCT03184935|Experimental|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
11228885|NCT03184935|Placebo Comparator|Control group|Basic medication: Decitabine; placebo: saline.
11228886|NCT03184922|Active Comparator|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
11228887|NCT03184922|Experimental|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
11228888|NCT03184909|Experimental|Tulsi active|
11228889|NCT03184909|Placebo Comparator|Tulsi placebo|
11228890|NCT03184896||Hip Fracture|
11228891|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
11228892|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
11228893|NCT03184870|Experimental|Combination Therapy 1|BMS-813160 with 5-fluorouracil (5-FU), leucovorin containing regimens in combination with irinotecan
11228894|NCT03184870|Experimental|Combination Therapy 2|BMS-813160, nab/paclitaxel and gemcitabine
11228895|NCT03184870|Experimental|Combination Therapy 3|BMS-813160 and Nivolumab
11228896|NCT03184870|Experimental|Combination Therapy 4|BMS-813160, nab/paclitaxel + gemcitabine, and Nivolumab
11228897|NCT03184870|Experimental|Combination Therapy 5|5-fluorouracil (5-FU), leucovorin containing regimens in combination with irinotecan
11228898|NCT03184870|Experimental|Combination Therapy 6|Nab/paclitaxel and gemcitabine
11228899|NCT03184870|Experimental|Monotherapy|BMS-813160
11228900|NCT03184857|Active Comparator|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
11228901|NCT03184857|Experimental|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
11228902|NCT03184844|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
11228903|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
11228904|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
11228905|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
11228906|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
11228907|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
11228908|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
11228909|NCT03184792|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous cervical electrical stimulation combined with physical therapy that targets rehabilitation of upper extremity functions
11228910|NCT03184792|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of upper extremity functions
11228911|NCT03184779|Experimental|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
11228912|NCT03184779|No Intervention|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
11228913|NCT03184766|Experimental|1|Treatment Order: Test, Comparator 1, Comparator 2
11228914|NCT03184766|Experimental|2|Treatment Order: Test, Comparator 2, Comparator 1
11228915|NCT03184766|Experimental|3|Treatment Order: Comparator 1, Test, Comparator 2
11228916|NCT03184766|Experimental|4|Treatment Order: Comparator 1, Comparator 2, Test
11228917|NCT03184766|Experimental|5|Treatment Order: Comparator 2, Test, Comparator 1
11228918|NCT03184766|Experimental|6|Treatment Order: Comparator 2, Comparator 1, Test
11228919|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
11228920|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
11228921|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
11228922|NCT03184714|No Intervention|Control|
11228923|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
11228924|NCT03184701|Experimental|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
11228925|NCT03184688|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
11228926|NCT03184688|Placebo Comparator|Normal saline|Normal saline for hydrodissection
11228927|NCT03184675|Experimental|Functional action observation training|
11228928|NCT03184675|Other|General action observation training group|
11228929|NCT03184662|Experimental|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.
~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
11228930|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
11228931|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
11228932|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
11228933|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
11228934|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
11228935|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
11228936|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
11228937|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
11228938|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
11228939|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
11228940|NCT03184584|Experimental|PBI-4050|
11229118|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
11230396|NCT03174483|Active Comparator|fluticasone|nasal spray will be used once daily
11228941|NCT03184571|Experimental|Bemcentinib + pembrolizumab|"Cohort A enrols patients who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind to receive bemcentinib (BGB324) in combination with pembrolizumab.
~Cohort B enrols patients with a maximum of 2 prior lines whereas the most recent line must have included a PD-(L)1 inhibitor to receive bemcentinib (BGB324) in combination with pembrolizumab.
~Bemcentinib capsules are administered at 400mg for days 1-3, and 200mg thereafter. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks."
11228942|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Bemcentinib (BGB324) in combination with pembrolizumab. Bemcentinib capsules are administered at 400mg on days 1-3, and 200mg there after. Pembrolizumab is an IV infusion, administered at a dose of 200mg every 3 weeks.
11228943|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
11228944|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
11228945|NCT03184532||D|diabetic patients
11228946|NCT03184532||ND|non-diabetic patients
11228947|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
11228948|NCT03184506|Sham Comparator|control group|
11228949|NCT03184506|Active Comparator|pre-warming group|
11228950|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
11228951|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
11228952|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
11228953|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
11228954|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
11228955|NCT03184467|Placebo Comparator|Control group|Normal saline 0.9%
11228956|NCT03184467|Experimental|Study group 1|GV1001 0.56 mg
11228957|NCT03184467|Experimental|Study group 2|GV1001 1.12 mg
11228958|NCT03184454|Experimental|Medtronic PC+S Deep Brain Stimulation|"Single open label arm.
~Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic PC+S deep brain stimulation (DBS) system."
11228959|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
11228960|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
11228961|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
11228962|NCT03184415|Active Comparator|DWC20155 Monotherapy|
11228963|NCT03184415|Active Comparator|DWC20156 Monotherapy|
11228964|NCT03184402|Experimental|DWJ1252|
11228965|NCT03184402|Active Comparator|Gasmotin|
11228966|NCT03184389|Other|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
11228967|NCT03184376|Experimental|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
11228968|NCT03184376|Placebo Comparator|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
11228969|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
11228970|NCT03184350|Other|Adjuvant pelvic proton radiation|
11228971|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
11228972|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
11228973|NCT03184324|Experimental|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
11228974|NCT03184324|Experimental|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
11228975|NCT03184324|Experimental|DWP14012 80mg|DWP14012 40mg*2, tablet, orally, once daily
11228976|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
11228977|NCT03184311|Experimental|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
11228978|NCT03184311|Placebo Comparator|Moderate-intensity continuous training (MCT)|A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
11228979|NCT03184298|Other|Group|Participants receive three interventions: Surveys, Interviews, and Group Workshops
11229004|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
11229005|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
11228980|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
11228981|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
11228982|NCT03184259|Experimental|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
11228983|NCT03184259|Experimental|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
11228984|NCT03184259|Placebo Comparator|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
11228985|NCT03184259|Placebo Comparator|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
11228986|NCT03184259|No Intervention|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
11228987|NCT03184246|Experimental|GlideScope|intubation with GlideScope
11228988|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
11228989|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
11228990|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.
~No rapid ventricular pacing is applied perioperatively."
11228991|NCT03184220|Experimental|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.
~Multimodal physical therapy program includes:
~Myofascial syndrome cervical therapy treatment."
11228992|NCT03184220|Experimental|CONTROL GROUP|"Multimodal physical therapy program includes:
~ultrasound therapy (US),
~transcutaneous electric nerve stimulation (TENS)
~massage."
11228993|NCT03184194|Experimental|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
11228994|NCT03184194|Experimental|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
11228995|NCT03184181|Experimental|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
11228996|NCT03184181|Active Comparator|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
11228997|NCT03184168|Experimental|treatment|[14C]lorlatinib
11228998|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
11228999|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
11229000|NCT03184142|Experimental|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
11229001|NCT03184142|Experimental|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
11229002|NCT03184142|Placebo Comparator|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
11229003|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
11229006|NCT03184116|No Intervention|Control|No additional intervention
11231019|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
11229007|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).
~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
11229008|NCT03184077|Active Comparator|Polyglactin 910|
11229009|NCT03184077|Active Comparator|poliglecaprone 25|
11229010|NCT03184064|Experimental|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
11229011|NCT03184064|Experimental|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
11229012|NCT03184064|Experimental|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
11229013|NCT03184064|Experimental|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
11229014|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
11229015|NCT03184038|Other|Assessment of neurocognitive function|Patients undergo assessment of neurocognitive function at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)
11229016|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
11229017|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
11229018|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
11229019|NCT03183999|Experimental|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
11229020|NCT03183999|Placebo Comparator|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
11229021|NCT03183986|Active Comparator|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
11229022|NCT03183986|Active Comparator|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
11229023|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
11229024|NCT03183973|Experimental|placebo group|
11229025|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
11229026|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
11229027|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
11229028|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
11229029|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
11229030|NCT03183908|Active Comparator|Adjuvanted influenza vaccine (FLUAD)|In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.
11229031|NCT03183908|Active Comparator|High-dose influenza vaccine (Fluzone HD)|In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.
11229032|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
11229033|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
11229034|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
11229035|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
11229036|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
11229037|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
11229038|NCT03183843|Active Comparator|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
11229039|NCT03183843|Active Comparator|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
11231020|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
11229040|NCT03183830|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
11229041|NCT03183830|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
11229042|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
11229043|NCT03183817|No Intervention|Usual Care|Evidence-based care
11229044|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
11229045|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
11229046|NCT03183791|Experimental|RELAX group|
11229047|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|
11229048|NCT03183778|Experimental|First Phase|During the first phase (week 1), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (1 serving/day), and eliminates high-potassium fruits and vegetables
11229049|NCT03183778|Active Comparator|Second Phase|During the second phase (weeks 2 and 3), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources
11229050|NCT03183765|Experimental|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
11229051|NCT03183765|Active Comparator|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
11229052|NCT03183752|Experimental|Metformin|patients randomized to Metformin group
11229053|NCT03183752|Placebo Comparator|Placebo|patients randomized to placebo group
11229054|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
11229055|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
11229056|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
11229057|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
11229058|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
11229059|NCT03183713|Active Comparator|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
11229060|NCT03183713|Active Comparator|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
11229061|NCT03183713|Active Comparator|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
11229062|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
11229063|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
11229064|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
11229065|NCT03183674|Experimental|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
11229066|NCT03183674|Placebo Comparator|placebo|saline nose spray, 0,9 %, once unique dose
11229067|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
11229068|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
11229069|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
11229070|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
11229071|NCT03183609|Active Comparator|Gluten|30 grams of gluten flour daily in protein shake
11229072|NCT03183609|Placebo Comparator|Placebo|30 grams of rice flour daily in protein shake
11229073|NCT03183596|Active Comparator|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
11229074|NCT03183596|Active Comparator|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
11229116|NCT03183245|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
11229117|NCT03183245|Active Comparator|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
11229075|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.
~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.
~IPF Patients will have a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
11229076|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.
~A repeat [18F]FP-R01-MG-F2 PET/CT scan will be performed within 3-8 weeks post initial scan if a signal is present in the first scan."
11229077|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
11229078|NCT03183557|Active Comparator|ZA alone|
11229079|NCT03183557|Active Comparator|ZA plus VD|
11229080|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
11229081|NCT03183518|Experimental|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
11229082|NCT03183518|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
11229083|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
11229084|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
11229085|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
11229086|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
11229087|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
11229088|NCT03183466|Experimental|Patients included in inclusion criteria|
11229089|NCT03183453|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
11229090|NCT03183453|No Intervention|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
11229091|NCT03183453|No Intervention|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
11229092|NCT03183440|Experimental|PREBIOTICS|188 pregnant women
11229093|NCT03183440|Placebo Comparator|PLACEBO|188 pregnant women
11229094|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
11229095|NCT03183427||Control group|Group of subjects without pineal cyst
11229096|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
11229097|NCT03183388|Experimental|BE-SMART|Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.
11229098|NCT03183375|Experimental|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
11229099|NCT03183375|No Intervention|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
11229100|NCT03183362|Experimental|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
11229101|NCT03183362|Active Comparator|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
11229102|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
11229103|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
11229104|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
11229105|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
11229106|NCT03183323|Experimental|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year periode. Electronic devices to trace activity.
11229107|NCT03183323|No Intervention|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
11229108|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
11229109|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
11229110|NCT03183297|Experimental|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
11229111|NCT03183297|Active Comparator|Naproxen|Naproxen 220mg or 440mg
11229112|NCT03183297|Active Comparator|Fexofenadine|fexofenadine 60mg or 120mg
11229113|NCT03183297|Placebo Comparator|Placebo|
11229114|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
11229115|NCT03183258|Experimental|Sentinel Skin Flap|
11229119|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
11229120|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
11229121|NCT03183219|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
11229122|NCT03183219|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11229123|NCT03183219|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
11229124|NCT03183206|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
11229125|NCT03183206|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
11229126|NCT03183206|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
11229127|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
11229128|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
11229129|NCT03183141|Experimental|SER-109|SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
11229130|NCT03183128|Experimental|SER-109|SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
11229131|NCT03183128|Placebo Comparator|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline
11229132|NCT03183115|Experimental|RFA group|Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD
11229133|NCT03183115|No Intervention|Control group|No intervention; surveillance endoscopy alone
11229134|NCT03183102|No Intervention|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
11229135|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
11229136|NCT03183089|Experimental|Active|
11229137|NCT03183089|Active Comparator|Active Comparator|
11229138|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
11229139|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
11229140|NCT03183063|Experimental|4DCT and SPECT/CT|Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
11229141|NCT03183063|Experimental|4DCT with BiPAP and SPECT/CT|Anticipated 5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP. Results in these patients will be analyzed for objective 6 only.
11229142|NCT03183063|Experimental|4DCT with CTA in suspected PE|Anticipated 124 participants with CTA ordered/performed for suspected PE will be enrolled to have 4DCT. Goal for analysis is 62 with positive CTA results for PE and 62 with negative CTA results for PE. Data will be analyzed for objectives 2 and 3.
11229143|NCT03183050|Experimental|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
11229144|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
11229145|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
11229146|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
11229147|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
11229148|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
11229149|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
11229150|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
11229151|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
11229152|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
11229153|NCT03182985|Experimental|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
11229244|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
11229417|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
11229154|NCT03182972|Experimental|Intervention arm|"Seminar presentation will be done using the followings:
~Power point presentation on the following topics as it relates to medication reconciliation:
~Communication skill (with patients and also with other members of the healthcare team)
~Documentation of pharmaceutical care activities
~Medication history taking
~Drug therapy problems
~Medication reconciliation practice
~Case studies on medication reconciliation
~Role plays on medication reconciliation"
11229155|NCT03182972|No Intervention|Control arm|Control group
11229156|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.
~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
11229157|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.
~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
11229158|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
11229159|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
11229160|NCT03182920|Experimental|200 mg Lasmiditan (Group 1 Elderly)|200 milligrams (mg) lasmiditan on Day 1 of 1 of 2 dosing periods.
11229161|NCT03182920|Placebo Comparator|Placebo (Group 1 Elderly)|Placebo on Day 1 of 1 of 2 dosing periods.
11229162|NCT03182920|Experimental|200 mg Lasmiditan (Group 2 Young)|200 mg lasmiditan on Day 1.
11229163|NCT03182907|Experimental|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
11229164|NCT03182907|Placebo Comparator|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose
11229165|NCT03182894|Experimental|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
11229166|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
11229167|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
11229168|NCT03182868|Experimental|Portable Assessment System (PAS) Goggles|Healthy volunteers wear goggles
11229169|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.
~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
11229170|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.
~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
11229171|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
11229172|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
11229173|NCT03182829||Factor Xa inhibitor|Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.
11229174|NCT03182829||Thrombin inhibitor|Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.
11229175|NCT03182816|Experimental|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
11229176|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
11229177|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
11229178|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
11229179|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
11229180|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
11229181|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
11229182|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
11229183|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
11229184|NCT03182751|Active Comparator|Tranexamic Acid Arm (TXA)|TXA will be administered intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours.
11229185|NCT03182751|Placebo Comparator|Control Arm|Patients in the control group will receive a placebo medication in the Emergency Department. Neither group will receive perioperative bolus dosing of TXA.
11229186|NCT03182738|Experimental|Intervention|VIP app that delivers HIV-related symptom strategies
11229187|NCT03182738|Sham Comparator|Control|VIP app without HIV-related symptom strategies
11229188|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
11229189|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
11229190|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
11229191|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
11229192|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
11229193|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
11229194|NCT03182686|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
11229195|NCT03182686|Other|Saline|Saline, solution, 4 mL, single intra-articular injection
11229196|NCT03182673|Experimental|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors
~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.
~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
11229197|NCT03182647||Non surgery|Patients were not treated with surgery initially
11229198|NCT03182647||Surgery|Patients had an initial surgical treatment
11229199|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
11229200|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
11229201|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
11229202|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
11229203|NCT03182634|Experimental|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
11229204|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
11229205|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
11229206|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
11229207|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
11229208|NCT03182595|Experimental|open---label|An open---label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period.
11229209|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.
~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.
~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
11229210|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.
~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.
~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
11229211|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
11229212|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
11229213|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
11229214|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
11229215|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
11229216|NCT03182543|Experimental|AM1|Mango pulp beverage
11229217|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
11229218|NCT03182543|Placebo Comparator|Control|Control beverage
11229219|NCT03182530|Active Comparator|ULTRA method group|
11229220|NCT03182530|Active Comparator|standard patent hemostasis group|
11229221|NCT03182530|Experimental|control group|
11229222|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
11229223|NCT03182504|Experimental|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
11229224|NCT03182491||Anaphylaxis|
11229225|NCT03182491||Febrile transfusion reactions|
11229226|NCT03182491||Mild allergic reactions|
11229227|NCT03182491||Healthy controls|
11229228|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
11229229|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
11229230|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
11229231|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
11229232|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
11229233|NCT03182439|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
11229234|NCT03182439|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
11229235|NCT03182439|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
11229236|NCT03182439|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
11229237|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.
~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).
~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.
~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
11229238|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.
~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).
~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
11229239|NCT03182413|Placebo Comparator|PBO|Placebo
11229240|NCT03182413|Active Comparator|MOD|Modafinil 100mg
11229241|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
11229242|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
11229243|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
11229245|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
11229246|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
11229247|NCT03182361|Experimental|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
11229248|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
11229249|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
11229250|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
11229251|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
11229252|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
11229253|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
11229254|NCT03182283|No Intervention|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
11229255|NCT03182283|Other|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
11229256|NCT03182270|Experimental|pancreatic cysts|
11229257|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
11229258|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
11229259|NCT03182244|Experimental|ASP2215|ASP2215 will be administered orally once daily.
11229260|NCT03182244|Active Comparator|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy).
11229261|NCT03182244|Experimental|ASP2215 PK in Chinese population|PK samples will be collected after single and multiple doses in Chinese subjects.
11229262|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
11229263|NCT03182205|Experimental|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
11229264|NCT03182205|Sham Comparator|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
11229265|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
11229266|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
11229267|NCT03182179|Experimental|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
11229268|NCT03182179|Experimental|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
11229269|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:
~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.
~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.
~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
11229270|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
11229271|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
11229272|NCT03182127|Other|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
11229273|NCT03182114|Placebo Comparator|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
11229274|NCT03182114|Experimental|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
11229275|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
11229276|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
11229277|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
11229314|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
11229278|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
11229279|NCT03182075|Experimental|Active Training|OCD participants will receive active emotional reactivity training (14 sessions) via computer.
11229280|NCT03182075|Sham Comparator|Passive Training|OCD participants will receive passive computerized training (14 sessions) via computer.
11229281|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
11229282|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.
~Postoperatively, standard oxygen therapy."
11229283|NCT03182049||GPA (Wegener's granulomatosis) patients|
11229284|NCT03182036|Experimental|Study group|Portable pulsed oxygen
11229285|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
11229286|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
11229287|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
11229288|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
11229289|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
11229290|NCT03181984|Experimental|Hemoporfin|
11229291|NCT03181971|Experimental|Water Access and Promotion|Intervention group will receive installation of water stations in high traffic areas, schoolwide promotion, and 4th graders will receive a curricula focused on increasing intake of water.
11229292|NCT03181971|No Intervention|Control|Usual care.
11229293|NCT03181958|Experimental|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:
~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
11229294|NCT03181958|Active Comparator|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
11229295|NCT03181958|Experimental|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
11229296|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
11229297|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
11229298|NCT03181932|Experimental|Vancomycin inhalation powder|30 mg twice daily (BID)
11229299|NCT03181932|Placebo Comparator|Placebo inhalation powder|Matching placebo inhaled twice daily (BID)
11229300|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
11229301|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
11229302|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
11229303|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
11229304|NCT03181893|Placebo Comparator|Placebo ARM|
11229305|NCT03181893|Experimental|PF-06823859 ARM high|
11229306|NCT03181893|Experimental|PF-06823859 ARM low|
11229307|NCT03181880|Active Comparator|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
11229308|NCT03181880|Active Comparator|Bronchodilators|The comparator arm consists of SOC.
11229309|NCT03181867|Experimental|1/18F-DCFPyL PET /CT and prostatectomy|18F-DCFPyL PET/CT imaging and possible prostatectomy
11229310|NCT03181867|Experimental|2/18F-DCFPyL PET/CT|18F-DCFPyL PET/CT imaging
11229311|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
11229312|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
11229313|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
11229318|NCT03181828|Active Comparator|AHA|All subjects (healthy adults and UCD patients) will receive a single oral dose of 60 mg/kg acetohydroxamic acid during one of the treatment periods, based on the randomization assignment determining whether treatment occurs in the first or the second treatment cycle; doses will be rounded to the nearest 250 mg to coincide with the available dosage form since the tablets cannot be scored. Patients will be instructed to fast for 4 hours prior to the study; subsequently, the 13C-Urea tracer will be administered 60 minutes after the ingestion of the acetohydroxamic acid dose.
11229319|NCT03181815|Experimental|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
11229320|NCT03181802|Experimental|botulinum toxin A|
11229321|NCT03181802|Placebo Comparator|Placebo|
11229322|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
11229323|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
11229324|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
11229325|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
11229326|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
11229327|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
11229328|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
11229329|NCT03181750|No Intervention|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
11229330|NCT03181750|Experimental|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
11229331|NCT03181737|Experimental|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms & complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.
~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
11229332|NCT03181737|Active Comparator|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
11229333|NCT03181737|No Intervention|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
11229334|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
11229335|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
11229336|NCT03181698||first group|patients with more than one episodes of mania
11229337|NCT03181698||second group|sex-matched and age- matched healthy controls
11229338|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
11229339|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
11229340|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
11229341|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
11229342|NCT03181659|Experimental|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
11229343|NCT03181659|Experimental|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
11229344|NCT03181659|Experimental|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
11229345|NCT03181659|Experimental|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
11229346|NCT03181646|No Intervention|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
11229347|NCT03181646|Experimental|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
11229348|NCT03181633|Experimental|ACH-0144471|All patients will receive ACH-0144471 during the treatment period.
11229349|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
11229350|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
11229351|NCT03181594|Experimental|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
11229352|NCT03181581|Experimental|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
11229353|NCT03181581|Experimental|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
11229354|NCT03181581|Active Comparator|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
11229355|NCT03181581|Active Comparator|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
11229356|NCT03181568|Other|Control|This arm group (control) will receive standard wound care of chronic wounds
11229357|NCT03181568|Other|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
11229358|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
11229359|NCT03181542|Experimental|Infrared vein illumination|Infrared illumination of veins, using the FDA approved AccuVein device, will be used to assist in vein location when inserting an intravenous access line
11229360|NCT03181542|No Intervention|Standard Technique|Standard vein location techniques will be used when inserting an intravenous access line
11229361|NCT03181529|Experimental|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
11229362|NCT03181529|Experimental|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
11229363|NCT03181516|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
11229364|NCT03181516|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
11229365|NCT03181503|Placebo Comparator|Placebo|Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
11229366|NCT03181503|Experimental|Nemolizumab 0.5 mg/kg|Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
11229367|NCT03181477|Other|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
11229368|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
11229369|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
11229370|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
11229371|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
11229372|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
11229373|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:
~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin
~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest
~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen
~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.
~In this group, will be administered 20 mL of 0.375% ropivacaine"
11229374|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:
~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin
~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest
~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen
~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.
~In this group, will be administered 20 mL of Saline"
11229375|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
11229376|NCT03181412||Patients with suspected ischemic stroke|The cohort will be constituted of patients treated for a stroke suspicion after calling emergency medical services of the Rhone and presenting a symptom-onset (the last time the patient was seen without deficit) less than 6 hours.
11229377|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
11229378|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
11229379|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
11229772|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
11229380|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
11229381|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
11229382|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
11229383|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
11229384|NCT03181347|Experimental|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Bypass surgery
11229385|NCT03181347|Experimental|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
11229386|NCT03181347|Active Comparator|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
11229387|NCT03181334|Active Comparator|Branch I|"Condition 1: (Standard Intervention)
~Mailed fecal immunochemical test (FIT) kit including the following:
~Invitation letter to complete free colorectal cancer (CRC) screening."
11229388|NCT03181334|Experimental|Branch II and Branch III|"Condition 2: (Time Guideline)
~Mailed fecal immunochemical test (FIT) kit including the following:
~Invitation to complete free colorectal cancer (CRC) screening within a specified time frame:
~Branch II - Brief Time (1-week)
~Branch III - Extended Time (3-weeks)"
11229389|NCT03181334|Experimental|Branch IV and Branch V|"Condition 3: (Time Guideline + Incentive)
~Mailed fecal immunochemical test (FIT) kit including the following:
~Invitation to complete free colorectal (CRC) screening within a specified time frame with a monetary incentive:
~Branch IV - High Incentive
~Branch V - Low Incentive"
11229390|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
11229391|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
11229392|NCT03181308|Experimental|TRC105 plus Nivolumab|
11229393|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
11229394|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
11229395|NCT03181282|Experimental|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
11229396|NCT03181282|No Intervention|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
11229397|NCT03181269|Experimental|Intervention education|Participants will receive the intervention education and data recording package.
11229398|NCT03181269|Placebo Comparator|Placebo education|Participants will receive the placebo educational and data recording package.
11229399|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
11229400|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
11229401|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
11229402|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
11229403|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
11229404|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
11229405|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
11229406|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
11229407|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
11229408|NCT03181204||Patients likely to develop COPD|"Patients in this group are relatively light smokers who have developed chronic obstructive lung disease (COPD).
~Intervention: Bronchial biopsy
~Intervention: Skin biopsy
~Intervention: Blood sample"
11229409|NCT03181204||Patients not likely to develop COPD|"Patients in this group are heavy smokers who have no signs of chronic obstructive lung disease (COPD).
~Intervention: Bronchial biopsy
~Intervention: Skin biopsy
~Intervention: Blood sample"
11229410|NCT03181191|Active Comparator|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
11229411|NCT03181191|Active Comparator|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
11229412|NCT03181191|Active Comparator|Healthy control subjects|Oral glucose tolerance test and biopsies
11229413|NCT03181178|Active Comparator|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
11229414|NCT03181178|Active Comparator|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
11229418|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
11229419|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
11229420|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
11229421|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
11229422|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
11229423|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
11229424|NCT03181126|Experimental|Venetoclax + Navitoclax + Chemotherapy|Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase [or any other forms of asparaginase], vincristine, dexamethasone) and tyrosine kinase inhibitor [TKI, if applicable]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.
11229425|NCT03181113||peginterferon alfa 2b|
11229426|NCT03181113||peginterferon alfa 2a|
11229427|NCT03181100|Experimental|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
11229428|NCT03181100|Experimental|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
11229429|NCT03181100|Experimental|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
11229430|NCT03181100|Experimental|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
11229431|NCT03181087|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
11229432|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
11229433|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
11229434|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
11229435|NCT03181035|Experimental|FAZA and pimonidazole|(18)F-Fluoroazomycin arabinoside (FAZA) will be administered via intravenous injection at a dose of 5.2 MBq/kg with a minimum dose of 200 Megabecquerel (MBq) (5.4 Millicurie (mCi)) and a maximum dose of 600 MBq (16.2 mCi) prior to positron emission tomography (PET) imaging. A single dose of oral pimonidazole capsules at a dose of 0.5 g/m2, will be taken by participants 16-20 hours prior to tumor resection surgery.
11229436|NCT03181022|No Intervention|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
11229437|NCT03181022|No Intervention|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
11229438|NCT03181022|No Intervention|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
11229439|NCT03181022|Experimental|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
11229440|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
11229441|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
11229442|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
11229443|NCT03180983|No Intervention|CONTROL GROUP|No intervention
11229444|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
11229445|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
11229446|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
11229447|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
11229448|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
11229449|NCT03180957|Experimental|Anti-TNF|adalimumab
11229450|NCT03180957|Placebo Comparator|Placebo|saline
11229451|NCT03180944|Experimental|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
11229452|NCT03180944|Experimental|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
11229453|NCT03180944|Experimental|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
11229454|NCT03180944|Experimental|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
11229455|NCT03180944|Experimental|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
11229456|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
11229457|NCT03180918|Experimental|testicular tissue cryopreservation|
11229458|NCT03180905|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
11229459|NCT03180905|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points
11229460|NCT03180879|Experimental|1|Treatment Order: Test, Reference, Comparator
11229461|NCT03180879|Experimental|2|Treatment Order: Test, Comparator, Reference
11229462|NCT03180879|Experimental|3|Treatment Order: Reference, Test, Comparator
11229463|NCT03180879|Experimental|4|Treatment Order: Reference, Comparator, Test
11229464|NCT03180879|Experimental|5|Treatment Order: Comparator, Test, Reference
11229465|NCT03180879|Experimental|6|Treatment Order: Comparator, Reference, Test
11229466|NCT03180866|No Intervention|Non-treatment Control|Control arm will not have any intervention
11229467|NCT03180866|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
11229468|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
11229469|NCT03180840|Experimental|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
11229470|NCT03180827|Experimental|ovarian tissue cryopreservation|
11229471|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
11229472|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
11229473|NCT03180801|Placebo Comparator|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
11229474|NCT03180801|Experimental|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
11229475|NCT03180801|Experimental|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
11229476|NCT03180788|Active Comparator|Traditional ESD|The patients in this Group will undergo traditional ESD.
11229477|NCT03180788|Experimental|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
11229478|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
11229479|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
11229480|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
11229481|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
11229482|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
11229483|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
11229484|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
11229485|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
11229486|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
11229487|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
11229488|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
11229489|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
11229490|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
11229491|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
11229492|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
11229493|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
11229494|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
11229495|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
11230249|NCT03175536||HDHP with PDL|Enrollees switched from a high-deductible health plan (HDHP) to a HDHP with a preventive drug list (PDL)
11229496|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
11229497|NCT03180749||Patients implanted with vendor B anchor|
11229498|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
11229499|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
11229500|NCT03180723|Experimental|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
11229501|NCT03180723|Active Comparator|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
11229502|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
11229503|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
11229504|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
11229505|NCT03180710|Active Comparator|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
11229506|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
11229507|NCT03180684|Experimental|VGX-3100 + EP|Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.
11229508|NCT03180684|Experimental|VGX-3100 + EP + Imiquimod|IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
11229509|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
11229510|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
11229511|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
11229512|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
11229513|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
11229514|NCT03180658|Active Comparator|controlled|CGF+bone graft
11229515|NCT03180645|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
11229516|NCT03180645|Other|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
11229517|NCT03180645|Other|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
11229518|NCT03180632|Active Comparator|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
11229519|NCT03180632|Placebo Comparator|Group B|Patient will receive a placebo similar in color, form and size.
11229520|NCT03180632|No Intervention|Group 3|Patient will receive no intervention.
11229521|NCT03180619|Experimental|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Virologically suppressed participants with chronic hepatitis B (CHB) and moderate or severe renal impairment taking TDF, a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to TAF.
11229522|NCT03180619|Experimental|Part A (Renal Impairment): End Stage Renal Disease|Virologically suppressed participants with CHB and end stage renal disease taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF.
11229523|NCT03180619|Experimental|Part B: Hepatic Impairment|Virologically suppressed participants with CHB and moderate or severe hepatic impairment taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF.
11229524|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
11229525|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
11229526|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
11229527|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
11229528|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.
~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.
~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
11229529|NCT03180567|Experimental|Warfarin resistant patients|Genetic Mutations
11229530|NCT03180567|Placebo Comparator|Control|Genetic Mutations
11229637|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
11229531|NCT03180554|Other|tVNS version 1|Transcutaneous vagus nerve stimulation (tVNS) version 1 will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
11229532|NCT03180554|Other|tVNS version 2|Transcutaneous vagus nerve stimulation (tVNS) version 2 will be delivered non-invasively via a portable take-home stimulation device which attaches to the center of the left ear lobe. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
11229533|NCT03180554|Other|MNRB version 1|Motivational nondirective resonance breathing (MNRB) version 1 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a deep breathing session. Participants will practice MNRB version 1 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
11229534|NCT03180554|Other|MNRB version 2|Motivational nondirective resonance breathing (MNRB) version 2 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a paced breathing session. Participants will practice MNRB version 2 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
11229535|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
11229536|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:
~live in areas where no DBT intervention is currently available OR
~were offered a place on the DBT programme but decided not to partake at that time"
11229537|NCT03180528|Experimental|Treatment (remetinostat)|Patients receive remetinostat topically TID for 6 weeks in the absence of disease progression or unacceptable toxicity.
11229538|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
11229539|NCT03180502|Active Comparator|Arm I (photon-based IMRT, temozolomide)|Patients undergo photon-based IMRT QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
11229540|NCT03180502|Experimental|Arm II (proton beam radiation therapy, temozolomide)|Patients undergo proton beam radiation therapy QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
11229541|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
11229542|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
11229543|NCT03180476|Experimental|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
11229544|NCT03180463|Experimental|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
11229545|NCT03180463|Placebo Comparator|Group 2|Core decompression surgery.
11229546|NCT03180450|Experimental|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
11229547|NCT03180450|Placebo Comparator|Control group|Conventional treatment
11229548|NCT03180437|Active Comparator|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
11229549|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
11229550|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
11229551|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
11229552|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
11229553|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
11229554|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.
~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
11229555|NCT03180398|Experimental|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
11229556|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
11229557|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
11229558|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
11229559|NCT03180359|Experimental|Patient already transplanted or waiting for a transplantation|
11229560|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
11229561|NCT03180346|Active Comparator|Standard of Care|
11229562|NCT03180333|Experimental|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
11229563|NCT03180333|Placebo Comparator|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
11229564|NCT03180333|Experimental|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
11229565|NCT03180333|Experimental|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
11229566|NCT03180333|Experimental|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
11229567|NCT03180320|Experimental|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
11229568|NCT03180320|Other|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
11229569|NCT03180307|Sham Comparator|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
11229570|NCT03180307|Experimental|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
11229571|NCT03180294|Experimental|Arm A (bupropion hydrochloride, placebo)|Patients receive bupropion hydrochloride PO QD on days 1-63 and placebo PO QD on days 8-71.
11229572|NCT03180294|Experimental|Arm B (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO QD on days 1-7 and 64-71, and BID on days 8-63.
11229573|NCT03180294|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD on days 1-7 and 64-71, and BID on days 8-63.
11229574|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
11229575|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
11229576|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
11229577|NCT03180268|Other|Arm I (Clinical Observation)|Patients undergo observation after gross total resection.
11229578|NCT03180268|Experimental|Arm II (Radiation Therapy)|Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions after gross total resection.
11229579|NCT03180255|Experimental|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
11229580|NCT03180255|Placebo Comparator|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
11229581|NCT03180242|Experimental|EG12014|EG12014
11229582|NCT03180242|Active Comparator|EU-sourced Herceptin|EU-sourced Herceptin
11229583|NCT03180242|Active Comparator|US-sourced Herceptin|US-sourced Herceptin
11229584|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
11229585|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
11229586|NCT03180216|Experimental|Prophylactic and treatment|"Virus Specific T cells (VSTs) for prophylactic and treatment of active viral infection(s) after HSCT.
~3 different dose levels starting with 1 x 10E7 /m2 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 2 x 10E7/m2 and a final dose 5 x 10E7 VSTs/m2"
11229587|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
11229588|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
11229589|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by
~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
11229590|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by
~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
11229591|NCT03180177|Experimental|Experimental group|"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
~2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks
~Interval debulking surgery
~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession
~2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
11229592|NCT03180177|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks
~Interval debulking surgery
~3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
11229593|NCT03180164|Other|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
11229594|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
11229595|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
11229596|NCT03180138|No Intervention|Controls|
11229597|NCT03180138|Active Comparator|Reminders alone|
11229598|NCT03180138|Active Comparator|Reminders + compliance-linked incentives|
11229599|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
11229600|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
11229601|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
11229602|NCT03180112||control group|Healthy children of matching age and sex.
11229603|NCT03180099|Active Comparator|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
11229604|NCT03180099|Active Comparator|Epidural Block|Epidural Block
11229605|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
11229606|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
11229607|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
11229608|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
11229609|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
11229610|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
11229611|NCT03180034|Experimental|Arm 1 (Gardasil 9 1-Dose Group)|5000 girls ages 12-16 years
11229612|NCT03180034|Experimental|Arm 2 (Cervarix 1-Dose Group)|5000 girls ages 12-16 years
11229613|NCT03180034|Active Comparator|Arm 3 (Gardasil 9 2-Dose Group)|5000 girls ages 12-16 years
11229614|NCT03180034|Active Comparator|Arm 4 (Cervarix 2-Dose Group)|5000 girls ages 12-16 years
11229615|NCT03180034|No Intervention|Epidemiologic HPV Survey Arm|4000 Unvaccinated women ages 17 to 20 (1000 women between 17 and 18; 1000 women between 18 and 19; 1000 women between 19 and 20; and 1000 women age 20); Followed for six months
11229616|NCT03180021||Patients with Lupus Nephritis|
11229617|NCT03180021||Patients with IgA Neuropathy|
11229618|NCT03180008|Active Comparator|Fit and Strong!|
11229619|NCT03180008|Experimental|Fit and Strong! Plus|
11229620|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
11229621|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
11229622|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.
~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
11229623|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
11229624|NCT03179956|Experimental|Ribociclib|
11229625|NCT03179943|Experimental|Atezolizumab + Guadecitabine|
11229626|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
11229627|NCT03179917|Experimental|Pembrolizumab and Involved Site Radiation Therapy|Following a PET/CT simulation to evaluate the extent of disease, pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Fourteen to 21 days after the completion of therapy, a PET/CT simulation will be repeated. Pts with complete response will proceed to 20 Gy of ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these ps will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts without a PET CR, but improvement on CT scan will have a repeat biopsy. If the biopsy is negative for Hodgkin Lymphoma, these pts will receive 30 Gy of ISRT. If the biopsy is positive for Hodgkin Lymphoma, they will receive 36-40 Gy ISRT. Pts with new sites of disease or progression on imaging will have a repeat biopsy, per treating physician's discretion & then be treated off study.
11229628|NCT03179904|Experimental|Treatment (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unexpected toxicity.
11229629|NCT03179891|Experimental|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
11229630|NCT03179891|Experimental|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
11229631|NCT03179878|Experimental|SYNB1020|SYNB1020
11229632|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
11229633|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
11229634|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
11229635|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
11229636|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
11229641|NCT03179774|Experimental|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
11229642|NCT03179774|No Intervention|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
11229643|NCT03179774|Experimental|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
11229644|NCT03179774|No Intervention|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
11229645|NCT03179761|Experimental|Group I (HD-TIV)|Patients receive HD-TIV intramuscularly once at baseline and once between 28-42 days.
11229646|NCT03179761|Active Comparator|Group 1(SD-QIV)|Patients receive SD-QIV intramuscularly once at baseline and once between 28-42 days.
11229647|NCT03179748||turoctocog alfa|Patients with haemophilia A
11229648|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
11229649|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
11229650|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
11229651|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
11229652|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
11229653|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
11229654|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
11229655|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
11229656|NCT03179696|Experimental|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
11229657|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
11229658|NCT03179683|No Intervention|No application|no treatment were aplied
11229659|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
11229660|NCT03179631|Experimental|Ataluren|10, 20 milligrams per kilogram (mg/kg)
11229661|NCT03179631|Placebo Comparator|Placebo|10, 20 mg/kg
11229662|NCT03179618|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
11229663|NCT03179618|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
11229664|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
11229665|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
11229666|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession
~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks
~Cytoreductive surgery
~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession
~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
11229667|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks
~Cytoreductive surgery
~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
11229668|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
11229669|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
11229670|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
11229671|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
11229672|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
11229673|NCT03179540|Experimental|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
11229674|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
11229675|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
11230348|NCT03174860|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
11229676|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
11229677|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
11229678|NCT03179501|Experimental|NP001|NP001
11229679|NCT03179501|Placebo Comparator|Placebo|Normal saline
11229680|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
11229681|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
11229682|NCT03179475|Other|Oxycodone Naloxone Combination|Open-Label
11229683|NCT03179462|Experimental|Pork intake|Subjects will consume 2 ounces of cooked lean pork following diet normalization for 3 days.
11229684|NCT03179462|Experimental|Mixed nuts intake|Subjects will consume 1 ounce of mixed nuts following diet normalization for 3 days.
11229685|NCT03179462|Experimental|Tofu intake|Subjects will consume 2 ounces of tofu following diet normalization for 3 days.
11229686|NCT03179449|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
11229687|NCT03179436|Experimental|Escalation: Dose Level (DL) 1 MK-1308 + Pembro: Cohort 1|On Cycle 1, Day 1 of the Dose Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with MK-1308 at dose level 1 (DL1). On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive MK-1308 at DL1 in combination with pembrolizumab (pembro) at pembrolizumab dose level 1 (PDL1) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
11229688|NCT03179436|Experimental|Escalation: DL 2 MK-1308 + Pembro: Cohort 2|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with MK-1308 at DL2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive MK-1308 at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
11229689|NCT03179436|Experimental|Escalation: DL 3 MK-1308 + Pembro: Cohort 3|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with MK-1308 at DL3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive MK-1308 at DL3 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
11229690|NCT03179436|Experimental|Confirmation: DL 1 MK-1308 Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive MK-1308 at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
11229691|NCT03179436|Experimental|Confirmation: DL 1 MK-1308 Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive MK-1308 at DL1 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and MK-1308 at DL1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
11229692|NCT03179436|Experimental|Confirmation: DL 2 MK-1308 Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive MK-1308 at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and MK-1308 at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
11229693|NCT03179436|Experimental|Confirmation: DL 2 MK-1308 Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with SCLC receive MK-1308 at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and MK-1308 at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
11229694|NCT03179436|Experimental|Confirmation: DL 2 MK-1308 Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive MK-1308 at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
11229695|NCT03179436|Experimental|Expansion: DL1 MK-1308 Schedule 2+PDL2 Pembro Schedule 2:Arm F|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with melanoma receive MK-1308 at DL1 in combination with pembrolizumab at pembrolizumab dose level 2 (PDL2). Both MK-1308 and pembrolizumab will be administered according to Schedule 2 for up to 24 months on study.
11229696|NCT03179436|Experimental|Expansion: DL1 MK-1308 Schedule 2 Monotherapy: Arm G|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with melanoma receive MK-1308 at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
11229697|NCT03179436|Experimental|Coformulation: MK-1308A Schedule 2: Arm I|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with advanced/metastatic solid tumors receive MK-1308A according to Schedule 2 for up to 24 months on study.
11229698|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
11229699|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
11229700|NCT03179410|Experimental|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
11229701|NCT03179397|Experimental|Model SC9|Investigational IOL
11229702|NCT03179397|Active Comparator|Model LI61SE|FDA Approved IOL
11229703|NCT03179384|Experimental|ceftriaxone treatment|
11229704|NCT03179371||1|Mothers whose fetus has CDH
11229705|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
11229706|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
11229707|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
11229708|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
11229709|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
11229710|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
11229711|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
11229712|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
11229713|NCT03179319|Experimental|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
11229714|NCT03179319|No Intervention|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
11229715|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
11229716|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
11229717|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
11229718|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
11229719|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
11229720|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
11229721|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
11229722|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
11229723|NCT03179228|Experimental|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
11229724|NCT03179202|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
11229725|NCT03179176|Experimental|HFUD utilisation|
11229726|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
11229727|NCT03179163|Experimental|Hypertensive - ACEi +SH|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
11229728|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
11229729|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
11229730|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
11229731|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
11229732|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
11229733|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
11229734|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
11229735|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
11229736|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
11229771|NCT03178851|Experimental|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
11229737|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
11229738|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
11229739|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
11229740|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
11229741|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
11229742|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
11229743|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
11229744|NCT03179007|Experimental|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
11229745|NCT03178994|Experimental|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
11229746|NCT03178994|Placebo Comparator|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
11229747|NCT03178981|Active Comparator|Conventional cigarette|Commercially-available combustible cigarette
11229748|NCT03178981|Experimental|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
11229749|NCT03178981|Experimental|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
11229750|NCT03178981|Experimental|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
11229751|NCT03178981|Experimental|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
11229752|NCT03178981|Active Comparator|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
11229753|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
11229754|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
11229755|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
11229756|NCT03178942|Active Comparator|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
11229757|NCT03178942|Experimental|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
11229758|NCT03178929|Experimental|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.
~2000mg, po"
11229759|NCT03178929|No Intervention|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
11229760|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
11229761|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
11229762|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
11229763|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
11229764|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.
~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
11229765|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
11229766|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
11229767|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
11229768|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
11229769|NCT03178851|Experimental|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
11229770|NCT03178851|Experimental|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
11229773|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
11229774|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
11229775|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.)
11229776|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years. )
11229777|NCT03178786|Experimental|Parkinson's Disease|
11229778|NCT03178786|Sham Comparator|Healthy Control Subjects|
11229779|NCT03178773|Active Comparator|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
11229780|NCT03178773|Experimental|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
11229781|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
11229782|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
11229783|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
11229784|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
11229785|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
11229786|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
11229787|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
11229788|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
11229789|NCT03178695|Experimental|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
11229790|NCT03178695|No Intervention|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
11229791|NCT03178669|Experimental|Cobitolimod Dose 31 mg x 2|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
11229792|NCT03178669|Experimental|Cobitolimod Dose 125 mg x 2|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
11229793|NCT03178669|Experimental|Cobitolimod Dose 250 mg x 2|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
11229794|NCT03178669|Experimental|Cobitolimod Dose 125 mg x 4|Dose 125 mg of cobitolimod, at 4 occasions
11229795|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
11229796|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:
~sorafenib tablet, 400mg, bid."
11229797|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
11229798|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
11229799|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
11229800|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
11229801|NCT03178630||Patients with autoimmune liver disease|"Patients with autoimmune liver disease
~Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.
~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
11229802|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
11229803|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
11229804|NCT03178604|Active Comparator|Classic massage|Classic massage (CM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (20 minutes in total). This procedure was repeated for each muscle group.
11229805|NCT03178604|Active Comparator|Sham massage|Sham massage (SM). 20 minutes in total soft effleurage was performed. This procedure was repeated for each muscle group.
11229806|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
11229807|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
11229808|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
11229809|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
11229810|NCT03178552|Experimental|Cohort A: Alectinib 600 Milligrams (mg)|"This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.
~Enrollment to Cohort A is complete."
11229811|NCT03178552|Experimental|Cohort B: Dose Finding Phase (DFP) Alectinib|"This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose.
~Enrollment to Cohort B is complete."
11229812|NCT03178552|Experimental|Cohort B: Dose Expansion Phase (DEP) Alectinib|"This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.
~Enrollment to Cohort B is complete."
11229813|NCT03178552|Experimental|Cohort C: Atezolizumab 1200 mg|"This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.
~Enrollment to Cohort C is complete."
11229814|NCT03178552|Active Comparator|Cohort C: Pemetrexed, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.
~Enrollment to Cohort C is complete."
11229815|NCT03178552|Active Comparator|Cohort C: Gemcitabine, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.
~Enrollment to Cohort C is complete."
11229816|NCT03178552|Experimental|Cohort D: Entrectinib 600 Milligrams (mg)|This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death.
11229817|NCT03178552|Experimental|Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib|This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
11229818|NCT03178539|Active Comparator|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
11229819|NCT03178539|Active Comparator|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
11229820|NCT03178526|Active Comparator|levostatin gel|levostatin gel 1.2% topical gel was put into teh periodontal pocket using an insulin syringe
11229821|NCT03178526|Placebo Comparator|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
11229822|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
11229823|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
11229824|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
11229825|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
11229826|NCT03178487|Active Comparator|Participants receiving Upadacitinib dose A|Participants receiving Upadacitinib dose A once daily.
11229827|NCT03178487|Placebo Comparator|Participants receiving placebo|Participants receiving placebo
11229828|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
11229829|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
11229830|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
11229831|NCT03178461|No Intervention|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.
~The composition of the fluids given will be normal saline with 5% dextrose."
11229985|NCT03177356|Active Comparator|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
11229832|NCT03178461|Experimental|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.
~The composition of the fluids given will be normal saline with 5% dextrose."
11229833|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
11229834|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
11229835|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
11229836|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
11229837|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
11229838|NCT03178409||HCC|Patients affected by classical HCC
11229839|NCT03178409||MFCCC|Patients affected by classical MFCCC
11229840|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
11229841|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
11229842|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
11229843|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
11229844|NCT03178383|Experimental|Integrated Approach|
11229845|NCT03178383|Active Comparator|Standard Comparison|
11229846|NCT03178370||Diabetic Gastroparesis|
11229847|NCT03178370||Idiopathic Gastroparesis|
11229848|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
11229849|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
11229850|NCT03178344|Experimental|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.
~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
11229851|NCT03178344|Experimental|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.
~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
11229852|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
11229853|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
11229854|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
11229855|NCT03178305|Experimental|Intervention|"Besides the behavior change programme (Do Something Different)
~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)
~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).
~Patients with hypertension will also be offered a bloodpressure monitor.
~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).
~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
11229856|NCT03178305|No Intervention|Care as usual|Patients in this arm will receive care as usual with no restrictions.
11229857|NCT03178292|Active Comparator|Levofloxacin|Levofloxacin 500 mg daily for 5 days
11229858|NCT03178292|Placebo Comparator|Placebo|Placebo tab daily for 5 days
11229859|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
11229860|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
11229861|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
11229862|NCT03178253||3|
11229863|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
11229864|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
11229865|NCT03178227|Experimental|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
11229866|NCT03178227|No Intervention|Control|No intervention.
11229867|NCT03178214|Experimental|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
11229868|NCT03178214|Experimental|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
11229869|NCT03178214|Active Comparator|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
11229870|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
11229871|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
11229872|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
11229873|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
11229874|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
11229875|NCT03178149|Experimental|ASP7317 Dose Escalation|Successive cohorts of participants (3 participants/ 3 cohort) will be treated in each escalating dose cohort (low cells/dose; medium cells/dose; high cells/dose). All participants in the low cells/dose and medium cells/dose cohorts may be treated simultaneously. The high cells/dose cohort will require sentinel dosing. After the first participant is dosed with high cells/dose and followed for 6 weeks the independent Data Safety Monitoring Board (DSMB) will review the safety data and images and recommend if the second and third participants may be treated with high cells/dose. One of the 3 doses will be selected for evaluation of efficacy and safety during the Proof of Concept (PoC) stage of the study. All participants will receive 13 weeks of immunosuppressive therapy (IMT) starting 1 week prior to day of transplant and continuing for 12 weeks posttransplant.
11229876|NCT03178149|Experimental|ASP7317 PoC Low Dose|Low cells/ dose will be administered to the study eye via a subretinal injection. All participants randomized to receive treatment with ASP7317 will receive 13 weeks of IMT starting 1 week prior to day of transplant and continuing for 12 weeks posttransplant.
11229877|NCT03178149|Experimental|ASP7317 PoC Selected Dose from Dose Escalation|Selected cells/ dose will be administered to the study eye via a subretinal injection. All participants randomized to receive treatment with ASP7317 will receive 13 weeks of IMT starting 1 week prior to day of transplant and continuing for 12 weeks posttransplant.
11229878|NCT03178149|Placebo Comparator|Placebo untreated group|Untreated participants with age-related macular degeneration (AMD)
11229879|NCT03178149|Experimental|ASP7317 Low Dose or Selected Dose Extension|If the primary endpoint for PoC is demonstrated for the selected cells/dose or low cells/dose of ASP7317, participants in the untreated control group, who completed the 26-week visit, will be allowed to cross over to treatment with ASP7317 in an extension stage of the protocol, provided the participant continues to meet eligibility criteria and are suitable for receiving IMT.
11229880|NCT03178149|Experimental|ASP7317 Safety Surveillance|Participants consented to participate in the safety surveillance will be monitored for the participants long term safety via an annual health questionnaire.
11229881|NCT03178136||case group|There is no intervention in case group.
11229882|NCT03178136||control group|The control group as the contrast for case group.
11229883|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
11229884|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
11229885|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
11229886|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).
~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
11229887|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
11229888|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
11229889|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.
~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
11229890|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
11229891|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
11229892|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
11229893|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
11229894|NCT03178019||Prediabetes group|Subjects with prediabetes
11229895|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
11229896|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
11229897|NCT03178006||obese|BMI 30-40kg/m2
11229898|NCT03178006||control|BMI 20-27,5kg/m2
11229986|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
11229899|NCT03177993|Experimental|IDA 1|"ivermectin, diethylcarbamazine and albendazole Day 0,
~permethrin Day 0 if excluded from ivermectin
~Details of dosing:
~ivermectin: 200 mcg/kg oral
~diethylcarbazine: 6mg/kg oral
~albendazole 400mg oral
~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
11229900|NCT03177993|Experimental|IDA 2|"ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8
~permethrin Day 0 and Day 8 if excluded from ivermectin
~Details of dosing:
~ivermectin: 200 mcg/kg oral
~diethylcarbazine: 6mg/kg oral
~albendazole 400mg oral
~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
11229901|NCT03177993|Active Comparator|DA|"diethylcarbamazine and albendazole Day 0
~permethrin Day 8 if scabies present in participant or household member
~Details of dosing:
~diethylcarbazine: 6mg/kg oral
~albendazole 400mg oral
~permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
11229902|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
11229903|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
11229904|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)
~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
11229905|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.
~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
11229906|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia
~Interventions: Psychoeducative advice to improve sleep"
11229907|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
11229908|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.
~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
11229909|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.
~Assigned Interventions
~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
11229910|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
11229911|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
11229912|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
11229913|NCT03177915|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
11229914|NCT03177915|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
11229915|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
11229916|NCT03177902||Control group|Healthy Volunteers
11229917|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
11229918|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);
~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
11229919|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
11229920|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
11229921|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
11229922|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11229923|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11229924|NCT03177837|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11229925|NCT03177837|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11229926|NCT03177824|Experimental|S|Sildenafil citrate (25mg)
11229927|NCT03177824|Placebo Comparator|P|placebo oral tablet
11229928|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11229929|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11229930|NCT03177798|Experimental|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)
~1 week washout
~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
11229931|NCT03177798|Experimental|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)
~1 week washout
~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
11229932|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
11229933|NCT03177785|No Intervention|Control|Wait-list control
11229934|NCT03177772||LTC Facility 1|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
11229935|NCT03177772||LTC Facility 2|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
11229936|NCT03177772||LTC Facility 3|Pre-loss Grief Support Group offered in long-term care facility for dementia family caregivers anticipating the death of their care recipient within next 6 month. Two hour sessions for 10 weeks include psychoeducation, motivational interviewing, cognitive behavioral and exposure approaches. Supportive others, selected by participants are included in two sessions.
11229937|NCT03177746|Experimental|Dapoxetine/Tadalafil 30/20 mg film coated tablet|
11229938|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
11229939|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
11229940|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
11229941|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
11229942|NCT03177681|Experimental|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.
~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.
~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.
~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
11229943|NCT03177681|Experimental|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.
~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.
~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.
~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
11229944|NCT03177668|Experimental|YS110|"Phase 1 part: Administration of 3 different dose cohort
~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
11229945|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
11229946|NCT03177655|Active Comparator|Journaling|Keeping a journal
11229947|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
11229948|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
11229949|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
11229950|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
11229951|NCT03177616|No Intervention|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
11229952|NCT03177616|Experimental|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
11229953|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
11229954|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
11229987|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
11229955|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
11229956|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
11229957|NCT03177590|Experimental|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
11229958|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
11229959|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
11229960|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
11229961|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
11229962|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
11229963|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
11229964|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
11229965|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
11229966|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
11229967|NCT03177525|Experimental|Social SUCCESS|
11229968|NCT03177525|Other|Wait List|
11229969|NCT03177512|Experimental|LYNX Mobile App|
11229970|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
11229971|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.
~Intervention: Procedure: Invasive PPG"
11229972|NCT03177473||CervicalStim PEMF group|all subjects will receive active CervicalStim bone growth stimulator
11229973|NCT03177460|Experimental|Arm A (daratumumab)|Patients receive daratumumab IV over 4-8 hours once weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy during week 6.
11229974|NCT03177460|Experimental|Arm B (FMS inhibitor JNJ-40346527)|Patients receive FMS inhibitor JNJ-40346527 PO BID for 4-5 weeks in the absence of disease progression or unacceptable toxicity. After a 3 day wash-out period, patients undergo radical prostatectomy.
11229975|NCT03177447|Other|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
11229976|NCT03177434|Active Comparator|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses
~Dosage:
~weight up to 8 kg - 1 sachet per day
~weight 8 - 12 kg - 2 sachets a day
~weight 12 - 20 kg - 3 sachets a day
~weight> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
11229977|NCT03177434|Active Comparator|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
11229978|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
11229979|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
11229980|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
11229981|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC
~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC
~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC
~PP100-01 treatment is administered intravenously over 5 minutes."
11229982|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
11229983|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
11229984|NCT03177356|Experimental|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
11229988|NCT03177291|Active Comparator|Squamous Cell Lung Cancer (SQCLC)|Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
11229989|NCT03177291|Active Comparator|Non-Squamous Cell Lung Cancer (SQCLC)|Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
11229990|NCT03177278|Experimental|Arm 1|
11229991|NCT03177265|Experimental|Text to Engage|This group will get 8 text messages that target common misperceptions around quitting and use of quit services prior to receiving the first counseling phone call.
11229992|NCT03177265|Other|Mail Notice|This group will only get a mailing indicating that they will receive a call from a quitline counseling in two weeks.
11229993|NCT03177265|Experimental|Text to Enhance|Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks.
11229994|NCT03177265|Active Comparator|Telephone Counseling|Telephone counseling condition will receive standard 8 weeks of telephone counseling only.
11229995|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine
~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
11229996|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline
~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
11229997|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.
~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
11229998|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
11229999|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
11230000|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
11230001|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
11230002|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
11230003|NCT03177187|Experimental|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.
~RECRUITING"
11230004|NCT03177174|Active Comparator|Docetaxel|
11230005|NCT03177174|Active Comparator|Cisplatin|
11230006|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
11230007|NCT03177161|Experimental|Postal Questionnaire|
11230008|NCT03177161|Experimental|Online Questionnaire|
11230009|NCT03177161|Experimental|Face-to-face Questionnaire|
11230010|NCT03177161|Experimental|Telephone Questionnaire|
11230011|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar
~NO active enrollment of parents
~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses
~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
11230012|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention
~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.
~Enroll 35 eligible parents per practice
~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.
~Dietitians will provide up to 6 telephone counseling sessions.
~•Parents will complete surveys after enrollment and at the end of intervention"
11230013|NCT03177135|Experimental|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
11230014|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
11230015|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
11230016|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
11230017|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
11230018|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
11230019|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
11230020|NCT03177083|Active Comparator|peginterferon beta-1a|
11230021|NCT03177083|Active Comparator|Current Therapy|
11230022|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
11230023|NCT03177057|Experimental|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
11230024|NCT03177057|Experimental|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
11230025|NCT03177057|Experimental|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
11230026|NCT03177057|Sham Comparator|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
11230027|NCT03177044|Experimental|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
11230028|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
11230029|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
11230030|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
11230031|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
11230032|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
11230033|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
11230034|NCT03176979|Experimental|Diagnostic (CESM with DBT)|Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
11230035|NCT03176966|Active Comparator|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
11230036|NCT03176966|Active Comparator|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
11230037|NCT03176953|Experimental|prolonged exposure + topiramate|psychotherapy plus active medication
11230038|NCT03176953|Active Comparator|prolonged exposure + placebo|psychotherapy plus placebo medication
11230039|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
11230040|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
11230041|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
11230042|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
11230043|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
11230044|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
11230045|NCT03176927|Experimental|Gastroparesis|"magnetogastrogram
~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
11230046|NCT03176927|Experimental|Gastrectomy|"magnetogastrogram
~Total or partial gastrectomy group"
11230047|NCT03176927|Experimental|Functional dyspepsia|"magnetogastrogram
~Children with functional dyspepsia"
11230048|NCT03176927|Experimental|Chronic nausea|"magnetogastrogram
~Children with chronic nausea"
11230049|NCT03176927|Experimental|Control participants|"magnetogastrogram
~Group without any gastrointestinal diseases."
11230050|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
11230051|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
11230052|NCT03176901|Experimental|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
11230053|NCT03176901|Active Comparator|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
11230054|NCT03176888|Experimental|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
11230055|NCT03176888|No Intervention|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
11230056|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
11230057|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
11230058|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
11230059|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
11230060|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
11230061|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
11230062|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
11230063|NCT03176836|Experimental|MRI Imaging|"Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called diffusion weighted or DW MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results."
11230064|NCT03176823|Sham Comparator|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
11230065|NCT03176823|Experimental|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
11230066|NCT03176810|Active Comparator|OCT-guided PCI|PCI is performed by OCT guidance.
11230067|NCT03176810|Active Comparator|Angiography-guided PCI|PCI is performed by angiography guidance alone.
11230068|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
11230069|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID
~Standard Condition Nicotine Patches:
~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
11230070|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID
~Standard Condition Placebo Patches:
~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
11230071|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22
~Extended Condition Nicotine Patches:
~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
11230072|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22
~Extended Condition Placebo Patches:
~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
11230073|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
11230074|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
11230075|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
11230076|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
11230077|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
11230078|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline
~+ Total Knee Replacement ( which will not be the intervention of interest)"
11230079|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline
~+ Total Knee Replacement ( which will not be the intervention of interest)"
11230080|NCT03176745||healthy controls|"no history of pulmonary disease
~absence of symptoms, smoking history < 10 pack years
~normal lung function testing"
11230116|NCT03176589|Active Comparator|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP) device or PEP bottle of 10-15 cm of water pressure
11230081|NCT03176745||chronic obstructive pulmonary disease|"clinical history and/or specialist diagnosis of COPD and risk factor(s)
~persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation
~dyspnea, cough and/or sputum production"
11230082|NCT03176745||bronchial asthma|"clinical history and/or specialist diagnosis of bronchial asthma
~respiratory symptoms compatible with asthma varying over time
~variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness
~exclusion of alternative explanation"
11230083|NCT03176745||sarcoidosis|"clinical history and/or specialist diagnosis of sarcoidosis
~lymphocytic alveolitis and CD4/CD8 > 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma
~exclusion of alternative explanation"
11230084|NCT03176732||Group 1: Normotensive|Categorized by 24-hr systolic BP (SBP): normotensive (< 125 mm Hg) on no BP medications
11230085|NCT03176732||Group 2: Controlled Hypertensive|Categorized by 24-hr systolic BP (SBP): controlled hypertensive (< 130 mm Hg) on BP medication(s) and/or lifestyle modification
11230086|NCT03176732||Group 3: Uncontrolled Hypertensive|Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications
11230087|NCT03176732||Group 4: Hypertensive|Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)
11230088|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
11230089|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
11230090|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
11230091|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
11230092|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
11230093|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
11230094|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
11230095|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
11230096|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
11230097|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
11230098|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
11230099|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
11230100|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
11230101|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
11230102|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
11230103|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
11230104|NCT03176667|Experimental|ESP for VATS|Erector Spinae plane (ESP) block
11230105|NCT03176667|Active Comparator|ICB for VATS|Intercostal block (ICB)
11230106|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
11230107|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
11230108|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
11230109|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
11230110|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
11230111|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
11230112|NCT03176615|Experimental|Group A (Cross-over Group 1)|Subjects randomly assigned to two experimental diets. This arm will receive high-fat meals first, followed by a washout period of two-seven days and then low-fat meals.
11230113|NCT03176615|Experimental|Group B (Cross-over Group 2)|Subjects randomly assigned to two experimental diets. This arm will receive low-fat meals first, followed by a washout period of two-seven days and then high-fat meals.
11230114|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
11230115|NCT03176589|Sham Comparator|sham PEP|3 cycles of 10 deep inspiration and expiration in a sham tube without expiratory resistance
11230117|NCT03176589|Experimental|deep breathing maneuvers|3 cycled of 10 deep breathing maneuvers without PEP or sham PEP
11230118|NCT03176576|Experimental|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
11230119|NCT03176576|Other|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
11230120|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
11230121|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
11230122|NCT03176537|Placebo Comparator|Placebo|Gel, daily
11230123|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
11230124|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
11230125|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
11230126|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
11230127|NCT03176511|Experimental|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
11230128|NCT03176511|Active Comparator|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
11230129|NCT03176498|Experimental|Experimental group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
11230130|NCT03176498|Placebo Comparator|Control group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo：saline
11230131|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
11230132|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
11230133|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
11230134|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
11230135|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
11230136|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
11230137|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
11230138|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
11230139|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
11230140|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
11230141|NCT03176420|Experimental|Symptomayic chronically occluded cervical ICA|
11230142|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.
~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
11230143|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
11230144|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
11230145|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
11230146|NCT03176355|Other|Chronic dacryocystitis patients|
11230147|NCT03176342|Experimental|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
11230148|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
11230149|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
11230150|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
11230151|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
11230152|NCT03176277|Experimental|ONO-7475: dose escalation|Successive dose escalation cohorts to determine MTD
11230153|NCT03176264|Experimental|PDR001|
11230178|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.
~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
11230179|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.
~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
11230349|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
11230154|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
11230155|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
11230156|NCT03176238|Experimental|everolimus + exemestane|Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily
11230157|NCT03176225|Experimental|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
11230158|NCT03176225|Active Comparator|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
11230159|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
11230160|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
11230161|NCT03176199|Experimental|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
11230162|NCT03176199|Active Comparator|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
11230163|NCT03176186|No Intervention|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
11230164|NCT03176186|Active Comparator|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
11230165|NCT03176173|Experimental|Arm I (image guided radiation therapy)|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.
11230166|NCT03176173|Active Comparator|Arm II (standard of care immunotherapy)|Patients who decline to undergo radiation therapy receive standard of care immunotherapy.
11230167|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
11230168|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
11230169|NCT03176134|Experimental|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
11230170|NCT03176134|Active Comparator|Cohort 1 Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
11230171|NCT03176134|Experimental|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
11230172|NCT03176134|Active Comparator|Cohort 2 Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
11230173|NCT03176134|Experimental|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
11230174|NCT03176134|Active Comparator|Cohort 3: Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
11230175|NCT03176134|Experimental|Cohort 4: Tedizolid phosphate Birth to <28 Days Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
11230176|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days
11230177|NCT03176121|Experimental|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.
~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
11230247|NCT03175549|Active Comparator|Otezla (apremilast)|100 mg (50 mg/bid) taken orally for 5 days after a 9 day titration to recommended dose
11230180|NCT03176095|Active Comparator|Probiotic Group|"The participants in the Probiotic group were provided with dietary supplements in the form as sachets with freeze dried bacteria (active lactobacilli culture) mixed with maltodextrin for daily intake (1 per day). The powder was dissolved in water or other non-alcoholic cold drink mixed with fruit before ingestion.
~The probiotic product consisted of two different bacterial strains."
11230181|NCT03176095|Placebo Comparator|Placebo Group|The participants in the Placebo group were provided with dietary supplements in the form as sachets with maltodextrin for daily intake (1 per day).
11230182|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:
~A reminder letter indicating need for screening
~A FIT kit with completion instructions
~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)
~A pre-paid return mailer for FIT Kit"
11230183|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:
~A reminder letter indicating need for screening
~Instructions for obtaining a FIT kit
~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
11230184|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:
~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
11230185|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
11230186|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
11230187|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
11230188|NCT03176043|Experimental|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
11230189|NCT03176043|Active Comparator|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate >90 /min, systolic BP <100 mmHg, respiratory rate >20, peripheral capillary refill >2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
11230190|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
11230191|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
11230192|NCT03176017|Active Comparator|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
11230193|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
11230194|NCT03176004|Experimental|Attention Bias Modification|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a threatening word.
11230195|NCT03176004|Active Comparator|Active Control Condition|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a word with a specific color.
11230196|NCT03176004|No Intervention|Wait List|Participants simply return after 8 weeks.
11230197|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
11230198|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
11230199|NCT03175952||PCI|
11230200|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
11230201|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
11230202|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
11230203|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
11230204|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
11230205|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
11230206|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
11230207|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
11230208|NCT03175887|Experimental|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
11230209|NCT03175887|Other|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.
~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
11230210|NCT03175874|Other|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
11230211|NCT03175874|Other|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
11230212|NCT03175874|Other|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
11230213|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
11230214|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))
~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))
~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
11230215|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
11230216|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
11230217|NCT03175809|Active Comparator|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
11230218|NCT03175809|Experimental|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
11230219|NCT03175796|Experimental|IMH-HV Treatment Group|Infant Mental Health-Home Visiting. Weekly home visits for up to one year by a trained IMH-HV treatment provider. Treatment delivery consistent with the IMH-HV manual.
11230220|NCT03175796|No Intervention|Treatment as Usual Control Group|No intervention provided as part of participation in this study; families are free to access community resources including any available treatment(s) in the community.
11230221|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
11230222|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
11230223|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
11230224|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
11230225|NCT03175757|Placebo Comparator|Placebo|Placebo
11230226|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
11230227|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
11230228|NCT03175731|Experimental|Proton Pump Inhibitors|Esomeprazole or Pantoprazole(or other PPIs) 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
11230229|NCT03175731|Placebo Comparator|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
11230230|NCT03175718|Experimental|VAC Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of Incisional Negative pressure wound therapy.
11230231|NCT03175718|Active Comparator|Control Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of standard gauze dressing with no negative pressure application.
11230232|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
11230233|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
11230234|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
11230235|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
11230236|NCT03175653|Experimental|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
11230237|NCT03175653|Active Comparator|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
11230238|NCT03175640|Experimental|Implementation intervention|
11230239|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
11230240|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
11230241|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
11230242|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
11230243|NCT03175588|Experimental|virtual rehabilitation|video based exercise
11230244|NCT03175588|No Intervention|physical Activity|different type of physical Activity
11230245|NCT03175562|Experimental|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
11230246|NCT03175562|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
11230250|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL). Enrollees who stayed in a HDHP without a PDL will also serve as controls for the study group who switch from HDHPs without PDLs to HDHPs with PDLs.
11230251|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
11230252|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
11230253|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
11230254|NCT03175510||patients group|Patients with low back pain (18-65 years)
11230255|NCT03175497|Experimental|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.
~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
11230256|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
11230257|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.
~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
11230258|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
11230259|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
11230260|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
11230261|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
11230262|NCT03175432|Experimental|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11230263|NCT03175432|Experimental|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11230264|NCT03175393||postprandial dyslipidemia|
11230265|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
11230266|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
11230267|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
11230268|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
11230269|NCT03175367|Experimental|Group A: matching placebo|Placebo SC QW for 16 weeks
11230270|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
11230271|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
11230272|NCT03175367|Experimental|Group B: matching placebo|Placebo IV Q4W for 24 weeks
11230273|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
11230274|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
11230275|NCT03175341|Experimental|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.
~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
11230276|NCT03175341|Active Comparator|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.
~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
11230277|NCT03175328|Experimental|early group|In the early group, continuous renal replacement therapies was started within 8 hours after randomization.
11230278|NCT03175328|Experimental|delayed group|In the delayed group, continuous renal replacement therapies was initiated if at least one of the following criteria was met: KDIGO 3, severe hyperkalemia, pulmonary edema, blood urea nitrogen level higher than 112 mg per deciliter after randomization.
11230279|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).
~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
11230280|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
11230350|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
11230281|NCT03175302||Surgical group|Baseline preoperative digital cognitive testing performance in adults to predict frequency and severity of clinician reported outcomes within the first three months post-surgery.
11230282|NCT03175302||Control|Non-surgery matched peers with the same testing.
11230283|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
11230284|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
11230285|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
11230286|NCT03175250|Active Comparator|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
11230287|NCT03175250|Active Comparator|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
11230288|NCT03175250|Experimental|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
11230289|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
11230290|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
11230291|NCT03175224|Experimental|Single-Arm|APL-101 Oral Capsules
11230292|NCT03175211|Experimental|BI 456906|
11230293|NCT03175211|Placebo Comparator|Placebo|
11230294|NCT03175198||Prazaxa Capsules Group|
11230295|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
11230296|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
11230297|NCT03175172|Experimental|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
11230298|NCT03175159|Active Comparator|Standard of Care (SOC)|Sexual risk-reduction counseling sessions.
11230299|NCT03175159|Active Comparator|Time & Intensity Matched Control|Relaxation therapy with educational support.
11230300|NCT03175159|Experimental|Behavioral Activation & Risk Reduction Counseling|Behavioral activation with risk reduction counseling.
11230301|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
11230302|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
11230303|NCT03175120|Experimental|Insulin degludec/liraglutide|
11230304|NCT03175120|Active Comparator|Insulin degludec|
11230305|NCT03175107|Experimental|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
11230306|NCT03175094|Experimental|Holistic Health Recovery Program for HIV+ Intervention|
11230307|NCT03175094|No Intervention|Control|
11230308|NCT03175081|Experimental|Test group|Patients will undergo elective bariatric surgery with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
11230309|NCT03175081|Experimental|Control group|Patients will undergo elective bariatric surgery with only normal saline injected along the stomach region at the end of the surgical procedure.
11230310|NCT03175068|Active Comparator|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
11230351|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
11230354|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
11230311|NCT03175068|Placebo Comparator|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
11230312|NCT03175055|Experimental|Phoenix|Phoenix
11230313|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
11230314|NCT03175029|Experimental|TAC-302|
11230315|NCT03175029|Placebo Comparator|Placebo|
11230316|NCT03175016|Experimental|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
11230317|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
11230318|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
11230319|NCT03175003|Experimental|Food Product 3|Experimental 1
11230320|NCT03175003|Experimental|Food Product 4|Experimental 2
11230321|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
11230322|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
11230323|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
11230324|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
11230325|NCT03174977|Experimental|18F-Raltegravir|
11230326|NCT03174964|Experimental|Treatment group|IVIg group
11230327|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
11230328|NCT03174951|Experimental|Treatment group|IVIg group
11230329|NCT03174951|No Intervention|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
11230330|NCT03174938|Other|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 250 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.
~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.
~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.
~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
11230331|NCT03174938|Other|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 250 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.
~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.
~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline."
11230332|NCT03174938|Other|COHORT C: SCD and MCI|"300 patients with either subjective cognitive decline (SCD; n=150) or mild cognitive impairment (MCI; n=150) will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, all cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio) will be included.
~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.
~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done every 2 years. Amyloid PET will be performed at baseline and after 4 years.
~A auxiliary cohort (Cohort C2) 150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y."
11230333|NCT03174938|Other|COHORT D: Dementia due to Alzheimer's disease|"175 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include 50 cases aged 40-65 years of age, 75 cases aged 66-79 years of age and 50 cases aged 80-100 years of age.
~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.
~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
11230352|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
11230353|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
11230395|NCT03174483|Experimental|hypertonic saline|nasal spray will be used twice daily
11230334|NCT03174938|Other|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:
~140 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD) (n=50), Progressive nonfluent aphasia (PNFA) (n=20), semantic dementia (SD) (n=20), Progressive supranuclear palsy (PSP) (n=30), Corticobasal degeneration (CBD) (n=20).
~50 cases with subcortical Vascular dementia (VaD).
~150 cases with either Parkinson's disease (PD) (n=50), Parkinson's disease with dementia (PDD) (n=30), Dementia with Lewy Bodies (DLB) (n=50), Multiple system atrophy (MSA) (n=20).
~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.
~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
11230335|NCT03174925|Experimental|Diagnostic (elastography)|Patients undergo elastography over 10 minutes prior to fine needle aspiration or surgical resection of the thyroid nodule.
11230336|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
11230337|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
11230338|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
11230339|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
11230340|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
11230341|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
11230342|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
11230343|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
11230344|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
11230345|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
11230346|NCT03174873|Other|Laparoscopy for unexplained infertile couples|
11230347|NCT03174860|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
11230355|NCT03174795|Experimental|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
11230356|NCT03174782|Active Comparator|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
11230357|NCT03174782|Placebo Comparator|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
11230358|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
11230359|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
11230360|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
11230361|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
11230362|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
11230363|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
11230364|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
11230365|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
11230366|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
11230367|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
11230368|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
11230369|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
11230370|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
11230371|NCT03174717|Experimental|Music intervention|LTC residents will participate in an individualized music performance with a musician
11230372|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
11230373|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
11230374|NCT03174678|Other|Control|Apple juice
11230375|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.
~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
11230376|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
11230377|NCT03174639|Experimental|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
11230378|NCT03174626|Experimental|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
11230379|NCT03174626|Other|Usual Care|No intervention is provided
11230380|NCT03174613|Experimental|LC51-0255|tablets, PO
11230381|NCT03174613|Placebo Comparator|Placebo|tablets, PO
11230382|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
11230383|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
11230384|NCT03174561|Other|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.
~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
11230385|NCT03174561|Other|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
11230386|NCT03174548|Experimental|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
11230387|NCT03174548|Experimental|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
11230388|NCT03174548|Experimental|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
11230389|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
11230390|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
11230391|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
11230392|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
11230393|NCT03174496||Children aged 4-7 years|
11230394|NCT03174496||Children and adolescents aged 8-16 years|
11230397|NCT03174470|Experimental|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
11230398|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
11230399|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
11230400|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
11230401|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
11230402|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
11230403|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
11230404|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
11230405|NCT03174405|Experimental|AVELUMAB|
11230406|NCT03174392|Experimental|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
11230407|NCT03174392|Active Comparator|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
11230408|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
11230409|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
11230410|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
11230411|NCT03174353|Experimental|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
11230412|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:
~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.
~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.
~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.
~This is in addition to the diet (see below, control group)"
11230413|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
11230414|NCT03174327|Other|Hepatic Transplantation|
11230415|NCT03174314|Experimental|50 visually impaired|50 visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
11230416|NCT03174314|Active Comparator|50 healthy controls|50 healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
11230417|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
11230418|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
11230419|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
11230420|NCT03174275|Experimental|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).
~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.
~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
11230472|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
11230473|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
11231021|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
11230421|NCT03174275|Experimental|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).
~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.
~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
11230422|NCT03174275|Experimental|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).
~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.
~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
11230423|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
11230424|NCT03174262|No Intervention|Control Group|
11230425|NCT03174249|Experimental|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
11230426|NCT03174236|Experimental|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day for a minimum of 48 hours and a usual maximum of seven days.
11230427|NCT03174236|Active Comparator|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours for a minimum of two days and a maximum of seven days.
11230428|NCT03174236|Experimental|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
11230429|NCT03174236|Placebo Comparator|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
11230430|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
11230431|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
11230432|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
11230433|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
11230434|NCT03174197|Experimental|Adjuvant phase (temozolomide, atezolizumab)|Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11230435|NCT03174197|Experimental|Concurrent phase (temozolomide, atezolizumab, RT)|Patients receive temozolomide PO daily on days 1-42 and atezolizumab IV over 30-60 minutes on day 1, 15, 29, and 42. Patients undergo RT 5 days per week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
11230436|NCT03174184|Experimental|Rifampin resistant A|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily (QD), MEROPENEM 2 grams (G) thrice daily (TID) intravenously, Amoxicillin/Clavulanate Potassium 500 milligrams (MG)-125 MG Oral Tablet once daily for 14 days
11230437|NCT03174184|Experimental|Rifampin resistant B|Participants with the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID (thrice daily) intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
11230438|NCT03174184|Experimental|Rifampin susceptible C|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive RIFAMPIN 20mg/kg once daily, MEROPENEM 2 grams TID (thrice daily) intravenously, Amx/Clv orally at a dose of 500 mg/125 mg thrice daily for 14 days
11230439|NCT03174184|Experimental|Rifampin susceptible D|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 2 grams TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
11230440|NCT03174184|Experimental|Rifampin susceptible E|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 1 gram TID intravenously, Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet once daily for 14 days
11230441|NCT03174184|Experimental|Rifampin susceptible F|Participants without the presence of rifampin resistance-conferring rpoB mutations in M. tuberculosis who will receive MEROPENEM 3 grams QD intravenously, Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet once daily for 14 days
11230442|NCT03174171|Experimental|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
11230443|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
11230444|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
11230474|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
11230475|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
11230476|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
11230477|NCT03173950|Experimental|1/Experimental Therapy|Participants will receive nivolumab at standard dose of240mg IV every 2 weeks for cycles 1 through 2, thendoses of 480mg every 4 weeks for a total of 14 additional doses
11230445|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
11230446|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
11230447|NCT03174145|Active Comparator|Active group|
11230448|NCT03174145|Sham Comparator|Control group|
11230449|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
11230450|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
11230451|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
11230452|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
11230453|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
11230454|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
11230455|NCT03174093|Experimental|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
11230456|NCT03174093|No Intervention|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
11230457|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
11230458|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
11230459|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
11230460|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
11230461|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
11230462|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
11230463|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
11230464|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
11230465|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
11230466|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
11230467|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
11230468|NCT03174015|Experimental|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
11230469|NCT03174015|No Intervention|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
11230470|NCT03174002|Experimental|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
11230471|NCT03174002|Active Comparator|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
11230478|NCT03173937|Experimental|1|CordIn(TM) is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
11230479|NCT03173924|Experimental|1/Experimental Intervention|18FDCFPyLis administered to cohorts
11230480|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
11230481|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
11230482|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
11230483|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
11230484|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
11230485|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
11230486|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
11230487|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
11230488|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
11230489|NCT03173859|Experimental|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
11230490|NCT03173859|Active Comparator|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
11230491|NCT03173846||Adult children of AD patients|
11230492|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
11230493|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.
~And they will be able to discuss their care needs with their health care practitioners."
11230494|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
11230495|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
11230496|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
11230497|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
11230498|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
11230499|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
11230563|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
11230500|NCT03173781|Experimental|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:
~Reaches the maximum permitted dosage of 600 mg TID;
~Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or
~Experiences intolerable adverse events (AEs)."
11230501|NCT03173781|Placebo Comparator|placebo|sugar pill
11230502|NCT03173768|No Intervention|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
11230503|NCT03173768|Experimental|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
11230504|NCT03173755||People with normal weight|
11230505|NCT03173755||people with overweight and obesity|
11230506|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
11230507|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
11230508|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
11230509|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
11230510|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
11230511|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
11230512|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
11230513|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
11230514|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
11230515|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
11230516|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
11230517|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
11230518|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
11230519|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
11230520|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
11230521|NCT03173703|Experimental|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
11230522|NCT03173703|Active Comparator|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
11230523|NCT03173690|Experimental|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
11230524|NCT03173690|Other|Control group|No intervention at the ICU, medication reconciliation at the ward
11230525|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
11230526|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
11230527|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
11230528|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
11230529|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
11230530|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
11230531|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
11230532|NCT03173625|Experimental|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
11230533|NCT03173625|Placebo Comparator|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
11230564|NCT03173456|Active Comparator|oxycodone/APAP|5 mg oxycodone + 325 mg acetaminophen
11230565|NCT03173456|Active Comparator|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
11230566|NCT03173456|Active Comparator|codeine/APAP|30 mg codeine + 300 mg acetaminophen
11230567|NCT03173456|Active Comparator|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
11230568|NCT03173456|Active Comparator|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
11230569|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
11230534|NCT03173612|Experimental|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
11230535|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal
~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
11230536|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
11230537|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
11230538|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
11230539|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
11230540|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal
~The single dose is 480mg."
11230541|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal
~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
11230542|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.
~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.
~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
11230543|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
11230544|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
11230545|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
11230546|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
11230547|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
11230548|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
11230549|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
11230550|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
11230551|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
11230552|NCT03173560|Experimental|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any >= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to [=] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
11230553|NCT03173560|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length = 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
11230554|NCT03173547|Active Comparator|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
11230555|NCT03173547|Placebo Comparator|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
11230556|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=175 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
11230557|NCT03173534|Experimental|TAVR + WATCHMAN|n=175 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
11230558|NCT03173521|Experimental|open label|
11230559|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11230560|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11230561|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
11230562|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
11230570|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
11231022|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
11230571|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
11230572|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
11230573|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
11230574|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
11230575|NCT03173391|Experimental|HMS5552|75mg BID
11230576|NCT03173391|Placebo Comparator|Placebo|BID
11230577|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
11230578|NCT03173378||Control|Adult age-matched family members of the patients
11230579|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
11230580|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
11230581|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
11230582|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
11230583|NCT03173326|Experimental|Subarachnoid block|
11230584|NCT03173326|Active Comparator|General anesthesia|
11230585|NCT03173313|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
11230586|NCT03173313|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
11230587|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
11230588|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
11230589|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
11230590|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
11230591|NCT03173248|Experimental|AG-120 (ivosidenib) with Azacitidine|
11230592|NCT03173248|Placebo Comparator|Placebo with Azacitidine|
11230593|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
11230594|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
11230595|NCT03173222|Active Comparator|EA1|
11230596|NCT03173222|Active Comparator|EA2|
11230597|NCT03173222|No Intervention|Control|
11230598|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
11230599|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
11230600|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
11230601|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:
~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
11230602|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :
~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
11230603|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
11230604|NCT03173170|Experimental|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
11230605|NCT03173157|Experimental|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
11230606|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
11230691|NCT03172650||study group|non alcoholic fatty liver disease patients
11230607|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
11230608|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
11230609|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
11230610|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
11230611|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
11230612|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
11230613|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
11230614|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs for up to 3 years.
11230615|NCT03173066|Experimental|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
11230616|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.
~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
11230617|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus
~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
11230618|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
11230619|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
11230620|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
11230621|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
11230622|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
11230623|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
11230624|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
11230625|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
11230626|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
11230627|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
11230628|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
11230629|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
11230630|NCT03172988|Experimental|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
11230631|NCT03172988|Experimental|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
11230632|NCT03172988|Experimental|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
11230692|NCT03172650||Control group|fatty liver patients
11230693|NCT03172637||Group A|50 female end stage renal disease patients
11230633|NCT03172988|Placebo Comparator|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
11230634|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
11230635|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
11230636|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
11230637|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
11230638|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
11230639|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
11230640|NCT03172936|Experimental|Dosing Schedule A|Patients will be treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks on followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
11230641|NCT03172936|Experimental|Dosing Schedule B|Patients will be treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
11230642|NCT03172923|Active Comparator|sliding hip screw|fixation of fracture with a sliding hip screw
11230643|NCT03172923|Experimental|intramedullary nail|fixation of the fracture with an intramedullary nail
11230644|NCT03172910|Experimental|Cohort 1|ciraparantag (60 mg)
11230645|NCT03172910|Experimental|Cohort 2|ciraparantag (120 mg)
11230646|NCT03172910|Experimental|Cohort 3|ciraparantag (180 mg)
11230647|NCT03172910|Experimental|Cohort 4|ciraparantag (30 mg)
11230648|NCT03172910|Placebo Comparator|Placebo|placebo (saline for injection)
11230649|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
11230650|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
11230651|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
11230652|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with moderate impairment of the liver (Child Pugh B)
11230653|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with severe impairment of the kidneys
11230654|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with severe impairment of the liver (Child Pugh C)
11230655|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):
~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
11230656|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):
~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
11230657|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.
~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
11230658|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
11230659|NCT03172845|Experimental|Vulnerable plaque|Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
11230660|NCT03172845|Active Comparator|Without any vulnerable plaqueStable plaque|patient with bifurcation lesion undergoing baseline coronary angiography and baseline OCT.
11230661|NCT03172832|Active Comparator|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
11230662|NCT03172832|Active Comparator|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
11230663|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
11230664|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
11230665|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
11230666|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
11230667|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
11230668|NCT03172780|Experimental|Diclofenac Sodium Gel|Diclofenac Sodium Gel, 1%
11230669|NCT03172780|Active Comparator|Voltaren® Gel|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
11230670|NCT03172780|Placebo Comparator|Placebo gel|Placebo gel
11230671|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
11230672|NCT03172767||Term Preschoolers|Term children who haven't attend school.
11230673|NCT03172754|Experimental|Phase I patients|Phase I patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
11230674|NCT03172754|Experimental|Phase II patients: cohort 1|Phase II cohort 1 patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
11230675|NCT03172754|Experimental|Phase II patients: cohort 2|Phase II cohort 2 patients must not have received prior systemic therapy for advanced RCC.
11230676|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
11230677|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
11230678|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
11230679|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
11230680|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.
~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
11230681|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.
~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
11230682|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.
~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
11230683|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
11230684|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
11230685|NCT03172689|Other|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
11230686|NCT03172676|No Intervention|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
11230687|NCT03172676|Active Comparator|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
11230688|NCT03172676|No Intervention|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
11230689|NCT03172663|Experimental|group 1|
11230690|NCT03172663|Active Comparator|group 2|
11230695|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
11230696|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
11230697|NCT03172611|Experimental|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
11230698|NCT03172598|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
11230699|NCT03172598|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
11230700|NCT03172598|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
11230701|NCT03172598|Experimental|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
11230702|NCT03172598|Experimental|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
11230703|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
11230704|NCT03172572||Indication for surgery|Solid neoplasms
11230705|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
11230706|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
11230707|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
11230708|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
11230709|NCT03172533|Active Comparator|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
11230710|NCT03172533|Placebo Comparator|placebo group|placebo
11230711|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
11230712|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
11230713|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
11230714|NCT03172494|Experimental|Insulin degludec/liraglutide|
11230715|NCT03172494|Active Comparator|Insulin degludec|
11230716|NCT03172494|Active Comparator|Liraglutide|
11230717|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
11230718|NCT03172481|Placebo Comparator|Placebo Treatment|
11230719|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
11230720|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
11230721|NCT03172442|Experimental|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
11230722|NCT03172442|No Intervention|Control group|without intervention
11230723|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
11230724|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
11230725|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
11230726|NCT03172416|Other|Oxaliplatin|"3+3 dose escalation of oxaliplatin
~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.
~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.
~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks
~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
11230727|NCT03172403|Experimental|Patients with digestive cancer requiring resection surgery|"Patients with cancer of digestive system requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.
~V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months"
11230728|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
11231023|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
11230729|NCT03172377|Experimental|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
11230730|NCT03172377|No Intervention|Control group|Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
11230731|NCT03172364|Experimental|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
11230732|NCT03172364|Experimental|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
11230733|NCT03172351|Experimental|EDoF1|
11230734|NCT03172351|Active Comparator|Monofocal|
11230735|NCT03172351|Active Comparator|EDoF2|
11230736|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml in prefilled syringe Every other week 40 mg Adalimumab, was subcutaneously administered to rheumatic patients during 6 months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over a six-month period.
11230737|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml in prefilled syringe Every other week 40 mg Adalimumab, was subcutaneously administered to rheumatic patients during 6 months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over a six-month period.
11230738|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
11230739|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
11230740|NCT03172299|Active Comparator|Injection of anti-VEGF|
11230741|NCT03172299|Placebo Comparator|false injection of anti-VEGF|
11230742|NCT03172286|Active Comparator|Patient treated with fake radiofrequencer|
11230743|NCT03172286|Experimental|Patient treated with radiofrequencer|
11230744|NCT03172273|Experimental|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
11230745|NCT03172273|Active Comparator|paracentesis|Paracentesis with albumine invision
11230746|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
11230747|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
11230748|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
11230749|NCT03172208|Experimental|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
11230750|NCT03172208|Placebo Comparator|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
11230751|NCT03172208|Experimental|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
11230752|NCT03172208|Experimental|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
11230753|NCT03172208|Experimental|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
11230754|NCT03172208|Placebo Comparator|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
11230755|NCT03172208|Experimental|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
11230756|NCT03172208|Placebo Comparator|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
11230757|NCT03172208|Experimental|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
11230758|NCT03172208|Placebo Comparator|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
11230759|NCT03172208|Experimental|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
11230760|NCT03172208|Placebo Comparator|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
11230761|NCT03172195|Experimental|Patients with ulcerative colitis|Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.
11230762|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
11230763|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
11230764|NCT03172169||Healthy control group|no intervention
11230765|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
11230766|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
11230767|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
11230768|NCT03172143|Active Comparator|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
11230769|NCT03172143|Active Comparator|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
11230770|NCT03172130|Experimental|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
11230851|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
11230771|NCT03172130|Sham Comparator|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
11230772|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
11230773|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
11230774|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
11230775|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.
~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
11230776|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
11230777|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
11230778|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
11230779|NCT03172078|Active Comparator|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
11230780|NCT03172078|Active Comparator|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
11230781|NCT03172065|Other|control group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline
11230782|NCT03172065|Other|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
11230783|NCT03172052|Experimental|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was <100 cc in 24 h provided that tube is patent and properly positioned.
11230784|NCT03172052|Experimental|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
11230785|NCT03172052|Experimental|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
11230786|NCT03172052|Experimental|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
11230787|NCT03172026|Experimental|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
11230788|NCT03172026|Placebo Comparator|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
11230789|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
11230790|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
11230791|NCT03172013||Healthy volunteers|Healthy individuals
11230792|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
11230793|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
11230794|NCT03171987|Experimental|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
11230795|NCT03171987|Active Comparator|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
11230796|NCT03171974|Experimental|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
11230797|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
11230798|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
11230799|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
11230800|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
11230801|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
11230802|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
11230803|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
11230804|NCT03171935|Active Comparator|Conventional Weaning|
11230805|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
11230806|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
11230807|NCT03171896|Experimental|Intervention|Medical clown
11230808|NCT03171896|Sham Comparator|No Intervention|No clown in the room
11230809|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
11230810|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
11230852|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
11230811|NCT03171831|Experimental|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).
~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）
~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
11230812|NCT03171818|Experimental|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
11230813|NCT03171818|Placebo Comparator|Placebo|Saline
11230814|NCT03171805|Experimental|Propranolol group|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
11230815|NCT03171805|No Intervention|control group|Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
11230816|NCT03171779||Usual practice|
11230817|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
11230818|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
11230819|NCT03171753|Experimental|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
11230820|NCT03171753|Active Comparator|Control|patients wear headphones for 30 minuts without any sound
11230821|NCT03171740|Active Comparator|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
11230822|NCT03171740|Active Comparator|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
11230823|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
11230824|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
11230825|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
11230826|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
11230827|NCT03171701||maturation of arteriovenous fistula|
11230828|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
11230829|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
11230830|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
11230831|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
11230832|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
11230833|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
11230834|NCT03171662|Experimental|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
11230835|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11230836|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
11230837|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
11230838|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
11230839|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
11230840|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
11230841|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
11230842|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
11230843|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
11230844|NCT03171597|Other|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
11230845|NCT03171597|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
11230846|NCT03171597|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
11230847|NCT03171597|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
11230848|NCT03171584|Experimental|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
11230849|NCT03171584|Experimental|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
11230850|NCT03171584|Experimental|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
11230890|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
11230853|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
11230854|NCT03171545|Experimental|Patient Activation|This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
11230855|NCT03171545|Experimental|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
11230856|NCT03171545|No Intervention|No Intervention|Patients in clinic receive usual care.
11230857|NCT03171545|Experimental|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
11230858|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
11230859|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
11230860|NCT03171519|Active Comparator|Exercise|
11230861|NCT03171519|Experimental|Exercise + acupuncture|
11230862|NCT03171506|Experimental|Usual care plus ketogenic diet|
11230863|NCT03171506|Placebo Comparator|Usual care plus AND diet|
11230864|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
11230865|NCT03171480|Active Comparator|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
11230866|NCT03171480|Placebo Comparator|Placebo|The pharmacy has compounded an identical appearing placebo
11230867|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
11230868|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
11230869|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
11230870|NCT03171441||Controls|eutrophic children
11230871|NCT03171441||Overweight|Overweight children
11230872|NCT03171441||Obese|Obese children
11230873|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
11230874|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
11230875|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):
~40mg RZL-012 -administered at 8 sites
~80mg RZL-012 - administered at 16 sites
~120mg RZL-012 - administered at 24 sites
~180mg RZL-012 - administered at 36 sited"
11230876|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
11230877|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
11230878|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
11230879|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
11230880|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
11230881|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.
~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
11230882|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
11230883|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
11230884|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
11230885|NCT03171363|Experimental|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
11230886|NCT03171350|Experimental|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
11230887|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
11230888|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
11230889|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
11230891|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
11230892|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
11230893|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
11230894|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
11230895|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
11230896|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
11230897|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
11230898|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
11230899|NCT03171272|Experimental|Experimental Group|
11230900|NCT03171272|Sham Comparator|Control Group|
11230901|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).
~Daily for up to 12 weeks."
11230902|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
11230903|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
11230904|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
11230905|NCT03171207|Experimental|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
11230906|NCT03171207|Experimental|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
11230907|NCT03171194|Experimental|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
11230908|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
11230909|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
11230910|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
11230911|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
11230912|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
11230913|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
11230914|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
11230915|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
11230916|NCT03171129|Experimental|High flow nasal cannula system w/ ADINA|The intervention is the insertion of the the ADINA device into the high flow nasal cannula system. ADINA will be placed according to weight class recommendations to increase the positive end expiratory pressure (PEEP). ADINA is actually a combination of the Neotech RAM Cannula and a clear Regulator/Pop off valve.
11230917|NCT03171129|Active Comparator|high flow nasal cannula system|High flow nasal cannula will deliver oxygen at 2-4 lpm of flow. High flow cannula are used to provide the control interface.
11230918|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
11230919|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
11230920|NCT03171116||RTx renal transplant|renal transplant recipients
11230921|NCT03171116||Controls|control subjects
11230922|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
11230923|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
11230924|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.
~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
11230925|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
11231024|NCT03170609|Placebo Comparator|Placebo|Saline control
11230926|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
11230927|NCT03171064|Experimental|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
11230928|NCT03171064|No Intervention|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
11230929|NCT03171051|Other|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.
~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
11230930|NCT03171038|Experimental|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
11230931|NCT03171038|No Intervention|Usual care group|Usual care from t0 up until the common stopping date (t2).
11230932|NCT03171025|Experimental|Nivolumab, all patients|
11230933|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
11230934|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
11230935|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
11230936|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
11230937|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
11230938|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
11230939|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
11230940|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
11230941|NCT03170986|No Intervention|Control Arm|
11230942|NCT03170973|Experimental|Comparison of fatty acids before and after exercise|
11230943|NCT03170973|No Intervention|Comparison of fatty acids at baseline and 24 hours after|
11230944|NCT03170960|Experimental|Dose Escalation|"Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard 3 plus 3 design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage."
11230945|NCT03170960|Experimental|Expansion Cohort 1|RCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
11230946|NCT03170960|Experimental|Expansion Cohort 2|UC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
11230947|NCT03170960|Experimental|Expansion Cohort 3|UC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
11230948|NCT03170960|Experimental|Expansion Cohort 4|UC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
11230949|NCT03170960|Experimental|Expansion Cohort 5|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
11230950|NCT03170960|Experimental|Expansion Cohort 6|CRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
11230951|NCT03170960|Experimental|Expansion Cohort 7|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
11230952|NCT03170960|Experimental|Expansion Cohort 8|Stage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
11230953|NCT03170960|Experimental|Expansion Cohort 9|Stage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
11230954|NCT03170960|Experimental|Expansion Cohort 10|RCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
11230955|NCT03170960|Experimental|Expansion Cohort 11|TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
11230956|NCT03170960|Experimental|Expansion Cohort 12|OC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
11231025|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
11230957|NCT03170960|Experimental|Expansion Cohort 13|EC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
11230958|NCT03170960|Experimental|Expansion Cohort 14|HCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
11230959|NCT03170960|Experimental|Expansion Cohort 15|GC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
11230960|NCT03170960|Experimental|Expansion Cohort 16|CRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
11230961|NCT03170960|Experimental|Expansion Cohort 17|H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
11230962|NCT03170960|Experimental|Expansion Cohort 18|DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
11230963|NCT03170960|Experimental|Expansion Cohort 19 (SAC)|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
11230964|NCT03170960|Experimental|Expansion Cohort 20 (SAC)|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
11230965|NCT03170960|Experimental|Expansion Cohort 21 (SAC)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
11230966|NCT03170960|Experimental|Expansion Cohort 22 (SAA)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
11230967|NCT03170960|Experimental|Expansion Cohort 23|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
11230968|NCT03170960|Experimental|Expansion Cohort 24|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
11230969|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
11230970|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
11230971|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
11230972|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
11230973|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
11230974|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
11230975|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
11230976|NCT03170895|Experimental|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.
~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.
~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
11230977|NCT03170882|Experimental|Ixazomib plus dexamethasone|Ixazomib 4 mg as starting dose, capsules, orally on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at Cycle 2 for participants who tolerate the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged >=75 years) tablets, orally, on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (up to 28 months).
11230978|NCT03170882|Active Comparator|Pomalidomide plus dexamethasone|Pomalidomide 4 mg, capsules, orally on Days 1 to 21 of each 28-day cycle plus dexamethasone 40 mg, (or 20 mg if participant is aged >=75 years), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study (up to 28 months).
11231016|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
11231017|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
11231018|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
11230979|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.
~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.
~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.
~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
11230980|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
11230981|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
11230982|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
11230983|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
11230984|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
11230985|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
11230986|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
11230987|NCT03170817||N13-ammonia Cardiac Rest/Stress PET/CT|Patients with coronary artery disease (CAD) undergo a Cardiac Perfusion Rest/Stress Digital PET/CT scan using the radiopharmaceutical N13-ammonia and Regadenoson (Lexiscan) to induce pharmacologic stress.
11230988|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
11230989|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
11230990|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
11230991|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
11230992|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:
~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);
~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);
~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
11230993|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
11230994|NCT03170739|Experimental|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
11230995|NCT03170739|Experimental|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
11230996|NCT03170739|Experimental|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
11230997|NCT03170739|No Intervention|Control group|No intervention
11230998|NCT03170726|Active Comparator|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
11230999|NCT03170726|Active Comparator|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
11231000|NCT03170726|Placebo Comparator|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
11231001|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
11231002|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
11231003|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
11231004|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
11231005|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
11231006|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
11231007|NCT03170687|Experimental|foot cast|
11231008|NCT03170687|Active Comparator|short leg cast|
11231009|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
11231010|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
11231011|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
11231012|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
11231013|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
11231014|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
11231015|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
11231026|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
11231027|NCT03170570|Experimental|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
11231028|NCT03170557|Active Comparator|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
11231029|NCT03170557|Sham Comparator|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
11231030|NCT03170544|Experimental|Part 1, MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
11231031|NCT03170544|Experimental|Part 1, MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
11231032|NCT03170544|Experimental|Part 1, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
11231033|NCT03170544|Experimental|Part 1, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
11231034|NCT03170544|Experimental|Part 1, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
11231035|NCT03170544|Active Comparator|Part 1, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
11231036|NCT03170544|Experimental|Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg|MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
11231037|NCT03170544|Experimental|Part 3, MK-1092, 8.0 nmol/kg|MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
11231038|NCT03170544|Experimental|Part 3, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
11231039|NCT03170544|Active Comparator|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
11231040|NCT03170544|Experimental|Part 4, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
11231041|NCT03170544|Experimental|Part 4, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
11231042|NCT03170544|Experimental|Part 4, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
11231043|NCT03170544|Active Comparator|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
11231044|NCT03170531||Custom MR spine coil|
11231045|NCT03170518|Experimental|Single-blind run-in Period: Placebo|Participants will receive 1 placebo tablet matching canagliflozin 100 milligram (mg) once-daily during the 2-week single-blind placebo run-in period.
11231046|NCT03170518|Experimental|Double-blind Treatment Phase: Canagliflozin or Placebo|Canagliflozin 100 mg/matching placebo once-daily during first 12 weeks. At Week 13, participants who have glycated hemoglobin (HbA1c) of greater than or equal to (>=)7.0 percent (%), estimated glomerular filtration rate (eGFR) >=60 milliliter/minute/1.73 meter square (mL/min/1.73 m^2) will be re-randomized to either remain on canagliflozin 100 mg/matching placebo or up-titrate to canagliflozin 300 mg/matching placebo till Week 52.
11231047|NCT03170505||Acellular Dermal Matrix|
11231048|NCT03170505||Conchal Cartilage|
11231049|NCT03170492|Experimental|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
11231050|NCT03170492|Active Comparator|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
11231051|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
11231052|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
11231053|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
11231054|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
11231055|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.
~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
11231056|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
11231057|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
11231058|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
11231059|NCT03170427|Sham Comparator|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
11231094|NCT03170206|Experimental|Binimetinib Phase 2|"Binimetinib will be administered orally twice daily
~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
11231060|NCT03170427|Active Comparator|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
11231061|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
11231062|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
11231063|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
11231064|NCT03170388|Experimental|IDP-126 Gel|Gel
11231065|NCT03170388|Active Comparator|IDP-126 Component A|Component A
11231066|NCT03170388|Active Comparator|IDP-126 Component B|Component B
11231067|NCT03170388|Active Comparator|IDP-126 Component C|Component C
11231068|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
11231069|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
11231070|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
11231071|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
11231072|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
11231073|NCT03170362|Experimental|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
11231074|NCT03170362|No Intervention|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
11231075|NCT03170349|Experimental|Edwards PASCAL Transcatheter Mitral Valve Repair System|
11231076|NCT03170336|Experimental|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
11231077|NCT03170336|Active Comparator|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
11231078|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
11231079|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
11231080|NCT03170310|Experimental|Apatinib|
11231081|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
11231082|NCT03170271|Experimental|Benralizumab (Medi-563)|Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
11231083|NCT03170271|Placebo Comparator|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
11231084|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
11231085|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Both groups will be debriefed at the end of the study.
11231086|NCT03170245||B thalassemia group|"Laboratory investigations :
~complete blood count
~renal and liver function tests
~serum ferritin
~lipid profile
~Interleukin -6
~HsC-RP
~Adiponectin level
~Imaging :
~Abdominal ultrasound
~Echocardiography
~Carotid intima media thickness"
11231087|NCT03170245||Control group|"Laboratory investigations :
~complete blood count
~renal and liver function tests
~serum ferritin
~lipid profile
~Interleukin -6
~HsC-RP
~Adiponectin level
~Imaging :
~Abdominal ultrasound
~Echocardiography
~Carotid intima media thickness"
11231088|NCT03170232|Experimental|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
11231089|NCT03170232|Placebo Comparator|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
11231090|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
11231091|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
11231092|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 1|"Palbociclib will be administered orally once daily
~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
~Binimetinib will be administered orally twice daily
~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
11231093|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 2|"Palbociclib will be administered orally once daily
~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
~Binimetinib will be administered orally twice daily
~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
11231095|NCT03170206|Experimental|Palbociclib Phase 2|"Palbociclib will be administered orally once daily
~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle"
11231096|NCT03170193|Experimental|AMG 529|Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
11231097|NCT03170193|Placebo Comparator|Placebo|Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
11231098|NCT03170180|Experimental|sunitinib|
11231099|NCT03170180|Experimental|gefitinib|
11231100|NCT03170180|Experimental|imatinib|
11231101|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
11231102|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
11231103|NCT03170154|Experimental|Clareon IOL|Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery
11231104|NCT03170141|Experimental|Antigen-specific IgT cells|Patients will receive non-myeloablative chemotherapy consisting of fludarabine and/or cyclophosphamide, followed by intravenous infusion of autologous IgT cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of IgT cells. The tested IgT cell dosage ranges from 1×10^5 /kg to 1×10^7 /kg
11231105|NCT03170128|Active Comparator|Outpatient Physical Therapy|
11231106|NCT03170128|Active Comparator|Home Exercises|
11231107|NCT03170115|Experimental|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
11231108|NCT03170115|Placebo Comparator|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
11231109|NCT03170102|Other|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
11231110|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
11231111|NCT03170089|No Intervention|Control|NO program or scaling done
11231112|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
11231113|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
11231114|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
11231115|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
11231116|NCT03170037|Active Comparator|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
11231117|NCT03170037|Experimental|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
11231118|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
11231119|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
11231120|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
11231121|NCT03169985|Active Comparator|Rosuvastatin plus ezetimibe arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.
11231122|NCT03169985|Active Comparator|High-dose rosuvastatin monotherapy arm|In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.
11231123|NCT03169972||Previously treated patients (PTPs)|PTPs: patients who had 4 or more days to other Factor VIII (FVIII) products
11231124|NCT03169972||Previously untreated patients (PUPs)|PUPs: patients who had 3 or less previous exposure days to other products
11231125|NCT03169959|Experimental|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
11231141|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
11231177|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
11231126|NCT03169959|Experimental|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
11231127|NCT03169959|Experimental|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
11231128|NCT03169959|Experimental|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
11231129|NCT03169959|Experimental|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
11231130|NCT03169959|Experimental|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.
~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.
~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
11231131|NCT03169959|Experimental|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
11231132|NCT03169959|Experimental|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
11231133|NCT03169959|Experimental|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
11231134|NCT03169959|Experimental|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
11231135|NCT03169959|Experimental|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
11231136|NCT03169959|Experimental|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:
~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.
~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.
~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.
~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
11231137|NCT03169946|Active Comparator|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
11231138|NCT03169946|Active Comparator|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
11231139|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
11231140|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
11231142|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
11231143|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
11231144|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
11231145|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
11231146|NCT03169868|Experimental|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
11231147|NCT03169868|No Intervention|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
11231148|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
11231149|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
11231150|NCT03169842|Experimental|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
11231151|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
11231152|NCT03169816|Experimental|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
11231153|NCT03169816|Placebo Comparator|Placebo|a placebo comparator capsule taken twice daily
11231154|NCT03169803|Experimental|Single arm, NeuroTronik CANS Therapy System|
11231155|NCT03169790|Experimental|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
11231156|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
11231157|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
11231158|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
11231159|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
11231160|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
11231161|NCT03169725|Experimental|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
11231162|NCT03169725|Experimental|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
11231163|NCT03169725|Experimental|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
11231164|NCT03169725|Active Comparator|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
11231165|NCT03169712|Active Comparator|CBT for PTSD|15 sessions of trauma-focused CBT
11231166|NCT03169712|Experimental|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
11231167|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
11231168|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
11231169|NCT03169686|Experimental|Intervention Group|"Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team. One to six messages will be sent per day for the time leading up to the quit date and 12 weeks after quit data.
~One to three messages will be sent per week until the end of the 24 weeks follow up after quit data. They will also be encouraged to send self-help, peer support messages in their group. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points."
11231170|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points.
11231171|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
11231172|NCT03169647|Experimental|Intervention|listening-based protocol (type A)
11231173|NCT03169647|Placebo Comparator|Control|listening-based protocol (type B)
11231174|NCT03169634|Experimental|short or long stemmed rTKR cemented|
11231175|NCT03169634|Experimental|Cone with short stem|
11231176|NCT03169634|Experimental|Cone with long stem|
11231178|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
11231179|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
11231180|NCT03169569|Experimental|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
11231181|NCT03169569|Active Comparator|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
11231182|NCT03169556|Experimental|video-laryngoscope guided lightwand|
11231183|NCT03169556|Active Comparator|lightwand|
11231184|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
11231185|NCT03169530|Active Comparator|Alcohol|One standard serving of alcohol (~15 gm) daily
11231186|NCT03169530|No Intervention|Abstention|Abstention from alcohol
11231187|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
11231188|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
11231189|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
11231190|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
11231191|NCT03169491|Experimental|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
11231192|NCT03169491|Sham Comparator|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
11231193|NCT03169491|Other|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
11231194|NCT03169478|No Intervention|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
11231195|NCT03169478|Experimental|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
11231196|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
11231197|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
11231198|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
11231199|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.
~Intervention: taking beta-blocker"
11231200|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
11231201|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
11231202|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
11231203|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
11231204|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
11231205|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
11231206|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
11231207|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
11231208|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
11231209|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
11231210|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
11231211|NCT03169335|Experimental|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
11231212|NCT03169335|Active Comparator|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
11231213|NCT03169322|Active Comparator|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
11231214|NCT03169322|Active Comparator|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
11231215|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
11231216|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
11231217|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
11231218|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
11231219|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
11231220|NCT03169257|Experimental|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
11231221|NCT03169257|No Intervention|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
11231222|NCT03169244|Active Comparator|Bupropion|Bupropion extended release
11231223|NCT03169244|Placebo Comparator|Placebo|Placebo oral tablet
11231224|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
11231225|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
11231226|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
11231227|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
11231228|NCT03169231|Placebo Comparator|Study Group E|Single peripheral IV infusion of placebo.
11231229|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
11231230|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
11231231|NCT03169205||preexisting Diabetes mellitus type 1|
11231232|NCT03169205||preexisting Diabetes mellitus type 2|
11231233|NCT03169205||Gestational Diabetes mellitus|
11231234|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
11231235|NCT03169179|Experimental|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
11231236|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
11231237|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
11231238|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
11231239|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
11231240|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
11231241|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
11231242|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
11231243|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
11231244|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
11231245|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
11231246|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
11231247|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
11231248|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
11231249|NCT03169088|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
11231250|NCT03169075|Experimental|ARM A: A|Supervised physical exercise programs (SPEP)
11231251|NCT03169075|Active Comparator|ARM B: B|Adapted physical activity (APA)
11231252|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
11231253|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11231254|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
11231255|NCT03169023|Experimental|Arm 1: ScaleDown (only first 16 patients)|"Baseline quality of life and image surveys
~Weigh themselves every day on the provided Wi-Fi Scale
~Personalized feedback with text message comes as soon as participants step on the scale
~At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed
~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website
~Only 16 participants were in this arm because ScaleDown went out of business
~At 12 month follow-up weight will be abstracted from medical record"
11231256|NCT03169023|Active Comparator|Arm 2: Enhanced Usual Care|"Baseline quality of life and image surveys
~Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise
~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed
~At 12 month follow-up weight will be abstracted from medical record"
11231257|NCT03169023|Experimental|Arm 3: iOTA|"Baseline quality of life and image surveys
~Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale
~Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months
~Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals
~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed
~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website
~At 12 month follow-up weight will be abstracted from medical record"
11231258|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
11231259|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
11231260|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
11231261|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
11231262|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
11231263|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
11231264|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
11231265|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
11231266|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
11231267|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
11231268|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
11231269|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
11231270|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
11231271|NCT03168971|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
11231272|NCT03168971|No Intervention|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
11231273|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
11231274|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
11231275|NCT03168945|Active Comparator|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
11231276|NCT03168945|Placebo Comparator|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
11231277|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
11231278|NCT03168906|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
11231279|NCT03168906|Placebo Comparator|Placebo|Placebo
11231280|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
11231281|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
11231282|NCT03168880|Active Comparator|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
11231283|NCT03168880|Experimental|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
11231284|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
11231285|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
11231286|NCT03168854|Experimental|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
11231287|NCT03168854|Experimental|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
11231288|NCT03168854|Active Comparator|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
11231289|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
11231290|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
11231291|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
11231292|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
11231293|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
11231294|NCT03168802|Active Comparator|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
11231295|NCT03168789|Experimental|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
11231296|NCT03168789|Active Comparator|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
11231297|NCT03168776|Experimental|BuMA Supreme Coronary Stent System|
11231298|NCT03168776|Active Comparator|Xience or Promus Everolimus Stent System|
11231299|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
11231300|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
11231301|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
11231302|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.
~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
11231303|NCT03168750|Other|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup|All patients enrolled will receive the Medacta Masterloc Stem and MPACT cup with Highcross PE liner.
11231304|NCT03168737|Experimental|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
11231305|NCT03168737|Experimental|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans >= 24 hours later up to 10 days.
11231306|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
11231307|NCT03168724|No Intervention|Control|Group not getting the intervention
11231308|NCT03168711|Experimental|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
11231309|NCT03168711|Placebo Comparator|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
11231310|NCT03168698|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
11231311|NCT03168698|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
11231312|NCT03168698|Active Comparator|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
11231313|NCT03168698|Active Comparator|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
11231314|NCT03168685|Experimental|Experimental|"Multiple device intervention
~SureSource Engage mobile application
~ActiGraph Link
~weight scale"
11231315|NCT03168672|Other|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
11231316|NCT03168659|Other|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
11231317|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
11231318|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
11231319|NCT03168633|Experimental|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.
~web-based DM2 information pages"
11231320|NCT03168620|Active Comparator|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
11231321|NCT03168620|Active Comparator|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
11231322|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
11231323|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
11231324|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
11231325|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
11231326|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
11231327|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
11231328|NCT03168555|Experimental|Intervention|chenodeoxycholic acid 1250mg po.
11231329|NCT03168542|Experimental|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
11231330|NCT03168542|Experimental|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
11231331|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
11231332|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
11231333|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
11231334|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
11231335|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
11231336|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
11231337|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
11231338|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
11231339|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
11231340|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
11231341|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
11231342|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
11231343|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
11231344|NCT03168477|Experimental|dry needling and spinal manipulation|
11231345|NCT03168477|Active Comparator|mobilization, exercise, modalities|
11231346|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
11231347|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
11231348|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
11231349|NCT03168438|Experimental|Arm 1: NY-ESO-1ᶜ²⁵⁹T cells|Subjects will receive one infusion of NY-ESO-1ᶜ²⁵⁹T cells on Day 1.
11231350|NCT03168438|Experimental|Arm 2: NY-ESO-1ᶜ²⁵⁹T in combination with pembrolizumab|NY-ESO-1ᶜ²⁵⁹T cells administered on Day 1, then pembrolizumab administered on Day 22 (3 weeks after initial infusion of NY-ESO-1ᶜ²⁵⁹T)
11231351|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
11231352|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
11231353|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
11231354|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
11231355|NCT03168399|Experimental|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
11231356|NCT03168386|Experimental|Intensive motor rehabilitation group|
11231357|NCT03168373|Experimental|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
11231358|NCT03168373|Active Comparator|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
11231359|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
11231360|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
11231361|NCT03168347|Active Comparator|Anecdotal Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
11231362|NCT03168347|Active Comparator|Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
11231363|NCT03168347|Active Comparator|Anecdotal + Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
11231364|NCT03168347|Placebo Comparator|No Evidence|Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
11231365|NCT03168334|Experimental|IDP-123 Lotion|lotion
11231366|NCT03168334|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle
11231367|NCT03168321|Experimental|IDP-123 Lotion|Lotion
11231368|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Lotion
11231369|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
11231370|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
11231371|NCT03168295|Experimental|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
11231372|NCT03168295|Active Comparator|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
11231373|NCT03168295|Other|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
11231374|NCT03168256|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
11231375|NCT03168256|Experimental|CF101 3mg|CF101 3mg, orally q12 hours
11231376|NCT03168256|Active Comparator|Apremilast 30mg|Apremilast 30mg, orally q12 hours
11231377|NCT03168256|Placebo Comparator|Placebo|Placebo control , orally q12 hours
11231378|NCT03168243|Experimental|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
11231379|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
11231380|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
11231381|NCT03168204|Experimental|Risk of being frail experimental group|
11231382|NCT03168204|No Intervention|Risk of being frail control group|
11231383|NCT03168204|No Intervention|No/low risk of being frail|
11231384|NCT03168204|No Intervention|Risk of being frail care avoiders|
11231385|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
11231386|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
11231387|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
11231388|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
11231389|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
11231390|NCT03168165|No Intervention|Usual Care|Usual care, no intervention
11231391|NCT03168165|Experimental|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
11231392|NCT03168152|Experimental|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
11231393|NCT03168152|Experimental|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
11231394|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
11231395|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
11231396|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.
~*Peanut skin prick test wheal ≥ 8 mm."
11231574|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
11231397|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.
~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
11231398|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.
~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
11231399|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
11231400|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
11231401|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
11231402|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
11231403|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
11231404|NCT03168074|Experimental|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
11231405|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.
~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
11231406|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
11231407|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).
~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
11231408|NCT03168022|Experimental|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
11231409|NCT03168022|Experimental|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
11231410|NCT03168009|Experimental|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
11231411|NCT03167996|Experimental|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit
~Lab testing is the same for both Group A/ control and Group B patients"
11231412|NCT03167996|No Intervention|Group A/ Control|"Group B will not have access to HealthPals app
~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up
~Lab testing is the same for both Group A/ control and Group B patients"
11231413|NCT03167983||dementia|patients with dementia
11231414|NCT03167983||control|healthy control
11231415|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
11231416|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
11231417|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
11231418|NCT03167944|Experimental|Conventional electrocautery|
11231419|NCT03167944|Experimental|Low thermal electrosurgery system|
11231420|NCT03167931|Experimental|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
11231421|NCT03167931|Experimental|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
11231422|NCT03167918|Experimental|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
11231423|NCT03167918|Experimental|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
11231424|NCT03167918|Experimental|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)& Xuefuzhuyu Decoction（100 ml bid，po)
11231425|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
11231426|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
11231427|NCT03167892|Experimental|Intervention|Oral screen
11231428|NCT03167892|No Intervention|Control|No intervention
11231575|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
11231429|NCT03167879|Experimental|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
11231430|NCT03167879|Experimental|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
11231431|NCT03167879|No Intervention|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
11231432|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
11231433|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
11231434|NCT03167853|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
11231435|NCT03167840|Experimental|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
11231436|NCT03167840|Experimental|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
11231437|NCT03167840|Experimental|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
11231438|NCT03167840|No Intervention|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
11231439|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
11231440|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
11231441|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
11231442|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
11231443|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
11231444|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
11231445|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
11231446|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
11231447|NCT03167775|Experimental|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
11231448|NCT03167762|Experimental|Study group|
11231449|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
11231450|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
11231451|NCT03167736|Experimental|Electric dry needling, manipulation|
11231452|NCT03167736|Active Comparator|conventional physical therapy|
11231453|NCT03167723|Experimental|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
11231454|NCT03167723|Experimental|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
11231455|NCT03167710|Experimental|dry needling, manipulation stretching|
11231456|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
11231457|NCT03167697|Experimental|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
11231458|NCT03167697|Active Comparator|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
11231459|NCT03167684|Experimental|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
11231460|NCT03167684|No Intervention|Control|Sham oral appliance device
11231461|NCT03167671|Active Comparator|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy.
11231462|NCT03167671|Experimental|AposTherapy|Treatment with at home AposTherapy with daily use of the shoe.
11231463|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
11231464|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
11231540|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
11231465|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
11231466|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
11231467|NCT03167645|No Intervention|Control|Standard clinical care
11231468|NCT03167632||dental patients|
11231469|NCT03167619|Experimental|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
11231470|NCT03167619|Experimental|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
11231471|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile for the next three months.
11231472|NCT03167606|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile and will be asked to complete their surveys every 3 months and return to the study site in 9 months for a follow-up visit (at which time they will receive the MyPEEPS Mobile intervention).
11231473|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
11231474|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
11231475|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
11231476|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
11231477|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
11231478|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
11231479|NCT03167554|Sham Comparator|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
11231480|NCT03167554|Experimental|Experimental group 1|Electrolysis application with monopolar needle.
11231481|NCT03167554|Experimental|Experimental group 2|Electrolysis application with bipolar needle.
11231482|NCT03167541|Experimental|1|Treatment Order: Test, Reference
11231483|NCT03167541|Experimental|2|Treatment Order: Reference, Test
11231484|NCT03167528|Experimental|Lung transplant|"Patients who must undergo a lung transplant at the FOCH hospital.
~Before and after transplantation, patients benefits of learning and realization sessions of complementary techniques:
~Relaxation,
~Hypnosis,
~Holistic gymnastics,
~Transcutaneous electrical nerve stimulation (TENS),
~Sophrology."
11231485|NCT03167515|Experimental|074-6751 Lotion|
11231486|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
11231487|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
11231488|NCT03167489|Experimental|Lifestyle Plus Emotional Regulation|The core intervention will last 5 months. Nutrition content: Mediterranean diet education, social support, self-regulation techniques, and environmental support. Physical activity content: education, guidance in starting a routine, and a walking program with pedometers, weekly physical activity tips and step goals. Emotion regulation content: based on Dialectical Behavior Therapy adapted to binge eating disorders and other ER sources, emphasizing identifying emotions, recognizing the causes of emotions, accepting and tolerating negative emotions, effective self-support and self-compassion, and the ability to manage situations that elicit negative emotions, as well as re-appraisal skills, which are identified as particularly influential on eating behaviors.
11231489|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
11231490|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
11231491|NCT03167463|Experimental|choanoplasty with flap|flap surgery
11231492|NCT03167450||Adults|Adults have sickle cell disease
11231493|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
11231494|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
11231495|NCT03167437|Placebo Comparator|1|participants will receive Vorinostat 100mg PO BID for 12 weeks
11231496|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
11231497|NCT03167411|Experimental|Bexagliflozin alone|
11231498|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
11231499|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
11231500|NCT03167385|Experimental|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
11231501|NCT03167372|Experimental|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.
~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
11231502|NCT03167372|Active Comparator|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.
~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
11231573|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
11231503|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
11231504|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
11231505|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
11231506|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
11231507|NCT03167307|Experimental|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to <13 year olds, and 1000mg EPA / 500mg DHA in the 13 to <18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
11231508|NCT03167307|Placebo Comparator|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
11231509|NCT03167294|Other|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
11231510|NCT03167281|No Intervention|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
11231511|NCT03167281|Experimental|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
11231512|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
11231513|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
11231514|NCT03167255|Experimental|NS-065/NCNP-01 40mg/kg|Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 168 weeks or until NS-065/NCNP-01 is commercially available, whichever is earlier.
11231515|NCT03167255|Experimental|NS-065/NCNP-01 80mg/kg|Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 168 weeks or until NS-065/NCNP-01 is commercially available, whichever is earlier.
11231516|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day|Cohort 1
11231517|NCT03167242|Experimental|KAF156 800 mg and LUM-SDF 960 mg QD for 1 day|Cohort 2
11231518|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 2 days|Cohort 3
11231519|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 480 mg QD for 3 days|Cohort 4
11231520|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 480 mg QD for 3 days|Cohort 5
11231521|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 3 days|Cohort 6
11231522|NCT03167242|Active Comparator|Coartem twice a day (BID) for 3 days|Cohort 7
11231523|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day|PK Run-in Cohort
11231524|NCT03167216|Experimental|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
11231525|NCT03167203|Experimental|hESC-RPE cells|Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells
11231526|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
11231527|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
11231528|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:
~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
11231529|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:
~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
11231530|NCT03167151|Experimental|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 & D64.
~Dose to be decided after safety run-in."
11231531|NCT03167151|Active Comparator|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
11231532|NCT03167138|Experimental|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
11231533|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
11231534|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
11231535|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
11231536|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
11231537|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
11231538|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
11231539|NCT03167086|Experimental|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
11231541|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
11231542|NCT03167073|Experimental|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
11231543|NCT03167073|Placebo Comparator|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
11231544|NCT03167060|Active Comparator|Active Rhinochill|Intranasal cooling device , using nasal cannula
11231545|NCT03167060|Sham Comparator|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
11231546|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).
~Patients will also receive standardised pain relief of paracetamol and fentanyl"
11231547|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.
~Patients will also receive standardised pain relief of paracetamol and fentanyl"
11231548|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11231549|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11231550|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
11231551|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.
~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).
~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
11231552|NCT03167008||fertile male group|"total of 30 fertile male (as control)
~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).
~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
11231553|NCT03166995|Experimental|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
11231554|NCT03166995|Experimental|Experimental group 2|Postural exercises group. 1hour, twice a week
11231555|NCT03166995|No Intervention|Control propriocepcion|No exercise, just proprioceptive control.
11231556|NCT03166982|Experimental|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
11231557|NCT03166982|Experimental|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
11231558|NCT03166969|Experimental|Patients taken care in neurovascular unit|
11231559|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.
~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
11231560|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:
~Subjects in the C group received isocaloric maltodextrin as placebo."
11231561|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
11231562|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
11231563|NCT03166930|Experimental|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
11231564|NCT03166930|Active Comparator|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management.
11231565|NCT03166917|Experimental|3D printing implant|3D printing implant in bone defect
11231566|NCT03166917|Placebo Comparator|Autogenous bone grafting|autogenous bone grafting in bone defect
11231567|NCT03166904|Experimental|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
11231568|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
11231569|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
11231570|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
11231571|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
11231572|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
11231576|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
11231577|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
11231578|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
11231579|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
11231580|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
11231581|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
11231582|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
11231583|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
11231584|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
11231585|NCT03166761|Experimental|Dexamethasone|dexamethasone injected into the sacroiliac joint
11231586|NCT03166761|Active Comparator|Triamcinolone|triamcinolone injected into the sacroiliac joint
11231587|NCT03166748|Active Comparator|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
11231588|NCT03166748|Experimental|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
11231589|NCT03166735|Experimental|BI 1467335 dose 1|
11231590|NCT03166735|Experimental|BI 1467335 dose 2|
11231591|NCT03166735|Experimental|BI 1467335 dose 3|
11231592|NCT03166735|Experimental|BI 1467335 dose 4|
11231593|NCT03166735|Placebo Comparator|Placebo|
11231594|NCT03166722|Experimental|Study group: Invos 5100|"Supplemental oxygen support and respiratory/circulatory support is guided by cerebral regional tissue oxygenation (crSO2) measured with near-infrared spectroscopy (INVOS 5100 ), in addition to the SpO2/HR (oxygen saturation/heart rate) monitoring according to routine."
11231595|NCT03166722|Active Comparator|Control group: Routine care|Supplemental oxygen support and respiratory/circulatory support is guided by SpO2/HR monitoring according to routine - The resuscitation team is blinded to the crSO2 monitoring.
11231596|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
11231597|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
11231598|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
11231599|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
11231600|NCT03166683|Experimental|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
11231601|NCT03166683|Active Comparator|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
11231602|NCT03166670||study group|children with acute secretory diarrhea
11231603|NCT03166670||Control group|normal healthy children
11231604|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
11231605|NCT03166644|Experimental|Intervention Group|Patients with standard practice
11231606|NCT03166631|Experimental|Part A|BI 891065 alone (Solid Tumours)
11231607|NCT03166631|Experimental|Part B|BI 891065 in combination with BI 754091 (Solid Tumours)
11231608|NCT03166631|Experimental|Part C|BI 891065 in combination with BI 754091 (Non Small Cell Lung Cancer)
11231609|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
11231610|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
11231611|NCT03166605|No Intervention|Control|"First group: Control
~Follow the current standard protocol used at Albany Medical Center that includes:
~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids
~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.
~Return to clinic (RTC) 8 hours after to remove equipment
~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
11231612|NCT03166605|Sham Comparator|Sham|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing
~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids
~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.
~Return to clinic (RTC) 8 hours after to remove equipment
~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
11231645|NCT03166358|No Intervention|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
11231613|NCT03166605|Experimental|Experiment|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing.
~Receive 3 ml simethicone 1 hours after capsule swallowing
~Receive 1.5 ml simethicone 2 hours after capsule swallowing
~Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids
~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.
~Return to clinic (RTC) 8 hours after to remove equipment
~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
11231614|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
11231615|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
11231616|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
11231617|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
11231618|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
11231619|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
11231620|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
11231621|NCT03166527|Other|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
11231622|NCT03166514|Experimental|Commercially Available Food Bar|62 g. Fitjoy Bar
11231623|NCT03166514|Placebo Comparator|Placebo|25 g. Dextrose
11231624|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
11231625|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
11231626|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
11231627|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
11231628|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
11231629|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
11231630|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
11231631|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
11231632|NCT03166449|Experimental|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
11231633|NCT03166449|Active Comparator|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
11231634|NCT03166436|Experimental|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
11231635|NCT03166436|Active Comparator|Stenting alone|Biliary stenting alone
11231636|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.
~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
11231637|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
11231638|NCT03166410|Experimental|Cell Treatment|
11231639|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..
~Preparation and administration of TIL
~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
11231640|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.
~interventions: 'conventional suture and tie'"
11231641|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
~interventions: electrosurgical bipolar sealing devices"
11231642|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
11231643|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
11231644|NCT03166358|Experimental|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
11231646|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
11231647|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
11231648|NCT03166345|No Intervention|No intervention|The control arm.
11231649|NCT03166332|Active Comparator|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
11231650|NCT03166332|Active Comparator|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
11231651|NCT03166332|No Intervention|No intervention|No intervention strategy
11231652|NCT03166319|Experimental|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
11231653|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
11231654|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
11231655|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
11231656|NCT03166293|Experimental|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
11231657|NCT03166293|Experimental|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
11231658|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
11231659|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
11231660|NCT03166254|Experimental|Cohort A: Stage IV squamous NSCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)
~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations
~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination
~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
11231661|NCT03166254|Experimental|Cohort B: Extensive stage SCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)
~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations
~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination
~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
11231662|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
11231663|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
11231664|NCT03166228|Active Comparator|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
11231665|NCT03166228|Placebo Comparator|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
11231666|NCT03166215|Placebo Comparator|Part 1: Placebo|TAK-935 matching-placebo tablets, orally or through gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) from Days 1 to 30 in dose titration period.
11231667|NCT03166215|Experimental|Part 1: TAK-935|TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
11231668|NCT03166215|Experimental|Part 2: TAK-935|TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 31 to 40 followed by TAK-935 100 mg tablets x1, x2 or x3, orally or through G-tube/PEG tube, BID from Days 31 to Day 85 as per investigator's discretion in the maintenance period. At the end of Part 2, the dose of TAK-935 was de-escalated until discontinuation.
11231669|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
11231670|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
11231671|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
11231672|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
11231673|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
11231674|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
11231675|NCT03166137|Experimental|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
11231676|NCT03166137|Active Comparator|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
11231677|NCT03166124|Experimental|Elderly Adults LY900014|Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
11231678|NCT03166124|Active Comparator|Elderly Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
11231679|NCT03166124|Experimental|Younger Adults LY900014|Single, SC 15-U dose of LY900014 in the younger adult group.
11231680|NCT03166124|Active Comparator|Younger Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.
11231681|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
11231682|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
11231683|NCT03166098||Diagnosis of Schizophrenia|
11231684|NCT03166098||Diagnosis of Bipolar Disorder|
11231685|NCT03166098||Unaffected siblings of the SZ groups|
11231686|NCT03166098||Unaffected siblings of the BP group|
11231687|NCT03166098||Healthy control (HC) comparison group|
11231688|NCT03166085|Experimental|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
11231689|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
11231690|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
11231691|NCT03166059|Experimental|Single arm|CaveoVasc® Thrombolysis Protection System
11231692|NCT03166046|Active Comparator|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
11231693|NCT03166046|Placebo Comparator|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
11231694|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
11231695|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
11231696|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
11231697|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
11231698|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
11231699|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
11231700|NCT03165994|Experimental|APX005M with chemoradiation|"APX005M: 0.3mg/kg dose intravenously over 1 hour, every 3 weeks x 3 doses (weeks 1, 4, and 7). Treatment begins 2 weeks prior to concurrent chemoradiation (chemoRT); continues during weeks 2 and 5 of chemoRT.
~Daily radiation therapy (RT): 28 fractions (28 days)
~Chemotherapy: Carboplatin and paclitaxel will be given intravenously over 1 hour, once weekly, for 5 weeks (days 1, 8, 15 22, and 29 of RT). Carboplatin dose will be area under curve (AUC) 2. Paclitaxel dose will be 50mg/m2.
~Surgical resection of tumor: between weeks 11-17"
11231701|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
11231702|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
11231703|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
11231704|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
11231705|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
11231710|NCT03165916|Experimental|Reconstruction with stent placement|Subjects will undergo biliary reconstruction with stent placement at the anastomosis site.
11231711|NCT03165916|No Intervention|Reconstruction without stent placement|Subjects will undergo biliary reconstruction without stent placement.
11231712|NCT03165903|Experimental|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
11231713|NCT03165903|Other|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
11231714|NCT03165890|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11231715|NCT03165890|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11231716|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
11231717|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
11231718|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
11231719|NCT03165864|Placebo Comparator|Placebo|Saline .9%
11231720|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
11231721|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
11231722|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
11231723|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
11231724|NCT03165825|Experimental|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
11231725|NCT03165825|Active Comparator|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
11231726|NCT03165812|Experimental|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
11231727|NCT03165812|Experimental|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
11231728|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
11231729|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
11231730|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
11231731|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
11231732|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
11231733|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
11231734|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
11231735|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
11231736|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
11231737|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
11231738|NCT03165734|Experimental|Pacritinib 200 mg BID|To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food
11231739|NCT03165734|Active Comparator|Physician's Choice (P/C) therapy|The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.
11231740|NCT03165721|Experimental|Arm 1|SGI-110 administered subcutaneously at 45mg/m2/day x 5 days on a 28-day cycle
11231741|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
11231742|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
11231743|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
11231744|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
11231745|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
11231746|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
11231747|NCT03165669|Experimental|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.
~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
11231748|NCT03165669|Active Comparator|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
11231749|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
11231750|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
11231751|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
11231752|NCT03165643||NGT-normal birth weight|
11231753|NCT03165643||NGT-macrosomia|
11231754|NCT03165643||GDM-normal birth weight|
11231755|NCT03165643||GDM-macrosomia|
11231756|NCT03165630|No Intervention|Group 1|Education or Control group.
11231757|NCT03165630|Experimental|Group 2|Transportation incentives
11231758|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
11231759|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
11231760|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
11231761|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
11231762|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
11231763|NCT03165591|Experimental|Experimental|Daily tablet of V3-P given orally for 2 months
11231764|NCT03165578|Experimental|Neurofeedback|Neurofeedback training.
11231765|NCT03165578|Sham Comparator|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
11231766|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
11231767|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
11231768|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
11231769|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
11231770|NCT03165526||First Cohort|All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
11231771|NCT03165526||Second Cohort|"This cohort will consist of subjects over the age of 18 years who have previously been successfully implanted with the PIVSD Occluder and the
~Subject or subject's legally authorized representative has provided consent to participate in this study.
~Subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.
~Therefore, this cohort will be composed of retrospectively enrolled subjects. This cohort will be utilized to determine acute and chronic closure and chronic survival."
11231772|NCT03165513|Experimental|Experimental arm|mhGAP-IG psychosocial intervention
11231773|NCT03165500|Active Comparator|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
11231774|NCT03165500|Active Comparator|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
11231775|NCT03165500|Active Comparator|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
11231776|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
11231777|NCT03165487||Triple Negative Breast Cancer|triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
11231778|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
11231779|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
11231859|NCT03164876|Experimental|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
11231780|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
11231781|NCT03165435|Experimental|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
11231782|NCT03165435|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
11231783|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
11231784|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
11231785|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
11231786|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
11231787|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
11231788|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
11231789|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
11231790|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
11231791|NCT03165357|Experimental|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
~Interventions:
~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
11231792|NCT03165357|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).
~Interventions:
~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
11231793|NCT03165344|Experimental|hydrocortisone group|
11231794|NCT03165344|Placebo Comparator|prednisone grope|
11231795|NCT03165331|Other|Intervention group|The intervention group will go through the intervention programme (Ung Face IT) after T1 and randomisation. Programme takes 7 weeks to complete + Treatment as usual (local health care services). Questionnaires after the 7 weeks (T2) and after three months (T3) and 6 months (T4).
11231796|NCT03165331|Other|Control group|Treatment as usual for three months after T1 and randomisation, with local health care support if needed. Questionnaires at T2 and T3 before participants are given access to the intervention (Ung Face IT) after three months. Questionnaire at T4 (post-intervention).
11231797|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
11231798|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
11231799|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
11231800|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
11231801|NCT03165292|Experimental|Arm A: High administered activity 131I- mIBG and Topotecan|"The trial will evaluate two randomised arms. Each arm includes
~three cycles of Temozolomide-Irinotecan, similar in both arms,
~a specific consolidation course detailed hereinafter,
~a BuMel sequence, followed by an ASCT, similar in both arms,
~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
11231802|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes
~three cycles of Temozolomide-Irinotecan, similar in both arms,
~a specific consolidation course detailed hereinafter,
~a BuMel sequence, followed by an ASCT, similar in both arms,
~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
11231803|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
11231804|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
11231805|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
11231806|NCT03165240|Experimental|BI 690517 Dose 1|
11231807|NCT03165240|Experimental|BI 690517 Dose 2|
11231808|NCT03165240|Experimental|BI 690517 Dose 3|
11231809|NCT03165240|Experimental|Eplerenone|
11231810|NCT03165240|Placebo Comparator|Placebo|
11231811|NCT03165227|Experimental|BI 685509 Dose 1|
11231812|NCT03165227|Experimental|BI 685509 Dose 2|
11231813|NCT03165227|Experimental|BI 685509 Dose 3|
11231817|NCT03165175|Experimental|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
11231818|NCT03165175|No Intervention|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
11231819|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
11231820|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
11231821|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
11231822|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
11231823|NCT03165136|Experimental|Hydroxychloroquine|The treatment will be orally administrated, at a daily dose of 400 mg of hydroxychloroquine . The treatment will be started before conception and will be stopped at the end of the tenth week of gestation or before in case of pregnancy loss.
11231824|NCT03165136|Placebo Comparator|Placebo|A similar placebo will be orally administrated every day.
11231825|NCT03165123|Placebo Comparator|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
11231826|NCT03165123|Active Comparator|Azithromycin group|The patients will receive 250 mg oral Azithromycin tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
11231827|NCT03165110|Experimental|Users of the Onyx Blood Glucose Meter/ app System at home|Participants have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin.
11231828|NCT03165097|Experimental|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.
~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
11231829|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
11231830|NCT03165097|Other|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
11231831|NCT03165097|Experimental|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
11231832|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
11231833|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
11231834|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
11231835|NCT03165071|Experimental|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
11231836|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
11231837|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
11231838|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
11231839|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
11231840|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
11231841|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
11231842|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
11231843|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
11231844|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
11231845|NCT03165006||Screened women with breast cancer|
11231846|NCT03164993|Placebo Comparator|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
11231847|NCT03164993|Active Comparator|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
11231848|NCT03164980|Experimental|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
11231849|NCT03164980|Experimental|Arm B|"Carboplatin/PLD
~Carboplatin/Gemcitabine
~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
11231850|NCT03164967|Other|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
11231851|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
11231852|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
11231853|NCT03164928|Other|Placebo|SC Q6M placebo
11231854|NCT03164928|Experimental|Denosumab|1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
11231855|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
11231856|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
11231857|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
11231858|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
11231860|NCT03164876|Placebo Comparator|Placebo|Placebo to match AUT00206 twice daily for 28 days
11231861|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
11231862|NCT03164811|Experimental|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV >13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
11231863|NCT03164811|Other|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
11231864|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.
~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
11231865|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
11231866|NCT03164772|Experimental|Arm A|The run-in dose evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (including subjects from the run-in).
11231867|NCT03164772|Experimental|Arm B|The run-in dose evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (including subjects from the run-in).
11231868|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
11231869|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
11231870|NCT03164733||<40|patients younger than 40 years
11231871|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
11231872|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
11231873|NCT03164733||>80|patients older than 80 years
11231874|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
11231875|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
11231876|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
11231877|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
11231878|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
11231879|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
11231880|NCT03164655|Experimental|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"HAI oxaliplatin 100 mg/m² on D1
~I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT
~modified FOLFIRI regimen without fluorouracil bolus
~I.V. irinotecan 180 mg/m² D1
~I.V. bolus 5-Fluorouracil (5-FU): 0
~I.V. leucovorin 400 mg/m² in 2 hours D1
~I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours"
11231881|NCT03164655|Active Comparator|conventional systemic CT|"Response to systemic induction CT
~Toxicity and duration of the systemic induction CT
~RAS status
~Current guidelines/standard of care"
11231882|NCT03164642|Experimental|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
11231883|NCT03164642|Placebo Comparator|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
11231884|NCT03164629|Experimental|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
11231885|NCT03164629|Active Comparator|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
11231886|NCT03164616|Experimental|Treatment Arm 1|durvalumab + tremelimumab combination therapy + SoC chemotherapy
11231887|NCT03164616|Experimental|Treatment Arm 2|durvalumab monotherapy + SoC chemotherapy
11231888|NCT03164616|Active Comparator|Treatment Arm 3|SoC chemotherapy alone
11231889|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
11231890|NCT03164590|Active Comparator|ketamine|
11231891|NCT03164590|Active Comparator|dexmedetomidine|
11231892|NCT03164590|Placebo Comparator|bupivacaine|
11231953|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
11231893|NCT03164577|Active Comparator|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
11231894|NCT03164577|Placebo Comparator|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
11231895|NCT03164564|Experimental|Arm A: CAB + Placebo TDF/FTC + CAB LA|During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
11231896|NCT03164564|Active Comparator|Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA|During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
11231897|NCT03164551|Active Comparator|GERI+ Incubator|
11231898|NCT03164551|Other|Conventional incubator|
11231899|NCT03164538|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
11231900|NCT03164538|Active Comparator|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
11231901|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
11231902|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
11231903|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
11231904|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
11231905|NCT03164499|Active Comparator|Control group|Individual counselling on lifestyles.
11231906|NCT03164499|Experimental|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
11231907|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
11231908|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
~plus orally placebo-azathioprine for 24 months"
11231909|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months
~plus 4 placebo-rituximab infusions given every 6 months for 18 months"
11231910|NCT03164460|Experimental|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
11231911|NCT03164460|Experimental|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
11231912|NCT03164447|Experimental|Multi-Drug Resistant|
11231913|NCT03164421|Experimental|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
11231914|NCT03164421|Active Comparator|L-carnitine|L-carnitine used by clomiphene resistant pcos women
11231915|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
11231916|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
11231917|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
11231918|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
11231919|NCT03164356|No Intervention|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
11231920|NCT03164356|Experimental|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
11231921|NCT03164356|No Intervention|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
11231922|NCT03164343|Experimental|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
11231923|NCT03164330|No Intervention|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
11231924|NCT03164330|Experimental|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
11231925|NCT03164330|Experimental|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
11231926|NCT03164330|Experimental|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
11231927|NCT03164330|Experimental|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
11231928|NCT03164330|Experimental|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
11231929|NCT03164330|Experimental|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.
~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
11231930|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
11231931|NCT03164317|Other|Control|No trained NCC and electronic decision support system
11231932|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
11231933|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
11231934|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
11231935|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
11231936|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
11231937|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
11231938|NCT03164252|Active Comparator|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
11231939|NCT03164252|Active Comparator|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
11231940|NCT03164252|Placebo Comparator|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
11231941|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
11231942|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
11231943|NCT03164226|Other|Patient consulting for chest Pain in ED|Any patient ≥ 30 years consulting for chest pain in the emergency department from 8:00 am to 8:00 pm (for the unavailability of the endopat device during the guard).
11231944|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
11231945|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
11231946|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
11231947|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
11231948|NCT03164187||Diabeton MR 60|
11231949|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
11231950|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
11231951|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
11231952|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
11232002|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
11231954|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
11231955|NCT03164122|Experimental|Intra-articular injection|
11231956|NCT03164109|Experimental|GC4419 IV|
11231957|NCT03164109|Placebo Comparator|Placebo|
11231958|NCT03164109|Active Comparator|Oral moxifloxacin|
11231959|NCT03164096|Experimental|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
11231960|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
11231961|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
11231962|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
11231963|NCT03164070||Control group|Control group of healthy persons
11231964|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA"|"Part 1 Tolerability with AZA - Low Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive low-risk intensifications I & II without azacitidine.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA."
11231965|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA"|"Part 1 Tolerability with DAC - Low Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive low-risk Intensifications I & II without decitabine.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
11231966|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | AZA+AE+Sor | AZA+MA+Sor"|"Part 2 Dose Expansion with AZA - Low Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and low- risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
11231967|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | DAC+AE+Sor|DAC+MA+Sor"|"Part 2 Dose Expansion with DAC - Low Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and low-risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
11231968|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with AZA - Intermediate Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive intermediate risk Intensifications I, II & III without azacitidine.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA,"
11231969|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with DAC - Intermediate Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive intermediate-risk Intensifications I, II & III without decitabine.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
11231970|NCT03164057|Experimental|"AZA| +ADE | +FLAG+Ida+Sor| +AE+Sor| +MA+Sor| +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - Intermediate-Risk
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and intermediate-risk Intensification I, II, and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
11231971|NCT03164057|Experimental|"DAC|+ADE | +FLAG+Ida+Sor | +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - Intermediate-Risk
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and intermediate-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
11231972|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I & II and high-risk intensifications I, II & III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
11231973|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I, II & III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
11231974|NCT03164057|Experimental|"AZA | + ADE | +FLAG+Ida+Sor| +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
11232000|NCT03163940|No Intervention|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
11232001|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
11231975|NCT03164057|Experimental|"DAC |+ADE |+FLAG+Ida+Sor |+AE+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (no donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
11231976|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA- High Risk (with donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
11231977|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (with donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
11231978|NCT03164057|Experimental|"DAC |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (with donor)
~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.
~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
11231979|NCT03164057|Experimental|"AZA |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (with donor)
~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensification I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.
~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
11231980|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
11231981|NCT03164031|Experimental|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
11231982|NCT03164031|Active Comparator|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
11231983|NCT03164005||Group 1|Normal weight subjects without metabolic diseases
11231984|NCT03164005||Group 2|Normal weight subjects with metabolic diseases
11231985|NCT03164005||Group 3|Obesity subjects without metabolic diseases
11231986|NCT03164005||Group 4|Obesity subjects with metabolic diseases
11231987|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
11231988|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
11231989|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:
~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
11231990|NCT03163979|Active Comparator|RapidArc|"RapidArc:
~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
11231991|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
11231992|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
11231993|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
11231994|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
11231995|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
11231996|NCT03163953|Experimental|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
11231997|NCT03163953|Experimental|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
11231998|NCT03163953|Other|Control|No intervention
11231999|NCT03163940|Experimental|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
11232003|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
11232004|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
11232005|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
11232006|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
11232007|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
11232008|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
11232009|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
11232010|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
11232011|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
11232012|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
11232013|NCT03163862|Placebo Comparator|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
11232014|NCT03163862|Experimental|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.
~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
11232015|NCT03163862|Sham Comparator|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
11232016|NCT03163849|Placebo Comparator|control group|oral tablets
11232017|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
11232018|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
11232019|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
11232020|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
11232021|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
11232022|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.
~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
11232023|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
11232024|NCT03163784|Placebo Comparator|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
11232025|NCT03163784|Experimental|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
11232026|NCT03163784|Experimental|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
11232027|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
11232028|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
11232029|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:
~Full medical History and physical examination
~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration
~Abdominal Ultrasound
~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
11232030|NCT03163732|Other|Large molecular profiling panel|This panel is FOne Panel with a 324 cancer-related gene.
11233503|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
11232031|NCT03163732|Other|Limited molecular profiling panel|This panel is CONTROL Panel with a 87 cancer-related gene.
11232032|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
11232033|NCT03163706|Experimental|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
11232034|NCT03163706|Other|Control group|Control, no schizophrenia
11232035|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
11232036|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
11232037|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
11232038|NCT03163667|Active Comparator|CB-839 plus everolimus|CBE: CB-839 is administered twice daily in combination with standard doses of everolimus
11232039|NCT03163667|Placebo Comparator|Placebo plus everolimus|PboE: Placebo is administered twice daily in combination with standard doses of everolimus
11232040|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
11232041|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
11232042|NCT03163641|Experimental|Treatment 1|Ocular Bandage Gel
11232043|NCT03163641|Experimental|Treatment 2|Ocular Bandage Gel
11232044|NCT03163641|Active Comparator|Control Group|Artificial tears with Acuvue Oasys
11232045|NCT03163628|Experimental|7 biomarkers combination|
11232046|NCT03163615|Experimental|Tibet Rhodiola Capsule|
11232047|NCT03163615|Placebo Comparator|Placebo oral capsule|
11232048|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
11232049|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
11232050|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
11232051|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
11232052|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
11232053|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
11232054|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
11232055|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
11232056|NCT03163550|Experimental|Cohort 1|Healthy volunteers
11232057|NCT03163550|Experimental|Cohort 2|Healthy volunteers
11232058|NCT03163550|Experimental|Cohort 3|Healthy volunteers
11232059|NCT03163550|Experimental|Cohort 4|Healthy volunteers
11232060|NCT03163550|Experimental|Cohort 5|Healthy volunteers
11232061|NCT03163537||Kidney transplantation, postmortal, day|
11232062|NCT03163537||Kidney transplantation, postmortal, night|
11232063|NCT03163537||Kidney transplantation, living donor|
11232064|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
11232065|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
11232066|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
11232067|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
11232068|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
11232069|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
11232070|NCT03163485|Experimental|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
11232071|NCT03163485|Other|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
11232072|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
11232073|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
11232074|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
11232108|NCT03163160|Experimental|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
11232109|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
11232075|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
11232076|NCT03163446|Experimental|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
11232077|NCT03163446|Placebo Comparator|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
11232078|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
11232079|NCT03163433|No Intervention|Control|Usual consultations
11232080|NCT03163420|Placebo Comparator|Placebo|placebo
11232081|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
11232082|NCT03163407|Active Comparator|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
11232083|NCT03163407|Active Comparator|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
11232084|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
11232085|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
11232086|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
11232087|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
11232088|NCT03163342|Other|Open label|Licensed seasonal influenza vaccine, intramuscular
11232089|NCT03163329|Experimental|TAVR group|
11232090|NCT03163329|Active Comparator|SAVR group|
11232091|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
11232092|NCT03163303|Experimental|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
11232093|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
11232094|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
11232095|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
11232096|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
11232097|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
11232098|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
11232099|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
11232100|NCT03163251|Experimental|READ-SG Cohort|Each post-graduate year will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
11232101|NCT03163238|Active Comparator|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
11232102|NCT03163238|Placebo Comparator|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
11232103|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
11232104|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
11232105|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
11232106|NCT03163173|Experimental|Single Arm - Treatment Group|30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
11232107|NCT03163160|Experimental|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
11232110|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
11233504|NCT03153215|Active Comparator|Control group|women with severe IUGR
11232111|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.
~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
11232112|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.
~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
11232113|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.
~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
11232114|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
11232115|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
11232116|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
11232117|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.
~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
11232118|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
11232119|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
11232120|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
11232121|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
11232122|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
11232123|NCT03163082|Active Comparator|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
11232124|NCT03163082|Active Comparator|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
11232125|NCT03163082|Active Comparator|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
11232126|NCT03163082|Active Comparator|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
11232127|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
11232531|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
11232128|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
11232129|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
11232130|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
11232131|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
11232132|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
11232133|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
11232134|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
11232135|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
11232136|NCT03163004|Experimental|Intervention group|Implementation of standing desks in the classroom
11232137|NCT03163004|No Intervention|Control group|
11232138|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
11232139|NCT03162991|No Intervention|12-Week Control Period|
11232140|NCT03162978|Experimental|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
11232141|NCT03162978|Experimental|HIIT only|High-intensity interval training (HIIT) only.
11232142|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
11232143|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
11232144|NCT03162926|Experimental|Single-group|Up to six (6) VC-02-20 implants
11232145|NCT03162913|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
11232146|NCT03162913|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
11232147|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
11232148|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
11232149|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
11232150|NCT03162874|Placebo Comparator|PLACEBO|
11232151|NCT03162874|Experimental|PXT002331 - 10mg|
11232152|NCT03162874|Experimental|PXT002331 - 30mg|
11232153|NCT03162861|Experimental|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
11232154|NCT03162861|Experimental|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
11232155|NCT03162848|Experimental|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
11232156|NCT03162848|No Intervention|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
11232157|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
11232158|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
11232159|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
11233311|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
11232160|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
11232161|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
11232162|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
11232163|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
11232164|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
11232165|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
11232166|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
11232167|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.1%)|
11232168|NCT03162783|Experimental|ADX-102 Ophthalmic Lipid Solution (0.5%)|
11232169|NCT03162770|Experimental|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
11232170|NCT03162770|No Intervention|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
11232171|NCT03162757|Experimental|Subclavian vein access|
11232172|NCT03162757|Experimental|Internal jugular vein access|
11232173|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
11232174|NCT03162731|Experimental|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over at least 30 minutes every 2 weeks and ipilimumab IV over at least 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
11232175|NCT03162718|Other|single arm|exercise
11232176|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
11232177|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
11232178|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
11232179|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
11232180|NCT03162640||P|for cannabis
11232181|NCT03162640||C|for the control group
11232182|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.
~When maximum tolerated dose reached, Dose Expansion Phase begins."
11232183|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
11232184|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
11232185|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
11232186|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
11232187|NCT03162614|Active Comparator|AduFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
11232188|NCT03162614|Experimental|2PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
11232189|NCT03162614|Experimental|PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
11232190|NCT03162614|Experimental|Adu2Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
11232191|NCT03162614|Active Comparator|Adu1Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
11233312|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
11232192|NCT03162614|Other|Control Group|Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
11232193|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
11232194|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
11232195|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
11232196|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
11232197|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
11232198|NCT03162549||Inflammatory Bowel Disease|Pts presenting to enrolling sites across the US are invited to enroll if eligible
11232199|NCT03162536|Experimental|Phase I : Dose Escalation and Determination of RP2D|Phase I : Dose Escalation and determination of RP2D, multiple dose levels of ARQ 531 to be evaluated
11232200|NCT03162536|Experimental|Phase II : Relapsed/Refractory (R/R) CLL/SLL subjects|Phase II : Relapsed/Refractory (R/R) CLL/SLL subjects with at least 2 prior systemic therapies and previously treated with a covalent Bruton's tyrosine kinase inhibitor (BTKi) who must have a documented BTK mutation on C481 residue
11232201|NCT03162536|Experimental|Phase II : R/R CLL/SLL Subjects|Phase II : R/R CLL/SLL subjects who have failed or were intolerant to a BTKi with documentation of the absence of BTK mutation on C481 residue
11232202|NCT03162536|Experimental|Phase II : Richter's Transformation Subjects|Phase II : Richter's transformation subjects who have failed at least one prior therapy
11232203|NCT03162536|Experimental|Phase II : Follicular Lymphoma (FL) Subjects|Phase II : Follicular Lymphoma (FL) subjects who have failed at least 2 prior systemic therapies and are histology grade 1, 2, or 3A
11232204|NCT03162536|Experimental|Phase II : Mantle Cell Lymphoma (MCL) Subjects|Phase II : Mantle Cell Lymphoma (MCL) subjects who have failed at least 2 prior systemic therapies
11232205|NCT03162536|Experimental|Phase II : Marginal Zone Lymphoma (MZL) Subjects|Phase II : Marginal Zone Lymphoma (MZL) subjects who have failed at least 2 prior systemic therapies
11232206|NCT03162536|Experimental|Phase II : High-grade B-cell Lymphoma Subjects|Phase II : High-grade B-cell lymphoma subjects who have failed at least 2 prior systemic therapies and have known MYC and BCL2 and/or BCL6 translocations
11232207|NCT03162536|Experimental|Phase II : Waldenström macroglobulinemia (WM) Subjects|Phase II : Waldenström macroglobulinemia (WM) subjects who have failed at least 2 prior systemic therapies
11232208|NCT03162536|Experimental|Food Effect Cohort: B-cell NHL, CLL/SLL and WM Patients|Food Effect Cohort: B-cell NHL, CLL/SLL and WM patients
11232209|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
11232210|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
11232211|NCT03162510|Experimental|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
11232212|NCT03162497|Experimental|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
11232213|NCT03162497|Active Comparator|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
11232214|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
11232215|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
11232216|NCT03162458|Experimental|Anaferon for children|
11232217|NCT03162458|Placebo Comparator|Placebo|
11232218|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
11232219|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
11232220|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
11232221|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
11232222|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
11232223|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
11232224|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
11232225|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
11233313|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
11232226|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
11232227|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
11232228|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
11232229|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
11232230|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
11232231|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
11232232|NCT03162367|Experimental|Autologous epidermal cell suspension group|
11232233|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
11232234|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
11232235|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
11232236|NCT03162341|Experimental|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.
~Those are interventions that are not part of the standard care of the patients."
11232237|NCT03162328|Placebo Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
11232238|NCT03162328|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
11232239|NCT03162315|No Intervention|Fresh embryo transfer|fresh embryo transfer (standard of care)
11232240|NCT03162315|Experimental|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
11232241|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
11232242|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
11232243|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
11232244|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
11232245|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
11232246|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
11232247|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
11232248|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
11232249|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
11232250|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
11232251|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
11232252|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
11232253|NCT03162237|Experimental|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg
11232254|NCT03162237|Active Comparator|AutologousTreg|Autologous Treg:2x10^6/Kg
11232255|NCT03162224|Experimental|HPV associated recurrent/metastatic HNSCC|Approximately 50 patients with HPV associated recurrent/metastatic HNSCC
11232357|NCT03161457|Experimental|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
11232256|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
11232257|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
11232258|NCT03162198||Cirrhosis with HCC|
11232259|NCT03162198||Cirrhosis without HCC|
11232260|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
11232261|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
11232262|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
11232263|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
11232264|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
11232265|NCT03162133|Experimental|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
11232266|NCT03162133|Experimental|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.
~After their post-assessment they were able to attend the Baduanjin classes."
11232267|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
11232268|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
11232269|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days
~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
11232270|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days
~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
11232271|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days
~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
11232272|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates
~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
11232273|NCT03162081||Non-users|"Age and gender matched controls not using the above
~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
11232274|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients
~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
11232275|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
11232276|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
11232277|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
11232278|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
11232279|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
11232280|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
11232281|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
11232282|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
11232283|NCT03162029||control group|CBCT imaging of medically-free participants
11232284|NCT03162016|Experimental|Transplants of acellular matrix|
11232285|NCT03162016|Active Comparator|Transplants of connective tissue|
11232286|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
11232287|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
11232358|NCT03161457|Active Comparator|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
11232288|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
11232289|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
11232290|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
11232291|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
11232292|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
11232293|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
11232294|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
11232295|NCT03161951||Control group|Control group of healthy persons
11232296|NCT03161938|Active Comparator|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
11232297|NCT03161938|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
11232298|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
11232299|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
11232300|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
11232301|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
11232302|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
11232303|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
11232304|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
11232305|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
11232306|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
11232307|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
11232308|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
11232309|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
11232310|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
11232311|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
11232312|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
11232313|NCT03161756|Experimental|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
11232314|NCT03161756|Experimental|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
11232315|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
11232316|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
11232317|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
11232318|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
11232319|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
11232320|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
11232321|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
11232322|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
11232323|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
11232324|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
11232325|NCT03161652|Placebo Comparator|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
11232326|NCT03161652|Experimental|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
11232327|NCT03161652|Placebo Comparator|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
11232328|NCT03161652|Experimental|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
11232329|NCT03161652|Placebo Comparator|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
11232330|NCT03161652|Experimental|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
11232331|NCT03161652|Placebo Comparator|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
11232332|NCT03161652|Experimental|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
11232333|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
11232334|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
11232335|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
11232336|NCT03161626||Moderate to Severe Factor X Deficiency|
11232337|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
11232338|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
11232339|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
11232340|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
11232341|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
11232342|NCT03161535|Experimental|exercise group|
11232343|NCT03161535|No Intervention|usual-care group|
11232344|NCT03161522|Experimental|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
11232345|NCT03161522|Experimental|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
11232346|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
11232347|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
11232348|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
11232349|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
11232350|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)
~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)
~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
11232351|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)
~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)
~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
11232352|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)
~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)
~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
11232353|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
11232354|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
11232355|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
11232356|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
11232359|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
11232360|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
11232361|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
11232362|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
11232363|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
11232364|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
11232365|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
11232366|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
11232367|NCT03161379|Experimental|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
11232368|NCT03161366|Experimental|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
11232369|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):
~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles
~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
11232370|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.
~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.
~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.
~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
11232371|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
11232372|NCT03161340|Experimental|Treatment group|Rapamycin group
11232373|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
11232374|NCT03161327|Other|ABI|ABI will be performed in patient
11232375|NCT03161314|Experimental|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
11232376|NCT03161314|Active Comparator|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
11232377|NCT03161301||Group 1|IL-37 genotype 1.1
11232378|NCT03161301||Group 2|IL-37 genotype 1.2
11232379|NCT03161301||Group 3|IL-37 genotype 2.2
11232380|NCT03161288|Experimental|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
11232381|NCT03161288|Experimental|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
11232382|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
11232383|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
11232384|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
11232385|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
11232386|NCT03161249|Experimental|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
11232387|NCT03161249|Other|Control group|"Control group: Treatment as usual
~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
11232388|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
11232389|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
11232390|NCT03161223|Other|A: Oral 5-azacitidine, durvalumab, romidepsin|Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
11232391|NCT03161223|Other|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
11232392|NCT03161223|Other|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
11232393|NCT03161223|Other|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
11232394|NCT03161210|Experimental|Dextrose Prolotherapy|
11232395|NCT03161210|Active Comparator|Local Anaesthetic|
11232396|NCT03161210|Placebo Comparator|Saline|
11232397|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
11232398|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
11232399|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:
~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling
~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
11232400|NCT03161158|Active Comparator|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
11232401|NCT03161158|Other|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
11232402|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
11232403|NCT03161132|Experimental|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
11232404|NCT03161132|Other|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
11232405|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
11232406|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
11232407|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
11232408|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
11232409|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
11232410|NCT03161093|Experimental|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
11232411|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
11232412|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
11232413|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
11232414|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
11232415|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
11232416|NCT03161067|Experimental|Surgical implantation of BiCNS|
11232417|NCT03161054|Experimental|One arm for all patient|"Induction phase:
~Eligible Pts will receive 6 cycles (every 28 days) of the DEVEC combination: DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and R:Rituximab ; R will be administered only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of R will not repeat it during the metronomic therapy.
~Super-frail patients will not receive etoposide during cycles 1 and 2.
~Maintenance Phase:
~Pts in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.
~Post Maintenance Phase:
~Pts in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance"
11232418|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
11232419|NCT03161028|Experimental|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
11232420|NCT03161028|Placebo Comparator|Arm 2: Placebo|59 subjects receive placebo daily
11232421|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
11232422|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
11232423|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
11232424|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
11232425|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
11232426|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
11232427|NCT03160989|Experimental|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
11232428|NCT03160976|No Intervention|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
11232429|NCT03160976|Active Comparator|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
11232430|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
11232431|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
11232432|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
11232433|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
11232434|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
11232435|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
11232436|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
11232437|NCT03160950|Experimental|LuxaCrown|
11232438|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
11232439|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
11232440|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.
~Preoperative counselling by surgeon, dietician and physiotherapist
~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)
~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics
~Avoid use of drains
~Early resumption of diet
~Early mobilisation with physiotherapist
~Dietary counselling by dietician
~Early discharge if fulfil discharge criteria.
~Discharge criteria:
~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization
~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
11232441|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.
~No preoperative counselling
~No Preoperative carbohydrate-loaded drink
~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.
~Routine use of drains
~Diet will be resumed when there is flatus clinically
~Mobilisation as per patient's wish
~Dietary counselling by dietician
~Discharge if fulfil discharge criteria.
~Discharge criteria:
~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization
~Patients will be seen in clinic on post-operative D14."
11232442|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
11232443|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
11232444|NCT03160898|Experimental|Reldesemtiv 150 mg twice daily|Patients in this arm took 1 reldesemtiv 150 mg oral tablet and 2 matching placebo tablets every 12 hours for 12 weeks.
11232445|NCT03160898|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm took 2 reldesemtiv 150 mg oral tablets and 1 matching placebo tablet every 12 hours for 12 weeks.
11232446|NCT03160898|Experimental|Reldesemtiv 450 mg twice daily|Patients in this arm took 3 reldesemtiv 150 mg oral tablets every 12 hours for 12 weeks.
11232447|NCT03160898|Placebo Comparator|Placebo|Patients in this arm took 3 placebo oral tablets every 12 hours for 12 weeks.
11232448|NCT03160885|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16
~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
11232449|NCT03160885|Placebo Comparator|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):
~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
11232450|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
11232451|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.
~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
11232452|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52
~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
11232453|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52
~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
11232454|NCT03160885|Experimental|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52
~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W
~OR
~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W
~• TCS = topical corticosteroids"
11232455|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
11232456|NCT03160859|Other|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
11232457|NCT03160859|Other|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
11232458|NCT03160833|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
11232459|NCT03160820|Other|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
11232460|NCT03160820|Other|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
11232461|NCT03160820|Other|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
11232462|NCT03160820|Other|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
11232463|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
11232464|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
11232465|NCT03160794|Experimental|[18F] DCFPyL PET/MRI|"[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.
~Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery."
11232466|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
11232467|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
11232468|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
11232469|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
11232470|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
11232471|NCT03160716|Other|Treatment|
11232472|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
11232473|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
11232474|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
11232475|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
11232476|NCT03160677|Experimental|Intensive blood pressure management|
11232477|NCT03160677|Active Comparator|Standard blood pressure management|
11232478|NCT03160664|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
11232479|NCT03160664|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
11232480|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
11232481|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
11232482|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
11232483|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
11232530|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
11232484|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
11232485|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
11232486|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
11232487|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
11232488|NCT03160599|Experimental|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.
~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
11232489|NCT03160586|Active Comparator|Stutter|Children who stuttering
11232490|NCT03160586|Active Comparator|Control|Children who non stuttering
11232491|NCT03160573|Active Comparator|Test-Unflavored Rinse|
11232492|NCT03160573|Active Comparator|Test-Flavored Rinse|
11232493|NCT03160573|Placebo Comparator|Placebo|
11232494|NCT03160560|Active Comparator|Test-Unflavored Rinse|
11232495|NCT03160560|Active Comparator|Test-Flavored Rinse|
11232496|NCT03160560|Placebo Comparator|Placebo|
11232497|NCT03160547|Active Comparator|Usual Protein/Amino Acid Group|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
11232498|NCT03160547|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
11232499|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
11232500|NCT03160534|No Intervention|Control|Only measurements
11232501|NCT03160521|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
11232502|NCT03160521|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
11232503|NCT03160521|Placebo Comparator|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
11232504|NCT03160482||Papillary carcinoma, classical variant|
11232505|NCT03160482||Follicular carcinoma|
11232506|NCT03160482||Colloid nodule|
11232507|NCT03160482||Hyperplastic nodule|
11232508|NCT03160482||Adenomatoid nodule|
11232509|NCT03160482||Follicular adenoma|
11232510|NCT03160482||Papillary carcinoma, follicular variant|
11232511|NCT03160482||Medullary carcinoma|
11232512|NCT03160482||Lymphocytic thyroiditis|
11232513|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
11232514|NCT03160456|Experimental|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
11232515|NCT03160456|Active Comparator|Continuous positive airway pressure|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography and the initial assessment will be repeated.
11232516|NCT03160443|Other|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.
~All of them are patients with an eating disorder."
11232517|NCT03160430|Experimental|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
11232518|NCT03160430|Placebo Comparator|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
11232519|NCT03160430|Placebo Comparator|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
11232520|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
11232521|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
11232522|NCT03160391|Experimental|Music Training|Music Training
11232523|NCT03160391|Active Comparator|Dance Training|Dance Training
11232524|NCT03160391|No Intervention|Passive control group|Passive control group
11232525|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
11232526|NCT03160378|Other|Control|Control participants will receive treatment as usual.
11232527|NCT03160365|Other|ACQUISITION OF IMAGES|4 MRIs were performed at Day 0, day 1, day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
11232528|NCT03160352|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
11232529|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
11232532|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
11232533|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
11232534|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
11232535|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
11232536|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
11232537|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
11232538|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
11232539|NCT03160235|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
11232540|NCT03160235|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
11232541|NCT03160235|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
11232542|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
11232543|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
11232544|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
11232545|NCT03160196|Experimental|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
11232546|NCT03160196|Active Comparator|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
11232547|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
11232548|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
11232549|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.
~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
11232550|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.
~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
11232551|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
11232552|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
11232553|NCT03160131|Experimental|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
11232554|NCT03160118|Other|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
11232555|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
11232556|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
11232727|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
11232557|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
11232558|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
11232559|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).
~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).
~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.
~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
11232560|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|
11232561|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
11232562|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
11232563|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
11232564|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
11232565|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
11232566|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
11232567|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
11232568|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
11232569|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
11232570|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
11232571|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
11232572|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
11232573|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
11232574|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
11232575|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
11232576|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
11232577|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
11232578|NCT03159962|Active Comparator|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
11232579|NCT03159962|Active Comparator|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
11232580|NCT03159962|No Intervention|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
11232581|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
11232582|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
11232583|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
11232584|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
11232585|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
11232649|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.
~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
11232586|NCT03159897|Experimental|Comparator arm|Patients will receive 2 courses of standard ABVD (ABVD-28, d1, d15, cycles of 28 days) and then proceed to interim PET/CT evaluation. Those with a PET-2-negative scan (score 1-3 on 5PS) will continue with additional 4 ABVD courses while those with a PET-2-positive (score 4-5) scan will be diverted towards an intensification phase with either escalated BEACOPP or HDT plus ASCR, according to the preference of the centre. Upon completion of treatment, patients will be categorized for response (Lugano2014) by comparing actual PET/CT imaging with baseline, whether 6 ABVD cycles or ABVDx2 + intensification phase with BEACOPP or HDT/ASCR. A salvage rescue program will be planned for patients with Stable (<PR) or Progressive Disease. 30 Gy Involved Site Radiotherapy (ISRT) will be delivered as consolidation treatment on initial bulky site(s) and 30-36 on focal PET rests scoring ≥ 3 on 5PS.
11232587|NCT03159897|Experimental|Experimental arm|Dose-dense and dose-intense ABVD regimen (ABVD DD-DI: intercycle 21 days, d1, d11; doxorubicin 35 mg/m2 DD 1 and 11) is given in cycles 1 to 4 and dose-dense ABVD (ABVD DD: intercycle 21 days, D1 and D11; conventional doxorubicin dose, e.g. 25 mg/m2 DD 1 and 11) is given as cycles 5 and 6). The treatment is not PET-adapted, and only patients with no response or progressive disease at interim FDG-PET as defined by the Lugano Classification (e.g., score 4 or 5 on 5PS with no significant change or with increased uptake matched with baseline and/or new FDG-avid foci consistent with lymphoma) will be diverted to salvage therapy. 30-36 Gy ISRT will be delivered as consolidation treatment on focal PET rests scoring ≥3 on 5PS at the end of ABVD DD-DI. No intentional consolidation radiotherapy on the initial bulky area(s) is scheduled.
11232588|NCT03159884|Experimental|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
11232589|NCT03159884|Experimental|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
11232590|NCT03159871|Experimental|Stratafix suture|
11232591|NCT03159871|Active Comparator|Vicryl suture|
11232592|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
11232593|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
11232594|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
11232595|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
11232596|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
11232597|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.
~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
11232598|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
11232599|NCT03159793|Active Comparator|Group A|Live Modelling
11232600|NCT03159793|Active Comparator|Group B|Filmed Modelling
11232601|NCT03159793|No Intervention|Group C|No Modelling
11232602|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
11232603|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
11232604|NCT03159754|Experimental|Early Appendectomy|
11232605|NCT03159754|Experimental|Interval Appendectomy|
11232606|NCT03159754|Experimental|No Appendectomy|
11232607|NCT03159741|Experimental|Inhibitor + GLP-2|
11232608|NCT03159741|Experimental|Placebo + GLP-2|
11232609|NCT03159741|Active Comparator|Placebo + GIP|
11232610|NCT03159741|Placebo Comparator|Placebo + Saline|
11232611|NCT03159728|Experimental|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
11232612|NCT03159728|No Intervention|Control group|"The control group will receive training about knowledge of chronic disease and care.
~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
11232613|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
11232614|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
11232615|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
11232650|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.
~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.
~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
11233014|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
11232616|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are < 60 years.
~Melphalan: 140 mg/m2/day IV on Day: -6
~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)
~TBI: 200 cGy Day: -1.
~For patients who are ≥ 60 years.
~Melphalan: 100 mg/m2/day IV on Day: -6
~Fludarabine: 40 mg/ m2/day IV Days: -5, -4, -3, -2
~TBI: 200 cGy; Days: -2, -1 (total of 400cGy)
~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):
~Melphalan: 70 mg/m2/day IV on Day -6.
~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.
~TBI: 200 cGy; Days -1."
11232617|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
11232618|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
11232619|NCT03159650|Experimental|intravascular ultrasonography guided|
11232620|NCT03159650|Active Comparator|Angiography guided|
11232621|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
11232622|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
11232623|NCT03159611|Experimental|Tenoten for children|
11232624|NCT03159611|Placebo Comparator|Placebo|
11232625|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
11232626|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
11232627|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
11232628|NCT03159585|Experimental|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
11232629|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
11232630|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
11232631|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
11232632|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
11232633|NCT03159533|Placebo Comparator|Control Group|Wait-list
11232634|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
11232635|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
11232636|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
11232637|NCT03159494|Experimental|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
11232638|NCT03159494|Experimental|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
11232639|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
11232640|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
11232641|NCT03159468|Experimental|Cognitive Restructuring & Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
11232642|NCT03159468|Experimental|Mindfulness & Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
11232643|NCT03159468|Experimental|Nutrition Information & Alcohol Condition|Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
11232644|NCT03159468|Experimental|Cognitive Restructuring & No Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
11232645|NCT03159468|Experimental|Mindfulness & No Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
11232646|NCT03159468|No Intervention|Nutrition Information & No Alcohol Condition|Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.
11232647|NCT03159455|Experimental|BI 1467335|
11232648|NCT03159455|Placebo Comparator|Placebo|
11232683|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
11233314|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
11232651|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.
~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.
~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
11232652|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.
~Intervention: Nasal breathing rehabilitation"
11232653|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.
~Intervention: Standard rehabilitation"
11232654|NCT03159416|Experimental|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
11232655|NCT03159416|Experimental|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
11232656|NCT03159416|Experimental|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
11232657|NCT03159416|Experimental|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
11232658|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
11232659|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
11232660|NCT03159377||Patients scheduled for a chest CT|Inpatients or outpatients scheduled for a chest CT in our medical center
11232661|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
11232662|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
11232663|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
11232664|NCT03159338|Active Comparator|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
11232665|NCT03159338|Placebo Comparator|Control group|In control site , placebo gel will be placed before rigid fixation
11232666|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
11232667|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
11232668|NCT03159312|Experimental|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
11232669|NCT03159312|No Intervention|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
11232670|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
11232671|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
11232672|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
11232673|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
11232674|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
11232675|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
11232676|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
11232677|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
11232678|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
11232679|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
11232680|NCT03159234|Other|Diabetic pregnant women|
11232681|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
11232682|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
11232684|NCT03159182|Experimental|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
11232685|NCT03159182|Active Comparator|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
11232686|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
11232687|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
11232688|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
11232689|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
11232690|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
11232691|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
11232692|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
11232693|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
11232694|NCT03159117|Experimental|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
11232695|NCT03159104|Experimental|Tenoten for children|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
11232696|NCT03159104|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
11232697|NCT03159091|Experimental|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
11232698|NCT03159091|Placebo Comparator|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
11232699|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
11232700|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
11232701|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
11232702|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
11232703|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
11232704|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
11232705|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
11232706|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
11232707|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
11232708|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
11232709|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
11232710|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
11232711|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
11232712|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
11232713|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
11232714|NCT03159000|Experimental|GONB of lidocaine/bupivacaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
11232715|NCT03159000|Placebo Comparator|Placebo injection of 1/3 saline|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
11232716|NCT03158974|Experimental|VIR007|Cream containing 10% EISO
11232717|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
11232718|NCT03158948|Experimental|MOTREM 1|0.3 mg/kg/h
11232719|NCT03158948|Experimental|MOTREM 2|1.0 mg/kg/h
11232720|NCT03158948|Experimental|MOTREM 3|3.0 mg/kg/h
11232721|NCT03158948|Placebo Comparator|Placebo|
11232722|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
11232723|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
11232724|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
11232725|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
11232726|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
11232728|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.
~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
11232729|NCT03158883|Experimental|Non-responders|"Patients who initially progress at first response assessment on a PD-1 inhibitor will be enrolled to the non-responder arm.
~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).
~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
11232730|NCT03158883|Experimental|Progressors|"Patients who initially present with PR, CR, or SD to a PD-1 inhibitor but subsequently progress will be enrolled to the progressor arm.
~Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).
~Stereotactic ablative radiotherapy (SAR): the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated."
11232731|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
11232732|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day
~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
11232733|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)
~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
11232734|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
11232735|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
11232736|NCT03158831|Other|Placebo-Controlled Graded Drug Challenge|This is a single arm study. All patients will receive a placebo prior to a graded drug challenge. Each patient serves as his/her own control.
11232737|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
11232738|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
11232739|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
11232740|NCT03158792|Active Comparator|Enoxaparin 20 mg|
11232741|NCT03158792|Active Comparator|Enoxaparin 30 mg|
11232742|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.
~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.
~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
11232743|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
11232744|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
11232745|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
11232746|NCT03158727|Experimental|Cx611|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each
11232747|NCT03158727|Placebo Comparator|Placebo|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate
11232748|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
11232749|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
11232750|NCT03158714|No Intervention|Control|No programming is offered.
11232751|NCT03158688|Active Comparator|Kd - Carfilzomib and Dexamethasone|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.
~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles."
11232788|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 800 mg i.v. for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
11232789|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
11232976|NCT03157128|Experimental|LOXO-292 (Selpercatinib)|Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended dose for Phase 2 (RP2D)
11232752|NCT03158688|Experimental|KdD - Carfilzomib, Dexamethasone and Daratumumab|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.
~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.
~Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only."
11232753|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.
~Intervention:
~-Procedure: Fractional carbon dioxide laser.
~-Drug: Topical corticosteroid.
~-Radiation: Ultraviolet B narrow band."
11232754|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
11232755|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
11232756|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
11232757|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
11232758|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
11232759|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
11232760|NCT03158597||AMI|
11232761|NCT03158597||Control|
11232762|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
11232763|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
11232764|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
11232765|NCT03158558|Experimental|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
11232766|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
11232767|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
11232768|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
11232769|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
11232770|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
11232771|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
11232772|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
11232773|NCT03158519|Experimental|iMETX intervention|Individualized exercise recommendation
11232774|NCT03158506|Experimental|[C14]-labelled HMS5552|
11232775|NCT03158480|Experimental|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
11232776|NCT03158480|Placebo Comparator|Placebo+interferon Group|saline as placebo plus interferon intervention
11232777|NCT03158467||Phase 1|
11232778|NCT03158467||Phase 2|
11232779|NCT03158454|Other|Capsula Closure|
11232780|NCT03158454|Other|Non-Capsula Closure|
11232781|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
11232782|NCT03158441||control|same patients , dynamic scan
11232783|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
11232784|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
11232785|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
11232786|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
11232787|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
11232888|NCT03157700|Experimental|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
11232790|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
11232791|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
11232792|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
11232793|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks
~followed by a 4 weeks break (after last dose of 2nd cycle)
~and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
11232794|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. for 6 months or until progression
~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
11232795|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally
~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution
~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
11232796|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally
~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine
~postoperative day 1 to 10: 1 placebo capsule x 3"
11232797|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:
~Test subjects undergo 48 hour exercise restriction and overnight fast.
~Study day 1:
~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.
~Study day 2:
~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.
~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.
~Study day 3:
~- Blood sample."
11232798|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.
~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.
~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
11232799|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
11232800|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
11232801|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
11232802|NCT03158324|Experimental|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
11232803|NCT03158311|Experimental|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
11232804|NCT03158311|Experimental|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
11232805|NCT03158311|Active Comparator|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
11232806|NCT03158285|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
11232807|NCT03158285|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
11232808|NCT03158285|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
11232809|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
11232810|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
11232811|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
11232812|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
11232813|NCT03158246|Experimental|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)
~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
11232814|NCT03158246|Active Comparator|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)
~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
11232815|NCT03158220|Experimental|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
11232816|NCT03158220|Active Comparator|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
11232977|NCT03157115|Experimental|HFrEF: Heart failure - reduced ejection fraction|Patients with heart failure and reduced ejection fraction (around 35%).
11232817|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
11232818|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
11232819|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
11232820|NCT03158168|Experimental|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.
~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
11232821|NCT03158168|Active Comparator|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis [19]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.
~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
11232822|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
11232823|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
11232824|NCT03158129|Experimental|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
11232825|NCT03158129|Experimental|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
11232826|NCT03158129|Experimental|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11232827|NCT03158129|Experimental|Arm D ipilimumab, nivolumab, cisplatin, docetaxel, pemetrexed|Patients receive Ipilimumab 1 mg/kg intravenously on day 1 only plus Nivolumab 360 mg IV every 3 weeks (D1, D22, D43) plus Cisplatin (or Carboplatin) and Docetaxel IV administered every 3 weeks (D1, D22, D43), up to a maximum of 3 cycles for squamous histology NSCLCs, or Ipilimumab 1 mg/kg intravenously on day 1 only plus Nivolumab 360 mg IV every 3 weeks (D1, D22, D43) plus Cisplatin (or Carboplatin) and Pemetrexed IV administered every 3 weeks (D1, D22, D43), up to a maximum of 3 cycles for non-squamous histology NSCLCs.
11232828|NCT03158116|Experimental|Treatment|All participants will be receiving the study drug
11232829|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
11232830|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
11232831|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
11232832|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
11232833|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
11232834|NCT03158064|Experimental|Duravalumab + Tremelimumab|"Duravalumab/Tremelimumab: Durvalumab and Tremelimumab will be administered by IV every 4 weeks for up to 4 doses/cycles, then Durvalumab by IV every 4 weeks starting at Week 16 for 9 doses (total treatment duration of 12 months).
~Participants enrolled now will receive tremelimumab *300mg with durvalumab 1500mg for 1 cycle followed by 12 cycles of durvalumab 1500mg every 4 weeks or until lack of clinical benefit or unacceptable toxicity."
11232835|NCT03158051|Experimental|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
11232836|NCT03158051|No Intervention|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
11232837|NCT03158038|Experimental|Monovalent Influenza Vaccine|Participants will receive a single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain] by intranasal spray on Day 1.
11232838|NCT03158038|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.
11232889|NCT03157700|No Intervention|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
11233012|NCT03156829|Experimental|Splint and cortico-steroid combined|
11232839|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
11232840|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
11232841|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
11232842|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
11232843|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
11232844|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
11232845|NCT03158012|Active Comparator|Active treatment|
11232846|NCT03158012|Placebo Comparator|Placebo treatment|
11232847|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
11232848|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
11232849|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
11232850|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
11232851|NCT03157973|Experimental|Education intervention|
11232852|NCT03157973|No Intervention|Standard of Care|
11232853|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
11232854|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
11232855|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
11232856|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
11232857|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
11232858|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
11232859|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
11232860|NCT03157934||Primary CSC admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
11232861|NCT03157934||Primary non-CSC SU admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
11232862|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
11232863|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
11232864|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
11232865|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
11232866|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
11232867|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral
~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
11232868|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral
~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
11232869|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
11232870|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
11232871|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
11232872|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
11232873|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
11232874|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
11232875|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
11232876|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
11232877|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
11232878|NCT03157778|Experimental|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
11232879|NCT03157778|Active Comparator|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
11232880|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
11232881|NCT03157765|No Intervention|Routine care|These patient receive routine care
11232882|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
11232883|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.
~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
11232884|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.
~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
11232885|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
11232886|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
11232887|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
11232890|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status
~Stool sampling before preventive gastroscopy and colonoscopy
~Questionnaires about general health, gastrointestinal symptoms and 3-day food record
~Collection of biopsies in duodenum during gastroscopy
~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
11232891|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status
~Stool sampling before indicated gastroscopy and colonoscopy
~Questionnaires about general health, gastrointestinal symptoms and 3-day food record
~Collection of biopsies in duodenum during gastroscopy
~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
11232892|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status
~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)
~Questionnaires about general health, gastrointestinal symptoms and 3-day food record
~Collection of biopsies in duodenum during gastroscopy
~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
11232893|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between
~01-Jan-2013 and 30-Sep-2016."
11232894|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.
~Inclusion Criteria:
~Patients included in the study will be:
~> 18 years of age
~Non-cardiac patients
~Non-obstetric patients
~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
11232895|NCT03157635|Experimental|Part 1 (Healthy Volunteers): Crovalimab|Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg). Doses are planned to be escalated up to Cohort 5.
11232896|NCT03157635|Placebo Comparator|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
11232897|NCT03157635|Experimental|Part 2 (PNH Participants): Crovalimab|PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
11232898|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab QW|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg QW on Day 8 for a maximum treatment duration of 5 months.
11232899|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q2W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg Q2W for a maximum treatment duration of 5 months.
11232900|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q4W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg Q4W starting on Day 8 for a maximum treatment duration of 5 months.
11232901|NCT03157635|Experimental|Part 4 (eculizumab pretreated PNH Participants): Crovalimab|"PNH Participants pretreated with eculizumab will receive crovalimab:
~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
11232902|NCT03157635|Experimental|Part 4 (treatment naïve PNH Participants): Crovalimab|"Treatment naïve PNH Participants will receive:
~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
11232903|NCT03157635|Experimental|OLE (PNH Participants): Crovalimab|PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight >/= 40 kg to < 100 kg) or 1020 mg SC Q4W (body weight >/= 100 kg) for up to a maximum treatment duration of five years from entry into OLE.
11232904|NCT03157622|Active Comparator|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
11232905|NCT03157622|Active Comparator|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
11232906|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
11232907|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
11232935|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
11232936|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
11233013|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
11232908|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.
~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.
~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.
~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.
~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .
~the same evaluation was carried out again 3 months after the intervention."
11232909|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
11232910|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
11232911|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
11232912|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
11232913|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
11232914|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
11232915|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
11232916|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
11232917|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
11232918|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
11232919|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
11232920|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
11232921|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
11232922|NCT03157544|Experimental|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
11232923|NCT03157531|Experimental|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
11232924|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
11232925|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
11232926|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
11232927|NCT03157492|Experimental|Aural Rehabilitation Group|The AR Group will receive six 90-minute sessions including auditory training, informational counseling, and communication strategies.
11232928|NCT03157492|Sham Comparator|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy.
11232929|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
11232930|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
11232931|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
11232932|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
11232933|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
11232934|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
11232937|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
11232938|NCT03157388|Experimental|Intervention|Combined Vancomycin and Gentamycin and Meropenem
11232939|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
11232940|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
11232941|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
11232942|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
11232943|NCT03157362|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
11232944|NCT03157362|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
11232945|NCT03157362|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
11232946|NCT03157362|Active Comparator|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
11232947|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
11232948|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
11232949|NCT03157336|Experimental|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
11232950|NCT03157336|Experimental|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
11232951|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
11232952|NCT03157310|Experimental|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
11232953|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
11232954|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
11232955|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
11232956|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
11232957|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
11232958|NCT03157258|Experimental|Social Network Endorsement|All participants will receive a brief single care-related counseling session and referral to HIV medical care upon enrollment. After randomization to this arm, all members of HIV+ social networks will attend a multi-session group intervention during which they will be trained to deliver messages endorsing compliance with medical guidelines and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained how to deliver effective messages.
11232959|NCT03157258|Active Comparator|HIV Counseling and Referral to Care|All study participants will receive a brief single care-related counseling session and referral to HIV medical care at baseline.
11232960|NCT03157245||participant|
11232961|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
11232962|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
11232963|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
11232964|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
11232965|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
11232966|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
11232967|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
11232968|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
11232969|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
11232970|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
11232971|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
11232972|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
11232973|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
11232974|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
11232975|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
11232978|NCT03157115|Active Comparator|Control|Patients with a cardiac condition but a normal ejection fraction (>45%), without heart failure. The patients from the HFrEF group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
11232979|NCT03157102|Experimental|HFNC group|
11232980|NCT03157102|Other|Standard Oxygen Therapy group (STO group)|
11232981|NCT03157089|Experimental|All patients|
11232982|NCT03157076|Active Comparator|Pacing mode with CLS|
11232983|NCT03157076|Active Comparator|Intrinsic mode|
11232984|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
11232985|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
11232986|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
11232987|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
11232988|NCT03157037|Experimental|Treatment HMed-IdeS|IdeS intravenous infusion 0.25 mg/kg BW intravenous infusion
11232989|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
11232990|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
11232991|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
11232992|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
11232993|NCT03156972|Active Comparator|Group a|
11232994|NCT03156972|Active Comparator|Group b|
11232995|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.
~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
11232996|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.
~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
11232997|NCT03156946|Experimental|Breastfeeding support program|
11232998|NCT03156946|Other|Usual or routine care|
11232999|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
11233000|NCT03156920|Active Comparator|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
11233001|NCT03156920|Placebo Comparator|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
11233002|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (BHD) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
11233003|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.
~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
11233004|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
11233005|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
11233006|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
11233007|NCT03156842|Experimental|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
11233008|NCT03156842|Active Comparator|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
11233009|NCT03156842|Active Comparator|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
11233010|NCT03156829|Experimental|Splint alone|
11233011|NCT03156829|Experimental|Cortico-steroid alone|
11233015|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
11233016|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
11233017|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
11233018|NCT03156764||Qp/Qs ratio monitoring|Qp/Qs ratio monitoring
11233019|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
11233020|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
11233021|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
11233022|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
11233023|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
11233024|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
11233025|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
11233026|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
11233027|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
11233028|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
11233029|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
11233030|NCT03156686|No Intervention|Control|Patients will be randomly assigned to conventional hospital care
11233031|NCT03156686|Experimental|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
11233032|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
11233033|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
11233034|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
11233035|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
11233036|NCT03156647||idiopathic Parkinson disease|
11233037|NCT03156647||iatrogenic parkinsonian syndrome|
11233038|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
11233039|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
11233040|NCT03156621|Experimental|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period
~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
11233041|NCT03156621|Experimental|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period
~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
11233042|NCT03156608|Experimental|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
11233043|NCT03156608|Active Comparator|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
11233044|NCT03156595|Placebo Comparator|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
11233045|NCT03156595|Experimental|Hypnosis session|Hypnosis sessions with nurses or psychologists, with deepening sessions to facilitate self-hypnosis learning.
11233046|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).
~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
11233047|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.
~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.
~Lesson 2 presents different strategies to generate helpful cognitions.
~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.
~Lesson 4 describes avoidance and safety behaviors and graded exposure.
~Lesson 5 is about problem solving and relapse prevention.
~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
11233048|NCT03156543|Experimental|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
11233049|NCT03156543|Experimental|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
11233145|NCT03155854|Active Comparator|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
11233050|NCT03156530|Experimental|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
11233051|NCT03156530|Placebo Comparator|Control|Not receive stimulation.
11233052|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
11233053|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
11233054|NCT03156504|Experimental|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
11233055|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
11233056|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
11233057|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
11233058|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
11233059|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
11233060|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
11233061|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
11233062|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
11233063|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
11233064|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
11233065|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
11233066|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:
~Have received clearance from a primary physician to perform a exercise stress test.
~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
11233067|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:
~Have received clearance from a primary physician to perform a exercise stress test.
~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
11233068|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
11233069|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
11233070|NCT03156374|Experimental|Ovulation test use|Use of both ovulation tests and standardised care
11233071|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
11233072|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
11233073|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
11233074|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.
~Information will be collected that allows the characterization:
~Sociodemographic
~Morbid
~Pharmaco-therapeutic
~Functionality before (baseline), during and after hospitalization
~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
11233075|NCT03156335|Experimental|Focused Ultrasound|
11233076|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
11233077|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
11233078|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
11233079|NCT03156296|Active Comparator|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
11233080|NCT03156296|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
11233081|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
11233082|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
11233083|NCT03156270|Experimental|Vivaer Stylus|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
11233084|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
11233085|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
11233086|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
11233087|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
11233088|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
11233089|NCT03156218|Experimental|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 300.
~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
11233090|NCT03156218|Experimental|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 100 and < 300.
~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
11233091|NCT03156205|Experimental|Interactive Music Therapy|
11233092|NCT03156205|Other|passive music listening|
11233093|NCT03156205|Other|passive earphone-use|
11233094|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
11233095|NCT03156179||Girls with type 1 diabetes|
11233096|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
11233097|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
11233098|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
11233099|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
11233100|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
11233101|NCT03156140|Experimental|motion|Right hand performs three different motion types
11233102|NCT03156127|Experimental|BR-UPS 5 mg tablet|
11233103|NCT03156127|Active Comparator|Inisia 5 mg tablet|
11233104|NCT03156114|Experimental|Part I - Dose--Escalation|
11233105|NCT03156114|Experimental|Part II - Dose-Expansion|
11233106|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
11233107|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
11233108|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.
~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.
~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
11233109|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
11233110|NCT03156062|Experimental|study group|
11233111|NCT03156062|Active Comparator|control group|
11233112|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
11233113|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
11233114|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
11233115|NCT03156036|Active Comparator|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
11233116|NCT03156036|Active Comparator|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
11233117|NCT03156036|Active Comparator|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.
~(n=37)"
11233118|NCT03156023|Active Comparator|Active|Receive active investigational product (AMG 570).
11233119|NCT03156023|Placebo Comparator|Placebo|Receive placebo investigational product
11233120|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
11233121|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
11233122|NCT03155997|Experimental|Abemaciclib + Standard Adjuvant Endocrine Therapy|Abemaciclib administered orally and standard adjuvant endocrine therapy administered according to package label.
11233123|NCT03155997|Other|Standard Adjuvant Endocrine Therapy|Standard adjuvant endocrine therapy administered according to package label.
11233124|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
11233125|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
11233126|NCT03155945|Experimental|APD371 low dose treatment|
11233127|NCT03155945|Experimental|APD371 high dose treatment|
11233128|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
11233129|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
11233130|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
11233131|NCT03155906|Experimental|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
11233132|NCT03155906|Active Comparator|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
11233133|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
11233134|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
11233135|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
11233136|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
11233137|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
11233138|NCT03155867|Active Comparator|Meal replacement A|
11233139|NCT03155867|Active Comparator|Meal replacement B|
11233140|NCT03155867|Active Comparator|Meal replacement C|
11233141|NCT03155867|Active Comparator|Meal replacement D|
11233142|NCT03155867|Active Comparator|Meal replacement E|
11233143|NCT03155867|Active Comparator|Meal replacement F|
11233144|NCT03155854|Active Comparator|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
11233146|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
11233147|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
11233148|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
11233149|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
11233150|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)
~MI TLIF at L4-5 (n=10)
~XLIF at L4-5 (n=10)"
11233151|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)
~MI TLIF at L5-S1 (n=10)
~XLIF at L5-S1 (n=10)"
11233152|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)
~MI TLIF at L4-5 and L5-S1 (n=10)
~XLIF at L4-5 and L5-S1 (n=10)"
11233153|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
11233154|NCT03155750|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
11233155|NCT03155750|Active Comparator|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
11233156|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
11233157|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
11233158|NCT03155724|Experimental|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
11233159|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
11233160|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
11233161|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side
~Intervention:
~Combination Product: microneedling and Platelet rich plasma.
~radiation : NB-UVB phototherapy"
11233162|NCT03155659||CHNS|
11233163|NCT03155659||NHANES|
11233164|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
11233165|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
11233166|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
11233167|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
11233168|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
11233169|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
11233170|NCT03155620|Experimental|Subprotcol M (HRAS gene alterations)|Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
11233171|NCT03155620|Experimental|Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)|Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive Trk inhibitor LOXO-101 PO or via nasogastric- or gastric-tube BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233172|NCT03155620|Experimental|Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)|Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive pan-FGFR tyrosine kinase inhibitor JNJ-42756493 PO once daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11233173|NCT03155620|Experimental|Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)|Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233174|NCT03155620|Experimental|Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)|Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233175|NCT03155620|Experimental|Subprotocol E (activating MAPK pathway gene mutation)|Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233176|NCT03155620|Experimental|Subprotocol F (ALK or ROS1 gene alteration)|Patients with an ALK or ROS1 gene alteration receive ensartinib (ALK Inhibitor X-396) PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233177|NCT03155620|Experimental|Subprotocol G (BRAF V600 gene mutation)|Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233379|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
11233178|NCT03155620|Experimental|Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)|Patients deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11233179|NCT03155620|Experimental|Subprotocol I (Rb positive, alterations in cell cycle genes)|Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11233180|NCT03155620|Experimental|Subprotocol J (MAPK pathway mutations)|Patients with MAPK pathway mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11233181|NCT03155620|Experimental|Subprotocol N (activating RET mutations)|Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
11233182|NCT03155607|No Intervention|Standard Care|
11233183|NCT03155607|Experimental|Virtual Reality Distraction|
11233184|NCT03155594|Experimental|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
11233185|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
11233186|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
11233187|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
11233188|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
11233189|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
11233190|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
11233191|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
11233192|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
11233193|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).
~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.
~Exclusion Criteria：
~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI>30 ④With serious postoperative complications."
11233194|NCT03155516|Experimental|GPM Ward|Good Pain management ward
11233195|NCT03155516|Active Comparator|Control Ward|Current practice controlled ward
11233196|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
11233197|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
11233198|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
11233199|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
11233200|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
11233201|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
11233202|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.
~Indocyanine Green (ICG) will be used in both groups."
11233203|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.
~Indocyanine Green (ICG) will be used in both groups."
11233204|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
11233205|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation
~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
11233206|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation
~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
11233207|NCT03155425|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
11233233|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
11233208|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
11233209|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
11233210|NCT03155399|Experimental|Proprioceptive based training (PBT)|The treatment will last one hour and will be divided as follows: 2 proprioceptive based stimulation sessions per 3 minutes for each movement, with a rest of 2 minutes between each session. Every patient will receive 15 treatments, 5 days a week, for 3 weeks.
11233211|NCT03155399|Other|Conventional neuromotor treatment (CNT)|The CNT group will be treated for one hour daily by means of a CNT programme. The treatment will last 3 weeks.
11233212|NCT03155386||Standard Angiomammography (SenoBright®)|
11233213|NCT03155386||Optimized angiomammography|
11233214|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction >60%)
11233215|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
11233216|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction <60%)
11233217|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :
~Recurrent episodes of irritability, fussing or crying from birth to 4 months of age
~Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks
~Episodes can not be attributed to another disorder"
11233218|NCT03155360||Infant without colics|
11233219|NCT03155347|Experimental|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR <= 3.2).
11233220|NCT03155347|Experimental|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
11233221|NCT03155347|Active Comparator|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
11233222|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
11233223|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
11233224|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
11233225|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
11233226|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
11233227|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
11233228|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
11233229|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
11233230|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
11233231|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
11233232|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
11233234|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
11233235|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
11233236|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
11233237|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
11233238|NCT03155204|Experimental|Test Product 1|tiotropium pMDI 2 inhalations
11233239|NCT03155204|Experimental|Test Product 2|tiotropium pMDI 2 inhalations
11233240|NCT03155204|Experimental|Test Product 3|tiotropium pMDI 2 inhalations
11233241|NCT03155204|Experimental|Test Product 4|tiotropium pMDI 2 inhalations
11233242|NCT03155204|Active Comparator|Commercial Product|tiotropium Respimat 2 inhalations
11233243|NCT03155191|Experimental|Dose Level -1 to 2|"0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.
~cohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg."
11233244|NCT03155178|Experimental|3M CHG/IPA Prep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
11233245|NCT03155178|Active Comparator|ChloraPrep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
11233246|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
11233247|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
11233248|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
11233249|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
11233250|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
11233251|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
11233252|NCT03155126||Saline group|Patients resuscitated with saline
11233253|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
11233254|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.
~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
11233255|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
11233256|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
11233257|NCT03155087||healthy subjects|the healthy subjects was not intervened
11233258|NCT03155074|Experimental|High-Intensity Training|
11233259|NCT03155074|No Intervention|Usual Care|
11233260|NCT03155061|Experimental|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
11233261|NCT03155061|Experimental|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
11233262|NCT03155061|Experimental|Part C (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
11233263|NCT03155048|Active Comparator|oral estradiol group|patients with the usage of 6 milligrams/day oral estradiol
11233264|NCT03155048|Active Comparator|estradiol transdermal patch group|patients with the usage of 3.9 milligrams estradiol transdermal patch
11233265|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
11233266|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
11233267|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
11233268|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
11233269|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
11233270|NCT03154996|Experimental|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
11233271|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
11233272|NCT03154970|Experimental|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
11233273|NCT03154970|No Intervention|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
11233274|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
11233275|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
11233276|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
11233277|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
11233278|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
11233279|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
11233280|NCT03154905||Control|Healthy controls
11233281|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
11233282|NCT03154892|Experimental|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
11233283|NCT03154892|Active Comparator|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
11233284|NCT03154879||Comatose cardiac arrest survivors|
11233285|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
11233286|NCT03154866|Placebo Comparator|Placebo|
11233287|NCT03154853|No Intervention|normal foot|no intervention
11233288|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
11233289|NCT03154840|Experimental|Eutropin 4IU|
11233290|NCT03154840|Experimental|Eutropin AQ 12IU|
11233291|NCT03154840|Experimental|Eutropin Pen 36IU|
11233292|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
11233293|NCT03154814|Experimental|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
11233294|NCT03154814|Placebo Comparator|control|conventional CPB was applied without ulinastatin treatment
11233295|NCT03154801|Experimental|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
11233296|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
11233297|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
11233298|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
11233299|NCT03154749|Experimental|TC|docetaxel/carboplatin as Neoadjuvant Treatment for Triple-Negative Breast Cancer
11233300|NCT03154749|Active Comparator|EC-T|epirubicin/cyclophosphamide followed by docetaxe as Neoadjuvant Treatment for Triple-Negative Breast Cancer
11233301|NCT03154736|Experimental|Interview|Individual interview an in a group interview. Socio-economic questionnaire
11233302|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
11233303|NCT03154710|Experimental|SENTINEL|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the SENTINEL application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
11233304|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
11233305|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
11233306|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
11233307|NCT03154671|Experimental|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
11233308|NCT03154671|No Intervention|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
11233309|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
11233310|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
11233315|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
11233316|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
11233317|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
11233318|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
11233319|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
11233320|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
11233321|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (neutral)|
11233322|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
11233323|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
11233324|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
11233325|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
11233326|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
11233327|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
11233328|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
11233329|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
11233330|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
11233331|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.
~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
11233332|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
11233333|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
11233334|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
11233335|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
11233336|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
11233337|NCT03154489|Other|Acenocoumarol|
11233338|NCT03154489|Other|control group|
11233339|NCT03154476|Experimental|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
11233340|NCT03154476|Placebo Comparator|Placebo|Subjects will receive placebo times per day for 12 months.
11233341|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
11233342|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
11233343|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
11233344|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
11233345|NCT03154424|Placebo Comparator|Bridging (control group)|External fixation in treatment the distal radius fracture
11233346|NCT03154424|Active Comparator|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
11233347|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
11233348|NCT03154398||1|case control
11233349|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.
~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
11233350|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
11233351|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
11233380|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
11233381|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
11233382|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
11233641|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
11233352|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
11233353|NCT03154333|Experimental|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
11233354|NCT03154333|Placebo Comparator|vehicle ointment|vehicle ointment will be used for 8 weeks
11233355|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 9, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
11233356|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
11233357|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
11233358|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
11233359|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
11233360|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
11233361|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
11233362|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
11233363|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
11233364|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
11233365|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
11233366|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
11233367|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
11233368|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
11233369|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
11233370|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
11233371|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
11233372|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
11233373|NCT03154216|Experimental|Exercise only|90 minutes of exercise
11233374|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
11233375|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
11233376|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
11233377|NCT03154190|Active Comparator|Arm A (usual care)|Patients receive usual care.
11233378|NCT03154190|Experimental|Arm B (health care coach support)|Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms.
11233383|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
11233384|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
11233385|NCT03154138|Experimental|Prismatic adaptation (PA) group|Patients in the experimental group will benefit from 10 sessions of adaptation prismatic (PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
11233386|NCT03154138|Placebo Comparator|Sham group|Patients in the sham group will benefit from 10 sessions of sham adaptation prismatic (S-PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
11233387|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
11233388|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
11233389|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
11233390|NCT03154086|Experimental|Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg|Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233391|NCT03154086|Experimental|Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233392|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233393|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233394|NCT03154086|Experimental|Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed|Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233395|NCT03154086|Experimental|Part A: Cohort 2: Placebo Fasted/Placebo Fed|Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233396|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150 mg/Placebo|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233397|NCT03154086|Experimental|Part A:Cohort 3: Placebo/GSK3352589 400 mg|Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233398|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
11233399|NCT03154086|Experimental|Part B: GSK3352589|Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.
11233400|NCT03154086|Placebo Comparator|Part B: Placebo|Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.
11233401|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
11233402|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
11233403|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
11233404|NCT03154047|Experimental|Open label|Open Label Study Drug NEOD001
11233405|NCT03154034||Severe mitral regurgitation|
11233406|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
11233407|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
11233408|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
11233409|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
11233410|NCT03153995|Experimental|sub-mucosal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-mucosall positions using the tunnel technique.
11233411|NCT03153982|Experimental|Head and neck squamous cell carcinoma|"Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery.
~Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg)."
11233412|NCT03153969|Experimental|SHOFU Beautifil II LS|Composite: SHOFU Beautifil II LS, Bonding Agent: SHOFU BeautiBond
11233413|NCT03153969|Active Comparator|3M/ESPE Filtek Supreme|Composite: 3M/ESPE Filtek Supreme, Bonding Agent: 3M/ESPE Scotchbond Universal
11233414|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
11233415|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
11233416|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
11233417|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
11233418|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
11233419|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
11233420|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
11233421|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
11233422|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
11233423|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
11233424|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
11233425|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
11233426|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
11233427|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
11233428|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
11233429|NCT03153826|Other|Patients|
11233430|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
11233431|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
11233432|NCT03153800|Experimental|Bronchial basal cells|
11233433|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
11233434|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
11233435|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
11233436|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
11233437|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
11233438|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
11233439|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
11233440|NCT03153722|Experimental|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
11233441|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
11233442|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
11233443|NCT03153683||Acute Ischemic Stroke Patients|This is a registry. No above standard of care interventions will take place. Participants must have an acute thromboembolus within an intracranial artery in the anterior circulation (internal carotid, anterior cerebral, middle cerebral), which undergoes mechanical thrombectomy per standard of care.
11233444|NCT03153670|Other|functional magnetic resonance imaging|1 Group Assigned
11233445|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
11233446|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
11233447|NCT03153644||Patients|Women with chronic medical conditions
11233448|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.
~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
11233449|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
11233450|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
11233451|NCT03153618|No Intervention|Control|Current standard of care will be followed
11233452|NCT03153605|Experimental|SATISI_7|
11233453|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
11233454|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
11233455|NCT03153579|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
11233456|NCT03153579|Other|LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo or lysergic acid diethylamide (LSD)
11233457|NCT03153566|Experimental|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
11233458|NCT03153566|Active Comparator|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
11233459|NCT03153566|Experimental|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
11233460|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
11233461|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
11233462|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).
~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
11233463|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.
~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
11233464|NCT03153527|Placebo Comparator|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
11233465|NCT03153527|Active Comparator|Verum group (control/standard arm)|If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
11233466|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.
~Cycle 1: in the peri-transplant and transplantation phase
~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
11233467|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
11233468|NCT03153488|Experimental|Methylphenidate|Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
11233469|NCT03153488|Experimental|Amphetamine|Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
11233470|NCT03153475|Other|ATTUNE Revision Knee System|The ATTUNE Revision system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in revision knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
11233471|NCT03153449|Other|ATTUNE Revision knee system|The ATTUNE Revision knees system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in complex primary knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
11233472|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
11233473|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
11233474|NCT03153423|Other|Basic intermittent exotropia patients|
11233475|NCT03153410|Experimental|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
11233476|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
11233477|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
11233478|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
11233479|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
11233480|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
11233481|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
11233482|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
11233483|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
11233484|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
11233485|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
11233486|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
11233487|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
11233488|NCT03153319|Experimental|Adalimumab|20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
11233489|NCT03153319|Placebo Comparator|Placebo|Saline placebo comparator
11233490|NCT03153319|Experimental|Open-label adalimumab|Open-label extension of adalimumab dose
11233491|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
11233492|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
11233493|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
11233494|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
11233495|NCT03153267|Active Comparator|EM-7 days doxycycline|
11233496|NCT03153267|Active Comparator|EM-14 days doxycycline|
11233497|NCT03153267|Placebo Comparator|Controls|
11233498|NCT03153254|Experimental|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
11233499|NCT03153254|Experimental|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
11233500|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
11233501|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
11233502|NCT03153228||Control|29 healthy volunteers.
11233505|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
11233506|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
11233507|NCT03153176|Experimental|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
11233508|NCT03153176|No Intervention|no intervention|Physical Education and school curriculum as usual
11233509|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
11233510|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:
~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or
~Direct thrombin inhibitor: Dabigatran or
~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
11233511|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:
~antiplatelet drug(s) or
~no antithrombotic drugs."
11233512|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
11233513|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
11233514|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
11233515|NCT03153124|No Intervention|Control|No intervention
11233516|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
11233517|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
11233518|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
11233519|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
11233520|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
11233521|NCT03153072|Other|A child with supraventricular tachycardia|
11233522|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
11233523|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
11233524|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
11233525|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
11233526|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
11233527|NCT03153020||Cohort of patients with stroke or transient ischemic attack|The cohort will be constituted of all consecutive patients admitted for a stroke or transient ischemic attack by the Rhône's emergency medical help service (SAMU), or in one of the emergency unit or stroke unit of the Rhône area, and presenting a symptom-onset (the last time the patient was seen without deficit) less than 24 hours.
11233528|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
11233529|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
11233530|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
11233531|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
11233532|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
11233533|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
11233534|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
11233535|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
11233536|NCT03152942|Experimental|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
11233537|NCT03152942|Active Comparator|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
11233538|NCT03152929|Active Comparator|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
11233539|NCT03152929|Active Comparator|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
11233540|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
11233541|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
11233542|NCT03152903|Placebo Comparator|Placebo|
11233543|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
11233544|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
11233545|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
11233546|NCT03152864|Experimental|Full Package|
11233547|NCT03152864|No Intervention|Sensing Only|
11233548|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
11233549|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
11233550|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.
~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.
~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
11233551|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.
~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.
~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
11233552|NCT03152825||Viable myocardium Group|"At least ONE of the following:
~Late gadolinium enhancement <75%.
~Improvement in segmental function ≥1 grade during low dose dobutamine"
11233553|NCT03152825||Non-viable myocardium group|"At least ONE of the following:
~Late gadolinium enhancement ≥75%.
~No improvement in segmental function during low dose dobutamine"
11233554|NCT03152825||Inducible ischaemia group|"At least ONE of the following:
~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine
~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
11233555|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
11233556|NCT03152812||free skin flaps|
11233557|NCT03152812||free muscle flaps|
11233558|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
11233559|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
11233560|NCT03152786|Experimental|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
11233561|NCT03152786|Active Comparator|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
11233562|NCT03152773|Experimental|1|Open label
11233563|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
11233564|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
11233565|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
11233566|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.
~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
11233567|NCT03152747||B|"Group B with no/partial PVD
~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.
~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
11233568|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
11233569|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
11233570|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
11233571|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
11233572|NCT03152682|Experimental|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
11233573|NCT03152682|Experimental|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
11233574|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
11233575|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
11233576|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
11233640|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
11233577|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
11233578|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
11233579|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
11233580|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
11233581|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
11233582|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
11233583|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
11233584|NCT03152552|Experimental|LIK066 2.5mg|Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
11233585|NCT03152552|Experimental|LIK066 10mg|Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
11233586|NCT03152552|Experimental|LIK066 50mg|Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
11233587|NCT03152552|Active Comparator|Empagliflozin|Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
11233588|NCT03152552|Placebo Comparator|Placebo|Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.
11233589|NCT03152539|Experimental|Development of MRI protocols|MRI exam to grade differents interventions for future research
11233590|NCT03152539|Experimental|Development of EEG protocols|EEF exam to grade differents interventions for future research
11233591|NCT03152539|Experimental|Development of NIRS protocols|NIRS exam to grade differents interventions for future research
11233592|NCT03152526|Other|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
11233593|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
11233594|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
11233595|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
11233596|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
11233597|NCT03152474|Active Comparator|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
11233598|NCT03152474|Active Comparator|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
11233599|NCT03152474|Placebo Comparator|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
11233600|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
11233601|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
11233602|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
11233603|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
11233604|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
11233605|NCT03152396|Other|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
11233606|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
11233607|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
11233608|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
11233637|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
11233638|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
11233639|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
11233609|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
11233610|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
11233611|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
11233612|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.
~The patients will be proposed to perform the following tests and to fill in questionnaires"
11233613|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.
~The patients will be proposed to perform the following tests and to fill in questionnaires"
11233614|NCT03152331|Experimental|Receptive Awareness Training|
11233615|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.
~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.
~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
11233616|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.
~Cyclophosphamide one intravenous injection 2 days prior to procedure.
~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.
~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
11233617|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
11233618|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
11233619|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
11233620|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
11233621|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
11233622|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
11233623|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
11233624|NCT03152253|Experimental|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
11233625|NCT03152253|Placebo Comparator|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
11233626|NCT03152240||Women patients|Women patients
11233627|NCT03152240||Men patients|Men patients
11233628|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
11233629|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
11233630|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
11233631|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:
~1 session of exercise counseling
~3 weekly 25-minute sessions of vigorous intensity aerobic exercise
~1 weekly Team RWB event
~4 biweekly assessments
~Participants will also complete an online assessment at week 9 to provide follow-up data."
11233632|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:
~1 weekly Team RWB event
~4 biweekly assessments
~Participants will also complete an online assessment at week 9 to provide follow-up data."
11233633|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:
~• 4 biweekly assessments
~Participants will also complete an online assessment at week 9 to provide follow-up data."
11233634|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
11233635|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
11233636|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
11233742|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
11233642|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
11233643|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
11233644|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
11233645|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
11233646|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
11233647|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
11233648|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
11233649|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
11233650|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
11233651|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
11233652|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
11233653|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
11233654|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
11233655|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.
~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.
~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
11233656|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
11233657|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
11233658|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
11233659|NCT03152019|Active Comparator|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
11233660|NCT03152019|Placebo Comparator|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
11233661|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
11233662|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
11233663|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
11233664|NCT03151993|Active Comparator|Actillyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
11233665|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
11233666|NCT03151980|Other|Untreated skin and sun exposure|
11233667|NCT03151967|Active Comparator|applicator containing active drug|Vaginal applicator containing Lactobacillus crispatus CTV-05
11233668|NCT03151967|Placebo Comparator|placebo vaginal applicator|Inactive vaginal applicator without any drug
11233669|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.
~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;
~Explore the regulation of hippo-YAP pathway in NESCs."
11233670|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
11233743|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
11233671|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam
~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System
~Vaginal smear for evaluation with Gram's stain and Nuget's criteria
~Vaginal swab for yeast culture
~Vaginal swab for Trichomonas vaginalis NAAT
~Vaginal swab for discrepant analysis testing"
11233672|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
11233673|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
11233674|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
11233675|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB
~Chidamide administered orally on D-7, -4, 0,+3
~Cladribine administered at 10mg on D-6 to D-2
~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.
~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.
~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.
~Interventions:
~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
11233676|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
11233677|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
11233678|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
11233679|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
11233680|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
11233681|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
11233682|NCT03151811|Experimental|Arm A: Melflufen+Dexamethasone|Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
11233683|NCT03151811|Active Comparator|Arm B: Pomalidomide+Dexamethasone|Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg on Days 1, 8, 15 and 22 of each 28-day cycle. Patients are to be treated until confirmed progression, unacceptable toxicity or the patient or investigator decides it is not in the patients best interest to continue.
11233684|NCT03151798|Experimental|Phase I: Observational studies|Patients are eligible who are undergoing either bariatric surgery or a liver biopsy for the diagnosis of nonalcoholic fatty liver disease
11233685|NCT03151798|Experimental|Phase II: Lifestyle treatment|Subjects will undergo lifestyle modification to cause weight loss and improved fitness
11233686|NCT03151798|Placebo Comparator|Phase II: Control treatment|Subjects will be given dietary advice and a stretching program.
11233687|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
11233688|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
11233689|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
11233690|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
11233691|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
11233692|NCT03151759||No radiotherapy|Surgery only
11233693|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
11233694|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
11233695|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
11233696|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
11233697|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
11233698|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
11233699|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
11233700|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
11233701|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
11233702|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
11233703|NCT03151707|Experimental|Nicotinamide riboside 1000 mg/day|
11233704|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
11233705|NCT03151681|Experimental|Propranolol pill + memory reactivation|
11233706|NCT03151681|No Intervention|Waitlist|
11233707|NCT03151668|Experimental|Dexmedetomidin|
11233708|NCT03151668|No Intervention|Midazolam|
11233709|NCT03151655|Experimental|MATTeRS Video|
11233710|NCT03151655|Active Comparator|Didactic Video|
11233711|NCT03151629||Castrate Resistant Prostate Cancer|
11233712|NCT03151629||Hormone Sensitive Prostate Cancer|
11233713|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
11233714|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
11233715|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
11233716|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)
~and
~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
11233717|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),
~and
~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days
~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
11233718|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
11233719|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
11233720|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
11233721|NCT03151551|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.
~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.
~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps."
11233722|NCT03151551|Active Comparator|Adalimumab|"80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.
~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps."
11233723|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
11233724|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
11233725|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
11233726|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
11233727|NCT03151499|Experimental|All Subjects|Reference Treatment (BI 409306) given alone followed by Test Treatment (BI 409306 + Rifampicin)
11233728|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
11233729|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
11233730|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
11233731|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
11233732|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
11233733|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
11233734|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
11233735|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
11233736|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
11233737|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
11233738|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
11233739|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
11233740|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
11233741|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
11233744|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
11233745|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
11233746|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
11233747|NCT03151395|Other|Total Group|A cohort of approximately 200 moderate to very severe COPD patients with at least 1 documented moderate or severe AECOPD in the year before enrolment and for whom sputum and blood samples will be collected during specified visits.
11233748|NCT03151382|Experimental|Experimental group|
11233749|NCT03151382|Other|Control group|
11233750|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
11233751|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
11233752|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
11233753|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
11233754|NCT03151330|Other|Screened arm|This will be an arm of women who are prospectively screened and receive a risk score for preterm birth. They will be recommended treatment strategies and their outcomes compared to an historical control.
11233755|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
11233756|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
11233757|NCT03151304|Experimental|Stage 1a and 1b open-label pracinostat plus azacitidine|"open-label single arm pracinostat plus azacitidine. Pracinostat: 45 mg administered orally 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.
~In later cycles (i.e., after Cycle 4), pracinostat dose reduction to 45 mg orally 3 days each week × 2 weeks (instead of 3 weeks) or dose interruption is allowed to manage toxicity such as fatigue, gastrointestinal toxicity, or myelosuppression.
~Azacitine: 75 mg/m2 for 7 days of each 28-day cycle. Administration will occur by subcutaneous (SC) injection, or IV infusion if SC injections are not tolerated, on one of two schedules:
~Schedule 1 - daily therapy on Days 1 through 7
~Schedule 2 - 5-2-2 schedule in which subjects receive azacitidine for 5 consecutive days (Days 1 through 5) with rest on Days 6 and 7, and resume azacitidine dosing the first two days of the next week (Days 8 and 9) of each 28-day cycle"
11233758|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
11233759|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
11233760|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
11233761|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
11233762|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
11233763|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
11233764|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
11233765|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
11233766|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of Ensite NavX without fluoroscopy.
11233767|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of X-ray plus any tree dimensional mapping system.
11233768|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.
~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
11233769|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.
~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
11233770|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
11233771|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
11233772|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
11233773|NCT03151239|Placebo Comparator|Placebo|
11233774|NCT03151239|Experimental|NMN supplementation|
11233775|NCT03151226|Other|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
11233776|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
11233777|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
11233778|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
11233779|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
11233780|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
11233781|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
11233782|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
11233783|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
11233784|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
11233785|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;
~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
11233786|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
11233787|NCT03151148|Experimental|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
11233788|NCT03151148|Placebo Comparator|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
11233789|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
11233790|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
11233791|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
11233792|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
11233793|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
11233794|NCT03151083|Experimental|Experimental Implementation strategy|The experimental implementation strategy consists of (1) a clinical intermediary for patient support, (2) provider/staff facilitation and education to empower adoption, (3) patient education to facilitate engagement and completion, and (4) a process of stepped-care to identify and refer individuals requiring a higher level of care.
11233795|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:
~San Rafael Petzal
~San Sebastian Huehuetenango
~San Gaspar Ixchil
~Santa Bárbara
~Colotenango
~Aguacatán"
11233796|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:
~Tamahú
~San Miguel Tucurú
~Panzós
~Senahú
~Telemán"
11233797|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:
~San Idelfonso Ixtahuacán
~La Democracia
~San Juan Atitán
~Tectitán
~Santiago Chimaltenango"
11233798|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:
~Lanquín
~Santa María Cahabón
~Chisec
~Chahal
~Raxruhá
~Campur"
11233799|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:
~Nenton
~Jacaltenango
~Todos Santos Cuchumatán
~Santa Eulalia
~San Mateo Ixtatán
~San Juan Ixcoy"
11233800|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:
~Santa Cruz Verapaz
~Tactic
~San Pedro Carchá
~San Juan Chamelco"
11233801|NCT03151057|Experimental|Idelalisib 100mg|"Idelalisib is an orally-administered, selective inhibitor of Phosphoinositide 3 kinase (PI3K)-delta which has been shown to be extremely effective in inducing partial to complete responses in many B-cell derived malignancies.
~intervention: 100mg Idelalisib twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant"
11233802|NCT03151057|Placebo Comparator|Placebo oral tablet|Placebo to be taken twice daily beginning +90(+/- 10) days after allo HSCT and continued through Day 270 post transplant
11233803|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:
~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;
~Plus/not plus:
~Rituximab 375mg/m2, i.v., Day 0"
11233804|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:
~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;
~Plus/not plus:
~Rituximab 375mg/m2, i.v., Day 0"
11233805|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
11233806|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
11233807|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
11234213|NCT03148327|Active Comparator|Regimen B: Phase II|Radiotherapy alone
11233808|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
11233809|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
11233810|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
11233811|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
11233812|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
11233813|NCT03150966|Experimental|Patients who received nanocurcumin|Patients who received nanocurcumin
11233814|NCT03150966|Placebo Comparator|Patients who received placebo|Patients who received placebo
11233815|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
11233816|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
11233817|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
11233818|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.
~ECG: 12 lead electrocardiogram that visualizes cardiac activity
~history and physical: background information about athlete's and their family history
~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
11233819|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
11233820|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
11233821|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
11233822|NCT03150914|Active Comparator|Treatment|Over-encapsulated 1 mg sirolimus tablet
11233823|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:
~Expression of insulin-like growth factor 1 receptor (IGF-1R)
~Adiponectin
~Leptin
~Resistin
~Osteocalcin
~Osteoprotegerin
~Insulin, c-peptid
~HOMA-IR"
11233824|NCT03150888||Hospital based hypertension cohort|
11233825|NCT03150888||Community based hypertension cohort|
11233826|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
11233827|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
11233828|NCT03150862|Experimental|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
11233829|NCT03150862|Experimental|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
11233830|NCT03150862|Experimental|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
11233831|NCT03150862|Experimental|Arm B (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
11233832|NCT03150862|Experimental|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
11233833|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
11233834|NCT03150849||patient group|patient with chronic lymphocytic leukemia
11233835|NCT03150849||control group|healthy control group
11233990|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
11233836|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
11233837|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
11233838|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
11233839|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
11233840|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
11233841|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
11233842|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
11233843|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
11233844|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
11233845|NCT03150810|Experimental|Arm A (Dose Escalation) TMZ Pulse Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
11233846|NCT03150810|Experimental|Arm B (Dose Escalation) TMZ Continuous Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
11233847|NCT03150810|Experimental|Dose Expansion, 6 cohorts|Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
11233848|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
11233849|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
11233850|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
11233851|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main
~EPIC club: 60min session / 2 times weekly / 7 weeks"
11233852|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator
~EPIC club: 60min session / 2 times weekly / 7 weeks"
11233853|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
11233854|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
11233855|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
11233856|NCT03150745|Other|Colposcopic group|
11233857|NCT03150745|Other|office hysteroscopic group|
11233858|NCT03150732|Active Comparator|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
11233859|NCT03150732|Active Comparator|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
11233860|NCT03150719|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
11233861|NCT03150719|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
11234028|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
11234029|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
11233862|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.
~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
11233863|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
11233864|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
11233865|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
11233866|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
11233867|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
11233868|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
11233869|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
11233870|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
11233871|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
11233872|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
11233873|NCT03150628|Experimental|Study population|
11233874|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
11233875|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
11233876|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
11233877|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
11233878|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
11233879|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
11233880|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
11233881|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
11233882|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
11233883|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
11233884|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
11233885|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
11233886|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
11233887|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
11233888|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
11233889|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
11233890|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
11233891|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
11233892|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
11233893|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
11233894|NCT03150511|Experimental|Tesamorelin treatment|
11233895|NCT03150511|Placebo Comparator|Placebo|
11233896|NCT03150498|Experimental|BTD-001 (fed)|
11233897|NCT03150498|Experimental|BTD-001 (fasted)|
11233898|NCT03150485|Experimental|etafilcon A Toric Multifocal|
11233899|NCT03150485|Active Comparator|etafilcon A Multifocal|
11233900|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.
~This type of Graft Matrix will be administered as the intervention."
11233901|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.
~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.
~This type of Graft Matrix will be administered as the intervention."
11233902|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
11233903|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
11233904|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
11233905|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
11233906|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
11233907|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
11233908|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
11233909|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
11233910|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
11233911|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
11233912|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
11233913|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
11233914|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
11233915|NCT03150368|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
11233916|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
11233917|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
11233918|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
11233919|NCT03150329|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO BID on days 1-5 and 8-12 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
11233920|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
11233921|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
11233922|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
11233923|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
11233924|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
11233925|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
11233926|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
11233927|NCT03150264|Experimental|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
11233928|NCT03150264|Active Comparator|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
11233929|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
11233930|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
11233931|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
11233932|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
11233933|NCT03150225|Experimental|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.
~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
11233934|NCT03150225|Active Comparator|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
11233935|NCT03150225|Experimental|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.
~In addition participants will receive starch capsules to be taken daily."
11233936|NCT03150225|No Intervention|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
11233937|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
11233938|NCT03150212|Placebo Comparator|Placebo|
11233939|NCT03150199|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
11233940|NCT03150199|Active Comparator|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
11233941|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
11233942|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
11233943|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
11233944|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
11233945|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
11233946|NCT03150160|Experimental|Simbrinza + Travatan|Brinzolamide 1%/brimonidine 0.2% fixed combination + travoprost 0.004% ophthalmic solution
11233947|NCT03150160|Placebo Comparator|Placebo + Travatan|Placebo + travoprost 0.004% ophthalmic solution
11233948|NCT03150147|Experimental|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
11233949|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
11233950|NCT03150134|Experimental|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
11233951|NCT03150134|Placebo Comparator|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
11233952|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
11233953|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
11233954|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
11233955|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
11233956|NCT03150108|Experimental|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
11233957|NCT03150095|Experimental|Health coaching|Patients will work with a health coach to improve self-management skills
11233958|NCT03150095|No Intervention|Control|Patients will receive usual pre-transplant education to improve self-management skills
11233959|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
11233960|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
11233961|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
11233962|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
11233963|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
11233964|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
11233965|NCT03150056|Experimental|GSK525762 + abiraterone (Arm A)|Eligible subjects will receive treatment with GSK525762 in combination with abiraterone. Subjects will be abiraterone-refractory or resistant from L2 and Lx lines of therapy. Two dose combinations, 60 mg or 80 mg of GSK525762 will be administered once daily. There is also a possibility of dose reduction to 40 mg in case of toxicity. Dosing will continue until unacceptable toxicity, progression of disease, withdrawal of consent, death, or completion of study. Subjects may also receive prednisone in combination with abiraterone dosing.
11233966|NCT03150056|Experimental|GSK525762 + Enzalutamide (Arm B)|Eligible subjects will receive treatment with GSK525762 in combination with enzalutamide. Subjects will be enzalutamide -refractory or resistant from L2 and Lx lines of therapy. Two to three dose combinations 80 mg, 100 mg and 120 mg of GSK525762 will be administered once daily based on the emerging data from the dose escalation part. There is also a possibility of dose reduction to 60 mg in case of toxicity. Dosing will continue until unacceptable toxicity, progression of disease, withdrawal of consent, death, or completion of study.
11233967|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
11233968|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
11233969|NCT03150030||Healthy controls|Healthy control subjects
11233970|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
11233971|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
11233972|NCT03150004|Experimental|CLAG-M regimen|Patients' treatment cycle is 30 days.
11233973|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
11233974|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
11233975|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
11233976|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
11233977|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
11233978|NCT03149926||Patients with Borderline Personality Disorder|
11233979|NCT03149926||Healthy controls|
11233980|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
11233981|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
11233982|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.
~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
11233983|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
11233984|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
11233985|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
11233986|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
11233987|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
11233988|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
11233989|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
11234214|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
11233991|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.
~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
11233992|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.
~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
11233993|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
11233994|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
11233995|NCT03149822|Experimental|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
11233996|NCT03149809|Active Comparator|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
11233997|NCT03149809|Active Comparator|Drug Therapy|Daily solifenacin drug therapy
11233998|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.
~Laboratory blood tests will be collected and analyzed"
11233999|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
11234000|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
11234001|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
11234002|NCT03149770|Experimental|1|Naloxone, intranasal 4mg
11234003|NCT03149770|Placebo Comparator|2|Placebo
11234004|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
11234005|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
11234006|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
11234007|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
11234008|NCT03149692|Experimental|Penile allograft|
11234009|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
11234010|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
11234011|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
11234012|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
11234013|NCT03149653|No Intervention|Comparator3|Healthy Control
11234014|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
11234015|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
11234016|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
11234017|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
11234018|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
11234019|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
11234020|NCT03149601||Obese|Participants with BMI > or = 95th percentile
11234021|NCT03149588|Experimental|propofol|
11234022|NCT03149588|Experimental|sevoflurane|
11234023|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
11234024|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
11234025|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
11234026|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
11234027|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
11234030|NCT03149549|Experimental|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
11234031|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
11234032|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
11234033|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
11234034|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
11234035|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
11234036|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
11234037|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
11234038|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
11234039|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
11234040|NCT03149510|Experimental|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
11234041|NCT03149510|No Intervention|Control Group|Participants will receive standard of care.
11234042|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
11234043|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
11234044|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
11234045|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
11234046|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
11234047|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
11234048|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
11234049|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
11234050|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
11234051|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
11234052|NCT03149432|Active Comparator|Reference analgesic|Gabapentin Rehabilitation Local care
11234053|NCT03149432|Experimental|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
11234054|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
11234055|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
11234056|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
11234057|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
11234058|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
11234059|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
11234060|NCT03149380|Experimental|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
11234061|NCT03149380|Sham Comparator|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
11234062|NCT03149367|Experimental|Fixed suture|
11234063|NCT03149367|Experimental|Adjustable suture|
11234064|NCT03149354|Other|Patients with HIV|Patients with HIV
11234065|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
11234066|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
11234067|NCT03149328|Experimental|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
11234068|NCT03149328|No Intervention|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
11234069|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
11234070|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
11234071|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
11234072|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
11234073|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
11234074|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
11234075|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
11234076|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
11234107|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
11234108|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
11234077|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.
~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
11234078|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
11234079|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa
~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
11234080|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
11234081|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group
~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
11234082|NCT03149237|No Intervention|Standard of Care|The 12 clinics randomized to the control arm will continue to provide standard of care (SOC) EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.
11234083|NCT03149237|Experimental|Couples-based Services|The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical EMTCT services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period at the EID clinic; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT.
11234084|NCT03149211|Active Comparator|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
11234085|NCT03149211|Experimental|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
11234086|NCT03149198|Experimental|Interventional group|Mat pilates exercises
11234087|NCT03149198|Active Comparator|Control group|Aquatic aerobic exercises
11234088|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
11234089|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
11234090|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
11234091|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
11234092|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
11234093|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
11234094|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
11234095|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
11234096|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
11234097|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
11234098|NCT03149120|Experimental|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
11234099|NCT03149120|Experimental|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
11234100|NCT03149107|Experimental|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).
~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
11234101|NCT03149107|Experimental|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
11234102|NCT03149107|Experimental|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).
~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
11234103|NCT03149107|Active Comparator|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
11234104|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
11234105|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
11234106|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
11234109|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
11234110|NCT03149042||CCTA|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
11234111|NCT03149029|Experimental|BRAFV600 mutant|"Pembrolizumab administered intravenously every three weeks
~Dabrafenib taken every twelve hours orally
~Trametinib taken every twelve hours orally"
11234112|NCT03149029|Experimental|BRAFV600 wild type|"Pembrolizumab administered intravenously every three weeks
~Trametinib taken every twelve hours orally"
11234113|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
11234114|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
11234115|NCT03149003|Experimental|Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab|
11234116|NCT03149003|Active Comparator|Arm 2: Bevacizumab|
11234117|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
11234118|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
11234119|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
11234120|NCT03148964||Follow-up Arm|Blood sampling only
11234121|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
11234122|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
11234123|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
11234124|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
11234125|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
11234126|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
11234127|NCT03148925|Experimental|SELA-070|
11234128|NCT03148925|Placebo Comparator|Saline|
11234129|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
11234130|NCT03148899|Experimental|Visit 1 Randomization|At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
11234131|NCT03148899|Experimental|Visit 2: Crossover Randomization|At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
11234132|NCT03148886|Experimental|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
11234133|NCT03148860|Active Comparator|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
11234134|NCT03148860|Placebo Comparator|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
11234135|NCT03148860|Active Comparator|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
11234136|NCT03148860|Placebo Comparator|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
11234137|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
11234138|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
11234139|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
11234140|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
11234175|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
11234215|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
11234141|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
11234142|NCT03148808|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
11234143|NCT03148795|Experimental|Talazoparib|Talazoparib 1 mg daily
11234144|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
11234145|NCT03148756|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
11234146|NCT03148756|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
11234147|NCT03148730|No Intervention|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
11234148|NCT03148730|Experimental|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
11234149|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
11234150|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
11234151|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
11234152|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
11234153|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
11234154|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
11234155|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
11234156|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
11234157|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
11234158|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
11234159|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
11234160|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
11234161|NCT03148652|Experimental|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
11234162|NCT03148652|Placebo Comparator|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
11234163|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
11234164|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
11234165|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
11234166|NCT03148626|Placebo Comparator|Control|Usual education.
11234167|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
11234168|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
11234169|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
11234170|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
11234171|NCT03148574|Experimental|misoprostol|intrauterine 400 microgram
11234172|NCT03148574|Active Comparator|oxytocin|intravenous infusion 10 units
11234173|NCT03148561|Other|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
11234174|NCT03148561|No Intervention|Expectant group|Women did not receive any medication.
11234176|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
11234177|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
11234178|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
11234179|NCT03148522|Experimental|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
11234180|NCT03148522|Experimental|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
11234181|NCT03148522|Experimental|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
11234182|NCT03148509|Experimental|bupropion|receive bupropion
11234183|NCT03148509|Experimental|risperidone|receive risperidone
11234184|NCT03148509|Experimental|aripiprazole|receive aripiprazole
11234185|NCT03148496|Experimental|Biologic Mesh and Small Bytes|Biologic mesh placement and small bytes used for suturing.
11234186|NCT03148496|Experimental|Small Bytes and No Biologic Mesh|Small bytes used for suturing with no placement of biologic mesh
11234187|NCT03148496|Experimental|Biologic mesh and Large Bytes|Biologic mesh placement and large bytes used for suturing
11234188|NCT03148496|Active Comparator|Large Bytes and no biologic mesh|Large bytes used for suturing and no placement of biologic mesh.
11234189|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
11234190|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
11234191|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
11234192|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
11234193|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
11234194|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
11234195|NCT03148457|Experimental|Early treatment|Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).
11234196|NCT03148457|Other|Late treatment|Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).
11234197|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
11234198|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
11234199|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
11234200|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
11234201|NCT03148418|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
11234202|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
11234203|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
11234204|NCT03148379|Experimental|Customized patient instruments|Experimental group: Patients randomized into this group will undergo surgery utilizing single-use Efficiency Instruments with patient-specific technique (MyKnee® patient-matched cutting blocks)
11234205|NCT03148379|Active Comparator|Traditional metal instruments|Control Group: Patients will undergo conventional surgical technique
11234206|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy
~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
11234207|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
11234208|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon
~Device for guidance: high-resolution ultrasound
~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)
~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon
~Device for guidance: high-resolution ultrasound
~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
11234209|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only
~Device for guidance: high-resolution ultrasound
~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)
~Intervention procedure: lidocaine injection into the subacromial bursa only
~Device for guidance: high-resolution ultrasound
~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
11234210|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
11234211|NCT03148327|Experimental|Regimen A: Phase I|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
11234212|NCT03148327|Experimental|Regimen A: Phase II|The intervention will be looking at radiotherapy + drug Durvalumab (MEDI 4736)
11234216|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
11234217|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
11234218|NCT03148288|Placebo Comparator|placebo|
11234219|NCT03148275|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 52 cycles in the absence of disease progression or unacceptable toxicity.
11234220|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
11234221|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
11234222|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
11234223|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
11234224|NCT03148236|Active Comparator|Vitamin C|
11234225|NCT03148236|Placebo Comparator|Placebo|
11234226|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
11234227|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
11234228|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
11234229|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
11234230|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
11234231|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
11234232|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
11234233|NCT03148171|Active Comparator|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
11234234|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
11234235|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
11234236|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
11234237|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
11234238|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
11234239|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
11234240|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
11234241|NCT03148080||Observational|Participants complete a Current Medical Conditions Form, the CogState web-based cognitive assessment, and a Self-Report Questionnaire administration over 45-60 minutes containing measures of work ability and other work-related measures, cognitive, physical, and psychosocial symptoms, and characteristics of workplace environment. Self-report measures of individual and family characteristics, resources, and demands are also included.
11234242|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
11234243|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
11234244|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
11234245|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
11234246|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
11234247|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
11234248|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
11234249|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
11234250|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
11234251|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
11234252|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
11234253|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
11234254|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
11234255|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
11234256|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
11234257|NCT03147950|Active Comparator|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
11234258|NCT03147950|Active Comparator|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
11234259|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
11234260|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
11234261|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
11234262|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
11234263|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
11234264|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
11234265|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
11234266|NCT03147885|Experimental|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11234267|NCT03147872|No Intervention|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
11234268|NCT03147872|Experimental|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
11234269|NCT03147859|Experimental|Vedolizumab infusions and ATI (Group A)|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of vedolizumab will be administered in 3 groups of 4 participants at 75, 150 and 300 mg doses. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
11234270|NCT03147859|Experimental|Vedolizumab infusions and ATI (Group B)|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of vedolizumab will be administered in 3 groups of 4 participants at 150, 300 and 600 mg doses. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
11234271|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.
~Keep the room temperature at 23-25˚C and wrap the baby if possible"
11234272|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
11234273|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
11234274|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
11234275|NCT03147807|Experimental|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
11234276|NCT03147807|No Intervention|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
11234277|NCT03147794|Experimental|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
11234278|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
11234279|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
11234280|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
11234281|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
11234282|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
11234283|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
11234284|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
11234285|NCT03147716|Active Comparator|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
11234314|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
11234504|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
11234286|NCT03147716|Experimental|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
11234287|NCT03147716|Experimental|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
11234288|NCT03147716|Experimental|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
11234289|NCT03147716|Experimental|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
11234290|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
11234291|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
11234292|NCT03147690|Experimental|Single|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
11234293|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
11234294|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
11234295|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
11234296|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.
~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
11234297|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
11234298|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
11234299|NCT03147638|Experimental|1 month|patient treated with Anti coagulation for one month
11234300|NCT03147638|Active Comparator|3 months|standard of care , treatment for 3 months
11234301|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
11234302|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
11234303|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
11234304|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
11234305|NCT03147599|Placebo Comparator|Placebo|Placebo
11234306|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
11234307|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
11234308|NCT03147573|Experimental|Blood pressure monitoring|
11234309|NCT03147560|Experimental|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
11234310|NCT03147560|Experimental|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
11234311|NCT03147560|Experimental|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
11234312|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
11234313|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
11234548|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
11234315|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
11234316|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
11234317|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
11234318|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
11234319|NCT03147508||Neck pain patients|
11234320|NCT03147495||the study group|The participants with medial compartment knee osteoarthritis and without lateral compartment knee osteoarthritis according to the Ahlbäck classification.
11234321|NCT03147495||the control group|The healthy volunteers without knee osteoarthritis according to the American College of Rheumatology criteria for the classification and reporting of OA of the knee joint. Radiographic evidence of the knee with Ahlbäck classification grade 0.
11234322|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
11234323|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
11234324|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
11234325|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
11234326|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
11234327|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
11234328|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
11234329|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.
~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
11234330|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
11234331|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
11234332|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
11234333|NCT03147404|Experimental|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
11234334|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
11234335|NCT03147378|Experimental|arm A Fasting-Fed condition|ModraDoc006/r will be administered in fasting condition week 1 and in fed condition week 2
11234336|NCT03147378|Experimental|arm B Fed-Fasting condition|ModraDoc006/r will be administered in fed condition week 1 and in fasting condition week 2
11234337|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
11234338|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
11234339|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
11234340|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
11234341|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
11234342|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
11234343|NCT03147339|No Intervention|control|Low calorie diet
11234344|NCT03147326|Other|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:
~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
11234345|NCT03147313|Sham Comparator|Sham|
11234346|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
11234347|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
11234348|NCT03147300|Active Comparator|Östergötland region - Control group|
11234349|NCT03147300|Experimental|Östergötland region - Intervention group|
11234350|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
11234351|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye
~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
11234352|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye
~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
~Avelumab will be administered intravebously once every 2 weeks"
11234353|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
11234354|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
11234355|NCT03147261|Experimental|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
11234356|NCT03147261|No Intervention|No intervention|Healthy diet recommendations following the usual pediatric advice
11234357|NCT03147248|Active Comparator|Cohort 1: CT-P13 IV 3 mg/kg|CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
11234358|NCT03147248|Experimental|Cohort 2: CT-P13 SC 90 mg|CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
11234359|NCT03147248|Experimental|Cohort 3: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
11234360|NCT03147248|Experimental|Cohort 4: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
11234361|NCT03147248|Experimental|Arm 1: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
11234362|NCT03147248|Active Comparator|Arm 2: CT-P13 IV 3 mg/kg|CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
11234363|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
11234364|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
11234365|NCT03147222|Experimental|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
11234366|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
11234367|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11234368|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11234369|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11234370|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11234371|NCT03147183||candidates for renal transplant|
11234372|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
11234373|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
11234374|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
11234375|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
11234376|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
11234377|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
11234378|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).
~Device: Fitmore Short Stem"
11234379|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).
~Device: CLS Straight Stem"
11234380|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
11234381|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
11234382|NCT03147092|Experimental|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
11234383|NCT03147079|Experimental|Intervention|Lifestyle intervention
11234384|NCT03147079|Experimental|Internal controls|
11234385|NCT03147079|Experimental|External controls|
11234386|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
11234387|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
11234388|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
11234389|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
11234549|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
11234390|NCT03147040|Experimental|Carboplatin/Atezolizumab|Carboplatin AUC=1.5, weekly schedule, maximum 12 administrations Atezolizumab, 1200 mg flat dose, 3-weekly schedule, starting after two administrations of carboplatin
11234391|NCT03147027||VT ablation group|
11234392|NCT03147027||medication group|
11234393|NCT03147014|Other|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
11234394|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
11234395|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
11234396|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
11234397|NCT03146988|Active Comparator|Neulasta®|
11234398|NCT03146975|No Intervention|Healthy|
11234399|NCT03146975|Experimental|Periodontitis without diabetes|
11234400|NCT03146975|Experimental|Periodontitis compensated diabetes|
11234401|NCT03146975|Experimental|Periodontitis decompensated diabetes|
11234402|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
11234403|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
11234404|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-2 weeks prior to and following Y90 radioembolization of hepatic metastases
11234405|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
11234406|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
11234407|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
11234408|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
11234409|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
11234410|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
11234411|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
11234412|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
11234413|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11234414|NCT03146858|Experimental|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
11234415|NCT03146845|Experimental|Allevyn Life Non-Bordered|Foam Dressing
11234416|NCT03146845|Other|Standard care|Standard care dressing
11234417|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
11234418|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
11234419|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
11234420|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
11234421|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
11234422|NCT03146806|Experimental|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
11234423|NCT03146780|Placebo Comparator|Conventional|
11234424|NCT03146780|Active Comparator|Digital 1|
11234425|NCT03146780|Active Comparator|Digital 2|
11234426|NCT03146780|Active Comparator|Digital 3|
11234427|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
11234428|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
11234429|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
11234430|NCT03146754|Active Comparator|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
11234431|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
11234432|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
11234433|NCT03146728||able-bodied|age height and weight matched able bodied
11234434|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
11234435|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
11234436|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:
~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).
~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
11234437|NCT03146663|Experimental|NUC-1031 500 mg/m2|NUC-1031 500 mg/m2 on days 1, 8, and 15
11234438|NCT03146663|Experimental|NUC-1031 750 mg/m2|NUC-1031 750 mg/m2 on Days 1, 8, and 15
11234439|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
11234440|NCT03146637|Experimental|Activated CIK and bispecific antibody|activated CIK and Bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
11234441|NCT03146637|Active Comparator|Activated CIK|activated CIK
11234442|NCT03146624|Experimental|attachment|attachment retained obturator
11234443|NCT03146624|Active Comparator|clasp|clasp retained obturator
11234444|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
11234445|NCT03146611||control|healthy sex and age matched group
11234446|NCT03146585||Patients on artificial ventilation|
11234447|NCT03146585||Patients on renal replacement therapy|
11234448|NCT03146585||Patients with targeted temperature management|
11234449|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
11234450|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
11234451|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.
~5 days per week, for 3 weeks, 15 minutes per day."
11234452|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.
~5 days per week, for 3 weeks, 15 minutes per day."
11234453|NCT03146546||Septic Shock|Patients with septic shock as defined by the Sepsis-3 criteria(9)
11234454|NCT03146546||Septic Shock with AKI|Patients with septic shock as defined by the Sepsis-3 criteria(9) with concomitant AKI
11234455|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
11234456|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
11234457|NCT03146520||Polyps|subjects with adenoma or polyps
11234458|NCT03146520||Other cancers|subjects with other cancers
11234459|NCT03146520||Healthy|subjects with no evidence of CRC
11234460|NCT03146494||STAAD|
11234461|NCT03146494||Normal|
11234462|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
11234463|NCT03146481|Placebo Comparator|placebo|Placebo
11234464|NCT03146468|Experimental|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
11234465|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
11234466|NCT03146442|Active Comparator|Normal Protein (NP) Breakfast|The participants in the NP Breakfast group will be provided with NP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The NP breakfasts will be 11% protein (10g protein), 63% CHO, and 26% fat. The types of protein incorporated within the NP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
11234502|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
11234503|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
11234467|NCT03146442|Experimental|High Protein (HP) Breakfast|The participants in the HP Breakfast group will be provided with HP Breakfasts to consume, at home, between 6:00-9:00 am each day over the 6-month intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The energy content of the breakfast meals is ~18% of daily energy intake estimated from the energy expenditure equations specific for adolescents ages 13-19y. The HP breakfasts will be 34% protein (30g protein), 40% CHO, and 26% fat. The types of protein incorporated within the HP and HP meals will include a combination of animal (egg, dairy, animal tissue) and plant-based proteins (soy, pea, gluten). An 8-d breakfast rotation will occur throughout the 6 months.
11234468|NCT03146442|Placebo Comparator|Breakfast Skipping (BS)|The participants in the BS group will continue to skip breakfast each day over the 6-month intervention. They will have nothing to eat or drink (besides water) until 11 am.
11234469|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
11234470|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
11234471|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
11234472|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
11234473|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
11234474|NCT03146403|Experimental|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
11234475|NCT03146403|Placebo Comparator|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
11234476|NCT03146390|Active Comparator|Essential oils (Listerine Mentol)|"a single mouthwash with 20 ml of essential oils for 30 seconds
~20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
11234477|NCT03146390|Placebo Comparator|Water|"a single mouthwash with 20 ml of sterile water for 30 seconds
~20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
11234478|NCT03146390|Experimental|Alcohol free essential oils|"a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds
~20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
11234479|NCT03146377|Experimental|Xeloxiri|
11234480|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
11234481|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
11234482|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
11234483|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
11234484|NCT03146338|Experimental|Magnesium-rich mineral water (Rozana)|Patients in this arm must take 1.5 Liter by day of a mineral water rich in magnesium (Rozana) during the treatment by anti-EGFR. The mineral water is provided.
11234485|NCT03146338|No Intervention|Standard|Patients will have the usual care (oral advice only according to the habits of the investigator)
11234486|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
11234487|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
11234488|NCT03146312|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
11234489|NCT03146312|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
11234490|NCT03146299|Active Comparator|Group A: TLH|
11234491|NCT03146299|Active Comparator|Group B: LAVH|
11234492|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
11234493|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
11234494|NCT03146286|Experimental|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
11234495|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
11234496|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
11234497|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
11234498|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
11234499|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
11234500|NCT03146234|Experimental|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.
~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
11234501|NCT03146221|Other|Person to be surgically treated for arteritis|
11234505|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
11234506|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
11234507|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
11234508|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
11234509|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
11234510|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
11234511|NCT03146156|Experimental|Lifestyle Intervention|Lifestyle coaches will provide personalized instruction on physical activity, dietary data, and behavioral strategies.
11234512|NCT03146156|No Intervention|Usual Care|The usual care/control groups will be followed by their primary Obstetrical provider. All overweight/obese women will be offered nutrition counseling early in pregnancy by a registered dietician to support GWG within the IOM guidelines.
11234513|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
11234514|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
11234515|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
11234516|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
11234517|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
11234518|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
11234519|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
11234520|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
11234521|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
11234522|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
11234523|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
11234524|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
11234525|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
11234526|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
11234527|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
11234528|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
11234529|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
11234530|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
11234531|NCT03146000|Experimental|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
11234532|NCT03146000|Active Comparator|meloxicam|women will receive one 15 mg meloxicam rectal suppository
11234533|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
11234534|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
11234535|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
11234536|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
11234537|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
11234538|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
11234539|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
11234540|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
11234541|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
11234542|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
11234543|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
11234544|NCT03145922||Sarcoidosis|
11234545|NCT03145922||Healthy Controls|
11234546|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
11234547|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
11234551|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
11234552|NCT03145870|Other|Patient with multiple symptomatic myeloma|
11234553|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven [68]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
11234554|NCT03145844||Direct Acting Agents|No Intervention
11234555|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
11234556|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
11234557|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
11234558|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
11234559|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
11234560|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
11234561|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
11234562|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
11234563|NCT03145766|Experimental|Group 1|Participants who receive five vaccine injections of VRVg 2 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
11234564|NCT03145766|Experimental|Group 2|Participants who receive five vaccine injections of VRVg 2 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
11234565|NCT03145766|Experimental|Group 3|Participants who receive five vaccine injections of VRVg 2 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
11234566|NCT03145766|Experimental|Group 4 (VRVg 1)|Participants who receive five vaccine injections of VRVg 1 at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
11234567|NCT03145766|Experimental|Group 5 (Imovax Rabies, control)|Participants who receive five vaccine injections of Imovax Rabies (control) at D0, D3, D7, D14, and D28. All patients also received human rabies immunoglobulins (HRIG) at D0.
11234568|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
11234569|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
11234570|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
11234571|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
11234572|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
11234573|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
11234574|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
11234575|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .
~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.
~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
11234576|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .
~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.
~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.
~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
11234577|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
11234608|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
11234609|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
11234610|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
11234578|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
11234579|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
11234580|NCT03145675|Experimental|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
11234581|NCT03145675|Active Comparator|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
11234582|NCT03145675|Experimental|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
11234583|NCT03145675|Active Comparator|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
11234584|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
11234585|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
11234586|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
11234587|NCT03145649||Healthy|Healthy mother-infant dyads
11234588|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
11234589|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
11234590|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
11234591|NCT03145610|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
11234592|NCT03145610|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
11234593|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
11234594|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
11234595|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
11234596|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
11234597|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
11234598|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
11234599|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
11234600|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
11234601|NCT03145532|Experimental|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
11234602|NCT03145532|Sham Comparator|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
11234603|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
11234604|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
11234605|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
11234606|NCT03145493|Experimental|Usage of suction drains|Usage of suction drains
11234607|NCT03145493|No Intervention|No usage of suction drains|No usage of suction drains
11234611|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
11234612|NCT03145454|Experimental|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
11234613|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
11234614|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
11234615|NCT03145415|Experimental|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
11234616|NCT03145415|Active Comparator|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
11234617|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
11234618|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
11234619|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
11234620|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
11234621|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
11234622|NCT03145363|Experimental|Intervention|receive interactive text messages
11234623|NCT03145363|Active Comparator|Control|Receive informational text messages
11234624|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
11234625|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
11234626|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
11234627|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
11234628|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
11234629|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
11234630|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
11234631|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
11234632|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.
~Treatment with single agent Abiraterone Acetate (AA) until progression"
11234633|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.
~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
11234634|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.
~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
11234635|NCT03145259|Other|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]
11234636|NCT03145259|Other|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) [47 h study duration]
11234637|NCT03145259|Other|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]
11234638|NCT03145246||tooth loss|regeneration treated teeth loss
11234639|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
11234640|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
11234641|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
11234642|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
11234643|NCT03145220|Active Comparator|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
11234717|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
11234644|NCT03145220|Placebo Comparator|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
11234645|NCT03145207|Other|name brand patch|name brand lidocaine patch
11234646|NCT03145207|Other|generic patch|generic lidocaine patch
11234647|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
11234648|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
11234649|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
11234650|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
11234651|NCT03145207|Other|both patches|brand name and generic lidocaine patch
11234652|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
11234653|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
11234654|NCT03145181|Experimental|Part 1: Dose Escalation (IV)|Participants will receive Teclistamab intravenously (IV).
11234655|NCT03145181|Experimental|Part 2: Dose Expansion (IV)|Participants will receive Teclistamab IV.
11234656|NCT03145181|Experimental|Part 1: Dose Escalation (SC)|Participants will receive Teclistamab subcutaneously (SC).
11234657|NCT03145181|Experimental|Part 2: Dose Expansion (SC)|Participants will receive Teclistamab SC.
11234658|NCT03145168|Experimental|High Target Mean Arterial Pressure|
11234659|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
11234660|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
11234661|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
11234662|NCT03145142|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infant at a speed of 20cm over 2 seconds.
11234663|NCT03145142|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for at least 60 seconds.
11234664|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
11234665|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
11234666|NCT03145116|Experimental|509|
11234667|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
11234668|NCT03145077|Experimental|Cohort 1 (DCE-MRI)|Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
11234669|NCT03145077|Experimental|Cohort 2 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
11234670|NCT03145077|Experimental|Cohort 3 (DCE-MRI)|Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
11234671|NCT03145077|Experimental|Cohort 4 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
11234672|NCT03145064|Experimental|Zanubrutinib|Participants receive zanubrutinib twice daily (BID)
11234673|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
11234674|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
11234675|NCT03145038|Experimental|Treatment A|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fed, American breakfast
11234676|NCT03145038|Experimental|Treatment B|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fasted
11234677|NCT03145038|Experimental|Treatment C|Single oral dose of 25 x 0.1 mg vericiguat high-dose pediatric formulation, fed, American breakfast
11234678|NCT03145038|Active Comparator|Treatment D|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, American breakfast
11234679|NCT03145038|Experimental|Treatment E|Single oral dose of 10 mg vericiguat crushed IR tablet, adult formulation, fed, American breakfast
11234680|NCT03145038|Experimental|Treatment F|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, continental breakfast
11234681|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.
~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
11234682|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
11234683|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
11234684|NCT03144999|Experimental|High Dose|AAVCAGsCD59
11234685|NCT03144986|Experimental|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.
~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
11234686|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
11234687|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
~After surgery, study patients will receive trastuzumab IV x 14 cycles"
11234688|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
11234689|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7
~6 subjects per each cohort
~twice administration with 4-week intervals"
11234690|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)
~2 subjects per each cohort
~twice administration with 4-week intervals"
11234691|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
11234692|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention) about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
11234693|NCT03144895|Other|Arterial catheter|by anatomical placement alone
11234694|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
11234695|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
11234696|NCT03144882|Placebo Comparator|placebo|control group
11234697|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.
~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
11234698|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
11234699|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
11234700|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
11234701|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
11234702|NCT03144830|Experimental|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
11234703|NCT03144817|No Intervention|Control Group|
11234704|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
11234705|NCT03144804|Experimental|Lamivudine|"Lamivudine administered orally every 4 weeks
~Treatment cycles will last 28 consecutive days
~The dosage will be determine by the PI"
11234706|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
11234707|NCT03144778|Experimental|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
11234708|NCT03144778|Experimental|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
11234709|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
11234710|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
11234711|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
11234712|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
11234713|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
11234714|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
11234715|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
11234716|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
11234718|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
11234719|NCT03144700||Compensated Cirrhosis|
11234720|NCT03144687|Experimental|Cohort A|Itacitinib plus ruxolitinib
11234721|NCT03144687|Experimental|Cohort B|Itacitinib alone
11234722|NCT03144674|Experimental|Cohort 1- Closed to Further enrollment|Participants who have received prior ibrutinib.
11234723|NCT03144674|Experimental|Cohort 2|Participants who have not received a prior BTK inhibitor.
11234724|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
11234725|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
11234726|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
11234727|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
11234728|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
11234729|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
11234730|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
11234731|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
11234732|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
11234733|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
11234734|NCT03144596|Experimental|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
11234735|NCT03144596|Active Comparator|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
11234736|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
11234737|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
11234738|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
11234739|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
11234740|NCT03144531|Experimental|SKIP Intervention|
11234741|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
11234742|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
11234743|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
11234744|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).
~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
11234780|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
11234781|NCT03144180|No Intervention|Control|The Q-cup will not be used to collect umbilical cord blood.
11234782|NCT03144180|Active Comparator|Study Group|The Q-cup will be used to collect umbilical cord blood.
11234745|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.
~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
11234746|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
11234747|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
11234748|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
11234749|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
11234750|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
11234751|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
11234752|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
11234753|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
11234754|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
11234755|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
11234756|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
11234757|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
11234758|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
11234759|NCT03144388|Experimental|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
11234760|NCT03144388|Active Comparator|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
11234761|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
11234762|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
11234763|NCT03144362|Active Comparator|Bilateral Sliding Technique|
11234764|NCT03144362|Active Comparator|Unilateral Sliding Techniques|
11234765|NCT03144362|No Intervention|Standard care|
11234766|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.
~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
11234767|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
11234768|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
11234769|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
11234770|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
11234771|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
11234772|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
11234773|NCT03144245|Experimental|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
11234774|NCT03144245|Experimental|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
11234775|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
11234776|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
11234777|NCT03144206|Experimental|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
11234778|NCT03144206|No Intervention|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
11234779|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
11234784|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
11234785|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
11234786|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
11234787|NCT03144128|Placebo Comparator|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
11234788|NCT03144128|Experimental|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
11234789|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
11234790|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
11234791|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
11234792|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
11234793|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
11234794|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
11234795|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
11234796|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
11234797|NCT03144089|Active Comparator|Guedel oral airway placed first|This group is randomized to receive the Guedel oral airway first and the Articulated Oral Airway second
11234798|NCT03144089|Experimental|Articulated Oral Airway placed first|This group is randomized to receive the Articulated Oral Airway first and the Guedel oral airway second
11234799|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
11234800|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
11234801|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
11234802|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
11234803|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:
~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy
~Clinician's diagnosis based on his/her assessment
~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
11234804|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:
~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
11234805|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:
~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
11234806|NCT03144050||0|Control - no diabetes
11234807|NCT03144050||1|Diabetes
11234808|NCT03144050||2|Diabetes w/neuropathy
11234809|NCT03144050||3|Diabetes with vascular disease
11234810|NCT03144050||4|Diabetes w/healed ulcer
11234811|NCT03144050||5|Diabetes with current ulcer
11234812|NCT03144024|Experimental|band|
11234813|NCT03144024|Active Comparator|Rigid ring|
11234814|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
11234815|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
11234816|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
11234817|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
11234818|NCT03143985|Experimental|Vactosertib + Pomalidomide|"Vactosertib tablets, taken once daily for the first and second dose levels and twice a day for third and fourth dose level levels for 5 days followed by 2 days without treatment, repeated for 28-day cycles until evidence of progressive disease, intolerable toxicity, or participant discontinuation.
~For dose escalation - dosing initiated at 60 mg once daily by oral administration and will be increased to determine MTD. Provisional subsequent doses are 60, 120, once daily and 100 mg and 200 mg twice daily on days 1-5, 8-12, 15-19 and 22-26. Extension cohorts will enter at 200 mg twice daily (i.e. if MTD not defined) for 12 months until progression or intolerable toxicity.
~POM is administered orally (4 mg/day daily on Days 1 - 21 days). Treatment will occur in a suitable outpatient ambulatory care setting that is equipped for monitoring of patients with hematopoietic malignancies undergoing early clinical trial research."
11234819|NCT03143972|Experimental|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.
~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
11235380|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
11234820|NCT03143972|Experimental|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
11234821|NCT03143972|Experimental|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).
~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
11234822|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
11234823|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
11234824|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
11234825|NCT03143920|Experimental|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
11234826|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
11234827|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
11234828|NCT03143894|Active Comparator|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
11234829|NCT03143894|Sham Comparator|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
11234830|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
11234831|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
11234832|NCT03143868|Experimental|Aerobic Exercise|
11234833|NCT03143868|Experimental|Resistance Exercise|
11234834|NCT03143868|Placebo Comparator|No Exercise|
11234835|NCT03143855|Experimental|Lorcaserin|
11234836|NCT03143855|Placebo Comparator|Control Group|
11234837|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
11234838|NCT03143829|Experimental|Intervention group|electronic Symptom Self-Management Training- CINV (eSSET-CINV) is an educational intervention administered once at the start of treatment
11234839|NCT03143829|Active Comparator|Wait Control group|The Wait control group receives the electronic Symptom Self-Management Training- CINV (eSSET-CINV) at the last study visit. Outcomes will be compared to the Intervention group at the end of the study.
11234840|NCT03143816|Active Comparator|Technosphere insulin (TI, Afrezza) -Treatment arm|
11234841|NCT03143816|No Intervention|Insulin Aspart ( Novolog) -Control arm|
11234842|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
11234843|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
11234844|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
11234845|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
11234846|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
11234847|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
11234848|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
11234849|NCT03143751|No Intervention|Control|Standard cares alone.
11234850|NCT03143738|Experimental|continuous anesthesia of adductor canal|
11234851|NCT03143738|Experimental|continuous anesthesia of femoral nerve|
11234852|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
11234853|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
11234854|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
11234855|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
11234856|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
11234857|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
11234858|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
11234859|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
11234860|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
11234861|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
11234862|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
11234863|NCT03143660|Active Comparator|Coaching|A parent support component consisting of eight weekly telephone counseling calls by centrally located nutritionists to provide parents coaching tailored to their family's unique needs to help them set goals and make targeted lifestyle changes recommended by the American Academy of Pediatrics (AAP) for Stage 1, Prevention Plus, accompanied by a parent booklet
11234864|NCT03143660|Active Comparator|Materials|Parents will receive the same educational materials provided in the Fitline family workbook mailed over 8 weeks to control for weekly contact and educational curriculum, but no Fitline counseling.
11234865|NCT03143647||Control|"Female
~Over 18 years of age
~American Society of Anesthesiologists physical fitness scale 1
~Not pregnant"
11234866|NCT03143647||Case|"Female
~Pregnant with possible pre-eclampsia
~Over 18 years of age
~American Society of Anesthesiologists physical fitness scale 1"
11234867|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:
~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
11234868|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
11234869|NCT03143621|Experimental|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
11234870|NCT03143621|Placebo Comparator|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
11234871|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
11234872|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
11234873|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
11234874|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
11234875|NCT03143582|Experimental|Running group|13 week, bi-weekly running group
11234876|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
11234877|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
11234878|NCT03143556|Experimental|Magnetic Stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for magnetic stent group will receive magnetic stent and the removal of stent would be done by help of magnetic device.
11234879|NCT03143556|No Intervention|Routine stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for routine stent would receive routine stent and the removal of stent would be done by cystoscopy
11234880|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
11234881|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
11234882|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
11234883|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
11234884|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
11234885|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
11234886|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
11234887|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
11234888|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
11234889|NCT03143504|Other|Single arm.|All participants in the same arm.
11234890|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
11234891|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
11234892|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
11234893|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
11234894|NCT03143465|Experimental|CGRP|
11234895|NCT03143465|Experimental|Sildenafil|
11234896|NCT03143465|Placebo Comparator|Placebo|
11234897|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
11234898|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
11234899|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
11234900|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
11234901|NCT03143426|Experimental|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
11234902|NCT03143426|No Intervention|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
11234903|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
11234904|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
11234905|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
11234906|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
11234907|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
11234908|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
11234909|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
11234910|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
11234911|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
11234912|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
11234913|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
11234914|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
11234915|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
11234916|NCT03143322|Experimental|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
11234917|NCT03143322|No Intervention|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)
11234918|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
11234919|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
11234920|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
11234921|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
11234922|NCT03143270|Experimental|Cohort 1, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Two weeks after deb-TACE, participants will begin nivolumab every two weeks for up to one year. If no participants experience a dose limiting toxicity (DLT), or 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 2.
11234923|NCT03143270|Experimental|Cohort 2, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Participants will receive nivolumab every two weeks for up to one year, starting 4 weeks prior to deb-TACE (week -4). Participants in this cohort will not receive nivolumab on the day of deb-TACE. If no participants experience a DLT in the initial group of 3 participants or if 1 of 6 participants experiences a DLT, a new group of participants will be enrolled into Cohort 3.
11234924|NCT03143270|Experimental|Cohort 3, deb-TACE + Nivolumab|3 eligible participants will undergo deb-TACE on Day 0 (+/- 5 days). Nivolumab will be dosed every two weeks starting 4 weeks prior to deb-TACE (Week 4) and continue every 2 weeks for up to one year. If no participants experience a DLT in the initial group of 3 participants, an additional 3 participants will be added to confirm safety. If less than or equal to 1 of 6 participants experiences a DLT, this will be considered the optimal schedule.
11234925|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
11234926|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
11234927|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
11234928|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
11234929|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
11234930|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
11234931|NCT03143218|Active Comparator|SMC with SP+AQ|Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
11234932|NCT03143218|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
11234933|NCT03143218|Active Comparator|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
11234934|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
11234935|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
11234936|NCT03143192|Experimental|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
11234937|NCT03143192|Sham Comparator|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
11234938|NCT03143166|Experimental|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
11234939|NCT03143153|Experimental|Nivolumab + Ipilimumab|
11234940|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
11234941|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
11234942|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
11234943|NCT03143140|Other|tumor ablation|ablation of tumor directly
11234944|NCT03143114|Experimental|Myomectomy|Women will be subjected to laparotomy to remove the myomas
11234945|NCT03143114|No Intervention|Conservative management|Women will not be subjected to surgery (conservative management)
11234946|NCT03143101|Experimental|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
11234947|NCT03143101|Experimental|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
11234948|NCT03143101|Experimental|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
11234949|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
11234950|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
11234951|NCT03143075|Active Comparator|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
11234952|NCT03143075|Active Comparator|Non-inflammation group|Subjects with CRP<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
11234953|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
11234954|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
11234955|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
11234956|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
11234957|NCT03143036|Experimental|Daratumumab, thalidomide and dexamethasone|
11234958|NCT03143023|Experimental|arginine toothpaste|
11234959|NCT03143023|Active Comparator|fluoride toothpaste|
11234960|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
11234961|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
11234962|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
11234963|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
11234964|NCT03142997||group S|anesthetized children on spontaneous ventilation.
11234965|NCT03142997||group C|anesthetized children on controlled ventilation.
11234966|NCT03142984|Experimental|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash & Shampoo product and Baby Lotion.
~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
11234967|NCT03142984|Experimental|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.
~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Alternative Baby Wash & Shampoo (GTIN/UPC # 5011451106260)"
11234968|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
11234969|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
11234970|NCT03142958|Other|Integra® Cadence™ Total Ankle System|
11234971|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
11234972|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
11234973|NCT03142932|Active Comparator|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
11234974|NCT03142932|Experimental|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.
~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
11234975|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
11234976|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
11234977|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
11234978|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
11234979|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
11234980|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
11234981|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule
~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
11234982|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule
~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
11234983|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill
~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
11234984|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes
~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
11234985|NCT03142880|Active Comparator|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
11234986|NCT03142880|Experimental|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
11234987|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
11234988|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
11234989|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.
~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
11234990|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
11234991|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).
~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
11234992|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
11234993|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
11234994|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
11234995|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
11234996|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
11235381|NCT03140306|Experimental|Low dose CT abdomen and pelvis|Low dose computed tomography
11234997|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.
~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.
~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
11234998|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.
~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.
~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
11234999|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).
~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
11235000|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
11235001|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
11235002|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
11235003|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
11235004|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
11235005|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
11235006|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
11235007|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
11235008|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
11235009|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
11235010|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
11235011|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
11235012|NCT03142724|Experimental|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-968.
11235013|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
11235014|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
11235015|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
11235016|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
11235017|NCT03142672|Active Comparator|Control group|Tooth filling
11235018|NCT03142646|Experimental|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
11235019|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study
~Inclusion criteria:
~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
11235020|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
11235021|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
~+ vitamin D3 IU for 10 days"
11235022|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
~+ vitamin D3 IU for 28 days"
11235023|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
11235024|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
11235025|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
11235102|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
11235026|NCT03142568|Experimental|Sildenafil cohort 1|Within cohort 1 infants will be randomized using a 3:1 scheme to receive sildenafil or placebo. Infants randomized to sildenafil will receive 0.125 mg/kg daily every 8 hours intravenously (IV), or 0.25 mg/kg daily every 8 hours enterally for 28 days.
11235027|NCT03142568|Placebo Comparator|Placebo cohort 1|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
11235028|NCT03142568|Experimental|Sildenafil cohort 2|Cohort 2 infants will receive sildenafil 0.5 mg/kg daily every 8 hours intravenously (IV) or 1 mg/kg daily every 8 hours enterally for 28 days.
11235029|NCT03142568|Placebo Comparator|Placebo cohort 2|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
11235030|NCT03142568|Experimental|Sildenafil cohort 3|Cohort 3 infants will receive sildenafil 1 mg/kg daily every 8 hours intravenously (IV) or 2 mg/kg daily every 8 hours enterally for 28 days.
11235031|NCT03142568|Placebo Comparator|Placebo cohort 3|Infants randomized to the placebo treatment group will receive the equivalent of dextrose 5% (sugar water) to be administered IV or enteral use.
11235032|NCT03142555|Experimental|Health talk plus intensive social media intervention|"Subjects in this group will receive:
~General health talk;
~Phone follow-up/counselling service (15 - 30 minutes);
~Social media (intensive reminders);
~Regular personalized what's app interaction ( up to 2 months duration)"
11235033|NCT03142555|Placebo Comparator|Health talk plus less intensive social media intervention|"Subjects in this group will receive:
~General health talk;
~Phone follow-up/counselling service (15 - 30 mintues);
~Social media ( less intensive reminders)"
11235034|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
11235035|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
11235036|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
11235037|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
11235038|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:
~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
~FOLFIRI
~Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.
~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
11235039|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
11235040|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
11235041|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
11235042|NCT03142490|Experimental|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
11235043|NCT03142490|Active Comparator|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
11235044|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
11235045|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
11235046|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
11235047|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
11235048|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
11235049|NCT03142451|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
11235050|NCT03142451|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
11235051|NCT03142438|Experimental|F&P Seal Improvement Project|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
11235052|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
11235053|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
11235054|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
11235055|NCT03142386|Active Comparator|Control Group|Physiotherapy
11235056|NCT03142373|Experimental|CV4 group|CV4 technique
11235057|NCT03142373|Experimental|RR group|Rib Raising technique
11235058|NCT03142373|Placebo Comparator|Placebo group|Light touch
11235059|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
11235060|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
11235103|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
11235061|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
11235062|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
11235063|NCT03142334|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 17 cycles.
11235064|NCT03142334|Placebo Comparator|Placebo|Participants receive placebo (saline solution) via IV infusion on Day 1 of each 3-week cycle for up to 17 cycles.
11235065|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
11235066|NCT03142308||Surgeons|Young surgeons in all surgical specialities
11235067|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
11235068|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
11235069|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
11235070|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
11235071|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
11235072|NCT03142256|Active Comparator|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
11235073|NCT03142256|No Intervention|No incentive|Truvada 200Mg-300Mg Tablet
11235074|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
11235075|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
11235076|NCT03142217|Other|Patient with Huntington's Disease|
11235077|NCT03142191|Experimental|CC-90001 400 mg PO QD|55 subjects will be randomized to CC-90001 400mg
11235078|NCT03142191|Experimental|CC-90001 200 mg PO QD|55 subjects will be randomized to CC-90001 200mg
11235079|NCT03142191|Placebo Comparator|Placebo PO QD|55 subjects will be randomized to placebo
11235080|NCT03142178|Experimental|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
11235081|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
11235082|NCT03142178|Experimental|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
11235083|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
11235084|NCT03142178|Experimental|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
11235085|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
11235086|NCT03142165|Experimental|BMS-986263|
11235087|NCT03142165|Placebo Comparator|Placebo|
11235088|NCT03142152|Experimental|Intervention Group|Carillon Mitral Contour System and Guideline Directed Heart Failure Medication
11235089|NCT03142152|Active Comparator|Control Group|Guideline Directed Heart Failure Medication
11235090|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib
~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib
~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
11235091|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
11235092|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
11235093|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
11235094|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
11235095|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
11235096|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA
~ECG-gated CT"
11235097|NCT03142061|Experimental|ECT|
11235098|NCT03142048|Experimental|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
11235099|NCT03142048|No Intervention|Comparison Group|Participants in the study that do not receive the intervention
11235100|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
11235101|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
11235382|NCT03140306|Experimental|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
11235104|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
11235105|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
11235106|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
11235107|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
11235108|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).
~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
11235109|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
11235110|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
11235111|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
11235112|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
11235113|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
11235114|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.
~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
11235115|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.
~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
11235116|NCT03141931|Experimental|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
11235117|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
11235118|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
11235119|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
11235120|NCT03141905|Active Comparator|Sick-Day Protocol|
11235121|NCT03141905|Placebo Comparator|Usual Care|
11235122|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
11235123|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
11235124|NCT03141879|No Intervention|Regular care|(Wait-list control)
11235125|NCT03141866|Experimental|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
11235126|NCT03141866|Experimental|Exercise Intervention 2: Machine-based resistance training|Specialised, chair-based resistance training equipment for older adults.
11235127|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
11235128|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
11235129|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
11235130|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
11235131|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
11235132|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
11235133|NCT03141814||asthma|20 patients with ongoing ashma
11235134|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
11235135|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
11235136|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
11235163|NCT03141632|Active Comparator|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
11235164|NCT03141632|Placebo Comparator|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
11235165|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
11235383|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
11235137|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
11235138|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
11235139|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
11235140|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
11235141|NCT03141788|Other|3M Clear Aligner|Clear Aligner for Orthodontic Treatment
11235142|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
11235143|NCT03141736|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235144|NCT03141736|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235145|NCT03141736|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235146|NCT03141736|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235147|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235148|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235149|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235150|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
11235151|NCT03141710|Experimental|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
11235152|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
11235153|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
11235154|NCT03141684|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11235155|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months
~Bicalutamide by mouth once/day for 6 months
~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
11235156|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months
~Abiraterone acetate by mouth once/day for 6 months
~Prednisone by mouth once/day for 6 months
~Apalutamide by mouth once/day for 6 months
~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
11235157|NCT03141658|Experimental|TS-134 20 mg|
11235158|NCT03141658|Experimental|TS-134 60 mg|
11235159|NCT03141658|Experimental|Placebo|
11235160|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
11235161|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
11235162|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
11235166|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
11235167|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
11235168|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
11235169|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
11235170|NCT03141580|Experimental|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
11235171|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
11235172|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
11235173|NCT03141554|Active Comparator|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C
~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
~Treatment C = Normal saline gargle (lukewarm)."
11235174|NCT03141554|Active Comparator|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A
~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
~Treatment C = Normal saline gargle (lukewarm).
~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
11235175|NCT03141554|Active Comparator|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -> A -> B
~Treatment C = Normal saline gargle (lukewarm).
~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
11235176|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
11235177|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
11235178|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
11235179|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
11235180|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
11235181|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
11235182|NCT03141502|Experimental|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
11235183|NCT03141502|Active Comparator|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
11235184|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
11235185|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
11235186|NCT03141476|Other|Cefuroxime 1,5g|BMI <30kg/m*m
11235187|NCT03141476|Other|Cefuroxime 3g|BMI 30-50kg/m*m
11235188|NCT03141476|Other|Cefuroxime 4,5g|BMI >50kg/m*m
11235189|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
11235190|NCT03141437|Active Comparator|Arm I (standard of care)|Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
11235191|NCT03141437|Experimental|Arm II (standard of care, decision-making website)|Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
11235192|NCT03141424|Active Comparator|Group A|Usual care. Unchanged asthma medication during the entire study period.
11235193|NCT03141424|Experimental|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
11235223|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
11235224|NCT03141203|Experimental|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
11235194|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
11235195|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
11235196|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
11235197|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
11235198|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
11235199|NCT03141359|Experimental|Single Arm|SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy
11235200|NCT03141346|Active Comparator|Control|A control health education program to promote general health and safety
11235201|NCT03141346|Experimental|Sugar Reduction Program Only|A health education program that focuses on sugar reduction
11235202|NCT03141346|Experimental|Sugar Reduction Program & Water Delivery|A health education program that focuses on sugar reduction and provides home bottled water delivery
11235203|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
11235204|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
11235205|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
11235206|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
11235207|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
11235208|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
11235209|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
11235210|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
11235211|NCT03141281|Experimental|IADL training|Participants will be enrolled in AARP's web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
11235212|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
11235213|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
11235214|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
11235215|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
11235216|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
11235217|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
11235218|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
11235219|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
11235220|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
11235221|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
11235222|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
11235329|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
11235225|NCT03141203|Experimental|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
11235226|NCT03141203|Experimental|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
11235227|NCT03141203|Experimental|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
11235228|NCT03141203|Experimental|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
11235229|NCT03141203|Experimental|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.
~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
11235230|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
11235231|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
11235232|NCT03141177|Experimental|Doublet|Nivolumab and Cabozantinib
11235233|NCT03141177|Active Comparator|Monotherapy|Sunitinib
11235234|NCT03141177|Experimental|Triplet|"Nivolumab, Ipilimumab, Cabozantinib
~*Enrollment to the triplet arm was discontinued by protocol amendment"
11235235|NCT03141164|Experimental|Training|Computerized vision training
11235236|NCT03141164|Sham Comparator|Control|Sham
11235237|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
11235238|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
11235239|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
11235240|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
11235241|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
11235242|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
11235243|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.
~In addition, patients also received standard therapy for scleroderma."
11235244|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
11235245|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
11235246|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
11235247|NCT03141099|Active Comparator|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
11235248|NCT03141099|Active Comparator|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
11235249|NCT03141099|Active Comparator|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
11235250|NCT03141099|Active Comparator|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
11235251|NCT03141086|Experimental|Group 1|LML134, then placebo
11235252|NCT03141086|Experimental|Group 2|Placebo, then LML134
11235253|NCT03141073|Experimental|HMS5552|75mg BID
11235254|NCT03141073|Placebo Comparator|Placebo|BID
11235255|NCT03141060|Experimental|Arm 1: Delamanid|Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
11235330|NCT03140540|Active Comparator|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
11235466|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
11235256|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
11235257|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
11235258|NCT03141034|Experimental|Irinotecan plus ramucirumab|-Patients will receive ramucirumab intravenously on an outpatient basis at a dose of 8 mg/kg over the course of 60 minutes on Day 1 of each 14-day cycle. They will then receive irinotecan intravenously at a dose of 180 mg/m2 over the course of 90 minutes on Day 1 of each 14-day cycle.
11235259|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:
~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
11235260|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:
~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
11235261|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
11235262|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
11235263|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
11235264|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
11235265|NCT03140969|Experimental|QR-110|Administered every 3 months
11235266|NCT03140956|Experimental|Levodopa formulation D|Levodopa formulation D
11235267|NCT03140956|Experimental|Levodopa formulation E|Levodopa formulation E
11235268|NCT03140956|Experimental|Levodopa formulation F|Levodopa formulation F
11235269|NCT03140956|Active Comparator|Sinemet IR 100/25mg|Sinemet IR 100/25MG
11235270|NCT03140956|Active Comparator|Sinemet CR 100/25mg|Sinemet IR 100/25MG
11235271|NCT03140956|Experimental|ODM-104 100mg|ODM-104 100MG
11235272|NCT03140956|Active Comparator|Carbidopa 20mg|Carbidopa 20MG
11235273|NCT03140956|Active Comparator|Carbidopa 65mg|Carbidopa 65MG
11235274|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
11235275|NCT03140930|Experimental|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
11235276|NCT03140930|Experimental|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
11235277|NCT03140930|Experimental|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
11235278|NCT03140930|Placebo Comparator|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
11235279|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
11235280|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
11235281|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
11235282|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
11235283|NCT03140878|Experimental|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
11235284|NCT03140878|Placebo Comparator|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
11235285|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
11235286|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
11235287|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
11235288|NCT03140852|Active Comparator|Treatment|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the spring 2017.
11235289|NCT03140852|Other|Control|Completes the Mind Over Matter; Healthy Bowels, Healthy Bladder workshop in the fall 2017.
11235331|NCT03140540|Active Comparator|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
11235558|NCT03138889|Experimental|Dose Optimization, Combo of NKTR-214 +Pembrolizumab(KEYTRUDA®)|NKTR-214 will be combined with pembrolizumab
11235290|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
11235291|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
11235292|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
11235293|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
11235294|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
11235295|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
11235296|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
11235297|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
11235298|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
11235299|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
11235300|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
11235301|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
11235302|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
11235303|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
11235304|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
11235305|NCT03140774||Cohort 3: Phase 2 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo
11235306|NCT03140748|Other|Patients with fungal peritonitis|
11235307|NCT03140748|Other|Patients with peritonitis without yeast|
11235308|NCT03140735|Other|Control group of 150 heart disease-free individuals|
11235309|NCT03140735|Other|Patients with aortic sclerosis|
11235310|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
11235311|NCT03140735|Other|Patients with Serious Aortic Retention|
11235312|NCT03140722|Experimental|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
11235313|NCT03140722|Active Comparator|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
11235314|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
11235315|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
11235316|NCT03140696|Experimental|Chicken egg alone|A chicken egg alone will be offered for 2 days by mouth for once a day
11235317|NCT03140696|Experimental|Egg and RUSF|A chicken egg and Ready to use supplementary food (RUSF) will be offered for 2 days by mouth for once a day
11235318|NCT03140696|Experimental|Egg and breast milk|A chicken egg and Mother's breast milk will be offered for 2 days by mouth for once a day
11235319|NCT03140670|Experimental|Single Arm|
11235320|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
11235321|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
11235322|NCT03140644|Experimental|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
11235323|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
11235324|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
11235325|NCT03140618|Experimental|LEPPIC|The light and environment project in psychiatric inpatient care
11235326|NCT03140566|Experimental|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
11235327|NCT03140566|Sham Comparator|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
11235328|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
11235332|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
11235333|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
11235334|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
11235335|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
11235336|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
11235337|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
11235338|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
11235339|NCT03140527|Active Comparator|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
11235340|NCT03140527|Placebo Comparator|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
11235341|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
11235342|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
11235343|NCT03140527|Active Comparator|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
11235344|NCT03140527|Placebo Comparator|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
11235345|NCT03140527|Active Comparator|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
11235346|NCT03140527|Placebo Comparator|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
11235347|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
11235348|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
11235349|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
11235350|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
11235377|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
11235378|NCT03140332|Other|Patient with CHC|
11235379|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
11235351|NCT03140488|No Intervention|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol
~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
11235352|NCT03140488|Experimental|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol
~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
11235353|NCT03140488|No Intervention|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol
~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
11235354|NCT03140488|Experimental|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol
~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
11235355|NCT03140475||Individuals with schizophrenia|"Behavioral variables:
~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)
~Physiological variables:
~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)
~Clinical variables:
~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents
~Neuropsychological variables:
~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
11235356|NCT03140475||Controls|"Behavioral variables:
~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /
~Physiological variables:
~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /
~Clinical variables:
~Calgary Depression Scale
~Neuropsychological variables:
~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
11235357|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
11235358|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
11235359|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
11235360|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
11235361|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
11235362|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
11235363|NCT03140423|Active Comparator|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
11235364|NCT03140423|Active Comparator|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
11235365|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
11235366|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
11235367|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
11235368|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
11235369|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
11235370|NCT03140384|Active Comparator|Administration of oral Misoprostol|
11235371|NCT03140384|Active Comparator|Administration of Misoprostol vaginally|
11235372|NCT03140384|Active Comparator|Administration of buccal Misoprostol|
11235373|NCT03140371|Experimental|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.
~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
11235374|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
11235375|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
11235376|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
11235384|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
11235385|NCT03140280|Experimental|Dietary Intervention|Freeze-dried black raspberry powder administration.
11235386|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
11235387|NCT03140254|Active Comparator|comparator|Chlorhexidine gluconate
11235388|NCT03140254|Experimental|experimental|BDIP-0001
11235389|NCT03140254|Placebo Comparator|placebo|Vehicle
11235390|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
11235391|NCT03140228|Experimental|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
11235392|NCT03140228|Active Comparator|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
11235393|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
11235394|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
11235395|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
11235396|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
11235397|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
11235398|NCT03140150|Experimental|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
11235399|NCT03140150|Other|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
11235400|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
11235401|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
11235402|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
11235403|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
11235404|NCT03140085|Active Comparator|Anbiotica|
11235405|NCT03140085|Active Comparator|Bacteriophages|
11235406|NCT03140085|Placebo Comparator|Placebo|
11235407|NCT03140072|Experimental|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
11235408|NCT03140072|Placebo Comparator|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
11235409|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
11235410|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
11235411|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
11235412|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
11235413|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
11235414|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
11235415|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
11235416|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
11235417|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
11235418|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
11235419|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
11235420|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
11235421|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
11235422|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
11235423|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
11235424|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
11235425|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
11235426|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
11235427|NCT03139942|Experimental|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
11235428|NCT03139916|Experimental|Bavituximab + Standard of Care Radiation + Temozolomide|"Bavituximab will be administered weekly intravenously
~Temozolomide will be administered daily
~Standard of Care Radiation will be administered per hospital guideline."
11235429|NCT03139890|Experimental|High-fat milkshake|
11235430|NCT03139890|Experimental|High-carbohydrate milkshake|
11235431|NCT03139890|Experimental|High-protein milkshake|
11235432|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.
~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.
~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
11235433|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
11235434|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.
~This group will be asked to provide a fecal and blood sample at one time point."
11235435|NCT03139864|Experimental|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
11235436|NCT03139864|Active Comparator|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
11235437|NCT03139851|Other|Cyclophosphamide and Pembrolizumab|"The treatments received are:
~cyclophosphamide (50 mg/day, daily, per os)
~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
11235438|NCT03139838|Active Comparator|EHR-Based Intervention A|Intervention A (Prognostication) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
11235439|NCT03139838|Active Comparator|EHR-Based Intervention B|Intervention B (Accountable Justification) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
11235440|NCT03139838|Active Comparator|Combined EHR-Based Intervention (A+B)|Intervention A and B prompts will be combined and triggered for eligible patients simultaneously. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
11235441|NCT03139838|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 5 months of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the hospital. The length of the control phase will differ at each hospital, dependent on the sequence in which hospitals are assigned to switch to the intervention phase.
11235442|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
11235443|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
11235444|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
11235445|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
11235446|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
11235447|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
11235448|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
11235449|NCT03139760|Experimental|POWERSforID|POWERSforID intervention group
11235450|NCT03139760|No Intervention|Control|Usual clinical care
11235451|NCT03139747|Experimental|Single Arm|
11235452|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
11235453|NCT03139721||Primary cohort|Subjects requiring aortic or mitral valve replacement
11235454|NCT03139708|Experimental|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
11235455|NCT03139708|Experimental|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
11235456|NCT03139708|Active Comparator|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
11235457|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
11235458|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
11235459|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
11235460|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
11235461|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
11235462|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
11235463|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
11235464|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
11235465|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
11235467|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
11235468|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
11235469|NCT03139604|Experimental|Itacitinib|Itacitinib plus corticosteroids
11235470|NCT03139604|Placebo Comparator|Placebo|Matching placebo plus corticosteroids
11235471|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
11235472|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
11235473|NCT03139578|Experimental|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
11235474|NCT03139578|Experimental|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
11235475|NCT03139578|Experimental|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
11235476|NCT03139578|Experimental|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
11235477|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
11235478|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
11235479|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
11235480|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
11235481|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
11235482|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
11235483|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
11235484|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
11235485|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
11235486|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
11235487|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
11235488|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
11235489|NCT03139487|Experimental|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks
~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
11235490|NCT03139474|Active Comparator|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
11235491|NCT03139474|Active Comparator|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
11235492|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
11235493|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
11235494|NCT03139448|Active Comparator|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
11235495|NCT03139448|Experimental|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
11235496|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
11235497|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
11235498|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
11235499|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
11235500|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
11235501|NCT03139396|Active Comparator|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
11235502|NCT03139396|Experimental|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
11235503|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
11235504|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
11235505|NCT03139370|Experimental|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.
~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
11235506|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
11235507|NCT03139344|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session low-frequency exercise or high-frequency exercise.
11235508|NCT03139344|Experimental|Training study|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with high-frequency exercise.
11235509|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
11235510|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
11235511|NCT03139305|Active Comparator|Glucagon Low Dose|
11235512|NCT03139305|Active Comparator|Glucagon High Dose|
11235513|NCT03139305|Placebo Comparator|Placebo|
11235514|NCT03139292|Experimental|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
11235515|NCT03139292|Experimental|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
11235516|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
11235517|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
11235518|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
11235519|NCT03139266|Other|Control Group|Treatment-as-usual
11235520|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.
~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
11235521|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
11235522|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
11235523|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
11235524|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
11235525|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
11235526|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
11235527|NCT03139227|Experimental|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
11235528|NCT03139214|Experimental|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
11235529|NCT03139214|No Intervention|Control|3 mailings about child development and stress management.
11235530|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
11235531|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
11235532|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
11235533|NCT03139175|Active Comparator|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
11235534|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
11235535|NCT03139149|Active Comparator|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
11235536|NCT03139149|Active Comparator|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
11235537|NCT03139136|Active Comparator|MBS2320|
11235538|NCT03139136|Placebo Comparator|Placebo|
11235539|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
11235540|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
11235541|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
11235542|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
11235543|NCT03139058|Other|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
11235544|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
11235545|NCT03139045|Active Comparator|Venous puncture without VVV|
11235546|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
11235547|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
11235548|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
11235549|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
11235550|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
11235551|NCT03138993|Active Comparator|Patient decision aid|
11235552|NCT03138993|Sham Comparator|General sleep education|
11235553|NCT03138980|Experimental|Mobile application|
11235554|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.
~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
11235555|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.
~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
11235556|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
11235557|NCT03138902|Experimental|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
11235559|NCT03138889|Experimental|Dose Expansion, Combo of NKTR-214 + Pembrolizumab(KEYTRUDA®)|NKTR-214 will be combined with pembrolizumab
11235560|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
11235561|NCT03138863|Experimental|Fetuses with Left CDH|Performance of fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
11235562|NCT03138850|Experimental|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
11235563|NCT03138850|Experimental|YX Mandibular advancement bite block|Mandibular advancement bite block group
11235564|NCT03138850|Experimental|Optiflow High flow nasal cannula|High flow nasal cannula group
11235565|NCT03138824|Experimental|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
11235566|NCT03138824|Experimental|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
11235567|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
11235568|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
11235569|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
11235570|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
11235571|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
11235572|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
11235573|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
11235574|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
11235575|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
11235576|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
11235577|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
11235578|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
11235579|NCT03138733|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg
11235580|NCT03138733|Active Comparator|Daptomycin|Daptomycin 6 mg/kg, with or without Aztreonam
11235581|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
11235582|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
11235583|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
11235584|NCT03138681|Placebo Comparator|Placebo|
11235585|NCT03138681|Experimental|ATP|
11235586|NCT03138681|Experimental|phosphocreatine|
11235587|NCT03138668|Experimental|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
11235588|NCT03138668|Experimental|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
11235589|NCT03138655|Experimental|Vedolizumab High dose group|Participants with UC or CD having baseline weight of >=30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of 10 kg to less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous (IV) infusion, on Day 1, Weeks 2, 6 and 14.
11235590|NCT03138655|Experimental|Vedolizumab Low dose group|Participants with UC or CD having baseline weight of >=30 kg will receive Vedolizumab 150 mg and participants with UC or CD having baseline weight of 10 kg to <30 kg will receive Vedolizumab 100 mg, IV infusion, on Day 1 and Weeks 2, 6 and 14. Participants assigned to the low dose group who do not achieve clinical response (based on pediatric UC/CDAI) at Week 14 will receive vedolizumab IV high dose (that is, 300 mg for participants >=30 kg baseline weight and 200 mg for participants 10 kg to <30 kg baseline weight).
11235591|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
11235592|NCT03138616|Experimental|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
11235593|NCT03138616|No Intervention|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~only receive lifestyle intervention."
11235594|NCT03138616|Experimental|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
11235595|NCT03138616|No Intervention|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.
~only receive lifestyle intervention."
11235596|NCT03138603|Experimental|Metoprolol|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg prior to extubation, and subsequently an oral doser 25mg metoprolol tartrate) in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
11235597|NCT03138603|Placebo Comparator|Placebo|Patients will receive up to 3 IV doses of placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
11235598|NCT03138590|Experimental|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
11235599|NCT03138590|Sham Comparator|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
11235600|NCT03138577|Other|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235601|NCT03138577|Other|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235602|NCT03138577|Other|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235603|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235604|NCT03138577|Other|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235605|NCT03138577|Other|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235606|NCT03138577|Other|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
11235607|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
11235608|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
11235609|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.
~A: Baseline - typical mealtimes in the home.
~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.
~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
11235610|NCT03138538|Experimental|Part 1: M8891|
11235611|NCT03138538|Experimental|Part 2A: Dose Escalation Cohort: M8891 and Cabozantinib|
11235612|NCT03138538|Experimental|Part 2B: Dose Expansion Cohort: M8891 and Cabozantinib|
11235613|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
11235614|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
11235615|NCT03138512|Experimental|Part A, Arm A: nivolumab + ipilimumab|
11235616|NCT03138512|Placebo Comparator|Part A, Arm B: nivolumab placebo + ipilimumab placebo|
11235617|NCT03138512|Experimental|Part B, Arm A: nivolumab + ipilimumab|
11235618|NCT03138512|Placebo Comparator|Part B, Arm B: nivolumab placebo + ipilimumab placebo|
11235619|NCT03138512|Experimental|Part B, Arm C: nivolumab + ipilimumab placebo|
11235620|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
11235621|NCT03138499|Experimental|Module B|Brentuximab alone
11235622|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
11235623|NCT03138447|Experimental|Prospective Cohort|
11235624|NCT03138447|No Intervention|Retrospective Cohort|
11235625|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
11235626|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.
~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.
~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
11235627|NCT03138421|Experimental|ABX-1431 HCl|
11235628|NCT03138421|Placebo Comparator|Placebo|
11235629|NCT03138408|Experimental|SC-004|
11235630|NCT03138408|Experimental|SC-004 and ABBV-181|
11235631|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
11235632|NCT03138382|Experimental|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
11235633|NCT03138382|Experimental|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
11235634|NCT03138356|Experimental|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
11235635|NCT03138356|Experimental|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
11235636|NCT03138356|Active Comparator|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
11235637|NCT03138356|Experimental|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state
~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
11235638|NCT03138356|Experimental|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
11235639|NCT03138356|Active Comparator|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
11235640|NCT03138356|Experimental|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
11235641|NCT03138356|Experimental|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
11235642|NCT03138356|Active Comparator|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.
~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
11235643|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
11235644|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
11235645|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
11235646|NCT03138304|Experimental|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
11235647|NCT03138304|Active Comparator|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
11235648|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
11235649|NCT03138278|No Intervention|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
11235650|NCT03138278|Active Comparator|Telephone support|ICU with day-time telephone support to care-givers
11235651|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
11235652|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
11235653|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
11235654|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)
~4 patients who have tested at staging, will be tested again after treatment.
~4 patients with treatment failure or recurrence."
11235655|NCT03138213|Experimental|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
11235656|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
11235657|NCT03138200|Other|Blood transfusion based on central venous oxygen saturation|
11235658|NCT03138187|No Intervention|control|without physical exercise sessions
11235659|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
11235660|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
11235661|NCT03138174||Diabetes|One group consisting of diabetic subjects
11235662|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.
~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
11235663|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
11235664|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
11235665|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
11235666|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
11235667|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
11235668|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
11235669|NCT03138096|Experimental|Group 1|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
11235670|NCT03138096|Experimental|Group 2|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
11235671|NCT03138096|Experimental|Group 3|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
11235672|NCT03138096|Other|Group 4|Infectivity control group
11235673|NCT03138096|Other|Group 5|Infectivity control group
11235674|NCT03138083|Experimental|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
11235675|NCT03138083|Experimental|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
11235676|NCT03138083|Experimental|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
11235677|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
11235678|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
11235679|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
11235680|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
11235681|NCT03138044|Experimental|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
11235682|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
11235683|NCT03138018|Active Comparator|Standard instruction|
11235684|NCT03138018|Experimental|Reduced threat instruction|
11235685|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
11235686|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
11235687|NCT03137992|Experimental|Test Product (tiotropium bromide inhalation powder)|"Single dose 18 mcg of test product (tiotropium bromide inhalation powder), a long acting muscarinic receptor antagonist, for double blind portion.
~Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness)."
11235688|NCT03137992|Active Comparator|Reference Product (Spriva®)|Single dose of reference product (Spiriva®) 18 mcg
11235689|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
11235690|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
11235691|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
11235692|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
11235693|NCT03137966|Active Comparator|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
11235694|NCT03137966|Placebo Comparator|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
11235695|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
11235696|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
11235697|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
11237423|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
11235698|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
11235699|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
11235700|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
11235701|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
11235702|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
11235703|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
11235704|NCT03137914|Experimental|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis). Hyaluronic acid is used only as a soluble medium to dilute the chondrocytes, so it is not considered as another experimental group, or as part of interest in this investigation.
11235705|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
11235706|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
11235707|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
11235708|NCT03137875||patient smear negative|patient with a negative TB microscopy result
11235709|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
11235710|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
11235711|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
11235712|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
11235713|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
11235714|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
11235715|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
11235716|NCT03137836|Experimental|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
11235717|NCT03137836|No Intervention|Control|Control classroom will maintain their routine in sitting desks.
11235718|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
11235719|NCT03137810|Experimental|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
11235720|NCT03137810|Active Comparator|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
11235721|NCT03137784|Other|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
11235722|NCT03137784|Other|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
11235723|NCT03137784|Other|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
11235724|NCT03137784|Other|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
11235725|NCT03137784|Other|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
11235726|NCT03137784|Other|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
11235727|NCT03137771|Active Comparator|Arm 1 (maintenance chemotherapy)|Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11235728|NCT03137771|Experimental|Arm 2 (SBRT + maintenance chemotherapy)|Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
11235729|NCT03137758|Experimental|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
11235730|NCT03137758|Experimental|Level 2 (100 mg) PCUR-101|
11235731|NCT03137758|Experimental|Level 3 (150 mg) PCUR-101|
11235732|NCT03137758|Experimental|Level 4 (200 mg) PCUR-101|
11235733|NCT03137758|Experimental|Level 5 (250 mg) PCUR-101|
11235734|NCT03137758|Experimental|Level 6 (300 mg) PCUR-101|
11235735|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
11235736|NCT03137732|Active Comparator|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
11235737|NCT03137732|Active Comparator|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
11235738|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
11235739|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
11235740|NCT03137680|No Intervention|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
11235741|NCT03137680|Experimental|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
11235742|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
11235743|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
11235744|NCT03137654|Active Comparator|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
11235745|NCT03137654|Active Comparator|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
11235746|NCT03137654|No Intervention|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
11235747|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:
~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
11235748|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
11235749|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
11235750|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery
~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.
~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
11235751|NCT03137602|Other|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
11235752|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
11235753|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
11235754|NCT03137576|Active Comparator|Paravertebral block (PVB)|"Intraoperative pain management
~Sedation
~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).
~Paravertebral Block
~Post operative pain management
~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
11235755|NCT03137576|Experimental|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management
~Sedation
~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).
~Erector Spinae Plane Block
~Post operative pain management
~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
11235756|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
11235757|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks
~Ivabradine is taken orally twice daily
~Dosage will be adjusted according to physician determination"
11235758|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks
~Placebo is taken orally twice daily
~Dosage will be adjusted according to physician determination"
11235759|NCT03137524|Experimental|Hand Held Fan Therapy|
11235760|NCT03137524|No Intervention|No Intervention|
11235761|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.
~The MG collects relevant clinical information
~The MG takes 2 photographs of the lesion with his smartphone.
~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information
~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.
~The dermatologist proposes an appointment to the patient."
11235762|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.
~General practitioners and dermatologists continue their practice in the usual way."
11235763|NCT03137498|Experimental|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
11235764|NCT03137498|Active Comparator|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
11235765|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
11237424|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
11235766|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
11235767|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
11235768|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
11235769|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
11235770|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
11235771|NCT03137446|No Intervention|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP>65, determined by the primary care team for the duration of the study.
11235772|NCT03137446|Experimental|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
11235773|NCT03137433|Experimental|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
11235774|NCT03137433|Experimental|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
11235775|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS > 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
11235776|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
11235777|NCT03137407|Experimental|DaxibotulinumtoxinA 240 units|Botulinum Toxins, Type A Intramuscular Injection
11235778|NCT03137407|Placebo Comparator|Placebo|Placebo Intramuscular Injection
11235779|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
11235780|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
11235781|NCT03137381|Experimental|CTP-543, 4 mg|Oral tablet, dosed twice-daily
11235782|NCT03137381|Experimental|CTP-543, 8 mg|Oral tablet, dosed twice-daily
11235783|NCT03137381|Experimental|CTP-543, 12 mg|Oral tablet, dosed twice-daily
11235784|NCT03137381|Placebo Comparator|Placebo|Oral tablet, dosed twice daily
11235785|NCT03137368|Experimental|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
11235786|NCT03137368|Active Comparator|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
11235787|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
11235788|NCT03137342|Experimental|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
11235789|NCT03137342|No Intervention|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
11235790|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
11235791|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
11235817|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangranosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
11237425|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
11235792|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.
~Subject demographic and contact information
~Co-morbid conditions
~Smoking history
~Medication history from patient and also from pharmacy used by subjects
~A respiratory exacerbation history in the past year
~Modified Medical Research Counsel (mMRC) dyspnea scale
~Quality of life measures
~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.
~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
11235793|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:
~Subject demographic and contact information
~Co-morbid conditions
~Smoking history
~Medication history from patient and also from pharmacy used by subjects
~A respiratory exacerbation history in the past year
~Modified Medical Research Counsel (mMRC) dyspnea scale
~Quality of life measures
~Pre and post-bronchodilator using Albuterol (BD) spirometry"
11235794|NCT03137290|Active Comparator|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
11235795|NCT03137290|Experimental|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
11235796|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
11235797|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
11235798|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
11235799|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
11235800|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.
~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
11235801|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.
~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
11235802|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
11235803|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
11235804|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
11235805|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
11235806|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
11235807|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.
~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
11235808|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.
~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
11235809|NCT03137212|Experimental|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
11235810|NCT03137212|Experimental|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
11235811|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
11235812|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
11235813|NCT03137186|Active Comparator|Investigational arm|Metformin will be added to standard of care
11235814|NCT03137186|No Intervention|Control arm|Patients will treated according to Standard of care only
11235815|NCT03137173|Experimental|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
11235816|NCT03137173|Active Comparator|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
11235857|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
11235818|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
11235819|NCT03137134|Active Comparator|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
11235820|NCT03137134|Experimental|Treatment B|(test) Crizotinib cMS 300 mg in fed state
11235821|NCT03137134|Experimental|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
11235822|NCT03137134|Experimental|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
11235823|NCT03137134|Experimental|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
11235824|NCT03137121|Experimental|Group 1|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
11235825|NCT03137121|Placebo Comparator|Group 2|Patients will receive a placebo orally for 1 to 7 days daily.
11235826|NCT03137108|Experimental|Incomplete Spinal cord injury|
11235827|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
11235828|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
11235829|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks
~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)
~Full dose: 3mgs/d (day 21- day 70)
~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
11235830|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks
~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)
~Full dose: 3mgs/d (day 21- day 70)
~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
11235831|NCT03137069|Placebo Comparator|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
11235832|NCT03137069|Experimental|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
11235833|NCT03137069|Placebo Comparator|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
11235834|NCT03137069|Experimental|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
11235835|NCT03137069|Experimental|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
11235836|NCT03137069|Experimental|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
11235837|NCT03137056|Active Comparator|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
11235838|NCT03137056|Active Comparator|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
11235839|NCT03137056|Active Comparator|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
11235840|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
11235841|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
11235842|NCT03137030|Experimental|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.
~(GRT7014 - Abuse Deterrend Tablet)"
11235843|NCT03137030|Experimental|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.
~(GRT7014 - Abuse Deterrend Tablet)"
11235844|NCT03137030|Active Comparator|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
11235845|NCT03137030|Active Comparator|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
11235846|NCT03137030|Experimental|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.
~(GRT7014 - Abuse Deterrend Tablet)"
11235847|NCT03137030|Active Comparator|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
11235848|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
11235849|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.
~The IMP must be administered as soon as the meal has been eaten."
11235850|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
11235851|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.
~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.
~The IMP must be administered as soon as the meal has been eaten."
11235852|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
11235853|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
11235854|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
11235855|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
11235856|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
11235858|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
11235859|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
11235860|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
11235861|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
11235862|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
11235863|NCT03136939||type 1 diabetes|
11235864|NCT03136939||type 2 diabetes|
11235865|NCT03136939||healthy people|
11235866|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
11235867|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
11235868|NCT03136900|Experimental|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
11235869|NCT03136900|Active Comparator|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
11235870|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
11235871|NCT03136874||Donors who procreated|
11235872|NCT03136874||Donors who don't procreated|
11235873|NCT03136861|Experimental|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
11235874|NCT03136861|Placebo Comparator|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
11235875|NCT03136861|Active Comparator|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
11235876|NCT03136861|Active Comparator|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
11235877|NCT03136861|Active Comparator|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
11235878|NCT03136861|Active Comparator|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
11235879|NCT03136861|Active Comparator|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
11235880|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
11235881|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
11235882|NCT03136822|Other|Control|Standard dressing
11235883|NCT03136822|Experimental|Treatment|Standard dressing + Wound dressing (DERMALIX)
11235884|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
11235885|NCT03136783|Other|Patient with stage IV melanoma|
11235886|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
11235887|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
11235888|NCT03136744|Experimental|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
11235889|NCT03136731||Healthy family members of celiac disease|Celiac disease screening, no intervention.
11235890|NCT03136731||Celiac disease index cases|Assessment of disease related factors, no intervention.
11235891|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
11235892|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
11235893|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
11235894|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
11235895|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
11235896|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
11235897|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
11235898|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
11235899|NCT03136666|Experimental|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
11235900|NCT03136653|Experimental|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
11235901|NCT03136640|Experimental|ModraDoc006/r|Weekly ModraDoc006/r treatment as ModraDoc006 (oral docetaxel) 10mg tablets combined with ritonavir 100mg tablets
11235902|NCT03136627|Experimental|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
11235903|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
11235904|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
11235905|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
11235906|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
11235907|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
11235908|NCT03136588|Experimental|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
11235909|NCT03136588|No Intervention|Control group|Use standard questionnaire to gather information for drug adherence
11235910|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
11235911|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
11235912|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
11235913|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
11235914|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
11235915|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
11235916|NCT03136510|Other|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
11235917|NCT03136510|Other|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
11235918|NCT03136497|Experimental|ABT-199 Plus Ibrutinib and Rituximab|Cycle length will be 28 days. Venetoclax will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
11235919|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
11235920|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
11235921|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.
~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.
~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
11235922|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.
~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.
~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
11235923|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.
~Inclusion criteria:
~Diabetes patients who consent to participate the study.
~Age 65+;
~Diagnosis code for diabetes in the last 2 years;
~Diagnosis code for at least one additional chronic condition in the last 2 years.
~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
11235924|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
11235925|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.
~Inclusion criteria:
~All patients age 18+ who registered at REACHnet.
~Able to provide informed consent
~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
11235926|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.
~Inclusion criteria:
~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.
~Able to provide informed consent
~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
11235927|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
11235928|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
11236074|NCT03135457|Other|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
11235929|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
11235930|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
11235931|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
11235932|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
11235933|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
11235934|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
11235935|NCT03136406|Experimental|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:
~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
11235936|NCT03136393|Active Comparator|Control|Community based antenatal counselling
11235937|NCT03136393|Experimental|Intervention|Community based dietary counselling
11235938|NCT03136380|Experimental|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
11235939|NCT03136380|Experimental|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
11235940|NCT03136380|Experimental|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
11235941|NCT03136380|Experimental|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
11235942|NCT03136380|Experimental|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
11235943|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
11235944|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
11235945|NCT03136367|No Intervention|Arm 3: Usual Care|
11235946|NCT03136354|Active Comparator|ESD Group|Endoscopic Submucosal Dissection
11235947|NCT03136354|Active Comparator|LAG Group|Laparoscopic Assisted Gastrectomy
11235948|NCT03136341|Active Comparator|Abobotulinum toxin A|
11235949|NCT03136341|Placebo Comparator|Placebo|
11235950|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
11235951|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
11235952|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
11235953|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
11235954|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
11235955|NCT03136276|Active Comparator|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
11235956|NCT03136276|Experimental|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
11235957|NCT03136263|Experimental|Drug order: Oxytocin - placebo|
11235958|NCT03136263|Experimental|Drug order: Placebo - oxytocin|
11235959|NCT03136250|Active Comparator|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
11235960|NCT03136250|Experimental|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
11235961|NCT03136250|Experimental|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
11235962|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
11235963|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
11235964|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
11235965|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
11235966|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
11235967|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
11235968|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
11235969|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
11235970|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
11235971|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
11235972|NCT03136185|Experimental|IMG-7289|Single starting dose with individualized dose titrations throughout
11235973|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
11235974|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
11235975|NCT03136146|Experimental|Treatment (combination chemotherapy)|See detailed description
11235976|NCT03136133|Active Comparator|Active protein drink|Active protein drink
11235977|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
11235978|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
11235979|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
11235980|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
11235981|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
11235982|NCT03136094|Placebo Comparator|SBIRT+Usual Care|The control arm of the trial will receive the usual care prescribed in the Screening, Brief Intervention and Referral to Treatment (SBIRT) model.
11235983|NCT03136094|Experimental|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants will receive caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
11235984|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:
~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
11235985|NCT03136068|Experimental|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
11235986|NCT03136068|Placebo Comparator|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
11235987|NCT03136055|Experimental|High-Grade Extrapulmonary NEC|"Part A: 200 mg of pembrolizumab will be given every three weeks via IV infusion.
~Part B: 200 mg of pembrolizumab will be given every three weeks via IV infusion and, either
~125 mg/m2 of irinotecan will be given via IV infusion in a two weeks on, one week off format in 3 week cycles, or
~80 mg/m2 of paclitaxel will be given every week via IV infusion."
11235988|NCT03136042|Experimental|physiotherapists maneuvers|physiotherapy techniques
11235989|NCT03136042|Active Comparator|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
11235990|NCT03136042|Active Comparator|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
11235991|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
11235992|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
11235993|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
11235994|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
11235995|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
11235996|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
11235997|NCT03136016|No Intervention|control|without any activity
11235998|NCT03136016|Experimental|educational activities|The students will receive educational activities in the classroom.
11235999|NCT03136016|Experimental|nudging|The students will receive changes in the school environment (nudge strategies);
11236000|NCT03136016|Experimental|nudging + educational activities|The students will receive educational activities and changes in the school environment.
11236001|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: Exercise"
11236071|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
11236002|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).
~Intervention #2: no further intervention (rest)"
11236003|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise
~Intervention #2: no further intervention (rest)"
11236004|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise
~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
11236005|NCT03135990|Experimental|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
11236006|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
11236007|NCT03135964|Active Comparator|foam|PU foam dressing from KCI
11236008|NCT03135964|Active Comparator|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
11236009|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)
~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection
~Administered on Day 2 of each cycle after TC administration"
11236010|NCT03135938|Active Comparator|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
11236011|NCT03135938|Active Comparator|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
11236012|NCT03135925|Other|Intervention|Exercise program
11236013|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
11236014|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
11236015|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
11236016|NCT03135899|Experimental|BI 443651|
11236017|NCT03135899|Placebo Comparator|Placebo|
11236018|NCT03135886|Experimental|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
11236019|NCT03135886|Experimental|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
11236020|NCT03135886|Other|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
11236021|NCT03135873|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
11236022|NCT03135873|Placebo Comparator|Placebo|This arm of patients will receive placebo for a 6 month period.
11236023|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
11236024|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
11236025|NCT03135834|Experimental|Group 1 (ACWY Naive subjects, MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
11236026|NCT03135834|Experimental|Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)|ACWY Naive subjects, rLP2086/MenACWY-CRM
11236027|NCT03135834|Experimental|Group 3 (ACWY Experienced subjects, MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
11236028|NCT03135834|Experimental|Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)|ACWY Experienced subjects, rLP2086/MenACWY-CRM
11236029|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g
~- 2 packets of sachets once before breakfast and once before dinner."
11236030|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.
~TCM Drug A:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g
~TCM Drug B:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g
~TCM Drug C:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g
~TCM Drug D:
~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
11236031|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
11236072|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
11236073|NCT03135457|Other|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
11236032|NCT03135782|Experimental|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.
~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.
~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
11236033|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
11236034|NCT03135756||Depression and anxiety symptoms|
11236035|NCT03135756||Healthy controls|
11236036|NCT03135704|Active Comparator|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
11236037|NCT03135704|Active Comparator|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
11236038|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
11236039|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
11236040|NCT03135652|Experimental|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
11236041|NCT03135652|Active Comparator|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
11236042|NCT03135639|Experimental|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.
~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.
~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
11236043|NCT03135639|Experimental|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.
~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.
~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
11236044|NCT03135626|Experimental|Biodentine|Biodentine pulpotomy agent
11236045|NCT03135626|Experimental|ProRoot MTA|ProRoot MTA pulpotomy agent
11236046|NCT03135626|Experimental|MTA Plus|MTA Plus pulpotomy agent
11236047|NCT03135626|Active Comparator|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
11236048|NCT03135613|Experimental|Normal|Participants of this group are as controls.
11236049|NCT03135613|Experimental|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
11236050|NCT03135600|Experimental|Normal|The participants from this group are healthy people.
11236051|NCT03135600|Experimental|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
11236052|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
11236053|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
11236054|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
11236055|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
11236056|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
11236057|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
11236058|NCT03135561|Experimental|pedometer-plus-email|
11236059|NCT03135561|Active Comparator|pedometer-only|
11236060|NCT03135548|Experimental|Spesolimab (low dose)|
11236061|NCT03135548|Experimental|Spesolimab (high dose)|
11236062|NCT03135548|Placebo Comparator|Placebo|
11236063|NCT03135535|Experimental|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
11236064|NCT03135522|Active Comparator|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
11236065|NCT03135522|Placebo Comparator|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
11236066|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
11236067|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
11236068|NCT03135496||Surgery with CEC|
11236069|NCT03135496||Without CEC|
11236070|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
11236075|NCT03135444|Experimental|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
11236076|NCT03135444|Experimental|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
11236077|NCT03135431|Experimental|Salpingectomy|Bilateral salpingectomy following cesarean delivery
11236078|NCT03135431|Active Comparator|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
11236079|NCT03135418|Experimental|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
11236080|NCT03135418|Sham Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
11236081|NCT03135405|No Intervention|Usual care|
11236082|NCT03135405|Experimental|Intervention|
11236083|NCT03135392|Active Comparator|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
11236084|NCT03135392|Active Comparator|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
11236085|NCT03135392|Experimental|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
11236086|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
11236087|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
11236088|NCT03135366|Active Comparator|Standard of Care (Control)|
11236089|NCT03135366|Experimental|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
11236090|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
11236091|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
11236092|NCT03135340|Experimental|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
11236093|NCT03135340|Active Comparator|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
11236094|NCT03135314|Active Comparator|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
11236095|NCT03135314|Placebo Comparator|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
11236096|NCT03135314|Active Comparator|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
11236097|NCT03135314|Placebo Comparator|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
11236098|NCT03135301|Experimental|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
11236099|NCT03135301|Active Comparator|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
11236100|NCT03135288|Experimental|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
11236101|NCT03135288|No Intervention|control group|will receive the same above adequate counseling with referral card but without any phone assistance
11236102|NCT03135275|Active Comparator|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
11236103|NCT03135275|Experimental|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure, the other significant coronary stenosis. All the revascularizations will be performed with Synergy™ stent.
11236104|NCT03135262|Experimental|Dose-Escalation Cohort: FL|Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose [MTD] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
11236105|NCT03135262|Experimental|Dose-Escalation Cohort: DLBCL|Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
11236106|NCT03135262|Experimental|Expansion Cohort: FL|Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
11236107|NCT03135262|Experimental|Expansion Cohort: DLBCL|Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
11236108|NCT03135249|Other|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:
~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.
~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
11236109|NCT03135236|Experimental|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
11236110|NCT03135223|Experimental|Intervention group|Co-created, school-based intervention to promote physical activity
11236111|NCT03135223|No Intervention|Control group|
11236112|NCT03135210|Active Comparator|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
11236113|NCT03135210|Experimental|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
11236114|NCT03135197||Migalastat|Migalastat administered according to SmPC
11236115|NCT03135184|Experimental|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
11236116|NCT03135171|Experimental|Trastuzumab, Pertuzumab and Tocilizumab|
11236117|NCT03135158||Women in labor|All participants who have a vaginal delivery
11236118|NCT03135145|Active Comparator|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
11236119|NCT03135145|Placebo Comparator|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
11236120|NCT03135132|Placebo Comparator|Control group|Usual dietary intake group
11236121|NCT03135132|Experimental|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
11236122|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
11236123|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
11236124|NCT03135106|Experimental|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
11236125|NCT03135106|Experimental|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
11236126|NCT03135106|Experimental|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
11236127|NCT03135093||Stroke subjects|
11236128|NCT03135093||Healthy subjects|
11236146|NCT03134950|Experimental|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
11236147|NCT03134950|No Intervention|Medical Treatment as Usual|Medical treatment as usual
11236437|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
11236129|NCT03135080|Experimental|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
11236130|NCT03135080|Active Comparator|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
11236131|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
11236132|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
11236133|NCT03135054|Experimental|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.
~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
11236134|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
11236135|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
11236136|NCT03135028|Experimental|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
11236137|NCT03135028|Experimental|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.
~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.
~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission [CR] or morphologic complete remission with incomplete blood count recovery [CRi] and do not require or cannot proceed to allogeneic stem cell transplantation [SCT] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
11236138|NCT03135015|Other|Lean Participants|Participants with BMI >18.5 and <25.0kg/m²
11236139|NCT03135015|Other|Overweight/Obese Participants|Participants with BMI ≥25.0 and <35.0kg/m²
11236140|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
11236141|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
11236142|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria
~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:
~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant
~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.
~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions
~Not demented"
11236143|NCT03134963||Alzheimer disease|"NIA/AA criteria
~Meets the criteria for dementia
~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains
~Insidious or gradual onset
~Clear history of worsening cognition by report or observation
~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:
~Amnestic: impaired learning and recall of recently learned information
~Non amnestic: language/visuospatial/executive dysfunction"
11236144|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:
~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.
~One or more of:
~Onset of dementia within 3 months of a diagnosed stroke
~Abrupt deterioration in cognitive function
~Fluctuating, stepwise progression of cognitive deficits"
11236145|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria
~No evidence of subjective or objective memory impairment on cognitive testing
~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
11236251|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
11236148|NCT03134937|Other|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
11236149|NCT03134924|Experimental|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
11236150|NCT03134924|Other|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
11236151|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
11236152|NCT03134911||anticoagulation non controlled patients|Treated with VKA
11236153|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
11236154|NCT03134872|Experimental|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
11236155|NCT03134872|Active Comparator|Chemotherapy|Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
11236156|NCT03134859|Experimental|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
11236157|NCT03134859|Experimental|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
11236158|NCT03134859|Experimental|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
11236159|NCT03134846|Experimental|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
11236160|NCT03134846|Experimental|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
11236161|NCT03134846|Experimental|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
11236162|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 15 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 15 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
11236163|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 25 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 25 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
11236164|NCT03134846|Experimental|After having established the optimal cetuximab-IRDye800CW dose|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
11236165|NCT03134833|Experimental|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.
~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
11236166|NCT03134833|Experimental|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
11236167|NCT03134833|Experimental|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
11236168|NCT03134833|Experimental|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
11236169|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
11236170|NCT03134794|Experimental|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).
~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
11236171|NCT03134794|No Intervention|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
11236172|NCT03134781|Experimental|Control|Participated only in measurements at baseline, at 20 weeks and at 40 weeks.
11236173|NCT03134781|Experimental|Training|Participated in a supervised 40-week DoIT workout exercise training program and in measurements at baseline, at 20 weeks and at 40 weeks.
11236174|NCT03134781|Experimental|Training-Detraining|Participated in a supervised 20-week DoIT workout exercise training program and then entered a 20-week detraining period. They also participated in measurements at baseline, at 20 weeks and at 40 weeks.
11236175|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
11236176|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
11236177|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
11236178|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
11236179|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
11236180|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours
~plus
~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
11236181|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg
~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
11236182|NCT03134716||Clinical follow-up|Clinical follow-up of MS-patients for 5 years. PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
11236183|NCT03134716||Healthy controls|comparison of healthy controls' and MS patients' PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
11236184|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
11236185|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
11236186|NCT03134690|Experimental|delayed start antagonist|30 women with f poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
11236187|NCT03134690|Experimental|conventional antagonist|30 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
11236188|NCT03134677|Experimental|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
11236189|NCT03134677|Experimental|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
11236190|NCT03134664|Experimental|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
11236191|NCT03134664|Experimental|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
11236192|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
11236193|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
11236194|NCT03134638|Experimental|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
11236195|NCT03134638|Experimental|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
11236196|NCT03134638|Experimental|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
11236197|NCT03134638|Experimental|Clear Cell Ovarian Cancer|Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
11236198|NCT03134638|Experimental|Advanced Solid Tumors|Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
11236199|NCT03134638|Experimental|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
11236200|NCT03134612|Active Comparator|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
11236438|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
11236201|NCT03134612|Active Comparator|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
11236202|NCT03134599|Active Comparator|etafilcon A|
11236203|NCT03134599|Active Comparator|methafilcon A - Interozzo|
11236204|NCT03134599|Active Comparator|methafilcon A - CVI|
11236205|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
11236206|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
11236207|NCT03134560|Active Comparator|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
11236208|NCT03134560|No Intervention|Without vein display instrument|vein cannulation was done without any vein display instrument
11236209|NCT03134547|Active Comparator|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
11236210|NCT03134547|Active Comparator|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
11236211|NCT03134534|Other|VATS group|Surgical procedure: VATS lobectomy
11236212|NCT03134534|Other|RATS group|Surgical procedure: RATS lobectomy
11236213|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
11236214|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
11236215|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
11236216|NCT03134495||non-exposed children|all children with no prescription of PPI
11236217|NCT03134482|Experimental|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.
~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.
~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.
~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
11236218|NCT03134482|Active Comparator|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.
~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.
~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.
~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.
~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
11236219|NCT03134469|Experimental|Probiotics|Intake of a probiotic capsule once daily
11236220|NCT03134469|Placebo Comparator|Placebo|Intake of a placebo capsule once daily
11236221|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
11236222|NCT03134443|Active Comparator|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
11236223|NCT03134443|Placebo Comparator|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
11236224|NCT03134430|Placebo Comparator|Normal saline|equal volume of normal saline as treatment group
11236225|NCT03134430|Active Comparator|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
11236226|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
11236227|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
11236228|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
11236229|NCT03134391|Active Comparator|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
11236230|NCT03134391|Active Comparator|EMLA|Subjects received EMLA before spinal anesthesia
11236231|NCT03134378|Experimental|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
11236232|NCT03134378|Placebo Comparator|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
11236233|NCT03134365|Experimental|Mixed meal|
11236234|NCT03134365|Active Comparator|Combined meal|
11236235|NCT03134352|Experimental|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
11236236|NCT03134352|Experimental|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
11236237|NCT03134352|Placebo Comparator|placebo group|Placebo AM + Placebo PM
11236238|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
11236239|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
11236240|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
11236241|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
11236242|NCT03134326|Experimental|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
11236243|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
11236244|NCT03134300|Active Comparator|Low SES|
11236245|NCT03134300|Placebo Comparator|Normal/high SES|
11236246|NCT03134287|Active Comparator|two-finger method|Those who received nasogastric tube placement by two-finger method
11236247|NCT03134287|Active Comparator|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
11236248|NCT03134274|Experimental|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
11236249|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
11236250|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
11236252|NCT03134248|Experimental|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
11236253|NCT03134248|Active Comparator|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
11236254|NCT03134248|Active Comparator|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
11236255|NCT03134235|Experimental|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
11236256|NCT03134222|Experimental|Lanraplenib 30 mg|Lanraplenib + filgotinib placebo for 48 weeks
11236257|NCT03134222|Experimental|Filgotinib 200 mg|Filgotinib + lanraplenib placebo for 48 weeks
11236258|NCT03134222|Placebo Comparator|Placebo|Filgotinib placebo + lanraplenib placebo for 12 weeks
11236259|NCT03134222|Experimental|Placebo to Lanraplenib 30 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
11236260|NCT03134222|Experimental|Placebo to Filgotinib 200 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
11236261|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
11236262|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
11236263|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
11236264|NCT03134196|Placebo Comparator|Placebo|Encapsulated masked placebo
11236265|NCT03134196|Active Comparator|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
11236266|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
11236267|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
11236268|NCT03134170|No Intervention|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
11236269|NCT03134170|Other|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
11236270|NCT03134157|Experimental|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
11236271|NCT03134157|Experimental|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
11236272|NCT03134157|Experimental|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
11236273|NCT03134144|Experimental|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
11236274|NCT03134144|Experimental|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
11236275|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
11236276|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
11236277|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
11236278|NCT03134092|No Intervention|Generalized Risk Communication (GRC)|Generalized Risk Communication (GRC): Participants in this arm will receive standard discharge instructions similar to instructions they would receive during usual care. This arm represents a standardized way of communicating post-discharge risk-benefit information about treatment options for patients with back pain and renal colic. The GRC, includes a standardized discharge information sheet about the clinical condition of interest and a written overview of population based evidence describing comparative benefits and side effects of alternative classes of medication acute pain.
11236279|NCT03134092|Active Comparator|Probabilistic Risk Communication (PRT)|Probabilistic Risk Communication (PRT): The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
11236280|NCT03134092|Active Comparator|Narrative Enhanced Risk Tool (NERT)|Narrative Enhanced Risk Tool (NERT): Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale related to prolonged opioid use. Narrative videos are developed from actual patient stories - put into a in a structured format of ~ 2-minute length and recorded.
11236281|NCT03134079|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
11236282|NCT03134079|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
11236283|NCT03134079|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):
~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
11236284|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
11236285|NCT03134053|Experimental|extracorporeal shock-wave|
11236286|NCT03134053|Sham Comparator|massage|
11236287|NCT03134040|Experimental|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
11236288|NCT03134040|Experimental|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
11236289|NCT03134040|Active Comparator|Control|Participants receive feedback on their exercise attendance on a weekly basis.
11236290|NCT03134027||Subjects from which PDXs have been generated.|Subjects will be identified from which PDXs have been generated from an already approved IRB protocol.
11236291|NCT03134014|No Intervention|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
11236292|NCT03134014|Active Comparator|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
11236293|NCT03134014|Active Comparator|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
11236294|NCT03134001|Experimental|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
11236295|NCT03134001|No Intervention|Control Group|Patients receiving oral analgesics by nurse, upon request
11236296|NCT03133975|Experimental|Treatment|Single high dose IM VIT D
11236297|NCT03133975|Active Comparator|Control|Usual diet mix of carbohydrates - lipid - protein - minerals & vitamins
11236298|NCT03133962|Other|Patients applying for CAP or long-term central catheter|
11236299|NCT03133949||Patients with idiopathic inflammatory aortitis|
11236300|NCT03133949||a group of witnesses|
11236301|NCT03133936|Experimental|influenza vaccination|Fluarix (GSK). A 0.5 mL dose will be administered at baseline.
11236302|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but <3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)[ ≥3.0logCCID50/ml but <3.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
11236303|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
11236304|NCT03133923|Active Comparator|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
11236305|NCT03133897|Active Comparator|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
11236306|NCT03133897|Experimental|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
11236307|NCT03133884|Experimental|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
11236308|NCT03133884|Other|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
11236309|NCT03133845|Active Comparator|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
11236310|NCT03133845|Experimental|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS>60-70. Discretionary use of intrathecal morphine may be used.
11236311|NCT03133832|Experimental|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
11236312|NCT03133832|Experimental|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
11236313|NCT03133832|Experimental|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
11236314|NCT03133819|Other|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
11236315|NCT03133806|Experimental|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
11236316|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
11236317|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
11236318|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
11236319|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
11236320|NCT03133780|Active Comparator|Ketamine|Patients will receive IV ketamine 0.5 mg/kg for 10 min
11236321|NCT03133780|Active Comparator|Midazolam|Patients will receive IV midazolam 0.05 mg/kg for 10 min
11236322|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
11236323|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
11236324|NCT03133754|Experimental|DP-PEEP|recruitment maneuver + individualized PEEP
11236325|NCT03133754|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
11236326|NCT03133741|Placebo Comparator|Placebo|Saline
11236327|NCT03133741|Other|GIP-A|Infusion of GIP-A alone as study tool.
11236328|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
11236329|NCT03133741|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
11236330|NCT03133728||Pre-Intervention Group|The Investigators will visit each of the selected 3 clusters (i.e. 6 primary health clinics) to construct a retrospective cohort of high-risk HIV-infected women who entered the national PMTCT program and received the SOC between June 1, 2017 and May 31, 2018. Using existing data through the electronic health record information (SmartCare and LIMS), the investigators will gather individual-level retrospective data on high-risk Mother-Infant Pairs (MIPs) from PMTCT enrolment through the child's ART enrolment, initiation, and retention rate at 3 months.
11236331|NCT03133728||Post-Intervention Group|Study Research Assistants (RA) will review routine patient files and registers, augmented by existing electronic health record information, to identify a new cohort of high-risk Mother-Infant Pairs (MIPs) at each study site between the dates of June 1, 2019 and May 31, 2020. The outreach team will include, at a minimum, the study RA, a study peer, and an HIV counselor from the health facility, who will carry the Alere™ q HIV-1/2 Detect with them. When the outreach team contacts a high-risk MIP at community level, the team will approach the MIP for study screening, consent, and enrolment procedures. Study staff will ask the parent/guardian if the parent/guardian would like the IYC to be tested at their home, at a community health post, or other private space in the community. The IYC will be tested using both the Alere™ q HIV-1/2 Detect platform and a reflex DBS PCR test to evaluate performance of the POC platform in a mobile setting against the gold standard.
11236332|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
11236333|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
11236334|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
11236335|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
11236336|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
11236337|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
11236338|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
11236374|NCT03133442|No Intervention|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
11236439|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
11236339|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
11236340|NCT03133676|Experimental|KA34 Active Drug|KA34 active drug in the dose range of 50 - 400 ug per knee
11236341|NCT03133676|Placebo Comparator|Placebo|Placebo is the formulation for KA34.
11236342|NCT03133663|Active Comparator|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
11236343|NCT03133663|Experimental|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
11236344|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
11236345|NCT03133637||Ceftriaxone Arm|
11236346|NCT03133611|Other|Parkinson's disease|Speech assessment. Routine clinical assessment.
11236347|NCT03133611|Other|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
11236348|NCT03133611|Other|Healthy controls|Speech assessment. Routine clinical assessment.
11236349|NCT03133572|Experimental|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
11236350|NCT03133572|Active Comparator|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
11236351|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
11236352|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
11236353|NCT03133559||Cohort 3|Matched healthy volunteers
11236354|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
11236355|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
11236356|NCT03133533|Active Comparator|laparoscopic|laparoscopic inguinal hernia repair
11236357|NCT03133533|Active Comparator|robot-assisted|robot-assisted inguinal hernia repair
11236358|NCT03133520|No Intervention|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
11236359|NCT03133520|Experimental|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
11236360|NCT03133507|Experimental|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
11236361|NCT03133507|Experimental|Reassurance Condition|Children will receive empathic support from the experimenter.
11236362|NCT03133507|Experimental|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
11236363|NCT03133494|Active Comparator|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
11236364|NCT03133494|Placebo Comparator|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
11236365|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
11236366|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
11236367|NCT03133468|Experimental|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
11236368|NCT03133468|Placebo Comparator|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
11236369|NCT03133468|Experimental|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
11236370|NCT03133468|Experimental|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
11236371|NCT03133468|Experimental|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
11236372|NCT03133468|Placebo Comparator|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
11236373|NCT03133455|Other|Patient with Fibromyalgia|
11236375|NCT03133442|Experimental|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
11236376|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
11236377|NCT03133416|Active Comparator|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
11236378|NCT03133416|Active Comparator|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
11236379|NCT03133416|Active Comparator|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
11236380|NCT03133377|Experimental|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
11236381|NCT03133377|No Intervention|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
11236382|NCT03133364|Active Comparator|Sensory optimized meals|"Intervention group is receiving:
~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
11236383|NCT03133364|Placebo Comparator|Control|"Control group is receiving:
~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
11236384|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
11236385|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
11236386|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
11236387|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
11236388|NCT03133299|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
11236389|NCT03133299|Experimental|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
11236390|NCT03133273|No Intervention|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
11236391|NCT03133273|Experimental|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
11236392|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
11236393|NCT03133247|Experimental|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
11236394|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
11236395|NCT03133221|Experimental|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
11236396|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
11236397|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
11236398|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
11236399|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
11236400|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
11236401|NCT03133182||Polypharmacy|People taking >=5 unique prescription drugs in the 3 months prior to surgery
11236402|NCT03133182||No polypharmacy|People taking <5 unique prescription drugs in the 3 months prior to surgery
11236403|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.
~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level
~Diagnostic Test: blood sample
~Diagnostic Test: Tricuspid regurge velocity"
11236404|NCT03133169||No chelation|"group 2: cases without chelation
~Diagnostic Test: blood sample
~Diagnostic Test: Tricuspid regurge velocity"
11236405|NCT03133169||splenectomy|"group 3: cases with splenectomy
~Diagnostic Test: blood sample
~Diagnostic Test: Tricuspid regurge velocity"
11236406|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
11236407|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
11236408|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
11236409|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
11236410|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
11236411|NCT03133143|Experimental|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
11236412|NCT03133143|Active Comparator|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
11236413|NCT03133143|No Intervention|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
11236414|NCT03133130|Experimental|BMT101|cp-lasiRNA
11236415|NCT03133130|Placebo Comparator|Placebo|Normal Saline
11236416|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
11236417|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
11236418|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
11236419|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.
~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
11236420|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.
~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
11236421|NCT03133078|Experimental|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
11236422|NCT03133078|Experimental|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
11236423|NCT03133065|Active Comparator|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
11236424|NCT03133065|Active Comparator|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
11236425|NCT03133052|Active Comparator|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
11236426|NCT03133052|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
11236427|NCT03133039|Active Comparator|bioabsorbable screw|
11236428|NCT03133039|Active Comparator|titanium screw|
11236429|NCT03133026|Active Comparator|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
11236430|NCT03133026|Active Comparator|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
11236431|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
11236432|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
11236433|NCT03132987|Experimental|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
11236434|NCT03132974|Experimental|SGHH|Admission to Sogyeonghwalhyeol-tang granule
11236435|NCT03132974|Experimental|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
11236436|NCT03132974|Placebo Comparator|Placebo with manipulation therapy|
11236440|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
11236441|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
11236442|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
11236443|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
11236444|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
11236445|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
11236446|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
11236447|NCT03132922|Experimental|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
11236448|NCT03132896||Patients with moderate or severe ARDS|
11236449|NCT03132818||Patients undergoing AMP with oocyte donation|
11236450|NCT03132818||Couples supported in AMP with sperm donation|
11236451|NCT03132818||Couples supported in AMP intra torque|
11236452|NCT03132805|No Intervention|Control|Schools which receive no intervention
11236453|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
11236454|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
11236455|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
11236456|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
11236457|NCT03132766|Experimental|New Hope + Elders' Resilience + CM|Participants will receive case management plus the New Hope curriculum and subsequently the Elders' Resilience curriculum.
11236458|NCT03132766|Experimental|New Hope + CM|Participants will receive case management plus the New Hope curriculum.
11236459|NCT03132766|Experimental|Elders' Resilience + CM|Participants will receive case management plus the Elders' Resilience curriculum.
11236460|NCT03132766|Active Comparator|CM alone|Participants will receive case management only.
11236461|NCT03132753|Experimental|SUPPORT Group|Subjects enrolled in the intervention.
11236462|NCT03132753|No Intervention|Treatment as Usual|Subjects enrolled in standard services.
11236463|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
11236464|NCT03132714|Active Comparator|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
11236465|NCT03132714|Active Comparator|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
11236466|NCT03132714|Active Comparator|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
11236467|NCT03132714|Active Comparator|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
11236468|NCT03132714|Active Comparator|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
11236469|NCT03132714|Active Comparator|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
11236470|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
11236471|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
11236472|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
11236473|NCT03132675|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
11236474|NCT03132662|Active Comparator|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
11236475|NCT03132662|Experimental|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
11236476|NCT03132662|No Intervention|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
11236477|NCT03132636|Experimental|Group 1- metastatic BCC|Administration of cemiplimab in accordance with protocol dosing regimen
11236478|NCT03132636|Experimental|Group 2 - unresectable locally advanced BCC|Administration of cemiplimab in accordance with protocol dosing regimen
11236479|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
11236480|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
11236481|NCT03132610|Active Comparator|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
11236482|NCT03132610|Placebo Comparator|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
11236483|NCT03132597|Experimental|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
11236484|NCT03132597|Experimental|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
11236485|NCT03132597|No Intervention|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
11236486|NCT03132584|Experimental|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:
~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
~Cyclophosphamide
~Alemtuzumab"
11236487|NCT03132571|Experimental|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
11236488|NCT03132571|Placebo Comparator|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
11236489|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
11236490|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
11236491|NCT03132545||PCOS|
11236492|NCT03132545||controls|
11236493|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 60 gray (Gy)|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 60 Gy in 2 Gy daily fractions
11236494|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 66 Gy|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 66 Gy in 2 Gy daily fractions
11236495|NCT03132532|Active Comparator|Chemotherapy and Proton Beam Therapy 72 Gy|Concurrent and consolidative chemotherapy carboplatin/paclitaxel & Proton Beam Therapy to 72 Gy in 2 Gy daily fractions
11236496|NCT03132519|Experimental|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
11236497|NCT03132519|Experimental|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
11236498|NCT03132519|Experimental|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
11236499|NCT03132519|Experimental|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
11236500|NCT03132519|Active Comparator|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
11236501|NCT03132519|Active Comparator|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
11236502|NCT03132506||paper-based patient-reported-outcomes|
11236503|NCT03132506||on web-based patient-reported-outcomes|
11236504|NCT03132480|Experimental|hypovolemia|
11236505|NCT03132467|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
11236506|NCT03132454|Experimental|Arm I (palbociclib, sorafenib)|Patients receive palbociclib PO QD on days 1-28. Patients also receive sorafenib PO QD on days 1-28 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11236507|NCT03132454|Experimental|Arm II (palbociclib, decitabine)|Patients receive palbociclib as in Arm I. Beginning cycle 2, patients receive palbociclib PO QC on days 1-7 and decitabine IV QD over 1 hour on days 8-17 of cycle 2 and days 8-12 of cycles 3-8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11236508|NCT03132454|Experimental|Arm III (palbociclib, dexamethasone)|Patients receive palbociclib as in Arm I. Patients also receive dexamethasone PO QD or IV over 15-30 minutes on days 1-4 and 15-18 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11236509|NCT03132441|Experimental|Cardiac Rehabilitation|"Strength Training for Frailty:
~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
11236510|NCT03132428||P Neonates|Premature (P) neonates [at least 27 weeks but less than 34 weeks of gestational age]
11236511|NCT03132428||TNT Neonates|Term-Near-Term (TNT) neonates at least 34 weeks of gestational age
11236512|NCT03132415|Experimental|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
11236513|NCT03132415|Active Comparator|Non-tailored HIV Test Locator|Participants randomized to the control condition will be directed to a website that includes information on the AIDSVU.org testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
11236514|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
11236515|NCT03132376|Experimental|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.
~The drinks consisted of the following:
~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
11236516|NCT03132337||Stem Cell Transplant|Serial Blood Draws
11236517|NCT03132324|Experimental|INCB059872 0.5 mg|INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
11236518|NCT03132324|Experimental|INCB059872 1 mg|INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
11236519|NCT03132324|Experimental|INCB059872 2 mg|INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
11236520|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).
~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
11236521|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.
~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
11236522|NCT03132298|Experimental|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
11236523|NCT03132298|Active Comparator|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
11236524|NCT03132285|Other|PrePex Day 0 foreskin removal|Day 0 foreskin removal
11236525|NCT03132272|Experimental|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
11236526|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
11236527|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
11236528|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.
~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
11236529|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.
~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
11236530|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
11236531|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
11236532|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
11236533|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
11236534|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
11236535|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
11236536|NCT03132194|Experimental|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)
~Topical, twice daily on the face for 84 days."
11236537|NCT03132194|Placebo Comparator|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)
~Topical, twice daily on the face for 84 days."
11236538|NCT03132194|Active Comparator|Aczone|"dapsone 7.5
~Topical, twice daily on the face for 84 days."
11236539|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
11236540|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
11236541|NCT03132168|Other|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
11236542|NCT03132155|Experimental|AMG 337|AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
11236543|NCT03132142|Experimental|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
11236544|NCT03132142|Experimental|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
11236545|NCT03132142|Experimental|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
11236546|NCT03132142|Placebo Comparator|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
11236547|NCT03132129||Type 2 diabetics|
11236548|NCT03132129||Healthy controls|
11236549|NCT03132116|Experimental|Gentamicin|intra-nodal injection of gentamicin
11236550|NCT03132116|Placebo Comparator|Placebo|intra-nodal injection of placebo
11236551|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
11236552|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
11236553|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
11236554|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
11236555|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
11236556|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
11236557|NCT03132051|Experimental|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
11236558|NCT03132038|Experimental|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3 mg/kg to be administered as a 60 minute IV infusion
11236559|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
11236560|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
11236561|NCT03132012|Experimental|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
11236562|NCT03132012|Active Comparator|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
11236563|NCT03131999|Experimental|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
11236564|NCT03131999|Placebo Comparator|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
11236565|NCT03131973|Experimental|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
11236566|NCT03131973|Experimental|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
11236567|NCT03131960|Experimental|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
11236568|NCT03131960|Active Comparator|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
11236569|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
11236570|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
11236571|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:
~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12
~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.
~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
11236572|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
11236573|NCT03131908|Experimental|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.
~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
11236574|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
11236609|NCT03131687|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
11236575|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
11236576|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
11236577|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
11236578|NCT03131882|Experimental|Hyaluronic acid|Hyaluronic acid
11236579|NCT03131882|Active Comparator|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
11236580|NCT03131856|Experimental|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
11236581|NCT03131856|No Intervention|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
11236582|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
11236583|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
11236584|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
11236585|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
11236586|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
11236587|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
11236588|NCT03131817|Experimental|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
11236589|NCT03131804|Experimental|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
11236590|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
11236591|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
11236592|NCT03131778|Active Comparator|Open Liver Resection|Conventional open liver resection trough subcostal incision
11236593|NCT03131778|Experimental|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
11236594|NCT03131765|Experimental|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.
~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
11236595|NCT03131752|Experimental|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.
~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
11236596|NCT03131752|No Intervention|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.
~Patients will be not receive intervention."
11236597|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
11236598|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
11236599|NCT03131726|Experimental|Simvastatin|simvastatin 40 mg daily for 6 months
11236600|NCT03131726|No Intervention|No treatment|No treatment
11236601|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
11236602|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
11236603|NCT03131700|Experimental|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
11236604|NCT03131700|Active Comparator|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
11236605|NCT03131687|Placebo Comparator|Placebo|Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
11236606|NCT03131687|Experimental|1 mg Tirzepatide|1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
11236607|NCT03131687|Experimental|5 mg Tirzepatide|5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
11236608|NCT03131687|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
11236610|NCT03131687|Active Comparator|1.5 mg Dulaglutide|1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.
11236611|NCT03131674|Experimental|Direct treatment|
11236612|NCT03131674|Experimental|Delayed treatment|
11236613|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
11236614|NCT03131648|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:
~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
11236615|NCT03131648|Placebo Comparator|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:
~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
11236616|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
11236617|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:
~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.
~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
11236618|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:
~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
11236619|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52:
~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
11236620|NCT03131648|Experimental|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:
~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.
~OR
~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.
~*TCS = topical corticosteroids."
11236621|NCT03131648|Experimental|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 [Short term extension (Japan only)] :
~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
11236622|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
11236623|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
11236624|NCT03131622|Experimental|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
11236625|NCT03131622|No Intervention|Control|
11236626|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
11236627|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
11236628|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
11236629|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
11236630|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
11236631|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
11236632|NCT03131583|Experimental|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.
11236633|NCT03131570|Experimental|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
11236634|NCT03131570|Placebo Comparator|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
11236635|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
11236636|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
11236637|NCT03131544|Experimental|FLA for BPH Active Treatment|
11236638|NCT03131531||Hodgkin lymphoma|
11236639|NCT03131531||Non-Hodgkin lymphoma|
11236640|NCT03131531||Myeloma|
11236641|NCT03131518|Other|E-bicycle|Access to an e-bicycle will be provided.
11236642|NCT03131518|Other|Longtail bicycle|Access to a longtail bicycle will be provided.
11236643|NCT03131518|Other|Traditional bicycle|Access to a traditional bicycle will be provided.
11236644|NCT03131479|Experimental|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
11236645|NCT03131479|Experimental|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
11236646|NCT03131479|Experimental|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
11236647|NCT03131479|Experimental|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
11236648|NCT03131479|Experimental|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
11236649|NCT03131466|Experimental|PRF Group|This group will undergo 42°C high-voltage pulsed radiofrequency treatment.
11236650|NCT03131466|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment with steroid and local anesthesia.
11236651|NCT03131453|Experimental|Arm#1: CNP520 50 mg|CNP520 50 mg capsule given p.o.
11236652|NCT03131453|Experimental|Arm#2: CNP520 15 mg|CNP520 15 mg capsule given p.o.
11236653|NCT03131453|Placebo Comparator|Arm#3: Placebo|Placebo to CNP520 capsule given p.o.
11236654|NCT03131440|Experimental|Experimental Condition #1|core, support calls
11236655|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
11236656|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
11236657|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
11236658|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
11236659|NCT03131440|Experimental|Experimental Condition #6|core, app+
11236660|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
11236661|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
11236662|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
11236663|NCT03131440|Experimental|Experimental Condition #10|core, buddy
11236664|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
11236665|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
11236666|NCT03131440|Experimental|Experimental Condition #13|core, online gym
11236667|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
11236668|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
11236669|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
11236670|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
11236671|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
11236672|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
11236673|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
11236674|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
11236675|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
11236676|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
11236677|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
11236678|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
11236679|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
11236680|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
11236681|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
11236682|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
11236683|NCT03131440|Experimental|Experimental Condition #30|core
11236684|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
11236685|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
11236686|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
11236687|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
11236688|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
11236689|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
11236690|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
11236691|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.
~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
11236715|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
11236692|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.
~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
11236693|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.
~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
11236694|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.
~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
11236695|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
11236696|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
11236697|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
11236698|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
11236699|NCT03131336|Experimental|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
11236700|NCT03131336|Placebo Comparator|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
11236701|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
11236702|NCT03131284|No Intervention|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
11236703|NCT03131284|Experimental|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
11236704|NCT03131271|Experimental|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
11236705|NCT03131271|No Intervention|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
11236706|NCT03131258|Other|Donor Nephrectomy|Donor Nephrectomy
11236707|NCT03131219|Experimental|Ravulizumab|
11236708|NCT03131206|Experimental|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.
~Alectinib
~Oral, BID
~A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
11236709|NCT03131206|Experimental|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.
~Alectinib
~Oral, BID, participants will receive the RP2D identified during Phase 1.
~Each treatment cycle will be defined as 28 consecutive days."
11236710|NCT03131206|Experimental|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.
~Alectinib
~Oral, BID, participants will receive the RP2D identified during Phase 1.
~Each treatment cycle will be defined as 28 consecutive days."
11236711|NCT03131206|Experimental|Cohort C|"Participants with RET-rearranged thyroid cancer
~Alectinib
~Oral, BID, participants will receive the RP2D identified during Phase 1.
~Each treatment cycle will be defined as 28 consecutive days."
11236712|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
11236713|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
11236714|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
11236825|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
11236716|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
11236717|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
11236718|NCT03131180|Experimental|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
11236719|NCT03131180|No Intervention|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
11236720|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
11236721|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
11236722|NCT03131154|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
11236723|NCT03131154|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Solution|
11236724|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
11236725|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
11236726|NCT03131128|Experimental|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
11236727|NCT03131128|Active Comparator|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
11236728|NCT03131115|Active Comparator|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
11236729|NCT03131115|Active Comparator|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
11236730|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
11236731|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
11236732|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites >500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
11236733|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
11236734|NCT03131050|Experimental|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
11236735|NCT03131050|Experimental|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
11236736|NCT03131050|Placebo Comparator|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
11236737|NCT03131037|Experimental|Study Arm|AdV-tk (aglatimagene besadenovec) + valacyclovir
11236738|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
11236739|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
11236740|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
11236741|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
11236742|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
11236743|NCT03130998|Active Comparator|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
11237426|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
11236744|NCT03130998|Experimental|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a remote knowledge broker (rKB) communicating via interactive technology. The rKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The rKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
11236745|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
11236746|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
11236747|NCT03130959|Experimental|Module A|nivolumab
11236748|NCT03130959|Experimental|Module B|nivolumab plus ipilimumab
11236749|NCT03130946|Experimental|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
11236750|NCT03130946|Active Comparator|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
11236751|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
11236752|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
11236753|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
11236754|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
11236755|NCT03130920|No Intervention|Control|
11236756|NCT03130920|Active Comparator|Remote ischemic preconditioning|
11236757|NCT03130920|Active Comparator|Local ischemic preconditioning|
11236758|NCT03130907|Active Comparator|Stent|
11236759|NCT03130907|Experimental|No stent|
11236760|NCT03130894||Healthy control|A FPG concentration < 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration < 7.8 mmol/l was considered normal glucose tolerance.
11236761|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
11236762|NCT03130881|Experimental|PLB1003|ALK-positive (ALK+) advanced NSCLC
11236763|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
11236764|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
11236765|NCT03130842|Active Comparator|Sublingual alprazolam|
11236766|NCT03130842|Active Comparator|Oral midazolam|
11236767|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
11236768|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
11236769|NCT03130816|Experimental|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.
~C. Oxygen saturation will be monitored during therapy."
11236770|NCT03130803|No Intervention|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
11236771|NCT03130803|Experimental|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
11236772|NCT03130790|Experimental|Varlititib+mFOLFOX6|
11236773|NCT03130790|Placebo Comparator|Placebo+mFOLFOX6|
11236774|NCT03130777|Experimental|SAPIEN 3 THV|To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System.
11236775|NCT03130764|Experimental|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
11236776|NCT03130751|Experimental|Mobile application|
11236777|NCT03130738|Active Comparator|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
11236778|NCT03130738|Active Comparator|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
11236779|NCT03130738|Placebo Comparator|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
11236780|NCT03130725|Experimental|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
11236781|NCT03130725|Active Comparator|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
11236782|NCT03130712|Experimental|GPC3-CART cells|
11236783|NCT03130699|Experimental|Dulce Digital|The first of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives one-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
11236784|NCT03130699|Experimental|Dulce Digital-Me (Automated Delivery)|The second of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
11236785|NCT03130699|Experimental|Dulce Digital-Me (Medical Assistant)|The third of the three arms of the parallel design: The group of participants randomly assigned to this arm of the study receives educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
11236786|NCT03130673||hip fracture|fracture of proximal femur
11236787|NCT03130660|Experimental|Short Axis Ultrasonography|one person does both ultrasound and line insertion
11236788|NCT03130660|Experimental|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
11236789|NCT03130647|Experimental|Focused ultrasound|Repeated measures sham control
11236790|NCT03130634|Experimental|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
11236791|NCT03130634|No Intervention|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
11236792|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
11236793|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
11236794|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.
~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
11236795|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
11236796|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
11236797|NCT03130582||Disease status at mobilization PR|
11236798|NCT03130582||Disease status at mobilization PD|
11236799|NCT03130569|No Intervention|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
11236800|NCT03130569|Experimental|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
11236801|NCT03130556|Experimental|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
11236802|NCT03130556|Experimental|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
11236803|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
11236804|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
11236805|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
11236806|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
11236807|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
11236808|NCT03130517|Other|Control group|Control group will recieve phototherapy only
11236809|NCT03130504|Active Comparator|17α hydroxy progesterone caproate group|
11236810|NCT03130504|No Intervention|No intervention group|
11236811|NCT03130491|Other|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
11236812|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
11236813|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
11236814|NCT03130452|Active Comparator|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
11236815|NCT03130452|Experimental|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
11236816|NCT03130452|Experimental|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
11236817|NCT03130439|Experimental|Abemaciclib|-Abemaciclib will be administered orally, twice daily on days 1 to 28
11236818|NCT03130426|Experimental|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
11236819|NCT03130426|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
11236820|NCT03130413|Experimental|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
11236821|NCT03130413|Active Comparator|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
11236822|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
11236823|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
11236824|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
11236826|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
11236827|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
11236828|NCT03130374|Experimental|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
11236829|NCT03130374|No Intervention|Control group|Patients treated according to current clinical protocols
11236830|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
11236831|NCT03130348|Experimental|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11236832|NCT03130335|Experimental|Bone Marrow Aspirate (BMA) Injection|
11236833|NCT03130322|Experimental|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
11236834|NCT03130322|Experimental|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
11236835|NCT03130322|Experimental|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
11236836|NCT03130322|Experimental|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
11236837|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
11236838|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
11236839|NCT03130270|Experimental|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
11236840|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
11236841|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
11236842|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
11236843|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
11236844|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
11236845|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
11236846|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
11236847|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
11236848|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
11236849|NCT03130179|Experimental|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
11236850|NCT03130179|Active Comparator|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
11236851|NCT03130166|Experimental|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
11236852|NCT03130166|Active Comparator|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
11236853|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
11236854|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
11236855|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
11236856|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
11236857|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
11236858|NCT03130127|Experimental|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
11237427|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
11236859|NCT03130127|Active Comparator|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
11236860|NCT03130114|Placebo Comparator|Control|Placebo mixture, 0.25 ml / kg / day
11236861|NCT03130114|Experimental|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
11236862|NCT03130101|Other|80% basal insulin reduction|
11236863|NCT03130101|Other|50% basal insulin reduction|
11236864|NCT03130101|Other|100% basal insulin reduction|
11236865|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
11236866|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
11236867|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
11236868|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
11236869|NCT03130036|Experimental|No risk of disease|Subjects with no identifiable risk of Alzheimer's Disease
11236870|NCT03130036|Experimental|Asymptomatic|Asymptomatic subjects with increased risk of Alzheimer's disease
11236871|NCT03130036|Experimental|Early Alzheimer's or Mild Cognitive Impairment|Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)
11236872|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
11236873|NCT03130010|Placebo Comparator|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
11236874|NCT03130010|Active Comparator|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
11236875|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
11236876|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
11236877|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
11236878|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
11236879|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
11236880|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
11236881|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
11236882|NCT03129932|Active Comparator|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
11236883|NCT03129932|Placebo Comparator|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
11236884|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
11236885|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
11236886|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
11236887|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
11236888|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
11236889|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
11236890|NCT03129880|Placebo Comparator|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
11236891|NCT03129880|Active Comparator|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
11236892|NCT03129854|Experimental|experimental group|Prostate cryotherapy plus ADT
11236893|NCT03129854|No Intervention|control group|standard of care ADT continually
11236894|NCT03129841|Experimental|early dinner+Diet|
11236895|NCT03129841|Experimental|late dinner+Diet|
11236896|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
11236897|NCT03129776|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
11236898|NCT03129776|Active Comparator|18F-FDG|Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.
11236899|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
11236900|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
11236901|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
11236902|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
11236903|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
11236904|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
11236905|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
11236906|NCT03129711|Experimental|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
11236907|NCT03129711|Active Comparator|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
11236908|NCT03129698|Other|Formerly Arm Label|Apatinib 250mg daily
11236909|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
11236910|NCT03129659|Experimental|CT-group|Coronary CT angiography
11236911|NCT03129646|Experimental|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
11236912|NCT03129646|Experimental|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
11236913|NCT03129646|Active Comparator|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
11236914|NCT03129633|Experimental|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
11236915|NCT03129633|No Intervention|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
11236916|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
11236917|NCT03129607||Observation group|Patients without POPF will be included into observation group.
11236918|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
11236919|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
11236920|NCT03129568|Experimental|CDC infusion|CDCs infusion by coronary intervention.
11236921|NCT03129568|No Intervention|Observation (Control group)|Coronary angiogram without placebo infusion.
11236922|NCT03129555|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236923|NCT03129555|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236924|NCT03129555|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236925|NCT03129555|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236926|NCT03129542|Active Comparator|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
11236927|NCT03129542|Placebo Comparator|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
11236928|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
11236929|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
11236930|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
11236931|NCT03129490|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236965|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
11236932|NCT03129490|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236933|NCT03129490|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236934|NCT03129490|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
11236935|NCT03129477|Experimental|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.
~• Education and adaptation of the patient to NIV."
11236936|NCT03129477|No Intervention|2- conventional monitoring group|"Conventional monitoring group
~• Education and adaptation of the patient to NIV."
11236937|NCT03129464|Experimental|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
11236938|NCT03129464|No Intervention|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
11236939|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
11236940|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
11236941|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
11236942|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
11236943|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
11236944|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
11236945|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
11236946|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
11236947|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
11236948|NCT03129425|Experimental|Intervention group|Sessions in groups
11236949|NCT03129425|Sham Comparator|Control group|Sessions in groups
11236950|NCT03129412|Experimental|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
11236951|NCT03129399|Experimental|King Vision video laryngoscope|
11236952|NCT03129399|Active Comparator|McGrath MAC video laryngoscope|
11236953|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)
~Maximum 3 application by the technician in charge of the study.
~Apply between 15 to 20 sec on hand and 40 sec on feet."
11236954|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):
~Maximum 3 application by the technician in charge of the study.
~Apply between 15 to 20 sec on hand and 40 sec on feet."
11236955|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):
~Maximum 3 application by the technician in charge of the study.
~Apply between 15 to 20 sec on hand and 40 sec on feet."
11236956|NCT03129360|Experimental|Levetiracetam 185 mg|A single dose of 185mg of levetiracetam be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
11236957|NCT03129360|Experimental|Levetiracetam 500mg|A single dose of 500mg of levetiracetam will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
11236958|NCT03129360|Placebo Comparator|Placebo|A single dose of placebo will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.
11236959|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
11236960|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
11236961|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
11236962|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
11236963|NCT03129334|Experimental|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
11236964|NCT03129334|No Intervention|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
11236966|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
11236967|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
11236968|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
11236969|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
11236970|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
11236971|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
11236972|NCT03129282|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
11236973|NCT03129282|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
11236974|NCT03129269|Experimental|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.
~Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.
~In addition, at 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check.
~PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance
~A blood sample for biobank will be taken at visit 2 and at the end of the study (visit 5)."
11236975|NCT03129256|Experimental|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
11236976|NCT03129230|Experimental|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
11236977|NCT03129217||Patients weaning from mechanical ventilation|
11236978|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
11236979|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
11236980|NCT03129191|Active Comparator|AB arm|"Sequence:
~Aided with non-invasive bone conduction hearing aid A
~Aided with non-invasive bone conduction hearing aid B"
11236981|NCT03129191|Active Comparator|BA arm|"Sequence:
~Aided with non-invasive bone conduction hearing aid B
~Aided with non-invasive bone conduction hearing aid A"
11236982|NCT03129178|Experimental|Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
11236983|NCT03129178|Experimental|Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
11236984|NCT03129165|Experimental|Screening and prevention of CVD|
11236985|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
11236986|NCT03129139|Experimental|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
11236987|NCT03129139|Experimental|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
11236988|NCT03129126|Experimental|LP-10 2mg|LP-10 (intravesical tacrolimus), 2mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
11236989|NCT03129126|Experimental|LP-10 4mg|LP-10 (intravesical tacrolimus), 4mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
11236990|NCT03129126|Experimental|LP-10 8mg|LP-10 (intravesical tacrolimus), 8mg reconstituted in sterile water for injection, intravesical instillations, up to two instillations, instillations will occur greater than 3 days but less than 7 days apart as needed.
11236991|NCT03129113|Experimental|maraviroc (Arm A)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).
11236992|NCT03129113|Experimental|metformin (Arm B)|metformin 500mg BID p/o.
11236993|NCT03129113|Experimental|maraviroc + metformin (Arm C)|maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.
11236994|NCT03129113|No Intervention|no adjunctive therapy (Arm D)|no adjunctive therapy
11236995|NCT03129100|Experimental|Dose Schedule 1 Ixekizumab|Ixekizumab given subcutaneously (SC).
11236996|NCT03129100|Experimental|Dose Schedule 2 Ixekizumab|Ixekizumab given SC.
11236997|NCT03129100|Placebo Comparator|Placebo|Placebo given SC.
11236998|NCT03129087|Experimental|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
11237068|NCT03128606|Experimental|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
11236999|NCT03129087|Experimental|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
11237000|NCT03129074|Experimental|Varlitinib given in combination with capecitabine|"PO varlitinib 300 mg BID
~PO capecitabine 1000 mg/m2 BID"
11237001|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
11237002|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
11237003|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
11237004|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
11237005|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
11237006|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
11237007|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
11237008|NCT03129022|Active Comparator|Successful epidural anaesthesia|It is defined as VAS score <5, 30 min after a loading dose, given after the last attempt.
11237009|NCT03129022|Active Comparator|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
11237010|NCT03129009|Active Comparator|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
11237011|NCT03129009|Experimental|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
11237012|NCT03128996|Experimental|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
11237013|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
11237014|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
11237015|NCT03128957|Experimental|Varying cerebral oxygenation with varying ventilation|Compare oxygenation under conditions of varying ventilation strategy. Low end tidal CO2/Low inspired oxygen vs High end tidal CO2/high inspired oxygen
11237016|NCT03128931|Experimental|Test Group|The subjects will be enrolled in the test group and will receive the Pediatric SedLine forehead EEG sensor.
11237017|NCT03128905|Active Comparator|Colchicine|Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
11237018|NCT03128905|Experimental|Prednisone (corticoids)|Patients assigned to this group will receive Prednisone : Cortancyl 20mg.
11237019|NCT03128892|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Noninvasive Oxygen Reserve Index - RD Lite Sensors
11237020|NCT03128879|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO QD and ibrutinib PO QD. Courses repeat every 4 weeks for up to 24 courses in the absence of disease progression or unaccepted toxicity.
11237021|NCT03128866|Experimental|Arm I (tranexamic acid)|Patients receive tranexamic acid IV over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity.
11237022|NCT03128866|Experimental|Arm II (no tranexamic acid)|Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity.
11237023|NCT03128853|Experimental|Test subjects|Each subject receives the Rad-67 and DCI Mini sensor that will measure hemoglobin repeatedly in order to compare those measurements against a blood sample reference.
11237024|NCT03128827|Experimental|Test Subjects|All test subjects were pediatric patients following general anesthesia who received the RAM sensor which measures respiration rate.
11237025|NCT03128814||Elite (pre)adolescent tennis players|
11237026|NCT03128814||Age- and gender-matched controls|
11237027|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
11237028|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
11237029|NCT03128788|Active Comparator|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
11237030|NCT03128788|Active Comparator|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
11237031|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
11237069|NCT03128606|Experimental|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
11237428|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
11237032|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
11237033|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
11237034|NCT03128775|No Intervention|Control|without any activity
11237035|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.
~Intervention: ILC2 levels in blood"
11237036|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.
~Intervention: ILC2 levels in blood"
11237037|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.
~These patients will be also attending to their regular psychiatric visits for medication control."
11237038|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
11237039|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
11237040|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
11237041|NCT03128723|Experimental|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
11237042|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
11237043|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
11237044|NCT03128697|Experimental|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
11237045|NCT03128697|Experimental|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
11237046|NCT03128697|Active Comparator|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
11237047|NCT03128697|Active Comparator|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
11237048|NCT03128684|Experimental|Small Green Lentil Muffin|
11237049|NCT03128684|Experimental|Split Red Lentil Muffin|
11237050|NCT03128684|Placebo Comparator|Wheat Muffin|
11237051|NCT03128684|Experimental|Small Green Lentil Chili|
11237052|NCT03128684|Experimental|Split Red Lentil Chili|
11237053|NCT03128684|Placebo Comparator|Rice Chili|
11237054|NCT03128671|Experimental|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
11237055|NCT03128671|No Intervention|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
11237056|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
11237057|NCT03128645||Group 1|Standard method group
11237058|NCT03128645||Group 2|Abdominal corset group
11237059|NCT03128619|Experimental|Arm A (copanlisib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression, or unacceptable toxicity.
11237060|NCT03128619|Experimental|Arm B (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11237061|NCT03128619|Experimental|Arm C (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive palbociclib PO QD for days 1-14 of course 1 and letrozole PO continuously on days 1-14. Patients then undergo biopsy. Patients then receive copanlisib IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment with copanlisib (MTD) and letrozole repeats every 28 days for up to 3.5 courses in the absence of disease progression or unacceptable toxicity.
11237062|NCT03128619|Experimental|Phase Ib (copanlisib, palbociclib, letrozole)|PHASE Ib: Patients with metastatic breast cancer receive copanlisib IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11237063|NCT03128606|Experimental|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
11237064|NCT03128606|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension.
11237065|NCT03128606|Experimental|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
11237066|NCT03128606|Experimental|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
11237067|NCT03128606|Experimental|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
11237429|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
11237070|NCT03128606|Experimental|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
11237071|NCT03128606|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension.
11237072|NCT03128606|Experimental|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
11237073|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
11237074|NCT03128606|Experimental|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
11237075|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
11237076|NCT03128593|Experimental|Experimental: JR-141|
11237077|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
11237078|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
11237079|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
11237080|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
11237081|NCT03128554|Experimental|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
11237082|NCT03128554|No Intervention|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
11237083|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
11237084|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
11237085|NCT03128528|Placebo Comparator|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
11237086|NCT03128528|Active Comparator|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
11237087|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
11237088|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
11237089|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
11237090|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
11237091|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
11237092|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
11237093|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
11237094|NCT03128476|Active Comparator|1 bottle|
11237095|NCT03128476|Active Comparator|2 bottles|
11237096|NCT03128476|Placebo Comparator|Placebo|
11237097|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
11237098|NCT03128463||effective group|visual improvement ≥5 letters and <15 letters in EDTRS table after intravitreal injection of conbercept
11237099|NCT03128463||invalid group|visual improvement <5 letters and visual reduction<5 letters in EDTRS table after intravitreal injection of Combercept
11237100|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
11237101|NCT03128450|Experimental|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.
~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
11237102|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
11237103|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.
~Assessments will take place at baseline, week 2, week 4, and week 8."
11237104|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
11237105|NCT03128411|Experimental|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
11237155|NCT03128073|Experimental|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
11237197|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
11237106|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
11237107|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
11237108|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
11237109|NCT03128359|Experimental|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.
~Patients undergo PBSC HCT on day 0.
~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
11237110|NCT03128359|Experimental|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.
~Patients undergo PBSC HCT on day 0.
~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
11237111|NCT03128359|Experimental|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.
~Patients undergo PBSC HCT on day 0.
~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
11237112|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
11237113|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
11237114|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
11237115|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
11237116|NCT03128320|Experimental|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
11237117|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
11237118|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
11237119|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
11237120|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
11237121|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
11237122|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
11237123|NCT03128268|Experimental|All Enrollees|"Intervention: Diagnostic test
~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
11237124|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
11237125|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
11237126|NCT03128242|Experimental|oxytocin group|oxytocin treatment
11237127|NCT03128242|Placebo Comparator|placebo group|placebo treatment
11237128|NCT03128216|Active Comparator|Blind Local Anesthetic Infiltration|
11237129|NCT03128216|Active Comparator|Transversals Fascia Block|
11237130|NCT03128216|Active Comparator|Spinal Anesthesia|
11237131|NCT03128203|Experimental|Oxytocin|
11237132|NCT03128203|Placebo Comparator|Placebo|
11237133|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
11237134|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
11237135|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
11237136|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
11237137|NCT03128164|Experimental|HMPL-689|HMPL-689, oral, BID, doses should be taken at ~12-hour intervals (eg, at ~8 AM and at ~8 PM)
11237138|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
11237139|NCT03128151||Control group|Treated according to usual clinical practice
11237140|NCT03128138|Experimental|25 mg SPH3127 tablet-Dose 1|"6 Volunteers, Single dose of SPH3127 tablet, 25mg, po. 1 tablet.
~2 Volunteers, Single dose of Placebo tablet, 25mg, po. 1 tablet."
11237141|NCT03128138|Experimental|50 mg SPH3127 tablet-Dose 2|"6 Volunteers, Single dose of SPH3127 tablet, 50mg, po. 1 tablet.
~2 Volunteers, Single dose of Placebo tablet, 50mg, po. 1 tablet."
11237142|NCT03128138|Experimental|100 mg SPH3127 tablet-Dose 3|"6 Volunteers, Single dose of SPH3127 tablet, 100mg, po. 1 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 1 tablet."
11237143|NCT03128138|Experimental|200 mg SPH3127 tablet-Dose 4|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 2 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 2 tablet."
11237144|NCT03128138|Experimental|400 mg SPH3127 tablet-Dose 5|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 4 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 4 tablet."
11237145|NCT03128138|Experimental|800 mg SPH3127 tablet-Dose 6|"6 Volunteers, Single dose of SPH3127 tablet,100mg, po. 8 tablet.
~2 Volunteers, Single dose of Placebo tablet, 100mg, po. 8 tablet."
11237146|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
11237147|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
11237148|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
11237149|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
11237150|NCT03128099|Experimental|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
11237151|NCT03128099|Experimental|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
11237152|NCT03128099|No Intervention|Healthy Control Participants|23 healthy control participants were recruited and consented to yield baseline comparison data. These participants did not undergo VR training. Only baseline comparison data were collected.
11237153|NCT03128086|Experimental|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
11237154|NCT03128086|No Intervention|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
11237156|NCT03128060|Experimental|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
11237157|NCT03128060|Active Comparator|Enhanced Usual Care|Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.
11237158|NCT03128047|Experimental|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.
~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
11237159|NCT03128034|Experimental|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27, or every 8 hours on day 0 and then reduced to every 12 hours on days 30-40. Patients with HLA-matched unrelated donors receive sirolimus PO QD on days -3 to 150 and then tapered to day 180.
11237160|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
11237161|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.
~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
11237162|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.
~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
11237163|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
11237164|NCT03128008|Experimental|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
11237165|NCT03127995|Experimental|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.
~If the patient is candidate for a boost it will be provided as follows:
~sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions
~or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
11237166|NCT03127995|Other|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.
~If the patient is candidate for a boost it will be provided as follows:
~sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions
~or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
11237167|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
11237168|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
11237169|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
11237170|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
11237171|NCT03127956|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
11237172|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.
~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
11237173|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.
~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
11237196|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
11237234|NCT03127397|No Intervention|Standard of Care|
11237174|NCT03127930|Experimental|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
11237175|NCT03127930|No Intervention|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
11237176|NCT03127917|Experimental|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
11237177|NCT03127917|Experimental|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
11237178|NCT03127904|Experimental|Vein Fitness|"Lymphomiokinetic exercises will be performed during a 1 hour period, with the patients in a supine position, legs elevated and properly positioned on a carpet; the knees will be mildly flexed to a comfortable point. The patients will put feet on the pedals of ankle extension/flexion device. The frequency will be around 15 to 20 cycles/minute, while the amplitude will be individually adjusted according to the range of movement of each patient. During the exercises, study personnel will manually drain the lower members.
~Compressive therapy will be applied as described in the control group arm.
~Care of the wound will be delivered as described in the control group arm."
11237179|NCT03127904|Active Comparator|Control group|"Compressive therapy will be applied to both groups by properly trained personnel. Each layer of the compressive boot will have a 50% overlap, from the base to of the fingers to 3 cm bellow the popliteal fossa. The interface pressure used will be of at least 50mmHg in supine position.
~Wound care will be delivered to every individual in both groups, 1 or 2 times each week by a nurse certified in wound management, following the principles of maintenance of a moisturized surface between the wound and its cover. The nurse will also carry out mechanical wound debriding and biofilm removal."
11237180|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
11237181|NCT03127891|Placebo Comparator|control group|no intervention
11237182|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
11237183|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
11237184|NCT03127852|Experimental|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
11237185|NCT03127852|No Intervention|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
11237186|NCT03127839|Active Comparator|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
11237187|NCT03127839|Active Comparator|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
11237188|NCT03127839|Active Comparator|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.
~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
11237189|NCT03127839|Active Comparator|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.
~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
11237190|NCT03127826|Active Comparator|Usual Care|"Managing Low Back Pain pamphlet from DoD/VA
~No specific guidance regarding physical therapy (PT) or other referrals, thus decision to refer or not will be made by the primary care manager (PCM) according to their preference"
11237191|NCT03127826|Experimental|Risk Stratified Care|"Managing Low Back Pain pamphlet from DoD/VA
~Self-management education and tools
~2-item spinal manipulation screening/delivery if indicated
~Low Risk:
~Home Exercise Program as indicated
~No referral for ongoing physical therapy
~Medium Risk and High Risk
~Referral to physical therapy for ongoing care at physical therapists discretion
~Managed by a psychologically informed physical therapy trained physical therapist"
11237192|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
11237193|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
11237194|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
11237195|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
11237198|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
11237199|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
11237200|NCT03127735|Experimental|BAY1436032|"Dose escalation:
~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.
~Dose expansion:
~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
11237201|NCT03127722|Experimental|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
11237202|NCT03127722|Active Comparator|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
11237203|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
11237204|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
11237205|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
11237206|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
11237207|NCT03127683|Experimental|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.
~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
11237208|NCT03127670|Experimental|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
11237209|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
11237210|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
11237211|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
11237212|NCT03127644|Placebo Comparator|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
11237213|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label antiplatelet agents, statins, ACE-I, and other antihypertensive medications where appropriate.
11237214|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
11237215|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
11237216|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
11237217|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
11237218|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
11237219|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
11237220|NCT03127553|No Intervention|A - control|Free diet with standard bread
11237221|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
11237222|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
11237223|NCT03127514|Placebo Comparator|Placebo|Placebo administered twice daily p.o. for 24 weeks
11237224|NCT03127514|Experimental|AMX0035|AMX0035 administered twice daily p.o. for 24 weeks
11237225|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
11237226|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
11237227|NCT03127462|Experimental|Individualized Education|
11237228|NCT03127462|No Intervention|Control group|
11237229|NCT03127449|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
11237230|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.
~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
~Data on tolerability are documented by the physicians."
11237231|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
11237232|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
11237233|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
11237235|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
11237236|NCT03127384|Experimental|No-treatment control|
11237237|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
11237238|NCT03127371|Experimental|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
11237239|NCT03127371|Experimental|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
11237240|NCT03127358|Active Comparator|Intervention|Participants will use a-DOT technology to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12-16 weeks.
11237241|NCT03127358|Placebo Comparator|Control|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12-16 weeks.
11237242|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
11237243|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
11237244|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
11237245|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
11237246|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment
~Polish version of BPS tool validation.
~Other Names:
~Pain assessment in non-verbal patients"
11237247|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment
~Polish version of BPS tool validation.
~Other Names:
~Pain assessment in non-verbal patients"
11237248|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
11237249|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
11237250|NCT03127280|No Intervention|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
11237251|NCT03127280|Experimental|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
11237252|NCT03127267|Experimental|Masitinib (4.5) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d
11237253|NCT03127267|Experimental|Masitinib (6.0) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.
11237254|NCT03127267|Placebo Comparator|Placebo & Riluzole|Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.
11237255|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
11237256|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
11237257|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
11237258|NCT03127228|Other|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
11237259|NCT03127228|Experimental|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
11237260|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
11237261|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
11237262|NCT03127202|Experimental|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
11237263|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
11237264|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
11237265|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
11237266|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
11237267|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
11237268|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.
~Intervention: Genome sequencing of fecal samples"
11237269|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.
~Intervention: Genome sequencing of fecal samples"
11237270|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
11237271|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.
~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
11237272|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
11237273|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
11237274|NCT03127137|Other|Control cohort Group|Control cohort group will receive medications not predetermined by the set protocol.
11237275|NCT03127137|Active Comparator|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
11237276|NCT03127137|Placebo Comparator|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
11237277|NCT03127124|Experimental|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
11237278|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
11237279|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
11237280|NCT03127072|Experimental|Arm A|RFA plus chemotherapy ± target therapy
11237281|NCT03127072|Active Comparator|Arm B|chemotherapy ± target therapy
11237282|NCT03127059|Experimental|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.
~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
11237283|NCT03127059|Other|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.
~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
11237284|NCT03127046|Experimental|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
11237285|NCT03127046|Experimental|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
11237286|NCT03127046|Experimental|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
11237287|NCT03127046|Experimental|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
11237288|NCT03127046|Experimental|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
11237289|NCT03127046|Experimental|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
11237290|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
11237291|NCT03127007|Experimental|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.
~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
11237292|NCT03127007|Active Comparator|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.
~Rectal surgery is planned during week 15"
11237293|NCT03126994|Experimental|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
11237294|NCT03126981|Experimental|Whole, natural almonds|1.5 oz of whole, natural almonds
11237295|NCT03126981|Placebo Comparator|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
11237328|NCT03126786|Sham Comparator|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
11237296|NCT03126968|Experimental|Prophylactic topical epinephrine|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
11237297|NCT03126968|Placebo Comparator|Placebo|Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.
11237298|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
11237299|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
11237300|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
11237301|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
11237302|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
11237303|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
11237304|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
11237305|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
11237306|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description.
11237307|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
11237308|NCT03126916|Experimental|Arm E (crizotinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
11237309|NCT03126903|Experimental|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
11237310|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
11237311|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
11237312|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
11237313|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
11237314|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.
~Fludarabine administered by vein on Days -5 to -3.
~Cyclophosphamide administered by vein on Day -3.
~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
11237315|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.
~Fludarabine administered by vein on Days -5 to -3.
~Cyclophosphamide administered by vein on Day -3.
~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
11237316|NCT03126851|Experimental|No age range / no explicit warning|Label: No age range and no explicit warning on front display panel of medication box.
11237317|NCT03126851|Experimental|age range / no explicit warning|Label: Age range present but no explicit warning on front display panel of medication box.
11237318|NCT03126851|Experimental|age range / explicit warning in words|Label: Age range present with explicit warning in words on front display panel of medication box.
11237319|NCT03126851|Experimental|age range / explicit warning+pictogram|Label: Age range present with explicit warning in words plus pictographic warning on front display panel of medication box.
11237320|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement < 10 ml, and / OR diaphragmatic thickening fraction < 36 %.
11237321|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement > 10 ml, and / OR diaphragmatic thickening fraction > 36 %.
11237322|NCT03126825|Other|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
11237323|NCT03126825|Other|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
11237324|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
11237325|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:
~Erlotinib 150mg. po, qd, daily, q 3weeks"
11237326|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
11237327|NCT03126786|Active Comparator|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
11237329|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
11237330|NCT03126760|Experimental|Acthar|Repository Corticotropin Injection 1 mL (80U) subcutaneously administered QD for 14 consecutive days
11237331|NCT03126760|Placebo Comparator|Placebo|Placebo 1 mL subcutaneously administered QD for 14 consecutive days.
11237332|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
11237333|NCT03126734|Experimental|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
11237334|NCT03126734|No Intervention|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
11237335|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
11237336|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
11237337|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
11237338|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
11237339|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:
~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
11237340|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:
~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
11237341|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:
~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
11237342|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:
~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.
~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
11237343|NCT03126682|Active Comparator|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
11237344|NCT03126682|Active Comparator|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
11237345|NCT03126669|Active Comparator|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
11237346|NCT03126669|Placebo Comparator|Placebo|normal air, in the hyperbaric chamber
11237347|NCT03126656|Experimental|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels <11.4 nmol / L);
11237348|NCT03126656|Experimental|Hypogonadic|patients just with hypogonadism (testosterone <11.4 nmol / L) in the absence of documented cardiovascular disease
11237349|NCT03126656|No Intervention|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels > 11.4 nmol / L), in optimized standard therapy for heart failure
11237350|NCT03126630|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
11237351|NCT03126630|Experimental|Group II (anetumab ravtansine, pembrolizumab)|Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11237352|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
11237353|NCT03126604||Cesarean section|Women underwent elective Cesarean section
11237354|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
11237355|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
11237356|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
11237357|NCT03126578|Experimental|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.
~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
11237358|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
11237359|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
11237360|NCT03126552|Experimental|Intervention|Four healthy hookworm-naive volunteers will be infected with 50 Necator americanus L3 larvae.
11237422|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
11237361|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
11237362|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
11237363|NCT03126526|Experimental|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
11237364|NCT03126526|Active Comparator|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
11237365|NCT03126526|No Intervention|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
11237366|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
11237367|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
11237368|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
11237369|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
11237370|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
11237371|NCT03126448|Other|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
11237372|NCT03126448|Other|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
11237373|NCT03126448|Other|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or < 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
11237374|NCT03126435|Experimental|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly plus gemcitabine 1000mg/m² once weekly for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
11237375|NCT03126435|Other|Gemcitabine|Gemcitabine 1000mg/m² once weekly, for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
11237376|NCT03126422|Experimental|Dexmedetomidine 0 μg/kg/min|
11237377|NCT03126422|Experimental|Dexmedetomidine 0.03 μg/kg/min|
11237378|NCT03126422|Experimental|Dexmedetomidine 0.06 μg/kg/min|
11237379|NCT03126422|Experimental|Dexmedetomidine 0.09 μg/kg/min|
11237380|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
11237381|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
11237382|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
11237383|NCT03126370|Experimental|TAF with a boosted PI and LDV/SOF|"Subjects who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.
~Subjects will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.
~After taking TAF/FTC for 12 weeks, subjects will then start taking ledipasvir 90mg/sofosbuvir 400mg (Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.
~Subjects will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
11237384|NCT03126357|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237385|NCT03126357|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237386|NCT03126357|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237387|NCT03126357|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237388|NCT03126357|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237389|NCT03126357|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237390|NCT03126357|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237391|NCT03126357|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237392|NCT03126357|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237393|NCT03126357|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
11237394|NCT03126344|Experimental|King Vision video laryngoscope|
11237395|NCT03126344|Experimental|McGrath MAC video laryngoscope|
11237396|NCT03126344|Active Comparator|Macintosh|
11237397|NCT03126331|Experimental|Cohort I: Intermittent Nivolumab|Nivolumab monotherapy. Participants who have initial 10% or greater tumor burden reduction will discontinue nivolumab until they experience a pre-specified disease progression at which time nivolumab will be restarted
11237398|NCT03126331|Experimental|Cohort II: combination ipilimumab/nivolumab|"Combination of ipilimumab/nivolumab for previously untreated intermediate and poor risk mRCC
~Includes participants treated front-line ipilimumab/nivolumab. Participants with treatment-naïve mRCC who receive up to four doses of induction ipilimumab/nivolumab and 24 weeks (+/- 8 weeks; minimum 3 infusions) of maintenance nivolumab and achieve stable disease (SD), complete response (CR), or partial response (PR) will be eligible for inclusion. Participants who achieve SD will continue with nivolumab maintenance per standard of care while those who achieve a PR or CR will enter an observation period off therapy. Upon disease progression, participants will be re-challenged with combination ipilimumab/nivolumab."
11237399|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
11237400|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
11237401|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
11237402|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
11237403|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
11237404|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
11237405|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
11237406|NCT03126266|Experimental|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
11237407|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
11237408|NCT03126227|Active Comparator|Peanut allergen formulation|Subjects will be randomized to active arm of ARC007 and will be administered IP (AR101) in escalating doses for approximately 6 months.
11237409|NCT03126227|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC007 and will be administered escalating doses of IP (placebo) for approximately 6 months.
11237410|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
11237411|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
11237412|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
11237413|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
11237414|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
11237415|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
11237416|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
11237417|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
11237418|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
11237419|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
11237420|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
11237421|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
11237430|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
11237431|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
11237432|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
11237433|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
11237434|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
11237435|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
11237436|NCT03126136|Experimental|Pregnant women|
11237437|NCT03126123|Other|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
11237438|NCT03126110|Experimental|INCAGN01876 + Nivolumab|INCAGN01876 combined with nivolumab.
11237439|NCT03126110|Experimental|INCAGN01876 + Ipilimumab|INCAGN01876 combined with ipilimumab.
11237440|NCT03126110|Experimental|INCAGN01876 + Nivolumab + Ipilimumab|INCAGN01876 combined with nivolumab and ipilimumab.
11237441|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
11237442|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.
~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.
~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
11237443|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.
~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.
~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
11237444|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.
~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.
~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
11237445|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
11237446|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
11237447|NCT03126058|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:
~Multimodal analgesia
~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet
~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.
~Early activity
~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
11237448|NCT03126045|Active Comparator|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
11237449|NCT03126045|Experimental|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
11237450|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.
~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
11237451|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.
~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
11237452|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
11237453|NCT03126019|Experimental|Group A|Parsaclisib once daily (QD) for 8 weeks followed by Parsaclisib once weekly
11237454|NCT03126019|Experimental|Group B|Parsaclisib QD
11237455|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
11237456|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
11237457|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
11237458|NCT03125980|Experimental|Perioperative chemotherapy with CapOX regimen|
11237459|NCT03125980|Active Comparator|Postoperative chemotherapy with CapOX regimen|
11237460|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
11237461|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
11237462|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
11237463|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
11237465|NCT03125915|Active Comparator|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
11237466|NCT03125915|Experimental|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
11237467|NCT03125915|Experimental|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
11237468|NCT03125915|Experimental|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
11237469|NCT03125902|Experimental|Atezolizumab and Paclitaxel|Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
11237470|NCT03125902|Placebo Comparator|Placebo and Paclitaxel|Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
11237471|NCT03125889|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
11237472|NCT03125876|Experimental|CT053PTSA|60mg-100mg
11237473|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
11237474|NCT03125850|Experimental|day-ward group|
11237475|NCT03125850|Active Comparator|inpatient group|
11237476|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
11237477|NCT03125824|Other|Tattoos previously treated in Soliton 2016-001 trial|Identical tattoos treated by Laser + AWD in Soliton's previous trial
11237478|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
11237479|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
11237480|NCT03125798|Experimental|LigaSure|In this arm, LigaSure™ will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
11237481|NCT03125798|Active Comparator|Monopolar electrocautery|In this arm, conventional monopolar electrocautery will be used for mediastinal lymph nodes dissection, according to standard surgical technique.
11237482|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
11237483|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
11237484|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
11237485|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
11237486|NCT03125759||Control|patients without any history of stroke
11237487|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
11237488|NCT03125746|Experimental|LXI-15029|
11237489|NCT03125746|Experimental|LXI-15029+Exemestane|
11237490|NCT03125733|Experimental|STESD|Submucosal tunneling endoscopic septum division
11237491|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
11237492|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
11237493|NCT03125694|Active Comparator|Sitagliptin|
11237494|NCT03125694|Active Comparator|Pioglitazone|
11237495|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
11237496|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
11237497|NCT03125668|Experimental|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
11237498|NCT03125668|Active Comparator|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
11237499|NCT03125642|Experimental|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
11237500|NCT03125642|Experimental|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
11237501|NCT03125642|Experimental|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
11237502|NCT03125629|Active Comparator|PET/CT & PET/MRI Scans Using 18F-FDG|Participants will undergo a PET/CT scan and an PET/MRI scan on the same day, with both scans utilizing 18F-FDG.
11237503|NCT03125629|Experimental|PET/CT & PET/MRI Scans Using 68Ga-DOTA-TATE|Participants will undergo a PET/CT scan and an PET/MRI scan on the same day, with both scans utilizing 68Ga-DOTA-TATE.
11237504|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
11237505|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
11237506|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.
~Consultation of the patient's medical files at the hospital."
11237507|NCT03125577|Experimental|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
11237508|NCT03125564|Experimental|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
11237509|NCT03125564|Sham Comparator|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
11237510|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
11237511|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
11237512|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
11237513|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
11237514|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
11237515|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
11237516|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
11237517|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
11237518|NCT03125512|Experimental|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
11237519|NCT03125512|Active Comparator|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
11237520|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
11237521|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
11237522|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
11237523|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
11237524|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
11237525|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
11237526|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
11237527|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
11237528|NCT03125434|Experimental|healthy volunteers|EOS full-spine, MRI, gait analysis
11237529|NCT03125421|Other|control period|standard preventive methods of pressure sores in each center
11237530|NCT03125421|Experimental|experimental period|experimental multifaceted preventive methods of pressure sores
11237531|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
11237532|NCT03125395|Experimental|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
11237533|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
11237534|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
11237535|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
11237536|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
11237537|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
11237538|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
11237539|NCT03125356|Experimental|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
11237540|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
11237541|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
11237542|NCT03125330|Experimental|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.
~Additional requirements for One-to-One Coaching:
~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.
~Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.
~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.
~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
11237543|NCT03125330|Active Comparator|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.
~Additional requirements:
~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.
~Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.
~Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.
~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.
~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
11237544|NCT03125330|No Intervention|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.
~Additional requirements:
~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
11237545|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
11237546|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
11237547|NCT03125317||The control group|no intervention
11237548|NCT03125304|Experimental|treatment group|Treatment group will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan.
11237549|NCT03125304|Placebo Comparator|control group|Control group will receive acupuncture at non-acupoints.
11237550|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
11237551|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
11237552|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
11237553|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
11237554|NCT03125252|Experimental|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
11237555|NCT03125252|Other|Control|Standard paramedical and medical practices
11237556|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.
~After the screening procedures confirm participation in the research study:
~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
~Merestinib
~LY2874455"
11237557|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
11237558|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
11237559|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
11237624|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM, (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
11237625|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
11237560|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.
~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
11237561|NCT03125187|Experimental|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
11237562|NCT03125187|Experimental|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
11237563|NCT03125174||control|healthy individuals with no history of lung disease
11237564|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
11237565|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
11237566|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
11237567|NCT03125148|Other|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
11237568|NCT03125148|Other|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
11237569|NCT03125083|Experimental|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
11237570|NCT03125070|Experimental|Group I (INSPIRE, survivorship care plan)|Patients receive immediate access to the INSPIRE online program and personalized survivorship care plan.
11237571|NCT03125070|Active Comparator|Group II (usual care)|Patients receive an online program linking to existing online survivor resources and a personalized survivorship care plan. Patients may receive access to the INSPIRE online program after 12 months.
11237572|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
11237573|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
11237574|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
11237575|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
11237576|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
11237577|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
11237578|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
11237579|NCT03124966|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
11237580|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
11237581|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
11237582|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
11237583|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
11237584|NCT03124875|Experimental|Treatment|Treated with the LimFlow Stent Graft System
11237585|NCT03124862|Experimental|Test group|The subjects will be enrolled into the test group and will receive ARM sensor.
11237586|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
11237587|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
11237588|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
11237589|NCT03124784|Experimental|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
11237590|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
11237591|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
11237592|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
11237593|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
11237594|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
11237595|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
11237622|NCT03124472|Active Comparator|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.
~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.
~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
11237623|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
11237596|NCT03124667|Active Comparator|Video Conditoin|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
11237597|NCT03124654||Education|
11237598|NCT03124641|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
11237599|NCT03124641|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
11237600|NCT03124628|Experimental|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
11237601|NCT03124628|Active Comparator|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
11237602|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
11237603|NCT03124602|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
11237604|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
11237605|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
11237606|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
11237607|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
11237608|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
11237609|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
11237610|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
11237611|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
11237612|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
11237613|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
11237614|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
11237615|NCT03124524|No Intervention|Control group|33 healthy controls
11237616|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
11237617|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
11237618|NCT03124498|Experimental|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule
~Phase II - The recommended dose level according to the results from Phase I"
11237619|NCT03124485|Experimental|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
11237620|NCT03124485|Active Comparator|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
11237621|NCT03124472|Active Comparator|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.
~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.
~Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.
~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
11237626|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
11237627|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
11237628|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
11237629|NCT03124446|Active Comparator|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
11237630|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
11237631|NCT03124420|Active Comparator|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
11237632|NCT03124420|Sham Comparator|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
11237633|NCT03124407|Active Comparator|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
11237634|NCT03124407|Placebo Comparator|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
11237635|NCT03124407|Active Comparator|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
11237636|NCT03124407|Placebo Comparator|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
11237637|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
11237638|NCT03124381|Active Comparator|Acne Mask|Cleanser, Acne Mask
11237639|NCT03124381|Experimental|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
11237640|NCT03124368|Experimental|Sentinel Group 1|All participants will receive ACH-0144471 during the treatment period.
11237641|NCT03124368|Experimental|Group 2|All participants will receive ACH-0144471 during the treatment period.
11237642|NCT03124355|Experimental|Placebo pill with vagal/sham stimulation|Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
11237643|NCT03124355|Experimental|Pyridostigmine with vagal/sham stimulation|Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
11237644|NCT03124355|Experimental|Galantamine with vagal/sham stimulation|Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation
11237645|NCT03124342|Experimental|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
11237646|NCT03124342|No Intervention|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
11237647|NCT03124329|Experimental|Coronally Advanced Flap|
11237648|NCT03124329|Experimental|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
11237649|NCT03124329|Experimental|Intrasulcular tunneling|
11237650|NCT03124329|Experimental|VISTA + Leukocyte-Platelet Rich Fibrin|
11237651|NCT03124316|No Intervention|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
11237652|NCT03124316|Experimental|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
11237653|NCT03124316|Experimental|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
11237654|NCT03124316|Experimental|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
11237655|NCT03124316|Experimental|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
11237656|NCT03124316|Experimental|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
11237657|NCT03124316|Experimental|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
11237658|NCT03124316|Experimental|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
11237659|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
11237660|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
11237661|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
11237662|NCT03124277|Other|Control group|Best local diet
11237663|NCT03124238|Experimental|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
11237664|NCT03124238|No Intervention|Control|Rest during 5 minutes in a prone position
11237665|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
11237666|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
11237667|NCT03124199|Experimental|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
11237668|NCT03124186|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
11237669|NCT03124186|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
11237670|NCT03124173|Other|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
11237671|NCT03124160|Experimental|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
11237672|NCT03124160|Active Comparator|ParaGard® CuT380A|ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
11237673|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
11237674|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
11237675|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
11237676|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
11237677|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
11237678|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
11237679|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
11237680|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
11237681|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
11237682|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
11237683|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
11237684|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
11237685|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
11237686|NCT03124095|Experimental|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
11237687|NCT03124095|No Intervention|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
11237688|NCT03124082|Active Comparator|opioid|remifentanil 0,15-0,25 mcg/kg/h
11237689|NCT03124082|Experimental|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
11237690|NCT03124069|Experimental|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
11237691|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
11237692|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
11237693|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
11237694|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
11237695|NCT03124017|Experimental|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
11237696|NCT03124017|No Intervention|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
11237697|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
11237698|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
11237699|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
11237700|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
11237701|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11237702|NCT03123939|Experimental|CTL019|all enrolled subjects will get the study treatment.
11237703|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
11237704|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
11237705|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
11237706|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
11237707|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
11237708|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
11237709|NCT03123874|Experimental|Sterile pump set-up first|Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
11237710|NCT03123874|Experimental|Mother's Own pump set-up first|Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.
11237711|NCT03123861|Active Comparator|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
11237712|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
11237713|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
11237714|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
11237715|NCT03123822|Experimental|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
11237716|NCT03123822|Experimental|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
11237717|NCT03123822|Experimental|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
11237718|NCT03123809|Active Comparator|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.
~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
11237719|NCT03123809|Placebo Comparator|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.
~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
11237720|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
11237721|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
11237722|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
11237723|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
11237724|NCT03123783|Experimental|APX005M in combination with nivolumab|Subjects will receive intravenously APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death.
11237725|NCT03123770|Experimental|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
11237726|NCT03123770|Active Comparator|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
11237727|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
11237728|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
11237729|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
11237730|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
11237731|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
11237732|NCT03123718|Other|Intrathecal Methotrexate|
11237733|NCT03123718|Active Comparator|High-dose Intravenous Methotrexate|
11237734|NCT03123692|Experimental|Treatment|14 days treatment with NBMI 300 mg/day
11237735|NCT03123692|Placebo Comparator|Placebo|14 days treatment with Placebo
11237736|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
11237737|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
11237738|NCT03123653|Experimental|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
11237739|NCT03123640|Experimental|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
11237740|NCT03123640|No Intervention|Control group|Standard treatment without pharmacist intervention in the emergency department
11237741|NCT03123627|Experimental|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
11237742|NCT03123627|Active Comparator|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
11237743|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
11237744|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
11237745|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
11237746|NCT03123588|Experimental|Ruxolitinib|
11237747|NCT03123588|Active Comparator|Anagrelide|
11237748|NCT03123562|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
11237749|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
11237750|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=188) of a previously completed two level cervical disc trial.
11237751|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
11237752|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
11237753|NCT03123523||Patients group|35 patients
11237754|NCT03123523||Healthy volunteers|20 healthy volunteers
11237755|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
11237756|NCT03123510|Placebo Comparator|placebo|sugar pills
11237757|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
11237758|NCT03123484|Experimental|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
11237759|NCT03123484|Active Comparator|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
11237760|NCT03123471|Experimental|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
11237761|NCT03123471|Placebo Comparator|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
11237762|NCT03123458|Experimental|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
11237763|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
11237764|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
11237765|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
11237766|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
11237767|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
11237768|NCT03123406|Experimental|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH>900 pg/ml from 1st to 32nd week.
11237769|NCT03123406|Experimental|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH<900 pg/ml from 1st to 32nd week.
11237770|NCT03123406|Experimental|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH<600 pg/ml from 1st to 32nd week.
11237771|NCT03123393|Experimental|Cohort A: TAK-659 100 mg|TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
11237772|NCT03123393|Experimental|Cohort B: TAK-659 Ramp-up Dosing|TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).
11237773|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
11237774|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
11237775|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
11237776|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
11237777|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
11237778|NCT03123328|Experimental|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
11237779|NCT03123315|Experimental|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
11237780|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
11237781|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
11237782|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
11237783|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
11237784|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
11237785|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.
~Note that same patients scanned with different radiotracers serve in both arms."
11237786|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
11237787|NCT03123250|Experimental|Aquablation procedure|
11237788|NCT03123237|Placebo Comparator|Control|"control will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
11237789|NCT03123237|Active Comparator|Diabetic|"diabetic cases will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
11237790|NCT03123237|Active Comparator|Hypertensive|"hypertesive cases will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
11237791|NCT03123237|Active Comparator|Diabetic & Hypertensive|"Diabetic & Hypertensive cases will be subjected to:
~• Quantitative Tc99m DMSA renal scan using SPECT technique."
11237792|NCT03123224|Experimental|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
11237793|NCT03123224|Active Comparator|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
11237794|NCT03123198|Experimental|Dialectical Behavior Therapy|All participants receive six months of standard DBT which includes individual therapy, skills training, and as-needed phone consultation.
11237795|NCT03123185|Experimental|Single rising dose part|Groups of healthy volunteers receive rising single doses of BI 705564
11237796|NCT03123185|Experimental|Food effect part|Groups of healthy volunteers receive single doses of BI 705564 with and without food
11237797|NCT03123172|Other|co2 gap|arterial and central venous blood gases to measure Co2 gap
11237798|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
11237799|NCT03123146|Experimental|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
11237800|NCT03123146|No Intervention|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
11237801|NCT03123120|Experimental|Spesolimab|
11237802|NCT03123120|Placebo Comparator|Placebo|
11237803|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
11237804|NCT03123094|Experimental|BI 655130 dose group 1 (Intravenous)|
11237805|NCT03123094|Experimental|BI 655130 dose group 2 (Intravenous)|
11237806|NCT03123094|Experimental|BI 655130 dose group 3 (Intravenous)|
11237807|NCT03123094|Experimental|BI 655130 dose group 4 (Subcutaneous)|
11237808|NCT03123094|Placebo Comparator|Matching placebo for each dose group (Intravenous)|
11237809|NCT03123094|Placebo Comparator|Matching placebo (Subcutaneous)|
11237810|NCT03123081|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
11237811|NCT03123081|No Intervention|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
11237812|NCT03123068|Active Comparator|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
11237813|NCT03123068|Placebo Comparator|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
11237814|NCT03123055|Experimental|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
11237815|NCT03123055|Experimental|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
11237816|NCT03123042|Experimental|Sentinel basin dissection|Intervention: Sentinel basin dissection
11237817|NCT03123016|Experimental|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
11237818|NCT03123003|Experimental|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
11237819|NCT03122990|Experimental|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
11237820|NCT03122990|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
11237821|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
11237822|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
11237823|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
11237824|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
11237825|NCT03122938|Experimental|Lactoferrin Group|lactoferrin-supplemented formula
11237826|NCT03122938|Placebo Comparator|Control Group|formula without lactoferrin supplementation
11237827|NCT03122925||Control|Healthy subjects
11237828|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
11237829|NCT03122912|Experimental|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
11237830|NCT03122912|Active Comparator|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
11237831|NCT03122899|Other|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
11237832|NCT03122899|Other|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
11237833|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
11237834|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
11237835|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
11237836|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
11237837|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
11237838|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
11237839|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
11237840|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
11237841|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
11237842|NCT03122860|Placebo Comparator|Vehicle|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
11237843|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
11237844|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
11237845|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
11237846|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
11237847|NCT03122821|Experimental|Group 1|Trans-cranial direct stimulation + Mental Imagery
11237848|NCT03122821|Active Comparator|Group 2|Trans-cranial direct stimulation
11237849|NCT03122821|Active Comparator|Group 3|Mental imagery
11237850|NCT03122821|No Intervention|Group 4|Conservative treatment
11237851|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:
~Moderate or severe neonatal encephalopathy
~Gestational age of 35+0 weeks or greater
~Singleton pregnancy
~Inborn
~The exclusion criteria will be:
~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia
~Major congenital abnormalities
~Less than 15 minutes of digital CTG recording from labour available"
11237852|NCT03122808||Control|"The inclusion criteria will be:
~Gestational age of 35+0 weeks or greater
~Singleton pregnancy
~Inborn
~The exclusion criteria will be:
~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes
~Admission to the neonatal unit
~Major congenital abnormalities
~Less than 15 minutes of digital CTG recording from labour available"
11237853|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
11237854|NCT03122782|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
11237855|NCT03122782|Placebo Comparator|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
11237856|NCT03122769|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
11237857|NCT03122756|Experimental|Group (D)|will include 50 women who will receive intravenous dexamethasone.
11237858|NCT03122756|Placebo Comparator|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
11237859|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
11237860|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
11237861|NCT03122717|Experimental|Gefitinib + Osimertinib|"Gerfitinib will administered orally at a pre determine dose daily
~Osimertinib will administered orally at a pre determine dose daily"
11237862|NCT03122704|Experimental|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
11237863|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
11237864|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
11237865|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
11237866|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
11237867|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
11237868|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
11237869|NCT03122678|Experimental|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
11237870|NCT03122678|Placebo Comparator|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
11237871|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
11237872|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
11237873|NCT03122652|Experimental|Terifunomide|
11237874|NCT03122652|Placebo Comparator|Placebo|
11237875|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
11237876|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
11237897|NCT03122496|Experimental|durvalumab (MEDI4736) & tremelimumab with SBRT|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks. SBRT delivered to one metastatic site per standard of care using a standard 9Gy x 3 fractions will be given within 2 weeks after the completion of the first cycle of durvalumab (MEDI4736) and tremelimumab. After 4 cycles of durvalumab (MEDI4736) and tremelimumab, patients will then continue with single agent durvalumab (MEDI4736) every 4 weeks until disease progression or unacceptable toxicity or a total of 12 months from date of initial treatment.
11237898|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
11237877|NCT03122626|Experimental|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
11237878|NCT03122626|No Intervention|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
11237879|NCT03122613|Active Comparator|Curcumin|Dietary supplements of Curcumin capsules
11237880|NCT03122613|Placebo Comparator|Curcumin Placebo|Identical looking placebo of the active arm
11237881|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
11237882|NCT03122587|Sham Comparator|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
11237883|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
11237884|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
11237885|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
11237886|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
11237887|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
11237888|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
11237889|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
11237890|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
11237891|NCT03122548|Experimental|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
11237892|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
11237893|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
11237894|NCT03122522|Experimental|ipilimumab and nivolumab|Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 & week 10) & repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks & then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy & subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
11237895|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
11237896|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
11237899|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
11237900|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
11237958|NCT03122054|Other|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
11237901|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
11237902|NCT03122444|Experimental|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
11237903|NCT03122431|Other|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
11237904|NCT03122431|No Intervention|Inactive SLE with standard dose of HCQ|This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) and in the other, the dose will be reduced to 400mg 3 times a week for two years.
11237905|NCT03122431|Active Comparator|Inactive SLE with reduced dose of HCQ|This subproject includes 2 arms of lupus patients with inactive disease: one group will be maintained on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced) for two years.
11237906|NCT03122431|Experimental|Active SLE with initial high dose of HCQ|This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for two years and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.
11237907|NCT03122431|No Intervention|Active SLE with standard dose of HCQ|This subproject includes 2 arms of lupus patients with active disease: one group will be started on standard dose of Hydroxychloroquine (400mg/day) for three months and in the other, the dose will be started at high dose 800mg/day (Hydroxychloroquine high) for three months.
11237908|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
11237909|NCT03122405|Experimental|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
11237910|NCT03122392|Experimental|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.
~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.
~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
11237911|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
11237912|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
11237913|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
11237914|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
11237915|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
11237916|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
11237917|NCT03122314|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
11237918|NCT03122314|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
11237919|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
11237920|NCT03122301|Sham Comparator|Saline|Saline injection
11237921|NCT03122288|Experimental|Individualized Cognitive Training|Participants randomized to this arm will receive 20 hours of computerized cognitive training in the two predominate cognitive domains in which they experience deficits that contribute to their HIV-Associated Neurocognitive Disorder diagnosis.
11237922|NCT03122288|Other|No-Contact Control|Participants in this arm will not receive any experimental or sham contact. They will only participate in the Baseline and Posttest assessments.
11237923|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:
~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.
~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
11237924|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
11237925|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
11237926|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
11237927|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
11237928|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
11237929|NCT03122236|Active Comparator|Standard walking with tDCS dosage A|Neurorehabilitation of Standard Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
11237930|NCT03122236|Active Comparator|Complex walking with tDCS dosage A|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
11237931|NCT03122236|Active Comparator|Complex walking with tDCS dosage B|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage B
11237932|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
11237933|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
11237934|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
11237935|NCT03122223|Placebo Comparator|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
11237936|NCT03122210|Other|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
11237937|NCT03122210|Other|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
11237938|NCT03122210|Other|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
11237939|NCT03122197|Experimental|Letrozole|Letrozole doses range includes 2.5, 3, 6, 9, and 12 mg daily.
11237940|NCT03122184|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
11237941|NCT03122184|Active Comparator|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
11237942|NCT03122171|Experimental|Prosthesis|
11237943|NCT03122158|Active Comparator|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
11237944|NCT03122158|Active Comparator|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
11237945|NCT03122145|Experimental|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
11237946|NCT03122145|Experimental|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
11237947|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
11237948|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
11237949|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.
~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.
~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
11237950|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
11237951|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
11237952|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
11237953|NCT03122080|Active Comparator|Electroacupuncture group|electroacupuncture+standard care
11237954|NCT03122080|Placebo Comparator|Control A group|placebo acupuncture+standard care
11237955|NCT03122080|Other|Control B group|standard care
11237956|NCT03122067|Experimental|oxytocin group|male participants with oxytocin treatment
11237957|NCT03122067|Placebo Comparator|placebo group|male participants with placebo treatment
11237959|NCT03122054|Other|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
11237960|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
11237961|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
11237962|NCT03122028|Experimental|LAmbre closure system|
11237963|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
11237964|NCT03122015|No Intervention|Standard care|
11237965|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
11237966|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
11237967|NCT03121989|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
~After the injection research, MRI will be done and images evaluated."
11237968|NCT03121989|Placebo Comparator|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
11237969|NCT03121976|Experimental|Ultrasound|Femoral catheters inserted using ultrasound only
11237970|NCT03121976|Active Comparator|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
11237971|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
11237972|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
11237973|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
11237974|NCT03121950|Active Comparator|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
11237975|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
11237976|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
11237977|NCT03121924|Experimental|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .
~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
11237978|NCT03121924|Experimental|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .
~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
11237979|NCT03121911|Experimental|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.
~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
11237980|NCT03121911|Experimental|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.
~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
11237981|NCT03121911|No Intervention|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
11238034|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
11238038|NCT03121430|Active Comparator|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
11237982|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.
~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
11237983|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.
~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
11237984|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
11237985|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
11237986|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
11237987|NCT03121846|Experimental|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
11237988|NCT03121833|Experimental|Endostar & AIM regimen / GT regimen|Endostar & AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
11237989|NCT03121833|Placebo Comparator|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
11237990|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
11237991|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
11237992|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
11237993|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
11237994|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
11237995|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
11237996|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
11237997|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
11237998|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
11237999|NCT03121742|Placebo Comparator|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
11238000|NCT03121742|Experimental|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
11238001|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:
~Multimodal analgesia
~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet
~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early
~Early activity
~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
11238002|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
11238003|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
11238004|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
11238005|NCT03121690|Experimental|prednisone|prednisone 40 mg/day for 7 days
11238006|NCT03121690|Experimental|placebo|5ml saline /day for 7 days
11238035|NCT03121456|Experimental|18F-FDG PET SCAN|"REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
~MRI DIFFUSION REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1."
11238036|NCT03121443||Patient position|Perfusion index
11238037|NCT03121430|Experimental|Group A|subjects using the drug eluting peripheral vascular stent system
11238007|NCT03121677|Experimental|Nivolumab/Poly-ICLC/Vaccine/+/- Rituximab|"All cycles are 4 weeks (wks), with nivolumab every 2 wks during Cycles 1-6 & every 4 wks during Cycles 7-12 & vaccine on Cycle 1 Days 1, 4, 8, 15; Cycle 2 Day 1; and then on Day 1 of Cycles 4, 6, 8, 10, 12
~After 2 cycles, restaging will be performed, & patients with CR, PR, or SD will continue on nivolumab + vaccine. Patients with evidence of PD may initiate anti-CD20 mAb therapy (drug to be determined by the treating physician) weekly for 4 wks during Cycle 3, followed by a dose on Day 1 of every other cycle (Cycles 6, 8, 10, and 12).
~After 6 cycles, restaging will be performed again, and patients with CR, PR, or SD will continue nivolumab + vaccine. Patients with PD at that time point (but not treated with anti-CD20 mAb therapy thus far on this protocol) will initiate anti-CD20 mAb (drug to be determined by the treating physician) therapy weekly for 4 wks during Cycle 7, followed by a dose Day 1 of Cycles 10 & 12 & 2 additional doses 8 wks apart."
11238008|NCT03121664|Experimental|Cohort 1|
11238009|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).
~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
11238010|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
11238011|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
11238012|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
11238013|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
11238014|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
11238015|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
11238016|NCT03121612|Experimental|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. [Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement]
11238017|NCT03121612|Active Comparator|Fisher-Paykel CPAP|Fisher-Paykel (F&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
11238018|NCT03121599|Experimental|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
11238019|NCT03121586|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, + background antipsychotic, taken once daily by mouth
11238020|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
11238021|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
11238022|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
11238023|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
11238024|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
11238025|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
11238026|NCT03121534|Experimental|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.
~Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab.
~Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment."
11238027|NCT03121521|Experimental|melatonin|Melatonin 10mg/d p.o.
11238028|NCT03121521|Placebo Comparator|placebo|placebo 10mg/d p.o.
11238029|NCT03121508|Other|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
11238030|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
11238031|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
11238032|NCT03121482|Active Comparator|HFNC alone|Control group
11238033|NCT03121482|Experimental|HFNC and NIV|
11238039|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
11238040|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
11238041|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
11238042|NCT03121391|No Intervention|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
11238043|NCT03121391|Active Comparator|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
11238044|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
11238045|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
11238046|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
11238047|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
11238048|NCT03121352|Experimental|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
11238049|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
11238050|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
11238051|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.
~Dose of tegafur-uracil will be based on patient's body surface area (BSA):
~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)
~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
11238052|NCT03121300||High Risk Lung Cancer Patients|
11238053|NCT03121287||Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test & 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
11238054|NCT03121274|Active Comparator|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
11238055|NCT03121274|Active Comparator|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
11238056|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
11238057|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
11238058|NCT03121248|Experimental|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
11238059|NCT03121248|Active Comparator|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
11238060|NCT03121248|Experimental|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
11238061|NCT03121248|Active Comparator|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
11238062|NCT03121248|Experimental|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
11238063|NCT03121248|Active Comparator|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
11238064|NCT03121248|Experimental|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
11238065|NCT03121248|Active Comparator|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
11238066|NCT03121248|Experimental|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
11238067|NCT03121248|Active Comparator|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
11238068|NCT03121222|Placebo Comparator|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
11238100|NCT03120962|Experimental|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
11238256|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
11238069|NCT03121222|Experimental|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
11238070|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
11238071|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
11238072|NCT03121183||Patients who have undergone an extraction of implantable pace|
11238073|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
11238074|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
11238075|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
11238076|NCT03121157|Experimental|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
11238077|NCT03121157|No Intervention|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
11238078|NCT03121144|Experimental|Masimo Centroid System|Single-arm study. All subjects are enrolled into the test group wherein the noninvasive positional monitoring device will be administered.
11238079|NCT03121131|Other|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
11238080|NCT03121131|Other|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
11238081|NCT03121131|Other|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
11238082|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
11238083|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
11238084|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
11238085|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
11238086|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
11238087|NCT03121066|Active Comparator|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
11238088|NCT03121066|Sham Comparator|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
11238089|NCT03121066|No Intervention|Non TMS Control group|Conventional intervention alone
11238090|NCT03121053|Active Comparator|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
11238091|NCT03121053|Active Comparator|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
11238092|NCT03121040|Experimental|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
11238093|NCT03121040|Experimental|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
11238094|NCT03121040|No Intervention|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
11238095|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
11238096|NCT03121001|Experimental|Subject treatment|Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter.
11238097|NCT03120988|Experimental|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
11238098|NCT03120975|Experimental|Computerized decision support|
11238099|NCT03120975|Active Comparator|Standard antibiotic stewardship|
11238101|NCT03120962|Active Comparator|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
11238102|NCT03120949|Experimental|Treatment Arm 1|Olokizumab 64 mg SC q4w + Methotrexate (oral)
11238103|NCT03120949|Experimental|Treatment Arm 2|Olokizumab 64 mg SC q2w + Methotrexate (oral)
11238104|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
11238105|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
11238106|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
11238107|NCT03120910|Experimental|Test Subjects|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensor, including nasal sensors, with the same or similar technology and materials as the Masimo FDA cleared devices and sensors.
11238108|NCT03120897|Experimental|Test group|The subjects will be enrolled into the test group and will receive RAM sensor.
11238109|NCT03120884|Experimental|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
11238110|NCT03120884|Experimental|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
11238111|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
11238112|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
11238113|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
11238114|NCT03120832|Experimental|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
11238115|NCT03120819|Active Comparator|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
11238116|NCT03120819|Experimental|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
11238117|NCT03120806|Active Comparator|continous subcuticular|skin closed with continous subcuticular mattress suture using non-absorbable polypropylene
11238118|NCT03120806|Active Comparator|Interrupted subcuticular|skin closed with interrupted subcuticular mattress suture using non-absorbable polypropylene
11238119|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
11238120|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
11238121|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
11238122|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
11238123|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
11238124|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
11238125|NCT03120754|Experimental|Experimental Group|Placement of peritoneal drainage
11238126|NCT03120754|Active Comparator|Control group|No peritoneal drainage
11238127|NCT03120728|Experimental|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
11238128|NCT03120728|Experimental|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
11238129|NCT03120728|Experimental|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
11238130|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
11238222|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
11238131|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
11238132|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
11238133|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
11238134|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
11238135|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
11238136|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
11238137|NCT03120650|Experimental|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
11238138|NCT03120650|Active Comparator|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
11238139|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
11238140|NCT03120637|No Intervention|Standard Treatment|
11238141|NCT03120624|Experimental|Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
11238142|NCT03120624|Experimental|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
11238143|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
11238144|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
11238145|NCT03120598|Active Comparator|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
11238146|NCT03120598|Experimental|ISF strategy|Behavioral: Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
11238147|NCT03120585|Experimental|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
11238148|NCT03120585|No Intervention|Control Group|Infants with respiratory distress will receive standard of care fluid management.
11238149|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.
~- Examination and diagnosis (15 min).
~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).
~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).
~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
11238150|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
11238184|NCT03120351|Experimental|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
11238254|NCT03119831|Experimental|C31G (Group A)|C31G
11238151|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).
~New Floss Holder - Gum Chucks/SMS"
11238152|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
11238153|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
11238154|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
11238155|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
11238156|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
11238157|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
11238158|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
11238159|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
11238160|NCT03120494|Experimental|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
11238161|NCT03120481||Normal control|
11238162|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
11238163|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
11238164|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
11238165|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
11238166|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
11238167|NCT03120442|Experimental|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
11238168|NCT03120442|Experimental|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
11238169|NCT03120442|Experimental|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
11238170|NCT03120429|Experimental|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
11238171|NCT03120429|Experimental|Control group|subjects will have no seafood.
11238172|NCT03120416|Experimental|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
11238173|NCT03120416|No Intervention|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
11238174|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
11238175|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
11238176|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
11238177|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
11238178|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
11238179|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
11238180|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
11238181|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
11238182|NCT03120364|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
11238183|NCT03120364|Active Comparator|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
11238255|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
11238185|NCT03120351|Placebo Comparator|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
11238186|NCT03120338|Experimental|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
~The DAWBA will be administered in addition to care as usual."
11238187|NCT03120338|No Intervention|Care as Usual|Care as usual
11238188|NCT03120325|Experimental|Vagal Nerve Stimulation|All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
11238189|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
~Other Names:
~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
11238190|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
11238191|NCT03120286||Overweight and obesity|Women with BMI >25
11238192|NCT03120286||Normal weight group|Women with BMI =18-24
11238193|NCT03120273|Experimental|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
11238194|NCT03120273|Active Comparator|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
11238195|NCT03120260|Experimental|Short Sleep|Diet+ have 5 hour sleep at night (SS)
11238196|NCT03120260|Experimental|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
11238197|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
11238198|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
11238199|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
11238200|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
11238201|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
11238202|NCT03120221||First trimester pregnant women|
11238203|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
11238204|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
11238205|NCT03120208|Experimental|Partners|
11238206|NCT03120195|Experimental|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
11238207|NCT03120182|Active Comparator|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
11238208|NCT03120182|Placebo Comparator|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
11238209|NCT03120169|Active Comparator|treadmill endurance training|
11238210|NCT03120169|Active Comparator|cycling endurance training|
11238211|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
11238212|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
11238213|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
11238214|NCT03120143|Experimental|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
11238215|NCT03120143|Experimental|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
11238216|NCT03120143|No Intervention|Control group|This group continued their usual life style without intervention
11238217|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
11238218|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
11238219|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
11238220|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
11238221|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
11238223|NCT03120117|Experimental|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
11238224|NCT03120104|Active Comparator|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
11238225|NCT03120104|Active Comparator|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) two weeks after the stoma closure
11238226|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
11238227|NCT03120065|Other|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
11238228|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
11238229|NCT03120026|Experimental|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
11238230|NCT03120026|Placebo Comparator|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
11238231|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
11238232|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
11238233|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
11238234|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
11238235|NCT03119974|Other|Tpo-RA discontinuation|
11238236|NCT03119961|Experimental|SONOCLOUD®|BBB opening by ultrasound
11238237|NCT03119948|Placebo Comparator|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
11238238|NCT03119948|Active Comparator|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
11238239|NCT03119948|Active Comparator|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
11238240|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
11238241|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
11238242|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
11238243|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
11238244|NCT03119909|Other|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.
~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
11238245|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
11238246|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
11238247|NCT03119883|Other|MGUS group|MGUS patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
11238248|NCT03119883|Other|Multiple Myeloma group|Multiple Myeloma patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
11238249|NCT03119870|Experimental|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
11238250|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
11238251|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
11238252|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
11238253|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
11238257|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
11238258|NCT03119792|Experimental|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
11238259|NCT03119792|Active Comparator|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
11238260|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
11238261|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
11238262|NCT03119766|Experimental|Kolofort|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
11238263|NCT03119766|Placebo Comparator|Placebo|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
11238264|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
11238265|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
11238266|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
11238267|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
11238268|NCT03119727|Other|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
11238269|NCT03119714|Active Comparator|Pemirolast|Pemirolast 200mg bid 14-16 days
11238270|NCT03119714|Placebo Comparator|Placebo Oral Tablet|Matching placebo bid 14-16 days
11238271|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
11238272|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
11238273|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
11238274|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
11238275|NCT03119688|Other|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
11238276|NCT03119688|Other|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
11238277|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
11238278|NCT03119662|Experimental|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
11238279|NCT03119662|Placebo Comparator|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
11238280|NCT03119649|Experimental|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
11238281|NCT03119649|Experimental|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
11238540|NCT03117959|Experimental|Stryker shape match|no longer RCT
11238282|NCT03119649|Experimental|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
11238283|NCT03119649|Experimental|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
11238284|NCT03119649|Placebo Comparator|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
11238285|NCT03119649|Placebo Comparator|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
11238286|NCT03119636|Experimental|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
11238287|NCT03119636|Experimental|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
11238288|NCT03119636|Experimental|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
11238289|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
11238290|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
11238291|NCT03119610|Experimental|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
11238292|NCT03119610|Experimental|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
11238293|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
11238294|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
11238295|NCT03119584|Active Comparator|1)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
11238296|NCT03119584|Active Comparator|2)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
11238297|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
11238298|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
11238299|NCT03119558|Experimental|18F-Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F-Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45-60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
11238300|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
11238301|NCT03119545|No Intervention|Comparison group|This Group will have standard care
11238302|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
11238303|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
11238304|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
11238305|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
11238306|NCT03119506||Long Recess Duration/Before Lunch|
11238307|NCT03119506||Short Recess Duration/Before Lunch|
11238308|NCT03119506||Long Recess Duration/After Lunch|
11238309|NCT03119506||Short Recess Duration/After Lunch|
11238310|NCT03119493|Experimental|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming [5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)], followed by periodized aerobic interval training on treadmill, and cooling down [5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest]
11238311|NCT03119493|No Intervention|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
11238312|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
11238313|NCT03119467|Experimental|Single arm|RP4010 to be administered
11238314|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
11238315|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
11238316|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
11238317|NCT03119441|Active Comparator|Dental floss|Dental floss
11238318|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
11238319|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
11238320|NCT03119415|Experimental|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
11238321|NCT03119415|No Intervention|Business as Usual|Schools continue with business as usual.
11238824|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
11238322|NCT03119402|Experimental|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
11238323|NCT03119402|Sham Comparator|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
11238324|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
11238325|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
11238326|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
11238327|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
11238328|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
11238329|NCT03119363|Experimental|Experimental Light|The experimental systematic light exposure consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses (AYO) each morning for 4 weeks. The AYO light glasses is a lightweight pair of glasses that emits light from LEDs at a distance of 15 millimeters (15mm, 0.015m) from the eye.
11238330|NCT03119363|Active Comparator|Comparison Light|The active comparator condition consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses each morning for 4 weeks.
11238331|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.
~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.
~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
11238332|NCT03119337|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
11238333|NCT03119337|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
11238334|NCT03119324|Experimental|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.
~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.
~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.
~Patients were instructed to perform the applications always at the same time."
11238335|NCT03119324|Placebo Comparator|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.
~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.
~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.
~Patients were instructed to perform the applications always at the same time."
11238336|NCT03119324|Active Comparator|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non-consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).
~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.
~Patients were instructed to assume the therapy always at the same time"
11238337|NCT03119311|Experimental|VOG group|Video-oculography
11238338|NCT03119311|Active Comparator|APCT group|alternative prism cover test
11238339|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
11238340|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
11238341|NCT03119298||Control group|Healthy subjects matched for age and sex
11238342|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
11238343|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
11238344|NCT03119259|Active Comparator|ABC Clinical Program Only and Usual Care|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.
11238345|NCT03119259|Experimental|BCN Mobile App Plus ABC and BCN Mobile app only|Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
11238346|NCT03119246|Experimental|HD patients|
11238347|NCT03119246|Experimental|Controls|
11238348|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
11238349|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
11238350|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
11238351|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
11238352|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
11238353|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
11238354|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.
~Single dose administration on a single occasion."
11238355|NCT03119181|Experimental|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
11238356|NCT03119181|Sham Comparator|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
11238357|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
11238358|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
11238359|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
11238360|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
11238361|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
11238362|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
11238363|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
11238364|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
11238365|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
11238366|NCT03119103|Other|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
11238367|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
11238368|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
11238369|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.
~Nanoliposomal irinotecan :
~Dose Level 1 50mg/m2 IV every 2 weeks"
11238370|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.
~Nanoliposomal irinotecan :
~Dose Level 2 70 mg/m2 IV every 2 weeks"
11238371|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.
~Nanoliposomal irinotecan :
~Dose Level 3 80mg/m2 IV every 2 weeks"
11238372|NCT03119051|Experimental|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
11238373|NCT03119051|No Intervention|no training|Patients will not undergo preoperative cognitive training.
11238374|NCT03119051|Experimental|Cognitive training and physical exercise|Patients will receive 3-4 times of 20-30 minutes' training game every week and 2 times of 60 minutes' Tai Chi Training
11238375|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
11238376|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
11238377|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
11238378|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
11238379|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
11238380|NCT03118999|Experimental|OM3-FFA|Omega3 linked to free fatty acids
11238381|NCT03118999|Experimental|OM3 -MAG|Omega3 linked to Monoacylglycerol
11238382|NCT03118999|Experimental|OM3-EE|Omega3 linked to ethylester
11238383|NCT03118986|Active Comparator|Olanzapine|Standard antiemetics plus olanzapine
11238384|NCT03118986|Placebo Comparator|Placebo Oral Tablet|Standard antiemetics plus placebo
11238385|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
11238386|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
11238387|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
11238388|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
11238389|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
11238390|NCT03118934|Experimental|AOA MF|Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 10 ± 3 days
11238391|NCT03118934|Experimental|DACP MF|Nelfilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
11238392|NCT03118934|Experimental|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
11238393|NCT03118921|Experimental|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software
11238394|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
11238395|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
11238396|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
11238397|NCT03118882|Active Comparator|Diet Group|
11238398|NCT03118882|Active Comparator|Physical activity group|
11238399|NCT03118882|Active Comparator|Physical activity and diet group|
11238400|NCT03118882|No Intervention|Control group|
11238401|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
11238402|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
11238403|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
11238404|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
11238405|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
11238406|NCT03118817|Experimental|HM95573|Single arm
11238407|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
11238408|NCT03118791|Placebo Comparator|Placebo|Capsules containing maltodextrin
11238409|NCT03118791|Active Comparator|80 mg ACN|Capsules containing 80 mg anthocyanins
11238410|NCT03118791|Active Comparator|160 mg ACN|Capsules containing 160 mg anthocyanins
11238411|NCT03118791|Active Comparator|240 mg ACN|Capsules containing 240 mg anthocyanins
11238412|NCT03118791|Active Comparator|320 mg ACN|Capsules containing 320 mg anthocyanins
11238413|NCT03118791|Active Comparator|480 mg ACN|Capsules containing 480 mg anthocyanins
11238414|NCT03118765|Experimental|Test Treatment T1: GSP304 Inhalation Solution|
11238415|NCT03118765|Experimental|Test Treatment T2: GSP304 Inhalation Solution|
11238416|NCT03118765|Experimental|Test Treatment T3: GSP304 Inhalation Solution|
11238417|NCT03118765|Placebo Comparator|Test Treatment T4: GSP304 Placebo Inhalation Solution|
11238418|NCT03118765|Active Comparator|Test Treatment T5: Spiriva® Respimat® inhalation spray|
11238419|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
11239345|NCT03112382|No Intervention|no vitamins|patients will be observed for 3 months
11238420|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
11238421|NCT03118739|Experimental|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
11238422|NCT03118739|Placebo Comparator|Placebo|Capsule administered orally, once daily for 24 weeks
11238423|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
11238424|NCT03118713|Experimental|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
11238425|NCT03118713|Experimental|glimepiride and metformin|Subjects will receive daily dosage of glimepiride and metformin as single tablets
11238426|NCT03118700|No Intervention|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
11238427|NCT03118700|Experimental|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
11238428|NCT03118700|Experimental|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
11238429|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
11238430|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1
~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
11238431|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home
~First stroke deficit with non-regressive clinical expression in 24 hours
~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities
~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)
~No psychiatric history that led to hospitalization for more than six months
~Written informed consent after reading the briefing note
~Patient affiliated or beneficiary of a social security scheme."
11238432|NCT03118635|Experimental|Intervention|Daily, four-hour physical activity intervention
11238433|NCT03118635|No Intervention|Control|No treatment control
11238434|NCT03118622||Pentax group|Intubation using Pentax
11238435|NCT03118622||Macintosh group|Intubation using Macintosh
11238436|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.
~Up to 150 participants will complete the Understanding Needs survey"
11238437|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
11238438|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
11238439|NCT03118583|Experimental|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
11238440|NCT03118570|Experimental|BPS804 Dose 1|BPS804 IV Infusion
11238441|NCT03118570|Experimental|BPS804 Dose 2|BPS804 IV Infusion
11238442|NCT03118570|Experimental|BPS804 Dose 3|BPS804 IV Infusion
11238443|NCT03118570|Experimental|BPS804 Dose 4|BPS804 IV Infusion
11238444|NCT03118557|Experimental|Pilates pelvic floor strengthening exercise|
11238445|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
11238446|NCT03118531|Experimental|Coronary Stent|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm)
11238447|NCT03118518|Active Comparator|Anti-arrhythmic drug|
11238448|NCT03118518|Experimental|Cryoablation|
11238449|NCT03118505|Experimental|Group 1|Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
11239346|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
11238450|NCT03118505|Experimental|Group 2|Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
11238451|NCT03118505|Experimental|Group 3|Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
11238452|NCT03118505|Active Comparator|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
11238453|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
11238454|NCT03118479|Experimental|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
11238455|NCT03118479|Experimental|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
11238456|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
11238457|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
11238458|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
11238459|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
11238460|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
11238461|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
11238462|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
11238463|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
11238464|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
11238465|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.
~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
11238466|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
11238467|NCT03118401|Experimental|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
11238468|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.
~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
11238469|NCT03118388|Experimental|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
11238470|NCT03118388|Experimental|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
11238471|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
11238472|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
11238473|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
11238474|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation Initial to maximum tolerated dose
11238475|NCT03118349|Experimental|Expansion Cohort|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
11238476|NCT03118336|Placebo Comparator|placebo group|
11238477|NCT03118336|Experimental|empaglifozine group|
11238478|NCT03118323||Patients in need of endodontic treatment|n = 200
11238479|NCT03118310|Placebo Comparator|Placebo|Placebo diet
11238480|NCT03118310|Experimental|5:2|5:2 diet
11238481|NCT03118310|Experimental|LCHF|LCHF diet
11238482|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
11238483|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
11239347|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
11238484|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
11238485|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
11238486|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
11238487|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
11238488|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
11238489|NCT03118258|Experimental|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
11238490|NCT03118258|Experimental|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.
~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
11238491|NCT03118245|Experimental|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children <5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
11238492|NCT03118245|Experimental|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
11238493|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
11238494|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
11238495|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
11238496|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
11238497|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
11238498|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
11238499|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
11238500|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
11238501|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
11238502|NCT03118167|Experimental|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
11238503|NCT03118167|Experimental|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
11238504|NCT03118167|Active Comparator|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
11238505|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
11238506|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
11238507|NCT03118141|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
11238508|NCT03118141|Active Comparator|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
11238509|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
11238510|NCT03118128|No Intervention|No metformin|
11238511|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
11238512|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
11238513|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
11238514|NCT03118089|Experimental|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
11238515|NCT03118089|No Intervention|Standard Care|Participants will remain on their current oral nutritional supplement
11238516|NCT03118076|Placebo Comparator|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
11238517|NCT03118076|Experimental|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
11238518|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
11238519|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
11238520|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
11238521|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
11238522|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
11238523|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
11238524|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
11238525|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
11238526|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
11238527|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
11238528|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
11238529|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
11238530|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
11238531|NCT03118011|Active Comparator|No smoking|The ward where the patients can not go out to smoke
11238532|NCT03118011|Placebo Comparator|Smoking|The ward where the patients can go out to smoke.
11238533|NCT03117998|Experimental|REMD-477 Treatment A|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
11238534|NCT03117998|Experimental|REMD-477 Treatment B|Administered as a repeated SC doses in subjects with Type 1 Diabetes
11238535|NCT03117998|Placebo Comparator|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
11238536|NCT03117985|Experimental|Antiretroviral therapy|Stopping antiretroviral therapy
11238537|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
11238538|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
11238539|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
11238541|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.
~Tumor tissues will be collected if available."
11238542|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
11238543|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
11238544|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
11238545|NCT03117920|Experimental|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
11238546|NCT03117907||Infants with low infectious status|
11238547|NCT03117907||Infants with high infectious status|
11238548|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
11238549|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
11238550|NCT03117881|Experimental|DirectCAM|The DirectCAM arm receives the intervention content via therapists at participating clinics.
11238551|NCT03117881|Experimental|TeleCAM|The TeleCAM arm receives the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
11238552|NCT03117881|Experimental|rDirectCAM|The rDirectCAM arm is being implemented in response to Covid-19. The rDirectCAM arm receives the intervention content delivered remotely in real-time by therapists via videoconferencing technology.
11238553|NCT03117855|Experimental|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
11238554|NCT03117842|Experimental|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
11238555|NCT03117842|No Intervention|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
11238556|NCT03117829|Experimental|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
11238557|NCT03117816|Experimental|investigational arm A|There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
11238558|NCT03117816|Other|surveillance arm B|"This is an open-label study with a surveillance group as comparator arm. Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further CML treatment."
11238559|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
11238560|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
11238561|NCT03117764|Active Comparator|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.
~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
11238562|NCT03117764|Experimental|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.
~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
11238563|NCT03117751|Experimental|B-ALL and B-LLy, Low Risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL1-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.
~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
11238564|NCT03117751|Experimental|B-ALL and B-LLy, Standard Risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD >5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and <1%), certain genetic subtypes and Down syndrome.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin."
11238565|NCT03117751|Experimental|B-ALL and B-LLy, High Risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor [CAR] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
11238618|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
11238566|NCT03117751|Experimental|T-ALL and T-LLy, Standard Risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
11238567|NCT03117751|Experimental|T-ALL and T-LLy, High Risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard risk T-ALL but are discontinued in Reintensification therapy.
~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
11238568|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine beginning with Continuation Week 1.
~Intervention: vincristine."
11238569|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment.
~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
11238570|NCT03117738|Experimental|AstroStem|
11238571|NCT03117738|Placebo Comparator|Placebo-Control|
11238572|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.
~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
11238573|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.
~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
11238574|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
11238575|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
11238576|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.
~Phase 1 :
~3 seated-standing passages with a handle equipped with 6 force captors
~3 seated-standing passages with the device"
11238577|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .
~Phase 1 :
~3 seated-standing passages without help
~3 seated-standing passages with a handle equipped with 6 force captors
~3 seated-standing passages with the device"
11238578|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
11238579|NCT03117686||patients after lung transplantation|10 patients > 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
11238580|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
11238581|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
11238582|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
11238583|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
11238584|NCT03117660|No Intervention|Control|Subjects will receive no treatment
11238585|NCT03117634|Active Comparator|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
11238586|NCT03117634|Experimental|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and ICGA. Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
11238587|NCT03117621||Patients initiating Blinatumomab|Patients initiating Blinatumomab after Country-Specific Reimbursement approval in routine clinical practice.
11238588|NCT03117608|Experimental|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
11238589|NCT03117608|Active Comparator|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
11238590|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
11238666|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
11239043|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
11238591|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
11238592|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
11238593|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
11238594|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
11238595|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
11238596|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
11238597|NCT03117530|Experimental|Minocycline|
11238598|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
11238599|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
11238600|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
11238601|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
11238602|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
11238603|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
11238604|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
11238605|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
11238606|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
11238607|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
11238608|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
11238609|NCT03117465|Experimental|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
11238610|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
11238611|NCT03117452|Experimental|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
11238612|NCT03117452|No Intervention|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
11238613|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
11238614|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
11238615|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).
~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
11238616|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.
~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
11238617|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
11238733|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
11238619|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
11238620|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
11238621|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
11238622|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
11238623|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
11238624|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
11238625|NCT03117374|Experimental|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
11238626|NCT03117374|No Intervention|Control|Participants were invited to follow the regular school curricular for an 8-week period
11238627|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone
~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)
~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk
~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
11238628|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
11238629|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
11238630|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
11238631|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
11238632|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:
~agave inulin (4 g) in powder
~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
11238633|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
11238634|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
11238635|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
11238636|NCT03117309|Experimental|PART A: Nivolumab|Nivolumab 240mg; Nivolumab 360mg
11238637|NCT03117309|Experimental|PART B: Nivolumab + Ipilimumab|Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
11238638|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
11238639|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
11238640|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
11238641|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
11238642|NCT03117270|Experimental|oral filgotinib tablets|
11238643|NCT03117270|Placebo Comparator|placebo tablets|
11238644|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
11238645|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
11238646|NCT03117244|Experimental|Exercise Group|
11238647|NCT03117244|Active Comparator|Exercise and NMES Group|
11238648|NCT03117244|No Intervention|Control Group|
11238649|NCT03117231|Experimental|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
11238650|NCT03117231|Sham Comparator|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
11238651|NCT03117205|Experimental|Kinesio Taping® group|
11238652|NCT03117205|Placebo Comparator|placebo group|
11238653|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
11238654|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
11238655|NCT03117179|Other|Patient with an interview|
11238656|NCT03117179|Other|Patient without an interview|
11238657|NCT03117166|Experimental|Lidocaine|treatment arm
11238658|NCT03117166|Placebo Comparator|Saline|placebo arm
11238659|NCT03117153|Experimental|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.
~everyday 3 times for 6 weeks"
11238660|NCT03117153|Placebo Comparator|placebo|"no active ingredients
~everyday 3 times for 6 weeks"
11238661|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
11238662|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
11238663|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
11238664|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
11238665|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
11238667|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
11238668|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
11238669|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.
~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
11238670|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
11238671|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
11238672|NCT03117075|Experimental|Experimental|"using device for scoring pain scale, named ANAPA®"
11238673|NCT03117062|Experimental|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
11238674|NCT03117062|No Intervention|non-occlusal reduction|occlusal surface left intact
11238675|NCT03117049|Experimental|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
11238676|NCT03117049|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
11238677|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
11238678|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
11238679|NCT03117023|No Intervention|control group|sufentanil + saline
11238680|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria
~Subjects should have at least one of the following problems
~Presence of hemophagocytosis in tissue or bone marrow
~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
~Age > 18 years
~Written informed consents
~Subjects receive steroids and etoposide"
11238681|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
11238682|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
11238683|NCT03116984|Active Comparator|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition for patients who are randomly assigned to group of TACE treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.It has a possibility of observeation alone if tumor achieves a complete response after two times TACE.
11238684|NCT03116984|Experimental|External-beam radiotherapy|EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
11238685|NCT03116971|Experimental|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
11238686|NCT03116971|Experimental|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
11238687|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.
~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
11238688|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.
~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
11238689|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
11238822|NCT03116048|Other|Control group (placebo group)|Chronic pain assessment with study questionnaire
11238690|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.
~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
11238691|NCT03116919|Other|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
11238692|NCT03116919|Other|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
11238693|NCT03116906|Experimental|BI 685509|multiple rising doses of BI 685509
11238694|NCT03116906|Placebo Comparator|Placebo|matching placebo
11238695|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
11238696|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
11238697|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
11238698|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
11238699|NCT03116880||Image registration|
11238700|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
11238701|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
11238702|NCT03116828|Experimental|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
11238703|NCT03116828|Experimental|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
11238704|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
11238705|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
11238706|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.
~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
11238707|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
11238708|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
11238709|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
11238710|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
11238711|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
11238712|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
11238713|NCT03116737|Experimental|Benzocaine Otic Solution|
11238714|NCT03116737|Placebo Comparator|Placebo|
11238715|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.
~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
11238716|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
11238717|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
11238718|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
11238719|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
11238720|NCT03116698|Experimental|Low dose DFD07 once daily|
11238721|NCT03116698|Experimental|High dose DFD07 once daily|
11238722|NCT03116698|Experimental|High dose DFD07 twice daily|
11238723|NCT03116698|Placebo Comparator|Placebo twice daily|
11238724|NCT03116685|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes HC-1
11238725|NCT03116685|Placebo Comparator|Placebo capsules|Placebo
11238726|NCT03116672|Experimental|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
11238727|NCT03116672|Experimental|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
11238728|NCT03116672|Experimental|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
11238729|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
11238730|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
11238731|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
11238732|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
11238734|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
11238735|NCT03116607|No Intervention|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
11238736|NCT03116607|Experimental|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.
~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
~patient education/ recommendations to the health team"
11238737|NCT03116594|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
11238738|NCT03116594|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
11238739|NCT03116594|Active Comparator|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
11238740|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.
~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
11238741|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
11238742|NCT03116568||IBD Case|"Pregnant women with IBD
~Newborns of pregnant women with IBD
~Family member of pregnant women with IBD
~Siblings of newborns"
11238743|NCT03116568||Control|"Pregnant women without IBD
~Newborns of pregnant women without IBD
~Family member of pregnant women without IBD
~Siblings of newborns"
11238744|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).
~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
11238745|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
11238746|NCT03116529|Experimental|Treatment|Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
11238747|NCT03116516|Other|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
11238748|NCT03116516|Other|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
11238749|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
11238750|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
11238751|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
11238752|NCT03116464|Experimental|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
11238753|NCT03116451|Experimental|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
11238754|NCT03116451|No Intervention|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
11238755|NCT03116438|Experimental|CADence3 Device|If you agree to participate in this study, you will be asked to allow recording of sounds from four (4) sites on your chest using the CADence device. The CADence test will take approximately 15 minutes to complete. This is a single-arm study.
11238823|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
11238756|NCT03116425|Experimental|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
11238757|NCT03116425|Experimental|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
11238758|NCT03116425|Active Comparator|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
11238759|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
11238760|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
11238761|NCT03116399|Experimental|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
11238762|NCT03116399|Placebo Comparator|Tablet Condition|Exposing participants to the regular computer/tablet
11238763|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of
~reporting all the falls occurring during the night
~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night
~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
11238764|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
11238765|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
11238766|NCT03116373|Active Comparator|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
11238767|NCT03116373|Active Comparator|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
11238768|NCT03116360|Experimental|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
11238769|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
11238770|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer ≥160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
11238771|NCT03116347|Active Comparator|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
11238772|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.
~Route of administration:Oral."
11238773|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.
~Route of administration:Oral."
11238774|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.
~Route of administration:Oral."
11238775|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
11238776|NCT03116295|Experimental|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC [AF] or a single 25 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
11238777|NCT03116295|Experimental|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC [AF], or a single 50 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
11238778|NCT03116282|Experimental|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
11238779|NCT03116282|No Intervention|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
11238780|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
11238781|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
11238782|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
11238783|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
11238784|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
11238785|NCT03116243||MSHS children and families|"Cohort includes:
~children (1272)
~parents (1272)
~teachers (159)
~teaching assistants (159)
~program and center directors (253)"
11238786|NCT03116230|Experimental|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
11238787|NCT03116230|Experimental|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
11238788|NCT03116204||Patients hospitalized in a FRC department|
11238789|NCT03116191|Experimental|SK-1404 high dose|
11238790|NCT03116191|Experimental|SK-1404 middle dose|
11238791|NCT03116191|Experimental|SK-1404 low dose|
11238792|NCT03116191|Placebo Comparator|Placebo|
11238793|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.
~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
11238794|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
11238795|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
11238796|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
11238797|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
11238798|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
11238799|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
11238800|NCT03116139|Active Comparator|Randomized to V/Q|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
11238801|NCT03116139|Active Comparator|Randomized to CT|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
11238802|NCT03116126|Active Comparator|Guanfacine|
11238803|NCT03116126|Placebo Comparator|Placebo|
11238804|NCT03116113|Experimental|Part I: Dose 1 AAV8-RPGR|Single, subretinal administration of dose 1 as a single dose AAV8-RPGR
11238805|NCT03116113|Experimental|Part I: Dose 2 AAV8-RPGR|Single, subretinal administration of dose 2 as a single dose AAV8-RPGR
11238806|NCT03116113|Experimental|Part I: Dose 3 AAV8-RPGR|Single, subretinal administration of dose 3 as a single dose AAV8-RPGR
11238807|NCT03116113|Experimental|Part I: Dose 4 AAV8-RPGR|Single, subretinal administration of dose 4 as a single dose AAV8-RPGR
11238808|NCT03116113|Experimental|Part I: Dose 5 AAV8-RPGR|Single, subretinal administration of dose 5 as a single dose AAV8-RPGR
11238809|NCT03116113|Experimental|Part I: Dose 6 AAV8-RPGR|Single, subretinal administration of dose 6 as a single dose AAV8-RPGR
11238810|NCT03116113|Experimental|Part II: High dose AAV8-RPGR|Single, subretinal administration of high dose AAV8-RPGR
11238811|NCT03116113|Experimental|Part II: Low dose AAV8-RPGR|Single, subretinal administration of Low dose AAV8-RPGR
11238812|NCT03116113|No Intervention|Part II: Untreated Group|Untreated group to allow for a controlled comparison of efficacy and safety
11238813|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
11238814|NCT03116087|Placebo Comparator|Placebo|Placebo patches
11238815|NCT03116074|No Intervention|Study 1: Pre-intervention 1|"Usual care.
~Patients/caregivers do not have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
11238816|NCT03116074|Experimental|Study 1: Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging
~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
11238817|NCT03116074|No Intervention|Study 1: Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.
~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
11238818|NCT03116074|No Intervention|Study 2: Pre-intervention|"Usual care on three general medicine units.
~Patients/caregivers do not have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
11238819|NCT03116074|Experimental|Study 2: Post-intervention|Patients/caregivers have access to the discharge preparation checklist. Providers have access to safety dashboard.
11238820|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
11238821|NCT03116048|Other|Pecs group (study group)|Chronic pain assessment with study questionnaire
11238825|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
11238826|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
11238827|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
11238828|NCT03116009|Active Comparator|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
11238829|NCT03116009|Experimental|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
11238830|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
11238831|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
11238832|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
11238833|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
11238834|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
11238835|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
11238836|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
11238837|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
11238838|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
11238839|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
11238840|NCT03115918|Active Comparator|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
11238841|NCT03115918|Active Comparator|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
11238842|NCT03115892|Experimental|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
11238843|NCT03115892|Active Comparator|control arm|Chlorhexidine Mouthwash twice daily for one week
11238844|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
11238845|NCT03115879|Experimental|Manipulation Group|Hip manipulation
11238846|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
11238847|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
11238848|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
11238849|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.
~Then HCTZ 25 mg po plus Placebo"
11238850|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.
~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
11238851|NCT03115840||Adults (≥18 years old) with critical illness|
11238852|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
11238853|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.
~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
11238854|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
11238855|NCT03115788|Active Comparator|No Intervention Game play|The person will be instructed how to hold the iPad and how to play the game.
11238856|NCT03115788|Experimental|Thermal pain and ipad performance|Interventions: Cold induced pain and heat induced pain. The whole group gets thermal heat (n=40) and half (n=20) get cold water foot immersion and half (n=20) get body temperature foot emersion. The person will be instructed how to hold the iPad and how to play the game. The person will then be allowed to play the game until the number of trials is completed or until the person no longer wishes to play.
11238857|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
11238858|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
11238859|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
11238860|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
11238861|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
11238862|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
11238863|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
11238864|NCT03115749|Sham Comparator|Crohn's disease patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
11238865|NCT03115749|Sham Comparator|Ulcerative colitis patient group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
11238866|NCT03115749|Sham Comparator|Control group|Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection
11238867|NCT03115736|Experimental|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
11238868|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
11238869|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
11238870|NCT03115697|Active Comparator|Lactulose with Rifaximin|
11238871|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
11238872|NCT03115671|Experimental|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
11238873|NCT03115671|No Intervention|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
11238874|NCT03115658|Experimental|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.
~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
11238875|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
11238876|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
11238877|NCT03115632||Obese asthmatic & lean asthmatic|men and women with asthma and either obese or lean BMI
11238878|NCT03115632||Obese non-asthmatic & lean non-asthmatic|men and women without asthma and either obese or lean BMI
11238879|NCT03115632||Asthmatic undergoing bariatric surgery|Obese asthmatic men and women undergoing bariatric surgery
11238880|NCT03115632||Non-asthmatic undergoing bariatric surgery|Obese men and women undergoing bariatric surgery
11238881|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
11238882|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
11238883|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
11238884|NCT03115593|Experimental|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).
~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
11238885|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
11238886|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
11238887|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
11238888|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
11238889|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
11238890|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
11238891|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
11238892|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
11238893|NCT03115515|Experimental|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:
~TSH>10mIU/L, increase by 3 doses/week
~TSH 5.0-9.9mIU/L, increase by 2 doses/week
~TSH 2.0-4.9mIU/L, increase by 1 dose/week
~TSH 0.4-1.9mIU/L, no change
~TSH<0.4mIU/L, decrease by 1 dose/week
~TSH<0.1mIU/L, decrease by 2 doses/week
~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
11238921|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
11238922|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
11238923|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
11239230|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
11238894|NCT03115515|Experimental|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:
~TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg
~TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg
~TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg
~TSH 0.4-1.9mIU/L, no change
~TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day
~TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day
~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
11238895|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
11238896|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
11238897|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
11238898|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
11238899|NCT03115476|Placebo Comparator|Vehicle gel|
11238900|NCT03115463|Experimental|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
11238901|NCT03115463|No Intervention|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
11238902|NCT03115463|Active Comparator|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
11238903|NCT03115437|Experimental|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
11238904|NCT03115437|Experimental|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
11238905|NCT03115424|Placebo Comparator|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
11238906|NCT03115424|Active Comparator|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
11238907|NCT03115424|Sham Comparator|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
11238908|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
11238909|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
11238910|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
11238911|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
11238912|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
11238913|NCT03115372|Experimental|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
11238914|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
11238915|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
11238916|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
11238917|NCT03115346|Experimental|decision aid|the experimental group will receive the decision aid
11238918|NCT03115346|No Intervention|control|the control group will only receive the survey
11238919|NCT03115333|Experimental|Diagnostic (DSC-MRI)|Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
11238920|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
11239445|NCT03111680|No Intervention|control|the control participants received no interventions
11238924|NCT03115294|Experimental|Study group|Patients undergo procedure with stepwise measurements and ventilator + volume adjustment + iv theophylline Myocardial movement recording using videoscanning
11238925|NCT03115268|Experimental|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
11238926|NCT03115268|Active Comparator|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
11238927|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
11238928|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.
~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
11238929|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
11238930|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
11238931|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
11238932|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
11238933|NCT03115203|Other|Facial paralysis|
11238934|NCT03115203|Other|Healthy subject|
11238935|NCT03115190|Other|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
11238936|NCT03115190|No Intervention|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
11238937|NCT03115190|No Intervention|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.
~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
11238938|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
11238939|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
11238940|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
11238941|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
11238942|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
11238943|NCT03115138|Other|Patients with glial tumor|
11238944|NCT03115125|Other|Adult patients with severe sepsis|
11238945|NCT03115112|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
11238946|NCT03115112|Active Comparator|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
11238947|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
11238948|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
11238949|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
11238950|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
11238951|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
11238952|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
11238953|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
11238954|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
11238955|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
11238956|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
11238957|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
11238958|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
11238959|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
11238960|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:
~intravenous injection
~0.35 mcg/kg
~in two minutes
~if shivering 5 minutes after delivery"
11238961|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:
~intravenous injection
~0.35 mg/kg
~in two minutes
~if shivering 5 minutes after delivery"
11238962|NCT03115034|Active Comparator|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
11238963|NCT03115034|Placebo Comparator|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
11238964|NCT03115034|Sham Comparator|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
11238965|NCT03115021|Experimental|Active tPCS / Sham tDCS|All subject will receive active tPCS and sham tDCS for 20 minutes simultaneously.
11238966|NCT03115021|Experimental|Sham tPCS / Active tDCS|All subject will receive sham tPCS and active tDCS for 20 minutes simultaneously.
11238967|NCT03115021|Experimental|Sham tPCS / Sham tDCS|All subject will receive sham tPCS and sham tDCS for 20 minutes simultaneously.
11238968|NCT03115008|Experimental|Video-based terminal feedback|
11238969|NCT03115008|No Intervention|Conventional concurrent feedback|
11238970|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
11238971|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
11238972|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
11238973|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
11238974|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
11238975|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
11238976|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
11238977|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
11238978|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
11238979|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
11238980|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
11238981|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
11238982|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
11238983|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
11238984|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
11238985|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
11238986|NCT03114956|Experimental|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
11238987|NCT03114956|Experimental|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
11238988|NCT03114956|Experimental|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
11238989|NCT03114956|Experimental|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
11238990|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
11238991|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
11238992|NCT03114930|Other|Standard output|
11238993|NCT03114930|Other|Non standard output|
11238994|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
11238995|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
11238996|NCT03114904|Other|"Usual weaning management"|
11238997|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
11238998|NCT03114891|Experimental|fMRI-guided target|This site of stimulation will be created from participants' individualized resting connectivity data to guide stimulation that we show is especially effective in influencing downstream brain areas of interest. We will focus on a target region of the lateral prefrontal cortex (LPFC) that our data suggest is particularly effective at influencing the sgACC. Theta-burst stimulation will be administered to this target.
11238999|NCT03114891|Active Comparator|Standard brain target|As an alternative brain target, we will also test the efficacy of the dorsolateral prefrontal cortex as a target given its precedence as an FDA-approved stimulation site for remediating depressive symptoms. Theta-burst stimulation will be administered to this target.
11239000|NCT03114878|Active Comparator|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
11239001|NCT03114878|Active Comparator|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
11239002|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
11239003|NCT03114852||CKD patients|"'blood collection'
~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
11239004|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
11239005|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
11239006|NCT03114826||Renal cell carcinoma in renal transplant patients|
11239007|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.
~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.
~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.
~After 1 week, participants will return for dose optimisation
~After 4-12 weeks of treatment, participants will have:
~repeat one hour MRI scan
~repeat HVPG to evaluate treatment response"
11239008|NCT03114800|Experimental|E-Scale|Weight monitoring
11239009|NCT03114787|Other|Patient receiving respiratory physiotherapy|
11239010|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
11239011|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
11239012|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
11239013|NCT03114761|Experimental|CTA-IH|
11239014|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
11239015|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
11239016|NCT03114722|Active Comparator|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
11239017|NCT03114722|Experimental|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
11239018|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
11239019|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
11239020|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
11239021|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
11239022|NCT03114683|Experimental|IBI308|
11239023|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
11239024|NCT03114657|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
11239025|NCT03114657|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
11239026|NCT03114644|Other|Babies born prematurely between 27 and 37 SA|
11239027|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
11239028|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
11239029|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
11239030|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
11239031|NCT03114605|No Intervention|Control|Waiting List
11239032|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.
~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
11239033|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.
~Review a 15-20 minute educational tool on a tablet about kidney health
~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
11239034|NCT03114579|Other|Measure of the cardiac output obtained by a reference methode|
11239035|NCT03114579|Other|Measurement of cardiac output obtained by NEXFIN HD.|
11239036|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
11239037|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
11239038|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
11239039|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
11239040|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
11239041|NCT03114527|Experimental|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
11239042|NCT03114527|Experimental|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
11239044|NCT03114501|Experimental|Yoga Program Group|"Participants take part in the partner-based yoga program.
~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
11239045|NCT03114501|Experimental|Waitlist Control Group (WLC)|"Participants receive standard of care.
~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
11239046|NCT03114488|Experimental|Anodal Stimulation|
11239047|NCT03114488|Sham Comparator|Sham Stimulation|
11239048|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
11239049|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
11239050|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.
~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
11239051|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
11239052|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
11239053|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
11239054|NCT03114423|Experimental|Treatment As Usual + Treatment with EMDR|
11239055|NCT03114423|Sham Comparator|Treatment As Usual + Cognitive Training|
11239056|NCT03114410|Experimental|Re:MIX|In the experimental arm, the Re:MIX curriculum was implemented. The Re:MIX curriculum is a comprehensive teen pregnancy prevention consisting of ten hour-long sessions, delivered approximately once per week. The Re:MIX curriculum is taught by a professional health educator, partnered with a young parent educator who is a young parent (aged 18-25).
11239057|NCT03114410|No Intervention|Comparison|"In the comparison arm, teachers were given the option of implementing the Healthy Youth, Healthy You curriculum (focusing on nutrition, mental health, and fitness) or proceed with business as usual (no curriculum)."
11239058|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
11239059|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
11239060|NCT03114384|Experimental|Healthy volunteers|
11239061|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
11239062|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
11239063|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
11239064|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
11239065|NCT03114345|Other|Single arm|Measurement of interface pressure and Measurement of micro-vascularization related parameters
11239066|NCT03114332|Experimental|Study Group|Patients for whom a subcutaneous drain was used
11239067|NCT03114332|No Intervention|Control group|No drain group
11239068|NCT03114319|Experimental|TNO155|TNO155 for oral administration
11239069|NCT03114319|Experimental|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
11239070|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
11239071|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
11239072|NCT03114293|No Intervention|Waiting group|Waiting group
11239073|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
11239074|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
11239075|NCT03114267||Patient with chronic lymphocytic thyroiditis|
11239076|NCT03114267||Healthy subjects|
11239077|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:
~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
11239078|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
11239079|NCT03114241|No Intervention|Control|Usual care.
11239080|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
11239443|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
11239081|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
11239082|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
11239083|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
11239084|NCT03114189|Active Comparator|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.
~Information about wrong and correct behaviour."
11239085|NCT03114189|Active Comparator|Care of sleep|Information about wrong and correct behaviour.
11239086|NCT03114176|Experimental|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference [CTRL] and to measure physiological modifications due to immersion [NTRX]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive [KETO-NTRX]
11239087|NCT03114163||SCCHN patients in Germany|Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Germany
11239088|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
11239089|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
11239090|NCT03114137||sickle cell patients|"age: five-year-old or more
~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0
~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
11239091|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients
~hospital staff or their children matched on country and age +/- 3 ans with the patients"
11239092|NCT03114124|Active Comparator|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
11239093|NCT03114124|Experimental|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
11239094|NCT03114111|Active Comparator|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
11239095|NCT03114111|Placebo Comparator|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
11239096|NCT03114098|Experimental|CYP2D6 gene abnormalities|"A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.
~Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.
~Electrocardiogram
~Clinical exam
~Clinical Global Impression Scale (CGI-S)
~Children's Global Assessment Scale (CGAS)
~Sheehan Disability Scale (SDS)
~Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )
~Wechsler Intelligence Scale for Children - 4 (WISC-4)
~Wechsler Adult Intelligence Scale 4 (WAIS 4)
~Diagnostic and Statistical Manual of Mental Disorders (DSM)
~Autism Diagnostic Interview (ADI)"
11239097|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
11239098|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
11239510|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
11239099|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
11239100|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
11239101|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
11239102|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
11239103|NCT03114033|Experimental|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
11239104|NCT03114033|Active Comparator|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
11239105|NCT03114020|Experimental|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
11239106|NCT03114020|Placebo Comparator|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
11239107|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
11239108|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
11239109|NCT03114007|No Intervention|Control|Treatment as usual
11239110|NCT03113994|Active Comparator|Rosuvastatin|
11239111|NCT03113994|Placebo Comparator|Placebo|
11239112|NCT03113981|Experimental|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
11239113|NCT03113981|Active Comparator|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
11239114|NCT03113968|Active Comparator|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
11239115|NCT03113968|Active Comparator|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
11239116|NCT03113955|Experimental|single -arm|A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
11239117|NCT03113942|Experimental|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
11239118|NCT03113929||Alcoholic Liver Disease Patients|
11239119|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
11239120|NCT03113916|No Intervention|Enhanced usual care|Printed materials
11239121|NCT03113903|Experimental|scheduled surgery|
11239122|NCT03113903|Other|healthy volunteers|
11239123|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
11239124|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
11239125|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
11239126|NCT03113864|Placebo Comparator|Placebo|Will be identical looking to treatment
11239127|NCT03113864|Experimental|Lutein|10 mg of FloraGLO Lutein
11239128|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
11239129|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
11239130|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
11239131|NCT03113812|Experimental|ABvac40|
11239132|NCT03113812|Placebo Comparator|Placebo|
11239133|NCT03113799|Other|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
11239134|NCT03113786|No Intervention|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
11239135|NCT03113786|Active Comparator|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
11241366|NCT03099109|Experimental|LY3321367 Dose Expansion|LY3321367 given IV.
11239136|NCT03113786|Active Comparator|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
11239137|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
11239138|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
11239139|NCT03113760|Experimental|Tadekinig alfa|Patients that have completed the SAOL phase without a flare will receive Tadekinig alfa for addition 8 weeks.
11239140|NCT03113760|Placebo Comparator|0.9% sodium chloride|Patients that have completed the SAOL phase without a flare will receive placebo comparator for addition 8 weeks.
11239141|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
11239142|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:
~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;
~Systemic antibiotic therapy for preventing infectious complications;
~Adequate analgesia and sedation;
~Decompression necrotomy in the first 24 hours following the burn trauma;
~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;
~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
11239143|NCT03113708|Sham Comparator|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
11239144|NCT03113708|Experimental|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
11239145|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
11239146|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
11239147|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
11239148|NCT03113656|Experimental|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
11239149|NCT03113656|Experimental|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
11239150|NCT03113643|Experimental|SL-401+ Azacitidine|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously
11239151|NCT03113643|Experimental|SL-401+ Azacitidine + Venetoclax|SL-401 will be administered every 4 weeks, on a 28 day cycle; SL-401 will be given intravenously; Azacitidine will be administered every 4 weeks, on a 28 day cycle; Azacitidine will be given intravenously or subcutaneously; Venetoclax will be administered for 21 days on a 28 day cycle; Venetoclax will be taken orally
11239152|NCT03113630|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
11239153|NCT03113630|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
11239154|NCT03113630|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
11239155|NCT03113630|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
11239156|NCT03113630|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
11239157|NCT03113630|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
11239158|NCT03113617|Experimental|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
11239159|NCT03113604||Patients with untreated CHC not sorafenib|
11239160|NCT03113604||Patients with non-sorafenib CHC|
11239161|NCT03113604||Patients with CHCs responding to sorafenib|
11239162|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
11239163|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
11239164|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.
~Each subjects will have the two CT-scans on the same day."
11239165|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
11239166|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
11239167|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
11239511|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
11239168|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
11239169|NCT03113500|Experimental|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
11239170|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
11239171|NCT03113474|Experimental|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
11239172|NCT03113474|Experimental|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
11239173|NCT03113461|Experimental|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
11239174|NCT03113461|Active Comparator|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
11239175|NCT03113461|No Intervention|No OSA|Study participants who do not have OSA
11239176|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
11239177|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
11239178|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
11239179|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
11239180|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
11239181|NCT03113422|Experimental|Induction Venetoclax|Cycle 1-6: Obinutuzumab intravenously (IV) and bendamustine IV. Cycle 2-6: Venetoclax (oral)
11239182|NCT03113422|Experimental|Maintenance Venetoclax|Patients with stable or improved disease will receive venetoclax by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab IV every 2 months for 12 cycles.
11239183|NCT03113409|Experimental|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
11239184|NCT03113409|Experimental|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
11239185|NCT03113409|Experimental|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
11239186|NCT03113396|Experimental|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
11239187|NCT03113396|Placebo Comparator|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
11239188|NCT03113383|Experimental|Primary Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
11239189|NCT03113383|Experimental|Expanded Selection Arm|Patient that meets the criteria for inclusion in the primary study arm but has one or more of the inclusion criteria which would exclude them from the primary study arm.
11239190|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
11239191|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
11239192|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
11239231|NCT03113084|Experimental|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
11239573|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
11239193|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
11239194|NCT03113344||Children with the usage of anti-infective drugs|
11239195|NCT03113318|Experimental|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
11239196|NCT03113318|Active Comparator|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
11239197|NCT03113305||Gastric bypass patients|Patients planned to undergo Gastric bypass procedure. Patients will be assessed -1 month, 3 month, 24 month and 48 months post surgery.
11239198|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
11239199|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
11239200|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
11239201|NCT03113279||Obese older individuals|Obese older individuals
11239202|NCT03113279||Lean older individuals|Lean older individuals
11239203|NCT03113279||Young lean individuals|Young lean individuals
11239204|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
11239205|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:
~1g of tranexamic acid by slow intravenous injection
~1g of tranexamic acid by syringe pump during 8 hours"
11239206|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:
~10 mL of 0.9% sodium chloride by slow intravenous injection
~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
11239207|NCT03113240|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
11239208|NCT03113240|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
11239209|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
11239210|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
11239211|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
11239212|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
11239213|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
11239214|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
11239215|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
11239216|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
11239217|NCT03113201|Experimental|Collabri Flex|Collaborative care
11239218|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
11239219|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
11239220|NCT03113175|Experimental|Collabri Flex|Collaborative care
11239221|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
11239222|NCT03113162|Experimental|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
11239223|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
11239224|NCT03113136|Active Comparator|Low wattage E cigarette device|
11239225|NCT03113136|Active Comparator|High wattage E cigarette device|
11239226|NCT03113136|Active Comparator|Usual brand cigarette|
11239227|NCT03113123|Other|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later
~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
11239228|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
11239229|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
11241367|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
11239232|NCT03113084|Experimental|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
11239233|NCT03113071|Experimental|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
11239234|NCT03113071|Experimental|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
11239235|NCT03113058|Experimental|study group|
11239236|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
11239237|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
11239238|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
11239239|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
11239240|NCT03113019|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
11239241|NCT03113006|Active Comparator|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
11239242|NCT03113006|Experimental|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
11239243|NCT03112993|Experimental|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
11239244|NCT03112993|Active Comparator|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.
~Dosing will be based on actual body weight not ideal body weight."
11239245|NCT03112980|Experimental|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
11239246|NCT03112980|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
11239247|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
11239248|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
11239249|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
11239250|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
11239251|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
11239252|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
11239253|NCT03112928|Experimental|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
11239254|NCT03112928|Active Comparator|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
11239255|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)
~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
11239256|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)
~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
11239257|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard|
11239258|NCT03112902|Sham Comparator|Effects of tACS during SWS- Sham|
11239259|NCT03112902|Active Comparator|Effects of tACS during SWS- Nested|
11239260|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard2|
11239261|NCT03112902|Sham Comparator|Effects of tACS during SWS- Sham2|
11239262|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active|
11239263|NCT03112902|Sham Comparator|Effects of tACS during SWS- Older Adults Sham|
11239264|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active|
11239265|NCT03112902|Sham Comparator|Effects of tACS during SWS- MCI Sham|
11239266|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
11239267|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
11239268|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
11239269|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
11239270|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
11239271|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
11239272|NCT03112863|Experimental|Bakuchiol|
11239273|NCT03112863|Active Comparator|Retinol|
11239274|NCT03112850|Active Comparator|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
11239275|NCT03112850|Active Comparator|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
11239276|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
11239277|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
11239278|NCT03112837|No Intervention|healthy control group|
11239279|NCT03112824|Experimental|Ashwagandaha Root Extract Capsule|Participants will take one 300 mg. Ashwaganda capsule twice a day for 12 weeks.
11239280|NCT03112824|Placebo Comparator|Placebo Capsule|Participants will take one placebo capsule twice a day for 12 weeks.
11239281|NCT03112811|Experimental|Intubated infant|
11239282|NCT03112811|Experimental|Extubated infant|
11239283|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
11239284|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
11239285|NCT03112772|Experimental|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
11239286|NCT03112772|Experimental|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
11239287|NCT03112772|No Intervention|Group III|No grafting materials will be inserted, so it serves as a negative control group.
11239288|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
11239289|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
11239290|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
11239291|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
11239292|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
11239293|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
11239294|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
11239295|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
11239296|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
11239297|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
11239298|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
11239299|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
11239300|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
11239301|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA and neopterin detection
11239302|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
11239343|NCT03112382|Active Comparator|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
11239344|NCT03112382|Active Comparator|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
11239303|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.
~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
11239304|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
11239305|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
11239306|NCT03112616||Left-brain damaged chronic patients|
11239307|NCT03112616||Right-brain damaged chronic patients|
11239308|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
11239309|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
11239310|NCT03112590|Experimental|Combination Therapy|"Phase 1: Participants with HER-2 positive metastatic breast cancer enrolled in groups of 3-6 or more; each group participant to be given the same dose and schedule of Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. If group participants do not have bad side effects, the next group will be given a higher dose of Interferon-gamma. This will continue until the highest safe dose of Interferon-gamma is found. Once highest safe dose of Interferon-gamma is found, participants may be enrolled in Phase II.
~Phase 2: Approximately 31 participants with Stage 2-3 HER2 positive early stage breast cancer enrolled to receive therapy with Interferon-gamma plus paclitaxel, trastuzumab, and pertuzumab. Interferon-gamma given at dose found in the Phase 1.
~Phase 2: Post therapy surgery."
11239311|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
11239312|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
11239313|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
11239314|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
11239315|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
11239316|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
11239317|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
11239318|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
11239319|NCT03112538|Active Comparator|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
11239320|NCT03112538|Active Comparator|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
11239321|NCT03112525||Patient under Rivaroxaban|
11239322|NCT03112525||Patient under Apixaban|
11239323|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
11239324|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
11239325|NCT03112499|Active Comparator|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
11239326|NCT03112499|Active Comparator|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
11239327|NCT03112499|Active Comparator|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
11239328|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
11239329|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
11239330|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
11239331|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side
11239332|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
11239333|NCT03112473|No Intervention|Control group|No Active intervention
11239334|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
11239335|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
11239336|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
11239337|NCT03112408|Experimental|FORWARD (Axe 1)|
11239338|NCT03112408|Experimental|BACKWARD (Axe 1)|
11239339|NCT03112408|Experimental|CONTROL (Axe 1)|
11239340|NCT03112408|Experimental|ADAPTATION (Axe 2)|
11239341|NCT03112408|Experimental|CONTROL (Axe 2)|
11239342|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
11239348|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
11239349|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
11239350|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
11239351|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
11239352|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
11239353|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
11239354|NCT03112304|Experimental|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
11239355|NCT03112304|Experimental|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
11239356|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
11239357|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
11239358|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
11239359|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
11239360|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
11239361|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
11239362|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
11239363|NCT03112226|Active Comparator|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
11239364|NCT03112226|Placebo Comparator|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
11239365|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
11239366|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
11239367|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:
~Partial meniscectomy
~Lavage
~Debridement
~Loose body removal
~Synovectomy
~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)
~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
11239368|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
11239369|NCT03112174|Experimental|Safety Run-in Period|"Subjects are enrolled into the open-label Safety Run-in Period to evaluate the occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent administration of ibrutinib and venetoclax.
~Safety run-in phase for the study is closed to further enrollment as of 07-Nov-2018."
11239370|NCT03112174|Experimental|Phase 3: Ibrutinb + Venetoclax|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
11239371|NCT03112174|Placebo Comparator|Phase 3: Ibrutinib + Placebo|Subjects will be randomized to receive ibrutinib and venetoclax/placebo until clinical disease progression or unacceptable toxicity
11239372|NCT03112174|Experimental|Treatment-naive|"This open-label arm is designed to explore the efficacy and safety of the combination of ibrutinib and venetoclax in subjects with treatment-naive MCL.
~Approximately 75 subjects (of which ~25 subjects with TP53 mutation) will be enrolled and treated with ibrutinib and venetoclax."
11239373|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
11239374|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
11239375|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
11239376|NCT03112148|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
11239377|NCT03112148|Experimental|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
11239378|NCT03112148|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
11239379|NCT03112148|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
11239380|NCT03112148|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
11239381|NCT03112148|Experimental|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
11239382|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
11239383|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
11239384|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
11239385|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
11239386|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
11239387|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
11239388|NCT03112109||Intervention Group|Patients receiving 'new care'
11239389|NCT03112109||Control group|Patients receiving 'old / usual care'
11239390|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
11239391|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
11239392|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
11239393|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
11239394|NCT03112070|Experimental|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
11239395|NCT03112070|No Intervention|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
11239396|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
11239397|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
11239398|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
11239399|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
11239400|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
11239401|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
11239402|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
11239403|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
11239404|NCT03112018|Active Comparator|Standard care|"Data strengthening
~modified Safe Childbirth Checklist (mSCC) implementation"
11239444|NCT03111680|Experimental|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
11239405|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening
~modified Safe Childbirth Checklist (mSCC) implementation
~Health provider training (PRONTO)
~Quality Improvement (QI) Cycles"
11239406|NCT03111992|Experimental|Arm A|Dose escalation of single agent CJM112
11239407|NCT03111992|Experimental|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
11239408|NCT03111992|Experimental|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
11239409|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
11239410|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
11239411|NCT03111966||Spanish cohort with HCV treated with DAA|
11239412|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
11239413|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
11239414|NCT03111940|Experimental|PCI optimisation|Post PCI FFR below 0.9
11239415|NCT03111940|No Intervention|No PCI optimisation|Post PCI FFR 0.9 or higher
11239416|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
11239417|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
11239418|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
11239419|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
11239420|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
11239421|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
11239422|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
11239423|NCT03111875|Active Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An Multi-Position Upper Body Warming Blanket forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
11239424|NCT03111875|Experimental|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
11239425|NCT03111849||hospitalized chronic obstructive patients|
11239426|NCT03111836|Sham Comparator|Control group|The Control group received limited to general information on blood pressure management
11239427|NCT03111836|Active Comparator|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
11239428|NCT03111836|Active Comparator|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
11239429|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
11239430|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
11239431|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
11239432|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
11239433|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
11239434|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
11239435|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
11239436|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
11239437|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
11239438|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
11239439|NCT03111745||1|Retrospective chart review of patients who have underwent hematopoietic stem celltransplantation (HSCT)
11239440|NCT03111732|Experimental|1/Arm 1|Pembrolizumab plus Oxaliplatin plus Capecitabine
11239441|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
11239442|NCT03111706||Intact scar|women with intact scar detected during cesarean section
11239446|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
11239447|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
11239448|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
11239449|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
11239450|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
11239451|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
11239452|NCT03111654|Other|Patients with pericardial closure of the auricle|
11239453|NCT03111654|Other|Patients without closure of the auricle|
11239454|NCT03111641|Experimental|Lung ultrasonography|
11239455|NCT03111628|Other|Omalizumab|Omalizumab 300mg every month for 3 doses
11239456|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
11239457|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
11239458|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
11239459|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
11239460|NCT03111602|Experimental|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
11239461|NCT03111602|No Intervention|control group|healthy group as comparator
11239462|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
11239463|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
11239464|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
11239465|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
11239466|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
11239467|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
11239468|NCT03111563|Other|warm saline|case group ,
11239469|NCT03111563|Other|room temperature|control group
11239470|NCT03111550|Other|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
11239471|NCT03111550|Other|Investigational Lens Device #2|Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
11239472|NCT03111550|Other|Control Device|Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
11239473|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
11239474|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
11239475|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
11239476|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
11239477|NCT03111524|Active Comparator|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
11239478|NCT03111524|Active Comparator|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
11239479|NCT03111524|Active Comparator|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
11239574|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
11239575|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
11239480|NCT03111524|Active Comparator|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
11239481|NCT03111524|Active Comparator|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
11239482|NCT03111524|Placebo Comparator|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
11239483|NCT03111524|Placebo Comparator|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
11239484|NCT03111524|Placebo Comparator|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
11239485|NCT03111524|Placebo Comparator|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
11239486|NCT03111524|Placebo Comparator|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
11239487|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
11239488|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
11239489|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
11239490|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
11239491|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
11239492|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
11239493|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
11239494|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
11239495|NCT03111446|Active Comparator|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
11239496|NCT03111446|Active Comparator|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
11239497|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
11239498|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
11239499|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
~Loading dose day 1. Maintenance dose over subsequent 7 days."
11239500|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
~Loading dose day 1. Maintenance dose over subsequent 7 days."
11239501|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.
~Loading dose day 1. Maintenance dose over subsequent 7 days."
11239502|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
11239503|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
11239504|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
11239505|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
11239506|NCT03111368|Active Comparator|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
11239507|NCT03111368|Active Comparator|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
11239508|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
11239509|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
11239512|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
~Intervention = NO aspiration of gastric residuals"
11239513|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
11239514|NCT03111316|Other|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
11239515|NCT03111316|Other|Foley Catheter Alone|a Foley catheter alone
11239516|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
11239517|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
11239518|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
11239519|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
11239520|NCT03111277|Experimental|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
11239521|NCT03111264|Experimental|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
11239522|NCT03111264|Experimental|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
11239523|NCT03111264|No Intervention|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
11239524|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
11239525|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
11239526|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
11239527|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
11239528|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
11239529|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
11239530|NCT03111212|Active Comparator|Iloprost|
11239531|NCT03111212|Placebo Comparator|control|
11239532|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
11239533|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
11239534|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
11239535|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
11239536|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
11239537|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
11239538|NCT03111173|Other|Holter device|Holter device to be attached to a Singleton or twin pregnant women at 32 weeks gestation to full term
11239539|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
11239540|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
11239541|NCT03111147|Experimental|0 degrees humeral component version|Reverse Total Shoulder Arthroplasty with humeral component positioned in 0 degrees of version
11239542|NCT03111147|Experimental|30 degrees humeral component retroversion|Reverse Total Shoulder Arthroplasty with humeral component positioned in 30 degrees of retroversion
11239543|NCT03111134|No Intervention|Routine Abdominal Closure|
11239544|NCT03111134|Experimental|New Abdominal Closure|modified component separation technique is used to abdomen closing.
11239576|NCT03110926|Experimental|Induction Chemotherapy /Chemoradiation|mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles - Carboplatin AUC 2mg/mL/min, Paclitaxel 50 mg/m2 and radiation therapy.
11239792|NCT03109574|Other|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
11239793|NCT03109574|Other|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
11239545|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
11239546|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
11239547|NCT03111108|Experimental|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
11239548|NCT03111108|Experimental|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
11239549|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
11239550|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
11239551|NCT03111082||Lean|BMI less than or equal to 29.9
11239552|NCT03111082||Obese|BMI between 30.0 and 39.9
11239553|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
11239554|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
11239555|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.
~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
11239556|NCT03111056|Experimental|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
11239557|NCT03111056|No Intervention|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
11239558|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
11239559|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
11239560|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
11239561|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
11239562|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
11239563|NCT03111004||Comparator Group|The comparator group receives usual care
11239564|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
11239565|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
11239566|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
11239567|NCT03110978|Experimental|Arm I (stereotactic body radiation therapy)|Patients undergo stereotactic body radiation therapy over 1-2 weeks.
11239568|NCT03110978|Experimental|Arm II (stereotactic body radiation therapy, nivolumab)|Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
11239569|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
11239570|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
11239571|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
11239572|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
11239577|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).
~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
11239578|NCT03110900|Active Comparator|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
11239579|NCT03110900|Experimental|loxapine|Inhaled loxapine 10mg + IM normal saline
11239580|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
11239581|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)
~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)
~video based education"
11239582|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)
~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)
~direct education"
11239583|NCT03110861|Experimental|Pulsta® Transcatheter Pulmonary Valve|Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
11239584|NCT03110848|Experimental|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
11239585|NCT03110848|Active Comparator|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
11239586|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
11239587|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
11239588|NCT03110822|Experimental|Rux Len and Steroid|Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
11239589|NCT03110822|Experimental|Rux and Steroid until progression, then add Len|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
11239590|NCT03110809|Placebo Comparator|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
11239591|NCT03110809|Placebo Comparator|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
11239592|NCT03110809|Experimental|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
11239593|NCT03110809|Experimental|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
11239594|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
11239595|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
11239596|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
11239597|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
11239598|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
11239599|NCT03110770|Experimental|Part A, Group 1|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.
11239600|NCT03110770|Experimental|Part A, Group 2|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.
11239601|NCT03110770|Experimental|Part A, Group 3|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 8 mg of vaccine.
11239602|NCT03110770|Experimental|Part B, Group 4|ZIKV vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 4 mg of vaccine.
11239603|NCT03110770|Placebo Comparator|Part B, Group 5|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days), 1 mL of placebo.
11239604|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
11239605|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
11239606|NCT03110757|Active Comparator|Group C|Euvax B Hepatitis B vaccine (n=4)
11239607|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
11239608|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
11239609|NCT03110757|Active Comparator|Group F|Euvax B Hepatitis B vaccine (n=4)
11239610|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
11239611|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
11239612|NCT03110757|Active Comparator|Group I|Euvax B Hepatitis B vaccine (n=4)
11239613|NCT03110744|Experimental|Palbociclib|application on 21 consecutive days of a 28 days cycle
11239614|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
11239615|NCT03110731|No Intervention|Control Group|no intervention
11239794|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
11239616|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
11239617|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.
~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
11239618|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
11239619|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
11239620|NCT03110692|No Intervention|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
11239621|NCT03110692|Experimental|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
11239622|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
11239623|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
11239624|NCT03110666|Experimental|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
11239625|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
11239626|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
11239627|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
11239628|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
11239629|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
11239630|NCT03110601|Active Comparator|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
11239631|NCT03110601|No Intervention|Washout Period|1 day where no stimulation is provided
11239632|NCT03110601|Experimental|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
11239633|NCT03110588|Experimental|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
11239634|NCT03110588|Experimental|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
11239635|NCT03110575|Experimental|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
11239636|NCT03110562|Active Comparator|selinexor+bortezomib+dexamethasone (SVd)|Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
11239637|NCT03110562|Active Comparator|bortezomib+dexamethasone (Vd)|Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For Cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For Cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
11239638|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
11239639|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
11239640|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
11239641|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
11239642|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
11239643|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
11239644|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
11239645|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
11239646|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
11239647|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
11239648|NCT03110523|Experimental|X0002|X0002, BID, n=500
11239649|NCT03110523|Placebo Comparator|Placebo|Placebo, BID, n=250
11239650|NCT03110510|Experimental|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
11239681|NCT03110354|Experimental|DS-3201b in AML or ALL|DS-3201b is administered orally to participants with AML or ALL at a starting dose of 100 mg once a day, and then possibly at higher doses depending on safety observations
11239651|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
11239652|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
11239653|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
11239654|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
11239655|NCT03110471||Neuadd Drymmau Care Home|As above
11239656|NCT03110471||Monkstone House,|As above
11239657|NCT03110471||Danygraig House|As above
11239658|NCT03110471||Ty Coch|As above
11239659|NCT03110471||Swn y mor|As above
11239660|NCT03110471||Hengoed court|As above
11239661|NCT03110471||Hengoed park|As above
11239662|NCT03110471||Cefn Lodge care home|As above
11239663|NCT03110458|Experimental|SENS-111 100mg|SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)
11239664|NCT03110458|Experimental|SENS-111 200mg|SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)
11239665|NCT03110458|Placebo Comparator|Placebo|Placebo: 2 placebo Oral Dispersible Tablets
11239666|NCT03110445|Experimental|rVV-740CTA vaccine|
11239667|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
11239668|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
11239669|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
11239670|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
11239671|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
11239672|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
11239673|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
11239674|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
11239675|NCT03110380|Experimental|B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for 48 Weeks
11239676|NCT03110380|Active Comparator|DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for 48 Weeks
11239677|NCT03110380|Experimental|Open-Label Extension Phase|After Week 48, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive open-label B/F/TAF for up to 96 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
11239678|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:
~- Memory reframe with parent facilitated by researcher:
~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
11239679|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.
~Participants will be randomized into this group:
~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
11239680|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.
~Participants will be randomized into this group:
~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
11239790|NCT03109587|Active Comparator|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
11239682|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
11239683|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
11239684|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
11239685|NCT03110315|Experimental|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
11239686|NCT03110315|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
11239687|NCT03110302|Active Comparator|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
11239688|NCT03110302|Active Comparator|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
11239689|NCT03110302|Experimental|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
11239690|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
11239691|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
11239692|NCT03110276|Experimental|EYP001a|
11239693|NCT03110276|Placebo Comparator|Placebo|
11239694|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
11239695|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
11239696|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
11239697|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
11239698|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
11239699|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
11239700|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
11239701|NCT03110198|Experimental|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
11239702|NCT03110198|Active Comparator|Mesalazine|Mesalazine （4g）enema
11239703|NCT03110198|Active Comparator|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
11239704|NCT03110185|Other|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
11239705|NCT03110185|Other|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
11239706|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
11239707|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
11239708|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
11239709|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
11239710|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.
~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
11239711|NCT03110133|Experimental|CP101|Full Spectrum Microbiota Capsule
11239712|NCT03110133|Placebo Comparator|Placebo|Matching Placebo Capsule
11239713|NCT03110120|Active Comparator|serratus|Serratus plane block and local control
11239714|NCT03110120|Sham Comparator|local|serratus control and local anesthesia
11239715|NCT03110107|Experimental|Ipilimumab Monotherapy|
11239716|NCT03110107|Experimental|Combination Therapy|
11239717|NCT03110107|Experimental|BMS-986218 Monotherapy|
11239718|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
11239719|NCT03110094|Other|Healthy volunteer|
11239720|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
11239721|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
11239722|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
11239723|NCT03110055|Experimental|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.
~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
11239724|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
11239725|NCT03110029|Active Comparator|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
11239726|NCT03110029|Placebo Comparator|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
11239727|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
11239728|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
11239729|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
11239730|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
11239731|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
11239732|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
11239733|NCT03109964|Active Comparator|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
11239734|NCT03109964|Experimental|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
11239735|NCT03109951|Other|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
11239736|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
11239737|NCT03109912|No Intervention|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
11239738|NCT03109912|Experimental|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
11239739|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
11239740|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
11239741|NCT03109886|Experimental|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
11239742|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
11239743|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
11239744|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
11239745|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
11239746|NCT03109834|Active Comparator|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)
~During weight stabilization phase (phase 2) MR counted to food choice option."
11239747|NCT03109834|Other|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)
~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
11239748|NCT03109834|Active Comparator|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)
~Duration: 6-month weight maintenance phase (phase 3)"
11239749|NCT03109834|Placebo Comparator|Placebo group|"Placebo capsules
~Duration: 6-month weight maintenance phase (phase 3)"
11239750|NCT03109821||THA patients|
11239751|NCT03109808|Experimental|e-health strategy|Assigned intervention: e-health strategy
11239752|NCT03109808|Active Comparator|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
11239791|NCT03109587|Placebo Comparator|Placebo|identical in appearance, but without probiotics.
11239753|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
11239754|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
11239755|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
11239756|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
11239757|NCT03109756|Experimental|Single-dose 5 mg OV101|
11239758|NCT03109743|Experimental|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for ~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
11239759|NCT03109743|Active Comparator|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
11239760|NCT03109730|Experimental|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
11239761|NCT03109730|Experimental|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
11239762|NCT03109730|Experimental|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
11239763|NCT03109730|Experimental|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
11239764|NCT03109730|Experimental|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
11239765|NCT03109730|Experimental|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
11239766|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
11239767|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
11239768|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
11239769|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
11239770|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
11239771|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
11239772|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
11239773|NCT03109678|Experimental|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
11239774|NCT03109678|Experimental|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
11239775|NCT03109678|Experimental|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
11239776|NCT03109678|Experimental|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
11239777|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
11239778|NCT03109652|Active Comparator|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
11239779|NCT03109652|Experimental|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
11239780|NCT03109652|Experimental|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
11239781|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
11239782|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
11239783|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
11239784|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
11239785|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
11239786|NCT03109600|Experimental|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
11239787|NCT03109600|Active Comparator|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
11239788|NCT03109600|Experimental|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
11239789|NCT03109600|Active Comparator|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
11239795|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
11239796|NCT03109522|Experimental|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
11239797|NCT03109522|Active Comparator|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
11239798|NCT03109509|Active Comparator|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
11239799|NCT03109509|Experimental|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
11239800|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
11239801|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
11239802|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
11239803|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.
~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
11239804|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.
~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
11239805|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
11239806|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.
~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
11239807|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
11239808|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
11239809|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
11239810|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
11239811|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
11239812|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
11239813|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
11239814|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
11239815|NCT03109379|Experimental|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
11239875|NCT03108963|Experimental|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
11239816|NCT03109379|Experimental|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
11239817|NCT03109366|Other|Online self-management support|Access to online self-management support tool for six months
11239818|NCT03109353|Experimental|ALA-ECP|Extracorporeal photopheresis (ECP) with 5-aminolevulinic acid replacing psoralen
11239819|NCT03109340|Active Comparator|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
11239820|NCT03109340|Experimental|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
11239821|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
11239822|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
11239823|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
11239824|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
11239825|NCT03109301|Experimental|Arm 1|Patients > 18 years of age
11239826|NCT03109301|Experimental|Arm 2|Patients < 18 years of age
11239827|NCT03109288|Experimental|Cobination Therapy|Any two-drug combination of study interventions
11239828|NCT03109288|Experimental|Monotherapy|Any of the study Interventions
11239829|NCT03109275|Active Comparator|Single MRI examination|40 subjects will benefit from a full MRI
11239830|NCT03109275|Sham Comparator|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
11239831|NCT03109262|Experimental|Diagnostic (Yttrium Y 90 glass microspheres PET/CT)|Immediately after standard of care SIRT, patients receive yttrium Y 90 glass microspheres and undergo PET/CT over 30 minutes.
11239832|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
11239833|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
11239834|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state. 5 dose GCSF (Neupogen) will be administered 5 days consecutively before bone marrow harvesting.
~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
11239835|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:
~Patients will receive 5 doses of GCSF (Neupogen)"
11239836|NCT03109223|Active Comparator|Commercially availabel infant formula|
11239837|NCT03109223|Experimental|Test formula with 2-FL|
11239838|NCT03109223|Active Comparator|Breast Fed|
11239839|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
11239840|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
11239841|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
11239842|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
11239843|NCT03109184|No Intervention|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
11239844|NCT03109184|Experimental|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
11239845|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
11239876|NCT03108963|Active Comparator|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
11239846|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.
~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
11239847|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.
~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.
~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
11239848|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
11239849|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
11239850|NCT03109132|Active Comparator|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
11239851|NCT03109132|Active Comparator|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
11239852|NCT03109132|Active Comparator|Model 3|Device - Experimental sample line Model 3
11239853|NCT03109132|Active Comparator|Model 4|Device - Experimental sample line Model 4
11239854|NCT03109132|Active Comparator|Model 5|Device - Experimental sample line Model 5
11239855|NCT03109132|Active Comparator|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
11239856|NCT03109119|Active Comparator|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
11239857|NCT03109119|Sham Comparator|Group P|These patients will be induced and maintained with propofol during anaesthesia.
11239858|NCT03109106|Experimental|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.
~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
11239859|NCT03109106|No Intervention|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
11239860|NCT03109093|Experimental|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.
~Patients entered with MRD level <10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab.
~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
11239861|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
11239862|NCT03109067|Experimental|Standardized meal|"Standardized meal for :
~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
11239863|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
11239864|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
11239865|NCT03109041|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
11239866|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
11239867|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
11239868|NCT03109015|Active Comparator|Schedule 4/2|
11239869|NCT03109015|Experimental|Schedule 2/1|
11239870|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
11239871|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
11239872|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
11239873|NCT03108976|Sham Comparator|Control group|Children with a typical development.
11239874|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
11239877|NCT03108950|Experimental|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
11239878|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
11239879|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
11239880|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
11239881|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
11239882|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
11239883|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
11239884|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
11239885|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
11239886|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
11239887|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
11239888|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
11239889|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
11239890|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
11239891|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
11239892|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
11239893|NCT03108820|Experimental|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
11239894|NCT03108820|Active Comparator|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
11239895|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
11239896|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
11239897|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
11239898|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
11239899|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:
~by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.
~endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.
~at least 2 features of cirrhosis:
~irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness > 4.0cm or > 5 rib units) on ultrasound ,CT or MRI;
~PLT<100×109/L without other causes;
~Serum album in<35 g/L or INR>1.3 or PT prolongs>3s;
~LSM>13 kpa (ALT<5×ULN)."
11239900|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
11239901|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
11239902|NCT03108781|Active Comparator|Lavender Oil|
11239903|NCT03108781|Placebo Comparator|sunflower oil|
11239904|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
11239905|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
11239906|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
11239907|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
11239908|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
11239909|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
11239910|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
11239911|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
11239912|NCT03108742|Experimental|dermal stapler|
11239913|NCT03108742|Active Comparator|classic intradermal suture|
11239914|NCT03108729|Experimental|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
11239915|NCT03108716|Experimental|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
11239916|NCT03108716|Experimental|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
11239917|NCT03108716|Experimental|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
11239918|NCT03108703|Experimental|SBRT|RCC patients
11239919|NCT03108690|Experimental|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
11239920|NCT03108690|No Intervention|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
11239921|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
11239922|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
11239923|NCT03108664|Experimental|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
11239924|NCT03108664|Experimental|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
11239925|NCT03108651|Active Comparator|Case|Motivational message will be administrated.
11239926|NCT03108651|No Intervention|Control|Motivational message will not be administrated.
11239927|NCT03108638||R3 Supervisor Strategy Region 1|First cohort to be trained and monitored with remote coaching in the R3 model
11239928|NCT03108638||R3 Supervisor Strategy Region 2|Second cohort to be trained and monitored with remote coaching in the R3 model
11239929|NCT03108638||R3 Supervisor Strategy Region 3|Third cohort to be trained and monitored with remote coaching in the R3 model
11239930|NCT03108638||R3 Supervisor Strategy Region 4|Fourth cohort to be trained and monitored with remote coaching in the R3 model
11239931|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
11239932|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
11239933|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
11239934|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
11239935|NCT03108586|Active Comparator|FDI|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
11239936|NCT03108586|Experimental|CARS|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
11239937|NCT03108560|Experimental|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
11239938|NCT03108560|Active Comparator|Lobectomy group|Patients receive lobectomy.
11239939|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
11239940|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
11239941|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
11239942|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
11239943|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
11239944|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
11239945|NCT03108521|Experimental|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
11239946|NCT03108521|No Intervention|non-T2DM group|Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.
11239947|NCT03108508|Experimental|Prod1|G5 Siliplant
11239948|NCT03108508|Experimental|Prod2|Orgono Powder®
11239949|NCT03108508|Experimental|Prod3|G7 ALOE
11239950|NCT03108495|Experimental|Cohort 1 LN-145 monotherapy|Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
11239951|NCT03108495|Experimental|Cohort 2 LN-145 monotherapy|Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
11239952|NCT03108495|Experimental|Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only|Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab +/- 3 weeks post IL-2 administration up to 24 months.
11239953|NCT03108495|Experimental|Cohort 4 - Non-enrolling Cohort|Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
11239954|NCT03108495|Experimental|Cohort 5 Retreatment Cohort|Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
11239955|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
11239956|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
11239957|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
11239958|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
11239959|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
11239960|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
11239961|NCT03108456|Active Comparator|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
11239962|NCT03108456|Active Comparator|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
11239963|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
11239964|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
11239965|NCT03108430||Inhalation pneumonia|
11239966|NCT03108430||Proven inhalations|
11239967|NCT03108430||Suspected inhalations (coma + anamnesis)|
11239968|NCT03108417|Experimental|cNEP|continuous negative external pressure will be used nightly by all participants
11239969|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
11239970|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
11239971|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
11239972|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
11239973|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
11239974|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
11239975|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
11239976|NCT03108365|Experimental|Axiostat|"Size: 1 x 1 cm
~Chitosan based haemostatic dressing"
11239977|NCT03108365|Active Comparator|Cotton Gauze|Size: 1 x 1 cm
11239978|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
11239979|NCT03108352|Sham Comparator|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
11239980|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
11239981|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
11239982|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
11239983|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
11239984|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
11239985|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
11240019|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
11239986|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
11239987|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
11239988|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
11239989|NCT03108287|Active Comparator|RAK therapy|rabeprazole+amoxicillin+clarithromycin
11239990|NCT03108287|Active Comparator|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
11239991|NCT03108274|Experimental|Part 1, Period 1|Single oral dose of Midazolam Day 1
11239992|NCT03108274|Experimental|Part 1, Period 2|Multiple oral doses of ACH-0144471 Day 1-4 Single oral single dose of Midazolam on Day 4
11239993|NCT03108274|Experimental|Part 2, Period 1|Single dose of Fexofenadine on Day 1
11239994|NCT03108274|Experimental|Part 2, Period 2|Multiple doses of ACH-0144471 on Days 1-6 Single dose of Fexofenadine on Day 4
11239995|NCT03108274|Experimental|Part 3, Period 1|Single dose of Mycophenolate Mofetil on Day 1
11239996|NCT03108274|Experimental|Part 3, Period 2|Multiple doses of ACH-0144471 on Days 1-6 Single dose of Mycophenolate Mofetil on Day 4
11239997|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
11239998|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
11239999|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
11240000|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
11240001|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
11240002|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
11240003|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
11240004|NCT03108209|Experimental|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
11240005|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
11240006|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
11240007|NCT03108170|Active Comparator|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
11240008|NCT03108170|Active Comparator|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
11240009|NCT03108157|Experimental|GROUP A: intervention group|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
11240010|NCT03108157|No Intervention|GROUP B: no intervention group|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
11240011|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
11240012|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
11240013|NCT03108131|Experimental|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11240014|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
11240015|NCT03108105|Experimental|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
11240016|NCT03108092|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
11240017|NCT03108092|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
11240018|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.
~Interventions are listed in the Interventions Section."
11241368|NCT03099109|Experimental|Japanese Arm D LY3321367|LY3321367 given IV.
11240020|NCT03108053|Active Comparator|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
11240021|NCT03108053|Experimental|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
11240022|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
11240023|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
11240024|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
11240025|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
11240026|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
11240027|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
11240028|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
11240029|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
11240030|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
11240031|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
11240032|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
11240033|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
11240034|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
11240035|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
11240036|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
11240037|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
11240038|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
11240039|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
11240040|NCT03107975|Experimental|Cell Therapy|intrathecal injection of human amniotic epithelial cells
11240041|NCT03107962|Experimental|PD-1 Blocking Antibody|Pembrolizumab
11240042|NCT03107949|Experimental|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
11240043|NCT03107936|Experimental|smokeSCREEN game play|Participants are instructed to access the web-based videogame intervention, smokeSCREEN, through a secured website and play the game using their unique User ID and password.
11240044|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
11240045|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
11240046|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
11240047|NCT03107897|No Intervention|Pre-procedure standard of care|No prehab prior to TAVR.
11240048|NCT03107897|Active Comparator|Prehab prior to TAVR procedure.|Individuals participate in prehabilitation prior to TAVR.
11240049|NCT03107884|Experimental|Metformin (Bed Rest)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
11240050|NCT03107884|Placebo Comparator|Placebo (Bed Rest)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
11240051|NCT03107884|Experimental|Metformin (2 week run-in only)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). These participants will not participate in the bed rest portion of the protocol.
11240052|NCT03107884|Placebo Comparator|Placebo (2 week run-in only)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
11240053|NCT03107871|Experimental|Arm A|Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months
11240054|NCT03107871|Placebo Comparator|Arm B|Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months
11240055|NCT03107858|Active Comparator|Norepinephrine|
11240056|NCT03107858|Active Comparator|Dopamine|
11240057|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
11240058|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
11240169|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
11240059|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
11240060|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
11240061|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
11240062|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
11240063|NCT03107806|Other|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
11240064|NCT03107806|Other|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
11240065|NCT03107793|Experimental|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
11240066|NCT03107793|Experimental|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
11240067|NCT03107793|Experimental|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with <25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with >=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
11240068|NCT03107793|Experimental|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score <=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
11240069|NCT03107780|Experimental|Treatment (MDM2 inhibitor AMG 232 [KRT-232])|"PART I: Patients with recurrent glioblastoma receive MDM2 inhibitor AMG 232 (KRT-232) PO QD for 2 days. Within 3-6 hours of the last dose, patients undergo standard of care surgery. Upon recovery (within 45 days), patients with TP53 wild-type tumors continue to receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7. Cycles repeat every 21 days in absence of disease progression or unacceptable toxicity.
~PART II: Within 6 weeks of standard of care surgery, patients with newly diagnosed glioblastoma undergo radiation therapy daily during weeks 1-6. Patients also receive MDM2 inhibitor AMG 232 (KRT-232) PO 3 times weekly on days 2, 3, and 5 for 6 weeks or 2 times weekly on days 2 and 4 for 6 weeks during radiation therapy.
~PART II (EXPANSION COHORT): Patients receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7. Cycles repeat every 21 days in absence of disease progression or unacceptable toxicity."
11240070|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
11240071|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
11240072|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
11240073|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
11240074|NCT03107741|No Intervention|Passive Control|Subjects in this group will not receive any intervention.
11240075|NCT03107741|Placebo Comparator|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
11240076|NCT03107741|Active Comparator|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
11240077|NCT03107728|Experimental|Advanced orthotic brace|
11240078|NCT03107728|Active Comparator|Conventional orthotic brace|
11240079|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
11240080|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
11240081|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
11240082|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
11240083|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
11240084|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
11240085|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
11240086|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
11240087|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
11240088|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
11240089|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
11240090|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
11240091|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
11240092|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
11240093|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
11240094|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
11240095|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
11240096|NCT03107546|Other|Skin graft|full thickness skin graft
11240097|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
11240098|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
11240099|NCT03107520|Experimental|DDH Surgical Reduction Patients|Infants treated for DDH who failed conservative measures and are undergoing intraoperative open or closed hip reduction. Intraoperative contrast-enhanced ultrasound using Lumason contrast agent will be administered to improve visualization of the epiphyseal vascularity after hip reduction and during placement of the spica cast.
11240100|NCT03107507|Active Comparator|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.
~Duration: until seizure free"
11240101|NCT03107507|Active Comparator|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.
~Duration: until seizure free"
11240102|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
11240103|NCT03107481|Active Comparator|Acetaminophen|
11240104|NCT03107481|Active Comparator|Hydromorphone|
11240105|NCT03107468|Experimental|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
11240106|NCT03107468|Active Comparator|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
11240107|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
11240108|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
11240109|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.
~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
11240110|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.
~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
11240111|NCT03107416|Experimental|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
11240112|NCT03107403|Experimental|Healthy subjects|
11240113|NCT03107390|Other|Patients with CD or RCH|
11240114|NCT03107390|Other|The control population|
11240115|NCT03107377|Active Comparator|EVO100|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
11240116|NCT03107377|Placebo Comparator|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
11240117|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
11240118|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
11240119|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
11240120|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
11240121|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
11240122|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
11240123|NCT03107325|Other|F-18 FDG|Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
11240124|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
11240125|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
11240126|NCT03107299|Other|Control|
11240127|NCT03107299|Other|Send sms to patients|
11240128|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
11240129|NCT03107286|Other|Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
11240130|NCT03107273||Diagnostic patient|
11240131|NCT03107273||Control|
11240132|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
11240133|NCT03107247|Other|Tc-99m MDP|Patients ages 1-16 years old will be included. Routine SPECT imaging will be collected 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ for 10-15 s per view using a 1282 matrix. Half of the subjects will also be imaged between 30 and 90 min, PA. The 2nd half will be at 4-6 h, PA. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
11240134|NCT03107234||Patient with breast cancer requiring surgery to|
11240135|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
11240136|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
11240137|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
11240138|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
11240139|NCT03107195|Other|Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
11240140|NCT03107182|Experimental|Induction Chemotherapy|"All enrolled patients will receive three 21-day cycles of chemotherapy consisting of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total), carboplatin (AUC 5 on day 1; 3 doses total), and nivolumab (360 mg on days 1; 3 doses total). Growth factor support will be provided using G-CSF administered on days 16-18.
~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy."
11240141|NCT03107182|Experimental|Single Modality De-escalation Arm (SDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.
~Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. De-intensified adjuvant RT will be given for adverse pathologic features. Patients may refuse TORS treatment.
~Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 G."
11240170|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
11240171|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
11240172|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
11240142|NCT03107182|Experimental|Intermediate De-escalation Arm (IDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.
~Patients who have low risk disease with <50% but ≥30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 45 Gy (3 cycles).
~Patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles)."
11240143|NCT03107182|Experimental|Regular Dose Arm (RDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.
~Patients who have low risk disease and <30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 75 Gy (5 cycles).
~Patients who have high risk disease and <50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).
~Any patient who has progressive disease will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
11240144|NCT03107169|Active Comparator|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
11240145|NCT03107169|Experimental|FMT-FURM|Patients in this arm receive FMT-FURM
11240146|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
11240147|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
11240148|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
11240149|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
11240150|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
11240151|NCT03107104|Experimental|Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
11240152|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
11240153|NCT03107078|Experimental|Group Ia|"I:The increase of fat volume dominates .
~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
11240154|NCT03107078|Experimental|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
11240155|NCT03107078|Experimental|Group IIa|"II:The increase of extraocular muscles volume dominates .
~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
11240156|NCT03107078|Experimental|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
11240157|NCT03107065|Experimental|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
11240158|NCT03107052|Experimental|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 milliliter {mL}] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
11240159|NCT03107052|Experimental|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 12, 24, and 36) through Week 36.
11240160|NCT03107052|Experimental|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
11240161|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
11240162|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
11240163|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
11240164|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
11240165|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
11240166|NCT03107013|Experimental|[14C]-BTD-001|
11240167|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
11240168|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
11240239|NCT03106558|Active Comparator|Robitic arm total knee replacement|
11240173|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
11240174|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
11240175|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
11240176|NCT03106935|Active Comparator|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
11240177|NCT03106935|No Intervention|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
11240178|NCT03106922|Experimental|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:
~2<=Age<6
~500 ml in 1-1.5 hours <= to 18 kg
~625 ml in 1-1.5 hours >18 kg 6<=Age<12:
~750 ml in 1-2 hours <=25 kg
~1000 ml in 1-2 hours 25-35 kg
~1250 ml in 1-2 hours >35 kg 12>=Age<18 :
~1500 ml in 2-3 hours <= 45 kg
~1750 ml in 2-3 hours>45 kg.
~Rescue dose (if no clear watery stools 3 hours after the entire solution):
~250 ml 2 Age <=6;
~500 ml 6 <=Age<12; up to a cumulative maximum volume of 2000 ml 12<=Age<18."
11240179|NCT03106922|Active Comparator|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:
~2<=Age<6:
~90 ml/kg in 1-1.5 hours 2<=Age<6
~80 ml/kg in 1-1.5 hours 5<=Age<6
~2<=Age<6:
~80 ml/kg in 1-2 hours 6<=Age<10
~70 ml/kg in 1-2 hours 10<=Age<12
~12<=Age<18:
~70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
11240180|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
11240181|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
11240182|NCT03106896||healthy control (CON group)|healthy population
11240183|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions
~Five five-minute blocks separate by 90-second rest periods"
11240184|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)
~Five five-minute blocks separate by 90-second rest periods"
11240185|NCT03106870|Active Comparator|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
11240186|NCT03106870|Active Comparator|insulin therapy only|Intervention 'Insulin Mixtard' had included
11240187|NCT03106857|Placebo Comparator|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
11240188|NCT03106857|No Intervention|Group B|No intervention
11240189|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
11240190|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
11240191|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
11240192|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
11240193|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
11240194|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
11240195|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
11240196|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
11240197|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
11240198|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
11240199|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
11240200|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
11240201|NCT03106779|Experimental|ABL001|patients will be treated with ABL001
11240202|NCT03106779|Active Comparator|Bosutinib|patients will be treated with bosutinib
11240203|NCT03106766|Experimental|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
11240204|NCT03106766|Experimental|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
11240205|NCT03106753|Active Comparator|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
11240240|NCT03106545|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
11240206|NCT03106753|Experimental|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
11240207|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
11240208|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
11240209|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
11240210|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
11240211|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
11240212|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
11240213|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
11240214|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
11240215|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
11240216|NCT03106701|Experimental|Ablation|Radiofrequency epicardial ablation
11240217|NCT03106688|Active Comparator|Low-risk group|Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
11240218|NCT03106688|Active Comparator|High-risk group|Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
11240219|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging
~Pre-treatment questionnaires and laboratory blood samples
~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)
~Follow-up (imaging, questionnaires, laboratory)
~Follow-up pain medication usage"
11240220|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging
~Pre-treatment questionnaires and laboratory blood samples
~Intervention (Varian Truebeam Radiotherapy System)
~Follow-up (imaging, questionnaires, laboratory)
~Follow-up pain medication usage"
11240221|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
11240222|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
11240223|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
11240224|NCT03106636|Active Comparator|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
11240225|NCT03106636|Experimental|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
11240226|NCT03106623|Experimental|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
11240227|NCT03106623|Active Comparator|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
11240228|NCT03106623|Placebo Comparator|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
11240229|NCT03106610|Experimental|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).
~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
11240230|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
11240231|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
11240232|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.
~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
11240233|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.
~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
11240234|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
11240235|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
11240236|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
11240237|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
11240238|NCT03106558|Active Comparator|Manual instrument total knee replacement|
11240241|NCT03106545|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
11240242|NCT03106545|Sham Comparator|General anesthesia|General anesthesia
11240243|NCT03106532|Experimental|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
11240244|NCT03106532|Experimental|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
11240245|NCT03106532|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
11240246|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
11240247|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
11240248|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
11240249|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
11240250|NCT03106493||Primary|Singletons and 1 twin of each pair
11240251|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
11240252|NCT03106493||Tertiary|Higher order multiples and siblings
11240253|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
11240254|NCT03106467|Experimental|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
11240255|NCT03106467|Active Comparator|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
11240256|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
11240257|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
11240258|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
11240259|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
11240260|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
11240261|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
11240262|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
11240263|NCT03106415|Experimental|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of course 1 and on days 1-21 of course 2 and subsequent courses. Patients also receive pembrolizumab IV over 30 minutes on day 1. Course 1 equals 14 days. Courses 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11240264|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
11240265|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
11240266|NCT03106389|Active Comparator|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
11240267|NCT03106389|Experimental|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
11240268|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
11240269|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
11240270|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
11240271|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
11240272|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
11240273|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
11240274|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
11240275|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
11240276|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
11240420|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
11240277|NCT03106311|Active Comparator|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
11240278|NCT03106311|Active Comparator|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
11240279|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
11240280|NCT03106285|Experimental|Lactobacillus reuteri DSM17938|Oil drops
11240281|NCT03106285|Placebo Comparator|Placebo|Oils drops
11240282|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
11240283|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
11240284|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
11240285|NCT03106246||T2DM|Patients with established type II diabetes.
11240286|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
11240287|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
11240288|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
11240289|NCT03106220|Active Comparator|home exercise|participate in home exercise program
11240290|NCT03106220|Placebo Comparator|standard care|encouraged to join physical therapy and walking goals
11240291|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
11240292|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.
~Case management"
11240293|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
11240294|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
11240295|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
11240296|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
11240297|NCT03106155|Experimental|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
11240298|NCT03106142|Other|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
11240299|NCT03106142|No Intervention|control group|The two case vignettes will also be presented to GP who did not received the intervention.
11240300|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
11240301|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
11240302|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
11240303|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
11240304|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
11240305|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
11240306|NCT03106077|Experimental|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
11240307|NCT03106077|Experimental|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
11240308|NCT03106064|Placebo Comparator|Usual Care Group|Intervention: Usual care
11240309|NCT03106064|Experimental|Intervention Group|Intervention:Promoting independence in self-care
11240310|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
11240311|NCT03106038|Experimental|Nerindocianine for Injection|One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.
11240312|NCT03106025|Experimental|Patients Receiving Ultrasound|Enrolled participants will receive a bedside ocular ultrasound of the affected eye and the ultrasound will be compared with the ophthalmologist diagnosis. The participant's medical record will also be reviewed for information regarding demographics, complications, and outcomes.
11240313|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
11240314|NCT03105986|Experimental|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
11240421|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
11240315|NCT03105986|Experimental|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
11240316|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
11240317|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .
~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
11240318|NCT03105960|Active Comparator|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash
~."
11240319|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
11240320|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
11240321|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
11240322|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
11240323|NCT03105921|Experimental|Electrodes|Electrodes
11240324|NCT03105908|Other|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
11240325|NCT03105908|Other|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
11240326|NCT03105882|Experimental|Neuro-Spinal Scaffold|
11240327|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
11240328|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
11240329|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
11240330|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
11240331|NCT03105843|Experimental|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
11240332|NCT03105843|Experimental|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
11240333|NCT03105843|Experimental|Control|Individuals with no history of asthma or chronic cough
11240334|NCT03105830|Experimental|intervention and data collection|pain management by iv paracetamol
11240335|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
11240336|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
11240337|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
11240338|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
11240339|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
11240340|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
11240341|NCT03105765|Active Comparator|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.
~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
11240342|NCT03105765|Placebo Comparator|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.
~Placebo (normal Saline) for 24 hours."
11240343|NCT03105752|Experimental|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
11240344|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
11240345|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
11240346|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
11240347|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
11240348|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is three patient safety checklists for patients to be performed: a) before admission to hospital; b) under hospital stay (discharge); c) after discharge from hospital.
11240349|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
11240350|NCT03105700|Experimental|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
11240351|NCT03105687|No Intervention|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.
~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
11240382|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
11240352|NCT03105687|Experimental|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
11240353|NCT03105674|Active Comparator|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
11240354|NCT03105674|Experimental|Multi-drug local anaesthetics|"Patients will receive a combination [Multi-drug local anesthetics (Combination)] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)
~Ropivacaine 0.5% - 30 ml
~Ketorolac 30mg/ml - 1 ml
~Kenalog 10 mg/ml - 5 ml
~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
11240355|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.
~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
11240356|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
11240357|NCT03105648||thyroid cancer|
11240358|NCT03105648||benign thyroid nodules|
11240359|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
11240360|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.
~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.
~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
11240361|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
11240362|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
11240363|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
11240364|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
11240365|NCT03105596|Experimental|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
11240366|NCT03105583||Pregnant women visiting the obstetrics department|
11240367|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
11240368|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
11240369|NCT03105544|No Intervention|Control|No intervention.
11240370|NCT03105518|Experimental|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
11240371|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
11240372|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
11240373|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
11240374|NCT03105492||Pregnant women|Women who are pregnant
11240375|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
11240376|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
11240377|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
11240378|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
11240379|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
11240380|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
11240381|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
11240533|NCT03104543|Experimental|Education|Educational materials
11240383|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
11240384|NCT03105440|Experimental|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
11240385|NCT03105440|Experimental|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.
~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
11240386|NCT03105440|Experimental|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.
~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
11240387|NCT03105440|Experimental|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
11240388|NCT03105440|Experimental|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
11240389|NCT03105440|Experimental|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
11240390|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
11240391|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
11240392|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
11240393|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
11240394|NCT03105362|Experimental|Amino Acid-ORS arm|Patients consumed an amino acid based oral rehydration solution (enterade®) as part of their oral rehydration care plan. Enterade® oral rehydration solution volumes varied from patient to patient depending on baseline clinical need.
11240395|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
11240396|NCT03105336|Experimental|axicabtagene ciloleucel|
11240397|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
11240398|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
11240399|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
11240400|NCT03105297|Experimental|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
11240401|NCT03105297|Experimental|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
11240402|NCT03105297|Experimental|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
11240403|NCT03105284|Active Comparator|Liposuction of fat|The intervention examined is the extraction method by liposuction.
11240404|NCT03105284|No Intervention|Excision of fat|Control group
11240405|NCT03105245|Active Comparator|Short time interval + Normal ventilation|
11240406|NCT03105245|Active Comparator|Short time interval + Hyperventilation|
11240407|NCT03105245|Active Comparator|Long time interval + Normal ventilation|
11240408|NCT03105245|Active Comparator|Long time interval + Hyperventilation|
11240409|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
11240410|NCT03105232||Group B|Buprenorfin
11240411|NCT03105232||Group C|Fentanyl
11240412|NCT03105232||Group D|Opioid rotation
11240413|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
11240414|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
11240415|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
11240416|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
11240417|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
11240418|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
11240419|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
11240422|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
11240423|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
11240424|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
11240425|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
11240426|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
11240427|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
11240428|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
11240429|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
11240430|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
11240431|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
11240432|NCT03105128|Placebo Comparator|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
11240433|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
11240434|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
11240435|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
11240436|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
11240437|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
11240438|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
11240439|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
11240440|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
11240441|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
11240442|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
11240443|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or Study M15-989 or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 beginning at Week 56.
11240444|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
11240445|NCT03105089|No Intervention|control|no intervention will be done
11240446|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
11240447|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
11240448|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
11240449|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
11240450|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
11240451|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
11240452|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
11240453|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
11240454|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
11240455|NCT03104998|Other|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
11240456|NCT03104985|Active Comparator|Conventional treatment|"Conventional treatment only.
~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2
~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.
~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
11240457|NCT03104985|Experimental|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:
~- 365-405nm, power 1-2mW, exposure 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min;
~- 365-405nm, 1-2mW, 2 min;
~- 520-525nm, 1-2mW, 5 min"
11240458|NCT03104972|Experimental|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
11240459|NCT03104972|Experimental|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
11240460|NCT03104972|Experimental|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
11240461|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
11240462|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
11240463|NCT03104946||Bronchopulmonary Dysplasia|
11240464|NCT03104946||Retinopathy|
11240465|NCT03104946||Severe Retinopathy|
11240466|NCT03104946||Neonatal Necrotizing Enterocolitis|
11240467|NCT03104946||Brain injury|
11240468|NCT03104946||sepsis|
11240469|NCT03104946||Patent Ductus Arteriosus|
11240470|NCT03104946||Respiratory Distress Syndrome|
11240471|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
11240472|NCT03104920|Experimental|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
11240473|NCT03104920|Active Comparator|Traditional treatment|We give routine clinic practices for the treatment of HCC.
11240474|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
11240475|NCT03104894|Experimental|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
11240476|NCT03104894|Sham Comparator|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
11240477|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
11240478|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
11240479|NCT03104868|No Intervention|Usual Care|Patients in this group will receive the usual standard of care.
11240480|NCT03104868|Experimental|Intervention|Patients in this group will receive the TAKE IT strategy components.
11240481|NCT03104855|Experimental|Single pharmacokinetics arm|
11240482|NCT03104842|Experimental|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Condolidation Treatment : Carfilzomin, Lenalidomid, Isatuximab (I-KRd), after intesification 4 cycles of I-KRd will be followed by IKR maintenance util pD or Toxicity
11240483|NCT03104842|Experimental|Arm B No-Transplantation|patients > 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Condolidation Treatment : Carfilzomin, Lenalidomid, Isatuximab (I-KRd),to be followed by I-KR maintenance util PD or Toxicity
11240484|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
11240485|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
11240486|NCT03104816|Experimental|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
11240487|NCT03104816|Experimental|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
11240488|NCT03104816|Active Comparator|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
11240489|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
11240490|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
11240491|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
11240492|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
11240493|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
11240494|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
11240495|NCT03104764|Active Comparator|Scalpel|Frenotomy performed with conventional scalpel
11240496|NCT03104764|Experimental|Er:YAG laser|Frenotomy performed with Er:YAG laser
11240497|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
11240498|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
11240499|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
11240500|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
11240501|NCT03104725|Experimental|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
11240502|NCT03104725|Experimental|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
11240503|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
11240504|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
11240505|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
11240506|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
11240507|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
11240508|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
11240509|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
11240510|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
11240511|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
11240512|NCT03104699|Experimental|Monotherapy|Dose of 3 mg/kg IV every 2 weeks for up to 24 months.
11240513|NCT03104686|Active Comparator|Bread|Bread (50g available carbohydrate, 109 g) eaten with 500 mL of water
11240514|NCT03104686|Experimental|Short pasta (dry)|Cooked penne (142 g; 71 g uncooked) eaten with 500 mL of water
11240515|NCT03104686|Experimental|Long pasta (dry)|Cooked spaghetti (142 g; 71 g uncooked) eaten with 500 mL of water
11240516|NCT03104686|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
11240517|NCT03104660|Experimental|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
11240518|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
11240519|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
11240520|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
11240521|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
11240522|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
11240523|NCT03104608|Active Comparator|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
11240524|NCT03104608|Placebo Comparator|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
11240525|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
11240526|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
11240527|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
11240528|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
11240529|NCT03104582|Experimental|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
11240530|NCT03104582|Active Comparator|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
11240531|NCT03104569|Experimental|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent
11240532|NCT03104569|No Intervention|Injection of normal contrast agent|Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent
11240534|NCT03104543|Active Comparator|Test results|Test results only; with delayed access to the experimental materials
11240535|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
11240536|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
11240537|NCT03104517|Experimental|AMDC-USR|AMDC-USR is the study product (autologous muscle derived cells for urinary sphincter repair).
11240538|NCT03104517|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
11240539|NCT03104504|No Intervention|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
11240540|NCT03104504|Other|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.
~suicide risk screening
~safety planning
~means restriction counseling
~Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
11240541|NCT03104491|Experimental|Inotuzumab Ozogamicin|Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach.
11240542|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
11240543|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
11240544|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle
~Ipilimumab will be administered intravenously once per cycle
~Radiation Therapy will be administered per hospital standard"
11240545|NCT03104426|Active Comparator|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
11240546|NCT03104426|No Intervention|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
11240547|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 1)|Participants randomized to receive risankizumab dose 1 in Induction Period 1.
11240548|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 1)|Participants randomized to receive risankizumab dose 2 in Induction Period 1.
11240549|NCT03104413|Placebo Comparator|Placebo (Induction Period 1)|Participants randomized to receive placebo for risankizumab in Induction Period 1.
11240550|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
11240551|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
11240552|NCT03104413|Experimental|Risankizumab Dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
11240553|NCT03104400|Experimental|ABT-494 Dose A + Placebo Adalimumab|It is administered once daily.
11240554|NCT03104400|Experimental|ABT-494 Dose B + Placebo Adalimumab|It is administered once daily.
11240555|NCT03104400|Active Comparator|Adalimumab + Placebo ABT-494|It is administered subcutaneously once every two weeks.
11240556|NCT03104400|Experimental|Placebo ABT-494 + Placebo Adalimumab Then ABT-494 Dose A|It is administered once daily.
11240557|NCT03104400|Experimental|Placebo ABT-494 + Placebo Adalimumab Then ABT-494 Dose B|It is administered once daily.
11240558|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
11240559|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
11240560|NCT03104374|Experimental|ABT-494 Dose A|It is administered once daily.
11240561|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose B|It is administered once daily.
11240562|NCT03104374|Experimental|ABT-494 Dose B|It is administered once daily.
11240563|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose A|It is administered once daily.
11240564|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
11240565|NCT03104348|Other|COPD screening|
11240566|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
11240567|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
11240568|NCT03104309|Other|Levonorgestrel intrauterine system|
11240569|NCT03104283|Experimental|Apatinib Group|take apatinib orally (425mg/d, once a day, continuously )
11240600|NCT03104075|Active Comparator|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
11240601|NCT03104075|Active Comparator|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
11240602|NCT03104062|Other|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
11240603|NCT03104062|Other|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
11240570|NCT03104270|Experimental|Elo Pom Car and Dex|"Drug dosing and administration:
~All drugs are administered on a 28-day cycle.
~Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2. 20 mg/kg on Day 1 of Cycles 3 and beyond.
~Pomalidomide: 3 mg PO on days 1-21
~Carfilzomib: 20 mg/m2 IV on days 1 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles.
~Dexamethasone: On days 1,8,15,22 of Cycle 1-2 and day 1 of Cycle 3 and every day 1 thereafter, pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO. On days 8,15,22 of Cycle 3 and beyond, 40mg of DEX PO or IV. On Day 8 and 15 of Cycle 3 and beyond, pre-treatment with DEX 40mg PO or IV at least 30 min and no more than 4 hours prior to the start of CFZ."
11240571|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
11240572|NCT03104257||Healthy Controls|Subjects with no current cannabis use
11240573|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
11240574|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
11240575|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
11240576|NCT03104218|Experimental|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
11240577|NCT03104218|Sham Comparator|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
11240578|NCT03104205|Experimental|Evaluate home-based MOWI|Conduct and assess the feasibility, acceptability, and potential effectiveness of home-based MOWI in improving physical function.
11240579|NCT03104192|Active Comparator|Develop & Refine MOWI w/o Amulet (2A)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
11240580|NCT03104192|Experimental|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
11240581|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit (2B)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
11240582|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit/Protein (2P)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
11240583|NCT03104179|Experimental|Treatment|CPB with Cytosorb
11240584|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
11240585|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
11240586|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
11240587|NCT03104153|No Intervention|Output-based|
11240588|NCT03104153|Active Comparator|Early-removal|
11240589|NCT03104140|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
11240590|NCT03104140|Active Comparator|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
11240591|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
11240592|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
11240593|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
11240594|NCT03104114|Placebo Comparator|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
11240595|NCT03104114|Experimental|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
11240596|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
11240597|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
11240598|NCT03104088||SPG4 patients|
11240599|NCT03104088||Healthy controls|
11240604|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
11240605|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
11240606|NCT03104036|Active Comparator|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
11240607|NCT03104036|Experimental|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
11240608|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
11240609|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
11240610|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
11240611|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
11240612|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
11240613|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
11240614|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
11240615|NCT03103984|Experimental|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
11240616|NCT03103984|Experimental|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
11240617|NCT03103971|Experimental|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
11240618|NCT03103958|Active Comparator|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
11240619|NCT03103958|Placebo Comparator|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
11240620|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
11240621|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
11240622|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
11240623|NCT03103919|Active Comparator|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
11240624|NCT03103919|Experimental|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
11240625|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
11240626|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
11240627|NCT03103893|Experimental|Rapamycin|Rapamycin
11240628|NCT03103880|Experimental|Medication Adherence and Pulmonary Function Tests|
11240629|NCT03103880|Experimental|Medication Adherence and Peak Flow Measurements|
11240630|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
11240631|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
11240632|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
11240633|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
11240634|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
11240635|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
11240636|NCT03103841||Children and young people with epilepsy|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
11240637|NCT03103841||Healthy controls|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
11240638|NCT03103828|Active Comparator|Computer-tailored intervention|
11240639|NCT03103828|Active Comparator|Motivational Interviewing|
11240640|NCT03103828|Active Comparator|Motivational Enhancement Therapy|
11240641|NCT03103828|No Intervention|Control Group|
11240642|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
11240643|NCT03103802|Experimental|Intra-oral scanning|
11240644|NCT03103802|Experimental|extra-oral scanning of the plaster model obtained via alginate|
11240645|NCT03103802|Experimental|extra-oral scanning of plaster model obtained via rubber base|
11240646|NCT03103802|Experimental|extra-oral scanning of the rubber base impression|
11240647|NCT03103802|Experimental|extra-oral scanning of the alginate impression|
11240648|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
11240649|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
11240650|NCT03103776|Other|Patients who have Graves disease|
11240651|NCT03103776|Other|Patients having a goiter|
11240652|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
11240653|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
11240654|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
11240655|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
11240656|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
11240657|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
11240658|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
11240659|NCT03103724|Experimental|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
11240660|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
11240661|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
11240662|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
11240663|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
11240664|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
11240665|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
11240666|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
11240667|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
11240668|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
11240669|NCT03103646|Experimental|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
11240670|NCT03103646|Experimental|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
11240671|NCT03103633|Experimental|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
11240672|NCT03103633|Sham Comparator|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
11240673|NCT03103594|Active Comparator|DMSO alone|Half of the patients will undergo DMSO instillation
11240674|NCT03103594|Experimental|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
11240675|NCT03103581|Experimental|BLI4700|BLI4700 Bowel Preparation
11240719|NCT03103334|Experimental|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
11240720|NCT03103334|Experimental|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
11240676|NCT03103568|Experimental|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.
~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
11240677|NCT03103568|Experimental|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.
~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
11240678|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
11240679|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
11240680|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
11240681|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
11240682|NCT03103516|Experimental|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
11240683|NCT03103516|Experimental|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
11240684|NCT03103490|Other|18F-FSPG PET/MRI|Patients undergoing 18F-FSPG PET/MRI scan
11240685|NCT03103490|Other|18F-FSPG PET/CT|Patients undergoing 18F-FSPG PET/CT scan
11240686|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.
~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
11240687|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
11240688|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
11240689|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
11240690|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240691|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240692|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240693|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240694|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240695|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240696|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.
~Intervention: BCD-121/ placebo"
11240697|NCT03103438|Experimental|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
11240698|NCT03103438|Experimental|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
11240699|NCT03103438|Experimental|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
11240721|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
11240700|NCT03103438|Experimental|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
11240701|NCT03103438|Experimental|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
11240702|NCT03103438|Experimental|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
11240703|NCT03103438|Experimental|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
11240704|NCT03103412|Experimental|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
11240705|NCT03103412|Experimental|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
11240706|NCT03103412|Experimental|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
11240707|NCT03103412|Placebo Comparator|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
11240708|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
11240709|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
11240710|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
11240711|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
11240712|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
11240713|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
11240714|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
11240715|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
11240716|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
11240717|NCT03103334|Experimental|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
11240718|NCT03103334|Experimental|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
11240722|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
11240723|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
11240724|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
11240725|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
11240726|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
11240727|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones
~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
11240728|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.
~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
11240729|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.
~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.
~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
11240730|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.
~This group does not receive the Challenge! Small Group Intervention.
~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
11240731|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
11240732|NCT03103256|Experimental|YHP1701|PO, Once daily (QD), 8 weeks
11240733|NCT03103256|Active Comparator|YHR1703|PO, Once daily (QD), 8 weeks
11240734|NCT03103256|Active Comparator|YHR1704|PO, Once daily (QD), 8 weeks
11240735|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
11240736|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
11240737|NCT03103217|Experimental|Brief CBT intervention|
11240738|NCT03103204|Experimental|Normal weight full-mouth disinfection|"Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
11240739|NCT03103204|Experimental|Overweight full-mouth disinfection|"Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
11240740|NCT03103204|Experimental|Obesity I full-mouth disinfection|"Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
11240741|NCT03103204|Experimental|Obesity II full-mouth disinfection|"Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
11240742|NCT03103204|Experimental|Obesity III full-mouth disinfection|"Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis
~Full-mouth manual scaling and root planing within 24 hours
~tongue cleaning with chlorhexidine gel 1% for 1 minute
~tonsils disinfection with chlorhexidine spray 0.2%
~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling
~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution
~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
11240743|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.
~50 subjects with pulmonary fibrosis secondary to collagen diseases."
11240744|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.
~75 subjects with collagen disease without pulmonary fibrosis."
11240745|NCT03103152|Experimental|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
11240746|NCT03103152|Experimental|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
11240747|NCT03103152|Experimental|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
11240748|NCT03103152|Placebo Comparator|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
11240749|NCT03103152|Experimental|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
11240750|NCT03103152|Experimental|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
11240751|NCT03103139|Active Comparator|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
11240752|NCT03103139|Experimental|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
11240753|NCT03103126|No Intervention|Control|Standard care.
11240754|NCT03103126|Experimental|Combined resistance exercise and walking|Combined resistance exercise and walking.
11240755|NCT03103100|Active Comparator|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
11240756|NCT03103100|Active Comparator|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
11240757|NCT03103100|Active Comparator|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
11240758|NCT03103087|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
11240759|NCT03103087|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
11240760|NCT03103087|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
11240761|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
11240762|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
11240763|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
11240764|NCT03103048|Active Comparator|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
11240765|NCT03103048|Placebo Comparator|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
11240766|NCT03103048|Active Comparator|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
11240767|NCT03103048|Active Comparator|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
11240768|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
11240769|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
11240770|NCT03103022|Experimental|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
11240771|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
11240772|NCT03102996|Experimental|Verum|Patients will receive Nephrotrans.
11240773|NCT03102996|Placebo Comparator|Placebo|Patients will receive Placebo.
11240774|NCT03102983|Experimental|Healthy Volonteers|
11240775|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
11240776|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
11240777|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
11240778|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
11240779|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
11240780|NCT03102918|Placebo Comparator|Placebo|Placebo
11240781|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
11240782|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
11240783|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
11240784|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
11240785|NCT03102866|Active Comparator|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
11240863|NCT03102346|No Intervention|routine group|no instructed exercise training
11240786|NCT03102866|Experimental|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
11240787|NCT03102853|Active Comparator|Nordic diet|
11240788|NCT03102853|Other|Control diet|
11240789|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
11240790|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
11240791|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
11240792|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
11240793|NCT03102814|Active Comparator|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
11240794|NCT03102814|Experimental|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
11240795|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
11240796|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
11240797|NCT03102788|Active Comparator|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
11240798|NCT03102788|Experimental|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
11240799|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
11240800|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
11240801|NCT03102762|Experimental|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
11240802|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:
~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
11240803|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
11240804|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
11240805|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
11240806|NCT03102736|Placebo Comparator|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
11240807|NCT03102736|Experimental|Nitroprusside and Ketamine|0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)
11240808|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
11240809|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
11240810|NCT03102710|Experimental|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
11240811|NCT03102710|Experimental|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
11240812|NCT03102710|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
11240813|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
11240814|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
11240815|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
11240816|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
11240817|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
11240818|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
11240819|NCT03102658|Experimental|Obese subjects 100mg|8 subjects with a BMI>40kg/m2 will receive 100mg Micafungin
11240820|NCT03102658|Active Comparator|Obese subjects 200mg|8 subjects with a BMI>40kg/m2 will receive 200mg Micafungin
11240821|NCT03102658|Active Comparator|non-obese subjects|8 non obese subjects with a BMI >18.5 and <25 kg/m2 will receive 100mg Micafungin
11240822|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
11240823|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
11240824|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
11240825|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
11240826|NCT03102606|Active Comparator|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|
11240827|NCT03102606|Experimental|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|
11240828|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
11240829|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
11240830|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
11240831|NCT03102580|Experimental|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
11240832|NCT03102580|No Intervention|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
11240833|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
11240834|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
11240835|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
11240836|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
11240837|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
11240838|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
11240839|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
11240840|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
11240841|NCT03102502|Experimental|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
11240842|NCT03102502|Active Comparator|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
11240843|NCT03102489|Experimental|BP101|Treatment with BP101
11240844|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
11240845|NCT03102476|Other|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
11240846|NCT03102463|Sham Comparator|Water Control|
11240847|NCT03102463|Active Comparator|Milk derived hydrolysate|
11240848|NCT03102463|Active Comparator|Parent Protein|
11240849|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
11240850|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
11240851|NCT03102424|Experimental|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
11240852|NCT03102424|Placebo Comparator|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
11240853|NCT03102398|Experimental|Single-arm and Open-label Study|
11240854|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
11240855|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
11240856|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
11240857|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
11240858|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
11240859|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
11240860|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
11240861|NCT03102359|No Intervention|Control|No intervention in this group
11240862|NCT03102346|Experimental|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
11240864|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
11240865|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
11240866|NCT03102320|Experimental|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.
~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
11240867|NCT03102320|Experimental|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
11240868|NCT03102320|Experimental|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
11240869|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
11240870|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
11240871|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
11240872|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
11240873|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
11240874|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
11240875|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
11240876|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
11240877|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
11240878|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
11240879|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
11240880|NCT03102242|Experimental|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.
~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions
~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.
~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
11240881|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks
~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
11240882|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
11240883|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
11240884|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
11240885|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
11240886|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
11240887|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
11240888|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
11240889|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
11240890|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
11240891|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
11240892|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
11240893|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
11240894|NCT03102190|Experimental|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
11240895|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
11240896|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
11240897|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
11240898|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
11240899|NCT03102125|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
11240900|NCT03102125|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
11240901|NCT03102125|Experimental|Cardiac allograft vasculopathy|Patients with allograft dysfunction from known cardiac allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
11240902|NCT03102125|Experimental|ACR/AMR|Patients with allograft dysfunction from prior episodes of acute cellular or antibody mediated rejection will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
11240903|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
11240904|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
11240905|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
11240906|NCT03102073||Radner test|reading speed evaluation
11240907|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
11240908|NCT03102047|Experimental|durvalumab|IV infusion once every 2 weeks for 4 total doses
11240909|NCT03102034|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
11240910|NCT03102034|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
11240911|NCT03102021|Active Comparator|1|erythropoeitin
11240912|NCT03102021|Placebo Comparator|2|saline placebo
11240913|NCT03102008|No Intervention|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
11240914|NCT03102008|No Intervention|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
11240915|NCT03102008|No Intervention|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
11240916|NCT03102008|Experimental|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
11240917|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
11240918|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
11240919|NCT03101982|No Intervention|control|ASIA score, blood taking
11240920|NCT03101956|Experimental|L/S Manipulation Study Group|
11240921|NCT03101956|Active Comparator|Control Group|
11240997|NCT03101371|Active Comparator|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
11240922|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
11240923|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
11240924|NCT03101930|Experimental|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
11240925|NCT03101930|Active Comparator|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
11240926|NCT03101930|Active Comparator|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
11240927|NCT03101917|Experimental|Visual assessment of electrode insertion|This arm will include the first 6 participants. In this group, a cut will be made near the eardrum and it will be lifted up so the surgeon can see the electrode as it goes into the cochlea.
11240928|NCT03101917|Experimental|Camera assessment of electrode insertion|This arm will include the next 6 participants. In this group, a tube with a camera will be inserted past the ear drum, by making a small hole in the ear drum, to see the electrode as it goes into the cochlea.
11240929|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).
~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
11240930|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).
~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
11240931|NCT03101891|Experimental|Serial amnioinfusions with isotonic fluid|Patients will undergo amnioinfusions with isotonic fluid every 1-2 weeks. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at a RAFT center.
11240932|NCT03101891|No Intervention|Expectant|Patients will be observed serially by ultrasound, fetal echocardiogram and MRI. Standard postnatal care will occur at a RAFT center.
11240933|NCT03101878|Experimental|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
11240934|NCT03101878|Placebo Comparator|Placebo|Saline .9%
11240935|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
11240936|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
11240937|NCT03101852|Experimental|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: WHO recommends a Plumpy Nut® prescription of 75 to 100 kcal/kg/d in children aged 5 to 10 years and 60 to 90 kcal/kg/d above that age. The lowest value was used and maximum energy intake provided by RUF was limited to 2,000 kcal/d i.e. 4 sachets in order to preserve habitual diet and prevent appetite saturation
11240938|NCT03101852|Experimental|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 60kcal/kg/day, limited to 4 doses/day.
11240939|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
11240940|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
11240941|NCT03101800|Experimental|Azathioprine and Allopurinol|
11240942|NCT03101800|Active Comparator|Azathioprine|
11240943|NCT03101787|No Intervention|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).
~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.
~No special preparations for the trial are needed before the patient's arrival."
11240998|NCT03101371|Experimental|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
11240999|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
11240944|NCT03101787|Experimental|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).
~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).
~Time from arrest to start of cannulation is < 60 minutes."
11240945|NCT03101774|Experimental|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
11240946|NCT03101774|Experimental|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
11240947|NCT03101774|Sham Comparator|control group|not conduct inspiratory muscle training for 8 weeks
11240948|NCT03101748|Experimental|Group A (Cohort 1 Phase Ib)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
11240949|NCT03101748|Experimental|Group B (Cohort 1 Phase II)|Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
11240950|NCT03101748|Experimental|Group C (Cohort 2)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin hydrochloride and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.
11240951|NCT03101722|Experimental|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day. BTHE：basic treatment and health education
11240952|NCT03101722|Sham Comparator|control|Participants in the BTHE group will receive advice regarding lifestyle modification, avoiding alcohol and cigarette consumption.
11240953|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
11240954|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
11240955|NCT03101670|Experimental|filgotinib|
11240956|NCT03101670|Placebo Comparator|placebo|
11240957|NCT03101644|Other|Darunavir|All patients treated with darunavir
11240958|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):
~Nutritional Assessment: Mini Nutritional Assessment (MNA)
~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.
~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)
~Psychological status: Geriatric Depression Scale (GDS)
~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)
~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)
~Age
~Haemoglobin
~Creatinine Clearance (CrCl)
~Presence of Geriatric Syndromes"
11240959|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
11240960|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
11240961|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
11240962|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
11240963|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
11240964|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
11240965|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
11240966|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
11240967|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
11240968|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
11240969|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
11240970|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
11241186|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.
~Blood sampling."
11240971|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
11240972|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks
~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks
~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks
~If there is continued benefit after 6 months, then:
~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
11240973|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab
~1 mg/kg IV on day 1 every 6 weeks
~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
11240974|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
11240975|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
11240976|NCT03101540|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
11240977|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
11240978|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
11240979|NCT03101488|Experimental|KN035|KN035 is to be injected subcutaneously 0.1mg/kg or 0.3mg/kg or 1mg/kg or 2.5mg/kg or 5mg/kg or 10mg/kg weekly until disease progresses or unacceptable tolerability occurs.
11240980|NCT03101475|Experimental|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
11240981|NCT03101462|Active Comparator|Group 1|One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0
11240982|NCT03101462|Active Comparator|Group 2|One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0
11240983|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
11240984|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
11240985|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
11240986|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)
~Washout 15 days
~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
11240987|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)
~Washout 15 days
~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
11240988|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
11240989|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
11240990|NCT03101410|Experimental|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
11240991|NCT03101410|Experimental|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
11240992|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
11240993|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
11240994|NCT03101397||stable group|not included in improved group or deteriorated group
11240995|NCT03101384||Patient with a diagnostic error|"Defined by one of :
~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician
~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.
~More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
11240996|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
11241369|NCT03099109|Experimental|Japanese Arm E LY3300054|LY3300054 given IV.
11241000|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
11241001|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
11241002|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
11241003|NCT03101332|Experimental|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
11241004|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a capsule containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
11241005|NCT03101319|Placebo Comparator|Antipsychotic and Placebo|Subjects randomised to the placebo arm will receive a capsule of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks.The subjects will continue to receive antipsychotics as per the decision of the treating team
11241006|NCT03101306|Experimental|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
11241007|NCT03101293|Experimental|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
11241008|NCT03101293|Experimental|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
11241009|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
11241010|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].
~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
11241011|NCT03101267|Experimental|ASP4070 4 mg|Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
11241012|NCT03101267|Experimental|ASP4070 1 mg|Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
11241013|NCT03101267|Placebo Comparator|Placebo|Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
11241014|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
11241015|NCT03101241|Experimental|CX-8998|
11241016|NCT03101241|Placebo Comparator|Placebo|
11241017|NCT03101228|Experimental|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
11241018|NCT03101228|No Intervention|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
11241019|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
11241020|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
11241021|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
11241022|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
11241023|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
11241024|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
11241025|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
11241026|NCT03101176|Experimental|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
11241027|NCT03101163|Experimental|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
11241028|NCT03101163|Active Comparator|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
11241029|NCT03101150|Active Comparator|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
11241030|NCT03101150|Experimental|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
11241031|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
11241032|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
11241033|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
11241034|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
11241035|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
11241036|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
11241037|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.
~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.
~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
11241038|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.
~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.
~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
11241039|NCT03101098|Experimental|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
11241040|NCT03101098|Active Comparator|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
11241041|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
11241042|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
11241043|NCT03101072|Active Comparator|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
11241044|NCT03101072|Experimental|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
11241045|NCT03101072|Experimental|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
11241046|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
11241047|NCT03101046|Other|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.
~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
11241048|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having <5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
11241049|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
11241050|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
11241051|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
11241052|NCT03101020|Placebo Comparator|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
11241053|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
11241054|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
11241055|NCT03100994|No Intervention|Group A|without nerve block
11241056|NCT03100994|Active Comparator|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
11241057|NCT03100994|Active Comparator|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
11241058|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
11241059|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
11241060|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
11241061|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
11241062|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
11241063|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
11241064|NCT03100942|Experimental|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
11241065|NCT03100942|Experimental|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
11241066|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
11241187|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).
~Blood sampling."
11241067|NCT03100942|Placebo Comparator|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:
~filgotinib + lanraplenib placebo + tirabrutinib placebo
~lanraplenib + filgotinib placebo + tirabrutinib placebo
~tirabrutinib + filgotinib placebo + lanraplenib placebo"
11241068|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
11241069|NCT03100916|Experimental|Dose Ranging Arm|
11241070|NCT03100916|Experimental|Food Effect arm|
11241071|NCT03100903|Experimental|BI 655130|
11241072|NCT03100890|No Intervention|Control|Non-active comparator
11241073|NCT03100890|Active Comparator|Balance-Proprioception (Hospital)|Preoperative training (hospital)
11241074|NCT03100890|Experimental|Balance-Proprioception (Home)|Preoperative training (home)
11241075|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.
~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.
~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
11241076|NCT03100864|Experimental|Spesolimab|
11241077|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
11241078|NCT03100838|Experimental|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
11241079|NCT03100838|Active Comparator|Nifedipine (Brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
11241080|NCT03100838|Active Comparator|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
11241081|NCT03100838|Active Comparator|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
11241082|NCT03100825|Experimental|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
11241083|NCT03100812|Experimental|Group A|
11241084|NCT03100812|Experimental|Group B|
11241085|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
11241086|NCT03100786|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
11241087|NCT03100786|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
11241088|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
11241089|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
11241090|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
11241091|NCT03100747|Active Comparator|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
11241092|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
11241093|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
11241094|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
11241095|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
11241096|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
11241097|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
11241098|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
11241099|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
11241100|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
11241101|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
11241102|NCT03100656|Other|Anorexia nervosa I|Anorexia nervosa with BMI <=17.5 kg/m² or BMI >17.5 kg/m² with regular binge-purge episodes
11241103|NCT03100656|Other|Anorexia nervosa II|Anorexia nervosa with BMI > 18.5 kg/m² for at least 12 months.
11241104|NCT03100656|Other|Controls|Healthy control women
11241105|NCT03100630|Active Comparator|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
11241106|NCT03100630|Active Comparator|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
11241107|NCT03100630|Active Comparator|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
11241108|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
11241234|NCT03099850||Chronic Pancreatitis|
11241235|NCT03099837||Pregnant mothers|
11241236|NCT03099837||infants|
11241109|NCT03100604|Experimental|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
11241110|NCT03100604|Experimental|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
11241111|NCT03100591|Experimental|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
11241112|NCT03100578|Experimental|PLASTIC STENT|"Endoscopic double pigtail plastic stent, with formal indication on pancreatic collection, according to the instruction forms of the manufacturer.
~Interventions associated:
~EUS-guided transmural drainage of pancretic collection: PLASTIC STENT."
11241113|NCT03100578|Active Comparator|SELF EXPANDABLE METALLIC STENT|"Lumen apposing metal stent with formal indicaction on pancreatic collection, according to the manufacturer instruction forms.
~Interventions associated:
~EUS-guided transmural drainage of pancretic collection: METALLIC STENT."
11241114|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
11241115|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
11241116|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP >= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
11241117|NCT03100539|Experimental|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
11241118|NCT03100539|No Intervention|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
11241119|NCT03100526|Experimental|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
11241120|NCT03100526|No Intervention|Usual care|High-Risk patients receiving care in PACT.
11241121|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
11241122|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
11241123|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
11241124|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
11241125|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
11241126|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
11241127|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
11241128|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
11241129|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
11241130|NCT03100448|Other|On1 Concept|On1 Concept & NobelActive implants
11241131|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
11241132|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
11241133|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
11241134|NCT03100435|No Intervention|No Treatment|No treatment (control)
11241135|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
11241136|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
11241137|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
11241138|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
11241139|NCT03100370|Active Comparator|tsDCS- Anodal Stimulation & robotic arm training (RAT)|anodal tsDCS over cervical spine, 2.5mA for 20 minutes
11241140|NCT03100370|Active Comparator|tsDCS- Cathodal Stimulation & RAT|cathodal tsDCS over cervical spine, 2.5mA for 20 minutes
11241141|NCT03100370|Sham Comparator|tsDCS- Sham Stimulation & RAT|sham tsDCS over cervical spine, 2.5mA for 20 minutes
11241142|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
11241143|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
11241144|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
11241145|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
11241146|NCT03100331|Experimental|Single Arm; all receive neuropsychological testing & follow-up|
11241147|NCT03100318|Experimental|FYU-981|
11241148|NCT03100318|Active Comparator|Benzbromarone|
11241149|NCT03100305||Extremely preterm infants|
11241150|NCT03100305||Very preterm infants|
11241151|NCT03100305||Moderately preterm infants|
11241152|NCT03100305||Late preterm infants|
11241153|NCT03100292|Experimental|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).
~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
11241154|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
11241155|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
11241156|NCT03100266|Placebo Comparator|placebo|Inactive capsules
11241157|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
11241158|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR
~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
11241159|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
11241160|NCT03100240|No Intervention|control group|long protocol
11241161|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
11241162|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
11241163|NCT03100214|Active Comparator|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
11241164|NCT03100214|Experimental|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
11241165|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
11241166|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
11241167|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
11241168|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.
~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly
~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
11241169|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
11241170|NCT03100162|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 3 months.
11241171|NCT03100162|Active Comparator|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
11241172|NCT03100162|Active Comparator|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
11241173|NCT03100149|Experimental|Part 1: RO7046015 High Dose|Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
11241174|NCT03100149|Experimental|Part 1: RO7046015 Low Dose|Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.
11241175|NCT03100149|Placebo Comparator|Part1: Placebo|Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.
11241176|NCT03100149|Experimental|Part 2: RO7046015 High Dose|Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
11241177|NCT03100149|Experimental|Part 2: RO7046015 Low Dose|Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
11241178|NCT03100149|Experimental|Part 3: RO7046015 High Dose|Part 2 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 5 years in Part 3.
11241179|NCT03100149|Experimental|Part 3: RO7046015 Low Dose|Part 2 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 5 years in Part 3.
11241180|NCT03100136|Experimental|[11C]PF-06809247|A dose intravenous injection of [11C]PF-06809247 followed by PET scanning.
11241181|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
11241182|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
11241183|NCT03100110|Experimental|NeuroCognitive Communicator|
11241184|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
11241185|NCT03100097|No Intervention|Medical Management|Normal medical management
11241237|NCT03099837||children|
11241188|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.
~Blood sampling"
11241189|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
11241190|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.
~Blood sampling."
11241191|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.
~Blood sampling."
11241192|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
11241193|NCT03100058|Experimental|LIK066 2.5mg qd (Epoch 3)|LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
11241194|NCT03100058|Placebo Comparator|Placebo (Epoch 3)|Matching placebo tablets for 24 weeks
11241195|NCT03100058|Experimental|LIK066 10mg qd (Epoch 3)|LIK066 10mg qd (once daily) dosing frequency for 24 weeks
11241196|NCT03100058|Experimental|LIK066 50mg qd (Epoch 3)|LIK066 50mg qd (once daily) dosing frequency for 24 weeks
11241197|NCT03100058|Experimental|LIK066 150mg qd (Epoch 3)|LIK066 150mg qd (once daily) dosing frequency for 24 weeks
11241198|NCT03100058|Experimental|LIK066 2.5mg bid (Epoch 3)|LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
11241199|NCT03100058|Experimental|LIK066 5mg bid (Epoch 3)|LIK066 5mg bid (once daily) dosing frequency for 24 weeks
11241200|NCT03100058|Experimental|LIK066 25mg bid (Epoch 3)|LIK066 25mg bid (once daily) dosing frequency for 24 weeks
11241201|NCT03100058|Experimental|LIK066 50mg bid (Epoch 3)|LIK066 50mg bid dosing frequency for 24 weeks
11241202|NCT03100058|Experimental|LIK066 qd/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
11241203|NCT03100058|Experimental|LIK066 bid/LIK066 35mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
11241204|NCT03100058|Experimental|Placebo/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
11241205|NCT03100058|Placebo Comparator|Placebo/Placebo (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
11241206|NCT03100045|Experimental|ART 200 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 200 mg/day
11241207|NCT03100045|Experimental|ART 200 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 200 mg/day
11241208|NCT03100045|Experimental|ART 400 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 400 mg/day
11241209|NCT03100045|Experimental|ART 400 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 400 mg/day
11241210|NCT03100045|Experimental|ART 600 mg, 2 cycles|Two five-day cycles of Artesunate suppositories, 600 mg/day
11241211|NCT03100045|Experimental|ART 600 mg, 3 cycles|Three five-day cycles of Artesunate suppositories, 600 mg/day
11241212|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
11241213|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
11241214|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
11241215|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
11241216|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
11241217|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
11241218|NCT03100006|Experimental|Nivolumab and Oregovomab|
11241219|NCT03099993|Other|A: Healthy volunteers|
11241220|NCT03099993|Other|B: Patient with heamiplegia|
11241221|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
11241222|NCT03099980|Experimental|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
11241223|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
11241224|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
11241225|NCT03099928||Qualitative Interviews|
11241226|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
11241227|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
11241228|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
11241229|NCT03099889|No Intervention|Control arm|Receive general health mailings
11241230|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
11241231|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
11241232|NCT03099863|Placebo Comparator|Standard Care|Standard cystoscopy with normal saline solution.
11241233|NCT03099863|Active Comparator|Neosporin G. U. Irrigant|Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
11241245|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
11241246|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
11241247|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
11241248|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
11241249|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
11241250|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
11241251|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
11241252|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
11241253|NCT03099772|Experimental|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
11241254|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
11241255|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
11241256|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
11241257|NCT03099746|Experimental|INVOLVE|"The first study condition, called Interactive Virtual Decision Support for End-of-Life and Palliative Care (INVOLVE) will consist of exposures to an avatar-based decision support technology that will be administered via tablet computer and allow SDMs opportunities to practice their communication and decision making skills through interactions with avatars that portray a decision coach and various healthcare providers."
11241258|NCT03099746|Experimental|Informational Support|The second condition, called Informational Support (IS), will also be administered via tablet computers and expose SDMs to educational resources of INVOLVE without the experiential components.
11241259|NCT03099746|Experimental|Usual Care|The third condition, usual care (UC), will expose SDMs to the routine communication and decisional support practices provided by the healthcare team.
11241260|NCT03099733|Experimental|concussion|patients who present to ED with concussion
11241261|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
11241262|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
11241263|NCT03099707|No Intervention|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
11241264|NCT03099707|Active Comparator|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
11241265|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
11241266|NCT03099694|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
11241267|NCT03099681||Epitheloid Sarcoma patients|Patients with diagnosis of localized or advanced epitheloid sarcoma seen in the Italian reference centers for sarcoma treatment that receive treatment for Epitheloid Sarcoma
11241268|NCT03099668|Experimental|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
11241269|NCT03099668|No Intervention|Routine care|Routine care
11241270|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
11241271|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
11241272|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
11241273|NCT03099629|Experimental|IMT|inspiratory muscle training
11241274|NCT03099616|Active Comparator|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
11241275|NCT03099616|Active Comparator|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
11241276|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
11241277|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
11241370|NCT03099109|Experimental|Japanese Arm F LY3321367 + LY3300054|LY3321367 and LY3300054 given IV.
11241278|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
11241279|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
11241280|NCT03099590|Experimental|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
11241281|NCT03099590|Placebo Comparator|Placebo Control|Matched dextran containing capsules will serve as placebo.
11241282|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
11241283|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
11241284|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
11241285|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
11241286|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
11241287|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
11241288|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
11241289|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
11241290|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
11241291|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
11241292|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
11241293|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
11241294|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
11241295|NCT03099512|Experimental|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
11241296|NCT03099512|Active Comparator|Ex Group|Individuals in this group who will perform exercises for knee only
11241297|NCT03099499|Experimental|ONC201 treatment Arm|
11241298|NCT03099486|Experimental|Regorafenib + 5FU/LV Treatment Arm|
11241299|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
11241300|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
11241301|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
11241302|NCT03099460|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
11241303|NCT03099460|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
11241304|NCT03099460|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
11241305|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
11241306|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
11241307|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
11241308|NCT03099434|Active Comparator|Live Donor Champion + Facebook App|The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
11241309|NCT03099434|Active Comparator|Facebook App|The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.
11241310|NCT03099434|No Intervention|Standard of Care|Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
11241311|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
11241312|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
11241313|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
11241314|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
11241315|NCT03099382|Experimental|SHR-1210|
11241316|NCT03099382|Active Comparator|Investigator's Choice Standard Therapy|Docetaxel or Irinotecan
11241317|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.
~Week 1: walk at least 3,000 steps every day.
~Week 2: walk at least 3,500 steps every day.
~Week 3: walk at least 4,000 steps every day.
~Week 4: walk at least 4,500 steps every day.
~Weeks 5-12: walk at least 5,000 steps every day."
11241318|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).
~Walk on a flat surface at a constant speed until there is mild to moderate pain
~Rest until the pain has completely ceased
~Resume walking at the same speed
~Increase the speed when you can walk 8 minutes without stopping for leg symptoms
~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
11241319|NCT03099356|Experimental|Cyclophosphamide and Sirolimus|Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
11241320|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
11241321|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
11241322|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
11241323|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
11241324|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
11241325|NCT03099304|Experimental|Ruxolitinib cream 1.5% twice daily (BID)|Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
11241326|NCT03099304|Experimental|Ruxolitinib cream 1.5% once daily (QD)|Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
11241327|NCT03099304|Experimental|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
11241328|NCT03099304|Experimental|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if < 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
11241329|NCT03099304|Placebo Comparator|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
11241330|NCT03099291|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the RSV D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
11241331|NCT03099291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11241332|NCT03099278|Experimental|Ezetimibe|
11241333|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
11241334|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.
~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:
~Parent-targeted BSweet2Babies video
~Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video
~BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units
~Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)
~Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
11241335|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
11241336|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
11241337|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
11241338|NCT03099226|Experimental|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.
~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.
~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.
~The patients were administered between 7:00 and 9:00 o'clock a.m"
11241418|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.
~Intervention: Non exposure to aircraft exhaust"
11241804|NCT03095950|Experimental|News without spin|News items reporting results of RCTs without spin
11241339|NCT03099226|Experimental|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.
~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.
~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.
~The patients were administered between 7:00 and 9:00 o'clock a.m"
11241340|NCT03099226|Experimental|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.
~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.
~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.
~The patients were administered between 7:00 and 9:00 o'clock a.m"
11241341|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
11241342|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
11241343|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
11241344|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
11241345|NCT03099187|Experimental|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
11241346|NCT03099187|Experimental|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
11241347|NCT03099174|Experimental|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
11241348|NCT03099174|Experimental|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
11241349|NCT03099174|Experimental|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
11241350|NCT03099174|Experimental|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
11241351|NCT03099174|Experimental|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
11241352|NCT03099174|Experimental|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
11241353|NCT03099174|Experimental|Cohort D1|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
11241354|NCT03099174|Experimental|Cohort D2|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
11241355|NCT03099161|Experimental|Preladenant 25 mg Twice a Day (BID)|During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
11241356|NCT03099161|Experimental|Preladenant 50 mg BID|During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
11241357|NCT03099161|Experimental|Preladenant + Pembrolizumab|During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
11241358|NCT03099148|Experimental|LY3337641 (R-fasted)|A single dose of LY3337641 reference formulation (R) given orally with water after an overnight fast in one of four periods.
11241359|NCT03099148|Experimental|LY3337641 (T1-fasted)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
11241360|NCT03099148|Experimental|LY3337641 (T1-fed)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
11241361|NCT03099148|Experimental|LY3337641 (T2-fasted)|A single dose of LY3337641 test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
11241362|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
11241363|NCT03099122|Experimental|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.
~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
11241364|NCT03099109|Experimental|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
11241365|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
11241371|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
11241372|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
11241373|NCT03099070|No Intervention|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
11241374|NCT03099070|Experimental|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
11241375|NCT03099070|Experimental|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
11241376|NCT03099070|Experimental|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
11241377|NCT03099044|Active Comparator|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
11241378|NCT03099044|Active Comparator|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
11241379|NCT03099044|Placebo Comparator|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
11241380|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
11241381|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
11241382|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
11241383|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
11241384|NCT03098992|Active Comparator|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
11241385|NCT03098992|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
11241386|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
11241387|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
11241388|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
11241389|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
11241390|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
11241391|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
11241392|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
11241393|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
11241394|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
11241395|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
11241396|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
11241397|NCT03098914||Beijing Haidian Hospital|
11241398|NCT03098914||Chinese PLA General Hospital|
11241399|NCT03098914||Beijing Tsinghua Chang gung Hospital|
11241400|NCT03098901|Other|no other arm|
11241401|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.
~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
11241402|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.
~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
11241403|NCT03098862||Direct EBOV exposure risk controls|
11241404|NCT03098862||EVD fatal cases|
11241405|NCT03098862||EVD survibor cases|
11241406|NCT03098862||No Known EBOV exposure population controls|
11241407|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
11241408|NCT03098849|No Intervention|Control Group|Standard care as usual
11241409|NCT03098836|Experimental|Caucasian|
11241410|NCT03098836|Experimental|African American|
11241411|NCT03098823|Experimental|RAYOS®|
11241412|NCT03098823|Active Comparator|IR prednisone|
11241413|NCT03098810|Placebo Comparator|Normal children|Placebo
11241414|NCT03098810|Experimental|Malnourished children|Oral zinc sulphate syrup
11241415|NCT03098797|Experimental|Experimental: Elamipretide|Patients will be randomized to receive 12 weeks of elamipretide in one of the two treatment periods. All subjects will receive 12 weeks of elamipretide and 12 weeks of placebo.
11241416|NCT03098797|Placebo Comparator|Placebo|Patients will be randomized to receive 12 weeks of placebo in one of the two treatment periods. All subjects will receive 12 weeks of placebo and 12 weeks of elamipretide.
11241417|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.
~Intervention: Exposure to aircraft exhaust"
11241419|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
11241420|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
11241421|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
11241422|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
11241423|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
11241424|NCT03098732|Experimental|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
11241425|NCT03098732|Sham Comparator|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
11241426|NCT03098719|Experimental|Intervention|
11241427|NCT03098719|No Intervention|Control|
11241428|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
11241429|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
11241430|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
11241431|NCT03098680|Experimental|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.
~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
11241432|NCT03098680|Experimental|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.
~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
11241433|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
11241434|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
11241435|NCT03098654|Experimental|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:
~Community mobilization activities to inform community members of available services
~Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.
~HIV counseling and serial rapid HIV testing
~Blood glucose and blood pressure testing
~DM/HTN medications as needed
~Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
11241436|NCT03098654|No Intervention|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
11241437|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
11241438|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
11241439|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
11241440|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
11241441|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
11241442|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
11241443|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
11241444|NCT03098576||Matched|Matched targeted drug treatment
11241445|NCT03098576||Control|Unmatched standard of care
11241446|NCT03098563|Experimental|Arm 1|Blinded study medication. This is a within-subject study so all session procedures will be identical. The specific medications administered that study day will be the only change each session. Study days will last approximately 8 hours and will be conducted on an outpatient basis. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
11241447|NCT03098563|Experimental|Arm 2|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
11241448|NCT03098563|Experimental|Arm 3|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
11241449|NCT03098563|Experimental|Arm 4|Blinded study medication. Participants will be asked to complete standardized pain testing procedures, do brief physical functioning testing, undergo blood draws and complete questionnaires and cognitive testing at multiple points over the course of each study visit.
11241450|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
11241451|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
11241452|NCT03098537|Active Comparator|Enteral nutrion only|
11241453|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
11241454|NCT03098524|Experimental|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
11241455|NCT03098524|Placebo Comparator|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
11241456|NCT03098511|Other|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
11241457|NCT03098498|Experimental|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
11241458|NCT03098498|Active Comparator|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
11241459|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
11241460|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
11241461|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
11241462|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
11241463|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
11241464|NCT03098446|Experimental|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
11241465|NCT03098446|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
11241466|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
11241467|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
11241468|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
11241469|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
11241470|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
11241471|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
11241472|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
11241473|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
11241474|NCT03098394|Experimental|Rapid Turnaround Test|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
11241475|NCT03098394|Active Comparator|Usual Care|Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.
11241549|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
11241476|NCT03098368|Active Comparator|Patient (active) group|"Rotigotine titration up to 16 mg/24 hr
~Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose
~Duration up to 12 weeks
~The treatment was titrated until optimal dosage
~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)
~(or patient can not tolerated the side effects such as dyskinesia)
~All previous dopaminergic medications were not allowed to adjusted during the study period."
11241477|NCT03098368|Placebo Comparator|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.
~Duration up to 12 weeks
~The treatment (placebo patch) was titrated until optimal dosage
~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)
~(or patient can not tolerated the side effects such as dyskinesia)
~All previous dopaminergic medications were not allowed to adjusted during the study period."
11241478|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
11241479|NCT03098342|Experimental|MB-PDT for Onychomycosis|
11241480|NCT03098342|Active Comparator|Amorolfine for Onychomycosis|
11241481|NCT03098329|Experimental|Ct/GC screening|Community screening of men for Ct and GC is not normally done. We are testing to see if this intervention will impact the rates of Ct and GC among women
11241482|NCT03098316||POAG|Primary open angle glaucoma patients
11241483|NCT03098316||NTG|Normal/Low tension glaucoma patients
11241484|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
11241485|NCT03098290||Intermittent Claudication|Mild to severe claudication
11241486|NCT03098290||Ischaemic Rest Pain|
11241487|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
11241488|NCT03098277|Experimental|Observational (physical activity, accelerometer, PROs)|Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.
11241489|NCT03098264|Experimental|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
11241490|NCT03098264|Active Comparator|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
11241491|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
11241492|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
11241493|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
11241494|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
11241495|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
11241496|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
11241497|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
11241498|NCT03098212|Experimental|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
11241499|NCT03098212|No Intervention|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
11241500|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
11241501|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
11241502|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
11241503|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
11241504|NCT03098186|Active Comparator|Intervention SMS|"SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.
~Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
11241505|NCT03098186|Placebo Comparator|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
11241506|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
11241507|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
11241508|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
11241509|NCT03098134|Experimental|VR-Video-Exposure|
11241510|NCT03098134|Active Comparator|Education-Video-|
11241511|NCT03098121|Experimental|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
11241512|NCT03098108|Experimental|CCPT|
11241513|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
11241514|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
11241515|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
11241516|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
11241517|NCT03098056|Experimental|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
11241518|NCT03098030|Experimental|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
11241519|NCT03098030|Active Comparator|Part 2: Irinotecan|Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
11241520|NCT03098030|Experimental|Part 2: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
11241521|NCT03098030|Active Comparator|Part 2: Topotecan|Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.
11241522|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
11241523|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
11241524|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
11241525|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
11241526|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
11241527|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
11241528|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
11241529|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
11241530|NCT03097978|Experimental|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
11241531|NCT03097978|Experimental|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
11241532|NCT03097978|Experimental|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
11241533|NCT03097978|Experimental|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
11241534|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan
~Physical activity
~Cognitive behavioral program"
11241535|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan
~Physical activity
~Cognitive Behavioral Program
~Protein Shakes
~Phytosterols supplement
~Berberine supplement
~Anti-oxidant supplement
~Probiotic supplement
~Fish Oil supplement
~Multiple Vitamin/Multiple Mineral supplement"
11241536|NCT03097939|Experimental|Nivolumab and Ipilimumab|
11241537|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
11241538|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
11241539|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
11241540|NCT03097900|Active Comparator|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
11241541|NCT03097900|Placebo Comparator|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
11241542|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
11241543|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
11241544|NCT03097874|Experimental|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
11241545|NCT03097874|Experimental|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
11241546|NCT03097861|Active Comparator|Lubiprostone Capsule|Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
11241547|NCT03097861|Experimental|Lubiprostone Sprinkle|Lubiprostone 24 mcg sprinkle BID for 7 days.
11241548|NCT03097861|Placebo Comparator|Placebo|Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.
11241550|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
11241551|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
11241552|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
11241553|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
11241554|NCT03097796|Experimental|PUL-042|PUL-042 Inhalation Solution
11241555|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
11241556|NCT03097783|No Intervention|No intervention arm|No treatment
11241557|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
11241558|NCT03097757|No Intervention|(standard of care fracture reduction|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray.
11241559|NCT03097757|Experimental|ultrasound guided fracture reduction|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
11241560|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
11241561|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
11241562|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
11241563|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
11241564|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
11241565|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
11241566|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
11241567|NCT03097666|Other|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
11241568|NCT03097653|Experimental|Decision-aid|
11241569|NCT03097653|Active Comparator|Standard information|
11241570|NCT03097640|Experimental|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
11241571|NCT03097640|No Intervention|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
11241572|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
11241573|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
11241574|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
11241575|NCT03097588|Experimental|Supportive care (NEPA)|Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.
11241576|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
11241577|NCT03097562|Experimental|CT1|"FLACS- Initial Wound parameters (CT1)
~Sample size calculation based on woundleak incidence estimated from preliminary results:
~For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.
~For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)
~A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
11241578|NCT03097562|Experimental|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.
~The traditional manual wound performed with a standard keratome wil be used as a reference."
11241579|NCT03097562|Active Comparator|MT control group|Standard manual technique (MT)
11241580|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
11241581|NCT03097549|Other|Tät®II Information app|"Information only.
~."
11241582|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
11241658|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
11241583|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
11241584|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:
~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed
~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)
~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
11241585|NCT03097510|Experimental|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
11241586|NCT03097510|No Intervention|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
11241587|NCT03097497|Experimental|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
11241588|NCT03097497|Active Comparator|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut
~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
11241589|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
11241590|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
11241591|NCT03097458|Experimental|Counselling|short-term counselling for families
11241592|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
11241593|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
11241594|NCT03097445|No Intervention|Control|No intervention control group
11241595|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.
11241596|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
11241597|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
11241598|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
11241599|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
11241600|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
11241601|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
11241602|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
11241603|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
11241604|NCT03097380|Experimental|AZD2115|
11241605|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
11241606|NCT03097380|Experimental|[11C]AZ13754366|
11241607|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
11241608|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
11241609|NCT03097341|Experimental|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
11241610|NCT03097341|Experimental|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
11241611|NCT03097341|Experimental|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
11241612|NCT03097341|Experimental|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
11241613|NCT03097341|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
11241614|NCT03097328|Experimental|TAK-228|"TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle
~Dosage will be determined by the study team"
11241615|NCT03097315|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
11241616|NCT03097289|Experimental|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
11241617|NCT03097276|Other|Patients who underwent open decompression surgery|
11241618|NCT03097263||Patients|Patients included for rehabilitation program
11241619|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
11241620|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
11241621|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
11241622|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
11241623|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
11241624|NCT03097224|No Intervention|Control group|Usual care
11241625|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
11241626|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
11241627|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
11241628|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
11241629|NCT03097198|Experimental|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
11241630|NCT03097198|Experimental|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
11241631|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx
~30 patients total"
11241632|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery
~10 x LAD 10 x RCA
~20 patients total"
11241633|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
11241634|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
11241635|NCT03097146|Other|comprehensive multidisciplinary stroke care|
11241636|NCT03097133|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
11241637|NCT03097133|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
11241638|NCT03097120|Active Comparator|unopposed estrogen|0.625 mg of conjugated equine estrogen
11241639|NCT03097120|Active Comparator|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
11241640|NCT03097120|Placebo Comparator|placebo|placebo
11241641|NCT03097107|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks
11241642|NCT03097107|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks
11241643|NCT03097107|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks
11241644|NCT03097107|Placebo Comparator|Placebo|Placebo tablet orally once a day for 12 weeks
11241645|NCT03097094|Active Comparator|Male dog|Male dog extract used for skin prick test and conjunctival provocation
11241646|NCT03097094|Active Comparator|Female dog|Female dog extract used for skin prick test and conjunctival provocation
11241647|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
11241648|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
11241649|NCT03097068|Experimental|0.3 mg Lucentis|Aqueous Humor sample post injection of 0.3 mg Lucentis
11241650|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
11241651|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
11241652|NCT03097042|Active Comparator|Study group|The catheter will be pulled back slowly and without rotation
11241653|NCT03097042|Active Comparator|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
11241654|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
11241655|NCT03097016|Experimental|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
11241656|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
11241657|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
11241805|NCT03095924|Active Comparator|News with Spin|News items reporting results of RCTs with spin
11241659|NCT03096964|Experimental|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
11241660|NCT03096964|Experimental|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
11241661|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
11241662|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
11241663|NCT03096938|Placebo Comparator|Normal screening group|patients receive the routine screening examination
11241664|NCT03096938|Experimental|methylation markers screening group|patients receive the methylation markers screening
11241665|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
11241666|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
11241667|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
11241668|NCT03096886|Experimental|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy
~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
11241669|NCT03096886|Experimental|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy
~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.
~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
11241670|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison
~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
11241671|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
11241672|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
11241673|NCT03096860|Experimental|Alcohol consumption and hookah|
11241674|NCT03096860|Placebo Comparator|Placebo consumption and hookah|
11241675|NCT03096847|Experimental|ribociclib + letrozole|"All patients will receive ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.
~Premenopausal patients additionally receive goserelin 3.6 mg i.m. monthly"
11241676|NCT03096834|Placebo Comparator|Placebo|Matching placebo injection, subcutaneous
11241677|NCT03096834|Experimental|AMG 334|AMG 334 injection, subcutaneous
11241678|NCT03096821|Other|ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
11241679|NCT03096808|Experimental|Adaptive Radiotherapy|Eligible patients will receive IMRT of 60-70Gy in 30-35 once-daily fractions with or without concurrent chemotherapy according to the current standard of care.
11241680|NCT03096795|Placebo Comparator|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
11241681|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
11241682|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
11241683|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
11241684|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
11241685|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
11241686|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
11241687|NCT03096795|Experimental|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
11241688|NCT03096795|Placebo Comparator|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
11241689|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
11241690|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
11241691|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
11241692|NCT03096795|Placebo Comparator|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
11241693|NCT03096795|Experimental|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
11241694|NCT03096782|Experimental|Group I (chemotherapy, TBI, cord blood)|"Patients receive rituximab IV on day -11, ATG IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1 hour, busulfan IV over 3 hours on days -7 through -4, and TBI on day -3. Patients then receive a cord blood transfusion IV on day 0.
~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
11241695|NCT03096782|Experimental|Group II (chemotherapy, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a cord blood transplant IV on day 0.
~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
11241696|NCT03096782|Experimental|Group III (chemotherapy, TBI, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.
~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
11241697|NCT03096769|Other|Study Arm|
11241698|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
11241699|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
11241700|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
11241701|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
11241702|NCT03096730|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
11241703|NCT03096730|Sham Comparator|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
11241704|NCT03096730|Active Comparator|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
11241705|NCT03096730|Active Comparator|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
11241706|NCT03096730|Active Comparator|Dexmedetomidine-Nalmefene|A dose of 0.2ug/kg nalmefene and a dose of 0.5ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
11241707|NCT03096704||slow transit time constipation|
11241708|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
11241709|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
11241710|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
11241711|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
11241712|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
11241713|NCT03096652|Active Comparator|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
11241714|NCT03096652|Active Comparator|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
11241715|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
11241716|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
11241717|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
11241718|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
11241719|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
11241720|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
11241721|NCT03096574||Pregnant women|"Over the age of 16
~Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust
~Able to read and write in English and give fully informed consent"
11241800|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
11241722|NCT03096574||Maternity healthcare professionals|"Over the age of 18
~Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust
~Able to read and write in English and give fully informed consent"
11241723|NCT03096574||UK General Practitioners|"Fully-qualified general practitioners practicing in the UK
~Able to read and write in English and give fully informed consent"
11241724|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
11241725|NCT03096548|Experimental|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
11241726|NCT03096548|Active Comparator|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
11241727|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
11241728|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
11241729|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
11241730|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
11241731|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
11241732|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
11241733|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
11241734|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
11241735|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
11241736|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.
~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
11241737|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
11241738|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
11241739|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
11241740|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
11241741|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
11241742|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
11241743|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
11241744|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
11241745|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
11241746|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.
~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
11241747|NCT03096392|Experimental|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
11241748|NCT03096392|Active Comparator|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
11241749|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
11241750|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
11241751|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
11241752|NCT03096353|Experimental|active agent/placebo|30 healthy participants will be enrolled in the study. Each participant will receive naloxone on one day, and saline on the other day.
11241753|NCT03096353|Experimental|placebo/active agent|30 healthy participants will be enrolled in the study. Each participant will receive naloxone on one day, and saline on the other day.
11241754|NCT03096340|Experimental|IT-141|
11241755|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
11241756|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
11241757|NCT03096314|Active Comparator|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
11241758|NCT03096314|Placebo Comparator|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
11241759|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
11241760|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).
~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.
~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
11241761|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
11241762|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
11241763|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
11241764|NCT03096275|Experimental|MMF+MTX+Glucocorticoids|Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
11241765|NCT03096275|Active Comparator|CYC/AZA+Glucocoticoids|Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
11241766|NCT03096262|Experimental|Stroke Patients|
11241767|NCT03096262|Active Comparator|Healthy Controls|
11241768|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
11241769|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
11241770|NCT03096223|Experimental|KHK4083|
11241771|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
11241772|NCT03096210|Other|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
11241801|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
11241802|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
11241803|NCT03095950|Active Comparator|News with Spin|News items reporting results of RCTs with spin
11241773|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
11241774|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
11241775|NCT03096184|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
11241776|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
11241777|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
11241778|NCT03096158|Experimental|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
11241779|NCT03096158|Experimental|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
11241780|NCT03096158|Experimental|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
11241781|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
11241782|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
11241783|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
11241784|NCT03096093|Experimental|Immunotherapy - pancreatic cancer|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.
11241785|NCT03096093|Experimental|Immunotherapy - other late stage cancers|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.
11241786|NCT03096080|Experimental|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
11241787|NCT03096080|Experimental|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
11241788|NCT03096080|Experimental|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
11241789|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
11241790|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
11241791|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
11241792|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
11241793|NCT03096041|Experimental|Experimental arm|Auriculotherapy for analgesic use
11241794|NCT03096041|Placebo Comparator|Controle arm|Placebo auriculotherapy
11241795|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 & 28 weeks.
11241796|NCT03096015|Experimental|Intensive Treatment for Aphasia|
11241797|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
11241798|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
11241799|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
11241806|NCT03095924|Experimental|News without spin|News items reporting results of RCTs without spin
11241807|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
11241808|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
11241809|NCT03095898|Experimental|True Acupuncture|
11241810|NCT03095898|Sham Comparator|Sham Acupuncture|
11241811|NCT03095898|No Intervention|Control Group|
11241812|NCT03095885|Other|Test Meal|controlled oxalate-rich test meal
11241813|NCT03095872|Experimental|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
11241814|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
11241815|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
11241816|NCT03095846|Experimental|Winter Swimmers|Individualized cooling protocol
11241817|NCT03095846|Experimental|Not-winter Swimmers|Individualized cooling protocol
11241818|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
11241819|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
11241820|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
11241821|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.
~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
11241822|NCT03095807|Experimental|NNC9204-1706 A|
11241823|NCT03095807|Placebo Comparator|Placebo|
11241824|NCT03095794|Experimental|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
11241825|NCT03095781|Experimental|Treatment (pembrolizumab, XL888)|Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11241826|NCT03095768|Experimental|Intervention|Lifestyle Education and Cooking Demonstration
11241827|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
11241828|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
11241829|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
11241830|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
11241831|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
11241832|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
11241833|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
11241834|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
11241835|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
11241836|NCT03095690|Other|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
11241837|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
11241838|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
11241839|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
11241840|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
11241841|NCT03095651|Experimental|T1DM MK-5160 16 nmol/kg|Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241842|NCT03095651|Experimental|T1DM MK-5160 32 nmol/kg|Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241843|NCT03095651|Experimental|T1DM MK-5160 64 nmol/kg|Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241844|NCT03095651|Active Comparator|T1DM Glargine 0.4 U/kg|Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241845|NCT03095651|Experimental|T2DM MK-5160 16 nmol/kg|Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241846|NCT03095651|Experimental|T2DM MK-5160 32 nmol/kg|Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241847|NCT03095651|Experimental|T2DM MK-5160 64 nmol/kg|Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241848|NCT03095651|Active Comparator|T2DM Glargine 0.6 U/kg|Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
11241849|NCT03095638|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
11241850|NCT03095638|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
11241851|NCT03095638|Experimental|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
11241852|NCT03095638|Experimental|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
11241853|NCT03095638|Experimental|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
11241854|NCT03095638|Experimental|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
11241855|NCT03095638|Experimental|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
11241856|NCT03095638|Experimental|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
11241857|NCT03095612|Experimental|Selinexor in Combination with Docetaxel|Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 100, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks.
11241858|NCT03095599|Experimental|Vaccine|Received one dose of IVACFLU-S vaccine intramuscularly.
11241859|NCT03095599|Placebo Comparator|Placebo|Received one dose of placebo intramuscularly.
11241860|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
11241861|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
11241862|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
11241863|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
11241864|NCT03095560|Experimental|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
11241865|NCT03095560|Experimental|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
11241866|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
11241867|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
11241868|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
11241869|NCT03095547|Experimental|F901318|F901318 alone
11241956|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
11241870|NCT03095534|Experimental|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
11241871|NCT03095521|Experimental|Arm A|Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
11241872|NCT03095521|Active Comparator|Arm B|ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
11241873|NCT03095508|Experimental|Angal S (Arm A)|Patients received Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
11241874|NCT03095508|Active Comparator|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
11241875|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
11241876|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
11241877|NCT03095482|Active Comparator|tDCS (mPFC+) + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 2 mA, followed by 30 minutes of in vivo exposure therapy.
11241878|NCT03095482|Active Comparator|tDCS (mPFC-) + In Vivo Exposure|Participants assigned to this condition will receive inhibitory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and excitatory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 2 mA. tDCS will be administered for 20 minutes at 2 mA, followed by 30 minutes of in vivo exposure therapy.
11241879|NCT03095482|Sham Comparator|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
11241880|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
11241881|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
11241882|NCT03095456|Experimental|Revefenacin|Active Revefenacin and placebo (in place of Spiriva Handihaler®)
11241883|NCT03095456|Active Comparator|Spiriva Handihaler®|Active Spiriva Handihaler® and placebo (in place of Revefenacin)
11241884|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
11241885|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
11241886|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
11241887|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
11241888|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
11241889|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
11241890|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
11241891|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
11241892|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.
~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
11241893|NCT03095404|Experimental|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
11241894|NCT03095404|Experimental|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
11241895|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
11241896|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
11241897|NCT03095391||Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
11241898|NCT03095391||Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
11241899|NCT03095378|Active Comparator|Control|Root treatment with scaling and root planing.
11241900|NCT03095378|Experimental|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
11241901|NCT03095378|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
11241902|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
11241903|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
11241904|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
11241905|NCT03095352|Experimental|Arm A|Arm A: Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
11241906|NCT03095352|Experimental|Arm B|Arm B: Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11241907|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
11241908|NCT03095339|No Intervention|Control|The control group did not receive any intervention
11241909|NCT03095326|Experimental|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
11241910|NCT03095326|Placebo Comparator|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
11241911|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
11241912|NCT03095287|Experimental|Alphanate|Daily intravenous infusion of Alphanate 100 IU/kg/day
11241913|NCT03095274|Experimental|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.
~Weight-based dosing should be used for patients <30 kg: durvalumab 20 mg/kg."
11241914|NCT03095274|Experimental|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.
~Weight-based dosing should be used for patients <30 kg: tremelimumab 1 mg/kg Q4."
11241915|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
11241916|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
11241917|NCT03095248|Experimental|Stratum 1 - NF2 related vestibular schwannomas|Stratum 1 will include patients with NF2 with vestibular schwannomas who exhibit hearing loss. Participants will receive continuous twice daily dosing of selumetinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
11241918|NCT03095248|Experimental|Stratum 2: other NF2 related tumors (meningiomas and ependymom|Stratum 2 will include patients who have progressive lesions other than VS (including non-vestibular schwannomas, meningiomas, and spinal cord lesions). Participants will receive continuous twice daily dosing of selumentinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
11241919|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
11241920|NCT03095222|Active Comparator|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
11241921|NCT03095222|Active Comparator|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
11241922|NCT03095209||Standard of care concurrent chemo-radiation therapy|
11241923|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
11241924|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
11241925|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
11241926|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
11241927|NCT03095170|Experimental|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.
~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
11241928|NCT03095170|Experimental|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.
~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
11241929|NCT03095170|Active Comparator|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
11241930|NCT03095157|Placebo Comparator|Placebo|
11241931|NCT03095157|Experimental|Treatment|
11241932|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
11241933|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
11241934|NCT03095131|Experimental|12-lead ECG|
11241935|NCT03095118|Experimental|Daratumumab|Daratumumab will be given intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
11241936|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.
~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
11241937|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.
~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
11241938|NCT03095092|Experimental|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
11241939|NCT03095092|Experimental|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
11241940|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
11241941|NCT03095066|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
11241942|NCT03095066|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
11241943|NCT03095053|Active Comparator|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
11241944|NCT03095053|No Intervention|Morphology group|morphological assessment of blastocyst by light microscope
11241945|NCT03095040|Experimental|CM082 combined with everolimus|
11241946|NCT03095040|Experimental|CM082|
11241947|NCT03095040|Active Comparator|Everolimus|
11241948|NCT03095027|Other|FID122819, then stenfilcon A|FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
11241949|NCT03095027|Other|Stenfilcon A, then FID122819|Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
11241950|NCT03095014|Experimental|Cesarean Myomectomy|Myomectomy plus Cesarean section
11241951|NCT03095014|Active Comparator|Cesarean section|Cesarean section only
11241952|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles
~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
11241953|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks
~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
11241954|NCT03094988|Other|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
11241955|NCT03094988|Experimental|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
11241957|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
11241958|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
11241959|NCT03094936|Other|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
11241960|NCT03094936|Active Comparator|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
11241961|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
11241962|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
11241963|NCT03094910|Other|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
11241964|NCT03094910|Other|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
11241965|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
11241966|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
11241967|NCT03094871|Experimental|Intervention group|FACE-PC comprises 3 weekly and 2 bi-weekly sessions (total 5 sessions), delivered by a bachelors' prepared nurse care manager (CM) over 8 weeks. Over the five sessions, the nurse care manager will (1) review the patient medical history and set health goals for depression and chronic condition with the dyad, (2) review all medication, the level of adherence, challenges and facilitating factors of adherence, (3) deliver brief behavioral activation therapy.
11241968|NCT03094871|No Intervention|Enhanced usual care group|Participants in this group will receive a typical primary care enhanced with reporting of their depression status and their goal for medical condition to their PCP for 8 weeks. Upon enrolment, a research nurse will review the patient medical history and identify goals for depression and a chronic condition with the dyad.
11241969|NCT03094858|Active Comparator|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
11241970|NCT03094858|Experimental|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
11241971|NCT03094845|Placebo Comparator|Placebo|
11241972|NCT03094845|Experimental|hdmASIT+TM|
11241973|NCT03094832|Experimental|ARQ 092 - Part A|One cohort of subjects at least 2 years of age with either PROS or PS
11241974|NCT03094832|Experimental|ARQ 092 - Part B, cohort 1|"Subjects with PROS who have a measurable lesion by volumetric MRI
~."
11241975|NCT03094832|Experimental|ARQ 092 - Part B, cohort 2|Subjects with PS who have a measurable lesion by standardized digital photography
11241976|NCT03094832|Experimental|ARQ 092 - Part B, cohort 3|Subjects with PROS or PS who do not meet all the eligibility criteria for cohorts 1 or 2
11241977|NCT03094832|Experimental|ARQ 092 - Part B, cohort 4|Subjects previously treated with ARQ 092 or currently receiving ARQ 092 under Compassionate Use/Expanded Access.
11241978|NCT03094819|No Intervention|Group 1|Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
11241979|NCT03094819|Experimental|Financial Incentive|Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
11241980|NCT03094819|Experimental|Retinal Care DR|Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
11241981|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
11241982|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
11241983|NCT03094793|Experimental|abnormal EEGs|
11241984|NCT03094780|Other|Quality of Life Counseling|
11241985|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
11241986|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
11241987|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
11241988|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
11241989|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
11241990|NCT03094715|Other|Best medical care|Best medical treatment
11241991|NCT03094689|No Intervention|Control group|
11241992|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
11241993|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
11241994|NCT03094676|No Intervention|Control|Only the HRV will be followed for two hours without intervention.
11241995|NCT03094676|Experimental|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
11241996|NCT03094676|Experimental|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
11241997|NCT03094676|Experimental|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
11241998|NCT03094676|Experimental|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
11241999|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)
~Injection prior to cementation
~bupivacaine 0.5% with epinephrine 30cc;
~methylprednisolone, 40 mg/ml, 1 ml
~cefazolin, 500 mg in 10 ml
~normal saline, 22cc
~Superficial injection prior to closure.
~20cc 0.25% bupivacaine
~2 mg IV dexamethasone."
11242000|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)
~Injection prior to cementation
~bupivacaine 0.25% with epinephrine 30cc;
~methylprednisolone, 40 mg/ml, 1 ml
~cefazolin, 500 mg in 10 ml
~normal saline, 22cc
~Superficial injection prior to closure.
~a. 20cc 0.25% bupivacaine
~Adductor canal block technique (supine position, post IV sedation)
~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
11242001|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
11242002|NCT03094637|Experimental|Treatment (azacitidine, pembrolizumab)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7, and pembrolizumab IV over 30 minutes every 3 weeks. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11242003|NCT03094624|Experimental|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
11242004|NCT03094624|Sham Comparator|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
11242005|NCT03094611|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
11242006|NCT03094598|No Intervention|Control|No intervention
11242007|NCT03094598|Experimental|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
11242008|NCT03094598|Experimental|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
11242009|NCT03094598|Experimental|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
11242010|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
11242011|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
11242012|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
11242013|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
11242014|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
11242015|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
11242016|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
11242017|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
11242018|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
11242019|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
11242020|NCT03094559|Experimental|FlowMet device|This is a feasibility study
11242021|NCT03094546|Experimental|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation):
11242022|NCT03094546|Placebo Comparator|Placebo|Intervention: Dietary Supplement Placebo:
11242023|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
11242024|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
11242025|NCT03094520|Experimental|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
11242026|NCT03094520|Sham Comparator|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
11242027|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
11242028|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
11242029|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
11242030|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
11242031|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
11242032|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
11242033|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
11242034|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
11242035|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
11242036|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
11242037|NCT03094468|Experimental|P-3058|
11242038|NCT03094468|Placebo Comparator|Vehicle|
11242039|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
11242040|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
11242041|NCT03094442|Active Comparator|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.
~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
11242042|NCT03094442|Placebo Comparator|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
11242043|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
11242044|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
11242045|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
11242046|NCT03094416|Experimental|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
11242047|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
11242048|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
11242049|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
11242050|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
11242051|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
11242052|NCT03094364|Active Comparator|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.
~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
11242053|NCT03094364|Active Comparator|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.
~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
11242160|NCT03093701|Experimental|Group 4|TLC399 (ProDex) 0.84 mg DSP with 50 mM PL
11242054|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
11242055|NCT03094351|Active Comparator|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
11242056|NCT03094325|Experimental|Septal myectomy|
11242057|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
11242058|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
11242059|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
11242060|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
11242061|NCT03094247|Active Comparator|Conventional RUTF (C-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. C-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
11242062|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to C-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
11242063|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
11242064|NCT03094234|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
11242065|NCT03094234|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
11242066|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
11242067|NCT03094208|Experimental|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
11242068|NCT03094208|Active Comparator|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
11242069|NCT03094195|Experimental|EMA401 25mg BID|Ema401 25 mg was administered orally twice a day
11242070|NCT03094195|Experimental|EMA401 100mg BID|Ema401 100 mg was administered orally twice a day
11242071|NCT03094195|Placebo Comparator|Placebo BID|Matching placebo capsules administered orally twice a day
11242072|NCT03094182|Experimental|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
11242073|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
11242074|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
11242075|NCT03094169|Experimental|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
11242076|NCT03094169|Experimental|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
11242077|NCT03094169|Experimental|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
11242078|NCT03094156|Experimental|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
11242079|NCT03094156|Experimental|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
11242080|NCT03094156|Experimental|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
11242081|NCT03094156|Experimental|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
11242082|NCT03094156|Experimental|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
11242083|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
11242084|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
11242085|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
11242086|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
11242087|NCT03094130|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
11242088|NCT03094130|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
11242089|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
11242090|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
11242091|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
11242092|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
11242093|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
11242094|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
11242095|NCT03094078|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin
11242096|NCT03094078|Experimental|News without spin|News items reporting results of pre-clinical studies without spin
11242097|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
11242098|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
11242099|NCT03094052|Experimental|Neratinib, Crofelemer, and Loperamide|"Neratinib 240 mg orally once a day for up to 2 years. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity.
~Intensive daily loperamide prophylaxis for the first 2 cycles (42 days) and then as needed. Days 1-14: 4 mg 3 times daily. Days 15-42: 4 mg twice per day.
~Crofelemer 125 mg bid for the first 2 cycles then as needed."
11242100|NCT03094052|Experimental|Neratinib, Trastuzumab, Crofelemer, and Loperamide|"Neratinib and Trastuzumab: Neratinib and at a dose of 240 mg orally while receiving maintenance adjuvant trastuzumab (duration of maintenance trastuzumab up to the treating physician). After the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib will continue as monotherapy for 52 weeks. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity.
~Intensive daily loperamide prophylaxis for the first 2 cycles (42 days) and then as needed. Days 1-14: 4 mg 3 times daily. Days 15-42: 4 mg twice per day.
~Crofelemer 125 mg bid for the first 2 cycles then as needed."
11242101|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
11242102|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
11242103|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
11242104|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
11242105|NCT03094000|Experimental|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
11242106|NCT03094000|Active Comparator|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
11242107|NCT03093987|No Intervention|control group|usual care
11242108|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
11242109|NCT03093974|Experimental|treatment|Inhaled colistimethate sodium twice daily
11242110|NCT03093974|Placebo Comparator|Saline solution|inhaled placebo twice daily
11242111|NCT03093961|Experimental|Intervention|IASD Implantation
11242112|NCT03093948|Experimental|Remote Ischemic post-conditioning|
11242113|NCT03093948|No Intervention|standard of care|
11242114|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.
~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
11242115|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
11242116|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
11242117|NCT03093922|Experimental|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
11242161|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
11242118|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).
~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.
~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
11242119|NCT03093896|Placebo Comparator|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
11242120|NCT03093896|Active Comparator|almonds, 1.5 ounces|almonds, 1.5 ounces/day
11242121|NCT03093896|Active Comparator|almonds, 3 ounces|almonds, 3 ounces/day
11242122|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
11242123|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
11242124|NCT03093870|Experimental|Varlitinib and Capecitabine|
11242125|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
11242126|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.
~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
11242127|NCT03093831|Experimental|Ibrutinib|
11242128|NCT03093818|Experimental|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
11242129|NCT03093818|No Intervention|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
11242130|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
11242131|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
11242132|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
11242133|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
11242134|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
11242135|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
11242136|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
11242137|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
11242138|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
11242139|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
11242140|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
11242141|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
11242142|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
11242143|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
11242144|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
11242145|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
11242146|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
11242147|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
11242148|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
11242149|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
11242150|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
11242151|NCT03093740|Experimental|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
11242152|NCT03093740|Experimental|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
11242153|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
11242154|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
11242155|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
11242156|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
11242157|NCT03093701|Experimental|Group 1|TLC399 (ProDex) 0.36mg DSP with 100 mM PL
11242158|NCT03093701|Experimental|Group 2|TLC399 (ProDex) 0.6 mg DSP with 100 mM PL
11242159|NCT03093701|Experimental|Group 3|TLC399 (ProDex) 0.6 mg DSP with 50 mM PL
11242162|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
11242163|NCT03093662|Experimental|Ventilation with nasal cannula first|Non-invasive positive pressure ventilation with nasal cannula first followed by non-invasive positive pressure ventilation without nasal cannula.
11242164|NCT03093662|Active Comparator|Ventilation without nasal cannula first|Non-invasive positive pressure ventilation without nasal cannula first followed by non-invasive positive pressure ventilation with nasal cannula.
11242165|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
11242166|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
11242167|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
11242168|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
11242169|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
11242170|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
11242171|NCT03093610|Active Comparator|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
11242172|NCT03093610|Active Comparator|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
11242173|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
11242174|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
11242175|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
11242176|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
11242177|NCT03093584|Active Comparator|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
11242178|NCT03093584|Experimental|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
11242179|NCT03093584|No Intervention|No intervention|No intervention, just observation and monitoring of outcome measures
11242180|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
11242181|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
11242182|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
11242183|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
11242184|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
11242185|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
11242186|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
11242187|NCT03093532|No Intervention|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
11242188|NCT03093532|Active Comparator|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:
~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
11242189|NCT03093532|Active Comparator|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
11242190|NCT03093519|Experimental|KHK6640|Intravenous administration
11242191|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
11242192|NCT03093506|Active Comparator|Low-dose rhEpo|RhEpo 60IU/kg/week
11242193|NCT03093506|Active Comparator|Micro-dose rhEpo|RhEpo 20IU/kg/week
11242194|NCT03093506|Placebo Comparator|Placebo Control|Saline
11242195|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
11242196|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
11242197|NCT03093480|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who meet the criteria for immune tolerance induction (ITI) success will enter the tapering period and will receive rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up will be 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
11242198|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
11242199|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
11242200|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
11242201|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
11242202|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
11242203|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
11242204|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
11242205|NCT03093428|Experimental|Radium-223|-Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
11242206|NCT03093428|Experimental|Pembrolizumab Plus Radium-223|"Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
~Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose"
11242207|NCT03093415|Active Comparator|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
11242208|NCT03093415|Active Comparator|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
11242209|NCT03093415|Other|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health & Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
11242210|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
11242211|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
11242212|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
11242213|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
11242214|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
11242215|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
11242216|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
11242217|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
11242218|NCT03093376|Experimental|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
11242219|NCT03093376|Placebo Comparator|Waitlist Control|No intervention between pre and post assessment. After post-waitlist assessment, children will be given a set of written materials, adapted from the Effortful Control Camp protocol, to complete at home with their caregivers.
11242220|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
11242221|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
11242222|NCT03093350|Experimental|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
11242223|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
11242224|NCT03093337|No Intervention|Control|No specific support.
11242225|NCT03093324|Experimental|ALKS 8700|Oral capsules, administered orally twice daily.
11242226|NCT03093324|Active Comparator|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
11242227|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
11242228|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
11242229|NCT03093298|Experimental|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
11242230|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
11242231|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily
~Docetaxel will be administered every 3 weeks intravenously
~Prednisone will be taken orally twice daily
~Leuprolide Acetate will be administered at the specification of the physician"
11242232|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
11242233|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
11242234|NCT03093246|Placebo Comparator|Control group|In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.
11242235|NCT03093246|Experimental|Test Group|In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
11242236|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)
~Association of hematoma evacuation surgery with clinical outcomes
~Associations of antithrombotic management with ischemic and hemorrhagic complications
~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
11242237|NCT03093220||community-acquired pneumonia|all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
11242238|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
11242239|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
11242240|NCT03093194|Active Comparator|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
11242241|NCT03093194|Placebo Comparator|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
11242242|NCT03093181|Placebo Comparator|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
11242243|NCT03093181|Experimental|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
11242244|NCT03093181|Active Comparator|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
11242245|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
11242246|NCT03093155|Active Comparator|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
11242247|NCT03093155|Experimental|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15
~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
11242248|NCT03093142|Experimental|tDCS & neurofeedback|30 minutes tDCS & 30 minutes neurofeedback
11242249|NCT03093142|Active Comparator|real neurofeedback|30 minutes real neurofeedback.
11242250|NCT03093142|Sham Comparator|sham neurofeedback|30 minutes sham neurofeedback.
11242251|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
11242252|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
11242253|NCT03093116|Experimental|Repotrectinib (TPX-0005)|"Phase 1
~Oral repotrectinib (TPX-0005):
~Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.
~Phase 2
~Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts
~EXP-1: ROS1 TKI-naïve ROS1+ NSCLC
~EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC
~EXP-3: 2 Prior ROS1 TKIs and 1 Platinum based chemo ROS1+ NSCLC
~EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)
~EXP-5: TRK TKI-naïve NTRK+ solid tumors
~EXP-6: TRK TKI-pretreated NTRK+ solid tumors"
11242254|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
11242255|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
11242256|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
11242257|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
11242258|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
11242259|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
11242260|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
11242261|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
11242262|NCT03093064|Experimental|Patient Group: Natalizumab|
11242263|NCT03093064|Placebo Comparator|Patient Group: Placebo|
11242264|NCT03093038|Active Comparator|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem and the Delta-TT cup with polyethylene insert
11242265|NCT03093038|Experimental|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem and the Delta-TT cup with ceramic insert
11242266|NCT03093038|Experimental|C2 stem & Delta-TT cup + ceramic|C2 femoral stem and the Delta-TT cup with ceramic insert
11242267|NCT03093025|Experimental|TS-121 10mg|
11242268|NCT03093025|Experimental|TS-121 50mg|
11242269|NCT03093025|Placebo Comparator|Placebo|
11242270|NCT03092999|Experimental|Healthy subjects|healthy subjects
11242271|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
11242272|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
11242273|NCT03092986|Active Comparator|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
11242274|NCT03092986|Experimental|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
11242275|NCT03092973||Epistaxis Group|
11242276|NCT03092973||Control Group|
11242277|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
11242278|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
11242279|NCT03092934|Experimental|LY3295668 (Phase 1)|Escalating doses ranging from 50 milligrams up to 1600 milligrams daily, administered orally in 21-day cycles
11242280|NCT03092934|Experimental|LY3295668 (Phase 2)|Daily dose level established in phase 1, administered orally in 21-day cycles
11242281|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
11242282|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
11242283|NCT03092908|Placebo Comparator|Control group|Administer 5 ml placebo (purified water) three times a day.
11242284|NCT03092908|Experimental|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
11242285|NCT03092895|Experimental|SHR-1210+Apatinib(Arm A）|
11242286|NCT03092895|Experimental|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
11242287|NCT03092882|Experimental|Intervention|Diabetes Self-Management Program
11242288|NCT03092882|No Intervention|Control|
11242289|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
11242290|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
11242291|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11242292|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11242293|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
11242294|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
11242295|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
11242296|NCT03092817|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
11242297|NCT03092817|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
11242298|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both
~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
11242299|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
11242300|NCT03092791|Experimental|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
11242301|NCT03092791|Placebo Comparator|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
11242302|NCT03092791|Experimental|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
11242303|NCT03092791|Active Comparator|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
11242304|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
11242305|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
11242306|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
11242307|NCT03092791|Active Comparator|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
11242308|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
11242309|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242310|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242311|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242312|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242313|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242314|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242315|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242316|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
11242317|NCT03092752||Patients with T2DM|
11242318|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
11242319|NCT03092726|Experimental|ASP8062|Participants received 30 mg of ASP8062 orally once daily for 8 weeks.
11242320|NCT03092726|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 8 weeks.
11242321|NCT03092713|Active Comparator|Cognitive Intervention and Supported Employment (CCI-SE)|Combined cognitive and vocational rehabilitation in a mixed design.
11242322|NCT03092713|Active Comparator|Control group|Usual follow-up assessment and treatment provided by the multidisciplinary TBI rehabilitation team.
11242323|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
11242324|NCT03092687||substance disorders|decedents with and without substance use disorders
11242325|NCT03092674|Active Comparator|Arm A (azacitidine)|Patients receive azacitidine SC or IV daily on days 1-7 or on an interrupted schedule which ensures that all 7 days of therapy are received within a 12 day period. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11242326|NCT03092674|Experimental|Arm B (azacitidine, nivolumab)|Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11242327|NCT03092674|Experimental|Arm C (azacitidine, midostaurin)|Patients receive azacitidine as in Arm A and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11242328|NCT03092674|Experimental|Arm D (decitabine, cytarabine)|"INDUCTION: Patients receive decitabine IV over 2 hours on days 1-5 and cytarabine IV continuously on days 6-11. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients deemed stable at the discretion of the treating physician receive decitabine as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11242329|NCT03092648|Experimental|Bronchial basal cells|
11242330|NCT03092648|No Intervention|Control|
11242331|NCT03092635|Experimental|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
11242332|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
11242333|NCT03092609|Experimental|Attention Bias Modification|
11242334|NCT03092609|Active Comparator|Attention Control|
11242335|NCT03092596|Experimental|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
11242336|NCT03092596|Experimental|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
11242337|NCT03092596|Experimental|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
11242338|NCT03092596|No Intervention|Treatment as usual|Patients will receive standard care.
11242339|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
11242340|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
11242341|NCT03092570|Experimental|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
11242342|NCT03092570|Sham Comparator|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
11242343|NCT03092570|Experimental|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
11242344|NCT03092570|Sham Comparator|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
11242345|NCT03092570|Experimental|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
11242346|NCT03092570|Sham Comparator|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
11242347|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
11242348|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
11242349|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
11242350|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
11242351|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
11242352|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
11242353|NCT03092531|Experimental|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates >90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
11242354|NCT03092531|No Intervention|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
11242355|NCT03092518|Experimental|1/Arm 1|HIPEC with gastrectomy
11242356|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
11242357|NCT03092492||Participants with bilateral early AMD|Participants with bilateral early AMD
11242358|NCT03092492||Participants with large RPD|Participants with large RPD
11242359|NCT03092492||Participants with small or medium-sized drusen|Participants with small or medium-sized reticular pseudodrusen (RPD)
11242360|NCT03092492||Unaffected Age-matched controls|Healthy age-matched controls
11242361|NCT03092479|Experimental|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
11242362|NCT03092479|No Intervention|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
11242363|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
11242364|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
11242365|NCT03092453|Experimental|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
11242366|NCT03092440||"Nursing students group"|nursing students
11242367|NCT03092440||"New nurses group"|Nurses with < 2 years experience
11242368|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
11242369|NCT03092427|Experimental|Probiotic VSL#3|
11242370|NCT03092427|Placebo Comparator|Placebo|
11242371|NCT03092414|Experimental|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
11242372|NCT03092414|Experimental|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
11242373|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
11242374|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
11242375|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
11242376|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
~Additionally, during daytime a special test with random parts of the study group basic is performed:
~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
11242377|NCT03092375|Experimental|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
11242378|NCT03092375|Experimental|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
11242379|NCT03092375|Experimental|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
11242380|NCT03092375|Experimental|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
11242381|NCT03092336|Experimental|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:
~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
11242382|NCT03092336|Experimental|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
11242383|NCT03092323|Experimental|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
11242384|NCT03092323|No Intervention|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
11242385|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
11242386|NCT03092297||ICU patients with anaemia|At admission to the ICU all patients, or their legal representatives, expected to stay at the ICU for longer than 24 hours will be asked to participate in the study and will be asked informed consent. ICU patients with anaemia in whom a central venous catheter is already in place and in whom a red cell transfusion is planned, will be included in the study.
11242387|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
11242388|NCT03092284|Placebo Comparator|Placebo|Saline
11242389|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
11242390|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
11242391|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
11242392|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
11242393|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
11242394|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
11242395|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
11242396|NCT03092219|Experimental|TEOSYAL RHA Redensity|Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
11242397|NCT03092219|No Intervention|No Treatment|No treatment control group (n=52).
11242398|NCT03092206|Experimental|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
11242399|NCT03092206|Experimental|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
11242400|NCT03092206|Experimental|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
11242401|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
11242402|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
11242403|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
11242404|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
11242405|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
11242406|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
11242407|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
11242408|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
11242409|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
11242410|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
11242411|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
11242412|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
11242413|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
11242414|NCT03092102|Experimental|A single dose HEC585（A1）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242415|NCT03092102|Experimental|A single dose HEC585（A2）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242416|NCT03092102|Experimental|A single dose HEC585/FE（A3）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule
~Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing"
11242417|NCT03092102|Experimental|A single dose HEC585（A4）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242418|NCT03092102|Experimental|A single dose HEC585（A5）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242419|NCT03092102|Experimental|A single dose HEC585（A6）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242420|NCT03092102|Experimental|A single dose HEC585（A7）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242421|NCT03092102|Experimental|A single dose HEC585（A8）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242422|NCT03092102|Experimental|Multiple doses HEC585（B1）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242423|NCT03092102|Experimental|Multiple doses HEC585（B2）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242424|NCT03092102|Experimental|Multiple doses HEC585（B3）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242425|NCT03092102|Experimental|Multiple doses HEC585（B4）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242426|NCT03092102|Experimental|Multiple doses HEC585（B5）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242427|NCT03092102|Experimental|Multiple doses HEC585（B6）|"Drug: HEC585 Capsule
~Drug: HEC585-matching placebo Capsule"
11242428|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
11242429|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
11242430|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
11242431|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
11242432|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
11242433|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
11242434|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
11242435|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
11242436|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
11242437|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
11242438|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
11242439|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
11242440|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
11242441|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
11242442|NCT03092024|Experimental|SPIN-HAND program|
11242443|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
11242444|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
11242445|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
11242446|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
11242447|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
11242448|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:
~PersonalFit - Breast shield & Brownie - Breast shield
~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
11242449|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:
~Brownie - Breast shield & PersonalFit - Breast shield
~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
11242450|NCT03091972|Experimental|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
11242451|NCT03091972|Active Comparator|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
11242452|NCT03091946|Placebo Comparator|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
11242453|NCT03091946|Experimental|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
11242454|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
11242455|NCT03091920|Experimental|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
11242456|NCT03091920|Experimental|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
11242457|NCT03091920|Placebo Comparator|Placebo|On Days 1-14: Placebo taken in AM and in PM.
11242458|NCT03091907||Case|Children with a history of necrotizing enterocolitis
11242459|NCT03091907||control|Children with no history of necrotizing enterocolitis
11242460|NCT03091894|Active Comparator|propofol|patients will receive only propofol intravenous infusion for sedation
11242461|NCT03091894|Active Comparator|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
11242462|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
11242463|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
11242464|NCT03091868|Experimental|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
11242465|NCT03091868|Experimental|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
11242466|NCT03091868|Experimental|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
11242467|NCT03091868|Experimental|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:
~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
11242468|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
11242469|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
11242470|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
11242471|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
11242472|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
11242473|NCT03091816|Experimental|Diagnostic (DPCT)|Patients undergo DPCT at baseline, during SBRT (after 2 of 3 fractions or 3 of 5 fractions), and then at 1 and 3 months post stereotactic body radiation therapy.
11242474|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
11242475|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
11242476|NCT03091790|Active Comparator|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
11242477|NCT03091790|Active Comparator|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
11242478|NCT03091777|Experimental|Test Drug|GDC-229 gel applied vaginally as directed.
11242479|NCT03091777|Active Comparator|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
11242480|NCT03091777|Placebo Comparator|Vehicle Placebo Gel|GDC-229 Vehicle
11242481|NCT03091764||NMIBC Patient High Risk|"Any of the following:
~T1 tumours
~CIS (carcinoma in situ)
~Multiple and recurring and large (>3cm) Ta, G1, G2 tumours (all these conditions must be presented)
~(Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years)"
11242482|NCT03091764||NMIBC Patient Intermediate Risk|"All cases between High and Low Risk
~(Patients requiring intravesical therapy which lasts between 6 weeks to 3 years)"
11242483|NCT03091764||NMIBC Patient Low Risk|"Primary, solitary, Ta, LG/G1, <3cm, no CIS
~(Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy)"
11242484|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
11242485|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
11242486|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
11242487|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
11242488|NCT03091712|Experimental|Paper Titration Tool and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.
~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
11242489|NCT03091712|No Intervention|Paper Titration tool|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).
~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
11242490|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
11242491|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
11242492|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)
~HAPA SB Intervention Slideshow"
11242493|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)
~HAPA MVPA Intervention Slideshow"
11242494|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)
~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
11242495|NCT03091673|Experimental|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
11242496|NCT03091673|Experimental|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
11242497|NCT03091660|Active Comparator|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
11242498|NCT03091660|Experimental|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
11242499|NCT03091660|Experimental|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
11242500|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
11242501|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
11242502|NCT03091634|Experimental|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
11242503|NCT03091634|Placebo Comparator|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
11242504|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
11242505|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
11242506|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
11242507|NCT03091582|Experimental|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
11242508|NCT03091582|Experimental|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
11242509|NCT03091569|Active Comparator|Vitamin K|
11242510|NCT03091569|Placebo Comparator|Control|
11242511|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
11242512|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
11242513|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
11242514|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
11242556|NCT03091192|Active Comparator|Sunitinib|See: intervention description
11242557|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
11242558|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
11242559|NCT03091166|Active Comparator|Dexmedetomidine|
11242515|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
11242516|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
11242517|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
11242518|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
11242519|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
11242520|NCT03091504|Experimental|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
11242521|NCT03091491|Experimental|Nivolumab|
11242522|NCT03091491|Experimental|Nivolumab and Ipilimumab|
11242523|NCT03091478|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
11242524|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
11242525|NCT03091439|Experimental|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
11242526|NCT03091439|Active Comparator|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
11242527|NCT03091426|Experimental|Omiganan 1%|
11242528|NCT03091426|Experimental|Omiganan 1.75%|
11242529|NCT03091426|Experimental|Omiganan 2.5%|
11242530|NCT03091426|Placebo Comparator|Vehicle|
11242531|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
11242532|NCT03091400|Experimental|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
11242533|NCT03091400|Placebo Comparator|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
11242534|NCT03091374|Experimental|Growth Hormone|
11242535|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
11242536|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
11242537|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
11242538|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
11242539|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
11242540|NCT03091322||SR-T group|single chamber pacemaker
11242541|NCT03091322||DR-T group|dual chamber pacemaker
11242542|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
11242543|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
11242544|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
11242545|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
11242546|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
11242547|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
11242548|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
11242549|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
11242550|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS
~BRAF V600 mutated
~Treat cohort with Dabrafenib
~Analysis
~Treat cohort with Dabrafenib"
11242551|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS
~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated
~Treat cohort with Dabrafenib and Trametinib
~Analysis
~Treat cohort with Dabrafenib and Trametinib"
11242552|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS
~KRAS or NRAS mutated
~Treat cohort with Trametinib
~Analysis
~Treat cohort with Trametinib"
11242553|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
11242554|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
11242555|NCT03091192|Experimental|Savolitinib|See: intervention description
11242561|NCT03091153|No Intervention|Control|Standard care. Annual medication review
11242562|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
11242563|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
11242564|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
11242565|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
11242566|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
11242567|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
11242568|NCT03091088|Active Comparator|Control|walking at an intense pace
11242569|NCT03091088|Experimental|Experimental|osteoporosis specific-oriented training
11242570|NCT03091075|Experimental|Treatment Group|receiving oral Oxandrolone 24 mg (12mg tablets) per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
11242571|NCT03091075|Placebo Comparator|Placebo Group|receiving placebo medication (Placebo Oral Tablet), oral tablet, with dosing beginning at time of surgery and continuing for 12 weeks postoperative
11242572|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
11242573|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
11242574|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
11242575|NCT03091036|Other|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
11242576|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:
~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
11242577|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
11242578|NCT03091010|Experimental|Fecal Microbiota Transplantation|
11242579|NCT03091010|Active Comparator|Steroid|
11242580|NCT03090997|Placebo Comparator|Group 1|vitamin C (500 mg/day/orally) + placebo
11242581|NCT03090997|Placebo Comparator|Group 2|resveratrol (500 mg/day/orally) + placebo
11242582|NCT03090997|Active Comparator|Group 3|vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
11242583|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
11242584|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
11242585|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
11242586|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
11242587|NCT03090958|Experimental|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
11242588|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
11242589|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
11242590|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
11242591|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
11242592|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
11242593|NCT03090880|No Intervention|Control|usual care,
11242594|NCT03090880|Experimental|Experimental|tinzaparin sodium
11242595|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
11242630|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
11242596|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.
~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.
~All care are planned and perform under the supervision or/and in collaboration with a caregiver.
~Each care is written down on a collecting sheet."
11242597|NCT03090854||Alzheimer disease patients|
11242598|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
11242599|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
11242600|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
11242601|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
11242602|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
11242603|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
11242604|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
11242605|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
11242606|NCT03090802|Experimental|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
11242607|NCT03090802|No Intervention|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
11242608|NCT03090789||Study Participant|Study participants can be individuals with either a clinical diagnosis or genetic confirmation of Friedreich ataxia. In addition, this study enrolls Friedreich ataxia carriers and unaffected controls.
11242609|NCT03090776|Other|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
11242610|NCT03090776|Other|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
11242611|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
11242612|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
11242613|NCT03090750|Experimental|Lavender|Lavender oil
11242614|NCT03090750|Experimental|Bergamot|Bergamot oil
11242615|NCT03090750|Placebo Comparator|Water|Water
11242616|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
11242617|NCT03090724|Experimental|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.
~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
11242618|NCT03090724|Experimental|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.
~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
11242619|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
11242620|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
11242621|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
11242622|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
11242623|NCT03090698|Active Comparator|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
11242624|NCT03090698|Active Comparator|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
11242625|NCT03090698|Active Comparator|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
11242626|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
11242627|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
11242628|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
11242629|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
11242631|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
11242632|NCT03090646|No Intervention|Standard of Care|Participants in the control arm will be instructed to attend required follow-up as is standard of care, but will not receive a financial incentive.
11242633|NCT03090646|Experimental|Financial Incentive|Up to three gift cards to a major online retailer will be mailed to participants assigned to the intervention arm after complete (i.e. all components addressed) and timely (i.e. within the policy-defined follow-up period) submission of follow-up data at each 6-month, 1-year, and 2-year follow-up visit.
11242634|NCT03090633|Experimental|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
11242635|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
11242636|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
11242637|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
11242638|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
11242639|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
11242640|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
11242641|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
11242642|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
11242643|NCT03090568|Experimental|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
11242644|NCT03090568|Experimental|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
11242645|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.
~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
11242646|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
11242647|NCT03090542|No Intervention|Control|
11242648|NCT03090542|Active Comparator|Product|
11242649|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
11242650|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
11242651|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
11242652|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
11242653|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
11242654|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
11242655|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
11242656|NCT03090490|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
11242657|NCT03090490|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
11242658|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
11242659|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
11242660|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
11242661|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
11242662|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
11242663|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
11242664|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
11242665|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
11242666|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
11242667|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
11242668|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
11242669|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
11242734|NCT03089918|Experimental|Part A (Healthy Adult Male Participants)|Participants will receive intravenous (IV) injection with 370 megabecquerel (MBq) 11C-JNJ-63779586 on Day 1 of Part A.
11242670|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.
~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.
~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
11242671|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.
~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.
~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
11242672|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
11242673|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
11242674|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
11242675|NCT03090347|Experimental|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
11242676|NCT03090334|Experimental|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:
~antifungal therapy will be stopped immediately after the BG response in case of serum BG <80 pg/ml in presence of clinical stability (CS);
~antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG <80 pg/ml in patients without CS. In these cases, if the following BG value is <80 pg/ml antifungal therapy will be stopped independently from the CS achievement.
~antifungal therapy will be continued until day 10 for BG levels >200 pg/ml"
11242677|NCT03090334|No Intervention|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.
~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
11242678|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
11242679|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
11242680|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
11242681|NCT03090321|Placebo Comparator|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
11242682|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
11242683|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
11242684|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally
~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
11242685|NCT03090256|Experimental|PanOptix IOL|AcrySof® IQ PanOptix™ IOL, bilateral implantation
11242686|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
11242687|NCT03090230|Experimental|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
11242688|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
11242689|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
11242690|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
11242691|NCT03090191|Experimental|Clostridium difficile vaccine|
11242692|NCT03090191|Placebo Comparator|Placebo|
11242693|NCT03090178|Experimental|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:
~sleep diary
~Pruritus
~dermatology life quality index"
11242694|NCT03090178|Active Comparator|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:
~sleep diary
~Pruritus
~dermatology life quality index"
11242695|NCT03090165|Experimental|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.
~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.
~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.
~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 46 patients."
11242696|NCT03090152|Active Comparator|Periarticular Injection (PAI)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.
~Peri-articular injection in the operating room
~Combined Spinal Epidural with 1.5% Mepivacaine 4cc
~A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV
~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
11242759|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
11242888|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
11242697|NCT03090152|Active Comparator|Epidural Patient-Controlled Analg (EPCA)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.
~Combined Spinal Epidural with 1.5% Mepivacaine 4cc
~A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.
~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
11242698|NCT03090152|Experimental|PAI + EPCA|"Aspirin and nerve pain medications including duloxetine and clonidine
~Combined Spinal Epidural with 1.5% Mepivacaine 4cc
~Anesthetic, Antiemetic and peri-articular injection in the operating room
~A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.
~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
11242699|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
11242700|NCT03090126||Alveolar hypoventilation|
11242701|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
11242702|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
11242703|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
11242704|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
11242705|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
11242706|NCT03090074|Active Comparator|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
11242707|NCT03090074|Active Comparator|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
11242708|NCT03090074|Active Comparator|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
11242709|NCT03090074|Active Comparator|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
11242710|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
11242711|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
11242712|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
11242713|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
11242714|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
11242715|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
11242716|NCT03090022|Active Comparator|Mesh implantation|Prior to closure of the abdominal wall a mesh will be implanted in a standardized fashion
11242717|NCT03090022|Active Comparator|Single running suture of abdominal fascia|The closure of the abdominal wall a Standard technique will be applied using a running suture
11242718|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
11242719|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
11242720|NCT03089996|Experimental|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
11242721|NCT03089996|Experimental|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
11242722|NCT03089996|Experimental|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
11242723|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
11242724|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
11242725|NCT03089983|Experimental|Naltrexone (NTX)|Participants who choose naltrexone (NTX) will receive an NTX implant that lasts for 90 days upon release from prison.
11242726|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
11242727|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
11242728|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
11242729|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
11242730|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
11242731|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
11242732|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
11242733|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
11242760|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
11242735|NCT03089918|Experimental|Part B (Mild AD and Healthy age- and Gender-Matched Controls)|Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
11242736|NCT03089905|Experimental|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.
~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.
~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
11242737|NCT03089905|Active Comparator|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
11242738|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
11242739|NCT03089879|Experimental|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
11242740|NCT03089879|Experimental|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
11242741|NCT03089879|Experimental|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
11242742|NCT03089866||ASA Patients I or II|Participants are healthy (BMI <35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
11242743|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
11242744|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
11242745|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
11242746|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
11242747|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
11242748|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
11242749|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
11242750|NCT03089788|Other|Home-based test and skin test|
11242751|NCT03089775|Experimental|BBI-2000|Cohort A
11242752|NCT03089775|Placebo Comparator|Vehicle|Cohort A
11242753|NCT03089775|Other|Multiple treatments|Cohort B
11242754|NCT03089762|Experimental|SVF and PRP|
11242755|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
11242756|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:
~At 24h from the time of CNS insult
~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult
~At 3, 6, and 12 months from the time of CNS insult
~Annually for the next four years Total of up to 16 blood draws.
~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:
~Age
~Sex
~History of prior CNS insult
~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients
~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.
~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
11242757|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:
~At 24h from the time of CNS insult
~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult
~At 3, 6, and 12 months from the time of CNS insult
~Annually for the next four years Total of up to 16 blood draws.
~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:
~Age
~Sex
~History of prior CNS insult
~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)
~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.
~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
11242758|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:
~At 24h from the time of CNS insult
~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult
~At 3, 6, and 12 months from the time of CNS insult
~Annually for the next four years Total of up to 16 blood draws.
~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:
~Age
~Sex
~History of prior CNS insult
~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.
~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.
~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
11242761|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.
~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
11242762|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.
~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
11242763|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.
~Applied colloid: hydroxyethyl starch"
11242764|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
11242765|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
11242766|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
11242767|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
11242768|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
11242769|NCT03089645|Experimental|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
11242770|NCT03089645|Experimental|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
11242771|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
11242772|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
11242773|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
11242774|NCT03089606|Other|C11-AMT PET|"Whole body FDG PET/CT scan with IV contrast will be performed at least 24 hours before C11-AMT PET scanning, as per standard of care.
~C11-AMT PET will be performed at least 24 hours before pembrolizumab treatment and at least 24 hours after FDG PET/CT scan.
~Pembrolizumab 200mg by IV flat dose will be administered over 30 minutes on Day 1; Pembrolizumab dosing will be repeated every 3 weeks until progression or subject withdrawal for other reasons.
~Whole body FDG PET/CT scan with IV contrast at end of treatment."
11242775|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
11242776|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
11242777|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
11242778|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
11242779|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
11242780|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
11242781|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
11242782|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
11242783|NCT03089541|Experimental|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
11242784|NCT03089528|Experimental|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
11242785|NCT03089528|Active Comparator|Direct laringoscopy|the trachea will be intubated using a laringoscope
11242786|NCT03089515|Active Comparator|Healthy Controls|
11242787|NCT03089515|Experimental|Survivors|
11242788|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
11242789|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
11242790|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
11242791|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
11242792|NCT03089476|Other|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
11242793|NCT03089476|Other|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
11242794|NCT03089463||Observation group|The entire participants in this study will be included in this group.
11242795|NCT03089450|Experimental|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
11242796|NCT03089450|Active Comparator|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
11242797|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
11242798|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
11242799|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
11242800|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
11242801|NCT03089398|Active Comparator|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
11242802|NCT03089398|Active Comparator|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
11242803|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
11242804|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
11242805|NCT03089372|Active Comparator|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
11242806|NCT03089372|Active Comparator|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
11242807|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
11242808|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
11242809|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
11242810|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
11242811|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy
~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
11242812|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
11242813|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
11242814|NCT03089294|Active Comparator|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
11242815|NCT03089294|Active Comparator|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
11242816|NCT03089294|Active Comparator|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
11242817|NCT03089294|Active Comparator|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
11242818|NCT03089281|Other|SmartDelay™ algorithm|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
11243816|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
11242819|NCT03089281|Other|Fixed AV Delay with BiV pacing|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
11242820|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.
~Polypectomy or biopsy will be performed if necessary (following current guidelines).
~Specific molecular analysis of serrated lesions and CRC will be carried out."
11242821|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
11242822|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
11242823|NCT03089216|Experimental|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
11242824|NCT03089216|Experimental|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
11242825|NCT03089216|Experimental|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
11242826|NCT03089216|Experimental|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
11242827|NCT03089203|Experimental|Cohort 1|CART T cells 1-3x10^7 Day 0
11242828|NCT03089203|Experimental|Cohort 2|Cart T cells 1-3x10^8 Day 0
11242829|NCT03089203|Experimental|Cohort -3|Cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day Day -3 CART T cells 1-3x10^7 Day 0
11242830|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
11242831|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
11242832|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
11242833|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
11242834|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
11242835|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
11242836|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
11242837|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
11242838|NCT03089138|Experimental|Regan Tangjiang，Simulation Shufengjiere Capsules|
11242839|NCT03089138|Active Comparator|Simulation Regan Tangjiang，Shufengjiere Capsules|
11242840|NCT03089138|Placebo Comparator|Simulation Regan Tangjiang and Shufengjiere Capsules|
11242841|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
11242842|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions
~Patients will receive:
~Psychoeducation
~Relaxation training for reducing physiological stress
~Behavioral techniques for managing acute breathlessness"
11242843|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
11242844|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
11242845|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
11242846|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
11242847|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
11242848|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
11242849|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
11242850|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
11242851|NCT03089060|Experimental|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
11242852|NCT03089060|Active Comparator|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
11242853|NCT03089047|Experimental|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
11242854|NCT03089047|Sham Comparator|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
11242855|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
11242856|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
11242887|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
11242857|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
11242858|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
11242859|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
11242860|NCT03088969||patient with a chronic back pain|
11242861|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
11242862|NCT03088956||Healthy|Healthy Participants (n=10)
11242863|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
11242864|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
11242865|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
11242866|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
11242867|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
11242868|NCT03088904|Experimental|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11242869|NCT03088904|Experimental|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
11242870|NCT03088904|Experimental|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
11242871|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
11242872|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
11242873|NCT03088878|Experimental|Phase 1b - Dose Finding|Cirmutuzumab followed by Cirmtuzumab plus ibrutinib
11242874|NCT03088878|Experimental|Phase 1b - Dose Expansion|Cirmtuzumab plus ibrutinib
11242875|NCT03088878|Experimental|Phase 2 - Cirmtuzumab plus ibrutinib|Phase 2 safety and efficacy evaluation
11242876|NCT03088878|Active Comparator|Phase 2 - Ibrutinib|Phase 2 safety and efficacy evaluation
11242877|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
11242878|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
11242879|NCT03088852|Active Comparator|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
11242880|NCT03088852|No Intervention|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
11242881|NCT03088839||30 ALS patients|
11242882|NCT03088839||30 healthy controls|
11242883|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
11242884|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
11242885|NCT03088813|Experimental|Experimental Arm|Irinotecan liposome injection
11242886|NCT03088813|Active Comparator|Control Arm|Topotecan
11242889|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
11242890|NCT03088787||Patients for TAVR|Patients for TAVR
11242891|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
11242892|NCT03088774|Experimental|Patient Handbook|Public available information.
11242893|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.
~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
11242894|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
11242895|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
11242896|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
11242897|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
11242898|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
11242899|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
11242900|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.
~GVHD Prevention Treatment:
~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.
~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.
~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
11242901|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
11242902|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
11242903|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
11242904|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
11242905|NCT03088670|Experimental|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
11242906|NCT03088670|Active Comparator|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
11242907|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
11242908|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
11242909|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
11242910|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
11242911|NCT03088631|Active Comparator|Metformin group|
11242912|NCT03088631|Placebo Comparator|Placebo group|
11242913|NCT03088618|Experimental|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
11242914|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
11242915|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
11242916|NCT03088592|Other|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
11242917|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
11242918|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
11242919|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:
~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
11242920|NCT03088540|Experimental|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
11242960|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
11242921|NCT03088527|Experimental|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.
~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
11242922|NCT03088514|Experimental|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
11242923|NCT03088514|Placebo Comparator|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
11242924|NCT03088514|Experimental|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
11242925|NCT03088514|Placebo Comparator|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
11242926|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
11242927|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.
~Brief talk by health professionals.
~Role-plays"
11242928|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
11242929|NCT03088488||Periodontally healthy subjects|
11242930|NCT03088488||Chronic periodontitis patients|
11242931|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
11242932|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
11242933|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
11242934|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
11242935|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
11242936|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
11242937|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
11242938|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
11242939|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
11242940|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
11242941|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
11242942|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
11242943|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
11242944|NCT03088358|Experimental|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
11242945|NCT03088358|Experimental|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
11242946|NCT03088358|Experimental|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
11242947|NCT03088358|Active Comparator|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
11242948|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
11242949|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
11242950|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
11242951|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
11242952|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
11242953|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
11242954|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
11242955|NCT03088280|Experimental|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
11242956|NCT03088280|Active Comparator|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
11242957|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
11242958|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
11242959|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
11243120|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 - < 12 years
11242961|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
11242962|NCT03088241|Experimental|Intervention|switch to second-line ART
11242963|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
11242964|NCT03088228||healthy pregnants|
11242965|NCT03088228||mild preeclampsia|
11242966|NCT03088228||severe preeclampsia|
11242967|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
11242968|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
11242969|NCT03088202|Experimental|Intervention arm|Educational program Standardized care pathways Early palliative care
11242970|NCT03088202|No Intervention|Control arm|Usual care
11242971|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
11242972|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
11242973|NCT03088189||Placebo|Mothers are receiving placebo
11242974|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.
~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
11242975|NCT03088163|Experimental|DWI-MRI|
11242976|NCT03088150|Active Comparator|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
11242977|NCT03088150|Experimental|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
11242978|NCT03088137|Experimental|Primapur (Follitropin alfa)|
11242979|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
11242980|NCT03088124|No Intervention|active surveillance|Active surveillance without androgen deprivation
11242981|NCT03088124|Experimental|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
11242982|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.
~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
11242983|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
11242984|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
11242985|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
11242986|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
11242987|NCT03088072|Other|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
11242988|NCT03088059|Experimental|Patient Cohort B1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
11242989|NCT03088059|Experimental|Patient Cohort B2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
11242990|NCT03088059|Experimental|Patient Cohort B3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
11242991|NCT03088059|Experimental|Patient Cohort B4|Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
11242992|NCT03088059|Experimental|Patient Cohort B5|Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
11242993|NCT03088059|Experimental|Patient Cohort B6|Patients with FGFR1/2/3 mRNA overexpression will receive rogaratinib
11242994|NCT03088059|Experimental|Patient Cohort I1|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
11242995|NCT03088059|Experimental|Patient Cohort I2|Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
11242996|NCT03088046|Other|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
11242997|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
11242998|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
11242999|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
11243121|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 - < 6 years
11243000|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
11243001|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
11243002|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance once during the study
11243003|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
11243004|NCT03087968|Experimental|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days
~HepQuant SHUNT Test"
11243005|NCT03087968|Placebo Comparator|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days
~HepQuant SHUNT Test"
11243006|NCT03087955|Experimental|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
11243007|NCT03087942|Experimental|Group 1|ESRD patients
11243008|NCT03087942|Experimental|Group 2|healthy volunteers
11243009|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
11243010|NCT03087942|Experimental|Group 4|mild renal impaired patients
11243011|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
11243012|NCT03087903|Experimental|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
11243013|NCT03087890|Active Comparator|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
11243014|NCT03087890|Placebo Comparator|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
11243015|NCT03087877|Other|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
11243016|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
11243017|NCT03087851|Active Comparator|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.
11243018|NCT03087851|Active Comparator|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.
~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
11243019|NCT03087851|Active Comparator|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.
~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
11243020|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
11243021|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
11243022|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
11243023|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
11243024|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
11243025|NCT03087799|No Intervention|Wait List Control|
11243026|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
11243027|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
11243028|NCT03087773|Active Comparator|Empagliflozin|The subjects will receive Empagliflozin 10mg.
11243029|NCT03087773|Placebo Comparator|Placebo Oral Tablet|The subjects will receive placebo.
11243030|NCT03087760|Experimental|Single Arm|Single Arm, Open Label
11243031|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
11243032|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
11243033|NCT03087734|Active Comparator|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
11243034|NCT03087734|Experimental|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
11243035|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
11243036|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
11243037|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
11243038|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
11243201|NCT03086460|Experimental|Treatment D|CHF 1531 pMDI Dose 4
11243039|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
11243040|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.
~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
11243041|NCT03087656|Active Comparator|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
11243042|NCT03087656|No Intervention|No Antibiotic arm|No prophylactic antibiotics will be administered.
11243043|NCT03087643|Experimental|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
11243044|NCT03087643|No Intervention|Control group - ctrl|Participants will receive ther standard therapies.
11243045|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
11243046|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
11243047|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
11243048|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
11243049|NCT03087617|Active Comparator|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
11243050|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
11243051|NCT03087617|Active Comparator|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
11243052|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
11243053|NCT03087604|Active Comparator|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
11243054|NCT03087604|Experimental|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
11243055|NCT03087591|Experimental|Treatment (APN401)|Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity.
11243056|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
11243057|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
11243058|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.
~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
11243059|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
11243060|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
11243061|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
11243062|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
11243063|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
11243064|NCT03087513|Active Comparator|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
11243065|NCT03087513|Active Comparator|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
11243066|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
11243067|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
11243068|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
11243069|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
11243070|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
11243071|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
11243072|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
11243073|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
11243074|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.
~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.
~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
11243075|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
11243076|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.
~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.
~PHASE II Cohort A (ALKi Naïve): those who have had no prior ALK inhibitor therapy (prior chemotherapy or immunotherapy is allowed). Aim 20 evaluable patients.
~Cohort B (Post-crizotinib PD): those who have received prior treatment with crizotinib and documented disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Aim 21 evaluable patients.
~Cohort C (PD on 2nd generation ALKi): those who have received prior treatment with 2nd generation ALKi (e.g. ceritinib, alectinib, loratinib, or brigatinib) and documented disease progression by RECIST 1.1 criteria. Aim 10 evaluable patients.
~The Phase II doses will be determined by Phase I dose escalation study"
11243077|NCT03087422|Experimental|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.
~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.
~Also, the patients allocated in this group will receive the standard care."
11243078|NCT03087422|No Intervention|control|The patients allocated in this group will receive the standard care.
11243079|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
11243080|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
11243081|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
11243082|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
11243083|NCT03087344|Experimental|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
11243084|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
11243085|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:
~3 sessions / week at least
~at least during 30 minutes each session
~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)
~during 3 months."
11243086|NCT03087318|Experimental|Private sport club|"Physical activity:
~3 sessions / week at least
~at least during 30 minutes each session
~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)
~during 3 months."
11243087|NCT03087318|Experimental|Sport association|"Physical activity:
~3 sessions / week at least
~at least during 30 minutes each session
~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)
~during 3 months."
11243088|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
11243089|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
11243090|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
11243091|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
11243092|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
11243093|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
11243094|NCT03087266|Experimental|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
11243095|NCT03087266|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
11243096|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
11243097|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
11243098|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
11243099|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
11243100|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
11243101|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
11243102|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
11243103|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
11243104|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
11243105|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
11243106|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
11243107|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
11243108|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
11243109|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
11243110|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
11243111|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
11243112|NCT03087110|Experimental|Cord blood infusion|Matched sibling donor cord blood cell infusion
11243113|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
11243114|NCT03087097|No Intervention|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
11243115|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
11243116|NCT03087071|Experimental|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
11243117|NCT03087071|Experimental|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11243118|NCT03087071|Experimental|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
11243119|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 - < 18 years
11243122|NCT03087032|Experimental|Liraglutide-bolus|'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
11243123|NCT03087032|Active Comparator|Basal-bolus|'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
11243124|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation
~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab
~Pembrolizumab will be administered on day 1 of each 21day cycle
~Pembrolizumab is delivered intravenously"
11243125|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle
~Pembrolizumab is delivered intravenously"
11243126|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
11243127|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
11243128|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
11243129|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
11243130|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
11243131|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
11243132|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
11243133|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
11243134|NCT03086954|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
11243135|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
11243136|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
11243137|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
11243138|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
11243139|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
11243140|NCT03086902|Experimental|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
11243141|NCT03086902|Active Comparator|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
11243142|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
11243143|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
11243144|NCT03086876|Experimental|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
11243202|NCT03086460|Experimental|Treatment E|Matched placebo
11243203|NCT03086460|Active Comparator|Treatment F|Formoterol fumarate inhalation solution, 20μg
11243145|NCT03086876|No Intervention|Treatment as usual (TAU)|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:
~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.
~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
11243146|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally
~Needle insertion by 10-15 mm and de qi sensation
~Park sham guide tubes
~Low frequency electronic stimulation (30 Hz)
~Retention for 20 minutes."
11243147|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally
~Needle installation without penetration
~Park sham guide tubes
~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction
~Retention for 20 minutes."
11243148|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
11243149|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
11243150|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
11243151|NCT03086837|No Intervention|Control|No information
11243152|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
11243153|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
11243154|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
11243155|NCT03086798|Experimental|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
11243156|NCT03086798|Experimental|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
11243157|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
11243158|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
11243159|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
11243160|NCT03086759|Experimental|Platelet rich plasm group|
11243161|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
11243162|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
11243163|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
11243164|NCT03086720|Experimental|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
11243165|NCT03086720|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching
11243166|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.
~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
11243167|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.
~Subjects will not be allowed to smoke until discharge at Visit 3."
11243168|NCT03086694||group surgery|using medications to maintain low stable blood pressure
11243169|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
11243170|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
11243171|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
11243172|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
11243173|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
11243174|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
11243175|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
11243176|NCT03086629|Other|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
11243177|NCT03086629|Other|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
11243986|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
11243178|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
11243179|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
11243180|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
11243181|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
11243182|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
11243183|NCT03086564|Experimental|ADCC & TACE|"The first course :
~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2*10^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.
~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.
~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
11243184|NCT03086564|Active Comparator|TACE|"Every course:
~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.
~The 31th day is the same as the first day in the second course.
~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
11243185|NCT03086551|Experimental|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
11243186|NCT03086551|Placebo Comparator|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
11243187|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
11243188|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
11243189|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
11243190|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
11243191|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
11243192|NCT03086486|Experimental|1200mg L x 26 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
11243193|NCT03086486|Experimental|1200 mg L x 9 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
11243194|NCT03086486|Experimental|600 mg L x 26 weeks + Pa + B|"1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
11243195|NCT03086486|Experimental|600 mg L x 9 weeks + Pa + B|"1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
11243196|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
11243197|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
11243198|NCT03086460|Experimental|Treatment A|CHF 1531 pMDI Dose 1
11243199|NCT03086460|Experimental|Treatment B|CHF 1531 pMDI Dose 2
11243200|NCT03086460|Experimental|Treatment C|CHF 1531 pMDI Dose 3
11243204|NCT03086447|Experimental|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
11243205|NCT03086447|Active Comparator|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
11243206|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
11243207|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
11243208|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
11243209|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
11243210|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
11243211|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
11243212|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
11243213|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
11243214|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
11243215|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given intravenously (IV).
11243216|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given IV.
11243217|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)|(Double Blind) Olaratumab, nab-paclitaxel and gemcitabine given IV.
11243218|NCT03086369|Placebo Comparator|Placebo + Nab-paclitaxel + Gemcitabine|(Double Blind) Placebo, nab-paclitaxel and gemcitabine given IV.
11243219|NCT03086356|Experimental|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
11243220|NCT03086343|Active Comparator|Abatacept|500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
11243221|NCT03086343|Experimental|Upadacitinib 15 mg|One 15 mg tablet taken once per day by mouth for 24 weeks
11243222|NCT03086330|Experimental|Semaglutide|
11243223|NCT03086330|Placebo Comparator|Placebo|
11243224|NCT03086317|Active Comparator|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
11243225|NCT03086317|Active Comparator|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
11243226|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
11243227|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
11243228|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
11243229|NCT03086278|Experimental|Single Ascending Dose|
11243230|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
11243231|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
11243232|NCT03086252|Experimental|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
11243233|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
11243234|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
11243235|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.
~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
11243236|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.
~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
11243237|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
11243238|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
11243239|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
11243240|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
11243241|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
11243242|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
11243243|NCT03086174|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
11243244|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
11243245|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
11243246|NCT03086148|Experimental|ketamine group|
11243247|NCT03086148|Placebo Comparator|normal saline group|
11243248|NCT03086135|Experimental|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
11243249|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
11243250|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
11243251|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
11243252|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
11243253|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
11243254|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
11243255|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
11243256|NCT03086057|Experimental|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
11243257|NCT03086057|Experimental|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
11243258|NCT03086057|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
11243259|NCT03086057|No Intervention|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
11243260|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 4 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily
~Participants who receive either heart or lung allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation."
11243261|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring
~Participants who receive either heart or lung allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
11243262|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
11243263|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
11243264|NCT03086018|Experimental|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
11243265|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
11243266|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
11243267|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
11243268|NCT03085979|Experimental|Burch|Burch Colposuspension
11243269|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
11243270|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
11243668|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
11243271|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
11243272|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
11243273|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
11243274|NCT03085940|Experimental|Hydroxychloroquine|
11243275|NCT03085940|Placebo Comparator|Placebo|
11243276|NCT03085927|Experimental|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
11243277|NCT03085927|Experimental|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
11243278|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
11243279|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
11243280|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
11243281|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
11243282|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
11243283|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
11243284|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
11243285|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
11243286|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
11243287|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
11243288|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio < 200.
11243289|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.
~Dose escalation phase: 6-12 patients
~MTD expansion cohort: 10 patients"
11243290|NCT03085836|Experimental|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
11243291|NCT03085836|Experimental|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
11243292|NCT03085836|Experimental|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
11243293|NCT03085810|Experimental|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.
11243294|NCT03085810|Active Comparator|Substudy Group 1|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration
11243295|NCT03085810|Experimental|Substudy Group 2|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration
11243296|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
11243297|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
11243298|NCT03085784|Experimental|Loading Dose|"20 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.
~Treat & Extend Protocol entails patients being extended as long as:
~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND
~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.
~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
11243299|NCT03085784|Experimental|Treat and Extend|"20 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.
~Treat & Extend Protocol entails patients being extended as long as:
~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND
~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.
~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
11243300|NCT03085771|Active Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
11243301|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
11243302|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
11243303|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
11243304|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
11243305|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
11243306|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
11243307|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
11243308|NCT03085719|Experimental|High Dose Radiation + Pembrolizumab|"High dose radiation will be given in 3 fractions
~Pembrolizumab administered intravenously on day one of each cycle."
11243309|NCT03085719|Experimental|High Dose + Low Dose Radiation + Pembrolizumab|"High Dose radiation will be given in 3 fractions
~Low Dose Radiation will be given in 2 fractions
~Pembrolizumab administered intravenously on day one of each cycle."
11243310|NCT03085706|Experimental|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
11243311|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
11243312|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
11243313|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
11243314|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
11243315|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
11243316|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
11243317|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
11243318|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
11243319|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.
~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:
~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)
~High flow rate: 40-50 L/min without additional oxygen
~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)
~High flow rate: 40-50 L/min with FiO2 of 28%"
11243320|NCT03085628|Experimental|Oxytocin|Oxytoxin nasal spray
11243321|NCT03085628|Placebo Comparator|Placebo|Placebo nasal spray
11243322|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
11243323|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
11243324|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
11243325|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
11243326|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
11243327|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
11243814|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
11243328|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
11243329|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
11243330|NCT03085550|No Intervention|Control|Conventional dressings management
11243331|NCT03085550|Experimental|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
11243332|NCT03085550|Experimental|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
11243333|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
11243334|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
11243335|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:
~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
11243336|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:
~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
11243337|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
11243338|NCT03085485|Placebo Comparator|Placebo|matching placebo
11243339|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
11243340|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
11243341|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
11243342|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
11243343|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
11243344|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
11243345|NCT03085446|Experimental|PDM nutritional intervention|
11243346|NCT03085446|Experimental|control|General information on nutrition and health
11243347|NCT03085433|Experimental|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
11243348|NCT03085433|Active Comparator|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
11243349|NCT03085420|Experimental|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
11243350|NCT03085420|No Intervention|<30% TBSA burn injury|For patients in Group 2 with <30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
11243351|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
11243352|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
11243353|NCT03085394|Active Comparator|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
11243354|NCT03085394|Placebo Comparator|Control Arm|Preoperative intravenous administration of 10ml normal saline.
11243355|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
11243356|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
11243357|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
11243358|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
11243359|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
11243360|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
11243361|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
11243389|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
11243362|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
11243363|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
11243364|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
11243365|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
11243366|NCT03085316|Experimental|Investigational Device|Patient who meets eligibility to be implanted with the St. Jude Medical Infinity™ Implantable Pulse Generator System (P140049), St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) Directional Lead and Extension (P140009), Swift-Lock™ Anchor (K092371), Butterfly anchor (P140009), manufactured by St. Jude Medical, Inc.
11243367|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
11243368|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
11243369|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
11243370|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
11243371|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
11243372|NCT03085277|Active Comparator|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
11243373|NCT03085277|Experimental|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
11243374|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
11243375|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
11243376|NCT03085251|Experimental|Blood glucose measurement|
11243377|NCT03085238|Experimental|M-Trap|
11243378|NCT03085225|Experimental|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.
~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
11243379|NCT03085212|Experimental|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
11243380|NCT03085212|Active Comparator|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
11243381|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
11243382|NCT03085173|Experimental|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
11243383|NCT03085160|Experimental|Learning to Breathe|Six-week mindfulness-based group program for adolescents
11243384|NCT03085160|Active Comparator|Health Education|Six-week health education group program for adolescents
11243385|NCT03085147|Experimental|Fluorescent PARPi Binding Imaging Agent PARPi-FL|In the phase I of the study, increasing concentrations of PARPi-FL will be used in up to 12 patients with OSCC to determine concentration that results in the highest contrast between tumor and normal mucosa. Dose escalation will be performed in groups of three patients until image contrast decreases, side effects are noted or the concentration of PARPi-FL exceeds 1μM. Imaging will be performed in the Department of Surgery during a presurgical visit including clinical examination of the oral cavity. In the phase II part of the study the concentration of PARPi-FL determined in phase I will be used to image 18 patients with OSCC on the day of surgery. Imaging findings will be correlated with histopathologic findings in the surgically resected specimens.
11243386|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
11243387|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
11243388|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
11243390|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
11243391|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
11243392|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
11243393|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
11243394|NCT03085095|Experimental|Relugolix|Relugolix for 48 weeks
11243395|NCT03085095|Active Comparator|Leuprolide Acetate|Leuprolide acetate for 48 weeks
11243396|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
11243397|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
11243398|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
11243399|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
11243400|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
11243401|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
11243402|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
11243403|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
11243404|NCT03085043|Experimental|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
11243405|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
11243406|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
11243407|NCT03085017|Active Comparator|Ostene|Application of Ostene onto cut sternal site for hemostasis.
11243408|NCT03085017|Experimental|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
11243409|NCT03085004|Active Comparator|Control Group|Cyst will be lavaged for 3 to 5 minutes with 98% ethanol. Following lavage with 98% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
11243410|NCT03085004|Experimental|Study group|Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
11243411|NCT03084991||OCT group|1500 STEMI patients with OCT imaging during PPCI
11243412|NCT03084991||CAG group|3000 STEMI patients without OCT imaging during PPCI
11243413|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
11243414|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
11243415|NCT03084952|Experimental|1 mg/day|
11243416|NCT03084952|Experimental|4 mg/day|
11243417|NCT03084952|Experimental|8 mg/day|
11243418|NCT03084952|Experimental|12 mg/day|
11243419|NCT03084952|Active Comparator|Glucantime|
11243420|NCT03084952|Experimental|Best dose 18-MC|
11243421|NCT03084952|Experimental|Minimum effective dose 18-MC|
11243422|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
11243423|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
11243424|NCT03084926|Experimental|MP0274|
11243425|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
11243426|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
11243427|NCT03084900|Experimental|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
11243428|NCT03084900|No Intervention|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
11243429|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
11243430|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
11243514|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
11243431|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
11243432|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
11243433|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
11243434|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:
~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic
~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
11243435|NCT03084848|Experimental|Active control|
11243436|NCT03084848|Experimental|Inhibitor control|
11243437|NCT03084835|Active Comparator|UC|Usual Care
11243438|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
11243439|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
11243440|NCT03084822|Experimental|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
11243441|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:
~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.
~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
11243442|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:
~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
11243443|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI Dose 1
11243444|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI Dose 2
11243445|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI Dose 3
11243446|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI Dose 4
11243447|NCT03084796|Placebo Comparator|Treatment E|Placebo Control
11243448|NCT03084796|Active Comparator|Treatment F|Tiotropium Bromide inhalation powder, 18 µg
11243449|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
11243450|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
11243451|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
11243452|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
11243453|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
11243454|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
11243455|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
11243456|NCT03084731|Experimental|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
11243457|NCT03084731|Experimental|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
11243458|NCT03084731|Experimental|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
11243459|NCT03084731|No Intervention|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : >-1
11243460|NCT03084718|Experimental|Treatment A|CHF 718 pMDI Dose 1
11243461|NCT03084718|Experimental|Treatment B|CHF 718 pMDI Dose 2
11243462|NCT03084718|Experimental|Treatment C|CHF 718 pMDI Dose 3
11243463|NCT03084718|Placebo Comparator|Treatment D|Placebo Control, Placebos
11243464|NCT03084718|Active Comparator|Treatment E|Beclomethasone dipropionate HFA, 80µg (pMDI)
11243515|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
11243465|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
11243466|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
11243467|NCT03084692|Experimental|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
11243468|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
11243469|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
11243470|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
11243471|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
11243472|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
11243473|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
11243474|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
11243475|NCT03084640|Experimental|Part 1: Dose-Escalation - CMP-001 (SC) and Pembrolizumab|Participants will receive up to 7 escalating dose levels (5 milligrams [mg], 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, and 20 mg) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
11243476|NCT03084640|Experimental|Part 1: Dose-Expansion - CMP-001 (SC) and Pembrolizumab|Participants will receive RP2D (as determined in Part 1 dose-escalation phase) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
11243477|NCT03084640|Experimental|Part 2: CMP-001 (SC and IT) and Pembrolizumab|Participants will receive CMP-001 via SC injection once weekly for 2 weeks, then IT injection once weekly for 4 weeks, and SC injection once weekly for every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule. CMP-001 planned IT dose level in Part 2 will be up to 10 mg and the SC dose will be the RP2D determined from Part 1 dose-escalation phase of the study.
11243478|NCT03084627|No Intervention|Generic dietary advice for pregnancy|
11243479|NCT03084627|Experimental|Generic dietary advice for pregnancy + Tailored dietary advice|
11243480|NCT03084614||Controls|non exposed controls
11243481|NCT03084614||donors with naturally enriched antimicrobial blood samples and|Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.
11243482|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
11243483|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
11243484|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
11243485|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
11243486|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
11243487|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
11243488|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
11243489|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
11243490|NCT03084549|Experimental|Ropivacaïne|
11243491|NCT03084549|Placebo Comparator|Placebo|
11243492|NCT03084536|Active Comparator|Preoperative PECS blocks|"PECS I & II block will be administered preoperatively
~For unilateral surgeries, PECS I block will be performed bupivacaine. The PECS II block will be performed with the same solution. If there is a contralateral surgery (simple mastectomy) a PECS II block will also be performed on the other side.
~To ensure blind integrity, study drug syringes will be marked only study drug and subject number
~Perioperative analgesic will be encouraged.. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative area. All patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist"
11243516|NCT03084341|No Intervention|Control Group|No intervention
11243493|NCT03084536|Placebo Comparator|Placebo PECS blocks|"A sham block (normal saline) will be placed preoperatively
~To ensure blind integrity, study drug syringes will be marked only study drug and subject number.
~Perioperative analgesic regimen will be encouraged. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative holding area. On the day of surgery all patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist."
11243494|NCT03084523|Experimental|1|60 patients with intracranial atherosclerosis
11243495|NCT03084523|Experimental|2|20 patients with intracranial aneurysm
11243496|NCT03084510|Experimental|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
11243497|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
11243498|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
11243499|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.
~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
11243500|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.
~Subjects in the control group didi not receive any dietary advice."
11243501|NCT03084471|Experimental|Combination therapy|"Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W:
~Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and
~Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab."
11243502|NCT03084471|Experimental|Monotherapy|Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.
11243503|NCT03084458|No Intervention|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
11243504|NCT03084458|Experimental|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
11243505|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
11243506|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
11243507|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
11243508|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
11243509|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
11243510|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
11243511|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
11243512|NCT03084380|Experimental|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
11243513|NCT03084367||iFR post angiographically successful PCI|
11243557|NCT03084094|Sham Comparator|Sham|sham stimulation
11243517|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
11243518|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
11243519|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
11243520|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
11243521|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
11243522|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
11243523|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
11243524|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
11243525|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
11243526|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
11243527|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
11243528|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
11243529|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
11243530|NCT03084276|Experimental|High-fat meal|
11243531|NCT03084276|Active Comparator|Low-fat meal|
11243532|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
11243533|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
11243534|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
11243535|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
11243536|NCT03084237|Experimental|HLX02+docetaxel|
11243537|NCT03084237|Active Comparator|Herceptin®+docetaxel|
11243538|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
11243539|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
11243540|NCT03084198|Active Comparator|Control group|Standard care for ALF
11243541|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
11243542|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
11243543|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys. Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
11243544|NCT03084159|Experimental|Intervention Only|A future arm will include patients at another site that will also receive the intervention of using an education worksheet during their appointment and fill out post intervention surveys. Providers/staff have not been involved in the initial design of the intervention process but will use it as part of the intervention delivery.
11243545|NCT03084159|No Intervention|Usual Care|A third site will include usual care, which does not include the intervention. Participants will be given post visit surveys similar to those in the two other study / intervention arms. This site will serve as a usual care comparison.
11243546|NCT03084146|Experimental|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
11243547|NCT03084146|No Intervention|Healthy Control|Healthy Control patients will receive no intervention
11243548|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.
~Intervention 'Therapeutic Education Strategy'"
11243549|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
11243550|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
11243551|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
11243552|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
11243553|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.
~Collection of bloods samples for the mother.
~Retrieval of umbilical cord blood.
~Retrieval of placenta.
~Collection of newborn's and mother's lock of hair.
~Dietetic patient outcomes questionnaires for the mother.
~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
11243554|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
11243555|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
11243556|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
11243558|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
11243559|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
11243560|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
11243561|NCT03084068|Experimental|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
11243562|NCT03084068|Placebo Comparator|Placebo Control|Open Rotator Cuff Repair with standard suture repair
11243563|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
11243564|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
11243565|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
11243566|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
11243567|NCT03084042||Healthy controls|Demographically matched healthy controls.
11243568|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
11243569|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
11243570|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
11243571|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
11243572|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
11243573|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
11243574|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
11243575|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
11243576|NCT03083990|Experimental|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
11243577|NCT03083990|Active Comparator|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
11243578|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
11243579|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
11243580|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
11243581|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
11243582|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
11243583|NCT03083938|Experimental|Omental Roll-up|
11243584|NCT03083938|No Intervention|No Omental Roll-up|
11243585|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
11243586|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
11243587|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
11243588|NCT03083912||Fortimel Complete|All of the residents included receive ONS
11243589|NCT03083899|Experimental|Diatast|Free patient-initiated use of out-patient services
11243590|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
11243591|NCT03083886|Active Comparator|Usual PCP led care|
11243592|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
11243593|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
11243594|NCT03083873|Experimental|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
11243595|NCT03083873|Experimental|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
11243596|NCT03083873|Experimental|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
11243597|NCT03083873|Experimental|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
11243598|NCT03083873|Experimental|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
11243599|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
11243600|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
11243601|NCT03083847|Experimental|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethame|Pilot Phase - 1 injection of 5x10^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
11243602|NCT03083847|Experimental|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
11243603|NCT03083847|Experimental|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
11243604|NCT03083847|Experimental|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
11243605|NCT03083847|Experimental|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
11243606|NCT03083847|Experimental|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
11243607|NCT03083847|Experimental|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
11243608|NCT03083847|Experimental|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
11243609|NCT03083847|Experimental|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
11243610|NCT03083847|Experimental|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
11243611|NCT03083834|Experimental|healthy subjects|low-dose cosyntropin stimulation test
11243612|NCT03083834|Experimental|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
11243613|NCT03083834|Experimental|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
11243614|NCT03083821|Experimental|Arm A|
11243615|NCT03083808|Experimental|Pembrolizumab 200mg IV every 21 days|Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m^2 IV D1 and D8 every three weeks, docetaxel 75mg/m^2 IV D1 every three weeks, or pemetrexed 500mg/m^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
11243616|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.
~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.
~These participants will continue to receive BC Diabetes standard care."
11243617|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
11243618|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
11243619|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
11243620|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
11243621|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
11243622|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
11243623|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
11243624|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
11243625|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)
~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
11243626|NCT03083717||Patients with compensated heart failure|
11243627|NCT03083717||Patients with decompensated heart failure|
11243628|NCT03083717||Healthy subjects|
11243629|NCT03083704|Experimental|Cohort 1|
11243630|NCT03083704|Experimental|Cohort 2|
11243631|NCT03083704|Experimental|Cohort 3|
11243632|NCT03083704|Experimental|Cohort 4|
11243633|NCT03083704|Experimental|Cohort 5|
11243634|NCT03083704|Experimental|Cohort 6|
11243635|NCT03083704|Experimental|Cohort 7|
11243636|NCT03083704|Experimental|Cohort 8|
11243637|NCT03083704|Experimental|Cohort 9|
11243638|NCT03083704|Experimental|Cohort 10|
11243639|NCT03083704|Experimental|Cohort 11|
11243667|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
11243640|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
11243641|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
11243642|NCT03083678|Experimental|Afatinib|Afatinib active treatment.
11243643|NCT03083665|Placebo Comparator|Placebo|"12 weeks Treatment Period: Subjects will receive Placebo
~4 weeks Down-Titration Period: Subjects will receive Placebo"
11243644|NCT03083665|Experimental|BRV 50 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 50 mg/day
~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day
~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period"
11243645|NCT03083665|Experimental|BRV 200 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 200 mg/day
~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day
~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period"
11243646|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
11243647|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
11243648|NCT03083639|Experimental|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
11243649|NCT03083639|Experimental|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
11243650|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
11243651|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
11243652|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles
~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,
~Eery 3 weeks"
11243653|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
11243654|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
11243655|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
11243656|NCT03083600|Placebo Comparator|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
11243657|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
11243658|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
11243659|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
11243660|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
11243661|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
11243662|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
11243663|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of LY3337641 administered orally, with a two week follow-up period.
11243664|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally, with a two week follow-up period.
11243665|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of LY3337641 administered orally, with a two week follow-up period.
11243666|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
11243669|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
11243670|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
11243671|NCT03083522|Experimental|OJS group|admission to Ojeok-san granule
11243672|NCT03083522|Placebo Comparator|Placebo Group|admission to placebo
11243673|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
11243674|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
11243675|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
11243676|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
11243677|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
11243678|NCT03083483|Experimental|Bilateral M1, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the bilateral M1 areas of the brain by measurement of 20% length of periauricular distance left and right of the vertex. The anode was placed on the left side and the cathode was placed on the right side.
11243679|NCT03083483|Experimental|SMA, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the supplementary motor area. The cathode was placed 10% of nasion-inion distance above the nasion and 15% of nasion-inion distance anterior to the vertex.
11243680|NCT03083483|Sham Comparator|sham tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants in this group were either randomized into either Bilateral or SMA configurations using the same measurements, but did not receive active stimulation. Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
11243681|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
11243682|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
11243683|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
11243684|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
11243685|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
11243686|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
11243687|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
11243688|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
11243689|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
11243690|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
11243691|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
11243692|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg·d in 3-4 divided dosages) given for 4 10 weeks (depending on postmenstrual gestational age at birth)
11243693|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
11243694|NCT03083418|Experimental|Control group|No EDP treatment.
11243695|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
11243696|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
11243697|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
11243698|NCT03083405||Healthy controls|Patients without diagnosed SB.
11243699|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
11243700|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
11243701|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
11243702|NCT03083366|Experimental|Sacral neuromodulation|Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.
11243703|NCT03083366|No Intervention|Standard care|Patients will receive standard neurogenic bladder care.
11243704|NCT03083353|Experimental|isradipine|Participants will receive 15mg of immediate release isradipine.
11243705|NCT03083353|Placebo Comparator|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
11243706|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
11243707|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
11243708|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.
~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
11243709|NCT03083314|Experimental|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
11243710|NCT03083314|Active Comparator|COMPLETE AXILLARY DISSECTION (ALND)|
11243711|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
11243712|NCT03083288|Experimental|Single Arm|
11243713|NCT03083275|Experimental|Resistance Training|
11243714|NCT03083275|No Intervention|Control|
11243715|NCT03083223||lung disease|Patients with lung disease
11243716|NCT03083210|Experimental|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
11243717|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
11243718|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
11243719|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
11243720|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
11243721|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
11243722|NCT03083171|Placebo Comparator|Placebo|
11243723|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
11243724|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
11243725|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
11243726|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
11243727|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
11243728|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
11243729|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
11243730|NCT03083132|Active Comparator|Early-start|24 weeks of modafinil 50 mg oral daily
11243731|NCT03083132|Placebo Comparator|Delayed-start|12 weeks of oral placebo followed by 12 weeks of modafinil 50 mg oral daily
11243732|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
11243733|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
11243734|NCT03083106|Other|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
11243735|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
11243736|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
11243737|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
11243738|NCT03083067|Experimental|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
11243739|NCT03083067|Active Comparator|Control(CT) group|CT group maintain the original treatment
11243740|NCT03083054|Experimental|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
11243741|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
11243742|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
11243743|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
11243744|NCT03083028|Active Comparator|Non Operative|"Non-Operative
~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
11243745|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
11243746|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
11243747|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
11243748|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
11243749|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
11243750|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
11243751|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
11243752|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
11243753|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
11243754|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
11243755|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
11243756|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
11243757|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
11243758|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).
~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.
~Each phone call will last approximately 5 minutes."
11243759|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
11243760|NCT03082898|Experimental|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
11243761|NCT03082898|Experimental|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
11243762|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
11243763|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
11243764|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
11243765|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
11243766|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
11243767|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
11243768|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
11243769|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
11243770|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
11243771|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
11243772|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
11243773|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
11243774|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
11243775|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
11243776|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
11243777|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
11243778|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
11243779|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
11243815|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
11243780|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
11243781|NCT03082755|Experimental|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
11243782|NCT03082755|Placebo Comparator|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
11243783|NCT03082742|Active Comparator|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
11243784|NCT03082742|Active Comparator|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
11243785|NCT03082729|Other|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
11243786|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
11243787|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
11243788|NCT03082703|Experimental|Text Messaging|
11243789|NCT03082703|No Intervention|Control|
11243790|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
11243791|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
11243792|NCT03082664|No Intervention|Standard dressing|Standard dressing will be applied after C-section.
11243793|NCT03082664|Experimental|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
11243794|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
11243795|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
11243796|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
11243797|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
11243798|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
11243799|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
11243800|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
11243801|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
11243802|NCT03082612|Experimental|Intervention plus usual care|Participants (patients and their family caregivers) in this study arm will receive the Overcoming Psychological Distress through Hymns Intervention.
11243803|NCT03082612|Active Comparator|Usual care|Immediately after randomization and completion of baseline measures, participants in this study arm will receive usual care. Patients and their family caregivers will receive the Overcoming Psychological Distress through Hymns Intervention after the 3 week period of usual care.
11243804|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
11243805|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
11243806|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
11243807|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
11243808|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
11243809|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
11243810|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
11243811|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
11243812|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.
~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.
~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
11243813|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.
~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.
~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
11243817|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
11243818|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
11243819|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
11243820|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC
~Pembrolizumab (Keytruda®):
~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.
~Cetuximab (Erbitux®):
~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
11243821|NCT03082508|Experimental|Algisyl|Algisyl device (implants) administered during a surgical procedure.
11243822|NCT03082508|Active Comparator|Standard Medical Therapy|as per protocol
11243823|NCT03082495|Experimental|Exercise|Aerobic exercise
11243824|NCT03082495|No Intervention|Usual Care|Standard medical care
11243825|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
11243826|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
11243827|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
11243828|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
11243829|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
11243830|NCT03082443|Experimental|Therapeutic group|
11243831|NCT03082443|No Intervention|Control group|
11243832|NCT03082430|Other|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
11243833|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.
~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
11243834|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:
~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
11243835|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
11243836|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
11243837|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
11243838|NCT03082391|Active Comparator|Heavyweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavyweight mesh.
11243839|NCT03082391|Active Comparator|Mediumweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a mediumweight mesh.
11243840|NCT03082365||pre-dialysis|
11243841|NCT03082365||end stage renal disease|
11243842|NCT03082352|Experimental|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
11243843|NCT03082352|Active Comparator|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
11243844|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
11243845|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
11243883|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
11243987|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
11243846|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time with 1/3 single and 2/3 bilateral leg movements.
11243847|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
11243848|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
11243849|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
11243850|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
11243851|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
11243852|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
11243853|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
11243854|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
11243855|NCT03082261|Other|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite IPG.
11243856|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
11243857|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
11243858|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
11243859|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
11243860|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
11243861|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
11243862|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
11243863|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
11243864|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
11243865|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
11243866|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
11243867|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
11243868|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
11243869|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
11243870|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
11243871|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
11243872|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
11243873|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
11243874|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
11243875|NCT03082209|Experimental|Dose Escalation|ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).
11243876|NCT03082209|Experimental|Dose Optimization for KRAS-mutant CRC|Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.
11243877|NCT03082209|Experimental|Dose Optimization for Pancreatic Cancer|Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).
11243878|NCT03082209|Experimental|Dose Optimization: ABBV-621 + Venetoclax for DLBCL|Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.
11243879|NCT03082209|Experimental|Dose Optimization: ABBV-621 Monotherapy for AML|Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.
11243880|NCT03082209|Experimental|Dose Optimization: ABBV-621 + Venetoclax for AML|Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.
11243881|NCT03082209|Experimental|Chemotherapy combination: ABBV-621+FOLFIRI|Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.
11243882|NCT03082209|Experimental|Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab|Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI
11243884|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
11243885|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
11243886|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
11243887|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
11243888|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
11243889|NCT03082157|No Intervention|Comparison|Exercise-only small group sessions
11243890|NCT03082144|Active Comparator|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
11243891|NCT03082144|Experimental|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
11243892|NCT03082131|Experimental|Group 1|"Order of treatments:
~A. Resistant Starch Wheat B. Regular Wheat"
11243893|NCT03082131|Experimental|Group 2|"Order of treatments:
~A. Regular Wheat B. Resistant Starch Wheat"
11243894|NCT03082118|Experimental|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
11243895|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
11243896|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
11243897|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
11243898|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
11243899|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
11243900|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
11243901|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
11243902|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
11243903|NCT03082066||Adults|Even or older 18 years
11243904|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
11243905|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
11243906|NCT03082040|Experimental|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
11243907|NCT03082040|Other|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
11243908|NCT03082027||ultrasonography|diagnostic tool
11243909|NCT03082027||operative release|
11243910|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
11243911|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
11243912|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
11243913|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.
~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
11243914|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.
~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.
~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
11243915|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer
~evaluation of disease status: endoscopy, CT, and/or PET-CT"
11243916|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer
~evaluation of disease status: endoscopy, CT, and/or PET-CT"
11243917|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
11243918|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
11243919|NCT03081962|Experimental|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
11243984|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
11244023|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
11243920|NCT03081962|Active Comparator|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
11243921|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
11243922|NCT03081949|No Intervention|Control|No treatment
11243923|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
11243924|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
11243925|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
11243926|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
11243927|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
11243928|NCT03081910|Experimental|CD5.CAR/28zeta CAR T cells|Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evalution without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.
11243929|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
11243930|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
11243931|NCT03081884|Experimental|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
11243932|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
11243933|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
11243934|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
11243935|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
11243936|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.
~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
11243937|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
11243938|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
11243939|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
11243940|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
11243941|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
11243942|NCT03081806|Experimental|Active drug|X0002, BID (approximately every 12 hours; n=400)
11243943|NCT03081806|Placebo Comparator|Placebo|Placebo, BID (approximately every 12 hours; n=200)
11243944|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
11243945|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
11243946|NCT03081780|Experimental|FATE NK-100|
11243947|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
11243948|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
11243985|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
11243949|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
11243950|NCT03081728|Experimental|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
11243951|NCT03081728|Experimental|control|IV analgesia only with diclofenac and paracetamol
11243952|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.
~A total of 1 to 10 x 10^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
11243953|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.
~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
11243954|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
11243955|NCT03081676|Active Comparator|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
11243956|NCT03081676|Active Comparator|Placebo + GIP|Placebo tablet + infusion of GIP
11243957|NCT03081676|Active Comparator|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
11243958|NCT03081676|Active Comparator|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
11243959|NCT03081676|Active Comparator|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
11243960|NCT03081676|Placebo Comparator|Placebo + Placebo|Placebo tablet + infusion of placebo (saline)
11243961|NCT03081663|Experimental|Quads-Sparing Approach with Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.
11243962|NCT03081663|Active Comparator|Medial Para-Patellar with Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
11243963|NCT03081663|Active Comparator|Quads-Sparing Approach w/o Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.
11243964|NCT03081663|Active Comparator|Medial Para-Patellar w/o Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
11243965|NCT03081650|Experimental|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.
~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
11243966|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
11243967|NCT03081624||Term Preschoolers|Term children who haven't attend school.
11243968|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
11243969|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
11243970|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
11243971|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
11243972|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
11243973|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
11243974|NCT03081585||Healthy Controls|Normal weight, healthy female participants
11243975|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
11243976|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
11243977|NCT03081559|Experimental|Intervention|Healthy Divas intervention
11243978|NCT03081559|No Intervention|Control|Treatment as usual
11243979|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.
~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
11243980|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
11243981|NCT03081533|Experimental|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
11243982|NCT03081533|No Intervention|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
11243983|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
11243988|NCT03081494|Experimental|spartalizumab (PDR001) + regorafenib|Subjects with metastatic MSS CRC received a combination of spartalizumab and regorafenib.
11243989|NCT03081481|Experimental|PRX302|intraprostatic administration
11243990|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
11243991|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
11243992|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
11243993|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
11243994|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
11243995|NCT03081429||Perioperative covert stroke|
11243996|NCT03081429||Postoperative cognitive dysfunction|
11243997|NCT03081416|Experimental|Intranasal Ketamine arm|Intranasal ketamine administered to participant
11243998|NCT03081416|Active Comparator|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
11243999|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
11244000|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
11244001|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
11244002|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
11244003|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
11244004|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing
~Skin conductance & cold pressor test
~Flow-mediated dilation testing"
11244005|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
11244006|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
11244007|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
11244008|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
11244009|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
11244010|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
11244011|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
11244012|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
11244013|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
11244014|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
11244015|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
11244016|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
11244017|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
11244018|NCT03081260|Other|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
11244019|NCT03081260|Other|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
11244020|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
11244021|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
11244022|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
11244024|NCT03081208|Experimental|Nolasiban 900 mg|
11244026|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:
~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
11244027|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:
~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
11244028|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)
~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
11244029|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
11244030|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
11244031|NCT03081156|Active Comparator|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
11244032|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
11244033|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
11244034|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
11244035|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
11244036|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
11244037|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
11244038|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
11244039|NCT03081104|Active Comparator|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
11244040|NCT03081104|Active Comparator|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
11244041|NCT03081104|Active Comparator|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
11244042|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
11244043|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.
~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
11244044|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
11244045|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
11244078|NCT03080883|Experimental|Group II (higher dose apixaban)|Patients receive higher dose apixaban PO BID for 365 days.
11244046|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
11244047|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
11244048|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
11244049|NCT03081065|No Intervention|Control|Usual care
11244050|NCT03081052|Active Comparator|Lung transplant with iNO|
11244051|NCT03081052|Active Comparator|Lung transplant with iEPO|
11244052|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
11244053|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
11244054|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
11244055|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
11244056|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.
11244057|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
11244058|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
11244059|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
11244060|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
11244061|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
11244062|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
11244063|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
11244064|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
11244065|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
11244066|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
11244067|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
11244068|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
11244069|NCT03080948||History of Melanoma (cases)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
11244070|NCT03080948||No Melanoma History (controls)|Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification. In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes. The evaluations needed for this study protocol will be primarily performed during routine clinical care.
11244071|NCT03080935|Experimental|Evolocumab|Single arm study administering Evolocumab.
11244072|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
11244073|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.
~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
11244074|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.
~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
11244075|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
11244076|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
11244077|NCT03080883|Experimental|Group I (lower dose apixaban)|Patients receive lower dose apixaban PO BID for 365 days.
11244448|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
11244079|NCT03080870|Experimental|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.
~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
11244080|NCT03080870|No Intervention|Control|Baseline and follow-up measurements.
11244081|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
11244082|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
11244083|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
11244084|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
11244085|NCT03080831|Active Comparator|Glucion 5%|
11244086|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
11244087|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
11244088|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
11244089|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
11244090|NCT03080792|Experimental|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
11244091|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
11244092|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
11244093|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.
~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.
~The drug will then be administrated intravenously.
~Dosage 20 mg/m2
~28-day course, for each course, receive decitabine for 10 days"
11244094|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
11244095|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
11244096|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
11244097|NCT03080714|Active Comparator|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
11244098|NCT03080714|Active Comparator|Subjects presenting with Retinal Disease|Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
11244099|NCT03080714|Active Comparator|Subjects presenting with Glaucoma|Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
11244100|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
11244101|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
11244102|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
11244103|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
11244104|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
11244105|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
11244106|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
11244107|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
11244108|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
11244109|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
11244110|NCT03080636|Experimental|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
11244111|NCT03080636|Experimental|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
11244150|NCT03080324|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
11244112|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
11244113|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
11244114|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
11244115|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
11244116|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
11244117|NCT03080558|Experimental|endometriosis recto vaginal node|
11244118|NCT03080545|Experimental|Open Label Enstilar|open label
11244119|NCT03080532||european population|
11244120|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
11244121|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
11244122|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
11244123|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)
~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
11244124|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo
~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
11244125|NCT03080480|Experimental|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
11244126|NCT03080467||Suture|Wound repair with suture
11244127|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
11244128|NCT03080454|Placebo Comparator|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
11244129|NCT03080454|Active Comparator|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
11244130|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
11244131|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
11244132|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
11244133|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
11244134|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
11244135|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
11244136|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
11244137|NCT03080415|Experimental|Combined Therapy SOF and DCV|
11244138|NCT03080402|Experimental|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
11244139|NCT03080402|No Intervention|Normal KAM|No intervention
11244140|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
11244141|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
11244142|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
11244143|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
11244144|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
11244145|NCT03080363|No Intervention|Group Control|No intervention
11244146|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
11244147|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
11244148|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
11244149|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
11244151|NCT03080324|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
11244152|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
11244153|NCT03080298|Experimental|Treatment with BP101|
11244154|NCT03080298|Placebo Comparator|Treatment with placebo|
11244155|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.
~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
11244156|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.
~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
11244157|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
11244158|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
11244159|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
11244160|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
11244161|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
11244162|NCT03080259|Active Comparator|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
11244163|NCT03080259|No Intervention|Treatment As Usual|Standard clinical care
11244164|NCT03080246|Active Comparator|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 2-3 days per week for about an hour each day. The investigators also have a site on High Point University's campus. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest and High Point University will go on for 9 months, followed by another 9 months of option to continue at facility, plus follow-up via email and 2 group meetings/runs at Fleet Feet (at around months 12 and 15).
11244165|NCT03080246|No Intervention|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings/runs at Fleet Feet (at around months 1, 3, 6, 12, and 15). After the 18 months, the participants will be offered a free 8-week strength training program at the Clinical Research Center or High Point University.
11244166|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital
~Consenting to participate in the study"
11244167|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
11244168|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
11244169|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
11244170|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
11244171|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
11244172|NCT03080207|Experimental|Low Level Laser|
11244173|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
11244174|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
11244175|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
11244176|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.
~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
11244177|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
11244178|NCT03080142|Experimental|Group 1|Single injection of Exparel
11244179|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
11244180|NCT03080129|Experimental|Cirrhosis + sarcopenia|Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
11244181|NCT03080129|No Intervention|Control|Patients with sarcopenia and no evidence of cirrhosis and healthy controls
11244182|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
11244183|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
11244184|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
11244185|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
11244186|NCT03080090|Experimental|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 60% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
11244187|NCT03080090|Active Comparator|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 20% to 40% of age-predicted HRmax.
11244188|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
11244189|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
11244190|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
11244191|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
11244192|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
11244193|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
11244194|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.
~It focuses on six essential key parts for the development of compassion:
~Developing attentional stability and clarity of the mind (Mindfulness)
~Cultivating insight into the nature of mental experience
~Cultivating self-compassion
~Developing impartiality
~Developing appreciation and affection for others
~Developing empathy and realizing engaged compassion"
11244195|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
11244196|NCT03079999|Experimental|Aspirin|Patients on the experimental arm will receive blinded aspirin. Pediatric subjects who weigh less than 110 lbs will take 81mg aspirin twice a day. All other subjects will take 325mg aspirin twice a day.
11244197|NCT03079999|Placebo Comparator|Placebo|Patients on the placebo arm will receive blinded placebo and take it twice a day.
11244198|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
11244199|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
11244200|NCT03079973|Experimental|P-3073|
11244201|NCT03079973|Placebo Comparator|Vehicle|
11244449|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
11244202|NCT03079960|Experimental|Electrophysiological recording and measurement devices|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.
~Cables and connectors of the macro electrodes will stay externalized for cDBS adjustment procedures. The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
11244203|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
11244204|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
11244205|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
11244206|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
11244207|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
11244208|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
11244209|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
11244210|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
11244211|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
11244212|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
11244213|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
11244214|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
11244215|NCT03079882||Living Donor Recipients|Recipients of renal transplants with the transplanted organ originating from living donors
11244216|NCT03079882||Deceased Donor Recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
11244217|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
11244218|NCT03079856|Experimental|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
11244219|NCT03079856|No Intervention|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
11244220|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
11244221|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
11244222|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
11244223|NCT03079830|Sham Comparator|Saline continous|Piritramid
11244224|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
11244225|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
11244226|NCT03079804|Experimental|Experimental MWM|"Other names:
~4 mobilizations - 10 seconds 20 seconds of rest"
11244227|NCT03079804|Active Comparator|Experimental Thrust|"Other names:
~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
11244228|NCT03079804|Placebo Comparator|Placebo|"Other names:
~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
11244229|NCT03079778|Active Comparator|TACE alone|Transarterial chemoembolization (TACE)
11244230|NCT03079778|Experimental|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
11244231|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
11244232|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
11244233|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
11245356|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
11244234|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
11244235|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
11244236|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
11244237|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
11244238|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
11244239|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
11244240|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
11244241|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
11244242|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
11244243|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
11244244|NCT03079648|Experimental|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
11244245|NCT03079648|Placebo Comparator|Placebo|Placebo for 12 weeks
11244246|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
11244247|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
11244248|NCT03079622|Active Comparator|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
11244249|NCT03079622|Active Comparator|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
11244250|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
11244251|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
11244252|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
11244253|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
11244254|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
11244255|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
11244256|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
11244257|NCT03079531|Experimental|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
11244258|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
11244259|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
11244260|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
11244261|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
11244262|NCT03079479||Two Years Group|
11244263|NCT03079479||Five Years Group|
11244264|NCT03079479||Ten Years Group|
11244265|NCT03079479||Control Group|
11244266|NCT03079466|Active Comparator|Treatment CPAP|A group treated with CPAP
11244267|NCT03079466|Sham Comparator|group without treatment|
11244268|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
11244269|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
11244270|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
11244271|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
11244272|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
11244273|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
11244330|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
11245357|NCT03071705|Experimental|Intervention|TKI plus Metformin
11244274|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.
~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
11244275|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
11244276|NCT03079388|Experimental|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
11244277|NCT03079388|Active Comparator|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
11244278|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
11244279|NCT03079375|Sham Comparator|basic intervention|Medication review
11244280|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
11244281|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
11244282|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
11244283|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
11244284|NCT03079336|Experimental|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
11244285|NCT03079336|Experimental|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
11244286|NCT03079323|Experimental|PART-trial|External beam radiotherapy
11244287|NCT03079310|Experimental|Spinal cord stimulation|Boston Scientific SCS system
11244288|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
11244289|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
11244290|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
11244291|NCT03079271|Other|open label|
11244292|NCT03079258|Experimental|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
11244293|NCT03079258|No Intervention|Control|Those randomized to the control group will continue with their standard care.
11244294|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
11244295|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
11244296|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
11244297|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
11244298|NCT03079232|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
11244299|NCT03079232|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
11244300|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
11244301|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
11244302|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
11244303|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
11244304|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
11244331|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
11245358|NCT03071705|Active Comparator|Control|TKI
11244305|NCT03079180|Experimental|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years
~Training programs:
~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.
~Training exercises: A Warm-up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.
~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
11244306|NCT03079180|Experimental|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years
~The training program and training exercises in this group are the same as for the Aged & strength training at 80% 1RM arm except for the two following parameters.
~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).
~The subjects will perform 6 to 12 repetitions at 55% 1RM.
~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
11244307|NCT03079180|Experimental|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years
~The training program and training exercises in this group are the same as for the Aged & strength training at 55% 1RM arm"
11244308|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
11244309|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
11244310|NCT03079154|Experimental|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
11244311|NCT03079154|Active Comparator|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
11244312|NCT03079154|No Intervention|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
11244313|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.
~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
11244314|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.
~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
11244315|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
11244316|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
11244317|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
11244318|NCT03079102|Experimental|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
11244319|NCT03079102|Placebo Comparator|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
11244320|NCT03079089|Other|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
11244321|NCT03079076|Active Comparator|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
11244322|NCT03079076|Placebo Comparator|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
11244323|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
11244324|NCT03079063|Experimental|Eptacog alfa biosimilar, additional immunogenicity cohort|Additional patients receiving eptacog alfa biosimilar for treatment of bleeding on demand - or - prophylaxis, over a 12 months period
11244325|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
11244326|NCT03079037||Stimulation|Traditional deep brain stimulation
11244327|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
11244328|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
11244329|NCT03079024|No Intervention|Treatment as Usual (TAU)|Treatment as Usual
11244377|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
11244378|NCT03078712|Active Comparator|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
11244332|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
11244333|NCT03078998|Experimental|Juvenile idiopathic Arthritis|
11244334|NCT03078998|Experimental|Obstetric Brachial Plexus Palsy|
11244335|NCT03078998|Experimental|Cerebral Palsy|
11244336|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
11244337|NCT03078972||Advanced Heart Failure|40 patients with advanced heart failure scheduled to undergo Left Ventricular Assist Device (LVAD) insertion will be recruited for testing. Test subjects will complete testing prior to, and following LVAD implantation.
11244338|NCT03078972||Healthy controls|10 age-matched healthy individuals will be recruited to establish normal/reference values.
11244339|NCT03078972||Mild Heart Failure|A second control group comprised of 10 age-matched individuals will be recruited to establish normal/reference values for individuals with mild, medically managed heart failure.
11244340|NCT03078946|Active Comparator|Dexmedetomidine Group (N=30)|
11244341|NCT03078946|Active Comparator|Morphine with Midazolam (N=30)|
11244342|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
11244343|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
11244344|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
11244345|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
11244346|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
11244347|NCT03078920|Other|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
11244348|NCT03078907|Experimental|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
11244349|NCT03078907|Placebo Comparator|Placebo|Regimen and titration scheme similar to those in the selexipag group
11244350|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
11244351|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
11244352|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
11244353|NCT03078855|Experimental|Vitamin D plus rituximab|
11244354|NCT03078855|Placebo Comparator|Placebo plus rituximab|
11244355|NCT03078842|Active Comparator|Zinc-20|Zinc tablets, 20 mg per day
11244356|NCT03078842|Experimental|Zinc-10|Zinc tablets, 10 mg per day
11244357|NCT03078842|Experimental|Zinc-05|Zinc tablets, 5 mg per day
11244358|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
11244359|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:
~Activa PC Primary Cell Neurostimulator - (Model 37601)
~Activa RC Rechargeable Neurostimulator - (Model 37612)
~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)
~DBS Lead - (Model 3387)
~DBS Extension - (Models 37085/6)
~Patient Programmer - (Model 37642)
~Test Stimulator - (Model 3625)
~N'Vision Clinician Programmer - (Model 8840)
~N'Vision Software Application Card - (Model 8870)"
11244360|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
11244361|NCT03078803|Placebo Comparator|Placebo|Water
11244362|NCT03078790|Experimental|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
11244363|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
11244364|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
11244365|NCT03078764|Experimental|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
11244366|NCT03078764|Experimental|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
11244367|NCT03078751|Experimental|Ribociclib + adjuvant endocrine therapy (ET)|"Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy.
~ET was one of these 3: Letrozole, Anastrozole, Exemestane"
11244368|NCT03078751|Placebo Comparator|Placebo + adjuvant endocrine therapy (ET)|Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 3: Letrozole 2.5 mg by mouth daily, Anastrozole 1 mg by mouth daily, Exemestane 25 mg by mouth daily
11244369|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
11244370|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
11244371|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
11244372|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
11244373|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
11244374|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
11244375|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
11244376|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
11244379|NCT03078712|Active Comparator|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
11244380|NCT03078699|Experimental|stereotactic body radiation therapy|
11244381|NCT03078686|Active Comparator|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
11244382|NCT03078686|Experimental|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
11244383|NCT03078686|Experimental|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
11244384|NCT03078686|Experimental|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
11244385|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
11244386|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
11244387|NCT03078673|Experimental|Control group|Only regular training
11244388|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
11244389|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
11244390|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
11244391|NCT03078634|Active Comparator|Multi-Disciplinary clinic|
11244392|NCT03078634|Placebo Comparator|Standard Gastrointestinal clinic|
11244393|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
11244394|NCT03078608|Experimental|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
11244395|NCT03078608|Active Comparator|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
11244396|NCT03078608|Other|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
11244397|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
11244398|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
11244399|NCT03078582|Experimental|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
11244400|NCT03078582|Experimental|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
11244401|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
11244402|NCT03078569|No Intervention|Control group|without testosterone treatment
11244403|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
11244404|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
11244405|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
11244406|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
11244407|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
11244408|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
11244409|NCT03078543|Other|ANTHEM™ PS Total Knee System implant|The ANTHEM™ PS Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
11244410|NCT03078530|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
11244411|NCT03078530|Experimental|Visbiome|Visbiome (probiotic mixture) is given to this group.
11244412|NCT03078530|Experimental|VSL #3|VSL #3 (probiotic mixture) is given to this group
11244413|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
11244414|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
11244415|NCT03078504|Experimental|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
11244447|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
11244416|NCT03078491|Experimental|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
11244417|NCT03078491|No Intervention|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
11244418|NCT03078478|Experimental|IDeg 200 U/mL|
11244419|NCT03078478|Active Comparator|IGlar 300 U/mL|
11244420|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
11244421|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
11244422|NCT03078452|Experimental|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
11244423|NCT03078452|Active Comparator|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
11244424|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
11244425|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
11244426|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
11244427|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
11244428|NCT03078400|Experimental|Safety Phase|"Six to 12 subjects
~Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles
~Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
11244429|NCT03078400|Experimental|Exploratory Expansion Phase|"Up to 12 subjects
~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
11244430|NCT03078374|Other|Reduced Anticoagulation|Reduced anticoagulation
11244431|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
11244432|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
11244433|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:
~Baseline
~6 month follow-up"
11244434|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:
~Baseline
~Post 6 month follow-up"
11244435|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
11244436|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
11244437|NCT03078322|Experimental|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
11244438|NCT03078322|Placebo Comparator|Placebo|Placebo
11244439|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
11244440|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
11244441|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
11244442|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
11244443|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
11244444|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
11244445|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
11244446|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
11244450|NCT03078218|No Intervention|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
11244451|NCT03078218|Experimental|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
11244452|NCT03078205|No Intervention|The control group|No Intervention
11244453|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
11244454|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
11244455|NCT03078192|Experimental|PVD, left heart disease, lung disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
11244456|NCT03078192|Experimental|Pulmonary Vascular Disease|92 subjects being evaluated for undergoing right heart catheterization for evaluation of PAH or other cardiac or pulmonary disease for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
11244457|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:
~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
11244458|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
11244459|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
11244460|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
11244461|NCT03078153|No Intervention|Control|No intervention
11244462|NCT03078140|Active Comparator|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
11244463|NCT03078140|Active Comparator|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
11244464|NCT03078127|Active Comparator|Sequence A|"In this arm, the interventions were performed in the following order:
~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
11244465|NCT03078127|Active Comparator|Sequence B|"In this arm, the interventions were performed in the following order:
~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
11244466|NCT03078127|Active Comparator|Sequence C|"In this arm, the interventions were performed in the following order:
~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
11244467|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
11244468|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
11244469|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
11244470|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
11244471|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
11244472|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
11244473|NCT03078088|Placebo Comparator|saline|normal saline
11244474|NCT03078088|Experimental|treatment|tham
11244475|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
11244476|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
11244477|NCT03078062|Active Comparator|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
11244478|NCT03078062|Placebo Comparator|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
11244479|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
11244480|NCT03078049||Sitagliptin|Patients take sitagliptin
11244481|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
11244482|NCT03078023|Experimental|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) > than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, >15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
11244483|NCT03078010|Active Comparator|Piperacillin-tazobactam|
11244484|NCT03078010|Experimental|cefepime|
11244642|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
11244485|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
11244486|NCT03077984|Experimental|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
11244487|NCT03077984|No Intervention|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
11244488|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
11244489|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
11244490|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
11244491|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
11244492|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
11244493|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.
~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
11244494|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
11244495|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
11244496|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.
~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
11244497|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.
~Patients who developped gastroœsophageal reflux de novo."
11244498|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
11244499|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
11244500|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
11244501|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
11244502|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
11244503|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
11244504|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
11244505|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
11244506|NCT03077854|Experimental|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy
~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
11244507|NCT03077854|Active Comparator|Standard-TRT|"Standard Thoracic Radiotherapy
~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
11244508|NCT03077841|Experimental|Arm I (hypofractionated partial breast irradiation)|Patients undergo hypofractionated partial breast irradiation daily for 10 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
11244509|NCT03077841|Active Comparator|Arm II (hypofractionated partial breast irradiation)|Patients undergo standard breast irradiation daily for 15 days. Patients may then receive 5 additional boost fractions at the discretion of the doctor.
11244510|NCT03077828|Experimental|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
11244511|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
11244512|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
11245359|NCT03071692|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
11244513|NCT03077802|Experimental|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
11244514|NCT03077802|Active Comparator|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
11244515|NCT03077802|Experimental|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
11244516|NCT03077802|Active Comparator|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
11244517|NCT03077789|Experimental|TRABECULOTOMY|
11244518|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:
~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy
~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).
~Biopsy of a metastatic site in the event of disease recurrence.
~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
11244519|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
11244520|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
11244521|NCT03077750|Experimental|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
11244522|NCT03077750|Placebo Comparator|Vehicle|Vehicle Gel Applied to Affected Area BID
11244523|NCT03077737|Experimental|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
11244524|NCT03077737|Active Comparator|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
11244525|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
11244526|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
11244527|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
11244528|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
11244529|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
11244530|NCT03077685|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
11244531|NCT03077685|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
11244532|NCT03077685|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
11244533|NCT03077685|Experimental|Second Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
11244534|NCT03077685|Experimental|Third Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
11244535|NCT03077672||NYP-WCM|The NYP-WCM cohort will consist of patients presenting to the NewYork-Presbyterian/Weill Cornell Medicine Emergency Department with suspected sepsis.
11244536|NCT03077672||NYP-BMH|The NYP-BMH cohort will consist of patients presenting to the NewYork-Presbyterian Brooklyn Methodist Hospital Emergency Department with suspected sepsis.
11244537|NCT03077659|Experimental|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
11244538|NCT03077659|Experimental|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
11244539|NCT03077659|Experimental|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
11244540|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
11245360|NCT03071692|Placebo Comparator|Control Group|Matching K-877 placebo tablet twice daily.
11245361|NCT03071679|Experimental|Omiganan|
11244541|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
11244542|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
11244543|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
11244544|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
11244545|NCT03077620|Experimental|Poor sleep group treatment 1|10mg Suvorexant tablet h.s. for two consecutive nights
11244546|NCT03077620|Placebo Comparator|Poor sleep group control|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
11244547|NCT03077620|Placebo Comparator|Good sleep group|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
11244548|NCT03077620|Experimental|Poor sleep group treatment 2|20mg Suvorexant tablet h.s. for two consecutive nights
11244549|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
11244550|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
11244551|NCT03077594|Other|Successfully ablated patients|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy.
11244552|NCT03077594|Other|Successfully ablated patients - VLE|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy. Volumetric laser endomicroscopy (VLE) will be done.
11244553|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
11244554|NCT03077581|Active Comparator|Rectus sheath block group|
11244555|NCT03077581|Active Comparator|local infiltration group|
11244556|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
11244557|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
11244558|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
11244559|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
11244560|NCT03077542|Experimental|recipient|recipient
11244561|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
11244562|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
11244563|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
11244564|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
11244565|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
11244566|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
11244567|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
11244568|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);
~SAD cohorts are defined as follows:
~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.
~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each
~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each
~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
11244569|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.
~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each
~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each
~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
11244570|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).
~FE Crossover:
~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
11244571|NCT03077464|Active Comparator|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
11244752|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
11244572|NCT03077464|Experimental|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
11244573|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.
~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
11244574|NCT03077438|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MenACYW Conjugate vaccine on Day 0.
11244575|NCT03077438|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MENVEO® Conjugate vaccine on Day 0.
11244576|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
11244577|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.
~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
11244578|NCT03077412|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
11244579|NCT03077412|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
11244580|NCT03077412|Experimental|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
11244581|NCT03077399|Experimental|stroke|stroke patients, application of SCALA
11244582|NCT03077399|Experimental|control|patients without stroke, application of SCALA
11244583|NCT03077386|Experimental|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
11244584|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
11244585|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
11244586|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
11244587|NCT03077360|Experimental|Weight loss only|
11244588|NCT03077360|Experimental|Exercise Only|
11244589|NCT03077360|No Intervention|Delayed Intervention Control|
11244590|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
11244591|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
11244592|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
11244593|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
11244594|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
11244595|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
11244596|NCT03077321|No Intervention|Control|Wait list control
11244597|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
11244598|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
11244599|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
11244600|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
11245362|NCT03071679|Experimental|Imiquimod|
11244601|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet
~Phase 2: consumption of HF meals for 4 weeks
~Phase 3: washout for 1 week, controlled maintenance diet
~Phase 4: consumption of HP meals for 4 weeks"
11244602|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet
~Phase 2: consumption of HP meals for 4 weeks
~Phase 3: washout for 1 week, controlled maintenance diet
~Phase 4: consumption of HF meals for 4 weeks"
11244603|NCT03077282|Experimental|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
11244604|NCT03077282|Experimental|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
11244605|NCT03077243|Experimental|≤ 10 pack years smoking history|
11244606|NCT03077243|Experimental|> 10 py smoking history, no p53 mutation|
11244607|NCT03077243|Active Comparator|> 10 py smoking history, p53 mutation|
11244608|NCT03077230|Experimental|Pre/Post Test of a Lung Cancer Screening Decision Aid|
11244609|NCT03077217|Active Comparator|high-dose rifaximin|
11244610|NCT03077217|No Intervention|control group|
11244611|NCT03077204|Other|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
11244612|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR 23, before the start of the radiotherapy, at the end of the radiotherapy and then at every follow-up visit ( the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
11244613|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
11244614|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
11244615|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
11244616|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
11244617|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
11244618|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
11244619|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
11244620|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
11244621|NCT03077126|Other|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
11244622|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.
~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
11244623|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
11244624|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
11244625|NCT03077074|Experimental|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
11244626|NCT03077061|Active Comparator|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
11244627|NCT03077061|Experimental|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
11244628|NCT03077048|No Intervention|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
11244629|NCT03077048|Experimental|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
11244630|NCT03077035|Experimental|glass ionomer sealant|
11244631|NCT03077035|Active Comparator|resin-based sealant|
11244632|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
11244633|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
11244634|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
11244635|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
11244636|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
11244637|NCT03076970|Experimental|Lasmiditan 200 mg|single oral tablet
11244638|NCT03076970|Active Comparator|Sumatriptan 100 mg|single oral tablet
11244639|NCT03076970|Experimental|Combination of lasmiditan and sumatriptan|single oral tablet of each
11244640|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
11244641|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
11244643|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
11244644|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
11244645|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
11244646|NCT03076918|Active Comparator|Conventional PDT|Aktilite® Galderma
11244647|NCT03076918|Experimental|FLEXITHERALIGHT PDT|Light Emitting Textile Device
11244648|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
11244649|NCT03076892|Active Comparator|Conventional PDT|Aktilite® Galderma
11244650|NCT03076892|Experimental|PHOS ISTOS PDT|Light Emitting textile device
11244651|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
11244652|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
11244653|NCT03076853||Patients with Pharmaceutical Record|
11244654|NCT03076840|Active Comparator|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
11244655|NCT03076840|Sham Comparator|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
11244656|NCT03076840|No Intervention|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
11244657|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
11244658|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
11244659|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
11244660|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
11244661|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.
~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
11244662|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.
~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
11244663|NCT03076775|Experimental|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
11244664|NCT03076775|No Intervention|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
11244665|NCT03076762|Experimental|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
11244666|NCT03076762|Active Comparator|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
11244667|NCT03076736|Active Comparator|Resource pack|Aphasia resource pack
11244668|NCT03076736|Experimental|Singing group + resource pack|Singing group + Aphasia resource pack
11244669|NCT03076723|Sham Comparator|Fixed opening pressure|The shunt opening pressure is changed to the same setting as at surgery.
11244670|NCT03076723|Experimental|Individual shunt opening pressure|The shunt opening pressure is adjusted (up one step, down one step or unchanged) according to an individual analysis of the pulsatility curve (as assessed after shunt surgery).
11244671|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
11244672|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
11244673|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
11244852|NCT03075332|Experimental|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
11244674|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
11244675|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
11244676|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
11244677|NCT03076684|Experimental|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
11244678|NCT03076684|Experimental|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
11244679|NCT03076684|No Intervention|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
11244680|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
11244681|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
11244682|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
11244683|NCT03076658|Other|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
11244684|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
11244685|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.
~Interventions:
~Cervical plus transcranial stimulation
~Cervical stimulation plus hand/wrist exercise
~Electromyographic (EMG)-triggered (closed-loop) stimulation"
11244686|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.
~Interventions:
~Cervical plus transcranial stimulation
~Cervical stimulation plus hand/wrist exercise
~Electromyographic (EMG)-triggered (closed-loop) stimulation"
11244687|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.
~Interventions:
~Cervical plus transcranial stimulation
~Cervical stimulation plus hand/wrist exercise
~Electromyographic (EMG)-triggered (closed-loop) stimulation"
11244688|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
11244689|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
11244690|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
11244691|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
11244692|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
11244693|NCT03076567||control|Controls from two previously conducted studies in China
11244694|NCT03076554|Experimental|Arm 1 Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverseevents.
11244695|NCT03076541||patients with restless legs syndrome|
11245363|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
11244696|NCT03076528|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle & foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
11244697|NCT03076528|Active Comparator|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
11244698|NCT03076515|Active Comparator|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
11244699|NCT03076515|Sham Comparator|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
11244700|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
11244701|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
11244702|NCT03076476|Active Comparator|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
11244703|NCT03076476|Experimental|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.
~After the interim analysis DES-slow to be compared with BVS."
11244704|NCT03076476|Experimental|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
11244705|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
11244706|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
11244707|NCT03076450|Active Comparator|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
11244708|NCT03076450|Experimental|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
11244709|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
~Interventions:
~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
11244710|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
11244711|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
11244712|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
11244713|NCT03076385|Experimental|VAL-506440|
11244714|NCT03076385|Placebo Comparator|Placebo|
11244715|NCT03076372|Experimental|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
11244716|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
11244717|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.
~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
11244718|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
11244719|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency an duration: topically applied every 12 hours for 6 months."
11244720|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency and duration: topically applied every 12 hours for 6 month"
11244721|NCT03076307|Experimental|Parkinson's disease|
11244722|NCT03076307|Active Comparator|Control group|
11244723|NCT03076294|Experimental|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
11244724|NCT03076294|Experimental|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
11244753|NCT03076060|Experimental|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.
~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
11245364|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
11244725|NCT03076294|Sham Comparator|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
11244726|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
11244727|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
11244728|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
11244729|NCT03076268|Experimental|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
11244730|NCT03076268|No Intervention|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
11244731|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
11244732|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
11244733|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
11244734|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
11244735|NCT03076216|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
11244736|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11244737|NCT03076190|No Intervention|Active Control Group (Health Education)|"Prior to surgery:
~Demographics survey
~Baseline surveys
~Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.
~Follow-up questions about the handouts (detailed above)
~Post-surgery:
~Daily surveys (detailed above)
~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
11244738|NCT03076190|Experimental|My Surgical Success Treatment Group|"Prior to surgery:
~Demographics survey
~Baseline surveys
~Intervention:
~90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.
~audio file
~personalized plan that incorporates the information learned in the video.
~Follow-up questions about the video (detailed above)
~Post-surgery:
~Daily surveys (detailed above)
~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
11244739|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
11244740|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
11244741|NCT03076164|Experimental|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
11244742|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
11244743|NCT03076138|Experimental|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
11244744|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
11244745|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
11244746|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin
~** Metformin and sulfonylurea's dosages
~Metformin 500 mg - 2550 mg
~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
11244747|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin
~** Metformin and sulfonylurea's dosages
~Metformin 500 mg - 2550 mg
~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
11244748|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
11244749|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
11244750|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
11244751|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
11244843|NCT03075397|Other|HIV-1 infected patients|Blood sample and sperm sample are collected
11244754|NCT03076060|Sham Comparator|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.
~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
11244755|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
11244756|NCT03076034|Experimental|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
11244757|NCT03076034|Experimental|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
11244758|NCT03076021|Other|Adolescents|dextromethorphan pre- and post isotretinoin
11244759|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
11244760|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
11244761|NCT03075956|Experimental|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
11244762|NCT03075956|Experimental|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
11244763|NCT03075956|Experimental|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
11244764|NCT03075956|Experimental|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
11244765|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
11244766|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
11244767|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
11244768|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
11244769|NCT03075917|Experimental|Experimental|questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
11244770|NCT03075904|Experimental|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
11244771|NCT03075904|Experimental|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
11244772|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
11244773|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
11244774|NCT03075878|Experimental|Cohort 1: ALXN1830|SYNT001 Dose 1
11244775|NCT03075878|Experimental|Cohort 2: ALXN1830|SYNT001 Dose 2
11244776|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
11244777|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
11244778|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
11244779|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
11244780|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
11244781|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.
~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
11244782|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
11244783|NCT03075800|No Intervention|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
11244784|NCT03075800|Experimental|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
11244785|NCT03075787||patients with obstructive sleep apneas|
11244786|NCT03075761|Experimental|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
11244787|NCT03075761|Active Comparator|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
11244788|NCT03075748|Experimental|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
11244789|NCT03075748|Experimental|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
11244790|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
11244791|NCT03075722|Experimental|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
11244792|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
11244793|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
11244794|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
11244795|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
11244796|NCT03075696|Experimental|Part I: Dose Escalation|Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.
11244797|NCT03075696|Experimental|Part II: Dose Escalation|"In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment). The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered.
~Monotherapy, glofitamab as a single agent: ascending doses of glofitamab will be administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined.
~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined.
~Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles."
11244798|NCT03075696|Experimental|Part III: Dose Expansion|"Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered.
~Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II."
11244799|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
11244800|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
11244801|NCT03075670|Experimental|N9-GP|
11244802|NCT03075670|Active Comparator|ALPROLIX®|
11244803|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
11244804|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
11244805|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
11244806|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
11244807|NCT03075644|Experimental|Somapacitan|
11244808|NCT03075644|Active Comparator|Norditropin|
11244809|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
11244810|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
11244811|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
11244812|NCT03075605||Subjects with previous attack|Subjects with previous attack
11244813|NCT03075605||Controls|Controls
11244814|NCT03075592||ERCP candidates|ERCP candidates
11244844|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
11244845|NCT03075371|Active Comparator|intragastric glucose administration|
11244846|NCT03075371|Placebo Comparator|intragastric water administration|
11244815|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11244816|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
11244817|NCT03075527|Experimental|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
11244818|NCT03075514|Active Comparator|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
11244819|NCT03075514|Active Comparator|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
11244820|NCT03075501|Active Comparator|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
11244821|NCT03075501|Other|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
11244822|NCT03075488|Active Comparator|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
11244823|NCT03075488|Experimental|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
11244824|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
11244825|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
11244826|NCT03075462|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
11244827|NCT03075436|Experimental|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
11244828|NCT03075436|Active Comparator|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
11244829|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a flat dose of 240 mg nivolumab biweekly until progression.
11244830|NCT03075423|Active Comparator|Sunitinib|Sunitinib will be administered at a starting dose of 50 mg/die p.o. for 4 weeks on and 2 weeks off per cycle until progression.
11244831|NCT03075410|Experimental|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
11244832|NCT03075410|Placebo Comparator|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
11244847|NCT03075358|Experimental|Lidocaine spray|
11244848|NCT03075358|Sham Comparator|Normal saline spray|
11244849|NCT03075358|No Intervention|No spray|
11244850|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
11244851|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
11244833|NCT03075410|Experimental|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
11244834|NCT03075410|Placebo Comparator|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
11244835|NCT03075410|Experimental|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
11244836|NCT03075410|Placebo Comparator|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
11244837|NCT03075410|Experimental|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
11244838|NCT03075410|Placebo Comparator|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
11244839|NCT03075410|Experimental|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
11244840|NCT03075410|Placebo Comparator|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
11244841|NCT03075410|Experimental|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
11244842|NCT03075410|Placebo Comparator|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
11244853|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
11244854|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
11244855|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
11244856|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
11244857|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
11244858|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
11244859|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
11244860|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
11244861|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
11244862|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
11244863|NCT03075254|Active Comparator|Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
11244864|NCT03075254|Experimental|Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
11244865|NCT03075254|Experimental|Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
11244866|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
11244867|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
11244868|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
11244869|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
11244870|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
11244871|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.
~Diet registration and testing at baseline, discharge and follow-up."
11244872|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.
~Diet registration and testing at baseline, discharge and follow-up."
11244873|NCT03075176|Active Comparator|Wavefront optimized LASIK|
11244874|NCT03075176|Active Comparator|Wavefront optimized Photorefractive Keratectomy|
11244875|NCT03075176|Active Comparator|Topography-guided LASIK|
11244876|NCT03075176|Active Comparator|Topography-guided Photorefractive Keratectomy|
11244877|NCT03075163|Experimental|Acupressure|Manual pressure will be applied on the wrists bilaterally.
11244878|NCT03075163|Active Comparator|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
11244879|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
11244880|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
11244881|NCT03075124|Experimental|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
11244882|NCT03075124|No Intervention|Control group|Guideline-driven standard medical treatment
11244883|NCT03075098|Experimental|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
11244884|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
11244885|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
11244886|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered
~A hippocampal sparing approach will be used when possible
~Dose will be 30 Gy in 10 fractions"
11244887|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered
~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
11244913|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
11244888|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
11244889|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
11244890|NCT03075046|Experimental|blue LED 405 nm in vulvovaginal candidiasis|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session. This part of the study will see if there is fungicidal effect of the blue led 405 nm
11244891|NCT03075046|Experimental|blue LED 405 nm in healthy women|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.This part of the study will see the security and the effects of the blue led 405 nm in healthy vaginal microflora
11244892|NCT03075046|No Intervention|Sociodemographic data of women with vulvovaginal candidiasis|The women will answer some questions of the anamnesis as: Age, weight, height, form of intimate hygiene, and others to evaluate possible correlations of these data with the presence of vulvovaginal candidiasis
11244893|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
11244894|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
11244895|NCT03075020|Active Comparator|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
11244896|NCT03075020|Placebo Comparator|Air|
11244897|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
11244898|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
11244899|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
11244900|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
11244901|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.
~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.
~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
11244902|NCT03074968|Placebo Comparator|control|normal saline
11244903|NCT03074968|Active Comparator|benzydamine hydrochloride|Benzydamine Hydrochloride
11244904|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position
~Apply elastic bandages to both legs without tension.
~Maintain supine position after injecting propofol.
~After 3 minutes from propofol injection, remove elastic bandages
~induction using propofol 2mg/kg
~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg
~intubate patient between 3 and 4 minutes after propofol injection
~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection
~phenylephrine injection if hypotension develops"
11244905|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position
~Apply elastic bandages to both legs without tension.
~After injecting propofol, apply Trendelenburg position ( 10 degree )
~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.
~induction using propofol 2mg/kg
~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg
~intubate patient between 3 and 4 minutes after propofol injection
~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection
~phenylephrine injection if hypotension develops"
11244906|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position
~Apply elastic bandages to both legs with tension.
~After injecting propofol, apply Trendelenburg position ( 10 degree )
~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.
~induction using propofol 2mg/kg
~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg
~intubate patient between 3 and 4 minutes after propofol injection
~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection
~phenylephrine injection if hypotension develops"
11244907|NCT03074942|Experimental|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
11244908|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
11244909|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
11244910|NCT03074916||DIP arthroplasty|
11244911|NCT03074916||DIP arthrodesis|
11244912|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
11244914|NCT03074890|Experimental|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
11244915|NCT03074890|No Intervention|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
11244916|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
11244917|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
11244918|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
11244919|NCT03074864|Experimental|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
11244920|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
11244921|NCT03074851|Other|informational intervention|to give 1 month informational intervention
11244922|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
11244923|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
11244924|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
11244925|NCT03074812|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation where current will be reduced to zero after standardized ramp up to 2 mA
11244926|NCT03074812|Experimental|Active tDCS|Transcranial direct current stimulation according to protocol maintained for 30 minutes after ramping up to 2 mA
11244927|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
11244928|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
11244929|NCT03074786|Experimental|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
11244930|NCT03074786|Experimental|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
11244931|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
11244932|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
11244933|NCT03074760||Contaminated acequias|
11244934|NCT03074760||Non-contaminated acequias|
11244935|NCT03074734|Other|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
11244936|NCT03074721|Other|PCI with PCI Suite Software|
11244937|NCT03074721|Other|conventional PCI|
11244938|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
11244939|NCT03074695|Experimental|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
11244940|NCT03074695|Experimental|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
11244941|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
11244942|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
11244943|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
11244972|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
11244973|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
11244974|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
11245365|NCT03071679|Placebo Comparator|Placebo|Vehicle
11244944|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
11244945|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
11244946|NCT03074656|Experimental|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
11244947|NCT03074656|Active Comparator|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
11244948|NCT03074643|Placebo Comparator|RecProt|Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
11244949|NCT03074643|Active Comparator|6-mon HiProt|Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
11244950|NCT03074643|Active Comparator|18-mon HiProt|"Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.
~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
11244951|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
11244952|NCT03074617|Experimental|LTE field|
11244953|NCT03074617|Sham Comparator|sham field|
11244954|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
11244955|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
11244956|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
11244957|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
11244958|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
11244959|NCT03074578|Experimental|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
11244960|NCT03074578|Sham Comparator|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
11244961|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
11244962|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
11244963|NCT03074552|Experimental|Probiotics|The probiotic preparation [ LactoLevure] will consist a combination of four probiotics.
11244964|NCT03074552|Placebo Comparator|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
11244965|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.
~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
11244966|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.
~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
11244967|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.
~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
11244968|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
11244969|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
11244970|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
11244971|NCT03074513|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11245077|NCT03073772|Active Comparator|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
11244975|NCT03074474|Other|OviTex Permanent 1S|All subjects included in this post-market study will have a ventral hernia repaired with OviTex Permanent 1S reinforced bioscaffold.
11244976|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
11244977|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
11244978|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
11244979|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
11244980|NCT03074435|No Intervention|Control|No intervention
11244981|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
11244982|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
11244983|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
11244984|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
11244985|NCT03074422|Experimental|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
11244986|NCT03074422|No Intervention|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
11244987|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
11244988|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
11244989|NCT03074396|Other|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
11244990|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
11244991|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
11244992|NCT03074344|Experimental|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
11244993|NCT03074344|Active Comparator|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
11244994|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11244995|NCT03074318|Experimental|Treatment (avelumab, trabectedin)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
11244996|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.
~Residual stenosis after lesion preparation : %DS <20%
~Delivery time : < 30 seconds
~Total inflation time : > at least 1 minute
~Previous BVS : DEB diameter ratio : > 1.0:1
~Maximum inflation pressure : at least above nominal pressure of DEB"
11244997|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
11244998|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
11244999|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
11245000|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
11245001|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
11245002|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
11245003|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.
~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
11245004|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.
~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
11245005|NCT03074240|Active Comparator|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
11245006|NCT03074240|Active Comparator|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
11245007|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
11245008|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
11245009|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
11245010|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
11245011|NCT03074188||pre-dialysis patients|
11245012|NCT03074188||end stage renal disease|
11245013|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
11245014|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
11245015|NCT03074162|Experimental|Diclofenac Sodium (A)|
11245016|NCT03074162|Experimental|Diclofenac & Capsaicin (B)|
11245017|NCT03074162|Active Comparator|Diclofenac Sodium Topical Gel|
11245018|NCT03074149||Idiopathic Pulmonary Disease patients|IPF patients/ only one group
11245019|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
11245020|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
11245021|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
11245022|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
11245023|NCT03074110|Active Comparator|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
11245024|NCT03074110|No Intervention|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
11245025|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
11245026|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
11245027|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
11245028|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
11245029|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
11245030|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
11245031|NCT03074045|Experimental|Test|LCS16 (Low-dose LNG IUS)
11245032|NCT03074045|Active Comparator|Reference|COC (Yarina)
11245033|NCT03074032|Experimental|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
11245034|NCT03074032|Experimental|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
11245035|NCT03074032|Experimental|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
11245036|NCT03074032|Experimental|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
11245037|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
11245038|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
11245039|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
11245040|NCT03074006|Experimental|low dose|
11245041|NCT03074006|Experimental|high dose|
11245042|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
11245043|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
11245044|NCT03073980|Experimental|Group 1: IV acetaminophen/PO placebo|In the pre-op suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
11245208|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
11245045|NCT03073980|Active Comparator|Group 2: IV placebo/PO acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
11245046|NCT03073980|Placebo Comparator|Group 3: Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
11245047|NCT03073967|Experimental|Part A, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) over 4 weeks
11245048|NCT03073967|Active Comparator|Part A, Foscarnet|iv solution, 40 mg/kg tid or 60mg/kg bid.
11245049|NCT03073967|Experimental|Part B, Pritelivir|Oral tablets, 100mg/day (400mg loading dose on day 1) over 4 weeks
11245050|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
11245051|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
11245052|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
11245053|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
11245054|NCT03073928|Active Comparator|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).
~We will administer injection of saline similar to experimental group to blind the patient"
11245055|NCT03073928|Experimental|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
11245056|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
11245057|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
11245058|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
11245059|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
11245060|NCT03073876|Experimental|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
11245061|NCT03073876|Placebo Comparator|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.
~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
11245062|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
11245063|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
11245064|NCT03073850|Experimental|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
11245065|NCT03073850|Experimental|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
11245066|NCT03073850|Active Comparator|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
11245067|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
11245068|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
11245069|NCT03073811|Experimental|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and four weeks after surgery.
11245070|NCT03073811|Active Comparator|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian and one oral nutrition supplement per day for two weeks before surgery.
11245071|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
11245072|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
11245073|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
11245074|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
11245075|NCT03073772|No Intervention|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
11245076|NCT03073772|Active Comparator|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
11245078|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
11245079|NCT03073759|Sham Comparator|Sham|Patients will receive a sham.
11245080|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
11245081|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
11245082|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
11245083|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
11245084|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
11245085|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
11245086|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
11245087|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
11245088|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
11245089|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
11245090|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
11245091|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
11245092|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
11245093|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
11245094|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
11245095|NCT03073642|Active Comparator|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.
~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
11245096|NCT03073642|Experimental|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.
~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.
~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
11245097|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
11245098|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
11245099|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
11245100|NCT03073603|Active Comparator|Drug Continuation Arm|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
11245101|NCT03073603|Experimental|Drug Discontinuation Arm|Participants who will discontinue their Disease Modifying Therapies (DMTs). No other changes to their treatment occur. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
11245102|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
11245103|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
11245104|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
11245105|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
11245106|NCT03073577|Experimental|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
11245107|NCT03073564|No Intervention|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
11245108|NCT03073564|Experimental|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
11245109|NCT03073564|Experimental|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
11245110|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
11245111|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
11245112|NCT03073525|Other|Part 1: Vigil + Atezo|Part 1 is a safety run-in cohort. Vigil immunotherapy will be administered at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. The initial dose is to be administered over one hour and if well tolerated, subsequent infusions may be administered over 30 minutes. Vigil should be administered first, followed 30 minutes later by atezolizumab.
11245113|NCT03073525|Experimental|Part 2: Vigil then Vigil + Atezo|"Part 2 is a randomized, open label intra-patient crossover study of Vigil, the checkpoint inhibitor Atezolizumab and the combination of the two agents.
~Vigil immunotherapy will be administered at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses for 2 cycles (1 cycle = 21 days)."
11245114|NCT03073525|Active Comparator|Part 2: Atezo then Vigil + Atezo|"Part 2 is a randomized, open label intra-patient crossover study of Vigil, the checkpoint inhibitor Atezolizumab and the combination of the two agents
~Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks for 2 cycles (1 cycle = 21 days). The initial dose is to be administered over one hour and if well tolerated, subsequent infusions may be administered over 30 minutes."
11245115|NCT03073525|Other|Part 3: Atezo Only|Part 3 is an expansion cohort. Once all Vigil doses have been exhausted, patients whose disease is stable or responding may continue Atezolizumab, only if pre-approved by Sponsor. Atezolizumab will be administered at a dose of 1200 mg as an intravenous infusion every 3 weeks until disease progression.
11245116|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
11245117|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
11245118|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
11245119|NCT03073486|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
11245120|NCT03073486|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
11245121|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
11245122|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
11245123|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
11245124|NCT03073460|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
11245125|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
11245126|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
11245127|NCT03073408|Active Comparator|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
11245128|NCT03073408|Experimental|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
11245129|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
11245130|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
11245131|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
11245132|NCT03073369|Placebo Comparator|Placebo|
11245133|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
11245134|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
11245135|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
11245136|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
11245209|NCT03072836|Experimental|CD alone|
11245210|NCT03072836|Experimental|SPA alone|
11245211|NCT03072836|Experimental|CD + SPA|
11245137|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
11245138|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
11245139|NCT03073330|Experimental|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
11245140|NCT03073330|Active Comparator|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
11245141|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
11245142|NCT03073317|No Intervention|CONTROL|Usual clinic control
11245143|NCT03073304|Active Comparator|Control|Erythrocyte based prime solution
11245144|NCT03073304|Experimental|Intervention|Crystalloid based prime solution
11245145|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
11245146|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
11245147|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
11245148|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
11245149|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
11245150|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
11245151|NCT03073252|Experimental|Normal Protein|Consumption of normal protein (NP) meal
11245152|NCT03073252|Experimental|High Protein|Consumption of high protein (HP) meal
11245153|NCT03073239||ALS epidemiological characterization|epidemiological characterization
11245154|NCT03073239||Genetic findings in ALS patients|genética characterization
11245155|NCT03073226|Experimental|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
11245156|NCT03073226|Experimental|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
11245157|NCT03073226|Experimental|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
11245158|NCT03073226|Experimental|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
11245159|NCT03073213|Experimental|Ixekizumab single dose|Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
11245160|NCT03073213|Experimental|Ixekizumab Multiple Regimen 1 (80mg Q2W)|Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
11245161|NCT03073213|Experimental|Ixekizumab Multiple Regimen 2 (80mg Q4W)|Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
11245162|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
11245163|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
11245164|NCT03073200|Experimental|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
11245165|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
11245166|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
11245167|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
11245168|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
11245169|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
11245170|NCT03073148|Experimental|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
11245171|NCT03073148|Placebo Comparator|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
11245419|NCT03071263|Experimental|Group 2 - Placebo|spironolactone + blinded placebo
11245172|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
11245173|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
11245174|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
11245175|NCT03073096|Other|Intervention arm|LVA at time of nodal dissection
11245176|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
11245177|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
11245178|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
11245179|NCT03073070|Experimental|Biotin labeled RBCs in 4-10 year old diabetes children|Biotin labeled autologous RBCs will be transfused to the subjects
11245180|NCT03073070|Experimental|Biotin labeled RBCs in 10-18 year old diabetes children|Biotin labeled autologous red blood cells will be transfused to the subjects
11245181|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
11245182|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
11245183|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
11245184|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
11245185|NCT03073031|Active Comparator|Intervention|Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
11245186|NCT03073031|No Intervention|Control|Patients have their side effects monitored by a physician every 3 weeks (control)
11245187|NCT03073018|Experimental|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
11245188|NCT03073018|Active Comparator|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
11245189|NCT03073018|Active Comparator|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
11245190|NCT03073018|Placebo Comparator|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
11245191|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
11245192|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
11245193|NCT03072992|Active Comparator|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
11245194|NCT03072992|Placebo Comparator|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
11245195|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
11245196|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
11245197|NCT03072940||Patients with idiopathic RBD|
11245198|NCT03072940||Healthy volunteers|
11245199|NCT03072927||MILD|All Medicare patients treated with MILD as reported via CPT® Code 0275T (or successor code(s)).
11245200|NCT03072927||Interspinous Process Decompression|All Medicare patients treated with interspinous process decompression (CPT Code 22869 or 22870, or successor code(s)) for the treatment of LSS with NC.
11245201|NCT03072914|No Intervention|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
11245202|NCT03072914|Active Comparator|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
11245203|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
11245204|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
11245205|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
11245206|NCT03072875|Experimental|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
11245207|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
11245463|NCT03070951|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back|
11245212|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
11245213|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
11245214|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
11245215|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
11245216|NCT03072784|Active Comparator|group S|short time <90 m aortic cross clamping
11245217|NCT03072784|Active Comparator|group L|> 90 minutes aortic cross clamping
11245218|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:
~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7
~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)
~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)
~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2
~Auto-SCT will take place on Day 0 as per institutional guidelines
~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
11245219|NCT03072758|Experimental|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
11245220|NCT03072758|No Intervention|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
11245221|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
11245222|NCT03072732|Other|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
11245223|NCT03072732|Other|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
11245224|NCT03072719|Experimental|Dentifrice containing stannous fluoride|Toothpaste
11245225|NCT03072719|Active Comparator|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
11245226|NCT03072706|Active Comparator|Standard group|2D X-ray templating technology
11245227|NCT03072706|Experimental|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
11245228|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
11245229|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
11245230|NCT03072693|No Intervention|Group 3|Patients will receive usual care.
11245231|NCT03072680|Experimental|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
11245232|NCT03072680|Experimental|BPS FUT|Participants practice BPS FUT during the two weeks.
11245233|NCT03072680|Active Comparator|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
11245234|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
11245235|NCT03072641|No Intervention|Control|
11245236|NCT03072628|Experimental|Nicotine: use e-cig with nicotine|One time exposure to e-cig with nicotine
11245237|NCT03072628|Experimental|no nicotine: use e-cig without nicotine|One time exposure to e-cig without nicotine
11245238|NCT03072628|Experimental|Nicotine inhaler: use a nictoine inhaler|One time exposure to nicotine inhaler
11245239|NCT03072628|Sham Comparator|Sham control|Use an empty e-cigarette
11245240|NCT03072615||1|receiving TE before and 30 min after TIPS
11245241|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
11245242|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
11245243|NCT03072602|Active Comparator|Whites|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
11245244|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
11245245|NCT03072550|Experimental|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
11245246|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
11245247|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
11245248|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
11245249|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
11245250|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
11245251|NCT03072472|Experimental|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
11245252|NCT03072472|No Intervention|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
11245253|NCT03072446|Experimental|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
11245254|NCT03072433|Active Comparator|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
11245255|NCT03072433|Experimental|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
11245256|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
11245257|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
11245258|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
11245259|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
11245260|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
11245261|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
11245262|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
11245263|NCT03072394|Experimental|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
11245264|NCT03072394|Active Comparator|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
11245265|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
11245266|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
11245267|NCT03072368|Active Comparator|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
11245268|NCT03072368|Active Comparator|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
11245269|NCT03072368|Active Comparator|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
11245270|NCT03072368|Active Comparator|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
11245271|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
11245272|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
11245273|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
11245274|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
11245275|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
11245276|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
11245277|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
11245278|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
11245279|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
11245280|NCT03072290|Experimental|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
11245281|NCT03072290|Active Comparator|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
11245282|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
11245283|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
11245320|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
11245284|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
11245285|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
11245286|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
11245287|NCT03072251||Anyone|Any individual may complete this survey
11245288|NCT03072238|Experimental|Ipatasertib + Abiraterone|Ipatasertib and abiraterone, administered orally, in 28-day cycles
11245289|NCT03072238|Active Comparator|Placebo + Abiraterone|Placebo plus abiraterone, administered orally, in 28-day cycles
11245290|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
11245291|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
11245292|NCT03072212||HIV infected with stroke|No intervention will be administered
11245293|NCT03072212||HIV uninfected with stroke|No intervention will be administered
11245294|NCT03072199|Experimental|Rituximab|
11245295|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG
~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
11245296|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG
~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
11245297|NCT03072160|Experimental|1/pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for two years.
11245298|NCT03072147|Active Comparator|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
11245299|NCT03072147|Placebo Comparator|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
11245300|NCT03072134|Experimental|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
11245301|NCT03072134|Experimental|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
11245302|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
11245303|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
11245304|NCT03072108|Experimental|Bonolive|
11245305|NCT03072108|Placebo Comparator|Placebo|
11245306|NCT03072095|Experimental|Text-only|Text-only outreach
11245307|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
11245308|NCT03072082|Experimental|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
11245309|NCT03072082|Placebo Comparator|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
11245310|NCT03072056|Experimental|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
11245311|NCT03072056|Experimental|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
11245312|NCT03072056|Experimental|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
11245313|NCT03072056|Experimental|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
11245314|NCT03072056|Experimental|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
11245315|NCT03072056|Experimental|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
11245316|NCT03072043|Experimental|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
11245317|NCT03072043|Experimental|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
11245318|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
11245319|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
11245321|NCT03072004|Sham Comparator|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
11245322|NCT03072004|Experimental|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
11245323|NCT03071991||Study group|Preincisional bupivacain will be used
11245324|NCT03071991||Control group|No preincisional anesthetic drug will be used
11245325|NCT03071978|Experimental|LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
11245326|NCT03071978|Active Comparator|BV pacing|Bi-Ventricular pacing
11245327|NCT03071965|Experimental|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
11245328|NCT03071965|Experimental|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
11245329|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
11245330|NCT03071926|Experimental|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
11245331|NCT03071913||Ancillary-correlative (biospecimen collection)|As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.
11245332|NCT03071900|Experimental|SCCHN|squamous cell carcinoma of the head and neck
11245333|NCT03071900|Experimental|Control|health volunteers
11245334|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
11245335|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose
~Twice daily for two consecutive days out of every seven days
~Cycles will last 28 days"
11245336|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
11245337|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
11245338|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
11245339|NCT03071822|Experimental|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
11245340|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
11245341|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
11245342|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
11245343|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
11245344|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
11245345|NCT03071783|No Intervention|conventional|conventional handle
11245346|NCT03071770|Experimental|ivosidenib (AG-120)|
11245347|NCT03071757|Experimental|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
11245348|NCT03071757|Experimental|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
11245349|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
11245350|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
11245351|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
11245352|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).
~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
11245353|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
11245354|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
11245355|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
11245366|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
11245367|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
11245368|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
11245369|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
11245370|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
11245371|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
11245372|NCT03071614|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
11245373|NCT03071614|Experimental|News without spin|News items reporting results of animal studies without spin.
11245374|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
11245375|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
11245376|NCT03071588|Active Comparator|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
11245377|NCT03071588|Experimental|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
11245378|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
11245379|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
11245380|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
11245381|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
11245382|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
11245383|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
11245384|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.
~Urine output will be recorded hourly for 6 hours."
11245385|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
11245386|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
11245387|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
11245388|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
11245389|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
11245390|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
11245391|NCT03071432|Active Comparator|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
11245420|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
11245421|NCT03071224|Experimental|[18F]MNI-946|To evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
11245422|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
11245392|NCT03071432|Active Comparator|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
11245393|NCT03071432|Active Comparator|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
11245394|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
11245395|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
11245396|NCT03071406|Active Comparator|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
11245397|NCT03071406|Active Comparator|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
11245398|NCT03071393|Active Comparator|Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen.
11245399|NCT03071393|Sham Comparator|Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo a sham placebo protocol with normal oxygen air (21% inspired oxygen).
11245400|NCT03071380|Experimental|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
11245401|NCT03071380|Active Comparator|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
11245402|NCT03071367|Experimental|Clinical Simulation|
11245403|NCT03071367|No Intervention|Classical Learning|
11245404|NCT03071354|Experimental|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.
~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
11245405|NCT03071354|Active Comparator|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.
~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
11245406|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
11245407|NCT03071328|Experimental|Bone metastatic site|
11245408|NCT03071328|Experimental|Liver metastatic site|
11245409|NCT03071328|Experimental|Lymph node metastatic site|
11245410|NCT03071328|Experimental|Soft tissue metastatic site|
11245411|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
11245412|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
11245413|NCT03071302|Active Comparator|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.
~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus
~Group C Keratoconus / Keratoconus"
11245414|NCT03071302|Placebo Comparator|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.
~Group B Sound Cornea / Sound Cornea"
11245415|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
11245416|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
11245417|NCT03071276|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
11245418|NCT03071263|Experimental|Group 1 - Patiromer|spironolactone + blinded patiromer
11245423|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
11245424|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
11245425|NCT03071198|Experimental|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
11245426|NCT03071198|Experimental|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
11245427|NCT03071198|Active Comparator|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
11245428|NCT03071185|Experimental|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
11245429|NCT03071185|No Intervention|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
11245430|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
11245431|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
11245432|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
11245433|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
11245434|NCT03071120|Experimental|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
11245435|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
11245436|NCT03071107|No Intervention|Control arm|Standard of care
11245437|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab|
11245438|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
11245439|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
11245440|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
11245441|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
11245442|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
11245443|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
11245444|NCT03071068|Experimental|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
11245445|NCT03071068|Experimental|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
11245446|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
11245447|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
11245448|NCT03071042|Experimental|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
11245449|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
11245450|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
11245451|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
11245452|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
11245453|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
11245454|NCT03070990|Experimental|Arm A: Enfortumab vedotin 1.0 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
11245455|NCT03070990|Experimental|Arm B: Enfortumab vedotin 1.25 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
11245456|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
11245457|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
11245458|NCT03070964|Experimental|Plitidepsin|
11245468|NCT03070899|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back|
11245469|NCT03070886|Active Comparator|Arm I (androgen deprivation therapy, EBRT)|Patients receive androgen deprivation therapy comprising leuprolide acetate, goserelin acetate, bicalutamide, flutamide, or nilutamide for 6 months. Beginning 8 weeks after the start of androgen deprivation therapy, patients receive EBRT for 7.5 weeks.
11245470|NCT03070886|Experimental|Arm II (androgen deprivation therapy, EBRT, docetaxel)|Patients receive androgen deprivation therapy and EBRT as in Arm I. Within 4-6 weeks after completion of radiation therapy, patients receive docetaxel IV on day 1 of every 21 days for 6 courses in the absence of disease progression or unexpected toxicity.
11245471|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
11245472|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
11245473|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
11245474|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
11245475|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
11245476|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
11245477|NCT03070834|Experimental|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
11245478|NCT03070834|No Intervention|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
11245479|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
11245480|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
11245481|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
11245482|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
11245483|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
11245484|NCT03070782|Experimental|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
11245485|NCT03070782|Experimental|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
11245486|NCT03070782|Experimental|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
11245487|NCT03070782|Experimental|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
11245488|NCT03070782|Experimental|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
11245489|NCT03070782|Placebo Comparator|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
11245490|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
11245491|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
11245492|NCT03070756|Other|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.
~Interventions:
~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
11245493|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
11245494|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
11245495|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.
~Placebo is used to control the administration effect."
11245496|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
11245497|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
11245498|NCT03070704||Insulin degludec /liraglutide|
11245499|NCT03070691|Active Comparator|LDE225 0.75% cream|
11245500|NCT03070691|Placebo Comparator|Vehicle|
11245501|NCT03070678|Experimental|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
11245502|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
11245503|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
11245722|NCT03069118|Placebo Comparator|Control|A list of online resources/waitlist
11245504|NCT03070652|Experimental|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
11245505|NCT03070652|Experimental|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
11245506|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
11245507|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
11245508|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
11245509|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
11245510|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
11245511|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
11245512|NCT03070600|Active Comparator|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
11245513|NCT03070600|Experimental|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
11245514|NCT03070587|Experimental|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
11245515|NCT03070587|No Intervention|Wait list Control|These participants will not be given an intervention until after they have completed the study.
11245516|NCT03070574|Experimental|2400 MG mesalamine (5-ASA) total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
11245517|NCT03070574|Experimental|1200 MG mesalamine (5-ASA) total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
11245518|NCT03070574|Placebo Comparator|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
11245519|NCT03070561|Experimental|Sublingual film with peanut extract|
11245520|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
11245521|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
11245522|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
11245523|NCT03070522|Active Comparator|Placebo|Placebo
11245524|NCT03070522|Active Comparator|Treatment|Prednisone
11245525|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
11245526|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
11245527|NCT03070496|Experimental|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :
~an additional blood sampling at 6 months
~an additional electrocardiogram (ECG) at 6 months
~Magnetic Resonance Imaging (MRI)
~Quality of life questionnaire"
11245528|NCT03070483|Experimental|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
11245529|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
11245530|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
11245531|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
11245532|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
11245533|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
11245534|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
11245535|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
11245536|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
11245537|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.
~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
11245538|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.
~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
11245539|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
11245540|NCT03070418|Experimental|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
11245541|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
11245542|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
11245543|NCT03070392|Experimental|IMCgp100|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
11245544|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine
~1 of 3 Investigator's Choice options: Systemic Ipilimumab
~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
11245545|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
11245546|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
11245547|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:
~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)
~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).
~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.
~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
11245548|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
11245549|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
11245550|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
11245551|NCT03070327|Experimental|BCMA Targeted CAR T Cells with or without Lenalidomide|
11245552|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
11245553|NCT03070301|Experimental|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
11245554|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
11245555|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
11245556|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
11245557|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
11245558|NCT03070262|Experimental|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
11245559|NCT03070262|Placebo Comparator|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
11245560|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
11245561|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
11245562|NCT03070223||Experimental: Pitavastatin|Participants who receive pitavastatin in the main study REPRIEVE (A5332).
11245563|NCT03070223||Placebo Comparator: Placebo|Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
11245564|NCT03070210|Other|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
11245565|NCT03070210|Active Comparator|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia <1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
11245566|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
11245567|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
11245568|NCT03070184|Experimental|African-American|Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
11245608|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
11245609|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
11245569|NCT03070184|Active Comparator|Caucasians (White)|Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
11245570|NCT03070171|Experimental|Dabigatran Etexilate Capsule|
11245571|NCT03070171|Experimental|Dabigatran Etexilate Tablet|
11245572|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
11245573|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
11245574|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training
~150 minute moderate aerobic activities, such as brisk walking
~Strength training 3 days /week
~One on one sessions with exercise physiologist
~Optional group sessions"
11245575|NCT03070145|No Intervention|Usual Care|Usual Care provided
11245576|NCT03070132|Experimental|BIIB074|Optimized oral dose three times daily (TID)
11245577|NCT03070132|Experimental|Placebo|Administered orally TID
11245578|NCT03070119|Experimental|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
11245579|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
11245580|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
11245581|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
11245582|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
11245583|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
11245584|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
11245585|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
11245586|NCT03070054|No Intervention|Control|non-LIA group prior to surgery
11245587|NCT03070054|Experimental|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
11245588|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
11245589|NCT03070028|Experimental|Phenol|crystallised phenol application
11245590|NCT03070028|Experimental|platelet rich plasma|PRP application
11245591|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
11245592|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
11245593|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
11245594|NCT03069989|Experimental|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11245595|NCT03069989|Placebo Comparator|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11245596|NCT03069989|Experimental|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11245597|NCT03069989|Placebo Comparator|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11245598|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
11245599|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
11245600|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
11245601|NCT03069950|Experimental|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
11245602|NCT03069950|Experimental|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
11245603|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
11245604|NCT03069924|Active Comparator|No NRT - No Messaging|Brief counseling, but no NRT and no gain-framed messaging.
11245605|NCT03069924|Active Comparator|NRT - No Messaging|Brief counseling plus NRT but no gain-framed messaging.
11245606|NCT03069924|Active Comparator|No NRT - Messaging|Brief counseling plus gain-framed messaging but no NRT.
11245607|NCT03069924|Experimental|NRT plus Messaging|Brief counseling plus NRT and gain-framed messaging.
11245610|NCT03069898|Experimental|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
11245611|NCT03069898|No Intervention|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
11245612|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
11245613|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
11245614|NCT03069872|Experimental|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
11245615|NCT03069859|Experimental|TXA (1g)|For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
11245616|NCT03069859|Placebo Comparator|Placebo (0.9% saline)|For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
11245617|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
11245618|NCT03069833|Experimental|Computer-aided diagnosis|
11245619|NCT03069833|No Intervention|traditional diagnosis|
11245620|NCT03069820|Experimental|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
11245621|NCT03069807|Experimental|Intervention|Participants with LTBI will be treated in the Community/Primary Care.
11245622|NCT03069807|Active Comparator|Control|Participants with LTBI will be treated in the Hospital/TB Clinic
11245623|NCT03069794|Other|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
11245624|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
11245625|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
11245626|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
11245627|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
11245628|NCT03069742|Experimental|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
11245629|NCT03069742|No Intervention|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
11245630|NCT03069729||Control group|non-diabetic; no intervention
11245631|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
11245632|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
11245633|NCT03069716|Experimental|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
11245634|NCT03069716|Other|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
11245635|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
11245636|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
11245637|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
11245638|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
11245639|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
11245640|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
11245641|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
11245642|NCT03069677|Active Comparator|Music group|research-selected music
11245643|NCT03069677|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
11245644|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
11245645|NCT03069664|No Intervention|Control group|
11245646|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.
~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
11245647|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
11245648|NCT03069638|Experimental|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
11245719|NCT03069131|Experimental|Active rifaximin|
11245649|NCT03069638|Active Comparator|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
11245650|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
11245651|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
11245652|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
11245653|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
11245654|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
11245655|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
11245656|NCT03069599||10 resection only|patients undergoing surgical resection only
11245657|NCT03069586|Other|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
11245658|NCT03069586|Active Comparator|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
11245659|NCT03069573||Eosinophilic Esophagitis - EoE|Diagnosis of pediatric EoE under current guidelines.
11245660|NCT03069573||Gastroesophageal reflux disease - GERD|Diagnosis of pediatric GERD under current guidelines.
11245661|NCT03069573||Control|Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.
11245662|NCT03069560|Experimental|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
11245663|NCT03069547|Active Comparator|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
11245664|NCT03069547|Active Comparator|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
11245665|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
11245666|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
11245667|NCT03069521|Other|EndoArt®|EndoArt® Artificial Endothelial Layer
11245668|NCT03069508|Experimental|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
11245669|NCT03069508|Experimental|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
11245670|NCT03069508|Experimental|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
11245671|NCT03069508|Experimental|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
11245672|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
11245673|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
11245674|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
11245675|NCT03069482|Experimental|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
11245676|NCT03069482|Active Comparator|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
11245677|NCT03069469|Other|Experimental Treatment|"Dose Escalation Phase: Increasing doses of DCC-3014 beginning at 10 mg QD for 28 day cycles until disease progression or unacceptable toxicity.
~Expansion Phase: Dosing of different patient cohorts at the dose level determined from the Dose Escalation Phase of the study."
11245678|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
11245679|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
11245680|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
11245681|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
11245720|NCT03069131|Placebo Comparator|Rifaximin placebo|
11245721|NCT03069118|Experimental|Treatment|Three-month intervention on the online Workit Health platform
11245682|NCT03069417|Experimental|Intervention: INSPireD|"This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aims to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content is based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression."
11245683|NCT03069417|Other|Wait-list control|The Wait-list control group will be referred to standard of care counseling services, and will start the intervention upon completion of the first experimental group. They will receive the intervention with the next experimental group cycle.
11245684|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
11245685|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
11245686|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
11245687|NCT03069365|Experimental|GLE/PIB for 8 weeks|HCV genotype 1,2,4-6 non-cirrhotic, treatment-naive or treatment-experienced; genotype 3 non-cirrhotic, treatment-naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 8 weeks
11245688|NCT03069365|Experimental|GLE/PIB for 12 weeks|HCV genotype 1,2,4-6 compensated cirrhosis, treatment-naive or treatment-experienced; genotype 3 compensated cirrhosis, treatment- naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 12 weeks
11245689|NCT03069365|Experimental|GLE/PIB for 16 weeks|HCV genotype 3 non-cirrhotic or with compensated cirrhosis, treatment-experienced participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 16 weeks
11245690|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
11245691|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
11245692|NCT03069339|Experimental|Carvedilol+EVL|
11245693|NCT03069339|Experimental|Carvedilol|
11245694|NCT03069339|Active Comparator|EVL|
11245695|NCT03069326|Experimental|Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
11245696|NCT03069313|Experimental|Arm I|Oral Vitamin B12
11245697|NCT03069300|Experimental|prednisolone+NAC|40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
11245698|NCT03069300|No Intervention|prednisolone|40mg prednisolone for 28 days
11245699|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
11245700|NCT03069274|Other|Control|Only general nutritional recommendations were given.
11245701|NCT03069274|Experimental|Intervention|General nutritional recommendations, change their drinking habits.
11245702|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
11245703|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
11245704|NCT03069248|Experimental|treatment arm|"Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.
~."
11245705|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
11245706|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
11245707|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
11245708|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
11245709|NCT03069222||Control|age and gender matched with patient enrolled
11245710|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
11245711|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
11245712|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
11245713|NCT03069170|Experimental|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
11245714|NCT03069170|Experimental|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
11245715|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
11245716|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
11245717|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
11245718|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
11245723|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
11245724|NCT03069092|Experimental|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
11245725|NCT03069092|Experimental|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
11245726|NCT03069092|Experimental|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
11245727|NCT03069092|No Intervention|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
11245728|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.
~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
11245729|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
11245730|NCT03069040|Experimental|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
11245731|NCT03069040|Active Comparator|radical hysterectomy|The patient recived surgury of radical hysterectomy.
11245732|NCT03069027|Placebo Comparator|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
11245733|NCT03069027|Active Comparator|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
11245734|NCT03069014|Active Comparator|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
11245735|NCT03069014|Active Comparator|800mg LM11A-31-BHS|800mg LM11A-31-BHS
11245736|NCT03069014|Placebo Comparator|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
11245737|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.
~Simeprevir 150 mg orally once-daily.
~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
11245738|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.
~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).
~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
11245739|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
11245740|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
11245741|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
11245742|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
11245743|NCT03068962|Experimental|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
11245744|NCT03068962|Experimental|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
11245745|NCT03068962|Experimental|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
11245746|NCT03068949|Active Comparator|FluBlok|
11245747|NCT03068949|Active Comparator|Fluzone|
11245748|NCT03068949|Active Comparator|FluCelVax|
11245749|NCT03068936|Experimental|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
11245750|NCT03068936|Other|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
11245751|NCT03068910|Experimental|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
11245752|NCT03068910|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
11245753|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
11245754|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
11246001|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
11245755|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
11245756|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.
~All participants receive a brief educational intervention."
11245757|NCT03068884|Sham Comparator|Tdcs sham|
11245758|NCT03068884|Placebo Comparator|Placebo|
11245759|NCT03068884|Experimental|Tdcs cathodal|
11245760|NCT03068884|Experimental|Tyrosine|
11245761|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
11245762|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
11245763|NCT03068858|Experimental|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
11245764|NCT03068858|No Intervention|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
11245765|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
11245766|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
11245767|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.
~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.
~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
11245768|NCT03068819|Experimental|CIML NK cell after T cell DLT|-The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, ara-C, and G-CSF (FLAG) to be started 2 to 4 weeks prior to the CIML NK cell infusion, with Day -1 the day of T cell DLI, and Day 0 denoting the CIML NK cell infusion day. The donor will undergo non-mobilized large volume (20L) leukapheresis on Day -2 or -1, anticipating processing for T cell DLI and NK cell isolation on Day -1.
11245769|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
11245770|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
11245771|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
11245772|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
11245773|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
11245774|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
11245775|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
11245776|NCT03068780|Experimental|Oleogel-S10|
11245777|NCT03068780|Placebo Comparator|Placebo|
11245778|NCT03068767|Experimental|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
11245779|NCT03068767|No Intervention|Control group|Patients without receiving vitamin D supplement
11245780|NCT03068754|Experimental|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.
~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
11245781|NCT03068754|Placebo Comparator|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.
~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
11245782|NCT03068754|Experimental|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
11245783|NCT03068754|Experimental|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
11245784|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
11245785|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
11245786|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
11245787|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
11245788|NCT03068728|Other|All Study Participants|"Participants received hemostatic packing agent in one nasal cavity and no packing in the other.
~Participants were randomized to one of three hemostatic packing agents (Arista, Nexfoam, Nasopore) through sealed envelope, chosen by surgeon prior to placement, with packing agent allocation and sidedness."
11245789|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
11245790|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
11245791|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
11245792|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
11245793|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
11245794|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
11245795|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
11245796|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:
~blood and saliva: at consultations after inclusion in the study
~faeces: day before the surgery
~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
11245797|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:
~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery
~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery
~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
11245798|NCT03068637|Experimental|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
11245799|NCT03068624|Experimental|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.
~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.
~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
11245800|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
11245801|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
11245802|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
11245803|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
11245804|NCT03068585|No Intervention|Control|Control therapy
11245805|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
11245806|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
11245807|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.
~Patient has to be aged ≥ 18
~Patient has to be able to complete questionnaire in French
~Patient must benefit from health insurance
~Patient must sign an informed consent form
~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
11245808|NCT03068546||Participants providing samples|NCI employees agreeing to provide samples for microbiome sample study
11245809|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
11245810|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
11245811|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
11245812|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.
~will be followed with PET MRI"
11245813|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.
~will be followed with PET MRI"
11245814|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
11245815|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
11245816|NCT03068494||Coronary Bifurcation Lesion|
11245817|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
11245818|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
11245819|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
11245820|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
11245821|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
11245822|NCT03068468|Experimental|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
11245823|NCT03068468|Placebo Comparator|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
11245824|NCT03068455|Experimental|nivolumab + ipilimumab|Specified Dose on Specified Days
11245825|NCT03068455|Experimental|nivolumab|Specified Dose on Specified Days
11245826|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
11245827|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
11245828|NCT03068416|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
11245829|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
11245830|NCT03068403|Other|Radiochemotherapy|
11245831|NCT03068390|Experimental|RICHH Intervention|The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads that we provide for all participants. Participants keep the mini-iPads at the end of the study. The program consists of 12 weekly sessions [30-45 minutes] followed by 8 bi-weekly [every other week] booster sessions and 6 monthly booster sessions that will be held at the caregivers' preferred times using a video conferencing program. A cardiac psychiatric advanced practice nurse certified cognitive behavioral therapy will deliver the intervention.
11245832|NCT03068390|Active Comparator|Usual care|The usual care control group will receive an attention placebo intervention in which the caregivers will receive mini-iPads loaded with Caregiver and CVD risk reduction pamphlets in PDF format along with the associated links from the American Heart Association. Because the investigators may identify CVD risk factors in baseline testing in participants who do not know they have them, it would be unethical not to provide at least usual care for these. Thus, all individuals enrolled in the study and in whom the investigators identify CVD risk factors will receive referral to a primary care provider for management of the CVD risk factors identified.
11245833|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
11245834|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
11245835|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
11245836|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
11245837|NCT03068338|Active Comparator|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
11245838|NCT03068338|Experimental|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
11245839|NCT03068325|Experimental|TF-EAT|
11245840|NCT03068312|Experimental|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
11245841|NCT03068312|Experimental|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
11245875|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
11245842|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
11245843|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
11245844|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
11245845|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
11245846|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
11245847|NCT03068273|Experimental|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
11245848|NCT03068273|Experimental|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
11245849|NCT03068260|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.
~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
11245850|NCT03068260|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.
~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
11245851|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
11245852|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
11245853|NCT03068234|Experimental|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
11245854|NCT03068234|Placebo Comparator|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
11245855|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
11245856|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
11245857|NCT03068208|Experimental|MB-PDT|
11245858|NCT03068208|No Intervention|Control|
11245859|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
11245860|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
11245861|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
11245862|NCT03068182|Experimental|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
11245863|NCT03068182|Experimental|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
11245864|NCT03068156|Experimental|excimer laser|
11245865|NCT03068156|No Intervention|Control|
11245866|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
11245867|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.
~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).
~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
11245868|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
11245869|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
11245870|NCT03068078|No Intervention|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
11245871|NCT03068078|Experimental|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
11245872|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
11245873|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
11245874|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
11246002|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
11245876|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
11245877|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
11245878|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
11245879|NCT03068026|Experimental|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
11245880|NCT03068026|Experimental|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
11245881|NCT03068013|Experimental|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
11245882|NCT03068013|Active Comparator|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
11245883|NCT03068000|Experimental|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
11245884|NCT03068000|Active Comparator|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
11245885|NCT03067987|Active Comparator|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
11245886|NCT03067987|Active Comparator|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)
~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
11245887|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
11245888|NCT03067961|Experimental|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
11245889|NCT03067961|Experimental|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
11245890|NCT03067948|Experimental|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
11245891|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
11245892|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
11245893|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
11245894|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
11245895|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.
~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.
~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).
~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
11245896|NCT03067870|Experimental|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
11245897|NCT03067857|Experimental|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
11245898|NCT03067844|Experimental|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
11245899|NCT03067844|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
11245900|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
11245901|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
11245902|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
11245903|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
11245904|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
11245905|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
11245906|NCT03067792|Active Comparator|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
11245907|NCT03067792|Active Comparator|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
11245908|NCT03067779|Other|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.
~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
11245909|NCT03067766|Experimental|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
11245910|NCT03067766|Experimental|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
11245911|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
11245912|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
11245913|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
11245914|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
11245915|NCT03067727|Experimental|Dinoprostone vaginal insert|
11245916|NCT03067727|Placebo Comparator|Placebo|
11245917|NCT03067714|Experimental|Active product: partially hydrolysed formula + synbiotics|
11245918|NCT03067714|Active Comparator|Control product: standard formula (intact protein)|
11245919|NCT03067701|Experimental|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
11245920|NCT03067688|Experimental|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
11245921|NCT03067688|Active Comparator|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
11245922|NCT03067688|Active Comparator|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
11245923|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
11245924|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
11245925|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
11245926|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
11245927|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
11245928|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
11245929|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
11245930|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.
~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
11245969|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
11245970|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
11246225|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
11245931|NCT03067623|Experimental|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
11245932|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
11245933|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
11245934|NCT03067571|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11245935|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to <2 months, children 2 to <12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
11245936|NCT03067558||Consistency evaluation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
11245937|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
11245938|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
11245939|NCT03067532|Experimental|A|
11245940|NCT03067532|Active Comparator|B|
11245941|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
11245942|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
11245943|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
11245944|NCT03067493|Experimental|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, >1) and type of surgery (RFA，hepatectomy).
11245945|NCT03067493|No Intervention|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first year and every 4 months in the second and third year.
11245946|NCT03067480|Experimental|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
11245947|NCT03067480|Experimental|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
11245948|NCT03067467|Active Comparator|Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
11245949|NCT03067467|Active Comparator|Controls|Healthy Control subjects will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI. This will be followed by a Brain MRI with gadolinium-based contrast.
11245950|NCT03067454|Other|conservative group|Treatment with early mobilisation
11245951|NCT03067454|Other|operative group|Treatment with operation
11245952|NCT03067441|Experimental|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
11245953|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
11245954|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
11245955|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
11245956|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
11245957|NCT03067402|Other|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
11245958|NCT03067402|Experimental|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
11245959|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
11245960|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
11245961|NCT03067376|Experimental|[14C]-CORT125134|Two capsules each containing 125 milligrams (mg) [14C]-CORT125134 administered to each participant on 1 occasion
11245962|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
11245963|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
11245964|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
11245965|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
11245966|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
11245967|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
11245968|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
11245971|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
11245972|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
11245973|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
11245974|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
11245975|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
11245976|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the UNC OASIS Clinics by trained clinicians.
11245977|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
11245978|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
11245979|NCT03067272|Experimental|FemBloc® Permanent Contraceptive System|Treatment of women who desire permanent birth control (female sterilization) by occlusion of the fallopian tubes.
11245980|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
11245981|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
11245982|NCT03067246|Active Comparator|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
11245983|NCT03067246|Active Comparator|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
11245984|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
11245985|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
11245986|NCT03067220|Experimental|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
11245987|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
11245988|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
11245989|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
11245990|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
11245991|NCT03067181|Experimental|Arm I (bleomycin, carboplatin, etoposide)|Patients receive bleomycin IV over 10 minutes and carboplatin IV over 1 hour on day 1. Patients also receive etoposide IV over 1-2 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11245992|NCT03067181|Experimental|Arm II (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on day 1. Patients also receive etoposide IV over 1-2 hours and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11245993|NCT03067181|Experimental|Arm III (bleomycin, etoposide, carboplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11245994|NCT03067181|Experimental|Arm IV (bleomycin, etoposide, cisplatin)|Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and cisplatin IV over 1-3 hours on days 1-5. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11245995|NCT03067181|Experimental|Low-Risk (observation)|Patients with stage I grade 2, 3 ovarian immature teratoma or low-risk stage I malignant germ cell tumors undergo observation and can transfer to standard risk arm when eligibility criteria are met.
11245996|NCT03067168|Active Comparator|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
11245997|NCT03067168|Placebo Comparator|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
11245998|NCT03067155|Experimental|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
11245999|NCT03067155|Active Comparator|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
11246003|NCT03067129|Experimental|Cohort 1: Adult formulation GLE/PIB subjects 12 to < 18yrs|Cohort 1: Adult formulation Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8, 12, or 16 weeks depending on their hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to < 18 years of age.
11246004|NCT03067129|Experimental|Cohort 2: Pediatric formulation GLE/PIB subjects 9 to < 12yrs|Cohort 2: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to < 12 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.
11246005|NCT03067129|Experimental|Cohort 3: Pediatric formulation GLE/PIB subjects 6 to < 9yrs|Cohort 3: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to < 9 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.
11246006|NCT03067129|Experimental|Cohort 4: Pediatric formulation GLE/PIB subjects 3 to < 6yrs|Cohort 4: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to < 6 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.
11246007|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
11246008|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
11246009|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
11246010|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
11246011|NCT03067090|Experimental|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
11246012|NCT03067077|Active Comparator|SMILE|SMILE surgery
11246013|NCT03067077|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
11246014|NCT03067051|Experimental|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.
~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.
~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).
~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
11246015|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
11246016|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
11246017|NCT03067025||30 youth with MS|
11246018|NCT03067025||30 healthy control participants|
11246019|NCT03067012|Experimental|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
11246020|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
11246021|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
11246022|NCT03066986|Experimental|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
11246023|NCT03066986|Experimental|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
11246024|NCT03066986|Active Comparator|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
11246025|NCT03066986|Experimental|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
11246026|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
11246027|NCT03066973|No Intervention|Control group|control group that received standard care service.
11246028|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
11246029|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
11246030|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
11246031|NCT03066934||NIV Failure Group|NIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
11246032|NCT03066934||NIV success group|Children who successfully managed their noninvasive ventilation therapy
11246033|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
11246034|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
11246035|NCT03066908|Experimental|Single Arm|Sinopsys® Lacrimal Stent
11246036|NCT03066895|Experimental|Experimental|BabyGentleStick
11246037|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
11246038|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
11246039|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
11246040|NCT03066869|Experimental|H.P. ACTHAR GEL|
11246041|NCT03066856|Experimental|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
11246042|NCT03066856|No Intervention|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
11246043|NCT03066843|Experimental|Zero incubation with ALA (5-aminolevulinic acid)|Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
11246044|NCT03066843|Experimental|One hour incubation with ALA (5-aminolevulinic acid)|Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
11246045|NCT03066830|Experimental|Sotagliflozin|A dose of sotagliflozin will be administered as 2 tablets, once daily, before the first meal of the day
11246046|NCT03066830|Placebo Comparator|Placebo|A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day
11246047|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
11246048|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
11246049|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.
~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).
~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
11246050|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).
~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).
~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).
~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
11246051|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:
~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.
~Supplied by Sabinsa Corporation"
11246052|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:
~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.
~Supplied by Sabinsa corporation"
11246053|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets
~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.
~Dose: subjects in this group will take 6 placebo tablets per day"
11246054|NCT03066778|Experimental|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
11246055|NCT03066778|Active Comparator|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
11246056|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
11246057|NCT03066752||7 pediatric-onset multiple sclerosis|
11246058|NCT03066752||7 non-patient healthy volunteers|
11246059|NCT03066739|Active Comparator|LO-low dose remifentanil|low dose remifentanil (LO, 0.1 micrograms/kg/mL),
11246060|NCT03066739|Active Comparator|HI-high dose remifentanil with placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
11246061|NCT03066739|Active Comparator|HN-high dose remifentanil with ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).
11246062|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
11246063|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
11246064|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
11246065|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
11246066|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
11246067|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
11246068|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
11246069|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
11246070|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
11246071|NCT03066674|Experimental|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
11246072|NCT03066674|Experimental|Control group|The Group will not receive Hand-on technique on the lumbar spine.
11246073|NCT03066648|Experimental|Decitabine and PDR001|Decitabine in combination with PDR001
11246074|NCT03066648|Experimental|Decitabine and MBG453|Decitabine in combination with MBG453
11246075|NCT03066648|Experimental|Decitabine, PDR001 and MBG453|Decitabine in combination with PDR001 and MBG453
11246076|NCT03066648|Experimental|MBG453|MBG453 alone
11246077|NCT03066648|Experimental|MBG453 and PDR001|MBG453 in combination with PDR001
11246078|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
11246079|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
11246080|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
11246081|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
11246082|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
11246083|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
11246084|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
11246085|NCT03066596|Experimental|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
11246086|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
11246087|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
11246088|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
11246089|NCT03066557|Active Comparator|study group|TACE and Apatinib
11246090|NCT03066557|Experimental|control group|TACE alone
11246091|NCT03066544|Active Comparator|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
11246092|NCT03066544|Active Comparator|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
11246093|NCT03066544|Active Comparator|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
11246094|NCT03066544|Active Comparator|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
11246095|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
11246096|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.
~Assigned Interventions: Behavioral: usual care (CBT)"
11246097|NCT03066518|Placebo Comparator|Melatonin|Melatonin 5 mg, daily, eight weeks
11246098|NCT03066518|Placebo Comparator|placebo|Placebo, daily, eight weeks
11246099|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
11246100|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
11246101|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
11246102|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
11246103|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
11246133|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
11246134|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
11246135|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
11246136|NCT03066206|Experimental|Treatment (poziotinib)|Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11246104|NCT03066466|Experimental|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant & continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
11246105|NCT03066466|Active Comparator|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
11246106|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
11246107|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
11246108|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
11246109|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
11246110|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
11246111|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.
~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
11246112|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.
~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
11246113|NCT03066388|Experimental|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
11246114|NCT03066375|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
11246115|NCT03066362|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
11246116|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
11246117|NCT03066349||Patients with PCOS undergoing IVM|
11246118|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
11246119|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
11246120|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
11246121|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
11246122|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
11246123|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
11246124|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
11246125|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
11246126|NCT03066271|Experimental|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.
~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
11246127|NCT03066271|Experimental|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
11246128|NCT03066258|Experimental|Dose 1|3E9 GC/eye of RGX-314
11246129|NCT03066258|Experimental|Dose 2|1E10 GC/eye of RGX-314
11246130|NCT03066258|Experimental|Dose 3|6E10 GC/eye of RGX-314
11246131|NCT03066258|Experimental|Dose 4|1.6E11 GC/eye of RGX-314
11246132|NCT03066258|Experimental|Dose 5|2.5E11 GC/eye of RGX-314
11246137|NCT03066193|Experimental|Dronabinol and Palmitoylethanolamide|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
11246138|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
11246139|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
11246140|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
11246141|NCT03066167||Controls|Healthy Controls with no known dysphagia
11246142|NCT03066154|Experimental|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
11246143|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
11246144|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
11246145|NCT03066128|Experimental|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
11246146|NCT03066128|Experimental|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
11246147|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
11246148|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.
~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
11246149|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
11246150|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
11246151|NCT03066076|Active Comparator|Thyroidectomy|Total thyroidectomy
11246152|NCT03066076|Active Comparator|Antithyroid drug|Thiamazol, Propylthiouracil
11246153|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
11246154|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
11246155|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
11246156|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
11246157|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
11246158|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
11246159|NCT03066011||Voriconazole Group|Oral and Intravenous
11246160|NCT03066011||Posaconazole Group|Oral and Intravenous
11246161|NCT03065998|Active Comparator|Drug-A|opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
11246162|NCT03065998|Active Comparator|Drug-B|baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
11246163|NCT03065972|Active Comparator|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
11246164|NCT03065972|Active Comparator|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
11246165|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
11246166|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
11246167|NCT03065946||Case series|Early wakening
11246168|NCT03065933|Experimental|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
11246169|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
11246170|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
11246198|NCT03065673|Active Comparator|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
11246171|NCT03065894|Experimental|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
11246172|NCT03065894|Active Comparator|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
11246173|NCT03065881|Active Comparator|Dilated versus Natural pupil|
11246174|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
11246175|NCT03065868|Experimental|eradictaion|H. pylori eradication group
11246176|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
11246177|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
11246178|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
11246179|NCT03065842|Experimental|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
11246180|NCT03065842|Active Comparator|Usual standards|Usual standards
11246181|NCT03065829|Experimental|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
11246182|NCT03065829|Experimental|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
11246183|NCT03065816|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
11246184|NCT03065816|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
11246185|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).
~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
11246186|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
11246187|NCT03065777|Experimental|ONE ENDO|Single file rotary system
11246188|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
11246189|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
11246190|NCT03065764|Other|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
11246191|NCT03065751|Active Comparator|TPE|
11246192|NCT03065751|No Intervention|Kontroll|
11246193|NCT03065738|Experimental|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
11246194|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.
~Procedure: Computed Tomography
~Drug: [F-18] fluoroestradiol: [F-18]FES
~Other: Laboratory Biomarker Analysis
~Procedure: Positron Emission Tomography"
11246195|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
11246196|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
11246197|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
11246199|NCT03065673|Placebo Comparator|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
11246200|NCT03065660|Active Comparator|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
11246201|NCT03065660|Placebo Comparator|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
11246202|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
11246203|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.
~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
11246204|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
11246205|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
11246206|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
11246207|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
11246208|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
11246209|NCT03065595|Placebo Comparator|Intervention|Ophicephalus striatus extract
11246210|NCT03065595|Active Comparator|Control|Placebo drug
11246211|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
11246212|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
11246213|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
11246214|NCT03065556|Experimental|188-0551 Solution|188-0551 Solution applied topically twice daily
11246215|NCT03065556|Placebo Comparator|Vehicle Solution|Vehicle Solution applied topically twice daily
11246216|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
11246217|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
11246218|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
11246219|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.
~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
11246220|NCT03065517|Experimental|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
11246221|NCT03065517|Placebo Comparator|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial.
11246222|NCT03065504|Active Comparator|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )
~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
11246223|NCT03065504|Active Comparator|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:
~Turmeric (Curcuma longa) - 50 mg/tablet
~Hemidesmus Indicus root (Anantamul)
~Indian Madder root
~Neem leaf
~Gotu Kola leaf
~Indian TInospora stem
~Amla fruit
~Licorice root
~Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
11246224|NCT03065504|Placebo Comparator|Placebo tablets group|"Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals
~Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder
~Dose: subjects in this group will take 2 tablets twice per day"
11246227|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
11246228|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
11246229|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
11246230|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
11246231|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
11246232|NCT03065439|Experimental|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
11246233|NCT03065439|Experimental|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
11246234|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
11246235|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
11246236|NCT03065400|Experimental|Pembolizumab|
11246237|NCT03065387|Experimental|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11246238|NCT03065387|Experimental|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11246239|NCT03065387|Experimental|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11246240|NCT03065374|Experimental|Treatment arm A|IMM-529, 1000 mg three times daily, orally
11246241|NCT03065374|Placebo Comparator|Treatment arm B|Matching Placebo, three times daily, orally
11246242|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.
~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
11246243|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
11246244|NCT03065348|Experimental|Intervention|"Around 2 to 4 weeks before surgery:
~Fried frailty score
~CARE score assessment
~NRS Kondrup assessment
~Plasma albumin and CRP values
~Start with daily oral whey protein administration until evening before surgery45
~Around 5-7 days before surgery:
~- Start with immunonutrition
~Evening before surgery:
~CARE score assessment
~NRS Kondrup
~CERAD cognition test assessment
~Plasma albumin and CRP values, urine specific gravity
~Carbohydrate loading
~If urine specific gravity is >1.020 then additional tap water drinking will be encouraged
~Day of surgery:
~Carbohydrate loading
~Start anesthesia with spinal anesthesia (continuous)
~POD 7:
~CARE assessment
~CERAD assessment
~Plasma albumin and CRP values
~POD14:
~CARE assessment
~Plasma albumin and CRP value
~POD 30:
~CARE assessment
~NRS Kondrup
~CERAD assessment
~Plasma albumin and CRP values
~POD 90:
~CARE assessment
~NRS Kondrup
~CERAD assessment"
11246245|NCT03065335|Experimental|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
11246246|NCT03065335|Other|Phase I|Low frequency Transcranial Magnetic Stimulation (TMS)
11246247|NCT03065335|Other|Phase II|Low frequency TMS
11246248|NCT03065335|Experimental|Phase II Arm 1a|Double-blind, single dose of 0.5 mg/kg IV ketamine concurrently with MEG
11246249|NCT03065335|Experimental|Phase II Arm 1b|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG
11246250|NCT03065335|Placebo Comparator|Phase II Arm 2a|Double-blind, single dose of 0.5 mg/kg IV saline
11246251|NCT03065335|Placebo Comparator|Phase II Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
11246252|NCT03065335|Other|Phase III|Low frequency Transcranial Magnetic Stimulation (TMS)
11246253|NCT03065335|Experimental|Phase III drug|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
11246254|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
11246255|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
11246305|NCT03064958|Experimental|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
11246306|NCT03064945|Sham Comparator|Shame device|
11246256|NCT03065296|Experimental|Musculoskeletal (MSK) Exercise Prescription|"Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.
~In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
~Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1
~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
11246257|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
11246258|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
11246259|NCT03065270|Experimental|A group|
11246260|NCT03065270|Experimental|B group|
11246261|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
11246262|NCT03065244|Active Comparator|IVIG|Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
11246263|NCT03065244|Active Comparator|Infliximab|Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours
11246264|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
11246265|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
11246266|NCT03065218|Experimental|99mTc sestamilbi|25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite
11246267|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
11246268|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
11246269|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
11246270|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
11246271|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
11246272|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
11246273|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
11246274|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy Followed by a period of detraining.
~They will then undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy"
11246275|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.
~They will then undergo the following:
~CPEX with/without stable isotope infusion
~Muscle biopsies
~Magnetic Resonance Spectroscopy"
11246276|NCT03065127|Experimental|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
11246277|NCT03065127|Experimental|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
11246278|NCT03065127|Experimental|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
11246279|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
11246280|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape
~Resistance to femoral head rotation and cut-out
~Active compression through linear motion without rotation
~Single subtrochanteric lag screw option for stable fractures below lesser trochanter
~Preloaded cannulated set screw converts construct to fixed angle device
~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon
~Clothespin tip for stress modulation in femoral shaft
~Potential for improved patient mobility and recovery
~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.
~Interventions:
~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
11246281|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.
~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.
~Participating sites may use whichever brand of SHS is currently in use.
~Interventions:
~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
11246282|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
11246283|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
11246284|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
11246285|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
11246286|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
11246287|NCT03065062|Experimental|Combination Of Palbociclib and Gedatolisib|"Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.
~Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
11246288|NCT03065049|Experimental|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
11246289|NCT03065049|Active Comparator|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
11246290|NCT03065049|No Intervention|Usual Care|Participants do not receive any intervention but participate in the assessments only.
11246291|NCT03065036|Experimental|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
11246292|NCT03065036|Other|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
11246293|NCT03065023|Experimental|Group A: Cutaenous lesions|Participants with transdermally/transmucosally injectable tumors including cutaneous, subcutaneous or lymph node injectable tumors received escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection twice each week (Q2W) over a period of 4 weeks. Participants may have continued to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years).
11246294|NCT03065023|Experimental|Group B: Liver lesions|Participants with injectable liver tumors or liver metastases were to receive escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection once each week over a period of 4 weeks. Participants were to have been able to continue to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years). (Group B was not started. Development will continue with new protocol.)
11246295|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
11246296|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
11246297|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
11246298|NCT03064984|Active Comparator|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
11246299|NCT03064984|Active Comparator|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
11246300|NCT03064971|Experimental|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
11246301|NCT03064971|Active Comparator|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
11246302|NCT03064971|Active Comparator|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
11246303|NCT03064958|Active Comparator|Control|Consumption of a high fat meal (1000kcal, 45g fat)
11246304|NCT03064958|Experimental|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
11246307|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
11246439|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
11246308|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).
~Post prandial test meal will be contain minimal amounts of spice."
11246309|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).
~Post prandial test meal will be contain a moderate amount of spice."
11246310|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).
~Post prandial test meal will be contain a culinary amount of spice."
11246311|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
11246312|NCT03064906|Other|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.
~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
11246313|NCT03064893|Active Comparator|Dermacell|Device for immediate implant based breast reconstruction
11246314|NCT03064893|Active Comparator|Alloderm|Device for immediate implant based breast reconstruction
11246315|NCT03064880|Active Comparator|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
11246316|NCT03064880|No Intervention|SV normalization|NO active fluid therapy.
11246317|NCT03064867|Experimental|Venetoclax + RICE|Venetoclax with rituximab, ifosfamide, carboplatin, and etoposide
11246318|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
11246319|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
11246320|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
11246321|NCT03064854|Experimental|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
11246322|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
11246323|NCT03064828|Active Comparator|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
11246324|NCT03064828|Experimental|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
11246325|NCT03064815|Experimental|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
11246326|NCT03064815|Experimental|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
11246327|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
11246328|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
11246329|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to
~Continuously capture multidimensional behavior as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.
~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision-suport system (CDSS) and Recommender operation.
~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessments, to the participants and in their own environment."
11246330|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
11246331|NCT03064763|Experimental|talimogene laherparepvec|All subjects will receive open-label talimogene laherparepvec
11246332|NCT03064750|Experimental|Pre-surgery exercise|pelvic floor exercises individually and in groups
11246333|NCT03064750|Other|Waiting list|wait as usual until surgery
11246334|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
11246335|NCT03064724|Experimental|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
11246336|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
11246337|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
11246338|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
11246339|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
11246340|NCT03064672|Experimental|induction by transcervical Balloon Catheters insertion|
11246341|NCT03064672|No Intervention|induction without transcervical Balloon Catheters|
11246342|NCT03064646|Experimental|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
11246379|NCT03064347|Active Comparator|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
11246440|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
11246343|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
11246344|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
11246345|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
11246346|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
11246347|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
11246348|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
11246349|NCT03064594||cornuostomy|cornuostomy
11246350|NCT03064594||wedge resection|wedge resection
11246351|NCT03064581|Experimental|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
11246352|NCT03064581|No Intervention|Control|Usual care with delayed intervention at the end of study.
11246353|NCT03064568|Experimental|Misoprostol 100Mcg Tab|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
11246354|NCT03064568|Placebo Comparator|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
11246355|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test
~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.
~Constant load exercise test
~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
11246356|NCT03064555||Healthy participants|"Cardiopulmonary exercise test
~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.
~Constant load exercise test
~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
11246357|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
11246358|NCT03064516|Experimental|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
11246359|NCT03064516|Active Comparator|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
11246360|NCT03064503|Experimental|Healthy volunteers|Sedentary healthy subjects will be recruited in this study. MRI, skin auto-fluorescence measures and blood sampling will be performed
11246361|NCT03064490|Other|Single arm interventional study|Single arm, non randomized, open label study. Subjects will receive three doses of neoadjuvant pembrolizumab (200 mg administered as an intravenous infusion over 30 minutes every 3 weeks). Pembrolizumab will be administered with weekly standard of care Carboplatin/Paclitaxel concurrent chemo-radiation therapy in the neo-adjuvant setting. Postoperatively, three additional cycles of pembrolizumab (200 mg every 3 weeks) will be administered as adjuvant therapy.
11246362|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.
~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
11246363|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
11246364|NCT03064464||CA-MRSA infection|None intervention
11246365|NCT03064464||HA-MRSA infection|None intervention
11246366|NCT03064464||CA-MSSA infection|None intervention
11246367|NCT03064451|Experimental|Intervention|cartofinder guided ablation followed by PVI
11246368|NCT03064438|Experimental|ACCU-D1|ACCU-D1 applied to the face twice daily for 12 weeks.
11246369|NCT03064438|Placebo Comparator|Vehicle Control|Vehicle applied to the face twice daily for 12 weeks.
11246370|NCT03064399|Experimental|lateral ligament repairment|
11246371|NCT03064399|Experimental|without lateral ligament repairment|
11246372|NCT03064386|Experimental|plate group|internal fixation with the plate
11246373|NCT03064386|Experimental|screw group|internal fixation with the screw
11246374|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
11246375|NCT03064347|Active Comparator|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
11246376|NCT03064347|Placebo Comparator|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
11246377|NCT03064347|Active Comparator|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
11246378|NCT03064347|Placebo Comparator|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
11246380|NCT03064347|Placebo Comparator|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
11246381|NCT03064347|Active Comparator|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
11246382|NCT03064347|Placebo Comparator|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
11246383|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.
~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
11246384|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
11246385|NCT03064321|Other|Information Control|General health information website
11246386|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
11246387|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
11246388|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
11246389|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
11246390|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
11246391|NCT03064282|Placebo Comparator|Placebo|Drug free base as placebo
11246392|NCT03064282|Experimental|group two- papaverine arm|papaverine in a suitable base
11246393|NCT03064269|Experimental|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
11246394|NCT03064256|Experimental|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.
~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
11246395|NCT03064256|No Intervention|Control Group|Control participants receive routine outpatient care for a 12-week period.
11246396|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
11246397|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.
~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.
~QoL questionnaire SF-12 and and a screening questionnaire were requested"
11246398|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.
~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
11246399|NCT03064217|Active Comparator|CLP and 12 weeks waiting|After core build-up and initial tooth preparation, a clinical crown lengthening procedure (CLP) will be performed. Restorative treatments will be initiated 12 weeks after CLPs.
11246400|NCT03064217|Experimental|Digital impression taken at surgery|The final impression will be taken at surgery. The final crown will be delivered at suture removal.
11246401|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
11246402|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
11246403|NCT03064191|Active Comparator|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
11246404|NCT03064191|Active Comparator|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
11246405|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
11246406|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
11246407|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
11246435|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
11246436|NCT03063983|No Intervention|Control|31 weeks of MAP
11246437|NCT03063970|Experimental|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
11246408|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
11246409|NCT03064139|Experimental|MCG - Mindful Walking|Participants will be trained in mindful walking technique
11246410|NCT03064139|Active Comparator|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
11246411|NCT03064126|Experimental|RANGER™ Paclitaxel Coated Balloon|"RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.
~Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon."
11246412|NCT03064126|Active Comparator|Standard Balloon Angioplasty|Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
11246413|NCT03064113|Experimental|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
11246414|NCT03064113|Experimental|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
11246415|NCT03064113|Experimental|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
11246416|NCT03064113|Experimental|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
11246417|NCT03064100||Specimens that meet inclusion criteria|
11246418|NCT03064074|Experimental|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).
~At each study visit, the participant may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug"
11246419|NCT03064074|Experimental|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).
~At each study visit, the participant may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug"
11246420|NCT03064074|Experimental|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.
~At each study visit, participants may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug
~Skeletal survey
~Peripheral quantitative CT (pQCT) of the forearm
~Quality of Life Surveys
~Pulmonary function test
~Walk test"
11246421|NCT03064074|Experimental|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.
~At each study visit, participants may have the following testing done:
~Physical exam
~Vitals
~Blood draw for safety labs, pharmacokinetics, etc
~If the participant is female, she will have a pregnancy test
~EKG
~DXA
~Infusion of the study drug
~Skeletal survey
~Peripheral quantitative CT (pQCT) of the forearm
~Quality of Life Surveys
~Pulmonary function test
~Walk test"
11246422|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
11246423|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
11246424|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
11246425|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
11246426|NCT03064035|Experimental|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.
~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
11246427|NCT03064035|Active Comparator|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:
~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR >6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
11246428|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
11246429|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
11246430|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
11246431|NCT03064022||Size for gestational age|Small size for gestational age
11246432|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
11246433|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
11246434|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
11246438|NCT03063970|Active Comparator|Comparison Group|Usual rehabilitation
11246441|NCT03063944|Experimental|Treatment (STAT inhibitor OPB-111077, decitabine)|Patients receive STAT inhibitor OPB-111077 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive decitabine IV on days 8-12. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11246442|NCT03063931|Experimental|magnesium|
11246443|NCT03063931|Placebo Comparator|placebo|
11246444|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
11246445|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
11246446|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
11246447|NCT03063892|Placebo Comparator|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
11246448|NCT03063892|Experimental|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
11246449|NCT03063879|Experimental|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
11246450|NCT03063866|Active Comparator|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
11246451|NCT03063866|Active Comparator|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
11246452|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
11246453|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
11246454|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
11246455|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
11246456|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
11246457|NCT03063814|Experimental|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
11246458|NCT03063814|Active Comparator|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
11246459|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
11246460|NCT03063788|Experimental|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
11246461|NCT03063788|Experimental|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
11246462|NCT03063788|Experimental|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
11246463|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
11246464|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
11246465|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
11246466|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
11246467|NCT03063775|No Intervention|5. Spongostan®|
11246468|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
11246469|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
11246470|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: no new participants are being enrolled in the arm at this time."
11246471|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: no new participants are being enrolled in the arm at this time."
11246495|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
11246699|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
11246472|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: no new participants are being enrolled in the arm at this time."
11246473|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
~Note: Arm D is closed for future enrollment"
11246474|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
11246475|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
11246476|NCT03063736|Experimental|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
11246477|NCT03063736|Placebo Comparator|Td vaccine only|Td vaccine (4 ug) (n=15)
11246478|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
11246479|NCT03063723||Healthy controls|10 Healthy controls without any treatment
11246480|NCT03063697||patients who check the safety data after taking Dilatrend SR|
11246481|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.
~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
11246482|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.
~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.
~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.
~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
11246483|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
11246484|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
11246485|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
11246486|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
11246487|NCT03063658|Active Comparator|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
11246488|NCT03063658|Active Comparator|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
11246489|NCT03063645|Experimental|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
11246490|NCT03063645|Experimental|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
11246491|NCT03063645|Experimental|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
11246492|NCT03063632|Experimental|Group I (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
11246493|NCT03063632|Experimental|Group II (pembrolizumab, interferon gamma-1b)|Patients pembrolizumab IV over 30 minutes on day 1 and interferon gamma-1b SC once a week. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity.
11246494|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
11246496|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
11246497|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
11246498|NCT03063580|Experimental|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
11246499|NCT03063567|Other|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
11246500|NCT03063567|Other|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
11246501|NCT03063567|Other|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
11246502|NCT03063554|Active Comparator|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
11246503|NCT03063554|Placebo Comparator|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
11246504|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
11246505|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
11246506|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.
~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips
~website and mobile app"
11246507|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.
~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips
~website and mobile app"
11246508|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
11246509|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
11246510|NCT03063489|Experimental|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
11246511|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.
~All subjects will undergo the same procedures and interventions."
11246512|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
11246513|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
11246514|NCT03063450|Experimental|Nivolumab|Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
11246515|NCT03063450|Placebo Comparator|Placebo|Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months
11246516|NCT03063437|Experimental|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
11246517|NCT03063437|Placebo Comparator|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
11246518|NCT03063424|Other|Healthy subjects|
11246519|NCT03063424|Other|Asthmatics with EIB|
11246520|NCT03063411|Experimental|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
11246521|NCT03063411|Active Comparator|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
11246522|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
11246523|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
11246524|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
11246525|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
11246526|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
11246527|NCT03063359|Experimental|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
11246528|NCT03063359|Active Comparator|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
11246529|NCT03063346|Experimental|Protein hydrolysate high dose|
11246530|NCT03063346|Experimental|Protein hydrolysate low dose|
11246531|NCT03063346|Placebo Comparator|Placebo|
11246532|NCT03063333|Experimental|Coping-oriented hypnosis|
11246533|NCT03063333|Placebo Comparator|Neutral hypnosis|
11246534|NCT03063333|No Intervention|current treatment only|
11246535|NCT03063320|Active Comparator|Low Spice|The test meal (~1200kcal and 44g fat) will contain ~0.6g of spice blend
11246536|NCT03063320|Experimental|Moderate Spice|The test meal (~1200kcal and 44g fat) will contain ~3.7g of spice blend
11246537|NCT03063320|Experimental|Culinary Spice|The test meal (~1200kcal and 44g fat) will contain ~7.4g of spice blend
11246538|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
11246539|NCT03063307|Experimental|Silver Diamine Fluoride|
11246540|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
11246541|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
11246542|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
11246543|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
11246544|NCT03063268|Experimental|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
11246545|NCT03063268|Experimental|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
11246546|NCT03063268|Active Comparator|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
11246547|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
11246548|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
11246549|NCT03063242|Experimental|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
11246550|NCT03063242|Experimental|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels <1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
11246551|NCT03063242|Experimental|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count <1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
11246552|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
11246553|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
11246554|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
11246555|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
11246556|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
11246557|NCT03063203|Experimental|Decitabine|"Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle
~Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.
~Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
11246558|NCT03063190|Placebo Comparator|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
11246559|NCT03063190|Active Comparator|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
11246560|NCT03063190|Placebo Comparator|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
11246561|NCT03063190|Active Comparator|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
11246700|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
11246562|NCT03063177|Experimental|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
11246563|NCT03063177|Experimental|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
11246564|NCT03063177|Experimental|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
11246565|NCT03063177|No Intervention|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
11246566|NCT03063164|Active Comparator|Intralase IFS|Intralase IFS vs. Visumax
11246567|NCT03063164|Active Comparator|Visumax|Visumax vs. Intralase iFS
11246568|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
11246569|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
11246570|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
11246571|NCT03063112|Active Comparator|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
11246572|NCT03063112|Placebo Comparator|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
11246573|NCT03063099|Experimental|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
11246574|NCT03063086|Active Comparator|Sequence 1|A-B-C
11246575|NCT03063086|Active Comparator|Sequence 2|A-C-B
11246576|NCT03063086|Active Comparator|Sequence 3|B-C-A
11246577|NCT03063086|Active Comparator|Sequence 4|B-A-C
11246578|NCT03063086|Active Comparator|Sequence 5|C-A-B
11246579|NCT03063086|Active Comparator|Sequence 6|C-B-A
11246580|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
11246581|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
11246582|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
11246583|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
11246584|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
11246585|NCT03063034|Active Comparator|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
11246586|NCT03063034|Active Comparator|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
11246587|NCT03063021|Experimental|Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)|Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) in the aqueous.
11246588|NCT03063021|Experimental|Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)|Subjects with RP who don't have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.
11246589|NCT03063008|Other|Lumbar fusion with PEEK cage|Control arm
11246590|NCT03063008|Other|Lumbar fusion with TiPEEK cage|Study arm
11246591|NCT03062995|Experimental|Active product: partially hydrolysed formula + synbiotics|partially hydrolysed formula + synbiotics
11246592|NCT03062995|Active Comparator|Control product: standard formula (intact protein)|standard formula (intact protein)
11246593|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
11246594|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
11246595|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
11246596|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
11246597|NCT03062956|Experimental|Single oral dose of MYK-491|single-dose, oral suspension
11246598|NCT03062956|Placebo Comparator|Single oral dose of placebo|single-dose, oral suspension
11246599|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
11246701|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
11246600|NCT03062930|Active Comparator|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
11246601|NCT03062930|Sham Comparator|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
11246602|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
11246603|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
11246604|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
11246605|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
11246606|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
11246607|NCT03062904|Experimental|drug|
11246608|NCT03062891|Experimental|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.
~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
11246609|NCT03062891|No Intervention|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
11246610|NCT03062878||Breast Cancer/Lymphoma Patient|Breast cancer or lymphoma patients currently undergoing anthracycline-based chemotherapy treatment. Patients are eligible if they have completed at least 1 cycle of chemotherapy. Free of known clinical cardiovascular disease.
11246611|NCT03062878||Breast Cancer/Lymphoma Survivor|Individuals with history of breast cancer or lymphoma (1-5 years removed from last date of chemotherapy) who have a treatment history of anthracycline-based chemotherapy. Free of known clinical cardiovascular disease.
11246612|NCT03062878||Control|Individuals with no history of caner or chemotherapy. Free of known clinical cardiovascular disease
11246613|NCT03062852|Experimental|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
11246614|NCT03062852|No Intervention|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
11246615|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
11246616|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
11246617|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
11246618|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
11246619|NCT03062800|Experimental|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):
~Pemetrexed + Platinum + Thalidomide [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn ]
~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):
~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
11246620|NCT03062800|Experimental|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):
~Pemetrexed + Platinum [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt ]
~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):
~Pemetrexed (500mg/m^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
11246621|NCT03062787|Experimental|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
11246622|NCT03062787|Active Comparator|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
11246623|NCT03062774|Experimental|PB-119|intervention: PB-119 injection
11246624|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
11246625|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
11246626|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
11246627|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
11246628|NCT03062722|Experimental|keyhole approach|open minimally invasive approach
11246629|NCT03062709|Experimental|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
11246702|NCT03062254|Experimental|Radium-223|
11246630|NCT03062696|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
11246631|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
11246632|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
11246633|NCT03062670|Experimental|Retreat|A full day off-site training session
11246634|NCT03062670|No Intervention|Control|Care teams normal process
11246635|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
11246636|NCT03062644|Experimental|MR308 100 mg bid|Tramadol/Celecoxib)
11246637|NCT03062644|Experimental|MR308 150 mg bid|Tramadol/Celecoxib
11246638|NCT03062644|Experimental|MR308 200 mg bid|Tramadol/Celecoxib
11246639|NCT03062644|Active Comparator|Tramadol 100 mg qid|Tramadol
11246640|NCT03062644|Active Comparator|Celecoxib 100 mg bid|Celecoxib
11246641|NCT03062644|Placebo Comparator|Placebo|Placebo
11246642|NCT03062618|Experimental|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
11246643|NCT03062618|Placebo Comparator|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
11246644|NCT03062618|Experimental|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
11246645|NCT03062618|Placebo Comparator|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
11246646|NCT03062618|Experimental|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
11246647|NCT03062618|Placebo Comparator|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
11246648|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
11246649|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
11246650|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
11246651|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
11246652|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
11246653|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
11246654|NCT03062566||Severe TBI patients|GCS 3-8
11246655|NCT03062553|Experimental|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.
~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.
~The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
11246656|NCT03062553|Experimental|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.
~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
11246657|NCT03062553|Experimental|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.
~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.
~TAU is a four week waitlist control group."
11246658|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
11246659|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
11246660|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.
~Interventions:
~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
11246697|NCT03062319|Active Comparator|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
11247040|NCT03059914|Active Comparator|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
11246661|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)
~Interventions:
~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
11246662|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
11246663|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
11246664|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
11246665|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
11246666|NCT03062488|Active Comparator|opioid only|2 mcg/Kg of fentanyl
11246667|NCT03062488|Active Comparator|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
11246668|NCT03062488|Active Comparator|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
11246669|NCT03062475|Experimental|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
11246670|NCT03062475|No Intervention|control group|Pregnant women allocated to this group receive standard prenatal care.
11246671|NCT03062462|Active Comparator|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
11246672|NCT03062462|Experimental|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
11246673|NCT03062449|Active Comparator|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
11246674|NCT03062449|Placebo Comparator|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
11246675|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
11246676|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
11246677|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11246678|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11246679|NCT03062410|Other|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
11246680|NCT03062397|Experimental|Low-dose group|JPI-289 Low dose or placebo
11246681|NCT03062397|Experimental|High-dose group|JPI-289 High dose or placebo
11246682|NCT03062397|Placebo Comparator|Placebo group|Same dosage of JPI-289 low and high dose
11246683|NCT03062384|Experimental|AT-001|Yeast-selenium supplement
11246684|NCT03062384|Placebo Comparator|Placebo|Yeast supplement devoid of selenium
11246685|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
11246686|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
11246687|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
11246688|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
11246689|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
11246690|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
11246691|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
11246692|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
11246693|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
11246694|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
11246695|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
11246696|NCT03062319|Active Comparator|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
11246698|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
11246703|NCT03062241|Experimental|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
11246704|NCT03062241|No Intervention|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
11246705|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.
~No interventions will be administered."
11246706|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
11246707|NCT03062215|No Intervention|Control Group|Waiting list
11246708|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
11246709|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
11246710|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
11246711|NCT03062176|Experimental|Active Treatment|Anakinra (Kineret)
11246712|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
11246713|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
11246714|NCT03062150|Placebo Comparator|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
11246715|NCT03062150|Active Comparator|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH
~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
11246716|NCT03062150|Active Comparator|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
11246717|NCT03062150|Active Comparator|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH
~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
11246718|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
11246719|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
11246720|NCT03062098|Experimental|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
11246721|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
11246722|NCT03062085||Age-related cataract group|Age-related cataract patients.
11246723|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
11246724|NCT03062059|Sham Comparator|Control arm|normal saline bladder irrigaiton
11246725|NCT03062059|Experimental|Intervention arm|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
11246726|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
11246727|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
11246728|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
11246729|NCT03062020|Experimental|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
11246730|NCT03062020|No Intervention|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
11246731|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
11246732|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
11246733|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
11246734|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
11246777|NCT03061734|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualified Migraine
11246735|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
11246736|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
11246737|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
11246738|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
11246739|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
11246740|NCT03061942|Active Comparator|Conventional|Arthroscopic rotator cuff repair without synovectomy
11246741|NCT03061942|Experimental|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
11246742|NCT03061929||Undernourised|Mother's with BMI less than 18.5
11246743|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
11246744|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
11246745|NCT03061916|Experimental|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
11246746|NCT03061916|Experimental|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
11246747|NCT03061916|Active Comparator|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
11246748|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
11246749|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
11246750|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
11246751|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
11246752|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
11246753|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
11246754|NCT03061877||Anxiety or depression|
11246755|NCT03061877||Non-anxiety or depression|
11246756|NCT03061864|No Intervention|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
11246757|NCT03061864|Experimental|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
11246758|NCT03061851|Experimental|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
11246759|NCT03061851|Experimental|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
11246760|NCT03061838|Active Comparator|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
11246761|NCT03061838|Experimental|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
11246762|NCT03061812|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine intravenous administration on Day 1 of a 42-Day cycle for 2 cycles.
11246763|NCT03061812|Active Comparator|Topotecan|Topotecan intravenous on Days 1 through 5 of each 21-Day cycle.
11246764|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).
~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
11246765|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
11246766|NCT03061786||AKI|
11246767|NCT03061786||non-AKI|
11246768|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
11246769|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
11246770|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
11246771|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
11246772|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
11246773|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
11246774|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
11246775|NCT03061734|Experimental|Naltrexon/Acetaminophen Capsules|Patients take one capsule containing naltrexone(regular dose) and one capsule containing acetaminophen together for a qualified Migraine
11246776|NCT03061734|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualified Migraine
11246778|NCT03061734|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualified Migraine
11246779|NCT03061734|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualified Migraine
11246780|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
11246781|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
11246782|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
11246783|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
11246784|NCT03061708|Experimental|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
11246785|NCT03061682|Experimental|Add on lens|
11246786|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)
~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)
~Tandem HDCT/autoSCT
~First HDCT (cyclophosphamide, etoposide, carboplatin)
~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)
~Local radiotherapy
~Retinoic acid, interleukin-2"
11246787|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
11246788|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
11246789|NCT03061617|Other|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
11246790|NCT03061617|Experimental|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
11246791|NCT03061604|Experimental|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.
~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
11246792|NCT03061604|Active Comparator|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.
~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
11246793|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.
~Pukka's Wholistic Turmeric"
11246794|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
11246795|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.
~Subjects in the non-dry eye criteria must meet all of the following criteria:
~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes
~OSDI questionnaire score <13.
~Fluorescein TBUT > 7 s in both eyes.
~CFS of 0 in all areas in both eyes.
~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
11246796|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.
~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:
~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye
~Mean CFS of ≥1 in either eye.
~Fluorescein TBUT ≤5 s in either eye.
~OSDI questionnaire score ≥20
~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
11246797|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.
~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:
~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye
~Mean CFS of ≥1 in either eye.
~Fluorescein TBUT ≤5 s in either eye.
~OSDI questionnaire score ≥20
~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
11246798|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
11246799|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
11246800|NCT03061552|Experimental|IVCD arm|IVCD-assisted determination of target post-dialysis weight
11246801|NCT03061552|No Intervention|conventional arm|conventional determination of target post-dialysis weight
11246802|NCT03061539|Experimental|Nivolumab & Ipilimumab|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
11246803|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
11246804|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
11246805|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).
~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).
~The investigation consist in:
~taking a preoperative blood sample to evaluate the MMPs circulating levels
~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
11246806|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.
~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).
~The investigation consist in:
~taking a preoperative blood sample to evaluate the MMPs circulating levels
~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
11246807|NCT03061474|Experimental|Nicotinamide|1500mg twice daily: 2, 750mg tablets taken orally twice daily
11246808|NCT03061474|Placebo Comparator|Placebo|1500mg twice daily: 2, 750mg tablets taken orally twice daily
11247043|NCT03059888|Experimental|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
11246809|NCT03061461|Active Comparator|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:
~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.
~Six treatment sessions, two treatment sessions per week.
~1000 radial shock waves per cm^2 wound and treatment session.
~Energy flux density 0.07 mJ/mm^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).
~Frequency of the radial shock waves set at 15 Hz."
11246810|NCT03061461|Sham Comparator|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:
~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.
~Six treatment sessions, two treatment sessions per week.
~1000 sham radial shock waves per cm^2 wound and treatment session.
~Energy flux density 0.00 mJ/mm^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).
~Frequency of the sham radial shock waves set at 15 Hz."
11246811|NCT03061448|Experimental|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
11246812|NCT03061448|Active Comparator|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
11246813|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
11246814|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
11246815|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
11246816|NCT03061422|Experimental|xylitol chewing gum|intervention
11246817|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
11246818|NCT03061422|Active Comparator|Paraffin pellet|comparator
11246819|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
11246820|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
11246821|NCT03061396|Experimental|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
11246822|NCT03061396|Experimental|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
11246823|NCT03061383|Active Comparator|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
11246824|NCT03061383|Active Comparator|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
11246825|NCT03061383|Placebo Comparator|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
11246826|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
11246827|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
11246828|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
11246829|NCT03061331|Experimental|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
11246830|NCT03061331|Experimental|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
11246831|NCT03061292|Experimental|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
11246832|NCT03061292|Sham Comparator|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
11246833|NCT03061279|Experimental|Fixation by Acutrak headless screw|
11246834|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
11246835|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
11246836|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
11246837|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
11246838|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
11246839|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
11246840|NCT03061240|Experimental|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
11246841|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
11246842|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
11246843|NCT03061214|Experimental|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
11246844|NCT03061214|Experimental|Semaglutide 1 mg OW + sitagliptin placebo OD|
11246845|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
11246846|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 1 mg OW|
11246847|NCT03061201|Experimental|Sequential dose escalation|SB-525 (PF-07055480) is administered as a single infusion
11246848|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11246849|NCT03061175|Experimental|Arm I (Web-Based Contralateral Prophylactic Mastectomy CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based Contralateral Prophylactic Mastectomy (CPM)- Decision Aid (DA).
11246850|NCT03061175|Experimental|Arm II (Usual Care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
11246851|NCT03061162|Experimental|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
11246852|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).
~Additionally, nerve and gliding exercises were administered."
11246853|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
11246854|NCT03061136|Placebo Comparator|Placebo|Placebo administered orally
11246855|NCT03061136|Experimental|Clonazepam 0.1mg|0.1mg clonazepam administered orally
11246856|NCT03061136|Experimental|Clonazepam 0.2mg|0.2mg clonazepam administered orally
11246857|NCT03061136|Experimental|Clonazepam 0.3mg|0.3mg clonazepam administered orally
11246858|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
11246859|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
11246860|NCT03061097|Experimental|Treatment (autologous fecal microbiota preparation)|"Autologous treatment preparation: Patient stool will be collected and processed into an auto-fecal microbiota preparation (FMP) formulation. In this treatment arm, the auto-FMP will be administered to the participant following an infectious episode requiring antibiotics.
~V-A Auto-FMP Enema (125 mL):
~Route of Administration: Enema nozzle will be inserted into rectum and contents expelled into the distal colon. Target dwell time is 1 hour. Participants will lie in the left lateral decubitas position but if mobility permits will rotate to supine and right lateral decubitus position.
~Dosing Regimen: 125mL x 1 dose"
11246861|NCT03061097|Placebo Comparator|Placebo|"Participants randomized to the placebo arm will receive a placebo FMT via enema. The placebo enema preparation interventional enema in appearance.
~The placebo enema preparation will be comprised of Sodium Chloride (0.9%, USP), Glycerol (12.5%, USP), and 8-12 drops brown food coloring (<1%), to prevent unmasking of the trial arms."
11246862|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
11246863|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
11246864|NCT03061058|Experimental|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.
~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).
~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).
~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).
~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w)."
11246865|NCT03061058|Active Comparator|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.
~Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w)."
11246866|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
11246867|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.
~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
11246868|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.
~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
11246869|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.
~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
11246870|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
11246871|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
11246872|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
11246873|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
11246874|NCT03061006|Experimental|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
11246875|NCT03061006|Active Comparator|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
11246876|NCT03060993|Placebo Comparator|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
11246877|NCT03060993|Active Comparator|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
11246878|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
11246879|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
11246880|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
11246881|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
11246882|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
11246883|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
11246884|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
11246885|NCT03060941|Experimental|Group 1|Physical activity education
11246886|NCT03060941|Experimental|Group 2|Physical activity education and facility access
11246887|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
11246888|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
11246889|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
11246890|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
11246891|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
11246892|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
11246893|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
11246894|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
11246895|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
11246896|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
11246897|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
11246898|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
11246899|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
11246900|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
11246901|NCT03060928|Active Comparator|Control|Arthroscopic Rotator Cuff Repair with standard treatment
11246902|NCT03060928|Experimental|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
11247041|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
11246903|NCT03060928|Experimental|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
11246904|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
11246905|NCT03060902|Experimental|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
11246906|NCT03060902|No Intervention|Family Services as Usual|Mothers will continue with services they are receiving in the community
11246907|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
11246908|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
11246909|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
11246910|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
11246911|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
11246912|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
11246913|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
11246914|NCT03060850|Experimental|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
11246915|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
11246916|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
11246917|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
11246918|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
11246919|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
11246920|NCT03060772|Experimental|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
11246921|NCT03060772|No Intervention|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
11246922|NCT03060772|No Intervention|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
11246923|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
11246924|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
11246925|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
11246926|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
11246927|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
11246928|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
11246929|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
11246930|NCT03060681|No Intervention|C group|
11246931|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.
~Nutritional therapy will be initiated in the first 24 hours after admission.
~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
11246932|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.
~Nutritional formula in this group will be Novasource senior (Nestle Health Care).
~Nutritional therapy will be initiated in the first 24 hours after admission."
11246933|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
11246934|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
11246935|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
11246936|NCT03060642||Controls|Non-BE endoscopic controls
11247044|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
11246937|NCT03060629|Experimental|Group 1|Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
11246938|NCT03060629|Placebo Comparator|Group 2|Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
11246939|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
11246940|NCT03060577|Experimental|Inclisiran-only|Participants will receive subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
11246941|NCT03060577|Active Comparator|Switching|Participants will receive self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, the participants will receive subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
11246942|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
11246943|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
11246944|NCT03060551|Experimental|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
11246945|NCT03060538|Experimental|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
11246946|NCT03060538|Placebo Comparator|Placebo|Participants will receive BFKB8488A-matching placebo.
11246947|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
11246948|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
11246949|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
11246950|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
11246951|NCT03060512|Active Comparator|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350
~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
11246952|NCT03060512|Active Comparator|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik
~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
11246953|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
11246954|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
11246955|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
11246956|NCT03060460|Experimental|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
11246957|NCT03060460|No Intervention|Conventional arm - Randomized group|Conventional arm during randomized phase
11246958|NCT03060460|No Intervention|Historical control group|Conventional arm, non-randomization phase
11247036|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
11247042|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
11246959|NCT03060447|Experimental|Vesatolimod|"Period 1: Participants will receive up to 10 doses of vesatolimod. Participants will continue to take their prescribed ART during this period.
~Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.
~Period 3: Participants may either enter in an optional analytical treatment interruption (ATI) extension period where they will continue to be off ART for up to an additional 6 months or restart ART and be monitored for additional 6 months."
11246960|NCT03060447|Experimental|Vesatolimod placebo|"Period 1: Participants will receive up to 10 doses of vesatolimod placebo. Participants will continue to take their prescribed ART during this period.
~Period 2: All participants will discontinue ART and be monitored for rebound in HIV-1 plasma viremia.
~Period 3: Participants may either enter in an optional analytical treatment interruption (ATI) extension period where they will continue to be off ART for up to an additional 6 months or restart ART and be monitored for additional 6 months."
11246961|NCT03060434|Active Comparator|Control|Ibuprofen
11246962|NCT03060434|Experimental|Pentoxifylline|Pentoxifylline oral tablets
11246963|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
11246964|NCT03060408||Open|Patients underwent open distal pancreatectomy
11246965|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
11246966|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:
~Days 1 and 2: 100 mL twice a day
~Days 3 and 4: 150 mL twice a day
~Days 5 and 6: 200 mL twice a day
~Days 7 to 14: 250 mL twice a day"
11246967|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.
~Progressive intake of intervention milk as follows:
~Days 1 and 2: 100 mL twice a day
~Days 3 and 4: 150 mL twice a day
~Days 5 and 6: 200 mL twice a day
~Days 7 to 14: 250 mL twice a day"
11246968|NCT03060382|Experimental|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
11246969|NCT03060382|Placebo Comparator|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
11246970|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:
~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
11246971|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:
~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
11246972|NCT03060356|Active Comparator|Melanoma|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
11246973|NCT03060356|Active Comparator|Breast|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
11246974|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
11246975|NCT03060330|Experimental|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
11246976|NCT03060330|Experimental|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
11246977|NCT03060317||Validation group DOC|Examination with neurological scales.
11246978|NCT03060304|Experimental|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
11246979|NCT03060304|Active Comparator|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness <7mm and E2<100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
11246980|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
11246981|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
11246982|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
11246983|NCT03060278|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
11247037|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
11247045|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
11246984|NCT03060278|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
11246985|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
11246986|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
11246987|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
11246988|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
11246989|NCT03060226|Other|Control group|
11246990|NCT03060226|Other|radiosensibility group|
11246991|NCT03060213|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
11246992|NCT03060213|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
11246993|NCT03060200|Experimental|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
11246994|NCT03060200|No Intervention|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
11246995|NCT03060200|Placebo Comparator|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
11246996|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
11246997|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|The treatment group will receive monitoring and prophylaxis of delirium. The study arm designed to prevent delirium incorporates reorientation (watches, calendar, family photos, use of hearing aids, glasses and dentures, cognitive stimulation (newspaper, magazines, radio, television), early mobilisation, early enteral nutrition, early removal of drains or catheters, normalizing sleep-awake-rhythm.
11246998|NCT03060174|No Intervention|Standard|The standard group will receive standard monitoring and standard treatment. The indication, choice and dosage of the medication used to treat delirium will be at the discretion of the ward doctor and will not be influenced by this study. The chosen medication as well as its dosage will be documented.
11246999|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.
~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
11247000|NCT03060148|Active Comparator|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
11247001|NCT03060148|No Intervention|Control|No implantation of Medtronic neurostimulation system
11247002|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
11247003|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
11247004|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
11247005|NCT03060122|No Intervention|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
11247006|NCT03060122|Experimental|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.
~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.
~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
11247007|NCT03060122|Active Comparator|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.
~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.
~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
11247008|NCT03060109||Suspected traumatic brain injury|
11247038|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
11247009|NCT03060096|Experimental|Moderate Anxiety/depression: Low Intensity Stepped care|participants with moderate symptoms (PHQ-9-14; GAD-7: 10-14) will be randomized to either low-intensity stepped care or enhanced usual care. Stepped care consist of a self-guided cognitive behavioral therapy (CBT) workbook to reduce anxiety and depressive symptoms and biweekly (every two weeks) check-in calls from research staff to assess changes in symptom severity/immediate need for psychiatric treatment and provide minimal support.
11247010|NCT03060096|Experimental|Severe Anxiety/depression: High Intensity Stepped Care|Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
11247011|NCT03060096|Active Comparator|Enhanced Usual Care Control (EUC)|"Participants randomized to EUC will receive information about local referrals/resources (support groups, mental health providers, etc.). They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the NCI to assist with transition from active treatment to survivorship. Participants will receive information on self-help workbooks for anxiety & depressive symptoms. EUC control will receive a copy of the CBT workbook on completion of the study."
11247012|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
11247013|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
11247014|NCT03060070|Placebo Comparator|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
11247015|NCT03060070|Active Comparator|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
11247016|NCT03060070|Active Comparator|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
11247017|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
11247018|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
11247019|NCT03060044|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
11247020|NCT03060044|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
11247021|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
11247022|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
11247023|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
11247024|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
11247025|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
11247026|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
11247027|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
11247028|NCT03059992|Experimental|Ibrexafungerp (SCY-078)|Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.
11247029|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
11247030|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
11247031|NCT03059966|Experimental|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
11247032|NCT03059966|Placebo Comparator|Placebo|Microsurgery for root coverage associated with a Placebo comparator
11247033|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.
~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
11247034|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.
~LDCT provider and patient discuss options for pharmacotherapy.
~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
11247035|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.
~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
11247039|NCT03059914|Experimental|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
11247046|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
11247047|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
11247048|NCT03059849|Active Comparator|Temporary increase in adalimumab|
11247049|NCT03059849|No Intervention|Continued monitoring as per standard of care|
11247050|NCT03059836|Experimental|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
11247051|NCT03059836|Placebo Comparator|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
11247052|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
11247053|NCT03059823|Experimental|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
11247054|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
11247055|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
11247056|NCT03059810|Experimental|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
11247057|NCT03059797|Experimental|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
11247058|NCT03059797|Placebo Comparator|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
11247059|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
11247060|NCT03059784|No Intervention|control|usual care without APP
11247061|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
11247062|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
11247063|NCT03059758|Experimental|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
11247064|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
11247065|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
11247066|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
11247067|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
11247068|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
11247069|NCT03059706|Experimental|RegenoGel-OSP™|
11247070|NCT03059706|Placebo Comparator|Placebo|
11247071|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
11247072|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
11247073|NCT03059680|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
11247074|NCT03059680|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
11247075|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:
~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)
~or re-induction by carboplatin - etoposide chemotherapy."
11247076|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
11247077|NCT03059654|Active Comparator|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
11247078|NCT03059654|Active Comparator|Surgical tracheostomy|Surgical tracheostomy
11247079|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
11247080|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
11247081|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
11247082|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
11247083|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
11247084|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
11247085|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
11247086|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
11247087|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
11247088|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
11247089|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
11247090|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
11247091|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
11247092|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
11247093|NCT03059524||patients with multiple organ failure|
11247094|NCT03059524||patients without multiple organ failure|
11247095|NCT03059524||normal subjects|
11247096|NCT03059511|Active Comparator|intravenous|single iv application of nalbuphine 0.05mg/kg
11247097|NCT03059511|Active Comparator|intranasal|single intranasal application of nalbuphine 0.1mg/kg in infants.
11247098|NCT03059498|Active Comparator|unilateral PECS block patients|unilateral PECS I and II block using bupivacaine
11247099|NCT03059498|Active Comparator|bilateral PECS block patients|bilateral PECS I and II block using bupivacaine
11247100|NCT03059485|Experimental|DC/AML Vaccine|- Patients will be vaccinated with DC/AML Fusion Vaccine
11247101|NCT03059485|Experimental|Observation|- Patients will be monitored with routine labs and bone marrow biopsies
11247102|NCT03059472|Experimental|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
11247103|NCT03059472|Experimental|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
11247104|NCT03059446|Experimental|Cenicriviroc|Cenicriviroc (CVC) 150 mg tablet once daily in the morning with food until CVC is commercially available or the study is terminated.
11247105|NCT03059433||AVID Intervention|175 students will be randomized via lottery by the participating high school to be part of the AVID program. These students will receive 4 surveys (8th, 9th, 10th, and 11th grade).
11247106|NCT03059433||Non AVID|175 students will be randomized via lottery by the participating high school to be part of our control group. This group of students will be similar to the AVID group, except they will not be in the AVID program. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
11247107|NCT03059433||High Performing|175 students who are identified as high performing (middle school grade point average >3.5) by the participating high school. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
11247108|NCT03059407|Other|Dog therapy only|Canine assisted therapy only during echocardiogram
11247109|NCT03059407|Other|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
11247110|NCT03059407|Other|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
11247111|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
11247112|NCT03059368|Experimental|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
11247113|NCT03059355|Experimental|Pilot Phase: Group 1 (UCMSCs)|Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
11247114|NCT03059355|Experimental|Pilot Phase: Group 2 (UCMSCs - 100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
11247115|NCT03059355|Experimental|Pilot Phase: Group 3 (BMMSCs - 20 million)|Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
11247116|NCT03059355|Experimental|Pilot Phase: Group 4 (BMMSCs -100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
11247117|NCT03059355|Experimental|Group A (UCMSCs - 20 Million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
11247118|NCT03059355|Experimental|Group B (UCMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
11247119|NCT03059355|Experimental|Group C (BMMSCs - 20 million)|Five (5) subjects will be treated with a single administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
11247120|NCT03059355|Experimental|Group D (BMMSCs - 100 million)|Five (5) subjects will be treated with a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
11247121|NCT03059355|Placebo Comparator|Group E (Placebo)|Five (5) subjects will be treated with a single administration of placebo delivered via peripheral intravenous infusion.
11247122|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
11247123|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
11247124|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
11247125|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
11247126|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
11247127|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
11247128|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
11247129|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
11247130|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247131|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247132|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247133|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247134|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247135|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247136|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247137|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
11247138|NCT03059290|Active Comparator|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
11247139|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
11247140|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
11247141|NCT03059264||Control|Healthy Children
11247142|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
11247143|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
11247144|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
11247145|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
11247146|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention for 10-min of contralesional 1Hz-repetitive transcranial magnetic stimulation(rTMS) or 10-min ipsilesional 5-Hz rTMS for 10 daily sessions; Computer-integrated Speech Training for 20 mins
11247147|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program. Computer-integrated Speech Training for 20 mins
11247148|NCT03059212|Experimental|5Hz rTMS|rTMS group
11247150|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
11247151|NCT03059186|Experimental|Intervention|Online daily gratitude journal.
11247152|NCT03059186|No Intervention|Control|
11247153|NCT03059173|Active Comparator|Inositol + Clomiphene Citrate|The experimental group will receive the dietary supplement: 4 g of MYO + 0.4 mg of FA per day per os (in 2 bags per day) in addition to the standard therapy Clomiphene citrate (CC).
11247154|NCT03059173|Placebo Comparator|Placebo + Clomiphene Citrate|The control group will receive the standard therapy CC and a placebo containing only 0.4 mg of FA.
11247155|NCT03059160|Experimental|open label|
11247156|NCT03059147|Experimental|SF1126 + Nivolumab|SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
11247157|NCT03059134|Experimental|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
11247158|NCT03059134|Active Comparator|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
11247159|NCT03059134|Active Comparator|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
11247160|NCT03059134|Active Comparator|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
11247161|NCT03059108|Experimental|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
11247162|NCT03059108|Active Comparator|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
11247163|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
11247164|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.
~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
11247165|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
11247166|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
11247167|NCT03059069|Experimental|Glitamin|800mg/day
11247168|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
11247169|NCT03059056|Experimental|pharmacokinetic evaluation|Empagliflozin 25 mg
11247170|NCT03059043|Experimental|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
11247171|NCT03059043|Active Comparator|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
11247172|NCT03059030|Experimental|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
11247173|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
11247174|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
11247175|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
11247176|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
11247177|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
11247178|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
11247179|NCT03058991|Experimental|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
11247180|NCT03058991|Experimental|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
11247216|NCT03058770|Experimental|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
11247217|NCT03058770|Active Comparator|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
11247181|NCT03058991|Active Comparator|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
11247182|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
11247183|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
11247184|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
11247185|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
11247186|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
11247187|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
11247188|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
11247189|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
11247190|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
11247191|NCT03058926||Chronic Pancreatitis|
11247192|NCT03058926||Diabetes|
11247193|NCT03058926||Pancreatic Cancer|
11247194|NCT03058900|Experimental|Fecal microbiota transplantation (FMT)|
11247195|NCT03058900|Sham Comparator|Placebo (saline)|
11247196|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
11247197|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
11247198|NCT03058887|No Intervention|Control group|No exercise intervention.
11247199|NCT03058874|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
11247200|NCT03058874|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
11247201|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
11247202|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
11247203|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
11247204|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
11247205|NCT03058822|Experimental|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
11247206|NCT03058822|Experimental|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
11247207|NCT03058822|Experimental|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
11247208|NCT03058822|Experimental|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
11247209|NCT03058822|Experimental|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
11247210|NCT03058822|Experimental|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
11247211|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
11247212|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
11247213|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
11247214|NCT03058783|Experimental|IDP-124 Lotion|Lotion
11247215|NCT03058783|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
11247219|NCT03058757|Experimental|Intervention arm|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
11247220|NCT03058744|Experimental|IDP-118 Lotion|8 Weeks
11247221|NCT03058744|Experimental|HP Monad Lotion|8 Weeks
11247222|NCT03058744|Active Comparator|Ultravate Cream|2 Weeks
11247223|NCT03058744|Active Comparator|Tazorac Cream|4 Weeks
11247224|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
11247225|NCT03058731||Control|Other biological mesh
11247226|NCT03058718|Experimental|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:
~No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.
~Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
11247227|NCT03058718|Active Comparator|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
11247228|NCT03058705|Experimental|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
11247229|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
11247230|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
11247231|NCT03058679|Experimental|Specific Carbohydrate Diet|
11247232|NCT03058679|Active Comparator|Mediterranean Style Diet|
11247233|NCT03058666|Experimental|Aerosolized Calfactant|"NICU Patients with a clinical diagnosis of RDS
~Inspired oxygen ≥21% to maintain adequate oxygen saturation
~Not Intubated
~Requiring Nasal continuous positive airway pressure"
11247234|NCT03058666|No Intervention|Usual Care|There will be no protocol driven interventions in the usual care group.
11247235|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
11247236|NCT03058640|Experimental|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
11247237|NCT03058640|No Intervention|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
11247238|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
11247239|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR < 0.80 in vessels ≥ 2.5 mm in diameter .
11247240|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
11247241|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
11247242|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND
~a first- or second-degree relative with acute leukemia or other myeloid malignancies
~a first- or second-degree relative with lymphoproliferative neoplasms
~or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
11247243|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
11247244|NCT03058575|Other|Control|No Intervention
11247245|NCT03058562|Experimental|Crossover Sequence A|"Each in the fasting state:
~Period 1: Single-dose matching placebo
~Period 2: Single-dose ABX-1431"
11247246|NCT03058562|Experimental|Crossover Sequence B|"Each in the fasting state:
~Period 1: Single-dose ABX-1431
~Period 2: Single-dose matching placebo"
11247247|NCT03058562|Experimental|Crossover Sequence C|"Each with a standard high fat meal:
~Period 3: Single-dose matching placebo
~Period 4: Single-dose ABX-1431"
11247248|NCT03058562|Experimental|Crossover Sequence D|"Each with a standard high fat meal:
~Period 3: Single-dose ABX-1431
~Period 4: Single-dose matching placebo"
11247249|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
11247725|NCT03055546|Placebo Comparator|Placebo|intranasal administration of placebo
11247250|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
11247251|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
11247252|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone
~400 mg micronized vaginal progesterone daily from randomization to 36 weeks
~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
11247253|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
11247254|NCT03058536|No Intervention|No intervention|Expectant management
11247255|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
11247256|NCT03058523||Pregnant|30 pregnant women
11247257|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
11247258|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
11247259|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
11247260|NCT03058484|No Intervention|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
11247261|NCT03058484|Experimental|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
11247262|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
11247263|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
11247264|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
11247265|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
11247266|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
11247267|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
11247268|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
11247269|NCT03058432|Experimental|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
11247270|NCT03058432|Active Comparator|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
11247271|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
11247272|NCT03058406||Eribulin mesylate|
11247273|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
11247274|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
11247275|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
11247276|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
11247277|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
11247278|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
11247279|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
11247280|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
11247281|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
11247282|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
11247283|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
11247284|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
11247285|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
11247286|NCT03058289|Experimental|Cohort A|"INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.
~Closed to enrollment"
11247287|NCT03058289|Experimental|Cohort B1|"INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor
~Closed to enrollment"
11247288|NCT03058289|Experimental|Cohort EA|"INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor
~Closed to enrollment"
11247289|NCT03058289|Experimental|Cohort EC|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor
~Closed to enrollment"
11247290|NCT03058289|Experimental|Cohort EC2|INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC
11247291|NCT03058289|Experimental|Cohort DEC: Safety with INT230-6|"INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.
~Closed to enrollment"
11247292|NCT03058289|Experimental|EC3: INT230-6 monotherapy fixed maximal dose|INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.
11247293|NCT03058289|Experimental|DEC2: INT230-6 combined with pembrolizumab|INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.
11247294|NCT03058289|Experimental|FEC: INT230-6 combined with ipilimumab|INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.
11247295|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
11247296|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
11247297|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
11247298|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
11247299|NCT03058263|Experimental|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
11247300|NCT03058263|Experimental|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
11247301|NCT03058250|No Intervention|Control|Standard of care, no intervention
11247302|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
11247303|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
11247304|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
11247305|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
11247306|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
11247307|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.
~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
11247308|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
11247309|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
11247310|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
11247311|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.
~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
11247312|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
11247313|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
11247314|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
11247315|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
11247316|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.
~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
11247805|NCT03054922|Active Comparator|Normal Saline|0.9% Sodium Chloride
11247317|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
11247318|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
11247319|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
11247320|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
11247321|NCT03058198|Experimental|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
11247322|NCT03058172|Other|Odors (food and non-food)|Odorants diluted in mineral oil.
11247323|NCT03058172|Other|Pictures (food and non-food)|Pictures of objects or scenes.
11247324|NCT03058159|Other|Subjects with a high dream recall frequency|
11247325|NCT03058159|Other|Subjects with a law dream recall frequency|
11247326|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
11247327|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
11247328|NCT03058133|Other|fMRI study|
11247329|NCT03058120|No Intervention|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
11247330|NCT03058120|Active Comparator|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
11247331|NCT03058107|Experimental|Nutrition Therapy (NT) group|Nutrition Therapy is intensive dietary counseling based on practical measurements of energy expenditure, rather than calculating it using theoretic formulas or no method at all.
11247332|NCT03058107|Active Comparator|Control Therapy (CT) group|Control Therapy is standard dietary counseling bij state-wide recognized onco-dietitians. Energy expenditure is never measured in this standard protocol.
11247333|NCT03058094|Experimental|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
11247334|NCT03058094|Active Comparator|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
11247335|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
11247336|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
11247337|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
11247338|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
11247339|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
11247340|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
11247341|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
11247342|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
11247343|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
11247344|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
11247345|NCT03058042|Experimental|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
11247346|NCT03058042|Sham Comparator|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
11247347|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
11247348|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
11247349|NCT03058016|Experimental|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.
~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
11247350|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
11247351|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
11247352|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
11247353|NCT03057977|Experimental|Empagliflozin|
11247354|NCT03057977|Placebo Comparator|Placebo|
11247355|NCT03057964|Experimental|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
11247356|NCT03057964|No Intervention|Control|
11247357|NCT03057951|Experimental|Empagliflozin|
11247358|NCT03057951|Placebo Comparator|Placebo|
11247359|NCT03057938|Experimental|18F-Florbetaben (FBB)|18F-Florbetaben
11247360|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
11247361|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
11247362|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
11247363|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
11247364|NCT03057912|No Intervention|Control group|Observation
11247365|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
11247366|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
11247367|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
11247368|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
11247369|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
11247370|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
11247371|NCT03057834|Active Comparator|Functionally impaired|Women with urinary incontinence and short physical performance battery score of <9
11247372|NCT03057834|Placebo Comparator|Functionally normal|Women with urinary incontinence and short physical performance battery score of > 10
11247373|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
11247374|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
11247375|NCT03057808|Experimental|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
11247376|NCT03057808|Experimental|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
11247377|NCT03057808|Experimental|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
11247378|NCT03057795|Experimental|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11247379|NCT03057782||Group A|"Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);
~Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
11247380|NCT03057782||Group B|"Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);
~Patients who are not anticipated to receive acute post-surgical NMB
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
11247381|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
11247413|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
11247382|NCT03057782||Group D|"No plan for surgery
~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
11247383|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
11247384|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
11247385|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
11247386|NCT03057730|Experimental|Group 1: Thin Biotype|"Gingival thickness < 0.8 mm
~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.
~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
11247387|NCT03057730|Experimental|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm
~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.
~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
11247388|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
11247389|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
11247390|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
11247391|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
11247392|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
11247393|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
11247394|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
11247395|NCT03057678|Experimental|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
11247396|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
11247397|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
11247398|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
11247399|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
11247400|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
11247401|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
11247402|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
11247403|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
11247404|NCT03057626||Observational (specimen collection)|Patients undergo collection of blood and urine samples on day 1. Patients also undergo clinical assessments, laboratory, radiographic, and other ancillary studies on day 1.
11247405|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
11247406|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Pac-CB combination
~Patients must self-identify as African ancestry (AA; includes African American).
~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.
~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.
~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
11247407|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination
~Patients must self-identify as African ancestry (includes African American).
~No prior systemic therapy for advanced or metastatic disease.
~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
11247408|NCT03057600|Experimental|Cohort 3 - Non-AA, 3rd line+|"Intervention = Pac-CB combination
~Patients do not self-identify as African ancestry.
~Otherwise have the same criteria as Cohort 1."
11247409|NCT03057600|Experimental|Cohort 4 - Non-AA, 1st line|"Intervention = Pac-CB combination
~Patients do not self-identify as African ancestry.
~Otherwise have the same criteria as Cohort 2."
11247410|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
11247411|NCT03057574|Experimental|Treatment|Follitropin Alfa (Gonapure)
11247412|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
11247642|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
11247414|NCT03057548|Active Comparator|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins
~or
~Radiofrequency ablation only of Pulmonary Veins
~Pulmonary Vein Isolation (PVI) alone."
11247415|NCT03057548|Experimental|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall
~or
~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall
~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
11247416|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
11247417|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
11247418|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
11247419|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
11247420|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.
~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.
~Standard LAR Octreotide will be administered.
~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.
~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
11247421|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
11247422|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
11247423|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
11247424|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
11247425|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
11247426|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
11247427|NCT03057470|Active Comparator|0% Bolus Insulin Correction|0% Bolus Insulin Correction
11247428|NCT03057470|Active Comparator|50% Bolus Insulin Correction|50% Bolus Insulin Correction
11247429|NCT03057470|Active Comparator|100% Bolus Insulin Correction|100% Bolus Insulin Correction
11247430|NCT03057470|Active Comparator|150% Bolus Insulin Correction|150% Bolus Insulin Correction
11247431|NCT03057457||Kidney Injury|
11247432|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
11247433|NCT03057431|Placebo Comparator|Placebo|Once daily for 3 years
11247434|NCT03057431|Experimental|12.5 mg hydrochlorothiazide|Once daily for 3 years
11247435|NCT03057431|Experimental|25.0 mg hydrochlorothiazide|Once daily for 3 years
11247436|NCT03057431|Experimental|50.0 mg hydrochlorothiazide|Once daily for 3 years
11247437|NCT03057418|Experimental|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.
~Mode of administration: intravenous."
11247438|NCT03057405||intra-operative CBCT|
11247439|NCT03057405||3D virtual planning + intra-operative navigation|
11247440|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
11247441|NCT03057392|Experimental|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
11247442|NCT03057392|Sham Comparator|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
11247443|NCT03057379|No Intervention|Control arm|Usual source of care
11247444|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
11247445|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
11247446|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
11247447|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
11247448|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
11247449|NCT03057340|Experimental|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
11247450|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
11247451|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
11247683|NCT03055845|Experimental|STA363 dose 3|
11247684|NCT03055845|Placebo Comparator|Placebo|
11247452|NCT03057314|Experimental|Amorphous calcium carbonate|"The investigation product will include:
~ACC tablets, containing 200 mg elemental calcium
~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
11247453|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
11247454|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
11247455|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
11247456|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
11247457|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
11247458|NCT03057236|No Intervention|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
11247459|NCT03057236|Experimental|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
11247460|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
11247461|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
11247462|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
11247463|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
11247464|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
11247465|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
11247466|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
11247467|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
11247468|NCT03057184|Experimental|Intervention group|behavioral intervention program
11247469|NCT03057184|No Intervention|Usual care|Usual care
11247470|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
11247471|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
11247472|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
11247473|NCT03057171||health individuals|patients who will undergo screening EGD
11247474|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
11247475|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
11247476|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
11247477|NCT03057158||4|Healthy Volunteers
11247478|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.
~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
11247479|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
11247480|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
11247481|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
11247482|NCT03057106|Active Comparator|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
11247483|NCT03057106|Active Comparator|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)
~Followed by:
~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
11247484|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
11247485|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
11247486|NCT03057080|Other|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
11247487|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
11247488|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
11247489|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
11247490|NCT03057041|Experimental|Fentanyl|
11247491|NCT03057041|Placebo Comparator|Placebo|
11247492|NCT03057028|Experimental|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
11247493|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
11247494|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
11247495|NCT03057002||HCM Group|HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
11247496|NCT03057002||Control Group|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
11247497|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
11247498|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
11247499|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
11247500|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
11247501|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
11247502|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
11247503|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
11247504|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
11247505|NCT03056950|No Intervention|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
11247506|NCT03056950|Active Comparator|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
11247507|NCT03056937||Obese with metabolic syndrome|bariatric surgery
11247508|NCT03056937||Obese without metabolic syndrome|bariatric surgery
11247509|NCT03056937||Healthy|Control
11247510|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
11247511|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
11247512|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
11247513|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
11247514|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
11247515|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
11247516|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
11247517|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
11247518|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
11247519|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
11247520|NCT03056872||Healthy Controls|Community sample
11247521|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
11247522|NCT03056846|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11247523|NCT03056846|Experimental|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11247524|NCT03056846|Experimental|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11247525|NCT03056846|Experimental|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11247526|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
11247527|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
11247528|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
11247529|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
11247530|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
11247531|NCT03056794||PDC Deficiency|Pyruvate Dehydrogenase Complex Deficiency Disease
11247532|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
11247533|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
11247534|NCT03056768|Active Comparator|active control|Health promotion provided by local health bureau.
11247535|NCT03056768|Experimental|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
11247536|NCT03056755|Experimental|Prior CDK 4/6 + aromatase|Patients who received any Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib 500 mg oral.+ fulvestrant 500 mg intramuscular (i.m)
11247537|NCT03056755|Experimental|Prior CDK 4/6 + fulvestrant|Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib 300 mg oral + letrozole 2.5 mg oral
11247538|NCT03056755|Experimental|Prior systemic chemo or ET|Patients who received systemic chemotherapy or endrocrine therapy (ET) , (including monotherapy or in combination with targeted therapy except CDK 4/6i + AI) as immediate prior treatment will receive alpelisib 300 mg oral + fulvestrant 500 mg i.m.
11247539|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
11247540|NCT03056729|Experimental|Cohort HV1|
11247541|NCT03056729|Experimental|Cohort HV2|
11247542|NCT03056729|Experimental|Cohort HV3|
11247543|NCT03056729|Experimental|Cohort HV4|
11247544|NCT03056729|Experimental|Cohort HV5|
11247545|NCT03056729|Experimental|Cohort AD1|
11247546|NCT03056716|Experimental|Silastic drain|Placement of 19FR silastic drain as basal drain
11247547|NCT03056716|Active Comparator|Conventional drain|Placement of 32FR conventional drain as basal drain
11247548|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
11247549|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
11247550|NCT03056690|Experimental|ASP0819|A single oral dose to be taken preferably in the morning with or without food
11247551|NCT03056690|Placebo Comparator|Placebo|A single oral dose to be taken preferably in the morning with or without food
11247552|NCT03056677|Experimental|Control|No Whey Protein
11247553|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
11247554|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
11247555|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
11247556|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
11247557|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
11247558|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
11247559|NCT03056638|Experimental|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
11247560|NCT03056638|Experimental|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
11247561|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
11247562|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
11247563|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
11247564|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
11247565|NCT03056612||ACLF|ACLF-patients were specified the patients who were admitted at hospital with ACLF,
11247685|NCT03055832|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
11247566|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected one to three days prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
11247567|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.
~Follow-up will be after 3, 6, and 12 month period."
11247568|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
11247569|NCT03056573|Experimental|Subclavian/axillary|Subclavian/axillary access route
11247570|NCT03056573|Experimental|Transaortic|Transaortic access route
11247571|NCT03056560|Experimental|Video Bystander Program|TakeCARE video
11247572|NCT03056560|No Intervention|Control Video|Study Skills Video
11247573|NCT03056547|Experimental|Induced dyspnea|
11247574|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.
~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
11247575|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
11247576|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
11247577|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
11247578|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
11247579|NCT03056482|Active Comparator|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
11247580|NCT03056482|Experimental|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
11247581|NCT03056482|Experimental|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
11247582|NCT03056469|Active Comparator|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
11247583|NCT03056469|Active Comparator|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
11247584|NCT03056469|No Intervention|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
11247585|NCT03056456|Experimental|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
11247586|NCT03056456|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
11247587|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
11247588|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
11247589|NCT03056430|Experimental|Training Group 1|Slackline training
11247590|NCT03056430|Experimental|Training Group 2|Slackline training
11247591|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
11247592|NCT03056417|No Intervention|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
11247593|NCT03056404|Experimental|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
11247594|NCT03056391|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.
~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
11247595|NCT03056391|No Intervention|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.
~If temperature >39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
11247596|NCT03056378|Experimental|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
11247597|NCT03056378|Active Comparator|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
11247598|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
11247599|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
11247600|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
11247724|NCT03055546|Experimental|Oxytocin|intranasal administration of oxytocin
11247601|NCT03056339|Experimental|Fludarabine + Cyclophosphamide + CAR-NK Cells|"On Days -5, -4, and -3, participants receive Fludarabine and Cyclophosphamide. Participants also receive Mesna before and after the cyclophosphamide dose.
~On Day 0, participants receive genetically modified NK cells as a cell infusion.
~If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they receive AP1903 by vein and possibly steroids by mouth or by vein."
11247602|NCT03056326|Experimental|CHF6333 Active|
11247603|NCT03056326|Placebo Comparator|Placebo|
11247604|NCT03056313|Experimental|proactive support of labor|delayed labor; 1 cm opening and painful contractions
11247605|NCT03056313|Active Comparator|support of labor as usual|delayed labor; 3-4 cm opening of the cervix and regular contractions
11247606|NCT03056300|Experimental|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
11247607|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
11247608|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
11247609|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
11247610|NCT03056287|Sham Comparator|Sham|Sham rTMS
11247611|NCT03056274|Active Comparator|Metformin arm|Metformin
11247612|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
11247613|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
11247614|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
11247615|NCT03056248|Active Comparator|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
11247616|NCT03056248|Placebo Comparator|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
11247617|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
11247618|NCT03056235|Placebo Comparator|Saline control|Saline
11247619|NCT03056222|Active Comparator|HeartLight® EGLA|Participants will be treated with the endoscopically guided laser ablation catheter
11247620|NCT03056222|Active Comparator|Contact Force Sensing Irrigated RF ablation|Participants will be treated with a contact force sensing irrigated radiofrequency ablation catheter
11247621|NCT03056209|Experimental|KL1333 25mg|Group 1
11247622|NCT03056209|Experimental|KL1333 50mg|Group 2
11247623|NCT03056209|Experimental|KL1333 100mg|Group 3
11247624|NCT03056209|Experimental|KL1333 200mg|Group 4
11247625|NCT03056209|Experimental|KL1333 400mg|Group 5
11247626|NCT03056209|Experimental|KL1333 600mg|Group 6
11247627|NCT03056209|Experimental|KL1333 800mg|Group 7
11247628|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
11247629|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
11247630|NCT03056170|Active Comparator|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
11247631|NCT03056170|Sham Comparator|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
11247632|NCT03056157|Experimental|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
11247633|NCT03056157|Active Comparator|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role, but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
11247634|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
11247635|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
11247636|NCT03056131|No Intervention|Control Group|
11247637|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
11247638|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
11247639|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
11247640|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
11247641|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
11247643|NCT03056092|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
11247644|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
11247645|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
11247646|NCT03056040|Experimental|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.
~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
11247647|NCT03056040|Active Comparator|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.
~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
11247648|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
11247649|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
11247650|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
11247651|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
11247652|NCT03056014|Placebo Comparator|placebo|
11247653|NCT03056014|Active Comparator|PUFA 1000 mg|
11247654|NCT03056014|Active Comparator|PUFA 2000 mg|
11247655|NCT03056014|Placebo Comparator|Placebo|
11247656|NCT03056001|Experimental|Pembrolizumab + doxorubicin|Participants receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of each cycle.
11247657|NCT03055988|Experimental|Tiotropium/Olodaterol Fixed Dose Combination|
11247658|NCT03055988|Active Comparator|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
11247659|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
11247660|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
11247661|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
11247662|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
11247663|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
11247664|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
11247665|NCT03055936|Experimental|levodopa with carbidopa lower doses|levodopa 50 mg, carbidopa 12,5 mg
11247666|NCT03055936|Experimental|levodopa with carbidopa and ODM-104|levodopa 50 mg or 100 mg or 150 mg, carbidopa 65 mg and ODM-104 50 mg or 100 mg
11247667|NCT03055936|Experimental|levodopa with carbidopa higher doses|levodopa 150 mg, carbidopa 37,5 mg
11247668|NCT03055936|Active Comparator|levodopa 100 mg with carbidopa|levodopa 100 mg (levodopa IR), carbidopa 65 or 25 mg
11247669|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
11247670|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
11247671|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
11247672|NCT03055897|Experimental|iLux 2020 System|Meibomian Gland Heating
11247673|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
11247674|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
11247675|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
11247676|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
11247677|NCT03055871|No Intervention|Standard education control group|The control group package will consist of Canada's PA guidelines recommending 180 min per week for young children, transitioning to 60 minutes of activity a day for children at five and a breakdown of ways for the parent to help their child achieve this PA (unstructured, endurance, strength, activities) commensurate with this guide. The guide also contains arguments and information about the benefits of PA.
11247678|NCT03055871|Other|Physical activity planning intervention|The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercise for children where they list physical activities that they have found fun in the past, as well as activities that they would find enjoyable to do as a family.
11247679|NCT03055871|Other|Habit formation intervention|The habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines, or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
11247680|NCT03055858|Experimental|PDA closure|
11247681|NCT03055845|Experimental|STA363 dose 1|
11247682|NCT03055845|Experimental|STA363 dose 2|
11247686|NCT03055832|Active Comparator|LipiFlow Thermal Pulsation System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
11247687|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
11247688|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
11247689|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
11247690|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
11247691|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
11247692|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
11247693|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
11247694|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
11247695|NCT03055754|Experimental|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
11247696|NCT03055754|Active Comparator|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
11247697|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
11247698|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
11247699|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks
~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
11247700|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
11247701|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
11247702|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
11247703|NCT03055702|Experimental|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
11247704|NCT03055702|No Intervention|Usual care group|Usual care, either telephone reminder or no reminder
11247705|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
11247706|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
11247707|NCT03055676|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
11247708|NCT03055676|Active Comparator|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
11247709|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
11247710|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
11247711|NCT03055650|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
11247712|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
11247713|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
11247714|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
11247715|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
11247716|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
11247717|NCT03055598|Experimental|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
11247718|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
11247719|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
11247720|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
11247721|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
11247722|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
11247723|NCT03055559||Globifer Forte|
11247726|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment.
11247727|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks).
11247728|NCT03055520|Experimental|arithmetic training (Kumon method)|
11247729|NCT03055520|Placebo Comparator|nonspecific recreation|
11247730|NCT03055507|Active Comparator|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN pain.
11247731|NCT03055507|Experimental|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
11247732|NCT03055494|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
11247733|NCT03055494|Placebo Comparator|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
11247734|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
11247735|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
11247736|NCT03055468|Experimental|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
11247737|NCT03055468|Active Comparator|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
11247738|NCT03055455||Sepsis|Children with severe sepsis or septic shock
11247739|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
11247740|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
11247741|NCT03055416|Other|Mobile Men App Prototype|Prototype of physical activity mobile app geared for African-American men.
11247742|NCT03055403|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
11247743|NCT03055403|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
11247744|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
11247745|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
11247746|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
11247747|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
11247748|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
11247749|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
11247750|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
11247751|NCT03055338|Experimental|MK-8189|Participants receive MK-8189 (4 mg controlled release [CR] oral tablet[s]) in combination with placebo matching risperidone (oral capsule[s]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
11247752|NCT03055338|Active Comparator|Risperidone|Participants receive risperidone (2 mg oral capsule[s]) in combination with placebo matching MK-8189 (oral tablet[s]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
11247753|NCT03055338|Placebo Comparator|Placebo|Participants receive both placebo matching MK-8189 (oral tablet[s]) as well as placebo matching Risperidone (oral capsule[s]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
11247754|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
11247755|NCT03055312|Active Comparator|TPC chemotherapy|"Conventional chemotherapy(choose a):
~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
11247756|NCT03055312|Experimental|Bicalutamide|Bicalutamide 150mg/day every 28 days
11247757|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
11247758|NCT03055286|Experimental|CWP232291 in combination with cytarabine (ara-C)|
11247759|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
11247760|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
11247761|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
11247762|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
11247763|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
11247764|NCT03055234|Experimental|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
11247765|NCT03055234|Placebo Comparator|Placebo|Placebo (sugar pill) for TID administration
11247766|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
11247767|NCT03055208|Experimental|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):
~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
11247768|NCT03055195|Experimental|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
11247769|NCT03055195|Placebo Comparator|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
11247770|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
11247771|NCT03055182|No Intervention|Control subjects|No intervention administered
11247772|NCT03055169||intensive care patients|patients with a least one organ dysfunction
11247773|NCT03055156|Experimental|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
11247774|NCT03055156|Experimental|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
11247775|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
11247776|NCT03055143|Active Comparator|Ref-08-038|
11247777|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
11247778|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
11247779|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
11247780|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
11247781|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
11247782|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
11247783|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
11247784|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
11247785|NCT03055078|Experimental|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
11247786|NCT03055052|Active Comparator|Control Formula|Standard formula for preterm infants.
11247787|NCT03055052|Experimental|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
11247788|NCT03055026|Experimental|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
11247789|NCT03055026|Placebo Comparator|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
11247790|NCT03055013|Experimental|Arm I (nivolumab, nephrectomy)|"Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 2 cycles. Patients then undergo partial or radical nephrectomy 7-28 days later. Patients then receive nivolumab over 30 IV on day 1. Treatment repeats every 14 days for 6 cycles, and then every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~Patients enrolled after Amendment 4 receive nivolumab IV over 30 minutes on day 1. Patients then undergo partial or radical nephrectomy 7-28 days later. Patient then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
11247791|NCT03055013|Active Comparator|Arm II (nephrectomy)|Patients undergo partial or radical nephrectomy within 8 weeks after registration followed by observation.
11247792|NCT03055000|Experimental|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
11247793|NCT03055000|Experimental|AGS-v with adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
11247794|NCT03055000|Placebo Comparator|Placebo|WFI (0.5mL) on Day 0 and Day 21
11247795|NCT03054987|Active Comparator|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
11247796|NCT03054987|Active Comparator|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
11247797|NCT03054974|Experimental|Modern rehabilitation treatment|Modern rehabilitation treatment
11247798|NCT03054974|Experimental|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
11247799|NCT03054974|Experimental|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
11247800|NCT03054974|Experimental|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
11247801|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
11247802|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
11247803|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
11247804|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
11247806|NCT03054922|Active Comparator|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:
~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
11247807|NCT03054922|Active Comparator|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
11247808|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
11247809|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
11247810|NCT03054896|Experimental|Venetoclax|"Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients
~Chemotherapy cycles will be administered approximately every 3 weeks
~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
11247811|NCT03054870|Active Comparator|Xe-133|"Xe-133 ventilation planar scintigraphy, performed per site standard of care procedures for subject medical need.
~Subjects will be administered approximately 10 to 30 millicurie (mCi) of Xe-133 by inhalation."
11247812|NCT03054870|Experimental|Technegas|Technegas ventilation planar scintigraphy Subjects will receive approximately 1.1 mCi of Technegas (Technetium-99m labeled carbon particles) by inhalation.
11247813|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
11247814|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
11247815|NCT03054844|Experimental|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
11247816|NCT03054844|Experimental|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
11247817|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
11247818|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
11247819|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
11247820|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
11247821|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.
~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
11247822|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
11247823|NCT03054805|No Intervention|Healthy Children|Healthy Children
11247824|NCT03054792|Experimental|FAZA - BOLD- DW- MRS|"18F-FAZA (F18-Fluoroazomycin Arabinoside) is a radioactive agent developed as a non-invasive probe for the assessment of cellular hypoxia. 18F-FAZA Injection is indicated in a single dose of (5.2 MBq/kg [0.14 mCi/kg]) Route/method of administration: intravenous injection.
~Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, MR Spectroscopy [MRS]"
11247825|NCT03054779|Experimental|Canola oil|regular canola oil
11247826|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
11247827|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
11247828|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization
~Interventions :Ranibizumab injection Interventions :Sham macular laser"
11247829|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization
~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
11247830|NCT03054753|Other|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
11247831|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
11247832|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
11247833|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call
11247834|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call
11247835|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
11247836|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
11247865|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
11247866|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
11247837|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.
~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
11247838|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.
~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
11247839|NCT03054688|Experimental|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
11247840|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:
~Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)
~A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)
~New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
11247841|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
11247842|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.
~All patients undergo spirometry before and on every second day after lung surgery."
11247843|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.
~All patients undergo spirometry before and on every second day after lung surgery."
11247844|NCT03054662|Experimental|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
11247845|NCT03054662|Experimental|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
11247846|NCT03054649|Experimental|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
11247847|NCT03054649|Experimental|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
11247848|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
11247849|NCT03054610|Active Comparator|Control|5 ml of local anesthetic (ropivacaine 7.5%)
11247850|NCT03054610|Active Comparator|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
11247851|NCT03054610|Experimental|BTX-A|200U Botulinum Toxins, Type A
11247852|NCT03054597|Experimental|Adults|"The arm consisted of adult participants who underwent:
~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
11247853|NCT03054597|Experimental|Children|"The arm consisted of child participants who underwent:
~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
11247854|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
11247855|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
11247856|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
11247857|NCT03054532|Experimental|Durvalumab and lenalidomide|"Open-label use of 2 drugs:
~Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.
~Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
11247858|NCT03054519|Active Comparator|Metformin|Metformin daily
11247859|NCT03054519|Placebo Comparator|Placebo|Placebo daily for six months.
11247860|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
11247861|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
11247862|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
11247863|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
11247864|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
11247867|NCT03054454|Active Comparator|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
11247868|NCT03054454|No Intervention|comparator|This group will receive usual care
11247869|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
11247870|NCT03054441||Control group|Children, Adolescents and Young with typical development
11247871|NCT03054428|Experimental|Placebo|Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling the amount of placebo on day 1 to match the loading dose). In order to maintain blinding for the study, participants in the <60 kilogram (kg) weight stratum received, in a 1:1 ratio, either placebo matching 200 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose) or placebo matching 300 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose). In the ≥60 kg weight stratum, the participants randomized to the placebo group received placebo matching 300 mg dupilumab (including doubling the amount of placebo on day 1 to match the loading dose).
11247872|NCT03054428|Experimental|Dupilumab 300 mg Q4W|Participants received once every 4 weeks (Q4W) subcutaneous (SC) injections of 300 milligrams (mg) dupilumab following a loading dose of 600 mg on day 1. In order to maintain blinding, all participants received an injection once every 2 weeks (Q2W) from day 1 to week 14. Participants received placebo 2 milliliter (mL) injection at the weeks dupilumab was not given.
11247873|NCT03054428|Experimental|Dupilumab 200 mg or 300 mg Q2W|Participants with baseline weight <60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
11247874|NCT03054415|Other|Healthy Subjects|
11247875|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
11247876|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
11247877|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
11247878|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
11247879|NCT03054376|Active Comparator|Immobilization|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will not be trained. After the two weeks the subjects will train both legs for four weeks.
11247880|NCT03054376|Active Comparator|Training of non-immobilized leg|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will be trained. After the two weeks the subjects will train both legs for four weeks.
11247881|NCT03054363|Experimental|Tucatinib in Combination with Palbociclib and Letrozole|During phase 1b part of this trial (N=20 patients), treatment will be administered in cycles of 28 days and consist of tucatinib 300 mg PO BID, palbociclib 125 mg PO daily for 21 days followed by 7 days off, and letrozole 2.5 mg PO daily. Dose modifications of tucatinib, palbociclib and letrozole will be allowed per protocol. There will be an interim safety analysis performed after enrollment of 10 patients. Safety analysis will take into account proportion of patients requiring dose modifications or interruption for therapy because of toxicity. If excessive toxicity or significant changes in PKs are found, further patients will be enrolled at a lower starting dose level. There will be a second interim safety analysis after enrollment of 20 patients in the study. Once the recommended phase II dose (RP2D) has been determined, testing of this drug combination will be expanded in the phase II part of this trial (N=20 patients) to determine the progression-free survival (PFS) rate.
11247882|NCT03054350|Experimental|Vadadustat, Dose 1|Daily oral dose
11247883|NCT03054350|Experimental|Vadadustat, Dose 2|Daily oral dose
11247884|NCT03054350|Experimental|Vadadustat, Dose 3|Daily oral dose
11247885|NCT03054350|Placebo Comparator|Placebo|Daily oral dose
11247886|NCT03054337|Experimental|Vadadustat, Dose 1|Daily oral dose
11247887|NCT03054337|Experimental|Vadadustat, Dose 2|Daily oral dose
11247888|NCT03054337|Experimental|Vadadustat, Dose 3|Daily oral dose
11247889|NCT03054337|Placebo Comparator|Placebo|Daily oral dose
11247890|NCT03054311|Experimental|Lifestyle Matters intervention|
11247891|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
11247892|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
11247893|NCT03054298|Active Comparator|Cohort 3|PERMANENTLY CLOSED
11247894|NCT03054298|Active Comparator|Cohort 4|PERMANENTLY CLOSED
11247895|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells on day 0 by intrapleural infusion (IP) through an indwelling pleural catheter. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.
11247896|NCT03054298|Active Comparator|Cohort 6|Single dose of 1-3x10^7 lentiviral transduced huCART-meso cells via IV infusion on Day 0, following a flat dose of 1 gram/m^2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion of huCART-meso cells may be followed by up to two (2) additional IV infusions of huCART-meso cells at the same dose level and administered between 21-42 days apart should subjects continue to meet eligibility criteria for each additional infusion. Should subjects remain eligible for additional infusions of huCART-meso cells, cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.
11247897|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
11247898|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
11247899|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
11247900|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
11247901|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
11247902|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
11247903|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
11247904|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
11247905|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
11247906|NCT03054220|Experimental|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
11247907|NCT03054220|Experimental|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
11247908|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
11247909|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
11247910|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
11247911|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
11247912|NCT03054194|Experimental|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
11247913|NCT03054194|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
11247914|NCT03054194|Experimental|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
11247915|NCT03054194|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
11247916|NCT03054194|Experimental|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
11247917|NCT03054194|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
11247918|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
11247919|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)
~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
11247920|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
11247921|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)
~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
11247922|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
11247923|NCT03054155|Experimental|Treatment Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
11247924|NCT03054155|No Intervention|Control Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
11247925|NCT03054142||AKI|
11247926|NCT03054142||non-AKI|
11247927|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.
~Patients will also implement home exercise program. Balance training will be non-supervised program."
11247928|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.
~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.
~Patients will also implement home exercise program."
11247929|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
11247930|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
11247931|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
11247932|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
11247933|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
11247934|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
11247935|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
11247936|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
11247937|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
11247938|NCT03054038|Experimental|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11247939|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
11247940|NCT03054012||CAS group|computer-assisted surgery group
11248036|NCT03053336|No Intervention|Control group|The control group will receive standard care
11247941|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
11247942|NCT03053986|Active Comparator|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
11247943|NCT03053986|Placebo Comparator|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
11247944|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
11247945|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
11247946|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
11247947|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
11247948|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
11247949|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
11247950|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
11247951|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
11247952|NCT03053908|Experimental|Elderly Patients|
11247953|NCT03053895|Experimental|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
11247954|NCT03053895|Active Comparator|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
11247955|NCT03053882|Active Comparator|green tea and peppermint|
11247956|NCT03053882|Active Comparator|peppermint and green tea|
11247957|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.
~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.
~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
11247958|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.
~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
11247959|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
11247960|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
11247961|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
11247962|NCT03053830|Experimental|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
11247963|NCT03053817|Experimental|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
11247964|NCT03053817|No Intervention|Control|No treatment
11247965|NCT03053804|Experimental|MR/PET|hypothesize that MR/PET can have better information than current CT image study
11247966|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
11247967|NCT03053778|Experimental|Intervention|Early follow-up after discharge
11247968|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
11247969|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
11247970|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
11247971|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
11247972|NCT03053752|Experimental|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
11247973|NCT03053739|Active Comparator|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug
~Tab Sildenafil 20 mg - three times a day for 6 months,and
~Tab Bosentan 62.5mg - twice a day for 6 months"
11247974|NCT03053739|Placebo Comparator|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
11247975|NCT03053726|Experimental|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
11248037|NCT03053323|Experimental|Lifestyle Intervention|
11247976|NCT03053726|Sham Comparator|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
11247977|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
11247978|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
11247979|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
11247980|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
11247981|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
11247982|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
11247983|NCT03053674|Experimental|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
11247984|NCT03053674|Active Comparator|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
11247985|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
11247986|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
11247987|NCT03053648|Experimental|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
11247988|NCT03053648|Active Comparator|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
11247989|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):
~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
11247990|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|Mirikizumab test formulation given as a single injection under the skin in healthy participants
11247991|NCT03053622|Experimental|Mirikizumab Test SC 2|Mirikizumab test formulation given as two injections under the skin in healthy participants
11247992|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|Mirikizumab test formulation given as an infusion into the vein in healthy participants
11247993|NCT03053622|Active Comparator|Mirikizumab Reference|Mirikizumab reference formulation given as three injections under the skin in healthy participants
11247994|NCT03053583|Active Comparator|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
11247995|NCT03053583|Active Comparator|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
11247996|NCT03053583|Active Comparator|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
11247997|NCT03053570|Experimental|Cryoballoon|
11247998|NCT03053570|Experimental|Radiofrequency Energy(Contact Force)|
11247999|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
11248000|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
11248001|NCT03053544|Experimental|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
11248002|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
11248003|NCT03053518|Active Comparator|Life Style|
11248004|NCT03053518|Experimental|Life Style + Metformin|
11248005|NCT03053505|Experimental|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
11248006|NCT03053505|Active Comparator|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
11248007|NCT03053505|Experimental|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
11248008|NCT03053492|Experimental|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
11248009|NCT03053492|Active Comparator|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
11248010|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
11248011|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
11248012|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
11248013|NCT03053466|Experimental|Single-Arm|APL-501
11248014|NCT03053453|Active Comparator|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
11248015|NCT03053453|Experimental|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
11248016|NCT03053440|Experimental|Arm A (Experimental Arm-BGB-3111)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]
11248017|NCT03053440|Active Comparator|Arm B (Active Comparator-Ibrutinib)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]
11248018|NCT03053440|Experimental|Arm C (Experimental Arm-BGB-3111)|Approximately 22 participants found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]
11248019|NCT03053427|Placebo Comparator|Placebo|Placebo was administered orally once daily after the evening meal.
11248020|NCT03053427|Experimental|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
11248021|NCT03053414|Active Comparator|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
11248022|NCT03053414|Active Comparator|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
11248023|NCT03053414|Active Comparator|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
11248024|NCT03053414|Active Comparator|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
11248025|NCT03053401||Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
11248026|NCT03053401||Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
11248027|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
11248028|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
11248029|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
11248030|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
11248031|NCT03053375|Experimental|Chronic; active device|MDCure active device
11248032|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
11248033|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65
~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.
~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
11248034|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
11248035|NCT03053336|Experimental|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.
~Intervention: App-technology to increase physical activity"
11248038|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis
~Patients treated with curative intent (stage I-IVb)"
11248039|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour
~Patients treated with curative intent (stage I-IVb)"
11248040|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
11248041|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
11248042|NCT03053284|Placebo Comparator|Placebo|Normal saline s.c. injection once
11248043|NCT03053284|Experimental|Pasireotide|Pasireotide 0.6mg s.c. once
11248044|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
11248045|NCT03053271|Placebo Comparator|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
11248046|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
11248047|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
11248048|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
11248049|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
11248050|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
11248051|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
11248052|NCT03053206|Experimental|ADE arm|"ADE arm
~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
11248053|NCT03053193||MammaPrint and BluePrint testing|All patients will receive MammaPrint and BluePrint testing using the full-genome testing data chip. Treatment will be at the discretion of the physician while adhering to NCCN guidelines.
11248054|NCT03053180||Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir|"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir/ritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.
~The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study."
11248055|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.
~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1
~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
11248056|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
11248057|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
11248058|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
11248059|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
11248060|NCT03053128|Experimental|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
11248061|NCT03053128|Sham Comparator|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
11248062|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
11248063|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
11248064|NCT03053102|Experimental|ACH-0144471|All patients will receive ACH-0144471 during the treatment period.
11248065|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
11248066|NCT03053089|Experimental|Stage 2 (children)|AGT-181
11248067|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
11248068|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
11248069|NCT03053063|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.
~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
11248070|NCT03053063|Experimental|SEL 18 mg|"Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.
~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
11248071|NCT03053063|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.
~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
11248072|NCT03053050|Experimental|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks
~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
11248073|NCT03053050|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks
~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
11248074|NCT03053050|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks
~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
11248075|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
11248076|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
11248077|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
11248078|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
11248079|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
11248080|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
11248081|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
11248082|NCT03052972|Experimental|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
11248083|NCT03052972|Experimental|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
11248084|NCT03052959|Experimental|Immediate Intervention|
11248085|NCT03052959|Other|Wait List Intervention|
11248086|NCT03052946|Active Comparator|Bulking agent|Bulking agent in fecal incontinence
11248087|NCT03052946|Placebo Comparator|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
11248088|NCT03052933|Experimental|Copanlisib/gemcitabine|
11248089|NCT03052920|Experimental|Cochlear Implantation|Cochlear implantation of the poor hearing ear
11248090|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
11248091|NCT03052894|Experimental|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
11248092|NCT03052894|Active Comparator|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
11248093|NCT03052881|Experimental|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
11248094|NCT03052881|No Intervention|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
11248095|NCT03052868|Other|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
11248096|NCT03052855|Other|Participants|All the participants of the 3 groups (depressed patients with suicide attempt, depressed patients without suicide attempt, healthy volunteers) will have to realize a MRI and biological samples.
11248097|NCT03052842|Other|Arm 1|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
11248098|NCT03052842|Other|Arm 2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
11248099|NCT03052842|Other|Arm 3|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
11248100|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
11248101|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
11248133|NCT03052582|Active Comparator|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
11248102|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.
~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.
~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge
~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.
~Patients will be discharged home with PO Tylenol and PO toradol PRN."
11248103|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3
~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain
~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain
~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.
~Patients will be discharged home with Motrin and Percocet for pain PRN."
11248104|NCT03052790|Active Comparator|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
11248105|NCT03052790|Experimental|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
11248106|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
11248107|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
11248108|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
11248109|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
11248110|NCT03052751|Experimental|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
11248111|NCT03052751|Experimental|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
11248112|NCT03052725|Experimental|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
11248113|NCT03052712|Active Comparator|Patients|battery of tests of social cognition
11248114|NCT03052712|Active Comparator|Control|battery of tests of social cognition
11248115|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
11248116|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
11248117|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.
~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
11248118|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.
~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
11248119|NCT03052660|Experimental|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
11248120|NCT03052660|Placebo Comparator|Placebo|Placebo, oral, once, 30-45 minutes before surgery
11248121|NCT03052647|Active Comparator|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
11248122|NCT03052647|Active Comparator|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
11248123|NCT03052634|Experimental|RC48-ADC 1.5 mg/kg (HER2 Positive)|
11248124|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Positive)|
11248125|NCT03052634|Experimental|RC48-ADC 2.5 mg/kg (HER2 Positive)|
11248126|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|
11248127|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
11248128|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
11248129|NCT03052608|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
11248130|NCT03052608|Active Comparator|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
11248131|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
11248132|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
11248134|NCT03052582|Active Comparator|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
11248135|NCT03052556|Other|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
11248136|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
11248137|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
11248138|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
11248139|NCT03052517|Experimental|QAW039 150mg|QAW039 Dose 1 once daily
11248140|NCT03052517|Experimental|QAW039 450 mg|QAW039 Dose 2 once daily
11248141|NCT03052517|Placebo Comparator|Placebo|Placebo once daily
11248142|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
11248143|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
11248144|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
11248145|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
11248146|NCT03052491|Experimental|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
11248147|NCT03052478|Experimental|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
11248148|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
11248149|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
11248150|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
11248151|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
11248152|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
11248153|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
11248154|NCT03052426|Active Comparator|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
11248155|NCT03052426|Active Comparator|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
11248156|NCT03052426|Active Comparator|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
11248157|NCT03052413|Active Comparator|Active|
11248158|NCT03052413|Placebo Comparator|Placebo|
11248159|NCT03052400|Experimental|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
11248160|NCT03052400|Placebo Comparator|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
11248161|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.
~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.
~Decortication of the bone bed to increase the blood supply to the onlay graft.
~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.
~Periosteal incisions are usually needed to allow tension free sutures.
~Vicryl 3/0 sutures for closer.
~augmentin 1g twice daily for 5 days.
~catflam 50g twice daily for 3 days"
11248162|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.
~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.
~Drilling of pilot drill and first drill only.
~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.
~splitting osteotomes are used and mallet to complete the splitting of the bony segment.
~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.
~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.
~Drilling through the bony segment and the block graft.
~Immediate implant placement
~chin graft block dental implants"
11248163|NCT03052374|No Intervention|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
11248164|NCT03052374|Experimental|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
11248259|NCT03051698|Placebo Comparator|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
11248165|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
11248166|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
11248167|NCT03052348|Active Comparator|Group R|Polyethylene glycol hexadecyl ether & betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
11248168|NCT03052348|Experimental|Group A|Fusidic acid & Polyethylene glycol hexadecyl ether,& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
11248169|NCT03052335|Experimental|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
11248170|NCT03052322|Experimental|MSB11022|
11248171|NCT03052322|Active Comparator|EU-Humira|
11248172|NCT03052283||Patients with CF|
11248173|NCT03052283||Age-matched healthy controls|
11248174|NCT03052270|Experimental|Vaginal progesterone and Pessary|"Short cervical length equal or less than 20 mm
~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.
~18 years or older at the time of enrollment.
~Consent to participate in the study
~Vaginal progesterone as standard of care plus Arabin pessary"
11248175|NCT03052270|Active Comparator|Vaginal progesterone only|"Short cervical length equal or less than 20 mm
~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.
~18 years or older at the time of enrollment.
~Consent to participate in the study
~Vaginal progesterone as standard of care"
11248176|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
11248177|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
11248178|NCT03052244|Experimental|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
11248179|NCT03052244|Sham Comparator|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
11248180|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
11248181|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
11248182|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
11248183|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
11248184|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.
~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.
~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.
~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.
~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.
~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
11248185|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.
~Matched individually with patients in the FAM group by age, sex, and municipality.
~Examined at inclusion and 52 weeks after inclusion.
~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
11248186|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)
~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
11248187|NCT03052179|Active Comparator|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
11248188|NCT03052179|Placebo Comparator|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
11248189|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
11248190|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
11248255|NCT03051724|No Intervention|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
11248256|NCT03051711|Experimental|GBT440 Dose 1|Dose 1
11248191|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
11248192|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
11248193|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
11248194|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
11248195|NCT03052127|Experimental|Single Low Dose Light-activated AU-011|Low dose Light-activated AU-011 followed by a single laser light application
11248196|NCT03052127|Experimental|Single Medium Dose Light-activated AU-011|Medium dose Light-activated AU-011 followed by a single laser light application
11248197|NCT03052127|Experimental|Single High Dose Light-activated AU-011|High dose Light-activated AU-011 followed by a single laser light application
11248198|NCT03052127|Experimental|2 Repeat Medium Dose Light-activated AU-011|2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application
11248199|NCT03052127|Experimental|3 Repeat Medium Dose Light-activated AU-011|3 repeat medium doses of Light-activated AU-011 followed by a single laser light application
11248200|NCT03052127|Experimental|Single High Dose Light-activated AU-011 x 2 lasers|High dose Light-activated AU-011 followed by two laser light applications
11248201|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011|3 repeat high doses of Light-activated AU-011 each followed by a single laser light application
11248202|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011 x 2 lasers|3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
11248203|NCT03052127|Experimental|Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers|Expansion of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications (up to 12 additional subjects)
11248204|NCT03052127|Experimental|Observation until Documented Growth of Tumor|Observation until documented growth of tumor and then treatment with 2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
11248205|NCT03052127|Experimental|2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
11248206|NCT03052127|Experimental|Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications in subjects with evidence of documented tumor growth prior to study entry
11248207|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
11248208|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
11248209|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
11248210|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
11248211|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
11248212|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
11248213|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
11248214|NCT03052023|Experimental|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
11248215|NCT03052023|Active Comparator|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
11248216|NCT03052023|Active Comparator|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
11248217|NCT03052010|Other|PrEP for HIV-1 uninfected partners and ART for HIV-1 infected|Integrated PrEP as a bridge to ART HIV-1 prevention strategy
11248218|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
11248219|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
11248220|NCT03051984|Experimental|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
11248221|NCT03051984|No Intervention|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
11248222|NCT03051971|Active Comparator|Jet nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a jet nebulizer
11248223|NCT03051971|Active Comparator|Vibrating Mesh Nebulizer|short-acting bronchodilator (albuterol and/or ipratropium bromide) according to standard of care practices and physician discretion will be administered with a vibrating mesh nebulizer
11248257|NCT03051711|Experimental|GBT440 Dose 2|Dose 2
11248258|NCT03051698|Experimental|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
11248224|NCT03051958|Experimental|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
11248225|NCT03051958|Active Comparator|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.
~After 12 weeks, patients in this arm are crossed over to treatment."
11248226|NCT03051945|Experimental|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
11248227|NCT03051945|Placebo Comparator|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
11248228|NCT03051932|Active Comparator|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
11248229|NCT03051932|Placebo Comparator|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
11248230|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
11248231|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
11248232|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
11248233|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
11248234|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
11248235|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
11248236|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
11248237|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
11248238|NCT03051880|Experimental|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
11248239|NCT03051880|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
11248240|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
11248241|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
11248242|NCT03051854|Experimental|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
11248243|NCT03051854|No Intervention|Control schools|The control school do not receive any intervention.
11248244|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
11248245|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
11248246|NCT03051789|Experimental|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
11248247|NCT03051789|Experimental|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
11248248|NCT03051789|Experimental|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
11248249|NCT03051789|No Intervention|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
11248250|NCT03051776|Experimental|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
11248251|NCT03051776|Active Comparator|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
11248252|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
11248253|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
11248254|NCT03051724|Experimental|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.
~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
11248300|NCT03051399|Placebo Comparator|Placebo|Maltodextrin, 500 mg/day, single serving
11248260|NCT03051698|Experimental|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
11248261|NCT03051685|Experimental|DFN-15 Dose 1|
11248262|NCT03051685|Experimental|DFN-15 Dose 2|
11248263|NCT03051685|Experimental|DFN-15 Dose 3|
11248264|NCT03051685|Active Comparator|Active Comparator|
11248265|NCT03051672|Experimental|Pembrolizumab With Radiation|"Pembrolizumab will be administered intravenously prior to radiation
~Pembrolizumab will be administered every 21 days
~Palliative radiotherapy will be given for 5 treatments"
11248266|NCT03051659|Experimental|Eribulin Mesylate|"Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle.
~Eribulin mesylate will be administered intravenously"
11248267|NCT03051659|Experimental|Eribulin Mesylate Combine with Pembrolizumab|"Pembrolizumab will be administered in clinic once per cycle
~Pembrolizumab will be given intravenously prior to Eribulin Mesylate
~Eribulin mesylate will be administered on Days 1 and 8 of each 21 day cycle.
~Eribulin mesylate will be administered intravenously"
11248268|NCT03051646|Experimental|Acetylsalicylic acid first, placebo second|Participant is administered acetylsalicylic acid one hour prior to exercise.
11248269|NCT03051646|Placebo Comparator|Placebo oral capsule first, ASA second|Participant is administered placebo one hour prior to exercise.
11248270|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
11248271|NCT03051633|No Intervention|Control|Assessment only
11248272|NCT03051607|Experimental|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
11248273|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
11248274|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
11248275|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
11248276|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
11248277|NCT03051568|Experimental|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
11248278|NCT03051555|Experimental|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
11248279|NCT03051542|Experimental|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
11248280|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
11248281|NCT03051516|Experimental|Arm I (recombinant human papillomavirus nonavalent vaccine)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
11248282|NCT03051516|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM at baseline, 2 months, and 6 months.
11248283|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
11248284|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
11248285|NCT03051490|Experimental|Liprotamase|Individually-optimized dose to be administered orally
11248286|NCT03051490|Active Comparator|porcine PERT|Individually-optimized dose to be administered orally
11248287|NCT03051477|Experimental|Helixor® M|Advanced solid tumors
11248288|NCT03051464|Experimental|Chemoradiation + EBRT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
11248289|NCT03051464|Experimental|Chemoradiation + HDRBT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
11248290|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:
~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).
~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
11248291|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:
~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).
~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
11248292|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
11248293|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
11248294|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
11248295|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
11248296|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
11248297|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
11248298|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
11248299|NCT03051412||Control|This is a control group with no history of knee pain.
11248301|NCT03051399|Active Comparator|EpiCor|EpiCor, 500 mg/day, single serving
11248302|NCT03051386|Experimental|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
11248303|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
11248304|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
11248305|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
11248306|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
11248307|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
11248308|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
11248309|NCT03051347|Other|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
11248310|NCT03051347|Other|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
11248311|NCT03051334||BiAV|Bicuspid aortic valve
11248312|NCT03051334||TAV|Tricuspid aortic valve
11248313|NCT03051321|Experimental|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
11248314|NCT03051308|Experimental|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
11248315|NCT03051308|Experimental|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
11248316|NCT03051308|Experimental|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
11248317|NCT03051308|Experimental|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
11248318|NCT03051308|Experimental|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
11248319|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
11248320|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
11248321|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
11248322|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
11248323|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
11248324|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
11248325|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
11248326|NCT03051256|Experimental|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
11248327|NCT03051256|Experimental|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
11248328|NCT03051256|Placebo Comparator|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
11248329|NCT03051243|Active Comparator|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
11248330|NCT03051243|Active Comparator|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
11248331|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
11248332|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
11248333|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
11248334|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
11248335|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
11248336|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
11248337|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
11248338|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
11248339|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
11248340|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
11248341|NCT03051178|Experimental|Subjects with Essential Tremor|This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
11248342|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
11248343|NCT03051152|Experimental|Elderly with CCS>5 - D1 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with limited lymphadenectomy
11248344|NCT03051152|Experimental|Elderly with CCS>5 - D2 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with extended lymphadenectomy
11248345|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
11248346|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
11248347|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
11248348|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
11248349|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
11248350|NCT03051087|Experimental|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
11248351|NCT03051087|Active Comparator|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
11248352|NCT03051074|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
11248353|NCT03051074|Active Comparator|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
11248354|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
11248355|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
11248356|NCT03051035|Experimental|KO-947|
11248357|NCT03051022|Active Comparator|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
11248358|NCT03051022|Active Comparator|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
11248359|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
11248360|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
11248361|NCT03051009|Experimental|Desmopressin ODT 25 μg (female)|New female subjects
11248362|NCT03051009|Experimental|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
11248363|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
11248364|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
11248365|NCT03051009|Experimental|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
11248366|NCT03051009|Experimental|Desmopressin ODT 50 μg (male)|New male subjects
11248367|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
11248368|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
11248369|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
11248370|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
11248371|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
11248372|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
11248373|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
11248374|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
11248375|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
11248376|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
11248377|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
11248378|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
11248445|NCT03050450|Experimental|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
11248379|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
11248380|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
11248381|NCT03050866|Other|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
11248382|NCT03050853|Experimental|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
11248383|NCT03050853|No Intervention|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
11248384|NCT03050840|Other|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
11248385|NCT03050840|Experimental|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
11248386|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
11248387|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
11248388|NCT03050814|Active Comparator|A /FOLFOX-A alone|Suubjects will receive FOLFOX + bevacizumab + for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine until disease progression.
11248389|NCT03050814|Experimental|B/Lead in, FOLFOX-A + Avelumab + Ad-CEA|Subjects will receive FOLFOX + bevacizumab + avelumab + Ad-CEA vaccine (given weeks 0,2,4,8,12,16 and then every 12 weeks) for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine + avelumab + Ad-CEA vaccine (following the every 12 week dosing schedule) until disease progression.
11248390|NCT03050801|Active Comparator|Frontal rTMS-Active|Prefrontal rTMS
11248391|NCT03050801|Experimental|Frontal rTMS-Experimental|Prefrontal rTMS
11248392|NCT03050801|Active Comparator|Parietal rTMS-Active|Prefrontal rTMS
11248393|NCT03050801|Active Comparator|Parietal rTMS-Active 2|Parietal rTMS
11248394|NCT03050801|Experimental|Parietal rTMS-Experimental|Parietal rTMS
11248395|NCT03050801|Active Comparator|Vertex rTMS-Active|Vertex rTMS
11248396|NCT03050801|Placebo Comparator|Vertex rTMS-Placebo|Vertex rTMS
11248397|NCT03050788|Experimental|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
11248398|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
11248399|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
11248400|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.
~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
11248401|NCT03050749|Other|Princess® VOLUME|
11248402|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
11248403|NCT03050723|Other|Princess® FILLER|
11248404|NCT03050710|Other|Princess® VOLUME Lidocaine|
11248405|NCT03050697|Experimental|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
11248406|NCT03050684|Active Comparator|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
11248407|NCT03050684|Placebo Comparator|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
11248408|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
11248409|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
11248410|NCT03050645||previous GDM|Women with previous GDM
11248411|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
11248412|NCT03050632|Experimental|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
11248413|NCT03050632|Placebo Comparator|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
11248414|NCT03050619||New users of Empagliflozin|New users of empagliflozin
11248415|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
11248416|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
11248417|NCT03050606|Experimental|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.
~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
11248418|NCT03050606|Active Comparator|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.
~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
11248419|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
11248420|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
11248421|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
11248422|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
11248423|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
11248424|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
11248425|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
11248426|NCT03050554|Experimental|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
11248427|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
11248428|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
11248429|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
11248430|NCT03050528|Experimental|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
11248431|NCT03050528|Active Comparator|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
11248432|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.
~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
11248433|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
11248434|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
11248435|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
11248436|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
11248437|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
11248438|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion of 9000 IU over the next 24 hours.
11248439|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24 hours.
11248440|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
11248441|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
11248442|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
11248443|NCT03050450|Experimental|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
11248444|NCT03050450|Experimental|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
11248859|NCT03047759|Active Comparator|Intervention B|air floss
11248446|NCT03050450|Experimental|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
11248447|NCT03050450|Experimental|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
11248448|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
11248449|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
11248450|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
11248451|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
11248452|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
11248453|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole per the core study
11248454|NCT03050385|Active Comparator|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)
~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
11248455|NCT03050385|Sham Comparator|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA
~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
11248456|NCT03050372|Experimental|Active Low Field Magnetic Stimulation|LFMS - Active
11248457|NCT03050372|Sham Comparator|Sham Low Field Magnetic Stimulation|LFMS - Sham
11248458|NCT03050359|Experimental|TAK-438 20 mg|H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
11248459|NCT03050359|Experimental|Lansoprazole 30 mg|H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
11248460|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
11248461|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
11248462|NCT03050320|Experimental|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
11248463|NCT03050320|Other|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
11248464|NCT03050307|Experimental|TAK-438 20 mg (HP- Participants)|TAK-438 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
11248465|NCT03050307|Experimental|TAK-438 20 mg (HP+ Participants)|TAK-438 20 mg, tablet, orally, twice daily and lansoprazole placebo-matching capsule, orally, twice daily along with bismuth-containing quadruple therapy (amoxicillin 1 g, twice daily, clarithromycin 500 mg twice daily, and bismuth potassium citrate 600 mg [equivalent to 220 mg bismuth] twice daily) for first 2 weeks. TAK-438 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 6 weeks.
11248466|NCT03050307|Active Comparator|Lansoprazole 30 mg (HP- Participants)|Lansoprazole 30 mg, capsule, orally, once daily and TAK-438 placebo-matching tablet, orally, once daily for up to 8 weeks.
11248467|NCT03050307|Active Comparator|Lansoprazole 30 mg (HP+ Participants)|Lansoprazole 30 mg, capsule, orally, twice daily and TAK-438 placebo-matching tablet, orally, twice daily along with bismuth-containing quadruple therapy (amoxicillin 1 g, twice daily, clarithromycin 500 mg, twice daily, and bismuth potassium citrate 600 mg [equivalent to 220 mg bismuth] twice daily) for first 2 weeks. Lansoprazole 30 mg, capsule, orally, once daily and TAK-438 placebo-matching tablet, orally, once daily for up to 6 weeks.
11248468|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
11248469|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
11248470|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
11248471|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
11248472|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
11248473|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
11248474|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~medical air (MA)
~Oxygen (2 Liter/min)
~Oxygen (4 Liter/min)"
11248475|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~medical air (MA)
~Oxygen (4 Liter/min)
~Oxygen (2 Liter/min)"
11248476|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (2 Liter/min)
~Medical air (MA)
~Oxygen (4 Liter/min)"
11248477|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (2 Liter/min)
~Oxygen (4 Liter/min)
~Medical air (MA)"
11248478|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (4 Liter/min)
~Medical air (MA)
~Oxygen (2 Liter/min)"
11248479|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
~Oxygen (4 Liter/min)
~Oxygen (2 Liter/min)
~Medical air (MA)"
11248480|NCT03050242|Experimental|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
11248481|NCT03050242|No Intervention|Control|No injection is conducted in this group.
11248482|NCT03050229|Experimental|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
11248483|NCT03050229|Placebo Comparator|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
11248484|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide
~ALT-803 Activation of Donor NK Cells
~ALT-803 to Facilitate NK Cell Survival and Expansion"
11248485|NCT03050203|Experimental|custom pack|
11248486|NCT03050203|Active Comparator|standard care|
11248487|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
11248488|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
11248489|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
11248490|NCT03050164|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
11248491|NCT03050164|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
11248492|NCT03050151|Experimental|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
11248493|NCT03050151|Experimental|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
11248494|NCT03050151|Experimental|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
11248495|NCT03050151|Experimental|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
11248496|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
11248497|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
11248498|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
11248499|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
11248500|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
11248501|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
11248502|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
11248503|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
11248504|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
11248505|NCT03050086|Experimental|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
11248506|NCT03050086|Experimental|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
11248507|NCT03050086|Placebo Comparator|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
11248508|NCT03050060|Experimental|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab.
11248509|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
11248510|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
11248511|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
11248512|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
11248513|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
11248514|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
11248515|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
11248516|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
11248517|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
11248518|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
11248519|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
11248520|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
11248521|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
11248522|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
11248523|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
11248524|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
11248525|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age > 10 years, height > 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
11248526|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
11248527|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
11248921|NCT03047317|Experimental|MABp1|
11248528|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
11248529|NCT03049982|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
11248530|NCT03049969|Experimental|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.
11248531|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
11248532|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
11248533|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
11248534|NCT03049930|Experimental|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
11248535|NCT03049930|Placebo Comparator|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
11248536|NCT03049917|No Intervention|No incentive|No incentive
11248537|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
11248538|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
11248539|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
11248540|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
11248541|NCT03049904|No Intervention|Wait List Control|Participants wait 3 weeks before receiving the intervention.
11248542|NCT03049904|Experimental|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
11248543|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
11248544|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
11248545|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
11248546|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
11248547|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
11248548|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
11248549|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
11248550|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
11248551|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
11248552|NCT03049839|Experimental|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
11248553|NCT03049839|Experimental|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).
~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
11248554|NCT03049839|Experimental|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.
~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
11248555|NCT03049826|Experimental|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
11248556|NCT03049826|No Intervention|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
11248557|NCT03049826|No Intervention|Healthy reference group|Healthy children
11248558|NCT03049813|Experimental|Virtual Reality Job Interview Training|Virtual Reality Job Interview Training
11248559|NCT03049813|Other|Supported Employment (Services as Usual)|Supported Employment (Services as Usual)
11248560|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
11248561|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
11248562|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
11248563|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
11248564|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
11248565|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
11248566|NCT03049761|Active Comparator|Water Flosser|Power interdental Cleaning Device
11248567|NCT03049761|Active Comparator|String floss|Manual interdental cleaning device
11248568|NCT03049761|Active Comparator|Manual Toothbrush|ADA standard manual toothbrush
11248569|NCT03049748|Active Comparator|Control Group|Participants in the control group (20 LVAD patients) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
11248570|NCT03049748|Experimental|Intervention Group|Participants in the experimental group (20 LVAD patients) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
11248571|NCT03049735|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
11248572|NCT03049735|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
11248573|NCT03049735|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
11248574|NCT03049722|Experimental|AVOPT Patient|
11248575|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
11248576|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
11248577|NCT03049696|No Intervention|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
11248578|NCT03049696|Experimental|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
11248579|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
11248580|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score > 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
11248581|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
11248582|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
11248583|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
11248584|NCT03049644|Active Comparator|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
11248585|NCT03049644|Active Comparator|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
11248586|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
11248587|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
11248588|NCT03049618|Experimental|Treatment (pembrolizumab, sEphB4-HSA)|Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
11248589|NCT03049605|Experimental|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
11248590|NCT03049605|Experimental|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
11248591|NCT03049605|Experimental|Medical therapy|Fifteen patients were received only medical treatment .
11248592|NCT03049592|Experimental|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
11248593|NCT03049592|No Intervention|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
11248594|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
11248595|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
11248596|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
11248597|NCT03049553|Other|HPV-test|Cobas HPV-DNA test is performed on the cervical sample in addition to the routine cytology
11248598|NCT03049553|No Intervention|Routine|Screening with cytology as usual in the cervical screening program
11248599|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
11248600|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
11248601|NCT03049527|Experimental|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
11248602|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
11248603|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
11248604|NCT03049488|Experimental|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
11248605|NCT03049488|Experimental|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
11248606|NCT03049488|Experimental|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)
~*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
11248607|NCT03049488|Experimental|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
11248608|NCT03049488|Experimental|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
11248609|NCT03049488|Experimental|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)
~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
11248610|NCT03049475||Control|Healthy, between age 18-80, African/African decent
11248611|NCT03049475||Subjects in steady State|Steady state is defined as the period from at any time 8 weeks prior to or after a crisis and samples obtained during this time would be considered steady state samples .
11248612|NCT03049462|Experimental|Cohort 1|Females taking 100 mg of mirabegron
11248613|NCT03049462|Active Comparator|Cohort 2A|Males taking 200mg mirabegron
11248614|NCT03049462|Placebo Comparator|Cohort 2B|Males taking placebo drug
11248615|NCT03049462|Active Comparator|Cohort 3A|Females taking 100 mg of mirabegron
11248616|NCT03049462|Placebo Comparator|Cohort 3B|Females taking placebo drug
11248617|NCT03049449|Experimental|1|All patients will be receiving starting dose: 0.3x106 CAR+ T cells/kg (weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells /kg)infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamid on days -5, -4,and -3
11248618|NCT03049436||Patients with program of adapted physical activity|
11248619|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
11248620|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
11248621|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
11248622|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
11248623|NCT03049397|Experimental|Supportive Care (Enhancing Connections program)|Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
11248624|NCT03049384|Active Comparator|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
11248625|NCT03049384|Experimental|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
11248626|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
11248627|NCT03049358|Experimental|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
11248628|NCT03049358|Sham Comparator|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
11248629|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
11248630|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
11248631|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
11248632|NCT03049306|Placebo Comparator|Placebo Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.
11248633|NCT03049306|Active Comparator|Propranolol Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.
11248634|NCT03049306|Active Comparator|CPAP|Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.
11248635|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
11248636|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
11248637|NCT03049280|Experimental|Transoral robotic surgery|
11248638|NCT03049267|Experimental|Apremilast|N=15
11248639|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
11248640|NCT03049254||Proband|Proband - the person who is the first to present with a diagnosis of AVC
11248641|NCT03049254||Family members (consultands)|First-degree relatives of probands with AVC (who may be living or deceased) In some circumstances where multiple family members are or may be affected, they may be eligible.
11248642|NCT03049241||knee extensors|
11248643|NCT03049241||ankle plantar|
11248644|NCT03049228||Type 2 Diabetic Patients|"Obese (BMI > 27 kg/m2 < 35 kg/m2)
~Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months
~They should have a (moderately) well-controlled diabetes (defined by a HbA1c<8%)"
11248645|NCT03049228||Obese Subjects|"A similar BMI as T2DM patients (BMI > 27 kg/m2< 35)
~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
11248646|NCT03049228||Lean subjects|"BMI between 20-25 kg/m2
~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
11248647|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
11248648|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
11248649|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
11248650|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: > 10 pack years. Definition of ex-smoker: > 2 years since smoke cessation.
11248651|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
11248652|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
11248653|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
11248654|NCT03049189|Experimental|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)
~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.
~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
11248655|NCT03049189|Active Comparator|Everolimus|"Everolimus (Afinitor ®)
~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
11248656|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
11248657|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
11248658|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
11248659|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
11248660|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
11248661|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
11248662|NCT03049124|Experimental|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
11248663|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
11248664|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
11248665|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
11248666|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
11248667|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
11248668|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
11248669|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
11248670|NCT03049059|Active Comparator|4% hydroquinone cream alone|
11248671|NCT03049046|Active Comparator|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
11248672|NCT03049046|Active Comparator|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
11248673|NCT03049046|Active Comparator|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
11248674|NCT03049046|Placebo Comparator|Placebo|Placebo once daily by mouth for 7 days
11248675|NCT03049033|Experimental|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and auditory cues to specifically improve fine motor movements.
11248676|NCT03049033|Active Comparator|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
11248677|NCT03049033|No Intervention|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
11248678|NCT03049033|Active Comparator|Music Supported Therapy (MST)|Music Supported Therapy uses musical instruments to train fine motor movements.
11248679|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
11248680|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
11248681|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
11248682|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
11248683|NCT03048994|Placebo Comparator|Placebo|Placebo
11248684|NCT03048994|Active Comparator|Glutamine|Glutamine
11248685|NCT03048981|Experimental|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
11248686|NCT03048968|Experimental|study group1: elderly adults|Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS
11248687|NCT03048968|Experimental|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
11248688|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
11248689|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
11248690|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
11248691|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
11248692|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
11248693|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
11248694|NCT03048916|Other|general swallowing therapy|"including:
~oral exercises
~tactile stimulation
~compensatory techniques
~swallowing maneuvers"
11248695|NCT03048916|Experimental|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
11248696|NCT03048916|Active Comparator|: the combined NMES and general swallowing therapies|
11248697|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
11248698|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
11248699|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
11248700|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
11248701|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
11248702|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
11248703|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
11248704|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
11248705|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
11248706|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
11248707|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
11248708|NCT03048838|Experimental|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
11248709|NCT03048838|Active Comparator|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
11248710|NCT03048825|Experimental|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
11248711|NCT03048825|Experimental|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
11248712|NCT03048825|Experimental|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
11248713|NCT03048825|Placebo Comparator|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.
~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
11248714|NCT03048812|Experimental|O'Ring attachment (A)|One arm of our research will receive O'Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
11248715|NCT03048812|Experimental|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
11248716|NCT03048799|Active Comparator|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
11248717|NCT03048799|Placebo Comparator|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.
~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
11248718|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
11248719|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
11248922|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
11248720|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece
~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
11248721|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece
~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
11248722|NCT03048760|Experimental|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan & 1 after approx. 2 weeks of radiotherapy treatment.
11248723|NCT03048747|Experimental|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
11248724|NCT03048734||Group (1): Men with Nocturia ≥2.|
11248725|NCT03048734||Group (2): Men with no nocturia (0-1).|
11248726|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
11248727|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
11248728|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
11248729|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
11248730|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
11248731|NCT03048695|No Intervention|Waiting list|
11248732|NCT03048682|Experimental|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.
~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
11248733|NCT03048682|Active Comparator|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.
~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
11248734|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
11248735|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
11248736|NCT03048656|Experimental|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
11248737|NCT03048656|Active Comparator|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
11248738|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
11248739|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
11248740|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
11248741|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
11248742|NCT03048604|Experimental|Genio(TM) system therapy|
11248743|NCT03048591|Experimental|Electroacupuncture group|
11248744|NCT03048591|No Intervention|control group|
11248745|NCT03048578|Experimental|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
11248746|NCT03048578|Placebo Comparator|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
11248747|NCT03048565|No Intervention|Usual care|No intervention
11248748|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
11248749|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
11248750|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
11248751|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
11248752|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
11248753|NCT03048526|Experimental|NovaTears®|
11248754|NCT03048526|Active Comparator|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
11248755|NCT03048500|Experimental|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
11248756|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
11248757|NCT03048461|Experimental|Platelet Rich Plasma|Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart
11248758|NCT03048461|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart
11248759|NCT03048448|Experimental|Fevipiprant 450mg|450mg Film Coated Tablet
11248760|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
11248761|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
11248762|NCT03048422|Experimental|Arm 1: Maternal DTG+FTC/TAF|Mothers will receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
11248763|NCT03048422|Experimental|Arm 2: Maternal DTG+FTC/TDF|Mothers will receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
11248764|NCT03048422|Active Comparator|Arm 3: Maternal EFV/FTC/TDF|Mothers will receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
11248765|NCT03048409||Enteral tube fed adults|Enteral formula
11248766|NCT03048396|Experimental|Uterus transplantation|
11248767|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
11248768|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
11248769|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
11248770|NCT03048370|Experimental|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
11248771|NCT03048370|Experimental|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
11248772|NCT03048370|Experimental|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
11248773|NCT03048370|Experimental|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
11248774|NCT03048370|Experimental|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
11248775|NCT03048370|Experimental|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
11248776|NCT03048357|Active Comparator|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
11248777|NCT03048357|Other|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
11248778|NCT03048344|Experimental|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
11248779|NCT03048344|Experimental|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
11248780|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.
~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
11248781|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
11248782|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
11248783|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
11248784|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
11248785|NCT03048292||Mobilized Patient|
11248786|NCT03048292||Core Comprehensive Stroke Center Treatment|
11248787|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
11248788|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
11248789|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
11248790|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
11248791|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
11248792|NCT03048227|Experimental|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
11248793|NCT03048227|No Intervention|Control|Patients will manage their diabetes as usual as recommended by their care team.
11248794|NCT03048214|Sham Comparator|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
11248795|NCT03048214|Experimental|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
11248796|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
11248797|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
11248798|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
11248799|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
11248800|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
11248801|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
11248802|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
11248803|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
11248804|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
11248805|NCT03048136|Experimental|Flat-Dose|Nivolumab flat dose + Ipilimumab
11248806|NCT03048136|Experimental|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
11248807|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
11248808|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
11248809|NCT03048110|Experimental|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
11248810|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
11248811|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
11248812|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
11248813|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
11248814|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
11248815|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
11248816|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
11248817|NCT03048045||Supportive Periodontal Treatment (SPT)|"at least 18 years old.
~periodontal treatment (antiinfective therapy with subgingival debridement under local anesthesia and if required periodontal surgery) at the Dept. of Periodontology starting after April 2005 durchgeführt.
~complete periodontal charting (PPD and PAL-V at 6 sites per tooth, furcation involvement [Hamp et al. 1975] at all furcation sites of multi-rooted teeth) prior to treatment (baseline, T0) and after completion of active periodontal treatment (APT) (reevaluation 1 or 2/start of supportive periodontal therapy, T1)
~radiographs of all teeth (periapical radiographs or panoramic radiograph) from baseline
~written informed consent"
11248818|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
11248819|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
11248820|NCT03048019||Tirofiban Therapy|
11248821|NCT03048019||Cangrelor Therapy|
11248822|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
11248823|NCT03047993|Experimental|Treatment (glutaminase inhibitor CB-839, azacitidine)|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.
11249308|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
11248824|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
11248825|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
11248826|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
11248827|NCT03047954|Experimental|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
11248828|NCT03047954|Placebo Comparator|Placebo|Matching placebo capsule
11248829|NCT03047941||All patients|All patients included in the present study
11248830|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.
~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.
~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
11248831|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
11248832|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
11248833|NCT03047902|Active Comparator|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.
~Intervention: Parents will be present for the questionnaire but not for the CO test."
11248834|NCT03047902|Active Comparator|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.
~Intervention: Parents will not be present for the questionnaire or the CO test"
11248835|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
11248836|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
11248837|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
11248838|NCT03047850||Study Group|All patients included in this study.
11248839|NCT03047837|Placebo Comparator|Arm A|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID)
11248840|NCT03047837|Experimental|Arm B|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
11248841|NCT03047837|Experimental|Arm C|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID)
11248842|NCT03047837|Experimental|Arm D|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
11248843|NCT03047824|Other|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
11248844|NCT03047824|Other|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
11248845|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
11248846|NCT03047798|Experimental|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
11248847|NCT03047798|Experimental|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
11248848|NCT03047798|Placebo Comparator|Control|The control mouthrinse only contained sodium fluoride
11248849|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
11248850|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
11248851|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
11248852|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
11248853|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
11248854|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
11248855|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
11248856|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
11248857|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
11248858|NCT03047759|Active Comparator|Intervention A|water flosser
11248860|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia excluding Fanconi Anemia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
11248861|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
11248862|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/ Fanconi Anemia|Patients with acquired or inherited bone marrow failure (iBMF) with Fanconi Anemia and related DNA Repair Disorders will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
11248863|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).
~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
11248864|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).
~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.
~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
11248865|NCT03047720|Other|One: Study Phases (S1 and S2)|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
11248866|NCT03047720|Other|Two: Study Phases (S2 and S1)|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
11248867|NCT03047707|Experimental|S-Shearwave and TE|
11248868|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
11248869|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
11248870|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
11248871|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
11248872|NCT03047668|Active Comparator|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
11248873|NCT03047668|Active Comparator|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), without walnuts / walnut-sunflower muffins
11248874|NCT03047668|Active Comparator|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
11248875|NCT03047668|Active Comparator|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), without walnuts / walnut-sunflower muffins
11248876|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
11248877|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
11248878|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
11248879|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
11248880|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
11248881|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
11248882|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
11248883|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
11248884|NCT03047590|Experimental|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
11248885|NCT03047590|Experimental|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
11248886|NCT03047590|Experimental|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
11248887|NCT03047590|Active Comparator|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
11248888|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
11248923|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
11248889|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
11248890|NCT03047564|Experimental|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
11248891|NCT03047564|Active Comparator|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
11248892|NCT03047551|Active Comparator|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.
~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
11248893|NCT03047551|Active Comparator|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.
~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
11248894|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
11248895|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
11248896|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
11248897|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
11248898|NCT03047512|Experimental|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
11248899|NCT03047512|No Intervention|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
11248900|NCT03047499||Scar Length|
11248901|NCT03047499||Vancouver scar scale|
11248902|NCT03047499||Scar width|
11248903|NCT03047473|Experimental|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
11248904|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses
~Intervention: multimodal evoked potentials"
11248905|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:
~Aged 18 to 58 years old, inclusive, at the time of informed consent.
~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.
~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb
~Have no comorbid condition (ie neuropathy) that could affect testing.
~Intervention: multimodal evoked potentials"
11248906|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
11248907|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
11248908|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
11248909|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
11248910|NCT03047408|Experimental|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
11248911|NCT03047395|Experimental|Risankizumab|Participants will receive risankizumab administered by subcutaneous injection.
11248912|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
11248913|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
11248914|NCT03047356|Experimental|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
11248915|NCT03047356|Experimental|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
11248916|NCT03047356|Placebo Comparator|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
11248917|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
11248918|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
11248919|NCT03047330|Experimental|Unfragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some unfragmented sleep periods.
11248920|NCT03047330|Experimental|Fragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some fragmented sleep periods.
11248924|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
11248925|NCT03047278|Active Comparator|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) was administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, was administered. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling.
11248926|NCT03047278|Experimental|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
11248927|NCT03047278|Experimental|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
11248928|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
11248929|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
11248930|NCT03047252|Experimental|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.
~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
11248931|NCT03047252|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
11248932|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
11248933|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11248934|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
11248935|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:
~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
11248936|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.
~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
11248937|NCT03047161||High-risk pregnancy|abnormal fetal heart rate or rhythm or risk of abnormal fetal heart rate or rhythm
11248938|NCT03047161||Uncomplicated pregnancy|uncomplicated pregnancy
11248939|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
11248940|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
11248941|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
11248942|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
11248943|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
11248944|NCT03047096|Experimental|HA & CS group|hyaluronic acid and corticosteroids
11248945|NCT03047096|Experimental|HA group|hyaluronic acid
11248946|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
11248947|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
11248948|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
11248949|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
11248950|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
11248951|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
11248952|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
11248953|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
11248954|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
11248955|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
11248956|NCT03047044|Active Comparator|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
11249057|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
11248957|NCT03047044|Experimental|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
11248958|NCT03047031||Group A|Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.
11248959|NCT03047031||Group B|Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.
11248960|NCT03047031||Group C|Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance
11248961|NCT03047018|Experimental|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
11248962|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
11248963|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
11248964|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts
~Dose Expansion Phase: Consists of 5 Cohorts
~Dose Extension Phase: Consists of 2 Cohorts"
11248965|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
11248966|NCT03046966|Other|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
11248967|NCT03046966|Other|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
11248968|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
11248969|NCT03046940|No Intervention|Control group|No communication with a doctor
11248970|NCT03046940|Experimental|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
11248971|NCT03046940|Experimental|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
11248972|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
11248973|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
11248974|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
11248975|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
11248976|NCT03046888|Experimental|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
11248977|NCT03046888|Experimental|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
11248978|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
11248979|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
11248980|NCT03046862|Experimental|Durvalumab/Tremelimumab+chemotherapy|Durvalumab and Tremelimumab in combination with gemcitabine/cisplatin.
11248981|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 IU intranasal Oxytocin
11248982|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
11248983|NCT03046810|Experimental|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
11248984|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
11248985|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
11248986|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.
~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
11248987|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
11249058|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
11249059|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
11249432|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
11248988|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
11248989|NCT03046758|Experimental|Participants|
11248990|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
11248991|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
11248992|NCT03046732|Experimental|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
11248993|NCT03046732|No Intervention|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
11248994|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
11248995|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
11248996|NCT03046706|Active Comparator|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
11248997|NCT03046706|Experimental|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
11248998|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
11248999|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
11249000|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
11249001|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
11249002|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
11249003|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
11249004|NCT03046654|Experimental|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
11249005|NCT03046641|Experimental|continuous training group|With the continuous training program
11249006|NCT03046641|Experimental|interval training group|With the interval training program
11249007|NCT03046628|Experimental|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
11249008|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
11249009|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
11249010|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
11249011|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
11249012|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
11249013|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
11249014|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
11249015|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
11249016|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
11249017|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
11249018|NCT03046550|Experimental|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
11249019|NCT03046550|Experimental|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
11249020|NCT03046550|Experimental|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
11249021|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
11249022|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
11249023|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
11249024|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
11249025|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
11249026|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
11249027|NCT03046498|Experimental|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
11249028|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
11249029|NCT03046485|No Intervention|Wait list control|Wait list control
11249060|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
11249061|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
11249835|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
11249030|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.
~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.
~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.
~Total duration 12 weeks/3 months"
11249031|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.
~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.
~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
11249032|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
11249033|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
11249034|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
11249035|NCT03046394|Active Comparator|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
11249036|NCT03046394|Active Comparator|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
11249037|NCT03046394|Active Comparator|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
11249038|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
11249039|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
11249040|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
11249041|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
11249042|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
11249043|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
11249044|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
11249045|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
11249046|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
11249047|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
11249048|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
11249049|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:
~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
11249050|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
11249051|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
11249052|NCT03046316|Other|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
11249053|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
11249054|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
11249055|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
11249056|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
11249062|NCT03046238|Active Comparator|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
11249063|NCT03046238|Placebo Comparator|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
11249064|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
11249065|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
11249066|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
11249067|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
11249068|NCT03046199|No Intervention|Control|
11249069|NCT03046199|Experimental|Questionnaire|
11249070|NCT03046199|Experimental|Coordination|
11249071|NCT03046199|Experimental|Questionnaire + coordination|
11249072|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation >12 month prior to inclution.
11249073|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
11249074|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass >12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
11249075|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
11249076|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
11249077|NCT03046160|Experimental|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)
~The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets
~tape (postural correction of scapular anterior tilt)
~A program of 12 neck and scapular exercises."
11249078|NCT03046160|Active Comparator|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)
~tape (postural correction of scapular anterior tilt)
~A program of 12 neck and scapular exercises."
11249079|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
11249080|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
11249081|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
11249082|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
11249083|NCT03046108|Active Comparator|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.
~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.
~Up to 4 injections are allow in the first three months of follow-up"
11249084|NCT03046108|Active Comparator|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.
~Up to 4 injections are allow in the first three months of follow-up"
11249085|NCT03046108|Active Comparator|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
11249086|NCT03046108|Experimental|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
11249087|NCT03046108|Experimental|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.
~Up to 4 injections are allow in the first three months of follow-up"
11249088|NCT03046108|Experimental|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
11249089|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
11249090|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
11249091|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
11249092|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
11251146|NCT03032198|Experimental|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
11249093|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
11249094|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
11249095|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
11249096|NCT03046056|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
11249097|NCT03046056|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
11249098|NCT03046056|Placebo Comparator|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
11249099|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed
~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation
~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™
~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.
~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
11249100|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.
~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
11249101|NCT03046030|Experimental|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
11249102|NCT03046017|Active Comparator|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
11249103|NCT03046017|Sham Comparator|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
11249104|NCT03046017|Other|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
11249105|NCT03046004|Experimental|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
11249106|NCT03046004|Active Comparator|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
11249107|NCT03045991|Experimental|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.
~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
11249108|NCT03045991|Active Comparator|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.
~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
11249109|NCT03045965|Experimental|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
11249110|NCT03045965|No Intervention|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
11249111|NCT03045952|Experimental|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
11249112|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
11249113|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
11249114|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
11249115|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
11249116|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
11249117|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
11249245|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
11249118|NCT03045887|Experimental|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
11249119|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
11249120|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
11249121|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
11249122|NCT03045887|Experimental|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
11249123|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
11249124|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
11249125|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
11249126|NCT03045887|Experimental|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
11249127|NCT03045887|Experimental|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
11249128|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
11249129|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
11249130|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
11249131|NCT03045874||22 parent-child dyads|The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
11249132|NCT03045874||5 childcare teachers|Teachers will be trained to deliver a brief sleep health intervention
11249133|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
11249134|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
11249135|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
11249136|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
11249137|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
11249138|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
11249139|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
11249140|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
11249141|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
11249142|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
11249143|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
11249144|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
11249246|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
11249145|NCT03045770|Experimental|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
11249146|NCT03045770|Experimental|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
11249147|NCT03045770|Experimental|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
11249148|NCT03045757||Healthy Newborn|Healthy Newborn
11249149|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
11249150|NCT03045744|Experimental|incomplete SCI patients|
11249151|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
11249152|NCT03045718|Experimental|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
11249153|NCT03045718|Other|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
11249154|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
11249155|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
11249156|NCT03045692|Active Comparator|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
11249157|NCT03045692|Experimental|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
11249158|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
11249159|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
11249160|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
11249161|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
11249162|NCT03045653|Experimental|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
11249163|NCT03045640|Experimental|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
11249164|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF
~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
11249165|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF
~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .
~One course includes 28 days."
11249166|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
11249167|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
11249168|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
11249169|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
11249170|NCT03045562|Placebo Comparator|Control group|Patients will be assigned to receive 100ml of normal saline
11249171|NCT03045562|Experimental|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
11249172|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
11249173|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
11249174|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
11249175|NCT03045523|Experimental|GLPG2222 Dose 1|
11249176|NCT03045523|Experimental|GLPG2222 Dose 2|
11249177|NCT03045523|Placebo Comparator|Placebo|
11249178|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
11249247|NCT03045016|Experimental|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
11249179|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
11249180|NCT03045484|Experimental|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
11249181|NCT03045484|Experimental|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
11249182|NCT03045471||R-EPOCH|
11249183|NCT03045471||R-CHOP|
11249184|NCT03045458|Active Comparator|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
11249185|NCT03045458|Active Comparator|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
11249186|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
11249187|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
11249188|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise
~regular rehabilitation programe
~alternative video-teaching materials"
11249189|NCT03045432|Other|control group|"regular passive ROM exercise
~regular rehabilitation programe
~regular oral-teaching materials"
11249190|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC
~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
11249191|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease
~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup
~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
11249192|NCT03045406|Experimental|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
11249193|NCT03045406|Active Comparator|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
11249194|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
11249195|NCT03045380|Experimental|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
11249196|NCT03045380|Active Comparator|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
11249197|NCT03045380|No Intervention|No intervention|Waitlist
11249198|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
11249199|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
11249200|NCT03045354|Experimental|French fries|Eggs with a side of French fries
11249201|NCT03045354|Experimental|Beans|Eggs with a side of beans
11249202|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
11249203|NCT03045354|Experimental|Breakfast skipping|No breakfast
11249204|NCT03045341|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
11249205|NCT03045341|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
11249206|NCT03045341|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
11249207|NCT03045341|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
11249208|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
11249209|NCT03045315|Experimental|women included in a IVF program|
11249210|NCT03045302|Experimental|BIM23B065|
11249211|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
11249212|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
11249213|NCT03045276|Active Comparator|Arm 1 - No Feedback, Minimum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos. They will receive compensation to encourage real-time adherence reporting. Subjects will also be able to log into a personal dashboard with a visual display of their weekly adherence performance and educational resources related to their primary disease. Every month, participants will receive a text encouraging them to visit their personal dashboard. The dashboard is able to track usage of the modules by individual. Parents/legal guardians will have access to these same educational materials via their own portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
11249248|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
11249249|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
11249214|NCT03045276|Active Comparator|Arm 2 - Feedback, Maximum Incentive|Subjects will receive daily text message reminders and report real-time treatment adherence with photos, and will have web access to the educational modules through their portal. Every month, participants will receive a text encouraging them to visit their portals. In contrast to Arm 1, they will receive their weekly performance results by text to their phone with tailored feedback. In Arm 2, subjects will receive a larger incentive if they perform their desired treatment behavior. Incentive notification will be texted to participants. Similarly to Arm 1, parents/legal guardians will have access to the same educational materials via their own WTH portals. Additionally, to mitigate the minimal risk of this study, parents/legal guardians will be notified if their child is excessively non-adherent.
11249215|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
11249216|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
11249217|NCT03045250|Active Comparator|Type 1 Diabetes|Subjects with known Type 1 diabetes
11249218|NCT03045250|Placebo Comparator|Healthy Controls|Healthy controls
11249219|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
11249220|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
11249221|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.
~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
11249222|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
11249223|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
11249224|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
11249225|NCT03045172|Active Comparator|Group 1|20 subjects with Platelet Rich Plasma injections
11249226|NCT03045172|Placebo Comparator|Group 2|10 subjects with placebo injections
11249227|NCT03045159|Experimental|Strong Families|parenting program
11249228|NCT03045159|Active Comparator|Strong Parents|self-care program
11249229|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
11249230|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
11249231|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
11249232|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
11249233|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
11249234|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
11249235|NCT03045120||bosutinib cohort|Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
11249236|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
11249237|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
11249238|NCT03045081|No Intervention|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
11249239|NCT03045081|Experimental|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
11249240|NCT03045068|Experimental|Study Group|"Platelet Transfusion Management
~Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35*C, (the Sano or BT shunt clip is still on in children with SV physiology)
~Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
11249241|NCT03045068|Active Comparator|Control Group|"Platelet Transfusion Management
~Pre-Termination of CPB- No intervention
~Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
11249242|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
11249243|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
11249244|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
11249250|NCT03044977|Experimental|Cohort 1|"This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)"
11249251|NCT03044977|Experimental|Cohort 2|"This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
11249252|NCT03044977|Experimental|Cohort 3|"This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
11249253|NCT03044977|Experimental|Cohort -1 (alternative cohort)|"This treatment arm is opened if Cohort 1 is not tolerated.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
11249254|NCT03044977|Experimental|Cohort 2.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
11249255|NCT03044977|Experimental|Cohort 2.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
11249256|NCT03044977|Experimental|Cohort 3.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
11249257|NCT03044977|Experimental|Cohort 3.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.
~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.
~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)
~No further dose evaluations are done after this cohort is completed."
11249258|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
11249259|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
11249260|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
11249261|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
11249262|NCT03044938|Experimental|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
11249263|NCT03044938|Placebo Comparator|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
11249264|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
11249265|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
11249266|NCT03044912|Experimental|treatment group|Mirabegron 50 mg for comparison
11249267|NCT03044912|Active Comparator|Comparative group|Patient take Mirabegron 25 mg
11249268|NCT03044899||Adult surgical patients|All surgeries in adult patients
11249269|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
11249270|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
11249271|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
11249272|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
11249273|NCT03044860|Experimental|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
11249274|NCT03044860|Experimental|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
11249275|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
11249276|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
11249277|NCT03044834||Pleuropulmonary Blastoma|"Patients born between 01/01/2000 and 01/01/2016 ;
~Followed up for PPB
~Treated in a French department of paediatric oncology or paediatric surgery
~Study agreement"
11249278|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
11249279|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
11249280|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
11249307|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
11249281|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
11249282|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
11249283|NCT03044769||Patient with CLA with surgery|
11249284|NCT03044769||Patient with CLA without surgery|
11249285|NCT03044756|Experimental|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
11249286|NCT03044756|No Intervention|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
11249287|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).
~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.
~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
11249288|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11249289|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.
~This group will also complete a 3-hour nutrition module prior to study completion."
11249290|NCT03044691|No Intervention|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
11249291|NCT03044691|Experimental|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
11249292|NCT03044678|Experimental|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
11249293|NCT03044678|Active Comparator|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
11249294|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
11249295|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
11249296|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
11249297|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
11249298|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
11249299|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
11249300|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
11249301|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
11249302|NCT03044626|Experimental|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:
~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.
~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
11249303|NCT03044626|Other|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:
~Nivolumab 240 mg fixed dose (q2w)."
11249304|NCT03044613|Experimental|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
11249305|NCT03044613|Experimental|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
11249306|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
11249309|NCT03044574|Experimental|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
11249310|NCT03044574|Active Comparator|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
11249311|NCT03044561|Experimental|Sildenafil citrate|
11249312|NCT03044561|Placebo Comparator|placebo|
11249313|NCT03044548|Experimental|Experimental|Supportive supervision
11249314|NCT03044548|No Intervention|Control|No intervention
11249315|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
11249316|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 4 years post-implant). Participants in this group must already have an MCS device in place.
11249317|NCT03044522|No Intervention|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
11249318|NCT03044522|Other|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
11249319|NCT03044509||TB exposure|
11249320|NCT03044509||TB infection (latent TB)|
11249321|NCT03044509||TB disease (active TB)|
11249322|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
11249323|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
11249324|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
11249325|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
11249326|NCT03044470|Experimental|Cold saline|Saline stored at 4 degrees centigrade
11249327|NCT03044470|Experimental|Normal Saline|Saline stored at room temperature
11249328|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
11249329|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
11249330|NCT03044444|Experimental|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
11249331|NCT03044444|Experimental|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
11249332|NCT03044444|Placebo Comparator|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
11249333|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
11249334|NCT03044418|Other|anesthesia with laser tube|The parameters and side effects of anesthesia are tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
11249335|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
11249336|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
11249337|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
11249338|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
11249339|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
11249340|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
11249341|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
11249342|NCT03044366||Comorbidities|Evaluate the average value of these data.
11249343|NCT03044353|Experimental|Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants|Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR will be included. Participants will receive 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
11249366|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
11249431|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
11249344|NCT03044353|Experimental|Group 2: Post-chemotherapy AL Amyloidosis participants|Immunoglobin light chain amyloidosis (AL) participants who attain either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
11249345|NCT03044353|Experimental|Group 3: Newly diagnosed Mayo stage II/IIIa AL participants|Newly diagnosed Mayo stage II/IIIa AL participants who attain a free light chain CR during the first 3 cycles of first-line chemotherapy where the first cycle was cyclophosphamide, bortezomib, dexamethasone (CyBorD) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.
11249346|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
11249347|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
11249348|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
11249349|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
11249350|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
11249351|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
11249352|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
11249353|NCT03044288|Experimental|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.
~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
11249354|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.
~New adhesive strip Standard adhesive strip"
11249355|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
11249356|NCT03044249|Experimental|MP-101|Escalating dose administered orally once daily, starting at 20 milligrams up to 60 milligrams
11249357|NCT03044249|Placebo Comparator|Placebo|Administered orally once daily
11249358|NCT03044236|Experimental|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
11249359|NCT03044236|Active Comparator|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
11249360|NCT03044210|Other|Cockayne patients|"Interventions performed:
~blood sample
~urinary collection
~metabolic evaluation
~clinical evaluation"
11249361|NCT03044210|Other|Control subjects|"Interventions performed:
~urinary collection
~metabolic evaluation
~clinical evaluation"
11249362|NCT03044197|Experimental|MRI/ultrasound transperineal prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
11249363|NCT03044197|Active Comparator|transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
11249364|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage
~AND
~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
11249365|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage
~AND
~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
11249367|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
11249368|NCT03044158|No Intervention|Control group|Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols
11249369|NCT03044158|Experimental|Intervention|Onsite molecular testing for TB with GeneXpert I + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback
11249370|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
11249371|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
11249372|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
11249373|NCT03044132|Experimental|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
11249374|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
11249375|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
11249376|NCT03044106|Active Comparator|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
11249377|NCT03044106|Sham Comparator|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
11249378|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
11249379|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.
~Mifepristone"
11249380|NCT03044080|Active Comparator|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
11249381|NCT03044080|Active Comparator|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
11249382|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
11249383|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
11249384|NCT03044054|Experimental|ECHOPULSE|ECHOPULSE HIFU
11249385|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
11249386|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
11249387|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
11249388|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
11249389|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
11249390|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
11249391|NCT03044015|Active Comparator|Control|Intervention as usual
11249392|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
11249393|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
11249394|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.
~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
11249395|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.
~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
11249427|NCT03043807|Experimental|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
11249428|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
11249429|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
11249396|NCT03043976|Active Comparator|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
11249397|NCT03043976|Active Comparator|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
11249398|NCT03043976|Placebo Comparator|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.
~If patients are not being started on drug therapy then they will be withdrawn from the study"
11249399|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
11249400|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
11249401|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
11249402|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
11249403|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
11249404|NCT03043937||cardiac patients WHO class 1,2|
11249405|NCT03043937||cardiac patients WHO class 3,4|
11249406|NCT03043924|Other|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
11249407|NCT03043924|Other|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
11249408|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
11249409|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
11249410|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.
~Intervention: Lung sound transmission measurement for part B(i) of the study."
11249411|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.
~Intervention: Lung sound transmission measurement for part B(ii) of the study."
11249412|NCT03043885|Experimental|PRF|
11249413|NCT03043885|Experimental|PRF+FDBA|
11249414|NCT03043885|Active Comparator|FDBA|
11249415|NCT03043885|Active Comparator|Blood Clot|
11249416|NCT03043872|Experimental|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
11249417|NCT03043872|Experimental|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
11249418|NCT03043872|Active Comparator|Arm 3|EP (carboplatin or cisplatin + etoposide)
11249419|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
11249420|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
11249421|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
11249422|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
11249423|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
11249424|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
11249425|NCT03043820|Active Comparator|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
11249426|NCT03043820|Placebo Comparator|Placebo|Placebo 2 tablets daily for 12 weeks.
11249430|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
11249433|NCT03043742|Experimental|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:
~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
11249434|NCT03043729|Active Comparator|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
11249435|NCT03043729|Experimental|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
11249436|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
11249437|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
11249438|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
11249439|NCT03043677||Non-inflamed|
11249440|NCT03043677||Inflamed ulcerative colitis|
11249441|NCT03043677||inflamed Crohn´s disease|
11249442|NCT03043664|Experimental|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) every 3 weeks and Somatuline Depot (lanreotide depot) 90mg subcutaneous (SQ) every 3 weeks
11249443|NCT03043651|Experimental|Oral treprostinil|Sustained-release tablets for TID administration
11249444|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
11249445|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
11249446|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
11249447|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
11249448|NCT03043612|Experimental|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
11249449|NCT03043612|Active Comparator|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
11249450|NCT03043599|Experimental|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
11249451|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
11249452|NCT03043573|Experimental|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
11249453|NCT03043573|Active Comparator|Supportive Therapy|Supportive Therapy focuses on: 1. Facilitating expression of affect; 2. Conveying to the patient that he or she is understood; 3. Offering empathy; and 4. Highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
11249454|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
11249455|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
11249456|NCT03043547|Experimental|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
11249457|NCT03043547|Other|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
11249458|NCT03043534|Experimental|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
11249459|NCT03043534|No Intervention|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
11249460|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
11249461|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
11249462|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
11249463|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
11249464|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.
~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
11249465|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.
~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
11249466|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
11249571|NCT03042728|Active Comparator|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
11249467|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
11249468|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
11249469|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
11249470|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
11249471|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
11249472|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
11249473|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
11249474|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
11249475|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
11249476|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.
~Days 2-8: Physical Activity Monitoring"
11249477|NCT03043456|Active Comparator|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
11249478|NCT03043456|Placebo Comparator|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
11249479|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
11249480|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
11249481|NCT03043430|Experimental|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
11249482|NCT03043430|Active Comparator|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
11249483|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
11249484|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
11249485|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
11249486|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
11249487|NCT03043378||Chronic Non-Malignant Pain - Cancer Patients|Chronic non-malignant pain among cancer patients undergoing a consultation at the outpatient Supportive Care Clinic at MD Anderson Cancer Center.
11249488|NCT03043365|Experimental|Arm 1: Control Fish Oil first, then Saury Oil|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm
11249489|NCT03043365|Experimental|Arm 2: Saury Oil first, then Control Fish Oil|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm
11249490|NCT03043365|No Intervention|Washout Period|8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.
11249491|NCT03043352|Experimental|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC < 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
11249492|NCT03043352|Active Comparator|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
11249642|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
11249493|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.
~All participants will complete the following interventions:
~Stool Specimen Collection
~Anal Swab Sampling
~Short Diet Assessment (SDA)
~NHANES Dietary Screener Questionnaire (DSQ)"
11249494|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.
~All participants will complete the following interventions:
~Stool Specimen Collection
~Anal Swab Sampling
~Short Diet Assessment (SDA)
~NHANES Dietary Screener Questionnaire (DSQ)"
11249495|NCT03043313|Experimental|Cohort A: Tucatinib + Trastuzumab|Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
11249496|NCT03043313|Experimental|Cohort B: Tucatinib + Trastuzumab|Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
11249497|NCT03043313|Experimental|Cohort C: Tucatinib Monotherapy|Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
11249498|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:
~No greater than 4 weeks prior to travel departure: Screening Criteria Review
~One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection
~Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection
~14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
11249499|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
11249500|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
11249501|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
11249502|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
11249503|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
11249504|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
11249505|NCT03043235||African American Females|No intervention
11249506|NCT03043235||African American Males|No intervention
11249507|NCT03043235||Caucasian Females|No intervention
11249508|NCT03043235||Caucasian Males|No intervention
11249509|NCT03043222|Experimental|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
11249510|NCT03043222|Active Comparator|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
11249511|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
11249512|NCT03043196|Active Comparator|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
11249513|NCT03043196|Placebo Comparator|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
11249514|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
11249515|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，<9
11249516|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
11249517|NCT03043144||End stage renal disease|Observational study, no intervention
11249518|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
11249519|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
11249520|NCT03043118|Experimental|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
11249521|NCT03043118|No Intervention|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
11249522|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
11249523|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
11249524|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
11249525|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
11249526|NCT03043066|Placebo Comparator|Group A -control group|15 subjects underwent scaling and root planing
11249527|NCT03043066|Active Comparator|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
11249528|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
11249529|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
11249530|NCT03043040|Experimental|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.
~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
11249643|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
11249531|NCT03043040|Active Comparator|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
11249532|NCT03043027|Experimental|Liposomal bupivicaine|
11249533|NCT03043027|Active Comparator|bupivicaine|
11249534|NCT03043027|Placebo Comparator|saline|
11249535|NCT03043014|Experimental|Mifépristone group|
11249536|NCT03043014|Active Comparator|misoprostol group|
11249537|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
11249538|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
11249539|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
11249540|NCT03042975||Spasmodic dysphonia|Patients with spasmodic dysphonia will undergo MRI of the brain and blood draw.
11249541|NCT03042975||Unaffected relatives|Unaffected relatives of patients with spasmodic dysphonia will undergo MRI of the brain and blood draw.
11249542|NCT03042975||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
11249543|NCT03042962||Patients with dystonia|Patients with dystonia (spasmodic dysphonia, singer's dystonia, writer's cramp, musician's focal hand dystonia) will undergo MRI of the brain and blood draw.
11249544|NCT03042962||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
11249545|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
11249546|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
11249547|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
11249548|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
11249549|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
11249550|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
11249551|NCT03042884|Experimental|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.
~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
11249552|NCT03042884|Experimental|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.
~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
11249553|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
11249554|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
11249555|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
11249556|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
11249557|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
11249558|NCT03042845|Experimental|Tiger cardiac catheter|
11249559|NCT03042832|Experimental|LOCI|Leadership development with coaching and organizational change support
11249560|NCT03042832|Active Comparator|WEBINAR|Webinar leadership training
11249561|NCT03042819|Experimental|Selinexor plus Doxorubicin|"Selinexor will be given by mouth (orally) once a week:
~Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg
~Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks."
11249562|NCT03042806|Other|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
11249563|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
11249564|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
11249565|NCT03042767|Experimental|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
11249566|NCT03042767|Placebo Comparator|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
11249567|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
11249568|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
11249569|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
11249570|NCT03042728|Active Comparator|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
11249572|NCT03042715||Psychological Intervention refinement|"Eight weekly sessions in-person or via telephone
~Qualitative interviews
~Feedback from 5-10 caregivers to refine the intervention."
11249573|NCT03042702|Experimental|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
11249574|NCT03042702|Experimental|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
11249575|NCT03042689|Experimental|Regorafenib|
11249576|NCT03042676||ATLG group|ATLG treatment for GVHD prophylaxis.
11249577|NCT03042676||no ATLG group|No ATLG treatment.
11249578|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
11249579|NCT03042650|Experimental|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
11249580|NCT03042650|Active Comparator|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
11249581|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
11249582|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
11249583|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
11249584|NCT03042611|Experimental|Apatinib|
11249585|NCT03042611|Experimental|Placebo|
11249586|NCT03042598|Experimental|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
11249587|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
11249588|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
11249589|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
11249590|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
11249591|NCT03042572|Experimental|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
11249592|NCT03042572|Placebo Comparator|Placebo|Intramuscular placebo injection
11249593|NCT03042559|Active Comparator|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
11249594|NCT03042559|Experimental|Sport cords|Resistive sports cord to resist knee flexion.
11249595|NCT03042546|Active Comparator|Calcium Sulphate|
11249596|NCT03042546|Active Comparator|PMMA|
11249597|NCT03042546|Active Comparator|Nothing|
11249598|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
11249599|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
11249600|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
11249601|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
11249602|NCT03042520||Sofosbuvir-based therapy observational group|"Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)
~Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.
~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:
~Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response
~Patients who have ever participated study will be collected as historical control."
11249603|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
11249604|NCT03042494|Placebo Comparator|Control|Isocaloric food without the test prebiotic.
11249605|NCT03042494|Experimental|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
11249738|NCT03041532|Experimental|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
11249606|NCT03042468|Experimental|All subjects|"177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
~68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging"
11249607|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
11249608|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
11249609|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
11249610|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
11249611|NCT03042442||health patients (controls)|Health patients
11249612|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
11249613|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
11249614|NCT03042416|Experimental|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
11249615|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
11249616|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
11249617|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
11249618|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
11249619|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
11249620|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
11249621|NCT03042364|No Intervention|No intervention|Standard treatment
11249622|NCT03042364|Experimental|Intervention|Endometrial scratching before standard treatment
11249623|NCT03042351|Other|Unique arm|Magic Kegel app
11249624|NCT03042338|Experimental|Central Executive Training1|Training tasks targeting working memory
11249625|NCT03042338|Active Comparator|Central Executive Training2|Training tasks targeting inhibitory control and response speed
11249626|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
11249627|NCT03042312|Experimental|Lu177-PSMA-617-dose 1|Repeated i.v. application of 6.0 GBq (gigabequerel )(±10%, arm 1) every 8±1 weeks;RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
11249628|NCT03042312|Experimental|Lu177-PSMA-617- dose 2|Repeated i.v. application of 7.4 GBq (±10%, arm 2) of drug every 8±1 weeks;RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
11249629|NCT03042299|Experimental|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
11249630|NCT03042299|Experimental|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
11249631|NCT03042273|Experimental|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
11249632|NCT03042273|Placebo Comparator|Placebo|1 capsule of Matching Placebo orally daily for 6 months
11249633|NCT03042260|Experimental|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
11249634|NCT03042260|Placebo Comparator|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.
~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
11249635|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
11249636|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
11249637|NCT03042234|Experimental|Group I|Adolescents obese with insulin resistance
11249638|NCT03042234|Experimental|Group II|Adolescents obese without insulin resistance
11249639|NCT03042234|Experimental|Group III|Adolescents eutrophyc
11249640|NCT03042208|Experimental|Intervention|Access to Weight Watchers in-person meetings and online tools.
11249641|NCT03042208|Other|Self-Guided Control Group|Received handout with basic weight management advice.
11249644|NCT03042182|Experimental|Single pill of V3-X vaccine administered once daily|One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months and changes in CA19.9 tumor marker from baseline levels versus post-treatment levels will be assessed as correlates of changes in tumor burden
11249645|NCT03042169|Active Comparator|Chemotherapy|Patients assigned to standard treatment will continue to receive the same chemotherapy regimen they received before randomization; alternative chemotherapy regimen might be discussed, according to local standards and national guidelines, in case of poor tolerance or pathological tumour progression (www.tncd.org).
11249646|NCT03042169|Experimental|Surgery|Patients assigned to surgical treatment will undergo gastrectomy between D1 and D30 after randomization, either subtotal or total gastrectomy, depending on the location of the primary tumour.Subtotal gastrectomy is recommended if allowing a complete resection of the primary tumour to limit postoperative morbidity
11249647|NCT03042143|Experimental|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
11249648|NCT03042143|Placebo Comparator|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
11249649|NCT03042130|Experimental|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject
~the medicine will be given twice within one week."
11249650|NCT03042130|Other|control|standard of care
11249651|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
11249652|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
11249653|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
11249654|NCT03042104|Experimental|TAVR|Transcatheter aortic valve replacement (TAVR) arm will have intervention with the Edwards SAPIEN 3 / SAPIEN 3 Ultra THV.
11249655|NCT03042104|No Intervention|CS|Clinical surveillance
11249656|NCT03042091|Active Comparator|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
11249657|NCT03042091|Experimental|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
11249658|NCT03042078|Experimental|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
11249659|NCT03042078|Active Comparator|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
11249660|NCT03042065|Experimental|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
11249661|NCT03042065|Active Comparator|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
11249662|NCT03042052||Patients suffering from NDO managed with Botox|"Doses used were 300 units Botox® from January 2001 to January 2011 and 200 units after 2011
~Frequency depended on patient's symptoms
~Duration was an outcome of the study"
11249663|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
11249664|NCT03042026||Acromegaly patients|Acromegaly patients
11249665|NCT03042026||Healthy subjects|Healthy volunteers
11249666|NCT03042013|Experimental|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
11249667|NCT03042000|Experimental|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
11249668|NCT03042000|Active Comparator|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
11249669|NCT03042000|Experimental|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
11249670|NCT03042000|Active Comparator|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
11249671|NCT03042000|Experimental|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
11249672|NCT03042000|Active Comparator|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
11249673|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR <60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment."
11249674|NCT03041974||Transfused critical care patients|Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
11249675|NCT03041961|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
11249676|NCT03041961|Active Comparator|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
11249677|NCT03041961|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
11249739|NCT03041532|Active Comparator|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
11249908|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
11249678|NCT03041948|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL).
11249679|NCT03041948|Experimental|ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL).
11249680|NCT03041935|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
11249681|NCT03041935|Experimental|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
11249682|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
11249683|NCT03041909|Experimental|Single Arm|Single Arm / open label
11249684|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
11249685|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
11249686|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
11249687|NCT03041896||Hybrid|coflex and fusion at adjacent levels
11249688|NCT03041883|Experimental|Kpro with crosslinked graft-support|Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
11249689|NCT03041883|Active Comparator|KPro with normal graft-support|Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
11249690|NCT03041870|Experimental|Dominance|Healthy subjects
11249691|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
11249692|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
11249693|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
11249694|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
11249695|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
11249696|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
11249697|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
11249698|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
11249699|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
11249700|NCT03041818|Experimental|hippotherapy|16 sessions of horseback riding therapy
11249701|NCT03041792|Experimental|Active|Liraglutide
11249702|NCT03041792|Placebo Comparator|Placebo|Placebo comparator
11249703|NCT03041779|Active Comparator|Paracetamol|Paracetamol 500Mg Suppository
11249704|NCT03041779|Active Comparator|Voltaren|Diclofenac Sodium 50Mg Suppository
11249705|NCT03041766|Experimental|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
11249706|NCT03041766|Experimental|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
11249707|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
11249708|NCT03041740|No Intervention|Usual Care (Control) Group|Control subjects will be treated as per standard of care for preterm infants with BPD.
11249709|NCT03041740|Active Comparator|Perfluorooctylbromide (PFOB) Group|Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
11249710|NCT03041727|Active Comparator|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.
~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
11249711|NCT03041727|Experimental|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
11249712|NCT03041714||Normal volunteers|people who are healthy and without tremor
11249713|NCT03041714||Essential tremor|Patients with essential tremor
11249714|NCT03041714||Dystonic tremor|patient with tremor who also have dystonia
11249715|NCT03041701|Experimental|1|Phase I: Combination of ganitumab and dasatinib with limited dose escalation of dasatinib
11249716|NCT03041701|Experimental|2|Phase II: Combination of ganitumab and dasatinib at the MTD (or highest safe dose)
11249717|NCT03041688|Experimental|Treatment (decitabine, MDM2 inhibitor AMG-232)|"Patients receive decitabine IV over 1 hour on days 1-10 and MDM2 inhibitor AMG-232 PO QD on days 4-10 and 18-24. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.
~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5 and AMG-232 PO QD on days 4-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11249718|NCT03041675|Experimental|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
11249719|NCT03041675|Sham Comparator|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
11249720|NCT03041649|Active Comparator|GT button change - Mic-Key|Subjects randomized to the Mic-Key arm will have the Mic-Key button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mini One button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
11249721|NCT03041649|Active Comparator|GT button change - Mini One|Subjects randomized to the Mini One arm will have the Mini One button placed initially at surgery, and at the first gastrostomy change in the clinic at 2 months, will change to the Mic-Key button. At the routine 4-month visit, parents will be asked which button they prefer to keep.
11249722|NCT03041636|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
11249723|NCT03041610|Experimental|Walking intervention|
11249724|NCT03041610|No Intervention|Control|
11249725|NCT03041597|Experimental|Immediate loading|
11249726|NCT03041597|Active Comparator|delayed loading|
11249727|NCT03041584|Experimental|Materialise Universal®/ mucosa (Mat Mu)|
11249728|NCT03041584|Experimental|Materialise Universal®/ bone (Mat Bo)|
11249729|NCT03041584|Experimental|FacilitateTM/ mucosa (Fac Mu)|
11249730|NCT03041584|Experimental|FacilitateTM/ bone (Fac Bo)|
11249731|NCT03041584|Active Comparator|mental navigation (Mental)|
11249732|NCT03041584|Active Comparator|pilot-drill template (Templ)|
11249733|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
11249734|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
11249735|NCT03041558|Experimental|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
11249736|NCT03041558|Active Comparator|SafeCare (SC)|SafeCare intervention as usual
11249737|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
11249834|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
11249740|NCT03041519|Experimental|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
11249741|NCT03041519|Active Comparator|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
11249742|NCT03041506|Active Comparator|Sedation|"Analgesia and sedation through IV medication for pain relief will be administered to the patient.
~Midazolam: up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 second).
~Ketamine: up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds)."
11249743|NCT03041506|Experimental|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.
~Lidocaine 2%: 15-20 ml."
11249744|NCT03041493|Experimental|Electronic cigarettes (EC) smokers|
11249745|NCT03041493|Experimental|traditional cigarette (TC) smokers|
11249746|NCT03041493|Active Comparator|nonsmokers|
11249747|NCT03041480||GROUP I|Estimation of serum lipid levels and Lp-PLA2 in generalized severe chronic periodontitis
11249748|NCT03041480||GROUP II|Estimation of serum lipid levels and Lp-PLA2 in generalized moderate chronic periodontitis
11249749|NCT03041480||GROUP III|Estimation of serum lipid levels and Lp-PLA2 in systemically and periodontally healthy controls
11249750|NCT03041467|Experimental|IN.PACT AV DCB|"PTA will be performed using the IN.PACT AV Access Drug Coated Balloon. IN.PACT AV Access DCB was the device name used during the clinical study. Medtronic has changed the name of the device to IN.PACT™ AV Paclitaxel-Coated Balloon Catheter (also referred as IN.PACT AV DCB). Hence, throughout posting, the study device will be referred to as the IN.PACT AV DCB."
11249751|NCT03041467|Active Comparator|Standard Balloon Angioplasty|PTA will be performed using a commercially available uncoated PTA balloon.
11249752|NCT03041454|Experimental|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
11249753|NCT03041454|No Intervention|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
11249754|NCT03041441|Experimental|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
11249755|NCT03041428|Experimental|Recruited patients|Ultraprotective ventilation
11249756|NCT03041415|Active Comparator|ALED Alone Physical Activity Program|"The Active Living Every Day (ALED) comprehensive 12-week PA training and support program is appropriate for delivery by trained instructors from diverse backgrounds.
~Participants are taught self-regulatory skills aimed at increasing and sustaining regular physical activities such as walking."
11249757|NCT03041415|Experimental|ALED + Our Voice PA Program|"The ALED physical activity program is combined with the Our Voice citizen science engagement program, which teaches participants how to assess the barriers and enablers of neighborhood physical activity using a simple mobile app.
~Residents then share their data and build consensus around major barriers and potential solutions, which they share with local decision makers."
11249758|NCT03041402|Active Comparator|PSP ventilation|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
11249759|NCT03041402|Active Comparator|NAVA ventilation|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
11249760|NCT03041402|Experimental|PSN ventilation|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
11249761|NCT03041389|Experimental|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
11249762|NCT03041389|Active Comparator|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
11249763|NCT03041376|Experimental|Walking intervention|
11249764|NCT03041376|No Intervention|Control|
11249765|NCT03041363|Experimental|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
11249766|NCT03041350|Experimental|Smartphone video-assisted ALS & Conventional CPR|"In study period, using this video medical control, high-quality CPR, cardiac arrest rhythm confirmation, defibrillation, proper drug administration instructions, advanced airway insertion, etc. are performed. The medical director then decides on patient transfer if the asystole and pulseless electrical activity findings are persistent even after more than 20-minutes of ALS.
~The conventional CPR is Basic life support only in the automatic external defibrillator (AED) mode 5-10 minutes at the scene, are not allowed to stop resuscitation at the scene unless there is a return of spontaneous circulation (ROSC) or pre-hospital cardiac arrest patient has already been transported to a hospital."
11249767|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
11249768|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
11249769|NCT03041324|Experimental|Experimental: Cohort 1: SB-913: Starting Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11249770|NCT03041324|Experimental|Experimental: Cohort 2: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11249771|NCT03041324|Experimental|Experimental: Cohort 3: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11249772|NCT03041324|Experimental|Experimental: Cohort 4: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11249773|NCT03041311|Experimental|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive trilaciclib 240 mg/m2 administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.
~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
11249774|NCT03041311|Experimental|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive placebo administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.
~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
11249775|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
11249776|NCT03041285|Experimental|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
11249777|NCT03041285|Experimental|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
11249778|NCT03041272||Nurses and nursing personnel|All registered nurses and assistive nursing personnel, including patient care associates (PCAs) , patient care technicians (PCTs), clinical technicians (CTs), primary employment on the study unit, minimum of 24 hours per week of employment on study unit.
11249779|NCT03041259|Experimental|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
11249780|NCT03041259|Experimental|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
11249781|NCT03041246|Experimental|Study group - Treatment with PFFM|Manual treatment for the pelvic floor will be provided in two sessions two weeks apart as long as guidance towards exercise for strengthening of the pelvic floor
11249782|NCT03041246|No Intervention|Control group -|Guidance towards exercise for strengthening of the pelvic floor with no other interventional treatment.
11249783|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
11249784|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
11249785|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
11249786|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
11249787|NCT03041181|Experimental|Arm A - Single Agent Chemotherapy + Nivolumab|"Single Agent Chemotherapy of choice plus nivolumab:
~Taxotere Pemetrexed Gemcitabine"
11249788|NCT03041181|Active Comparator|Arm B - Single Agent Chemotherapy|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
11249789|NCT03041155|Experimental|treatment|Muscle respiratory training
11249790|NCT03041155|No Intervention|control|No intervention
11249791|NCT03041142|Experimental|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;
~1 session/week 60 minutes nutrition education week;
~1 session/week 120 minutes behaviour therapy.
~Mothers
~1 sessions/week 50-60 minutes of physical activity;
~1 session/week 60 minutes nutrition education week;
~1 session/week 120 minutes behaviour therapy."
11249792|NCT03041142|Active Comparator|Routine|Mothers and children followed their routine activities
11249793|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
11249794|NCT03041129||Metformin PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
11249795|NCT03041129||Oral Contraceptive PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
11249796|NCT03041129||Obese Control group-(Study arm not funded)|Obese Regular menses at least 18 months post-menarche Females only
11249797|NCT03041116|Experimental|fosmetpantotenate (RE-024)|Administered as powder for reconstitution.
11249798|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
11249799|NCT03041103|Experimental|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
11249800|NCT03041103|Experimental|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
11249801|NCT03041090|Experimental|Static Imaging participants|"This arm of the study assessed participants' static PET/CT images. These were the standard of care images acquired after their standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.
~Intervention was Lucerno sensors (Lucerno Device Identity Document (LD ID), Lucerno Device 1 (LD1), Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
11249802|NCT03041090|Experimental|Dynamic image participants|"This arm of the study assessed participants' dynamic PET/CT images. These were the study related images of and around the injection site acquired during the participants' standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.
~Intervention was Lucerno sensors (LD ID, LD1, Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
11249803|NCT03041077|Experimental|Instaflex Advanced|Dietary supplement: Joint function
11249804|NCT03041077|Placebo Comparator|Placebo|Dietary supplement: Placebo
11249805|NCT03041064|Experimental|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
11249806|NCT03041064|Experimental|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
11249807|NCT03041051|Experimental|PCV13|
11249808|NCT03041051|Experimental|PPV23|
11249809|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
11249810|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
11249811|NCT03041025|Experimental|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
11249812|NCT03041025|Experimental|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
11249813|NCT03041025|Placebo Comparator|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
11249814|NCT03041025|Placebo Comparator|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
11249815|NCT03041012|Placebo Comparator|antiretrovirals|Standard of care
11249816|NCT03041012|Active Comparator|antiretrovirals + romidepsin|Standard of care + LRA
11249817|NCT03041012|Active Comparator|antiretrovirals + 3BNC117|Standard of care + bNAb
11249818|NCT03041012|Active Comparator|antiretrovirals + romidepsin + 3BNC117|Standard of care + LRA + bNAb
11249819|NCT03040999|Experimental|Pembrolizumab + Cisplatin + CRT|Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.
11249820|NCT03040999|Placebo Comparator|Placebo + Cisplatin + CRT|Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.
11249821|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
11249822|NCT03040973|Experimental|INC280|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent INC280 protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
11249823|NCT03040973|Experimental|INC280/EGF816|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
11249824|NCT03040973|Active Comparator|INC280/Gefitinib|The starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated.
11249825|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
11249826|NCT03040947||Diseased (Suspected or Known Cardiac Conditions)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
11249827|NCT03040934|Active Comparator|Firehawk implantation|98 subjects will be enrolled to receive a test device (Firehawk™).
11249828|NCT03040934|Active Comparator|XIENCE implantation|98 subjects will be enrolled to receive a control device (XIENCE).
11249829|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
11249830|NCT03040895|Experimental|ICDP-intervention for caregivers|Group-based ICDP-intervention for caregivers through a sequence of eight meetings. The groups are led by facilitators trained in the ICDP.
11249831|NCT03040895|Other|Treatment as usual|Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
11249832|NCT03040882|Experimental|cotton sock|
11249833|NCT03040882|Active Comparator|Elastic Compression Wraps|
11249836|NCT03040856|Experimental|Alpha Linolenic Acid enriched diet|Enriched diet with 2 capsules of ALA supplementation a day - 630 mg in each capsule. Total amount of 1260 mg (Daily recommended dose is 1-2 g).
11249837|NCT03040856|Experimental|Omega 3 enriched diet ( DHA+EPA)|Enriched diet with 2 capsules of DHA+EPA supplementation a day (Each capsule consist of 240 mg DHA and 360 mg EPA).
11249838|NCT03040856|Placebo Comparator|Placebo|Control group - Will receive 2 placebo capsule a day - containing olive oil
11249839|NCT03040830|Experimental|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
11249840|NCT03040830|Active Comparator|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
11249841|NCT03040817|Experimental|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
11249842|NCT03040817|Active Comparator|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
11249843|NCT03040804|Experimental|Low Dose Radiotherapy|Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week
11249844|NCT03040791|Experimental|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
11249845|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
11249846|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
11249847|NCT03040765|Active Comparator|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe
~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
11249848|NCT03040765|Active Comparator|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj
~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
11249849|NCT03040752|Active Comparator|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
11249850|NCT03040752|Active Comparator|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
11249851|NCT03040739||case|
11249852|NCT03040739||control|
11249853|NCT03040726|Experimental|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
11249854|NCT03040726|Placebo Comparator|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
11249855|NCT03040713|Experimental|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
11249856|NCT03040700|No Intervention|Clinical|Regular medical visits every 6 months.
11249857|NCT03040700|Experimental|Myocardial Perfusion Scan|Myocardial perfusion stress test using cardiac scintigraphy (Sestamibi) at rest and during pharmacological stress (dipyridamole)
11249858|NCT03040700|Experimental|Coronary CTA|Coronary computed tomography angiography
11249859|NCT03040687|Experimental|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
11249860|NCT03040687|Experimental|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
11249861|NCT03040687|Experimental|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
11249862|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
11249863|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
11249864|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
11249865|NCT03040648|Experimental|cervical TFEB under DSA|cervical TFEB was performed under DSA
11249866|NCT03040648|Active Comparator|TFEB under RTF|cervical TFEB was performed under RTF
11249867|NCT03040635|Experimental|Risdiplam '2' Milligrams (mg)|A single dose of 2 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
11249868|NCT03040635|Experimental|Risdiplam '6' mg|A single dose of 6 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
11249869|NCT03040635|Experimental|Risdiplam '12' mg|A single dose of 12 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
11249870|NCT03040635|Placebo Comparator|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
11249871|NCT03040622||Watchman Left Atrial Appendage Closure|
11249872|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
11249873|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
11249874|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
11249875|NCT03040596|Experimental|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
11249876|NCT03040596|Other|voice therapy only|standard voice therapy
11249877|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
11249878|NCT03040570|Experimental|Conservative oxygenation target|Children in the conservative oxygenation target group receive treatment targeting oxygen saturation values of 88-92%.
11249879|NCT03040570|Active Comparator|Liberal oxygenation target|Children in the liberal oxygenation target group receive treatment targeting oxygen saturation values of >94%.
11250116|NCT03038919|Other|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
11249880|NCT03040557|Active Comparator|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (MFG), acute n=12 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
11249881|NCT03040557|Active Comparator|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (COIG, acute n=14 and chronic=14) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
11249882|NCT03040544|Experimental|LTB-Curriculum|First group/arm undergo MIS training according to the LTB curriculum after the first own laparoscopic cholecystectomy in the OR as a baseline. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using the Global Operational Assessment of Laparoscopic Skill (GOALS) score.
11249883|NCT03040544|Active Comparator|no LTB-Curriculums|Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
11249884|NCT03040531|Experimental|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.
~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
11249885|NCT03040531|Active Comparator|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.
~Once a week subjects will take one tablet containing 70mg alendronate."
11249886|NCT03040518|Experimental|Narrative SMS|"Participants will receive narrative SMS for 12 months.
~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
11249887|NCT03040518|Experimental|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.
~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
11249888|NCT03040518|No Intervention|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.
~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
11249889|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
11249890|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
11249891|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
11249892|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
11249893|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
11249894|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
11249895|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
11249896|NCT03040453|Other|Microwave ablation|20 patients will be treated with microwave ablation
11249897|NCT03040453|Other|Irreversible electroporation|20 patients will be treated with irreversible electroporation
11249898|NCT03040440|Active Comparator|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
11249899|NCT03040440|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
11249900|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
11249901|NCT03040414|Active Comparator|PID Algorithm|Participants will receive insulin delivered by the Medtronic Minimed 670G 3.0 HCL system using a PID algorithm..
11249902|NCT03040414|Experimental|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system (Minimed 670G 4.0 AHCL) with Guardian Sensor (3) continuous glucose monitoring sensor.
11249903|NCT03040401|Experimental|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.
~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.
~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
11249904|NCT03040401|Experimental|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.
~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.
~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
11249905|NCT03040401|Experimental|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.
~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.
~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
11249906|NCT03040375|Experimental|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
11249907|NCT03040375|No Intervention|Non peer counselling|Usual health messages
11249909|NCT03040349|Experimental|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
11249910|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
11249911|NCT03040336|No Intervention|Standard of Care|Standard of Care
11249912|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
11249913|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
11249914|NCT03040310|Experimental|Back Rx program|Study patients will use their smartphone apps to view their Back Rx program content, exercises, and videos.
11249915|NCT03040297|Active Comparator|TGI 6 L/min|Tracheal gas insufflation 6 L/min
11249916|NCT03040297|Active Comparator|TGI 11 L/min|Tracheal gas insufflation 11 L/min
11249917|NCT03040297|Active Comparator|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
11249918|NCT03040284|Experimental|aneurysmal subarachnoid hemorrhage|
11249919|NCT03040271|Experimental|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
11249920|NCT03040271|No Intervention|Control group|Group of students not receiving any intervention
11249921|NCT03040258|Experimental|Intervention group- Health-E-PALS-Pilot|Group of students receiving the school-based intervention: Health-E-PALS (pilot), it consists of in class activities and lessons.
11249922|NCT03040258|No Intervention|Control group|Group of students not receiving any intervention
11249923|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
11249924|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
11249925|NCT03040232|Experimental|MPFl Reconstruction|subjects that have had MPFL reconstruction surgery
11249926|NCT03040232|Active Comparator|Active Controls|subjects that have not had MPFL reconstruction surgery
11249927|NCT03040219|Active Comparator|Treatment group|
11249928|NCT03040219|Placebo Comparator|Control|
11249929|NCT03040206||Nodal PTCL|"newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative) between January 1, 2005 and Jun 30, 2016
~initially treated with curative intent
~Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
11249930|NCT03040193|Experimental|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
11249931|NCT03040193|Placebo Comparator|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
11249932|NCT03040180|Experimental|Electrochemotherapy with bleomycin|"Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.
~BSA by Du Bois formula."
11249933|NCT03040180|No Intervention|Standard care|Standard care
11249934|NCT03040167|Placebo Comparator|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
11249935|NCT03040167|Active Comparator|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
11249936|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
11249937|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
11249938|NCT03040141|Experimental|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
11249939|NCT03040141|Experimental|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
11249940|NCT03040141|Placebo Comparator|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
11249941|NCT03040128|Placebo Comparator|placebo|normal saline infusion
11249942|NCT03040128|Experimental|minocycline|intravenous minocycline
11249943|NCT03040102|Experimental|Hospice Video Educational Tool|"The hospice video educational tool is a 6 minute video
~Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
11249944|NCT03040102|Active Comparator|Hospice Verbal Narrative|"The RA will read a verbal narrative that is identical to the narrative of the video to participants
~Standard of Care practice is used"
11249945|NCT03040089|Experimental|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
11249946|NCT03040089|Sham Comparator|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
11249947|NCT03040076|Experimental|Cognitive Bias Treatment|Intervention condition
11249948|NCT03040076|Active Comparator|Relaxation Condition|Active control condition
11249949|NCT03040063|Experimental|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
11249950|NCT03040063|Experimental|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
11249951|NCT03040050|Other|Men scheduled for prostate biopsy randomized to Control|
11249952|NCT03040050|Experimental|Men scheduled for a prostate biopsy randomized to Intervention|
11249953|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
11249954|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
11249955|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
11249956|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
11249957|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
11249958|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
11249959|NCT03039998||HAP Patients|HAP, intubated and mechanically ventilated.
11249960|NCT03039985|Experimental|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
11249961|NCT03039985|Experimental|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
11249962|NCT03039985|Experimental|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
11249963|NCT03039985|Experimental|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
11249964|NCT03039972||Pulmonary Hypertension|Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
11249965|NCT03039959||Pulmonary hypertension cohort|Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.
11249966|NCT03039959||Heart failure cohort|Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.
11249967|NCT03039946|Experimental|Closed-loop GDFT|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid maintenance with Plasmalyte is carried out using a closed-loop system guided by the Clearsight non-invasive hemodynamic flow monitor.
11249968|NCT03039946|Active Comparator|Restrictive fluid therapy|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid management is based on a restrictive (4ml/kg/h) Plasmalyte infusion.
11249969|NCT03039933|Active Comparator|Fear of Hypoglycemia Intervention|
11249970|NCT03039933|Other|Treatment As Usual|
11249971|NCT03039920|Active Comparator|Electronic cigarette with or without nicotine|Electronic cigarette assisted cessation program
11249972|NCT03039920|Active Comparator|Smoker control|Conventional cigarette smoking continuation
11249973|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
11249974|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
11249975|NCT03039868||Normal Pap smears|This is the control group.
11249976|NCT03039868||Abnormal Pap smears|This is the case group.
11249977|NCT03039855|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
11249978|NCT03039842|Experimental|30 mg DM|30mg dextromethorphan+valproate
11249979|NCT03039842|Experimental|5 mg MM|5mg memantine+valproate
11249980|NCT03039842|Experimental|DM+MM|dextromethorphan+memantine+ valproate
11249981|NCT03039842|Placebo Comparator|placebo|Placebo+valproate
11249982|NCT03039829|Experimental|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
11249983|NCT03039829|Active Comparator|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
11249984|NCT03039829|Placebo Comparator|Placebo|Placebo at 6.0 grams dextrose
11249985|NCT03039816|Active Comparator|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
11249986|NCT03039816|Placebo Comparator|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
11249987|NCT03039803|Active Comparator|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
11249988|NCT03039803|Active Comparator|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
11249989|NCT03039790|Experimental|NoV Vaccine|Participants who previously received NoV vaccine adjuvanted with aluminum as aluminum hydroxide or with monophosphoryl lipid A (MPL), injection, intramuscularly as planned in studies NOR-107, NOR-210 and NOR-204 will be assessed over 5 years post-primary vaccination. Vaccine formulations according to the parent trials: NOR-107, 210 and 204.
11249990|NCT03039764|No Intervention|Standard occupational therapy|This group will receiving standard occupational therapy for the treatment of acute stroke.
11249991|NCT03039764|Experimental|SOT plus VR Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
11249992|NCT03039751|Experimental|AdvVEGF-D|Intramyocardial AdVEGF-D
11249993|NCT03039751|Placebo Comparator|Control|Intramyocardial placebo (buffer solution without gene)
11249994|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
11249995|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
11249996|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
11249997|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
11249998|NCT03039699|Experimental|Ergoferon|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
11249999|NCT03039699|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
11250000|NCT03039686|Experimental|RO7239361, dose 1|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
11250001|NCT03039686|Experimental|RO7239361, dose 2|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
11250002|NCT03039686|Placebo Comparator|Placebo|Placebo solution taken subcutaneously on specified days over a 48 week blinded period
11250003|NCT03039673|Experimental|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.
~Intervention: Riluzole Intervention: IL-2"
11250004|NCT03039673|Placebo Comparator|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.
~Intervention: Riluzole Intervention: 5% glucose water solution"
11250005|NCT03039660|Experimental|RefreshMD|An online course for sleep improvement in medical students
11250006|NCT03039660|Placebo Comparator|Bond Between Us|An online course covering communication skills and the physician-patient relationship
11250007|NCT03039647||Entry Point IR (SSPG, HOMA-IR)|All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
11250008|NCT03039647||Change in IR (HOMA-IR)|The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
11250009|NCT03039621|Experimental|Ergoferon|Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
11250010|NCT03039621|Placebo Comparator|Placebo|Placebo using Ergoferon scheme.
11250011|NCT03039608|Experimental|combination group|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
11250012|NCT03039608|Active Comparator|control group|oral steroid administration（prednisone）
11250013|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
11250014|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
11250015|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
11250016|NCT03039569|Experimental|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
11250017|NCT03039569|No Intervention|Control|Participants will not receive text message intervention. This is the measurement-only group
11250018|NCT03039556|Experimental|Change in physical activity for older adults|Older adult participants undergo alterations in daily ambulation by completing Normal Daily Steps for one week, followed by a two-week Step-Reduction and a subsequent Return to Normal Daily Steps for two weeks
11250019|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
11250117|NCT03038906||Cohort|Patients enrolling in NHLBI PETAL Network ROSE study of cisatracurium for moderate/severe ARDS at participating centers
11250020|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
11250021|NCT03039530|Experimental|Treatment Group|Group CBT for PPD. Women in the treatment group will attend a 9-week group CBT intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
11250022|NCT03039530|Active Comparator|Control Group|Standard Care. The usual care group will receive standard care from their family physician and midwife or obstetrician. They will also be made aware of the perinatal programming available to them through Niagara Region Public Health. Women and family physicians will also receive a copy of the Canadian Practice Guidelines for the Treatment of Perinatal Depression.
11250023|NCT03039517|Experimental|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
11250024|NCT03039517|Experimental|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
11250025|NCT03039504|Experimental|Potensa|succinate-based dietary supplement
11250026|NCT03039504|Placebo Comparator|Placebo|placebo
11250027|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
11250028|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
11250029|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count >200 to receive PPV23 only
~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
11250030|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PPV23 only
~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
11250031|NCT03039491|Active Comparator|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
11250032|NCT03039491|Active Comparator|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.
~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
11250033|NCT03039491|Active Comparator|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
11250034|NCT03039491|Active Comparator|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23
~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
11250035|NCT03039478|Active Comparator|Xylitol 7g in 300mL tap water|12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
11250036|NCT03039478|Active Comparator|Xylitol 17g in 300mL tap water|12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
11250037|NCT03039478|Active Comparator|Xylitol 35g in 300mL tap water|12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
11250038|NCT03039478|Active Comparator|Erythritol 10g in 300mL tap water|12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
11250039|NCT03039478|Active Comparator|Erythritol 25g in 300mL tap water|12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
11250040|NCT03039478|Active Comparator|Erythritol 50g in 300mL tap water|12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
11250041|NCT03039465|Experimental|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
11250042|NCT03039452|Experimental|High intensity interval training|
11250043|NCT03039439||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.
11250044|NCT03039426|Experimental|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
11250045|NCT03039426|Active Comparator|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
11250046|NCT03039413|Experimental|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
11250047|NCT03039400|Experimental|Web-based physio group|Those in the web-based physio group will have an individual exercise program set up by a treating physiotherapist on webbasedphysio.com after an initial face-to-face assessment. They will be encouraged to undertake their exercise program at least twice per week and diarize their work. Participants will receive a weekly phone call from their treating physiotherapist for the first two weeks. The treating physiotherapist will review the exercise diary of each participant every two weeks, and remotely alter the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
11250118|NCT03038893|Experimental|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
11250119|NCT03038893|Active Comparator|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
11250048|NCT03039400|Active Comparator|Standard care group|Those in the standard care group will have their exercise program explained to them at an initial face-to-face assessment with a treating physiotherapist as per usual care. They will receive a written, home-based exercise program. Participants in the usual care group will also be encouraged to undertake their exercise program at least twice per week, and will be asked to keep an exercise diary, in paper format. Participants in the usual care group will also receive a weekly phone call from the physiotherapist for the first two weeks to check on progress.
11250049|NCT03039387|Active Comparator|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
11250050|NCT03039387|Placebo Comparator|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
11250051|NCT03039374||OASI patients|All patients older than 18 and a 3rd or 4th degree perineal tear during birth meet the inclusion criteria. All women who have obtained such a injury during birth in the Vaasa or Seinäjoki Central hospitals will be evaluated for eligibility.
11250052|NCT03039361|Experimental|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
11250053|NCT03039361|No Intervention|Control|Standard of Care, Existing PTSD therapy
11250054|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
11250055|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
11250056|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
11250057|NCT03039322||HCC|
11250058|NCT03039322||liver cirrhosis No HCC|
11250059|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
11250060|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
11250061|NCT03039283||Nucleus CI532 cochlear implant|
11250062|NCT03039270|Active Comparator|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
11250063|NCT03039270|Experimental|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
11250064|NCT03039257|Other|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
11250065|NCT03039244|Experimental|Test Group|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
11250066|NCT03039244|Sham Comparator|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
11250067|NCT03039231|Experimental|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
11250068|NCT03039218|Active Comparator|Active|Subjects assigned to this group will receive Active treatments using the Dornier Aries 2.
11250069|NCT03039218|Placebo Comparator|Placebo / Sham|Subjects assigned to this group will receive placebo / sham (no active treatment).
11250070|NCT03039205|Active Comparator|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
11250071|NCT03039205|Active Comparator|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
11250072|NCT03039205|Active Comparator|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
11250073|NCT03039205|Active Comparator|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
11250074|NCT03039192|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
11250075|NCT03039192|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
11250076|NCT03039179|Experimental|Polyurethane foam|
11250077|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
11250078|NCT03039166|Experimental|parkinson|
11250079|NCT03039166|Experimental|partial epilepsy|
11250080|NCT03039166|Experimental|alzheimer disease|
11250081|NCT03039166|Experimental|multiple sclerosis|
11250082|NCT03039166|Experimental|amyotrophic lateral sclerosis|
11250083|NCT03039166|Active Comparator|healthy control patients|
11250120|NCT03038880|Experimental|Faricimab (Short interval)|Faricimab will be given via intravitreal (IVT) administration at a short interval duration during the 52 weeks treatment period.
11250121|NCT03038880|Experimental|Faricimab (Long interval)|Faricimab will be given via IVT administration at a long interval duration during the 52 weeks treatment period.
11251147|NCT03032185|Active Comparator|Active TENS|Active TENS, 10 Hz/200 μs
11250084|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
11250085|NCT03039127|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
11250086|NCT03039114|Experimental|Parsaclisib + Hexal and Gazyvaro|
11250087|NCT03039101|Experimental|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
11250088|NCT03039101|Placebo Comparator|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
11250089|NCT03039088||Fibromyalgia patients|
11250090|NCT03039088||Not fibromyalgia patients|
11250091|NCT03039075|Active Comparator|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
11250092|NCT03039075|Active Comparator|Glucophage|The original drug of metformin
11250093|NCT03039062||Chemotherapy group|A total of 120 malignant tumor patients who need to receive chemotherapy are involved for miR-122 detection. They are from 3 centers, 40 for each center. For the first cycle of chemotherapy, the investigators will collect 0.5-1ml blood from the remained blood sample after routine blood test during chemotherapy for each patient.Each patient will have a routine blood test before(±3 days) each cycle of chemotherapy and 7(±3)days after chemotherapy. A routine blood test will include the test of ALT,AST,ALP and TBIL. Sample collection will stop after 4 cycles of chemotherapy. All blood samples collected by investigators are the remained sample after routine tests. Patients in routine care will also have blood tests before each cycle and on day 7(+/- 3) of each cycle of chemotherapy. These patients will also have blood test at these time points even if they are not in this trial.
11250094|NCT03039062||Healthy population|Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
11250095|NCT03039062||Patients of intensive care unit|Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
11250096|NCT03039049|Experimental|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.
~Other Names:
~• Decapeptyl 0.1 mg"
11250097|NCT03039049|No Intervention|Control|No intervention
11250098|NCT03039036|Experimental|Early Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy within 1 hour of Foley catheter removal.
11250099|NCT03039036|Active Comparator|Delayed Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy no sooner than 4 hours following removal of Foley catheter.
11250100|NCT03039023|Experimental|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
11250101|NCT03039023|Experimental|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
11250102|NCT03039023|Experimental|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
11250103|NCT03039023|Experimental|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
11250104|NCT03038984|Experimental|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
11250105|NCT03038984|Active Comparator|On demand|screening On demand: (home monitoring: FC and DA)
11250106|NCT03038971|Other|Concentration 1: Short and Tall Ragweed Mix|
11250107|NCT03038971|Other|Concentration 2: Short and Tall Ragweed Mix|
11250108|NCT03038971|Other|Placebo: Saline with 0.4% Phenol|
11250109|NCT03038958|Active Comparator|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
11250110|NCT03038958|Active Comparator|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
11250111|NCT03038945|Experimental|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
11250112|NCT03038945|Active Comparator|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
11250113|NCT03038932||Discovery Cohort|"A minimum of 50 recurrent Atopic Dermatitis with a history of Eczema Herpeticum(ADEH+), 500 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-), and 237 Non-Atopic (NA) European American participants from the Atopic Dermatitis Research Network (ADRN) DNA Repository.
~The study will learn from this cohort:
~All Single Nucleotide Variants (SNVs) in ADEH+
~ADEH+ specific deleterious SNVs
~The study will determine the function of:
~4. ADEH+ risk variants"
11250114|NCT03038932||Independent populations of participants|"Two independent populations of participants:
~Children, aged 3-17 years and
~Adults 18-64 years of age.
~A minimum of 12 recurrent Atopic Dermatitis with a history of Eczema Herpeticum (ADEH+) with ≥3 Eczema Herpeticum (EH) episodes, 12 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-) and 12 Non-Atopic (NA) participants will be enrolled in each of the two populations."
11250115|NCT03038919|Experimental|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
11250122|NCT03038880|Active Comparator|Ranibizumab|Ranibizumab will be given via IVT administration during the 52 weeks treatment period.
11250123|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
11250124|NCT03038867|Placebo Comparator|Placebo|Placebo
11250125|NCT03038854|Experimental|Test GUM|This group will drink a test toddler growing up milk (GUM) with higher amounts of key nutrients
11250126|NCT03038854|Active Comparator|Standard GUM|This group will drink a standard toddler growing up milk (GUM)
11250127|NCT03038854|Placebo Comparator|Comparator Group|This group will drink liquid full fat cows' milk
11250128|NCT03038854|No Intervention|Population Group|This group will eat and drink their usual foods with no interventions.
11250129|NCT03038828|Experimental|Arm A|Cohort A - 200IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off two weeks, then repeat 200IU 5 days/week x 2 weeks.
11250130|NCT03038828|Experimental|Arm B|Arm B - 400IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off 2 weeks, 400IU 5 days/week x 2 weeks.
11250131|NCT03038815|Experimental|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
11250132|NCT03038815|Experimental|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
11250133|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
11250134|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
11250135|NCT03038776|Experimental|1|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
11250136|NCT03038776|Experimental|2|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
11250137|NCT03038776|Experimental|3|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
11250138|NCT03038776|Experimental|4|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
11250139|NCT03038776|Experimental|5|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
11250140|NCT03038776|Experimental|6|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
11250141|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
11250142|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
11250143|NCT03038750||EDNRA Sub-study|"Study population will be split into two groups defined by the allele of EDNRA the participant possesses:
~Participants Homozygous for the A-allele of EDNRA, are assigned to the 'case' group.
~Participants that are Homozygous for the G-allele will be assigned to the 'control' group.
~20 participants will be recruited to each group, 40 in total."
11250144|NCT03038750||PNPLA3 Sub-study|"Study population will be split into two groups defined by the allele of PNPLA3 the participant possesses:
~Participants Homozygous for the G-allele of PNPLA3, are assigned to the 'case' group.
~Participants that are Homozygous for the C-allele of PNPLA3 will be assigned to the 'control' group.
~60 participants will be recruited to each group, 120 in total."
11250145|NCT03038750||PROCR Sub-study|"Study population will be split into two groups defined by the allele of PROCR the participant possesses:
~Participants Homozygous for the G-allele of PROCR, are assigned to the 'case' group.
~Participants that are Homozygous for the A-allele of PROCR will be assigned to the 'control' group.
~30 participants will be recruited to each group, 60 in total."
11250146|NCT03038737|Active Comparator|group 1|patients will receive partial denture constructed from breflex material
11250147|NCT03038737|Experimental|group 2|patients will receive partial denture constructed from PEEK material
11250148|NCT03038724|Other|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
11250149|NCT03038724|Other|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
11250150|NCT03038711|Experimental|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
11250151|NCT03038711|Experimental|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
11250152|NCT03038711|Experimental|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
11250153|NCT03038685|Experimental|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
11250154|NCT03038685|No Intervention|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
11250155|NCT03038672|Active Comparator|Group I (nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
11251148|NCT03032185|Sham Comparator|Not Active TENS|Sham TENS
11250156|NCT03038672|Experimental|Group II (varlilumab, nivolumab)|Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
11250157|NCT03038659||Penile Duplex|Measuring intima media thickness
11250158|NCT03038646|Experimental|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
11250159|NCT03038646|Experimental|Regimen B|32 mg MIN-101 MR administered in the fasted state
11250160|NCT03038646|Experimental|Regimen C|32 mg MIN-101 MR administered in the fasted state
11250161|NCT03038646|Experimental|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
11250162|NCT03038633|Experimental|Cohort 1|"900 mg novel medical food containing 22.2mg iron
~receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
11250163|NCT03038633|Experimental|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron
~receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
11250164|NCT03038633|Experimental|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron
~receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
11250165|NCT03038633|Experimental|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron
~receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated
~receive a phone call from coordinator between Day 5-9 to assess side effects and medications
~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
11250166|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug
~Other Names:
~Saxenda
~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
11250167|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL
~Other Names:
~Placebo
~Saline injection
~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
11250168|NCT03038607|Active Comparator|Aspirin group|
11250169|NCT03038607|No Intervention|No intervention|
11250170|NCT03038594|Experimental|Growth Hormone|Daily subcutaneous injections of 0.05 mg/kg/day of Growth Hormone [somatropin, Genotropin, Pfizer, New York, NY] will be administered, from one week prior to discharge until 9 months post-burn.
11250171|NCT03038594|Placebo Comparator|0.09% saline solution|Daily subcutaneous injections of 0.09% of saline solution will be administered, from one week prior to discharge until 9 months post-burn.
11250172|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
11250173|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
11250174|NCT03038568||Cohort 1|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 12
11250175|NCT03038568||Cohort 2|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 14
11250176|NCT03038568||Cohort 3|-15 second time gap between routine abdominal CT and add on CT, Noise Index of 16
11250177|NCT03038568||Cohort 4|-10 second time gap between routine abdominal CT and add on CT, Noise index 12
11250178|NCT03038568||Cohort 5|-10 second time gap between routine abdominal CT and add on CT, Noise index 14
11250179|NCT03038568||Cohort 6|-10 second time gap between routine abdominal CT and add on CT, Noise index 16
11250180|NCT03038568||Cohort 7|- 5 second time gap between routine abdominal CT and add on CT, Noise index 12
11250181|NCT03038568||Cohort 8|- 5 second time gap between routine abdominal CT and add on CT, Noise index 14
11250182|NCT03038568||Cohort 9|- 5 second time gap between routine abdominal CT and add on CT, Noise index 16
11250183|NCT03038568||Cohort 10|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12
11250184|NCT03038568||Cohort 11|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14
11250185|NCT03038568||Cohort 12|+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16
11250186|NCT03038568||Cohort 13|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12
11250187|NCT03038568||Cohort 14|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14
11250188|NCT03038568||Cohort 15|+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16
11250189|NCT03038568||Cohort 16|+ 15 second time gap between routine abdominal CT and add on CT, Noise 12
11250190|NCT03038568||Cohort 17|+ 15 second time gap between routine abdominal CT and add on CT, Noise 14
11250191|NCT03038568||Cohort 18|+ 15 second time gap between routine abdominal CT and add on CT, Noise 16
11250192|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
11250193|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
11250194|NCT03038542|Experimental|Treatment Text Arm|
11250195|NCT03038542|Active Comparator|Standard Text Arm|
11250196|NCT03038529|Other|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.
~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
11250197|NCT03038529|Active Comparator|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).
~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
11250198|NCT03038516|Active Comparator|Vitamin D|Cholecalciferol (Detremin) solved in MIGLYOL® 812
11250199|NCT03038516|Placebo Comparator|Placebo|MIGLYOL® 812
11250200|NCT03038503|No Intervention|A|standard care septic shock according sepsis bundles
11250201|NCT03038503|Experimental|B|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
11250202|NCT03038503|Experimental|C|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
11250203|NCT03038490|Experimental|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
11250204|NCT03038490|No Intervention|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
11250205|NCT03038477|Experimental|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
11250206|NCT03038477|No Intervention|No Durvalumab|Patients in Arm B will be observed.
11250207|NCT03038451|Experimental|s-amlodipine besylate 2,5 and 5 mg tablets|
11250208|NCT03038438|Experimental|Abre|Abre Venous Self-expanding Stent System
11250209|NCT03038425|Placebo Comparator|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
11250210|NCT03038425|Active Comparator|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
11250211|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
11250212|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
11250213|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
11250214|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
11250215|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
11250216|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
11250217|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
11250218|NCT03038373||Group III|Lean Diabetics, No surgery
11250219|NCT03038373||Group IV|Lean Non Diabetics, No surgery
11250220|NCT03038347|Experimental|Training|In the training group, participants work six weeks on the training program, one module per week. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises that participants perform independently. The main purpose of this intervention is the improvement of cross-cultural competencies in psychotherapists
11250221|NCT03038347|Active Comparator|Education only|In the education only group, participants work six weeks on a slimmed down version of the training program. The modules only contain text-based information without any exercises. After completion, participants receive access to the practical exercises, case studies and video files as well. Main purpose of the education only group is to determine whether the practical part of the training program can offer additional benefit.
11250222|NCT03038347|No Intervention|Waiting control|Initially, participants do not receive any training contents. After a six week waiting period, they can participate in the training program as well. Modules are equivalent to those of the training group. Purpose of this group is to determine whether the training program is effective.
11250223|NCT03038334|Experimental|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
11250224|NCT03038321|Active Comparator|solifenacin|(Sofenacin ''solifenacin 10 m'') [Marcyrl Pharmaceutical Industries - Egypt]
11250225|NCT03038321|Active Comparator|levofloxacin|(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]
11250226|NCT03038321|Active Comparator|lornoxicam|(Xefo ''lornoxicam 8 mg'') [Multi-Apex - Egypt, under license of: NYCOMED, Austria]
11250227|NCT03038308|Experimental|Drug|
11250228|NCT03038295|Experimental|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).
~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
11250229|NCT03038295|Placebo Comparator|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
11250230|NCT03038295|Experimental|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .
~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
11250327|NCT03037619|Experimental|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
11250231|NCT03038295|Placebo Comparator|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
11250232|NCT03038282|Experimental|Chromium Chloride|Participants transdermal chromium chloride 50 to 600 mcg/day.
11250233|NCT03038282|Experimental|Individual Exercise|Exercise 150 minutes per week (over 3 to 5 days) for 12 weeks.
11250234|NCT03038282|No Intervention|Control Group|Participants or participant's caregiver will be provided educational materials on starting an exercise program and instructions for the application of transdermal chromium chloride, but will receive no formal support for their exercise program.
11250235|NCT03038269|Sham Comparator|Sham tDCS|Participant will receive a placebo-type stimulation followed by upper extremity robotic training.
11250236|NCT03038269|Active Comparator|Active tDCS|Participant will receive active transcranial direct current stimulation followed by upper extremity robotic training.
11250237|NCT03038256|Experimental|4 Cycles XELOX pre- TME|experimental group (arm B): concurrent capecitabine-based long-term radiotherapy, 4 cycles of XELOX as neoadjuvant chemotherapy and TME surgery
11250238|NCT03038256|Active Comparator|6 Cycles XELOX post- TME|control group (arm A): concurrent capecitabine-based long-term radiotherapy, TME surgery and 6 cycles of XELOX as adjuvant chemotherapy.
11250239|NCT03038243|Experimental|Cohort 1|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
11250240|NCT03038243|Experimental|Cohort 2|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
11250241|NCT03038243|Experimental|Cohort 3|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
11250242|NCT03038230|Experimental|MCLA-117 bispecific antibody|"Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.
~Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment."
11250243|NCT03038217|Experimental|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
11250244|NCT03038217|Experimental|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
11250245|NCT03038217|Experimental|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
11250246|NCT03038217|Experimental|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
11250247|NCT03038204||PMA+MVA+CABG|patients with ischemic cardiomyopathy and mitral regurgitation who underwent coronary artery bypass grafting, mitral annuloplasty, and papillary muscles approximation.
11250248|NCT03038204||MVA+CABG|patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting and mitral valve annuloplasty.
11250249|NCT03038178|Experimental|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
11250250|NCT03038152|Experimental|Diagnostic (Magseed marker)|Patients receive the Magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =< 3mm from the clipped node. Patients then undergo axillary lymph node localization and targeted dissection within 30 days.
11250251|NCT03038139|Experimental|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.
~Applying exercises 3 times per week."
11250252|NCT03038139|Experimental|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.
~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.
~Applying exercises 3 times per week."
11250253|NCT03038126|Active Comparator|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
11250254|NCT03038126|Placebo Comparator|Usual care|
11250255|NCT03038113|Experimental|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
11250256|NCT03038113|Experimental|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
11250257|NCT03038100|Experimental|Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
11250328|NCT03037619|Experimental|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
11250476|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
11250258|NCT03038100|Placebo Comparator|Placebo With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
11250259|NCT03038087|Experimental|SENSE Device Monitoring in ICH Patients|
11250260|NCT03038061|Experimental|Experimental group|Patients undergoing Laparoscopic Surgery
11250261|NCT03038048|Experimental|33 g needle - right eye|33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye
11250262|NCT03038048|Experimental|33 g needle - left eye|33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye
11250263|NCT03038035|Active Comparator|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day
~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
11250264|NCT03038035|Placebo Comparator|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.
~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
11250265|NCT03038022|Experimental|MGL-3196|Study Drug
11250266|NCT03038022|Placebo Comparator|Placebo|Matching Placebo
11250267|NCT03038009|Active Comparator|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
11250268|NCT03038009|Experimental|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
11250269|NCT03037983|Active Comparator|Active rTMS|Subjects will receive actual rTMS treatment.
11250270|NCT03037983|Sham Comparator|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
11250271|NCT03037970|Experimental|ABSOLVE|Type I collagen sheet soaked in a solution containing rhPDGF-BB.
11250272|NCT03037970|Placebo Comparator|Placebo|Collagen sheet soaked with saline solution.
11250273|NCT03037957||Group A Strep Assay|
11250274|NCT03037944|Experimental|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
11250275|NCT03037944|Experimental|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
11250276|NCT03037931|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose 2 doses intravenously of 15mg/kg to a maximum individual dose of 750mg 7 days apart and a maximum combined dose of 1500mg - repeated every 6 months as indicated by iron indices
11250277|NCT03037931|Placebo Comparator|Placebos|Normal saline 15ml - 2 doses 7 days apart repeated every 6 months.
11250278|NCT03037918|Experimental|Treatment Group|"Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.
~Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28."
11250279|NCT03037918|No Intervention|Control Group|Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.
11250280|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
11250281|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
11250282|NCT03037892|Active Comparator|Midazolam and Fentanyl|Midazolam and Fentanyl Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain
11250283|NCT03037892|Experimental|Midazolam and Remifentanil|Midazolam and Remifentanil Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
11250284|NCT03037892|Experimental|Remifentanil|Remifentanil Group Patients will receive only Remifentanil in the same doses as given in group 2. During the procedure if the pain is excessive and persistent in spite of increasing the respective doses as prescribed in each group, or causing loss of cooperation of patient and interfering in the performance of procedure, the patients will be given sleep dose of Inj Propofol and further anaesthesia care as required will be provided for same.
11250285|NCT03037879|Experimental|SPT|Speed of Processing Training
11250286|NCT03037879|Active Comparator|Control Group SPT|Control group to SPT treatment group
11250287|NCT03037879|Experimental|mSMT|Story Memory Technique
11250288|NCT03037879|Active Comparator|Control mSMT|Control group to mSMT treatment group
11250397|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
11251211|NCT03031665||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
11250289|NCT03037866|Experimental|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
11250290|NCT03037866|No Intervention|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
11250291|NCT03037853||Healthy volunteers|Healthy volunteers
11250292|NCT03037840||cancer patients|Low intensity amplitude-modulated RF EMFs
11250293|NCT03037840||healthy participators|Low intensity amplitude-modulated RF EMFs
11250294|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
11250295|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
11250296|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
11250297|NCT03037814|Other|Compomer|Adhesive agent+Compomer
11250298|NCT03037814|Other|RMGIC|Primer+RMGIC
11250299|NCT03037814|Other|Giomer|Adhesive Agent+ Giomer
11250300|NCT03037814|Other|Amalgam|Amalgam
11250301|NCT03037801|No Intervention|Control|
11250302|NCT03037801|Experimental|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
11250303|NCT03037788|Experimental|WO3979|Formulation containing WO3979 for topical application
11250304|NCT03037788|Experimental|WO3970|Formulation containing WO3970 for topical application
11250305|NCT03037788|Experimental|WO3992|Formulation containing WO3992 for topical application
11250306|NCT03037788|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
11250307|NCT03037775|Other|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
11250308|NCT03037749|Experimental|Distressed Violent Partners|Distressed violent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
11250309|NCT03037749|Experimental|Distressed Nonviolent Partners|Distressed nonviolent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
11250310|NCT03037736|Placebo Comparator|Placebo|Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
11250311|NCT03037736|Active Comparator|5-Fluorouracil|Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
11250312|NCT03037736|Active Comparator|Bevacizumab|Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
11250313|NCT03037723|Other|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
11250314|NCT03037697|Experimental|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
11250315|NCT03037697|Active Comparator|Traditional Treatment Arm|"Traditional Treatment Arm
~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board
~3 months"
11250316|NCT03037684||chronic pain|individuals suffering from chronic pain
11250317|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
11250318|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
11250319|NCT03037658|Experimental|Personal - self|Participants had the opportunity to earn money for themselves by increasing their average steps per day.
11250320|NCT03037658|Experimental|Prosocial - loved one|Participants had the opportunity to earn money for a loved one of their choice by increasing their average steps per day.
11250321|NCT03037658|Experimental|Prosocial - charity|Participants had the opportunity to earn money for a charity of their choice by increasing their average steps per day.
11250322|NCT03037658|Experimental|Choice|Participants were given the choice to earn money either for themselves, a loved one, or a charity by increasing their average steps per day.
11250323|NCT03037658|No Intervention|Control|Participants were not offered a financial incentive to increase their average steps per day. They simply wore the pedometer for three weeks.
11250324|NCT03037645|Experimental|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
11250325|NCT03037632|Experimental|Communication Tool|
11250326|NCT03037632|No Intervention|No Communication Tool|
11250329|NCT03037606|Experimental|Rabelis DDR 50 mg Capsules and 1 placebo tablet|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
11250330|NCT03037606|Active Comparator|Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
11250331|NCT03037593|Experimental|Intervention|4000 IU vitamin D3 +prenatal vitamin
11250332|NCT03037593|No Intervention|Control|standard prenatal vitamin
11250333|NCT03037580|Experimental|Oral treprostinil|Sustained-release oral tablets for TID administration
11250334|NCT03037580|Placebo Comparator|Placebo|Placebo (sugar pill) for TID oral administration
11250335|NCT03037567|Experimental|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
11250336|NCT03037554|Experimental|Lateralized Thermal Sleepwear|For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
11250337|NCT03037554|Sham Comparator|Sham-Lateralized Sleepwear|For two consecutive nights subjects will wear Sham-Lateralized Sleepwear
11250338|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
11250339|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
11250340|NCT03037528|Experimental|Positive Affect, Mindfulness, Tracking|Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
11250341|NCT03037528|Experimental|Mindfulness, Tracking|Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
11250342|NCT03037528|Experimental|Positive Affect, Tracking|Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
11250343|NCT03037528|Experimental|Tracking|Participants will be asked to actively track what they eat in addition to receiving the core program.
11250344|NCT03037528|Experimental|Positive Affect, Mindfulness|Participants will receive information about positive affect and mindfulness in addition to the core program.
11250345|NCT03037528|Experimental|Positive Affect|Participants will receive information about positive affect in addition to the core program.
11250346|NCT03037528|Experimental|Mindfulness|Participants will receive information about mindfulness in addition to the core program.
11250347|NCT03037528|Experimental|No Extras|Participants will receive the core program.
11250348|NCT03037515|Active Comparator|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
11250349|NCT03037515|Active Comparator|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
11250350|NCT03037502|Experimental|Intervention: Tailor Made|Intervention Arm: In the pilot intervention, participants will receive: tailored goals/ messages, self-monitoring, weekly small groups to receive health education and community-based information and resources. Participants will also complete two assessment with blood work and anthropometric measurements. These intervention components were selected based on investigator's formative research and experience using them in prior studies. These components will be implemented simultaneously as they complement one another. While all of these components have not been tested together in an intervention for this population, they are variations and enhancements of previous interventions by the investigators.
11250351|NCT03037502|No Intervention|Comparison|Comparison Condition: Participants in the attention control group will receive self-help materials on how to improve healthy eating, physical activity and weight loss, self-monitoring, and complete two assessments with blood work and anthropometric measurements. Participants in this condition will receive a copy of their assessment data and the nurses will provide this personalized information as well as answer any questions participants may have about their assessment results.
11250352|NCT03037489|Experimental|MIV-711|MIV-711 for a total of 26 weeks
11250353|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Studies 2 and 3 will receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
11250354|NCT03037476|Experimental|In-person PFI|Participants randomized to the in-person PFI condition in Study 3 will be scheduled to meet with a trained intervention provider in a Student Counseling and Health Center setting for a 1.5 hour session to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback. The intervention provider will utilize a motivational interviewing approach in reviewing the students personalized feedback with them. They will use the student's past experiences with PSM as a starting point and will help the student to develop discrepancies, elicit change talk, provide students with opportunities to more thoroughly explore and question their beliefs, and offer alternatives by reviewing their personalized responses.
11250355|NCT03037476|No Intervention|Control|The control group will only receive assessments in Studies 2 and 3.
11250356|NCT03037463||Parkinson's Disease|
11250357|NCT03037463||Control|
11250358|NCT03037450|Other|Miniinvasive corneal neurotization|
11250398|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
11250399|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
11250359|NCT03037437|Experimental|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
11250360|NCT03037437|Experimental|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
11250361|NCT03037424|Active Comparator|Fibrinogen concentrate Octafibrin|
11250362|NCT03037424|Active Comparator|Cryoprecipitate|
11250363|NCT03037411||ELUVIA stent implantation|Peripheral stenting
11250364|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
11250365|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
11250366|NCT03037385|Experimental|Phase 1 Dose Escalation|Multiple doses of pralsetinib (BLU-667) for oral administration.
11250367|NCT03037385|Experimental|Phase 2 Dose Expansion|Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
11250368|NCT03037372|Experimental|ART-Atorvastatin adjunct therapy|ART, atorvastatin
11250369|NCT03037372|Experimental|ART-Rosuvastatin adjunct therapy|ART, rosuvastatin
11250370|NCT03037372|Experimental|ART-without statin adjunct therapy|ART, no statin
11250371|NCT03037372|Experimental|Healthy-HIV-negative|Age-matched HIV-negative, healthy volunteers from the same community
11250372|NCT03037359||Bivigam|Patients with primary immunodeficiency disease treated with Bivigam™
11250373|NCT03037359||Other IGIV|Patients with primary immunodeficiency disease treated with other IGIVs
11250374|NCT03037346|Experimental|Supportive Care (questionnaires, educational video)|Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
11250375|NCT03037333|Other|fluoroscopy|
11250376|NCT03037333|Other|ECG/ECHO|
11250377|NCT03037320|Experimental|group A|root coverage to be performed by semilunar vestibular incision technique
11250378|NCT03037320|Other|group B|root coverage by coronally advanced flap
11250379|NCT03037307|Experimental|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
11250380|NCT03037307|Active Comparator|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
11250381|NCT03037307|Other|Negative Control|Participants of this group will not be assigned to any treatment.
11250382|NCT03037294|No Intervention|Control group|Subjects in the control group will receive no intervention.
11250383|NCT03037294|Experimental|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
11250384|NCT03037294|Experimental|Corticosteroid group|Subjects in the corticosteroid group will receive a single intra-articular corticosteroid injection in the affected knee on the first day of the 2-week preoperative period.
11250385|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
11250386|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
11250387|NCT03037268||Patients undergoing dilated examination|"examined in the Retina Service of Wills Eye Hospital
~with and without visually significant posterior retinal or optic nerve pathology
~imaged with a Lytro Plenoptic Camera and 28D lens"
11250388|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
11250389|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.
~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG
~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG
~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU
~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
11250390|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.
~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG
~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG
~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU
~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
11250391|NCT03037216|Experimental|Experimental Exercise-Training Intervention|Subjects will undergo a 10-week aerobic exercise protocol.
11250392|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
11250393|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
11250394|NCT03037203|Placebo Comparator|Arm C|Placebo
11250395|NCT03037190|Experimental|Group A|Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes
11250396|NCT03037190|No Intervention|B normal diet|Group B will have normal not glutenfree diet, no planned intervention
11250400|NCT03037164|Experimental|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
11250401|NCT03037164|Active Comparator|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
11250402|NCT03037151|Experimental|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
11250403|NCT03037151|Experimental|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
11250404|NCT03037151|Experimental|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
11250405|NCT03037151|Experimental|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
11250406|NCT03037138|Other|Washed-out scale after using BFR profiling|Blood flow profiling will be used as intervention for washed-out dialysis patients
11250407|NCT03037125|Active Comparator|Control Arm|Split crest without PRF
11250408|NCT03037125|Experimental|Intervention Arm|Split crest with PRF
11250409|NCT03037112|Active Comparator|Education|All providers will receive identical training on the appropriate prescribing of antibiotics for ARTIs in a 20 minute presentation. Follow up refresher video clips will also be available for all providers to view at their convenience throughout the study. Parents in both arms will receive identical high quality education on the pros and cons of antibiotics and tips for communicating with their provider.
11250410|NCT03037112|Active Comparator|Communication Skills|Providers randomized to the communication intervention will receive additional training on communication skills in a 40 minute communication skills training session. This training session will include good and bad communication examples, training on positive and negative behavioral framing, and education regarding key drivers of patient satisfaction.
11250411|NCT03037099|Experimental|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
11250412|NCT03037099|No Intervention|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
11250413|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
11250414|NCT03037073|Active Comparator|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
11250415|NCT03037073|Active Comparator|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
11250416|NCT03037060|Experimental|Experimental|"5 experimental sessions per participant:
~(1) [11C]-(+)-PHNO PET scan, (2), Alcohol Self-Administration, (3) Craving Task, (4) MRI scan and (5) Neuropsychological Assessment."
11250417|NCT03037047|Placebo Comparator|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
11250418|NCT03037047|Experimental|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
11250419|NCT03037034|Experimental|Forcep Strip Method Treatment|patients who have Gastrointestinal Subepithelial Tumors Originating from the Muscularis Propria are enrolled
11250420|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
11250421|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
11250422|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
11250423|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
11250424|NCT03037008|Active Comparator|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
11250425|NCT03037008|Active Comparator|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
11250426|NCT03036995|Experimental|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
11250427|NCT03036995|Placebo Comparator|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
11250428|NCT03036982||Use of Mobile ACT|Will answer ACT (or cACT) and other asthma questions using mobile app
11250429|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
11250430|NCT03036943|Experimental|Fluciclovine (18F) PET/CT|
11250431|NCT03036930|Experimental|Prevention (Gardasil 9 HPV vaccine)|Participants receive the first dose of the recombinant human papillomavirus nonavalent vaccine IM at baseline, at least 30 days prior to the kidney transplant surgery. The second dose is given at least one month after the first dose. The third dose is given at least five months after the first dose and at least three months after the second dose. The timing of the second and third doses is dependent on the scheduling of the kidney transplant surgery. Patients are followed up at 6- and 12-months after the kidney transplant surgery to measure vaccine-induced immune responses. Patients may receive either one, two, or all three vaccine doses prior to the kidney transplant surgery, and are offered additional visits at least one year after the surgery to complete any remaining doses of the three-dose vaccine series.
11250475|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
11250432|NCT03036904|Experimental|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
11250433|NCT03036891|Experimental|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
11250434|NCT03036891|Placebo Comparator|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
11250435|NCT03036878|Experimental|ReNu Injection|Injection of ReNu allograft into the joint capsule.
11250436|NCT03036865|Experimental|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
11250437|NCT03036865|Placebo Comparator|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
11250438|NCT03036865|Experimental|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
11250439|NCT03036865|Placebo Comparator|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
11250440|NCT03036865|Experimental|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
11250441|NCT03036865|Placebo Comparator|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
11250442|NCT03036865|Experimental|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
11250443|NCT03036865|Placebo Comparator|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
11250444|NCT03036865|Experimental|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
11250445|NCT03036865|Placebo Comparator|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
11250446|NCT03036865|Experimental|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
11250447|NCT03036865|Experimental|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
11250448|NCT03036865|Placebo Comparator|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
11250449|NCT03036865|Experimental|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
11250450|NCT03036865|Placebo Comparator|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
11250451|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11250452|NCT03036839|Experimental|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
11250453|NCT03036839|Experimental|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
11250454|NCT03036839|Experimental|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
11250455|NCT03036826||Piperacillin/Tazobactam|Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy
11250456|NCT03036826||Meropenem|Group of patients receiving Meropenem as antiinfective therapy
11250457|NCT03036813|Active Comparator|Dose 1|voxelotor
11250458|NCT03036813|Active Comparator|Dose 2|voxelotor
11250459|NCT03036813|Placebo Comparator|Placebo|Placebo
11250460|NCT03036800|Experimental|Targeted Prescribing Pathway (LIRA 3mg + Standard Care)|Standard care plus targeted use of the intervention Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply
11250461|NCT03036800|Active Comparator|Standard Care|standard Tier 3 obesity specialist service care
11250462|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
11250463|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
11250464|NCT03036774|Experimental|Diabetic patient|Diabetic patients (type 1 or type 2 diabetes) with scheduled surgery . Ultrasonic measurement of antral area
11250465|NCT03036774|Other|Non diabetic patient|"Patients with scheduled surgery without history of diabetes or a current, treated or untreated, diabetic disease.
~Ultrasonic measurement of antral area"
11250466|NCT03036761|Experimental|AUR+: Auriculotherapy|Patients benefit from 3 sessions of auriculotherapy at one month intervals.
11250467|NCT03036761|No Intervention|AUR-: No auriculotherapy|Patients do not benefit from auriculotherapy.
11250468|NCT03036748|Experimental|TX control|Kidney transplant recipients with ACR <30mg/g
11250469|NCT03036748|Experimental|TX Proteinuria|Kidney transplant recipients with ACR> 300mg/g
11250470|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.
~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
11250471|NCT03036722|Experimental|Flaxseed porridge group|22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.
11250472|NCT03036722|Placebo Comparator|Placebo control porridge group|22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).
11250473|NCT03036709|Experimental|VRC-HIVMAB01060-00-AB (VRC01)|"VRC01 is a monoclonal antibody directed towards the site of CD4 attachment on the HIV-1 gp120 envelope (Env) glycoprotein.
~VRC01 will be administered at a dose of 40 mg/kg intravenously every three weeks to participants assigned to the intervention arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first."
11250474|NCT03036709|Placebo Comparator|Sodium Chloride for Injection USP, 0.9%|Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously every three weeks to participants assigned to the placebo arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.
11250821|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
11250477|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
11250478|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
11250479|NCT03036657|Experimental|Manual Acupuncture|"Device:
~Sterile single-use MAC acupuncture needles - 0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea
~Used for Intervention:
~Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
11250480|NCT03036657|Experimental|Low-Frequency Electroacupuncture|"Device:
~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
~Used for Intervention:
~Low-frequency Continuous Electroacupuncture (2Hz) to PC3, PC5 or HT3, HT4 for 20 min"
11250481|NCT03036657|Experimental|High-Frequency Electroacupuncture|"Device:
~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
~Used for Intervention:
~High-frequency Continuous Electroacupuncture (100 Hz) to PC3, PC5 or HT3, HT4 for 20 min"
11250482|NCT03036644|Experimental|e-cigarette nic_O LT|e-cigarette (without nicotine; low temperature)
11250483|NCT03036644|Experimental|e-cigarette Nic_1 LT|e-cigarette (with nicotine; low temperature)
11250484|NCT03036644|Experimental|e-cigarette Nic_0 HT|e-cigarette (without nicotine; high temperature)
11250485|NCT03036644|Experimental|e-cigarette NIC_1 HT|e-cigarette (with nicotine; high temperature)
11250486|NCT03036644|Active Comparator|Tobacco cigarette|Tobacco cigarette
11250487|NCT03036644|Placebo Comparator|Placebo|No E-cigarettes, Nor tobocco cigarettes
11250488|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
11250489|NCT03036631||General Anesthesia|
11250490|NCT03036618|Placebo Comparator|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
11250491|NCT03036618|Experimental|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
11250492|NCT03036605|Active Comparator|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
11250493|NCT03036605|Active Comparator|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
11250494|NCT03036592|Experimental|MTNR1B CC|Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
11250495|NCT03036592|Experimental|MTNR1B GG|Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
11250496|NCT03036592|Experimental|MTNR1B CG|Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
11250497|NCT03036579|Experimental|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
11250498|NCT03036579|Experimental|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
11250499|NCT03036566|Experimental|Bridge|Three unit high strength ceramic (lithium disilicate/emaxCAD by Ivoclar) bridges replacing a single tooth.
11250500|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.
~(iii) duration of symptoms: more than 3 months."
11250501|NCT03036527|Experimental|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
11250502|NCT03036527|Experimental|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
11250503|NCT03036527|Experimental|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
11250504|NCT03036514|Experimental|Case|Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
11250505|NCT03036514|Active Comparator|Control|Patient-controlled intravenous analgesia (PCIA) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. This classic patient-controlled IV-pump contains 1mg/ml morphine and 50mcg/ml dehydrobenzperidol. Pump characteristics include 1ml each asked bolus, lockout interval of 8 minutes.
11250506|NCT03036501|Experimental|[^14C]-Risdiplam|Participants will be administered with [^14C]-Risdiplam solution orally under fasted conditions on Day 1.
11250507|NCT03036488|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
11250589|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
11250508|NCT03036488|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
11250509|NCT03036462|Experimental|Verum group (FCM)|I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is > 16.0 g/dL or ferritin is > 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
11250510|NCT03036462|Placebo Comparator|Placebo group (NaCL)|Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.
11250511|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
11250512|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
11250513|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
11250514|NCT03036436|Experimental|Intervention|Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
11250515|NCT03036423|Active Comparator|Online video education|Participants will have computer access to a library of videos, including various lectures and demonstrations of interest, from which to select and view.
11250516|NCT03036423|Active Comparator|Computerized mental exercises|Participants will use a computer to do a variety of activities which are customizable to their own abilities and progress.
11250517|NCT03036410|Other|bimodal user|wearing one hearing aid and one CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
11250518|NCT03036410|Other|unilateral hearing aid users|wearing one hearing aid Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
11250519|NCT03036410|Other|bilateral hearing aid users|wearing two hearing aids Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
11250520|NCT03036410|Other|CI users|wearing CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
11250521|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250522|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250523|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250524|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250525|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250526|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250527|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250556|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
11250822|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
11250528|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250529|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250530|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
11250531|NCT03036371|Experimental|High Intensity Interval Exercise|home exercise sessions
11250532|NCT03036358|Other|Teledermatology consult|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment will be entered into the patients chart.
11250533|NCT03036358|Other|Routine Care|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment WILL NOT be entered into the patients chart
11250534|NCT03036345|Experimental|Surgery patients|Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.
11250535|NCT03036332|Experimental|intervention|Aerobic interval training
11250536|NCT03036332|No Intervention|Control group|The participants performed only initial evaluation and at the end of the study
11250537|NCT03036319|Experimental|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
11250538|NCT03036319|Placebo Comparator|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
11250539|NCT03036319|Experimental|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
11250540|NCT03036319|Experimental|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
11250541|NCT03036319|Experimental|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
11250542|NCT03036319|Experimental|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
11250543|NCT03036319|Experimental|Active and Sham TES|Participants will receive active and sham TES
11250544|NCT03036306|Experimental|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
11250545|NCT03036306|Experimental|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
11250546|NCT03036306|Placebo Comparator|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
11250547|NCT03036293|Experimental|Tenoten, 2 tablets twice a day (4 tablets a day)|Oral administration. Dose per administration: 2 tablets. The product should be administered outside of meals (between meals or fluid intakes), the tablets should be held in mouth until complete dissolution.
11250548|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice a day (4 tablets a day)|Oral administration. Dose per administration: 2 tablets. The product should be administered outside of meals (between meals or fluid intakes), the tablets should be held in mouth until complete dissolution.
11250549|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets a day)|Oral administration. Dose per administration: 2 tablets. The product should be administered outside of meals (between meals or fluid intakes), the tablets should be held in mouth until complete dissolution.
11250550|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets a day)|Oral administration. Dose per administration: 2 tablets. The product should be administered outside of meals (between meals or fluid intakes), the tablets should be held in mouth until complete dissolution.
11250551|NCT03036280|Experimental|Core Study: Elenbecestat (E2609) 50 mg|Participants will receive one 50 milligram (mg) elenbecestat (E2609) tablet orally once a day in the morning. The core study will be double blinded.
11250552|NCT03036280|Placebo Comparator|Core Study: Placebo|Participants will receive one matching placebo tablet orally once a day in the morning. The core study will be double blinded.
11250553|NCT03036280|Experimental|Open Label Extension Phase: Elenbecestat (E2609) 50 mg|Participants completing the core study will receive one 50 milligram (mg) elenbecestat (E2609) tablet orally once a day in the morning.
11250554|NCT03036267|Experimental|BREATHE|7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach
11250555|NCT03036267|Active Comparator|Attention Control Condition|7-minute diet and exercise discussion
11251007|NCT03033147|Placebo Comparator|Placebo|placebo 30 minutes before root canal treatment
11250557|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
11250558|NCT03036241|Experimental|Drug-eluting balloon|
11250559|NCT03036241|Active Comparator|Conventional angioplasty|
11250560|NCT03036228|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution or tablets to be taken BID. Each cycle is defined as 28 days.
11250561|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
11250562|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
11250563|NCT03036202||one group|All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
11250564|NCT03036189|Experimental|Intervention arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
11250565|NCT03036189|Experimental|Wait-list control arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
11250566|NCT03036176|Other|SAM intervention group|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
11250567|NCT03036176|Other|SAM control Group|The control children received routine medical treatment and nutritional rehabilitation services in hospital. Though they had access to playground facilities neither the control children nor their caregivers had access to the playroom materials and the basic orientation on child care, feeding and stimulation.
11250568|NCT03036163|Experimental|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
11250569|NCT03036163|Experimental|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
11250570|NCT03036163|Experimental|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
11250571|NCT03036163|Experimental|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
11250572|NCT03036163|Experimental|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
11250573|NCT03036163|Experimental|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
11250574|NCT03036163|Experimental|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
11250575|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
11250576|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
11250577|NCT03036137|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
11250578|NCT03036137|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
11250579|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
11250580|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
11250581|NCT03036111|Sham Comparator|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
11250582|NCT03036111|Active Comparator|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
11250583|NCT03036098|Experimental|Arm A: Investigational immunotherapy|
11250584|NCT03036098|Active Comparator|Arm B: Standard of care chemotherapy|
11250585|NCT03036098|Experimental|Arm C: Investigational immunotherapy|
11250586|NCT03036098|Active Comparator|Arm D: Standard of care chemotherapy|
11250587|NCT03036085|Active Comparator|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
11250588|NCT03036085|Experimental|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
11251008|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
11250590|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
11250591|NCT03036059|Active Comparator|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
11250592|NCT03036059|Experimental|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
11250593|NCT03036046|Experimental|F901318 with fluconazole low dose|safety assessment
11250594|NCT03036046|Experimental|F901318 with fluconazole high dose|safety assessment
11250595|NCT03036046|Experimental|F901318 with posaconazole|safety assessment
11250596|NCT03036033|Experimental|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
11250597|NCT03036020|Experimental|Contraindication anesthesiologists|Ability of anesthesiologists to detect contraindications to thrombolysis in acute stroke patients prehospital by interpretation of prehospital cerebral CT scans
11250598|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
11250599|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
11250600|NCT03035994|Experimental|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
11250601|NCT03035994|Experimental|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
11250602|NCT03035994|Experimental|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
11250603|NCT03035994|No Intervention|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
11250604|NCT03035981|Experimental|White rice, low amylose|Cooked white rice with low amylose content
11250605|NCT03035981|Experimental|White rice, high amylose|Cooked white rice with high amylose content
11250606|NCT03035981|Experimental|White rice, slow|Cooked white rice with slow digesting starch
11250607|NCT03035981|Experimental|White rice, resistant|Cooked white rice with resistant starch
11250608|NCT03035981|Experimental|Brown rice, low amylose|Cooked brown rice with low amylose content
11250609|NCT03035981|Experimental|Brown rice, high amylose|Cooked brown rice with high amylose content
11250610|NCT03035981|Experimental|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
11250611|NCT03035968|Experimental|Vojta arm|Patients in the interventional arm are treated with Vojta therapy from randomization until discharge.
11250612|NCT03035968|Active Comparator|conventional physiotherapy arm|Patients in this control arm are treated with conventional physiotherapy for motor improvement from randomization until discharge.
11250613|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
11250614|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
11250615|NCT03035942|Experimental|D Group|Dexamethasone 8 mg
11250616|NCT03035942|Experimental|O group|Ondansetron 4 mg
11250617|NCT03035942|Placebo Comparator|S group|Normal saline (5 mL total volume)
11250618|NCT03035929|Experimental|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.
~All subjects will undergo the same procedures and interventions."
11250619|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
11250620|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
11250621|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
11250622|NCT03035903|Experimental|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
11250623|NCT03035903|Active Comparator|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
11250624|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
11250625|NCT03035877|Experimental|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
11250626|NCT03035877|Active Comparator|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
11250627|NCT03035864|Experimental|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
11250628|NCT03035864|Placebo Comparator|Vehicle|Vehicle eye drops six times daily
11250698|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
11250699|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
11250629|NCT03035851|Experimental|Aerobic exercise|Participants will take part in a supervised 6-month-long aerobic (walk/jog) training program held 3 days/week. Each session will include a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions will follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cool-down, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise will increase from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity will be based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity will build from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
11250630|NCT03035851|Other|Stretch and Strength|A control group will meet on a similar schedule as the exercise group for sessions on stretching and toning but without aerobic exercise. Based on prior RCTs of similar interventions the investigators expect this control to be ineffective or minimally effective, but anticipate that it will increase participant enthusiasm and retention. All assessments will be conducted in this arm.
11250631|NCT03035838|Other|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
11250632|NCT03035825|Experimental|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
11250633|NCT03035825|Active Comparator|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
11250634|NCT03035812|Experimental|Alkali|Patients in whom an oral alkalinization whatever the formulation
11250635|NCT03035799|Experimental|Paleolithic Diet|Paleolithic Diet
11250636|NCT03035799|Active Comparator|General Healthful Diet|General Healthful Diet
11250637|NCT03035773|Experimental|ARM A|SCP document delivered to the patient & Primary Care Provider
11250638|NCT03035773|Experimental|ARM B|SCP document provided to the patient in an in-person survivorship visit and copy sent to PCP
11250639|NCT03035773|Experimental|ARM C|SCP document provided to the patient in an in-person survivorship visit with an additional follow-up visit and copy of the document sent to PCP
11250640|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
11250641|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
11250642|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
11250643|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
11250644|NCT03035734|Active Comparator|A|Single oral dose BMS-986141 Form A tablet under fasting conditions
11250645|NCT03035734|Experimental|B|Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions
11250646|NCT03035734|Experimental|C|Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions
11250647|NCT03035734|Experimental|D|Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions
11250648|NCT03035721|Experimental|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
11250649|NCT03035721|Active Comparator|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
11250650|NCT03035721|No Intervention|Breastfeeding group|Breastfed full term healthy infants
11250651|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
11250652|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
11250653|NCT03035695|Experimental|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.
~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
11250654|NCT03035695|Active Comparator|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
11250655|NCT03035682|Active Comparator|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
11250656|NCT03035682|Experimental|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
11250657|NCT03035669|Experimental|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
11250658|NCT03035669|Active Comparator|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
11250659|NCT03035656|Experimental|Experimental|Administration of epidural Ropivaciane
11250660|NCT03035656|Placebo Comparator|Control|Administration of saline
11250661|NCT03035643|Experimental|Ascyrus Medical Dissection Stent|Ascyrus Medical Dissection Stent placement
11250662|NCT03035630|Experimental|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:
~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.
~Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.
~Second-Line Medication:
~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.
~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
11250760|NCT03034928|Other|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
11250818|NCT03034551|No Intervention|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
11250663|NCT03035630|Experimental|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:
~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.
~Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.
~Second-Line Medication:
~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.
~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
11250664|NCT03035617|Placebo Comparator|Controlled Arm|Mesh will be soaked in normal saline solution as is routinely done.
11250665|NCT03035617|Experimental|Intervention Arm|Mesh will be soaked in .5% bupivacaine solution before application.
11250666|NCT03035604||Nutritional geriatric assessment|Participants undergo nutritional geriatric assessment over 15 minutes in person or on the phone every 3 months for 12 months.
11250667|NCT03035591|Experimental|ODM-207|Escalating doses of ODM-207
11250668|NCT03035578|Experimental|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:
~a)patients <1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to <5kg, morphine 1mg/25mL.
~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates < 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
11250669|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
11250670|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
11250671|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
11250672|NCT03035552|Experimental|Treatment prior to surgery|Infants randomized to receive the pacifier activated music player and mother's voice treatment prior to surgery for 5 sessions, and mother's voice playing freely post surgery.
11250673|NCT03035552|Experimental|Treatment post surgery|Infants randomized to receive the mother's voice playing freely prior to surgery,and pacifier activated music player and mother's voice treatment post surgery for 5 sessions.
11250674|NCT03035539|Active Comparator|Standard treatment|Standard treatment after randomization
11250675|NCT03035539|Experimental|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
11250676|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
11250677|NCT03035513||CSWS patients|The data of CSWS patients will be statistically compared to healthy volunteers
11250678|NCT03035513||healthy volunteers|The data of CSWS patients will be statistically compared to healthy volunteers
11250679|NCT03035500|Experimental|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
11250680|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:
~Low resolution transrectal ultrasound examination (LR-TRUS)
~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
11250681|NCT03035474|Other|Direct & Digital|Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence
11250682|NCT03035474|Other|Direct & Registry|Health system engagement to improve local QI programs and patient and control
11250683|NCT03035474|Other|Digital & Registry|Patient engagement to improve self-management/medication adherence and control
11250684|NCT03035474|No Intervention|Registry|Control
11250685|NCT03035448|Experimental|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.
~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
11250686|NCT03035448|Experimental|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.
~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
11250687|NCT03035435||study group|fast-track rehabilitation
11250688|NCT03035435||control group|standard care rehabilitation
11250689|NCT03035422|Other|Patients with primary refractory acute myeloid leukemia|Patients with primary refractory acute myeloid leukemia
11250690|NCT03035409|Experimental|Supportive Care (anamorelin, physical activity, counseling)|Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.
11250691|NCT03035396|Experimental|Diassess Influenza A and B Test|
11250692|NCT03035383|Experimental|Purse String Technique|Thyroidectomy closure is performed using purse string technique.
11250693|NCT03035383|Active Comparator|Conventional technique|Thyroidectomy closure is performed using conventional technique.
11250694|NCT03035370|Experimental|Viaskin PT 25 mcg|Viaskin PT 25 mcg
11250695|NCT03035370|Experimental|Viaskin PT 50 mcg|Viaskin PT 50 mcg
11250696|NCT03035370|Placebo Comparator|Viaskin PT Placebo|Viaskin PT Placebo
11250697|NCT03035357|Experimental|Daratumumab|Participants receive Daratumumab by vein over about 1 hour 1 time a week during Weeks 1-4.
11250700|NCT03035331|Experimental|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of cycles 2 and 3, and day 2 of cycles 4 and 5. Patients undergo cryosurgery on day 2 of cycle 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of cycles 2-5. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who are CR, PR, or SD after completion of therapy, may receive pembrolizumab for an additional 18 cycles in the absence of disease progression or unacceptable toxicity.
11250701|NCT03035305|Experimental|SMC and LNS (intervention group)|Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
11250702|NCT03035305|Other|SMC only (control group)|Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
11250703|NCT03035279|Experimental|Arm A|SC-006 Dose regimen finding
11250704|NCT03035279|Experimental|Arm B|SC-006 Dose expansion
11250705|NCT03035279|Experimental|Arm C|SC-006 and ABBV-181 Combination escalation and expansion
11250706|NCT03035266|Experimental|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
11250707|NCT03035266|Active Comparator|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
11250708|NCT03035253|Experimental|OMP-305B83 combined with FOLFIRI or FOLFOX|
11250709|NCT03035240|Experimental|Financial Education Intervention|
11250710|NCT03035240|No Intervention|No Financial Education Intervention|
11250711|NCT03035227|Active Comparator|Catheter Ablation|Catheter ablation procedure of atrial and/or ventricular arrhythmias.
11250712|NCT03035227|Active Comparator|Medical Therapy|Medical management using antiarrhythmic drugs per standard of care of treating physician.
11250713|NCT03035214|Other|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or <80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
11250714|NCT03035201||Cocoa extract + multivitamin|2 capsules containing 750 mg/d cocoa extract; daily MTV
11250715|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 750 mg/d cocoa extract; daily MTV placebo
11250716|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
11250717|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
11250718|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
11250719|NCT03035175|Experimental|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
11250720|NCT03035175|Active Comparator|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
11250721|NCT03035162|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20 minutes for the active conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
11250722|NCT03035162|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow only 2 minutes for the sham conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
11250723|NCT03035149|Experimental|Weight Management Program|Obese subjects participate in a year long medically supervised weight management program.
11250724|NCT03035149|No Intervention|Normal Weight Controls|Normal weight age and sex-matched controls. Unlike the obese subjects, the controls did not participate in the Weight Management Program. Pulmonary function, exercise performance and dyspnea results for normal weight controls were compared against the results for obese subjects.
11250725|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
11250726|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
11250727|NCT03035123|No Intervention|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
11250761|NCT03034928|Other|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
11250819|NCT03034538|Active Comparator|100mg|Zonegran 100mg
11250820|NCT03034538|Active Comparator|200mg|Zonegran 200mg
11250728|NCT03035123|Experimental|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.
~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.
~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
11250729|NCT03035110|Experimental|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
11250730|NCT03035084|Experimental|Group-2-D3|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
11250731|NCT03035084|Placebo Comparator|Group-2-Placebo|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
11250732|NCT03035084|Experimental|Group-1-D2|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
11250733|NCT03035084|Placebo Comparator|Group-1-Placebo|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.
11250734|NCT03035071|Experimental|minimally invasive esophagectomy|minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
11250735|NCT03035071|Active Comparator|open esophagectomy|open gastric mobilization and gastric tube formation
11250736|NCT03035058|Experimental|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
11250737|NCT03035058|Experimental|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
11250738|NCT03035058|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
11250739|NCT03035045|Experimental|Comparator1: Paracetamol 650 mg (325 mg/tablet) oral|Drug: Paracetamol Comparison pain score between paracetamol and placebo
11250740|NCT03035045|Placebo Comparator|Comparator 2: Placebo oral|Drug: placebo Comparison pain score between paracetamol and placebo
11250741|NCT03035032|Experimental|Leuprolide group|Leuprolide will be administered for 18 months.
11250742|NCT03035019|Experimental|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
11250743|NCT03035006|Experimental|Lipotecan based chemoradiotherapy|Patients will receive Lipotecan based CCRT. Lipotecan will be given as a 30-minute (±3 minutes) iv infusion qw for 6 weeks at the predefined dose level for each cohort. A total of 6 doses of Lipotecan will be administered to each patient in conjunction with RT at 3.5 Gy per fraction for 16 fractions. During CCRT period, Lipotecan should be given within 2 hours prior to the start of RT, and the Lipotecan and RT should be delivered on the same day, unless any conditions fulfils with the dose interruption standards. Radiotherapy treatment, at the allocated dose level, is only permitted if the normal tissue dose constrain criteria are maintained
11250744|NCT03034993|Experimental|Text Messaging|This group will receive text messages with appointment reminders, medication taking education and motivation, and for reporting of mood.
11250745|NCT03034993|Placebo Comparator|Control|This group will receive simple text messages about general health promotion, such as about the importance of drinking water on hot days, using sunscreen, etc.
11250746|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
11250747|NCT03034967|Experimental|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
11250748|NCT03034967|Experimental|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
11250749|NCT03034967|Experimental|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
11250750|NCT03034967|Experimental|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
11250751|NCT03034967|Experimental|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
11250752|NCT03034967|Placebo Comparator|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
11250753|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
11250754|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
11250755|NCT03034941|Active Comparator|metformin group|Drug: metformin
11250756|NCT03034941|Active Comparator|COMBI group|Drug: liraglutide + metformin
11250757|NCT03034941|No Intervention|CONTROL group|control group of obese PCOS patients without therapy
11250758|NCT03034928|Other|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
11250759|NCT03034928|Other|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
11250762|NCT03034915|Experimental|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
11250763|NCT03034915|Experimental|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
11250764|NCT03034915|Experimental|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
11250765|NCT03034889||Exposed|Children age 4-10 who required general anesthesia before the age of 36 months in the context of surgical and diagnostic procedures or sedation during intensive care, excluding neurosurgical interventions or cardiac surgery as well as preexisting hereditary or acquired neurocognitive deficits
11250766|NCT03034889||Control|Children age 4-10 who did not require any anesthesia before the age of 36 months. Excluding preexisting hereditary or acquired neurocognitive deficits.
11250767|NCT03034863|Experimental|Treatment|SAFER: A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
11250768|NCT03034863|Active Comparator|Control|The comparison condition will be an assessment-only enhanced treatment-as-usual (E-TAU), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran?s primary mental health provider.
11250769|NCT03034850||CRS/HIPEC|Patients with a confirmed histological diagnosis of peritoneal disease treated by cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC).
11250770|NCT03034837|Active Comparator|Resin sealant|"Sealing pit and fissures of the included permanent first molars using SDI conseal f resin sealant material once at the baseline of the study."
11250771|NCT03034837|Experimental|ART sealant|"Sealing pit and fissures of the included permanent first molars using 3M ESPE KetacTM Molar Easymix glass ionomer cement material once at the baseline of the study."
11250772|NCT03034824|Experimental|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
11250773|NCT03034824|Experimental|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
11250774|NCT03034824|Experimental|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
11250775|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
11250776|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
11250777|NCT03034785|No Intervention|Group 1|Term
11250778|NCT03034785|No Intervention|Group 2|Preterm
11250779|NCT03034785|Experimental|Group 3|Term
11250780|NCT03034785|Experimental|Group 4|Preterm
11250781|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
11250782|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
11250783|NCT03034759|Experimental|All participants|+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
11250784|NCT03034746|Experimental|Alzheimer's Disease (G1)|(G1) physical activity (PA)
11250785|NCT03034746|Experimental|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
11250786|NCT03034746|No Intervention|Healthy Old Subjects (G1)|Control group old
11250787|NCT03034746|No Intervention|Healthy young Subjects (G2)|Control group young
11250788|NCT03034733|Experimental|dexamethasone 0,15 mg/kg|single-dose intravenous dexamethasone 0,15 mg/kg, intraoperative
11250789|NCT03034733|Experimental|dexamethasone 0,25 mg/kg|single-dose intravenous dexamethasone 0,25 mg/kg, intraoperative
11250790|NCT03034733|Placebo Comparator|Sodium Chloride, (24)NaCl 0,9%|single-dose intravenous saline, intraoperative
11250791|NCT03034720|Experimental|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
11250792|NCT03034720|No Intervention|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
11250793|NCT03034707|Experimental|Biotin arm|biotin 10 mg/day for 7 days
11250794|NCT03034694|Placebo Comparator|Routine Care|The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
11250795|NCT03034694|Experimental|Teledermatology INtervention|The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
11250796|NCT03034681|Other|Vojta|Vojta therapy consists in activating certain overall and innate locomotion patterns or complexes: reflex creeping and reflex rolling, which provokes the contraction of striated muscle in the entire body in a determined coordination with the central nervous system (CNS). These patterns are triggered from different positions (prone, supine and side lying) and only with certain stimulation. They contain all the locomotion components: automatic postural control, uprighting and phase movements. This therapy allows for the changing from pathological patterns to painless and cheaper patterns. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
11250797|NCT03034681|Active Comparator|TENS|TENS procedure used at our unit consists in applying a high frequency current (80Hz), which is the most effective way to combat pain, for a phase duration of 60-200 microseconds at a comfortable range. Electrodes are placed on the skin over the sciatic nerve path, the (-) cathode on the most painful area as it is the most stimulating and the (+) another is placed distal. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
11250798|NCT03034668|Experimental|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
11250799|NCT03034668|Experimental|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
11250800|NCT03034668|Placebo Comparator|Placebo|Maltodextrin
11250801|NCT03034655|Experimental|CDP exercises (10 sessions)|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
11250802|NCT03034655|Experimental|CDP exercises (5 sessions)|Group B. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
11250803|NCT03034655|Experimental|Mobile posturography exercises (10 sess)|Group C. Up to six tasks with the most prominent deviations from normative control values were included in the training program. Training was performed by using the training function of Vertiguard1-RT device. This neurofeedback system contains one vibration stimulator on the front, back, left and right side, respectively. Training was performed daily under supervision of a physician over 2 weeks (10 sessions, weekend was excluded). A training session consisted of 5 repetitions of six selected training tasks. The patient received a vibrotactile feedback signal during training in those directions which showed a higher body sway than preset thresholds. Vibration was reinforced with increasing sway No vibrotactile feedback was applied if the patient's sway was below preset thresholds. The exercise difficulty was progressively increase throughout the rehabilitation sessions.
11250804|NCT03034655|Experimental|Mobile posturography exercises (5 sess)|Group D. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
11250805|NCT03034642|Experimental|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.
~Drugs: No test substances, only moderate conscious sedation using standard medications.
~Devices: No test devices."
11250806|NCT03034642|Experimental|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.
~Drugs: No test substances, only moderate conscious sedation using standard medications.
~Devices: No test devices."
11250807|NCT03034629|Experimental|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
11250808|NCT03034616|Experimental|ex vivo activation|"'OLIVA device' in patients that undergo oophorectomy on the cortex of the removed ovary we will perform 5 parallel slashes 3 cm long.
~this will be followed by investigation by the pathologist as to the depth of cuts."
11250809|NCT03034616|Active Comparator|in vivo activation|'OLIVA device' in patients undergoing oophorectomy before the resection from is pedicle on cortex of the ovary we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels.
11250810|NCT03034616|Active Comparator|POI OLIVA|'OLIVA device' in patients with premature ovarian failure and following safety data from arm 2 activation by ovarian slashing will be performed laparoscopically by closed cutting device (OLIVA). follow-up by sonography and hormonal markers of ovarian activity
11250811|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of Nutri-jelly with PEITC for 200 milligrams per day, five days per week for 3 months.
11250812|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of Nutri-jelly for 200 milligrams per day, five days per week for 3 months.
11250813|NCT03034577|Active Comparator|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more
~Neostigmine"
11250814|NCT03034577|Active Comparator|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
11250815|NCT03034564|Active Comparator|1|Active group started 100 mg TID, increased by 100 mg per interval (i.e. 100 TID) every 2 days till on 600 TID, or until intolerable dose is achieved at which time the next highest dose will be maintained (increments of 100 TID will be used).
11250816|NCT03034564|Placebo Comparator|2|Dosing regimen identical to active group
11250817|NCT03034551|Experimental|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
11250823|NCT03034499|Active Comparator|Single-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by single-port sacrocolpopexy.
11250824|NCT03034499|Active Comparator|Multi-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by multi- port sacrocolpopexy.
11250825|NCT03034486|Experimental|A single sequence, 3-period|
11250826|NCT03034473|Other|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
11250827|NCT03034460|Experimental|CD5024 1% cream|Active drug;
11250828|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
11250829|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
11250830|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
11250831|NCT03034447|Other|Asthma|Children and teenagers with persistent asthma will perform questionnaires, lung function test, and home sleep study
11250832|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
11250833|NCT03034421|Active Comparator|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
11250834|NCT03034421|No Intervention|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
11250835|NCT03034408|Other|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
11250836|NCT03034408|Other|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
11250837|NCT03034395|Other|Wide Local Excision 1cm|
11250838|NCT03034395|Other|Wide Local Excision 2cm|
11250839|NCT03034382|Experimental|Morphine|5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
11250840|NCT03034382|Experimental|Nalbuphine|5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
11250841|NCT03034382|Experimental|Morphine and Nalbuphine|"5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
~combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block"
11250842|NCT03034382|Placebo Comparator|Bupivacaine 0.5%|10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.
11250843|NCT03034369||Safety Net Clinic Patients|A Cohort of patients in 12 different primary care clinics will be studied to measure how changes in different integration factors impacts the following patient reported outcomes at baseline and 12 months: Access to Care, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, and Social Support. Health care claims data will be accessed to analyze Depression Screening, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, and Post-Admission follow-up at baseline and 12 months.
11250844|NCT03034356|Experimental|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
11250845|NCT03034356|Experimental|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
11250846|NCT03034343|Experimental|TAU+mindfulness applied face to face|4 sessions of 90 minutes/session Mindfulness based intervention applied in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is one month.
11250847|NCT03034343|Experimental|TAU + Mindfulness ICTs intervention|4 sessions of 60 minutes/session Mindfulness based intervention applied by ICTs (Internet-based program). The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the online program is two months.
11250848|NCT03034343|No Intervention|Usual medical treatment (TAU)|In this group the general practitioner will apply the usual treatment (medication) but there will be no psychological treatment.
11250849|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
11250850|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
11250851|NCT03034317|Active Comparator|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
11250852|NCT03034317|No Intervention|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
11250853|NCT03034304|Experimental|MASCT-I alone or in combination with chemical drugs or in comb|"Group 1: treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
~Group 2: treatment with MASCT-I in combination with ifosfamide. In the event of disease progression, treatment with a combination of PD1 antibodies is added. Patients with soft tissue sarcomas should be discontinued and treated with MASCT-I +PD1 antibody only until disease progression occurs again.
~Group 3: Advanced metastatic or recurrent urothelial carcinoma, soft tissue sarcoma/osteosarcoma, and cholangiocarcinoma that progressed after first-line chemotherapy were treated with MASCT-I combined with PD1 antibody until the disease progressed. If disease progression occurs during treatment, treatment is discontinued and follow-up is initiated.
~Group 4: Recurrent metastatic solid tumors that had failed previous treatment with PD1 antibody were treated with MASCT-I regimen 2 + PD1 antibody until the disease progressed."
11250854|NCT03034291|Experimental|Cacao 70%|Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.
11250855|NCT03034291|Placebo Comparator|White chocolate|Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.
11250856|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
11250857|NCT03034239|Experimental|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
11250858|NCT03034239|Placebo Comparator|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
11250859|NCT03034226|Active Comparator|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
11250860|NCT03034226|Active Comparator|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
11250861|NCT03034213|Active Comparator|Treatment|Gentrix(TM) Surgical Matrix
11250862|NCT03034213|Active Comparator|Control|Standard of care mesh
11250863|NCT03034200|Experimental|ONC201 phase 2 d1d2 weekly cohort|625 mg ONC201 by mouth daily for 2 consecutive days weekly
11250864|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.
~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
11250865|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
11250866|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
11250867|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
11250868|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
11250869|NCT03034148|Other|Coronary artery disease|blood sampling for biomarkers assessment in a population undergoing coronary angiogram
11250870|NCT03034135|Experimental|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
11250871|NCT03034109|Experimental|tDCS conventional stimulation|"Transcranial Direct Current Stimulation:
~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes."
11250872|NCT03034109|Experimental|High Definition (HD)-tDCS stimulation|"Transcranial Direct Current Stimulation:
~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes."
11250873|NCT03034109|Sham Comparator|tDCS sham stimulation|"Transcranial Direct Current Stimulation:
~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators."
11250874|NCT03034096|Experimental|Propofol infusion|Maintenance of general anesthesia with propofol infusion
11250875|NCT03034096|Experimental|Volatile agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
11250876|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
11250877|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
11250878|NCT03034070|Other|Diagnostic performance 3D T1|A 3D T1-weighted GE mDixon MR imaging sequence will be added to the routine 3D T1-weighted FSE sequence. mDixon sub-sequences (Fat and In Phase) are compared to 3D T1-weighted FSE in terms of diagnostic accuracy for M and N staging in prostate cancer patients: Fat, In Phase, Fat+In Phase and the routine 3D T1 will be analyzed separately, blindly and randomly.
11250879|NCT03034057|Other|sayana press|single arm
11250880|NCT03034018|Experimental|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
11250881|NCT03034018|Placebo Comparator|placebo|placebo taken at bedtime for four weeks
11250882|NCT03034005|Experimental|Patients with asthma|6 weeks treatment with 1600 ug budesonide
11250883|NCT03034005|No Intervention|Healthy Controls|Healthy controls to establish baseline level of Na/K pumps.
11250884|NCT03033992|Experimental|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
11250885|NCT03033953|Placebo Comparator|Milk supplementation|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g milk protein.
11250886|NCT03033953|Experimental|Native whey|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g native whey protein.
11250887|NCT03033940||ATTUNE TM subjects|
11250888|NCT03033940||PFC Sigma subjects|
11250889|NCT03033927||Participants with Stage IV Pancreatic Cancer|
11250890|NCT03033914|Experimental|< 60 years of age with advanced stage (HL) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of A(B)VD and 8 doses of nivolumab. In dose level 1, patients will receive nivolumab in combination with AVD during cycle 6 only followed by 6 additional doses of nivolumab. In subsequent dose levels, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. A PET scan will be performed after 2 cycles of ABVD and those with a PET-negative response (defined by Deauville 1, 2 or 3) will proceed with 4 additional cycles of ABVD or AVD (per treating physician preference).
11250891|NCT03033914|Experimental|60 years of age and older with HL (any stage) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of AVD and 12 doses of nivolumab. In this cohort, patients will receive nivolumab in combination with AVD during cycles 5 and 6 only, followed by 8 additional doses of nivolumab. In subsequent cohorts, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3.
11250892|NCT03033888|Other|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
11250893|NCT03033888|No Intervention|Control Group|
11250894|NCT03033875|Experimental|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program immediately.
11250895|NCT03033875|Other|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Healthy Living Education Program. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
11250896|NCT03033875|No Intervention|Usual Care Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to continue to receive care through whatever arrangement has been in place. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
11250897|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|Implant of Abbott Bioresorbable stent
11250898|NCT03033862||Intervention with Drug Eluting Stent|implant of drug eluting stent
11250899|NCT03033849|Experimental|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
11250900|NCT03033836|Experimental|single arm|ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
11250901|NCT03033823|Experimental|Intervention|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
11250902|NCT03033823|Placebo Comparator|Control|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
11250903|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
11250904|NCT03033797|Experimental|MoviLetrando-MoveHero|Half of the children will play first two different levels of the game MoviLetrando (2 minutes each) and, after the game MoveHero, more 2 minutes
11250905|NCT03033797|Experimental|MoveHero-MoviLetrando|The other half of the children will play first 2 minutes of the game MoveHero and after, two different levels of the Game MoviLetrando, two minutes each.
11250906|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
11250907|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
11250908|NCT03033771|Experimental|Treatment|Patients presenting with chronic type B aortic dissection will have the MFM implanted.
11250909|NCT03033745|Experimental|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
11250910|NCT03033745|Experimental|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
11250911|NCT03033745|Experimental|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
11250912|NCT03033732|Other|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
11250913|NCT03033732|Other|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
11250914|NCT03033719|Active Comparator|Laparotomy|Open surgery
11250915|NCT03033719|Experimental|Laparoscopy|Minimally invasive surgery
11250916|NCT03033706|Active Comparator|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.
11250917|NCT03033706|Placebo Comparator|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
11250918|NCT03033693|Other|The deep anesthesia group|
11250919|NCT03033693|Other|The light anesthesia group|
11250920|NCT03033680|Experimental|Multiple System Atrophy (MSA)|Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a [F-18]PBR06 PET scan at baseline, and at 9 months follow-up.
11250921|NCT03033667|Experimental|Glucose group (G group)|patients received 500 cc of glucose 10% that containing 50 g of glucose and provides patients with 200 Kcal with 556 mosmoles/L.
11251143|NCT03032237|Experimental|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
11250922|NCT03033667|Experimental|Lipid Group (L group)|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid and provides patients with 200 Kcal with osmolarity of 380 mosmoles /L.
11250923|NCT03033667|Experimental|Control Group (C group)|patients was fasting overnight from 11 pm till 9 am except for clear fluids that was allowed till 5 am.
11250924|NCT03033654|Experimental|Intervention|Two Consecutive Sunscreen Applications
11250925|NCT03033641|Experimental|Ablation procedure|
11250926|NCT03033628|Experimental|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
11250927|NCT03033628|Active Comparator|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
11250928|NCT03033615|Active Comparator|Chest CT|Conventional processing vs. PixelShine processing
11250929|NCT03033615|Active Comparator|Abdominal CT|Conventional processing vs. PixelShine processing
11250930|NCT03033602|Experimental|Written exposure therapy|5 sessions of imaginal exposure therapy.
11250931|NCT03033602|Active Comparator|CPT, cognitive only|12 sessions of cognitive therapy.
11250932|NCT03033589|Active Comparator|Adductor Canal Nerve Block|
11250933|NCT03033589|Active Comparator|Femoral Nerve block|
11250934|NCT03033576|Active Comparator|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11250935|NCT03033576|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11250936|NCT03033563||Testicular tissue versus ejaculate|Evaluation of ICSI outcome.
11250937|NCT03033550|Experimental|single|single arm- behavioral educational intervention of a brief negotiated mobile application
11250938|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
11250939|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
11250940|NCT03033524|Experimental|Cohort 1|Patients will be treated with 8mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
11250941|NCT03033524|Experimental|Cohort 2|Patients will be treated with 12mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
11250942|NCT03033524|Experimental|Cohort 3|Patients will be treated with 12mg/kg of TTAC-0001 weekly in every 4 weeks of cycle.
11250943|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
11250944|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
11250945|NCT03033498|Experimental|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
11250946|NCT03033498|Experimental|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
11250947|NCT03033498|Experimental|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
11250948|NCT03033498|Experimental|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
11250949|NCT03033498|Experimental|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
11250950|NCT03033498|Experimental|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
11250951|NCT03033498|Experimental|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
11250952|NCT03033498|Experimental|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
11250953|NCT03033485|Experimental|Melanoma patients|Melanoma patients enrolled for the clinical diagnosis study are performed with both 18F-P3BZA PET/CT and18F-FDG PET/CT scans before surgery.
11250954|NCT03033472|Experimental|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
11250955|NCT03033472|Placebo Comparator|Placebo|placebo 30 minutes Orally before treatment
11250956|NCT03033459|Experimental|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
11250957|NCT03033459|Active Comparator|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
11250958|NCT03033446|Experimental|Y90-Radioembolization and Nivolumab|
11250959|NCT03033433|Experimental|DCB-DM101, 500 mg tablet, determination of optimal dose|Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
11250960|NCT03033420|Experimental|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
11250961|NCT03033420|No Intervention|Control group|Treatment-as-usual
11250962|NCT03033407|Experimental|Intervention-Maintenance group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. This study was divided into two phases. In six-month phase 1 study, the participants in I-M group received tailored mobile coaching. And during the second half six-month phase 2 study, they could receive only regular information messages without individualized coaching.
11250963|NCT03033407|Active Comparator|Control-Intervention group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
11250964|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
11250965|NCT03033381|Active Comparator|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
11250966|NCT03033381|Sham Comparator|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
11250967|NCT03033368|Experimental|opened label|Open-label, single-arm study, rilpivirine is the study drug
11250968|NCT03033355||Pre- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction prior to receiving intradetrusor injection of Botulinum Toxin-A.
11250969|NCT03033355||Post- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction who receive intradetrusor Botulinum Toxin-A.
11250970|NCT03033342|Experimental|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
11250971|NCT03033342|Experimental|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
11250972|NCT03033342|Experimental|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
11250973|NCT03033342|Placebo Comparator|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
11250974|NCT03033342|Placebo Comparator|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
11250975|NCT03033342|Placebo Comparator|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
11250976|NCT03033329|Experimental|Single intravenous doses of MRX-4|Single escalating intravenous doses of MRX-4 from 150 mg to 1800 mg
11250977|NCT03033329|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-4
11250978|NCT03033329|Active Comparator|Multiple intravenous doses of MRX-4|Twice daily escalating intravenous doses of MRX-4 for 10 days: 600 mg, 900 mg, 1200 mg, and 1500 mg
11250979|NCT03033329|Placebo Comparator|Multiple intravenous doses of placebo|Twice daily intravenous doses of placebo to match MRX-4 for 10 days
11250980|NCT03033329|Active Comparator|Single dose of intravenous and oral MRX-4|Crossover of single dose of intravenous and oral MRX-4
11250981|NCT03033316|Experimental|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
11250982|NCT03033303|Experimental|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
11250983|NCT03033290|Experimental|Bu-Zhong-Yi-Qi-Tang (BZYQT)|capsule of BZYQT, 4gm tid, 12gm a day for 2 months
11250984|NCT03033290|Placebo Comparator|placebo control|similar placebo capsule 4gm tid, 12gm a day for 2 months
11250985|NCT03033277|Placebo Comparator|Control group|Hormone replacement therapy, placebo transplantation.
11250986|NCT03033277|Experimental|Experimental group|Hormone replacement therapy,HUC-MSCs transplantation.
11250987|NCT03033264|Experimental|BMI>30+Dinoprostone|Women with a BMI>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
11250988|NCT03033264|Experimental|BMI<30+Dinoprostone|Women with a BMI<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
11250989|NCT03033264|Experimental|BMI>30+Cervical ripening balloon|Women with a BMI>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
11250990|NCT03033264|Experimental|BMI<30+Cervical ripening balloon|Women with a BMI<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
11250991|NCT03033251|Active Comparator|Non invasive ventilation|Patients will receive non invasive ventilation with setting decided by the attending physician.
11250992|NCT03033251|Active Comparator|High Flow 50 L/min|High Flow Oxygen Cannula with a flow set at 50 L/min.
11250993|NCT03033251|Active Comparator|High Flow 30 L/min|High Flow Oxygen Cannula with a flow set at 30 L/min.
11250994|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152, 160- and 168-month follow-up contacts.
~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018."
11250995|NCT03033225|Experimental|Treatment (verteporfin, EUS-guided PDT)|Patients receive verteporfin IV and after 60 minutes undergo EUS-guided PDT.
11250996|NCT03033212|Experimental|Early Structured Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 7 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
11250997|NCT03033212|Experimental|Delayed Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 13 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
11250998|NCT03033212|Active Comparator|Self Rehabilitation|Patients will begin Self-Guided Rehabilitation at 7 weeks postoperatively in a self-guided fashion. They will be provided with instructions for recommended exercises. They will undergo rehabilitation for a total of 10 weeks.
11250999|NCT03033199|Active Comparator|Probiotic Agent Combining HD-DXM|"probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
~Dexamethasone 40mg per day, 4 consecutive day"
11251000|NCT03033199|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days
11251001|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
11251002|NCT03033173||CTS group|
11251003|NCT03033173||Healthy subjects|
11251004|NCT03033160|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
11251005|NCT03033160|No Intervention|Observation|Observation
11251006|NCT03033147|Experimental|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
11251009|NCT03033121|Active Comparator|group A|Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
11251010|NCT03033121|Active Comparator|group B|Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
11251011|NCT03033108|Experimental|Emixustat Dose 1|
11251012|NCT03033108|Experimental|Emixustat Dose 2|
11251013|NCT03033108|Experimental|Emixustat Dose 3|
11251014|NCT03033095|Experimental|etanercept|"The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
~Modality of administration :
~Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit."
11251015|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
11251016|NCT03033082||Normal males|Questionnaire sheets.
11251017|NCT03033069|Experimental|Brexpiprazole Monotherapy|Flexible dose
11251018|NCT03033069|Active Comparator|Brexpiprazole & Zoloft (sertaline) Combination Therapy|Flexible dose
11251019|NCT03033069|Active Comparator|Zoloft (setraline) monotherapy|Flexible dose
11251020|NCT03033069|Placebo Comparator|Placebo|Placebo
11251021|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
11251022|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
11251023|NCT03033043|Experimental|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
11251024|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
11251025|NCT03033017||HIV-infected on antiretroviral therapy 2 years|HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
11251026|NCT03033004|Active Comparator|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
11251027|NCT03033004|Active Comparator|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
11251028|NCT03033004|Active Comparator|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
11251029|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
11251030|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
11251031|NCT03032978|Experimental|Calcium silicate|intervention
11251032|NCT03032978|Active Comparator|Calcium Hydroxide|Comparator
11251033|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
11251034|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
11251035|NCT03032952|Experimental|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
11251036|NCT03032952|No Intervention|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
11251037|NCT03032926||Open Trial|N/A - Open Trial
11251038|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
11251039|NCT03032913||Non-cancer patients|Patients with no Cancer
11251040|NCT03032887|Experimental|voice prompts|Agitation (education, reminders and optimising materials) plus voice prompts
11251041|NCT03032887|Other|no voice prompts|only Agitation (education, reminders and optimising materials); no voice prompts
11251042|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
11251043|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
11251044|NCT03032861|Experimental|Orange juice|Ten women will consume 100% orange juice (300 mL/day) during 60 days.
11251045|NCT03032848|Active Comparator|Conjugated Estrogen Group|use of 1 gram per day
11251046|NCT03032848|Active Comparator|Promestriene Group|use of 1 gram per day
11251047|NCT03032848|Active Comparator|Estriol Group|use of 1 gram per day
11251048|NCT03032848|Placebo Comparator|Vaginal Moisturizer Cream|use of 1 gram per day
11251049|NCT03032835||Study participants|No intervention
11251050|NCT03032822||All Patients|All cystectomy patients who consent for the study
11251051|NCT03032809||Intracranial vasculopathy|Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.
11251052|NCT03032796|Experimental|BBT|Body-Brain Trainer
11251053|NCT03032796|Active Comparator|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
11251054|NCT03032796|Active Comparator|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
11251055|NCT03032796|Placebo Comparator|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
11251056|NCT03032783|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
11251057|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
11251058|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
11251059|NCT03032757|Experimental|Resting leg of young males|
11251060|NCT03032757|Experimental|Exercising leg of young males|
11251061|NCT03032757|Experimental|Resting leg of elderly males|
11251062|NCT03032757|Experimental|Exercising leg of elderly males|
11251063|NCT03032744|Experimental|Intervention|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the intervention group will be prescribed the appropriate asthma therapy based on their assessment (i.e. providing 'asthma assessment & management'), and receive the morning dose of their daily asthma controller medication at school on school days.
11251064|NCT03032744|Active Comparator|Usual Care|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
11251065|NCT03032731|Experimental|Website and pedometer Intervention|Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals. The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website. For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress. After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
11251066|NCT03032731|Other|Control|Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)). Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks. Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
11251067|NCT03032718|Experimental|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
11251068|NCT03032718|No Intervention|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
11251069|NCT03032705|Experimental|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
11251070|NCT03032705|Active Comparator|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
11251071|NCT03032692|Experimental|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
11251072|NCT03032692|Active Comparator|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
11251073|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
11251074|NCT03032666|Experimental|sofosbuvir/velpatasvir|Epclusa
11251141|NCT03032250|Experimental|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
11251144|NCT03032237|Placebo Comparator|Standard assortment|The control group receives standard meals and food products.
11251075|NCT03032653|Active Comparator|Late WB|Intervention: Patients receive a plaster splint in the operating room. They are not permitted to WB or ROM on the affected limb at this stage. At the first follow-up appointment (two weeks post-op), the splint is removed and a removable pre-fabricated walking boot applied. At this stage the patient is permitted to WB as tolerated while wearing the boot, and to perform ROM exercises with the boot removed. At six weeks post-op, the boot is discontinued and full unrestricted and unprotected weightbearing and ROM is permitted.
11251076|NCT03032653|Experimental|Immediate unprotected WB and ROM|Patient do NOT receive a brace or splint of any kind. They are permitted to weightbear and range of motion as tolerated within the limitations of their own comfort. Use of ambulatory aids of any kind is permitted as needed without restrictions.
11251077|NCT03032640|Active Comparator|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
11251078|NCT03032640|Active Comparator|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
11251079|NCT03032640|Active Comparator|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
11251080|NCT03032640|Active Comparator|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
11251081|NCT03032627|Other|Cardiac surgery|Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.
11251082|NCT03032614|Experimental|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
11251083|NCT03032601|Active Comparator|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 600mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
11251084|NCT03032601|No Intervention|Control Cohort|Standard of Care Treatment
11251085|NCT03032588|Experimental|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
11251086|NCT03032588|Active Comparator|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
11251087|NCT03032575|Other|sample size 100|Study Design: This is a prospective observational cohort of Thai MSM who initiated ART at the time of AHI, defined as the first 30 days after HIV acquisition (Fiebig stages 1 through 5). Volunteers will be examined at baseline to determine the prevalence of HPV infection and HSIL at HIV diagnosis. They will then be followed longitudinally for new incidence of HPV and HSIL, as well as progression or regression of existing lesions.
11251088|NCT03032562||1|Patients with neuromuscular disease
11251089|NCT03032562||2|Patients with chronic obstructive pulmonary disease
11251090|NCT03032549|Experimental|RTD|2.1 g. beta alanine, 1.3 g arginine nitrate, 200 mg caffeine, 65 mg niacin, 325 mcg folic acid, 45 mcg vitamin B12
11251091|NCT03032549|Placebo Comparator|Placebo|dextrose and non-caloric flavoring
11251092|NCT03032536|Experimental|Treatments A, B, C|"Part 1: Cross-Over
~Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.
~Treatment B: AL-3778 2 x 300-mg tablets (fasted) once
~Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
11251093|NCT03032536|Experimental|Treatments D, E, F|"Part 2 (optional): Cross-Over
~Treatment D: AL-3778 2×300-mg tablets (fasted) once.
~Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg
~Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
11251094|NCT03032536|Experimental|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.
~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:
~600mg: 2 x 300-mg OR
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
11251095|NCT03032536|Active Comparator|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
11251096|NCT03032536|Experimental|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.
~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:
~600mg: 2 x 300-mg OR
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
11251097|NCT03032536|Active Comparator|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
11251098|NCT03032536|Experimental|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.
~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:
~600mg: 2 x 300-mg OR
~1000mg: 2 x 500-mg OR
~800mg: 1 x 300-mg + 1 x 500-mg OR
~700mg: 1 x 200-mg + 1 x 500-mg"
11251099|NCT03032523|Experimental|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
11251100|NCT03032523|No Intervention|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
11251101|NCT03032510|Experimental|Eravacycline (Intravenous)/Levofloxacin (Oral)|
11251102|NCT03032510|Active Comparator|Ertapenem (Intravenous)/Levofloxacin (Oral)|
11251142|NCT03032250|Experimental|Group II No interventionist sessions|Caregivers receive educational intervention as in Group I but do not attend interventionist sessions
11251145|NCT03032211|Experimental|Treatment|Alfapump
11251103|NCT03032497|Experimental|EEG-based BCI analysis of fear avoidance|"All participants complete two experiments one after another-EEG patterns, skin conductance and pulse rate are recorded. The EEG cap is mounted on the participant's head, the GSR sensor secured on the fingers and the PPG sensor secured on the wrist using a Velcro strap. Exp 1-participants watch a series of 15, 1 min videos of people doing daily activities. Exp 2-participants do 15 movements (15 reps each in 1 min) as guided by a physiotherapist. 2 identical buzzers (labelled lesser pain and more pain) are available to press accordingly should participants experience 'lesser' or 'more' pain any time during the experiment. If 'more' pain experienced, participants' condition will be assessed and they can choose to continue the experiment at a lower intensity or stop."
11251104|NCT03032484|Experimental|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
11251105|NCT03032484|Experimental|Bevacizumab|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle.
11251106|NCT03032471||DCI group|"Patients that experience DCI, defined as
~Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and
~Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
11251107|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
11251108|NCT03032458|Active Comparator|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
11251109|NCT03032458|Active Comparator|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
11251110|NCT03032458|Active Comparator|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
11251111|NCT03032445|Experimental|Alcoholic beer|At least 6% alcohol content
11251112|NCT03032445|Placebo Comparator|Non alcoholic beer|Less than 0.5% alcohol content
11251113|NCT03032432|Experimental|Dynamic elastic garment and injection|
11251114|NCT03032432|Active Comparator|Corticosteroid injection|
11251115|NCT03032419|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
11251116|NCT03032419|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
11251117|NCT03032406|Experimental|HCQ alone (Arm A)|
11251118|NCT03032406|Experimental|EVE alone (Arm B)|
11251119|NCT03032406|Experimental|combination HCQ and EVE (Arm C)|
11251120|NCT03032406|Experimental|observation (Arm D)|
11251121|NCT03032393|Experimental|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
11251122|NCT03032393|Active Comparator|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
11251123|NCT03032380|Experimental|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
11251124|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
11251125|NCT03032367|Other|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
11251126|NCT03032367|Other|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
11251127|NCT03032354|Experimental|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
11251128|NCT03032354|Placebo Comparator|Placebo arm: Placebo group|Placebo - maltodextrin
11251129|NCT03032341||Patient group|20 patient in poor mobility group (MAT-sf < 51.38 in men and <45.61 in women), mid-mobility group (51.38< MAT-sf≤65.5 in men and 45.61≤MAT-sf<54.02) and high mobility group (MAT-sf>65.5 in men and MAT-sf>54.02 in women) for a total of 60 patients.
11251130|NCT03032341||Surrogate group|A family member/caregiver that attends visits with the patient and will be asked to answer the Mobility Assessment Test questionnaire on behalf of the patient at the initial visit and the follow up visit 1-14 days later.
11251131|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
11251132|NCT03032315|Experimental|TAH(80/10/12.5) tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide(80/10/12.5) tablet
11251133|NCT03032315|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
11251134|NCT03032302|Experimental|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
11251135|NCT03032302|Experimental|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
11251136|NCT03032302|No Intervention|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
11251137|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
11251138|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
11251139|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
11251140|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
11251149|NCT03032172|Experimental|Risdiplam|Participants will receive multiple doses of risdiplam orally once daily for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label extension (OLE) phase.
11251150|NCT03032159|No Intervention|Control Group|Participants randomized to the control group will receive their usual asthma care from their provider. Additionally, participants in the control group will receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment.
11251151|NCT03032159|Experimental|Text2Breathe Study Group|"The study group spends about 10-20 minutes learning about ways to have better communication with their child's primary care provider about his/her asthma. Additionally this group is enrolled in the Text2Breathe messaging program which sends asthma related educational text messages 2 times a week for 3 months. Participants randomized to the study group will also receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment."
11251152|NCT03032146|Experimental|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
11251153|NCT03032146|No Intervention|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
11251154|NCT03032133|Active Comparator|Regional pain control|Regional pain catheter
11251155|NCT03032133|Experimental|Local pain control|Local intraarticular pain catheter
11251156|NCT03032120|Experimental|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
11251157|NCT03032120|Experimental|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
11251158|NCT03032120|Experimental|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
11251159|NCT03032107|Experimental|Pembrolizumab Combine With Trastuzumab Emtansine|"Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
~Pembrolizumab will be administered prior to T-DM1 administration
~Pembrolizumab will be given at a predetermine dose
~T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
~T-DM1 will be given at a predetermine dose"
11251160|NCT03032094|Active Comparator|1mm thick graft|connective tissue graft of 1mm thickness
11251161|NCT03032094|Active Comparator|2mm thick graft|connective tissue graft of 2mm thickness
11251162|NCT03032081|Experimental|High Intensity Group|3 set of 4 minutes of cycling intense exercise, 4 days per week, for 8 weeks at about 80% to 90% of heart rate reserve
11251163|NCT03032081|Active Comparator|Moderate Intensity Group|40 to 47 minutes of continuous cycling exercise at 50% to 60% of heart rate reserve, 4 days per week, for 8 weeks.
11251164|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
11251165|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.
~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .
~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
11251166|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.
~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .
~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
11251167|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 7|
11251168|NCT03032042|Experimental|azithromycin at day 0, albendazole at day 7|
11251169|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 0|
11251170|NCT03032042|Other|Delayed treatment|albendazole at day 7, azithromycin at day 7
11251171|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
11251172|NCT03032003|Active Comparator|Cysticlean arm|Cysticlean (2 BID for 15 days)
11251173|NCT03032003|Placebo Comparator|Placebo arm|Placebo (2 BID for 15 days)
11251174|NCT03031990|Experimental|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
11251175|NCT03031990|No Intervention|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
11251176|NCT03031977|Experimental|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
11251177|NCT03031977|Sham Comparator|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
11251278|NCT03031249|Active Comparator|High Dose of Cytarabine|Patients receive high dose of cytarabine.
11251178|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
11251179|NCT03031951|Experimental|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 90-120 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
11251180|NCT03031951|No Intervention|Control Group - Waiting List|"Participants assigned to the control group will have access to the intervention after the 12-month period - waiting list. Meanwhile, participants will receive multimedia health information fortnightly by e-mail over the first 4-month period. The health information covers healthy lifestyle topics.
~During the 12 months of study participation, control group participants will be instructed to maintain their baseline level of physical activity. Individuals assigned to the control group will be asked to maintain their current nutritional practices and physical activity patterns."
11251181|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
11251182|NCT03031925|Experimental|SLE patients|Systemic Lupus Erythematosus
11251183|NCT03031925|Active Comparator|control subjects|age- and sex-matched control subjects
11251184|NCT03031912|Active Comparator|Group 1: 50 HIV-infected adults CD4 ≥ 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
11251185|NCT03031912|Active Comparator|Group 2: 50 HIV-infected adults CD4 > 350 and < 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
11251186|NCT03031912|Active Comparator|Group 3: 50 HIV-infected adults CD4 ≥ 200 and ≤ 350 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of theV920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
11251187|NCT03031912|Active Comparator|Group 4: HIV infected adolescents CD4 ≥ 200 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
11251188|NCT03031899||Rose Bengal positive lesion and biopsy|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
11251189|NCT03031899||Toluidine blue positive lesion and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
11251190|NCT03031886|Experimental|high GI|Cereal, milk, tea, cheese, steamed glutinous rice with chicken, carrots, bread, strawberry jam, margarine, high GI sweetener (sucrose).
11251191|NCT03031886|Experimental|Low GI|Cereal, milk, tea, steamed basmati rice with chicken, spinach, bread, strawberry jam, low GI sweetener (isomaltulose).
11251192|NCT03031873|Other|MRI perfusion imaging|"SWAN imaging on the GE 3 T has been attempted but the preliminary evidence suggest that the images are of low resolution and difficult to interpret. Similarly, early experience with TRMRA suggest poor spatial and temporal resolution using the standard out-of-the-box protocols.
~Thus, there is a significant opportunity to improve SWAN and TRMRA, to evaluate the evolution of progressive obliteration of the AVM nidus. Specifically, this is attractive for brain AVMs that are treated with radiosurgery as MRI is required for clinical grounds for treatment planning purposes."
11251193|NCT03031847|Other|Pacemaker|Cardiac resynchronization therapy Pacemaker
11251194|NCT03031847|Other|Defibrillator|Cardiac resynchronization therapy Defibrillator
11251195|NCT03031821|Experimental|Metformin|Metformin 850 mg PO OD X 30 days, then 850mg PO BID for a total of 18 months
11251196|NCT03031821|Placebo Comparator|Placebo|"Placebo Oral Tablet
~1 tablet (850mg) PO OD X 30 days, then 850mg PO BID for a total of 18 months"
11251197|NCT03031808|Other|Lidocaine spray|Endotracheal lidocaine spray prior to intubation
11251198|NCT03031808|Other|Muscle relaxant|Muscle relaxant prior to intubation
11251199|NCT03031808|Other|No Muscle relaxant, no Lidocaine|'No Muscle relaxant, no Lidocaine Control group
11251200|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
11251201|NCT03031795|Placebo Comparator|placebo|look alike placebo
11251202|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
11251203|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|Placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
11251204|NCT03031756|Experimental|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
11251205|NCT03031756|Active Comparator|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
11251206|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
11251207|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
11251208|NCT03031704||Endoscopic mucosectomy|
11251209|NCT03031691|Experimental|Brontictuzumab and trifluridine/tipiracil|Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label.
11251210|NCT03031678|Other|Study procedures|
11251212|NCT03031665||Remitted MDD|Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
11251213|NCT03031665||Control Subjects|Subjects who have no history of clinical depression or other psychological disorder.
11251214|NCT03031652||Enrolled group|Patients who had senile cataract and underwent phacoemulsification with topical anesthesia.
11251215|NCT03031639||Endoscopic|This group is the patients who underwent endoscopic approaches thyroidectomy.
11251216|NCT03031639||Conventional|This group is the patients who underwent conventional approach thyroidectomy
11251217|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
11251218|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
11251219|NCT03031613|Experimental|PEEP group|Application of 5 cmH2O PEEP during mechanical ventilation
11251220|NCT03031613|Active Comparator|ZEEP group|No application of PEEP during mechanical ventilation
11251221|NCT03031600|Active Comparator|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
11251222|NCT03031600|Experimental|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
11251223|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
11251224|NCT03031574|Active Comparator|Food Effect|SUVN-D4010 tablets single dose
11251225|NCT03031574|Active Comparator|Gender Effect|SUVN-D4010 tablets single dose
11251226|NCT03031574|Active Comparator|Age Effect|SUVN-D4010 tablets single dose
11251227|NCT03031561|Experimental|Diagnostic (standard ultrasound, MicroPure, biopsy)|Patients undergo grayscale and MicroPure ultrasound imaging followed by sonographic or stereotactic guided core needle biopsy or surgical resection. Surgical specimens are then x-rayed.
11251228|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and point-of-care ultrasound exam
11251229|NCT03031548||Chest X-ray|Child undergoing procedure in CVL requiring and ETT and CXR by fluoroscopy
11251230|NCT03031535|Experimental|Study Part 1 - Arm 1|Day 1 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 7 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms.
11251231|NCT03031535|Experimental|Study Part 1 - Arm 2|Day 1 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 5 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 2000 micrograms.
11251232|NCT03031535|Experimental|Study Part 1 - Arm 3|Day 1 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 3 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 1200 micrograms.
11251233|NCT03031535|Experimental|Study Part 1 - Arm 4|Day 1 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 400 micrograms.
11251234|NCT03031535|Experimental|Study Part 2 - Arm 1|Day 1 - 1 microgram/kilogram of growth hormone-releasing hormone (GHRH) + 30 grams arginine hydrochloride; Day 3 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
11251235|NCT03031535|Experimental|Study Part 2 - Arm 2|Day 1 - 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 3 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
11251236|NCT03031522|Experimental|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
11251237|NCT03031522|Experimental|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
11251238|NCT03031522|Experimental|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
11251239|NCT03031522|Experimental|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
11251240|NCT03031522|Experimental|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
11251241|NCT03031522|Experimental|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
11251242|NCT03031509|Experimental|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
11251243|NCT03031509|Sham Comparator|debridement surgery|debridement surgery
11251244|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
11251279|NCT03031249|Experimental|HDAC + ATRA + ATO|Patients receive high dose of cytarabine plus ATRA and ATO treatment.
11251245|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
11251246|NCT03031483|Experimental|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
11251247|NCT03031470|Experimental|Reparixin|Reparixin 2.772 mg/kg/hour 168 hrs continuous intravenous infusion
11251248|NCT03031470|Other|Standard Care Procedures|No treatment; standard care procedure
11251249|NCT03031457||1|Patients undergo primary fascial closure of abdominal donor-site
11251250|NCT03031444|Active Comparator|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab [Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks] or FOLFOX plus Cetuximab [Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks]
11251251|NCT03031444|Active Comparator|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks] or FOLFOX[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks] or CapeOX[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks] was adopted in this control arm.
11251252|NCT03031431|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens [soft, semisoft, or hardened]).
11251253|NCT03031418||Cohort 1|Enroll up to 500 patients to confirm performance of ExoDx Prostate IntelliScore (EPI) for men scheduled for initial biopsy. The treating physician will collect a urine sample from from a consented subject to test before their scheduled prostate biopsy (during your established clinic visit).
11251254|NCT03031418||Cohort 2|Enroll up to 500 patients to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy. The treating physician will collect a urine sample for testing and 2 weeks later discuss whether to perform a prostate biopsy with the subject knowing the results of the urine test and comparing them to the overall consensus report from Cohort 1 as well as other clinical factors the treating physician would otherwise use to determine whether they should have a prostate biopsy.
11251255|NCT03031405|Experimental|Oxytocin and trauma film paradigm|
11251256|NCT03031405|Placebo Comparator|Placebo and trauma film paradigm|
11251257|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
11251258|NCT03031392||non-peri-implantitis patients|Individuals with implants <2mm of radiographic bone loss
11251259|NCT03031379|No Intervention|A - control|standard fast, at least 6 hours prior to tracheotomy
11251260|NCT03031379|Experimental|B - shortened fast|fast of only 45 minutes prior to incision
11251261|NCT03031366|Experimental|3D roadmap|TIPS was established using 3d roadmap guidance
11251262|NCT03031366|Active Comparator|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
11251263|NCT03031353|Experimental|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
11251264|NCT03031353|Active Comparator|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
11251265|NCT03031340|Placebo Comparator|Placebo|
11251266|NCT03031340|Experimental|Pregabalin|
11251267|NCT03031327|Experimental|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
11251268|NCT03031327|Experimental|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
11251269|NCT03031327|Active Comparator|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
11251270|NCT03031314|Active Comparator|Standard suture|standard suture used (monocryl)
11251271|NCT03031314|Active Comparator|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
11251272|NCT03031301|Active Comparator|Vibrant capsule|Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment
11251273|NCT03031301|Sham Comparator|Sham capsule|Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment
11251274|NCT03031288|Experimental|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
11251275|NCT03031288|Experimental|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
11251276|NCT03031262|Active Comparator|High Dose of Cytarabine|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
11251277|NCT03031262|Experimental|HDAC + Chidamide|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
11251280|NCT03031236|Active Comparator|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
11251281|NCT03031236|No Intervention|Only regular health messages|Only regular health message from government health services
11251282|NCT03031223|Experimental|low-level laser therapy|"The treatment group will receive LLLT following the protocol outlined below:
~LLLT protocol - radiance will be administered to the injury site transcutaneously at a wavelength of 808 nm using a Twin Flex Evolution diode laser (MMO Equipamento Opto-Eletronicos, Brazil). Twelve sessions will be held (three per week over four weeks). The dose administered to the surface of the skin will be 983 J/cm2 per session, with a treatment area of 4.72 W/cm² and total radiant energy of 25 J. According to the literature, this dose is capable of enhancing functional recovery following an injury."
11251283|NCT03031223|Placebo Comparator|placebo|laser therapy is applied at low intensity without emitting radiation.
11251284|NCT03031210|Experimental|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
11251285|NCT03031210|Active Comparator|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
11251286|NCT03031197|Experimental|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
11251287|NCT03031197|No Intervention|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
11251288|NCT03031184|Experimental|Mirtazapine|15mg of Mirtazapine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
11251289|NCT03031184|Placebo Comparator|Placebo|Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
11251290|NCT03031171|Experimental|Navigated: Screening patient navigation|Clinic patients who received navigation
11251291|NCT03031171|Active Comparator|Non-Navigated|Randomly matched sample of non-navigated clinic patients
11251292|NCT03031158|Experimental|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
11251293|NCT03031158|Active Comparator|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
11251294|NCT03031145|Active Comparator|Felis Domesticus treated Non-smoker|
11251295|NCT03031145|Active Comparator|Felis Domesticus treated E-cigarette smoker|
11251296|NCT03031145|Active Comparator|Felis Domesticus treated Cigarette smoker|
11251297|NCT03031132|Experimental|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
11251298|NCT03031132|Experimental|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
11251299|NCT03031132|Experimental|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until ~5h post habitual breakfast time on testing day 7.
11251300|NCT03031119|Placebo Comparator|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
11251301|NCT03031119|Experimental|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
11251302|NCT03031119|Experimental|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
11251303|NCT03031093|Experimental|Healthy, non obese + HFNC|Healthy, non obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251323|NCT03031015|Active Comparator|Plating|The mean age of group A was 39 years (range, 19-61 years). There were 51 male and 13 female patients. The mean time from injury to operation was 6±5.53 days. Injured digits included index (n=21), long (n=17), ring (n=10), and little (n=16) fingers. Types of fractures were transversal (n=34), oblique or spiral (n=11), and comminuted (n=19) fractures.The patients were treated with Plating.
11251324|NCT03031002|Experimental|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
11251325|NCT03031002|No Intervention|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
11251304|NCT03031093|Active Comparator|Healthy, non obese|Healthy, non obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251305|NCT03031093|Experimental|COPD, non obese + HFNC|non obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251306|NCT03031093|Active Comparator|COPD, non obese|non obese COPD participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251307|NCT03031093|Experimental|healthy, obese + HFNC|Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251308|NCT03031093|Active Comparator|healthy, obese|Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251309|NCT03031093|Experimental|COPD, obese + HFNC|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251310|NCT03031093|Active Comparator|COPD, obese|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
11251311|NCT03031080|Active Comparator|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
11251312|NCT03031080|No Intervention|Un-Splinted|Patients will not wear a night splint
11251313|NCT03031067|Experimental|Machine perfusion - Kidney|The marginal kidney will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
11251314|NCT03031067|No Intervention|Static cold storage - Kidney|The marginal kidney that was stored to cold (SCS), previously.
11251315|NCT03031067|Experimental|Machine perfusion - Liver|The marginal liver will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
11251316|NCT03031067|No Intervention|Static cold storage - Liver|The marginal liver that was stored to cold (SCS), previously.
11251317|NCT03031054|Experimental|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
11251318|NCT03031054|Active Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
11251319|NCT03031041|Experimental|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
11251320|NCT03031041|Active Comparator|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
11251321|NCT03031028|Other|ketogenic diet|Ketogenic diet
11251322|NCT03031015|Experimental|Cemented K-wire Fixation|The mean age of group A was 41 years (range, 18-63 years). There were 56 male and 11 female patients. The mean time from injury to operation was 5±4.53 days. Injured digits included index (n=24), long (n=19), ring (n=9), and little (n=15) fingers. Types of fractures were transversal (n=31), oblique or spiral (n=14), and comminuted (n=22) fractures. The patients were treated with Cemented K-wire Fixation.
11251326|NCT03030989|Active Comparator|Chlorhexidine Gluconate 2% Wipe|
11251328|NCT03030976|Experimental|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
11251329|NCT03030976|Experimental|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
11251330|NCT03030963|Experimental|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
11251331|NCT03030963|Active Comparator|Control group|ventilator inspiration to expiration ratio will be set 1:2.
11251332|NCT03030950|Experimental|Dexmedetomidine group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
11251333|NCT03030950|Placebo Comparator|Control group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
11251334|NCT03030937|Experimental|Irinotecan plus apatinib|"Irinotecan:160mg/m2, ivgtt,given on the eighth day; Apatinib:initial dose:250mg,oral,once a day, after meal ( try to take the medicine at the same time of the dauntoy ).
~Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities."
11251335|NCT03030937|Active Comparator|Irinotecan|Irinotecan:180mg/m2, ivgtt,given on the eighth day. Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities.
11251336|NCT03030911|Active Comparator|Dexmedetomidine group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.
~Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1)
~Intervention: indirect calorimetry"
11251337|NCT03030911|Placebo Comparator|midazolam group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.
~Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1.
~Intervention: indirect calorimetry"
11251338|NCT03030898|Other|respiratory variation of the right internal jugular vein|
11251339|NCT03030885|Experimental|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.
~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
11251340|NCT03030872||Predicate software|Olea Sphere PACS with Perfusion and DWI Modules
11251341|NCT03030872||Investigational software|Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging
11251342|NCT03030859|Experimental|Group I (Usual Care)|Patients receive monthly automated system telephone call for 12 months.
11251343|NCT03030859|Experimental|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
11251344|NCT03030859|Experimental|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
11251345|NCT03030846|Experimental|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
11251346|NCT03030846|Experimental|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
11251347|NCT03030820|Experimental|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
11251348|NCT03030794|Active Comparator|Repetitive TMS|Subjects will receive the repetitive transcranial magnetic stimulation study procedure.
11251349|NCT03030794|Placebo Comparator|No (blocked) repetitive TMS|Subjects will not receive the repetitive transcranial magnetic stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked.
11251350|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
11251351|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
11251352|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
11251353|NCT03030729||Intermediate AMD|
11251354|NCT03030729||Advanced AMD|
11251355|NCT03030729||DR without macular edema|
11251356|NCT03030729||DR with macular edema|
11251357|NCT03030716|Experimental|0.03 mg 95% condensed proanthocyanidin|0.03 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.03 g 95% condensed proanthocyanidins from grape seed extract at week 4
11251358|NCT03030716|Experimental|0.25 g 95% condensed proanthocyanidin|0.25 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.25 g 95% condensed proanthocyanidins from grape seed extract at week 4
11251359|NCT03030716|Experimental|1.5 g 95% condensed proanthocyanidin|1.5 g 95% condensed proanthocyanidins from grape seed extract at week 0 1.5 g 95% condensed proanthocyanidins from grape seed extract at week 4
11251360|NCT03030703|Experimental|350 mg phytic acid|350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
11251361|NCT03030690|Experimental|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
11251362|NCT03030690|Active Comparator|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
11251363|NCT03030690|Active Comparator|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
11251364|NCT03030677|Other|Interventional Without Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound without injecting 10 ml of lidocaine 1% as a dissecting solution
11251365|NCT03030677|Other|Interventional With Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound after injecting 10 ml of lidocaine 1% as a dissecting solution
11251366|NCT03030664|Active Comparator|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
11251367|NCT03030664|Placebo Comparator|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
11251368|NCT03030651|Experimental|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
11251369|NCT03030651|No Intervention|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
11251370|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
11251371|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
11251372|NCT03030625|Other|IGRT/VMAT focal therapy boost to DIL|Localized prostate cancer (PCa) of intermediate and high risk according to NCCN criteria
11251373|NCT03030612|Experimental|ARGX-110 with Azacytidine (AZA)|"Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV).
~Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m^2 BSA, administered SC/IV as per local practice."
11251374|NCT03030599|Placebo Comparator|Placebo|Placebo
11251375|NCT03030599|Experimental|JZP-258|JZP-258
11251376|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
11251377|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:
~75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),
~50 patients with Parkinson's disease dementia (PDD),
~50 patients with Dementia with Lewy Bodies (DLB) and
~25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
11251378|NCT03030586||Healthy Controls|200 healthy subjects
11251379|NCT03030573|Other|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
11251380|NCT03030560|Active Comparator|Lidocaine group|Patients will receive lidocaine infusion.
11251381|NCT03030560|Placebo Comparator|Control group|Patients will receive 0.9% Sodium-chloride infusion infusion
11251382|NCT03030547|Experimental|Muscle Disease Group|Adult patients with muscle diseases diagnosed by neurologist, will wear SenseWear activity monitor for 5 days
11251383|NCT03030547|Active Comparator|Healthy Individuals Group|Healthy individuals with similar demographic characteristics as adult patients with muscle diseases, will wear SenseWear activity monitor for 5 days
11251384|NCT03030534|Experimental|Experimental Group|Educational Package and software package
11251385|NCT03030534|Active Comparator|Control group|Health promotion tips
11251386|NCT03030521||experimental group|In this group, the specimen of aortic wall is bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
11251387|NCT03030521||control group|In this group, the specimen of aortic wall is not bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
11251388|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
11251389|NCT03030495||Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve<2 & Index of microvascular resistance>25U
11251390|NCT03030495||No Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve>2 & Index of microvascular resistance<25U
11251391|NCT03030482|Experimental|Touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
11251392|NCT03030482|No Intervention|control|standard care ICU
11251393|NCT03030469|Experimental|10-pill default|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
11251394|NCT03030469|Experimental|5-pill default|New opioid analgesic prescriptions will automatically default to 5 pills.
11251395|NCT03030469|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
11251396|NCT03030456|No Intervention|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
11251397|NCT03030456|Experimental|Power Plate®|Power Plate®: training of elderly women
11251398|NCT03030443||Oral Sedation|"Patients in this group will receive a standard procedure first trimester abortion using oral sedation for pain management following the clinic's protocol.
~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
11251399|NCT03030443||Nitrous Oxide|"Patients in this group will receive a standard procedure first trimester abortion using titrated nitrous oxide for pain management following the clinic's protocol.
~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
11251400|NCT03030430|Experimental|BAT1706|BAT1706 injection
11251401|NCT03030430|Active Comparator|EU-sourced Avastin|EU-sourced Avastin
11251402|NCT03030430|Active Comparator|US-sourced Avastin|US-sourced Avastin
11251403|NCT03030417|Experimental|Treatment Arm|LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
11251404|NCT03030404||Cohort 1|Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
11251405|NCT03030378|Experimental|Treatment (recombinant interleukin-12, pembrolizumab)|Patients receive recombinant interleukin-12 SC on days 2, 5, 9, and 12 and pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of subsequent cycles. Treatment continues for 28 days for cycle 1 and repeats every 21 days for subsequent cycles for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patient then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity.
11251406|NCT03030365||Healthy Controls|"Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
11251407|NCT03030365||Amnestic Mild cognitive impaired|"Patients diagnosed with mild cognitive impairment, exhibiting impairment mostly in memory that is significant but does not interfere with everyday activities.
~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
11251408|NCT03030365||Alzheimer's disease patients|"Patients exhibiting significant loss of intellectual ability that interferes with everyday functioning that meet Alzheimer's pattern of decline, and following exclusion of alternative neurodegenerative, cerebrovascular, and metabolic etiologies.
~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
11251409|NCT03030352|Experimental|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
11251410|NCT03030352|No Intervention|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
11251411|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
11251412|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
11251413|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
11251414|NCT03030326|Experimental|Heart rate variability biofeedback|This group will receive treatment in the first three months of the study and will be observed during the second three months
11251415|NCT03030326|No Intervention|Observation first|This group will be observed during the first three months and given biofeedback during the second three months
11251416|NCT03030313|Experimental|Respiration rate monitoring|Reassure Non-Contact Respiration Monitor
11251417|NCT03030300|Experimental|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
11251418|NCT03030287|Experimental|OMP-305B83 plus paclitaxel|
11251419|NCT03030274|Experimental|Occlutech AFR Device|Prospective, multicenter, open-label, non-randomized pilot study to assess safety and efficacy of implantation of the Occlutech® AFR device in patients with HFrEF and HFp
11251420|NCT03030261|Experimental|Elotuzumab + Pomalidomide + Dexamethasone|"Patients will undergo standard of care ASCT melphalan conditioning. Administration of melphalan and the second ASCT will be done as part of routine care and procedures are not dictated by this protocol.
~Continuation therapy with Elo-Pom-Dex will begin between Days 80 and 120 following the second ASCT:
~Elotuzumab on Days 1 and 15 for Cycles 1-6 followed by 20 mg/kg on Day 1 for Cycles 7+
~Pomalidomide daily on Days 1-21 of all cycles
~Dexamethasone on Days 1 and 15 of all cycles
~Continuation therapy may continue until relapse or progression."
11251421|NCT03030248|Active Comparator|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
11251422|NCT03030248|Placebo Comparator|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
11251423|NCT03030235|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks
11251424|NCT03030235|Placebo Comparator|Placebo|Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks
11251425|NCT03030222|Active Comparator|Empagliflozin|Empagliflozin 10 mg tab, once daily, for 12 weeks
11251426|NCT03030222|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 12 weeks
11251427|NCT03030209||Distal Pancreatectomy|Patients undergoing distal pancreatectomy
11251428|NCT03030196|Active Comparator|Denosumab|subcutaneous injection with 60 mg Denosumab once
11251429|NCT03030196|Placebo Comparator|Placebo|subcutaneous injection with NaCl once
11251430|NCT03030183|Experimental|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
11251431|NCT03030170|Experimental|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
11251432|NCT03030170|Active Comparator|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
11251433|NCT03030157|Experimental|Long-term Intravesical Instillation of pirarubicin(THP)|A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 72-168 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
11251434|NCT03030157|Active Comparator|Single Intravesical Instillation of pirarubicin|A single intravesical instillation of THP after nephroureterectomy was performed. This instillation was initiated within 72-168 hours after surgery . THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
11251435|NCT03030144|No Intervention|Control group|Routine nursing care
11251436|NCT03030144|Other|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
11251437|NCT03030131|Experimental|Durvalumab|durvalumab 750 mg IV J1, J15, J29
11251438|NCT03030118|Active Comparator|Hydroxychloroquine|Hydroxychloroquine will be administered as a once daily dose of 200 or 400 mg, based on the patient's weight. Treatment will be for 96 weeks.
11251439|NCT03030118|Placebo Comparator|Placebo oral capsule|Placebo will be administered as one or two capsules as a single daily dose, based on the patient's weight. Treatment will be for 96 weeks.
11251440|NCT03030105|Placebo Comparator|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
11251441|NCT03030105|Placebo Comparator|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
11251442|NCT03030105|Experimental|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
11251443|NCT03030105|Experimental|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
11251444|NCT03030105|Active Comparator|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
11251445|NCT03030105|Experimental|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
11251446|NCT03030092|No Intervention|Control group|Today's standard care
11251447|NCT03030092|Experimental|Intervention group|Maximal Strength Training
11251448|NCT03030079|Experimental|Experimental Electrical stimulation Regimen|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
11251449|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
11251450|NCT03030053|Experimental|Active|Cocoa-Flavanol Supplements: 3 capsules per day each containing 300mg (total dose of 900mg daily) for 24 weeks
11251451|NCT03030053|Placebo Comparator|Control|Control Supplements: 0mg cocoa-flavanols per day for 24 weeks
11251452|NCT03030040|Experimental|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
11251453|NCT03030040|No Intervention|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
11251454|NCT03030027|Experimental|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
11251455|NCT03030027|Other|Basic Skills Building|This arm focuses on skill building.
11251456|NCT03030014|Experimental|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.
~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
11251457|NCT03030014|Placebo Comparator|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
11251458|NCT03030001|Experimental|PD-1 antibody expressing CAR-T cells|PD-1 antibody expressing mesothelin specific CAR-T cells
11251459|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
11251460|NCT03029988|Experimental|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.
~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
11251461|NCT03029975|Active Comparator|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
11251462|NCT03029975|Experimental|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
11251463|NCT03029962|Experimental|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
11251464|NCT03029962|No Intervention|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
11251465|NCT03029949|Experimental|ACT with VR|acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management
11251466|NCT03029949|Active Comparator|Self-treatment VR|self-treatment vestibular rehabilitation in addition to clinical management
11251467|NCT03029936||Obesity Group|
11251468|NCT03029936||Asthma Group|
11251469|NCT03029936||Obesity-Asthma Group|
11251470|NCT03029936||Control|
11251471|NCT03029923|Experimental|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
11251472|NCT03029923|Active Comparator|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
11251473|NCT03029910|Experimental|Cryotherapy and eccentric exercise|
11251474|NCT03029910|Experimental|Vibration and eccentric exercise|
11251475|NCT03029910|No Intervention|Control|
11251476|NCT03029897|Experimental|experimental|Patients are educated on the use of a mobile application to report adverse drug reactions
11251477|NCT03029897|No Intervention|control|Patients are not educated on the use of a mobile application to report adverse drug reactions
11251478|NCT03029884|Active Comparator|Active DBS|Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in active DBS, blinded to the participant.
11251479|NCT03029884|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. Brain recordings will remain active during this period. Both thalamic pain syndrome and phantom pain participants will participate in inactive DBS, blinded to the participant.
11251480|NCT03029871|Experimental|Arm 1|Nine subjects (3 cohorts, 3 subjects/cohort) with medically inoperable stage I/IIA (T1a - T2b) NSCLC with tumors measuring > 2 to ≤ 5 cm will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels (1 x 1011 vp, 3 x 1011 vp, 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors). Two days later, subjects will be administered (orally) a 10 day course of 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy along with 48 Gy (4 fractions of 12 Gy) of SBRT. Prior to and following the adenovirus injection, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify HSV-1 TK gene expression.
11251481|NCT03029845|Active Comparator|propranolol 1|20 mg propranolol twice a day
11251482|NCT03029845|Active Comparator|propranolol 2|10 mg propranolol twice a day
11251483|NCT03029845|Placebo Comparator|Placebo|Placebo twice a day
11251484|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
11251485|NCT03029832|Active Comparator|Atezolizumab|
11251486|NCT03029819|Active Comparator|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
11251487|NCT03029819|Experimental|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
11251488|NCT03029806|Active Comparator|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
11251489|NCT03029806|Placebo Comparator|Cauc risk allele|Caucasians carrying the LSD1 affected allele
11251490|NCT03029806|Placebo Comparator|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
11251491|NCT03029806|Placebo Comparator|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
11251492|NCT03029793||Biomarkers and Imaging analysis|This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
11251493|NCT03029780|Experimental|Co-Administration|Nivolumab and Ipilimumab Co-Administration
11251494|NCT03029780|Experimental|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
11251495|NCT03029767|Experimental|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
11251496|NCT03029767|Experimental|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
11251497|NCT03029767|Experimental|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
11251498|NCT03029767|No Intervention|Control group|standard or usual activity carried out.Additional intervention will not be given.
11251499|NCT03029754|Experimental|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
11251500|NCT03029754|No Intervention|No leg raise|Participants will lie flat prior to IV insertion.
11251501|NCT03029741|Experimental|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.
~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy subjects."
11251502|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
11251503|NCT03029715|Other|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
11251505|NCT03029702|Active Comparator|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
11251506|NCT03029702|Active Comparator|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
11251507|NCT03029689|Experimental|Current ART + Raltegravir|Current ART + Raltegravir
11251508|NCT03029689|Placebo Comparator|Current ART + placebo|Current ART + placebo
11251509|NCT03029676|Experimental|Group B|spinal anesthesia premedication with benzodiazepine and opioid
11251510|NCT03029676|Active Comparator|Group K|spinal anesthesia premedication with opioid
11251511|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
11251512|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
11251513|NCT03029637|Experimental|No preparation resin bonded bridges|RBBs with no or minimal preparation of their abutment teeth
11251514|NCT03029637|Active Comparator|Routine resin bonded bridges|RBBs with routine tooth preparation of their abutment teeth
11251515|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
11251516|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
11251517|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11251518|NCT03029585|Experimental|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
11251519|NCT03029585|Experimental|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
11251520|NCT03029585|Experimental|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
11251521|NCT03029585|Experimental|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
11251522|NCT03029585|Active Comparator|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
11251523|NCT03029572|Active Comparator|Standard diet|Standard healthy diet after RYGB surgery
11251524|NCT03029572|Experimental|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
11251525|NCT03029559|Experimental|IH + ITL|Subjects will be exposed to a session of Intermittent hypoxia (IH) (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of Inspiratory threshold loading (ITL) at 80%MIP (10 breaths per set).
11251526|NCT03029559|Experimental|Intermittent hypoxia (IH)|Subjects will only be exposed to a session of intermittent hypoxia.
11251527|NCT03029559|Experimental|Sham IH + ITL|Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
11251528|NCT03029559|Sham Comparator|Sham IH|Sham intermittent hypoxia subjects will be exposed to a single 45-minute session of sham IH alone.
11251529|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.
~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
11251530|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
11251531|NCT03029533|Experimental|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
11251532|NCT03029533|Active Comparator|Leuplin DPS Inj|Leuplin DPS Inj
11251533|NCT03029520|Active Comparator|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
11251534|NCT03029520|Active Comparator|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
11251535|NCT03029520|Active Comparator|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
11251536|NCT03029520|Active Comparator|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
11251537|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT
~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
11251538|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
11251539|NCT03029494|Experimental|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
11251540|NCT03029494|Active Comparator|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
11251541|NCT03029494|No Intervention|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
11251542|NCT03029468|Experimental|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
11251543|NCT03029468|Active Comparator|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their personal or study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
11251544|NCT03029468|No Intervention|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
11251545|NCT03029455|Experimental|Part A: VX-659 or Matching Placebo|Part A includes single-dose escalation.
11251546|NCT03029455|Experimental|Part B: VX-659 or Matching Placebo|Part B includes multiple-dose escalation.
11251547|NCT03029455|Experimental|Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
11251548|NCT03029455|Experimental|Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part D includes subjects with CF. Participants will receive TC or matching placebos.
11251549|NCT03029442|Experimental|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
11251550|NCT03029442|Placebo Comparator|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
11251551|NCT03029442|Experimental|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
11251552|NCT03029442|Placebo Comparator|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
11251553|NCT03029429|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
11251554|NCT03029429|Placebo Comparator|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
11251555|NCT03029416|Experimental|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
11251556|NCT03029416|Experimental|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
11251557|NCT03029403|Experimental|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
11251558|NCT03029403|Experimental|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
11251559|NCT03029403|Experimental|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
11251560|NCT03029403|Experimental|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
11251561|NCT03029390|Experimental|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.
~The patients will have a forced titration period:
~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
11251562|NCT03029390|Experimental|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.
~The patients will have a forced titration period:
~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).
~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
11251563|NCT03029377|Experimental|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
11251564|NCT03029377|Active Comparator|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
11251565|NCT03029364||Male and Female Adults|Completion of Study Protocol
11251566|NCT03029351|Experimental|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
11251567|NCT03029351|Placebo Comparator|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
11252030|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
11251568|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
11251569|NCT03029312|Experimental|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
11251570|NCT03029312|No Intervention|Regular Care|Regular Care, including physiotherapy for 5 months
11251571|NCT03029299|No Intervention|Control|Subjects receive standard of care testing as determined by the clinician.
11251572|NCT03029299|Experimental|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
11251573|NCT03029286|Experimental|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
11251574|NCT03029286|Active Comparator|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
11251575|NCT03029273|Experimental|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with Cyclophosphamide (250-500mg/m2/day) and Fludarabine (25mg/m2/day) for 3 days.
~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject."
11251576|NCT03029260|Experimental|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
11251577|NCT03029260|Active Comparator|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
11251578|NCT03029247|Active Comparator|Participants receiving Epoetin alfa|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
11251579|NCT03029247|Experimental|Participants receiving Daprodustat|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
11251580|NCT03029234|Experimental|Carfilzomib with Dexamethasone|"Participants will receive carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).
~Participants will also receive 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.
~Participants will receive treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, non-compliance, or intercurrent illness or worsening of a chronic condition, whichever occurs first."
11251581|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
11251582|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
11251583|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
11251639|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
11251584|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
11251585|NCT03029208|Experimental|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
11251586|NCT03029208|Active Comparator|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
11251587|NCT03029195|Experimental|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
11251588|NCT03029195|No Intervention|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
11251589|NCT03029195|No Intervention|Age matched Norms|Normal (non-cleft) age matched infants
11251590|NCT03029182|Experimental|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
11251591|NCT03029182|Active Comparator|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
11251592|NCT03029169|Active Comparator|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.
~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
11251593|NCT03029169|Active Comparator|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.
~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
11251594|NCT03029156|Active Comparator|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
11251595|NCT03029156|Experimental|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
11251596|NCT03029143|Experimental|Vedolizumab IV Standard Treatment Arm|Vedolizumab 300 milligram (mg), IV infusion on Day 1 and Week 2 as induction therapy in Lead-in Period followed by vedolizumab 300 mg, IV infusion, once in every 8 weeks (Q8W) (Weeks 6, 14, and 22) as standard treatment.
11251597|NCT03029143|Experimental|Vedolizumab IV Dose Optimized Arm|Vedolizumab 300 mg, IV infusion on Day 1 and Week 2 as induction therapy in Lead-in Period followed by Regimen A: vedolizumab 600 mg, IV infusion at Week 6 and 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26), or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 6, 10, 14, 18, 22 and 26). At Week 14 and beyond, dosing in the dose optimized arm will continue as previously assigned unless the subjects most recent preceding serum vedolizumab concentration is >90 microg/mL. In the event that steady-state Ctrough levels exceed safety exposure limits of 90 microg/mL, the next dose will be withheld and another Pharmacokinetics (PK) sample will be taken 1 week prior to the next scheduled dose. If at the next scheduled visit the Ctrough is still >90 microg/mL, the next dose will be similarly held and the PK repeated 1 week prior to the next scheduled dose. Once Ctrough is <90 microg/mL, the subject will move to the next lowest dose.
11251598|NCT03029130|Experimental|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
11251599|NCT03029130|No Intervention|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
11251600|NCT03029117||corrected and uncorrected rheumatic valve lesions|
11251601|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
11251602|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
11251603|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
11251604|NCT03029091|Experimental|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
11251605|NCT03029091|Experimental|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
11251606|NCT03029091|Experimental|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
11251607|NCT03029078|Experimental|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.
~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.
~Patient will be monitored for 24h to rule out potential adverse events."
11251608|NCT03029065||lung adenocarcinoma with brain (meningeal) metastasis|
11251609|NCT03029052|No Intervention|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
11251610|NCT03029052|Experimental|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
11251611|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
11251612|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
11251613|NCT03029039||blood donor voluntary|Blood samples will be collected.
11251640|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
11251641|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
11251642|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
11251614|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
11251615|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
11251616|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
11251617|NCT03029013|Experimental|experimental group|Apatinib and chemotherapy
11251618|NCT03029000|Experimental|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.
~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.
~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
11251619|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
11251620|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
11251621|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
11251622|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
11251623|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
11251624|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
11251625|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
11251626|NCT03028974|Other|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
11251627|NCT03028974|Other|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
11251628|NCT03028961|Experimental|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
11251629|NCT03028961|Active Comparator|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
11251630|NCT03028948|Experimental|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
11251631|NCT03028948|Active Comparator|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
11251632|NCT03028935|Experimental|Prevention (exercise, nutrition education program)|Exercise Intervention & Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
11251633|NCT03028922|Other|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
11251634|NCT03028909|Experimental|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
11251635|NCT03028909|Experimental|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
11251636|NCT03028909|Active Comparator|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
11251637|NCT03028896|No Intervention|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
11251638|NCT03028896|Experimental|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
11251643|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
11251644|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
11251645|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
11251646|NCT03028844|No Intervention|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
11251647|NCT03028844|Experimental|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
11251648|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
11251649|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
11251650|NCT03028805|No Intervention|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
11251651|NCT03028805|Active Comparator|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
11251652|NCT03028805|Active Comparator|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
11251653|NCT03028805|Active Comparator|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
11251654|NCT03028792|Experimental|Attention Modification Training|Attention Modification Program Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral stimuli.
11251655|NCT03028792|Sham Comparator|Attention Control Training|Placebo Comparator: Attention Control Condition Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral stimuli or the threat stimuli.
11251656|NCT03028779|Experimental|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
11251657|NCT03028766|Experimental|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
11251658|NCT03028766|Experimental|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
11251659|NCT03028753|Experimental|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
11251660|NCT03028740|Experimental|Drug: Cenicriviroc|150 mg cenicriviroc
11251661|NCT03028740|Placebo Comparator|Drug: Placebo|Placebo
11251662|NCT03028727|Active Comparator|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
11251663|NCT03028727|Experimental|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
11251664|NCT03028714|Experimental|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
11251665|NCT03028714|No Intervention|Control group|Participants in the control group will receive no intervention.
11251666|NCT03028701|Experimental|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
11251667|NCT03028688|No Intervention|Current standard of care|Participants in the current standard of care will receive the usual anesthesia care for upper GI endoscopy. In addition participants will have transcutaneous PCO2 measurements performed.
11251668|NCT03028688|Experimental|High flow nasal cannula group|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen and will also have transcutaneous PCO2 measurements performed.
11251669|NCT03028675||Multiple Sclerosis|
11251670|NCT03028675||Healthy Volunteer|10 age-matched control volunteers
11251671|NCT03028662|Experimental|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
11251672|NCT03028662|Active Comparator|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
11251673|NCT03028662|Active Comparator|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
11251674|NCT03028649|Experimental|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.
~Interventions:
~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.
~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
11251704|NCT03028441|Experimental|Group 3-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
11251675|NCT03028649|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.
~Interventions:
~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.
~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
11251676|NCT03028623|Other|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
11251677|NCT03028623|Experimental|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
11251678|NCT03028610|Experimental|Acessa™ System|radiofrequency generator
11251679|NCT03028597|Experimental|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
11251680|NCT03028597|Active Comparator|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
11251681|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:
~Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation
~Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor
~Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians
~Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
11251682|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.
~Survey of clinicians will be sent via e-mail."
11251683|NCT03028571|Placebo Comparator|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
11251684|NCT03028571|Experimental|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
11251685|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
~Between the ages of 21-35 years old."
11251686|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes >5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
11251687|NCT03028545|Other|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
11251688|NCT03028545|Other|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
11251689|NCT03028545|Other|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
11251690|NCT03028545|Other|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
11251691|NCT03028532|Experimental|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
11251692|NCT03028519|Experimental|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
11251693|NCT03028493|Experimental|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
11251694|NCT03028493|Active Comparator|Original SAFE Intervention|Original version of the SAFE intervention.
11251695|NCT03028480||Subjects with Bronchial asthma|Subjects with a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications will be enrolled
11251696|NCT03028467|Experimental|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
11251697|NCT03028467|Experimental|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
11251698|NCT03028467|Experimental|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
11251699|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
11251700|NCT03028454|Experimental|Ginger Root Capsule|
11251701|NCT03028454|Placebo Comparator|Placebo Capsule|
11251702|NCT03028441|Experimental|Group 1- low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
11251703|NCT03028441|Experimental|Group 2-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
11251748|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
11251705|NCT03028441|Experimental|Group 4 -high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
11251706|NCT03028441|Experimental|Group 5-high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
11251707|NCT03028441|Experimental|Group 6-dose-High Dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
11251708|NCT03028428|Experimental|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
11251709|NCT03028428|Active Comparator|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
11251710|NCT03028415|Experimental|AMPLEX®|
11251711|NCT03028415|Active Comparator|Autogenous Bone Graft (ABG)|
11251712|NCT03028402||Asymptomatic Controls|Individuals who have no history of neck pain, trauma or surgery, similar in age and sex to the surgical patients
11251713|NCT03028402||C5-C6 arthrodesis|Patients scheduled to undergo C5-C6 anterior cervical arthrodesis
11251714|NCT03028402||C6-C7 arthrodesis|Patients scheduled to undergo C6-C7 anterior cervical arthrodesis
11251715|NCT03028402||C4-C5-C6 arthrodesis|Patients scheduled to undergo C4-C5-C6 anterior cervical arthrodesis
11251716|NCT03028402||C5-C6-C7 arthrodesis|Patients scheduled to undergo C5-C6-C7 anterior cervical arthrodesis
11251717|NCT03028389|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
11251718|NCT03028389|No Intervention|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
11251719|NCT03028376||Moderate TBI patients|GCS 9-13
11251720|NCT03028363|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
11251721|NCT03028363|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
11251722|NCT03028350|Experimental|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
11251723|NCT03028350|Placebo Comparator|Placebo Oral Capsule|Oral placebo daily for 8 weeks
11251724|NCT03028337|Experimental|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
11251725|NCT03028337|Active Comparator|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
11251726|NCT03028324|Experimental|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
11251727|NCT03028311|Other|Treatment (angiography, yttrium Y-90 radioembolization)|"The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging.
~All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours."
11251728|NCT03028298|Experimental|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
11251729|NCT03028298|Experimental|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
11251730|NCT03028285|Experimental|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
11251731|NCT03028285|Experimental|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
11251732|NCT03028285|Experimental|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
11251733|NCT03028272|Active Comparator|Fascia|Autologous donor substrate
11251734|NCT03028272|Experimental|Skye Barrier|Amniotic membrane allograft
11251735|NCT03028259||lab results|monitoring of
11251736|NCT03028246|Experimental|ExAblate 4000 System|MR-Guided Focused Ultrasound
11251737|NCT03028233|Experimental|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
11251738|NCT03028233|Active Comparator|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
11251739|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
11251740|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
11251741|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
11251742|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
11251743|NCT03028194|Experimental|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
11251744|NCT03028194|Placebo Comparator|Placebo|No procedure performed after delivery of the placenta.
11251745|NCT03028181||1|Control group non-exposed to tobacco smoking
11251746|NCT03028181||2|Control group exposed to tobacco smoking
11251747|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
11251749|NCT03028168|Experimental|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
11251750|NCT03028168|Experimental|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
11251751|NCT03028168|Experimental|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
11251752|NCT03028155|Active Comparator|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
11251753|NCT03028155|Active Comparator|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
11251754|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
11251755|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
11251756|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
11251757|NCT03028129|Experimental|Treatment|Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
11251758|NCT03028129|Placebo Comparator|Control|Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).
11251759|NCT03028116|Active Comparator|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
11251760|NCT03028116|Placebo Comparator|Placebo|Water for Injection
11251761|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.
~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
11251762|NCT03028077|Experimental|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
11251763|NCT03028077|Experimental|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
11251764|NCT03028077|Placebo Comparator|Placebo|Placebo for 12 weeks
11251765|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
11251766|NCT03028038|Experimental|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
11251767|NCT03028038|Experimental|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
11251768|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
11251769|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
11251770|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
11251771|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
11251772|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
11251773|NCT03027999|Experimental|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
11251774|NCT03027999|No Intervention|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
11251775|NCT03027986|Experimental|postural rehabilitation program based on sensory-motor control|
11251776|NCT03027986|No Intervention|Standard physiotherapy|
11251777|NCT03027973|Experimental|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
11251778|NCT03027973|Active Comparator|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
11251779|NCT03027960|Experimental|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
11254458|NCT03009994|Other|Non exteriorization group|Uterine incision will be repaired intra abdominally
11251780|NCT03027960|Experimental|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
11251781|NCT03027947|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
11251782|NCT03027934|Active Comparator|Group 1|
11251783|NCT03027934|Active Comparator|Group 2|
11251784|NCT03027921|Experimental|hepatic ultrasound|all patients will have hepatic ultrasound
11251785|NCT03027908|Experimental|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
11251786|NCT03027908|Active Comparator|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
11251787|NCT03027895|Experimental|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
11251788|NCT03027895|Active Comparator|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
11251789|NCT03027869|Active Comparator|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
11251790|NCT03027869|Sham Comparator|Sham tDCS|30sec ramp-up and 30sec ramp-down
11251791|NCT03027869|Active Comparator|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
11251792|NCT03027856|Experimental|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
11251793|NCT03027843|Active Comparator|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
11251794|NCT03027843|No Intervention|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
11251795|NCT03027830|Experimental|iFR pressure-wire|
11251796|NCT03027830|Active Comparator|Conventional|
11251797|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
11251798|NCT03027791|Experimental|Parishoners at HUMC|African-American adults aged 18-85 who attend services at Holman United Methodist Church will be exposed to Group Sessions for 12 weeks and Virtual Reality for 6 weeks.
11251799|NCT03027778|Experimental|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
11251800|NCT03027778|No Intervention|Usual care|Participants receive their usual dialysis for the duration of 4 months.
11251801|NCT03027765||Egyptian children|"Population1:
~Egyptian children with constructed space maintainers at Cairo University."
11251802|NCT03027765||Pediatric dentists|"Population2:
~Pediatric dentists at Cairo University."
11251803|NCT03027752|Active Comparator|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
11251804|NCT03027752|Experimental|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
11251805|NCT03027739|Experimental|Arm 1|CART-19 cells treated
11251806|NCT03027726|Active Comparator|Control group|Family-based lifestyle education and psycho-educational program
11251807|NCT03027726|Experimental|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
11251808|NCT03027713|Other|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
11251809|NCT03027713|Other|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
11251810|NCT03027700|Active Comparator|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
11251811|NCT03027700|Active Comparator|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
11251812|NCT03027700|Active Comparator|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
11251813|NCT03027700|Active Comparator|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
11251814|NCT03027687|Experimental|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
11251815|NCT03027687|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
11251816|NCT03027674|Experimental|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
11251817|NCT03027674|Active Comparator|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
11251818|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
11251819|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
11251820|NCT03027648|Other|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
11251821|NCT03027635|Experimental|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
11251822|NCT03027635|Active Comparator|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
11251823|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
11251824|NCT03027609|Experimental|AR-105|One intravenous infusion of AR-105 20mg/'kg
11251825|NCT03027609|Placebo Comparator|Control|Matching placebo
11251826|NCT03027596|Experimental|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
11251827|NCT03027596|No Intervention|Control group|no intervention
11251828|NCT03027583|Experimental|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
11251829|NCT03027583|Placebo Comparator|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
11251830|NCT03027570|Experimental|Control|Five-month program at two centers for the treatment of overweight children.
11251831|NCT03027570|Experimental|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
11251832|NCT03027557|Experimental|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
11251833|NCT03027557|Active Comparator|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
11251834|NCT03027557|Placebo Comparator|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
11251835|NCT03027544|Experimental|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.
~Intervention：tomotherapy"
11251836|NCT03027531|Experimental|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
11251837|NCT03027531|Experimental|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
11251838|NCT03027518|Other|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
11251839|NCT03027518|Other|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
11251840|NCT03027505|Experimental|MUAC<125mm|no medical complication
11251841|NCT03027492|Active Comparator|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
11251842|NCT03027492|Active Comparator|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
11251843|NCT03027492|Active Comparator|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
11251844|NCT03027492|Active Comparator|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
11251873|NCT03027284|Experimental|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
11252028|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
11251845|NCT03027492|Active Comparator|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
11251846|NCT03027492|Active Comparator|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
11251847|NCT03027479|Experimental|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
11251848|NCT03027479|Other|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
11251849|NCT03027466|Experimental|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will recieve affirmation text messages throughout the study"
11251850|NCT03027466|Active Comparator|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not recieve affirmation text messages throughout the study"
11251851|NCT03027466|Active Comparator|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
11251852|NCT03027466|Placebo Comparator|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free UK appwithout any affirmation content Smoke Free UK app(no baseline affirmation quiz and no affirmation textmessages)
11251853|NCT03027440||CPP Cohort|offspring born to historic CPP cohort participant mothers between 1959 and 1966 who were known to be alive at age 7 (if still alive at the time of NDI search, ages 50 to 57 years old)
11251854|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
11251855|NCT03027414|Active Comparator|Substudy 1 and 2 Active|HVs that receive active TMS over the right dlPFC
11251856|NCT03027414|Sham Comparator|Substudy 1 and 2 Sham|HVs that receive sham TMS over the right dlFPC
11251857|NCT03027414|Experimental|Substudy 3 offline|HVs will receive offline TMS to the lest IPS (FPN)
11251858|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
11251859|NCT03027388|Experimental|1/LB100|Treatment with LB100
11251860|NCT03027375|Experimental|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
11251861|NCT03027375|Placebo Comparator|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks).
11251862|NCT03027362|Experimental|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
11251863|NCT03027362|Active Comparator|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
11251864|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.
~The exclusion criteria will be:
~age younger than 18 years
~renal and liver failure and insufficiency
~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)
~any type of cancer
~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption
~transplantation
~sarcoidosis
~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism
~familial hypocalciuric hypercalcemia
~hypophosphoremia sustained by genetic causes or secondary to other causes."
11251865|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.
~The exclusion criteria will be:
~age younger than 18 years
~renal and liver failure and insufficiency
~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)
~any type of cancer
~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption
~transplantation
~sarcoidosis
~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism
~familial hypocalciuric hypercalcemia
~hypophosphoremia sustained by genetic causes or secondary to other causes."
11251866|NCT03027336|Experimental|coleosoma|coleosoma 500mg tablet daily
11251867|NCT03027336|Placebo Comparator|placebo|placebo tablets
11251868|NCT03027323|Other|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
11251869|NCT03027323|No Intervention|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
11251870|NCT03027310||Healthy Volunteers|adult healthy volunteers
11251871|NCT03027310||tremor patients|adult patients with tremor
11251872|NCT03027284|Experimental|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
11252029|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
11251874|NCT03027284|Experimental|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
11251875|NCT03027258|Experimental|Intervention|mHealth intervention
11251876|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
11251877|NCT03027206|Experimental|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
11251878|NCT03027206|Experimental|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
11251879|NCT03027193|Experimental|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^9 vp through intramuscular route.
11251880|NCT03027193|Experimental|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10^10 vp through intramuscular route.
11251881|NCT03027193|Experimental|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^10 vp through intramuscular route.
11251882|NCT03027193|Experimental|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10^7 pfu through intramuscular route.
11251883|NCT03027193|Experimental|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10^8 pfu through intramuscular route.
11251884|NCT03027193|Experimental|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10^10 vp followed by MVA HAV, 2 x 10^8 pfu (8 weeks apart) through intramuscular route.
11251885|NCT03027180|Active Comparator|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
11251886|NCT03027180|Experimental|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
11251887|NCT03027180|Experimental|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
11251888|NCT03027167|Active Comparator|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
11251889|NCT03027167|Experimental|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
11251890|NCT03027154|Experimental|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
11251891|NCT03027154|Experimental|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
11251892|NCT03027154|Experimental|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
11251893|NCT03027154|Experimental|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
11251894|NCT03027141|Active Comparator|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
11251895|NCT03027141|Experimental|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
11251896|NCT03027128|Experimental|haNK™ for Infusion|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous Infusion
11251897|NCT03027115|Experimental|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
11251898|NCT03027115|No Intervention|Control|no treatment
11251899|NCT03027102|Experimental|Patient Arm|Patients will receive DNT cells from healthy donors.
11251900|NCT03027102|No Intervention|Donor Arm|Healthy volunteer donors will donate blood.
11251901|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
11251902|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
11251903|NCT03027076||Women with UCPPS|Collect midstream urine samples
11251904|NCT03027076||Asymptomatic Women|Collect midstream urine samples
11251965|NCT03026608|Active Comparator|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
11251905|NCT03027063|Experimental|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.
~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
11251906|NCT03027063|Active Comparator|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
11251907|NCT03027050|Experimental|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
11251908|NCT03027050|Active Comparator|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
11251909|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
11251910|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
11251911|NCT03027024|Experimental|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
11251912|NCT03027011|Active Comparator|Remote Ischemic Preconditioning(RIPC)|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
11251913|NCT03027011|Placebo Comparator|Control|Control group without remote ischemic preconditioning
11251914|NCT03026998|Other|MRI|
11251915|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.
~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
11251916|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
11251917|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
11251918|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
11251919|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
11251920|NCT03026959|Experimental|Mindfulness Group|Participants assigned to the mindfulness group will attend four weekly sessions that are each 1.5 hours in length. The sessions will follow the structure described by Short, Mazmanian, Ozen, & Bédard (2015). The structure is designed to first enhance learners' foundation skills in mindfulness and progresses into teaching learners more advanced mindfulness skills.
11251921|NCT03026959|No Intervention|Social (control) Group|Participants assigned to the social group will also attend four weekly sessions that are each 1.5 hours in length. Each session will have participants focus on a creative tasks while permitting task related discussion. In this way the format is designed to parallel the mindfulness group, where participants engage in a new activity each week and have an opportunity to discuss the activities with the group without engaging in any formal intervention.
11251922|NCT03026946|Active Comparator|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
11251923|NCT03026946|Active Comparator|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
11251924|NCT03026933|Experimental|Treatment|KI1107
11251925|NCT03026933|Active Comparator|Control|Rosuvastatin calcium
11251926|NCT03026920|Experimental|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
11251927|NCT03026907|Active Comparator|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
11251928|NCT03026907|Active Comparator|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
11251929|NCT03026894|Active Comparator|CD group|Panoramic Radiographs and T-Scan III occlusal system
11251930|NCT03026894|Active Comparator|IOD group|Panoramic Radiographs and T-Scan III occlusal system
11251931|NCT03026881|Experimental|Fluzoparib + Apatinib + Paclitaxel|
11251932|NCT03026868|Experimental|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
11251933|NCT03026855|Experimental|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
11251934|NCT03026842|Experimental|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
11251993|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.
~All of them are suicide attempters without psychotic features"
11251935|NCT03026842|Active Comparator|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
11251936|NCT03026829|Experimental|CART sound therapy|
11251937|NCT03026816|Experimental|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation
11251938|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
11251939|NCT03026790|Active Comparator|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
11251940|NCT03026790|Active Comparator|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
11251941|NCT03026790|Active Comparator|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
11251942|NCT03026790|Active Comparator|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
11251943|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
11251944|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
11251945|NCT03026764|Experimental|Outpatient|Patients in the outpatient group (same day discharge following THA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
11251946|NCT03026764|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following THA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
11251947|NCT03026738|Experimental|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
11251948|NCT03026738|Active Comparator|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
11251949|NCT03026725|Experimental|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
11251950|NCT03026725|Placebo Comparator|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
11251951|NCT03026712|Experimental|Real tDCS|
11251952|NCT03026712|Sham Comparator|Sham tDCS|
11251953|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
11251954|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
11251955|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
11251956|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
11251957|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
11251958|NCT03026686||Controls|women with similar risk factors but did not require readmission
11251959|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
11251960|NCT03026660|Experimental|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
11251961|NCT03026660|Placebo Comparator|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
11251962|NCT03026621|Placebo Comparator|Placebo|This will be an herbal tea the looks similar to the control.
11251963|NCT03026621|Experimental|Lignite Extract|This will be the Restore gut supplement
11251964|NCT03026608|Experimental|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
11252027|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
11251966|NCT03026569|Experimental|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
11251967|NCT03026569|No Intervention|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
11251968|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
11251969|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
11251970|NCT03026543|Experimental|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
11251971|NCT03026543|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
11251972|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
11251973|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
11251974|NCT03026517|Experimental|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The maximally tolerated Phenformin dose was determined to be 100 mg BID. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor.
11251975|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
11251976|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
11251977|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
11251978|NCT03026478|Experimental|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
11251979|NCT03026478|Active Comparator|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
11251980|NCT03026465|Experimental|Coroflex ISAR stent|PCI with a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR stent) with very thin struts (50 µm). During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
11251981|NCT03026465|Active Comparator|Biomatrix stent|PCI with a biodegradable-polymer biolimus-eluting stent (Biomatrix stent) with 120 µm struts. During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
11251982|NCT03026452|Experimental|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
11251983|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
11251984|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.
11251985|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.
11251986|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.
11251987|NCT03026426|Experimental|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.
~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
11251988|NCT03026426|No Intervention|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
11251989|NCT03026413|Experimental|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
11251990|NCT03026413|Active Comparator|Control arm|pulmonary vein isolation without contact force
11251991|NCT03026400|Other|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
11251992|NCT03026400|Other|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
11251994|NCT03026374|Experimental|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
11251995|NCT03026374|No Intervention|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
11251996|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.
~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
11251997|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.
~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
11251998|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.
~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
11251999|NCT03026348|Active Comparator|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
11252000|NCT03026348|Active Comparator|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
11252001|NCT03026348|Active Comparator|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
11252002|NCT03026348|Active Comparator|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
11252003|NCT03026348|Active Comparator|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
11252004|NCT03026348|Active Comparator|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
11252005|NCT03026348|Active Comparator|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
11252006|NCT03026348|Active Comparator|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
11252007|NCT03026348|Active Comparator|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
11252008|NCT03026348|Active Comparator|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
11252009|NCT03026348|Active Comparator|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
11252010|NCT03026348|Placebo Comparator|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
11252011|NCT03026335|Experimental|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
11252012|NCT03026335|Active Comparator|Control/Comparison Group|Business as usual with students in non-intervened schools
11252013|NCT03026322|Active Comparator|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
11252014|NCT03026322|Active Comparator|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
11252015|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
11252016|NCT03026309||healthy|healthy volunteers.
11252017|NCT03026296|Experimental|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
11252018|NCT03026283||1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
11252019|NCT03026270|Other|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
11252020|NCT03026270|Other|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
11252021|NCT03026257|Experimental|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
11252022|NCT03026257|Active Comparator|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
11252023|NCT03026244|Active Comparator|Nutritional intervention product|Milk protein, prebiotics, vitamin D
11252024|NCT03026244|Placebo Comparator|Placebo product|placebo product
11252025|NCT03026231|Active Comparator|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
11252026|NCT03026231|Placebo Comparator|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
11252031|NCT03026205|Experimental|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
11252032|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
11252033|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
11252034|NCT03026179|Other|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
11252035|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).
~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
11252036|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).
~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
11252037|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).
~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
11252038|NCT03026153|Other|Control group - Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
11252039|NCT03026153|Other|Intervention Group - Oral Survey 2|Oral Survey 2 will be administered as the intervention : patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
11252040|NCT03026140|Active Comparator|group 1|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)
11252041|NCT03026140|Experimental|group 2|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)
11252042|NCT03026127|Experimental|CRISP|Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
11252043|NCT03026127|Active Comparator|Supportive Therapy (ST)|Supportive Therapy focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
11252044|NCT03026101|Experimental|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
11252045|NCT03026088|Experimental|Bisoprolol|
11252046|NCT03026075|Experimental|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
11252047|NCT03026062|Experimental|Arm I (sequential tremelimumab, durvalumab)|Participants receive tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Participants then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
11252048|NCT03026062|Experimental|Arm II (combination tremelimumab, durvalumab)|Participants receive tremelimumab IV and durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Participants then receive durvalumab IV on day 1. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
11252049|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
11252050|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
11252051|NCT03026036||MDD|Patients with current Major Depressive Disorder
11252052|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
11252053|NCT03026036||HC|Healthy control participants
11252054|NCT03026023|Experimental|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
11252055|NCT03025997|Active Comparator|Active yoghurt|Yoghurt snack containing encapsulated lipid
11252056|NCT03025997|Placebo Comparator|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid
~+ empty encapsulation matrix"
11252057|NCT03025984|Active Comparator|Texting|"Patients in the Texting group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed."
11252058|NCT03025984|No Intervention|No texting|Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.
11254848|NCT03007264|Experimental|CAP treated|volar arm will be treated with cold atmospheric plasma.
11252059|NCT03025971|Other|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
11252060|NCT03025958|Experimental|Nimotuzumab|Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
11252061|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
11252062|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
11252063|NCT03025932||Patient cohort|Patients who underwent laparoscopic hernia repair of giant hiatal hernia with mesh and received anterior fundoplication
11252064|NCT03025906|Experimental|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
11252065|NCT03025906|Experimental|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
11252066|NCT03025893|Experimental|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
11252067|NCT03025893|Active Comparator|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
11252068|NCT03025880|Experimental|Single arm|"Eligible patients will be enrolled and treated with Pembrolizumab (P) at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle in combination with Gemcitabine (G) at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with P in the initial exploratory run-in-phase if necessary) as a IV infusion on day 1 and 8 of each 21-day cycle.
~Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of G in combination with fixed doses of P."
11252069|NCT03025841|Other|Ceftaroline|Patients receive Ceftaroline 600mg BID
11252070|NCT03025828|Experimental|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
11252071|NCT03025815|Experimental|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
11252072|NCT03025815|Sham Comparator|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
11252073|NCT03025789|Experimental|Open label arm|children and adults to receive fexinidazole either as inpatients or outpatients.
11252074|NCT03025776||stroke|individuals chronic (> 6 months) post-stroke
11252075|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
11252076|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
11252077|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
11252078|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
11252079|NCT03025750|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
11252080|NCT03025750|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
11252081|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
11252082|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
11252083|NCT03025724|No Intervention|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
11252084|NCT03025724|Experimental|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
11252085|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
11252086|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
11252087|NCT03025698|Experimental|Cohort A (Option 1)|
11252088|NCT03025698|Experimental|Cohort A (option 2)|
11252089|NCT03025698|Experimental|Cohort B|
11252090|NCT03025685|Experimental|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
11252091|NCT03025685|Active Comparator|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
11252092|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
11252093|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
11252094|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
11252095|NCT03025633|Other|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
11252096|NCT03025633|No Intervention|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
11252097|NCT03025620|Placebo Comparator|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
11252098|NCT03025620|Active Comparator|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
11252099|NCT03025607|No Intervention|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
11252100|NCT03025607|Experimental|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
11252101|NCT03025607|Experimental|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
11252102|NCT03025594|Experimental|Gonyautoxin|Gonyautoxin 40mcg
11252103|NCT03025594|Active Comparator|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
11252104|NCT03025581|Active Comparator|Intervention group|Nipple stimulation.
11252105|NCT03025581|No Intervention|Control group|No intervention (expectant management only).
11252106|NCT03025568|Active Comparator|group 1|Patient will receive partial denture constructed from Bre_flex
11252107|NCT03025568|Experimental|group 2|Patients will receive removable partial denture constructed from PEEK
11252108|NCT03025555|Active Comparator|group 1|patients will receive partial denture constructed from breflex material.
11252109|NCT03025555|Experimental|group 2|patients will receive partial denture constructed from PEEK material.
11252110|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
11252111|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
11252112|NCT03025529|Experimental|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
11252113|NCT03025529|Sham Comparator|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
11252114|NCT03025529|No Intervention|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
11252115|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.
~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
11252116|NCT03025503|Experimental|nipple stimulation|
11252117|NCT03025503|No Intervention|no intervention|
11252118|NCT03025490|No Intervention|standard of Care|Patient undergoing sedation, treatment team does not have capnography data available.
11252119|NCT03025490|Experimental|Capnography|Patient undergoing sedation, treatment team does have capnography data available.
11252120|NCT03025477|Active Comparator|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.
~The regimen of administration of the chemotherapy is as following:
~Carboplatin AUC 6 - IV - Day (D) 1
~Paclitaxel 80mg / m² - IV - D1, D8, D15
~one cycle every 3 weeks"
11252121|NCT03025477|Experimental|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.
~Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.
~Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.
~The regimen of administration of the chemotherapy is as following:
~Cisplatin 80mg / m² - IV or IP - D1
~Epirubicin 60mg / m² - IV - D3
~one Cycle every 3 weeks."
11252122|NCT03025451|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
11252123|NCT03025425|Experimental|MPV-arm|Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
11252124|NCT03025412|Experimental|Endoscopic surgery|Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
11252125|NCT03025412|Active Comparator|Conservative treatment|Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.
11252126|NCT03025399|Experimental|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
11252127|NCT03025399|Placebo Comparator|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
11252128|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
11252129|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
11252130|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
11252131|NCT03025347|Experimental|Control|Experimental day where participants rest.
11252132|NCT03025347|Experimental|Exercise|Experimental day where participants complete a run.
11252133|NCT03025334|Sham Comparator|Sham tDCS|sham tDCS (30sec ramp-up and 3sec ramp-down)
11252134|NCT03025334|Active Comparator|Real tDCS right|Real anodal tDCS (right DLPFC)
11252135|NCT03025321|Experimental|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
11252136|NCT03025321|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
11252137|NCT03025308|Experimental|Blinded Phase: Filgotinib 200 mg|Filgotinib 200 mg plus placebo to match (PTM) filgotinib 100 mg for up to 6 years
11252138|NCT03025308|Experimental|Blinded Phase: Filgotinib 100 mg|Filgotinib 100 mg plus PTM filgotinib 200 mg for up to 6 years
11252139|NCT03025308|Experimental|Open Label Phase: Filgotinib 200 mg|Filgotinib 200 mg for up to 6 years
11252140|NCT03025308|Experimental|Open Label Phase: Filgotinib 100 mg|Filgotinib 100 mg for up to 6 years
11252141|NCT03025295|Experimental|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
11252142|NCT03025295|Placebo Comparator|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
11252143|NCT03025282|Experimental|CD10367 3% Solution - Non-desquamated zone|
11252144|NCT03025282|Experimental|CD10367 1% Solution - Non-desquamated zone|
11252145|NCT03025282|Placebo Comparator|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
11252146|NCT03025282|Active Comparator|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
11252147|NCT03025282|Experimental|CD10367 3% Solution - Desquamated zone|
11252148|NCT03025282|Placebo Comparator|CD10367 solution placebo - Desquamated zone|
11252149|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
11252150|NCT03025256|Experimental|Treatment (nivolumab)|Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11252151|NCT03025243|Experimental|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
11252152|NCT03025243|Active Comparator|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
11252153|NCT03025230|Experimental|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
11252154|NCT03025230|Active Comparator|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
11252155|NCT03025217|Experimental|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
11252156|NCT03025204|Active Comparator|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
11252157|NCT03025204|Experimental|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
11252158|NCT03025204|Active Comparator|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
11252159|NCT03025191|Experimental|Prison Connect|
11252160|NCT03025178|Experimental|Central venous catheterization|Central venous catheterization will be performed using 4Fr central venous catheter at left internal jugular vein in infant. The tip of central venous catheter will be confirmed by transthoracic echocardiography. The actual insertion depth of central venous catheter will be compared to the predicted insertion depth derived from two calculation methods using height and the distance between the anatomical landmarks.
11252196|NCT03024970|Experimental|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
11252161|NCT03025165|Experimental|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
11252162|NCT03025165|Experimental|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
11252163|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
11252164|NCT03025152|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
11252165|NCT03025152|Placebo Comparator|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
11252166|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
11252167|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
11252168|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
11252169|NCT03025126|Experimental|HEAD Rehabilitation|rehabilitation with IT multimedial devices
11252170|NCT03025126|Active Comparator|Usual care program|usual care program
11252171|NCT03025113|Experimental|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
11252172|NCT03025113|Active Comparator|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
11252173|NCT03025100||Prospective|A sample of 120 patients aged 60 years or older admitted to General Medicine at Duke University Hospital will be enrolled in the prospective cohort study. A convenience sample will be derived from a randomized daily list of general medicine admissions; weekend admissions will be excluded as these patients will not be captured within 24 hours of hospital admission.
11252174|NCT03025087|Experimental|Phase 1|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.
11252175|NCT03025087|Experimental|Phase 2|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 1-5
11252176|NCT03025087|Experimental|Phase 3|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 1-5.
11252177|NCT03025087|Experimental|Phase 4|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 1-5.
11252178|NCT03025087|Experimental|Phase 5|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ 1-2 hours after separation from CPB or at end of noncardiac surgery followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 1-5.
11252179|NCT03025061||15 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 15 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
11252180|NCT03025061||30 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 30 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
11252181|NCT03025035|Experimental|Pembrolizumab + Olaparib|This is an open-label, single-arm pilot study of pembrolizumab (study drug) in combination with Olaparib (standard of care) in 20 subjects with advanced BRCA mutation-associated breast cancer having progressed through at least a standard first line therapy.
11252182|NCT03025022|Experimental|14C-JNJ-42847922 40 miiligram (mg)|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.
11252183|NCT03025009|Experimental|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
11252184|NCT03025009|Placebo Comparator|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
11252185|NCT03025009|Experimental|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
11252186|NCT03025009|Active Comparator|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
11252187|NCT03025009|Active Comparator|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
11252188|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
11252189|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
11252190|NCT03024983|Active Comparator|Control|Glucose monohydrate (isoglucidic portion -50 g of available carbohydrates-)
11252191|NCT03024983|Experimental|Semolina|Semolina soup (isoglucidic portion -50 g of available carbohydrates-)
11252192|NCT03024983|Experimental|Bread|Bread (isoglucidic portion -50 g of available carbohydrates-)
11252193|NCT03024983|Experimental|Short pasta (fresh)|Fresh penne (isoglucidic portion -50 g of available carbohydrates-)
11252194|NCT03024983|Experimental|Short pasta (dry)|Short pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
11252195|NCT03024983|Experimental|Long pasta (dry)|Long pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
11252197|NCT03024970|Active Comparator|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
11252198|NCT03024957|Active Comparator|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
11252199|NCT03024957|Active Comparator|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
11252200|NCT03024957|Active Comparator|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
11252201|NCT03024944|Experimental|Brain Imaging with 18F-THK-5351|This group consists of 30 adult subjects: 10 with Type 2 diabetes, 10 with pre-diabetes, and 10 with normal glucose tolerance. Each subject will receive a baseline scan and a follow-up PET scan with 18F-THK-5351.
11252202|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
11252203|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
11252204|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
11252205|NCT03024905|Experimental|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.
~Interventions are behavioural and device:
~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
11252206|NCT03024905|Experimental|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.
~Interventions are behavioural and device:
~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
11252207|NCT03024905|Experimental|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.
~Interventions are behavioural and device:
~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
11252208|NCT03024905|Experimental|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.
~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.
~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
11252209|NCT03024892|Experimental|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
11252210|NCT03024892|Experimental|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
11252211|NCT03024892|Sham Comparator|LC conventional|Patients received conventional laparoscopic cholecystectomy
11252212|NCT03024892|Sham Comparator|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
11252213|NCT03024879|Active Comparator|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
11252214|NCT03024879|Placebo Comparator|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
11252215|NCT03024866||Electronic Brachytherapy|Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System
11252216|NCT03024866||Mohs Surgery|Previously completed treatment for non-melanoma skin cancer using Mohs Surgery
11252217|NCT03024853|Experimental|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
11252218|NCT03024853|Experimental|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
11252219|NCT03024853|Experimental|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
~This is the original BPS exercise (already validated in other studies)."
11252220|NCT03024853|Active Comparator|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
11252221|NCT03024840|Experimental|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
11252222|NCT03024840|Experimental|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
11252223|NCT03024827|Experimental|Medical Cannabis Oil|CanniMed® 1:20
11252224|NCT03024814|Experimental|acetaminophen group|Babies who took acetaminophen
11252225|NCT03024814|Experimental|Placebo group (Dextrose 5)|Babies who took placebo
11252226|NCT03024801|Experimental|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
11252227|NCT03024801|Experimental|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
11252228|NCT03024775|Active Comparator|Active Comparator 1|Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
11252229|NCT03024775|Active Comparator|Active Comparator 2|Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
11252230|NCT03024775|Placebo Comparator|Placebo 1|Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
11252231|NCT03024775|Placebo Comparator|Placebo 2|Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
11252232|NCT03024762|Experimental|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
11252233|NCT03024762|No Intervention|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
11252234|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
11252235|NCT03024710|Experimental|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.
~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
11252236|NCT03024710|No Intervention|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
11252237|NCT03024697|Active Comparator|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
11252238|NCT03024697|Active Comparator|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
11252239|NCT03024697|Active Comparator|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
11252240|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
11252241|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
11252242|NCT03024671|Experimental|patch test|Patients with patch test of cosmetics
11252243|NCT03024658|No Intervention|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
11252244|NCT03024658|Experimental|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
11252245|NCT03024645|Experimental|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
11252246|NCT03024645|Active Comparator|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
11252247|NCT03024632||trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a trial of labor
11252248|NCT03024632||No trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a a repeat cesarean section
11252249|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
11252250|NCT03024606|No Intervention|control group|No text messages
11252251|NCT03024593|Experimental|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
11252252|NCT03024593|No Intervention|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
11252253|NCT03024580|Experimental|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
11252254|NCT03024580|Active Comparator|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
11252255|NCT03024580|Active Comparator|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
11252256|NCT03024580|Active Comparator|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
11252257|NCT03024580|Active Comparator|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
11252258|NCT03024580|Active Comparator|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
11252259|NCT03024567|Active Comparator|Salt|6 grams sodium chloride per day for 14 days
11252260|NCT03024567|Placebo Comparator|Placebo|6 grams gelatine per day for 14 days
11252261|NCT03024554|Experimental|treatment|aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
11252262|NCT03024541||LASA study|
11252263|NCT03024541||InterRAI consortium|
11252264|NCT03024528||CAM-ICU (+)|Delirious patients.
11252265|NCT03024528||CAM-ICU (-)|Non-delirious patients
11252266|NCT03024515|Experimental|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
11252267|NCT03024515|Experimental|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
11252268|NCT03024502|Experimental|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
11252269|NCT03024502|Experimental|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
11252270|NCT03024502|Experimental|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
11252271|NCT03024489|Experimental|Palbociclib-Cetuximab-IMRT|"IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
~Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
~Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
11252272|NCT03024476|Experimental|Intensive management arm|"Description:
~Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan
~Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).
~Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.
~Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee."
11252273|NCT03024476|Active Comparator|Control arm|"Description:
~Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.
~Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups)."
11252274|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
11252275|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.
~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
11252276|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.
~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
11252277|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 inhibitor.
~Patients in Cohort B will be treated with atezolizumab alone. If there is no response to atezolizumab, then the recommended phase II dose of entinostat will be added to the standard dose of atezolizumab. If there is a response to atezolizumab, patients will continue to be treated with atezolizumab alone."
11252278|NCT03024424|Experimental|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
11252279|NCT03024424|Active Comparator|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
11252280|NCT03024411|Experimental|Music/video games|iPod (Music/video games)
11252281|NCT03024411|No Intervention|No intervention|No intervention
11252282|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
11252283|NCT03024372|Active Comparator|Conventional sutures|AV fistula creation with sutures
11252284|NCT03024372|Active Comparator|Anastoclips|AV fistula creation with clips
11252285|NCT03024359|Active Comparator|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
11252286|NCT03024359|Active Comparator|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
11252287|NCT03024333||Healthy subjects|"Healthy subjects are:
~Between 19-60 years old
~Able to sign the informed consent after the whole study is explained to them
~Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery
~Able to sit upright with or without back support of chair
~No other diseases affect swallowing function"
11252288|NCT03024320|Experimental|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
11252360|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) under fasting conditions.
11252289|NCT03024320|Experimental|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program, as well as group-based tele-coaching session.
11252290|NCT03024320|Active Comparator|Attention Control|Participants receive health-focused articles and infographics throughout 48 weeks and receive a Fitbit.
11252291|NCT03024307|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
11252292|NCT03024307|No Intervention|usual care only|Patients were provided with usual care.
11252293|NCT03024294|Other|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
11252294|NCT03024268|Experimental|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
11252295|NCT03024268|No Intervention|B: no intervention|Best medical supportive care (n=40)
11252296|NCT03024255|Experimental|BBI-4000 Concentration 1|Low Concentration
11252297|NCT03024255|Experimental|BBI-4000 Concentration 2|Medium Concentration
11252298|NCT03024255|Experimental|BBI-4000 Concentration 3|High Concentration
11252299|NCT03024255|Placebo Comparator|Vehicle|Vehicle (Placebo)
11252300|NCT03024242|Experimental|Tight vaginoscope|The vaginoscope was extracted and loaded inside a thick rubber ring before its reinsertion inside the vagina again. To avoid leakage from the center of the thick rubber ring, the vaginoscopy is inserted through a premade central cruciate incision.
11252301|NCT03024229|Other|LifePort® perfusion machine|Metabolomic analysis of the preservation fluid of the graft, donor and recipient urine by nuclear magnetic resonance spectroscopy, and if possible by liquid and gas chromatography coupled with mass spectrometry.
11252302|NCT03024216|Experimental|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
11252303|NCT03024216|Experimental|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
11252304|NCT03024203|Experimental|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
11252305|NCT03024203|Experimental|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
11252306|NCT03024190|Experimental|with Kinesiotaping|"stretching exercises combined with Kinesiotaping
~regular OT rehabilitation program for 3 weeks"
11252307|NCT03024190|Other|control group|"the patients will receive 15-min stretching exercises
~regular OT rehabilitation program for 3 weeks"
11252308|NCT03024177|Experimental|Vapendavir 528 mg|
11252309|NCT03024177|Placebo Comparator|Placebo|
11252310|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
11252311|NCT03024151|Active Comparator|T4/T3 combination replacement|Comthyroid
11252312|NCT03024151|Active Comparator|T4 mono replacement|Synthroid
11252313|NCT03024138||Repeat CT|
11252314|NCT03024125|Experimental|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
11252315|NCT03024125|Placebo Comparator|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
11252316|NCT03024112|Experimental|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
11252317|NCT03024112|Active Comparator|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
11252318|NCT03024099|Experimental|Hippotherapy once a week|Hippotherapy once a week;
11252319|NCT03024099|Experimental|Hippotherapy twice a week|hippotherapy twice a week
11252320|NCT03024086|Experimental|DWJ1252|DWJ1252 + Placebo of Gasmotin
11252321|NCT03024086|Active Comparator|Gasmotin|Gasmotin + Placebo of DWJ1252
11252322|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
11252323|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
11252324|NCT03024060|Experimental|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
11252325|NCT03024060|Experimental|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
11252326|NCT03024060|Placebo Comparator|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
11252327|NCT03024034|Active Comparator|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
11252328|NCT03024034|Active Comparator|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
11252329|NCT03024034|Active Comparator|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
11252330|NCT03024034|Active Comparator|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
11252331|NCT03024034|Active Comparator|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
11252332|NCT03024034|Active Comparator|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
11252333|NCT03024034|Active Comparator|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
11252334|NCT03024008|Experimental|Intervention Arm|"Clinical Interventions:
~Blood tests: complete blood count, full blood chemistry and biochemistry including phosphate, alkaline phosphatase, calcium, renal and liver function, and coagulation. Serology tests: HIV, Hepatitis B, Hepatitis C.
~Xray
~Urine Test
~CT
~Liposuction - harvest of 50-300ml autologous adipose tissue from the subject's abdomen
~Single transplantation of Investigational Medicinal Product BonoFill-II into long bone extra-articular comminuted fracture or large bone defect/critical gap"
11252335|NCT03023995|Experimental|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
11252336|NCT03023995|Active Comparator|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
11252337|NCT03023982|Experimental|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
11252338|NCT03023982|Active Comparator|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
11252339|NCT03023969|Active Comparator|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
11252340|NCT03023969|Active Comparator|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
11252341|NCT03023956||ANF|anatomic neck fractures of proximal humerus
11252342|NCT03023956||SNF|surgical neck fractures of proximal humerus
11252343|NCT03023943|Experimental|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
11252344|NCT03023930|Experimental|Evidenced-based Practice Dissemination|Evaluating standard dissemination practice compared with implementation facilitation
11252345|NCT03023917|Active Comparator|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
11252346|NCT03023917|Experimental|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
11252347|NCT03023904|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
11252348|NCT03023891|Experimental|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone
~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
11252349|NCT03023878|Experimental|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.
~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.
~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
11252350|NCT03023865|Experimental|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
11252351|NCT03023852|Experimental|Panel 1: Group 1|Participants will receive Treatment A (JNJ-63623872 600 milligram (mg) (2*300 mg) oral tablets [reference]) followed by Treatment B (JNJ- 63623872 600 mg (2*300 mg) concept oral tablet formulation 1 (test 1) and then Treatment C (JNJ-63623872 600 mg (2*300 mg) concept oral tablet formulation 2 (test 2). Each treatment period will be separated 7 days washout period.
11252352|NCT03023852|Experimental|Panel 1: Group 2|Participants in Group 2 will receive Treatment A followed by Treatment C and then Treatment B with a washout period of minimum 7 days.
11252353|NCT03023852|Experimental|Panel 1: Group 3|Participants in Group 3 will receive Treatment B followed by Treatment A and then Treatment C with a washout period of minimum 7 days.
11252354|NCT03023852|Experimental|Panel 1: Group 4|Participants in Group 4 will receive Treatment B followed by Treatment C and then Treatment A with a washout period of minimum 7 days.
11252355|NCT03023852|Experimental|Panel 1: Group 5|Participants in Group 5 will receive Treatment C followed by Treatment A and then Treatment B with a washout period of minimum 7 days.
11252356|NCT03023852|Experimental|Panel 1: Group 6|Participants in Group 6 will receive Treatment C followed by Treatment B and then Treatment A with a washout period of minimum 7 days.
11252357|NCT03023852|Experimental|Panel 2: Group 7|Participants in Group 7 will receive Treatment D [JNJ-63623872/37.5 mg Oseltamivir oral fixed dose combination (FDC) tablet concept formulation (test 3)] followed by Treatment E (JNJ-63623872 600 mg, administered as 2*300 mg and Oseltamivir 75 mg, administered as 1*75 mg). Both treatment periods will be separated with a minimum of 7 days washout period.
11252358|NCT03023852|Experimental|Panel 2: Group 8|Participants in Group 8 will receive Treatment E followed by Treatment D with a washout period of minimum 7 days.
11252359|NCT03023839||Severe trauma patients|Severe Trauma patients (ISS >15) admitted to Intensive Care Unit (ICU)
11252361|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) under fasting conditions.
11252362|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
11252363|NCT03023813|Experimental|Intervention|Individualized preventive care recommendations will be distributed to subjects.
11252364|NCT03023813|No Intervention|Control|Usual care
11252365|NCT03023800|Experimental|Buckle|Macular buckling and intraocular gas (C3F8) injection.
11252366|NCT03023800|Active Comparator|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
11252367|NCT03023787|Experimental|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
11252368|NCT03023787|Placebo Comparator|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
11252369|NCT03023774|Other|neupogen|neupogen (granulocyte colony-stimulating factor) 30 IU once intrauterine at the time of ovum pickup
11252370|NCT03023761|Active Comparator|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
11252371|NCT03023761|Placebo Comparator|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
11252372|NCT03023748|Experimental|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.
~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
11252373|NCT03023722|Experimental|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
11252374|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
11252375|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
11252376|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
11252377|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
11252378|NCT03023683|Other|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
11252379|NCT03023683|Other|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
11252380|NCT03023670|Active Comparator|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
11252381|NCT03023670|Active Comparator|Group B|This group will receive low rate (4\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
11252382|NCT03023657|Experimental|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
11252383|NCT03023644|Experimental|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
11252384|NCT03023644|No Intervention|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
11252385|NCT03023631|Experimental|Prevention (Gardasil 9 vaccine)|Patients undergo standard of care allogeneic stem cell transplant. 6-12 months following transplant, patients receive recombinant human papillomavirus nonavalent vaccine IM on day 0 and at 2 and 6 months in the absence of disease progression or unacceptable toxicity.
11252386|NCT03023618|No Intervention|control group|patients before 2014, in which fluids were administered without FloTrac monitoring
11252387|NCT03023618|Active Comparator|case group|patients after 2014, after management of fluid therapy has been guided by FloTrac parameters as a standard clinical practice (NICE protocol)
11252388|NCT03023605|No Intervention|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
11252389|NCT03023605|Experimental|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.
~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
11252390|NCT03023592|Experimental|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
11252391|NCT03023579|Experimental|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
11252535|NCT03022565|Experimental|Vorinostat|"Vorinostat:
~400 mg orally, once daily for 15 days."
11252392|NCT03023566||Dotarem Enhanced MRI|All pediatric patients (< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
11252393|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
11252394|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
11252395|NCT03023540|Active Comparator|PXT3003 dose 1|Period 1, PXT3003 : Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
11252396|NCT03023540|Active Comparator|PXT3003 dose 2|"Period 1, PXT3003: Liquid oral solution (1.2 mg/mL baclofen, 0.14 mg/mL naltrexone HCl and 420 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
~Period 2, PXT3003: Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 10 mL bid (taken morning and evening with food) for 9 consecutive months"
11252397|NCT03023527|Experimental|nivo-pom-dex|Nivolumab in combination with Pomalidomide and low dose dexamethasone
11252398|NCT03023527|Experimental|nivo-pom-dex-elo|Pomalidomide in combination with Nivolumab , dexamethasone and elotuzumab
11252399|NCT03023514|Experimental|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
11252400|NCT03023514|Active Comparator|P|vaginal Progesterone
11252401|NCT03023501|Experimental|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
11252402|NCT03023501|Placebo Comparator|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
11252403|NCT03023488|Experimental|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
11252404|NCT03023475|Active Comparator|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
11252405|NCT03023475|Active Comparator|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
11252406|NCT03023462|Active Comparator|Transmuscular Quadratus lumborum Block|A single shot unilateral transmuscular Quadratus lumborum Block with Ropivacaine 7,5 mg/ml, 20 ml
11252407|NCT03023462|Active Comparator|TAP Block|A single shot unilateral TAP block with Ropivacaine 7,5 mg/ml, 20 ml
11252408|NCT03023449|Experimental|Healthy Controls|The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be called at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
11252409|NCT03023449|Experimental|Acute Ischemic Stroke|Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
11252410|NCT03023436|Experimental|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.
~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
11252411|NCT03023423|Experimental|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
11252412|NCT03023423|Experimental|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
11252413|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
11252414|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
11252415|NCT03023397|Other|Der f treated Non-smoker|
11252416|NCT03023397|Other|Der f treated Cigarette smoker|
11252417|NCT03023397|Other|Der f treated E-cig user|
11252418|NCT03023358|Experimental|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
11252419|NCT03023358|Active Comparator|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
11252420|NCT03023345|Experimental|Microwave|Microwave trans rectal focal treatment
11252421|NCT03023332|Experimental|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
11252422|NCT03023332|Experimental|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
11252423|NCT03023332|No Intervention|Control|No intervention or treatment
11252424|NCT03023332|Active Comparator|Usual care|Bipolar education
11252425|NCT03023319|Experimental|Bosutinib and Pemetrexed|Bosutinib and pemetrexed
11252426|NCT03023306|Active Comparator|preemptive group|"The preemptive group will receive the anti-emetic regimen i.v. (4 mg of ondansetron) 1h before the start of surgery. During surgery, 30 min before the end of operation, this group will receive i.v. 0.9% NaCl in equal volumes.The intervention consists of the different time points of antiemetic treatment, thus 1h before surgery vs intraopertively.
~Intervention: Antiemetic treatment 1h before surgery"
11252427|NCT03023306|Other|intraoperative group|"The preventive group will receive i.v. 0.9% NaCl 1h before surgery and ondansetron 4 mg 30 min before the end of surgery at equal volumes.
~Intervention: Antiemetic treatment intraoperatively"
11252428|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
11252429|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
11252430|NCT03023267|Experimental|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
11252431|NCT03023267|Active Comparator|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
11252432|NCT03023254|Other|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-week Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
11252433|NCT03023254|No Intervention|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
11252434|NCT03023241|Experimental|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
11252435|NCT03023228|Experimental|diabetes self-management education|Diabetes survival skills self-management education (DSME) program content was aligned with American Diabetes Association and Joint Commission suggested key areas for hospital diabetes education. Content areas were as follows: when and how to take diabetes medications; glycemic goals and self-blood glucose monitoring; definition, prevention, recognition, and treatment of hypoglycemia and hyperglycemia; what to do before you see the dietitian; sick day management; and when to call the doctor or go to the ED. Program content was created for delivery via either DVD or print format.
11252436|NCT03023215|Experimental|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
11252437|NCT03023215|Active Comparator|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
11252438|NCT03023215|Active Comparator|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).
~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
11252439|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.
~All standard of care functions will be performed by standard procedures."
11252440|NCT03023189|Active Comparator|Tranexamic acid|At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
11252441|NCT03023189|Placebo Comparator|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
11252442|NCT03023176|Other|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
11252443|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
11252444|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
11252445|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
11252446|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
11252447|NCT03023150|Experimental|Ischemic Preconditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
11252448|NCT03023150|Sham Comparator|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
11252536|NCT03022552||MINOCA|Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
11252449|NCT03023137|Active Comparator|Walking & dietary modification (W&D)|W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
11252450|NCT03023137|No Intervention|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
11252451|NCT03023124|Experimental|Trabectedin|trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
11252452|NCT03023124|Experimental|Adriamycin and Dacarbazine|Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
11252453|NCT03023111|Active Comparator|Sbv|"Meglumine antimoniate (Glucantime):
~Dosage: 20 mg / kg / day, intravenously, during 20 days."
11252454|NCT03023111|Experimental|Miltefosine plus placebo|Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)
11252455|NCT03023111|Experimental|Miltefosine plus GM-CSF|Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)
11252456|NCT03023098|Experimental|Drug-eluting balloon|
11252457|NCT03023098|Active Comparator|Conventional PTA|
11252458|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
11252459|NCT03023072||Phase 1|Subjects will use the incontinence pad with incontinence detection notifications turned on
11252460|NCT03023072||Phase 2|Subjects will use the incontinence pad with incontinence notification turned off
11252461|NCT03023059|Experimental|Escalating dose of carbidopa-levodopa|The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
11252462|NCT03023046|Experimental|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11252463|NCT03023033|Experimental|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
11252464|NCT03023033|Experimental|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
11252465|NCT03023033|No Intervention|Clinic group 3|Services provided under the Ministry of Health standard care
11252466|NCT03023020|Other|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).
~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
11252467|NCT03023020|Other|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).
~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
11252468|NCT03023007|Experimental|Loco-regional anaesthesia|Loco-regional anaesthesia Anesthesia technique used : loco-regional PECS for patients requiring Mastectomy; And/or Axillary node dissection ; And/or Reconstruction of breast by prosthesis
11252469|NCT03022994||NCWS patients|"Forty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2016 and February 2017 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
11252470|NCT03022994||IBS patients|"Forty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as control group. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
11252471|NCT03022981|Experimental|12 to < 18 Years Old|"PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) 400/100 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.
~Treatment Phase: SOF/VEL 400/100 mg once daily for 12 weeks."
11252472|NCT03022981|Experimental|6 to < 12 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.
~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks."
11252473|NCT03022981|Experimental|3 to < 6 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 7 days for participants who weigh < 17 kg. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.
~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 12 weeks for participants who weigh < 17 kg."
11252474|NCT03022968|Experimental|Alzheimer disease|[18F]T807 PET
11252475|NCT03022968|Experimental|Benson disease|[18F]T807 PET
11252476|NCT03022968|Experimental|Healthy volunteer|[18F]T807 PET
11252477|NCT03022955|Active Comparator|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
11252478|NCT03022955|Active Comparator|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
11252479|NCT03022955|Placebo Comparator|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
11252480|NCT03022955|Placebo Comparator|White chocolate: Physiological Measurement|150 g white chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
11252481|NCT03022942|Experimental|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
11252482|NCT03022942|Active Comparator|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
11252483|NCT03022929|No Intervention|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
11252484|NCT03022929|Experimental|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
11252485|NCT03022916|Active Comparator|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
11252486|NCT03022916|Placebo Comparator|Nail Polish Only|Both big toes will use nail polish only
11252487|NCT03022916|Active Comparator|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
11252488|NCT03022916|Active Comparator|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
11252489|NCT03022903|Other|Photodynamic Therapy (PDT)|PDT with ALA (photosensitizer) for 3 hours
11252490|NCT03022890|Experimental|Hatha yoga|12 weeks of hatha yoga classes, once per week
11252491|NCT03022890|Placebo Comparator|Health education|12 weeks of health education classes, once per week
11252492|NCT03022877|Placebo Comparator|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
11252493|NCT03022877|Active Comparator|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
11252494|NCT03022877|Active Comparator|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
11252495|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
11252496|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
11252497|NCT03022851|Experimental|Occlutech AFR Device|Patients who will get the AFR Device implantation
11252498|NCT03022838|Active Comparator|Caffeine|Caffeine tablets (Recip) 100 mg, 300-800 mg
11252499|NCT03022838|Placebo Comparator|Placebo|Placebo tablets
11252500|NCT03022825|Experimental|BCG+ALT-803|
11252501|NCT03022812|Active Comparator|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
11252502|NCT03022812|Experimental|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
11252503|NCT03022799|Experimental|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
11252504|NCT03022799|Placebo Comparator|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
11252983|NCT03019510|Placebo Comparator|no exercise|Subjects will be studied from 6 pm to 7 am following 48 hr of no exercise
11252505|NCT03022786|No Intervention|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
11252506|NCT03022786|No Intervention|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.
~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
11252507|NCT03022786|Other|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
11252508|NCT03022773|Other|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
11252509|NCT03022760|Active Comparator|Work-related measures|"One-day training for GP:s and rehabilitation coordinators
~A treatment protocol which includes contact with the patient's employer
~Clinical support from the Institute of Stress Medicine"
11252510|NCT03022760|No Intervention|Treatment as usual|
11252511|NCT03022747|Active Comparator|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
11252512|NCT03022747|Experimental|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
11252513|NCT03022734|Experimental|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
11252514|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.
~No interventions are planned."
11252515|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.
~No interventions are planned."
11252516|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.
~no interventions are planned."
11252517|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.
~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:
~Tetralogy of Fallot
~Truncus Arteriosus
~Pulmonary Atresia
~Transposition of Great Arteries with Ventricular Septal Defect
~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes
~In addition, the PV conduit can be used for the following indications:
~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).
~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
11252518|NCT03022695|Experimental|Treatment with high-intensity focused ultrasound|
11252519|NCT03022682||IDEO Cohort|"Adipose tissue samples are collected from all subjects, including aspirational subcutaneous biopsies from nonsurgical subjects and excisional biopsies, performed intra-operatively by surgical collaborators as required.
~Participants also undergo anthropometric measurements, stool collection, blood sample collection for circulating blood cells, serum, and plasma.
~Dual-energy x-ray absorptiometry (DXA) scan for amount and distribution of body fat as well as bone density is performed.
~Study subjects complete validated questionnaire inventories to measure bio-behavioral issues such as depression, stress, health locus of control, and dietary habits."
11252520|NCT03022669|Experimental|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
11252521|NCT03022669|Experimental|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
11252522|NCT03022669|Experimental|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
11252523|NCT03022656|Active Comparator|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
11252524|NCT03022656|Active Comparator|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
11252525|NCT03022643|No Intervention|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
11252526|NCT03022643|No Intervention|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
11252527|NCT03022643|Experimental|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
11252528|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
11252529|NCT03022630|Other|Usual hepatic care|Usual hepatic care
11252530|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
11252531|NCT03022604|Experimental|C4/Generation 4|12 grams of C4/Generation 4 Extreme
11252532|NCT03022604|Active Comparator|C450X|12 grams of C4X (150% of regular dose)
11252533|NCT03022604|Placebo Comparator|Placebo|12 grams of flavored dextrose
11252534|NCT03022578|Experimental|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
11252537|NCT03022552||MI-CAD|Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
11252538|NCT03022552||CATH-NOCA|Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
11252539|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
11252540|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
11252541|NCT03022513|Active Comparator|NCWS patients|Fifty consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
11252542|NCT03022513|No Intervention|CD patients|Fifty sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as first control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
11252543|NCT03022513|No Intervention|IBS patients|Fifty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as second control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo.
11252544|NCT03022500|Experimental|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
11252545|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for at least 12 months for endpoints.
11252546|NCT03022474|Experimental|Intervention group|
11252547|NCT03022474|No Intervention|Control group|
11252548|NCT03022461||Ongoing HM3 CE Mark study patients|The study will include the ongoing HM3 CE Mark study patients that have consented to continue the long term follow-up data collection.
11252549|NCT03022448||Treatment Group|Trabectedin will be used according to the local SmPC. Modification of the treatment schedule should follow the standard medical practice at the discretion of the treating physician and is not part of this Observational Plan.
11252550|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
11252551|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
11252552|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
11252553|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
11252554|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
11252555|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
11252556|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
11252557|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
11252558|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
11252559|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
11252560|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
11252561|NCT03022409|Experimental|AZD6738|AZD6738 (160 mg) tablet twice daily continuous dosing for a minimum of 9 days and a maximum of 21 days.
11252562|NCT03022409|Experimental|Olaparib|Olaparib (300 mg) tablets administered orally twice daily continuously for a minimum of 9 days and a maximum of 21 days.
11252563|NCT03022396|Other|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
11252564|NCT03022396|Other|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
11252565|NCT03022396|Other|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
11252566|NCT03022396|Other|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
11252567|NCT03022396|Other|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
11252568|NCT03022396|Other|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
11252569|NCT03022383|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the DRI OCT Triton Plus device
11252570|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
11252571|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
11252572|NCT03022344|Sham Comparator|Healthy|Patients in this cohort consist of 100 healthy patients
11252573|NCT03022344|Sham Comparator|Diabetes mellitus|Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
11252574|NCT03022331||Observational|
11252575|NCT03022318|Experimental|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
11252576|NCT03022318|Experimental|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
11252577|NCT03022305|Experimental|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
11252578|NCT03022305|Experimental|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
11252579|NCT03022305|No Intervention|Group three - no treatment|No physical therapy treatment will be given to this group.
11252580|NCT03022292|Experimental|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
11252581|NCT03022279|Active Comparator|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
11252582|NCT03022279|Active Comparator|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
11252583|NCT03022266|Experimental|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
11252584|NCT03022266|No Intervention|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
11252585|NCT03022253|Experimental|Liberal Platelet transfusion group|"Platelet transfusion to maintain a platelet count above 1,00,000 per microliter until one of the endpoints is met.
~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:
~Ibuprofen:
~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
~Paracetamol:
~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
11252586|NCT03022253|Active Comparator|Restrictive platelet transfusion group|"Platelet transfusion for standard criteria.
~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:
~Ibuprofen:
~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
~Paracetamol:
~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
11252587|NCT03022240|Experimental|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
11252588|NCT03022240|Experimental|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
11252589|NCT03022227|Experimental|group A start with the remote session followed by on site|
11252590|NCT03022227|Active Comparator|group B start with on site followed by telemedecine|
11252591|NCT03022214|Experimental|Placebo|5 capsules of placebo (microcrystalline cellulose) taken once in the morning with breakfast and once in the evening with dinner for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal
11252592|NCT03022214|Experimental|Intervention|"For presentation to volunteers, the daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:
~EnduraCell broccoli sprout powder: 3 capsules
~Bulk Powders Green tea extract: 1 capsule
~Bulk Powders Cinnamon Bark Extract: 1 capsule to be taken for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal"
11252593|NCT03022201|Experimental|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
11252594|NCT03022201|Active Comparator|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
11252595|NCT03022188||Observational|Observational
11252632|NCT03021928|Experimental|228 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
11252596|NCT03022175|Experimental|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.
~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.
~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
11252597|NCT03022175|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).
~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.
~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
11252598|NCT03022149|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
11252599|NCT03022149|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
11252600|NCT03022136|Experimental|Epidural Block|Epidural block for patients undergoing urological surgery
11252601|NCT03022123|Experimental|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
11252602|NCT03022123|Active Comparator|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
11252603|NCT03022110|Active Comparator|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
11252604|NCT03022110|Experimental|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
11252605|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
11252606|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
11252607|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
11252608|NCT03022097|Placebo Comparator|Placebo|Placebo
11252609|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
11252610|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
11252611|NCT03022071|Experimental|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
11252612|NCT03022071|Active Comparator|Psychodynamic psychotherapy|The included patients will receive time-limited psychodynamic psychotherapy for 28 weeks.
11252613|NCT03022058|Experimental|Patients with type 1 diabetes mellitus|
11252614|NCT03022045|Experimental|Risankizumab 75 mg|Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
11252615|NCT03022045|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
11252616|NCT03022032|Experimental|Comparing Steps Collected by Accelerometer|"10 patients will be enrolled in stage 1 to refine the HOPE App intervention
~All participants will receive :
~HOPE App
~The Fitbit Zip
~The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
11252617|NCT03022032|Other|Usual care|"Stage 2 will consist of arm 2-5 and will enroll 100 patients randomized.
~Usual care
~The app will also collect passive data from the smartphone"
11252618|NCT03022032|Experimental|Wearable accelerometer|"Participants will be asked to wear the Fitbit
~The Hope App will measure daily steps
~The app will also collect passive data from the smartphone"
11252619|NCT03022032|Experimental|Refined smartphone app|"Participants will be prompted to answer questions about their quality of life and physical health daily
~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.
~The app will also collect passive data from the smartphone"
11252620|NCT03022032|Experimental|Refined smartphone app and accelerometer|"Participants will be prompted to answer questions about their quality of life and physical health daily
~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.
~Participants will be asked to wear the Fitbit
~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
11252621|NCT03022019|No Intervention|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
11252622|NCT03022019|Experimental|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
11252623|NCT03022006|Other|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
11252624|NCT03021993|Experimental|Nivolumab|Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
11252625|NCT03021980|Experimental|SuperFIT|This is the intervention group. They will receive the intervention SuperFIT.
11252626|NCT03021980|No Intervention|Control|This is the control group. Participants will receive 'care as usual' in this arm.
11252627|NCT03021954|Experimental|Platelet rich plasma|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
11252628|NCT03021954|No Intervention|Control|No intervention given, patient will only get local anesthesia injection before perineoraphy
11252629|NCT03021941|Other|Elelyso 60 units/kg|All patients receive 60 units/kg of Elelyso.
11252630|NCT03021928|Experimental|60 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
11252631|NCT03021928|Experimental|132 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
11252633|NCT03021928|Experimental|324 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
11252634|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
11252635|NCT03021902|Experimental|IV amino acid + in-bed cycle ergometry|Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise
11252636|NCT03021902|No Intervention|Usual care|Participants randomized to the usual care arm will receive usual care protein and exercise.
11252637|NCT03021889|Experimental|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
11252638|NCT03021889|Other|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
11252639|NCT03021876|Placebo Comparator|ordinary group|usual intake prior to liver surgery
11252640|NCT03021876|Active Comparator|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
11252641|NCT03021863|Active Comparator|Group A Reminder|Tone of reminder email (duty 14 days followed by duty for non-responders 28 days)
11252642|NCT03021863|Active Comparator|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement for non-responders 28 days)
11252643|NCT03021863|Active Comparator|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
11252644|NCT03021863|Active Comparator|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
11252645|NCT03021863|Active Comparator|Group E Reminder|Tone of reminder email (generic reminders at 14 days followed by generic for non-responders 28 days)
11252646|NCT03021863|Active Comparator|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
11252647|NCT03021863|Active Comparator|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
11252648|NCT03021863|Active Comparator|Group H Reminder|Tone of reminder email (duty 14 days followed by generic for non-responders 28 days)
11252649|NCT03021863|Active Comparator|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic for non-responders 28 days)
11252650|NCT03021850|Active Comparator|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
11252651|NCT03021850|Active Comparator|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
11252652|NCT03021850|Other|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
11252653|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
11252654|NCT03021824||Moderate-Severe ARDS|All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.
11252655|NCT03021811|Other|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
11252656|NCT03021785|Experimental|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
11252657|NCT03021785|Experimental|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
11252658|NCT03021785|Experimental|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
11252659|NCT03021772|Active Comparator|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
11252660|NCT03021772|Active Comparator|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
11252661|NCT03021759|No Intervention|Control|No intervention
11252662|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
11252663|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
11252687|NCT03021616|Placebo Comparator|placebo control|32oz placebo control drink
11252664|NCT03021746|Experimental|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
11252665|NCT03021746|Experimental|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
11252666|NCT03021746|Experimental|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
11252667|NCT03021733||Non-operative|Patients whom elected non-operative treatment
11252668|NCT03021733||Operative|Patients whom elected operative treatment
11252669|NCT03021720|Active Comparator|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
11252670|NCT03021720|Experimental|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
11252671|NCT03021694|Experimental|Young Males Week 1|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
11252672|NCT03021694|Experimental|Young Males Week 3|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
11252673|NCT03021694|Experimental|Young Males Week 5|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
11252674|NCT03021681|Other|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
11252675|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
11252676|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
11252677|NCT03021655|Experimental|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
11252678|NCT03021655|Experimental|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
11252679|NCT03021655|Other|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
11252680|NCT03021642|Experimental|First Tepotinib Test, Then Tepotinib Reference|
11252681|NCT03021642|Experimental|First Tepotinib Reference, Then Tepotinib Test|
11252682|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
11252683|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
11252684|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
11252685|NCT03021616|Experimental|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
11252686|NCT03021616|Active Comparator|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
11252688|NCT03021603|Experimental|Intervention Group|"This is a 4-week Brief Hope Intervention
~Four sessions in total:
~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.
~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
11252689|NCT03021603|Experimental|Control Group|"Standard care:
~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
11252690|NCT03021590|Experimental|Clarithromycin :Concomitant Therapy|Amoxicillin 1000 mg Tablets, Clarithromycin 500 mg Tablets , Tinidazole 500 mg Tablets and Esomeprazole 20 mg Capsule each every 12 hours for 14 days all by mouth
11252691|NCT03021590|Active Comparator|Levofloxacin :Concomitant Therapy|Levofloxacin 500 mg Tablets Amoxicillin 1000 mg Tablets,Tinidazole 500 mg Tablets and Esomeprazole 20 mg each every 12 hours for 14 days all by mouth
11252692|NCT03021577|Active Comparator|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
11252693|NCT03021577|Active Comparator|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
11252694|NCT03021551||BMI>30, <40 m/kg2|Obese
11252695|NCT03021551||BMI >18.5 m/kg2, <25 m/kg2|Normal BMI
11252696|NCT03021538||Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
11252697|NCT03021538||Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
11252698|NCT03021525|Experimental|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
11252699|NCT03021525|Active Comparator|Control|Patients in the control group will be treated according to established basic treatment goals.
11252700|NCT03021512||Group 1 (BFG)|(Bifocal group). Subjects that underwent bifocal intraocular lenses implantation. (ie. Phaco with Restor intervention).
11252701|NCT03021512||Group 2 (TFG)|(Trifocal group). Subjects that underwent trifocal intraocular lenses implantation. (ie. Phaco with Panoptix intervention).
11252702|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg BID
11252703|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules BID
11252704|NCT03021486|Experimental|Group I (haloperidol)|Patients receive haloperidol IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
11252705|NCT03021486|Experimental|Group II (chlorpromazine)|Patients receive chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
11252706|NCT03021486|Experimental|Group III (haloperidol, chlorpromazine)|Patients receive haloperidol and chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
11252707|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11252708|NCT03021434|Experimental|Standard Testing|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
11252709|NCT03021434|Experimental|Test Kits|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. Data collectors will demonstrate the use of the low-cost microbiological water test kits and test household stored drinking water. A study team member will return to the household within 72 hours and review the household-specific water quality information from the initial test with household members. Households will be given 10 water test kits to use at their discretion over the 1-2 month follow up period. They will be appropriately trained in how to both perform the test and interpret the results. Households will also review information on safe water handling, storage, and use behaviours.
11252710|NCT03021434|Active Comparator|Comparison|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Results from this analysis will be returned to the household at project endline. A study team member will return to the household within 72 hours to review the information on safe water handling, storage, and use behaviours.
11252711|NCT03021421|Sham Comparator|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
11252712|NCT03021421|Active Comparator|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)
~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
11252713|NCT03021408|Experimental|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
11252714|NCT03021408|Experimental|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
11252715|NCT03021408|Experimental|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
11252716|NCT03021395|Experimental|MRD-positive|MRD-positive patients receive Decitabine regimen.
11252717|NCT03021395|No Intervention|MRD-negative|MRD-negative patients receive no intervention.
11252718|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
11252719|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and <1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
11252720|NCT03021369|Active Comparator|Pleural drainage system Medela|These patients receive the digital Medela system
11252721|NCT03021369|Active Comparator|Pleural drainage system Ocean|These patients receive the analogue Maquet system
11252722|NCT03021356|Active Comparator|Trifecta aortic xenograft|The Trifecta aortic xenograft is implanted in these patients.
11252723|NCT03021356|Active Comparator|Magna Ease aortic xenograft|The Magna Ease aortic xenograft is implanted in these patients.
11252724|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
11252725|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
11252726|NCT03021330|Active Comparator|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
11252727|NCT03021330|Experimental|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
11252728|NCT03021317|Experimental|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
11252729|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
11252730|NCT03021291|Experimental|Gelesis100|Gelesis100 (2.25 g) twice daily
11252731|NCT03021278|Experimental|Saline Injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
11252732|NCT03021278|Experimental|Sham Injection|In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
11252733|NCT03021278|No Intervention|Control Group|The control group will not receive any kind of pain or pinprick sensation.
11252734|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
11252735|NCT03021252|Experimental|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
11252736|NCT03021252|Sham Comparator|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
11252737|NCT03021239|Active Comparator|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
11252738|NCT03021239|Active Comparator|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
11252739|NCT03021226|Experimental|Group I: Adults|Participants in Group I will be adults ages 20 to 24 years of age, 50 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
11252740|NCT03021226|No Intervention|Group II: No Intervention: Adults|Participants in Group II will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
11252741|NCT03021200|Experimental|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
11252742|NCT03021200|Experimental|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
11252743|NCT03021200|Experimental|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
11252744|NCT03021187|Experimental|Semaglutide 3 mg|
11252745|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg|
11252746|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg + 14 mg|
11252747|NCT03021187|Placebo Comparator|Placebo|
11252748|NCT03021174|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
11252749|NCT03021174|Active Comparator|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
11252750|NCT03021161|Experimental|intervention group|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).
11252751|NCT03021161|Placebo Comparator|Placebo Oral Capsule|The control group will receive once daily similar capsules containing placebo.
11252752|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
11252753|NCT03021135|Active Comparator|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
11252754|NCT03021135|Experimental|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
11252755|NCT03021122|Experimental|Arm A (PedAMINES™ / Conventional Method)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of PedAMINES™ first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of a Conventional Method.
11252756|NCT03021122|Active Comparator|Arm B (Conventional Method / PedAMINES™)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of a Conventional Method first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of PedAMINES™.
11252757|NCT03021109|Experimental|Inferior vena cava diameteres|Measurement of inferior vena cava diameters with ultrasound
11252758|NCT03021083|Experimental|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.
~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.
~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
11252759|NCT03021070|Experimental|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
11252760|NCT03021070|No Intervention|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
11252761|NCT03021057|Experimental|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
11252762|NCT03021044|Other|STANDARD OF CARE|The standard of care group will be recommended about medications and a correct life style (physical activity, low salt and low fat diet, no smoking) in order to prevent cardiovascular events. In this 15-minutes talk study doctor will explain to patients and relatives the importance of aerobic physical activity (30-60 minutes daily, moderate intensity, for example speedy walking, for at least 5 days/weekly) with the aim of reducing cardiovascular risk. Patients will also receive a brochure with clear explanations. Study doctor and study coordinator will be helpful for any question and they will ensure that patients and relatives understand the importance of physical activity for cardiovascular health.
11252763|NCT03021044|Experimental|PHYSICAL ACTIVITY INTERVENTION|Besides standard of care, the experimental group will participate to a program of physical activity intervention. Following hospital discharge, participants in stable clinical conditions will be referred by their cardiologist to the exercise-based secondary prevention program. All exercise testing and training sessions will be performed without discontinuing the prescribed medications. On admission to the program, and quarterly during follow-up, each patient will perform a 1-km treadmill walk test as previously described (1k-TWT).
11252764|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
11252765|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
11252766|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
11252767|NCT03021005|Experimental|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
11252768|NCT03021005|No Intervention|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
11252769|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
11252770|NCT03020979|Experimental|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
11252771|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
11252772|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
11252773|NCT03020953|Experimental|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
11252774|NCT03020953|Active Comparator|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
11252775|NCT03020927|Active Comparator|Therapist Delivered|Children in the therapist-delivered condition will receive two, 60-minute long sessions of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. Parents will be permitted to observe sessions via live video, but will not be directly involved in intervention.
11252776|NCT03020927|Experimental|Parent + Therapist Delivered|Children in the parent + therapist-delivered condition will receive one, 60-minute long session of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. During the same period of time, parents/guardians of children will receive one, 60-minute long parent education session per week with graduate and post-graduate research staff, aimed at teaching parents to implement Reciprocal Imitation Training at home with the child.
11252777|NCT03020914|Experimental|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
11252920|NCT03020017|Experimental|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
11252778|NCT03020914|No Intervention|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
11252779|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.
~Marker located during surgery using the Sentimag system, and removed with the lesion."
11252780|NCT03020875|Active Comparator|PO Acetaminophen|"Preop:
~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.
~Postop:
~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:
~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.
~Postop supplemental pain medications:
~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
11252781|NCT03020875|Active Comparator|Intravenous Acetaminophen|"Preop:
~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.
~Postop:
~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:
~• IV Acetaminophen 1,000 mg [100 ml] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.
~Postop supplemental pain medications:
~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
11252782|NCT03020862|Experimental|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.
~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
11252783|NCT03020862|Experimental|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
11252784|NCT03020836|Other|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
11252785|NCT03020836|Other|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
11252786|NCT03020823|Experimental|SCB01A alone|intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
11252787|NCT03020797|Experimental|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
11252788|NCT03020797|Placebo Comparator|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
11252789|NCT03020784|Placebo Comparator|Placebo|IV placebo
11252790|NCT03020784|Experimental|PF-06818883|Experimental drug
11252791|NCT03020771|Active Comparator|5 mcg IM|
11252792|NCT03020771|Active Comparator|5 mcg SC|
11252793|NCT03020771|Placebo Comparator|5 mcg IM control|0.9% NaCl Solution
11252794|NCT03020771|Placebo Comparator|5 mcg SC control|0.9% NaCl Solution
11252795|NCT03020771|Active Comparator|10 mcg IM|
11252796|NCT03020771|Active Comparator|10 mcg SC|
11252797|NCT03020758|Experimental|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
11252798|NCT03020758|Experimental|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
11252799|NCT03020745|Experimental|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
11252800|NCT03020745|Experimental|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
11252801|NCT03020745|Experimental|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
11252802|NCT03020745|Experimental|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
11252803|NCT03020745|Experimental|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 <= 240 mg or matching placebo
11252804|NCT03020745|Experimental|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
11252839|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
11252805|NCT03020732|Experimental|test groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups.In test groups, a special centrifuge machine(Medifuge) and subjects venous blood were used to obtain Concentrated growth factor. A special compress was used to transform Concentrated growth factor membrane.
11252806|NCT03020732|Active Comparator|control groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups. In control groups, subepithelial connective tissue graft was taken from the palatal canine teeth-first molar teeth area with a trap door technique according to the width of the exposed root surface and the adjacent bone margins. The graft's thickness was adjusted between 1.5 and 2 mm.
11252807|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
11252808|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
11252809|NCT03020706|Experimental|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
11252810|NCT03020706|No Intervention|Control|No intervention
11252811|NCT03020693|Experimental|Invasive electrostimulation combined with exercises.|Dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to therapeutic intensity) combined with exercises program.
11252812|NCT03020693|Active Comparator|Placebo electrostimulation and exercises.|Sham dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to non-therapeutic intensity) with surface electrodes combined with exercises program.
11252813|NCT03020680|Experimental|ubiquinol|It is the reduced form of coenzyme Q10
11252814|NCT03020680|Active Comparator|ubiquinone|It is the oxidized form of coenzyme Q10
11252815|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
11252816|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
11252817|NCT03020654|Experimental|Treatment group|Virtual environment with fast moving objects these are graded in intensity from 1-7. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
11252818|NCT03020654|Active Comparator|Control group|Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
11252819|NCT03020641|Experimental|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
11252820|NCT03020641|Active Comparator|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
11252821|NCT03020628|Experimental|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
11252822|NCT03020628|Active Comparator|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
11252823|NCT03020615|Active Comparator|Stable Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
11252824|NCT03020615|Experimental|Intensive Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
11252825|NCT03020602|Experimental|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11252826|NCT03020589|Experimental|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
11252827|NCT03020589|No Intervention|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
11252828|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
11252829|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
11252830|NCT03020563|Active Comparator|Liposomal Bupivacaine|Time release Bupivacaine
11252831|NCT03020563|Placebo Comparator|Bupivacaine|Immediate Acting Bupivacaine
11252832|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
11252833|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
11252834|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
11252835|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
11252836|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
11252837|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
11252838|NCT03020511|Other|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
11252840|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
11252841|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
11252842|NCT03020485|Experimental|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
11252843|NCT03020485|Experimental|Sucrose|50g of sucrose dissolved in 250ml of water
11252844|NCT03020472|Experimental|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
11252845|NCT03020459|Experimental|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
11252846|NCT03020459|Active Comparator|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
11252847|NCT03020446|Experimental|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
11252848|NCT03020433|Active Comparator|rTMS Contralesional M1 Inhibition|
11252849|NCT03020433|Active Comparator|rTMS Contralesional PMC facilitation|
11252850|NCT03020433|Active Comparator|rTMS Ipsilesional PMC facilitation|
11252851|NCT03020433|Sham Comparator|rTMS Sham at Ipsilesional M1|
11252852|NCT03020420|Experimental|treatment arm|receive cicatricell cream
11252853|NCT03020420|No Intervention|control arm|to treatment
11252854|NCT03020407|Experimental|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI > 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI > 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI < 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
11252855|NCT03020407|No Intervention|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
11252856|NCT03020394||Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
11252857|NCT03020394||Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
11252858|NCT03020394||High flow nasal cannula|High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
11252859|NCT03020381||Cognitively Normal (Control Group)|Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
11252860|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
11252861|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 60 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
11252862|NCT03020368|Experimental|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
11252863|NCT03020368|Active Comparator|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
11252864|NCT03020355|Experimental|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
11252865|NCT03020355|Active Comparator|not Placental Blood Drainage|In the control group, the clamped cord will not released.
11252866|NCT03020329|Experimental|Paclitaxel liposome, Cisplatin, 5-Fu,|Patients receive paclitaxel liposome(135mg/m2 on day 1), cisplatin (75mg/m2 on day 1,Separate injection on day 1 to 3) and fluorouracil (3750mg/m2 CIV 120h) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
11252950|NCT03019770|Experimental|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
11252867|NCT03020316|No Intervention|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.
~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
11252868|NCT03020316|Active Comparator|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.
~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
11252869|NCT03020316|Active Comparator|Peer Mentor|"We are no longer recruiting in this arm.
~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
11252870|NCT03020303|Placebo Comparator|Placebo Oral Tablet|A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance
11252871|NCT03020303|Active Comparator|Spironolactone 25 MG Tablet|25 mg of active spironolactone in tablet form
11252872|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
11252873|NCT03020277|Other|ASD children families|
11252874|NCT03020264|Experimental|Patients older than 75 years|Collection of hypoglycaemia épisodes with the glycemic sensor FREESTYLE Libre Pro
11252875|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
11252876|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
11252877|NCT03020238|Placebo Comparator|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
11252878|NCT03020238|Active Comparator|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
11252879|NCT03020225|Active Comparator|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
11252880|NCT03020225|Experimental|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
11252881|NCT03020225|Experimental|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
11252882|NCT03020212|Active Comparator|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
11252883|NCT03020212|No Intervention|Not oxygen|No intervention ( no therapy with oxygen)
11252884|NCT03020199|Experimental|A1|80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.
11252885|NCT03020199|Active Comparator|B1|80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.
11252886|NCT03020199|Experimental|A2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
11252887|NCT03020199|Experimental|C1|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)
11252888|NCT03020199|Experimental|C2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
11252889|NCT03020186|Placebo Comparator|Physical activity|Physical activity (PA) group will receive free gym memberships and the instruction necessary to engage in moderate-intensity physical activity, ~80% of which will have an aerobic component. The participants will get basic health promoting guideline for healthy diet .
11252890|NCT03020186|Experimental|Physical activity+ MED diet|On top of the PA intervention described in Arm 1, the participants will be guided for moderate weight loss with a traditional Mediterranean (MED) diet, low in simple carbohydrates. The diet will include 1oz/day of walnuts that will be provided free of charge.
11252891|NCT03020186|Experimental|Physical activity+ green-MED diet|"On top of the PA intervention described in Arm 1, the participants will guided for moderate weight loss with a MED diet, low in simple carbohydrates that will be rich in plants and polyphenols and low in processed meat. The diet will include 1oz/day of walnuts, 3-4 cups/day of green tea and ~500cc green shake/dinner based on specific strain of duckweed [Wolffia globose, Mankai], an aquatic plant, which might serve as a plant protein source. All the above will be provided free of charge."
11252892|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
11252893|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
11252894|NCT03020160|Experimental|Emicizumab: Expansion Part|Participants will received SC emicizumab at a loading dose of 3 mg/kg every week for initial 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
11252895|NCT03020160|Experimental|Emicizumab: PK Run-in Part|Participants will received SC emicizumab at a dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
11252896|NCT03020147||early BCG|Children received BCG soon after their birth between 2008 and 2013.
11252897|NCT03020147||delayed BCG|Children received BCG when they are 2,5kg between 2008 and 2013.
11252898|NCT03020134|Experimental|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
11252899|NCT03020134|Placebo Comparator|Placebo Group|Placebo
11252919|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
11252900|NCT03020121|Experimental|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
11252901|NCT03020108||Group 1|The group 1 will comprise of 30 patients with benign ovarian cysts such as mature teratoma or simple serous cysts on ultrasound examination.
11252902|NCT03020108||Group 2|The group 2 will comprise of 30 patients with diagnosis of stage 1-2 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
11252903|NCT03020108||Group 3|The group 3 will comprise of 30 patients with diagnosis of stage 3-4 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
11252904|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
11252905|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
11252906|NCT03020069|Experimental|Glucose Meter|Continuing Glucose Monitoring Device
11252907|NCT03020069|Active Comparator|No Glucose Meter|Average Blood glucose measure
11252908|NCT03020056|Placebo Comparator|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
11252909|NCT03020056|Experimental|expedited surgery|Cataract surgery will be performed within 4 weeks.
11252910|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.
~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
11252911|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1
~And: No VHR characteristics
~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
11252912|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)
~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
11252913|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~All treatment completed 24 months from date of complete remission."
11252914|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~All treatment completed 24 months from date of complete remission."
11252915|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~All treatment completed 24 months from date of complete remission."
11252916|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)
~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:
~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).
~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
11252917|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
11252918|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL
11252921|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
11252922|NCT03019991|Experimental|PK Group (Danoprevir,Ritonavir)|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;
11252923|NCT03019991|Placebo Comparator|Placebo Group|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;
11252924|NCT03019965|Active Comparator|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
11252925|NCT03019965|Experimental|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
11252926|NCT03019965|Active Comparator|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
11252927|NCT03019965|Experimental|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
11252928|NCT03019965|Active Comparator|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
11252929|NCT03019965|Experimental|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
11252930|NCT03019939|Experimental|Prevention (isavuconazole)|Patients receive isavuconazole PO every 8 hours for 6 doses and then QD or IV over 1 hour every 8 hours for 6 doses and then QD for up to 4 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
11252931|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
11252932|NCT03019861|Active Comparator|Ayurvedic nutritional counseling|Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.
11252933|NCT03019861|Active Comparator|Conventional nutritional counseling|Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.
11252934|NCT03019848|Experimental|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
11252935|NCT03019848|Placebo Comparator|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
11252936|NCT03019835|Active Comparator|GROUP 1|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
11252937|NCT03019835|Active Comparator|GROUP 2|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
11252938|NCT03019835|Active Comparator|GROUP 3|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
11252939|NCT03019835|Active Comparator|GROUP 4|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
11252940|NCT03019835|Active Comparator|CONTROL|A control group : not receiving an antagonist (spontaneous recovery)
11252941|NCT03019822|Other|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
11252942|NCT03019822|Other|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
11252943|NCT03019822|Other|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
11252944|NCT03019822|Other|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
11252945|NCT03019809|Experimental|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
11252946|NCT03019796|Placebo Comparator|NO EXERCISE TRAINING|"The participants of this arm will remain physically inactive (i.e., less than 1 day a week of exercise) during the 4 months of intervention.
~The investigators will withhold their medication during 48 h to achieve 2 conditions:
~no exercise, no medication.
~no exercise, yes medication."
11252947|NCT03019796|Experimental|EXERCISE TRAINING|"The participants of this arm will exercise during 4 months (i.e., 3 days a week during 45-60 min) at workloads individualized by percent heart rate of either continuous or intervallic aerobic exercise, with increases in workload as exercise adaptations manifest during training.
~The investigators will withhold their habitual medication during 48 h to achieve the following 2 conditions:
~c) yes exercise, no medication d) yes exercise, yes medication."
11252948|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
11252949|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
11252951|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
11252952|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
11252953|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
11252954|NCT03019744|Experimental|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
11252955|NCT03019744|Active Comparator|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
11252956|NCT03019731|Experimental|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
11252957|NCT03019718|Experimental|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
11252958|NCT03019705||Participants|Individuals with pathological health anxiety
11252959|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
11252960|NCT03019679||Study group|Patients with polycystic ovary syndrome
11252961|NCT03019679||Control group|Patients without polycyctic ovary syndrome
11252962|NCT03019666|Experimental|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
11252963|NCT03019666|Experimental|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
11252964|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
11252965|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
11252966|NCT03019640|Experimental|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
11252967|NCT03019627|Experimental|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
11252968|NCT03019627|Placebo Comparator|Vehicle|vehicle eye drops six times daily
11252969|NCT03019614|Experimental|Group 1|"Volunteers in group 1 received the following interventions:
~Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).
~Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).
~Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).
~Each administration of IMP was separated by a washout period of at least 7 days."
11252970|NCT03019614|Experimental|Group 2|"Volunteers in group 2 received the following interventions:
~Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).
~Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).
~Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).
~Each administration of IMP was separated by a washout period of at least 7 days."
11252971|NCT03019601|Experimental|Group education|Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions.
11252972|NCT03019588|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
11252973|NCT03019588|Active Comparator|Paclitaxel 80 mg/m^2|Participants receive paclitaxel 80 mg/m^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.
11252974|NCT03019575|Experimental|Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)|Participants will receive Corifollitropin alfa 100 μg (body weight ≤60 kg) or 150 μg (body weight >60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1/Week 0 through Week 64) and hCG 500-5000 IU by SC injection; first dose will be administered on the last day of Week 12 (Day 85), and treatment will continue, twice a week, from Week 13 through Week 64.
11252975|NCT03019562|Experimental|Oxycodone|4mg of oxycodone iv bolus
11252976|NCT03019562|Active Comparator|Fentanyl|50ug of fentanyl iv bolus
11252977|NCT03019549|Experimental|Rosuvastatin|Period 1: 20 mg rosuvastatin administered once orally (PO)
11252978|NCT03019549|Experimental|Lanabecestat + Rosuvastatin|Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
11252979|NCT03019536|Experimental|LY3303560 IV|Multiple doses of LY3303560 administered intravenously (IV) for up to 48 weeks, followed by a 16 week follow-up period
11252980|NCT03019536|Experimental|Placebo IV|Multiple doses of placebo administered IV for up to 48 weeks, followed by a 16 week follow-up period
11252981|NCT03019523|Placebo Comparator|Sugar Pill|Maltodextrin (~2 grams to match weight of active treatment) placebo pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
11252982|NCT03019523|Active Comparator|Caffeine Blend|75 mg caffeine, 75 mg theanine, and 2g tyrosine pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
11252984|NCT03019510|Active Comparator|morning exercise|Subjects will be studied from 6 pm to 7 am. Subjects will have exercised at 7 am on that day.
11252985|NCT03019510|Active Comparator|evening exercise|Subjects will be studied from 6 pm to 7 am. Subjects will exercise at 8 pm following dinner on the study day.
11252986|NCT03019497|Experimental|CBT-E|CBT-E refers to Cognitive Behavioral Therapy with specific modules. In the CBT-E condition and following the identification of the needs identified during the evaluation, additional strategies will be added to the CBT strategies for PTSD to address one or more of the seven related problem types that emerged as a result of the traumatic event: 1) major depression, 2) sleep disorders, 3) pain, 4) stressors, 5) inadequate social support, 6) substance use disorder, and 7) anxiety disorder.
11252987|NCT03019497|Active Comparator|CBT-C|CBT-C refers to Cognitive Behavioral Therapy without specific modules. CBT-C participants will be offered only cognitive-behavioral intervention strategies to alleviate the symptoms of each of the PTSD diagnostic criteria.
11252988|NCT03019484|Experimental|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
11252989|NCT03019484|No Intervention|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.
~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
11252990|NCT03019471||Lung cancer|Isolate Tumor DNA from the patients blood.
11252991|NCT03019471||Breast cancer|Isolate Tumor DNA from the patients blood.
11252992|NCT03019471||Colorectal cancer|Isolate Tumor DNA from the patients blood.
11252993|NCT03019471||Glioma|Isolate Tumor DNA from the patients blood.
11252994|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
11252995|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
11252996|NCT03019419|Experimental|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
11252997|NCT03019419|Experimental|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
11252998|NCT03019419|Placebo Comparator|Placebo|Once daily placebo for control for 48 weeks
11252999|NCT03019406|Experimental|avalglucosidase alfa|Administered intravenously every 2 weeks as an ascending dose cohort
11253000|NCT03019406|Active Comparator|alglucosidase alfa|administered intravenously at current stable dose (i.e. administered regularly for a minimum of 6 months immediately prior to study entry)
11253001|NCT03019393|Other|Beef|Beef topside fully cooked, 200g
11253002|NCT03019380|Experimental|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
11253003|NCT03019367|Active Comparator|Umbilical cord milking UCM|Milking the umbilical cord 4 times towards the infant at a speed of 20cm/2seconds.
11253004|NCT03019367|Active Comparator|Delayed cord clamping DCC|Delayed clamping of the umbilical cord for at least 60 seconds.
11253005|NCT03019354|Experimental|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
11253006|NCT03019354|Active Comparator|Oxygen mask|oxygen mask was used during intravenous general anesthesia
11253007|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
11253008|NCT03019302|Experimental|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
11253009|NCT03019289|Experimental|pridopidine|Pridopidine (TV-7820) capsules
11253010|NCT03019276|Experimental|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11253011|NCT03019263|Experimental|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
11253012|NCT03019263|Active Comparator|Control|Nutritional counseling
11253013|NCT03019250|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
11253014|NCT03019250|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
11253015|NCT03019237|Experimental|intranasal anti-IgE|Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
11253016|NCT03019237|Active Comparator|intranasal allergen|GMP produced rBet v 1 will be freshly diluted in sterile 0.9% sodium chloride solution (50 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
11253017|NCT03019237|Placebo Comparator|intranasal saline|Sterile 0.9% sodium chloride solution will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
11253018|NCT03019224|Placebo Comparator|Group 1|The use of desensitizing dentifrice [Sucralose (S) Control dentifrice)] in plastic tray.
11253019|NCT03019224|Experimental|Group 2|The use of desensitizing dentifrice [Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)] in plastic tray.
11253020|NCT03019224|Experimental|Group 3|The use of desensitizing dentifrice [Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)] in plastic tray.
11253021|NCT03019224|Experimental|Group 4|The use of desensitizing dentifrice [Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate] in plastic tray.
11253022|NCT03019211|Experimental|Hydrotherapy|Exercise performed in an aquatic environment. The participants will perform static/dynamic exercises (balance and resistance training) in an aquatic environment. Training volume and intensity we will increase systematically over 12 weeks.
11253023|NCT03019211|Active Comparator|Control|The participants will perform exercises (balance and resistance training) like hydrotherapy group but out of the aquatic environment, during a 12 weeks training period (3sessions/week). Training volume and intensity we will increase systematically over 12 weeks.
11253024|NCT03019198|Experimental|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
11253025|NCT03019198|Placebo Comparator|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
11253026|NCT03019185|Experimental|Phase 2 Cohort|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
11253027|NCT03019185|Active Comparator|Phase 3 Bardoxolone Cohort|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
11253028|NCT03019185|Placebo Comparator|Phase 3 Placebo Cohort|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
11253029|NCT03019172|Experimental|Lactobacillus reuteri|Women in experimental branch will receive two sachets. Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
11253030|NCT03019172|Placebo Comparator|Sachet with cranberry + placebo|Women in control branch will receive two sachets. Sachet one contains only Maltodextrin and sachet two contains instant cranberry drinkcomposed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica Both sachets should be emptied in a glass and mixed with 200 ml of cold water
11253031|NCT03019159||Tele-consulting|One visit out of two takes place with teleconsulting and the other is a face-to-face consultation
11253032|NCT03019159||No tele-consulting|
11253033|NCT03019146|Experimental|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
11253034|NCT03019146|Experimental|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
11253035|NCT03019146|Experimental|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
11253036|NCT03019146|No Intervention|Control|No intervention
11253037|NCT03019133|No Intervention|Usual Care|Usual care will be provided.
11253038|NCT03019133|Active Comparator|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
11253039|NCT03019133|Active Comparator|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
11253040|NCT03019120|Experimental|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
11253041|NCT03019094|Experimental|Treatment|Implantation of the RENOVA tibial nerve stimulation system
11253042|NCT03019081|Experimental|Anorexia nervosa-study drug|"Drug: Isoproterenol Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant. The isoproterenol dose will range from 0.1 micrograms to 4.0 micrograms and exposure during each visit will not exceed 25.0 micrograms. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
~Other Names: Isuprel"
11253043|NCT03019081|Placebo Comparator|Anorexia nervosa-placebo|"Drug: Normal Saline Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
~Other Names:
~Saline"
11253044|NCT03019055|Experimental|CAR-20/19-T cells|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion
11253103|NCT03018652|Experimental|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
11253045|NCT03019042|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 30 g/day (contain 10.1 herb materials) during entire follow up period (2 years). HGMX is composed of 10 dietary Chinese herbs (including ginseng (Renshen), tuckahoe (Fuling), coixenolide (Yiyiren), Chinese yam (Shanyao), lotus seed (Lianzi), amomum (Sharen), platycodon (Jiegen), white hyacinth bean (Baibiandou), licorice (Gancao), and orange peel (Jupi)), early rice, and oats.
11253046|NCT03019042|Placebo Comparator|placebo|Patients in this arm receive placebo, with oral dose of 30 g/day during entire follow up period (2 years). The placebo is only consist of early rice and oats.
11253047|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
11253048|NCT03019016||Robotic RC (IA)|Benign or malignant disease under going a right colectomy.
11253049|NCT03019016||Robotic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
11253050|NCT03019016||Laparoscopic RC (IA)|Patients with benign or malignant disease under going a right colectomy.
11253051|NCT03019016||Laparoscopic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
11253052|NCT03019003|Experimental|Azacitidine, Durvalumab, and Tremelimumab|Azacitidine will be administered alone in Cycle 1 and the combination of azacitidine, durvalumab, and tremelimumab therapy will be given in Cycles 2-5. Azacitidine and durvalumab will be given in Cycles 6-12.
11253053|NCT03018990|Active Comparator|Alcoholic liver fibrosis|
11253054|NCT03018990|Active Comparator|Non-alcoholic steatohepatitis|
11253055|NCT03018990|Active Comparator|Healthy control|
11253056|NCT03018977|Active Comparator|Sedative weaning protocol|We create the new sedative weaning protocol and then use the sedative weaning protocol.
11253057|NCT03018977|Placebo Comparator|Usual Care|no use sedative weaning protocol. Sedative or/and analgesic medications are adjusted base on physician
11253058|NCT03018964|Experimental|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
11253059|NCT03018964|Active Comparator|Ca-SILC|No solo surgery, operation with a camera operator in SILC
11253060|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
11253061|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
11253062|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
11253063|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
11253064|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
11253065|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.
~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.
~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
11253066|NCT03018912|Experimental|Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Investigators or research associates will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
11253067|NCT03018912|No Intervention|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
11253068|NCT03018899|Experimental|paravertebral block|patients received ultrasound guided two-segment paravertebral block for percutaneous nephrolithotomy
11253069|NCT03018899|Active Comparator|Epidural|patients received thoracic epidural anesthesia for percutaneous nephrolithotomy
11253070|NCT03018886|Other|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
11253071|NCT03018886|Experimental|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
11253072|NCT03018873|Experimental|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).
~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
11253130|NCT03018483|Active Comparator|Conventional PSV|
11253131|NCT03018483|Active Comparator|Automated PSV|
11253132|NCT03018483|Active Comparator|NAVA|
11253073|NCT03018873|Active Comparator|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
11253074|NCT03018873|No Intervention|control group|routine treatment, no RIPC
11253075|NCT03018860|Experimental|"Moderate management"|Women are encouraged by physicians to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.
11253076|NCT03018860|Active Comparator|"Intensive management"|Usual obstetrical care in France
11253077|NCT03018834|Experimental|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
11253078|NCT03018834|Placebo Comparator|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
11253079|NCT03018821|Active Comparator|Standard CMF|"Standard Chinese medical formulas (CMF) for the corresponding TCM syndromes, plus an anti-virus treatment of western drugs (such as Entecavir or Tenofovir).
~Yinchengao Decoction plus Ganlu Detoxification Pill for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao
~Chaihu Shugan San for the TCM syndrome: Liver depression and qi stagnation
~Xiaoyao powder for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
~Yiguan Decoction for the TCM syndrome: Yin deficiency of liver and kidney
~Fuzilizhong Decoction plus Jinkui Shenqi Bolus for the TCM syndrome: Yang deficiency of spleen and kidney
~Ge Xia Zhu Yu Decoction for the TCM syndrome: Internal blood stasis"
11253080|NCT03018821|Experimental|Advanced CMF|"Advanced TCM formulas for corresponding TCM syndromes provided by famous TCM doctors who were national wide known in China, plus an anti-virus western drugs (such as Entecavir or Tenofovir).
~Taohong Huazhuo Decoction for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao
~Soothe the liver and regulate qi Decoction for the TCM syndrome: Liver depression and qi stagnation
~Supplemented Ganbi Decoction for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
~Supplemented Zimu Dan for the TCM syndrome: Yin deficiency of liver and kidney
~Guifu Erxian Decoction for the TCM syndrome: Yang deficiency of spleen and kidney
~Supplemented Ganji Decoction for the TCM syndrome: Internal blood stasis"
11253081|NCT03018821|Experimental|Pure Entecavir or Tenofovir|Use an anti-virus western drug alone (such as Entecavir or Tenofovir).
11253082|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
11253083|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
11253084|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
11253085|NCT03018795|Active Comparator|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
11253086|NCT03018795|Active Comparator|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
11253087|NCT03018782|Other|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
11253088|NCT03018769||chronic SCAD|
11253089|NCT03018756|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
11253090|NCT03018756|Placebo Comparator|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
11253091|NCT03018743||dapoxetine treatment group|Consecutive patients who seek medical treatment for PE will be enrolled in the study.
11253092|NCT03018730|Experimental|PRX-102|PRX-102 infusion every 2 weeks
11253093|NCT03018717|Other|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
11253094|NCT03018717|Other|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
11253095|NCT03018704|Placebo Comparator|Placebo|a placebo control arm
11253096|NCT03018704|Experimental|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients.
11253097|NCT03018691|Experimental|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
11253098|NCT03018691|Experimental|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
11253099|NCT03018691|Placebo Comparator|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
11253100|NCT03018678||Patients with HOFH|No intervention
11253101|NCT03018665|Experimental|Exenatide and Metformin|Exenatide in Combination With Metformin
11253102|NCT03018665|Active Comparator|BIAsp30 and Metformin|BIAsp30 in Combination With Metformin
11253360|NCT03016949|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
11253104|NCT03018652|Placebo Comparator|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
11253105|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
11253106|NCT03018626|Active Comparator|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
11253107|NCT03018626|Experimental|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
11253108|NCT03018613|Active Comparator|treatment for part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.
11253109|NCT03018613|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.
11253110|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
11253111|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
11253112|NCT03018587|Experimental|TruSculpt|Subject(s) will receive 1 radio frequency treatment in desired area.
11253113|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
11253114|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
11253115|NCT03018561|Active Comparator|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
11253116|NCT03018561|Experimental|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
11253117|NCT03018561|Experimental|patients with coronary heart disease|CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
11253118|NCT03018561|Experimental|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:
~≥18 years
~Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)
~NYHA functional class I-III
~Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).
~Able to perform an symptom limited exercise test.
~Capacity and willingness to sign the informed consent form."
11253119|NCT03018548|Experimental|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
11253120|NCT03018535|Experimental|RITUXIMAB|1 g. IV of Rituximab on days 1 and 15
11253121|NCT03018535|Active Comparator|Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for 3 doses; oral methylprednisolone (0.4mg/kg/day) or prednisone (0.5/mg/kg/day); Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
11253122|NCT03018509|Experimental|JTE-451 Dose 1|JTE-451 dose 1 for 28 days
11253123|NCT03018509|Experimental|JTE-451 Dose 2|JTE-451 dose 2 for 28 days
11253124|NCT03018509|Experimental|JTE-451 Dose 3|JTE-451 dose 3 for 28 days
11253125|NCT03018509|Experimental|JTE-451 Dose 4|JTE-451 dose 4 for 28 days
11253126|NCT03018509|Experimental|Placebo|Placebo for 28 days
11253127|NCT03018496|Experimental|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
11253128|NCT03018496|Experimental|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
11253129|NCT03018483|Experimental|Variable PSV|
11253133|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
11253134|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
11253135|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
11253136|NCT03018457||patients who need a dental implants|
11253137|NCT03018444|Experimental|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
11253138|NCT03018444|Placebo Comparator|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
11253139|NCT03018431||Physician routine evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon clinical and biological, associated with standard radiographs, performed by the physician in chrage of the patient.
11253140|NCT03018431||independent evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon early CT scan, and repeated lung ultrasonography, performed by an independent operator.
11253141|NCT03018418|Experimental|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
11253142|NCT03018405|Experimental|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
11253143|NCT03018405|Experimental|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort cohort 8-9 ( only in CRC) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
11253144|NCT03018392|Experimental|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
11253145|NCT03018379||Assessment of body composition|The collection of the samples and the analyses were undertaken according to the guidelines of the International Atomic Energy Agency. In brief, after having emptied the bladder, each participant provided a predose saliva sample using a cotton ball.A 99.8 % deuterium dose of 0.5 g per kg body weight was given orally to the participant. The postdose sample was collected from 3h to 4h after the administration of the dose. The saliva samples were stored at 20°C until analysis by Fourier transform infrared spectroscopy (FTIR).
11253146|NCT03018379||Assessment of energy expenditure|"Each participant provided a predose urine sample. A dose of doubly labelled water 2.625 ml per kg body weight was given orally to the participant.
~The post dose sample was collected at 3h to 4h , and on days 3, 7 and 14 after dosing. An aliquot of those samples were stored at 20°C in tightly sealed containers until analysis by isotope-ratio mass spectrometry (IRMS)."
11253147|NCT03018379||Assessment of physical activity|The participants were instructed to wear the accelerometer triaxial (GT3X+) attached to an elasticized belt around the waist, once they woke up until bed time at night for 7 consecutive days and to remove the accelerometer any time they were to perform activities that involve the use of water and when going to bed.
11253148|NCT03018366|Active Comparator|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (200mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 200mg is a peanut based product
11253149|NCT03018366|Placebo Comparator|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
11253150|NCT03018353|Other|Navigation services with sof/vel therapy|This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
11253151|NCT03018340|Experimental|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
11253152|NCT03018340|Placebo Comparator|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
11253153|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
11253154|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
11253155|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
11253156|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
11253157|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility <%32 and Kruger morphology <4%.
11253158|NCT03018301|Active Comparator|Ketamine group|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
11253159|NCT03018301|Placebo Comparator|Control group|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
11253160|NCT03018288|Experimental|1/RT+TMZ+Pembrolizumab|Standard treatment with experimental treatment (pembro) added
11253161|NCT03018288|Experimental|2/RT+TMZ+Pembrolizumab+ HSPPC-96 Vaccine|Standard treatment with experimental treatment (pembro+ vaccine) added
11253162|NCT03018288|Placebo Comparator|3/RT+TMZ+Pembrolizumab + Placebo Vaccine|Standard treatment with experimental treatment and placebo added
11253163|NCT03018275|Experimental|1|"Vials of lyophilized R mucosa (103, 104, or 105 CFU)"
11253164|NCT03018262|Other|Healthy Volunteers|Healthy volunteers
11253165|NCT03018249|Active Comparator|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
11253166|NCT03018249|Experimental|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
11253167|NCT03018236|Experimental|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
11253168|NCT03018236|Placebo Comparator|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
11253169|NCT03018236|Experimental|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
11253170|NCT03018236|Placebo Comparator|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
11253171|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.
~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.
~Peripheral blood hematopoietic cell transplantation
~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.
~Growth factor support: G-CSF"
11253172|NCT03018197|Experimental|Medication Education|Patients will receive training on the use of the personal health record and health education via the personal health record.
11253173|NCT03018197|No Intervention|No Medication Education|Patients will receive the current standard of care for the personal health record. Patients will not receive training on the use of the personal health record or health education via the personal health record.
11253174|NCT03018171|Experimental|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
11253175|NCT03018171|Active Comparator|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
11253176|NCT03018158|No Intervention|dentulous|MR Imaging was collected with condition at the tongue at rest position.
11253177|NCT03018158|No Intervention|edentulous without denture wear.|MR Imaging was collected without denture wear.
11253178|NCT03018158|Experimental|edentulous with denture wear.|MR Imaging was collected with denture wear.
11253179|NCT03018145|Experimental|Standard stretcher group|Use a standard stretcher car as a transporting method in the operating room
11253180|NCT03018145|Active Comparator|Wagon group|Use a wagon as a transporting method in the operating room
11253181|NCT03018132|Other|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
11253182|NCT03018119|Active Comparator|Anesthesiologists|Total: 11 Intervention: Survey
11253183|NCT03018119|Active Comparator|Obstetricians|Total: 11 Intervention: Survey
11253184|NCT03018119|Active Comparator|Registered Nurses|Total: 10 Intervention: Survey
11253185|NCT03018119|Active Comparator|Surgical Technicians|Total: 6 Intervention: Survey
11253186|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
11253187|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
11253188|NCT03018093|Experimental|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
11253189|NCT03018080|Experimental|Cohort A|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
11253190|NCT03018080|Experimental|Cohort B|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
11253191|NCT03018067|Placebo Comparator|Placebo|Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.
11253192|NCT03018067|Experimental|10 g qd|RDX227675, 10 g qd
11253193|NCT03018067|Experimental|20 g qd|RDX227675, 20 g qd
11253194|NCT03018067|Experimental|30 g qd|RDX227675, 30 g qd
11253195|NCT03018054|Experimental|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
11253196|NCT03018054|Experimental|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
11253197|NCT03018054|Placebo Comparator|Placebo|Participants will receive matching placebo once daily after breakfast.
11253198|NCT03018041|Experimental|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
11253199|NCT03018041|Placebo Comparator|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
11253200|NCT03018028|Experimental|Oral semaglutide 3 mg|
11253201|NCT03018028|Experimental|Oral semaglutide 7 mg|
11253202|NCT03018028|Experimental|Oral semaglutide 14 mg|
11253203|NCT03018028|Placebo Comparator|Oral placebo|
11253204|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
11253205|NCT03018015|Experimental|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
11253206|NCT03018015|Active Comparator|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
11253207|NCT03018015|Active Comparator|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
11253237|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
11253208|NCT03018002|No Intervention|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
11253209|NCT03018002|Experimental|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
11253210|NCT03017989|Experimental|NIRF imaging|After the white light (WL) imaging, NIRF imaging will be performed. 2.5 mg of ICG will be administered i.v. up to 5 times if needed. The lesions identified in WL, are inspected in NIRF mode. The surgeon indicated whether the lesions are more easily identified in WL or the NIRF mode and scores the visibility on a 1-10 scale. Next, inspection will take place for lesions that are seen in NIRF mode but not in WL. Biopsies will be taken from the lesions and from normal tissue for reference and sent for histology. Evaluation will take place whether the lesions differ in histological characteristics
11253211|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
11253212|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
11253213|NCT03017963|Experimental|dose-escalation cohort|Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.
11253214|NCT03017950|Experimental|Part1 (A)|"Number of Subjects: 10
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: CKD-330
~IPs for Period 2: CKD-330 + D086"
11253215|NCT03017950|Experimental|Part1 (B)|"Number of Subjects: 10
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: CKD-330 + D086
~IPs for Period 2: CKD-330"
11253216|NCT03017950|Experimental|Part2 (A)|"Number of Subjects: 30
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: D086
~IPs for Period 2: CKD-330 + D086"
11253217|NCT03017950|Experimental|Part2 (B)|"Number of Subjects: 30
~Number of days for Period 1: 8
~Number of days for Period 2: 8
~Number of days for wash-out between period 1 and period 2: 14
~IPs for Period 1: CKD-330 + D086
~IPs for Period 2: D086"
11253218|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
11253219|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
11253220|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
11253221|NCT03017911||Patients with PICC Lines|All patients included in this study have undergone PICC Line placement before enrollment.
11253222|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
11253223|NCT03017885||Group A|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.
11253224|NCT03017885||Group B|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .
11253225|NCT03017885||Group C|Patients who have been newly prescribed nintedanib & docetaxel at the time of participation in the active surveillance.
11253226|NCT03017872|Active Comparator|Standard of Care (SoC) arm|2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
11253227|NCT03017872|Experimental|Dolutegravir arm|Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
11253228|NCT03017872|Experimental|Dolutegravir 2NRTI arm (D2N)|Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)
11253229|NCT03017859|Experimental|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
11253230|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
11253231|NCT03017833|Experimental|Treatment (metformin, sapanisertib)|Patients receive metformin PO 1-3 times daily on days 1-42 and sapanisertib PO daily on days 15-42 of cycle 1. Patients then receive metformin PO daily and sapanisertib PO daily on days 1-28 of cycle 2 and beyond. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11253232|NCT03017820|Experimental|Treatment (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1, and then undergo SPECT/CT 3-5 days later.
11253233|NCT03017807|Experimental|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance.
11253234|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
11253235|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
11253236|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
11253238|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
11253239|NCT03017768|Active Comparator|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
11253240|NCT03017768|Placebo Comparator|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
11253241|NCT03017716|No Intervention|IBP patients on standard therapy|IBP patients on standard therapy.
11253242|NCT03017716|Active Comparator|IBP patients on standard therapy and GFD|IBP patients on standard therapy and GFD
11253243|NCT03017703|Experimental|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
11253244|NCT03017703|Experimental|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
11253245|NCT03017690||lanreotide group (Somatuline Depot®)|
11253246|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
11253247|NCT03017677||Group|
11253248|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
11253249|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
11253250|NCT03017651|Experimental|OM3-supplement 1|1 g capsule for OM3-supplement 1 given once
11253251|NCT03017651|Active Comparator|OM3-supplement 2|1 g capsule for OM3-supplement 2 given once
11253252|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
11253253|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:
~Maximal PACU VAS pain score (per nursing charts)
~Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)
~POD 24 and 48 hours and 4 weeks Respiratory complications"
11253254|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
11253255|NCT03017599|Experimental|Intervention group|EUS-FNB using 20-gauge procore needle
11253256|NCT03017586|Experimental|STN|DBS target with Subthalamic Nucleus (STN).
11253257|NCT03017586|Experimental|GPi|DBS target with Globus Pallidus Internus (GPi).
11253258|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
11253259|NCT03017560|Experimental|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
11253260|NCT03017560|No Intervention|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
11253261|NCT03017547|Experimental|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
11253262|NCT03017547|Placebo Comparator|Placebo|Placebo IV once daily on Study Day 1-4
11253263|NCT03017534|Experimental|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
11253264|NCT03017534|Experimental|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
11253265|NCT03017534|Experimental|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
11253266|NCT03017534|Experimental|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
11253267|NCT03017534|Experimental|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
11253268|NCT03017534|Experimental|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
11253269|NCT03017534|Experimental|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
11253270|NCT03017534|Experimental|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
11253271|NCT03017521|Experimental|TAS-117|TAS-117, 16mg, orally, daily
11253296|NCT03017365|Experimental|F-URT|Free weight unstable resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
11255438|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
11253272|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
11253273|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
11253274|NCT03017495|Experimental|Food effect and Drug-Drug interaction|Treatments will be given to all subjects in the same fixed sequence: Treatment A (Day 1, single dose of midazolam, fasted), Treatment B (Day 2, single dose of ACT-541468 followed by single dose of midazolam, fasted), Treatment C (Day 4, single dose ACT-541468, fed), Treatment D (multiple doses of ACT-541468 from Day 5 to Day 8 + single dose of midazolam on Day 8, fasted).
11253275|NCT03017469|Experimental|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
11253276|NCT03017469|No Intervention|Control Group|Nurses who do not participate in the ARISE Intervention
11253277|NCT03017456|No Intervention|Usual Care (UC)|Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
11253278|NCT03017456|Active Comparator|SCP-Intervention vs usual care|behavioral intervention vs control Patients in the SCP-Int arm will be asked to attend a one-time appointment with a trained oncology nurse. The SCP-Int is comprised of a 30-minute nurse-led face-to-face intervention and the provision of a tailored PC-specific SCP (PC-SCP). Persistent effects and concerns that are identified will prompt the development of a tailored management plan captured within the PC-SCP. Relevant patient education materials will be linked electronically. Nurses will use motivational interviewing techniques to effective in increase healthy behaviors and empower the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support.
11253279|NCT03017443|Experimental|Nutrisystem My Way|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem My Way plan.
11253280|NCT03017443|Experimental|Nutrisystem Turbo 10|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem Turbo 10 plan.
11253281|NCT03017443|Experimental|Nutrisystem DASH|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem DASH plan.
11253282|NCT03017443|Active Comparator|Dieting on Your Own (DIY) - DASH|All subjects provided publically available information on the DASH diet and instructed to follow a reduced calorie DASH diet meal plan on their own.
11253283|NCT03017430|Experimental|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
11253284|NCT03017430|Active Comparator|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
11253285|NCT03017417|Experimental|Exercise Intervention arm|"exercise training intervention to include:
~DEXA scan will collect data on via a full body scan to determine post-cranial appendicular whole body LM, whole body fat free mass (FFM) and whole body FM.
~Muscle Strength assessment
~Physical function assessment
~Questionnaires and diet diaries"
11253286|NCT03017417|Active Comparator|standard of care arm|"standard treatment
~exercise advice
~Questionnaires"
11253287|NCT03017404|Experimental|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
11253288|NCT03017404|Experimental|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
11253289|NCT03017404|Experimental|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
11253290|NCT03017404|Experimental|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
11253291|NCT03017391|Active Comparator|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
11253292|NCT03017391|Active Comparator|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.
~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
11253293|NCT03017378|Active Comparator|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
11253294|NCT03017378|Active Comparator|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
11253295|NCT03017365|Active Comparator|M-SRT|Machine-based stable resistance training. Exercising 'traditional' machine-based resistance training.
11253297|NCT03017365|Experimental|M-ART|Machine-based adductor/abductor resistance training. Exercising with 'traditional' adductor/abductor machines.
11253298|NCT03017352|Experimental|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
11253299|NCT03017352|Placebo Comparator|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
11253300|NCT03017339|Experimental|Laser Group|The subjects participated in a functional exercise program associated with low level laser therapy applied in the quadriceps, hamstrings and triceps sural
11253301|NCT03017339|Placebo Comparator|Placebo Group|The subjects participated in a functional exercise program associated with placebo low level laser therapy applied in the quadriceps, hamstrings and triceps sural
11253302|NCT03017326|Other|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
11253303|NCT03017326|Active Comparator|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
11253304|NCT03017326|Active Comparator|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
11253305|NCT03017326|Active Comparator|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
11253306|NCT03017326|Other|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
11253307|NCT03017326|Active Comparator|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
11253308|NCT03017300|Experimental|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
11253309|NCT03017300|Experimental|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
11253310|NCT03017287|Experimental|GlucoMe App|Self monitoring of glucose blood measurements using the GlucoMe glucose monitoring glucose device and App
11253311|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
11253312|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
11253313|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
11253314|NCT03017248|Active Comparator|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
11253315|NCT03017248|Experimental|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
11253316|NCT03017248|Experimental|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
11253317|NCT03017235|Experimental|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
11253318|NCT03017235|Active Comparator|PREPOPIK®|
11253319|NCT03017222|Active Comparator|Ondansetron group|
11253320|NCT03017222|Experimental|Ramosetron group|
11253321|NCT03017209|Experimental|Locally-prepared bar|The bar is similar to one tested recently in a pilot study and is a locally prepared bar designed to facilitate growth and cognitive development. It will provide 300 kcal/day and will have ≈20-30% of energy from protein (of which 25-50% is from an animal protein source), 20-35% from total carbohydrate and ≈40-60% from fat. The bar will be fortified with vitamins and minerals to meet USAID recommendations for moderate malnutrition and Dietary Reference Intake recommendations for at-risk and healthy children of the ages studied, and at the same time will not exceed Upper Level nutrient recommendations for any micronutrient. Ingredients in the bar will be a combination of local products and imported shelf-stable ingredients.
11253322|NCT03017209|Active Comparator|USAID Corn Soy Blend Plus|The usual-intervention condition will be 300 kcal/day of USAID Corn Soy Blend Plus cooked in the usual manner with fortified vegetable oil (10:3 ratio) and sugar. The community health workers or other designated villagers will prepare the supplement freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
11253323|NCT03017209|Placebo Comparator|Locally-purchased rice|The placebo condition will be 300 kcal/day of locally-purchased rice cooked with a small amount of oil (10:2 ratio), which mimics the usual breakfast of children in this region. The community health workers or other designated villagers will prepare the rice freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
11253324|NCT03017196|Experimental|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
11253325|NCT03017196|No Intervention|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
11253326|NCT03017183|Other|EBUS-TBNA - Endobrochial Forceps Biopsy|In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
11253327|NCT03017183|Other|Forceps - EBUS-TBNA|In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
11253328|NCT03017170|Experimental|Cranberry|500mg Dried Cranberry
11253329|NCT03017170|Placebo Comparator|Placebo Oral Capsule|Color Matching Placebo
11253330|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
11253331|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
11253332|NCT03017118|Experimental|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
11253333|NCT03017118|Placebo Comparator|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
11253334|NCT03017105|Active Comparator|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
11253335|NCT03017105|Experimental|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
11253336|NCT03017092|Experimental|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
11253337|NCT03017079|Experimental|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.
~Intervention: Other: bolus Intermittent enteral feeding"
11253338|NCT03017079|Placebo Comparator|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.
~Intervention: Other: Standard enteral feeding"
11253339|NCT03017066|Experimental|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
11253340|NCT03017066|Experimental|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
11253341|NCT03017053|Experimental|Radiotherapy|Primary surgery & Radiotherapy
11253342|NCT03017053|Active Comparator|Elective neck dissection|Primary surgery & Elective neck dissection
11253343|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
11253344|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
11253345|NCT03017027|Experimental|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
11253346|NCT03017027|Other|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
11253347|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
11253348|NCT03017001|Experimental|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
11253349|NCT03017001|Experimental|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
11253350|NCT03017001|Experimental|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
11253351|NCT03017001|No Intervention|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
11253352|NCT03016988|Other|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
11253353|NCT03016975|Experimental|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
11253354|NCT03016975|No Intervention|Control|Guideline directed medical therapy (GDMT)
11253355|NCT03016962|Experimental|Cap-assisted colonoscopy|cap-assisted colonoscopy
11253356|NCT03016962|Active Comparator|Standard colonoscopy|Standard colonoscopy
11253357|NCT03016949|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
11253358|NCT03016949|Experimental|Group B|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
11253359|NCT03016949|Experimental|Group C|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
11253361|NCT03016949|Experimental|Group E|3 doses IPV IM at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
11253362|NCT03016949|Experimental|Group F|3 doses f-IPV ID at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
11253363|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI <2 and NSQIP- MICA <1%
11253364|NCT03016923|Experimental|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
11253365|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
11253366|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
11253367|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
11253368|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
11253369|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
11253370|NCT03016884|Experimental|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
11253371|NCT03016884|Experimental|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
11253372|NCT03016871|Experimental|Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
11253373|NCT03016871|Experimental|Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11253374|NCT03016858|Experimental|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
11253375|NCT03016858|Active Comparator|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
11253376|NCT03016832|Experimental|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
11253377|NCT03016832|Active Comparator|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
11253378|NCT03016832|Other|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
11253379|NCT03016819|Experimental|Indication A: ASPS AL3818 Arm - OPEN|All subjects with ASPS will be assigned to the open-label AL3818 arm to receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11253380|NCT03016819|Experimental|Indication B: LMS AL3818 Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11253381|NCT03016819|Active Comparator|Indication B: LMS Dacarbazine Arm - CLOSED|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
11253382|NCT03016819|Experimental|Indication C: SS AL3818 Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to AL3818 will receive 12 mg AL3818 capsules orally once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
11253383|NCT03016819|Active Comparator|Indication C: SS Dacarbazine Arm - CLOSED|Subjects with SS will be randomized in a 2:1 ratio to receive either AL3818 or IV dacarbazine. Subjects randomized to IV dacarbazine will receive dacarbazine at a dose of 1000 mg/m^2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle.
11253384|NCT03016819|Placebo Comparator|Indication D: LMS AL3818 or Placebo Arm - OPEN|Subjects with LMS will be randomized in a 2:1 ratio to receive either AL3818 or placebo in a double-blind manner. AL3818 or placebo will be administrated as one 12 mg capsule orally once daily in 21-day cycles for 14 days on treatment (Days 1-14) and 7 days off treatment (Days 15-21).
11253385|NCT03016806|Other|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
11253409|NCT03016624|Active Comparator|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
11253410|NCT03016624|Active Comparator|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
11253411|NCT03016611|Active Comparator|Chewing Ticagrelor|
11253386|NCT03016806|Other|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
11253387|NCT03016806|Other|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
11253388|NCT03016806|Other|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
11253389|NCT03016793|Experimental|puerarin and β- tricalcium phosphate|"purabone (puerarin) is an osteoinductive bone grafts used to augment bone healing.
~β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing"
11253390|NCT03016793|Active Comparator|β- tricalcium phosphate alone|β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing
11253391|NCT03016780|Active Comparator|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
11253392|NCT03016780|Placebo Comparator|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
11253393|NCT03016767|Experimental|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.
~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
11253394|NCT03016767|No Intervention|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
11253395|NCT03016741|Other|Arm I (abiraterone acetate, prednisone)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive abiraterone acetate PO and prednisone PO BID in the absence of disease progression or unacceptable toxicity. Patients then undergo cognitive assessment comprising of neuro-cognitive tests and assessments of overall quality of life, fatigue, pain, and symptoms at baseline, 3, 6, and 12 months. Patients also undergo MRI program for 40 minutes comprising of DTI, fMRI, ASL MRI, MPRAGE MRI, FLAIR MRI, and BOLD MRI at baseline and 3 months.
11253396|NCT03016741|Other|Arm II (enzalutamide)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo cognitive assessment and MRI program as in Arm I.
11253397|NCT03016728|Experimental|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
11253398|NCT03016728|No Intervention|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
11253399|NCT03016715|Experimental|Treatment|Sirolimus, 2% topical ointment will be used during randomization
11253400|NCT03016715|Placebo Comparator|Vehicle|A placebo topical ointment will be used during randomization.
11253401|NCT03016702|Experimental|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
11253402|NCT03016702|Experimental|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
11253403|NCT03016676|Experimental|Spinal manipulation|Spinal manipulation -High velocity low amplitude thrust (HVLA), Dosages : 2 repetition at the same time, Duration-10-20 minutes. total 2 weeks.
11253404|NCT03016676|Experimental|Exercise therapy|Exercise Therapy(ET): Exercise therapy (ET) 3 program: self education, supervised exercise visits, and home exercise. Duration-45 minutes,Total number of visits 12 for 2 weeks.
11253405|NCT03016663||Breast Lipofilling Technique|Preliminary MRI breast were performed for volumetric measurement. Fat harvesting performed by same surgeon using water-assisted liposuction (WAL) and subsequent washing with buffered lactate in a standardized technique. Fat transfer performed using Berlin autologous lipotransplantation technique according to the BEAULI protocol .Patient were followed up monthly and MRI breast were repeated at 1st and 6th months after lipofilling. Clinical assessment and MRI Volumetric measurement performed using OsiriX (v7.0.3, 64 bit, Pixmeo c) software by same radiologist based on predefined operational procedure
11253406|NCT03016650|Active Comparator|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
11253407|NCT03016650|Active Comparator|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
11253408|NCT03016637|Experimental|EUS biopsy|EUS guided SharkCore (TM) biopsy of pancreatic lesions suspected of malignancy
11253412|NCT03016611|Experimental|Chewing Prasugrel|
11253413|NCT03016598|Experimental|Oxytocin|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
11253414|NCT03016598|Placebo Comparator|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
11253415|NCT03016585|Experimental|Tai Chi Training|Tai Chi exercises 3 times per wk for 12 weeks
11253416|NCT03016585|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 weeks.
11253417|NCT03016572|Experimental|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
11253418|NCT03016572|Experimental|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
11253419|NCT03016572|Experimental|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
11253420|NCT03016559|Other|releasing muscle|The physical therapist placed thumbs on the quadratus lumborum to release muscle.
11253421|NCT03016546|Experimental|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
11253422|NCT03016546|Active Comparator|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
11253423|NCT03016533|Experimental|Dolutegravir (Tivicay)|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 10 milligram (mg), 25 mg and 50 mg; and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant is discontinued, or until development of dolutegravir is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
11253424|NCT03016533|Experimental|ABC/DTG/3TC|All participants will receive ABC/DTG/3TC immediate release tablets or film-coated dispersible tablets at appropriate doses selected as per their weight bands. For those participants who were previously receiving ABC/DTG/3TC in study P2019 (parent study), ABC/DTG/3TC will be supplied as immediate release tablets containing 600 mg, 50 mg and 300 mg of ABC, DTG, and 3TC respectively and film-coated dispersible tablets containing 60 mg, 5 mg and 30 mg of ABC, DTG, and 3TC respectively. Participants will receive ABC/DTG/3TC until age-appropriate formulations are available to them from some other source, until participant is no longer deriving benefit from treatment, or until participant is discontinued, or until development of ABC/DTG/3TC is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
11253425|NCT03016520|Experimental|Test drug|DWJ1392
11253426|NCT03016520|Experimental|Reference drug|DWC20164
11253427|NCT03016494|Experimental|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
11253428|NCT03016494|Experimental|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
11253429|NCT03016481|Active Comparator|the Community Health Worker -Personalized Support for Progress|Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
11253430|NCT03016481|Active Comparator|Care as Usual- Social Worker|Patients in the Care as Usual- Social Worker (CAU-SW) arm, will do intake with a social worker, who follows hospital procedures for intake and referrals, does a needs assessment, and offers safety planning in referral.
11253431|NCT03016468|Experimental|Parenteral Remodulin then Oral Treprostinil|
11253432|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
11253433|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
11253434|NCT03016455||Stable patients|No DSA No cAMR
11253435|NCT03016442|Experimental|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
11254301|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
11253436|NCT03016442|Active Comparator|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
11253437|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
11253438|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
11253439|NCT03016403|Experimental|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
11253440|NCT03016403|Active Comparator|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
11253441|NCT03016377|Experimental|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
11253442|NCT03016377|Experimental|Expansion Cohort Second Administration of iC9-CAR19 cells|After the recommended phase 2 dose (RP2D) of iC9-CAR19 T cells has been determined in adults, up to 18 additional adult subjects will be enrolled in an expansion cohort at the RP2D. In the expansion cohort, subjects will be offered a second infusion of iC9-CAR19 T cells based on B-cell recovery and minimal residual disease (MRD) status. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before second administration of iC9-CAR19 T cells.
11253443|NCT03016364|Experimental|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
11253444|NCT03016351|Experimental|Aerobic Training|Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
11253445|NCT03016351|Experimental|Resistance Training|Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
11253446|NCT03016338|Experimental|Niraparib +TSR-042|200/300 mg Niraparib by mouth once a day for 21 days cycle. 500 mg of TSR-042 intravenously on the first day of each cycle.
11253447|NCT03016325|Experimental|Part 1 Cohort 1 HNO Donor|
11253448|NCT03016325|Placebo Comparator|Placebo Part 1 Cohort 1|
11253449|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- low dose|
11253450|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- high dose|
11253451|NCT03016325|Placebo Comparator|Placebo Part 2 Cohort 2|
11253452|NCT03016312|Experimental|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
11253453|NCT03016312|Active Comparator|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
11253454|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
11253455|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
11253456|NCT03016286|Experimental|WBV group|whole-body vibration (WBV) group
11253457|NCT03016273|Experimental|Bladder flap|The bladder flap is made by superficially incising and dissecting the peritoneal lining to separate the urinary bladder from the lower uterine segment.
11253458|NCT03016273|No Intervention|Non bladder flap|
11253459|NCT03016260||Infliximab (Remicade®)|
11253460|NCT03016260||Adalimumab (Humira®)|
11253461|NCT03016260||Etanercept (Enbrel®)|
11253462|NCT03016260||Golimumab (Simponi®)|
11253463|NCT03016260||Certolizumab Pegol (Cimzia®)|
11253464|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
11253465|NCT03016260||Etanercept biosimilar (Benepali®)|
11253466|NCT03016260||Infliximab biosimilar (Flixabi®)|
11253467|NCT03016247|Active Comparator|Enhanced Usual Care|Group will receive a single visit with a Nutritionist for dietary and physical activity counseling
11253468|NCT03016247|Experimental|TRUST intervention|Group will receive parent-adolescent trust-building and weight self-management training.
11253469|NCT03016234|Active Comparator|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
11253470|NCT03016234|Active Comparator|Propofol|intravenous anesthesia administration for maintenance of anesthesia
11253471|NCT03016221|Experimental|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253472|NCT03016221|No Intervention|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
11253473|NCT03016221|Experimental|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253474|NCT03016221|No Intervention|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
11253475|NCT03016221|Experimental|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253476|NCT03016221|No Intervention|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
11253477|NCT03016221|Experimental|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253478|NCT03016221|No Intervention|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
11253479|NCT03016221|Experimental|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253480|NCT03016221|No Intervention|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
11253481|NCT03016221|Experimental|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253482|NCT03016221|No Intervention|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
11253483|NCT03016221|Experimental|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253484|NCT03016221|No Intervention|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
11253485|NCT03016221|Experimental|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
11253486|NCT03016221|No Intervention|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
11253487|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
11253488|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
11253489|NCT03016182|Active Comparator|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
11253490|NCT03016182|Placebo Comparator|Control|Control group without remote ischemic preconditioning
11253491|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
11253492|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
11253493|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
11253494|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
11253495|NCT03016143|Active Comparator|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
11253496|NCT03016143|Active Comparator|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
11253497|NCT03016143|Experimental|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
11253498|NCT03016143|Experimental|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
11253499|NCT03016130|Active Comparator|Liberalized Hospital Diet (Diet A)|Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
11253500|NCT03016130|Active Comparator|Neutropenic Diet (Diet B)|Diet B is the hospital neutropenic diet.
11253533|NCT03015883|Experimental|Diffusing Alpha Radiation Emitters Therapy (DaRT)|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices
11253534|NCT03015870|Experimental|Feedback|Behavioral: Vocal exercise with real-time feedback.
11253535|NCT03015870|Active Comparator|Recording|Behavioral: Vocal exercise with recording
11253501|NCT03016117|Experimental|Pecs II block and parasternal block|Pecs II block and parasternal block performed to provide anesthesia of breast, before of quadrantectomy with or without axillary dissection. Pecs II block performed at the 4th rib level and 20 ml of 0.5% Levobupivacaine injected, and parasternal block performed at the level of the 2nd and 4th intercostal space level, and 4 ml of 0.375% Levobupivacaine injected
11253502|NCT03016104|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
11253503|NCT03016104|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
11253504|NCT03016091|Experimental|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
11253505|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
11253506|NCT03016065|Experimental|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
11253507|NCT03016065|Placebo Comparator|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
11253508|NCT03016052|Experimental|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
11253509|NCT03016039|Experimental|Dietary supplementation|This group will receive Dietary supplementation
11253510|NCT03016039|No Intervention|conventional treatment|conventional Antibiotic treatment without curcumin supplementation
11253511|NCT03016026|Experimental|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
11253512|NCT03016013|Placebo Comparator|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
11253513|NCT03016013|Experimental|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
11253514|NCT03016000|Experimental|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
11253515|NCT03016000|Other|Observation|Observation
11253516|NCT03015987|Experimental|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
11253517|NCT03015987|Active Comparator|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.
~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
11253518|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
11253519|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
11253520|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
11253521|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|
11253522|NCT03015961|Placebo Comparator|bupivacaine HCl|
11253523|NCT03015948|Experimental|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
11253524|NCT03015948|Experimental|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
11253525|NCT03015948|Experimental|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
11253526|NCT03015948|Experimental|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
11253527|NCT03015948|Experimental|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
11253528|NCT03015935||Optical|visual-assisted entry
11253529|NCT03015935||Veress|Veress entry
11253530|NCT03015922|Experimental|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.
~Plus (all patients):
~REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
11253531|NCT03015909|Other|Eutropin pen inj.|
11253532|NCT03015896|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11254302|NCT03010943|Experimental|Brain surgery with virtual reality headset|
11253536|NCT03015857|Active Comparator|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
11253537|NCT03015857|Active Comparator|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
11253538|NCT03015831|Active Comparator|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
11253539|NCT03015831|Placebo Comparator|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
11253540|NCT03015818|Experimental|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
11253541|NCT03015805|Experimental|Contingency Management|This group will receive regular probation services but will also receive the Contingency Management program for substance abuse from their juvenile probation officer during regular meetings.
11253542|NCT03015805|Active Comparator|Probation as Usual|This group will receive regular services that are usually provided by juvenile probation officers.
11253543|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
11253544|NCT03015779|Experimental|experimental group|cultured autologous oral mucosal epithelial cell sheet
11253545|NCT03015766|Experimental|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
11253546|NCT03015766|Sham Comparator|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
11253547|NCT03015753|Experimental|Tai Chi training|The participants in this arm will receive 12-week Tai Chi training (1 hour per day, 5 days per week).
11253548|NCT03015753|Other|Waiting list control group|Participants in this arm will be asked to maintain their usual lifestyles and exercises for 12 weeks. At the end of the trial , the participants will be offered Tai Chi training similar as Tai Chi group.
11253549|NCT03015740|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
11253550|NCT03015727|Experimental|IC+RT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.
11253551|NCT03015727|Active Comparator|IC+CCRT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.
11253552|NCT03015714|Active Comparator|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
11253553|NCT03015714|Active Comparator|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
11253554|NCT03015701|Experimental|Arm 1|Mifepristone 200 mg orally daily for two years
11253555|NCT03015701|Placebo Comparator|Arm 2|Placebo orally daily for two years
11253556|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
11253557|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
11253558|NCT03015675|Experimental|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks
~mFOLOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
11253559|NCT03015675|Active Comparator|mFOLFOX6 group|"mFOLOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
11253560|NCT03015662|Experimental|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
11253561|NCT03015662|Active Comparator|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
11253604|NCT03015467|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline (NS) according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 2.
11256818|NCT02993640|Experimental|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
11253562|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.
~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
11253563|NCT03015636|Experimental|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
11253564|NCT03015636|Other|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
11253565|NCT03015623|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
11253566|NCT03015623|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
11253567|NCT03015623|Sham Comparator|Control|Sham device containing no MSCs
11253568|NCT03015610|Placebo Comparator|Placebo|participants will receive oral blinded matched placebo once daily
11253569|NCT03015610|Experimental|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
11253570|NCT03015597|Experimental|Contingency Management: smoking|"Contingency Management: smoking
~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
11253571|NCT03015597|Placebo Comparator|Contingency Management: attendance|"Contingency Management: attendance
~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
11253572|NCT03015584||Septic patients admitted to the ICU|
11253573|NCT03015571|Experimental|NBI|Use of Narrow Band Imaging with regular care of cervical inlet patches detection.
11253574|NCT03015571|Placebo Comparator|WL|Use of High Definition White Light (WL) with regular care of cervical inlet patches detection.
11253575|NCT03015571|Experimental|NBI increased care|Use of Narrow Band Imaging with increased care of cervical inlet patches detection.
11253576|NCT03015571|Placebo Comparator|WL increased care|Use of High Definition White Light (WL) with increased care of cervical inlet patches detection.
11253577|NCT03015558|Experimental|patients|
11253578|NCT03015558|Active Comparator|healthy subjects|
11253579|NCT03015545|Active Comparator|Control|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval, but no vibration will be given.
11253580|NCT03015545|Active Comparator|High intensity whole body vibration|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval. The whole body vibration platform will be set with frequency at 30Hz and amplitude at 1.5mm.
11253581|NCT03015532|Experimental|Cohort 1 Group 1|HTX-011 (200 mg)
11253582|NCT03015532|Placebo Comparator|Cohort 1 Group 2|Saline placebo
11253583|NCT03015532|Active Comparator|Cohort 1 Group 3|Bupivacaine HCl without epinephrine 0.25% (125 mg)
11253584|NCT03015532|Experimental|Cohort 2 Group 1|HTX-011 (400 mg)
11253585|NCT03015532|Experimental|Cohort 2 Group 2|HTX-011 (400 mg) plus ropivacaine 0.5% (50 mg)
11253586|NCT03015532|Placebo Comparator|Cohort 2 Group 3|Saline placebo
11253587|NCT03015532|Active Comparator|Cohort 2 Group 4|Bupivacaine HCl without epinephrine 0.25% (125 mg)
11253588|NCT03015519|Experimental|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
11253589|NCT03015519|Placebo Comparator|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
11253590|NCT03015519|Experimental|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
11253591|NCT03015519|Placebo Comparator|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
11253592|NCT03015519|Experimental|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
11253593|NCT03015519|Placebo Comparator|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
11253594|NCT03015506|Active Comparator|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
11253595|NCT03015506|Experimental|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
11253596|NCT03015506|Experimental|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
11253597|NCT03015506|Experimental|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
11253598|NCT03015506|Experimental|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
11253599|NCT03015493|Experimental|Neural mobilization and traction|Patients in this group are treated with neural mobilization techniques combined with cervical traction
11253600|NCT03015493|Experimental|Traction group|Patients in this group are treated with cervical traction
11253601|NCT03015493|No Intervention|Control group|Patients in this group comprise the control group and are not treated with any intervention
11253602|NCT03015480|Experimental|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
11253603|NCT03015467|Active Comparator|treatment for part 1|Fecal Microbiota Transplantation (FMT) and traditional treatments according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 1.
11253605|NCT03015454|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
11253606|NCT03015454|Active Comparator|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
11253607|NCT03015441|Other|Arm 1: Fermented milk product containing probiotics|
11253608|NCT03015441|Other|Arm 2: Milk-based non-fermented dairy product|
11253609|NCT03015428|Experimental|Psychoeducation|"Interventions:
~Give information Teach and train strategies"
11253610|NCT03015415|Experimental|surgical|Patients undergoing surgical elbow arthrolysis. Elbow Open Arthrolyses
11253611|NCT03015415|Experimental|non-surgical|Patients submitted to a non-surgical rehabilitation protocol using splints Non-surgical intervention
11253612|NCT03015402|Experimental|Sodium Nitrite|
11253613|NCT03015402|Placebo Comparator|Placebo|
11253614|NCT03015389||Barrett's associated esophageal dysplasia|
11253615|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
11253616|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
11253617|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
11253618|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
11253619|NCT03015337|Experimental|New Physical Education Instructions|
11253620|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
11253621|NCT03015311|Experimental|Intensive BP control|SBP within 110 - <130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - <130 mm Hg.
11253622|NCT03015311|Active Comparator|Standard BP control|SBP within 130 - <150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - <150 mm Hg.
11253623|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
11253624|NCT03015285|Experimental|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
11253625|NCT03015285|Active Comparator|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
11253626|NCT03015272|Experimental|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
11253627|NCT03015272|Active Comparator|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
11253628|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
11253629|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
11253630|NCT03015259|Placebo Comparator|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
11253631|NCT03015246|Placebo Comparator|Extended-Release Morphine + placebo stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. The placebo stressor will be administered on one day.
11253632|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day.
11253633|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. The placebo stressor will be administered on one day.
11253634|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + placebo stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. The placebo stressor will be administered on one day.
11253635|NCT03015246|Experimental|Extended-Release Morphine + active stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
11253636|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
11253637|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
11253638|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + active stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
11253639|NCT03015220|Experimental|Oral semaglutide 3 mg|
11253640|NCT03015220|Experimental|Oral semaglutide 7 mg|
11253641|NCT03015220|Experimental|Oral semaglutide 14 mg|
11253642|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
11253643|NCT03015207|Experimental|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
11253644|NCT03015207|Placebo Comparator|Placebo|Injected s.c. /subcutaneously (under the skin)
11253645|NCT03015194|Experimental|Arm 1|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with TEE or intracardiac echocardiography.
11253646|NCT03015181|Experimental|Group 1: 1 mg/kg IV Single Dose|Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
11253647|NCT03015181|Experimental|Group 2: 5 mg/kg IV Single Dose|Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
11253648|NCT03015181|Experimental|Group 3: 5 mg/kg SC Single Dose|Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
11253649|NCT03015181|Experimental|Group 4: 20 mg/kg IV Single Dose|Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
11253650|NCT03015181|Experimental|Group 5: 40 mg/kg IV Single Dose|Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
11253651|NCT03015181|Experimental|Group 6: 5 mg/kg SC Multiple Doses|Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
11253652|NCT03015181|Experimental|Group 7: 20 mg/kg IV Multiple Doses|Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.
11253653|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
11253654|NCT03015155|Experimental|Hypothermia|Infusion of Cold Saline into Local Infarction Myocardium. A standard working guide-wire, Runthrough NS (Terumo, Japan), is advanced into the distal part of the target coronary artery by using angiography. Compared to the standard PPCI after the balloon expansion, the aspirated catheter (Diver C.E. MAX, Italy) is firstly placed at the location of the distal occlusion lesion to achieve local myocardial hypothermia by infusing the cold saline (4℃, 2.5ml/min, 5min). Then we retract the aspirated catheter, following the balloon expansion and the drug eluting stent implanting. Subsequently, the infusion catheter is tautologically placed at the location of the opened occlusion, within the stent, to persistently perfuse the infarct myocardium with cold saline (4℃, 2.5ml/min, 15min).
11253655|NCT03015155|No Intervention|Standard treatment|We place a standard working guide-wire, Runthrough NS (Terumo Corporation, Japan), crossover the criminal lesion of to the distal of the target coronary artery after angiography. Then the pre-dilated balloon is placed at the occluded lesion site to expand the criminal vessel without hypothermia intervention. The operation will be completed when the flow of target coronary artery achieves TIMI class 3 after the drug eluting stent implanting.
11253656|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
11253657|NCT03015129|Experimental|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
11253658|NCT03015129|Experimental|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
11253659|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
11253660|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
11253661|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
11253662|NCT03015103|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
11253663|NCT03015090|Experimental|theophylline|
11253664|NCT03015077|Active Comparator|Glutamine|"intake of 5g glutamine and 10g maltodextrin. Oral glutamine is a food additive issued by food and drug government in Taiwan with number 009929.L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin.
~The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy."
11253665|NCT03015077|Placebo Comparator|placebo|intake of 15g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
11253666|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
11253667|NCT03015051|Experimental|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
11253668|NCT03015051|Active Comparator|Low flow|Low flow (max 3 L/min) oxygen therapy
11253669|NCT03015025||Stable treatment with acenocoumarol|Patients in stable anticoagulant treatment with acenocoumarol for auricular fibrillation, venous thromboembolic disease and/or cardiac valve replacement.
11253764|NCT03014401|Experimental|Stem Cells|Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.
11253765|NCT03014401|Active Comparator|Placebo|Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation
11253766|NCT03014388|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
11253670|NCT03015012|Active Comparator|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
11253671|NCT03015012|Experimental|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
11253672|NCT03014999|Experimental|High frequency rTMS|Volunteers will be submitted to high frequency of repetitive transcranial magnetic stimulation (20Hz)
11253673|NCT03014999|Experimental|Low frequency rTMS|Volunteers will be submitted to low frequency of repetitive transcranial magnetic stimulation (1Hz)
11253674|NCT03014999|Sham Comparator|Sham rTMS|Volunteers will be submitted to sham session of repetitive transcranial magnetic stimulation
11253675|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
11253676|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
11253677|NCT03014973|Experimental|prostate cancer patients resistant to castration|
11253678|NCT03014973|Experimental|patients naif of hormonal treatment|
11253679|NCT03014960|Experimental|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
11253680|NCT03014960|No Intervention|Control Condition|No intervention
11253681|NCT03014947|Experimental|MSB11022|
11253682|NCT03014947|Active Comparator|US-licensed Humira|
11253683|NCT03014947|Active Comparator|EU-approved Humira|
11253684|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
11253685|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
11253686|NCT03014921|Placebo Comparator|placebo injection group|saline solution injection as placebo
11253687|NCT03014921|Active Comparator|iron injection group|iron injection
11253688|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
11253689|NCT03014908||NMR-C|non-diabetic children and adolescents
11253690|NCT03014895|Placebo Comparator|Cohort 1: Placebo|Intravenous placebo infusion
11253691|NCT03014895|Experimental|Cohort 1: E3112|Intravenous E3112 infusion
11253692|NCT03014895|Placebo Comparator|Cohort 2: Placebo|Intravenous placebo infusion
11253693|NCT03014895|Experimental|Cohort 2: E3112|Intravenous E3112 infusion
11253694|NCT03014895|Placebo Comparator|Cohort 3: Placebo|Intravenous placebo infusion
11253695|NCT03014895|Experimental|Cohort 3: E3112|Intravenous E3112 infusion
11253696|NCT03014895|Placebo Comparator|Cohort 4: Placebo|Intravenous placebo infusion
11253697|NCT03014895|Experimental|Cohort 4: E3112|Intravenous E3112 infusion
11253698|NCT03014895|Placebo Comparator|Cohort 5: Placebo|Intravenous placebo infusion
11253699|NCT03014895|Experimental|Cohort 5: E3112|Intravenous E3112 infusion
11253700|NCT03014882|Other|Antioxidant treatment|
11253701|NCT03014869|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.
11253702|NCT03014869|No Intervention|Noninvasive positive ventilation|Parameters are set according to NPPV protocols
11253703|NCT03014856||OB-NMR|overweight and obese children and adolescents
11253704|NCT03014856||NMR-C|normal-weight children and adolescents
11253705|NCT03014843|Active Comparator|Naloxone|Administration of a centrally acting µ-opioid receptor antagonist Naloxone (20µg/kg/h intravenous infusion after 0.4mg bolus) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
11253706|NCT03014843|Active Comparator|Methylnaltrexone bromide|Administration of a peripherally acting µ-opioid receptor antagonist Methylnaltrexone (12mg/0.6mL subcutaneous injection) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
11253707|NCT03014843|Placebo Comparator|Placebo|Administration of placebo injection (1mL 0.9% saline IV or 0.6 IM) as a control condition to compare to the administration of naloxone or methylnaltrexone bromide in the multimodal esophageal stimulation protocol.
11253708|NCT03014830|Active Comparator|Alirocumab|Subjects will receive alirocumab for 6 weeks.
11253709|NCT03014830|Placebo Comparator|Placebos|Subjects will receive placebo for 6 weeks.
11253710|NCT03014817|Experimental|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
11253711|NCT03014817|Active Comparator|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
11253712|NCT03014804|Experimental|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
11253713|NCT03014804|Experimental|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
11253767|NCT03014388|Experimental|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
11256819|NCT02993627|Experimental|Spirulina|daily intake of spirulina tablets weight reduction diet therapy
11253714|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.
~Large artery endothelial function:
~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)
~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)
~Forearm blood flow
~Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)
~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)
~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
11253715|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.
~Large artery endothelial function:
~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)
~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)
~Forearm blood flow
~Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)
~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)
~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
11253716|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.
~Large artery endothelial function:
~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms
~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms
~Recruited from community-based cohort studies - CLEAREST and ACCT
~Equal recruitment across the following parameters:
~Age: 3 groups <30, 30-60, >60 years
~Gender
~BMI: 3 groups <25, 25-30, >30 Kg/m2"
11253717|NCT03014778|Experimental|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
11253718|NCT03014778|Active Comparator|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
11253719|NCT03014752|Active Comparator|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
11253720|NCT03014752|Active Comparator|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
11253721|NCT03014726|Experimental|DCB Treatment|Stricture patients treated by DCB
11253722|NCT03014713|Active Comparator|Control Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
11253723|NCT03014713|Experimental|Dexmedetomidine Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
11253724|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
11253725|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
11253726|NCT03014687|Placebo Comparator|Standard Nasal Care|One dose of preoperative intravenous (iv) antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Postoperative antibiotics: Study participants will receive one dose only of postoperative intravenous antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Placebo PO BID (twice daily) will commence on the morning of postoperative day 1 and continue for 7 days.
11253727|NCT03014687|Experimental|Standard Nasal Care + Oral Antibiotics|One dose of preoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg) will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Participants will receive 1 dose only of postoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Oral antibiotics will commence on the morning of postoperative day 1; this group will receive oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.
11253728|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
11253729|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
11253730|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
11253731|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
11253768|NCT03014375|Experimental|Etamicastat|Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules
11253769|NCT03014362|Active Comparator|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;
~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.
~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
11253732|NCT03014648|Experimental|Atezolizumab|"Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV over 60 (plus or minus 15) minutes for first infusion; can be decreased to 30 (plus or minus 10) minutes for subsequent cycles.
~Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression.
~There will be no dose reduction for Atezolizumab. Patients may temporarily suspend study treatment for up to 84 days beyond the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If Atezolizumab is held because of adverse events for greater than 84 days beyond the scheduled date of infusion, the patient will be discontinued from Atezolizumab and will be followed for safety and efficacy."
11253733|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
11253734|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
11253735|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
11253736|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
11253737|NCT03014596|Experimental|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
11253738|NCT03014596|No Intervention|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
11253739|NCT03014583|Experimental|HF/TCS/BURST|HF/TCS/BURST
11253740|NCT03014583|Experimental|HF/BURST/TCS|HF/BURST/TCS
11253741|NCT03014583|Experimental|BURST/HF/TCS|BURST/HF/TCS
11253742|NCT03014583|Experimental|BURST/TCS/HF|BURST/TCS/HF
11253743|NCT03014583|Experimental|TCS/BURST/HF|TCS/BURST/HF
11253744|NCT03014583|Experimental|TCS/HF/BURST|TCS/HF/BURST
11253745|NCT03014570|Active Comparator|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
11253746|NCT03014570|Experimental|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
11253747|NCT03014557||WATCHMAN|subjects with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN left atrial appendage closure device
11253748|NCT03014544||Group 1: Sequence AABB|Participants of main study with Major Depressive Disorder (MDD) will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
11253749|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
11253750|NCT03014531|Experimental|almond|In this group, participants were provided with 56 g of almonds per day either as preload before meals or snack between meals. A snack was defined as an eating event that occurred between participants' regular meals, specifically two hours before and after meals. All the participants in almond group were provided daily portions of packaged almonds.
11253751|NCT03014531|Other|high-carbohydrate control food item|In this group, participants were provided with high-carbohydrate control food item that had a similar number of calories as 56 g of almonds.
11253752|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
11253753|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
11253754|NCT03014505|Experimental|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
11253755|NCT03014505|Active Comparator|The traditional treatments|
11253756|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
11253757|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
11253758|NCT03014479|Experimental|Trelagliptin|Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
11253759|NCT03014479|Active Comparator|Daily DPP-4 inhibitors|An inhibitor orally administered at the dosage and administration in the package inserts for each drug, for up to 12 weeks.
11253760|NCT03014466|Active Comparator|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
11253761|NCT03014466|Experimental|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
11253762|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
11253763|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
11253770|NCT03014362|Sham Comparator|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;
~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
11253771|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
11253772|NCT03014336|No Intervention|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
11253773|NCT03014336|Experimental|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
11253774|NCT03014323|Experimental|Galantamine then Placebo, WW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)
11253775|NCT03014323|Placebo Comparator|Placebo then Galantamine, WW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)
11253776|NCT03014323|Experimental|Galantamine then Placebo, AAW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)
11253777|NCT03014323|Placebo Comparator|Placebo then Galantamine, AAW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)
11253778|NCT03014310|Experimental|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
11253779|NCT03014310|Experimental|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
11253780|NCT03014310|Active Comparator|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
11253781|NCT03014310|Experimental|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
11253782|NCT03014310|Experimental|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
11253783|NCT03014310|Active Comparator|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
11253784|NCT03014297|Experimental|everolimus + fosbretabulin|everolimus + fosbretabulin
11253785|NCT03014271|Experimental|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide (SOS) Prevention Program
11253786|NCT03014271|Active Comparator|SOS Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program after 16 months.
11253787|NCT03014258|Active Comparator|Control Cohort 1|Immunologic malaria-naïve subjects will undergo CHMI #2 with 5 NF54 P. falciparum-infected mosquitoes at months 8-9. n=6.
11253788|NCT03014258|Active Comparator|Control Cohort 2|Immunologic malaria-naïve subjects will undergo a CHMI #3 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #2. n=6.
11253789|NCT03014258|Active Comparator|Control Cohort 3|Immunologic malaria-naïve subjects will undergo a CHMI #4 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #3. n=6.
11253790|NCT03014258|Active Comparator|Control Cohort 4|Immunologic malaria-naïve subjects will undergo a CHMI #5 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #4. n=6.
11253791|NCT03014258|Experimental|Repeat CHMI|Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
11253792|NCT03014245||Pregnant|Normal pregnant women (first baby) singleton
11253793|NCT03014245||Control|Non pregnant healthy women
11253794|NCT03014232|Experimental|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
11253795|NCT03014232|Active Comparator|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
11253796|NCT03014219|Experimental|Only 1 arm: treatment with MSC-AFP|Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells.
11253797|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
11253798|NCT03014167|Experimental|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
11253799|NCT03014167|Active Comparator|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
11253800|NCT03014154|Active Comparator|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
11253828|NCT03013998|Experimental|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
11253801|NCT03014154|Active Comparator|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
11253802|NCT03014141|Active Comparator|Oat bran (Oatwell 28)|A beverage containing 11 gram (3 gram of oat beta-glucan) of Oat bran (Oatwell 28) will be consumed before breakfast
11253803|NCT03014141|Placebo Comparator|Maltodextrin|A beverage containing 11 gram of maltodextrin will be consumed before breakfast.
11253804|NCT03014128||Inspection and Packaging|self-descriptive
11253805|NCT03014128||Grinding, Polishing and Matting|self-descriptive
11253806|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
11253807|NCT03014115|Active Comparator|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
11253808|NCT03014115|Experimental|DHA|0% ARA +0.4% DHA in infant formula per day
11253809|NCT03014102|Experimental|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
11253810|NCT03014102|Active Comparator|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
11253811|NCT03014089|Experimental|mRNA-1325|
11253812|NCT03014089|Placebo Comparator|Placebo|0.9% sodium chloride
11253813|NCT03014076|Experimental|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
11253814|NCT03014076|Active Comparator|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
11253815|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
11253816|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
11253817|NCT03014050|Experimental|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
11253818|NCT03014050|Active Comparator|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
11253819|NCT03014037|Other|Unilateral Procurement of Bone Marrow|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.
11253820|NCT03014037|Experimental|Bilateral Bone Marrow Procurement|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow.
11253821|NCT03014024|Experimental|Low-Level Laser therapy|After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
11253822|NCT03014024|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, patients will be treated with placebo LLLT. This placebo laser is identical in appearance to the other super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated on the same areas, and have the same procedure and time. Since the light from the laser is invisible neither the participant nor the therapist will know whether the laser is a placebo.
11253823|NCT03014011|Other|Hypoglycaemic clamp first, then euglyceamic clamp|First intervention with a hypoglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with an euglycaemic clamp (approximately 5 hours).
11253824|NCT03014011|Other|Euglycaemic clamp first, then hypoglycaemic clamp|First intervention with an euglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with a hypoglycaemic clamp (approximately 5 hours).
11253825|NCT03013998|Experimental|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
11253826|NCT03013998|Experimental|BAML-16-001-S2|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
11253827|NCT03013998|Experimental|BAML-16-001-S3|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
11253891|NCT03013556|Active Comparator|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
11253829|NCT03013998|Experimental|BAML-16-001-S5|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
11253830|NCT03013998|Experimental|BAML-16-001-S6|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
11253831|NCT03013998|Experimental|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
11253832|NCT03013998|Experimental|BAML-16-001-S16|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
11253833|NCT03013998|Experimental|BAML-16-001-S8|This is an open-label Phase 2/1b clinical study of gilteritinib as a single agent stratified into 2 cohorts in phase 2 portion based upon dominant versus non-dominant FLT3 mutation status. Cohort 1, Dominant FLT3, will include patients with either FLT3-ITD with allelic ratio of ≥0.5 stratified based upon the prioritization schema of the master trial; FLT3-TKD with highest variant allele frequency among mutations studied for stratification; or FLT3-TKD with second highest variant allele frequency in setting of DNMT3A, TET2, ASXL1, BCORL1, JAK2, and SF3B1 or other spliceosome family member. Cohort 2, non-dominant FLT3, will include the remainder of patients with FLT3-ITD or FLT3-TKD stratified based upon the master umbrella study protocol. For the phase 1b portion, gilteritinib will be given in combination with decitabine for non-responding patients to test the efficacy of gilteritinib in combination with decitabine in elderly AML with FLT3 mutation.
11253834|NCT03013998|Experimental|BAML-16-001-COV1 (Acalabrutinib)|This is the treatment arm in a non-blinded Phase 2 sub-study trial of Acalabrutinib in patients with hematologic malignancies and hospitalization for confirmed PCR+ SARS-CoV-2 infection. Patients will be randomized in a 1:1 fashion to receive Acalabrutinib + standard therapy or standard therapy alone for COVID-19.
11253835|NCT03013998|Active Comparator|BAML-16-001-COV1 (Standard Therapy)|This is the comparator arm in a non-blinded Phase 2 sub-study trial of Acalabrutinib in patients with hematologic malignancies and hospitalization for confirmed PCR+ SARS-CoV-2 infection. Patients will be randomized in a 1:1 fashion to receive Acalabrutinib + standard therapy or standard therapy alone for COVID-19.
11253836|NCT03013998|Experimental|BAML-16-001-S10|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
11253837|NCT03013998|Experimental|BAML-16-001-S14|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
11253838|NCT03013985|Experimental|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
11253839|NCT03013985|Active Comparator|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
11253840|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
11253841|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
11253842|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
11253843|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
11253844|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
11253845|NCT03013946|Experimental|Arm A (Coaching)|Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
11253846|NCT03013946|No Intervention|Arm B (Control)|Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
11253847|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11253848|NCT03013907|Experimental|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
11253849|NCT03013907|Active Comparator|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
11253850|NCT03013881|Experimental|UB-921 2 mg/kg (Main-study)|Intravenous infusion
11253851|NCT03013881|Experimental|UB-921 6 mg/kg (Main-study)|Intravenous infusion
11253852|NCT03013881|Experimental|UB-921 8 mg/kg (Main-study)|Intravenous infusion
11253853|NCT03013881|Experimental|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
11253854|NCT03013881|Active Comparator|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
11253855|NCT03013855|Active Comparator|FIT-SOC|Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
11253856|NCT03013855|Experimental|FIT-DRE|Fecal immunochemical test completed with stool collected during digital rectal exam.
11253857|NCT03013842|Experimental|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
11253858|NCT03013829|No Intervention|Usual Care|"Potential LKDs and recipients will receive standard-of-care LD (Live Donor) and KPD education. As noted previously, during standard care, incompatible potential LKDs are informed of the KPD option and the potential LKD is provided with living donation information and a link to the UNOS KPD website, which includes a written description of KPD. This information is available in English and Spanish. For those who do not have internet access, the written educational materials are mailed. The potential LKD is advised to call the donor nurse coordinator with any questions about KPD and/or to initiate the full donation evaluation. This process occurs for the intended recipient only if their potential donor decides to initiate the full evaluation.
~For study purposes, potential LKDs and waitlisted recipients assigned to the UC group will be sent an email after randomization, which will include a link and a reminder to review their transplant center's standard of care educational materials."
11253859|NCT03013829|Experimental|Video-Based KPD education|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch the embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
11253860|NCT03013816|Experimental|Testimonial Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
11253861|NCT03013816|Experimental|Informational Messaging|This video mirrors common educational campaigns and included segments of HRSA's animated video, Organ Donation and Transplantation: How Does it Work? The IM video presents facts about donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, donation myths, and the importance of communicating with parents about donation. Information about how to register as a donor is also included. The video contains no personal testimonials.
11253862|NCT03013816|Experimental|Blended Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
11253863|NCT03013803|Experimental|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
11253864|NCT03013790|Active Comparator|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
11253865|NCT03013790|Active Comparator|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
11253866|NCT03013790|Placebo Comparator|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
11253892|NCT03013556|Experimental|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
11253867|NCT03013777|Experimental|Cognitive behavioral therapy (CBT)|The patient would participate in eight forty-five minute sessions of CBT with a mental health therapist. Cognitive behavioral therapy (CBT), defined as a program of interventions that utilize education to teach relaxation, healthy coping skills, stress management, assertiveness training in order to help the individual identify and correct maladaptive beliefs in combination with education to help practice symptom reduction and improve quality of life and function.
11253868|NCT03013764|Placebo Comparator|normal protein intake|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
11253869|NCT03013764|Experimental|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
11253870|NCT03013751|Experimental|Drug|Udenafil administered for 52 weeks
11253871|NCT03013738|Experimental|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.
~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.
~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
11253872|NCT03013738|Other|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
11253873|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
11253874|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
11253875|NCT03013712|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
11253876|NCT03013699|Active Comparator|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
11253877|NCT03013699|Experimental|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
11253878|NCT03013686|Active Comparator|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.
~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
11253879|NCT03013686|Active Comparator|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.
~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
11253880|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
11253881|NCT03013660|No Intervention|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
11253882|NCT03013660|Experimental|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
11253883|NCT03013647|Other|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
11253884|NCT03013634|Experimental|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
11253885|NCT03013634|Placebo Comparator|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
11253886|NCT03013608|Experimental|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
11253887|NCT03013595|Experimental|TRAM feedback|"The completion of the Transition Readiness and Appropriateness Measure (TRAM, a standardized structured assessment ) prior to the transition boundary by the child and adolescent mental health service (CAMHS) clinician, young person and parent/carer.
~Feedback of TRAM findings to the CAMHS clinician to support decisions made regarding transition, communication with stakeholders and the transition process. Clinicians will be expected to communicate the findings to the young person and parent/carer, and, if a referral is made, to send the TRAM feedback to the adult clinician along with the referral letter.
~The clinicians will also receive information prior to recruitment begin on the use of TRAM and the way in which it fits in with optimal transition."
11253888|NCT03013595|No Intervention|Usual care|Patients, parent/carers and clinicians in the control arm will complete the TRAM prior to the transition boundary, but the clinicians won't receive any feedback from it nor any information on the benefits of using the decision support tool.
11253889|NCT03013582|Experimental|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
11253890|NCT03013582|Placebo Comparator|Tenolysis control|Standard surgical tenolysis alone
11253893|NCT03013556|Experimental|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
11253894|NCT03013543|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
11253895|NCT03013530||Patients with chronic disease|
11253896|NCT03013517|Experimental|Viaskin Peanut 250µg|
11253897|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.
~Neoadjuvant chemotherapy:
~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
11253898|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.
~Neoadjuvant chemotherapy:
~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
11253899|NCT03013491|Experimental|CX-072|Monotherapy CX-072
11253900|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
11253901|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
11253902|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
11253903|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
11253904|NCT03013478|No Intervention|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
11253905|NCT03013478|Active Comparator|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
11253906|NCT03013465|Other|Control Diet|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of broccoli (control).
11253907|NCT03013465|Active Comparator|Brassica Diet|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily.
11253908|NCT03013452|Active Comparator|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
11253909|NCT03013452|Active Comparator|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
11253910|NCT03013439|Experimental|cohort 1 iron isomaltoside|treated with first dose level of iron isomaltoside
11253911|NCT03013439|Experimental|cohort 2 iron isomaltoside|treated with second dose level of iron isomaltoside
11253912|NCT03013439|Experimental|cohort 3 iron isomaltoside|treated with third dose level of iron isomaltoside
11253913|NCT03013439|Experimental|cohort 4 iron isomaltoside|treated with fourth dose level of iron isomaltoside
11253914|NCT03013426|Experimental|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
11253915|NCT03013413|Experimental|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
11253916|NCT03013400|Active Comparator|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
11253917|NCT03013400|Placebo Comparator|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
11253918|NCT03013387|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|"The 90Y--DOTA-tyr3-Octreotide initial, Cycle 1 dose will be 50 mCi/m2 in children; 120 mCi in adults. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed. Cycles 2 and 3 doses will be determined by dosimetry-based calculation of renal doses from previous cycles; total renal dose ≤ 23Gy. 90Y-DOTA-tyr3-Octreotide will be administered with an amino acid solution to prevent radiation damage to kidneys. Amino acid infusion will begin 30 min prior to infusion of 90Y-DOTATOC and continue 3.5 hrs after infusion of study drugs.
~68Ga-DOTATOC will be administered intravenously to perform the PET/CT scan. The dose will be 3-5 mCi (target 4mCi). The pediatric dose will be 0.043 mCi/kg with a minimum dose of 0.3 mCi and a maximum dose of 3 mCi in children <18 years old."
11253919|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment
~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
11253920|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.
~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
11253921|NCT03013361|Active Comparator|Group B (n=20)|Group B (n=20): The patients in this group were infiltrated with 3 mL of 0.5% bupivacaine.
11253922|NCT03013361|Active Comparator|Group R (n=20):|Group R (n=20): The patients in this group were infiltrated with 3 mL of 0.5% ropivacaine.
11253923|NCT03013361|Placebo Comparator|Group S (n=20, Control):|Group S (n=20, Control): The patients in this group were infiltrated with 3 mL of normal saline.
11253924|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
11253965|NCT03013114|Experimental|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
11253925|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
11253926|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
11253927|NCT03013335|Experimental|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).
~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
11253928|NCT03013322|Active Comparator|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
11253929|NCT03013322|Placebo Comparator|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
11253930|NCT03013309|Experimental|Intervention|Receives the Family Check-Up 4 Health
11253931|NCT03013309|Experimental|Control|Receives Treatment as Usual
11253932|NCT03013296|Placebo Comparator|Placebo|Saline
11253933|NCT03013296|Other|GIP-A|Infusion of GIP-A alone as study tool.
11253934|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
11253935|NCT03013296|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
11253936|NCT03013270|Experimental|ARIS group|Aerobic-Resistance-Inspiratory
11253937|NCT03013270|Active Comparator|AT/RT group|Aerobic-Resistance
11253938|NCT03013270|Active Comparator|AT/IMT group|Aerobic-Inspiratory
11253939|NCT03013270|Active Comparator|AT group|Aerobic Training
11253940|NCT03013257|Experimental|High Intensity Focused Ultrasound|Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
11253941|NCT03013257|No Intervention|Fixed-dose radioiodine-131|Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
11253942|NCT03013244|No Intervention|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
11253943|NCT03013244|Experimental|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
11253944|NCT03013231||s/p ACLR|Patients having undergone ACL Reconstruction Surgery with goal of returning to sport. 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
11253945|NCT03013218|Experimental|ALX148|The Part 1 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks.
11253946|NCT03013218|Experimental|ALX148 + Pembrolizumab|The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
11253947|NCT03013218|Experimental|ALX148 + Trastuzumab|The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
11253948|NCT03013218|Experimental|ALX148 + Rituximab|The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with rituximab infusions.
11253949|NCT03013218|Experimental|ALX148 + Pembrolizumab + 5FU + Platinum|The Part 2 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
11253950|NCT03013218|Experimental|ALX148 + Trastuzumab + Ramucirumab + Paclitaxel|The Part 2 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
11253951|NCT03013205|Experimental|PT+IA+CHL|"Intraarticular triamcinolone injection
~Intraarticular Xylocaine injection
~Coracohumeral ligament triamcinolone injection
~Physiotherapy"
11253952|NCT03013205|Active Comparator|PT+IA|"Intraarticular triamcinolone injection
~Intraarticular Xylocaine injection
~Physiotherapy"
11253953|NCT03013192|No Intervention|Control|No text message reminders, usual patient protocol
11253954|NCT03013192|Experimental|Intervention (text messaging)|Text message reminders for PT
11253955|NCT03013179||Black/African American Women and their 3-5 year old children|
11253956|NCT03013166||Cohort 1|IR hydrocortisone
11253957|NCT03013166||Cohort 2|IR prednisolone
11253958|NCT03013166||Cohort 3|MR hydrocortisone
11253959|NCT03013166||Cohort 4|IR to MR hydrocortisone
11253960|NCT03013153|Experimental|Low ligation with apical lymph node dissection|Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
11253961|NCT03013153|Active Comparator|High ligation|Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
11253962|NCT03013140|Experimental|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) <5%"
11253963|NCT03013140|Active Comparator|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
11253964|NCT03013127|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg i.v. every 3 weeks for up to 35 cycles
11256994|NCT02992457|Active Comparator|Ritaprevir, paritaprevir, ombetasvir|Querevo for 3 months
11253966|NCT03013101|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
11253967|NCT03013088|Experimental|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
11253968|NCT03013075|Experimental|SPINAL PLUS GENERAL ANESTHESIA|Patient will receive the intervention SPINAL ANESTHESIA before the start of surgery using Bupivacaine heavy 40 mg and Morphine 250 micro grams comprising a total volume of 8 ml to achieve a spinal block up to T2 level followed by general anesthesia
11253969|NCT03013075|Active Comparator|ONLY GENERAL ANESTHESIA|Patient will receive only general anesthesia before the start of surgery
11253970|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP > 25 mm Hg at rest or >30 mm Hg during exercise with PVR > 3 wood units and PCWP < 15 mm Hg.
11253971|NCT03013049|Active Comparator|Non cultured epidermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.
11253972|NCT03013049|Experimental|Non cultured dermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done.
11253973|NCT03013036|Other|Group I|Patients between 1 and 2 years
11253974|NCT03013036|Other|Group II|patients between 3 and 5 years
11253975|NCT03013036|Other|Group III|patients between 6 and 8 years
11253976|NCT03013023|Placebo Comparator|Routine care|Control group
11253977|NCT03013023|Active Comparator|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
11253978|NCT03013023|Active Comparator|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
11253979|NCT03013023|Active Comparator|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
11253980|NCT03013010|Experimental|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.
~5 weeks preoperative chemoradiotherapy.
~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.
~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
11253981|NCT03013010|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.
~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
11253982|NCT03012997|Active Comparator|Active Comparator: 40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the induction, surgery and in Postoperative care unit.
11253983|NCT03012997|Active Comparator|Active Comparator: 100% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen during 100% induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.
11253984|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
11253985|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
11253986|NCT03012971|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
11253987|NCT03012971|Placebo Comparator|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
11253988|NCT03012958|Active Comparator|Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.
~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
11253989|NCT03012958|Experimental|Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.
~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
11253990|NCT03012945|Experimental|Combined epidural-general anesthesia|Patients assigned to this group (experimental group) receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
11254303|NCT03010930|Experimental|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
11253991|NCT03012945|Active Comparator|General anesthesia|Patients assigned to this group (control group) receive general anesthesia and postoperative patient-controlled intravenous analgesia.
11253992|NCT03012932|Other|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
11253993|NCT03012919|Other|active decision support system (GDT protocol)|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
11253994|NCT03012893|Experimental|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
11253995|NCT03012893|Experimental|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
11253996|NCT03012893|Active Comparator|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
11253997|NCT03012880|Experimental|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
11253998|NCT03012867|Active Comparator|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
11253999|NCT03012867|Active Comparator|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
11254000|NCT03012854|Experimental|short-myotomy|Short-POEM for patients with esophageal achalasia
11254001|NCT03012854|Active Comparator|long-myotomy|Long-POEM for patients with esophageal achalasia
11254002|NCT03012854|Experimental|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
11254003|NCT03012854|Active Comparator|circular myotomy|Circular-POEM for patients with esophageal achalasia
11254004|NCT03012841|Experimental|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
11254005|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
11254006|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
11254007|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
11254008|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
11254009|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
11254010|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
11254011|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
11254012|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
11254013|NCT03012789|Other|Post Surgery|
11254014|NCT03012776|Experimental|TOPS System|Investigational surgical treatment using TOPS System
11254015|NCT03012776|Active Comparator|Transforaminal Lumbar Interbody Fusion (TLIF)|Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
11254016|NCT03012763|Placebo Comparator|non-caloric water|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
11254017|NCT03012763|Active Comparator|caloric drink|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
11254018|NCT03012763|Active Comparator|grapefruit juice|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
11254019|NCT03012750|Experimental|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
11254020|NCT03012737|Other|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
11254021|NCT03012724|Active Comparator|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
11254022|NCT03012724|Experimental|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
11254023|NCT03012711|Experimental|Training|Neuromuscular exercise training group will complete a 5 week NME training program
11254024|NCT03012711|No Intervention|Control|Control group will have 5 weeks with no intervention prior to being re-tested
11254025|NCT03012698|Experimental|RMS treatment|
11254081|NCT03012230|Experimental|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11254026|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11254027|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11254028|NCT03012659|Experimental|Intervention Arm|Full-day contraceptive counseling training for health center staff
11254029|NCT03012659|No Intervention|Control Arm|Usual care
11254030|NCT03012646|Experimental|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
11254031|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
11254032|NCT03012607|Experimental|Perfect Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] once daily for 6 weeks
11254033|NCT03012607|Experimental|Moderate Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 4 times per week (Monday, Wednesday, Friday, and Saturday) for 6 weeks
11254034|NCT03012607|Experimental|Poor Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 2 times per week (Monday, Thursday) for 6 weeks
11254035|NCT03012594|Experimental|Lanreotide|Open label
11254036|NCT03012581|Experimental|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
11254037|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
11254038|NCT03012542|Experimental|Diet 1|Administered for 8 weeks.
11254039|NCT03012542|Experimental|Diet 2|Administered for 8 weeks.
11254040|NCT03012529|Active Comparator|Active drug|Patients receive oral adjunctive rifampin therapy
11254041|NCT03012529|Placebo Comparator|Placebo|Patients receive oral riboflavin
11254042|NCT03012516|Experimental|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
11254043|NCT03012516|Active Comparator|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
11254044|NCT03012503|Placebo Comparator|Control|Five minutes before cervical manipulation, controls received a placebo gel applied to their neck.
11254045|NCT03012503|Experimental|Treatment|Five minutes before cervical manipulation the treatment group received a menthol containing gel (Biofreeze®) applied to their neck.
11254046|NCT03012490|Active Comparator|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
11254047|NCT03012490|Experimental|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
11254048|NCT03012477|Experimental|AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatinIV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days later.
~- AZD1775 will be administered as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.
~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
11254049|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
11254050|NCT03012451|Experimental|Advancing Adolescents|Received structured eight-week psychosocial sessions
11254051|NCT03012451|No Intervention|Control|Controls wait-listed for the intervention, matched for age and urban residence
11254052|NCT03012438|Experimental|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.
~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
11254082|NCT03012217||Specimens that meet inclusion criteria|
11254083|NCT03012204|Experimental|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
11254084|NCT03012204|Experimental|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
11254459|NCT03009981|Active Comparator|Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide|Patients will receive degarelix OR leuprolide with bicalutamide.
11254053|NCT03012425|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Session 1- Review of initial sleep diary, formulation of impression of type/subtype of insomnia, determine modifiable factors, address immediate concerns about participation, discuss motivation & compliance. Session 2- Review of sleep diary, present 4-P model of insomnia, prescribe Sleep Restriction & Stimulus Control Therapy. Session 3- Review of sleep diary, continue with stimulus control & sleep restriction procedures, review of sleep hygiene. Session 4- Review of sleep diary, continue with stimulus control & sleep restriction procedures, introduce & practice relaxation strategies. Session 5- Review of sleep diary, continue with stimulus control & sleep restriction procedures, conduct cognitive therapy to address dysfunctional thoughts underlying insomnia. Session 6- Review of sleep diary, continue with stimulus control & sleep restriction procedures Session 7- Review of sleep diary & overall progress, discuss relapse prevention, further sleep restriction guidelines & prophylaxis.
11254054|NCT03012425|Experimental|Acupuncture|Session 1 - Detailed history and examination, introduction to acupuncture. Sessions 2 - 10 - Each session will begin with insertion and manipulation of needles, which will remain in place for 30 minutes.
11254055|NCT03012412|Experimental|Mindfulness Based Program for Infertility|"Behavioral: MBPI
~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
11254056|NCT03012412|No Intervention|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
11254057|NCT03012399|Experimental|Group I (hypnosedation)|Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.
11254058|NCT03012399|Active Comparator|Group II (verbal support)|Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.
11254059|NCT03012386|Experimental|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
11254060|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (A)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
11254061|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (B)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
11254062|NCT03012360|Placebo Comparator|no antibiotic treatment for VAT|3 days of placebo
11254063|NCT03012360|Experimental|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:
~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .
~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.
~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.
~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
11254064|NCT03012347|Experimental|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
11254065|NCT03012334|Experimental|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
11254066|NCT03012334|Experimental|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
11254067|NCT03012334|Experimental|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
11254068|NCT03012334|Active Comparator|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
11254069|NCT03012334|Placebo Comparator|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
11254070|NCT03012321|Active Comparator|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
11254071|NCT03012321|Active Comparator|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
11254072|NCT03012321|Active Comparator|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
11254073|NCT03012321|Active Comparator|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
11254074|NCT03012282|Experimental|Diagnostic (CT perfusion sequence)|Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.
11254075|NCT03012269|Experimental|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
11254076|NCT03012269|No Intervention|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
11254077|NCT03012256|Experimental|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
11254078|NCT03012256|No Intervention|Control|Home care (standard of care)
11254079|NCT03012243|Active Comparator|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
11254080|NCT03012243|Experimental|Gallbladder aspiration|Gallblader aspiration without drain
11254849|NCT03007264|Experimental|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
11254085|NCT03012204|Active Comparator|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
11254086|NCT03012204|Sham Comparator|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
11254087|NCT03012191|Experimental|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
11254088|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
11254089|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
11254090|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
11254091|NCT03012165|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
11254092|NCT03012152|Active Comparator|Standard conservative group|"Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
~."
11254093|NCT03012152|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
11254094|NCT03012139||Cancer with cachexia|Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
11254095|NCT03012139||Cancer without cachexia|Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
11254096|NCT03012139||No cancer|Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
11254097|NCT03012126|Experimental|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
11254098|NCT03012126|Experimental|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
11254099|NCT03012113|Other|Short term mild cooling|Subjects will undergo a short term mild cooling protocol consisting of personalized water cooling method for approximately 2 hours.
11254100|NCT03012113|Active Comparator|Mirabegron|Subjects will receive one dosage of 200 mg Mirabegron (Astellas Pharma).
11254101|NCT03012113|Placebo Comparator|Placebo|Subjects will receive one dosage of Placebo, which is packed and labeled to mach the active compound.
11254102|NCT03012100|Experimental|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of cycle 1 only. Starting cycle 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
11254103|NCT03012100|Placebo Comparator|Arm II (placebo, sargramostim)|Patients receive cyclophosphamide as in Arm I. Starting cycle 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
11254104|NCT03012087|Experimental|Intervention Group|MyHealthyChoices
11254105|NCT03012087|Placebo Comparator|Control Group|Health Risk Assessment
11254106|NCT03012074|Experimental|Patients with Type II Diabetes|Patients with Type II Diabetes
11254107|NCT03012061|Placebo Comparator|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
11254108|NCT03012061|Experimental|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
11254109|NCT03012061|Experimental|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
11254110|NCT03012048|Experimental|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.
~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
11254111|NCT03012048|Active Comparator|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.
~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
11254112|NCT03012048|Active Comparator|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
11254113|NCT03012048|No Intervention|No intervention|Households are encouraged to continue their usual water treatment practices.
11255144|NCT03005366|Active Comparator|Flecainide|Conventional cardioversion group using intravenous flecainide.
11254114|NCT03012035|Experimental|experimental group|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
11254115|NCT03012035|Other|comparator group|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
11254116|NCT03012022||Healthy Volunteers|
11254117|NCT03012009|Active Comparator|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
11254118|NCT03012009|Active Comparator|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
11254119|NCT03011996|Experimental|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
11254120|NCT03011996|Experimental|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
11254121|NCT03011996|Active Comparator|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
11254122|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
11254123|NCT03011996|Experimental|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
11254124|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
11254125|NCT03011983||Adolescents With Concussion|Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
11254126|NCT03011983||Adolescents Without Concussion|Age- and gender-matched healthy controls (n=160) will be recruited to establish a normative database of whole-brain slow-wave maps from MEG resting-state data as well as white-matter diffusion measures from MRI.
11254127|NCT03011970|Active Comparator|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
11254128|NCT03011970|Active Comparator|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
11254129|NCT03011970|Active Comparator|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
11254130|NCT03011970|Active Comparator|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
11254131|NCT03011970|Active Comparator|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
11254132|NCT03011970|Placebo Comparator|Placebo|Placebo nasal spray.
11254133|NCT03011957||Group 1|HIV positive viral load < 200 copies/ml 50-65 years old CD4 > 350 cells/ml Male or Female
11254134|NCT03011957||Group 2|HIV negative 50-65 years old CD4 > 350 cells/ml Male or Female
11254135|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
11254136|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
11254137|NCT03011931|Experimental|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
11254138|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
11254139|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
11254140|NCT03011905|Experimental|Dexamethasone|Single dose of dexamethasone (Dexagalen) 16 mg iv during operation.
11254141|NCT03011905|Placebo Comparator|Control|Single dose of NaCl, 4 ml, iv during operation.
11254142|NCT03011892|Experimental|Ruxolitinib cream 1.5% BID|Ruxolitinib cream 1.5% applied BID for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
11254143|NCT03011892|Experimental|Ruxolitinib cream 1.5% QD|Ruxolitinib cream 1.5% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
11254144|NCT03011892|Experimental|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
11254145|NCT03011892|Experimental|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% applied QD for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
11254146|NCT03011892|Active Comparator|Triamcinolone 0.1% cream BID|"Vehicle cream applied BID for 4 weeks after triamcinolone 0.1% cream applied BID for initial 4 weeks.
~At Week 8, subjects who meet criteria will be offered open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks."
11255145|NCT03005366|Active Comparator|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
11254147|NCT03011892|Placebo Comparator|Vehicle cream|Vehicle cream applied BID for 8 weeks. At Week 8, subjects who meet criteria will be offered open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
11254148|NCT03011879||1.STEMI patients with symptom onset within 30 days|First round enrollment of STEMI patients with symptom onset within 30 days
11254149|NCT03011879||2.STEMI patients with symptom onset within 30 days|Second round enrollment of STEMI patients with symptom onset within 30 days
11254150|NCT03011879||3.STEMI patients with symptom onset within 30 days|Third round enrollment of STEMI patients with symptom onset within 30 days
11254151|NCT03011866|Experimental|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.
~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
11254152|NCT03011866|Other|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.
~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
11254153|NCT03011853||Non-invasive only|Non-invasive ventilation as first and only respiratory support
11254154|NCT03011853||Invasive|Invasive ventilation with intubation as first respiratory support
11254155|NCT03011853||NIV+Inv|Non-invasive ventilation as first respiratory support followed by invasive ventilation with intubation
11254156|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.
~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
11254157|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
11254158|NCT03011827|Experimental|Prospective cohort|Fibrinogen and/or platelet administration
11254159|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11254160|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11254161|NCT03011801|Experimental|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
11254162|NCT03011801|Placebo Comparator|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
11254163|NCT03011788|Active Comparator|Single day|Single day Golytely purge 4L purge
11254164|NCT03011788|Active Comparator|2 day colon purge|Two days of Golytely purge 8L purge
11254165|NCT03011775|Experimental|study|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
11254166|NCT03011775|Other|control|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
11254167|NCT03011762|Other|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
11254168|NCT03011749|Experimental|FLT PET/CT|FLT PET/CT
11254169|NCT03011736|Experimental|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
11254170|NCT03011723|Experimental|Music therapy|10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions. The treatment is administered individually.
11254171|NCT03011710|Experimental|E-cigarette with nicotine|Nicotine level: 6 mg/ml
11254172|NCT03011710|Experimental|E-cigarette without nicotine|Nicotine level: 0 mg/ml
11254173|NCT03011710|Experimental|Conventional cigarette|Nicotine content: 0,5mg
11254174|NCT03011710|Placebo Comparator|Cigarette tip|Placebo device
11254175|NCT03011684|Experimental|ER Positive - Letrozole|
11254176|NCT03011684|Experimental|ER Positive - Tamoxifen|
11254177|NCT03011684|No Intervention|ER Negative|
11254178|NCT03011671|Experimental|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
11254304|NCT03010930|Sham Comparator|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
11254179|NCT03011658|Placebo Comparator|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
11254180|NCT03011658|Other|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
11254181|NCT03011645|Active Comparator|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
11254182|NCT03011645|Active Comparator|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
11254183|NCT03011645|Placebo Comparator|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
11254184|NCT03011632|Experimental|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
11254185|NCT03011632|Placebo Comparator|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
11254186|NCT03011619|Active Comparator|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
11254187|NCT03011619|Experimental|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
11254188|NCT03011606|Experimental|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
11254189|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
11254190|NCT03011580|Experimental|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.
~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
11254191|NCT03011580|Placebo Comparator|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
11254192|NCT03011567|Experimental|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
11254193|NCT03011567|Experimental|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
11254194|NCT03011567|Experimental|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
11254195|NCT03011567|Experimental|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
11254196|NCT03011554|Experimental|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
11254197|NCT03011541|Active Comparator|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
11254198|NCT03011541|Active Comparator|Arm 2|BMSC provided retrobulbar, subtenon, intravitreal and intravenous for one or both eyes
11254199|NCT03011541|Active Comparator|Arm 3|BMSC provided either intraoptic nerve or subretinal for eye with worse vision with fellow eye receiving either retrobulbar and subtenon or retrobulbar, subtenon and intravitreal; followed by intravenous.
11254200|NCT03011528|Other|VDC - IE x2 & Surgery|"Patients in Arm A receive
~VDC-IE x2: Intensified induction phase:
~4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association
~Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added
~Maintenance phase
~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association
~2nd year : Cyclophosphamide po 25 mg/m²"
11254201|NCT03011528|Other|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive
~VDC-IE & TEMIRI: Intensified induction phase:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:
~4 cycles of TEMIRI (Temozolomide-Irinotecan) association
~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Maintenance phase
~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association
~2nd year : Cyclophosphamide po 25 mg/m²"
11254202|NCT03011528|Other|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive
~VDC-IE x2: Intensified induction phase:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Maintenance phase
~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association
~2nd year : Cyclophosphamide po 25 mg/m²"
11254342|NCT03010683|Active Comparator|Metformin|
11255201|NCT03005054|Experimental|StrataGraft skin tissue|
11254203|NCT03011528|Other|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive
~VDC-IE & TEMIRI: Intensified induction phase:
~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:
~4 cycles of TEMIRI (Temozolomide-Irinotecan) association
~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.
~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion
~Maintenance phase
~1st year : VCC (Vincristine Cyclophosphamide Celecoxib) association
~2nd year : Cyclophosphamide po 25 mg/m²"
11254204|NCT03011515||LRTI patients|Patients with suspicion of LRTI, excluding episodes of COPD exacerbations
11254205|NCT03011515||Non-infectious patients|Afebrile patients with no apparent infectious disease
11254206|NCT03011515||LRTI patients with COPD|Patients with suspicion of LRTI in a sub-group of patients with COPD
11254207|NCT03011502|Experimental|Experimental arm|
11254208|NCT03011489|Experimental|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
11254209|NCT03011489|No Intervention|control group|This group will not receive any treatment
11254210|NCT03011476|Active Comparator|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
11254211|NCT03011476|Placebo Comparator|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
11254212|NCT03011463|Active Comparator|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
11254213|NCT03011463|Active Comparator|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
11254214|NCT03011463|Active Comparator|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
11254215|NCT03011463|Active Comparator|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
11254216|NCT03011463|Active Comparator|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
11254217|NCT03011463|Active Comparator|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
11254218|NCT03011450|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
11254219|NCT03011450|Active Comparator|40 week extension|K-877 or fenofibrate comparator for 40 weeks
11254220|NCT03011437||cases|Patients who undergo esophagogastroduodenoscopy during 01/12/2016 and 31/12/2016 in the First People's Hospital of Kashgar Region.
11254221|NCT03011424|Experimental|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
11254222|NCT03011385|Experimental|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
11254223|NCT03011385|Experimental|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
11254224|NCT03011385|Experimental|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
11254225|NCT03011385|Active Comparator|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
11254226|NCT03011372|Experimental|Pemigatinib|
11254227|NCT03011359|Experimental|1) Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
11254228|NCT03011359|Active Comparator|2) Optimizing B.I PCA mode|Optimizing Basal Infusion (New) PCA mode(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
11254229|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
11254294|NCT03011008|Experimental|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
11254295|NCT03011008|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
11254230|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
11254231|NCT03011333|Experimental|Group 1|HTX-011 60 mg
11254232|NCT03011333|Experimental|Group 2|HTX-011 120 mg
11254233|NCT03011333|Experimental|Group 3|HTX-011 240 mg
11254234|NCT03011333|Experimental|Group 4|HTX-011 400 mg
11254235|NCT03011333|Active Comparator|Group 5|Bupivacaine HCl 50 mg
11254236|NCT03011333|Placebo Comparator|Group 6|Saline Placebo
11254237|NCT03011320|Experimental|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 4 mg/m2 EC1456 at <8 hours prior to surgery"
11254238|NCT03011320|Experimental|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
11254239|NCT03011320|Experimental|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 8 mg/m2 EC1456 at <8 hours prior to surgery"
11254240|NCT03011320|Experimental|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
11254241|NCT03011307|Experimental|Oxytocin|Oxytocin 100 micrograms administered intrathecally
11254242|NCT03011307|Placebo Comparator|Placebos|Placebo injection administered intrathecally
11254243|NCT03011294|Active Comparator|CPAP (in the partner)|Positive airway pressure for treating OSA in the bed partner.
11254244|NCT03011294|Placebo Comparator|Nasal strips (in the partner)|Nasal dilator as a placebo for treating OSA in the bed partner.
11254245|NCT03011281||RA patients who start Tofacitinib|Korean RA patients who start Tofacitinib with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate or biologics.
11254246|NCT03011268|Experimental|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
11254247|NCT03011268|Active Comparator|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
11254248|NCT03011255|Experimental|peptide specific CTL arm|peptide specific CTL, radiation
11254249|NCT03011242||Longitudinal Cohort: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis starting standard of care treatment with a TNFi or non-biologic DMARD.
11254250|NCT03011242||Assay Development: Healthy or Psoriatic Arthritis|Individuals that are healthy or with a diagnosis of Psoriatic Arthritis will be enrolled for blood draws for assay development and/or for an ultrasound for development of techniques and scoring system validation.
11254251|NCT03011242||Cross-Sectional: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis in good disease state on stable non-biologic DMARDS or on stable TNFi.
11254252|NCT03011229|Active Comparator|Pro Core|Subject is randomized to ProCore standard needle.
11254253|NCT03011229|Experimental|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
11254254|NCT03011216|Experimental|Adaptive emotional cognitive control training|"Adaptive emotional n-back task: On each trial of this task, participants are presented with an emotional facial expression. Participants have to indicate whether the emotion presented in the current trial is the same as n trials back. In order to train participants at their individual ability level, the n-level varies by trial block based on participants' performance on the previous block.
~The adaptive emotional n-back task is assumed to train the ability to continuously update emotional material in working memory."
11254255|NCT03011216|Active Comparator|Placebo training|"Adaptive non-emotional feature match task: On each trial of this task, participants are presented with two panels containing 8-12 shapes each. Participants are asked to compare the two panels and decide whether or not they are identical. The panels contain a minimum of 8 shapes and a maximum of 12 shapes, depending on participants' performance on the previous block.
~The adaptive non-emotional feature match task is assumed to train the speed of responding (involving processes like visual search and concentration). It does not trait working memory updating."
11254256|NCT03011203|Experimental|Ketone-ester drink|Oral intake - physical exercise
11254257|NCT03011203|Active Comparator|Carbohydrate drink|Oral intake - physical exercise
11254258|NCT03011190|Experimental|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
11254296|NCT03010995|Active Comparator|18 mg nicotine|E-cigarette with 18 mg nicotine
11254297|NCT03010995|Active Comparator|9 mg nicotine|E-cigarette with 9 mg nicotine
11254298|NCT03010995|Placebo Comparator|0 mg nicotine|E-cigarette with 0 mg nicotine
11254299|NCT03010982|Experimental|Tazemetostat and [14C] Tazemetostat|"Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;
~A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat on Day 15;
~A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of [14C] tazemetostat on Day 16."
11254259|NCT03011190|Active Comparator|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
11254260|NCT03011177|Experimental|teneligliptin|teneligliptin 20mg qd
11254261|NCT03011177|Active Comparator|linagliptin|linagliptin 5mg qd
11254262|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
11254263|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
11254264|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
11254265|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
11254266|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
11254267|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
11254268|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
11254269|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
11254270|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
11254271|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
11254272|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
11254273|NCT03011125|Placebo Comparator|placebo|
11254274|NCT03011125|Experimental|Dexlansoprazole Injection|
11254275|NCT03011112||KL 1|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
11254276|NCT03011112||KL 2|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
11254277|NCT03011112||KL 3|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
11254278|NCT03011112||KL 4|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
11254279|NCT03011099|Experimental|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
11254280|NCT03011099|Active Comparator|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
11254281|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
11254282|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
11254283|NCT03011060|Experimental|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.
~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
11254284|NCT03011060|Experimental|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
11254285|NCT03011060|No Intervention|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
11254286|NCT03011047|Experimental|endoscopic trans-antral approach|The maxillary sinus and prolapsed orbital contents will be visualized employing a 30-degree endoscope for the repair of orbital blow out fracture (sinus scope 4 mm, 30 degrees short one 17 cm).
11254287|NCT03011047|Active Comparator|trans-orbital surgical approach|trans-orbital surgical approach through the lower eyelid Sub-ciliary incision ( through the lower eyelid) The skin incision is made just below the eyelashes.
11254288|NCT03011034|Experimental|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
11254289|NCT03011034|Experimental|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
11254290|NCT03011021|Experimental|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
11254291|NCT03011021|Active Comparator|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.
11254292|NCT03011021|Active Comparator|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
11254293|NCT03011021|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
11254300|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
11254305|NCT03010917|Experimental|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
11254306|NCT03010917|Placebo Comparator|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
11254307|NCT03010904|Experimental|pasteurized milk|milk that has undergone pasteurization treatment
11254308|NCT03010904|Experimental|homogenized pasteurized milk|Milk that has undergone homogenization and pasteurization treatment
11254309|NCT03010904|Experimental|UHT milk|Milk that has undergone homogenization and ultra high temperature treatment
11254310|NCT03010891|Active Comparator|control condition|Preterm infants in the control condition will receive only usual NICU care, plus positioning and gentle touch during intrusive procedures.
11254311|NCT03010891|Experimental|experimental condition|The bundle of supportive interventions will be designed to alleviate preterm infants' stress/pain from birth to discharge from the hospital NICU.
11254312|NCT03010878|Experimental|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
11254313|NCT03010878|Experimental|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
11254314|NCT03010865|Experimental|Sodium Butyrate|Dietary Supplement: Sodium Butyrate 4.38 gms of sodium butyrate per day for 12 weeks
11254315|NCT03010865|Placebo Comparator|Placebo Oral Capsule|Placebo Oral Capsule placebo capsules containing approximately 9 mg of sodium butyrate per day
11254316|NCT03010852|No Intervention|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
11254317|NCT03010852|Experimental|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
11254318|NCT03010839|Active Comparator|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
11254319|NCT03010839|Placebo Comparator|Control|Control group without remote ischemic preconditioning
11254320|NCT03010826||40 Demyelinating Disease patients|
11254321|NCT03010826||40 Non-patient participants|
11254322|NCT03010813|Experimental|Novel single port robotic system|A single port innovation designed to deliver an articulating 3D high definition camera and three fully articulating instruments through a single 25-mm cannula
11254323|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
11254324|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
11254325|NCT03010787|Experimental|Part 1|Single ascending dose of oral V565
11254326|NCT03010787|Experimental|Part 2 - V565|Single dose level of oral V565 TID for 14 days
11254327|NCT03010787|Placebo Comparator|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
11254328|NCT03010787|Experimental|Part 3|Single dose of V565 in patient volunteers
11254329|NCT03010787|Experimental|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
11254330|NCT03010774|Experimental|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
11254331|NCT03010774|Active Comparator|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
11254332|NCT03010761|Experimental|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
11254333|NCT03010761|Experimental|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
11254334|NCT03010761|Experimental|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
11254335|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
11254336|NCT03010735|Active Comparator|Probiotics|The patient take two chewing tablet per day, which contain 4.0E+10 CFU of probiotics.
11254337|NCT03010735|Placebo Comparator|Placebo|The patient take two placebo chewing tablet per day.
11254338|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle
~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
11254339|NCT03010696||Healthy subjects|Normal kidney function
11254340|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
11254341|NCT03010683|Active Comparator|liraglutide|
11254343|NCT03010670|Experimental|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
11254344|NCT03010670|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
11254345|NCT03010657|Experimental|Experimental intervention|Subjects will add certain foods to what they normally eat.
11254346|NCT03010657|No Intervention|Non-experimental intervention|Subjects will continue eating normally.
11254347|NCT03010657|No Intervention|Observational|Subjects will continue eating normally.
11254348|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
11254349|NCT03010631|Active Comparator|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
11254350|NCT03010631|Experimental|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
11254351|NCT03010631|Experimental|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
11254352|NCT03010631|Experimental|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
11254353|NCT03010618|Other|Study Group|
11254354|NCT03010605|Active Comparator|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
11254355|NCT03010605|Active Comparator|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
11254356|NCT03010579|Experimental|erythropoietin group|For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
11254357|NCT03010579|Active Comparator|iron supplementation|If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
11254358|NCT03010553|Experimental|Oropharynx|Tumors of the oropharynx T1T2N0 treated with radiotherapy
11254359|NCT03010553|Experimental|Larynx|Tumors of the T1T2N0 larynx treated by surgery, laser or robot
11254360|NCT03010540|Experimental|Morphine Plus Fentanyl|
11254361|NCT03010540|Active Comparator|Fentanyl only|
11254362|NCT03010527|Placebo Comparator|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
11254363|NCT03010527|Experimental|Bimekizumab dosing regimen 1|Subjects will receive bimekizumab injections every four weeks (Q4W)
11254364|NCT03010527|Experimental|Bimekizumab dosing regimen 2|Subjects will receive bimekizumab injections every four weeks (Q4W)
11254365|NCT03010527|Experimental|Bimekizumab dosing regimen 3|Subjects will receive bimekizumab injections every four weeks (Q4W)
11254366|NCT03010514||case|
11254367|NCT03010514||control|
11254368|NCT03010501|Experimental|100% Food Energy Density|Baseline Food Energy Density
11254369|NCT03010501|Experimental|80% Food Energy Density|Lower Food Energy Density
11254370|NCT03010501|Experimental|120% Food Energy Density|Higher Food Energy Density
11254371|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
11254372|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
11254373|NCT03010475|Experimental|Furosemide/Rosuvastatin/SNAC/Semaglutide|
11254374|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
11254375|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
11254376|NCT03010449|Experimental|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
11254377|NCT03010436|Other|Open-Label|All subjects will receive the study medication- benralizumab
11254378|NCT03010423|Experimental|Nicorandil|
11254379|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
11254380|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
11254381|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
11254382|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
11254383|NCT03010384|Active Comparator|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
11254384|NCT03010384|No Intervention|Control|Standard treatment from the Department of Rheumatology
11254385|NCT03010371|Experimental|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the presential version of the positive psychotherapy
11254386|NCT03010371|Experimental|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
11254387|NCT03010371|Experimental|Cognitive Behavioral Therapy|A group of breast cancer survivors are randomly allocated to the presential cognitive behavioral therapy (Cognitive Behavioral Stress Management, CBSM)
11254417|NCT03010176|Experimental|Part 1 Arm 2: MK-1454+Pembro (Cut/Subcut Lesions)|Participants with cut or subcut lesions receive escalating doses of MK-1454 via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond PLUS pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
11254388|NCT03010358|Experimental|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity. Patients who do not receive MRD may continue receive entospletinib beyond 12 cycles with approval from the treating physician and sponsor-investigator in the absence of disease progression or unacceptable toxicity.
11254389|NCT03010345|Experimental|Osmed self inflating tissue expanders|All patients will undergo a two-stage procedure ,second stage under General endotracheal anesthesia. The first stage will be placement of the expanders. The second stage will be 21 days later, with removal of the expanders, palatal revision, and closure of the oronasal fistula
11254390|NCT03010345|Experimental|Iliac bone graft|Placement of bone graft without the use of self inflating expanders
11254391|NCT03010319|Experimental|PriMatrix|Arm will receive PriMatrix Dermal Repair Scaffold plus secondary dressings to maintain a moist wound healing environment and an appropriate off-loading device.
11254392|NCT03010319|Active Comparator|Standard of Care|Arm will receive moist wound therapy consisting of 0.9% Sodium Chloride gel plus secondary dressings and an appropriate off-loading device.
11254393|NCT03010306|No Intervention|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
11254394|NCT03010306|Active Comparator|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation & knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
11254395|NCT03010280|Experimental|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
11254396|NCT03010280|Active Comparator|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
11254397|NCT03010267|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
11254398|NCT03010267|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
11254399|NCT03010254|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
11254400|NCT03010254|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
11254401|NCT03010241|Experimental|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
11254402|NCT03010241|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
11254403|NCT03010228|Active Comparator|VLA15 12 µg with Alum|VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).
11254404|NCT03010228|Active Comparator|VLA15 12 µg w/o Alum|VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).
11254405|NCT03010228|Active Comparator|VLA15 48 µg with Alum|VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).
11254406|NCT03010228|Active Comparator|VLA15 48 µg w/o Alum|VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).
11254407|NCT03010228|Active Comparator|VLA15 90 µg with Alum|VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).
11254408|NCT03010228|Active Comparator|VLA15 90 µg w/o Alum|VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).
11254409|NCT03010215|Other|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
11254410|NCT03010202|Experimental|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
11254411|NCT03010202|No Intervention|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
11254412|NCT03010202|Experimental|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
11254413|NCT03010202|No Intervention|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
11254414|NCT03010189|Experimental|Patient|Cluster headache patients are examined with light reflex pupillometry, two weeks actigraphy and heart-rate variability monitoring both in headache phase and remission phase.
11254415|NCT03010189|Active Comparator|Controls|Healthy controls undergo the same examinations once: light reflex pupillometry, actigraphy and heart-rate variability monitoring.
11254416|NCT03010176|Experimental|Part 1 Arm 1: MK-1454 (Cut/Subcut Lesions)|Participants with cutaneous (cut) or subcutaneous (subcut) lesions receive escalating doses of MK-1454 monotherapy via IT injection on Days 1, 8 and 15 of each 21-day cycle for Cycles 1, 2 and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond for up to 35 cycles (up to approximately 2 years).
11254433|NCT03010085|Active Comparator|A (Open left-sided hepatectomy)|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
11257060|NCT02992041|Experimental|Lower dose VVZ-149 Injections|
11254418|NCT03010176|Experimental|Part 1 Arm 3: MK-1454+Pembro (Visceral Lesions)|Participants with visceral lesions receive escalating dose frequencies of MK-1454 via IT injection at escalating dose frequencies (Day 1 of each 21-day cycle for up to 35 cycles, then Days 1 and 8 of each 21-day cycle for two cycles, then Day 1 of each 21 day cycle up to 35 cycles, then Days 1, 8 and 15 of each 21-day cycle for two cycles followed by Day 1 of each 21-day cycle up to 35 cycles, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
11254419|NCT03010176|Experimental|Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory|Participants with HNSCC who are anti-programmed cell death-1 or anti-programmed cell death-ligand 1 refractory receive MK-1454 at the preliminary Recommended Phase 2 Dose (RP2D) determined by dose escalation in Part 1 Arm 1 and 2 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
11254420|NCT03010176|Experimental|Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC|Participants with TNBC who are anti-PD-1/PD-L1 treatment-naïve or who have refractory unresectable locally advanced or metastatic TNBC receive MK-1454 at the preliminary RP2D determined by dose escalation in Part 1 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
11254421|NCT03010176|Experimental|Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver|Participants with solid tumors with liver metastases/lesions who are anti-PD-1/PD-L1 treatment-naïve receive MK-1454 at the preliminary RP2D based on Part 1: MK-1454+pembro (visceral lesions) treatment arm via IT injection in a to-be-determined dose and frequency, based on data from Arm 3, PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
11254422|NCT03010163|Active Comparator|Health Fair + Pedometer|Participants will get free weight, height, waist, and blood pressure testing at health fairs stationed at NYC taxi garage bases and airport taxi holding lots. Health fair staff will follow up with participants who need to see a doctor due to a high blood pressure reading or other unusual result that needs a physician follow-up. All participants will be given a pedometer with instructions on how to use it to track their daily step counts. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
11254423|NCT03010163|Experimental|Health Fair, Pedometer + Text Messaging|In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
11254424|NCT03010163|Experimental|Health Fair, Pedometer, Social Network Support|Each participant in this group will receive the health fair services with general follow-up along with a pedometer with instructions on how to use the device to track daily step counts. Additionally, participants in this group will be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given a social network guide to train their family and/or friends on how to best motivate the participants . Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
11254425|NCT03010163|Experimental|Health Fair, Pedometer, Text Msg, Social Network Support|Participants in this group will receive the health fair service with general follow-up, along with a pedometer with instructions on how to use the device to track daily step counts. Participants will also receive daily healthy living advice through encouraging text messages about walking through text messages sent by our staff to participants' cellular phones. Participants will also be asked to provide the names of family or friends who will form a social support network team. This team will provide encouragement and remind participants to maintain a healthy lifestyle and increase daily walking activities. Participants will be given tools to train their family and/or friends on how to best motivate the drivers. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
11254426|NCT03010150||Observational (blood tests, questionnaires)|Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
11254427|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
11254428|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
11254429|NCT03010124|Other|Patients with ovarian cancer|
11254430|NCT03010111|Other|health care workers|health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital
11254431|NCT03010098|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
11254432|NCT03010098|Experimental|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
11254434|NCT03010085|Experimental|B (Laparoscopic left-sided hepatectomy)|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
11254435|NCT03010072|Active Comparator|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
11254436|NCT03010072|Active Comparator|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
11254437|NCT03010059|Experimental|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254438|NCT03010059|Experimental|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254439|NCT03010059|Experimental|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254440|NCT03010059|Experimental|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254441|NCT03010059|Experimental|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254442|NCT03010059|Experimental|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254443|NCT03010059|Experimental|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254444|NCT03010059|Experimental|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254445|NCT03010059|Experimental|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254446|NCT03010059|Experimental|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254447|NCT03010059|Experimental|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254448|NCT03010059|Experimental|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
11254449|NCT03010046|Experimental|ANX005 Monotherapy|ANX005 intravenous infusion
11254450|NCT03010046|Experimental|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
11254451|NCT03010046|Placebo Comparator|Placebo|Placebo intravenous infusion
11254452|NCT03010033|No Intervention|regular care|[Control group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary and regular rehabilitation-propaganda; postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time) and early ambulation unless serious patients.
11254453|NCT03010033|Experimental|pulmonary rehabilitation|[Study group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary, regular rehabilitation-propaganda and interventional pulmonary rehabilitation (preoperative part); postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time), early ambulation unless serious patients and interventional pulmonary rehabilitation (postoperative part).
11254454|NCT03010020|Experimental|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
11254455|NCT03010020|Placebo Comparator|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
11254456|NCT03010020|No Intervention|STI-Negative|MSM without rectal GC and/or CT infection
11254457|NCT03009994|Other|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
11254460|NCT03009981|Experimental|Arm B: Degarelix/Apalutamide|Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
11254461|NCT03009981|Experimental|Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone|Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
11254462|NCT03009968|No Intervention|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
11254463|NCT03009968|Experimental|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
11254464|NCT03009955||Group P|patients who received primary caesarean section
11254465|NCT03009955||Group R|patients who received repeated caesarean section
11254466|NCT03009916|Other|Healthy controls|Healthy controls found according to the protocol
11254467|NCT03009916|Other|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
11254468|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
11254469|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
11254470|NCT03009890|Experimental|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
11254471|NCT03009890|Active Comparator|Plaster immobilization|Standard local hospital protocol for cast treatment
11254472|NCT03009877|Active Comparator|Preoxygenation with face mask|Standard preoxygenation with a mask will be performed for five minutes. Once preoxygenation is complete, patients will be induced with standard induction medications including lidocaine, midazolam, fentanyl and propofol. Once the patient is apneic, one breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. The 5.5mm flexible intubation scope will be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope. Once the flexible intubation scope is in the trachea, the endotracheal tube (7.0 mm unless otherwise specified) will be advanced. Ventilation will not begin until the primary or secondary endpoints are reached.
11254473|NCT03009877|Experimental|Preoxygenation via hi flow nasal cannula|The high flow nasal cannula (Optiflow) will be applied as soon as the patient is in the operating room. The patient will be preoxygenated with high flow nasal cannula at 50 L/min for 5 minutes. After induction, general anesthesia will be maintained with a propofol infusion. One breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. Upon apnea, the Optiflow™ flow will be increased to 70 L/min and jaw thrust will be performed until the patient is adequately relaxed. The video laryngoscope (C-MAC) will then be introduced into the oropharynx and the flexible intubation scope advanced into the trachea with the assistance of the C-MAC. Once the flexible intubation scope is in the trachea, the endotracheal tube will be advanced.
11254474|NCT03009864|Experimental|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
11254475|NCT03009864|Placebo Comparator|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription
~, every bag weighs 4.87g, take it one bag each time, two times a day."
11254476|NCT03009851|Experimental|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
11254477|NCT03009851|No Intervention|Control|The control group only received the typical activities conducted in LTC facilities.
11254478|NCT03009838|Active Comparator|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
11254479|NCT03009838|Active Comparator|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
11254480|NCT03009812|Active Comparator|Group 1|26 subjects who are planned for transverse uterine incision
11254481|NCT03009812|Active Comparator|Group 2|26 subjects who are planned for longitudinal uterine incision
11254482|NCT03009799|Active Comparator|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
11254483|NCT03009799|Placebo Comparator|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
11254484|NCT03009786||Elderly institutionalized subjects or outpatients|
11254485|NCT03009773|Experimental|multitasking walking|Multitasking Group: rehabilitation multitasking walking.
11254486|NCT03009773|Active Comparator|walking simple task|Simple task group : Traditional walking rehabilitation
11254487|NCT03009760|Experimental|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
11254488|NCT03009760|Experimental|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
11254489|NCT03009760|Experimental|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
11254490|NCT03009760|Experimental|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
11254491|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
11254492|NCT03009734|Other|ATx201 (2% dermal formulation A) and Placebo|
11254493|NCT03009734|Other|ATx201 (2% dermal formulation B) and Placebo|
11254494|NCT03009734|Other|ATx201 (2% dermal formulation C) and Placebo|
11254495|NCT03009708|Experimental|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
11255202|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
11254496|NCT03009695|Experimental|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
11254497|NCT03009695|Experimental|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
11254498|NCT03009695|Experimental|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
11254499|NCT03009695|Experimental|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
11254500|NCT03009695|Sham Comparator|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.
~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).
~In this group, stimulation will be performed with the following features:
~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
11254501|NCT03009682|Other|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
11254502|NCT03009643|Experimental|iNO Group|Patients are treated with iNO at a concentration of 5-10 ppm for 3-5 days according to the clinical conditions
11254503|NCT03009643|Other|Control|Patients are treated without iNO.
11254504|NCT03009630|Experimental|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
11254505|NCT03009617|Experimental|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
11254506|NCT03009617|No Intervention|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
11254507|NCT03009604|Experimental|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
11254508|NCT03009604|Active Comparator|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation.
11254509|NCT03009591|Experimental|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
11254510|NCT03009591|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
11254511|NCT03009578|Experimental|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = [body weight (kilogram)× (15-actual Hemoglobin)] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
11254512|NCT03009578|Active Comparator|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
11254513|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
11254514|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
11257061|NCT02992041|Experimental|Higher dose VVZ-149 Injections|
11254515|NCT03009539|Experimental|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
11254516|NCT03009539|No Intervention|Treatment as Usual|Participants in this condition will not receive an intervention.
11254517|NCT03009526|Active Comparator|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
11254518|NCT03009526|Experimental|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:
~24-35.9 kg: Two tablets
~36-59.9 kg: Three tablets
~60-79.9 kg: Four tablets
~≥80 kg: Five tablets"
11254519|NCT03009513|Experimental|single arm|
11254520|NCT03009500|Active Comparator|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
11254521|NCT03009500|Active Comparator|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
11254522|NCT03009500|Placebo Comparator|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
11254523|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
11254524|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
11254525|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
11254526|NCT03009474|Experimental|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
11254527|NCT03009474|Active Comparator|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
11254528|NCT03009461|Experimental|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
11254529|NCT03009461|Active Comparator|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
11254530|NCT03009448||Late onset depression|
11254531|NCT03009435|Experimental|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :
~Tarnier and Chantreuil technique
~or SOGC technique"
11254532|NCT03009435|No Intervention|expectative management|Expectative management . No manual rotation
11254533|NCT03009422|Experimental|Treatment|CO2 fractional laser with local application of Pentostam
11254534|NCT03009422|Active Comparator|control|Intra-lesinal Pentostam injedction
11254535|NCT03009409|Active Comparator|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
11254536|NCT03009409|Placebo Comparator|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
11254537|NCT03009396|Experimental|RHB-104|RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, 10 mg clofazimine
11254538|NCT03009383|Experimental|A bedside portable endoscopy|
11254539|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at< 20 weeks of gestation.
11254540|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
11254541|NCT03009357||control|euthyroid, healthy adults
11254542|NCT03009344|Experimental|tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later).
11254543|NCT03009331|Experimental|Prone position|Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.
11254544|NCT03009331|Active Comparator|Supine position|Intervention: Lungrecruitment in supine position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s. Clinical routine.
11254545|NCT03009318|Other|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
11254546|NCT03009305|Experimental|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
11254547|NCT03009292|Experimental|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
11254548|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
11254549|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
11254550|NCT03009266|Experimental|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
11254551|NCT03009266|Experimental|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
11254552|NCT03009253|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
11254553|NCT03009253|Experimental|Chemotherapy Group|"Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
~Followed by Concurrent chemoradiotherapy:
~(Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)"
11255439|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
11254554|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
11254555|NCT03009227|Active Comparator|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
11254556|NCT03009227|Experimental|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
11254557|NCT03009214|Experimental|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion
~Planned doses are:
~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
11254558|NCT03009201|Experimental|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11254559|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
11254560|NCT03009162|Experimental|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
11254561|NCT03009162|Experimental|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
11254562|NCT03009149|Experimental|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
11254563|NCT03009136|Experimental|SCRT group|3g, three times a day, each taken before or between meals
11254564|NCT03009136|Placebo Comparator|placebo group|3g, three times a day, each taken before or between meals
11254565|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
11254566|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
11254567|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
11254568|NCT03009110|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
11254569|NCT03009110|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
11254570|NCT03009097|Active Comparator|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
11254571|NCT03009097|Active Comparator|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
11254572|NCT03009084|Experimental|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
11254573|NCT03009084|No Intervention|Control group|Usual care.
11254574|NCT03009071|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
11254575|NCT03009071|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
11254576|NCT03009058|Experimental|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
11254577|NCT03009058|Experimental|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254578|NCT03009058|Experimental|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine +capecitabine combination therapy.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254579|NCT03009058|Experimental|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.
~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254580|NCT03009058|Experimental|IMM-101+FOLFOX colorectal cancer|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254581|NCT03009058|Experimental|IMM-101+FOLFIRI+CETUXIMAB CRC|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254582|NCT03009058|Experimental|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
11257062|NCT02992041|Placebo Comparator|Placebo|
11254583|NCT03009058|Experimental|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
11254584|NCT03009058|Experimental|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.
~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254585|NCT03009058|Experimental|IMM-101+anti-PD1 lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.
~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
11254586|NCT03009058|Experimental|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
11254587|NCT03009058|Experimental|IMM-101+anti-PD1 melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
11254588|NCT03009058|Experimental|IMM-101+ anti-CTLA-4 melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
11254589|NCT03009058|Experimental|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
11254590|NCT03009058|Experimental|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254591|NCT03009058|Experimental|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
11254592|NCT03009058|Experimental|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.
~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
11254593|NCT03009045|Experimental|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
11254594|NCT03009032|Experimental|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
11254595|NCT03009032|Placebo Comparator|PLACEBO|Lactose
11254596|NCT03009019|Experimental|DFN-15 Active|DFN-15 Active
11254597|NCT03009019|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
11254598|NCT03009006|Experimental|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
11254599|NCT03009006|Experimental|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
11254600|NCT03009006|Placebo Comparator|Placebo|Mechanical preparation without intracanal medications.
11254601|NCT03008993|Experimental|Post-Intervention|The HQIS comprises three phases: 1) clinician training - to improve communication-relational skills and to instruct on the project; 2) center support - 4 on site visits by experts of the project team, aimed to introduce the project and boost motivation, instruct staff on how to implement recommendations, help with context analysis and identification of solutions; assess actual implementation in the center; 3) implementation of EBM recommendations.
11254602|NCT03008993|No Intervention|Control|
11254603|NCT03008980||Community GI Group|Diagnostic Test
11254604|NCT03008980||Academic GI Group|Diagnostic Test
11254605|NCT03008980||Academic Esophageal Dysplasia and Cancer|Diagnostic Test
11254606|NCT03008980||Community Barrett's Esophagus Screening|Diagnostic Test
11254607|NCT03008980||Community Esophageal Dysplasia|Diagnostic Test
11254608|NCT03008980||Post-Ablation BE and Esophagus Dysplasia|Diagnostic Test
11254609|NCT03008980||GERD, BE, and Esophageal Dysplasia|Diagnostic Test
11254610|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
11254611|NCT03008954|Placebo Comparator|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
11254612|NCT03008954|Experimental|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
11254613|NCT03008954|Experimental|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
11254614|NCT03008941|Experimental|FMT|"Fecal microbiota capsules (provided by Openbiome).
~Dosage:
~Induction: 10 capsules (single dose)
~Maintenance: 5 capsules, weekly, during 7 weeks."
11254615|NCT03008941|Placebo Comparator|Placebo|"Placebo capsules (provided by Openbiome).
~Dosage:
~Induction: 10 capsules (single dose)
~Maintenance: 5 capsules, weekly, during 7 weeks."
11254616|NCT03008928|No Intervention|Control|No intervention
11254617|NCT03008928|Experimental|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
11254618|NCT03008915|Active Comparator|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
11254619|NCT03008915|Placebo Comparator|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
11254620|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
11254621|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
11254622|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
11254623|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
11254624|NCT03008876|Experimental|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
11254625|NCT03008876|Active Comparator|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
11254626|NCT03008863|Experimental|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.
~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
11254627|NCT03008863|No Intervention|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
11254628|NCT03008850|Active Comparator|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
11254629|NCT03008850|Active Comparator|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
11254630|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
11254631|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
11254632|NCT03008811|Active Comparator|Cryoballoon|Pulmonary vein isolation with cryoballoon catheter.
11254633|NCT03008811|Active Comparator|Radiofrequency|Pulmonary vein isolation with radiofrequency ablation catheter.
11254634|NCT03008798|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
11254635|NCT03008798|Placebo Comparator|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
11254636|NCT03008785|Experimental|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
11254637|NCT03008785|Experimental|group placebo and exercise|The placebo group received 100mg containing starch of corn.
11254638|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
11254639|NCT03008772||Stent Types|the stent types for angina classification at follow up
11254640|NCT03008759|Placebo Comparator|Placebo|Dentifrice without fluoride
11254641|NCT03008759|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
11254642|NCT03008759|Experimental|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
11254643|NCT03008759|Experimental|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
11254644|NCT03008746|Experimental|not Pseudomonas aeruginosa colonized|
11254645|NCT03008746|Experimental|Pseudomonas aeruginosa colonized|
11254646|NCT03008746|Experimental|Pseudomonas aeruginosa OprD mutant colonized|
11254647|NCT03008733|Active Comparator|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
11254648|NCT03008733|Active Comparator|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
11254649|NCT03008733|Active Comparator|anti MAG|patient with neuropathy antibody Anti-MAG
11254650|NCT03008733|Placebo Comparator|healthy|healthy patient
11254651|NCT03008720|Active Comparator|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
11254652|NCT03008720|Placebo Comparator|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
11254653|NCT03008720|Active Comparator|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
11254654|NCT03008720|Placebo Comparator|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
11254655|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
11254656|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
11254657|NCT03008694|Experimental|1|PET/CT
11254658|NCT03008681|Experimental|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.
~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.
~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
11254659|NCT03008668|Experimental|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
11254660|NCT03008668|Active Comparator|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
11254661|NCT03008655|Active Comparator|Nd-YAG|ND-YAG only
11254662|NCT03008655|Experimental|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
11254663|NCT03008642|Experimental|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
11254664|NCT03008629|Experimental|Podofix nail brace|for mild ingrown toenails
11254665|NCT03008629|Experimental|Combiped nail brace|for Severe dystrophic ingrown toenails
11254666|NCT03008629|Experimental|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
11254667|NCT03008616|Active Comparator|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
11254668|NCT03008616|Placebo Comparator|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
11254669|NCT03008603|Experimental|Procedures with XACT Robotic System|CT-guided minimally invasive percutaneous procedures using the XACT Robotics system
11254670|NCT03008590|Other|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
11254671|NCT03008590|Other|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
11254672|NCT03008577|No Intervention|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
11254673|NCT03008577|Active Comparator|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
11254674|NCT03008551|Experimental|Empagliflozin group|Each participant will receive empagliflozin 25mg daily for 3 months
11254675|NCT03008551|Active Comparator|Metformin group|Each participant will receive metformin 1500mg daily for 3 months
11254676|NCT03008538|Experimental|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
11254677|NCT03008538|Active Comparator|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
11254678|NCT03008525|Experimental|obese patients (group OB)|patients with body mass index ≥ 35 kg/m²
11254679|NCT03008525|Active Comparator|non-obese patients (group NO)|patients with body mass index < 30 kg/m²
11254680|NCT03008512|Experimental|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
11254681|NCT03008499|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254682|NCT03008499|No Intervention|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254683|NCT03008486|Active Comparator|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
11254684|NCT03008486|Placebo Comparator|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
11254685|NCT03008486|Active Comparator|Stroke - real|Spastic patients stroke receiving the real soft splint
11254686|NCT03008486|Placebo Comparator|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
11254710|NCT03008330|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254711|NCT03008330|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254687|NCT03008473|Experimental|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
11254688|NCT03008473|Experimental|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
11254689|NCT03008460|Experimental|Eziclen®/Izinova®|
11254690|NCT03008460|Active Comparator|Klean-Prep®|
11254691|NCT03008447|Experimental|LEM5; LEM10; PBO; ZOL|Participants will receive LEM5 (one lemborexant [LEM] 5 milligram [mg] tablet and one zolpidem [ZOL]-matched placebo [PBO] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
11254692|NCT03008447|Experimental|LEM10; ZOL; LEM5; PBO|Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
11254693|NCT03008447|Experimental|ZOL; PBO; LEM10; LEM5|Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
11254694|NCT03008447|Experimental|PBO; LEM5; ZOL; LEM10|Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
11254695|NCT03008434|Experimental|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
11254696|NCT03008421|Experimental|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
11254697|NCT03008421|Placebo Comparator|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
11254698|NCT03008408|Experimental|Arm I (ribociclib, everolimus, letrozole)|Patients receive ribociclib PO QD, everolimus PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11254699|NCT03008408|Experimental|Arm II (everolimus, letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11254700|NCT03008395|Experimental|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
11254701|NCT03008395|Active Comparator|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
11254702|NCT03008382|Other|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.
~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
11254703|NCT03008382|Other|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.
~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
11254704|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11254705|NCT03008356|Experimental|L-carnitine|Oral L-carnitine 1000mg twice daily
11254706|NCT03008356|Experimental|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
11254707|NCT03008356|Placebo Comparator|Placebo|Placebo capsules twice daily
11254708|NCT03008343|Experimental|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254709|NCT03008343|Active Comparator|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254712|NCT03008317|Active Comparator|non metallic|PEEK denture base,
11254713|NCT03008317|Placebo Comparator|metallic denture base|cobalt chromium alloy denture base
11254714|NCT03008304|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254715|NCT03008304|No Intervention|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254716|NCT03008291||Heart Failure Group|Patients who have left bundle branch block (LBBB), right bundle branch block (RBBB) or interventricular conduction delay (IVCD) with a QRS duration of greater than 120 ms and left ventricular ejection fraction (LVEF) ≤ 35% will be enrolled in this arm. The primary care physician will have recommended either CRT-D Implantation or CRT-P Implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
11254717|NCT03008291||Atrioventricular Block Group|Patients who have developed second or third degree atrioventricular block (AV block). The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
11254718|NCT03008278|Experimental|Treatment (olaparib, ramucirumab)|Patients receive olaparib PO BID on days 1-14 and ramucirumab IV over 60 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11254719|NCT03008265||Colonic cancer resection|
11254720|NCT03008239|Experimental|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.
~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
11254721|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
11254722|NCT03008200||RDS +|postpartum RDS developed group
11254723|NCT03008200||RDS -|postpartum RDS undeveloped group
11254724|NCT03008187|Experimental|SEL24/MEN1703|"SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
~Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.
~Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1."
11254725|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.
~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.
~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
11254726|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.
~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
11254727|NCT03008161|Experimental|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
11254728|NCT03008161|Experimental|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
11254729|NCT03008161|Experimental|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
11254730|NCT03008161|Experimental|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
11254731|NCT03008148|Active Comparator|Radiation,Temozolomide|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
~Rest Phase: Rest for 4 weeks.
~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
~Maintenance Phase: No maintenance treatment until disease progression confirmed."
11254732|NCT03008148|Experimental|Radiation,Temozolomide,Siroquine(JP001)|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).
~Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.
~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).
~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
11254733|NCT03008122|Experimental|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
11254734|NCT03008122|Experimental|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
11254735|NCT03008109|Experimental|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
11254736|NCT03008083|Active Comparator|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
11254737|NCT03008083|Active Comparator|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
11254738|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
11254739|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
11254740|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
11254741|NCT03008057|Active Comparator|vitamin D supplementation|patients with type 2 diabetes receive 1 tablet (4000 IU ) vitamin D supplementation, one time a day, for 3 months.
11254742|NCT03008057|Placebo Comparator|vitamin D placebo|patients with type 2 diabetes receive one tablet of vitamin D placebo for 3 months
11254763|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
11254743|NCT03008044|Experimental|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
11254744|NCT03008044|Experimental|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
11254745|NCT03008031|Experimental|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
11254746|NCT03008031|Experimental|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
11254747|NCT03008031|Experimental|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
11254748|NCT03008018|Other|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
11254749|NCT03008005|Placebo Comparator|Placebo Oral Capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.
~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
11254750|NCT03008005|Experimental|Dronabinol Cap 5 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.
~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
11254751|NCT03008005|Experimental|Dronabinol Cap 10 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.
~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
11254752|NCT03007992|Experimental|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
11254753|NCT03007979|Experimental|Palbociclib + letrozole or + fulvestrant|"Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).
~Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.
~Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
~Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.
~Optional research biopsy at baseline and progression
~Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
11254754|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
11254755|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
11254756|NCT03007953|Experimental|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
11254757|NCT03007953|No Intervention|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
11254758|NCT03007940|Experimental|NIATx Strategy|"The implementation intervention, NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective."
11254759|NCT03007940|Placebo Comparator|Wait List Control|The wait-list control group will receive the NIATx strategy at the end of the twelve month implementation period for the initial cohort. During the first year of the study, they will follow a business as usual approach to the integration of co-occurring substance use and mental health services.
11254760|NCT03007927|Experimental|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
11254761|NCT03007927|Active Comparator|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
11254762|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
11254764|NCT03007901|Experimental|Pilot Cohort 1|This Pilot Study will be conducted to allow us to evaluate and test the various study processes, including: consent/enrollment, run-in-trial monitoring, measurement tools, outcome assessment, educational materials, and especially the mindfulness-based climate action trainings. The pilot study does not include a control group, and data will not be used for efficacy outcome analysis.
11254765|NCT03007888|Other|Sequence 1|Treatment Period 1: ER CD-LD Capsules - 15 days; Washout Period 7-days; Treatment Period 2- IR CD-LD Tablet - 15 days
11254766|NCT03007888|Other|Sequence 2|Treatment Period 1- IR CD-LD Tablet - 15 days; Washout Period 7-days; Treatment Period 2- ER CD-LD Capsules - 15 days
11254767|NCT03007875|Experimental|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254768|NCT03007875|No Intervention|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254769|NCT03007836|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254770|NCT03007836|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254771|NCT03007823|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254772|NCT03007823|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11254773|NCT03007810|Experimental|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
11254774|NCT03007810|Placebo Comparator|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
11254775|NCT03007797||vaccination rate- pregnant- influenca|
11254776|NCT03007784|Experimental|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
11254777|NCT03007784|Active Comparator|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
11254778|NCT03007771|Experimental|MR-HIFU|"Philips 1.5T MRI scanner equipped with a Sonalleve V2 HIFU system will be used
~Will be scanned in the MRI in 1 or more positions to the extremities and/or pelvis while aligned to the HIFU system. The HIFU device will then be used to apply sub-clinical levels (≤ 41°C) of heat to one or more small volumes. Regions will be heated to the desired temperature for variable short durations of time not exceeding 30 minutes.
~After the session is complete, the patient will be removed from the MR-HIFU system and, following a 15-30-minute period of monitoring for any adverse events, allowed to leave.
~Before the scan, after the scan and 5-10 days following the scan, participants will be asked to rate any pain, discomfort, in the area to be heated, as well as any anxiety or claustrophobia on a scale of 1-10 with 1 being minimal/none and 10 being extreme. The skin area to be treated will also be reviewed for any redness/discoloration."
11254779|NCT03007758|Active Comparator|robotic ventral hernia repair (VHR)|Robotic VHR
11254780|NCT03007758|Active Comparator|open ventral hernia repair (VHR)|Open VHR
11254781|NCT03007745|Experimental|REVAMP|Veterans randomized to this arm will have access to the Remote Veteran Apnea Management Platform (REVAMP) a personalized, interactive website that allows Veterans to be evaluated for OSA without travelling to the sleep center.
11254782|NCT03007745|Active Comparator|In-person management|Veterans randomized to this arm will receive standard in-person management of their sleep apnea in the sleep center.
11254783|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
11254784|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
11254785|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
11254819|NCT03007446|Experimental|Apatinib plus Oxaliplatin/S-1|"Apatinib :
~A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.
~Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.
~S-1:40mg，bid，d1-14，po，in a 21 day cycle."
11254850|NCT03007264|No Intervention|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
11254786|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.
~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1
~Pembrolizumab: Given IV every 21 days for up to 13 doses
~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
11254787|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
11254788|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
11254789|NCT03007693|Experimental|JNJ-61393215 (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 once daily for 7 days. 4 sequential cohorts will be enrolled to evaluate escalating doses which will be defined, based on safety, tolerability and pharmacokinetic (PK) data from the preceding cohorts. Dose adjustment/selection (increase/decrease) for the next cohort will be based on the JNJ- 61393215 PK profile up to and including the last day of dosing (24 hours postdose) and the safety and tolerability profile of the current cohort.
11254790|NCT03007693|Placebo Comparator|Placebo (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 matching placebo for 7 days.
11254791|NCT03007680|Experimental|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
11254792|NCT03007680|No Intervention|No core muscle activation|
11254793|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
11254794|NCT03007654|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
11254795|NCT03007654|No Intervention|No treatment|standard treatment for surgery
11254796|NCT03007654|Active Comparator|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
11254797|NCT03007641|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.
~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.
~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
11254798|NCT03007628|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
11254799|NCT03007628|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
11254800|NCT03007615|Experimental|Experimental group|
11254801|NCT03007602|Experimental|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
11254802|NCT03007602|No Intervention|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
11254803|NCT03007589|Other|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
11254804|NCT03007589|Other|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
11254805|NCT03007576|Experimental|RegStem|Autologous MSC, 5×10^7 cells, one injection
11254806|NCT03007563|Experimental|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
11254807|NCT03007550|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
11254808|NCT03007550|Other|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
11254809|NCT03007537|Placebo Comparator|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
11254810|NCT03007537|Experimental|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
11254811|NCT03007524|Experimental|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
11254812|NCT03007524|Active Comparator|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
11254813|NCT03007511|Experimental|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
11254814|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
11254815|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
11254816|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
11254817|NCT03007459||Female Fitness Athletes|Psychological health and physiological health of fitness athletes
11254818|NCT03007459||Female, physically active Controls|Psychological health and physiological health of female controls
11254820|NCT03007433|Experimental|healthy volunteers|60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (<40, 41-60, >60) are recruited.
11254821|NCT03007433|Experimental|Functional dyspeptic patients|20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population
11254822|NCT03007420|Experimental|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.
~If patients exhibit < 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
11254823|NCT03007420|Experimental|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.
~If patients exhibit < 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
11254824|NCT03007407|Experimental|durvalumab and tremelimumab|
11254825|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
11254826|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
11254827|NCT03007381|Experimental|Ketorolac tromethamine|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
11254828|NCT03007381|Sham Comparator|Normal Saline|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
11254829|NCT03007368|Experimental|Rice|Cooked white rice and tomato-based sauce
11254830|NCT03007368|Experimental|Potato|Cooked white peeled potato and tomato-based sauce
11254831|NCT03007368|Experimental|Pasta|Cooked macaroni product and tomato-based sauce
11254832|NCT03007368|Experimental|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
11254833|NCT03007368|Experimental|Millet thick porridge|Millet thick porridge and tomato-based sauce
11254834|NCT03007368|Experimental|Millet couscous|Cooked millet couscous and tomato-based sauce
11254835|NCT03007368|Experimental|Millet thin porridge|Millet thin porridge
11254836|NCT03007368|Experimental|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
11254837|NCT03007342|Experimental|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
11254838|NCT03007342|Placebo Comparator|control group|Oral tablet placebo every 12 hours for five days.
11254839|NCT03007329|Active Comparator|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily & Exenatide 2mg subcutaneous once weekly
11254840|NCT03007329|Placebo Comparator|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily & Exenatide matching Placebo 2mg subcutaneous once weekly
11254841|NCT03007316|Experimental|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
11254842|NCT03007316|No Intervention|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
11254843|NCT03007303||schizophrenia|"15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT.
~The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated."
11254844|NCT03007303||health controls|15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
11254845|NCT03007290|Experimental|Treatment group|Group with therapeutic drug monitoring
11254846|NCT03007277|Experimental|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
11254847|NCT03007277|Active Comparator|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
11254851|NCT03007251|Experimental|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
11254852|NCT03007251|Experimental|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
11254853|NCT03007251|Experimental|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
11254854|NCT03007251|Active Comparator|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
11254855|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
11254856|NCT03007225|Active Comparator|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
11254857|NCT03007225|Active Comparator|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
11254858|NCT03007212|Experimental|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
11254859|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
11254860|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
11254861|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
11254862|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
11254863|NCT03007160|Experimental|Experimental group|Potassium Citrate Extended-release Tablets
11254864|NCT03007160|No Intervention|Blank control group|Subjects do not take the investigational product
11254865|NCT03007147|Experimental|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
11254866|NCT03007147|Experimental|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
11254867|NCT03007147|Experimental|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
11254868|NCT03007121|Experimental|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
11254869|NCT03007121|Active Comparator|Bupivacaine + Sufentanil epidural|An epidural catheter will be inserted before induction of anaesthesia in a sitting position between T9 and T10 - T12 and L1 vertebrae. A test dose of 4 ml 0.5 bupivacaine will be administered to rule out intravascular injection or subarachnoid or subdural block. Standard general anaesthesia will be performed. Thirty minutes before the end of the surgery, patients will be administered a bolus of a mixture of bupivacaine 0.5% (3 ml) + sufentanil 10 mcg (2 ml) + NS 5 ml followed by a continuous infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h. At the same time patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
11254870|NCT03007121|Active Comparator|Morphine intravenous|Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be < 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.
11254871|NCT03007108|Experimental|healthy infants|
11254872|NCT03007095|Experimental|preterm children|
11254873|NCT03007095|Active Comparator|term children|
11254874|NCT03007069|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
11254875|NCT03007069|Active Comparator|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
11254876|NCT03007056||Period 1|year 2011 nCPAP
11254877|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
11254878|NCT03007043||Normal responders|Normal response following IVF
11254879|NCT03007043||Suboptimal responders|Suboptimal response following IVF
11254880|NCT03007030|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11254881|NCT03007017|Experimental|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
11254882|NCT03007017|Active Comparator|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
11254883|NCT03007004|Experimental|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
11254884|NCT03007004|Sham Comparator|Physiological saline (control drug) group|"0.2mL in one injection site
~Total 1.0mL (For both hands total 2.0 mL)"
11254885|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
11254886|NCT03006991||poor efficacy|patients can not reach effective outcome.
11254887|NCT03006978|Experimental|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
11254888|NCT03006978|Active Comparator|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
11254889|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (octocog alfa) or Adynovi® (rurioctocog alfa pegol), or patients using already myPKFit®.
~Patients will be given a dose of octocog alfa or rurioctocog alfa pegol according to usual clinical practice, and two blood samples will be taken in case of octocog alfa: one sample will be extracted 3-4h postdose (+/- 30 minutes), and the second sample will be extracted 24-32h postdose (+/- 60 minutes). In case of rurioctocog alfa pegol, the first sample is taken in the same conditions than octocog alfa, and the second sample will be extracted 48h postdose (+/- 120 minutes), and other sample post 72h(+/- 120 minutes) optional."
11254890|NCT03006952|Active Comparator|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
11254891|NCT03006952|Active Comparator|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
11254892|NCT03006926|Experimental|lenvatinib 8 or 12 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
11254893|NCT03006913|Active Comparator|Randomization to counseling: In-person|Behavioral: Comparing genetic counseling modes.
11254894|NCT03006913|Active Comparator|Randomization to counseling: By phone|Behavioral: Comparing genetic counseling modes.
11254895|NCT03006913|Active Comparator|Randomization to counseling: By video|Behavioral: Comparing genetic counseling modes.
11254896|NCT03006900|Experimental|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
11254897|NCT03006900|Active Comparator|Massage|Massage (once per week for one hour)
11254898|NCT03006887|Experimental|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle
11254899|NCT03006874|Experimental|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
11254900|NCT03006874|Experimental|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
11254901|NCT03006874|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
11254902|NCT03006861|Experimental|Oral creatine supplementation|21 g/d oral creatine for 7 days
11254903|NCT03006861|Placebo Comparator|Oral placebo supplementation|21 g/d oral placebo for 7 days
11254904|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.
~Interventions: Avelumab and quality of life questionnaires."
11254905|NCT03006835|Experimental|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
11254906|NCT03006835|Experimental|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
11254907|NCT03006835|Experimental|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
11254908|NCT03006835|Active Comparator|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
11254909|NCT03006822|Experimental|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
11254910|NCT03006822|Experimental|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
11254911|NCT03006822|Experimental|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
11254912|NCT03006809|Experimental|1|pretreatment antibiotics + FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
11254913|NCT03006809|Experimental|2|no antibiotics, FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
11254914|NCT03006809|Experimental|3|pretreatment antibiotics + FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
11254915|NCT03006809|Experimental|4|no antibiotics, FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
11254916|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
11254917|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
11254918|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
11254919|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
11254920|NCT03006770|Experimental|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
11254921|NCT03006770|Placebo Comparator|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
11254922|NCT03006757|Experimental|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
11254923|NCT03006757|Experimental|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
11254924|NCT03006744|Experimental|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
11254925|NCT03006744|Placebo Comparator|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
11254926|NCT03006731|Experimental|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
11254927|NCT03006731|Active Comparator|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
11254928|NCT03006718|Experimental|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.
~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
11254929|NCT03006705|Experimental|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.
~S-1 therapy(maximum 1 year):
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
~CapeOX Therapy(maximum 6 months):
~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
11254930|NCT03006705|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).
~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.
~S-1 therapy(maximum 1 year):
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
~CapeOX Therapy(maximum 6 months):
~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
11254931|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
11254932|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
11254933|NCT03006679|Experimental|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
11254934|NCT03006679|Active Comparator|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
11254935|NCT03006679|Experimental|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
11254936|NCT03006679|Active Comparator|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
11254937|NCT03006666|Active Comparator|Control Group (Data Only)|The teams randomly allocated to the Control Group will not have access to CHWs.
11254938|NCT03006666|Experimental|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
11254939|NCT03006640|Placebo Comparator|Control group|
11254940|NCT03006640|Active Comparator|NTG group|
11254941|NCT03006627|Active Comparator|Male group|All male patients scheduled for upper abdominal surgeries
11254942|NCT03006627|Active Comparator|Female group|All female patients scheduled for upper abdominal surgeries
11254943|NCT03006614|Experimental|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
11254944|NCT03006614|Active Comparator|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
11254945|NCT03006601|Placebo Comparator|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
11254946|NCT03006601|Experimental|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
11254947|NCT03006588|Experimental|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
11255043|NCT03005990|Experimental|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
11255044|NCT03005990|No Intervention|Control group|Control group only provide standard outpatient care program.
11254948|NCT03006575|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose at the initial course: 40-51Gy/10-17f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 15-24 Gy/5-8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
11254949|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
11254950|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
11254951|NCT03006549|Experimental|Emergency Manual|emergency manual present
11254952|NCT03006549|No Intervention|No Emergency|NO emergency manual present
11254953|NCT03006536|Experimental|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
11254954|NCT03006536|Sham Comparator|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
11254955|NCT03006523|Active Comparator|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
11254956|NCT03006523|Experimental|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
11254957|NCT03006510|Active Comparator|Alert|If glucose <90 mg/dl and hypoglycemia prediction score >35, then alert with suggestion for intervention sent to treating team
11254958|NCT03006510|No Intervention|No alert|Routine standard care. If glucose <90 mg/dl and hypoglycemia prediction score >35, then report for investigators will be collected, but no active alert will be sent to teams.
11254959|NCT03006497|No Intervention|Control|The control group will not participate in any exercise program. However, at the end, home based exercises and special advice will be given to the participants.
11254960|NCT03006497|Experimental|Intervention|The intervention group will participate in an exercise program based on motor learning principles for 4 weeks/3 sessions per week, for a total of 12 sessions of 30-45 minutes each.
11254961|NCT03006484||Before Period|Patients who developed in-hosptial cardiac arrest before the implementation of new legislation on life-sustaining treatments
11254962|NCT03006484||After Period|Patients who developed in-hosptial cardiac arrest after the implementation of new legislation on life-sustaining treatments
11254963|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
11254964|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
11254965|NCT03006458|Experimental|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.
~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
11254966|NCT03006458|Active Comparator|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
11254967|NCT03006445|Experimental|FYU-981|
11254968|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
11254969|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
11254970|NCT03006419|Active Comparator|Group A (Basiliximab group)|Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.
11254971|NCT03006419|Experimental|B (Low-dose Thymoglobulin group)|Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.
11254972|NCT03006406|Active Comparator|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
11254973|NCT03006406|Experimental|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
11254974|NCT03006393|Experimental|Infliximab|Participants randomized to the infliximab group will receive one infusion of infliximab at 5mg/kg body weight.
11254975|NCT03006393|Placebo Comparator|Placebo|Participants randomized to the placebo group will receive one placebo infusion.
11254976|NCT03006380|Experimental|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
11254977|NCT03006380|Experimental|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
11254978|NCT03006367|Experimental|NFC-1 100 mg|Single Dose of NFC-1 100 mg
11254979|NCT03006367|Experimental|NFC-1 200 mg|Single Dose of NFC-1 200 mg
11254980|NCT03006367|Experimental|NFC-1 400 mg|Single Dose of NFC-1 400 mg
11254981|NCT03006367|Experimental|NFC-1 800 mg|Single Dose of NFC-1 800 mg
11255011|NCT03006185|Active Comparator|Test Area B|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
11255105|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.
~4000 pregnant women in early pregnancy will be studied in this cohort."
11254982|NCT03006354|Experimental|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.
~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.
~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
11254983|NCT03006354|Active Comparator|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.
~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.
~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
11254984|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
11254985|NCT03006341||Warfarin|NVAF patients initiating warfarin
11254986|NCT03006328|Experimental|Obese Subjects + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
11254987|NCT03006328|Active Comparator|Obese Subjects + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
11254988|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants <65 years old and will accrue a total of 20 patients.
11254989|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants >/= 65 years and will accrue a total of 20 patients.
11254990|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207|
11254991|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CRS-207|
11254992|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
11254993|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
11254994|NCT03006276|Experimental|DFN-15 Active|DFN-15 Active
11254995|NCT03006276|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
11254996|NCT03006263|Experimental|Totally Laparoscopic Total Gastrectomy|Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.
11254997|NCT03006263|Experimental|Laparoscopy Assisted Total Gastrectomy|Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
11254998|NCT03006250|Experimental|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
11254999|NCT03006250|Active Comparator|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
11255000|NCT03006237|Experimental|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
11255001|NCT03006224|Active Comparator|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
11255002|NCT03006224|Active Comparator|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
11255003|NCT03006211|Active Comparator|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
11255004|NCT03006211|Active Comparator|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
11255005|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
11255006|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
11255007|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
11255008|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
11255009|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
11255010|NCT03006185|Active Comparator|Test Area A|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
11255106|NCT03005587||Cirrhotics with no previous decompensation|
11255012|NCT03006172|Experimental|Stage I Arm A: GDC-0077 Single Agent|Participants will receive GDC-0077 in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of GDC-0077 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255013|NCT03006172|Experimental|Stage I Arm B: GDC-0077 + Palbociclib + Letrozole|Participants will receive GDC-0077 in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255014|NCT03006172|Experimental|Stage I Arm C: GDC-0077 + Letrozole|Participants will receive GDC-0077 in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of GDC-0077 will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255015|NCT03006172|Experimental|Stage II Arm B: GDC-0077 + Palbociclib + Letrozole|Participants will receive GDC-0077 on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of GDC-0077 will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255016|NCT03006172|Experimental|Stage II Arm C: GDC-0077 + Letrozole|Participants will receive GDC-0077 in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of GDC-0077 will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255017|NCT03006172|Experimental|Stage II Arm D: GDC-0077 + Fulvestrant|Participants will receive GDC-0077 on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of GDC-0077 will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255018|NCT03006172|Experimental|Stage II Arm E: GDC-0077 + Palbociclib + Fulvestrant|Participants will receive GDC-0077 (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of GDC-0077 will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255019|NCT03006172|Experimental|Stage II Arm F: GDC-0077+Palbociclib+Fulvestrant+Metformin|Participants will receive GDC-0077 (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of GDC-0077 will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
11255020|NCT03006159|Experimental|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
11255021|NCT03006159|Experimental|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
11255022|NCT03006159|Experimental|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
11255023|NCT03006146|Experimental|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
11255024|NCT03006120||Group 1|Conservative management
11255025|NCT03006120||Group 2|Angiografic stenting
11255026|NCT03006120||Group 3|Surgery
11255027|NCT03006107|Experimental|intraligamentary injection of piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .
~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
11255028|NCT03006107|Active Comparator|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
11255029|NCT03006081|Experimental|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
11255030|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A or Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
11255031|NCT03006068|Experimental|Participants receiving Placebo|The participants in this arm will receive placebo until study is unblinded.
11255032|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose C|The participants in this arm will receive Upadacitinib (ABT-494) dose C.
11255033|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
11255034|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
11255035|NCT03006055|Experimental|MBC Group|metastatic breast cancer Age：18-75 ECOG:0-2
11255036|NCT03006055|Experimental|Control Group|benign breast tumour Age：18-75 ECOG:0-2
11255037|NCT03006029|Experimental|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
11255038|NCT03006016|Experimental|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
11255039|NCT03006016|Placebo Comparator|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
11255040|NCT03006003|Experimental|Raloxifene group|Raloxifene treatment
11255041|NCT03006003|Active Comparator|Comparator group|Alendronate treatment
11255042|NCT03006003|No Intervention|Control group|To refuse anti-osteoporosis treatment
11255107|NCT03005587||Cirrhotics with previous one or more than one decompensation|
11255045|NCT03005977|Other|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)
~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
11255046|NCT03005964|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
11255047|NCT03005964|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles.
11255048|NCT03005951|Experimental|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
11255049|NCT03005951|Experimental|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
11255050|NCT03005938|Experimental|Spinal manipulation|Spinal manipulation
11255051|NCT03005938|Sham Comparator|Imitation of the spinal manipulation|Imitation of the spinal manipulation
11255052|NCT03005925|Experimental|connected group|remote monitoring by smartphone in the care management of patients with rheumatoid arthritis
11255053|NCT03005925|Active Comparator|control group|standard outpatient follow-up by physical consultation
11255054|NCT03005912|Placebo Comparator|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
11255055|NCT03005912|Active Comparator|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
11255056|NCT03005912|Active Comparator|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
11255057|NCT03005912|Active Comparator|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
11255058|NCT03005899|Experimental|SyB P-1501 group|One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
11255059|NCT03005899|Placebo Comparator|SyB P-1501 placebo group|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
11255060|NCT03005886|Experimental|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:
~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
11255061|NCT03005886|Active Comparator|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:
~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
11255062|NCT03005886|Sham Comparator|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
11255063|NCT03005873|Experimental|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
11255064|NCT03005873|Experimental|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
11255065|NCT03005873|Placebo Comparator|Placebo group|1.5 mL normal saline
11255066|NCT03005860|Active Comparator|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
11255067|NCT03005860|Experimental|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI [target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
11255068|NCT03005847|Experimental|FPP arm|active treatment with fermented papaya preparation
11255069|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
11255070|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
11255104|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).
~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.
~3400 pregnant women in early pregnancy will be studied in this cohort."
11255071|NCT03005821|Experimental|pediatric massage|Patients will receive Montmorillonite Powder and racecadotril granules as usual care according to different age or weight. Intravenous infusion, Oral Rehydration Salts (ORS), Zn,and antibiotics will be used if the pediatrician in charge considers necessary. Patients will receive Chinese pediatric massage once per day and for three days continuously. A cloak which can cover the child's hands and upper body will be required to put on, all the manipulations will be done under the cloak. Six acupoints will be adopted,i.e. Neibagua, Dachang,Xiaochang, Banmen, Fu, Tuishang Qijiegu. Each visit, children who are under 2 years old will receive manipulations on Neibagua for 500 times, 300 times for the other 5 acupoints each; if they are from 2-3 years old, the manipulations on Neibagua will be 700 times and 500 times for the other 5 acupoints respectively; while the manipulations on Neibagua will be 1000 times, and 800 times for the other 5 acupoints if the children are from 4-6 years old.
11255072|NCT03005821|Sham Comparator|sham massage|Patients will receive the same usual care as the experimental group. For the sham massage, the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead childrens' hand or childrens' body. Patients will be required to put on the same kind of cloak as that for the the experimental group, all the manipulations will be done under the cloak. The manipulation times for each acupoints will be the same as those for experimental group in accordance with different age. The sham massage will be given once per day for 3 days continuously.
11255073|NCT03005808|No Intervention|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
11255074|NCT03005808|Experimental|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
11255075|NCT03005808|Experimental|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
11255076|NCT03005795|Experimental|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
11255077|NCT03005795|Active Comparator|Colposcopy without music|During the colposcopic examination women will not hear music
11255078|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
11255079|NCT03005782|Experimental|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
11255080|NCT03005756|Experimental|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
11255081|NCT03005743|Experimental|MR based BT|Magnetic Resonance Image based Brachytherapy
11255082|NCT03005743|Other|Conventional BT|Conventional Radiograph based Brachytherapy
11255083|NCT03005730|Experimental|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
11255084|NCT03005730|Placebo Comparator|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
11255085|NCT03005717|Experimental|Active High|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
11255086|NCT03005717|Experimental|Active Low|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
11255087|NCT03005717|Placebo Comparator|Placebo|Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
11255088|NCT03005704|Experimental|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
11255089|NCT03005704|No Intervention|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
11255090|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
11255091|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
11255092|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
11255093|NCT03005678|Active Comparator|Denosumab|denosumab subcutaneous 60mg every 6 months
11255094|NCT03005678|Placebo Comparator|Alendronate|alendronate 70mg orally every week
11255095|NCT03005665|Experimental|Group A - Acetazolamide|Acetazolamide 5 mg/kg diluted in 10 ml normal saline through orogastric Ryle's Tube soon after the induction of anaesthesia followed by 10 ml normal saline flush.
11255096|NCT03005665|Placebo Comparator|Group s - Normal saline|20 ml normal saline total volume.
11255097|NCT03005652|Experimental|Mindfulness intervention|
11255098|NCT03005652|Active Comparator|Health education intervention|
11255099|NCT03005639|Experimental|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
11255100|NCT03005626|Experimental|Therapeutic education|Structured therapeutic education programs
11255101|NCT03005626|Active Comparator|Control group|standard outpatient follow-up
11255102|NCT03005613|Active Comparator|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
11255103|NCT03005613|Experimental|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
11255142|NCT03005379|Active Comparator|1|Fecal Microbiota Therapy (FMT)
11255143|NCT03005379|Placebo Comparator|2|Placebo
11255108|NCT03005574|Experimental|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
11255109|NCT03005574|Active Comparator|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
11255110|NCT03005561|Experimental|Intervention|100 participants that will be participating in the Play Back meetings.
11255111|NCT03005561|No Intervention|Control|100 participants that will not be participating in the Play Back meetings.
11255112|NCT03005548|Experimental|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
11255113|NCT03005548|Sham Comparator|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
11255114|NCT03005535|Active Comparator|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
11255115|NCT03005535|Placebo Comparator|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
11255116|NCT03005522|Placebo Comparator|placebo|dosed with placebo
11255117|NCT03005522|Active Comparator|intervention|10mg oral dexamethasone
11255118|NCT03005509|No Intervention|Pre-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.
~The Trauma Quality Improvement Meeting (TQIM) checklist will not be introduced during this phase."
11255119|NCT03005509|Other|Post-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.
~The Trauma Quality Improvement Meeting (TQIM) checklist will be used at all Trauma Quality Improvement Meetings (TQIMs)"
11255120|NCT03005496|Placebo Comparator|Intervention|"Nifedipin 4x10 mg oral
~Dexamethasone 2x6 mg iv for 2 days
~Zinc 50 mg/day
~Beta-carotene 25,000 IU
~Vitamin D3 50,000 IU/weekly"
11255121|NCT03005496|Active Comparator|Control|"Nifedipin 4x10 mg
~Dexamethasone 2x6 mg iv for 2 days"
11255122|NCT03005483|Experimental|Gabapentin|Gabapentin 10 mg/kg in children submitted unilateral limb surgery
11255123|NCT03005483|Placebo Comparator|Placebo|Placebo in children submitted unilateral limb surgery
11255124|NCT03005470|Experimental|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
11255125|NCT03005470|Experimental|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
11255126|NCT03005470|Experimental|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
11255127|NCT03005470|Active Comparator|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
11255128|NCT03005457|Experimental|Stroke|
11255129|NCT03005457|Experimental|Hemiparesis other|
11255130|NCT03005444|Experimental|Anticoagulation|Rivaroxaban：10mg/d for 2 years
11255131|NCT03005444|No Intervention|Non-anticoagulated|No anticoagulants will be used.
11255132|NCT03005431|Experimental|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
11255133|NCT03005431|No Intervention|Waitlist control group|These parents will receive regular or typical services
11255134|NCT03005418|Experimental|Limb Cohort|Patients with limb-threatening vascular trauma in an extremity will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
11255135|NCT03005418|Experimental|Torso Cohort|Patients with life-threatening vascular trauma in the torso will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
11255136|NCT03005405|Active Comparator|restoration - control|Restoration
11255137|NCT03005405|Experimental|sealant - test|Sealant
11255138|NCT03005392|Experimental|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
11255139|NCT03005392|Experimental|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
11255140|NCT03005392|Experimental|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
11255141|NCT03005392|No Intervention|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
11255146|NCT03005353|Experimental|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
11255147|NCT03005353|Active Comparator|clotrimazole|Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
11255148|NCT03005340|Active Comparator|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
11255149|NCT03005340|Active Comparator|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
11255150|NCT03005340|Active Comparator|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
11255151|NCT03005340|Active Comparator|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
11255152|NCT03005340|Active Comparator|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
11255153|NCT03005340|Active Comparator|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
11255154|NCT03005327|Experimental|X4P-001|"Initial Treatment Phase: Participants will initiate treatment with mavorixafor at 50 milligrams (mg) once daily (QD) orally or a higher dose, with potential escalation based on area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values to a maximum total daily dose of 400 mg. Participants are expected to receive treatment for 24 weeks in the initial Treatment Period or until development of a treatment-limiting toxicity (TLT).
~Extension Phase: All participants will receive mavorixafor; the dose will not exceed 400 mg. In the Extension Phase, treatment may continue until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the sponsor."
11255155|NCT03005314|Other|Surgery|Postoperative chemotherapy group
11255156|NCT03005314|Other|Chemotherapy|Preoperative chemotherapy group
11255157|NCT03005301|Experimental|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
11255158|NCT03005301|Active Comparator|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
11255159|NCT03005288|Experimental|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
11255160|NCT03005288|Placebo Comparator|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
11255161|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).
~Follicle and endometrium can be evaluated: on the day of final injection or one day later.
~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.
~OPU: 1,5 day after hCG injection (normally 36-42 hours later).
~Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.
~Embryo transfer: 3 days after OPU.
~Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
11255162|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.
~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.
~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
11255163|NCT03005249|Experimental|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
11255164|NCT03005249|Experimental|the control group|The patients will be assigned to the control group for cerebral palsy.
11255165|NCT03005236|Experimental|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
11255166|NCT03005236|Active Comparator|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
11255167|NCT03005223|Experimental|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
11255168|NCT03005223|Experimental|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
11255169|NCT03005210|Experimental|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
11255170|NCT03005210|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
11255171|NCT03005210|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
11255172|NCT03005184|Experimental|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255173|NCT03005184|Experimental|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255174|NCT03005184|Experimental|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255175|NCT03005184|Experimental|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255176|NCT03005184|Experimental|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255177|NCT03005184|Experimental|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255178|NCT03005184|Experimental|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255179|NCT03005184|Experimental|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255180|NCT03005184|Experimental|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255181|NCT03005184|Experimental|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255182|NCT03005184|Experimental|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255183|NCT03005184|Experimental|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
11255184|NCT03005171|Active Comparator|Epidural|"Epidural catheters will be placed in the 9th or 10th thoracic intervertebral space prior to induction of anesthesia.Through the thoracic epidural catheter 0.125% bupivacaine at a rate of 5 mL/h will be infused.
~The infusion continues for 24h"
11255185|NCT03005171|Active Comparator|Lidocaine|"Intravenous lidocaine infusion will typically start in the operating room prior to induction of anesthesia at a rate of 2 to 3 mg/min. Postoperatively, the rate will be decreased to 0.5 to 1 mg/min.
~The infusion continues for 24h"
11255186|NCT03005158|Other|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
11255187|NCT03005158|Other|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
11255188|NCT03005158|Active Comparator|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
11255189|NCT03005145|Active Comparator|Short duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
11255190|NCT03005145|Active Comparator|Long duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
11255191|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
11255192|NCT03005132||GBM tissues|GBM tissues from GBM patients
11255193|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
11255194|NCT03005119|Experimental|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
11255195|NCT03005119|Placebo Comparator|Placebo|PTL201 and placebo capsules will be identical in appearance
11255196|NCT03005106|Experimental|StrataGraft Skin Tissue|
11255197|NCT03005093||CAREGIVERS|Caregivers of pediatric patients with swallowing disorders will be recruited.
11255198|NCT03005093||CHILDREN OF CAREGIVERS|Pediatric patients with swallowing disorders will be recruited.
11255199|NCT03005067|Experimental|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
11255200|NCT03005067|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
11255203|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
11255204|NCT03005028||Control|
11255205|NCT03005015|Experimental|Lenvatinib|Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
11255206|NCT03005015|Active Comparator|Doxorubicin|Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
11255207|NCT03005002|Experimental|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
11255208|NCT03004989||Programme 1|RTW group in day clinics
11255209|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
11255210|NCT03004989||Programme 3|My work and I
11255211|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
11255212|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
11255213|NCT03004963|Active Comparator|clinical group|evaluate the volume status just according to clinical indexes in this group.
11255214|NCT03004963|Experimental|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
11255215|NCT03004937|Experimental|Single-Arm, Non-Randomized, Stepped Wedge|All patients who meet the inclusion criteria will receive the same intervention.
11255216|NCT03004924|Experimental|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
11255217|NCT03004924|Active Comparator|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
11255218|NCT03004924|Placebo Comparator|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
11255219|NCT03004911|Experimental|Mobile application|
11255220|NCT03004911|Active Comparator|Paper booklet|
11255221|NCT03004898|Experimental|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
11255222|NCT03004885|Experimental|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
11255223|NCT03004885|Experimental|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
11255224|NCT03004885|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
11255225|NCT03004859||Adults ≥ 65 with a positive test result|Adults ≥ 65 that are got a positive test result were asked to visit their general practitioner and are called for an interview two times, 8 weeks and 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacies as well as of the two telephone interviews are compared to the results of the adults ≥ 65 with a negative test result.
11255226|NCT03004859||Adults ≥ 65 with a negative test result|Adults ≥ 65 that are got a negative test result are called for an interview 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacy as well as of the telephone interview are compared to the results of the adults ≥ 65 with a positive test result.
11255227|NCT03004846|Experimental|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
11255228|NCT03004846|Experimental|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
11255229|NCT03004833|Experimental|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
11255230|NCT03004833|Experimental|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
11255231|NCT03004820|Experimental|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
11255232|NCT03004807|Experimental|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
11255233|NCT03004807|Placebo Comparator|Control|Matching tablet to active multivitamin arm: 1/day
11255234|NCT03004781|No Intervention|Waiting-list|8-week period without intervention, N=45
11255235|NCT03004781|Experimental|self-efficacy|8-week group-based parenting program on self-efficacy beliefs, N=19
11255236|NCT03004781|Experimental|self-efficacy/emotion coaching|8-week group-based parenting program on self-efficacy beliefs and emotion coaching practice, N=26
11255237|NCT03004768|Experimental|Single dose of radiolabeled BMS-986165|
11255238|NCT03004742|Experimental|Flavonoid|Flavonoid supplement
11255239|NCT03004742|Placebo Comparator|Placebo|Placebo
11255240|NCT03004729|Other|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
11255241|NCT03004703|Experimental|Active drug|Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
11255242|NCT03004703|Placebo Comparator|Placebo|Sodium chloride 0.9%; 100 ml i.v. once.
11255243|NCT03004690|Experimental|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
11255244|NCT03004690|Experimental|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
11255245|NCT03004677|Experimental|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
11255246|NCT03004677|Active Comparator|Standard Care|Infants and parents will receive standard care provided in the NICU
11255247|NCT03004664||Support Empowerment Model|"The Center for Diabetes Education at the University of New Mexico Hospital (CDE) uses the Diabetes Self-Management Support Empowerment Model (DSMS). The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions. Patients attend a six-week group instructional session with 9 hours of class plus an individual follow-up with a certified diabetes educator. The group sessions have discussion supported by didactic conversation maps where the facilitator guides but does not control the conversation based on session thematic goals."
11255248|NCT03004664||The Chronic Care Model|One Hope Centro de Vida Diabetes Program is based on the Chronic Care Model (CCM). The CCM involves 6 synergistic domains: 1.) Improved access to care, 2.) Patient self-management support, 3.) Patient decision support, 4.) Care coordination, 5.) Integrated health information systems, and 6.) Access to community resources. To create a holistic care regime, the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design.
11255249|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
11255250|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
11255251|NCT03004638|Experimental|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
11255252|NCT03004638|Placebo Comparator|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
11255253|NCT03004638|Experimental|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
11255254|NCT03004638|Experimental|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
11255255|NCT03004638|Experimental|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
11255256|NCT03004638|Placebo Comparator|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
11255257|NCT03004625|Experimental|Study Arm|HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)
11255258|NCT03004612|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 24 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
11255259|NCT03004612|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 24 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
11255260|NCT03004599|Other|Transcatheter Aortic Valve Implantation (TAVI)|
11255261|NCT03004586|Experimental|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
11255262|NCT03004586|Experimental|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
11255263|NCT03004573|Experimental|Deep brain stimulation|
11255264|NCT03004560|Active Comparator|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
11255265|NCT03004560|Active Comparator|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
11255266|NCT03004547||Chronic hemodialysis patients|Patients on standard in-centre 3 times a week hemodialysis
11255267|NCT03004547||Peritoneal dialysis patients|Patients on peritoneal dialysis
11255268|NCT03004547||Adult and paediatric patients with CKD stage 1-5|Patients with chronic kidney disease stage 1-5 (not dialysis dependent)
11255269|NCT03004547||Healthy adult and paediatric controls|Subjects without kidney disease
11255270|NCT03004547||Heart failure patients with and without renal dysfunction|Heart failure patients (atrial fibrillation etc ...) with and without renal dysfunction
11255271|NCT03004534|Experimental|Presurgical Molecular Assessment|Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
11255272|NCT03004521|Active Comparator|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
11255273|NCT03004521|Experimental|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
11255274|NCT03004508|Experimental|Gingko biloba Extract|
11255275|NCT03004508|Placebo Comparator|Placebo|
11255276|NCT03004495|Experimental|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
11255277|NCT03004495|Active Comparator|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
11255278|NCT03004495|Active Comparator|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
11255279|NCT03004469|Experimental|P-3074 + Finasteride Placebo|Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
11255280|NCT03004469|Placebo Comparator|P-3074 Vehicle + Finasteride Placebo|Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
11255281|NCT03004469|Active Comparator|Oral Finasteride + P-3074 Vehicle|Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.
11255282|NCT03004456|Experimental|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
11255283|NCT03004456|No Intervention|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
11255284|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
11255285|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
11255286|NCT03004430|Experimental|MAM|Mantra Meditation Group
11255287|NCT03004430|Active Comparator|PMR|Progressive Muscle Relaxation Group
11255288|NCT03004417|Experimental|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
11255289|NCT03004417|Experimental|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
11255290|NCT03004417|Placebo Comparator|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
11255291|NCT03004404|Experimental|BI 730357|
11255292|NCT03004404|Placebo Comparator|Placebo|
11255293|NCT03004378|No Intervention|Control|Participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
11255294|NCT03004378|Experimental|Intervention|Fitbit (activity tracker) + participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
11255295|NCT03004365|Active Comparator|Study Arm 1|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
11255296|NCT03004365|Active Comparator|Study Arm 2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
11255297|NCT03004365|Active Comparator|Study Arm 3|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
11255298|NCT03004352|Experimental|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
11255299|NCT03004352|No Intervention|control subjects-control|
11255300|NCT03004352|Experimental|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
11255301|NCT03004352|No Intervention|hypoxemic COPD-control|
11255302|NCT03004352|Experimental|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
11255303|NCT03004352|Experimental|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
11255304|NCT03004339|Experimental|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
11255305|NCT03004339|Experimental|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
11255306|NCT03004339|Experimental|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
11255307|NCT03004339|Experimental|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
11255308|NCT03004339|Placebo Comparator|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
11255309|NCT03004339|Active Comparator|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
11255310|NCT03004313|Experimental|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:
~Blood and urine samples will be collected
~Complete a series of questionnaires; some of which will be completed daily
~Quantitative Sensory Test (QST)will be performed
~Magnetic Resonance Imaging (MRI)
~PET imaging (during and outside of a migraine attack)"
11255311|NCT03004313|Active Comparator|Healthy|"20 healthy subjects will undergo the following:
~Blood and urine samples will be collected
~Complete a series of questionnaires; some of which will be completed daily
~Quantitative Sensory Test (QST)will be performed
~Magnetic Resonance Imaging (MRI)
~PET imaging"
11255312|NCT03004300|Active Comparator|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
11255313|NCT03004300|Experimental|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
11255314|NCT03004300|Experimental|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
11255315|NCT03004287|Experimental|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).
~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.
~Immunological Consolidation 1: Daratumumab.
~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).
~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.
~Immunological Consolidation 2: Daratumumab.
~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.
~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
11255316|NCT03004274|Active Comparator|Running sutures|Deep layers will be closed using running sutures
11255317|NCT03004274|Experimental|Interrupted sutures|Deep layers will be closed using interrupted sutures
11255343|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
11255344|NCT03004040||Control|matched control subjects (non-LCII)
11255345|NCT03004027|Experimental|Enhanced|self help leaflet enhanced with implementation intentions
11255346|NCT03004027|Active Comparator|Standard|self help leaflet standard (without implementation intentions)
11257193|NCT02991209|Experimental|Tostran 2%|1 years treatment with transdermal Tostran 2%
11255318|NCT03004261|Experimental|CMV-CTL|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.
11255319|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
11255320|NCT03004222|Experimental|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
11255321|NCT03004222|Placebo Comparator|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
11255322|NCT03004209|Other|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
11255323|NCT03004196|Active Comparator|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
11255324|NCT03004196|Experimental|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
11255325|NCT03004196|Experimental|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
11255326|NCT03004183|Experimental|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.
~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.
~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.
~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
11255327|NCT03004170|Experimental|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher & Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
11255328|NCT03004170|Active Comparator|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus & Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
11255329|NCT03004157|Experimental|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
11255330|NCT03004157|Experimental|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
11255331|NCT03004157|Experimental|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
11255332|NCT03004144|Other|FLOAT-Support|
11255333|NCT03004131|Experimental|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
11255334|NCT03004131|Placebo Comparator|Placebo|Nasal spray with no active dose plus Placebo tablet
11255335|NCT03004131|Active Comparator|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
11255336|NCT03004118|Active Comparator|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
11255337|NCT03004118|Placebo Comparator|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
11255338|NCT03004105|Experimental|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
11255339|NCT03004105|Experimental|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.
~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
11255340|NCT03004105|Experimental|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
11255341|NCT03004092|Experimental|Total cohort|
11255342|NCT03004053||Volunteers will be identified by the Head and Neck Service|25 volunteers (Part I - 8 volunteers. Part II - 17 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
11255437|NCT03003364|Placebo Comparator|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
11255347|NCT03004027|No Intervention|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
11255348|NCT03004014|No Intervention|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
11255349|NCT03004014|Other|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep
~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
11255350|NCT03004001|Experimental|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
11255351|NCT03004001|Placebo Comparator|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
11255352|NCT03003988|Experimental|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
11255353|NCT03003988|Active Comparator|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
11255354|NCT03003988|Placebo Comparator|Placebo|6.5 g. dextrose
11255355|NCT03003975|Active Comparator|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).
~If the vein then is isolated after a single application, the operator can move on to the next vein."
11255356|NCT03003975|Active Comparator|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
11255357|NCT03003962|Experimental|Arm 1: Durvalumab|Anti-PD-L1 monoclonal Antibody monotherapy
11255358|NCT03003962|Active Comparator|Arm 2: Standard of Care|Standard of Care Platinum-Based chemotherapy
11255359|NCT03003949|Placebo Comparator|Placebos|Placebo patches for 16 weeks/
11255360|NCT03003949|Active Comparator|Estradiol|Transdermal for 16 weeks
11255361|NCT03003949|Placebo Comparator|Placebo Oral Tablet|Placebo pill every day during weeks 17-18 and again at weeks 25-26
11255362|NCT03003949|Active Comparator|Progesterone|Oral progesterone (200 mg) daily during weeks 17-18 and again at weeks 25-26.
11255363|NCT03003936|Experimental|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
11255364|NCT03003936|Experimental|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
11255365|NCT03003923|Experimental|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
11255366|NCT03003923|Experimental|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
11255367|NCT03003923|Experimental|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
11255368|NCT03003923|No Intervention|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
11255369|NCT03003910|Experimental|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.
~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
11255370|NCT03003910|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
11255371|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
11255372|NCT03003897||Placebo Treatment|Participants receiving placebo.
11255373|NCT03003884|Experimental|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
11255374|NCT03003884|Experimental|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
11255375|NCT03003884|Experimental|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
11255376|NCT03003884|Experimental|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
11255377|NCT03003884|Active Comparator|Propofol|IV of Propofol at 1.5mg/kg for initial dose
11255378|NCT03003871|Experimental|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
11255379|NCT03003871|Active Comparator|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
11255380|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
11255381|NCT03003832|Experimental|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
11255382|NCT03003832|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
11255383|NCT03003819|Active Comparator|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
11255384|NCT03003819|Active Comparator|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
11255385|NCT03003806|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
11255386|NCT03003806|Active Comparator|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
11255387|NCT03003793||Control group|Healthy control subjects
11255388|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
11255389|NCT03003780|Experimental|Mindful Steps|Web-based behavioral intervention
11255390|NCT03003780|No Intervention|Usual Care|
11255391|NCT03003754|Experimental|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.
~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
11255392|NCT03003754|Active Comparator|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
11255393|NCT03003728|Experimental|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
11255394|NCT03003715|Experimental|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
11255395|NCT03003715|Experimental|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
11255396|NCT03003702|Experimental|ETH|Overnight monitoring
11255397|NCT03003702|Other|CTH|Morning monitoring
11255398|NCT03003689|Active Comparator|Scaling and Root Planing|"Hand instruments + ultrasonic scaler
~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
11255399|NCT03003689|Experimental|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler
~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
11255400|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).
~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
11255401|NCT03003663|Experimental|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
11255402|NCT03003650|Experimental|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
11255403|NCT03003637|Experimental|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
11255404|NCT03003624|Experimental|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
11255405|NCT03003624|Experimental|Cautery group|Electrosurgery tip was used to give incisions.
11255406|NCT03003624|Active Comparator|BP Blade group|No.15 surgical blade was used to give incisions.
11255407|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
11255408|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
11255409|NCT03003598|Active Comparator|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
11255410|NCT03003598|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
11255411|NCT03003585|Active Comparator|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
11255412|NCT03003585|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
11255413|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
11255414|NCT03003559|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
11255415|NCT03003559|No Intervention|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
11255416|NCT03003546|Experimental|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11255417|NCT03003533|Experimental|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
11255418|NCT03003520|Experimental|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.
~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
11255419|NCT03003520|Experimental|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.
~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.
~Enrollment into Arm B was discontinued."
11255420|NCT03003507|Active Comparator|Diet 1|Low-carbohydrate Enteral Formula With Fructose
11255421|NCT03003507|Active Comparator|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
11255422|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
11255423|NCT03003468|Experimental|Arm A - Phase Ib|"Dose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 of each 21 day cycle. Imprime PGG will be administered at 2mg/kg on Day 1,8, and 15 of cycles 1-4, and on Day 1 of cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab.
~Experimental: Arm A - Phase II Investigational Treatment The maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 for cycles 1-4, and on Day 1 of cycles 5-16.
~Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 for Cycles 1-4 and on Day 1 only for Cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab."
11255424|NCT03003455|Active Comparator|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
11255425|NCT03003455|Experimental|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
11255426|NCT03003442|Experimental|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
11255427|NCT03003442|Placebo Comparator|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
11255428|NCT03003429|Experimental|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
11255429|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
11255430|NCT03003403|Experimental|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
11255431|NCT03003403|No Intervention|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
11255432|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
11255433|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
11255434|NCT03003377|Experimental|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
11255435|NCT03003377|Active Comparator|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
11255436|NCT03003364|Experimental|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
11255440|NCT03003338|Experimental|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
11255441|NCT03003338|Experimental|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
11255442|NCT03003325|Active Comparator|Phlebotomies + ASA|Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
11255443|NCT03003325|Experimental|Phlebotomies + ASA + AOP2014|Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
11255444|NCT03003299|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
11255445|NCT03003299|Experimental|Failing transcatheter valve|Patients with a failing transcatheter bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
11255446|NCT03003286|Experimental|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
11255447|NCT03003286|Experimental|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
11255448|NCT03003273|Experimental|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
11255449|NCT03003273|Active Comparator|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
11255450|NCT03003260|Experimental|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
11255451|NCT03003260|Experimental|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
11255452|NCT03003247|Experimental|IDP-120 Gel|IDP-120 Gel is a combination treatment
11255453|NCT03003247|Active Comparator|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
11255454|NCT03003247|Active Comparator|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
11255455|NCT03003247|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
11255456|NCT03003234|Other|Duodenal fluid aspiration|
11255457|NCT03003221|Active Comparator|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
11255458|NCT03003221|Experimental|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
11255459|NCT03003208|Other|Pulmonary rehabilitation|
11255460|NCT03003195|Experimental|Vaccination: Montanide ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
11255461|NCT03003182||in clinical trials|
11255462|NCT03003182||out of clinical trials|
11255463|NCT03003169||ambulatory surgery description|
11255464|NCT03003156|Experimental|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
11255465|NCT03003156|Experimental|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
11255466|NCT03003143|Experimental|Vigabatrin treatment group|
11255467|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
11255468|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
11255469|NCT03003117|Experimental|Intervention Program|Experimental: Intervention Program
11255470|NCT03003117|Active Comparator|Usual Care|Active comparator: Usual Care
11255471|NCT03003104|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
11255472|NCT03003104|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
11255473|NCT03003091|Experimental|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
11255474|NCT03003091|Active Comparator|Traditional patient education|The participants received all structured information
11255475|NCT03003078|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
11255476|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
11255477|NCT03003039|Experimental|GB241|GB241:375 mg/m2, iv, one infusion
11255478|NCT03003039|Active Comparator|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
11255479|NCT03003026|Experimental|Novel task-specific program|Intervention arm - see detailed intervention group description below
11255480|NCT03003026|Active Comparator|Parent-led home-based program|Comparison arm - see detailed comparison group description below
11255481|NCT03003013|Active Comparator|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
11255482|NCT03003013|Active Comparator|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
11255483|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
11255484|NCT03003000|Active Comparator|ibuprofen|
11255485|NCT03003000|Placebo Comparator|placebo|
11255486|NCT03002987|Active Comparator|Intervention, education|Education of leaders (3 hours) in how to implement Active Pregnancy policy at their departements/workplaces
11255487|NCT03002987|No Intervention|control|as usual
11255488|NCT03002974|Experimental|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
11255489|NCT03002974|Experimental|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
11255490|NCT03002974|Active Comparator|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
11255491|NCT03002961|Experimental|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
11255492|NCT03002961|Experimental|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
11255493|NCT03002961|Experimental|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
11255494|NCT03002961|Experimental|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
11255495|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
11255496|NCT03002935|Experimental|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
11255497|NCT03002922|Experimental|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
11255498|NCT03002909|Active Comparator|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
11255499|NCT03002909|Active Comparator|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
11255500|NCT03002896|Experimental|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
11255501|NCT03002896|Active Comparator|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
11255502|NCT03002883|Placebo Comparator|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
11255503|NCT03002883|Active Comparator|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
11255504|NCT03002883|Active Comparator|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
11255505|NCT03002870|Other|Endometriosis|Patients whom pathology results post surgery document endometriosis
11255506|NCT03002857|Experimental|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
11255507|NCT03002857|Experimental|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
11255508|NCT03002857|Experimental|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
11255509|NCT03002844|Experimental|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
11255510|NCT03002844|Experimental|EGFR-TK Inhibitor|Gefitinib
11255511|NCT03002831|Experimental|CIK combined chemotherapy|Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.
11255512|NCT03002831|Active Comparator|Chemotherapy|Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w
11255513|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
11255514|NCT03002792||general anesthesia|caries treatment under general anesthesia
11255515|NCT03002792||caries treatment only|caries treatment without general anesthesia
11255516|NCT03002779|Experimental|JNJ-53718678|
11255517|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
11255518|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
11255519|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
11255520|NCT03002740||NVAF patients newly prescribed apixaban|
11255521|NCT03002740||NVAF patients newly prescribed rivaroxaban|
11255522|NCT03002740||NVAF patients newly prescribed dabigatran|
11255523|NCT03002740||NVAF patients newly prescribed VKA|
11255524|NCT03002714|Experimental|Exercise|Performance of two resistance exercise sessions
11255525|NCT03002701|No Intervention|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
11255526|NCT03002701|Active Comparator|Intervention group|After implementation the intervention package will be implemented as standard care.
11256542|NCT02995759||SE before Seizure Action Plan|450 patients with status epilepticus prior to seizure action plan initiation
11255527|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
11255528|NCT03002675|Experimental|exenatide|Participants will receive exenatide (Bydureon, 2mg s.c. 1x/wk, AstraZeneca) during 12 weeks
11255529|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI <18.5 underweight (Group 1)
11255530|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
11255531|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
11255532|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ>30 obese (Group 4)
11255533|NCT03002649|Experimental|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
11255534|NCT03002636|Experimental|Morbid Obesity group|Morbid Obesity group(n=300)
11255535|NCT03002636|Experimental|severe Obesity group|severe Obesity group (n=300)
11255536|NCT03002636|Other|non-Obesity group|non-Obesity group(n=300)
11255537|NCT03002623|Experimental|Group|CUDC-907 for thyroid cancer
11255538|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
11255539|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
11255540|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
11255541|NCT03002597|Experimental|Blind Children|Children between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
11255542|NCT03002597|Experimental|Sighted Children|Children between the ages of 4 and 17 who are sighted in both eyes.
11255543|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.
~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).
~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
11255544|NCT03002571|Experimental|IDP-124 Lotion|Lotion
11255545|NCT03002571|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
11255546|NCT03002558||control (non-OSA)|Patients without sleep apnoea
11255547|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
11255548|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
11255549|NCT03002545|Placebo Comparator|Placebo|identically tasting and looking Placebo
11255550|NCT03002545|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
11255551|NCT03002532|Active Comparator|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
11255552|NCT03002532|Experimental|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
11255553|NCT03002519|Experimental|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
11255554|NCT03002506|Experimental|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
11255555|NCT03002493|Experimental|Eribulin mesylate + Rifampicin|
11255556|NCT03002480|Other|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
11255557|NCT03002467|Experimental|PESI score|treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care)
11255558|NCT03002467|No Intervention|Standard care|standard care (i.e. no formally calculation of PESI on top)
11255559|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
11255560|NCT03002441|Active Comparator|Same-day Dilators|Participants will have Dilapan-S cervical dilators placed 4-6 hours prior to D&E and will receive 400 mcg buccal misoprostol pills 3 hours prior to D&E.
11255561|NCT03002441|Active Comparator|Overnight dilators|Participants will have Dilapan-S cervical dilators placed the day prior to their D&E procedure and will receive buccal placebo pills (vitamin B12) 3 hours prior to D&E.
11255562|NCT03002428|Experimental|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
11255563|NCT03002428|Active Comparator|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
11255564|NCT03002415|Experimental|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention.
~Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days."
11256543|NCT02995759||SE after Seizure Action Plan|450 patients with status epilepticus after seizure action plan initiation
11255565|NCT03002415|Placebo Comparator|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
11255566|NCT03002402|Experimental|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
11255567|NCT03002389|Other|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.
~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
11255568|NCT03002376|Experimental|REGN2810|REGN2810 treatment
11255569|NCT03002363|Experimental|Video Modeling Intervention|The intervention group receives a video that is a behavior modeling video that walks through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment.
11255570|NCT03002363|Placebo Comparator|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
11255571|NCT03002337|Experimental|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
11255572|NCT03002337|Experimental|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
11255573|NCT03002337|No Intervention|Control|the control group received only routine prenatal care.
11255574|NCT03002324|Active Comparator|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
11255575|NCT03002324|Experimental|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
11255576|NCT03002324|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
11255577|NCT03002311|No Intervention|Control|Receiving current standard of care as designated by emergency department (ED) standard operating practice.
11255578|NCT03002311|Experimental|Epharmix/CareSignal eHealth Intervention|After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).
11255579|NCT03002298|Experimental|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
11255580|NCT03002298|Experimental|DMD button-press task|Experimental group that made the task pressing the button
11255581|NCT03002298|Active Comparator|Control group gesture task|Control group that made the task using a gesture in front of a webcam
11255582|NCT03002298|Active Comparator|Control group button-press task|Control group that made the task pressing the button
11255583|NCT03002285|Experimental|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
11255584|NCT03002285|Active Comparator|Control group|Group with typical development that performed the Fitts law in a computer task
11255585|NCT03002272||TAVR|This observational study will enroll subjects that underwent TAVR more than 3 years ago.
11255586|NCT03002272||SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
11255587|NCT03002259|No Intervention|Control|No placebo required
11255588|NCT03002259|Active Comparator|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
11255589|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
11255590|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
11255591|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
11255592|NCT03002233|Experimental|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
11255593|NCT03002220|Experimental|open-label|Patient will be treated with radium-223 at a dose of 55 kBq (after 2015 NIST implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
11255594|NCT03002207|Experimental|The defect is repaired and sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured.
11255595|NCT03002207|Experimental|The defect is repaired but not sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy.
11255789|NCT03000868|Experimental|Cold EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
11255596|NCT03002207|Experimental|The defect is sutured but not repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
11255597|NCT03002207|No Intervention|The defect is neither sutured nor repaired|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
11255598|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
11255599|NCT03002181|Experimental|PNE group|Pain neurophysiology education group.
11255600|NCT03002181|Experimental|Red Flag group|Red Flags education group.
11255601|NCT03002168|Active Comparator|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
11255602|NCT03002168|Placebo Comparator|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
11255603|NCT03002155|Experimental|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
11255604|NCT03002155|No Intervention|Control|Usual care.
11255605|NCT03002142|Experimental|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
11255606|NCT03002142|Placebo Comparator|Patients treated with placebo device|Patients fitted with non-functional hearing aids
11255607|NCT03002129|Other|fluid challenge|
11255608|NCT03002116|Active Comparator|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
11255609|NCT03002116|Experimental|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
11255610|NCT03002116|Experimental|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
11255611|NCT03002116|Experimental|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
11255612|NCT03002103|Experimental|ET+P+G|
11255613|NCT03002103|Active Comparator|Control|
11255614|NCT03002090|Experimental|Iron trained|
11255615|NCT03002090|Experimental|Iron Untrained|
11255616|NCT03002090|Experimental|BZKL Trained|
11255617|NCT03002090|Experimental|BZKL Untrained|
11255618|NCT03002090|Experimental|Placebo Trained|
11255619|NCT03002090|Placebo Comparator|Placebo Untrained|
11255620|NCT03002077|Experimental|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
11255621|NCT03002064|Experimental|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
11255622|NCT03002064|Active Comparator|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
11255623|NCT03002051|Experimental|EUS guided drainage|Patients suffering from the conditions in focus would receive EUS guided drainage with the lumen apposing stent
11255624|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
11255625|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
11255626|NCT03002025|Experimental|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
11255627|NCT03002025|Experimental|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
11255628|NCT03002025|Experimental|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
11255629|NCT03002025|Experimental|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
11255630|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
11255631|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
11255632|NCT03001999|Experimental|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
11255633|NCT03001986|Experimental|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
11255634|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
11255635|NCT03001960|Experimental|Group 1- PREloading BEFORE TAVI|"Aspirin 100 mg loading orally 6-12 hours before TAVI and
~Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
11255636|NCT03001960|Experimental|Group 2 - POSTLoading AFTER TAVI|"Aspirin 100 mg loading orally 6-12 hours after TAVI and
~Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
11255637|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
11255638|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
11255639|NCT03001921||Hemodialysis patients|End stage renal disease patients receiving hemodialysis treatment
11255640|NCT03001908|Active Comparator|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
11255641|NCT03001908|Active Comparator|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
11255642|NCT03001908|Experimental|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
11255643|NCT03001908|Experimental|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
11255644|NCT03001895|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
11255645|NCT03001882|Experimental|Combination therapy|Nivolumab + Ipilimumab
11255646|NCT03001869|Experimental|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
11255647|NCT03001856|Experimental|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
11255648|NCT03001856|Experimental|Intradermal Suture|Conventional interrupted intradermal suture
11255649|NCT03001843|Active Comparator|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
11255650|NCT03001843|Active Comparator|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
11255651|NCT03001830|Experimental|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
11255652|NCT03001817|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
11255653|NCT03001817|Active Comparator|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
11255654|NCT03001804||Cohort A|Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
11255655|NCT03001804||Cohort B|Initial treatment (up to 8 cycles): Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsule by mouth (PO) on day 1 through 14 of a 21 day cycle, Bortezomib 1.3mg/m2 s.c. on day 1, 4, 8, and 11 of a 21 day cycle, and Dexamethasone 20mg PO on days 1,2,4,5,8,9,11,12 of a 21 day cycle; Successive Treatment: Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
11255656|NCT03001791|Experimental|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
11255657|NCT03001791|Experimental|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
11255658|NCT03001791|Experimental|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
11255659|NCT03001778|Experimental|Usability Testing|Prototype testing
11255660|NCT03001765|Other|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
11255661|NCT03001752|Active Comparator|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
11255662|NCT03001752|Active Comparator|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
11255663|NCT03001752|Active Comparator|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
11255664|NCT03001739|Experimental|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg
11255665|NCT03001739|Active Comparator|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
11255666|NCT03001726|Experimental|Gastrectomy plus chemotherapy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
11255667|NCT03001726|Other|chemotherapy alone|Patients received chemotherapy alone.All patients received oral S1 80 mg/m2 per day (80-120 mg/day total dose depending on the patient's body surface area as follows: <1.25 m2, 80 mg; 1.25-1.5 m2, 100 mg; and >1.5 m2, 120 mg) on days 1-21 of every 3-week cycle, oxaliplatin 100 mg/m2 on day 1 of every 3-week cycle and docetaxel 40mg/m2 on day 1 of every 3-weeks cycle.
11255668|NCT03001713|Active Comparator|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
11255669|NCT03001713|Active Comparator|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
11255670|NCT03001700|Experimental|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
11255671|NCT03001687|Experimental|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
11255672|NCT03001687|Placebo Comparator|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
11255673|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
11255674|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
11255675|NCT03001661|Active Comparator|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
11255676|NCT03001661|Experimental|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
11255677|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
11255678|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
11255679|NCT03001635|Experimental|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
11255680|NCT03001635|Placebo Comparator|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
11255681|NCT03001622|Other|IFX-1|
11255682|NCT03001609|Experimental|AC0010|each participant will be given a single dose of 14C-labeled AC0010
11255683|NCT03001596|Experimental|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
11255684|NCT03001596|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
11255685|NCT03001583|Experimental|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
11255686|NCT03001583|Active Comparator|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
11255687|NCT03001570|Experimental|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.
~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:
~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
11255688|NCT03001557|Experimental|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
11255689|NCT03001557|Experimental|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
11255690|NCT03001557|Experimental|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
11255691|NCT03001557|Experimental|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
11255692|NCT03001557|Placebo Comparator|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
11255693|NCT03001544|Experimental|Experimental Ascending Dose Cohort|TS23
11255694|NCT03001531|Active Comparator|HydroSun|application of ultraviolet light for 30 minutes
11255695|NCT03001531|Active Comparator|Hilotherm|application of heat (maximum of 43°C) for 30 minutes
11255696|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
11255697|NCT03001505||Patients with pancreatic cancer|Patients diagnosed with pancreatic cancer evaluated at this institution.
11255897|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
11255698|NCT03001479|No Intervention|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
11255699|NCT03001479|Experimental|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
11255700|NCT03001466|Experimental|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
11255701|NCT03001466|Placebo Comparator|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
11255702|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
11255703|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
11255704|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
11255705|NCT03001427|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
11255706|NCT03001427|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
11255707|NCT03001414|Experimental|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
11255708|NCT03001414|Experimental|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
11255709|NCT03001414|Experimental|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
11255710|NCT03001401|Active Comparator|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
11255711|NCT03001401|Active Comparator|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
11255712|NCT03001375|Active Comparator|Mobilization group|Laparoscopic splenic flexure mobilization will be done.
11255713|NCT03001375|Active Comparator|Non mobilization group|No mobilization of splenic flexure.
11255714|NCT03001362|Experimental|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
11255715|NCT03001349|Experimental|Diagnostic (gallium Ga 68-edotreotide, PET/CT)|Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.
11255716|NCT03001323|Experimental|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
11255717|NCT03001323|Active Comparator|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.
11255718|NCT03001310|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of range AAV - CNGB3
11255719|NCT03001310|Experimental|Biological-medium dose AAV - CNGB3|Subretinal administration of a single medium dose of range AAV - CNGB3
11255720|NCT03001310|Experimental|Biological-high dose AAV - CNGB3|Subretinal administration of a single high dose of range AAV - CNGB3
11255721|NCT03001297|Experimental|MEDI5884 Dose 1|Participants will receive single dose of MEDI5884 Dose 1 injection SC on Day 1.
11255722|NCT03001297|Placebo Comparator|Placebo|Placebo will be administered subcutaneously (SC).
11255723|NCT03001297|Experimental|MEDI5884 Dose 2|Participants will receive single dose of MEDI5884 Dose 2 injection SC on Day 1.
11255724|NCT03001297|Experimental|MEDI5884 Dose 3|Participants will receive single dose of MEDI5884 Dose 3 injection SC on Day 1.
11255725|NCT03001297|Experimental|MEDI5884 Dose 4|Participants will receive single dose of MEDI5884 Dose 4 injection SC on Day 1.
11255726|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
11255727|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
11255728|NCT03001271|Experimental|Healthy Subjects|Placebo and Angiotensin-(1-7) acute infusion
11255729|NCT03001271|Experimental|Hypertensive Subjects|Placebo and Angiotensin-(1-7) acute infusion
11255730|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.
~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
11255787|NCT03000894|No Intervention|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
11255731|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.
~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
11255732|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.
~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
11255733|NCT03001245|Experimental|IPC|Interpersonal Counseling
11255734|NCT03001245|Active Comparator|ST|Standard treatment
11255735|NCT03001232|Experimental|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
11255736|NCT03001232|No Intervention|Care as usual|The control group received care as usual
11255737|NCT03001219|Placebo Comparator|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
11255738|NCT03001219|Experimental|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
11255739|NCT03001219|Placebo Comparator|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
11255740|NCT03001219|Experimental|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
11255741|NCT03001219|Placebo Comparator|Part 3: Placebo|"Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
~NOTE: Part 3 was not conducted."
11255742|NCT03001219|Experimental|Part 3: RO7123520|"Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
~NOTE: Part 3 was not conducted."
11255743|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :
~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
11255744|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :
~For patients referred to stress imaging with suspected ischemia."
11255745|NCT03001193|Experimental|DF01 low dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in low dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
11255746|NCT03001193|Experimental|DF01 medium dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in medium dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
11255747|NCT03001193|Experimental|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
11255748|NCT03001193|Placebo Comparator|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
11255749|NCT03001154|Experimental|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
11255750|NCT03001154|Experimental|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
11255751|NCT03001141||Single group - observational|
11255752|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
11255753|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
11255754|NCT03001115||Participants with Hidradenitis suppurativa (HS)|Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.
11255755|NCT03001102|Sham Comparator|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
11255756|NCT03001102|Experimental|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
11255757|NCT03001102|Active Comparator|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
11255758|NCT03001089|Active Comparator|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
11255759|NCT03001089|Placebo Comparator|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
11255760|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
11255761|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
11255762|NCT03001063|Experimental|Intervention|This arm will receive the Supported Self- Management intervention, which consists of bibliotherapy that is provided with the regular support of health or social workers for a duration of two months.
11255763|NCT03001063|Other|Control|This arm will receive enhanced treatment as usual, which consists of a leaflet with information about depression and regular care as provided by primary care centres. The control arm will receive the intervention after the intervention arm has completed the intervention period.
11257194|NCT02991209|Placebo Comparator|Placebo|1 years treatment with placebo gel
11255764|NCT03001050|Other|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
11255765|NCT03001037||Group A - Low Back Pain|"Group A:
~Subject provides written authorization and/or consent per institution and geographical requirements
~Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100
~Subjects in Group A are intended to be assessed with ViMove based on standard of care
~Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment
~Observational study, no intervention"
11255766|NCT03001037||Group B - Without Low Back Pain|"Subject is without current low back pain
~Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months
~Subject is willing to follow up 3 months post initial assessment
~Observational study, no intervention"
11255767|NCT03001024|Experimental|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary [UC] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
11255768|NCT03001024|Active Comparator|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
11255769|NCT03001011|Placebo Comparator|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (<=) 4.6 mg/dL (<=1.49 mmol/L).
11255770|NCT03001011|Experimental|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus <=4.6 mg/dL (<=1.49 mmol/L).
11255771|NCT03000998|Experimental|Web App Intervention Group|The BoyVac mobile web app will be evaluated in a pair-matched group-randomized pretest-posttest controlled design. In Year 2, 30 clinics in New Mexico will be pair-matched and one member of each pair will be randomized to the intervention (mobile web app) or a usual and customary (UC) HPV vaccine adoption procedures comparison group. Clinics will be paired based on similarities in patient demographic (ethnicity and % Medicaid patients) and location (urban and rural).
11255772|NCT03000998|Active Comparator|Usual Customary Care Group|Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
11255773|NCT03000985|Experimental|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
11255774|NCT03000985|No Intervention|Control|Treatment as usual
11255775|NCT03000972|Active Comparator|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
11255776|NCT03000972|Experimental|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
11255777|NCT03000946|Experimental|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
11255778|NCT03000946|Active Comparator|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
11255779|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
11255780|NCT03000920|No Intervention|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
11255781|NCT03000920|Experimental|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
11255782|NCT03000920|Experimental|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
11255783|NCT03000920|Experimental|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
11255784|NCT03000907|Experimental|Intervention|"diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.
~physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
11255785|NCT03000907|No Intervention|Control|Clinical practise
11255786|NCT03000894|Experimental|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
11255788|NCT03000881|Experimental|Cohort 6|This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours.
11255790|NCT03000868|Active Comparator|Hot EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
11255791|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
11255792|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
11255793|NCT03000842|Experimental|Healthy Subjects|transcutaneous vagal nerve stimulation
11255794|NCT03000842|Experimental|Hypertensive Subjects|transcutaneous vagal nerve stimulation
11255795|NCT03000829|Experimental|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest response team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
11255796|NCT03000829|Placebo Comparator|Control|"Simulated observation by ICU physician by displaying a silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site participants will be told that an intensive care physician is observing the mock code."
11255797|NCT03000816|Experimental|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
11255798|NCT03000803|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
11255799|NCT03000803|Active Comparator|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
11255800|NCT03000790|Experimental|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.
~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
11255801|NCT03000777|Experimental|Melatonin plus Zinc|Melatonin plus Zinc
11255802|NCT03000777|Placebo Comparator|Placebo|Isomaltose
11255803|NCT03000764|Experimental|Biomarkers|
11255804|NCT03000751|Active Comparator|Track A|Simple Audit Report In-Person Meeting Multi-Component Intervention
11255805|NCT03000751|Active Comparator|Track B|In-Person Meeting Simple Audit Report Multi-Component Intervention
11255806|NCT03000751|Other|Track C|Simple Audit Report Multi-Component Intervention
11255807|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age >=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
11255808|NCT03000725|Active Comparator|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
11255809|NCT03000725|Active Comparator|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
11255810|NCT03000712|Experimental|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
11255811|NCT03000712|No Intervention|No treatment|No treatment (after high tibial osteotomy)
11255812|NCT03000699|Experimental|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
11255813|NCT03000699|No Intervention|Assessment-Only Control|No training will be provided.
11255814|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
11255815|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
11255816|NCT03000673|Active Comparator|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
11255817|NCT03000673|Active Comparator|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
11255818|NCT03000673|Active Comparator|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
11255819|NCT03000673|Active Comparator|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
11255820|NCT03000660|Experimental|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
11255821|NCT03000647|Active Comparator|Guided Pelvic floor exercises|Pelvic floor exercises guided by a physiotherapist
11255822|NCT03000647|Active Comparator|Non-guided pelvic floor exercises|Pelvic floor exercises not guided
11255823|NCT03000634|Experimental|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
11255824|NCT03000634|Other|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
11255825|NCT03000621||Patients with liver injury|
11255826|NCT03000621||Healthy subjects|
11255827|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
11255828|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
11255829|NCT03000595|Experimental|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
11255830|NCT03000595|Placebo Comparator|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
11255831|NCT03000582|Experimental|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
11255832|NCT03000582|Active Comparator|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
11255833|NCT03000582|Active Comparator|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
11255834|NCT03000582|Placebo Comparator|Placebo|6.5 gm dextrose
11255835|NCT03000569|Experimental|Part A: Antiparkinsonian Agent(s) Followed by SAGE-217|Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.
11255836|NCT03000569|Experimental|Part B: Antiparkinsonian Agent(s) + SAGE-217|Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.
11255837|NCT03000556|Experimental|experience|
11255838|NCT03000556|No Intervention|control|
11255839|NCT03000543|No Intervention|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
11255840|NCT03000543|Experimental|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
11255841|NCT03000530|Experimental|SAGE-217 dosing|SAGE-217
11255842|NCT03000530|Placebo Comparator|Placebo|Placebo
11255843|NCT03000504|Experimental|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
11255844|NCT03000504|Active Comparator|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
11255845|NCT03000478|Active Comparator|Prolonged Exposure|12 sessions of PE as per protocol
11255846|NCT03000478|Experimental|VRET|12 sessions of Virtual Reality Exposure Therapy
11255847|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
11255848|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.
~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
11255849|NCT03000439|Experimental|Tofacitinib 5 mg BID|oral, twice daily, tablet or solution.
11255850|NCT03000439|Placebo Comparator|Placebo|
11255851|NCT03000426|Sham Comparator|Free gingival graft + PBM Sham|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which do not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications.
11255852|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 60|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 60 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 60 Joules/cm2 and a time of 56 seconds per point (1,68 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
11255853|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 15|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 15 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 Joules/cm2 and a time of 14 seconds per point (0,42 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
11255854|NCT03000413|Experimental|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
11255855|NCT03000413|Active Comparator|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
11255856|NCT03000400|Experimental|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
11255857|NCT03000400|Active Comparator|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
11255858|NCT03000387|Experimental|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
11255859|NCT03000387|Placebo Comparator|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
11255860|NCT03000387|Active Comparator|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
11255898|NCT03000140|Experimental|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
11258380|NCT02982941|Experimental|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
11255861|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:
~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
11255862|NCT03000361|Experimental|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
11255863|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
11255864|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
11255865|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
11255866|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
11255867|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
11255868|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
11255869|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
11255870|NCT03000335||Remission|B-ALL patients who are in remission
11255871|NCT03000322|Experimental|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
11255872|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
11255873|NCT03000296|Experimental|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
11255874|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
11255875|NCT03000270|Active Comparator|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
11255876|NCT03000270|Active Comparator|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
11255877|NCT03000257|Experimental|ABBV-181 plus Venetoclax|Venetoclax will be taken once daily beginning 7 days prior to cycle 1 and continuing daily for a 28 day cycle and ABBV-181 will be administered every 4 weeks.
11255878|NCT03000257|Experimental|ABBV-181|ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine or venetoclax.
11255879|NCT03000257|Experimental|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
11255880|NCT03000244||1/Patients|Patients who underwent hematopoietic stem cell transplant for any indication (malignant ornon-malignant).
11255881|NCT03000244||2/Donors|Related stem cell donors of those in Patients cohort.
11255882|NCT03000244||3/Parents of patients|Parents/guardians of minors enrolled in cohort 1
11255883|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
11255884|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
11255885|NCT03000218|Experimental|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
11255886|NCT03000218|Experimental|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
11255887|NCT03000218|Placebo Comparator|Placebo|Day 1 to 56: Placebo bid
11255888|NCT03000205|Experimental|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
11255889|NCT03000205|Placebo Comparator|Normal Saline|normal saline and Lidocaine as placebo for sham group
11255890|NCT03000192||Breast cancer|Women aged <50 years
11255891|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
11255892|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
11255893|NCT03000179|Experimental|Avelumab Monotherapy|Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.
11255894|NCT03000166|Experimental|intervention group|Participants assigned to the intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
11255895|NCT03000166|No Intervention|usual care group|Participants assigned to the usual care group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
11255896|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
11255899|NCT03000140|Active Comparator|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
11255900|NCT03000127|Experimental|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
11255901|NCT03000114|Active Comparator|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
11255902|NCT03000114|Active Comparator|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
11255903|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
11255904|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
11255905|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
11255906|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
11255907|NCT03000075|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11255908|NCT03000075|Experimental|Risankizumab 75 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11255909|NCT03000075|Experimental|Risankizumab 150 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11255910|NCT03000062|Experimental|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.
~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.
~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.
~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
11255911|NCT03000062|No Intervention|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.
~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.
~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
11255912|NCT03000036|Other|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
11255913|NCT03000010|Active Comparator|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
11255914|NCT03000010|Active Comparator|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
11255915|NCT02999997|Experimental|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
11255916|NCT02999997|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
11255917|NCT02999984|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
11255918|NCT02999971|Experimental|circuit class therapy in water|CCT on water. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
11255919|NCT02999971|Experimental|circuit class therapy on land|CCT on land. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
11255920|NCT02999958|No Intervention|Control|Sequential culture media without addition of antioxidants
11255921|NCT02999958|Active Comparator|Treatment|Sequential culture media with the addition of antioxidants
11255922|NCT02999945|Active Comparator|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
11255923|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
11255959|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
11255924|NCT02999945|Active Comparator|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
11255925|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
11255926|NCT02999932|Experimental|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
11255927|NCT02999932|Active Comparator|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
11255928|NCT02999919|Active Comparator|BMI ≥ 30|BMI ≥ 30
11255929|NCT02999919|Active Comparator|BMI < 30|BMI <30
11255930|NCT02999906|Placebo Comparator|Placebo|Matching placebo (sugar pill)
11255931|NCT02999906|Active Comparator|Active|Oral treprostinil sustained release tablet
11255932|NCT02999893|Experimental|APR-246|"The trial regimen consists of the investigational agent APR-246, along with standard chemotherapy, Cisplatin and 5-FU. A maximum of 8 cycles of treatment will be given.
~APR-246 and 5-FU must both commence on Day 1 and given on days 1 to 4 via intravenous infusion over 6 hours, whilst 5-FU must be given as a continuous infusion over 96 hours.
~On Days 2-4, APR-246 must be given first via intravenous infusion over 6 hours, then commence cisplatin via intravenous infusion over one hour.
~This is a dose-escalation study to determine the maximum tolerated dose (MTD) of the combination therapy. The 3 dose levels are described as follows:
~Dose Level 1:
~APR-246 Dose: 75mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI
~Dose Level 2:
~APR-246 Dose: 100mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI
~Dose Level -1:
~APR-246 Dose: 50mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI"
11255933|NCT02999880|Experimental|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
11255934|NCT02999880|No Intervention|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
11255935|NCT02999867|Experimental|M1 triticale and mung bean|M1: triticale and mung bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
11255936|NCT02999867|Experimental|M2 adzuki bean|M2: adzuki bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
11255937|NCT02999854|Experimental|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
11255938|NCT02999854|Active Comparator|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
11255939|NCT02999841|Experimental|Group A|Acarbose
11255940|NCT02999841|Active Comparator|Group B|Vildagliptin
11255941|NCT02999828|Experimental|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
11255942|NCT02999815|Active Comparator|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
11255943|NCT02999815|Sham Comparator|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
11255944|NCT02999802|Experimental|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
11255945|NCT02999789|Active Comparator|Intervention group|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
11255946|NCT02999789|Placebo Comparator|Placebo|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
11255947|NCT02999776|Active Comparator|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
11255948|NCT02999776|Experimental|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
11255949|NCT02999776|Active Comparator|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
11255950|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
11255951|NCT02999750|Other|individual therapy|individual therapy
11255952|NCT02999737|Other|Platelet Rich Plasma for 4 sessions|Autologous Platelet Rich Plasma injected in the scalp monthly x 3 then every 3 months x 1
11255953|NCT02999737|Other|Platelet rich plasma for 2 sessions|Autologous Platelet Rich Plasma injected in the scalp every 3 months
11255954|NCT02999724|Experimental|gabapentin|gabapentin 300-600 mg 1 hour preop
11255955|NCT02999724|Placebo Comparator|placebo|placebo capsule(s) 1 hour preop
11255956|NCT02999711|Experimental|Cohort 1|REGN3500 low dose or placebo
11255957|NCT02999711|Experimental|Cohort 2|REGN3500 medium dose or placebo
11255958|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
11255960|NCT02999685|Active Comparator|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
11255961|NCT02999685|Active Comparator|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
11255962|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
11255963|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
11255964|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
11255965|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
11255966|NCT02999646|Experimental|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
11255967|NCT02999633|Experimental|Isatuximab|Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
11255968|NCT02999620|Active Comparator|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
11255969|NCT02999620|Placebo Comparator|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
11255970|NCT02999607|Experimental|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
11255971|NCT02999607|Sham Comparator|Sham tDCS|Comparator to active arm
11255972|NCT02999594|Experimental|tramadol|50mg tramadol hydrochloride will be used intramuscularly as an experimental drug for evaluating its safety and efficacy as labor analgesic
11255973|NCT02999594|Placebo Comparator|distilled water|2ml distilled water intramuscularly will be used as a placebo.
11255974|NCT02999581|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 10 mg Bitter Orange (Citrus Aurantium) fruit standardized for 30% synephrine (Advantra Z), 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
11255975|NCT02999581|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
11255976|NCT02999581|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
11255977|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
11255978|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
11255979|NCT02999555|Experimental|Aspirated follicular fluid|Follicular fluid aspirated by follicle size and tested for the novel markers after eggs were identified and separated for the purpose of fertilization
11255980|NCT02999542|Experimental|Music|Children will receive music via headphones
11255981|NCT02999542|Experimental|No music|Children will listen to silence via headphones
11255982|NCT02999529|Experimental|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
11255983|NCT02999516|Experimental|Motor imaginary|Intervention with Motor imaginary with video
11255984|NCT02999516|Experimental|Non Motor imaginary|Intervention with Rest without motor imaginary
11255985|NCT02999516|Experimental|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
11255986|NCT02999516|Sham Comparator|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
11255987|NCT02999516|Experimental|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
11255988|NCT02999516|Sham Comparator|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
11255989|NCT02999503|Experimental|Nutritional intervention|Patients subject to nutritional education by CINUSA group protocol
11255990|NCT02999503|No Intervention|No intervention|Patients not subject to nutritional education
11255991|NCT02999490|No Intervention|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
11255992|NCT02999490|Experimental|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
11255993|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in
~Biopsy will be performed
~Post mono therapy Nab-Paclitaxel administered weekly
~Post mono therapy Pembrolizumab administered every 3 weeks
~Agents administered for a total of 15 weeks"
11255994|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in
~Biopsy will be performed
~Post mono therapy Nab-Paclitaxel administered weekly
~Post mono therapy Pembrolizumab administered every 3 weeks
~Agents administered for a total of 14 weeks"
11255995|NCT02999464|Experimental|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
11255996|NCT02999464|Active Comparator|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
11255997|NCT02999451|Experimental|snare group|snare-assisted POEM
11255998|NCT02999451|Active Comparator|conventional group|knife-assisted POEM
11255999|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:
~Single ventricle physiology s/p Fontan
~Heart failure diagnosed by a cardiologist
~Pulmonary hypertension diagnosed by cath"
11256000|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
11256001|NCT02999425|Experimental|Education|Educational intervention to study participants
11256002|NCT02999412|Active Comparator|Comprehensive medication review (I1)|
11256003|NCT02999412|Active Comparator|Comprehensive medication review with active follow-up (I2)|
11256004|NCT02999412|Other|Usual care (Control)|
11256005|NCT02999399|Experimental|[D10]phe and Brussels sprouts|All subjects are given 1 microgram [D10]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
11256006|NCT02999373|Experimental|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
11256007|NCT02999373|Placebo Comparator|Placebo|0.9% sodium chloride infusion 24 hours after birth
11256008|NCT02999360|Experimental|Treatment 1|
11256009|NCT02999360|Active Comparator|Treatment 2|
11256010|NCT02999347||Cases|Women having undergone at least one pregnancy/delivery after their MUS surgery
11256011|NCT02999347||Controls|Every case will be matched with two controls. The controls will be matched with the study cases' age and year of surgery (+- 2 years of age if a perfect match is not obtainable). These controls have not undergone a subsequent pregnancy/delivery.
11256012|NCT02999334|No Intervention|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
11256013|NCT02999334|Experimental|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
11256014|NCT02999321|Experimental|0% aspartame (water)|participants will not have any aspartame, this is a control.
11256015|NCT02999321|Experimental|5 mg aspartame|participants will receive 5 mg aspartame in a beverage.
11256016|NCT02999321|Experimental|15mg aspartame|participants will receive 5 mg aspartame in a beverage, and 10mg in capsules.
11256017|NCT02999308|Experimental|single arm|
11256018|NCT02999295|Experimental|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
11256019|NCT02999295|Experimental|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
11256020|NCT02999282|Experimental|Presymptomatic real tDCS|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
11256021|NCT02999282|Sham Comparator|Presymptomatic sham tDCS|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
11256022|NCT02999282|Experimental|Symptomatic real tDCS|Symptomatic patients - 10 days anodal transcranial direct current stimulation
11256023|NCT02999282|Sham Comparator|Symptomatic sham tDCS|Symptomatic patients - 10 days sham transcranial direct current stimulation
11256024|NCT02999269|Experimental|600 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
11256025|NCT02999269|Experimental|700 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
11256026|NCT02999269|Active Comparator|800 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
11256027|NCT02999256|Placebo Comparator|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.
~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
11256028|NCT02999256|Experimental|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.
~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
11256029|NCT02999243|Experimental|HIV self-testing|HIV self-testing kits plus harm reduction education materials will be offered to the intervention group.
11256030|NCT02999243|Placebo Comparator|Education|Harm reduction educational materials will be offered to the control group.
11256031|NCT02999230|Active Comparator|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
11256032|NCT02999230|Placebo Comparator|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
11256033|NCT02999230|Active Comparator|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
11256034|NCT02999230|Placebo Comparator|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
11256035|NCT02999217|Active Comparator|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
11256036|NCT02999217|Placebo Comparator|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
11256037|NCT02999204|Active Comparator|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
11256038|NCT02999204|Experimental|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
11256039|NCT02999191|Experimental|BI 1467335 (Treatment A)|Tablet under fasted conditions
11256040|NCT02999191|Experimental|BI 1467335 (Treatment B)|Oral solution under fasted conditions
11256041|NCT02999191|Experimental|BI 1467335 (Treatment C)|Tablet under fed conditions
11256042|NCT02999178|Experimental|Nintedanib|
11256043|NCT02999178|Placebo Comparator|Placebo|
11256044|NCT02999165||CPAP group|25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
11256045|NCT02999165||HHFNC group|25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.
11256046|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
11256047|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
11256048|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
11256049|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
11256050|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
11256051|NCT02999126|Experimental|Group 1|Patients < 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
11256052|NCT02999126|Experimental|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
11256053|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
11256054|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
11256055|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
11256056|NCT02999087|Active Comparator|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment
~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2
~Maintenance phase : no treatment until follow-up phase"
11256057|NCT02999087|Experimental|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg
~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg
~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
11256058|NCT02999087|Experimental|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg
~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg
~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
11256059|NCT02999087|Active Comparator|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2
~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2
~Maintenance phase : no treatment until follow-up phase"
11256060|NCT02999074|Active Comparator|Resistance exercise|
11256061|NCT02999074|Active Comparator|Aerobic exercise|
11256062|NCT02999074|Other|Waitlist control|
11256063|NCT02999048|No Intervention|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
11256064|NCT02999048|Other|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
11256065|NCT02999035||corneal sensitivity measurement|"Air jet aesthesiometry and liquid jet aesthesiometry:
~All patients will receive the same intervention of corneal sensitivity measurement with air jet aesthesiometry and liquid jet aesthesiometry.
~Thresholds represent the intensity of air / liquid jet that can just be perceived by the patients."
11256066|NCT02999022|Experimental|Lithium carbonate|Lithium carbonate 300mg capsule; once per day for 2 weeks.
11256067|NCT02999022|Placebo Comparator|Lactose placebo|Lactose placebo capsule; once per day for 2 weeks.
11256068|NCT02999009|Other|Trident II Tritanium Acetabular Shell|
11256069|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
11256070|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
11256071|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
11256072|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
11256073|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
11256074|NCT02998996|Active Comparator|i.n. comparator|
11256075|NCT02998983|Experimental|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
11256076|NCT02998970|Placebo Comparator|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
11256077|NCT02998970|Active Comparator|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
11256078|NCT02998957|Experimental|AcuTENS|"Stimulation using a portable TENS electrostimulation device at Dingchuan point using a biphasic rectangular wave with a frequency of 2Hz and a pulse width of 200 ms. The stimulation will be achieved using the highest intensity tolerated by the patient without pain during 40 minuts.
~Once a day during 5 consecutive days."
11256079|NCT02998957|Sham Comparator|Sham AcuTENS|"Stimulation using a modified portable TENS electrostimulation device at Dingchuan point with no electrical output, even though the screen will light up and display the same data as in the unmodified device during 40 minuts. Patients in this group will be informed that, due to the frequency of stimulation, it is unlikely that they will feel the electric stimulation.
~Once a day during 5 consecutive days."
11256080|NCT02998931|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
11256081|NCT02998931|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
11256082|NCT02998918|Experimental|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
11256083|NCT02998918|Experimental|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
11256084|NCT02998905|Experimental|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
11256085|NCT02998905|Active Comparator|Acetylsalicylic Acid|Acetylsalicylic acid
11256086|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
11256087|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
11256088|NCT02998879|Experimental|Velmanase Alfa|velmanase alfa 1mg/kg body weight infusion
11256089|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
11256090|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
11256091|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
11256092|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
11256093|NCT02998827|Experimental|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
11256094|NCT02998827|Active Comparator|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
11256095|NCT02998814|Active Comparator|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
11256155|NCT02998450|Experimental|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
11256464|NCT02996344|Active Comparator|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
11256096|NCT02998814|Active Comparator|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
11256097|NCT02998814|Active Comparator|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
11256098|NCT02998814|Active Comparator|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
11256099|NCT02998801|Placebo Comparator|Watch video using IPAD|Patient will watch the educational video using an IPAD
11256100|NCT02998801|Active Comparator|Watch video using VR goggles|Patient will watch the educational video using VR goggles
11256101|NCT02998775|Other|6 participants with mild renal impairment|Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
11256102|NCT02998775|Other|6 participants with moderate renal impairment|Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
11256103|NCT02998775|Other|6 participants with severe renal impairment|Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
11256104|NCT02998775|Other|8 participants normal renal status|Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
11256105|NCT02998775|Other|6 participants with mild hepatic impairment|Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
11256106|NCT02998775|Other|6 participants with moderate hepatic impairment|Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
11256107|NCT02998775|Other|6 participants with severe hepatic impairment|Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
11256108|NCT02998775|Other|8 participants normal hepatic status|Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
11256109|NCT02998736|Experimental|Intervention|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.
~Influenza vaccine 0.5mL day of surgery"
11256110|NCT02998723|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
11256111|NCT02998723|Active Comparator|Late booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
11256112|NCT02998723|No Intervention|Control group|The control group will receive no booster at all.
11256113|NCT02998697|Experimental|Treated Group|Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days
11256114|NCT02998697|Placebo Comparator|Control Group|Systolic heart failure patients received placebo oral capsule t.i.d for 90 days
11256115|NCT02998684|Active Comparator|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
11256116|NCT02998684|Sham Comparator|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
11256117|NCT02998671|Experimental|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
11256118|NCT02998671|Experimental|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
11256119|NCT02998671|Placebo Comparator|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
11256120|NCT02998658|Experimental|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
11256121|NCT02998658|Active Comparator|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
11256122|NCT02998645|Experimental|Eltrombopag + cyclosporine|Planned duration of treatment with eltrombopag & cyclosporine is 6 months (for all patients); the planned duration of treatment with cyclosporine (cyclosporine tapering) is 18 months (for responder patients only).
11256123|NCT02998632|Experimental|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.
~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.
~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
11256156|NCT02998450|Experimental|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
11256157|NCT02998450|Experimental|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
11256538|NCT02995785|Other|Experimental:simulation-based training|Experimental
11256124|NCT02998632|Active Comparator|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.
~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.
~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.
~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
11256125|NCT02998619||Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
11256126|NCT02998606|Experimental|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
11256127|NCT02998606|Placebo Comparator|Control Group|Placebo Oral Capsule 25 mg, daily
11256128|NCT02998593|Experimental|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
11256129|NCT02998593|Placebo Comparator|Placebo|500 mg of placebo once time a day
11256130|NCT02998580|Active Comparator|Convential Sequential Bilateral rTMS|"LFR followed by HFL.
~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
11256131|NCT02998580|Experimental|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.
~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
11256132|NCT02998567|Experimental|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
11256133|NCT02998567|Experimental|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
11256134|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
11256135|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
11256136|NCT02998541|Experimental|SHP640|Participants will receive one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
11256137|NCT02998541|Active Comparator|PVP-I 0.6%|Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
11256138|NCT02998541|Placebo Comparator|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days.
11256139|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
11256140|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
11256141|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
11256142|NCT02998515|Experimental|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
11256143|NCT02998515|Experimental|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
11256144|NCT02998502|Experimental|Device Group|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
11256145|NCT02998502|No Intervention|Control Group|The device will be given to those in the control group after 8-week baseline period.
11256146|NCT02998489|Experimental|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
11256147|NCT02998489|Active Comparator|Traditional milk advancement|20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
11256148|NCT02998476|Experimental|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
11256149|NCT02998476|Experimental|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
11256150|NCT02998463|Experimental|Snuby® users|This group receives the Snuby® skin-to-skin facilitating garment to use in the first six weeks following birth with their baby. The use of the Snuby® garment is participant led, and used for as long and as often as they wish in the six week period.
11256151|NCT02998463|No Intervention|Conventional Care|This group does not receive any intervention, and collects data on the research outcomes when having conventionally facilitated skin-to-skin contact, using a towel, blanket, or clothing as preferred. Skin-to-skin contact frequency and duration is dictated by the participant.
11256152|NCT02998450|Experimental|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
11256153|NCT02998450|Experimental|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
11256154|NCT02998450|Experimental|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.
~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
11256158|NCT02998437|Experimental|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day
~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
11256159|NCT02998437|Active Comparator|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
11256160|NCT02998437|Active Comparator|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day
~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
11256161|NCT02998424|Experimental|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.
~Pupillary diameter measurement after 10 minutes."
11256162|NCT02998424|Experimental|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.
~Pupillary diameter measurement after 10 minutes."
11256163|NCT02998424|Experimental|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.
~Pupillary diameter measurement after 10 minutes."
11256164|NCT02998411||AI treatment and dosage|
11256165|NCT02998385|Active Comparator|Radiotherapy|"Arm A
~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.
~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
11256166|NCT02998385|Experimental|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy
~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).
~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.
~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
11256167|NCT02998359|Active Comparator|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
11256168|NCT02998359|Active Comparator|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
11256169|NCT02998333|Active Comparator|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
11256170|NCT02998333|Active Comparator|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
11256171|NCT02998320|Experimental|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
11256172|NCT02998307|Experimental|Monthly|Receive bedside CPR training monthly
11256173|NCT02998307|Experimental|3 months|Receive bedside CPR training every 3 months
11256174|NCT02998307|Experimental|6 months|Receive bedside CPR training every 6 months
11256175|NCT02998307|No Intervention|Control|No additional training and only performance evaluation after 1 year
11256176|NCT02998294|Experimental|Respiratory monitoring group|
11256177|NCT02998281|Active Comparator|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
11256178|NCT02998281|Sham Comparator|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
11256179|NCT02998268|Other|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.
~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
11256180|NCT02998268|Experimental|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.
~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
11256181|NCT02998255|Experimental|Single dose of 2L PEG|2 L of PEG solution was used on the day of colonoscopy.
11256182|NCT02998255|Active Comparator|Split-dose of 4L PEG|Split-dose of 4l PEG was used before and on the day of colonoscopy
11256183|NCT02998242|Active Comparator|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
11256184|NCT02998242|Experimental|RT with apatinib|selected dose administered PO during and after SBRT
11256185|NCT02998229|Experimental|Artisse™ Intrasaccular Device|
11256186|NCT02998203|No Intervention|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
11256187|NCT02998203|Experimental|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
11256188|NCT02998190|Experimental|Single oral dose of EB8018|Single ascending doses, sequential group design
11256189|NCT02998190|Placebo Comparator|Single oral dose of placebo|Single doses, matching placebo
11256190|NCT02998190|Experimental|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
11256191|NCT02998190|Placebo Comparator|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
11256192|NCT02998164|Experimental|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
11256193|NCT02998164|Active Comparator|usual care|This group will be usual care children are already receiving.
11256194|NCT02998151|Placebo Comparator|Placebo|Placebo pill
11256195|NCT02998151|Experimental|Acamprosate|
11256196|NCT02998151|Experimental|Lovastatin|
11256197|NCT02998151|Experimental|Minocycline|
11256198|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
11256199|NCT02998112|Placebo Comparator|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
11256200|NCT02998112|Experimental|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
11256201|NCT02998099|Experimental|Aged 18-45 years|A single dose of IV rivipansel over 20 minutes.
11256202|NCT02998099|Experimental|Aged 65 and older|A single dose of IV rivipansel over 20 minutes.
11256203|NCT02998086|Experimental|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
11256204|NCT02998086|Experimental|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
11256205|NCT02998086|No Intervention|Usual Care|Usual non-directed psychosocial supportive care
11256206|NCT02998073|Experimental|Conduct Disorder|Participants are justice-involved youth with conduct disorder. Participants will receive Stop, Now and Plan (SNAP) psychosocial intervention.
11256207|NCT02998073|No Intervention|Control|Participants are healthy males. Participants receive no intervention.
11256208|NCT02998060|Active Comparator|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
11256209|NCT02998060|Active Comparator|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
11256210|NCT02998060|Active Comparator|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
11256211|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.
~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
11256212|NCT02998034|Experimental|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
11256213|NCT02998034|Experimental|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
11256214|NCT02998021|Experimental|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
11256215|NCT02998021|Active Comparator|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
11256216|NCT02998008|Other|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
11256217|NCT02998008|Other|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
11256218|NCT02997995|Experimental|Immune-attractant/lymphocyte activation|After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
11256219|NCT02997982|Experimental|Valaciclovir treatment|Valaciclovir 500Mg Tablet
11256220|NCT02997969|Active Comparator|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
11256221|NCT02997969|Active Comparator|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
11256222|NCT02997969|Placebo Comparator|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
11256223|NCT02997969|Active Comparator|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
11256224|NCT02997969|Active Comparator|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
11256225|NCT02997969|Placebo Comparator|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
11256226|NCT02997956|Experimental|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.
~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
11256539|NCT02995785|Other|Active comparatorr: traditional training|Traditional
11258846|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
11256227|NCT02997943|Experimental|Step 1: Optimal First Line Treatment|"Participants will first be randomized to an optimal first line treatment in order to compare APP vs. APP + coaching. Participants assigned to Step 1 treatment APP will receive a study-specific smartphone application. Participants assigned to Step 1 treatment APP + coaching will receive a study-specific smartphone application plus 12 weekly telephone coaching sessions."
11256228|NCT02997943|Experimental|Step 2: Optimal Strategy to Address Nonresponse|Beginning at week 2, participants who are identified as treatment non-responders will be re-randomized in order to compare two strategies to address non-response: a modest step-up or vigorous step-up treatment augmentation tactic. Step 2 treatment strategy: modest step-up will include provision of an additional mHealth intervention component (push notifications). Step 2 treatment strategy vigorous step-up will include provision of an additional mHealth intervention component (push notifications), plus a traditional weight loss intervention component (coaching, meal replacements). Participants will continue to receive their first line treatment.
11256229|NCT02997930|Experimental|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
11256230|NCT02997917|Experimental|Education|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the real education group, solutions at suprathreshold concentration for detection will be given with a subsequent comment on the flavor and an explanation of the components and preparation of the soup (low temperature cooking to preserve flavors).
11256231|NCT02997917|Sham Comparator|Sham|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the sham education group solutions at subthreshold concentration for detection with no explanation will be provided.
11256232|NCT02997904|Experimental|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
11256233|NCT02997904|Placebo Comparator|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
11256234|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
11256235|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
11256236|NCT02997878|Experimental|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
11256237|NCT02997878|Experimental|AiH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
11256238|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
11256239|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
11256240|NCT02997852|Experimental|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
11256241|NCT02997852|No Intervention|Control|Usual care in the intensive care unit.
11256242|NCT02997839|No Intervention|group 2|no intervention
11256243|NCT02997839|Other|group 1|sleep disruption
11256244|NCT02997826|Other|1 to 21-days old child|
11256245|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
11256246|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
11256247|NCT02997800|Experimental|Esmolol|Esmolol infusion and 1 ml saline infusion
11256248|NCT02997800|Experimental|Labetalol|Labetalol Bolus and saline infusion
11256249|NCT02997800|Active Comparator|Fentanyl|Fentanyl Bolus and saline infusion
11256250|NCT02997787||adenomyosis|First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
11256251|NCT02997787||leiomyoma|Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
11256252|NCT02997787||control|Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
11256253|NCT02997774|Active Comparator|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
11256254|NCT02997774|Experimental|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
11256319|NCT02997306|Experimental|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
11256255|NCT02997761|Experimental|Treatment (ibrutinib, blinatumomab)|"INDUCTION THERAPY: Patients receive ibrutinib PO QD on days 1-49 of course 1 and days 1-42 of course 2, and blinatumomab IV on days 8-35 of course 1 and days 1-28 of course 2 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Patients with CR/CRi after Induction Therapy receive ibrutinib PO QD on days 1-42 and blinatumomab IV on days 1-28. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11256256|NCT02997748|No Intervention|Observational group|No intervention, standard care
11256257|NCT02997748|Sham Comparator|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
11256258|NCT02997748|Experimental|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
11256259|NCT02997748|Experimental|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
11256260|NCT02997748|Experimental|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
11256261|NCT02997748|Experimental|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
11256262|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
11256263|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
11256264|NCT02997722|Experimental|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
11256265|NCT02997722|Placebo Comparator|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
11256266|NCT02997709||COMBINE Patients|"Blood specimen collection
~Expanded Prostate Cancer Index Composite-SF-12
~Memorial Anxiety Scale for Prostate Cancer patients
~International Prostate Symptom Score
~Multiparametric MRI (mpMRI) of the prostate
~MRI-US fusion guided biopsy"
11256267|NCT02997696|Experimental|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
11256268|NCT02997696|Experimental|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
11256269|NCT02997696|Placebo Comparator|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
11256270|NCT02997683|Experimental|3-month home based training on whole body vibration platform|This Group will receive a training device to perform their given exercises on
11256271|NCT02997683|Placebo Comparator|3-month home based training on floor|This Group will perform their given exercises at home on the floor
11256272|NCT02997670|Experimental|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
11256273|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
11256274|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
11256275|NCT02997644|Experimental|Video Education|Video education delivered on a tablet computer
11256276|NCT02997644|Placebo Comparator|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
11256277|NCT02997631|Experimental|MEDi Distraction|The intervention will be the use of the MEDi robot. The robot will be at the child's eye level, and will be programmed to introduce itself, interact with the child, and make encouraging comments about how brave he/she was. The duration of its actions will coincide with the length of the procedure (approximately 5-8 minutes).
11256278|NCT02997631|No Intervention|Standard Care|The control group will receive standard care, which generally includes the use of topical anesthetic cream. This comparison is based on the pragmatic preferences of physicians at the Stollery Children's Hospital as well as precedent in the literature. Overall, it is felt that any new intervention (e.g., the MEDi robot) should be compared to what is currently in practice (i.e., standard care), as no single distraction therapy is consistently and routinely employed in EDs at this time.
11256279|NCT02997618|Active Comparator|Control|"1. Usual care (control)
~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:
~Smoking Exercise Weight Diet"
11256316|NCT02997332|Experimental|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
11256317|NCT02997319||Night Shift-Workers|
11256318|NCT02997319||Day Workers|
11256362|NCT02997033||Total study cohort|
11259105|NCT02977832|Experimental|odyliresin|Odyliresin (Iresine celosia) 2 ml
11256280|NCT02997618|Experimental|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:
~Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.
~Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.
~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
11256281|NCT02997605|Active Comparator|Glucocorticoid (GC) tapering|"GC tapering group: patients will be asked to taper prednisone taken every morning at 8.00 AM by decreasing the daily dose by 1 mg every month as soon as they are in remission or Low Disease Activity (LDA). In addition they will receive a placebo of 20 mg/day of hydrocortisone (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg/day (at 8.00 AM) of hydrocortisone placebo for 3 months before discontinuing the hydrocortisone placebo."
11256282|NCT02997605|Active Comparator|Hydrocortisone replacer|"Hydrocortisone replacer group: patients will replace prednisone with 20 mg of hydrocortisone on a daily basis (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg daily (at 8.00 AM) for 3 months then stop as soon as they are in remission or LDA, as well as a prednisone placebo (at 8.00 AM) with a schedule to taper the prednisone placebo by 1mg/day every month until discontinuation."
11256283|NCT02997592|Experimental|SpinCare|Patients with partial thickness burns treated with the SpinCare dressing
11256284|NCT02997579|Experimental|patellar resurfacing|patellar resurfacing TKA
11256285|NCT02997579|No Intervention|patellar non-resurfacing|patellar non-resurfacing TKA
11256286|NCT02997566||Autistic Disorder|Age: 3 to 14 years-old Gender: male and female Autism Spectrum Disorder
11256287|NCT02997566||Typical|Age: 3 to 14 years-old Gender: male and female Typical
11256288|NCT02997553|Experimental|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.
~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
11256289|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
11256290|NCT02997527|Experimental|Intraluminal impedance testing|"During the participant's clinical endoscopy the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope.
~The catheter (tiny tube) will be placed through the endoscope in your esophagus 1 cm above where your stomach and esophagus meet for 5 seconds.
~At 2 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds
~And at 3 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.
~At 4 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.
~At 5 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds."
11256291|NCT02997514|Active Comparator|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
11256292|NCT02997514|Active Comparator|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
11256293|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
11256294|NCT02997488||McGrath|McGrath Videolaryngoscope
11256295|NCT02997488||Pentax|Pentax Airwayscope
11256296|NCT02997475||Women with Bulimia Nervosa|
11256297|NCT02997475||Women Healthy Controls|
11256298|NCT02997462||Heart Failure|"Heart Failure patients admitted to the ICU or Heart Failure Service.
~No changes in service-directed plan of care for patients."
11256299|NCT02997462||Healthy Control|Healthy, age-matched controls.
11256300|NCT02997449||NSCLC, SABR, nodal staging|Patients with a clinical or pathological diagnosis of Non-Small Cell Lung Cancer (NSCLC), and who are medically inoperable or refuse surgery, are eligible if Stereotactic ablative radiotherapy (SABR) is recommended by a multi-disciplinary tumor board. All patients undergo complete mediastinal and hilar staging procedure (EBUS+EUS-B). Pre endoscopy imaging data will be compared with endosonography data.
11256301|NCT02997436|Experimental|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).
~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
11256302|NCT02997410|Experimental|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
11256303|NCT02997410|Placebo Comparator|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
11256304|NCT02997410|Experimental|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
11256305|NCT02997397||tourniquet (+)|The cases in which the tourniquet technique is used
11256306|NCT02997397||tourniquet(-)|The cases in which the tourniquet technique is not used
11256307|NCT02997384||General practitioner|
11256308|NCT02997384||gynecologist|
11256309|NCT02997384||radiologist|
11256310|NCT02997371|Placebo Comparator|Placebo|Isotonic saline administered as an injection and infusion
11256311|NCT02997371|Experimental|1.5 g Kineret|Kineret provided as a 500 mg injection followed by a 1g infusion.
11256312|NCT02997371|Experimental|3.0 g Kineret|Kineret provided as a 500 mg injection followed by a 2.5g infusion.
11256313|NCT02997358|Active Comparator|Doxorubicin|6 cycles - 1 cycle every 3 weeks (day 1 to day 21) On day 1: Doxorubicin 75 mg/m² IV
11256314|NCT02997358|Experimental|doxorubicin + trabectedin followed by maintenance trabectedin|"Doxorubicin + trabectedin 6 cycles - 1 cycle every 3 weeks (day 1 to day 21) Doxorubicin 60 mg/m² IV D1, then Trabectedin 1.1 mg/m² per CIV 3 hours D1. Surgery for residual disease is possible after 6 cycles (in case of non evolutive disease)
~In case of response or stable disease after 6 cycles 3-weeks cycle until disease progression or for a maximum of 12 months of treatment (maximum 17 cycles in maintenance therapy), whichever occurs first Trabectedin 1.1 mg/m² per CIV 3 hours"
11256315|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
11256540|NCT02995772|Active Comparator|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
11256320|NCT02997306|Experimental|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
11256321|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
11256322|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
11256323|NCT02997280|Experimental|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight > 40 kg, 0.15 mg/kg bid for children with body weight < 40 kg.
11256324|NCT02997267|Experimental|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
11256325|NCT02997267|Active Comparator|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
11256326|NCT02997241|Other|high genetic risk and high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
11256327|NCT02997241|Active Comparator|low genetic risk but high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
11256328|NCT02997241|Active Comparator|high genetic risk but low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
11256329|NCT02997241|Other|low genetic risk and low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
11256330|NCT02997228|Active Comparator|Arm I (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Cycles of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11256331|NCT02997228|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL)
11256332|NCT02997228|Experimental|Arm III (atezolizumab, bevacizumab, mFOLFOX6)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Cycles of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11256333|NCT02997215|Experimental|intravenous lidocaine|intravenous lidocaine 1.5mg/kg during induction then infused at 2mg/kg/h until the end of procedure.
11256334|NCT02997215|Placebo Comparator|saline placebo|same amount volume saline infusion
11256335|NCT02997202|Experimental|Gilteritinib|Participants will take gilteritinib once daily for continuous daily dosing.
11256336|NCT02997202|Placebo Comparator|Placebo|Participants will take placebo once daily for continuous daily dosing.
11256337|NCT02997189|Active Comparator|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
11256338|NCT02997189|No Intervention|Control|The ear not receiving OTO-104 will receive no treatment
11256339|NCT02997176|Experimental|Group A (control, normal hepatic function)|
11256340|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
11256341|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
11256342|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
11256343|NCT02997163|Experimental|Group A (control, normal renal function)|
11256344|NCT02997163|Experimental|Group B (mild renal impairment)|
11256345|NCT02997163|Experimental|Group C (moderate renal impairment)|
11256346|NCT02997163|Experimental|Group D (severe renal impairment)|
11256347|NCT02997150|Experimental|IL-2 low dose|
11256348|NCT02997137|Active Comparator|BOT-01|Dietary supplement: specific amino acid composition with micronutrients
11256349|NCT02997137|Placebo Comparator|Placebo|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
11256350|NCT02997124|Experimental|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
11256351|NCT02997124|Experimental|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
11256352|NCT02997111|Other|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
11256353|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
11256354|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
11256355|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
11256356|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
11256357|NCT02997059|Experimental|Fluconazole|200mg per day for 6 months
11256358|NCT02997059|Placebo Comparator|Placebo|One capsule per day for 6 months
11256359|NCT02997046||Pre-transplant assessment|"CTA abdominal and aortoiliac vasculature before transplantation
~FeMRA abdominal and aortoiliac vasculature & CMR before transplantation"
11256360|NCT02997046||Mapping & surveillance (for fistula)|"US vascular mapping before fistula creation
~6 week US fistula arm
~FeMRA fistula arm/central veins & CMR before fistula creation and at 6 weeks"
11256361|NCT02997046||Mapping & surveillance (for graft)|"US vascular mapping before graft creation
~6 week US graft arm
~FeMRA fistula arm/central veins & CMR before graft creation and at 6 weeks"
11256363|NCT02997020||CRS Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
11256364|NCT02997020||Control Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
11256365|NCT02997007|Experimental|MCI-active|Patients will receive verum tDCS over the angular gyrus on five consecutive days.
11256366|NCT02997007|Sham Comparator|MCI-sham|Patients will receive sham tDCS over the angular gyrus on five consecutive days.
11256367|NCT02997007|Experimental|Healthy Old-active|Participants will receive verum tDCS over the angular gyrus on five consecutive days.
11256368|NCT02997007|Sham Comparator|Healthy old-sham|Participants will receive sham tDCS over the angular gyrus on five consecutive days.
11256369|NCT02996981||Cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2016 and September 2016 and discharged home with an indwelling urinary catheter following the surgery. This group of people had cranberry juice capsules prescribed.
11256370|NCT02996981||No cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2015 and September 2015. This group of people did not have cranberry juice capsules prescribed.
11256371|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
11256372|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
11256373|NCT02996955|Experimental|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
11256374|NCT02996955|Active Comparator|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
11256375|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
11256376|NCT02996929|Experimental|Study group|Subjects who are scheduled for CIED lead extraction with the LC system
11256377|NCT02996916|Active Comparator|Olmesartan|Olmesartan 10-40mg daily
11256378|NCT02996916|Active Comparator|Amlodipine|Amlodipine 2.5-10mg daily
11256379|NCT02996890|Experimental|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
11256380|NCT02996890|Experimental|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
11256381|NCT02996890|Experimental|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
11256382|NCT02996890|Placebo Comparator|Placebo|Physiological saline, two treatments
11256383|NCT02996877||Guideline Directed Medical Therapy|Patients who have an initial treatment strategy of using guideline-directed medical therapy only.
11256384|NCT02996877||Percutaneous Coronary Intervention|Patients who will have a Percutaneous Coronary Intervention as the initial treatment strategy along with guideline directed medical therapy.
11256385|NCT02996864|Experimental|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
11256386|NCT02996864|Placebo Comparator|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
11256387|NCT02996838|Experimental|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11256388|NCT02996825|Experimental|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
11256389|NCT02996812|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
11256390|NCT02996812|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
11256391|NCT02996812|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
11256392|NCT02996812|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
11256393|NCT02996799|No Intervention|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
11256394|NCT02996799|Experimental|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
11256395|NCT02996786|Experimental|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
11256396|NCT02996786|Placebo Comparator|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
11256397|NCT02996773|Experimental|Cyclophosphamide and Bendamustine|Several dose levels are planned to gradually decrease cyclophosphamide and replace with bendamustine on Day 4+ post-transplant.
11256398|NCT02996760|Experimental|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.
~Less than 5mm despite 10 days with standard doses of estrogen"
11256399|NCT02996760|No Intervention|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.
~More than 5mm despite 10 days with standard doses of estrogen"
11256458|NCT02996383|Active Comparator|Cemented hemiarthroplasty|Treatment of the fracture by a replacement arthroplasty with a cemented CPT hemiarthroplasty (manafactured by Zimmer company, Warsaw IN, USA) inserted via an anteriolateral approach to the hip
11256400|NCT02996721|No Intervention|Standard of Care|Patients randomized to the standard of care arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25[OH] Vit D testing, use of vitamin D supplementation, and outcomes.
11256401|NCT02996721|Experimental|Treatment|Patients randomized to the treatment arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25[OH] Vit D >40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25[OH] Vit D levels are <40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25[OH] Vit D level. At 3 months, if 25[OH] Vit D >40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25[OH] Vit D <40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25[OH] Vit D reaches a level >40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25[OH] Vit D testing.
11256402|NCT02996708||Group with teleconsultation - before period|
11256403|NCT02996708||Group without teleconsultation - before period|
11256404|NCT02996708||Group with teleconsultation - after period|
11256405|NCT02996708||Group without teleconsultation - after period|
11256406|NCT02996695|Experimental|204,800 PfSPZ of PfSPZ Challenge|204,800 PfSPZ of PfSPZ Challenge every 4 weeks x 3 doses by DVI, n=31
11256407|NCT02996695|Placebo Comparator|NaCl placebo|NaCl placebo every 4 weeks x 3 doses by DVI, n=31
11256408|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11256409|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
11256410|NCT02996669||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
11256411|NCT02996669||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
11256412|NCT02996656|Active Comparator|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
11256413|NCT02996656|Experimental|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
11256414|NCT02996643|No Intervention|Traditional method|The traditional brace design method will be used to design a spinal brace.
11256415|NCT02996643|Active Comparator|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
11256416|NCT02996630|Other|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
11256417|NCT02996630|Other|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
11256418|NCT02996617|Active Comparator|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L for total 4 courses.
11256419|NCT02996617|Experimental|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.
11256420|NCT02996604|Experimental|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
11256421|NCT02996604|Experimental|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
11256422|NCT02996604|Active Comparator|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
11256423|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
11256459|NCT02996383|Active Comparator|Internal fixation|Internal fixation of the fracture with a screw and plate device (Targon FN plate, Aesculap cooperation, Tuttingham, Germany)
11256460|NCT02996370|Active Comparator|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
11256461|NCT02996370|Active Comparator|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
11256424|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
11256425|NCT02996578|Active Comparator|Solid Matrix - Intervention|"Dietary Supplement: polyphenol rich chocolate bar
~17.5g of commercially available dark chocolate will be consumed daily for 8 weeks"
11256426|NCT02996578|Active Comparator|Powder Matrix - Intervention|"Dietary Supplement: polyphenol rich cocoa powder
~6g of commercially available cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
11256427|NCT02996578|Placebo Comparator|Solid Matrix Intervention - Placebo|"Dietary Supplement: low polyphenol chocolate
~17.5g of commercially available, nutritionally similar, dark chocolate will be consumed daily for 8 weeks"
11256428|NCT02996578|Placebo Comparator|Powder Matrix - Placebo|"Dietary Supplement: nutritionally similar low polyphenol cocoa powder
~6g of commercially available, nutritionally similar, cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
11256429|NCT02996565|Active Comparator|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
11256430|NCT02996565|Active Comparator|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
11256431|NCT02996552|Experimental|M & T Repair Group|Both mitral and tricuspid valves repair
11256432|NCT02996552|Active Comparator|Mitral-Only Group|Only mitral valve repair
11256433|NCT02996539||Type 2 diabetes|With Clinical examination and laboratory measurements
11256434|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
11256435|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
11256436|NCT02996513|Experimental|Retinol Isotope dilution (RID)|A once-off dose of 0.4 mg 13C4-retinyl acetate will be administered to subjects as a capsule
11256437|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
11256438|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
11256439|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
11256440|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
11256441|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
11256442|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
11256443|NCT02996487|Placebo Comparator|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
11256444|NCT02996487|Active Comparator|vancomycin|Vancomycin 125 mg by mouth every 6 hours
11256445|NCT02996474|Experimental|Pembrolizumab and Decitabine for treatment of AML|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
11256446|NCT02996461|Experimental|Group 1|ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
11256447|NCT02996461|Experimental|Group 2|ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
11256448|NCT02996461|Experimental|Group 3|ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
11256449|NCT02996448|Experimental|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
11256450|NCT02996435|Experimental|Mobile Adherence Platform|Participant adherence will be monitored using a mobile application and platform which provides a real-time reminder that alerts the participant to take his or her medication. The application will also send an alert to the participant when a refill is needed based on calculated medication or pill supply. The intervention will focus only on daily adherence to rivaroxaban.
11256451|NCT02996435|Other|Control: Standard of Care|Participants will receive physician- or nurse-guided standard of care for their rivaroxaban adherence. No drug will be administered as part of this study.
11256452|NCT02996422|Experimental|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
11256453|NCT02996422|No Intervention|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
11256454|NCT02996422|Experimental|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
11256455|NCT02996409|Experimental|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
11256456|NCT02996409|Placebo Comparator|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
11256457|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
11256462|NCT02996357||Cases|Patients with IAD Category 2 (red skin with skin breakdown)
11256463|NCT02996357||Controls|Patients with IAD Cat. 0 (at risk, no redness and skin intact)
11256465|NCT02996344|Experimental|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
11256466|NCT02996331|Active Comparator|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
11256467|NCT02996331|Experimental|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
11256468|NCT02996331|Experimental|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
11256469|NCT02996318|Experimental|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
11256470|NCT02996318|Active Comparator|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
11256471|NCT02996305|Experimental|OV101 regimen 1|OV101 once daily
11256472|NCT02996305|Experimental|OV101 regimen 2|OV101 twice daily
11256473|NCT02996305|Placebo Comparator|Placebo|Twice daily
11256474|NCT02996292|Experimental|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
11256475|NCT02996292|Experimental|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
11256476|NCT02996292|Experimental|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
11256477|NCT02996279||group 1|maternal chorioamnionitis
11256478|NCT02996279||group 2|no maternal chorioamnionitis
11256479|NCT02996266|Experimental|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
11256480|NCT02996266|Active Comparator|Standard Care|Standard care in which fever may spontaneously develop
11256481|NCT02996240|Experimental|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
11256482|NCT02996227|Experimental|TAP block with Exparel|Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
11256483|NCT02996227|Active Comparator|Epidural analgesia with Bupivacaine|Epidural catheters with an infusion of Bupivacaine standard solution without additives
11256484|NCT02996214|Experimental|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
11256485|NCT02996214|Active Comparator|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
11256486|NCT02996201|Experimental|Electronic reporting of PRO-CTCAE items|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
11256487|NCT02996201|No Intervention|Standard practice|
11256488|NCT02996188||Patients with refractory tense ascites|
11256489|NCT02996175|Experimental|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.
~Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems
~Information on healthy sleep hygiene, preventative techniques, and use of visual supports
~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking
~Information on procedures for delayed sleep onset and problematic sleep associations
~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
11256490|NCT02996175|Active Comparator|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
11256491|NCT02996136|Experimental|Nasal Swab|Nasal Swab
11256492|NCT02996136|Experimental|Nasopharyngeal Swab|Nasopharyngeal Swab
11256493|NCT02996123|Experimental|cad/cam maxillary dentures|single maxillary dentures fabricated by cad/cam method
11256494|NCT02996123|Active Comparator|conventional dentures|heat cured single maxillary dentures
11256495|NCT02996110|Active Comparator|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
11256496|NCT02996110|Experimental|Nivolumab + Relatlimab|Nivolumab + Relatlimab
11256497|NCT02996110|Experimental|Nivolumab + BMS-986205|Nivolumab + BMS-986205
11256498|NCT02996110|Experimental|Nivolumab + BMS-813160|Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
11256499|NCT02996097|Experimental|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
11256500|NCT02996097|Active Comparator|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
11256501|NCT02996071|Active Comparator|low waist to height ratio|laparoscopic sleeve gastrectomy
11256502|NCT02996071|Active Comparator|high waist to height ratio|laparoscopic sleeve gastrectomy
11256503|NCT02996058|Active Comparator|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
11256541|NCT02995772|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
11256504|NCT02996058|Active Comparator|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
11256505|NCT02996045|Experimental|Treatment|Clinical Decision Support (CDS)
11256506|NCT02996045|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
11256507|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
11256508|NCT02996019|Experimental|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
11256509|NCT02996019|Active Comparator|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
11256510|NCT02996019|Experimental|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
11256511|NCT02996019|Active Comparator|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
11256512|NCT02995993|Experimental|Moss-aGal|Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion
11256513|NCT02995980|Experimental|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
11256514|NCT02995967|Active Comparator|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
11256515|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
11256516|NCT02995954|Active Comparator|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
11256517|NCT02995954|Active Comparator|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
11256518|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
11256519|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
11256520|NCT02995928|Experimental|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
11256521|NCT02995928|Active Comparator|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure >25 mm Hg for 1-12 hours to keep the patients safe.
11256522|NCT02995915|Experimental|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
11256523|NCT02995915|Active Comparator|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
11256524|NCT02995902|Experimental|FLT-PET/MRI|
11256525|NCT02995889|Experimental|FLT-PET|
11256526|NCT02995876|No Intervention|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
11256527|NCT02995876|Experimental|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
11256528|NCT02995876|Experimental|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
11256529|NCT02995863|Experimental|Experimental Group|Rigid rocker sole footwear
11256530|NCT02995863|Active Comparator|Control Group|Therapeutic footwear
11256531|NCT02995850|Experimental|anti-cancer drug|
11256532|NCT02995837||Obstructive Sleep Apnea Syndrome (OSAS)|"The study duration is estimated at 12-14 months approximately. However, this will depend on the timing of treatment as they will undergo testing pre- and post-OSAS treatment. Participation will entail a total of 8 visits including:
~Pre-treatment - neurocognitive testing, and CBF during wakefulness testing duration is one full day. The CBF nighttime testing is one full night.
~Post-treatment - Six to twelve weeks after clinically indicated surgical treatment, OSAS participants will have a repeat baseline polysomnogram (one full night) to assess for residual OSA. Six and twelve months after the surgical treatment, the sleep study with the nighttime CBF testing, as well as the daytime neurocognitive testing and CBF testing will be repeated to assess for changes."
11256533|NCT02995837||Controls|The study will include 7 total visits for controls: a baseline sleep study to ensure normalcy, three full days of neurocognitive testing and CBF testing (baseline, 6 and 12 months), and three sleep studies with CBF testing (baseline, 6 and 12 months). A daytime visit and one night time visit may be scheduled during a 24-hour period if the participant and family wish so. Otherwise, they will be scheduled on separate days.
11256534|NCT02995811||Observational Cohort|"On Days 1, 3, 7 and 10 of ICU admission, patients will undergo ultrasound assessment of the diaphragm, transverse and rectus abdominis, quadriceps rectus femoris, and tibialis anterior muscles. Imaging all four muscles together requires approximately 1 hour.
~Physical activity monitoring: On Days 1-10 of ICU admission patients will wear an activity monitor. These devices use several inertial motion sensors to track the movement and acceleration of the limbs in horizontal and vertical directions.
~Patients will also undergo daily assessment of global peripheral skeletal muscle strength assessed by the Medical Research Council Sum-score and global function measured by the Chelsea Critical Care Physical Assessment Scale"
11256535|NCT02995798||Group A|T-score ≥-1
11256536|NCT02995798||Group B|-2.5<T-score<-1.0
11256537|NCT02995798||Group C|T-score≤-2.5
11256544|NCT02995746|Experimental|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
11256545|NCT02995733|Active Comparator|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
11256546|NCT02995733|No Intervention|Usual Care|Provider-enhanced usual care arm; no change in asthma management
11256547|NCT02995720|Experimental|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
11256548|NCT02995720|Active Comparator|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
11256549|NCT02995707|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
11256550|NCT02995694|Experimental|Test|Estradiol Vaginal Cream
11256551|NCT02995694|Active Comparator|Reference.|Estrace Vaginal Cream
11256552|NCT02995694|Placebo Comparator|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
11256553|NCT02995681|Experimental|Pulmonary rehab and balance training|The intervention group will receive standard pulmonary rehab plus additional balance training.
11256554|NCT02995681|Active Comparator|Pulmonary rehab|The control group will receive pulmonary rehab only and a pulmonary rehab home program (walking and lower extremity resistance exercises) upon discharge from pulmonary. They will also receive the same monthly phone calls and three home visits at three, six and nine months to ensure proper technique and progression.
11256555|NCT02995668|No Intervention|Control|Non-active comparator
11256556|NCT02995668|Active Comparator|Strength-Function|Active comparator
11256557|NCT02995668|Experimental|Balance-Proprioception|Experimental
11256558|NCT02995655|Experimental|CX-01 + Azacitidine|"CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
~Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
~Up to 6 cycles of treatment allowed"
11256559|NCT02995642|Experimental|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
11256560|NCT02995629|Experimental|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
11256561|NCT02995629|Experimental|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
11256562|NCT02995616|Experimental|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
11256563|NCT02995603|Experimental|Patient rotation|Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.
11256564|NCT02995590|Experimental|MRI of lung motion during breathing|"A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.
~A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.
~Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.
~During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.
~Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.
~Hyperpolarized helium 3 imaging will be performed at breath hold."
11256565|NCT02995577||Feeding tolerant|Patients that are able to reach 80-100% of full enteral feeds (whether fed by mouth or through a nasogastric tube) 7 days after the initiation of feeds. Patients will be excluded from this group if they are ever diagnosed with NEC at any time during this hospitalization.
11256566|NCT02995577||Feeding intolerant|Patients with GI symptoms (vomiting, abdominal distention, diarrhea, hematemesis, and/or hematochezia) that persist for 48 hours or longer while needing to be NPO, this patient is retrospectively categorized into the feeding intolerance group. Patients with feeding intolerance may also include infants that are made NPO, placed on bowel rest, and are started on antibiotics to rule out NEC, but are never diagnosed with NEC. Exclusion criteria include patients that are continued on antibiotics for greater than 48 hours due to diagnosed bacterial sepsis or diagnosed NEC, and those that have a positive blood, urine, or sputum culture.
11256567|NCT02995577||Necrotizing enterocolitis|Any infant that is diagnosed (radiographically, by Bell's criteria) with and treated for NEC.
11256568|NCT02995564|Experimental|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
11256569|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
11256597|NCT02995304|Active Comparator|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
11256598|NCT02995291|Placebo Comparator|Control|1.7ml saline water
11256599|NCT02995291|Experimental|OraVerse|1.7ml OraVerse
11256657|NCT02994784|Experimental|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
11256570|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
11256571|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
11256572|NCT02995512|Experimental|Myocardial Infarction (MI) Patients|
11256573|NCT02995486|No Intervention|Control|Standard care with only an educational pamphlet.
11256574|NCT02995486|Experimental|Intervention|Post-discharge exercise group
11256575|NCT02995473|Experimental|NP000888|Pharmaceutical form: Ointment
11256576|NCT02995473|Placebo Comparator|Vehicle|Pharmaceutical form: Ointment
11256577|NCT02995460|Experimental|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
11256578|NCT02995460|No Intervention|controls|No change in diet and training habits
11256579|NCT02995447||epilepsy patients|The group consists of patients with therapy refractory epilepsy, in which intracerebral electrodes were implanted to locate the seizure origin and to determine whether the patients are eligible for epilepsy surgery. In an observational study, differences between surface and intracerebral EEG are recorded.
11256580|NCT02995434|Experimental|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
11256581|NCT02995434|Active Comparator|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the Virtual Reality headset use). These will be functionally similar to the VR experiences.
11256582|NCT02995408|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
11256583|NCT02995408|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
11256584|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
11256585|NCT02995382|Experimental|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
11256586|NCT02995369|Other|Dryshield Isolation (right)|Dryshield will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
11256587|NCT02995369|Other|Cotton Roll Isolation (right)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
11256588|NCT02995369|Other|Dryshield Isolation (left)|Dryshield will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
11256589|NCT02995369|Other|Cotton Roll Isolation (left)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
11256590|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
11256591|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
11256592|NCT02995343|Experimental|Hypogastric and/or uterine artery ligation|Patients who had been ligated hypogastric artery and or uterine artery for ceasing uterine bleeding during c-section
11256593|NCT02995343|No Intervention|Normal postpartum women|
11256594|NCT02995330|Experimental|Bone marrow transplantation|"Bone marrow transplantation followed by Cytoxan and testosterone
~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen
~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.
~Subjects will receive GVHD prophylaxis consisting of:
~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning [dose adjusted to maintain trough level of 5-15 ng/mL] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.
~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.
~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses
~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180."
11256595|NCT02995317||Fall accidents|
11256596|NCT02995304|Active Comparator|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
11256600|NCT02995265|Experimental|Exoskeleton Program|Exoskeleton-based walking rehabilitation until discharge (or to a maximum of 8 weeks), 3 - 5 days a week for 30-60 minutes per session. Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke. The exoskeleton will allow standing and walking with full weight bearing from the first sessions in rehabilitation.
11256601|NCT02995265|Active Comparator|Usual Care Program|Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
11256602|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
11256603|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.
~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
11256604|NCT02995239|Active Comparator|CJ-12420 formulation 1|CJ-12420 formulation 1
11256605|NCT02995239|Active Comparator|CJ-12420 formulation 2|CJ-12420 formulation 2
11256606|NCT02995226|Other|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
11256607|NCT02995226|Other|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
11256608|NCT02995226|Other|Controls (with no eating disorder)|Other
11256609|NCT02995213|Experimental|Feedback Intervention|
11256610|NCT02995200|Experimental|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
11256611|NCT02995200|No Intervention|Healthy Control Group|
11256612|NCT02995187|Experimental|Apatinib Mesylate tablet|Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).
11256613|NCT02995174|Experimental|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
11256614|NCT02995174|Placebo Comparator|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
11256615|NCT02995161|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256616|NCT02995148|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256617|NCT02995135|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256618|NCT02995122|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256619|NCT02995109|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256620|NCT02995083|Active Comparator|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
11256621|NCT02995083|Placebo Comparator|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
11256622|NCT02995083|Sham Comparator|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
11256623|NCT02995070|Experimental|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
11256624|NCT02995070|Sham Comparator|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
11256626|NCT02995044|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256627|NCT02995031|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256628|NCT02995018|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256629|NCT02995005|Experimental|Tenofovir Disoproxil Fumarate|Women early in pregnancy (end of first or beginning second trimester) will be treated with TDF to determine the efficacy of this strategy to bring >=95% of women to undetectable HBV DNA levels at delivery.
11256630|NCT02994992|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11256631|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
11256632|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
11256633|NCT02994966|Experimental|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
11256634|NCT02994966|Active Comparator|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
11256635|NCT02994953|Experimental|Avelumab and M9241|
11256636|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (MTD)|
11256637|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (RP2D) (Expansion cohort)|
11256638|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
11256639|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
11256640|NCT02994927|Experimental|CCX168 (avacopan)|CCX168 in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
11256641|NCT02994927|Active Comparator|Prednisone|Prednisone in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
11256642|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
11256643|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
11256644|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
11256645|NCT02994901||Group 1|Geriatric patient with Sarcopenia
11256646|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
11256647|NCT02994901||Group 3|healthy control group
11256648|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
11256649|NCT02994875|Placebo Comparator|Placebo First|Placebo - Participants will receive placebo for one week. Following a two-week washout period, they will receive NAC for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
11256650|NCT02994875|Active Comparator|NAC First|N-acetylcysteine - Participants will receive NAC for one week. Following a two-week washout period, they will receive placebo for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
11256651|NCT02994862|Experimental|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
11256652|NCT02994862|Active Comparator|Conventional Bonding|Normal Bonding Method
11256653|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
11256654|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
11256655|NCT02994810|Experimental|Intervention group|Guidelines and review of the breastfeeding techniques.
11256656|NCT02994810|No Intervention|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
11259106|NCT02977832|Experimental|alphalytic|alpha-antagonist (alfuzosin 10 mg)
11256658|NCT02994771|Active Comparator|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
11256659|NCT02994771|Active Comparator|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
11256660|NCT02994758|Other|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
11256661|NCT02994745|Experimental|A fixed dose combination group|A fixed dose combination of Fimasartan/Atorvastatin
11256662|NCT02994745|Active Comparator|Co-administration group|Co-administration of Fimasartan and Atorvastatin
11256663|NCT02994732|Experimental|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
11256664|NCT02994719||Neurological Disease subjects|Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
11256665|NCT02994719||Healthy control subjects|The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
11256666|NCT02994719||Ataxia Subjects|The ataxia subjects will participate in an additional cohort that will test and validate the gait model.
11256667|NCT02994719||Huntington Disease Subjects|The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.
11256668|NCT02994706|Experimental|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
11256669|NCT02994706|Active Comparator|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
11256670|NCT02994693||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
11256671|NCT02994680|Experimental|Intervention arm|"Will receive:
~Three-burner LPG stove (at enrollment)
~Delivery of LPG tanks (beginning at enrollment for one year)
~The study will be conducted over three years, with staggered enrollment over one year, one year of observations during the intervention period, and one year of follow-up observations after the intervention period for each participant.
~Participants in the intervention arm will receive an LPG stove upon enrollment and the research team will deliver fuel twice monthly to their homes during the first year. Participants in the intervention arm will not receive fuel during the second year, but researchers will encourage these participants to continue using LPG fuel for cooking."
11256672|NCT02994680|Active Comparator|Control arm|"Will receive:
~Three-burner LPG stove (one year after enrollment)
~Vouchers for LPG tanks (one year after enrollment)
~Participants in the control arm but will not receive an LPG stove or fuel during the first year. Instead, participants will receive an LPG stove at the end of the first year and vouchers to obtain free fuel at distribution centers during the course of the second year."
11256673|NCT02994667||Pacemaker After TAVR|The study cohort will comprise all consecutive patients who undergo permanent pacemaker placement for new conduction disturbances after TAVR at THHBP between 1/1/2015 and 12/31/2016.
11256674|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
11256675|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
11256676|NCT02994641||Adverse discharge disposition|Patients who were discharged to a skilled nursing facility or died in the hospital
11256677|NCT02994641||No adverse discharge disposition|Patients who were not discharged to a skilled nursing facility or did not die in the hospital
11256678|NCT02994628|Active Comparator|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
11256679|NCT02994628|Experimental|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
11256680|NCT02994628|Experimental|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
11256681|NCT02994628|Experimental|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
11256682|NCT02994615||hypertrophic cardiomyopathy|
11256683|NCT02994615||Control|
11256684|NCT02994602|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
11256721|NCT02994342|No Intervention|Lifestyle counseling|Every subject has been observed for 56 consecutive days
11256820|NCT02993627|Placebo Comparator|placebo|daily intake of placebo tablets weight reduction diet therapy
11259107|NCT02977819|Experimental|Meditation program|Meditation courses and at-home practice
11256685|NCT02994589|Experimental|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
11256686|NCT02994589|Active Comparator|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
11256687|NCT02994589|Active Comparator|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
11256688|NCT02994576|Experimental|Stage IB(≥ 2 cm)-IIIA non N2, resectable and untreated NSCLC|
11256689|NCT02994563|Experimental|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
11256690|NCT02994550|Experimental|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
11256691|NCT02994550|Experimental|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
11256692|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
11256693|NCT02994524|Other|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
11256694|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
11256695|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
11256696|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
11256697|NCT02994485|Active Comparator|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
11256698|NCT02994485|No Intervention|no treatment|no treatment
11256699|NCT02994472|Experimental|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.
~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
11256700|NCT02994459||Metabolically Normal Obese (likely insulin sensitive)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
11256701|NCT02994459||Metabolically Abnormal Obese (likely insulin resistant)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
11256702|NCT02994459||Metabolically Normal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
11256703|NCT02994459||Metabolically Abnormal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
11256704|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
11256705|NCT02994433|Experimental|Nitrous Oxide|One hour inhalation of nitrous oxide
11256706|NCT02994433|Placebo Comparator|Placebo Gas|One hour inhalation of placebo gas
11256707|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
11256708|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
11256709|NCT02994407|Experimental|N8-GP s.c.|
11256710|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
11256711|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
11256712|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
11256713|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
11256714|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
11256715|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
11256716|NCT02994381|Experimental|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
11256717|NCT02994368||Observation|No intervention
11256718|NCT02994355|Experimental|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
11256719|NCT02994355|No Intervention|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
11256720|NCT02994342|Active Comparator|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
11256722|NCT02994329|Active Comparator|Oral HIV self test|In this arm, community health workers conducting door-to-door HIV testing will offer oral HIV self testing (OraQuick® HIV Self-Test (Orasure Technologies, Thailand)) as an alternative to standard of care finger-prick HIV testing for individuals who are present at the time of the visit. In addition they will provide demonstration to an adult who is present at the time of the visit and leave up to 2 oral HIV self test kits to allow testing with the partner
11256723|NCT02994329|No Intervention|Standard of Care|In this arm community health workers will conduct door-to-door HIV testing using the current Zambian national HIV testing algorithm of finger-prick rapid HIV tests
11256724|NCT02994316|Experimental|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate < 15mmol/L)"
11256725|NCT02994316|Sham Comparator|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate> 15 mmol/L)"
11256726|NCT02994290|Experimental|receive inpatient HPV vaccine|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
11256727|NCT02994290|Experimental|decline the inpatient dose|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
11256728|NCT02994277|Experimental|UVa and ITBA/UNLP algorithm arm|To control glycaemia in T1DM patients through UVa and ITBA/UNLP algorithm
11256729|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
11256730|NCT02994238|Experimental|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
11256731|NCT02994238|No Intervention|Control|The control group will receive only standardized education.
11256732|NCT02994225|Experimental|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.
~Near Infra-red images acquisition is performed during surgery"
11256733|NCT02994212|Experimental|Intervention group|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF. Anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response.
11256734|NCT02994199|Experimental|Active video gaming|Participants will engage in active video game play.
11256735|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
11256736|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
11256737|NCT02994173|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
11256738|NCT02994173|Active Comparator|Ketamine 0.25|Oxycodone 1 mg / ml + S-ketamine 0.25 mg / ml (ratio 1:0.25)
11256739|NCT02994173|Active Comparator|Ketamine 0.5|Oxycodone 1 mg / ml + S-ketamine 0.5 mg / ml (ratio 1:0.5)
11256740|NCT02994173|Active Comparator|Ketamine 0.75|Oxycodone 1 mg / ml + S-ketamine 0.75 mg / ml (ratio 1:0.75)
11256741|NCT02994160|Experimental|FastLIFE electrodes|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
11256742|NCT02994147|Placebo Comparator|Placebo|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.
~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
11256743|NCT02994147|Experimental|AC-201CR 72mg|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.
~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
11256744|NCT02994134|Active Comparator|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
11256745|NCT02994134|Experimental|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
11256746|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
11256747|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
11256815|NCT02993666|Experimental|upper body|warming with upper body blankets
11256816|NCT02993666|Experimental|lower body|warming with lower body blankets
11256748|NCT02994108|Experimental|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.
~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
11256749|NCT02994108|Active Comparator|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.
~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
11256750|NCT02994095|Experimental|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
11256751|NCT02994082|Experimental|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
11256752|NCT02994082|Active Comparator|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
11256753|NCT02994069|Experimental|Every 3 Weeks Cisplatin + XRT|Every 3 Weeks Cisplatin + XRT
11256754|NCT02994069|Experimental|Weekly Cisplatin + XRT|Weekly Cisplatin + XRT
11256755|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
11256756|NCT02994043|Active Comparator|MBRP|
11256757|NCT02994043|Active Comparator|RP|
11256758|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
11256759|NCT02994017|Other|cystic fibrosis patients|
11256760|NCT02993991|Experimental|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.
~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
11256761|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
11256762|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
11256763|NCT02993965|No Intervention|Control 11-17|No additional intervention done aside from usual care for 11-17 year olds
11256764|NCT02993965|Experimental|1 R/R per Dose 11-17|Sending up to one recall notice per dose of HPV vaccine needed for 11-17 year olds
11256765|NCT02993965|Experimental|2 R/R per Dose 11-17|Sending up to two recall notices per dose of HPV vaccine needed for 11-17 year olds
11256766|NCT02993965|Experimental|3 R/R per Dose 11-17|Sending up to three recall notices per dose of HPV vaccine needed for 11-17 year olds
11256767|NCT02993965|No Intervention|Control 11-14|No additional intervention done aside from usual care for 11-14 year olds
11256768|NCT02993965|Experimental|Phone R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via autodialer for 11-14 year olds
11256769|NCT02993965|Experimental|Mail R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via mailed postcards for 11-14 year olds
11256770|NCT02993952|Active Comparator|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
11256771|NCT02993952|Sham Comparator|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
11256772|NCT02993939|Active Comparator|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
11256773|NCT02993939|Experimental|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
11256774|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
11256775|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
11256817|NCT02993653|Experimental|Intensity-modulated radiotheapy arm|Intensity-modulated radiotheapy with stereotactic boost or intracavitary radiotherapy
11256776|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 [i.e. 1 day] to 12 months).
11256777|NCT02993913|Experimental|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
11256778|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
11256779|NCT02993887|Placebo Comparator|Mindfulness|Mindfulness (Decentering) only using the Stop, Breathe, Think Smart Phone application
11256780|NCT02993887|Experimental|Resourcefulness and Mindfulness|Resourcefulness Training (a cognitive behavioral intervention that teaches self-help and help-seeking skills) and Mindfulness using the Stop, Think, Breathe app.
11256781|NCT02993874|Experimental|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
11256782|NCT02993874|Placebo Comparator|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
11256783|NCT02993861||Levetiracetam|Children with epilepsy who are treated with levetiracetam per local standard of care
11256784|NCT02993861||Valproic Acid|Children with epilepsy who are treated with valproic acid per local standard of care
11256785|NCT02993861||Topiramate|Children with epilepsy who are treated with topiramate per local standard of care
11256786|NCT02993861||Oxcarbazepine|Children with epilepsy who are treated with oxcarbazepine per local standard of care
11256787|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
11256788|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
11256789|NCT02993835|Active Comparator|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
11256790|NCT02993835|Active Comparator|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
11256791|NCT02993835|Experimental|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
11256792|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
11256793|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
11256794|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
11256795|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
11256796|NCT02993809|Experimental|BM-ECs and PRPE|Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
11256797|NCT02993809|Active Comparator|BM-ECs|Intramuscular injection of bone marrow derived endothelial cells only.
11256798|NCT02993783|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
11256799|NCT02993783|Experimental|Vedolizumab 600 mg|Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
11256800|NCT02993770|Experimental|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
11256801|NCT02993770|Active Comparator|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
11256802|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
11256803|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
11256804|NCT02993744||Case Group|75 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, threatening preterm delivery, application of Betamethasone
11256805|NCT02993744||Control Group|65 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, no threatening preterm delivery
11256806|NCT02993731|Experimental|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
11256807|NCT02993731|Active Comparator|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
11256808|NCT02993718|Experimental|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
11256809|NCT02993718|Experimental|Propofol|Intraoperative sedation is performed by using propofol
11256810|NCT02993705|Experimental|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
11256811|NCT02993692|Other|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
11256812|NCT02993692|Other|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
11256813|NCT02993679|Other|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
11256814|NCT02993679|Other|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
11256821|NCT02993601||20 outpatients with peripheral oedema|20 outpatients with clinically detectable peripheral oedema for 1 set of measurements.
11256822|NCT02993601||20 cardiology controls|20 outpatients with heart failure without clinically detectable peripheral oedema (control group) for 1 set of measurements.
11256823|NCT02993601||10 in-patients peripheral oedema|10 in patients hospitalised as a result of heart failure and fluid congestion with peripheral oedema, those patients will have several sets of measurements taken over time to measure the reduction of peripheral oedema which is likely to show common features with the formation of peripheral oedema.
11256824|NCT02993601||30 control without cardiac conditions|less than 30 normal controls (healthy volunteers and patients without heart failure) in the age group 55 and above who agree to have images taken using the Heartfelt-1 device (not the whole set of measurements).
11256825|NCT02993588|Experimental|Melatonin|Melatonin 6 mg tablet once daily.
11256826|NCT02993588|Placebo Comparator|Placebo|Placebo tablet once daily
11256827|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
11256828|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
11256829|NCT02993523|Placebo Comparator|Placebo followed by Azacitidine|Matching Placebo for Venetoclax 400 mg orally QD on Days 1 - 28 plus Azacitidine 75 mg/m^2 SC or IV QD on Days 1 - 7 (28-day cycle)
11256830|NCT02993523|Active Comparator|Venetoclax followed by Azacitidine|Venetoclax 400 mg orally every day (QD) on Days 1 - 28 plus Azacitidine 75 mg/m^2 subcutaneously (SC) or intravenous (IV) QD on Cycle Days 1 - 7 (28-day cycle)
11256831|NCT02993510|Active Comparator|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
11256832|NCT02993510|Experimental|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
11256833|NCT02993510|Experimental|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
11256834|NCT02993497|Experimental|Respiratory monitoring group|
11256835|NCT02993484|Experimental|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
11256836|NCT02993484|Experimental|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
11256837|NCT02993484|Experimental|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
11256838|NCT02993484|Experimental|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
11256839|NCT02993484|Experimental|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
11256840|NCT02993484|Experimental|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
11256841|NCT02993484|Experimental|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
11256842|NCT02993484|Experimental|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
11256843|NCT02993471|Experimental|Drug Cocktail|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).
11256844|NCT02993471|Experimental|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
11256845|NCT02993458|Experimental|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
11256846|NCT02993458|Active Comparator|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
11256847|NCT02993458|Active Comparator|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
11256848|NCT02993458|Active Comparator|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
11256849|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
11256850|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
11256851|NCT02993432|Active Comparator|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
11256852|NCT02993432|Experimental|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
11256890|NCT02993159|Experimental|Arm I (afimoxifene, placebo)|Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
11256853|NCT02993419|Experimental|Bacillus licheniformis Intervention|The intervention is use Bacillus licheniformis particles，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
11256854|NCT02993419|Placebo Comparator|placebo Intervention|The intervention is use placebo，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
11256855|NCT02993406|Experimental|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
11256856|NCT02993406|Placebo Comparator|Placebo Comparator|Matching placebo tablet taken orally, once daily
11256857|NCT02993393||Teachers|Anesthesiologists who have involved in SBL and PBL with more than 3 years of experience in teaching
11256858|NCT02993393||Students|Students were nurse anesthetist students in the academic years of 2015
11256859|NCT02993380|Experimental|Stir-fried olive oil group|olive oil in heated under 150 degrees
11256860|NCT02993380|Experimental|Natural olive oil group|olive oil in without heated
11256861|NCT02993367|Experimental|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
11256862|NCT02993367|Placebo Comparator|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
11256863|NCT02993354||Pregnant women|Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.
11256864|NCT02993341|Experimental|Tranexamic Acid Wash|Participants in the experimental arm will receive a wash of tranexamic acid topically at the site of surgery.
11256865|NCT02993341|Placebo Comparator|Saline Wash|Participants in the control arm will receive a wash of saline topically at the site of surgery.
11256866|NCT02993328|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
11256867|NCT02993328|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
11256868|NCT02993315|Experimental|nDC vaccination arm|Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10^6 nDC).
11256869|NCT02993315|Placebo Comparator|placebo arm|Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
11256870|NCT02993302|Active Comparator|PTU-Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
11256871|NCT02993302|Placebo Comparator|PTU-Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
11256872|NCT02993289|Active Comparator|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
11256873|NCT02993289|Active Comparator|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
11256874|NCT02993289|Active Comparator|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
11256875|NCT02993289|No Intervention|Control group 1: Episodic migraine|
11256876|NCT02993289|No Intervention|Control group 2: Healthy volunteers|
11256877|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
11256878|NCT02993263|Other|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
11256879|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
11256880|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
11256881|NCT02993237|Experimental|Group 1: DRV/COBI Placebo followed by D/C/F/TAF Placebo|Participants will receive fixed dose combination (FDC) of darunavir/cobicistat (DRV/COBI) matching placebo tablets (Intake 1) and FDC of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
11256882|NCT02993237|Experimental|Group 2: D/C/F/TAF Placebo followed by DRV/COBI Placebo|Participants will receive FDC of D/C/F/TAF matching placebo tablets (Intake 1) and FDC of DRV/COBI matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
11256883|NCT02993224|Experimental|Deferasirox DT followed by FCT|"Deferasirox dispersable tablet (DT) will be provided for 24 weeks. At the completion of 24 weeks patients will be transitioned on Week 25 to an equivalent dose of the deferasirox film casted tablet (FCT) formulation and continue treatment to Week 48 (EOT of Core Phase).
~Patients can then continue deferasirox FCT formulation as per the judgment of the investigator, through an extension phase for maximum of 12 months counting from last dose of deferasirox FCT received at the end of period 2 on Core Phase."
11256884|NCT02993211|Active Comparator|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
11256885|NCT02993211|Experimental|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
11256886|NCT02993198|Experimental|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
11256887|NCT02993198|No Intervention|No Therapy|Standard of care monitoring without prophylactic treatment.
11256888|NCT02993185|Experimental|Your Move|Sex education intervention
11256889|NCT02993185|Active Comparator|Eat Smart|Nutrition education intervention
11256929|NCT02992899|Experimental|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
11256891|NCT02993159|Active Comparator|Arm II (placebo, tamoxifen citrate)|Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
11256892|NCT02993146|Experimental|Treatment (ropidoxuridine, WBRT)|Patients receive ropidoxuridine PO QD on days 1-28 and undergo WBRT daily for not more than 5 days per week beginning on day 8 for a total of 15 fractions in the absence of disease progression or unacceptable toxicity.
11256893|NCT02993133|Experimental|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
11256894|NCT02993120||Cohort 1|For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.
11256895|NCT02993120||Cohort 2|• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.
11256896|NCT02993120||Cohort 3|For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks
11256897|NCT02993107|Other|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
11256898|NCT02993107|Other|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
11256899|NCT02993094|Experimental|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.
~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
11256900|NCT02993068|Experimental|Arm A (online education)|Patients watch genetic testing online educational video and receive genetic testing online test results report.
11256901|NCT02993068|Experimental|Arm B (online education, post telephone counseling)|Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
11256902|NCT02993068|Active Comparator|Arm C (online education, pre- and post-telephone counselling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
11256903|NCT02993068|Experimental|Arm D (online education, pre-telephone counseling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
11256904|NCT02993055|Experimental|Ulimorelin|Active
11256905|NCT02993055|Placebo Comparator|Placebo|Placebo
11256906|NCT02993042|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
11256907|NCT02993029|Experimental|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
11256908|NCT02993029|Active Comparator|celecoxib|celecoxib capsule 200mg qd by mouth.
11256909|NCT02993016|Experimental|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
11256910|NCT02993016|Active Comparator|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
11256911|NCT02993003|Other|Children between 7 months and 12 months|nasopharyngeal probe will be marked with indelible ink from 2-10 cm in 1-cm increments and inserted 10 cm
11256912|NCT02993003|Other|children between 1 and 5 years|nasopharyngeal probe will be marked with indelible ink from 2-15 cm in 1.5-cm increments and inserted 10 cm
11256913|NCT02993003|Other|children between 6 and 12 years|a nasopharyngeal probe will be marked with indelible ink from 2 to 20 cm at 2 cm increments from its tip, and inserted 20 cm
11256914|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
11256915|NCT02992977|Experimental|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
11256916|NCT02992964|Experimental|Nivolumab|"Regimen: Nivolumab will be administered every 14 days until disease progression or treatment discontinuation due to unacceptable toxicities. Treatment may extend up to 2 years in patients who show clinical and radiological benefit.
~Dose: 3 mg/kg intravenously as a continuous infusion over 60 min (+/-10 min window)"
11256917|NCT02992951|Experimental|DACC-Coated Post-Operative Dressing|DACC-Coated Post-Operative Dressing
11256918|NCT02992951|No Intervention|Non-DACC coated Occlusive Post-operative Film Dressing|Non-DACC coated Occlusive Post-operative Film Dressing
11256919|NCT02992938|Experimental|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
11256920|NCT02992938|Placebo Comparator|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
11256921|NCT02992925|Experimental|Cohort 1: BK1310-High|
11256922|NCT02992925|Experimental|Cohort 1: BK1310-Low|
11256923|NCT02992925|Experimental|Cohort 2: BK1310-High or -Low|Either BK1310-High or -Low will be chosen based on the result of cohort 1
11256924|NCT02992925|Active Comparator|Cohort 2: ActHIB® and Tetrabik|
11256925|NCT02992912|Experimental|Cohort 1: metastatic colorectal cancer|
11256926|NCT02992912|Experimental|Cohort 2: metastatic non-small lung cancer|
11256927|NCT02992912|Experimental|Cohort 3: metastatic renal cell carcinoma|
11256928|NCT02992912|Experimental|Cohort 4: metastatic sarcoma|
11256930|NCT02992899|Sham Comparator|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
11256931|NCT02992886|Experimental|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
11256932|NCT02992873|Experimental|Layperson allocated to fetch an AED and start CPR|In the intervention group mobile lifesavers will be directed to fetch the nearest AED and then attach it to the victim of OHCA. At least 1 volunteer will be directed to start CPR only
11256933|NCT02992873|Active Comparator|Layperson allocated to start CPR|In the control group all mobile lifesavers will be directed to the patient to start CPR.
11256934|NCT02992860|Experimental|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
11256935|NCT02992847||Dotarem|At least 5 injection with Dotarem exclusively
11256936|NCT02992847||Multihance|At least 5 injection with Multihance exclusively
11256937|NCT02992834|Active Comparator|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
11256938|NCT02992834|Active Comparator|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
11256939|NCT02992821|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries by junior doctors. All participants will then be examined by reference imaging in specific ultrasound laboratories with conventional high end equipment and new doppler techniques and when appropriate computer tomography or magnetic resonance imaging.
11256940|NCT02992808|Active Comparator|Recombinant preparations|
11256941|NCT02992808|Active Comparator|HP-HMG|Highly purified human menopausal gonadotropin
11256942|NCT02992795||Cohort Ia|Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
11256943|NCT02992795||Cohort Ib|Athletes in this cohort are subjects currently subscribed to the Head Health Network. They will have a BrainPulse recording completed every week through the entire season. Similarly, if subjects in this cohort sustain an injury, they will crossover to Cohort II.
11256944|NCT02992795||Cohort IIa|Athletes from Cohort I will be assigned to cohort IIa once they sustain an injury other than concussion. They will have been pulled out of the game by the athletic trainer and removed from play until at least the end of the game. Once the subjects have been assigned to Cohort IIa, they will have a BrainPulse recording and a symptom evaluation within 3 days of their injury. After two weeks of recovery, subjects in this cohort will return to Cohort 1 and resume their participation in the study in their respective sub-cohort.
11256945|NCT02992795||Cohort IIb|Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
11256946|NCT02992782|Active Comparator|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
11256947|NCT02992782|Experimental|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
11256948|NCT02992782|Experimental|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
11256949|NCT02992756|Experimental|PRP patients|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-4 oocytes.
11256950|NCT02992756|No Intervention|No PRP patients|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-4 oocytes.
11256951|NCT02992743|Experimental|Autologous genetically modified T Cells, NY-ESO-1ᶜ²⁵⁹T|Genetic: Autologous genetically modified T Cells, NY-ESO-1ᶜ²⁵⁹T Cytoreductive chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 1.
11256952|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
11256953|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
11256954|NCT02992704|Experimental|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
11256955|NCT02992704|Experimental|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
11256956|NCT02992704|No Intervention|Control|No treatment for 72 weeks
11256957|NCT02992691|Experimental|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
11256958|NCT02992691|Experimental|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
11256959|NCT02992691|Experimental|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
11256960|NCT02992691|Active Comparator|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
11256961|NCT02992691|Other|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
11256962|NCT02992678|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
11256963|NCT02992678|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
11256964|NCT02992665|Experimental|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
11256965|NCT02992665|Experimental|Placebo|Placebo was used to control the group of Calcium ionophore
11256966|NCT02992652|Active Comparator|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
11256967|NCT02992652|No Intervention|Control Group|Underwent ERCP without allopurinol prophylaxis
11256968|NCT02992639|Placebo Comparator|Control group|No calorie restriction group
11256969|NCT02992639|Experimental|Weight loss group|Mild calorie restriction group (300kcal/day intake reduction)
11256970|NCT02992626|Experimental|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
11256971|NCT02992626|Experimental|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
11256972|NCT02992613|Experimental|Ultra-Congruent(UC) group|Ultra-Congruent(UC) insert will be used in total knee arthroplasty.
11256973|NCT02992613|Active Comparator|posterior-stabilized(PS) group|Posterior-stabilized(PS) insert will be used in total knee arthroplasty.
11256974|NCT02992600||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
11256975|NCT02992600||control group|we enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
11256976|NCT02992574|Experimental|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
11256977|NCT02992574|No Intervention|Observation (No PMRT)|No adjuvant radiotherapy will be given.
11256978|NCT02992561|Active Comparator|Narrative Exposure Therapy (FORNET, adapted version)|Version of Narrative Exposure Therapy for Forensic Offender Rehabilitation including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
11256979|NCT02992561|No Intervention|Waitlist control or treatment as usual|No intervention or non-specific measures of support on request
11256980|NCT02992548|Experimental|pravastatin group|Use of pravastatin 20mg to 40mg
11256981|NCT02992535|Experimental|Single arm|Intense pulse light therapy (E-Schwin)
11256982|NCT02992522|Experimental|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11256983|NCT02992509|Other|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
11256984|NCT02992496|Active Comparator|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
11256985|NCT02992496|Active Comparator|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
11256986|NCT02992483|Experimental|MIK665|
11256987|NCT02992470|Experimental|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
11256988|NCT02992470|Placebo Comparator|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
11256989|NCT02992457|Active Comparator|Sof-Riba|Sofosbuvir ribavirin 6 months.
11256990|NCT02992457|Active Comparator|Sof- Riba- Pegylated interferon|Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
11256991|NCT02992457|Active Comparator|Sof- Olysio|Sofosbuvir and simeprevir for 3 months.
11256992|NCT02992457|Active Comparator|Sof- Dacla|Sofosbuvir and Daclatasvir for 3 months.
11256993|NCT02992457|Active Comparator|Harvony|Sofosbuvir and ledipasvir for 3 months
11256995|NCT02992457|Active Comparator|Salvage therapy|sofosbuvir, daclatasvir, simeprevir,ribavirin or sofosbuvir and querevo
11256996|NCT02992444|Experimental|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.
~There is one visit:
~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
11256997|NCT02992431|Active Comparator|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
11256998|NCT02992431|Experimental|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
11256999|NCT02992418|Experimental|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
11257000|NCT02992418|Experimental|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
11257001|NCT02992405|Experimental|FOCUS Resilience Enhancement Program|Those assigned to the immediate treatment group will participate in the 10-week treatment.
11257002|NCT02992405|Experimental|Waitlist Treatment|After the 10-week immediate treatment period, wait-list control participants will be administered the treatment.
11257003|NCT02992392|Experimental|Liposic|Liposic was applied to one eye of patients in this group
11257004|NCT02992392|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
11257005|NCT02992379|Active Comparator|stabilizing splint|Active Comparator: stabilizing splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
11257006|NCT02992379|Experimental|pivot splint|"Experimental: pivot splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks.
~Other Names: PS"
11257007|NCT02992366|Experimental|socket shield (A)|"Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.
~After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.
~The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.
~The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)
~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
11257008|NCT02992366|Active Comparator|conventional immediate implant (B)|"Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.
~The implant fixture will be inserted in the empty socket by conventional manner.
~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
11257009|NCT02992353|Active Comparator|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
11257010|NCT02992353|Active Comparator|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
11257011|NCT02992340|Experimental|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
11257012|NCT02992327||Cohort|Patients age ≥ 8 years of age with a GCS >13 presenting to the emergency department with a diagnosis of concussion.
11257013|NCT02992314|Experimental|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.
~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.
~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
11257014|NCT02992314|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
11257015|NCT02992301|Experimental|Open Label|All enrolled patients will receive open label Praluent (Alirocumab).
11257016|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
11257017|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
11257018|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
11257019|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
11257020|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
11257021|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
11257022|NCT02992275|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
11257023|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
11257024|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
11257299|NCT02990533|Experimental|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
11257025|NCT02992210|Experimental|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
11257026|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
11257027|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
11257028|NCT02992184||HCV patients|228 HCV patients
11257029|NCT02992184||control|189 controls
11257030|NCT02992171|Experimental|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
11257031|NCT02992158|Experimental|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
11257032|NCT02992158|Other|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
11257033|NCT02992145||Case group: This group will include forty (40) preeclampt|
11257034|NCT02992145||Control group: This group will include forty (40) normoten|
11257035|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
11257036|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
11257037|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
11257038|NCT02992119|Experimental|Group 1|RTS,S/AS01B Fractional dose
11257039|NCT02992119|Experimental|Group 2|Double RTS,S/AS01E Fractional dose
11257040|NCT02992119|Experimental|Group 3|RTS,S/AS01E Standard dose
11257041|NCT02992119|Experimental|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
11257042|NCT02992119|Experimental|Group 5|RTS,S/AS01E Fractional dose
11257043|NCT02992119|Experimental|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
11257044|NCT02992119|Experimental|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
11257045|NCT02992106|Other|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
11257046|NCT02992106|Other|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI > 29 kg/m² during their singleton pregnancy.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
11257047|NCT02992106|Other|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
11257048|NCT02992106|Other|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.
~All participating children will undergo the same examinations:
~Parental questionnaires
~Blood sample
~Urine sample
~Anthropometric measurements
~Abdominal ultrasound (fat mass)
~EndoPAT"
11257049|NCT02992093||obese with PCOS|all the indicators
11257050|NCT02992093||nonobese with PCOS|all the indicators
11257051|NCT02992093||PCOS with IGT|all the indicators
11257052|NCT02992093||PCOS with T2DM|all the indicators
11257053|NCT02992093||Healthy volunteers|all the indicators
11257054|NCT02992080|Other|Cystic fibrosis Patients|
11257055|NCT02992080|Other|Patients without fibrosis cystic|
11257056|NCT02992080|Other|Cystic fibrosis Patients (secondary use of samples)|
11257057|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
11257058|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
11257059|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
11257063|NCT02992028|Experimental|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
11257064|NCT02992028|Placebo Comparator|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
11257065|NCT02992015|Experimental|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
11257066|NCT02991989|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening. They will also be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers.
11257067|NCT02991989|Other|Yogurt Only Group|For 28 days, this group will be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers. Apart from consuming the yogurt, this group will be asked to continue their normal lifestyle.
11257068|NCT02991976|Active Comparator|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
11257069|NCT02991976|Active Comparator|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
11257070|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
11257071|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
11257072|NCT02991950|Experimental|parnaparin sodium|"Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.
~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.
~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI"
11257073|NCT02991950|No Intervention|no treatment|Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.
11257074|NCT02991937|Active Comparator|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
11257075|NCT02991937|Active Comparator|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
11257076|NCT02991911|Experimental|Arm A|MEDI3726 Post-Chemo
11257077|NCT02991911|Experimental|Arm B|MEDI3726 Pre-Chemo
11257078|NCT02991911|Experimental|Arm C|MEDI3726 & Enzalutamide Combo
11257079|NCT02991898|Experimental|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
11257080|NCT02991885|Experimental|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
11257081|NCT02991885|Placebo Comparator|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
11257082|NCT02991872|Other|V49_24E1 Group|Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49_24 (NCT01680016), will be invited to participate to this extension study.
11257083|NCT02991859|Experimental|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
11257084|NCT02991859|Experimental|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
11257085|NCT02991859|Experimental|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
11257451|NCT02989389|Placebo Comparator|Placebo (Part B)|Participants received placebo identical to LY3323795 orally.
11257086|NCT02991859|Experimental|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
11257087|NCT02991859|Experimental|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
11257088|NCT02991859|Experimental|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
11257089|NCT02991859|Experimental|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
11257090|NCT02991859|Experimental|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
11257091|NCT02991859|Experimental|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
11257092|NCT02991859|Experimental|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
11257093|NCT02991859|Experimental|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
11257151|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
11257452|NCT02989389|Experimental|LY3323795 (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
11257094|NCT02991859|Experimental|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
11257095|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
11257096|NCT02991833|Experimental|Of A New Incontinence Care Product|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
11257097|NCT02991833|Active Comparator|Diaper|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
11257098|NCT02991820|Experimental|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
11257099|NCT02991820|Experimental|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
11257100|NCT02991807|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg or 2.5mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
11257101|NCT02991807|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
11257102|NCT02991781|Experimental|COPD Patients|"C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) < 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production
~Biofeedback and Neurofeedback Training
~Varenicline use for smoking cessation
~Passive Control"
11257103|NCT02991781|Experimental|Asthma Patients|"Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by >12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) <8 mg or mannitol provocation test (with FEV1 decrease of 15%)
~Biofeedback and Neurofeedback Training
~Varenicline use for smoking cessation
~Passive Control"
11257104|NCT02991781|Experimental|Smokers|"Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.
~Biofeedback and Neurofeedback Training
~Varenicline use for smoking cessation
~Sham Neurofeedback
~Passive Control"
11257105|NCT02991768|Experimental|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
11257106|NCT02991768|Placebo Comparator|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
11257107|NCT02991742||Iodixanol|Iodixanol contrast media
11257108|NCT02991742||Ioxaglate|Ioxaglate contrast media
11257109|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
11257110|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
11257111|NCT02991716||Recorded patients|Patients requiring Intracradiac Defibrillator (ICD) implantation, Electrophysiology (EP) study or a holter monitor recording, mainly due to suspected ventricular tachy - arrhythmias
11257112|NCT02991703|Active Comparator|SphygmoCor®|
11257113|NCT02991703|Experimental|pOpmètre®|
11257114|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
11257115|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
11257116|NCT02991677|Other|control|This is an attention control group with regular contact by study staff.
11257117|NCT02991677|Experimental|aerobic exercise|Aerobic exercise intervention is for 12 weeks 3 times weekly with training on site.
11257118|NCT02991677|Experimental|resistive training|Intervention is for 12 weeks 3 times weekly with training on site.
11257119|NCT02991664|Active Comparator|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
11257120|NCT02991664|Active Comparator|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
11257121|NCT02991651|Experimental|Dose Level 1|IRX4204 5 mg/day PO + erlotinib 100 mg/day PO
11257122|NCT02991651|Experimental|Dose Level 2|IRX4204 5 mg/day PO + erlotinib 150 mg/day PO
11257123|NCT02991651|Experimental|Dose Level 3|IRX4204 10 mg/day PO + erlotinib 150 mg/day PO
11257124|NCT02991638|Other|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
11257125|NCT02991625|Experimental|Placebos|Chronic Back Pain participants will enter an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
11257126|NCT02991625|Other|Waitlist|Chronic Back Pain participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar.
11257127|NCT02991625|Other|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
11257128|NCT02991612|Experimental|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
11257129|NCT02991612|No Intervention|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
11257130|NCT02991599|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11257131|NCT02991599|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11257132|NCT02991586|Experimental|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
11257133|NCT02991586|No Intervention|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
11257134|NCT02991573|Active Comparator|existing adhesive (control)|control adhesive
11257135|NCT02991573|Experimental|new adhesive: technique 1|Prime & Bond Universal: technique 1
11257136|NCT02991573|Experimental|new adhesive: technique 2|Prime & Bond Universal: technique 2
11257137|NCT02991560|Experimental|Kinesio tape (KT)|The KT group was taped 2 days a week for 4 weeks using the muscle and fascia correction techniques
11257138|NCT02991560|Experimental|Athletic taping (AT)|An athletic tape with adhesive backing was used (38 mm wide-Muller Protape-The Netherlands).
11257139|NCT02991534|Other|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
11257140|NCT02991521|Experimental|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
11257141|NCT02991508|Placebo Comparator|Placebo|Vehicle (20 mM His/HCl pH 6.0)
11257142|NCT02991508|Active Comparator|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
11257143|NCT02991508|Active Comparator|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
11257144|NCT02991508|Active Comparator|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
11257145|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
11257146|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
11257147|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
11257148|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
11257149|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
11257150|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
11257152|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
11257153|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
11257154|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
11257155|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
11257156|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
11257157|NCT02991482|Experimental|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
11257158|NCT02991482|Active Comparator|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.
~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
11257159|NCT02991469|Experimental|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
11257160|NCT02991456|Active Comparator|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
11257161|NCT02991456|Active Comparator|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
11257162|NCT02991443|Experimental|Mindfulness based stress reduction|Parents of children with IBD will undergo mindfulness based stress reduction (MBSR) intervention consisted of 8 group sessions. The effect on stress and anxiety will be assessed using 3 validated questionnaires which will be filled prior to intervention, at the end of intervention and 3 months following intervention.
11257163|NCT02991430|Active Comparator|active|active neuromodulation
11257164|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
11257165|NCT02991417|Experimental|CDVAX|
11257166|NCT02991404|Active Comparator|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
~Multimodal peripheral nerve block injection."
11257167|NCT02991404|Sham Comparator|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
11257168|NCT02991378|Experimental|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
11257169|NCT02991378|No Intervention|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
11257170|NCT02991365|Active Comparator|nasal insulin|daily administration of 160 U of human insulin as nasal spray
11257171|NCT02991365|Placebo Comparator|placebo spray|daily administration of placebo solution as nasal spray
11257172|NCT02991352|Experimental|Experimental|Image guided needle placement into vascular malformations based on MRI
11257173|NCT02991339|Experimental|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
11257174|NCT02991339|No Intervention|control|Patients are not treated with glucocorticoids.
11257175|NCT02991326|Experimental|Test Group (TG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to Osteopathic Manipulative Treatment - OMT.
11257176|NCT02991326|Sham Comparator|Control Group (CG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to sham intervention (Osteopathic Manipulative Treatment simulated).
11257177|NCT02991313|Experimental|Endocardial Ablation Procedure|ablation with Linear type catheter
11257178|NCT02991287||Chronic post-surgical pain patients|Patients scheduled for differents types of surgery (inguinal, hernia repair, abdominal hysterectomy, vaginal hysterectomy, and thoracotomy).
11257179|NCT02991274||T790M mutation test|genomic testing of T790M mutation
11257180|NCT02991261|Experimental|SPARC001 type I|Treatment type I
11257181|NCT02991261|Experimental|SPARC001 type II|Treatment type II
11257182|NCT02991261|Active Comparator|Reference001 type I|Hydrocodone-Acetaminophen
11257183|NCT02991261|Active Comparator|Reference type II|Hydrocodone-Acetaminophen
11257184|NCT02991248|Experimental|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
11257185|NCT02991248|Active Comparator|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
11257186|NCT02991248|Placebo Comparator|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
11257187|NCT02991235|Experimental|PRJ212|PRJ212 is a nutritional product with active food ingredients.
11257188|NCT02991235|Placebo Comparator|Placebo|Placebo is like PRJ212 without active food ingredients.
11257189|NCT02991222|Experimental|SPARC001 type I|Treatment type I
11257190|NCT02991222|Experimental|SPARC001 type II|Treatment type II
11257195|NCT02991196|Experimental|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
11257196|NCT02991183|Experimental|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
11257197|NCT02991170|Active Comparator|control group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
11257198|NCT02991170|Experimental|interventional group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
11257199|NCT02991144|Experimental|Dose 1: 2.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
11257200|NCT02991144|Experimental|Dose 2: 6.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
11257201|NCT02991144|Experimental|Dose 3: 1.0 × 10^13 GC/kg|DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
11257202|NCT02991144|Experimental|Dosing Process Optimization at Optical Biological Dose (OBD)|Oral prednisone (or prednisolone), 60 mg tapered over 9 weeks, initiated before dosing with DTX301. DTX301 (scAAV8OTC; optimal biologic dose) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
11257203|NCT02991131||Tedizolid|Hospitalized ABSSSI patients treated with tedizolid
11257204|NCT02991131||Linezolid|Hospitalized ABSSSI patients treated with linezolid
11257205|NCT02991118|Experimental|bempedoic acid|bempedoic acid 180 mg/day
11257206|NCT02991118|Placebo Comparator|Placebo|Placebo control
11257207|NCT02991105||Solid organ transplant recipients|National cohort = 85,410 solid organ transplant recipients receiving their transplant between January 1st 1985 to December 31st 2015
11257208|NCT02991092|Experimental|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
11257209|NCT02991092|Other|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
11257210|NCT02991079|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
11257211|NCT02991079|Experimental|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
11257212|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
11257213|NCT02991066||Control|healthy volunteers.
11257214|NCT02991053|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
11257215|NCT02991053|Active Comparator|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
11257216|NCT02991053|Active Comparator|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
11257217|NCT02991053|Active Comparator|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
11257218|NCT02991053|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
11257219|NCT02991040|Experimental|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
11257220|NCT02991027|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be imaged using 2 different light sources using the DRI Triton
11257221|NCT02991014|Active Comparator|researcher-selected frequency-modulated music|
11257222|NCT02991014|Placebo Comparator|researcher-selected non-modulated music|
11257223|NCT02991014|Experimental|participant-selected non-modulated music|
11257224|NCT02991001|Experimental|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
11257225|NCT02991001|Placebo Comparator|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
11257226|NCT02990988||Iron repletion|Subjects participating in the associated study under the Iron Repletion arm will also provide stool collection and answers to questionnaire and diet diary.
11257227|NCT02990988||Placebo|Subjects participating in the associated study under the Placebo arm will also provide stool collection and answers to questionnaire and diet diary.
11257228|NCT02990975|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
11257229|NCT02990975|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
11257230|NCT02990975|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
11257231|NCT02990962|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
11257232|NCT02990962|Active Comparator|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
11257233|NCT02990949|Experimental|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
11257234|NCT02990949|No Intervention|Control group|
11257235|NCT02990936||head and neck squamous cell carcinoma|Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
11257236|NCT02990923|No Intervention|Control|In this group, patients will use traditional standard hemodialysis connector and receive typical disinfection management
11257237|NCT02990923|Experimental|Only High-Flow Valve|In this group, patients will use High-Flow Needleless Valve instead of traditional standard hemodialysia connector, but still receiving typical disinfection management
11257238|NCT02990923|Experimental|Both Divices|In this group, patients will receive both High-Flow Needleless Valve and DualCap Disinfection Devices in hemodialysis
11257239|NCT02990910|Other|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
11257240|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
11257241|NCT02990897|No Intervention|Control Group|Patients with Stage 3,4, or 5 CKD who are randomized to the control arm will receive standard care.
11257242|NCT02990897|Experimental|Intervention Group|Patients with Stage 3,4, or 5 CKD who are randomized to the intervention group will receive care from a physician who has been exposed to the intervention: a clinical decision support message. This clinical decision support message shows the patient's risk of kidney failure over the next 5 years.
11257243|NCT02990884|Active Comparator|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
11257244|NCT02990884|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
11257245|NCT02990884|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
11257246|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
11257247|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
11257248|NCT02990858|Experimental|PRO 140|
11257249|NCT02990845|Experimental|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
11257250|NCT02990832|Experimental|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
11257251|NCT02990819|Other|Reduced intensity regimen|Conditioning regimen is dependent on patient diagnosis and age. Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care reduced intensity conditioning will include Busulfan, Fludarbine, Thiotepa followed by stem cell infusion.
11257252|NCT02990819|Other|Myeloablative regimen|"Conditioning regimen is dependent on patient diagnosis and age. Patients with chronic granulomatous disease or Wiskott-Aldrich syndrome will receive cyclophosphamide in lieu of thiotepa to ensure engraftment.
~Myeloablative regimen with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care myeloablative regimen will include Busulfan, Fludarbine, Thiotepa, or Cyclophosamide followed by stem cell infusion."
11257253|NCT02990819|Other|Immunotherapy|Conditioning regimen is dependent on patient diagnosis and age. Severe combined immunodeficiency (SCID) patients will be conditioned with immunotherapy only followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Immunotherapy regimen will include anti-thymocyte globulin followed by stem cell infusion.
11257254|NCT02990806|Experimental|NI-071|Proposed biosimilar
11257255|NCT02990806|Active Comparator|Infliximab|Reference product
11257256|NCT02990793|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
11257257|NCT02990793|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
11257258|NCT02990780|Active Comparator|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
11257259|NCT02990780|Experimental|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
11257260|NCT02990767||observational women|collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation.
11257261|NCT02990754|Experimental|Intervention Group|Individuals attending one or more fearless physical activity events
11257262|NCT02990741||Usual screening group|ECG recordings at baseline plus at 1 and 2 year of follow-up; three ECG recordings in total.
11257263|NCT02990741||Intensive screening subgroup|ECG recordings at baseline plus quarterly during follow-up, at months 3, 6, 9 ,12, 15, 18, 21 and 24; 9 ECG recordings in total.
11257264|NCT02990741||More intensive screening subgroup|ECG recordings at baseline plus weekly during the first month of follow-up and quarterly afterwards, at weeks 1, 2, 3 and 4 and months 3, 6, 9, 12, 15, 18, 21 and 24; 13 ECG recordings in total.
11257295|NCT02990546|Other|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal > 65 mmHg
11257296|NCT02990533|Placebo Comparator|Placebo|Placebo Supplement Placebo Injection
11257297|NCT02990533|Experimental|Testosterone|Placebo Supplement Testosterone Injection
11257298|NCT02990533|Experimental|Protein Supplement|Protein Supplement Placebo Injection
11257265|NCT02990728|Experimental|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
11257266|NCT02990728|Active Comparator|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
11257267|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
11257268|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
11257269|NCT02990702|Active Comparator|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
11257270|NCT02990702|Active Comparator|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
11257271|NCT02990689|Active Comparator|809M|bifocal intraocular lens (IOL)
11257272|NCT02990689|Active Comparator|839MP|trifocal intraocular lens (IOL)
11257273|NCT02990689|Active Comparator|SN6AD1|bifocal intraocular lens (IOL)
11257274|NCT02990676|Experimental|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
11257275|NCT02990676|No Intervention|Control group|Asked to continue as normal
11257276|NCT02990663|Experimental|Bedtime BP Meds|Use of blood pressure lowering medication at bedtime
11257277|NCT02990663|Active Comparator|Morning BP Meds|Use of blood pressure lowering medication in the morning
11257278|NCT02990650|Active Comparator|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
11257279|NCT02990650|Experimental|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
11257280|NCT02990650|Experimental|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
11257281|NCT02990637|Active Comparator|OLECOL|Olive leaf extract
11257282|NCT02990637|Placebo Comparator|Placebo|Maltodextrin
11257283|NCT02990624|Active Comparator|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
11257284|NCT02990624|Active Comparator|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
11257285|NCT02990624|No Intervention|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
11257286|NCT02990611||Nivolumab monotherapy|Patients who start treatment with nivolumab monotherapy for the first time
11257287|NCT02990611||Nivolumab/Ipilimumab combination therapy|Patients who start treatment with the combination therapy of nivolumab with ipilimumab
11257288|NCT02990611||Adjuvant Nivolumab therapy|Patients who start adjuvant therapy with nivolumab after complete tumor resection
11257289|NCT02990585|Active Comparator|One individual back school session|The 1 individual session will consist of a 60 min 1-on-1 education/exercise session with an athletic trainer. Information will be an abbreviated version of the 8-session school and fill focus on the strengthening, stretching, pain control and movement re-education most needed for the individual.
11257290|NCT02990585|Active Comparator|8 group session of back school|All sessions last 45-60 minutes. There will be up to 8 participants in each session which will be led by an athletic trainer or rehabilitation trainer. Pain management, prevention strategies, and active treatment will be covered in the 8 sessions. Active treatment includes strengthening, stretching, pain control, movement re-education, and walking.
11257291|NCT02990572||Amish and Mennonite|"Agree to allow access to past, current, and future medical records
~Provide a detailed family health history
~Provide contact information that may be used for future approach regarding research studies"
11257292|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
11257293|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
11257294|NCT02990546|Experimental|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
11257300|NCT02990507|Experimental|AVEED|AVEED is composed of arm and leg cranks that can be used independently or together with a virtual exercise environment (VEE). Participants rotate arm and/or leg cranks under 4 conditions for 5 min each with a 5 min rest between: 1) Arm rotation with VEE, while sitting or standing (AVEED: Arm rotation, video display); 2) Arm rotation without VEE, while sitting or standing (AVEED: Arm rotation, without video display); 3) Leg rotation with arm-energy input to assist the legs with VEE, while sitting (AVEED: Leg rotation, arm-energy input, video display); 4) Leg rotation with arm-energy input to assist the legs without VEE, while sitting (AVEED: Leg rotation, arm-energy input, without video display). VEE controlled with voice commands, leaning, or keyboard buttons.
11257301|NCT02990494|Active Comparator|STANDARD|12-week Internet-delivered behavioral weight loss program
11257302|NCT02990494|Experimental|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
11257303|NCT02990494|Experimental|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
11257304|NCT02990481|Experimental|Arm 1 - TRK-950|"Solid tumor
~TRK-950 (Three dose levels will be explored during Arm 1)"
11257305|NCT02990481|Experimental|Arm 2 - TRK-950|"Colon cancer
~TRK-950 (Low dose and High dose)"
11257306|NCT02990481|Experimental|Arm 3 -TRK-950|"Cholangiocarcinomas
~TRK-950 (Low dose)"
11257307|NCT02990468|Experimental|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
11257308|NCT02990455|Experimental|Reduced Nicotine Cigarette - Moderate|Nicotine Research Cigarette Drug Supply Program Category Codes NRC600 and NRC601 (menthol); each cigarette contains 0.8mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
11257309|NCT02990455|Experimental|Reduced Nicotine Cigarette - Low|Nicotine Research Cigarette Drug Supply Program Category Codes NRC102 and NRC103 (menthol); each cigarette contains 0.03mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
11257310|NCT02990442|Experimental|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
11257311|NCT02990429|Experimental|Forced Air warmer (bair hugger)|".
~In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC"
11257312|NCT02990429|Experimental|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
11257313|NCT02990416|Experimental|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
11257314|NCT02990403|Experimental|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
11257315|NCT02990403|Experimental|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
11257316|NCT02990403|Experimental|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
11257317|NCT02990403|Experimental|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
11257318|NCT02990403|Other|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
11257319|NCT02990377|Experimental|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
11257320|NCT02990377|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
11257321|NCT02990364|Active Comparator|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.
~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
11257322|NCT02990364|Active Comparator|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.
~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
11257323|NCT02990364|Active Comparator|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.
~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
11257324|NCT02990364|Active Comparator|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.
~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
11257453|NCT02989389|Experimental|LY3323795 + Itraconazole (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
11257325|NCT02990351||HCC patients|29 HCC patients who had loco regional therapies for HCC were analyzed. Twenty patients met the Milan criteria (68.97%) & 4 (13.8%) were beyond Milan but met UCSF criteria and 5 were exceeding UCSF criteria (17.2%).All patients underwent preoperative LRTs, The protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before LT and their outcomes after LT were recorded.
11257326|NCT02990338|Active Comparator|Pd (pomalidomide + dexamethasone)|Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).
11257327|NCT02990338|Experimental|IPd (isatuximab + pomalidomide + dexamethasone)|Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants >= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).
11257328|NCT02990325|Experimental|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
11257329|NCT02990325|Experimental|ABX464 50mg|ABX464, 50mg per Capsule One Capsule per day for 28 or 84 days
11257330|NCT02990312|Experimental|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
11257331|NCT02990299|No Intervention|Usual Care|Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will crossover to the mDAS intervention arm for one year.
11257332|NCT02990299|Experimental|mHealth for Diabetes Adherence Support|Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
11257333|NCT02990286|Experimental|Rituximab with Mycophenolate Mofetil|
11257334|NCT02990286|Placebo Comparator|Placebo of rituximab with Mycophenolate Mofetil|
11257335|NCT02990273|Active Comparator|TEG|Blood transfusion
11257336|NCT02990273|Active Comparator|PT/INR|Blood transfusion
11257337|NCT02990260|Active Comparator|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
11257338|NCT02990260|Active Comparator|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
11257339|NCT02990260|Placebo Comparator|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
11257340|NCT02990247|Experimental|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
11257341|NCT02990234|Active Comparator|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
11257342|NCT02990234|Placebo Comparator|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
11257343|NCT02990221|Active Comparator|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
11257344|NCT02990221|Active Comparator|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
11257345|NCT02990208|Experimental|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
11257346|NCT02990208|Active Comparator|VR exposure|Virtual Reality Exposure Therapy
11257347|NCT02990195|Other|Double enterostomy|
11257348|NCT02990169|Active Comparator|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
11257349|NCT02990169|Active Comparator|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
11257350|NCT02990156|Experimental|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
11257351|NCT02990156|Active Comparator|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
11257352|NCT02990143|No Intervention|Glaucoma Drainage implant no Ologen|The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
11257353|NCT02990143|Active Comparator|Glaucoma Drainage implant with Ologen|the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
11257354|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
11257380|NCT02989948|Experimental|Physician-modified fenestrated endovascular graft|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
11257355|NCT02990117||Asthmatic patient|Asthma patients aged >18 in out-patient clinic of the first affiliated hospital of Xi'an Jiaotong university from November 2016 to January 2018 were investigated. A two-stage study was applied which was non-assumptive deep dive qualitative scoping to investigate the determinants of poor compliance in stage 1 asthma patients, and developed new questionnaire for cross sectional survey in stage 2 to obtain more accurate information about the critical issues on asthma management.
11257356|NCT02990091|Experimental|1,000mg/day n-3 HUFA|Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
11257357|NCT02990091|Experimental|4,000 mg/day n-3 HUFA|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
11257358|NCT02990091|Placebo Comparator|1 capsule safflower seed oil|Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
11257359|NCT02990091|Placebo Comparator|4 capsules safflower seed oil|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
11257360|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
11257361|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
11257362|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
11257363|NCT02990065|Experimental|PROTEIN-FORTIFIED DIET|The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
11257364|NCT02990065|No Intervention|STANDARD DIET|The standard diet consists on an energy goal based on weight formula (20-25 kcal/kg/die). According to the ICU nutritional protocol, EN is started at an initial rate of 10ml/h, and increased by 20ml/h every 12 hours in the absence of significant gastric residuals (<250ml), with the aim of reaching the energy goal within 72 hours from admission. The EN formulae used are standard (1-1,5 kcal/ml, 40g/l protein). If enteral nutrition is not tolerated or is not indicated, supplemental PN is used to make up the energy shortfall. The PN formula used is standard (1000 kcal/l, 37 g/l protein).
11257365|NCT02990052|Active Comparator|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
11257366|NCT02990052|Active Comparator|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
11257367|NCT02990039|Experimental|Counseling letter (intervention group)|Participants of the intervention group received a brief counseling letter intervention aiming to reduce sedentary time and to increase physical activity. The intervention comprised up to three tailored letters based on separate questionnaires.
11257368|NCT02990039|No Intervention|No counseling letter (control group)|Participants of the control group did not received the brief counseling letter intervention.
11257369|NCT02990026|Experimental|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
11257370|NCT02990026|Active Comparator|Control|Standard probation - delivered by a standard probation officer - care as usual
11257371|NCT02990013|Experimental|Treatment arm|All patients will be in the treatment arm where they will be subject to skin testing with various cleansing agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
11257372|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
11257373|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
11257374|NCT02989987|Active Comparator|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
11257375|NCT02989987|Active Comparator|Treatment-as-usual|Social support (provided on demand)
11257376|NCT02989974|Experimental|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
11257377|NCT02989974|Experimental|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
11257378|NCT02989961|Experimental|A-Resticutis|Autologous, Activated-Platelets type of preparation.
11257379|NCT02989961|Placebo Comparator|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
11257450|NCT02989389|Experimental|LY3323795 (Part B)|Participants received 6 mg, 20 mg and 80 mg of LY3323795 orally.
11257381|NCT02989935|Experimental|Fluticasone vilanterol bronchodilator|"Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler.
~Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation."
11257382|NCT02989922|Experimental|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
11257383|NCT02989922|Experimental|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
11257384|NCT02989909|Active Comparator|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
11257385|NCT02989909|Experimental|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
11257386|NCT02989883|Other|Peroral endoscopic myotomy (POEM)|Patients who received POEM
11257387|NCT02989870|Experimental|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
11257388|NCT02989857|Active Comparator|AG-120 experimental study drug|AG-120, 500mg daily continuous dosing
11257389|NCT02989857|Placebo Comparator|AG-120 matched placebo|AG-120 matched placebo, daily continuous dosing. Subjects who experience disease progression and were receiving placebo, will be allowed to cross-over and receive AG-120
11257390|NCT02989844|Experimental|N-803|
11257391|NCT02989831|Experimental|Vibrating insoles 'on'|Duration: 30-60 seconds
11257392|NCT02989831|No Intervention|Vibrating insoles 'off'|Duration: 30-60 seconds
11257393|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
11257394|NCT02989805|Active Comparator|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
11257395|NCT02989805|Experimental|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
11257396|NCT02989792|Other|Unique study arm|
11257397|NCT02989779|Experimental|Active/Placebo crossover|NK1 Antagonist 7 days followed by placebo 7 days.
11257398|NCT02989779|Active Comparator|Placebo/Active Crossover|Placebo for 7 days followed by NK1 Antagonist 7 days.
11257399|NCT02989766|Active Comparator|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
11257400|NCT02989766|No Intervention|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
11257401|NCT02989753|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
11257402|NCT02989753|Experimental|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
11257403|NCT02989753|Experimental|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
11257404|NCT02989740||Group A|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
11257405|NCT02989740||Group B|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
11257406|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
11257407|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
11257408|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
11257409|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
11257410|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
11257411|NCT02989714|Experimental|HD IL2 and Nivolumab|
11257412|NCT02989701|Experimental|Single arm|
11257413|NCT02989688|Active Comparator|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
11257414|NCT02989688|Active Comparator|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
11257415|NCT02989688|Active Comparator|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
11257416|NCT02989675|Experimental|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
11257417|NCT02989675|No Intervention|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
11257418|NCT02989662|Active Comparator|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
11257419|NCT02989662|Placebo Comparator|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
11257420|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
11257421|NCT02989636|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
11257422|NCT02989636|Experimental|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
11257423|NCT02989623|Experimental|Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)|Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.
11257424|NCT02989610|Experimental|Omnidirectional followed by directional DBS|Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
11257425|NCT02989597|Experimental|Intra-operative Methadone Hydrochloride|Patient who will be given a single dose of intra-operative methadone, and having standard care otherwise
11257426|NCT02989597|Active Comparator|Control|Patients administered standard of care
11257427|NCT02989584|Experimental|Atezolizumab, Gemcitabine, Cisplatin|"This is a two phase study with a single study arm for each phase.
~For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.
~Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously."
11257428|NCT02989571|Placebo Comparator|Group 1 - Placebo Arm|Intravenous normal saline administered at 125ml/hr
11257429|NCT02989571|Active Comparator|Group 2 - Intervention Arm|Intravenous normal saline administered at 250ml/hr
11257430|NCT02989558|Active Comparator|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
11257431|NCT02989558|Active Comparator|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
11257432|NCT02989545|No Intervention|Off treatment|2 week period without intervention
11257433|NCT02989545|Experimental|Treatment period|2 week period with intervention
11257434|NCT02989519|No Intervention|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
11257435|NCT02989519|Experimental|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
11257436|NCT02989519|Experimental|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
11257437|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
11257438|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
11257439|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
11257440|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
11257441|NCT02989467|Active Comparator|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
11257442|NCT02989467|Placebo Comparator|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
11257443|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
11257444|NCT02989428|Experimental|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
11257445|NCT02989428|No Intervention|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
11257446|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
11257447|NCT02989402|Experimental|Rivastigmine patch|15 cm2 patch sizes loaded with 27 mg of rivastigmine
11257448|NCT02989389|Experimental|LY3323795 (Part A)|Participants received escalating doses of 0.3 mg (milligrams), 1 mg, 3 mg, 10 mg, 30 mg and 100 mg of LY3323795 orally.
11257449|NCT02989389|Placebo Comparator|Placebo (Part A)|Participants received placebo identical to LY3323795 orally.
11257454|NCT02989376|Experimental|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
11257455|NCT02989363|Experimental|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
11257456|NCT02989363|Experimental|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
11257457|NCT02989363|Experimental|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
11257458|NCT02989363|Experimental|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
11257459|NCT02989350|Active Comparator|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
11257460|NCT02989350|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
11257461|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
11257462|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
11257463|NCT02989324|Experimental|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
11257464|NCT02989324|Active Comparator|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
11257465|NCT02989311|Active Comparator|Study 1:Morning test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the morning test meal A:12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe.
~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
11257466|NCT02989311|Active Comparator|Study 1:Afternoon test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the afternoon test meal B:12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10mg of 56Fe.
~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
11257467|NCT02989311|Active Comparator|Study 2: Consecutive meals+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meals:Test meal A will contain 12mg of ferrous sulphate given as 2mg 54Fe and 10mg 56Fe. Test meal B will contain 12mg of ferrous sulphate given as 2mg 57Fe and 10mg 56Fe.
~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
11257468|NCT02989311|Active Comparator|Study 2:Alternate meal+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meal C: 12mg of ferrous sulphate given as 2mg 58Fe and 10mg.
~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
11257469|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
11257470|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
11257471|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
11257472|NCT02989272|Placebo Comparator|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
11257473|NCT02989272|Experimental|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
11257474|NCT02989259|Experimental|apatinib|apatinib 500mg p.o. qd
11257475|NCT02989246|Experimental|Intervention Arm|Ventilator management using the proposed protocol in both acute and weaning phases. Patients will be managed according the the Ventilator protocol using the esophageal catheter for the weaning phase
11257476|NCT02989233|Active Comparator|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257477|NCT02989233|Active Comparator|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257478|NCT02989233|Active Comparator|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257479|NCT02989233|Active Comparator|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257480|NCT02989233|Active Comparator|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257481|NCT02989233|Active Comparator|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257482|NCT02989233|Active Comparator|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257483|NCT02989233|Active Comparator|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257484|NCT02989233|Active Comparator|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257485|NCT02989233|Active Comparator|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257486|NCT02989233|Active Comparator|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257487|NCT02989233|Active Comparator|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
11257488|NCT02989220|Experimental|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
11257489|NCT02989220|No Intervention|Control Group|Will follow the current recommended care pathway
11257490|NCT02989207|Active Comparator|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
11257491|NCT02989207|Active Comparator|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
11257492|NCT02989207|Active Comparator|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
11257493|NCT02989194|Experimental|VIS410 low dose|Single intravenous fixed low dose of VIS410
11257494|NCT02989194|Experimental|VIS410 high dose|Single intravenous fixed high dose of VIS410
11257495|NCT02989194|Placebo Comparator|Placebo|Single intravenous placebo infusion
11257496|NCT02989181|Experimental|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
11257497|NCT02989181|No Intervention|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
11257498|NCT02989168|Experimental|GBT440 900 mg Dose|"Part A, 900 mg
~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
11257499|NCT02989168|Experimental|GBT440 1500 mg Dose|"Part B , 1500 mg
~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
11257500|NCT02989142|No Intervention|Control arm|No intervention
11257501|NCT02989142|Experimental|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.
~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
11257502|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.
~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
11257503|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.
~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
11257504|NCT02989116|Experimental|Preterm Inhibition|"In children born very preterm:
~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
11257505|NCT02989116|Experimental|Full-term Inhibition|"In children born full-term:
~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
11257506|NCT02989116|Experimental|Full-term Working memory|"In children born full-term:
~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
11257507|NCT02989116|Experimental|Full-term Mindfulness|"In children born full-term:
~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
11257508|NCT02989116|Active Comparator|Full-term Active control|"In children born full-term:
~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
11257509|NCT02989103||Hyperthyroidism Follow-up Cohort Study|Hyperthyroid patients enrolled and treated between 1946 and 1964 in 25 U.S. and 1 UK site
11257510|NCT02989090|Experimental|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
11257511|NCT02989090|Active Comparator|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
11257512|NCT02989090|No Intervention|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
11257513|NCT02989077||Group A|Having combined coronary and cerebral ischemia.
11257514|NCT02989077||Group B|Having only coronary ischemia
11257515|NCT02989077||group C|Having only cerebral ischemia
11257516|NCT02989064|Experimental|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
11257517|NCT02989051|Experimental|Restrictive fluid treatment|Restrictive fluid regimen
11257518|NCT02989051|Active Comparator|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
11257519|NCT02989038|Experimental|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
11257520|NCT02989038|Experimental|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
11257521|NCT02989038|Experimental|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
11257522|NCT02989038|Experimental|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
11257523|NCT02989038|Experimental|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
11257524|NCT02989038|Experimental|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
11257525|NCT02989025|Experimental|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
11257526|NCT02989012|Experimental|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
11257527|NCT02989012|Sham Comparator|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
11257528|NCT02988999|Experimental|D-allulose|D-allulose 5 gm 3 times a day
11257529|NCT02988999|Active Comparator|erythritol|erythritol 5 gm 3 times a day
11257530|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.
~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
11257531|NCT02988973|Experimental|Subjects converting from rHuEPO or DA to ASP1517|ASP1517 will be administered for 52 weeks.
11257532|NCT02988973|Experimental|Subjects converting from rHuEPO or DA to DA|DA will be administered for 24 weeks.
11257533|NCT02988973|Experimental|Subjects converting from CERA to ASP1517|ASP1517 will be administered for 52 weeks.
11257534|NCT02988960|Experimental|Escalating Arm 1: ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
11257535|NCT02988960|Experimental|Escalating Arm 2: ABBV-927|Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
11257536|NCT02988960|Experimental|Escalating Arm 3: ABBV-927+ABBV-181|Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
11257537|NCT02988960|Experimental|Escalating Arm 4: ABBV-927+ABBV-181|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
11257538|NCT02988960|Experimental|Escalating Arm 5 (Japan): ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
11257539|NCT02988960|Experimental|Escalating Arm 6 (Japan): ABBV-927+ABBV-181|Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
11257540|NCT02988960|Experimental|Expansion Arm A: ABBV-927|Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
11257541|NCT02988960|Experimental|Expansion Arm B: ABBV-927+ABBV-181|Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
11257542|NCT02988960|Experimental|Expansion Arm C: ABBV-927+ABBV-181|Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
11257543|NCT02988947|Experimental|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
11257544|NCT02988947|No Intervention|Control Group|No intervention / Standard care
11257545|NCT02988921|Experimental|Esophageal or esophagogastric cancer|
11257546|NCT02988908|Experimental|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.
~Participants also received 2 weeks of memory training at weeks 13-14"
11257547|NCT02988908|Placebo Comparator|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.
~Participants also received 2 weeks of memory training at weeks 13-14"
11257548|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
11257549|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
11257550|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
11257551|NCT02988869|Experimental|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
11257552|NCT02988869|Active Comparator|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
11257553|NCT02988869|Active Comparator|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
11257554|NCT02988856|Experimental|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
11257555|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.
~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
11257556|NCT02988830|Experimental|Chronic lumbar pain|
11257557|NCT02988817|Experimental|Enapotamab vedotin (HuMax-AXL-ADC)|All arms of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC)
11257669|NCT02987907|Placebo Comparator|control group|use normal saline 2ml I.A. during TACE
11257558|NCT02988804|Active Comparator|endotracheal tube|"Procedure: Endotracheal tube
~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:
~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)
~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)
~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
11257559|NCT02988804|Active Comparator|Laryngeal mask|"Procedure: Laryngeal mask
~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:
~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)
~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)
~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
11257560|NCT02988791|Experimental|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
11257561|NCT02988791|Placebo Comparator|Placebo|Placebo
11257562|NCT02988778|Experimental|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
~Treatment of 28 days."
11257563|NCT02988778|Active Comparator|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
~Treatment of 28 days."
11257564|NCT02988765|Experimental|Invasive vulvar cancer (IVC)|"Vulvar carcinoma (stromal infiltration > 1 mm)
~Histotypes different from squamous cells carcinomas are included"
11257565|NCT02988752|Experimental|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
11257566|NCT02988752|Active Comparator|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
11257567|NCT02988739|Experimental|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.
~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
11257568|NCT02988739|Active Comparator|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
11257569|NCT02988726|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11257570|NCT02988713|Experimental|Spinal cord stimulation|Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
11257571|NCT02988700|Active Comparator|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
~be given by ."
11257572|NCT02988700|Active Comparator|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
11257573|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
11257574|NCT02988661|Active Comparator|Chronic Disease Self-management Program (CDSMP)|A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
11257575|NCT02988661|No Intervention|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
11257576|NCT02988648|Experimental|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
11257577|NCT02988635|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
11257578|NCT02988635|No Intervention|Standard of Care|Subjects receive standard of care.
11257579|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
11257580|NCT02988609|Experimental|Concussion Group|Players with a recent (<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
11257581|NCT02988609|Active Comparator|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
11257582|NCT02988596|Active Comparator|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich/Berlin protocol). This protocol will follow the Zurich/Berlin guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
11257670|NCT02987881|Experimental|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
11257583|NCT02988596|Experimental|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich/Berlin protocol).
11257584|NCT02988583|Experimental|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
11257585|NCT02988583|Active Comparator|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
11257586|NCT02988570|Experimental|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
11257587|NCT02988557|Experimental|Treadmill|
11257588|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
11257589|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
11257590|NCT02988531|Experimental|PET/MR|Participants to have PET/MR scan
11257591|NCT02988518|Experimental|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
11257592|NCT02988492|Other|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
11257593|NCT02988466|Experimental|Arm A: Haplo-HCT <55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients <55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2
11257594|NCT02988466|Experimental|CLOSED Arm B: Haplo-HCT ≥55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
11257595|NCT02988466|Experimental|Arm C: Haplo-HCT HCT-CI ≤2 aged ≥55 and < 65yo|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and < 65 years old.
11257596|NCT02988466|Experimental|Arm D: Haplo-HCT aged ≥65 and ≤75yo OR any age HCT-CI ≥3|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
11257597|NCT02988453|Experimental|MBT-CD|Mentalization-based treatment program
11257598|NCT02988440|Other|PDR001 + Sorafenib|PDR001 at 400 mg given intravenously every 4 weeks and sorafenib 400 mg taken orally once or twice per day (escalating doses)
11257599|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
11257600|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
11257601|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
11257602|NCT02988401|Experimental|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
11257603|NCT02988401|Experimental|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
11257604|NCT02988401|Placebo Comparator|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
11257605|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
11257606|NCT02988375|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
11257607|NCT02988375|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
11257608|NCT02988362|Experimental|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
11257609|NCT02988362|Experimental|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
11257610|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
11257611|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
11257612|NCT02988323|Experimental|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
11257671|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
11257613|NCT02988323|Experimental|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
11257614|NCT02988323|Other|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
11257615|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
11257616|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
11257617|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
11257618|NCT02988297|Experimental|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
11257619|NCT02988297|Placebo Comparator|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
11257620|NCT02988271|Experimental|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
11257621|NCT02988271|Active Comparator|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
11257622|NCT02988258|Experimental|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^4 T cells/kg recipient weight
11257623|NCT02988258|Experimental|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^5 T cells/kg recipient weight
11257624|NCT02988258|Experimental|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10^3 T cells/kg recipient weight
11257625|NCT02988245|Experimental|Genetically-Guided Treatment for HTN|Using a patient's genetic composition to guide BP prescribing for patients with hypertension, post diagnosis.
11257626|NCT02988245|Active Comparator|JNC-8-Guided Treatment|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension, post diagnosis.
11257627|NCT02988232|Experimental|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
11257628|NCT02988232|Placebo Comparator|Placebo|admission to placebo
11257629|NCT02988219|Active Comparator|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
11257630|NCT02988219|Experimental|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
11257631|NCT02988206|Other|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
11257632|NCT02988206|Other|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
11257633|NCT02988193|Experimental|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:
~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;
~medication treatment recommendation;
~active link to access additional treatment analysis tools."
11257634|NCT02988193|No Intervention|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
11257635|NCT02988180|Other|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
11257636|NCT02988180|Other|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
11257637|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
11257638|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
11257639|NCT02988115|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
11257640|NCT02988115|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
11257641|NCT02988089|Experimental|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.
~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.
~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
11258546|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
11257642|NCT02988089|Experimental|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
11257643|NCT02988089|Other|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
11257644|NCT02988089|Other|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
11257645|NCT02988076|No Intervention|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
11257646|NCT02988076|Active Comparator|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
11257647|NCT02988063|Experimental|Compression plus PEM|Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy. If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
11257648|NCT02988050|Other|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
11257649|NCT02988050|Other|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
11257650|NCT02988037|Experimental|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
11257651|NCT02988024|Experimental|LY03005|LY03005 80 mg
11257652|NCT02988024|Active Comparator|Pristiq|Pristiq 50 mg
11257653|NCT02988011|Active Comparator|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
11257654|NCT02988011|Active Comparator|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
11257655|NCT02987998|Experimental|Resectable Patients|Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy
11257656|NCT02987985|Experimental|Opioid-free anesthesia|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis
11257657|NCT02987985|Active Comparator|Opioid-sparing anesthesia|Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis
11257658|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
11257659|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
11257660|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
11257661|NCT02987959|Experimental|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
11257662|NCT02987946|Active Comparator|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
11257663|NCT02987946|Experimental|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
11257664|NCT02987933||Chronic Pain|Adults, > 6 months duration, daily pain
11257665|NCT02987933||Healthy Normals|Age and gender matched controls
11257666|NCT02987920|Active Comparator|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.
~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
11257667|NCT02987920|Experimental|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet
~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
11257668|NCT02987907|Experimental|treatment group|use dexamethasone 10mg (2ml) I.A. during TACE
11257672|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
11257673|NCT02987855|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
11257674|NCT02987855|Experimental|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
11257675|NCT02987855|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
11257676|NCT02987842|Experimental|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
11257677|NCT02987842|Sham Comparator|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
11257678|NCT02987829|Experimental|TRC253|Single-agent TRC253 to be administered as oral capsules once daily. The proposed TRC253 doses are 40 mg, 80 mg, 160 mg, 240 mg, 320 mg, and 400 mg.
11257679|NCT02987816|Sham Comparator|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
11257680|NCT02987816|Experimental|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
11257681|NCT02987803|No Intervention|Control Group|Participants in the control group will receive educational articles about obstetric hospitals. The articles will prompt the participant to look up hospitals in their geographic location. Participants will not know they are participating in a trial.
11257682|NCT02987803|Experimental|Data Group|"Participants in the intervention group will receive an educational module designed to support them in selecting a delivering hospital, which will include an educational video, articles, and a data tool with cesarean delivery rate data for hospitals in their geographic location.
~Participants will not know they are participating in a trial."
11257683|NCT02987790|Experimental|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are <35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak > 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
11257684|NCT02987790|No Intervention|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:
~7 full days for most infections
~10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.
~14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
11257685|NCT02987764|Experimental|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
11257686|NCT02987764|No Intervention|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
11257687|NCT02987751|Experimental|Glargine + Glulisine|Insulin Glargine + Glulisine (12U/day + 4U/day) at pre-breakfast/dinner for 24 weeks
11257688|NCT02987751|Active Comparator|Premixed Analogue Insulin (70/30)|Premixed analogue Insulin (70/30) 16U/day at pre-breakfast/dinner for 24 weeks
11257689|NCT02987738|Experimental|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
11257690|NCT02987738|Placebo Comparator|Placebo Oral Tablets|two administrations identical to the experimental drug
11257691|NCT02987725|Active Comparator|Attention Control|Participants will listen to a 30-minute historical story.
11257692|NCT02987725|Experimental|Hypnosis|Participants will receive a 30-minute hypnosis session
11257693|NCT02987712|No Intervention|Survey 1|Common practice
11257694|NCT02987712|Experimental|Survey 2|Thromboelastography based protocol
11257695|NCT02987699|Experimental|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
11257696|NCT02987699|Experimental|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
11257697|NCT02987699|Experimental|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
11257698|NCT02987686|Experimental|Topical Infliximab|Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
11257699|NCT02987686|No Intervention|Observational group|Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
11257700|NCT02987673|Experimental|Mini/One anastomosis gastric bypass|Execution of a laparoscopic mini/one anastomosis gastric bypass (MGB/OAGB)
11257701|NCT02987673|Active Comparator|Laparoscopic sleeve gastrectomy|Execution of a laparoscopic sleeve gastrectomy (LSG)
11257702|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
11257703|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
11257704|NCT02987647|Experimental|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.
~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
11257705|NCT02987647|Active Comparator|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.
~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
11257706|NCT02987647|Active Comparator|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.
~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
11257707|NCT02987647|Active Comparator|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.
~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
11257708|NCT02987634|Experimental|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
11257709|NCT02987634|Active Comparator|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
11257710|NCT02987621|Experimental|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.
~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.
~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
11257711|NCT02987621|Experimental|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.
~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.
~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
11257712|NCT02987608|No Intervention|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
11257713|NCT02987608|Experimental|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
11257714|NCT02987595|Experimental|Whole-grain rye then wheat|Whole-grain rye, high lignan Whole-grain rye products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain wheat products for 8 weeks
11257715|NCT02987595|Experimental|Whole-grain wheat then rye|Whole-grain wheat, low lignan Whole-grain wheat products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain rye products for 8 weeks
11257716|NCT02987582|Experimental|Emotion-focused mindfulness group|8-week mindfulness group
11257717|NCT02987569|Experimental|Group One|Intervention
11257718|NCT02987569|Active Comparator|Group Two|Control
11257719|NCT02987556|Active Comparator|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
11257720|NCT02987556|Experimental|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
11257721|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
11257722|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:
~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.
~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
11257723|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
11257724|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
11257725|NCT02987517|Experimental|Cadence|Runners who use an increased running cadence of 7.5 percent over preferred running cadence.
11257726|NCT02987517|Experimental|Forefoot Strike|Runners who use a forefoot strike instead of a rear foot strike
11257727|NCT02987504|Experimental|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.
~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
11257728|NCT02987491|Experimental|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.
~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
11258449|NCT02982512|Experimental|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
11257729|NCT02987491|No Intervention|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.
~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
11257730|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
11257731|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
11257732|NCT02987452|Experimental|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
11257733|NCT02987452|Active Comparator|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
11257734|NCT02987452|Active Comparator|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
11257735|NCT02987439|No Intervention|Standard care group|"Standard medical treatment for the exacerbation of COPD
~Standard medical treatment of COPD according to GOLD
~A visit by a pulmonary nurse at the patients own home 3-5 days after discharge. Lung function and smoking history is recorded. Correct use of inhaler is instructed.
~Visit in the outpatient clinic within the next 2-6 months after discharge as follow-up
~In the outpatient clinic they will receive an offer of pulmonary rehabilitation"
11257736|NCT02987439|Experimental|Rehabilitation group|"The group will begin pulmonary rehabilitation during hospital admission. Afterwards a rehabilitation program twice weekly for 7 weeks.
~Beside rehabilitation they will receive same treatment as the standard care group"
11257737|NCT02987426|Experimental|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
11257738|NCT02987426|No Intervention|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
11257739|NCT02987413|Experimental|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
11257740|NCT02987400|Experimental|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
11257741|NCT02987387||TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
11257742|NCT02987374|Other|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
11257743|NCT02987361|Experimental|treatment group 1|anodal stimulation on the lesioned primary motor cortex DC-STIMULATOR PLUS
11257744|NCT02987361|Experimental|treatment group 2|cathodal stimulation on the non-lesioned primary motor cortex DC-STIMULATOR PLUS
11257745|NCT02987361|Experimental|treatment group 3|dual stimulation such as anodal stimulation on the lesioned side and cathodal stimulation on the non-lesioned side DC-STIMULATOR PLUS
11257746|NCT02987361|Sham Comparator|sham group|sham group
11257747|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
11257748|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
11257749|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
11257750|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
11257751|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
11257752|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
11257753|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
11257754|NCT02987335||Nondiabetic Subjects|N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
11257755|NCT02987322|Experimental|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
11257756|NCT02987296|Active Comparator|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
11257757|NCT02987296|Placebo Comparator|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
11257758|NCT02987270|Experimental|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
11257759|NCT02987270|No Intervention|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
11257760|NCT02987257|Placebo Comparator|Harmonized supportive care|Harmonized supportive care with placebo cyclosporine days 0-14 and etanercept placebo days 0 and 3
11257761|NCT02987257|Active Comparator|Cyclosporine 5mg/kg bid days 0-14|Harmonized supportive care with placebo etanercept days 0 and 3
11257762|NCT02987257|Active Comparator|Etanercept 50mg sc day 0 and day 3|Harmonized supportive care with placebo cyclosporine days 0-14
11257763|NCT02987244|Experimental|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
11257764|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
11257765|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
11257766|NCT02987218|Active Comparator|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
11257767|NCT02987218|Active Comparator|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
11257768|NCT02987205|Experimental|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
11257769|NCT02987205|Active Comparator|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
11257770|NCT02987192|Experimental|traditional group|Traditional group patients will receive cutting type 22 gauge needles
11257771|NCT02987192|Experimental|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
11257772|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.
~Age ≥18 years and able to give written informed consent to the study
~On chronic hemodialysis for ≥ 90 days at time of enrollment
~Ability to read
~Consent to have video recording taken during study visit"
11257773|NCT02987166|Experimental|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.
~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.
~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
11257774|NCT02987166|Experimental|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.
~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.
~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
11257775|NCT02987166|Experimental|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.
~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.
~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
11257776|NCT02987153|Experimental|KYPHO-IORT - 10 Gy and Kyphoplasty|Intra-operative radiation therapy followed by standard kyphoplasty
11257777|NCT02987140|Experimental|PD+FoG|PD patients with FoG
11257778|NCT02987140|Active Comparator|PD-FoG|PD patients without FoG
11257779|NCT02987140|Active Comparator|Control|age-matched non-disabled adults
11257780|NCT02987114|Experimental|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
11257781|NCT02987101|Experimental|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.
~Standard wound care is given independent of this study."
11257782|NCT02987101|Other|Standard of care|Standard wound care is given independent of this study.
11257783|NCT02987075|Other|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
11257784|NCT02987075|Other|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
11257785|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
11257786|NCT02987062||Warfarin|Patients with AF treated with warfarin.
11257787|NCT02987062||Apixaban|Patients with AF treated with apixaban.
11257788|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
11257789|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
11257820|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
11257821|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
11257790|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
11257791|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
11257792|NCT02987036|Experimental|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
11257793|NCT02987036|Other|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
11257794|NCT02987010|Experimental|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
11257795|NCT02987010|Experimental|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
11257796|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
11257797|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
11257798|NCT02986971|Experimental|New IMD|Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
11257799|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
11257800|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
11257801|NCT02986945|Experimental|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT-an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.
~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
11257802|NCT02986945|Other|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
11257803|NCT02986932|Experimental|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
11257804|NCT02986919|Experimental|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
11257805|NCT02986906|Experimental|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
11257806|NCT02986906|Active Comparator|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
11257807|NCT02986893|Experimental|Dietary Intervention Arm|Participants will be assigned to follow a specific dietary intervention for 6 months
11257808|NCT02986893|Experimental|Non-dietary Intervention Arm|Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
11257809|NCT02986880|Experimental|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
11257810|NCT02986880|Experimental|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
11257811|NCT02986880|Experimental|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
11257812|NCT02986880|Experimental|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
11257813|NCT02986880|Experimental|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
11257814|NCT02986880|Experimental|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
11257815|NCT02986880|Experimental|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
11257816|NCT02986880|Experimental|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
11257817|NCT02986880|Experimental|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
11257818|NCT02986880|Placebo Comparator|Group P|Patients receiving placebo in the third muscles groups
11257819|NCT02986867|Experimental|SAbR|SAbR treatment of lesions
11258547|NCT02981875|Experimental|experimental|oculomotor training
11257822|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
11257823|NCT02986828|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
11257824|NCT02986828|Active Comparator|Normal saline|Normal saline for ultrasound-guided hydrodissection
11257825|NCT02986815|Experimental|[11C]Acetate Brain Imaging|[11C]Acetate will be administered The patient will have one intravenous line placed prior to [11C]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which [11C]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
11257826|NCT02986802||Cohort A|Women with genital herpes receiving treatment before the 3rd trimester
11257827|NCT02986802||Cohort B|Women with genital herpes receiving treatment after the 3rd trimester
11257828|NCT02986802||Cohort C|Women with untreated genital herpes
11257829|NCT02986802||Cohort D|Women (controls) with neither genital herpes nor treatment
11257830|NCT02986776|Active Comparator|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
11257831|NCT02986776|Active Comparator|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
11257832|NCT02986776|Active Comparator|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
11257833|NCT02986776|Active Comparator|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
11257834|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
11257835|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
11257836|NCT02986750|Experimental|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
11257837|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
11257838|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
11257839|NCT02986737|Experimental|ACURATE neo™ and ACURATE TA™ LP|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System
11257840|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
11257841|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
11257842|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
11257843|NCT02986698|Experimental|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).
~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
11257844|NCT02986685|Experimental|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
11257845|NCT02986685|Other|rabeprazole|rabeprazole 20mg once daily
11257846|NCT02986672|Active Comparator|Calanus oil|Children receiving omega-3 in form om calanus oil in capsule form
11257847|NCT02986672|Placebo Comparator|Placebo|Children receiving medical paraffin in capsule form (2 ml volume per day)
11257848|NCT02986659|Active Comparator|Metformin then Placebo|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months. Will then cross over to 3 months on placebo.
11257849|NCT02986659|Placebo Comparator|Placebo then Metormin|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months. After 3 months on placebo, participants will then cross over to 3 months of metformin as described in the other arm.
11257850|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
11257851|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
11257852|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
11257853|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
11257854|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
11257855|NCT02986607|Experimental|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.
~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
11257856|NCT02986594|Experimental|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
11257857|NCT02986594|Experimental|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
11257858|NCT02986594|Experimental|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
11257859|NCT02986568|Experimental|Cervical cancer|"Primary cervical cancer patients, FIGO stage IB1-IIB
~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy
~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
11257860|NCT02986568|Experimental|Uterine cancer|"Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA
~Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy
~Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy"
11257861|NCT02986568|Experimental|Cervical cancer, pelvic sidewall invasion|"Cervical cancer patients showing pelvic sidewall invasion
~Primary cervical cancer
~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy
~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
11257862|NCT02986568|Experimental|Non-cervical cancer, pelvic sidewall invasion|"Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis
~Patients showing uncontrolled pelvic pain due to the tumor invasion"
11257863|NCT02986555|Placebo Comparator|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
11257864|NCT02986555|Active Comparator|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
11257865|NCT02986542|Active Comparator|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
11257866|NCT02986542|Active Comparator|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
11257867|NCT02986529|Active Comparator|GV-971 150mg/capsule|900mg, oral
11257868|NCT02986529|Experimental|GV-971 300mg/capsule|900mg, oral
11257869|NCT02986529|Experimental|GV-971 450mg/capsule|900mg, oral
11257870|NCT02986529|Placebo Comparator|Placebo|Oral
11257871|NCT02986516|Experimental|Randomized Cohort|Participants who will decided to undergo to randomization, will receive surgical treatment or definitive radiotherapy according with randomization assignment
11257872|NCT02986516|Active Comparator|Prospective Cohort|Participants who will not decide to be randomized, will received the surgical or definite radiotherapy treatment according to their choice
11257873|NCT02986503||Chemotherapy for Good responder|Doxorubicin + cisplatin + ifosfamide Pre-operative and post-operative chemotherapy for patients with good responder high grade osteosarcoma
11257874|NCT02986503||Chemotherapy for Poor responder|Doxorubicin+cisplatin+ifosfamide+methotrexate Pre-operative and post-operative chemotherapy for patients with poor responder high grade osteosarcoma
11257875|NCT02986490|Other|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
11257876|NCT02986477|Other|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
11257877|NCT02986464|Active Comparator|Standard pharmacological treatment|
11257878|NCT02986464|Experimental|Virtual Reality distraction|
11257879|NCT02986451|Experimental|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
11257880|NCT02986438|Active Comparator|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
11257881|NCT02986438|Sham Comparator|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
11257882|NCT02986425|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
11258543|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
11257883|NCT02986425|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
11257884|NCT02986412|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
11257885|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
11257886|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
11257887|NCT02986386|Experimental|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
11257888|NCT02986386|Other|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
11257889|NCT02986386|Experimental|Intervention 2|Orthodontic treatment of malocclusion.
11257890|NCT02986386|Other|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
11257891|NCT02986373|Experimental|Risankizumab|Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.
11257892|NCT02986360|Active Comparator|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
11257893|NCT02986360|No Intervention|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
11257894|NCT02986347|Active Comparator|Intravenous regional anesthesia (Bier)|The anesthetic technique described by Bier will be done by the anesthesiologist. The following steps were followed: 1)Placement double tourniquet on the proximal portion of the arm 2)Asepsis and antisepsis of the operative limb 3)Puncture and venous catheterization most distal in the limb 4)Elevation of limb for 1 to 2 minutes, next the limb will be spirally wrapped with Esmarch from the distal to proximal 5)The proximal cuff will be inflated 6)Withdrawal of Esmarch and injection of 40ml of lidocaine without epinephrine at 0.5% 7)Removal the canula until the distal cuff is inflated and the proximal cuff is emptied 8)Removal of the club must be done after the surgery, at least 40 minutes after the injection of the anesthetic.
11257895|NCT02986347|Active Comparator|Local anesthesia with adrenaline|Patients will be anesthetized by surgeons, who are familiar with the technique described by Lalonde. Around thirty minutes before surgery, will be infused with 20 ml of an anesthetic solution. The infiltrated solution is composed of 1% lidocaine with epinephrine in 1: 100,000. Initially 10 mL of the solution will be applied slowly in the flexion fold region of the wrist just below the skin and subfascial plane. The needle is moved slowly. The needle is then redirected to the radial side of the proximal palmar region for infiltration of another 2-3 mL of the subcutaneous solution. The remaining 7-8mL in the subdermal plane and anterior to the transverse carpal ligament.
11257896|NCT02986334|No Intervention|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
11257897|NCT02986334|Active Comparator|Active Treatment Intervention|Naproxen & Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
11257898|NCT02986334|Placebo Comparator|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
11257899|NCT02986321|Experimental|CHF6001 DOSE1|DOSE1
11257900|NCT02986321|Experimental|CHF6001 DOSE2|DOSE2
11257901|NCT02986321|Experimental|CHF6001 DOSE3|DOSE3
11257902|NCT02986321|Experimental|CHF6001 DOSE4|DOSE4
11257903|NCT02986321|Placebo Comparator|Matched placebo|placebo control
11257904|NCT02986321|Active Comparator|Budesonide|Budesonide DPI 800µg
11257905|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
11257906|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
11257907|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
11257908|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
11257909|NCT02986282|Other|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
11257910|NCT02986269|Experimental|Group SB|"Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is spontaneous breathing(SB) without pressure support ventilation (PSV) under laryngeal mask airway (LMA).
~General anesthesia across LMA under SB without PSV"
11257911|NCT02986269|Active Comparator|Group PSV|General anesthesia across LMA under SB with PSV Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is SB with PSV under LMA.
11257912|NCT02986256|No Intervention|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
11257913|NCT02986256|Experimental|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
11257914|NCT02986243|Experimental|Treatment|Subjects receive a diet plan and exercise regimen.
11257915|NCT02986230|Experimental|PCP-focused group|The PCP-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
11257937|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
11258548|NCT02981875|Placebo Comparator|control|placebo vision training exercises
11257916|NCT02986230|Experimental|SDMT-focused group|The SDMT-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The SDMT-focused arm also provides shared decision making tools to patient and provider at the time of the visit.
11257917|NCT02986217|No Intervention|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
11257918|NCT02986217|Experimental|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
11257919|NCT02986204|Other|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
11257920|NCT02986204|Other|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
11257921|NCT02986191|Experimental|Mucograft|One side of the mouth will be subjected to Mucograft in this split-mouth study design.
11257922|NCT02986191|Active Comparator|Connective tissue graft|The opposite side of the mouth will be subjected to a connective tissue graft.
11257923|NCT02986178|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|Polio/Rhinovirus Recombinant (PVSRIPO)
11257924|NCT02986165|Placebo Comparator|Placebo control|100 g of flavoured water
11257925|NCT02986165|Experimental|Low dose pomace extract|1 g pomace extract powder
11257926|NCT02986165|Experimental|High dose pomace extract|2.5 g pomace extract powder
11257927|NCT02986152|Experimental|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
11257928|NCT02986152|Other|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
11257929|NCT02986139|Experimental|Sequence AB|Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
11257930|NCT02986139|Experimental|Sequence BA|Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).
11257931|NCT02986126|Active Comparator|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
11257932|NCT02986126|Active Comparator|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
11257933|NCT02986113|Experimental|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
11257934|NCT02986113|Active Comparator|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
11257935|NCT02986100|Experimental|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.
~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
11257936|NCT02986087|Experimental|Fetal Tracheal Occlusion|Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.
11257938|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
11257939|NCT02986061|Active Comparator|Control Group|Patients with indwelling urinary catheter
11257940|NCT02986061|No Intervention|Study Group|Patients without indwelling urinary catheter
11257941|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
11257942|NCT02986035|Experimental|Intervention|
11257943|NCT02986022|Experimental|Resilience|Participants will receive four sessions covering Resilience intervention content
11257944|NCT02986022|Active Comparator|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
11257945|NCT02986009|Experimental|Parenting|To receive the parenting intervention
11257946|NCT02986009|Experimental|Information|To receive the information intervention
11257947|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
11257948|NCT02985996|Experimental|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
11257949|NCT02985996|Experimental|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
11257950|NCT02985996|Experimental|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
11257951|NCT02985996|Experimental|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
11257952|NCT02985983|Experimental|KHK4827|KHK4827 administered SC
11257953|NCT02985983|Placebo Comparator|Placebo|Placebo administered SC
11257954|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
11257955|NCT02985957|Experimental|Cohort A (Arm A)|
11257956|NCT02985957|Experimental|Cohort B (Arm B)|
11257957|NCT02985957|Experimental|Cohort C (Arm C)|
11257958|NCT02985957|Experimental|Cohort D (Arm D1)|
11257959|NCT02985957|Experimental|Cohort D (Arm D2)|
11257960|NCT02985957|Experimental|Cohort D (Arm D3)|
11257961|NCT02985957|Experimental|Cohort D (Arm D4)|
11257962|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
11257963|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
11257964|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
11257965|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
11257966|NCT02985931||Suspected CAD subjects|
11257967|NCT02985918|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
11257968|NCT02985918|Active Comparator|Conventional-intensity NPPV|The patients will receive conventional-intensity noninvasive positive pressure ventilation.
11257969|NCT02985905|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
11257970|NCT02985905|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
11257971|NCT02985892|Experimental|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
11257972|NCT02985892|Experimental|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
11257973|NCT02985879|Placebo Comparator|Group 3|Placebo for ABBV-8E12
11257974|NCT02985879|Experimental|Group 1|Dose 1 ABBV-8E12
11257975|NCT02985879|Experimental|Group 2|Dose 2 ABBV-8E12
11257976|NCT02985866|Experimental|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
11257977|NCT02985866|Active Comparator|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
11257978|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
11257979|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
11257980|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
11257981|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
11257982|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.
11257983|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
11258049|NCT02985320|Experimental|PhaseⅡExperimental Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of low dosage investigational sIPV"
11257984|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
11257985|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
11257986|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
11257987|NCT02985775|Experimental|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
11257988|NCT02985762|Other|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
11257989|NCT02985749|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
11257990|NCT02985736|Experimental|open label|
11257991|NCT02985723|Experimental|939MP|AT LISA tri toric 939MP intraocular lens
11257992|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
11257993|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
11257994|NCT02985697|Experimental|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
11257995|NCT02985697|Experimental|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
11257996|NCT02985697|Experimental|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
11257997|NCT02985697|Active Comparator|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
11257998|NCT02985684|Experimental|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
11257999|NCT02985671|Experimental|Experimental Drug & Voltaren Placebo|"Orphenadrine + acetaminophen + caffeine + diclofenac sodium & Placebo of Voltaren
~01 tablet of experimental drug (orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg) + 01 tablet of placebo of Voltaren, to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
11258000|NCT02985671|Active Comparator|Voltaren® + Experimental Drug Placebo|"Voltaren & Placebo of Orphenadrine + acetaminophen + caffeine + diclofenac sodium
~01 tablet of Voltaren + 01 tablet of placebo of experimental drug (orphenadrine, acetaminophen, caffeine and diclofenac sodium), to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
11258001|NCT02985645|Experimental|Treatment|maxillary sinus augmentation with CGF
11258002|NCT02985632|Experimental|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
11258003|NCT02985632|Experimental|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
11258004|NCT02985632|Experimental|Healthy Subjects|Subjects given an oral dose of BMS-986141.
11258005|NCT02985619|Active Comparator|Bevacizumabe|"6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata), monthly for central sufoveal thickness map more than 300µm by Optic Coherence Tomography."
11258006|NCT02985619|Active Comparator|Triamcinolone|6 months treatment with 0.03ml (1mg) intravitreous injection of triamcinolone each 3 months for central sufoveal thickness map more than 300µm by Optic Coherence Tomography.
11258007|NCT02985606|Active Comparator|Caffeine -60|Caffeine at 60 minutes prior to time trial
11258008|NCT02985606|Active Comparator|Caffeine -30|Caffeine at 30 minutes prior to time trial
11258009|NCT02985606|Active Comparator|Caffeine 0|Caffeine immediately prior to time trial
11258010|NCT02985606|Placebo Comparator|Placebo|Placebo drink at all time points
11258011|NCT02985593|Experimental|KHK4083|IV/SC administration
11258012|NCT02985593|Placebo Comparator|Placebo|IV/SC administration
11258013|NCT02985580|Active Comparator|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
11258014|NCT02985580|Placebo Comparator|Placebo|Placebo concentrate consumed daily for 12 weeks.
11258015|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
11258109|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
11258016|NCT02985567||Safety of sedation|"Documentation of:
~The need for repeat dosing of chloral hydrate.
~The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge
~Interventions required for the patient including administration of oxygen, and need for intubation."
11258017|NCT02985554|Experimental|Nivolumab|Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
11258018|NCT02985541|Experimental|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena, an Levonorgestrel intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg Levonorgestrel per day.
11258019|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
11258020|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
11258021|NCT02985515|Experimental|Smell Training|Participants will first undergo a 30-day trial of budesonide nasal saline irrigation. If there is no subsequent improvement in olfaction, participants will undergo a 12-week smell training intervention.
11258022|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
11258023|NCT02985489|Experimental|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
11258024|NCT02985489|No Intervention|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
11258025|NCT02985476|Active Comparator|Interventional|Care as usual plus 8 weekly ELIJAH health reports shared with the participant and General Practitioner for 6 months i.e.: My history, My plan, My Update delivered via post or by email (dependant on participant preference) in addition to care as usual.
11258026|NCT02985476|No Intervention|Observational|Care as usual dictated by disease pathway of diagnosed inflammatory bowel disease i.e.; access to out-patient and in-patient hospital based care and community health resources via General Practitioner.
11258027|NCT02985437|Experimental|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
11258028|NCT02985437|Active Comparator|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
11258029|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
11258030|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
11258031|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
11258032|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:
~Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen
~Those compatible with life are managed by full investigation and given standard care for each case"
11258033|NCT02985385||Normal Fetal Ultrasounds|Given normal care
11258034|NCT02985372|Experimental|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
11258035|NCT02985359||Comparison district|Existing routine community health services by government
11258036|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
11258037|NCT02985346|Experimental|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
11258038|NCT02985346|Active Comparator|Control group|Patients received standard treatment
11258039|NCT02985333|Experimental|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
11258040|NCT02985320|Experimental|Phase I Adult Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of high dosage investigational sIPV"
11258041|NCT02985320|Experimental|Phase I Adult Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of medium dosage investigational sIPV"
11258042|NCT02985320|Experimental|Phase I Child Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of high dosage investigational sIPV"
11258043|NCT02985320|Experimental|Phase I Child Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;
~Intervention: Single-dose regimen of medium dosage investigational sIPV"
11258044|NCT02985320|Experimental|Phase I Infant Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of high dosage investigational sIPV"
11258045|NCT02985320|Experimental|Phase I Infant Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of medium dosage investigational sIPV"
11258046|NCT02985320|Experimental|Phase I Infant Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of low dosage investigational sIPV"
11258047|NCT02985320|Experimental|PhaseⅡExperimental Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of high dosage investigational sIPV"
11258048|NCT02985320|Experimental|PhaseⅡExperimental Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of medium dosage investigational sIPV"
11258050|NCT02985320|Active Comparator|PhaseⅡControl Group -commercialized sIPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention:Three-dose regimen of commercialized sIPV"
11258051|NCT02985320|Active Comparator|PhaseⅡ Control Group -commercialized IPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;
~Intervention: Three-dose regimen of commercialized IPV"
11258052|NCT02985307|Experimental|Short Message Text Service|Participants receive short messages daily via their mobile phone
11258053|NCT02985307|Active Comparator|Standard Weight Management Group|Participants attend standard group weight management sessions
11258054|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
11258055|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
11258056|NCT02985281|Active Comparator|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).
~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
11258057|NCT02985281|Active Comparator|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.
~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).
~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
11258058|NCT02985268|Active Comparator|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
11258059|NCT02985268|Active Comparator|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
11258060|NCT02985268|Active Comparator|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.
~CRT-D will be programmed to ON"
11258061|NCT02985268|Active Comparator|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.
~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
11258062|NCT02985255|Experimental|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
11258063|NCT02985242|Experimental|Empagliflozin/glimepiride placebo|"Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily
~Duration of treatment: 12 months"
11258064|NCT02985242|Active Comparator|Glimepiride/empagliflozin placebo|"Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily
~Duration of treatment: 12 months"
11258065|NCT02985229|Experimental|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
11258066|NCT02985216|Experimental|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
11258067|NCT02985216|Active Comparator|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
11258068|NCT02985203|Experimental|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
11258069|NCT02985203|No Intervention|Physician's choice|Observation or maintenance therapy other than orla navelbine.
11258070|NCT02985190|Experimental|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles
~in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles
~in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
11258071|NCT02985177|Active Comparator|INF + HM|The participant will receive a dose of intranasal fentanyl (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral hydromorphone (0.04mg/kg up to a maximum of 2 mg).
11258072|NCT02985177|Active Comparator|INF + IBU|The participant will receive a dose of intranasal (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral ibuprofen (10 mg/kg up to a maximum of 600 mg)
11258073|NCT02985164|Experimental|PDSa (Pocket radiation dosimeter a)|"A co-researcher reset and prepared 4 pocket dosimeters (PDS) and labelled as PDSa1, PDSa2, PDSb1 and PDSb2.
~The PDSa1 and PDSa2 were placed on the outside and inside of a lead shirt respectively. The shirt-covered box was close to an anesthetic machine. This box would represent anesthetic personnel on duty and marked as position A. Position A was 160 cm. above the floor"
11258074|NCT02985164|Experimental|PDSb (Pocket radiation dosimeter b)|"The PDSb1 and PDSb2 were placed on the outside and inside of the glass shield of control room respectively. This glass shield would represent all personnel working in the operating theatre and marked as position B.
~Position B was 160 cm. above the floor."
11258110|NCT02984878|Experimental|Revanesse Ultra|Revanesse Ultra open label retreatment
11258549|NCT02981862|Experimental|CaptHPV method|
11258075|NCT02985151|Active Comparator|High Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at either the Mid mode or the Deep mode of the laser at visits three months apart. Thereafter, individuals in this group will be offered a third optional treatment at one of these settings.
11258076|NCT02985151|Placebo Comparator|Low Energy Treatment Group|Subjects in this group will receive at least two Syneron-Candela CO2RE laser treatments set at the Light mode of the laser at visits three months apart. Individuals in this group will be offered two optional high energy treatments subsequent to receiving the two light energy treatments.
11258077|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
11258078|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
11258079|NCT02985125|Experimental|Phase I - Dose Level 1|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 250mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
11258080|NCT02985125|Experimental|Phase I - Dose Level 2|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 300mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
11258081|NCT02985125|Experimental|Phase I - Dose Level -1|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 200mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
11258082|NCT02985125|Experimental|Phase I - Dose Level -2|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - 150mg Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
11258083|NCT02985125|Experimental|Phase II - Dose|"Treatment cycles are 28 days long.
~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21
~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
11258084|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
11258085|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
11258086|NCT02985099|Active Comparator|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
11258087|NCT02985099|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
11258088|NCT02985086|Active Comparator|Immediate induction with antibiotic prophylaxis|Immediate induction with antibiotic prophylaxis
11258089|NCT02985086|Active Comparator|Immediate induction without antibiotic prophylaxis|Immediate induction without antibiotic prophylaxis
11258090|NCT02985086|Active Comparator|Delayed induction with antibiotic prophylaxis|Delayed induction (>= 12 hours after PROM) with antibiotic prophylaxis
11258091|NCT02985073|Experimental|Veritas® mesh|Use of Veritas mesh in conjunction with immediate breast reconstruction on one side
11258092|NCT02985073|Experimental|TIGR® mesh|Use of TIGR® mesh in conjunction with immediate breast reconstruction on one side
11258093|NCT02985060|Experimental|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
11258094|NCT02985060|Other|Control group|Stroke care based on international guidelines
11258095|NCT02985047|Experimental|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
11258096|NCT02985047|No Intervention|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
11258097|NCT02985021|Experimental|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.
~Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity."
11258098|NCT02984995|Experimental|Initial dose 30 mg/day quizartinib|Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
11258099|NCT02984995|Experimental|Initial dose 20 mg/day quizartinib|Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
11258100|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 milligrams per deciliter (mg/dL).
11258101|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
11258102|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
11258103|NCT02984969||Healthy subjects|Healthy controls
11258104|NCT02984943|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen
11258105|NCT02984930|Experimental|PPI + mosapride group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
11258106|NCT02984930|Placebo Comparator|PPI + placebo group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus placebo drug of mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
11258107|NCT02984917|Experimental|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
11258108|NCT02984917|Experimental|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
11258200|NCT02984267|Other|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
11258111|NCT02984865|Active Comparator|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
11258112|NCT02984865|Experimental|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
11258113|NCT02984865|Experimental|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
11258114|NCT02984865|Experimental|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
11258115|NCT02984865|Other|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
11258116|NCT02984852|Experimental|Treatment sequence ABC|Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
11258117|NCT02984852|Experimental|Treatment sequence ACB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment A in treatment session 1, then Treatment C in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
11258118|NCT02984852|Experimental|Treatment sequence BCA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment C in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
11258119|NCT02984852|Experimental|Treatment sequence BAC|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment A in session 2 followed by Treatment C in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
11258120|NCT02984852|Experimental|Treatment sequence CAB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment A in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
11258121|NCT02984852|Experimental|Treatment sequence CBA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment B in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
11258122|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.
~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
11258123|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.
~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
11258124|NCT02984826|Active Comparator|Strength training|Intervention with specific strength training program runs for 10 weeks.
11258125|NCT02984826|Active Comparator|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
11258126|NCT02984813|Experimental|GlaucoHealth|2 pills once daily in the morning for 3 months
11258127|NCT02984813|Experimental|GlaucoSelect|2 pills once daily in the morning for 3 months
11258128|NCT02984813|Placebo Comparator|Placebo|2 pills once daily in the morning for 3 months
11258129|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
11258130|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
11258131|NCT02984787|Experimental|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
11258132|NCT02984787|Active Comparator|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
11258133|NCT02984774|Experimental|Infertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
11258134|NCT02984774|Experimental|Fertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
11258135|NCT02984774|Other|Control|Ovarian tissue sampling, endometrial sampling from hysterectomy and oophorectomy pieces and peripheric blood sampling during intravenous catheterization during anesthesia.
11258136|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
11258290|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
11258137|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
11258138|NCT02984748||Cochlear Implant Recipients|
11258139|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
11258140|NCT02984722|Experimental|1|PCOS women treated with 1500 mg/die of extended-release metformin
11258141|NCT02984722|Experimental|2|PCOS women treated with 1500 mg/die of immediate-release metformin
11258142|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
11258143|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
11258144|NCT02984696|Experimental|Hormonal Replace Therapy|1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months
11258145|NCT02984683|Experimental|SAR566658 (Part 1)|SAR566658 will be given as Dose 1 (cohort 1) and Dose 2 (cohort 2) at Day 1 and Day 8 every 3 weeks intravenously
11258146|NCT02984683|Experimental|SAR566658 (Part 2)|SAR566658 (Part 2) - SAR566658 will be given as Dose 1 or Dose 2 (depending on dose level selected from part 1) at Day 1 and Day 8 every 3 weeks intravenously
11258147|NCT02984670|Experimental|Behavior Therapy|
11258148|NCT02984670|Experimental|Cognitive Therapy|
11258149|NCT02984670|Other|Waitlist|
11258150|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
11258151|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
11258152|NCT02984644|Active Comparator|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
11258153|NCT02984644|Placebo Comparator|Placebo|16 subjects will receive placebo
11258154|NCT02984631|Other|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
11258155|NCT02984631|Other|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
11258156|NCT02984618|Experimental|Treatment group|Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
11258157|NCT02984618|Active Comparator|Control group|Patients will receive classic epidural blood patch with 20ml of autologous blood
11258158|NCT02984605|Experimental|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement & exercise prescription
~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
11258159|NCT02984605|No Intervention|Control group|"Arm：Hypoglycemic agents
~without take nutrition meal replacement & exercise prescription"
11258160|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
11258161|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
11258162|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.
~Investigators and Operators were blinded to all other results for a sample upon data entry."
11258163|NCT02984566|Experimental|SABR with or without KIM|All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.
11258164|NCT02984540|Experimental|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
11258165|NCT02984540|Experimental|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
11258166|NCT02984527|Active Comparator|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
11258167|NCT02984527|Active Comparator|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
11258168|NCT02984514|Experimental|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
11258291|NCT02983591|Experimental|Misoprostol|Rectal misoprostol
11258292|NCT02983591|Experimental|Oxytocin|intravenous oxytocin
11258169|NCT02984501|Experimental|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
11258170|NCT02984488|Experimental|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
11258171|NCT02984488|Active Comparator|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
11258172|NCT02984475|Active Comparator|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
11258173|NCT02984475|No Intervention|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
11258174|NCT02984462|Experimental|screw fixation|Surgical Percutaneous Akin osteotomy with fixation by a percutaneous cannulated screw and forefoot surgery dressing.
11258175|NCT02984462|No Intervention|No fixation|Surgical Percutaneous Akin osteotomy non-fixed, hold by forefoot surgery dressing.
11258176|NCT02984449|Experimental|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
11258177|NCT02984449|Active Comparator|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
11258178|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
11258179|NCT02984410|Other|Intensity-Modulated Radiation Therapy (IMRT)|PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
11258180|NCT02984410|Other|Trans Oral Surgery (TOS)|"The following surgical techniques are allowed:
~Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)"
11258181|NCT02984397|Experimental|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
11258182|NCT02984397|Placebo Comparator|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
11258183|NCT02984397|Active Comparator|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
11258184|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
11258185|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
11258186|NCT02984371|Experimental|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
11258187|NCT02984371|Active Comparator|Group 2|Coronary artery bypass grafting
11258188|NCT02984358|Placebo Comparator|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
11258189|NCT02984358|Active Comparator|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
11258190|NCT02984358|Active Comparator|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
11258191|NCT02984345|Active Comparator|Mycoprotein beverage|
11258192|NCT02984345|Placebo Comparator|Milk protein beverage|
11258193|NCT02984332|Experimental|Lower limb immobilisation|All participants will undergo 7 days of unilateral leg immobilization. Participants will wear a leg brace (Donjoy X-ACT, DJO Global, USA) on one of their legs which will fix the leg at 40 degrees of flexion for the 7 days. Participants will not be allowed to remove the brace at any stage and are prohibited from bearing weight on the immobilized leg, and will ambulate on crutches throughout the week of immobilization.
11258194|NCT02984319|Active Comparator|Cherry|Cherry concentrate
11258195|NCT02984319|Placebo Comparator|Placebo|Placebo concentrate
11258196|NCT02984306|Experimental|Dietary supplement|
11258197|NCT02984293|Active Comparator|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
11258198|NCT02984293|Placebo Comparator|Placebo|The participants will receive matched placebo orally once daily for 28 days.
11258199|NCT02984267|Experimental|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
11258654|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
11258201|NCT02984254|Experimental|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
11258202|NCT02984254|Experimental|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
11258203|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
11258204|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
11258205|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
11258206|NCT02984228|Active Comparator|Platelet-rich plasma (PRP)|Patients will receive an injection of PRP.
11258207|NCT02984228|Active Comparator|Hyaluronic Acid|Patients will receive an injection of hyaluronic acid.
11258208|NCT02984202|Experimental|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
11258209|NCT02984189|Experimental|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
11258210|NCT02984189|Active Comparator|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
11258211|NCT02984189|Sham Comparator|Sham Group|6 cmH20 will be used for training.
11258212|NCT02984176|Active Comparator|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
11258213|NCT02984176|Placebo Comparator|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
11258214|NCT02984163|Experimental|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
11258215|NCT02984150|Experimental|fatty acid|the nutrient that can be widely found in daily food.
11258216|NCT02984150|Sham Comparator|saline|saline
11258217|NCT02984137|Experimental|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
11258218|NCT02984137|Active Comparator|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
11258219|NCT02984137|Placebo Comparator|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
11258220|NCT02984124|Experimental|Intervention|Participants (n= approximately 90 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
11258221|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 90 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
11258222|NCT02984111|Active Comparator|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
11258223|NCT02984111|Active Comparator|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
11258224|NCT02984111|Placebo Comparator|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
11258225|NCT02984098|Experimental|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
11258226|NCT02984098|Active Comparator|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
11258227|NCT02984085|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.
~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
11258228|NCT02984072|Active Comparator|Menthol|5% menthol in aqueous cream (Dermacool Forte)
11258229|NCT02984072|Placebo Comparator|Placebo|Aqueous cream
11258259|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
11258376|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
11258230|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.
~Pain questionnaires:
~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
11258231|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
~Pain questionnaires:
~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
11258232|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
11258233|NCT02984046|Experimental|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
11258234|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
11258235|NCT02984007|Experimental|Motivational Interviewing|Educational session based on the motivational interviewing
11258236|NCT02984007|Other|Information flyer|Information flyer on childhood vaccines
11258237|NCT02983994||Patients with asthma with an inhaled steroid|Patients with a diagnosis of asthma with indication of Treatment with an inhaled steroid (CI)
11258238|NCT02983994||Patients with asthma with an inhaled Beta agonist|Patients with a diagnosis of asthma with indication of Treatment with an inhaled Beta agonist (LABA)
11258239|NCT02983981|Experimental|open label|Topicort topical spray
11258240|NCT02983955|Other|SCI with Tetraplegia|
11258241|NCT02983942|Experimental|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
11258242|NCT02983942|Active Comparator|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
11258243|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
11258244|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
11258245|NCT02983916||Group 1: adhesiolysis|Group 1 (the operative group) consisted of all patients who underwent laparoscopy and/or laparotomy. Typically patients had positive cine-MRI. A few patients with inconclusive cine-MRI who underwent diagnostic laparoscopy are also included in this group. Patients with no adhesions found during operation remain in group 1, because analysis is performed on intention-to-treat basis.
11258246|NCT02983916||Group 2: Adhesions, conservative|Patients with evidence of adhesions based on cine-MRI who did not undergo laparoscopy or laparotomy.
11258247|NCT02983916||Group 3: No adhesions|Patients in whom no evidence of adhesions was found on cine-MRI, and who did not undergo laparoscopy or laparotomy .
11258248|NCT02983903|Experimental|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
11258249|NCT02983890|Active Comparator|Arm of study1|Dicloxacillin tablets.
11258250|NCT02983890|Placebo Comparator|Arm of study 2|No treatment
11258251|NCT02983877|Experimental|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.
~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
11258252|NCT02983864|Active Comparator|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
11258253|NCT02983864|Active Comparator|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
11258254|NCT02983851|Experimental|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
11258255|NCT02983851|Active Comparator|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
11258256|NCT02983838||depression with cognitive impairment|depression onset after 60 years old with subjective cognitive impairment
11258257|NCT02983838||depression without cognitive impairment|depression onset after 60 years old without subjective cognitive impairment
11258258|NCT02983838||normal control|older than 65 years, free from other neurocognitive disorder
11259568|NCT02974595||1|Participants age 0-99 will have a known autoinflammatory disease
11258260|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
11258261|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
11258262|NCT02983799|Experimental|gBRCAm;|germline BRCA mutant
11258263|NCT02983799|Experimental|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
11258264|NCT02983799|Experimental|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
11258265|NCT02983799|Experimental|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
11258266|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.
~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
11258267|NCT02983773|Experimental|High THC dose|1 marijuana cigarette (7.2% THC)
11258268|NCT02983773|Experimental|Low THC dose|1 marijuana cigarette (3.0% THC)
11258269|NCT02983773|Placebo Comparator|Placebo|Placebo marijuana cigarette
11258270|NCT02983760|Active Comparator|Planar V/Q-based strategy|Control arm
11258271|NCT02983760|Active Comparator|CTPA-based strategy|Control arm
11258272|NCT02983760|Experimental|V/Q SPECT-based strategy|Experimental arm
11258273|NCT02983747|Experimental|PRP Treatment(P)|PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
11258274|NCT02983747|Active Comparator|Medication Treatment(M)|NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
11258275|NCT02983734|Active Comparator|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
~DCS = d-cycloserine
~Dosage: 100mg
~Dosage form: Pill, administered orally
~Frequency: Daily for four weeks"
11258276|NCT02983734|Placebo Comparator|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
11258277|NCT02983721|Active Comparator|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
11258278|NCT02983721|Active Comparator|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
11258279|NCT02983708|Experimental|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
11258280|NCT02983708|Placebo Comparator|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
11258281|NCT02983695|Experimental|treatment|all participants will be in this arm and will receive study drug 'Cannabidiol-Rich whole Plant Extract (TIL-TC150) to assess dosing and tolerability according to study protocol
11258282|NCT02983682|Experimental|Lidocaine Infusion|All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
11258283|NCT02983669|Experimental|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
11258284|NCT02983669|Placebo Comparator|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
11258285|NCT02983617|Experimental|Tirabrutinib + Entospletinib|Participants will receive tirabrutinib and entospletinib for up to 104 weeks.
11258286|NCT02983617|Experimental|Tirabrutinib + Entospletinib + Obinutuzumab|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and entospletinib for up to 104 weeks.
11258287|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
11258288|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
11258289|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
11258293|NCT02983578|Experimental|Treatment (danvatirsen, durvalumab)|Patients receive danvatirsen IV over 1 hour on days 7, 5 and 3 prior to cycle 1, then on days 1, 8, 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11258294|NCT02983565|No Intervention|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
11258295|NCT02983565|Experimental|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
11258296|NCT02983552|Experimental|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
11258297|NCT02983552|Active Comparator|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
11258298|NCT02983513|Experimental|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.
~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
11258299|NCT02983513|No Intervention|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
11258300|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
11258301|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.
~Nasopharyngeal sampling:
~A nasopharyngeal sample collected from each nostril by aspiration or swabbing
~Blood sampling:
~A blood sample collected by fingerprick"
11258302|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis
~Blood sampling:
~A blood sample collected by fingerprick"
11258303|NCT02983461|Placebo Comparator|Placebo|Double Blind Placebo 3 times a day for 10 weeks.
11258304|NCT02983461|Active Comparator|Sildenafil|Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.
11258305|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.
~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
11258306|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.
~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
11258307|NCT02983435|Experimental|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
11258308|NCT02983435|Active Comparator|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
11258309|NCT02983422|Active Comparator|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
11258310|NCT02983422|Placebo Comparator|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
11258311|NCT02983409||Pstone|Adult Patients (> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
11258312|NCT02983396|Experimental|no transmural ischemia (NTI) and transmural ischemia (TI)|"Case cross-over from no transmural ischemia (NTI) to transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)
~Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia."
11258313|NCT02983383|Active Comparator|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
11258314|NCT02983383|Active Comparator|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
11258315|NCT02983370|Experimental|Blind volunteer|Blind volunteers will be implanted with our existing vision neuroprosthetic system, which utilizes a FDA cleared microelectrode array, using a minicraniotomy. The array will be implanted near the occipital pole or in extra striate areas. The investigators will collect descriptive feedback regarding thresholds, evoked perceptions and stimulation parameters leading to recognizable patterns.
11258377|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
11259569|NCT02974595||2|Unaffected relatives age 3-99 years
11258316|NCT02983357||Case Series Study|Subjects who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of Orthopaedic Surgery at University of Nebraska Medical Center / Nebraska Medicine and are now at least 9 years out from surgery.
11258317|NCT02983344|Active Comparator|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
11258318|NCT02983344|Active Comparator|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
11258319|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
11258320|NCT02983305|Experimental|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
11258321|NCT02983305|Experimental|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
11258322|NCT02983279|Experimental|Dietary counseling, caloric restriction diet|Patients then undergo 25% caloric intake for 3-12 weeks prior to definitive cancer surgery.
11258323|NCT02983266|Experimental|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
11258324|NCT02983266|Experimental|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
11258325|NCT02983266|Sham Comparator|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
11258326|NCT02983266|Experimental|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.
~Device: InTENsity MicroCombo"
11258327|NCT02983266|Experimental|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.
~Device: InTENsity MicroCombo"
11258328|NCT02983266|Placebo Comparator|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.
~Device: InTENsity MicroCombo"
11258329|NCT02983266|Experimental|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.
~Device: InTENsity MicroCombo"
11258330|NCT02983266|Experimental|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.
~Device: InTENsity MicroCombo"
11258331|NCT02983266|Experimental|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.
~Device: InTENsity MicroCombo"
11258332|NCT02983253||Patients with HHT|blood sample of patients with HHT
11258333|NCT02983253||probands|blood sample of healthy controls
11258334|NCT02983240|Experimental|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
11258335|NCT02983240|Experimental|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
11258336|NCT02983240|Experimental|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
11258337|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 1|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
11258338|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 2|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
11258339|NCT02983214|Active Comparator|Clopidogrel|Clopidogrel 75 mg/day
11258340|NCT02983214|Active Comparator|Clopidogrel plus cilostazol|Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day
11258378|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
11258379|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
11258341|NCT02983201|Active Comparator|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
11258342|NCT02983201|Experimental|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
11258343|NCT02983188|Active Comparator|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
11258344|NCT02983188|Placebo Comparator|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
11258345|NCT02983175|Experimental|ultrasound assessment of gastric content|
11258346|NCT02983149|Other|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
11258347|NCT02983149|Other|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
11258348|NCT02983149|Other|EZ blocker|One lung ventilation will be achieved using the EZ blocker
11258349|NCT02983136|Experimental|Study site|The study arm will consist of managers and staff at at the operating department of a University hospital in western Sweden' The intervention is based on partnership, dialogue and inter-professional learning
11258350|NCT02983136|No Intervention|Control site|The Control arm will consist of managers and staff at at the operating department of a University hospital in south Sweden
11258351|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
11258352|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
11258353|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
11258354|NCT02983110||Cohort E|Group E will be HIV infected men
11258355|NCT02983097|Experimental|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide
~Dosage:
~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.
~peripheral stem cell collection after cycle 1 or 2"
11258356|NCT02983084|Experimental|Multiforce|Variable modulus version of a current orthodontic archwire
11258357|NCT02983084|Active Comparator|CuNiTi A|".016 current orthodontic archwire"
11258358|NCT02983084|Active Comparator|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
11258359|NCT02983071|Experimental|Once-Daily G1T38 Dosing|G1T38 (lerociclib) orally (once daily) in combination with fulvestrant.
11258360|NCT02983071|Experimental|Twice-Daily G1T38 Dosing|G1T38 (lerociclib) orally (twice daily) in combination with fulvestrant.
11258361|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
11258362|NCT02983045|Experimental|Dose Escalation: Combination of NKTR-214 + nivolumab|NKTR-214 in escalating doses will be combined with one of the two proposed doses of nivolumab. The goal of this dose escalation Part 1 of the study is to find the RP2D.
11258363|NCT02983045|Experimental|Dose Expansion: Combination of NKTR-214 + nivolumab|"Combination of NKTR-214+nivolumab in combination with cytotoxic chemotherapies for the following 2 cohorts of the Part 2:
~NSCLC 1L nonsquamous plus platinum/pemetrexed NSCLC 1L squamous plus platinum/taxane"
11258364|NCT02983045|Experimental|Experimental: Combination of NKTR-214 + nivolumab + ipi|NKTR-214 will be combined with nivolumab and ipilimumab. The goal of this dose schedule finding part of the study is to define the RP2D and administration schedule.
11258365|NCT02983045|Experimental|Dose Expansion of the Part 3 RP2D|Experimental Combination of NKTR-214 + nivolumab + ipilimumab that may enroll between 12-26 patients per tumor type
11258366|NCT02983032|Experimental|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
11258367|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
11258368|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
11258369|NCT02983006|Experimental|DS-8273a & Nivolumab|Patient groups (cohorts) will receive a single dose level of DS 8273a & Nivolumab; DS 8273a will be increased in subsequent cohorts.
11258370|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
11258371|NCT02982980|Experimental|Physiotherapy Guidance Mastectomy|Patients who underwent radical breast surgery, received pre and postoperative assessment and orientation.
11258372|NCT02982980|Experimental|Phys Muscle strengthening Mastectomy|Patients who underwent radical breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
11258373|NCT02982980|Experimental|Physiotherapy Guidance Quadrantectomy|Patients who underwent partial breast surgery, received pre and postoperative assessment and orientation.
11258374|NCT02982980|Experimental|Phys Muscle strengthening Quadrantectomy|Patients who underwent partial breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
11258375|NCT02982967|Other|Physical Activity|Single-arm study with recreational physical activity intervention by 10 weeks (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
11258381|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
11258382|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
11258383|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
11258384|NCT02982902|Experimental|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
11258385|NCT02982889|Experimental|LIQ865A bupivacaine formulation|Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg
11258386|NCT02982889|Experimental|LIQ865B bupivacaine formulation|Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg
11258387|NCT02982889|Placebo Comparator|Diluent for LIQ865|Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf
11258388|NCT02982889|Active Comparator|0.5% bupivacaine hydrochoride|Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).
11258389|NCT02982876|No Intervention|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
11258390|NCT02982876|Active Comparator|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
11258391|NCT02982863||All Patients|
11258392|NCT02982850|Experimental|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
11258393|NCT02982850|Active Comparator|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
11258394|NCT02982837|Experimental|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
11258395|NCT02982837|Active Comparator|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
11258396|NCT02982824|Experimental|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.
11258397|NCT02982824|Placebo Comparator|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
11258398|NCT02982824|No Intervention|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
11258399|NCT02982811|No Intervention|Control group|Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
11258400|NCT02982811|Experimental|Experimental group|Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
11258401|NCT02982798|Experimental|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
11258402|NCT02982798|Experimental|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
11258403|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.
~Doses will be tailored and adjust as need it"
11258404|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.
~Standard Flavored gums will be used as needed for 10 weeks."
11258405|NCT02982759|Other|Comparison Arm|The comparison group will receive 2 generic newsletters
11258406|NCT02982759|Experimental|Intervention Arm|The intervention arm will receive the multi-level intervention.
11258407|NCT02982746|Experimental|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
11258408|NCT02982746|No Intervention|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
11258409|NCT02982733|Active Comparator|ABS|Ankaferd blood stopper
11258410|NCT02982733|Placebo Comparator|CS|Conventional sterile gauze
11258411|NCT02982733|Active Comparator|TR BAND|Dedicated hemostatic device
11258412|NCT02982720|Experimental|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
11258413|NCT02982707|Experimental|Mild Hepatic Subjects|Subjects are given a single dose of BMS-986177
11258414|NCT02982707|Experimental|Moderate Hepatic Subjects|Subjects are given a single dose of BMS-986177
11258415|NCT02982707|Experimental|Healthy Match Subjects|Subjects are given a single dose of BMS-986177
11258416|NCT02982694|Experimental|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be < 10 days.
11259570|NCT02974595||3|Healthy Volunteers age 18-99 years
11258417|NCT02982681|Experimental|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
11258418|NCT02982681|Active Comparator|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
11258419|NCT02982668|Active Comparator|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
11258420|NCT02982668|Experimental|Modified full enteral feeding|Consistent with full enteral feeding plan, preventively add erythromycin or mosapride everyday to improve gastrointestinal (GI) motility.
11258421|NCT02982668|Experimental|Permissive underfeeding|The caloric goal of the first day is one-third of caloric requirements, the second day is 40-60% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
11258422|NCT02982655|Experimental|Individualized BP lowering|Management policy is to lower the systolic or diastolic BP by 10-15% within 2 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
11258423|NCT02982655|Active Comparator|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP > 200 mmHg or diastolic BP >110 mmHg in patients with ischemic stroke, and systolic BP > 180 mmHg or diastolic BP > 110 mmHg in patients with cerebral hemorrhage.
11258424|NCT02982642|Experimental|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
11258425|NCT02982642|Placebo Comparator|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
11258426|NCT02982629|Placebo Comparator|Usual Care|Patients in this group do not receive any letters or phone calls after missing follow-up appointment.
11258427|NCT02982629|Active Comparator|Reminder Letter Intervention|Patients in this group receive letters and phone calls after missing follow-up appointment to reschedule the appointment.
11258428|NCT02982616|Experimental|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
11258429|NCT02982616|Experimental|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
11258430|NCT02982616|Experimental|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
11258431|NCT02982616|Placebo Comparator|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
11258432|NCT02982603|Experimental|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
11258433|NCT02982603|Active Comparator|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
11258434|NCT02982603|Placebo Comparator|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
11258435|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
11258436|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
11258437|NCT02982577|Experimental|Pilocarpine|Spray with Pilocarpine
11258438|NCT02982577|Placebo Comparator|Placebo|Spray without Pilocarpine
11258439|NCT02982564|Experimental|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
11258440|NCT02982564|Experimental|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
11258441|NCT02982551|Experimental|Hyperinsulinemic Clamp|Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
11258442|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
11258443|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
11258444|NCT02982525|Experimental|No Mussels|The control group will continue to consume their normal habitual diet
11258445|NCT02982525|Experimental|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
11258446|NCT02982525|Experimental|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
11258447|NCT02982525|Experimental|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
11258448|NCT02982512|No Intervention|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
11258450|NCT02982499||control group|Healthy participants will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
11258451|NCT02982499||optic neuropathy group|Participants with optic neuropathy will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
11258452|NCT02982486|Experimental|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
11258453|NCT02982460|Experimental|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
11258454|NCT02982460|Active Comparator|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
11258455|NCT02982447|Active Comparator|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
11258456|NCT02982447|Experimental|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
11258457|NCT02982434|Experimental|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
11258458|NCT02982434|Active Comparator|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
11258459|NCT02982421|Experimental|Research|Group Art Therapy
11258460|NCT02982421|Sham Comparator|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
11258461|NCT02982408|Experimental|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW<10th percentile)
11258462|NCT02982408|Experimental|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
11258463|NCT02982395|Experimental|Nanoxel®M|75 mg in 100mL normal saline
11258464|NCT02982395|Active Comparator|Mitomycin|40 mg in 100mL normal saline
11258465|NCT02982382|Experimental|Manipulative Treatment|Subjects will receive Manipulative Therapy
11258466|NCT02982382|Sham Comparator|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
11258467|NCT02982369|Experimental|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.
~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
11258468|NCT02982369|Sham Comparator|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
11258469|NCT02982356|Other|Fetal Selective Reduction Technology|Potassium chloride fetal heart injection in the dichorial twins with abnormal chromosome and structure
11258470|NCT02982356|No Intervention|control group|normal dichorial twins without any intervention
11258471|NCT02982343|Experimental|Falls management plus exercise training|Falls management and education session. Home proximal lower limb strength training and multi-sensory balance training.
11258472|NCT02982343|Active Comparator|Falls management only|Falls management and education session only.
11258473|NCT02982330|Experimental|Low Carbohydrate Breakfast|Breakfast composition containing <10% carbohydrate, 75% fat, 15% protein Matched calories
11258474|NCT02982330|Active Comparator|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
11258475|NCT02982317||Study group|All patients recruited will undergo the same protocol. An anesthesiologist will perform manual palpation of the patients lumbar spine and identification of the intervertebral spaces from L1-S1. A member of the UBC Department of Engineering will perform the US scanning and level identification using the novel US technology. In addition, freehand US will be used by two practitioners to determine the participant's lumbar level locations as per gold standard.
11258476|NCT02982304|Active Comparator|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
11258544|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
11258477|NCT02982304|Experimental|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
11258478|NCT02982304|Experimental|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
11258479|NCT02982291|Active Comparator|Standard|
11258480|NCT02982291|Experimental|Individualized|
11258481|NCT02982278|Experimental|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. Registered Nurse (RN) developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
11258482|NCT02982278|Experimental|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
11258483|NCT02982252|Experimental|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
11258484|NCT02982252|No Intervention|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
11258485|NCT02982252|Experimental|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
11258486|NCT02982252|No Intervention|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
11258487|NCT02982239|Other|Sleep Intervention|N=20 Participants received fitness tracker, information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks
11258488|NCT02982239|Other|Sleep Intervention plus Tech|N=20 Participants received fitness tracker, LED light, Blue-blocking glasses along with information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks.
11258489|NCT02982226|Experimental|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
11258490|NCT02982226|Active Comparator|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
11258491|NCT02982213|No Intervention|No companion present|No companion is present during the placement of the epidural catheter.
11258492|NCT02982213|Active Comparator|Companion present|A companion will be present during the placement of the epidural catheter.
11258493|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
11258494|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
11258495|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
11258496|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
11258497|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
11258498|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
11258499|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
11258500|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
11258501|NCT02982174|Experimental|Normal Eyes|Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
11258502|NCT02982161|Active Comparator|MR308 100 mg bid|Tramadol/Celecoxib 100 mg
11258503|NCT02982161|Active Comparator|MR308 150 mg bid|Tramadol/Celecoxib 150 mg
11258504|NCT02982161|Active Comparator|MR308 200 mg bid|Tramadol/Celecoxib 200 mg
11258505|NCT02982161|Active Comparator|Tramadol 100 mg qid|Tramadol IR 100 mg
11258506|NCT02982161|Placebo Comparator|Placebo|Placebo to match MR308 and Tramadol IR
11258507|NCT02982148|Experimental|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
11258545|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
11258508|NCT02982148|Active Comparator|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
11258509|NCT02982135|Other|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
11258510|NCT02982135|Other|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
11258511|NCT02982122|Experimental|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
11258512|NCT02982122|Active Comparator|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.
~CPPopt information is recorded but hidden for the treating clinicians."
11258513|NCT02982109||Postop pain level 1|Minor postoperative pain anticipated
11258514|NCT02982109||Postop pain level 2|Might experience postoperative pain
11258515|NCT02982109||Postop pain level 3|Moderate pain/substantial surgery performed
11258516|NCT02982109||Postop pain level 4|Severe postoperative pain expected/major surgery
11258517|NCT02982096|Active Comparator|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
11258518|NCT02982096|Other|Standard of Care|Standard of Care: Acellular wound management
11258519|NCT02982083|Active Comparator|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
11258520|NCT02982083|Placebo Comparator|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
11258521|NCT02982070|Experimental|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
11258522|NCT02982070|No Intervention|College as Usual|no training provided
11258523|NCT02982057|Active Comparator|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.
~Intervention:Device"
11258524|NCT02982057|Active Comparator|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.
~Intervention: medical treatment"
11258525|NCT02982044|Experimental|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
11258526|NCT02982031|Sham Comparator|shamrock|shamrock: both left and right sided scan,both intertransverse and transverse process window
11258527|NCT02982031|Active Comparator|paramedian transverse scan|paramedian transverse scan (PMTS): both left and right, both intertransverse and transverse process window
11258528|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
11258529|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
11258530|NCT02982005|Experimental|KHK4827|KHK4827 administered SC
11258531|NCT02982005|Placebo Comparator|Placebo|Placebo administered SC
11258532|NCT02981979|Active Comparator|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
11258533|NCT02981979|Placebo Comparator|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
11258534|NCT02981966|Active Comparator|Normal Glucose Tolerance (NGT)|Individuals with normal glucose tolerance - dapagliflozin vs placebo
11258535|NCT02981966|Active Comparator|T2DM individuals|Individuals with type 2 diabetes mellitus - dapagliflozin vs placebo
11258536|NCT02981953|Other|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
11258537|NCT02981940|Experimental|Abemaciclib with Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule
~Patients who require re-operation will receive a short preoperative course of Abemaciclib
~Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier.
~After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days."
11258538|NCT02981940|Experimental|Abemaciclib without Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule. Each Cycle last 28 days.
~NOTE: enrollment to this arm is complete"
11258539|NCT02981927|No Intervention|Control|24 h habitual physical activity fed in energy balance
11258540|NCT02981927|Experimental|Bed rest matched diet|24 hour period of whole body bed-rest with a matched diet
11258541|NCT02981927|Experimental|Bed rest balanced diet|24 hour period of whole body bed-rest fed in energy balance
11258542|NCT02981914|Experimental|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
11258550|NCT02981836|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated varicella vaccine;"
11258551|NCT02981836|Sham Comparator|Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;
~Intervention: diluent of lyophilized vaccine;"
11258552|NCT02981823|Experimental|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
11258553|NCT02981810|Active Comparator|control|tonsillectomy
11258554|NCT02981810|Experimental|coblation|coblation of the tonsills
11258555|NCT02981797||Radium 223 Standard of Care|Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
11258556|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
11258557|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
11258558|NCT02981771|Experimental|experiment|A physical activity program that is based on balance and coordination exercises
11258559|NCT02981771|Placebo Comparator|control|A physical activity program that is based on strength exercises
11258560|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
11258561|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
11258562|NCT02981745|Experimental|CT-1530|
11258563|NCT02981732|Experimental|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
11258564|NCT02981732|No Intervention|the control group|the control group,there is no intervention
11258565|NCT02981719|Experimental|IRE+chemo|irreversible electroporation with chemotherapy：Gemcitabine in pancreatic cancer
11258566|NCT02981706|Active Comparator|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
11258567|NCT02981706|Active Comparator|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
11258568|NCT02981693|Experimental|iRoot SP sealer|iRoot SP sealer was used as root canal sealer in root canal obturation.
11258569|NCT02981693|Active Comparator|AH Plus sealer|AH Plus sealer was used as a gold standard to be compared with iRoot SP sealer in root canal obturation.
11258570|NCT02981680|Experimental|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
11258571|NCT02981680|Sham Comparator|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
11258572|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
11258573|NCT02981654|Experimental|Femilift treatment|"The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.
~Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length."
11258574|NCT02981641|Experimental|Intraoperative radiotherapy (IORT) Group|Radiotherapy (Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1) + Sequential chemotherapy
11258575|NCT02981641|Experimental|Concurrent Chemoradiotherapy (CCRT) Group|Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
11258576|NCT02981628|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11258577|NCT02981615|Experimental|treatment arm|Subjects allocated to the treatment arm of the study will be administrated Levofloxacin 500mg/d given p.o. once a day, starting on day 10 from beginning of each cycle until day 28 on an ambulatory basis. Levofloxacin will be continued in the first 4 Azacytidine cycles.
11258578|NCT02981615|Placebo Comparator|placebo|Subject allocated to the placebo arm will be treated with placebo once a day, starting on day 10 from beginning until day 28 of each of the first 4 cycles.
11258579|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
11258580|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
11258581|NCT02981576|Active Comparator|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
11258582|NCT02981576|Active Comparator|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
11258583|NCT02981563|Experimental|Time Together|"Time Together as described under Interventions"
11258584|NCT02981537|Experimental|two-staged|positioning endobronchial blockers to appropriate bronchus with two-staged methods
11258585|NCT02981537|Active Comparator|single-staged|positioning endobronchial blockers with traditional single-staged methods
11258586|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
11258587|NCT02981498|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
11258588|NCT02981485|Experimental|Experimental|Treatment of breast cancer related lymphedema by fat grafting
11258589|NCT02981472|Experimental|Apixaban|
11258590|NCT02981472|Active Comparator|LMWH/VKA|
11258591|NCT02981459|Experimental|Mirabegron 25 mg or 50 mg|
11258592|NCT02981446|Experimental|DE-117 ophthalmic solution|
11258593|NCT02981446|Active Comparator|Latanoprost ophthalmic solution 0.005%|
11258594|NCT02981420|No Intervention|Pre-intervention|Pre-intervention baseline comparison
11258595|NCT02981420|Experimental|Safety Planning|Intervention group
11258596|NCT02981420|No Intervention|Regression discontinuity|Subthreshold no intervention
11258597|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
11258598|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
11258599|NCT02981394||BMAC Group|Intervention Group
11258600|NCT02981381|Experimental|Active sTMS (NEST-1)|"Subjects randomized to this group will receive 20 active synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 active sTMS sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place on the last day of active sTMS.
~Participants that elect to participate in the open-label continuation phase, will receive an additional 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.
~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
11258601|NCT02981381|Sham Comparator|Sham sTMS (SHAM)|"Subjects randomized to this group will receive 20 sham synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 sham sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place immediately after the final sham session.
~Participants that elect to participate in the open-label continuation phase, will receive 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.
~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
11258602|NCT02981368|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
11258603|NCT02981355|Active Comparator|Microfracture treatment|Microfracture surgery of the femoral condyle
11258604|NCT02981355|Experimental|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
11258605|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
11258606|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
11258607|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
11258608|NCT02981329|Experimental|Group A: Hydroxyurea + Metformin|Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.
11258609|NCT02981329|Experimental|Group B: Metformin (Group B has closed to enrollment)|Subjects who are not taking Hydroxyurea as part of standard of care and have sickle cell anemia.
11258610|NCT02981316|Active Comparator|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
11258611|NCT02981316|Active Comparator|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
11258612|NCT02981316|Active Comparator|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
11258613|NCT02981316|Active Comparator|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
11258614|NCT02981303|Experimental|Melanoma|Imprime PGG + Pembrolizumab
11258615|NCT02981303|Experimental|Triple Negative Breast Cancer|Imprime PGG + Pembrolizumab
11258616|NCT02981290|Experimental|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
11258617|NCT02981290|Experimental|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
11258618|NCT02981290|Experimental|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
11258655|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:
~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
11259571|NCT02974582|Experimental|1/Part 1|60 Participants of high and low SES
11258619|NCT02981290|Experimental|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
11258620|NCT02981277|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
11258621|NCT02981277|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
11258622|NCT02981264|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
11258623|NCT02981264|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
11258624|NCT02981251|Experimental|Intervention|Health education with support by trained female health volunteer
11258625|NCT02981251|No Intervention|Control|Extra intervention will not be provided except usual care by their physician of the participant.
11258626|NCT02981212|Experimental|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
11258627|NCT02981212|Active Comparator|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
11258628|NCT02981199|Active Comparator|Micro-SCT|"patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.
~microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles"
11258629|NCT02981199|Active Comparator|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.
11258630|NCT02981186|Experimental|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
11258631|NCT02981186|Active Comparator|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
11258632|NCT02981173|Active Comparator|Psilocybin High Dose|
11258633|NCT02981173|Active Comparator|Psilocybin Low Dose|
11258634|NCT02981173|Placebo Comparator|Placebo|
11258635|NCT02981160|No Intervention|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
11258636|NCT02981160|Experimental|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
11258637|NCT02981147|Experimental|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
11258638|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
11258639|NCT02981121|No Intervention|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
11258640|NCT02981121|Experimental|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).
~Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)
~Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
11258641|NCT02981121|Active Comparator|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
11258642|NCT02981108|Experimental|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
11258643|NCT02981108|Experimental|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
11258644|NCT02981108|Experimental|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
11258645|NCT02981108|Experimental|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
11258646|NCT02981108|Experimental|Escalation Cohort 5|Oral Once-Daily Administration of HS-10296(MTD)
11258647|NCT02981108|Experimental|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 220mg
11258648|NCT02981108|Experimental|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 260mg
11258649|NCT02981108|Experimental|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
11258650|NCT02981108|Experimental|Phase 2 Expansion|Oral Once-Daily Administration of HS-10296 (MTD or RP2D)
11258651|NCT02981095|Active Comparator|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
11258652|NCT02981095|Placebo Comparator|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
11258653|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
11258656|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
11258657|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:
~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS
~Dapagliflozin:
~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
11258658|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
11258659|NCT02981056|Active Comparator|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).
~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
11258660|NCT02981056|Active Comparator|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).
~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
11258661|NCT02981056|Active Comparator|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
11258662|NCT02981030|Experimental|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
11258663|NCT02981017|No Intervention|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
11258664|NCT02981017|Experimental|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
11258665|NCT02980991|Experimental|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
11258666|NCT02980978|Experimental|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
11258667|NCT02980978|No Intervention|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
11258668|NCT02980965|Experimental|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
11258669|NCT02980965|Active Comparator|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
11258670|NCT02980952|Placebo Comparator|Energy-balanced diet|Forearm immobilization whilst consuming an energy-balanced diet
11258671|NCT02980952|Experimental|High-fat overfeeding|Forearm immobilization whilst consuming a high-fat diet, 50% energy excess
11258672|NCT02980939|Placebo Comparator|Euhydration - no thirst|
11258673|NCT02980939|Experimental|Dehydration - no Thirst|
11258674|NCT02980926|Experimental|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
11258675|NCT02980926|Active Comparator|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
11258676|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
11258677|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
11258678|NCT02980900|Placebo Comparator|Placebo supplement|Post exercise placebo supplement Pre bed placebo supplement
11258679|NCT02980900|Active Comparator|Post exercise supplement|Post exercise protein-polyphenol supplement Pre bed placebo supplement
11258680|NCT02980900|Active Comparator|Pre bed supplement|Post exercise placebo supplement Pre bed protein-polyphenol supplement
11258681|NCT02980900|Active Comparator|Post exercise + pre bed supplement|Post exercise protein-polyphenol supplement Pre bed protein-polyphenol supplement
11258682|NCT02980887||Controls|Healthy controls No intervention as this is an observational study
11258683|NCT02980887||Pulmonary Vascular Disease|Pulmonary Vascular Disease at risk for pulmonary hypertension
11258684|NCT02980887||Pulmonary Hypertension|Those meeting WSPH/WHO group classifications 1-5 of pulmonary hypertension
11258685|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
11258686|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
11258687|NCT02980861|Experimental|Laparoscopic total gastrectomy|Participants including in the laparoscopic total gastrectomy (LTG) group will undergo LTG with spleen-preserving splenic hilum lymph nodes dissection.
11258688|NCT02980861|Active Comparator|Open total gastrectomy|Participants who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
11258689|NCT02980848||Screening group|Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
11258781|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
11258690|NCT02980848||Women with breast cancer|Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
11258691|NCT02980835|Experimental|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
11258692|NCT02980835|Active Comparator|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
11258693|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register
~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register
~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
11258694|NCT02980809|Experimental|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
11258695|NCT02980809|Placebo Comparator|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
11258696|NCT02980796|Experimental|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
11258697|NCT02980796|Active Comparator|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
11258698|NCT02980783|Experimental|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
11258699|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
11258700|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
11258701|NCT02980770||Normal Blood Gases|Normal Blood Gases
11258702|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
11258703|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
11258704|NCT02980757|Active Comparator|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
11258705|NCT02980744|Experimental|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
11258706|NCT02980731|Experimental|Venetoclax|Venetoclax will be administered orally 20 mg once daily (QD) beginning with a dose-titration phase, and then escalated up to 400 mg QD.
11258707|NCT02980718|Experimental|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
11258708|NCT02980718|Experimental|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
11258709|NCT02980718|No Intervention|controls|20 participants represent a control group with no olfactory training
11258710|NCT02980705|Experimental|SUNPG1622 I|SUNPG1622 I dose
11258711|NCT02980705|Placebo Comparator|Placebo|Placebo dose
11258712|NCT02980692|Experimental|SUNPG1623 I|Short-term dose
11258713|NCT02980692|Experimental|SUNPG1623 II|Mid-term dose
11258714|NCT02980692|Experimental|SUNPG1623 dose III|Mid-term dose
11258715|NCT02980692|Experimental|SUNPG1623 dose IV|Mid to long-term dose
11258716|NCT02980692|Placebo Comparator|Placebo|Mid to long-term dose
11258717|NCT02980679|Experimental|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
11258718|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
11258719|NCT02980653|Experimental|Megestrol|Single arm
11258720|NCT02980627|Experimental|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
11258721|NCT02980614|Experimental|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:
~4D MR sequence in cine mode 4D velocity mapping sequence"
11258722|NCT02980601|Experimental|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
11258723|NCT02980601|Active Comparator|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
11258724|NCT02980588|Other|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
11258725|NCT02980575|Experimental|Exercise with music|Participants will listen to music when they exercise
11258726|NCT02980575|Active Comparator|Exercise|Participants will not listen to music when they exercise
11258727|NCT02980562|Active Comparator|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
11258728|NCT02980562|Active Comparator|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
11258729|NCT02980523|Experimental|PRO-157 BID (2 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days
~instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
11258730|NCT02980523|Experimental|PRO-157 TID (3 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
11258731|NCT02980523|Experimental|PRO-157 QID (4 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
11258732|NCT02980523|Active Comparator|Moxifloxacin (Vigamox®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
11258733|NCT02980523|Active Comparator|Gatifloxacin (Zymar®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:
~instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.
~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
11258734|NCT02980510|Experimental|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² given as a 2-hour intravenous (IV) infusion with the addition, after 30 minutes of irinotecan 150 mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400 mg/m² IV bolus then 5-fluoruracil (5-FU) 2400 mg/m² over 46 hours continuous infusion.
11258735|NCT02980510|Active Comparator|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² IV infusion over 2 hours followed by fluorouracil 400 mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
11258736|NCT02980497|Active Comparator|Listerine Zero Mouthwash (without alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Zero Mouthwash (without alcohol) for 30 seconds.
11258737|NCT02980497|Active Comparator|Listerine Antiseptic Mouthwash (with alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Antiseptic Mouthwash (with alcohol) for 30 seconds.
11258738|NCT02980497|No Intervention|Brush only|Brush only twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush.
11258739|NCT02980484|Experimental|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
11258740|NCT02980484|Sham Comparator|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
11258741|NCT02980458|Experimental|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
11258742|NCT02980458|Active Comparator|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
11258743|NCT02980445|No Intervention|Control|
11258744|NCT02980445|Experimental|Outdoor Activity 1|40min outdoor time in total.
11258745|NCT02980445|Experimental|Outdoor Activity 2|80min outdoor time in total
11258746|NCT02980432|Experimental|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
11258747|NCT02980419|Experimental|intervention arm|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
11258842|NCT02979834||Late perception group|The group which late perception of fetal movement (>75 percentile)
11258844|NCT02979808|Experimental|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
11258748|NCT02980406|Active Comparator|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
11258749|NCT02980406|Active Comparator|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
11258750|NCT02980406|Active Comparator|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
11258751|NCT02980406|Placebo Comparator|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
11258752|NCT02980393|Experimental|Lifestyle intervention|Participants are guided by a fitness specialist who will help the participants to incorporate physical activity into their daily life. Based on the cardiologist assessment, an individual home-based exercise program will be developed. Participants are also guided and advised on nutrition with emphasis on low fat content and increased fiber. The nutrition counseling will focus on sustainable changes and will help participants to make healthy food choices.
11258753|NCT02980380||Locked-in and complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state as well as in transition from locked-in to complete locked-in state who have no means of communication.
11258754|NCT02980367|Experimental|ACL Rehabilitation Group|Non-surgical management [Rehabilitation] with option for later Anterior Cruciate Ligament (ACL) reconstruction, only if required.
11258755|NCT02980367|Active Comparator|ACL Reconstruction Group|Surgical Management - Anterior Cruciate Ligament (ACL) reconstruction surgery
11258756|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
11258757|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
11258758|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
11258759|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
11258760|NCT02980341|Experimental|Dose Escalation Part|Participants receive U3-1402 from 1.6 mg/kg to 9.6 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
11258761|NCT02980341|Experimental|Dose Finding Part|Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
11258762|NCT02980341|Experimental|Dose Expansion Part|Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.
11258763|NCT02980328|Experimental|LLLT group|Low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each
11258764|NCT02980328|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
11258765|NCT02980315|Experimental|CAR-T cells|the group treat with CAR-T cells
11258766|NCT02980315|No Intervention|placebo|the group treat with CAR-T cells
11258767|NCT02980302|Other|Patient|
11258768|NCT02980302|Other|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
11258769|NCT02980302|Other|Two control patients|
11258770|NCT02980289||Patients|Patients over 18 years old with advanced cancer defined as metastatic disease, no curable treatment options. The patients may not have received chemotherapy or irradiation within 4 weeks, no operations within 2 weeks and no general anesthesia within 4 days.
11258771|NCT02980276|Active Comparator|Treatment|Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
11258772|NCT02980276|Placebo Comparator|Control|Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
11258773|NCT02980263|Experimental|Kawasaki patients|
11258774|NCT02980250|Experimental|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
11258775|NCT02980250|Experimental|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
11258776|NCT02980250|Experimental|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
11258777|NCT02980250|Placebo Comparator|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
11258778|NCT02980237|Experimental|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. The course could be access in the workplace but they will be additional support.
11258779|NCT02980237|Active Comparator|eHealth|This group will receive an e-learning education program same as the intervention group . However, the participants will not receive additional support by team.
11258780|NCT02980224|Experimental|OmegaD|OmegaD Softgels
11258782|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
11258783|NCT02980198|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
11258784|NCT02980198|Placebo Comparator|Placebo|Placebo + ISA 51
11258785|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
11258786|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
11258787|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
11258788|NCT02980159||Before triage liaison physician|All patients admitted before the introduction of the function of triage liaison physician.
11258789|NCT02980159||After triage liaison physician|All patients admitted after the introduction of the function of triage liaison physician.
11258790|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
11258791|NCT02980133|Placebo Comparator|Placebo MDPI|Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
11258792|NCT02980133|Experimental|Fp MDPI 25 mcg BID|Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
11258793|NCT02980133|Experimental|Fp MDPI 50 mcg BID|Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
11258794|NCT02980133|Experimental|FS MDPI 50/12.5 mcg BID|Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
11258795|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off <17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
11258796|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range <17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
11258797|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
11258798|NCT02980107|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
11258799|NCT02980107|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
11258800|NCT02980094|Placebo Comparator|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
11258801|NCT02980094|Experimental|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
11258802|NCT02980094|Experimental|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
11258803|NCT02980094|Experimental|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
11258804|NCT02980081||Plain abdominal x-ray|All patients admitted to 2 EDs and with a prescription of an abdominal plain x-ray.
11258805|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
11258806|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
11258807|NCT02980055|Experimental|Test: collagen matrix|Root coverage using collagen matrix
11258808|NCT02980055|Active Comparator|Control: connective tissue graft|Root coverage using connective tissue graft
11258809|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
11258810|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
11258811|NCT02980029|Experimental|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme.
11258812|NCT02980029|Placebo Comparator|Placebo|Placebo
11258813|NCT02980016|Active Comparator|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
11258814|NCT02980016|Active Comparator|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
11258815|NCT02980016|Active Comparator|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
11258843|NCT02979821|Experimental|Poziotinib|The study drug(poziotinib) will be administered orally as one 12 mg tablet once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug 12 mg daily can be reduced to 8 mg once daily according to dose reduction criteria.
11258816|NCT02980003|Active Comparator|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
11258817|NCT02980003|Active Comparator|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
11258818|NCT02980003|Experimental|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.
~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
11258819|NCT02979990|Placebo Comparator|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
11258820|NCT02979990|Experimental|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
11258821|NCT02979977|Experimental|All subjects|Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 30 mg per day and weekly/bi-weekly intravenous cetuximab.
11258822|NCT02979964|Experimental|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
11258823|NCT02979964|Experimental|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
11258824|NCT02979964|Experimental|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
11258825|NCT02979964|Experimental|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
11258826|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
11258827|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
11258828|NCT02979912|Experimental|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
11258829|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
11258830|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
11258831|NCT02979886|Experimental|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150~300 IU. An appropriate dose of HMG (75~150 IU) will be added when follicles are larger than 12~14mm in diameter. When one leading follicle is >18mm in diameter, or two follicles are >17mm in diameter, or three follicles are >16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
11258832|NCT02979873|Experimental|Sirolimus|sirolimus
11258833|NCT02979873|No Intervention|Standard of Care|No intervention
11258834|NCT02979860|No Intervention|Typical sleep schedule|"Children in this arm will be asked to maintain their current sleep schedule. No prescription will be provided other than to sleep how they typically would sleep."
11258835|NCT02979860|Experimental|Enhance time in bed by 90 min/night|Sleep duration - 90 minutes: Children in this arm will be asked to get into bed and to turn their lights out 90 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
11258836|NCT02979860|Experimental|Enhance time in bed by 45 min/night|Sleep duration - 45 minutes:Children in this arm will be asked to get into bed and to turn their lights out 45 minutes earlier than their typical bedtime. Bedtimes and wake times will remain consistent across the 4-week experimental phase of the study.
11258837|NCT02979860|Experimental|Regularize sleep schedule|Sleep timing: Children in this arm will be asked to get into bed at a consistent bedtime each night and wake at a consistent time each morning such that time in bed achieved during baseline is maintained during the 4-week experimental phase; only timing of bedtimes/wake times will be manipulated in this arm.
11258838|NCT02979847|Experimental|Treated|hybrid approach (epicardial and subsequent endocardial mappings and ablations)
11258839|NCT02979847|Active Comparator|Control|conventional endocardial approach
11258840|NCT02979834||Early perception group|The group with early perception of fetal movement (<25th percentile)
11258841|NCT02979834||Average perception group|The group with average perception of fetal movement (>25th and <75th percentile)
11258845|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
11258847|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
11258848|NCT02979769|Experimental|Palovarotene dose level 1|Adult Cohort subjects (those with at least 90% skeletal maturity) will receive 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups.
11258849|NCT02979769|Experimental|Palovarotene dose level 2|During an eligible flare-up, Pediatric Cohort subjects (those with less than 90% skeletal maturity) will receive weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days.
11258850|NCT02979756|Experimental|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
11258851|NCT02979756|No Intervention|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
11258852|NCT02979743|Placebo Comparator|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
11258853|NCT02979743|Active Comparator|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
11258854|NCT02979730|Active Comparator|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
11258855|NCT02979730|Experimental|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
11258856|NCT02979717|Experimental|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
11258857|NCT02979717|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
11258858|NCT02979704|Active Comparator|Rosuvastatin|Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.
11258859|NCT02979704|Active Comparator|Atorvastatin|Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
11258860|NCT02979691|Active Comparator|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
11258861|NCT02979691|Experimental|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
11258862|NCT02979678|Experimental|Questionnaire|Breast cancer
11258863|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
11258864|NCT02979665||Control|DME consults not requiring anti-VEGF
11258865|NCT02979639|Experimental|GSK1437173A Group|Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
11258866|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:
~Fever >39
~Lower respiratory tract infection
~Acute otitis media
~Serious extra-pulmonary manifestations (myositis, encephalitis)"
11258867|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
11258868|NCT02979613|Experimental|TAF 25 mg|Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
11258869|NCT02979613|Active Comparator|TDF 300 mg|DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
11258870|NCT02979587|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
11258871|NCT02979574|Active Comparator|Electro-Acupuncture (EA) Procedure|Participants will receive 10 treatment of EA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
11258872|NCT02979574|Active Comparator|Battle Field Acupuncture (BFA) Procedure|Participants will receive 10 treatment of BFA acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week).
11258873|NCT02979574|Active Comparator|Wait List Control (WLC) Usual Care Procedure|Subjects in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers, including analgesic medications. After the 12 week follow up period, patients in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
11258874|NCT02979561|Experimental|group of dabigatran|
11258875|NCT02979561|Active Comparator|group of warfarin|
11258876|NCT02979548|Experimental|Group A : Aprepitant (Add on therapy)|Aprepitant group will receive aprepitant capsules 1 h prior to chemotherapy on days 1-3 in addition to 5HT3 RA (Ondansetron). The dose of aprepitant will be given based on weight groups Weight 15-40 kg : Aprepitant 80 mg on days 1-3 Weight > 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
11258877|NCT02979548|Active Comparator|Group B : 5HT3 RA (Ondansetron)|"On the day of chemotherapy, ondansetron will be administered to all patients as per our institutional practice in a dose of 0.15 mg/kg as an intravenous bolus 30 minutes before chemotherapy followed by every 8 hourly for 8 days.
~Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day."
11258878|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
11258879|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
11258880|NCT02979522|Experimental|Brentuximab vedotin 48 mg/m^2|Brentuximab vedotin 48 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and Dacarbazine 375 mg/m^2, intravenous infusion, once on Day 1 and 15 of each 28-day cycle for up to 6 cycles. If the first 6 participants complete the dose limiting toxicity (DLT) observation period with 0 or 1 participant experiencing a DLT, 48 mg/m^2 will be established as the recommended dose for phase 2 study. If at any time more than 1 participant out of a maximum 6 DLT-evaluable participants experiences a DLT, brentuximab vedotin dose will be reduced to 36 mg/m^2. If 0 or 1 participant experiences a DLT among the 6 participants treated at 36 mg/m^2, 36 mg/m^2 will be established as recommended dose for phase 2 study. If more than 1 participant experiences a DLT in the first 6 participants treated at 36 mg/m^2, the study will be discontinued.
11258881|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
11258882|NCT02979496|Other|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
11258883|NCT02979496|Experimental|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
11258884|NCT02979496|Experimental|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
11258885|NCT02979496|Other|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
11258886|NCT02979483|Other|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
11258887|NCT02979457|No Intervention|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
11258888|NCT02979457|Experimental|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
11258889|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
11258890|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
11258891|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
11258892|NCT02979431|Experimental|ALX-0171 3.0 mg/kg|Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
11258893|NCT02979431|Experimental|ALX-0171 6.0 mg/kg|Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
11258894|NCT02979431|Experimental|ALX-0171 Dose 9.0mg/kg|Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
11258895|NCT02979431|Placebo Comparator|Placebo|Inhalation of Placebo once daily for 3 consecutive days
11258896|NCT02979405|Experimental|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
11258897|NCT02979405|Placebo Comparator|group 2|Saline solution 21 cc, infusion during 5 minutes
11258898|NCT02979392|Experimental|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
11258899|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
11258900|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
11258901|NCT02979366|Experimental|S64315 (also referred as MIK665) administered once a week|
11258902|NCT02979366|Experimental|S64315 (also referred as MIK665) administered twice a week|
11258903|NCT02979353|Experimental|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
11258904|NCT02979353|No Intervention|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
11258905|NCT02979327|Experimental|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
11258906|NCT02979327|Experimental|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
11258937|NCT02979119||Cohort II|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2009 until January 1st 2020 who have been or are to be treated with coagulation proteins in one of the participating centres
11258907|NCT02979314|Experimental|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
11258908|NCT02979301|Experimental|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
11258909|NCT02979301|Experimental|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
11258910|NCT02979288|Experimental|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
11258911|NCT02979288|Active Comparator|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
11258912|NCT02979288|Experimental|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
11258913|NCT02979288|Active Comparator|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
11258914|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
11258915|NCT02979262|Experimental|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
11258916|NCT02979262|Active Comparator|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
11258917|NCT02979249|Experimental|Oral Iron|standard dose of iron pills
11258918|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
11258919|NCT02979223|Experimental|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
11258920|NCT02979223|Active Comparator|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
11258921|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
11258922|NCT02979197|Experimental|Amlodipine+Celecoxib|OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
11258923|NCT02979197|Active Comparator|Amlodipine+Placebo|OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
11258924|NCT02979197|Sham Comparator|Placebo+Placebo|Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
11258925|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
11258926|NCT02979171|Active Comparator|LMA-Classic|airway management with LMA-Classic
11258927|NCT02979171|Active Comparator|LMA-Flexible|airway management with LMA-Flexible
11258928|NCT02979171|Active Comparator|LMA-Proseal|airway management with LMA-Proseal
11258929|NCT02979158|Experimental|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
11258930|NCT02979158|Experimental|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
11258931|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
11258932|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
11258933|NCT02979132|Active Comparator|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
11258934|NCT02979132|Active Comparator|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
11258935|NCT02979132|Active Comparator|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
11258936|NCT02979119||Cohort I|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2000 until January 1st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
11258938|NCT02979119||Cohort III|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2020 until January 1st 2030 who have been or are to be treated with coagulation proteins in one of the participating centres
11258939|NCT02979106|Experimental|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
11258940|NCT02979093|Other|Addicted|The addiction group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
11258941|NCT02979093|Other|Control|The control group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
11258942|NCT02979080|Experimental|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
11258943|NCT02979067|Active Comparator|High-flow 100% oxygen|Nasal oxygen flow
11258944|NCT02979067|Active Comparator|Low-flow 100% oxygen|Nasal oxygen flow
11258945|NCT02979067|Active Comparator|High-flow 30% oxygen|Nasal oxygen flow
11258946|NCT02979054|Experimental|T4020|1 drop every other day during 5 days
11258947|NCT02979054|Placebo Comparator|Saline solution|1 drop every other day during 5 days
11258948|NCT02979041|Active Comparator|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
11258949|NCT02979041|Experimental|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
11258950|NCT02979028|Experimental|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
11258951|NCT02979028|Sham Comparator|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
11258952|NCT02979028|Placebo Comparator|Control group|Control patients will receive the same treatment without electrical stimulation.
11258953|NCT02979015|Experimental|Alirocumab|Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
11258954|NCT02979015|Placebo Comparator|Placebo|Subcutaneous injection of a single dose of matching placebo
11258955|NCT02978989|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC.
11258956|NCT02978989|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
11258957|NCT02978976|Experimental|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
11258958|NCT02978976|Placebo Comparator|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
11258959|NCT02978963|Experimental|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
11258960|NCT02978950|Experimental|Surveillance arm|Bilateral duplex ultrasound surveillance
11258961|NCT02978950|Active Comparator|No surveillance arm|no duplex ultrasound surveillance
11258962|NCT02978937||Metabolically healthy and abnormal obese|Obese patients divided into two groups according to their metabolic profile (healthy vs unhealthy)
11258963|NCT02978924|Active Comparator|Cathodal tsDCS|20 min of active treatment
11258964|NCT02978924|Sham Comparator|Sham tsDCS|20 min of sham treatment
11258965|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
11258966|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :
~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
11258967|NCT02978898||PB peripheral blood|"Samples obtained from patients with :
~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
11258968|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
11258969|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
11258970|NCT02978859|Experimental|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
11259010|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
11258971|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
11258972|NCT02978833|Experimental|PRP|
11258973|NCT02978833|Active Comparator|Whole Blood|
11258974|NCT02978820|Experimental|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
11258975|NCT02978820|Experimental|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
11258976|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.
~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
11258977|NCT02978781|Experimental|SAGE-217 dosing|SAGE-217
11258978|NCT02978781|Placebo Comparator|Placebo|Placebo
11258979|NCT02978768|Experimental|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
11258980|NCT02978768|Experimental|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
11258981|NCT02978768|Experimental|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
11258982|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
11258983|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
11258984|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
11258985|NCT02978742|Experimental|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
11258986|NCT02978742|Active Comparator|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
11258987|NCT02978729|Active Comparator|Telephone|Telephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
11258988|NCT02978729|Experimental|Videoconference|Two-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
11258989|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin|GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
11258990|NCT02978716|Experimental|Group 2: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV prior to GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
11258991|NCT02978716|Experimental|Group 3: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV on Days 1, 2, 8 and 9. GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 2 and 9 in 21-day cycles.
11258992|NCT02978690|Experimental|BI655130|
11258993|NCT02978677|Experimental|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
11258994|NCT02978677|Experimental|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
11258995|NCT02978677|Active Comparator|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
11258996|NCT02978664|Active Comparator|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
11258997|NCT02978664|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
11258998|NCT02978664|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
11258999|NCT02978651|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
11259000|NCT02978651|Placebo Comparator|Placebo|Placebo
11259001|NCT02978638|Other|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
11259002|NCT02978625|Experimental|Treatment (talimogene laherparepvec, nivolumab)|Patients receive talimogene laherparepvec IT on day 1. Patients without response at week 12 may also receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11259003|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
11259004|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
11259005|NCT02978599|Experimental|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
11259006|NCT02978599|Experimental|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
11259007|NCT02978599|Placebo Comparator|Placebo|Placebo daily for 5 days
11259008|NCT02978586|Experimental|[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of [Ga-68]PSMA tumor uptake
11259009|NCT02978573|Experimental|Cartiva|Cartiva Synthetic Cartilage Implant
11259011|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
11259012|NCT02978547|Experimental|Metformin|All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.
11259013|NCT02978534||Quetiapine|Patients taking quetiapine during pregnancy are eligible to participate in the study. Their dose and plasma concentration levels of quetiapine will be monitored throughout pregnancy and up to three months postpartum.
11259014|NCT02978521|Experimental|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:
~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
11259015|NCT02978521|No Intervention|Control Group|CG will receive information and recommendations on physical activity
11259016|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
11259017|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
11259018|NCT02978495|Experimental|A- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
11259019|NCT02978495|Active Comparator|B- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
11259020|NCT02978495|Experimental|C- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
11259021|NCT02978495|Active Comparator|D- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
11259022|NCT02978482|Experimental|durvalumab|durvalumab alone
11259023|NCT02978482|Experimental|durvalumab+tremelimumab|durvalumab plus tremelimumab
11259024|NCT02978469|Experimental|Life style changing: reducing sedentary behavior|Meetings with social worker and physical therapist.
11259025|NCT02978469|Active Comparator|Physical exercise group|Physical therapy exercise training in group, strengthening and stretching muscles.
11259026|NCT02978456|Experimental|quantitative coronary angiography guided|
11259027|NCT02978456|Active Comparator|Intravascular ultrasound guided|
11259028|NCT02978443|Experimental|Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
11259029|NCT02978430|Active Comparator|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
11259030|NCT02978430|Active Comparator|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.
~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
11259031|NCT02978417|Active Comparator|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
11259032|NCT02978417|Active Comparator|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
11259033|NCT02978404|Experimental|Radiosurgery and Nivolumab|"Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)
~Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter."
11259034|NCT02978391|Experimental|EWD|Adhesive, synthetic biopolymer powder
11259035|NCT02978391|Active Comparator|epinephrine|Submucosal epinephrine injection
11259074|NCT02978079|Experimental|Pupillometry in stroke patients|All eligible patients will undergo pupillometry test for the finding of Horner's syndrome
11259036|NCT02978365|Experimental|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
11259037|NCT02978352|Experimental|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
11259038|NCT02978352|Experimental|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
11259039|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
11259040|NCT02978326|Experimental|SAGE-217 dosing|SAGE-217
11259041|NCT02978326|Placebo Comparator|Placebo|Placebo
11259042|NCT02978313|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
11259043|NCT02978313|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
11259044|NCT02978300|Active Comparator|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
11259045|NCT02978300|Experimental|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
11259046|NCT02978287|No Intervention|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
11259047|NCT02978287|Experimental|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
11259048|NCT02978287|Experimental|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
11259049|NCT02978287|Experimental|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
11259050|NCT02978287|Experimental|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
11259051|NCT02978274||experimental group|MMF withdrawal by engraftment post haplo-SCT
11259052|NCT02978274||control group|MMF withdrawal by 2 month post haplo-SCT
11259053|NCT02978261|Experimental|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
11259054|NCT02978235|Experimental|TAS4464|
11259055|NCT02978222|Experimental|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
11259056|NCT02978222|Placebo Comparator|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
11259057|NCT02978209|No Intervention|Only moisturizer, no carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. One body half
11259058|NCT02978209|Active Comparator|Moisturizer + 7,5 % carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. Other body half
11259059|NCT02978196|Experimental|Injection of 99m-Tc-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.
11259060|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
11259061|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
11259062|NCT02978170|Experimental|Diagnostic (CBCT)|Patients undergo CBCT during standard of care bronchoscopy.
11259063|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
11259064|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
11259065|NCT02978144|Other|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
11259066|NCT02978144|Other|Current smokers|Healthy controls who are currently smoking (> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
11259067|NCT02978144|Other|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
11259068|NCT02978144|Other|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
11259069|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
11259070|NCT02978118||Group A|Subjects in Group A (patients with metastatic renal cell carcinoma starting immune therapy) will have PBMC, plasma storage and analysis for immune cell profiles at baseline, 4 weeks, 12 weeks, and upon disease progression on treatment. Patients will have CTC assessment at baseline, 4 weeks, and upon disease progression. Urinary specimens will be collected at baseline, 4 weeks, 12 weeks, and disease progression. Fecal specimens will be collected at baseline (within 3 days of cycle 1 day 1), 4 weeks, and upon disease progression.
11259071|NCT02978118||Group B|Subjects in Group B (patients with metastatic urothelial carcinoma) will have PBMC and plasma storage and analysis for immune cell profiles at baseline, 4 weeks, 12 weeks, and upon disease progression on treatment. Patients will have CTC assessment at baseline, 4 weeks, and disease progression. Urinary specimens will be collected at baseline, 4 weeks, 12 weeks, and disease progression. Fecal specimens will be collected at baseline (within 3 days of cycle 1 day 1), 4 weeks, and upon disease progression.
11259072|NCT02978105|Experimental|Experimental|self-conditioning techniques plus standard care
11259073|NCT02978105|Active Comparator|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
11259077|NCT02978040|Experimental|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
11259078|NCT02978040|Active Comparator|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min).
11259079|NCT02978040|Active Comparator|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
11259080|NCT02978027|Active Comparator|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
11259081|NCT02978027|Active Comparator|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
11259082|NCT02978027|Experimental|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
11259083|NCT02978014|Experimental|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
11259084|NCT02978014|No Intervention|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
11259085|NCT02978001||Patients with Psoriasis|Patients with moderate to severe psoriasis (PASI>8)
11259086|NCT02978001||Healthy Control Subjects|Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
11259087|NCT02977988|Experimental|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
11259088|NCT02977988|Active Comparator|Active Comparator|Brain and Recovery (B&R)
11259089|NCT02977975|Experimental|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
11259090|NCT02977975|Other|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
11259091|NCT02977962|Experimental|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
11259092|NCT02977962|Placebo Comparator|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
11259093|NCT02977923|Active Comparator|Standard pharmacological treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
11259094|NCT02977923|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
11259095|NCT02977910|Experimental|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
11259096|NCT02977910|No Intervention|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
11259097|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
11259098|NCT02977884|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
11259099|NCT02977871|No Intervention|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
11259100|NCT02977871|Active Comparator|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
11259101|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
11259102|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
11259103|NCT02977845|Experimental|Primary aim|The primary aim of this study is to assess the effect of Qigong on managing dyspnea, fatigue, and anxiety (as a cluster) in lung cancer patients.
11259104|NCT02977845|Experimental|Secondary aim|The secondary aim of this study is exploring the effect of Qigong on cough which is another common symptom linked with dyspnea, fatigue, and anxiety as a cluster, and QOL in lung cancer patients.
11259108|NCT02977819|Active Comparator|English learning courses|English learning courses and at-home practice
11259109|NCT02977819|No Intervention|No intervention|
11259110|NCT02977793||Non-pathologic young adults|18-28 years old
11259111|NCT02977793||Non-pathologic adults|29-80 years old
11259112|NCT02977793||Pathologic adults|29-80 years old
11259113|NCT02977780|Active Comparator|Temozolomide|"Daily Radiation for a maximum of 49 days.
~Temozolomide will be administered orally on a daily dosing schedule
~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
~Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
11259114|NCT02977780|Experimental|Abemaciclib with Temozolomide|"Daily Radiation for a maximum of 49 days.
~Temozolomide will be administered orally on a daily dosing schedule during radiation
~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
~Abemaciclib will be taken post radiation at a twice daily oral pre-determined dose"
11259115|NCT02977780|Experimental|CC-115|"Twice daily oral dosing of CC-115
~Daily Radiation for a maximum of 49 days
~CC115 will also be taken twice daily post radiation"
11259116|NCT02977780|Experimental|Neratinib with Temozolomide|"Daily Radiation for a maximum of 49 days.
~Temozolomide will be administered orally on a daily dosing schedule
~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy
~Neratinib will be taken post radiation at a daily oral pre-determine dose"
11259117|NCT02977767|Experimental|Conversational hypnosis|Use of conversational hypnosis during the tracheal cannula replacement
11259118|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
11259119|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
11259120|NCT02977715|Experimental|Intervention|Up to 1600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation [n=1000 subjects] or lyophilized formulation [n=600 subjects]) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
11259121|NCT02977689|Experimental|IDH305|IDH305 550 mg, oral, two times per day
11259122|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
11259123|NCT02977637|Experimental|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
11259124|NCT02977624|Experimental|Hadassah Medical Organization, Jerusalem, Israel|
11259125|NCT02977611|Experimental|High Dose, Rapid Infusion Iron Sucrose|Patients will receive an infusion of 500 mg of iron sucrose over one hour and will be monitored for four hours.
11259126|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
11259127|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
11259128|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
11259129|NCT02977585|Active Comparator|group 1|high level support
11259130|NCT02977585|No Intervention|group 0|low level support
11259131|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
11259132|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
11259133|NCT02977559|Experimental|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
11259134|NCT02977559|Experimental|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
11259135|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA >= 2 based on a reduced left ventricular ejection fraction (LV-EF <= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
11259136|NCT02977533|Experimental|GZ402668|Dose 1 (up to a maximum optional Dose 2) will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
11259137|NCT02977533|Placebo Comparator|Placebo|A dose of matching placebo will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
11259219|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
11259138|NCT02977520|Experimental|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
11259139|NCT02977520|No Intervention|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
11259140|NCT02977507|Experimental|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
11259141|NCT02977507|Active Comparator|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the other side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
11259142|NCT02977494|Experimental|Daratumumab Bortezomib|
11259143|NCT02977468|Experimental|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein one to two times before Intraoperative radiation therapy (IORT).
~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
11259144|NCT02977442|Experimental|exercise|12 week exercise program, 5 days/week, 60 min/day
11259145|NCT02977442|No Intervention|standard of care|12 week standard of care recommendations
11259146|NCT02977429|Active Comparator|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:
~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
11259147|NCT02977429|Sham Comparator|control group|"The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:
~ScvO2<70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
11259148|NCT02977416|Experimental|patients treated withTNF blockade|22 patients treated with TNF blockade
11259149|NCT02977416|Experimental|patients without TNF blockade|22 patients without TNF blockade
11259150|NCT02977416|Experimental|healthy subjects|22 matched healthy subjects by pubertal stage and sex
11259151|NCT02977403|Sham Comparator|AB Control|Control condition - the probe is equally likely to replace the food picture and the neutral picture. There is no correlation between picture type and probe location, and no training of attention should occur.
11259152|NCT02977403|Experimental|AB Retraining|Active treatment - the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
11259153|NCT02977403|Active Comparator|Booster Training|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
11259154|NCT02977403|Other|Booster Training other|3 months after the randomized program is completed, each subject can elect to use open-label attention bias retraining for 2 weeks
11259155|NCT02977390|Other|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.
~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.
~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
11259156|NCT02977377|Active Comparator|Whole body vibration/ Exercise|Exercise therapy and whole body vibration will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. Whole body vibration (20-30 Hz, minimum amplitude) will be applied to cases in the form of 4 sets (1 min application and 1min rest) before exercises. After 1 week washout period, exercise program will apply for 8 weeks.
11259157|NCT02977377|Active Comparator|Exercise/ Whole body vibration|Exercise therapy will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise therapy and whole body vibration will be applied together for 8 weeks.
11259158|NCT02977364|Experimental|HS-10241 100mg|HS-10241 100mg daily
11259159|NCT02977364|Experimental|HS-10241 200mg|HS-10241 200mg daily
11259160|NCT02977364|Experimental|HS-10241 400mg|HS-10241 400mg daily
11259161|NCT02977364|Experimental|HS-10241 600mg|HS-10241 600mg daily
11259162|NCT02977364|Experimental|HS-10241 800mg|HS-10241 800mg daily
11259163|NCT02977364|Experimental|HS-10241 1000mg|HS-10241 1000mg daily
11259164|NCT02977351|Experimental|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
11259165|NCT02977351|Active Comparator|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
11259166|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
11259167|NCT02977325||water cure exclusively|This group followed exclusively the water cure
11259168|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
11259169|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
11259170|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
11259171|NCT02977286|Experimental|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:
~Adverse event potentially attributable to the study drug.
~Use of Relistor.
~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.
~The participant has been administered 10 days of study medication.
~The participant is discharged from the ICU.
~The participant requires the initiation of a strong CYP3A4 inhibitor medication.
~Other Name: Movantik"
11259172|NCT02977286|Placebo Comparator|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:
~Adverse event potentially attributable to the study drug.
~Use of Relistor.
~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.
~The participant has been administered 10 days of study medication.
~The participant is discharged from the ICU.
~The participant requires the initiation of a strong CYP3A4 inhibitor medication.
~Other Name: AstraZeneca provided Movantik placebo"
11259173|NCT02977273|Experimental|Test Meal 1|Thin/100% portion
11259174|NCT02977273|Experimental|Test Meal 2|Thin/150% portion
11259175|NCT02977273|Experimental|Test Meal 3|Thick/100% Portion
11259176|NCT02977273|Experimental|Test Meal 4|Thick/150% Portion
11259177|NCT02977260|Experimental|Test Meal 1|Thin/Low Energy
11259178|NCT02977260|Experimental|Test Meal 2|Thin/High Energy
11259179|NCT02977260|Experimental|Test Meal 3|Thick/Low Energy
11259180|NCT02977260|Experimental|Test Meal 4|Thick/High Energy
11259181|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
11259182|NCT02977234|Experimental|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
11259183|NCT02977221|Experimental|Piezosurgery|Piezosurgery will be performed on the anterior lower segment of the dental arch in order to accelerate the correction of mandibular anterior crowding.
11259184|NCT02977221|No Intervention|Ordinary Alignment|Treatment will be provided to the patients without any surgical interventions.
11259185|NCT02977208|Active Comparator|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.
~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
11259186|NCT02977208|Active Comparator|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.
~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
11259187|NCT02977195|Experimental|NP137|Therapeutic Class Recombinant humanized IgG1 monoclonal antibody against Netrin 1, Administered. Route of Administration is intravenous infusion over 180 min, given every 2 week at 14 mg/kg.
11259188|NCT02977182|No Intervention|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
11259189|NCT02977182|Experimental|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
11259190|NCT02977169|Experimental|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
11259191|NCT02977169|Placebo Comparator|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
11259220|NCT02977000|Experimental|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
11259192|NCT02977156|Experimental|Combination PexaVec + Ipilimumab|"PEXA-VEC (Pexastimogene devacirepvec): Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF of Classe 1, administered by Intra-tumoral injection with fixed-dosage regimen of 1x109 pfu (9.0 Log pfu)/ injection. Up to 5 IT injections, at Week 1 Day 1, Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed in case of disease progression following a documented objective response at W12. Provided by Transgene.
~IPILIMUMAB: Anti-CTLA-4 monoclonal antibody (IgG1k) produced in CHO cells by recombinant DNA technology, administered by Intra-tumoral injection. Up to 4 IT injections at Week 3 Day 1, Week 5 Day 1 and Week 9 Day 1, and one additional IT treatment allowed In case of disease progression following a documented objective response at W12. Four dose levels of ipilimumab will be tested in dose escalation step: 2.5mg, 5mg, 7.5mg, 10mg, 20mg or 40 mg."
11259193|NCT02977143|Experimental|Fluid responsiveness test|"First, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation).
~Second, measure the increase in cardiac index after administration of volulyte 300 ml.
~If cardiac index increase more than 10%, fluid responsiveness is confirmed."
11259194|NCT02977130|Experimental|Map group|patients receiving general shared care for diabetes and the conversation map intervention
11259195|NCT02977130|Active Comparator|Control group|patients receiving general shared care for diabetes
11259196|NCT02977117|Experimental|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
11259197|NCT02977117|Active Comparator|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
11259198|NCT02977104|Other|Patients in afib or flutter|Maestro ECG
11259199|NCT02977104|Other|Patients in sinus rhythm|Maestro ECG
11259200|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
11259201|NCT02977091||short stature|healthy short children
11259202|NCT02977078|Sham Comparator|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
11259203|NCT02977078|Experimental|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
11259204|NCT02977065|Active Comparator|Atorvastatin 20 mg|To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks
11259205|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 50 mg|To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks
11259206|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 100 mg|To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
11259207|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 200 mg|To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks
11259208|NCT02977065|Active Comparator|Rosuvastatin 10 mg|To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks
11259209|NCT02977065|Experimental|Rosuvastatin 10 mg + CKD-519 100 mg|To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
11259210|NCT02977052|Experimental|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
11259211|NCT02977052|Experimental|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
11259212|NCT02977052|Experimental|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
11259213|NCT02977052|Experimental|PRADO extension cohort|"Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B.
~Surgery and adjuvant therapy
~Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes.
~Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment.
~Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK"
11259214|NCT02977039|Experimental|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
11259215|NCT02977039|Experimental|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
11259216|NCT02977026|No Intervention|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
11259217|NCT02977026|Experimental|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
11259218|NCT02977026|Experimental|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
11259246|NCT02976766|Placebo Comparator|Placebo|
11259221|NCT02976987|Experimental|Cidofovir|Women receiving an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (CIN 2 and 3).
11259222|NCT02976974|Experimental|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
11259223|NCT02976974|Experimental|Therapeutic exercise (E)|"E: Therapeutic Exercise.
~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.
~Thoracic column movements: Flexion-extension"
11259224|NCT02976961|Experimental|Intervention|Implantable cardioverter defibrillator implant + usual care + supportive care given via an e-health platform. The supportive care consists of information, dialogue with a nurse or psychologist, CBT-based psychological intervention online, quizzes to increase knowledge
11259225|NCT02976961|No Intervention|Usual care|Implantable cardioverter defibrillator implant + usual care
11259226|NCT02976935||Healthy Volunteers|Subjects will receive 1L non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath while the MRI scan is performed. Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2:Identical to Study Visit 1 but with the further series of inhalations being up to a maximum of 4 (maximum total exposure to hyperpolarised 129Xenon will be 5L).Optional Study Visit #3: Identical to Study Visit 2 (maximum total exposure to hyperpolarised 129Xenon will be 5L)
11259227|NCT02976935||Chronic Obstructive Pulmonary Disease|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
11259228|NCT02976935||Idiopathic Pulmonary Fibrosis|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
11259229|NCT02976922|Active Comparator|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
11259230|NCT02976922|Placebo Comparator|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
11259231|NCT02976909|Experimental|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
11259232|NCT02976896|Experimental|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
11259233|NCT02976883|Experimental|[18F]HX4 diagnostic PET/CT scan|[18F]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
11259234|NCT02976870|Experimental|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
11259235|NCT02976857|Experimental|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
11259236|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
11259237|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
11259238|NCT02976831|Experimental|AZD0284|"Part 1A:
~Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL.
~Part 1B (food cohort):
~Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL.
~Part 2:
~In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
11259239|NCT02976831|Active Comparator|Placebo|"Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing.
~Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
11259240|NCT02976805|Experimental|Regimen A|4L PegLyte + 15 mg bisacodyl
11259241|NCT02976805|Experimental|Regimen B|6L PegLyte + 15 mg bisacodyl
11259242|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
11259243|NCT02976779|Experimental|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
11259244|NCT02976779|Placebo Comparator|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
11259245|NCT02976766|Experimental|Gypenosides|
11259247|NCT02976753||Elocta|Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
11259248|NCT02976753||Conventional factor VIII product|Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
11259249|NCT02976740|Experimental|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
11259250|NCT02976727|Experimental|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
11259251|NCT02976727|Active Comparator|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
11259252|NCT02976714|Other|CF patients|CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care.
11259253|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
11259254|NCT02976701|Placebo Comparator|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
11259255|NCT02976688|Experimental|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
11259256|NCT02976675|Experimental|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
11259257|NCT02976675|Experimental|PEG-somatropin per two weeks|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
11259258|NCT02976675|Active Comparator|Jintropin AQ|Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks
11259259|NCT02976662|Experimental|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
11259260|NCT02976662|No Intervention|Without Artificial shrinkage|Vitrify expanded blastocysts.
11259261|NCT02976636|Active Comparator|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
11259262|NCT02976636|Experimental|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
11259263|NCT02976623|Other|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
11259264|NCT02976623|No Intervention|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
11259265|NCT02976610|No Intervention|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
11259266|NCT02976610|Experimental|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.
~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
11259267|NCT02976597|Active Comparator|Bupivacaine 0.25%|Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side on each side at end of the surgery.
11259268|NCT02976597|Active Comparator|Morphine 10mg|Morphine 10mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery.Patients will recieve 5mg morphine on each side
11259269|NCT02976597|Active Comparator|Morphine 15mg|Morphine 15mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery. Patients will recieve 7.5mg morphine on each side
11259270|NCT02976571|Experimental|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
11259271|NCT02976571|Active Comparator|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
11259272|NCT02976571|Active Comparator|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
11259273|NCT02976571|Placebo Comparator|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
11259274|NCT02976558|Experimental|Treatment Group|"Interventions:
~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.
~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
11259275|NCT02976558|No Intervention|Control Group|control group. No interventions
11259276|NCT02976545|Other|PNES|Psychogenic Non-epileptic Seizures subjects
11259277|NCT02976545|Other|PTSD|Post Traumatic Stress Disorder
11259278|NCT02976545|Other|Healthy controls|Healthy controls
11259279|NCT02976532|Other|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
11259280|NCT02976519|Experimental|BI 443651|
11259281|NCT02976519|Placebo Comparator|Placebo|
11259282|NCT02976506|Experimental|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
11259283|NCT02976506|Experimental|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
11259284|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
11259285|NCT02976480|Active Comparator|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
11259286|NCT02976480|Experimental|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
11259287|NCT02976467|Experimental|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
11259288|NCT02976467|Placebo Comparator|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
11259289|NCT02976454|Experimental|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
11259290|NCT02976454|Active Comparator|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
11259291|NCT02976441|Experimental|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide
~Focal radiation therapy: standard of care dose daily for approximately 6 weeks
~Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation
~2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient
~Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
11259292|NCT02976428|Active Comparator|Standard Soft Tissue Balancing|In the control group where the sensor device is not used in optimization of knee balance and alignment, definitive implants will be cemented in place and the sensor trial inserted using a thickness based on prior standard bearing insert trialing. Peak load data will be captured intraoperatively through full ROM. Custom shims will be affixed to the sensor to replicate thickness of the standard trial. The knee will then be cycled and loads recorded in the medial and lateral compartments at 10, 45 and 90 degrees of flexion. The surgeon will be blinded to the sensor output and the system will be located outside of their visual field.
11259293|NCT02976428|Experimental|Sensor Guided Soft Tissue Balancing|In the experimental group where the sensor device is used to optimize balance and alignment, the sensor trial will be inserted and tibial baseplate rotated until medial and lateral femoral contact points are parallel on the sensor output. Quantitative balance is defined as a mediolateral intercompartmental loading difference of ≤15 pounds. Flexion balance is achieved when femoral contact point position is within the midposterior third of the tibial insert and intercompartmental loads are balanced. Loads in the medial and lateral compartments are recorded at 10, 45 and 90 degrees. If compartment loads differ by >15 lbs between compartments, unbalanced, further soft tissue release/bone resection will be done to achieve a side to side compartment pressure difference of <15 lbs through ROM.
11259294|NCT02976402|Experimental|SBRT|"Postoperative RT consisting in:
~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week
~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
11259295|NCT02976389|Experimental|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
11259296|NCT02976389|Active Comparator|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
11259297|NCT02976389|Active Comparator|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
11259298|NCT02976376|Experimental|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
11259299|NCT02976376|No Intervention|Control|Patients who are randomized to the control group will receive regular care.
11259300|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
11259301|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
11259302|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
11259303|NCT02976337|Experimental|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
11259304|NCT02976337|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
11259305|NCT02976324|Experimental|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
11259306|NCT02976324|No Intervention|control group|No inervention, just receive conventional therapy
11259307|NCT02976311|Active Comparator|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
11259308|NCT02976311|Active Comparator|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
11259309|NCT02976298|Sham Comparator|transcranial magnetic stimulation|sham transcranial magnetic stimulation
11259310|NCT02976298|Experimental|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
11259311|NCT02976298|Experimental|cerebellar stimulation|cerebellar transcranial magnetic stimulation
11259312|NCT02976272||patients with myeloma multiple|
11259313|NCT02976259|Experimental|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
11259314|NCT02976246|Active Comparator|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
11259315|NCT02976246|Placebo Comparator|RenaKvit-vessel Control|One tablet of non-active drug given once daily
11259316|NCT02976246|Active Comparator|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
11259317|NCT02976246|Placebo Comparator|RenaKvit-bone control|One tablet of non-active drug given once daily
11259318|NCT02976233||Acute Respiratory Failure in NIV|
11259319|NCT02976220|Experimental|Digital Education|1 month digital education program
11259320|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
11259321|NCT02976194|Experimental|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
11259322|NCT02976168|No Intervention|Horizontal|Subjects will be in horizontal supine Position for 21 hours
11259323|NCT02976168|Experimental|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
11259324|NCT02976155|No Intervention|Pre-intervention|enteral nutrition according routine practice
11259325|NCT02976155|Experimental|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
11259326|NCT02976142|Experimental|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
11259327|NCT02976142|No Intervention|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
11259328|NCT02976129|Experimental|V565|V565 TID PO for 6 weeks
11259329|NCT02976129|Placebo Comparator|Placebo|Placebo TID PO for 6 weeks
11259330|NCT02976116|Experimental|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
11259331|NCT02976103|Other|Standard Care|-Standard Care pain medicine/management will be given
11259332|NCT02976103|Experimental|JACKI® RECOVERY JACKET + Standard Care|"Patient will be encouraged to use the Jacki Recovery Jacket at home
~Patient will be taught how to tuck the drainage tubes in the jacket pocket
~Patient will be taught how to un-tuck the drainage tubes from jacket pocket
~Standard care pain medicine/management will be given"
11259333|NCT02976077|Experimental|RC2S+|"RC2S+
~Preparation sessions (sessions 1 & 2):
~Functional Outcomes Scale - Social Cognition (ERF-CS)
~Psychoeducation about social cognitive impairments
~Concrete objectives
~Cognitive remediation (sessions 3 to 22):
~Paper-and-pencil session
~Simulation session
~Home-based task
~Transfer sessions (sessions 23 & 24):
~Transfer of skills in dayly life - generalization
~Assessment of the achievement of objectives"
11259334|NCT02976077|Active Comparator|Control therapy|"Control therapy
~Preparation sessions (sessions 1 & 2):
~Functional Outcomes Scale - Neurocognition
~Psychoeducation about cognitive impairments
~Concrete objectives
~Cognitive remediation (sessions 3 to 24):
~Paper-and-pencil session
~Simulation session
~Home-based task"
11259335|NCT02976064|Experimental|PreHab_Intervention|Experimental group of the prehabilitation trial
11259336|NCT02976064|No Intervention|PreHab_Control|Control group of the prehabilitation trial
11259337|NCT02976064|Experimental|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
11259338|NCT02976064|No Intervention|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
11259339|NCT02976064|Experimental|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
11259340|NCT02976064|No Intervention|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
11259341|NCT02976051|Experimental|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
11259342|NCT02976038|Experimental|elamipretide|Open-label once daily subcutaneous injection of 40mg elamipretide
11259343|NCT02976025|Experimental|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
11259344|NCT02976025|Active Comparator|Collaborative Care|This comparator arm will consist of 10 cluster randomized health centers who receive training in collaborative care.
11259345|NCT02976012|Active Comparator|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
11259346|NCT02976012|Active Comparator|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
11259347|NCT02975999|Experimental|Vasopressin|Vasopressin at 0.4mU/kg/min
11259348|NCT02975999|Placebo Comparator|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
11259349|NCT02975986|Other|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
11259350|NCT02975973|Experimental|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
11259351|NCT02975973|Experimental|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
11259352|NCT02975973|Experimental|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
11259353|NCT02975973|Sham Comparator|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
11259354|NCT02975960|Experimental|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
11259355|NCT02975947|Active Comparator|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
11259356|NCT02975947|Experimental|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
11259357|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
11259358|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
11259359|NCT02975921|No Intervention|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
11259360|NCT02975921|Experimental|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
11259361|NCT02975921|No Intervention|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
11259362|NCT02975921|Experimental|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
11259363|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
11259364|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
11259365|NCT02975882|Experimental|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on cycle 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on cycle 2. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11259366|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
11259367|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
11259368|NCT02975856|Experimental|Table Red Wine|250 ml Table Red Wine (12% ethanol)
11259369|NCT02975856|Experimental|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
11259370|NCT02975843|Experimental|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
11259371|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
11259372|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
11259373|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
11259374|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
11259375|NCT02975817|Experimental|Hibler's|Insert description from protocol
11259376|NCT02975817|Active Comparator|Warm Air|Insert description from protocol
11259377|NCT02975804|Experimental|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
11259378|NCT02975804|No Intervention|Standard Therapy|Children in the control group will continue their usual therapy.
11259379|NCT02975791|Active Comparator|palpation|"Marking the cricothyroid membrane after ultrasound
~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
11259380|NCT02975791|Active Comparator|ultrasound|"Marking of the cricothyroid membrane after Palpation
~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
11259381|NCT02975778|Experimental|Aged, 80 and over|
11259382|NCT02975765|Experimental|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
11259383|NCT02975765|No Intervention|Traditional method|No intervention is going to be applied to the patients in this group.
11259384|NCT02975739|Experimental|Holmium-166 microspheres|Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.
11259385|NCT02975726|Experimental|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
11259386|NCT02975726|Active Comparator|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
11259387|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated
~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
11259388|NCT02975687|Experimental|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
11259389|NCT02975674|Experimental|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
11259390|NCT02975674|Active Comparator|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
11259391|NCT02975661||Observational 1|Huaier Granule
11259392|NCT02975661||Observational 2|Radiotherapy or chemotherapy
11259393|NCT02975661||Observational 3|treatment abandoned
11259394|NCT02975661||Observational 4|Huaier Granule & Radiotherapy or chemotherapy
11259395|NCT02975648|Active Comparator|Usual Care|At discharge, paticipants received guidance from health professionals. The paticipants had a medical return five to seven months after the percutaneous coronary intervention.
11259396|NCT02975648|Experimental|Educational model + follow up|The paticipants received the hospital's instructions at discharge and participated in the educational program (booklets with telephone follow-up). The paticipants had a medical return five to seven months after discharge
11259397|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
11259398|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
11259399|NCT02975622|Active Comparator|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
11259400|NCT02975622|Active Comparator|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
11259401|NCT02975609|Active Comparator|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
11259402|NCT02975609|Experimental|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
11259403|NCT02975596|Other|Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
11259404|NCT02975596|Other|College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
11259405|NCT02975596|Other|Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
11259406|NCT02975596|No Intervention|Parent focus group|Parents discussed barriers and reviewed MenB education materials.
11259407|NCT02975596|No Intervention|Provider focus groups|Providers discussed barriers and reviewed MenB education materials.
11259408|NCT02975583|Active Comparator|Experimental: Vorapaxar|Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity
11259409|NCT02975583|Placebo Comparator|Placebo Comparator: Placebos|Medication: Matching Placebo Daily tablet
11259410|NCT02975570|Experimental|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
11259411|NCT02975570|Experimental|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
11259412|NCT02975570|Experimental|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
11259413|NCT02975570|Experimental|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
11259566|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
11259414|NCT02975570|Experimental|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
11259415|NCT02975570|Active Comparator|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
11259416|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
11259417|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
11259418|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
11259419|NCT02975544|Experimental|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
11259420|NCT02975544|No Intervention|Control group|Continued with their habitual school routine
11259421|NCT02975531|Experimental|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
11259422|NCT02975531|Experimental|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
11259423|NCT02975531|Experimental|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
11259424|NCT02975531|Experimental|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
11259425|NCT02975531|Experimental|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
11259426|NCT02975518|Active Comparator|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
11259427|NCT02975518|Active Comparator|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
11259428|NCT02975518|Experimental|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
11259429|NCT02975518|Experimental|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
11259430|NCT02975505|Experimental|Strict SBP Target|Target Systolic Blood Pressure <120 mm Hg
11259431|NCT02975505|No Intervention|Usual SBP Target|Target Systolic Blood Pressure 130-140 mm Hg
11259432|NCT02975492|Experimental|Cholecalciferol sequential dose|cholecalciferol : 100 000 Unit International (UI), sequential dose (2 mL)
11259433|NCT02975492|Experimental|Cholecalciferol daily dose|cholecalciferol : 1000 UI, daily dose during 28 days (0.1 ml by day)
11259434|NCT02975479|Placebo Comparator|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
11259435|NCT02975479|Active Comparator|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.
~***IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. ***"
11259436|NCT02975466|Experimental|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
11259437|NCT02975466|Experimental|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
11259438|NCT02975466|Experimental|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
11259439|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
11259440|NCT02975440|Experimental|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
11259441|NCT02975427||Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
11259442|NCT02975388|Experimental|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
11259443|NCT02975388|Experimental|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
11259444|NCT02975388|Experimental|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
11259445|NCT02975388|Active Comparator|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
11259446|NCT02975388|Experimental|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
11259447|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
11259448|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
11259449|NCT02975362|Experimental|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
11259450|NCT02975362|Experimental|Rehabilitation|Rehabilitation Treatment
11259451|NCT02975349|Experimental|M2951 Low dose|
11259452|NCT02975349|Experimental|M2951 Mid dose|
11259453|NCT02975349|Experimental|M2951 High dose|
11259454|NCT02975349|Experimental|Placebo/M2951|
11259455|NCT02975349|Active Comparator|Tecfidera|
11259456|NCT02975336|Placebo Comparator|Placebo: Double-Blind Treatment Period|
11259457|NCT02975336|Experimental|M2951: Double-Blind Treatment Period|
11259458|NCT02975336|Experimental|M2951 Mid Dose: Double-Blind Treatment Period|
11259459|NCT02975336|Experimental|M2951 High dose: Double-Blind Treatment Period|
11259460|NCT02975336|Experimental|M2951: Open-Label Extension Period|
11259461|NCT02975323|Experimental|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
11259462|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
11259463|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
11259464|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT, Patch), smoking cessation counseling
11259465|NCT02975297|Placebo Comparator|plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT, Patch), smoking cessation counseling
11259466|NCT02975271|Experimental|Serlopitant|Dose of experimental drug Serlopitant
11259467|NCT02975271|Placebo Comparator|Placebo|Matching dose of Placebo
11259468|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
11259469|NCT02975232|Experimental|Treatment|F&V economic incentive with Cooking Matters store tour
11259470|NCT02975232|No Intervention|Control|no intervention
11259471|NCT02975219|Experimental|Treatment group|4.5mg Bevacizumab-800CW intravenously
11259472|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
11259473|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
11259474|NCT02975206|Placebo Comparator|Placebo Oral Tablet|matching placebo tablets
11259475|NCT02975193|Active Comparator|Control group|"Healthy adults ages 18-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.
~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
11259476|NCT02975193|Active Comparator|Parkinson's disease group with DBS|"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.
~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
11259477|NCT02975180|Experimental|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
11259478|NCT02975180|Experimental|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
11259479|NCT02975167|Experimental|Inpatient|"Subjects randomized to this group will receive the same intervention as the outpatient group -- cervical ripening with Foley catheter -- but remain within the hospital. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.
~The intervention: randomization to inpatient cervical ripening"
11259480|NCT02975167|Experimental|Outpatient|"Subjects randomized to this group will receive the same intervention as the inpatient group -- cervical ripening with Foley catheter -- but will be discharged home. Subjects will be asked to return to the hospital when the catheter falls out or if 24 hours has elapsed. They will be given detailed instructions and provided a 24 hour phone number to call should they have any concerns. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.
~The intervention: randomization to outpatient cervical ripening"
11259481|NCT02975154|Active Comparator|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.
~Previous treatments will be continued."
11259482|NCT02975154|Active Comparator|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
11259483|NCT02975154|Sham Comparator|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
11259484|NCT02975154|No Intervention|No Intervention|No Intervention. Previous treatments will be continued.
11259485|NCT02975141|Experimental|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
11259486|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
11259487|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
11259488|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
11259489|NCT02975128|Experimental|Patients|
11259490|NCT02975102|Experimental|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
11259491|NCT02975102|Active Comparator|Vismed® Multi|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
11259492|NCT02975089|No Intervention|Control|A leaflet of healthy diet for elderly
11259493|NCT02975089|Experimental|Nutritional Intervention 1|"Multi-nutrient supplement"
11259494|NCT02975089|Experimental|Nutritional Intervention 2|"Multi-nutrient & soy protein supplement"
11259495|NCT02975089|Experimental|Nutritional Intervention 3|Nutrition education on balanced diet & food supplement
11259496|NCT02975076|Experimental|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
11259497|NCT02975076|Placebo Comparator|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
11259498|NCT02975063|Experimental|A&T IYCF intervention|A&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
11259499|NCT02975063|No Intervention|Control|No intervention.
11259500|NCT02975050||Side location|u-Cor device will be applied on side location
11259501|NCT02975050||Front location|u-Cor device will be applied on front location
11259502|NCT02975037|Experimental|sildenafil+erythromycin|Sildenafil 25 mg PO (single dose); Erythromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Erythromycin 250 mg PO (single dose)
11259503|NCT02975037|Experimental|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
11259504|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
11259505|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
11259506|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
11259507|NCT02974998|Experimental|Young Women's Health CoOp (YWHC)/ HTC|Participants received an enhanced gender-focused HTC intervention.
11259508|NCT02974998|Active Comparator|Standard HTC|Participants received the standard HTC available in South Africa for this population.
11259509|NCT02974985|Experimental|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
11259510|NCT02974985|Experimental|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
11259511|NCT02974972||Pith Moromo 2 Cohort|
11259512|NCT02974959|Experimental|gammaCore active device|Patients in this arm will be using an active device which delivers a treatment dose of current to the vagus nerve twice daily for 120 seconds
11259513|NCT02974959|Sham Comparator|gammaCore Sham device|Patients in this arm will be using a sham device which does not deliver a treatment dose of current, but will deliver enough current to cause tingling on the skin.
11259514|NCT02974946|Experimental|Study group|Patients will receive the RenalGuard system
11259515|NCT02974946|No Intervention|Control group|Standard practice will be performed with no RenalGuard system
11259516|NCT02974933|Experimental|apatinib|combined with pemetrexed
11259517|NCT02974920|Active Comparator|Aspirin 100 mg|100 mg of aspirin daily for 180 days
11259518|NCT02974920|Active Comparator|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
11259519|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
11259520|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
11259521|NCT02974894|Experimental|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
11259522|NCT02974894|Placebo Comparator|Placebo|Capsules containing potato starch
11259523|NCT02974881|Experimental|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
11259524|NCT02974868|Experimental|Cohort 1|PF-06651600
11259525|NCT02974868|Experimental|Cohort 2|PF-06700841
11259526|NCT02974868|Placebo Comparator|Cohort placebo|placebo
11259527|NCT02974855|Experimental|PF-06741086 (Cohort 1)|
11259528|NCT02974855|Experimental|PF-06741086 (Cohort 2)|
11259529|NCT02974855|Experimental|PF-06741086 (Cohort 3)|
11259530|NCT02974855|Experimental|PF-06741086 (Cohort 4)|
11259531|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
11259532|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
11259567|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
11259533|NCT02974816|No Intervention|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
11259534|NCT02974816|Experimental|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
11259535|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
11259536|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
11259537|NCT02974777|Active Comparator|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
11259538|NCT02974777|Active Comparator|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
11259539|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
11259540|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
11259541|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
11259542|NCT02974738|Experimental|Part 1A|"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors."
11259543|NCT02974738|Experimental|Part 1B|"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC."
11259544|NCT02974738|Experimental|Part 2|"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
11259545|NCT02974738|Experimental|Part 2A|"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide
~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
11259546|NCT02974725|Experimental|LXH254+LTT462|
11259547|NCT02974725|Experimental|LXH254+Trametinib|
11259548|NCT02974725|Experimental|LXH254+Ribociclib|
11259549|NCT02974712|Experimental|Fentanyl|After routine Induction, fentanyl was administrated.
11259550|NCT02974712|Placebo Comparator|Saline|After routine Induction, same volume saline was administrated.
11259551|NCT02974699|Experimental|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
11259552|NCT02974699|Placebo Comparator|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
11259553|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
11259554|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
11259555|NCT02974673|Experimental|Ejaculatory test|Measures of sphincter pressures during ejaculation
11259556|NCT02974660|Active Comparator|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
11259557|NCT02974660|Placebo Comparator|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
11259558|NCT02974647|Experimental|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
11259559|NCT02974647|Experimental|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
11259560|NCT02974647|Experimental|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
11259561|NCT02974634|Active Comparator|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
11259562|NCT02974634|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
11259563|NCT02974621|Experimental|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11259564|NCT02974621|Experimental|Arm B (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11259565|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
11259572|NCT02974582|Experimental|2/Part 2 - Discount Coupons|Randomized to view direct mail marketing
11259573|NCT02974582|Experimental|3/Part 2 - No Discount Coupons|Randomized to view direct mail marketing
11259574|NCT02974582|Experimental|4/Part 2 - Control|Randomized to view direct mail marketing
11259575|NCT02974569||C-SCAT|C-SCAT arm: Completes and uses Computerized Symptom Capture Tool (C-SCAT) during visit with provider for two clinic visits.
11259576|NCT02974556|Active Comparator|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.
~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
11259577|NCT02974556|Experimental|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.
~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
11259578|NCT02974543|Other|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.
~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
11259579|NCT02974543|Other|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.
~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
11259580|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
11259581|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
11259582|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
11259583|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
11259584|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
11259585|NCT02974504|Experimental|evogliptin|evogliptin 5mg qd
11259586|NCT02974504|Active Comparator|linagliptin|linagliptin 5mg qd
11259587|NCT02974491|Experimental|Apple Juice|
11259588|NCT02974478|Experimental|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
11259589|NCT02974478|Experimental|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
11259590|NCT02974478|Experimental|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
11259591|NCT02974465|Experimental|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
11259592|NCT02974465|Sham Comparator|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
11259593|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
11259594|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
11259595|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
11259596|NCT02974439|Experimental|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
11259597|NCT02974439|Active Comparator|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
11259598|NCT02974426|Experimental|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
11259599|NCT02974426|Active Comparator|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
11259600|NCT02974413|Experimental|Intervention|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.
11259601|NCT02974413|No Intervention|Control|The study will also include a Control Group (CG), and the participants of this group will participate in conversation circles at the beginning and the end of the six month follow-up.
11259940|NCT02972229|Active Comparator|whole body group|10x3 Gy IMRT on whole vertebral body
11259602|NCT02974400|Experimental|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
11259603|NCT02974400|No Intervention|Wait-List|Wait-list control group (8 weeks)
11259604|NCT02974387|Active Comparator|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
11259605|NCT02974387|Active Comparator|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
11259606|NCT02974374|Experimental|PF-06835919|
11259607|NCT02974374|Placebo Comparator|Placebo|
11259608|NCT02974361|Active Comparator|Part A Ibuprofen control|
11259609|NCT02974361|Experimental|Part A Ibuprofen-LDH|
11259610|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 1|
11259611|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 2|
11259612|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 3|
11259613|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 4|
11259614|NCT02974361|Active Comparator|Part A Ibuprofen Lysine|
11259615|NCT02974361|Active Comparator|Part B Ibuprofen|
11259616|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 1|
11259617|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 2|
11259618|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 3|
11259619|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 4|
11259620|NCT02974361|Active Comparator|Part C Ibuprofen|
11259621|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 1|
11259622|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 2|
11259623|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 3|
11259624|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 5|
11259625|NCT02974348|Active Comparator|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
11259626|NCT02974348|Active Comparator|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
11259627|NCT02974348|Active Comparator|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
11259628|NCT02974348|Other|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
11259629|NCT02974348|Other|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
11259630|NCT02974348|Other|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
11259631|NCT02974335||Identify screening and intervention approaches|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
11259632|NCT02974322|Experimental|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
11259633|NCT02974322|Experimental|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
11259634|NCT02974322|Placebo Comparator|Placebo once daily|Placebo once daily (QD)
11259635|NCT02974309|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
11259636|NCT02974309|Sham Comparator|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
11259637|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
11259638|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
11259639|NCT02974283|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
11259640|NCT02974283|No Intervention|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
11259641|NCT02974270|Experimental|Leuprolide acetate|
11259642|NCT02974257|Experimental|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
11259643|NCT02974257|Placebo Comparator|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
11259644|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
11259645|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
11259646|NCT02974205|Active Comparator|Rehabilitation with orthosis (Jack brace)|
11259647|NCT02974205|Active Comparator|Rehabilitation without orthosis|
11259648|NCT02974205|Active Comparator|Rehabilitation with orthosis (össur brace)|
11259649|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
11259650|NCT02974166|Active Comparator|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
11259651|NCT02974166|Experimental|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
11259652|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
11259653|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
11259654|NCT02974153|Placebo Comparator|Placebo|Placebo (IV)
11259655|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
11259656|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
11259657|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
11259658|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
11259659|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
11259660|NCT02974101|Experimental|spinal cord stimulation(RestoreSensor)|
11259661|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
11259662|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
11259663|NCT02974075|Experimental|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
11259664|NCT02974062|Experimental|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
11259665|NCT02974062|No Intervention|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
11259666|NCT02974049|Active Comparator|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
11259667|NCT02974049|Experimental|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
11259668|NCT02974049|Experimental|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
11259669|NCT02974049|Experimental|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
11259670|NCT02974036|Experimental|Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
11259671|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
11259672|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone componenet of NRX-101
11259673|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib mesylate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 courses.
11259674|NCT02973971||Healthy subjects|
11259675|NCT02973971||Alzheimer patients|
11259676|NCT02973958|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen post-operatively as needed.
11259677|NCT02973958|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
11259678|NCT02973945|Experimental|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
11259679|NCT02973945|Active Comparator|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
11259680|NCT02973932|Experimental|Internet-based psychotherapy|
11259681|NCT02973919|Experimental|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
11259682|NCT02973919|Active Comparator|Control|virtual reality exposure therapy
11259683|NCT02973906|Other|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
11259684|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
11259685|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
11259686|NCT02973893|Placebo Comparator|Placebo plus Standard Care|Placebo plus Standard Care
11259687|NCT02973893|Experimental|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose [LD])
11259688|NCT02973893|Experimental|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose [HD])
11259689|NCT02973880|Experimental|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.
~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
11259690|NCT02973880|Active Comparator|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.
~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
11259691|NCT02973867||Cohort called Elodie|Obese patients
11259692|NCT02973841|Experimental|Sono-ease group|insertion IJV catheter using sono-ease device
11259693|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
11259694|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
11259695|NCT02973828||C) Pathway development studies|Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
11259696|NCT02973828||D) On going imaging development & quality improvement|This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.
11259697|NCT02973815|Experimental|NU-HOME Intervention|Participants randomized to the intervention condition will receive the NU-HOME family intervention program that includes group sessions with other families focused on nutrition education, cooking skills, and physical activity. The intervention program also includes individual goal setting phone calls with parents and online, complementary materials.
11259698|NCT02973815|No Intervention|Delayed Intervention|Participants randomized to the delayed intervention condition will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a shortened version of the NU-HOME intervention program that was offered to the intervention families.
11259699|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
11259700|NCT02973789|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with immune checkpoint inhibitors or docetaxel
11259701|NCT02973789|Active Comparator|Best Standard of Care|Patients receive best standard of care with immune checkpoint inhibitors or docetaxel
11259702|NCT02973776|Experimental|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
11259703|NCT02973776|Active Comparator|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
11259704|NCT02973776|Active Comparator|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
11259705|NCT02973776|Active Comparator|Elocon®|"Elocon® mometasone furoate 0.1% cream
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
11259706|NCT02973776|Active Comparator|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
11259707|NCT02973776|Placebo Comparator|LEO 90100 foam vehicle|"LEO 90100 foam vehicle
~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
11259708|NCT02973763|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
11259742|NCT02973516|Experimental|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
11259709|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
11259710|NCT02973737|Experimental|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
11259711|NCT02973737|Active Comparator|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
11259712|NCT02973724|Experimental|Remifentanil|Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
11259713|NCT02973711|Experimental|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.
~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
11259714|NCT02973698|Other|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
11259715|NCT02973698|Other|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
11259716|NCT02973698|Other|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
11259717|NCT02973685|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
11259718|NCT02973685|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, with or without MMC), and embolization with polyvinyl alcohol particles (PVA).
11259719|NCT02973672|Experimental|SGM-101|
11259720|NCT02973659|Experimental|patients with palmar hyperhidrosis|oxybutynin Vs placebo
11259721|NCT02973659|Experimental|patients with plantar hyperhidrosis|oxybutynin Vs placebo
11259722|NCT02973659|Experimental|patients with axillary hyperhidrosis|oxybutynin Vs placebo
11259723|NCT02973646|Experimental|Nucleos(t)ide analogues treatment|Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
11259724|NCT02973646|Active Comparator|Peginterferon treatment|Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
11259725|NCT02973633|Active Comparator|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
11259726|NCT02973633|Active Comparator|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
11259727|NCT02973633|Active Comparator|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
11259728|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
11259729|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
11259730|NCT02973594|Active Comparator|Ivabradine|Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
11259731|NCT02973594|Placebo Comparator|Placebo|Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
11259732|NCT02973581|Experimental|metamizol|analgesic drug
11259733|NCT02973581|Experimental|acetaminophen|analgesic drug
11259734|NCT02973581|Experimental|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
11259735|NCT02973581|Experimental|Proxymetacaine|topical analgesia
11259736|NCT02973581|Placebo Comparator|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
11259737|NCT02973555|Experimental|PRP injection|
11259738|NCT02973542|Experimental|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
11259739|NCT02973542|Placebo Comparator|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
11259740|NCT02973529|Experimental|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
11259741|NCT02973529|Experimental|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
11259939|NCT02972229|Experimental|partial body group|10x(3-5) Gy IMRT on partial vertebral body
11259743|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
11259744|NCT02973490|Experimental|Transanal Tube Drainage|patients with transanal tube drainage after ESD
11259745|NCT02973490|No Intervention|Without Transanal Tube Drainage|patients without transanal tube drainage after ESD
11259746|NCT02973477|Experimental|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
11259747|NCT02973477|Experimental|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
11259748|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
11259749|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
11259750|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
11259751|NCT02973451|Active Comparator|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
11259752|NCT02973451|Active Comparator|local|Trocar Site Infiltration of Bupivacaine
11259753|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
11259754|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
11259755|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
11259756|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
11259757|NCT02973425|Active Comparator|NRT and mHealth assessment tool without feedback|"For the comparison group, implementation will be balanced in all variables except the Take a Break Intervention. The investigators will balance the two groups further by having the comparison (NRT-Sampling group) complete mHealth assessments (without feedback or goal-setting) as an attention control.
~Participants randomized to the comparison group will only have access to a mHealth assessment tool similar to the Challenge Quizzes but without feedback."
11259758|NCT02973425|Experimental|Take a Break as an augmentation to NRT in Motivation|"The Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase. Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At weeks 1 and 3 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and collect data.Participants in the intervention will receive the full tool suite."
11259759|NCT02973399|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
11259760|NCT02973386|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
11259761|NCT02973386|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
11259762|NCT02973373|Experimental|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
11259763|NCT02973373|Active Comparator|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
11259764|NCT02973360|Experimental|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
11259765|NCT02973360|Experimental|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
11259766|NCT02973360|Experimental|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
11259767|NCT02973360|Placebo Comparator|Placebo|Soybean oil
11259768|NCT02973347|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
11259769|NCT02973347|Active Comparator|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
11259770|NCT02973334|Experimental|Sugar|Effects of ingestion of sugar-sweetened beverages on acute stress response
11259771|NCT02973334|Experimental|Artificial sweetener|Effects of ingestion of artificially-sweetened beverages on acute stress response
11259772|NCT02973334|Active Comparator|Water|Effects of ingestion of water on acute stress response
11259773|NCT02973321|Experimental|SAR425899 low dose|SAR425899 will be administered once daily in addition to metformin if any
11259774|NCT02973321|Experimental|SAR425899 mid dose|SAR425899 will be administered once daily in addition to metformin if any
11259775|NCT02973321|Experimental|SAR425899 high dose|SAR425899 will be administered once daily in addition to metformin if any
11259776|NCT02973321|Placebo Comparator|Placebo low dose|Placebo will be administered once daily in addition to metformin if any
11259777|NCT02973321|Placebo Comparator|Placebo mid dose|Placebo will be administered once daily in addition to metformin if any
11259778|NCT02973321|Placebo Comparator|Placebo high dose|Placebo will be administered once daily in addition to metformin if any
11259779|NCT02973321|Active Comparator|Liraglutide|Liraglutide will be administered once daily in addition to metformin if any
11259780|NCT02973308|Other|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
11259781|NCT02973308|Other|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
11259782|NCT02973308|Other|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
11259783|NCT02973308|Other|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
11259784|NCT02973295|Experimental|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
11259785|NCT02973295|Placebo Comparator|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
11259786|NCT02973269|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
11259787|NCT02973269|Placebo Comparator|Placebo|Placebo Intramuscular injection
11259788|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
11259789|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
11259790|NCT02973217|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
11259791|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
11259792|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
11259793|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
11259794|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
11259795|NCT02973191|Experimental|JCAR015 administration|Single dose of 1.0-3.0 mg/m^2 IV cyclophosphamide, JCAR015 Dose 1 1x10^6 Tcells/kg, JCAR015 Dose 2 3x10^6 Tcells/kg
11259796|NCT02973178|Other|Usability|Evaluate and validate the user-interface of the Scanadu Urine Device by the intended users for human factors and user interface of the Scanadu Urine Device.
11259797|NCT02973178|Active Comparator|Method Comparison|"Evaluate and validate the clinical performance of the Scanadu Urine Device in the hands of intended users as compared to:
~The visual read of chemical test strips performed by lab technicians utilizing the Siemens Multistix® 10SG technology (K905396),
~Scanadu Urine Device tests performed by lab technicians."
11259798|NCT02973178|Other|Reproducibility|Evaluate the reproducibility in the hands of the lay-users after repeated testing of samples with known test levels.
11259799|NCT02973152|Active Comparator|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
11259800|NCT02973152|Active Comparator|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
11259801|NCT02973139|Active Comparator|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
11259802|NCT02973139|Active Comparator|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
11259803|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
11259804|NCT02973113|Experimental|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.
~EBVST- 1 x 10^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.
~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
11259805|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
11259806|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
11259807|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
11259808|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
11259809|NCT02973087|Experimental|All Study Participants|Participants will receive prophylaxis with rVWF in two cohorts: on-demand (OD) cohort (previously treated with OD) and pdVWF switch cohort (participants switching from prophylactic treatment with pdVWF).
11259810|NCT02973074|Other|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
11259811|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
11259812|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
11259813|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
11259814|NCT02973048|Active Comparator|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
11259815|NCT02973035|Experimental|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
11259816|NCT02973035|Experimental|Valsartan|Valsartan 40mg added to antihypertensive therapy
11259817|NCT02973022||Community CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group in the community will be exposed to the modified CC&S educational sessions in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational sessions. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
11259818|NCT02973022||Community Control Group|Once participants are randomized, they will be given survey 1. The control group in the community will be exposed to a nutrition education program in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational session. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
11259819|NCT02973022||ACEC CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group at ACEC (Adams-Columbia Electric Company) will be exposed to the modified CC&S educational sessions in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. The researchers anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
11259820|NCT02973022||ACEC Control Group|Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
11259821|NCT02972996|Experimental|Blueberry|
11259822|NCT02972996|Placebo Comparator|Placebo|
11259823|NCT02972983|Placebo Comparator|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
11259824|NCT02972983|Experimental|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
11259825|NCT02972970|Other|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
11259826|NCT02972957|Experimental|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
11259827|NCT02972957|Experimental|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
11259828|NCT02972957|No Intervention|Unvaccinated|control group C
11259829|NCT02972957|Experimental|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
11259830|NCT02972944|Experimental|Cholecystectomy group|Cholecystectomy group will undergo laparoscopic cholecystectomy within 48 hrs after randomization.
11259831|NCT02972944|Active Comparator|Non-operative group|Patients of non-operative group will be treated conservatively with intravenous antibiotics (cefuroxime) at surgical ward. Elective cholecystectomy will not be arranged.
11259832|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
11259833|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
11259834|NCT02972918||Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
11259835|NCT02972905|Placebo Comparator|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
11259836|NCT02972905|Experimental|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
11259837|NCT02972905|Experimental|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
11259838|NCT02972905|Experimental|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
11259839|NCT02972905|Placebo Comparator|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
11259840|NCT02972905|Experimental|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
11259841|NCT02972905|Experimental|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
11259842|NCT02972905|Experimental|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
11259843|NCT02972879|Active Comparator|Therapeutic Modalities|"Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing
~Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.
~Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
11259844|NCT02972879|Active Comparator|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
11259845|NCT02972866|Experimental|Noex 32mcg|"Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.
~Tretament of 28 days."
11259846|NCT02972866|Experimental|Budecort Aqua 32 mcg|"Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.
~Tretament of 28 days."
11259847|NCT02972853|Experimental|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study. For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, we acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional pilot fMRI study."
11259848|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
11259849|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
11259850|NCT02972827|Experimental|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
11259851|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
11259852|NCT02972801|Experimental|Testicular tissue biopsy|Testicular biopsy
11259853|NCT02972788|Experimental|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
11259854|NCT02972788|Sham Comparator|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
11259855|NCT02972762|Active Comparator|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
11259856|NCT02972762|Active Comparator|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
11259857|NCT02972749|Experimental|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
11259858|NCT02972749|No Intervention|Control|No intervention. patients are instructed to continue prescribed medical therapy.
11259859|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
11259860|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
11259861|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
11259862|NCT02972723|Experimental|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
11259863|NCT02972710|Active Comparator|Supine thoracic spine manipulation|Supine thoracic spine thrust manipulation (lying face-up on the treatment table) will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
11259864|NCT02972710|Active Comparator|Seated thoracic spine manipulation|Seated thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
11259865|NCT02972697|Experimental|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
11259866|NCT02972684|No Intervention|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
11259867|NCT02972684|Experimental|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
11259868|NCT02972671|Experimental|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
11259869|NCT02972671|Active Comparator|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
11259870|NCT02972658|Experimental|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
11259871|NCT02972658|Experimental|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
11259872|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
11259873|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
11259874|NCT02972645|Experimental|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
11259875|NCT02972645|Placebo Comparator|Placebo|Placebo administered SC
11259876|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
11259877|NCT02972619|Experimental|Intervention|Structured multicomponent intervention (MCI)
11259878|NCT02972619|No Intervention|Usual Care|Control group receive usual care in the polyclinics
11259879|NCT02972593|Other|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb >7 g/dL.
11259880|NCT02972593|Other|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb > 5.5 g/dL.
11259881|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
11259882|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
11259883|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
11259884|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
11259885|NCT02972567|Experimental|Probiotic|Lactobacillus strain
11259886|NCT02972567|Placebo Comparator|Control|Maltodextrin
11259887|NCT02972554|Experimental|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
11259888|NCT02972554|Placebo Comparator|Placebo|This is the control group given a placebo.
11259889|NCT02972541|Experimental|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
11259890|NCT02972541|Active Comparator|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
11259891|NCT02972528|Active Comparator|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
11259892|NCT02972528|Placebo Comparator|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
11259893|NCT02972515|Experimental|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
11259894|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
11259895|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
11259896|NCT02972489|Experimental|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
11259897|NCT02972489|Active Comparator|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
11259898|NCT02972476|Active Comparator|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
11259899|NCT02972476|Active Comparator|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
11259900|NCT02972476|Active Comparator|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
11259901|NCT02972476|Active Comparator|4: Duaklir Genuair|Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
11259902|NCT02972463|Placebo Comparator|Placebo|9 maltodextrin capsules, once daily for 12 weeks
11259903|NCT02972463|Experimental|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
11259904|NCT02972463|Experimental|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
11259905|NCT02972463|Experimental|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
11259906|NCT02972450|Experimental|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:
~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
11259907|NCT02972450|Experimental|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
11259908|NCT02972450|Experimental|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
11259909|NCT02972450|Placebo Comparator|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.
~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.
~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
11259910|NCT02972424|Experimental|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
11259911|NCT02972424|Placebo Comparator|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
11259912|NCT02972411|Experimental|Intervention|Voluntary increase in respiration
11259913|NCT02972411|Active Comparator|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
11259914|NCT02972398|Experimental|NAC group|"Participants of NAC group receive 1000 mg NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
11259915|NCT02972398|Placebo Comparator|Placebo group|"Participants of Placebo group receive placebo matched with NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)"
11259916|NCT02972372|Active Comparator|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
11259917|NCT02972372|Active Comparator|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
11259918|NCT02972359|Experimental|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
11259919|NCT02972346|Experimental|ACTH(+)|routine treatment + ACTH
11259920|NCT02972346|No Intervention|ACTH(-)|routine treatment
11259921|NCT02972333|Experimental|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
11259922|NCT02972320|Experimental|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
11259923|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
11259924|NCT02972294|Experimental|TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
11259925|NCT02972294|Experimental|Placebo TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
11259926|NCT02972294|Experimental|TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
11259927|NCT02972294|Experimental|Placebo TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid
11259928|NCT02972281|Other|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
11259929|NCT02972268|Experimental|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
11259930|NCT02972268|Placebo Comparator|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
11259931|NCT02972255|Experimental|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
11259932|NCT02972255|Placebo Comparator|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
11259933|NCT02972255|Experimental|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than [>] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
11259934|NCT02972255|Placebo Comparator|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
11259935|NCT02972255|Experimental|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
11259936|NCT02972255|Placebo Comparator|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
11259937|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
11259938|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
11259941|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
11259942|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
11259943|NCT02972203|Experimental|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
11259944|NCT02972203|Active Comparator|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
11259945|NCT02972190|Experimental|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
11259946|NCT02972190|Active Comparator|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
11259947|NCT02972177|Experimental|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
11259948|NCT02972177|Experimental|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
11259949|NCT02972164|No Intervention|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
11259950|NCT02972164|Experimental|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
11259951|NCT02972151|Experimental|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
11259952|NCT02972151|Active Comparator|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.
~（3 months after the start of the trial and 1 months after the end of the trial.）"
11259953|NCT02972125|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
11259954|NCT02972125|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
11259955|NCT02972112|Active Comparator|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
11259956|NCT02972112|Sham Comparator|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
11259957|NCT02972099|Experimental|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.
~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
11259958|NCT02972099|Placebo Comparator|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
11259959|NCT02972086|Experimental|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
11259960|NCT02972073|Experimental|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:
~core stabilization exercise
~movement system impairment approach
~neuromuscular activation using suspension
~kinematic linkage imbalance"
11259961|NCT02972073|No Intervention|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
11259962|NCT02972060|Active Comparator|ADT|"The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.
~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
11259963|NCT02972060|Experimental|ODM 201|"ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.
~Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.
~Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment."
11259964|NCT02972047|Experimental|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.
~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.
~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker
~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
11259965|NCT02972047|Sham Comparator|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)
~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)
~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker
~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
11259966|NCT02972034|Experimental|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
11259967|NCT02972034|Experimental|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11259968|NCT02972034|Experimental|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
11259969|NCT02972034|Experimental|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
11259970|NCT02972021|Other|control|Pure oxygen by nasal cannula group
11259971|NCT02972021|Experimental|HFNC|oxygen by High-flow nasal cannula
11259972|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
11259973|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
11259974|NCT02971995|Experimental|Prostate cancer/TEP scan|
11259975|NCT02971995|Active Comparator|Prostate cancer/mpMRI|
11259976|NCT02971982|Experimental|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
11259977|NCT02971982|Experimental|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
11259978|NCT02971956|Experimental|Pembrolizumab|"Pembrolizumab administered every three weeks
~Pembrolizumab will be given intravenously"
11259979|NCT02971943|Other|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
11259980|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
11259981|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
11259982|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
11259983|NCT02971917|Experimental|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
11259984|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
11259985|NCT02971891|Experimental|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
11259986|NCT02971891|Placebo Comparator|Vehicle|Vehicle Topical Gel
11259987|NCT02971878|No Intervention|Control|Culture media without addition of antioxidants
11259988|NCT02971878|Active Comparator|Treatment|Culture media with the addition of antioxidants
11259989|NCT02971865|Experimental|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
11260031|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:
~necrotizing enterocolitis (stage ≥2)
~spontaneous intestinal perforation
~feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
11259990|NCT02971865|Active Comparator|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
11259991|NCT02971839|Experimental|VX-561 20 mg|
11259992|NCT02971839|Experimental|VX-561 100 mg|
11259993|NCT02971839|Experimental|VX-561 150 mg|
11259994|NCT02971839|Active Comparator|Ivacaftor|
11259995|NCT02971839|Placebo Comparator|Placebo|
11259996|NCT02971826|Experimental|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
11259997|NCT02971813|Experimental|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
11259998|NCT02971813|Active Comparator|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
11259999|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.
~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
11260000|NCT02971787|Experimental|Probiotics and salt|Lactobacillus enrichment and salt increase
11260001|NCT02971774||questionnary|self administered questionnary
11260002|NCT02971761|Experimental|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
11260003|NCT02971748|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11260004|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
11260005|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
11260006|NCT02971722|Experimental|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260007|NCT02971722|Experimental|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260008|NCT02971722|Experimental|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260009|NCT02971722|Placebo Comparator|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260010|NCT02971722|Experimental|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260011|NCT02971722|Experimental|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260012|NCT02971722|Experimental|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260013|NCT02971722|Placebo Comparator|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
11260014|NCT02971709|Experimental|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
11260015|NCT02971709|No Intervention|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
11260016|NCT02971696|Experimental|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
11260017|NCT02971696|Active Comparator|HCC patients (Group 2)|Patient will take best supportive care
11260018|NCT02971683|Active Comparator|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
11260019|NCT02971683|Placebo Comparator|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
11260020|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
11260021|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
11260022|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
11260023|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
11260024|NCT02971644|Experimental|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
11260025|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
11260026|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
11260027|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
11260028|NCT02971605|Experimental|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
11260029|NCT02971592|Experimental|Experimental|
11260030|NCT02971592|Placebo Comparator|Placebo|
11260032|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
11260033|NCT02971553|Experimental|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
11260034|NCT02971553|Active Comparator|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
11260035|NCT02971540|Experimental|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
11260036|NCT02971540|Experimental|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
11260037|NCT02971540|Experimental|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
11260038|NCT02971540|Experimental|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
11260039|NCT02971540|Experimental|control group|no pre-emptive analgesia will be used.
11260040|NCT02971527|Experimental|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
11260041|NCT02971527|Experimental|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
11260042|NCT02971514|Experimental|Floss-Brush group|The participants flossed first followed by brushing
11260043|NCT02971514|Active Comparator|Brush-Floss group|They used dental floss after brushing
11260044|NCT02971501|Experimental|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11260045|NCT02971501|Experimental|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11260046|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
11260047|NCT02971475|Experimental|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
11260048|NCT02971475|Active Comparator|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
11260049|NCT02971462|Experimental|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
11260050|NCT02971462|No Intervention|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
11260051|NCT02971449|Experimental|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
11260052|NCT02971449|Active Comparator|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
11260053|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
11260054|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
11260055|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
11260056|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
11260057|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
11260058|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
11260059|NCT02971423|Experimental|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
11260060|NCT02971423|Experimental|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
11260061|NCT02971423|Experimental|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
11260062|NCT02971423|Experimental|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
11260063|NCT02971423|Experimental|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
11260064|NCT02971423|Experimental|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
11260085|NCT02971306|Experimental|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
11260065|NCT02971423|Experimental|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
11260066|NCT02971423|Experimental|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
11260067|NCT02971423|Experimental|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
11260068|NCT02971423|Experimental|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
11260069|NCT02971423|Experimental|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
11260070|NCT02971423|Experimental|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
11260071|NCT02971423|Experimental|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
11260072|NCT02971423|Experimental|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
11260073|NCT02971423|Experimental|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
11260074|NCT02971410|Experimental|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
11260075|NCT02971397|Experimental|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity >= 10% and > 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
11260076|NCT02971384|Experimental|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
11260077|NCT02971384|Active Comparator|Vitamin C Tablets|synthetically produced ascorbic acid
11260078|NCT02971371|Experimental|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
11260079|NCT02971371|Active Comparator|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
11260080|NCT02971358|Experimental|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
11260081|NCT02971345|Experimental|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.
~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
11260082|NCT02971345|Active Comparator|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
11260083|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
11260084|NCT02971306|Active Comparator|Standard Medical therapy|standard medical therapy
11260086|NCT02971306|Experimental|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
11260087|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
11260088|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
11260089|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
11260090|NCT02971254|Active Comparator|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
11260091|NCT02971254|Active Comparator|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
11260092|NCT02971241|Experimental|Immediate intervention group|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.
~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers with a lead instructor."
11260093|NCT02971241|Other|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
11260094|NCT02971228|Experimental|Part 1, Lilly glucagon or ZP4207|In Part 1, up to 10 patients will participate in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
11260095|NCT02971228|Experimental|Part 1, ZP4207 or Lilly Glucagon|In Part 1, up to 10 patients will participate in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
11260096|NCT02971228|Experimental|Part 2, Lilly glucagon or ZP4207|In Part 2, up to 10 new patients will participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
11260097|NCT02971228|Experimental|Part 2, ZP4207 or Lilly Glucagon|In Part 2, up to 10 new patients will participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
11260098|NCT02971215|Experimental|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
11260099|NCT02971215|Sham Comparator|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
11260100|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
11260101|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
11260102|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
11260103|NCT02971189|Other|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
11260104|NCT02971176|Experimental|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
11260105|NCT02971176|Active Comparator|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
11260106|NCT02971163|Experimental|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
11260107|NCT02971163|No Intervention|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
11260108|NCT02971150|Experimental|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
11260109|NCT02971150|No Intervention|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
11260110|NCT02971137|Experimental|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
11260111|NCT02971137|Active Comparator|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
11260112|NCT02971124||Healthy Elderly|
11260113|NCT02971124||Mild Cognitive Impaired Elderly|
11260114|NCT02971098|Experimental|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
11260115|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men < 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density < 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
11260116|NCT02971072|Experimental|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
11260117|NCT02971059|Experimental|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
11260118|NCT02971059|Experimental|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
11260119|NCT02971046|Experimental|Protein intake|Varying protein intakes.
11260120|NCT02971033|Placebo Comparator|placebo|placebo
11260121|NCT02971033|Experimental|20mg/day ezetimibe|20mg/day ezetimibe
11260122|NCT02971033|Experimental|40mg/day exetimibe|40mg/day ezetimibe
11260123|NCT02971020|Other|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
11260124|NCT02971020|Other|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
11260125|NCT02971007|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
11260126|NCT02971007|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
11260127|NCT02971007|Active Comparator|Fluconazole 150 mg|Fluconazole Diflucan
11260128|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates <34 weeks with in 48 hours of admission
11260129|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)
~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
11260130|NCT02970968|Experimental|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
11260131|NCT02970968|Placebo Comparator|Placebo|Placebo oral capsule for 4 weeks.
11260132|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
11260133|NCT02970942|Experimental|Semaglutide 0,1 mg|
11260134|NCT02970942|Experimental|Semaglutide 0,2 mg|
11260135|NCT02970942|Experimental|Semaglutide 0,4 mg|
11260136|NCT02970942|Placebo Comparator|Placebo 1|
11260137|NCT02970942|Placebo Comparator|Placebo 2|
11260138|NCT02970942|Placebo Comparator|Placebo 3|
11260139|NCT02970929|Experimental|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
11260140|NCT02970916|Experimental|FOLFIRI+aflibercept|
11260141|NCT02970903|Experimental|VitalPAD|Using VitalPAD prototype device
11260142|NCT02970903|Active Comparator|Control|Using traditional tools (monitors, paper records)
11260143|NCT02970890|Placebo Comparator|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
11260144|NCT02970890|Active Comparator|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
11260145|NCT02970877|Experimental|Allogenic treatment group|Fecal filtrate from 150 g stool from healthy lean donors
11260146|NCT02970877|Placebo Comparator|Autologous control group|Fecal filtrate from 150 g of the recipient's own stool
11260147|NCT02970864|Experimental|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
11260148|NCT02970838|Experimental|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
11260149|NCT02970825|Experimental|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining structured aerobic exercise (at least 20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
11260150|NCT02970825|Active Comparator|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, social relaxation, flexibility training).
11260151|NCT02970812|Experimental|Electrical Muscle Stimulation|EMS program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
11260152|NCT02970812|Placebo Comparator|Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
11260153|NCT02970786|Experimental|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c[RGDyK])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
11260154|NCT02970773|Other|rivaroxaban|Rivaroxaban Oral Tablet
11260155|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
11260156|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
11260157|NCT02970734|Experimental|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
11260158|NCT02970734|Active Comparator|Resource webpage|Webpage that provides general resources on anxiety
11260159|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
11260160|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
11260161|NCT02970708|Experimental|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
11260162|NCT02970708|Active Comparator|Patching group|amblyopia in patching group will receive patching treatment.
11260163|NCT02970695|Active Comparator|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
11260164|NCT02970695|Active Comparator|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
11260165|NCT02970695|Experimental|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
11260166|NCT02970682|Experimental|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
11260167|NCT02970682|Experimental|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
11260168|NCT02970682|Experimental|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
11260169|NCT02970669|Active Comparator|Enalapril|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.
~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
11260170|NCT02970669|Experimental|Sacubitril/Valsartan|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may have sequentially been up-titrated to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.
~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1. Patients may sequentially have been up-titrated to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
11260202|NCT02970396|Active Comparator|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
11260203|NCT02970383|Experimental|10 group|Initial prescription for 10 narcotic tabs
11260204|NCT02970383|Active Comparator|30 group|Initial prescription for 30 narcotic tabs
11260171|NCT02970656|Experimental|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
11260172|NCT02970656|No Intervention|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
11260173|NCT02970643|Experimental|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
11260174|NCT02970630|Experimental|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.
~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
11260175|NCT02970617|Active Comparator|Group A (no bell after final radiation)|Patients undergo standard of care radiation therapy with or without chemotherapy.
11260176|NCT02970617|Experimental|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
11260177|NCT02970604|Experimental|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
11260178|NCT02970604|No Intervention|No treatment|No treatment for 7 days
11260179|NCT02970591|Experimental|Diet B|Low carbohydrate diet
11260180|NCT02970591|Active Comparator|Medical treatment|Optimized Medical treatment
11260181|NCT02970591|Experimental|Diet A|Traditional dietary advice and low FODMAP content
11260182|NCT02970578|Experimental|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
11260183|NCT02970565|Experimental|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
11260184|NCT02970565|Experimental|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
11260185|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
11260186|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
11260187|NCT02970539|Experimental|Oraxol +Ramucirumab|"Oraxol (oral HM30181 + oral paclitaxel)
~HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets
~Paclitaxel - supplied as 30-mg capsules Ramucirumab - supplied as a solution at a concentration of 10 mg/mL"
11260188|NCT02970526||colorectal cancer survivors|
11260189|NCT02970513|Experimental|patients operated on for colorectal cancer|
11260190|NCT02970500|Experimental|Methylphenidate HCl 10Mg SR|Participants of the intervention group (n=20) will receive 1 capsule of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 1 and 2 capsules of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 2.
11260191|NCT02970500|Placebo Comparator|Placebo Group|Participants of the control group (n=20) will receive 1 capsule of placebo each morning during 14 days during phase 1 and 2 capsules of placebo each morning during 14 days during phase 2.
11260192|NCT02970487|Experimental|investigational device|Subjects implanted with the Precisight intraocular lens.
11260193|NCT02970474|Other|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
11260194|NCT02970461|Placebo Comparator|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
11260195|NCT02970461|Experimental|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
11260196|NCT02970448|Experimental|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
11260197|NCT02970435|Experimental|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
11260198|NCT02970435|Active Comparator|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
11260199|NCT02970409|Active Comparator|heparin|Catheter Lock Therapy with Heparin
11260200|NCT02970409|Experimental|saline|Catheter Lock Therapy with saline
11260201|NCT02970396|Active Comparator|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
11260205|NCT02970357|Other|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
11260206|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
11260207|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
11260208|NCT02970331|Experimental|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
11260209|NCT02970318|Experimental|Acalabrutinib (ACP-196)|Acalabrutinib (ACP-196) Monotherapy
11260210|NCT02970318|Active Comparator|Rituximab Plus Idelalisib or Bendamustine|Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
11260211|NCT02970305|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
11260212|NCT02970305|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
11260213|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
11260214|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
11260215|NCT02970279|Experimental|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;
~Implementation intentions
~Dose-response psychoeducation"
11260216|NCT02970253|Active Comparator|Capsular resection|Capsular resection
11260217|NCT02970253|Active Comparator|Capsular retention|Capsular retention
11260218|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
11260219|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
11260220|NCT02970240||Control group|Healthy control persons
11260221|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
11260222|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
11260223|NCT02970201|Other|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
11260224|NCT02970201|Other|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
11260225|NCT02970188|No Intervention|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
11260226|NCT02970188|Experimental|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
11260227|NCT02970175|Experimental|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
11260228|NCT02970175|Placebo Comparator|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
11260229|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
11260230|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
11260231|NCT02970136|Experimental|Home Based Screening|The participant will have the option of choosing between the clinic visit or receiving home-based screening tests (OraQuick Swab, OraQuick Fingerstick, Fecal Immunochemical Test) delivered by the community health worker
11260232|NCT02970136|Active Comparator|Clinic Based Screening|The participant will meet the Community Health Worker and will be navigated to a clinic appointment for standard screening tests
11260233|NCT02970123|Experimental|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
11260234|NCT02970123|No Intervention|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
11260235|NCT02970097|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
11260236|NCT02970097|Active Comparator|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
11260237|NCT02970084|Experimental|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.
~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
11260238|NCT02970084|No Intervention|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
11260239|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
11260240|NCT02970058|Active Comparator|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
11260241|NCT02970058|Placebo Comparator|Control|30 patients will receive sterile saline post-spinal anesthesia
11260269|NCT02969850|Experimental|Vitamin D Supplementation|Participant will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
11260242|NCT02970045||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
11260243|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
11260244|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
11260245|NCT02970019|Experimental|K0706|K0706 will be administered once a day
11260246|NCT02970019|Experimental|Placebo|Placebo will be administered once a day
11260247|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
11260248|NCT02969993|Experimental|Questionnaire|Questionnaire to previously operated patients
11260249|NCT02969980|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
11260250|NCT02969967|Experimental|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
11260251|NCT02969954|Experimental|Intervention arm|Study has one arm - who will all receive the intervention
11260252|NCT02969941|Active Comparator|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
11260253|NCT02969941|Placebo Comparator|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
11260254|NCT02969928|Active Comparator|Amoxicillin and Metronidazole|In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
11260255|NCT02969928|Experimental|Clarithromycin|In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
11260256|NCT02969915|Active Comparator|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
11260257|NCT02969915|Experimental|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
11260258|NCT02969902|Experimental|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
11260259|NCT02969902|Active Comparator|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
11260260|NCT02969889|Active Comparator|intubation time|handling the device till the endotracheal tube passing through the glottis
11260261|NCT02969889|Active Comparator|insertion time|handling of the device till the glottic visualization
11260262|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
11260263|NCT02969863|Active Comparator|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.
~Monitored for hypoglycemia"
11260264|NCT02969863|Active Comparator|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.
~Not monitored for hypoglycemia"
11260265|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.
~Monitored for hypoglycemia"
11260266|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.
~Not monitored for hypoglycemia"
11260267|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.
~Monitored for hypoglycemia"
11260268|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.
~Not monitored for hypoglycemia"
11260459|NCT02968563|Experimental|Tirabrutinib + Idelalisib|Participants will receive tirabrutinib and idelalisib for up to 104 weeks.
11260270|NCT02969850|Placebo Comparator|Placebo|Participant will receive a placebo. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
11260271|NCT02969837|Experimental|E-KRd regimen|Participants will receive elotuzumab, carfilzomib, lenalidomide, and dexamethasone.
11260272|NCT02969837|Experimental|E-Rd Regimen|Participants will receive elotuzumab, lenalidomide, and dexamethasone.
11260273|NCT02969824|No Intervention|Usual Care Group|"These individuals will undergo a period of physical rest and standard care until symptoms spontaneously resolve. For the purposes of this study, rest will be defined as the avoidance of any activities beyond those of daily living, including participation in sport and physical activity. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines."
11260274|NCT02969824|Experimental|Aerobic Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
11260275|NCT02969798|No Intervention|Healthy normal glucose tolerance (NGT) subjects|Subjects (Fasting Plasma Glucose or FPG < 100 mg/dl and 2-h PG < 140 mg/dl) without FH (family history) of diabetes in a first degree relative
11260276|NCT02969798|Active Comparator|Isolated IGT with Dapagliflozin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive dapagliflozin, 10 mg/day
11260277|NCT02969798|Active Comparator|Isolated IGT with Saxagliptin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive saxagliptin, 5 mg/day
11260278|NCT02969798|Active Comparator|Isolated IGT with Pioglitazone|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
11260279|NCT02969798|Active Comparator|Isolated IGT with Metformin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
11260280|NCT02969798|Active Comparator|Isolated IFG with Dapagliflozin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive dapagloflozin, 10mg/day
11260281|NCT02969798|Active Comparator|Isolated IFG with Saxagliptin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive saxagliptin, 10mg/day
11260282|NCT02969798|Active Comparator|Isolated IFG with Pioglitazone|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
11260283|NCT02969798|Active Comparator|Isolated IFG with Metformin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
11260284|NCT02969798|Active Comparator|IGT plus IFG with Dapagliflozin|Healthy subjects with IGT plus IFG will receive dapagliflozin, 10mg/day
11260285|NCT02969798|Active Comparator|IGT plus IFG with Saxagliptin|Healthy subjects with IGT plus IFG will receive saxagliptin, 10mg/day
11260286|NCT02969798|Active Comparator|IGT plus IFG with Pioglitazone|Healthy subjects with IGT plus IFG will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
11260287|NCT02969798|Active Comparator|IGT plus IFG with Metformin|Healthy subjects with IGT plus IFG will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
11260288|NCT02969785|Experimental|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
11260289|NCT02969785|Active Comparator|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
11260290|NCT02969772|Experimental|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
11260291|NCT02969772|Experimental|Training protocol|Training with electrical stimulation of upper limb
11260292|NCT02969759|Other|Patients|ALS defined by El Escorial Criteria.
11260293|NCT02969759|Other|Controls|Asymptomatic subjects with normal examination.
11260294|NCT02969746|Experimental|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
11260295|NCT02969746|No Intervention|control|Standard practice
11260296|NCT02969733|Experimental|Xylocaine|intravenous administration
11260297|NCT02969733|Experimental|Ketamine|intravenous administration
11260298|NCT02969733|Placebo Comparator|isotonic saline serum|isotonic saline serum intravenous administration
11260299|NCT02969720|Experimental|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
11260300|NCT02969720|Placebo Comparator|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
11260301|NCT02969707|Experimental|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
11260302|NCT02969707|Sham Comparator|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
11260303|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.
~The patients will answer to the G-STAT questionnaire."
11260304|NCT02969681|Experimental|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
~mFOLFOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
~with or without bevacizumab 5mg/kg, every 2 weeks"
11260305|NCT02969681|Active Comparator|Chemotherapy group|"mFOLFOX6:
~Oxaliplatin 85 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
~with or without bevacizumab 5mg/kg, every 2 weeks"
11260306|NCT02969655|Experimental|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
11260307|NCT02969655|Active Comparator|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
11260308|NCT02969642|Sham Comparator|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
11260309|NCT02969642|Active Comparator|Treatment|Treatment laser.
11260310|NCT02969629|Experimental|apomorphine|1.5 mg apomorphine, administered subcutaneously
11260311|NCT02969629|Placebo Comparator|Normal saline|saline, administered subcutaneously
11260312|NCT02969603|Other|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
11260313|NCT02969603|Other|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined [11C]acetate PET/MRI scan
11260314|NCT02969590|No Intervention|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
11260315|NCT02969590|Active Comparator|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).
~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.
~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.
~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
11260316|NCT02969590|Active Comparator|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).
~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.
~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.
~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
11260317|NCT02969577|Experimental|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
11260318|NCT02969577|Active Comparator|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
11260319|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
11260320|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
11260321|NCT02969538|Other|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
11260322|NCT02969538|Experimental|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
11260323|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
11260324|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
11260325|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
11260326|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
11260327|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
11260328|NCT02969512|Experimental|HIPPER|"The HIPPER group will receive 10 interactive online modules (~20 minutes each). HIPPER participants will receive email or phone contact (participant preference) to provide them with website portal access consisting of the web address, simple instructions to access the website using personalized encrypted login information to the site, and a personalized exercise program.
~Participants in the HIPPER group will also receive an exercise program. The exercise program is created by the Trainer (using the participant's baseline data) and will be provided to the participant by email or phone when providing the web portal access. Participants will be encouraged to accumulate a minimum of 30 minutes of moderate intensity physical activity, at least 5 days per week."
11260329|NCT02969512|Active Comparator|In-Person Education|To provide a comparable level of education, participants in the In-Person Education group will receive 2 x 2-hour in-person educational small group sessions as per current practice. Each session is two hours long. There will be no tailored exercise program encouraged for participants in this group. The total participation time for this group will be four hours.
11260330|NCT02969473|Active Comparator|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
11260331|NCT02969473|Experimental|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
11260332|NCT02969460|Experimental|Neurotrack Virtual Cognitive Health Program|This program is a multi-domain lifestyle intervention designed to prevent or delay cognitive decline and impairment in older at-risk adults. The first 6 months of the program emphasizes lifestyle change, while the last 6 months of the program emphasizes habit reinforcement. The program focuses on nutrition, physical exercise, and cognitive training.
11260333|NCT02969447|Experimental|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
11260334|NCT02969447|No Intervention|No additional medication after fetal expulsion|
11260335|NCT02969434|Experimental|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
11260336|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
11260337|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
11260338|NCT02969408|Experimental|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
11260339|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
11260340|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
11260341|NCT02969369|Experimental|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
11260342|NCT02969369|Placebo Comparator|Placebo Capsule|Placebo once daily
11260343|NCT02969356|Experimental|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary treatment target (TT) limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
11260344|NCT02969343|Experimental|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
11260345|NCT02969343|No Intervention|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
11260346|NCT02969330|Experimental|Glucose|Glucose ingestion
11260347|NCT02969330|Active Comparator|PES|Single session of short PES treatment before glucose ingestion.
11260348|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
11260349|NCT02969304||Off-Label|Any DMF prescription for MS patients <18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
11260350|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
11260351|NCT02969291|Other|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
11260352|NCT02969278|Experimental|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:
~T > 4 cm;
~multicentric tumors (mono or bilateral);
~primary lesion completely excised during prior diagnostic surgery
~patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0
~previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
11260353|NCT02969265|Experimental|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.
~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.
~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
11260354|NCT02969265|Experimental|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.
~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.
~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
11260355|NCT02969252|Other|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
11260356|NCT02969239|Experimental|norepinephrine|norepinephrine 5mcg intravenously administered
11260357|NCT02969239|Active Comparator|phenylephrine|phenylephrine 100mcg intravenously administered
11260358|NCT02969226|Active Comparator|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS> 0 and =< 8 cm H2O with PEEP> 0 and =< 5 cm H2O.
11260359|NCT02969226|Experimental|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team [RTs and physicians]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS>0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O.
11260360|NCT02969226|Active Comparator|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
11260462|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
11260361|NCT02969226|Active Comparator|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
11260362|NCT02969213||Genetic|patients with Gene detection (+)
11260363|NCT02969213||Metabolism|patients with Metabolic disturbance
11260364|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
11260365|NCT02969213||infection|patients with the Infection of central nervous system
11260366|NCT02969213||structure|patients with abnormal image of brain
11260367|NCT02969213||unknown|patients not found any reason
11260368|NCT02969187|Experimental|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
11260369|NCT02969187|Active Comparator|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
11260370|NCT02969148|Experimental|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
11260371|NCT02969148|Active Comparator|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
11260372|NCT02969135|Experimental|Progressive early passive and active movement|Active exercise starts one week after surgery.
11260373|NCT02969135|Active Comparator|Limited early passive movement|Active exercise starts six weeks after surgery.
11260374|NCT02969122|Active Comparator|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
11260375|NCT02969122|Experimental|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
11260376|NCT02969096|Experimental|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
11260377|NCT02969083|Other|Radical nephro-ureterectomy (RNU)|Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) <55 ml/min or unfit for cisplatin-based chemotherapy)
11260378|NCT02969083|Other|Gemcitabine/Cisplatin plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery
11260379|NCT02969083|Other|RNU plus Gemcitabine/Cisplatin|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery
11260380|NCT02969083|Other|M-VAC protocol plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery
11260381|NCT02969083|Other|RNU plus M-VAC protocol|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery
11260382|NCT02969070|Active Comparator|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
11260383|NCT02969070|Active Comparator|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
11260384|NCT02969057|No Intervention|Breakfast only|Control breakfast providing 50g carbohydrate
11260385|NCT02969057|Active Comparator|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
11260386|NCT02969057|Active Comparator|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
11260387|NCT02969057|Active Comparator|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
11260388|NCT02969057|Active Comparator|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
11260389|NCT02969044|Experimental|PF-06651600|Study Drug
11260390|NCT02969044|Placebo Comparator|Placebo|Placebo
11260460|NCT02968563|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and idelalisib for up to 104 weeks.
11260489|NCT02968342|Placebo Comparator|Placebo|Oral multivitamin supplement
11260391|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
11260392|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
11260393|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
11260394|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
11260395|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
11260396|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
11260397|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
11260398|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
11260399|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
11260400|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
11260401|NCT02969005|Experimental|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
11260402|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
11260403|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
11260404|NCT02968966|Experimental|Therapy regime|Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
11260405|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.
~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
11260406|NCT02968927|Active Comparator|2HRbEZ/4HRb|2HRbZE
11260407|NCT02968927|Experimental|Everolimus|Everolimus 0.5 MG
11260408|NCT02968927|Experimental|Auranofin|Auranofin 6 MG
11260409|NCT02968927|Experimental|Vitamin D|Vitamin D3
11260410|NCT02968927|Experimental|CC-11050|CC-11050
11260411|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
11260412|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
11260413|NCT02968901|Experimental|bitherapy|Macitentan and tadalafil
11260414|NCT02968888|Placebo Comparator|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
11260415|NCT02968888|Experimental|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
11260416|NCT02968888|Experimental|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
11260417|NCT02968875|Active Comparator|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
11260418|NCT02968875|Active Comparator|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
11260419|NCT02968849|Active Comparator|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
11260420|NCT02968849|Placebo Comparator|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
11260421|NCT02968836|Active Comparator|Active group|Blend of amino acids
11260422|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
11260423|NCT02968823|Active Comparator|Licorice|Licorice gargle
11260424|NCT02968823|Placebo Comparator|Sugar water|Sugar gargle
11260425|NCT02968810|Experimental|Group I (simvastatin)|Patients receive simvastatin PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
11260426|NCT02968810|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
11260461|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
11260427|NCT02968784|Experimental|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.
~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.
~Additional foci in the same hemisphere that are confirmed by biopsy and are < Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
11260428|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
11260429|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
11260430|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
11260431|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
11260432|NCT02968732|Experimental|Surgical|
11260433|NCT02968719|Experimental|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.
~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
11260434|NCT02968719|Experimental|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.
~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
11260435|NCT02968719|Active Comparator|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
11260436|NCT02968719|Experimental|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
11260437|NCT02968719|Experimental|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
11260438|NCT02968706|Experimental|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
11260439|NCT02968706|Active Comparator|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
11260440|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
11260441|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
11260442|NCT02968680|Experimental|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
11260443|NCT02968667|Experimental|Intervention|Intervention group received 6 weeks of empowerment program
11260444|NCT02968667|No Intervention|Treatment as usual|Medications
11260445|NCT02968654|Other|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
11260446|NCT02968654|Other|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
11260447|NCT02968641|Active Comparator|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
11260448|NCT02968641|Active Comparator|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
11260449|NCT02968641|Active Comparator|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
11260450|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.
~Interventions:
~Video Electroencephalogram (EEG)
~Point-of Care Blood Sugar Testing
~Medical Record Data Extraction
~Maternal Questionnaire"
11260451|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.
~Interventions:
~Video Electroencephalogram (EEG)
~Point-of Care Blood Sugar Testing
~Medical Record Data Extraction
~Maternal Questionnaire"
11260452|NCT02968615|Experimental|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
11260453|NCT02968602|Experimental|Minocycline|Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
11260454|NCT02968602|Placebo Comparator|Placebo|Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
11260455|NCT02968589|Experimental|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.
~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.
~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
11260456|NCT02968589|Active Comparator|Other training|"A training session for caregivers of patients with hip fracture on patient management.
~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
11260457|NCT02968576|Active Comparator|Truvada|Naked form Truvada (drug)
11260458|NCT02968576|Experimental|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
11260463|NCT02968537|Experimental|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
11260464|NCT02968537|Experimental|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
11260465|NCT02968537|Placebo Comparator|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
11260466|NCT02968537|Experimental|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
11260467|NCT02968537|Experimental|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
11260468|NCT02968537|Placebo Comparator|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
11260469|NCT02968511|Experimental|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
11260470|NCT02968498|Active Comparator|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
11260471|NCT02968498|Active Comparator|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
11260472|NCT02968485|Experimental|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
11260473|NCT02968472|Experimental|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
11260474|NCT02968459|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord MSCs
11260475|NCT02968459|Placebo Comparator|Placebo-Controlled Group|1ml of 0.9% saline
11260476|NCT02968446|Placebo Comparator|Group 1: 4 placebo - 0 Vitamin D with Valchlor|Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
11260477|NCT02968446|Experimental|Group 2: 0 placebo - 4 Vitamin D with mechloroethamine|Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.
11260478|NCT02968433|Experimental|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.
~Participants will receive 1 unit of young plasma, twice a week over a four week duration.
~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
11260479|NCT02968420|Active Comparator|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
11260480|NCT02968420|Active Comparator|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
11260481|NCT02968420|Active Comparator|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
11260482|NCT02968394|Experimental|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
11260483|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
11260484|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
11260485|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
11260486|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
11260487|NCT02968355||Subjects/Specimens|Subjects/Specimens that meet the eligibility criteria
11260488|NCT02968342|Experimental|Vaginal progesterone 8%|Vaginal progesterone application 8%
11260490|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
11260491|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
11260492|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
11260493|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
11260494|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
11260495|NCT02968303|Experimental|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
11260496|NCT02968303|No Intervention|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
11260497|NCT02968290|Active Comparator|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
11260498|NCT02968290|Active Comparator|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
11260499|NCT02968277|Experimental|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
11260500|NCT02968277|Experimental|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
11260501|NCT02968277|Experimental|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
11260502|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
11260503|NCT02968251|Experimental|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
11260504|NCT02968251|No Intervention|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
11260505|NCT02968238|Active Comparator|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
11260506|NCT02968238|Active Comparator|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
11260507|NCT02968238|Active Comparator|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
11260508|NCT02968238|Active Comparator|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
11260509|NCT02968225|Experimental|Computer Game|"All Computer Game participants will complete:
~online screening
~Diagnostic and eye-tracking pre-testing
~2 month intervention
~Eye-tracking post-testing"
11260510|NCT02968225|No Intervention|Waitlist control|"All Treatment as usual control participants will complete:
~online screening
~Diagnostic and eye-tracking pre-testing
~Eye-tracking post-testing"
11260511|NCT02968212|Experimental|clofazimine|Participants receive lamprene
11260512|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
11260513|NCT02968199|Experimental|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
11260514|NCT02968186|Experimental|Implementation program|Health professionals will receive a training and support implementation program
11260515|NCT02968186|No Intervention|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
11260516|NCT02968173|Experimental|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
11260517|NCT02968160|Experimental|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks
~* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
11260518|NCT02968160|Active Comparator|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks
~* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
11260519|NCT02968147|Experimental|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
11260520|NCT02968147|Experimental|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
11260521|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
11260522|NCT02968121|Experimental|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
11260523|NCT02968121|Experimental|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
11260524|NCT02968121|Experimental|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
11260525|NCT02968121|Experimental|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
11260526|NCT02968121|Experimental|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
11260527|NCT02968108|Experimental|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than < 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to >= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at week 8.
11260528|NCT02968108|Experimental|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects <40 kg or 390 mg for subjects >= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects <40 kg or 90 mg for subjects >= 40 kg at week 8.
11260529|NCT02968095|Experimental|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
11260530|NCT02968095|Active Comparator|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
11260531|NCT02968082|Placebo Comparator|Placebo group (P group)|"The group that not existed scopolamine ingredient.
~dosage form: apply
~dosage: 1.5 mg
~frequency: 1 times (at 9 p.m. of the day before the operation day)
~duration: Until the 24hr after operation.
~Patients will be applied patch that not existed scopolamine ingredient."
11260532|NCT02968082|Experimental|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'
~The group that existed scopolamine ingredient
~dosage form: apply
~dosage: 1.5 mg
~frequency: 1 times (at 9 p.m. of the day before the operation day)
~duration: Until the 24hr after operation.
~Patients will be applied patch that existed scopolamine ingredient."
11260533|NCT02968069|Experimental|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
11260534|NCT02968056|Experimental|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
11260535|NCT02968056|Active Comparator|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
11260536|NCT02968043|Active Comparator|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
11260537|NCT02968043|Experimental|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
11260538|NCT02968030|Experimental|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
11260539|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
11260540|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
11260541|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
11260542|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
11260543|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
11260544|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
11260545|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
11260546|NCT02967965||Cohort|Clinical Evaluation, Coronarography, Imagery by MRI, Echocardiography and Biologial samples will be collected for each patient.
11260547|NCT02967952|Active Comparator|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
11260548|NCT02967952|Active Comparator|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
11260549|NCT02967939|Experimental|DA-2802|DA-2802 319mg tablet qd
11260550|NCT02967939|Active Comparator|Viread®|Viread® 300mg tablet qd
11260551|NCT02967926|Experimental|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
11260552|NCT02967913|Experimental|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
11260553|NCT02967913|No Intervention|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
11260554|NCT02967887|Experimental|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
11260555|NCT02967874|Experimental|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.
~This group of subjects (n=16) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
11260556|NCT02967874|Active Comparator|Intra-articular Hyaluronic Acid|This group of subjects (n=11) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
11260557|NCT02967861|Active Comparator|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP & pranayama for 3 months
11260558|NCT02967861|Placebo Comparator|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
11260559|NCT02967848||Patients with Cancers in Liver|Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
11260560|NCT02967835|Experimental|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
11260600|NCT02967549|Experimental|NAVA then PAV|Infants randomised to NAVA then PAV
11260561|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.
~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
11260562|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.
~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
11260563|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
11260564|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
11260565|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
11260566|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
11260567|NCT02967783|Active Comparator|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
11260568|NCT02967783|Experimental|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
11260569|NCT02967783|Experimental|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
11260570|NCT02967770|Experimental|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
11260571|NCT02967770|Active Comparator|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
11260572|NCT02967757||liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg|
11260573|NCT02967744|Experimental|NSAID treatment|8 weeks of NSAID treatment
11260574|NCT02967731|Experimental|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
11260575|NCT02967718||Control group|the healthy patients
11260576|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
11260577|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
11260578|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
11260579|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
11260580|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
11260581|NCT02967705|Experimental|Pain management group|6 + 1 meetings 2 hours each
11260582|NCT02967705|No Intervention|Treatment as usual|Waiting list - will receive treatment as usual
11260583|NCT02967692|Experimental|Investigational treatment arm|"Part 1: Safety run-in Up to 18 evaluable patients with previously untreated unresectable or metastatic BRAF V600 mutated melanoma will be enrolled and treated at different dose levels to determine the recommended Phase 3 regimen of PDR001 in combination with dabrafenib and trametinib.
~Part 2: Biomarker cohort Approximately 20 patients with previously unresectable or metastatic BRAF V600 mutated melanoma will be enrolled to describe changes in the immune microenvironment and biomarker modulations
~Part 3: Randomized double blind Approximately 500 patients with previously untreated unresectable and metastatic BRAF V600 mutated melanoma will be enrolled to compare the anti-tumor activity of PDR001 in combination with dabrafenib and trametinib versus placebo plus dabrafenib and trametinib."
11260584|NCT02967692|Placebo Comparator|Placebo comparator arm|Matching placebo in combination with dabrafenib and trametinib
11260585|NCT02967679|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 48 weeks
11260586|NCT02967666|Experimental|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
11260587|NCT02967653|Placebo Comparator|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
11260588|NCT02967653|Experimental|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
11260589|NCT02967640|Experimental|Ketalar|ketalar injection, subacromial
11260590|NCT02967640|Placebo Comparator|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
11260591|NCT02967627|Experimental|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
11260592|NCT02967627|Active Comparator|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
11260593|NCT02967614|Experimental|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days
~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
11260594|NCT02967614|Experimental|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days
~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
11260595|NCT02967601||Elective Cesarean Section|
11260596|NCT02967588|Experimental|Intervention|
11260597|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
11260598|NCT02967562|Active Comparator|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
11260599|NCT02967562|Experimental|Sustained inflation|One fifteen second 'sustained inflation'
11260601|NCT02967549|Experimental|PAV then NAVA|Infants randomised to PAV then NAVA
11260602|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) >5 events/hour and <10 events/hour with Epworth Sleepiness Score (ESS)>9.
11260603|NCT02967536||Severe OSA|Untreated OSA patients. AHI >30 events/hour, with excessive sleepiness (ESS >9).
11260604|NCT02967536||Healthy control|Healthy control. AHI <5 events/hour.
11260605|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
11260606|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
11260607|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
11260608|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
11260609|NCT02967497|No Intervention|Blank|No intervention, just observation.
11260610|NCT02967497|Experimental|YQ1 group|Cisplatin-based chemotherapy + YQ1
11260611|NCT02967484|Experimental|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.
~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
11260612|NCT02967484|No Intervention|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.
~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
11260613|NCT02967471||ARDS group|
11260614|NCT02967471||control group|
11260615|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
11260616|NCT02967445|Experimental|Cervical pessary|Arabin Pessary
11260617|NCT02967445|Active Comparator|Cervical cerclage|McDonald Cerclage
11260618|NCT02967432|Experimental|Mupirocin|
11260619|NCT02967432|Placebo Comparator|Petroleum jelly|
11260620|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
11260621|NCT02967419||Control group|People who had normal pregnancy
11260622|NCT02967406|Experimental|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
11260623|NCT02967406|No Intervention|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
11260624|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
11260625|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
11260626|NCT02967380|Experimental|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
11260627|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
11260628|NCT02967354|Experimental|Healthy control|Healthy control
11260629|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
11260630|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
11260631|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
11260632|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
11260633|NCT02967341|Other|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
11260634|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
11260635|NCT02967315|Experimental|Study Group|"Procedures include:
~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
11260636|NCT02967302|Experimental|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
11260637|NCT02967302|Active Comparator|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
11260638|NCT02967302|Placebo Comparator|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
11260639|NCT02967289|Experimental|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
11260640|NCT02967289|Active Comparator|Arm B|mFOLFOX 6 Folfox Protocol
11260641|NCT02967276|Experimental|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.
~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
11260642|NCT02967263||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
11260643|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
11260644|NCT02967237|Experimental|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
11260645|NCT02967224|Experimental|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
11260646|NCT02967224|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
11260647|NCT02967211|Experimental|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
11260648|NCT02967211|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
11260649|NCT02967198|Experimental|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
11260650|NCT02967185|Experimental|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
11260651|NCT02967185|No Intervention|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
11260652|NCT02967172|Experimental|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:
~20 mL injected into the peri-incisional soft tissues in a circumferential fashion
~5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
~Interventions:
~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
11260653|NCT02967172|No Intervention|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
11260654|NCT02967159|Experimental|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
11260655|NCT02967159|Experimental|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
11260656|NCT02967159|Experimental|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
11260657|NCT02967159|Experimental|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
11260658|NCT02967146|Experimental|Mediclore|
11260659|NCT02967146|No Intervention|Not done|Standard treatment for surgery
11260660|NCT02967133|Active Comparator|Arm A|Nivolumab q 14 days until disease progression/toxicity
11260661|NCT02967133|Active Comparator|Arm B|"Nivolumab every 21 days until disease progression
~Nab-paclitaxel every 21 days"
11260662|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
11260663|NCT02967107|Active Comparator|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
11260664|NCT02967107|Active Comparator|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
11260665|NCT02967094|Experimental|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
11260666|NCT02967094|No Intervention|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
11260667|NCT02967094|Placebo Comparator|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
11260668|NCT02967081||Pulp necrosis|
11260669|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
11260670|NCT02967081||Irreversible pulpitis|
11260671|NCT02967081||Normal pulp|
11260672|NCT02967042|Other|18F-PET-TT|
11260673|NCT02967029|Active Comparator|b group|b group controlled hypotension with esmolol hydrochloride
11260674|NCT02967029|Active Comparator|r group|r group controlled hypotension with remifentanil hydrochloride
11260675|NCT02967016|Experimental|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
11260676|NCT02967016|Experimental|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
11260677|NCT02966990|Other|hand orthosis patients|Patients using hand orthosis for better hand function
11260678|NCT02966977|Active Comparator|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
11260679|NCT02966977|Experimental|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
11260680|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
11260681|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
11260682|NCT02966964|Placebo Comparator|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
11260683|NCT02966951|Experimental|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
11260684|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
11260685|NCT02966925|Experimental|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
11260686|NCT02966912|Experimental|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
11260687|NCT02966912|Active Comparator|Comparator|20 participants will receive no treatment
11260688|NCT02966899|Experimental|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
11260689|NCT02966886|Active Comparator|Participants with 10-15 degrees of glenoid retroversion|
11260690|NCT02966886|Active Comparator|Participants with >15 degrees of glenoid retroversion|
11260691|NCT02966873|Experimental|N-Acetylcysteine (NAC) Treatment Group|"Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.
~Participant will receive one week of study medication at a time from the study physician or the study coordinator. The study medication provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
11260692|NCT02966873|Placebo Comparator|Placebo Group|"Participant will receive 12 weeks of inactive placebo comparator daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.
~Participant will receive one week of study medication (placebo) at a time from the study physician or the study coordinator. The study medication (placebo) provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
11260693|NCT02966860|Experimental|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
11260694|NCT02966847|Experimental|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
11260695|NCT02966834|Placebo Comparator|Placebo|Subjects will receive matching placebo
11260696|NCT02966834|Experimental|GSK2330672 20 mg once daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
11260697|NCT02966834|Experimental|GSK2330672 90 mg once daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
11260698|NCT02966834|Experimental|GSK2330672 180 mg once daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
11260699|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Subjects will receive GSK2330672 and matching placebo to maintain blind
11260700|NCT02966821|Experimental|Surufatinib|Surufatinib 300mg once-daily
11260701|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
11260702|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 8 Weeks|Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
11260703|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 12 Weeks|Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.
11260704|NCT02966782|Experimental|Venetoclax monotherapy (Cohort 1)|
11260705|NCT02966782|Experimental|Venetoclax + azacitidine (Cohort 2)|
11260706|NCT02966782|Experimental|Safety Expansion (Cohort 3)|
11260707|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (>/= 60 Gy) plus Platinum-based Chemotherapy
11260708|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus >/= 45Gy) followed by Surgery
11260709|NCT02966756|Experimental|Venetoclax|Participants will receive various doses of venetoclax once daily (QD).
11260710|NCT02966743|Experimental|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
11260711|NCT02966743|Active Comparator|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
11260712|NCT02966730|Experimental|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
11260713|NCT02966717|Active Comparator|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
11260797|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
11260714|NCT02966717|Experimental|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
11260715|NCT02966704|Experimental|meal 1|mixed meal with high level of intrinsically labeled milk protein
11260716|NCT02966704|Experimental|meal 2|mixed meal with low level of intrinsically labeled milk protein
11260717|NCT02966691|Active Comparator|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :
~a positive result of bladder endoscopy
~or an negative endoscopy and a positive result of the conventional cytology
~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
11260718|NCT02966691|Active Comparator|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.
~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
11260719|NCT02966691|Active Comparator|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).
~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
11260720|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
11260721|NCT02966665|Experimental|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260722|NCT02966665|Experimental|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260723|NCT02966665|Experimental|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260724|NCT02966665|Experimental|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260725|NCT02966665|Experimental|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260726|NCT02966665|Experimental|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260727|NCT02966665|Experimental|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
11260728|NCT02966652|Active Comparator|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
11260729|NCT02966652|Experimental|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
11260730|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
11260731|NCT02966613|Active Comparator|CI|TKA using conventional instrumentation (CI)
11260732|NCT02966613|Experimental|PSCG|TKA performed using Patient specific cutting guides (PSCG)
11260733|NCT02966613|Experimental|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
11260798|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
11260734|NCT02966600|Experimental|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
11260735|NCT02966600|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine
11260736|NCT02966587|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
11260737|NCT02966574|Experimental|metastatic breast cancer|
11260738|NCT02966561|Experimental|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
11260739|NCT02966561|Active Comparator|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
11260740|NCT02966548|Experimental|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
11260741|NCT02966548|Experimental|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
11260742|NCT02966535|Experimental|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
11260743|NCT02966535|Active Comparator|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
11260744|NCT02966522|Experimental|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
11260745|NCT02966509|Experimental|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
11260746|NCT02966509|No Intervention|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
11260747|NCT02966496|Experimental|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
11260748|NCT02966496|Experimental|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
11260749|NCT02966483|Experimental|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
11260750|NCT02966483|Active Comparator|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
11260751|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
11260752|NCT02966457|Experimental|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
11260753|NCT02966457|No Intervention|"Wait and watch strategy"|Group without decolonization interventions
11260754|NCT02966444|Experimental|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
11260755|NCT02966444|Experimental|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
11260756|NCT02966444|Experimental|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
11260757|NCT02966431|Experimental|Counseling|Receive counseling for 8-wks
11260758|NCT02966431|Placebo Comparator|Control|Does not receive counseling for 8-wks
11260759|NCT02966418|Active Comparator|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
11260760|NCT02966418|Sham Comparator|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
11260761|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
11260762|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
11260763|NCT02966392|Experimental|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
11260764|NCT02966392|No Intervention|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
11260765|NCT02966379|Experimental|Cochlear implantation|Cochlear implantation with EVO electrode lead. This electrode lead has been specially designed for atraumatic surgery, in order to preserve the residual hearing of the patients included in the study. All patients are implanted with the same electrode lead.
11260766|NCT02966366|Experimental|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
11260767|NCT02966353|Experimental|All Subjects|10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.
11260768|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
11260769|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
11260770|NCT02966327|Experimental|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
11260771|NCT02966327|Other|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
11260772|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
11260773|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
11260774|NCT02966301|Experimental|interventional|Single arm : Arsenic trioxide Injectable Solution
11260775|NCT02966288|Experimental|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
11260776|NCT02966288|Active Comparator|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
11260777|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.
~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
11260778|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.
~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
11260779|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
11260780|NCT02966249|Other|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
11260781|NCT02966249|Active Comparator|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
11260782|NCT02966249|Active Comparator|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
11260783|NCT02966249|Placebo Comparator|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
11260784|NCT02966249|Other|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
11260785|NCT02966249|Other|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
11260786|NCT02966236|Experimental|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
11260787|NCT02966236|Placebo Comparator|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
11260788|NCT02966223|Experimental|MRI and HIDA scan|
11260789|NCT02966197|Experimental|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
11260790|NCT02966197|No Intervention|Control group|no intervention
11260791|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
11260792|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
11260793|NCT02966171|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
11260794|NCT02966158|Experimental|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.
~The AIT exercise protocol includes the following components:
~Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.
~Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.
~Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
11260795|NCT02966158|No Intervention|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.
~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.
~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
11260796|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
11260799|NCT02966132|Experimental|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
11260800|NCT02966132|Active Comparator|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
11260801|NCT02966119|Experimental|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
11260802|NCT02966119|No Intervention|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
11260803|NCT02966106|Active Comparator|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
11260804|NCT02966106|Placebo Comparator|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
11260805|NCT02966093|Experimental|Lenvatinib|In the randomization phase, participants will receive lenvatinib until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
11260806|NCT02966093|Experimental|Placebo|In the randomization phase, participants will receive lenvatinib matched placebo until disease progression. Participants who discontinue due to confirmed disease progression will enter Extension Phase. Participants who discontinue without confirmed disease progression will be followed for tumor assessment until confirmed disease progression or initiation of anticancer therapy, at which time the participants will enter Follow-up period of Extension Phase.
11260807|NCT02966080|Other|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
11260808|NCT02966080|Other|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
11260809|NCT02966067|Experimental|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
11260810|NCT02966067|Active Comparator|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
11260811|NCT02966054|Experimental|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
11260812|NCT02966054|No Intervention|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
11260813|NCT02966041|Experimental|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
11260814|NCT02966041|Placebo Comparator|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
11260815|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
11260816|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
11260817|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
11260818|NCT02966015|Experimental|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
11260819|NCT02966002|Experimental|Intervention: aspirin|650 mg. Twice a day for 8 weeks
11260820|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
11260821|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
11260822|NCT02965976|Experimental|Arm I (botulinum toxin type A, esophagectomy)|Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
11260823|NCT02965976|Active Comparator|Arm II (esophagectomy)|Patients undergo standard minimally invasive esophagectomy.
11260824|NCT02965963|Experimental|Dopamine|Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max
11260825|NCT02965963|Experimental|Metoclopramide|Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max
11260826|NCT02965963|Experimental|Placebos|Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max
11260827|NCT02965950|Experimental|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide
11260828|NCT02965950|Experimental|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide
11260829|NCT02965950|Experimental|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide
11260830|NCT02965950|Experimental|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide
11260900|NCT02965482|Active Comparator|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
11260831|NCT02965937|Experimental|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
11260832|NCT02965937|Active Comparator|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
11260833|NCT02965924|Experimental|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
11260834|NCT02965911|Active Comparator|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
11260835|NCT02965911|Experimental|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
11260836|NCT02965898|Active Comparator|Vitamin D 100ug|The highest safest dose. Expected to lower risk of chronic pancreatitis after acute pancreatitis.
11260837|NCT02965898|Placebo Comparator|Vitamin D 10ug|Placebo dose. Minimal recommended dose
11260838|NCT02965885|Experimental|TAS-116|
11260839|NCT02965872||Healthy individuals|
11260840|NCT02965859|Experimental|Metacavir Enteric-coated Capsule 80mg|"Metacavir Enteric-coated Capsules 80mg
~Metacavir Enteric-coated Capsules Placebo 240mg
~Adefovir Dipivoxil Capsule Placebo 10mg;"
11260841|NCT02965859|Active Comparator|Metacavir Enteric-coated Capsules 160mg|"Metacavir Enteric-coated Capsules 160mg
~Metacavir Enteric-coated Capsules Placebo 160mg
~Adefovir Dipivoxil Capsule Placebo 10mg;"
11260842|NCT02965859|Placebo Comparator|Metacavir Enteric-coated Capsules 320mg|"Metacavir Enteric-coated Capsules 320mg
~Adefovir Dipivoxil Capsule Placebo 10mg"
11260843|NCT02965859|Active Comparator|Adefovir Dipivoxil Capsule|"Metacavir Enteric-coated Capsules Placebo 320mg
~Adefovir Dipivoxil Capsule 10mg;"
11260844|NCT02965859|Placebo Comparator|Placebo|"Metacavir Enteric-coated Capsules Placebo 320mg
~Adefovir Dipivoxil Capsule Placebo 10mg;"
11260845|NCT02965846|Experimental|AGN-195263|
11260846|NCT02965846|Placebo Comparator|Vehicle|
11260847|NCT02965833|Other|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
11260848|NCT02965833|Other|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
11260849|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
11260850|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
11260851|NCT02965807|Experimental|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
11260852|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
11260853|NCT02965794||Care Pathway|Care pathways for colorectal cancer
11260854|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
11260855|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
11260856|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
11260857|NCT02965768|Active Comparator|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
11260858|NCT02965768|Other|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo
~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
11260859|NCT02965755|Other|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
11260860|NCT02965742|Experimental|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
11260861|NCT02965742|Experimental|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
11260862|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
11261042|NCT02964598|Experimental|Sleep coaching + bright light|A combination of the two
11260863|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
11260864|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
11260865|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
11260866|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity.
11260867|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity.
11260868|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity.
11260869|NCT02965690|Active Comparator|NexGen CR|Patients receive a NexGen Total Knee Replacement
11260870|NCT02965690|Active Comparator|GMK Sphere|Patients receive a GMK Total Knee Replacement
11260871|NCT02965677|Experimental|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
11260872|NCT02965677|Active Comparator|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
11260873|NCT02965664|Experimental|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
11260874|NCT02965664|Placebo Comparator|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
11260875|NCT02965651|Experimental|ECA System|Access to website and virtual patient advocate
11260876|NCT02965651|No Intervention|Standard of Care|Patient information sheets and meditation CD
11260877|NCT02965638|Active Comparator|Oxygen Group|The mothers will be asked to be on 4 liter of oxygen through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
11260878|NCT02965638|Placebo Comparator|Control Group|The mothers will be asked to be on air through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
11260879|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
11260880|NCT02965612|Experimental|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
11260881|NCT02965612|Active Comparator|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
11260882|NCT02965599|Experimental|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
11260883|NCT02965599|Placebo Comparator|Placebo|Subjects will receive placebo for 28 days.
11260884|NCT02965586|Active Comparator|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
11260885|NCT02965586|Active Comparator|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
11260886|NCT02965586|Placebo Comparator|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
11260887|NCT02965573|Active Comparator|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
11260888|NCT02965573|Placebo Comparator|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
11260889|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
11260890|NCT02965547|Experimental|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation)
11260891|NCT02965534|Experimental|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
11260892|NCT02965534|Active Comparator|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
11260893|NCT02965521|Experimental|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
11260894|NCT02965521|No Intervention|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
11260895|NCT02965508|Experimental|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
11260896|NCT02965508|Active Comparator|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
11260897|NCT02965495|Experimental|YYD302 2ml|YYD302 2ml
11260898|NCT02965495|Experimental|YYD302 3ml|YYD302 3ml
11260899|NCT02965495|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
11260901|NCT02965482|Active Comparator|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
11260902|NCT02965469|No Intervention|Usual care|Participants randomized to this arm will have no change to their usual care
11260903|NCT02965469|Experimental|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
11260904|NCT02965456|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
11260905|NCT02965456|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
11260906|NCT02965443|Active Comparator|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
11260907|NCT02965443|Placebo Comparator|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
11260908|NCT02965430|Experimental|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
11260909|NCT02965417|Experimental|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
11260910|NCT02965404|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated varicella vaccine."
11260911|NCT02965404|Active Comparator|Positive Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;
~Intervention: control live attenuated varicella vaccine."
11260912|NCT02965404|Sham Comparator|Negative Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;
~Intervention: diluent of lyophilized vaccine."
11260913|NCT02965378|Experimental|Arm I (AZD4547)|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11260914|NCT02965378|Experimental|Arm II (docetaxel - closed to accrual 12/18/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients may be eligible to re-register to Arm III.
11260915|NCT02965378|Experimental|Arm III (AZD4547 re-registration)|Patients in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11260916|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
11260917|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
11260918|NCT02965352|Experimental|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
11260919|NCT02965326|Other|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
11260920|NCT02965326|Other|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
11260921|NCT02965326|Other|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
11260922|NCT02965313|Active Comparator|SSLS Procedure|
11260923|NCT02965313|Active Comparator|BSSVF-M Procedure|
11260924|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
11260925|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
11260926|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
11260927|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.
~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
11260928|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
11260929|NCT02965274|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
11260930|NCT02965274|Active Comparator|Reference|Warner Chilcott LLC, USA
11260931|NCT02965261|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
11260932|NCT02965261|Active Comparator|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
11260933|NCT02965248|Active Comparator|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
11260934|NCT02965248|Experimental|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
11260935|NCT02965248|Experimental|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
11260936|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
11260937|NCT02965235||POCD|Patients who develop POCD after surgery.
11260938|NCT02965222|Experimental|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
11261043|NCT02964585|Active Comparator|Active Arm|100 mg of Canagliflozin for 16 weeks
11260939|NCT02965222|Experimental|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
11260940|NCT02965209|Experimental|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
11260941|NCT02965196|Active Comparator|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
11260942|NCT02965196|Placebo Comparator|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
11260943|NCT02965183|Experimental|Temperature measurements|
11260944|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
11260945|NCT02965157|Experimental|CART20|
11260946|NCT02965144||HGG patients|single-group study- long term survivors
11260947|NCT02965131|No Intervention|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
11260948|NCT02965131|Experimental|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
11260949|NCT02965118|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
11260950|NCT02965118|Placebo Comparator|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
11260951|NCT02965105|Experimental|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
11260952|NCT02965105|Experimental|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
11260953|NCT02965092|Experimental|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
11260954|NCT02965066|Experimental|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
11260955|NCT02965066|Experimental|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
11260956|NCT02965053|Experimental|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
11260957|NCT02965053|Experimental|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
11260958|NCT02965053|Experimental|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
11260959|NCT02965053|Experimental|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
11260960|NCT02965040|Experimental|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m^2. Single dose of roxadustat
11260961|NCT02965040|Experimental|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m^2. Single dose of roxadustat
11260962|NCT02965040|Experimental|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
11260963|NCT02965040|Experimental|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
11260964|NCT02965027|Experimental|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
11260965|NCT02965027|Placebo Comparator|Placebo|Placebo capsules
11260966|NCT02965014|Experimental|Face-to-Face Young Women's CoOp (YWC)|Participants in this arm will be offered a two-session face-to-face Young Women's CoOp (YWC) intervention.
11260967|NCT02965014|Experimental|mHealth Young Women's CoOp (YWC)|Participants in this arm will be offered training on the mobile health application mHealth Young Women's CoOp (YWC) and offered tablets with the mHealth application to complete the two-session intervention.
11260968|NCT02965014|Active Comparator|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing services.
11260969|NCT02965001|Experimental|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
11260970|NCT02964988|Experimental|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
11260971|NCT02964975|Active Comparator|Optimal medical therapy|conservative treatment
11260972|NCT02964975|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
11260973|NCT02964962|Experimental|29 mm LOTUS Edge™|
11260974|NCT02964949|Experimental|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
11260975|NCT02964949|Active Comparator|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
11260976|NCT02964936|Experimental|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
11261044|NCT02964585|Placebo Comparator|Placebo Arm|Placebo for 16 weeks
11260977|NCT02964936|Experimental|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
11260978|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
11260979|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
11260980|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.
11260981|NCT02964910|Experimental|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
11260982|NCT02964910|Active Comparator|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
11260983|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
11260984|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
11260985|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.
~And one week of intensive, one-on-one reading tutoring intervention"
11260986|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
11260987|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
11260988|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.
~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
11260989|NCT02964871|Active Comparator|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
11260990|NCT02964871|Placebo Comparator|LTCF Control|"Usual care.
~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
11260991|NCT02964858|Active Comparator|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
11260992|NCT02964858|Experimental|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
11260993|NCT02964845|Experimental|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
11260994|NCT02964845|Other|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
11260995|NCT02964832|Active Comparator|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
11260996|NCT02964832|Active Comparator|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
11260997|NCT02964832|Active Comparator|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
11260998|NCT02964819|Active Comparator|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
11261045|NCT02964572|Active Comparator|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
11261046|NCT02964572|Experimental|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
11260999|NCT02964819|Experimental|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
11261000|NCT02964819|Placebo Comparator|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
11261001|NCT02964806|Other|Ordinary Diet|Ordinary Diet
11261002|NCT02964806|Other|Modified Atkin's Diet|Modified Atkin's Diet
11261003|NCT02964806|Other|Ketogenic Diet|Ketogenic Diet
11261004|NCT02964793|Experimental|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
11261005|NCT02964793|No Intervention|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
11261006|NCT02964780||Gastric Bypass Surgery|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
11261007|NCT02964780||Conservative weight loss|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
11261008|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
11261009|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
11261010|NCT02964754|Experimental|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
11261011|NCT02964754|Experimental|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
11261012|NCT02964741|Active Comparator|Migraine Patients Active Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
~*Active Comparator"
11261013|NCT02964741|Sham Comparator|Migraine Patients Sham Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
~*Sham Comparator"
11261014|NCT02964741|No Intervention|Healthy Control Group|"Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).
~Healthy volunteer data (n </= 10) may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
11261015|NCT02964728|Experimental|Botulinum toxin type A|Botulinum neurotoxin injections
11261016|NCT02964728|Placebo Comparator|Placebo|Normal saline solution injections
11261017|NCT02964715|Experimental|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
11261018|NCT02964702|Experimental|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
11261019|NCT02964689|Experimental|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:
~Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib
~Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
11261020|NCT02964676|Experimental|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
11261021|NCT02964676|Active Comparator|Trab group|PACG in AIT group will receive trabeculectomy.
11261022|NCT02964650|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
11261023|NCT02964650|Experimental|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
11261024|NCT02964637||Progressive supranuclear palsy|Observational Study
11261025|NCT02964637||Corticobasal syndrome|Observational Study
11261026|NCT02964637||Behavoral variant FTD|Observational Study
11261027|NCT02964637||Semantic variant PPA|Observational Study
11261028|NCT02964637||Non-fluent variant PPA|Observational Study
11261029|NCT02964637||FTD-motor neuron disease|Observational Study
11261030|NCT02964637||Healthy controls|Observational Study
11261031|NCT02964624|Other|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
11261032|NCT02964611||Alzheimer's disease|Observational Study
11261033|NCT02964611||Parkinson's disease|Observational Study
11261034|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
11261035|NCT02964611||Healthy Controls|Observational Study
11261036|NCT02964598|Experimental|Control|Minimal information on sleep timing
11261037|NCT02964598|Experimental|Psychoeducation|An extensive psychoeducational platform
11261038|NCT02964598|Experimental|Bright light|Bright light treatment with 10 000 lux at max
11261039|NCT02964598|Experimental|Gamified intervention|A new gamified intervention designed for mobile phones
11261040|NCT02964598|Experimental|Bright light and gamified intervention|A combination of the two
11261041|NCT02964598|Experimental|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
11261047|NCT02964559|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11261048|NCT02964546||Blood sample|
11261049|NCT02964533|Experimental|TFM|thunder-fire moxibustion therapy
11261050|NCT02964533|Active Comparator|MSM|common moxa-stick moxibustion therapy
11261051|NCT02964520|Experimental|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
11261052|NCT02964520|Sham Comparator|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).
~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
11261053|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|In Phase I, all subjects will receive treatment with GSK525762 in combination with fulvestrant. Dosing will be continued until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
11261054|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|Subjects will receive treatment with GSK525762 in combination with fulvestrant, at a GSK525762-dose level selected from Phase I. Dosing will be continued until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
11261055|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|In Phase II, subjects will receive treatment with placebo in combination with fulvestrant. Dosing will be continued until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
11261056|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
11261057|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
11261058|NCT02964468|Experimental|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
11261059|NCT02964468|Active Comparator|Treatment with 3DCRT|3DCRT treatment (sequential boost)
11261060|NCT02964455|Experimental|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation.
11261061|NCT02964442|Experimental|Capsinoids|8 gel capsules equivalent to 12mg
11261062|NCT02964442|Experimental|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
11261063|NCT02964429|Experimental|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
11261064|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
11261065|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
11261066|NCT02964403|Experimental|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
11261067|NCT02964403|Active Comparator|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
11261068|NCT02964390|Experimental|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
11261069|NCT02964377|Experimental|Open-label (+)- Epicatechin|8-weeks open-label (+)- Epicatechin at 25mg/day twice per day, 25mg/day three times per day, or 75mg/day at two times per day.
11261070|NCT02964351||High PSA (prostate-specific antigen) levels|
11261071|NCT02964338|Placebo Comparator|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
11261072|NCT02964338|Experimental|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
11261073|NCT02964338|Experimental|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
11261074|NCT02964325|Experimental|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
11261075|NCT02964325|Active Comparator|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
11261076|NCT02964312|Other|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
11261077|NCT02964299||Standard|Standard bite block
11261078|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
11261079|NCT02964286|Experimental|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
11261080|NCT02964286|No Intervention|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
11261110|NCT02964039|Sham Comparator|Activity matched control|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in transparent mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
11261081|NCT02964273|Experimental|Tolvaptan|"Participants received Tolvaptan (TLV) spray dried, immediate release tablets orally as a split-dose, with first dose taken upon awakening and second dose taken approximately 8 hours later for up to data cut-off date 2 December 2019 (12 months) in Phase A followed by open-label tolvaptan for 24 months in Phase B. Starting doses of active tolvaptan were based on weight:
~≥ 20 kg to < 45 kg, 15/7.5 mg TLV split-dose
~≥ 45 kg to ≤ 75 kg, 30/15 mg TLV split-dose
~75 kg, 45/15 mg TLV split-dose After 1 week, participants received up titrated active tolvaptan.
~≥ 20 kg to < 45 kg, 30/15 mg TLV split-dose
~≥ 45 kg to ≤ 75 kg, 45/15 mg TLV split-dose
~75 kg, 60/30 mg TLV split-dose Participants who completed Phase A were eligible for Phase B to receive tolvaptan based on the body weight up to Month 24."
11261082|NCT02964273|Placebo Comparator|Placebo|"Participants received matching-placebo spray dried, immediate release tablets orally as a split-dose, with first dose taken upon awakening and second dose taken approximately 8 hours later for up to data cut-off date 2 December 2019 (12 months) in Phase A followed by open-label matching-placebo for 24 months in Phase B. Starting doses were based on weight:
~≥ 20 kg to < 45 kg, 15/7.5 mg matching placebo split-dose
~≥ 45 kg to ≤ 75 kg, 30/15 mg matching placebo split-dose
~75 kg, 45/15 mg matching placebo split-dose After 1 week, participants received up titrated doses.
~≥ 20 kg to < 45 kg, 30/15 mg matching placebo split-dose
~≥ 45 kg to ≤ 75 kg, 45/15 mg matching placebo split-dose
~75 kg, 60/30 mg matching placebo split-dose Participants who completed Phase A were eligible for Phase B to receive tolvaptan based on the body weight up to Month 24."
11261083|NCT02964260|Experimental|TAE combined ablation simultaneously|TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
11261084|NCT02964260|Other|TACE combined ablation sequentially|TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
11261085|NCT02964247|Experimental|liraglutide + SGLT2i ± metformin|
11261086|NCT02964247|Placebo Comparator|liraglutide placebo + SGLT2i ± metformin|
11261087|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
11261088|NCT02964234|Experimental|Education|Behavior: Education
11261089|NCT02964195|Experimental|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
11261090|NCT02964195|No Intervention|Control|Routine endoscopic treatment without prophylactic use of antibiotics
11261091|NCT02964182|Experimental|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.
~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.
~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
11261092|NCT02964182|Experimental|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.
~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.
~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
11261093|NCT02964169|Experimental|Family Planning Support|Family planning voucher and phone reminders
11261094|NCT02964169|No Intervention|No Family Planning Support|Routine care
11261095|NCT02964156|Experimental|Walking test using insoles|Supersole
11261096|NCT02964156|Experimental|Walking test not using insoles|no intervention
11261097|NCT02964143|Experimental|Experimental group|Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device
11261098|NCT02964143|Active Comparator|Control group 1|Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil® Plus
11261099|NCT02964143|Active Comparator|Control group 2|Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1
11261100|NCT02964130|Other|Follow-up patient|Medical follow-up visit
11261101|NCT02964104|Experimental|Insulin 287 + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
11261102|NCT02964104|Active Comparator|Insulin degludec + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
11261103|NCT02964091|Other|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
11261104|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
11261105|NCT02964065|Experimental|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
11261106|NCT02964065|Placebo Comparator|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
11261107|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
11261108|NCT02964039|Experimental|Error reduction|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error reduction mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
11261109|NCT02964039|Experimental|Error augmentation|"Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in error augmentation mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period."
11261111|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
11261112|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
11261113|NCT02964013|Experimental|vibostolimab|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of vibostolimab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261114|NCT02964013|Experimental|vibostolimab + pembrolizumab (pembro)|During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of vibostolimab has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of vibostolimab is established, participants will continue receiving the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261115|NCT02964013|Experimental|Advanced solid tumor cohort|Participants will receive the RPTD of vibostolimab monotherapy or the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261116|NCT02964013|Experimental|Randomized dose 1 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261117|NCT02964013|Experimental|Randomized dose 2 comparison cohort|Participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261118|NCT02964013|Experimental|vibostolimab +pembro+pemetrexed+carboplatin|Participants will receive a fixed dose of vibostolimab in combination with 200 mg pembrolizumab, 500 mg/m^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of vibostolimab in combination with 200 mg pembrolizumab and 500 mg/m^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
11261119|NCT02964013|Experimental|vibostolimab Dose 1 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261120|NCT02964013|Experimental|vibostolimab Dose 2 Japanese cohort|Japanese participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
11261121|NCT02964013|Experimental|MK-7684A|Participants will receive a fixed dose of MK-7684A, consisting of 200 mg of vibostolimab + 200 mg pembrolizumab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
11261122|NCT02964000|Active Comparator|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.
~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.
~Each treatment session will last for 20-40 minutes."
11261123|NCT02964000|Experimental|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.
~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.
~Each treatment session will last for 20-40 minutes."
11261124|NCT02964000|Experimental|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.
~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.
~Each treatment session will last for 20-40 minutes."
11261125|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
11261126|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
11261127|NCT02963974|Experimental|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
11261128|NCT02963961|Experimental|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
11261129|NCT02963961|No Intervention|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
11261130|NCT02963948||Medical Staff|Approximately 40 medical staff will be enrolled for the focus groups
11261131|NCT02963948||Medical staff surveyed using SAAS|Approximately 100 medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS)
11261132|NCT02963948||Wave 1 Patients|Approximately 200 patients at a Wave 1 clinic
11261133|NCT02963935|Experimental|Liraglutide|
11261134|NCT02963935|Placebo Comparator|Placebo|
11261135|NCT02963922|Experimental|liraglutide 3.0 mg|
11261136|NCT02963922|Placebo Comparator|Placebo|
11261137|NCT02963909|Experimental|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
11261138|NCT02963909|Experimental|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
11261139|NCT02963909|Experimental|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
11261140|NCT02963896|Experimental|gentamicin|intratympanic application of gentamicin 0.5 ml
11261141|NCT02963883|Experimental|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
11261142|NCT02963883|Active Comparator|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of <9 g / dl for patients with cardiovascular antecedents.
11261143|NCT02963870|Experimental|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
11261144|NCT02963870|Active Comparator|standard treatment only.|group receiving standard treatment only.
11261145|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
11261146|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
11261147|NCT02963831|Experimental|Dose Escalation|"During Phase 1 of the study, subjects will be evaluated for DLTs before proceeding to a subsequent cohort. Dose escalation for the determination of RCD will be performed based on the available dose levels and the respective rules for a standard 3 + 3 dose escalation study design.
~For Cohort A, ONCOS-102 will be given as monotherapy the first six weeks, and then durvalumab (1500 mg) will be starting on day 71.
~For Cohorts B and C, ONCOS-102 will be administered for a total of 6 weeks while durvalumab will be given for a total of 12 four-week cycles."
11261148|NCT02963831|Experimental|Cohort 1: Platinum-resistant epithelial ovarian cancer|ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
11261149|NCT02963831|Experimental|Cohort 2: Colorectal cancer|ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
11261150|NCT02963818|Experimental|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
11261151|NCT02963818|Experimental|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
11261152|NCT02963818|Experimental|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
11261153|NCT02963805|Experimental|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
11261154|NCT02963805|Experimental|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
11261155|NCT02963805|Experimental|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
11261156|NCT02963805|No Intervention|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
11261157|NCT02963792|Experimental|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.
~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
11261158|NCT02963792|Experimental|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.
~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.
~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
11261159|NCT02963779|Experimental|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
11261160|NCT02963779|Experimental|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
11261161|NCT02963779|Placebo Comparator|Placebo (Part A)|Placebo administered orally in healthy participants
11261162|NCT02963779|Active Comparator|Apremilast (Part B)|Oral dose of apremilast in healthy participants
11261163|NCT02963766|Experimental|Dose 1 Dulaglutide|Dulaglutide given subcutaneously (SC).
11261164|NCT02963766|Experimental|Dose 2 Dulaglutide|Dulaglutide given SC.
11261165|NCT02963766|Placebo Comparator|Placebo|Placebo given SC.
11261166|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
11261167|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
11261168|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
11261169|NCT02963727|Experimental|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
11261170|NCT02963714|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11261171|NCT02963714|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
11261172|NCT02963701|Experimental|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
11261173|NCT02963701|Active Comparator|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
11261174|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
11261175|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
11261176|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
11261177|NCT02963662|Experimental|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
11261178|NCT02963662|Experimental|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
11261179|NCT02963662|No Intervention|Normal BMI group|no intervention
11261180|NCT02963649|Experimental|drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.
11261181|NCT02963649|Active Comparator|Standard angioplasty balloon|standard PTA balloon
11261182|NCT02963636|Experimental|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
11261183|NCT02963610|Experimental|Pembrolizumab, Lenalidomide|"Phase I The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. The dose of lenalidomide will depend upon the patient cohort. Cohort 1 will receive 10mg, Cohort II will receive 15mg and cohort 3 will receive 20mg of lenalidomide.
~Phase II The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. Maximum Tolerated Dose (MTD) of lenalidomide as determined by the Phase I study will be given in Phase II study."
11261184|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
11261185|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
11261186|NCT02963584|Experimental|intervention group|Patients in this group will receive CTO Choice (decision aid).
11261187|NCT02963584|No Intervention|control group|Patients in this group will receive usual primary care.
11261188|NCT02963571|Experimental|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
11261189|NCT02963558|Experimental|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
11261190|NCT02963558|No Intervention|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
11261191|NCT02963545|Experimental|Patients presenting cerebral infarction|no intervention of health product administration,
11261192|NCT02963545|Other|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
11261193|NCT02963519|Experimental|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
11261194|NCT02963519|Active Comparator|Dressings|Dressings Adapted to the case
11261195|NCT02963506|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
11261196|NCT02963506|Experimental|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
11261197|NCT02963506|Experimental|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
11261198|NCT02963506|Experimental|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
11261199|NCT02963506|Experimental|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
11261200|NCT02963493|Experimental|melphalan flufenamide (melflufen) + dexamethasone|Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
11261201|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
11261202|NCT02963480||SIRS|Patients, who developed postoperative SIRS
11261203|NCT02963467|Other|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
11261204|NCT02963467|Other|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
11261205|NCT02963467|Other|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
11261206|NCT02963454|Experimental|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).
~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
11261207|NCT02963454|Active Comparator|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.
~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
11261208|NCT02963428|No Intervention|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
11261209|NCT02963428|Experimental|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:
~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
11261210|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
11261211|NCT02963402||Tocilizumab treated|
11261212|NCT02963402||Anti-TNF treated|
11261213|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
11261214|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
11261215|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
11261216|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
11261217|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
11261218|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
11261219|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
11261220|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
11261221|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
11261222|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
11261223|NCT02963363|Experimental|Interventional|"Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :
~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks"
11261224|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
11261225|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
11261226|NCT02963324|Experimental|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
11261227|NCT02963311|Experimental|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by >70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
11261228|NCT02963298|Active Comparator|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
11261229|NCT02963298|No Intervention|control|Repetitive testing of blood Glutamate levels without CRRT
11261230|NCT02963285||0 to 6 months|
11261231|NCT02963285||7 months to less than 1 year|
11261232|NCT02963285||1 to less than 2 years|
11261233|NCT02963285||2 to less than 6 years|
11261234|NCT02963285||6 to 12 years|
11261235|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines
11261236|NCT02963272|Other|ST2-guided strategy|Management of patients follow the international guidelines but are also guided by the ST2, to adapt the drugs indicated in patients with HF.
11261237|NCT02963246|Experimental|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
11261238|NCT02963246|No Intervention|Control Group|Treatment-as-usual control
11261239|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
11261240|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
11261241|NCT02963220|Experimental|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
11261242|NCT02963207|Experimental|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
11261243|NCT02963207|Active Comparator|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
11261244|NCT02963194|Experimental|Oxytocin|Oxytoxin nasal spray
11261245|NCT02963194|Placebo Comparator|Placebo|Placebo nasal spray
11261246|NCT02963181|Experimental|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
11261247|NCT02963181|Experimental|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
11261248|NCT02963168|Experimental|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
11261249|NCT02963155|Experimental|Metastatic prostate cancer blood samples|
11261250|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.
~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
11261251|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.
~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
11261252|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.
~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
11261253|NCT02963129|Experimental|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
11261254|NCT02963129|Placebo Comparator|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
11261255|NCT02963116|Experimental|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
11261256|NCT02963116|Experimental|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
11261257|NCT02963116|Experimental|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
11261258|NCT02963116|Experimental|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
11261259|NCT02963116|Experimental|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
11261260|NCT02963103|Experimental|Tacrolimus group|oral
11261261|NCT02963090|Active Comparator|Topotecan|Topotecan IV at 1265mg/m^2 Days 1-5 of every 21 day cycle
11261262|NCT02963090|Experimental|Pembrolizumab|Pembrolizumab IV 200mg infusion Day 1 of every 21 day cycle
11261263|NCT02963077|Experimental|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
11261264|NCT02963077|Experimental|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
11261265|NCT02963077|Experimental|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
11261266|NCT02963077|Experimental|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
11261267|NCT02963077|Experimental|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
11261268|NCT02963077|Placebo Comparator|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
11261269|NCT02963077|Placebo Comparator|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
11261270|NCT02963077|Placebo Comparator|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
11261271|NCT02963077|Placebo Comparator|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
11261272|NCT02963077|Placebo Comparator|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
11261273|NCT02963077|Experimental|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
11261274|NCT02963077|Placebo Comparator|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
11261275|NCT02963077|Experimental|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
11261276|NCT02963077|Placebo Comparator|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
11261277|NCT02963077|Experimental|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
11261278|NCT02963077|Placebo Comparator|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
11261279|NCT02963077|Experimental|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
11261280|NCT02963077|Active Comparator|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
11261281|NCT02963077|Experimental|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
11261282|NCT02963077|Placebo Comparator|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
11261283|NCT02963077|Active Comparator|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
11261284|NCT02963077|Placebo Comparator|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
11261285|NCT02963077|Experimental|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
11261286|NCT02963077|Placebo Comparator|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
11261287|NCT02963064|Experimental|Blood Stem Cell Transplant w/ anti-CD117 conditioning|The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID.The study plans to assess AMG 191 in different dose cohorts. Patients will receive a single dose of intravenous AMG 191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.
11261288|NCT02963051|Experimental|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)
~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
11261327|NCT02962791|Active Comparator|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
11261289|NCT02963051|Experimental|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)
~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
11261290|NCT02963051|Experimental|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases
~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
11261291|NCT02963038|Experimental|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
11261292|NCT02963025|Other|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
11261293|NCT02963025|Other|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
11261294|NCT02962999|Experimental|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
11261295|NCT02962999|Placebo Comparator|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
11261296|NCT02962986|Active Comparator|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
11261297|NCT02962986|Active Comparator|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
11261298|NCT02962973|Experimental|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
11261299|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
11261300|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
11261301|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
11261302|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
11261303|NCT02962947|Placebo Comparator|PLACEBO|Placebo will be taken daily during the study period
11261304|NCT02962947|Active Comparator|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
11261305|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
11261306|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
11261307|NCT02962921|Experimental|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.
~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
11261308|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
11261309|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
11261310|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
11261311|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
11261312|NCT02962895|Experimental|VAY736 dose 1|VAY736 low
11261313|NCT02962895|Experimental|VAY736 dose 2|VAY736 medium
11261314|NCT02962895|Experimental|VAY736 dose 3|VAY736 high
11261315|NCT02962895|Placebo Comparator|Placebo|Placebo control
11261316|NCT02962882|Experimental|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
11261317|NCT02962882|Experimental|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
11261318|NCT02962869|Experimental|BAY987517|All subjects are patched with the same product
11261319|NCT02962856|Experimental|BAY987517|All subjects are patched with the same product.
11261320|NCT02962843|Experimental|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
11261321|NCT02962843|No Intervention|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
11261322|NCT02962830|Experimental|Sufentanil|
11261323|NCT02962817|Experimental|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.
~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
11261324|NCT02962817|Active Comparator|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
11261325|NCT02962804|Experimental|Nivolumab plus radiation|Nivolumab plus radiation
11261326|NCT02962791|Experimental|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
11261394|NCT02962323|Active Comparator|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
11261328|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
11261329|NCT02962752|Experimental|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
11261330|NCT02962752|Placebo Comparator|Placebo|Sugar, flavour and volume matched placebo control drink.
11261331|NCT02962739|Active Comparator|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
11261332|NCT02962739|Active Comparator|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
11261333|NCT02962739|Active Comparator|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
11261334|NCT02962739|Active Comparator|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
11261335|NCT02962739|Active Comparator|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
11261336|NCT02962739|Active Comparator|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
11261337|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
11261338|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
11261339|NCT02962713|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
11261340|NCT02962713|Experimental|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
11261341|NCT02962700|Experimental|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
11261342|NCT02962700|Active Comparator|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.
~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
11261343|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
11261344|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
11261345|NCT02962674|Other|Treatment|
11261346|NCT02962661|Experimental|Arm I (hMSCs IV)|Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
11261347|NCT02962661|Experimental|Arm II (hMSCs transendocardially)|Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
11261348|NCT02962661|Active Comparator|Arm III (standard of care)|Patients receive standard of care treatment for heart failure.
11261349|NCT02962648|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
11261350|NCT02962635||Hemodialysis patients|"A total of 30 patients
~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
11261351|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients
~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
11261352|NCT02962622|Experimental|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
11261353|NCT02962622|Experimental|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
11261354|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
11261355|NCT02962609|Experimental|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
11261356|NCT02962583|Experimental|Probiotic|Daily probiotic consumption
11261357|NCT02962583|Placebo Comparator|Placebo|Daily placebo consumption
11261358|NCT02962570|Experimental|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped
~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped
~Repeat until the end of the surgical procedure"
11261359|NCT02962557|No Intervention|Control|The control group will receive no prompts by the recorded voice.
11261360|NCT02962557|Experimental|Experimental|The experimental group will receive playback of recorded verbal prompts to breathe with an optional shoulder shake.
11261361|NCT02962544|Active Comparator|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
11261362|NCT02962544|Active Comparator|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
11261363|NCT02962531|Experimental|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
11261364|NCT02962531|Experimental|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
11261365|NCT02962531|Experimental|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
11261366|NCT02962518|Active Comparator|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
11261367|NCT02962518|Experimental|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
11261368|NCT02962492|Active Comparator|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
11261369|NCT02962492|Active Comparator|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
11261370|NCT02962492|Placebo Comparator|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
11261371|NCT02962492|Active Comparator|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
11261372|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
11261373|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
11261374|NCT02962479||TNF blocker-naïve nrSpA patients|
11261375|NCT02962479||TNF blocker-exposed nrSpA patients|
11261376|NCT02962479||Healthy Participants|
11261377|NCT02962466|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
11261378|NCT02962466|No Intervention|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
11261379|NCT02962466|No Intervention|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
11261380|NCT02962453|Experimental|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
11261381|NCT02962453|Active Comparator|Ground Walker|Rehabilitation using walker for 5days.
11261382|NCT02962440|Experimental|Somapacitan|
11261383|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
11261384|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
11261385|NCT02962414|Experimental|everolimus|everolimus, 2mg dispersible tablets
11261386|NCT02962401|Experimental|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab
~Cycle 1 :
~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15
~Cycle 2 - 6 :
~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1
~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
11261387|NCT02962388|Active Comparator|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
11261388|NCT02962388|Experimental|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.
~Maximum dose 25 mg BID."
11261389|NCT02962375|Experimental|Active Treatment|100% orange juice with orange pomace fiber
11261390|NCT02962375|Placebo Comparator|Control Treatment|100% orange juice
11261391|NCT02962336|Experimental|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
11261392|NCT02962336|Active Comparator|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
11261393|NCT02962323|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
11261395|NCT02962310|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
11261396|NCT02962310|Active Comparator|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
11261397|NCT02962297|Experimental|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
11261398|NCT02962297|Placebo Comparator|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
11261399|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
11261400|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
11261401|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
11261402|NCT02962258|Experimental|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
11261403|NCT02962258|Active Comparator|Reference|Tribenzor of Daichi Sankyo Inc., USA
11261404|NCT02962245|Active Comparator|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
11261405|NCT02962245|Placebo Comparator|regular treatment group|regular treatment untill recurrence in one year
11261406|NCT02962232|Experimental|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
11261407|NCT02962232|Active Comparator|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
11261408|NCT02962219|Experimental|Intervention|A pre-operative personalised exercise programme (my-PEP).
11261409|NCT02962219|Other|Control|Standard care
11261410|NCT02962206|Active Comparator|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
11261411|NCT02962206|Experimental|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
11261412|NCT02962180|Experimental|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
11261413|NCT02962167|Experimental|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
11261414|NCT02962167|Experimental|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
11261415|NCT02962167|Experimental|Disseminated Recurrent Medulloblastoma|Patients must have disseminated recurrent medulloblastoma (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
11261416|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable
~They will undergo the following:
~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
11261417|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder
~They will undergo the following:
~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
11261418|NCT02962141|Experimental|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
11261419|NCT02962141|Active Comparator|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
11261420|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
11261421|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
11261422|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
11261423|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
11261424|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg PO/NGT/OGT daily x 5 days
11261425|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil daily x 5 days
11261426|NCT02962089|Placebo Comparator|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
11261427|NCT02962089|Active Comparator|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
11261428|NCT02962063|Experimental|Esophageal Cancer|This is a phase Ib/II trial of durvalumab (MEDI4736), a monoclonal antibody against programmed death ligand-1 (PD-L1)), and tremelimumab, an anti-CTLA-4 antibody, in combination with chemoradiation for patients with locally advanced (TanyN+M0 or T3-4NanyM0) esophageal or gastroesophageal (GE) junction adenocarcinoma.
11261429|NCT02962050||ALS|Participants enrolled will complete the following tests: Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, reflexive cough testing, Pulmonary Function Testing; Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
11261430|NCT02962037|No Intervention|Base line|the subject will take the tests in the morning and the evening
11261431|NCT02962037|Experimental|After treatment|the subject will take the tests in the morning and the evening
11261432|NCT02962024|Active Comparator|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
11261433|NCT02962024|Placebo Comparator|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
11261434|NCT02962011|Experimental|Knotless barbed suture|
11261435|NCT02962011|Active Comparator|polyglactin 910|Vicryl
11261436|NCT02961998|Experimental|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
11261437|NCT02961998|Active Comparator|Control group|Patients take sorafenib only.
11261438|NCT02961972|Placebo Comparator|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
11261439|NCT02961972|Experimental|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
11261440|NCT02961959|Experimental|Surgery|Arthrodesis of SI-joint/s, physiotherapy
11261441|NCT02961959|Active Comparator|Non-surgery|Non-surgery, physiotherapy
11261442|NCT02961946|Active Comparator|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
11261443|NCT02961946|Active Comparator|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
11261444|NCT02961946|Active Comparator|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
11261445|NCT02961933|Experimental|Apneic oxygenation|
11261446|NCT02961933|Active Comparator|non-apneic oxygenation|
11261447|NCT02961920|Experimental|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
11261448|NCT02961920|Active Comparator|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
11261449|NCT02961907|No Intervention|Control|"The usual routine course includes :
~a clinico-biological evaluation of infertility causes
~a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy
~collection of blood and sperm samples"
11261450|NCT02961907|Experimental|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
11261451|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
11261452|NCT02961881|Experimental|blinatumomab|
11261453|NCT02961868|Experimental|Prospective cohort|3 years follow-up
11261454|NCT02961855|Experimental|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
11261455|NCT02961855|Active Comparator|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
11261456|NCT02961842|Experimental|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
11261457|NCT02961842|Active Comparator|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
11261458|NCT02961829|No Intervention|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
11261459|NCT02961829|Experimental|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
11261460|NCT02961829|Experimental|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
11261461|NCT02961829|Experimental|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
11261462|NCT02961829|Experimental|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
11261463|NCT02961829|Experimental|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
11261490|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
11261491|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
11261528|NCT02961361|Experimental|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
11261464|NCT02961816|Experimental|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
~Panobinostat daily from Day -9 to -2.
~Gemcitabine administered on Days -8 and -3.
~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
~Melphalan on Days -3 and -2.
~Rituximab on Day -9 for participants with CD20+ tumors.
~Dexamethasone twice a day from Day -8 AM to Day -2 PM.
~Caphosol oral rinses 30 mL four times a day used from Day -8.
~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
~Pyridoxine three times a day from Day -1.
~Stem cells administered by vein on Day 0.
~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
11261465|NCT02961816|Experimental|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
~Panobinostat daily from Day -9 to -2.
~Gemcitabine administered on Days -8 and -3.
~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
~Melphalan on Days -3 and -2.
~Rituximab on Day -9 for participants with CD20+ tumors.
~Dexamethasone twice a day from Day -8 AM to Day -2 PM.
~Caphosol oral rinses 30 mL four times a day used from Day -8.
~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
~Pyridoxine three times a day from Day -1.
~Stem cells administered by vein on Day 0.
~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
11261466|NCT02961816|Experimental|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.
~Panobinostat daily from Day -9 to -2.
~Gemcitabine administered on Days -8 and -3.
~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
~Melphalan on Days -3 and -2.
~Rituximab on Day -9 for participants with CD20+ tumors.
~Dexamethasone twice a day from Day -8 AM to Day -2 PM.
~Caphosol oral rinses 30 mL four times a day used from Day -8.
~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
~Pyridoxine three times a day from Day -1.
~Stem cells administered by vein on Day 0.
~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
11261467|NCT02961803|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
11261468|NCT02961803|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
11261469|NCT02961790|Experimental|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
11261470|NCT02961790|Placebo Comparator|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
11261471|NCT02961790|Experimental|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
11261472|NCT02961790|Placebo Comparator|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
11261473|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
11261474|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
11261475|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
11261476|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
11261477|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
11261478|NCT02961751|Other|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
11261479|NCT02961738|Active Comparator|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
11261480|NCT02961738|Experimental|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
11261481|NCT02961725|Experimental|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
11261482|NCT02961712|Experimental|cell therapy|NK cells and amniotic epithelial cells
11261483|NCT02961699|Experimental|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
11261484|NCT02961699|Active Comparator|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
11261485|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
11261486|NCT02961673|Experimental|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
11261487|NCT02961673|Active Comparator|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
11261488|NCT02961660|Experimental|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
11261489|NCT02961660|Experimental|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
11261492|NCT02961634|Experimental|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.
~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
11261493|NCT02961634|Active Comparator|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
11261494|NCT02961621|Experimental|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
11261495|NCT02961621|No Intervention|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
11261496|NCT02961608|Experimental|study group|
11261497|NCT02961595|No Intervention|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
11261498|NCT02961595|Active Comparator|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
11261499|NCT02961582|Experimental|Sacral Neuromodulation|
11261500|NCT02961582|Other|Personalized Conservative Treatment|
11261501|NCT02961569|Other|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
11261502|NCT02961556|Experimental|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
11261503|NCT02961543|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
11261504|NCT02961543|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
11261505|NCT02961530|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
11261506|NCT02961530|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.
~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
11261507|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
11261508|NCT02961504|Experimental|HLCM051 (MultiStem)|single dose of 1.2 billion HLCM051 cells
11261509|NCT02961504|Placebo Comparator|Placebo|a single dose of placebo
11261510|NCT02961478|Experimental|Iohexol plasmatic clearance|
11261511|NCT02961465||Sacral Neuromodulation (SNM)|
11261512|NCT02961452||Peanut allergic children|
11261513|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
11261514|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
11261515|NCT02961426|Experimental|sofosbuvir + ravidasvir|12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients
11261516|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
11261517|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
11261518|NCT02961413||cohort 3|Bicyclol
11261519|NCT02961413||cohort 4|Silibinin capsules
11261520|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
11261521|NCT02961413||cohort 6|N- acetylcysteine
11261522|NCT02961400|Experimental|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
11261523|NCT02961400|Experimental|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
11261524|NCT02961400|Other|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
11261525|NCT02961387|Experimental|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
11261526|NCT02961387|Sham Comparator|Oxygen-making machine treatment|Inhalation of oxygen.
11261527|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
11261529|NCT02961361|Experimental|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
11261530|NCT02961348|Active Comparator|Early start of NOAC|Day 1 to day 4 after ischemic stroke onset
11261531|NCT02961348|Active Comparator|Late start of NOAC|Day 5 to day 10 after ischemic stroke onset
11261532|NCT02961335|Experimental|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
11261533|NCT02961322|Experimental|lobo isthmectomy|
11261534|NCT02961309|Experimental|Active THC|5.6% THC via smoked marijuana cigarette
11261535|NCT02961309|Experimental|Placebo|Placebo THC via smoked cigarette
11261536|NCT02961283|Experimental|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
11261537|NCT02961283|Experimental|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
11261538|NCT02961283|Experimental|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
11261539|NCT02961283|Experimental|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
11261540|NCT02961270|Experimental|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
11261541|NCT02961257|Experimental|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).
~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel."
11261542|NCT02961257|Experimental|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
11261543|NCT02961244|No Intervention|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
11261544|NCT02961244|Active Comparator|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
11261545|NCT02961231|Active Comparator|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
11261546|NCT02961231|Active Comparator|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
11261547|NCT02961231|Experimental|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
11261548|NCT02961231|Experimental|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
11261549|NCT02961218|Placebo Comparator|Placebo|Matching placebo administered subcutaneously
11261550|NCT02961218|Experimental|Ilaris, Canakinumab|Randomized drug administration for 24 weeks duration (6 drug administrations each 28 days apart) followed by an additional 24-week open label phase (6 drug administrations each 28 days apart).
11261551|NCT02961205|Experimental|Oral Nutritional Supplementation|Patients randomized to the interventional arm will receive Ensure Enlive (Abbott Nutrition), a high energy, high protein oral supplement.
11261552|NCT02961205|No Intervention|Standard of care|Patients randomized to the control arm will continue their usual diet.
11261553|NCT02961192|No Intervention|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
11261554|NCT02961192|Experimental|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
11261555|NCT02961192|Experimental|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
11261556|NCT02961192|Experimental|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
11261557|NCT02961179|Experimental|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
11261558|NCT02961179|Placebo Comparator|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
11261559|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
11261560|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
11261561|NCT02961140|Experimental|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
11261562|NCT02961140|Active Comparator|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
11261563|NCT02961127||group 1|no drugs were used in our study
11261564|NCT02961127||group 2|
11261565|NCT02961114|Experimental|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
11261566|NCT02961114|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
11261567|NCT02961114|Experimental|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
11261888|NCT02959177|Placebo Comparator|Placebo|Placebo administered SC once a month for 6 months.
11261568|NCT02961101|Experimental|Anti-PD-1 antibody+decitabine|Decitabine will be administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 200mg on day8 IV Q3 weeks until progression.
11261569|NCT02961101|Experimental|Anti-PD-1 antibody|Anti-PD-1 antibody 200mg IV Q3 weeks until progression.
11261570|NCT02961101|Experimental|Anti-PD-1 antibody+chemotherapy|Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
11261571|NCT02961075|Experimental|Cricothyroid|local surface anesthesia by Cricothyroid
11261572|NCT02961075|Experimental|Laryngeal tube|local surface anesthesia by Laryngeal tube
11261573|NCT02961062|Experimental|Treatment Sequence 1|
11261574|NCT02961062|Placebo Comparator|Treatment Sequence 2|
11261575|NCT02961049|Active Comparator|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
11261576|NCT02961049|Active Comparator|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
11261577|NCT02961049|Active Comparator|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
11261578|NCT02961049|Active Comparator|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
11261579|NCT02961036|Experimental|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
11261580|NCT02961036|Active Comparator|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
11261581|NCT02961036|Active Comparator|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
11261582|NCT02961036|Active Comparator|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
11261583|NCT02961036|Active Comparator|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
11261584|NCT02961036|Experimental|Group A reminder|One survey reminder at 14 days
11261585|NCT02961036|Active Comparator|Group B reminders|Two survey reminders 14 days and 28 days
11261586|NCT02961023|Active Comparator|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
11261587|NCT02961023|Other|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
11261588|NCT02961010|Experimental|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
11261589|NCT02961010|No Intervention|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
11261590|NCT02960997|Experimental|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
11261591|NCT02960997|Placebo Comparator|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
11261592|NCT02960984|Experimental|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
11261593|NCT02960984|No Intervention|Baseline|No intervention is planned
11261594|NCT02960945|Experimental|CTP-543|Tablet, single oral dose
11261595|NCT02960945|Active Comparator|Jakafi|Tablet, single oral dose
11261596|NCT02960932|Experimental|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
11261597|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1A|ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261598|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1B|ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261599|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4A|ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261600|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4B|ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261931|NCT02958865|Experimental|PF-06700841 Drug Dose Level 3|Delivered orally for 8 weeks.
11261601|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261602|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2B|ccRCC molecular subgroup 2 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261603|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3B|ccRCC molecular subgroup 3 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261604|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
11261605|NCT02960893|Experimental|Troriluzole|"Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.
~Troriluzole/Troriluzole - Extension Phase: Participants received Troriluzole 140 mg capsules orally QD for 48 weeks."
11261606|NCT02960893|Placebo Comparator|Placebo|"Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.
~Placebo/Troriluzole - Extension Phase: Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks."
11261607|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
11261608|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
11261609|NCT02960854|Experimental|Nivolumab 1|Dose 1
11261610|NCT02960854|Experimental|Nivolumab 2|Dose 2
11261611|NCT02960841|Experimental|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
11261612|NCT02960841|Active Comparator|Conventional treatment|Conventional treatment active comparator
11261613|NCT02960828|Experimental|"Intervention-Device:_Laser"|"Subthreshold focal photocoagulation
~Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
11261614|NCT02960828|No Intervention|Control|Contralateral eye
11261615|NCT02960815|Active Comparator|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
11261616|NCT02960815|Experimental|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
11261617|NCT02960815|Experimental|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
11261618|NCT02960802|Active Comparator|kidney transplant patient|kidney transplantation is intervention
11261619|NCT02960802|No Intervention|healthy control|no intervention
11261620|NCT02960789|Experimental|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.
~Interventions:
~Undertake and record a formalized clinical assessment of hydration status
~Take a measurement of body weight on calibrated scales
~RF wristband hydration status measurement
~Measure capillary refill time with manual stopwatch
~CRT device hydration status measurement"
11261621|NCT02960776|No Intervention|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
11261622|NCT02960776|Experimental|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
11261623|NCT02960763|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
11261624|NCT02960763|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
11261625|NCT02960763|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
11261626|NCT02960763|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
11261627|NCT02960763|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
11261628|NCT02960750|Experimental|Intervention group|Had access to the W@WS website program during 19 weeks.
11261629|NCT02960750|Active Comparator|Active comparison group|Maintained habitual behavior.
11261630|NCT02960737|Experimental|Intervention group|Intensive training with oral screen (intervention group) and traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
11261631|NCT02960737|No Intervention|Control group|Traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
11261632|NCT02960724|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
11261633|NCT02960711|Experimental|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
11261634|NCT02960711|Placebo Comparator|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
11261635|NCT02960711|Experimental|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
11261636|NCT02960711|Placebo Comparator|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
11261637|NCT02960698|Active Comparator|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
11261638|NCT02960698|Active Comparator|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
11261639|NCT02960698|Placebo Comparator|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
11261640|NCT02960659|Active Comparator|1|RCT: Metformin and liraglutide vs. metformin alone
11261641|NCT02960659|Experimental|2|Substudy: Metformin treated vs. control (no treatment)
11261642|NCT02960646|Experimental|Treatment (peripheral blood stem cell transplantation)|Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
11261643|NCT02960633|Active Comparator|THA with Collar|THA with Collar
11261644|NCT02960633|Active Comparator|THA without Collar|THA without Collar
11261645|NCT02960607|Experimental|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
11261646|NCT02960594|Experimental|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261647|NCT02960594|Experimental|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261648|NCT02960594|Experimental|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261649|NCT02960594|Experimental|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261650|NCT02960594|Experimental|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261651|NCT02960594|Experimental|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261652|NCT02960594|Experimental|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261653|NCT02960594|Experimental|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261654|NCT02960594|Experimental|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261655|NCT02960594|Experimental|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
11261656|NCT02960581|Experimental|Group 1A|HIV-uninfected participants
11261657|NCT02960581|Experimental|Group 1B|HIV-uninfected participants
11261658|NCT02960581|Experimental|Group 1C|HIV-uninfected participants
11261659|NCT02960581|Experimental|Group 2A|HIV-infected on ART, (<50 cp/ml)
11261660|NCT02960581|Experimental|Group 2B|HIV-infected on ART, (<50 cp/ml)
11261661|NCT02960581|Experimental|Group 2C|HIV-infected on ART, (<50 cp/ml)
11261662|NCT02960581|Experimental|Group 3A|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
11261663|NCT02960581|Experimental|Group 3B|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
11261664|NCT02960581|Experimental|Arm 1D|HIV-uninfected participants
11261665|NCT02960568|Experimental|Primaquine|Poor and Intermediate Metabolizers will receive 30 mg oral primaquine (PQ) and have peripheral blood draws over a 24-hour period to measure PQ pharmacokinetics
11261666|NCT02960568|No Intervention|No primaquine|Extensive and Ultra Metabolizers will not be eligible for the pharmacokinetic portion of the study and participation will be complete after receiving genotype information
11261667|NCT02960555|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.
11261668|NCT02960542|Experimental|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
11261669|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
11261670|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
11261671|NCT02960503|Active Comparator|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
11261672|NCT02960503|Placebo Comparator|Placebo arm|Control arm: placebo three times a week for 6 months
11261673|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
11261702|NCT02960295|Experimental|Virtual visit|"Self-monitoring of blood glucose (four times daily).
~Self-weighing (weekly).
~Self-checking of blood pressure (weekly).
~Checking fetal heart rate (weekly).
~Visits with caregivers."
11261674|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
11261675|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
11261676|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
11261677|NCT02960477|Experimental|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
11261678|NCT02960477|Active Comparator|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
11261679|NCT02960464|Active Comparator|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
11261680|NCT02960464|Sham Comparator|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
11261681|NCT02960451|Experimental|PRIME care|Specialized care in the PRIME clinic
11261682|NCT02960451|Active Comparator|Usual care|Usual care in the community
11261683|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
11261684|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
11261685|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
11261686|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
11261687|NCT02960425|Experimental|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
11261688|NCT02960425|Experimental|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
11261689|NCT02960412|Experimental|furosemide|furosemide 10mg (1mL) IV push for one dose
11261690|NCT02960412|Placebo Comparator|placebo|normal saline 1mL IV push for one dose
11261691|NCT02960399|Experimental|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
11261692|NCT02960399|Active Comparator|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
11261693|NCT02960386|Other|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
11261694|NCT02960373|Active Comparator|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
11261695|NCT02960373|Experimental|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
11261696|NCT02960373|Experimental|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
11261697|NCT02960373|Experimental|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
11261698|NCT02960347|Experimental|Active tDCS|open label active tDCS treatment
11261699|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
11261700|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
11261701|NCT02960308||Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
11261703|NCT02960282||Ancillary-Correlative (gut microbiome analysis)|Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.
11261704|NCT02960269|Experimental|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
11261705|NCT02960256||Patients admitted to an internal medicine department due to an|
11261706|NCT02960243|Sham Comparator|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
11261707|NCT02960243|Experimental|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
11261708|NCT02960243|Experimental|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
11261709|NCT02960243|Experimental|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:
~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes
~In between switching to each test, there will be a 5 minute washout period."
11261710|NCT02960230|Experimental|Stratum A: Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
11261711|NCT02960230|Experimental|Stratum B: Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
11261712|NCT02960230|Experimental|Stratum C: Newly Diagnosed DIPG or other Midline Glioma|Newly diagnosed children with DIPG or other midline gliomas (excluding spinal cord tumors) who are positive for HLA-A2 (02:01) and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Nivolumab will also be given via IV. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks. Nivolumab will continue to be given every 3 weeks throughout all of treatment.
11261713|NCT02960217|Experimental|Double-Blind UX007 Followed by Placebo|"Participants will first receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks.
~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
11261714|NCT02960217|Experimental|Double Blind Placebo Followed by UX007|"Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks.
~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
11261715|NCT02960204|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
11261716|NCT02960204|Active Comparator|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
11261717|NCT02960204|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
11261718|NCT02960204|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
11261719|NCT02960191|Other|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
11261720|NCT02960191|Other|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
11261721|NCT02960191|Other|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
11261787|NCT02959879|Experimental|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
11261722|NCT02960178|Experimental|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
11261723|NCT02960178|Active Comparator|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
11261724|NCT02960165|Experimental|Virtual interface group A|Older adults that started the practice on the virtual interface
11261725|NCT02960165|Experimental|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
11261726|NCT02960165|Active Comparator|Real interface group A|Older adults that started the practice on the virtual interface
11261727|NCT02960165|Active Comparator|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
11261728|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
11261729|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
11261730|NCT02960152||Control|interview and periodontal full-mouth examination
11261731|NCT02960139|Experimental|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
11261732|NCT02960139|No Intervention|Control- Standard of Care|Control group is standard closure of anastomosis.
11261733|NCT02960126|Active Comparator|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
11261734|NCT02960126|Experimental|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
11261735|NCT02960113|Experimental|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
11261736|NCT02960113|Experimental|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
11261737|NCT02960113|Experimental|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
11261738|NCT02960100|Experimental|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
11261739|NCT02960100|Active Comparator|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
11261740|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
11261741|NCT02960087|Active Comparator|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
11261742|NCT02960074|Experimental|Non-antibiotics Arm|The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
11261743|NCT02960074|Experimental|Antibiotics Arm|An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
11261744|NCT02960061|Experimental|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
11261745|NCT02960061|Sham Comparator|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
11261746|NCT02960048|Active Comparator|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .
~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.
~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .
~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
11261747|NCT02960048|Experimental|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .
~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .
~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
11261748|NCT02960035|Experimental|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
11261788|NCT02959879|Experimental|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
11261932|NCT02958865|Placebo Comparator|PF-06700841 Placebo|Delivered orally for 8 weeks.
11261749|NCT02960035|Experimental|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
11261750|NCT02960035|Placebo Comparator|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
11261751|NCT02960022|Experimental|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day
11261752|NCT02960022|Experimental|enzalutamide plus abiraterone acetate and prednisone|Subjects enrolling from study 9785-CL-0011 will receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily
11261753|NCT02960009|Experimental|Anode HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
11261754|NCT02960009|Experimental|Cathode HD-tDCS|The center cathode is fixed on the contralesional primary motor cortex and the 4 surrounding anode electrodes will be placed about 6 cm to the center.
11261755|NCT02960009|Placebo Comparator|Sham HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
11261756|NCT02959996|Placebo Comparator|Placebo|Normal saline will be infiltrated
11261757|NCT02959996|Active Comparator|Intervention|Liposomal bupivacaine will be infiltrated
11261758|NCT02959983|Active Comparator|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
11261759|NCT02959983|Placebo Comparator|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
11261760|NCT02959970|Experimental|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
11261761|NCT02959970|Experimental|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
11261762|NCT02959957|Experimental|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
11261763|NCT02959957|Active Comparator|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
11261764|NCT02959944|Experimental|Ibrutinib|Ibrutinib in combination with prednisone
11261765|NCT02959944|Placebo Comparator|Placebo|Placebo in combination with prednisone
11261766|NCT02959931|Experimental|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~2400 mg of dietary potassium.
11261767|NCT02959931|Active Comparator|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~540 mg of dietary potassium.
11261768|NCT02959918|Experimental|SEL-037 Pegsiticase LD(low dose) alone|
11261769|NCT02959918|Experimental|SEL-037 Pegsiticase HD(high dose) alone|
11261770|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (1a)|
11261771|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (1b)|
11261772|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (2a)|
11261773|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (2b)|
11261774|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3a)|
11261775|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3b)|
11261776|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4a)|
11261777|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4b)|
11261778|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5a)|
11261779|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5b)|
11261780|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6a)|
11261781|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6b)|
11261782|NCT02959905|Experimental|medium dose of preparative regimen|Patients will receive medium dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
11261783|NCT02959905|Experimental|low dose of preparative regimen|Patients will receive low dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
11261784|NCT02959905|Experimental|no preparative regimen|Patients will only receive TSA-CTL.
11261785|NCT02959892|Experimental|TAK-041 20 mg|[11C] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
11261786|NCT02959892|Experimental|TAK-041 40 mg|[11C] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
11261887|NCT02959177|Experimental|240 mg Galcanezumab|120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
11262105|NCT02957812|No Intervention|Control|Wearing own footwear
11261789|NCT02959879|Active Comparator|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.
~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
11261790|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
11261791|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
11261792|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
11261793|NCT02959840|No Intervention|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
11261794|NCT02959840|Active Comparator|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
11261795|NCT02959840|Experimental|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
11261796|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
11261797|NCT02959801|Experimental|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
11261798|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
11261799|NCT02959775|Experimental|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
11261800|NCT02959775|Experimental|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
11261801|NCT02959775|No Intervention|Control|Receive no vaccination during the study period
11261802|NCT02959762|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
11261803|NCT02959762|Active Comparator|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
11261804|NCT02959762|Active Comparator|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
11261805|NCT02959749|Active Comparator|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
11261806|NCT02959749|Experimental|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
11261807|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
11261808|NCT02959736||Spectrum|Music Therapy (MATADOC)
11261809|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
11261810|NCT02959710|Experimental|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
11261811|NCT02959710|Experimental|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
11261812|NCT02959710|Experimental|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
11261813|NCT02959697|Experimental|Subcut. + Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
11261814|NCT02959697|Sham Comparator|Subcut. + Sham Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.
11261815|NCT02959671|Experimental|Lower Anterior EXD-952 Self-ligating Brackets|
11261816|NCT02959658|Active Comparator|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
11261817|NCT02959658|Placebo Comparator|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
11261818|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
11261819|NCT02959645||Healthy control|Healthy Volunteers
11261820|NCT02959632|Experimental|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).
~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
11261821|NCT02959619|Experimental|Ensartinib|Escalating dose of ensartinib was orally given once er day
11261822|NCT02959606|Experimental|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.
~Other Name: Anplone SR"
11261823|NCT02959606|Active Comparator|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.
~Other Name: Plavix"
11261824|NCT02959593|Experimental|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
11261825|NCT02959593|Experimental|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
11261826|NCT02959580|Experimental|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
11261827|NCT02959580|Active Comparator|surgical|lesion extended excision
11261828|NCT02959567|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
11261829|NCT02959554|Experimental|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
11261830|NCT02959554|Active Comparator|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
11261831|NCT02959541|Other|Calciumfolinat 60 mg/m²|Intravenous infusion of Calciumfolinat 60 mg/m²given to patients with colon cancer at the time for the operation of the colon cancer.
11261832|NCT02959541|Other|Calciumfolinat 200 mg/m²|Intravenous infusion of Calciumfolinat 200 mg/m² given to patients with colon cancer at the time for the operation of the colon cancer.
11261833|NCT02959541|Other|Calciumfolinat 500 mg/ m²|Intravenous infusion of Calciumfolinat 500 mg/ m² given to patients with colon cancer at the time for the operation of the colon cancer.
11261834|NCT02959528|Active Comparator|Control|ADHD group treated with visual-perceptual training
11261835|NCT02959528|Experimental|Experiment|ADHD group treated with working memory training
11261836|NCT02959515|Active Comparator|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
11261837|NCT02959515|Active Comparator|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
11261838|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
11261839|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
11261840|NCT02959489|Active Comparator|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
11261841|NCT02959489|Experimental|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
11261842|NCT02959476|Experimental|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
11261843|NCT02959476|Placebo Comparator|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
11261844|NCT02959463|Experimental|Cohort 1 (hemithoracic radiation therapy, pembrolizumab)|Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11261845|NCT02959463|Experimental|Cohort 2 (palliative radiation therapy, pembrolizumab)|Patients undergo palliative radiation therapy over 1-3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax). After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11261846|NCT02959450|Experimental|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
11261847|NCT02959450|No Intervention|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
11261848|NCT02959437|Experimental|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
11261849|NCT02959437|Experimental|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
11261850|NCT02959437|Experimental|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
11261851|NCT02959411|Experimental|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
11261852|NCT02959411|Active Comparator|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
11261853|NCT02959398|Active Comparator|standard mammography|standard mammography
11261854|NCT02959398|Experimental|standard mammography and tomosynthesis|standard mammography and tomosynthesis
11261855|NCT02959385|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
11261856|NCT02959385|Active Comparator|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:
~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
11261857|NCT02959372|Experimental|lung ultrasound group|lung ultrasound results
11261858|NCT02959372|Placebo Comparator|control group|The attending physician will not have the result of the lung ultrasound
11261859|NCT02959359|Other|DAA treatment arm|Active DAA treatment ('Ledipasvir 90mg/Sofosbuvir 400 mg plus Ribavirin' ) for HCV-HCC patients after curative resection or ablation.
11261860|NCT02959346|Sham Comparator|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
11261861|NCT02959346|Experimental|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
11261862|NCT02959333|Experimental|hAEC treatment|hAEC: human amniotic epithelial cells 3-5*10^7 /5 ml
11261863|NCT02959320|Active Comparator|Direct Anterior Approach|All patients receiving a hip hemiarthroplasty through a Direct Anterior Approach (DAA) will have their surgeries performed with the aid of fluoroscopy on an OSI Hana table that allows the operative limb to be manipulated through range of motion and traction while keeping the pelvis stabilized. This table also has a radiolucent platform about the pelvis, enabling the surgery to be fluoroscopically assisted. The incision for the DAA will extend from a proximal point about 2 cm distal and 2 cm lateral to the ASIS to a point 8-12 cm distal and slightly lateral to this.
11261864|NCT02959320|Active Comparator|Anterolateral Approach|All patients receiving a hip hemiarthroplasty through an the Anterolateral Approach (ALA) will have their surgeries performed on a standard OR table in a contralateral lateral decubitus position. With the leg in the position of sleep, a straight 8-12 cm incision will be made, centered over the greater trochanter and femoral shaft with 1/3 of the incision extending superior to the tip of the greater trochanter.
11261865|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
11261866|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
11261867|NCT02959294|Experimental|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
11261868|NCT02959294|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
11261869|NCT02959294|Experimental|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
11261870|NCT02959281|Experimental|Hemodynamic data available|Providing caring physicians with hemodynamic variables measured using the NICAS system.
11261871|NCT02959281|No Intervention|Hemodynamic data not available|Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
11261872|NCT02959268|Other|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
11261873|NCT02959255|Active Comparator|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
11261874|NCT02959255|Active Comparator|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
11261875|NCT02959229|Experimental|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
11261876|NCT02959229|Experimental|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
11261877|NCT02959229|Active Comparator|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
11261878|NCT02959216|Experimental|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
11261879|NCT02959216|Placebo Comparator|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
11261880|NCT02959190|Experimental|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
11261881|NCT02959190|Experimental|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
11261882|NCT02959190|Experimental|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
11261883|NCT02959190|Experimental|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
11261884|NCT02959190|Experimental|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
11261885|NCT02959190|Experimental|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
11261886|NCT02959177|Experimental|120 milligrams (mg) Galcanezumab|120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
11261889|NCT02959164|Experimental|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.
~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
11261890|NCT02959151|Experimental|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
11261891|NCT02959138|Experimental|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of lanraplenib
11261892|NCT02959138|Experimental|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of lanraplenib
11261893|NCT02959138|Experimental|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of lanraplenib
11261894|NCT02959125|Experimental|Intervention|"Intervention
~NutFish based supplementation for 60 days
~Multiple micro nutrient for 60 days
~Health education in pregnancy class"
11261895|NCT02959125|Active Comparator|Control|"Control
~Government food supplementation for 60 days
~Iron Folic acid for 60 days
~Health education in pregnancy class"
11261896|NCT02959112|Active Comparator|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
11261897|NCT02959112|Placebo Comparator|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
11261898|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
11261899|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
11261900|NCT02959086||1|Patients were diagnosed since January 2002.
11261901|NCT02959060|Experimental|BMS-986177 and Rifampin|
11261902|NCT02959047|Experimental|Alirocumab|Alirocumab 150mg SQ every 2 weeks
11261903|NCT02959047|Placebo Comparator|Placebo|Matched placebo
11261904|NCT02959034||BMI > 95%|No Intervention
11261905|NCT02959034||Healthy Weight Siblings|Control
11261906|NCT02959034||Healthy Weight Unrelated|Control
11261907|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
11261908|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
11261909|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
11261910|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.
~Hypertension group will measure TOI and BP."
11261911|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
11261912|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
11261913|NCT02958982|Experimental|RP3128|RP3128, A CRAC channel modulator
11261914|NCT02958982|Placebo Comparator|Placebo|Placebo
11261915|NCT02958969|Experimental|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
11261916|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
11261917|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
11261918|NCT02958943|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
11261919|NCT02958943|No Intervention|No Alert|Each provider in the non-alert group will receive no such notification.
11261920|NCT02958930|Experimental|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
11261921|NCT02958917|Placebo Comparator|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
11261922|NCT02958917|Active Comparator|Placebo|The placebo will be visually similar to pirfenidone.
11261923|NCT02958878|Experimental|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
11261924|NCT02958878|Placebo Comparator|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
11261925|NCT02958865|Experimental|PF-06651600 Drug Dose Level 1|Delivered orally for 8 weeks
11261926|NCT02958865|Experimental|PF-06651600 Drug Dose Level 2|Delivered orally for 8 weeks
11261927|NCT02958865|Experimental|PF-06651600 Drug Dose Level 3|Delivered orally for 8 weeks.
11261928|NCT02958865|Placebo Comparator|PF-06651600 Placebo|Delivered orally for 8 weeks.
11261929|NCT02958865|Experimental|PF-06700841 Drug Dose Level 1|Delivered orally for 8 weeks
11261930|NCT02958865|Experimental|PF-06700841 Drug Dose Level 2|Delivered orally for 8 weeks.
11261933|NCT02958865|Experimental|PF-06651600 Drug Dose Level 4|Delivered orally for 24 weeks.
11261934|NCT02958865|Experimental|PF-06700841 Drug Dose Level 4|Delivered orally for 24 weeks.
11261935|NCT02958852|Active Comparator|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
11261936|NCT02958852|Experimental|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
11261937|NCT02958852|Other|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
11261938|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
11261939|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
11261940|NCT02958826||No Smoke Evacuation|No Smoke Evacuation Group, anonymous questionnaire administered
11261941|NCT02958826||Smoke Evacuation|Smoke Evacuation Group, anonymous questionnaire administered
11261942|NCT02958813|Experimental|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
11261943|NCT02958813|Placebo Comparator|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
11261944|NCT02958800|Experimental|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
11261945|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
11261946|NCT02958774|Experimental|Hypofractionated Radiation Therapy|Daily for 4 weeks
11261947|NCT02958761|Experimental|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
11261948|NCT02958761|Active Comparator|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
11261949|NCT02958748||ARDS|Patients admitted to ICU with diagnosis of ARDS,which happened in 48hours.
11261950|NCT02958748||Control|Heathy vonlunteers
11261951|NCT02958735|No Intervention|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
11261952|NCT02958735|Experimental|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
11261953|NCT02958735|Experimental|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
11261954|NCT02958722|Active Comparator|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
11261955|NCT02958722|Active Comparator|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
11261956|NCT02958709|Experimental|high dose RIF, INH, PZA, EMB|Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.
11261957|NCT02958709|Experimental|high dose RIF, INH, PZA, LEVO|Arm 2 participants will receive high-dose rifampicin plus levofloxacin for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
11261958|NCT02958709|Active Comparator|standard dose RIF, INH, PZA, EMB|Arm 3 participants will receive standard of care dose rifampicin plus ethambutol for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.
11261959|NCT02958696|Active Comparator|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
11261960|NCT02958696|Active Comparator|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
11261961|NCT02958696|Active Comparator|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
11261962|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
11261963|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
11261964|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
11261965|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
11261966|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
11261967|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
11261968|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
11261969|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
11261970|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
11261971|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
11261972|NCT02958670|Experimental|18F-AV-1451-PET|All subjects receive a Scan for assessment of TAU with the radiotracer 18-F-AV-1451
11261973|NCT02958657|Experimental|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
11261974|NCT02958657|No Intervention|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
11261975|NCT02958644|Experimental|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
11261976|NCT02958644|Placebo Comparator|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.
~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
11261977|NCT02958631|Experimental|Fimasartan|Fimasartan 60mg, QD
11261978|NCT02958631|Active Comparator|Losartan|Losartan 50mg, QD
11261979|NCT02958618|Experimental|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
11261980|NCT02958618|Experimental|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
11261981|NCT02958618|Experimental|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
11261982|NCT02958605|Experimental|Smartphone|Smartphone application
11261983|NCT02958605|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
11261984|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
11261985|NCT02958579||Obesity|Body mass index (BMI) score > 25.2 kg/m2 for women and > 27.3 kg/m2 for men or Waist circumference > 90 cm
11261986|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;
~Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)
~Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test
~Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)
~Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;
~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
11261987|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
11261988|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
11261989|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of <40 mg/dL for men, <50 mg/dL for women,
11261990|NCT02958566|Active Comparator|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.
~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
11261991|NCT02958566|Experimental|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
11261992|NCT02958553|Other|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
11261993|NCT02958540|Experimental|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
11261994|NCT02958540|Experimental|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
11261995|NCT02958540|Placebo Comparator|placebo|12 subjects receiving placebo
11261996|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
11261997|NCT02958514|Other|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
11261998|NCT02958514|Experimental|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
11261999|NCT02958501|Active Comparator|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
11262000|NCT02958501|Active Comparator|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
11262001|NCT02958488|Experimental|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
11262002|NCT02958475|Experimental|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
11262003|NCT02958475|Active Comparator|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
11262004|NCT02958475|Active Comparator|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
11262005|NCT02958462|Other|Potential Premyeloid Cancer or Bone Marrow Failure Patients|Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies
11262006|NCT02958449|Experimental|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
11262007|NCT02958449|No Intervention|Control - Standard Closure|Standard closure with no intervention
11262008|NCT02958436|Experimental|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
11262009|NCT02958436|Experimental|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
11262010|NCT02958436|Experimental|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
11262011|NCT02958436|Experimental|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
11262012|NCT02958436|Experimental|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
11262013|NCT02958423|Experimental|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
11262014|NCT02958423|Experimental|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
11262015|NCT02958423|Experimental|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
11262016|NCT02958423|Experimental|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
11262017|NCT02958410|Experimental|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11262018|NCT02958397|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11262019|NCT02958384|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11262020|NCT02958371|Experimental|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
11262021|NCT02958358|Experimental|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
11262022|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
11262023|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
11262024|NCT02958332|Experimental|video game program|Participants will play video games during 30 min , all along 5 sessions.
11262025|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
11262026|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
11262027|NCT02958306|Experimental|platelet rich plasma|autologous blood product
11262028|NCT02958306|No Intervention|no platelet rich plasma|control
11262029|NCT02958293||December admission|The elective surgery group of people whose admission was the end of the calendar year (December) corresponding with insurance deductible year-end.
11262030|NCT02958293||Non-December admission|The elective surgery group of people whose admission was between January and November.
11262031|NCT02958280|Experimental|Brief Advice Plus the Fit&Sober App|"Phase 1 (app development & Open Pilot) will consist of: 1) development of the Fit&Sober prototype; 2) series of usability studies with patients with AUDs; and 3) An open pilot of a 12-week trial (n=20) to test the feasibility and acceptability of the Fit&Sober app with patients with AUDs in early recovery.
~Phase 2: RCT of the Fit&Sober app with 160 patients with AUD"
11262032|NCT02958280|Active Comparator|Brief Advice for Physical Activity|Phase 2: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
11262033|NCT02958267|Experimental|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
11262034|NCT02958267|Active Comparator|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
11262035|NCT02958228|Experimental|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, & Shah, 2009) and clinical (e.g. Blackwell & Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
11262036|NCT02958228|Active Comparator|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
11262037|NCT02958228|Active Comparator|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
11262038|NCT02958215|Placebo Comparator|Group A|This group will include patients with orthostatic hypotension and will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
11262039|NCT02958215|Active Comparator|Group B|This group will include patients with orthostatic hypotension and will be managed with prophylaxis single dose of phenylephrine, 50 ug IV, will be administered immediately before the spinal block then the patients will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
11262040|NCT02958202|Experimental|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
11262041|NCT02958202|Experimental|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
11262042|NCT02958202|Experimental|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
11262043|NCT02958189|Experimental|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
11262044|NCT02958189|Active Comparator|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
11262045|NCT02958176|Experimental|HRV Biofeedback|At home HRV biofeedback using mobile device
11262046|NCT02958176|Experimental|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
11262047|NCT02958176|No Intervention|Wait List|Wait list control
11262048|NCT02958163|Active Comparator|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.
~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.
~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
11262049|NCT02958163|Experimental|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.
~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.
~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
11262050|NCT02958150|Experimental|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
11262051|NCT02958150|Active Comparator|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
11262052|NCT02958137||Isolated CMC|Arthroscopic Resection Arthroplasty of isolated CMC joint OA. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
11262053|NCT02958137||Pantrapezial|Arthroscopic Resection Arthroplasty of simultaneous ARA of both the CMC and the STT joints. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
11262054|NCT02958111|Experimental|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
11262055|NCT02958111|No Intervention|Observation|Clinical follow-up and surveillance only
11262056|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
11262057|NCT02958098||Stroke|Individuals with stroke before age 50 years
11262058|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
11262059|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
11262060|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
11262061|NCT02958085|Experimental|NNC0174-0833|
11262062|NCT02958085|Placebo Comparator|Placebo|
11262063|NCT02958072|Experimental|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
11262064|NCT02958072|Active Comparator|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
11262065|NCT02958059|Experimental|Treatment|The intervention group
11262066|NCT02958059|Placebo Comparator|Comparator|The comparator group
11262067|NCT02958046|Experimental|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
11262068|NCT02958033|Experimental|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
11262069|NCT02958033|Placebo Comparator|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
11262070|NCT02958007|Experimental|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
11262071|NCT02958007|Active Comparator|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
11262072|NCT02957994|Experimental|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
11262073|NCT02957981|Experimental|Web-Based Counseling|Genetic information provided via an individually tailored website.
11262074|NCT02957981|Active Comparator|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
11262075|NCT02957968|Experimental|Cohort A: Triple Negative Breast Cancer (TNBC)|Triple Negative Breast Cancer (Cohort A): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel and carboplatin.
11262076|NCT02957968|Experimental|Cohort B: HER2-negative hormone receptor-positive tumors|HER2-negative hormone receptor-positive tumors (Cohort B): Decitabine IV over 60 minutes on 4 days and pembrolizumab IV over 30 minutes on days 8 and 22. Four cycles of dose-dense doxorubicin and cyclophosphamide (AC), followed by 12 doses of weekly paclitaxel.
11262077|NCT02957955|Experimental|Interventional|Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
11262078|NCT02957955|No Intervention|Non interventional|Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
11262079|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
11262080|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
11262081|NCT02957929|Experimental|Cohort 1a, Period A|single intravenous dose, crossover
11262082|NCT02957929|Experimental|Cohort 1a, Period B|single oral dose, crossover
11262083|NCT02957929|Experimental|Cohort 1a, Period C|single oral dose
11262084|NCT02957929|Experimental|Cohort 1a, Period D|single oral dose, crossover
11262085|NCT02957929|Experimental|Cohort 1b, Period E|Single oral dose under fasted conditions, crossover
11262086|NCT02957929|Experimental|Cohort 1b, Period F|Single oral dose under fed conditions, crossover
11262087|NCT02957929|Experimental|Cohort 2|Multiple oral doses
11262088|NCT02957929|Experimental|Cohort 3|Multiple oral doses
11262089|NCT02957929|Experimental|Cohort 4|Multiple oral doses in presence of CYP probe substrates
11262090|NCT02957903|Experimental|Treatment A|"Injection around the lateral femoral cutaneous nerve:
~8 ml Ropivacaine 0.75 %."
11262091|NCT02957903|Placebo Comparator|Treatment B|"Injection around the lateral femoral cutaneous nerve:
~8 ml isotonic Saline."
11262092|NCT02957890|Experimental|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
11262093|NCT02957890|Placebo Comparator|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
11262094|NCT02957877|Experimental|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
11262095|NCT02957877|Active Comparator|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
11262096|NCT02957864|Experimental|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
11262097|NCT02957864|Active Comparator|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
11262098|NCT02957851|Placebo Comparator|Oxygen/Nitrogen (22%/78%)|Medical Air
11262099|NCT02957851|Active Comparator|Nitrous Oxide/Oxygen (50%/50%)|EMONO
11262100|NCT02957838|Experimental|Non-diabetics|Non-diabetic volunteers with HbA1c < 6.5%. Subjects will be treated with C18:0 supplementation or mock.
11262101|NCT02957838|Experimental|Type 2 Diabetics|Type 2 Diabetes according to common definitions, but we exclude insulin-treated Type 2 diabetics because nutritional intervention is more difficult/risky. Subjects will be treated with C18:0 supplementation or mock.
11262102|NCT02957825|No Intervention|Control|Routine monitoring
11262103|NCT02957825|Experimental|Continuous wireless monitoring|Continuous wireless monitoring
11262104|NCT02957812|Experimental|Orthotics|Custom made orthotic provided for study
11262106|NCT02957799|Experimental|Accountable Condition- 8 clinics|In the Accountable Condition, the intervention includes mothers who will receive home visits from government-funded CHW who will be trained once under Philani and receive ongoing monitoring and supervision.
11262107|NCT02957799|Experimental|Control Condition- 8 clinics|The Control Condition will include mothers who receive home visits from government-funded CHW who will be trained once under Philani and receive supervision and monitoring consistent with local government practices.
11262108|NCT02957786|Experimental|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).
~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.
~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
11262109|NCT02957786|Active Comparator|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).
~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.
~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
11262110|NCT02957773|Experimental|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
11262111|NCT02957773|Experimental|Art activities|Art activities and daily activities group for 90 minutes.
11262112|NCT02957773|Experimental|Qigong|A Qigong and daily activities group for 90 minutes
11262113|NCT02957773|Other|Daily activities|A daily activities group for 90-minutes.
11262114|NCT02957747|Experimental|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
11262115|NCT02957747|No Intervention|Control|Participants randomized to this arm will receive referrals to VA and community resources
11262116|NCT02957734|Experimental|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
11262117|NCT02957721|Other|Behavioral self-management|Eligible patients who are registered on the practice EHR linked portal will be invited to join the study. Following informed consent, enrollment and randomization, participants in the treatment group will receive the type 2 diabetes behavioral self-management education intervention; comprised of 9 modules derived from Medline Plus.
11262118|NCT02957721|No Intervention|Usual Care|Usual care includes whatever care and services the patient's clinical provides as well as generic type 2 diabetes education built into the patient's EHR linked portal.
11262119|NCT02957708|Experimental|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
11262120|NCT02957708|Active Comparator|Control|conventional occupational therapy
11262121|NCT02957695|Placebo Comparator|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
11262122|NCT02957695|Active Comparator|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
11262123|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
11262124|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
11262125|NCT02957669|Experimental|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
11262126|NCT02957669|Active Comparator|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
11262127|NCT02957656|Experimental|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
11262128|NCT02957656|Experimental|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
11262129|NCT02957656|Experimental|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
11262130|NCT02957656|Experimental|University of Rochester URMC 13-001 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
11262131|NCT02957656|Experimental|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
11262132|NCT02957643|Placebo Comparator|pregnant women|iron dosage 1 per day for 3 months
11262133|NCT02957643|Experimental|pregnant women with anemia|iron dosage 1 per day for 6 months
11262134|NCT02957630|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
11262135|NCT02957630|Active Comparator|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
11262136|NCT02957630|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
11262137|NCT02957617|Experimental|BIIB074|BIIB074 orally twice daily
11262138|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), who were exposed to Evolocumab (Repatha) during pregnancy
11262139|NCT02957604||Comparison Group I|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH) who were not exposed to Evolocumab during pregnancy
11262140|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), and who were not exposed to Evolocumab during pregnancy.
11262141|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to Evolocumab (Repatha) but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
11262142|NCT02957591|Experimental|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
11262143|NCT02957591|Placebo Comparator|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
11262144|NCT02957578|Experimental|Solo TTD|Placement of tympanostomy tube with Solo TTD
11262145|NCT02957565|Experimental|Video 1: No EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
11262146|NCT02957565|Experimental|Video 1: No EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
11262147|NCT02957565|Experimental|Video 2: With EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
11262148|NCT02957565|Experimental|Video 2: With EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.
~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
11262149|NCT02957552|Experimental|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10^6 MSCs/kg body weight:
~first administration intraoperatively via intraportal infusion
~second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)
~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
11262150|NCT02957539|No Intervention|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
11262151|NCT02957539|Experimental|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
11262152|NCT02957539|Experimental|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
11262153|NCT02957526|Experimental|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
11262154|NCT02957526|Active Comparator|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
11262155|NCT02957513|Experimental|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
11262188|NCT02957305|Active Comparator|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
11262189|NCT02957305|Experimental|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
11262156|NCT02957513|Experimental|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
11262157|NCT02957513|Active Comparator|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:
~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.
~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.
~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
11262158|NCT02957500|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
11262159|NCT02957500|No Intervention|No treatment|standard treatment for surgery
11262160|NCT02957474|Experimental|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
11262161|NCT02957474|Experimental|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
11262162|NCT02957474|Experimental|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
11262163|NCT02957474|Experimental|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
11262164|NCT02957461||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
11262165|NCT02957461||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
11262166|NCT02957448|Experimental|BMS 986141 and Rifampin|
11262167|NCT02957435|Experimental|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
11262168|NCT02957422|Experimental|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
11262169|NCT02957422|Active Comparator|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
11262170|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
11262171|NCT02957396|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
11262172|NCT02957396|Experimental|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
11262173|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
11262174|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
11262175|NCT02957383|Experimental|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
11262176|NCT02957383|Experimental|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
11262177|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
11262178|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
11262179|NCT02957344||Text without context|
11262180|NCT02957344||Text with context|
11262181|NCT02957344||Map without context|
11262182|NCT02957344||Map with context|
11262183|NCT02957331|Experimental|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
11262184|NCT02957331|No Intervention|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
11262185|NCT02957318|Experimental|FiberBind|
11262186|NCT02957318|Experimental|RG-I fiber|
11262187|NCT02957318|Placebo Comparator|Placebo|
11262190|NCT02957292|Experimental|Levonorgestrel IUD|13,5 mg Levonorgestrel intrauterine device
11262191|NCT02957292|Active Comparator|Copper IUD|Copper (380mm2) intrauterine device
11262192|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
11262193|NCT02957279||Healthy control group|Healthy volunteers.
11262194|NCT02957266|Active Comparator|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
11262195|NCT02957266|Experimental|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.
~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
11262196|NCT02957253|Experimental|Intervention (CI)|Compensated intervention (CI). Nurse-led clinic one time per year. Focus on Life style and risk factors.
11262197|NCT02957253|No Intervention|Control (CC)|Compensated Control (CC)
11262198|NCT02957253|Experimental|Intervention (DI)|Decompensated intervention (DI). Nurse-led clinic two times every month to every third month. Focus on Lifestyle, risk factors, nutrition, selfcare and psychosocial needs
11262199|NCT02957253|No Intervention|Control (DC)|Decompensated Control (DC)
11262200|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
11262201|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
11262202|NCT02957227||1|cohort 1: Older adults with memory impairment
11262203|NCT02957227||2|cohort 2: Age matched healthy controls
11262204|NCT02957214|Experimental|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
11262205|NCT02957201|Other|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
11262206|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
11262207|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
11262208|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
11262209|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
11262210|NCT02957162|Other|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
11262211|NCT02957149|Experimental|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
11262212|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
11262213|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
11262214|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.
~60 patients with organic brain syndrome will receive their first doses (n=2-3) of auto-M2-BFs in clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose.
~The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
11262215|NCT02957097|Experimental|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
11262216|NCT02957097|Placebo Comparator|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
11262217|NCT02957058|Active Comparator|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
11262218|NCT02957058|Active Comparator|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
11262219|NCT02957045|Experimental|Cough|
11262220|NCT02957032|Experimental|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
11262252|NCT02956772|Experimental|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
11262253|NCT02956772|Active Comparator|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
11262221|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):
~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.
~Phase II (Activity Evaluation):
~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
11262222|NCT02956993|Active Comparator|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
11262223|NCT02956993|Placebo Comparator|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
11262224|NCT02956980|Experimental|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
11262225|NCT02956980|Experimental|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
11262226|NCT02956967||Patients receiving Nivestim|
11262227|NCT02956954|Experimental|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
11262228|NCT02956954|Sham Comparator|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
11262229|NCT02956941|Experimental|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
11262230|NCT02956941|No Intervention|Control cluster|Control group will receive routine dietary practices.
11262231|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
11262232|NCT02956902|No Intervention|Waiting list control|
11262233|NCT02956902|Experimental|Intervention|Clinician-supported smartphone application intervention
11262234|NCT02956889|Experimental|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
11262235|NCT02956876|Experimental|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
11262236|NCT02956876|Other|Standard consultation|standard chemotherapy for colorectal cancer
11262237|NCT02956863|Active Comparator|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
11262238|NCT02956863|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
11262239|NCT02956850|Experimental|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
11262240|NCT02956850|Experimental|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (100 mg, 140 mg, and 170 mg as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
11262241|NCT02956850|Experimental|Part II: CHB Participants|CHB participants will receive RO7020531 (150 mg and 170 mg as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41, unless in Cohort 4 in case of QW dosing as dose modification.
11262242|NCT02956837|Experimental|GSK3003891A vaccine formulation 1 Group|Subjects in this group received a single 30 micrograms (µg) dose injection of the investigational GSK3003891A vaccine at Day 0.
11262243|NCT02956837|Experimental|GSK3003891A vaccine formulation 2 Group|Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.
11262244|NCT02956837|Experimental|GSK3003891A vaccine formulation 3 Group|Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.
11262245|NCT02956837|Placebo Comparator|Control Group|Subjects in this group received a single placebo injection at Day 0.
11262246|NCT02956811|Active Comparator|Active|Dapagliflozin 10mg once daily for 12 months
11262247|NCT02956811|Placebo Comparator|Placebo|Placebo 10mg once daily for 12 months
11262248|NCT02956798|Experimental|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
11262249|NCT02956785|Active Comparator|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
11262250|NCT02956785|Active Comparator|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
11262251|NCT02956785|Active Comparator|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
11262254|NCT02956759|Experimental|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
11262255|NCT02956759|Active Comparator|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
11262256|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
11262257|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
11262258|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
11262259|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
11262260|NCT02956733|Active Comparator|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
11262261|NCT02956733|Active Comparator|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
11262262|NCT02956720|Experimental|single arm|
11262263|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.
~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.
~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
11262264|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
11262265|NCT02956694|Experimental|Professional training|Professional e-learning program on shared decision making including two components: (1) a self-directed e-learning activity on shared decision making, lasting about 1 hour, that participants could complete in several sittings; and (2) five evidence summaries named Decision Boxes (DBs).
11262266|NCT02956681|Active Comparator|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
11262267|NCT02956681|Active Comparator|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
11262268|NCT02956668|Experimental|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.
~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.
~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.
~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
11262269|NCT02956668|Active Comparator|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.
~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
11262270|NCT02956655|Experimental|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
11262271|NCT02956655|Active Comparator|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
11262272|NCT02956642|Experimental|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
11262273|NCT02956642|Active Comparator|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
11262274|NCT02956629|Experimental|HCV GT1|Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
11262275|NCT02956629|Experimental|HCV GT2|Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
11262276|NCT02956629|Experimental|HCV GT3|Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
11262277|NCT02956629|Experimental|HCV GT4|Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
11262278|NCT02956629|Experimental|HCV GT5|Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
11262279|NCT02956629|Experimental|HCV GT6|Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
11262317|NCT02956447|Experimental|Pulsatile kisspeptin|Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
11262280|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
11262281|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
11262282|NCT02956603|Experimental|Neuroma Graft|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
11262283|NCT02956603|Experimental|Prosthetic Control Graft|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
11262284|NCT02956603|Experimental|Able Bodied|The investigators will place small electrodes percutaneously into intact muscles in the arm to record EMG signals and electrically stimulate the intact nerves nearby.
11262285|NCT02956590|Active Comparator|Pitavastatin|Study Drug
11262286|NCT02956590|Placebo Comparator|Placebo|Placebo
11262287|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
11262288|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
11262289|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
11262290|NCT02956564|Other|exposure group|subjects in this group are those who accept intrauterine intervention
11262291|NCT02956564|No Intervention|control group|subjects in this group are those who do not accept intrauterine intervention
11262292|NCT02956551|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
11262293|NCT02956538|Experimental|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
11262294|NCT02956538|Active Comparator|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
11262295|NCT02956525|Experimental|Dexibuprofen 200 mg - Fed|Fed condition
11262296|NCT02956525|Experimental|Dexibuprofen 200 mg - Fasting|Fasting condition
11262297|NCT02956512|Experimental|Dexibuprofen 300mg - Fed|Fed condition
11262298|NCT02956512|Experimental|Dexibuprofen 300mg - Fasting|Fasting condition
11262299|NCT02956499|Experimental|Cohort 1|single intravenous dose
11262300|NCT02956499|Experimental|Cohort 2|single intravenous dose
11262301|NCT02956499|Experimental|Cohort 3|single intravenous dose
11262302|NCT02956499|Experimental|Cohort 4|single intravenous dose
11262303|NCT02956499|Experimental|Cohort 5|single intravenous dose
11262304|NCT02956499|Experimental|Cohort 6|single intravenous dose
11262305|NCT02956499|Experimental|Cohort 7|multiple intravenous doses
11262306|NCT02956499|Experimental|Cohort 8|multiple intravenous doses
11262307|NCT02956499|Experimental|Cohort 9|multiple intravenous doses
11262308|NCT02956499|Experimental|Cohort 10|multiple intravenous doses
11262309|NCT02956486|Experimental|Core Study: Elenbecestat (E2609) 50 mg|Participants will receive one 50 milligram (mg) elenbecestat (E2609) tablet orally once a day in the morning. The core study will be double blinded.
11262310|NCT02956486|Placebo Comparator|Core Study: Placebo|Participants will receive one matching placebo tablet orally once a day in the morning. The core study will be double blinded.
11262311|NCT02956486|Experimental|Open Label Extension Phase: Elenbecestat (E2609) 50 mg|Participants completing the core study will receive one 50 milligram (mg) elenbecestat (E2609) tablet orally once a day in the morning.
11262312|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed
~Supine MRI will be performed
~Participant will receive mammography and ultrasound
~Breast Radiologist will take a brief survey.
~All new patients will receive Neoadjuvant Therapy via standard of care
~Standard of care will be performed"
11262313|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
11262314|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
11262315|NCT02956447|Experimental|Kisspeptin Bolus|Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.
11262316|NCT02956447|No Intervention|Baseline|Blood sampling every 10 minutes
11262318|NCT02956434|Experimental|Brief family intervention|Participants will receive the BFI in this arm of the study. The BFI is a 2-session intervention for family members of Veterans who are beginning PTSD treatment.
11262319|NCT02956434|No Intervention|No intervention|Participants will not receive the BFI in this arm of the study. They will be eligible for any usual support or programming for the families of Veterans.
11262320|NCT02956421|Active Comparator|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
11262321|NCT02956421|Experimental|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
11262322|NCT02956408|Active Comparator|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
11262323|NCT02956408|Experimental|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
11262324|NCT02956395|Active Comparator|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
11262325|NCT02956395|No Intervention|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
11262326|NCT02956382|Experimental|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg
~Each medication is taken daily. Treatment cycles are 28 days long."
11262327|NCT02956382|Experimental|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg
~Each medication is taken daily. Treatment cycles are 28 days long."
11262328|NCT02956382|Experimental|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg
~Each medication is taken daily. Treatment cycles are 28 days long."
11262329|NCT02956382|Experimental|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg
~Each medication is taken daily. Treatment cycles are 28 days long."
11262330|NCT02956382|Experimental|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
11262331|NCT02956369|Placebo Comparator|Control|10 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
11262332|NCT02956369|Active Comparator|SATIOSTAT|10 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
11262333|NCT02956356|Placebo Comparator|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
11262334|NCT02956356|Active Comparator|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
11262335|NCT02956356|Placebo Comparator|Control treatment + meal intake|Control treatment as preload followed by a test meal
11262336|NCT02956356|Active Comparator|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
11262337|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
11262338|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
11262339|NCT02956330||CLS1003-201|Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.
11262340|NCT02956317|Active Comparator|STP705|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
11262341|NCT02956317|Placebo Comparator|Placebo|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
11262342|NCT02956304|Other|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
11262343|NCT02956304|Other|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
11262344|NCT02956304|Other|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
11262345|NCT02956304|Other|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
11262346|NCT02956304|Other|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
11262347|NCT02956304|Other|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
11262348|NCT02956291|Experimental|Newly Diagnosed Brain Tumors|Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
11262349|NCT02956291|Experimental|Treated tumors with possible recurrence|Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
11262350|NCT02956278|Placebo Comparator|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
11262351|NCT02956278|Experimental|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
11262391|NCT02956057|Active Comparator|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
11262352|NCT02956278|Experimental|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
11262353|NCT02956265|Experimental|Patients - Suffering from carcinomatous or polymorphous skin|
11262354|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
11262355|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
11262356|NCT02956239|Experimental|Thermocoagulation (device)|VIA Positive women will be treated by the new device for thermocoagulation
11262357|NCT02956239|Active Comparator|Cryotherapy (device)|VIA positive women will be treated by cryotherapy
11262358|NCT02956239|Active Comparator|LEEP (device)|VIA Positive women not suitable for thermo-coagulation or cryotherapy will be treated by LEEP
11262359|NCT02956226|Experimental|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
11262360|NCT02956226|Placebo Comparator|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
11262361|NCT02956226|Experimental|Cannabinoids - whole plant extract|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
11262362|NCT02956213|Experimental|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
11262363|NCT02956213|Active Comparator|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
11262364|NCT02956200|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
11262365|NCT02956200|No Intervention|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
11262366|NCT02956187|Experimental|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
11262367|NCT02956187|Active Comparator|Fiber supplementation|Constipation will be treated by a fiber supplement
11262368|NCT02956174|Experimental|Co-Cr single crown|Co-Cr single crown
11262369|NCT02956174|Active Comparator|Contralateral sound tooth|Contralateral sound tooth
11262370|NCT02956161|Experimental|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
11262371|NCT02956161|Experimental|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
11262372|NCT02956161|Sham Comparator|No stimulation|The device is worn without any auditory stimulations delivered.
11262373|NCT02956148|Experimental|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.
~The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
11262374|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
11262375|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
11262376|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
11262377|NCT02956109|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
11262378|NCT02956109|Experimental|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
11262379|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
11262380|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
11262381|NCT02956096|Active Comparator|tDCS device and Treatmill|The stimulation is accomplished with a direct current-tDCS Stimulator Plus device, via two surface electrodes sponge (non-metallic) 5-7 cm2 in saline moistened with a 2mA current during 20 minutes after hemodinamic analysis is performed for 15 minutes and then made only training treadmill for 20 minutes. Placebo tDCS will follow the same procedures, but the tDCS device will only be switched on for 20 seconds. The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve (MACKO , 2005).
11262382|NCT02956096|Sham Comparator|1- tDCS|1. Who received stimulation transcranial direct current active will receive Sham stimulation and who received the placebo stimulation receive active stimulation and then the two groups will do the workout on the treadmill
11262383|NCT02956083|Active Comparator|Lipid based artificial tears|Patients use lipid based artificial tears
11262384|NCT02956083|Active Comparator|Non-lipid based artificial tears|patients use non-lipid based artificial tears
11262385|NCT02956083|Placebo Comparator|Saline|patients use saline
11262386|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
11262387|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
11262388|NCT02956057|Active Comparator|PEG1D|Polyethylene glycols single dose a day before colonoscopy
11262389|NCT02956057|Active Comparator|PEG2D|Polyethylene glycols split dose
11262390|NCT02956057|Active Comparator|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
11262392|NCT02956057|Active Comparator|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
11262393|NCT02956057|Active Comparator|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
11262394|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
11262395|NCT02956044|Active Comparator|Group 1: Metformin alone|
11262396|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
11262397|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
11262398|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
11262399|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
11262400|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
11262401|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
11262402|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
11262403|NCT02956031||HIV pos|those who serologically tested positive for HIV
11262404|NCT02956031||HIV neg|those who serologically tested negative for HIV
11262405|NCT02956031||HIV unk|those with no available serological test for HIV
11262406|NCT02956005|Other|Envarsus|Open Label; Envarsus XR started at the time of transplant. Initial dosing of 0.17mg/kg. Target trough level of 8-10 ng/mL
11262407|NCT02955992|No Intervention|standard of care|
11262408|NCT02955992|Experimental|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.
~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.
~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:
~Preparation for the death : Prepare the relative for the patient's imminent death
~During the dying and death process: The physician enters the patient's room at least once to check on the relatives
~After the patient's death: the physician and the nurse meet the relative"
11262409|NCT02955979||CT scan with iodinated contrast agents|Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
11262410|NCT02955966|Experimental|Patient with invasive pulmonary aspergillosis|Blood collection and imaging 18F-FDG-PET/CT
11262411|NCT02955953|Experimental|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
11262412|NCT02955953|Experimental|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
11262413|NCT02955940|Experimental|Ruxolitinib|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
11262414|NCT02955940|Experimental|Ruxolitinib plus background cancer therapy|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
11262415|NCT02955940|Experimental|Background cancer therapy alone|Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.
11262416|NCT02955927|Experimental|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
11262417|NCT02955927|Active Comparator|ortho-k|participants will receive treatment of ortho-k alone
11262418|NCT02955914||Optimism|Based on quality of life assessment
11262419|NCT02955914||Pessimism|Based on quality of life assessment
11262420|NCT02955901|Active Comparator|3-day low residue diet|Group A - 3 day low residue diet prior to the colonoscopy
11262421|NCT02955901|Placebo Comparator|1-day low residue diet|Group B - 1 day low residue diet prior to the colonoscopy
11262422|NCT02955888|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
11262423|NCT02955888|Placebo Comparator|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
11262424|NCT02955875|Experimental|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
11262425|NCT02955875|No Intervention|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
11262426|NCT02955862|Other|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months."
11262427|NCT02955849|Experimental|SLT laser group|"selective laser trabeculoplasty for 360 degrees the study eye.
~Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;
~Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.
~Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)."
11262428|NCT02955849|No Intervention|Standard care group|"Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).
~Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.
~Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.
~Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)"
11262468|NCT02955576|Placebo Comparator|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
11262429|NCT02955849|No Intervention|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
11262430|NCT02955823|Experimental|1 arm for all patient: Ritux-Dexame-Lena|Rituximab-Dexamethasone-Lenalidomide
11262431|NCT02955810|Experimental|CyBorD-DARA|
11262432|NCT02955797|Experimental|Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
11262433|NCT02955797|Experimental|Group 2 (Meningococcal Vaccine-Naive): Nimenrix®|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
11262434|NCT02955797|Experimental|Group 3 (MenC-Primed): MenACYW Conjugate Vaccine|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
11262435|NCT02955797|Experimental|Group 4 (MenC-Primed): Nimenrix®|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
11262436|NCT02955784|Experimental|Sinasprite Mobile App|Mobile App
11262437|NCT02955771|Experimental|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
11262438|NCT02955771|Experimental|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
11262439|NCT02955771|Other|Stenting|Endoscopic or percutaneous stenting alone will be performed.
11262440|NCT02955758|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11262441|NCT02955732|Experimental|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
11262442|NCT02955719|Experimental|Enrolled Cases|"Integrated Care Pathway with different treatment interventions
~Interventions include:
~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
11262443|NCT02955719|No Intervention|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
11262444|NCT02955706|Experimental|Active|Acetyl-L-carnitine (DongA ST)
11262445|NCT02955706|Placebo Comparator|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
11262446|NCT02955693|Other|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
11262447|NCT02955693|Other|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
11262448|NCT02955693|Other|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
11262449|NCT02955693|Other|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
11262450|NCT02955680|Experimental|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
11262451|NCT02955680|Active Comparator|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
11262452|NCT02955667|Experimental|invivo microscopy group|patients receive invivo micro-colposcopy examination and do not have to receive the biopsies
11262453|NCT02955667|Other|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
11262454|NCT02955654|Experimental|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
11262455|NCT02955654|Active Comparator|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
11262456|NCT02955654|Other|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
11262457|NCT02955641|Active Comparator|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
11262458|NCT02955641|Active Comparator|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
11262459|NCT02955641|Active Comparator|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
11262460|NCT02955641|Active Comparator|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
11262461|NCT02955628|Experimental|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
11262462|NCT02955615|Experimental|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
11262463|NCT02955615|Placebo Comparator|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
11262464|NCT02955602|Experimental|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
11262465|NCT02955602|Experimental|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
11262466|NCT02955602|Experimental|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
11262467|NCT02955589|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
11262469|NCT02955576|Active Comparator|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
11262470|NCT02955576|Experimental|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
11262471|NCT02955563|Experimental|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
11262472|NCT02955563|No Intervention|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
11262473|NCT02955550|Experimental|PNK-007 and rhIL-2|Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 7 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
11262474|NCT02955537|No Intervention|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
11262475|NCT02955537|Experimental|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
11262476|NCT02955524|Experimental|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.
~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
11262477|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:
~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
11262478|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:
~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
11262479|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:
~Inscope DL-blade size 3.5"
11262480|NCT02955498|Experimental|R-T|First period: administration of reference drug, Second period: administration of test drug
11262481|NCT02955498|Experimental|T-R|First period: administration of test drug, Second period: administration of reference drug
11262482|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
11262483|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
11262484|NCT02955472|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
11262485|NCT02955472|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
11262486|NCT02955459|Experimental|VNRX-5133|IV infusion
11262487|NCT02955459|Placebo Comparator|Placebo|IV infusion
11262488|NCT02955433|Experimental|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
11262489|NCT02955433|No Intervention|Control|The control arm will receive an appointment reminder, but no free transportation offer.
11262490|NCT02955420|Experimental|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:
~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.
~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).
~Part B:
~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose < 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.
~Part C:
~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
11262491|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
11262492|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
11262493|NCT02955394|Placebo Comparator|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
11262494|NCT02955394|Experimental|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
11262495|NCT02955381|Experimental|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
11262496|NCT02955381|Placebo Comparator|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
11262497|NCT02955368|Experimental|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
11262498|NCT02955368|Active Comparator|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
11262499|NCT02955368|Active Comparator|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
11262558|NCT02954978|Active Comparator|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
11262500|NCT02955355|Experimental|HYQVIA|All study Participants will receive SC HYQVIA/HyQvia at a dose of 80 Unit per gram (U/g) subcutaneously (SC) administered at a dosing frequency of every 2, 3, or 4 weeks interval for the first two doses and then for every 12 weeks until relapse or until predetermined study end for the specific country.
11262501|NCT02955329|Experimental|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
11262502|NCT02955329|Experimental|THC|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
11262503|NCT02955329|Experimental|Nicotine/THC|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
11262504|NCT02955303|Experimental|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
11262505|NCT02955290|Experimental|Phase I (CIMAvax, nivolumab)|"LOADING PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.
~MAINTENANCE PHASE I: Patients who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks."
11262506|NCT02955290|Experimental|Phase II Study A and B (CIMAvax, nivolumab)|PHASE II STUDY A and B: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer >= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.
11262507|NCT02955290|Experimental|Phase II Study C (CIMAvax, pembrolizumab)|PHASE II STUDY C: Patients with PD-L1 expression >= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 2 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11262508|NCT02955277|Experimental|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by six weekly sessions (of 60 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
11262509|NCT02955277|No Intervention|standard care|Participants will receive standard medical care with no TECH protocol.
11262510|NCT02955277|Active Comparator|active standard care|Partivipans will receive six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.
11262511|NCT02955264|Experimental|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
11262512|NCT02955251|Experimental|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
11262513|NCT02955251|Experimental|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
11262514|NCT02955251|Experimental|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
11262515|NCT02955251|Experimental|Arm 2|ABBV-428 plus nivolumab.
11262516|NCT02955238|Experimental|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
11262517|NCT02955238|No Intervention|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
11262518|NCT02955225|Experimental|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
11262519|NCT02955225|Active Comparator|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
11262520|NCT02955212|Placebo Comparator|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
11262521|NCT02955212|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
11262522|NCT02955199|Experimental|Mothering From the Inside Out|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
11262559|NCT02954965|Experimental|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
11262985|NCT02952157|Active Comparator|Lidocaine|Lidocaine jelly will be applied to the endotracheal tube.
11262523|NCT02955199|Active Comparator|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
11262524|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
11262525|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
11262526|NCT02955173|Experimental|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
11262527|NCT02955173|Experimental|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
11262528|NCT02955173|Experimental|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
11262529|NCT02955173|Experimental|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
11262530|NCT02955160|Experimental|Multivalent|Pneumococcal conjugate vaccine
11262531|NCT02955160|Active Comparator|Tdap|Tetanus, diphtheria, and pertussis vaccine
11262532|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
11262533|NCT02955134|Experimental|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
11262534|NCT02955134|Placebo Comparator|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
11262535|NCT02955121|Active Comparator|Pharmacogenetic Results Available to Provider|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
11262536|NCT02955121|No Intervention|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
11262537|NCT02955108|Experimental|music first then no music|
11262538|NCT02955108|Experimental|no music first then music|
11262539|NCT02955095|Experimental|Current cigarette smoker|
11262540|NCT02955082|Experimental|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
11262541|NCT02955069|Experimental|PDR001|PDR001 administered via intravenous infusion once every 4 weeks.
11262542|NCT02955056|Experimental|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
11262543|NCT02955056|No Intervention|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
11262544|NCT02955043|Experimental|Behavioral intervention|Participants will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. The intervention will be delivered in three 45-60 minute face-to-face sessions at approximately 3-4, 8, and 12 weeks post-HSCT with brief telephone coaching calls scheduled between sessions. Participants will be encouraged to use the behavioral strategies from hospital discharge through 18 weeks post-HSCT. Participants will be asked to complete a daily checklist indicating which intervention strategies they used. Participants will also receive standard medical care following HSCT.
11262545|NCT02955043|No Intervention|Usual care|Participants will receive standard medical care following HSCT.
11262546|NCT02955030|Experimental|NSV0001(Cohort1)|15 µg of hemagglutinin [HA] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
11262547|NCT02955030|Experimental|NSV0001(Cohort2)|30 µg of hemagglutinin[HA] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
11262548|NCT02955030|Experimental|NSV0001(Cohort3)|60 µg of hemagglutinin[HA] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
11262549|NCT02955030|Placebo Comparator|Placebo|0 µg of hemagglutinin[HA] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
11262550|NCT02955030|Active Comparator|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
11262551|NCT02955017|Active Comparator|Traditional follow-up|
11262552|NCT02955017|Experimental|"Distance follow-up new technologies"|
11262553|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks
11262554|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks
11262555|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks
11262556|NCT02954978|Placebo Comparator|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
11262557|NCT02954978|Active Comparator|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
11262560|NCT02954965|Experimental|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
11262561|NCT02954965|No Intervention|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
11262562|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
11262563|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
11262564|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
11262565|NCT02954939|Active Comparator|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
11262566|NCT02954939|Placebo Comparator|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
11262567|NCT02954926|Experimental|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
11262568|NCT02954926|No Intervention|Control|No intervention
11262569|NCT02954913|Experimental|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
11262570|NCT02954900|Other|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
11262571|NCT02954887|Experimental|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.
~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
11262572|NCT02954874|Experimental|Arm I (observation)|Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
11262573|NCT02954874|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
11262574|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
11262575|NCT02954848|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
11262576|NCT02954848|Experimental|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
11262577|NCT02954835|Active Comparator|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
11262578|NCT02954835|Active Comparator|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
11262579|NCT02954822|Experimental|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
11262580|NCT02954822|Experimental|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
11262581|NCT02954809|Experimental|Experimental|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
11262582|NCT02954809|Active Comparator|Attention Control|Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
11262583|NCT02954796|Experimental|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
11262584|NCT02954783|Experimental|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
11262585|NCT02954783|Active Comparator|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
11262586|NCT02954770||Fitbit® challenger|The residents who participated a Fitbit® challenge study about one year ago
11262587|NCT02954757|Experimental|Treatment arm|HIFU treatment
11262588|NCT02954744|Experimental|Treatment arm|HIFU treatment
11262589|NCT02954731|Experimental|UP-CBT|"The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions."
11262590|NCT02954731|Active Comparator|Standard-CBT|Group CBT following Danish versions of diagnosis specific manuals (Social Anxiety Disorder (SAD) Group; Depression (DEP) Group; Agoraphobia/Panic Disorder (Ag/PD) (standard-CBT). The original elements of psychoeducation, cognitive restructuring, and exposure/activity scheduling are present in the applied manuals. Standard-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
11262591|NCT02954718|Experimental|1|patient-centered task oriented activity training in real life
11262592|NCT02954718|Experimental|2|patient-centered video-based task oriented activity training
11262593|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
11262594|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).
~10 milliliter of blood are collected from these donors"
11262595|NCT02954692|Experimental|Insulin glargine (U300)|Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.
11262596|NCT02954666|Experimental|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
11262597|NCT02954666|Experimental|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
11262598|NCT02954653|Experimental|Dose Escalation|Single agent PF-06747143 dose escalation
11262599|NCT02954653|Active Comparator|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
11262600|NCT02954653|Active Comparator|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
11262601|NCT02954653|Experimental|Cohort 3|PF-06747143 dose expansion as a single agent.
11262602|NCT02954640|Other|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.
~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.
~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
11262603|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
11262604|NCT02954614|Experimental|Intervention group|Active play in after school programs (ASP). Training program for ASP staff.
11262605|NCT02954614|No Intervention|Control group|ASP as usual.
11262606|NCT02954601|Active Comparator|Placebo|Placebo (fish oil)
11262607|NCT02954601|Active Comparator|Dose1|Dose 1 ORMD-0801 (qd)
11262608|NCT02954601|Active Comparator|Dose2|Dose 2 ORMD-0801 (bid)
11262609|NCT02954601|Active Comparator|Dose 3|Dose 3 ORMD-0801 (tid)
11262610|NCT02954588|Active Comparator|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
11262611|NCT02954588|Active Comparator|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
11262612|NCT02954588|Placebo Comparator|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
11262613|NCT02954575|Experimental|All patients|All patients will receive Wilate for prophylactic treatment
11262614|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
11262615|NCT02954549|Active Comparator|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, >30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
11262616|NCT02954549|Experimental|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of < 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
11262617|NCT02954549|Experimental|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of <30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
11262618|NCT02954536|Experimental|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
11262619|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.
~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).
~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).
~There is no limit to the number of cycles a patient can receive.
~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
11262620|NCT02954510|Experimental|Intervention|Single arm utilizing ferumoxytol
11262621|NCT02954497|Experimental|Jarvik 2015 Device VAD|New, experimental continuous flow VAD
11262622|NCT02954484|Active Comparator|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
11262623|NCT02954484|Placebo Comparator|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
11262624|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
11262625|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
11262626|NCT02954445|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11262627|NCT02954432|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
11262628|NCT02954432|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
11262629|NCT02954419||IgA nephropathy group|Eligible biopsy-proven primary IgA nephropathy patients.
11262630|NCT02954406|Experimental|Dose Escalation Phase Cohort A:TAK-659 + Bendamustine|TAK-659 60 milligram (mg), immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 milligram per square meter (mg/m^2), infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
11262631|NCT02954406|Experimental|Dose Escalation Phase Cohort B:TAK-659+Bendamustine+Rituximab|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
11262632|NCT02954406|Experimental|Dose Escalation Phase Cohort C: TAK-659 + Gemcitabine|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
11262633|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 + Lenalidomide|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
11262634|NCT02954406|Experimental|Dose Escalation Phase Cohort E: TAK-659 + Ibrutinib|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
11262635|NCT02954406|Experimental|Safety Expansion Phase Cohort B:TAK-659+Bendamustine+Rituximab|TAK-659 TBD, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants with advanced ollicular lymphoma (FL) or marginal zone lymphoma (MZL). The TAK-659 dose will be the MTD / maximally administered dose (MAD)/ RP2D as determined in the dose escalation phase. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
11262636|NCT02954393|Placebo Comparator|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
11262637|NCT02954393|Active Comparator|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
11262638|NCT02954393|Active Comparator|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
11262639|NCT02954380|Experimental|ZIO/ILR|THe Zio ILR arm will already have an ILR implanted for standard of care and will receive the Zio patch
11262640|NCT02954367|Experimental|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
11262641|NCT02954367|Placebo Comparator|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
11262642|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
11262643|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
11262644|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
11262645|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
11262646|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
11262647|NCT02954328|Experimental|tDCS|"The active tDCS condition will consist of 4 visit:
~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:
~Sham
~motor M1 area
~motor M1 + Dorsolateral Prefrontal cortex
~Dorsolateral Prefrontal cortex.
~The tDCS condition will be randomized and double blinded"
11262648|NCT02954315|Experimental|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
11262649|NCT02954315|No Intervention|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
11262695|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
11262650|NCT02954302|Experimental|PrPD with RGA|Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
11262651|NCT02954302|Experimental|conventional PrPD|Patients who will undergo conventional PrPD.
11262652|NCT02954289|Other|Dietary intervention|Dietary intervention
11262653|NCT02954276|Experimental|75 mg Omexa sumatriptan sublingual tablet|
11262654|NCT02954276|Active Comparator|100 mg Imitrex oral tablet|
11262655|NCT02954263|Experimental|TD-1439|Capsule formulation
11262656|NCT02954263|Placebo Comparator|Placebo|Capsule formulation
11262657|NCT02954250|No Intervention|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
11262658|NCT02954250|Experimental|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
11262659|NCT02954224|Experimental|CPAP therapy arm|Auto-titrating Continuous Positive Airway Pressure (CPAP)) treatment will be given on postoperative days 1, 2, and 3.
11262660|NCT02954224|No Intervention|Control arm|no auto-titrating CPAP, standard care
11262661|NCT02954211|Experimental|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
11262662|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
11262663|NCT02954198|Active Comparator|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
11262664|NCT02954185|Experimental|WellClub Device|Hand held device that patients use for home therapy
11262665|NCT02954185|Active Comparator|Standard Therapy|Standard care therapy for should pain
11262666|NCT02954172|Experimental|Bevacizumab in combination withPaclitaxel/Carboplatin|Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
11262667|NCT02954172|Active Comparator|Avastin in combination with Paclitaxel/Carboplatin|Drug avastin15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
11262668|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
11262669|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
11262670|NCT02954146|Active Comparator|CBT only|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT only) sessions for anger management.
11262671|NCT02954146|Experimental|CBT + Connectd mobile health app|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT) sessions for anger management. In addition, veterans in this group will also receive instructions for using Connectd mobile health app with a family member or friend that will provide data for the CBT clinician.
11262672|NCT02954133|Experimental|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
11262673|NCT02954133|Experimental|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
11262674|NCT02954133|Experimental|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
11262675|NCT02954133|Experimental|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
11262676|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
11262677|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
11262678|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
11262679|NCT02954120||(PCOS+CP+)|PCOS participants with CP
11262680|NCT02954107||Absence epilepsy|Children aged 6-12 years of age primarily presenting with episodes of brief loss of consciousness (absences) in an otherwise normal child in the previous 2 years. With an EEG showing 3 Hz (2.5-4.5 Hz) generalized rhythmic spike-and-wave complexes with a discharge duration of at least 3 seconds on a present or former EEG.
11262681|NCT02954107||Controls|Overall healthy children aged 6-12 years of age following a regular school without major problems.
11262682|NCT02954068|Active Comparator|IV Infusion|Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU
11262683|NCT02954068|Active Comparator|IM administration|Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml
11262684|NCT02954055|Active Comparator|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
11262685|NCT02954055|Experimental|Arm B|"Metronomic VEX:
~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
11262686|NCT02954042|Experimental|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
11262687|NCT02954042|Placebo Comparator|Placebo Probe|Placebo probe
11262688|NCT02954029|Experimental|Study group (transradial cohort)|device-assisted compression with ezClot pad
11262689|NCT02954029|Experimental|Study group (transfemoral cohort)|manual compression with ezClot pad
11262690|NCT02954029|Active Comparator|Control group (transradial cohort)|Rotary compression device
11262691|NCT02954029|Active Comparator|Control group (transfemoral cohort)|manual compression with BloodSTOP ix pad
11262692|NCT02954016|Experimental|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
11262693|NCT02954003|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
11262694|NCT02953990|Experimental|MOMS Program|The MOMS Program involves: (1) mindfulness of symptoms and goal-setting through a nurse-participant partnership, and (2) 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home activity. Participants will engage in 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home practice.
11262697|NCT02953964|Experimental|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
11262698|NCT02953964|Experimental|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
11262699|NCT02953964|Active Comparator|Behavioral : control group|Participants receive cognitive stimulation intervention
11262700|NCT02953951||Stored Blood Cells|"Blood transfusion:
~Stored blood cells transfused patients"
11262701|NCT02953951||Autologous Salvaged Blood|"Blood transfusion:
~Autologous salvaged blood transfused patients"
11262702|NCT02953951||Control|"Blood transfusion:
~No transfusion patients"
11262703|NCT02953938|Active Comparator|mono therapy|ranibizumab alone
11262704|NCT02953938|Experimental|combination therapy|ranibizumab with Grid&Direct short pulse laser photocoagulation
11262705|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
11262706|NCT02953912|Experimental|Reciproc single-file.|The Reciproc is a single-file nickel-titanium systems used in reciprocating motion, made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue .
11262707|NCT02953912|Active Comparator|One Shape single-file .|One Shape is single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue. with electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
11262708|NCT02953899|Experimental|Contingency Management|This is a treatment where participants earn points for treatment attendance and for providing evidence of gambling abstinence. These points are added to study accounts that can be redeemed for goods and services available at a variety of on-line businesses (e.g., Amazon, Walmart, etc.). Submission of evidence of gambling behaviour or non-attendance at an on-line counselling session re-sets subsequent points to the starting level. The CM procedure is implemented as part of the CBT counselling session.
11262709|NCT02953899|Active Comparator|Cognitive Behavioural Therapy|"CBT is currently considered best practice for the treatment of problem gambling, as noted in the National Health and Medical Research Council (Australia) endorsed Clinical Guidelines for problem and pathological gambling treatment (Problem Gambling Research and Treatment Centre, 2011). CBT is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling and substance use. Techniques include psychoeducation, behavioural interventions, and cognitive strategies. Participants are expected to attend on-line counselling sessions three times a week for approximately 12 weeks. All participants will receive individual counselling from an experienced counsellor/therapist."
11262710|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
11262711|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
11262712|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
11262713|NCT02953847|Other|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
11262714|NCT02953847|Other|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
11262715|NCT02953847|Other|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
11262716|NCT02953847|Other|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
11262717|NCT02953847|Other|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
11262718|NCT02953847|Other|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz
~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
11262719|NCT02953834|Experimental|Kisspeptin and Insulin Resistance Test|intravenous administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
11262720|NCT02953834|Placebo Comparator|Placebo and Insulin Resistance Test|intravenous administration of IV fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
11262721|NCT02953821|Experimental|Acthar Gel|Participants receive Acthar Gel every other day for 4 weeks, and then twice per week for 20 weeks
11262722|NCT02953821|Placebo Comparator|Placebo Gel|Participants receive Placebo Gel every other day for 4 weeks, and then twice per week for 20 weeks
11262723|NCT02953808|Experimental|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
11262724|NCT02953808|Experimental|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
11262907|NCT02952755|Experimental|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
11262725|NCT02953808|Experimental|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
11262726|NCT02953808|Experimental|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
11262727|NCT02953808|Placebo Comparator|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
11262728|NCT02953782|Experimental|Magrolimab + Cetuximab (Phase 1b, Dose escalation)|"Participants with advanced solid tumors will be given a starting priming dose of 1 mg/kg magrolimab on Day 1 followed by 10 mg/kg maintenance doses on Days 8, 15, and 22. Cetuximab will be given at a reduced dose of 300 mg/m^2 on Day 8 followed by 200 mg/m^2 on Days 15 and 22. Magrolimab and cetuximab will continue to be given weekly during subsequent cycles.
~Based on dose limiting toxicities (DLTs) observed, additional participants will be enrolled and administered priming dose of 1 mg/kg magrolimab followed by escalating maintenance doses of up to 45 mg/kg + cetuximab up to 250 mg/m^2 to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab."
11262729|NCT02953782|Experimental|Magrolimab + Cetuximab (Phase 2, KRAS Wild-Type)|After the dose escalating phase (Phase 1b) has completed and an RP2D for magrolimab in combination with cetuximab is determined, participants with advanced CRC who have KRAS wild-type tumors will receive the RP2D of magrolimab in combination with cetuximab 400 mg/m^2 on Day 8 followed by 250 mg/m^2 weekly.
11262730|NCT02953782|Experimental|Magrolimab + Cetuximab (Phase 2, KRAS Mutant)|After the RP2D tolerability is confirmed in the KRAS wild-type cohort, participants with advanced CRC who have KRAS mutant will receive the RP2D of magrolimab in combination with cetuximab 400 mg/m^2 on Day 8 followed by 250 mg/m^2 weekly.
11262731|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
11262732|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
11262733|NCT02953756||Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery (GKRS)
11262734|NCT02953743|Experimental|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
11262735|NCT02953743|Experimental|Lenvatinib 8 mg|Participants weighing < 60 kg will be enrolled in this arm.
11262736|NCT02953730|Experimental|PEG-rhG-CSF|
11262737|NCT02953717|Active Comparator|Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery
11262738|NCT02953717|Active Comparator|Whole Brain Radiation Therapy (WBRT)|Whole Brain Radiation Therapy
11262739|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
11262740|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
11262741|NCT02953691|Experimental|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
11262742|NCT02953691|Placebo Comparator|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
11262743|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
11262744|NCT02953665|Active Comparator|Liraglutide|Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
11262745|NCT02953665|Placebo Comparator|Placebo|Placebo will be self-administered subcutaneously once daily according to the same schedule.
11262746|NCT02953652|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
11262747|NCT02953639|Experimental|Basmisanil 240 mg|Participants will receive basmisanil twice daily orally for 24 weeks.
11262748|NCT02953639|Experimental|Basmisanil 80 mg|Participants will receive basmisanil twice daily orally for 24 weeks.
11262749|NCT02953639|Placebo Comparator|Placebo|Participants will receive matching placebo to basmisanil twice daily orally for 24 weeks.
11262750|NCT02953626|Experimental|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
11262751|NCT02953626|No Intervention|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
11262752|NCT02953613|Experimental|Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
11262753|NCT02953600|Experimental|Standard Dose Spirulina Platensis|Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
11262754|NCT02953600|Active Comparator|Zero Spirulina Platensis|Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
11262755|NCT02953600|Active Comparator|Double Dose Spirulina Platensis|same as usual, non pill taken
11262813|NCT02953249||Control group|The control group will include 30 healthy subjects, without diabetes mellitus, in need of tooth extraction
11262756|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) NJ/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
11262757|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) NJ/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
11262758|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) PO/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
11262759|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) PO/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
11262760|NCT02953574|Experimental|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.
~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
11262761|NCT02953574|No Intervention|usual nursing care|
11262762|NCT02953561|Experimental|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11262763|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
11262764|NCT02953535|Experimental|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
11262765|NCT02953535|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11262766|NCT02953535|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11262767|NCT02953522|Other|191 mcg/day of Folate|Diet with 191 mcg/day of Folate
11262768|NCT02953522|Other|90 mcg/day of Folate|Diet with 90 mcg/day of Folate
11262769|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 1b Dose Escalation|Participants with B-cell non-Hodgkin's lymphoma will receive 1 mg/kg magrolimab priming dose on Day 1 of Cycle 1 followed by weekly maintenance doses of 10, 20, 30, or 45 mg/kg on Days 8, 15, 22 for Cycle 1 and Days 1, 8, 15, and 22 for each cycle to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose and schedule (RP2DS) in combination with rituxumab 375 mg/m^2. Cycle length is 28 days.
11262770|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Indolent Lymphoma|Participants with indolent lymphoma will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
11262771|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma|Participants with diffuse large B-cell lymphoma (DLBCL) will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
11262772|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2. Cycle length is 28 days.
11262773|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive magrolimab at a dose determined from Phase 1b Safety Dose-Escalation Phase in combination with rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2.
11262774|NCT02953496|Experimental|vonapanitase|
11262775|NCT02953483|Experimental|Acellular first|Lung preservative solution without red blood cells will be used for perfusion in the initial 2 hours followed by addition of red blood cells for the next two hours
11262776|NCT02953483|Experimental|Cellular first|Lung preservative solution will contain red blood cells for the first two hours followed by acellular perfusate for the next two hours
11262777|NCT02953470|Experimental|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
11262814|NCT02953236|Experimental|Instrumented massage|
11262815|NCT02953236|Active Comparator|Manual massage|
11262816|NCT02953210|Experimental|GF general free|pre induction midazolam 50ug.kg-1, clonidine 1ug.kg induction dexter ketamine 0.2mg.kg, lidocaine 1.5mg.kg, propofol 2mg.kg,rocuronium 0.6mg.kg maintenance isoflurane 1 CAM, lidocaine 2mg.kg.h
11262778|NCT02953470|Active Comparator|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
11262779|NCT02953457|Experimental|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11262780|NCT02953444|No Intervention|Wait List Control|Participants receive daily email surveys for two weeks before being given access to the brief-mindfulness-practice training materials.
11262781|NCT02953444|Experimental|Thirty-Second Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a thirty-second mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
11262782|NCT02953444|Active Comparator|Three-Minute Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a three minute mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
11262783|NCT02953431|Placebo Comparator|Sham CPAP|Participants will be randomized to Sham CPAP
11262784|NCT02953431|Active Comparator|CPAP 10|Participants will be randomized to CPAP 10
11262785|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
11262786|NCT02953392|Active Comparator|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
11262787|NCT02953392|Active Comparator|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
11262788|NCT02953392|Active Comparator|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
11262789|NCT02953392|Active Comparator|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
11262790|NCT02953379|Experimental|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
11262791|NCT02953379|Active Comparator|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
11262792|NCT02953366|Experimental|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
11262793|NCT02953366|Active Comparator|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
11262794|NCT02953353|Active Comparator|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
11262795|NCT02953353|Sham Comparator|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
11262796|NCT02953340|Experimental|Docetaxel +Cyclophosphamide+ SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)
~Supplied in prefilled single-use syringes for subcutaneous injection
~Administered on Day 2 of each cycle"
11262797|NCT02953340|Active Comparator|Docetaxel +Cyclophosphamide+ Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta®)
~Single-dose subcutaneous injection on Day 2 of each cycle."
11262798|NCT02953327|Experimental|Intervention arm|Intervention arm, these participants will receive BCG vaccination.
11262799|NCT02953327|Placebo Comparator|Placebo arm|The placebo arm will receive BCG solvent.
11262800|NCT02953314|Experimental|Part A|"Participants weighing <25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.
~Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days."
11262801|NCT02953314|Experimental|Part B|"Participants weighing <40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.
~Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks."
11262802|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
11262803|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
11262804|NCT02953288||Benign thyroid nodules|Benign thyroid nodules
11262805|NCT02953288||Thyroid Carcinoma|Thyroid Carcinoma
11262806|NCT02953275|Experimental|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
11262807|NCT02953275|Placebo Comparator|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
11262808|NCT02953262|Experimental|Encouragement Arm 1|Participants in this encouragement condition will receive a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
11262809|NCT02953262|Experimental|Encouragement Arm 2|Participants in this encouragement condition will receive the same training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
11262810|NCT02953262|Experimental|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (training guide and group training offer) but will also be offered a one-on-one My HealtheVet training
11262811|NCT02953262|Other|Attention Control Comparison Arm|The Comparison condition will receive a mailed brochure with basic My HealtheVet content.
11262812|NCT02953249||Study group|The study group will include 30 subjects with type 1 diabetes mellitus who require extraction of 1 or more erupted teeth
11262817|NCT02953210|Active Comparator|GBal general balanced|pre induction with midazolam 50 ug.kg induction fentanyl 3ug.kg, propofol 2mg.kg, rocuronium 0.6mg.k maintenance isoflurane 1 CAM and fentanyl as needed
11262818|NCT02953197|Experimental|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
11262819|NCT02953184|Active Comparator|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
11262820|NCT02953184|Experimental|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
11262821|NCT02953171|Experimental|Raw sauerkraut+Probiotic capsule|75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
11262822|NCT02953171|Experimental|Raw sauerkraut+placebo capsule|75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
11262823|NCT02953171|Experimental|Pasteurized sauerkraut+Probiotic capsule|75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
11262824|NCT02953171|Placebo Comparator|Pasteurized sauerkraut+Placebo capsule|75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
11262825|NCT02953158|Experimental|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
11262826|NCT02953158|Active Comparator|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
11262827|NCT02953145|Experimental|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
11262828|NCT02953145|No Intervention|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
11262829|NCT02953132|Experimental|Single ascending dose, MT-4129 or Placebo|
11262830|NCT02953132|Experimental|Multiple ascending dose, MT-4129 or Placebo|
11262831|NCT02953119|Experimental|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:
~5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)
~Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series
~Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
11262832|NCT02953119|No Intervention|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
11262833|NCT02953106|Active Comparator|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
11262834|NCT02953106|Placebo Comparator|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
11262835|NCT02953093|Other|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
11262836|NCT02953093|Other|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
11262837|NCT02953080|Active Comparator|Call for Life UgandaTM|Call for Life UgandaTM Janssen Global Public Health Research and Development, in close collaboration with the Infectious Disease Institute Kampala (IDI), has developed Call for Life UgandaTM tailored to the needs of PLHIV in Uganda. Call for Life UgandaTM is based on the CONNECT FOR LIFETM technology (CFL2015.01 or higher version) and the MOTECH platform, an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation, and was released under the terms of the MOTECH open source license agreement
11262838|NCT02953080|Active Comparator|No call for life UgandaTM|No call for life UgandaTM
11262839|NCT02953067|Active Comparator|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
11262840|NCT02953067|Active Comparator|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
11262841|NCT02953067|Active Comparator|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
11262842|NCT02953054|Active Comparator|DMTS|DMTS applied to the upper arm
11262843|NCT02953054|Placebo Comparator|Placebo|Placebo patches to match DMTS applied to the upper arm
11262844|NCT02953041|Experimental|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
11262845|NCT02953041|Experimental|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
11262846|NCT02953041|Experimental|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
11262847|NCT02953028|Active Comparator|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
11262848|NCT02953028|Active Comparator|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
11262849|NCT02953015|Experimental|Manipulative articulatory and myofascial techniques Group|Manipulative and myofascial techniques
11262850|NCT02953015|Active Comparator|Transcutaneous Electrical Nerve Stimulation Group|Electrical Nerve Stimulation
11262851|NCT02952989|Experimental|SGN-2FF|Dose escalation and dose expansion
11262852|NCT02952989|Experimental|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
11262853|NCT02952976|Active Comparator|Abthera|Patients with open abdomen submitted to treatment with the Abthera dressing
11262854|NCT02952976|Active Comparator|Barker|Patients with open abdomen submitted to treatment with the Baker dressing
11262855|NCT02952963|Experimental|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
11262856|NCT02952963|Experimental|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
11262857|NCT02952950|Other|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
11262858|NCT02952950|No Intervention|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
11262859|NCT02952937|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
11262860|NCT02952937|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).
~wash-out period: over 7 days.
~Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
11262861|NCT02952924|Placebo Comparator|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
11262862|NCT02952924|Experimental|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
11262863|NCT02952924|Placebo Comparator|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.
11262864|NCT02952924|Experimental|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
11262865|NCT02952924|Placebo Comparator|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
11262866|NCT02952924|Experimental|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
11262867|NCT02952924|Experimental|Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)|Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
11262868|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort B)|Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
11262869|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort C)|Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.
11262870|NCT02952911|Experimental|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
11262871|NCT02952911|Other|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
11262872|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
11262873|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
11262874|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
11262875|NCT02952885|Experimental|Pegvisomant|Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.
11262876|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
11262877|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
11262878|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
11262879|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
11262880|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
11262881|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
11262882|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
11262883|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
11262884|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
11262885|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
11262886|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
11262887|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
11262888|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
11262889|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
11262890|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
11262891|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
11262892|NCT02952859||historic control group|Work-up and follow-up of the historic control will be performed through similar means by contacting primary care physicians and/or medical oncologists, if information cannot be received, the patient will be directly contacted. In case the patient cannot be reached and no other information can be received on patients outcome, the death registry will be contacted.
11262893|NCT02952859||comparator group|All patients with potentially and borderline resectable pancreatic cancer are potentially candidates for IRE and will be considered for this treatment. Patient will be recruited/referred through daily clinical practice from the Inselspital Bern. Final inclusion into the study will be performed by the responsible investigators at the Inselspital Bern. Patients will be included according to the inclusion/exclusion criteria mentioned.
11262894|NCT02952846|No Intervention|Before algorithm|Observational
11262895|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
11262896|NCT02952833|Experimental|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
11262897|NCT02952833|Experimental|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
11262898|NCT02952833|Experimental|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
11262899|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
11262900|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
11262901|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
11262902|NCT02952807|Active Comparator|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
11262903|NCT02952807|Active Comparator|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
11262904|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
11262905|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
11262906|NCT02952768|Other|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
11264773|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
11262908|NCT02952755|Experimental|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
11262909|NCT02952742|Experimental|Black Cohosh Therapy|Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
11262910|NCT02952742|Placebo Comparator|Placebo|Subjects will take 2 capsules, identical to the Black Cohosh capsules, by mouth each. Subject's will remain on this study arm for 8 weeks.
11262911|NCT02952729|Experimental|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
11262912|NCT02952716|Experimental|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
11262913|NCT02952716|Placebo Comparator|control group|hyperbaric oxygen
11262914|NCT02952703|Active Comparator|First Breath|brief pre-natal smoking cessation counseling
11262915|NCT02952703|Experimental|Striving to Quit|Additional pre-natal counseling (in-person and telephonic); post delivery counseling (in-person and telephonic) and incentives
11262916|NCT02952690|Active Comparator|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
11262917|NCT02952690|Experimental|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
11262918|NCT02952677|Experimental|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
11262919|NCT02952677|Sham Comparator|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
11262920|NCT02952677|Other|Control|Participants receive usual care only during the intervention period.
11262921|NCT02952664|Experimental|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
11262922|NCT02952651|Experimental|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
11262923|NCT02952638||Healthy|BMI is between 20 and 25
11262924|NCT02952638||Overweight|BMI is between 25 and 30
11262925|NCT02952638||Obese|BMI is between 30 and 40
11262926|NCT02952625|Other|Single arm imaging study|Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
11262927|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
11262928|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase
~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase
~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
11262929|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase
~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase
~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
11262930|NCT02952573|Experimental|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.
~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).
~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
11262931|NCT02952573|Experimental|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.
~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).
~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
11262932|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
11262933|NCT02952547|Experimental|Test / Reference Drug|DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
11262934|NCT02952547|Experimental|Reference / Test Drug|Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
11262935|NCT02952534|Experimental|Rucaparib|Oral rucaparib (monotherapy)
11262936|NCT02952521||Epithelial ovarian cancer|"Whole blood sample collection
~Up to 3 fresh tumor tissue core biopsies
~Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
11262937|NCT02952508|Experimental|CLR 131, intravenous administration|CLR 131
11262983|NCT02952170|Experimental|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
11262938|NCT02952495|Experimental|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
11262939|NCT02952495|No Intervention|No intervention|Participants will NOT Participate in the online alcohol education class.
11262940|NCT02952482||newborns testing for ALD|newborns testing for ALD
11262941|NCT02952469|Experimental|(68Ga)PSMA-HBED-CC|Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen
11262942|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
11262943|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
11262944|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
11262945|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
11262946|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
11262947|NCT02952430||Frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of greater than or equal to five.
~This group will then be observed after intervention to review outcomes."
11262948|NCT02952430||Not frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of less than five.
~This group will then be observed after intervention to review outcomes."
11262949|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
11262950|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
11262951|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
11262952|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
11262953|NCT02952391||Parkinson's disease patients|patients with Parkinson's disease, between the ages of 45 and 65, with a disease duration of 3 - 10 years
11262954|NCT02952391||healthy control subjects|Healthy control subjects, between the ages of 45 and 65
11262955|NCT02952378|Experimental|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
11262956|NCT02952378|Experimental|Healthy individuals|Healthy individuals without allergies.
11262957|NCT02952365|Other|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
11262958|NCT02952352|Experimental|Diabetes Intervention|Diabetes Prevention Program
11262959|NCT02952352|Other|Delayed Intervention|Diabetes Prevention Program
11262960|NCT02952339|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
11262961|NCT02952339|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
11262962|NCT02952326|Experimental|XP Endo Finisher|
11262963|NCT02952326|Active Comparator|Conventional needle irrigation|
11262964|NCT02952313|Other|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
11262965|NCT02952300|Experimental|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
11262966|NCT02952300|Active Comparator|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
11262967|NCT02952287|Experimental|Study Participants|4D PC MRI acquisition
11262968|NCT02952274|Active Comparator|locater attachment|mandibular overdenture retained with single midline implant using locator attachment
11262969|NCT02952274|Active Comparator|ball attachment|mandibular overdenture retained with single midline implant using ball attachment
11262970|NCT02952261|Other|CT-guided localization|This group of participants received conventional CT-guided lung nodule localization.
11262971|NCT02952261|Experimental|template-guided localization|Three-dimensional printed template was customized based on participant's computed tomography information. Participants received template-guided lung nodule localization.
11262972|NCT02952248|Experimental|BI 754091|
11262973|NCT02952235|Other|SPF50+|SPF 50+ assigned to Left side of face SPF 100+ assigned to Right side of face
11262974|NCT02952235|Other|SPF100+|SPF 100+ assigned to Left side of face SPF 50+ assigned to Right side of face
11262975|NCT02952222|Active Comparator|Propofol (Group P)|Propofol only
11262976|NCT02952222|Active Comparator|Propofol with Dexmedetomidine (Group DP)|Propofol with Dexmedetomidine
11262977|NCT02952209|No Intervention|No Treatment|Tooth extraction with no bone graft.
11262978|NCT02952209|Active Comparator|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
11262979|NCT02952196|Placebo Comparator|placebo|
11262980|NCT02952196|Experimental|cannabinoid dose 1|
11262981|NCT02952196|Experimental|cannabinoid dose 2|
11262982|NCT02952183|Experimental|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
11262984|NCT02952157|Sham Comparator|Control|Normal saline will be applied to the endotracheal tube.
11262986|NCT02952144|Experimental|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
11262987|NCT02952144|No Intervention|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
11262988|NCT02952131|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
11262989|NCT02952131|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
11262990|NCT02952131|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
11262991|NCT02952118|Experimental|one night with the device and one night without the device.|"The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the Forrest epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the Forrest epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home."
11262992|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
11262993|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
11262994|NCT02952092|Experimental|ASP1517 Group|Subjects will take the study drug at two- or three-day intervals.
11262995|NCT02952092|Experimental|Darbepoetin alfa Group|Subjects will take the study drug once a week.
11262996|NCT02952079|Active Comparator|BlephEx treatment|Treatment with the BlephEx instrument (lid margin exfoliation)
11262997|NCT02952079|Active Comparator|MiBoFlo treatment|Treatment with the MiboFlo equipment (heat therapy to eyelids)
11262998|NCT02952066|Experimental|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
11262999|NCT02952053|Experimental|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
11263000|NCT02952053|Active Comparator|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
11263001|NCT02952040|Experimental|ASP1517 alone period preceding group|Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
11263002|NCT02952040|Experimental|ASP1517+lanthanum period preceding group|Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
11263003|NCT02952027|Experimental|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
11263004|NCT02952027|Placebo Comparator|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
11263005|NCT02952014|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
11263006|NCT02952014|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
11263007|NCT02952014|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
11263008|NCT02952001||CLS1001-301|Those subjects who completed participation in CLS1001-301 who have not received additional therapy.
11263009|NCT02951988|Experimental|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) once a week during OLTP followed by rapastinel 450 mg IV once a week during DBTP.
11263010|NCT02951988|Experimental|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV once a week during OLTP followed by rapastinel 450 mg IV once every 2 weeks during DBTP.
11263011|NCT02951988|Placebo Comparator|Placebo|Rapastinel 450 mg IV once a week during OLTP followed by placebo-matching rapastinel 450 mg IV once a week during DBTP.
11263012|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
11263013|NCT02951962|Experimental|Twynsta 80/5mg|Day 1 ~ Day 9 : Twynsta 80/5mg / Day 10 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
11263014|NCT02951962|Experimental|Crestor 20mg|Day 1 ~ Day 5 : Crestor 20mg / Day 6 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
11263015|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
11263016|NCT02951936|Experimental|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.
~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
11263017|NCT02951936|Sham Comparator|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
11263018|NCT02951923|Experimental|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
11263019|NCT02951923|Active Comparator|Soy powder|8 weeks of Soy powder, 60g per day
11263020|NCT02951910|Experimental|Intervention|Patients receiving zinc-hyaluronate eye drop
11263021|NCT02951897|Active Comparator|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
11263022|NCT02951897|Placebo Comparator|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
11263023|NCT02951897|Placebo Comparator|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
11263024|NCT02951897|Active Comparator|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
11263025|NCT02951897|Placebo Comparator|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
11263026|NCT02951897|Placebo Comparator|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
11263027|NCT02951884|Experimental|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
11263028|NCT02951884|Experimental|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
11263029|NCT02951884|No Intervention|Control|Participants assigned to this arm receive no injection or aspiration therapy.
11263030|NCT02951871||LP: Lymphoma Progression|
11263031|NCT02951871||TRM: Treatment Related Mortality|
11263032|NCT02951871||NHM: Non hematologic malignancy|
11263033|NCT02951871||OC: Other Cause|
11263034|NCT02951858|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
11263035|NCT02951858|Active Comparator|Control Group|The participants only receive the materials about the harm of substance use.
11263036|NCT02951845|Experimental|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram [mg], Fasted) then Treatment B1 (Direct Compression Tablets, 5*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263037|NCT02951845|Experimental|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263038|NCT02951845|Experimental|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263039|NCT02951845|Experimental|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263040|NCT02951845|Experimental|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263041|NCT02951845|Experimental|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263042|NCT02951845|Experimental|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263043|NCT02951845|Experimental|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263044|NCT02951845|Experimental|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263045|NCT02951845|Experimental|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263046|NCT02951845|Experimental|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263047|NCT02951845|Experimental|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
11263048|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
11263049|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
11263050|NCT02951806|Active Comparator|(R) Rapid spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 15 seconds then 10 mg hyperbaric bupivacaine.
11263051|NCT02951806|Active Comparator|(S) Slow spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
11263052|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C>4)
11263053|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
11263054|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
11263055|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
11263056|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
11263057|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
11263058|NCT02951780|Experimental|LY3185643|LY3185643 administered subcutaneous (SC)
11263059|NCT02951780|Experimental|rGlucagon|rGlucagon administered subcutaneous (SC)
11263060|NCT02951767|Experimental|Cohort 1: Treatment-naive Cisplatin Ineligible Participants|Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
11263061|NCT02951754|Experimental|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
11263062|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
11263063|NCT02951728|Experimental|Decitabine plus R-CHOP|"Rituximab 375 mg/m2 IV d6; Cyclophosphamide 750mg/m2 IV d7; Doxorubicin 50mg/m2 IV d7; Vincristine 1.4 mg/m2 IV d7; Prednisone 60 mg/m2 PO d7-11;
~Decitabine will be administered intravenously at dose levels as follow in Phase 1:
~Dose level 1: Decitabine 10 mg/m2 days 1-5; Dose level 2: Decitabine 15 mg/m2 days 1-5; Dose level 3: Decitabine 20 mg/m2 days 1-5 and determine the maximum tolerated dose.
~In phase 2, Decitabine will be administered intravenously at MTD."
11263064|NCT02951715|Experimental|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
11263065|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
11263066|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
11263067|NCT02951689|Experimental|Probiotic|Multi-strain probiotic
11263068|NCT02951689|Placebo Comparator|Placebo|Maltodextrin placebo
11263069|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.
~Amoxicillin 250 mg , three times daily for five days."
11263070|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
11263071|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
11263072|NCT02951663|Experimental|Protein Supplement|Ready to drink blinded protein supplement
11263073|NCT02951663|No Intervention|Control|Control group
11263074|NCT02951650|Experimental|Cyberonics VNS|Cyberonics VNS
11263075|NCT02951637|Experimental|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
11263076|NCT02951637|Experimental|Group B|Patient will be administrated with gefitinib
11263077|NCT02951624|Experimental|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
11263078|NCT02951624|Experimental|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
11263079|NCT02951624|Experimental|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
11263080|NCT02951624|Experimental|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
11263081|NCT02951611|Sham Comparator|Sham stimulation|Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.
11263082|NCT02951611|Experimental|Treatment: Acupuncture stimulation|Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.
11263083|NCT02951598|Other|MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
11263084|NCT02951598|Other|Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
11263085|NCT02951598|Other|MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
11263086|NCT02951598|Other|Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
11263087|NCT02951585|Experimental|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
11263088|NCT02951585|Placebo Comparator|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
11263089|NCT02951572|Other|Patients with RLD initiating NIV|Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation
11263090|NCT02951559|Experimental|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
11263091|NCT02951546|Experimental|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;
~Aerobic exercise training for a 4-month period;"
11263207|NCT02951065|Active Comparator|Soft bristle brush|Subjects will be assigned to use a soft, nylon-bristled tooth brush for one year twice daily
11263092|NCT02951546|Experimental|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;
~Aerobic exercise training for a 4- month period;"
11263093|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
11263094|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
11263095|NCT02951520|Experimental|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
11263096|NCT02951507|Active Comparator|Conventional partial denture|Intervention will be O T unilateral attachment
11263097|NCT02951507|Active Comparator|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
11263098|NCT02951494|Active Comparator|AlterG Anti-gravity treadmill|cont. aerobic exercise training with lower body weight support
11263099|NCT02951494|No Intervention|Exercise without body weight support|cont. aerobic exercise training without lower body weight support
11263100|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
11263101|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
11263102|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
11263103|NCT02951455|Experimental|CD-LC|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Licensed Clinician (LC).
11263104|NCT02951455|Experimental|CBP- LC|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Licensed Clinician (LC)
11263105|NCT02951455|Experimental|QLW- LC|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life Wheel, Licensed Clinician (LC)
11263106|NCT02951455|Experimental|CD & CBP- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
11263107|NCT02951455|Experimental|CD & QLW- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
11263108|NCT02951455|Experimental|QLW & Capacity Building ProjectCBP- LC|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks. Licensed Clinician (LC)
11263109|NCT02951455|Experimental|QLW & CD & CBP-LC|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
11263110|NCT02951455|Experimental|LC|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes.Licensed Clinician (LC)
11263111|NCT02951455|Experimental|CD- PF|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Peer Facilitator (PF)
11263112|NCT02951455|Experimental|CBP- PF|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Peer Facilitator (PF)
11263113|NCT02951455|Experimental|QLW-PF|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life wheel, Peer Facilitator (PF)
11263114|NCT02951455|Experimental|CD & CBP- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions. Peer Facilitator (PF)
11263115|NCT02951455|Experimental|CD & QLW- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
11263116|NCT02951455|Experimental|QLW & CBP- PF|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks.Peer Facilitator (PF)
11263117|NCT02951455|Experimental|CD & QLW & CBP- PF|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
11263118|NCT02951455|Experimental|PF|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes. Peer Facilitator (PF)
11263119|NCT02951442|Experimental|Renal Transplant|
11263120|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
11263121|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
11263122|NCT02951416||Idiopathic Pulmonary Fibrosis (IPF)|"IPF diagnosis according to the guidelines of 2011 (AJRCCM 2011; 183:788). For patients diagnosed prior to 2011, the criteria of the consensus statement 2000 apply (AJRCCM 2000;161:646).
~Patient registry (observation and biomaterial sampling)."
11263123|NCT02951416||Non-specific interstitial pneumonia|"Non-specific interstitial pneumonia (NSIP) based on the histopathological demonstration of an NSIP pattern.
~Patient registry (observation and biomaterial sampling)."
11263124|NCT02951416||Cryptogenic organising pneumonia (COP)|"COP characterised histologically by an organising pneumonia with intraluminal organising fibrosis in the alveolar ducts and alveolar spaces.
~Patient registry (observation and biomaterial sampling)."
11263125|NCT02951416||Acute interstitial pneumonia (AIP)|"Histological pattern of diffuse alveolar damage (DAD), characterised by hyaline membranes, alveolar oedema and a marked interstitial and alveolar inflammatory reaction.
~Patient registry (observation and biomaterial sampling)."
11263126|NCT02951416||Lymphoid interstitial pneumonia (LIP)|"Histological pattern of LIP primary or secondary (e.g. rheumatoid arthritis, Sjögren's syndrome, pernicious anaemia, chronic active hepatitis, systemic lupus erythematosus (SLE), primary biliary cirrhosis, myasthenia gravis, severe immune deficiency syndromes (AIDS)).
~Patient registry (observation and biomaterial sampling)."
11263127|NCT02951416||respiratory bronchiolitis-ILD (RB-ILD)|Histological pattern of RB-ILD or typical clinical and radiological findings. Patient registry (observation and biomaterial sampling).
11263128|NCT02951416||Desquamative Interstitial Pneumonia|"Histological pattern of Desquamative Interstitial Pneumonia (DIP). The picture is similar to RB-ILD, but the distribution pattern is much more homogeneous and does not even have the bronchiolocentric distribution.
~Patient registry (observation and biomaterial sampling)."
11263129|NCT02951416||Hypersensitivity Pneumonitis|"Hypersensitivity Pneumonitis (HP) characterized by exposure to inhaled organic antigens and development of antibodies. Typical clinical and radiological findings, lymphocytosis in bronchoalveolar lavage (BAL) or histology showing HP granulomas.
~Patient registry (observation and biomaterial sampling)."
11263130|NCT02951416||Sarcoidosis|"Histological pattern with sarcoid granulomas or typical clinical and radiological findings with a lymphocytosis in BAL.
~Patient registry (observation and biomaterial sampling)."
11263131|NCT02951416||Lung Cancer|"Histological confirmation of Lung Cancer. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
11263132|NCT02951416||Chronic Obstructive Pulmonary Disease|"Obstructive spirometry and physical history suggesting Chronic Obstructive Pulmonary Disease (COPD). Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
11263133|NCT02951416||Pulmonary Hypertension|"Pulmonary Hypertension (PH) diagnosed through right heart catheterisation. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
11263134|NCT02951416||Sleep Apnea|"Sleep Apnea diagnosed by polysomnography. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
11263135|NCT02951416||Asthma|"Asthma diagnosed by positive bronchoprovocation test and typical history or bronchoreversibility in the lung function measurement or through peak flow measurement. Patients will be included as control group.
~Patient registry (observation and biomaterial sampling)."
11263136|NCT02951416||Control/Health Individuals|Healthy volunteers not suffering from any lung disease as control group. Patient registry (observation and biomaterial sampling).
11263137|NCT02951403|Experimental|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
11263138|NCT02951403|Other|Conservative treatment|Patients to whom special physiotherapy will be advised.
11263139|NCT02951390|Active Comparator|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
11263140|NCT02951390|No Intervention|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
11263141|NCT02951377|No Intervention|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
11263142|NCT02951377|Experimental|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
11263143|NCT02951364||LDV/SOF|Adult Korean participants and pediatric Korean participants aged 12 to <18 years with genotype 1, 2, 4, 5, and 6 chronic HCV infection who are initiating commercial Harvoni regimen
11263144|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
11263145|NCT02951351|Experimental|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
11263146|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.
~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
11263147|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
11263148|NCT02951325|No Intervention|Standard|"Surgery +/- chemotherapy only
~Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.
~Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.
~No radiation therapy will be given."
11263149|NCT02951325|Experimental|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention
~Radiation Therapy:
~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.
~Dose Prescription:
~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.
~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
11263150|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
11263151|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
11263152|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
11263153|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
11263154|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
11263155|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
11263156|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
11263157|NCT02951299|Experimental|pentoxifylline group|Received oral pentoxifylline (400 mg) three times a day for 14 days.
11263158|NCT02951299|No Intervention|no treatment group|No intervention.
11263159|NCT02951286|Experimental|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
11263160|NCT02951286|Experimental|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
11263161|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
11263162|NCT02951260|Experimental|Metformin|17 days metformin treatment
11263163|NCT02951260|Placebo Comparator|Placebo|17 days placebo treatment
11263164|NCT02951234|Experimental|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
11263165|NCT02951234|Active Comparator|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
11263166|NCT02951221|Experimental|Cohort 1|Treatment sub groups A and B
11263167|NCT02951221|Experimental|Cohort 2|Treatment sub groups C and D
11263168|NCT02951208|Experimental|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
11263169|NCT02951208|Sham Comparator|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
11263170|NCT02951195|Experimental|Heterozygous F508del/MF Cohort 1A: Triple Combination (TC)|"VX-152 100 milligrams (mg) administered every 12 hours (q12h). TEZ 100 mg once daily (qd). IVA 150 mg q12h.
~Morning Dose: VX-152 + TEZ/IVA
~Evening Dose: VX-152 + IVA"
11263171|NCT02951195|Placebo Comparator|Heterozygous F508del/MF Cohort 1A: TC|Placebos matched to VX-152, TEZ/IVA, and IVA.
11263172|NCT02951195|Experimental|Heterozygous F508del/MF Cohort 1B: TC|"To be initiated after blinded review of Cohort 1A, if supported by safety and PK Data.
~The dosage of VX-152 may be adjusted based on data from Cohort 1A.
~Morning Dose: VX-152 + TEZ/IVA
~Evening Dose: VX-152 + IVA"
11263173|NCT02951195|Placebo Comparator|Heterozygous F508del/MF Cohort 1B: Triple Placebo|Placebos matched to VX-152, TEZ/IVA, and IVA.
11263174|NCT02951195|Experimental|Heterozygous F508del/MF Cohort 1C: TC|"To be initiated after blinded review of Cohort 1B, if supported by safety and PK Data.
~The dosage of VX-152 to be determined based on data from Cohort 1B.
~Morning Dose: VX-152 + TEZ/IVA
~Evening Dose: VX-152 + IVA"
11263175|NCT02951195|Placebo Comparator|Heterozygous F508del/MF Cohort 1C: Triple Placebo|Placebos matched to VX-152, TEZ/IVA, and IVA.
11263176|NCT02951195|Experimental|Homozygous F508del/F508del Cohort 2A: TC|"To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.
~The dosage of VX-152 to be determined based on data from Cohort 1A (and from Cohort 1B, if applicable.)
~Morning Dose: VX-152 + TEZ/IVA
~Evening Dose: VX-152 + IVA
~The experimental period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
11263177|NCT02951195|Active Comparator|Homozygous F508del/F508del Cohort 2A: TEZ/IVA|"To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.
~Morning Dose: Placebo + TEZ/IVA
~Evening Dose: Placebo + IVA
~The active comparator period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
11263178|NCT02951195|Experimental|Homozygous F508del/F508del Cohort 2B: TC|"To be initiated after blinded review of Cohort 2A, if supported by safety and PK Data.
~The dosage of VX-152 to be determined based on data from Cohorts 1A, 1B, and 2B, as applicable.
~Morning Dose: VX-152 + TEZ/IVA
~Evening Dose: VX-152 + IVA
~The experimental period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
11263179|NCT02951195|Active Comparator|Homozygous F508del/F508del Cohort 2B: TEZ/IVA|"To be initiated after blinded review of Cohort 1A or Cohort 1B, if supported by safety and PK Data.
~Morning Dose: Placebo + TEZ/IVA Evening Dose: Placebo + IVA
~The active comparator period will be preceded by a 4-week run-in period and followed by a 2-week washout period, during both of which subjects will receive:
~TEZ 100 mg administered once daily (qd). IVA 150 mg q12h."
11263180|NCT02951182|Placebo Comparator|Part 1: Placebo - Cohort 1A and 1B Combined|Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
11263181|NCT02951182|Experimental|Part 1 Cohort 1A: Triple Combination (TC)|Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
11263182|NCT02951182|Experimental|Part 1 Cohort 1B: TC Low Dose|Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
11263183|NCT02951182|Experimental|Part 1 Cohort 1B: TC High Dose|Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
11263184|NCT02951182|Active Comparator|Part 2: TEZ/IVA|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
11263185|NCT02951182|Experimental|Part 2: TC-2|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
11263186|NCT02951156|Experimental|Phase 1b Arm A|avelumab/utomilumab/rituximab
11263187|NCT02951156|Experimental|Phase 1b Arm B|avelumab/utomilumab/azacitidine
11263188|NCT02951156|Experimental|Phase 1b Arm C|avelumab/rituximab/bendamustine
11263189|NCT02951156|Experimental|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
11263190|NCT02951156|Active Comparator|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
11263191|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
11263192|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
11263193|NCT02951143|Experimental|1.4 mg/g Concentration|Participants in this arm will experience the 1.4 mg/g Concentration
11263194|NCT02951143|Experimental|2.5 mg/g Concentration|Participants in this arm will experience the 2.5 mg/g Concentration
11263195|NCT02951143|Experimental|5.6 mg/g Concentration|Participants in this arm will experience the 5.6 mg/g Concentration
11263196|NCT02951143|Experimental|17.4 mg/g Concentration|Participants in this arm will experience the 17.4 mg/g Concentration
11263197|NCT02951130|Experimental|Milrinone|Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to < 7. The maximum duration of study drug infusion is 72 hours.
11263198|NCT02951130|Placebo Comparator|5% dextrose (D5W)|An equivalent volume of 5% dextrose (D5W) will be used for infants randomized to the placebo arm.
11263199|NCT02951117|Experimental|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily [QD]) and dexamethasone (40 mg once weekly [Q1W]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
11263200|NCT02951117|Experimental|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).
~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
11263201|NCT02951104|Experimental|USCOM|
11263202|NCT02951091||biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets [Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
11263203|NCT02951091||control group|
11263204|NCT02951078|Experimental|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
11263205|NCT02951078|Active Comparator|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
11263206|NCT02951065|Experimental|Bristle-less brush|Subjects will be assigned to use a bristle-less manual tooth brush with short, rubbery cones for one year twice daily
11265001|NCT02938624|Experimental|cohort1|Pembrolizumab 200 mg I.V single dose
11263208|NCT02951052|Experimental|CAB LA + RPV LA every 4 weeks|Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
11263209|NCT02951052|Active Comparator|Current antiretroviral regimen|Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
11263210|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
11263211|NCT02951026||0.03mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.03mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
11263212|NCT02951026||0.07mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.07mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
11263213|NCT02951026||0.23mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.23mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
11263214|NCT02951026||Placebo (previously injected)|"Subjects in this group received a single intra-articular injection of placebo into the target knee during the parent study prior to enrolling in this observational study."
11263215|NCT02951013|Experimental|restrictive group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 6g/dL, with a target hemoglobin range of 7.5-8.0g/dL.
11263216|NCT02951013|Active Comparator|liberal group|Patients in this group will have a transfusion when the hemoglobin concentration falls below 8g/dL, with a target hemoglobin range of 9.5-10.0g/dL.
11263217|NCT02951000|Active Comparator|platysma suture|running suture of the platysma with 3/0 polyglactin
11263218|NCT02951000|Active Comparator|no platysma suture|no platysma suture
11263219|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants
~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
11263220|NCT02950974|Active Comparator|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
11263221|NCT02950974|Experimental|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
11263222|NCT02950961|Other|Arm 1: nonrandomized stepped wedge|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In the context of the nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) at a site makes her/his first referral to the CCWV care manager. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
11263223|NCT02950948|Experimental|Progesterone|25 mg of progesterone will be administered daily by subcutaneous injection.
11263224|NCT02950948|Placebo Comparator|Placebo|25 mg of progesterone will be administered daily by subcutaneous injection.
11263225|NCT02950935|Experimental|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
11263226|NCT02950935|Placebo Comparator|Placebo|placebo will be administered twice à day until the 12th week of gestation.
11263227|NCT02950922|Experimental|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
11263228|NCT02950922|Experimental|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
11263229|NCT02950922|Placebo Comparator|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
11263230|NCT02950909|Experimental|Emphasized exercise group|Patients in the emphasized exercise group performed exercises emphasizing the deep cervical extensor muscles applying a resistance at the level of the vertebral arch of C4 either therapeutically with the therapist's fingers or as a home exercise with the aid of a towel or belt. These exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, a dynamic exercise was added moving the head from maximal flexion to maximal extension keeping the gaze fixed at an object lying between both elbows hoping to activate more the extensors in the lower cervical spine.
11263231|NCT02950909|Experimental|General exercise group|Patients in the general exercise group performed exercises targeting all cervical extensor muscles including the superficial ones applying resistance at the head pushing against a wall or the therapist's hand or as a home exercise with the aid of a towel. As in the other group, these exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, the same dynamic exercise was added as in the other group with the only difference that the gaze was fixed at an object lying between both hands hoping to activate all cervical extensors
11263232|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
11263233|NCT02950883|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
11263234|NCT02950883|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
11263235|NCT02950870|Experimental|group treated|this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.
11263236|NCT02950870|No Intervention|group untreated|Control group
11263237|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
11263238|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
11265002|NCT02938624|Experimental|Cohort II|Pembrolizumab 200 mg I.V Twice interval 21 days
11263239|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
11263240|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
11263241|NCT02950818|Experimental|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
11263242|NCT02950818|No Intervention|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
11263243|NCT02950805|Experimental|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
11263244|NCT02950805|Experimental|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
11263245|NCT02950792|Experimental|ViewRay MRI-IGART|"ViewRay MRI-Image-Guided Adaptive Radiation Therapy (IGART):
~Daily MRI on ViewRay 5 days per week for 4 weeks in combination with weekly standard of care chemo-radiation.
~Daily MRI on ViewRay during Week 5 in combination with Stereotactic Body Radiation Therapy boost for daily for up to 1 week.
~Continued standard of care consolidation chemotherapy every 21 days for 3 cycles, beginning 4 - 6 weeks after completion radiation therapy, ."
11263246|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor
~Neovax is a combination of Poly-ICLC and Neoantigen Peptides
~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22
~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20
~Ipilimumab will be injected within 1 cm of each NeoVax administration"
11263247|NCT02950766|Experimental|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor
~Neovax is a combination of Poly-ICLC and Neoantigen Peptides
~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22
~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
11263248|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
11263249|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
11263250|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
11263251|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
11263252|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
11263253|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
11263254|NCT02950727|Experimental|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
11263255|NCT02950727|Active Comparator|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
11263256|NCT02950714|Experimental|LIN_NOW|Participants from CaNIOS centres randomized to the NOW group will be provided immediate access to the lupus interactive navigator (LIN), a web-based program developed to promote engagement and self-care in lupus.
11263257|NCT02950714|Active Comparator|LIN_WAIT|Participants from CaNIOS centres randomized to the WAIT group will have usual care for three months prior to crossing over to access to the LIN.
11263258|NCT02950688|Experimental|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
11263259|NCT02950688|Placebo Comparator|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
11263260|NCT02950675||Normal Adult|Control:Normal Adult
11263261|NCT02950675||Burn Patient|The burn patient will be identified according to the diagnoses (ICD-9-CM code: 940-949).
11263262|NCT02950662|Active Comparator|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
11263263|NCT02950662|Active Comparator|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
11263264|NCT02950649|Experimental|Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
11263265|NCT02950649|Active Comparator|No Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
11263266|NCT02950636|Experimental|Restorative Yoga|Subjects will participate in a structured restorative yoga program. Subjects will attend a 60 minute restorative yoga class twice a week for 8 weeks in a yoga studio.
11263267|NCT02950623|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
11263268|NCT02950623|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
11263269|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
11263270|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
11263271|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
11263272|NCT02950584|Experimental|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
11263273|NCT02950584|Placebo Comparator|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
11263274|NCT02950571|Active Comparator|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
11263275|NCT02950571|Experimental|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.
~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.
~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
11263276|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
11263277|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
11263278|NCT02950545|Experimental|Placebo, Spherical, then Toric Lenses|Crossover order 1
11263279|NCT02950545|Experimental|Placebo, Toric, then Spherical Lenses|Crossover order 2
11263280|NCT02950545|Experimental|Spherical, Placebo, then Toric Lenses|Crossover order 3
11263281|NCT02950545|Experimental|Spherical, Toric, then Placebo Lenses|Crossover order 4
11263282|NCT02950545|Experimental|Toric, Placebo, then Spherical Lenses|Crossover order 5
11263283|NCT02950545|Experimental|Toric, Spherical, then Placebo Lenses|Crossover order 6
11263284|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
11263285|NCT02950519|Active Comparator|As needed Cuff Pressure Checks|Cuff pressure checks upon intubation and after any manipulation of ET tube
11263286|NCT02950519|Experimental|Cuff Pressure checks every 8 hrs|Cuff pressure checks upon intubation, after manipulation of ET tube, and minimum of 8 hr interval
11263287|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
11263288|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
11263289|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
11263290|NCT02950480|Experimental|Zafirlukast|Zafirlukast
11263291|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
11263292|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
11263293|NCT02950454|Experimental|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
11263294|NCT02950454|Active Comparator|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
11263295|NCT02950441|Experimental|Nicotinamide Riboside|1000mg (2x250mg tablets twice daily)
11263296|NCT02950441|Placebo Comparator|Placebo|Two tablets twice daily
11263297|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
11263298|NCT02950415|Other|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
11263299|NCT02950415|Other|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
11263300|NCT02950415|Other|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
11263301|NCT02950415|Other|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
11263302|NCT02950402|Experimental|Two Dried Plums per day|Two Dried Plums per day is approximately 14 g.
11263303|NCT02950402|Experimental|Six Dried Plums per day|Six Dried Plums per day is approximately 42 g.
11263304|NCT02950389|Experimental|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
11263305|NCT02950389|Experimental|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
11263306|NCT02950376||Group1：amphetamine abusers|
11263307|NCT02950376||Group2: health control|
11263308|NCT02950376||Group3: norm of assessment system|
11263309|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
11263310|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
11263311|NCT02950337|Experimental|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
11263312|NCT02950337|Experimental|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
11263313|NCT02950337|Experimental|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
11263314|NCT02950324|Experimental|Prehabilitation|Patients in this (intervention) arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'.
11263315|NCT02950324|Active Comparator|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
11263316|NCT02950311|Experimental|Intranasal xylitol spray|Two sprays each nostril, twice a day.
11263317|NCT02950311|Placebo Comparator|Intranasal saline spray|Two sprays each nostril, twice a day.
11263318|NCT02950285|Experimental|Baseline alert|For patients randomly selected for the baseline alert arm, their physicians will be alerted via email that a patient(s) under their care has atrial fibrillation, is at high risk of stroke, and is not currently anticoagulated. Physicians will also be asked to complete a survey related to anticoagulation for each patient and will be provided with educational resources and consultation services.
11263319|NCT02950285|No Intervention|3-month alert arm|For patients randomly selected for the 3-month alert arm, their physicians will not be notified during the 3-month study follow-up period. Instead, PCPs will be sent alerts after 3-months via email for these patients.
11263320|NCT02950259|Experimental|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
11263321|NCT02950259|Experimental|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
11263322|NCT02950246|Experimental|2% alcoholic chlorhexidine group|"Skin preparation Use of 10 ml of 2% alcoholic Chlorhexidine drug for disinfection in place of povidone iodine without scrubing device Wait at least 30 secondes for drying Perineural catheterization implementation Ultrasonography use"
11263323|NCT02950246|Active Comparator|povidon iodine group|"Skin preparation Use of 10 ml of povidone iodine drug for disinfection with scrubing device Wait at least 30 seondes for drying Perineural catheterization implementation Ultrasonography use"
11263324|NCT02950233|Experimental|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
11263325|NCT02950233|Experimental|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).
~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
11263326|NCT02950233|Experimental|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
11263327|NCT02950233|Placebo Comparator|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).
~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
11263328|NCT02950220|Experimental|Arm 1|
11263329|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
11263330|NCT02950181|Experimental|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
11263331|NCT02950168||Edoxaban|All patients treated with edoxaban with a planned or unplanned diagnostic or interventional procedure
11263332|NCT02950155|Experimental|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
11263333|NCT02950155|Sham Comparator|Sodium Chloride solution|A single infusion with sodium chloride solution.
11263334|NCT02950142|Experimental|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
11263335|NCT02950142|Active Comparator|CPOE without order sets|Physicians who use CPOE without order sets.
11263336|NCT02950129|Other|measurements of gait|all subjects will undergo 6 tests to assess gait before and after SIJ; SIJ pain diagnostic tests
11263337|NCT02950116|Active Comparator|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
11263338|NCT02950116|Active Comparator|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
11263339|NCT02950116|Active Comparator|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
11263340|NCT02950103|Experimental|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
11263341|NCT02950090|Experimental|MobilWise|MobilWise will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) via Fitabase to: allow a remote coach to view and collect physical activity data generated by the personal monitor, and use that data to formulate and provide tailored behavioral support, using motivational interviewing. The coach has a phone conversation weekly x 12 using motivational interviewing with participants to set goals and encourage activity. Coaches mention patient use of treatment elements (accountability) and will be positively reinforcing for adherent participants, or will include positive statements for those who are not adherent (supportive).Participants are also encouraged to use all the features of Fitbit (social networking, challenges, email reminders).
11263342|NCT02950090|Active Comparator|Fitbit Only|will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) to monitor their own progress and physical activity level without coaching support. Participants are again encouraged to use all the features of Fitbit (social networking, challenges, email reminders) to achieve activity levels.
11263343|NCT02950090|No Intervention|Waitlist Control|Participants in the waitlist arm have exposure to the usual wellness supports provided by the company: Motiva is the internal corporate wellness program that is under the direction of the Chief Medical Officer. Initiated in 2000, Motiva is staffed by two full- time health professionals and two full-time healthy lifestyle professionals. Motiva provides wellness programming year round on a BCBSIL intranet web page plus an individual page called myMotiva, where self- assessment of health risks, including weight and physical activity behavior, is encouraged. Participating in myMotiva allows individuals to earn up to $200 per year in an incentive program called Wellness Rewards
11263344|NCT02950077|Experimental|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
11263345|NCT02950064|Experimental|BTP-114|Intravenous (IV) treatment n 21-day cycles
11263346|NCT02950051|Active Comparator|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)
~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
11263347|NCT02950051|Experimental|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
11263348|NCT02950051|Experimental|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
11263349|NCT02950051|Experimental|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.
~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
11263350|NCT02950038|Experimental|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.
~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
11263351|NCT02950025|Active Comparator|Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)
~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments
~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site
~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
11263352|NCT02950025|Experimental|Arm B: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)
~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments
~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site
~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day
~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
11263353|NCT02950012|Experimental|OPTI-BIOME™ Bacillus subtilis MB40|
11263354|NCT02950012|Placebo Comparator|Placebo|
11263355|NCT02949999|Experimental|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
11263356|NCT02949999|Experimental|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
11263357|NCT02949999|Experimental|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
11263358|NCT02949999|Experimental|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
11263359|NCT02949999|Placebo Comparator|Placebo voclosporin|placebo BID
11263360|NCT02949986|Experimental|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
11263361|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg BID
11263362|NCT02949960|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
11263363|NCT02949960|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
11263364|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.
~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
11263365|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.
~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
11263366|NCT02949934|Active Comparator|Tolcapone|Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days
11263367|NCT02949934|Placebo Comparator|Placebo|Placebo three times per day for eight days
11263368|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
11263369|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
11263370|NCT02949908||Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)|
11263371|NCT02949895|Experimental|Dose Escalation Dose 1|BMS-986012 Dose Escalation Dose 1
11263372|NCT02949895|Experimental|Dose Escalation Dose 2|BMS-986012 Dose Escalation Dose 2
11263373|NCT02949895|Experimental|Chemotherapy Combination|BMS-986012 + Cisplatin + Etoposide
11263374|NCT02949882|Experimental|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
11263375|NCT02949882|Active Comparator|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
11263412|NCT02949583|Experimental|Punica granatum Linn.|The childrens used the mouthwash contain pomegranate 6,25% twice daily for 14 days.
11263376|NCT02949869|Experimental|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
11263377|NCT02949856|Experimental|Tapered|Mallinckrodt, COVIDIEN
11263378|NCT02949856|Active Comparator|Cylindrical|Endotracheal tube, Unomedical
11263379|NCT02949843|Experimental|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
11263380|NCT02949843|Experimental|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
11263381|NCT02949843|Experimental|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
11263382|NCT02949830|Experimental|givosiran (ALN-AS1)|
11263383|NCT02949817|Experimental|IMU sensor training group(intervention group)|video-game based rehabilitation therapy system training group
11263384|NCT02949817|Active Comparator|Conventional OT group (control group)|conventional training group (control group)
11263385|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
11263386|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
11263387|NCT02949791|Active Comparator|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
11263388|NCT02949791|Experimental|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
11263389|NCT02949778|Active Comparator|Ropivacaine 3.75mg/mL|QL-block using 20 mL ropivacaine 3.75mg/mL
11263390|NCT02949778|Placebo Comparator|Sodium chloride 9 mg/mL|QL-block using 20 mL sterile sodium chloride 9 mg/mL
11263391|NCT02949765|Active Comparator|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
11263392|NCT02949765|Experimental|Iron-rich diet|Iron-rich diet recommendations are given
11263393|NCT02949752|Experimental|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
11263394|NCT02949739|Active Comparator|Intensive lifestyle modification|"the investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study (Index cases). Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).
~Intensive lifestyle modification follows clinically accepted, evidence based strategies to achieve >7% reduction in weight through improved diet and increased physical activity, and is delivered as 9 face-face and 13 telephone contact sessions over 12 months.
~Index cases will be followed for three years to identify new-onset T2D."
11263395|NCT02949739|No Intervention|Usual Care|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study.
~Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).
~Usual care group will comprise one diabetes prevention session and written material."
11263396|NCT02949726|Other|Cancer-treated patients receiving NIRFLI|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
11263397|NCT02949713|Experimental|Text messaging-motivational interviewing|Participants will register their phone numbers into an automated SMS software (provided by WelTel.org). Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, 10, 14, and 24. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
11263398|NCT02949713|No Intervention|Usual standard of care|Usual standard of care
11263399|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.
~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
11263400|NCT02949687|Experimental|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
11263401|NCT02949674|Experimental|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
11263402|NCT02949674|Experimental|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
11263403|NCT02949674|No Intervention|Control|No application of anesthetic
11263404|NCT02949661|Experimental|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block using levobupivacaine
11263405|NCT02949661|Active Comparator|Local wound infiltration|Patients will receive local wound infiltration with levobupivacaine after the conclusion of surgery
11263406|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
11263407|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
11263408|NCT02949622|Experimental|Multimodal intervention program|The intervention program will be in group format, with a size of 10 to 12 patients per group and with an extension of 12 sessions. The treatment program will feature sessions with psychoeducation of metabolic syndrome and treatment model, problem solving, stress management, anger management, social skills, self-efficacy and social support.
11263409|NCT02949622|Active Comparator|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
11263410|NCT02949609|Experimental|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
11263411|NCT02949609|Active Comparator|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
11263413|NCT02949583|Active Comparator|chlorhexidine|The childrens used the mouthwash contain chlorhexidine 0.12% twice daily for 14 days.
11263414|NCT02949570|Experimental|Treatment|
11263415|NCT02949557|Active Comparator|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
11263416|NCT02949557|Active Comparator|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
11263417|NCT02949544|Other|water immersion|patients with heart failure will be immersed to the neck for 15 minutes
11263418|NCT02949531|Active Comparator|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
11263419|NCT02949531|Active Comparator|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
11263420|NCT02949531|Active Comparator|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
11263421|NCT02949518|Experimental|Enhanced Recovery Pathway for Spine|
11263422|NCT02949518|No Intervention|Usual Care|
11263423|NCT02949505|Experimental|Intervention arm|12-week home prehabilitation program
11263424|NCT02949492|Experimental|IL-2 arm|Liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
11263425|NCT02949479|Other|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
11263426|NCT02949466|Experimental|triamcinolone and hyaluronic acid group|combined triamcinolone (Triamcinolone 10 mg 1cc) and hyaluronic acid (2 cc) injections: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
11263427|NCT02949466|Active Comparator|hyaluronic acid group|hyaluronic acid (2cc) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
11263428|NCT02949453|Experimental|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
11263429|NCT02949440|Experimental|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
11263430|NCT02949440|Active Comparator|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
11263431|NCT02949414|Experimental|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
11263432|NCT02949401|No Intervention|Standard of Care|"No research intervention to be administered.
~Participants will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time."
11263433|NCT02949401|Experimental|Virtual Reality|The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
11263434|NCT02949388|Placebo Comparator|Placebo|Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days
11263435|NCT02949388|Active Comparator|300 mg (150 mg BID)|Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days
11263436|NCT02949388|Active Comparator|400 mg (200 mg BID)|Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days
11263437|NCT02949375|Placebo Comparator|Placebo Arm|Gel capsule containing Placebo to be taken once per day
11263438|NCT02949375|Active Comparator|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
11263439|NCT02949375|Active Comparator|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
11263440|NCT02949362|Experimental|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
11263441|NCT02949349|Experimental|MMF 500mg|Mycophenolate mofetil 500mg, PO BID
11263442|NCT02949349|Experimental|MMF 750mg|Mycophenolate mofetil 750mg, PO BID
11263443|NCT02949349|Active Comparator|AZA|Azathioprine 1mg/kg, PO BID
11263444|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
11263541|NCT02948647|No Intervention|Control Group|Will receive standard of care, which is general dietary advice
11263445|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
11263446|NCT02949323||children with urinary stones|children with urinary stones
11263447|NCT02949323||children without urinary stones|children without urinary stones
11263448|NCT02949310|Placebo Comparator|Control|Placebo use instead of nefopam
11263449|NCT02949310|Experimental|Nefopam|Intraoperative use of nefopam 40 mg
11263450|NCT02949297|Other|Ovation Alto Abdominal Stent Graft System|Endovascular repair of AAA using the Ovation Alto Abdominal Stent Graft System.
11263451|NCT02949284|Experimental|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
11263452|NCT02949284|Active Comparator|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
11263453|NCT02949284|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
11263454|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
11263455|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
11263456|NCT02949258|Experimental|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
11263457|NCT02949245||Groups/Cohorts|"Surgical treatment
~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
11263458|NCT02949232|Experimental|Prednisolone|Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
11263459|NCT02949232|Placebo Comparator|Placebo Oral Tablet|Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
11263460|NCT02949219|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11263461|NCT02949206|Experimental|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
11263462|NCT02949206|Experimental|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
11263463|NCT02949206|Experimental|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
11263464|NCT02949206|Experimental|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
11263465|NCT02949206|Experimental|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
11263466|NCT02949206|Experimental|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
11263467|NCT02949206|Experimental|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
11263468|NCT02949206|Experimental|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
11263469|NCT02949206|Experimental|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
11263470|NCT02949206|Experimental|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
11263471|NCT02949193|Experimental|evogliptin|evogliptin 5mg qd add-on to metformin
11263472|NCT02949193|Active Comparator|sitagliptin|sitagliptin 100mg qd add-on to metformin
11263473|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
11263474|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
11263475|NCT02949167|Experimental|MyHealth intervention arm|Nurse-led follow-up
11263476|NCT02949167|No Intervention|MyHealth Control condition|Physician-led follow-up
11263477|NCT02949154||Metastatic melanoma patients|All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
11263478|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
11263479|NCT02949128|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.
~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first."
11263480|NCT02949115|Experimental|70 mL red beetroot juice|70 mL red beetroot juice naturally containing 300 mg nitrate.
11263481|NCT02949115|Active Comparator|70 mL placebo drink plus potassium nitrate|70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.
11263482|NCT02949115|Active Comparator|70 mL red beetroot juice without nitrate|70 mL red beetroot juice per day without nitrate.
11263483|NCT02949115|Placebo Comparator|70 mL placebo drink|70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.
11263484|NCT02949102|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
11263485|NCT02949102|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
11263486|NCT02949089|Experimental|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
11263487|NCT02949076|Experimental|Exercise|Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
11263488|NCT02949050|Experimental|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
11263489|NCT02949050|No Intervention|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
11263490|NCT02949037|Experimental|Intervention|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
11263491|NCT02949037|No Intervention|Control|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
11263492|NCT02949024|Experimental|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
11263493|NCT02949024|Experimental|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
11263494|NCT02949011|Experimental|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
11263495|NCT02949011|Active Comparator|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
11263496|NCT02949011|Placebo Comparator|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
11263497|NCT02948998|No Intervention|control|The participants in control group do not take spironolactone.
11263498|NCT02948998|Experimental|spironolactone|The participants in spironolactone group take 10-20mg spironolactone orally and daily.
11263499|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
11263500|NCT02948972|Experimental|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
11263501|NCT02948972|Active Comparator|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
11263502|NCT02948959|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks added to current controller medications
11263503|NCT02948959|Placebo Comparator|Placebo|Matching placebo (for dupilumab) will be administered every 2 weeks added to current controller medications
11263504|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
11263505|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
11263506|NCT02948920|Experimental|Ephedrine|Intravenous 9 mg of ephedrine (3 ml) given at finishing local anesthetic administration for spinal anesthesia
11263507|NCT02948920|Placebo Comparator|NSS|Intravenous normal saline 3 ml given at finishing local anesthetic administration for spinal anesthesia
11263508|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
11263509|NCT02948894|Experimental|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
11263510|NCT02948894|Placebo Comparator|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
11263511|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
11263512|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
11263513|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:
~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
11263514|NCT02948842|Experimental|Treatment Group|Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.
11263515|NCT02948842|Placebo Comparator|Control Group|On day of treatment, patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of injectable normal saline. The depth and location of the needle will be determined pre-procedurally with urethral ultrasonography with the needle in a semi-parallel manner into the plaque as to avoid perforation into nearby structures. Injections will be performed at a single site.
11263516|NCT02948829|Experimental|Tetravalent Dengue Vaccine Candidate|Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL, subcutaneous injection on Day 1 and Day 90.
11263517|NCT02948816|Experimental|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
11263518|NCT02948816|Experimental|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
11263519|NCT02948816|Active Comparator|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
11263520|NCT02948803|Experimental|Intervention group|smartphone based intervention with Active Coach app: participants in the intervention group will use a newly developed smartphone app in combination with a Fitbit Charge activity tracker for 9 weeks. The app aims to promote an active lifestyle.
11263521|NCT02948803|No Intervention|control group|participants in the control groups only receive a flyer with standard information about an active lifestyle
11263522|NCT02948790|Experimental|Neuristim|Electrical stimulation with the Neuristim and auditory nerve electrical response measurements (wave V).
11263523|NCT02948790|Active Comparator|Digisonic SP EVO cochlear implant|Electrical stimulation with the patient's cochlear implant and auditory nerve electrical response measurements (wave V).
11263524|NCT02948777|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
11263525|NCT02948764|Other|single-arm study|This project is designed as a one-armed diagnostic study. Every patient included in the study will undergo the same diagnostic test, the vacuum-assisted biopsy, after NACT and before surgery according to guidelines.
11263526|NCT02948738|Experimental|Interactive Education|Interactive asthma education
11263527|NCT02948738|Active Comparator|Standard Education|Standard asthma education
11263528|NCT02948725|Experimental|cross-education + standard rehabilitation|The cross-education group will engage in strength training of the non-paretic hand in addition to standard rehabilitation. Cross-education will be progressive in nature, beginning with 2 sets of 8 repetitions and increasing up to a maximum of 6 sets of 8 repetitions of maximal voluntary effort isometric handgrip contractions as tolerated. Grip training will be performed using standard grip trainers (Digi-Flex Grip trainers) to train both finger flexors and full hand and wrist isometric contractions. In addition, patients will perform controlled dynamic wrist flexion and extension training of the non-paretic hand using exercise tubing with the same prescription. Patients will be asked to complete exercises 3 times per week for 26 weeks, and to record adherence in a training log. An average of one session per week will be considered 'trained'.
11263529|NCT02948725|No Intervention|standard rehabilitation|Standardized rehabilitation involves several strategies tailored to the patient and remains somewhat based on clinician preference. These therapies may involve functional electrical stimulation, neuro-facilitation, strengthening, range of motion (ROM), mirror therapy, and force-use therapy (e.g., CIMT). Patients engage in therapy 5 days per week as inpatients, and 2 days per week as outpatients with additional home exercises. Specific therapies for each patient will be tracked using a therapy log.
11263530|NCT02948712|Experimental|Survivor Distress|This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.
11263531|NCT02948699|Experimental|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
11263532|NCT02948699|No Intervention|Regular diet|Regular diet without other nutritional intervention.
11263533|NCT02948686|Active Comparator|SET (Self-Etching)|55 teeth will receive restorations using Self-Etching Application Strategy
11263534|NCT02948686|Experimental|SEE (Selective Enamel Etching)|55 teeth will receive restorations using Enamel Etching Application Strategy
11263535|NCT02948686|Experimental|SETT (Self-Etching, more time)|55 teeth will receive restorations using Self Etching with Extended time Application Strategy
11263536|NCT02948686|Experimental|SETL (Self-Etching, more layers)|55 teeth will receive restorations using Self Etching with Extended layers number Strategy
11263537|NCT02948673|Placebo Comparator|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
11263538|NCT02948673|Active Comparator|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
11263539|NCT02948660|Other|acute consciousness disorders group|"Duration time of coma <= 3 weeks.
~This group will receive sleep EEG monitoring, serum melatonin and orexin level testing, and Zolpidem Tartrate Tablets or melatonin treatment."
11263540|NCT02948660|Other|chronic consciousness disorders group|"Duration time of coma > 3 weeks.
~This group received sleep EEG monitoring, serum melatonin and orexin testing, and Zolpidem Tartrate Tablets or melatonin treatment."
11263542|NCT02948647|Experimental|Intervention Group|Will receive standard of care as well as sugar-reduction education
11263543|NCT02948634|Sham Comparator|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
11263544|NCT02948634|Active Comparator|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
11263545|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
11263546|NCT02948595|Experimental|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
11263547|NCT02948595|Experimental|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
11263548|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
11263549|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
11263550|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
11263551|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
11263552|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
11263553|NCT02948582|Placebo Comparator|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
11263554|NCT02948569|Experimental|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.
11263555|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
11263556|NCT02948543|Experimental|Treatment (Arm B):Intravesical BCG + MMC|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.
~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.
~Dosage of Mitomycin (MMC) fixed at 40mg per instillation."
11263557|NCT02948543|Other|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.
~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
11263558|NCT02948517|Experimental|Time restricted feeding|Time restricted feeding
11263559|NCT02948517|No Intervention|Control|No intervention
11263560|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
11263561|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
11263562|NCT02948491|Experimental|Music therapy|First. Recording of the voice of the mother singing the song to the child. (To choose this option, the song must be sung to the child during pregnancy at least 2 to 3 times per week. Second. The mother's favorite song, obtained externally. (To choose this option, the mother must bring the song that she that she listened to frequently, at least 5 times per week). Third. Pre-determined lullaby. (This option refers only to the lullaby melody or Brahms lullaby, edited to obtain stable volumes and normalization of the audio, with the effect of progressively appearing and fading for the first and last 10 seconds of the intervention with music therapy, so there are no drastic acoustic changes in the intervention. Audacity editing software will be used.)
11263563|NCT02948491|No Intervention|Without sound emission|"The infant does not receive any sound emission because the baffle will be turned off.
~One of the three intervention options are chosen. The parents are told that their child may be randomly assigned to either the therapeutic or control group."
11263564|NCT02948478||Precarious patients|Precarious patients - exposed - will be those identified as precarious by at least one of the three scores (EPICES, Pascal, European Deprivation Index)
11263565|NCT02948478||Non precarious patients|Non precarious patient - non exposed - will be all the patients identified as non-precarious by the three scores (EPICES, Pascal, European Deprivation Index)
11263566|NCT02948452||Anorexia|fMRI: reward task, anxiety provocation
11263567|NCT02948452||Mild anxiety comparison group|fMRI: reward task, anxiety provocation
11263568|NCT02948439|Experimental|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
11263569|NCT02948439|No Intervention|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
11263605|NCT02948127|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
11263606|NCT02948114|Active Comparator|Control: Cow milk-based infant formula|Cow milk-based infant formula
11263570|NCT02948426|Experimental|ES1 Phase 1 Dose Escalation Arm|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design.
11263571|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the MTD
11263572|NCT02948413||Single Group of patients with Cancer|Patients with cancer (lymphoma, leukemia, prostate cancer, and mesothelioma) on clinical trials at the NIH Clinical Center.
11263573|NCT02948400|Experimental|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
11263574|NCT02948400|Active Comparator|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
11263575|NCT02948374||Delirium positive|Patients with a positive CAM-ICU test
11263576|NCT02948374||Delirium negative|Patient without delirium determined with the CAM-ICU test
11263577|NCT02948361|Experimental|QT Ultrasound breast scan|
11263578|NCT02948348|Experimental|Nivolumab|chemoradiotherapy with capecitabine+ Nivolumab + surgical therapy
11263579|NCT02948322|Experimental|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
11263580|NCT02948322|Active Comparator|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
11263581|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
11263582|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
11263583|NCT02948283|Experimental|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.
~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11263584|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
11263585|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
11263586|NCT02948244|Active Comparator|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
11263587|NCT02948244|Active Comparator|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
11263588|NCT02948231|Experimental|Mistral|
11263589|NCT02948218|Active Comparator|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
11263590|NCT02948218|Active Comparator|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
11263591|NCT02948218|Active Comparator|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
11263592|NCT02948218|Active Comparator|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
11263593|NCT02948205|Experimental|3D group|infertility patient get TU-LESS by 3D Laparoscopy
11263594|NCT02948205|Other|normal group|infertility patient get normal laparoscopic surgery
11263595|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
11263596|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
11263597|NCT02948179|Experimental|Preimplantation genetic diagnosis group|ADPKD patients will complete the whole process of preimplantation genetic diagnosis with healthy baby without pathogenic gene inheritance.
11263598|NCT02948179|No Intervention|Natural pregnancy group|ADPKD patients, pathogenic mutations in PKD1, have natural pregnancy without preimplantation genetic diagnosis.The investigators will perform genetic tests on the blood or umbilical cord blood of infants born between January 2014 and June 2020.
11263599|NCT02948166|Active Comparator|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
11263600|NCT02948166|Experimental|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
11263601|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
11263602|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
11263603|NCT02948140|Experimental|Stroke|
11263604|NCT02948127|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
11263607|NCT02948114|Experimental|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
11263608|NCT02948114|Experimental|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
11263609|NCT02948114|Experimental|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
11263610|NCT02948114|No Intervention|Human Milk Reference|Human Milk Reference
11263611|NCT02948101|Experimental|Treatment (PD 0360324, cyclophosphamide)|Patients receive anti-CSF1 monoclonal antibody anti-CSF1 monoclonal antibody PD 0360324 IV over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide PO QD. Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11263612|NCT02948075|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x [GFR (ml/min) + 25] on Day 7 up to 6 cycles.
11263613|NCT02948036|Experimental|MMT|Mobile-device, plasticity-based adaptive cognitive treatment
11263614|NCT02948023|No Intervention|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
11263615|NCT02948023|Active Comparator|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
11263616|NCT02948010|Active Comparator|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
11263617|NCT02948010|Active Comparator|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
11263618|NCT02948010|Active Comparator|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
11263619|NCT02948010|Active Comparator|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
11263620|NCT02948010|Active Comparator|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
11263621|NCT02948010|Active Comparator|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
11263622|NCT02948010|Active Comparator|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
11263623|NCT02948010|Active Comparator|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
11263624|NCT02948010|Active Comparator|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
11263625|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
11263626|NCT02947984|Experimental|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
11263627|NCT02947984|Experimental|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
11263628|NCT02947971|Experimental|OFDI Imaging|Experimental OFDI Imaging
11263629|NCT02947958|Experimental|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
11263630|NCT02947958|Active Comparator|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
11263631|NCT02947945|Other|Open-Label|all subjects will receive the study medication- reslizumab.
11263632|NCT02947932|Experimental|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
11263633|NCT02947932|Active Comparator|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
11263634|NCT02947919|Experimental|Intervention|Music in the perioperative period
11263635|NCT02947919|No Intervention|Control|Usual treatment
11263636|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
11263637|NCT02947906||Control Group|Healthy participants
11263638|NCT02947893|Placebo Comparator|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
11263639|NCT02947893|Active Comparator|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
11263640|NCT02947880|Experimental|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
11263641|NCT02947880|Placebo Comparator|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
11263642|NCT02947867|Experimental|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
11263643|NCT02947867|Experimental|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
11263644|NCT02947867|Placebo Comparator|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
11263645|NCT02947854|Experimental|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol [poly-ICLC]) followed by light application.
11263646|NCT02947854|Experimental|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
11263647|NCT02947854|Experimental|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
11263648|NCT02947841|Placebo Comparator|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
11263649|NCT02947841|Active Comparator|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
11263650|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
11263651|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
11263652|NCT02947815|Experimental|NABOTA|Single-dose
11263653|NCT02947815|Active Comparator|BOTOX|Single-dose
11263654|NCT02947802|Experimental|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
11263655|NCT02947802|Experimental|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
11263656|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
11263657|NCT02947776|Active Comparator|USUAL|Usual care
11263658|NCT02947776|Experimental|PEER|Usual care + peer-befriending
11263659|NCT02947763|Active Comparator|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
11263660|NCT02947763|No Intervention|single visit|single visit root canal treatment without any intra-canal medication
11263661|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
11263662|NCT02947750|Active Comparator|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
11263663|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
11263664|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
11263665|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
11263666|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
11263667|NCT02947737|Experimental|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
11263668|NCT02947737|Active Comparator|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
11263669|NCT02947724|No Intervention|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
11263670|NCT02947724|No Intervention|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
11263671|NCT02947724|Active Comparator|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
11263672|NCT02947724|Active Comparator|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
11263673|NCT02947711|Experimental|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
11263674|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
11263675|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
11263676|NCT02947685|Experimental|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
11263677|NCT02947685|Active Comparator|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
11263678|NCT02947672|Active Comparator|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
11263679|NCT02947672|Active Comparator|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
11263680|NCT02947646|Experimental|BabyGentleStick™ ON|Experimental intervention to be compared to the Active Comparator.
11263681|NCT02947646|Active Comparator|BabyGentleStick™ OFF|Active Comparator intervention to be compared to the Experimental Treatment.
11263682|NCT02947633|Experimental|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
11263683|NCT02947633|Active Comparator|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
11263684|NCT02947620|Active Comparator|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
11263685|NCT02947620|Placebo Comparator|Metformin|Metformin, QD
11263686|NCT02947620|Placebo Comparator|Atorvastatin|Atorvastatin, QD
11263687|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
11263688|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
11263689|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
11263690|NCT02947581|Experimental|Interventions|Albendazole and praziquantel. Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
11263691|NCT02947581|Active Comparator|Comparison regime|Albendazole and praziquantel placebo. Albendazole: 15 mg/k/d (days 1 to 30) and prazicuantel placebo in similar doses 50 mg/k/d (days 1 to 15).
11263692|NCT02947568||CKD|chronic kidney disease
11263693|NCT02947568||DM|diabetes mellitus
11263694|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
11263695|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
11263696|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
11263697|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
11263698|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
11263699|NCT02947542|Experimental|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
11263700|NCT02947542|Experimental|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
11263701|NCT02947542|Active Comparator|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
11263702|NCT02947529|Experimental|Hemiarthroplasty|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
11263703|NCT02947529|Experimental|Intramedullary nail|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
11263704|NCT02947516|Active Comparator|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
11263705|NCT02947516|Experimental|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
11263706|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin HCL 850 CF (1-3 times daily) added to usual care from start of the diagnosis GDM.
~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.
~Intervention: metformin HCF 850 CF (1-3 times daily) on top of usual care."
11263707|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.
~Intervention: usual care."
11263708|NCT02947490|Sham Comparator|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
11263709|NCT02947490|Placebo Comparator|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week & arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
11263710|NCT02947490|Active Comparator|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse & supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
11263711|NCT02947477|Experimental|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
11263712|NCT02947477|No Intervention|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
11263713|NCT02947464|Active Comparator|Control|Standard clinical practice
11263714|NCT02947464|Experimental|Intervention|Standard clinical practice + Rapid Maxillary Expansion
11263715|NCT02947451|Experimental|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
11263716|NCT02947451|Experimental|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
11263717|NCT02947438|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU
~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
11263718|NCT02947438|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU
~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
11263719|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
11263720|NCT02947399|Other|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
11263721|NCT02947386|Experimental|Treatment (nivolumab, nimotuzumab)|Patients receive nivolumab IV over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11263722|NCT02947373|Other|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
11263723|NCT02947360|Experimental|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
11263724|NCT02947347|Experimental|(Part 1 : Arm A) ibrutinib + rituximab|"Subjects will receive 560mg of ibrutinib and rituximab 375mg/m^2 weekly x4 with maintenance.
~In Part 1, Arm A to Arm B ratio is 3:1"
11263725|NCT02947347|Placebo Comparator|(Part 1 : Arm B) placebo + rituximab|"Subjects will receive placebo and rituximab 375mg/m^2 weekly x4 with maintenance.
~In Part 1, Arm A to Arm B ratio is 3:1"
11263726|NCT02947347|Experimental|(Part 2 : Arm A1) ibrutinib|"Subjects will receive 560mg of ibrutinib
~Part 1 Arm A subjects will be re-randomized 1:1 into Part 1 Arm A1 or Arm A2"
11263727|NCT02947347|Placebo Comparator|(Part 2 : Arm A2) placebo|"Subjects will receive placebo
~Part 1 Arm A subjects will be re-randomized 1:1 into Part 2 Arm A1 or Arm A2"
11263728|NCT02947347|Placebo Comparator|(Part 2 : Arm B) placebo|"Subjects will receive placebo
~Part 1 Arm B subjects will be re-randomized into Part 2 Arm B"
11263729|NCT02947334|Experimental|Bococizumab|Bococizumab Q2wks
11263730|NCT02947334|Placebo Comparator|Placebo|Bococizumab placebo Q2wks
11263731|NCT02947321|Experimental|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
11263732|NCT02947321|Sham Comparator|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
11263733|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
11263734|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
11263735|NCT02947282|Active Comparator|Intervention|Educational Workshop
11263736|NCT02947282|No Intervention|Control|They will continue regular prenatal care as planned
11263737|NCT02947269|Experimental|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
11263738|NCT02947269|Placebo Comparator|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
11263739|NCT02947256|Active Comparator|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
11263740|NCT02947256|Experimental|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
~Operative procedure of by RI approach:"
11263741|NCT02947243|Active Comparator|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
11263742|NCT02947243|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
11263743|NCT02947230|Experimental|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
11263744|NCT02947230|No Intervention|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
11263745|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
11263746|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
11263747|NCT02947204|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
11263748|NCT02947204|Experimental|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
11263749|NCT02947191|Experimental|Collagen membrane + HUC-MSCs|
11263750|NCT02947178|Active Comparator|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
11263751|NCT02947178|Active Comparator|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
11263752|NCT02947165|Experimental|NIS793|
11263753|NCT02947165|Experimental|NIS793 + PDR001|
11263754|NCT02947152|Experimental|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
11263755|NCT02947152|Experimental|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
11263756|NCT02947152|Experimental|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
11263757|NCT02947139|Experimental|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
11263758|NCT02947139|Experimental|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
11263759|NCT02947126|Experimental|Cystic Fibrosis (HS, IS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day,
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
11263760|NCT02947126|Experimental|Cystic Fibrosis (IS, HS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day.
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
11263761|NCT02947126|Experimental|Parents of CF subjects|"Ages 18 and older, biological parent of a CF patient who is also enrolled in the study
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)"
11263762|NCT02947126|Experimental|non CF controls|"Ages 18 and older with no history of lung disease
~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)."
11263763|NCT02947113|Experimental|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
11263764|NCT02947100|Experimental|SCD-Omegatex™|single arm
11263765|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
11263766|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
11263767|NCT02947074|No Intervention|Control|Waiting list
11263768|NCT02947074|Experimental|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
11263769|NCT02947061|Experimental|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
11263770|NCT02947061|Active Comparator|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
11263771|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
11263772|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
11263773|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
11263774|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
11263775|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
11263776|NCT02947035|Experimental|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
11263777|NCT02947035|Experimental|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
11263778|NCT02947022|Experimental|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
11263779|NCT02947009|Experimental|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.
~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
11263780|NCT02947009|Active Comparator|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.
~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
11263781|NCT02946996|Experimental|OPC|Subjects will take one OPC capsule at the same time each morning and evening, approximately 12 hours apart during weeks 1-12.
11263782|NCT02946983|Active Comparator|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
11263783|NCT02946983|Active Comparator|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
11263784|NCT02946983|Placebo Comparator|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
11263785|NCT02946983|Placebo Comparator|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
11263786|NCT02946970|Placebo Comparator|Control|Intragastric infusion
11263787|NCT02946970|Experimental|Quinine hydrochloride|Intragastric infusion
11263788|NCT02946957|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
11263789|NCT02946957|Active Comparator|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
11263790|NCT02946944|Experimental|double drug therapy|
11263791|NCT02946944|Active Comparator|mono drug therapy|
11263792|NCT02946931||Prizbind|patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
11263793|NCT02946918|Experimental|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
11263794|NCT02946918|Experimental|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
11263795|NCT02946905||SCD participant|No intervention
11263796|NCT02946905||Non-SCD participant|No intervention
11263797|NCT02946892|Experimental|Carvedilol|Study participants will receive carvedilol for 12 weeks
11263798|NCT02946892|Experimental|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
11263799|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
11263800|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
11263801|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
11263802|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
11263803|NCT02946853|Active Comparator|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
11263804|NCT02946853|Experimental|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
11263805|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
11263806|NCT02946827|Experimental|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
11263807|NCT02946827|Active Comparator|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
11263808|NCT02946814|Active Comparator|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
11263809|NCT02946814|Experimental|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
11263810|NCT02946814|Sham Comparator|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
11263811|NCT02946801|Active Comparator|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
11263812|NCT02946801|Experimental|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
11263813|NCT02946801|Sham Comparator|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
11263814|NCT02946788|Experimental|BPX-01 1%|BPX-01 1% minocycline topical gel
11263815|NCT02946788|Experimental|BPX-01 2%|BPX-01 2% minocycline topical gel
11263816|NCT02946762|Other|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
11263817|NCT02946749||Shanghai First Maternity and Infant Hospital|
11263818|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
11263819|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
11263820|NCT02946749||The Sixth people's hospital of Shanghai|
11263821|NCT02946736|Experimental|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
11263822|NCT02946736|Experimental|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
11263823|NCT02946723|Experimental|US group|lead implantation surgery for SNM using ultrasound guided technique
11263824|NCT02946723|Sham Comparator|X-ray group|lead implantation surgery for SNM using X-ray guided technique
11263825|NCT02946697|No Intervention|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
11263826|NCT02946697|Experimental|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
11263827|NCT02946684|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
11263828|NCT02946684|Active Comparator|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
11263829|NCT02946671|Experimental|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
11263830|NCT02946671|Experimental|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
11263831|NCT02946671|Experimental|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
11263832|NCT02946658|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
11263833|NCT02946658|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
11263834|NCT02946658|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
11263835|NCT02946645|Active Comparator|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
11263836|NCT02946645|Active Comparator|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
11263837|NCT02946645|Placebo Comparator|Placebo|TMD placebo group.
11263838|NCT02946632|Experimental|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
11263839|NCT02946632|Active Comparator|Stepwise add-on therapy group|"Participants were started on metformin 1000mg once daily after screening & assignment
~At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
11263840|NCT02946619|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
11263841|NCT02946619|Experimental|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
11263842|NCT02946619|Experimental|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
11263843|NCT02946606|Experimental|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
11263844|NCT02946606|Experimental|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
11263845|NCT02946606|Experimental|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
11263846|NCT02946593|Experimental|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
11263847|NCT02946593|Active Comparator|Control|Participants in the control group will receive written information about preventing outdoor falls.
11263848|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
11263849|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
11263850|NCT02946567|Experimental|Noisy City|Participant will play the Noisy City game developed by this project.
11263851|NCT02946567|Placebo Comparator|Control|Participant will play a generic game.
11263852|NCT02946554|Other|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.
~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
11263853|NCT02946554|Other|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
11263854|NCT02946541|Experimental|evogliptin 5mg|evogliptin 5mg QD
11263855|NCT02946541|Placebo Comparator|placebo|Placebo QD
11263856|NCT02946528|Experimental|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
11263857|NCT02946528|Active Comparator|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
11263858|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
11263911|NCT02946164|Active Comparator|Intervention: 'Stick To It' Intervention|Behavioral intervention.
11263912|NCT02946151|Experimental|Implantation|Implantation of a subcutaneous electrode and connection to the external logging device
11263859|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
11263860|NCT02946502|Experimental|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
11263861|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
11263862|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
11263863|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
11263864|NCT02946463|Experimental|Ravulizumab|"Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.
~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
11263865|NCT02946463|Active Comparator|Eculizumab|"Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.
~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
11263866|NCT02946450||Not applicable-observational study|Not applicable-observational study
11263867|NCT02946437|Experimental|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.
~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
11263868|NCT02946437|Active Comparator|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
11263869|NCT02946437|Other|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
11263870|NCT02946424|Experimental|Simvastatin treatment|Simvastatin for one year time period
11263871|NCT02946424|Placebo Comparator|Placebo treatment|Placebo for one year time period
11263872|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
11263873|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
11263874|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
11263875|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
11263876|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
11263877|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
11263878|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
11263879|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
11263880|NCT02946372|Experimental|ILMT|internal limiting membrane autologous transplantation (ILMT)
11263881|NCT02946359|Experimental|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
11263882|NCT02946359|Experimental|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
11263883|NCT02946359|Experimental|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
11263884|NCT02946346|Experimental|Vaginal and blood sampling|
11263913|NCT02946138|Experimental|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
11263885|NCT02946333||Patient with MM who are not candidates for ASCT|Patients with newly diagnosed MM who are not candidates for ASCT and who are going to start drug treatment for the study disease and patient who is capable of understanding and filling in the study questionnaires At least 450 patients will be enrolled in a 2-year period. Patients must meet all of the inclusion criteria and none of the exclusion criteria and must have previously granted their informed consent in writing.
11263886|NCT02946320|Active Comparator|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
11263887|NCT02946320|Experimental|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
11263888|NCT02946320|Experimental|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
11263889|NCT02946307|Experimental|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter>2.00 mm） in small vessel cohort
11263890|NCT02946307|Active Comparator|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
11263891|NCT02946307|Other|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
11263892|NCT02946294|Active Comparator|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
11263893|NCT02946294|Active Comparator|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
11263894|NCT02946281|Experimental|Intervention|
11263895|NCT02946281|No Intervention|Care as usual|
11263896|NCT02946268|Experimental|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
11263897|NCT02946268|Experimental|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
11263898|NCT02946268|Experimental|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
11263899|NCT02946255|Experimental|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
11263900|NCT02946255|Experimental|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
11263901|NCT02946255|Active Comparator|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
11263902|NCT02946242|Other|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
11263903|NCT02946229|Other|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
11263904|NCT02946203|Active Comparator|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
11263905|NCT02946203|Active Comparator|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
11263906|NCT02946190|Experimental|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
11263907|NCT02946190|Active Comparator|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
11263908|NCT02946177|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
11263909|NCT02946177|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
11263910|NCT02946164|No Intervention|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
11263914|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
11263915|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
11263916|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
11263917|NCT02946112||Shoulder pain|volleyball players with shoulder pain
11263918|NCT02946112||No shoulder pain|volleyball players without shoulder pain
11263919|NCT02946099|Experimental|Reciproc file|Reciproc files in reciprocating motion
11263920|NCT02946099|Active Comparator|ProTaper Next file|ProTaper Next files in continuous rotary motion
11263921|NCT02946086|Experimental|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
11263922|NCT02946086|Active Comparator|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
11263923|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
11263924|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
11263925|NCT02946060|Sham Comparator|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
11263926|NCT02946060|Active Comparator|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
11263927|NCT02946060|Experimental|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
11263928|NCT02946047|Experimental|Treatment group|Patients will be given at least one treatment cycle of Ixazomib.
11263929|NCT02946034|Experimental|Treatment 1|12 week therapy with Viekira Pak ± ribavirin
11263930|NCT02946034|Experimental|Treatment 2|12 week therapy with Mavyret
11263931|NCT02946021|Experimental|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
11263932|NCT02946021|Experimental|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
11263933|NCT02946008|Experimental|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
11263934|NCT02945982|Placebo Comparator|Entecavir/Carvedilol|Tablet with Entrcavir and Carvedilol
11263935|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
11263936|NCT02945969|Experimental|Low Sodium Diet|Behavioral modification to decrease dietary sodium intake to ≤2,300 mg/day for 24 weeks. The intervention program consists of two phases. An initial 12-week intensive phase will include weekly individual and group sessions. This will be followed by a 12-week maintenance phase that includes telephone counseling sessions every 2 weeks.
11263937|NCT02945969|No Intervention|Usual Diet|No dietary intervention.
11263938|NCT02945956|Placebo Comparator|Entecavir|Tablet with Entrcavir
11263939|NCT02945956|Experimental|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
11263940|NCT02945943|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
11263941|NCT02945943|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
11263942|NCT02945891|Experimental|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
11263943|NCT02945865|Experimental|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
11263944|NCT02945865|No Intervention|Control arm: No treatment|Treatment us usual
11263945|NCT02945852|Experimental|refractory SCLC|Patients receive apatinib 500mg/d until progressive Disease(PD).
11263946|NCT02945839|Active Comparator|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
11263947|NCT02945839|Active Comparator|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
11263948|NCT02945826|Experimental|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
11263949|NCT02945813|Experimental|Arm A: Metformin|"Metformin - 850mg PO BID; 48 weeks
~Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
11263950|NCT02945813|Active Comparator|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
11263951|NCT02945800|Experimental|Combination Therapy|Participants will receive nab-Paclitaxel and Gemcitabine on days 1, 8, and 15 of each 28 day cycle, for up to 12 cycles.
11263952|NCT02945787|Experimental|Extended Self-help|Spanish-Language Version of the Stop Smoking for Good: The Extended Self-help condition will comprise the 11 Stop Smoking for Good booklets and 9 supportive My Story pamphlets transcreated for Spanish speaking smokers.
11265003|NCT02938624|Experimental|Cohort III|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
11263953|NCT02945787|Active Comparator|Usual Care (UC)|NCI-Produced Spanish-language Self-help Booklet: The UC control condition enhances the external validity of the study by providing a comparison to an existing, credible intervention that a smoker could receive in a medical setting or elsewhere.
11263954|NCT02945774|Experimental|(18F)-FEPPA|
11263955|NCT02945761|Active Comparator|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
11263956|NCT02945761|Active Comparator|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
11263957|NCT02945735|Experimental|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
11263958|NCT02945735|Placebo Comparator|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
11263959|NCT02945722|Active Comparator|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
11263960|NCT02945722|Placebo Comparator|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
11263961|NCT02945709|Experimental|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
11263962|NCT02945709|Active Comparator|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
11263963|NCT02945709|Placebo Comparator|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
11263964|NCT02945696|No Intervention|Local port site injection|
11263965|NCT02945696|No Intervention|Ultrasound-guided nerve blocks|
11263966|NCT02945696|Experimental|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
11263967|NCT02945683|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
11263968|NCT02945683|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 3 months
11263969|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
11263970|NCT02945644|Placebo Comparator|Placebo|pill filled with inert material
11263971|NCT02945644|Active Comparator|Trazodone 50mg|
11263972|NCT02945644|Active Comparator|Trazodone 100mg|
11263973|NCT02945631|Experimental|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
11263974|NCT02945618|Experimental|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.
~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
11263975|NCT02945618|Active Comparator|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
11263976|NCT02945605|Experimental|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
11263977|NCT02945605|Active Comparator|Standard of Care|Participants in this group will receive standard care as directed by their physician.
11263978|NCT02945592|Experimental|Intervention|"adaptive, therapeutic cueing during reading tasks
~adaptive, therapeutic cueing during visuo spatial tasks"
11263979|NCT02945592|No Intervention|Control|- unspecific neglect treatment
11263980|NCT02945579|Experimental|Treatment (whole breast irradiation, EBRT)|Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation.
11263981|NCT02945566|Active Comparator|Standard TME surgery|Radical total mesorectal excision
11263982|NCT02945566|Experimental|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
11263983|NCT02945566|Experimental|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
11263984|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
11263985|NCT02945553|Active Comparator|Microstimulation|Microstimulation
11263986|NCT02945527|Active Comparator|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
11263987|NCT02945527|Active Comparator|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
11263988|NCT02945527|No Intervention|No additional anti-edema treatment|No additional treatment
11263989|NCT02945501|Experimental|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
11263990|NCT02945501|Sham Comparator|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
11263991|NCT02945488|Experimental|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
11263992|NCT02945488|Experimental|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
11263993|NCT02945488|Experimental|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
11263994|NCT02945488|Active Comparator|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
11263995|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
11263996|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2
11263997|NCT02945475||overweight|Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2
11263998|NCT02945462|Experimental|autologous mesenchymal stem cells|"Intervention:
~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
11263999|NCT02945449|Experimental|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
11264000|NCT02945436|Active Comparator|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
11264001|NCT02945436|Experimental|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
11264002|NCT02945436|Experimental|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
11264003|NCT02945436|Experimental|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
11264004|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
11264005|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
11264006|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
11264007|NCT02945397|Active Comparator|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
11264008|NCT02945397|Active Comparator|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
11264009|NCT02945384|Experimental|Creating Connections|Dual-generation intervention: child component delivered in classroom setting, parent component delivered in small-group setting
11264010|NCT02945384|No Intervention|Head Start as usual|Regular Head Start curriculum
11264011|NCT02945371|Experimental|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.
~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.
~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
11264012|NCT02945371|Active Comparator|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
11264013|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
11264014|NCT02945332|Experimental|Required supervised walking|Device: Fitbit Flexes
11264015|NCT02945332|Active Comparator|Non-required supervised walking|Device: Fitbit Flexes
11264016|NCT02945306|Experimental|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
11264017|NCT02945306|Active Comparator|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
11264018|NCT02945293|Other|Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
11264019|NCT02945280|Experimental|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
11264020|NCT02945267|Experimental|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
11265004|NCT02938624|Experimental|COHORT -1|Pembrolizumab 100 mg I.V single dose
11264021|NCT02945267|Active Comparator|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
11264022|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
11264023|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
11264024|NCT02945241|Experimental|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
11264025|NCT02945241|Other|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
11264026|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
11264027|NCT02945215|Experimental|IBI301|
11264028|NCT02945215|Active Comparator|Rituximab|
11264029|NCT02945202|Other|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
11264030|NCT02945189||Peri menopausal|Participants aged 41-55 years
11264031|NCT02945189||post menopausal|participants aged 56-65 years
11264032|NCT02945176|Experimental|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.
~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation
~Accessories: MESOGRAPH reading device, Implant Injector"
11264033|NCT02945163|Experimental|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
11264034|NCT02945163|Active Comparator|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
11264035|NCT02945150|Experimental|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor
~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
11264036|NCT02945124|Experimental|Normal children with K Tape|
11264037|NCT02945124|No Intervention|Normal children without K Tape|
11264038|NCT02945124|Experimental|DCD with K Tape|
11264039|NCT02945124|No Intervention|DCD without K Tape|
11264040|NCT02945111|Experimental|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
11264041|NCT02945111|Active Comparator|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
11264042|NCT02945098|No Intervention|Control group|No intervention. Remained five minutes at rest.
11264043|NCT02945098|Placebo Comparator|Placebo group|Apply Kinesio Taping without tension.
11264044|NCT02945098|Experimental|KT group|Apply Kinesio Taping application with tension.
11264045|NCT02945085|Experimental|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
11264046|NCT02945085|Active Comparator|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
11264047|NCT02945072|Active Comparator|Sevoflurane group|general anesthesia will be maintained with sevoflurane
11264048|NCT02945072|Experimental|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
11264049|NCT02945059|Experimental|1|Patients will undergo reversible PVE before major hepatic resection.
11264050|NCT02945046|Placebo Comparator|Placebo|Participants will receive placebo administered via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injection at Weeks 4 and 8, respectively.
11264051|NCT02945046|Experimental|Fremanezumab 675 mg/Placebo/Placebo|Participants will receive placebo as an approximately 1-hour intravenous infusion followed by fremanezumab at 675 milligrams (mg) administered as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 and placebo administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
11264052|NCT02945046|Experimental|Fremanezumab 900/225/225 mg|Participants will receive fremanezumab at 900 mg administered via an approximately 1-hour intravenous infusion followed by 3 placebo subcutaneous injections at Week 0 and fremanezumab at 225 mg administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
11264053|NCT02945033|Experimental|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
11264054|NCT02945033|Placebo Comparator|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
11264117|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
11264055|NCT02945020|Experimental|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
11264056|NCT02945007|Experimental|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
11264057|NCT02945007|Experimental|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).
~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
11264058|NCT02945007|Experimental|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).
~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
11264059|NCT02945007|Experimental|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).
~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
11264060|NCT02945007|Experimental|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).
~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
11264061|NCT02945007|Experimental|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).
~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
11264062|NCT02945007|Experimental|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).
~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
11264063|NCT02945007|Experimental|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).
~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
11264064|NCT02944994|Experimental|Unified Protocol|Unified Protocol-psychotherapy
11264065|NCT02944994|Experimental|Routine Care|Routine Care psychotherapy comparison
11264066|NCT02944981|Experimental|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
11264067|NCT02944981|Placebo Comparator|Placebo|Patient receiving oral placebo tablet preoperatively
11264068|NCT02944968|Experimental|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
11264069|NCT02944955|Experimental|BLEX 404 Oral Liquid|"Part I:
~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.
~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.
~Part II:
~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.
~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
11264070|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
11264071|NCT02944929|Experimental|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
11264072|NCT02944929|No Intervention|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
11264073|NCT02944916|Experimental|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
11264074|NCT02944890|Experimental|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
11264075|NCT02944890|Active Comparator|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
11264076|NCT02944877|Experimental|intervention|experimental
11264077|NCT02944877|Other|control|Other
11264078|NCT02944864|Experimental|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11264079|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
11264080|NCT02944838|Active Comparator|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
11264118|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
11264119|NCT02944604|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
11264081|NCT02944838|Active Comparator|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
11264082|NCT02944825|Active Comparator|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
11264083|NCT02944825|Active Comparator|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
11264084|NCT02944812|Experimental|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
11264085|NCT02944799|Active Comparator|Alendronate|Continues treatment with alendronate, 70mgs oral tablet once every week
11264086|NCT02944799|Placebo Comparator|Placebo|Placebo tablets, one every week
11264087|NCT02944786|Experimental|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
11264088|NCT02944786|No Intervention|Control|Standard care
11264089|NCT02944773|Experimental|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
11264090|NCT02944773|No Intervention|without FTD|20 infants use not a FTD in the procedure of daily weight
11264091|NCT02944760|Experimental|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
11264092|NCT02944760|Placebo Comparator|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
11264093|NCT02944747|Experimental|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
11264094|NCT02944747|Experimental|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
11264095|NCT02944747|Experimental|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
11264096|NCT02944747|No Intervention|Comparison|The participants will not receive any of the interventions that are focused in this study.
11264097|NCT02944734|Experimental|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
11264098|NCT02944734|Experimental|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
11264099|NCT02944734|Experimental|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
11264100|NCT02944734|Experimental|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
11264101|NCT02944734|Experimental|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
11264102|NCT02944734|Experimental|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
11264103|NCT02944734|Experimental|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
11264104|NCT02944734|Experimental|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
11264105|NCT02944721|Other|Transversal study|Patients who had surgery for breast cancer for 2 years or less
11264106|NCT02944721|Other|Longitudinal study|Patients that must be operated for a breast cancer
11264107|NCT02944708|Active Comparator|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
11264108|NCT02944708|Experimental|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
11264109|NCT02944708|Experimental|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
11264110|NCT02944682|Experimental|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
11264111|NCT02944682|No Intervention|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
11264112|NCT02944656|Experimental|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
11264113|NCT02944656|Placebo Comparator|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
11264114|NCT02944643|Experimental|Active group|Will get the mindfulness and support groups
11264115|NCT02944630|Experimental|Experimental:|Receiving psychotherapy and medical treatment.
11264116|NCT02944630|No Intervention|Control|Awaiting group: Receiving medical treatment.
11264311|NCT02943356|Experimental|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
11264120|NCT02944578|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 12 weeks.
11264121|NCT02944578|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of a placebo once a week for 12 weeks.
11264122|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
11264123|NCT02944552|Experimental|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
11264124|NCT02944552|Experimental|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
11264125|NCT02944552|Active Comparator|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
11264126|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
11264127|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
11264128|NCT02944526|Experimental|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.
~3 successive blocks are realized at 1 week interval."
11264129|NCT02944526|Placebo Comparator|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.
~3 successive blocks are realized at 1 week interval."
11264130|NCT02944513|Experimental|Experimental|Subjects will receive the Quell device
11264131|NCT02944513|No Intervention|Control|Subjects will not receive the Quell device
11264132|NCT02944500|Experimental|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
11264133|NCT02944500|Experimental|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
11264134|NCT02944487|Experimental|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
11264135|NCT02944487|Experimental|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
11264136|NCT02944487|Placebo Comparator|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
11264137|NCT02944487|Placebo Comparator|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
11264138|NCT02944474|Experimental|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
11264139|NCT02944474|Experimental|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
11264140|NCT02944474|Experimental|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
11264141|NCT02944474|Experimental|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
11264142|NCT02944474|Placebo Comparator|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
11264143|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
11264144|NCT02944448|Active Comparator|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
11264145|NCT02944448|Active Comparator|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
11264146|NCT02944448|Active Comparator|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
11264147|NCT02944448|Placebo Comparator|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
11264148|NCT02944435|Experimental|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
11264149|NCT02944435|Active Comparator|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
11264150|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
11264151|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
11264152|NCT02944396|Experimental|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
11264153|NCT02944396|Experimental|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
11264154|NCT02944383|Experimental|Gemcabene 300 mg|Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
11264155|NCT02944383|Experimental|Gemcabene 600 mg|Participants received 600 mg Gemcabene orally, once daily for 12 weeks.
11264156|NCT02944383|Placebo Comparator|Placebo|Participants received matching placebo orally, once daily for 12 weeks.
11264157|NCT02944370|Experimental|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
11264312|NCT02943330||Hemodialysis|Hemodialysis patients
11264158|NCT02944357|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo cystectomy during course 8.
~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
11264159|NCT02944344|Experimental|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
11264160|NCT02944344|Other|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
11264161|NCT02944318|Experimental|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
11264162|NCT02944318|No Intervention|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
11264163|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
11264164|NCT02944292|Experimental|All enrolled patients|"Study population:
~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned
~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
11264165|NCT02944279||Peking University Third Hospital|
11264166|NCT02944279||Beijing Friendship Hospital|
11264167|NCT02944279||Beijing Shijitan Hospital|
11264168|NCT02944279||Beijing Xiyuan Hospital|
11264169|NCT02944279||China-Japan Friendship Hospital|
11264170|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of > 50%, iii.Left ventricular end diastolic area of < 10 cm2 iv. VTI variation with respiration of < 12.5%, are grouped under the hypovolaemia group .
11264171|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
11264172|NCT02944253|Experimental|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates for 8 weeks.
11264173|NCT02944253|Experimental|Low energy diet 100 gram carbohydrates|isocaloric (4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 100 gram carbohydrates for 8 weeks.
11264174|NCT02944253|Experimental|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates for 8 weeks.
11264175|NCT02944227|Experimental|Lucentis|Lucentis fixed treatment
11264176|NCT02944214|Experimental|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
11264177|NCT02944214|Experimental|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
11264178|NCT02944201|Experimental|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
11264179|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
11264180|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
11264181|NCT02944175|Experimental|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
11264182|NCT02944175|Active Comparator|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
11264183|NCT02944162|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
11264184|NCT02944149|Active Comparator|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
11264185|NCT02944149|Experimental|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
11264186|NCT02944136|Active Comparator|Enhanced Usual Care|Referred to a therapist and/or psychiatrist in their home town depending on the type of treatment they prefer (e.g., behavioral and/or medication)
11264187|NCT02944136|Experimental|stepped collaborative care|At least biweekly contact from a care coordinator by phone and face-to- face visits occurring approximately every 2 months during the patients outpatient visits or treatment, and 24/7 access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
11264188|NCT02944123|Other|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
11264313|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
11264189|NCT02944123|Experimental|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
11264190|NCT02944123|Experimental|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
11264191|NCT02944110|Active Comparator|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
11264192|NCT02944110|Placebo Comparator|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
11264193|NCT02944110|Active Comparator|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
11264194|NCT02944110|Placebo Comparator|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
11264195|NCT02944097|Experimental|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
11264196|NCT02944097|Experimental|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
11264197|NCT02944084|Experimental|Rice bran extract|2 g of unprocessed rice bran extract
11264198|NCT02944084|Experimental|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
11264199|NCT02944084|Experimental|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
11264200|NCT02944071|Experimental|(Ranger & Ranger LE) and Ranger DCB|"The working length is 80cm and 135cm for Ranger DCB catheter and 90 cm and 150cm for Ranger SL and Ranger LE DCB catheter.
~Multiple interventions:
~Prior to or during Index Procedure:
~Prior to treatment of the index limb, successful (< 30% residual stenosis) treatment of ipsilateral iliac inflow lesions may be performed
~Prior to treatment of the index limb, successful treatment of the arteries of the non-index limb may be performed
~Prior to treatment of the index limb, absence of clinical complications such as embolism, thrombosis, severe dissection, vessel rupture must be confirmed."
11264201|NCT02944058|Active Comparator|Philos plate|Intervention is surgery with Philos plate
11264202|NCT02944058|Active Comparator|Multiloc nail|Intervention is surgery with Multiloc nail
11264203|NCT02944045|Placebo Comparator|Placebo|Saline serum, same volume as in the Experimental arm.
11264204|NCT02944045|Experimental|Steroids|"Methylprednisolone intra veinous
~Day 1 to 5 : 30mg twice per day
~Day 6 to 10 : 30mg per day
~Day 11 to 21 : 20mg per day"
11264205|NCT02944032|Experimental|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
11264206|NCT02944032|Active Comparator|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
11264207|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
11264208|NCT02943993||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
11264209|NCT02943980|Experimental|CMAC Videolaryngoscope|tracheal intubation using CMAC
11264210|NCT02943980|Experimental|Macintosh laryngoscope|tracheal intubation using Macintosh laryngoscope
11264211|NCT02943967|Active Comparator|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.
~Both procedures will have the same post operative treatment :
~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
11264212|NCT02943967|Active Comparator|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.
~Both procedures will have the same post operative treatment :
~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
11264213|NCT02943954|Other|Angiography guided PCI|Revascularisation of non-culprit lesions guided by PCI
11264214|NCT02943954|Other|FFR guided PCI|Revascularisation of non-culprit lesions guided by FFR measurement
11264215|NCT02943941|Other|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
11264216|NCT02943928|Experimental|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis.
11264217|NCT02943928|Experimental|Traditional method by experience|Operator inserted the double lumen tube by experience
11264314|NCT02943317|Experimental|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
11264218|NCT02943915|Experimental|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
11264219|NCT02943915|Active Comparator|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
11264220|NCT02943915|No Intervention|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
11264221|NCT02943902|Experimental|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
11264222|NCT02943902|Experimental|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
11264223|NCT02943902|Experimental|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
11264224|NCT02943902|Experimental|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
11264225|NCT02943902|Active Comparator|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
11264226|NCT02943902|Active Comparator|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
11264227|NCT02943889|Experimental|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
11264228|NCT02943889|No Intervention|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
11264229|NCT02943876|No Intervention|Control|Serves as a control group, receiving generic information about depression and self-help.
11264230|NCT02943876|Experimental|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
11264231|NCT02943863|Active Comparator|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
11264232|NCT02943863|Active Comparator|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
11264233|NCT02943850|Experimental|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
11264234|NCT02943837|Active Comparator|EUS-FNA|Device: 22G FNA needle
11264235|NCT02943837|Experimental|EUS-FNB|Device: 20G FNB needle
11264236|NCT02943824|Experimental|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
11264237|NCT02943824|Active Comparator|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
11264238|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
11264239|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
11264240|NCT02943798|Experimental|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
11264241|NCT02943798|Experimental|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
11264242|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet for transitioning at end of treatment. Dosing must follow the locally approved label.
11264243|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
11264244|NCT02943772|Experimental|Local hypothermia|Local application of a brick cooled to -20(celsius)
11264245|NCT02943772|Sham Comparator|Control|Local application of a brick in room temperature
11264246|NCT02943759|Experimental|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
11264247|NCT02943759|Active Comparator|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
11264248|NCT02943746|Active Comparator|Control Group (Standard Protein Diet)|"Infants will receive a standard feeding regimen which consists of mother's own milk or donor human milk (DHM) with DHM derived fortifier.
~Once daily, a 24 hour batch of human milk is prepared for each infant (standard practice). A 2.5 mL sample will be analyzed for calories, protein, fat, and carbohydrates. Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day of protein. Data will be recorded for milk analysis, nutrition, and infant growth.
~The diet will be continued until approximately 35 to 36 weeks postmenstrual age at which point a DXA scan will be performed.
~A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.
~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
11264315|NCT02943317|Experimental|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
11264249|NCT02943746|Experimental|Intervention Group (High Protein Diet)|"The intervention group will receive the same standard feeding regimen with the addition of extra milk fortification to give a high protein diet.
~Human milk will be prepared and analyzed in the same method as the control group. Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
~The diet will be continued until approximately 35 to 36 weeks PMA at which point a DXA scan will be performed.
~Infants will have 3 sets of labs. A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.
~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
11264250|NCT02943733|Experimental|TAS-102 and TMZ|"Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ). Treatment cycles are 28 days, with TAS-102 administered orally twice daily days 1-5 and 8-12, and TMZ administered orally days 8-12. No treatment medications administered days 13-28 of each cycle. Growth factor support is required during Part 1 and should be dosed per institutional standards.
~Part 2: expansion phase to evaluate preliminary efficacy of MTD. Subjects treated with the recommended phase 2 drug doses determined in part 1. Treatment will continue for up to 13 cycles (approx. 12 months). Growth factor support is allowed during Part 2 and should be dosed per institutional standards."
11264251|NCT02943720|Placebo Comparator|placebo|5 SC injections in 2 months
11264252|NCT02943720|Experimental|AllerT 50 ug|5 SC injections in 2 months
11264253|NCT02943720|Experimental|AllerT 10 ug|5 SC injections in 2 months
11264254|NCT02943707|Experimental|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
11264255|NCT02943707|Active Comparator|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
11264256|NCT02943694|Experimental|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
11264257|NCT02943681|Experimental|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
11264258|NCT02943681|No Intervention|Control|Nothing
11264259|NCT02943668|Experimental|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
11264260|NCT02943655|Active Comparator|combined oral contraceptives|oral second generation pills one tablet daily
11264261|NCT02943655|Active Comparator|medroxyprogesterone acetate|oral 5 mg daily
11264262|NCT02943655|Active Comparator|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
11264263|NCT02943642|Experimental|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
11264264|NCT02943642|Active Comparator|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
11264265|NCT02943642|Experimental|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
11264266|NCT02943629|Experimental|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
11264267|NCT02943629|Other|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
11264268|NCT02943629|Experimental|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
11264269|NCT02943629|Other|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
11264270|NCT02943616|Experimental|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
11264271|NCT02943603|Experimental|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
11264272|NCT02943590|Placebo Comparator|Placebo|Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
11264273|NCT02943590|Experimental|Atorvastatin|Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
11264274|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11264275|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11264276|NCT02943564|Experimental|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11264277|NCT02943564|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11264278|NCT02943564|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11264279|NCT02943551|Other|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.
~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
11264280|NCT02943551|Other|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.
~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
11264281|NCT02943538|Experimental|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
11264282|NCT02943538|Experimental|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
11264283|NCT02943538|Active Comparator|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
11264284|NCT02943525|Experimental|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
11264285|NCT02943525|No Intervention|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
11264286|NCT02943512|Experimental|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
11264287|NCT02943512|No Intervention|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
11264288|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
11264289|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
11264290|NCT02943486|Experimental|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
11264291|NCT02943486|Active Comparator|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
11264292|NCT02943486|Active Comparator|Fitostimoline|Topical application of fitostimoline every other day
11264293|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
11264294|NCT02943460|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match Cilofexor 100 mg for 12 weeks
11264295|NCT02943460|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match Cilofexor 30 mg for 12 weeks
11264296|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match Cilofexor 30 mg + placebo to match Cilofexor 100 mg for 12 weeks
11264297|NCT02943460|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive Cilofexor for an additional 96 weeks.
11264298|NCT02943447|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
11264299|NCT02943447|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
11264300|NCT02943447|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
11264301|NCT02943447|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
11264302|NCT02943434|Other|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
11264303|NCT02943434|Other|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
11264304|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
11264305|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
11264306|NCT02943395|Experimental|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
11264307|NCT02943395|Active Comparator|light cured adhesive resin cement|resin cement that only get activated by light
11264308|NCT02943382|Experimental|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
11264309|NCT02943369|Experimental|Cangrelor|Ticagrelor will be followed by Cangrelor
11264310|NCT02943369|Active Comparator|Ticagrelor|Ticagrelor only
11264316|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
11264317|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
11264318|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
11264319|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
11264320|NCT02943278|Placebo Comparator|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
11264321|NCT02943278|Active Comparator|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
11264322|NCT02943265|Experimental|Complex Care Survivors|Patients eligible for the study who will receive Care Coordination Strategies.
11264323|NCT02943252|Experimental|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
11264324|NCT02943239|Experimental|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
11264325|NCT02943239|Experimental|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
11264326|NCT02943239|Experimental|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
11264327|NCT02943239|Experimental|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
11264328|NCT02943239|Experimental|Panel E|REGN2477 (Regimen 5) or placebo
11264329|NCT02943239|Experimental|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
11264330|NCT02943239|Experimental|Panel G|REGN2477 (Regimen 7) or placebo
11264331|NCT02943226|Experimental|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
11264332|NCT02943226|Active Comparator|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
11264333|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
11264334|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
11264335|NCT02943187|Experimental|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
11264336|NCT02943174|Experimental|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 6 to 12 participants).
~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
11264337|NCT02943174|Other|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
11264338|NCT02943161|Experimental|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
11264339|NCT02943135|Active Comparator|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
11264340|NCT02943135|Placebo Comparator|placebo|Self-administered gel 10 min before intrauterine device insertion
11264341|NCT02943109|Experimental|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
11264342|NCT02943109|Experimental|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
11264343|NCT02943109|Experimental|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
11264344|NCT02943109|Experimental|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
11264345|NCT02943096|Active Comparator|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
11264346|NCT02943096|Placebo Comparator|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
11264347|NCT02943083|Experimental|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
11264348|NCT02943083|Active Comparator|Home Intervention|Only perform relaxation exercise at home
11264349|NCT02943083|No Intervention|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
11264350|NCT02943083|No Intervention|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
11264351|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
11264352|NCT02943057|Experimental|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
11264353|NCT02943031|Experimental|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
11264354|NCT02943018||anovaginal distance variation|3 measurements
11264355|NCT02943005|Active Comparator|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
11265005|NCT02938611||The study population|Persons with stage >=4 chronic kidney disease.
11264356|NCT02943005|Experimental|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
11264357|NCT02942992|No Intervention|Control|Usual Care Group
11264358|NCT02942992|Other|Intervention|Intervention Group
11264359|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
11264360|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
11264361|NCT02942966|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
11264362|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
11264363|NCT02942940|Active Comparator|mobile app|
11264364|NCT02942940|Active Comparator|in-person|
11264365|NCT02942927|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:
~Medication reconciliation
~Identification of patient priorities for care
~Identification of medications that are potentially appropriate for discontinuation/dose reduction
~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
~Identification of medications for trial of discontinuation/dose reduction (shared decision making)
~Pause of medication and clinical monitoring"
11264366|NCT02942927|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
11264367|NCT02942914|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
11264368|NCT02942914|Placebo Comparator|Placebo|Placebo (sterile saline) administered SC.
11264369|NCT02942914|Active Comparator|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
11264370|NCT02942888|Active Comparator|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
11264371|NCT02942888|Experimental|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
11264372|NCT02942875|Experimental|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
11264373|NCT02942875|Active Comparator|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
11264374|NCT02942823|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
11264375|NCT02942823|No Intervention|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
11264376|NCT02942810|Experimental|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
11264377|NCT02942797||NRS 2002 score ≥ 3|
11264378|NCT02942797||NRS 2002 score < 3|
11264379|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
11264380|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
11264381|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
11264382|NCT02942771|Experimental|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
11264383|NCT02942771|Placebo Comparator|Placebo|No drug intervention.
11264384|NCT02942758|Experimental|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
11264385|NCT02942758|Active Comparator|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
11264386|NCT02942745|Placebo Comparator|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
11264387|NCT02942745|Experimental|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
11264388|NCT02942732|Other|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
11264389|NCT02942732|Other|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
11264390|NCT02942732|Other|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
11264391|NCT02942732|Other|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
11264392|NCT02942719||Shanghai First Maternity and Infant Hospital|
11264393|NCT02942719||Dalian Maternity and Child Health Hospital|
11264394|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
11264395|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
11264396|NCT02942719||The Children and Women's Healthcare of Laiwu City|
11264397|NCT02942719||Suzhou Municipal Hospital|
11264398|NCT02942719||Wenling Women's and Children's Hospital|
11264399|NCT02942719||First Affiliated Hospital of Kunming Medical University|
11264400|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
11264401|NCT02942719||Xinxiang Maternity and Child Health Hospital|
11264402|NCT02942719||Yanshi People's Hospital|
11264403|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
11264404|NCT02942719||Northwest Women and Children's Hospital|
11264405|NCT02942719||Suining Central Hospital|
11264406|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
11264407|NCT02942719||Fujian Province Maternity and Child Health Hospital|
11264408|NCT02942719||Qinghai Red Cross Hospital|
11264409|NCT02942719||Xinjiang Maternity and Child Health Hospital|
11264410|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
11264411|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
11264412|NCT02942706|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
11264413|NCT02942706|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
11264414|NCT02942693|Experimental|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
11264415|NCT02942693|Experimental|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
11264416|NCT02942680|Experimental|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
11264417|NCT02942680|Other|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
11264418|NCT02942667||Subjects undergoing high quality MRI Scans|
11264419|NCT02942654|Experimental|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
11264420|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
11264421|NCT02942641|Experimental|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
11264422|NCT02942641|Experimental|Clean intermittent catheterization (CIC)|CIC as the intervention .
11264423|NCT02942628|Experimental|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
11264424|NCT02942628|Active Comparator|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
11264425|NCT02942615|Experimental|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
11264426|NCT02942615|No Intervention|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
11264427|NCT02942602|Experimental|Atorvastatin 20 mg|lipid lowering treatment
11264428|NCT02942602|Experimental|Cholestyramine 8 g|lipid lowering treatment
11264429|NCT02942602|Experimental|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
11264430|NCT02942602|Experimental|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
11264431|NCT02942602|Active Comparator|Life style modification for management of dyslipidemia|
11264432|NCT02942589|Experimental|100% Portions|Meal portion size: 100%
11264433|NCT02942589|Experimental|125% Portions|Meal portion size: 125%
11264434|NCT02942589|Experimental|150% Portions|Meal portion size: 150%
11264435|NCT02942589|Experimental|175% Portions|Meal portion size: 175%
11264436|NCT02942576|Experimental|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
11264437|NCT02942576|Active Comparator|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
11264438|NCT02942563|Experimental|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
11264439|NCT02942550|Active Comparator|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
11264440|NCT02942550|Placebo Comparator|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
11264441|NCT02942537|Experimental|Intervention|Microwave treatment
11264442|NCT02942537|Active Comparator|Control|Uterine artery embolization
11264443|NCT02942524|Experimental|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
11264444|NCT02942498|Experimental|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
11264445|NCT02942498|Placebo Comparator|Placebo|Placebo solution
11264446|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
11264447|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
11264485|NCT02942251|Experimental|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
11264486|NCT02942251|Experimental|Comorbidity|A group patients with physical or mental disorders comorbidities.
11264448|NCT02942459|Experimental|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).
~A Manual is created and trained with the Music Therapists, which distinguishes between
~Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,
~Essential but not Unique Principles,
~Acceptable but not necessary Principles,
~Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
11264449|NCT02942459|Active Comparator|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.
~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
11264450|NCT02942446|Experimental|Headgear|Investigative Headgear with CPAP mask
11264451|NCT02942433|Experimental|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
11264452|NCT02942433|Other|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
11264453|NCT02942420|Experimental|Dose Group A|Bucillamine 300 mg/day
11264454|NCT02942420|Experimental|Dose Group B|Bucillamine 600 mg/day
11264455|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
11264456|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
11264457|NCT02942381|Active Comparator|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
11264458|NCT02942381|Placebo Comparator|Placebo|Placebo and supportive treatment
11264459|NCT02942368|Experimental|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
11264460|NCT02942355|Experimental|Cohort A: First-line therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
11264461|NCT02942355|Experimental|Cohort B: Maintenance therapy|Anastrozole by mouth daily and palbociclib by mouth Days 1-21 on a 28 day cycle
11264462|NCT02942329|Experimental|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
11264463|NCT02942316|Experimental|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
11264464|NCT02942303|Active Comparator|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
11264465|NCT02942303|Active Comparator|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
11264466|NCT02942290|Experimental|Venetoclax + Azacitidine|
11264467|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
11264468|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
11264469|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
11264470|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
11264471|NCT02942277|Experimental|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
11264472|NCT02942277|Experimental|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
11264473|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
11264474|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
11264475|NCT02942277|Active Comparator|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
11264476|NCT02942277|Active Comparator|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
11264477|NCT02942277|Active Comparator|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
11264478|NCT02942264|Experimental|Phase I Arm 1|dose dense TMZ 125 mg/m2 x 7 days on / 7days off plus Zotiraciclib (TG02) dose escatlation
11264479|NCT02942264|Experimental|Phase I Arm 2|metronomic TMZ 50 mg/ m2 daily plus Zotiraciclib (TG02) doseescalation
11264480|NCT02942264|Experimental|Phase II Arm 1|"MTD of Zotiraciclib (TG02) from phase I plus and winner of dd vs metronomic TMZ from phase I"
11264481|NCT02942264|Active Comparator|Phase II Arm 2|"winner of dd vs metronomic TMZ from phase I alone"
11264482|NCT02942251|Experimental|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
11264483|NCT02942251|Experimental|Psycho-social|A group patients with significant high risk of psycho-social problems.
11264484|NCT02942251|Experimental|immunology|A group patients with significant high risk of immune disturbance.
11264487|NCT02942251|Experimental|Treatment as usual|Control group.
11264488|NCT02942238|Experimental|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
11264489|NCT02942238|Active Comparator|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
11264490|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
11264491|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
11264492|NCT02942212|Experimental|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.
~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
11264493|NCT02942212|Active Comparator|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.
~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
11264494|NCT02942212|Experimental|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.
~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.
~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
11264495|NCT02942199|Experimental|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
11264496|NCT02942173|No Intervention|CD45RA-|
11264497|NCT02942173|Experimental|CD45RA+|
11264498|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
11264499|NCT02942147|Active Comparator|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
11264500|NCT02942147|Active Comparator|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
11264501|NCT02942147|Active Comparator|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
11264502|NCT02942121|Experimental|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
11264503|NCT02942108|Active Comparator|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
11264504|NCT02942108|Experimental|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
11264505|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.
~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
11264506|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.
~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
11264507|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.
~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
11264508|NCT02942082|Experimental|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
11264509|NCT02942082|Placebo Comparator|glycrin|glycrin will be applied on tooth before and /or after bleaching.
11264510|NCT02942056|Experimental|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
11264511|NCT02942056|Placebo Comparator|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
11264512|NCT02942043|Experimental|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
11264513|NCT02942043|Experimental|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
11264545|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
11264514|NCT02942043|Experimental|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
11264515|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
11264516|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
11264517|NCT02942017|Placebo Comparator|Placebo|Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
11264518|NCT02942017|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
11264519|NCT02942004|Placebo Comparator|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
11264520|NCT02942004|Experimental|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
11264521|NCT02942004|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
11264522|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
11264523|NCT02941978|Experimental|Subject on Motivational Interview|"Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician for an interactive session and will be given an educational leaflet. Both methods will aim to educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.
~Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient, aiming to improve adherence to OAC."
11264524|NCT02941978|Active Comparator|Subject Control|Patients assigned to the control group will receive usual treatment and will be contacted via telephone for a pre-specified interview at 1 year after discharge for outcome assessment.
11264525|NCT02941965|Experimental|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
11264526|NCT02941965|Experimental|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.
~A maximum of 2 embryos will be transferred for each treatment cycle."
11264527|NCT02941939|Active Comparator|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
11264528|NCT02941939|Experimental|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
11264529|NCT02941926|Experimental|Ribociclib + letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
11264530|NCT02941913|Experimental|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
11264531|NCT02941913|Experimental|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
11264532|NCT02941900||Non-melanoma skin cancers (NMSCs)|
11264533|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
11264534|NCT02941874||Healthy volunteers IRAP measurement|
11264535|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
11264536|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
11264537|NCT02941848|Experimental|Group1|"C → A + B
~A : HGP0816 B : HGP1404 C : HCP1306"
11264538|NCT02941848|Experimental|Group2|"A + B → C
~A : HGP0816 B : HGP1404 C : HCP1306"
11264539|NCT02941835|Other|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
11264540|NCT02941822|Experimental|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:
~Day 1-7, 60 mg
~Day 8-14, 120 mg
~Day 15-21, 180 mg
~Day 22-28, 300 mg
~Day 29-186, 420 mg"
11264541|NCT02941809|Experimental|Open-Label Placebo (OLP)|Participants who are randomly assigned to group OLP will receive placebo pills. In Phase 1 of the study (first two weeks), participants in this group are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), OLP participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. OLP participants will meet with the study team at five time points: at baseline (entry into treatment), 2 weeks post-baseline, and 1-, 2- and 3-months post-baseline.
11264542|NCT02941809|No Intervention|Treatment as Usual (TAU)|Participants assigned to TAU will not be given placebo pills, but all interactions with the study team (5 meetings total) will be matched in frequency and length.
11264543|NCT02941796|Experimental|Sequence 1|"T → R
~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
11264544|NCT02941796|Experimental|Sequence 2|"R → T
~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
11264546|NCT02941770|No Intervention|Control group|"Clinic standard care protocol:
~Baseline evaluation session with a Pediatrician for initial screening;
~Appointment with a Dietitian;
~A brochure with physical activity guidelines for youth with examples of physical exercises."
11264547|NCT02941770|Experimental|Intervention group I|"Clinic standard care protocol;
~Physical activity consultation (Physical activity behavior change);"
11264548|NCT02941770|Experimental|Intervention group II|"Clinic standard care protocol;
~Physical activity consultation;
~2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
11264549|NCT02941757|Experimental|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
11264550|NCT02941757|No Intervention|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
11264551|NCT02941744|Experimental|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
11264552|NCT02941731|Experimental|Sequence 1|HIP1403→HGP0919
11264553|NCT02941731|Experimental|Sequence 2|HGP0919→HIP1403
11264554|NCT02941718|Experimental|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.
~Smoking Cessation intervention components include:
~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)
~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.
~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
11264555|NCT02941718|Active Comparator|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.
~Smoking Cessation intervention components include:
~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)
~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.
~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
11264556|NCT02941705|Active Comparator|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
11264557|NCT02941705|Placebo Comparator|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
11264558|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
11264559|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
11264560|NCT02941679|Experimental|HCP1202|Test
11264561|NCT02941679|Active Comparator|HGP1011|Control
11264562|NCT02941679|Active Comparator|HCP0910|Control
11264563|NCT02941666||Collapse ON group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.
11264564|NCT02941666||Pre-collapse group|This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.
11264565|NCT02941666||FAI group|This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement.
11264566|NCT02941653|Active Comparator|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
11264567|NCT02941653|Experimental|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
11264568|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
11264569|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
11264570|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
11264571|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
11264572|NCT02941627|Experimental|Cochlear Implant|Neuro Cochlear Implant System
11264573|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
11264574|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
11264575|NCT02941601|Experimental|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
11264576|NCT02941601|Experimental|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
11264577|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
11264578|NCT02941575|Active Comparator|Control|Implant superstructure crown: All ceramic, IPS Emax
11264579|NCT02941575|Experimental|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
11264580|NCT02941562|Experimental|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
11264581|NCT02941562|Active Comparator|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
11264582|NCT02941549|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
11264583|NCT02941549|Experimental|500 mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
11264584|NCT02941549|Experimental|1000 mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
11264585|NCT02941536|Other|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
11264586|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:
~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
11264587|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.
~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
11264588|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.
~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
11264589|NCT02941510|Experimental|Budesonide|Will participate in all study activities but will receive budesonide.
11264590|NCT02941510|Placebo Comparator|Placebo|Will participate in all study activities but will receive placebo.
11264591|NCT02941497|Experimental|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
11264592|NCT02941497|Experimental|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
11264593|NCT02941484|Experimental|1 early oral intake|early oral intake since postoperative day 1.
11264594|NCT02941484|Experimental|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
11264595|NCT02941471|Experimental|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
11264596|NCT02941471|Active Comparator|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
11264597|NCT02941458||Non-small cell lung cancer|patients treated for a non small cell lung cancer
11264598|NCT02941458||Small cell lung cancer|patients treated for a small cell lung cancer
11264599|NCT02941458||Mesotelioma|patients treated for a mesotelioma
11264600|NCT02941458||timic cancer|patients treated for a timic cancer
11264601|NCT02941458||carcinoid cancer|patients treated for a carcinoid cancer
11264602|NCT02941445|Experimental|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
11264603|NCT02941445|Experimental|MET (metformin)|metformin 1000 mg BID
11264604|NCT02941432|Other|Black tea|Black tea compress treatment
11264605|NCT02941419|Experimental|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
11264606|NCT02941406||Healthy subjects|"Men and Women aged 18 and older
~Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
~Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
11264607|NCT02941406||Age-related macular degeneration patients|"Men and Women aged 18 and older
~Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
11264608|NCT02941393|Active Comparator|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
11264609|NCT02941393|Active Comparator|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
11264610|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
11264611|NCT02941367|Experimental|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
11264612|NCT02941367|Active Comparator|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
11264613|NCT02941354|Experimental|Turoctocog alfa|
11264614|NCT02941328|Experimental|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
11264615|NCT02941328|Placebo Comparator|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
11264616|NCT02941315|Experimental|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
11264617|NCT02941315|Placebo Comparator|etiology unconfirmed WO acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
11264618|NCT02941315|Placebo Comparator|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
11264619|NCT02941315|Experimental|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
11264620|NCT02941302|Experimental|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
11264621|NCT02941289|Experimental|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
11264622|NCT02941289|Active Comparator|Control patient|patient with MMSE score equal or > 27
11264623|NCT02941276|Experimental|Group A|Active electrostimulator device
11264624|NCT02941276|Sham Comparator|Group B|Sham electrostimulator device
11264625|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with AMD
11264626|NCT02941250|Experimental|treatment|patients receiving ISSD emulator
11264627|NCT02941237|Other|Healthcare worker measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
11264628|NCT02941237|Other|Expert measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
11264629|NCT02941224|Experimental|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
11264630|NCT02941211|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
11264631|NCT02941198|Active Comparator|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
11264632|NCT02941198|Active Comparator|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
11264633|NCT02941185|Other|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
11264634|NCT02941185|Active Comparator|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
11264635|NCT02941185|Active Comparator|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
11264636|NCT02941172|Other|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
11264637|NCT02941172|Other|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
11264638|NCT02941172|Other|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
11264639|NCT02941159|Active Comparator|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
11264640|NCT02941159|Placebo Comparator|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
11264641|NCT02941146|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen with a new applicator design.
11264642|NCT02941133|Experimental|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
11264643|NCT02941133|Experimental|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
11264644|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
11264645|NCT02941107|Experimental|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
11264646|NCT02941107|Placebo Comparator|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
11264647|NCT02941094|Active Comparator|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
11264648|NCT02941094|Active Comparator|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
11264649|NCT02941094|Active Comparator|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
11264650|NCT02941081|Experimental|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
11264651|NCT02941081|Active Comparator|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
11265006|NCT02938598|Experimental|A|Engagement On - Problem Solving High - Motivation On
11264652|NCT02941081|Placebo Comparator|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
11264653|NCT02941068|Experimental|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
11264654|NCT02941068|No Intervention|Empirical group|
11264655|NCT02941055|Experimental|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
11264656|NCT02941055|Active Comparator|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
11264657|NCT02941042|Experimental|NNC9204-1177|
11264658|NCT02941042|Placebo Comparator|Placebo|
11264659|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
11264660|NCT02941016|Experimental|Lipid lowering|
11264661|NCT02941003|Experimental|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
11264662|NCT02941003|Experimental|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
11264663|NCT02940990|Placebo Comparator|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
11264664|NCT02940990|Experimental|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
11264665|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
11264666|NCT02940964|Experimental|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
11264667|NCT02940964|Active Comparator|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
11264668|NCT02940951|Other|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
11264669|NCT02940951|Experimental|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) to document, monitor and address the quality of life concerns of patients and family caregivers.
11264670|NCT02940938|Experimental|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
11264671|NCT02940925|Experimental|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT)."
11264672|NCT02940925|Active Comparator|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
11264673|NCT02940912|Active Comparator|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
11264674|NCT02940912|Placebo Comparator|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
11264675|NCT02940899|Active Comparator|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
11264676|NCT02940899|Active Comparator|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
11264677|NCT02940886|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
11264678|NCT02940886|Active Comparator|Iron sucrose|Administered IV
11264679|NCT02940873|Experimental|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
11264680|NCT02940873|Active Comparator|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
11264681|NCT02940860|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
11264682|NCT02940860|Active Comparator|Iron sucrose|Administered IV
11264722|NCT02940587|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
11264683|NCT02940847|Active Comparator|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
11264684|NCT02940847|Active Comparator|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
11264685|NCT02940834||patients with sodium imbalance|
11264686|NCT02940834||patients without sodium imbalance|
11264687|NCT02940821|Active Comparator|Whitening and Dentifrice|
11264688|NCT02940821|Active Comparator|Whitening Dentifrice|
11264689|NCT02940821|Active Comparator|Dentifrice|
11264690|NCT02940808|Other|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
11264691|NCT02940808|Other|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
11264692|NCT02940795|Experimental|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
11264693|NCT02940795|Experimental|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
11264694|NCT02940782|Experimental|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
11264695|NCT02940782|Active Comparator|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
11264696|NCT02940769|Experimental|light glasses|Study subjects will wear light glasses
11264697|NCT02940769|Sham Comparator|sham glasses (placebo)|Study subjects will wear sham glasses
11264698|NCT02940756|Experimental|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
11264699|NCT02940756|Experimental|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
11264700|NCT02940756|Experimental|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
11264701|NCT02940743|Active Comparator|Education (Edu)|
11264702|NCT02940743|Active Comparator|Edu + Self-Monitoring (SM)|
11264703|NCT02940743|Active Comparator|Edu + SM + Social Cognitive Theory (SCT)|
11264704|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
11264705|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
11264706|NCT02940717|Experimental|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
11264707|NCT02940717|Active Comparator|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
11264708|NCT02940704|Experimental|Reciproc|"Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.
~Size: R40 (40/0.06)"
11264709|NCT02940704|Active Comparator|One Shape|"One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.
~Size: 25/0.06"
11264710|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
11264711|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
11264712|NCT02940665||Conventional|Conventional group received conventional care.
11264713|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
11264714|NCT02940639||Nivolumab monotherapy (cohort 1)|Participants with advanced/metastatic RCC initiating Nivolumab monotherapy after prior therapy
11264715|NCT02940639||Nivolumab and ipilimumab combination therapy (cohort 2)|Participants with advanced/metastatic RCC initiating 1st line therapy with nivolumab and ipilimumab combination therapy.
11264716|NCT02940626|Placebo Comparator|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
11264717|NCT02940626|Experimental|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
11264718|NCT02940613|Experimental|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
11264719|NCT02940613|No Intervention|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
11264720|NCT02940600|Experimental|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
11264721|NCT02940600|Active Comparator|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
11264723|NCT02940587|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
11264724|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
11264725|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
11264726|NCT02940561|Experimental|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
11264727|NCT02940561|Active Comparator|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
11264728|NCT02940548|Active Comparator|Nifedipine GITS|Nifedipine GITS 30~60mg/day
11264729|NCT02940548|Active Comparator|Amlodipine besylate|Amlodipine besylate 5~10mg/day
11264730|NCT02940535|Experimental|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
11264731|NCT02940535|Active Comparator|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
11264732|NCT02940522|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector
11264733|NCT02940522|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle
11264734|NCT02940509|Active Comparator|Ketamine plus Magnesium sulfate|Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
11264735|NCT02940509|Placebo Comparator|Placebo|Normal Saline (NaCl 0.9%)
11264736|NCT02940496|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11264737|NCT02940496|Experimental|Arm B (pembrolizumab, elbasvir/grazoprevir, ribavirin)|Patients receive pembrolizumab as in arm A. Patients also receive elbasvir/grazoprevir orally PO QD and ribavirin PO QD on days 1-28. Treatment continues for 12-16 weeks in the absence of disease progression or unacceptable toxicity.
11264738|NCT02940483|Experimental|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
11264739|NCT02940470|Experimental|Calorie restricted diet plus exercise|See Intervention Description
11264740|NCT02940470|Active Comparator|Weight management classes|See Intervention Description
11264741|NCT02940457|Experimental|Verum tDCS|prefrontal anodal stimulation
11264742|NCT02940457|Experimental|Sham tDCS|sham stimulation, same electrode positions
11264743|NCT02940444|Experimental|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
11264744|NCT02940444|Active Comparator|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
11264745|NCT02940431|Experimental|High Autonomy|Children will choose active video games for use during the study.
11264746|NCT02940431|Experimental|Low Autonomy|Children will be assigned active video games for use during the study.
11264747|NCT02940418|Active Comparator|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.
~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
11264748|NCT02940418|Active Comparator|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.
~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
11264749|NCT02940405|Experimental|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
11264750|NCT02940405|Placebo Comparator|placebo tablet|One tablet of a placebo one hour before endodontic treatment
11264751|NCT02940392|Experimental|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
11264752|NCT02940379|Experimental|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
11264753|NCT02940379|Experimental|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
11264754|NCT02940366|Experimental|Pitavastatin 4 mg orally daily|
11264755|NCT02940366|Placebo Comparator|Atorvastatin 20 mg orally daily|
11264756|NCT02940353|Other|Treatment with Trefoil concept|Treatment
11264757|NCT02940314|Experimental|sequence 1|HGP1103→HIP1503
11264758|NCT02940314|Experimental|Sequence 2|HIP1503→HGP1103
11264759|NCT02940301|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
11264760|NCT02940288|Experimental|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
11264761|NCT02940288|Sham Comparator|Control|Participants will be randomized to receive bilateral sham acupuncture.
11264762|NCT02940275||Hypertension|
11264763|NCT02940275||Diabetes mellitus|
11264764|NCT02940275||Hypertension and diabetes mellitus|
11264765|NCT02940275||End stage kidney disease|
11264766|NCT02940275||Kidney transplant recipient|
11264767|NCT02940275||Coronary artery disease|
11264768|NCT02940275||Peripheral arterial occlusive disease|
11264769|NCT02940262|Experimental|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
11264770|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
11264771|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
11264772|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
11264774|NCT02940236||Multimodal analgesia|Patients scheduled for general surgery and requiring multimodal analgesia in preoperative period.
11264775|NCT02940223|Experimental|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
11264776|NCT02940223|Experimental|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
11264777|NCT02940223|Experimental|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
11264778|NCT02940210|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
11264779|NCT02940210|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
11264780|NCT02940197|Experimental|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
11264781|NCT02940197|Experimental|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
11264782|NCT02940184|Experimental|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)
~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
11264783|NCT02940184|Experimental|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
11264784|NCT02940171||Early surgery|Early Excision of full thickness burn First excision surgery of full -thickness burn performed within 48 hours from burn injury
11264785|NCT02940171||Late surgery|Late Excision of full thickness burn First excision surgery of full -thickness burn performed after 48 hours from burn injury
11264786|NCT02940158|Other|1/2 cup|1/2 cup serving size arm
11264787|NCT02940158|Other|1/4 cup|1/4 cup serving size arm
11264788|NCT02940145|Experimental|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.
~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
11264789|NCT02940145|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
11264790|NCT02940132|Experimental|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
11264791|NCT02940119|Active Comparator|Active PBMT|The volunteers received active phototherapy in each session.
11264792|NCT02940119|Placebo Comparator|Placebo PBMT|The volunteers received placebo phototherapy in each session.
11264793|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
11264794|NCT02940106|Active Comparator|open device|New cryopreservation system.
11264795|NCT02940093||Stem cell transplant recipient|
11264796|NCT02940093||Stem cell donor|
11264797|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
11264798|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
11264799|NCT02940067|Experimental|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
11264800|NCT02940067|No Intervention|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
11264801|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:
~diarrhea
~nocturnal diarrhea
~body weight loss (>5%)
~abdominal pain
~perianal lesions."
11264802|NCT02940028|Experimental|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
11264803|NCT02940028|Other|Control writing intervention|The control group will receive a control writing condition (fact based writing).
11264804|NCT02940015||Anonymous Sample Collection - Adults (ASCA)|Healthy Volunteers ages 18 and older
11264805|NCT02940002|Experimental|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
11264806|NCT02940002|Experimental|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
11264807|NCT02940002|Experimental|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
11264808|NCT02940002|Experimental|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
11264809|NCT02940002|Active Comparator|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
11264810|NCT02940002|Active Comparator|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
11265000|NCT02938650|Other|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
11264811|NCT02939989|Experimental|ABT-493/ABT-530 + SOF + RBV for 16 weeks|ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + RBV (600 - 1200 mg) daily in two divided doses (based on baseline age and weight) for 16 weeks.
11264812|NCT02939989|Experimental|ABT-493/ABT-530 + SOF + RBV for 12 weeks|ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + RBV (600 - 1200 mg) daily in two divided doses (based on baseline age and weight) for 12 weeks.
11264813|NCT02939976|Active Comparator|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
11264814|NCT02939976|Experimental|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
11264815|NCT02939976|Experimental|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
11264816|NCT02939963|Experimental|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC
11264817|NCT02939963|Experimental|pressure support 7 cm H2O PEP 4 cm H2O then ATC|ventilator is set to pressure support ventilation mode at set pressure 7 cm H2O above PEEP level of 4 cm H2O
11264818|NCT02939950|Experimental|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
11264819|NCT02939950|Active Comparator|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
11264820|NCT02939937|Experimental|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
11264821|NCT02939937|Experimental|placebo|patients received placebo 100 mg three time daily for 3 months
11264822|NCT02939924|Experimental|DCB treatment|Patient treated with Kanshas DCB
11264823|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
11264824|NCT02939898|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
11264825|NCT02939898|Active Comparator|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
11264826|NCT02939872|Experimental|DAPT|Dual antiplatelet therapy : aspirin and clopidogrel
11264827|NCT02939872|Active Comparator|Clopidogrel only|Clopidogrel monotherapy
11264828|NCT02939859|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
11264829|NCT02939859|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
11264830|NCT02939859|Experimental|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
11264831|NCT02939846|Experimental|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
11264832|NCT02939833|Experimental|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
11264833|NCT02939833|Placebo Comparator|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
11264834|NCT02939807|Experimental|advanced HCC, tumor progression with sorafenib|Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.
11264835|NCT02939794|Active Comparator|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
11264836|NCT02939794|Placebo Comparator|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
11264837|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
11264838|NCT02939768|Experimental|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
11264839|NCT02939768|No Intervention|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
11264840|NCT02939755|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
11264916|NCT02939248|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
11264918|NCT02939235|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
11264841|NCT02939755|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
11264842|NCT02939742|Experimental|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
11264843|NCT02939742|Placebo Comparator|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
11264844|NCT02939729|Experimental|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
11264845|NCT02939729|No Intervention|Standard Care|This group will receive standard preoperative information and education only.
11264846|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
11264847|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
11264848|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
11264849|NCT02939703|Active Comparator|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
11264850|NCT02939703|Experimental|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
11264851|NCT02939690|Experimental|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
11264852|NCT02939690|Active Comparator|UVC and Birth weight based formula|UVC insertion depth=[(3× birth weight (Kg) + 9)/2+1)] cm
11264853|NCT02939677|Other|Targeted exercise|Targeted exercise intervention
11264854|NCT02939677|No Intervention|care as usual|home based exercises
11264855|NCT02939664|Active Comparator|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
11264856|NCT02939664|Active Comparator|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
11264857|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
11264858|NCT02939638|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
11264859|NCT02939638|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
11264860|NCT02939625|Active Comparator|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
11264861|NCT02939625|Active Comparator|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
11264862|NCT02939625|Active Comparator|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
11264863|NCT02939612|Experimental|App for Stress management|Participants will get access to two modules per week for five weeks (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
11264864|NCT02939612|No Intervention|Waitlist control group|Participants will get treatment as usual during the study. After the one year study follow up they will receive the stress management app.
11264865|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg
~-active patients will continue at the dose they finished on the QCC374X2201 study"
11264866|NCT02939586|Active Comparator|Haemodialysis|regular convectional haemodialysis 3times/weekly
11264867|NCT02939586|Active Comparator|Haemodiafiltration|post-dilution haemodiafiltration
11264868|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
11264869|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
11264870|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
11264871|NCT02939547|Active Comparator|Hydroxypropyl-best-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
11264872|NCT02939547|Active Comparator|Hydroxypropyl-best-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
11264873|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
11264874|NCT02939521|Experimental|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
11264875|NCT02939508|Experimental|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
11264917|NCT02939248|Active Comparator|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
11264999|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
11264876|NCT02939508|Active Comparator|Non-colon originated|"NCOG met one of the two following criteria:
~History of nerve damage that could affect colon movement (colon [-innervating] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;
~Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
11264877|NCT02939495|Experimental|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
11264878|NCT02939482|Active Comparator|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
11264879|NCT02939482|Experimental|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
11264880|NCT02939469|Experimental|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
11264881|NCT02939456|Other|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
11264882|NCT02939443|Other|cross-sectional study|
11264883|NCT02939430|Active Comparator|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
11264884|NCT02939430|Experimental|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
11264885|NCT02939417|Experimental|using grape seed extract|Grape seed extract as collagen cross-linking agent
11264886|NCT02939417|Active Comparator|without uing grape seed extract|
11264887|NCT02939404||healthy volunteers|non-diabetic healthy volunteers at a stable weight
11264888|NCT02939391|Experimental|KW-6356 Low Dose|Oral administration
11264889|NCT02939391|Experimental|KW-6356 High Dose|Oral administration
11264890|NCT02939391|Placebo Comparator|Placebo|Oral administration
11264891|NCT02939378|Experimental|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
11264892|NCT02939378|Other|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
11264893|NCT02939365|Experimental|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.
~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
11264894|NCT02939352|Experimental|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
11264895|NCT02939352|Experimental|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
11264896|NCT02939339|Experimental|real treatment|continuous theta burst stimulation (real) will be delivered
11264897|NCT02939339|Sham Comparator|sham treatment|continuous theta burst stimulation (sham) will be delivered
11264898|NCT02939326|Placebo Comparator|Placebo|"Intervention: Drug: Placebo
~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area."
11264899|NCT02939326|Active Comparator|EB-001 Dose 1 (1X)|"Intervention: Drug: EB-001
~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
11264900|NCT02939326|Active Comparator|EB-001 Dose 2 (3X)|"Intervention: Drug: EB-001, 3X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
11264901|NCT02939326|Active Comparator|EB-001 Dose 3 (9X)|"Intervention: Drug: EB-001, 9X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
11264902|NCT02939326|Active Comparator|EB-001 Dose 4 (12X)|"Intervention: Drug: EB-001, 12X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
11264903|NCT02939326|Active Comparator|EB-001 Dose 5 (16X)|"Intervention: Drug: EB-001, 16X Dose 1
~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
11264904|NCT02939326|Active Comparator|EB-001 Dose 6 (21X)|Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
11264905|NCT02939326|Active Comparator|EB-001 Dose 7 (28X)|"Intervention: Drug: EB-001, 28X Dose 1
~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
11264906|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
11264907|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
11264908|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
11264909|NCT02939300|Experimental|Combination Of Nivolumab with Ipilimumab|"All patients will be treated with the combination regimen of Nivolumab at pre-determine dose with Ipilimumab at a pre-determine dose.This will be followed by Nivolumab Monotherapy.
~Each treatment Cycle will last 6 weeks"
11264910|NCT02939287|Active Comparator|Aprepitant|aprepitant plus standard anti-emetic regimen
11264911|NCT02939287|Experimental|Olanzapine|olanzapine plus standard anti-emetic regimen
11264912|NCT02939287|Experimental|Aprepitant plus olanzapine|aprepitant and olanzapine plus standard anti-emetic regimen
11264913|NCT02939274|Other|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
11264914|NCT02939261|Active Comparator|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
11264915|NCT02939261|Experimental|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
11264919|NCT02939235|Active Comparator|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
11264920|NCT02939222|Other|Routine implant placement|No comparison needed
11264921|NCT02939209|Experimental|Hydromorphone|Patients will be given 2 mg hydromorphone (immediate release) in the post anesthetic care unit.
11264922|NCT02939209|Placebo Comparator|Placebo|Patients will be given placebo in the post anesthetic care unit.
11264923|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
11264924|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
11264925|NCT02939183|Experimental|Part 1 Arm 1|Oprozomib (Immediate Release) plus dexamethasone
11264926|NCT02939183|Experimental|Part 1 Arm 2|Oprozomib (Gastro-retentive) plus dexamethasone
11264927|NCT02939183|Experimental|Part 2 Arm 1|Oprozomib (Immediate release) plus pomalidomide and dexamethasone
11264928|NCT02939183|Experimental|Part 2 Arm 2|Oprozomib (Gastro-retentive) plus pomalidomide and dexamethasone
11264929|NCT02939170|Experimental|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
11264930|NCT02939170|Active Comparator|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
11264931|NCT02939144|Experimental|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
11264932|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
11264933|NCT02939131|Active Comparator|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
11264934|NCT02939105|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the upper arm, can be reduced.
11264935|NCT02939092|Experimental|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
11264936|NCT02939092|Active Comparator|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
11264937|NCT02939079|Experimental|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
11264938|NCT02939079|Active Comparator|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
11264939|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
11264940|NCT02939040|Experimental|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
11264941|NCT02939040|No Intervention|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
11264942|NCT02939027|Experimental|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
11264943|NCT02939027|Experimental|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
11264944|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
11264945|NCT02939001|Experimental|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
11264946|NCT02938988|Experimental|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
11264947|NCT02938988|Active Comparator|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
11264948|NCT02938975|Placebo Comparator|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
11264949|NCT02938975|Active Comparator|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.
~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.
~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
11264950|NCT02938975|Active Comparator|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.
~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft
~Placebo lotion: liposome lotion with no DEET"
11264951|NCT02938975|Active Comparator|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.
~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
11264952|NCT02938962|Active Comparator|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
11264953|NCT02938962|Active Comparator|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
11264954|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
11264955|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
11264956|NCT02938936|Experimental|Scheduling Intervention|Pre-natal visit scheduling
11264957|NCT02938936|No Intervention|Control|
11264958|NCT02938923|Experimental|Exercise + Testosterone (EX + T)|Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
11264959|NCT02938923|Placebo Comparator|Exercise + Placebo (EX + P)|Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.
11264960|NCT02938923|Other|Enhanced Usual Care (EUC)|Home exercise program 3 times per week and monthly health education modules, both for six months duration.
11264961|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
11264962|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
11264963|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
11264964|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
11264965|NCT02938897|Experimental|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
11264966|NCT02938897|Active Comparator|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
11264967|NCT02938884|Active Comparator|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.
~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
11264968|NCT02938884|No Intervention|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
11264969|NCT02938871|Active Comparator|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
11264970|NCT02938871|Placebo Comparator|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
11264971|NCT02938858||ATRA-chimio|according to usual practice center
11264972|NCT02938858||ATRA-ATO|according to usual practice center
11264973|NCT02938845|Experimental|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
11264974|NCT02938845|Experimental|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
11264975|NCT02938832|Active Comparator|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
11264976|NCT02938832|Active Comparator|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
11264977|NCT02938819|Experimental|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
11264978|NCT02938819|Active Comparator|Control group|Patients in the control group received a standard upper limb intervention
11264979|NCT02938806||Obese/overweight children with T1D|No intervention
11264980|NCT02938806||Normal weight children with T1D|No intervention
11264981|NCT02938806||Obese/overweight children, no diabetes|No intervention
11264982|NCT02938806||Healthy, normal weight children|No intervention
11264983|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) intravenously for 7 doses then every 12 weeks for 2 doses.
11264984|NCT02938780|Placebo Comparator|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
11264985|NCT02938780|Experimental|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
11264986|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
11264987|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
11264988|NCT02938754|Experimental|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
11264989|NCT02938754|Active Comparator|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
11264990|NCT02938741|Experimental|r-ATG Immunosuppressive agents|"Rabbit Anti-human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.
~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
11264991|NCT02938741|Placebo Comparator|placebo|"Rabbit Anti-human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.
~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
11264992|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
11264993|NCT02938715|Experimental|Feedback group (teledermatology)|
11264994|NCT02938715|No Intervention|Control group (phone only)|
11264995|NCT02938702||Active surveillance|Group with active surveillance of their PTC
11264996|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
11264997|NCT02938689|Experimental|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
11264998|NCT02938689|Active Comparator|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
11265007|NCT02938598|Experimental|B|Engagement On - Problem Solving Low - Motivation On
11265008|NCT02938598|Experimental|C|Engagement On - Problem Solving High - Motivation Off
11265009|NCT02938598|Experimental|D|Engagement On - Problem Solving Low - Motivation Off
11265010|NCT02938598|Experimental|E|Engagement Off - Problem Solving High - Motivation On
11265011|NCT02938598|Experimental|F|Engagement Off - Problem Solving Low - Motivation On
11265012|NCT02938598|Experimental|G|Engagement Off - Problem Solving High - Motivation Off
11265013|NCT02938598|Experimental|H|Engagement Off - Problem Solving Low - Motivation Off
11265014|NCT02938585|Experimental|Prophylactic treatment|
11265015|NCT02938585|Experimental|On-demand treatment|
11265016|NCT02938572|Experimental|NNC0143-0406|
11265017|NCT02938572|Active Comparator|Insulin aspart|
11265018|NCT02938559|Experimental|Cognitive Therapy plus Memory Support|
11265019|NCT02938559|Active Comparator|Cognitive Therapy-as-usual|
11265020|NCT02938546|Active Comparator|before therapy|18F-FDG PET/CT performed before therapy
11265021|NCT02938546|Experimental|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
11265022|NCT02938546|Experimental|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
11265023|NCT02938533|No Intervention|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
11265024|NCT02938533|Experimental|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
11265025|NCT02938520|Experimental|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
11265026|NCT02938520|Active Comparator|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
11265027|NCT02938507|Experimental|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
11265028|NCT02938507|Experimental|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
11265029|NCT02938494|Experimental|IDP-123 Lotion|Lotion
11265030|NCT02938494|Active Comparator|Tazorac Cream|Cream
11265031|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
11265032|NCT02938494|Active Comparator|Vehicle Cream|Cream
11265033|NCT02938468|Active Comparator|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
11265034|NCT02938468|Experimental|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
11265035|NCT02938442|Active Comparator|Standard Chemotherapy|"The first or control arm will receive standard chemotherapy for triple negative breast cancer."
11265036|NCT02938442|Active Comparator|Standard Chemotherapy + Vaccine|"The second or chemo + vaccine arm will receive the same standard chemotherapy plus P10s-PADRE vaccine."
11265037|NCT02938429|Other|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.
~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).
~Participants will complete a questionnaire to access factors that can affect endothelial function."
11265038|NCT02938429|Other|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.
~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).
~Participants will complete a questionnaire to access factors that can affect endothelial function."
11265039|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
11265040|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
11265041|NCT02938403|Experimental|In vivo group|Those who receive in vivo counseling and Nicotine Replacement Therapy (NRT)
11265042|NCT02938403|Active Comparator|Controls|Standard smoking cessation counseling and Nicotine Replacement Therapy (NRT)
11265043|NCT02938377|Active Comparator|No dx of alcohol use disorder, panic or depre|Computerized Brief Intervention (CBI)- a video about alcohol abuse
11265044|NCT02938377|Active Comparator|Risky drinking, no dx of AUD, has panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy
11265189|NCT02937337|Experimental|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
11265045|NCT02938377|Active Comparator|Dx of AUD with or without panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy plus a recommendation for Alcohol Pharmacotherapy (APT). The drugs recommended in the APT are all standard of care drugs for alcohol treatment and are not under study in this protocol.
11265046|NCT02938364|Experimental|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
11265047|NCT02938364|Experimental|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
11265048|NCT02938364|Placebo Comparator|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
11265049|NCT02938351|Experimental|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
11265050|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
11265051|NCT02938325||No intervention: General Anesthesia|"Thirty patients undergoing elective surgery under general anesthesia who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the surgery, patients will be questioned for awareness under anesthesia by Modified Brice Questionnaire.
~There will be no intervention. Patients will be anesthetized with general anesthesia as they were supposed to be for their elective surgery. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
11265052|NCT02938325||No intervention: Sedation|"Fourty patients undergoing elective cardiac catheterization under conscious sedation who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the procedure, patients will be questioned for awareness under sedation by Modified Brice Questionnaire.
~There will be no intervention. Patients will be anesthetized with sedation as they were supposed to be for their elective cardiac catheterization. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
11265053|NCT02938325||No Intervention - Awake Volunteers|EEG and BIS will be recorded in twenty volunteers, for 10 minutes, in supine position, while their eyes are closed. This recording will be utilized as for positive control for recall.
11265054|NCT02938312|Active Comparator|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
11265055|NCT02938312|Experimental|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
11265056|NCT02938299|Experimental|Arm 1: neoadjuvant + surgery|"Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors of a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks (or until all injectable tumors have disappeared, or intolerance to study treatment or in the opinion of the investigator immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first).
~Newly occurring injectable melanoma lesions within the 4 weeks treatment period will also be treated as described. Surgical resection of all existing metastases will follow within 4 weeks after end of treatment. Surgery will be performed after the safety evaluation carried out at week 5 and, if indicated, may be carried out on the same day of the safety evaluation."
11265057|NCT02938299|Active Comparator|Arm 2: surgery alone|Patients in Arm 2 will receive directly surgical resection of melanoma tumor lesions within 4 weeks after randomization.
11265058|NCT02938286|Experimental|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
11265059|NCT02938286|Experimental|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
11265060|NCT02938286|Experimental|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
11265061|NCT02938286|Experimental|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
11265062|NCT02938273|Experimental|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
11265063|NCT02938260||Diltiazem|
11265064|NCT02938260||Metoprolol|
11265065|NCT02938247|Experimental|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
11265066|NCT02938234|Experimental|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
11265067|NCT02938221|Experimental|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
11265068|NCT02938208|Experimental|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
11265069|NCT02938195|Experimental|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
11265070|NCT02938182|Experimental|clopidogrel|clopidogrel tablet 75mg daily for three months
11265071|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise
~walking exercise: treadmill gait with tolerable gait speed
~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
11265072|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise
~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.
~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
11265073|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise
~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.
~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.
~walking exercise:treadmill gait with tolerable gait speed"
11265074|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)
~Only educate the flexibility exercise(stretching exercise)
~Don't educate the walking exercise method and stabilization exercise method"
11265075|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
11265076|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
11265077|NCT02938130|Other|Wellness Programs|Community Partners and Community LIFE programs
11265078|NCT02938117|Experimental|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
11265079|NCT02938117|Experimental|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
11265080|NCT02938104|Experimental|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:
~Receive a personalized physical exercise program
~Receive nutritional counselling with whey protein isolate powder
~Receive relaxation techniques"
11265081|NCT02938104|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
11265082|NCT02938091|Experimental|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
11265083|NCT02938091|Experimental|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
11265084|NCT02938078|Experimental|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
11265085|NCT02938078|No Intervention|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
11265086|NCT02938065|Other|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
11265087|NCT02938065|Other|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
11265088|NCT02938065|Other|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
11265089|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).
~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
11265090|NCT02938039|Active Comparator|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
11265091|NCT02938039|Active Comparator|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
11265092|NCT02938026|No Intervention|Control|Usual care
11265093|NCT02938026|Experimental|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
11265094|NCT02938026|Experimental|Bariatric surgery|Bariatric surgery
11265095|NCT02938013|Experimental|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
11265096|NCT02938013|Active Comparator|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
11265097|NCT02938013|Active Comparator|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
11265098|NCT02938000|Experimental|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
11265099|NCT02938000|Placebo Comparator|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
11265100|NCT02937987||Group 1|non-obese type 2 DM
11265101|NCT02937987||Group 2|obese type 2 DM
11265102|NCT02937974|Experimental|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
11265103|NCT02937974|Placebo Comparator|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
11265104|NCT02937961|Experimental|Early SLED|
11265105|NCT02937961|Active Comparator|Late SLED|
11265106|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
11265107|NCT02937935|Experimental|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
11265108|NCT02937935|Active Comparator|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow >200 mL/min and a dialysate flow >500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
11265109|NCT02937922|Active Comparator|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
11265110|NCT02937922|Active Comparator|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
11265111|NCT02937922|Active Comparator|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
11265112|NCT02937909|Experimental|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
11265113|NCT02937909|No Intervention|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
11265114|NCT02937896|Experimental|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
11265115|NCT02937896|Active Comparator|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
11265116|NCT02937883|Experimental|empowerment intervention|Empowerment intervention
11265117|NCT02937883|No Intervention|regular care|Regular care, care as usual
11265118|NCT02937870|Experimental|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
11265119|NCT02937870|Experimental|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
11265120|NCT02937870|Active Comparator|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
11265121|NCT02937870|Other|Negative Control|
11265122|NCT02937857|Active Comparator|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
11265123|NCT02937857|Experimental|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
11265124|NCT02937844|Experimental|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
11265125|NCT02937831||All Study Participants|
11265126|NCT02937818|Experimental|ARM A|
11265127|NCT02937818|Experimental|ARM B|
11265128|NCT02937818|Experimental|ARM C|
11265186|NCT02937363|Experimental|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
11265129|NCT02937805|Experimental|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
11265130|NCT02937805|Active Comparator|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
11265131|NCT02937805|No Intervention|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
11265132|NCT02937792|No Intervention|CONTROL|one with intrathecal 12.5 mg bupivacaine
11265133|NCT02937792|Experimental|experimental|one group with intrathecal 15 mg bupivacaine
11265134|NCT02937779|Experimental|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.
~No treatment for negative HBe Ag women"
11265135|NCT02937766|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
11265136|NCT02937766|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
11265137|NCT02937740|Other|Naive patients - ARM 1|"NATESTO Testosterone Nasal Gel administered intranasally to patients with no prior TRT experience. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.
~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
11265138|NCT02937740|Other|Non-naive patients - ARM 2|"NATESTO Testosterone Nasal Gel administered intranasally to patients who had prior TRT. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.
~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
11265139|NCT02937727|Experimental|MRI compatible and LFP recordable implantable stimulator|
11265140|NCT02937714|Experimental|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
11265141|NCT02937714|No Intervention|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
11265142|NCT02937701|Experimental|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.
~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
11265143|NCT02937701|Active Comparator|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.
~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
11265144|NCT02937675|Experimental|Tomivosertib (eFT-508) Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
11265145|NCT02937675|Experimental|Tomivosertib (eFT-508) Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas
11265146|NCT02937662|Experimental|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
11265147|NCT02937662|Active Comparator|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
11265148|NCT02937649|Experimental|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
11265149|NCT02937649|Active Comparator|Laparoscopic sleeve gastrectomy using standard care bougie|Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
11265150|NCT02937636|Experimental|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
11265151|NCT02937636|Active Comparator|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
11265152|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
11265153|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
11265154|NCT02937597|Active Comparator|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
11265155|NCT02937597|Active Comparator|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
11265187|NCT02937363|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
11265188|NCT02937350|Experimental|Study Population|D6-25-hydroxyvitamin D3
11265156|NCT02937597|Experimental|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
11265157|NCT02937584|Experimental|GP MDI (PT001) 14.4 μg|Glycopyrronium
11265158|NCT02937584|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
11265159|NCT02937571|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone|"Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.
~Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
~Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days
~Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23
~Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23"
11265160|NCT02937558|Experimental|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
11265161|NCT02937558|Placebo Comparator|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
11265162|NCT02937558|Experimental|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
11265163|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
11265164|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
11265165|NCT02937532|Placebo Comparator|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
11265166|NCT02937532|Active Comparator|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
11265167|NCT02937519|Experimental|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
11265168|NCT02937519|Other|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
11265169|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
11265170|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
11265171|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
11265172|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
11265173|NCT02937480|Experimental|Experimental group|Task-specific training
11265174|NCT02937480|Sham Comparator|Control group|Global stretching, memory exercises, health care orientation
11265175|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
11265176|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
11265177|NCT02937428|Experimental|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
11265178|NCT02937428|Active Comparator|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
11265179|NCT02937428|Experimental|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
11265180|NCT02937428|Active Comparator|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
11265181|NCT02937415|Experimental|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
11265182|NCT02937415|Active Comparator|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
11265183|NCT02937402|Experimental|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
11265184|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
11265185|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
11265190|NCT02937337|Active Comparator|Blind|Laryngeal mask insertion using standard index finger-guided technique
11265191|NCT02937324|Active Comparator|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
11265192|NCT02937324|Experimental|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
11265193|NCT02937311|Experimental|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
11265194|NCT02937311|Experimental|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
11265195|NCT02937311|Experimental|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
11265196|NCT02937298|Experimental|Control Meal|Control meal using standard breakfast foods.
11265197|NCT02937298|Experimental|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
11265198|NCT02937298|Experimental|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
11265199|NCT02937298|Experimental|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
11265200|NCT02937285|Active Comparator|Standard care|Interferon alone
11265201|NCT02937285|Experimental|Experimental group|Mitoxantrone for 6 month followed by interferon
11265202|NCT02937272|Experimental|LY3200882 Schedule 1 Escalation|
11265203|NCT02937272|Experimental|LY3200882 Schedule 2 Escalation|
11265204|NCT02937272|Experimental|LY3200882 Schedule 1 Expansion|
11265205|NCT02937272|Experimental|LY3200882 Schedule 2 Expansion|
11265206|NCT02937272|Experimental|LY3200882 + LY3300054|
11265207|NCT02937272|Experimental|LY3200882 + Gemcitabine + nab-Paclitaxel|
11265208|NCT02937272|Experimental|LY3200882 + Cisplatin + Radiation|
11265209|NCT02937272|Experimental|Japanese Arm LY3200882|
11265210|NCT02937259|Experimental|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
11265211|NCT02937246|Experimental|the intervention group|Partial covered double bare metal stent
11265212|NCT02937246|Active Comparator|the control group|Uncovered double bare metal stent
11265213|NCT02937233|Experimental|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
11265214|NCT02937233|Experimental|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
11265215|NCT02937233|Experimental|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
11265216|NCT02937220|Experimental|Monolithic zirconia crowns|New crown material to restore dental implants
11265217|NCT02937220|Active Comparator|metal ceramic crowns|conventional crown material for restoring dental implants
11265218|NCT02937207|Experimental|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265219|NCT02937207|Placebo Comparator|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265220|NCT02937207|Experimental|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265221|NCT02937207|Placebo Comparator|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265222|NCT02937207|Experimental|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265223|NCT02937207|Placebo Comparator|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265224|NCT02937207|Experimental|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265225|NCT02937207|Placebo Comparator|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
11265226|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
11265227|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
11265228|NCT02937181|Experimental|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
11265229|NCT02937168|Experimental|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
11265327|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
11265328|NCT02936518|Experimental|Intervention|
11265230|NCT02937168|Experimental|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
11265231|NCT02937168|Placebo Comparator|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
11265232|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
11265233|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
11265234|NCT02937142|Experimental|Cognitive behavior group therapy|Cognitive behavior group therapy in weekly 1,5 hour sessions during 12 weeks, 8 participants and 2 therapists per group, in addition to education on ADHD, and ADHD medication if indicated.
11265235|NCT02937142|Other|Controls|Treatment as usual: Education on ADHD, and ADHD medication if indicated.
11265236|NCT02937116|Experimental|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.
~Drug: IBI308"
11265237|NCT02937116|Experimental|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308"
11265238|NCT02937116|Experimental|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308"
11265239|NCT02937116|Experimental|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308"
11265240|NCT02937116|Experimental|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308 Drug: Cisplatinum Drug: Pemetrexed"
11265241|NCT02937116|Experimental|Phase 1b Cohort E|Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
11265242|NCT02937116|Experimental|Phase 1b Cohort F|Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
11265243|NCT02937116|Experimental|Phase 1b Cohort G|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308\etoposide\cisplatin"
11265244|NCT02937116|Experimental|Phase 1b Cohort H|"Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.
~Drug: IBI308\irinotecan\5-FU"
11265245|NCT02937103|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11265246|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.
~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):
~chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);
~total or free T levels above the reference interval and/or excessive facial hair, acne;
~transvaginal ultrasound with polycystic ovaries.
~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
11265247|NCT02937090||Control|Women matched for age and BMI.
11265248|NCT02937064||Controls|Controls
11265249|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
11265250|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
11265251|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
11265252|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
11265253|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
11265254|NCT02937051|Active Comparator|Own Brand Cigarette Condition|
11265255|NCT02937051|Experimental|Original-flavor Black&Mild cigar|
11265256|NCT02937051|Experimental|Apple-flavor Black&Mild cigar|
11265257|NCT02937051|Experimental|Cream-flavor Black&Mild cigar|
11265258|NCT02937051|Experimental|Wine-flavor Black&Mild cigar|
11265259|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
11265260|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
11265261|NCT02937025|Experimental|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
11265262|NCT02937012|Experimental|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
11265263|NCT02937012|Placebo Comparator|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
11265264|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
11265265|NCT02936973|Experimental|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
11265266|NCT02936973|Sham Comparator|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
11265267|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
11265268|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.
~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
11265269|NCT02936934|Active Comparator|Morphine|Multimodal analgesia to morphine
11265270|NCT02936934|Experimental|Oxycodone|Multimodal analgesia to oxycodone
11265271|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
11265272|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
11265273|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
11265274|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
11265275|NCT02936895|Experimental|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
11265276|NCT02936895|Placebo Comparator|Placebo|Placebo (same size and shape) for 2 days
11265277|NCT02936882|Other|Preoperative gastric ultrasonography|
11265278|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
11265279|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
11265280|NCT02936856|Experimental|After Hepatic Arteriography|
11265281|NCT02936856|Active Comparator|Before Hepatic Arteriography|
11265282|NCT02936843|Experimental|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
11265283|NCT02936843|Placebo Comparator|Comparator|Placebo for Salsalate, 2 tablets by mouth, 3 times daily for 12 months
11265284|NCT02936830|Placebo Comparator|Control|21 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
11265285|NCT02936830|Active Comparator|Fluoride group|21 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
11265286|NCT02936830|Experimental|Nanohydroxyapetite|21 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
11265287|NCT02936817|Other|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
11265288|NCT02936804|Experimental|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
11265289|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
11265290|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
11265291|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
11265292|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
11265293|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
11265294|NCT02936765|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
11265295|NCT02936765|Active Comparator|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
11265329|NCT02936505|Active Comparator|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
11265330|NCT02936505|Experimental|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
11265331|NCT02936492|Experimental|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
11265296|NCT02936752|Experimental|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
11265297|NCT02936739|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
11265298|NCT02936739|Active Comparator|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
11265299|NCT02936726|Active Comparator|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.
~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
11265300|NCT02936726|Experimental|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.
~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)
~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
11265301|NCT02936713|Experimental|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
11265302|NCT02936713|Experimental|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
11265303|NCT02936700|Other|Control group|Add on relaxation group
11265304|NCT02936700|Experimental|Therapy ACT|Add on ACT group
11265305|NCT02936687|Experimental|Metabolic Syndrome NOS Inhibition|Will occur over two separate study visits after screening. Eligible subjects with MetSyn will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
11265306|NCT02936687|Experimental|Metabolic Syndrome ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male subjects with MetSyn will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
11265307|NCT02936687|Experimental|Control NOS Inhibition|Will occur over two separate study visits after screening. Eligible control subjects will undergo NOS Inhibition during one visit and placebo infusion in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
11265308|NCT02936687|Experimental|Control ET-1 Inhibition|Will occur over two separate study visits after screening. Eligible male control subjects will complete an oral ET-1 Inhibition during one visit and an oral placebo in the other visit. Subjects will also undergo 3 Tesla MRI scanning and an intravenous catheter, and will complete an Oral Glucose Tolerance Test during the study visits. More details under Study Description.
11265309|NCT02936674|Experimental|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
11265310|NCT02936674|Active Comparator|Light 2|Light 2 will be a standard LED bulb.
11265311|NCT02936661|Experimental|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
11265312|NCT02936661|Placebo Comparator|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
11265313|NCT02936648|Experimental|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
11265314|NCT02936635|Experimental|tirasemtiv|tirasemtiv 250-500 mg/day
11265315|NCT02936622|Experimental|Stent 1|Zilver® PTX Stent
11265316|NCT02936622|Experimental|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
11265317|NCT02936622|Experimental|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
11265318|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
11265319|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
11265320|NCT02936596|Experimental|Ursodeoxycholic acid + immunosuppressive agents group|Ursodeoxycholic acid + immunosuppressive agents
11265321|NCT02936596|Active Comparator|Ursodeoxycholic acid group|Ursodeoxycholic acid
11265322|NCT02936583|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11265323|NCT02936570|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11265324|NCT02936557|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11265325|NCT02936544|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11265326|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
11265332|NCT02936492|Placebo Comparator|Placebo|Topical treatment using matching amount of placebo
11265333|NCT02936492|Active Comparator|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
11265334|NCT02936479|Experimental|Berinert treatment|
11265335|NCT02936466|Experimental|Interventional group|Bipolife group
11265336|NCT02936466|No Intervention|Control group|No specific intervention, treatment as usual
11265337|NCT02936453|Experimental|All patients|"Patients will participate during 8-12 months, during which there will be :
~Pre-implant evaluations (6-8 weeks)
~Device implantation and stimulation optimization (6-8 weeks)
~Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.
~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
11265338|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
11265339|NCT02936427|No Intervention|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
11265340|NCT02936427|Experimental|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
11265341|NCT02936427|Experimental|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
11265342|NCT02936414|Experimental|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
11265343|NCT02936414|Placebo Comparator|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
11265344|NCT02936401|Experimental|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
11265345|NCT02936401|Experimental|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
11265346|NCT02936388|Experimental|Arm A|SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)
11265347|NCT02936388|Active Comparator|Arm B|DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)
11265348|NCT02936375|Experimental|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
11265349|NCT02936375|Active Comparator|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
11265350|NCT02936362|Other|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
11265351|NCT02936362|Other|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
11265352|NCT02936336|No Intervention|Control|without exercise intervention
11265353|NCT02936336|Experimental|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
11265354|NCT02936323|Experimental|PEN-221|intravenous administration of PEN-221
11265355|NCT02936310|Experimental|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.
~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
11265356|NCT02936297|Placebo Comparator|Lactose free placebo|Lactose free placebo pill
11265357|NCT02936297|Active Comparator|Low dose Gluten (0.5g)|Low dose gluten pill
11265358|NCT02936297|Active Comparator|High Dose Gluten (2.0g)|High dose gluten pill
11265359|NCT02936284|Experimental|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
11265360|NCT02936284|Active Comparator|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
11265361|NCT02936271|Active Comparator|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
11265362|NCT02936271|Placebo Comparator|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
11265363|NCT02936258|Other|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
11265364|NCT02936258|Active Comparator|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
11265365|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
11265366|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
11265367|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
11265368|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
11265369|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
11265370|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
11265371|NCT02936206|Experimental|Fulvestrant|750 mg injection in 3 divided doses
11265372|NCT02936206|Active Comparator|Tamoxifen|20mg orally
11265373|NCT02936193|Experimental|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
11265374|NCT02936193|Active Comparator|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
11265375|NCT02936180|Active Comparator|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
11265376|NCT02936180|Active Comparator|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
11265377|NCT02936167|Experimental|Ringer Lactate|fluid
11265378|NCT02936167|Experimental|Plasmalyte|fluid
11265379|NCT02936154|Experimental|300 mg|
11265380|NCT02936154|Placebo Comparator|placebo|
11265381|NCT02936141|Experimental|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
11265382|NCT02936128|Experimental|TruSkin®|Cryopreserved skin allograft
11265383|NCT02936128|Active Comparator|Wound Cover|Active Comparator for Venous Leg Ulcers
11265384|NCT02936115|Experimental|TruSkin®|Cryopreserved skin allograft
11265385|NCT02936115|Active Comparator|Wound Cover|Active Comparator for Diabetic Foot Ulcers
11265386|NCT02936102|Experimental|FAZ053 single agent|
11265387|NCT02936102|Experimental|FAZ053 + PDR001|
11265388|NCT02936089|Experimental|Risk Stratification-directed Therapy|AE AML patients first received IA or DA induction therapy, and then received two courses of IDAC (Ara-C 1-2 g/m2 q12 h ×6 cycles). Subsequently, different subgroups of AE AML received different treatment based on risk stratification. For low-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or autologous HSCT. For intermediate-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or allogeneic HSCT. High-risk AE AML all received allogeneic HSCT.
11265389|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
11265390|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
11265391|NCT02936063|Experimental|Surgical staples|Skin closure with surgical staples
11265392|NCT02936063|Experimental|Sutures|Skin closure with subcuticular sutures
11265393|NCT02936050|Other|Intervention|"Experimental: Addition of diagnostic ultrasound performed by nurses at the outpatient heart failure clinic. Interpretation by specialist per telemedicine.
~No Control arm"
11265394|NCT02936037|Placebo Comparator|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
11265395|NCT02936037|Experimental|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
11265396|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
11265397|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
11265398|NCT02936011|Other|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
11265399|NCT02935998|Experimental|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
11265400|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.
~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.
~Participants will be assessed (clinically or by telephone) over a period of 180 days."
11265401|NCT02935972|Active Comparator|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
11265402|NCT02935972|Active Comparator|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
11265403|NCT02935972|Active Comparator|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
11265404|NCT02935959|Active Comparator|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
11265405|NCT02935959|Active Comparator|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
11265406|NCT02935959|Active Comparator|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
11265407|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
11265408|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
11265409|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
11265410|NCT02935933|Active Comparator|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
11265411|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
11265412|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
11265413|NCT02935920|Experimental|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
11265414|NCT02935920|No Intervention|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
11265415|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
11265416|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.
~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
11265417|NCT02935881|Active Comparator|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
11265418|NCT02935881|Sham Comparator|Placebo Arm|Stretta device used but RFA will not be generated.
11265419|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
11265420|NCT02935868||Control Group|Patients without systemic diseases
11265421|NCT02935855|Active Comparator|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
11265422|NCT02935855|Active Comparator|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
11265423|NCT02935855|Active Comparator|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
11265424|NCT02935855|Active Comparator|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
11265425|NCT02935842|Experimental|Specific SL-therapy for PD (with and without DBS)|Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
11265426|NCT02935842|Active Comparator|rBMT for PD (with and without DBS)|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
11265427|NCT02935842|No Intervention|PD (with and without DBS); no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
11265428|NCT02935842|No Intervention|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
11265429|NCT02935829|Experimental|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11265452|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
11265453|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
11265430|NCT02935829|Experimental|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
11265431|NCT02935829|Experimental|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11265432|NCT02935829|Experimental|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11265433|NCT02935829|Experimental|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
11265434|NCT02935829|Experimental|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
11265435|NCT02935803|Other|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
11265436|NCT02935803|Other|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
11265437|NCT02935790|Experimental|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
11265438|NCT02935777|Experimental|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules
~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
11265439|NCT02935777|Placebo Comparator|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
11265440|NCT02935764|Experimental|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
11265441|NCT02935764|Active Comparator|IRINOTECAN|irinotecan
11265442|NCT02935738|Experimental|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
11265443|NCT02935738|Experimental|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
11265444|NCT02935738|No Intervention|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
11265445|NCT02935738|No Intervention|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
11265446|NCT02935725|Experimental|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
11265447|NCT02935725|Experimental|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
11265448|NCT02935725|Placebo Comparator|Placebo + Ketamine|Placebo + ketamine
11265449|NCT02935725|Placebo Comparator|Placebo + Saline|Placebo + saline
11265450|NCT02935712|Experimental|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
11265451|NCT02935712|Experimental|Part B|Subjects received 2 treatments (AZD8601+Placebo)
11265454|NCT02935686|Experimental|Group 1: Ad26.Mos4.HIV + Clade C gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
11265455|NCT02935686|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140 mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
11265456|NCT02935686|Placebo Comparator|Group 3: Placebo|Participants will receive a single placebo injection at Weeks 0 and 12, followed by two placebo injections at Weeks 24 and 48.
11265457|NCT02935686|Experimental|Group 1b: Ad26.Mos4.HIV + gp140 HIV Bivalent Vaccine|Participants enrolled in the LTE phase will receive late boost vaccination Ad26.Mos4.HIV and bivalent gp140 within 4 weeks prior to Week 192 until 4 months after Week 192 (that is, approximately 3 years after the 4th vaccination of the primary vaccination series).
11265458|NCT02935686|Placebo Comparator|Group 2b: Placebo|Participants will receive placebo injection at Week 192 -4 weeks/+4 months, that is, approximately 3 years after the 4th vaccination of the primary vaccination series.
11265459|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
11265460|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
11265461|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
11265462|NCT02935660|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
11265463|NCT02935647|Experimental|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
11265464|NCT02935634|Active Comparator|Nivolumab (nivo) and Ipilimumab (ipi) Combination|
11265465|NCT02935634|Experimental|nivo and Relatlimab Combination|
11265466|NCT02935634|Experimental|nivo and BMS-986205 Combination|
11265467|NCT02935634|Experimental|Nivo and rucaparib Combination|
11265468|NCT02935634|Experimental|Ipi with rucaparib Combination|
11265469|NCT02935634|Experimental|nivo with ipi and rucaparib|
11265470|NCT02935621|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
11265471|NCT02935621|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
11265472|NCT02935608|Experimental|BIIB074 high dose|Administered twice daily (BID)
11265473|NCT02935608|Experimental|BIIB074 low dose|Administered BID
11265474|NCT02935608|Placebo Comparator|Placebo|Placebo administered BID
11265475|NCT02935595|Experimental|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
11265476|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
11265477|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
11265478|NCT02935569|Experimental|Compression Headband|a compression headband, placed only at the time of irradiation
11265479|NCT02935556||post partum pre-eclampsia|women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
11265480|NCT02935556||controls|women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
11265481|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
11265482|NCT02935530|Experimental|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
11265483|NCT02935530|Active Comparator|LMWH|4250 I.U. subcutaneous injection for 5-10 days
11265484|NCT02935530|Experimental|Argatroban|20mg, injection for 5-10 days
11265485|NCT02935517|Experimental|Group 1: 4.0 x 10^10 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265486|NCT02935517|Experimental|Group 2: 1.2 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265487|NCT02935517|Experimental|Group 3: 3.6 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265488|NCT02935517|Experimental|Group 3a: 3.6 x 10^11 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265489|NCT02935517|Experimental|Group 4: 1.1 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265490|NCT02935517|Experimental|Group 4a: 1.1 x 10^12 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265491|NCT02935517|Experimental|Group 5: 3.2 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
11265492|NCT02935517|Experimental|Group 6: MTD of AGTC-402|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGA3 study drug determined by Groups 1-5.
11265493|NCT02935504|Experimental|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
11265494|NCT02935504|Active Comparator|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
11265495|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
11265496|NCT02935478|Experimental|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
11265497|NCT02935465|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
11265498|NCT02935465|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
11265499|NCT02935452|Active Comparator|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
11265500|NCT02935452|No Intervention|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
11265501|NCT02935439|Active Comparator|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
11265502|NCT02935439|No Intervention|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
11265503|NCT02935426|Experimental|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
11265504|NCT02935426|Active Comparator|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
11265505|NCT02935413|Active Comparator|tDCS|group receiving complete treatment of transcranial direct current stimulation
11265506|NCT02935413|Active Comparator|Standard rehabilitation|Standard rehabilitation procedures
11265507|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
11265508|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
11265509|NCT02935387|Experimental|Taper methotrexate, then golimumab|Taper methotrexate 25>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50>0mg/month during 24 weeks.
11265510|NCT02935387|Active Comparator|Taper golimumab, then methotrexate|Taper golimumab 50>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25>0mg/wk during 24 weeks.
11265511|NCT02935374|Active Comparator|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
11265512|NCT02935374|Active Comparator|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
11265513|NCT02935374|No Intervention|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
11265514|NCT02935374|Other|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
11265515|NCT02935361|Experimental|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11265516|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
11265517|NCT02935322|Active Comparator|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
11265518|NCT02935322|Active Comparator|0.2 % NaF mouthrinse|A mouthrinse containing NaF
11265519|NCT02935322|Active Comparator|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
11265520|NCT02935322|Placebo Comparator|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
11265521|NCT02935309|Experimental|Pre-Surgery Chemotherapy/Radiotherapy|Pre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
11265522|NCT02935296|No Intervention|Control|Standard of Care
11265523|NCT02935296|Experimental|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
11265524|NCT02935283||OTCD participants|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD who can undergo MRI and behavioral testing
11265525|NCT02935283||Normal controls|Healthy males or females without known medical or metabolic disorder (control group) who can undergo MRI and behavioral testing
11265526|NCT02935283||HA recovery group|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD or participants with CPS-1 who have had a recent hyperammonemic episode who can undergo MRI and behavioral testing
11265527|NCT02935283||Distal UCD|Males and females with ASSD and ASLD who can undergo MRI and behavioral testing
11265528|NCT02935270||Stroke Survivors|Individuals who have experienced a unilateral hemispheric stroke
11265529|NCT02935257|Experimental|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
11265530|NCT02935231|Experimental|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
11265531|NCT02935231|Experimental|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
11265532|NCT02935231|Experimental|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
11265533|NCT02935231|Active Comparator|Control|This control group receives a health warning leaflet.
11265534|NCT02935218|Other|Parenting Skills for Mothers with BPD|single-arm study
11265535|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11265536|NCT02935192|Experimental|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
11265537|NCT02935192|Placebo Comparator|Placebo Arm|Phosphate buffered saline
11265538|NCT02935179|Placebo Comparator|Control Group|Normal diet with 1500~2000 kcal
11265539|NCT02935179|Experimental|Treatment Group|White sweet potato diet with 1500~2000 kcal
11265540|NCT02935166|Placebo Comparator|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
11265541|NCT02935166|Active Comparator|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
11265542|NCT02935166|Active Comparator|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
11265543|NCT02935153|Experimental|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11265544|NCT02935127|Experimental|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
11265545|NCT02935127|Experimental|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
11265546|NCT02935114|Experimental|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)
~37% Carbamide Peroxide application (2 sessions of 45 minutes)
~Tooth sensitivity (Verbal and visual scale) and color evaluation"
11265547|NCT02935114|Active Comparator|35% Hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)
~35% Hydrogen Peroxide application (2 sessions of 45 minutes)
~Tooth sensitivity (Verbal and visual scale) and color evaluation"
11265548|NCT02935101|Experimental|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
11265549|NCT02935101|Placebo Comparator|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
11265550|NCT02935075|Experimental|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
11265551|NCT02935075|Active Comparator|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
11265552|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
11265553|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
11265554|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
11265555|NCT02935036|Experimental|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
11265556|NCT02935036|Placebo Comparator|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
11265557|NCT02935023|Experimental|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
11265558|NCT02935010|Experimental|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
11265559|NCT02935010|Active Comparator|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
11265560|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
11265650|NCT02934386|Experimental|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
11265561|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
11265562|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
11265563|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
11265564|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
11265565|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
11265566|NCT02934958|Active Comparator|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
11265567|NCT02934958|Experimental|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
11265568|NCT02934945|Other|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
11265569|NCT02934945|Other|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
11265570|NCT02934932|Experimental|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
11265571|NCT02934932|Experimental|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
11265572|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
11265573|NCT02934919|Experimental|nalmefene|
11265574|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
11265575|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
11265576|NCT02934893|Experimental|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
11265577|NCT02934893|Active Comparator|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
11265578|NCT02934893|No Intervention|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
11265579|NCT02934880|Experimental|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
11265580|NCT02934880|Active Comparator|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
11265581|NCT02934867|Experimental|CONTARM|Protocol phone advice
11265582|NCT02934867|Other|CONTHAB|Usual phone advice
11265583|NCT02934854||Observation|Patients with the Creatine Deficiency Syndromes or high-grade suspicion for the Creatine Deficiency Syndromes
11265584|NCT02934841|Experimental|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
11265585|NCT02934841|Sham Comparator|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
11265586|NCT02934828|Experimental|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
11265587|NCT02934828|Active Comparator|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
11265588|NCT02934815|Experimental|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
11265589|NCT02934815|No Intervention|Control group|No intervention
11265590|NCT02934789|Active Comparator|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
11265591|NCT02934789|Active Comparator|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
11265592|NCT02934776|Experimental|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
11265593|NCT02934763|Placebo Comparator|Placebo|Saline solution by target controlled infusion
11265594|NCT02934763|Active Comparator|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
11265595|NCT02934763|Active Comparator|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
11265596|NCT02934750|Experimental|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
11265597|NCT02934750|No Intervention|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
11265598|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.
~Interventions:
~Self sample from vagina using Rover's Evalyn Brush
~Self sample from the oral cavity using COPAN's FloqSwab
~Questionnaire"
11265651|NCT02934373|Active Comparator|A New Sound Processor|Sound Processor is the next generation sound processor.
11265599|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine
~Interventions:
~Self sample from vagina using Rover's Evalyn Brush
~Self sample from the oral cavity using COPAN's FloqSwab
~Questionnaire"
11265600|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
11265601|NCT02934685|Experimental|hypofraction|70 Gy in 28 fractions over 5.6 weeks
11265602|NCT02934685|Active Comparator|convention|80Gy in 40 fractions over 8 weeks
11265603|NCT02934659|Experimental|Investigational|Intervention - Atlas Knee System device for medial knee osteoarthritis
11265604|NCT02934646|Experimental|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
11265605|NCT02934633|Experimental|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
11265606|NCT02934633|Active Comparator|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
11265607|NCT02934620|Experimental|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
11265608|NCT02934620|Active Comparator|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
11265609|NCT02934607|Active Comparator|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
11265610|NCT02934607|Experimental|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
11265611|NCT02934607|Active Comparator|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
11265612|NCT02934607|Experimental|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
11265613|NCT02934594||Group A|Motor function intact group: received palliative decompression
11265614|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
11265615|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
11265616|NCT02934568|Experimental|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
11265617|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
11265618|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
11265619|NCT02934542|No Intervention|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
11265620|NCT02934542|Experimental|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
11265621|NCT02934529|Active Comparator|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab
~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.
~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
11265622|NCT02934529|Experimental|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab
~Administration every 2 weeks for a maximum of 12 cycles
~Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,
~Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
11265623|NCT02934529|Experimental|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.
~Folinic acid, 5-FU, Bevacizumab
~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.
~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
11265624|NCT02934529|Active Comparator|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013
~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice
~Administration until progression occurs in the third line or unacceptable toxicity"
11265625|NCT02934529|Experimental|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly
~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity
~or depending on the patient's general condition and the study physician's decision
~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
11265626|NCT02934516|Experimental|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
11265627|NCT02934516|Active Comparator|Classic push method|Cesarean section with push method
11265652|NCT02934373|No Intervention|Subject's own sound processor|
11265684|NCT02934178|Placebo Comparator|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
11265628|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.
~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.
~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.
~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
11265629|NCT02934490|Experimental|Treatment group|
11265630|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
11265631|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
11265632|NCT02934464|Experimental|A|"RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle
~PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
11265633|NCT02934464|Active Comparator|B|"FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.
~mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.
~XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
11265634|NCT02934438|Active Comparator|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
11265635|NCT02934438|Placebo Comparator|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
11265636|NCT02934425|Placebo Comparator|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
11265637|NCT02934425|Experimental|High pork protein breakfast|High pork protein breakfast
11265638|NCT02934412|Experimental|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
11265639|NCT02934412|Experimental|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
11265640|NCT02934412|Experimental|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
11265641|NCT02934412|Experimental|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
11265642|NCT02934412|Experimental|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
11265643|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
11265644|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.
~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control
~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
11265645|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.
~Study subjects: Subjects with established primary (adrenal) AI"
11265646|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.
~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
11265647|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.
~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.
~Study subjects: Subjects with suspected PHA."
11265648|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.
~Study subjects: Adult subjects with established clinical and biochemical GHD."
11265649|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.
~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
11265653|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
11265654|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
11265655|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
11265656|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
11265657|NCT02934334||MDD|Major Depressive Disorder
11265658|NCT02934321|Active Comparator|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
11265659|NCT02934321|Experimental|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
11265660|NCT02934308|Experimental|ICU patients|
11265661|NCT02934295|Experimental|Pregnant women|
11265662|NCT02934269|Experimental|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
11265663|NCT02934269|Experimental|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
11265664|NCT02934269|Experimental|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
11265665|NCT02934269|Experimental|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
11265666|NCT02934269|Experimental|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
11265667|NCT02934269|Experimental|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
11265668|NCT02934256|Experimental|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
11265669|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
11265670|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
11265671|NCT02934230|Experimental|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
11265672|NCT02934230|No Intervention|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
11265673|NCT02934217|Experimental|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
11265674|NCT02934217|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
11265675|NCT02934204|Experimental|MTX and Temozolomide|"Induction therapy:
~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles
~Consolidation therapy:
~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
11265676|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
11265677|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
11265678|NCT02934178|Experimental|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
11265679|NCT02934178|Experimental|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
11265680|NCT02934178|Experimental|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
11265681|NCT02934178|Experimental|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
11265682|NCT02934178|Placebo Comparator|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
11265683|NCT02934178|Placebo Comparator|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
11265685|NCT02934178|Placebo Comparator|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
11265686|NCT02934165|Experimental|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
11265687|NCT02934165|Active Comparator|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
11265688|NCT02934152|Experimental|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
11265689|NCT02934152|Experimental|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
11265690|NCT02934152|Active Comparator|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
11265691|NCT02934139|Experimental|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
11265692|NCT02934139|Experimental|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
11265693|NCT02934139|Experimental|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
11265694|NCT02934139|Experimental|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
11265695|NCT02934139|Placebo Comparator|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
11265696|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
11265697|NCT02934113|No Intervention|Control|
11265698|NCT02934113|Experimental|iOTA and HWPP|
11265699|NCT02934113|Experimental|HWPP|
11265700|NCT02934100|Active Comparator|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
11265701|NCT02934100|Active Comparator|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
11265702|NCT02934100|Active Comparator|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
11265703|NCT02934100|Sham Comparator|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
11265704|NCT02934087|Active Comparator|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
11265705|NCT02934087|Active Comparator|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
11265706|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
11265707|NCT02934061|Experimental|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
11265708|NCT02934061|Active Comparator|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
11265709|NCT02934048|Experimental|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
11265710|NCT02934048|Experimental|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
11265711|NCT02934048|Experimental|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
11265712|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
11265713|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
11265714|NCT02934022|Other|Maraviroc|
11265715|NCT02934009|Experimental|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement. The measurement will be repeated on three different days with each patient.
11265716|NCT02934009|Experimental|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
11265717|NCT02933996|Experimental|TEAS+GA group|"The patients of TEAS+GA group will receive TEAS therapy in perioperative period.
~GA: general anesthesia"
11265718|NCT02933996|Sham Comparator|Sham TEAS+GA group|The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
11265719|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
11265720|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
11265721|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
11265763|NCT02933749|Active Comparator|The sitting|The sitting position Device sCtO2 Device BIS
11265722|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
11265723|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).
~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
11265724|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
11265725|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
11265726|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
11265727|NCT02933918|Experimental|Probiotics|
11265728|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
11265729|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
11265730|NCT02933892|Active Comparator|Transradial Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the arm access site (transradial access).
11265731|NCT02933892|Active Comparator|Transfemoral Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the inner thigh access site (transfemoral access).
11265732|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
11265733|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
11265734|NCT02933866|Experimental|DSXS topical|applied once daily for 28 days
11265735|NCT02933866|Placebo Comparator|Vehicle topical|applied once daily for 28 days
11265736|NCT02933853|Experimental|Faster Aspart|
11265737|NCT02933853|Active Comparator|Insulin Aspart|
11265738|NCT02933840|Experimental|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
11265739|NCT02933840|No Intervention|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
11265740|NCT02933827|Experimental|Low dose:|ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)
11265741|NCT02933827|Experimental|Middle dose|ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)
11265742|NCT02933827|Experimental|High dose|ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)
11265743|NCT02933814|No Intervention|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
11265744|NCT02933814|Experimental|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
11265745|NCT02933801|Experimental|Arm A: ODM-201|600mg ODM-201 BID (twice daily) and Best Supportive Care until progression
11265746|NCT02933801|Placebo Comparator|Arm B: Placebo|Placebo BID (twice daily) and Best Supportive Care until progression
11265747|NCT02933788|Experimental|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
11265748|NCT02933788|Active Comparator|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
11265749|NCT02933775|Experimental|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
11265750|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
11265751|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
11265752|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
11265753|NCT02933762|Experimental|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
11265754|NCT02933762|Experimental|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (<=) 600 mg] of JNJ-54175446, to be determined.
11265755|NCT02933762|Experimental|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (<= 600 mg) of JNJ-54175446, to be determined.
11265756|NCT02933762|Experimental|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
11265757|NCT02933762|Experimental|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
11265758|NCT02933762|Experimental|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
11265759|NCT02933762|Experimental|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
11265760|NCT02933762|Experimental|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
11265761|NCT02933762|Experimental|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
11265762|NCT02933762|Experimental|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
11265802|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
11265764|NCT02933749|Active Comparator|The prone|The prone position Device sCtO2 Device BIS
11265765|NCT02933736|Experimental|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:
~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection
~Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection
~Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection"
11265766|NCT02933723|Experimental|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
11265767|NCT02933723|Active Comparator|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
11265768|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
11265769|NCT02933697|Active Comparator|Apixaban|2.5 mg apixaban twice daily for 6 to 60 months
11265770|NCT02933697|Active Comparator|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 6 to 60 months
11265771|NCT02933684|Experimental|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
11265772|NCT02933684|Placebo Comparator|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
11265773|NCT02933671|Experimental|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
11265774|NCT02933671|Placebo Comparator|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
11265775|NCT02933658|Experimental|Reference1|single(Reference1) -> combination(Reference1+Reference2)
11265776|NCT02933658|Experimental|Reference2|single(Reference2) -> combination(Reference1+Reference2)
11265777|NCT02933645|Active Comparator|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
11265778|NCT02933645|Placebo Comparator|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.
~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
11265779|NCT02933632|Active Comparator|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
11265780|NCT02933632|Active Comparator|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
11265781|NCT02933606|Experimental|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
11265782|NCT02933606|Experimental|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
11265783|NCT02933606|Experimental|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
11265784|NCT02933606|Placebo Comparator|Placebo b.i.d.|Suspension administered orally for 12 weeks.
11265785|NCT02933593|Active Comparator|labetalol|labetalol
11265786|NCT02933593|Active Comparator|hydralazine|Hydralazine
11265787|NCT02933593|Active Comparator|nifedipine|nifedipine
11265788|NCT02933580|Experimental|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.
11265789|NCT02933580|Experimental|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.
11265790|NCT02933580|Experimental|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.
11265791|NCT02933580|Experimental|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.
11265792|NCT02933567|Experimental|CSC OnDemand Pilo|Pilot Intervention
11265793|NCT02933554|Experimental|NASH- Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
11265794|NCT02933528|Experimental|Dsxs topical product|treatment with DSXS once daily for 28 days
11265795|NCT02933515|Experimental|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
11265796|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
11265797|NCT02933489|Experimental|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
11265798|NCT02933489|Experimental|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
11265799|NCT02933476|Experimental|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
11265800|NCT02933463|Experimental|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
11265801|NCT02933463|Active Comparator|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
11265804|NCT02933437|Experimental|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
11265805|NCT02933424|No Intervention|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
11265806|NCT02933424|Experimental|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
11265807|NCT02933424|Experimental|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
11265808|NCT02933424|Experimental|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
11265809|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
11265810|NCT02933398|Active Comparator|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
11265811|NCT02933398|Active Comparator|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
11265812|NCT02933385|Experimental|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
11265813|NCT02933385|Experimental|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
11265814|NCT02933385|Experimental|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
11265815|NCT02933385|Experimental|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
11265816|NCT02933385|No Intervention|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
11265817|NCT02933372|Experimental|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
11265818|NCT02933372|Experimental|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
11265819|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups [7].
11265820|NCT02933333|Experimental|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
11265821|NCT02933333|Experimental|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
11265822|NCT02933333|Experimental|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
11265823|NCT02933320|Experimental|Part A: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy)
11265824|NCT02933320|Experimental|Part B: Arm 1: BI-1206 single agent expansion phase|Arm 1 will be an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A. This expansion will include a minimum of 12 chronic lymphocytic leukaemia (CLL) and six mantle cell lymphoma (MCL) patients
11265825|NCT02933320|Experimental|Part B: Arm 2: combination of BI-1206 with Rituximab|Arm 2 will be an investigation of combination treatment of BI-1206 with Rituximab. Arm 2 will involve an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts) and subsequent expansion of up to 25 patients at the identified recommended combination dose. This expansion will include a minimum of 12 CLL and six mantle cell MCL patients. CLL patients recruited to the expansion will receive one rituximab infusion, one week before commencing the four weeks of combination induction therapy.
11265826|NCT02933307|No Intervention|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
11265827|NCT02933307|Experimental|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
11265828|NCT02933307|Experimental|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
11265829|NCT02933294|Active Comparator|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
11265830|NCT02933294|Active Comparator|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
11265831|NCT02933281|Experimental|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
11265832|NCT02933281|Experimental|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
11265833|NCT02933281|Experimental|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
11265834|NCT02933281|Experimental|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
11265835|NCT02933281|Experimental|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
11265836|NCT02933281|Experimental|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
11265837|NCT02933281|Experimental|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
11265838|NCT02933281|Experimental|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
11265839|NCT02933281|Active Comparator|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
11265840|NCT02933268|Active Comparator|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality > 300 mOsmo/kg
11265841|NCT02933268|Active Comparator|High water intake|Personalised daily water intake prescription to achieve target urine osmolality < 270 mOsm/kg.
11265842|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F every 2 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo sigmoidoscopies on week 9 and restaging scans on week 12. If no PD, option to continue treatment every 2 weeks until intolerance or progression. Option to extend nivolumabinterval to 4 weeks after 1 year
11265843|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Patients will undergo prostatectomy on week 9.
11265844|NCT02933242|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy
11265845|NCT02933229|Experimental|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.
~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
11265846|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
11265847|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
11265848|NCT02933190|Other|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
11265849|NCT02933177|Experimental|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
11265850|NCT02933177|Experimental|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
11265851|NCT02933164|Experimental|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
11265852|NCT02933151|Other|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
11265853|NCT02933151|Other|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
11265854|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
11265855|NCT02933125|Experimental|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
11265856|NCT02933125|Active Comparator|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
11265857|NCT02933112|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
11265858|NCT02933099|Experimental|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
11265859|NCT02933099|Active Comparator|Control arm|palonosetron+dexamethasone
11265860|NCT02933086|Experimental|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
11265861|NCT02933086|Experimental|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
11265862|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
11265863|NCT02933060|Experimental|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
11265864|NCT02933060|Sham Comparator|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
11265865|NCT02933047|Active Comparator|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
11265866|NCT02933047|Placebo Comparator|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
11265867|NCT02933034|Experimental|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
11265868|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
11265869|NCT02933008|Experimental|aNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
11265870|NCT02933008|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
11265871|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
11265872|NCT02932969|Experimental|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
11265873|NCT02932969|Experimental|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
11265874|NCT02932969|Experimental|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
11265875|NCT02932956|Experimental|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
11265876|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11266447|NCT02929147|Experimental|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
11265877|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
11265878|NCT02932930|Active Comparator|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.
~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
11265879|NCT02932930|Placebo Comparator|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.
~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
11265880|NCT02932917|Experimental|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
11265881|NCT02932904|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
11265882|NCT02932904|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
11265883|NCT02932904|Active Comparator|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
11265884|NCT02932904|Placebo Comparator|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
11265885|NCT02932891|Experimental|DSXS topical|active treatment
11265886|NCT02932878|Experimental|DSXS topical|administered twice daily for 28 days
11265887|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
11265888|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
11265889|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
11265890|NCT02932852|Active Comparator|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
11265891|NCT02932852|Active Comparator|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
11265892|NCT02932852|Active Comparator|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
11265893|NCT02932839|Experimental|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
11265894|NCT02932826|Experimental|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
11265895|NCT02932826|Active Comparator|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
11265896|NCT02932813|Experimental|Intervention Group|"THINK intervention:
~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
11265897|NCT02932813|No Intervention|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
11265898|NCT02932800|Active Comparator|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
11265899|NCT02932800|Active Comparator|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
11265900|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
11265901|NCT02932787|No Intervention|Control|
11265902|NCT02932774|Experimental|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
11265903|NCT02932774|Active Comparator|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
11265904|NCT02932774|Placebo Comparator|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
11265905|NCT02932761|Experimental|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
11265941|NCT02932501||MRONJ|"Patients diagnosed of medication-related osteonecrosis of the jaw (MRONJ). Treatment strategies vary depending on the stage of MRONJ and can be of different nature as:
~Conservative treatment Surgical treatment Adjuvant non-surgical treatment"
11266629|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
11265906|NCT02932761|Placebo Comparator|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
11265907|NCT02932748|Experimental|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
11265908|NCT02932748|Experimental|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
11265909|NCT02932748|Active Comparator|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
11265910|NCT02932722|Sham Comparator|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
11265911|NCT02932722|Active Comparator|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
11265912|NCT02932722|Active Comparator|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
11265913|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
11265914|NCT02932696|Experimental|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.
~Intervention: Cardiac training program"
11265915|NCT02932696|No Intervention|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
11265916|NCT02932683|Experimental|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
11265917|NCT02932683|No Intervention|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
11265918|NCT02932670|Active Comparator|costoclavicular inflaclavicular block|costoclavicular block with similar volume
11265919|NCT02932670|Experimental|costoclavicular block|costoclavicular block with decreasing volume
11265920|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
11265921|NCT02932631|Active Comparator|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:
~stretching, strengthening and/or mobilization;
~functional training of the affected muscles;
~functional training of the paretic limb."
11265922|NCT02932631|Experimental|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
11265923|NCT02932618|Experimental|On-demand Treatment|Participants will receive treatment for non-surgical bleeding episodes over a 12 to 18-month period.
11265924|NCT02932618|Experimental|Elective Surgery|12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
11265925|NCT02932618|Experimental|Emergency Surgery|Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
11265926|NCT02932605|Experimental|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
11265927|NCT02932605|Placebo Comparator|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
11265928|NCT02932592|Experimental|Dysglycemic group|"Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.
~Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus."
11265929|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
11265930|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
11265931|NCT02932566|Active Comparator|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
11265932|NCT02932566|Placebo Comparator|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
11265933|NCT02932553|Experimental|BVS and OMT|Optimal medical treatment + BVS implantation
11265934|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
11265935|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
11265936|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
11265937|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
11265938|NCT02932527|Experimental|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
11265939|NCT02932527|Other|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
11265942|NCT02932488|Experimental|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.
~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
11265943|NCT02932475|Active Comparator|Treatment|Metformin 1000 mg twice a day
11265944|NCT02932475|Sham Comparator|Placebo|Placebo, identical to Metformin
11265945|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
11265946|NCT02932462|Placebo Comparator|Placebo|Vehicle
11265947|NCT02932436|Experimental|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
11265948|NCT02932436|Experimental|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
11265949|NCT02932423|Other|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
11265950|NCT02932423|Other|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
11265951|NCT02932410|Experimental|Macitentan|Macitentan is administered once daily via oral route
11265952|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and i.v./s.c. prostanoids.
11265953|NCT02932397|Active Comparator|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
11265954|NCT02932397|Placebo Comparator|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
11265955|NCT02932384|Active Comparator|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
11265956|NCT02932384|Experimental|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
11265957|NCT02932371|Experimental|Cardiac Surgery|
11265958|NCT02932358|Active Comparator|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
11265959|NCT02932358|Active Comparator|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
11265960|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
11265961|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
11265962|NCT02932332|Active Comparator|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
11265963|NCT02932332|Active Comparator|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
11265964|NCT02932332|Sham Comparator|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
11265965|NCT02932332|Sham Comparator|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
11265966|NCT02932319|Active Comparator|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
11265967|NCT02932319|Sham Comparator|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
11265968|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
11265969|NCT02932306|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
11265970|NCT02932293|Experimental|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is <500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is >500 IU/ml.
11265971|NCT02932293|Experimental|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is <500 IU/ml or (b) 8 weeks if HCV VL on day 2 is >500 IU/ml.
11265972|NCT02932280|Experimental|Neratinib|There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
11265973|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
11265974|NCT02932254|Active Comparator|Magnesium Sulfate|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.
~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.
~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
11265975|NCT02932254|Placebo Comparator|Saline Solution|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.
~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.
~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
11265976|NCT02932241|Experimental|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
11265977|NCT02932241|No Intervention|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
11265978|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
11265979|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
11265980|NCT02932215|Experimental|All participants|All participants will receive open label lorcaserin
11265981|NCT02932202|Experimental|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
11265982|NCT02932202|Placebo Comparator|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
11265983|NCT02932189|No Intervention|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
11265984|NCT02932189|Experimental|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.
~Device: K5 Power Breath"
11265985|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
11265986|NCT02932150|Experimental|TAF (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive TAF 25 mg tablet for 24 weeks
11265987|NCT02932150|Placebo Comparator|Placebo (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive placebo tablet for 24 weeks
11265988|NCT02932150|Experimental|TAF (Cohort 2 Group 1)|Participants (6 to < 12 years) weighing ≥ 25 kg will receive TAF 25 mg tablet for 24 weeks
11265989|NCT02932150|Experimental|TAF (Cohort 2 Group 2)|Participants (6 to < 12 years) weighing ≥ 17 kg to < 25 kg will receive TAF 15 mg tablet for 24 weeks
11265990|NCT02932150|Experimental|TAF (Cohort 2 Group 3)|Participants (2 to < 6 years) weighing < 17 kg who are unable to swallow a tablet will receive oral granules of TAF (dose to be determined) for 24 weeks.
11265991|NCT02932150|Experimental|TAF (Cohort 2 Placebo)|Participants will receive matching placebo of TAF (tablet or oral granules) for 24 weeks.
11265992|NCT02932150|Experimental|Open-Label TAF|Following 24 weeks of blinded randomized treatment, participants will be eligible to participate in an open-label extension phase to receive TAF for an additional 216 weeks.
11265993|NCT02932137|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
11265994|NCT02932137|No Intervention|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
11265995|NCT02932124||1|manual chest compressions
11265996|NCT02932124||2|mechanical chest compression
11265997|NCT02932111|Experimental|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
11265998|NCT02932111|Placebo Comparator|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
11266029|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
11265999|NCT02932098|Experimental|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
11266000|NCT02932098|Active Comparator|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
11266001|NCT02932085|Active Comparator|rTMS + Wash-out period + Sham|"Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)
~Two weeks wash-out period
~Five consecutive daily sham stimulation sessions"
11266002|NCT02932085|Sham Comparator|Sham + Wash-out period + rTMS|"Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)
~Two weeks wash-out period
~Five consecutive daily repetitive transcranial magnetic stimulation sessions"
11266003|NCT02932059|Experimental|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
11266004|NCT02932059|Experimental|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
11266005|NCT02932059|Experimental|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
11266006|NCT02932059|Experimental|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
11266007|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
11266008|NCT02932033|Active Comparator|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
11266009|NCT02932033|Experimental|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
11266010|NCT02932020|Experimental|Group A|"Randomized 10 subjects
~Visit 1:
~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
11266011|NCT02932020|Other|Group B|"Randomized 10 subjects
~Visit 1:
~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).
~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
11266012|NCT02932007|Experimental|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
11266013|NCT02931994|No Intervention|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
11266014|NCT02931994|Active Comparator|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
11266015|NCT02931994|Active Comparator|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
11266016|NCT02931994|No Intervention|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
11266017|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
11266018|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.
~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
11266019|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.
~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
11266020|NCT02931955||Control Group|"The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.
~The patients will receive usual standard of care and no intervention."
11266021|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
11266022|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
11266023|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
11266024|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
11266025|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
11266026|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
11266027|NCT02931929|Other|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
11266028|NCT02931916||healthy group|recruited for evaluation of system reliability
11266030|NCT02931903|Experimental|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
11266031|NCT02931903|Active Comparator|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
11266032|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
11266033|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
11266034|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
11266035|NCT02931877|Experimental|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
11266036|NCT02931877|Active Comparator|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
11266037|NCT02931864|No Intervention|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
11266038|NCT02931864|Experimental|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
11266039|NCT02931864|Active Comparator|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
11266040|NCT02931864|Active Comparator|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
11266041|NCT02931851|Placebo Comparator|Placebo|Standard Information
11266042|NCT02931851|Active Comparator|Intervention|Professionally developed website for relatives of ICU patients
11266043|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
11266044|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
11266045|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
11266046|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
11266047|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
11266048|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
11266049|NCT02931825|Experimental|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
11266050|NCT02931825|No Intervention|Control|No intervention (what is done currently)
11266051|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
11266052|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
11266053|NCT02931812||Healthy subjects|30 healthy subjects to compare
11266054|NCT02931799|Experimental|Nurse Follow-Up and Electronic Monitoring|
11266055|NCT02931799|Active Comparator|Minimal Intervention|
11266056|NCT02931786|Active Comparator|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
11266057|NCT02931786|Active Comparator|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
11266058|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
11266059|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
11266060|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
11266061|NCT02931760|Active Comparator|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
11266062|NCT02931760|Active Comparator|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
11266063|NCT02931747|Placebo Comparator|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
11266064|NCT02931747|Active Comparator|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
11266065|NCT02931747|Active Comparator|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
11266066|NCT02931734|Active Comparator|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
11266067|NCT02931734|Active Comparator|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
11266068|NCT02931734|Active Comparator|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
11266069|NCT02931734|Active Comparator|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
11266070|NCT02931734|Active Comparator|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
11266071|NCT02931734|Active Comparator|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
11266072|NCT02931734|Active Comparator|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
11266073|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
11266074|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
11266179|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
11266180|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
11266075|NCT02931708|Experimental|DFES group|"Diaphragm Functional Electrical Stimulation:
~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.
~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
11266076|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum
~ECG
~circulating sex hormones levels"
11266077|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum
~ECG
~circulating sex hormones levels"
11266078|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
11266079|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
11266080|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
11266081|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
11266082|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
11266083|NCT02931656|Experimental|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
11266084|NCT02931656|Active Comparator|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
11266085|NCT02931643|Placebo Comparator|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
11266086|NCT02931643|Experimental|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
11266087|NCT02931630|Experimental|HP/HF|Whey protein powder / High fiber bread
11266088|NCT02931630|Experimental|HP/LF|Whey protein powder / Low fiber bread
11266089|NCT02931630|Experimental|LP/HF|Maltodextrin powder / High fiber bread
11266090|NCT02931630|Experimental|LP/LF|Maltodextrin powder / Low fiber bread
11266091|NCT02931617|Active Comparator|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
11266092|NCT02931617|Experimental|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
11266093|NCT02931604|Experimental|Sinus irrigation|Sinus irrigation intervention
11266094|NCT02931591|Active Comparator|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
11266095|NCT02931591|Placebo Comparator|GH+Placebo|Children will be given both GH and Placebo for 6 months
11266096|NCT02931578|Active Comparator|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
11266097|NCT02931578|Active Comparator|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
11266098|NCT02931578|Active Comparator|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
11266099|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
11266100|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
11266101|NCT02931552|Experimental|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
11266102|NCT02931552|No Intervention|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
11266103|NCT02931539|Experimental|Maribavir Treatment|Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.
11266104|NCT02931539|Active Comparator|Investigator-Assigned Treatment|Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
11266105|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
11266106|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
11266107|NCT02931513||PBC patients|Patients with primary biliary cholangitis
11266108|NCT02931487|Experimental|Attentional Bias Modification|ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
11266109|NCT02931487|Sham Comparator|Sham comparator|Sham condition without modification of attentional bias. These trials are identical in structure to the ABM trials with the exception that target probes replaced negative and positive images with equal frequency.
11266110|NCT02931474|Placebo Comparator|Placebo|Salt Water Solution
11266111|NCT02931474|Experimental|Tesamorelin|Growth Hormone-Releasing
11266112|NCT02931461|Experimental|needle Procore ®|
11266113|NCT02931461|Active Comparator|needle Cook®|
11266114|NCT02931435|Active Comparator|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
11266115|NCT02931435|Sham Comparator|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
11266116|NCT02931422|Experimental|Low Financial Incentive|Conditional cash transfer upon HIV testing
11266117|NCT02931422|Experimental|Medium Financial Incentive|Conditional cash transfer upon HIV testing
11266118|NCT02931422|Experimental|High Financial Incentive|Conditional cash transfer upon HIV testing
11266119|NCT02931409|Experimental|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
11266120|NCT02931409|Active Comparator|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
11266121|NCT02931396|Experimental|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
11266122|NCT02931396|No Intervention|Control|Participants will be asked to continue their activities of daily living as usual.
11266123|NCT02931383|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
11266124|NCT02931383|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
11266125|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
11266126|NCT02931357|Experimental|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
11266127|NCT02931357|Active Comparator|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
11266128|NCT02931344|Experimental|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
11266129|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
11266130|NCT02931318|Experimental|Nevsehir|People Living in the City Center of Nevşehir
11266131|NCT02931305|Experimental|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
11266132|NCT02931305|Placebo Comparator|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
11266133|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
11266134|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
11266135|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
11266136|NCT02931240|Experimental|Treatment|Treatment with the Revivent TC System
11266137|NCT02931240|No Intervention|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
11266138|NCT02931227|Experimental|Brain-injured group|
11266139|NCT02931227|Experimental|Hypothermia group|
11266140|NCT02931227|Experimental|Hyperthermia group|
11266141|NCT02931227|Experimental|PICCO group|
11266142|NCT02931214|Experimental|GMI-1359|Dose escalation
11266143|NCT02931214|Experimental|Placebo|Dose escalation
11266144|NCT02931201|Experimental|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
11266145|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
11266146|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
11266147|NCT02931175|Experimental|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
11266148|NCT02931175|Experimental|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
11266181|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
11266630|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
11266149|NCT02931162|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
11266150|NCT02931162|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
11266151|NCT02931149|Experimental|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
11266152|NCT02931136|Active Comparator|treatment group|Huperzine A treatment.
11266153|NCT02931136|Placebo Comparator|Placebo group|The placebo in 52 weeks.
11266154|NCT02931123|No Intervention|standard|
11266155|NCT02931123|Experimental|treatment|rifaximine and lattulose plus low proteine diet
11266156|NCT02931110|Experimental|CBL0137 Dose Escalation|"Dose Level 1: 150mg/m2, IV
~Dose Level 2: 180mg/m2, IV
~Dose Level 3: 240mg/m2, IV
~Dose Level 4: 320mg/m2, IV
~Dose Level 5: 400mg/m2, IV
~Dose Level 6: 540mg/m2, IV
~Dose Level 7: 650mg/m2, IV
~Dose Level 8: 780mg/m2, IV
~Dose Level 9: 950mg/m2, IV
~Dose Level 10: 1150mg/m2, IV
~Dose Level 11: 1400mg/m2, IV
~Dose Level 12: 1700mg/m2, IV
~Dose Level 13: 2000mg/m2, IV
~Dose Level 14: 2400mg/m2, IV
~Dose Level 15: 2900mg/m2, IV
~Dose Level 16: 3500mg/m2, IV"
11266157|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
11266158|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
11266159|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
11266160|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
11266161|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
11266162|NCT02931071|Experimental|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
11266163|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
~The knee-extension resistance training exercise is performed with an elastic exercise band."
11266164|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
~The knee-extension resistance training exercise is performed with an elastic exercise band."
11266165|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
~The knee-extension resistance training exercise is performed with an elastic exercise band."
11266166|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
11266167|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
11266168|NCT02931032|Experimental|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.
~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
11266169|NCT02931019|Experimental|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.
~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
11266170|NCT02931019|Experimental|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
11266171|NCT02931006|Placebo Comparator|control|
11266172|NCT02931006|Active Comparator|experimental|
11266173|NCT02930993|Experimental|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.
~CAR T dosage ranging from 5×10^4 /kg to 1×10^7 /kg will be tested ."
11266174|NCT02930980|Experimental|Investigational Software|Investigational Software loaded on Micra device
11266175|NCT02930967|Experimental|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.
~CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested."
11266176|NCT02930954|Active Comparator|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
11266177|NCT02930954|Experimental|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
11266178|NCT02930954|Experimental|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
11266182|NCT02930902|Active Comparator|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
11266183|NCT02930902|Experimental|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
11266184|NCT02930889|Experimental|Prostate Artery Embolization|Prostate Artery Embolization
11266185|NCT02930876|Experimental|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
11266186|NCT02930876|Experimental|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
11266187|NCT02930876|No Intervention|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
11266188|NCT02930863|Active Comparator|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
11266189|NCT02930863|Experimental|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
11266190|NCT02930850|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter sensor for measurement of hemoglobin.
11266191|NCT02930837|Experimental|alteplase|
11266192|NCT02930824|Experimental|Genotype guided treatment|For patients randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
11266193|NCT02930824|No Intervention|Conventional treatment|For patients randomized to the genotype-supported arm a no genotype will be provided to physicians to assist in dosing.
11266194|NCT02930811|Experimental|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
11266195|NCT02930811|Placebo Comparator|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
11266196|NCT02930798|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11266197|NCT02930785|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11266198|NCT02930772|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11266199|NCT02930759|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11266200|NCT02930746|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11266201|NCT02930733|Active Comparator|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
11266202|NCT02930733|Placebo Comparator|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
11266203|NCT02930707|Active Comparator|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
11266204|NCT02930707|Placebo Comparator|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
11266205|NCT02930694|Experimental|Group 1: Treatment Sequence AB|Participants will receive Treatment A [JNJ-54175446, 50 milligram (mg) capsule] on Day 1 of period 1 followed by Treatment B [JNJ-54175446, 50 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
11266206|NCT02930694|Experimental|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
11266207|NCT02930694|Experimental|Group 2: Treatment Sequence CD|Participants will receive Treatment C [JNJ-54175446, 100 mg capsule] on Day 1 of period 1 followed by Treatment D [JNJ-54175446, 100 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
11266208|NCT02930694|Experimental|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
11266209|NCT02930681|Placebo Comparator|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
11266210|NCT02930681|Experimental|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
11266211|NCT02930681|Experimental|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
11266212|NCT02930668|Placebo Comparator|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.
~Subjects will take 2 capsules three times a day, 30 mins before meals."
11266213|NCT02930668|Experimental|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg
~Subjects will take 2 capsules three times a day, 30 mins before meals."
11266214|NCT02930668|Experimental|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg
~Subjects will take 2 capsules three times a day, 30 mins before meals."
11266215|NCT02930655|Experimental|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
11266216|NCT02930655|Experimental|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
11266217|NCT02930642|Experimental|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
11266218|NCT02930642|Active Comparator|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
11266219|NCT02930642|No Intervention|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
11266220|NCT02930616|Experimental|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
11266221|NCT02930616|Active Comparator|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
11266222|NCT02930603||Control|Control: Healthy child
11266223|NCT02930603||Experimental|Patients with Developmental Disabilities
11266224|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
11266225|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
11266226|NCT02930590|Active Comparator|Standard mattress|basic foam
11266227|NCT02930564|Experimental|a milk fat or gluten challenge|patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.
11266228|NCT02930551|Active Comparator|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
11266229|NCT02930551|Placebo Comparator|Isotonic Saline|Isotonic Saline 2 ml Injection
11266230|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
11266231|NCT02930525|Active Comparator|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
11266232|NCT02930525|Experimental|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
11266233|NCT02930512||patients with idiopathic Parkinson's disease|
11266234|NCT02930499|Experimental|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
11266235|NCT02930499|Active Comparator|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
11266236|NCT02930486|Active Comparator|ZipTight|ZipTight suture endobutton
11266237|NCT02930486|Active Comparator|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
11266238|NCT02930473|Experimental|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
11266239|NCT02930473|Active Comparator|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
11266240|NCT02930447|Experimental|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
11266241|NCT02930447|No Intervention|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
11266242|NCT02930434|Active Comparator|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
11266243|NCT02930434|Active Comparator|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
11266244|NCT02930421|Experimental|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
11266245|NCT02930421|No Intervention|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
11266246|NCT02930395||professional rugby players|
11266247|NCT02930382|Experimental|BAROREFLEX|
11266248|NCT02930369|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
11266249|NCT02930369|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
11266250|NCT02930356|Experimental|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
11266251|NCT02930356|Experimental|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
11266252|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
11266253|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
11266254|NCT02930330|Experimental|Interval|"2x / week INT
~2x / week CONT"
11266255|NCT02930330|Active Comparator|Continuous|4x / week CONT
11266256|NCT02930317|Experimental|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
11266257|NCT02930317|Experimental|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
11266258|NCT02930304|Experimental|first physiotherapy|cold pack, TENS, exercise
11266259|NCT02930304|Experimental|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
11266260|NCT02930304|Experimental|third physiotherapy|cold pack, TENS, ESWT, exercise
11266261|NCT02930265|Active Comparator|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
11266262|NCT02930265|No Intervention|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
11266263|NCT02930252|Experimental|Niti-S Biliary ComVi Stent|"Device:
~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
11266264|NCT02930252|Active Comparator|Niti-S Stent (D-type)|"Device:
~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.
~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
11266265|NCT02930239|Experimental|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
11266266|NCT02930239|Active Comparator|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
11266267|NCT02930226|Experimental|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
11266268|NCT02930226|Experimental|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
11266269|NCT02930226|Experimental|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
11266270|NCT02930226|Experimental|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
11266271|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
11266272|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
11266273|NCT02930200|Active Comparator|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
11266274|NCT02930200|Active Comparator|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
11266304|NCT02929992|Experimental|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
11267192|NCT02924441|Experimental|Left Breast Lidocaine and calming music|Group 3 - left breast lidocaine & calming music
11266275|NCT02930200|Experimental|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
11266276|NCT02930174|Active Comparator|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
11266277|NCT02930174|Active Comparator|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
11266278|NCT02930161|Experimental|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
11266279|NCT02930161|Experimental|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
11266280|NCT02930161|Placebo Comparator|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
11266281|NCT02930148|Experimental|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
11266282|NCT02930148|No Intervention|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
11266283|NCT02930135|Experimental|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite
~Local anesthesia administration
~Isolation of tooth with rubber dam
~Opening of the cavity and the removal of undermined enamel
~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed
~Partial removal of carious dentin on the pulp wall.
~Washing the cavity and dryness
~Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)
~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
11266284|NCT02930135|Active Comparator|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite
~Local anesthesia administration
~Isolation of tooth with rubber dam
~Opening of the cavity and the removal of undermined enamel
~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed
~Partial removal of carious dentin on the pulp wall.
~Washing the cavity and dryness
~Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)
~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
11266285|NCT02930122|Experimental|Arm 1|Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury
11266286|NCT02930122|Placebo Comparator|Placebo Control|Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury
11266287|NCT02930109|Experimental|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour
~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.
~Phase II: maximum tolerated dose. given as a 1 hour infusion
~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
11266288|NCT02930096||pulsatility index mesured with doppler ultrasound|
11266289|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA>=2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
11266290|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA<2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
11266291|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA>=2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
11266292|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA<2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
11266293|NCT02930057|Experimental|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
11266294|NCT02930057|Other|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
11266295|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
11266296|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
11266297|NCT02930031|Experimental|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
11266298|NCT02930031|Active Comparator|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
11266299|NCT02930018|Placebo Comparator|Placebo|Drug vehicle only
11266300|NCT02930018|Experimental|NA-1, 2.6 mg/kg|Single intravenous infusion of NA-1 over 10 ± 1 minutes
11266301|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
11266302|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
11266303|NCT02929992|Experimental|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
11266719|NCT02927340|Experimental|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
11266305|NCT02929992|Active Comparator|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
11266306|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
11266307|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
11266308|NCT02929966|Placebo Comparator|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
11266309|NCT02929966|Experimental|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
11266310|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.
~chart review"
11266311|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
11266312|NCT02929940||PiZZ|Observational
11266313|NCT02929940||PiMZ|Observational
11266314|NCT02929940||Other AATD variants|Observational
11266315|NCT02929940||PiMM (Control)|Observational
11266316|NCT02929927|Experimental|2% NaOCl|Rubber dam isolation，tooth disinfection ，acess to the pulp of the chamber ,microbiological sample with two sterile paper points #20,then Mechanical preparation with NITIMTWO to 25#06 ,then use the kerr files hand instrument enlarger the apical to #40,and cleaned with 5 ml of 2.0% NaOCl between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2% NaOCl ,17% ethylene diamine tetra-acetic acid (EDTA) for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer ,then take the sample again,then drying the canal ,warm vertical condensation +AH-PLUS pasta,ZOE to seal the crown cavity ,one week later ,take crown restoration .Follow up at 1,7days ,3, 6,12 and 24 months.
11266317|NCT02929927|Experimental|PDT+2% NaOCl|Rubber dam isolation，tooth disinfection ，acess to the pulp of the chamber ,microbiological sample with two sterile paper points #20,then Mechanical preparation with NITIMTWO to 25#06 ,then use the kerr files hand instrument enlarger the apical to #40,and cleaned with 5 ml of 2.0% NaOCl between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2% NaOCl ,then17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer ,drying the canal ,PDT,then take the sample again,then drying the canal ,warm vertical condensation +AH-PLUS pasta,ZOE to seal the crown cavity ,one week later ,take crown restoration .Follow up at 1,7days ,3, 6,12 and 24 months.
11266318|NCT02929927|Experimental|PDT+1% NaOCl|Rubber dam isolation，tooth disinfection ，acess to the pulp of the chamber ,microbiological sample with two sterile paper points #20,then Mechanical preparation with NITIMTWO to 25#06 ,then use the kerr files hand instrument enlarger the apical to #40,and cleaned with 5 ml of 1.0% NaOCl between each endodontic file, At the end of the procedure, root canals were ultrasonic irrigated with 1.0% NaOClfor 1min, then17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer ,drying the canal,PDT,then take the sample again,then drying the canal ,warm vertical condensation +AH-PLUS pasta,ZOE to seal the crown cavity ,one week later ,take crown restoration .Follow up at 1,7days ,3, 6,12 and 24 months.
11266319|NCT02929914|Experimental|Control|Rubber dam isolation，tooth drying，remove caries incompletely,microbiological sample with otoscope curette,dentin wash with sodium 0.9% saline,sampling again.Indirect pulp treatment with calcium hydroxide(CH).Restoration with resin(Z350,3M);Follow up at 6,12 and 24 months.
11266320|NCT02929914|Experimental|PDT+CH|Rubber dam isolation，tooth drying，remove caries incompletely,microbiological sample with otoscope curette,disinfect the remaining dentin with antimicrobial photodynamic therapy(DENFOTEX PADplus),sampling again.Indirect pulp treatment with calcium hydroxide(CH).Restoration with resin(Z350,3M);Follow up at 6,12 and 24 months.
11266321|NCT02929901|Active Comparator|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
11266322|NCT02929901|Active Comparator|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
11266323|NCT02929901|Active Comparator|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
11266324|NCT02929901|Placebo Comparator|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
11266325|NCT02929888|Experimental|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
11266326|NCT02929888|Active Comparator|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
11266364|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
11266984|NCT02925663|Experimental|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
11266327|NCT02929875|Experimental|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:
~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
11266328|NCT02929875|No Intervention|Control (No intervention)|No educational intervention provided to subjects in control group
11266329|NCT02929862|Experimental|Single Agent 55716|
11266330|NCT02929849|Experimental|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
11266331|NCT02929849|Active Comparator|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
11266332|NCT02929849|Placebo Comparator|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
11266333|NCT02929836|Active Comparator|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
11266334|NCT02929836|Active Comparator|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
11266335|NCT02929836|Active Comparator|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
11266336|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
11266337|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
11266338|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
11266339|NCT02929810|Experimental|sleep extension|
11266340|NCT02929810|Active Comparator|sleep maintenance|
11266341|NCT02929797|Experimental|AKT + gemcitabine|gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
11266342|NCT02929797|Active Comparator|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
11266343|NCT02929784|Experimental|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
11266344|NCT02929784|Sham Comparator|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
11266345|NCT02929784|No Intervention|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
11266346|NCT02929771|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
11266347|NCT02929771|Active Comparator|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
11266348|NCT02929758|Active Comparator|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
11266349|NCT02929758|Active Comparator|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
11266350|NCT02929758|Other|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
11266351|NCT02929758|Other|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
11266352|NCT02929745|Experimental|10 HLA-Cw6+|HLA-Cw6+ patients will donate blood and skin samples
11266353|NCT02929745|Experimental|10 HLA Cw6-|HLA-Cw6- patients will donate blood and skin samples
11266354|NCT02929745|Experimental|Healthy Skin|Healthy patients will donate blood and skin samples
11266355|NCT02929732|Experimental|Willis-Ekbom disease patients (CASE)|
11266356|NCT02929732|Experimental|Healthy volunteers (CONTROL)|
11266357|NCT02929719|Experimental|Test Gel 5%|Topical, twice daily on the face for 84 days.
11266358|NCT02929719|Active Comparator|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
11266359|NCT02929719|Placebo Comparator|Placebo Gel|Topical, twice daily on the face for 84 days
11266360|NCT02929706|Experimental|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
11266361|NCT02929706|No Intervention|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
11266362|NCT02929693|Experimental|combination|YYJD plus gefitinib
11266363|NCT02929693|Placebo Comparator|controll|placebo plus gefitinib
11266441|NCT02929186|Experimental|Opt-In|Opt-In Outreach
11266365|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
11266366|NCT02929654|Active Comparator|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
11266367|NCT02929654|Experimental|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
11266368|NCT02929654|Experimental|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
11266369|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
11266370|NCT02929628|Experimental|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
11266371|NCT02929628|Sham Comparator|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
11266372|NCT02929615|Experimental|Treatment group|
11266373|NCT02929589|Experimental|Opioid naïve patients-Group A|"Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
~."
11266374|NCT02929589|Experimental|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
11266375|NCT02929589|Placebo Comparator|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
11266376|NCT02929589|Experimental|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
11266377|NCT02929576|Experimental|Double-blind enzalutamide with paclitaxel|
11266378|NCT02929576|Placebo Comparator|Double-blind placebo with paclitaxel|
11266379|NCT02929576|Experimental|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
11266380|NCT02929563|Experimental|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
11266381|NCT02929563|Placebo Comparator|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
11266382|NCT02929550||Well-controlled cohort (LDL-C ≤ 1.8 mmol/L)|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation with well-controlled LDL-cholesterol
11266383|NCT02929550||Non-controlled cohort|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation and with not well-controlled LDL-C
11266384|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
11266385|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
11266386|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
11266387|NCT02929524|Experimental|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
11266388|NCT02929524|Placebo Comparator|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
11266389|NCT02929511|Experimental|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
11266390|NCT02929511|Experimental|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
11266391|NCT02929511|Active Comparator|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
11266392|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
11266393|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
11266394|NCT02929485|Experimental|Experimental: Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
11266395|NCT02929485|Placebo Comparator|Comparator: Placebo|Drug: Placebo for tolcapone administered at study visit
11266396|NCT02929485|Experimental|Experimental: Bromocriptine|Drug: Bromocriptine 1.25mg (single dose) administered at study visit
11266442|NCT02929186|Experimental|Opt-Out|Opt-Out Outreach
11266443|NCT02929173|Active Comparator|Group 2|E-max is un allceram crown
11266444|NCT02929173|Experimental|Group 1|Bio HPP crown is a hybrid crown
11266445|NCT02929160|Experimental|PCN|Percutaneous nephrostomy
11266397|NCT02929472|Experimental|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
11266398|NCT02929472|Other|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
11266399|NCT02929459|Experimental|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
11266400|NCT02929459|Experimental|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
11266401|NCT02929459|Placebo Comparator|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
11266402|NCT02929446|Experimental|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
11266403|NCT02929446|No Intervention|Control|No mobilisation or breathing exercises until discharge or maximum 6 hours
11266404|NCT02929446|Experimental|Mobilisation and breathing exercises (PEP)|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
11266405|NCT02929433|Experimental|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
11266406|NCT02929433|No Intervention|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
11266407|NCT02929420|Experimental|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
11266408|NCT02929420|Placebo Comparator|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.
~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
11266409|NCT02929407|Experimental|FE 204205|
11266410|NCT02929407|Placebo Comparator|Placebo|
11266411|NCT02929394|Active Comparator|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
11266412|NCT02929394|No Intervention|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
11266413|NCT02929381|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
11266414|NCT02929381|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
11266415|NCT02929368|Active Comparator|Fluoroscopy|PICC Implantation under x-ray
11266416|NCT02929368|Active Comparator|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
11266417|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
11266418|NCT02929342|Experimental|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
11266419|NCT02929342|Experimental|[14C]-Pitolisant|[14C]-Pitolisant, oral single dose administration at Day8.
11266420|NCT02929329|Experimental|Active Treatment|Oral omecamtiv mecarbil twice daily for up to 208 weeks
11266421|NCT02929329|Placebo Comparator|Placebo|Oral placebo twice daily for up to 208 weeks
11266422|NCT02929316|Experimental|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
11266423|NCT02929290|Experimental|BPI-9016M|Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
11266424|NCT02929277|Other|single arm study|
11266425|NCT02929264|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
11266426|NCT02929264|Placebo Comparator|Placebo|Placebo, capsules, single dose
11266427|NCT02929264|No Intervention|Control|No Intervention
11266428|NCT02929251|Active Comparator|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
11266429|NCT02929251|Experimental|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
11266430|NCT02929251|Experimental|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
11266431|NCT02929238|Experimental|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
11266432|NCT02929238|Experimental|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
11266433|NCT02929225|Experimental|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
11266434|NCT02929225|Placebo Comparator|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
11266435|NCT02929212|Other|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
11266436|NCT02929212|Other|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
11266437|NCT02929212|Other|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
11266438|NCT02929212|Other|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
11266439|NCT02929199|Active Comparator|group A|Pressable E- max, an all ceramic crown
11266440|NCT02929199|Experimental|Group B|BIO-Hpp hybrid crown
11266448|NCT02929147|Experimental|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
11266449|NCT02929147|Active Comparator|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
11266450|NCT02929134|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
11266451|NCT02929134|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
11266452|NCT02929121|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
11266453|NCT02929121|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
11266454|NCT02929108|No Intervention|Enhanced Usual Care|This group will receive usual hospice care which has been enhanced as the staff have been trained in shared decision making.
11266455|NCT02929108|Experimental|Facebook|This group only participates in the Facebook groups, not in the shared decision making
11266456|NCT02929108|Experimental|ACCESS|This group participates in facebook and web conferencing for shared decision making
11266457|NCT02929095|Experimental|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
11266458|NCT02929095|Active Comparator|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
11266459|NCT02929082|Experimental|Group 1 : volunteer patient|Group 1 will be constituted of 20 volunteer patients coming for abdominal MRI with no known hepatic disease, in order to determine the feasibility of FRM . A 5-minute- additional sequence to measure FRM will be done for the volunteers.
11266460|NCT02929082|Experimental|Group 2 : patient with resectable HCC|"Group 2 will be constituted of 60 patients with resectable HCC eligible for surgery. This group will enable to evaluate the gold standard.
~A 5-minute- additional sequence to measure FRM will be done while MRI sequence."
11266461|NCT02929082|Experimental|Group 3 : patient with HCC eligible for TACE|"Group 3 will be constituted of 50 patients with HCC eligible for transplant with transcatheter arterial chemoembolization (TACE) treatment as pending treatment before transplant. This groups will enable to evaluate the efficiency of TACE through the necrosis percentage in treated HCC.
~A 5-minute- additional sequence to measure FRM will be done while MRI sequence"
11266462|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
11266463|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
11266464|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
11266465|NCT02929056|Placebo Comparator|SOC alginate dressing|SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
11266466|NCT02929056|Experimental|AmnioExCel dressing|AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
11266467|NCT02929043||Dentine hypersensitivity subjects|
11266468|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
11266469|NCT02929017|Other|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
11266470|NCT02929017|Other|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
11266471|NCT02929004|Experimental|Vibrasens|"In addition of classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction, this group will follow a local vibration training, using small and portable vibrator device.
~Training programme: vibration training 3/week from Day 1 to Day 60"
11266472|NCT02929004|No Intervention|Usual activities|Usual activities from day 1 to Day 60 during their classical physiotherapist sessions for the readaptation following anterior cruciate ligament reconstruction.
11266909|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
11266473|NCT02928991|Experimental|Acquired Aplastic Anemia (AA)|Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.
11266474|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.
11266475|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.
11266476|NCT02928978|Experimental|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
11266477|NCT02928978|Placebo Comparator|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
11266478|NCT02928965|Experimental|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the remainder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
11266479|NCT02928965|Placebo Comparator|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
11266480|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
11266481|NCT02928952|No Intervention|DSME alone|Usual care control
11266482|NCT02928939||Multimorbid patients|
11266483|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
11266484|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
11266485|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
11266486|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
11266487|NCT02928900|Experimental|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
11266488|NCT02928900|No Intervention|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
11266489|NCT02928887|Experimental|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
11266490|NCT02928887|No Intervention|Ambient light|Exposure to ambient, white fluorescent light
11266491|NCT02928874|Experimental|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
11266492|NCT02928874|Experimental|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
11266493|NCT02928861|Experimental|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
11266494|NCT02928848|Experimental|tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
11266495|NCT02928848|Sham Comparator|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
11266496|NCT02928835|Experimental|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
11266497|NCT02928835|No Intervention|Control group|Control group received standardized physical therapy intervention.
11266498|NCT02928822|Experimental|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
11266499|NCT02928822|Active Comparator|Control Group|Conventional aphasia therapy.
11266500|NCT02928809|No Intervention|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
11266501|NCT02928809|Experimental|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
11266502|NCT02928809|No Intervention|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
11266503|NCT02928809|Experimental|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
11266504|NCT02928809|Placebo Comparator|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
11266505|NCT02928809|Placebo Comparator|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
11266506|NCT02928796||Trainees|Registrar Cardiologists
11266507|NCT02928796||Trainers|Consultant Cardiologists
11266508|NCT02928783|Experimental|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
11266509|NCT02928783|No Intervention|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
11266510|NCT02928770|Experimental|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
11266511|NCT02928757|Experimental|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
11266512|NCT02928757|No Intervention|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
11266513|NCT02928744|Experimental|COPD|
11266514|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.
~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
11266515|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.
~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
11266516|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
11266517|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
11266518|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
11266519|NCT02928692|Placebo Comparator|Placebo|Placebo administered before surgery
11266520|NCT02928692|Experimental|Minocycline|Minocycline was administrated before surgery
11266521|NCT02928692|No Intervention|Volunteers|Health people for calculate the incidence of POCD
11266522|NCT02928679|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
11266523|NCT02928679|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
11266524|NCT02928666|Experimental|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
11266525|NCT02928666|No Intervention|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
11266526|NCT02928653|Active Comparator|Sucrose Sweetened Beverage|100-140 g sucrose/day
11266527|NCT02928653|Experimental|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
11266528|NCT02928653|Experimental|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
11266529|NCT02928653|Experimental|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
11266530|NCT02928653|Experimental|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
11266531|NCT02928640|Experimental|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
11266532|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
11266533|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
11266534|NCT02928614|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
11266535|NCT02928614|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
11266536|NCT02928601|Experimental|Ondansetron|
11266537|NCT02928601|Active Comparator|Saline|
11266572|NCT02928315|Active Comparator|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
11266573|NCT02928315|Placebo Comparator|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
11266538|NCT02928575|Experimental|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
11266539|NCT02928562|No Intervention|Control|TKA patients without exercise intervention
11266540|NCT02928562|Experimental|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
11266541|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
11266542|NCT02928523|Experimental|Autologous Fecal Microbiota Transplantation|Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.
11266543|NCT02928510|Experimental|Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
11266544|NCT02928497|Experimental|WATCHMAN (Device)|WATCHMAN LAAC Device implant including modified post-implant drug regimen.
11266545|NCT02928497|Active Comparator|Control|Single antiplatelet therapy or no therapy (Control) at the discretion of the study physician for the duration of the trial.
11266546|NCT02928484|Active Comparator|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
11266547|NCT02928484|Placebo Comparator|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
11266548|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
11266549|NCT02928458|Active Comparator|Omnipaque|Arm 1
11266550|NCT02928458|Active Comparator|MD-Gastroview|Arm 2
11266551|NCT02928445|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
11266552|NCT02928445|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
11266553|NCT02928432|Experimental|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
11266554|NCT02928419|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
11266555|NCT02928419|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
11266556|NCT02928406|Experimental|Atezolizumab|Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
11266557|NCT02928393|Experimental|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
11266558|NCT02928393|Placebo Comparator|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
11266559|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
11266560|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
11266561|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
11266562|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
11266563|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
11266564|NCT02928354|Experimental|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
11266565|NCT02928354|Experimental|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
11266566|NCT02928354|Experimental|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
11266567|NCT02928341|No Intervention|No intervention|Current water supply access
11266568|NCT02928341|Experimental|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
11266569|NCT02928328|Experimental|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
11266570|NCT02928328|Experimental|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
11266571|NCT02928328|Experimental|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
11266574|NCT02928302|Experimental|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
11266576|NCT02928289|Active Comparator|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
11266577|NCT02928289|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
11266578|NCT02928276|Experimental|All patients|All eligible patients
11266579|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
11266580|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
11266581|NCT02928250|Active Comparator|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
11266582|NCT02928250|Placebo Comparator|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
11266583|NCT02928237|Active Comparator|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
11266584|NCT02928237|Placebo Comparator|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
11266585|NCT02928224|Experimental|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
11266586|NCT02928224|Experimental|Doublet Arm|Encorafenib + cetuximab.
11266587|NCT02928224|Active Comparator|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
11266588|NCT02928211|Experimental|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
11266589|NCT02928198|Active Comparator|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
11266590|NCT02928198|Active Comparator|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
11266591|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
11266592|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
11266593|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
11266594|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
11266595|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
11266596|NCT02928159|Experimental|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
11266597|NCT02928146|Active Comparator|Lichtenstein technique|Lichtenstein inguinal hernia repair
11266598|NCT02928146|Active Comparator|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
11266599|NCT02928146|Active Comparator|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
11266600|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
11266601|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
11266602|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
11266603|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
11266604|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
11266605|NCT02928107|Experimental|At-Home Telephone Screening (Tele-HS)|Subjects receive printed educational materials about hearing loss and access to at-home Tele-HS
11266606|NCT02928107|Experimental|PCP Encouragement, At-Home Tele-HS|Subjects receives encouragement from primary care provider (PCP) or hearing screening, printed materials and access to at-home Tele-HS.
11266607|NCT02928107|Experimental|PCP Encouragement, In-Office Tele-HS|Subjects receives PCP encouragement for hearing screening, printed materials and access to Tele-HS while in clinic.
11266608|NCT02928107|No Intervention|CHEER Cohort (non-randomized)|Participants will complete a one page questionnaire related to Red Flag conditions during a routine Otolaryngology appointment for suspected hearing loss. The audiologist will be complete a questionnaire about the participants audiological assessment including Red Flag conditions. The Otolaryngology provider will complete a questionnaire about the participants otoscopic exam findings, Red Flag conditions, and indicate if any other conditions exist that me be considered a medical contraindication to hearing aid fitting.
11266609|NCT02928094|Experimental|A: Ad5FGF-4|Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.
11266610|NCT02928094|Placebo Comparator|B: Placebo|Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.
11266631|NCT02927977|Active Comparator|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
11267014|NCT02925481|Active Comparator|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
11266611|NCT02928081|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
11266612|NCT02928081|Other|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
11266613|NCT02928068|Experimental|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
11266614|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
11266615|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
11266616|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
11266617|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
11266618|NCT02928029|Experimental|Phase1, arm1: 33 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
11266619|NCT02928029|Experimental|Phase1, arm2: 55 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
11266620|NCT02928029|Placebo Comparator|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
11266621|NCT02928029|Experimental|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
11266622|NCT02928016|Experimental|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
11266623|NCT02928016|Experimental|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
11266624|NCT02928016|Experimental|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
11266625|NCT02928016|Experimental|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
11266626|NCT02928016|Experimental|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
11266627|NCT02928016|Experimental|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
11266628|NCT02928003|Experimental|Lung Surgery|
11266632|NCT02927977|Experimental|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
11266633|NCT02927964|Experimental|Treatment (radiation therapy, TLR9 agonist SD-101, ibrutinib)|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also receive ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity.
11266634|NCT02927951|Experimental|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
11266635|NCT02927951|Placebo Comparator|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
11266636|NCT02927938|Other|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)
~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:
~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)
~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)
~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
11266637|NCT02927938|Other|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)
~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:
~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)
~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)
~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
11266638|NCT02927938|No Intervention|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
11266639|NCT02927938|No Intervention|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:
~Lack the immunophenotype of interest,
~Cytarabine based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit or refusal)] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)
~HMA-based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit, lack of donor, refusal)] and do not receive HCT
~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.
~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
11266640|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
11266641|NCT02927912|Experimental|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
11266642|NCT02927899|Experimental|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
11266643|NCT02927886|Experimental|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
11266644|NCT02927886|Placebo Comparator|Intrapyloric injection of botulinum toxin|
11266645|NCT02927873|Experimental|RSV LD Group|Subjects in this group will receive 2 doses of 0.5 ml of ChAd155 5x10^9 vp, one month apart of the RSV vaccine low dose (LD).
11266646|NCT02927873|Experimental|RSV MD Group|Subjects in this group will receive 2 doses of 0.15 ml of ChAd155 5x10^10 vp, one month apart of the RSV vaccine middle dose (MD).
11266647|NCT02927873|Experimental|RSV HD Group|Subjects in this group will receive 2 doses of 0.5 ml of ChAd155 5x10^10 vp, one month apart of the RSV vaccine high dose (HD).
11266648|NCT02927873|Placebo Comparator|Placebo LD group|Subjects in this group will receive 2 doses of 0.15 ml of placebo, one month apart.
11266649|NCT02927873|Placebo Comparator|Placebo MD group|Subjects in this group will receive 2 doses of 0.5 ml of placebo, one month apart.
11266650|NCT02927873|Placebo Comparator|Placebo HD group|Subjects in this group will receive 2 doses of 0.5 ml of placebo one month apart.
11266651|NCT02927847|Experimental|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
11266652|NCT02927847|Active Comparator|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
11266653|NCT02927834|Active Comparator|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
11266654|NCT02927834|Active Comparator|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
11266655|NCT02927834|Active Comparator|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
11266656|NCT02927821|Experimental|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
11266657|NCT02927821|No Intervention|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
11266658|NCT02927808|Experimental|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
11266659|NCT02927808|No Intervention|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
11266660|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
11266661|NCT02927782|Active Comparator|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
11266662|NCT02927782|Experimental|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
11266663|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
11266664|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
11266665|NCT02927743|Active Comparator|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
11266666|NCT02927743|No Intervention|control|GPs will register data without receiving online feed-back
11266667|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
11266668|NCT02927730||negative retainted placenta histology|
11266669|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
11266670|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
11266671|NCT02927691|Experimental|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
11266672|NCT02927691|Other|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
11266673|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
11266674|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
11266675|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery & Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
11266676|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
11266677|NCT02927639|No Intervention|Control|This group will receive the usual standard of care for 6 months.
11266678|NCT02927626|Experimental|Yang Yin Fu Zheng therapy|
11266679|NCT02927626|Placebo Comparator|Routine medical care|
11266680|NCT02927600|Experimental|Low GI Rice Breakfast|Intake of low GI breakfast
11266681|NCT02927600|Experimental|High GI rice Breakfast|Intake of High GI breakfast
11266682|NCT02927600|Experimental|Low GI Rice Dinner|Intake of low GI dinner
11266683|NCT02927600|Experimental|High GI Rice Dinner|Intake of High GI dinner
11266684|NCT02927587|Experimental|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
11266685|NCT02927587|Other|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
11266686|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
11266687|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
11266688|NCT02927522|Placebo Comparator|Control|Placebo was administrated
11266689|NCT02927522|Experimental|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
11266690|NCT02927496|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
11266691|NCT02927496|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
11266692|NCT02927483|Experimental|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
11266693|NCT02927483|Active Comparator|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
11266694|NCT02927470|Experimental|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
11266695|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
11266696|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
11266697|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
11266698|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
11266699|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
11266700|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
11266701|NCT02927444|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
11266702|NCT02927444|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
11266703|NCT02927431|Experimental|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
11266704|NCT02927431|Experimental|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
11266705|NCT02927431|Placebo Comparator|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
11266706|NCT02927418|Experimental|Strength & Conditioning|Supervised S & C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
11266707|NCT02927418|Active Comparator|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
11266708|NCT02927405|Placebo Comparator|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
11266709|NCT02927405|Experimental|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
11266710|NCT02927392|Experimental|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
11266711|NCT02927392|No Intervention|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
11266712|NCT02927379|Active Comparator|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
11266713|NCT02927379|Active Comparator|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
11266714|NCT02927379|Placebo Comparator|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
11266715|NCT02927366|Experimental|QCC374|Adult patients with pulmonary arterial hypertension (PAH) on QCC374. All patients were initiated at 0.03 mg BID (Day 1-3), and were up-titrated to next higher dose 0.06 mg BID (Day 4) and increased to 0.12 mg BID (Day 7-14).
11266716|NCT02927366|Placebo Comparator|Placebo|Adult patients with pulmonary arterial hypertension (PAH) on placebo matching to QCC374 doses (0.03 mg BID (Day 1-3), 0.06 mg BID (Day 4) and 0.12 mg BID (Day 7-14)).
11266720|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.
~Zero Echo Time (ZTE) scan for head attenuation"
11266721|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.
~PET/MR Q Static (Q. MRAC)"
11266722|NCT02927314|Placebo Comparator|Placebo|Placebo tablets orally q12h
11266723|NCT02927314|Active Comparator|CF102 12.5mg|CF102 tablets orally q12h
11266724|NCT02927314|Active Comparator|CF102 25mg|CF102 tablets orally q12h
11266725|NCT02927301|Experimental|Atezolizumab|Participants will first receive two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrate clinical benefit will be eligible to receive up to 12 months of atezolizumab.
11266726|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
11266727|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
11266728|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
11266729|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
11266730|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
11266731|NCT02927275|Experimental|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
11266732|NCT02927275|Experimental|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
11266733|NCT02927275|Experimental|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
11266734|NCT02927275|Other|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
11266735|NCT02927262|Experimental|ASP2215|Subjects will be treated with ASP2215 once daily (continuously for up to 2 years).
11266736|NCT02927262|Placebo Comparator|Placebo|Subjects will be treated with matching placebo tablets once daily (continuously for up to 2 years).
11266737|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
11266738|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
11266739|NCT02927236|Experimental|Cocaine-Active|Designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
11266740|NCT02927236|Sham Comparator|Cocaine-Sham|To test the efficacy of iTBS.
11266741|NCT02927236|No Intervention|Healthy Control - Protocol Training|staff training and equipment testing purposes
11266742|NCT02927236|Other|Healthy Control-Main|Population comparison of acute experimental iTBS.
11266743|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
11266744|NCT02927223|Experimental|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
11266745|NCT02927210|Placebo Comparator|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
11266746|NCT02927210|Experimental|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
11266747|NCT02927197|Experimental|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
11266748|NCT02927197|No Intervention|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
11266749|NCT02927184|Placebo Comparator|Placebo|Placebo capsule
11266750|NCT02927184|Experimental|VK2809 (5mg)|5mg VK2809 capsule
11266751|NCT02927184|Experimental|VK2809 (10mg)|10mg VK2809 capsule
11266752|NCT02927184|Experimental|VK2809 (10mg QOD)|10mg VK2809 capsule
11266753|NCT02927171|No Intervention|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
11266754|NCT02927171|Experimental|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
11266755|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
11266756|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.
~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
11266757|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0
~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
11266758|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
11266759|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
11266760|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.
~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
11266761|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
11266762|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
11266763|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
11266764|NCT02927132|Experimental|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
11266765|NCT02927132|Experimental|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
11266766|NCT02927132|Experimental|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
11266767|NCT02927132|Experimental|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
11266768|NCT02927132|No Intervention|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.
~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
11266769|NCT02927132|Experimental|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
11266770|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
11266771|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
11266772|NCT02927106||Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
11266773|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
11266774|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
11266775|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1)|ACE-083 150 mg IM, once every 3 weeks for up to 5 doses.
11266776|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2)|ACE-083 200 mg IM, once every 3 weeks for up to 5 doses.
11266777|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3)|ACE-083 up to 250 mg IM, once every 3 weeks for up to 5 doses.
11266778|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC, IM tibialis anterior muscle)|Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses.
11266779|NCT02927080|Experimental|ACE-083 (Part 2, PL, IM tibialis anterior muscle)|Open-Label ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 8 doses.
11266780|NCT02927080|Experimental|ACE-083, (Part 2, DB-PC, IM biceps brachii muscle)|Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (biceps brachii muscle) or placebo, once every 3 weeks for up to 9 doses.
11266781|NCT02927080|Experimental|ACE-083 (Part 2, OP, biceps brachii muscle)|Open-Label ACE-083 up to 250 mg IM (biceps brachii muscle), once every 3 weeks for up to 8 doses.
11266782|NCT02927067|Experimental|Maribavir/ Placebo|Participants will receive 400 milligrams (mg) of maribavir (2*200 mg tablets) twice daily (BID) orally along with a placebo matched to valganciclovir for 8 weeks.
11266783|NCT02927067|Active Comparator|Valganciclovir/ Placebo|Participants will receive 900 mg of valganciclovir (2*450 mg tablets) BID orally along with a placebo matched to maribavir for 8 weeks. Valganciclovir dose may be adjusted to 450 mg BID or 450 mg QD during the study for renal function impairment or neutropenia.
11266784|NCT02927054|Other|Internal Medicine Residents|Sepsis education provided to internal medicine residents
11266785|NCT02927054|Other|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
11266786|NCT02927054|Other|Orthopedic Residents|Sepsis education provided to orthopedic residents
11266787|NCT02927054|Other|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
11266788|NCT02927054|Other|General Surgery Residents|Sepsis education provided to general surgery residents
11266789|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
11266790|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
11266791|NCT02927028|Other|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
11266792|NCT02927015|Experimental|Purple Majesty potato chips|Purple Majesty potato chips
11266793|NCT02927015|Experimental|Mountain Rose potato chips|Mountain Rose potato chips
11266794|NCT02927015|Experimental|White potato chips|White potato chips
11266795|NCT02927015|Experimental|Crackers|Crackers
11266796|NCT02927002|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
11266797|NCT02927002|Sham Comparator|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
11266798|NCT02926989|Experimental|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
11266799|NCT02926989|Active Comparator|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
11266800|NCT02926976|Active Comparator|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
11266801|NCT02926976|Active Comparator|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
11266802|NCT02926976|Active Comparator|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.
11266803|NCT02926976|Active Comparator|clozapine|only clozapine, dosage and frequency:300~600 mg/d;
11266804|NCT02926976|Active Comparator|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
11266805|NCT02926976|Active Comparator|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
11266806|NCT02926963|Experimental|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
11266807|NCT02926950|Experimental|Sotagliflozin|A dose of sotagliflozin (SAR439954) will be administered as 2 tablets, once daily, before the first meal of the day. Metformin will be administered per Principal Investigator.
11266808|NCT02926950|Placebo Comparator|Placebo|A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day. Metformin will be administered per Principal Investigator.
11266809|NCT02926937|Experimental|Sotagliflozin Dose 1|Sotagliflozin dose 1 will be administered as 2 tablets, once daily, before the first meal of the day
11266810|NCT02926937|Experimental|Sotagliflozin Dose 2|Sotagliflozin dose 2 will be administered as 1 tablet of sotagliflozin plus 1 placebo tablet, once daily, before the first meal of the day
11266811|NCT02926937|Placebo Comparator|Placebo|A matching placebo will be administered as 2 tablets, once daily, before the first meal of the day
11266812|NCT02926924|Active Comparator|Wound Vac|Wound vac
11266813|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
11266814|NCT02926911|Active Comparator|Surgery|DCIS - Surgery +/- radiation choice for endocrine therapy (MMG q 12 months x 5 years usual care for recurrent disease)
11266815|NCT02926911|Experimental|Active Monitoring|DCIS - Choice for endocrine therapy (MMG q 6 months x 5 years GCC for invasive progression)
11266816|NCT02926898|Experimental|ZX008 - 0.2 mg/kg/day - Cohort 1|"ZX008 0.2 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.
~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
11266817|NCT02926898|Experimental|ZX008 - 0.4 mg/kg/day - Cohort 1|"ZX008 - 0.4 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.
~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
11266818|NCT02926898|Experimental|ZX008 - 20 mg/day maximum - Cohort 2|"ZX008 - 20 mg/day maximum dose is supplied as an oral solution administered twice a day day (BID) in equally divided doses with food. Dose to be determined based on based on Cohort 1 .
~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
11266819|NCT02926898|Placebo Comparator|Matching Placebo - Cohort 2|Matching placebo will be administered twice a day (BID) in equally divided doses with food.
11266820|NCT02926885|Active Comparator|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
11266821|NCT02926885|Experimental|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
11266910|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
11266822|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
11266823|NCT02926859|Experimental|Cannabidiol|Cannabidiol as add-on to individualized pharmacological treatment
11266824|NCT02926859|Placebo Comparator|Placebo|Placebo as add-on to individualized pharmacological treatment
11266825|NCT02926846|Experimental|Lavage arm|Intravenous vancomycin & gentamicin with adjunctive lavage
11266826|NCT02926846|Active Comparator|Standard treatment arm|Intraperitoneal vancomycin & gentamicin
11266827|NCT02926833|Experimental|KTE-C19 + ATZ|Participants will receive conditioning chemotherapy consisting of 30 mg/m^2 fludarabine and 500 mg/m^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days. Treatment with ATZ will begin 21 days following KTE-C19 (Phase 1 Cohort 1), 14 days following KTE-C19 (Phase 1 Cohort 2), and 1 day following KTE-C19 (Phase 1, Cohort 3 & Phase 2).
11266828|NCT02926820|Experimental|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
11266829|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
11266830|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
11266831|NCT02926794|Experimental|SA and II|Combined self-affirmation and implementations intention arm
11266832|NCT02926794|Experimental|SA and No II|Self-affirmation and control intentions condition
11266833|NCT02926794|Experimental|No SA and II|Implementation intentions intervention and control writing task
11266834|NCT02926794|Experimental|No SA and No II|Control writing task and control intentions condition
11266835|NCT02926781|Experimental|osteotome technique|transcrestal sinus floor elevation using osteotomes
11266836|NCT02926781|Active Comparator|drills|transcrestal sinus floor elevation using drills
11266837|NCT02926768|Experimental|Daily dose of CK-101|Daily oral dose of CK-101
11266838|NCT02926755|Experimental|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
11266839|NCT02926729|Experimental|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
11266840|NCT02926729|Active Comparator|Control|Standard lumpectomy without nonlinear microscopy imaging.
11266841|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
11266842|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
11266843|NCT02926690|Experimental|OTS167PO|
11266844|NCT02926677|Experimental|Cue-Centered Treatment (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
11266845|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
11266846|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
11266847|NCT02926651|Active Comparator|Conventional Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
11266848|NCT02926651|Active Comparator|Conventional Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA (Tranexamic Acid) 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
11266849|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Hip Arthroplasty (THA)|THA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
11266850|NCT02926651|Experimental|Multi-Dose Oral TXA, Total Knee Arthroplasty (TKA)|TKA patients will be given three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
11266851|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
11266852|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
11266853|NCT02926625|Active Comparator|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
11266854|NCT02926625|Experimental|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
11266855|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
11266856|NCT02926599|Experimental|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).
~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
11266857|NCT02926599|No Intervention|Control|"No particular training.
~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
11266858|NCT02926586|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.
11266859|NCT02926586|Active Comparator|high-dose cytarabine|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
11266860|NCT02926573|Active Comparator|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
11266861|NCT02926573|Placebo Comparator|Placebo|Placebo liquid by mouth or Per Tube twice a day
11266862|NCT02926547||CCIS|
11266863|NCT02926547||invasive breast cancer|
11266864|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
11266865|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
11266866|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
11266867|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
11266868|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
11266869|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
11266870|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
11266871|NCT02926508|Experimental|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
11266872|NCT02926508|Placebo Comparator|Placebo|Maltodextrin
11266873|NCT02926495|Active Comparator|Treatment (ON)|
11266874|NCT02926495|Sham Comparator|Control (OFF)|
11266875|NCT02926482|No Intervention|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
11266876|NCT02926482|Experimental|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
11266877|NCT02926469|No Intervention|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
11266878|NCT02926469|Experimental|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
11266879|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.
11266880|NCT02926443|Active Comparator|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
11266881|NCT02926443|Experimental|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
11266882|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
11266883|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
11266884|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
11266885|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
11266886|NCT02926430|Experimental|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
11266887|NCT02926404||Pediatric patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) <18Years old
11266888|NCT02926404||Adult patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) >18Years old
11266889|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
11266890|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
11266891|NCT02926378|Experimental|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
11266892|NCT02926365|Experimental|ICBT|Therapist-supported internet-delivered CBT
11266893|NCT02926352|Experimental|Extinction Training with LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear domain. 15 minutes after fear extinction, participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system; to stimulate the vmPFC). Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
11266894|NCT02926352|Active Comparator|Extinction Training with Sham LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear. 15 minutes after fear extinction, participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
11266895|NCT02926352|Experimental|LLLT alone|Participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). F3 corresponds with the left dorsolateral prefrontal cortex and F4 corresponds with the right dorsolateral prefrontal cortex. Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
11266896|NCT02926352|Sham Comparator|Sham LLLT alone|Participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
11266897|NCT02926339|Experimental|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
11266898|NCT02926339|No Intervention|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
11266899|NCT02926326|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1
~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
11266900|NCT02926313|No Intervention|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
11266901|NCT02926313|Experimental|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
11266902|NCT02926287|Experimental|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
11266903|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure <100 will receive up to 6 units of whole blood when available.
11266904|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure <100, as well as adult male patients with systolic blood pressure <100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
11266905|NCT02926248|Experimental|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
11266906|NCT02926248|Placebo Comparator|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
11266907|NCT02926235|Experimental|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
11266908|NCT02926235|Placebo Comparator|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
11266911|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
11266912|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
11266913|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
11266914|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
11266915|NCT02926183|Experimental|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
11266916|NCT02926170|Experimental|rivaroxaban|Rivaroxaban 20 mg per day
11266917|NCT02926170|Active Comparator|acenocumarol|INR adjusted dose
11266918|NCT02926157|Experimental|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
11266919|NCT02926157|No Intervention|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
11266920|NCT02926144|Experimental|Laryngoscope with video|Use of the video-laryngoscope McGrath Mac with use of the video feature
11266921|NCT02926144|Active Comparator|Laryngoscope without video|Use of the video-laryngoscope McGrath Mac without use of the video feature
11266922|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
11266923|NCT02926118|Experimental|Low glycemic load|Low glycemic load
11266924|NCT02926118|Experimental|High glycemic load|High glycemic load
11266925|NCT02926105|Experimental|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
11266926|NCT02926105|Experimental|Otago|Individually tailored exercise programme
11266927|NCT02926105|Active Comparator|Helsana booklet|Helsana recommendations and exercises
11266928|NCT02926092||Arm 1|Observation of progression of disease over time.
11266929|NCT02926079||Pregnant women diagnosed with gestational diabetes|
11266930|NCT02926079||Pregnant women with normal pregnancy|
11266931|NCT02926066|Experimental|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect
~Dosage form: Aqueous solution Dose(s): 1.81x10^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
11266932|NCT02926053|Experimental|Patient group|"All patients receive the same treatment.
~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.
~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.
~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.
~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
11266933|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
11266934|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
11266935|NCT02926014|Experimental|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.
~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
11266936|NCT02926014|Other|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
11266937|NCT02925988|Other|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
11266938|NCT02925975|Other|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
11266939|NCT02925975|Experimental|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
11266940|NCT02925975|Experimental|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
11266941|NCT02925975|Active Comparator|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
11266981|NCT02925715|Experimental|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
11266982|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks IV
11266983|NCT02925676|Experimental|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
11267515|NCT02922413|Placebo Comparator|Placebo|A double blind dose of saline.
11266942|NCT02925962|Experimental|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.
~CDSS overview:
~The study MDs order CKD triple marker tests
~Patients will go to the lab as per usual clinical care
~Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines
~Results will also be sent to the Study MD's for monitoring
~At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP
~If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
11266943|NCT02925962|Experimental|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.
~CDSS Plus overview:
~At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit
~The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit
~On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance
~A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
11266944|NCT02925962|No Intervention|Usual Care|Patients continue to receive usual care by their provider.
11266945|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
11266946|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
11266947|NCT02925936|Active Comparator|Cathode|Thyroid facing the cathode end of xray machine
11266948|NCT02925936|Active Comparator|Anode|Thyroid facing the anode end of xray machine
11266949|NCT02925923|Active Comparator|Ticagrelor|crushed ticagrelor (180 mg); (n=50 patients)
11266950|NCT02925923|Active Comparator|Eptifibatide bolus+clopidogrel|Eptifibatide bolus (180 mcg/kg x 2 boluses) + clopidogrel 600 mg and heparin low-dose (n=50 patients)
11266951|NCT02925910|Other|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
11266952|NCT02925910|Other|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
11266953|NCT02925897|Experimental|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
11266954|NCT02925897|No Intervention|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
11266955|NCT02925884|Experimental|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
11266956|NCT02925884|No Intervention|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
11266957|NCT02925871||transitions|current transitions from the stroke unit to the home
11266958|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
11266959|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
11266960|NCT02925845|Experimental|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
11266961|NCT02925845|No Intervention|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
11266962|NCT02925832|Experimental|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
11266963|NCT02925832|Experimental|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
11266964|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
11266965|NCT02925806||ER/LA opioids included in the class REMS|
11266966|NCT02925806||IR Opioids|
11266967|NCT02925806||Celecoxib|
11266968|NCT02925806||Benzodiazepines|
11266969|NCT02925793|Experimental|1% DS107 cream|Participants in this group will receive 1% DS107 cream twice daily.
11266970|NCT02925793|Experimental|5% DS107 cream|Participants in this group will receive 5% DS107 cream twice daily.
11266971|NCT02925793|Placebo Comparator|Vehicle cream|Participants in this group will receive matching placebo cream twice daily.
11266972|NCT02925780|Experimental|Resin infiltration|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated using the resin infiltrant Icon (DMG, Germany). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
11266973|NCT02925780|Active Comparator|Microabrasion|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated by microabrasion using the microabrasive material Opalustre (Ultradent, USA). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
11266974|NCT02925767|Experimental|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
11266975|NCT02925767|Active Comparator|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
11266976|NCT02925741|Experimental|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
11266977|NCT02925741|No Intervention|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
11266978|NCT02925728|Experimental|Nutrition with Finger-Food|Nutrition with Finger-Food
11266979|NCT02925728|Active Comparator|Nutrition without Finger-Food|Nutrition without Finger-Food
11266980|NCT02925715|Experimental|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
11266985|NCT02925650|Experimental|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
11266986|NCT02925650|Experimental|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
11266987|NCT02925650|Experimental|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
11266988|NCT02925650|Placebo Comparator|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
11266989|NCT02925637|Active Comparator|treatment group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
11266990|NCT02925637|No Intervention|control group|control group receiving standard care - cognitive and functional assesment
11266991|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
11266992|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
11266993|NCT02925598|Experimental|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
11266994|NCT02925598|Experimental|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
11266995|NCT02925598|Experimental|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
11266996|NCT02925585||Pre/post pelvic floor surgery imaging|
11266997|NCT02925572|Experimental|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
11266998|NCT02925572|Experimental|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
11266999|NCT02925559|Experimental|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
11267000|NCT02925559|Active Comparator|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
11267001|NCT02925546|Experimental|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
11267002|NCT02925546|Experimental|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
11267003|NCT02925546|Experimental|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
11267004|NCT02925546|Experimental|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
11267005|NCT02925546|Experimental|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
11267006|NCT02925546|Experimental|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
11267007|NCT02925533|Experimental|B-701 and Pembrolizumab|"B-701 will be administered every 3 weeks intravenously
~Pembrolizumab will be administered every 3 weeks intravenously"
11267008|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
11267009|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
11267010|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
11267011|NCT02925494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
11267012|NCT02925481|Experimental|Low dose Yoga|12 week online yoga for 60 minutes per week
11267013|NCT02925481|Experimental|Moderate dose Yoga|12 week online yoga for 150 minutes per week
11267015|NCT02925468|Experimental|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
11267016|NCT02925468|No Intervention|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
11267017|NCT02925455|Experimental|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
11267018|NCT02925455|Active Comparator|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
11267019|NCT02925442|Experimental|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
11267020|NCT02925442|Experimental|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
11267021|NCT02925442|Sham Comparator|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
11267022|NCT02925416|Experimental|Two doses oritavancin|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL D5W will be administered.
11267023|NCT02925416|Other|One dose oritavancin, one dose placebo|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, a placebo (D5W) will be administered.
11267024|NCT02925403|Active Comparator|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
11267025|NCT02925403|Active Comparator|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
11267026|NCT02925403|Placebo Comparator|Group 3|Saline injection on days 0, 28, and 56.
11267027|NCT02925377|Experimental|Neuromuscular|Neuromuscular warm-up
11267028|NCT02925377|Active Comparator|Control|Standard warm-up
11267029|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
11267030|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
11267031|NCT02925351|Experimental|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
11267032|NCT02925338||Patients treated with Inflectra|
11267033|NCT02925325|Experimental|Music Therapy|Music therapy 8 weekly sessions
11267034|NCT02925325|Active Comparator|Usual Treatment|It is the usual medical treatment.
11267035|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
11267036|NCT02925312|No Intervention|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
11267037|NCT02925299|Experimental|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
11267038|NCT02925299|Active Comparator|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
11267039|NCT02925286|Experimental|Intervention group|Five organizations will get the intervention during fall/winter 2016.
11267040|NCT02925286|No Intervention|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
11267041|NCT02925273|Other|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
11267042|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria
~Ileal pouch reservoir in situ
~Greater than three years since closure of ileostomy
~Normal pouch function as defined by Orësland score of <4
~Never had a diagnosis of pouchitis
~Never had treatment for pouchitis
~No evidence of pouchitis on rigid pouchoscopy
~CRP <10"
11267043|NCT02925247|Other|patient with atrial fibrillation|
11267044|NCT02925234|Experimental|Panitumumab|Panitumumab for patients with a molecular tumor profile that can potentially be targeted by Panitumumab.
11267045|NCT02925234|Experimental|Olaparib|Olaparib for patients with a molecular tumor profile that can potentially be targeted by Olaparib.
11267046|NCT02925234|Experimental|Dabrafenib|Dabrafenib for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib.
11267047|NCT02925234|Experimental|Nilotinib|Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.
11267048|NCT02925234|Experimental|Trametinib|Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.
11267049|NCT02925234|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.
11267050|NCT02925234|Experimental|Trastuzumab & Pertuzumab (combination)|Trastuzumab and Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab and Pertuzumab.
11267051|NCT02925234|Experimental|Vemurafenib & Cobimetinib (combination)|Vemurafenib and Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib and Cobimetinib.
11267052|NCT02925234|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.
11267053|NCT02925234|Experimental|Regorafenib|Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.
11267054|NCT02925234|Experimental|Nivolumab|Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.
11267055|NCT02925234|Experimental|Afatinib|Afatinib for patients with a molecular tumor profile that can potentially be targeted by Afatinib.
11267056|NCT02925234|Experimental|Dabrafenib & trametinib (combination)|Dabrafenib and trametinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib and trametinib.
11267057|NCT02925234|Experimental|Ribociclib|Ribociclib for patients with a molecular tumor profile that can potentially be targeted by Ribociclib.
11267058|NCT02925234|Experimental|Lenvatinib|Lenvatinib for patients with a molecular tumor profile that can potentially be targeted by Lenvatinib.
11267059|NCT02925234|Experimental|Pembrolizumab|Pembrolizumab for patients with a molecular tumor profile that can potentially be targeted by Pembrolizumab.
11267060|NCT02925234|Experimental|Durvalumab|Durvalumab for patients with a molecular tumor profile that can potentially be targeted by Durvalumab.
11267061|NCT02925234|Experimental|Rucaparib|Rucaparib for patients with a molecular tumor profile that can potentially be targeted by Rucaparib.
11267062|NCT02925234|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
11267063|NCT02925234|Experimental|Palbociclib|Palbociclib for patients with a molecular tumor profile that can potentially be targeted by Palbociclib.
11267064|NCT02925234|Experimental|Crizotinib|Crizotinib for patients with a molecular tumor profile that can potentially be targeted by Crizotinib.
11267065|NCT02925234|Experimental|Sunitinib|Sunitinib for patients with a molecular tumor profile that can potentially be targeted by Sunitinib.
11267066|NCT02925234|Experimental|Cabozantinib|Cabozantinib for patients with a molecular tumor profile that can potentially be targeted by Cabozantinib.
11267067|NCT02925234|Experimental|Brigatinib|Brigatinib for patients with a molecular tumor profile that can potentially be targeted by Brigatinib.
11267068|NCT02925234|Experimental|Abemaciclib|Abemaciclib for patients with a molecular tumor profile that can potentially be targeted by Abemaciclib.
11267069|NCT02925234|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
11267070|NCT02925234|Experimental|Atezolizumab/bevacizumab|Atezolizumab and bevacizumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab and bevacizumab.
11267071|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with tolvaptan or already treated with tolvaptan will be eligible.
11267072|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
11267073|NCT02925195|Experimental|Active Treatment|
11267074|NCT02925195|Placebo Comparator|Placebo|Placebo
11267075|NCT02925182|Experimental|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
11267076|NCT02925182|Placebo Comparator|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
11267077|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
11267078|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
11267079|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
11267080|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
11267081|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
11267082|NCT02925143|Experimental|E-learning course|
11267083|NCT02925130|Experimental|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
11267084|NCT02925130|Experimental|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
11267085|NCT02925130|Placebo Comparator|Placebo|Acute oral intake of a placebo
11267086|NCT02925117|Placebo Comparator|Placebo|Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
11267852|NCT02920164|No Intervention|Standard therapy|No intervention, just observation
11267087|NCT02925117|Experimental|Upadacitinib 7.5 mg|Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
11267088|NCT02925117|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
11267089|NCT02925117|Experimental|Upadacitinib 30 mg|Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
11267090|NCT02925104|Experimental|INC280|
11267091|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
11267092|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
11267093|NCT02925065|Experimental|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
11267094|NCT02925065|Experimental|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
11267095|NCT02925052|Experimental|GTG|Gastric tube placement using the Gastric Tube Guide
11267096|NCT02925052|Other|Conventional|Gastric tube placement using a conventional method, according to local protocol.
11267097|NCT02925039|Experimental|Experimental|Sit to stand training augmented with technology delivered movement feedback
11267098|NCT02925039|Active Comparator|Control|Sit to stand training as per normal practice
11267099|NCT02925026|Experimental|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
11267100|NCT02925026|Placebo Comparator|Placebo|rice flour
11267101|NCT02925013|Experimental|Study group|Pregnant women at delivery
11267102|NCT02925013|Other|Control group|Women in fertility age not pregnant
11267103|NCT02925000|Experimental|TLC178|Liposomal Vinorelbine
11267104|NCT02924987|Other|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
11267105|NCT02924974|Sham Comparator|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
11267106|NCT02924974|Experimental|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
11267107|NCT02924961|Experimental|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
11267108|NCT02924961|Active Comparator|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
11267109|NCT02924948|No Intervention|Conventional insertion|EUS will be inserted with conventional method.
11267110|NCT02924948|Experimental|Balloon inflated insertion|EUS will be inserted with balloon inflated method
11267111|NCT02924935|Experimental|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
11267112|NCT02924922|Active Comparator|Laparoscopic partial nephrectomy|"Inclusion criteria fulfilled:
~Baseline Abdomen CT/MRI
~Patient Age, Weight, Height, Co-Medication
~Informed Consent
~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)
~During hospitalization, one day before laparoscopic partial nephrectomy:
~eGFR
~sCreatinine
~Hemoglobin
~After surgery:
~Assessment of eGFR 4 days after operation
~Hb assessment every 6 H in the first 48 H
~Assessment of adverse events
~Histological Results
~6, 12, 24 months after intervention:
~Creatinine Clearance (only performed at 6 months follow-up)
~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)
~eGFR
~Assessment of adverse events
~Assessment of possible recurrence
~Assesment of kidney volume variation"
11267113|NCT02924922|Active Comparator|Robot assisted partial nephrectomy|"Inclusion criteria fulfilled:
~Baseline Abdomen CT/MRI
~Patient Age, Weight, Height, Co-Medication
~Informed Consent
~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)
~During hospitalization, one day before robot assisted partial nephrectomy:
~eGFR
~sCreatinine
~Hemoglobin
~After surgery:
~Assessment of eGFR 4 days after operation
~Hb assessment every 6 H in the first 48 H
~Assessment of adverse events
~Histological Results
~6, 12, 24 months after intervention:
~Creatinine Clearance (only performed at 6 months follow-up)
~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)
~eGFR
~Assessment of adverse events
~Assessment of possible recurrence
~Assesment of kidney volume variation"
11267114|NCT02924909|Experimental|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
11267115|NCT02924896|Other|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
11267116|NCT02924896|Other|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
11267117|NCT02924896|Other|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
11267118|NCT02924896|Other|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
11267119|NCT02924896|Other|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
11267120|NCT02924896|Other|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
11267121|NCT02924883|Experimental|Trastuzumab Emtansine + Atezolizumab|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
11267122|NCT02924883|Active Comparator|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
11267123|NCT02924870|Active Comparator|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
11267124|NCT02924870|Experimental|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
11267125|NCT02924857|Experimental|Test Group (Chocolate Touch)|"The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.
~The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.
~If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
11267126|NCT02924857|Active Comparator|Control Group (Lutonix Drug Coated Balloon)|"Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.
~The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).
~If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.
~Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
11267127|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
11267128|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
11267129|NCT02924831|Experimental|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
11267130|NCT02924831|Experimental|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
11267131|NCT02924831|Placebo Comparator|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
11267132|NCT02924831|Experimental|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
11267133|NCT02924831|Experimental|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
11267134|NCT02924818|Experimental|Chronic Obstructive Pulmonary disease (COPD)|
11267135|NCT02924818|Experimental|Cystic Fibrosis (CF)|
11267136|NCT02924818|Experimental|bronchiectasis|
11267137|NCT02924818|Experimental|Interstitial lung disease (ILD)|
11267138|NCT02924818|Experimental|controls|
11267139|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
11267140|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
11267141|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
11267142|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
11267143|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
11267144|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
11267145|NCT02924766|Experimental|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
11267146|NCT02924753|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
11267147|NCT02924740|Active Comparator|control|pelvic floor muscle training
11267148|NCT02924740|Experimental|intervention|vaginal tampon training.
11267149|NCT02924727|Experimental|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).
~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.
~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
11267150|NCT02924727|Active Comparator|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).
~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.
~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
11267151|NCT02924714|Other|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
11267152|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
11267153|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11267191|NCT02924441|Experimental|Right Breast Lidocaine and no music|Group 2 - right breast lidocaine & no calming music
11267154|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11267155|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11267156|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11267157|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11267158|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11267159|NCT02924675|Experimental|pregabalin group|
11267160|NCT02924675|Placebo Comparator|Placebo group|
11267161|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
11267162|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
11267163|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
11267164|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
11267165|NCT02924649|Experimental|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
11267166|NCT02924649|No Intervention|Standard care group|The standard care group will receive daily mobilisation to the seated position.
11267167|NCT02924636|Experimental|Intervention|personalized and online intervention. The intervention website will provide secure communication with dietician and lifestyle coaches. Women will receive emails and monthly newsletters with new content and reminder.
11267168|NCT02924636|No Intervention|Control|standard care with oral information about the goal of nutritional needs during pregnancy and gestational weight gain guidelines according to BMI
11267169|NCT02924597|Experimental|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
11267170|NCT02924597|Active Comparator|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
11267171|NCT02924571|Experimental|Bone Marrow Aspirate Concentrate (BMAC)|
11267172|NCT02924571|Active Comparator|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|
11267173|NCT02924558|Experimental|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
11267174|NCT02924558|Placebo Comparator|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
11267175|NCT02924532||Patients with total thiroidectomy|
11267176|NCT02924506|Other|Fixed Core|Cervical arthroplasty with fixed core prothesis
11267177|NCT02924506|Other|Movable Core|Cervical arthroplasty with movable core prothesis
11267178|NCT02924493|Experimental|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
11267179|NCT02924493|Placebo Comparator|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
11267180|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
11267181|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
11267182|NCT02924467|No Intervention|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
11267183|NCT02924467|Experimental|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
11267184|NCT02924467|Experimental|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
11267185|NCT02924467|Experimental|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
11267186|NCT02924454|Experimental|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
11267187|NCT02924454|Experimental|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
11267188|NCT02924454|Experimental|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
11267189|NCT02924454|Experimental|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
11267190|NCT02924441|Experimental|Right Breast Lidocaine and calming music|Group 1 - right breast lidocaine & calming music
11267193|NCT02924441|Experimental|Left Breast Lidocaine and no music|Group 4 - left breast lidocaine & no calming music
11267194|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.
~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.
~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
11267195|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.
~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
11267196|NCT02924415|Experimental|Tele-care support|Online psychoeducation treatment using new technologies
11267197|NCT02924415|Active Comparator|Control group|Standard care
11267198|NCT02924402|Experimental|Non-CLL B Cell Malignancies (Group NHL)|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
11267199|NCT02924402|Experimental|CLL/SLL (Group CLL)|XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion
11267200|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
11267201|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
11267202|NCT02924376|Experimental|Cohort A Pemigatinib|Pemigatinib in subjects with FGFR2 translocation with a documented fusion partner in central laboratory report
11267203|NCT02924376|Experimental|Cohort B Pemigatinib|Pemigatinibin subjects with other FGF/FGFR alterations
11267204|NCT02924376|Experimental|Cohort C Pemigatinib|Pemigatinib in subjects negative for FGF/FGFR alteration
11267205|NCT02924363||Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- & post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
11267206|NCT02924350|Experimental|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
11267207|NCT02924350|Active Comparator|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
11267208|NCT02924337|Experimental|Imeglimin therapeutic dose|Tablet, oral, single dose
11267209|NCT02924337|Experimental|Imeglimin supratherapeutic dose|Tablet, oral, single dose
11267210|NCT02924337|Placebo Comparator|Placebo|Tablet, oral, single dose
11267211|NCT02924337|Active Comparator|Moxifloxacin|Tablet, oral, single dose (400 mg)
11267212|NCT02924324|Active Comparator|propofol alone|1st Bone Marrow procedure (BM) Intervention A: propofol alone. Crossover for second BM procedure propofol & ropivacaine
11267213|NCT02924324|Experimental|propofol and ropivacaine|1st BM procedure: Intervention B: propofol & ropivacaine. Crossover for second BM procedure propofol alone
11267214|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
11267215|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
11267216|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
11267217|NCT02924298|Experimental|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate > 60 mL/min/1.73m^2, to undergo SLIMM intervention
11267218|NCT02924298|Experimental|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to < 60 mL/min/1.73m^2, to undergo SLIMM intervention
11267219|NCT02924285|Active Comparator|Procedure|Radiofrequency catheter ablation
11267220|NCT02924285|Active Comparator|Antiarrhythmic Drug|Amiodarone
11267221|NCT02924272|Experimental|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until ixazomib is available to the participant through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
11267222|NCT02924259|Experimental|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
11267223|NCT02924246|Placebo Comparator|Control group|Regular cholera vaccination
11267224|NCT02924246|Active Comparator|Raw milk|Cholera vaccination - raw milk
11267225|NCT02924246|Active Comparator|Pasteurized milk|Cholera vaccination - pasteurized milk
11267226|NCT02924246|Active Comparator|UHT milk|Cholera vaccination - UHT milk
11267227|NCT02924233|Experimental|Sym004 + nivolumab|"Phase 1b, dose-escalation:
~Dose Level 1: Sym004 + nivolumab (Q2W)
~Dose Level 2: Sym004 + nivolumab (Q2W)
~Dose Level -1: Sym004 + nivolumab, if needed"
11267228|NCT02924233|Experimental|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:
~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
11267229|NCT02924233|Active Comparator|Nivolumab|"Phase 2b, dose-expansion:
~Receiving nivolumab monotherapy (Q2W)"
11267230|NCT02924220||Case patients|"Patients with culture-proven listeriosis. Case patients are classified in 3 groups :
~Septicemic infections: isolation of Lm in blood cultures.
~CNS infections: isolation of Lm in cerebrospinal fluid, or brain stereotaxic biopsy, or by isolation of Lm in the blood with concomitant meningitis, or radiological encephalitis, rhombencephalitis, brain abscess or meningitis.
~MF infections: defined by isolation of Lm in any maternal/fetal/neonatal bacteriological sample.
~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
11267231|NCT02924220||Control patients|"Patients without listeriosis but compatible clinical presentation. Control patients are divided in 3 groups.
~Septicemic controls: febrile patient with same co-morbidities as septicemic cases.
~CNS controls: patient with any neurological symptom leading to the empiric prescription of amoxicillin at meningeal dosage because of listeriosis presumption.
~MF controls: febrile pregnant patient without obvious focal infection.
~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
11267232|NCT02924207|Experimental|Intervention|Path Electronic decision support arm
11267233|NCT02924194|Experimental|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
11267234|NCT02924194|Experimental|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
11267235|NCT02924181|Active Comparator|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
11267236|NCT02924181|Active Comparator|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
11267237|NCT02924181|Active Comparator|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
11267238|NCT02924181|Active Comparator|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
11267239|NCT02924168|Experimental|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density [EFD] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
11267240|NCT02924168|Sham Comparator|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
11267241|NCT02924155|Experimental|SJP002|single/repeated administration
11267242|NCT02924155|Placebo Comparator|SJP002 placebo|single/repeated administration
11267243|NCT02924142|Experimental|Intervention|Mandibular removable partial denture with OT Cap attachment
11267244|NCT02924142|No Intervention|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
11267245|NCT02924129|Experimental|Evoke SCS with Feedback|closed-loop/automatic stimulation
11267246|NCT02924129|Active Comparator|Evoke SCS with Conventional|open-loop/manual stimulation
11267247|NCT02924116|Experimental|Bioboosti|Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
11267248|NCT02924116|Experimental|Sustained Efficacy|"Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia.
~Subjects will use it once a day for about one hour, before habitual sleep time."
11267249|NCT02924116|Experimental|Insomnia and migraine|Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.
11267355|NCT02923466|Experimental|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
11267443|NCT02922894|Experimental|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
11267250|NCT02924103|Active Comparator|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.
~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
11267251|NCT02924103|Active Comparator|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
11267252|NCT02924090|Active Comparator|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
11267253|NCT02924090|Active Comparator|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
11267254|NCT02924090|Active Comparator|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
11267255|NCT02924090|Active Comparator|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
11267256|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
11267257|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
11267258|NCT02924051|Experimental|Motivational Interview (MI)|Intervention group participants receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse
11267259|NCT02924051|Active Comparator|Cooking Skills/Nutritional Education|Participants in this arm receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
11267260|NCT02924038|Experimental|IMA950/poly-ICLC subcutaneous (subQ) + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
11267261|NCT02924038|Experimental|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
11267262|NCT02924025|Experimental|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
11267263|NCT02924025|No Intervention|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
11267264|NCT02924012|Experimental|active video game|An active game session lasting 40 minutes
11267265|NCT02924012|Other|sedentary video game|An sedentary game session lasting 40 minutes
11267266|NCT02924012|Other|walking|An walking lasting 40 minutes
11267267|NCT02923999|Experimental|Dose cohort 1|P2G12 0.125g
11267268|NCT02923999|Experimental|Dose cohort 2|P2G12 0.25g
11267269|NCT02923999|Experimental|Dose cohort 3|P2G12 0.5g
11267270|NCT02923986|Experimental|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
11267271|NCT02923986|Experimental|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
11267272|NCT02923973|Experimental|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
11267273|NCT02923973|No Intervention|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
11267274|NCT02923960|Active Comparator|Standard ONS|liquid oral nutritional supplement
11267275|NCT02923960|Experimental|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
11267276|NCT02923960|Active Comparator|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
11267277|NCT02923947|Experimental|Normal renal function|For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.
11267278|NCT02923947|Experimental|Severe renal impairment|For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance <30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.
11267279|NCT02923934|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
11267316|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.
~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
11267411|NCT02923089|Experimental|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
11267280|NCT02923921|Experimental|Pegilodecakin + FOLFOX|Pegilodecakin 5 microgram per kilogram (μg/kg) dosed as one of the following 2 fixed doses: 0.4 milligram (mg) for participants weighing ≤80 kg or 0.8 mg for participants weighing>80 kg on Days 1-5 and Days 8-12 subcutaneously (SC) plus FOLFOX [dl-Leucovorin (dl-LV) 400 milligram per meter square (mg/m2) and oxaliplatin 85 mg/m2 followed by bolus 5-fluorouracil (5-FU) 400 mg/m2 and a 46 to 48 hour infusion of 5- FU 2400 mg/m2] initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression. After discontinuation of FOLFOX in the absence of tumor progression [that is (i.e., completion of the planned 12 cycles or unacceptable FOLFOX related toxicity], Pegilodecakin 10µg/kg maintenance treatment administered as one of the 2 fixed doses, either 0.8 mg for participants weighing ≤80 kg or 1.6 mg for participants weighing>80 kg.
11267281|NCT02923921|Active Comparator|FOLFOX|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression.
11267282|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
11267283|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
11267284|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
11267285|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
11267286|NCT02923869|Active Comparator|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
11267287|NCT02923869|Active Comparator|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
11267288|NCT02923856|Experimental|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
11267289|NCT02923856|Experimental|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
11267290|NCT02923856|Experimental|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
11267291|NCT02923856|Experimental|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
11267292|NCT02923856|Experimental|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
11267293|NCT02923856|Experimental|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
11267294|NCT02923856|Experimental|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
11267295|NCT02923843|Experimental|intervention|Comprehensive Geriatric Assessment
11267296|NCT02923843|No Intervention|control|Standard care
11267297|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
11267298|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
11267299|NCT02923817|Experimental|Treatment|
11267300|NCT02923804|Experimental|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
11267301|NCT02923804|Placebo Comparator|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
11267302|NCT02923791|Experimental|Filgrastim Hospira|
11267303|NCT02923791|Active Comparator|US-Approved Neupogen|
11267304|NCT02923778|Experimental|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy at weeks 2-6.
11267305|NCT02923765|Active Comparator|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
11267306|NCT02923765|No Intervention|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
11267307|NCT02923765|No Intervention|healthy participant (HP)|healthy control
11267308|NCT02923739|Active Comparator|Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11267309|NCT02923739|Experimental|Arm II (paclitaxel, bevacizumab, emactuzumab)|Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11267310|NCT02923726|Active Comparator|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
11267311|NCT02923726|Experimental|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
11267312|NCT02923700|Experimental|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
11267313|NCT02923700|Experimental|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
11267314|NCT02923687|Active Comparator|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
11267315|NCT02923687|Placebo Comparator|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
11267412|NCT02923089|Placebo Comparator|Potato Soup|Soup: 25g available carbohydrate from potato
11267317|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.
~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
11267318|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.
~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).
~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
11267319|NCT02923661|Experimental|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
11267320|NCT02923661|Active Comparator|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
11267321|NCT02923648||Very/extremely prematurely born with BPD|Very/extremely prematurely born (gestational age [GA]< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-23 years
11267322|NCT02923648||Very/extremely prematurely born without BPD|Very/extremely prematurely born (GA< 32 weeks) without BPD in the neonatal period, age 18-23 years
11267323|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA> 37 weeks), age 18-23 years
11267324|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA>37 weeks), age 18-23 years
11267325|NCT02923635|Active Comparator|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
11267326|NCT02923635|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
11267327|NCT02923622||Traditional Chinese and Western medicine combined group|
11267328|NCT02923622||Traditional Chinese medicine group|
11267329|NCT02923622||Western medicine group|
11267330|NCT02923609|Active Comparator|SC Group|After enrollment, all patients will receive 5-day stem cell mobilization with G-CSF. Thereafter, patients will be randomly allocated to either active (SC Group) or control group (Controls) in a 2:1 ratio. Patients in the SC Group will undergo apheresis; CD34+ cells will be collected with immunomagnetic selection, and delivered transendocardialy in the target areas defined by electroanatomical mapping.
11267331|NCT02923609|Placebo Comparator|Control|In the Control group, no apheresis or immunomagnetic selection of CD34+ cells will be performed; the patients will receive transendocardial injections of placebo using the same electroanatomical mapping protocol as in patients from the SC Group.
11267332|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
11267333|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
11267334|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
11267335|NCT02923583|Experimental|M834|M834 (abatacept biosimilar candidate)
11267336|NCT02923583|Active Comparator|US Orencia®|US-sourced Orencia® (abatacept)
11267337|NCT02923583|Active Comparator|EU Orencia®|EU-sourced Orencia® (abatacept)
11267338|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
11267339|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
11267340|NCT02923557|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
11267341|NCT02923557|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
11267342|NCT02923544|Experimental|total laparoscopic or robotic-assisted hysterectomy|The YUMI manipulator will be placed at the start of each case. During the surgery, the surgeon will track any intraoperative complications. The surgeon fellow will also note the feasibility of placing the uterine manipulator.After surgery, the surgeon will complete the product evaluation form.
11267343|NCT02923531|Experimental|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study treatment will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
11267344|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
11267345|NCT02923518||Control group|Those without a positive score on the two scores listed above.
11267346|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
11267347|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
11267348|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
11267349|NCT02923492|Experimental|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
11267350|NCT02923492|Experimental|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
11267351|NCT02923492|No Intervention|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
11267352|NCT02923479|Experimental|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:
~General Rehabilitation
~Specific ankle rehabilitation by ARBOT device"
11267353|NCT02923479|Other|Control Group|"The patients in the Control Group underwent to following interventions:
~General Rehabilitation
~Specific ankle rehabilitation performed by physiotherapist
~Specific ankle rehabilitation by Biodex System 3 dynamometer
~Specific ankle rehabilitation by ProKin PK254 platform."
11267354|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
11267356|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.
~Avelumab will be administered intravenously every 2 weeks starting on day 1."
11267357|NCT02923453|Placebo Comparator|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
11267358|NCT02923453|Active Comparator|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
11267359|NCT02923440|Experimental|Congenital heart defects|
11267360|NCT02923427|Active Comparator|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
11267361|NCT02923427|Experimental|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
11267362|NCT02923414|Active Comparator|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
11267363|NCT02923414|Active Comparator|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
11267364|NCT02923401|Experimental|High-Intensity Interval Training (HIIT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.
~Participants receive written materials and instructions on how to perform their exercises.
~Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.
~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.
~One (1) time each month, participant attends a motivational session."
11267365|NCT02923401|Experimental|Moderate-Intensity Continuous Training (MICT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.
~Participants receive written materials and instructions on how to perform their exercises.
~Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.
~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.
~One (1) time each month, participant attends a motivational session."
11267366|NCT02923401|Active Comparator|Control Group|"Participants receive written materials and counseling by an exercise physiologist.
~Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals.
~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.
~One (1) time each month, participant attends a motivational session."
11267367|NCT02923388|Active Comparator|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
11267368|NCT02923388|Placebo Comparator|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
11267369|NCT02923375|Experimental|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
11267370|NCT02923375|Experimental|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
11267371|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
11267372|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
11267373|NCT02923349|Experimental|INCAGN01949|
11267374|NCT02923336|Other|Smart pill|Single group, before and after, the same group is going to be its own control
11267375|NCT02923323|Experimental|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
11267376|NCT02923323|Active Comparator|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
11267377|NCT02923310|Experimental|Osteoarthrits G II and III|Group of treatment
11267378|NCT02923310|Experimental|Osteoarthrits GIV|Group of treatment
11267379|NCT02923297|Other|Parkinson's disease patients|blood sampling
11267380|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
11267381|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
11267382|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.
~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
11267413|NCT02923089|Experimental|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
11267414|NCT02923089|Experimental|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
11267415|NCT02923089|Placebo Comparator|Rice Chili|Chili: 25g available carbohydrate from rice
11267416|NCT02923076|Experimental|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
11267442|NCT02922894|Experimental|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
11267383|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.
~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
11267384|NCT02923258|Experimental|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
11267385|NCT02923258|Active Comparator|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
11267386|NCT02923245|Experimental|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
11267387|NCT02923245|No Intervention|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
11267388|NCT02923232|Experimental|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
11267389|NCT02923219|Experimental|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
11267390|NCT02923206|Experimental|Phase 0 - healthy volunteers|Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
11267391|NCT02923206|Experimental|Phase A - preeclampsia patients|Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
11267392|NCT02923206|Experimental|Phase B - preeclampsia patients|Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
11267393|NCT02923193|Experimental|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
11267394|NCT02923193|Active Comparator|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
11267395|NCT02923180|Experimental|Enoblituzumab|15mg/kg IV (in the vein) weekly for 6 weeks
11267396|NCT02923167|Experimental|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on particpant fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
11267397|NCT02923154|Experimental|MT-3995|
11267398|NCT02923154|Placebo Comparator|Placebo|
11267399|NCT02923141|Active Comparator|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
11267400|NCT02923141|Active Comparator|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
11267401|NCT02923128|Active Comparator|Dexmedetomidine+routine PCIA|Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
11267402|NCT02923128|Sham Comparator|Routine PCIA|Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
11267403|NCT02923115|Experimental|DS-1040b|Participants who are randomized to receive DS-1040b as a single, continuous intravenous infusion (initial loading dose 3-6 mg). All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
11267404|NCT02923115|Placebo Comparator|Placebo|Participants who are randomized to receive placebo as a single, continuous intravenous infusion. All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
11267405|NCT02923102|Active Comparator|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
11267406|NCT02923102|Placebo Comparator|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
11267407|NCT02923089|Experimental|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
11267408|NCT02923089|Experimental|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
11267409|NCT02923089|Placebo Comparator|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
11267410|NCT02923089|Experimental|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
11267417|NCT02923063|Experimental|Combined Aerobic and Resistance Exercise|"Exercise will be supervised by exercise trainers 3 days per week for 12 weeks. Aerobic intervention sessions of 30-minute duration will target 60-80% of the maximal heart rate (or rating of perceived exertion of 13 on a scale of 6-20). We will encourage adherence to 50% ambulatory based and 50% cycling based aerobic exercise each session targeting the same goal heart rate.
~Resistance exercises occur 3 times weekly. The load will be adjusted for each exercise as needed on successive sets to ensure that subjects achieved momentary failure in the target repetition range. The load will be increased based on the supervising researcher's assessment of what would be required to reach momentary failure in the desired loading range; if less than 8 repetitions were accomplished, the load was similarly decreased. All routines will be directly supervised by the research team to ensure proper performance of the respective routines."
11267418|NCT02923063|No Intervention|Usual Care|"The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
11267419|NCT02923050|No Intervention|Waitlist control|
11267420|NCT02923050|Experimental|10-week family meals program|
11267421|NCT02923037|Experimental|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
11267422|NCT02923024|No Intervention|Usual Care|This arm will be usual care and there will be no intervention.
11267423|NCT02923024|Experimental|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
11267424|NCT02923024|Experimental|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
11267425|NCT02923011|Active Comparator|MRgFUS|Magnetic resonance-guided focused ultrasound ablation
11267426|NCT02923011|Active Comparator|CTgRFA|Computed tomography-guided radiofrequency ablation
11267427|NCT02922985|Placebo Comparator|Placebo Control Group|Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.
11267428|NCT02922985|Active Comparator|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications: Patients will receive the pre-operative dose of IV acetaminophen 1 g within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of either 20 mL of bupivacaine 0.25% after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive 60 mg of IM ketorolac.
11267429|NCT02922972|Experimental|Platelet Rich Plasma|Interventions: Four injections of PRP: The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
11267430|NCT02922959|Active Comparator|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.
~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
11267431|NCT02922959|Experimental|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.
~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
11267432|NCT02922946|Experimental|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.
~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
11267433|NCT02922946|Experimental|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.
~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.
~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
11267434|NCT02922933|Active Comparator|Omeprazole|"Treatment A: 5mg entinostat on Day 1
~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
11267435|NCT02922933|Active Comparator|Famotidine|"Treatment C: 5mg entinostat on Day 1
~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
11267436|NCT02922933|Active Comparator|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water
~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
11267437|NCT02922920|Experimental|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
11267438|NCT02922920|Placebo Comparator|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
11267439|NCT02922907|Experimental|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
11267440|NCT02922907|Placebo Comparator|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
11267441|NCT02922894|Experimental|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
11267444|NCT02922881|Experimental|Ulcerative Colitis Diet|Participants will receive a structured 12-week diet with a step down phase.
11267445|NCT02922868|Experimental|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
11267446|NCT02922868|Active Comparator|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
11267447|NCT02922855|No Intervention|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
11267448|NCT02922855|Active Comparator|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
11267449|NCT02922855|Experimental|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
11267450|NCT02922855|Experimental|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
11267451|NCT02922842|Active Comparator|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
11267452|NCT02922842|Active Comparator|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
11267453|NCT02922842|Sham Comparator|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
11267454|NCT02922816|Placebo Comparator|Control arm|The control arm will participate in the bowel preparation and stool or perirectal swab sampling but will not receive Fecal Microbiota Transplant (FMT) nor will they be fasting during their first study cycle (Cycle 0). Participants testing positive for a multi-drug resistant organism at the of Cycle 0 will be eligible to receive microbiota restoration transplant (MRT) for up to two cycles, as necessary (Cycles 1 and 2).
11267455|NCT02922816|Experimental|Fecal Microbiota Transplant (FMT)|The experimental arm will participate in the bowel preparation, stool or perirectal swab sampling, and will receive Fecal Microbiota Transplant (FMT) using Allogeneic Human Stool in Glycerol 10% (AHSG) on Day 1 of each cycle (Cycles 1 and 2).
11267456|NCT02922803|Active Comparator|Vitamin D insufficient|Subjects with Vitamin D level in blood > 25 nmool/L < 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
11267457|NCT02922803|Active Comparator|Vitamin D deficient|Subjects with Vitamin D level in blood < 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
11267458|NCT02922790|Active Comparator|Control|"Subjects will review standard health information on the health consequences of smoking.
~Subjects will have blood drawn but it will not be tested for DNA damage."
11267459|NCT02922790|Active Comparator|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.
~Subjects will have blood drawn and the feedback will be presented at Visit 2."
11267460|NCT02922790|Active Comparator|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.
~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
11267461|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
11267462|NCT02922764|Experimental|Single agent RGX-104|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors.
11267463|NCT02922764|Experimental|RGX-104 combined with nivolumab|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors. Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PDL1 and PD-L2.
11267464|NCT02922764|Experimental|RGX-104 combined with ipilimumab|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors. Ipilimumab is a recombinant human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated protetin 4 (CTLA-4).
11267465|NCT02922764|Experimental|RGX-104 combined with docetaxel|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors. Docetaxel is an anti-mitotic chemotherapy that binds to microtubules, blocking mitosis by inhibiting mitotic spindle assembly.
11267466|NCT02922764|Experimental|RGX-104 combined with pembrolizumab and carboplatin/pemetrexed|RGX-104 is a small molecule agonist of the liver X receptor (LXR), a member of the nuclear receptor family of transcription factors. Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2. Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links. Pemetrexed is an antifolate, disrupting folate-dependent metabolic processes essential for cell replication.
11267467|NCT02922751||All Subjects|All subjects will be recruited from the Children parent studies: LOGIC (NCT00571272), BASIC (NCT00345553) and PROBE (NCT00061828) and will undergo Liver Stiffness Measurement (LSM). Subjects in these studies have one or more of the following conditions: biliary atresia (BA), Alpha1 Anti-trypsin Deficiency (A1AT) or Alagille Syndrome (ALGS).
11267468|NCT02922738|Experimental|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
11267469|NCT02922738|No Intervention|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
11267470|NCT02922725|Active Comparator|Depressed patients receiving study drug|Participants diagnosed with MDD
11267471|NCT02922725|Placebo Comparator|Depressed patients receiving placebo|Participants diagnosed with MDD
11267472|NCT02922725|No Intervention|Healthy Control|
11267473|NCT02922712|Experimental|NISE 100mg|Nise 100mg given BD for 3 weeks
11267474|NCT02922699|Experimental|Omeprazole 40mg|Omez 40mg OD
11267476|NCT02922686|Active Comparator|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
11267477|NCT02922686|Placebo Comparator|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
11267478|NCT02922673|Experimental|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
11267479|NCT02922673|Active Comparator|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
11267480|NCT02922673|Placebo Comparator|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
11267481|NCT02922660|Experimental|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
11267482|NCT02922660|Experimental|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
11267483|NCT02922647|Experimental|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
11267484|NCT02922647|Active Comparator|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
11267485|NCT02922634||older surgical patients|older surgical patients presenting for elective thoracic surgery (specifically, thoracoscopic lung resection, lobectomy, thoracotomy, or esophagectomy) and to neurological posterior thoracolumbar spine surgery by neurosurgeons Dr. Groff, Dr. Lu and Dr. Chi
11267486|NCT02922595|Active Comparator|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
11267487|NCT02922595|Experimental|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
11267488|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 gram IV TXA intraoperatively at the end of surgery one time
11267489|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
11267490|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
11267491|NCT02922569|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
11267492|NCT02922569|Active Comparator|Active Comparator|Commercially available computerized training and traumatic brain injury information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
11267493|NCT02922556|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
11267494|NCT02922556|Active Comparator|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
11267495|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
11267496|NCT02922530|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
11267497|NCT02922530|Active Comparator|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
11267498|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
11267499|NCT02922517||controls|patients without HCM
11267500|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
11267501|NCT02922504|Experimental|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use before the procedure
11267502|NCT02922504|Active Comparator|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
11267503|NCT02922491|Experimental|Group 1|"400 mg Vitamin E of synthetic source
~1 once daily during 2 months"
11267504|NCT02922491|Experimental|Group 2|"400 mg Vitamin E of natural source
~1 once daily during 2 months"
11267505|NCT02922491|Placebo Comparator|Group control|"400 mg of starch
~1 once daily during 2 months"
11267506|NCT02922491|No Intervention|No intervention|Without intervention
11267507|NCT02922465|Experimental|K-877 & Clopidogrel|K-877 & Clopidogrel orally
11267508|NCT02922452|Experimental|BMS-986141 and Dilitazem|
11267509|NCT02922439|Experimental|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
11267510|NCT02922439|Active Comparator|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
11267511|NCT02922426|Experimental|ALKS 3831|Oral, bilayer tablet
11267512|NCT02922426|Active Comparator|Olanzapine|Oral, bilayer tablet
11267513|NCT02922426|Placebo Comparator|Placebo|Oral, bilayer tablet
11267514|NCT02922413|Experimental|Hemin for injection|Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
11267516|NCT02922400|Experimental|Social Cognition Assessment and Training|Assessment and training program to enhance social function
11267517|NCT02922387|Experimental|Varenicline + Behavioral support|varenicline and behavioral support
11267518|NCT02922387|Active Comparator|Behavioral support|behavioral support
11267519|NCT02922374|Experimental|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
11267520|NCT02922348|Experimental|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
11267521|NCT02922348|Experimental|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
11267522|NCT02922335|Experimental|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
11267523|NCT02922335|Active Comparator|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
11267524|NCT02922322|Active Comparator|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
11267525|NCT02922322|No Intervention|Control Group|The control group was composed by 15 participants that received no intervention
11267526|NCT02922309|Experimental|experimental|Vocal Training via Telepractice
11267527|NCT02922309|Active Comparator|control|Vocal Training via face-to-face practice
11267528|NCT02922283|Experimental|IL2-PET scan|[18F]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
11267529|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
11267530|NCT02922244|No Intervention|Standard skin care|standard skin care
11267531|NCT02922244|Placebo Comparator|Control|Moisture Cream
11267532|NCT02922244|Active Comparator|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
11267533|NCT02922244|Active Comparator|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
11267534|NCT02922244|Active Comparator|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
11267535|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
11267536|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
11267537|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
11267538|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
11267539|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
11267540|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
11267541|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
11267542|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
11267543|NCT02922166|Experimental|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
11267544|NCT02922166|Placebo Comparator|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
11267545|NCT02922153|Experimental|Cryoanalgesia + Standard of Care (SOC)|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
11267546|NCT02922153|Active Comparator|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
11267547|NCT02922140|No Intervention|control group|will receive standard care by physician in attendance
11267548|NCT02922140|Active Comparator|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
11267549|NCT02922127|Other|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
11267550|NCT02922127|Other|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
11267551|NCT02922114|Experimental|Ultrasonography|B-mode and power Doppler Ultrasonography examination
11267552|NCT02922101|Experimental|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
11267553|NCT02922101|Active Comparator|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
11267554|NCT02922075|Placebo Comparator|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
11267555|NCT02922075|Experimental|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
11267585|NCT02921854|Experimental|All included patients|3 times Blood withdrawal for each patient (25ml each)
11267556|NCT02922075|Experimental|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
11267557|NCT02922062|Experimental|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
11267558|NCT02922062|Active Comparator|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
11267559|NCT02922049|Other|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.
~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
11267560|NCT02922036|Experimental|Treatment|WiSE System therapy ON with Guideline Directed Medical Therapy
11267561|NCT02922036|Sham Comparator|Control|WiSE System therapy OFF with Guideline Directed Medical Therapy
11267562|NCT02922023|Active Comparator|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
11267563|NCT02922023|Active Comparator|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
11267564|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
11267565|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
11267566|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
11267567|NCT02921984|Experimental|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
11267568|NCT02921984|Experimental|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
11267569|NCT02921984|Experimental|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
11267570|NCT02921971|Experimental|SAR156597|SAR156597 will be given on a specific time period
11267571|NCT02921971|Placebo Comparator|Placebo|Placebo will be given on a specific time period
11267572|NCT02921945|Experimental|SCT800|
11267573|NCT02921932|Active Comparator|Intervention|"In the interventional arm, patients will be given:
~A 'Threshold' Inspiratory Muscle Trainer
~A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).
~Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.
~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
11267574|NCT02921932|No Intervention|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
11267575|NCT02921919|Experimental|Talazoparib|
11267576|NCT02921906|Experimental|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
11267577|NCT02921906|Active Comparator|Non-diabetic controls|People without diabetes.
11267578|NCT02921906|Active Comparator|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
11267579|NCT02921893|Experimental|Group I (ixazomib citrate, lenalidomide, dexamethasone,ASCT)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 courses of treatment.
11267580|NCT02921893|Experimental|Group II (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11267581|NCT02921880|Experimental|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
11267582|NCT02921880|No Intervention|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
11267583|NCT02921867|Experimental|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
11267584|NCT02921867|No Intervention|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
11267586|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
11267587|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
11267588|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
11267589|NCT02921815||Patients with myeloid leukemia|All del(5q) Myelodysplastic syndrome (MDS) patients in the all-case surveillance in whom transformation to acute myeloid leukemia has not been documented at the end of the observation period of the all-case surveillance.
11267590|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
11267591|NCT02921789|Active Comparator|Standard of Care Regimen|Standard of Care regimen (basiliximab induction, tacrolimus, methylprednisone, prednisone and MMF).
11267592|NCT02921789|Experimental|Bleselumab Regimen|Bleselumab regimen (basiliximab, methylprednisone, prednisone, bleselumab and tacrolimus).
11267593|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.
~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.
~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
11267594|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.
~Intervention is usability tasks with the VidaTalk app"
11267595|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
~Intervention will be receipt of VidaTalk tablet application."
11267596|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.
~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
11267597|NCT02921776|No Intervention|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.
~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
11267598|NCT02921763||Dydrogesterone|Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.
11267599|NCT02921750|Experimental|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
11267600|NCT02921750|Active Comparator|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
11267601|NCT02921737|Experimental|Treatment Arm|TAS-102
11267602|NCT02921724|Experimental|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
11267603|NCT02921711||LVIS®|
11267604|NCT02921698||FRED®|
11267605|NCT02921685|Experimental|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
11267606|NCT02921672|Active Comparator|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
11267682|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
11267607|NCT02921672|Active Comparator|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
11267608|NCT02921672|Experimental|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
11267609|NCT02921659|Placebo Comparator|Placebo|placebo, 500 mg, 2x/day for 6 weeks
11267610|NCT02921659|Active Comparator|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
11267611|NCT02921646|Other|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
11267612|NCT02921633|Experimental|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
11267613|NCT02921633|No Intervention|Control|No centrally-sent invitation letter.
11267614|NCT02921620|Experimental|PRX-102|PRX-102 infusions every 2 weeks
11267615|NCT02921620|Placebo Comparator|Placebo|Placebo infusions every 2 weeks
11267616|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
11267617|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
11267618|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
11267619|NCT02921568|Other|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
11267620|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
11267621|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
11267622|NCT02921542||Homogenous Lesions|
11267623|NCT02921542||Heterogenous Lesions|
11267624|NCT02921542||Calcific Lesions|
11267625|NCT02921542||Restenotic Lesions|
11267626|NCT02921529|Experimental|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
11267627|NCT02921529|Sham Comparator|false stimulation|Attach electrodes without electric current
11267628|NCT02921516|Experimental|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
11267629|NCT02921516|Active Comparator|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
11267630|NCT02921516|Placebo Comparator|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
11267631|NCT02921503|Experimental|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
11267632|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
11267633|NCT02921477|Experimental|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
11267634|NCT02921464||Group A|Group A - without known pre-existing SIHD
11267635|NCT02921464||Group B|Group B - with known pre-existing SIHD.
11267636|NCT02921451|Other|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
11267637|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
11267638|NCT02921425|Experimental|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
11267639|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
11267640|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
11267641|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
11267642|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
11267643|NCT02921386|Other|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
11267644|NCT02921386|Other|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
11267683|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
11267645|NCT02921386|Other|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
11267646|NCT02921386|Other|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
11267647|NCT02921386|Other|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
11267648|NCT02921373|Experimental|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.
~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
11267649|NCT02921373|Experimental|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.
~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
11267650|NCT02921360|Experimental|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
11267651|NCT02921360|No Intervention|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
11267652|NCT02921347|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
11267653|NCT02921347|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
11267654|NCT02921334|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
11267655|NCT02921334|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
11267656|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
11267657|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
11267658|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
11267659|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
11267660|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
11267661|NCT02921269|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11267662|NCT02921256|Active Comparator|Arm I (mFOLFOX6, RT, capecitabine)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
11267663|NCT02921256|Experimental|Arm II (mFOLFOX6, RT, capecitabine, veliparib)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
11267664|NCT02921256|Experimental|Arm III (mFOLFOX6, RT, capecitabine, pembrolizumab)|ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11267665|NCT02921243||Stool Sample Collection|
11267666|NCT02921243||Prebiotic|
11267667|NCT02921230|Experimental|ELUVIA Stent Implantation|Peripheral stenting
11267668|NCT02921230|Active Comparator|control Bare Metal Stent Implantation|Peripheral stenting
11267669|NCT02921217|Experimental|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
11267670|NCT02921217|Experimental|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
11267671|NCT02921217|Placebo Comparator|Control|Control
11267672|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
11267673|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
11267674|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
11267675|NCT02921165|Active Comparator|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
11267676|NCT02921165|Experimental|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
11267677|NCT02921165|Experimental|Group 3|Non Hypertensive Intervention: On normal saline rinses.
11267678|NCT02921152|Other|all|All patients with early breast cancer
11267679|NCT02921139|Experimental|Arm I|Stereotactic ablative radiotherapy (SABR)
11267680|NCT02921139|Active Comparator|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
11267681|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
11267684|NCT02921100|Other|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
11267685|NCT02921100|Other|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
11267686|NCT02921087|Other|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
11267687|NCT02921087|Other|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
11267688|NCT02921074|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
11267689|NCT02921074|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
11267690|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.
~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.
~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
11267691|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
11267692|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
11267693|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
11267694|NCT02921022|Experimental|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
11267695|NCT02921022|Experimental|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
11267696|NCT02921009|Experimental|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
11267697|NCT02920996|Experimental|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
11267698|NCT02920996|Experimental|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
11267699|NCT02920983|Active Comparator|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
11267700|NCT02920983|Active Comparator|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
11267701|NCT02920983|Active Comparator|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
11267702|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
11267703|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
11267704|NCT02920957|Active Comparator|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
11267705|NCT02920957|Active Comparator|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
11267706|NCT02920944|Experimental|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
11267707|NCT02920944|Active Comparator|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
11267708|NCT02920931|Experimental|A|"st period: Tenofovir disoproxil fumarate
~nd period: Tenofovir Disoproxil"
11267709|NCT02920931|Active Comparator|B|"st period: Tenofovir disoproxil
~nd period: Tenofovir Disoproxil fumarate"
11267710|NCT02920918|Active Comparator|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
11267711|NCT02920918|Active Comparator|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
11267712|NCT02920905|Experimental|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
11267713|NCT02920905|Experimental|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
11267714|NCT02920905|Experimental|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
11267764|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
11267765|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
11267766|NCT02920723|Experimental|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
11267715|NCT02920892|Experimental|AFQ056 group with language intervention|12 month treatment phase during which subjects are randomized to AFQ056. The initial dose of AFQ056 will be 25 mg BID. If the subject has no side effects the dose will be titrated (mandatory titration if no side effects) to the next level, 50 mg BID, 75 mg BID and 100 mg BID in order. A flexible dose design will mimic practice, and allow use of maximum tolerated dose (MTD) which is likely to be most effective. The dose can be adjusted weekly through week 7. After 7 weeks the dose will be fixed, and at the 2 month visit all subjects will initiate the language intervention, remaining on a stable AFQ056/placebo dose for the next 6 months.
11267716|NCT02920892|Placebo Comparator|Placebo group with language intervention|12-month treatment phase during which subjects are randomized to placebo. At the 2 month visit (language intervention baseline visit) all subjects will initiate the language intervention, remaining on placebo dose for the next 6 months.
11267717|NCT02920879|Other|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
11267718|NCT02920879|Other|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
11267719|NCT02920879|Other|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
11267720|NCT02920879|Other|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
11267721|NCT02920866|Experimental|Functional Strength Integration (FSI)|Progressive strength training exercise, specific functional activity to improve pelvic stability and core muscle strength
11267722|NCT02920866|Active Comparator|Control Group (CON)|Usual care, continuing education on postsurgical precautions
11267723|NCT02920853|Experimental|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
11267724|NCT02920853|Active Comparator|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
11267725|NCT02920840|Active Comparator|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
11267726|NCT02920840|Experimental|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
11267727|NCT02920840|Active Comparator|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
11267728|NCT02920827|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
11267729|NCT02920827|Placebo Comparator|Placebo Vaginal Ring|Placebo vaginal ring
11267730|NCT02920814|Experimental|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
11267731|NCT02920801|Experimental|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
11267732|NCT02920801|Active Comparator|metformin group|metformin group consumed metformin 1500mg per day for 12 week
11267733|NCT02920788|Experimental|Veteran Mild TBI Group - GOALS Intervention|Veterans ages 18+ with chronic mild TBI, to undergo GOALS cognitive training as an intervention.
11267734|NCT02920788|Active Comparator|Veteran Mild TBI - Treatment as Usual|Veterans ages 18+ with chronic mild TBI, matched by demographic and clinical criteria to the GOALS group, to receive the standard clinical care.
11267735|NCT02920788|No Intervention|Veteran Non TBI - No Treatment|Veterans ages 18+ with no history of TBI, to undergo Neuropsychologic evaluation and MR Imaging with no intervention.
11267736|NCT02920775||Pain|
11267737|NCT02920775||PCP|
11267738|NCT02920775||Dentist|
11267739|NCT02920775||Surgery|
11267740|NCT02920775||Emergency Medicine|
11267741|NCT02920775||Oncology|
11267742|NCT02920775||Hospice and Palliative Medicine|
11267743|NCT02920775||Anesthesiology|
11267744|NCT02920775||Neurology|
11267745|NCT02920775||Nurse Practitioners|
11267746|NCT02920775||Pediatrics|
11267747|NCT02920775||Physical Medicine & Rehabilitation|
11267748|NCT02920775||Physician Assistant|
11267749|NCT02920775||Rheumatology|
11267750|NCT02920775||All Other Specialties|
11267751|NCT02920762||Buprenorphine|
11267752|NCT02920762||Fentanyl|
11267753|NCT02920762||Hydromorphone HCl|
11267754|NCT02920762||Morphine Sulfate|
11267755|NCT02920762||Morphine Sulfate Beads|
11267756|NCT02920762||Oxycodone HCl|
11267757|NCT02920762||Oxymorphone HCl|
11267758|NCT02920762||Tapentadol|
11267759|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
11267760|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
11267761|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
11267762|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
11267763|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
11267767|NCT02920723|Other|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
11267768|NCT02920710|Experimental|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
11267769|NCT02920697|Experimental|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
11267770|NCT02920697|Experimental|Chronic Lymphocytic Leukaemia (CLL)|
11267771|NCT02920684|Active Comparator|Passive legs mobilisation|A physiotherapist performs passive legs movement
11267772|NCT02920684|Active Comparator|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
11267773|NCT02920684|Active Comparator|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
11267774|NCT02920684|Active Comparator|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
11267775|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
11267776|NCT02920671||Obese|BMI > 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
11267777|NCT02920671||Normal Weight & Overweight|BMI 18.5 - < 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
11267778|NCT02920658|Experimental|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
11267779|NCT02920658|Active Comparator|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
11267780|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
11267781|NCT02920632|Experimental|Online cognitive training 1 (N=70)|Eight-week, three times a week during 45 minutes cognitive training
11267782|NCT02920632|Active Comparator|Online cognitive training 2 (N=70)|Eight-week, three times a week during 45 minutes cognitive activities
11267783|NCT02920632|No Intervention|Healthy control subjects (N=30)|Reference group to compare cognitive training effects to
11267784|NCT02920606|Active Comparator|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.
~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
11267785|NCT02920606|Experimental|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
11267786|NCT02920593|Experimental|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
11267787|NCT02920593|No Intervention|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
11267788|NCT02920580|Active Comparator|Extubation|Extubation by removal of endotracheal tube.
11267789|NCT02920580|Active Comparator|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
11267790|NCT02920567|Experimental|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
11267791|NCT02920567|Placebo Comparator|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
11267792|NCT02920554|Active Comparator|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
11267793|NCT02920554|Active Comparator|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
11267794|NCT02920541|Experimental|S 055746|
11267795|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
11267796|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
11267797|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
11267798|NCT02920515|Experimental|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
11267799|NCT02920515|Active Comparator|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
11267800|NCT02920515|No Intervention|blank group|without therapy
11267801|NCT02920502|Placebo Comparator|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
11267802|NCT02920502|Experimental|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
11267803|NCT02920502|Experimental|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
11267804|NCT02920502|Experimental|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
11267805|NCT02920489|Experimental|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
11267851|NCT02920164|Placebo Comparator|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
11267806|NCT02920489|Active Comparator|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
11267807|NCT02920476|Experimental|Treatment arm|TAS-102
11267808|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
11267809|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
11267810|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
11267811|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
11267812|NCT02920450|Experimental|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
11267813|NCT02920437|Experimental|Intervention group|Four-week weekly intervention to reduce salt intake.
11267814|NCT02920437|Other|Control group|Usual government pamphlets.
11267815|NCT02920424|Experimental|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 [4 active: 1 placebo]).
11267816|NCT02920424|Experimental|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 [5 active: 1 placebo]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
11267817|NCT02920411|Experimental|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:
~Pediatopic treatment cream during acute stages of atopic dermatitis and
~Pediatopic body lotion during stable stages"
11267818|NCT02920398|Experimental|N8-GP pivotal|
11267819|NCT02920398|Active Comparator|N8-GP commercial|
11267820|NCT02920385|Experimental|Levothyroxine/SNAC/Placebo/Semaglutide|
11267821|NCT02920372|Experimental|EPOETIN ALFA|
11267822|NCT02920359|Experimental|LEUPRORELIN ACETATE|
11267823|NCT02920333|Experimental|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
11267824|NCT02920333|Experimental|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
11267825|NCT02920333|Sham Comparator|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
11267826|NCT02920320|Experimental|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink & Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
11267827|NCT02920320|No Intervention|Waiting control group|
11267828|NCT02920307|Experimental|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
11267829|NCT02920307|Active Comparator|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
11267830|NCT02920307|Experimental|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
11267831|NCT02920307|Active Comparator|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
11267832|NCT02920294|Active Comparator|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
11267833|NCT02920294|Active Comparator|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
11267834|NCT02920294|Placebo Comparator|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
11267835|NCT02920268|Experimental|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
11267836|NCT02920268|No Intervention|Controls|No intervention
11267837|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
11267838|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
11267839|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
11267840|NCT02920242|Experimental|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
11267841|NCT02920242|Active Comparator|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
11267842|NCT02920242|Placebo Comparator|Placebo|Patients received placebo tablet 3 times per day for 3 days.
11267843|NCT02920229|Experimental|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
11267844|NCT02920216|Experimental|eligible patient for a salvage surgery|
11267845|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
11267846|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
11267847|NCT02920190|Experimental|Liraglutide Group|Participants in this group will receive the Liraglutide intervention for 12 months
11267848|NCT02920177|Experimental|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
11267849|NCT02920177|Active Comparator|Kenalog 10 mg/mL Injectable Suspension|corticosteroid injection into the head-neck junction of the hip joint
11267850|NCT02920164|Active Comparator|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
11267853|NCT02920151|Experimental|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
11267854|NCT02920151|No Intervention|CONTROL GROUP|usual routine
11267855|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
11267856|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
11267857|NCT02920125|Active Comparator|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.
~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
11267858|NCT02920125|Placebo Comparator|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
11267859|NCT02920112|Experimental|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
11267860|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
11267861|NCT02920086|Experimental|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
11267862|NCT02920086|Experimental|Decision Support Program|Decision support education for family members of an elderly critically ill patient
11267863|NCT02920086|No Intervention|Usual Care|No intervention
11267864|NCT02920060|Experimental|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
11267865|NCT02920060|Active Comparator|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
11267866|NCT02920047|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)
~There will be a washout of 14 days between the each period."
11267867|NCT02920047|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)
~There will be a washout of 14 days between the each period."
11267868|NCT02920047|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)
~There will be a washout of 14 days between the each period."
11267869|NCT02920034|Active Comparator|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
11267870|NCT02920034|Experimental|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
11267871|NCT02920034|Experimental|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
11267872|NCT02920021|Experimental|ANB020|ANB020, administration of ANB020
11267873|NCT02920021|Placebo Comparator|Placebo|Placebo, administration of Placebo
11267874|NCT02920008|Experimental|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m2 in 28-day cycles (delayed as necessary to allow blood count recovery).
11267875|NCT02920008|Active Comparator|Treatment Choice (TC)|"High intensity
~Low intensity
~Best supportive care (BSC)."
11267876|NCT02919995|Experimental|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
11267877|NCT02919995|Experimental|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
11267878|NCT02919995|Placebo Comparator|Placebo|Inhaled placebo dose
11267879|NCT02919969|Experimental|Pembrolizumab|"Pembrolizumab is administered every 3 week intravenously
~Dosage to be determine by physician"
11267880|NCT02919956||Group I: CBF-I Single Ventricles|The 1st group (cohort group) will be patients who were enrolled in the original NIH CBF grant. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
11267881|NCT02919956||Group II: Prospective Single Ventricles|The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
11267882|NCT02919956||Group III: CBF-I Normal Controls|The 3rd group (cohort group) will be normal controls who were enrolled in the original CBF grant. These patients will have Neurodevelopmental Testing. The data from these patients' MRI from CBF-I (original CBF grant) will be used.
11267883|NCT02919956||Group IV: Prospective Normal Controls|The 4th group (cross sectional group) will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for clinically indicated MRIs and found to have structurally normal cardiac and brain anatomy. These patients will have an abbreviated research MRI, lasting 15-20 minutes, added onto their clinically-indicated MRI at CHOP. They will also have Neurodevelopmental Testing.
11267884|NCT02919956||Volunteer Group|There will also be a volunteer group of one to five volunteers that will be enrolled prior to enrollment in the other four study groups. These volunteers will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for a clinically-indicated MRI and consent to have an additional 15-20 minutes of research MRI scanning. The purpose will be to ensure that the brain MRI sequences run correctly and produce useful information before the patient and normal control enrollment begins. The volunteers will not undergo neurodevelopmental testing.
11267885|NCT02919930|Other|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
11267886|NCT02919930|Other|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
11267918|NCT02919670|Experimental|Enterade and Standard Supportive Care|"Two 8 oz. bottles of Enterade will be administered daily
~Enterade will be given orally from admission until day +14 or until discharge
~Standard Supportive Care will be administered according to institution's practice"
11267887|NCT02919917|Experimental|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.
~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).
~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
11267888|NCT02919917|Experimental|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.
~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).
~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
11267889|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
11267890|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
11267891|NCT02919878|Experimental|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).
~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.
~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
11267892|NCT02919865|Other|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
11267893|NCT02919852|Other|laparoscopic retrovesical colpopectinopexia|new operative technic
11267894|NCT02919826|Experimental|DBT Group|Adapted Dialectical Behaviour Therapy
11267895|NCT02919826|No Intervention|Control Arm|People in this group will receive treatment as usual
11267896|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
11267897|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
11267898|NCT02919800|Experimental|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life [t1/2] ~10 h, terminal t1/2 ~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 ~1 h, terminal t1/2 ~10 h) (Fares et al., 1992).
11267899|NCT02919800|Placebo Comparator|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
11267900|NCT02919787|Active Comparator|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
11267901|NCT02919787|Experimental|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
11267902|NCT02919774|Experimental|POMA 40 mg BID|40 mg BID for 10 days
11267903|NCT02919774|Experimental|POMA 160 mg BID|160 mg BID for 10 days
11267904|NCT02919774|Placebo Comparator|Placebo|Placebo BID for 10 days
11267905|NCT02919761|Experimental|Part 1: All Enrolled Participants|All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
11267906|NCT02919761|Experimental|Part 2: Acthar Gel|Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
11267907|NCT02919761|Placebo Comparator|Part 2: Placebo|Participants receive Placebo 1 mL twice weekly for an additional 12 weeks
11267908|NCT02919748|Experimental|Intervention arm|Choral Singing
11267909|NCT02919748|Active Comparator|Control arm|General Health Education Program and Group Activities
11267910|NCT02919735|Experimental|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
11267911|NCT02919735|Placebo Comparator|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
11267912|NCT02919722|Experimental|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
11267913|NCT02919709|Experimental|thoracic or abdominal aortic aneurysm|
11267914|NCT02919696|Experimental|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
11267915|NCT02919696|Experimental|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
11267916|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks
~Ipilimumab to be delivered at a pre-determine dose for one week
~Blood Sample Collected
~Standard of Care Surgery"
11267917|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks
~Blood Sample Collected
~Standard of Care Surgery"
11267919|NCT02919670|Placebo Comparator|Placebo and Standard Supportive Care|"Two 8 oz. bottles of Placebo will be administered daily
~Placebo will be given orally from admission until day +14 or until discharge
~Standard Supportive Care will be administered according to institution's practice"
11267920|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.
~Intervention: Weekly blood draws will determine the effect on blood protein levels."
11267921|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.
~Intervention: Weekly blood draws will determine the effect on blood protein levels."
11267922|NCT02919644|Experimental|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
11267923|NCT02919631|Active Comparator|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
11267924|NCT02919631|Placebo Comparator|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
11267925|NCT02919618|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to a region of the heart determined by EP-guidance, using noninvasive electrical mapping combined with anatomic imaging.
11267926|NCT02919605|Experimental|Single dose of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
11267927|NCT02919605|Experimental|Two doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
11267928|NCT02919605|Experimental|Three doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.
11267929|NCT02919592|Experimental|Primary Breast Augmentation|Participants who meet the requirements for primary breast augmentation (have not had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
11267930|NCT02919592|Experimental|Revision Breast Augmentation|Participants who meet the requirements for revision breast augmentation (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast implants
11267931|NCT02919592|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
11267932|NCT02919592|Experimental|Revision Breast Reconstruction|Participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
11267933|NCT02919592|Active Comparator|Other Aesthetic Surgery|Participants who meet the requirements for other aesthetic surgery procedures, which may not include silicone implants (breast or otherwise)
11267934|NCT02919579|Experimental|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3.
11267935|NCT02919579|Experimental|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
11267936|NCT02919579|Experimental|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
11267937|NCT02919579|Experimental|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
11267938|NCT02919579|Experimental|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
11267939|NCT02919579|Experimental|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
11267940|NCT02919579|Experimental|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
11267941|NCT02919553|Experimental|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
11267942|NCT02919553|Active Comparator|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
11267943|NCT02919540|Experimental|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
11267944|NCT02919540|No Intervention|control group|routine care will be implemented
11267945|NCT02919527|Experimental|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
11267946|NCT02919527|Active Comparator|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
11267947|NCT02919527|No Intervention|Control|No Intervention
11267948|NCT02919514|Active Comparator|Physical training on hard surface|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
11267949|NCT02919514|Experimental|Physical training on sand surface|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
11267950|NCT02919514|Experimental|Physical training on soft surface|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
11267951|NCT02919501|Experimental|IV vortioxetine|
11267952|NCT02919501|Placebo Comparator|IV placebo|
11267953|NCT02919488|Experimental|Exercise Condition|
11267954|NCT02919488|Active Comparator|Control Condition|
11267955|NCT02919475|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
11267956|NCT02919475|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
11267957|NCT02919475|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
11267958|NCT02919475|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
11267959|NCT02919475|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
11267960|NCT02919462|Experimental|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.
~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
11267961|NCT02919462|Active Comparator|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.
~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).
~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
11267962|NCT02919449|Experimental|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
11267963|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
11267964|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
11267965|NCT02919423|Active Comparator|10 Hz TMS|active TMS will be administered
11267966|NCT02919423|Active Comparator|1 Hz TMS|active TMS will be administered
11267967|NCT02919410|Active Comparator|Surgery performed using iodophor-impregnated adhesive drapes|
11267968|NCT02919410|Other|Surgery performed without iodophor-impregnated adhesive drapes|
11267969|NCT02919397|Experimental|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
11267970|NCT02919397|Active Comparator|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
11267971|NCT02919384|Experimental|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
11267972|NCT02919384|No Intervention|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
11267973|NCT02919371|Experimental|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
11267974|NCT02919358|Experimental|Music|Exposure to music, twice per day for the study period
11267975|NCT02919358|Other|Control|No intervention; standard care.
11267976|NCT02919345|Experimental|Dapagliflozin|Dapagliflozin 10 mg in addition to Metformin 1500 mg
11267977|NCT02919345|Active Comparator|Glibenclamide|Glibenclamide 5mg in addition to Metformin 1500 mg
11267978|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
11267979|NCT02919319|Experimental|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
11267980|NCT02919319|Experimental|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
11267981|NCT02919319|Experimental|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
11267982|NCT02919319|Experimental|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
11267983|NCT02919319|Experimental|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
11267984|NCT02919306|Experimental|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.
11267985|NCT02919306|Placebo Comparator|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
11267986|NCT02919293|Experimental|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
11267987|NCT02919293|Active Comparator|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
11267988|NCT02919280||No treatment|This is an observational study. No intervention / treatment involved.
11268085|NCT02918825|Experimental|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
11267989|NCT02919267|Other|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
11267990|NCT02919267|Other|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
11267991|NCT02919254|Active Comparator|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
11267992|NCT02919254|Active Comparator|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
11267993|NCT02919254|Placebo Comparator|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
11267994|NCT02919241|Experimental|Diagnostic interview|Intervention for this group include diagnostic interview. Oral health Impact Profile (OHIP 14) and Spielberg State and Trait Anxiety (STAI-1) questionnaires and behaviour analyses are used in diagnostic interview.
11267995|NCT02919241|Experimental|Combined interview and treatment|Intervention for this group include both the diagnostic interview and one session treatment.
11267996|NCT02919228|Experimental|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11267997|NCT02919228|Experimental|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11267998|NCT02919228|Experimental|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11267999|NCT02919228|Experimental|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11268000|NCT02919228|Experimental|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11268001|NCT02919228|Experimental|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11268002|NCT02919228|Experimental|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11268003|NCT02919228|Experimental|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
11268004|NCT02919215|Experimental|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
11268005|NCT02919215|No Intervention|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
11268006|NCT02919202|Experimental|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
11268007|NCT02919202|Active Comparator|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
11268008|NCT02919189|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268009|NCT02919189|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268010|NCT02919189|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268011|NCT02919189|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268012|NCT02919189|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268013|NCT02919189|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268014|NCT02919189|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268015|NCT02919189|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268016|NCT02919176|Active Comparator|Mirabegron|Mirabegron 50 mg/day
11268017|NCT02919176|Active Comparator|Pioglitazone|Pioglitazone 30 mg/day
11268018|NCT02919176|Experimental|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
11268019|NCT02919163|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268020|NCT02919163|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268021|NCT02919163|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268022|NCT02919163|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268023|NCT02919163|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268024|NCT02919163|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268025|NCT02919163|Experimental|Visible light exposure White 30 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268026|NCT02919163|Experimental|Visible light exposure White 120 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11268027|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.
~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
11268028|NCT02919137|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268029|NCT02919137|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268030|NCT02919137|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268031|NCT02919137|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268032|NCT02919137|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268033|NCT02919137|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268034|NCT02919137|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268035|NCT02919137|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
11268036|NCT02919124|Experimental|Echoclip device|Ultrasonography using the echoclip device
11268037|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
11268038|NCT02919098|Experimental|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
11268039|NCT02919098|Placebo Comparator|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.
~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
11268040|NCT02919085|Experimental|Mobilization|
11268041|NCT02919072|Experimental|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
11268042|NCT02919072|Active Comparator|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
11268043|NCT02919059|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
11268044|NCT02919059|Active Comparator|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
11268045|NCT02919046|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
11268046|NCT02919033|Placebo Comparator|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
11268047|NCT02919033|Experimental|Self-management|"BP tele-monitor & App based self-management supports
~Patient proficiency training"
11268048|NCT02919033|Experimental|PCTM intervention|"BP tele-monitor & App-based self-management supports
~Patient proficiency training
~PCP & cardiologist training of using Web-based analytics
~Proactive and interactive care by PCPs and cardiologists"
11268049|NCT02919020|Experimental|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
11268050|NCT02919020|Experimental|resistance exercise|Resistance exercise to strengthen lower limbs
11268051|NCT02919007|Experimental|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
11268052|NCT02918994|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
11268053|NCT02918981|Active Comparator|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
11268054|NCT02918981|Experimental|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
11268055|NCT02918981|Experimental|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
11268086|NCT02918825|Active Comparator|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
11268056|NCT02918981|Experimental|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
11268057|NCT02918981|Sham Comparator|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
11268058|NCT02918968|Experimental|Enzalutamide Preceding Group|Enzalutamide will be administered as the 1st line AAT. After the confirmation of PSA relapse, medication will be changed from enzalutamide to flutamide as the 2nd line AAT.
11268059|NCT02918968|Experimental|Flutamide Preceding Group|Flutamide will be administered as the 1st line AAT. After the confirmation of PSA relapse, medication will be changed from flutamide to enzalutamide as the 2nd line AAT.
11268060|NCT02918955|Active Comparator|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
11268061|NCT02918955|Experimental|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
11268062|NCT02918955|Active Comparator|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
11268063|NCT02918955|Experimental|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
11268064|NCT02918929|Experimental|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
11268065|NCT02918929|Experimental|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
11268066|NCT02918929|Placebo Comparator|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
11268067|NCT02918929|Placebo Comparator|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
11268068|NCT02918916|Experimental|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).
~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.
~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
11268069|NCT02918916|Placebo Comparator|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.
~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
11268070|NCT02918916|No Intervention|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
11268071|NCT02918903|Experimental|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
11268072|NCT02918903|Active Comparator|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
11268073|NCT02918890|Experimental|CIMT|Procedure: Constraint-Induced Movement Therapy 90 hours Other Name: CIT, CI Therapy, restraint therapy, PT, OT, rehab
11268074|NCT02918890|Experimental|HABIT|Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) 90 hours Other Name: HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
11268075|NCT02918877|Experimental|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
11268076|NCT02918877|Active Comparator|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
11268077|NCT02918864|Experimental|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
11268078|NCT02918864|Active Comparator|Facilitated Play|The active comparison condition is a facilitated play therapy group.
11268079|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
11268080|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
11268081|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
11268082|NCT02918838|Experimental|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
11268083|NCT02918838|Experimental|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
11268084|NCT02918838|Active Comparator|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
11268087|NCT02918812|Experimental|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
11268088|NCT02918812|Active Comparator|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
11268089|NCT02918799|Other|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
11268090|NCT02918786|Active Comparator|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
11268091|NCT02918786|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
11268092|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
11268093|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
11268094|NCT02918760|Experimental|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
11268095|NCT02918760|Placebo Comparator|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
11268096|NCT02918747|Experimental|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.
~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.
~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
11268097|NCT02918747|Active Comparator|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1; Pegaspargase 2000U/m2 im，day 2 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.
~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
11268098|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
11268099|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
11268100|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
11268101|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
11268102|NCT02918708|Active Comparator|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
11268103|NCT02918708|Active Comparator|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
11268104|NCT02918682|Experimental|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
11268105|NCT02918682|No Intervention|Control Group|Participants from the control group will not perform any kind of physical exercise.
11268106|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
11268107|NCT02918656|Experimental|Infographics|Infographic presentation of health information
11268108|NCT02918656|Active Comparator|Plain Language Summary|PLS presentation of health information
11268109|NCT02918656|Active Comparator|Scientific abstract|Scientific abstract presentation of health information
11268110|NCT02918643|Active Comparator|Application|7 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
11268111|NCT02918643|Sham Comparator|Control|7 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
11268112|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
11268113|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
11268114|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268115|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268147|NCT02918448|No Intervention|control group|control group that did not perform any type of physical exercise
11268116|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268117|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268118|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268119|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268120|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
11268121|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
11268122|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
11268123|NCT02918604|Other|B : veinsite access|infrared technology vein access
11268124|NCT02918604|Active Comparator|A: control group|conventional vein access
11268125|NCT02918591|Experimental|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
11268126|NCT02918578|Experimental|"Phone group"|see intervention description
11268127|NCT02918578|Experimental|"Phone and SMS group"|see intervention description
11268128|NCT02918578|Active Comparator|"single writing group"|see intervention description
11268129|NCT02918565|Experimental|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
11268130|NCT02918565|Experimental|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
11268131|NCT02918565|Experimental|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
11268132|NCT02918565|Experimental|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
11268133|NCT02918565|No Intervention|Control|12 weeks of text message assessments without any feedback
11268134|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
11268135|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
11268136|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
11268137|NCT02918526|Experimental|Laryngeal Mask|laryngeal mask (LMA)
11268138|NCT02918526|Active Comparator|Oro Tracheal Intubation|oro tracheal intubation
11268139|NCT02918513|Experimental|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
11268140|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
11268141|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
11268142|NCT02918487|Experimental|Active|[Formoterol + Fluticasone] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
11268143|NCT02918487|Placebo Comparator|Placebo|[Formoterol + Fluticasone] conventional along with inert similar looking placebo capsules
11268144|NCT02918474|Experimental|Supportive care (decision making tool)|Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
11268145|NCT02918461|Experimental|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
11268146|NCT02918448|Experimental|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
11268148|NCT02918435|No Intervention|Usual Care-Control|Participants in the usual care group will receive standard pediatric care.
11268149|NCT02918435|Experimental|On-site WE CARE implementation arm|"WE CARE will be implemented in the study site using a facilitated on-site strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via an on-site team which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room."
11268150|NCT02918435|Experimental|Self-directed web-based WE CARE implementation arm|WE CARE will be implemented in the study site using a web-based implementation strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via web-based tools (e.g., web-based seminar) which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room
11268151|NCT02918422|Experimental|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
11268152|NCT02918422|Experimental|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
11268153|NCT02918422|Experimental|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
11268154|NCT02918422|Experimental|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
11268155|NCT02918409|Active Comparator|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
11268156|NCT02918409|Active Comparator|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
11268157|NCT02918409|Active Comparator|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
11268158|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
11268159|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
11268160|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
11268161|NCT02918383|Other|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
11268162|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
11268163|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
11268164|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
11268165|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
11268166|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
11268167|NCT02918331|Experimental|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram [mg/kg]) will be administered by intravenous [IV] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.
~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
11268168|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
11268169|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
11268170|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
11268171|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
11268416|NCT02916719|Experimental|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
11268172|NCT02918305|Sham Comparator|PRDS-001 Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using PRDS-001 System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
11268173|NCT02918305|Sham Comparator|Sham Procedure|Randomization will occur following the diagnostic renal angiography. For blinded patients randomized to control, the diagnostic renal angiography will be considered the sham procedure.
11268174|NCT02918292|Experimental|Haplo Bone Marrow HSCT|Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.
11268175|NCT02918279|Experimental|Liraglutide|
11268176|NCT02918279|Placebo Comparator|Placebo|
11268177|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
11268178|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268179|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268180|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268181|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268182|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268196|NCT02918201|Experimental|topical tranexamic acid|tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
11268197|NCT02918201|Placebo Comparator|placebo control|Saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
11268198|NCT02918188|Experimental|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
11268417|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
11268418|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
11268183|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268184|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268185|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268186|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268187|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
11268188|NCT02918253|Experimental|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
11268189|NCT02918253|Active Comparator|No tumour visible on MRI|Whole-gland HDR Brachytherapy
11268190|NCT02918240|Experimental|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
11268191|NCT02918240|Experimental|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
11268192|NCT02918240|Experimental|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
11268193|NCT02918240|Experimental|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
11268194|NCT02918227|Experimental|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
11268195|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
11268254|NCT02917785|Experimental|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
11268199|NCT02918175|Other|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
11268200|NCT02918175|No Intervention|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
11268201|NCT02918162|Experimental|Pembrolizumab|"All study subjects will receive standard of care chemotherapy regimen for 3 cycles prior to and 3 cycles following surgery in combination with Pembrolizumab with an additional cycle of Pembrolizumab (4 total) in the pre-operative period. Additionally subjects will complete 12 months of maintenance Pembrolizumab (14 additional doses to complete 17 post-operative cycles) following completion of post-operative chemotherapy.
~Standard of care combination chemotherapy regimen has a 21-day cycle."
11268202|NCT02918149|Other|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
11268203|NCT02918149|Experimental|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
11268204|NCT02918136|Experimental|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
11268205|NCT02918136|Active Comparator|cortisone injection|ultrasound guided injection of cortisone
11268206|NCT02918123|Experimental|Treatment|"FURESTEM-CD Inj. 5.0x10^7 cells
~FURESTEM-CD Inj. 1.0x10^7 cells
~FURESTEM-CD Inj. 2.0x10^8 cells"
11268207|NCT02918110|Experimental|Cytotec|orally administrated solution of misoprostol (Cytotec®)
11268208|NCT02918110|Experimental|Misodel|vaginal slow release misoprostol (Misodel®)
11268209|NCT02918097|Experimental|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.
~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.
~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.
~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.
~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step
~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
11268210|NCT02918084|Sham Comparator|ARM A|Adjuvant chemotherapy → Aromatase inhibitors x 5 yrs (sequential arm)
11268211|NCT02918084|Experimental|ARM B|Adjuvant chemotherapy + Aromatase inhibitors x 5 yrs (concurrent arm)
11268212|NCT02918071|Experimental|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
11268213|NCT02918058|Active Comparator|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
11268214|NCT02918058|Active Comparator|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
11268215|NCT02918058|Active Comparator|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
11268216|NCT02918045|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
11268217|NCT02918045|Active Comparator|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
11268218|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
11268219|NCT02918019|Experimental|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
11268220|NCT02918019|Experimental|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
11268221|NCT02918019|Experimental|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
11268222|NCT02918019|Placebo Comparator|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
11268223|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
11268224|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
11268225|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
11268226|NCT02917993|Experimental|Itacitinib + osimertinib|
11268227|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
11268228|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
11268229|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
11268230|NCT02917967|Experimental|BTX injection group|Botulinum toxin injection group
11268255|NCT02917785|No Intervention|Control|
11268316|NCT02917356|Active Comparator|Non-spiritual Laying on of Hands group|"Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)
~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
11268231|NCT02917954|No Intervention|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
11268232|NCT02917954|Experimental|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.
~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
11268233|NCT02917941|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.
11268234|NCT02917928|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
11268235|NCT02917928|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
11268236|NCT02917915|Experimental|New Canadian Standardized PR|"Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress & anxiety, nutrition, leisure & travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.
~Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
11268237|NCT02917915|Active Comparator|Traditional PR|"Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies & pulmonary function tests, health and air quality, healthier eating, travel, stress management & relaxation, tips to remember/summary of content.
~Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
11268238|NCT02917902|Experimental|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
11268239|NCT02917902|Other|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
11268240|NCT02917889|Experimental|Caffeine protocol|300 mg in pills
11268241|NCT02917889|Experimental|Placebo protocol|300 mg in pills
11268242|NCT02917863|Experimental|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).
~Dosage in children with hypothyroidism:
~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die
~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die
~Dosage in adults:
~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).
~Dosage will be adjusted according to TSH level."
11268243|NCT02917863|Active Comparator|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).
~Dosage in children with acquired hypothyroidism:
~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area
~Dosage in adults:
~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).
~Dosage will be adjusted according to TSH level."
11268244|NCT02917850|Active Comparator|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
11268245|NCT02917850|Active Comparator|Control|Patients who benefit from a conventional rehabilitation program
11268246|NCT02917837|Active Comparator|Usual QCNL report group|Physicians receive the usual Quality of Care Newfoundland and Labrador utilization report: This reports ranks the physician on a figure of their peers according to the total number of tests ordered in a one-year period.
11268247|NCT02917837|Experimental|Usual QCNL report plus detailing.|This group receives the usual QCNL report described above. Shortly after the reports are sent, this group will be contacted at least three times to attempt to arrange a single in-person detailing session.
11268248|NCT02917837|Experimental|New utilization report|This group will receive a new type of report that shows individual physician ordering per 100 patients compared to the mean of all physicians, adjusted for patient complexity (age, sex, comorbidity, education, income, rurality).
11268249|NCT02917837|Experimental|New utilization report plus detailing|New type of report plus detailing as described above.
11268250|NCT02917824|Experimental|High-intensity IMT|Participants enrolled in this arm received high-intensity IMT
11268251|NCT02917824|Active Comparator|Low-intensity IMT|Participants enrolled in this arm received low-intensity IMT
11268252|NCT02917811||ICU patients|
11268253|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
11268256|NCT02917772|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy
~If CR/PR: Nivolumab Maintenance Mono-Therapy
~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy
~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
11268257|NCT02917759||Hepatocellular cancer|Surgical waste tissue will be collected after removal of a liver tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
11268258|NCT02917759||Cholangiocarcinoma|Surgical waste tissue will be collected after removal of a biliary tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
11268259|NCT02917746|Experimental|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
11268260|NCT02917746|Active Comparator|Standard treatment arm|Treatment by large loop excision of the transformation zone.
11268261|NCT02917733|Experimental|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
11268262|NCT02917720|Experimental|TKI-stop, pre-treatment with nilotinib|"Treatment after unsuccessful 1st or 2nd discontinuation at least two year with nilotinib (300 mg/bid). In total, retreatment with TKI for at least 3 years before entering screening for stopping phase is warranted. Clinical monitoring every 3 months during this 2 years.
~Patients who re-achieved and maintained MR4 for at least 12 months and MR4.5 for at least 6 months can enter screening phase for TFR .If MR4.5 is confirmed by an validated laboratory, patient may enter stopping phase of the study. Patient not fulfilling these criteria can be screened again every 3 months until month 48. After TKI-stop hematological monitoring and quantitative PCR of BCR/ABL1 (month 1-6 after stopping: monthly; month 7-12 after stopping: every 1.5 months, thereafter once every three months, for 3 years in total.
~Relapse is defined as BCR-ABL1 > 0.1% on IS at a single time point (loss of MMR) In case of relapse restart of TKI. In general, the same TKI (nilotinib) as before second stop is recommended"
11268263|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
11268264|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
11268265|NCT02917707||liver metastasis tissues|liver metastasis tissues
11268266|NCT02917681|Experimental|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
11268267|NCT02917668|Active Comparator|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
11268268|NCT02917668|Active Comparator|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
11268269|NCT02917655|Experimental|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
11268270|NCT02917655|Other|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.
~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
11268271|NCT02917642|Experimental|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
11268272|NCT02917642|Active Comparator|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
11268273|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
11268274|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
11268275|NCT02917616|Experimental|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
11268276|NCT02917616|Active Comparator|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
11268277|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
11268278|NCT02917603|No Intervention|Control|These family and residents will receive usual care
11268279|NCT02917590|Experimental|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
11268280|NCT02917590|Sham Comparator|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
11268281|NCT02917577|Active Comparator|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
11268282|NCT02917577|Active Comparator|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
11268283|NCT02917564|Sham Comparator|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.
~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected."
11268284|NCT02917564|Active Comparator|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.
~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down."
11268285|NCT02917551|Active Comparator|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
11268286|NCT02917551|Active Comparator|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
11268287|NCT02917538|Experimental|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
11268288|NCT02917538|Active Comparator|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
11268289|NCT02917525|Experimental|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
11268290|NCT02917525|Placebo Comparator|Placebo|22 patients will receive placebo during 18 months.
11268291|NCT02917512|Experimental|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)
~1 drop b.i.d at 12 hour interval for 12 weeks"
11268292|NCT02917512|Experimental|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)
~1 drop b.i.d at 12 hour interval for 12 weeks"
11268293|NCT02917512|Active Comparator|Restasis|"Restasis(Cyclosporine 0.05%)
~1 drop b.i.d at 12 hour interval for 12 weeks"
11268294|NCT02917512|Placebo Comparator|Placebo(without main component)|"Placebo
~1 drop b.i.d at 12 hour interval for 12 weeks"
11268295|NCT02917499|Experimental|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
11268296|NCT02917499|No Intervention|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
11268297|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
11268298|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
11268299|NCT02917473|Other|Control|"Education and counseling as commonly delivered to the patients in clinical practice.
~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
11268300|NCT02917473|Experimental|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.
~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
11268301|NCT02917460|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
11268302|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
11268303|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
11268304|NCT02917434|Active Comparator|Patients with PsA and obesity|Very Low Energy Diet (VLED)
11268305|NCT02917434|Other|Patients with obesity|Very Low Energy Diet (VLED)
11268306|NCT02917421|Experimental|Cohort 1|"(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
~Radiation therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
11268307|NCT02917421|Experimental|Cohort 2|"In addition to receiving radiation to the original tumor bed, patients will also receive radiation to Level III axillary nodes and Supraclavicular nodes: 3D-CRT or IMRT at 2.7 Gy X 15 fraction (40.50 Gy)
~Radiation Therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
11268308|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
11268309|NCT02917395|Experimental|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.
~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
11268310|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
11268311|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
11268312|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
11268313|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
11268314|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
11268315|NCT02917356|Experimental|Spiritual laying on of hands group|"Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)
~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
11268317|NCT02917356|Sham Comparator|Control Group (CG)|"Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)
~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
11268318|NCT02917343|Experimental|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
11268319|NCT02917330|Experimental|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
11268320|NCT02917330|No Intervention|Control group|Treatment as usual
11268321|NCT02917304|Experimental|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
11268322|NCT02917291|Experimental|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (8 patients)
11268323|NCT02917291|Other|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (20 patients)
11268324|NCT02917291|Experimental|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (20 patients)
11268325|NCT02917278|Experimental|Meals|High-protein renal-specific meals
11268326|NCT02917278|No Intervention|Control|No Meals
11268327|NCT02917265|Experimental|TENS for vagus stimulation|A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
11268328|NCT02917265|Sham Comparator|TENS for sham stimulation|A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
11268329|NCT02917252|Active Comparator|Intervention|Subjects drink 3-hydroxybuturate
11268330|NCT02917252|Placebo Comparator|Placebo|Subjects drink saline
11268331|NCT02917226|Experimental|Clinical decision support and monitoring system|
11268332|NCT02917226|No Intervention|Control Group|
11268333|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction < 45% in the first 24-72 h after symptoms onset.
~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.
~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
11268334|NCT02917200|Active Comparator|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
11268335|NCT02917200|Experimental|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
11268336|NCT02917200|Experimental|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
11268337|NCT02917200|Experimental|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
11268338|NCT02917200|Experimental|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
11268339|NCT02917200|Experimental|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
11268340|NCT02917200|Experimental|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
11268341|NCT02917200|Experimental|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
11268342|NCT02917200|Experimental|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
11268343|NCT02917200|Experimental|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
11268344|NCT02917200|Experimental|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
11268345|NCT02917200|Other|CTRL|Negative control, tid, 7 days
11268346|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
11268347|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
11268348|NCT02917174|Experimental|mobile management|use mobile management to improve asthma control
11268349|NCT02917174|Other|Traditional management|use Traditional management to improve asthma control
11268350|NCT02917161|Experimental|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
11268351|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
11268352|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
11268353|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
11268354|NCT02917122|Placebo Comparator|sertraline + sham tDCS|Patients will take sham tDCS.
11268355|NCT02917122|Active Comparator|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
11268356|NCT02917109|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
11268357|NCT02917096|Experimental|Treatment (ruxolitinib phosphate, chemotherapy,allogeneic HCT)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5, melphalan IV over 20 minutes on day -4, and ruxolitinib phosphate PO BID on days -3 to 30 with a taper for 2-3 weeks in the absence of disease progression or unacceptable toxicity. Patients being treated with ruxolitinib phosphate prior to allogeneic HCT as standard therapy may continue receiving ruxolitinib phosphate.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -3 and convert to PO daily when the patient is able to tolerate and absorb oral medications. Patients also receive sirolimus PO daily beginning on day -3. Treatment continues in the absence of GVHD.
~STEM CELL TRANSPLANT: Patients undergo allogeneic HCT on day 0."
11268413|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
11268414|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
11268419|NCT02916693|Experimental|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
11268358|NCT02917083|Experimental|CD30.CAR T Cells|"Each patient will receive one infusion of CAR modified T cells.
~Unless post autologous transplant, patients will receive Cyclophosphamide and Fludarabine to induce lymphopenia.
~Patients post autologous stem cell transplantation will receive T cell infusion starting at least 14 days after the date of transplant, unless there is clear evidence of relapse, then T-cell infusion can occur at any time after transplant. No lymphodepleting chemotherapy will be given to these patients."
11268359|NCT02917070||Patients|Patients who have chronic kidney diseases
11268360|NCT02917070||Healthy controls|Healthy subjects
11268361|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
11268362|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
11268363|NCT02917044|Active Comparator|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
11268364|NCT02917044|Experimental|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
11268365|NCT02917031|Active Comparator|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
11268366|NCT02917031|Active Comparator|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
11268367|NCT02917031|Placebo Comparator|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
11268368|NCT02917018|Active Comparator|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
11268369|NCT02917018|Active Comparator|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
11268370|NCT02917018|Active Comparator|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
11268371|NCT02917005|Experimental|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
11268372|NCT02917005|Active Comparator|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
11268373|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
11268374|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
11268375|NCT02916979|Other|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
11268376|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
11268377|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
11268378|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
11268379|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
11268380|NCT02916953|Experimental|Treatment|All subjects who meet the inclusion and exclusion criteria will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) treatment
11268381|NCT02916940|Experimental|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
11268382|NCT02916940|No Intervention|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
11268383|NCT02916927|Experimental|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
11268384|NCT02916927|Active Comparator|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
11268385|NCT02916914|Other|Q2 feeding|feeding intervals: 2 hours
11268386|NCT02916914|No Intervention|Q3feeding|feeding intervals: 3 hours
11268387|NCT02916901|Experimental|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
11268388|NCT02916901|Placebo Comparator|Placebo|placebo
11268389|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
11268390|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
11268391|NCT02916862|Experimental|Soluble Corn Fiber (SCF) + Calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
11268392|NCT02916862|Active Comparator|Soluble Corn Fiber (SCF) without calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
11268393|NCT02916862|Placebo Comparator|Placebo|This group will receive a similar supplement without SCF or calcium, administered twice a day
11268394|NCT02916862|Placebo Comparator|Placebo + calcium|This group will receive a similar supplement without SCF + 600 mg/d of elemental calcium carbonate, administered twice a day
11268415|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
11268503|NCT02916121|Experimental|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
11268395|NCT02916849|Experimental|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
11268396|NCT02916849|Active Comparator|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
11268397|NCT02916849|Experimental|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
11268398|NCT02916849|Experimental|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
11268399|NCT02916849|Active Comparator|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
11268400|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
11268401|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
11268402|NCT02916810|Active Comparator|Active rTMS stimulation|Real active rTMS stimulation.
11268403|NCT02916810|Sham Comparator|Sham rTMS stimulation|Sham repetitive TMS stimulation.
11268404|NCT02916797|Experimental|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
11268405|NCT02916797|No Intervention|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
11268406|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
11268407|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
11268408|NCT02916771|Experimental|Ixazomib|"Cycles 1-9
~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle
~Lenalidomide is administered orally on days 1-21 on a 28 days cycle
~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle
~Cycle 10-24
~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle
~Lenalidomide is administered orally on days 1-21 on a 28 days cycle
~Supportive measures consistent with optimal patient care may be given throughout the study"
11268409|NCT02916758|Experimental|Let's Go Community Mobility Program|Participation in 4 week program
11268410|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
11268411|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
11268412|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
11268420|NCT02916680|Experimental|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
11268421|NCT02916667|Active Comparator|CNdiet|CNdiet includes chrono nutritional dietary guidelines
11268422|NCT02916667|Placebo Comparator|GDMdiet|GDMdiet includes regular GDM diet
11268423|NCT02916654|Active Comparator|sulphate iron|patients administered with sulphate iron
11268424|NCT02916654|Experimental|sucrosomial iron|patients administered with sucrosomial iron
11268425|NCT02916641|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
11268426|NCT02916641|Active Comparator|Monotherapy|UDCA monotherapy
11268427|NCT02916628|Experimental|Group 1|auricular acupressure + group counseling
11268428|NCT02916628|Placebo Comparator|Group 2|placebo acupressure + group counseling
11268429|NCT02916628|No Intervention|Group 3|self-help smoking cessation
11268430|NCT02916628|No Intervention|Group 4|Non-smokers
11268431|NCT02916615|Active Comparator|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
11268432|NCT02916615|Placebo Comparator|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
11268433|NCT02916615|Active Comparator|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
11268434|NCT02916602|Experimental|Treatment|HCP1401
11268435|NCT02916602|Active Comparator|Reference|HCP0605
11268436|NCT02916589|Placebo Comparator|Baseline|The subjects will start with one week eating their normal diet.
11268437|NCT02916589|Active Comparator|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
11268438|NCT02916576|Experimental|Blood glucose measurement|
11268439|NCT02916563|Experimental|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
11268440|NCT02916550|Experimental|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
11268441|NCT02916537|Experimental|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
11268442|NCT02916537|Experimental|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).
~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
11268443|NCT02916524|Experimental|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
11268444|NCT02916524|Active Comparator|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
11268445|NCT02916511|Experimental|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.
~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.
~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5"
11268446|NCT02916498|Active Comparator|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
11268447|NCT02916498|Experimental|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
11268448|NCT02916485|Experimental|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
11268449|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
11268450|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
11268451|NCT02916459|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
11268452|NCT02916459|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
11268453|NCT02916446|Experimental|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
11268454|NCT02916446|Placebo Comparator|Placebo|Placebo patch, daily administration
11268455|NCT02916433|No Intervention|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
11268456|NCT02916433|Experimental|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
11268457|NCT02916420|Experimental|Treatment|Pomalidomide plus low-dose Dexamethasone
11268458|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
11268459|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
11268460|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
11268461|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
11268462|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
11268463|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
11268464|NCT02916381|Experimental|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
11268465|NCT02916381|Sham Comparator|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
11268466|NCT02916368||with surgery|
11268467|NCT02916368||with chemotherapy or radiotherapy|
11268468|NCT02916355|Experimental|Normal BMI|Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
11268469|NCT02916355|Experimental|Overweight|Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
11268470|NCT02916342|Active Comparator|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
11268471|NCT02916342|Experimental|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
11268472|NCT02916329|Experimental|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
11268473|NCT02916329|Experimental|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
11268474|NCT02916329|Experimental|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
11268475|NCT02916329|Experimental|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
11268476|NCT02916329|Experimental|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
11268477|NCT02916329|Experimental|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
11268478|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
11268479|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
11268480|NCT02916290|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
11268481|NCT02916290|Active Comparator|Monotherapy|UDCA monotherapy
11268482|NCT02916264|Active Comparator|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose < 3 mg/kg, is performed by an anesthesiologist.
11268483|NCT02916264|No Intervention|no scalp block|An anesthesiology will pretend to perform the scalp block,
11268484|NCT02916251|Experimental|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
11268485|NCT02916251|Active Comparator|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
11268486|NCT02916238|Experimental|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
11268487|NCT02916238|Active Comparator|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
11268488|NCT02916225|Active Comparator|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
11268489|NCT02916225|Placebo Comparator|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
11268490|NCT02916212|Experimental|Experimental|Hospital units where alarms have been optimized
11268491|NCT02916212|No Intervention|Control|Hospital units where alarms remain unchanged
11268492|NCT02916199|Experimental|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis
~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
11268493|NCT02916199|Active Comparator|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis
~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
11268494|NCT02916186|Experimental|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
11268495|NCT02916186|Active Comparator|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
11268496|NCT02916173|Experimental|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
11268497|NCT02916173|Active Comparator|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
11268498|NCT02916160|Experimental|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
11268499|NCT02916147|Experimental|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
11268500|NCT02916147|Active Comparator|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
11268501|NCT02916134|Active Comparator|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
11268502|NCT02916134|Experimental|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
11268505|NCT02916108||Concussion|"Study group include up to 30 children with history of concussion in the last 24 hours before admitting to emergency department.
~Reading EEG."
11268506|NCT02916108||Isolated limb injury|"Cohort group include up to 30 children with history of isolated limb injury in the last 24 hours before admitting to emergency department.
~Reading EEG."
11268507|NCT02916095|Experimental|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
11268508|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
11268509|NCT02916069|Active Comparator|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
11268510|NCT02916069|No Intervention|Group 2|Patients will be monitored without any interference based on such monitors
11268511|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
11268512|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
11268513|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
11268514|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
11268515|NCT02916017||Participants receiving adalimumab|Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
11268516|NCT02916004|Other|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
11268517|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
11268518|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
11268519|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
11268520|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
11268521|NCT02915965|Experimental|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
11268522|NCT02915952|Active Comparator|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
11268523|NCT02915952|Active Comparator|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
11268524|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
11268525|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
11268526|NCT02915926|Active Comparator|OT|standard OT
11268527|NCT02915926|Experimental|OT+OPC|occupational performance coaching
11268528|NCT02915913|Experimental|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
11268529|NCT02915913|Experimental|Resistance training|One session for 30-60 minutes of resistance exercise
11268530|NCT02915913|Experimental|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
11268531|NCT02915913|Placebo Comparator|Non-exercise|Non-exercise
11268532|NCT02915900|Experimental|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
11268533|NCT02915900|Active Comparator|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
11268534|NCT02915887|Experimental|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
11268535|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:
~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;
~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
11268536|NCT02915874|No Intervention|Control|Subjects randomized to not receive treatment.
11268537|NCT02915861||EXPa|Scrub typhus patients: Group A
11268538|NCT02915861||EXPb|Scrub typhus patients: Group B
11268539|NCT02915861||EXPc|Scrub typhus patients: Group C
11268540|NCT02915861||EXC|Control group
11268541|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
11268609|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
11268542|NCT02915835|Active Comparator|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
11268543|NCT02915835|Placebo Comparator|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
11268544|NCT02915822|Experimental|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
11268545|NCT02915822|Active Comparator|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
11268546|NCT02915809|Experimental|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
11268547|NCT02915809|Active Comparator|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
11268548|NCT02915796|Experimental|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
11268549|NCT02915796|Active Comparator|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
11268550|NCT02915796|Placebo Comparator|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
11268551|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
11268552|NCT02915770|Experimental|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
11268553|NCT02915770|Active Comparator|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
11268554|NCT02915757|Experimental|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
11268555|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
11268556|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
11268557|NCT02915718|Experimental|experimental group|protein A immunoadsorption for 5 days
11268558|NCT02915718|No Intervention|control group|non intervention
11268559|NCT02915705|Experimental|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
11268560|NCT02915705|Active Comparator|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
11268561|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
11268562|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
11268563|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:
~81 depressed patients admitted after a recent suicidal act (<8 days)
~81 depressed subjects with a past history of suicidal act (>1month)
~80 depressed subjects without any personal history of suicidal behaviour"
11268564|NCT02915666|Experimental|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
11268565|NCT02915653|No Intervention|Control|Control: not receiving any intervention
11268566|NCT02915653|Experimental|Intervention 1|Receiving educational materials on a new diagnostic service
11268567|NCT02915653|Experimental|Intervention 2|Receiving educational materials on a new diagnostic service
11268568|NCT02915640|Experimental|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
11268569|NCT02915640|No Intervention|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
11268570|NCT02915627|Active Comparator|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
11268571|NCT02915627|Active Comparator|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
11268572|NCT02915627|Active Comparator|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
11268573|NCT02915614|Active Comparator|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
11268574|NCT02915614|Experimental|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
11268707|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
11268575|NCT02915601|Experimental|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
11268576|NCT02915601|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
11268577|NCT02915588|Active Comparator|Primary Active|Early postoperative isometric activation of the rotator cuff
11268578|NCT02915588|Active Comparator|Primary Passive|Standard postoperative passive movement rehabilitation protocol
11268579|NCT02915575|Other|Control Arm (usual care)|Participants will be discharged as per usual ward discharge protocols.
11268580|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
11268581|NCT02915562|Active Comparator|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
11268582|NCT02915562|Active Comparator|Non-depressive Group|GDS 15 (Geriatric Depression Score) <5 Points at baseline
11268583|NCT02915549|Experimental|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
11268584|NCT02915549|Active Comparator|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
11268585|NCT02915523|Active Comparator|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on D1 and D8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
11268586|NCT02915523|Placebo Comparator|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on D1 and D8 of each cycle.
11268587|NCT02915510|Experimental|GMP|Single arm designed, 3 day baseline, 28day on GMP
11268588|NCT02915497|No Intervention|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
11268589|NCT02915497|Experimental|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
11268590|NCT02915484|Experimental|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
11268591|NCT02915484|Experimental|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
11268592|NCT02915471|Experimental|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
11268593|NCT02915471|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
11268594|NCT02915445|Experimental|CAR-T cells recognizing EpCAM|Autologous T cells from patient are engineered to expressing a special chimeric antigen receptor to recognizing EpCAM by lentiviral vector. The engineered T cells were then endowed cytotoxicity to the tumor cells and hold the potential to inhibit the advance of tumors.
11268595|NCT02915432|Experimental|3 mg/kg anti-PD-1 mAb JS001 Q2W|Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.
11268596|NCT02915432|Experimental|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
11268597|NCT02915432|Experimental|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death
11268598|NCT02915419|Active Comparator|group A|prp revascularization
11268599|NCT02915419|Experimental|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
11268600|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
11268601|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
11268602|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
11268603|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
11268604|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
11268605|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
11268606|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
11268607|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
11268608|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
11268748|NCT02914522|Experimental|Filgotinib 100 mg (Induction Study)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 10 weeks
11268610|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
11268611|NCT02915354|Experimental|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
11268612|NCT02915328|Experimental|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
11268613|NCT02915328|Experimental|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
11268614|NCT02915328|Experimental|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
11268615|NCT02915328|Experimental|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
11268616|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
11268617|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
11268618|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
11268619|NCT02915302|Active Comparator|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
11268620|NCT02915302|Experimental|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
11268621|NCT02915289|Active Comparator|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
11268622|NCT02915289|Active Comparator|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
11268623|NCT02915276|Active Comparator|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
11268624|NCT02915276|Active Comparator|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
11268625|NCT02915263|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
11268626|NCT02915263|Experimental|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
11268627|NCT02915250|Experimental|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
11268628|NCT02915250|Active Comparator|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
11268629|NCT02915250|Active Comparator|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
11268630|NCT02915237|Experimental|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
11268631|NCT02915237|Experimental|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
11268632|NCT02915237|Experimental|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
11268633|NCT02915237|Placebo Comparator|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
11268634|NCT02915237|Placebo Comparator|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
11268635|NCT02915237|Placebo Comparator|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
11268636|NCT02915224||Obinutuzumab|Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
11268637|NCT02915211|Experimental|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
11268638|NCT02915198|Experimental|Metformin|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
11268639|NCT02915198|Placebo Comparator|Placebo|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
11268640|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
11268641|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
11268668|NCT02915016|Placebo Comparator|Group 8: Placebo|Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.
11268703|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patienten cohort included according to the inclusion criteria
11268704|NCT02914769|Placebo Comparator|placebo|patients receiving a passive placebo
11268705|NCT02914769|Experimental|Ayahuasca|patients receiving Ayahuasca
11268642|NCT02915172|Experimental|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.
~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.
~All participants receive the same dose of Capecitabine.
~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.
~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.
~All participants receive the same dose of Capecitabine."
11268643|NCT02915159|Experimental|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
11268644|NCT02915159|Placebo Comparator|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
11268645|NCT02915146|Active Comparator|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
11268646|NCT02915146|Active Comparator|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
11268647|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
11268648|NCT02915120|Active Comparator|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at < 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
11268649|NCT02915120|Sham Comparator|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
11268650|NCT02915107|Experimental|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
11268651|NCT02915107|Active Comparator|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
11268652|NCT02915081|Experimental|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
11268653|NCT02915081|No Intervention|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
11268654|NCT02915068|No Intervention|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
11268655|NCT02915068|Experimental|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
11268656|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
11268657|NCT02915042|Experimental|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
11268658|NCT02915042|Placebo Comparator|Placebo group|Intervention group 2: placebo
11268659|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:
~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
11268660|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
11268661|NCT02915016|Experimental|Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.
11268662|NCT02915016|Experimental|Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
11268663|NCT02915016|Experimental|Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
11268664|NCT02915016|Experimental|Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
11268665|NCT02915016|Experimental|Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
11268666|NCT02915016|Experimental|Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
11268667|NCT02915016|Experimental|Group 7: Placebo + Protein/AS01B|Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
11268706|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
11268669|NCT02915003|Experimental|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
11268670|NCT02915003|No Intervention|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
11268671|NCT02914990|Experimental|BPI-15086|BPI-15086, orally administered daily
11268672|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
11268673|NCT02914964|Experimental|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
11268674|NCT02914964|Experimental|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
11268675|NCT02914951|Experimental|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
11268676|NCT02914938|Experimental|ME-401 Alone|This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
11268677|NCT02914938|Experimental|ME-401 in Combination with Rituximab|The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
11268678|NCT02914938|Experimental|ME-401 in Combination with Zanubrutinib|The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).
11268679|NCT02914925|Experimental|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
11268680|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
11268681|NCT02914899|Active Comparator|Pilot RCT Control Group|Eligible NYC Chinese livery drivers will receive written materials only
11268682|NCT02914899|Experimental|Pilot RCT CHW Intervention Group|Eligible NYC Chinese livery drivers will receive written materials and navigation for shared decision making (SDM) and lung cancer screening (LCS).
11268683|NCT02914899|Experimental|Focus Group|The investigators conducted a series of 4-6 focus groups with Chinese livery drivers who (currently, or in the past) smoke.
11268684|NCT02914899|Experimental|In-Depth Interview Group|12-15 in-depth interviews with livery base management and staff, and with 12-15 primary care physicians (PCPs), clinic directors, hospital CFOs, heads of financial services and counseling, and heads of radiology facilities serving the Chinese community.
11268685|NCT02914899|Experimental|Pre-pilot Group|Approximately 10 Chinese livery drivers who smoke or who quit smoking with the past 15 years and have a 30 pack-year history of smoking
11268686|NCT02914886|Experimental|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
11268687|NCT02914886|Active Comparator|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
11268688|NCT02914873|Active Comparator|Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and curative treatment are performed according to the urologist's judgement.
11268689|NCT02914873|Experimental|Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
11268690|NCT02914860|Experimental|Volunteers|Healthy volunteers
11268691|NCT02914860|Active Comparator|PAF|Patients with paroxysmal atrial fibrillation
11268692|NCT02914860|Active Comparator|Pers AF|Patients with persistent atrial fibrillation
11268693|NCT02914860|Active Comparator|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
11268694|NCT02914847|Experimental|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
11268695|NCT02914847|No Intervention|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
11268696|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
11268697|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
11268698|NCT02914821|No Intervention|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
11268699|NCT02914821|Experimental|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
11268700|NCT02914821|Experimental|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
11268701|NCT02914821|Experimental|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
11268702|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
11268708|NCT02914743|Experimental|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
11268709|NCT02914743|Experimental|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
11268710|NCT02914743|No Intervention|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
11268711|NCT02914704|Experimental|Patients treated with MRI-HIFU|
11268712|NCT02914691|Active Comparator|Active|Dapagliflozin 10 mg once daily tablet treatment
11268713|NCT02914691|Placebo Comparator|Placebo|Identical once daily tablet treatment
11268714|NCT02914678|No Intervention|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
11268715|NCT02914678|Experimental|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
11268716|NCT02914665|Experimental|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
11268717|NCT02914665|Placebo Comparator|Placebo|Placebo once daily for 7 consecutive days
11268718|NCT02914652|Experimental|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
11268719|NCT02914652|Experimental|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
11268720|NCT02914652|Experimental|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
11268721|NCT02914639|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
11268722|NCT02914639|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
11268723|NCT02914626|Experimental|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
11268724|NCT02914626|Sham Comparator|Control|Standard of care therapy
11268725|NCT02914613|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
11268726|NCT02914613|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
11268727|NCT02914600|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 432 weeks
11268728|NCT02914600|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 432 weeks
11268729|NCT02914600|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg for up to 432 weeks
11268730|NCT02914600|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 432 weeks
11268731|NCT02914600|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 432 weeks
11268732|NCT02914587|Experimental|ARTAS System|Implantation with the ARTAS System.
11268733|NCT02914587|Active Comparator|Manual Implantation|Implantation manually.
11268734|NCT02914574|Other|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
11268735|NCT02914561|Experimental|Filgotinib 200 mg (Induction Study)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
11268736|NCT02914561|Experimental|Filgotinib 100 mg (Induction Study)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for 10 weeks
11268737|NCT02914561|Placebo Comparator|Placebo (Induction Study)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
11268738|NCT02914561|Experimental|Maintenance Study|Participants who meet response or remission criteria at Week 10 will continue into the Maintenance Study and receive filgotinib and/or placebo for 48 weeks.
11268739|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
11268740|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
11268741|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
11268742|NCT02914535|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
11268743|NCT02914535|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
11268744|NCT02914535|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
11268745|NCT02914535|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 336 weeks
11268746|NCT02914535|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 336 weeks
11268747|NCT02914522|Experimental|Filgotinib 200 mg (Induction Study)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
11268749|NCT02914522|Placebo Comparator|Placebo (Induction Study)|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 10 weeks
11268750|NCT02914522|Experimental|Maintenance Study|Participants who meet response or remission criteria at Week 10 will continue into Maintenance Study and will receive filgotinib and/or placebo for 48 weeks.
11268751|NCT02914509|Experimental|OTX-TP|OTX-TP (sustained release travoprost) Intracanalicular Depot
11268752|NCT02914509|Placebo Comparator|PV|PV (Placebo Vehicle) Intracanalicular Depot
11268753|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
11268754|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
11268755|NCT02914483|Other|Enhanced Usual Care (EUC)|
11268756|NCT02914483|Other|Stress Management|
11268757|NCT02914470|Experimental|carbo, cyclo, atezolizumab|The starting dose is carboplatin AUC 5mg/ml*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously
11268758|NCT02914457|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
11268759|NCT02914431|Experimental|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
11268760|NCT02914431|No Intervention|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
11268761|NCT02914418|Experimental|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
11268762|NCT02914418|Sham Comparator|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
11268763|NCT02914405|Experimental|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:
~Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)
~Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)
~Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
11268764|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
11268765|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
11268766|NCT02914379|Experimental|[¹⁴C]-LY3337641|Oral dose of LY3337641 containing 120 microcuries of radioactivity.
11268767|NCT02914366|Experimental|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by ~3mg/kg to a dose of 1050 mg/day (~l5 mg/kg/day).
11268768|NCT02914366|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
11268769|NCT02914353|Experimental|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg
~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
11268770|NCT02914353|Placebo Comparator|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;
~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
11268771|NCT02914340|Experimental|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
11268772|NCT02914327|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
11268773|NCT02914314|Experimental|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
11268831|NCT02913898|Placebo Comparator|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
11268832|NCT02913885|Active Comparator|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
11268774|NCT02914301|Active Comparator|Babyscripts Prenatal App|For patients allocated to the study group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients who were allocated to the intervention arm, the clinician will told that they are in intervention group and therefore will be receiving regular app-based education and clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
11268775|NCT02914301|Placebo Comparator|Placebo|For patients cared for by clinicians allocated to the usual care arm, the clinician will discuss the management options and scheduling procedures with the parent in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.
11268776|NCT02914275|Experimental|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
11268777|NCT02914275|Experimental|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
11268778|NCT02914275|Active Comparator|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
11268779|NCT02914275|Active Comparator|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
11268780|NCT02914262|Experimental|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
11268781|NCT02914262|Placebo Comparator|Placebo:Cohort 1-6|"Intervention Placebo:
~Two subjects per cohort will receive single oral doses of placebo"
11268782|NCT02914249|Experimental|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
11268783|NCT02914249|No Intervention|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
11268784|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
11268785|NCT02914223|Experimental|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
11268786|NCT02914223|Experimental|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
11268787|NCT02914210|Other|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
11268788|NCT02914210|Other|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
11268789|NCT02914197|Experimental|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:
~Decision aid
~YouTube video
~Group information session"
11268790|NCT02914197|No Intervention|Control|Standard information leaflet for breast screening from Cancer Care Ontario
11268791|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
11268792|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
11268793|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
11268794|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
11268795|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
11268796|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
11268797|NCT02914158|Experimental|Goserelin and aromatase inhibitors|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.
~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
11268798|NCT02914158|Active Comparator|Goserelin and tamoxifen|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.
~Tamoxifen: 20mg oral for every day, for 5 years."
11268799|NCT02914145|Other|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
11268800|NCT02914132|Other|Seraph 100 Filter|Renal replacement patient with bacteremia.
11268801|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.
~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
11268802|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
11268803|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
11268804|NCT02914093|Experimental|IMT-feasibility|Single arm intervention
11268833|NCT02913885|Experimental|Group 1|fluoride varnish inhibit progression of white spot lesion
11268834|NCT02913859|Experimental|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
11268835|NCT02913859|Active Comparator|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
11268805|NCT02914067|Experimental|Cohort 1|"Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later.
~Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time"
11268806|NCT02914067|Experimental|Cohort 2|"Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 3 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient.
~Patients in Cohort 1 will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 3 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans)."
11268807|NCT02914067|Experimental|Cohort 3|"During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time.
~rsfcMRI will be obtained annually for total of 3 rsfcMRIs for each patient."
11268808|NCT02914054|Active Comparator|Conventional Prednisone receiving group|Patients in PDN arm received PDN
11268809|NCT02914054|Active Comparator|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
11268810|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD >0 cm.
11268811|NCT02914028|Active Comparator|Tramadol and paracetamol|subjects were administered intravenous analgesia (control group) Tramadol 100 mg and paracetamol 1000 mg at the end of the surgery
11268812|NCT02914028|Active Comparator|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
11268813|NCT02914015|Experimental|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
11268814|NCT02914015|Active Comparator|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
11268815|NCT02914002|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
11268816|NCT02914002|No Intervention|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
11268817|NCT02914002|No Intervention|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
11268818|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
11268819|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
11268820|NCT02913976|Experimental|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
11268821|NCT02913976|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
11268822|NCT02913963|Active Comparator|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
11268823|NCT02913963|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
11268824|NCT02913937|Active Comparator|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
11268825|NCT02913937|Experimental|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
11268826|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
11268827|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
11268828|NCT02913911|Experimental|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
11268829|NCT02913911|Sham Comparator|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
11268830|NCT02913898|Experimental|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
11268959|NCT02912975|Experimental|Mirror treatment|Five minutes treatment period twice a day for three weeks
11268836|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
11268837|NCT02913833|Experimental|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
11268838|NCT02913833|No Intervention|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
11268839|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
11268840|NCT02913807|Placebo Comparator|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
11268841|NCT02913807|Experimental|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
11268842|NCT02913781|Experimental|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
11268843|NCT02913768|Active Comparator|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
11268844|NCT02913768|Placebo Comparator|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
11268845|NCT02913755|Experimental|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
11268846|NCT02913755|Active Comparator|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
11268847|NCT02913742|Experimental|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
11268848|NCT02913729|Experimental|radiotherapy in arm 1|pre-operative accelerated partial breast irradiation
11268849|NCT02913729|Active Comparator|radiotherapy in arm 2|post-operative accelerated partial breast irradiation
11268850|NCT02913716|Experimental|Defactinib treatment|Single dose of 400 mg [14C]-defactinib, oral suspension
11268851|NCT02913703|Experimental|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
11268852|NCT02913703|Experimental|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
11268853|NCT02913703|Experimental|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
11268854|NCT02913703|Experimental|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
11268855|NCT02913703|Experimental|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
11268856|NCT02913703|Experimental|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
11268857|NCT02913690|Placebo Comparator|Control group|Control group will be supplemented with placebo for 12 months.
11268858|NCT02913690|Active Comparator|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
11268859|NCT02913677|Active Comparator|group 1|prolonged minimal enteral nutrition
11268860|NCT02913677|Placebo Comparator|group 2|slowly advancing enteral nutrition
11268861|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
11268862|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
11268863|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
11268864|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
11268865|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
11268866|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
11268867|NCT02913625|Experimental|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
11268868|NCT02913625|Active Comparator|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
11268960|NCT02912975|Active Comparator|Tactile treatment|Tactile massage twice a day for three weeks
11269078|NCT02912143||newly diagnosed children with hemophilia|no intervention
11269079|NCT02912130|No Intervention|Control|No Intervention
11268869|NCT02913612|Experimental|Intervention Group|Subjects assigned to this arm will be randomized to either 0.25% Timolol or 0.5% Timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol, if on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin alternative treatment.
11268870|NCT02913612|No Intervention|Non-Intervention Group|Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.
11268871|NCT02913573|Experimental|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
11268872|NCT02913573|No Intervention|GA only|Patients will receive standard general anesthesia.
11268873|NCT02913547|Experimental|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.
~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
11268874|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
11268875|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
11268876|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
11268877|NCT02913508|Experimental|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
11268878|NCT02913508|Experimental|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
11268879|NCT02913508|Experimental|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
11268880|NCT02913508|Experimental|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
11268881|NCT02913508|Experimental|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
11268882|NCT02913495|Experimental|Vaginal Progesterone|200mg micronized progesterone vaginally, to be taken daily starting at 16 0/7 - 23 6/7 weeks, and continued daily until 36 6/7 weeks' gestation or delivery
11268883|NCT02913495|Active Comparator|Intramuscular Progesterone|250mg intramuscular progesterone to be administered weekly starting at 16 0/7 - 23 6/7 weeks, and continued weekly until 36 6/7 weeks' or delivery.
11268884|NCT02913482|Experimental|Part 1 (Dose Finding): Risdiplam (RO7034067)|Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
11268885|NCT02913482|Experimental|Part 2 (Confirmatory): Risdiplam (RO7034067)|Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
11268886|NCT02913469|Experimental|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
11268887|NCT02913469|Active Comparator|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
11268888|NCT02913469|Sham Comparator|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
11268889|NCT02913469|Placebo Comparator|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
11268890|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
11268891|NCT02913443|Experimental|Introductory Cohort - 400 μg RO7051790|Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
11268892|NCT02913443|Experimental|Dose Escalation - 1000 μg RO7051790|1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
11268893|NCT02913443|Experimental|Dose Escalation - 1300 μg RO7051790|1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
11268894|NCT02913443|Experimental|Dose Escalation - 1900 μg RO7051790|1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
11268895|NCT02913430|Active Comparator|Arm A|fulvestrant administered 500mg IM Q28 days plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
11268896|NCT02913430|Active Comparator|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
11268897|NCT02913417|Experimental|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
11268898|NCT02913404|Experimental|ACL Reconstruction|"Surgical Protocol
~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
11269077|NCT02912156|Active Comparator|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
11268899|NCT02913404|Experimental|ACL Recon. extra-articular-tenodesis|"Surgical Protocol
~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
11268900|NCT02913391|Experimental|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
11268901|NCT02913391|Active Comparator|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
11268902|NCT02913378|Experimental|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
11268903|NCT02913378|Active Comparator|Conservative|Conservative treatment with sling and rehabilitation
11268904|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
11268905|NCT02913352|Active Comparator|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
11268906|NCT02913352|Experimental|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
11268907|NCT02913339|Experimental|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be > 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
11268908|NCT02913339|Active Comparator|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:
~If the CHW calculates the risk of CVD to be > 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
11268909|NCT02913326|Experimental|Dabigatran etexilate|
11268910|NCT02913326|Active Comparator|Warfarin|
11268911|NCT02913313|Experimental|Part 1A- Dose Escalation- Monotherapy|Specified dose on specified days
11268912|NCT02913313|Experimental|Part 1B- Dose Escalation- Combination Therapy|Specified dose on specified days
11268913|NCT02913313|Experimental|Part 2A- Expansion- Monotherapy|Specified dose on specified days
11268914|NCT02913313|Experimental|Part 2B- Expansion- Combination Therapy|Specified dose on specified days
11268915|NCT02913300|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
11268916|NCT02913300|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
11268917|NCT02913287|Placebo Comparator|Placebo|Maltodextrin
11268918|NCT02913287|Experimental|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
11268919|NCT02913274|Experimental|"DEB arm"|dilation by a high-pressure conventional angioplasty balloon (sized to fit the reference native vein diameter) until disappearance of the stenotic obstructive area and achievement of technical success (possibility of changing balloon size or dilation pressure) then dilation by a DEB.
11268920|NCT02913274|Active Comparator|"conventional angioplasty arm"|dilation will be performed by a conventional high-pressure balloon until technical success is achieved (possibility of changing balloon size or dilation pressure), then by a sham balloon i.e a conventional low-pressure balloon (placebo)
11268921|NCT02913261|Active Comparator|Ruxolitinib|Ruxolitinib 10 mg Bis In Diem (BID)
11268922|NCT02913261|Active Comparator|Best Available Therapy (BAT)|As selected by the investigator
11268923|NCT02913248|Experimental|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
11268924|NCT02913235|Experimental|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
11268925|NCT02913222|Experimental|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
11268958|NCT02912988|No Intervention|Control group|"Standard treatment:
~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
11268926|NCT02913222|Active Comparator|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
11268927|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
11268928|NCT02913196|Experimental|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
11268929|NCT02913183|Experimental|young Fresh Frozen Plasma|"Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.
~Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
11268930|NCT02913183|Placebo Comparator|old Fresh Frozen Plasma|"Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.
~Old plasma exchange over a course of 3 consecutive days after stroke onset.
~Patients will receive usual care and drug use in hospital."
11268931|NCT02913170|Experimental|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
11268932|NCT02913170|Placebo Comparator|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
11268933|NCT02913157|Experimental|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
11268934|NCT02913131|Experimental|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
11268935|NCT02913131|Experimental|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
11268936|NCT02913118|Experimental|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
11268937|NCT02913118|Placebo Comparator|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
11268938|NCT02913105|Experimental|LMB763|Oral dose once daily for 12 weeks (84 days)
11268939|NCT02913105|Placebo Comparator|Placebo|Oral dose once daily for 12 weeks (84 days)
11268940|NCT02913092|Experimental|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed and responded to (e.g. outreach worker contacts the participant for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide asthma education over the phone
11268941|NCT02913092|No Intervention|Usual Care|Usual care group will receive the electronic tracker but the sensor-generated alerts will not be delivered. If the usual care group rescue inhaler data reveals frequent use of rescue medication (daily use for >3 days) investigators will reach out (via app or phone call) to advise the participant to see their physician
11268942|NCT02913079|Experimental|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
11268943|NCT02913079|Placebo Comparator|Sitting|During this condition, participants will work in the sitting position only.
11268944|NCT02913066|Experimental|Single drug|S-1 concurrent Radiotherapy
11268945|NCT02913066|Active Comparator|Double drug|S-1 plus cisplatin concurrent Radiotherapy
11268946|NCT02913053|Active Comparator|Aerobic exercise|
11268947|NCT02913053|Active Comparator|Stretching and Toning|
11268948|NCT02913053|No Intervention|Usual care: Control Group|
11268949|NCT02913040|Experimental|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
11268950|NCT02913040|Active Comparator|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
11268951|NCT02913027|No Intervention|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
11268952|NCT02913027|Active Comparator|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
11268953|NCT02913014|Active Comparator|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
11268954|NCT02913014|No Intervention|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
11268955|NCT02913001|Experimental|Low Glycemic Load Diet|Participants received a diet education to follow a low glycemic load diet and received some low glycemic load staple foods.
11268956|NCT02913001|Active Comparator|Usual Eating Plan|Participants received a diet education to continue with their usual diet.
11268957|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:
~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
11268961|NCT02912962|Experimental|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.
~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
11268962|NCT02912962|Experimental|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
11268963|NCT02912949|Experimental|Part 2 Pancreatic cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
11268964|NCT02912949|Experimental|Part 2 NSCLC cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
11268965|NCT02912949|Experimental|Part 2 Solid tumour (basket) harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
11268966|NCT02912936|Experimental|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
11268967|NCT02912936|Placebo Comparator|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
11268968|NCT02912923|Experimental|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
11268969|NCT02912923|Experimental|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
11268970|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
11268971|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
11268972|NCT02912897|Experimental|Cellular therapy with EBV specific autologous CTL infusion|
11268973|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
11268974|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
11268975|NCT02912871|Experimental|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
11268976|NCT02912858|Experimental|geko plus R-2|neuromuscular electrostimulation
11268977|NCT02912845|Experimental|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
11268978|NCT02912832|Experimental|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.
~Operators were blinded to all other results for a sample upon data entry."
11268979|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
11268980|NCT02912793|Active Comparator|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
11268981|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
11268982|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
11268983|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
11268984|NCT02912754|Experimental|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
11268985|NCT02912754|No Intervention|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
11268986|NCT02912741|Experimental|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
11268987|NCT02912741|Active Comparator|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
11268988|NCT02912728|Active Comparator|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
11268989|NCT02912728|Active Comparator|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.
~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.
~Participants will be instructed to use the CGM as per the FDA labeling."
11268990|NCT02912728|No Intervention|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
11268991|NCT02912715|Experimental|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
11268992|NCT02912702|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
11268993|NCT02912702|Active Comparator|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
11268994|NCT02912689|Experimental|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
11268995|NCT02912689|Active Comparator|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
11268996|NCT02912676|Experimental|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
11268997|NCT02912663|Experimental|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
11268998|NCT02912663|Placebo Comparator|Placebo|Control group will receive saline only
11268999|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
11269000|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
11269001|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
11269002|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
11269003|NCT02912637||CF patients|Hyperpolarized Xenon MRI
11269004|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
11269005|NCT02912611|Other|Moderate and High risk for AKI|
11269006|NCT02912598|Active Comparator|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
11269007|NCT02912598|Active Comparator|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
11269008|NCT02912598|Experimental|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
11269009|NCT02912598|Active Comparator|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
11269010|NCT02912585|Experimental|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
11269011|NCT02912585|Placebo Comparator|Placebo|Oropharyngeal administration of sterile water.
11269012|NCT02912585|Active Comparator|Donor human milk|Oropharyngeal administration of donor human milk.
11269013|NCT02912572|Experimental|Pole Mutated Endometrial Cancer|Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
11269014|NCT02912572|Experimental|MSS Endometrial Cancer|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
11269015|NCT02912572|Experimental|MSS Avelumab/Talazoparib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
11269016|NCT02912572|Experimental|MSS Avelumab/Axitinib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Axitinib will be administered twice per day by mouth
11269017|NCT02912559|Experimental|Arm I (combination chemotherapy, atezolizumab)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes starting on day 1 of cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity.
11269018|NCT02912559|Active Comparator|Arm II (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11269019|NCT02912546|Active Comparator|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
11269020|NCT02912546|Active Comparator|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
11269021|NCT02912533|Experimental|JR-131|
11269022|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
11269023|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
11269024|NCT02912507|Experimental|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
11269025|NCT02912507|Active Comparator|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
11269026|NCT02912494|Experimental|JR-131|
11269027|NCT02912494|Active Comparator|Darbepoetin alfa|
11269028|NCT02912481|Experimental|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
11269029|NCT02912481|Active Comparator|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
11269030|NCT02912481|Active Comparator|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
11269031|NCT02912468|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
11269032|NCT02912468|Experimental|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
11269033|NCT02912455|Active Comparator|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
11269034|NCT02912455|Placebo Comparator|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
11269035|NCT02912442||Infertile women study 1|
11269036|NCT02912442||Infertile women study 2|
11269037|NCT02912442||Repeated pregnancy loss|
11269038|NCT02912429|Other|Inlay|specific technical type of patellofemoral arthroplasty
11269039|NCT02912429|Other|Onlay|specific technical type of patellofemoral arthroplasty
11269040|NCT02912416|Experimental|Probiotics|Capsule with probiotics
11269041|NCT02912416|Placebo Comparator|Placebo|Capsule with placebo
11269042|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
11269043|NCT02912390|Active Comparator|Cerclage|- Macdonald cerclage placed in standard fashion
11269044|NCT02912390|Active Comparator|Expectant management|- Patient is placed on activity restrictions
11269045|NCT02912377|Experimental|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
11269046|NCT02912377|Experimental|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
11269047|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
11269048|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
11269049|NCT02912338|Experimental|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
11269050|NCT02912338|Active Comparator|Control Group|not change lifestyle
11269051|NCT02912325|Other|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
11269052|NCT02912312|Experimental|Arm I: Hypofractionated Regional Nodal Irradiation (RNI)|Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
11269053|NCT02912312|Active Comparator|Arm II: Standard Regional Nodal Irradiation (RNI)|Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
11269054|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
11269055|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
11269056|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
11269057|NCT02912286|Active Comparator|conventional needle irrigation|side-vented needle used for endodontic irrigation
11269058|NCT02912286|Experimental|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
11269059|NCT02912286|Experimental|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
11269060|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
11269061|NCT02912260|Experimental|MGL-3196|Study Drug
11269062|NCT02912260|Placebo Comparator|Placebo|Matching Placebo
11269063|NCT02912247|Experimental|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
11269064|NCT02912247|Active Comparator|adalimumab|adalimumab 40mg administered subcutaneously once
11269065|NCT02912234|Experimental|Apixaban and Clarithromycin|
11269066|NCT02912221|No Intervention|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
11269067|NCT02912221|Active Comparator|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
11269068|NCT02912208|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
11269069|NCT02912208|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
11269070|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.
~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
11269071|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.
~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
11269072|NCT02912182|Placebo Comparator|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
11269073|NCT02912182|Active Comparator|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
11269074|NCT02912182|Active Comparator|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
11269075|NCT02912169|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
11269076|NCT02912156|Experimental|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
11269080|NCT02912130|Experimental|Exercise|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
~Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
11269081|NCT02912130|Experimental|Exercise+Nutrition|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise
~Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
11269082|NCT02912130|Experimental|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
11269083|NCT02912104|Experimental|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of primary ovarian insufficiency(POI) patients
11269084|NCT02912078|Experimental|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
11269085|NCT02912078|Active Comparator|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
11269086|NCT02912052|Experimental|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
11269087|NCT02912052|Active Comparator|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
11269088|NCT02912026|Experimental|Intravenous|Intravenous AUC0-infinity
11269089|NCT02912026|Experimental|Oral|Oral AUC0-infinity
11269090|NCT02912013|Experimental|Me mini|Subjects treated with Me mini device
11269091|NCT02912000|Experimental|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
11269092|NCT02912000|No Intervention|Control|Care as usual: No electronic tablet in waiting room
11269093|NCT02911987|Experimental|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
11269094|NCT02911987|Experimental|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
11269095|NCT02911987|Experimental|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
11269096|NCT02911987|Experimental|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
11269097|NCT02911987|Active Comparator|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
11269098|NCT02911974|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
11269099|NCT02911974|Active Comparator|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
11269100|NCT02911961|Experimental|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
11269101|NCT02911961|No Intervention|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
11269102|NCT02911948|Experimental|Insulin degludec/liraglutide|
11269103|NCT02911948|Active Comparator|Insulin degludec|
11269104|NCT02911935|Active Comparator|Oral azithromycin|Oral Azithromycin
11269105|NCT02911935|Placebo Comparator|Placebo|Oral Placebo
11269106|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.
~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
11269107|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.
~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
11269108|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
11269109|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
11269110|NCT02911883||Normal|Not having glaucoma or retinal pathology
11269111|NCT02911883||Glaucoma|Having glaucoma.
11269112|NCT02911883||Retina|Having retinal pathology
11269113|NCT02911870|Experimental|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
11269114|NCT02911870|Placebo Comparator|Part A, placebo|Single dose at corresponding dose levels.
11269115|NCT02911870|Experimental|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
11269116|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
11269117|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
11269118|NCT02911831|Experimental|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.
~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
11269119|NCT02911831|Placebo Comparator|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.
~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
11269120|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
11269121|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
11269122|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
11269123|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
11269124|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
11269125|NCT02911805|Active Comparator|Aerobic Exercise|Exercise 3 times a week
11269126|NCT02911805|Placebo Comparator|Balance Training|Group balance training 3 times a week
11269127|NCT02911792|Experimental|Dapagliflozin|Subjects will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization we will add Dapagliflozin to current metformin.
11269128|NCT02911792|Active Comparator|Metformin|Subjects who Drug naïve we will give Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization we will add Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
11269129|NCT02911779|Other|change of medilateral angle line|change of medilateral angle line during crowning of the head
11269130|NCT02911766|Active Comparator|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,
~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
11269131|NCT02911766|Experimental|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse
~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
11269132|NCT02911766|Experimental|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.
~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
11269133|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
11269134|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
11269135|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
11269136|NCT02911740|Experimental|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
11269137|NCT02911740|No Intervention|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
11269138|NCT02911727|Experimental|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
11269139|NCT02911727|No Intervention|Standard discharge|Discharge at least 48 hours after elective cesarean section.
11269140|NCT02911714|Experimental|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
11269141|NCT02911714|Experimental|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
11269142|NCT02911701|Experimental|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
11269143|NCT02911701|Active Comparator|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
11269144|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
11269145|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
11269146|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
11269425|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
11269147|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
11269148|NCT02911662|Experimental|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
11269149|NCT02911662|Active Comparator|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
11269150|NCT02911649|Experimental|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
11269151|NCT02911649|Experimental|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
11269152|NCT02911649|Experimental|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
11269153|NCT02911649|No Intervention|Control Group|Participants in this group will receive usual care
11269154|NCT02911636|Experimental|Arm 1|Pelvic SABR with intra-prostatic SABR
11269155|NCT02911623|Experimental|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
11269156|NCT02911610|Experimental|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
11269157|NCT02911610|Other|volar plate|surgery of wrist fractures with volar plate
11269158|NCT02911597|Experimental|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.
~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
11269159|NCT02911597|Experimental|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.
~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
11269160|NCT02911584|Active Comparator|Sacral colpopexy|Laparoscopic procedure
11269161|NCT02911584|Active Comparator|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
11269162|NCT02911571|Experimental|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
11269163|NCT02911532|Experimental|Optical Coherence tomography|
11269164|NCT02911519|Experimental|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
11269165|NCT02911519|Active Comparator|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
11269166|NCT02911493|Experimental|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
11269167|NCT02911493|Active Comparator|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
11269168|NCT02911480|Experimental|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
11269169|NCT02911480|Experimental|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
11269170|NCT02911480|Experimental|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
11269171|NCT02911480|Experimental|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
11269172|NCT02911480|Experimental|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
11269173|NCT02911467|Experimental|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
11269174|NCT02911454|Experimental|Healthy infants: fully or partly formula fed|
11269175|NCT02911441|Experimental|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
11269426|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
11269176|NCT02911441|No Intervention|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
11269177|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
11269178|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
11269179|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
11269180|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
11269181|NCT02911389|Active Comparator|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
11269182|NCT02911389|Active Comparator|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
11269183|NCT02911389|Active Comparator|outpatient PT|outpatient physical therapy
11269184|NCT02911363|Active Comparator|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
11269185|NCT02911363|Active Comparator|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
11269186|NCT02911350|Experimental|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:
~Lupron / Flutamide
~Zoladex/ Flutamide
~Lupron/ Casodex
~Zoladex/ Casodex
~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday & Wednesday or Tuesday & Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) & 45 mg/m2 (dose level VI).
~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
11269187|NCT02911337|Experimental|Lifestyle modification|Lifestyle modification
11269188|NCT02911324|Experimental|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
11269189|NCT02911324|Experimental|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
11269190|NCT02911311|Experimental|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
11269191|NCT02911311|Active Comparator|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
11269192|NCT02911298|Experimental|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
11269193|NCT02911298|Active Comparator|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
11269194|NCT02911285|Experimental|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
11269195|NCT02911285|Placebo Comparator|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
11269196|NCT02911272|Active Comparator|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
11269197|NCT02911272|Experimental|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
11269198|NCT02911259|Experimental|Group 1|Post-operative suction is set to -2 cmH2O.
11269199|NCT02911259|Active Comparator|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
11269200|NCT02911220|Other|blood sample for genetic evaluation|a blood sample is collected once for genetic analysis
11269201|NCT02911207|Experimental|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
11269202|NCT02911207|Active Comparator|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
11269203|NCT02911194|Experimental|Treatment|a2 milk intervention period
11269204|NCT02911194|Placebo Comparator|Control|a1 containing milk (normal) intervention period
11269205|NCT02911168|Active Comparator|Proximal Intercostal Block|See Intervention Section
11269206|NCT02911168|Active Comparator|Paravertebral Block|See Intervention Section
11269207|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
11269208|NCT02911142|Experimental|1|Lenalidomide, Rituximab, Prednisone, Etopiside, Doxorubicin, Vincristine and Cyclophosphamide
11269209|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
11269210|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
11269211|NCT02911116|Experimental|IV and subcutaneous|initial IV ustekinumab followed by subcutaneous injection at Week 8
11269212|NCT02911116|Experimental|Subcutaneous Only|Subcutaneous injections of Ustekinumab
11269213|NCT02911103|Experimental|Active|Single Arm Study
11269214|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SEAddictions Unit.
11269215|NCT02911064||Assessment Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being.
11269216|NCT02911051|Experimental|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
11269217|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
11269218|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
11269219|NCT02910999||NSCLC patients with squamous tumor histology|
11269220|NCT02910999||NSCLC patients with non-squamous tumor histology|
11269221|NCT02910986|No Intervention|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
11269222|NCT02910986|Active Comparator|Enhanced|Usual Care plus a written educational brochure
11269223|NCT02910986|Active Comparator|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
11269224|NCT02910973|Active Comparator|Vagus Nerve Stimulation|Device: Vagus nerve stimulation Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
11269225|NCT02910973|Sham Comparator|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
11269226|NCT02910960|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
11269227|NCT02910960|Active Comparator|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
11269228|NCT02910947|Experimental|quadratus lumborum|
11269229|NCT02910947|Experimental|TAP(Transversus abdominis plane)|
11269230|NCT02910934|Experimental|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
11269231|NCT02910934|No Intervention|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
11269232|NCT02910895|Other|single arm|single tumor biopsy
11269233|NCT02910882|Experimental|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:
~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).
~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);
~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:
~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
11269234|NCT02910869||Successful weight loss|Patients who have lost =>5% of their weight after completing MOVE! or TeleMOVE!
11269235|NCT02910869||Unsuccessful weight loss|Patients who have lost <5% of their weight after completing MOVE! or TeleMOVE!
11269236|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.
~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.
~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
~External beam Radiotherapy
~Surgery"
11269237|NCT02910817|Experimental|Metformin-treated group|51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
11269238|NCT02910817|Placebo Comparator|Placebo|A cohort of fifty-one cross matched PCOS women
11269239|NCT02910804|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
11269240|NCT02910791||atopic dermatitis|up to 40 subjects with atopic dermatitis will be enrolled into study.
11269241|NCT02910791||psoriasis|up to 20 subjects with psoriasis will be enrolled into study.
11269242|NCT02910791||people without skin conditions|Up to 40 subjects without skin conditions will be enrolled into study.
11269243|NCT02910778|Experimental|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
11269244|NCT02910778|Placebo Comparator|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
11269245|NCT02910765|Active Comparator|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
11269246|NCT02910765|Placebo Comparator|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
11269247|NCT02910752|Experimental|"CLAM|PBSC"|CLAM chemotherapy with mobilized PBSC infusion: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
11269248|NCT02910739|Experimental|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
11269249|NCT02910739|Active Comparator|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
11269250|NCT02910739|Experimental|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
11269251|NCT02910739|Active Comparator|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
11269252|NCT02910726|Experimental|Sentinel Lymph Node Biopsy|This is a single-center clinical trial to evaluate non-inferiority of ICG-guided SLN biopsy compared with the gold standard TcL-guided SLN biopsy in pediatric patients with solid tumors. Each patient will undergo TcL, consistent with the standard of care, but the surgeon will be blinded to the results preoperatively. Intraoperatively, ICG injection and transdermal lymphography will be used to identify the draining nodal basin and the position of the sentinel nodes. ICG transdermal lymphography will be considered successful if SLNs can be visualized on near-infrared imaging. After the transdermal lymphography results have been recorded, the surgeon will be unblinded to the TcL mapping.
11269253|NCT02910713|Experimental|Intranasal Application|Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
11269254|NCT02910713|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
11269255|NCT02910700|Experimental|Arm A (NDT): Nivolumab + Dabrafenib + Trametinib|Patients receive nivolumab IV over 30 minutes on day 1, dabrafenib PO BID on days 1-28, and trametinib PO QD on days 1-28.
11269256|NCT02910700|Experimental|Arm B (NT, closed to accrual): Nivolumab + Trametinib|Patients receive nivolumab IV over 30 minutes on day 1 and trametinib PO QD on days 1-28.
11269257|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
11269258|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine & CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
11269259|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh & Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. & 15- 17 y.)
11269260|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
11269261|NCT02910648|Experimental|Approach/Inhibit group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.
~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.
~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
11269262|NCT02910648|Sham Comparator|Sham sound cues group|"Participants in the experimental group and control sham sound cues group will complete the Modified Go/No-Go Task.
~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.
~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
11269263|NCT02910648|Sham Comparator|Sham go/no-go group|"Participants in the control sham go/no-go group will complete a modified Go/No-Go Task with sham approach and inhibit items.
~Following completion of post-training assessment measures, participants will be given the opportunity to take a 90-minute while undergoing real-time sleep monitoring.
~White noise will be played via headphones. Upon entering Stage N3 sleep and/or after having been asleep for 20 minutes and currently in any stage sleep other than N1, sound cues will be played to participants via headphones based on their randomization to 1 of 3 experimental groups."
11269264|NCT02910635|Experimental|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
11269265|NCT02910635|Experimental|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
11269266|NCT02910635|Active Comparator|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
11269267|NCT02910635|Placebo Comparator|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
11269268|NCT02910635|Placebo Comparator|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
11269269|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
11269270|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
11269271|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
11269272|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
11269273|NCT02910596|Experimental|A|"Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day
~In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.
~Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
11269274|NCT02910596|Experimental|B|"Early bladder training Start on 3rd - 5th postoperative day
~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
11269275|NCT02910596|Experimental|C|"Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day
~should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.
~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
11269276|NCT02910596|Other|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
11269277|NCT02910583|Experimental|MRD Cohort Randomized ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity
11269278|NCT02910583|Placebo Comparator|MRD Cohort Randomized Placebo to match ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive matching ibrutinib placebo capsules orally once daily on a continuous schedule until MRD-positive relapse, clinical disease progression or unacceptable toxicity.
11269279|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules and venetoclax 400 mg tablets orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity.
11269280|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous scheduled until clinical disease progression or unacceptable toxicity.
11269281|NCT02910583|Experimental|Fixed Duration Cohort - Open Label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
11269282|NCT02910570|Experimental|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
11269283|NCT02910570|Placebo Comparator|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
11269284|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
11269285|NCT02910531|Experimental|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.
~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.
~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
11269286|NCT02910531|Placebo Comparator|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.
~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.
~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
11269287|NCT02910518|Experimental|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
11269288|NCT02910518|Active Comparator|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
11269289|NCT02910505|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
11269290|NCT02910492|Experimental|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
11269291|NCT02910479|Experimental|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
11269431|NCT02909478|Active Comparator|Control arm|Dexamethasone+ Tropisetron
11269292|NCT02910466|Experimental|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 48 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
11269293|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
11269294|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
11269295|NCT02910440|Experimental|DCL-101|
11269296|NCT02910440|Active Comparator|GoLytely|
11269297|NCT02910427|Placebo Comparator|Na salt|regular salt
11269298|NCT02910427|Active Comparator|K salt|potassium-enriched salt
11269299|NCT02910427|Active Comparator|K/Mg salt|potassium and magnesium-enriched salt
11269300|NCT02910414|Experimental|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
11269301|NCT02910414|Sham Comparator|Renal Angiography Only (Sham Procedure)|The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).
11269302|NCT02910401|Active Comparator|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
11269303|NCT02910401|Active Comparator|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
11269304|NCT02910401|Active Comparator|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
11269305|NCT02910388|Experimental|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
11269306|NCT02910388|Active Comparator|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
11269307|NCT02910375|Other|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (<80 kg) or 100mg (>80 kg body weight)
11269308|NCT02910375|Other|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (<80 kg) or 100mg every 4 weeks (>80 kg body weight)
11269309|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
11269310|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
11269311|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
11269312|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
11269313|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
11269314|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
11269315|NCT02910310|No Intervention|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
11269316|NCT02910310|Experimental|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
11269317|NCT02910245|Active Comparator|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
11269318|NCT02910245|Placebo Comparator|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
11269319|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
11269320|NCT02910219|Experimental|Treatment|Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.
11269321|NCT02910219|No Intervention|Control|Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.
11269322|NCT02910206|Experimental|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
11269323|NCT02910206|Experimental|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
11269324|NCT02910193||alcohol-dependent patients|
11269325|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
11269326|NCT02910193||healthy control subjects|
11269327|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
11269328|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
11269329|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
11269354|NCT02909972|Experimental|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
11269427|NCT02909504|Other|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
11269428|NCT02909491||Cases|Inpatient with severe behavioural disorders
11269330|NCT02910154|Experimental|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.
~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
11269331|NCT02910154|No Intervention|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
11269332|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
11269333|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
11269334|NCT02910128|Experimental|School intervention|chiquichefs education innovation
11269335|NCT02910128|No Intervention|control school|A primary schools will function as control schools.
11269336|NCT02910115|Other|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
11269337|NCT02910115|Experimental|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.
~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
11269338|NCT02910102|Other|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
11269339|NCT02910102|Other|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
11269340|NCT02910089|Other|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
11269341|NCT02910089|No Intervention|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
11269342|NCT02910076|Experimental|Healthy volunteers|
11269343|NCT02910076|Experimental|Diabetes patients|
11269344|NCT02910063|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
11269345|NCT02910050|Experimental|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
11269346|NCT02910037|Experimental|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
11269347|NCT02910024|Active Comparator|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
11269348|NCT02910024|Sham Comparator|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
11269349|NCT02910011|Experimental|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
11269350|NCT02909985|Experimental|Visual response to IR|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source
~10 colorblind participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source
~For both groups, as intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
11269351|NCT02909985|Experimental|Electroretinography|"5 healthy participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR
~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
11269352|NCT02909985|Experimental|Visual Evoke Potential Test|"5 healthy participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR
~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
11269353|NCT02909972|Experimental|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
11269429|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
11269355|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.
~The weight-based dosing schedule is as follows:
~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
11269356|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
11269357|NCT02909946|Active Comparator|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
11269358|NCT02909946|No Intervention|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
11269359|NCT02909933|Experimental|liraglutide|liraglutide 3 mg QD for 12 weeks
11269360|NCT02909933|Experimental|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
11269361|NCT02909920|Experimental|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
11269362|NCT02909920|Active Comparator|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
11269363|NCT02909907|Experimental|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
11269364|NCT02909907|Experimental|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
11269365|NCT02909894|Experimental|Prolonged Sitting|
11269366|NCT02909894|Active Comparator|Light intensity arm ergometry breaks|
11269367|NCT02909881|Experimental|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
11269368|NCT02909868|Experimental|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
11269369|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
11269370|NCT02909842|Experimental|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
11269371|NCT02909842|Placebo Comparator|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
11269372|NCT02909829|Experimental|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
11269373|NCT02909829|Experimental|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
11269374|NCT02909829|Active Comparator|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
11269375|NCT02909803|Experimental|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
11269376|NCT02909803|Active Comparator|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
11269377|NCT02909790|Experimental|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
11269378|NCT02909790|Sham Comparator|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
11269379|NCT02909777|Experimental|CUDC-907|"CUDC-907 orally administered
~CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing
~Dose level assigned at registration
~Pre-dose pharmacokinetic blood sample will be collected
~Dose escalation will follow a standard 3+3 design"
11269380|NCT02909764|No Intervention|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
11269381|NCT02909764|Experimental|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
11269382|NCT02909751|Active Comparator|Neoadjuvant chemotherapy|"HER2 negative:
~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv
~HER2 positive:
~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
11269430|NCT02909478|Experimental|Aprepitant arm|Aprepitant + Tropisetron
11269383|NCT02909751|Experimental|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:
~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.
~Daily: Tocotrienol 300 mg x 3
~HER2 positive:
~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.
~Daily: Tocotrienol 300 mg x 3"
11269384|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
11269385|NCT02909725|Experimental|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( >50 minutes) of sedentary time.
11269386|NCT02909725|Experimental|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
11269387|NCT02909725|Active Comparator|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
11269388|NCT02909712|Active Comparator|sulfadoxine-pyrimethamine (SP)|"Group 1 (50 CareStart™ RDT-positive women)
~Group 2 (50 CareStart™ RDT-negative women)
~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
11269389|NCT02909712|Experimental|dihydroartemisinin-piperaquine (DHA-PQP)|"Group 3 (50 CareStart™ RDT-positive women)
~Group 4 (50 CareStart™ RDT-negative women)
~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
11269390|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
11269391|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
11269392|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
11269393|NCT02909686|Experimental|Boswellia Serrata|400-800mg in capsule form by mouth every day
11269394|NCT02909686|Experimental|Curcumin|1000-2000mg in capsule form by mouth every day
11269395|NCT02909686|Experimental|Epimedium|1000-2000mg in capsule form by mouth every day
11269396|NCT02909686|Experimental|Fisetin|200-800mg in capsule form by mouth every day
11269397|NCT02909686|Experimental|Luteolin|200-400mg in capsule form by mouth every day
11269398|NCT02909686|Experimental|Nettle|435-1305mg in capsule form by mouth every day
11269399|NCT02909686|Experimental|Pycnogenol|200-400mg in capsule form by mouth every day
11269400|NCT02909686|Experimental|Reishi Mushroom|1600-3200mg in capsule form by mouth every day
11269401|NCT02909686|Experimental|Resveratrol|200-600mg in capsule form by mouth every day
11269402|NCT02909686|Placebo Comparator|Placebo|in capsule form by mouth every day
11269403|NCT02909673|Experimental|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
11269404|NCT02909673|No Intervention|Control|Control: Treatment as usual (standard health class curriculum)
11269405|NCT02909660|Experimental|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
11269406|NCT02909660|Active Comparator|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
11269407|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
11269408|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
11269409|NCT02909621|Active Comparator|Group A|Group A: FLEXOFYTOL® high dosage
11269410|NCT02909621|Active Comparator|Group B|Group B: FLEXOFYTOL® low dosage
11269411|NCT02909621|Placebo Comparator|Group C|Group C: PLACEBO
11269412|NCT02909608||Controls|
11269413|NCT02909608||Children With Pulmonary Hypertension|
11269414|NCT02909595|Experimental|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
11269415|NCT02909595|Active Comparator|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
11269416|NCT02909582|No Intervention|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
11269417|NCT02909582|Experimental|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
11269418|NCT02909569|Experimental|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
11269419|NCT02909556|Experimental|ACURATE neo AS|
11269420|NCT02909530|Active Comparator|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
11269421|NCT02909530|Active Comparator|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
11269422|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
11269423|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
11269424|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
11269432|NCT02909465|Placebo Comparator|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
11269433|NCT02909465|Experimental|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
11269434|NCT02909465|Experimental|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
11269435|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
11269436|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
11269437|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
11269438|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
11269439|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
11269440|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.
~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
11269441|NCT02909413|Experimental|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
11269442|NCT02909413|Active Comparator|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
11269443|NCT02909400|Experimental|Treatment A|Oral administration of 100 mg KH176 twice daily
11269444|NCT02909400|Placebo Comparator|Treatment B|Oral administration of matching placebo twice daily
11269445|NCT02909387|Experimental|Stratum A|This group will be the first to receive the Project UPLIFT intervention, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by phone for one hour once a week for 8 weeks.
11269446|NCT02909387|Active Comparator|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10-week waiting period.
11269447|NCT02909374|Experimental|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
11269448|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
11269449|NCT02909335|Active Comparator|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
11269450|NCT02909335|Experimental|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
11269451|NCT02909322|Active Comparator|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
11269452|NCT02909322|Experimental|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
11269453|NCT02909309|Other|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.
~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
11269454|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
11269455|NCT02909270|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
11269456|NCT02909270|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
11269457|NCT02909257|Experimental|same dose|patient is exposed to the same previously successful dose
11269458|NCT02909257|Experimental|lower dose|patient is exposed to a lower concentration dose
11269459|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
11269460|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
11269461|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
11269462|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
11269463|NCT02909218|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
11269464|NCT02909218|Experimental|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
11269465|NCT02909205|Other|control|First phase : before training / sensitization / booklet delivery
11269466|NCT02909205|Other|post intervention|Second phase : after training / sensitization / booklet delivery
11269467|NCT02909192|Active Comparator|Bright light therapy|Participants will be treated twice daily with bright light therapy.
11269468|NCT02909192|Active Comparator|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
11269469|NCT02909179|Experimental|mCARE-II|mCARE-II supported service provision through existing community health workforce.
11269470|NCT02909179|No Intervention|Comparison|Standard of care, paper-based service provision through existing community health workforce.
11269471|NCT02909166|Active Comparator|aliskiren|Aliskiren 300 once a day (q.d)
11269472|NCT02909166|Placebo Comparator|placebo|Placebo once a day (q.d)
11269473|NCT02909153|Experimental|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
11269474|NCT02909153|Experimental|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
11269475|NCT02909140|Experimental|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
11269476|NCT02909140|Experimental|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
11269477|NCT02909140|Experimental|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
11269478|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
11269479|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
11269480|NCT02909114|Experimental|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
11269481|NCT02909101|Experimental|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
11269482|NCT02909101|Sham Comparator|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
11269483|NCT02909088|Experimental|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
11269484|NCT02909088|Experimental|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
11269485|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
11269486|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
11269487|NCT02909049|Active Comparator|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
11269488|NCT02909049|Experimental|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
11269489|NCT02909036|Experimental|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
11269490|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
11269491|NCT02909010|Active Comparator|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
11269492|NCT02909010|Placebo Comparator|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
11269493|NCT02908997|Experimental|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
11269494|NCT02908997|Experimental|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
11269495|NCT02908997|Experimental|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
11269496|NCT02908984|Experimental|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a period of 4 weeks and recommendations for further training.
11269497|NCT02908984|Active Comparator|Standard primary health care|This represents individualized therapy administered by the primary physician.
11269498|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
11269499|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
11269500|NCT02908958|Experimental|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
11269501|NCT02908958|Experimental|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
11269502|NCT02908945|Experimental|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
11269503|NCT02908945|Experimental|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
11269504|NCT02908945|Other|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
11269505|NCT02908932|Experimental|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
11269506|NCT02908932|Placebo Comparator|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
11269507|NCT02908919|Active Comparator|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
11269508|NCT02908919|Active Comparator|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
11269509|NCT02908919|Active Comparator|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
11269510|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), IV every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1.
11269511|NCT02908893|Experimental|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.
~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.
~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
11269512|NCT02908893|Active Comparator|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.
~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.
~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
11269513|NCT02908893|No Intervention|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
11269514|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
11269515|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
11269516|NCT02908854|Experimental|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
11269517|NCT02908841|Other|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
11269518|NCT02908841|Other|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
11269519|NCT02908828|Experimental|Calanus oil|4 capsules of 500 mg Calanus oil once every day
11269520|NCT02908828|Placebo Comparator|Placebo|4 capsules of 500 mg dietary oil once every day
11269521|NCT02908815|Experimental|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
11269522|NCT02908815|Experimental|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
11269523|NCT02908815|Sham Comparator|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
11269524|NCT02908815|Sham Comparator|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
11269525|NCT02908802|Active Comparator|Probiotic|Probiotic capsules: two capsules twice a day
11269526|NCT02908802|Placebo Comparator|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
11269527|NCT02908789|Other|Antimicrobial photodynamic therapy (aPDT)|The technique consists of a basic protocol of two steps: the use of a photosensitizer and the laser application. In the first step, the cavity was dried and then 0.01% methylene blue solution (Formula & Ação, São Paulo, Brazil) was applied to the entire cavity using a carpule in order to keep in contact with all the walls. It remained in the cavity for a pre-irradiation period of 5 minutes. In the second step, the excess of 0.01% methylene blue solution was removed and the cavity was irradiated with an Indium Gallium Aluminum Phosphorus diode laser (InGaAlP) (Laser DUO®, MM Optics, São Carlos, São Paulo, Brazil) with a wavelength of 660 nm (visible red), a spot area of 3mm2, and fixed output power of 100 mW. We adopted the following parameters: energy of 9 J with 90 seconds of exposure time. The irradiation was applied in continuous mode and the laser array was positioned, in contact, directly over the central part of the cavity.
11269528|NCT02908776|Experimental|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
11269529|NCT02908776|Placebo Comparator|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
11269530|NCT02908763|Experimental|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg <1000 IU/ mL and HBV DNA<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
11269531|NCT02908763|No Intervention|Observing Group|Only observing and following up in this group.
11269532|NCT02908750|Experimental|osimertinib and fexofenadine|Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine
11269533|NCT02908737|Experimental|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
11269534|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
11269535|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
11269536|NCT02908711|Active Comparator|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).
~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
11269537|NCT02908711|Active Comparator|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).
~Patients randomized to this group will receive the block at the end of the surgery."
11269538|NCT02908698|Experimental|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:
~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
11269539|NCT02908698|Placebo Comparator|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
11269540|NCT02908685|Experimental|Part 1 Group A: Adolescents and Adults (Risdiplam)|Adolescent and adult participants aged 12-25 years will receive risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in open-label extension (OLE) phase.
11269541|NCT02908685|Placebo Comparator|Part 1 Group A: Adolescents and Adults (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.
11269542|NCT02908685|Placebo Comparator|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.
11269543|NCT02908685|Experimental|Part 1 Group B: Children (Risdiplam)|Children aged 2-11 years will receive risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.
11269544|NCT02908685|Placebo Comparator|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to risdiplam. After 12 months of treatment with placebo, participants will be switched to risdiplam and treatment will then continue until Month 24. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.
11269545|NCT02908685|Experimental|Part 2: Risdiplam|Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study, for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.
11269569|NCT02908503|Other|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
11269570|NCT02908503|Other|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
11269571|NCT02908503|Other|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
11269572|NCT02908503|Other|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
11269573|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
11274103|NCT02875470|Experimental|Intensiv Perio Set|Root planing with diamond burs
11269546|NCT02908672|Experimental|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
11269547|NCT02908672|Experimental|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
11269548|NCT02908646|Experimental|microcoil|patients who plan for microcoil localization
11269549|NCT02908646|Placebo Comparator|hookwire|patients who plan for hookwire localization
11269550|NCT02908633|Active Comparator|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
11269551|NCT02908633|Active Comparator|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
11269552|NCT02908633|Active Comparator|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
11269553|NCT02908620|Experimental|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
11269554|NCT02908620|Experimental|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
11269555|NCT02908620|Experimental|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
11269556|NCT02908620|Experimental|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
11269557|NCT02908607|Experimental|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
11269558|NCT02908594|Experimental|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
11269559|NCT02908594|No Intervention|control group|The control group received routine care
11269560|NCT02908581|Active Comparator|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
11269561|NCT02908581|Experimental|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
11269562|NCT02908568|Experimental|Spring device|Brisk dilatation of fhe mouth.
11269563|NCT02908568|Sham Comparator|Mandible stimulator|Stimulation of fhe mouth.
11269564|NCT02908555||no intervention|Descriptive study without groups
11269565|NCT02908529|Placebo Comparator|Placebo|Placebo 2 hours before bedtime
11269566|NCT02908529|Active Comparator|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
11269567|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
11269568|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
11269574|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
11269575|NCT02908477|Experimental|De-escalated Adjuvant Radiation Therapy|Docetaxel 15 mg/m2 days 1, 8 + Radiation Therapy (RT) 30 Gy/1.5 Gy fractions twice daily (b.i.d.) days 1-12 only (intermediate risk) or 36 Gy/1.8 Gy b.i.d. fractions (high risk)
11269576|NCT02908477|Active Comparator|Standard of Care Treatment|RT 60 Gy/2 Gy fractions daily (qday) days 1-40. For high risk, add weekly Cisplatin 40 mg/m2 (Around days 1, 8, 15, 22, 29, 36)
11269577|NCT02908464|Experimental|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
11269578|NCT02908464|No Intervention|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
11269579|NCT02908451|Experimental|AbGn-107|AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
11269580|NCT02908438|Experimental|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
11269581|NCT02908438|No Intervention|control group|Control group receive only the routine LPS.
11269582|NCT02908425|Other|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
11269583|NCT02908412|Experimental|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
11269584|NCT02908412|Experimental|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
11269585|NCT02908399|Experimental|Thermal Imaging|Imaging using a thermal camera
11269586|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
11269587|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
11269588|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
11269589|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD> 50).
11269590|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
11269591|NCT02908347|Experimental|MP1032|"Test Product:
~100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days"
11269592|NCT02908347|Experimental|Placebo|"Placebo to MP1032:
~2 capsules of Placebo are provided orally twice daily for 42 days"
11269593|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
11269594|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
11269595|NCT02908321|Active Comparator|CBT|
11269596|NCT02908321|No Intervention|WL|
11269597|NCT02908308|Active Comparator|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
11269598|NCT02908308|Experimental|Hypothermia|Targeted temperature management to 33°C for up to 28h.
11269599|NCT02908295|Experimental|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
11269600|NCT02908295|Placebo Comparator|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
11269601|NCT02908282|Other|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
11269602|NCT02908282|Other|C (control)-group|Povidone: Usage according to instructions for use.
11269603|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
11269604|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to < 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
11269605|NCT02908269|Experimental|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
11269606|NCT02908256|Experimental|PVI group|Monitoring of the PVI during the surgical intervention
11269607|NCT02908256|Active Comparator|Delta PP group|Monitoring of the deltaPP during the surgical intervention
11269608|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
11269609|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
11269610|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
11269611|NCT02908230|Placebo Comparator|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
11269612|NCT02908230|Active Comparator|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
11269613|NCT02908230|Experimental|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
11269614|NCT02908217|Experimental|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
11269615|NCT02908217|Placebo Comparator|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
11269616|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
11269617|NCT02908204||Traditional surgery|Patients underwent traditional surgery
11269618|NCT02908191|Experimental|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
11269619|NCT02908191|Experimental|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
11269620|NCT02908191|Experimental|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
11269621|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.
~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
11269622|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.
~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
11269623|NCT02908165|Experimental|Group A- continuous schedule|Subjects with HCC randomized to group A
11269624|NCT02908165|Active Comparator|Group B- sequential schedule|Subjects with HCC randomized to group B
11269625|NCT02908152|Active Comparator|curcumin|curcumin
11269626|NCT02908152|Placebo Comparator|placebo|
11269627|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
11269628|NCT02908126|Experimental|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
11269629|NCT02908126|Experimental|Oxytocin tablet|single dose of oxytocin tablet
11269630|NCT02908113|Other|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
11269631|NCT02908113|Other|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
11269632|NCT02908100|Placebo Comparator|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
11269633|NCT02908100|Experimental|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
11269634|NCT02908100|Experimental|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
11269635|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
11269636|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
11269637|NCT02908074|Experimental|Experimental: Regimen 1|Drug: BGS649 Dose 1 weekly
11269638|NCT02908074|Experimental|Experimental: Regimen 2|Drug: BGS649 Dose 2 weekly
11269639|NCT02908074|Experimental|Experimental: Regimen 3|Drug: BGS649 Dose 3 weekly
11269640|NCT02908061|Active Comparator|Surgery (Usual approach group)|standard surgery
11269641|NCT02908061|Experimental|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
11269642|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
11269643|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
11269644|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
11269645|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
11269646|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
11269647|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
11269648|NCT02908035|Placebo Comparator|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
11269649|NCT02908022|Experimental|Interaction|"Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.
~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
11269650|NCT02908022|Experimental|No Interaction|"The clinician and the patient will first be introduced at the MRI sessions.
~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
11269651|NCT02907996||Sofosbuvir|Adult Korean participants with genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean participants aged 12 to <18 years with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens
11269652|NCT02907983|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
11269653|NCT02907983|Sham Comparator|Saline|Saline injection
11269654|NCT02907957|Active Comparator|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
11269655|NCT02907957|Sham Comparator|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
11269656|NCT02907944|No Intervention|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
11269657|NCT02907944|Experimental|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
11269658|NCT02907931|Experimental|Subjects|Lower Body Negative Pressure
11269659|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles
~Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
11269660|NCT02907905|Other|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
11269661|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
11269662|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
11269663|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
11269664|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
11269665|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
11269666|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
11269667|NCT02907853|Experimental|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
11269668|NCT02907840|Experimental|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
11269669|NCT02907827|Experimental|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
11269670|NCT02907827|Experimental|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
11269671|NCT02907814|Experimental|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
11269672|NCT02907814|Experimental|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
11269673|NCT02907801|Experimental|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
11269674|NCT02907788||Cystic Fibrosis patients|Patient with cystic fibrosis diagnosed by Heel-prick screening
11269675|NCT02907788||non-CF patients|Children who undergo bronchoscopy for another reason, without CF: eg gastro-esophageal reflux.
11269676|NCT02907775|Active Comparator|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
11269677|NCT02907775|Active Comparator|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
11269678|NCT02907749|Active Comparator|Carvedilol|Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
11269679|NCT02907749|Experimental|Spironolactone and carvedilol|"Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
~Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose"
11269680|NCT02907723|Experimental|Continuous Sleep Recording|Continuous Sleep Recording in Patients
11269681|NCT02907710|Experimental|concurrent chemoradiotherapy + endostar|"Drug: Endostar
~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy
~Drug: DDP
~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles
~Radiation: IMRT
~IMRT:70-74Gy"
11269682|NCT02907710|Active Comparator|concurrent chemoradiotherapy|"Drug: DDP
~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles
~Radiation: IMRT
~IMRT:70-74Gy"
11269683|NCT02907697|Experimental|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
11269684|NCT02907697|Active Comparator|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
11269685|NCT02907684|Experimental|Almonds|Almond snacks
11269686|NCT02907684|Placebo Comparator|Control muffins/crackers|Muffin/Cracker snacks
11269687|NCT02907671|Active Comparator|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
11269688|NCT02907671|Active Comparator|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
11269689|NCT02907658|Experimental|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
11269690|NCT02907658|No Intervention|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
11269691|NCT02907645|Experimental|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
11269692|NCT02907645|Experimental|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
11269693|NCT02907645|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
11269694|NCT02907632|Experimental|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
11269695|NCT02907632|Placebo Comparator|Placebo|Blind and randomized allocation to placebo
11269696|NCT02907619|Experimental|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
11269697|NCT02907593|Experimental|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
11269698|NCT02907593|Experimental|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
11269699|NCT02907593|Experimental|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
11269700|NCT02907593|Experimental|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
11269701|NCT02907580|Experimental|Local educational data|Local-based educational handout
11269702|NCT02907580|Experimental|National educational data|National-based educational handout
11269703|NCT02907580|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
11269704|NCT02907567|Active Comparator|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
11269705|NCT02907567|Active Comparator|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
11269706|NCT02907567|Placebo Comparator|Placebo|4 subjects randomized to matching placebo of CT1812
11269707|NCT02907554|Placebo Comparator|control group|control group receives a placebo
11269708|NCT02907554|Experimental|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
11269709|NCT02907541|Experimental|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
11269710|NCT02907541|Active Comparator|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
11269711|NCT02907541|Active Comparator|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
11269712|NCT02907528|Placebo Comparator|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
11269713|NCT02907528|Active Comparator|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
11269714|NCT02907528|Experimental|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
11269715|NCT02907515|Experimental|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
11269716|NCT02907515|Active Comparator|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
11269717|NCT02907502|Experimental|Experimental formula|Young-child formula with low protein content
11269718|NCT02907502|Active Comparator|Control formula|Young-child formula with protein content similar to that of cow's milk
11269719|NCT02907489|No Intervention|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
11269720|NCT02907489|Other|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
11269721|NCT02907476|Experimental|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
11269722|NCT02907476|Active Comparator|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
11269723|NCT02907450|Experimental|Clinical evaluation of the tolerance of the orthosis|
11269724|NCT02907437|Active Comparator|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
11269725|NCT02907437|Placebo Comparator|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
11269726|NCT02907424|Active Comparator|BP-100|standard treatment
11269727|NCT02907424|Experimental|Num Trey|locally produced RUTF
11269728|NCT02907411|Experimental|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
11269729|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
11269730|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
11269731|NCT02907385|Experimental|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
11269732|NCT02907385|No Intervention|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
11269733|NCT02907372|Other|cognitive tests|
11269734|NCT02907359|Experimental|Guadecitabine|Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
11269735|NCT02907359|Active Comparator|Treatment Choice|"Best Supportive Care.
~Low dose cytarabine.
~Standard Intensive Chemotherapy."
11269736|NCT02907346|Experimental|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
11269737|NCT02907333|Active Comparator|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
11269738|NCT02907333|No Intervention|Control group|Women who are not contacted with advise to use condoms
11269739|NCT02907320|Experimental|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
11269740|NCT02907320|Active Comparator|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
11269741|NCT02907320|Placebo Comparator|placebo|MPFF = Micronized Purified Flavonoid Fraction
11269742|NCT02907307|Experimental|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
11269743|NCT02907307|Experimental|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
11269744|NCT02907307|Active Comparator|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
11269745|NCT02907294|Experimental|PBF-999|
11269746|NCT02907294|Placebo Comparator|Placebo|
11269747|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
11269748|NCT02907281||Healthy volunteers|Healthy volunteers
11269749|NCT02907268|Active Comparator|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
11269750|NCT02907268|Active Comparator|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
11269751|NCT02907255|Experimental|Oximetry monitor|"Standard care plus
~Wireless respiratory monitoring
~Covidien
~Alarm triggers:
~SpO2 ≤89% (heart rate) HR < 50 or > 120"
11269752|NCT02907255|No Intervention|Standard of Care|"• Standard care:
~1:4 patient to nurse ratio
~Vital signs every 4 hours
~Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
11269753|NCT02907242|No Intervention|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
11269754|NCT02907242|Other|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5
11269755|NCT02907229|Experimental|Treatment group|neuroendovascular therapy(NCVC-CS1)
11269879|NCT02906410|Experimental|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
11269756|NCT02907216|Experimental|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
11269757|NCT02907216|Active Comparator|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
11269758|NCT02907190|Experimental|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
11269759|NCT02907190|Active Comparator|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
11269760|NCT02907177|Experimental|Ponesimod|Ponesimod
11269761|NCT02907177|Placebo Comparator|Placebo|Placebo
11269762|NCT02907164|Active Comparator|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
11269763|NCT02907164|Experimental|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
11269764|NCT02907164|Experimental|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
11269765|NCT02907164|Experimental|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
11269766|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
11269767|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
11269768|NCT02907138|Experimental|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
11269769|NCT02907138|Active Comparator|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
11269770|NCT02907125|Experimental|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.
~This intervention will be delivered in each school over the academic year."
11269771|NCT02907125|Experimental|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.
~This intervention will be delivered in each school over the academic year."
11269772|NCT02907125|Active Comparator|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
11269773|NCT02907112|No Intervention|Control|Participants to continue on their habitual diet for 4 weeks
11269774|NCT02907112|Experimental|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
11269775|NCT02907099|Experimental|Treatment (CXCR4 antagonist BL-8040, pembrolizumab)|Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11269776|NCT02907086||colorectal cancer|
11269777|NCT02907086||melanoma|
11269778|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
11269779|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
11269910|NCT02906176|Experimental|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
11269780|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
11269781|NCT02907060|Experimental|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
11269782|NCT02907060|Active Comparator|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
11269783|NCT02907047|Active Comparator|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
11269784|NCT02907047|Other|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
11269785|NCT02907034|Experimental|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
11269786|NCT02907034|Active Comparator|Group 2|First, classical narrative approach (CN), then virtual reality approach
11269787|NCT02907021|Experimental|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
11269788|NCT02906995|Experimental|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
11269789|NCT02906995|Active Comparator|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
11269790|NCT02906982|Experimental|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
11269791|NCT02906982|Experimental|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
11269792|NCT02906982|No Intervention|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
11269793|NCT02906969|Experimental|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
11269794|NCT02906969|Placebo Comparator|Control|Non-colonoscopy video as a control.
11269795|NCT02906956|Experimental|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
11269796|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
11269797|NCT02906930|Experimental|3 mg oral semaglutide|
11269798|NCT02906930|Experimental|7 mg oral semaglutide|
11269799|NCT02906930|Experimental|14 mg oral semaglutide|
11269800|NCT02906930|Placebo Comparator|Placebo|
11269801|NCT02906917|Experimental|IDegAsp|
11269802|NCT02906917|Active Comparator|IGlar + IAsp|
11269803|NCT02906904|Experimental|CASE (adult sleepwalking patients)|
11269804|NCT02906904|Experimental|CONTROL (adult healthy volunteers)|
11269805|NCT02906891|Experimental|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
11269806|NCT02906839|Experimental|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
11269807|NCT02906839|No Intervention|Control group|No SAS screening will be performed in this group before the end of the 2 year follow up period.
11269808|NCT02906826|No Intervention|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
11269809|NCT02906826|Active Comparator|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
11269810|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
11269811|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
11274104|NCT02875470|Active Comparator|Gracey curette|Root planing with Gracey curettes
11269812|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
11269813|NCT02906800|Experimental|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
11269814|NCT02906787|Experimental|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
11269815|NCT02906787|Placebo Comparator|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
11269816|NCT02906761|Experimental|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
11269817|NCT02906761|Placebo Comparator|Placebo|Placebo (2 tablets) twice daily for 6 months
11269818|NCT02906748|Experimental|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
11269819|NCT02906748|Active Comparator|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
11269820|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
11269821|NCT02906722|Experimental|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
11269822|NCT02906722|Active Comparator|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
11269823|NCT02906709|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
11269824|NCT02906709|Experimental|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
11269825|NCT02906696|Experimental|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11269826|NCT02906683|Experimental|TAS-303 3mg|
11269827|NCT02906683|Experimental|TAS-303 6mg|
11269828|NCT02906683|Placebo Comparator|Placebo|
11269829|NCT02906670|Experimental|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
11269830|NCT02906670|Experimental|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
11269831|NCT02906670|Experimental|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
11269832|NCT02906670|Experimental|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
11269833|NCT02906670|Experimental|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
11269834|NCT02906670|Experimental|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
11269835|NCT02906670|Experimental|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
11269836|NCT02906670|Experimental|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
11269837|NCT02906670|Experimental|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
11269838|NCT02906670|Experimental|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
11270085|NCT02904993|Other|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
11269839|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
11269840|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
11269841|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
11269842|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
11269843|NCT02906657|Experimental|Medication reconciliation|Medication reconciliation involving a pharmacist using electronic pharmaceutical records
11269844|NCT02906657|No Intervention|Control|Usual Care
11269845|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
11269846|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
11269847|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
11269848|NCT02906618|Experimental|LY3039478 - Oral|LY3039478 given once, orally
11269849|NCT02906618|Experimental|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
11269850|NCT02906605|Experimental|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
11269851|NCT02906605|Experimental|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
11269852|NCT02906579|Experimental|IW-1973|Placebo taken once daily Day 1-Day 3; 10 mg IW-1973 take once daily Day 4-Day 6; 20 mg IW-1973 taken once daily Day 7-Day 9; 30 mg IW-1973 taken once daily Day 10-Day 12; 40 mg IW-1973 taken once daily Day 13-Day 15; 50 mg IW-1973 taken once daily Day 16-Day 18
11269853|NCT02906566|Other|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
11269854|NCT02906566|No Intervention|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
11269855|NCT02906553|Experimental|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
11269856|NCT02906553|Placebo Comparator|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
11269857|NCT02906540|Experimental|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
11269858|NCT02906540|Experimental|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
11269859|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
11269860|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
11269861|NCT02906514|Experimental|Hydroxyethyl starch 130/0.4|
11269862|NCT02906514|Placebo Comparator|Sodium Chloride 0.9%|
11269863|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
11269864|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
11269865|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
11269866|NCT02906488||Patients with Parkinson's Disease|
11269867|NCT02906475|Other|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
11269868|NCT02906475|No Intervention|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
11269869|NCT02906462|Other|Usual Practices|Usual Practices
11269870|NCT02906462|Other|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
11269871|NCT02906449|Experimental|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
11269872|NCT02906449|Active Comparator|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
11269873|NCT02906436|Experimental|ExVivo lung reconditioning|
11269874|NCT02906423||Allina health patients|
11269875|NCT02906410|No Intervention|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
11269876|NCT02906410|Experimental|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
11269877|NCT02906410|Experimental|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
11269878|NCT02906410|No Intervention|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
11269880|NCT02906410|Experimental|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
11269881|NCT02906397|Experimental|Experimental: Galunisertib/SBRT|Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28
11269882|NCT02906384|No Intervention|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
11269883|NCT02906384|Experimental|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin<9Gy Dmax<16Gy.
~Radiation technique: VMAT."
11269884|NCT02906371|Active Comparator|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
11269885|NCT02906371|Active Comparator|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
11269886|NCT02906358|Active Comparator|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
11269887|NCT02906358|Active Comparator|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
11269888|NCT02906345|No Intervention|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
11269889|NCT02906345|Active Comparator|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
11269890|NCT02906345|Active Comparator|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
11269891|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.
~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.
~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
11269892|NCT02906306|Experimental|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
11269893|NCT02906306|Experimental|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
11269894|NCT02906293||Healthy Participants|Potential participants will self-refer.
11269895|NCT02906280|Experimental|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
11269896|NCT02906280|Active Comparator|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
11269897|NCT02906267|Other|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
11269898|NCT02906267|Other|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
11269899|NCT02906267|Other|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
11269900|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:
~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
11269901|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:
~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
11269902|NCT02906241|Experimental|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
11269903|NCT02906241|No Intervention|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
11269904|NCT02906241|Other|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
11269905|NCT02906228|Experimental|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
11269906|NCT02906228|Experimental|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
11269907|NCT02906228|Experimental|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
11269908|NCT02906215|Experimental|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
11269909|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
11269911|NCT02906176|Experimental|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
11269912|NCT02906163|Experimental|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
11269913|NCT02906163|Experimental|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
11269914|NCT02906163|Active Comparator|SoC (tyrosine kinase inhibitor)|12 months
11269915|NCT02906150|Experimental|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
11269916|NCT02906150|Active Comparator|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
11269917|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:
~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling
~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling
~10 subjects will have both a gastroscopy and a coloscopy"
11269918|NCT02906137|Other|Uninfected-controls|"30 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:
~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling
~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling
~10 subjects will have both a gastroscopy and a coloscopy"
11269919|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
11269920|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
11269921|NCT02906111|Active Comparator|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
11269922|NCT02906111|Active Comparator|Control group, no estriol treatment|Procedure: vaginal surgery
11269923|NCT02906098|Experimental|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
11269924|NCT02906098|Active Comparator|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
11269925|NCT02906085|Experimental|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
11269926|NCT02906085|Placebo Comparator|Placebo|Intravenous infusion of placebo (isotonic saline)
11269927|NCT02906072|Experimental|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
11269928|NCT02906072|Other|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
11269929|NCT02906059|Experimental|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)
~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks
~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks
~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks
~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
11269930|NCT02906046|Placebo Comparator|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
11269931|NCT02906046|Other|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
11269932|NCT02906046|Other|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
11269933|NCT02906033|Experimental|Intervention group|New perioperative practice model.
11269934|NCT02906033|No Intervention|Control group|Traditional practice model.
11269935|NCT02906020|Experimental|GZ/SAR402671|Part 1: Increasing dose of GZ/SAR402671 will be administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) will be administered once per day.
11269936|NCT02906020|Placebo Comparator|Placebo|A matching placebo for Parts 1 and 2 will be administered once per day.
11269937|NCT02906007|Experimental|Bedaquiline (BDQ)|Participants will receive bedaquiline (BDQ) once a day for 2 weeks. For the next 22 weeks, participants will take BDQ 3 times a week on Monday, Wednesday, and Friday.
11269938|NCT02905994|Experimental|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3
~Cytarabine continuous infusion days 1-7
~Idarubicin IV bolus on days 1, 2, and 3.
~Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8
~Patients will receive Standard Anti Fungal and Standard Antibiotic during induction
~A bone marrow biopsy will be performed according to standard practice on day 14"
11269939|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
11269963|NCT02905812|Active Comparator|RGI & Massage|"relaxation and guided imagery with background music (RGI) (40 min, headphones)
~a brief moderate pressure massage session (massage: 15 min)"
11269964|NCT02905812|No Intervention|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
11270143|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
11269940|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
11269941|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
11269942|NCT02905968|Experimental|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
11269943|NCT02905968|No Intervention|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
11269944|NCT02905955|Other|Prevena|
11269945|NCT02905942|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
11269946|NCT02905942|Active Comparator|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
11269947|NCT02905929|Experimental|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
11269948|NCT02905929|Active Comparator|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
11269949|NCT02905916|Experimental|PEG-rhG-CSF|
11269950|NCT02905903|Other|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
11269951|NCT02905890|Experimental|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
11269952|NCT02905890|Active Comparator|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
11269953|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
11269954|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
11269955|NCT02905877||Healthy control|Healthy age matched controls
11269956|NCT02905864|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
11269957|NCT02905864|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.
~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
11269958|NCT02905851|Placebo Comparator|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
11269959|NCT02905851|Active Comparator|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.
~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:
~Continue current dose
~Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.
~Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
11269960|NCT02905838|Active Comparator|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
11269961|NCT02905838|Active Comparator|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
11269962|NCT02905825|Experimental|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
11270078|NCT02905019|Active Comparator|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
11269965|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
11269966|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
11269967|NCT02905773|Other|postoperative pain|postoperative pain
11269968|NCT02905773|Other|intensity|intensity
11269969|NCT02905760|Experimental|Furosemide|Furosemide and Placebo filling (Glucose 5%).
11269970|NCT02905760|Active Comparator|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling
~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
11269971|NCT02905747|Experimental|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
11269972|NCT02905734|Experimental|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
11269973|NCT02905734|Placebo Comparator|placebo patch|Single administration of a placebo patch
11269974|NCT02905721|Experimental|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
11269975|NCT02905708|Active Comparator|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.
~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
11269976|NCT02905708|Active Comparator|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
11269977|NCT02905695|Experimental|Group A|Chirocaine
11269978|NCT02905695|Placebo Comparator|Group B|Placebo
11269979|NCT02905682|Experimental|Desmopressin|Desmopressin ODT
11269980|NCT02905682|Placebo Comparator|Placebo|Placebo ODT
11269981|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
11269982|NCT02905656|Placebo Comparator|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
11269983|NCT02905656|Experimental|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
11269984|NCT02905656|Experimental|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
11269985|NCT02905656|Experimental|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
11269986|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
11269987|NCT02905630|Experimental|Exercise training|High intensity aerobic exercise training
11269988|NCT02905630|No Intervention|No training|No exercise training, only ordinary daily life activities.
11269989|NCT02905617||Primary Augmentation|
11269990|NCT02905617||Revision Augmentation|
11269991|NCT02905604|Experimental|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
11269992|NCT02905604|Sham Comparator|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
11269993|NCT02905591|Experimental|ChemoRT + Ascorbate|Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
11269994|NCT02905578|Experimental|Ascorbate group|"Each cycle is 4 calendar weeks
~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
11269995|NCT02905578|Active Comparator|Control|"Each cycle is 4 calendar weeks
~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
11269996|NCT02905565|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
11269997|NCT02905565|Active Comparator|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
11269998|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
11269999|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS
~Patient will be paired to index case by:
~Hospital site
~Age
~Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
11270079|NCT02905006|Placebo Comparator|Placebo|
11270000|NCT02905539|Experimental|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
11270001|NCT02905539|Active Comparator|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
11270002|NCT02905526|Experimental|Intervention|App plus the contraceptive instant messages
11270003|NCT02905526|Placebo Comparator|Control|App only
11270004|NCT02905513|Experimental|Intervention|App plus the contraceptive instant messages
11270005|NCT02905513|Placebo Comparator|Control|App only
11270006|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
11270007|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
11270008|NCT02905474|Experimental|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
11270009|NCT02905474|Active Comparator|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
11270010|NCT02905461|Experimental|Intervention|Contraceptive text messages
11270011|NCT02905461|Placebo Comparator|Control|Text messages not about contraception
11270012|NCT02905448|Experimental|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
11270013|NCT02905435|Experimental|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
11270014|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
11270015|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
11270016|NCT02905409|Active Comparator|4PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.
11270017|NCT02905409|Experimental|2PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.
11270018|NCT02905396|Experimental|Spinal cord stimulation|implantation of spinal cord stimulator
11270019|NCT02905383|Experimental|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
11270020|NCT02905383|No Intervention|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
11270021|NCT02905370|Experimental|Progressive Multi-Component (PMC)|High intensity strength training protocol, daily protein supplementation, functionally enhanced transitions of care
11270022|NCT02905370|Active Comparator|Usual Care (UC)|Low intensity rehabilitation protocol, standard education for nutrition, standard transitions of care
11270023|NCT02905357||MINOCA|OCT and CMR imaging
11270024|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
11270025|NCT02905344||1|Control, no anatomical model used for description
11270026|NCT02905344||2|Anatomical model used for description
11270027|NCT02905331|Experimental|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
11270028|NCT02905331|Experimental|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
11270029|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
11270030|NCT02905305|Experimental|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
11270031|NCT02905305|Active Comparator|Contour Advance|Standard Contour Advance electrode array
11270032|NCT02905279|Active Comparator|Biofeedback|Biofeedback Relaxation Training
11270033|NCT02905279|Active Comparator|Standard Exposure|Exposure Therapy
11270034|NCT02905279|Experimental|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
11270035|NCT02905279|Experimental|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
11270036|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
11270037|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
11270038|NCT02905253|Experimental|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
11270039|NCT02905253|Placebo Comparator|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
11270080|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
11270081|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
11270040|NCT02905253|Experimental|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
11270041|NCT02905253|Placebo Comparator|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
11270042|NCT02905253|Experimental|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
11270043|NCT02905240|Experimental|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
11270044|NCT02905240|Other|Saline|Saline control
11270045|NCT02905227|Experimental|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
11270046|NCT02905227|Experimental|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
11270047|NCT02905227|Experimental|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
11270048|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
11270049|NCT02905188|Experimental|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
11270050|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
11270051|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
11270052|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
11270053|NCT02905149|Experimental|Serrato|Standard anesthesia+serratus plane block.
11270054|NCT02905149|Placebo Comparator|Control|Standard anesthesia
11270055|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :
~with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)
~or uncharacterized antibodies"
11270056|NCT02905123|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
11270057|NCT02905123|No Intervention|Control|No Intervention Control
11270058|NCT02905110|Experimental|Methotrexate / Etoposide Infusion|12 infusions of intraventricular Methotrexate and 15 infusions of intraventricular Etoposide into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle. Methotrexate will be infused twice weekly for 6 weeks and etoposide will be infused 5 times a week on weeks 1, 3 , and 5.
11270059|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
11270060|NCT02905071|Experimental|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
11270061|NCT02905071|Experimental|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
11270062|NCT02905071|Experimental|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
11270063|NCT02905071|Experimental|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
11270064|NCT02905058|Experimental|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
11270065|NCT02905058|Placebo Comparator|Placebo|women will take one placebo tablet one hour before the procedure
11270066|NCT02905045|Active Comparator|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
11270067|NCT02905045|Placebo Comparator|Placebo|women will take one tablet placebo one hour before the procedure
11270068|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
11270069|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
11270070|NCT02905019|Active Comparator|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
11270071|NCT02905019|Active Comparator|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
11270072|NCT02905019|Active Comparator|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
11270073|NCT02905019|No Intervention|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
11270074|NCT02905019|No Intervention|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
11270075|NCT02905019|No Intervention|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
11270076|NCT02905019|Active Comparator|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
11270077|NCT02905019|No Intervention|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
11270082|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
11270086|NCT02904993|Active Comparator|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
11270087|NCT02904980|Experimental|Technical Training Group|15 children diagnosed with DCD
11270088|NCT02904980|Experimental|Quiet Eye Training Group|15 children diagnosed with DCD
11270089|NCT02904967|Experimental|patients with recurrent VTE|
11270090|NCT02904967|Active Comparator|patients with only one episode of VTE|
11270091|NCT02904954|Experimental|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) via IV infusion administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy will be given for 12 months post-operatively.
11270092|NCT02904954|Experimental|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) via IV infusion administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy will be given for 12 months post-operatively.
11270093|NCT02904941|Experimental|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
11270094|NCT02904941|Active Comparator|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
11270095|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
11270096|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
11270097|NCT02904902|Experimental|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
11270098|NCT02904889|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
11270099|NCT02904889|Active Comparator|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
11270100|NCT02904876|Experimental|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
11270101|NCT02904863|Experimental|patients with HUS|
11270102|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
11270103|NCT02904837|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
11270104|NCT02904837|Active Comparator|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
11270105|NCT02904824|Experimental|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
11270106|NCT02904824|Active Comparator|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
11270107|NCT02904811|Experimental|Intervention group|"Testing for Ct infection immediately
~Participants will perform self-taken vaginal samples.
~The positive results for Ct will be examined and treated and their partner will also be informed to do so."
11270108|NCT02904811|Experimental|Control group|Testing for Ct infection at the end of the study
11270109|NCT02904798|Experimental|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.
~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
11270110|NCT02904785|Experimental|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
11270111|NCT02904785|Sham Comparator|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
11270112|NCT02904772|Other|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
11270113|NCT02904772|Other|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
11270114|NCT02904759|Experimental|Desmopressin 25 µg|Desmopressin ODT
11270115|NCT02904759|Experimental|Desmopressin 50 µg|Desmopressin ODT
11270116|NCT02904759|Placebo Comparator|Placebo|Placebo ODT
11270117|NCT02904746|Experimental|Intervention|Participants receiving the Make It! intervention
11270118|NCT02904746|No Intervention|Control|Care as usual
11270119|NCT02904733|Experimental|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
11272312|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
11270120|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
11270121|NCT02904668|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-management program and manual therapy program
11270122|NCT02904668|Active Comparator|Control group|"The intervention consisted of 45-minute manual therapy sessions. Manual therapy included hands-on muscular mobilization techniques (aimed at improving soft tissue function), specific articular mobilization techniques (to improve overall joint function and decrease any restrictions in movement at single or multiple segmental levels in the cervical spine), and coordination or stabilization techniques (to improve postural control, coordination, and movement patterns by using the stabilizing cervical musculature)"
11270123|NCT02904655|Active Comparator|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
11270124|NCT02904655|No Intervention|control diet|Participants were instructed to consume their usual diet.
11270125|NCT02904642|No Intervention|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
11270126|NCT02904642|Experimental|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
11270127|NCT02904642|Experimental|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
11270128|NCT02904629|Experimental|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
11270129|NCT02904629|Other|Control|"The control program includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
11270130|NCT02904616|Experimental|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.
~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
11270131|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
11270132|NCT02904577||Training and validation cohort|"One cohort: from this cohort 2/3 of patients will be randomly separated after registration in training sample, to develop a prognostic model, and 1/3 in test sample, to validate the prognostic score obtained from the prognostic model.
~The training cohort aims to develop a prognostic model and a resulting score, on the basis of clinical, biochemical and blood count parameters, in patients with non-follicular indolent lymphomas.
~Intervention: any treatment, watch and wait policy included
~The validation cohort is aims to assess the prognostic score on a collected set of data in parallel but independently of the sample training.
~Intervention: any treatment, watch and wait policy included"
11270133|NCT02904564|Experimental|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
11270134|NCT02904564|Placebo Comparator|MMP with saline infusion|MMP with saline infusion using tattoo device
11270135|NCT02904551|Experimental|Experimental|Free gingival grafts
11270136|NCT02904551|Active Comparator|Control|Oral prophylaxis
11270137|NCT02904538|Experimental|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
11270138|NCT02904538|Experimental|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
11270139|NCT02904525|Experimental|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
11270140|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
11270141|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
11270142|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
11270144|NCT02904486|Experimental|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
11270145|NCT02904486|Experimental|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
11270146|NCT02904473|Experimental|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
11270147|NCT02904473|No Intervention|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
11270148|NCT02904473|No Intervention|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
11270149|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
11270150|NCT02904421||Group 1|the placebo group
11270151|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
11270152|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
11270153|NCT02904408|Experimental|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
11270154|NCT02904408|No Intervention|Control|control group (awaiting group) (receiving medical/surgical treatment)
11270155|NCT02904369|Experimental|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
11270156|NCT02904369|Experimental|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
11270157|NCT02904369|Active Comparator|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
11270158|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
11270159|NCT02904343|Experimental|Group of domestic hemodialysis machine|
11270160|NCT02904343|Active Comparator|Group of imported hemodialysis machine|
11270161|NCT02904330|Experimental|Single dose|The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
11270162|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
11270163|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
11270164|NCT02904304|Experimental|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.
~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
11270165|NCT02904304|Placebo Comparator|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.
~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
11270166|NCT02904278|Experimental|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.
~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.
~Duration of participation: up to 12 months post heart transplantation."
11270167|NCT02904278|Other|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.
~Duration of participation: up to 12 months post heart transplantation."
11270168|NCT02904265|Active Comparator|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
11270169|NCT02904265|Experimental|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
11270170|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
11270171|NCT02904226|Experimental|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
11270172|NCT02904226|Experimental|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
11270173|NCT02904226|Experimental|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
11270174|NCT02904226|Experimental|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
11270175|NCT02904226|Experimental|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
11270176|NCT02904226|Experimental|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
11270177|NCT02904226|Experimental|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
11272313|NCT02888847|Active Comparator|Philips Zoom! White Speed whitening lamp|Philips Zoom! White Speed whitening lamp
11270178|NCT02904226|Experimental|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
11270179|NCT02904213|Experimental|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
11270180|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
11270181|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
11270182|NCT02904187|Other|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
11270183|NCT02904187|Other|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
11270184|NCT02904174|Experimental|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
11270185|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
11270186|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
11270187|NCT02904148|Experimental|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
11270188|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
11270189|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
11270190|NCT02904122|Other|Teleconsultation|Teleconsultation using a specific camera SoproCare®6
11270191|NCT02904109|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
11270192|NCT02904109|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
11270193|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
11270194|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
11270195|NCT02904083|Experimental|specific training of professionals|patients from centers where professionals have received specific training
11270196|NCT02904083|Active Comparator|control training of professionals|patients from centers where professionals have received control training
11270197|NCT02904070|Experimental|Threat of premature delivery|"Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;
~Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
11270198|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
11270199|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
11270200|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
11270201|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
11270202|NCT02904031|Experimental|FOLFOX plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;
~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
11270203|NCT02904031|Experimental|5FU/LV plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;
~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;
~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
11270204|NCT02904005|Other|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
11270205|NCT02903992|Other|All patients recruited|All patients who are enrolled in study with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
11270206|NCT02903979|Experimental|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
11270207|NCT02903979|Active Comparator|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
11272314|NCT02888847|Sham Comparator|Philips Zoom! Advanced power lamp|Philips Zoom! Advanced power whitening lamp
11270208|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
11270209|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
11270210|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
11270211|NCT02903940|Experimental|CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
11270212|NCT02903927|Experimental|CT LUCIA|
11270213|NCT02903927|Active Comparator|Acrysof IQ Sn60WF|
11270214|NCT02903914|Experimental|Monotherapy Dose Escalation Solid Tumors|Monotherapy Part 1a: INCB001158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).
11270215|NCT02903914|Experimental|INCB001158 as Monotherapy in NSCLC|Monotherapy Part 2a: INCB001158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR and Anaplastic Lymphoma Kinase (ALK) negative) previously treated with Standard of Care (SOC).
11270216|NCT02903914|Experimental|INCB001158 as Monotherapy in CRC|Monotherapy Part 2b: INCB001158 administered orally at the RP2D in patients with advanced/metastatic CRC previously treated with SOC.
11270217|NCT02903914|Experimental|INCB001158 as Monotherapy in Solid Tumors|Monotherapy Part 2c: INCB001158 administered orally at the RP2D in patients with Bladder Cancer, Gastric or Gastroesophageal Junction (GEJ) Cancer, Renal Cell Cancer (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Cell Cancer (UCC), or Melanoma, previously treated with SOC.
11270218|NCT02903914|Experimental|INCB001158 as Monotherapy - Capsule-Tablet Crossover PK study|Monotherapy Part 2d: INCB001158 administered orally at the RP2D in patients with any tumor types in Parts 2a, 2b, or 2c.
11270219|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Combination Dose Escalation|Combination Part 1b: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma. Multiple dose levels will be explored to determine the recommended phase 2 dose (RP2D).
11270220|NCT02903914|Experimental|INCB001158 and anti-PD-1 in NSCLC|Part 3a: INCB001158 and Pembrolizumab the combination RP2D in patients with advanced/metastatic NSCLC (EGFR and ALK negative) with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
11270221|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Melanoma|Part 3b: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic Melanoma with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
11270222|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Urothelial Carcinoma|Part 3c: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic Urothelial Carcinoma with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
11270223|NCT02903914|Experimental|INCB001158 and anti-PD-1 in MSI CRC|Part 3d: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic MSI CRC with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
11270224|NCT02903914|Experimental|INCB001158 and anti-PD-1 in MSS CRC|Part 3e: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic MSS CRC that have received at least 1 prior 5-FU containing therapy and must not have had any prior checkpoint inhibitor therapy.
11270225|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Gastric/GE Junction|Part 3f: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic Gastric/GE Junction that have never received prior checkpoint inhibitor therapy.
11270226|NCT02903914|Experimental|INCB001158 and anti-PD-1 in SCCHN|Part 3g: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic SCCHN that have never received prior checkpoint inhibitor therapy.
11270227|NCT02903914|Experimental|INCB001158 and anti-PD-1 in Mesothelioma|Part 3h: INCB001158 and Pembrolizumab at the combination RP2D administered in patients with advanced/metastatic mesothelioma that have received or were unable to receive standard front line standard therapy and have never received prior checkpoint inhibitor therapy.
11270228|NCT02903914|Experimental|INCB001158 & anti-PD-1 w/ moderately impaired renal function|Combination Part 1c: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma with Moderately impaired renal function (defined as CrCl 30-49 mL/min calculated by the Cockcroft-Gault formula)
11270229|NCT02903901|Placebo Comparator|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
11270230|NCT02903901|Active Comparator|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
11270231|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
11270232|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
11270233|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
11270234|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
11270235|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
11270236|NCT02903862|Experimental|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
11270270|NCT02903537|Experimental|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
11270237|NCT02903862|Other|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
11270238|NCT02903849|Experimental|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
11270239|NCT02903849|Experimental|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
11270240|NCT02903836|Experimental|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
11270241|NCT02903836|Experimental|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
11270242|NCT02903836|Active Comparator|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
11270243|NCT02903823|Experimental|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
11270244|NCT02903810|Experimental|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
11270245|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
11270246|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
11270247|NCT02903784|Other|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
11270248|NCT02903784|Other|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
11270249|NCT02903771|Experimental|Part A and Part B|"Part A (Dose Escalation):
~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.
~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.
~Part B (Expansion Cohort):
~An expansion cohort of an additional 12 patients will be recruited at the MTD."
11270250|NCT02903719|Other|Group A|"st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml
~nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
11270251|NCT02903719|Other|Group B|"st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml
~nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
11270252|NCT02903680|Active Comparator|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
11270253|NCT02903680|Placebo Comparator|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
11270254|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
11270255|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
11270256|NCT02903641|No Intervention|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
11270257|NCT02903641|Experimental|Personalized information only|Household received the personalized information about the index child's height.
11270258|NCT02903641|Experimental|Labeled cash transfer only|Household received the labeled cash transfer.
11270259|NCT02903641|Experimental|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
11270260|NCT02903628|Experimental|eye health education|
11270261|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
11270262|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
11270263|NCT02903602|Experimental|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.
~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
11270264|NCT02903602|Active Comparator|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.
~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
11270265|NCT02903576|Active Comparator|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
11270266|NCT02903576|Active Comparator|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
11270267|NCT02903537|Experimental|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
11270268|NCT02903537|Experimental|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
11270269|NCT02903537|Experimental|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
11270271|NCT02903524|Active Comparator|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
11270272|NCT02903524|Experimental|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
11270273|NCT02903511|Experimental|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
11270274|NCT02903511|Placebo Comparator|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
11270275|NCT02903498|Experimental|UFT treatment|Uracil and Tegafur
11270276|NCT02903498|No Intervention|comparator|no treatment, follow-up at regular time
11270277|NCT02903485|Experimental|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
11270278|NCT02903485|Active Comparator|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
11270279|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
11270280|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
11270281|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
11270282|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
11270283|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
11270284|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
11270285|NCT02903446|Active Comparator|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
11270286|NCT02903446|No Intervention|Control|Standard urate lowering therapy
11270287|NCT02903433|Experimental|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
11270288|NCT02903433|Active Comparator|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
11270289|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
11270290|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
11270291|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
11270292|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
11270293|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.
~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
11270294|NCT02903368|Experimental|Apalutamide & Abiraterone Acetate|"Eligible Participants will be randomized to receive;
~Abiraterone acetate, Apalutamide, Leuprolide, Prednisone (6 months)
~Radical Prostatectomy (RP)"
11270295|NCT02903368|Experimental|Abiraterone Acetate|"Eligible Participants will be randomized to receive;
~Abiraterone acetate, Leuprolide, Prednisone (6 months)
~RP"
11270296|NCT02903368|Other|Observation-Post RP|"Following RP, patient will be randomized
~Patients will be followed and observed by the physician.
~no treatment and observation only (current standard of care)"
11270297|NCT02903368|Experimental|Apalutamide & Abiraterone Acetate-Post RP|"Following RP, patient will be randomized
~- 12 months of abiraterone acetate, Apalutamide, leuprolide and prednisone"
11270298|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
11270299|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
11270300|NCT02903342|Experimental|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
11270301|NCT02903342|No Intervention|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
11270302|NCT02903329|Active Comparator|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
11270303|NCT02903329|Active Comparator|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
11270304|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
11270305|NCT02903303|Other|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
11270306|NCT02903290|Other|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
11270307|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
11270308|NCT02903264||Control|Healthy non-pregnant females
11270309|NCT02903251|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.
~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
11270310|NCT02903251|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.
~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
11270311|NCT02903238|Experimental|Placebo|placebo capsule
11270312|NCT02903225|No Intervention|Usual Care|usual care and no changes in their previous physical activity
11270313|NCT02903225|Active Comparator|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
11270314|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
11270315|NCT02903199|Experimental|Whey Protein|Whey protein (18g) experimental supplement
11270316|NCT02903199|Experimental|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
11270317|NCT02903199|Placebo Comparator|Placebo|Water placebo supplement
11270318|NCT02903186|Experimental|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
11270319|NCT02903186|Active Comparator|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
11270320|NCT02903173||Women who undergo cesarean delivery|
11270321|NCT02903160|Experimental|Intensive, Non-Cross Reactive Therapy|Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223
11270322|NCT02903147|Experimental|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
11270323|NCT02903147|Active Comparator|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
11270324|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI>30) or normal weight (BMI<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
11270325|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
11270326|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
11270327|NCT02903108|Active Comparator|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
11270328|NCT02903108|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
11270329|NCT02903095|Experimental|TD-1439|Capsule formulation
11270330|NCT02903095|Placebo Comparator|Placebo|Capsule formulation
11270331|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
11272348|NCT02888574|Experimental|Intranasal Oxytocin|Oxytocin nasal spray delivered bi-daily over a 14-day period at 24-IU per dose
11270332|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
11270333|NCT02903069|Experimental|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT
~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
11270334|NCT02903069|Experimental|Stage 1: Adjuvant Treatment|MRZ + TMZ
11270335|NCT02903069|Experimental|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ
~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
11270336|NCT02903069|Experimental|Optune Arm|MRZ + TMZ + Optune
11270337|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
11270338|NCT02903056||Control-normal|Healthy people
11270339|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
11270340|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
11270341|NCT02903030|Experimental|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
11270342|NCT02903030|Placebo Comparator|Placebo, Then Visbiome|Placebo matched to probiotic.
11270343|NCT02903017|Active Comparator|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
11270344|NCT02903017|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
11270345|NCT02903004|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
11270346|NCT02903004|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
11270347|NCT02902978|Experimental|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
11270348|NCT02902978|Experimental|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
11270349|NCT02902965|Experimental|Ibrutinib+ Bortezomib+ Dexamethasone|
11270350|NCT02902952|Experimental|Physical Exercise Condition|An eight week physical exercise intervention
11270351|NCT02902952|Active Comparator|Control Condition|An eight week control condition consisting of sedentary activities
11270352|NCT02902939|No Intervention|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
11270353|NCT02902939|Active Comparator|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
11270354|NCT02902926|Experimental|Low FODMAPs Diet|"Instructed to low FODMAPs diet when patients signed the informed consent.
~Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
11270355|NCT02902926|Placebo Comparator|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
11270356|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
11270357|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
11270358|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
11270359|NCT02902913|Active Comparator|Ibuprofen|Ibuprofen, 400 mg
11270360|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
11270361|NCT02902887|Experimental|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
11270362|NCT02902887|No Intervention|Observation|No intervention, just observation
11270363|NCT02902874|Experimental|Patients treated for anaplastic large cell lymphoma ( ALCL )|
11270364|NCT02902861|Active Comparator|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
11270365|NCT02902861|Placebo Comparator|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
11270366|NCT02902835|Active Comparator|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
11270367|NCT02902835|Experimental|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
11270368|NCT02902822|Active Comparator|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
11270369|NCT02902822|Experimental|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
11270370|NCT02902809|Experimental|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
11270371|NCT02902796|Active Comparator|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
11270372|NCT02902796|Active Comparator|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
11270373|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
11270374|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
11270375|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
11270376|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
11270377|NCT02902757|Experimental|Treatment (FDG PET/CT)|Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
11270378|NCT02902744|Experimental|ILUVIEN 0.19 MG|
11270379|NCT02902731|Placebo Comparator|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
11270380|NCT02902731|Experimental|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.
~Intervention Anakinra in add on Therapy."
11270381|NCT02902718|Experimental|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
11270382|NCT02902705|Experimental|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
11270383|NCT02902705|Other|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
11270384|NCT02902692|Experimental|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
11270385|NCT02902679|Experimental|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
11270386|NCT02902666|Experimental|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.
~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
11270387|NCT02902666|Active Comparator|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
11270388|NCT02902653|Experimental|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
11270389|NCT02902653|Active Comparator|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
11270390|NCT02902653|Active Comparator|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
11270391|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
11270392|NCT02902627|Experimental|Metastatic cancer|
11270393|NCT02902614|Experimental|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
11270394|NCT02902614|Experimental|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
11270395|NCT02902601|Experimental|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
11270396|NCT02902601|Experimental|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
11270397|NCT02902601|Placebo Comparator|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
11270398|NCT02902588|Experimental|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
11270399|NCT02902588|Other|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
11270400|NCT02902588|Experimental|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
11270401|NCT02902575|Experimental|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
11270402|NCT02902562|Other|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
11270403|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
11270404|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
11270405|NCT02902536||Normal Controls|Patients without myasthenia
11270406|NCT02902523|Active Comparator|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
11270407|NCT02902523|Experimental|HUG116 tablet 245mg|Tenofovir disoproxil
11270408|NCT02902510|Experimental|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
11270409|NCT02902510|No Intervention|Wait List Control|There was no intervention during the WLC.
11270410|NCT02902484|Experimental|Nintedanib Monotherapy|"One cycle of Nintedanib monotherapy followed by a total of eight cycles of both Nintedanib and the chemotherapeutic agents, or until disease progression, whichever comes first.
~Nintedanib dose escalation: 150, 200 mg PO BID
~Nab-paclitaxel: 125 mg/m2 day 1,8,15 every 28 days
~Gemcitabine: 1000 mg /m2 day 1,8,15 every 28 days"
11270411|NCT02902471|Experimental|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
11270412|NCT02902458|Experimental|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
11270413|NCT02902458|No Intervention|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
11270414|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
11270415|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.
~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.
~oral swab for polymorphism exploration"
11270416|NCT02902432|Placebo Comparator|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
11270417|NCT02902432|Experimental|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
11270418|NCT02902419|Active Comparator|1|Wound dressing removal was performed between 12-30 hours postoperatively.
11270419|NCT02902419|Active Comparator|2|Wound dressing removal was performed between 30-48 hours postoperatively.
11270420|NCT02902406||normal oral mucosa|
11270421|NCT02902406||oral precancerous lesion or oral cancer|
11270422|NCT02902393||Success of revascularisation|
11270423|NCT02902380|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
11270424|NCT02902380|Placebo Comparator|Control Group|0.9% saline infusion
11270425|NCT02902367|Experimental|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
11270426|NCT02902367|Other|Control group|Usual care; no restriction for exercise, Three months
11270427|NCT02902354|Other|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
11270428|NCT02902341|Active Comparator|Control|Standard protocol nutrition.
11270429|NCT02902341|Experimental|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
11270430|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
11270431|NCT02902315|Active Comparator|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
11270432|NCT02902315|Active Comparator|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
11270465|NCT02902107|Experimental|surgical resection and intraoperative radiation therapy (IORT)|Brachytherapy will be administered using the CivaSheet, a novel permanent LDR palladium-103 (Pd-103) planar brachytherapy device that is applied directly to the surgical resection bed.
11270466|NCT02902094|Experimental|Experimental|Drug eluting angioplasty balloons
11270467|NCT02902094|Active Comparator|Control|Non-drug eluting balloons
11270433|NCT02902315|Active Comparator|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
11270434|NCT02902315|Active Comparator|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
11270435|NCT02902302|Experimental|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
11270436|NCT02902302|Active Comparator|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
11270437|NCT02902289|Experimental|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
11270438|NCT02902289|Active Comparator|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
11270439|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
11270440|NCT02902250|Active Comparator|vertebroplasty|vertebroplasty for compression fracture
11270441|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
11270442|NCT02902224|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
11270443|NCT02902224|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
11270444|NCT02902224|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
11270445|NCT02902211|Experimental|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
11270446|NCT02902211|Active Comparator|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
11270447|NCT02902198|Placebo Comparator|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
11270448|NCT02902198|Placebo Comparator|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
11270449|NCT02902198|Active Comparator|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
11270450|NCT02902198|Active Comparator|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
11270451|NCT02902198|Active Comparator|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
11270452|NCT02902198|Active Comparator|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
11270453|NCT02902198|Active Comparator|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
11270454|NCT02902198|Active Comparator|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
11270455|NCT02902185|Experimental|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
11270456|NCT02902185|Placebo Comparator|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
11270457|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
11270458|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
11270459|NCT02902159|Experimental|BWW|Free access to online peer support through BWW for 6 months
11270460|NCT02902159|Experimental|MZ|Access to NHS Moodzone Information Only
11270461|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
11270462|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
11270463|NCT02902133|Other|Acetazolamide Arm|Acetazolamide 500 mg twice per day for 5 consecutive days post standard-of-care endoscopic skull base surgery
11270464|NCT02902120|Experimental|Post-transplant|This arm will evaluate the treatment of patients with HCV and chronic kidney disease (GFR <50) who have had a kidney transplant using grazoprevir and elbasvir.
11270468|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
11270469|NCT02902081|Experimental|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
11270470|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
11270471|NCT02902055|Active Comparator|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
11270472|NCT02902055|Active Comparator|Isotonic saline|
11270473|NCT02902042|Experimental|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
11270474|NCT02902042|Experimental|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
11270475|NCT02902029|Experimental|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib [960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.
~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).
~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
11270476|NCT02902029|Experimental|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.
~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.
~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
11270477|NCT02902016|Experimental|Lactase expression induction by GED|
11270478|NCT02902003|No Intervention|Control|Not eligible for program services
11270479|NCT02902003|Active Comparator|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
11270480|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
11270481|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
11270482|NCT02901977|Experimental|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
11270483|NCT02901977|Active Comparator|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
11270484|NCT02901964|Experimental|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
11270485|NCT02901964|Active Comparator|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
11270486|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
11270487|NCT02901938|Experimental|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
11270488|NCT02901938|Experimental|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
11270489|NCT02901925|Experimental|ABY-029|ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
11270490|NCT02901912||Active|Women who perform at least 3h of physical activity per week
11270491|NCT02901912||Sedentary|Women who did not perform any kind of exercise
11270492|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11270493|NCT02901886|Experimental|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.
~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.
~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.
~The participants will note their tobacco and NRT consumption in a smoking diary."
11270494|NCT02901886|No Intervention|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
11270495|NCT02901873|Active Comparator|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
11270496|NCT02901873|Active Comparator|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
11270497|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
11270498|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
11270499|NCT02901847|Other|Intervention|PAD tailored care
11270500|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
11270606|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.
~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
11270501|NCT02901821||Concussion|Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.
11270502|NCT02901808||NOMI|Patients suffering from NOMI
11270503|NCT02901808||No-NOMI|Patients not suffering from NOMI
11270504|NCT02901782|Experimental|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
11270505|NCT02901769|Experimental|Depressed suicide attempters|20 subjects
11270506|NCT02901769|Experimental|Depressed patients with past history of|20 subjects
11270507|NCT02901769|Experimental|Depressed patients with no history of|20 subjects
11270508|NCT02901769|Placebo Comparator|Healthy controls|20 subjects
11270509|NCT02901743|Active Comparator|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
11270510|NCT02901743|Active Comparator|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
11270511|NCT02901730|Experimental|532nm laser group|LPI with 532nm laser.
11270512|NCT02901730|Experimental|561nm laser group|LPI with 561nm laser.
11270513|NCT02901717|Active Comparator|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
11270514|NCT02901717|Experimental|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
11270515|NCT02901704|Experimental|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
11270516|NCT02901704|Sham Comparator|Sham procedure|Renal anigography
11270517|NCT02901691|Experimental|Deaf children|
11270518|NCT02901691|Placebo Comparator|healthy volonteer children|
11270519|NCT02901678|Active Comparator|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
11270520|NCT02901678|Experimental|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
11270521|NCT02901665|No Intervention|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
11270522|NCT02901665|Active Comparator|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
11270523|NCT02901652|Active Comparator|NIPPV|"noninvasive respiratory support devices
~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
11270524|NCT02901652|Active Comparator|BİPAP|"noninvasive respiratory support devices
~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
11270525|NCT02901639|Experimental|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
11270526|NCT02901639|No Intervention|NO counseling|will not receive any counseling about contraceptive methods
11270527|NCT02901626|Experimental|Pessary|Arabin pessary. Participants where local standard of care includes vaginal progesterone will also receive progesterone.
11270528|NCT02901626|No Intervention|No Pessary|Participants that do not receive a pessary will receive the usual standard of care, including vaginal progesterone if that is the local standard.
11270529|NCT02901613|No Intervention|Retrospective|Standard dry sterile dressing
11270530|NCT02901613|Experimental|Prospective|Negative-pressure wound therapy
11270531|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
11270532|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
11270533|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
11270534|NCT02901587|Experimental|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
11270535|NCT02901587|Experimental|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
11270536|NCT02901587|Experimental|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
11270537|NCT02901574|Active Comparator|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
11270538|NCT02901574|Sham Comparator|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
11270539|NCT02901561|Experimental|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
11270540|NCT02901561|Active Comparator|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
11270607|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
11270541|NCT02901548|Experimental|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
11270542|NCT02901535|Active Comparator|Control|Spirometry in baseline Spirometry - 20 weeks
11270543|NCT02901535|Experimental|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
11270544|NCT02901522|Active Comparator|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
11270545|NCT02901522|Experimental|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
11270546|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
11270547|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
11270548|NCT02901496|Experimental|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
11270549|NCT02901496|Experimental|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
11270550|NCT02901496|Experimental|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
11270551|NCT02901496|Placebo Comparator|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
11270552|NCT02901496|Experimental|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
11270553|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.
~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
11270554|NCT02901457|Experimental|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
11270555|NCT02901457|No Intervention|Control group|Students do not receive the intervention program.
11270556|NCT02901431|Placebo Comparator|Placebo|Participants will receive a matching placebo orally. Approximate treatment duration will be up to 24 weeks.
11270557|NCT02901431|Experimental|Balovaptan (RO5285119) 10 mg/d equivalent|Participants will receive age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration will be up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
11270558|NCT02901431|Experimental|Balovaptan (RO5285119) 4 mg/d equivalent|Participants will receive age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration will be up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
11270559|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
11270560|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
11270561|NCT02901405|Experimental|Negative Pressure Wound Therapy|120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
11270562|NCT02901405|Active Comparator|Standard dressings|Absorbant dressings applied in a standard fashion, i.e. only changed as necessary
11270563|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
11270564|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
11270565|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
11270566|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
11270567|NCT02901379|Experimental|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
11270568|NCT02901379|Active Comparator|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
11270569|NCT02901366|Experimental|14C-FYU-981|14C-FYU-981, (Oral single dosing)
11270570|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index>5.0 and ≤8.0cm.
~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
11270571|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
11270572|NCT02901327|Experimental|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
11270573|NCT02901327|Active Comparator|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
11270574|NCT02901314|Experimental|MyRoad|Receives usual care heart failure education before discharge AND a card at discharge that provided pre-recorded audio messages that can be played back on-demand on 4 themes: heart failure signs/symptoms assessment, medications, activity and exercise and diet and a general message about the importance of follow-up post discharge and following the plan of care.
11270575|NCT02901314|No Intervention|Usual care|Receives usual care heart failure education before discharge
11270576|NCT02901301|Experimental|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
11270674|NCT02900560|Active Comparator|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
11270577|NCT02901288|Experimental|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.
~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
11270578|NCT02901288|Experimental|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
11270579|NCT02901288|Active Comparator|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).
~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).
~."
11270580|NCT02901275|Experimental|5 outpatient sessions|This is a within-subject study so all session procedures will be identical, however the specific medications provided as part of the double-blinded study medications may change during each session. During each session, which will last up to 8 hours a day and will be conducted on an outpatient basis, participants will be asked to complete standardized pain testing procedures, as well as questionnaires about how they are feeling and to complete cognitive tasks.
11270581|NCT02901262||qEEG patients|All the patients with continuous EEG (>24 hours) in teh two study units
11270582|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.
~Second step: Sertraline 200mg + lithium (900mg-1500mg)
~Non responsive patients: 3rd step.
~Third step: Nortriptyline 100mg
~Non responsive patients: 4th step.
~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)
~Non responsive patients : 5th step
~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients
~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
11270583|NCT02901236|Active Comparator|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
11270584|NCT02901236|Active Comparator|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
11270585|NCT02901223|Active Comparator|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
11270586|NCT02901223|Active Comparator|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
11270587|NCT02901210|Experimental|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
11270588|NCT02901197|Active Comparator|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
11270589|NCT02901197|Active Comparator|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
11270590|NCT02901184|Active Comparator|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.
11270591|NCT02901184|Placebo Comparator|Standard care alone|Patients in the control arm will get the standard care alone
11270592|NCT02901171|Experimental|Combined Treatment|ACT group treatment combined with smartphone application
11270593|NCT02901171|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT group treatment
11270594|NCT02901171|Active Comparator|Behavioural Support Programme|Group based Behavioural Support Programme
11270595|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
11270596|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
11270597|NCT02901145|Experimental|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
11270598|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
11270599|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
11270600|NCT02901119|Experimental|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
11270601|NCT02901119|Active Comparator|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
11270602|NCT02901106|Experimental|Patient with recurring-remitting MS|
11270603|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
11270604|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
11270605|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
11270608|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
11270609|NCT02901028|Experimental|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
11270610|NCT02901028|Sham Comparator|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
11270611|NCT02901015|Other|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
11270612|NCT02901015|Other|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
11270613|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
11270614|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
11270615|NCT02900989|Other|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
11270616|NCT02900989|Other|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if >=15 yo and the SIQ-Fr Junior composed of 15 items if <15 yo
11270617|NCT02900976|Experimental|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a complete response (CR) after induction receive additional rituximab or biosimilar as in induction.
11270618|NCT02900976|Experimental|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who do not achieve a CR to induction, all relapsed patients after induction, and all patients with refractory disease who received rituximab or biosimilar within 90 days according to institutional guidelines, receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Cycle continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first cycle of cycle allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional cycle.
11270619|NCT02900963|Other|Nutrition state determination|"Determination of nutritional state and inflammatory status:
~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
11270620|NCT02900950|Experimental|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:
~Anterior surface of the pancreas (yellow);
~Posterior surface of the pancreas (orange);
~Superior mesenteric/portal vein groove (blu);
~Superior mesenteric artery margin (retroperitoneal margin) (red);
~Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
11270621|NCT02900950|Other|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
11270622|NCT02900937|Experimental|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
11270623|NCT02900911|Experimental|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
11270624|NCT02900911|Active Comparator|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
11270625|NCT02900898|Experimental|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.
~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
11270626|NCT02900898|Experimental|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
11270627|NCT02900898|Experimental|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
11270628|NCT02900898|Active Comparator|Control|This group will not carry out interventions.
11270629|NCT02900820|Experimental|Novel intervention group|Discontinuing antibiotic therapy.
11270630|NCT02900820|Experimental|Usual intervention group|Usual strategy of continuing antibiotic treatment.
11270675|NCT02900534|Experimental|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
11270676|NCT02900534|No Intervention|Waiting control group|
11270677|NCT02900508|Experimental|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
11270631|NCT02900794|Other|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
11270632|NCT02900794|Other|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
11270633|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
11270634|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
11270635|NCT02900768|Experimental|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
11270636|NCT02900768|No Intervention|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
11270637|NCT02900755|Experimental|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
11270638|NCT02900742|Experimental|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
11270639|NCT02900742|Placebo Comparator|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
11270640|NCT02900729|Experimental|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
11270641|NCT02900729|Active Comparator|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
11270642|NCT02900716|Experimental|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
11270643|NCT02900716|Experimental|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
11270644|NCT02900716|Experimental|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:
~daily x 21 days every 28 days"
11270645|NCT02900703||PATIENT|
11270646|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
11270647|NCT02900690||Standard care|without use of the Novoseven
11270648|NCT02900677|Experimental|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
11270649|NCT02900677|No Intervention|Control|usual care
11270650|NCT02900664|Experimental|PDR001+canakinumab in TNBC|
11270651|NCT02900664|Experimental|PDR001+CJM112 in TNBC|
11270652|NCT02900664|Experimental|PDR001+trametinib in TNBC|
11270653|NCT02900664|Experimental|PDR001+EGF816 in TNBC|
11270654|NCT02900664|Experimental|PDR001+canakinumab in NSCLC|
11270655|NCT02900664|Experimental|PDR001+CJM112 in NSCLC|
11270656|NCT02900664|Experimental|PDR001+ trametinib in NSCLC|
11270657|NCT02900664|Experimental|PDR001+EGF816 in NSCLC|
11270658|NCT02900664|Experimental|PDR001+canakinumab in CRC|
11270659|NCT02900664|Experimental|PDR001+ CJM112 in CRC|
11270660|NCT02900664|Experimental|PDR001+trametinib in CRC|
11270661|NCT02900664|Experimental|PDR001+ EGF816 in CRC|
11270662|NCT02900664|Experimental|canakinumab in TNBC|
11270663|NCT02900664|Experimental|canakinumab in NSCLC|
11270664|NCT02900664|Experimental|canakinumab in CRC|
11270665|NCT02900651|Experimental|Phase I - All|advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma.
11270666|NCT02900638|Experimental|Intervention (Mentor/Mentee)|
11270667|NCT02900638|No Intervention|Wait list control|
11270668|NCT02900612|Experimental|WA (Water Aerobics Training)|Water aerobics training.
11270669|NCT02900612|Experimental|WR (Water Resistance Training)|Resistance aquatic training.
11270670|NCT02900612|Active Comparator|CG (Control Group)|Control Group.
11270671|NCT02900560|Active Comparator|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
11270672|NCT02900560|Active Comparator|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
11270673|NCT02900560|Active Comparator|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
11270678|NCT02900508|Active Comparator|Control training|Participants in the control training group received a 4-week conventional training.
11270679|NCT02900495|Experimental|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
11270680|NCT02900495|Experimental|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
11270681|NCT02900495|Experimental|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
11270682|NCT02900495|Placebo Comparator|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
11270683|NCT02900482||case group|Patients with a history of congenital hip dislocation
11270684|NCT02900482||control group|Patients with no history of congenital hip dislocation
11270685|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
11270686|NCT02900469|Experimental|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection
~Surgery: 2-4 weeks after denosumab"
11270687|NCT02900443|Experimental|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
11270688|NCT02900443|Active Comparator|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
11270689|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
11270690|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
11270691|NCT02900417|Experimental|sitagliptin|All the patients will receive sitagliptin 100mg daily.
11270692|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
11270693|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
11270694|NCT02900378|Experimental|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
11270695|NCT02900378|Active Comparator|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
11270696|NCT02900365|Experimental|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery & IOL implantation"
11270697|NCT02900365|Experimental|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery & IOL implantation."
11270698|NCT02900352|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
11270699|NCT02900352|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
11270700|NCT02900339|Experimental|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
11270701|NCT02900326|Placebo Comparator|Control patients with no intervention|group without intervention
11270702|NCT02900326|Experimental|Endurance training program (8 weeks) group|only physical training group
11270703|NCT02900326|Experimental|MBSR group (mindfulness-based-stress-reduction)|only mental training group(8 weeks)
11270704|NCT02900326|Experimental|Endurance training program combined with MBSR sessions|Endurance training program combined with MBSR sessions, during 8 weeks (mindfulness-based-stress-reduction)
11270705|NCT02900313|Other|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
11270706|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
11270707|NCT02900235|Experimental|MT-3995|[14C]-MT-3995 after a single oral dose
11270708|NCT02900222|Experimental|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
11270819|NCT02899260|No Intervention|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
11271299|NCT02896062|Active Comparator|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
11270709|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
11270710|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
11270711|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
11270712|NCT02900196|Experimental|1 - Test|
11270713|NCT02900196|Placebo Comparator|2 - Placebo|
11270714|NCT02900183|Experimental|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
11270715|NCT02900157|Experimental|MEDI9090|
11270716|NCT02900144|Experimental|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
11270717|NCT02900144|Active Comparator|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
11270718|NCT02900131|Experimental|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
11270719|NCT02900131|Experimental|trial group 2|Participants will receive Jaungo twice a day for three weeks.
11270720|NCT02900131|Placebo Comparator|control group|Participants will receive placebo twice a day for three weeks.
11270721|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
11270722|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
11270723|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
11270724|NCT02900105|Experimental|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
11270725|NCT02900092|Experimental|Ganaxolone|Participants received ganaxolone
11270726|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
11270727|NCT02900053|Active Comparator|Arm 1|Cerebral modulation using tDCS (transcranial Direct-Current Stimulation) associated with repetitive traumatic exposure using a personal traumatic script
11270728|NCT02900053|Placebo Comparator|Arm 2|Placebo cerebral modulation using sham-tDCS associated with repetitive traumatic exposure using a personal traumatic script
11270729|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
11270730|NCT02900027|Experimental|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
11270731|NCT02900027|Placebo Comparator|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
11270732|NCT02900014|Experimental|Children with cleft|
11270733|NCT02900001|Active Comparator|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
11270734|NCT02900001|Experimental|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
11270735|NCT02899988|Experimental|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
11270736|NCT02899988|Experimental|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
11270737|NCT02899988|Experimental|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
11270738|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC Q8W.
11270739|NCT02899975|Other|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
11270740|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
11270741|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
11270742|NCT02899936|Active Comparator|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
11270743|NCT02899936|Experimental|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
11270744|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
11270745|NCT02899910|Experimental|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
11270746|NCT02899910|Active Comparator|Health education|Standardized health education for weight loss
11270747|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
11270748|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
11270749|NCT02899871||case|aetiology of joint symptoms
11270750|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
11270751|NCT02899845|Experimental|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
11270752|NCT02899845|Active Comparator|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
11270753|NCT02899832||NIRS|Near Infra Red Spectroscopy.
11270754|NCT02899819|Experimental|meconium|The meconium will be sampled in the first 2 days of life
11270755|NCT02899806|Placebo Comparator|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
11270756|NCT02899806|Experimental|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
11270757|NCT02899793|Experimental|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
11270758|NCT02899780|Experimental|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
11270759|NCT02899754|Experimental|Intervention Group|Participants in this arm will use the lung cancer screening decision aid (LCSDecTool)
11270760|NCT02899754|Active Comparator|Control Group|Content that provides general information on disease prevention and health promotion unrelated to lung cancer. The information will be delivered on the same modality and take a similar amount of time to administer.
11270761|NCT02899741|Experimental|Omega-3|One group of this study. Omega-3 will be administered for thee months.
11270762|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.
~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.
~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
11270763|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
11270764|NCT02899702|Experimental|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
11270765|NCT02899702|Placebo Comparator|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.
~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
11270766|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
11270767|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
11270768|NCT02899676|Experimental|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
11270769|NCT02899676|Experimental|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
11270770|NCT02899676|Experimental|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
11270771|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
11270772|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
11270773|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
11270774|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
11270775|NCT02899637|Experimental|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
11270776|NCT02899637|Sham Comparator|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
11270777|NCT02899624|Experimental|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
11270778|NCT02899624|Active Comparator|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
11270779|NCT02899624|Active Comparator|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
11270780|NCT02899611|Experimental|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
11270781|NCT02899598|Experimental|Pregnant women|
11270782|NCT02899585|Experimental|Group A|Elaboration of the questionnaires
11270783|NCT02899585|Experimental|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
11270784|NCT02899572|Experimental|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
11270785|NCT02899572|No Intervention|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
11270786|NCT02899559|Experimental|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
11270787|NCT02899559|Experimental|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
11270849|NCT02899026|Experimental|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
11270788|NCT02899559|Experimental|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
11270789|NCT02899533||FES PET/CT scan|All subjects will receive an [18F]FES PET/CT scan.
11270790|NCT02899520|Active Comparator|Group A|Reference method
11270791|NCT02899520|Experimental|Group B|CMP ® method (Knowledge and Control of Perineum)
11270792|NCT02899507|Experimental|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
11270793|NCT02899507|No Intervention|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
11270794|NCT02899494|Other|Group A|Antenatal classes
11270795|NCT02899494|Experimental|Group B|Physical and psychic preparation
11270796|NCT02899481|Experimental|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
11270797|NCT02899481|No Intervention|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
11270798|NCT02899468|Experimental|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
11270799|NCT02899468|Other|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
11270800|NCT02899455|Experimental|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
11270801|NCT02899455|Active Comparator|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
11270802|NCT02899455|Active Comparator|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
11270803|NCT02899442|No Intervention|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.
~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:
~Information about health risks for night workers
~Dietetic intake
~Leisure physical activities
~Sleep and alertness
~Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)
~That's a current practice in France for Occupational physicians."
11270804|NCT02899442|Experimental|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
11270805|NCT02899403|Experimental|healthy subjects|
11270806|NCT02899390|Experimental|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
11270807|NCT02899377|Experimental|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
11270808|NCT02899377|Experimental|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of <=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
11270809|NCT02899364|Experimental|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
11270810|NCT02899364|Placebo Comparator|Sodium chloride 0.9%|50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
11270811|NCT02899351||Infants less than 12 months|intubated infants in ICU
11270812|NCT02899338|Experimental|BI695501 Autoinjector|
11270813|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
11270814|NCT02899299|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
11270815|NCT02899299|Active Comparator|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
11270816|NCT02899286|Experimental|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
11270817|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
11270818|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
11270820|NCT02899260|Experimental|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
11270821|NCT02899247|Experimental|No Surface Sealant|Resin composite only
11270822|NCT02899247|Active Comparator|With surface Sealant|Resin composite with surface sealant application
11270823|NCT02899234|Active Comparator|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
11270824|NCT02899234|Active Comparator|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
11270825|NCT02899221|Experimental|Treatment (high dose rate brachytherapy, hyperthermia)|Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.
11270826|NCT02899195|Experimental|Concurrent Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion.
11270827|NCT02899195|Experimental|Maintenance Durvalumab|After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
11270828|NCT02899182|Placebo Comparator|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
11270829|NCT02899182|Experimental|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
11270830|NCT02899169|Experimental|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
11270831|NCT02899169|Active Comparator|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
11270832|NCT02899156|Active Comparator|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
11270833|NCT02899156|Placebo Comparator|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
11270834|NCT02899143|Experimental|Group 5-days|5-days targeted antibiotic therapy
11270835|NCT02899143|Other|Group 10-days|10-days targeted antibiotic therapy
11270836|NCT02899130|Experimental|Polyherbal|Combination of 3 whole herbs in a capsule
11270837|NCT02899130|Placebo Comparator|Matching placebo|Similar looking inert capsules
11270838|NCT02899117|Experimental|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
11270839|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
11270840|NCT02899091|Experimental|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
11270841|NCT02899091|Placebo Comparator|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
11270842|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11270843|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
11270844|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
11270845|NCT02899052|Experimental|Venetoclax + Carfilzomib + Dexamethasone|"Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 9-18 subjects. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 - 31 additional subjects. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy.
~Part 3: Further evaluation of the efficacy of the VenKd combination after completion of Part 1 and Part 2 in 60 additional subjects."
11270846|NCT02899039|Experimental|IgG4-related disease|Subjects suffering from IgG4-related disease
11270847|NCT02899039|Active Comparator|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
11270848|NCT02899039|Active Comparator|Healthy controls|Healthy subjects
11270910|NCT02898571|Experimental|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
11270850|NCT02899026|Experimental|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
11270851|NCT02899026|Placebo Comparator|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
11270852|NCT02899000|Experimental|Acne treatment|"Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)
~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)"
11270853|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
11270854|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
11270855|NCT02898961|Experimental|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.
~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
11270856|NCT02898922|Experimental|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
11270857|NCT02898922|Active Comparator|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
11270858|NCT02898909|Experimental|16 pieces fragmentation|
11270859|NCT02898909|Active Comparator|8 pieces fragmentation|
11270860|NCT02898896|Other|HIV-infected patients|HIV-infected patients >= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA < 50 copies >= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
11270861|NCT02898883|Experimental|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
11270862|NCT02898883|No Intervention|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
11270863|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
11270864|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
11270865|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
11270866|NCT02898844|No Intervention|Control Condition|Neither roommate dieted.
11270867|NCT02898844|Experimental|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
11270868|NCT02898844|Experimental|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
11270869|NCT02898831|No Intervention|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
11270870|NCT02898831|Experimental|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
11270871|NCT02898818||symptomless|vaginal and oral swab sample, questionnaire
11270872|NCT02898818||vaginal discharge|vaginal and oral swab sample, questionnaire
11270873|NCT02898818||atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
11270874|NCT02898818||no atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
11270875|NCT02898818||lichen planus|vaginal and oral swab sample, questionnaire, papa smear
11270876|NCT02898805|Experimental|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
11270877|NCT02898805|Active Comparator|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
11270878|NCT02898792|Experimental|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
11270879|NCT02898792|Experimental|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
11270880|NCT02898792|Experimental|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
11270911|NCT02898571|Experimental|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
11270912|NCT02898558|Experimental|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
11270881|NCT02898779|Experimental|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.
~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
11270882|NCT02898779|Experimental|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.
~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
11270883|NCT02898766|Active Comparator|Enteral Nutrition Formula 1|Enteral Nutrition Formula
11270884|NCT02898766|Active Comparator|Enteral Nutrition Formula 2|Enteral Nutrition Formula
11270885|NCT02898753|Experimental|VAL-1221 3 mg/kg|"Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.
~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data."
11270886|NCT02898753|Experimental|VAL-1221 10 mg/kg|"Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.
~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data."
11270887|NCT02898753|Experimental|VAL-1221 30 mg/kg|"Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions.
~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week."
11270888|NCT02898753|Active Comparator|rhGAA|"Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme.
~Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week."
11270889|NCT02898740|Experimental|Exercise|Structured exercise
11270890|NCT02898740|Active Comparator|Health Education|Health education
11270891|NCT02898727|Other|Local Therapy|"The local therapy offered will be determined by the participant's doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases.
~Neurosurgery: The surgery may be performed up to 6 weeks before participant being registered on the trial or up to 4 weeks after registration.
~Sometimes stereotactic radiosurgery is required to be delivered to the cavity left after the metastasis has been removed (Cavity Boost).
~Stereotactic Radiosurgery: Treatment is to commence within 4 weeks of study registration. The size, number and location of the brain metastasis will determine the dose and fractionation schedule of radiotherapy."
11270892|NCT02898701|Active Comparator|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
11270893|NCT02898701|Experimental|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
11270894|NCT02898701|Active Comparator|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
11270895|NCT02898688|Other|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
11270896|NCT02898688|Experimental|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
11270897|NCT02898688|Experimental|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
11270898|NCT02898688|Experimental|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
11270899|NCT02898675|Experimental|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
11270900|NCT02898675|Active Comparator|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
11270901|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
11270902|NCT02898662|Placebo Comparator|Placebo|Matching placebo
11270903|NCT02898649|Experimental|IRE|The intervention group
11270904|NCT02898610|Active Comparator|Colchicine treatment|Colchicine 0.5mg/day plus usual care for 60 months
11270905|NCT02898610|No Intervention|Usual Standard of care alone|Normal standard of care remains for these patients
11270906|NCT02898597|Experimental|Video|Video-call delivered cognitive behavioral therapy
11270907|NCT02898597|Active Comparator|Voice|Voice-call delivered cognitive behavioral therapy
11270908|NCT02898584|Other|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
11270909|NCT02898571|Placebo Comparator|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
11270913|NCT02898545|Other|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
11270914|NCT02898545|No Intervention|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
11270915|NCT02898532|Active Comparator|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
11270916|NCT02898532|No Intervention|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
11270917|NCT02898506|Active Comparator|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
11270918|NCT02898506|Placebo Comparator|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
11270919|NCT02898480|Experimental|Remote ischemic conditioning|
11270920|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
11270921|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
11270922|NCT02898454|Experimental|Dupilumab 300 mg q2w|Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
11270923|NCT02898454|Experimental|Dupilumab 300 mg q2w then q4w|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
11270924|NCT02898454|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
11270925|NCT02898441|Active Comparator|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
11270926|NCT02898441|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care
11270927|NCT02898428||New mothers|New mothers with type 1 diabetes
11270928|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
11270929|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
11270930|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
11270931|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
11270932|NCT02898376|Experimental|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
11270933|NCT02898376|Active Comparator|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
11270934|NCT02898350|Active Comparator|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
11270935|NCT02898350|Active Comparator|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
11270936|NCT02898350|Active Comparator|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
11270937|NCT02898350|Active Comparator|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
11270938|NCT02898337||Methadone-induced QTc interval prolongation|
11270939|NCT02898337||Methadone-treated patients, no QT interval prolongation|
11270940|NCT02898324|Experimental|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
11270941|NCT02898324|Experimental|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
11270942|NCT02898324|No Intervention|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
11270943|NCT02898298|Experimental|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
11270944|NCT02898298|Active Comparator|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
11270945|NCT02898285|Active Comparator|Personal time condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
11270946|NCT02898285|Experimental|Individual sport condition|People randomized to this group will select an individual sport. They will be asked to participate in this individual sport for three months.
11270947|NCT02898285|Experimental|Team sport condition|People randomized to this group will select a team sport. They will be asked to participate in the team sport for three months (length of the team sport season).
11270948|NCT02898259|Experimental|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
11271300|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
11270949|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).
~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.
~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.
~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
11270950|NCT02898233|Active Comparator|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
11270951|NCT02898233|Sham Comparator|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
11270952|NCT02898233|Other|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
11270953|NCT02898207|Experimental|Treatment (olaparib and onalespib)|Patients receive olaparib PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients receive olaparib PO BID on days 1-28 and onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11270954|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
11270955|NCT02898181|Experimental|Tragus Stimulation|In this group patients will receive tragus stimulation for 8 hours per day during hospital stay.
11270956|NCT02898181|No Intervention|Control group|No tragus stimulation will be done
11270957|NCT02898168|Experimental|WA|
11270958|NCT02898168|Active Comparator|Control|
11270959|NCT02898142|Experimental|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
11270960|NCT02898142|Experimental|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
11270961|NCT02898129|Experimental|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
11270962|NCT02898129|Experimental|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
11270963|NCT02898129|Experimental|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
11270964|NCT02898129|Experimental|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
11270965|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
11270966|NCT02898103|Experimental|Electrical current|electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes
11270967|NCT02898103|Placebo Comparator|Placebo|NO electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes
11270968|NCT02898077|Experimental|Ramucirumab + Paclitaxel|Ramucirumab intravenously (IV) on days 1 and 15 every 28-day cycle. Paclitaxel IV on days 1, 8, and 15 of every 28-day cycle. Participants will continue treatment until discontinuation criteria are met.
11270969|NCT02898077|Experimental|Placebo + Paclitaxel|Placebo IV on days 1 and 15 every 28-day cycle. Paclitaxel IV on days 1, 8, and 15 of every 28-day cycle. Participants will continue treatment until discontinuation criteria are met.
11270970|NCT02898064|Other|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
11270971|NCT02898064|Other|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
11270972|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.
~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
11270973|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.
~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
11270974|NCT02898038|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
11270975|NCT02898025|Active Comparator|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
11270976|NCT02898025|Active Comparator|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
11270977|NCT02898025|Active Comparator|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
11270978|NCT02898025|Placebo Comparator|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
11270979|NCT02898012|Experimental|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
11270980|NCT02897999|Experimental|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
11270981|NCT02897999|Experimental|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
11270982|NCT02897999|Experimental|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
11270983|NCT02897999|Experimental|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
11270984|NCT02897999|Experimental|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
11270985|NCT02897999|Experimental|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
11270986|NCT02897999|Experimental|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
11270987|NCT02897999|Experimental|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
11270988|NCT02897999|Experimental|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
11270989|NCT02897999|Experimental|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
11270990|NCT02897986|Experimental|patients with refractory/relapsing solid tumors|
11270991|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
11270992|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
11270993|NCT02897973||Controls|Able-bodied individuals without amputation
11270994|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
11270995|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
11270996|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
11270997|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.
~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
11270998|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
11270999|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
11271000|NCT02897895|Experimental|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
11271001|NCT02897895|Active Comparator|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
11271002|NCT02897882|Experimental|Lung transplant|Pain evaluation
11271003|NCT02897869|Experimental|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
11271004|NCT02897869|Experimental|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
11271005|NCT02897856|Active Comparator|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
11271006|NCT02897856|Active Comparator|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
11271007|NCT02897843|Sham Comparator|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
11271008|NCT02897843|Experimental|tDCS|20 minute tDCS sessions
11271009|NCT02897830|Experimental|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
11271010|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
11271011|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
11271012|NCT02897804|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
11271013|NCT02897804|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
11271014|NCT02897804|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
11271015|NCT02897804|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
11271016|NCT02897804|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
11271017|NCT02897804|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
11271018|NCT02897804|Experimental|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
11271019|NCT02897804|Experimental|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11271020|NCT02897804|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
11271021|NCT02897804|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
11271022|NCT02897804|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
11271023|NCT02897804|Experimental|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
11271024|NCT02897804|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
11271025|NCT02897804|Experimental|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
11271026|NCT02897804|Experimental|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
11271027|NCT02897804|Experimental|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11271028|NCT02897804|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
11271029|NCT02897804|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
11271030|NCT02897804|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
11271031|NCT02897804|Experimental|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11271032|NCT02897804|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
11271033|NCT02897804|Experimental|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
11271034|NCT02897804|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
11271035|NCT02897804|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11271036|NCT02897804|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
11271037|NCT02897804|Experimental|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
11271038|NCT02897804|Experimental|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
11271039|NCT02897804|Experimental|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11271040|NCT02897804|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
11271041|NCT02897804|Experimental|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
11271042|NCT02897804|Experimental|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
11271043|NCT02897804|Experimental|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
11271044|NCT02897791|Experimental|Impaired Rt. Hemisphere patients|20 first stroke patients
11271045|NCT02897791|Experimental|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
11271046|NCT02897778|Active Comparator|Entinostat|15 patients will be randomized to receive a single, supratherapeutic dose of entinostat
11271047|NCT02897778|Placebo Comparator|Placebo|15 patients will be randomized to receive a single dose of placebo
11271048|NCT02897765|Experimental|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
11271049|NCT02897752|Experimental|WalkAide|
11271050|NCT02897752|Active Comparator|Usual gait Training|
11271051|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
11271052|NCT02897739||Health Volunteers|Participants who have normal hearts.
11271053|NCT02897726|Experimental|NVP-1402|NVP-1402 was administered once a day for 24 hours
11271054|NCT02897726|Active Comparator|NVP-1402R|Active comparator was administered twice a day for 24 hours
11271055|NCT02897713|Experimental|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
11271056|NCT02897713|Active Comparator|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
11271057|NCT02897700|Experimental|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.
~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
11271058|NCT02897700|Experimental|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.
~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
11271059|NCT02897700|Placebo Comparator|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
11271060|NCT02897687|Experimental|Facebook Group|Social skills training within an online group.
11271061|NCT02897687|Active Comparator|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
11271062|NCT02897674|Experimental|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
11271063|NCT02897674|Experimental|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
11271064|NCT02897661|Experimental|Early WMT and EEN|WMT (day1), EEN (day1-15)
11271065|NCT02897661|Experimental|Late WMT and EEN|WMT (day8), EEN (day1-15)
11271066|NCT02897635|Experimental|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
11271067|NCT02897622|Other|Case management|Case management
11271068|NCT02897609||A simple questionary filled|
11271069|NCT02897596|Experimental|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
11271070|NCT02897596|Experimental|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
11271071|NCT02897583|Experimental|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
11271072|NCT02897583|Sham Comparator|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
11271073|NCT02897570|Active Comparator|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
11271074|NCT02897570|Experimental|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
11271075|NCT02897570|Experimental|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
11271076|NCT02897570|Experimental|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
11271077|NCT02897557|Experimental|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
11271078|NCT02897544|Experimental|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
11271079|NCT02897531|Active Comparator|ES anastomosis|Stapled end-to-side anastomosis
11271080|NCT02897531|Active Comparator|SS anastomosis|Stapled side-to-side anastomosis
11271081|NCT02897518|Experimental|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
11271082|NCT02897518|Active Comparator|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
11271083|NCT02897505|Experimental|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
11271084|NCT02897479|Experimental|Savolitinib|Pulmonary Sarcomatoid Carcinomas
11271123|NCT02897219|Experimental|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
11271124|NCT02897206|Experimental|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
11271125|NCT02897206|Placebo Comparator|Placebo group|Identical placebo administered in identical dosage, timing and duration.
11271374|NCT02895477|Experimental|Intervention group|Hearing aid
11271375|NCT02895477|Experimental|Test group|Hearing aid
11271085|NCT02897466|Experimental|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.
~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
11271086|NCT02897466|No Intervention|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.
~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
11271087|NCT02897453||The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
11271088|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
11271089|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
11271090|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants undergo collection of blood and oral gargle samples.
~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, undergo collection of oral gargle sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, and ultrasound once every 6 months for 5 years. Participants also undergo collection of blood."
11271091|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
11271092|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
11271093|NCT02897414||Overall group that includes all prescription opioids except|
11271094|NCT02897414||Comparator Group taking benzodiazepines|
11271095|NCT02897414||Comparator Group taking IR hydrocodone|
11271096|NCT02897401|Experimental|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
11271097|NCT02897401|Experimental|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
11271098|NCT02897401|Experimental|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
11271099|NCT02897401|Placebo Comparator|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
11271100|NCT02897388|No Intervention|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
11271101|NCT02897388|Experimental|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
11271102|NCT02897375|Experimental|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11271103|NCT02897375|Experimental|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11271104|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
11271105|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
11271106|NCT02897349|Experimental|linagliptin|
11271107|NCT02897349|Placebo Comparator|Placebo|
11271108|NCT02897336|Experimental|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
11271109|NCT02897336|Active Comparator|interlaminar|interlaminar epidural corticosteroid injection
11271110|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
11271111|NCT02897284|Experimental|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
11271112|NCT02897284|Active Comparator|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
11271113|NCT02897284|No Intervention|Control|waiting list
11271114|NCT02897258||Without anticoagulant/antiplatelet|
11271115|NCT02897258||Treated with antiplatelet only|
11271116|NCT02897258||Treated with anticoagulant only|
11271117|NCT02897258||With antiplatelet/anticoagulant|
11271118|NCT02897245||Patient with intentionally stop|
11271119|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
11271120|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
11271121|NCT02897219|Experimental|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
11271122|NCT02897219|Placebo Comparator|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
11271126|NCT02897193|Active Comparator|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
11271127|NCT02897193|Experimental|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
11271128|NCT02897180|Placebo Comparator|Placebo|Subjects will receive a total of 14 capsules with Placebo
11271129|NCT02897180|Experimental|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
11271130|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.
~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
11271131|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.
~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
11271132|NCT02897167||Controls|Healthy subjects without psychotic disorder.
11271133|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
11271134|NCT02897141|Placebo Comparator|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
11271135|NCT02897115|Experimental|Treat-to-Target (T2T)|Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
11271136|NCT02897115|Active Comparator|Standard of Care (SOC)|Participants received treatment as prescribed by their physician according to the local standard of care.
11271137|NCT02897102|Active Comparator|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
11271138|NCT02897102|Experimental|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
11271139|NCT02897089|No Intervention|acid-etch|Acid etch+fissure sealant
11271140|NCT02897089|Other|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
11271141|NCT02897089|Other|All Bond universal|All Bond universal adhesive agent+fissure sealant
11271142|NCT02897089|Other|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
11271143|NCT02897089|Other|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
11271144|NCT02897089|Other|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
11271145|NCT02897089|Other|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
11271146|NCT02897089|Other|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
11271147|NCT02897076|Active Comparator|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.
~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.
~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
11271148|NCT02897076|Placebo Comparator|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.
~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.
~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
11271149|NCT02897063|Experimental|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
11271150|NCT02897063|Experimental|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
11271151|NCT02897050|Experimental|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
11271152|NCT02897050|Active Comparator|T followed by FEC|Docetaxel 100mg/m2, iv, d1 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
11271153|NCT02897037|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
11271292|NCT02896101|Active Comparator|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
11271154|NCT02897037|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
11271155|NCT02897024|Active Comparator|Usual weekly|Usual weekly physical therapy is 1 hours of therapy one day per week for 40 weeks.
11271156|NCT02897024|Experimental|High intensity periodic|High intensity periodic physical therapy is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
11271157|NCT02897011|Sham Comparator|Group 1: MTX continue|Group will continue MTX after vaccination
11271158|NCT02897011|Experimental|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
11271159|NCT02896998|Other|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
11271160|NCT02896998|Experimental|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
11271161|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
11271162|NCT02896972|Active Comparator|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
11271163|NCT02896972|Active Comparator|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
11271164|NCT02896959|Experimental|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
11271165|NCT02896959|Experimental|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
11271166|NCT02896959|Experimental|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
11271167|NCT02896946|Experimental|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
11271168|NCT02896933||patients with multiple sclerosis|recruited in a former study
11271169|NCT02896933||healthy control subjects|
11271170|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
11271171|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11271172|NCT02896894|Experimental|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
11271173|NCT02896894|Other|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
11271174|NCT02896894|Experimental|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
11271175|NCT02896894|No Intervention|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
11271176|NCT02896868|Experimental|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
11271177|NCT02896868|Placebo Comparator|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
11271178|NCT02896855|Active Comparator|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg/m^2]), administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
11271179|NCT02896855|Experimental|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m^2), administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
11271180|NCT02896842|No Intervention|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
11271181|NCT02896842|Active Comparator|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage < 1000 ng/ml
11271182|NCT02896842|Experimental|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage < 1000 ng/ml
11271183|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
11271184|NCT02896816|Experimental|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.
~Surface EMG, MRI and PET scan will be performed at baseline."
11271185|NCT02896816|Active Comparator|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
11271186|NCT02896803|Experimental|Experimental|mFLOX
11271187|NCT02896790||Stage 1|Patients without therapeutic education
11271188|NCT02896790||Stage 2|Patients with therapeutic education
11271189|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
11271190|NCT02896777|Experimental|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
11271293|NCT02896101|Placebo Comparator|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
11271294|NCT02896088|Other|test tooth groups|test tooth groups
11271295|NCT02896088|Other|control tooth groups|control tooth groups
11271191|NCT02896777|Experimental|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
11271192|NCT02896764|Experimental|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
11271193|NCT02896751|Experimental|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
11271194|NCT02896725|Experimental|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
11271195|NCT02896725|Active Comparator|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
11271196|NCT02896712|Active Comparator|ACT plus CM|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered to help decrease experiential avoidance while increasing acceptance and willingness to experience unpleasant thoughts, feelings, and physical symptoms.
11271197|NCT02896712|Active Comparator|ACT plus CM, with Placebo|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
11271198|NCT02896712|Experimental|ACT plus CM, with Modafinil|Acceptance and Commitment Therapy along with Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
11271199|NCT02896712|Active Comparator|DC plus CM|Drug Counseling and Contingency Management for cocaine use will be administered to help educate patients about important concepts in addiction recovery.
11271200|NCT02896712|Active Comparator|DC plus CM, with Placebo|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a placebo capsule during Phase 2 (weeks 5-12).
11271201|NCT02896712|Experimental|DC plus CM, with Modafinil|Drug Counseling and Contingency Management for cocaine use will be administered and augmented with a Modafinil (300mg) capsule during Phase 2 (weeks 5-12).
11271202|NCT02896699|Experimental|PrEP Intervention Group|Group training session including HIV Education, PrEP Education, Following the training session Booster phone calls HIv and syphillis testing
11271203|NCT02896699|Active Comparator|Control Group|Group HIV risk vignettes
11271204|NCT02896686|Active Comparator|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
11271205|NCT02896686|Experimental|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.
~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.
~The skin will be closed using a subcutaneous purse-string closure"
11271206|NCT02896673|Experimental|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.
~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
11271207|NCT02896660|Experimental|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
11271208|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
11271209|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
11271210|NCT02896634||group with none|Selection of samples from biobank with groups with none
11271211|NCT02896634||group with both|Selection of samples from biobank with groups with both.
11271212|NCT02896621|Experimental|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.
~A capsule with both drugs was taken once daily in the morning for eight weeks."
11271213|NCT02896621|Active Comparator|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
11271214|NCT02896608||Dravet syndrome - HCN1 channel mutation|early infantile epileptic encephalopathy with HCN1 channel mutation
11271215|NCT02896608||control with epilepsy|
11271216|NCT02896608||control without epilepsy|
11271217|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
11271218|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
11271219|NCT02896582|Experimental|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
11271220|NCT02896569|Experimental|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
11271221|NCT02896569|No Intervention|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
11271222|NCT02896556|Experimental|Resin infiltrate|This is a single-arm study. Resin infiltration technique will be performed to all patients.
11271296|NCT02896075|Experimental|Leg with Delayed Onset Muscle Soreness|young healthy people with delayed onset muscle soreness in either the right or left leg will go through the 30 Minute Comedy Video and the 30 Minute Documentary Video.
11271297|NCT02896075|Sham Comparator|Leg w/o Delayed Onset Muscle Soreness|young healthy people with delayed onset muscle soreness with no soreness in the right or left leg will go through the 30 Minute Comedy Video and the 30 Minute Documentary Video.
11271223|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
11271224|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
11271225|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
11271226|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
11271227|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
11271228|NCT02896491|Experimental|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
11271229|NCT02896491|Experimental|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:
~exposure with TETRA (6W/kg)"
11271230|NCT02896491|Sham Comparator|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
11271231|NCT02896465|Active Comparator|ORS+ZINC|Oral rehydration solution + Zinc
11271232|NCT02896465|Experimental|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
11271233|NCT02896465|Placebo Comparator|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
11271234|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
11271235|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
11271236|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
11271237|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
11271238|NCT02896439|Experimental|Neurophysiological monitoring|
11271239|NCT02896426|Experimental|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
11271240|NCT02896426|Active Comparator|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
11271241|NCT02896413|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
11271242|NCT02896413|Placebo Comparator|Control Group|0.9% saline infusion
11271243|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
11271244|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
11271245|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
11271246|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
11271247|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
11271248|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
11271249|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
11271250|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
11271251|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
11271252|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
11271253|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
11271254|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
11271255|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
11271256|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
11271257|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
11271258|NCT02896400|No Intervention|Control|Control arm, no intervention
11271259|NCT02896374|Experimental|Patients|Treated or hospitalized patients for schizophrenia.
11271260|NCT02896374|Experimental|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
11271261|NCT02896361|Experimental|Stimulation order 1|"Stimulations delivered in following order:
~Standard burst
~Burst Microdosing 1
~Burst Microdosing 2"
11271262|NCT02896361|Experimental|Stimulation order 2|"Stimulations delivered in following order:
~Burst Microdosing 1
~Burst Microdosing 2
~Standard burst"
11271263|NCT02896361|Experimental|Stimulation order 3|"Stimulations delivered in following order:
~Burst Microdosing 2
~Standard burst
~Burst Microdosing 1"
11271264|NCT02896348|Experimental|SynPhNe therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities.
~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system."
11271298|NCT02896062|Experimental|Treatment group|In the treatment phase subjects receive a sleep-coaching
11271265|NCT02896348|Active Comparator|Conventional therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities.
~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage."
11271266|NCT02896335|Experimental|Palbociclib|"Description Patients who fulfill eligibility criteria will be entered into the trial to receive Palbociclib
~After the screening procedures confirm participation in the research study:
~Palbociclib- Fixed Dose, daily for 21 days per cycle.
~The participant will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
11271267|NCT02896322|Experimental|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
11271268|NCT02896309|Experimental|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
11271269|NCT02896309|Active Comparator|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
11271270|NCT02896309|No Intervention|No treatment|No treatment
11271271|NCT02896296|Experimental|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.
~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
11271272|NCT02896283|Experimental|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
11271273|NCT02896283|Placebo Comparator|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
11271274|NCT02896270|Experimental|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).
~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).
~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
11271275|NCT02896257|Other|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
11271276|NCT02896257|No Intervention|Usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
11271277|NCT02896231|Experimental|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
11271278|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
11271279|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
11271280|NCT02896205|Experimental|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
11271281|NCT02896205|Placebo Comparator|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
11271282|NCT02896192|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
11271283|NCT02896192|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
11271284|NCT02896179|Experimental|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
11271285|NCT02896179|Active Comparator|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
11271286|NCT02896166|Experimental|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
11271287|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
11271288|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
11271289|NCT02896127|Experimental|Secukinumab|Secukinumab 150 mg s.c.
11271290|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
11271291|NCT02896101|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
11271301|NCT02896036|Experimental|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
11271302|NCT02896036|Active Comparator|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
11271303|NCT02896023|Active Comparator|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
11271304|NCT02896023|Active Comparator|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
11271305|NCT02896010|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
11271306|NCT02896010|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
11271307|NCT02895997|Experimental|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
11271308|NCT02895984|Experimental|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
11271309|NCT02895984|No Intervention|Natural History Control (NHC)|Students in the NHC group will receive no contact.
11271310|NCT02895958|Other|Administration of Zepatier|
11271311|NCT02895945|Experimental|BAX802 in Surgery|Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.
11271312|NCT02895932|Experimental|Case|Patients with diagnosed Parkinson's disease
11271313|NCT02895932|Experimental|Control|Healthy adults
11271314|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
11271315|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
11271316|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
11271317|NCT02895893|Experimental|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
11271318|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
11271319|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
11271320|NCT02895867|Experimental|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
11271321|NCT02895867|Experimental|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
11271322|NCT02895867|Other|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
11271323|NCT02895854|Active Comparator|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
11271324|NCT02895854|Active Comparator|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
11271325|NCT02895841|No Intervention|Standard of Care|Patients will continue with their normal Standard of Care for their condition
11271326|NCT02895841|Experimental|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
11271327|NCT02895828|Experimental|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
11271328|NCT02895828|Experimental|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
11271329|NCT02895815|Experimental|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
11271330|NCT02895815|Experimental|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system.
11271331|NCT02895815|No Intervention|Control Group|Participants will undergo observations without surgery.
11271332|NCT02895802|Other|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
11271333|NCT02895802|Other|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
11271334|NCT02895802|Other|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
11271335|NCT02895802|Other|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
11271336|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
11271337|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
11271338|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
11271339|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
11271340|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
11271341|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
11271342|NCT02895750|Experimental|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
11271343|NCT02895750|Experimental|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
11271344|NCT02895750|Experimental|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
11271345|NCT02895737|Other|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
11271346|NCT02895737|Other|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
11271347|NCT02895737|Other|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
11271348|NCT02895737|Other|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
11271349|NCT02895724|Experimental|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
11271350|NCT02895724|No Intervention|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
11271351|NCT02895711||Patients with urolithiasis|To record the effective radiation dose to the patient during endourologic procedures to treat urolithiasis
11271352|NCT02895698|Active Comparator|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
11271353|NCT02895698|Other|Control group|stretching exercise + active dorsiflexion without cupping
11271354|NCT02895685|Experimental|Dyad training|Participants randomized to train in pairs during the whole 6-week course
11271355|NCT02895685|No Intervention|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
11271356|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
11271357|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
11271358|NCT02895659|Active Comparator|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
11271359|NCT02895659|Active Comparator|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
11271360|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
11271361|NCT02895646||Control|No specific clinical investigation for control subjects
11271362|NCT02895633|Experimental|Patients with bone or peripheral soft-tissue tumor|
11271363|NCT02895620|Other|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
11271364|NCT02895555|Active Comparator|Allograft group, standard treatment|Control group, standard treatment. Aprox 50 g pr level fused.
11271365|NCT02895555|Experimental|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Aprox 5 ml pr level fused.
11271366|NCT02895542||Oral Anti-Cancer Agent|No intervention
11271367|NCT02895529|Experimental|Itraconazole|
11271368|NCT02895529|Active Comparator|Caspofungin|
11271369|NCT02895516|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
11271370|NCT02895503|Experimental|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
11271371|NCT02895503|Active Comparator|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
11271372|NCT02895490|Experimental|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
11271373|NCT02895490|Active Comparator|Arm II (control)|Patients receive information about the LINC group.
11271376|NCT02895464|Experimental|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
11271377|NCT02895464|Other|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
11271378|NCT02895451|Experimental|Extended behavioral intervention|Specific goal-setting, self-monitoring and feed-back
11271379|NCT02895451|No Intervention|Usual care|Hospital-based or home-based aerobic exercise 3 times a week with a duration of 30-60 minutes and an intensity of 40-80 % of Vo2max and resistance exercise 2 times a week of 1-3 sets of 10-15 repetitions. The exercise period is 16 weeks.
11271380|NCT02895438|Experimental|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
11271381|NCT02895438|Active Comparator|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
11271382|NCT02895412|Experimental|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.
~Donor-derived WT1-CTL and P-CTL.
~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.
~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
11271383|NCT02895386|Active Comparator|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
11271384|NCT02895386|Sham Comparator|Control Group B|Sham procedure and continuing current antihypertensive medications.
11271385|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
11271386|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
11271387|NCT02895360|Experimental|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
11271388|NCT02895360|Experimental|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
11271389|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
11271390|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
11271391|NCT02895334|Experimental|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
11271392|NCT02895334|No Intervention|Standard of Care|Caregivers will complete 4 follow up assessments.
11271393|NCT02895321|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense and Colgate Protection Caries and Placebo gel.
~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.
~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
11271394|NCT02895308|Experimental|Online|The Online psychoeducation is presented on on a webpage.
11271395|NCT02895308|Active Comparator|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
11271396|NCT02895295|Active Comparator|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and will be provided with a list of resources available in the community to help them choose a prescription drug plan.
11271397|NCT02895295|Experimental|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
11271398|NCT02895295|Active Comparator|Individual Analysis|"Participants randomized to Individual Analysis arm will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
11271399|NCT02895269|Experimental|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
11271445|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
11271400|NCT02895269|Active Comparator|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
11271401|NCT02895243|Experimental|Prehabilitation|
11271402|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
11271403|NCT02895217|Experimental|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
11271404|NCT02895217|Experimental|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
11271405|NCT02895204|Experimental|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
11271406|NCT02895204|Placebo Comparator|Placebo group|Placebo supplementation
11271407|NCT02895191|Experimental|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
11271408|NCT02895191|Experimental|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
11271409|NCT02895191|Experimental|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
11271410|NCT02895191|Placebo Comparator|control group|Placebo
11271411|NCT02895178|Experimental|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
11271412|NCT02895178|No Intervention|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
11271413|NCT02895178|Sham Comparator|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
11271414|NCT02895152|Experimental|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
11271415|NCT02895152|No Intervention|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
11271416|NCT02895139|Experimental|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
11271417|NCT02895139|Other|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
11271418|NCT02895139|Other|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
11271419|NCT02895126|Experimental|"Appui Parental program (44 cases)"|
11271420|NCT02895126|Other|Regular parental support (44 cases)|Usual intervention
11271421|NCT02895113|Experimental|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
11271422|NCT02895113|Placebo Comparator|Placebo|Patients will be treated with placebo for one year
11271423|NCT02895100|Experimental|PTG-100 (150 mg QD)|Low dose
11271424|NCT02895100|Experimental|PTG-100 (300 mg QD)|Medium dose
11271425|NCT02895100|Experimental|PTG-100 (900 mg QD)|High dose
11271426|NCT02895100|Placebo Comparator|Placebo group|Placebo control
11271427|NCT02895087||Cohort 1: Diurnal Variation Group|Cohort recruitment - open to recruitment
11271428|NCT02895087||Cohort 2: External Stress Group|Cohort recruitment - closed to recruitment
11271429|NCT02895074|Experimental|femtosecond laser-assisted cataract surgery group|
11271430|NCT02895074|Experimental|conventional phacoemulsification surgery group|
11271431|NCT02895061|Experimental|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
11271432|NCT02895061|Experimental|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
11271433|NCT02895048||Chronic heart failure|
11271434|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
11271435|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
11271436|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
11271437|NCT02895022|Experimental|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
11271438|NCT02895009|Other|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
11271439|NCT02895009|Experimental|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
11271440|NCT02894996|Other|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
11271441|NCT02894983|Other|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
11271442|NCT02894983|Other|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
11271443|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
11271444|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
11272508|NCT02887365|Experimental|tegafur-uracil|tegafur-uracil treatment in patients with stage II MSI-L or MSS colon cancer
11271446|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
11271447|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
11271448|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
11271449|NCT02894957|Experimental|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.
~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
11271450|NCT02894957|Active Comparator|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
11271451|NCT02894944|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
11271452|NCT02894931|Sham Comparator|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
11271453|NCT02894931|Active Comparator|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
11271454|NCT02894931|Experimental|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
11271455|NCT02894931|Experimental|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
11271456|NCT02894931|Experimental|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
11271457|NCT02894931|Experimental|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
11271458|NCT02894931|Experimental|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
11271459|NCT02894931|Experimental|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
11271460|NCT02894931|Experimental|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
11271461|NCT02894931|Experimental|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
11271462|NCT02894931|Experimental|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
11271463|NCT02894931|Experimental|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
11271464|NCT02894931|Experimental|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
11271465|NCT02894931|Experimental|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
11271466|NCT02894931|Experimental|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
11271467|NCT02894918|Experimental|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
11271468|NCT02894918|No Intervention|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
11271469|NCT02894905|Experimental|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2*400-mg tablets).
11271470|NCT02894905|Experimental|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
11271471|NCT02894905|Experimental|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
11271472|NCT02894905|Experimental|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
11271473|NCT02894892|Active Comparator|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
11271474|NCT02894892|Active Comparator|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
11271475|NCT02894892|Active Comparator|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
11271476|NCT02894892|Active Comparator|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
11271477|NCT02894892|Active Comparator|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
11271478|NCT02894892|Active Comparator|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
11272509|NCT02887365|No Intervention|Observation|Observation for one year
11271479|NCT02894892|Other|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
11271480|NCT02894879|Experimental|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
11271481|NCT02894879|Sham Comparator|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
11271482|NCT02894866|Experimental|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
11271483|NCT02894866|No Intervention|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
11271484|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
11271485|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
11271486|NCT02894827||EMS|
11271487|NCT02894827||Control|
11271488|NCT02894814|Active Comparator|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
11271489|NCT02894814|Active Comparator|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
11271490|NCT02894814|No Intervention|Observational part of the study|Data collection on patients under the traditional medication system
11271491|NCT02894788||ICU|patients postoperatively admitted to ICU
11271492|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
11271493|NCT02894775||included in a clinical trial|
11271494|NCT02894775||not included in a clinical trial|
11271495|NCT02894749|No Intervention|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
11271496|NCT02894749|Experimental|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
11271497|NCT02894736|Experimental|Active tDCS|Soterix tDCS machine is used to administer active stimulation
11271498|NCT02894723|Active Comparator|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
11271499|NCT02894723|Placebo Comparator|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
11271500|NCT02894710|Experimental|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
11271501|NCT02894710|Placebo Comparator|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
11271502|NCT02894697|Active Comparator|Angiography-guidance|
11271503|NCT02894697|Experimental|OCT-guidance|
11271504|NCT02894684|Experimental|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
11271505|NCT02894684|Active Comparator|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
11271506|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
11271507|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
11271508|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
11271509|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
11271510|NCT02894658|Experimental|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
11271511|NCT02894658|Active Comparator|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
11271512|NCT02894645|Other|Standard Risk (SR)|
11271513|NCT02894645|Other|Intermediate Risk (IR)|
11271514|NCT02894645|Other|High risk (HR)|
11271515|NCT02894632|Experimental|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
11271516|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
11271517|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
11271518|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11274455|NCT02873104|Sham Comparator|Sham|truSculpt rf device, non-therapeutic settings
11271519|NCT02894593|Active Comparator|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11271520|NCT02894593|Placebo Comparator|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11271521|NCT02894593|Experimental|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
11271522|NCT02894567|Experimental|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
11271523|NCT02894554|Placebo Comparator|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
11271524|NCT02894554|Active Comparator|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
11271525|NCT02894541|Experimental|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
11271526|NCT02894541|Experimental|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
11271527|NCT02894541|Experimental|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
11271528|NCT02894541|Experimental|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
11271529|NCT02894528|Experimental|Ridge Preservation (Test Group)|
11271530|NCT02894528|Active Comparator|Ridge Preservation (Control Group)|
11271531|NCT02894515|Experimental|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
11271532|NCT02894515|Experimental|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
11271533|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
11271534|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
11271535|NCT02894502|No Intervention|Control group|This Group will receive the usual care
11271536|NCT02894489|Experimental|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
11271537|NCT02894489|Experimental|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
11271538|NCT02894437||patients|SCI recruited Physical Medicine and Nantes University Hospital Rehabilitation. Recruitment will try to balance the number of people in four sub-groups followed and complicated (= history of pelvic pressure sores), not followed and uncomplicated, monitored and uncomplicated, not followed and complicated
11271539|NCT02894437||health professionals|those involved in the chain of care Spinal Cord concerning various professions (including medical, paramedical and administrative) decision and variable influence on the organization of the die care of spinal injuries.
11271540|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
11271541|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
11271542|NCT02894398|Experimental|Palbociclib+AI or Fulvestrant|Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.
11271543|NCT02894385|Experimental|Part 1 - Subjects with severe renal impairment|Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
11271544|NCT02894385|Experimental|Part 1 - Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
11271545|NCT02894385|Experimental|Part 1 - Healthy subjects|Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
11271546|NCT02894372|Experimental|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
11271547|NCT02894372|Experimental|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
11271548|NCT02894359||CD patients|10 patients with a cervical dystonia
11271549|NCT02894359||control subjects|10 healthy patients
11271550|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
11271551|NCT02894333||Patients with Parkinson's disease|
11271552|NCT02894320||Parkinson's disease|
11271553|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
11271554|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
11271555|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
11271556|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
11271557|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
11271558|NCT02894268|Experimental|Regimen A|esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg
11271559|NCT02894268|Active Comparator|Regimen B|two sensitivity antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg
11271560|NCT02894255|Experimental|PCI and CABG|
11271561|NCT02894242|Experimental|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
11271562|NCT02894229|No Intervention|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
11271563|NCT02894229|Active Comparator|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
11271564|NCT02894229|Active Comparator|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
11271565|NCT02894203|Experimental|Mindfulness|
11271566|NCT02894203|Active Comparator|Hatha Yoga|
11271567|NCT02894203|No Intervention|Wait-list|
11271568|NCT02894177|Experimental|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
11271569|NCT02894151|Active Comparator|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.
~It was inserted only first time entry in the study."
11271570|NCT02894151|Active Comparator|DMPA|DMPA was given in trimonthly intramuscular injection.
11271571|NCT02894138|Experimental|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
11271572|NCT02894138|Placebo Comparator|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
11271573|NCT02894138|No Intervention|Observational|10 patients with IMR <30 will undergo the same follow-up as the randomised patients
11271574|NCT02894125||old subject|
11271575|NCT02894112|Experimental|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
11271576|NCT02894112|Experimental|High fat tolerance test|single high fat load determined by body weight.
11271577|NCT02894099|Experimental|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
11271578|NCT02894099|Experimental|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
11271579|NCT02894099|Experimental|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
11271580|NCT02894099|Experimental|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
11271581|NCT02894073|No Intervention|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
11271582|NCT02894073|Experimental|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
11271583|NCT02894060|Experimental|blood|blood tests
11271584|NCT02894021|Active Comparator|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
11271585|NCT02894021|Experimental|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
11271586|NCT02894008|Experimental|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
11271587|NCT02894008|Experimental|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
11271588|NCT02893995|Experimental|Slow Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
11271589|NCT02893995|Experimental|Rapid Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.
11271590|NCT02893982|Experimental|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
11271591|NCT02893969|Experimental|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
11271592|NCT02893969|Sham Comparator|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
11271593|NCT02893956|Experimental|echocardiography with postural support then standard condition|the first echocardiography (ultrasound) is performed with a postural support then the second echocardiography is performed with standard condition
11271594|NCT02893956|Active Comparator|echocardiography with standard condition then support postural|the first echocardiography (ultrasounds) is performed with standard condition (usual) and the second echocardiography is performed with a postural support
11271595|NCT02893943|Active Comparator|Probiotics|1 capsule per day containing probiotics
11271596|NCT02893943|Placebo Comparator|Placebo|1 capsule per day without probiotics
11271597|NCT02893930|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11271598|NCT02893917|Experimental|Arm A (olaparib, cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11272671|NCT02885974|Experimental|Celecoxib plus Gemcitabine/Cisplatin chemo|Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy
11271599|NCT02893917|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11271600|NCT02893904|Experimental|Propofol|General anesthesia by TCI Propofol and Remifentanil guided by BIS EEG monitoring intervention
11271601|NCT02893904|Experimental|Sevoflurane|General anesthesia by Sevoflurane and Remifentanil guided by BIS EEG monitoring intervention
11271602|NCT02893891|Active Comparator|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
11271603|NCT02893891|Active Comparator|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
11271604|NCT02893891|Active Comparator|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
11271605|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
11271606|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
11271607|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
11271608|NCT02893865|Experimental|Experimental|Continuous positive airway pressure Patients will receive continuous positive airway pressure during three months
11271609|NCT02893865|Sham Comparator|Sham Comparator|Sham-continuous positive airway pressure Patients will receive sham-continuous positive airway pressure during 3 months
11271610|NCT02893852|Active Comparator|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
11271611|NCT02893852|Experimental|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
11271612|NCT02893839|Other|Prick to prick|
11271613|NCT02893826|Experimental|EG-1962 Group|1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
11271614|NCT02893826|Active Comparator|Enteral Nimodipine Group|Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)
11271615|NCT02893800|Other|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
11271616|NCT02893800|Other|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
11271617|NCT02893787||Patients treated with anthracyclines in childhood|
11271618|NCT02893787||Healthy volunteers|
11271619|NCT02893774|Experimental|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
11271620|NCT02893748|Active Comparator|1: HyGIeaCare Prep and Colonoscopy|"Patients will receive:
~HyGIeaCare Prep
~Colonoscopy"
11271621|NCT02893748|Active Comparator|2: Split-dose PEG Prep and Colonoscopy|"Patients will receive:
~Split-dose PEG
~Colonoscopy"
11271622|NCT02893735|Active Comparator|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
11271623|NCT02893735|Active Comparator|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
11271624|NCT02893722|Experimental|atosiban|"Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute.
~Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg.
~Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg."
11271625|NCT02893722|Placebo Comparator|0.9% salain|intravenous injection of 0.9% saline in one minute before transfer. Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
11271626|NCT02893709|Experimental|Omeprazole|A course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
11271627|NCT02893696|Active Comparator|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
11271628|NCT02893696|Active Comparator|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
11271629|NCT02893670|Other|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:
~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
11271630|NCT02893618|Experimental|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
11271631|NCT02893618|Experimental|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
11271632|NCT02893618|Experimental|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
11271633|NCT02893618|Experimental|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
11271634|NCT02893618|Experimental|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
11271635|NCT02893605||Cases|Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
11271636|NCT02893605||Controls|Controls correspond to spouses/partners of patients.
11271637|NCT02893579|Experimental|Early Intervention|Stress reduction intervention 1 time a month
11271638|NCT02893579|Experimental|Delayed Intervention|Wait list Control
11271639|NCT02893566|Experimental|Mi Band Step Challenge|
11271640|NCT02893553|Experimental|Study 1|Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
11272703|NCT02885714|Active Comparator|Group II|Rotator cuff repair + supervised specific exercises
11271641|NCT02893553|Experimental|Study 2|Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
11271642|NCT02893540|Experimental|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
11271643|NCT02893540|Active Comparator|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
11271644|NCT02893527|Experimental|"Group intervention"|Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
11271645|NCT02893527|No Intervention|"Group standard"|conventional support
11271646|NCT02893514|Placebo Comparator|Screening Only (SO)|
11271647|NCT02893514|Experimental|Substance Use Screening and Intervention Tool (SUSIT)|
11271648|NCT02893488|Experimental|SEQUENCE ABCDE|Participants will receive treatment A in period 1, treatment B in period 2, treatment C in period 3, treatment D in period 4 and treatment E in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with zero mineral content (ZMC) water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 milliliter (mL) stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 minutes(mins), re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
11271649|NCT02893488|Experimental|SEQUENCE BCDEA|Participants will receive treatment B in period 1, treatment C in period 2, treatment D in period 3, treatment E in period 4 and treatment A in period 5 (one treatment per period). Where A= EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
11271650|NCT02893488|Experimental|SEQUENCE CDEAB|Participants will receive treatment C in period 1, treatment D in period 2, treatment E in period 3, treatment A in period 4 and treatment B in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
11271651|NCT02893488|Experimental|SEQUENCE DEABC|Participants will receive treatment D in period 1, treatment E in period 2, treatment A in period 3, treatment B in period 4 and treatment C in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
11271652|NCT02893488|Experimental|SEQUENCE EABCD|Participants will receive treatment E in period 1, treatment A in period 2, treatment B in period 3, treatment C in period 4 and treatment D in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
11271653|NCT02893449|Other|SICRPPD group|(Specific Individual Cognitive Remediation Program in Parkinson's Disease). Group of patients profiting from a structured program of preoperative cognitive remediation
11271654|NCT02893449|Other|ICM group: Intensive Care Management|Group of patients profiting from a preoperative non structured support
11271655|NCT02893449|Other|CG group: Control Group|No supplementary support
11271656|NCT02893436||Curarized patients|
11271657|NCT02893423|Active Comparator|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
11271658|NCT02893423|Active Comparator|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
11271659|NCT02893423|No Intervention|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
11271660|NCT02893397|Experimental|Group I (supervised exercise)|Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
11271661|NCT02893397|Experimental|Group II (fitbit)|Patients wear a fitbit.
11271662|NCT02893384|Experimental|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.
~Local Anesthetic Injection above the serratus anterior"
11271663|NCT02893384|No Intervention|Control Arm|Retrospective control group who have not had the new injection technique.
11271664|NCT02893358|Active Comparator|Active treatment|Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP<130/80 mmHg, and daytime BP <135/85 mmHg, and nighttime BP <120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.
11271665|NCT02893358|Placebo Comparator|Placebo|Placebo tablets are identical to the active study drugs, with a similar schedule of administration.
11272259|NCT02889224|Experimental|Hypercortisolism|Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
11271666|NCT02893345|Experimental|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
11271667|NCT02893345|Active Comparator|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
11271668|NCT02893332|Active Comparator|TKI without SBRT|"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.
~The oligometastatic disease will not receive SBRT"
11271669|NCT02893332|Experimental|TKI with SBRT|"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.
~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions."
11271670|NCT02893319|No Intervention|Breastfeeding|control group
11271671|NCT02893319|Active Comparator|5 oz bottle|Subject will feed infant with 5oz medela bottle
11271672|NCT02893319|Active Comparator|8 oz bottle|Subject will feed infant with 8oz medela bottle
11271673|NCT02893306|Experimental|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
11271674|NCT02893293|Active Comparator|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
11271675|NCT02893293|Sham Comparator|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
11271676|NCT02893267|Experimental|PNS + PT|The PNS+PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
11271677|NCT02893267|Active Comparator|PNS + sham-PT|The PNS + sham-PT Group will receive peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of sham outpatient physical therapy not focused on shoulder pain over the same four week period.
11271678|NCT02893267|Active Comparator|sham-PNS + PT|The sham-PNS + PT Group will receive sham peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period, and also receive eight 60-minute sessions of outpatient physical therapy focused on shoulder pain over the same four week period.
11271679|NCT02893254|Experimental|IBI303|IBI303 40mg administered subcutaneously every other week, 12cycles
11271680|NCT02893254|Active Comparator|Adalimumab|Adalimumab 40mg administered subcutaneously every other week
11271681|NCT02893241||Cohort A|Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
11271682|NCT02893241||Cohort B|Patients, who undergo caesarean section under spinal anaesthesia
11271683|NCT02893228|Experimental|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
11271684|NCT02893228|Active Comparator|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
11271685|NCT02893215||Heart failure|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
11271686|NCT02893215||Diabetes mellitus II|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
11271687|NCT02893202|Experimental|Ride On Center for Kids (ROCK) facility|8-week therapeutic horseback riding
11271688|NCT02893202|Experimental|Triple H Equitherapy Facility|8-week therapeutic horseback riding
11271689|NCT02893202|Experimental|Rainer Therapeutic Riding facility|8-week therapeutic horseback riding
11271690|NCT02893202|Experimental|REACH Therapeutic Riding facility|8-week therapeutic horseback riding
11271691|NCT02893202|Experimental|Courtney Cares Riding facility|8-week therapeutic horseback riding
11271692|NCT02893189|Experimental|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
11271693|NCT02893176|Placebo Comparator|Placebo|10mg will be administered one time daily
11271694|NCT02893176|Active Comparator|Active|10mg macitentan will be administered one time daily
11271718|NCT02892968|Experimental|U/S Guided Regional Anesthesia|"Fascia-Iliaca Block(FIB) Femoral Nerve Block(FNB)
~All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. EPs will then be trained to use two approaches to ultrasound (U/S) guided regional anesthesia, the fascia iliaca and femoral nerve blocks. Which block that will be used will be randomly determined at the individual patient level"
11272260|NCT02889224|Experimental|Hydrocortisone|Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
11271695|NCT02893163|Experimental|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
11271696|NCT02893163|Active Comparator|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
11271697|NCT02893150|Active Comparator|TAU (treatment as usual)|The Treatment as Usual (TAU) will be considered as following: 1) In the cases of individuals presenting overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, primary care teams propose the improvement of the life style (more physically active, and with a better eating behaviour) in order to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²). 2) For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities (psycho-education), it is evaluated the need for individual dietary prescription by a nutritionist.
11271698|NCT02893150|Active Comparator|TAU+MBHP|"The Mindfulness-based Health Promotion (MBHP) developed by our research group (generic protocol) will be adapted from the Mindfulness-based Stress Reduction program (MBSR), It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems], which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice."
11271699|NCT02893150|Experimental|TAU+MB-EAT|The Mindfulness-based Eating Awareness (MB-EAT) protocol consists in ten weekly sessions of 2,5 hour to improve compulsive eating, and to promote conscious eating.
11271700|NCT02893137|Experimental|Craniectomy and Optune|Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
11271701|NCT02893124|Experimental|PEG-IFN group|HBeAg-negative CHB patients with HBsAg <1000 IU/ mL and HBV DNA<100 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
11271702|NCT02893124|No Intervention|NAs group|CHB patients do not need to change their NAs treatment.
11271703|NCT02893111|Experimental|Bortezomib (Velcade)|A proteasome inhibitor
11271704|NCT02893098|Experimental|Humia inj.|Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.
11271705|NCT02893098|Active Comparator|High Hyal Plus inj.|Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks
11271706|NCT02893085||patients with malignant biliary stricture|
11271707|NCT02893085||patients with benign biliary diseases|
11271708|NCT02893072|Experimental|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
11271709|NCT02893046||Population at Risk|Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.
11271710|NCT02893046||Prison population|"Proposal of participation to a  consultation arrivants  by the staff of medical units correctional"
11271711|NCT02893033|Experimental|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
11271712|NCT02893033|Sham Comparator|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
11271713|NCT02893007|Experimental|Brief family-centered care program|The Brief family-centered care (BFCC) program was developed and provided for hospitalized patients with BPD and their family caregivers.The BFCC protocol is outlined as 4 treatment sessions, specific goals, and example questions. Four 90-minute in-depth sessions for each dyad were initially held in a quiet interview room to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
11271714|NCT02893007|No Intervention|treatment-as-usual (TAU)|All patients were given the standard hospital-provided services: psychiatric nursing care, occupational therapy, and pharmacotherapy. All of the family caregivers were only to attend a routine 60-minute family discussion group about violence and suicide prevention without any specific patient-family dyad interview.
11271715|NCT02892994|Experimental|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm^2 and 100% duty cycle on each masseter muscle.
11271716|NCT02892994|Placebo Comparator|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
11271717|NCT02892981|Other|Pulmonary hypertension patients|All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests
11271751|NCT02892747|Experimental|Educational Program for prevention of malnutrition|In addition to the usual nutritional assessment, the patients in the experimental arm benefit of a personalized educational program for prevention of malnutrition. This program aims to monitor energy and protein intake in addition to managing sodium intake, notably by offering personalized menu ideas and recipes.
11272704|NCT02885701|Experimental|No splint|
11271719|NCT02892968|No Intervention|Current Local Standard Analgesia|"All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. Physicians who are in the control group will provide current local standard of analgesic care for hip fracture patients such as the use of IV opiods with supplemental acetaminophen and non-steroidal anti-inflammatory agents until they receive training."
11271720|NCT02892955|Experimental|Experimental: HeartMate 3 LVAS (HM3 LVAS)|The study will be a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
11271721|NCT02892942|Active Comparator|Control Group|"Background therapy which is the usual COH treatment:
~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,
~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®."
11271722|NCT02892942|Experimental|NATOS Group|"Background therapy which is the usual COH treatment:
~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,
~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®.
~GnRH antagonist treatment (Cetrotide®, MerckSerono Pharmaceuticals) will be reinforced and patients will receive 1.5 mg/day (6 ampoules of 0.25 mg), S.C., starting on day 1 (S1) of Gonal-F® treatment until dhCG"
11271723|NCT02892929|Experimental|Motivational Interviewing|The motivational interview is a style of care that evokes the patient their motivations to make behavioral changes in the interests of their own health. It is a technique centered in patient to explore and resolve their ambivalence to modify unhealthy behavior.
11271724|NCT02892929|Active Comparator|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation. In this type of consultation the health professional who plans the action plan for the patient and determines how it will be the patient's lifestyle modification.
11271725|NCT02892916|Experimental|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
11271726|NCT02892916|Placebo Comparator|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
11271727|NCT02892903|No Intervention|Conventional angiography|Routine angiography will be performed according to local best practice
11271728|NCT02892903|Experimental|Routine Measurement of FFR|Additional investigation with the measurement of FFR in all major vessels
11271729|NCT02892890|Experimental|patients with CIDP|
11271730|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
11271731|NCT02892877||Invasive mole|
11271732|NCT02892877||Choriocarcinoma|
11271733|NCT02892877||Post-molar neoplasia|
11271734|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
11271735|NCT02892864|Active Comparator|Control arm|Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
11271736|NCT02892864|Experimental|Experimental Virtual Arm|Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
11271737|NCT02892851|Experimental|Deep brain stimulation (DBS)|Deep brain stimulation of the subthalamic nuclei (STN-DBS)
11271738|NCT02892838|Experimental|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
11271739|NCT02892838|Active Comparator|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
11271740|NCT02892825|Experimental|music group|music listening
11271741|NCT02892825|Active Comparator|no music group|no music listening
11271742|NCT02892812|Experimental|LBVE013|13-valent pneumococcal conjugate vaccine
11271743|NCT02892812|Experimental|LBVE014|14-valent pneumococcal conjugate vaccine
11271744|NCT02892812|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
11271745|NCT02892799|Active Comparator|Standard of Care|Patients randomized to the usual care arm will be treated almost the same as if they do not enroll in the study. They will be managed in accordance with best ICU (intensive care unit) practices, with treatment decisions made by the treating team. Often this will include blood draws (often 2 teaspoons once or twice per day, but sometimes exceeding this), assessments of cardiac function, assessments of fluid status, and other measures as dictated by the presenting illness (this is broad and will include antibiotics, diuretics, cardiac medications, ventilator and oxygen management, etc.). Patients in the usual care arm will not have diuresis managed by NICOM.
11271746|NCT02892799|Experimental|NICOM-Guided Diuresis|"Within 4 hours, patients will have their blood pressure obtained, a NICOM-based assessment of PLR (passive leg raise)-induced change in cardiac index, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7 am). This will allow determination of the fluid goal over the next 4 hours. Patients will receive furosemide to achieve the goal fluid balance, if needed as described in the accompanying protocol. Monitoring of electrolytes and renal function will be at the discretion of the treating physician.
~Following the initial evaluation, at set times spaced every 4 hours apart, patients will have an ongoing evaluation of the day's fluid balance, hourly urinary output, and PLR/NICOM values. This diuresis protocol will continue for a total of seven 24-hour periods or until the primary means of oxygenation/ventilation has been withdrawn, whichever occurs first. Patients will be followed for a total of 60 days to evaluate outcome data."
11271747|NCT02892786|Experimental|experimental|
11271748|NCT02892773|Other|Incentive Spirometry Group|"Participant will be asked to take 10 deep breaths through the mouthpiece of an incentive spirometer, followed by a 60 second pause.
~This cycle will be repeated two more times.
~A Respiratory Therapist will coach participants three times per day.
~Each duration of Incentive Spirometry will last about 15 minutes."
11271749|NCT02892773|Active Comparator|EzPAP® Positive Airway Pressure Group|"Participant will be coached by a Respiratory Therapist to breathe through the mouthpiece of an EzPAP® device for 10 breaths, followed by a 60 second pause.
~This cycle will be repeated two more times.
~The Respiratory Therapist will coach participants three times per day.
~Each duration of EzPAP® therapy will last about 15 minutes."
11271750|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
11272309|NCT02888860||Group 2|Patients without colonization during follow up
11271752|NCT02892747|No Intervention|Control|In the control arm, patients are followed-up by the cardiologist and the nutritionist, and did not benefit of the personalized educational program for prevention of malnutrition.
11271753|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
11271754|NCT02892721|No Intervention|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
11271755|NCT02892721|Other|Training with feedback|See intervention description
11271756|NCT02892708|Active Comparator|Surgery|Surgical resection followed by radiation therapy
11271757|NCT02892708|Experimental|radiotherapy alone|radiotherapy after a brain biopsy
11271758|NCT02892695|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
11271759|NCT02892682|Other|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
11271760|NCT02892682|Other|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
11271761|NCT02892682|Other|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
11271762|NCT02892682|Other|ARM 4 US|Arm of superficial nettle rashes: blood test
11271763|NCT02892669||patients admitted to the intensive care department|
11271764|NCT02892643|Experimental|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
11271765|NCT02892643|Active Comparator|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
11271766|NCT02892630||Pregnant ITP women|Pregnant women more than 18 years old, with primary ITP diagnosis before pregnancy
11271767|NCT02892630||Control ITP Women (Non pregnant)|Primary ITP women more than 18 years old, at more than one year from a precedent pregnancy
11271768|NCT02892630||De novo ITP pregnant women|Pregnant women more than 18 years old, with newly diagnosed thrombocytopenia during pregnancy
11271769|NCT02892617||Group 1|Patients with low back pain lasting for more than 6 months, debilitating, with the presence of type 1 Modic disc disease on MRI at the operated disc, eligible for a disc prosthesis or arthrodesis anterior approach
11271770|NCT02892617||Group 2|Patients underwent surgery for nerve root pain by disc herniation on MRI viewable with a radio-clinical concordance with or without Modic 1 disc disease in the operated disc
11271771|NCT02892604|Experimental|insulin delivery driven by inControl|"Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.
~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data."
11271772|NCT02892591|Experimental|Cannabis|Medium dose THC, single administration, vaporized
11271773|NCT02892591|Active Comparator|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
11271774|NCT02892591|Placebo Comparator|Placebo|No active study drug
11271775|NCT02892578|Experimental|electrocardiogram|Patient will take an electrocardiogram in order to detect atrial fibrillation
11271776|NCT02892565|Experimental|Cases|Patients with SLE and/or APL and first vein thrombosis episode
11271777|NCT02892565|Other|Controls|age-matched; Patients with SLE and/or APL
11271778|NCT02892552|Experimental|Cone Beam|Patients included will have first a MultiSlice Computed tomography (MSCT) as usual and then a Cone Beam Computed Tomography (CBCT)
11271779|NCT02892526||Vital wounds|from abdominoplasty of alive persons
11271780|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
11271781|NCT02892513|Experimental|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
11271782|NCT02892513|Sham Comparator|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
11271783|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
11271784|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
11271785|NCT02892487|Experimental|Early active swallowing therapy|
11271786|NCT02892487|No Intervention|Usual care|
11271787|NCT02892474||Hybrid Coronary Revascularization (HCR)|Patients who are scheduled to have the hybrid coronary revascularization (HCR) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
11271788|NCT02892474||Coronary Artery Bypass Grafting (CABG)|Patients who are scheduled to have the coronary artery bypass grafting (CABG) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
11271841|NCT02892045||TOFWatch versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus TOF-Watch Acceleromyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg
11271789|NCT02892461|Experimental|Umbilical cord milking|The cord will be cut at 25 cm from the umbilical stump within 30 seconds after the infant is taken out from the uterus and its blood will be milked to the infant gently and thoroughly in 30 seconds during resuscitation on the radiant warmer, and then the cord will be cut at 2 to 3 cm from the umbilical stump.
11271790|NCT02892461|No Intervention|Routine clinical treatment and care|The cord will be dealt with routine clinical method, which means it will be cut twice within 1minute after the infant is taken out from the uterus, the first cut is on the operating table, while the second cut is on the radiant warmer.
11271791|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
11271792|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
11271793|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
11271794|NCT02892435|Experimental|Prevena arm|patients underwent to contaminated/dirty surgery who positioned incisional negative pressure wound therapy and kept for six days
11271795|NCT02892435|Active Comparator|Control arm|patients underwent to contaminated/dirty surgery who positioned conventional dressing
11271796|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
11271797|NCT02892409|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
11271798|NCT02892409|Experimental|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
11271799|NCT02892396||COPD patients & conventional cigarettes|COPD patients regular smokers of conventional cigarettes with no desire to quit smoking habit.
11271800|NCT02892396||COPD patients & electronic cigarettes|COPD patients who had been users of electronic cigarettes for at least 8 weeks. They will be provided with an specific type of electronic cigarette and the same dosage of inhaled nicotine.
11271801|NCT02892370|Experimental|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
11271802|NCT02892370|Experimental|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
11271803|NCT02892357|Experimental|Treatment group|Participants in this group take the herbal compound of Jianpi Qinghua granules and half-dose omeprazole tablet.Jianpi Qinghua granule:one bag after 1 hour of breakfast and supper(twice a day) for 4 weeks.Half-dose omeprazole tablet:1 tablet of real omeprazole (10mg) and 1 tablet of Sham(10mg),once a day before breakfast for 4 weeks.
11271804|NCT02892357|Active Comparator|Control group|Participants in this group take the sham herbal granules twice a day as treatment group and two pieces of real omeprazole tablet(10mg each) once a day before breakfast for 4 weeks.
11271805|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
11271806|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
11271807|NCT02892331|No Intervention|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
11271808|NCT02892331|Experimental|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
11271809|NCT02892331|Experimental|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
11271810|NCT02892318|Experimental|Cohort A1: Safety Cohort (Relapsed/refractory AML)|An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams [mg] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter [mg/m^2] subcutaneously [SC] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
11271811|NCT02892318|Experimental|Cohort A2: Expansion Cohort (Relapsed/refractory AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
11271842|NCT02892032|Experimental|Attention Modification Training|ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful
11271843|NCT02892032|Placebo Comparator|No Attention Modification Training|There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen.
11271844|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
11271845|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
11271846|NCT02892006|Experimental|Intervention|All participants in the study will participate a 6 week improv intervention.
11271812|NCT02892318|Experimental|Cohort A3: Safety Cohort (Previously Untreated AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
11271813|NCT02892318|Experimental|Cohort A4: Expansion Cohort (Previously Untreated AML)|If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
11271814|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
11271815|NCT02892279|Experimental|Diesel exhaust exposure|A single arm study in which first a baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute diesel exhaust will start.
11271816|NCT02892266||Adolescent Transplant Recipients|"Questionnaire battery at enrollment (Participants and their parents/guardians)
~Clinical data from patient's chart (6 months of retrospective data & 6 months of prospective tacrolimus trough level data)"
11271817|NCT02892253|Experimental|NIR+ group|"Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND).
~Parathyroid identification was done with the use of NIR (intervention group, NIR+ group)"
11271818|NCT02892253|No Intervention|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
11271819|NCT02892227|Experimental|JET ECHO|Transmitral flow estimation
11271820|NCT02892227|No Intervention|NO JET ECHO|no bedside echocardiography
11271821|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
11271822|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
11271823|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
11271824|NCT02892201|Experimental|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation
~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
11271825|NCT02892162|Experimental|With additional LAAW linear ablation|Patients who undergo CPVI+LA roof linear ablation+/ MI linear ablation, and additional LAAW linear ablation using ThermoCool SmartTouch catheter.
11271826|NCT02892162|Active Comparator|Without additional LAAW linear ablation|Patients who undergo CPVI+LA roof +/ MI linear ablation using ThermoCool SmartTouch catheter, without LAAW linear ablation.
11271827|NCT02892149|Experimental|Vadadustat|
11271828|NCT02892149|Active Comparator|darbepoetin alfa|
11271829|NCT02892123|Experimental|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
11271830|NCT02892110|Experimental|Varenicline|2 mg daily
11271831|NCT02892110|Placebo Comparator|Placebo|2 mg daily
11271832|NCT02892097|Active Comparator|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
11271833|NCT02892097|Active Comparator|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
11271834|NCT02892097|Sham Comparator|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
11271835|NCT02892084|Experimental|Uphill COMa training|Walking on an inclined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
11271836|NCT02892084|Experimental|Downhill COMa training|Walking on a declined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
11271837|NCT02892071|Active Comparator|22% TCA peel|22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
11271838|NCT02892071|Active Comparator|CO2 laser|CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
11271839|NCT02892071|Active Comparator|Qs-NdYAG laser|Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
11271840|NCT02892045||MMG versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus Mechanomyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg.
11271991|NCT02890966|Experimental|Cohort 3|5mg SHR4640 or placebo
11271992|NCT02890966|Experimental|Cohort 4|10mg SHR4640 or placebo
11271847|NCT02891993|Experimental|IMPROVED Intervention|"Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer.
~The clinical team will view reports detailing their patients' symptom burden
~Clinicians will be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
11271848|NCT02891993|Active Comparator|Usual Care|"Patients randomized to Usual Care will self-report their symptoms each day using a tablet computer
~Patients will report their symptoms to their clinicians as they usually would
~Clinicians will not be provided with a graphic depiction of their patients' daily symptom trajectory for that admission"
11271849|NCT02891980|Experimental|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
11271850|NCT02891980|Experimental|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
11271851|NCT02891980|Experimental|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
11271852|NCT02891980|Experimental|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
11271853|NCT02891967|Other|Bulk full composite (3M)|bulk fill composite in posterior class one cavities
11271854|NCT02891967|Other|Incremental packing composite resin|Nano resin composite (K Z350 xt) restoration in class one cavities
11271855|NCT02891954|Experimental|Single arm|Healthy volunteers will receive canagliflozin to assess pharmacodynamic responses to drug.
11271856|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
11271857|NCT02891928|Experimental|with rocker sole|patient were wearing the rocker soles shoes during investigation
11271858|NCT02891928|Placebo Comparator|without rocker sole|patient were wearing normal shoes during investigation
11271859|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
11271860|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
11271861|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
11271862|NCT02891850|Experimental|BAY63-2521|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
11271863|NCT02891850|Active Comparator|Sildenafil or Tadalafil|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
11271864|NCT02891837|Experimental|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;
~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;
~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;
~9 mg/kg/hr continuous infusion for up to 48 hours."
11271865|NCT02891837|Placebo Comparator|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;
~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;
~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;
~9 mg/kg/hr continuous infusion for up to 48 hours."
11271866|NCT02891824|Placebo Comparator|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:
~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
11271867|NCT02891824|Experimental|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:
~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression
~."
11271868|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
11271869|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
11271870|NCT02891798|Experimental|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
11271871|NCT02891798|Active Comparator|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
11271872|NCT02891785|Experimental|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
11271873|NCT02891785|No Intervention|standard care|Standard care will be described as part of the study.
11271874|NCT02891772||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
11271875|NCT02891759|Experimental|Group A: Alloderm RTU|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.
~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group A will receive Alloderm RTU
~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
11271993|NCT02890953|Placebo Comparator|Control|Control group receives placebo medication (normal saline)
11272705|NCT02885701|Experimental|Removable Splint|
11271876|NCT02891759|Experimental|Group B: Cortiva 1mm Allograft Dermis|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.
~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis
~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
11271877|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
11271878|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
11271879|NCT02891720|Active Comparator|ARM A: Proteus Sensor System (PSS) First|ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
11271880|NCT02891720|No Intervention|ARM B: SOC First|ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
11271881|NCT02891707|Active Comparator|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
11271882|NCT02891707|Active Comparator|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
11271883|NCT02891694||recurrent corneal erosion|
11271884|NCT02891694||control patients (refractive surgery)|
11271885|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.
~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.
~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
11271886|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.
~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.
~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
11271887|NCT02891668||Hypothyroid|Levothyroxine treatment
11271888|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
11271889|NCT02891655||surgery for keratoconus|
11271890|NCT02891655||refractive surgery (control patients)|
11271891|NCT02891642||Malignancy, Serous effusion|Analysis of serous effusion through immunomagnetic detection device
11271892|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
11271893|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
11271894|NCT02891616|Experimental|FDG-PET/CT + FLT-PET/CT + PET/MR|"-Baseline, Week 3 (between days 14-20), Week 6 (between days 35-41)
~FDG-PET/CT - Patients required to fast for at least 4 hours prior to FDG administration. Roughly 60 minutes prior to PET/CT imaging, FDG will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.
~FLT-PET/CT - Patients required to fast for at least 4 hours prior to FLT administration. Roughly 80 minutes prior to PET/CT imaging, FLT will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.
~PET/MR - A limited whole body scan performed immediately following PET/CT imaging when possible. Should be performed at least once at each time-point. This scan will be of a more limited area and be performed for no more than 30 minutes."
11271895|NCT02891603|Experimental|Pacritinib with Sirolimus and Tacrolimus|"Pacritinib added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).
~Pacritinib will begin the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant.
~Sirolimus will be given the day before transplant and continued daily for at least one year.
~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
11271896|NCT02891590|Experimental|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
11271897|NCT02891564|Placebo Comparator|Control Arm (R 33)|a mobile 3D video game to be used as placebo.
11271898|NCT02891564|Experimental|Intervention Arm (R 33)|a mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
11271899|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
11271900|NCT02891538|Experimental|epigallocatechin gallate (EGCG)|Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.
11271901|NCT02891538|No Intervention|Observation Only|Standard of care surgical resection followed by standard of care colonoscopy at year.
11271902|NCT02891525|Active Comparator|50g glucose intragastric|50g glucose dissolved in 250mL tap water given via nasogastric tube
11271903|NCT02891525|Active Comparator|25g fructose intragastric|25g glucose dissolved in 250mL tap water given via nasogastric tube
11271904|NCT02891525|Active Comparator|220mg acesulfame-K intragastric|220mg acesulfame-K dissolved in 250mL tap water given via nasogastric tube
11271905|NCT02891525|Placebo Comparator|250mL tap water intragastric|250mL tap water given via nasogastric tube
11272706|NCT02885701|Experimental|Non-removable Splint|
11271906|NCT02891512|Experimental|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
11271907|NCT02891512|Placebo Comparator|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
11271908|NCT02891499|Experimental|LLLT + immediate force|Use of Low-level laser therapy and not mediate orthodontic force application (150 gF the day of the implantation).
11271909|NCT02891499|Experimental|LLLT + mediate force|Use of Low-level laser therapy and mediate orthodontic force application (150 gF 4 weeks after the day of the implantation).
11271910|NCT02891499|No Intervention|Immediate force application|Not mediate orthodontic force application (150 gF the day of the implantation), without use of Low-level laser therapy.
11271911|NCT02891499|Experimental|Mediate force application|Mediate orthodontic force application (150 gF 4 weeks after the day of the implantation), without use of Low-level laser therapy.
11271912|NCT02891486||Incidence of surgical site infection|The number of spinal surgery patients with surgical site infections.
11271913|NCT02891473|Experimental|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
11271914|NCT02891473|Active Comparator|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
11271915|NCT02891460|Experimental|40 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
11271916|NCT02891460|Experimental|80 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
11271917|NCT02891447|Experimental|Treatment (mitomycin, cisplatin)|Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.
11271918|NCT02891434|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
11271919|NCT02891434|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
11271920|NCT02891434|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
11271921|NCT02891434|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
11271922|NCT02891434|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
11271923|NCT02891434|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
11271924|NCT02891421|Other|Therapeutic Horseback Riding|Therapeutic Horseback Riding: Veterans were matched to a horse by the instructor and occupational therapist for best fit and the same horse was ridden each week
11271925|NCT02891421|Other|Standard Care|Participants received standard care.
11271926|NCT02891408|Experimental|Cohort 1 (Mild Hepatic Impairment)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of 20 mg (2 x 10 mg) firsocostat capsule (s).
11271927|NCT02891408|Experimental|Cohort 2 (Moderate Hepatic Impairment)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of 20 mg (2 x 10 mg) firsocostat capsule (s).
11271928|NCT02891408|Experimental|Cohort 3 (Severe Hepatic Impairment)|Based on the cumulative review of safety and PK data from Cohorts 1 and 2, Cohort 3 may or may not be initiated at the discretion of the investigator and Sponsor. If Cohort 3 is initiated, participants with severe hepatic impairment and matched healthy controls will receive a single dose of 5 mg (1 x 5 mg) firsocostat tablet (s).
11271929|NCT02891408|Experimental|Cohort 4 (Mild Hepatic Impairment)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of 48 mg (1 x 48 mg) fenofibrate tablet (s).
11271930|NCT02891395|Experimental|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.
~Salvage phase:
~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
11271931|NCT02891382|Experimental|Individual incentives - Arm 1|This arm receives diabetes education + goal setting + individual rewards
11271932|NCT02891382|Experimental|Mixed incentives (Altruism) - Arm 2|This arm receives diabetes education + goal setting + companion support + individual rewards
11271933|NCT02891382|Experimental|Mixed Incentives (Cooperation) - Arm 3|This arm receives diabetes education + goal setting + companion support + shared rewards
11271934|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
11271935|NCT02891343|Experimental|Healthy volunteers|
11271936|NCT02891330|Experimental|Dietary and nutritional recommendations|Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse
11271937|NCT02891330|No Intervention|Standard of care|Postoperative standard of care
11271994|NCT02890953|Experimental|MSC group|MSC group receives mesenchymal stem cells transplantation (Pneumostem)
11271995|NCT02890940|Experimental|Pet Therapy|
11272310|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
11271938|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
11271939|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
11271940|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
11271941|NCT02891304||Quarterly Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive objective feedback every 3-months on trainee overall performance including learning curves on ACE tool performance, performance relative to de-identified anonymous peers on each of the individual skills (e.g. fine tip control), and the global assessment for technical and cognitive skill achievement. For those skills which are not advanced/superior - trainees will additionally receive links to online didactic videos which teach these skills.
11271942|NCT02891304||Annual Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive learning curves at the end of each training year. Learning curves, relative to de-identified anonymous peers will be provided to program directors annually (June).
11271943|NCT02891278|Experimental|Sertraline with cytosine arabinoside|"All subjects will receive the following:
~Induction phase
~Sertraline, twice daily at one of the pre-defined dose levels
~Cytosine arabinoside, on days 1 and 10
~Consolidation phase
~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:
~Allogeneic SCT and off study
~Repeat cycle of oral sertraline and cytosine arabinoside IV infusion
~Maintenance phase with sertraline for cycles of 28 days in length"
11271944|NCT02891265|No Intervention|Group A|Group A - smoking cessation with no assistance
11271945|NCT02891265|Placebo Comparator|Group B|Group B - smoking cessation with the addition of a smoking cessation patch
11271946|NCT02891252|Active Comparator|outpatient|outpatient
11271947|NCT02891252|No Intervention|inpatient|inpatient
11271948|NCT02891239|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
11271949|NCT02891226|Experimental|Mirikizumab Dose Level 1|"Period 1 (Weeks 0 -12) Mirikizumab dose level 1
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 1 or dose level 4 or dose level 3
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
11271950|NCT02891226|Experimental|Mirikizumab Dose Level 2|"Period 1 (Weeks 0 -12) Mirikizumab dose level 2
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 2 or dose level 4 or dose level 3
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
11271951|NCT02891226|Experimental|Mirikizumab Dose Level 3|"Period 1 (Weeks 0 -12) Mirikizumab dose level 3
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3 or dose level 4
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
11271952|NCT02891226|Placebo Comparator|Placebo|"Period 1 (Weeks 0 -12) Placebo
~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3
~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
11271953|NCT02891213||LE (Lupus Erythematosus) group|"Samples of the LE (Lupus Erythematosus) group from a specimen collection : Lupus BioBanque du Rhin Supérieur (LBBR UF 9882).
~It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank Lupus BioBanque du Rhin Supérieur (project : LBBR UF 9882)."
11271954|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
11271955|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
11271956|NCT02891187|Active Comparator|Outpatient Clinic Visits|Outpatient clinic visits for postoperative care is currently the standard of care. Patients who undergo surgery for a pelvic floor disorder will be scheduled appointments in the outpatient clinic at 1-2 weeks, 6 weeks, and 3 months where they will be evaluated by a physician.
11271957|NCT02891187|Active Comparator|Telephone Follow-up|Patients will be called instead of returning to clinic for postoperative care at 1-2 weeks, 6 weeks, and 3 months.
11271958|NCT02891174|Active Comparator|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
11271959|NCT02891174|Active Comparator|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
11271960|NCT02891161|Experimental|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
11272042|NCT02890628||SMRU health staff of antenatal clinics (ANC)|1 Focus group discussion of 6-10 Shoklo Malaria Research Unit antenatal clinic staff
11271961|NCT02891161|Experimental|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
11271962|NCT02891148|Experimental|BI 690517|
11271963|NCT02891135|No Intervention|Standard|Patients randomized to the standard arm will receive standard procedures for initiating antiretroviral therapy for HIV.
11271964|NCT02891135|Experimental|Intervention|Patients randomized to the intervention arm will be offered immediate treatment initiation under the intervention algorithm (SLATE).
11271965|NCT02891109||patients group|Adults patients with chronic immune thrombocytopenia
11271966|NCT02891109||control group|Adults without immune thrombocytopenia
11271967|NCT02891083|Experimental|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
11271968|NCT02891083|Experimental|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
11271969|NCT02891083|Other|Control group|Surgery alone
11271970|NCT02891070|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
11271971|NCT02891070|Active Comparator|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
11271972|NCT02891057|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11271973|NCT02891044|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11271974|NCT02891031|Active Comparator|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
11271975|NCT02891031|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
11271976|NCT02891018|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
11271977|NCT02891018|Experimental|paclitaxel release coronary balloon catheter|Patients treated with paclitaxel release coronary balloon catheter
11271978|NCT02891005|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
11271979|NCT02891005|Experimental|common balloon catheter|Patients treated with common balloon catheter
11271980|NCT02890992|Experimental|Cohort 1 - Alirocumab 30 mg Q2W: <50 kg|"Period 1: Participants with body weight less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT).
~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
11271981|NCT02890992|Experimental|Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg|"Period 1: Participants with body weight greater than or equal to (>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
11271982|NCT02890992|Experimental|Cohort 2 - Alirocumab 40 mg Q2W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT.
~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still < 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
11271983|NCT02890992|Experimental|Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130."
11271984|NCT02890992|Experimental|Cohort 3 - Alirocumab 75 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT.
~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
11271985|NCT02890992|Experimental|Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
11271986|NCT02890992|Experimental|Cohort 4 - Alirocumab 150 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT.
~Period 2: Participants with body weight < 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48."
11271987|NCT02890992|Experimental|Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT.
~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48."
11271988|NCT02890979|Experimental|Screening (cytology collection)|Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.
11271989|NCT02890966|Experimental|Cohort 1|1mg SHR4640 or placebo
11271990|NCT02890966|Experimental|Cohort 2|2.5mg SHR4640 or placebo
11271996|NCT02890927|Experimental|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
11271997|NCT02890927|No Intervention|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
11271998|NCT02890914|No Intervention|Standard Education|These residents received their standard residency education and experience.
11271999|NCT02890914|Experimental|DVD Intervention|These residents received a one-hour long DVD lecture in addition to standard residency education and experience.
11272000|NCT02890888|Experimental|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
11272001|NCT02890875|Active Comparator|Ethanol lock|70% ethanol
11272002|NCT02890875|Active Comparator|Heparin lock|Heparinized saline (100 U/mL)
11272003|NCT02890862||20 healthy volunteers|
11272004|NCT02890862||Dupuytren disease|10 patients dupuytren disease
11272005|NCT02890862||Tendon pathology|10 patients with tendon pathology
11272006|NCT02890862||wrist osteoarthritis|10 patients with wrist osteoarthritis
11272007|NCT02890849|Experimental|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
11272008|NCT02890836||Pregnant women with pre-existing diabetes|Inclusion of 400 women is anticipated.
11272009|NCT02890836||Healthy pregnant women|Inclusion of 100 women is anticipated
11272010|NCT02890823|Experimental|EIAEDs-1000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
11272011|NCT02890823|Experimental|EIAEDs-3000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
11272012|NCT02890823|Experimental|EIAEDs-6000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
11272013|NCT02890823|Active Comparator|non-EIAEDs-1000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
11272014|NCT02890823|Active Comparator|non-EIAEDs-3000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
11272015|NCT02890823|Active Comparator|non-EIAEDs-6000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
11272016|NCT02890810|Experimental|Verum Electroacupuncture|Active Intervention
11272017|NCT02890810|Placebo Comparator|Placebo Electroacupuncture|Validated Control
11272018|NCT02890797|Other|Bronchiolitis children|Under two years old patient with bronchiolitis will have thoracic radiology
11272019|NCT02890784|Active Comparator|A. Standard arm|100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)
11272020|NCT02890784|Experimental|B. Study arm|100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)
11272021|NCT02890771|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice
11272022|NCT02890771|Experimental|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
11272023|NCT02890771|Experimental|SRP with turmeric massaging|SRP with turmeric massaging on half arch
11272024|NCT02890758|Experimental|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
11272025|NCT02890758|Active Comparator|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
11272026|NCT02890745|Experimental|Empagliflozin|One tablet 25 mg empagliflozin every morning for 14 days
11272027|NCT02890745|Placebo Comparator|Placebo|One tablet placebo every morning for 14 days
11272028|NCT02890732|Experimental|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
11272029|NCT02890719|Experimental|Genotype 1B|treatment 12 weeks
11272030|NCT02890719|Experimental|Genotype 1A and 4|treatment 16 weeks
11272031|NCT02890706|Other|Patients|Each patient undergo the same CT protocol. Theobservers will observe the detection of the perfusion defects in two different techniques.
11272032|NCT02890693|Experimental|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
11272033|NCT02890693|No Intervention|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
11272034|NCT02890680|Experimental|Platelet-rich fibrin group|Use platelet-rich fibrin after mandibular third molar extraction
11272035|NCT02890680|Placebo Comparator|Control group|mandibular third molar extraction
11272036|NCT02890667||Beneficiaries|Incident cancer for Beneficiaries present in the EGB on January 1, 2012.
11272037|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :
~First time measure : 1 month before the scoliosis surgery
~Second time measure : 3 months after the scoliosis surgery
~Third time measure : 1 year after the scoliosis surgery"
11272038|NCT02890641||drug resistant epilepsy|Sequencing of paired blood-brain DNA samples
11272039|NCT02890628||pregnant/post-natal adolescents (<20 years)|12-24 individual with pregnant or postnatal adolescent girls (<20 years) will be interviewed.
11272040|NCT02890628||non-pregnant female adolescents (<20 years)|1 Focus group discussion of 6-10 non-pregnant female adolescents (<20 years)
11272041|NCT02890628||male adolescents (<20 year)|1 Focus group discussion of 6-10 adolescent men (<20 years)
11272156|NCT02889965||Primary progressive MS (PPMS)|
11272043|NCT02890615|Experimental|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.
~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
11272044|NCT02890615|No Intervention|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
11272045|NCT02890602|Experimental|Darbepoietin alfa|Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
11272046|NCT02890589|Experimental|SYNERGY Stent|The SYNERGY™ stent is a Device marked CE (European Conformity), platinum chromium coronary stent, currently developped by Boston Scientific™. This stent has been designed with the goal of providing optimal and rapid healing within the vessel using a bioabsorbable polymer to elute everolimus.
11272047|NCT02890589|Experimental|BVS device|The ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold (BVS 1.1, Abbott Vascular, California, USA, CE approved) is Device marked CE, currently the most studied PLA (Polylactic acid) based scaffold. It consists of PLLA (Poly I-lactic acid) backbone with 1:1 PDLLA (Poly-DL Lactic Acid) drug surface coating and a total strut thickness of 156 μm.
11272048|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
11272049|NCT02890563|No Intervention|No Compression|Patients in this group will not receive any compression after treatment.
11272050|NCT02890563|Active Comparator|Compression|Patients in this group will use compression stockings for seven days after treatment (2 days continuously and 5 days during daytime).
11272051|NCT02890550||30 Patients Alström syndrome|
11272052|NCT02890550||60 Related patients Alström syndrome|
11272053|NCT02890537|Experimental|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
11272054|NCT02890537|Active Comparator|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
11272055|NCT02890524|Experimental|Night guard|the night guard made of EVA
11272056|NCT02890524|Placebo Comparator|Placebo night guard|Placebo night guard made of EVA
11272057|NCT02890511|Experimental|DHP107(Oral paclitaxel)|"Phase I (determining MTD) The patients diagnosed with either advanced or metastatic solid cancers were enrolled. The administered dose was escalated in a step-wise manner by an increment of 2 x 50 mg/m2 at each dose level. Three patients were treated for toxicity evaluation for each dose level.
~Phase IIa (efficacy evaluation) The safety and efficacy of the corresponding dose was investigated more closely by increasing the patient number to 6 or more patients in the dose tentatively determined as recommended dose for phase IIa clinical trial."
11272058|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
11272059|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
11272060|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
11272061|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
11272062|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
11272063|NCT02890472||prenatal diagnosis of a fetal 22q11 deletion syndrome|
11272064|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
11272065|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
11272066|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
11272067|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
11272068|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
11272069|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
11272070|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
11272071|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
11272072|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
11272073|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
11272074|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
11272075|NCT02890446|Experimental|External Focus (EF)|"Participants received arm training using the InMotion2 robot under external focus practice conditions and instructions. Participants practiced arm reaching by playing a simple video game.
~EF instructions: Focus on moving the yellow ball on the screen in a smooth, straight line at a constant speed; Move the yellow ball toward the blinking red/orange light; and Hit the center of the target and try not to overshoot the target"
11272257|NCT02889237|No Intervention|Already on treatment with Calcium or vitamin D|Patients who are already treated with Calcium or Vitamin D.
11272076|NCT02890446|Experimental|Internal Focus (IF)|"Participants received arm training using the InMotion2 robot without the video game interface. Participants were instructed to think about how they were moving their arm while completing the arm training tasks.
~IF instructions:
~think about how you're moving your arm; push your arm away from you; pull your arm toward you; move your arm to the right/left"
11272077|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
11272078|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
11272079|NCT02890394|Experimental|2 minutes Group|The group was perform the technique inhibition suboccipital two minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
11272080|NCT02890394|Experimental|4 minutes Group|The group was perform the technique inhibition suboccipital four minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
11272081|NCT02890394|Experimental|8 minutes Group|The group was perform the technique inhibition suboccipital eight minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
11272082|NCT02890394|No Intervention|not intervention Group|The not intervention group will be asked to lie supine on the table for ten minutes, collecting data by measuring with algometer and test repositioning of the head before and after laying.
11272083|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
11272084|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
11272085|NCT02890368|Experimental|TTI-621 Monotherapy Escalation|TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
11272086|NCT02890368|Experimental|TTI-621 Monotherapy (Single Lesion)|TTI-621 Single Lesion Injection Expansion Cohort
11272087|NCT02890368|Experimental|TTI-621 Monotherapy (Multiple Lesions)|TTI-621 Multiple Lesion Injections Expansion Cohort
11272088|NCT02890368|Experimental|TTI-621 + PD-1/PD-L1 Inhibitor|Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
11272089|NCT02890368|Experimental|TTI-621 + Pegylated Interferon-α2a|Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
11272090|NCT02890368|Experimental|TTI-621 + T-Vec|Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
11272091|NCT02890368|Experimental|TTI-621 + Radiation|Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy
11272092|NCT02890355|Experimental|Arm I (veliparib and mFOLFIRI)|Patients receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
11272093|NCT02890355|Active Comparator|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
11272094|NCT02890342||Affected Patients with Propionic Acidemia|Patients with Propionic Acidemia
11272095|NCT02890342||Unaffected Family Members|Unaffected family members
11272096|NCT02890329|Experimental|Arm A (decitabine, ipilimumab)|"PRIMING PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.
~INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
11272097|NCT02890329|Experimental|Arm B (decitabine, ipilimumab)|"PRIMING PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.
~INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
11272098|NCT02890316|Experimental|Radiation therapy with Homeopathy|Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
11272099|NCT02890316|Placebo Comparator|Radiation therapy with placebo|Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
11272100|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
11272101|NCT02890290|Active Comparator|Intervention|Marine protein hydrolysate pills (3000mg)
11272102|NCT02890290|Placebo Comparator|Control|Placebo pills (gum arabicum)
11272103|NCT02890277|Experimental|Treatment group|
11272104|NCT02890238|Active Comparator|sildenafil citrate|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
11272105|NCT02890238|Placebo Comparator|placebo group|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
11272106|NCT02890225|Other|3|Patients in 3 days
11272107|NCT02890225|Other|10|Patients in10ys
11272108|NCT02890225|Experimental|30|Patients in10ys
11272109|NCT02890212|Experimental|selenium|subjects resistant to treatment of major depression with sertraline who were randomized and ingest selenium pills (400 microgram) during six weeks
11272110|NCT02890212|Placebo Comparator|placebo|subjects resistant to treatment of major depression with sertraline who were randomized and ingest placebo pills
11272258|NCT02889224|Active Comparator|Obese|Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
11272111|NCT02890199|Active Comparator|Lidocaine group|0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy
11272112|NCT02890199|Experimental|Bupivacaine liposomal group|1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy
11272113|NCT02890186|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
11272114|NCT02890186|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
11272115|NCT02890173|Experimental|CS-3150 2.5 mg|CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
11272116|NCT02890173|Experimental|CS-3150 5.0 mg|CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
11272117|NCT02890173|Active Comparator|Eplerenone|Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks
11272118|NCT02890160|Experimental|Firesorb|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
11272119|NCT02890160|Active Comparator|XIENCE|Implantation of the XIENCE Everolimus Eluting Coronary Stent System
11272120|NCT02890108|Experimental|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
11272121|NCT02890108|Experimental|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
11272122|NCT02890095|Experimental|Arm A = Breast Cancer surgery|Arm A : women undergoing breast cancer surgery.
11272123|NCT02890095|Other|Arm B = Control (plastic surgery)|Arm B : women undergoing breast surgery for the purpose of plastic surgery
11272124|NCT02890082|Experimental|Tamoxifen stim in early follicular phase|Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
11272125|NCT02890082|Other|Tamoxifen stim in late follicular phase|Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
11272126|NCT02890082|Other|Tamoxifen stim in luteal phase|Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
11272127|NCT02890069|Experimental|CRC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
11272128|NCT02890069|Experimental|NSCLC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
11272129|NCT02890069|Experimental|TNBC - PDR001 + LCL161|Enrollment to this combination arm is closed to further enrollment.
11272130|NCT02890069|Experimental|CRC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
11272131|NCT02890069|Experimental|NSCLC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
11272132|NCT02890069|Experimental|TNBC - PDR001+ Everolimus|Enrollment to this combination arm is closed to further enrollment.
11272133|NCT02890069|Experimental|CRC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
11272134|NCT02890069|Experimental|NSCLC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
11272135|NCT02890069|Experimental|TNBC - PDR001 + Panobinostat|Enrollment to this combination arm is closed to further enrollment.
11272136|NCT02890069|Experimental|CRC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
11272137|NCT02890069|Experimental|TNBC - PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
11272138|NCT02890069|Experimental|NSCLC- PDR001 + QBM076|Enrollment to this combination arm is closed to further enrollment.
11272139|NCT02890069|Experimental|CRC - PDR001 + HDM201|Dose escalation completed, expansion arm.
11272140|NCT02890069|Experimental|RCC - PDR001 + HDM201|Dose escalation completed, expansion arm.
11272141|NCT02890056|Experimental|H2GO! intervention|H2GO! is a community-based behavioral intervention to reduce sugar-sweetened beverage consumption and promote water intake among school-age youth and parents.The intervention consists of 6 weekly group-based sessions (1-hour sessions twice a week) that target beverage knowledge, attitudes, and behaviors through interactive activities, youth-produced narratives, and parent-child activities. The intervention is delivered through a youth-based community setting (Boys and Girls Clubs of America) by trained Boys and Girls Club staff.
11272142|NCT02890056|No Intervention|Comparison|Usual care will take place at the comparison site (standard programming at the Boys and Girls Club comparison site).
11272143|NCT02890043|Experimental|Robot|Intervention: Surgery: robot-assisted spine surgery, device: TiRobot surgery system
11272144|NCT02890043|Active Comparator|Free-hand|Intervention: Surgery: free-hand surgery
11272145|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
11272146|NCT02890017|Experimental|Hotel-Ambu|Outpatient surgery with a patient-hotel night
11272147|NCT02890017|Other|conventional hospitalization|conventional hospitalization
11272148|NCT02889991|Experimental|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
11272149|NCT02889991|Experimental|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
11272150|NCT02889991|Experimental|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
11272151|NCT02889991|Sham Comparator|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
11272152|NCT02889978||Cancer arm|Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
11272153|NCT02889978||Non-cancer arm|Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
11272154|NCT02889965||Radiologically Isolated Syndromes (RIS)|
11272155|NCT02889965||Clinically Isolated Syndromes (RIS)|
11272157|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
11272158|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
11272159|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
11272160|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
11272161|NCT02889939|Other|UC + ETT|"An enriched comprehensive task-specific therapy (ETT) program combining intensive and task-specific therapy with the sensory-motor, social, and cognitive stimulation inherent to environmental enrichment.
~The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control."
11272162|NCT02889926|Experimental|a swab according to the method of Levine|
11272163|NCT02889926|Experimental|Bacteriological referred to biopsy|
11272164|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
11272165|NCT02889887||preterm|infants who born before 37 completed weeks
11272166|NCT02889874|No Intervention|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
11272167|NCT02889874|Experimental|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
11272168|NCT02889861|Experimental|Regimen 1|IMCgp100 (77 kDa bi-specific protein) weekly dosing regimen (QW)
11272169|NCT02889848|Sham Comparator|Saline only|Injection of saline to assess the injection procedure
11272170|NCT02889848|Experimental|1.16 mg EN3835|Injection of maximum marketed dose of EN3835 regardless of fibroid size
11272171|NCT02889848|Experimental|Dose 1|Injection of 0.05 mg EN3835 per cm3 fibroid
11272172|NCT02889848|Experimental|Dose 2|Injection of 0.1 mg EN3835 per cm3 fibroid
11272173|NCT02889848|Experimental|Dose 3|Injection of 0.2 mg EN3835 per cm3 fibroid
11272174|NCT02889835|Active Comparator|Universal Composite|Supreme Universal Restorative
11272175|NCT02889835|Experimental|Flowable Composite|Supreme Flowable Restorative
11272176|NCT02889835|Experimental|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
11272177|NCT02889822|Experimental|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd
~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
11272178|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
11272179|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
11272180|NCT02889796|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B + placebo to match adalimumab in addition to a stable dose of MTX
11272181|NCT02889796|Experimental|Filgotinib Dose B|Filgotinib dose B + placebo to match filgotinib dose A + placebo to match adalimumab in addition to a stable dose of MTX
11272182|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + adalimumab in addition to a stable dose of MTX
11272183|NCT02889796|Placebo Comparator|Placebo|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + placebo to match adalimumab in addition to a stable dose of MTX
11272184|NCT02889757|Experimental|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
11272185|NCT02889757|Experimental|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
11272186|NCT02889757|Placebo Comparator|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
11272187|NCT02889744|Active Comparator|36-TH|Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
11272188|NCT02889744|Active Comparator|33-TH|Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
11272189|NCT02889718|Experimental|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
11272190|NCT02889692|Experimental|TCM granules plus EGFR-TKIs|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day，until progression or unacceptable toxicity."
11272191|NCT02889692|Placebo Comparator|Placebo granules plus EGFR-TKIs|Placebo granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day until progression or unacceptable toxicity.
11272311|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
11272192|NCT02889679|Experimental|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
11272193|NCT02889679|Active Comparator|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
11272194|NCT02889666|Experimental|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
11272195|NCT02889666|Experimental|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
11272196|NCT02889666|Experimental|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
11272197|NCT02889666|Experimental|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
11272198|NCT02889666|Experimental|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
11272199|NCT02889666|Experimental|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
11272200|NCT02889666|Experimental|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
11272201|NCT02889666|Placebo Comparator|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
11272202|NCT02889640|No Intervention|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
11272203|NCT02889640|Experimental|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
11272204|NCT02889640|Experimental|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
11272205|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo repeated FMT with ~50ml microbiota suspension.
11272206|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
11272207|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
11272208|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
11272209|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.
~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
11272210|NCT02889549|Experimental|Ticagrelor 22.5 mg|Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
11272211|NCT02889549|Experimental|Ticagrelor 45 mg|Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
11272212|NCT02889549|Experimental|Ticagrelor 90 mg|Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
11272213|NCT02889549|Active Comparator|Clopidogrel|Clopidogrel (75mg, once daily, oral) treatment for 1 month.
11272214|NCT02889536||Focus group interview, stoma clinics|Qualitative data collection. Patients attending stoma clinics in the capital region
11272215|NCT02889536||Focus group interview, referred|Qualitative data collection. Patients referred to repair surgery at a specific hospital in the capital region
11272216|NCT02889523|Experimental|DLBCL cohort|"RCHOP + tazemetostat:
~- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days
~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
~Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
11272217|NCT02889523|Experimental|FL cohort|"RCHOP + tazemetostat:
~Induction
~RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):
~6 cycles, every 21 days
~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days
~Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID
~Maintenance
~Tazemetostat : 6 months (every 8 weeks)
~Rituximab : 24 months (every 8 weeks)"
11272218|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
11272219|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
11272220|NCT02889497|Experimental|300 subjects receive the first batch vaccine|300 subjects will be randomly received the first batch vaccine
11272221|NCT02889497|Experimental|300 subjects receive the second batch vaccine|300 subjects will be randomly received the second batch vaccine
11272222|NCT02889497|Experimental|300 subjects receive the third batch vaccine|300 subjects will be randomly received the third batch vaccine
11272223|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
11272224|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
11272225|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
11272226|NCT02889471|Experimental|ERCP with nasobiliary catheter|
11272227|NCT02889471|Active Comparator|ERCP only|
11272228|NCT02889458||Case|"Inclusion Criteria
~Female
~aged 18 or above
~Chinese
~Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)
~Able to speak Cantonese
~Newly diagnosed with breast cancer or DCIS in 24 weeks
~Exclusion Criteria
~- Undergoing treatment for any non-breast cancer
~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
11272229|NCT02889458||Control|"Inclusion Criteria
~Female
~aged 18 or above
~Chinese
~Usually residing in Hong Kong
~Able to speak Cantonese
~Exclusion Criteria
~- History of any cancer
~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
11272230|NCT02889432|Experimental|Melatonin|Oral Melatonin 10mg Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
11272231|NCT02889432|Placebo Comparator|Placebo|Placebo tabs Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
11272232|NCT02889419|Experimental|Evaluation of underwear Selfia®|Every patient is his own control.
11272233|NCT02889406|Experimental|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.
~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
11272234|NCT02889406|No Intervention|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
11272235|NCT02889393|No Intervention|Standard of care|The usual standard of care for the treatment of enterocutaneous fistulas includes meticulous wound care, optimization of nutrition (either parenteral or enteral), use of acid-suppression medications such as histamine receptor antagonists or proton-pump inhibitors, and anti-motility agents such as loperamide.
11272236|NCT02889393|Experimental|teduglutide plus standard of care|In addition to all the standard of care treatments, experimental therapy will include a daily subcutaneous injection to 0.05 mg/kg of teduglutide.
11272237|NCT02889380||Cetrotide|This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome.
11272238|NCT02889367|Experimental|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
11272239|NCT02889367|Experimental|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
11272240|NCT02889367|Experimental|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
11272241|NCT02889354|Experimental|Cognitive-behavioral therapy|
11272242|NCT02889341|Placebo Comparator|Placebo|Placebo
11272243|NCT02889341|Active Comparator|500 mg DHA/day|500 mg DHA/day
11272244|NCT02889341|Active Comparator|1g DHA/day|1g DHA/day
11272245|NCT02889341|Active Comparator|2g DHA/day|2g DHA/day
11272246|NCT02889328|Experimental|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
11272247|NCT02889302|Experimental|KPS-0373|
11272248|NCT02889302|Placebo Comparator|Placebo|
11272249|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
11272250|NCT02889276|Active Comparator|Control|Unsupervised activity
11272251|NCT02889276|Experimental|Functional Resistance Training (FRT)|Supervised, group-based functional resistance training
11272252|NCT02889250|Experimental|Open Label DBS|6 months of DBS
11272253|NCT02889237|No Intervention|Standard care|Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
11272254|NCT02889237|Active Comparator|Calcium|Immediate administration of daily calcium supplementation (1000 mg calcium)
11272255|NCT02889237|Active Comparator|Calcium and low dose vitamin D|Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
11272256|NCT02889237|Active Comparator|Calcium and high dose vitamin D|Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
11272261|NCT02889224|Experimental|Control|Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
11272262|NCT02889211|Active Comparator|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
11272263|NCT02889211|Experimental|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
11272264|NCT02889211|Experimental|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
11272265|NCT02889211|Experimental|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
11272266|NCT02889198|Experimental|Intervention group|Centers in this group will be granted immediate access to the Go NAP SACC website following randomization with minimal support from a local technical assistance provider. The center director will have 4 months to use Go NAPSACC tools.
11272267|NCT02889198|No Intervention|Control group|During the study, centers in this group will receive no intervention. However, they will be granted delayed access to the Go NAP SACC website and technical assistance support after post-intervention measures are collected.
11272268|NCT02889185|Experimental|Adaptative optics retinal camera|
11272269|NCT02889172|Experimental|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
11272270|NCT02889172|No Intervention|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
11272271|NCT02889159|Other|Candida albicans antigen|useful in measuring the capacity of a person to manifest a delayed-type hypersensitivity response
11272272|NCT02889159|Other|histamine phosphate|useful to assess type I IgE-mediated hypersensitivity reactions
11272273|NCT02889159|Other|imiquimod 5% cream|direct stimulator of TLR-7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response
11272274|NCT02889159|Other|tape stripping|to create alterations in key inflammatory mediators involved in both the innate and adaptive immune responses
11272275|NCT02889159|No Intervention|Control|control sample from both sun exposed and non-sun exposed skin
11272276|NCT02889146|Active Comparator|Control group|Conventional Physical Therapy: motor physical therapy delivered by the intensive care unit physical therapists, according to his own criteria, without following any protocol. Respiratory therapy.
11272277|NCT02889146|Experimental|Protocol group|Early and progressive mobilization program: motor physical therapy delivered by a trained physical therapist according to the mobilization protocol, in which patient progress according to his performance. Respiratory therapy.
11272278|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
11272279|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
11272280|NCT02889107|No Intervention|standard care|Patients received standard listening strategies for 10 weeks
11272281|NCT02889107|Experimental|intervention|Patients received an assistive listening device (personal frequency modulated systems) for 10 weeks
11272282|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
11272283|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
11272284|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
11272285|NCT02889068||Intellectual disability|
11272286|NCT02889042|Experimental|Volunteers repeated drug poisoning|performing MRI and a biological assessment
11272287|NCT02889042|Other|Volunteers single drug poisoning|performing MRI and a biological assessment
11272288|NCT02889042|Other|alcoholic|performing MRI and a biological assessment
11272289|NCT02889042|Other|volunteers|performing MRI and a biological assessment
11272290|NCT02889029|Experimental|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
11272291|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
11272292|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
11272293|NCT02889003|Experimental|CML patients following molecular response loss|
11272294|NCT02888990|Experimental|Treatment Arm|standard treatment + dasatinib
11272295|NCT02888964|Experimental|ACTOS treatment|Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events
11272296|NCT02888951||Diabetic Group|A group of diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
11272297|NCT02888951||Non-Diabetic Group|A group of non-diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
11272298|NCT02888938||Patients suspected of SpA|
11272299|NCT02888925|Other|Epilepsy|Patients do face specific tests during conventional pre-lobectomy intercritical assessment hospitalization (inclusion, day 0) and after 6 and 18 months from anterior temporal lobectomy
11272300|NCT02888925|Other|Control|Control individuals do face specific tests during inclusion visit (day 0) and after X months (X = time from day 0 and lobectomy of matched patient + 6 months)
11272301|NCT02888912|Active Comparator|EQUIA|randomly applied
11272302|NCT02888912|Active Comparator|Gradia Direct Posterior|randomly applied
11272303|NCT02888899|Experimental|Standard treatment|
11272304|NCT02888899|Experimental|PTNS in addition to standard treatment|
11272305|NCT02888886|Experimental|COPD|
11272306|NCT02888873|Active Comparator|Charisma|applied randomly
11272307|NCT02888873|Active Comparator|Charisma classic|applied randomly
11272308|NCT02888860||Group 1|Patients with candidemia
11272315|NCT02888834||Adverse drug reaction|Patients aged over 65 years who presented a serious adverse drug reaction notified to the Regional Pharmacovigilance Center of Champagne-Ardenne between January and May 2013 were included in the study.
11272316|NCT02888821|Experimental|CLS-FUERTE|Families will receive the CLS-FUERTE intervention in the fall of the 2016-2017 school year. CLS-FUERTE includes caretaker, child and teacher components implemented during a 6 week period. All content of group sessions will be derived from the manualized CLS-FUERTE treatment protocol developed by the PI and study staff.
11272317|NCT02888821|Other|Business as Usual (BAU) Waitlist Control|Families will receive school services as usual while on a waitlist to receive CLS-FUERTE in the spring of the 2016-2017 school year.
11272318|NCT02888808||Erosive GERD|Gastroscopy examination.
11272319|NCT02888808||Control population|Gastroscopy examination.
11272320|NCT02888795|Experimental|hypertonic dextrose prolotherapy|
11272321|NCT02888782|Experimental|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
11272322|NCT02888782|No Intervention|Control|Receive regular physician follow up
11272323|NCT02888769|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week.
11272324|NCT02888769|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
11272325|NCT02888756|Experimental|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
11272326|NCT02888756|Active Comparator|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
11272327|NCT02888756|Placebo Comparator|Placebo|Water for injection 3 vaccinations, two weeks interval
11272328|NCT02888743|Experimental|Arm A (tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.
11272329|NCT02888743|Experimental|Arm B (tremelimumab, Durvalumab, RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
11272330|NCT02888743|Experimental|Arm C (tremelimumab, durvalumab, and RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
11272331|NCT02888730|Experimental|Tobramycin nebulized nasally|Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
11272332|NCT02888730|Placebo Comparator|Physiologic serum nebulized nasally|Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days
11272333|NCT02888717|Experimental|OSNA stadification during surgery|The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and will be analysis both by histological analysis and OSNA analysis
11272334|NCT02888704|Experimental|intervention: Biological: ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.
~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
11272335|NCT02888691|Experimental|Low Carbohydrate Diet|< 100 grams of carbohydrate per day
11272336|NCT02888691|Experimental|High Carbohydrate Diet|> 250 grams of carbohydrate per day
11272337|NCT02888678|Experimental|ES + HIV Prevention|"Economic Strengthening + HIV prevention education combined intervention consists of 2 parts.
~Impumelelo: This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
~Vhutshilo 2.2: . This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy."
11272338|NCT02888678|Experimental|ES only|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
11272339|NCT02888678|Experimental|HIV only|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
11272340|NCT02888678|No Intervention|No intervention (control)|The control group will not receive the ES or HIV prevention interventions. They will receive the basic package of services available to all beneficiaries of Future Families.
11272341|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11272342|NCT02888613|Other|Mini laparotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with transperitoneal approach
11272343|NCT02888613|Other|Mini lumbotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with retroperitoneal approach
11272344|NCT02888600|Active Comparator|Mindfulness Training|The Mindfulness Meditation Program consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily mindfulness meditation homework.
11272345|NCT02888600|Active Comparator|Health Education|The Health Education Program also consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily health practice homework
11272346|NCT02888587||Control group|no gastrointestinal symptoms
11272347|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
11272349|NCT02888574|Placebo Comparator|Placebo|Placebo nasal spray containing the same ingredients as the active nasal spray minus the oxytocin and packaged in an identical bottle. To be delivered bi-daily over a 14-day period at 24-IU per dose
11272350|NCT02888548|Experimental|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
11272351|NCT02888548|Experimental|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
11272352|NCT02888509||healthy control|Well mathed with patients in age, gender, education
11272353|NCT02888509||major depression disorder|patients with major depression disorder
11272354|NCT02888509||anxiety disorder|patients with anxiety disorder
11272355|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
11272356|NCT02888496||PMR patients|Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
11272357|NCT02888496||Healthy controls|Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease
11272358|NCT02888457|Other|AOM (acute otitis media)|Infants (6-30 months of age) with acute otitis media
11272359|NCT02888457|Other|DCC (day-care centers)|Healthy infants (6-30 months of age) attending day-care centers
11272360|NCT02888444|Active Comparator|Varenicline plus behavioural support|12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
11272361|NCT02888444|Placebo Comparator|Placebo plus behavioural support|12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support
11272362|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
11272363|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
11272364|NCT02888418|Experimental|One dose of HPV vaccine in women aged 18 to 30|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 18 to 30.
11272365|NCT02888418|Placebo Comparator|Placebo in women aged 18 to 30|Placebo in women aged 18 to 30.
11272366|NCT02888418|Experimental|One dose of HPV vaccine in women aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 9 to 17.
11272367|NCT02888418|Placebo Comparator|Placebo in women aged 9 to 17|Placebo in women aged 9 to 17.
11272368|NCT02888418|Experimental|One dose of HPV vaccine in men aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in men aged 9 to 17.
11272369|NCT02888418|Placebo Comparator|Placebo in men aged 9 to 17|Placebo in men aged 9 to 17.
11272370|NCT02888405|Experimental|High-carbohydrate diet|Single day of 9 g/kg body weight consumption of carbohydrate. Isocaloric to very low-carbohydrate condition.
11272371|NCT02888405|Experimental|Very low-carbohydrate diet|Single day of 1 - 1.5 g/kg body weight consumption of carbohydrate. Isocaloric to high-carbohydrate condition.
11272372|NCT02888392|Experimental|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
11272373|NCT02888392|Active Comparator|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
11272374|NCT02888379|Experimental|TOP1288 200 mg Rectal Solution|TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks
11272375|NCT02888379|Placebo Comparator|Placebo Rectal Solution|Placebo (for TOP1288) Rectal Solution Once Daily for 4 Weeks
11272376|NCT02888366||1|Breath samples taken, no treatment given.
11272377|NCT02888353|Experimental|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).
~Patients will not be pre-screened prior to hospital visit."
11272378|NCT02888340|Experimental|Acupuncture|One session of acupuncture prior to receiving pain medications after arriving to the emergency department with pain as a symptom.
11272379|NCT02888340|No Intervention|Usual Care|Usual care for pain, without intervention, after arriving to the emergency department with pain as a symptom.
11272380|NCT02888327|Other|Oseltamivir and AL-794|Oseltamivir alone and with AL-794 over fourteen days.
11272381|NCT02888327|Other|Digoxin, Midazolam, and AL-794|Single doses of Digoxin and Midazolam with and without AL-794 over seventeen days.
11272382|NCT02888327|Other|Pitavastatin and AL-794|Single doses of Pitavastatin with and without AL-794 over seventeen days.
11272383|NCT02888327|Other|JNJ-63623872 and AL-794|JNJ-63623872 alone and with AL-794 over fourteen days.
11272384|NCT02888301||Basic science (18F-clofarabine biodistribution)|Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
11272385|NCT02888288|Experimental|Mental Health Intervention|This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
11272386|NCT02888288|Active Comparator|Standard of Care|This arm includes standard medical care and adherence counseling with routine education prior to the start of the HIV youth clinic from which participants are recruited.
11272387|NCT02888275|Experimental|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
11272388|NCT02888275|Active Comparator|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
11272389|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
11272390|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
11272391|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
11272392|NCT02888249|Experimental|Cigarette W|"Altered composition cigarettes
~moisture = 12.20 %, tar = 10.40 mg/cigarette, total particulate matter = 12.0 mg/cigarette, high sugar content"
11272393|NCT02888249|Experimental|Cigarette X|"Altered composition cigarettes
~moisture = 12.10 %, tar = 8.60 mg/cigarette, total particulate matter = 9.60 mg/cigarette, low sugar content"
11272925|NCT02883972|Experimental|Intervention letter|Behavioural insights informed invitation letter only
11272394|NCT02888249|Experimental|Cigarette Y|"Altered composition cigarettes
~moisture = 13.20 %, tar = 9.10 mg/cigarette, total particulate matter = 10.10 mg/cigarette, low sugar content"
11272395|NCT02888249|Experimental|Cigarette Z|"Altered composition cigarettes
~moisture = 13.60 %, tar = 8.10 mg/cigarette, total particulate matter = 9.10 mg/cigarette, low sugar content"
11272396|NCT02888236|Experimental|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
11272397|NCT02888236|Placebo Comparator|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
11272398|NCT02888223|Experimental|Group A|a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)
11272399|NCT02888223|Experimental|Group B|a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)
11272400|NCT02888210|Experimental|MD-15|Investigational intraocular lens
11272401|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
11272402|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
11272403|NCT02888158|Active Comparator|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.
~Intervention: Pelvic Trainer"
11272404|NCT02888158|Experimental|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.
~Intervention: Robotic assistance
~Intervention: Pelvic Trainer"
11272405|NCT02888132|Experimental|Hypertrophic Obstructive Cardiomyopathy|
11272406|NCT02888119|Active Comparator|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
11272407|NCT02888119|Active Comparator|Mild Osteoarthritis|
11272408|NCT02888119|Active Comparator|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
11272409|NCT02888106|Active Comparator|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
11272410|NCT02888106|Experimental|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
11272411|NCT02888106|Experimental|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
11272412|NCT02888106|Experimental|Arm D|Myrcludex B 2 mg for 48 weeks
11272413|NCT02888106|Experimental|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
11272414|NCT02888106|Experimental|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
11272415|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
11272416|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
11272417|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
11272418|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
11272419|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.
~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
11272420|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.
~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
11272421|NCT02888054|Experimental|Sequence ABBA|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
11272422|NCT02888054|Experimental|Sequence BABA|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
11272423|NCT02888054|Experimental|Sequence ABAB|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
11272424|NCT02888054|Experimental|Sequence BAAB|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
11272425|NCT02888041|Experimental|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
11272426|NCT02888041|Active Comparator|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
11272427|NCT02888028|Active Comparator|ICD remote monitoring|Active Comparator: ICD remote monitoring additionally to regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement
11272428|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
11272967|NCT02883621|Active Comparator|Group A|subjects receive standard upper endoscopy
11272429|NCT02888015|Other|Upper extremity exercise|Five upper extremity exercises will be provided to each of the 10 participants to complete on a daily basis. Exercises included shoulder flexion, elbow flexion/extension, shoulder abduction, internal/external rotation
11272430|NCT02888002|Experimental|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
11272431|NCT02888002|Experimental|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
11272432|NCT02887989|Experimental|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
11272433|NCT02887989|Sham Comparator|'Health and Wellness Channel'|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
11272434|NCT02887976|Experimental|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)
11272435|NCT02887950|Active Comparator|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
11272436|NCT02887950|Experimental|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.
~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
11272437|NCT02887950|Experimental|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.
~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
11272438|NCT02887937||Breast Mass 4a-cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
11272439|NCT02887937||Breast Mass 4a- non cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
11272440|NCT02887937||Breast Mass 4b|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
11272441|NCT02887937||Breast Mass 4c|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
11272442|NCT02887924|Active Comparator|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
11272443|NCT02887924|Placebo Comparator|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
11272444|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
11272445|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
11272446|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
11272447|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
11272448|NCT02887898|Active Comparator|Carb counting and bolus calculator|Education in carb counting and the use of an automated bolus calculator
11272449|NCT02887898|Placebo Comparator|Carb counting|Education in carb counting and manual calculation of insulin bolus
11272450|NCT02887872|Experimental|Pilot data|Four participants with chronic stroke participated in a 45-minute combined electrical stimulation-dynamic hand orthosis regimen using the affected upper extremity (UE) 5X/week for 6 weeks.
11272451|NCT02887859|Experimental|HAV Treatment|Human Acellular Vessel (HAV)
11272452|NCT02887846|Active Comparator|group 1|Heated humidified high-flow nasal cannula therapy device for post extubation
11272453|NCT02887846|Active Comparator|group 2|Nasal continuous positive airway pressure for post extubation
11272968|NCT02883621|Experimental|Group B|subjects receive cap assisted upper endoscopy
11272454|NCT02887833||XRT for Cancer induced bone pain|Will have community based assessment before and after radiotherapy to assess feasibility of using a clinical biomarker (thermal sensory testing) to predict treatment response
11272455|NCT02887820|Other|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
11272456|NCT02887807|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
11272457|NCT02887807|Placebo Comparator|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
11272458|NCT02887794|Experimental|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
11272459|NCT02887768|Experimental|Treatment|Epicardial Infarct Repair with CorMatrix-ECM in addition to coronary artery bypass grafting
11272460|NCT02887755|Experimental|Amputee Group|In this study n=20 returning US military combatants between 18 and 45 years of age who have unilateral transtibial or transfemoral amputation will be asked to perform two aerobic exercise tests while we4aring the NIRS sensor. Subjects must be medically cleared and able to complete approximately 30 minutes of physical activity.
11272461|NCT02887703|Experimental|Sensory Augmentation Group 1|Each subject in Group 1 will undergo 6 weeks of balance training with sensory augmentation followed by 6 weeks of balance training without sensory augmentation.
11272462|NCT02887703|Experimental|Sensory Augmentation Group 2|Each subject in Group 2 will undergo 6 weeks of balance training without sensory augmentation followed by 6 weeks of balance training with sensory augmentation.
11272463|NCT02887690|Experimental|Modular Prosthetic Limb|The Defense Advanced Research Projects Agency's (DARPA) advanced upper limb prosthesis, the Modular Prosthetic Limb (MPL)
11272464|NCT02887677|Active Comparator|Dapagliflozin|Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
11272465|NCT02887677|Placebo Comparator|Placebo|Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
11272466|NCT02887664||Blood test in Mothers of SGA Infants|In mothers of Small for Gestational Age (SGA) Infants, maternal and cord blood test will be performed
11272467|NCT02887664||Blood test in Mothers of AGA infants|In mothers of Appropriate for Gestational Age (AGA) Infants, maternal and cord blood test will be performed
11272468|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
11272469|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
11272470|NCT02887638|Experimental|headache|Patients diagnosed (neurologist - anesthesiologist - manual therapist) with tension-type and/or cervicogenic headache. During a first phase the sitting-posture, dura mater profile and pain-profile of the Headache-group will be analyzed. In a second phase, the patients will be sub-classified according to the data-analysis and receive intervention (Individual Profile Analysis +Physical therapy Intervention)
11272471|NCT02887638|No Intervention|asymptomatic controls|Asymptomatic controls, matched for gender and age. During a first phase the sitting-posture, dura mater profile and pain-profile of the control-group will be analyzed.
11272472|NCT02887625|Experimental|Combination Therapy|pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week
11272473|NCT02887625|Active Comparator|Insulin Therapy|"insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) <110 mg/dl.
~and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c <7.0% and postprandial plasma glucose (PPG) <140 mg/dl"
11272474|NCT02887599|Other|Patient Group|Pancreatic cancer patients
11272475|NCT02887599|Other|Control Group|Healthy people without evidence of malignancy
11272476|NCT02887586|Experimental|Auricular Needling group|Patients will receive auricular needling for 4 weeks .
11272477|NCT02887586|No Intervention|control group|This group will receive no treatment. Subjects will be assessed at baseline and the 2th, 4th and 8th week.
11272478|NCT02887573|Experimental|Free-residue nutrients+PEG|"Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.
~Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.
~Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy."
11272479|NCT02887573|Experimental|Low fiber diet+PEG|"Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.
~Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.
~Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.
~Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy."
11272480|NCT02887560|Experimental|All patient|Only one arm has been specified for the protocol. This arm included all study patient (33) for which the intervention is to be administered
11272481|NCT02887547|No Intervention|Control|Control group, with traditional orthodontic mechanics for anterior retraction. Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
11272563|NCT02886884|Experimental|20 million allogeneic hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
11272482|NCT02887547|Experimental|Acceleration|Group with micro-osteoperforation for accelerated tooth movement during anterior retraction, Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
11272483|NCT02887534|Experimental|Arm 1|three times medication; SPARC1401-low dose
11272484|NCT02887534|Experimental|Arm 2|three times medication; SPARC1401-mid dose
11272485|NCT02887534|Experimental|Arm 3|three times medication; SPARC1401-high dose
11272486|NCT02887534|Active Comparator|Active comparator|Reference1401; To be administered 3 times a day
11272487|NCT02887534|Placebo Comparator|Arm 5|Placebo1401 - 3 three times a day
11272488|NCT02887521|Experimental|Pulmonary Rehabilitation (PR)|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
11272489|NCT02887521|Active Comparator|Standard of Care|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
11272490|NCT02887508|Experimental|HINTS Intervention|The HINTS intervention consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills related to a specific topic relevant to online partner seeking and transmission risk reduction, including Internet safety and communication, condom negotiation, and serostatus disclosure.
11272491|NCT02887508|Active Comparator|Healthy Living Control|The Healthy Living Control condition consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills to address non-sexual health-related topics particularly relevant to individuals living with HIV, such as nutrition, healthy eating, portion control, exercise and staying active, and stress reduction.
11272492|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
11272493|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
11272494|NCT02887469|Active Comparator|Intermittent bolus group|"<<Within 6hr>>
~Moderately Severe : 3% saline 2ml/kg over 20min *1 (unknown bwt 100ml)
~Severe :3% saline 2ml/kg over 20min *2 (unknown bwt 100ml)
~<additional treatment> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief
~<<During 6-24hr>>
~- Moderately Severe or Severe
~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief
~<<During 24-48hr>>
~Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief"
11272495|NCT02887469|Active Comparator|slow continuous infusion group|"<<Within 24hr>>
~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)
~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)
~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)
~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na
~if △ Na inc <0.5mmol/hr or △ Na inc <3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped
~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr
~: maintain infusion rate
~<<During 24-48hr>>
~- Moderately Severe and Severe
~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)
~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief
~: stop 3% saline infusion regardless of △ Na
~if △ Na inc <1.5mmol/6hr
~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped
~if △ Na inc ≥ 1.5mmol/6hr
~: maintain infusion rate"
11272496|NCT02887456|Active Comparator|Vitapex|Endodontic treatment using Vitapex
11272497|NCT02887456|Experimental|MTA paste|Endodontic treatment using MTA paste
11272498|NCT02887430|Experimental|intervention|Participants will be received 8 sessions of foot reflexology therapy, 30 minutes each (2 sessions per week of 4 weeks) and low back pain standard care
11272499|NCT02887430|No Intervention|control|participants will be received standard care in general practice
11272500|NCT02887417||patients|glioblastoma patients
11272501|NCT02887417||controls|healthy controls
11272502|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).
~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).
~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
11272503|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).
~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).
~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
11272504|NCT02887391||Conventional Hemodialysis|Control group 4 hours of hemodialysis 3x per week (12 hours hemodialysis/week)
11272505|NCT02887391||In-Centre Nocturnal Hemodialysis|8 hours of hemodialysis 3x per week (24 hours hemodialysis/week)
11272506|NCT02887378|Experimental|hot clamps|reusable hot biopsy forceps
11272507|NCT02887378|Active Comparator|normal clamps|normal clamps
11272510|NCT02887339|Experimental|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
11272511|NCT02887339|Experimental|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
11272512|NCT02887326||age 15-25 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
11272513|NCT02887326||age 25-35 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
11272514|NCT02887326||age 35-45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
11272515|NCT02887326||> age 45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
11272516|NCT02887313|Experimental|Locally advanced rectal cancer|Locally advanced rectal cancer receiveing total neoadjuvant treatment
11272517|NCT02887300|No Intervention|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:
~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
11272518|NCT02887300|Experimental|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.
~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:
~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
11272519|NCT02887261|Other|Power Port|patients who received power injectable port
11272520|NCT02887261|Active Comparator|Conventional Port|patients who received conventional port ( not power injectable)
11272521|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.
~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
11272522|NCT02887235|No Intervention|Standard of Care (SOC) Meals|Patient assigned in this arm will receive standard of care nutritional services including nutrition consult, evaluation, and as needed follow-ups.
11272523|NCT02887235|Active Comparator|Medically tailored meals|Patient assigned in this arm will receive home delivered, medically tailored meals (HDMTM) in addition to the standard nutritional care.
11272524|NCT02887222|Active Comparator|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11272525|NCT02887222|Active Comparator|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11272526|NCT02887222|Active Comparator|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11272527|NCT02887222|Active Comparator|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11272528|NCT02887222|Active Comparator|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11272529|NCT02887222|Active Comparator|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11272530|NCT02887209|Experimental|CBT-I|This is a single arm study in which all participants receive the intervention (cognitive behavioural therapy for insomnia)
11272531|NCT02887183|Other|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).
~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
11272532|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).
~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia
~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.
~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
11272561|NCT02886910|Active Comparator|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
11272669|NCT02885987|No Intervention|Standard Colonoscopy|AmplifEYE will not be used.
11272533|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.
~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.
~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.
~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
11272534|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:
~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.
~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.
~Ocular and systemic health data will be extracted from the study participant's medical record."
11272535|NCT02887144|Experimental|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:
~SenSura test product
~SenSura"
11272536|NCT02887144|Experimental|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:
~SenSura
~SunSura test product"
11272537|NCT02887131|Experimental|Healthy volunteers|
11272538|NCT02887131|Experimental|Arthritis|
11272539|NCT02887131|Experimental|Instability|
11272540|NCT02887118||Common arm|Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated
11272541|NCT02887105||Patients with cerebrovascular accident|
11272542|NCT02887066||Patients with thoracic pain and suspicion of ACS|
11272543|NCT02887053|Experimental|All subjects|All subjects will have an MRI examination
11272544|NCT02887040|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
11272545|NCT02887040|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
11272546|NCT02887027|Experimental|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
11272547|NCT02887027|Experimental|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
11272548|NCT02887027|Experimental|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
11272549|NCT02887014|Experimental|Group A|Participants getting SPECIFIC VERBAL INSTRUCTIONS before starting bowel preparation (Group A).
11272550|NCT02887014|No Intervention|Group B|Participants getting ordinary instructions as usual in each of the participating centers (Group B).
11272551|NCT02887001|Other|BMO|
11272552|NCT02886988|Experimental|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
11272553|NCT02886988|Placebo Comparator|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
11272554|NCT02886975|Experimental|low protein diet plus α-keto acid|A comparison of normal diet and low protein diet plus α-keto acid after intervention in the same individual
11272555|NCT02886962|Experimental|No anticoagulation|No oral anticoagulation, and no monitoring of the INR.
11272556|NCT02886962|Active Comparator|Oral anticoagulation with vitamin K antagonists|"VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.
~Antiplatelet therapy will be provided only if recent acute coronary syndrome (< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population."
11272557|NCT02886936|Experimental|iFIT Group|This is a feasibility and effectiveness study to assess the iFIT transtibial and transfemoral prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
11272558|NCT02886923|Experimental|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
11272559|NCT02886923|Active Comparator|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
11272560|NCT02886910|Experimental|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
11272562|NCT02886897|Experimental|D-CIK and anti-PD-1 Immunotherapy|D-CIK was incubated with anti-PD-1 antibody before infused back into participants
11272564|NCT02886884|Experimental|100 million hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
11272565|NCT02886871|Experimental|Personalized Steps Goal|Step Goal Delivery by Smartphone
11272566|NCT02886871|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
11272567|NCT02886858|Experimental|tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
11272568|NCT02886858|Sham Comparator|Sham tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
11272569|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
11272570|NCT02886845||healthy controls|Woman without breast cancer
11272571|NCT02886832|Experimental|Prostate Health formulation|Prostate Health formulation
11272572|NCT02886819|Experimental|WBV group|whole-body vibration (WBV) group
11272573|NCT02886806|Experimental|high risk vascular surgery|Patients scheduled for high risk vascular surgery under automated total closed loop intravenous anesthesia and fluid management
11272574|NCT02886793|Experimental|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
11272575|NCT02886780|Experimental|Concentrated Exposure Treatment (cET)|Please refer to:Havnen, A., Hansen, B., Öst, L.-G. & Kvale, G. Concentrated ERP delivered in a group setting: An effectiveness study. Journal of Obsessive Compulsive and Related Disorders 3, 319-324 (2014)
11272576|NCT02886780|Active Comparator|Self-help|"The self-help condition (SH):
~Foa, E.B. & Kozak, M.J. Mastery of obsessive-compulsive disorder: Client workbook, (Graywind Publications, New York, 1997)."
11272577|NCT02886780|No Intervention|Wait list|
11272578|NCT02886767|Experimental|skin-to-skin contact (SSC)|Experimental: a daily skin-to-skin contact (SSC) at least 15 minutes in length
11272579|NCT02886767|No Intervention|Control: hospital routine care|As the hospital routine. Allow the father to visit the neonate, touching the neonate
11272580|NCT02886754|Active Comparator|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
11272581|NCT02886754|Active Comparator|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
11272582|NCT02886754|Experimental|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
11272583|NCT02886741|Other|Quality Improvement Campaign|"IHI designed and encouraged implementation of a five-component enhanced surgical site infection (SSI) prevention bundle with three relatively new evidence-based practices and two Surgical Care Improvement Program (SCIP) practices.
~The campaign recruited state organizations to share information about evidence-based practices and publicize IHI activities and intervention materials (a How-to Guide, evidence reviews, a summary of the business case for interventions, and tip sheets for surgeons, other providers, patients and families). A project website and email listserv offered learning opportunities including webinar calls, faculty-led office hours, and town hall meetings."
11272584|NCT02886741|No Intervention|Comparison|Matched state pairs received no campaign intervention and experienced usual care
11272585|NCT02886728|Experimental|Filgotinib Dose A + MTX|Filgotinib dose A + placebo to match filgotinib dose B + MTX
11272586|NCT02886728|Experimental|Filgotinib Dose B + MTX|Filgotinib dose B + placebo to match filgotinib dose A + MTX
11272587|NCT02886728|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B + placebo to match MTX
11272588|NCT02886728|Active Comparator|MTX|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + MTX
11272589|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
11272590|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
11272591|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
11272592|NCT02886702|Experimental|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
11272593|NCT02886702|Active Comparator|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
11272594|NCT02886702|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
11272595|NCT02886689||1|patients will be those receiving any biotherapy
11272596|NCT02886689||2|patients will be those not receiving biotherapy : non indication, refusal, contraindication.
11272597|NCT02886676|Experimental|Spirulina capsules and scaling & root planing|Patients in test group will be provided with Spirulina capsules 2gm daily, after meals for 1 month
11272598|NCT02886676|Active Comparator|Placebo capsules and scaling & root planing|Patients in test group will be provided with placebo capsules after meals for 1 month
11272599|NCT02886663|Experimental|immediate rehabilitation|
11272600|NCT02886663|Other|delayed rehabilitation|
11272601|NCT02886650|Experimental|Thermocoagulation|
11272602|NCT02886637||Acinetobacter baumannii infection|Critically ill patients infect with Acinetobacter baumannii
11272603|NCT02886624|Experimental|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
11272604|NCT02886598||Firmagon®|Treatment according to standard clinical practice.
11272605|NCT02886585|Experimental|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases
~Baseline Brain MRI and PET CT
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.
~Brain MRI and PET/CT"
11272606|NCT02886585|Experimental|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases
~Baseline Brain MRI and PET CT
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.
~Brain MRI and PET/CT"
11272607|NCT02886585|Experimental|Neoplastic Meningitis-Cohort C|"Neoplastic Meningitis
~Histologically confirmed solid malignancy
~Positive Cytology
~Baseline Brain MRI
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.
~Brain MRI and PET/CT"
11272608|NCT02886585|Experimental|1-4 Brain Metastases from Melanoma Cohort D|"1-4 Brain Metastases from Melanoma
~Clinical indication for stereostatic radiosurgery
~Evaluable extracranial focus
~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.
~Brain MRI and PET CT"
11272609|NCT02886572|Experimental|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
11272610|NCT02886559|Experimental|DCCAG|Chidamide 30mg twice for one week decitabine 20mg/m^2 for 5 days
11272611|NCT02886520|Active Comparator|PVDF transobturator tape|Transobturator tension-free suburethral tape made of polyvinylidene fluoride.
11272612|NCT02886520|Active Comparator|PP transobturator tape|Transobturator tension-free suburethral tape made of polypropylene.
11272613|NCT02886507|Active Comparator|NSK-SD (nattokinase)|One capsule (100 mg) nattokinase/day for the 8-week study duration.
11272614|NCT02886507|Placebo Comparator|Placebo|One capsule placebo/day for the 8-week study duration.
11272615|NCT02886494|Active Comparator|BAC|
11272616|NCT02886494|Placebo Comparator|Matched vehicle|
11272617|NCT02886468|Experimental|ultrasound images|ultrasound images of the anterolateral aspect of the mid-right thigh
11272618|NCT02886455|Experimental|Cohort 4|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin at two different time points (4 and 24 hours).
~There are two visits:
~Visit 1:
~Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 4 hours before being removed
~Visit 2: Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 24 hours before being removed"
11272619|NCT02886442|Experimental|Cohort 3|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.
~There are two kinds of visits:
~Visit 1:
~Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.
~Visit 2:
~Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.
~Visit 2:"
11272620|NCT02886429|Active Comparator|Group A|Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
11272621|NCT02886429|Active Comparator|Group B|Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
11272622|NCT02886403|Experimental|Cohort 02|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.
~There are two visits:
~The first visit:
~Two adhesive strips (standard adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not.
~The second visit:
~Two adhesive strips (new adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not."
11272623|NCT02886390|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
11272624|NCT02886390|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
11272625|NCT02886377||NMOSD-ON|NMOSD-ON included patients who met the established diagnostic criteria for NMO or NMOSD published by Wingerchuk et al,with AQP4 seropositive according to the results of the AQP4-Ab test.
11272626|NCT02886377||MS-ON|MS-ON group patients included typical acute demyelinating ON with brain lesions fulfilling the revised McDonald criteria or clinical isolate syndrome (CIS), with AQP4 seronegative according to the results of the AQP4-Ab test.
11272627|NCT02886377||Healthy controls|Age- and gender- matched healthy controls.
11272628|NCT02886364|Other|Women delivered at AAC Hospital|The intervention is only being implemented at the Ángel Albino Corzo Hospital due to limited funding. The site was selected by the Ministry of Health in Chiapas as a hospital that would benefit from improved quality of care around childbirth. There are no other arms in this study.
11272629|NCT02886351|Experimental|nitrous oxide|Administration of high concentration of nitrous oxygen in pediatric dentistry
11272630|NCT02886338|Experimental|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
11272631|NCT02886299|Active Comparator|Fenofibrate group|Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
11272632|NCT02886299|Active Comparator|Simvastatin group|Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).
11272670|NCT02885987|Experimental|Colonoscopy with AmplifEYE|AmplifEYE accessory device will be attached to the colonoscope prior to starting the procedure
11272633|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
11272634|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
11272635|NCT02886273||Group 1|SCA with first MI (n = 43)
11272636|NCT02886273||Group 2|SCA with AMI and previous MI (n = 10)
11272637|NCT02886273||Group 3|SCA without AMI and without former heart disease (n = 3)
11272638|NCT02886273||Group 4|SCA without AMI and with known heart disease (n = 18)
11272639|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
11272640|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
11272641|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
11272642|NCT02886221|Other|HV patients|patients with symptomatic Hallux Valgus treated my Reverdin-Isham Osteotomy
11272643|NCT02886208|Experimental|Intervention|This study has a single arm. All participants in a summer employment program at an urban farm in Indianapolis, IN are invited to participate.
11272644|NCT02886195|Experimental|PC plus erlotinib|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy
11272645|NCT02886195|Active Comparator|erlotinib|"erlotinib 150mg/d until progress disease"
11272646|NCT02886195|Active Comparator|PC|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles
11272647|NCT02886182||group A|pregnants who were positivity for serum HBsAg for more than 6 months and HBeAg , HBV DNA >106IU/mL, alanine aminotransferase (ALT) below 35 IU/mL (ULN=40IU/mL) and no received nucleoside analogue antiviral therapy were enrolled into group A
11272648|NCT02886182||group B|the CHB infection pregnants with undetectable HBVDNA were enrolled into group B(control group)
11272649|NCT02886169|Experimental|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
11272650|NCT02886169|Placebo Comparator|unsupplemented group|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
11272651|NCT02886156|Experimental|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
11272652|NCT02886156|Active Comparator|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
11272653|NCT02886143|Experimental|Active Voiding Trial (instillation of sterile saline)|Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.
11272654|NCT02886143|Active Comparator|Passive Voiding Trial|For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.
11272655|NCT02886130|Placebo Comparator|Placebo|Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
11272656|NCT02886130|Experimental|Alpha-GPC|Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
11272657|NCT02886104|Active Comparator|CRLM resection group|Resection of both primary and secondary tumors in SCRLM and resection of MCRLM. Interventions: Simultaneous resection of both primary and secondary tumors in SCRLM and resection of MCRLM.
11272658|NCT02886104|Experimental|CRLM ablation group|"Ablation of CRLM after resection of primary tumor in SCRLM and ablation of MCRLM.
~Interventions: Ablation of liver metastasis within 30 days after resection of primary tumor in SCRLM and ablation of MCRLM."
11272659|NCT02886078|Experimental|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
11272660|NCT02886078|Active Comparator|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
11272661|NCT02886065|Experimental|PVX-410 + Citarinostat|"Participants will receive:
~6 biweekly doses of PVX-410
~6 biweekly doses of Hiltonol
~3 monthly cycles of Citarinostat"
11272662|NCT02886065|Experimental|PVX-410 + Citarinostat + Lenalidomide|"Participants will receive:
~6 biweekly doses of PVX-410
~6 biweekly doses of Hiltonol
~3 monthly cycles of Citarinostat
~3 monthly cycles of Lenalidomide"
11272663|NCT02886052|Experimental|ICBT for insomnia|Therapist guided Internet-CBT for insomnia
11272664|NCT02886052|Active Comparator|Active control|Written information on sleep, insomnia, and sleep hygiene
11272665|NCT02886039|Other|patients|Patient with cardiac arrest benefiting an electroencephalogram
11272666|NCT02886026|Active Comparator|Inpatient TUR-BT|Transurethral bladder tumor resection in operating theatre as inpatient.
11272667|NCT02886026|Experimental|laser bladder tumor destruction|Outpatient laser mediated destruction of bladder tumors (LMD-BT)
11272668|NCT02886013||Mexican adolescents|"Students without known disease, between 14 and 18 years from the Lic. Adolfo Lopez Mateos Preparatory school of the Autonomous University of the State of Mexico (UAEMex)."
11272672|NCT02885961|Other|Dabigatran|"All patients will be entered into the arm, i.e. this is a single arm study. All patients will complete 2 FDG PET scans. All patients will receive dabigatran (direct thrombin inhibitor) at a dose of 110mg twice daily (oral).
~The drug will be given for 24 days (+/-3 days). The variation in duration reflects that scans are completed Monday to Friday only."
11272673|NCT02885948|Experimental|Naloxone|"The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.
~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution."
11272674|NCT02885948|Placebo Comparator|Saline|The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.
11272675|NCT02885935|Experimental|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
11272676|NCT02885935|Experimental|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
11272677|NCT02885909|Active Comparator|Insulin protocal with CGM|Insulin protocal with continue glucose monitor
11272678|NCT02885909|Active Comparator|Insulin protocal|Insulin protocal with convential glucose monitor
11272679|NCT02885909|No Intervention|Convential treatment|Convential insulin treatment and glucose monitor
11272680|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
11272681|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
11272682|NCT02885883|Active Comparator|a control group|
11272683|NCT02885883|Experimental|patients with paroxysmal or persistent AF|
11272684|NCT02885883|Experimental|patients with permanent AF|
11272685|NCT02885870|Experimental|Patient|"Patient with :
~Spinal muscular atrophy (n=25)
~X-linked spinobulbar muscular atrophy (n=25)
~Amyotrophic lateral sclerosis (n=25)"
11272686|NCT02885870|Experimental|Healthy subject|Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
11272687|NCT02885857|Experimental|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
11272688|NCT02885844|Experimental|INVERTED VISION|inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
11272689|NCT02885844|Active Comparator|NORMAL VISION|During normal vision trials, subject's field of view will be restricted by goggles without lenses (see below) in order to be equivalent to the inverted vision one.
11272690|NCT02885831||A - Abduction splintage|Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
11272691|NCT02885831||B - Surveillance|No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients
11272692|NCT02885805|Experimental|SPF evaluation + Control|Fair-skinned subjects in good health with Skin Types I, II or III.
11272693|NCT02885792|Experimental|Debuting and chronic schizophrenia|"ILLNESS HISTORY:
~Existing psychiatric and somatic diagnosis and treatment
~Charlson co-morbidity
~MEASURE OF SOCIAL CONDITIONS
~- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.
~MEASURE OF PSYCHIATRIC CONDITION::
~Positive and Negative Syndrome Scale (PANSS)
~Clinical Global Impression Scale (CGI)
~Columbia Suicide Severity Rating Scale (C-SSRS)
~Beck Cognitive Insight Scale
~Birchwood Insight Scale
~CARDIOVASCULAR MEASUREMENT:
~CT Coronary angiography (CT-CAG)
~Echocardiography
~Heart rate variability (HRV)
~Pulmonary function test (PFT)
~Toe blood pressure (TBP)
~Blood test
~Body composition analysis
~CT scan of upper abdomen
~Cardiovascular magnetic resonance imaging (CMR)
~Adipose tissue biopsy"
11272694|NCT02885792|Active Comparator|Matched controls|"CARDIOVASCULAR MEASUREMENT:
~CT Coronary angiography (CT-CAG)
~Echocardiography
~Heart rate variability (HRV)
~Pulmonary function test (PFT)
~Toe blood pressure (TBP)
~Blood test
~Body composition analysis
~CT scan of upper abdomen
~Cardiovascular magnetic resonance imaging (CMR)
~Adipose tissue biopsy"
11272695|NCT02885779||Patient having an operating indication of adnexa surgery|Patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy
11272696|NCT02885766|Experimental|PF-114|"PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.
~When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.
~Orally, once daily"
11272697|NCT02885753|Experimental|Experimental arm with oxaliplatin intra-arterial|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intra-arterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
11272698|NCT02885753|Active Comparator|Reference arm with oxaliplatin intravenous|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
11272699|NCT02885740|Experimental|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
11272700|NCT02885740|Active Comparator|Control|Patients having a junctional supraventricular tachycardia in normal heart
11272701|NCT02885727|Experimental|Durvalumab + Radiation therapy|"Durvalumab (MEDI4736) 750 mg (or 10mg/kg if the patient weighs <30 kg) IV Q2W over 1 hour for all patients + Radiation therapy
~First lesion to receive 25 Gy / 5 daily consecutive fractions of 5 Gy
~Second lesion to receive15 Gy / 5 daily consecutive fractions"
11272702|NCT02885714|Placebo Comparator|Group I|Placebo surgery + supervised specific exercises
11272707|NCT02885688|Other|Standard-of-Care Treatment for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment alone for up to 7 days.
11272708|NCT02885688|Experimental|Standard-of-Care Treatment Plus Liquid Nutrition for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment plus plus liquid nutrition for up to 7 days.
11272709|NCT02885675||ARDS|
11272710|NCT02885675||Healthy control|
11272711|NCT02885662|Experimental|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
11272712|NCT02885649|Experimental|Treatment (enzalutamide, nephrectomy)|Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.
11272713|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
11272714|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
11272715|NCT02885610|Placebo Comparator|Placebo Comparator|Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
11272716|NCT02885610|Experimental|RC18 80 mg plus standard therapy|RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
11272717|NCT02885610|Experimental|RC18 160 mg plus standard therapy|RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
11272718|NCT02885610|Experimental|RC18 240 mg plus standard therapy|RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses
11272719|NCT02885597|Experimental|Juanbi group|participants should administrate both Juanbi pill and Methotrexate
11272720|NCT02885597|Placebo Comparator|placebo group|participants should administrate both Juanbi pill placebo and Methotrexate
11272721|NCT02885584|Experimental|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
11272722|NCT02885584|No Intervention|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
11272723|NCT02885571|Active Comparator|MAD for subjective compliance|MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
11272724|NCT02885571|Experimental|MAD for objective compliance|MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.
11272725|NCT02885558|Experimental|L + T-type|8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
11272726|NCT02885558|Active Comparator|L-Type|8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
11272727|NCT02885545|Experimental|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
11272728|NCT02885545|Active Comparator|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
11272729|NCT02885519|No Intervention|Control|Standard treatment and standard vocational rehabilitation
11272730|NCT02885519|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
11272731|NCT02885519|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
11272732|NCT02885506|Experimental|Cohort 1|Oral administration of P218 capsules 10 mg
11272733|NCT02885506|Experimental|Cohort 2|Oral administration of P218 capsules 30 mg
11272734|NCT02885506|Experimental|Cohort 3|Oral administration of P218 capsules 100 mg
11272735|NCT02885506|Experimental|Cohort 4|Oral administration of P218 capsules 250 mg
11272736|NCT02885506|Experimental|Cohort 5|Oral administration of P218 capsules 500 mg
11272737|NCT02885506|Experimental|Cohort 6|Oral administration of P218 capsules 750 mg
11272738|NCT02885506|Experimental|Cohort 7|Oral administration of P218 capsules 1000 mg
11272739|NCT02885506|Placebo Comparator|Cohort 8 - Pooled Placebo|Oral administration of P218 matching placebo
11272740|NCT02885506|Experimental|Fed - Fasted|Oral administration of P218 capsules 250 mg Under fed then fasted conditions.
11272741|NCT02885506|Experimental|Fasted - Fed|Oral administration of P218 capsules 250 mg Under fasted then fed conditions.
11272742|NCT02885493||Falls is <or = 1 year|Patients whose number of falls is <or = 1 year
11272743|NCT02885493||falls is> 1 year|Patients whose numbers falls is> 1 year
11272744|NCT02885467|Active Comparator|Control|Standard total knee arthroplasty performed through medial parapatellar approach
11272745|NCT02885467|Experimental|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
11272746|NCT02885454|Experimental|OC + AL-335 + ODV + 3-DAA combination|Participants will receive single dose of 3 milligram (mg) drospirenone/0.02 mg ethinylestradiol [OC] on Day 1, AL-335 800 mg once daily on Days 5 and 6, a single dose of AL-335 800 mg + a single dose of OC on Day 7, ODV 25 mg once daily on Days 12 to 24, followed by a single dose of ODV 25 mg and a single dose of OC on Day 25, followed by ODV 25 mg + AL-335 800 mg + simeprevir (SMV) 75 mg [3-DAA combination] once daily on Days 26 to 31, followed by a single dose of 3-DAA combination and a single dose of OC on Day 32.
11272747|NCT02885441|Experimental|Ketorolac|Ketorolac,10 mg, 3 times daily from time of enrollment until 72 hours from enrollment for up to a maximum of 9 doses, along with the standard medical treatment
11272748|NCT02885441|No Intervention|Control|The standard medical treatment
11272749|NCT02885402|Experimental|Osteoarthritis patient|
11272750|NCT02885402|Placebo Comparator|Healthy volunteers|
11272751|NCT02885376|Experimental|Dentoxol|Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. Subjects will use Dentoxol® mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
11272752|NCT02885376|Placebo Comparator|Placebo|The placebo rinse will be identical in color, taste and consistency as the Dentoxol rinse and will be packaged in identical bottles with the same labels. Subjects will use placebo mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
11272753|NCT02885363|Experimental|Patients with newly diagnosed Left Ventricular Non Compaction|Patient newly diagnosed with Left Ventricular Non Compaction (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
11272754|NCT02885363|Active Comparator|Patients with Idiopathic Dilated Cardiomyopathy|Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
11272755|NCT02885350|Active Comparator|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
11272756|NCT02885350|Experimental|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
11272757|NCT02885350|Active Comparator|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
11272758|NCT02885350|Experimental|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
11272759|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.
~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
11272760|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.
~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.
~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.
~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.
~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
11272761|NCT02885324|Experimental|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
11272762|NCT02885311|Other|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
11272763|NCT02885311|Other|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
11272764|NCT02885311|Other|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy [MBSCT]) adapted from our two prior protocols. These participants will also receive follow up assessments.
11272765|NCT02885311|Other|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
11272766|NCT02885298||Supine intubations (0-10 degrees)|Intubations performed with patient positioned 0-10 degrees. Patient supine.
11272767|NCT02885298||Inclined (11-44 degrees)|Intubations performed with 11-44 degrees of elevation.
11272768|NCT02885298||Upright (45 degrees or greater)|intubations performed with patient elevated to 45 degrees or greater
11272769|NCT02885285|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11272770|NCT02885285|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11272771|NCT02885285|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11272772|NCT02885285|Active Comparator|No Exercise Class|Subjects randomly selected for the no class group will not participate in the study exercise classes. Subjects will still complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
11272773|NCT02885272|Experimental|Diagnostic (PET/CT)|Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
11272774|NCT02885259|Experimental|HyQvia|human immunoglobulin and one vial of recombinant human hyaluronidase (rHuPH20
11272775|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
11272776|NCT02885233|Active Comparator|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
11272777|NCT02885233|Placebo Comparator|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
11272778|NCT02885220|Active Comparator|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
11272779|NCT02885220|Experimental|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
11272780|NCT02885207|Other|Focal epilepsy of unknown cause|
11272781|NCT02885194|Other|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
11272782|NCT02885181|Experimental|GS-9876 - 30 mg|GS-9876 30 mg + filgotinib placebo for 12 weeks
11272783|NCT02885181|Experimental|GS-9876 - 10 mg|GS-9876 10 mg + filgotinib placebo for 12 weeks
11272784|NCT02885181|Experimental|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
11272785|NCT02885181|Placebo Comparator|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
11272786|NCT02885168|Experimental|Shock + Treatment|Patients treated with activated protein C
11272787|NCT02885168|Other|Shock|Patients not treated with activated protein C
11272788|NCT02885155||Patients with pulmonary arterial hypertension|
11272789|NCT02885142|Experimental|Transanal endoscopic microsurgery group|
11272790|NCT02885142|Active Comparator|endoscopic submucosal dissection group|
11272791|NCT02885116|Placebo Comparator|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
11272792|NCT02885116|Active Comparator|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
11272793|NCT02885103|Placebo Comparator|inhalation with nebulizer|inhalation with an nebulizer via mouth
11272794|NCT02885103|Active Comparator|inhalation with nebulizer and NHF|inhalation with combination of nebulizer and nasal high flow (NHF) via nasal cavity
11272795|NCT02885090|Experimental|RTT patient|Blood sampling
11272796|NCT02885090|Experimental|Parents|Blood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
11272797|NCT02885077|Experimental|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
11272798|NCT02885077|Sham Comparator|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
11272799|NCT02885051|Experimental|preterm newborn|Newborns hospitalized in the neonatal or Neonatal Resuscitation unit of Brest University Hospital and born before 36 weeks of gestation who will have recording of skin conductance and heart rate variability.
11272800|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:
~Broccoli Sprout Extract + Nasal Fluticasone
~Broccoli Sprout Extract + normal saline nasal spray
~Placebo Pill + Nasal Fluticasone
~Placebo Pill + normal saline nasal spray"
11272801|NCT02885025|Active Comparator|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:
~Broccoli Sprout Extract + Nasal Fluticasone
~Broccoli Sprout Extract + normal saline nasal spray
~Placebo Pill + Nasal Fluticasone
~Placebo Pill + normal saline nasal spray"
11272802|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:
~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
11272803|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:
~Broccoli Sprout Extract + Nasal Fluticasone
~Broccoli Sprout Extract + normal saline nasal spray
~Placebo Pill + Nasal Fluticasone
~Placebo Pill + normal saline nasal spray"
11272804|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
11272805|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
11272806|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
11272807|NCT02884986|Active Comparator|Etoricoxib|120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
11272808|NCT02884986|Placebo Comparator|Placebo|120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
11272809|NCT02884960|Experimental|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
11272810|NCT02884960|Active Comparator|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
11272811|NCT02884921|Active Comparator|Preemptive Paracetamol|Preemptive Paracetamol
11272812|NCT02884921|Active Comparator|Post surgery Paracetamol|Post surgery Paracetamol
11272813|NCT02884921|Placebo Comparator|Placebo|Placebo
11272814|NCT02884908|Experimental|Pregabalin + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
11272815|NCT02884908|Experimental|Pregabalin + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive study medication (Pregabalin) and Brief Behavioral Compliance Enhancement Treatment (BBCET).
11272816|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/I/II type|This group will be comprised of subjects with the NI/I/II type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
11272817|NCT02884908|Placebo Comparator|Placebo + BBCET - NI/NI type|This group will be comprised of subjects with the NI/NI type who receive placebo and Brief Behavioral Compliance Enhancement Treatment (BBCET).
11272818|NCT02884895|Experimental|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
11272819|NCT02884895|Active Comparator|Direct Laryngoscopy|Direct Laryngoscopy
11272820|NCT02884882|Other|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
11272821|NCT02884882|Placebo Comparator|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
11272822|NCT02884869|Experimental|Intubating laryngeal Mask|Intubating laryngeal Mask
11272823|NCT02884869|Active Comparator|Direct laryngoscopy|Intubating laryngeal Mask
11272824|NCT02884856||Females observers (F)|those with female gender characteristics
11272825|NCT02884856||Male observers (M)|those with male gender characteristics
11272826|NCT02884843|Active Comparator|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
11272827|NCT02884843|Active Comparator|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
11272828|NCT02884830|Placebo Comparator|Sham CPAP|Sham continuous positive airway pressure is a CPAP given at too low pressure to have any physiological effect on upper airways patency and on lung volumes
11272829|NCT02884830|Active Comparator|Efficace CPAP|Continuous positive airway pressure is a CPAP given at effective pressure to decrease the work of breathing in COPD patients
11272830|NCT02884817|Experimental|Listerine prof.gum.ther|"The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson & Johnson,USA).
~Intervention; Rinsing 30 sec with test solution twice daily for 21 days"
11272831|NCT02884817|Placebo Comparator|21.6% hydroalcoholic|"a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.
~Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days"
11272832|NCT02884817|Sham Comparator|Plain sterile water|"Plain sterile water.
~Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days"
11272833|NCT02884791|Experimental|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
11272834|NCT02884791|Experimental|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
11272835|NCT02884778|Experimental|NoL index in response to stimulation|"There is only one arm in this study. The intervention is not a drug, but it is the stimulus applied to the patient such as intubation and a standardized electrical stimulus applied on the forearm of the anesthetized patient. There are several stimuli that are the so-called interventions and the NoL index and the classical vital signs (heart rate, mean blood pressure, BISspectral index) are registered in response to these stimuli in an observational manner."
11272836|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
11272837|NCT02884739||schizophrenia|
11272838|NCT02884739||chronic psychiatric disorder other than schizophrenia|
11272839|NCT02884726|Experimental|BMS-986148 intravenous infusion|
11272840|NCT02884713|Experimental|Levofloxacin and Doxycycline and Esomeprazole|The rescue treatment was given for ten days consisting of levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily
11272841|NCT02884700||Severe legionellosis cases|Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
11272842|NCT02884674|Active Comparator|active Transcranial Magnetic Stimulation|Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
11272843|NCT02884674|Placebo Comparator|Placebo|Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
11272844|NCT02884661||Hospitalization in Cardiology department|Patients cared by the Cardiology department
11272845|NCT02884661||Hospitalization in Geriatric unit|Patients cared by the Geriatric unit
11272846|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
11272847|NCT02884635|Experimental|ASP1707|ASP1707 will be orally administered for 12 weeks.
11272848|NCT02884635|Placebo Comparator|Placebo|Placebo will be orally administered for 12 weeks.
11272849|NCT02884622|Other|CF patients|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added and blood sampling will be collected for this study
11272850|NCT02884583|Experimental|Pulmonary function test|Patients hospitalized for Oral Food Challenge realize pulmonary function test
11272851|NCT02884557|Other|PSC + IBD group|collection of gut biopsies collection of blood samples in patients with PSC and IBD
11272852|NCT02884557|Other|IBD alone group|collection of gut biopsies collection of blood samples in patients with IBD alone
11272853|NCT02884544|Experimental|HLD100|"HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
~HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
~HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
~HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)"
11272854|NCT02884531|Experimental|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
11272855|NCT02884531|Active Comparator|Patient Education|Patients will only participate in Patient Education
11272856|NCT02884518|Experimental|patient group|The patient group recruits subjects diagnosed with first episode psychosis which occurred within 2 years and having been treated with antipsychotics for 1 year. Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity. And patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
11272857|NCT02884518|Other|healthy control group|Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
11272858|NCT02884505||Patients with Hypersomnolence|Patients referred for polysomnography and multiple sleep latency test
11272859|NCT02884492|Experimental|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
11272860|NCT02884492|Active Comparator|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
11272861|NCT02884479|Experimental|PT-112 + Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
11272862|NCT02884466|Experimental|Intervention group|The intervention group will receive a multidisciplinary rehabilitation intervention consisting of: 1) a pre-admission day, 2) two weeks of home-based activities, 3) two-week inpatient period, 4) four weeks of home-based activities, 5) 1st two-days inpatient follow-up, 6) six weeks of home-based activities and 7) 2nd two-days inpatient follow-up.
11272863|NCT02884466|Active Comparator|Usual care group|The usual care group will receive a four-week inpatient multidisciplinary rehabilitation intervention.
11272864|NCT02884453|Experimental|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
11272865|NCT02884440|Experimental|TAP block ropivacaine|Bilateral ultrasound guided with 15 ml ropivacaine 5mg/ml on each side under general anesthesia at the end of the intervention
11272866|NCT02884440|Placebo Comparator|TAP block placebo|Bilateral ultrasound guided with 15 ml saline on each side under general anesthesia at the end of the intervention
11272867|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
11272868|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
11272869|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
11272870|NCT02884414|Experimental|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
11272871|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
11272872|NCT02884388|Experimental|experimental group|Combined nerve block will be used, involving lower lumbar plexus, sciatic nerve, and paraspinal nerve L1-2.
11272873|NCT02884388|Experimental|control group|General anesthesia will be used in this group.
11272874|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
11272875|NCT02884349|Experimental|RoM assessment|All patients recruited to the study.
11272876|NCT02884323|Experimental|geko device arm|
11272877|NCT02884310|Experimental|SPI group|"Remifentanil titration before tracheal intubation and skin incision according to the SPI gradient obtained after a nociceptive test using a tetanic stimulus of 100 Hz, 60 milliamperes during 30 seconds performed at a 3 ng/ml level of the remifentanil concentration.
~During surgery, the effect site remifentanil concentration was either increased or decreased by 1 ng/ml to maintain SPI below 40 or above 20, respectively."
11272878|NCT02884310|Active Comparator|Control group|"The remifentanil concentration before tracheal intubation and skin incision was fixed at 4 ng/ml.
~During surgery, the remifentanil concentration was adapted according to the hemodynamic answer of the patient. It was changed by 1 ng/ml stepwise variations to maintain heart rate and mean blood pressure within 20% of the patient reference hemodynamic values."
11272879|NCT02884297|Experimental|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
11272880|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
11272881|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
11274603|NCT02872051|No Intervention|Control|Standard treatment and standard vocational rehabilitation
11272882|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
11272883|NCT02884258||Control Group|1. Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age. 2. non-operated severely obese women
11272884|NCT02884245|Experimental|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
11272885|NCT02884245|No Intervention|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
11272886|NCT02884232||Workers exposed to wood dust|
11272887|NCT02884219|Active Comparator|Early Treatment with cyclooxygenase inhibitors|Treatment of PDA that starts within the first 3 days of life using cyclooxygenase-inhibitors (Ibuprofen or Indomethacin)
11272888|NCT02884219|Sham Comparator|Expectative Treatment|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
11272889|NCT02884206|Experimental|LCZ696|Patients will receive LCZ696 at 100 mg twice daily during a single-blind treatment run-in period to ensure patients tolerate this medication before they are randomized. Down-titration is not allowed during this period. Patients who are able to tolerate LCZ696 100 mg twice daily are eligible to enter the randomized treatment period. Patients randomized to receive LCZ696 will be given LCZ696 at 200 mg twice daily. Patients will receive randomized study drug for three years.
11272890|NCT02884206|Active Comparator|Valsartan|Patients will receive valsartan at 40mg and/or 80mg twice daily during a single-blind treatment run-in period. Following the run-in period, patients randomized to receive valsartan will be given valsartan at 160 mg twice daily for three years.
11272891|NCT02884193|Experimental|Brief Cooling (Quick Icing)|Group receiving the application of cold on the ventral side of the dominant forearm for 30 seconds, using the technique of ice beakers dynamically.
11272892|NCT02884193|Active Comparator|Prolonged Cold|"Group receiving the intervention of ice bag for a period of 5 and a half minutes from 1 minute, on the ventral side of the dominant forearm"
11272893|NCT02884193|Sham Comparator|Control|"Group receives a placebo application through an ice bag empty. The bag will be applied from 1 minute to 6 and a half minutes, as the group of prolonged cold"
11272894|NCT02884180|Active Comparator|Treatment A|Dexamethasone 24 mg i.v. after start of anaesthesia
11272895|NCT02884180|Placebo Comparator|Treatment B|Saline isotonic i.v. after start of anaesthesia
11272896|NCT02884167||Patients with constipation|
11272897|NCT02884167||Healthy individuals without constipation|
11272898|NCT02884154|Other|Arm who will undergo EUS-FNB|
11272899|NCT02884141||Patients|"Patients with documented fibromuscular dysplasia (see inclusion criteria).
~Non-usual care added acts:
~blood sampling
~urine sampling
~renal echography"
11272900|NCT02884128|Experimental|PEP02 + 5-FU/LV|The initial starting dose of PEP02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-FU and LV were given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. PEP02 was administered on Day 1; 5-FU/LV was started after the end of PEP02 infusion on Day 1 and also on Day 8.
11272901|NCT02884115|Active Comparator|Retreatment group|Serofast early syphilis cases retreated with three doses benzathine penicillin
11272902|NCT02884115|No Intervention|Control group|Absence of any retreatment
11272903|NCT02884089|Placebo Comparator|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
11272904|NCT02884089|Experimental|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
11272905|NCT02884089|Placebo Comparator|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
11272906|NCT02884089|Experimental|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
11272907|NCT02884076||Symptomatic Hemorrhoid|Consecutive patients with symptomatic hemorrhoids presenting to our clinic
11272908|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
11272909|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
11272910|NCT02884050|Experimental|Topiramate|single, 100mg oral dose of topiramate
11272911|NCT02884050|Placebo Comparator|Placebo|matched inactive placebo
11272912|NCT02884037||1|Rifaxmin group
11272913|NCT02884037||2|placebo group
11272914|NCT02884024||lean|healthy subject undergoing routine screening colonoscopy, BMI< or = 25
11272915|NCT02884024||mildly obese|healthy subject undergoing routine screening colonoscopy, BMI 30-33.9
11272916|NCT02884024||moderate-to-severe obese|healthy subject undergoing routine screening colonoscopy, BMI 34+
11272917|NCT02884011||No chronic antihypertensives|not on either a chronic β-blocker or ACE-Inhibitor
11272918|NCT02884011||β-blocker|on chronic β-blocker
11272919|NCT02884011||ACE-Inhibitor|on chronic ACE-Inhibitor
11272920|NCT02884011||Both β-blocker and ACE-inhibitor|on both chronic β-blocker and ACE-inhibitor
11272921|NCT02883998|Active Comparator|Outpatient Physical Therapy Group|Once the patient is cleared for discharged from the hospital, the patient will be given a prescription for outpatient physical therapy to attend 3 times per week for 6 weeks.
11272922|NCT02883998|Experimental|Home Base Physical Therapy Group|Patients will be provided a packet of exercises and equipment to perform the home based physical therapy program. Patients will attend a single session of outpatient physical therapy prior to surgery no more than 4 weeks prior to the procedure to teach the patient how to perform the exercises.
11272923|NCT02883985|Experimental|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
11272924|NCT02883972|Experimental|Intervention letter and reminder|Behavioural insights informed invitation letter and SMS/email reminder message
11272926|NCT02883972|Experimental|Control letter and reminder|Control invitation letter and SMS/email reminder message
11272927|NCT02883972|Active Comparator|Control letter|Control invitation letter only
11272928|NCT02883959|Experimental|music therapy|Music therapy
11272929|NCT02883959|No Intervention|control arm|No music
11272930|NCT02883946||hairy-cell leukemia|Patients with hairy-cell leukemia.
11272931|NCT02883933||melanoma|Patients with melanoma.
11272932|NCT02883920||workers of Champagne vineyard|
11272933|NCT02883907||Healthy volunteers|
11272934|NCT02883907||Osteoarthritis patients|
11272935|NCT02883894||bullous pemphigoid|Patients with bullous pemphigoid.
11272936|NCT02883881||No eye rubbing|
11272937|NCT02883881||with eye rubbing|
11272938|NCT02883868||patients treated with CXL|
11272939|NCT02883842|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
11272940|NCT02883842|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
11272941|NCT02883829|Experimental|Peer-Based Delivery|The Peer-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a peer will be the spokesperson delivering the intervention content.
11272942|NCT02883829|Experimental|Provider-Based Delivery|The Provider-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a healthcare provider will be the spokesperson delivering the intervention content.
11272943|NCT02883816|Experimental|cystic fibrosis|assessment of lung function in newborns screened for cystic fibrosis
11272944|NCT02883803|Experimental|MSC|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.
11272945|NCT02883803|Sham Comparator|Placebo|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.
11272946|NCT02883790|Experimental|Somnage|Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
11272947|NCT02883790|Placebo Comparator|Placebo|Oral administration o.d.
11272948|NCT02883777|Experimental|High Protein and Low Glycemic Index Diet|A protocol of a high protein and low glycemic index diet.
11272949|NCT02883777|Active Comparator|Conventional Diet|A protocol of a conventional diet.
11272950|NCT02883751|Active Comparator|Control group|Control group - gold standard: Conventional ulcer treatment with Rayon® and essential fatty acids (Dersani®). Cleaning of the surgical wound will be performed with saline solution. The wound will then be covered with a sterile polyethylene film, over which the LED plate will be positioned for placebo treatment (emission of sound, but with the device switched off). After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
11272951|NCT02883751|Experimental|LED group|LED group: Cleaning of the surgical wound will be performed with saline solution and the wound will be covered with a sterile polyethylene film, over which the LED plate will be positioned for active treatment with the device switched on. After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
11272952|NCT02883738|Experimental|upper limb tremor|
11272953|NCT02883725||Esophageal atresia|
11272954|NCT02883699|Active Comparator|Endurance Training Group 1|Standard endurance training
11272955|NCT02883699|Experimental|Endurance Training Group 2|Polarized endurance training
11272956|NCT02883699|Active Comparator|Resistance Training Group 1|Standard resistance training
11272957|NCT02883699|Experimental|Resistance Training Group 2|Daily undulating periodization resistance training
11272958|NCT02883686|Experimental|Alma Mentoring plus usual care|Alma peer-mentoring
11272959|NCT02883686|No Intervention|Enhanced Usual Care|Usual care for depression within the Kaiser Permanente of Colorado healthcare system plus study monitoring of depression symptoms and feedback.
11272960|NCT02883673|Experimental|Intervention|Jada System for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
11272961|NCT02883660||Cases|"patients who had empirically defined increased AEs on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
11272962|NCT02883660||Controls|"patients who did not have empirically defined increased AEs with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were nonresponders to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
11272963|NCT02883647||retreatment|"Patients with HBV DNA > 2000 IU/ml and ALT ≥ 5×ULN;
~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have clinical symptoms.
~Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again."
11272964|NCT02883647||non-retreatment|"Patients with HBV DNA ≤ 2000 IU/ml;
~Patients with HBV DNA > 2000 IU/ml and ALT ≤ 2×ULN;
~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have no clinical symptoms."
11272965|NCT02883634|Experimental|specific manipulation|"Participants allocated to group specific manipulation, will have their lumbar spine manipulated according to the previous clinical examination."
11272966|NCT02883634|Experimental|non-specific manipulation|"Participants allocated to group non-specific manipulation will have their upper thoracic spine manipulated (also known as global manipulation) regardless of the previous clinical examination."
11272969|NCT02883608|Experimental|Initial cap assisted endoscopy|undergo initial cap assisted forward-viewing endoscope then side-viewing duodenoscope
11272970|NCT02883608|Active Comparator|Initial standard endoscopy|undergo initial side-viewing duodenoscope then cap assisted forward-viewing endoscope
11272971|NCT02883595|Experimental|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
11272972|NCT02883595|Placebo Comparator|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
11272973|NCT02883582|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
11272974|NCT02883582|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
11272975|NCT02883569|Active Comparator|HIVD-OP|open or endoscopic discectomy
11272976|NCT02883569|Experimental|HIVD-NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
11272977|NCT02883569|Active Comparator|LSS w/o instability -OP|decompression, instrumentation and fusion
11272978|NCT02883569|Experimental|LSS w/o instability -NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
11272979|NCT02883569|Active Comparator|LSS w/ instability - OP|decompression, instrumentation and fusion
11272980|NCT02883569|Experimental|LSS w/ instability - NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
11272981|NCT02883569|Active Comparator|No intervention group|exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
11272982|NCT02883569|Experimental|Intervention group|epidural block, epidural adhesiolysis
11272983|NCT02883556|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
11272984|NCT02883543|Experimental|icotinib plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy.
11272985|NCT02883543|Active Comparator|icotinib|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
11272986|NCT02883543|Active Comparator|chemotherapy plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy.
11272987|NCT02883530||Biomarker optimised patients|Optimised biomarker/Th2 low n=40
11272988|NCT02883530||non -optimised/Th2 low patients|Patients identified in clinic with FeNO <30 ppb. Those who at screening demonstrate FeNO <30 ppb and blood eosinophil count ≤0.20 x109/L will be considered to be non-optimised biomarker-low patients (Th2-low) and will proceed to bronchoscopy n=80
11272989|NCT02883530||corticosteroid-resistant biomarker|Patients identified in clinic with FeNO >45 ppb who have failed to suppress their FeNO during FeNO suppression testing. These patients are considered adherent to inhaled corticosteroids. Those who at screening also demonstrate blood eosinophils of >0.3x109/L n=40
11272990|NCT02883517||Aggressive primary cutaneous lymphomas|"Mycosis fungoides ≥ T2b
~Primary cutaneous T helper follicular lymphoma ≥ T2
~Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome."
11272991|NCT02883504|Experimental|Echocardiography|
11272992|NCT02883478|Active Comparator|Treatment group A|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 3 milliwatt/cm² (mW/cm²) for 30 minutes.
~Device: UV-X 1000 irradiator (3 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
11272993|NCT02883478|Active Comparator|Treatment group B|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 9 mW/cm² for 10 minutes.
~Device: UV-X 2000 irradiator (9 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
11272994|NCT02883465|Other|Single arm|
11272995|NCT02883452|Active Comparator|Cohort 1: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
11272996|NCT02883452|Experimental|Cohort 2: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
11272997|NCT02883452|Experimental|Cohort 3: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
11272998|NCT02883452|Experimental|Cohort 4: CT-P13 SC 240 mg|CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
11272999|NCT02883452|Experimental|Arm 1: CT-P13 SC 120/240 mg|CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
11273000|NCT02883452|Active Comparator|Arm 2: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)
11273001|NCT02883439|Experimental|2|MP29-02 137 microgram, one time only 1 spray
11273002|NCT02883439|Active Comparator|1|fluticasone propionate 50 microgram, one time only 1 spray
11273003|NCT02883426|Experimental|Group 1: H3N2v Seronegative Adults: H3N2v LAIV|Participants will receive one dose of H3N2v LAIV on Day 0 (study entry). They will then receive one dose of H3N2v IIV on Day 84.
11273004|NCT02883426|Experimental|Group 2: H3N2v Seropositive Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
11273005|NCT02883426|Placebo Comparator|Group 2: H3N2v Seropositive Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
11273006|NCT02883426|Experimental|Group 3: H3N2v Seronegative Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
11273007|NCT02883426|Placebo Comparator|Group 3: H3N2v Seronegative Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
11273008|NCT02883426|Experimental|Group 4: Children: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
11273009|NCT02883426|Placebo Comparator|Group 4: Children: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
11273010|NCT02883413|Experimental|CRT +Teach the Parent|The Teach the Parent (TtP) addition to CRT is designed to increase parental understanding of their adolescents' thinking styles. We hypothesize that by doing so, parents will be more likely to challenge eating disorder behaviors and be less likely to accommodate behavioral symptoms of the eating disorder (e.g., make something low-fat for dinner because it will be easier). In this arm, adolescents will explain what they learned during CRT and walk their parents though at least 4 tasks during each TtP session. Parents and child will not be permitted to speak about the eating disorder during these sessions. TtP sessions will occur 3-4 times during hospitalization and will be guided by the adolescent.
11273011|NCT02883413|Active Comparator|CRT + Family Fun Time|In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
11273012|NCT02883413|No Intervention|Treatment as Usual (TAU)|Adolescents in this condition will not receive any additional treatment. They will have a standard hospital stay with all normal contact with health professionals.
11273013|NCT02883400|No Intervention|SOC-Standard of care|standard of care, nontreatment
11273014|NCT02883400|Experimental|spironolactone|spironolactone
11273015|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
11273016|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
11273017|NCT02883374|Experimental|Chidamide|Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
11273018|NCT02883361|Experimental|Treatment|Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
11273019|NCT02883361|Placebo Comparator|Control|Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
11273020|NCT02883322||Initial|Patients answering the initial translation
11273021|NCT02883322||Committee-only|Patients answering the translation modified by an expert committee
11273022|NCT02883322||BT-only|Patients answering the translation modified with the use of a back-translation
11273023|NCT02883322||Both|Patients answering the translation modified by an expert committee with the use of a back-translation
11273024|NCT02883296|Experimental|Patients with perianal fistulizing Crohn's disease|
11273025|NCT02883283|Active Comparator|Epidural Catheter Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
11273026|NCT02883283|Experimental|Epidural Needle Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural needle prior to catheter placement. Epidural loading dose via epidural needle.
11273027|NCT02883270|Experimental|RAGT treatment group|Robotic-assisted gait training （RAGT）is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation after some neuropathy. The investigators use LokoHelp for training, which is provided to the feet and the patient actively controls the knee and hip joints. The participants of RAGT treatment group receive 30 min conventional rehabilitation and 30 min robotic-assisted gait training daily for 8 weeks.
11273028|NCT02883270|Placebo Comparator|controls|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
11273029|NCT02883257|Experimental|Cognitive Behavioral Therapy|"20 individual 60-minute appointments over the course of 16 weeks
~Consistent with Beck, Rush, Shaw, and Emery (1979)"
11273030|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
11273031|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
11273032|NCT02883218||Comunity-acquired severe sepsis patients|Patients with new-onset community-acquired severe sepsis within 24h without confounding factors in immune status
11273033|NCT02883218||Non-severe sepsis patients|Patients between 18 and 90 years of age and be admitted to the ICU without a diagnosis of severe sepsis.
11273034|NCT02883218||Healthy controls|Heathy vonlunteers between 18 and 90 years of age.
11273035|NCT02883192|Experimental|ondansetron|ondansetron
11273036|NCT02883192|Placebo Comparator|Placebo|Placebo
11273037|NCT02883179|Active Comparator|lidocaine injection|5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
11273038|NCT02883179|Experimental|lidocaine-prilocaine cream|5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing
11273039|NCT02883166|Other|group 1|1000mg abiraterone fasted followed by 500 mg with breakfast
11273040|NCT02883166|Other|group 2|500 mg abiraterone with breakfast followed by 1000mg fasted
11273041|NCT02883153|Experimental|Zirconium-89 girentuximab PET/CT|A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
11273042|NCT02883127||The study group|Receives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
11273043|NCT02883127||The control group|Was given the same routine care with the same treatment goals, but without motivational interviewing.
11273044|NCT02883114|Experimental|single cohort|single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
11273045|NCT02883101|Active Comparator|Pulmonary rehabilitation group|"Participants randomised to the PR group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.
~The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.
~The Rehabilitation Programme will include the following:
~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
11273046|NCT02883101|No Intervention|Standard care group|"Candidates randomized to the standard care group will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training."
11273047|NCT02883088||LAD-group|Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).
11273048|NCT02883075|Sham Comparator|Supine position|Supine position Supine position after placement of spinal anesthetic
11273049|NCT02883075|Active Comparator|Right lateral position|Right lateral position Right lateral after placement of spinal anesthetic
11273050|NCT02883075|Active Comparator|Left lateral position|Left lateral position Left lateral after placement of spinal anesthetic
11273051|NCT02883062|Active Comparator|Arm A (carboplatin, paclitaxel, mastectomy, lumpectomy)|Patients receive carboplatin IV over 30 minutes Q3W and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11273052|NCT02883062|Experimental|Arm B (atezolizumab, carboplatin, paclitaxel, breast surgery)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV over 30 minutes Q3W, and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11273053|NCT02883049|Experimental|DS HR B-ALL (RER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.
~See outline for details."
11273054|NCT02883049|Experimental|DS HR B-ALL (SER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.
~See outline for details."
11273055|NCT02883049|Experimental|Group I Arm A (HR B-ALL)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
11273056|NCT02883049|Experimental|Group I Arm B (HR B-ALL) (CLOSED 03/19/2018)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
11273057|NCT02883049|Active Comparator|Group II Arm A (VHR B-ALL - Control Arm)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
11273058|NCT02883049|Experimental|Group II Arm B (VHR B-ALL - Exp Arm1) (CLOSED 02/15/2017)|"Patients receive consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
11273059|NCT02883049|Experimental|Group II Arm C (VHR B-ALL - Exp Arm 2) (CLOSED 09/12/2014)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.
~See outline for details."
11273060|NCT02883049|Experimental|Group III PH-like predicted TKI-sensitive kinase mutation|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.
~See outline for details."
11273061|NCT02883036||Patients with chronic myeloid leukemia|100 adult patients(age>18 years),with chronic myeloid leukemia defined by the World Health Organization(WHO) criteria
11273062|NCT02883036||Healthy volunteers|Healthy volunteers
11273063|NCT02883023|Experimental|Electrosclerotherapy|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will be treated with electrosclerotherapy
11273064|NCT02883023|Active Comparator|Intralesional bleomycin injections|One region of interest in the capillary malformation will be treated with intralesional bleomycin injections without electroporation
11273065|NCT02883023|No Intervention|No treatment|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will not be treated.
11273066|NCT02883010|Experimental|PICO|Single use NPWT (PICO Softport V1.6)
11273067|NCT02883010|Other|Standard care|Gauze dressing, Film dressing, foam dressing, skin glue, no dressing
11273068|NCT02882997|Experimental|Duck Duck Punch|"Community dwelling stroke survivors: Stroke survivors will install an interactive computer game in their home. Subjects will be instructed to play the computer game as much as you want to every day for 7 days. Inpatient stroke patients: The interactive computer game will be installed at a local inpatient stroke rehabilitation hospital. Subjects will be instructed to play this game as much as you want to during non-therapy hours (evenings and weekends) over the next 7 days."
11273069|NCT02882997|Active Comparator|Standard activities|"Community dwelling stroke survivors: Subjects will receive a hard-copy handout of an arm home exercise program and given the instructions to do these exercises as many times as you can daily. Inpatient stroke patients: Subjects will be encouraged to participate in standard evening/weekend recreational activities and to remember to use the paretic arm as much as you can."
11273070|NCT02882984|Active Comparator|WBRT along with TKI|"Drug: EGFR-TKI
~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
~Other Name: Gefitinib/Tarceva/Icotinib
~Radiation: whole brain radiotherapy
~3750Gy/15F
~Other Name: WBRT"
11273512|NCT02879916|Active Comparator|Stellate ganglion block|Levobupivacaine 3ml perineural stellate ganglion injection
11273071|NCT02882984|Experimental|HFSRS with EGFR TKI|"Drug: EGFR-TKI
~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
~Other Name: Gefitinib/Tarceva/Icotinib
~Radiation: whole brain radiotherapy
~25 to 40 Gy/5F
~Other Name: HFSRS"
11273072|NCT02882945||Group A|150 healthy blood donors without a family history of diabetes mellitus
11273073|NCT02882945||Group B|200 cases of type 2 DM without complications (group B), there were 62 males and 108 females, aged 29-53, with an average age of 42 ± 9 years
11273074|NCT02882945||Group C|120 cases of type 2 DM with macroangiopathy complication (group C), there were 70 males and 50 females, aged 40-53, with an average age of 47 ± 6 years. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD
11273075|NCT02882932|Other|Super Oxidized Solution|Procedure/Surgery: Super Oxidized Solution(SOS) in group I - SOS with normal saline solution was used
11273076|NCT02882932|Other|normal saline|"Procedure/Surgery: normal saline
~In group II - patients underwent normal saline wash and bacterial load was noted."
11273077|NCT02882919|Experimental|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
11273078|NCT02882919|No Intervention|Usual care|In the usual care group, patients are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors
11273079|NCT02882893|Experimental|DWP450|Single-dose
11273080|NCT02882893|Active Comparator|Botox|Single-dose
11273081|NCT02882880|Other|Started|Intervention: Treatment with the Luco Hybrid OSA Appliance (LHOA) Group 1, fitted with LHOA Group 2: LHOA removed for 48 hours
11273082|NCT02882880|Active Comparator|Completed|Intervention: The LUco Hybrid OSA APpliance The subjects that actually completed the study in both groups. Group 1 n = 32, in Group 2 n=19
11273083|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
11273084|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
11273085|NCT02882841|Other|Single-arm study|
11273086|NCT02882828|Experimental|DBS (dried blood spots) collection|In this study, we make a switch from Prograf® to Envarsus®. Patients will be trained to collect their blood from a finger prick on filter paper. DBS will be done at home, collected on filter paper and mailed by the patients to a centralized laboratory (Department of Pharmacology, Toxicology and Pharmacovigilance at Limoges University Hospital), where tacrolimus concentration will be determined by HPLC-MS/MS
11273087|NCT02882815|Other|IrisFIT PFO Occluder|Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
11273088|NCT02882802|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
11273089|NCT02882802|Active Comparator|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
11273090|NCT02882789|Experimental|LCB01-0371 200mg|LCB01-0371 IV 200 mg
11273091|NCT02882789|Experimental|LCB01-0371 400mg|LCB01-0371 IV 400 mg
11273092|NCT02882789|Experimental|LCB01-0371 800mg|LCB01-0371 IV 800 mg
11273093|NCT02882776|Other|Ginger drink once daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water once a day for continuous 5 days.
11273094|NCT02882776|Other|Ginger drink twice daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water twice a day for continuous 5 days.
11273095|NCT02882763|Experimental|Parents As Teachers (PAT)|c.f. intervention
11273096|NCT02882763|No Intervention|control group condition|Families in the control group condition did not receive the home visiting program PAT, but were informed about support services in their community. The use of these services was permitted for ethical reasons; however, parents were regularly asked about the nature and intensity of the retrieved services. Additionally, all parents received incentives, such as greeting cards, small birthday presents, and monetary reimbursements.
11273097|NCT02882750||Surgical Patients|Early stage NSCLC patients submitted to Surgical Resection
11273098|NCT02882750||SABR Patients|Early stage NSCLC patients submitted to SABR
11273099|NCT02882737|Experimental|Exercise and glucagon before exercise|"120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.
~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.
~When exercise is ended a single subcutaneous bolus of 0.2 ml saline is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
11273516|NCT02879877|Placebo Comparator|Placebo (intravenous)|Single dose placebo comparator for each cohort of iv administration.
11273100|NCT02882737|Active Comparator|Exercise and glucagon after exercise|"120 minutes after breakfast; a single subcutaneous bolus of 0.2 ml saline is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.
~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.
~Low-dose glucagon phase: When exercise is ended or when hypoglycemia occurs (≤3.9 mmol/l); a single subcutaneous bolus of 200μg glucagon is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
11273101|NCT02882737|Active Comparator|Resting and glucagon after resting|"120 minutes after breakfast; a single subcutaneous bolus of 200μg placebo is administered.
~Resting: After placebo injection the patient will be resting on a hospital bed for 45 minutes. The patient do not know if placebo or glucagon is administered.
~Low-dose glucagon phase: After 45 minutes of resting or when hypoglycemia occurs, a single subcutaneous bolus of 200μg glucagon is administered.
~Safety issues: If plasma glucose drops < 2.5 mmol/l at two consecutive measurements with 5 min interval or the patient experiences unbearable symptoms of hypoglycemia even after glucagon administration, 20 g carbohydrate is given orally. If plasma glucose drops< 2.3 mmol/l or doesn't raise sufficient after oral glucose, we will give intravenøs glucose to the patient. The study will then end and a new study day will be planned."
11273102|NCT02882724|Experimental|Exercise training|
11273103|NCT02882724|Experimental|Control|Control group did not do any exercise training.
11273104|NCT02882711|Experimental|ketamine|
11273105|NCT02882698|Experimental|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
11273106|NCT02882698|Experimental|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
11273107|NCT02882698|Active Comparator|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
11273108|NCT02882698|Active Comparator|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
11273109|NCT02882685|Active Comparator|RYGB|Roux-en-Y gastric bypass
11273110|NCT02882685|Active Comparator|SAGB|Single anastomosis gastric bypass
11273111|NCT02882672|Experimental|Experimental|experimental group did 8 weeks exercise training
11273112|NCT02882672|Experimental|Control|Control group did not do any exercise training.
11273113|NCT02882659|Experimental|Dendritic Killer Cell (DKC)|All enrolled patients received one treatment cycle of DKC cell therapy, which consists of 5 infusion cycles approximately 23 days apart. There were 3 dose levels: 5 x 10^6, 1 x 10^7, and 5 x 10^7 cells, and the protocol followed a traditional 3+3 dose escalation design.
11273114|NCT02882646|Experimental|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.
~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
11273115|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
11273116|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
11273117|NCT02882620|Experimental|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
11273118|NCT02882620|Experimental|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
11273119|NCT02882620|Experimental|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
11273120|NCT02882607|Experimental|Intervention group|Reproductive Health Peer Groups
11273121|NCT02882607|No Intervention|Control group|no intervention
11273122|NCT02882594||CIBA Study Cohort|Patients aged 1 to 13 years undergoing inhalation inductions for general anesthesia
11273123|NCT02882581|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
11273124|NCT02882568|Other|investigational|Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
11273125|NCT02882555|Experimental|Children|"12 concentrations of caspaicin are administered: - 0.6, 1.2, 2.4, 4.8, 9.8, 19.5, 39, 78.1, 156.2, 312.5, 625, 1250 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.
~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline
~At least 1-hour-interval (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
11273177|NCT02882308|Experimental|Combination of cisplatin and olaparib|Patients in the cisplatin - olaparib combination arm will receive treatment until the 5th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day.
11273513|NCT02879903|Experimental|biofilm tobacco effect|Group smokers - patients will receive periodontal treatment and biofilm will be collected.
11273126|NCT02882555|Active Comparator|Adults|"As reference for more precise assessment of effects of development.
~12 concentrations of caspaicin are administered: 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.
~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline
~At least 1-hour-interval (in order to minimize tachyphylaxy)
~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
11273127|NCT02882542|Experimental|Visible light exposure Orange 30 lux|The participants will be exposed to orange LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273128|NCT02882542|Experimental|Visible light exposure Orange 120 lux|The participants will be exposed to orange LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273129|NCT02882542|Experimental|Visible light exposure Cyan 30 lux|The participants will be exposed to cyan LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273130|NCT02882542|Experimental|Visible light exposure Cyan 120 lux|The participants will be exposed to Cyan LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273131|NCT02882542|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273132|NCT02882542|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273133|NCT02882529|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273134|NCT02882529|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273135|NCT02882529|Experimental|Visible light exposure Yellow 30 lux|The participants will be exposed to yellow LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273136|NCT02882529|Experimental|Visible light exposure Yellow 120 lux|The participants will be exposed to yellow LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273137|NCT02882529|Experimental|Visible light exposure Violet 30 lux|The participants will be exposed to violet LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273138|NCT02882529|Experimental|Visible light exposure Violet 120 lux|The participants will be exposed to violet LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273139|NCT02882516|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273140|NCT02882516|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273141|NCT02882516|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273142|NCT02882516|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273143|NCT02882516|No Intervention|darkness|The participants will not be exposed to any light but stay in darkness for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
11273144|NCT02882503|Experimental|EUS-RFA|monopolar radiofrequency probe (1.2 mm Habib endoscopic ultrasound - radiofrequency ablation (EUS-RFA) catheter) and 19 or 22 gauge fine needle aspiration (FNA) needle
11273145|NCT02882490|Experimental|Parent training (PT)|The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
11273146|NCT02882490|Experimental|Supportive Therapy (ST)|The ST arm receives a 10-week supportive group treatment. Parents are invited to discuss relevant problems that have occurred during the previous week. A therapist moderate the discussion but does not provide information about the behavioral techniques included in the PT group. Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
11273147|NCT02882477|Experimental|Deferiprone and Acetylcystein|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200 mg divided in 2 doses 5 months duration
11273148|NCT02882477|Experimental|Deferiprone and Acetylcystein with Sitagliptin and Metformin|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200mg divided in 2 doses PO Januet 50/500 if BW < 30kg and 50/850 if BW> 30kg *2/D 5 months duration
11273149|NCT02882464|Experimental|2PRF+CAF|"Two tubes of blood samples were centrifuged by PC-02 Centrifuged device. This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France). PRF were prepared for patients in 2 layer platelet rich fibrin membrane with coronally advanced flap group (2PRF+CAF).
~Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 2PRF+CAF group: two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flpa is positioned coronally."
11273150|NCT02882464|Experimental|4PRF+CAF|Four tubes of blood samples were centrifuged by PC-02 Centrifuged device,four layers of PRF membranes were prepared for patients in 4 layer platelet rich fibrin membrane with coronally advanced flap.(4PRF+CAF). This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France) Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 4PRF+CAF group: four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flap is coronally positioned.
11273151|NCT02882464|Active Comparator|CTG+CAF|"The surgical technique in coronally advanced flap with subepithelial connective tissue graft (CTG+CAF) group was envelope technique as described by Raetzke. The papillae were dis epithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. The connective tissue graft was harvested from the palate using trap-door technique described by Edel. Epithelial layer was elevated with a horizontal and two vertical incisions. The connective tissue graft was harvested as 1 mm by using a standard caliper, then epithelial layer was sutured by resorbable suture. The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ."
11273152|NCT02882451|Experimental|pinaverium bromide|take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally
11273153|NCT02882451|Placebo Comparator|Vitamin C|take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally
11273154|NCT02882438|Active Comparator|Infected group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
11273155|NCT02882438|Placebo Comparator|Control group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
11273156|NCT02882425|Experimental|Intravenous selexipag (Pilot phase)|Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
11273157|NCT02882425|Experimental|Sequence A-B (Main phase)|Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
11273158|NCT02882425|Experimental|Sequence B-A (Main phase)|Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.
11273159|NCT02882412||patient group|
11273160|NCT02882399|Experimental|Shortystrap|
11273161|NCT02882386|Placebo Comparator|Milk 1%|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
11273162|NCT02882386|Experimental|Whey protein concentrate 80 (WPC-80)|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
11273163|NCT02882386|Experimental|Microparticulated whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
11273164|NCT02882386|Experimental|Hydrolyzed whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
11273165|NCT02882386|Experimental|Native whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
11273166|NCT02882373|Experimental|Group I (arginine)|Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
11273167|NCT02882373|Placebo Comparator|Group II (placebo)|Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
11273168|NCT02882360|Experimental|Elective LSCS--Kerlix AMD|Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
11273169|NCT02882360|Placebo Comparator|Elective LSCS--Placebo|Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
11273170|NCT02882360|Experimental|Labouring LSCS--Kerlix AMD|Kerlix-AMD applied to wound post-operatively for 2 weeks
11273171|NCT02882360|Placebo Comparator|Labouring LSCS--Placebo|Normal gauze applied to wound post-operatively for 2 weeks
11273172|NCT02882347|Experimental|somatostatin group|The investigators administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time < 50% and serum total bilirubin > 2.9mg/dl after liver resection) until recovery from liver failure.
11273173|NCT02882334|Experimental|Finger individuation training|Finger Force Manipulandum
11273174|NCT02882334|Active Comparator|control|conventional physiotherapy
11273175|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.
~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
11273176|NCT02882308|Experimental|Monotherapy with olaparib|Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
11273339|NCT02881216|Other|Synergy Stent|Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
11273178|NCT02882308|No Intervention|No treatment arm|"Patients in the no treatment arm will wait to be operated or have a second biopsy on the 23rd - 29th day.Optionally, patients who have a baseline FDG-PET/CT scan may be re-examined on the 22nd -28th day by the same modality to assess metabolic response."
11273179|NCT02882308|Experimental|Combination of durvalumab and olaparib|Patients in the durvalumab - olaparib combination arm will receive treatment until the 21th-28th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
11273180|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
11273181|NCT02882295||control|age and gender matched
11273182|NCT02882282|Active Comparator|Arm A (observation)|Patients undergo observation.
11273183|NCT02882282|Experimental|Arm B (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11273184|NCT02882269|Active Comparator|Postoperative chemotherapy|Patients receive 6 months of chemotherapy after surgery.
11273185|NCT02882269|Experimental|Neoadjuvant chemotherapy|Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.
11273186|NCT02882256|Experimental|Intervention|Patients will receive video discharge instructions in addition to standard written discharge instructions.
11273187|NCT02882256|No Intervention|Control|Patients will receive standard written discharge instructions.
11273188|NCT02882230||exposition to the drugs|patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
11273189|NCT02882230||patients non exposed to the drugs|
11273190|NCT02882217|Active Comparator|XC8 10mg|Cohort 1: 8 subjects will be randomized in a 3:1 ratio to be treated either with 10mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
11273191|NCT02882217|Active Comparator|XC8 50mg|Cohort 2: 8 subjects will be randomized in a 3:1 ratio to be treated either with 50mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
11273192|NCT02882217|Active Comparator|XC8 200mg|Cohort 3: 16 subjects will be randomized in a 3:1 ratio to be treated either with 200mg XC8 (12 subjects) or placebo (4 subjects, see placebo arm)
11273193|NCT02882217|Placebo Comparator|Placebo|Placebo comparator arm consists of 2 subjects in the cohorts 1 and 2 each and 4 subjects in the cohort 3.
11273194|NCT02882204||First Episode Patients|First episode patients new to the PEPP program.
11273195|NCT02882204||Chronic Patients|Existing patients who have been enrolled in the PEPP program for >3 years
11273196|NCT02882204||Healthy Controls|Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
11273197|NCT02882204||Cliniucal High Risk patients|Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
11273198|NCT02882191|Experimental|LevoCept IUD|LevoCept IUD placement
11273199|NCT02882165|Experimental|Intervention arm|Participants receive a comprehensive medical review by a Respiratory Clinical Fellow.
11273200|NCT02882165|No Intervention|Control arm|Participants receive usual care as required via their primary care practice.
11273201|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
11273202|NCT02882152|Active Comparator|Morphine|intrathecal morphine
11273203|NCT02882139||Electrical storm|Documentation of 3 or more episodes of sustained ventricular arrhythmia within 24h or documentation of sustained ventricular tachycardia lasted at least 12h
11273204|NCT02882126|Experimental|Subcutaneous Treprostinil|Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
11273205|NCT02882113|Experimental|Expressor|CYP3A5 expressor; containing CYP3A5*1 wild-type allele(*1/*1 type & *1/*3 type) intervention: Advagraf conversion
11273206|NCT02882113|Active Comparator|Non-expressor|CYP3A5 non-expressor: without CYP3A5*1 allele( *3/*3 type) intervention: Advagraf conversion
11273207|NCT02882100|Experimental|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
11273208|NCT02882100|Active Comparator|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
11273209|NCT02882087|Experimental|Placebo Comparator|Placebo SC plus MTX. Patients received placebo SC weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
11273210|NCT02882087|Experimental|Experimental: RC18 160 mg plus MTX|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
11273211|NCT02882074|Other|Human albumin|Human albumin 5% during surgery.
11273212|NCT02882074|Other|Hydroxyethyl starch|Hydroxyethyl starch 6% (130/0.4) solution during surgery
11273213|NCT02882061|Experimental|CTDT positive|All subjects with a positive cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
11273214|NCT02882061|Active Comparator|CTDT negative|All subjects with a negative cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
11273215|NCT02882048|Experimental|Medication management & NADA Protocol|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens, and NADA protocol administered biweekly
11273216|NCT02882048|Active Comparator|Medication management|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens.
11273340|NCT02881203|Experimental|Breathe Well + RPM|Participants will receive Breathe Well audiovisual feedback in addition to the RPM system
11273341|NCT02881203|Active Comparator|RPM|Varian's RPM system is the current standard of care at Royal North Shore Hospital where this trial is to be run.
11273217|NCT02882035|Experimental|OFA (opioid free anesthesia)|"All drugs were given IV. Induction in the opioid free group began with a loading dose of clonidine (0.2 mcg kg-1), a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).
~General anesthesia was maintained with sevoflurane (MAC: 1) (adapted according to hemodynamic stability).
~Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups. A bolus of ketamine (0.2mg kg -1) was given if necessary in the opioid free group (up to three bolus max. were permitted).
~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.
~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
11273218|NCT02882035|No Intervention|OA (opioid anesthesia)|"All drugs were given IV. Induction in the opioid group began with remifentanil TCI, a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).
~General anesthesia was maintained with sevoflurane (MAC: 1). Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups.
~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.
~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
11273219|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
11273220|NCT02882009|Experimental|Gantenerumab + Placebo|Participants will be randomized to receive gantenerumab HCLF and placebo solution via SC injection according to different sequences for the site of administration and different injection speeds.
11273221|NCT02881996|Experimental|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
11273222|NCT02881996|Active Comparator|No IV tylenol|Same as above without IV tylenol.
11273223|NCT02881983||STA group|Short-term alcohol abstinent patients (after 1 month of withdrawal)
11273224|NCT02881983||LTA group|Long-term alcohol abstinent patients (at least 6 months of abstinence)
11273225|NCT02881983||Control group|Healthy subjects
11273226|NCT02881970|Experimental|Neonatal hypoxic-ischaemic encephalopathy|
11273227|NCT02881957|Placebo Comparator|Control|Placebo control (simple oral syrup)
11273228|NCT02881957|Experimental|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
11273229|NCT02881944|Experimental|Low FODMAP (modified healthy) Diet|Low FODMAP diet for 3 weeks. Veterans will be provided a diet containing foods low in FODMAP.
11273230|NCT02881944|Experimental|High FODMAP (typical healthy) Diet|High FODMAP diet for 3 weeks. Veterans will be provided a typically healthy diet following US Dietary Guidelines, containing foods high in FODMAPs
11273231|NCT02881931||Pre-Manifest HDGEC Participant|
11273232|NCT02881931||Early-Manifest HDGEC Participant|
11273233|NCT02881931||Corresponding HDGEC participant Companion|
11273234|NCT02881918||squamous cell carcinoma|Patients affected by Head & Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
11273235|NCT02881905|Active Comparator|ball attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment
11273236|NCT02881905|Experimental|CM LOC attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment
11273237|NCT02881879|Experimental|Allergovac depot with HDM extract|Extract of mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae (50:50) adsorbed onto aluminum hydroxide 0.33%.
11273238|NCT02881866|Active Comparator|Air Hunger|"Previous studies have shown that inhaled furosemide relieves 'air hunger'.
~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.
~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. ."
11273239|NCT02881866|Experimental|Work Effort|Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .
11273240|NCT02881853|Experimental|Part A1|XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
11273241|NCT02881853|Experimental|Part A2|XmAb7195 for SC injection; dose level 1; 4 once weekly doses
11273242|NCT02881853|Experimental|Part A3|XmAb7195 for SC injection; dose level 2; 4 once weekly doses
11273243|NCT02881853|Experimental|Part A4|XmAb7195 for SC injection; dose level 3; 4 once weekly doses
11273244|NCT02881853|Experimental|Part A5|XmAb7195 for SC injection; dose level 4; 4 once weekly doses
11273245|NCT02881853|Experimental|Part B6|XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
11273246|NCT02881853|Experimental|Part B7|XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
11273247|NCT02881853|Experimental|Part B8|XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
11273248|NCT02881853|Experimental|Part B9|XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
11273249|NCT02881840|Experimental|14C-APD421|
11273250|NCT02881827|Active Comparator|Infrared Laser|Using a laser in the infrared wave spectrum (780 nm)
11273251|NCT02881827|Active Comparator|Red Laser|Using laser red wave spectrum (662 nm)
11273252|NCT02881827|Placebo Comparator|Placebo|Simulation of treatment with the device switched off
11273517|NCT02879877|Experimental|UCB7858 (subcutaneous)|Various single doses, administered to various cohorts.
11273253|NCT02881827|Active Comparator|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied
~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two ( statistically ) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug , which serves to prevent bias and isolating effects of such drugs."
11273254|NCT02881814|Experimental|Lung ultrasound and clinical decision|
11273255|NCT02881788||Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a traumatic brain injury. We are hoping to find patterns that may indicate a TBI in the data we collect.
11273256|NCT02881788||Non-Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a non-trauma related brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as healthy controls.
11273257|NCT02881788||Control|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have not recently sustained any brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as subjects who have had a non-trauma related brain injury.
11273258|NCT02881775|Experimental|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
11273259|NCT02881775|Sham Comparator|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
11273260|NCT02881762|Active Comparator|Immediate start maraviroc|To start maraviroc immediately after randomization.
11273261|NCT02881762|Active Comparator|Delayed start maraviroc|To start maraviroc 8 weeks after enrollment.
11273262|NCT02881749|Experimental|TSEBT & mechlorethamine gel 0.016%|All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
11273263|NCT02881736|Experimental|Pateint with chronic stroke|
11273264|NCT02881736|Active Comparator|Healthy volunteer|
11273265|NCT02881723|Experimental|Treatment for oropharyngeal cancer by surgery|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery
11273266|NCT02881723|Experimental|Treatment for oropharyngeal cancer by radio-chemotherapy|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy
11273267|NCT02881697||Obese insulin-resistant subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery
11273268|NCT02881697||Lean insulin-sensitive controls|Adipose tissue sampling in normal weight patients (BMI < 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery
11273269|NCT02881697||Obese diabetic subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; diabetic, scheduled for elective bariatric surgery
11273270|NCT02881684|Experimental|Treatment|"Intervention:
~Device: Aspiration Therapy (AspireAssist)
~- Subjects randomized to the treatment group will undergo an endoscopic procedure to have the experimental device (i.e. the A-tube) inserted. This will be followed by regular follow up visits and lifestyle therapy matched to the control group. The device will be removed at the end of one year and this group will be observed for one year more to determine if there is any legacy effect.
~Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy"
11273271|NCT02881684|Active Comparator|Control|"Intervention:
~(1) Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy
~- Subjects randomized to the control group will receive lifestyle management matched to the treatment group in the first year. At the end of one year, they will be crossed over to treatment and the A-tube will be inserted. They will then follow up the same follow up schedule of the treatment group during the first year."
11273272|NCT02881671||Patients with congenital atrioventricular block|Patient with congenital atrioventricular block
11273273|NCT02881671||relatives with congenital atrioventricular block|Normal relatives of patients with congenital atrioventricular block
11273274|NCT02881671||Patients with progressive Cardiac Conduction Disease|Patients with progressive Cardiac Conduction Disease,
11273275|NCT02881671||relatives with progressive Cardiac Conduction disesae|Normal relatives of patients with progressive Cardiac Conduction Disease
11273276|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
11273277|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
11273278|NCT02881645||Best practices|Assessment of critical incidents linked to nursing with a best practices protocol
11273279|NCT02881645||Common practices|Assessment of critical incidents linked to nursing in common practices
11273280|NCT02881632||Healthy infants aged 0-2|Healthy infants aged 0-2 year with no respiratory diseases to provide a reference values. A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person.
11273281|NCT02881632||Infants aged 0-1 with Bronchiolitis|Infants admitted to hospital within last 24hrs (AVB participants only). A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person
11273282|NCT02881619|Placebo Comparator|Placebo|Placebo - (inert content)
11273283|NCT02881619|Experimental|Experimental -|400 mg of NAISE etodolac
11273284|NCT02881606|Active Comparator|Naso-alveolar molding (NAM)|Active plates and nasal stents (Grayson method)
11273285|NCT02881606|Active Comparator|Computer aided design NAM (CAD/NAM)|Computer aided design active plates and nasal stents
11273286|NCT02881567|Experimental|Daclizumab|
11273287|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.
~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.
~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
11273288|NCT02881541|Experimental|Patients having Enhanced Support|"A preoperative consultation with a nurse. This time will be dedicated to the preparation of returning home: explanation of the clinical pathway, realization of postoperative wound care, information on pain management and answer any questions the patient.
~A nurse call on D + 1, the day after the operation to ensure the smooth running of returning home, assess postoperative pain, the correct performance of local care, answer questions from the patient, and provide advice to to limit pain .. A reminder to J2 / J3 will be produced at the request of the patient or on FDI initiative if particular difficulties are reported"
11273289|NCT02881541|Experimental|Patients having usual care|no intervention will be made for this group. Patients will receive usual care respecting intern procedure
11273290|NCT02881528|Experimental|Metformin Hydrochloride|"Metformin Hydrochloride Ph Eur oral solution (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).
~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
11273291|NCT02881528|Placebo Comparator|Placebo|"Placebo (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).
~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
11273292|NCT02881515|Experimental|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
11273293|NCT02881515|Experimental|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
11273294|NCT02881502||healthy control group|Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
11273295|NCT02881502||mild and moderate asthma group|Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
11273296|NCT02881502||severe asthma group|Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
11273297|NCT02881489|Experimental|Autologous BM-MSCs injection|Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
11273298|NCT02881476|Experimental|Allogeneic WJ-MSCs injection|Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
11273299|NCT02881463|Experimental|Home Exercise Program|8- week therapeutical exercise program performing at home for women with knee joint osteoarthritis
11273300|NCT02881437|Experimental|IgHy10 (HyQvia)|"Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:
~The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose
~During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).
~At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose."
11273301|NCT02881424||alcohol-dependent patients|a group of 34 alcohol-dependent patients, currently abstinent
11273302|NCT02881424||healthy controls|a group of control subjects, without neurologic or psychiatric disease, matched for age and sex with the alcohol-dependent participants
11273303|NCT02881411|Active Comparator|Self-soft tissue therapy|Intervention group: Fibromyalgia coping skills programme plus self-soft tissue therapy (SSTT) SSTT consists of MTrP therapy on TrP sites in either the lower leg/foot or forearm/hand. MTrP therapy will be administered by the researcher for only two sessions which will include training to teach the participant how to do SSTT on themselves. All participants in the intervention group will also receive an advice booklet for SSTT.
11273304|NCT02881411|Active Comparator|Fibromyalgia coping skills programme|Control group:Fibromyalgia coping skills programme only. The FCSP is a non-pharmacological, multidisciplinary exercise and education group programme. Its main aims are to provide condition-specific, patient centred, self-management education and advice, in line with national drivers for long-term conditions and international FMS clinical guidelines.
11273514|NCT02879903|Experimental|biofilm non smoker effect|Group Non Smokers - patients will receive periodontal treatment and biofilm will be collected.
11273305|NCT02881398|Experimental|mHealth|Each participant randomized to a mHealth assessment were evaluated with: (1) structural abnormalities with handheld-echocardiography (Vscan®, General Electric Healthcare); (2) vital signs with smartphone-connected oxymetry and blood pressure monitors (iHealthLabs®); (3) functional assessments on a 6-minute walk test with a trial-axial activity monitor (Ozeri®); (4) cardiac rhythm abnormalities with smartphone-connected- iECG (AliveCor®) and; (5)point-of-care testing with fingerstick B-type natriuretic peptide (Alere). All study participants then underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
11273306|NCT02881398|Active Comparator|Standard-Care|Each participant randomized to a standard-assessment were evaluated with the resource available at the institution including a physical examination,12 lead-ECG, radiographic, laboratory testing as clinically required. All study participants underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
11273307|NCT02881385||E5 Esense 10%|PSV mode using E5 ventilator with Esense 10%
11273308|NCT02881385||E5 Esense 30%|PSV mode using E5 ventilator with Esense 30%
11273309|NCT02881385||E5 Esense 50%|PSV mode using E5 ventilator with Esense 50%
11273310|NCT02881385||Servo-I Esense 10%|PSV mode using Servo-I ventilator with Esense 10%
11273311|NCT02881385||Servo-I Esense 30%|PSV mode using Servo-I ventilator with Esense 30%
11273312|NCT02881385||Servo-I Esense 50%|PSV mode using Servo-I ventilator with Esense 50%
11273313|NCT02881385||E5 Esense autocycle|PSV mode using E5 ventilator with Esense Auto cycle
11273314|NCT02881372|Experimental|Oral food desensitization|All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
11273315|NCT02881359||LifeSeal® Kit|creation of a coloanal or colorectal anastomosis
11273316|NCT02881346||Enstilar®|Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.
11273317|NCT02881320|Experimental|Cohort 1 (12 to < 18 years of age and weight ≥ 35 kg)|"Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48.
~Part B: Following confirmation of BIC PK data from Cohort 1 Part A, participants will receive the adult strength B/F/TAF through Week 48."
11273318|NCT02881320|Experimental|Cohort 2 (6 to < 12 years of age and weight ≥ 25 kg)|"Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48.
~Part B: Following confirmation of BIC PK data from Cohort 2 Part A, participants will receive the adult strength B/F/TAF FDC through Week 48."
11273319|NCT02881320|Experimental|Cohort 3 (≥ 2 years of age and weight ≥ 14 to < 25 kg)|"Part A: Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive the low dose B/F/TAF FDC tablet through Week 48.
~Part B: Following confirmation of BIC PK data from Cohort 3 Part A, participants will receive the low dose B/F/TAF FDC tablet through Week 48."
11273320|NCT02881320|Experimental|Cohort 4 Group 1 (≥ 2 years of age and weight ≥ 14 to < 25 kg)|"Due to Cohort 3 Part A Intensive PK evaluation at Week 2 with the low dose B/F/TAF FDC tablet, participants will not participate in an Intensive PK evaluation at Week 2.
~Participants will receive B/F/TAF FDC tablets for oral suspension (TOS) through Week 48."
11273321|NCT02881320|Experimental|Cohort 4 Group 2 (≥ 1 month of age and weight ≥ 10 to < 14 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS through Week 48.
11273322|NCT02881320|Experimental|Cohort 4 Group 3 (≥ 1 month of age and weight ≥ 6 to < 10 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS through Week 48.
11273323|NCT02881320|Experimental|Cohort 4 Group 4 (≥ 1 month of age and weight ≥ 3 to < 6 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS through Week 48.
11273324|NCT02881320|Experimental|Open-Label Extension|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive adult strength B/F/TAF FDC, low dose B/F/TAF FDC, or B/F/TAF FDC TOS (based on age and weight) until it becomes available for use according to the participant's age and weight or the product becomes accessible to participants through an access program.
11273325|NCT02881307|Experimental|Dietary Supplement|
11273326|NCT02881307|Active Comparator|Dietary Counseling|
11273327|NCT02881294|Active Comparator|Food Effect|SUVN-G3031 tablets single dose
11273328|NCT02881294|Active Comparator|Gender Effect|SUVN-G3031 tablets single dose
11273329|NCT02881294|Active Comparator|Age Effect|SUVN-G3031 tablets single dose
11273330|NCT02881281|Other|Education|Education program
11273331|NCT02881281|Other|Control Group|no intervention
11273332|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
11273333|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
11273334|NCT02881255|Other|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
11273335|NCT02881255|Other|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
11273336|NCT02881242|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
11273337|NCT02881229||Women in the Vulvar Specialty Clinic|Information will be collected from all patients presenting with vulvar complaints who have been seen by Dr. Schlosser in the Vulvar Mucosal Specialty Clinic at Northwestern Medical Group.
11273338|NCT02881216|Other|Common DES|Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
11273342|NCT02881190|Experimental|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.
11273343|NCT02881177|Experimental|Oxytocin|Oxytocin 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
11273344|NCT02881177|Placebo Comparator|Placebo|Placebo 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
11273345|NCT02881164|Experimental|Low glycemic index breakfast|Low glycemic index breakfast (GI=45)
11273346|NCT02881164|Active Comparator|High glycemic index breakfast|High glycemic index breakfast (GI=80)
11273347|NCT02881151|Experimental|Treatment|Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.
11273348|NCT02881138|Experimental|RC48-ADC|Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
11273349|NCT02881125|Experimental|Treatment (paclitaxel, nortriptyline hydrochloride)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride PO QD on days 1-7, BID on days 8-14, and TID on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11273350|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
11273351|NCT02881099||Recent diagnosis (P3)|Primary cohort; participants recruited if diagnosed within the last three years
11273352|NCT02881099||Early diagnosis (P50)|Participants recruited if diagnosed before the age of 50 years old
11273353|NCT02881099||Relatives (R)|Siblings of existing participants
11273354|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
11273355|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
11273356|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
11273357|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
11273358|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
11273359|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
11273360|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
11273361|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
11273362|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
11273363|NCT02881073|No Intervention|Control|"Eligible women at participating centres prior to roll-out of PlGF testing (as per stepped wedge trial design) will be managed according to HSE/Institute of Obstetrician and Gynaecologists' National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia or by NICE guidelines for Management of Hypertension in Pregnancy for those in Northern Ireland."
11273364|NCT02881073|Active Comparator|Maternal plasma PlGF quantification|"Women in the interventional arm will have an additional point of care test performed at the time of enrolment for immediate PlGF quantification. The PlGF measurement will be reported as the absolute value in pg/ml with the following ranges given:
~PlGF <12 pg/ml: Very low
~PlGF ≥12 and <100 pg/ml: Low
~PlGF ≥100 pg/ml: Normal
~All hospitals will follow National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia with the additional integration of PlGF results as indicated in the algorithm."
11273365|NCT02881060|Active Comparator|Ethanol|Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
11273366|NCT02881060|Placebo Comparator|Non-ethanol|Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
11273367|NCT02881047|Experimental|rAblative Fractional Laser for Sclerotic GVHD-Associated Joint|"Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
11273368|NCT02881034||Hepatitis C patients|Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir
11273369|NCT02881021|Experimental|Rehabilitation program and kinesiotaping.|"Each patient will attend 10 physiotherapy sessions over six. Patients from the Experimental group (KT group) will receive the same standardized rehabilitation program as control group (No-KT group) including manual therapy, movement training, stretching, muscular strengthening, and patient education.
~Only KT-group (experimental) will receive therapeutic KT added to the rehabilitation program.
~Kinesio® Tex Classic will be applied using a combination of techniques designed for RCTe and underlying symptoms following the instructions and principles described by Kase et al (2003).
~Kinesiotaping strips will be weaned gradually, according to the individual improvements of deficits evaluated weekly by the physiotherapist treating."
11273449|NCT02880410|Experimental|LITT Treatment w/radiation therapy and temozolomide|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System in combination with radiation therapy and temozolomide
11273515|NCT02879877|Experimental|UCB7858 (intravenous)|Various single doses, administered to various cohorts.
11273370|NCT02881021|Active Comparator|Rehabilitation program.|"Each patient will attend 10 physiotherapy sessions over six. Patients allocated at the control group (No-KT group) will receive only the rehabilitation program, including manual therapy, movement training, stretching, muscular strengthening, and patient education.
~The rehabilitation program will be exactly the same applied to the experimental group (KT group)."
11273371|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
11273372|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
11273373|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
11273374|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg daily for 24 weeks
11273375|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
11273376|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
11273377|NCT02880995|Experimental|patient group|"50 Drug-naïve patients with first episode psychosis (We anticipate the non-responder rate will be 30% of the patients)
~Drug-naïve
~Diagnosed as first episode psychosis
~The total score of PANSS>70
~No co-morbid psychiatric illness (including drug dependence/abuse)
~They will also undergo PET scan at the baseline. And the investigators are going to determine treatment response after 6 weeks of treatment with amisulpride. Also they should complete clinical scales at 0, 2, 4, 6, and 8 week."
11273378|NCT02880995|Other|healthy control group|"12 healthy volunteers
~No history of psychiatric disorder (including drug dependence/abuse)
~No history of physical illness
~No contra-indication to scanning
~They will also undergo PET scan at the baseline"
11273379|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
11273380|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
11273381|NCT02880969|Experimental|Patient with end stage renal disease undergoing dialysis|
11273382|NCT02880956|Experimental|Group 2|Dose 2 ABBV-8E12
11273383|NCT02880956|Experimental|Group 3|Dose 3 ABBV-8E12
11273384|NCT02880956|Experimental|Group 1|Dose 1 ABBV-8E12
11273385|NCT02880956|Placebo Comparator|Group 4|Placebo for ABBV-8E12
11273386|NCT02880943|Experimental|Group A|"Group A: patients with bone disease mainly will be treated with XOFIGO® alone.
~Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A."
11273387|NCT02880943|Experimental|Group B|Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
11273388|NCT02880930|Experimental|Vitamin D supplement (Cholecalciferol)|Participants will be given oral Fultium-D3 drops (Internis) contain 400 IU cholecalciferol/day for a period of 3 months. Daily vitamin D3 supplementation dose will be increased to 1,000 IU for an additional 3 months if plasma 25(OH)D still below 75 nmol/L.
11273389|NCT02880917|Active Comparator|Cognitive training + tDCs-Active|tDCs active left dorsolateral prefrontal cortex (2mA,20 min) and Cognitive training (20min) at the same time.
11273390|NCT02880917|Sham Comparator|Cognitive training+ tDCs-Sham|tDCs Sham dorsolateral prefrontal cortex ((2mA,20 min) and Cognitive training (20min) at the same time.
11273391|NCT02880891|Experimental|splinted|splinted crown
11273392|NCT02880891|No Intervention|non-splinted|single crown
11273393|NCT02880878|Experimental|Early Surgical Hematoma Evacuation|Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
11273394|NCT02880878|No Intervention|Medical Management|Subjects will receive standard of care medical management for ICH.
11273395|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
11273396|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
11273397|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
11273398|NCT02880839|Experimental|Partial cervical lamina excision group|Patients in the cervical lamina partial excision group underwent partial cervical lamina excision and cervical pedicle screw internal fixation.
11273399|NCT02880839|Experimental|Pipeline-dredge discharge group|Patients in the pipeline-dredge discharge group underwent pipeline-dredge discharge and cervical pedicle screw internal fixation.
11273400|NCT02880839|Experimental|Digital navigation group|Patients in the digital navigation group underwent digital navigation-assisted cervical pedicle placement.
11273401|NCT02880813|Experimental|Gastric|gastric infusion
11273402|NCT02880813|Experimental|Duodenal|Duodenal infusion
11273403|NCT02880800|Experimental|Analgesia, patient controlled|Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of either morphine or hydromorphone.
11273404|NCT02880800|Active Comparator|Analgesia, as per needed|Patients will receive intravenous (IV) opioids as per needed.
11273405|NCT02880787|Other|Adult population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
11273406|NCT02880787|Other|Adult population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
11273407|NCT02880787|Other|Pediatric population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
11273408|NCT02880787|Other|Pediatric population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
11273409|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
11273410|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
11273509|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
11273586|NCT02879422|Other|Diabetic patients with non proliferative diabetic retinopathy|
11273411|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
11273412|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
11273413|NCT02880748|Experimental|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum.
11273414|NCT02880748|Active Comparator|Air insufflation (AI) method|Air insufflation (AI) method was used for insertion to the cecum.
11273415|NCT02880735|Experimental|Non Invasive Ventilation.|"It will provide noninvasive mechanical ventilation with the following specifications:
~Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months."
11273416|NCT02880722||IBS patients|IBS according to Rome IV criteria.
11273417|NCT02880722||Healthy control group|Healthy volunteers without abdominal complaints fulfilling Rome IV criteria for IBS.
11273418|NCT02880709|Experimental|Special diet|Special diet with taste, energy-and protein content adjusted according to previous finding
11273419|NCT02880709|No Intervention|Usual diet|Patients habitual diet
11273420|NCT02880696|Experimental|Test (Regular)|Regular stimulation sequence & DCS
11273421|NCT02880696|Active Comparator|Control (Random)|Random stimulation sequence & DCS
11273422|NCT02880683|Experimental|Single arm, transvenous cardiac autonomic nerve stimulation|
11273423|NCT02880670|Experimental|Single dose of radiolabeled BMS-986142|
11273424|NCT02880657|Experimental|SODB®-physical training|This arm receives daily two capsules of SODB® 40mg containing 560 UI of superoxide dismutase, associated with standardized physical training
11273425|NCT02880657|Experimental|Placebo-physical training|This arm receives daily two capsules of Placebo containing excipients only, associated with standardized physical training
11273426|NCT02880605||appropriate in appropriate indications|
11273427|NCT02880605||inappropriate in appropriate indications|
11273428|NCT02880605||appropriate in inappropriate indications|
11273429|NCT02880605||inappropriate in inappropriate indications|
11273430|NCT02880592|Experimental|Fresh amniotic membrane/standard of care|This group will receive the Affinity Allograft and standard of care.
11273431|NCT02880592|Active Comparator|Standard of Care|This group will receive standard of care for diabetic foot ulcers that includes offloading of the diabetic foot ulcer, debridement, and infection management using the appropriate dressings.
11273432|NCT02880566|Experimental|Treatment|Full scalp block performed with a total of 30 ml of levobupivacaine 0.33 %.
11273433|NCT02880566|Placebo Comparator|Control|Full scalp block performed with a total of 30 ml of normal saline.
11273434|NCT02880540|Active Comparator|Control Group|Fentanyl 50 micrograms IV every 15 minutes up to 3 doses in postanesthesia recovery room and Morphine 2mg IV every 2 hours for 2days on hospital floor
11273435|NCT02880540|Experimental|Dexmedetomidine Treated|Dexmedetomidine IV bolus 1.5microgram/kilogram and a continuous infusion starting at 0.1 microgram/kilogram/hour during surgery
11273436|NCT02880527||patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis will be used:
~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;
~general practitioners
~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )
~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
11273437|NCT02880514|Experimental|PROPEL Mini Sinus Implant|Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
11273438|NCT02880514|Active Comparator|Balloon Sinus Dilation Alone|In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement
11273439|NCT02880501|Experimental|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.
11273440|NCT02880475|Experimental|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
11273441|NCT02880475|Experimental|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
11273442|NCT02880462|Active Comparator|high dose sulforaphane|The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
11273443|NCT02880462|Active Comparator|low dose sulforaphane|The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
11273444|NCT02880462|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
11273445|NCT02880449|Experimental|Intervention|The intervention will be conducted in pre-existing older women's groups based in community centres. The intervention will consist of three educational sessions, encouragement to enlist the support of a partner or 'buddy' (e.g. a spouse, partner or friend), an information pack (containing information on the local area, walking routes, points of interest) and the option of weekly telephone contact. Participants will be given the opportunity to discuss their progress and share feedback with the rest of the group at weekly meetings.
11273446|NCT02880449|No Intervention|Control|Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
11273447|NCT02880423|Other|salpingectomy group I|salpingectomy during cesarean section for sterilization
11273448|NCT02880423|Active Comparator|tubal ligation group II|tubal ligation in cesarean section
11273450|NCT02880397|Active Comparator|Garcinia Mangostana|The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
11273451|NCT02880397|Placebo Comparator|Placebo gel|The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.
11273452|NCT02880384|Experimental|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
11273453|NCT02880371|Experimental|Phase 1b/Part A|Patients in Part A will receive escalating doses of single-agent ARRY-382 in combination with 2 mg/kg pembrolizumab.
11273454|NCT02880371|Experimental|Phase 2|Patients in Phase 2 will receive the MTD/RP2D dose of ARRY-382 determined during Part A in combination with 200mg pembrolizumab.
11273455|NCT02880345|Active Comparator|Cohort 1 - 8 Gy x 3 fractions|8 Gy x 3 fractions
11273456|NCT02880345|Active Comparator|Cohort 2 - 17 Gy x 1 fractions|17 Gy x 1 fraction
11273457|NCT02880332|Active Comparator|Usual care + Extra care|This group will receive usual care and one additional session; extra care.
11273458|NCT02880332|Experimental|Usual care + PNE|Next to usual care, this group will also receive pain neuroscience education.
11273459|NCT02880319|Experimental|Oligometastatic Disease|"Stereotactic Body Radiation Therapy (SBRT)to up to 3 sites of disease occurring in the bone or spine
~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.
~Dosage will be determined by physician"
11273460|NCT02880319|Experimental|Metastatic Disease|"Stereotactic Body Radiation Therapy (SBRT) to site(s) of disease occurring in the bone or spine
~Treatments will be delivered on a dedicated stereotactic linear accelerator that includes onboard conebeamCT imaging and orthogonal 2D/3D matching with robotic couch top.
~Dosage will be determined by physician"
11273461|NCT02880306||RA cohort|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria.
11273462|NCT02880306||Non-RA cohort|Participants who were ≥18 years of age, without a RA diagnosis
11273463|NCT02880293|Experimental|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
11273464|NCT02880280|Experimental|Human Menopausal Gonadotropin|Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
11273465|NCT02880280|Experimental|Human Chorionic Gonadotropin|Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation
11273466|NCT02880267|Other|CGM Users|Glucose challenge during a clinic sessions to assess performance of CGM compared to reference measurement
11273467|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
11273468|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
11273469|NCT02880241|Experimental|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
11273470|NCT02880241|Experimental|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
11273471|NCT02880241|Experimental|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
11273472|NCT02880241|Experimental|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
11273473|NCT02880241|Experimental|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
11273474|NCT02880241|Experimental|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
11273475|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
11273476|NCT02880215|Experimental|Attention Bias Modification|Behavioral intervention designed to improved negative attention bias.
11273477|NCT02880215|Experimental|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
11273478|NCT02880215|No Intervention|Assessment Only|Assessment only with no active intervention.
11273479|NCT02880202|Other|Massage Therapy|Massage therapy for hospice patients.
11273480|NCT02880189|Other|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
11273481|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.
~Subjects will use Fitbit Zip to track step counts"
11273482|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
11273483|NCT02880150|Other|Elite climbers|Elite climbers selected in a national group for their previous performances at high altitude
11273484|NCT02880150|Other|Sea level sportsmen|Control group with similar anthropometric, age, gender and maximal normoxic oxygen consumption that the elite climber group
11273485|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
11273510|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
11273511|NCT02879916|Placebo Comparator|Placebo|NaCl 0.9% 3ml perineural stellate ganglion injection
11273486|NCT02880124|Experimental|Maple syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
11273487|NCT02880124|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
11273488|NCT02880124|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
11273489|NCT02880124|Active Comparator|Sport drink|A Gatorade (TM) solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
11273490|NCT02880124|Placebo Comparator|Trace|A solution containing stevia (sugar substitute) and trace amounts of glucose (3g) labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
11273491|NCT02880111||group 1|CF patients with Pseudomonas aeruginosa chronic colonization.
11273492|NCT02880111||group 2|CF patients without a Pseudomonas aeruginosa chronic colonization.
11273493|NCT02880072|Experimental|refeeding syndrome|6 patients with head and neck cancer and refeeding syndrome, 4 different of preparations of phosphate orally
11273494|NCT02880072|Experimental|no refeeding syndrome|6 patients with head and neck cancer without refeeding syndrome, 4 different of preparations of phosphate orally
11273495|NCT02880046||Melanoma (LyteloMel)|
11273496|NCT02880046||Lung cancer (TeloCap)|
11273497|NCT02880046||Renal carcinoma (EMIR)|
11273498|NCT02880033|Active Comparator|Parkinson's disease|ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
11273499|NCT02880033|Active Comparator|Amyotrophic lateral sclerosis|ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
11273500|NCT02880033|Placebo Comparator|healthy age and sex matched controls|ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
11273501|NCT02880020|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11273502|NCT02880020|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes every 6 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11273503|NCT02880007|Experimental|ARM A|Dose Optimization in 3D Pulsed Dose Rate Brachytherapy
11273504|NCT02879994|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11273505|NCT02879981||Pediatric Participants With Acute Bronchitis|Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label will be observed for safety.
11273506|NCT02879968||Head and Neck squamous cell carcinoma|"A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.
~The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).
~The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula."
11273507|NCT02879955|Experimental|10 gastric bypass operated patients|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
11273508|NCT02879955|Experimental|10 healthy control subjects|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
11274604|NCT02872051|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
11273518|NCT02879877|Placebo Comparator|Placebo (subcutaneous)|Single dose placebo comparator for each cohort of sc administration.
11273519|NCT02879864|Experimental|Light therapy|Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes. Light therapy begins immediately after receipt of the luminometer. The total duration of daily outpatient therapy program is 6 months. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24. They will complete the same day or the day before, and / or before any chemotherapy. A follow-up visit will be performed 1 month after the end of therapy (week 28).
11273520|NCT02879864|Active Comparator|usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
11273521|NCT02879838||Occupational Asthma|
11273522|NCT02879838||Work Aggravated Asthma|
11273523|NCT02879838||Non-Work-Related Asthma|
11273524|NCT02879825|Experimental|Group A|Mitral valve prolapse without mitral regurgitation
11273525|NCT02879825|Experimental|Group B|Mitral valve prolapse with trivial mitral regurgitation
11273526|NCT02879825|Experimental|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
11273527|NCT02879825|Experimental|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
11273528|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
11273529|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
11273530|NCT02879799|Experimental|Implement Family Integrated Care|Dynamic education and support intervention for families of preterm infants.
11273531|NCT02879799|No Intervention|Monitor Standard Practices|Standard nursing care of preterm infants and their families.
11273532|NCT02879786|Experimental|Phonological dyslexia|Children with phonological dyslexia
11273533|NCT02879786|Experimental|Visuo-attentional dyslexia|Children with visuo-attentional dyslexia
11273534|NCT02879786|Other|Control|Control children, age-matched
11273535|NCT02879773||Lung cancer|Patients undergoing thoracic surgery for suspected or confirmed lung cancer; including wedge resection, segmentectomy, lobectomy, bilobectomy or pneumonectomy. CTPVe will be modelled to predict postoperative lung function.
11273536|NCT02879773||Emphysema|Patients undergoing assessment of emphysema/chronic obstructive pulmonary disease (COPD) for potential surgical intervention; including lung volume reduction surgery, endobronchial valve insertion or endobronchial coil insertion. CTPVe will be modelled to predict postoperative lung function.
11273537|NCT02879773||Interstitial lung disease|Patients undergoing assessment or treatment of suspected or confirmed interstitial lung disease. CTPVe will be modelled to aid diagnosis of the subtype of interstitial lung disease confirmed by histological diagnosis.
11273538|NCT02879760|Experimental|Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab|"Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.
~MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 & 18 at 1x 10e10 pfu.
~Cohort 2: Days 15 & 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22."
11273539|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
11273540|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
11273541|NCT02879734|No Intervention|Without Omentopexy|Patients that did not undergo prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter
11273542|NCT02879734|Experimental|With Omentopexy|Patients that underwent prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter. Intervention = Prophylactic laparoscopic omentopexy
11273543|NCT02879721|No Intervention|no drug|No drug and no intervention
11273544|NCT02879721|Active Comparator|AT1R-antagonist|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily
11273545|NCT02879721|Active Comparator|ACE-inhibitor|Angiotensin converting enzyme inhibitor, (enalapril) 5 mg once daily
11273546|NCT02879708|No Intervention|Control|40 (of 120) randomly selected villages receive no intervention
11273547|NCT02879708|Other|Information Only|"40 randomly selected villages are assigned to the information only arm where households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village."
11273548|NCT02879708|Other|Information and Facilitation|The remaining 40 villages will receive similar information as the villages in the Information Only Arm, but will also have facilitators present that ensure the existence of the VHSNC at the village level as well as the occurrence of VHSNC monthly meetings.
11273549|NCT02879695|Experimental|Treatment (blinatumomab, nivolumab, ipilimumab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year.
11273550|NCT02879682|Active Comparator|nTMS|presurgical motor mapping by nTMS and fusion with intraoperative neuronavigation
11273551|NCT02879682|Sham Comparator|non-nTMS|presurgical motor mapping by nTMS without access of the surgeon to these data
11273613|NCT02879188|Experimental|Ambulation|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
11273552|NCT02879669|Experimental|ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)|ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
11273553|NCT02879669|Active Comparator|Pemetrexed/cisplatin (carboplatin)|Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
11273554|NCT02879656|Other|Cohort 1|"Early ustable fracture:
~Phase 1:
~After closed reduction, if satisfactory reduction is not achieved fulfilling the inclusion criteria, the patient is allocated to Cohort 1. The patient is randomized to either non-operative (=Arm 1) or operative treatment (=Arm 2). Patients allocated to non-operative treatment will undergo a standard treatment protocol. Patients allocated to operative treatment will undergo a surgery with volar locking plate with modified Henry's volar approach."
11273555|NCT02879656|Other|Cohort 2|"Early stable fracture:
~Phase 1:
~After closed reduction, if satisfactory position is achieved, the patient is allocated to Cohort 2 and conservative treatment is performed as usually.
~Phase 2:
~Patients allocated to Cohort 2, will visit orthopedic outpatient clinic in 1 week in the hospital where the treatment was initially started. If reduction is maintained the patient will undergo standard follow-up visits. If reduction is lost to fulfill the inclusion criteria for surgery the patient is asked to participate to phase 2 of this study. After the patient´s enrollment has been confirmed and informed consent is signed, the patient is randomized to either non-operative (=Arm 3N) or operative treatment (=Arm 3O). If allocated to non-operative treatment patient will undergo the same protocol as those in the Arm 1. Patients allocated to operative treatment will undergo surgery with volar locking plate with standard volar approach."
11273556|NCT02879643|Experimental|Cohort A: Marqibo and UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.
~Dexamethasone orally twice daily on days 1-5 and 15-19.
~Mitoxantrone: given by intravenous (IV) infusion on days 1 and 2.
~PEG-asparaginase: given as an injection into the muscle on says 3 and 17.
~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
11273557|NCT02879643|Experimental|Cohort B: Marqibo and lower intensity UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.
~Dexamethasone orally twice daily on days 1-5 and 15-19.
~PEG-asparaginase: given as an injection into the muscle on days 3 and 17.
~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
11273558|NCT02879643|Experimental|Cohort C: Marqibo and maintenance regimen|"Marqibo®: given by intravenous (IV) infusion on day 1
~Dexamethasone orally twice daily on days 1-5
~Methotrexate: given orally on days 1 and 8
~Mercaptopurine: given orally daily on days 1-13"
11273559|NCT02879630||Obese Patients|
11273560|NCT02879630||Non-obese Patients|
11273561|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
11273562|NCT02879604|Experimental|Compensatory cognitive training|Compensatory cognitive training
11273563|NCT02879604|Placebo Comparator|usual treatment|usual treatment for shizophrenai
11273564|NCT02879591|Experimental|Patients with schizophrenia|Patients with schizophrenia
11273565|NCT02879591|Placebo Comparator|Healthy volunteers|Healthy volunteers
11273566|NCT02879578|Experimental|NBI-98854|NBI-98854 administered once daily for up to 24 weeks
11273567|NCT02879565|Other|qualitative and neuroimaging research|
11273568|NCT02879552||Traditional upper blepharoplasty|Patients with an odd total number of letters in their first name received traditional upper blepharoplasty.
11273569|NCT02879552||Brassiere suture with blepharoplasty|The rest of the patients received orbicularis oculi muscle fixation to periosteum (brassiere sutures)
11273570|NCT02879539|Experimental|MP3000-ACE strategy|MP3000 sound coding strategy or ACE strategy with lower stimulation rate
11273571|NCT02879526|Experimental|C-CPT|
11273572|NCT02879513|Active Comparator|Switch to CEF|Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
11273573|NCT02879513|Experimental|Continue the neoadjuvant regimen|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
11273574|NCT02879513|Experimental|Pathological complete response group with chemotherapy|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
11273575|NCT02879513|No Intervention|Pathological complete response group with no chemotherapy|
11273576|NCT02879487|Active Comparator|Coagulation mode|Colpotomy will be performed by monopolar needle electrode using coagulation mode
11273577|NCT02879487|Active Comparator|Cut mode|Colpotomy will be performed by monopolar needle electrode using cut mode
11273578|NCT02879474||Patient with melanoma|
11273579|NCT02879461|Active Comparator|Lumbar Decompression plus Physical Therapy|First group will be submitted to lumbar decompression L3 to S1 and physical therapy with exercise Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
11273580|NCT02879461|Active Comparator|Physical Therapy|Second group physical therapy alone, with exercises Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
11273581|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
11273582|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
11273583|NCT02879435|Experimental|bupivacaine|Intervention
11273584|NCT02879435|Placebo Comparator|Placebo|Control
11273585|NCT02879422|Other|Diabetic patients with proliferative diabetic retinopathy|
11273587|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl
~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
11273588|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl
~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
11273589|NCT02879396|Experimental|Study Participants|A maximum of 50 participants will be enrolled in the study per the inclusion and exclusion criteria. The participants will be residents of SLH who are 55 years old or older. They will have had one or more EMS calls made, ED visit or hospital admission in the past year, as determined by the incidence report at SLH. The study participants will receive PA4LE program.
11273590|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
11273591|NCT02879383|Sham Comparator|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
11273592|NCT02879370|Experimental|TICRANT|Transanal Inspection and management of low ColoRectal Anastomosis
11273593|NCT02879357|Experimental|Trained Clinicians|Training in Serious Illness Communication Guide
11273594|NCT02879357|No Intervention|Untrained Clinicians|No training in Serious Illness Communication Guide
11273595|NCT02879344|Other|Patient undergoing ECMO|
11273596|NCT02879331|Active Comparator|10 coils in upper lobes|10 coils in upper lobes
11273597|NCT02879331|Experimental|15 coils in upper and lower lobes|15 coils in upper and lower lobes
11273598|NCT02879318|Active Comparator|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 8, 15 Q28 days.
11273599|NCT02879318|Experimental|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.
~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
11273600|NCT02879305|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
11273601|NCT02879305|Active Comparator|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
11273602|NCT02879279|Experimental|Robotic rehabilitation|In the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
11273603|NCT02879279|Active Comparator|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
11273604|NCT02879266|Experimental|TetraVax-DV TV005|Participants will receive a subcutaneous injection of TetraVax-DV TV005 at study entry (Day 0).
11273605|NCT02879266|Placebo Comparator|Placebo|Participants will receive a subcutaneous injection of placebo at study entry (Day 0).
11273606|NCT02879240|Other|Group animated cartoon-black screen (AB)|In this group, children will be exposed to a animated cartoon during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to a black screen in the same conditions for one other week.
11273607|NCT02879240|Other|Group black screen - animated cartoon (BA)|In this group, children will be exposed to a black screen during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to an animated cartoon in the same conditions for one other week.
11273608|NCT02879227|Active Comparator|Arm Cisplatin|Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
11273609|NCT02879227|Experimental|Arm Oxaliplatin|Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
11273610|NCT02879214|Experimental|SIDE cervical trial|To Maximal downstage locally advanced squamous cell cervical cancer before minimal invasive surgical resection. The SIDE study is to use both RT dose escalation to the biological target defined by PET and Chemo dose escalation composited with two drugs to achieve maximal reduction of tumor burden, providing feasibility of minimal invasive surgical resection.
11273611|NCT02879201|Active Comparator|Slow efficiency dialysis|SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
11273612|NCT02879201|No Intervention|Continuous renal replacement therapy|CRRT is a kind of therapy involved continuos dialysis throughout 24 hours by using Edward Delivery system (Edward Life Science) as continuous venovenous hemodiafiltration (CVVHDF) mode using Aquamax HF 12 dialyzer. Blood flow rate was kept from 100-200 mL/hr and target effluent rates of 20 mL/hr . The substitution fluid was infused at a rate of 1,000 ml/hr with ultrafiltration rate at 100-300 mL/hr.Intervention here is the different mode of dialysis
11273941|NCT02876666|Experimental|Coach Intervention|
11273942|NCT02876666|No Intervention|Usual Care|
11273614|NCT02879188|Active Comparator|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
11273615|NCT02879162|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
11273616|NCT02879149||Group 1|Standard Rigid Fixation plus autograft
11273617|NCT02879149||Group 2|Standard rigid fixation plus AUGMENT® Bone Graft
11273618|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
11273619|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
11273620|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
11273621|NCT02879110|Experimental|Sulforaphane group|The patients will take sulforaphane for 12 weeks.
11273622|NCT02879110|Placebo Comparator|Placebo group|The patients will take placebo for 12 weeks.
11273623|NCT02879097|Experimental|CBT124 arm|CBT124 plus carboplatin and paclitaxel
11273624|NCT02879097|Active Comparator|EU Sourced Avastin® arm|EU-sourced Avastin® plus carboplatin and paclitaxel
11273625|NCT02879058|No Intervention|Without Ultrasound|Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
11273626|NCT02879058|Experimental|With Ultrasound|Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography
11273627|NCT02879045|Experimental|elasticity Belly® oil|Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil
11273628|NCT02879019|Sham Comparator|Stretching exercise group|Patients will receive two session per week of stretching classes.
11273629|NCT02879019|Experimental|Walking training group|Patients will perform two walking sessions per week.
11273630|NCT02879006|Active Comparator|Chinese Herbal Medication|
11273631|NCT02879006|Placebo Comparator|Placebo|
11273632|NCT02878993||Intubated infants|Recording of diaphragm EMG
11273633|NCT02878980|Experimental|Arm I (exercise intervention)|Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
11273634|NCT02878954|Other|No intervention|160 men and women with PAD will be recruited.
11273635|NCT02878954|Other|Control session|40 patients (men and women) will complete this session.
11273636|NCT02878954|Other|Exercise session|40 patients (men and women) will complete this session.
11273637|NCT02878941|Other|Elbow Fracture|Patients with an intraarticular elbow fracture and/or dislocation. Synovial fluid from the injured elbow will be obtained during the subject's emergency department encounter by one of the Chief Residents or Attending surgeon as part of standard of care procedures for pain control-related injection and aspiration. Patients with an intraarticular elbow fracture and/or dislocation receive an intraarticular elbow injection with anesthetic (i.e. lidocaine or marcaine) to provide analgesia for elbow range of motion testing and orthopaedic reduction maneveuers as the current standard of care. The patients would be asked to consent for 2 elbow joint aspirations: 1.Aspiration of the injured elbow at time of surgical fracture fixation; 2.Aspiration of the uninjured elbow at time of surgical fracture fixation.
11273638|NCT02878928|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|Medical providers for IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
11273639|NCT02878928|No Intervention|Control Group|Medical providers for the Control Group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
11273640|NCT02878915|Active Comparator|Ultrasound guided femoral puncture|
11273641|NCT02878915|No Intervention|palpation guided femoral puncture|
11273642|NCT02878902||Before implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2012 to December 31, 2013"
11273643|NCT02878902||Post implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2014 to December 31, 2015"
11273644|NCT02878889|Experimental|Arm 1|S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
11273645|NCT02878876|Experimental|Sequence A1-A2|Dietary Supplement: Oral consumption of milk with sequence A1-A2
11273646|NCT02878876|Experimental|Sequence A2-A1|Dietary Supplement: Oral consumption of milk with sequence A2-A1
11273647|NCT02878863|Experimental|Paeoniflorin + phosphatidylcholine or silymarin|Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin
11273648|NCT02878863|Active Comparator|Phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin
11273649|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
11273650|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
11273651|NCT02878837|Active Comparator|DEX|Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.
11273652|NCT02878837|Active Comparator|MDZ|Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1
11273653|NCT02878824||HK-Children|This is a group of typically-developing children ages 7-12 years old who are of Chinese ethnicity, born and raised in Hong Kong (n=32).
11273654|NCT02878824||FHK-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity; either born, migrated and/or raised in Hong Kong (n=32).
11273943|NCT02876653|Other|Severe OSA|Patients with severe OSA (AHI > 30)
11273655|NCT02878824||FU-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in an urban area in the Philippines (n=32).
11273656|NCT02878824||FR-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in a rural area in the Philippines (n=32).
11273657|NCT02878798|Placebo Comparator|Placebo|An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
11273658|NCT02878798|Experimental|Topiramate|Oral topiramate
11273659|NCT02878785|Experimental|Decitabine and Talazoparib Combo|"Phase 1:
~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28.
~The 'outer layer' of this nested dose escalation trial will escalate the dose of the two drugs by sequentially going through dose levels 1-6 in the table found in the protocol. The standard algorithm of the 3+3 design will be applied.
~Phase 2:
~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28. Phase 2 doses will be determined based on data from Phase 1."
11273660|NCT02878772|Active Comparator|vinpocetine group|Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
11273661|NCT02878772|Placebo Comparator|Control group|Patients will receive aspirin only.
11273662|NCT02878759|Experimental|Wristbot|WristBot will be used as diagnostic tool to evaluate the novel technology and the associated protocol for proprioception quantification during rehabilitation. The main objective is to provide clinicians with a reliable instrument able to overcome the limitations in proprioceptive measurement by current clinical methodologies.
11273663|NCT02878746|Experimental|Robotic mirror therapy|For 30 min per day for two weeks (10 sessions)
11273664|NCT02878746|Active Comparator|Conventional mirror therapy|For 30 min per day for two weeks (10 sessions)
11273665|NCT02878733||Albumin|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
11273666|NCT02878733||Crystalloid Only|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
11273667|NCT02878720|Experimental|Robotic therapy and real tVNS|This group receives REAL vagus nerve stimulation during robotic rehabilitation.
11273668|NCT02878720|Active Comparator|Robotic therapy and sham tVNS|This group receives SHAM VNS during robotic rehabilitation. Sham VNS is not effective. Both groups receive the same amount of robotic rehabilitation.
11273669|NCT02878707|Experimental|DEX|Intraoperative intravenous infusion of dexmedetomidine
11273670|NCT02878707|Placebo Comparator|Control|Intraoperative intravenous infusion of 0.9% saline
11273671|NCT02878694|Experimental|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections
11273672|NCT02878681|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab for six months
11273673|NCT02878681|Experimental|Group 2|Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.
11273674|NCT02878681|Experimental|Group 3|Monthly injections of 2 mg aflibercept for six months
11273675|NCT02878616|Experimental|LFG316 + IVIG|
11273676|NCT02878616|Experimental|LFG316 alone|
11273677|NCT02878603|Experimental|caplacizumab|Initial i.v. dose followed by daily s.c. injections for a maximum period of 6 months
11273678|NCT02878590|Experimental|BONGO DEVICE|All participants that qualify will receive the intervention of the Bongo device
11273679|NCT02878577||EEG fMRI TBI Mild/Moderate-Severe severity|patient population who suffered a brain trauma (traumatic brain injury, TBI). with a Glasgow Coma Scale between 3-15
11273680|NCT02878577||EEG fMRI Control group|healthy subjects with out a traumatic brain injury
11273681|NCT02878564|Experimental|Praziquantel treatment|Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.
11273682|NCT02878551|Experimental|Prehabilitation program|Multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
11273683|NCT02878538|Active Comparator|deferiprone|Deferiprone will be administered three times a day (25mg/kg). Total dose per day will depend on participants' body weight for one, three month block.
11273684|NCT02878538|Placebo Comparator|Placebo Phase|Placebo tablets with inactive substance will be used. Total number of placebo tablets will be equivalent to the active tablets administered depending on participants' body weight for two, three month blocks.
11273685|NCT02878525|Experimental|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
11273686|NCT02878525|Active Comparator|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
11273687|NCT02878512|Active Comparator|PCNL under General Anesthesia|Patients were premedicated with Inj. Atropine 0.06 mg intramuscularly half an hour prior to surgery, IV ranitidine 1mg kg-1, IV ondansetron 0.08mg kg-1 IV midazolam 0.02mg kg-1 and Pentazocine 0.3 mg/kg. Anaesthesia was induced with IV Thiopentone sodium 3-5 mg kg-1 and Vecuronium 0.1mg kg-1.and then intubated. Anaesthesia was maintained on 50 %:50% nitrous oxide and oxygen, vecuronium and propofol infusion . At the end of the surgery postoperative analgesia was given with IV tarmadol and local nfiltration with 0.25% bupivacaine at the surgical site. Patients were reversed with IV glycopyrrolate 0.008mg kg-1 and IV neostigmine 0.06mg kg-1 and extubated.
11273688|NCT02878512|Experimental|PCNL under Segmental epidural Anesthesia|epidural space was located at T12 -L1 or L1-L2 space .The epidural catheter was inserted cephalad 5 cm upwards in the epidural space (tip approximately at T8 to T9). and test dose of 3 ml of 2% Adrenalized Lignocaine was administered..loading dose of 0.5% Bupivacaine, approximately 8 to 10 ml was injected epidurally with regular negative aspiration to block T6- T12 segments, if desired level was not achieved then additional dose of 1 to 1.5 ml 0.5% bupivacaine per spared segment was given to achieve the desired level.Motor blockade of the lower limbs was checked and noted before lithotomy, before prone and at the end of the surgery using Bromage scale. After two segment regression of sensory level epidural top up with 1/4th of initial dose 2 to 3 ml of 0.5% Bupivacaine was given. At the end of the surgery 8ml of 0.125% Bupivacaine was administered for postoperative analgesia and the catheter was removed.
11273689|NCT02878499|Other|ASD|
11273944|NCT02876653|Other|Moderate OSA|Patients with moderate OSA (5 < AHI ≤ 30)
11273690|NCT02878486|Experimental|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
11273691|NCT02878486|Active Comparator|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
11273692|NCT02878473|Experimental|Liver transplantation|The intervention will consist of liver transplantation
11273693|NCT02878460|Experimental|monitoring with ORI + SpO2|"Patients receive the regular monitoring with SpO2, but in this group, the ORI parameters is shown on the scope.
~Lower and upper SpO2 limits are prescribed for each patient."
11273694|NCT02878460|Other|monitoring with SpO2|"Patients receive the regular monitoring; the ORI parameters is not shown (but it is recorded each time a blood gas is drown).
~Lower and upper SpO2 limits are prescribed for each patient."
11273695|NCT02878447|Experimental|External Beam Radiotherapy|Patients will receive radiotherapy (3.5Gy weekly for 5 fractions to a maximum of 17G) prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue
11273696|NCT02878447|No Intervention|Control|Patients will receive best medical care.
11273697|NCT02878434||Study group|
11273698|NCT02878434||control group|
11273699|NCT02878421|Active Comparator|tobacco cigarette|Intervention: tobacco cigarettes min 15/day
11273700|NCT02878421|Active Comparator|e.cigarettes + 16mg nicotine & flavor|Intervention: One flavoured electronic cigarette 16mg nicotine/day
11273701|NCT02878421|Active Comparator|e.cigarettes + 0mg nicotine & flavour|Intervention: One electronic cigarette with flavour +0mg nicotine/day
11273702|NCT02878408|Other|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
11273703|NCT02878408|Other|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
11273704|NCT02878408|Other|stable Bipolar disorder|blood sampling and data collection (only one visit)
11273705|NCT02878408|Other|stable Schizophrenia|blood sampling and data collection (only one visit)
11273706|NCT02878408|Other|healthy control|blood sampling and data collection (only one visit)
11273707|NCT02878395||Crohn's disease|
11273708|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
11273709|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
11273710|NCT02878356|Active Comparator|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
11273711|NCT02878356|Active Comparator|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
11273712|NCT02878356|Active Comparator|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
11273713|NCT02878343|Active Comparator|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
11273714|NCT02878343|Active Comparator|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
11273715|NCT02878343|Active Comparator|Incentive and environmental strategies|A combination of incentives and environmental strategies
11273716|NCT02878343|No Intervention|Usual care|Standard employee wellness benefits
11273717|NCT02878330|Placebo Comparator|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
11273718|NCT02878330|Experimental|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
11273719|NCT02878317||Malnourished participants|"Presence of malnutrition will be assessed by using the Subjective Global Assessment.
~Once the identified malnourished participants have given their informed consent, they will receive intensive dietitian supervised nutritional support with the aim of improving their malnutrition. In addition, participants will receive standard dietary advice for people on dialysis based on the Nutritional Guidelines in CKD published by the Renal Association in March 2010 in the UK (Wright and Jones, 2010) and will include the following: energy (35 kcal/kg/day) and protein intake (1.2 g/kg/day), as well as potassium, phosphate and sodium restriction, according with biochemical blood parameters."
11273720|NCT02878291|Experimental|High dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,40μg/dose
11273721|NCT02878291|Experimental|low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,20μg/dose
11273722|NCT02878278|Experimental|Chidamide BIW|Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
11273723|NCT02878278|Experimental|Chidamide QD|Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
11273724|NCT02878265|Placebo Comparator|Vitamin A|A single dose of 20,000IU Vitamin A for the whole study period
11273725|NCT02878265|Active Comparator|Vitamin A and zinc|A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months
11273726|NCT02878265|Active Comparator|Vitamin A , Zinc and Multivitamin|A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months
11273727|NCT02878239||Early OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with early knee osteoarthritis because their Kellgren-Lawrence Scores were Grade I.
11273728|NCT02878239||Moderate OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade II.
11273729|NCT02878239||Severe OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade III/IV.
11273730|NCT02878239||Asymptomatic Participants|The asymptomatic participants（>35 years） has no history of knee pain, trauma, surgery, or obvious gait abnormalities. They are set as controls in the study.
11273731|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
11273732|NCT02878200|Experimental|reactive treatment|Household members; defined as those sharing the same sleeping area, in the intervention villages, will be treated with a full course of dihydroartemisinin-piperaquine (DHAP)
11273733|NCT02878200|No Intervention|standard care|In control villages, no household treatment will be done
11273734|NCT02878187||placenta previa|all women managed by conservative surgical techniques during cesarean section after intraoperative hemorrhage due to placenta previa/accreta
11273735|NCT02878187||healthy controls|women delivered by Cesarean for any other indication with no intraoperative hemorrhage or any additional surgical techniques performed during Cesarean
11273736|NCT02878174|Active Comparator|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
11273737|NCT02878174|Experimental|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
11273738|NCT02878161|Experimental|A group|Infliximab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
11273739|NCT02878161|Experimental|B group|Etanercept plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
11273740|NCT02878161|Experimental|C group|Adalimumab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
11273741|NCT02878148|Experimental|Patients with suspected acute uncomplicated renal colic|Diagnostic imaging
11273742|NCT02878135|Experimental|fast vulsellum|rapid ratchet of the vulsellum
11273743|NCT02878135|Active Comparator|slow vulsellum|Placement of the tenaculum over 7-10 seconds and not allowing the vulsellum to ratchet audibly.
11273744|NCT02878122||Patients with epithelial ovarian cancer|Cancer treatment
11273745|NCT02878109||Post-treatment phase group|29 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE).
11273746|NCT02878109||Pre-treatment phase group|11 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before treatment (if any).
11273747|NCT02878096|Experimental|[14C]-SK-1404|
11273748|NCT02878083|Experimental|VEDOLIZUMAB|300 mg IV
11273749|NCT02878070|Experimental|Peer Health Coaching|Calls from a Peer Health Coach for 6 months
11273750|NCT02878070|No Intervention|Usual Care|
11273751|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
11273752|NCT02878044|Experimental|Implementation Arm|
11273753|NCT02878031|Experimental|Oral amoxicillin for CI pneumonia|Community management of chest indrawing pneumonia using oral amoxicillin by CHWs
11273754|NCT02878018||TCM intervention|Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
11273755|NCT02878018||WM conventional intervention|The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
11273756|NCT02878005|Active Comparator|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
11273757|NCT02878005|Active Comparator|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
11273758|NCT02877992|Active Comparator|Donors|Oocyte donors without infertility problems
11273759|NCT02877992|Experimental|PCOS|Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria
11273760|NCT02877992|Experimental|Endometriosis|Patients with endometriosis (I-IV)
11273761|NCT02877992|Experimental|Age|Patients with advanced maternal age (38 years or more)
11273762|NCT02877992|Experimental|Low ovarian response|Patients with low ovarian response according to Bologna criteria
11273763|NCT02877979|Experimental|DS003 vaginal tablet|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
11273764|NCT02877979|Placebo Comparator|placebo|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
11273765|NCT02877966|Experimental|Arm A|Amixea- patented stoechiometrical mixture of EAA & AA
11273766|NCT02877966|Placebo Comparator|Arm B|Placebo
11273767|NCT02877953|No Intervention|Control group|The conventional care was performed for the patients of control group
11273768|NCT02877953|Experimental|Intervention group|the prevention of complications post-TIPS
11273769|NCT02877940|Active Comparator|ProSeal Laryngeal mask airway|ProSeal will be inserted in mechanically ventilated patients undergoing elective surgeries.
11273770|NCT02877940|Active Comparator|Laryngeal Tube Suction- Disposable|LTS-D will be inserted in mechanically ventilated patients undergoing elective surgeries.
11273771|NCT02877940|Active Comparator|Group I|i-gel will be inserted in mechanically ventilated patients undergoing elective surgeries..
11273772|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
11273773|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
11273774|NCT02877901|Active Comparator|tolterodine-treated group|they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
11273775|NCT02877901|Placebo Comparator|placebo-control group|they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated
11273945|NCT02876653|Other|Healthy volunteers|Healthy volunteers (AHI ≤ 5)
11273776|NCT02877888|Experimental|drug fluoride varnish /strength 22600ppm|intervention: drug :fluoride varnish 22600ppm topical application every 6 months for a total period of 2 years
11273777|NCT02877888|No Intervention|placebo comparator|placebo:use of routine dental advice
11273778|NCT02877875|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC;Chorpita & Weisz, 2009), and (2) a youth monitoring and feedback system (MFS).
11273779|NCT02877875|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
11273780|NCT02877862|Experimental|Intervention|Receive 7-day mAGIC app intervention and handout
11273781|NCT02877862|No Intervention|Control|Handout only
11273782|NCT02877849||Individuals with Alcohol Use Disorder|Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
11273783|NCT02877849||Healthy Volunteers|Healthy volunteers with comparable age and gender to the patient group will be recruited through community advertisements. We will collect brain imaging data, this is an observational study.
11273784|NCT02877836|Other|Segmentary dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
11273785|NCT02877836|Other|Hemidystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
11273786|NCT02877836|Other|Generalized dystonia|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
11273787|NCT02877836|Other|Healthy control subjects|to identify movement-related functional magnetic resonance imaging (fMRI) activation patterns
11273788|NCT02877823|Experimental|Treatment|"Home delivery of bottled water supplying 48 oz. /day for the child and 24 oz. /day per other household members (up to 6 family members).
~Child pedometer use and activity tracking to encourage child physical activity/goal setting and engage parents in monitoring their child's health behavior.
~Family Navigator Services by telephone with the parent to help engage and empower parents in child healthy lifestyle changes. They will also be able to assist with resource needs for the household (food/housing services).
~Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks daily and limit fruit juice to one hundred percent real fruit juice."
11273789|NCT02877823|Active Comparator|Control|Healthy Lifestyle Education based on the American Academy of Pediatrics Institute for the Healthiest Childhood Weight daily guidelines which are 5 fruit and vegetable servings, two hours or less screen time, one hour or more physical activity, no sugary drinks and limit fruit juice to one hundred percent real fruit juice.
11273790|NCT02877810|Experimental|Telemedicine|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telemedicine, a live, interactive, audiovisual teleconferencing system, from a pediatric critical care physician.
11273791|NCT02877810|Active Comparator|Telephone|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telephone, from a pediatric critical care physician..
11273792|NCT02877797|No Intervention|standard Esophagogastroduodenoscopy|standard Esophagogastroduodenoscopy
11273793|NCT02877797|Experimental|cap assisted Esophagogastroduodenoscopy|cap assisted Esophagogastroduodenoscopy
11273794|NCT02877784||Screening|Participants enrolled will undergo testing of the swallowing mechanism
11273795|NCT02877771|Experimental|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses CGM values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
11273796|NCT02877758|Experimental|Experimental|Tomorrowlabs cosmeceutical formulation is applied to the face of the subjects twice daily for 3 consecutive months.
11273797|NCT02877758|Sham Comparator|Control|Tomorrowlabs cosmeceutical formulation without the active ingredient is applied to the face of the subjects twice daily for 3 consecutive months.
11273798|NCT02877745||no SDB|apnea-hyponea index <15/hour
11273799|NCT02877745||SDB|apnea-hyponea index >=15/hour
11273800|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
11273801|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
11273802|NCT02877719||Children from low-income families|Children from low-income families were invited to fill in a set of questionnaires.
11273803|NCT02877719||Children from high income families|Children from high-income families were invited to fill in a set of questionnaires.
11273804|NCT02877693|Other|Thoracic MRI Scan|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
11273805|NCT02877680|Experimental|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
11273806|NCT02877680|No Intervention|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
11273807|NCT02877667|Experimental|Open label device treatment|Up to four passes with Q-Switched laser alternating with acoustic wave device
11273808|NCT02877654|Experimental|Irritable Bowel Syndrome|
11273809|NCT02877641|Active Comparator|Control arm (multivitamin, placebo)|Patients receive a placebo and multivitamin orally each day for 52 weeks.
11273810|NCT02877641|Experimental|Supplementation arm (multivitamin, cholecalciferol)|Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.
11273811|NCT02877615|Experimental|S 44819 150 mg twice a day|
11273812|NCT02877615|Experimental|S 44819 300 mg twice a day|
11273813|NCT02877615|Placebo Comparator|Placebo|
11273814|NCT02877602||Experience of liver disease|This is defined as either those who have had direct experience of liver disease as sufferers, or the carers of those who have had liver disease. Each individual receives an MRI (LiverMultiScan), with many also receiving a FibroScan.
11273815|NCT02877589||solid tumor|Patients receiving chemotherapy for solid tumors in Ambulatory Medicine Unit of the Reims University Hospital (France) between May 14, 2012 and July 31, 2013.
11273816|NCT02877576|Experimental|Epileptic patient|micro-electrode recordings interventions: Implantation of mixed intracerebral electrodes Face detection Face individualization
11273817|NCT02877563||Patients with PAD|Patients with PAD who are to undergo surgical or percutaneous revascularization.
11273818|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:
~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)
~Part B - dose expansion:
~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD
~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
11273819|NCT02877537|Experimental|Asthma child|
11273820|NCT02877537|Experimental|Control adult|
11273821|NCT02877537|Experimental|Control child|
11273822|NCT02877524|Experimental|Adaptive support ventilation|Adaptive support ventilation during NIV for acute exacerbation of COPD
11273823|NCT02877524|Active Comparator|Pressure support ventilation|Pressure support ventilation during NIV for acute exacerbation of COPD
11273824|NCT02877511|Experimental|Arm 1|2/3 of subjects testing the test article
11273825|NCT02877511|Active Comparator|Arm 2|1/3 of subjects testing the marketed control
11273826|NCT02877498|Experimental|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
11273827|NCT02877498|Active Comparator|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
11273828|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
11273829|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
11273830|NCT02877472|Experimental|Experimental group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression and porous tantalum rod implantation (experimental group).
11273831|NCT02877472|Experimental|Control group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression (control group).
11273832|NCT02877459|Experimental|AeriSeal System|Subjects will be treated with AeriSeal Foam.
11273833|NCT02877433|Active Comparator|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
11273834|NCT02877433|Experimental|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
11273835|NCT02877420|Experimental|Non-Technical Skills Training Curriculum|This group will receive 4 hours of small-group and hands-on sessions and 1 hour of didactic NTS sessions. Participants will watch a video that demonstrates ideal endoscopic performance. They will use the E-NTS Checklist during the integrated scenario training. This checklist targets NTS. The group will be given 7 hours of expert-assisted instruction on the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (6 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist who will demonstrate techniques, answer questions and provide individualized performance feedback with a focus on NTS. The last three hours on the high fidelity simulator will be an integrated scenario (IG) featuring standardized patient (SP) and standardized nurse (SN). Feedback will be given after each IG by the instructor, SP and SN. Participants can view the E-NTS Checklist before and after each case.
11273836|NCT02877420|Active Comparator|Conventional Simulation Training Group|This group will receive 4 hours of small-group and hands-on sessions on colonoscopy theory from an expert endoscopist. The core curriculum is designed on the basis of the American Society for Gastrointestinal Endoscopy colonoscopy curriculum and an endoscopic training textbook. This curriculum has been shown to be effective when compared to self-regulated learning on the simulator. The sessions will be interlaced with eight hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and on the high-fidelity VR simulator (7 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist. The expert will demonstrate techniques, answer questions and provide feedback on global performance. Feedback, in the form of performance metrics, will be provided by the simulator upon completion/failure of each module.
11273837|NCT02877407|Other|laparoscopic/robotic-assisted hysteropexy|patient who undergo laparoscopic/robotic-assisted hysteropexy
11273838|NCT02877407|Other|vaginal hysterectomy|patient who undergo vaginal hysterectomy
11273839|NCT02877394|Experimental|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
11273840|NCT02877394|Sham Comparator|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
11273841|NCT02877381|Active Comparator|Single IV Dose|• 1 gram IV TXA administered at time of prepping and draping
11273842|NCT02877381|Active Comparator|Double Dose IV|"1 gram IV TXA administered at time of prepping and draping
~1 gram IV TXA administered prior to tourniquet deflation"
11273843|NCT02877381|Active Comparator|IV + Topical|"1 gram IV TXA administered at time of prepping and draping
~1 gram topical TXA injected intra-articular following closure of the arthrotomy"
11273844|NCT02877381|Active Comparator|Repeated Oral Dose|• Three 650 mg tablets of TXA administered two hours prior surgery with a second dose given 6 hours postoperatively and a final dose given the morning of postoperative day 1
11273845|NCT02877368||gastrointestinal stromal tumours|Patients with advanced or high-risk resected gastrointestinal stromal tumours (GIST) .
11273846|NCT02877355|Experimental|Semaglutide|
11273847|NCT02877342||Pre-intervention|All injured patients arriving by ambulance (to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving without notification buy ambulance service
11273848|NCT02877342||Post-Intervention|All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
11273849|NCT02877329|Experimental|Internet-delivered ACT|Guided Internet-delivered Acceptance and commitment therapy for 8 weeks
11273850|NCT02877329|No Intervention|Wait list control|No treatment during 8 weeks
11273851|NCT02877316|Experimental|MYPLAN app|MYPLAN app (safety plan) as part of treatment
11273852|NCT02877316|Active Comparator|Safety plan on paper|Safety plan on paper as part of treatment
11273853|NCT02877303|Experimental|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
11273854|NCT02877290|Experimental|cycling test first with NIV, then without NIV|patients in this arm will perform their first constant work rate test while using NIV and the second constant work rate test without NIV
11273855|NCT02877290|Experimental|cycling test first without NIV, then with NIV|patients in this arm will perform their first constant work rate test without NIV and the second constant work rate test with NIV
11273856|NCT02877277|Experimental|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
11273857|NCT02877277|Placebo Comparator|Placebo|Oral intake of placebo tablet daily for 56 days
11273858|NCT02877264|Experimental|Vapendavir Capsule, 264 mg|Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules
11273859|NCT02877264|Experimental|Vapendavir Tablets, 264 mg|Vapendavir free base tablets containing 264 mg of vapendavir
11273860|NCT02877264|Experimental|Vapendavir Oral Suspension, 264 mg|Vapendavir free base as a 24 mg/mL oral suspension
11273861|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
11273862|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
11273863|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
11273864|NCT02877238|Active Comparator|Group A|Sevoflurane plus remote ischemic preconditioning anesthesia will be induced and maintain with sevoflurane in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
11273865|NCT02877238|Active Comparator|Group B|anesthesia will be induced and maintain with total intravenous anesthesia (propofol, midazolam plus fentanyl) during plus remote ischemic preconditioning in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
11273866|NCT02877225|Experimental|Treatment Sequence 1 : ABAB|Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
11273867|NCT02877225|Experimental|Treatment Sequence 2 : BABA|Participants will receive (Treatment B) Period 1, then Treatment A in Period 2, then Treatment B in Period 3 and then followed by Treatment A in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
11273868|NCT02877212|Experimental|Study subjects|Steroid refractory ITP patients will be given Eltrombopag to investigate the association of treatment outcome with Fc Receptor polymorphism and THPO expression in responders and non responders following comparison correlation with ITP patients treated with standard IST as control group
11273869|NCT02877199||HCV triple therapy|Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
11273870|NCT02877186|Experimental|Diet Soda|Consumption of diet soda three times daily for one week
11273871|NCT02877186|Placebo Comparator|Carbonated Water|Consumption of plain, unsweetened, carbonated water three times daily for one week
11273872|NCT02877173|Experimental|Alprostadil Liposomes for Injection|Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
11273873|NCT02877173|Active Comparator|Alprostadil Injection|Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
11273874|NCT02877160|Experimental|Reference Formulation Fasted|150 mg of AL-794 study drug in suspension dosed in a fasted condition
11273875|NCT02877160|Experimental|Test Formulation Fasted|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition
11273876|NCT02877160|Experimental|Test Formulation Fed|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition
11273877|NCT02877147|Experimental|$60 SEBTC Benefit Group|Households received $60 per summer month when school was not in session for each eligible child (Summers 2011-2013).
11273878|NCT02877147|Experimental|$30 SEBTC Benefit Group|Households received $30 per summer month when school was not in session for each eligible child (Summer 2013 only).
11273879|NCT02877147|No Intervention|No Intervention Group|Households with eligible children were not issued SEBTC benefits (Summers 2011 and 2012)
11274132|NCT02875275|Active Comparator|Glucose with grass jelly solution|Control drink plus 3.12 g grass jelly powder
11273880|NCT02877134|Experimental|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
11273881|NCT02877134|Experimental|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
11273882|NCT02877134|Experimental|Part II : Placebo|Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive placebo up to 52 weeks (for a total of up to 72 weeks of placebo in Part II).
11273883|NCT02877134|Experimental|Part II : JNJ-64304500 High Dose|JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 high dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).
11273884|NCT02877134|Experimental|Part II : JNJ-64304500 Middle Dose|JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 middle dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).
11273885|NCT02877134|Experimental|Part II : JNJ-64304500 Low Dose|JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 low dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).
11273886|NCT02877134|Experimental|Part II : Ustekinumab|Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive Ustekinumab up to 52 weeks (for a total of up to 72 weeks of Ustekinumab in Part II).
11273887|NCT02877108||Adasuve|These patients will receive Adasuve for treatment of agitation.
11273888|NCT02877108||Haloperidol/Lorazepam|These patients will receive haloperidol/lorazepam for treatment of agitation.
11273889|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
11273890|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
11273891|NCT02877069|Experimental|VYC-12 Injectable Gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection on Day 0 in the face and if applicable neck areas. Participants are eligible to receive up to 3 treatments including an optional top-up and an optional second treatment.
11273892|NCT02877056||Colorectal Cancer|Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
11273893|NCT02877043||patients undergoing lung resection|
11273894|NCT02877030|Experimental|Test control group|Start the sensorimotor exercises protocol with video game immediately after the first evaluation
11273895|NCT02877030|Active Comparator|Control test group|Start of sensorimotor exercises with video game protocol after ten weeks
11273896|NCT02877030|No Intervention|comparison group|No intervention
11273897|NCT02877017|No Intervention|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
11273898|NCT02877017|Experimental|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
11273899|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
11273900|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
11273901|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
11273902|NCT02876991|Other|Sodium fluoride PET|"Before inclusion, patients undergo choline PET to assess an occult recurrence of prostate cancer.
~After inclusion, they undergo sodium fluoride PET."
11273903|NCT02876978|Experimental|CAR-GPC3 T cells|"Intravenous infusion with escalating dose is adopted in this study.
~Total dosage: 1 x 10^5 - 2 x 10^9 CAR-GPC3 T cells/kg
~The next dose and interval depends on the response of the subject to previous dose.
~Lymphodepletion:
~Fludarabine: 30 mg/m^2/day x 4 days; Cyclophosphamide: 500 mg/m^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response."
11273904|NCT02876965|Active Comparator|Physical Exercise|Aerobic physical exercise protocol of moderate intensity, for 12 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
11273905|NCT02876965|Experimental|Muscle Stretching|Stretching program on the main muscle groups of the body, for 12 weeks, 1sessions per week, about 45 minutes.
11273906|NCT02876952|Active Comparator|Attention Control Group (AC)|Moderate to high- intensity physical activity and Mediterranean Diet recommendations
11273946|NCT02876640|Experimental|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery.
11273947|NCT02876627|Experimental|breast cancer|Effect of exercise training on breast cancer patient
11274171|NCT02874989|Placebo Comparator|Placebo|
11273907|NCT02876952|Experimental|HV-HIIT|"Supervised high volume and high intensity interval training exercise group with Mediterranean Diet recommendations.
~High-intensity [heart rate (HR) values up to second ventilatory threshold (VT2) to peak intensity] interval training and high-volume increasing gradually from 20 to 40 min and alternating high and moderate [HR values between first ventilatory threshold (VT1) and VT2] intensities at different protocols."
11273908|NCT02876952|Experimental|LV-HIIT|"Supervised low volume and high intensity interval training exercise group with Mediterranean Diet recommendations.
~High-intensity (HR values up to VT2 to peak intensity) interval training and low-volume (20 min) alternating high and moderate (HR values between VT1 and VT2) intensities at different protocols."
11273909|NCT02876939|Experimental|HSAN III|
11273910|NCT02876939|Active Comparator|Control Subjects|
11273911|NCT02876926|Experimental|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
11273912|NCT02876926|Active Comparator|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
11273913|NCT02876926|Sham Comparator|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
11273914|NCT02876913||Group Nasotracheal Intubation|Patients who are scheduled for nasotracheal intubation for general anesthesia
11273915|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
11273916|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
11273917|NCT02876900|Placebo Comparator|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
11273918|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
11273919|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
11273920|NCT02876874||the patients group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
11273921|NCT02876874||the health group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
11273922|NCT02876861|Active Comparator|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.
~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
11273923|NCT02876861|Experimental|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group
~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):
~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
~Surgery:
~2-3weeks after Neoadjuvant chemotherapy
~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.
~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
11273924|NCT02876848|Experimental|Intervention Site|"The hospital that will be the intervention site will have access to the OPTIMUM e-health tool. The intervention site cancer care team will receive the following OPTIMUM e-health alerts:
~An electronic alert of increased Adjuvant Endocrine Therapy discontinuation risk.
~An adherence to Adjuvant Endocrine Therapy monitor.
~An electronic discontinuation occurrence alert"
11273925|NCT02876848|No Intervention|Control Site|The hospital that will be the control site will not have access to the OPTIMUM e-health tool. The cancer care team will continue to deliver care according to standard processes.
11273926|NCT02876835|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
11273927|NCT02876835|Active Comparator|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
11273928|NCT02876822|Experimental|Vitamin D|Enrolled subjects will receive one observed oral vitamin D dose (based on current vitamin D status and rounded to the nearest 5000IU) within 2 weeks prior to their HSCT.
11273929|NCT02876796|Experimental|50 mg GS-0976 (Cohort 1)|"Sequence 1:
~Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
~Sequence 2:
~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution"
11273930|NCT02876796|Experimental|200 mg GS-0976 (Cohort 2)|"Sequence 3:
~Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
~Sequence 4:
~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution"
11273931|NCT02876796|Experimental|20 mg GS-0976 (Cohort 3)|"Sequence 5:
~Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution
~Sequence 6:
~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution"
11273932|NCT02876770|Experimental|Melatonin|
11273933|NCT02876770|Placebo Comparator|Placebo|
11273934|NCT02876757||5ARI Users|
11273935|NCT02876757||Non 5ARI users|
11273936|NCT02876731|Other|single group|PET-CT MRI
11273937|NCT02876718||Rivaroxaban, BAY59-7939|It is a single-arm study in which only patients who switched from a VKA to a NOAC treatment will be included.
11273938|NCT02876705|Experimental|Pain Patterns|In this vein, we tend to study and delineate individualized pain and discomfort patterns in exercise.
11273939|NCT02876679|Experimental|Cyclophosphamide|50mg/Kg/day cyclophosphamide (day +3 and +4)
11273940|NCT02876679|Active Comparator|Anti-Thymocyte Globulin|2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)
11273948|NCT02876601|Active Comparator|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
11273949|NCT02876601|Placebo Comparator|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
11273950|NCT02876601|Other|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
11273951|NCT02876601|Other|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa
~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
11273952|NCT02876588|Active Comparator|Unrestricted|"Users have unrestricted access to open up to a maximum of 4 patient records at a time in the EHR"
11273953|NCT02876588|Active Comparator|Restricted|"Users have restricted access to open a maximum of 1 patient record at a time in the EHR"
11273954|NCT02876575|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
11273955|NCT02876562|Experimental|root coverage with collagen matrix|evaluation of root coverage achieved by collagen matrix in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
11273956|NCT02876562|Active Comparator|root coverage with connective tissue graft|evaluation of root coverage achieved by connective tissue graft in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
11273957|NCT02876549|Experimental|G6PD Normal|
11273958|NCT02876549|Experimental|G6PD Deficient|
11273959|NCT02876536|Experimental|TNES with sending electrical impulses|The MS patients will receive electrical impulses by TENS device for 30 minutes a day, for 5 days a week and in 6 weeks
11273960|NCT02876536|Sham Comparator|TENS without sending electrical impulses|The MS patients will use the TENS device for 30 minutes a day, for 5 days a week and in 6 weeks without receiving any electrical impulses
11273961|NCT02876523||Patients with a hilar biliary stricture requiring a drainage|Drainage performed by endoscopy, echo-endoscopy or percutaneously
11273962|NCT02876510|Experimental|IMA101 product only (Cohort 1)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~Infusion of the IMA101 T-cell product(s)
~Post-infusion administration of low-dose recombinant human interleukin-2"
11273963|NCT02876510|Experimental|IMA101 product + atezolizumab (Cohort 2)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
~Infusion of the IMA101 T-cell product(s)
~Post-infusion administration of low-dose recombinant human interleukin-2
~Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year"
11273964|NCT02876497|Experimental|Study arm|
11273965|NCT02876484|Experimental|Placebo|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.
~25 ml water"
11273966|NCT02876484|Experimental|Chenodeoxycholic Acid|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt
11273967|NCT02876484|Experimental|Colesevelam|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
11273968|NCT02876484|Experimental|Colesevelam x 2|plus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
11273969|NCT02876471|No Intervention|OSA group|100 severe OSA patients without hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS),demographic and anthropometric data The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated
11273970|NCT02876471|Other|OSA with hypertension|100 severe OSA patients with hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS), antihypertensive medicine demographic and anthropometric data. The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated.Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood pressure control, the investigators would give one-night CPAP.
11273971|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
11273972|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
11273973|NCT02876445|Other|Caregiver Evaluation|ZARIT Burden Interview
11273974|NCT02876432|Experimental|Device: Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.
~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
11273975|NCT02876432|Sham Comparator|Device: Sham Electroacupuncture|In sham electroacupuncture (Sham) the investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
11273976|NCT02876432|Active Comparator|Drug: Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
11273977|NCT02876393||Cases|Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
11273978|NCT02876393||Control definition|Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
11273979|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
11273980|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
11273981|NCT02876367||Acute scrub typhus (Group 1)|Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using <1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
11273982|NCT02876367||Scrub typhus serosurvey (Group 2)|Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
11273983|NCT02876354|Experimental|Menaquinone 360|All patients in the study will be assigned to receive menaquinone 360 μg /d for 4 weeks.
11273984|NCT02876341||No chronic antihypertensives|Not on either a chronic β-blocker or ACE-Inhibitor
11273985|NCT02876341||Chronic antihypertensives|On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
11273986|NCT02876328|Experimental|Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost|Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.
11273987|NCT02876328|Placebo Comparator|Placebo (0.5 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
11273988|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.
11273989|NCT02876328|Experimental|rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost|Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.
11273990|NCT02876328|Placebo Comparator|Placebo (1 mL)|Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.
11273991|NCT02876315|Experimental|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
11273992|NCT02876315|Placebo Comparator|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
11273993|NCT02876302|Experimental|Paclitaxel (12weeks)|"Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively
~16 patients will be randomized from the Run-In 7 days of Ruxolitinib
~The drug will be administered at a pre-determine dosage"
11273994|NCT02876302|Experimental|Ruxolitinib with Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively
~16 patients will be randomized from the Run-In 7 days of Ruxolitinib
~The drug will be administered at a pre-determine dosage"
11273995|NCT02876302|Experimental|Ruxolitinib and Paclitaxel (12weeks)|"Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively
~32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel
~The drug will be administered at a pre-determine dosage"
11273996|NCT02876289||patients treated with Perampanel|
11273997|NCT02876276|Active Comparator|HA filler group|6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
11273998|NCT02876276|Placebo Comparator|saline filler group|with saline same protocol was performed as mentioned in test group
11273999|NCT02876263||Study group|Elective and emergency surgery for aneurysm or dissections of the ascending aorta, operated under extracorporeal circulation, protective deep therapeutic hypothermia and circulatory arrest.
11274000|NCT02876263||On-pump CABG Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease under extracorporeal circulation
11274001|NCT02876263||OPCAB Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease with a beating heart
11274002|NCT02876250|Experimental|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
11274003|NCT02876250|Placebo Comparator|Control|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
11274004|NCT02876237|Experimental|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later.
~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
11274005|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 1: SRP)|Stage 1 Safety Run-in Phase (SRP): Approximately 12 participants will receive cobimetinib 60 milligrams (mg) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 milligrams per kilogram (mg/kg) administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to Stage 2: dose expansion phase. If the results from the safety run-in phase require dose reduction in cobimetinib, then an additional Stage 1 cohort will be opened. Treatment will continue until the participant has disease progression according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
11274006|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: BC)|Stage 2 Biopsy Cohort (BC): Approximately 7 evaluable participants in the biopsy cohort in expansion phase will receive bevacizumab 5 mg/kg IV on Cycle 1 Days 1 and 15 (tumor biopsy on Cycle 1 Day 8) and cobimetinib (at dose determined during safety run-in phase) orally on Cycle 1 Day 15 to Cycle 2 Day 14 (tumor biopsy on Cycle 1 Day 22). From Cycle 2 onwards, participants will follow the same treatment regimen for bevacizumab and atezolizumab (optional tumor biopsy on Cycle 2 Day 22) as those in the safety run-in phase and expansion cohort, and for cobimetinib cycles start at Day 15 and will continue 21 days to Day 7 of next cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Biopsies must be collected before the initiation of cobimetinib and atezolizumab. Treatment will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, decision to withdraw, or pregnancy, whichever occurs first.
11274007|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: EC)|Stage 2 Expansion Cohort (EC): Approximately 14 participants will receive cobimetinib (at dose determined during safety run-in phase) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 mg/kg administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Treatment will continue until the participant has disease progression according to RECIST v1.1, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
11274008|NCT02876211|Experimental|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week & epoetin
11274009|NCT02876211|Placebo Comparator|placebo plus epoetin beta|Placebo 2 capsules/three times per week & epoetin
11274010|NCT02876198||Patients treated with anti-VEGF|
11274011|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
11274012|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted psychotherapy.
11274013|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
11274014|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
11274015|NCT02876146|Other|Hepatic alveolar echinococcosis|"Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)
~Standardized earlier withdrawal of benzimidazole :
~Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)
~Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)"
11274016|NCT02876133|Experimental|Narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
11274017|NCT02876133|Placebo Comparator|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
11274018|NCT02876120|Other|Pre- and post-implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.
~Post-implementation phase: during the post-implementation phase the GPs and PTs will treat persons with hip or knee osteoarthritis according to the START treatment model including providing information/patient education program, supervised exercise and advice/support to loose weight and other non-surgical evidence based treatments modalities prior to being referred to an orthopaedic surgeon"
11274019|NCT02876107|Experimental|Group A (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 1 hour on day 1 of cycle 0 and over 30 minutes on days 1, 8, and 15 of cycles 1-4. Patients also receive paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1 of cycles 1-4. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
11274020|NCT02876107|Experimental|Group B (paclitaxel, carboplatin)|Patients receive paclitaxel, carboplatin, doxorubicin, and cyclophosphamide as in Group A. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
11274021|NCT02876094|Experimental|Open-label|All patients will be treated at each dose of oral once daily celecoxib (40, 80 and 160 mcg/kg) for a period of two weeks, for a total of 6 weeks (42 days) of treatment.
11274022|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
11274023|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.
~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
11274024|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
11274025|NCT02876029|Other|Reference|White wheat bread
11274026|NCT02876029|Other|Test product|Pasta
11274027|NCT02876016|Experimental|awake brain surgery|Exploration of the cortical area of the brain awake surgery
11274028|NCT02876003|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
11274029|NCT02875990|Experimental|patients with invasive cervical cancer|Blood sample
11274030|NCT02875977|Experimental|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
11274031|NCT02875977|Active Comparator|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
11274032|NCT02875964|Experimental|registration of intracerebral activity|epileptic patient receiving implantation of intracranial electrodes
11274033|NCT02875951||ER positive, HER2 negative breast cancer patients|Postmenopausal patients with hormone receptor positive, HER2 receptor negative breast cancer
11274034|NCT02875938|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
11274035|NCT02875925|Experimental|MTM|Patients will receive MTM at an individualized frequency for 1 year.
11274036|NCT02875925|No Intervention|Control|Patients enrolled in the control group will not experience any change in their medical care.
11274037|NCT02875912|No Intervention|Usual Care|Family members are surveyed at enrollment, day 5 (if patient is still in ICU), and 90 days post ICU discharge for symptoms of PTSD, depression, and anxiety as well as for concordance of care at enrollment and ICU day 5. Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed to establish baseline data
11274038|NCT02875912|Experimental|Family Care Rituals Intervention|At enrollment, family members are given a handout/pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so. The families are then surveyed in the same way as they were during the usual care, with nursing completing the same surveys as well to compare against the baseline data
11274039|NCT02875886|Active Comparator|Diuretic treatment|Patients receive amiloride and hydrochlorothiazide
11274040|NCT02875886|Active Comparator|Low-sodium diet|Patients are put on a low-sodium diet (60 mmol/day)
11274041|NCT02875873|Experimental|Plasma-Lyte, Slow Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
11274042|NCT02875873|Experimental|Plasma-Lyte, Fast Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
11274043|NCT02875873|Experimental|Saline 0.9%, Slow Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
11274044|NCT02875873|Experimental|Saline 0.9%, Fast Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
11274045|NCT02875860|Other|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
11274046|NCT02875860|Experimental|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
11274047|NCT02875847|Active Comparator|HMO1|Daily bolus of HMO1
11274048|NCT02875847|Active Comparator|HMO2|Daily bolus of HMO2
11274049|NCT02875847|Placebo Comparator|Dextropur|Daily bolus of dextropur
11274050|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
11274051|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
11274052|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
11274053|NCT02875821|Experimental|Group IMP|Group IMP (Ipragliflozin with Metformin with Pioglitazone)
11274054|NCT02875821|Active Comparator|Group MP|Group MP (Metformin with Pioglitazone)
11274055|NCT02875808||patients|patients with an external ventricular drainage
11274056|NCT02875795|Experimental|speech intelligibility|speech intelligibility is registered by an automatic speech processing tool
11274057|NCT02875782|Experimental|DM intervention|Subjects will receive a patient-centered motivational intervention with two components: (1) the stage-matched smoking cessation intervention and (2) the relationship between smoking and diabetic complications. All subjects will receive a self-help cessation manual with DM components and take the exhaled carbon monoxide test. The total counseling process will take about 20 minutes. Three consecutive (3-, 6- and 12-month) follow ups will be conducted. Also, the counselor will further the progress of their action plan and barriers encountered in the behavioral change process as well as engage them in the process, enhance their self-efficacy, and identify individual barriers and facilitators.
11274058|NCT02875782|Placebo Comparator|Control group|Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
11274059|NCT02875769|Experimental|Test: Mouthwash CPC+Zn+F|To rinse with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
11274060|NCT02875769|Active Comparator|Positive control: Mouthwash CHX|To rinse with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
11274061|NCT02875769|Placebo Comparator|Negative control A: No rinsing|No rinsing with pre-procedural mouthwash + full mouth dental prophylaxis using ultrasonic scaler.
11274062|NCT02875769|Placebo Comparator|Negative control B: Water|To rinse with pre-procedural mouthwash containing water from a three-way syringe (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
11274063|NCT02875756|Experimental|10 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
11274064|NCT02875756|Active Comparator|20 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
11274065|NCT02875743|Experimental|Posaconazole|
11274066|NCT02875730|Experimental|CMRI Pulse Sequence|Patients will have late gadolinium cardiac magnetic resonance images of the individual pulmonary veins acquired with the standard and the cylindrical navigator preparatory pulse sequences for comparison.
11274067|NCT02875717||Control|
11274068|NCT02875717||Acetylsalicylic acid|Patients that were on medication with Acetylsalicylic acid on the date of shockwave lithotripsy
11274069|NCT02875717||Low Molecular weight heparin|Patients that were on medication with low molecular heparin on the date of shockwave lithotripsy
11274070|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
11274071|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
11274072|NCT02875691|Active Comparator|green tea extract|Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
11274073|NCT02875691|Placebo Comparator|Placebo|Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
11274074|NCT02875678|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
11274075|NCT02875678|Placebo Comparator|Placebo|Placebo, capsules, single dose
11274076|NCT02875665|Experimental|geko device arm|geko™ devices (acting on the posterior tibial nerve) to be used on alternate days over seven days, for an hour per day
11274077|NCT02875652|Experimental|Blood sampling|
11274078|NCT02875639|Experimental|tonifying qi group|tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)
11274079|NCT02875639|Experimental|activating blood group|which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)
11274080|NCT02875639|Experimental|qi and blood group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)
11274081|NCT02875639|Active Comparator|QISHEN YIQI DRIPPING PILLS group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)
11274082|NCT02875639|Sham Comparator|placebo group|which treated by the simulation of Chinese patent medicine (major components:excipient)
11274083|NCT02875626|Experimental|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
11274084|NCT02875613|Experimental|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
11274085|NCT02875600|Experimental|Nutri drink|MRI flow measurements of mesenterial vessels and portal vein before and after stimulation with nutritional drink
11274086|NCT02875587|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
11274087|NCT02875587|Experimental|Calcium gluconate infusion group|Calcium gluconate is administered starting on the day of HCG administration.
11274088|NCT02875574||All participants|
11274089|NCT02875561|Active Comparator|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
11274090|NCT02875561|Experimental|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
11274091|NCT02875548|Experimental|Open-label Tazemetostat|Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.
11274092|NCT02875535|No Intervention|Usual Care|Standard school nurse care for suicide prevention.
11274093|NCT02875535|Experimental|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
11274094|NCT02875522|Experimental|Patients with COPD|Stable patients with COPD participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
11274095|NCT02875522|Active Comparator|Healthy Controls|Age, sex, BMI and activity matched controls participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
11274096|NCT02875496||Healthy aging|Subjects meeting criteria for healthy aging No intervention administered
11274097|NCT02875496||Early Alzheimer Disease|Subjects meeting criteria for Early Alzheimer Disease No intervention administered
11274098|NCT02875496||Depression|Subjects meeting criteria for Depression No intervention administered
11274099|NCT02875496||MCI-Mild Cognitive Impairment|Subjects meeting criteria for MCI-Mild Cognitive Impairment No intervention administered
11274100|NCT02875496||General Arm|Subjects not meeting criteria for any of the other arms (Healthy, Early Alzheimer's, Depression, or MCI)
11274101|NCT02875483|Placebo Comparator|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
11274102|NCT02875483|Experimental|Expedited Scheduling|Group allocated to expedited scheduling practices
11274105|NCT02875457|Experimental|Arm A|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
11274106|NCT02875457|Placebo Comparator|Arm B|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.
11274107|NCT02875444||"group abdominal aortic aneurysm"|Patients with non-operated abdominal aortic aneurysm with angio-CT realized between 01/01 2010 au 04/15/2012
11274108|NCT02875431||ACDF or cervical vertebral body replacement|
11274109|NCT02875418|Experimental|EUM and tocodynamometry|Pregnant women with gestational age 24+0/7 to 33+6/7 weeks of gestation and contractions, cramping, pelvic pressure or backache.
11274110|NCT02875405|Experimental|Received pericardiotomy|Patient will receive a posterior left pericardiotomy at the time of surgery
11274111|NCT02875405|No Intervention|No Pericardiotomy|Patient will not receive posterior left pericardiotomy.
11274112|NCT02875392|Experimental|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
11274113|NCT02875392|Placebo Comparator|placebo pills|placebo capsule 6 per day (before breakfast and supper)
11274114|NCT02875379|Experimental|HME|Passive humidification with heat and moisture exchanger, Y-piece circuit.
11274115|NCT02875379|Experimental|HH33|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
11274116|NCT02875379|Experimental|HH37|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
11274117|NCT02875379|Experimental|NoH|Passive humidification, double tube circuit
11274118|NCT02875366|Placebo Comparator|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
11274119|NCT02875366|Experimental|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
11274120|NCT02875353|Other|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
11274121|NCT02875353|Experimental|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
11274122|NCT02875340|Experimental|VAL401 treatment|Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
11274123|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.
~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
11274124|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.
~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:
~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
11274125|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.
~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.
~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
11274126|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
11274127|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
11274128|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
11274129|NCT02875288|Experimental|Liposomal Bupivicaine arm|"Post procedure, infiltrate wounds with liposomal bupivacaine
~Liposomal Bupivacaine (Brand name Exparel) 266 milligram (mg)/20 mL to be diluted to 30 mL with normal saline
~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
11274130|NCT02875288|Active Comparator|Plain Bupivicaine|"Post procedure, infiltrate wounds with plain bupivicaine
~Plain Bupivacaine 0.25%, volume of 30 mL
~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
11274131|NCT02875275|No Intervention|Glucose Solution only|Control drink containing 50 g carbohydrate
11274133|NCT02875275|Active Comparator|Glucose with grass jelly (solid)|Control drink plus 3.12 g grass jelly powder in solid form
11274134|NCT02875275|No Intervention|Porridge and juice only|Control breakfast containing 50 g carbohydrate.
11274135|NCT02875275|Active Comparator|Porridge and juice with coconut oil|Control breakfast, plus 25g coconut oil
11274136|NCT02875275|Active Comparator|Porridge and juice with coconut oil gel|Control breakfast, plus 25g coconut oil gel
11274137|NCT02875262|Experimental|Treatment|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day. duration 3 days
11274138|NCT02875262|Placebo Comparator|placebo|NaCl 0.9% in similar dosis to treatment arm
11274139|NCT02875236|Placebo Comparator|Control|Ringer-acetat
11274140|NCT02875236|Active Comparator|Intervention|OctaplasLG®
11274141|NCT02875223|Experimental|CC-90011 Administration|Subjects will administer CC-90011 orally once weekly in each 4 -week (28 day) Cycle. Alternative dosing schedules may be implemented based on the review of clinical safety and laboratory data by the SRC. CC-90011 will be administered with at least 240 mL of water. Subjects should fast for a minimum of 4 hours in both Parts A and B prior to CC-90011 administration and refrain from any food intake for up to 1 hour after dosing
11274142|NCT02875210|Experimental|Patient with anterior cruciate ligament rupture|Anterior laxity of patient was measure with 4 laximeters:Telos, reference laximeter and with three other instruments called, KT-1000, GnrB and Rolimeter.
11274143|NCT02875197||Healthy Controls|"Males and females 18-50 years old
~Up to 20 able-bodied sex, age, height, and weight-matched subjects"
11274144|NCT02875197||Lower Extremity Amputees|"Males & females 18-50 years old
~Must have a unilateral, transtibial amputation & must have been prescribed a running-specific prosthesis
~Subject with amputations resulting from trauma, congenital reasons, or cancer treatment unless cancer is in remission or treatments do not impact gait function
~Physician approval to run
~4 months experience using a running-specific prosthesis"
11274145|NCT02875184||Psoriatic arthritis patients treated with apremilast|Psoriatic arthritis patients who are treated with apremilast according to daily practice
11274146|NCT02875171||Anthracycline therapy|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
11274147|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
11274148|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
11274149|NCT02875145||Keratoplasty with cataract surgery|Patients who underwent keratoplasty who also underwent a cataract surgery during follow up.
11274150|NCT02875145||Keratoplasty without cataract surgery|Patients who underwent keratoplasty who never underwent cataract surgery.
11274151|NCT02875132|Experimental|pembrolizumab|
11274152|NCT02875119|Experimental|Griffithsin Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer Griffithsin Gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
11274153|NCT02875119|Placebo Comparator|Placebo Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer placebo gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
11274154|NCT02875106||Atrial Fibrillation Patients|Adult female and male patients with diagnosed atrial fibrillation
11274155|NCT02875106||Sinus Rhythm Patients|Adult female and male patients with diagnosed sinus rhythm
11274156|NCT02875093|Other|ADI-PEG 20 Plus Low Dose Cytarabine|This is a phase 1, open label trial of ADI-PEG 20 (18 and 36 mg/m2) weekly in combination with low-dose cytarabine (20 mg BID [twice daily] for 10 days, every 28 days)
11274157|NCT02875080|Experimental|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
11274158|NCT02875080|Experimental|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
11274159|NCT02875080|Experimental|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
11274160|NCT02875067|Experimental|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions
~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
11274161|NCT02875054|Active Comparator|Continued Casting|Participants with 24 hour cast wear (continued casting) for the entire duration of the constraint portion of camp (2 initial weeks).
11274162|NCT02875054|Active Comparator|Intermittent Casting|Participants who wear a univalve cast for 3 hours of constraint camp with home exercise program of 2 hours cast wear on the weekends (intermittent casting).
11274163|NCT02875041|Experimental|Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy|TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
11274164|NCT02875041|Active Comparator|MAGSTIM Rapid2 Therapy System|MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
11274165|NCT02875028|Experimental|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
11274166|NCT02875028|Placebo Comparator|Placebo|subjects will be treated with 4 empty lactose-starch capsules
11274167|NCT02875015|Experimental|Liposomal Bupivacaine|20mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
11274168|NCT02875015|Active Comparator|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
11274169|NCT02875002|Experimental|All subjects|Subjects have relapsed and refractory aggressive B- and T-cell lymphomas and will receive both Belinostat and Volasertib.
11274170|NCT02874989|Experimental|Dasatinib + Quercetin|
11274172|NCT02874976|Experimental|Experimental: Group A|"Active and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group A, received program 1 before aerobic training, and the same program 1 after training"
11274173|NCT02874976|Experimental|Experimental: Group B|"Active and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 1 before aerobic training, and program 2 after training."
11274174|NCT02874976|Experimental|Experimental: Group C|"Placebo and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group C, received program 2 before aerobic training, and program 1 after training."
11274175|NCT02874976|Experimental|Experimental: Group D|"Placebo and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
11274176|NCT02874963|Active Comparator|Surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Non-Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Intervention:
~Procedure: Surgery (Tooth Extraction)"
11274177|NCT02874963|Active Comparator|Surgical and non-surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Non-Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.
~Interventions:
~Procedure: Surgery (Tooth Extraction)
~Procedure: Non-surgical periodontal therapy-full mouth scaling and root planing (FM-SRP) with ultrasonic device and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus, post operative rinsing thrice a day for 3 weeks."
11274178|NCT02874950|Experimental|Office exercise training|A package of exercise raining was defined by the researcher and one of the intervention group did it for 6 months.
11274179|NCT02874950|Experimental|Ergonomic modification|The ergonomic group, followed 6 months ergonomic modification.
11274180|NCT02874950|Experimental|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months ergonomic modification.
11274181|NCT02874950|Experimental|Control|Control group did not do any exercise and did not follow any ergonomic modification.
11274182|NCT02874937|Active Comparator|Atomoxetine|2 doses of atomoxetine 40mg PO (evening before and morning of study)
11274183|NCT02874937|Placebo Comparator|Placebo|2 doses of matching placebo 40 mg PO (evening before and morning of study)
11274184|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
11274185|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
11274186|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
11274187|NCT02874911|Experimental|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
11274188|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
11274189|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
11274190|NCT02874885||Ancillary-Correlative (biospecimen collection)|Patients and healthy participants undergo collection of blood sample at baseline. Patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back.
11274191|NCT02874872|Experimental|OASIS Collaborative|The nursing homes in this arm will receive facilitated implementation of two tools aimed at minimizing unnecessary antibiotic use. Facilitated implementation includes coaching of the nursing home staff on use of the tools. In addition, nursing home management will be coached on how to monitor implementation fidelity, antibiotic utilization, and consequences to over- and under-utilization of antibiotics as feedback on the effectiveness of the intervention. Finally, nursing home management will receive coaching on how to develop and implement a sustain plan for the OASIS intervention.
11274192|NCT02874872|No Intervention|Control|The nursing homes in this arm will continue care as usual, with no tools or facilitated implementation.
11274193|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
11274194|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
11274195|NCT02874833|Experimental|Exercise Group|Experimental arm type will assess whether a newly developed, supervised 8-week individualized, internet-based exercise therapy is effective in reducing depressive symptoms.
11274196|NCT02874833|No Intervention|Treatment as usual group|Treatment as usual. Other form of therapy (e.g. antidepressive medication) will not be affected.
11274197|NCT02874820|Experimental|Patient Group|Baseline PET scan followed by a blocked PET scan
11274198|NCT02874807|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg once daily for four days
11274199|NCT02874807|Placebo Comparator|Placebo|Treatment with Placebo once daily for four days
11274200|NCT02874794|Experimental|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
11274201|NCT02874794|Active Comparator|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
11274202|NCT02874768|Experimental|dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
11274203|NCT02874768|Active Comparator|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
11274204|NCT02874755|Experimental|Tuberculosis Program (PPIA)|Half of the 300 participants were randomly selected to be sensitized and engaged into the program, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if networked into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free and/or subsidized diagnostic testing and referrals to providers for free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests; training opportunities, and access to a referral network.
11274205|NCT02874755|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining half of the sample in Mumbai selected randomly will be phased into the program at least a year after the PPIA arm. However, during the year of the study, they will not be networked into the program.
11274206|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
11274207|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
11274208|NCT02874729||Healthy donors|No interventions
11274209|NCT02874729||Cancer patients|No interventions
11274210|NCT02874716|Experimental|Tuberculosis Program (PPIA)|In Patna, 171 of the 321 participants were randomly selected to be sensitized and engaged into the program in Phase 1, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if engaged into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free or subsidized diagnostic testing and free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests and anti-TB treatment; financial incentives to providers based on certain indicators; training opportunities, and access to a referral network.
11274211|NCT02874716|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining part of the sample in Patna selected randomly will be phased into the program at least a year after the PPIA arm in Phase 2. However, during the year of the study, they will not be engaged into the program.
11274212|NCT02874703||HIV-positive|
11274213|NCT02874703||HIV-negative|
11274214|NCT02874690|Active Comparator|Autism Spectrum (ASD) + ADHD with Methylphenidate|Autism Spectrum Disorder comorbid with Attention Deficit Hyperactivity Disorder receives methylphenidate
11274215|NCT02874690|Placebo Comparator|Autism Spectrum (ASD) + ADHD with Placebo|Autism Spectrum Disorder comorbid with Attention Deficit Hyperactivity Disorder receives a placebo
11274216|NCT02874690|No Intervention|Autism Spectrum Disorder (ASD)|Autism Spectrum Disorder without Attention Deficit Hyperactivity Disorder
11274217|NCT02874677|No Intervention|Control|Routine activities
11274218|NCT02874677|Experimental|Experimental|Effort reeducation program : 3 sessions of 20 minutes per week during 6 weeks
11274219|NCT02874664|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
11274220|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
11274221|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
11274222|NCT02874638|Experimental|BASE egg protein|0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
11274223|NCT02874638|Experimental|BCAA-enriched egg protein|branched-chain amino acid-enriched egg protein
11274224|NCT02874638|Experimental|small amount of essential amino acids|small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
11274225|NCT02874638|Experimental|large amount of essential amino acids|large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
11274226|NCT02874625|Active Comparator|Treatment 1|Dental restoration performed with glass-ionomer materials.
11274227|NCT02874625|Experimental|Treatment 2|Dental restoration performed with resin-based composites.
11274228|NCT02874612||Young Adults with Type 1 Diabetes Mellitus|All YA (ages 18-24) who are seen in the Cincinnati Children's Hospital Medical Center Diabetes Clinic and have recently (< 4 months) completed the Transition Readiness assessment tool as part of their standard clinical care is eligible for the study.
11274229|NCT02874599|Experimental|Patients|Patients who require multiple dental restorations. Teeth will be restored with commercial restorative composites
11274230|NCT02874586|Experimental|Plasma exchange combination of immunosuppressive regimens|Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
11274231|NCT02874573|Active Comparator|Treatment Group|Subjects in the tocilizumab group will receive a 4 mg/kg infusion at baseline, and weeks 4 and 8, as per the recommended starting dosing for rheumatoid arthritis
11274232|NCT02874573|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the tocilizumab group) at baseline, and weeks 4 and 8.
11274233|NCT02874560||Schizophrenia|350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).
11274234|NCT02874547|Experimental|Intervention|Patients will receive five visits with a CHW during a 6 month period (two in-person and three by telephone). At the first visit, patients will meet the CHW who is trained in motivational interviewing techniques to deliver coaching to work on behavioral changes and introduce a 60 minute Digital Video Disc of five patient stories of individuals who have managed to control their hypertension.
11274235|NCT02874547|Other|Delayed Intervention|Patients will receive print materials at time of consent and randomization. Four to six months after randomization, DI patients will receive an invitation to schedule an in-person visit at the health center to begin receiving the intervention protocol.
11274265|NCT02874352|Other|healthy volunteers|control group with healthy volunteers/ high resolution impedance manometry with Automated Impedance Manometry analysis
11274266|NCT02874339|Experimental|Optiflow Group|High flow nasal oxygen therapy
11274267|NCT02874339|Active Comparator|NIV group|
11274236|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
11274237|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
11274238|NCT02874521|Experimental|Intra-dialytic LF-EMS|Performed twice weekly whilst seated on a standard dialysis chair. Delivered by adhesive electrodes in a neoprene garment, applied bilaterally to the quadriceps and hamstrings. Cardiovascular stimulus via rapid, rhythmical, sub-tetanic contractions. Short bursts of four pulses repeatedly delivered by stimulator at a frequency of 4Hz. Current amplitude adjustable from 40 - 200 mA with inbuilt controller. Conducted for one hour at the maximum tolerable intensity. Five minute warm-up and cool down at a lower frequency (3 Hz).
11274239|NCT02874521|Experimental|Intra-dialytic cycle training|Semi-recumbent cycling performed twice weekly whilst seated on a standard dialysis chair. Performed for up to one hour per session, initially at a workload (Watts) equivalent to that achieved at 40-60% VO2 reserve during cardiopulmonary exercise test. Exercise intensity regulated using a combination of heart rate and rating of perceived exertion (12-14). Workload adjusted weekly and controlled with a combination of pedal resistance and cadence to provide a personalised exercise prescription. Five minute warm-up and cool down each session.
11274240|NCT02874521|No Intervention|Usual care|Continuation of dialysis treatment without the addition of an intra-dialytic exercise intervention.
11274241|NCT02874495||Healthy volunteers|22 persons.
11274242|NCT02874495||Patients with Crohn's disease|22 patients.
11274243|NCT02874482||Patients with schizophrenia|30 patients with schizophrenia (diagnosis based on the standard DSM criteria)
11274244|NCT02874482||Controls|30 healthy controls without any psychiatric or neurological diagnosis
11274245|NCT02874469|No Intervention|Control group (first period)|Patients treated as recommended with usual care in a center.
11274246|NCT02874469|Experimental|Group with diary (second period)|Intervention group = On top of usual care, an intensive care unit diary will be implemented for patients within the first 8 hours following their admission.
11274247|NCT02874456|Experimental|virus detection|detection of ZIKA virus in blood and sperm
11274248|NCT02874443|Experimental|Intervention centers|"Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.
~Intervention centers will receive knowledge translation of labor management guidelines"
11274249|NCT02874443|No Intervention|Control centers|No intervention at control centers
11274250|NCT02874430|Experimental|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11274251|NCT02874417|Experimental|Psychoeducation|The program was designed to dispel exaggerated thoughts surrounding the danger of the experience of anxiety symptoms, specifically focusing on fears regarding feelings of cognitive dyscontrol. The psychoeducation portion contains video animation and audio narration throughout, as well as some interactive features . Participants are provided with corrective information about the experience of anxiety-related sensations, with a particular focus on dispelling myths commonly held by individuals with high anxiety sensitivity cognitive concerns . Participants are taught that anxiety-related sensations are not dangerous and that they may have developed a conditioned fear to these symptoms of arousal.
11274252|NCT02874417|Placebo Comparator|Health and Wellness|The controlled condition consisted Physical Health Education Training (PHET), a computerized presentation which focuses on information on general healthy living. The PHET program contains information on nutrition, alcohol, water consumption, exercise, sexual health, hygiene, stress management, life organization, social support, positive outlook, and sleep.
11274253|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11274254|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11274255|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11274256|NCT02874391||AV fistula group|
11274257|NCT02874391||Control group|
11274258|NCT02874378|Experimental|study group|Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
11274259|NCT02874378|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
11274260|NCT02874365|Experimental|Crohn disorder|arm composed by 30 patients with Crohn disorder
11274261|NCT02874365|Experimental|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
11274262|NCT02874365|Experimental|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
11274263|NCT02874365|Sham Comparator|witness|arm composed by 30 patients with no intestinal disorders
11274264|NCT02874352|Other|intensive care patients|intensive care patients with tracheostomy/ high resolution impedance manometry with Automated Impedance Manometry analysis
11274268|NCT02874326|Experimental|Active comparator: Octreotide LAR|Sandostatin LAR Sandostatin LAR 20 mg will be administered once every 4 weeks as a intramuscular injection
11274269|NCT02874313|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
11274270|NCT02874313|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin
11274271|NCT02874300|No Intervention|Control|The control arm will comprise the offer of an assessment by a standard community falls prevention service.
11274272|NCT02874300|Other|High intensity supervision arm|high-intensity supervision
11274273|NCT02874300|Other|Moderate intensity supervision arm|Moderate intensity supervision
11274274|NCT02874287|Other|Hydroxychloroquine|Subjects are treated with hydroxychloroquine sulfate tablets.All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
11274275|NCT02874287|Other|placebo|Subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
11274276|NCT02874274|Active Comparator|100 Non-Homebound Subjects|outpatient healthcare utilization and self-reported illness.
11274277|NCT02874274|Active Comparator|60 Homebound Subjects|Will test the feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
11274278|NCT02874261|Experimental|Whole Body Periodic Acceleration|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation is 120 cycles/minute; cpm) as well as a distance traveled 16 mm."
11274279|NCT02874248|Active Comparator|Group 1: 15 mg E4/3 mg DRSP (n=10)|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
11274280|NCT02874248|Placebo Comparator|Group1: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
11274281|NCT02874248|Active Comparator|Group 2: 30 mg E4/6 mg DRSP (n=10)|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
11274282|NCT02874248|Experimental|Group 2: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
11274283|NCT02874248|Active Comparator|Group 3: 60 mg E4/12 mg DRSP (n=10)|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
11274284|NCT02874248|Placebo Comparator|Group 3: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
11274285|NCT02874248|Active Comparator|Group 4: 75 mg E4/15 mg DRSP (n=9)|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
11274286|NCT02874248|Placebo Comparator|Group 4: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
11274287|NCT02874235|Experimental|Music therapy treatment|35 patients receiving each 16 sessions of Receptive music therapy
11274288|NCT02874235|Active Comparator|Standard treatment|35 patients receiving each 16 sessions of Psychological treatment
11274289|NCT02874222||Caucasian|surveys completed by subject n=600, nationally
11274290|NCT02874222||African-American|surveys completed by subject n=200, nationally
11274291|NCT02874222||Asian|surveys completed by subject n=200, nationally
11274292|NCT02874209|Experimental|Patient with amyotrophic lateral sclerosis|ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium
11274293|NCT02874209|Placebo Comparator|Healthy volunteer|Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium
11274294|NCT02874196|Experimental|Patients with painful prosthesis|
11274295|NCT02874183|Experimental|Pharmacist intervention group|"The intervention group will receive:
~A phone call 48h-72h after discharge from the hospital to ensure that the patient filled their prescriptions and started taking their medication.
~A phone call five to seven days after discharge to reinforce the education using the teach back technique1. Patients will be asked about their medications, what are they for, how to use them, and what side effects to watch for, based on the education and information that was provided to them at discharge."
11274296|NCT02874183|No Intervention|usual care group|The control group will receive the usual standard care available at West Kendall Baptist Hospital.
11274297|NCT02874170|Experimental|drepanocytose affected patient|
11274298|NCT02874170|Other|Healthy volunteers|
11274299|NCT02874144|Experimental|AZ Compound|40 mg 12 weeks TID po
11274300|NCT02874144|Placebo Comparator|Placebo|40 mg 12 weeks TID po
11274301|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
11274302|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
11274303|NCT02874118|Experimental|HIV Patient population over 50 years old|
11274304|NCT02874105|Experimental|experimental group|Dynamic Humeral Centering
11274305|NCT02874105|Active Comparator|control group|Conventional physiotherapy
11274306|NCT02874092|Active Comparator|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
11274307|NCT02874092|Active Comparator|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
11274308|NCT02874079|Experimental|bullous pemphigoid|patients with bullous pemphigoid
11274309|NCT02874079|Active Comparator|no bullous pemphigoid|patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
11274310|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
11274311|NCT02874053||Healthy|Healthy Volunteers
11274312|NCT02874040|Experimental|Experimental|endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar
11274313|NCT02874027||TBI Patients with depression|All the patients should be diagnosed by CCMD-3(evaluation of depression)
11274314|NCT02874027||TBI Patients without depression|
11274315|NCT02874014|Experimental|Hypofractionation Proton beam therapy|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
11274316|NCT02873988||patients with COPD|patients with COPD
11274317|NCT02873988||patients without COPD|patients without COPD
11274318|NCT02873975|Experimental|Homologous Repair (HR) Deficiency|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
11274319|NCT02873975|Experimental|Replicative Stress|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
11274320|NCT02873975|Experimental|CCNE1 Amplification|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
11274321|NCT02873962|Experimental|Nivolumab with Bevacizumab|Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
11274322|NCT02873962|Experimental|Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
11274323|NCT02873949|Other|1. Periodontitis patients|30 patients consulting at Odontology department for periodontal treatment
11274324|NCT02873949|Other|2. Control|10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
11274325|NCT02873936|Experimental|Filgotinib Dose A|Filgotinib dose A + placebo to match filgotinib dose B + a stable dose of permitted csDMARD(s)
11274326|NCT02873936|Experimental|Filgotinib Dose B|Filgotinib dose B + placebo to match filgotinib dose A + a stable dose of permitted csDMARD(s)
11274327|NCT02873936|Placebo Comparator|Placebo|Placebo to match filgotinib dose A + placebo to match filgotinib dose B + a stable dose of permitted csDMARD(s)
11274328|NCT02873923||metastatic soft tissue sarcomas|No intervention : Meta-analysis of randomized controlled trials (RCT) conducted on patients with metastatic soft-tissue sarcoma treated with chemotherapy
11274329|NCT02873923||adjuvant breast cancer|No intervention : Meta-analysis of randomized controlled trials (RCT) conducted on patients with breast cancer treated with adjuvant chemotherapy
11274330|NCT02873910|Experimental|IQP-AS-119|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
11274331|NCT02873910|Placebo Comparator|Placebo|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
11274332|NCT02873897|Other|"Group meals on wheels at home"|
11274333|NCT02873897|Other|"Group residents of old people's homes - EHPAD"|
11274334|NCT02873884||case-management|Patients will meet the case-manager 5 times per month during 1h30 in community living
11274335|NCT02873884||traditional nursing|Patients will meet the case-manager 2 times per month during 1h00 in hospital
11274336|NCT02873871|Other|Control group|Standardized compressive dressing
11274337|NCT02873871|Experimental|Intervention group|Hemostasis with TerumoBand®
11274338|NCT02873858|Active Comparator|1.independent patients|
11274339|NCT02873858|Experimental|2. less mobile patients|
11274340|NCT02873858|Experimental|patient in a residence|
11274341|NCT02873858|Experimental|patients in a home for the elderly (EHPAD)|
11274342|NCT02873845||PATIENT|Patients with colon cancer
11274343|NCT02873845||THE SPOUSE/PARTNER|The spouse/partner of patients with colon cancer
11274344|NCT02873832||MPS|
11274345|NCT02873832||Control|
11274346|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
11274347|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
11274348|NCT02873806|Other|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost
~Intervention:
~Implantation of two iStent inject micro-bypass stents
~Tobramycin
~Dexamethasone"
11274349|NCT02873793||7/8 cases pure seminomas|
11274350|NCT02873793||5 cases of non-seminoma|
11274351|NCT02873793||3 cases of composite tumours seminoma/non-seminoma.|
11274352|NCT02873767|Placebo Comparator|Placebo|Single dose placebo comparator for each active arm
11274353|NCT02873767|Experimental|UCB4019 Dose 1|Dose 1 calculated based on body weight
11274354|NCT02873767|Experimental|UCB4019 Dose 2|Dose 2 calculated based on body weight
11274355|NCT02873767|Experimental|UCB4019 Dose 3|Dose 3 calculated based on body weight
11274356|NCT02873767|Experimental|UCB4019 Dose 4|Dose 4 calculated based on body weight
11274357|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
11274452|NCT02873117||5 alpha reductase inhibitor|
11274453|NCT02873117||Any other drug for benign prostate hyperplasia|
11274358|NCT02873741||Validation Study|Participants will undergo a perianal and digital anorectal exam, a high resolution anoscopy, and cervical and anal swabs to determine the best method to identify women at high risk for anal cancer.
11274359|NCT02873728|Experimental|RIC|In the study group, a blood pressure cuff will be inflated to 50 mmHg above systolic blood pressure while the performing investigator examines the radial pulse to ensure complete blood flow obstruction. Ischemia will be performed for 3 cycles of 5 min each and 10 min resting between cycles.
11274360|NCT02873728|Sham Comparator|Control|In the control group, a blood pressure cuff will be inflated to 10 mmHg (Sham procedure) for 3 cycles of 5 min each and 10 min resting between cycles.
11274361|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
11274362|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two yeart study
11274363|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
11274364|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
11274365|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
11274366|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
11274367|NCT02873689|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
11274368|NCT02873689|Experimental|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
11274369|NCT02873676|Experimental|nutritional intervention|This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
11274370|NCT02873676|Experimental|resistance training program|This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
11274371|NCT02873676|Experimental|lifestyle modification project|This group receive multi-dimensional intensive nutritional intervention and resistance training program.
11274372|NCT02873676|Placebo Comparator|control|This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
11274373|NCT02873663|Experimental|heavy drinkers|Plasma and head hair collection
11274374|NCT02873663|Experimental|teetotalers|Plasma and head hair collection
11274375|NCT02873650|Experimental|Group 1 - Control group|
11274376|NCT02873650|Experimental|Group 2-Moderate hepatic impairment|
11274377|NCT02873650|Experimental|Group 3-Severe hepatic impairment|
11274378|NCT02873637|Experimental|under sartorial catheter|catheter under sartorial
11274379|NCT02873637|Other|femoral catheter|femoral catheter
11274380|NCT02873611|Experimental|MRI scanning and the genicular ablation|patients undergoing both MRI scanning and the genicular ablation procedure. additional MRI testing of apprx. 0.5-1 hour
11274381|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane
11274382|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
11274383|NCT02873572|Experimental|online poker gamblers|Recruitment by forums of online poker gamblers: an explanation of the research is sent with the dedicated link of the research.
11274384|NCT02873572|Experimental|casino gamblers|Recruitment to the casino gates: an explanation of the research is sent with the dedicated e-link of the research and they could answer directly to the questionnaire (1st step) on sites.
11274385|NCT02873572|Experimental|MMORPG gamers|Recruitment by forums of MMORPG (as guilds): an explanation of the research is sent with the dedicated link of the research.
11274386|NCT02873572|Experimental|no gamer subjects|Recruitment by poster.
11274387|NCT02873559|No Intervention|Controls|A control group, which is 20 weeks with placebo injections without training.
11274388|NCT02873559|Experimental|Testosterone|A testosterone group given 20 weeks on testosterone injections without training
11274389|NCT02873559|Experimental|Training|A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
11274390|NCT02873559|Experimental|Testosterone and training|A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
11274391|NCT02873546|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
11274392|NCT02873546|Sham Comparator|sham tDCS on left DLPFC (F3)|Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
11274393|NCT02873533|Other|A-Elderly patients with cancer|geriatric care and longitudinal follow up
11274394|NCT02873520|Experimental|Precision Cells combined with Chemotherapy treatment:|Precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
11274395|NCT02873520|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
11274396|NCT02873507|Experimental|MRI of donor liver|MRI evaluation of graft steatosis in donor liver prior to transplantation
11274397|NCT02873494||PHYSIOFLOW PF05 Lab1TM|Impedance cardiography
11274398|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
11274399|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
11274400|NCT02873468|Experimental|Florence 30|
11274401|NCT02873468|Experimental|Florence 60|
11274402|NCT02873468|Experimental|Florence 90|
11274403|NCT02873468|Placebo Comparator|Placebo|
11274404|NCT02873455|Experimental|watching video|Short video clip including the circumstance of operation theater, and surgeon's interview
11274405|NCT02873442|Experimental|Precision cells combined with TACE|"Transcatheter Arterial Chemoembolization:
~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
11274406|NCT02873442|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
11274407|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
11274408|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
11274409|NCT02873416|Experimental|Precision cells combined with Chemotherapy treatment:|Once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
11274410|NCT02873416|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
11274411|NCT02873403|Experimental|KNEEMO knee brace & Popular knee brace|Patients having medial knee osteoarthritis
11274412|NCT02873403|Experimental|Popular knee brace &KNEEMO knee brace|Patients having medial knee osteoarthritis
11274413|NCT02873390|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
11274414|NCT02873377|Experimental|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling & Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
11274415|NCT02873377|Active Comparator|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
11274416|NCT02873364|Active Comparator|Vitamin D3 (Low dose)|Daily 600 unites of vitamin D + Cetirizine 10mg twice a day
11274417|NCT02873364|Experimental|Vitamin D3 (High dose)|Daily 4000 unites vitamin D + Cetirizine 10mg twice a day
11274418|NCT02873351|Experimental|carbidopa-levodopa 25-100 mg|Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
11274419|NCT02873351|Placebo Comparator|Placebo for carbidopa-levodopa 25-100 mg|Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
11274420|NCT02873338|Active Comparator|Idarubicin + Cytarabine|"Induction:
~Idarubicin - 12 mg/m2/day slow IV injection for 3 days;
~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 7 days
~Re-induction - same as above or:
~Idarubicin - 12 mg/m2/day slow IV injection for 2 days;
~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days
~Consolidation:
~Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days"
11274421|NCT02873338|Experimental|Idarubicin+Cytarabine+lower dose CX-01|"Induction:
~Idarubicin - 12 mg/m2/day slow IV injection for 3 days;
~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 7 days;
~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 7 days
~Re-induction - same as above or:
~Idarubicin - 12 mg/m2/day slow IV injection for 2 days;
~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days
~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 5 days
~Consolidation:
~Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days
~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 5 days"
11274422|NCT02873338|Experimental|Idarubicin+Cytarabine+higher dose CX-01|"Induction:
~Idarubicin: 12 mg/m2/day slow IV injection for 3 days;
~Cytarabine: 100 mg/m2/day continuous 24-hour IV infusion for 7 days;
~CX-01: 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 7 days
~Re-Induction - same as above or:
~Idarubicin - 12 mg/m2/day slow IV injection for 2 days;
~Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days;
~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 5 days
~Consolidation:
~Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days
~CX-01 - 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 5 days"
11274423|NCT02873312|Experimental|StimRouter Treatment|The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months.
11274454|NCT02873104|Active Comparator|Treatment|truSculpt rf device, therapeutic settings
11274424|NCT02873312|Sham Comparator|StimRouter Control|The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months.
11274425|NCT02873299|No Intervention|Treatment as usual|Treatment as usual, wait list control group
11274426|NCT02873299|Active Comparator|rTMS at 10Hz|10 Hz rTMS of the right dorsolateral prefrontal cortex
11274427|NCT02873299|Active Comparator|rTMS at 20Hz|20 Hz rTMS of the right dorsolateral prefrontal cortex
11274428|NCT02873286|Experimental|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
11274429|NCT02873286|Experimental|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
11274430|NCT02873286|Experimental|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
11274431|NCT02873286|Experimental|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
11274432|NCT02873286|Experimental|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
11274433|NCT02873273|Experimental|Dexamethasone delivery system|
11274434|NCT02873260|Experimental|TetraVax-DV-TV005 + rDEN3Δ30|Participants will receive the TetraVax-DV-TV005 vaccine at Day 0 and the rDEN3Δ30 virus at Day 180.
11274435|NCT02873260|Placebo Comparator|Placebo + rDEN3Δ30|Participants will receive placebo at Day 0 and the rDEN3Δ30 virus at Day 180.
11274436|NCT02873234||Traditional Chinese Medicine|Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
11274437|NCT02873234||TCM plus antidepressants|This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
11274438|NCT02873234||Antidepressants|Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
11274439|NCT02873221|Active Comparator|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
11274440|NCT02873221|Experimental|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
11274441|NCT02873221|Experimental|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
11274442|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
11274443|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11274444|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11274445|NCT02873182|Experimental|Autonomic nervous system monitoring|During standard intraoperative neuromonitoring, additional smooth muscle free-running and stimulated EMG will be recorded from corporal tissues (corpus spongiosum) of male and female genitalia from all patients who consent to participate in the study. EMG data and additional demographics and clinical data (e.g. operative time, adverse events) will be collected for each patient.
11274446|NCT02873156|Experimental|E2027|"Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:
~Part A Cohort 1: 50 mg (1 × 50 mg capsule)
~Cohort 2: 100 mg (2 × 50 mg capsules)
~Cohort 3: 200 mg (4 × 50 mg capsules)
~Cohort 4: 400 mg (8 × 50 mg capsules)
~Cohort 6: 25 mg (5 × 5 mg capsules) Part B
~Cohort 5: 400 mg (8 × 50 mg capsule)
~Part C:
~• Cohort 7: 50 mg (1 × 50 mg capsules)
~Part D:
~Cohort 8: 5 mg (1 × 5 mg capsules)
~Cohort 9: 10 mg (2 × 5 mg capsules)"
11274447|NCT02873156|Placebo Comparator|Placebo|Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.
11274448|NCT02873143||The APA2011 cohort|In September 2011, students at 4 upper secondary schools in Aalborg were invited to answer an online questionnaire and to be part of the APA2011 cohort. From 2846 potential responders, 2200 adolescents responded to the questionnaire, corresponding to a response rate of 77%. A total of 504 adolescents indicating knee pain at least monthly were successfully contacted (a response rate of 83% of those who reported their telephone numbers) and were asked standardized questions on the telephone. This forms the cohort of 504 adolescents with knee pain. In addition a random selected group of adolescents without knee pain in 2011 will be contacted and asked the same questions as those with knee pain.
11274449|NCT02873130|Experimental|Behavioral: Telepractice Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) through West Chester University's Desire 2 Learn (D2L) software program. Synchronous and asynchronous learning opportunities are provided through D2L over a four week period. The GVPM includes vocal hygiene, vocal education, and vocal training.
11274450|NCT02873130|Experimental|Behavioral: In-person Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) at West Chester University in-person. The GVPM will meet for 2 hours once a week for four weeks. The GVPM includes vocal hygiene, vocal education, and vocal training.
11274451|NCT02873130|Sham Comparator|Behavioral: Telepractice, Vocal Hygiene and Vocal Education|Participants will complete Vocal Hygiene and Vocal Education through West Chester University's Desire 2 Learn (D2L) software program. Asynchronous learning opportunities are provided through D2L over a one week period.
11274456|NCT02873091|Active Comparator|CEI|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose
11274457|NCT02873091|Active Comparator|PIEB 1|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose
11274458|NCT02873091|Active Comparator|PIEB 2|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose
11274459|NCT02873078|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of cognitive behavior therapy (CBT). Parents will also receive 10 weekly modules. Main components in the children's modules are exposure for abdominal symptoms, feared stimuli and situations in which the children are afraid of having symptoms. The parental receive information on how they can support their children in the treatment and how to reinforce health y behaviors and decrease attention to pain behaviors. Therapist support is provided through written messages within the secure platform.
11274460|NCT02873078|No Intervention|Waiting list|This is a wait-list control where the children and parents are allowed to carry on with any contacts within the health-care system, exempt for psychological treatments.
11274461|NCT02873065|Experimental|Ilaprazole|Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.
11274462|NCT02873065|Active Comparator|Esoprazole|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.
11274463|NCT02873026|No Intervention|Standard care|The patient will receive the standard care given to all patients that have received a vitrectomy following open globe trauma.
11274464|NCT02873026|Experimental|Triamcinolone acetonide|Triamcinolone Acetonide 4mg/0.1ml intravitreal cavity and 40mg/1ml subtenons to be injected at the time of the vitrectomy. Patients will then receive standard care following operation.
11274465|NCT02873013||Prostate Cancer|About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
11274466|NCT02873000|No Intervention|Routine Care Group|Routine Care (R): Standard of care therapy based on admitting diagnosis
11274467|NCT02873000|Experimental|Experimental Group|"Intervention 1 (E1): addition of incentive spirometry every hour while awake;
~There will be a computerized protocol with specific instructions documenting:
~compliance
~patient position while using [sitting up vs laying flat in bed]
~inspiratory volume attained
~effort, motivation and compliance will subjectively be documented using a visual analogue 0-5 point scale."
11274468|NCT02872987||B-ALL/NHL|
11274469|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
11274470|NCT02872974||Exposed|Offspring of woman with GDM
11274471|NCT02872974||Not exposed|Offspring of woman without GDM
11274472|NCT02872961||SIBO Positive|Positive small bowel aspirate culture and/or positive glucose breath test
11274473|NCT02872961||SIBO Negative|Negative small bowel aspirate culture and negative glucose breath test
11274474|NCT02872948||70 euploïdes foeti samples|"Patients with foetus euploïde (no sick)"
11274475|NCT02872948||30 trisomies 21 samples|"Patients with foetus reached(affected) by trisomy 21 (sick)"
11274476|NCT02872935|Placebo Comparator|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
11274477|NCT02872935|Experimental|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
11274478|NCT02872922|Active Comparator|Endothelial function after CWUT|Endothelial function of the all patients before and after application continuous waveform of ultrasound therapy (CWUT) measured by technique flow-mediated dilation (FMD).
11274479|NCT02872922|Active Comparator|Endothelial function after PWUT|Endothelial function of the all patients before and after application pulsed waveform of ultrasound therapy (PWUT) measured by technique flow-mediated dilation (FMD).
11274480|NCT02872922|Active Comparator|Endothelial function after PLACEBO|In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off. Endothelial function of the all patients before and after application placebo waveform of ultrasound therapy measured by technique flow-mediated dilation (FMD)
11274481|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED portable PDT treatment
11274482|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
11274483|NCT02872896|Experimental|ClearSight device|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.
11274484|NCT02872896|Sham Comparator|Non-ClearSight|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.
11274485|NCT02872883|Experimental|Expectant management and minimal vaginal examinations|Expectant management up to approximately 96hours and vaginal examinations only when necessary during active labour
11274486|NCT02872883|Experimental|Expectant management and routine vaginal examinations|Expectant management up to approximately 96hours and routine vaginal examinations during active labour
11274487|NCT02872883|Experimental|Active management and minimal vaginal examinations|Induction of labour at approximately 24hours and vaginal examinations only when necessary during active labour
11274488|NCT02872883|Active Comparator|Active management and routine vaginal examinations|Induction of labour at approximately 24hours and routine vaginal examinations
11274489|NCT02872870||Control adults|lexical tests and electroencephalogram (EEG).
11274490|NCT02872870||Dyslexic patients|lexical tests
11274491|NCT02872870||Dysphasic patients|lexical tests
11274492|NCT02872857|Placebo Comparator|Placebo|
11274493|NCT02872857|Experimental|8mg galantamine twice daily|
11274494|NCT02872857|Experimental|12mg galantamine twice daily|
11274495|NCT02872831|Active Comparator|22G SharkCore™ needle|Covidien has recently released a novel SharkCore™ Fine Needle Biopsy (FNB) system for EUS-guided tissue acquisition of solid gastrointestinal lesions. With its unique bevel design, this needle has shown promising results to acquire histologic tissue as per oral communication with physicians around the country
11274496|NCT02872831|Active Comparator|22G BNX EUS-FNA needle|The standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle is routinely used for the evaluation of solid mass lesions in the pancreas and gastrointestinal tract.
11274497|NCT02872818|Active Comparator|Control group|Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
11274498|NCT02872818|Active Comparator|Metformin group|Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
11274499|NCT02872818|Active Comparator|Medroxyprogesterone acetate group|Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
11274500|NCT02872805|Active Comparator|PEPFAR Enhanced Standard of Care (PESCA)|This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites. We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care
11274501|NCT02872805|Experimental|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
11274502|NCT02872792|Experimental|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
11274503|NCT02872792|Active Comparator|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
11274504|NCT02872779|Experimental|Patients Treated for Metastatic Colorectal cancer|Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer
11274505|NCT02872766|Experimental|Corneal cross linking (CXL)|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
11274506|NCT02872753|Experimental|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
11274507|NCT02872753|Other|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
11274508|NCT02872740|Experimental|Embolization of Left Gastric Artery|These patients will have their left gastric artery embolized
11274509|NCT02872740|Experimental|Embolization of Gastroepiploic Artery|These patients will have their gastroepiploic artery embolized
11274510|NCT02872727||Air France Company's Employees Working|Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations
11274511|NCT02872714|Experimental|Cohort A-ID (Intermittent Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
11274512|NCT02872714|Experimental|Cohort A-CD (Continuous Dose) Pemigatinib|Pemigatinib in subjects with FGFR3 mutations or fusions.
11274513|NCT02872714|Experimental|Cohort B Pemigatinib|Pemigatinib in subjects with other FGF/FGFR alterations.
11274514|NCT02872701|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
11274515|NCT02872688|Experimental|GanedenBC30|
11274516|NCT02872675|Experimental|HOST-DM059 (Prebiotic)|HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics. HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g. The β-Galacotosidase Enzyme, & Bifidobacterium Bifidum). The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria. HOST-DM059 encourages the growth and development of Bifidobacteria. Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
11274517|NCT02872675|Placebo Comparator|Maltodextrin|Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
11274518|NCT02872649|Experimental|study medication|Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate >80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
11274519|NCT02872649|Active Comparator|control group|Phenprocoumon dosage according to INR
11274520|NCT02872636|Experimental|Treatment Group|
11274521|NCT02872623|Experimental|experimental group|patients clinically suspected of having a tumor of the small intestine
11274522|NCT02872610|Experimental|Self-help Online|6 weeks of internet-based self-help intervention
11274523|NCT02872610|No Intervention|Wait-list|Waiting list control condition
11274524|NCT02872597|Experimental|Treatment|Inhaled ipratropium bromide 250mcg given via nebulization every 6 hours for up to 5 days
11274525|NCT02872597|Placebo Comparator|Placebo|Inhaled normal saline 1.25mL given via nebulization every 6 hours for up to 5 days
11274526|NCT02872584||Prednisone|Patients with dermatological conditions requiring high dose long term glucocorticoid treatment
11274527|NCT02872571|Experimental|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
11274558|NCT02872337|Experimental|Experimental (Intervention): PreopPT Group|This group will undergo the group preoperative education session. Following this session (intervention) this group underwent a one-time, one-on-one preoperative PT session. They also were given access to a web-based microsite which was customized to surgeon
11274559|NCT02872337|Placebo Comparator|Control (standard of care): No PreopPT Group|This group underwent the current of standard of care at our institution. This only includes the group preoperative education session. No further preoperative education was given.
11274560|NCT02872324|Experimental|Sessions of Mindfulness Based Cognitive Therapy (MBCT)|
11274605|NCT02872051|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
11274528|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:
~The study coordinator will provide the decision aid for the parent/clinician dyad.
~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.
~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.
~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.
~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
11274529|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
11274530|NCT02872545|Experimental|forward tilted|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in forward tilted position
11274531|NCT02872545|Other|semi sitting|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in semi sitting
11274532|NCT02872545|Other|dorsal decubitus|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in dorsal decubitus
11274533|NCT02872532|Experimental|Testicular tissue|Children faced with a fertility threatening diagnosis or treatment plan will be offered testicular tissue cryopreservation, particularly if pre-pubescent and without other options to preserve fertility.
11274534|NCT02872519|Experimental|Experimental|Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).
11274535|NCT02872506|Active Comparator|medical treatment by Anti TNF|The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time
11274536|NCT02872506|Active Comparator|ileocecal resection|The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy
11274537|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
11274538|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
11274539|NCT02872480|Experimental|ACTIVE Training|Healthy participants will be progressed from 60-80% of their VO2max as determined by the progressive exercise test over the course of 6 30-minute training sessions. Concussed participants will begin 30-minute training sessions at 60% of the VO2 achieved at symptom exacerbation of the exercise test. Intensity will be progressed as tolerated by the participant and training sessions will continue until the participant is asymptomatic for 24 consecutive hours (total number of sessions variable based on clinical recovery).
11274540|NCT02872480|No Intervention|Control|Healthy controls will be asked to follow their normal routine for rest and physical activity. Concussed controls will be asked to follow the guidance for rest and activity as prescribed by the physicians and athletic trainers overseeing their clinical care.
11274541|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
11274542|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
11274543|NCT02872454|Experimental|Text Messaging|
11274544|NCT02872441|Experimental|diagnosis of disease associated with IgG4|patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
11274545|NCT02872428|Experimental|Valproic acid (Depacon)|Valproic acid by IV infusion over one hour
11274546|NCT02872428|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
11274547|NCT02872415|Experimental|The forearm as blood puncture site|The child receives a puncture blood on the forearm
11274548|NCT02872415|Placebo Comparator|Fingers like blood puncture site|Premature receiving a puncture blood on the finger
11274549|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.
~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
11274550|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
11274551|NCT02872389|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
11274552|NCT02872389|Experimental|Desflurane|Anesthesia was maintained with desflurane.
11274553|NCT02872376||Anemic|Anemic patients
11274554|NCT02872363|No Intervention|Control|The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
11274555|NCT02872363|Experimental|Intervention A - Behavioural Regulation|Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
11274556|NCT02872363|Experimental|Intervention B - Priority|Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
11274557|NCT02872350|Experimental|Premature with necrotizing enterocolitis|
11274561|NCT02872311|Active Comparator|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
11274562|NCT02872311|Active Comparator|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
11274563|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
11274564|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
11274565|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
11274566|NCT02872298|Experimental|Treatment|Treatment: Targeted Lung Denervation (TLD)
11274567|NCT02872285|Experimental|LYC-30937-EC 25 mg PO once daily (QD)|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
11274568|NCT02872285|Placebo Comparator|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
11274569|NCT02872272|Experimental|Treatment with Amikacin|Dressing impregnated by administration of amikacin
11274570|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week
~Treatment until disease progression, or unacceptable toxicity"
11274571|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.
~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily
~Treatment until disease progression, or unacceptable toxicity"
11274572|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week
~Treatment until disease progression, or unacceptable toxicity"
11274573|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily
~Treatment until disease progression, or unacceptable toxicity"
11274574|NCT02872246|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
11274575|NCT02872233|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
11274576|NCT02872220|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products compared to that of a negative control [0.9% NaCl] were tested simultaneously on each subject.
11274577|NCT02872207|Experimental|Suncare agent 1 + control|Application of control and test product into one of the subjects two eyes.
11274578|NCT02872207|Experimental|Suncare agent 2 + control|Application of control and test product into one of the subjects two eyes.
11274579|NCT02872194|Experimental|Suncare agent A + control|Application of control and test product into one of the subjects two eyes.
11274580|NCT02872194|Experimental|Suncare agent B + control|Application of control and test product into one of the subjects two eyes.
11274581|NCT02872194|Experimental|Suncare agent C + control|Application of control and test product into one of the subjects two eyes.
11274582|NCT02872181|Experimental|BMI <30|Pregnant women undergoing C/S with BMI <30
11274583|NCT02872181|Experimental|BMI 30-40|Pregnant women undergoing C/S with BMI 30-40
11274584|NCT02872181|Experimental|BMI >40|Pregnant women undergoing C/S with BMI >40
11274585|NCT02872155|Experimental|Oral hydratation|
11274586|NCT02872155|Active Comparator|Endovenous hydratation|
11274587|NCT02872142|Experimental|Albutein 5%|Plasma exchanges with Albutein 5% as a replacement solution
11274588|NCT02872129||166 women with FM/CWP|166 women with Fibromyalgia (FM) or Chronic Widespread Pain (CWP) that participated in an Randomised Controlled Trial called GAU in western Sweden 2004-2005.
11274589|NCT02872116|Experimental|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy
~Enrollment is closed for this arm"
11274590|NCT02872116|Active Comparator|XELOX (Oxaliplatin + Capecitabine)|
11274591|NCT02872116|Active Comparator|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
11274592|NCT02872116|Experimental|Nivolumab + XELOX|
11274593|NCT02872116|Experimental|Nivolumab + FOLFOX|
11274594|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
11274595|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
11274596|NCT02872090|Experimental|Arm 1|The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo
11274597|NCT02872090|Experimental|Arm 2|The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol
11274598|NCT02872090|Experimental|Arm 3|The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,
11274599|NCT02872090|Experimental|Arm 4|The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium
11274600|NCT02872077|Active Comparator|Auricular Acupuncture|Study subjects randomized to this group will receive auricular acupuncture: the investigator will evaluate the infant using an ear point locator to determine active sites, and will place acupuncture needles in the active sites found in one ear. Acupuncture sites will be alternated every 3 days between right and left ear.
11274601|NCT02872077|No Intervention|Control|The subjects randomized to the control group will have NO interventions, and will continue to receive routine care for NAS, pharmacologic and non-pharmacologic, per NICU protocol.
11274602|NCT02872064|Experimental|Treatment with PDT|A single intravenous injection of Verteporfin (0.4mg/kg) will be administered, at least 60minutes and up to 90 minutes before laser activation. A 690nm red laser light will be delivered with a diffuser laser fibre inserted through the skin into the breast tissue, with light dose escalation after every three patients. All patients will have fixed dose of the photosensitizer but variable light dose.
11274606|NCT02872038|Experimental|Treatment|Cefepime intraperitoneal continuous dosing
11274607|NCT02872038|Active Comparator|Control|Cefazolin plus Ceftazidime intraperitoneal continuous dosing
11274608|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 2 doses|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
11274609|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
11274610|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
11274611|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
11274612|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
11274613|NCT02872012|Experimental|Cryoanesthesia Device -7 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
11274614|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
11274615|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.
~Comment: Cryoanesthesia Device is the name of the device."
11274616|NCT02872012|Active Comparator|Lidocaine|"Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.
~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye."
11274617|NCT02871999|Active Comparator|Control group|This group receives normal treatment after surgery,with no acupuncture.
11274618|NCT02871999|Experimental|Experimental group|This group receives acupuncture therapy besides normal treatment after surgery. The acupuncture therapy starts after 24 hours of surgery, 1 time a day, 30 minutes every time, until the fifth day.
11274619|NCT02871986||Individuals with hypogonadism|Individuals with hypogonadism requiring pubertal induction. Participants will receive oestrogen therapy in the form of transdermal oestrogen patch, which is standard care.
11274620|NCT02871973|Experimental|SDP|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visit.
11274621|NCT02871973|Active Comparator|CDC Handout|Families in the control group will receive the Center for Disease Control and Prevention (CDC) Handout at enrollment.
11274622|NCT02871960|Experimental|Robotic colectomy|Patients undergoing robotic colectomy for colorectal cancer
11274623|NCT02871960|Active Comparator|Laparoscopic colectomy|Patients undergoing laparoscopic colectomy for colorectal cancer
11274624|NCT02871934|Experimental|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
11274625|NCT02871934|Experimental|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
11274626|NCT02871921|Experimental|Conversational Engagement|Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months). Under an exploratory aim, a limited number of participants will be further followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from topic options. Participants will also receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions.
11274627|NCT02871921|No Intervention|Control Group|Participants will receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions
11274628|NCT02871908|Experimental|L reuteri DSM 17938|L reuteri DSM 17938 2 x 10^8 twice daily
11274629|NCT02871908|Placebo Comparator|Controls|Identically appearing placebo twice daily
11274630|NCT02871882|Active Comparator|Ox bile extract|Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
11274631|NCT02871882|Placebo Comparator|Placebo|Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
11274632|NCT02871869|Active Comparator|Control group A|Control group A was treated with single R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
11274660|NCT02871713|Experimental|Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg)
11274712|NCT02871427|Experimental|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
11274633|NCT02871869|Experimental|Trial group A|Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
11274634|NCT02871869|Active Comparator|Control group B|Control group B was treated with single CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
11274635|NCT02871869|Experimental|Trial group B|Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
11274636|NCT02871856|Other|Single|Single arm only, CT screening of lung
11274637|NCT02871843|Experimental|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
11274638|NCT02871830|Experimental|Physical activity intervention group|
11274639|NCT02871830|No Intervention|Control group|
11274640|NCT02871817||Normal Vision|Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
11274641|NCT02871817||Age-related macular degeneration|Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
11274642|NCT02871817||Diabetic retinopathy|Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
11274643|NCT02871804|Active Comparator|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
11274644|NCT02871804|Experimental|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
11274645|NCT02871791|Experimental|Palbociclib, Everolimus, Exemestane|"Palbociclib will be administered orally, once daily for 21 consecutive days followed by a 7-day rest (28-day cycle)
~Everolimus will be administered orally, once daily on a 28 day schedule
~Exemestane will be administered orally, once daily on a 28 day schedule
~Participants will be treated with increasing/decreasing doses of palbociclib and everolimus to establish MTD(s)/RP2D for both drugs in the setting of the triple combination of palbociclib, everolimus and exemestane"
11274646|NCT02871778|Experimental|VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor|"Part A/ Treatment Period 1: VX-371 in Hypertonic Saline
~Part A/ Treatment Period 2: Hypertonic Saline
~Part B/ Treatment Period 3: Hypertonic Saline + Ivacaftor"
11274647|NCT02871778|Experimental|HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor|"Part A/ Treatment Period 1: Hypertonic Saline
~Part A/ Treatment Period 2: VX-371 in Hypertonic Saline
~Part B/ Treatment Period 3: VX-371 in Hypertonic Saline + Ivacaftor"
11274648|NCT02871778|Experimental|VX-371, then Placebo, then Placebo + Ivacaftor|"Part A/ Treatment Period 1: VX-371
~Part A/ Treatment Period 2: Placebo
~Part B/ Treatment Period 3: Placebo + Ivacaftor"
11274649|NCT02871778|Experimental|Placebo, then VX-371, then VX-371 + Ivacaftor|"Part A/ Treatment Period 1: Placebo
~Part A/ Treatment Period 2: VX-371
~Part B/ Treatment Period 3: VX-371 + Ivacaftor"
11274650|NCT02871765|Experimental|education group|In education group, each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department by researchers. Three months later, participants in the education group received a follow-up phone call in order to clarify any questions related to the brochure. All participants completed posttest at 6-month follow-up.
11274651|NCT02871765|No Intervention|control group|The control group received the brochure only.
11274652|NCT02871752|Experimental|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
11274653|NCT02871752|Active Comparator|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
11274654|NCT02871739|Experimental|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
11274655|NCT02871739|Experimental|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
11274656|NCT02871739|Experimental|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
11274657|NCT02871739|Experimental|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
11274658|NCT02871726|Experimental|Experimental|TRUS and TRUS-Robot will be used during prostate biopsy
11274659|NCT02871713|Active Comparator|Intrathecal morphine|Intrathecal morphine 100 mcg
11274661|NCT02871713|Experimental|Intrathecal morphine + Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg) + Intrathecal morphine 100 mcg
11274662|NCT02871700|Experimental|Action observation therapy (AOT)|Action observation therapy (AOT)
11274663|NCT02871700|Experimental|Mirror therapy (MT)|Mirror therapy (MT)
11274664|NCT02871700|Active Comparator|Control group|Customary bilateral UE training
11274665|NCT02871687|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
11274666|NCT02871687|Active Comparator|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
11274667|NCT02871687|Active Comparator|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.
11274668|NCT02871674|Experimental|Intervention group|Participants in the intervention group will receive behavioural training by psychologists in three sessions over three weeks
11274669|NCT02871674|No Intervention|Control group - usual care|Participants in the control group will receive usual care. They will also attend their usual appointments with the psychiatrists. They will not receive any intervention.
11274670|NCT02871661|Active Comparator|Amitriptyline|This group will be treated with medication alone (amitriptyline hydrochloride, 25 mg) for chronic vulvar pain (vulvodynia).
11274671|NCT02871661|Active Comparator|Amitriptyline plus kinesiotherapy|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus pelvic floor exercises such as Kegel contractions and stretching of pelvic floor muscles with patients own hands.
11274672|NCT02871661|Active Comparator|Amitriptyline plus IC (Quark)|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus electrical stimulation with Interferential Current (manufacturer: Quark Medical; Model: Dualpex 961 - program number 42): two electrodes put into the perineal surface area emitting interferential current, once a week for twenty minutes each, for eight weeks long.
11274673|NCT02871648|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
11274674|NCT02871648|Active Comparator|Fludrocortisone|Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
11274675|NCT02871648|Active Comparator|Epleronone|Subjects will receive 100 mg of epleronone on one of three study days.
11274676|NCT02871635|Experimental|BI 695501|
11274677|NCT02871635|Active Comparator|HUMIRA + BI 695501|
11274678|NCT02871609||Patients with longterm ureteral stent|
11274679|NCT02871596|Experimental|Placebo,Flavonoids,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
11274680|NCT02871596|Experimental|Placebo,Flavonoids+Prebiotics,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
11274681|NCT02871596|Experimental|Flavonoids,Placebo,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
11274682|NCT02871596|Experimental|Flavonoids,Flavonoids+Prebiotics,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
11274683|NCT02871596|Experimental|Flavonoids+Prebiotics,Placebo,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
11274684|NCT02871596|Experimental|Flavonoids+Prebiotics,Flavonoids,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
11274685|NCT02871583|Active Comparator|lichtenstein|lichtenstein procedure
11274686|NCT02871583|Active Comparator|Kugel|Kugel procedure
11274687|NCT02871583|No Intervention|control|healthy volunteers
11274688|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
11274689|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
11274690|NCT02871544|Sham Comparator|Low BNP and Low NGAL Group|BNP≤100pg/ml and NGAL≤153pg/ml
11274691|NCT02871544|Active Comparator|High BNP and Low NGAL Group|BNP>100pg/ml and NGAL≤153pg/ml
11274692|NCT02871544|Active Comparator|Low BNP and High NGAL Group|BNP≤100pg/ml and NGAL>153pg/ml
11274693|NCT02871544|Active Comparator|High BNP and High NGAL Group|BNP>100pg/ml and NGAL>153pg/ml
11274694|NCT02871531|Experimental|Pneumatic retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy
11274695|NCT02871531|Experimental|Vitrectomy|Patients with retinal detachment allocated to vitrectomy
11274696|NCT02871518|Experimental|Two cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
11274697|NCT02871518|Active Comparator|Three cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
11274698|NCT02871505|Experimental|Molecular subtyping (14d/f) of Treponema pallidum|Benzathine Penicillin G treatment
11274699|NCT02871505|Experimental|Molecular subtyping (others) of Treponema pallidum|Benzathine Penicillin G treatment
11274700|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
11274701|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
11274702|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
11274703|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
11274704|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
11274705|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
11274706|NCT02871466|Experimental|stem cells infusion|
11274707|NCT02871453|Experimental|Acupuncture combined rehabilitation|"Scalp acupuncture treatment
~Rehabilitation treatment"
11274708|NCT02871453|Experimental|Rehabilitation|Rehabilitation treatment
11274709|NCT02871440|Experimental|Eye drop 1|Omega 3
11274710|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
11274711|NCT02871440|Active Comparator|Eye drop 3|Optive
11274713|NCT02871414|Experimental|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
11274714|NCT02871414|Experimental|REST - Late Group|Control - No treatment for 7 weeks, then provided 7 weeks of sleep skills education provided in group and one-on-one format
11274715|NCT02871401|Experimental|Valganciclovir|Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
11274716|NCT02871401|Placebo Comparator|Placebo|Placebo, 2 pills by mouth one time per day x 12 weeks
11274717|NCT02871388|Experimental|CONECT|12 week program with additional follow up at 24 weeks.
11274718|NCT02871388|No Intervention|Control|Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
11274719|NCT02871375|Other|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
11274720|NCT02871375|Other|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
11274721|NCT02871362|Experimental|IQP-AS-118|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
11274722|NCT02871362|Placebo Comparator|Placebo|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
11274723|NCT02871349|Experimental|Propanolol and MRI|Participants will receive propranolol via oral capsule, crushed tablet, or liquid daily. The drug dosage will be titrated slowly to ensure the drug is tolerated well. Those aged 15-24 will have an MRI before starting drug.
11274724|NCT02871349|Placebo Comparator|Placebo and MRI|Participants will receive placebo via oral capsule, crushed tablet, or liquid daily. Those aged 15-24 will have an MRI before starting drug.
11274725|NCT02871323|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with SD, no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses.
11274726|NCT02871310|Experimental|IQP-AS-118|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
11274727|NCT02871310|Placebo Comparator|Placebo|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
11274728|NCT02871297|Experimental|Vortioxetine tablets|Vortioxetine tablets for 26 weeks
11274729|NCT02871297|Experimental|Vortioxetine|Single dose of vortioxetine oral drops (only a subset of patients)
11274730|NCT02871284|Experimental|Sensorimotor training (EI)|The participants of the experimental intervention arm will take part in a 45 minutes sensorimotor training class two times a week for a maximum of 24 weeks at the NCT (National Center for Tumor Diseases). Highly qualified exercise therapists will guide the class. Class size will be no bigger than 8 patients to ensure adequate individual supervision and guidance. Additionally, participants will be asked to perform one weekly 15 minutes home-based sessions without supervision. Participants who are not able to come to the NCT Heidelberg 2x/week will be offered a home-based sensorimotor program including the same exercises. At the beginning, participants will receive an appointment for an individual face-to-face counseling session at the NCT. During this appointment, the patient will receive an exercise manual for individualized home-based sensorimotor training and a practical introduction by the exercise therapist.
11274731|NCT02871284|Active Comparator|machine-based resistance training (AC)|Participants of the active control arm will receive machine-based resistance training. The supervised resistance exercise program will be undertaken twice weekly in small groups (not more than 12 people per group) of participants and will be guided by an exercise physiotherapist over a maximum of 24 weeks. All sessions will start with a warm-up and finish with a cool-down (comprising exercise on a cycle ergometer or treadmill at a relatively low intensity and stretching activities) and will take approximately 45 minutes. Additionally, participants will be asked to perform a weekly 15 minutes home-based resistance training session without supervision
11274732|NCT02871284|No Intervention|usual care|Participants will receive usual care with no additional exercise training or intervention
11274733|NCT02871271|Experimental|IQP-AS-121|To be taken once daily dosing of 1 tablet in the morning.
11274734|NCT02871258|Other|The MetaNeb® System Treatment|Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
11274735|NCT02871245|Active Comparator|Comparator Group|Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.
11274736|NCT02871245|Experimental|Acupuncture Therapy Group|Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row
11274737|NCT02871232||Intentional exposures among adolescents and adults|
11274738|NCT02871232||Unintentional exposures among infants and children|
11274739|NCT02871219|Experimental|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
11274740|NCT02871206|Experimental|Adjuvanted Influenza Vaccine|Fluad
11274741|NCT02871206|Active Comparator|Quadrivalent Influenza Vaccine|Fluzone
11274742|NCT02871193|Sham Comparator|Group C（Control）|Group C received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml combined with general anesthesia and intravenous patient controlled analgesia pump.
11274743|NCT02871193|Experimental|Group R(Ropivacaine)|Group R received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20 ml combined with general anesthesia and intravenous patient controlled analgesia pump.
11274744|NCT02871193|Experimental|Group D(Dexamethasone)|Group D received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg combined with general anesthesia and intravenous patient controlled analgesia pump.
11274745|NCT02871180|Other|With late night snack|At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.
11274746|NCT02871180|Other|Without late night snack|Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..
11274747|NCT02871167|Experimental|Oocyte/embryo cryopreservation|"Controlled ovarian hyperstimulation (COH)
~Oocyte/embryo freezing"
11274748|NCT02871154|Experimental|Delay|Delaying oocyte pick up beyond 39 hours post hCG
11274749|NCT02871141||ECT group|Patients with a major depressive episode treated with ECT. Patients will be investigated (i) prior to the 1st ECT session, (ii) after the 4th ECT session, (iii) after the 12th ECT session, and (iv) 6 months after the 1st ECT session.
11274750|NCT02871141||Antidepressant group|Patients with a major depressive episode treated with antidepressants. Patients will be investigated (i) prior to treatment, (ii) after 10 days of treatment, (iii) after 4 weeks of treatment, and (iv) after 6 months.
11274751|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
11274752|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
11274753|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
11274754|NCT02871115|Experimental|Pharmacy Intervention|"Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will
~Perform detailed medication reconciliation
~Obtain allergy and vaccination history
~Evaluate and document polypharmacy (number of medications)
~Document their findings in the medical record and discuss their recommendations (in-person, phone call, email) with each patient's oncology team"
11274755|NCT02871115|Active Comparator|Usual Care|"Participants receiving Usual Oncology Care will not meet with the pharmacist unless indicated as part of their routine clinical care
~Study staff will obtain all patient-reported measures from the patient.
~Remind participant to complete self-report measures"
11274756|NCT02871102|Experimental|Intervention Arm|
11274757|NCT02871089|Experimental|24/7 Closed loop delivery|Unsupervised home use of day and night automated closed-loop insulin delivery system FlorenceM (Medtronic 640G insulin pump, guardian 3 CGM and Android smartphone) of CamAPS FX (Dana insulin pump, Dexcom G6 CGM and App on Android smartphone) until 24 months after diagnosis
11274758|NCT02871089|Active Comparator|Multiple Daily Injections|Participants will apply standard insulin therapy using multiple daily injections via insulin pens during the 24 months control period
11274759|NCT02871076|Experimental|Verum Acupuncture|Patients will receive verum acupuncture twice weekly for twelve weeks.
11274760|NCT02871076|Placebo Comparator|Sham Placebo Acupuncture|Patients will receive sham placebo acupuncture twice weekly for twelve weeks.
11274761|NCT02871063||High altitude ARDS|ARDS diagnosed at altitudes greater than 1500 meters above sea level
11274762|NCT02871063||Sea level ARDS|ARDS diagnosed at altitudes below 1500 meters above sea level
11274763|NCT02871050||Castleman Disease Patients|Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
11274764|NCT02871037|Experimental|Part 1_Cohort 1_Active|Single, escalating dose of PF-05221304
11274765|NCT02871037|Placebo Comparator|Part 1_Cohort 1_Placebo|Single dose of Placebo
11274766|NCT02871037|Experimental|Part 1_Cohort 2_Active|Single, escalating dose of PF-05221304
11274767|NCT02871037|Experimental|Part 1_Cohort 2_Placebo|Single dose of Placebo
11274768|NCT02871037|Experimental|Part 2_Active|Repeated, escalating doses of PF-05221304
11274769|NCT02871037|Placebo Comparator|Part 2_Placebo|Repeated doses of placebo
11274770|NCT02871037|Experimental|Part 3|Single dose of PF-05221304 with and without food
11274771|NCT02871024|Experimental|Intervention arm|Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart
11274772|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
11274773|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
11274774|NCT02870998|Experimental|Active learning|Educational strategies will be used to foster active learning.
11274775|NCT02870998|Active Comparator|Passive learning|Traditional educational strategies (lecture) will be used.
11274776|NCT02870985|Experimental|BIOTRONIK Orsiro SES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the experimental arm will be implanted with BIOTRONIK sirolimus eluting coronary stent(Orsiro).
11274777|NCT02870985|Active Comparator|Abbott Xience Prime™ EES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the comparator arm will be implanted with Abbott everolimus eluting coronary stent(Xience Prime™).
11274778|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
11274779|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
11274780|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
11274781|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
11274782|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
11274783|NCT02870946|Experimental|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced.
11274784|NCT02870946|Experimental|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
11274785|NCT02870933|Experimental|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
11274786|NCT02870933|No Intervention|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
11274787|NCT02870920|Active Comparator|Best Supportive Care|Best supportive care available
11274788|NCT02870920|Experimental|Durvalumab plus Tremelimumab and Best Supportive Care|Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care
11274789|NCT02870907|Experimental|Low risk group|
11274790|NCT02870907|Experimental|Intermediate risk sub group 1|2 cycles (4 courses): 2 courses of etoposide and Carboplatin from D1 to D5 and Vincristin at D22 and D26- Cyclophosphamide from D22 to D26.
11274791|NCT02870907|Experimental|Intermediate risk sub group 2|2 courses of Vincristin and Carboplatin
11274792|NCT02870907|Experimental|High risk group|"Orbital irradiation
~3 cycles of two different types of alternating chemotherapy courses (id 6 courses) :
~Etoposide (100 mg/m²/d) and Carboplatin (160 mg/m²/d) with intrathecal Thiotepa injection.
~Vincristin (1,5 mg/m²/d) - Cyclophosphamide (1000 mg/m²/d)
~Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamide.
~High dose chemotherapy :
~Carboplatin (AUC : 7/d) - etoposide (250 mg/m²/d) - Thiotepa (300 mg/m²/d)
~Peripheral bood stem cell transplantation."
11274793|NCT02870868|Experimental|Slow breathing with exhale greater than inhale|
11274794|NCT02870868|Experimental|Slow breathing with exhale equal to inhale|
11274795|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
11274796|NCT02870855|No Intervention|Control group|blastocyst transfer
11274797|NCT02870842|Placebo Comparator|Control|Perform recruitment maneuver with fraction of inspired oxygen (FiO2) of 1.0 after intubation under lung ultrasound guidance and maintain FiO2 of 0.6 during the general anesthesia.
11274798|NCT02870842|Active Comparator|Low FiO2|Perform recruitment maneuver with low FiO2 of 0.3 after intubation under lung ultrasound guidance and maintain FiO2 of 0.3 during the general anesthesia.
11274799|NCT02870829|Experimental|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
11274800|NCT02870829|No Intervention|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
11274801|NCT02870816|Active Comparator|Tissue engineered skin substitute|Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
11274802|NCT02870816|Experimental|Amnionic membrane graft|Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
11274803|NCT02870790|Experimental|treatment|A single open-label arm. All participants receive daily oral pill containing TDF/FTC
11274804|NCT02870777|Experimental|MRD-directed therapy|
11274805|NCT02870764|Active Comparator|Dan-shen extract|Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.
11274806|NCT02870764|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.
11274807|NCT02870751|Experimental|ST-only ETEC strain TW11681 or TW10722|Oral inoculum of several doses of bacteria to establish range to achieve diarrhea attack rate in around 70% of volunteers.
11274808|NCT02870738|Active Comparator|Pelvic Floor Physical Therapy|One hour of pelvic floor physical therapy twice weekly for 8 weeks
11274809|NCT02870738|Active Comparator|Bladder Instillations|Bladder instillation of lidocaine, kenalog, heparin sulphate, and bicarbonate twice weekly for 8 weeks
11274810|NCT02870725|No Intervention|Control Group (Treatment As Usual)|Individuals randomized into the control condition will not receive any active treatment but will have access to customary, community-based supportive services. These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of comparison for those in the other arm of the study.
11274811|NCT02870725|Experimental|CBT Individual Psychotherapy (Treatment)|Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
11274812|NCT02870712|Experimental|suture directed|The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
11274813|NCT02870712|Active Comparator|systematic suture|systematic suture tears following current recommendations
11274814|NCT02870699|Experimental|ARM A|"Evonail film forming solution : 1 daily application on the left hand
~Placebo excipient : 1 daily application on the right hand"
11274815|NCT02870699|Active Comparator|ARM B|"Evonail film forming solution : 1 daily application on the right hand
~Placebo excipient : 1 daily application on the left hand"
11274816|NCT02870686|Active Comparator|ERCP without the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to the EUS guided ERCP without fluoroscopy clear all of the bile duct stones.
11274817|NCT02870686|Active Comparator|ERCP with the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to underwent ERCP with the use of fluoroscopy to clear all of the bile duct stones.
11274818|NCT02870673|Active Comparator|Injection of Shincort 0.5 ml and Xylocaine 0.5ml mixture|"In the first week of recruitment, this group will receive the local injection around the distal wrist crease with mixture of Shincort Inj(10mg/ml) 0.5 ml and xylocaine(20mg/ml) 0.5 ml only one time.
~The ultrasound-guided procedure is performed by the orthopedic physician."
11274819|NCT02870673|Experimental|sham electroacupuncture|"In this group, the participants receive acupuncture treatment and only 2 minutes electrical stimulation.
~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant. After 2 minutes, the stimulator will turn off spontaneously and the participant will not be informed.
~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
11274820|NCT02870673|Experimental|electroacupuncture|"In this group, the participants receive acupuncture treatment and 20 minutes electrical stimulation.
~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant.
~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
11274821|NCT02870647|Other|Single arm study|only 1 arm - no comparison nor randomization in this study
11274822|NCT02870634|Experimental|Cu(II)ATSM|Cu(II)ATSM capsules, administered orally once daily
11274823|NCT02870608|Experimental|preterm labor group|Pregnant women hospitalized for preterm labor
11274824|NCT02870608|Other|control group|Pregnant women with a normal pregnancy
11274825|NCT02870595|Active Comparator|Parallel lidocaine injection|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
11274826|NCT02870595|Sham Comparator|Parallel|In the sham comparator, the device will be placed on the skin, but not turned on. Digit block anesthesia will progress in usual fashion as with active comparator, except without the vibratory device engaged.
11274827|NCT02870582|Experimental|Donafenib|Donafenib 300mg bid on 1-21 days of each 28 days cycle.
11274828|NCT02870582|Placebo Comparator|Placebo|Placebo 300mg bid on 1-21days of each 28 days cycle.
11274829|NCT02870569|Experimental|Donafenib1|This is the lower dose group. Donafenib 200mg bid
11274830|NCT02870569|Active Comparator|Donafenib2|This is the higher dose group. Donafenib 300mg bid
11274831|NCT02870556|Experimental|EP, Cervical epidural group|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive cervical epidural analgesia in addition to the standard general anesthesia (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) Cervical epidural technique: epidural needle will be inserted at C 6-C7 or C7-T1 under fluoroscopy in prone position, 6 ml of 0.125% bupivacaine and fentanyl 2 mic/ ml will be administered before skin incision followed by 4 ml of the same injectate, will be infused continously for 2 days
11274832|NCT02870556|Active Comparator|GA, General anesthesia|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive standard general anesthesia only (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) in addition to postoperative analgesia through patient controlled intravenous morphine analgesia (PCA), that involve 1 mg continuous infusion and 2 mg boluses with lockout interval 10 min
11274833|NCT02870543|Placebo Comparator|Placebo|Placebo
11274834|NCT02870543|Active Comparator|Phytolacca decandra|The Phytolacca decandra with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
11274835|NCT02870543|Active Comparator|Melissa officinalis|The Melissa officinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
11274836|NCT02870543|Experimental|Phyt.decandra + Melissa offic.|The combination of Phytolacca decandra with Melissa offcicinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
11274837|NCT02870530|Experimental|division-less gastric bypass|
11274838|NCT02870530|Active Comparator|mini-gastric bypass|
11274839|NCT02870517|Experimental|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
11274840|NCT02870517|Active Comparator|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
11274841|NCT02870504|Experimental|corneoscleral limbus group|Laser spot locates on the corneoscleral limbus.
11274842|NCT02870504|Experimental|One spot group|Laser spot locates on one spot away from the corneoscleral limbus
11274843|NCT02870504|Experimental|Two spots group|Laser spot locates on two spots away from the corneoscleral limbus
11274844|NCT02870491|No Intervention|Control|Existing standard of care.
11274845|NCT02870491|Experimental|Free Distribute+Preemptive Delivery|Community health workers (CHWs) will deliver oral rehydration salts (ORS) and zinc for free to all households in their catchment area with a child under 5-years-old at the beginning of the study.
11274846|NCT02870491|Experimental|Cost Sharing + Preemptive Delivery|CHWs will visit all households with a child under 5-years-old at the beginning of the study and offer to sell ORS and zinc to caretakers at the time of the visit for them to store in their homes.
11274847|NCT02870491|Experimental|Free Distribution Upon Retrieval|CHWs will visit all households with a child under 5-years-old at the beginning of the study and inform caretakers that they have ORS and zinc available for free that caretakers can retrieved from the CHWs home if needed.
11274848|NCT02870478|Active Comparator|0.01% atropine daily|Nightly dosing of 0.01% atropine
11274849|NCT02870478|Experimental|0.01% atropine twice per week|Atropine dosed twice per week
11274850|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
11274851|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
11274852|NCT02870452|Experimental|Hypnosis|Hypnosis for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
11274853|NCT02870452|Experimental|Cognitive-Behavioral Therapy|Cognitive Behavioral Therapy for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
11274854|NCT02870452|No Intervention|Control Group|No psychological intervention - standard Haemophilia care
11274855|NCT02870439|Experimental|patients with at least 20% of wounded burns body|
11274856|NCT02870439|Experimental|patients with at least 5% of wounded burns body|
11274857|NCT02870439|Experimental|patients with post-surgical wounds with skin resection|
11274858|NCT02870426||Group 1A:|Donors after brainstem death (DBDs) undergoing solid organ donation
11274859|NCT02870426||Group 1B:|Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
11274860|NCT02870426||Group 2:|Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
11274861|NCT02870413|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 12 weeks post-partum. Services will be available through mobile phone app.
11274862|NCT02870413|No Intervention|Usual care|Participants in the control arm will receive care as usual.
11274863|NCT02870400|Experimental|REGN2477|Cohorts 1 - 5 will receive REGN2477
11274864|NCT02870400|Experimental|Placebo|Cohorts 1 - 5 will receive placebo
11274865|NCT02870387|Active Comparator|Usual Inpatient Care|Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
11274866|NCT02870387|Experimental|Comprehensive Care with Inpatient Consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
11274867|NCT02870361|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
11274868|NCT02870361|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
11274869|NCT02870348|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg administered weekly via intravenous administration
11274870|NCT02870335|Experimental|Manual Therapy|The objective of treatment is to restore esta possible limitation of global mobility to major lower limb joints and remove any tensions from the musculature involved in a relevant way in this sport.
11274871|NCT02870335|Active Comparator|Proprioceptive neuromuscular facilitation|It is a stretching technique with the aim of increasing the ROM. It includes passive static stretching and contract-relax.
11274872|NCT02870322|Active Comparator|Fruit and Vegetable CSA Prescription|"Study participants randomized to the CSA group will be expected to pick up their weekly CSA box at University Health Services and to commit to using and consuming as much of the produce as they are able. CSA group participants will also be required to attend two cooking and food preparation classes coordinated by Slow Food UW. The classes will teach study participants how to properly clean and prepare the fruits and vegetables from a weekly CSA box, and also offer techniques and show them how to cook the foods in a healthy manner. These classes will also educate study participants on the benefits of eating fruits and vegetables and buying them from local farmers. These two classes will only exist for study participants in this fruit and veggie CSA group. Participants in the CSA group will also be required to take a field trip to the farm providing their CSA share, which will offer the opportunity for participants to gain a better understanding of from where their food comes."
11274873|NCT02870322|Active Comparator|Bikeshare Prescription|"Study participants randomized to the bikeshare group will be expected to use B-cycle bikes for transportation and/or recreation as much as is safe and appropriate. Bikeshare group participants will be required to attend one bicycle use/safety course. This course will introduce the B-cycle program, demonstrate use of the B-cycle station, provide information use of helmets and safety gear, and provide information on the basics of cycling and keeping yourself safe and comfortable while riding in traffic. The study participants in this group will also be required to attend a class on the benefits of exercise, including bicycling, among other forms of physical activity. This class will be offered by the University Health Services Wellness program. B-cycle usage, including estimated distance traveled and frequency of use, will be tracked via the B-cycle Madison website."
11274874|NCT02870322|No Intervention|Control|"Study participants in the control group will receive continued usual care from University Health Services providers, which includes educational brochures on healthy eating and exercising, plus a cash payment. Control group participants are not part of a wait-list group."
11274875|NCT02870309|Experimental|Alpha-1 MP|IV infusions of 60 mg/kg Alpha-1 MP administered weekly over 8 weeks at an infusion rate not to exceed 0.08 mL/kg/min over approximately 15 minutes
11274876|NCT02870296|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
11274877|NCT02870296|Experimental|Intervention|Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
11274878|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
~Group (A) Started Lithium (900mg-1500mg)
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.
~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).
~Non responsive patients: 3rd step.
~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).
~Non responsive patients: 4th step.
~Fourth step: Association with risperidone (1-6mg)"
11274879|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
~Group (B) Started Valproic Acid (1000mg-1500mg).
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.
~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.
~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.
~Fourth step: Association with risperidone (1-6mg)"
11274880|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).
~Group (C) Started Carbamazepine (600mg-1200mg).
~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.
~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.
~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.
~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.
~Fourth step: Association with risperidone (1-6mg)"
11274881|NCT02870270||Head and neck cancer patients|Patients with head and neck cancer who were ≥ 18 years old and had ≥ 16 teeth and no removable prosthesis or dental implants consisting of more than one teeth were included
11274882|NCT02870257|Experimental|Progressive overload strengthening group|"Strengthening protocol with progressive load
~Strengthening muscle exercises for the shoulder and scapular with progressive increase of load during 10 weeks (20 sessions)"
11274883|NCT02870257|Active Comparator|Strengthening group|"Strengthening protocol without progressive load
~Strengthening muscle exercises for the shoulder and scapular without increase of load (minimal load) during 10 weeks (20 sessions)"
11274884|NCT02870244|Experimental|Escalating Doses|Three patients will be treated at the first & each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level & an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.
11274885|NCT02870231|Experimental|NNC9204-0530 / Placebo and Liraglutide 1.8|
11274886|NCT02870231|Active Comparator|NNC9204-0530 /Placebo and Liraglutide 3.0|
11274887|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
11274888|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
11274889|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
11274890|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
11274891|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.
~Smoking research cigarettes with e-cigarette"
11274892|NCT02870218|Experimental|Halo G6 & Tribeca e-liquid|"Difference detection assessments.
~Nicotine discrimination thresholds"
11274893|NCT02870218|Experimental|Spectrum Research Cigarette|"Difference detection assessments.
~Nicotine discrimination thresholds"
11274894|NCT02870205|Experimental|GSP 301 NS|
11274895|NCT02870205|Active Comparator|GOM-NS|
11274896|NCT02870205|Active Comparator|GMM-2 NS|
11274897|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
11274898|NCT02870192|Experimental|Rectal Prolapse|Patients with rectal prolapse, who will underwent laparoscopic ventral mesh rectopexy. The implemented mesh may be synthetic or biological.
11274899|NCT02870179||Healthy volunteer|Smoker or non-smoker
11274900|NCT02870153|Experimental|SOX(oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
11274901|NCT02870153|Active Comparator|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
11274902|NCT02870140|Experimental|SUPRAFLEX|Percutaneous Coronary Intervention with the SUPRAFLEX Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
11274903|NCT02870140|Active Comparator|XIENCE|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
11274904|NCT02870101|Other|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
11274905|NCT02870088|Active Comparator|Prolonged Sitting|Participants sat on a chair during the trial.
11274906|NCT02870088|Experimental|Breaking Sitting|Participants walked regularly during the trial.
11274907|NCT02870075|Active Comparator|Fed exercise|Fed prior to exercise
11274908|NCT02870075|Active Comparator|Fasted exercise|Fasted prior to exercise
11274909|NCT02870062|Experimental|Chlorhexidine|Intervention: daily baths with chlorhexidine wipes, oral spray and shampoo. This arm will receive daily bathing with chlorhexidine wipes at 2% (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México) plus an oral spray application of chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied.
11274910|NCT02870062|Placebo Comparator|Placebo|Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
11274911|NCT02870049|Experimental|Inreach strategy|This consists of a community health worker-delivered in clinic education regrading CRC screening with a fecal immunochemical test (FIT) kit, and telephone reminders.
11274912|NCT02870049|Experimental|Outreach strategy|This consists of mailed invitations to complete screening with an enclosed fecal immunochemical test (FIT) kit and telephone reminders.
11274913|NCT02870049|Experimental|Both Inreach and Outreach strategies|This is a combination of the above two strategies: Inreach and Outreach combined.
11274914|NCT02870049|Active Comparator|Usual care|Usual care in the clinic using the fecal immunochemical test (FIT) kit.
11274915|NCT02870036|Experimental|Pharmacokinetic data investigation of Simmitecan|To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors
11274916|NCT02870036|Experimental|Dose escalation study of Simmitecan combined therapy|To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor
11274917|NCT02870036|Experimental|Dose extension study of Simmitecan monotherapy|To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)
11274918|NCT02870036|Experimental|Dose extension study of Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D
11274919|NCT02870036|Experimental|Dose escalation&extension Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with gastrointestinal tumors, and to determine RP2D and MTD
11274920|NCT02870036|Experimental|Dose extension study of Simmitecan combined therapy|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with specific tumors
11274921|NCT02870023|Experimental|Balance training|"All sessions will start with a ten minute warm-up on either a treadmill or a cycle.
~The balance intervention will be conducted in stations/domains where balance is challenged in the five different functions: standing, walking, sit to stand, stepping, and a station that exercises vestibular and gaze control.
~Progression is achieved by adding exercises with increased balance requirements and by adding additional motoric and cognitive tasks to the exercises-dual-tasking.
~Intensity of the exercises is defined from an error-rate where an adequate level is 20-40 percent.
~The intervention is conducted according to a standardized framework that describes examples of exercises and progressions."
11274922|NCT02870023|Experimental|Strength training|"All sessions will start with a ten minute warm-up on a stationary bicycle, followed by strength training of primary muscle synergies in the lower extremities. All exercises will be performed on machines with patients sitting or lying, adequately supported. The exercises are leg press, knee extension, hip flexion, hamstring curl, and hip extension. Exercises are performed with a fast concentric phase and a slow eccentric phase..
~Set, repetition, and load:
~Weeks 1 and 2, 3 sets of 10 repetitions at a load of 15 repetitions maximum (RM)
~Weeks 3 and 4, 3 sets of 12 repetitions at a load of 12RM
~Weeks 5 and 6, 4 sets of 12 repetitions at a load of 12RM
~Weeks 7 and 8, 4 sets of 10 repetitions at a load of 10RM
~Weeks 9 and 10, 4 sets of 8 repetitions at a load of 8RM."
11274923|NCT02870023|No Intervention|Control group|On a waitlist. After ten weeks of waiting, and intervention that contains 50 percent strength training and 50 percent balance training begins.
11274924|NCT02870010|Experimental|non-metastatic hepatocellular carcinoma|"Radiation : Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
~Biological : blood samples (5 ml) will be taken"
11274925|NCT02869997|Experimental|Single arm|arm wherein all patients Suppression Ratio evaluated by BIS will be collected
11274926|NCT02869984|Experimental|Treatment|ramosetron treatment for 4 weeks from 1mo after anterior resection for rectal cancer
11274927|NCT02869984|No Intervention|Control|No treatment
11274928|NCT02869971|Experimental|Embolization|Prostatic Arteries Embolization
11274929|NCT02869971|Active Comparator|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
11274930|NCT02869958|Active Comparator|1: Written action plan|Written action plan
11274931|NCT02869958|Experimental|2: Digital action plan|Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
11274932|NCT02869945|Other|COMT HH|COMT HH gene
11274933|NCT02869945|Other|COMT HL|COMT HL gene
11274934|NCT02869945|Other|COMT LL|COMT LL gene
11274935|NCT02869932|Other|Atypical and classic cystic fibrosis|Lung CT scan without injection
11274936|NCT02869919||Patients with AKI|critically ill patients with acute kidney injury
11274937|NCT02869919||Patients without AKI|critically ill patients without acute kidney injury
11274938|NCT02869906||FFR and iFR|The investigators compare FFR and iFR values in the acute phase of STEMI and in the subacute phase, 5-7 days after STEMI.
11274939|NCT02869893|Other|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
11274940|NCT02869880|Active Comparator|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial.
11274941|NCT02869880|Experimental|Enhanced Pre-consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
11274942|NCT02869867|No Intervention|Qutenza® without refrigerated cushion|Qutenza® without refrigerated cushion
11274943|NCT02869867|Experimental|Qutenza® with refrigerated cushion|Qutenza® with refrigerated cushion
11274944|NCT02869854|Active Comparator|PAP only|This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
11274945|NCT02869854|Active Comparator|Mindfulness only|Mindfulness. This group will receive a group course in mindfulness during 8 weeks once a week, and with 20 minutes of daily personal training. Three and six months after inclusion they will answer a new set of surveys and fasting blood samples.
11274946|NCT02869854|Experimental|Combination of the two groups|Mindfulness and physical activity prescription. This group will get a combination of the two other groups. PAP will be prescribed during the first meeting and another one after 3 months. During the first 8 weeks once a week they will participate in a mindfulness training group and also preform 20 minutes of daily training. The same surveys as the other groups and fasting blood samples
11274947|NCT02869841|Active Comparator|Continuous rectus sheath analgesia|Local anesthetic continuous infusion with infusion pumps
11274948|NCT02869841|Active Comparator|Bolus rectus sheath analgesia|Bolus administration of local anesthetic
11274949|NCT02869841|Active Comparator|Single dose rectus sheath analgesia|single dose administration of local anesthetic
11274950|NCT02869841|Placebo Comparator|Placebo|no rectus sheath analgesia
11274951|NCT02869828|Other|monitoring by arterial catheter and Spot-on|
11274952|NCT02869828|Other|monitoring by oesophagus tube and Spot-on|
11274953|NCT02869815||ICG+Methylene Blue|"ICG+Methylene Blue:
~Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery."
11274954|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy.
~Participants will undergo serial collection of plasma, serum and urine (at BC Cancer only) samples."
11274955|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.
~Participants will undergo serial collection of plasma, serum and urine (at BC Cancer only) samples."
11274956|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
11274957|NCT02869776|Experimental|Rapid finger stick|HIV and HCV testing through rapid finger stick. Behavioral questionnaires will also be administered.
11274958|NCT02869776|Experimental|Standard venipuncture|HIV and HCV testing through venipuncture. Behavioral questionnaires will also be administered.
11274959|NCT02869763|Experimental|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.
~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
11274960|NCT02869763|Experimental|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.
~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
11274961|NCT02869763|Placebo Comparator|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
11274962|NCT02869750||Obese PCOS|PCOS patients with BMI more than 25 kg/m2
11274963|NCT02869750||Lean PCOS|PCOS patients with BMI less than 25 kg/m2
11274964|NCT02869750||PCOS with normal HOMA2-1R|PCOS without Insuline resistance
11274965|NCT02869750||PCOS with elevated HOMA2-IR|PCOS with Insuline resistance
11274966|NCT02869724|Active Comparator|Weekly divided delivery|Hospitalized for voluntary drug intoxications.
11274967|NCT02869724|Active Comparator|Monthly divided delivery|Hospitalized for voluntary drug intoxications.
11274968|NCT02869698|Experimental|Evaluation of cognitive functions by Spectral Dynamic Imaging|Evaluation of cognitive functions by SDI will be conducted during the exploration SEEG (which usually lasts from 1 to 3 weeks), and started a few days after implantation of intracranial electrodes
11274969|NCT02869685|Other|a prospective, open,phase I clinical study|We have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
11274970|NCT02869672|Experimental|age of 18-50 years old, experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
11274971|NCT02869672|Active Comparator|age of 18-50 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
11274972|NCT02869672|Experimental|age of 7-17 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
11274973|NCT02869672|Active Comparator|age of 7-17 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
11274974|NCT02869672|Experimental|age of 2-6 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
11274975|NCT02869672|Active Comparator|age of 2-6 years old,control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
11274976|NCT02869659|Active Comparator|Control/Delayed Weight Loss Group|"Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program.
~No outcome data will be collected at the end of the delayed weight loss phase."
11274977|NCT02869659|Experimental|Weight Loss Group|"Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study.
~This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day.
~Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity.
~Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start."
11274978|NCT02869646|Experimental|Verum acupuncture|Traditional Chinese Medicine (TCM) based acupuncture at prescribed sites
11274979|NCT02869646|Sham Comparator|Minimal needling|shallow and non-acupoint needles at same number of sites
11274980|NCT02869633|Experimental|Treatment (ibrutinib)|Beginning between 60-90 days post donor stem cell transplant, patients receive ibrutinib PO QD until 1 year post donor stem cell transplant in the absence of disease progression or unacceptable toxicity.
11274981|NCT02869620||Patients with thyroid cancer diagnosis|
11274982|NCT02869607||Patients with breast cancer diagnosis|
11274983|NCT02869594||Patients with prostate cancer diagnosis|
11274984|NCT02869581||Patients with diagnosis of Pancreatic neoplasms|
11274985|NCT02869568||Patients with ovarian cancer diagnosis|
11274986|NCT02869555||Patients with multiple myeloma diagnosis|
11274987|NCT02869542||Patients with lymphoma diagnosis|
11274988|NCT02869529||Chronic lymphatic leukemia diagnosis|
11274989|NCT02869516||Patient with new diagnosis of Acute Leukemia|
11274990|NCT02869503||Patients with colorectal cancer diagnosis|
11274991|NCT02869490||Patients with cervical cancer diagnosis|
11274992|NCT02869477||Patients with cardia cancer diagnosis|
11274993|NCT02869464||Patients presenting with IA|These patients will undergo an abdominal ultrasound (Imaging - Ultrasound) to test for abdominal aortic aneurysm(s). RNA, DNA testing will be planned on banked samples
11274994|NCT02869464||Patients presenting with AAA|These patients will undergo a non-contrast enhanced magnetic resonance angiogram (MRA) (Imaging - MRA) to test for intracranial aneurysm(s). RNA, DNA testing will be planned on banked samples
11274995|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
11274996|NCT02869438|Experimental|Benralizumab arm|Benralizumab administered subcutaneously
11274997|NCT02869438|Placebo Comparator|Placebo arm|Placebo administered subcutaneously
11274998|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
11274999|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
11275000|NCT02869412|Experimental|Group I (BCG website)|Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
11275001|NCT02869412|Active Comparator|Group II (passive website)|Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
11275002|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
11275003|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
11275004|NCT02869386|Experimental|STEMO deployment|STEMO is a specialized stroke ambulance providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
11275005|NCT02869386|Active Comparator|Regular care|Regular prehospital care consists of an ambulance. In suspected life-threatening cases an emergency physician is sent to the emergency scene in parallel.
11275006|NCT02869373|Experimental|Exercise|spinal stabilization exercise program was applied
11275007|NCT02869373|No Intervention|Control|
11275008|NCT02869360||Multiple Sclerosis (MS) patients|4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
11275009|NCT02869360||Healthy Controls|4 Healthy volunteers aged between 18-60 years of age
11275010|NCT02869347|Active Comparator|Conestat alfa|Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
11275011|NCT02869347|Placebo Comparator|Sodium chloride 0.9%|Intravenous injection of sodium chloride 0.9%.
11275012|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
11275013|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
11275084|NCT02868840|Active Comparator|Symptom management group|manage stroke symptom through phone and text message along with other rehabilitation therapy.
11275014|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
11275015|NCT02869321|Experimental|Fentanyl|"Administration of Morphine Sulfate Placebo and Fentanyl
~Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy
~+
~Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy
~Administration 1+2 if pain after 4 hours from gastrostomy"
11275016|NCT02869321|Placebo Comparator|Morphine Sulfate|"Administration of Morphine Sulfate and Fentanyl Placebo
~Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy
~+
~Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy
~Administration 1+2 if pain after 4 hours from gastrostomy"
11275017|NCT02869308|Other|Myocardial angioscintigraphy|
11275018|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
11275019|NCT02869282||Prospective cohort|Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
11275020|NCT02869269||Early stage|patients who diagnosed as TNM stage 1 and 2
11275021|NCT02869269||Late stage|patients who diagnosed as TNM stage 3 and 4
11275022|NCT02869243|Experimental|hrBMP4|Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium
11275023|NCT02869230|Other|Radioguided occult lesion localization|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
11275024|NCT02869230|Experimental|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
11275025|NCT02869217|Experimental|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.
~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.
~TBI-1301 cells will be infused on Day 0 at a dose of 5x10^9 cells.
~*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
11275026|NCT02869217|Experimental|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.
~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.
~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10^9 cells."
11275027|NCT02869204|Experimental|Leucocyte - Platelet rich Plasma and Dietary Supplements|"An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.
~A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30"
11275028|NCT02869204|No Intervention|Treatment as usual|Patients are treated as usual.
11275029|NCT02869191||blood cultures|Admitted patients in critical care who need blood cultures
11275030|NCT02869191||blood cultures Getafe|Data collection of patients included in study
11275031|NCT02869165|Experimental|Premarin vaginal cream|The Premarin vaginal cream 1 gram will be inserted into the vaginal three times were week at nights for 3 months.
11275032|NCT02869165|Experimental|Apricot kernel oil|One teaspoonful will be applied per vagina nights for 3 months.
11275033|NCT02869152|Experimental|Intraoperative sentinel lymph node mapping|Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
11275034|NCT02869139|Experimental|Package of mentholated measures|Package of mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
11275035|NCT02869139|Active Comparator|Package of non-mentholated measures|Package of non-mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
11275036|NCT02869126|Experimental|Patients|Patients with abnormalities of myocardial perfusion detected with stress tomoscintigraphy, undergo double isotope myocardial tomoscintigraphy using Thallium-201 and 99mTc-sestamibi and traditional myocardial tomoscintigraphy using 99mTc-sestamibi with a semiconductor camera
11275037|NCT02869113|Experimental|Sunscreen agent A + control|Application of control and test product into one of the subjects two eyes.
11275038|NCT02869113|Experimental|Sunscreen agent B + control|Application of control and test product into one of the subjects two eyes.
11275039|NCT02869113|Experimental|Sunscreen agent C + control|Application of control and test product into one of the subjects two eyes.
11275040|NCT02869100|Experimental|Spondyloarthritis Patients|
11275041|NCT02869087|Experimental|Single Group|Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold
11275042|NCT02869074||VWD Spanish Cohort|"Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.
~Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene"
11275043|NCT02869061|Experimental|ADRC injection|Subjects will be undergone liposuction under local anesthesia. Adipose-derived regenerative cells (ADRC) will be isolated from lipoaspirate by enzymatic digestion. Transurethral bladder neck resection followed by the injection of ADRC suspension will be performed. This is a single arm study with no control. All patients receive cell therapy.
11275085|NCT02868827|Experimental|Cholecalciferol|This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
11277150|NCT02854631|Placebo Comparator|Prednisolone|Selonsertib placebo + prednisolone for 28 days
11275044|NCT02869048||ALS patients|Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
11275045|NCT02869048||Control group with patients with other neurological disease|Patients referred to hospital with symptoms of acute or chronic headache.
11275046|NCT02869048||Neurologically healthy control group|Patients having orthopaedic surgery performed in spinal anaesthesia.
11275047|NCT02869035|Experimental|Treatment of MDD patients|Treatment of MDD patients with escitalopram
11275048|NCT02869035|No Intervention|Healthy controls|No treatment.
11275049|NCT02869035|Experimental|Shift of treatment for MDD patients|Treatment of MDD patients with duloxetine
11275050|NCT02869022|Experimental|Custodiol-N|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
11275051|NCT02869022|Active Comparator|Custodiol|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
11275052|NCT02869009|Experimental|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
11275053|NCT02869009|Experimental|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
11275054|NCT02868996|Experimental|Low dose (Part A)|Recombinant human tissue kallikrein
11275055|NCT02868996|Experimental|Medium low dose (Part A)|Recombinant human tissue kallikrein
11275056|NCT02868996|Experimental|Medium high dose (Part A)|Recombinant human tissue kallikrein
11275057|NCT02868996|Experimental|High dose (Part A)|Recombinant human tissue kallikrein
11275058|NCT02868996|Experimental|Subcutaneous (Part B)|Recombinant human tissue kallikrein
11275059|NCT02868996|Experimental|IV (Part B)|Recombinant human tissue kallikrein
11275060|NCT02868983|Experimental|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:
~A. Identification B. Assessment C. Treatment D. Surveillance"
11275061|NCT02868983|No Intervention|Co-Location|A Behavioral Health Clinician (BHC) such as a psychologist or counselor is housed in or near the primary care practice.
11275062|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
11275063|NCT02868957|Active Comparator|Impression data from reference scanner|desktop scanner was used as a reference scanner. According to the data of the manufacturer, the accuracy is less than 20 µm and the scan points more than 100,000.
11275064|NCT02868957|Experimental|Trios|"Trios is a scanner with real time rendering type adopting the confocal principle, and scans the object while showing the scanned area on a screen.
~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of Trios intra-oral scanner."
11275065|NCT02868957|Experimental|iTero|"iTero captures teeth and periodontal soft tissue using a red laser beam and parallel confocal imaging technology. This system with a focal depth of 300 can capture up to 100,000 of laser points, and each of such laser points is separated at a 50 mm gap.
~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of iTero intra-oral scanner."
11275066|NCT02868944|Experimental|experimental group|sequential combined spinal epidural with local anesthetic injection associated with morphine
11275067|NCT02868944|Active Comparator|control group|sequential combined spinal epidural with local anesthetic injection alone
11275068|NCT02868931|Experimental|INPUT|INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump. Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life. Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
11275069|NCT02868931|No Intervention|Waiting list|Patients are randomly assigned to the waiting list. After completion of the 6-month follow-up, these patients will also receive training with INPUT.
11275070|NCT02868918|Experimental|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
11275071|NCT02868918|Active Comparator|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
11275072|NCT02868905|Other|Control group|Control group
11275073|NCT02868905|Other|Obese group|Obese group
11275074|NCT02868905|Other|Non-obese AD group|Non-obese AD groups
11275075|NCT02868905|Other|Obese AD group|Obese AD group
11275076|NCT02868892|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
11275077|NCT02868879||Schizophrenia|
11275078|NCT02868879||Normal controls.|
11275079|NCT02868866|Experimental|Immediate intervention|Training of church committee followed by 12 months of technical assistance phone calls.
11275080|NCT02868866|No Intervention|Delayed intervention|20 churches are followed but receive no intervention.
11275081|NCT02868853|Experimental|Photo App|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile dietary tracking application(Photo App). This Photo App allows participants to track meals by taking photos.
11275082|NCT02868853|Active Comparator|Diet App|Participants in this group will receive podcasts twice weekly in conjunction with an app (Diet App) to track their diet by entering in foods and beverages consumed.
11275083|NCT02868840|Experimental|Tai Chi group|Tai Chi exercise, twice a week, one hour per session. participated in Tai Chi either while seated or standing upon their comfort level.
11275153|NCT02868346|Experimental|Patients admitted for sexually transmitted infection|
11275086|NCT02868827|Placebo Comparator|Placebo|This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
11275087|NCT02868814|Experimental|330mg/day|330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
11275088|NCT02868814|Experimental|495mg/day|495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
11275089|NCT02868814|Placebo Comparator|Placebo|1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
11275090|NCT02868801|Placebo Comparator|Placebo|placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
11275091|NCT02868801|Experimental|Pregabalin SR tablet 165mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
11275092|NCT02868801|Experimental|Pregabalin SR tablet 330mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
11275093|NCT02868801|Experimental|Pregabalin SR tablet 660mg/day|2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
11275094|NCT02868788|Other|high fat high calorie|Subjects in this arm will receive high fat high calorie meal
11275095|NCT02868788|Experimental|high fat high calorie plus fiber|Subjects in this arm will receive high fat high calorie meal plus dietary fiber supplementation
11275096|NCT02868775||Interstitial cystitis/bladder pain syndrome|These are the patients that will be evaluated in this study.
11275097|NCT02868749|Experimental|Hyaluronic Acid filler 1 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery
~Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery"
11275098|NCT02868749|Active Comparator|Hyaluronic Acid filler 2 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery
~Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery"
11275099|NCT02868736||Suspected Periprosthetic Joint Infection|Individuals who are suspected of having Periprosthetic Joint Infection (PJI)
11275100|NCT02868723|No Intervention|Control; standard of care|All the subjects enrolled in this arm will receive counseling as the usual standard of care by the stroke neurologists. These will include procedures and guidelines as approved by American Heart Association (AHA), follow up and guidance as offered by Hamad General Hospital's policies.
11275101|NCT02868723|Active Comparator|Intervention; Lifestyle counselling: Behavioural|Subjects in this group will receive a more detailed guidance on rigorous management of stroke and will be provided assistance from a stroke trained nurse and pharmacist additional to the counseling offered by the Stroke Neurologist.
11275102|NCT02868710|Experimental|Individualized method|"3 days a week of exercise at the following intensity and energy expenditure:
~Week 1: HR > VT1; 5.6 kcal/kg/wk Week 2: HR > VT1; 8.4 kcal/kg/wk Week 3: HR > VT1; 11.2 kcal/kg/wk Week 4: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 5-6: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 7: HR ≥ VT1 to <VT2; 12.6 kcal/kg/wk Week 8: HR ≥ VT1 to <VT2; 14 kcal/kg/wk Week 9-10: HR ≥ VT2; 14 kcal/kg/wk Week 11-12: HR ≥ VT2; 15.4 kcal/kg/wk"
11275103|NCT02868710|Experimental|Standardized method|"3 days a week of exercise at the following intensity and energy expenditure:
~Week 1: 40-45% HRR; 5.6 kcal/kg/wk Week 2: 40-45% HRR; 8.4 kcal/kg/wk Week 3: 40-45% HRR; 11.2 kcal/kg/wk Week 4: 50-55% HRR; 11.2 kcal/kg/wk Week 5-6: 55-60% HRR; 11.2 kcal/kg/wk Week 7: 55-60% HRR; 12.6 kcal/kg/wk Week 8: 55-60% HRR; 14 kcal/kg/wk Week 9-10: 60-65% HRR; 14 kcal/kg/wk Week 11-12: 60-65% HRR; 15.4 kcal/kg/wk"
11275104|NCT02868710|No Intervention|Control|"non-exercise control group
~Testing at baseline and post-program (12 weeks)"
11275105|NCT02868697|Active Comparator|A|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of of all Hemodialysis sessions and during all interdialytic periods
11275106|NCT02868697|Experimental|B|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of the first two session only per week and during first two interdialytic periods then TauroLock U 25000at the end of third session before week end, (over the week end).
11275107|NCT02868684||mild traumatic brain injury|
11275108|NCT02868684||Healthy controls|
11275109|NCT02868671|Experimental|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), RN4 (Guan Yuan), ST36 (Zusanli) (front treatment) or Du20, GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 6 required points, acupuncturist will be allowed to choose 4 more points. The 4 supplemental points may be chosen from the following: LR2 (Xin Jian), HT7 (Shenmen), PC6 (Neiguan), GB34 (Yang Ling Quan), GB39 (Xuan Zhong), SI3 (Hou Xi), RN6 (Qi Hai), RN24 (Cheng Jiang),KI 3 (Taixi), KI 6 (Zhao Hai), ST40 (Feng Long), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL19 (Dan Shu), BL20 (Pi Shu), BL60 (Kun Lun). Auricular acupuncture will be employed.
11275110|NCT02868671|Sham Comparator|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. In the sham procedure, a needle guiding tube will be tapped on the surface of the skin near, but not on, each of the 10 acupuncture points that would have been selected for true acupuncture. The needle guiding tube will be used to create sensations that mimic needle manipulation.
11275111|NCT02868671|No Intervention|No Intervention|All participants in this study will receive usual care. For those assigned to true acupuncture and sham acupuncture, the usual care will be in addition to their acupuncture.
11275112|NCT02868658|Experimental|Health-care workers|Health-care workers recruited in the study will have blood sampling and naso-pharyngeal bottle-brush sampling
11275113|NCT02868645|Experimental|Patients with bone fibrous dysplasia|Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
11275114|NCT02868645|No Intervention|Control subjects|Control subjects will have no intervention
11275115|NCT02868632|Experimental|Cohort A: MEDI4736 + SBRT|MEDI4736 10 mg/kg IV every 2 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
11275783|NCT02864212||Blood pressure monitoring|Invasive blood pressure will be monitor in patients undergoing cardiac surgery.
11275116|NCT02868632|Experimental|Cohort B:Tremelimumab + SBRT|Tremelimumab 10 mg/kg IV every 4 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
11275117|NCT02868632|Experimental|Cohort C: MEDI4736 + Tremelimumab + SBRT|MEDI4736 + Tremelimumab (recommended phase 2 IV dose for combination) plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 16 Subjects
11275118|NCT02868619|Other|Healthy controls|Non obese adolescents without Binge Eating Disorder (BED)
11275119|NCT02868619|Other|Patients with BED|Obese adolescents with BED with Binge Eating Disorder (BED)
11275120|NCT02868606||Historical control group (H)|Winthrop patients with diabetes hospitalized between August 1, 2010 and March 31, 2011
11275121|NCT02868606||Intervention group (I)|Winthrop patients with diabetes hospitalized between August 1, 2011 and March 31, 2012
11275122|NCT02868606||Parallel control group (P-sub-H)|Patients with diabetes hospitalized between August 1, 2010 and March 31, 2011 at 7 control hospitals located in the New York City metropolitan region
11275123|NCT02868606||Parallel control group (I-sub-H)|Patients with diabetes hospitalized between August 1, 2011 and March 31, 2012 at 7 control hospitals located in the New York City metropolitan region
11275124|NCT02868593|Experimental|Patient with clinical meningitis or meningo-encephalitis|
11275125|NCT02868580|Experimental|Single arm open label|All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg
11275126|NCT02868567|Experimental|Ampyra|Ampyra open label
11275127|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
11275128|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
11275129|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
11275130|NCT02868541||Haaj pilgrim|Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
11275131|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
11275132|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
11275133|NCT02868515|Experimental|Oatmeal containing beta-glucan|43 g cereal containing 3g fiber per serving
11275134|NCT02868502||Trabeculectomy|Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
11275135|NCT02868502||Ahmed Glaucoma Valve implantation|Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
11275136|NCT02868502||Cyclophotocoagulation|Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
11275137|NCT02868502||Ocular hypotensive eye drops|"Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.
~IOP measurement in different positions."
11275138|NCT02868502||Ocular Hypertension|"Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..
~IOP measurement in different positions."
11275139|NCT02868502||Control|"Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.
~IOP measurement in different positions."
11275140|NCT02868489|Experimental|Proprietary Blend - LactoWise®|After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
11275141|NCT02868489|Placebo Comparator|Control|For the control group, prior to surgery and after consenting to enroll in the study participants will also be asked to complete the Gastrointestinal Quality of Life Index. Participants of the control group will be administered their supply of a matching placebo. They will be required to take 1 capsule per day at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
11275142|NCT02868450|Experimental|Patients with HLA-DQB1 06 and/or HLA-DRB 13|
11275143|NCT02868437|Active Comparator|Group 1|The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure
11275144|NCT02868437|No Intervention|Group 2|The patients who are having curettage for retained product after second trimester abortion will receive no intervention
11275145|NCT02868424|Experimental|fRPE cells|Subretinal transplantation of fRPE cells in experimental eye
11275146|NCT02868411|Experimental|Patients admitted for traveller's fever|
11275147|NCT02868385|Active Comparator|Control group (A)|1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
11275148|NCT02868385|Experimental|Intervention group (B)|4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.
11275149|NCT02868372|Active Comparator|Betadine group|Subcutaneous tissues of cesarean section wounds are swabbed with10% undiluted Povidone Iodine solution without mobbing before closure of subcutaneous tissues
11275150|NCT02868372|No Intervention|No intervention group|No swabbing of subcutaneous tissue of cesarean section wounds
11275151|NCT02868359||Pregabalin / Other analgesics|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
11275152|NCT02868359||Other analgesics|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
11275154|NCT02868320|Experimental|Intervention group|This group received a diabetes instruction booklet in addition to daily educational SMS messages and weekly reminders
11275155|NCT02868320|Active Comparator|Control group|This group only received a diabetes instruction booklet
11275156|NCT02868307|Experimental|Patient prsenting schizophrenia|
11275157|NCT02868294|Experimental|Patient receiving the Fassier-Duval Nail|Implementation of a telescopic system intramedullary
11275158|NCT02868281|Experimental|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for >=3 months then step-down the treatment; if ACT score >=20, <25 or ACT=25 for <3 months then there will be no change and if ACT score less than (<=) 19 then step-up the treatment.
11275159|NCT02868281|Active Comparator|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
11275160|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
11275161|NCT02868255||Ascites|"30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
11275162|NCT02868255||Resections|"30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
11275163|NCT02868255||blood samples|"blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
11275164|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
11275165|NCT02868229|Experimental|COR-001|
11275166|NCT02868229|Placebo Comparator|Placebo|
11275167|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
11275168|NCT02868216|No Intervention|Without management training|No anger management training
11275169|NCT02868203|Active Comparator|OCT at 3 months|OCT at 3 months and 12 OCT at 3 months
11275170|NCT02868203|Active Comparator|OCT at 6months|OCT at 6 months and 12 OCT at 3 months
11275171|NCT02868190|Other|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
11275172|NCT02868177|Experimental|Totum-63|The studied active product is a food supplement formula in shape of capsule which contains Totum-63 (a patented mixture of dry extracts from 5 plants), active ingredient of Valedia
11275173|NCT02868177|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging in which all ingredients are replaced by maltodextrin.
11275174|NCT02868164|Experimental|Fecal Microbiota Transplantation (FMT)|
11275175|NCT02868164|Active Comparator|Weight Reduction|
11275176|NCT02868151|No Intervention|GROUP A|Standard treatment followed in the regional cancer center for prevention and treatment of oral mucositis during chemo radiotherapy of cancers. 20% Benzocaine 15grms. twice daily for the entire treatment period
11275177|NCT02868151|Experimental|GROUP B|"Ascorbic acid oral supplementation 1g four times daily for the entire treatment period of 30 days and after treatment by tapering the dose of the drug to half for another month. The drug has to be started 2 days prior to initiation of treatment of cancer.
~Subdivided into 2 groups , 30 patients in each : sub group 1: only radiotherapy patients, subgroup 2 includes concurrent chemo-radiotherapy patients."
11275178|NCT02868151|Experimental|GROUP C|Zinc acetate tablets 50mg orally
11275179|NCT02868112|Experimental|Transdisciplinary Intervention|"Patients randomized to the Transdisciplinary Intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool.
~-Investigators will test a two-visit Transdisciplinary Intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit."
11275180|NCT02868112|Active Comparator|Usual Care|Participants receiving Usual Oncology Care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
11275181|NCT02868099|Placebo Comparator|Placebo|Subjects received placebo for injection treatment will be administered subcutaneously once a week
11275182|NCT02868099|Experimental|Drug|Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week
11275183|NCT02868086|Experimental|Tested patients|Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography
11275184|NCT02868086|Active Comparator|Control patients|Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans
11275185|NCT02868073|Experimental|H1N1 (high dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
11275223|NCT02867878|Placebo Comparator|Saline solution|Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
11275186|NCT02868073|Experimental|H1N1 (low dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
11275187|NCT02868073|Placebo Comparator|Placebo Tablets|Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
11275188|NCT02868060|Experimental|1 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
11275189|NCT02868060|Experimental|3 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
11275190|NCT02868047||Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination with suspected chronic pancreatitis
11275191|NCT02868047||NOT Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination without suspected chronic pancreatitis.
11275192|NCT02868034|Experimental|SMT Only|Patients receive 2 sessions on SMT during week 1, no additional treatment.
11275193|NCT02868034|Experimental|SMT extended|2 sessions of SMT in week 1 and 6 additional sessions of SMT during weeks 2-4.
11275194|NCT02868034|Experimental|SMT with Activation Exercises|2 sessions of SMT during week 1 and 6 additional sessions of lumbar multifidus activating exercises during weeks 2-4.
11275195|NCT02868034|Experimental|SMT with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of spinal mobilizing exercises during weeks 2-4.
11275196|NCT02868034|Experimental|SMT with Mobilizing and Activation Exercises|2 sessions of SMT during week 1; 6 sessions of lumbar multifidus activating exercises and spinal mobilizing exercises during weeks 2-4.
11275197|NCT02868034|Experimental|SMT extended with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and spinal mobilizing exercises during weeks 2-4.
11275198|NCT02868034|Experimental|SMT extended with Activation Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and lumbar multifidus activating exercises during weeks 2-4.
11275199|NCT02868034|Experimental|SMT extended with Activation and Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT, multifidus activating and spinal mobilizing exercises during weeks 2-4.
11275200|NCT02868021|Placebo Comparator|NO-EX group|Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.
11275201|NCT02868021|Experimental|EX-BFR group|Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.
11275202|NCT02868008|Experimental|fMRI guided AVM resection|fMRI guided microsurgical resection of brain AVMs
11275203|NCT02867995|No Intervention|Control|No glaucoma drop aid control
11275204|NCT02867995|Active Comparator|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
11275205|NCT02867982|Other|Subcrestal|implants that are placed below the alveolar ridge
11275206|NCT02867982|Other|Paracrestal|implants that are placed flush to the alveolar ridge
11275207|NCT02867969|Other|Motor training|The motor training comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
11275208|NCT02867956|Experimental|Apatinib + Etoposide|"Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles."
11275209|NCT02867943||respiratory rate is 10 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
11275210|NCT02867943||respiratory rate is 12 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
11275211|NCT02867943||respiratory rate is 14 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
11275212|NCT02867943||respiratory rate is 16 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;
~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
11275213|NCT02867930|Active Comparator|Group D|Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
11275214|NCT02867930|Active Comparator|Group KF|Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
11275215|NCT02867917|Other|Total group|Volcolon sugar free & Metamucil Orange & Psyllium Orange in a randomized order.
11275216|NCT02867904|Placebo Comparator|Group A|After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
11275217|NCT02867904|Experimental|Group B|After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.
11275218|NCT02867891||Chemotherapy alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
11275219|NCT02867891||Chemotherapy/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
11275220|NCT02867891||Sorafenib alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
11275221|NCT02867891||Sorafenib/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
11275222|NCT02867878|Experimental|Adenosine|Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
11275850|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
11275224|NCT02867865|Active Comparator|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.
~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
11275225|NCT02867865|Experimental|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.
~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
11275226|NCT02867852|Experimental|Abiraterone acetate|Abiraterone acetate 1 g/day must be taken as four 250-mg tablets daily on an empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Prednisone (prednisolone when prednisone is not available) 5 mg will be given orally twice a day.
11275227|NCT02867839|Experimental|A: postoperative Oxaliplatin plus S-1|"Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.
~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40~60mg bid, po, d1~14, q3W (6 months)"
11275228|NCT02867839|Active Comparator|B: postoperative S-1 only|"Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.
~S-1: 40~60mg bid, po, d1~14, q3W (12 months)"
11275229|NCT02867826|Experimental|Cap-assisted endoscopy|forward-viewing endoscope with a Cap attached at the tip
11275230|NCT02867813|Experimental|evolocumab (AMG 145)|All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.
11275231|NCT02867800|Experimental|Standard GVHD Prophylaxis + Abatacept|"Subjects will receive
~premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)
~immunosuppression (Alemtuzumab, or Thymoglobulin)
~conditioning regimen (Fludarabine, Thiotepa, and Melphalan)
~GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0."
11275232|NCT02867787|Experimental|Botox arm|intramuscular injection of botulinum toxin
11275233|NCT02867774|Experimental|Intervention|This pilot study will enroll 25 women age 18-65 with greater than six months of noncyclic pelvic pain. Subjects will participate in an 8-week physical activity program specifically designed for patients with chronic pain and supervised by personal trainers and exercise physiologists in a rehab-focused, medically-based fitness center. Subjects will complete web-based assessment tools at the start of the program, immediately after completion of the 8-week program and four weeks after the conclusion of the program (at the 12-week time point).
11275234|NCT02867761|Active Comparator|Indacaterol/Glycopyrrolate|indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily for 12 weeks
11275235|NCT02867761|Placebo Comparator|Placebo|Placebo 27.5/15.6 mcg inhaled twice daily for 12 weeks
11275236|NCT02867748|Experimental|1|TVT-Abbrevo
11275237|NCT02867748|Experimental|2|Serasis
11275238|NCT02867735|Experimental|LKA651|
11275239|NCT02867735|Sham Comparator|Sham Comparator|
11275240|NCT02867722|Experimental|Daylight PDT|Patients will receive daylight-PDT treatment (aminolevulinic acid)
11275241|NCT02867709|Experimental|Ubrogepant 25 mg|1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
11275242|NCT02867709|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
11275243|NCT02867709|Placebo Comparator|Placebo|1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
11275244|NCT02867696|Active Comparator|Standard Care|Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
11275245|NCT02867696|Experimental|Technology-based Intervention (TECH)|TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.
11275246|NCT02867683|Experimental|Vibrotactile Feedback|Balance exercises completed while vibration was applied to the trunk (anterior, posterior, right, and left) if postural sway exceeded a pre-determined threshold during the exercise.
11275247|NCT02867683|No Intervention|Without Vibrotactile Feedback|Balance training without feedback
11275248|NCT02867670||Transcranial Magnetic Stimulation of Motor Cortex|All study participants will receive real TMS stimulation over the primary motor cortex in order to collect physiological measures which will later be correlated with measures of neuroplasticity. There is NO placebo stimulation.
11275249|NCT02867670||Transcranial Magnetic Stimulation of Language Cortex|All study participants will receive real TMS stimulation over the language cortex and a control site (i.e. vertex). Transient changes in speech production will be recorded and compared to measures of neuroplasticity. There is NO placebo stimulation.
11275250|NCT02867657|Experimental|Mindfulness in nature|A five day mindfulness retreat in nature
11275251|NCT02867657|Active Comparator|Mindfulness indoor|A five day mindfulness retreat indoor
11275252|NCT02867657|No Intervention|Wait list control|A wait list control group, that 6 months later is offered a two-day mindfulness retreat in nature
11275253|NCT02867644|Active Comparator|standard care|
11275254|NCT02867644|Experimental|standard care+conversational hypnosis|
11275255|NCT02867631|No Intervention|Enhanced control|Regular care as provided by the community based organization from which the convenience sample is recruited with one year of assessments only
11275256|NCT02867631|Experimental|Intervention|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
11275257|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
11275258|NCT02867605|Other|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
11275259|NCT02867592|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11275260|NCT02867579|Other|women with denial pregnancy|women with denial pregnancy
11275261|NCT02867579|Other|women without denial pregnancy|women without denial pregnancy
11275262|NCT02867566|Experimental|IBI301|IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
11275263|NCT02867566|Active Comparator|Rituximab|Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
11275264|NCT02867553|Experimental|Rituximab by intravenous|attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
11275265|NCT02867553|Active Comparator|multi-field radiotherapy|multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
11275266|NCT02867540|Experimental|experimental group|Patient's with Crohn's disease who have had ileocolic resection
11275267|NCT02867514|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
11275268|NCT02867514|Sham Comparator|sham tDCS on left DLPFC (F3)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
11275269|NCT02867514|Active Comparator|anodal tDCS on right DLPFC (F4)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
11275270|NCT02867514|Sham Comparator|sham tDCS on right DLPFC (F4)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
11275271|NCT02867501||Aneurysmatic disease|Patients with dilatative arteriopathy (DA) the aortic diameter must be > 3 cm or the popliteal artery diameter > 1.5 cm
11275272|NCT02867501||Peripheral arterial occlusive disease|Patients with arterial occlusive disease (PAOD) defined with an Ankle brachial index (ABI) < 0.9 and positive criteria in the Edinburgh questionnaire.
11275273|NCT02867501||Healthy|Control group of age matched persons without PAOD (ABI > 0.9) and without DA.
11275274|NCT02867475|Other|A|Physical activity motivation
11275275|NCT02867462|Other|A-Standard Care|standard care
11275276|NCT02867462|Experimental|B-manipulator consultation radiotherapy added to standard care|manipulator consultation radiotherapy added to standard care
11275277|NCT02867449|Experimental|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
11275278|NCT02867449|Experimental|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
11275279|NCT02867436|Experimental|Gluten-free diet|Gluten-free diet
11275280|NCT02867436|No Intervention|Conventional diet|Conventional diet
11275281|NCT02867423|Other|A - CK boost radiation|CK boost radiation
11275282|NCT02867397|Other|Teysuno (S1) in combination with epirubicin and oxaliplatin|
11275283|NCT02867384|Active Comparator|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.
~Premedication with histamine blockers and acetaminophen will be provided
~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
11275284|NCT02867384|Sham Comparator|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.
~Premedication with histamine blockers and acetaminophen will be provided
~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
11275285|NCT02867371|Experimental|-Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
11275286|NCT02867358|Active Comparator|High dose of KT07 capsule|It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).
11275287|NCT02867358|Active Comparator|Low dose of KT07 capsule|It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).
11275288|NCT02867358|Placebo Comparator|Placebo|It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.
11275289|NCT02867345||Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
11275290|NCT02867345||Comparable group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 wild-type T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
11275291|NCT02867332|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
11275292|NCT02867332|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment."
11275293|NCT02867319|Experimental|age of 18-50 years old|
11275294|NCT02867319|Experimental|age of 7-17 years old|
11275295|NCT02867319|Experimental|age of 2-6 years old|
11275296|NCT02867306|Experimental|ASP1707 and methotrexate (MTX)|On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadministered on Day 8.
11275297|NCT02867293|Active Comparator|Preop-drainage|ascites drained over the pre-operative week through multiple ultrasound guided paracentesis
11275298|NCT02867293|Active Comparator|Op-drainage|ascetic fluid drained through an abdominal incision after anesthesia
11275299|NCT02867280|Experimental|Sorafenib|Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
11275300|NCT02867280|No Intervention|Control|No use of Sorafenib (Nexavar). Regular treatment.
11275301|NCT02867267|Experimental|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
11275302|NCT02867267|Placebo Comparator|Placebo|1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
11275303|NCT02867254||Groups1|15 patients with type 2 diabetes mellitus with periodontal endodontic lesions
11275304|NCT02867254||Groups 2|15 non-diabetics with periodontal endodontic lesions
11275305|NCT02867241|Experimental|Intervention|"Motivational interviews (3 visits) + supportive phone calls
~Feedback of child hair nicotine levels
~Feedback of home air quality (PM2.5)
~New Media (Website and/or Facebook with information and parental forum)"
11275306|NCT02867241|Other|Control Regular|This group will get no intervention during the study period. Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
11275307|NCT02867241|Other|Control Expanded|This group will get no intervention during the study period. However, participants will fill out a detailed questionnaire on parental perceptions of exposure and risk, as well as questions on social norms, self-efficacy, and knowledge Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
11275308|NCT02867228|Other|Single Observational Group|Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.
11275309|NCT02867215|Active Comparator|Barley bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
11275310|NCT02867215|Active Comparator|Wheat bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
11275311|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
11275312|NCT02867202|Experimental|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
11275313|NCT02867189|Experimental|atlas of micro-instrument|anterior chamber cell counts and visual and intraocular pressures on postoperative days 1,3,7,14 by atlas of micro-instrument training method.
11275314|NCT02867189|No Intervention|traditional training|anterior chamber cell counts and visual and intraocular pressures on postoperative days1,3,7,14 by traditional training method.
11275315|NCT02867176|Other|Corneal collagen CXL epi-off|For the epithelium-off procedure, the corneal epithelium is removed with a 10-minute soak time with isotonic riboflavin 0.1% solution and 4 minutes of exposure with 30 mw/cm2 ultraviolet-A irradiation.
11275316|NCT02867176|Other|Corneal collagen CXL epi-on|For the epithelium-on procedure, riboflavin is applied for a total soak of 4 minutes; the cornea is then completely rinsed with additional riboflavin for a total of 6 minutes. The ultraviolet-A irradiation is performed for 2 minutes and 40 seconds at 45mw/cm2.
11275317|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
11275318|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
11275319|NCT02867137||Mild TBI patients|
11275320|NCT02867124|Experimental|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
11275321|NCT02867124|Active Comparator|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
11277151|NCT02854618|Experimental|Everolimus treatment|
11275322|NCT02867111|Other|ICSI Control|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with no intervention of the Sperm Selection Assay
11275323|NCT02867111|Placebo Comparator|ICSI + SSA placebo|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with control solution (culture medium)
11275324|NCT02867111|Experimental|ICSI + SSA Attractant substance|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with attractant solution (attractant diluted in culture medium at 10 pM)
11275325|NCT02867098|Experimental|Cohort 1|Dose Level 1 XmAb5871 given SC Q14days X 3
11275326|NCT02867098|Experimental|Cohort 2|Dose Level 2 XmAb5871 given SC Q14days X 3
11275327|NCT02867098|Experimental|Cohort 3|Dose Level 3 XmAb5871 given SC Q14days X 3
11275328|NCT02867098|Experimental|Cohort 4|Dose Level 4 XmAb5871 given IV Q14days X 3
11275329|NCT02867098|Experimental|Cohort 5|Dose Level 5 XmAb5871 given SC Q7days X 3
11275330|NCT02867085||Group 1 (MDS group)|
11275331|NCT02867085||Group 2 (control group)|
11275332|NCT02867072|Active Comparator|Open appendectomy|Subjects that underwent open surgery for appendicitis
11275333|NCT02867072|Active Comparator|Laparoscopic appendectomy|Subjects that underwent laparoscopic surgery for appendicitis
11275334|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
11275335|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
11275336|NCT02867046|Experimental|medial approach group|
11275337|NCT02867046|Active Comparator|lateral approach group|
11275338|NCT02867033|Other|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
11275339|NCT02867020|Active Comparator|Abiraterone acetate + Prednisone + ADT (Goserelin)|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)
~Prednisone administered at a 5 mg twice daily oral dose
~Goserelin administered as subcutaneous injections of 10.8mg every 3 months"
11275340|NCT02867020|Experimental|APALUTAMIDE monotherapy|o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)
11275341|NCT02867020|Experimental|Abiraterone acetate + Prednisone + APALUTAMIDE|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)
~Prednisone administered at a 5 mg twice daily oral dose
~APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)"
11275342|NCT02867007|Experimental|KHK2455 + Mogamulizumab|"Part 1 (Dose Escalation Part): Will identify the MTD for the KHK2455 monotherapy run-in and for the combination regimen (KHK2455 monotherapy [Cycle 0] followed by KHK2455 +mogamulizumab combination [Cycle 1]).
~Part 2 (Expansion Part): Subjects with a selected tumor type will be enrolled and treated with the recommended dose of KHK2455 established in Part 1 in combination with mogamulizumab."
11275343|NCT02866994|Experimental|Project Connect Online (PCO)|Creation of personal website to share breast cancer experience with friends and family
11275344|NCT02866994|Experimental|PCO PLUS|Creation of personal website to share breast cancer experience with friends and family, as well as other women diagnosed with breast cancer
11275345|NCT02866981|Experimental|Observation|Patients that meet all inclusion and exclusion criteria are monitored every 2 months for two years or until a therapeutic intervention is warranted.
11275346|NCT02866968|Experimental|Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|All patients included will undergo FLAPS in one eye.
11275347|NCT02866955|Other|GROUP E (Estramustine)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine
11275348|NCT02866955|Other|GROUP T (Tamoxifen)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen
11275349|NCT02866942|Experimental|Asthma|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
11275350|NCT02866929|Active Comparator|Conventional orthodontic treatment|Patients that will receive conventional orthodontics
11275351|NCT02866929|Experimental|Orthodontics with decortication|Patients that will receive orthodontic treatment with selective alveolar decortication
11275352|NCT02866929|Experimental|Orthodontics decortication and Mucograft|Orthodontic treatment, selective alveolar decortication and Mucograft® on the mandibular anterior segment
11275353|NCT02866929|Experimental|Orthodontics and Mucograft®|Patients that will receive orthodontic treatment and Mucograft® on the mandibular anterior segment
11275354|NCT02866916|Experimental|Dose escalation|"The standard method 3+3 will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01.
~Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent.
~Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase."
11275355|NCT02866903|Experimental|Patients with peritoneal carcinosis|Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
11275356|NCT02866890|Experimental|Laryngeal Tube Suction size 1|Measurement of leak pressure
11275357|NCT02866890|Experimental|Laryngeal Tube Suction size 2|Measurement of leak pressure
11275358|NCT02866890|Experimental|Laryngeal Tube Suction size 2.5|Measurement of leak pressure
11275359|NCT02866877||Subarachnoid Hemorrhage|
11275360|NCT02866864||Subjects with animal allergy|Subjects who suffer from allergic symptom during contact with animal
11275361|NCT02866864||Subjects without animal allergy|Subjects who do not suffer from allergic symptom during contact with animal
11275362|NCT02866851|Experimental|Monitoring by Web application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
11275363|NCT02866838|Experimental|Tranexamic acid|Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.
11275364|NCT02866838|Placebo Comparator|Placebo|Saline 0.9% given in identical dosage as experimental
11275365|NCT02866825|Active Comparator|IFX-1|dose escalating single i.v. administration of IFX-1 (verum)
11275366|NCT02866825|Placebo Comparator|Placebo|dose escalating mimicing single i.v. administration of placebo
11275367|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
11275368|NCT02866799|Experimental|Multi-PAP intervention|Complex intervention with general practitioners and patients
11275369|NCT02866799|Active Comparator|Usual care|Patients will receive the usual clinical care
11275370|NCT02866786|Active Comparator|OCP only arm|OCP containing 35 microgram ethinyl estradiol and 2 milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
11275371|NCT02866786|Active Comparator|Metformin arm|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
11275372|NCT02866773|Experimental|PA1:Education sessions, Reminders, Whataps group|The intervention includes Physical activity knowledge enhancement session, Physical activity anti-inertia Reminders , Physical activity ambassadors' electronic communication group.
11275373|NCT02866773|Active Comparator|PA2:Education sessions, Reminders|The intervention includes Physical activity knowledge enhancement session and Physical activity anti-inertia Reminders
11275374|NCT02866773|Active Comparator|PA3:Education sessions, Whataps group|The intervention includes Physical activity knowledge enhancement session and Physical activity ambassadors' electronic communication group.
11275375|NCT02866773|Active Comparator|PA4:Education sessions|The intervention includes Physical activity knowledge enhancement session only.
11275376|NCT02866773|Experimental|HD1:Education sessions, Reminders, Whataps group|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , Health diet ambassadors' electronic communication group.
11275377|NCT02866773|Active Comparator|HD2:Education sessions, Reminders|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , and Health diet ambassadors' electronic communication group.
11275378|NCT02866773|Active Comparator|HD3:Education sessions, Whataps group|The intervention includes Health diet knowledge enhancement session and Health diet ambassadors' electronic communication group.
11275379|NCT02866773|Active Comparator|HD4:Education sessions|The intervention includes Health diet knowledge enhancement session only.
11275380|NCT02866747|Active Comparator|Arm A: radiation therapy alone|Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.
11275381|NCT02866747|Experimental|Arm B: combined treatment|"hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.
~* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I."
11275382|NCT02866734|Active Comparator|Free screening group|Subjects in this group receive free diabetic retinopathy screening.
11275383|NCT02866734|Active Comparator|Pay screening group ($150)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$150.
11275384|NCT02866734|Active Comparator|Pay screening group ($300)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$300.
11275385|NCT02866721|Experimental|Human Allogeneic Mesenchymal Stem Cells|"One time IV Infusion of up to 5 x 10^6 allogeneic hMSCs/kg of body weight. A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
11275386|NCT02866708|Experimental|Intermittent negative pressure (INP) therapy|"At baseline, the participants will be randomized into 2 groups: 1) INP therapy or 2) control with no INP therapy.
~The 1) patients randomized to INP therapy will start with 8 weeks INP therapy two hours per day divided into timed sections (1-3 times per day or use the device as many times as practical for the individual as long as the total time is two hours). After 8 weeks of INP therapy, final measures will be performed at the Vascular lab before the participants starts their 8-week control period."
11275387|NCT02866708|No Intervention|Control|The participants randomized to control will continue their usual wound care for 8 weeks without INP therapy. The control group will start INP therapy after 8 weeks. After 8-weeks without intervention, the participants allocated to the control-group will be asked to start with INP therapy for 8 weeks before a final examination. The participants in the control group will receive vascular assesment at baseline, week 8 (end of control).
11275388|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
11275389|NCT02866682|Other|Brand Tacrolimus Only : Prograf|Arm 1 will receive brand tacrolimus for the entire study
11275390|NCT02866682|Other|Generic A Only|Arm 2 will receive specific generic tacrolimus for the entire study
11275391|NCT02866669|Active Comparator|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
11275392|NCT02866669|Experimental|Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
11275393|NCT02866669|Experimental|Peer coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
11275394|NCT02866669|Experimental|Peer coach and Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. The patients will also be matched with peer advisors who will work with the participants for 12 months.
11275395|NCT02866656|Experimental|control group|patients were given Conventional conservative treatment；
11275396|NCT02866656|Experimental|therapeutic ultrasound group|patients were given Conventional conservative treatment and low intensity ultrasonic treatment ；
11275397|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
11275398|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
11275399|NCT02866630||Cardiopulmonary bypass (Sevoflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of sevoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
11275400|NCT02866630||Cardiopulmonary bypass (Desflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of desflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
11275401|NCT02866617|Experimental|Conventional|T1-T2 : VFR constructed on conventional study model T2-T3 : VFR constructed on 3D reconstructed study model
11275402|NCT02866617|Experimental|3D|T1-T2 : VFR constructed on 3D reconstructed study model T2-T3 :VFR constructed on conventional study model
11275403|NCT02866604|Active Comparator|Strerofundin|Days of intervention: 3 days
11275404|NCT02866604|Active Comparator|0.9% saline|Days of intervention: 3 days
11275405|NCT02866591|Experimental|Arm A|Patients have a mammography performed by themselves according to auto-compression procedure. The radiologist leads the compression at a minimum threshold of 40 Newton, then leaves the control of the compression to the patient. The radiologist treats only the positioning of the breast on the sensor.
11275406|NCT02866591|Active Comparator|Arm B|Patients have a mammography performed by the radiologist according to standard procedure.
11275407|NCT02866578|Experimental|Open lung protective ventilation|"Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.
~PEEP at 8 cmH2O.
~Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.
~Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
11275408|NCT02866578|No Intervention|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
11275409|NCT02866565|Experimental|Diabetic foot ulcer|
11275410|NCT02866552|Placebo Comparator|PLACEBO|Patients will receive an injection of placebo
11275411|NCT02866552|Experimental|DRUG : Stromal Vascular Fraction|Patients will receive an injection of Stromal Vascular Fraction injection
11275412|NCT02866539|Active Comparator|Polyherbal capsule|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
11275413|NCT02866539|Placebo Comparator|Placebo|Placebo will contain an inert substance
11275414|NCT02866526||group1|adolescents (14-17 years old)
11275415|NCT02866526||group 2|young adults (20-29 years old)
11275416|NCT02866513|Other|Patient mechanically ventilated with APRV mode|
11275417|NCT02866500|Experimental|oral cancer|
11275418|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history
~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
11275419|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
11275420|NCT02866474|Other|- Puteaux or Paris for elderly persons|
11275421|NCT02866474|Other|-Two EHPAD in Lyon for elderly persons living|
11275422|NCT02866461||Fibromyalgia|No treatment
11275423|NCT02866448|Placebo Comparator|Vehicle control|"Subjects will consume
~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid
~1 x 75mg cellulose pill"
11275424|NCT02866448|Experimental|Isoquercetin|"Subjects will consume
~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid
~1 x 75mg cellulose pill"
11275425|NCT02866448|Active Comparator|Aspirin|"Subjects will consume
~1 x 75mg dispersible aspirin
~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid"
11275426|NCT02866448|Experimental|Isoquercetin plus Aspirin|"Subjects will consume
~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid
~1 x 75mg dispersible aspirin"
11275449|NCT02866305|Experimental|HRCT with bullae, treatment VATS.|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
11277152|NCT02854605|Experimental|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
11275427|NCT02866435|Experimental|Euglycemia pre-conditioning|Participants will undergo two euglycemia (normal blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where the target glucose during the clamp will be 95 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
11275428|NCT02866435|Experimental|Hypoglycemia pre-conditioning|Participants will undergo two hypoglycemia (low blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where target glucose during the clamp will be 50 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
11275429|NCT02866422||OCD|
11275430|NCT02866422||Healthy Controls|
11275431|NCT02866409|Experimental|Bupivacaine,dexmedetomidine scalp block|Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept < 2 mg /kg for scalp block
11275432|NCT02866409|Active Comparator|bupivacaine dexmedetomidine infiltration|The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
11275433|NCT02866409|Active Comparator|bupivacaine infiltration|The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
11275434|NCT02866396||Pregabalin patients|Same dose of preoperative pregabalin 1h after surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration (PACU if NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
11275435|NCT02866396||Naive patients|Pregabalin 150mg PO initiated 1h before surgery and associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
11275436|NCT02866383|Experimental|Nivolumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT and then every 2 weeks (q2w), for a maximum of 52 weeks
11275437|NCT02866383|Experimental|Nivolumab & Ipilimumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT. Thirty minutes after the completion of nivolumab infusion patients will receive ipilimumab 1 mg/kg over 90 minutes IV as an IV infusion. Nivolumab will be given every 2 weeks (q2w) and ipilimumab every 6 weeks (q6w), respectively for a maximum of 52 weeks
11275438|NCT02866370|Experimental|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously
11275439|NCT02866370|Active Comparator|Chemotherapy|"Ovarian Cancer Patients:
~Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days
~Endometrial Cancer Patients:
~Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days
~Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
11275440|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
11275441|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
11275442|NCT02866331|Experimental|CB + G-CSF|
11275443|NCT02866331|Placebo Comparator|CB + placebo|
11275444|NCT02866331|Experimental|G-CSF|
11275445|NCT02866331|Placebo Comparator|Placebo|
11275446|NCT02866318||Novice practitioners|Residents in Emergency department who has no experiences of echocardiography prior to the study.
11275447|NCT02866305|Experimental|HRCT with bullae, treatment conservative|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
11275448|NCT02866305|Experimental|HRCT no bullae, treatment conservative|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
11275851|NCT02863705|Experimental|COMBIGAN®|One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
11275450|NCT02866305|Experimental|HRCT no bullae, treatment VATS.|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
11275451|NCT02866292||non-pregnant nulliparous|Nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
11275452|NCT02866292||primigravid|Pregnant women on her first pregnancy and gestational age above 14 weeks. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
11275453|NCT02866279|Experimental|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
11275454|NCT02866279|Experimental|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
11275455|NCT02866279|Active Comparator|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
11275456|NCT02866266||All commercially insured patients in the HIRD|
11275457|NCT02866266||All Medicaid patients in a participating state Medicaid plan|
11275458|NCT02866253|Experimental|DHEA Group|DHEA 25mg t.i.d. for more than 12weeks
11275459|NCT02866253|No Intervention|Control Group|patients without any DHEA
11275460|NCT02866240|Experimental|Single arm|Cathodal Transcranial Direct Current Stimulation (tDCS)
11275461|NCT02866227|Experimental|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
11275462|NCT02866227|Experimental|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
11275463|NCT02866214|Experimental|Group I|This Group of Patients will receive Febuxostat Drug along with their Standard Treatment.
11275464|NCT02866214|Placebo Comparator|Group II|This Group of Patients will receive Placebo along with their standard Treatment.
11275465|NCT02866201|Experimental|Patient suffering from traveler's diarrhoea|Patient suffering form traveler's diarrhoea during a stay (up to 3 months) outside metropolitan France
11275466|NCT02866175|Experimental|Edoxaban Regimen|Participants will be randomized to receive edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5 mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) used.
11275467|NCT02866175|Active Comparator|Vitamin K Antagonist Regimen|Participants will be randomized to receive VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) and aspirin (100 mg once-daily, for a minimum of 1 month and up to 12 months duration.
11275468|NCT02866162||patients with neutropenia|
11275469|NCT02866149|Other|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.
~Timing of blood sampling:
~inclusion
~after #8 weeks on therapy
~at progression or 6 months from inclusion for patient without progressive disease
~if toxicity grade 3 or 4, or grade 2 until 1 month."
11275470|NCT02866149|Other|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).
~Timing of blood sampling:
~inclusion
~after 1 cycle of therapy (weeks 3-4)
~up to 2 other samples, timepoints decided by the investigator"
11275471|NCT02866149|Experimental|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).
~One tumor sampling.
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
11275472|NCT02866149|Other|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.
~One tumor sampling.
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
11275473|NCT02866149|Other|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
11275474|NCT02866149|Other|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib
~Timing of blood sampling:
~Inclusion day (2 samples)
~after #2 weeks of therapy
~after #4 weeks of therapy
~at progression."
11275475|NCT02866149|Other|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
11275476|NCT02866149|Other|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients
~Timing of blood sampling:
~Inclusion
~up to 3 other samples, timepoints decided by the investigator."
11275477|NCT02866149|Other|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.
~Blood sampling at 4 timepoints."
11275478|NCT02866149|Other|"Cohort 10 - Palbociclib II"|"Monitoring of patient with a metastatic breast cancer treated by palbociclib.
~Timing of blood sampling:
~Inclusion
~after #4 weeks of therapy
~at the first tumoral evaluation (month 3 or 4)
~at progression."
11275479|NCT02866149|Other|Cohort 11 - Sarcomas|The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.
11275480|NCT02866149|Other|Cohort 12 - Faslorad|"Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.
~Timing of blood sampling:
~Inclusion
~after #3-5 weeks of therapy
~at the first tumoral evaluation (month 2 or 3)
~at progression."
11275481|NCT02866149|Other|Cohort 13 - MUm|"The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).
~Timing of blood sampling:
~J1C1
~J2C1
~J1C2
~J1C5 (first tumoral evaluation)."
11275482|NCT02866149|Other|Cohort 14 - CNBC Snipe|"This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.
~One tumour sampling.
~Timing of blood sampling:
~before treatment
~at W8 of treatment (after radiological examination)
~at W12 of treatment
~at progression or 18 months after the beginning of treatment"
11275483|NCT02866149|Other|Cohort 15 - Breast CLI|"This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.
~Timing of blood sampling:
~At inclusion
~After biopsy post inclusion (or in 15 days after)
~after 1 or 2 months of treatment
~at progression or 18 months after inclusion"
11275484|NCT02866136|Other|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).
~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
11275485|NCT02866136|Other|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.
~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
11275486|NCT02866136|Other|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
11275487|NCT02866123|Experimental|patient with insertion of an NGT|
11275488|NCT02866110|Experimental|Treatment group|25 patients with BPD. In a diagnostic session, diagnostics of psychiatric disorders are conducted. For BPD diagnosis, the International Personality Disorder Examination (IPDE) is used and symptom severity is assessed with the Borderline Symptom List. The Treatment group will receive fMRI amygdala neurofeedback training (3 sessions within 2 weeks). Patients in regular psychotherapeutic treatment (treatment-as-usual) will not be excluded.
11275489|NCT02866097|Experimental|Intervention|mHealth inventory management and referrals via text messaging plus supportive supervision of CHWs via an mHealth strategy
11275490|NCT02866097|Placebo Comparator|Control|ICCM current standard of care with CHWs operating under standard conditions without enhanced inventory management or supportive supervision by mHealth
11275491|NCT02866084|Experimental|Device|Neuromodulation
11275492|NCT02866071|Active Comparator|Ketamine|50mg IN Ketamine Hydrochloride
11275493|NCT02866071|Placebo Comparator|Placebo|50mg IN placebo
11275494|NCT02866058||Cesarean|Mothers delivered by cesarean section
11275495|NCT02866058||Vaginal|Mothers delivered by vaginal delivery
11275496|NCT02866045|Active Comparator|EUS-guided Fine Needle Biopsy|EUS-FNB is performed using a 22 or 25 G SharkCore biopsy needle with a minimum of 3 passes into the lesion.
11275497|NCT02866045|Experimental|Single incision needle knife biopsy|SINK biopsy is performed under direct endoscopic visualization via EGD with a minimum of 3 biopsy samples obtained.
11275498|NCT02866032|Experimental|MOB015B|
11275499|NCT02866032|Active Comparator|Ciclopirox 80 mg/g|
11275500|NCT02866019|Experimental|CLS2702C/CLS2702D|
11275501|NCT02866006|Experimental|BVAC-C|BVAC-C IV injection at 0, 4, 8th weeks.
11275502|NCT02865993|Other|Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
11275503|NCT02865993|Other|No Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
11275504|NCT02865980|Experimental|inflammation|The effect of washing with betadine and clove extract on incidence of inflammation place logging shaldon catheter in the hemodialysis patients
11275505|NCT02865980|Experimental|infection|The effect of washing with betadine and clove extract on incidence of infection place logging shaldon catheter in the hemodialysis patients
11275506|NCT02865967|Experimental|Block1_Intervention|Usual care + a-GPS
11275507|NCT02865967|Other|Block1_Control|Usual Care
11275508|NCT02865967|Experimental|Block2_Intervention|Usual care + a-GPS
11275509|NCT02865967|Other|Block2_Control|Usual care
11275510|NCT02865967|Experimental|Block3_Intervention|Usual care + a-GPS
11275511|NCT02865967|Other|Block3_Control|Usual care
11275512|NCT02865954|Experimental|iball intervention|Use of iball pelvic floor training mhealth application for 16 weeks.
11275513|NCT02865954|No Intervention|Standard Care|Standard Care - control group
11275514|NCT02865941|Experimental|5 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.
~Routine fortifier will be added to breast milk batches.
~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
11275515|NCT02865941|Experimental|1 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.
~Routine fortifier will be added to breast milk batches.
~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
11275516|NCT02865928|Experimental|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivacaine HCl.
11275517|NCT02865928|Placebo Comparator|Normal Saline|Placebo injection on operated side, same technique as experimental group.
11275518|NCT02865915|Placebo Comparator|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
11275519|NCT02865915|Experimental|MLE4901|Plain, round, biconvex, white film-coated tablets administered twice per day
11275520|NCT02865902|Experimental|Test Group|In Test group, the free gingival graft donor sites of each experimental group received low-level laser therapy by Ezlase; Biolase® at doses of 8.6 J/cm2.
11275521|NCT02865902|Sham Comparator|Control Group|In Control Group, the low-level laser therapy by Ezlase; Biolase® was performedin a same manner with test group at free gingival graft donor sites. However, no irradiation was occurred because of not pushing the start button.
11275522|NCT02865889||Uterine oncologic Indications for surgery|
11275852|NCT02863705|Experimental|COMBIGAN® + LUMIGAN® 0.01%|LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
11275523|NCT02865876|Experimental|Accelerated Corneal Cross-linking|Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.
11275524|NCT02865876|Sham Comparator|Sham Accelerated Corneal Cross-linking|"Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted the impregnation phase applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged."
11275525|NCT02865863|Experimental|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
11275526|NCT02865863|Placebo Comparator|Placebo|
11275527|NCT02865850|Experimental|Vadadustat|
11275528|NCT02865850|Active Comparator|darbepoetin alfa|
11275529|NCT02865837|Experimental|ARM 1|
11275530|NCT02865824|Active Comparator|Continue thienopyridine|Patients continue dual antiplatelet therapy (DAT) before colonoscopy and all polyps are removed by cold snare polypectomy.
11275531|NCT02865824|Experimental|Discontinue thienopyridine|Patients discontinue thienopyridines for 1 week before colonoscopy and all polyps are removed by cold snare polypectomy.
11275532|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.
~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.
~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)
~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV
~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
11275533|NCT02865785|Active Comparator|Study Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20% (100 mL of intralipid 20% diluted in 250 mL sterile i.v. saline administered i.v. over two hours), once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
11275534|NCT02865785|Placebo Comparator|Placebo Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
11275535|NCT02865772||observational|healthy newborns
11275536|NCT02865759|Experimental|Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, in a brochure and at a website. The practice is described as spending 15 minutes every day from gestational week 28 to get to know the fetal movement pattern. The fetus must be awake when she practice Mindfetalness and the woman is suggested to lay on her left side when she observe the fetal movements. In the brochure as well at the website the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek health-care without unnecessary delay.
11275537|NCT02865759|No Intervention|Routine Care|No activities will take place in the antenatal clinics randomized to routine care.
11275538|NCT02865746|Active Comparator|Group betamethasone|Active Comparator: betamethasone disodium phosphate at a concentration of 4 mg / ml - dosage of 0.05 mg / kg
11275539|NCT02865746|Placebo Comparator|Group placebo|sterile saline solution (sodium chloride 0.9% - 1 ml ampoules) - dosage of 0.05 mg / kg
11275540|NCT02865733|Experimental|Remodulin Injection|Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
11275541|NCT02865733|Placebo Comparator|Distilled water group|Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours
11275542|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
11275543|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
11275544|NCT02865707|Experimental|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
11275545|NCT02865707|Placebo Comparator|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
11275546|NCT02865681|Active Comparator|Conventional IVF|Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
11275853|NCT02863679|Experimental|Tetracaine hydrochloride gel group|Patients in getracaine hydrochloride gel group were covered with a gauze with tetracaine hydrochloride gel on the cervix after hysteroscopic insertion of utrauterine balloon stent.
11275547|NCT02865681|Experimental|IVF protocol using nasal gonadotropins|Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
11275548|NCT02865668|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11275549|NCT02865668|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11275550|NCT02865668|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11275551|NCT02865668|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11275552|NCT02865655||CSD-TVU|Cesarean Section Scar Evaluation by TVU
11275553|NCT02865655||CSD-MRI|Cesarean Section Scar Evaluation by MRI
11275554|NCT02865655||CSD-MRI with saline|Cesarean Section Scar Evaluation by MRI with saline
11275555|NCT02865655||CSD-Hysteroscopic|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy
11275556|NCT02865642|Experimental|Serotonin Uptake Inhibitors|"Treatment 1: Starting with Escitalopram 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage increase of 5mg/day till target dose of Escitalopram 20mg/day.
~Subjects will remain on Escitalopram 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by dosage reduction of Escitalopram 10mg/day for one week."
11275557|NCT02865642|Placebo Comparator|Placebo|"Treatment 2: Starting with Placebo 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage of 5mg/day till target dose of Placebo 20mg/day.
~Subjects will remain on Placebo 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by Placebo 10mg/day for one week."
11275558|NCT02865629|Experimental|N-acetyl cysteine|Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
11275559|NCT02865616|Experimental|MET-2 Capsules|"Patients will be on vancomycin to control symptoms up until the time of the treatment.
~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.
~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.
~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..
~All patients will be followed up for 120 days after the last treatment has been received."
11275560|NCT02865603|Experimental|PAX Good Behavior Game|The intervention is delivered by teachers within the normal school curriculum. Teachers from intervention classes completed 3-day training and were supported by the mentor, who visited their class during the 2016/17 school year and provided counseling via e-mail and phone. During the second year (2017/18) teachers could use the PAX GBG methods, but they did not receive additional support from the mentors.
11275561|NCT02865603|No Intervention|Waitlist control group|Control group continue their normal activities without intervention. After a post-test assessment in spring 2018 the control group teachers will be trained and supported to implement PAX GBG.
11275562|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
11275563|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
11275564|NCT02865577||Adult asthma|"Adult asthma subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.
~Participants will undergo following study assessments:
~Clinical History
~Health status and disease control questionnaires
~Focused physical examination
~Electrocardiogram (ECG)
~Blood test
~Spirometry
~Echocardiogram
~Cardiac magnetic resonance (CMR) imaging
~CMR survey"
11275565|NCT02865577||Adult COPD|"Adult COPD subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.
~Participants will undergo following study assessments:
~Clinical History
~Health status and disease control questionnaires
~Focused physical examination
~Electrocardiogram (ECG)
~Blood test
~Spirometry
~Echocardiogram
~Cardiac magnetic resonance (CMR) imaging
~CMR survey"
11275566|NCT02865577||Healthy participants|"Healthy participants with no past history of cardiovascular or respiratory disease.
~Participants will undergo following study assessments:
~Clinical History
~Focused physical examination
~Electrocardiogram (ECG)
~Blood test
~Spirometry
~Echocardiogram
~Cardiac magnetic resonance (CMR) imaging
~CMR survey"
11275567|NCT02865564|Active Comparator|Intervention group|The intervention group will receive 5 drops, a minimum of 100 million live Lactobacillus reuteri DSM 17938 a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
11277091|NCT02854982||No Prostate Cancer|Group drawn of the control group of the case control study, entitled EPICAP
11275568|NCT02865564|Placebo Comparator|Placebo group|Placebo group will receive 5 drops of maltodextrin in the some oil suspension a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
11275569|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
11275570|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
11275571|NCT02865538|Placebo Comparator|BAY3427080 Placebo|
11275572|NCT02865538|Experimental|50mg BAY3427080|
11275573|NCT02865538|Experimental|100mg BAY3427080|
11275574|NCT02865538|Experimental|150mg BAY3427080|
11275575|NCT02865538|Experimental|200mg BAY3427080|
11275576|NCT02865512|Active Comparator|supine position|thoracic epidural catheterization with supine position
11275577|NCT02865512|Active Comparator|flexed lateral position|thoracic epidural catheterization with flexed lateral position
11275578|NCT02865499|Experimental|acarbose|all participants will receive acarbose
11275579|NCT02865486|Experimental|Lipid emulsion: visit 2|One of four randomly assigned lipid emulsions
11275580|NCT02865486|Experimental|Lipid emulsion: visit 3|One of four randomly assigned lipid emulsions
11275581|NCT02865486|Experimental|Lipid emulsion: visit 4|One of four randomly assigned lipid emulsions
11275582|NCT02865473|No Intervention|primary open angle glaucoma patients|
11275583|NCT02865473|No Intervention|patients with primary angle closure|
11275584|NCT02865473|No Intervention|patients with neovascular glaucoma|
11275585|NCT02865473|No Intervention|PEX glaucoma patients|
11275586|NCT02865473|No Intervention|glaucoma patients with filtering bleb|
11275587|NCT02865473|Experimental|healthy volunteers|instillation of antiglaucoma treatment in the study eye
11275588|NCT02865460|Experimental|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
11275589|NCT02865460|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x 200 mg for 4 months) with food each morning-upon waking
11275590|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
11275591|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275592|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275593|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275594|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275595|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275596|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275597|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275598|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275599|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
11275600|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
11275601|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
11275602|NCT02865421|Experimental|Stem cells|adipose tissue derived stromal vascular fraction was used
11275603|NCT02865421|Experimental|platelet rich plasma|platelet rich plasma isolated after centrifugation from the pt was transplanted
11275604|NCT02865408|Active Comparator|Group 1: Peptamen 1.5% via enteral only|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard EN Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d
11275605|NCT02865408|Active Comparator|Group 2: Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive the same enteral feeding as group 1 (Peptamen 1.5) but in addition will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/d
11275606|NCT02865408|Active Comparator|Group 3: Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids (Prosol 20%) in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/day.
11275607|NCT02865395|Experimental|Pre-operative Suppository|A B&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
11275608|NCT02865395|Active Comparator|Post-operative Suppository|A B&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
11275609|NCT02865395|Placebo Comparator|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
11275610|NCT02865382|Active Comparator|Group A|white light was used for both insertion and withdrawal of the colonoscope
11275611|NCT02865382|Experimental|Group B|Insertion to cecum was performed under white light and once the cecum was reached,the OE mode was swithed on during withdrawal of endoscope for complete colonic examination
11275612|NCT02865369||Daclatasvir plus Asunaprevir treatment|Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography
11275613|NCT02865356|Experimental|Cyclosporine 5% Solution|"SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.
~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
11275614|NCT02865356|Placebo Comparator|Placebo|"SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.
~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
11275615|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
11275616|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
11275617|NCT02865317||Study group|Patients with obstetrical brachial plexus injury involving upper trunk (C5-6)
11275618|NCT02865304|Experimental|endostar; taxane|Endostar was administered at 7.5 mg/m2, d1-14, q21d and was continued until progressive disease, unacceptable toxicity, consent withdrawal, or completion of 24 months. In the same time,Taxane-based chemotherapy was continued until progressive disease, unacceptable toxicity, consent withdrawal, or up to 8 cycles.
11275619|NCT02865291|Experimental|ForConti device|Use the device up to 12 hours/day for 4 weeks
11275620|NCT02865278|Experimental|Polyphenol-rich drink|The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
11275621|NCT02865278|Placebo Comparator|Placebo drink|The participants consume the control drink.After 3 hours they consume a standard meal to evaluate the metabolic response after a placebo.
11275622|NCT02865265||Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.
~An ultrasound-guided ipsilateral PaB was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
11275623|NCT02865252|Active Comparator|MWM treatment|"Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.
~MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range."
11275624|NCT02865252|Sham Comparator|MWM sham|The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
11275625|NCT02865239|Placebo Comparator|Supine position|3.0 tesla MRI in supine position
11275626|NCT02865239|Active Comparator|Prone position|3.0 tesla MRI in prone position
11275627|NCT02865226|Experimental|experimental group|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
11275628|NCT02865226|Active Comparator|control group|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual)
11275629|NCT02865213|Experimental|Miniplates + OBA|"The intrusion of posterior teeth using Miniplates + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniplates.
~The miniplates are for Jeil Dual top® anchor system, Jeil medical corporation, #702,kolon science valley 2nd, 811, Guro-Dong, Guro-Gu, Seoul, 152-050, Korea. Tel: 82.2.850.3500. Fax: 82.2.850.3537. homepage: www.jeilmed.co.kr/ E-mail: mktg@jeilmed.co.kr"
11275630|NCT02865213|Experimental|Miniscrews + OBA|"The intrusion of posterior teeth using Miniscrews + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniscrews.
~The miniscrews are for Denxy ® dental orthodontic products, Denxy technology co, limited . 404,Lihuabuilding,Furongroad, Changsha, Hunan, China. Tel: 0086-731-89717339. Fax: 0086-731-82237315. Homepage: www.denxy-orthodontic.com/email: DENXYDENTALBOSS@126.COM"
11275631|NCT02865213|Experimental|Only OBA|The intrusion of posterior teeth using OBA only will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth only.
11275854|NCT02863679|Placebo Comparator|Control group|Patients in control group were covered with a gauze with saline on the cervix after hysteroscopic insertion of utrauterine balloon stent.
11275632|NCT02865200|Experimental|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique. The needles were kept on the body for 20 minutes and at the 10th minute, the needle was rolled and re-stimulation was enabled. The treatment was applied twice a week, which is equal to 6 sessions in total.
11275633|NCT02865200|Experimental|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again. The period of treatment was 6 sessions in total with 25 minutes of each.
~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
11275634|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
11275635|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
11275636|NCT02865174|Active Comparator|Topical tranexamic acid|Intraarticular application of tranexamic acid Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
11275637|NCT02865174|Active Comparator|Floseal®|"Floseal® was applied on potential bleeding sites before prosthesis implantation.
~Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay"
11275638|NCT02865174|Placebo Comparator|Control group|No intervention before closure of joint capsule. Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
11275639|NCT02865161||NISELAT|Amtolmetin guacil should be taken in fasting conditions. The recommended dose is 600 mg b.i.d. Maximum daily dose - 1800 mg
11275640|NCT02865148|Experimental|Cognitive behavioral therapy (CBT) group|Participants will receive 4 sessions that lasts approximately 50 mins. The sessions will teach patients to manage their symptoms.
11275641|NCT02865148|No Intervention|Waitlist control (WLC) group|The WLC group receives standard usual care before being offered the same CBT protocol and assessment thereafter.
11275642|NCT02865135|Experimental|DPX-E7 Vaccine|Subjects will 2 priming doses of DPX-E7 at a pre-determine dosage 3 weeks apart followed by a predetermine booster dose every 8 weeks until clinical progression.
11275643|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
11275644|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
11275645|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
11275646|NCT02865083|Active Comparator|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
11275647|NCT02865083|No Intervention|Standard|Patients will receive use of the standard of care option which is the montgomery straps
11275648|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
11275649|NCT02865070||10 babies (full term, ages 37-42 weeks)|
11275650|NCT02865070||5 babies (premature, ages 34-37 weeks)|
11275651|NCT02865070||5 babies (premature, ages 31-34 weeks)|
11275652|NCT02865070||5 babies (premature, ages 28-31 weeks)|
11275653|NCT02865070||5 babies (premature, ages 25-28 weeks)|
11275654|NCT02865070||5 babies (premature, ages 23-25 weeks)|
11275655|NCT02865070||30 babies (any gestational age under 6 months)|
11275656|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
11275657|NCT02865057||3rd year Residents|3rd year Ob, Gyn Residents
11275658|NCT02865057||4th Year Residents|4th year Ob, Gyn Residents
11275659|NCT02865044|Active Comparator|Wax Ester Marine Oil|Active: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules)
11275660|NCT02865044|Other|Ethyl Ester Marine Oil|Control: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule)
11275661|NCT02865031|Experimental|Decorin|Intravitreal injection of 200-400 ug of Decorin.
11275662|NCT02865018|Experimental|cetirizine|10mg oral each day
11275663|NCT02865005|Active Comparator|Dapsone 5.0% Gel (Allergan)|Dapsone 5.0% Gel applied twice daily for 84 days
11275664|NCT02865005|Experimental|Dapsone 5.0% Gel (SEEGPharm)|Dapsone 5.0% Gel applied twice daily for 84 days
11275665|NCT02865005|Placebo Comparator|Placebo|Vehicle of Experimental Gel applied twice daily for 84 days
11275666|NCT02864992|Experimental|Tepotinib|
11275667|NCT02864966|Other|Other|This is a safety study where a marketed product will be placed on healthy adult skin.
11275668|NCT02864953|Experimental|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
11275669|NCT02864953|Placebo Comparator|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
11275670|NCT02864940|Experimental|Intervention Arm|Using the cognitive exercises on Lumosity for 10 weeks
11275671|NCT02864940|Active Comparator|Control Arm|Using online crossword puzzles for 10 weeks.
11275672|NCT02864927|Experimental|Menactra Group 1|Participants aged 9 to 23 months will receive 2 doses of Menactra
11275673|NCT02864927|Experimental|Menactra Group 2|Participants aged 2 to 55 years will receive 1 dose of Menactra
11275674|NCT02864914||Empagliflozin|Patients initiating Empagliflozin treatment within the study period
11275675|NCT02864914||DPP-4 inhibitors|Patients initiating DPP-4 inhibitor treatment within the study period
11275676|NCT02864901|Experimental|KSL-W 30 mg|3 times per day over 4 treatment days
11275677|NCT02864901|Placebo Comparator|Chewing Gum Placebo|3 times per day over 4 treatment days
11275678|NCT02864888|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
11275679|NCT02864888|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 24 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
11275680|NCT02864875|No Intervention|Control|Not to receive an early replacement of fibrinogen
11275681|NCT02864875|Experimental|Intervention|Receive early replacement through fibrinogen concentrate (50mg per kg of body weight)
11275682|NCT02864862|Active Comparator|Immediate implant|Immediate implant alone
11275683|NCT02864862|Active Comparator|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
11275684|NCT02864862|Active Comparator|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
11275685|NCT02864849|Experimental|TNT|"Patients with MRI defined high-risk rectal cancer will receive chemotherapy before and after chemoradiation, and will not receive adjuvant treatment. This arm is called total neoadjuvant treatment (TNT). The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX (Capecitabine+Oxaliplatin) over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.
~Finally, patients will receive TME (Total mesorectal excision) following TNT if no metastasis occurs."
11275686|NCT02864836||Patients with head or neck cancer|Samples collection
11275687|NCT02864836||Patients with lymphoma|Samples collection
11275688|NCT02864836||Patients without tumoral pathology|Samples collection
11275689|NCT02864823|Experimental|Perichondrium|Perichondrium Autografts
11275690|NCT02864810|Experimental|[18F]GP1 PET/CT imaging|"Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).
~Intravenous injection and PET/CT scanning of [18F]GP1"
11275691|NCT02864797|Experimental|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software.
11275692|NCT02864784|Experimental|Amorphous calcium carbonate|Subjects in this arm of the study will receive AMOR-1 tablets, containing 200 mg elemental calcium in addition to the standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
11275693|NCT02864784|Placebo Comparator|Placebo|Subjects in this arm of the study will receive Placebo tablets in addition to standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
11275694|NCT02864771||1|Derivation cohort (n=474); may be analyzed separately or combined with cohort #2 to enhance statistical power
11275695|NCT02864771||2|Validation cohort (patient #475 and after); may be combined with cohort #1 to enhance statistical power
11275696|NCT02864758||Group 1|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with rivaroxaban
11275697|NCT02864758||Group 2|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin k anatognists
11275698|NCT02864758||Group 3|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with dabigatran
11275699|NCT02864745|Experimental|Early rehabilitation arm|These patients will receive very early (<48 hours after ICU admission), protocolised, intensive rehabilitation, which will include functional electrical stimulation-assisted cycle ergometry.
11275700|NCT02864745|Active Comparator|Standard-of-care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
11275701|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
11275702|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
11275703|NCT02864719|Experimental|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
11275704|NCT02864706|Experimental|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
11275705|NCT02864706|Active Comparator|Control|patients received standard CsA, MMF and corticosteroids
11275706|NCT02864693|Active Comparator|Configuration A (Kinnex)|
11275707|NCT02864693|Active Comparator|Configuration B (Pacifica LP)|
11275708|NCT02864680|Other|Cannabis users|
11275709|NCT02864680|Other|Healthy volunteers, not cannabis/tobacco users|
11275710|NCT02864680|Other|Healthy volunteers, tobacco users|
11275711|NCT02864680|Other|Schizophrenia patients|
11275712|NCT02864654|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate Adipose-derived regenerative cells (ADRC). After isolation 10 mL of autologous ADRC suspension will be injected intramuscularly, close to the site of muscle injury. 10 to 20 injections will be performed so as to infiltrate the injured muscle
11275780|NCT02864225|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
11275713|NCT02864641|Experimental|TX Group: Planet K Treatment|Participants in the TX Group will receive access to Planet K. Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Adolescent and young adult participants will then receive a mobile phone preloaded with the Planet K app and a brief orientation to the app and associated website.
11275714|NCT02864641|No Intervention|CO Group: Treatment-as-usual|A national sample of CKD participants will be recruited. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet K app and website but will receive email reminders to complete surveys online at each time point.
11275715|NCT02864628|Experimental|Group 1|≥55 year old healthy subjects, receiving either 5x10E7 TCID50 MVA-BN-RSV or Placebo intranasal application
11275716|NCT02864628|Experimental|Group 2|≥55 year old healthy subjects, receiving either 1x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
11275717|NCT02864628|Experimental|Group 3|≥55 year old healthy subjects, receiving either 5x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
11275718|NCT02864628|Experimental|Group 4|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intranasal and intramuscular application
11275719|NCT02864628|Experimental|Group 5|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intramuscular application
11275720|NCT02864615|Experimental|Stereotactic Body Radiation Therapy|Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
11275721|NCT02864602|Experimental|Dexamethasone 2mg|The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
11275722|NCT02864602|Experimental|Dexamethasone 4mg|The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
11275723|NCT02864602|Experimental|Dexamethasone 8mg|The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
11275724|NCT02864589|Experimental|I-HRT|Internet-delivered habit reversal training
11275725|NCT02864589|Experimental|I-ERP|Internet-delivered exposure and response prevention
11275726|NCT02864576|Experimental|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:
~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.
~Aerobic Exercise:
~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
11275727|NCT02864576|Active Comparator|Cognitive Remediation_Health Promotion|"Cognitive Remediation:
~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.
~Health Promotion:
~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
11275728|NCT02864563|Experimental|Prospective cohort|
11275729|NCT02864550|Experimental|Doxycycline arm|Participants in this intervention group will receive doxycycline 100mg orally daily, which is available as a 100mg capsule. This single daily dose was chosen to maximize adherence, given the common use of once-daily Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), as well as its efficacy as once-daily prophylaxis against malaria and its utility as dosing as infrequent as once weekly for another spirochete infection, leptospirosis.
11275730|NCT02864550|Placebo Comparator|Placebo arm|Participants in this control group will receive a placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group.
11275731|NCT02864537|No Intervention|Conventional treatment|Conventional anticoagulation treatment Before enrolment
11275732|NCT02864537|Experimental|Self-management|Trained to monitor INR and dose warfarin
11275733|NCT02864524|Experimental|Manipulative and Massage Therapy|"Ten sessions (2/week):
~High speed and low amplitude technique to lower cervical spine (C3-C4).
~Dog technique flexion for high thoracic area (T1-T4).
~Dog technique flexion for mid-thoracic area (T5-T8).
~Dog technique flexed to low thoracic (T6-T12).
~Classic Massage Therapy during 40 minutes (2 time / week):"
11275734|NCT02864524|Active Comparator|Exercise Program|Ten sessions (2 time/ week): Initial heating and continuing with aerobic and muscle stretching exercises.
11275735|NCT02864511|Experimental|Intervention group|
11275736|NCT02864498|Experimental|1g Oral DS107|1g Oral DS107 to be administered once-daily for 8 weeks.
11275737|NCT02864498|Experimental|2g Oral DS107|2g Oral DS107 to be administered once daily for 8 weeks.
11275738|NCT02864498|Placebo Comparator|Placebo|Placebo orally administered once-daily for 8 weeks.
11275739|NCT02864485|Experimental|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
11275740|NCT02864472|Other|combination Tx|combination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
11275741|NCT02864472|Other|mono Tx|Ranibizumab (at 4 weeks interval) *3 (M0-2) + ranibizumab PRN (M3-6)
11275742|NCT02864459|Experimental|Muscular ultrasound|
11275743|NCT02864433||Controls for non-cholera diarrhea cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
11275744|NCT02864433||Non-cholera diarrhea cases|- Cases of acute watery diarrhea that present for healthcare at the study sites, but that test negative for cholera
11275745|NCT02864433||Controls for cholera cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
11275746|NCT02864433||Cholera cases|- Those with cholera-related diarrhea who present to healthcare at the study sites.
11275781|NCT02864212||Glucose monitoring|Glucose will be monitor in patients using fast-acting insulin.
11275782|NCT02864212||Depth of anesthesia monitoring|Depth of anesthesia will be monitor in patients undergoing cardiac surgery.
11275747|NCT02864420|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vitals and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
11275748|NCT02864420|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
11275749|NCT02864407||Vahelva group|Korean patients with COPD who are newly prescribed with Vahelva Respimat
11275750|NCT02864394|Experimental|Pembrolizumab|Participants with NSCLC receive pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
11275751|NCT02864394|Experimental|Docetaxel|Participants with NSCLC receive Docetaxel 75 mg/m^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue, or consent withdrawal.
11275752|NCT02864381|Experimental|Andecaliximab + Nivolumab|Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
11275753|NCT02864381|Active Comparator|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
11275754|NCT02864368|Experimental|5-day TMZ|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
11275755|NCT02864368|Experimental|21-day TMZ|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
11275756|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
11275757|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
11275758|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
11275759|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
11275760|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
11275761|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
11275762|NCT02864303|Other|Patients with Alzheimer disease|Saliva samples were collected on this patients
11275763|NCT02864290|Experimental|Dose Escalation of ASP1235 (AGS62P1) Schedule A|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 21 days.
11275764|NCT02864290|Experimental|Dose Escalation of ASP1235 (AGS62P1) Schedule B|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose. A cycle is 28 days.
11275765|NCT02864290|Experimental|Dose Expansion of ASP1235 (AGS62P1) Schedule A|Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once every three weeks (Q3W).
11275766|NCT02864290|Experimental|Dose Expansion of ASP1235 (AGS62P1) Schedule B|Once the maximum tolerated dose (MTD) or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion every other week of a 4-week cycle (Q2W).
11275767|NCT02864290|Experimental|Dose Escalation of ASP1235 (AGS62P1) Schedule C|Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once weekly for three weeks of a 4-week cycle to determine the MTD or recommended Phase 2 dose. A cycle is 28 days.
11275768|NCT02864290|Experimental|Dose Expansion of ASP1235 (AGS62P1) Schedule C|Once the MTD or recommended Phase 2 dose has been determined, an expansion cohort of up to 25 subjects may be enrolled. Subjects will receive ASP1235 (AGS62P1) as an intravenous infusion once weekly for three weeks pf a 4-week cycle.
11275769|NCT02864277|No Intervention|No Intervention Conventional Strategy|Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
11275770|NCT02864277|Experimental|ERAS Group|ERAS (enhanced recovery after surgery)
11275771|NCT02864264|Experimental|Single Ascending Dose (SAD) - IV Panel|Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
11275772|NCT02864264|Experimental|Single Ascending Dose (SAD) - SC Panel|Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
11275773|NCT02864264|Experimental|Multiple Ascending Dose (MAD) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
11275774|NCT02864264|Experimental|Proof of Mechanism (POM) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
11275775|NCT02864251|Experimental|Nivolumab+Platinum doublet chemotherapy|
11275776|NCT02864251|Experimental|Nivolumab + Ipilimumab|Enrollment is closed for this arm
11275777|NCT02864251|Active Comparator|Platinum doublet chemotherapy|
11275778|NCT02864238||Pre intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2013 prior to the institution of the electronic milestone pathway
11275779|NCT02864238||post intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2014 after the electronic milestone pathway had been instituted
11275784|NCT02864199|Experimental|Group A: Moderate Renal Impairment|Participants with CrCl 30 to 50 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 micrograms (mcg) via subcutaneous (SC) injection once weekly, in combination with ribavirin, 600 milligrams (mg) orally (PO) daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
11275785|NCT02864199|Experimental|Group B: Severe Renal Impairment|Participants with CrCl <30 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 400 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
11275786|NCT02864199|Experimental|Group C: Hemodialysis/ESRD|Participants requiring hemodialysis will receive 12 weeks of peginterferon alfa-2a, 135 mcg via SC injection once weekly, in combination with ribavirin, 200 mg PO every morning. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
11275787|NCT02864199|Experimental|Group D: Normal Renal Function|Participants with CrCl >80 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 800 to 1200 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
11275788|NCT02864186|Active Comparator|control|Women wont use support bra for six months
11275789|NCT02864186|Active Comparator|surgical support bra|Women will use surgical support bra 24 hours a day for six months
11275790|NCT02864186|Active Comparator|common support bra|Women will use common support bra 24 hours a day for six months
11275791|NCT02864160|Experimental|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
11275792|NCT02864160|Active Comparator|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
11275793|NCT02864147|Experimental|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
11275794|NCT02864147|Active Comparator|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
11275795|NCT02864147|No Intervention|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
11275796|NCT02864121|Experimental|arm 1|all patients included in IDAHO study
11275797|NCT02864108||Those with trisomy 21|People aged 6 months to 89 years old who have some form of trisomy 21.
11275798|NCT02864108||Controls|People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.
11275799|NCT02864095|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
11275800|NCT02864095|Experimental|Topical epinephrine|Topical epinephrine
11275801|NCT02864095|Active Comparator|Control|No epinephrine
11275802|NCT02864082|Other|Group 1|"Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side).
~Part 2: Patients will apply PAT-001, 0.1% to both Treatment Areas."
11275803|NCT02864082|Other|Group 2 (Part 1)|"Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side).
~Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas."
11275804|NCT02864069|Experimental|Walking Intervention|
11275805|NCT02864069|Experimental|Cognitive Training Intervention|
11275806|NCT02864069|Experimental|Combined Intervention|
11275807|NCT02864056|No Intervention|Control|Usual care
11275808|NCT02864056|Experimental|Tai Chi|Completes 50 hours of Tai Chi, a combination of in-class and at-home practise.
11275809|NCT02864043|Other|EGD with NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe following standard of care endoscopy
11275810|NCT02864030|Other|Single arm with Eribulin mesylate|
11275811|NCT02864017|Experimental|L-Citrulline group|Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
11275812|NCT02864017|Placebo Comparator|Control group|Enteral nutrition 5-day placebo treatment
11275813|NCT02864004|Experimental|APO group|An apomorphine pump will be installed and adjusted. The target dose corresponds to the patient's individual optimized dose :maximum dose of 10 mg/hour for 16 hours
11275814|NCT02864004|Active Comparator|Control group|Patients will be optimally treated with oral dopaminergic therapy to obtain the best medical treatment (BMT) defined as the most efficient single treatment options or their combination.
11275815|NCT02863991|Experimental|ONC201|Single agent ONC201.
11275816|NCT02863978|Experimental|Digi-NewB Cohort|Multimodal signal acquisitions
11275817|NCT02863965||High definition endoscopy and optic enhancement|All the patients underwent routine preparation before the procedure. The detected lesions in high definition endoscopy were observed with optic enhancement mode. The endoscopist was required to give the real-time descriptions of surface pit patterns of the lesions, based on surface pattern classification. After that, biopsy specimens will be obtained respectively by forceps from each detected lesion recorded for histologic diagnosis.
11275855|NCT02863640||Exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
11275818|NCT02863952|Other|EARLY POST-STRESS EF CHANGE|There is only a single arm. All patients undergoing the routine myocardial perfusion SPECT study will also have additional (earlier) image acquisition in order to assess the relation of early wall motion abnormalities to the severity of myocardial ischemia.
11275819|NCT02863939|Other|NICAS|There is only one arm - a single cohort. All patients undergoing the nuclear stress test will also have the NICAS evaluation.
11275820|NCT02863926|Experimental|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
11275821|NCT02863926|Experimental|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
11275822|NCT02863926|Experimental|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
11275823|NCT02863913|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
11275824|NCT02863913|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.
~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
11275825|NCT02863900|Experimental|Experimental arm|subtypes of BC (namely luminal A and luminal B, HER2+, TN)
11275826|NCT02863887|Experimental|Weight loss intervention|Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.
11275827|NCT02863887|Experimental|Delayed Treatment Control Group|Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.
11275828|NCT02863874|Active Comparator|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
11275829|NCT02863874|Active Comparator|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
11275830|NCT02863861|Experimental|Group PK|Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed.
11275831|NCT02863861|Experimental|Group DK|Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required
11275832|NCT02863848|Placebo Comparator|Placebo|Maltodextrin 2g, twice per day, 6 weeks
11275833|NCT02863848|Active Comparator|Inulin-type fructans|Orafti inulin-type fructans 2g, twice per day, 6 weeks
11275834|NCT02863835|Experimental|Intervention 1|"A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.
~Each participant will then have continuous assessment of the following whilst self venting:
~Spirometry - FEV1, FVC, MVV
~Muscle strength measurements: MIP, MEP, SNIP
~Borg scale, mMRC, Visual Analogue Scale for breathlessness
~Electrical impedance tomography
~EMGpara
~Transcutaneous measurement of CO2 and 02 level
~End-tidal CO2 monitoring
~Pneumotachography"
11275835|NCT02863822|Experimental|Low FODMAP|Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.
11275836|NCT02863822|Active Comparator|Choose My Plate|Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
11275837|NCT02863809|Experimental|Active Treatment Arm|De-epithelialized corneas cross-linked with riboflavin 0.1% and dextran 20% solution AND ultraviolet A light (UVA Light Source).
11275838|NCT02863809|Active Comparator|Control Treatment Arm|De-epithelialized corneas will be exposed to only riboflavin 0.1% with dextran 20% solution (NO ultraviolet A light).
11275839|NCT02863783|Experimental|Fiducial Placement|EUS with Fiducial Placement into Tumor
11275840|NCT02863770|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
11275841|NCT02863757||CHB Group|Patients with chronic hepatitis B
11275842|NCT02863757||CHB/NAFLD Group|Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
11275843|NCT02863757||NAFLD Group|Patients with nonalcoholic fatty liver disease
11275844|NCT02863744|Experimental|CAF+SCTG|
11275845|NCT02863731|Experimental|Alternating postures: first day|Alternating body postures on the first day of measurement. Sitting body posture on the second day of measurement.
11275846|NCT02863731|Experimental|Alternating postures: second day|Alternating body postures on the second day of measurement. Sitting body posture on the first day of measurement.
11275847|NCT02863731|No Intervention|Control group|Sitting body posture on both days of measurement.
11275848|NCT02863718|No Intervention|Watch & wait|Watch & wait
11275849|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
11275856|NCT02863640||Non exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
11275857|NCT02863627|Experimental|Newborn Care Pathway|two telephone interviews conducted after the emergency department visit will be used to gather data to meet the objectives of this study.
11275858|NCT02863614|Experimental|Ibuprofen+Lorazepam|Oral ibuprofen (600 mg) + lorazepam (1 mg); one hour before endometrial scratching.
11275859|NCT02863614|Active Comparator|Ibuprofen|Oral ibuprofen (600 mg) + Placebo; one hour before endometrial scratching.
11275860|NCT02863614|Placebo Comparator|Placebo|Placebo + Placebo; one hour before endometrial scratching.
11275861|NCT02863588|Experimental|seropositive for Toxoplasma gondii|
11275862|NCT02863575|Experimental|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
11275863|NCT02863575|Active Comparator|Ibuprofen|Ibuprofen 400 mg
11275864|NCT02863575|Placebo Comparator|Placebo|Placebo comparator
11275865|NCT02863562|Experimental|Group 1|"This group included 16 subjects. They received kinesio taping for both ankle joints and and performed proprioceptive exercises.
~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training."
11275866|NCT02863562|Experimental|Group 2|"This group received placebo kinesio taping for ankle joint (no tension) and performed proprioceptive exercises.
~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training in the same way as before but with no tension. It was removed on the second day of training."
11275867|NCT02863562|Experimental|Group 3|This group received kinesio taping for ankle joint. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training.
11275868|NCT02863536|Other|Polybactum®|"Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.
~Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis."
11275869|NCT02863523|Experimental|Integrated Behavioral Intervention|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
11275870|NCT02863523|No Intervention|Usual Care|Patients receive usual care
11275871|NCT02863510|Experimental|Renal Denervation|Participation receiving renal sympathetic denervation
11275872|NCT02863497|Active Comparator|Mindfulness Intervention|For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
11275873|NCT02863497|No Intervention|No Intervention|For those who are not in the intervention group they will simply be asked to fill the initial questionnaire and the 3 month post questionnaire. They will not participate in any other questionnaires.
11275874|NCT02863484|Active Comparator|Conventional surgery intra-dural|This arm will be surgically operated by direct attack of the tumour after opening the dura
11275875|NCT02863484|Experimental|Pealing surgery extra-dural|This arm the pealing of the outer layer of the lateral wall of the cavernous sinus will be done before the dura is opened. After the pealing is completed, the middle meningeal artery will be divided at the foramen spinosum. Then, the dura will be opened and the tumour attacked.
11275876|NCT02863471|Experimental|Gemcitabine|1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes
11275877|NCT02863445|Active Comparator|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
11275878|NCT02863445|Experimental|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
11275879|NCT02863419|Experimental|Oral Semaglutide|
11275880|NCT02863419|Active Comparator|Liraglutide|
11275881|NCT02863419|Placebo Comparator|Placebo|
11275882|NCT02863406|Experimental|Healthy volunteers|Bronchoalveolar lavage in healthy volunteers
11275883|NCT02863406|Experimental|Patients suffering from sarcoidosis|Bronchoalveolar lavage in patients suffering from sarcoidosis
11275884|NCT02863393|Experimental|Diaphragmatic breathing exercise|The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.
11275885|NCT02863380|Experimental|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.
~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
11275886|NCT02863380|Active Comparator|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
11275923|NCT02863120|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants
11277203|NCT02854280|Active Comparator|Healthy Volunteers|36 control patients
11275887|NCT02863380|Active Comparator|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
11275888|NCT02863367|Experimental|Treatment group|Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
11275889|NCT02863354|Experimental|Q4WKS|Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections.
11275890|NCT02863354|Experimental|Q12WKS|Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.
11275891|NCT02863341|Experimental|naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
11275892|NCT02863341|No Intervention|naive Wait-list Control arm|
11275893|NCT02863341|Experimental|non-naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
11275894|NCT02863341|No Intervention|non-naive Wait-list Control arm|
11275895|NCT02863328|Experimental|14 mg oral semaglutide|
11275896|NCT02863328|Active Comparator|25 mg empagliflozin|
11275897|NCT02863315|Experimental|tsDCS|In the tsDCS group, anodal tsDCS will be applied for 20 minutes.
11275898|NCT02863315|Placebo Comparator|sham|In sham tsDCS group, the current of anodal tsDCS will be discontinued after 30 s while the power indicator remained on for 20 minutes.
11275899|NCT02863302|Experimental|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment until the end of hospitalization.
11275900|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
11275901|NCT02863276|Experimental|Intensified insulin group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
11275902|NCT02863276|No Intervention|Control group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses
11275903|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
11275904|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
11275905|NCT02863250||Massively transfused patients|Patients (18+ years) who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red cells in any 4 hour period)
11275906|NCT02863237||weaning failure group|Patients reconnected to the ventilator within 48 hours after SBT will be designated the weaning failure group
11275907|NCT02863237||weaning success group|Patients who pass the SBT and breathing without ventilator support within 48 hours are designated the weaning success group
11275908|NCT02863224||Healthy control|
11275909|NCT02863224||Ocular hypertension|
11275910|NCT02863224||Primary open angle glaucoma|
11275911|NCT02863224||Normal tension glaucoma|
11275912|NCT02863211||HAPPY Hearts Cohort|One-thousand women 55 years of age or older will be recruited to be screened through the HAPPY Hearts protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
11275913|NCT02863198|Active Comparator|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
11275914|NCT02863198|No Intervention|non endometrial injury|non endometrial injury was done only for patient of the control group
11275915|NCT02863185|Experimental|Pitavastatin group|Use of 2mg or 4mg Pitavastatin
11275916|NCT02863185|Active Comparator|Atorvastatin group|Use of 10mg or 20mg Atorvastatin
11275917|NCT02863172||Consenting Proband Group|Questionnaires completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
11275918|NCT02863172||Family Members (MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
11275919|NCT02863172||Family Members (Not MDA Registered Patients) Group|Health questionnaire completed at baseline. Blood sample taken at baseline. Follow-up questionnaire completed at least 1 time in 5 years.
11275920|NCT02863159|Active Comparator|Treatment Group 1|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +3.25D (ZLB00) in their non-dominant eye.
11275921|NCT02863159|Active Comparator|Treatment Group 2|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +4.00D (ZMB00) in their non-dominant eye.
11275922|NCT02863133|Experimental|Easyx Liquid Embolic|embolization of intracranial malformations and fistulas and brain tumours with Easyx Liquid Embolic
11275924|NCT02863120|Active Comparator|Adductor canal and tibial nerve block|Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour
11275925|NCT02863107||Observational (questionnaire, biospecimen collection)|"PATIENTS: Patients complete questionnaires over 30-50 minutes about work, family history, medical history, health habits, and experience as a cancer survivor (quality of life, well-being, concerns, types of health care, and follow-up care received). Patients also undergo collection of blood or saliva samples. Active patients, who have undergone treatment at MD Anderson Cancer Center within the past year, complete additional questionnaires at 6 and 12 months after treatment completion, and then every year for up to 5 years. Patients, who have completed treatment over 1 year ago or were diagnosed over the age of 65, complete questionnaires every year for up to 5 years. Patients medical records are also reviewed.
~FAMILY MEMBERS: Participants complete questionnaires over 10-15 minutes. Participants also undergo collection of blood or saliva samples once."
11275926|NCT02863094|Active Comparator|Real Stimulation|The continuous theta burst stimulation (cTBS) protocol lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. In the cTBS session, this 40s protocol was repeated for three times (1800 pulses in total) separated by two 15 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
11275927|NCT02863094|Sham Comparator|Placebo Stimulation|The procedure of this protocol was performed by a placebo coil. Each session lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first sham TBS session and after the last sham TBS session.
11275928|NCT02863081||Healthcare providers|All healthcare providers working in the participating LTACH will be asked to complete 2 surveys and invited to participate in focus group meetings
11275929|NCT02863081||Patients|81 LTACH patients will be enrolled over the course of a 9 month period. Each patient and their LAR will be interviewed at the time of LTACH admission to garner information about their pre hospitalization physical, functional, and cognitive health status. Each day enrolled patients will undergo daily symptom assessments and medical record reviews. At the time of LTACH discharge all enrolled patients will be interviewed again to garner information about their discharge physical, functional, and cognitive health status.
11275930|NCT02863068|Placebo Comparator|control|patients will receive placebo and standard of care
11275931|NCT02863068|Experimental|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
11275932|NCT02863055|Experimental|Nintedanib|200 mg twice a day per os
11275933|NCT02863055|Placebo Comparator|Placebo|Placebo match twice a day per os
11275934|NCT02863042|Experimental|Deltoid Tendon Repaired|Repair Deltoid Tendon
11275935|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|
11275936|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
11275937|NCT02863016||Concentrate SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)
11275938|NCT02863016||Concentrate SelectBag Citrate|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)
11275939|NCT02862990||Pre menopausal women with breast cancer|Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy
11275940|NCT02862977|Experimental|EMS association|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h.
11275941|NCT02862977|Active Comparator|Miosan Caf®|The patient will take 2 tablets (combination of Cyclobenzaprine and caffeine), oral, per day, each 12h.
11275942|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
11275943|NCT02862951||Term pregnancy (>37 weeks gestation)|Term pregnancy (>37 weeks gestation)
11275944|NCT02862938|Experimental|NT-501 ECT Implant|"On eligible participants that are randomized to this group, the NT-501 Investigational product will be implanted in the study eye, and participants will be followed for 24 months.
~The investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary neurotrophic factor (CNTF) receptor after intraocular implantation."
11275945|NCT02862938|Sham Comparator|Sham|To maintain masking, participants randomized to this group receive sham surgery and will be followed for 12 months. Following analysis of the 6 month data, if the open label extension (OLE) is not triggered, patients in the control group will continue on the original study schedule timeline trough month 24. If OLE is triggered participants will be offered the NT-501 ECT investigational product and will followed for additional 12 months.
11275946|NCT02862925|No Intervention|Pre-Intervention|A consecutive sample of 350 patients will be collected. After informed consent, data will be abstracted from the patient's record including day and time of delivery, method of delivery, parity, gestational age, meconium presence, heart rate abnormality and induction methods. For CD, the following data will be collected: decision-to-delivery time, Partogram adherence, time of each FSST, Apgar score, date and time of delivery and Comorbidities such as: Hypertension-spectrum disorders, Malaria, Postpartum Hemorrhage, Macrosomia, History of CD, Diabetes, Sickle Cell, and HIV status.
11275947|NCT02862925|Experimental|Post-intervention|The study will take place on the labor ward at KCMC in Moshi, Tanzania. It will involve women who present to the labor ward in labor or who undergo an induction of labor. A consecutive sample of 350 patients will be collected. Study investigators will be present for 24 hours a day, 7 days a week on a rotating schedule during the enrollment period. All patients who fit inclusion and exclusion criteria will be approached if they are deemed medically stable.
11275948|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
11276429|NCT02859493|Active Comparator|Saccharomyces cerevisiae|Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
11275949|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
11275950|NCT02862899|Experimental|Heating cable|
11275951|NCT02862886|Other|N°1|
11275952|NCT02862873|Experimental|Ondansetron|
11275953|NCT02862873|Placebo Comparator|Saline solution|
11275954|NCT02862860|Experimental|patients with type-1 diabetes|
11275955|NCT02862860|Placebo Comparator|Controls|
11275956|NCT02862847||gastroenteritis|
11275957|NCT02862847||control|
11275958|NCT02862834||patients with poikiloderma|
11275959|NCT02862821|Experimental|validation of EEfRT task|20 healthy volunteers will be recruted to validate motivation EEfRT task which is adaptated to HR-EEG
11275960|NCT02862821|Experimental|biomarkers identification|20 addict online poker gamblers and 20 non-addict online poker gamblers will be recruted : After standardized questionnaires to define the socio-demographic data, the diagnosis of gambling addiction (Diagnostic and Statistical Manual of Mental Disorder 5th edition DSM-5), screening for comorbidities addictive, the level of anxiety and impulsivity, brain acvtivity will be registred (by randomisation between the 2 tasks) with HR-EEG: during the performance of a task of motivation evaluation laboratory (EEfRT) adaptated for high-resolution electroencephalography AND during a laboratory task that assesses decision making in conditions of uncertainty (IGT) with its version for high-resolution electroencephalography has already been validated in a previous study (Giustiniani et al., 2015).
11275961|NCT02862821|Experimental|biomarkers validation|13 online poker gamblers will be recruted, independently of their dependance profile and they will realize the same task that in precedent arm (quaestionnaires and 2 tasks adaptated to HR-EEG).
11275962|NCT02862795|Other|HPV detection in anal canal samples|
11275963|NCT02862782|Experimental|hCG|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono)
11275964|NCT02862782|Experimental|hCG + GnRH agonist|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono) and GnRH agonist - Gonadotropin - releasing hormone (Decapeptyl 0.2mg - Ferring Gmgh)
11275965|NCT02862769|Experimental|Lidocaine infusion|first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion
11275966|NCT02862769|Placebo Comparator|Saline Infusion|The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.
11275967|NCT02862756|Experimental|patient with endovascular treatment|
11275968|NCT02862743|Experimental|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
11275969|NCT02862730|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
11275970|NCT02862730|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
11275971|NCT02862730|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
11275972|NCT02862730|Active Comparator|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
11275973|NCT02862717||Hemodialysis (HD)|HD patients in MOH dialysis centres notified to NRR.
11275974|NCT02862717||Continuous ambulatory peritoneal dialysis (CAPD)|CAPD patients in MOH dialysis centres notified to NRR.
11275975|NCT02862704|Experimental|MG7-CART|A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance. The dose is 1-6x108 MG7-CAR positive T cells. The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
11275976|NCT02862691|Active Comparator|Oral analgesic|2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
11275977|NCT02862691|Experimental|Injectable local anesthetic|local injection or nerve block with bupivicaine 0.5%
11275978|NCT02862678|Experimental|Patients with head and neck squamous cell carcinoma|
11275979|NCT02862665|Experimental|IV iron|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
11275980|NCT02862665|Placebo Comparator|Control|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
11275981|NCT02862652|Experimental|children with acute lymphoblastic leukemia|
11275982|NCT02862639|Experimental|injection of viscosupplementation and corticosteroid|experimental group
11275983|NCT02862639|Active Comparator|injection of corticosteroid|control group
11275984|NCT02862613|Experimental|Precision Cells|"Precision Cells combined with Transcatheter Arterial Chemoembolization:
~Transcatheter Arterial Chemoembolization:
~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
11275985|NCT02862613|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
11276087|NCT02861911|Sham Comparator|Control group|The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
11275986|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
11275987|NCT02862587|Experimental|Precision Cells|"precision cells combined with Chemotherapy treatment:
~Chemotherapy:
~once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods."
11275988|NCT02862587|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
11275989|NCT02862574|Experimental|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
11275990|NCT02862574|Experimental|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
11275991|NCT02862574|Placebo Comparator|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
11275992|NCT02862574|Experimental|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
11275993|NCT02862561|Experimental|Precision Cell Immunotherapy|"Precision Cells combined with Chemotherapy treatment: Chemotherapy:
~once a week with a total of six times before 60 days prior to the start of drawing blood. Precision Cells：once per 3 weeks with a total of three periods."
11275994|NCT02862561|Active Comparator|Chemotherapy|"Chemotherapy:
~once a week with a total of six times before 60 days prior to the start of drawing blood."
11275995|NCT02862548|Experimental|TAF|TAF for 48 weeks
11275996|NCT02862548|Active Comparator|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
11275997|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF for an additional 144 weeks.
11275998|NCT02862535|Experimental|Andecaliximab Monotherapy (Cohort 1)|Up to 6 participants will receive andecaliximab 800 mg until disease progression. If 2 or more participants experience dose limiting toxicities (DLT) within the first 28 days, up to 6 additional participants will be enrolled to receive andecaliximab 600 mg. If 2 additional DLTs occur at 600 mg, the study will be discontinued.
11275999|NCT02862535|Experimental|Combination Therapy Andecaliximab and SP (Cohort 2)|Up to 6 participants will receive andecaliximab 800 mg until disease progression in combination with S-1 plus cisplatin (SP) chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice and/or the in-country label). The dose of andecaliximab is based on safety data from cohort 1.
11276000|NCT02862535|Experimental|Combination Therapy Andecaliximab and SOX (Cohort 3)|Up to 10 participants will receive andecaliximab 1200 mg until disease progression in combination with 80 mg/day to 120 mg/day S-1 depending on body surface area (BSA) plus 100mg/m^2 oxaliplatin (SOX) chemotherapy. The dose of andecaliximab is based on safety data from cohort 1 and other ongoing phase 1 studies of andecaliximab.
11276001|NCT02862535|Experimental|Combination Therapy Andecaliximab and Nivolumab (Cohort 4)|Up to 10 participants will receive andecaliximab 800 mg until disease progression in combination with 3 mg/kg nivolumab chemotherapy. The dose of andecliximab is based on safety data from cohort 1.
11276002|NCT02862522||Women With CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
11276003|NCT02862522||Women Without CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
11276004|NCT02862509|Experimental|Budesonide nasal instillation|budesonide(0.5mg/2ml) 1 respule plus normal saline solution 120ml instilled in vertex to floor position daily
11276005|NCT02862509|Placebo Comparator|Normal saline nasal instillation|Normal saline solution instilled in vertex to floor position daily
11276006|NCT02862496||hyperemesis gravidarum|hyperemesis gravidarum group consisting of 30 pregnant women between 7-20 weeks of gestation with diagnosed hyperemesis gravidarum.
11276007|NCT02862496||Control group|control group consisting of 30 health pregnant women between 7-20 weeks of gestation with excluded hyperemesis gravidarum.
11276008|NCT02862483|Experimental|Experimental|Tamsulosin 0.2mg and Tadalafil 5mg
11276009|NCT02862483|Active Comparator|Comparator|placebo for Tamsulosin 0.2mg and Tadalafil 5mg
11276010|NCT02862457|Experimental|Epacadostat (Epacad)|Cycle 1 is a dose escalation study in which participants will receive 25, 100, or 300 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 with a washout on Days 6 and 7. On Day 8 of Cycle 1 participants will receive a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25, 100, or 300 mg of epacadostat orally BID on Days 8-28. For Cycles 2 through 35 participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25, 100, or 300 mg of epacadostat orally BID on Days 1-21.
11276011|NCT02862457|Experimental|Epacad+Pembrolizumab (Pembro)|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25, 100, or 300 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles.
11276012|NCT02862457|Experimental|Epacad+Pembro+Cisplatin+Pemetrexed|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of 75 mg/m^2 Cisplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.
11276013|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Pemetrexed|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of Area Under the Curve (AUC) 5 Carboplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.
11276014|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Paclitaxel|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of AUC6 Carboplatin and 200 mg/m^2 Paclitaxel on Day 1 for the first 4 cycles.
11276015|NCT02862444||intervention group|Culturally Appropriate Intervention
11276016|NCT02862431|Experimental|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
11276017|NCT02862431|Experimental|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
11276018|NCT02862431|Experimental|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
11276019|NCT02862431|Experimental|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
11276020|NCT02862418||Pulmonary disease|UTE MRI
11276021|NCT02862418||Control|UTE MRI
11276022|NCT02862405||Patients with loss of central vision|Patients coming in ophthalmic consultation will be selected for the study. The diagnosis of this disease is based on clinical examination, and imaging of the retina.Patients with only loss of central vision will be selected.
11276023|NCT02862405||Patients with loss of peripheral vision|Patients coming in ophthalmic consultation will be selected for the study. Patients with loss of peripheral vision will be selected on the bases of presence of tunnel vision.
11276024|NCT02862405||Control group|Patients without loss of vision.
11276025|NCT02862379|Experimental|Elderly patients that fall|Personalized rehabilitation program for elderly patients that fall for the first time. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors.
11276026|NCT02862366||Primary Myelofibrosis (PMF)|Blood sampling during routine visit
11276027|NCT02862366||Essential thrombocytosis (ET)|Blood sampling during routine visit
11276028|NCT02862366||Polycythemia vera (PV)|Blood sampling during routine visit
11276029|NCT02862353||patients with thrombocytopenia drug|
11276030|NCT02862340|Other|Autistic disorder|Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
11276031|NCT02862327|Active Comparator|intravenous dexamethasone|intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
11276032|NCT02862327|Placebo Comparator|intravenous placebo|intravenous injection of 2ml of NaCl 0.9% during regional anesthesia
11276033|NCT02862314|Experimental|procalcitonin group|The procalcitonin concentration is measured at inclusion.
11276034|NCT02862314|No Intervention|control group|Concentrations of procalcitonin are not measured. .
11276035|NCT02862301|Other|Control group|Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
11276036|NCT02862301|Experimental|CIS group|patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.
11276037|NCT02862288|Experimental|Renal tumor|Microwave ablation of renal tumor
11276038|NCT02862288|Experimental|Lung tumor|Microwave ablation of lung tumor
11276039|NCT02862288|Experimental|Bone tumor|Microwave ablation of bone tumor
11276040|NCT02862275|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity.
11276041|NCT02862262|Experimental|Blinded, Prospective Arm (1)|Clinical performance of the ARIES Bordetella Assay for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.
11276042|NCT02862262|Experimental|Blinded, Pre-selected Arm (2)|In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance of the ARIES Bordetella Assay will be tested using banked, pre-selected, positive clinical specimens.
11276043|NCT02862262|Experimental|Blinded, Contrived Arm (3)|Contrived specimens will be tested using the ARIES Bordetella Assay to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.
11276044|NCT02862249|Experimental|Faecal microbiota transplantation|Faecal microbiota transplantation.
11276045|NCT02862249|Placebo Comparator|Placebo|Placebo solution.
11276046|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 250 mg)|
11276047|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 500 mg)|
11276048|NCT02862223|Experimental|Neoprinol|
11276049|NCT02862210|Experimental|Lithium carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
11276050|NCT02862210|Placebo Comparator|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.
11276051|NCT02862197||study group|hemodialysis treated patients as described in the inclusion of the study
11276052|NCT02862171|Experimental|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
11276053|NCT02862158|Experimental|Experimental|FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss
11276054|NCT02862145|Experimental|Treatment with MRX34|Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
11276055|NCT02862132|Experimental|Vedolizumab|IV Vedolizumab 177mg/m2 Body Surface Area (BSA), max. 300mg Induction regimen: 0,2,6 and then every 8 weeks
11276056|NCT02862119|Experimental|FFR Treatment Arm|"Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of >0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued.
~Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study."
11276057|NCT02862119|Active Comparator|Conservative Treatment Arm|Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
11276058|NCT02862106|Experimental|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
11276059|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
11276060|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
11276061|NCT02862106|No Intervention|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
11276062|NCT02862106|No Intervention|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
11276063|NCT02862106|No Intervention|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
11276064|NCT02862093|Active Comparator|Deep rTMS|The intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
11276065|NCT02862093|Placebo Comparator|Placebo|The sham stimulation consisted of rTMS sessions without an effective instrument operation.
11276066|NCT02862054|Experimental|Splenectomy|Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
11276067|NCT02862041|Active Comparator|Group Echogenic|Ultrasound guided infraclavicular brachial plexus block with Pajunk sonoplex echogenic needle
11276068|NCT02862041|Placebo Comparator|Group Nonechogenic|Non echogenic needle group, ultrasound guided infraclavicular brachial plexus block with Stimuplex Braun non echogenic needle
11276069|NCT02862028|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
11276070|NCT02862015|Experimental|Oncothermia|Patients with oncothermia treatment and palliative chemotherapy
11276071|NCT02862015|Active Comparator|Control|Patients with palliative chemotherapy only
11276072|NCT02862002|Experimental|"Therapeutic Patient Education (E.T.P)of type caratif"|Patients in arm E.T.P benefit of the nursing consultation E.T.P,
11276073|NCT02862002|Active Comparator|standard care|patients receiving standard care of cancer pain.
11276074|NCT02861989||Osteoporotic women|women over 50 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
11276075|NCT02861989||At risk women|women over 50 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
11276076|NCT02861989||Osteoporotic men|Men over 60 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
11276077|NCT02861989||At-risk men|Men over 60 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
11276078|NCT02861989||General practitioners|General practitioners from the Rhône area, France
11276079|NCT02861963|Experimental|Right ventricle outflow tract reconstruction|RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure
11276080|NCT02861963|Active Comparator|Systemic-to-pulmonary artery shunts|systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)
11276081|NCT02861950|Active Comparator|Caudal block|Patients will receive a caudal block with 0.75-1ml/kg of 0.2% ropivacaine.
11276082|NCT02861950|Active Comparator|Penile Nerve Block|Patients will receive a dorsal penile nerve block with up to 0.75ml/kg of 0.25% bupivacaine.
11276083|NCT02861937|No Intervention|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
11276084|NCT02861937|Active Comparator|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)
~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)
~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
11276085|NCT02861937|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.
~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
11276086|NCT02861924|Experimental|microcirculatory responses|"Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).
~A pressure is applied to the subject's arm. this causes a localized ischemia. the measures responses to this ischemia will be made by the imager speckle (LSCI) give the microvascular perfusion data."
11276088|NCT02861911|Active Comparator|Active NMES group|Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).
11276089|NCT02861898|Experimental|Intra-arterial Cetuximab after BBBD|Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2
11276090|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
11276091|NCT02861872||IP Patients|women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy will be studied.
11276092|NCT02861859|Placebo Comparator|Placebo Comparator|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4).
~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle,), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4)."
11276093|NCT02861859|Active Comparator|Olanzapine|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO, OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4).
~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4)."
11276094|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
11276095|NCT02861833||Patients with a cancerous wound|major patients followed in a cancer ward and holders of a cancerous wound.
11276096|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:
~Complete a diagnostic screening interview at baseline.
~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.
~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.
~Complete 9 follow-up phone calls to assess for relapse."
11276097|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:
~Complete a diagnostic screening interview at baseline.
~Complete questionnaires and computer tasks at baseline and 2 month time points.
~Complete MRI brain imaging data collection at the baseline and 2 month time points."
11276098|NCT02861807|Experimental|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
11276099|NCT02861807|Sham Comparator|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
11276100|NCT02861794|Other|GMK Sphere|Patients receive a GMK Sphere Total Knee Replacement.
11276101|NCT02861781||Type 2 diabetes|Type 2 diabetes according to ADA criteria
11276102|NCT02861781||Insulin resistance non diabetes|HOMA-IR criteria ≥ 3
11276103|NCT02861781||Insulin sensitivity non diabetes|HOMA-IR criteria < 3
11276104|NCT02861768|Experimental|diagnosis of M.tuberculosis infection|
11276105|NCT02861755|Experimental|Arm 1|The MARIGOLD positive emotions course plus a blend of enhancements to include: 5-minutes of weekly facilitator contact, online discussion board, or gamification through virtual flower badges.
11276106|NCT02861755|Experimental|Arm 2|Emotion reporting control condition. Reporting daily emotions for the same duration of the online emotions course.
11276107|NCT02861742|Other|Study procedure|Delivery of questionnaires, Questionnaire T1 to fill, Questionnaire T2 to fill, Questionnaire T3 to fill, Questionnaire T4 to fill, Questionnaire T5 to fill
11276108|NCT02861729|Experimental|Suprinity|Vita Suprinity® (VITA Zahnfabrik H. Rauter GmbH & Co.KG- Germany) Zirconia reinforced lithium silicate PCRs
11276109|NCT02861729|Active Comparator|e.max|IPS-e.max® CAD (Ivoclar Vivadent AG, Schaan - Liechtenstein) lithium disilicate PCRs
11276110|NCT02861716|Experimental|fentanyl and dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl and dexmedetomidine in 2ml volume will be injected slowly over 20 seconds.
11276111|NCT02861716|Active Comparator|dexmedetomidine and placebo for fentanyl|intrathecal bupivacaine (0.5%) 0.4mg/kg plus dexmedetomidine 0.2 μg/kg in 2ml volume and placebo (for fentanyl 0.2 μg/kg) it will be injected slowly over 20 seconds.
11276112|NCT02861716|Active Comparator|fentanyl and placebo for dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl 0.2 μg/kg in 2ml volume and placebo (for dexmedetomidine 0.2 μg/kg) it will be injected slowly over 20 seconds.
11276113|NCT02861703|Experimental|Online lifestyle intervention|"A weekly psychosocial intervention (Online Lifestyle Intervention) delivered in an online group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
11276114|NCT02861690|Experimental|Treatment group|patients received Liposomal Paclitaxel and Nedaplatin every 21 days until the presence of progressive disease or unacceptable toxicity
11276115|NCT02861677|No Intervention|Control group|The control group will receive the usual medical care by physicians and nurses
11276116|NCT02861677|Experimental|Intervention group|the intervention group will receive clinical pharmacy services
11276117|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
11276291|NCT02860481|Other|second cohort : 100 patients|Patients with breast cancer of with ovarian and/or endometrial cancer
11276118|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
11276119|NCT02861638|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
11276120|NCT02861638|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
11276121|NCT02861625||Group A|letter of condolence offering to the reliable person a post-death consultation with the reference physician (sent between J15 and J30 post death)
11276122|NCT02861625||Group B|no intervention, i.e without a letter of condolence proposing a consultation with the reference physician
11276123|NCT02861612||Nerve Transfer|This is an observational study that looks at function and quality of life in patients before and after nerve transfer surgery.
11276124|NCT02861599|Experimental|proprioceptive therapy|
11276125|NCT02861599|Placebo Comparator|speech therapy|
11276126|NCT02861586|Experimental|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276127|NCT02861586|Active Comparator|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276128|NCT02861586|Experimental|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276129|NCT02861586|Active Comparator|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276130|NCT02861586|Experimental|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276131|NCT02861586|Experimental|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276132|NCT02861586|Experimental|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276133|NCT02861586|Experimental|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.
~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
11276134|NCT02861573|Experimental|pembrolizumab+olaparib|Participants with adenocarcinoma (AC) mCRPC in Cohort A will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablets by mouth (PO) twice a day (BID) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with olaparib will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
11276135|NCT02861573|Experimental|pembrolizumab+docetaxel+prednisone|Participants with AC mCRPC in Cohort B will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel 75 mg/m^2 IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Participants will only be permitted to receive a maximum of 10 cycles of docetaxel and prednisone. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
11276136|NCT02861573|Experimental|pembrolizumab+enzalutamide|Participants with AC mCRPC in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
11276137|NCT02861573|Experimental|pembrolizumab+abiraterone+prednisone|Participants with AC mCRPC in Cohort D will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
11276138|NCT02861573|Experimental|pembrolizumab+lenvatinib: AC|Participants with AC mCRPC in Cohort E will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
11276292|NCT02860468|Experimental|Cranberry juice consumption|participants in this arm will be provided cranberry juice to consume for 21 days in total
11276139|NCT02861573|Experimental|pembrolizumab+lenvatinib:t-NE|Participants with neuroendocrine (t-NE) mCRPC in Cohort F will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
11276140|NCT02861573|Experimental|MK-7684A (coformulation of pembrolizumab+vibostolimab):AC|Participants with AC mCRPC in Cohort G will receive MK-7684A, a coformulation fixed dose combination of 200 mg MK-7684 (vibostolimab) and 200 mg pembrolizumab Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
11276141|NCT02861573|Experimental|MK-7684A (coformulation of pembrolizumab+vibostolimab):t-NE|Participants with t-NE mCRPC in Cohort H will receive MK-7684A, a coformulation fixed dose combination of 200 mg MK-7684 (vibostolimab) and 200 mg pembrolizumab Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
11276142|NCT02861573|Experimental|pembrolizumab+carboplatin+etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 1 will receive pembrolizumab 200 mg IV on Day 1 Q3W + carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 Q3W + etoposide 100 mg/m^2 IV on Days 1, 2, and 3 Q3W. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 or 2 of the 3 drugs due to adverse events in the combination may continue the study with the other combination drug/drugs.
11276143|NCT02861573|Experimental|carboplatin+etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 2 will receive carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 Q3W + etoposide 100 mg/m^2 IV on Days 1, 2, and 3 Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
11276144|NCT02861560|Experimental|dHACM|Dehydrated human amnion/chorion membrane (dHACM)
11276145|NCT02861547||Traumatic brain injury|
11276146|NCT02861534|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
11276147|NCT02861534|Placebo Comparator|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
11276148|NCT02861521|Experimental|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
11276149|NCT02861521|Sham Comparator|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
11276150|NCT02861508|Active Comparator|Usual care|Usual care as determined by treating team. Ultrasound may still be part of the workup per the treating team's discretion.
11276151|NCT02861508|Experimental|Early POCUS|Point-of-care ultrasound protocol will involve cardiac views (for pericardial effusion, left ventricular function, left and right ventricular equality, aortic root dilation, and inferior vena cava status), lung views (for pneumothorax, signs of alveolar interstitial syndrome), abdominal views for free fluid, and a view of the abdominal aorta for aneurysm.
11276152|NCT02861495|Experimental|humeral nail|Surgical fixation with a humeral compression/distraction nail.
11276153|NCT02861482|Experimental|Bakri Ballon|All the enrolled patients who would undergo the laying of Bakri Balloon
11276154|NCT02861469||Main carers|Individual semi-structured interviews
11276155|NCT02861469||General practitioners|Individual semi-structured interviews
11276156|NCT02861456|Active Comparator|Standard Care Group|Patient in the treatment arm will receive the Standard Model of Care as prescribed for their condition by their physician including but not limited to Advanced imaging, Rest, Bracing, Physical Therapy, and Medication.
11276157|NCT02861456|Experimental|Functional Progression Group|Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
11276158|NCT02861430||Patients|
11276159|NCT02861417|Experimental|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
11276160|NCT02861417|Experimental|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
11276161|NCT02861417|Experimental|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score > 3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
11276162|NCT02861417|Experimental|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score >3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
11276163|NCT02861417|Experimental|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
11276164|NCT02861417|Experimental|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
11276165|NCT02861404||Salicylate ointment|patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)
11276166|NCT02861404||Imiquimod|patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)
11276167|NCT02861404||5-Fluoro-Uracil|patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)
11276168|NCT02861404||Cryotherapy|patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)
11276169|NCT02861404||placebo|patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)
11276170|NCT02861391|Experimental|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed in urodynamic testing intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
11276171|NCT02861378|Experimental|Phentolamine mesylate|Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
11276172|NCT02861378|Placebo Comparator|Water|Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).
11276173|NCT02861352|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 10 mg/d and 25 mg supplemental zinc/d
11276174|NCT02861339|Experimental|Keratoconus and IBD|Opthalmologic measure with DM OPD scan III (Nidek)
11276175|NCT02861326|Other|Patients|Non-surgical periodontal treatment has performed to patients. Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
11276176|NCT02861313|Experimental|CM LOC attachment|CM LOC attachment other names: resin matrix attachment
11276177|NCT02861313|Active Comparator|ball attachment|ball attachment other names metallic ball attachment
11276178|NCT02861300|Experimental|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
11276179|NCT02861287||Study cohort|patients with Multiple Myeloma who underwent PBSC mobilization since December 2009 and who received plerixafor in line with inclusion criteria
11276180|NCT02861287||Historical cohort|patients with Multiple Myeloma who underwent PBSC mobilization immediately prior to marketing authorization and clinical utilization of Plerixafor which is before December 2009 (over the 2007-2009 period)
11276181|NCT02861274|Active Comparator|electrophysiological testing|Patients will receive a pacemaker.
11276182|NCT02861274|No Intervention|control group|These subjects will receive cardicor® (beta blockers).
11276183|NCT02861261|Experimental|Group A|
11276184|NCT02861261|Experimental|Group B|
11276185|NCT02861261|Experimental|Group C|
11276186|NCT02861261|Placebo Comparator|Group D|
11276187|NCT02861248|Experimental|Laser treatment|Fractional micro-plasma radiofrequency treatment given to 95 patients with non-hypertrophic burn scar.
11276188|NCT02861235|Experimental|1. stress thallium-201 tomoscintigraphy|
11276189|NCT02861235|Experimental|2. stress technetium-99m tomoscintigraphy 1|
11276190|NCT02861235|Experimental|3. stress technetium-99m tomoscintigraphy 2|
11276191|NCT02861235|Experimental|4. stress technetium-99m tomoscintigraphy 3|
11276192|NCT02861235|Experimental|5. rest thallium-201 tomoscintigraphy|
11276193|NCT02861235|Experimental|6. rest technetium-99m tomoscintigraphy|
11276194|NCT02861222|Experimental|MYOCET|2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.
11276195|NCT02861209|No Intervention|Non-care pathway|"This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months.
~The decision to start with an oral anticancer therapy depends solely on the treating physician."
11276196|NCT02861209|Experimental|Care Pathway|"This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months.
~The decision to start with an oral anticancer therapy depends solely on the treating physician."
11276197|NCT02861196|Experimental|Therapy Arm|Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
11276198|NCT02861183|Experimental|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
11276199|NCT02861183|Placebo Comparator|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
11276200|NCT02861170|Experimental|Brief Mindfulness-Based Intervention|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety as well as a 10-minute mindfulness-based intervention called a body scan at 3 different time-points (T1 - 1 week prior to surgery, T2 - within 4 hours before surgery, and T3 - approximately 24 hours after transfer from recovery to the orthopedic floor).
11276201|NCT02861170|No Intervention|Education|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety.
11276202|NCT02861157|Experimental|TX Condition: Planet T1D Intervention|Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.
11276203|NCT02861157|No Intervention|CO Condition: Treatment-As-Usual|A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.
11276204|NCT02861144|Other|Intervention|"Patient participants in the intervention arm will receive diabetes self-management program, Ma ka hana ka ̒ike which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 4.5 months. After 4.5 months, the patient will receive 4 monthly boosters by mail that will reinforce information from the Ma ka hana ka ̒ike program. Completion of diabetes process and glycemic outcomes will trigger the modest financial incentives.
~Health care provider participants in the intervention arm will receive educational resources, Hanapū Provider Toolbox to guide their patients to optimal glycemic control.They will receive modest financial incentives when their patients complete clinical tests and achieve glycemic target."
11276205|NCT02861144|No Intervention|Usual Care|"Patient participants in the usual care arm will receive 5 mail-out diabetes self management education booklets endorsed by the American Diabetes Association (ADA) and the National Institute for Diabetes, Digestive and Kidney disease for 4.5 months. Patients will see their doctor according to usual care practice. After 4.5 months, the patients will receive 4 monthly boosters in mail reinforcing the previous mail-out diabetes self-management program materials.
~Health care provider participants in the usual care arm will receive the latest ADA guidelines to use in their treatment plan of their patients."
11276206|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
11276207|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
11276208|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
11276209|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
11276210|NCT02861105|Active Comparator|LMWH supplementation|40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
11276211|NCT02861105|Placebo Comparator|0.9% saline solution|0.9% saline injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
11276212|NCT02861079|Experimental|Propess with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
11276213|NCT02861079|Active Comparator|Propess vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
11276214|NCT02861066|Experimental|Mindfulness-based Intervention|6 week, abbreviated group MBI treatment for depression and anxiety
11276215|NCT02861053|Experimental|chronic quiet inflammatory bowel disease patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with regular and moderate physical activity
11276216|NCT02861053|Sham Comparator|chronic quiet inflammatory bowel disease Patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with no regular and moderate physical activity more than usual
11276217|NCT02861040|Experimental|Treatment (volasertib, vincristine sulfate liposome)|Patients receive volasertib IV over 1 hour on day 1 and vincristine sulfate liposome IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression, development of an inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw or treating investigator determines that the patient should be taken off treatment for any reason.
11276218|NCT02861027|Active Comparator|PPTHA|Control Group performs the PPTHA.
11276219|NCT02861027|Experimental|FES and PPTHA|The Intervention Group performs the PPTHA associated with FES.
11276220|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
11276221|NCT02861001|Active Comparator|bronchoscopic guidance|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
11276222|NCT02861001|Experimental|tube mounted camera guidance|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
11276223|NCT02860988|Experimental|MCCC treatment|Participants receive newly supported services to enhance fatherhood and parenting for individuals with substance use issues.
11276293|NCT02860468|Placebo Comparator|Placebo juice consumption|participants in this arm will be provided placebo juice to consume for 21 days in total
11277153|NCT02854605|Experimental|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
11276224|NCT02860975|Experimental|Inhaled Nitrogen|A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
11276225|NCT02860962|Active Comparator|Dextromethorphan|2 doses of Dextromethorphan 75mg oral (PO), separated by 4 hours
11276226|NCT02860962|Placebo Comparator|Placebo|2 doses of placebo (oral/PO), separated by 4 hours
11276227|NCT02860949|Experimental|LAI with PCI|Local anesthetic infiltration with posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area, Lateral gutter area and Posterior capsular area)
11276228|NCT02860949|Active Comparator|LAI without PCI|Local anesthetic infiltration without posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area and Lateral gutter area)
11276229|NCT02860936|Experimental|Lenvatinib|24 mg of lenvatinib will be administered daily to patients until progression of disease or intolerable toxicity or other criteria for discontinuation is met.
11276230|NCT02860923|Experimental|Exenatide|Treatment with exenatide at the initial dose of 5 µg x 2/day (subcutaneously administered) during 4 weeks, and treatment with 10 µg x 2/day during 5 months.
11276231|NCT02860923|Placebo Comparator|Placebo|Patients will be maintained on placebo (injected subcutaneously, twice a day) with the same dose and frequency than exenatide arm.
11276232|NCT02860910|Experimental|Cognitive Behavioral Group Therapy|"The six CBGT sessions are outlined in the manual entitled: Managing Hot Flushes with Group Cognitive Behaviour Therapy: An Evidenced-Based Treatment Manual for Health Care Professionals (Hunter & Smith, 2015) as follows:
~Session 1: Psycho-education and the cognitive behavioural model Session 2: Stress management, improving wellbeing and identifying precipitants Session 3: Managing hot flushes using a cognitive behavioural approach Session 4: Managing night sweats and improving sleep (part one) Session 5: Managing night sweats and improving sleep (part two) Session 6: Review and maintaining changes (One alteration: Open discussion about mood disorders, anxiety and the psychological impact instead of the psychological impact of breast cancer)"
11276233|NCT02860897|Experimental|Vaginal estrogen cream|
11276234|NCT02860897|Experimental|Vaginal estrogen tablet|
11276235|NCT02860884||simple fatty liver|patients with fatty liver disease
11276236|NCT02860884||NASH|patients with nonalcoholic steatohepatitis
11276237|NCT02860858|Experimental|Aflibercept|
11276238|NCT02860845|Experimental|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
11276239|NCT02860845|Active Comparator|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
11276240|NCT02860819|Experimental|Gemcitabine, Carboplatin, Veliparib|Gemcitabine 800mg/m2 day 1 and 8 every 3 weeks; Carboplatin AUC = 4, day 1, every 3 weeks, Veliparib 250mg bid day continuously.
11276241|NCT02860806|Experimental|Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)|Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
11276242|NCT02860806|Experimental|Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
11276243|NCT02860806|Experimental|Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
11276244|NCT02860806|Experimental|Part 2: Group 1 (EFG)|Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
11276245|NCT02860806|Experimental|Part 2: Group 2 (FGE)|Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
11276246|NCT02860806|Experimental|Part 2: Group 3 (GEF)|Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
11276247|NCT02860806|Experimental|Part 2: Group 4 (GFE)|Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
11276248|NCT02860806|Experimental|Part 2: Group 5 (FEG)|Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
11276249|NCT02860806|Experimental|Part 2: Group 6 (EGF)|Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
11276250|NCT02860806|Experimental|Part 3: JNJ-63623872 300 mg|Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
11276251|NCT02860793|Experimental|AML patients at diagnosis|
11276252|NCT02860780|Experimental|Part A: prexasertib + ralimetinib|"Cohort 1: 60 milligrams (mg) prexasertib (LY2606368) given intravenously (IV) and 100 mg ralimetinib given orally.
~Cohort 2: 60 mg prexasertib (LY2606368) given intravenously (IV) and 200 mg ralimetinib given orally."
11276253|NCT02860780|Experimental|Part B1: prexasertib + ralimetinib (colorectal cancer)|60 mg prexasertib (LY2696368) given IV and 200 mg ralimetinib given orally. Participants receive prexasertib IV on Days 1 and 15 and ralimetinib every 12 hours (Q12H) Days 1 and 14 of a 28 day cycle.
11276254|NCT02860754|Other|Six-minute walk test|All patients will perform six-minute walk test before surgery, in the preoperative clinic
11276255|NCT02860741|Experimental|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
11277154|NCT02854605|Placebo Comparator|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
11276256|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
11276257|NCT02860728|Experimental|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
11276258|NCT02860715|Experimental|Cohort 1|GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
11276259|NCT02860715|Experimental|Cohort 2|GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
11276260|NCT02860715|Experimental|Cohort 3|GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
11276261|NCT02860702|Experimental|Exclusive Human Milk|All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery
11276262|NCT02860702|Active Comparator|Human/Bovine Milk|All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery
11276263|NCT02860676|Experimental|Cirmtuzumab|
11276264|NCT02860663|Active Comparator|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
11276265|NCT02860663|Active Comparator|Vitamin D2|10 ug/d of vitamin D2 for 6 weeks
11276266|NCT02860663|Active Comparator|25OHD|10 ug/ of 25OHD for 6 weeks
11276267|NCT02860650|Experimental|Group 1: AD26.Filo/MVA-BN-Filo or Placebo|Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
11276268|NCT02860650|Experimental|Group 2: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.
11276269|NCT02860650|Experimental|Group 3: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.
11276270|NCT02860650|Experimental|Subset of Group 3: AD26.Filo or Placebo|The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.
11276271|NCT02860650|Experimental|Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
11276272|NCT02860624|Experimental|10 mg ilaprazole|
11276273|NCT02860624|Active Comparator|40 mg esomeprazole|
11276274|NCT02860611||Type 1 Diabetes|Patients with type 1 diabetes
11276275|NCT02860611||Type 2 Diabetes|Patients with type 2 diabetes
11276276|NCT02860611||Control|Healthy volunteers
11276277|NCT02860598||Group 1|Patient with AML de novo or secondary myelodysplasia, in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy
11276278|NCT02860598||Group 2|Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, myeloma, myeloproliferative syndrome (MDS)) and candidate for blood marrow or stem cell or placental blood transplantation.
11276279|NCT02860572|Experimental|follow-up without intervention|No intervention to increase the urine output within 2 hours will be done.
11276280|NCT02860572|Active Comparator|Standard group - fluid bolus|Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
11276281|NCT02860559|Experimental|TBX-1400 treatment|Single intravenous infusion of TBX-1400
11276282|NCT02860546|Experimental|TAS-102 and Nivolumab|
11276283|NCT02860533|Experimental|Blood pressure measurement|six repetitive blood pressure measurements with iPhone and conventional oscillometric cuff device during stress testing will be performed
11276284|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
11276285|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
11276286|NCT02860494|Experimental|Topical everolimus 0.1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
11276287|NCT02860494|Experimental|Topical everolimus 0.5%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
11276288|NCT02860494|Experimental|Topical everolimus 1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
11276289|NCT02860494|Placebo Comparator|Topical placebo|Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
11276290|NCT02860481|Other|first cohort : first 100 patients|first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type
11276294|NCT02860455|Other|SpCO and COHb measurement|"SpCO measurement (Experimental) : Non invasive pulse CO-oximetry will be carried out in all patients simultaneously with venous blood sampling for standard laboratory blood gas analysis, at time of prehospital management by emergency medical services
~COHb measurement (Active comparator) : Blood carboxyhemoglobin testing will be carried out in all patients"
11276295|NCT02860442|Experimental|Smartphone brief intervention (SP-BI)|
11276296|NCT02860442|Placebo Comparator|Enhanced Usual Care (EUC)|
11276297|NCT02860429|Experimental|Cinobufacini injection|"Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
~Duration:6 chemotherapy cycles."
11276298|NCT02860429|Other|Control group|Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
11276299|NCT02860403|Experimental|C6-C7 patients|C6-C7 patients able to recover tenodesis grasp.
11276300|NCT02860403|Experimental|C5-C6 patients|C5-C6 patients for whom surgery for rehabilitation of an upper limb is indicated with a upper limit of one year after trauma, and after complete clinical and functional evaluation
11276301|NCT02860403|No Intervention|Control group|a control group (n=6) matched on age and sex to C6-C7 without medical history or neurological disorder
11276302|NCT02860390|No Intervention|Adolescent - Control|Usual care arm of subjects aged 13-19 years old
11276303|NCT02860390|Experimental|Adolescent - SMS|Subjects aged 13-19 years and receiving Denver Health Asthma Management Program (text messaging intervention)
11276304|NCT02860390|Experimental|Adolescent - SMS plus support person|Subjects aged 13-19 years, Denver Health Asthma Management Program (text messaging intervention) sent to subjects and subjects' chosen Person of Support.
11276305|NCT02860390|No Intervention|Adult - Control|Usual care arm of subjects aged 20-40 years old.
11276306|NCT02860390|Experimental|Adult - SMS|Subjects aged 20-40 years and receiving Denver Health Asthma Management Program (text messaging intervention).
11276307|NCT02860377|Active Comparator|stranger's voice|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
11276308|NCT02860377|Experimental|maternal voice|At the end of surgery, patients were stimulated to wake up by recorded maternal voice, which was recorded before the operation.
11276309|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
11276310|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
11276311|NCT02860338||GROUP 1- CNS Protocol|"Patients in a specialized dementia practice. Evaluated and treated for hypoxia, elevated BNP, hyperhomocysteinemia, B 12 deficiency as measured by elevated methymalonic acid, Vitamin D 25-OH deficiency, elevated CRP, and decreased IGF-1, and other metabolic abnormalities.
~Treated with maximal doses of acetylcholinesterase inhibitors, memantine, methylfolate/methylB12/N-acetylcysteine, dextromethorphan/quinidine, and SSRI's; dose and duration based on protocol."
11276312|NCT02860338||GROUP 2- Community Care|Patients referred to a neuropsychology practice for cognitive evaluation and treated for MCI or dementia by their primary care clinician or non-dementia specialist according to specific provider's usual practice pattern.
11276313|NCT02860325|Experimental|NIV-NAVA|Patients allocated to non-invasive NAVA
11276314|NCT02860325|Active Comparator|Conventional|Patients allocated to nasal CPAP or non-synchronized nasal IPPV
11276315|NCT02860312|Active Comparator|Exercisers|Intradialytic exercise on stationary bicycles
11276316|NCT02860312|Placebo Comparator|Non Exercisers|No intradialytic exercise
11276317|NCT02860299|Experimental|Citrate lock|
11276318|NCT02860299|Active Comparator|Heparin lock|
11276319|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
11276320|NCT02860273|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO at 21%
~Constant Treadmill Load Test (CTLT) using HFNCO at 21%"
11276321|NCT02860273|Other|Control Group|"Incremental Load Treadmill Test (ILTT) at Room Air
~Constant Treadmill Load Test (CTLT) at Room Air"
11276322|NCT02860260|Experimental|Patients with fibrinolysis|
11276323|NCT02860260|Placebo Comparator|Patients without fibrinolysis|
11276324|NCT02860234||Group A:Clinical complete response (cCR)|Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
11276325|NCT02860234||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
11276326|NCT02860234||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).
11276327|NCT02860221|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
11276328|NCT02860221|Experimental|Topical epinephrine|Topical epinephrine
11276329|NCT02860221|Active Comparator|Control|No epinephrine
11276330|NCT02860208||3 years follow-up|all patients who received surgical treatment for peri-implantitis during a Randomized and Controlled Trial registered in ClinicalTrials.gov NCT NCT01857804
11276331|NCT02860195|Experimental|healthy volunteers|
11276332|NCT02860182||experimental|patients with acute type A dissection
11276333|NCT02860182||control|patients without any pathology of the ascending aorta, but having the same characteristics as the sick patients, in terms of age and vascular risk factors including high blood pressure
11276334|NCT02860169|Experimental|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
11276375|NCT02859896|Active Comparator|Rocaltrol|Rocaltrol (Calcitriol) will be administered orally seven days/week. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
11276335|NCT02860169|Placebo Comparator|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
11276336|NCT02860156||HIV+/DD+|Subjects are HIV positive and have diastolic dysfunction
11276337|NCT02860156||HIV+/DD-|Subjects are HIV positive and do not have diastolic dysfunction
11276338|NCT02860156||HIV-/DD+|Subjects do not have HIV and have diastolic dysfunction
11276339|NCT02860143||studying ventilation during sedation|Comparing ventilation during sedation with capnography
11276340|NCT02860130|Experimental|Prismocitrate 18|
11276341|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
11276342|NCT02860117|Active Comparator|Ketatamine|Ketamine continuous infusion 0,2mg/kg/h
11276343|NCT02860117|Placebo Comparator|Placebo|Placebo in continuous infusion
11276344|NCT02860104|Other|microwave ablation|microwave ablation
11276345|NCT02860091||Ropivacaine infusion|Patients receiving continuous ropivacaine infusion for approximately 7 days via paravertebral nerve block or erector spinae catheter managed according to existing institutional protocols.
11276346|NCT02860078|Active Comparator|Ultrasound|The group I will be subjected to epidural infiltration using methylprednisolone acetate diluted in ropivacaine 0.1%. Initially the sacral hiatus is identified by palpation. After, the ultrasound device is used (USG) for the puncture, with a linear transducer of high frequency. At the end of corticosteroid administration, the placement of the needle tip will be checked with fluoroscopy and noted.
11276347|NCT02860078|Active Comparator|Radioscopy|The group II will be subjected to infiltration using methylprednisolone acetate diluted in ropivacaine 0.1% . However, only radioscopy be used to guide the puncture.
11276348|NCT02860065|Experimental|CPC-201|combination of solifenacin and high doses of donepezil
11276349|NCT02860052|Experimental|SB208 2%|Apply once daily to one or both feet for 14 days
11276350|NCT02860052|Experimental|SB208 4%|Apply once daily to one or both feet for 14 days
11276351|NCT02860052|Experimental|SB208 16%|Apply once daily to one or both feet for 14 days
11276352|NCT02860052|Placebo Comparator|Vehicle Gel|Apply once daily to one or both feet for 14 days
11276353|NCT02860039|Experimental|Group 1 - High Dose HD-TIV|Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.
11276354|NCT02860039|Active Comparator|Group 2 - Standard Dose QIV|Patients receive standard dose QIV IM on day 0 and day 28.
11276355|NCT02860026|Active Comparator|Control|Marketed cow's milk-based infant formula
11276356|NCT02860026|Experimental|Investigational|Cow's milk-based infant formula with added nutrients
11276357|NCT02860013|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling heart failure in general. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
11276358|NCT02860013|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with heart failure are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). Heart failure patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing heart failure. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in heart failure and definitely not on call
11276359|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
11276360|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11276361|NCT02859987|Active Comparator|Landmark Technique|Blinded method for catheter placement
11276362|NCT02859987|Experimental|Ultrasound-guided Technique|Use sonography for catheter placement
11276363|NCT02859974|Experimental|Respiratory retraining for PVFMD|Single arm study
11276364|NCT02859961|Experimental|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
11276365|NCT02859961|Experimental|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
11276366|NCT02859961|Experimental|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
11276367|NCT02859948|Experimental|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
11276368|NCT02859935|No Intervention|Control group|The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
11276369|NCT02859935|Other|Intervention group|The intervention group will receive -besides standard care- additional questionnaires depending on their baseline questionnaires and in case of an indication for mental health problems, feedback and referral to relevant mental health and addiction care will be provided.
11276370|NCT02859922|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
11276371|NCT02859922|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
11276372|NCT02859909|Experimental|2 day treatment schedule|Patients will receive a dosage of 1 g/kg bw per day of BT595 for 2 consecutive days
11276373|NCT02859909|Experimental|5 day treatment schedule|Patients will receive a dosage of 0.4 g/kg bw per day of BT595 for 5 consecutive days
11276374|NCT02859896|Experimental|Hectorol|Hectorol (Doxercalciferol) will be administered orally two to three times weekly dependent on patient age. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
11276428|NCT02859506|Active Comparator|stable liver damage|
11276376|NCT02859857|Experimental|Rising dose; safety and tolerance|Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.
11276377|NCT02859857|Experimental|Solid tumor patients|Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
11276378|NCT02859857|Experimental|Glioblastoma Multiforme patients|Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
11276379|NCT02859857|Experimental|Gastrointestinal tumor patients|Cohort of patients with Gastrointestinal tumors as defined in the protocol and administered BXQ-350 at the 2.4 mg/kg dose level.
11276380|NCT02859857|Experimental|Ependymoma tumor patients|Cohort of patients with ependymoma administered BXQ-350 at the 2.4 mg/kg dose level.
11276381|NCT02859857|Experimental|Solid tumor patients other than HGG|Cohort of patients with advanced solid tumors other than HGG administered BXQ-350 at the 2.4 mg/kg dose level.
11276382|NCT02859844|Experimental|TTNS ON|Transcutaneous tibial nerve stimulation
11276383|NCT02859844|Sham Comparator|TTNS OFF|Sham/placebo stimulation
11276384|NCT02859831||with construction work|
11276385|NCT02859831||without construction work|
11276386|NCT02859818|Other|adolescents with type 1 diabetes|adolescents with type 1 diabetes following their participation in therapeutic education program
11276387|NCT02859792|Placebo Comparator|Placebo|
11276388|NCT02859792|Experimental|Experimental|
11276389|NCT02859779|Other|mediterranean adolescents with type 1 diabetes|
11276390|NCT02859766|Experimental|Abicipar Pegol_Repeat Dose|Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. [Day 1, Weeks 4 and 8]
11276391|NCT02859766|Experimental|Abicipar Pegol_Single Dose|Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.
11276392|NCT02859753|Experimental|RFA|
11276393|NCT02859753|Active Comparator|MCT|
11276394|NCT02859740||permanent prosthesis|
11276395|NCT02859740||Temporary prosthesis|
11276396|NCT02859727|Experimental|CDZ173|140mg/day
11276397|NCT02859714||colorectal adenoma|
11276398|NCT02859701|Experimental|AK002|AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses
11276399|NCT02859701|Placebo Comparator|Placebo|Placebo administered as anl IV infusion
11276400|NCT02859688||SRS patient|
11276401|NCT02859688||father SRS patient|
11276402|NCT02859688||control patient|
11276403|NCT02859675||Crohn and anti-TNF treatment|Tests at 3 or 4 weeks after the beginning of anti-TNF treatment
11276404|NCT02859675||Crohn and without anti-TNF treatment|tests performed according to patient availability
11276405|NCT02859675||Control|tests performed according to patient availability
11276406|NCT02859649|Experimental|healthy volunteers|
11276407|NCT02859610|Other|cirrhotic patients|We prospectively included 90 cirrhotic patients .
11276408|NCT02859610|Other|healthy volunteers|The pilot cohort was compared with 10 healthy volunteers.
11276409|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
11276410|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
11276411|NCT02859584|Other|no serious acute hepatitis|
11276412|NCT02859584|Other|Serious acute hepatitis|
11276413|NCT02859584|Other|Healthy volunteers|
11276414|NCT02859584|Other|Surrenal insufficiency|
11276415|NCT02859571|Active Comparator|Continuous oxytocin|oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery.
11276416|NCT02859571|Experimental|intermittent oxytocin|oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group.
11276417|NCT02859558|Experimental|Arm 1: Fiebig I II|Participants enrolled during Fiebig stages I-II will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
11276418|NCT02859558|Experimental|Arm 2: Fiebig III IV|Participants enrolled during Fiebig stages III-IV will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
11276419|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stages V will receive antiretroviral therapy consisting of either one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg (also known as EVG/COBI/FTC/TAF or Genvoya) by mouth daily or another medically-appropriate antiretroviral therapy
11276420|NCT02859545|Experimental|Validation Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to validate which is provided by the research assistant.
11276421|NCT02859545|Placebo Comparator|Education Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to ask questions about treatments, which is provided by the research assistant.
11276422|NCT02859532|Experimental|Diagnosis of deep vein thrombosis|All subjects with proximal DVT will have quantitative elastography SWIRE, thrombin generation test and rotational thromboelastometry test.
11276423|NCT02859519|Experimental|MOB015B|
11276424|NCT02859519|Placebo Comparator|MOB015B Vehicle|
11276425|NCT02859506|Experimental|liver transplant|
11276426|NCT02859506|Active Comparator|kidney transplant|
11276427|NCT02859506|Placebo Comparator|control|
11276430|NCT02859493|Placebo Comparator|Maize starch and magnesium stearate|Placebo presented in a vaginal capsule. 1 capsule a day for 14 days
11276431|NCT02859480|Experimental|Rosuvastatin 5mg|Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention
11276432|NCT02859480|Active Comparator|Rosuvastatin 20mg|Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention
11276433|NCT02859467|Experimental|Kinesio Taping and Inhibitory Treatment Techniques|"During each session participants will receive the application kinesio taping in trapezius, infraspinatus and paravertebral muscles.
~Inhibitory Treatment Techniques:
~Release Technique of the trapezius muscle.
~Release Technique for scalene muscles.
~Technique suboccipital inhibition.
~Technique hands crossed for induction dorsal superficial fascia."
11276434|NCT02859467|Active Comparator|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
11276435|NCT02859454|Experimental|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
11276436|NCT02859441|Experimental|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
11276437|NCT02859428||Patients with hereditary spastic paraplegia (HSP)|Patients with hereditary spastic paraplegia types 3A, 4 and 31.
11276438|NCT02859415|Experimental|Phase I|Escalating doses of Mithramycin
11276439|NCT02859415|Experimental|Phase II|Mithramycin administered at MTD
11276440|NCT02859402|Experimental|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
11276441|NCT02859376|Active Comparator|sucrose24% 2 minutes before|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure
11276442|NCT02859376|Experimental|sucrose24% 2minutes before and during|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure
11276443|NCT02859363||Young stroke|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing for the 26 common Fabry mutation types in Taiwan.
11276444|NCT02859350|Experimental|Group 1a (PfSPZ Vaccine)|18-35 years; n= 20; 3 doses of 2.7x10^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
11276445|NCT02859350|Placebo Comparator|Group 1a (normal saline)|18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
11276446|NCT02859350|Experimental|Group 1b (PfSPZ CVac)|18-35 years; n=20; 3 doses of 1.0x10^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
11276447|NCT02859350|Placebo Comparator|Group 1b (normal saline)|18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
11276448|NCT02859350|Experimental|Group 2 (PfSPZ Vaccine)|36-65 years; n=12; 3 doses of 2.7x10^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
11276449|NCT02859350|Placebo Comparator|Group 2 (normal saline)|36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
11276450|NCT02859350|Experimental|Group 3 (PfSPZ Vaccine)|11-17 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
11276451|NCT02859350|Placebo Comparator|Group 3 (normal saline)|11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
11276452|NCT02859350|Experimental|Group 4 (PfSPZ Vaccine)|6-10 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
11276453|NCT02859350|Placebo Comparator|Group 4 (normal saline)|6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
11276454|NCT02859350|Experimental|Group 5 (PfSPZ Vaccine)|1-5 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
11276455|NCT02859350|Placebo Comparator|Group 5 (normal saline)|1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
11276456|NCT02859350|Experimental|Group 6a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 9.0x10^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
11276457|NCT02859350|Experimental|Group 6b (PfSPZ Vaccine)|6-11 months; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
11276458|NCT02859350|Placebo Comparator|Group 6b (normal saline)|6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
11276459|NCT02859337|Active Comparator|UPA-ECx1 followed by ECx2|Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.
11276460|NCT02859337|Experimental|UPA-ECx2 followed by ECx1|Ulipristal acetate 60mg orally x 1 dose, washout cycle, and then in next menstrual cycle 30mg orally x 1 dose. Timing of dosage depends on follicle measurements.
11276461|NCT02859337|Other|UPA-ECx1 Normal BMI/weight|Ulipristal acetate 30mg orally x 1 dose. timing of dosage depends on follicle measurements. This is to obtain a normal BMI control group.
11276462|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
11276463|NCT02859311|Experimental|Withdrawal of therapy|Gradual, supervised withdrawal of medical therapy over 4-16 weeks
11276464|NCT02859311|No Intervention|Control|Continuation of usually prescribed pharmacological therapy
11276465|NCT02859298|Experimental|Suspicion of threat of premature delivery|10 consecutive patients arriving at the Brugmann maternity with suspicion of a threat of premature delivery will be encouraged to participate in this study, before the onset of any tocolytic treatment. The patient will receive an standard examination of the cervix and at the same time a polarimetric measurement.
11276466|NCT02859298|Active Comparator|Normal pregnancy|10 control patients, with the same term of pregnancy, will be benefit from the same measurements.
11276467|NCT02859285|Active Comparator|Estradiol vulvar cream|"The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.
~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
11276468|NCT02859285|Placebo Comparator|Placebo cream|"The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.
~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
11276469|NCT02859259|Experimental|Treatment A: reference extended-release (ER) 1 tablet at 600mg|A single dose of BMS-663068 administered orally as specified
11276470|NCT02859259|Experimental|Treatment B: low-dose ER 4 tablets at 150mg|A single dose (4 tablets) of BMS-663068 administered orally as specified
11276471|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
11276472|NCT02859233|No Intervention|Control group|Routine advices about the interest of increase fluid after lumbar puncture to prevent PDPH will be transmitted: 2 liters will be provided to be drunk in 2 hours.
11276473|NCT02859233|Experimental|Interventional group|Lack of hyperhydration : no particular advices will be transmitted about the interest of oral hyperhydration. 500 milliliters will be provided in case of thirst, according to patient's convenience.
11276474|NCT02859220|Other|group 1|group 1 : Roche Elecsys intact PTH
11276475|NCT02859220|Other|group 2|group 2 : PTH 1-84 complete (PAC) report and CAP / PTH 7-84 (CIP), Duo PTH IRMA Scantibodies
11276476|NCT02859207|Experimental|Cohort 1|Participants with mild hepatic impairment (Child-Pugh class A).
11276477|NCT02859207|Experimental|Cohort 1C|Healthy participants (control) matched to participants in Cohort 1.
11276478|NCT02859207|Experimental|Cohort 2|Participants with moderate hepatic impairment (Child-Pugh class B)
11276479|NCT02859207|Experimental|Cohort 2C|Healthy participants (control) matched to participants in Cohort 2
11276480|NCT02859194|Experimental|Veno-veno-arterial ECMO group|
11276481|NCT02859181|Experimental|Active, Adolescent males|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
11276482|NCT02859168|Experimental|Myofascial Induction session|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
11276483|NCT02859168|Placebo Comparator|Placebo session|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
11276484|NCT02859155|Other|Multiviceral resection colorectal cancer|Multiviceral resection surgery of 2 or more intrabdominal organs en bloc with colorectal cancer
11276485|NCT02859142|Experimental|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.
~Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions
~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
11276486|NCT02859142|Active Comparator|Standard Treatment|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits.
~NicodermCQ (Nicotine Patches): Administered according to package insert directions
~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
11276487|NCT02859129|Experimental|Rosuvastatin|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
11276488|NCT02859129|Experimental|Epanova®|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)
11276489|NCT02859129|Experimental|Epanova® + Crestor®|Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24
11276490|NCT02859129|Active Comparator|Vascepa®|Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).
11276491|NCT02859116||Collection of digestive tissues|Digestive tissues will be collected from participants undergoing scheduled (non-emergent) gastrointestinal surgery.
11276492|NCT02859103|Active Comparator|Treatment|Patients in this arm will receive treatment with desvenlafaxine for 8 weeks.
11276493|NCT02859103|No Intervention|Healthy Control|Patients in this arm are healthy controls and will not receive any medication.
11276494|NCT02859090|Experimental|patient|
11276495|NCT02859077|Experimental|EGFR-TKI and Chemotherapy|NSCLC patients
11276496|NCT02859064|Experimental|Lanreotide/Y-90 microspheres|"Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy.
~Y-90 (Yttrium-90) microspheres [SIR-Spheres therapy]: dose and treatment day to be determined by treating radiation oncologist."
11276497|NCT02859051|No Intervention|control|No intervention
11276498|NCT02859051|Experimental|robot|Humanoid robot interacts with child, teaching breathing and coping strategies.
11276499|NCT02859038|Experimental|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy.
11276500|NCT02859038|Active Comparator|Neoadjuvant chemotherapy|neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery. The maximal time interval between course 3 chemotherapy and IDS is 6 weeks. And then 3 cycles of adjuvant chemotherapy.
11276501|NCT02859025|Active Comparator|A:Iiac|Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.
11276584|NCT02858505|Active Comparator|54 mg elemental iron group|received 54 mg elemental iron once daily starting at 12 weeks until 36 weeks
11276502|NCT02859025|Experimental|B:MSCs+LRCP|Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect
11276503|NCT02859025|Experimental|C:MSCs+liac|Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.
11276504|NCT02859012|Experimental|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
11276505|NCT02859012|Active Comparator|observation|Observation. if disease progression is detected, cross-over will be permitted.
11276506|NCT02858999|Experimental|treatment|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles PAD-VCD
11276507|NCT02858986|Experimental|3D laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 3D laparoscopic system
11276508|NCT02858986|Experimental|4K laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 4K laparoscopic system
11276509|NCT02858973|Experimental|Q203|Q203 tablets
11276510|NCT02858973|Placebo Comparator|Placebo|Placebo tablets
11276511|NCT02858960|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO
~Constant Treadmill Load Test (CTLT) using HFNCO"
11276512|NCT02858960|Active Comparator|The Venturi Mask|"Incremental Load Treadmill Test (ILTT) using venturi mask
~Constant Treadmill Load Test (CTLT) using venturi mask"
11276513|NCT02858947|Active Comparator|Aelite Flo|Microhybrid flowable composite
11276514|NCT02858947|Active Comparator|x-tra base|Bulk-fill flowable composite
11276515|NCT02858934|Experimental|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
11276516|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
11276517|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
11276518|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
11276519|NCT02858908|Experimental|Cohort 1 - Tideglusib|1000 mg tideglusib, orally, once daily
11276520|NCT02858908|Experimental|Cohort 2 - Tideglusib|400 mg tideglusib, orally, once daily
11276521|NCT02858895|Experimental|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).*
~*Subjects may be eligible to receive a second administration of MDNA55."
11276522|NCT02858882||Swimmers|Screening of elite athletes
11276523|NCT02858869|Experimental|Arm A (pembrolizumab, SRS 6 Gy, CLOSED):|Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat Q3W for at least 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo 5 SRS fractions between days 2-15 of course 1.
11276524|NCT02858869|Experimental|Arm B (pembrolizumab, SRS 9 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 3 SRS fractions between days 2-15 of course 1.
11276525|NCT02858869|Experimental|Arm C (pembrolizumab, SRS 18-21 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 1 SRS fraction between days 2-3 of course 1.
11276526|NCT02858856|Experimental|A group|Take Sipjeondaebo-tang on 0~2 week, 3~5 week of clinical trial period, total of 4 weeks
11276527|NCT02858856|Experimental|B group|Take Sipjeondaebo-tang on 6~8 week, 9~11 week of clinical trial period, total of 4 weeks
11276528|NCT02858843|Experimental|Lumacaftor-ivacaftor|Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.
11276529|NCT02858830|Other|Group 1: Healthy Subject|Healthy Subject (Control) will undergo assessments before and after ingesting a high fat mixed meal.
11276530|NCT02858830|Other|Group 2: FPL Subject|FPL Subject will undergo assessments before and after ingesting a high fat mixed meal.
11276531|NCT02858817|Experimental|51,200 PfSPZ|Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
11276532|NCT02858817|Experimental|150,000 PfSPZ|Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
11276533|NCT02858817|Placebo Comparator|Placebo|Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
11276534|NCT02858804|Experimental|Etoposide|50 mg/m2, IV, d1-4
11276535|NCT02858804|Experimental|Doxorubicin|10 mg/m2, IV, d1-4
11276536|NCT02858804|Experimental|Dexamethasone|30 mg/d, d1-5
11276537|NCT02858804|Experimental|Vincristine|0.4 mg/m2, IV, d1-4
11276538|NCT02858804|Experimental|Cyclophosphamide|750 mg/m2 ,d5
11276539|NCT02858804|Experimental|Cytarabine|2g/m2, q12h, d1
11276540|NCT02858804|Experimental|Cisplatin|100mg/ m2,IV, d1
11276541|NCT02858804|Experimental|Rituximab|375 mg/m2 IV, d1
11276542|NCT02858804|Experimental|Thalidomide|50-150mg/d, po, d1-28
11276543|NCT02858804|Experimental|Prednisone|0.5mg/Kg, po, qod
11276544|NCT02858791||Healthy Controls|"Subjects are made up of healthy adults
~Interventions:
~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
11276545|NCT02858791||Affected|"Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease
~Interventions:
~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
11276546|NCT02858778|Experimental|Interventional group (Ig)|The interventional group (Ig) will have an early palliative care consultation ordered during their stay in the emergency department.
11276547|NCT02858778|No Intervention|Control group (Cg)|The control group will be treated as standard of care. Palliative care consultations may or may not be ordered at the attending physician's discretion.
11276548|NCT02858765|Experimental|white polychromatic light A|
11276549|NCT02858765|Experimental|white polychromatic light B|
11276550|NCT02858765|Experimental|white polychromatic light C|
11276551|NCT02858765|Experimental|white polychromatic light D|
11276552|NCT02858752|Experimental|Healthy Children|Memory and Attention in healthy children will be assessed non-invasively through behavioral and electrophysiological measures while participants will perform passive or active computer task involving auditory and/or visual perception.
11276553|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
11276554|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
11276555|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
11276556|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
11276557|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
11276558|NCT02858713|No Intervention|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
11276559|NCT02858700|Experimental|umbilical cord blood procalcitonin|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
11276560|NCT02858687|Experimental|Patients with clinical diagnosis of tonsillitis|
11276561|NCT02858674|Experimental|Active Alerting Mechanism|Traditional Pop Up Alert used in Epic
11276562|NCT02858674|Active Comparator|Passive Alerting Mechanism|Noninterruptive alert that sits in the checklist
11276563|NCT02858661|Experimental|Patients diagnosed with clinical meningitis|Patients admitted in emergency rooms for clinical meningitis, for which a nasopharyngeal swab will be performed in order to confirm the etiological diagnosis of meningitis
11276564|NCT02858648|Experimental|Behavior intervention with smart phone based self-monitoring|Patients in this group were asked to attend 11 group and 1 individual session over 6 months, and received a smartphone with two downloaded applications to monitor diet, physical activity, weight, and blood glucose (connected with a blue tooth glucometer) throughout 6 months.
11276565|NCT02858648|Experimental|Behavior intervention with paper diary based self-monitoring|Patients in this group were asked to attend 11 group sessions and 1 individual session over 6 months, and received paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer to monitor diet, physical activity, weight, and blood glucose throughout 6 months.
11276566|NCT02858648|No Intervention|Usual care|Patients in this group received no intervention, they continue to receive usual diabetes care and education from the recruitment clinic.
11276567|NCT02858635|Experimental|Suicide attempters|Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
11276568|NCT02858622|Active Comparator|dual TAB group|22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
11276569|NCT02858622|Sham Comparator|control group|22 patients who will not receive dual TAB block
11276570|NCT02858609|Experimental|Patients with Diarrhoea|Patients admitted in emergency room with Diarrhoea
11276571|NCT02858596|Experimental|Semi-solid feed group|Given semi-solid feed protocol
11276572|NCT02858596|Placebo Comparator|Liquid feed group|Given liquid feed protocol
11276573|NCT02858583|Experimental|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI."
11276574|NCT02858583|Active Comparator|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
11276575|NCT02858570|Experimental|MenCC-BIO Vaccine|Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old)For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
11276576|NCT02858570|Active Comparator|combined - CRM197|Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
11276577|NCT02858557|Experimental|Group A|Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
11276578|NCT02858557|Experimental|Group B|Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
11276579|NCT02858544||Group1 - Validation Group|n=890 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
11276580|NCT02858544||Group 2 - Cross Validation Group|n=900 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
11276581|NCT02858531||patients < 24 months or 60 years with bronchiolitis or ARF|ARF = Acute Renal Failure
11276582|NCT02858518||patients with atrial fibrillation with anticoagulant treatment|
11276583|NCT02858505|Active Comparator|27 mg elemental iron group|received 27 mg elemental iron once daily starting at 12 weeks until 36 weeks
11276585|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
11276586|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
11276587|NCT02858479|Other|patients with pain allodynic peripheral|
11276588|NCT02858479|Other|patients with pain allodynic central|
11276589|NCT02858466|Experimental|peripheric nervous lesion|MRI scan
11276590|NCT02858466|Experimental|medullar or encephalic lesion|MRI scan
11276591|NCT02858466|Other|control group|MRI scan
11276592|NCT02858453|Experimental|AQX-1125 100 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
11276593|NCT02858453|Experimental|AQX-1125 200 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
11276594|NCT02858453|Placebo Comparator|Placebo|2 placebo tablets, by mouth, once per day for 12 weeks; followed by randomization to 100 mg or 200 mg AQX-1125 for a 52-week Extension Period
11276595|NCT02858440|Experimental|DTPa-IPV/Hib Group|All subjects receive three doses of primary vaccination of the study vaccine, Infanrix-IPV/Hib (DTPa-IPV/Hib), at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
11276596|NCT02858427|Experimental|depressed with suicide attempt (SA)|elderly depressed patients with a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
11276597|NCT02858427|Experimental|depressed without a history of SA|elderly depressed patients without a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
11276598|NCT02858414|Experimental|blood sample|
11276599|NCT02858401|Experimental|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
11276600|NCT02858401|Experimental|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
11276601|NCT02858401|Experimental|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
11276602|NCT02858401|Experimental|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
11276603|NCT02858401|Experimental|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
11276604|NCT02858401|Experimental|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
11276605|NCT02858401|Experimental|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
11276606|NCT02858401|Experimental|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
11276607|NCT02858401|Experimental|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
11276608|NCT02858401|Placebo Comparator|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
11276609|NCT02858388|Active Comparator|SN45|Sinuclean Nebules 45
11276610|NCT02858388|Placebo Comparator|Sal|Saline solution
11276611|NCT02858362|Experimental|Cohort 1: SMT C1100 Formulation 1|Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
11276612|NCT02858362|Experimental|Cohort 2: SMT C1100 Formulation 2|Participants received 1 g SMT C1100 formulation 2 orally twice-daily for at least 48 weeks.
11276613|NCT02858362|Experimental|Cohort 3: SMT C1100 Formulation 1|Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
11276614|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
11276615|NCT02858336|Active Comparator|Control|All participants will receive the NEA availability to act as their own control to the experimental DEA intervention.
11276616|NCT02858336|Experimental|Experimental|All participants will be in the experimental arm and received the DEA intervention.
11276617|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
11276618|NCT02858310|Experimental|Arm 1: Phase I|Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR Cells at escalating doses, followed by aldesleukin.
11276619|NCT02858310|Experimental|Arm 2: Phase II|1 x 10 e11 E7 Cells that was determined in Phase I +aldesleukin
11276620|NCT02858297|Experimental|Glucosamine/Corticosteroid 4|Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
11276621|NCT02858297|Experimental|Glucosamine/Corticosteroid 2|Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
11276622|NCT02858297|Active Comparator|Corticosteroid|Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
11276623|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
11276624|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
11276625|NCT02858271|Experimental|AKB-9778|Single dose of [14C]-radiolabeled subcutaneous (SC) injection of AKB-9778 in the morning of Day 1
11276626|NCT02858258|Active Comparator|Standard Arm A|"R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
~Drug: R-CHOP/R-DHAP
~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM"
11276680|NCT02857842|Active Comparator|Standard of care|Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days
11276681|NCT02857829|Placebo Comparator|Placebo|
11276627|NCT02858258|Experimental|Experimental Arm A+I|"R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)
~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM
~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)"
11276628|NCT02858258|Experimental|Experimental Arm I|"R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle
~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)
~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)"
11276629|NCT02858245||Commercial MitraClip® patients|Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
11276630|NCT02858232|Experimental|solid tumor|Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
11276631|NCT02858219|Experimental|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).
~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
11276632|NCT02858219|Placebo Comparator|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
11276633|NCT02858206|Experimental|Neoadjuvant nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.
~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
11276634|NCT02858206|Active Comparator|Neoadjuvant chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.
~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
11276635|NCT02858206|Experimental|Radical nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
11276636|NCT02858206|Active Comparator|Radical chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
11276637|NCT02858193|Experimental|1.35 g SCMC- lys powder|1.35 g of SMC L-lysine monohydrate salt powder for solution
11276638|NCT02858193|Experimental|Fluifort® syrup|Fluifort® syrup 90 mg SCMC-lys/mL
11276639|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)
~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
11276640|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)
~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
11276641|NCT02858167|Experimental|FDG-PET|
11276642|NCT02858154|Other|Crossover HFNC and Oxygen by Cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (oxygen by nasal cannula)
11276643|NCT02858115||one lung ventilation lung|patients requiring one lung ventilation lung resection.
11276644|NCT02858102|Active Comparator|Active treatment group|Physical activity program: 36 sessions of physical activity lasting between 30-60 minutes for 12 weeks, three days per week.
11276645|NCT02858102|No Intervention|Control group|No physical activity program
11276646|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
11276647|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
11276648|NCT02858063||Pending chemotherapy +/- trastuzumab|In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
11276649|NCT02858063||pending trastazumab +/- hormone therapy|In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
11276751|NCT02857322|Other|subjects with documented psychiatric pathology|
11276650|NCT02858063||pending hormone therapy alone|In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
11276651|NCT02858063||pending afercare period|In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
11276652|NCT02858050||MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
11276653|NCT02858050||MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
11276654|NCT02858037|Experimental|HIV Open-label Prevention|"Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women
~MTN-020:NCT01617096 MTN-025: NCT02858037"
11276655|NCT02858024|Active Comparator|Cohort I|In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
11276656|NCT02858024|Active Comparator|Cohort II|In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
11276657|NCT02858011|Active Comparator|Control and comparison group -cash transfer program|The program is implemented during 48 months. During the first 36 months the control group does not receive any intervention. During the last 12 months eligible beneficiaries receive cash transfer and accompanying information sessions on health, child nutrition, household economics every three months (identical to experimental group).
11276658|NCT02858011|Experimental|Jigisemejiri cash transfer program|Unconditional cash is distributed every 3 months to beneficiaries of the Jigisemejiri program. During cash handouts, information sessions on health, child nutrition, households economics and education are organized by local NGOs.
11276659|NCT02858011|Experimental|Jigisemejiri - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women receiving rations of fortified flour (PNP) during the last 12 months of the project
11276660|NCT02858011|Active Comparator|Control and comparison group - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women
11276661|NCT02857998|Experimental|HMPL-523|Oral administration, at dose of 200, 400, 600 and 800 mg once daily;at dose of 200,300, 400mg twice daily at Dose-escalation stage; At Dose-expansion stage, if patients dosing at 600mgQD.
11276662|NCT02857985|Experimental|Patient with Myocardial Infarction|
11276663|NCT02857972|Experimental|Wondaleaf®|This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
11276664|NCT02857959|Experimental|single dose benzathine penicillin G.|single dose benzathine penicillin G.
11276665|NCT02857959|Active Comparator|three doses of benzathine penicillin G.|three doses of benzathine penicillin G.
11276666|NCT02857946|Experimental|A Test|Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin
11276667|NCT02857946|Active Comparator|B Reference|Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin
11276668|NCT02857933|Other|Frequency Level 1 - Daily Therapy|Level 1 daily physical therapy is 2 hours of one-on-one physical therapy per day for 20 straight weekdays
11276669|NCT02857933|Other|Frequency Level 2 - Intermediate Therapy|Level 2 intermediate physical therapy is 2 hours of therapy per day 3 days per week for 6.6 weeks
11276670|NCT02857933|Other|Frequency Level 3 - Usual Therapy|Level 3 usual weekly physical therapy is 2 hours of therapy one day per week for 20 weeks.
11276671|NCT02857920|Experimental|Bevacizumab and NK immunotherapy|In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11276672|NCT02857920|Active Comparator|Bevacizumab|In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11276673|NCT02857907||ATG group|Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
11276674|NCT02857907||anti-CD25 group|Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
11276675|NCT02857881|Experimental|Evolutive keratoconus|
11276676|NCT02857868|Experimental|ABL001|
11276677|NCT02857855|Experimental|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
11276678|NCT02857855|Active Comparator|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
11276679|NCT02857842|Experimental|Blood eosinophil guided prednisolone treatment|Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood <0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.
11277200|NCT02854293||control group|"Conventional palliative management
~76 patients"
11276682|NCT02857829|Active Comparator|Caffeine-alone|The effects of the combination will be compared to both placebo and caffeine-alone, to test the hypothesis that the blend of ingredients will enhance cognitive measures greater than the most commonly used cognitive enhancer, caffeine.
11276683|NCT02857829|Experimental|CAF+|
11276684|NCT02857816|Other|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
11276685|NCT02857803|Experimental|Virtual Reality|The Virtual Reality group will perform personalised activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
11276686|NCT02857803|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalised to their deficits and generated automatically through a Task Generator.
11276687|NCT02857803|Active Comparator|Conventional Therapy|The Conventional Therapy group will perform the activities offered by the public health system, which are motor-focused.
11276688|NCT02857777|Experimental|Cohort 1: Japanese elderly subjects (Esketamine)|Subjects will receive Treatment A (28 milligram [mg] of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0) in Period 1, Treatment B (56 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0 and 5 minutes) in Period 2 and then Treatment C (84 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0, 5, and 10 minutes) in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
11276689|NCT02857777|Active Comparator|Cohort 2: Japanese healthy subjects (Esketamine)|Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
11276690|NCT02857764||Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users|Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
11276691|NCT02857764||Canagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.
11276692|NCT02857764||Dapagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
11276693|NCT02857764||Empagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
11276694|NCT02857764||First-time Non-SGLT2i AHA New Users|Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
11276695|NCT02857751||Surf therapy cohort 1|The first cohort of participants to enroll in the study (i.e., participants in the first 6-week program)
11276696|NCT02857751||Surf therapy cohort 2|The second cohort of participants to enroll in the study (i.e., participants in the second 6-week program)
11276697|NCT02857751||Surf therapy cohort 3|The third cohort of participants to enroll in the study (i.e., participants in the third 6-week program)
11276698|NCT02857751||Surf therapy cohort 4|The fourth cohort of participants to enroll in the study (i.e., participants in the fourth 6-week program)
11276699|NCT02857751||Surf therapy cohort 5|The fifth cohort of participants to enroll in the study (i.e., participants in the fifth 6-week program)
11276700|NCT02857738|Experimental|SPF evaluation|Subjects with Good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
11276701|NCT02857725|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were considered for SPF testing.
11276702|NCT02857712|Experimental|Axitinib|Axitinib will be administered at 5 mg BID (starting dose); in case of no adverse events above CTCAE version 4.0 Grade 2 for a consecutive 2-week periods, the dose may be increased to 7 mg BID and further to 10 mg BID using the same criteria until tumor progression, unacceptable toxicity or other criteria for discontinuation is met.
11276703|NCT02857686|Active Comparator|arm intravenous regional anesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
11276704|NCT02857686|Experimental|forearm intravenous regional anesthesia|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
11276705|NCT02857673|Experimental|Intervention Group|The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
11276706|NCT02857673|Active Comparator|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers. The study team member will not be trained in CAPPS and will adhere to a case management model consistent with resources available in the medical home, checking in with control families and offering to help identify existing clinic and community resources as needed.
11276707|NCT02857660|Experimental|Whole-Body Electromyostimulation and Protein|16 weeks of whole-body intervention 1.5 x 20 min week with bipolar current up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
11276708|NCT02857660|Active Comparator|Protein supplementation|up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
11276709|NCT02857660|No Intervention|sedentary Control Group|No protein supplementation or WB-EMS-application, but up to 800 IU/d Vitamin D-Supplementation
11276710|NCT02857647|Experimental|The experimental group|"Participants who will assigned to the experimental group will be asked to watch an information video of 30 minutes 1-2 weeks prior to the surgery date.
~n=100."
11276711|NCT02857647|No Intervention|The control group|"Participants who will assigned to the control group will receive standard care and will not asked to watch a videotaped lecture prior to the surgery.
~n=100."
11276712|NCT02857634||Bladder tumor resection|
11276713|NCT02857608|Experimental|Lymphoseek - 0.5 mCi, 50 ug|A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
11276714|NCT02857595|Active Comparator|Online Weight Loss Program|
11276715|NCT02857595|Experimental|Online Weight Loss Program + Nomogram|
11276716|NCT02857595|Experimental|Online Weight Loss Program + Nomogram + Bite Counter|
11276717|NCT02857582|Active Comparator|Vancomycin|Secondary treatment for relapse of Clostridium difficile infection.
11276718|NCT02857582|Experimental|Cultured human intestinal microbiota1|Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
11276719|NCT02857582|Experimental|Cultured human intestinal microbiota2|Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.
11276720|NCT02857569|Experimental|Experimental IT Arm|"ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response, eradication of all injectable sites, disease progression or toxicity, for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).
~nivolumab: 1mg/kg, IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
11276721|NCT02857569|Active Comparator|Standard Arm|"ipilimumab: 3mg/kg, IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.
~nivolumab: 1mg/kg, IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
11276722|NCT02857556|Other|group with stage 3 kidney failure (diabetic or not)|
11276723|NCT02857556|Other|group with stage 5 kidney failure (diabetic or not)|
11276724|NCT02857543|Active Comparator|plant-based diet|Plant-based diet with as few added oils and fats as possible
11276725|NCT02857543|Active Comparator|American Heart Association|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, and lean meat and fish in moderation.
11276726|NCT02857543|Active Comparator|Mediterranean|Diet encourages fruits, vegetables, whole grains, and low sodium intake but permits non-whole grains, low-fat dairy, selected plant oils, with more emphasis on fish and extra virgin olive oil and/or nuts.
11276727|NCT02857530|Experimental|rhTPO|rhTPO injection
11276728|NCT02857530|Placebo Comparator|control|without rhTPO injection
11276729|NCT02857517|Experimental|intravitreal 0.05ml conbercept for ICNV|0.05ml conbercept ,1 injection with PRN
11276730|NCT02857504|Other|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
11276731|NCT02857504|Other|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
11276732|NCT02857491|Experimental|ranibizumab|Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.
11276733|NCT02857491|Sham Comparator|control|Sham intravitreal injection one week before vitrectomy.
11276734|NCT02857478|Experimental|Safety of a Sunscreen product|Sunscreen product safety evaluation under supervised out-door conditions on sport users.
11276735|NCT02857465|Experimental|Epidural analgesia + DEXAMETHASONE|Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
11276736|NCT02857465|Placebo Comparator|Epidural analgesia + PLACEBO|Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
11276737|NCT02857452||Lupus|
11276738|NCT02857439|Other|MD as first examiner|Patients will be examined according to a standardized physical examination item list
11276739|NCT02857439|Other|Triage nurse as first examiner|Patients will be examined according to a standardized physical examination item list
11276740|NCT02857426|Experimental|Nivolumab for population with PCNSL|Specified dose on specified days
11276741|NCT02857426|Experimental|Nivolumab for population with PTL|Specified dose on specified days
11276742|NCT02857400|Other|Arm A (standard)|
11276743|NCT02857400|Experimental|Arm B (experimental)|
11276744|NCT02857387|Experimental|acute coronary syndrome|
11276745|NCT02857374|Experimental|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
11276746|NCT02857361|Experimental|Treatment A: Simultaneous Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
11276747|NCT02857361|Experimental|Treatment B: Sequential Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
11276748|NCT02857348|Experimental|Adventure video game|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for one hour.
11276749|NCT02857348|Active Comparator|Educational Module|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least one hour on the combined tasks.
11276750|NCT02857335|Other|study group|patients with benign intracranial hypertension ages 8-16 years
11276752|NCT02857309|Other|Device implant|Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
11276753|NCT02857309|Active Comparator|Optimal medical therapy|Patients randomized to the control group will receive optimal medical therapy for heart failure.
11276754|NCT02857283|Experimental|Filtered Air, then Ozone|Participants in this arm will first receive filtered clean air followed by ozone
11276755|NCT02857283|Experimental|Ozone, then Filtered Air|Participants in this arm will first receive ozone followed by filtered clean air
11276756|NCT02857270|Experimental|LY3214996 Dose Escalation|LY3214996 given orally once a day (or twice a day) for 21 days.
11276757|NCT02857270|Experimental|LY3214996 + Midazolam|"(Preliminary Drug-Drug Interactions [DDI])
~LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days)."
11276758|NCT02857270|Experimental|LY3214996 Dose Expansion|LY3214996 given orally (once a day) during each 21 day cycle.
11276759|NCT02857270|Experimental|LY3214996 + Abemaciclib|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.
11276760|NCT02857270|Experimental|LY3214996 + Nab-Paclitaxel + Gemcitabine|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.
11276761|NCT02857270|Experimental|LY3214996 + Encorafenib + Cetuximab|Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.
11276762|NCT02857270|Experimental|Japan Part 1|LY3214996 given orally.
11276763|NCT02857270|Experimental|Japan Part 2|LY3214996 given orally and abemaciclib given orally.
11276764|NCT02857257|Experimental|Treatment arm|Only one treatment arm. Patients are allocated under disease condition and later treated with ACHIM. The post-treatment disease progression is monitored.
11276765|NCT02857244|Other|Open-Label Treatment Arm|"Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week.
~After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week.
~Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil."
11276766|NCT02857218|Experimental|Diagnostic (ferumoxytol, MRI)|Patients receive ferumoxytol IV over 15 minutes and then undergo ferumoxytol-enhanced MRI (Magnetic Resonance Imaging) after 24-36 hours and before surgery at week 12.
11276767|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
11276768|NCT02857192|Experimental|Horton|
11276769|NCT02857192|Placebo Comparator|control|
11276770|NCT02857166|Experimental|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
11276771|NCT02857153|Experimental|Low-level MAP|According to grouping, MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
11276772|NCT02857153|Experimental|High-level MAP|According to grouping, MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
11276773|NCT02857127|Experimental|Intervention Group|A group of people who participated in the walking program during a six month period. This group also received an educational material and attended meetings for behavioral change strategies.
11276774|NCT02857127|No Intervention|Control Group|A group of people who did not receive the educational material and did not participated in any of the activities offered by the research team, such as walking classes and meetings for behavioral change.
11276775|NCT02857114|Other|massage|
11276776|NCT02857088|Experimental|depressed patients|patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
11276777|NCT02857088|Experimental|non depressed subject|subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
11276778|NCT02857075||Rhesus positive individuals|Red cell concentrates from RH1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
11276779|NCT02857075||Rhesus negative individuals|red cell concentrates from RH-1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
11276780|NCT02857062|Experimental|E45 Eczema Repair Emollient|Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
11276781|NCT02857049|Experimental|Geriatric patients administered with ONS|Oral nutritional supplements (ONS) degustation
11276782|NCT02857036|Experimental|responder|responder to antidepressant treatment
11276783|NCT02857036|Experimental|non responder|non responder to antidepressant treatment
11276784|NCT02857023|Experimental|Cogmed intervention|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
11276785|NCT02857023|Experimental|Cogmed-waitlist control|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
11276786|NCT02857010|Experimental|Allogenic Mesenchymal stem cells|Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
11276787|NCT02857010|Placebo Comparator|Placebo|Solution without cells on days 1, 4, 11 and 18
11276864|NCT02856477|Experimental|adapted treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
11276865|NCT02856477|Experimental|non-adaptated treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
11276788|NCT02856997|Experimental|Chidamide with ICE regimen|"Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours during Ifosfamide transfusion, ivg, d1-4; Carboplatin AUC=4, d2,ivg; etoposide 65mg/m 2, d1-4, ivg. 3 weeks as 1 course, for 6 courses.
~if the effect is PR or better than PR, go to auto-stem cell transplantation, no further treatment with Chidamide is needed.
~If the effect is PR or better than PR and no auto-stem cell transplantation available,Chidamide 20mg orally, twice every week, till the end of the trial."
11276789|NCT02856984||ZIKV infected women|The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.
11276790|NCT02856984||Control (uninfected women)|The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.
11276791|NCT02856958|Experimental|Operative|Peroneal nerve decompression
11276792|NCT02856958|Active Comparator|Non-operative|Physical therapy
11276793|NCT02856932|Experimental|Glass Ionomer with Glass Hybrid technology|Intervention
11276794|NCT02856932|Active Comparator|Conventional high viscosity Glass Ionomer|Comparator
11276795|NCT02856919|Other|Mirvaso® gel|Mirvaso® gel (5 mg/g brimonidine tartrate)
11276796|NCT02856906|Experimental|Occlusal adjustment group|Patients in this group will receive treatment of occlusal adjustment based on the clinical and lab examination results.
11276797|NCT02856893|Experimental|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
11276798|NCT02856893|Experimental|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
11276799|NCT02856893|Active Comparator|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
11276800|NCT02856880|Experimental|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
11276801|NCT02856880|Experimental|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
11276802|NCT02856880|Active Comparator|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
11276803|NCT02856880|Active Comparator|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
11276804|NCT02856880|Active Comparator|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
11276805|NCT02856867|Active Comparator|mFOLFOX6 + Nintedanib|"Patients will receive nintedanib in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).
~Dose modification of nintedanib and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
11276806|NCT02856867|Placebo Comparator|mFOLFOX6 + Placebo|"Patients will receive placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).
~Dose modification of placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
11276807|NCT02856854|Experimental|EMB-001 (oral)|EMB-001 will be orally administered for 7 consecutive days, twice daily for 6 days followed on the last day by one EMB-001 oral dose (QD) in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
11276808|NCT02856854|Placebo Comparator|Placebo (oral)|PLB-to-match EMB-001 will be orally administered for 7 consecutive days, BID for 6 days, followed on the last day by one PLB oral dose in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
11276809|NCT02856841||optimum cytoreduction|without any gross tumor residue after surgery
11276810|NCT02856841||Suboptimum cytoreduction|with any gross tumor residue after surgery
11276811|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
11276812|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
11276813|NCT02856815|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 12 times(5 treatments at a frequency of once per week, followed by 5 treatments every 2 weeks, and finally 2 treatments every 4 weeks.
11276814|NCT02856815|No Intervention|Non-treatment group|Non-treatment
11276815|NCT02856802|Experimental|DFN-02|DFN-02 Active
11276816|NCT02856802|Other|Placebo|DFN-02 Placebo
11276817|NCT02856789||Healthy volunteers (HV)|"HV without any known treatment, without any coagulation trouble and with normal hemostasis results.
~FS and TEG will be processed to define the most relevant parameters for normal range and the correlation between both assays.
~Tests performed on HV :
~Routine hemostasis tests
~Fibrin structure (FS)
~Thromboelastography (TEG)
~Specialized hemostasis tests"
11276818|NCT02856789||Patients without coagulation disorder|"Hospitalized patients without coagulation disorder or abnormal hemostasis and hematological results and witout ongoing treatment (mainly anticoagulant treatment). FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.
~Tests performed on patients :
~Routine hemostasis tests
~Fibrin structure (FS)
~Thromboelastography (TEG)"
11276866|NCT02856464|Experimental|Experimental|
11276867|NCT02856464|Other|Control|
11276868|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
11276819|NCT02856789||Patients with coagulation disorders|"Hospitalized patients with coagulation disorders, mainly trauma patients or abnormal hemostasis and hematological results, mainly decreased fibrinogen level . FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.
~Tests performed on patients :
~Routine hemostasis tests
~Fibrin structure (FS)
~Thromboelastography (TEG)"
11276820|NCT02856776|Experimental|Arm 1: 600 IU vitamin D|Subject will receive 600 IUs of vitamin D3/day for 24 weeks.
11276821|NCT02856776|Experimental|Arm 2: 4,000 IU vitamin D|Subject will receive 4,000 IUs of vitamin D3/day for 24 weeks
11276822|NCT02856776|Experimental|Arm 3: 10,000 IU vitamin D|Subjet will receive 10,000 IUs of vitamin D3/day for 24 weeks
11276823|NCT02856776|Experimental|Arm 4: Mixed vitamin D dosages|Subject will receive 600 IUs of vitamin D3/day for the first 8 weeks, 4,000 IUs of vitamin D3/day for the next 8 weeks, and 10,000 IUs of vitamin D3/day for the final 8 weeks.
11276824|NCT02856750|Experimental|gabapentin|gabapentin 300 mg three times daily x 30 d
11276825|NCT02856750|No Intervention|placebo|no gabapentin administered to this arm.
11276826|NCT02856737|Experimental|Earplugs and eye masks (to be used concurrently)|Group will include patients consented to the use of earplugs and eye masks. Patients will participate in the intervention nightly
11276827|NCT02856724|Experimental|Early amniotomy and PGE2|10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
11276828|NCT02856724|Active Comparator|PGE2|10 mg PGE2 vaginal ovul(Propess)
11276829|NCT02856711|Experimental|Trauma-informed group|These groups will use the enhanced Centering Pregnancy curriculum.
11276830|NCT02856711|No Intervention|Control group|These groups will use the standard CenteringPregnancy curriculum.
11276831|NCT02856698|Experimental|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
11276832|NCT02856698|Active Comparator|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
11276833|NCT02856685|Experimental|PLM60|Mitoxantrone Hydrochloride Liposome
11276834|NCT02856672|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
11276835|NCT02856672|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
11276836|NCT02856646||Population with Condition|Community Sample
11276837|NCT02856633||Vitaliti System|
11276838|NCT02856620||Moderate AS with HF|
11276839|NCT02856620||Severe AS with HF|
11276840|NCT02856620||Moderate AS without HF|
11276841|NCT02856620||Severe AS without HF|
11276842|NCT02856620||HFpEF without AS|
11276843|NCT02856620||Normal age-matched controls|
11276844|NCT02856607||Group I|patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
11276845|NCT02856607||Group II|patients secondary addressed to a referent center with cardiac surgery
11276846|NCT02856607||Group III|patients for which the totality medical care are performed in non-referent health center
11276847|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
11276848|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
11276849|NCT02856581|Experimental|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
11276850|NCT02856581|Placebo Comparator|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
11276851|NCT02856568|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, ricolinostat)|Patients receive cisplatin IV followed by gemcitabine hydrochloride IV on days 1 and 8, and ricolinostat PO on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11276852|NCT02856555|Experimental|Firsocostat 5 mg|Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
11276853|NCT02856555|Experimental|Firsocostat 20 mg|Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
11276854|NCT02856555|Experimental|Placebo|Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
11276855|NCT02856529|Experimental|Intervention|A BICSL certified trainer conduct the intervention. It includes hand on training session standardized in a scientific way. The participants trained on hand hygiene and use of PPE. Also, it includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator.
11276856|NCT02856529|Active Comparator|Control|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
11276857|NCT02856516|Experimental|Boost Glucose Control (A)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
11276858|NCT02856516|Experimental|Boost Glucose Control (B)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
11276859|NCT02856516|Active Comparator|Boost Original|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.
11276860|NCT02856503|Experimental|Phase 1 - Group A - VD 3 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.
11276861|NCT02856503|Active Comparator|Phase 1 - Group B - VD 4 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks
11276862|NCT02856503|Active Comparator|Phase 1 - Group C - VD 5 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.
11276863|NCT02856503|Experimental|Phase 2 - VD|Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.
11276877|NCT02856412|Experimental|Veterans Group Exercise|Exercise 3 times weekly (for 12 weeks), with each total workout lasting approximately 60 minutes. Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
11276878|NCT02856412|Active Comparator|Illness Management and Recovery|Attend 3 health education classes weekly (for 12 weeks), with each class lasting approximately 60 minutes. Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
11276879|NCT02856386|Experimental|polyphenol supplement|Dietary supplement administered 8 mL once daily
11276880|NCT02856373|Other|CPVT|catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
11276881|NCT02856373|Other|long QT syndrome|long QT syndrome patients
11276882|NCT02856373|Other|ARVC|arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
11276883|NCT02856373|Other|HCM|hypertrophic cardiomyopathy (HCM) patients
11276884|NCT02856373|Other|DCM|dilated non-ischemic cardiomyopathy (DCM) patients
11276885|NCT02856373|Other|ICM|ischemic cardiomyopathy (ICM) patients
11276886|NCT02856360|Experimental|Moderate Stiffness|Shoe condition that has moderate stiffness
11276887|NCT02856360|Active Comparator|High Stiffness|Shoe condition that has high stiffness
11276888|NCT02856347|Other|PET 18-FDOPA|"18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).
~PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).
~Other series of images will be done 50 min after tracer injection. Images will be interpreted."
11276889|NCT02856334||Chronic pelvic pain|Women with chronic pelvic pain
11276890|NCT02856334||Control group|Healthy women
11276891|NCT02856308|Experimental|Hairstetics hair implant device|Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject. The implantation will be carried out according to the device IFU.
11276892|NCT02856295|Active Comparator|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight < 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, >170kg-100mg.
11276893|NCT02856295|Active Comparator|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
11276894|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
11276895|NCT02856269|Active Comparator|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
11276896|NCT02856269|Active Comparator|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
11276897|NCT02856256|Experimental|RedBull® energy drink|
11276898|NCT02856230|Experimental|Ranger SL DEB angioplasty|patients filling general and angiographic inclusion/exclusion criteria will have an BTK angioplasty using one or several Ranger SL drug-eluting balloons
11276899|NCT02856217|Active Comparator|tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal tunneling in SCP: creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum.
11276900|NCT02856217|Active Comparator|non-tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal non-tunneling group in SCP: incised and sutured peritoneum between vaginal apex and sacrum
11276901|NCT02856204||Diagnostic (collection of blood samples)|Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
11276902|NCT02856191|Other|Septic shock|
11276903|NCT02856178|Experimental|F901318 + Caspofungin|"Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:
~Day 1: 4.0 mg/kg i.v. b.i.d.
~Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.
~Day after last i.v. application: 2.0 mg/kg oral q.d.
~Concomitant medication:
~For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:
~Chemo day 4: Caspofungin 70 mg i.v. q.d.
~Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.
~All patients will undergo chemotherapy for acute leukaemia according to local clinical standard."
11276904|NCT02856165|Experimental|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher&Paykel (F&P), NZ)
11276905|NCT02856165|Active Comparator|Low-flow oxygen therapy|Low-flow oxygen therapy with standard nasal canula
11276906|NCT02856152|Experimental|Treatment A Then B Then D Then C|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment A on Day 1 of first intervention period, followed by Treatment B on Day 1 of second intervention period, followed by Treatment D on Day 1 of third intervention period, and then Treatment C on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
11276934|NCT02855983|Other|B (Standard of care initially)|"B PATHWAY -
~Intervention: standard of care (observation) for the first year, followed by autologous fat grafting to the foot
~Observation visit will occur first, next the subject will have two Observation visits V1 (Month 2) and V2 (Month 6). The subject will then crossover to Pathway A. The subject will be assessed by the PI his/her for continued study eligibility. Once the continued eligibility has been determined, the subject will have the interventional fat graft procedure and subsequent post-operative follow up visits (V1-V4). After completion of Post-op V4 (Month 6), the subject will have completed study participation."
11276935|NCT02855970|Experimental|patient|
11276907|NCT02856152|Experimental|Treatment B, Then C, Then A, Then D|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment B on Day 1 of first intervention period, followed by Treatment C on Day 1 of second intervention period, followed by Treatment A on Day 1 of third intervention period, and then Treatment D on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
11276908|NCT02856152|Experimental|Treatment C, Then D, Then B, Then A|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment C on Day 1 of first intervention period, followed by Treatment D on Day 1 of second intervention period, followed by Treatment B on Day 1 of third intervention period, and then Treatment A on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
11276909|NCT02856152|Experimental|Treatment D, Then A, Then C, Then B|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment D on Day 1 of first intervention period, followed by Treatment A on Day 1 of second intervention period, followed by Treatment C on Day 1 of third intervention period, and then Treatment B on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
11276910|NCT02856139||1 (MB- and VL-)|without mottled fluorescent band (MB) and vascular leakage (VL)
11276911|NCT02856139||2 (MB+ and VL-)|with mottled fluorescent band (MB), without vascular leakage (VL)
11276912|NCT02856139||3 (MB-/+ and VL+)|with or without mottled fluorescent band (MB), with vascular leakage (VL)
11276913|NCT02856126|Experimental|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
11276914|NCT02856126|Active Comparator|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
11276915|NCT02856113|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
11276916|NCT02856113|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
11276917|NCT02856100||Patients with CRPC, evidence of metastases, planned treatment|
11276918|NCT02856087|Placebo Comparator|group LR|low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
11276919|NCT02856087|Active Comparator|group HR|High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
11276920|NCT02856087|Experimental|group HR-N|remifentanil infusion at 4ng/ml of Ce with naloxone infusion
11276921|NCT02856074|Experimental|Ischemic stroke patients|
11276922|NCT02856061|Other|PRT|Children with ASD who are currently receiving PRT treatment.
11276923|NCT02856061|No Intervention|Wait List / Non-Treatment Control|Children with ASD who are not currently receiving PRT treatment.
11276924|NCT02856061|No Intervention|Typically Developing|Children without ASD or developmental delay.
11276925|NCT02856048|Experimental|Triptorelin (GnRHa) + Chemotherapy|Triptorelin LP 3 mg (DECAPEPTYL LP 3 mg, IPSEN) 3 mg every 28±3 days, intramuscular during chemotherapy
11276926|NCT02856048|No Intervention|Chemotherapy alone|Patient having a chemotherapy without drug injection for fertility preservation
11276927|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.
~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
11276928|NCT02856022|Experimental|Electrical ilioinguinal nerve stimulation|
11276929|NCT02856022|Active Comparator|Intravesical Irrigation|
11276930|NCT02856009|Experimental|patient|
11276931|NCT02855996|Experimental|Intervention|"Fathers will be randomly assigned to participate in the Fathers in Action/Padres Activos (FA/PA) intervention program to support fathers' healthy relationships with their children and support their co-parenting skills."
11276932|NCT02855996|No Intervention|Control|"Fathers waitlisted for participation in the Fathers in Action/Padres Activos (FA/PA) program."
11276933|NCT02855983|Experimental|A (Fat grafting initially)|"A PATHWAY -
~Intervention: autologous fat grafting to the foot, occur first
~Fat graft study intervention procedure to occur first, next post-operative follow up visits (V1-V4). The Subject will after Month 6 (V4) crossover to Pathway B to complete Observation visits V1 (Month 2) and V2 (Month 6). After completion of V2 (Month 6), the subject will have completed study participation."
11276936|NCT02855957|Other|Blood sample|A blood collection is carry out in the three populations of patients during the day of their enrolment.
11276937|NCT02855944|Experimental|Rucaparib|"Drug: Oral rucaparib
~600 mg BID Other Names: •CO-338
~PF 01367338
~AG 14699
~Rubraca"
11276988|NCT02855619|Active Comparator|Cader|A threshold-based IMT is performed like used by Cader in a randomized trial in 2012, in a view of inspiratory endurance increase.
11277201|NCT02854280|Active Comparator|Chronic Obstructive Pulmonary Disease (COPD)|18 patients
11276938|NCT02855944|Active Comparator|Chemotherapy|"Monotherapy platinum (cisplatin or carboplatin) or platinum-based doublet chemotherapy (carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
~Single agent paclitaxel will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision."
11276939|NCT02855931|Experimental|Middle turbinate resection|Resection of one middle turbinate
11276940|NCT02855931|No Intervention|Middle turbinate preservation|Preservation of one middle turbinate
11276941|NCT02855918|Other|Blood sample for genetic purpose|"All the participants performed the same evaluations and blood analysis.
~The study is composed of 3 groups :
~depressed patients with an history of suicide attempt
~depressed patients without any history of suicide attempt
~healthy controls without any history of psychopathology"
11276942|NCT02855905|Experimental|Coronary artery disease patients|Coronary artery disease patients are exposed to brief cold exposure (-15 C for 30 min) mainly subjected to facial region during which their cardiovascular responses are registered. Exposure was repeated 4 times: rest and exercise in 22 C and rest and exercise in -15 C.
11276943|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
11276944|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
11276945|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
11276946|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration
~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
11276947|NCT02855879||CAD patients|
11276948|NCT02855866|Experimental|cryotherapy|
11276949|NCT02855866|Active Comparator|Cortisone aerosol|
11276950|NCT02855866|Placebo Comparator|Management|
11276951|NCT02855853|Experimental|serious game|
11276952|NCT02855853|Placebo Comparator|control|
11276953|NCT02855840||systemic lupus erythematous|
11276954|NCT02855840||systemic sclerosis|
11276955|NCT02855840||inflammatory myopathy|
11276956|NCT02855801|Experimental|constant exercise without cryotherapy|constant exercise without cryotherapy
11276957|NCT02855801|Experimental|constant exercise with cryotherapy|constant exercise with cryotherapy
11276958|NCT02855801|Experimental|intermittent exercise, no cryotherapy|intermittent exercise without cryotherapy
11276959|NCT02855801|Experimental|intermittent exercise and cryotherapy|intermittent exercise with cryotherapy
11276960|NCT02855788|Experimental|POLF regimen|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
11276961|NCT02855775|Experimental|Bevacizumab|Bevacizumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
11276962|NCT02855775|Experimental|Trastuzumab|Trastuzumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
11276963|NCT02855762|Other|Dietary Intervention Group|Subject will be guided to eat a high polyunsaturated fatty acid diet.
11276964|NCT02855749|No Intervention|landmark group|percutaneous tracheostomy with traditional landmark technique
11276965|NCT02855749|Active Comparator|ultrasound-guided long axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided in plane technique
11276966|NCT02855749|Active Comparator|ultrasound-guided short axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided out of plane technique
11276967|NCT02855736|Experimental|Intervention group|Positive Psychology (gratitude journal)
11276968|NCT02855736|Placebo Comparator|Control group|Alimentary list
11276969|NCT02855723|Active Comparator|GS strategy|sentinel node biopsy
11276970|NCT02855723|Other|Classic strategy|systematic lymphadenectomy
11276971|NCT02855710|Other|No training|Parkinsonian Patients with no Rhythm Workers training perceptive timing and senrorimotor timing
11276972|NCT02855710|Other|Perceptive timing training|Parkinsonian Patients with Rhythm Workers training perceptive timing
11276973|NCT02855710|Other|Sensorimotor timing training|Parkinsonian Patients with Rhythm Workers training sensorimotor timing
11276974|NCT02855710|Other|Healthy volunteers|Healthy people with Rhythm Workers training perceptive timing
11276975|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
11276976|NCT02855684|Experimental|Toujeo - insulin glargine (U300)|Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
11276977|NCT02855684|Active Comparator|Lantus - insulin glargine|Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
11276978|NCT02855671||Healthy volunteers|
11276979|NCT02855671||Sepsis|
11276980|NCT02855671||Severe sepsis/septic shock|
11276981|NCT02855658|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
11276982|NCT02855658|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
11276983|NCT02855645|Experimental|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
11276984|NCT02855645|Placebo Comparator|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
11276985|NCT02855632|Experimental|G-CSF|G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
11276986|NCT02855632|Placebo Comparator|Normal saline|equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
11276987|NCT02855619|Active Comparator|Martin|A threshold-based IMT is performed like used by Martin in a randomized trial in 2011, in a view of inspiratory strength increase.
11276989|NCT02855619|Experimental|EDRIC|A new threshold-based IMT is performed, in a view of both inspiratory strength and endurance increase.
11276990|NCT02855593||Physicians|Physicians who perform acupuncture
11276991|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
11276992|NCT02855580||PGX Testing Based Treatment|Treatment will be administered based on the results that are obtained from the pharmacogenomics testing. Results from testing will be provided two weeks after specimen collection.
11276993|NCT02855580||Standard of Care Treatment|Treatment will be based off of the standard of care. Results from pharmacogenomics testing will be provided at the end of the study.
11276994|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
11276995|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
11276996|NCT02855541|Experimental|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
11276997|NCT02855528|Experimental|Reduction of radiation dose and diagnostic accuracy|Reduction of radiation dose during coronary artery calcium scoring with the use of a tin filter system.
11276998|NCT02855515|Experimental|Short-time diagnostic anaesthesia|The study population will consist of patients with obstructive sleep apnoea, which will be classified as mild, moderate, severe (patients who failed or refused primary CPAP treatment). The patients will undergo a short-time general anaesthesia in order to diagnose OSA when relaxed.
11276999|NCT02855502|Active Comparator|Prednisolone|dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
11277000|NCT02855502|Placebo Comparator|Placebo|placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
11277001|NCT02855489|Experimental|Attitudes Only|The attitudes condition targeted cognitive and affective attitudes by pairing attitudinal messages with pictures, and included an evaluative conditioning task.
11277002|NCT02855489|Experimental|Norms Only|The norms condition utilized a group-affirmation exercise, personalized feedback, and group norms in an attempt to greater condom use norms.
11277003|NCT02855489|Experimental|Perceived Behavioral Control Only|The PBC condition included a condom application video, lubrication instructions, condom negotiation videos, and a detailed description regarding purchasing condoms.
11277004|NCT02855489|Experimental|Intentions Only|The intentions condition utilized implementation intentions in order to create condom use intentions.
11277005|NCT02855489|Experimental|Three Constructs|A three construct condition, which included attitudes, norms, and perceived behavioral control represented the core components of the TPB that are thought to work through intentions to result in behavior change.
11277006|NCT02855489|Experimental|Four Constructs|"A four construct condition (i.e., attitudes, norms, PBC, and intentions) was designed to represent the full TPB model intervention which we expected would be more successful than either the three-construct intervention or any of the single construct interventions."
11277007|NCT02855489|No Intervention|No-Treatment, Control|A no-treatment control condition, which solely consisted of pretest and posttest assessments, was included. This allowed us to obtain important information about how the theoretical constructs in the TPB change over time (or do not) in the absence of an experimental manipulation.
11277008|NCT02855476||Early Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD
11277009|NCT02855476||Late Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort
11277010|NCT02855476||Early Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD
11277011|NCT02855476||Moderate Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD
11277012|NCT02855476||Late Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD
11277013|NCT02855476||Controls|Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.
11277014|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
11277015|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
11277016|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
11277017|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
11277018|NCT02855424|No Intervention|control|traditional rehabilitation merely, no ergocycling training
11277019|NCT02855424|Experimental|the low-intensity exercise group|traditional rehabilitation plus the low-intensity ergocycling exercise training
11277020|NCT02855424|Experimental|the moderate-intensity exercise group|traditional rehabilitation plus the moderate-intensity ergocycling exercise training
11277021|NCT02855411|Experimental|0.15 mg PF-04958242|Participants received 0.15 mg oral capsule, twice daily (BID) for 12 weeks
11277022|NCT02855411|Experimental|0.5 mg PF-04958242|Participants received 0.5 mg oral capsule, twice daily (BID) for 12 weeks
11277023|NCT02855411|Placebo Comparator|Placebo|Participants received matching placebo oral capsule, twice daily (BID) for 12 weeks
11277024|NCT02855385||Patient group|This are patients who have current or previous history of rectal bleeding
11277025|NCT02855385||General Practitioner group|This are General practitioner who are in public or private hospitals who treat patients with rectal bleeding
11277027|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
11277028|NCT02855359|Experimental|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
11277029|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
11277030|NCT02855359|Active Comparator|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
11277031|NCT02855346|Experimental|200 mg of DPV|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
11277032|NCT02855346|Experimental|200 mg of DPV + 320 mg LNG|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
11277033|NCT02855333||Merendino Group (MER)|Patients who underwent merendino procedure for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
11277034|NCT02855333||Control Group (CON)|Patients who underwent alternative surgery for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
11277035|NCT02855320|Experimental|PE (patient education)|Nurse-led self-management education intervention : The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
11277036|NCT02855320|No Intervention|Standard|The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
11277037|NCT02855307|Active Comparator|Unannounced exercise|The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
11277038|NCT02855307|Active Comparator|Announced exercise with pre-meal full bolus|The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
11277039|NCT02855307|Active Comparator|Announced exercise with reduced insulin bolus|The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.
11277040|NCT02855294|Active Comparator|Oral contraceptive pills users|The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
11277041|NCT02855294|No Intervention|control|no drugs
11277042|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
11277043|NCT02855268|Experimental|Lademirsen (SAR339375)|Eligible participants will receive subcutaneous injection every week for 48 weeks
11277044|NCT02855268|Placebo Comparator|Placebo|Eligible participants will receive subcutaneous injection every week for 48 weeks
11277045|NCT02855255|Active Comparator|NHS smoking cessation|NHS 1-1 smoking cessation programme. One thirty minute session followed by up to five shorter sessions (approx.10/15minutes) comprising Cognitive Behavioural Therapy/Motivational Interviewing to assist with smoking cessation.
11277046|NCT02855255|Active Comparator|Allen Carr's Easyway smoking cessation|Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
11277047|NCT02855242|Other|Intervention Program Group|Lifestyle Counseling
11277048|NCT02855242|Active Comparator|Controls Group|No lifestyle counseling
11277049|NCT02855229||Phase 1 Participants [No Study Drug]|Phase 1 participants are not being assigned to any study drug.
11277050|NCT02855229||Phase 2 Participants [Placebo]|Phase 2 participants that are randomly assigned to the placebo.
11277051|NCT02855229||Phase 2 Participants [Methylphenidate]|Phase 2 participants that are randomly assigned to take methylphenidate.
11277052|NCT02855229||Phase 2 Participants [Modafinil]|Phase 2 participants that are randomly assigned to take modafinil.
11277053|NCT02855216|Experimental|Manual technique of sub-occipital inhibition|"The technique applied to Manual Group was performed with the patient supine position. Physiotherapist in a sitting position at the head of the subject with forearms resting on the table . Suboccipital region was located , and flexing the metacarpophalangeal joints 90º a pressure was made ventrally , relaxing the rest of the head in the heel of the hand.
~The technique was performed for 5 minutes"
11277054|NCT02855216|Experimental|Self-treatment by way of Occipivot®|The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
11277055|NCT02855203|Experimental|SABR + Pembrolizumab|SABR treatment (18Gy-20Gy/1#) followed by 200mg pembrolizumab IV once every 3 weeks for a total of 8 cycles
11277092|NCT02854969|No Intervention|epinephrine auto-injector|3 months using the epinephrine auto-injector alone, and after that 3 more months using the epinephrine auto-injector + medical device
11277202|NCT02854280|Active Comparator|Sleep Apnea Obstructive (OSA)|18 patients
11277056|NCT02855190|Experimental|68Ga-citrate and 18F-FDG PET scans|The recruited subject with surgery/pathology proved periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.
11277057|NCT02855177|Placebo Comparator|Placebo|Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
11277058|NCT02855177|Experimental|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
11277059|NCT02855164|Experimental|Part A - Arm A|Tropifexor (LJN452)- - dose 1
11277060|NCT02855164|Experimental|Part A - Arm B|Tropifexor (LJN452)- - dose 2
11277061|NCT02855164|Experimental|Part A - Arm C|Tropifezor (LJN452)- - dose 3
11277062|NCT02855164|Experimental|Part A - Arm D|Tropifexor (LJN452)- - dose 4
11277063|NCT02855164|Placebo Comparator|Part A - Arm E|Placebo
11277064|NCT02855164|Experimental|Part B - Arm F|Tropifexor (LJN452)- - dose to be determined
11277065|NCT02855164|Experimental|Part B - Arm G|Tropifexor (LJN452)- - dose to be determined
11277066|NCT02855164|Placebo Comparator|Part B - Arm H|Placebo
11277067|NCT02855164|Experimental|Part C- Arm I|Tropifexor (LJN452)- dose 9
11277068|NCT02855164|Experimental|Part C- Arm J|Tropifexor (LJN452)- dose 10
11277069|NCT02855164|Placebo Comparator|Part C- Arm K|Placebo
11277070|NCT02855138|Active Comparator|study group|The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
11277071|NCT02855138|No Intervention|control group|The control group of this study was pretreatment period of the same volunteer patients.
11277072|NCT02855125|Active Comparator|Combination Therapy (TAS-114/S-1) versus Monotherapy (S-1).|Treatment cycle of the experimental arm (TAS-114/S-1) and control arm (S-1 alone) will be 21 days: 14 days of treatment and 7 days recovery.
11277073|NCT02855125|Active Comparator|Monotherapy (S-1)|Treatment cycle of the active control arm (S-1) be 21 days: 14 days of treatment and 7 days recovery
11277074|NCT02855112|No Intervention|Control|A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.
11277075|NCT02855112|Experimental|Adipose derived Mesenchymal Stem cell|A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks.
11277076|NCT02855099|Active Comparator|CR group|patients will be referred to our rehabilitation centre at the following week after the procedure, and assigned to a personalized rehabilitation program for duration of 3 month.
11277077|NCT02855099|No Intervention|conservative group|No intervention
11277078|NCT02855086|Experimental|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.
~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
11277079|NCT02855086|Experimental|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.
~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
11277080|NCT02855073|Experimental|ReJoinTM Group|Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.
11277081|NCT02855073|Active Comparator|Sodium Hyaluronate Group|subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.
11277082|NCT02855060|Experimental|Pelvic Binder|Commercially available device used to stabilize the pelvis
11277083|NCT02855060|No Intervention|No Binder|Standard of care
11277084|NCT02855034|Other|Blood sample|All the patients performed the same blood samples for dosage: copeptin and protein S100B
11277085|NCT02855021|Other|Parkinson disease|Patients with a Parkinson disease with clinical diagnosis made for at least 5 years
11277086|NCT02855008|Experimental|STEPS|Experimental: Individuals with ID and residential staff in group homes receive 6 one-hour STEPS sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games to build group cohesiveness, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice social problem-solving skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
11277087|NCT02855008|Active Comparator|Food for Life|Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
11277088|NCT02854995|Other|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce.
11277089|NCT02854995|Other|preputioplasty with intralesional injection of triamcinolone|(ii) preputioplasty with intralesional injection of triamcinolone: longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile.
11277090|NCT02854982||Prostate Cancer|Group drawn of the case group of the case control study, entitled EPICAP
11277093|NCT02854969|Experimental|epinephrine auto-injector + medical device|"Device: Anapphylaxis is a medical device with a case for an epinephrine autoinjector that connects via Bluetooth to a mobile application
~3 months using the epinephrine auto-injector + medical device , and after that 3 more months using the epinephrine auto-injector alone"
11277094|NCT02854956|Other|X-linked Mental retardation|This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.
11277095|NCT02854956|Other|Control Group|This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.
11277096|NCT02854943||Critically ill patients|Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018.
11277097|NCT02854917||Memantine Alone|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine for a period of 28 weeks."
11277098|NCT02854917||Memantine plus Individualized Management of AD|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine plus individualized management of AD for a period of 28 weeks."
11277099|NCT02854904|Experimental|Dexmedetomidine intervention|Dexmedetomidine (1 ug/kg/hr) during anesthesia.
11277100|NCT02854904|Placebo Comparator|Placebo|Infusion of normal saline during anesthesia.
11277101|NCT02854878|Experimental|treatment|
11277102|NCT02854865||Echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
11277103|NCT02854852||Patients undergoing general anesthesia|Patients ASA 1-3, undergoing different types of general anesthesia, in supine position, with standard or advanced hemodynamic monitoring.
11277104|NCT02854839|No Intervention|The Control Group|Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.
11277105|NCT02854839|Experimental|The Treatment Group (MG4101)|Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
11277106|NCT02854826||UCLA Ronald Reagan Medical Center|"Site 1 (UCLA Regan Medical Center): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
11277107|NCT02854826||Huntington Hospital|"Site 2 (Huntington Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research Council/ Evidence Based Practice will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
11277108|NCT02854826||Torrance Memorial Hospital|"Site 3 (Torrance Memorial Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/ Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
11277109|NCT02854813||Group 1|Patients with a OAB-V8 score ≥8
11277110|NCT02854813||Group 2|Patients with a OAB-V8 score <8
11277111|NCT02854800|Experimental|Weekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
11277112|NCT02854800|Experimental|Biweekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once bi-weekly. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
11277113|NCT02854800|Experimental|Monthly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per month. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
11277114|NCT02854787|Active Comparator|Phenylephrine|A bolus of 100 mcg
11277115|NCT02854787|Active Comparator|Norepinephrine|A bolus of 0,2 mcg/kg
11277116|NCT02854774|Active Comparator|Knee muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of knee extensor muscles.
11277117|NCT02854774|Active Comparator|Hip muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of hip extensor muscles.
11277118|NCT02854761|Experimental|SC administration|Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
11277119|NCT02854761|Experimental|IM administration|Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
11277120|NCT02854748|Experimental|Empagliflozin / Lobeglitazone / Empa.+Lobe.|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
11277148|NCT02854644|Experimental|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
11277121|NCT02854748|Experimental|Empagliflozin / Empa.+Lobe. / Lobeglitazone|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
11277122|NCT02854748|Experimental|Lobeglitazone / Empagliflozin / Empa.+Lobe.|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
11277123|NCT02854748|Experimental|Lobeglitazone / Empa.+Lobe. / Empagliflozin|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
11277124|NCT02854748|Experimental|Empa.+Lobe. / Empagliflozin / Lobeglitazone|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
11277125|NCT02854748|Experimental|Empa.+Lobe. / Lobeglitazone / Empagliflozin|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
11277126|NCT02854735||Head and neck neoplasm|Patients with stage III-IV head and neck cancer (squamous cell carcinoma) patient undergoing CCRT
11277127|NCT02854722|Experimental|Deferasirox and calcium-vitamin D3|"Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.
~Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy."
11277128|NCT02854722|Placebo Comparator|Calcium-vitamin D3|Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
11277129|NCT02854709|No Intervention|Control|Continue with habitual sleep duration
11277130|NCT02854709|Experimental|Intervention|Sleep extension
11277131|NCT02854696|Experimental|Islet graft|Patients who receive islet graft Intervention : Procedure/Surgery
11277132|NCT02854696|Active Comparator|Best medical care|Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment
11277133|NCT02854683|Experimental|Normal Saline|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
11277134|NCT02854683|Experimental|Oral rehydration solution|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
11277135|NCT02854670|Experimental|Capsaicin patch|Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.
11277136|NCT02854657|Experimental|skin self-examination|"Participants from the treatment arms of the original RCT. It is anticipated that 228 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study. These subjects received Skin Self- examination structured training.
~The subject are being followed for an additional period of time after receiving an educational intervention."
11277137|NCT02854657|Experimental|Skin Self- examination:Distance (remote) learning|Participants receive the Skin Self- examination structured training with partner assistance educational intervention via mailed workbook while under the customary care of their own dermatologists. It is anticipated that 50 new participant dyads will be recruited and randomized to this group.
11277138|NCT02854657|Active Comparator|Active control|"Participants from the control arm of the original RCT. It is anticipated that 100 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study.
~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the Skin Self- examination structured training with partner assistance."
11277139|NCT02854657|Placebo Comparator|Assessment-only control|"Participants who receive customary care from their own dermatologists. It is anticipated that 150 new participant dyads will be recruited and randomized to this group.
~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the structured training in skin self-examination with partner assistance."
11277140|NCT02854657|No Intervention|Observational study 1|"Feasibility of wearing 2 sensors No intervention. At the conclusion of the study, participants receive a report of their UV exposure and physical activity over the 7 days of the study.
~N= 10"
11277141|NCT02854657|No Intervention|Observational study 2|"Feasibility of completing online daily survey. The research team will strive to integrate event level data in real -time No intervention. At the conclusion of the study, participants receive an event level reports of their daily UV exposure and physical activity over the 7 days of the study.
~N= 30"
11277142|NCT02854657|No Intervention|Relationship Factors Study Observational Study|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.
~No intervention- Control group. n=144 Results pending*"
11277143|NCT02854657|Active Comparator|Relationship Factors Study- Skin Self Examination|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.
~Intervention= Skin self-examination training n=197 Results Pending*"
11277144|NCT02854657|Active Comparator|Comparison of distance (remote) learning vs in-person learning|Controls re-enrolled from the original study (n=38) and newly enrolled in the distance (remote) learning (n=106) are compared with participants receiving the workbook in-person in the original study and re-enrolled (n=134) and participants newly enrolled in distance (remote) learning, who had the workbook mailed to them (n=63). Online surveys assessed SSE knowledge, confidence, anxiety and performance. Electronic health record review identified biopsies of concerning moles and the number of melanomas identified.
11277145|NCT02854644|Experimental|glioma|1 additional blood sample for patients with glioma and without treatment
11277146|NCT02854644|Experimental|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
11277147|NCT02854644|Experimental|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
11277149|NCT02854631|Experimental|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
11277155|NCT02854592||rtPA|Intravenous rt-PA thrombolysis shall be administered within 4.5 h after symptom onset, at a dose of 0.9 mg/kg body weight (maximum, 90 mg), with 10% of the dose given as a bolus over 1 min and the remaining 90% infused over 60 min.
11277156|NCT02854592||urokinase|1,000,000-1,500,000 units of urokinase intravenous infused over 30 minutes within 4.5 h of stroke onset .
11277157|NCT02854579|Experimental|Neural progenitor cell|Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
11277158|NCT02854579|Experimental|Paracrine factors|Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy
11277159|NCT02854579|Experimental|Progenitor cell and paracrine factors|Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
11277160|NCT02854579|No Intervention|Routine therapy|neonates only receive routine therapy
11277161|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
11277162|NCT02854553|Experimental|TAP|Transversus abdominis plane block
11277163|NCT02854553|Experimental|TAP and rectus sheath block|Transversus abdominis plane block with rectus sheath block
11277164|NCT02854553|No Intervention|control|no truncal blocks, conventional analgesia
11277165|NCT02854540|Experimental|Hand A (iontophoresis) vs. Hand B (no treatment)|During the treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device. Participants will also be asked to leave the other hand untreated.
11277166|NCT02854527|Experimental|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
11277167|NCT02854527|Experimental|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
11277168|NCT02854527|Experimental|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
11277169|NCT02854527|Experimental|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
11277170|NCT02854527|Experimental|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
11277171|NCT02854514||aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated with endometrial secretion then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
11277172|NCT02854501||Uncomplicated pregnancies|
11277173|NCT02854501||Preeclampsia|
11277174|NCT02854501||Isolated IUGR|
11277175|NCT02854501||Any complication|
11277176|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
11277177|NCT02854475|Experimental|Proband group|Raman spectroscopy and venous blood collection
11277178|NCT02854462|Experimental|Language comprehension intervention|The intervention will run for 4 weeks. Caregivers will be provided with storybooks (e.g., Percy the Park Keeper) that have been amended to include inference-eliciting questions. Caregivers will be trained (with a video) to ask these questions and respond to their children's answers during shared reading sessions. They will be asked to read one book per day. Caregivers will keep a reading diary.
11277179|NCT02854462|Active Comparator|Counting intervention|The intervention will run for 4 weeks. Caregivers will be provided with a book 'At home with counting' that is made up of age appropriate maths exercises. Caregivers will trained (with a video) to work through one page of the book per day. This should take the same amount of time as the activity in the language intervention condition. Caregivers will keep a counting diary.
11277180|NCT02854436|Experimental|Niraparib|Participants will receive 300 milligram (mg) niraparib (3 capsules*100 mg) orally once daily.
11277181|NCT02854423||biodegradable polymer|
11277182|NCT02854423||durable-polymer|
11277183|NCT02854410|Experimental|Sodium nitrate supplementation|Patients will receive Sodium nitrate supplementation from 7 days before radiotherapy to one month after the end of radiotherapy
11277184|NCT02854410|Placebo Comparator|Placebo Comparator(sodium chloride)|Patients will receive placebo from 7 days before radiotherapy to one month after the end of radiotherapy
11277185|NCT02854397||patients with hereditary angioedema|A blood sample will be performed in crisis and 7 days after the crisis.
11277186|NCT02854397||patients with angioedema resulting of mast cell activation|A blood sample will be performed in crisis and 7 days after the crisis.
11277187|NCT02854397||healthy patients, without angioedema|A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.
11277188|NCT02854384||Epilepsy Patients|males and females whose age more than 18 years, diagnosed with epilepsy, regardless of whether symptomatic,idiopathic ,focal or generalized
11277189|NCT02854384||Healthy Control|males and females whose age more than 18 years
11277190|NCT02854371|Experimental|CLD and LC|Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
11277191|NCT02854358|Active Comparator|control|In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
11277192|NCT02854358|Experimental|intervention|Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks
11277193|NCT02854345|Experimental|Tomoscintigraphic parathyroid imaging on a CZT camera|Tomoscintigraphic parathyroid imaging on a CZT camera
11277194|NCT02854332|Active Comparator|MRI by rTMS|Patients which received an MRI study of cortical plasticity by rTMS.
11277195|NCT02854332|Active Comparator|MRI by tDCS|Patients which received an MRI study of cortical plasticity by tDCS.
11277196|NCT02854319|Experimental|LOTUS Edge Valve System|Transcatheter aortic valve implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
11277197|NCT02854306|Active Comparator|Surgery|Obese patient without mindfulness program in parallel.
11277198|NCT02854306|Active Comparator|Surgery with mindfulness program|Obese patient following a mindfulness program in parallel.
11277199|NCT02854293||Booklet-Question List (BQL) group|76 patients
11277204|NCT02854267||group without guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all registered situations of brain death patients on the database (nationwide) minus the situations occuring in the group with guide (22 intensive care units forming the 'RESEAU NORD FRANCILIEN' network). The period before the diffusion of the guide is from 1st of july 2012 to 30th of june 2014
11277205|NCT02854267||group without guide, after guide's diffusion|For this group, only the primary objective (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all the registered situations of brain death patients on the database minus the situations occuring in the group with guide ('RESEAU NORD FRANCILIEN'). The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
11277206|NCT02854267||Group with guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018.
11277207|NCT02854267||Group with guide, after guide's diffusion|For this group, the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database. The secondary endpoints (level of anxiety of the caregivers before the meeting with the next of kins as measured by the french short version of Spielberger test and compliance to the guide) will be assessed by the datasheet prospectively filled by the caregivers. The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
11277208|NCT02854254|Experimental|PICC|peripherally inserted central catheter
11277209|NCT02854254|Other|Control|peripherally venous access
11277210|NCT02854241|Experimental|LC group|LC group under surveillance of biannual ultrasonography and annual noncontrast liver MRI. Six month after the last MRI, contrast enhanced liver CT is performed to investigate presence of HCC.
11277211|NCT02854215|Other|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
11277212|NCT02854202|Experimental|Arm 1-Whey protein|In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey
11277213|NCT02854202|Active Comparator|Arm 2 Breakfast- other proteins|In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast
11277214|NCT02854202|Placebo Comparator|Arm 3 Breakfast- low protein|In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast
11277215|NCT02854189|Other|patients with genu recurvatum|The medial osteoarthritis knees with genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
11277216|NCT02854189|Other|patients without genu recurvatum|The medial osteoarthritis knees without genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
11277217|NCT02854176|Experimental|Somatosensory electrical stimulation|
11277218|NCT02854176|Sham Comparator|Control|
11277219|NCT02854163|Experimental|Secukinumab|"Secukinumab will be given to all 20 patients registered (Secukinumab group). All doses will be given subcutaneously using the following schedule: 4 weekly injections of 150 or 300 mg subcutaneous injections depending the severity of skin involvement, followed by 11 monthly subcutaneous injections of 150mg.
~Patients will continue to use their normal DMARDs treatment."
11277220|NCT02854137|Experimental|Sunscreen / Arm 1|Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.
11277221|NCT02854137|Other|Control|A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or steriled dropper.
11277222|NCT02854124||Patients with stage Ib and II melanoma|Melanoma and peritumoral skin excision
11277223|NCT02854111|Active Comparator|oral glucose tolerance test|75-g glucose A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink a sweet liquid containing 75 g-glucose. Blood samples will be collected at timed intervals of 1 and 2 hours after you drink the glucose. This is a standard method for diagnosis of diabetes mellitus that called oral glucose tolerance test or OGTT.
11277224|NCT02854111|Experimental|ice cream|A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink ice cream that contained carbohydrate 73.9 g. Blood samples will be collected at timed intervals of 1 and 2 hours after you eat the ice cream.
11277225|NCT02854098||with functional constipation|n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
11277226|NCT02854098||without functional constipation|n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
11277227|NCT02854085|Experimental|Art Therapy|Art Therapy, 24 sessions
11277228|NCT02854085|Experimental|Music Reminiscence Activity|Music Reminiscence Activity, 24 sessions
11277229|NCT02854085|No Intervention|Control|Participants will not participate in either of the interventions and will continue life as usual.
11277230|NCT02854072|Experimental|GV1001 + gemcitabine/capecitabine|
11277231|NCT02854072|Active Comparator|gemcitabine/capecitabine|
11277232|NCT02854059|Experimental|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
11277233|NCT02854059|Experimental|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
11277234|NCT02854046||Calciphylaxis Cases|Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
11277235|NCT02854046||Witness cases|"Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging"
11277236|NCT02854033||Cognitively Normal (CN)|"135-500 newly enrolled participants with no apparent memory problems, and 295-300 cognitively normal participants followed from the ADNI2 study.
~Currently recruiting non-Caucasian participants only for the normal cognition group."
11277237|NCT02854033||Mild Cognitive Impairment (MCI)|150 - 515 newly enrolled participants with mild cognitive impairment (MCI), and 275-320 MCI participants followed from the ADNI2 study.
11277238|NCT02854033||Mild Alzheimer's Disease (AD) dementia|85 - 185 newly enrolled participants with mild Alzheimer's disease (AD) dementia, and 130 - 150 mild AD participants followed from the ADNI2 study.
11277239|NCT02854020||An asian airline|
11277240|NCT02854007||Coronary stenosis treated with Absorb|Patients with ischemic heart disease who have undergone percutaneous coronary revascularization with Absorb according to standard clinical practice. One thousand revascularized patients will be recruited at 40 siteS.
11277241|NCT02853981|Active Comparator|Harmonic scalpel group|group of donors whom will undergo liver transection using harmonic scalpel.
11277242|NCT02853981|Active Comparator|clamp-crush group|group of donors whom will undergo liver transection using Kelly clamp.
11277243|NCT02853968||Castleman's Patients|Castleman's patients with HHV8 negative multicentric MCD
11277244|NCT02853968||Related Disease Controls|Controls with inflammatory diseases similar to idiopathic multicentric Castleman's: i.e. HHV8+ MCD, HLH, Hodgkin disease
11277245|NCT02853968||Healthy Donor Controls|Healthy subjects used for controls. These healthy subjects have no history of autoimmune disorders.
11277246|NCT02853942|Experimental|Stem cell therapy group|Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.
11277247|NCT02853942|Experimental|Neurotrophic drugs treatment group|Patients were treated with routine drug therapy，do not inject stem cell to the facial nerve of patient
11277248|NCT02853929|Experimental|dTpa Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
11277249|NCT02853929|Active Comparator|Control Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
11277250|NCT02853916|Active Comparator|500 mg InSea2®|
11277251|NCT02853916|Active Comparator|250 mg InSea2®|
11277252|NCT02853916|Placebo Comparator|Placebo|
11277253|NCT02853903|Experimental|Allogenic NK immunotherapy|In this group, the patients will receive more than 4 times of allogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277254|NCT02853903|Active Comparator|Autogenic NK immunotherapy|In this group, the patients will receive more than 4 times of autogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277255|NCT02853890||pregnant woman|
11277256|NCT02853877|Experimental|Weekly Incentive|Participants in the Weekly Incentive arm will be asked to weigh in each week during a 12 week intervention period. They will receive tailored messages and have an opportunity to win a financial reward each week they meet their weight loss goal. Participants will be asked to complete a final weight measurement at week 24.
11277257|NCT02853877|No Intervention|Weekly Weigh-In|Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
11277258|NCT02853864|Placebo Comparator|Propofol and 0.0 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
11277259|NCT02853864|Experimental|Propofol and 0.4 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
11277260|NCT02853864|Experimental|Propofol and 0.6 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
11277261|NCT02853864|Experimental|Propofol and 0.8 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
11277262|NCT02853851||France|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
11277356|NCT02853136|Experimental|Test Treatment (pilot phase)|Fluvoxamin and low dose of BI 409306
11277263|NCT02853851||Italy|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
11277264|NCT02853851||spain|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
11277265|NCT02853851||montreal|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
11277266|NCT02853838|Experimental|Prolonged slow expiration+provoked coughing+ST|Prolonged slow expiration+provoked coughing+Standard Therapy
11277267|NCT02853838|Active Comparator|Manual chest wall vibration+ST|Manual chest wall vibration+Standard Therapy
11277268|NCT02853825|No Intervention|Wait List Control Group|No interventions given, this is a wait list control group.
11277269|NCT02853825|Experimental|Intervention Group|Receive relationship skill enhancement classes with access to parenting, employment services, and financial services.
11277270|NCT02853812|Other|single sided tinnitus|patients with single sided tinnitus on which functional brain MRI is assessed
11277271|NCT02853799|Other|Continuous Enteral Feeding|"Crossover Study:
~Randomized to continuous enteral feeding first then crossed over to receive versus intermittent enteral feeding next."
11277272|NCT02853799|Other|intermittent enteral feeding|"Crossover Study:
~Randomized to intermittent enteral feeding first then crossed over to receive versus continuous enteral feeding next."
11277273|NCT02853786|Experimental|LENA and advices|With the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
11277274|NCT02853786|Active Comparator|LENA without advices|Regular speech therapy follow blindly the results of LENA
11277275|NCT02853773|Experimental|Artificial sweetener|Effects of co-ingestion of artificially sweetened beverage on the response to a test meal
11277276|NCT02853773|Active Comparator|Sugar|Effects of co-ingestion of sugar-sweetened beverage on the response to a test meal
11277277|NCT02853773|Active Comparator|Water|Effects of co-ingestion of water on the response to a test meal
11277278|NCT02853760|Experimental|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).
~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
11277279|NCT02853760|Active Comparator|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.
~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
11277280|NCT02853760|No Intervention|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
11277281|NCT02853734|Experimental|SEVERE PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
11277282|NCT02853734|Other|NO PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
11277283|NCT02853721|Experimental|Experimental group|iPTH at 6 hours after surgery
11277284|NCT02853721|Other|Control group|no dosage of iPTH
11277285|NCT02853682||presence of a vascular dysfunction|plasma
11277286|NCT02853682||absence of vascular dysfunction|plasma
11277287|NCT02853669|Experimental|group (A) lumber plexus block|Ultrasound-guided Lumber plexus Block (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation.
11277288|NCT02853669|Experimental|Group (B) adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
11277289|NCT02853643|Experimental|25 mg Dose|Single dose of 25 mg ASN002
11277290|NCT02853643|Experimental|50 mg Dose|Single dose of 50 mg ASN002
11277291|NCT02853643|Experimental|100 mg Food effect cross over|100 mg single dose under both fasted and fed conditions in a cross over fashion
11277292|NCT02853630|Active Comparator|Metformin|Tablet Metformin 1000 - 2500 mg/day for 96 weeks
11277293|NCT02853630|Experimental|Vildagliptin|Tablet Vildagliptin 100mg/day for 96 weeks
11277294|NCT02853617|Experimental|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
11277295|NCT02853617|Experimental|AV0328 - Cohort 2|Cohorts 2 will receive 30 µg to be given as an IM injection
11277296|NCT02853617|Experimental|AV0328 - Cohort 3|Cohorts 3 will receive 75 µg to be given as an IM injection
11277297|NCT02853617|Experimental|AV0328 - Cohort 4|Cohorts 4 will receive 150 µg to be given as an IM injection
11277298|NCT02853604|Placebo Comparator|Reference Treatment Group (Arm A)|Placebo Arm A
11277299|NCT02853604|Experimental|Experimental Treatment Group (Arm B)|"ADXS11-001
~1:2 Arm A to Arm B"
11277300|NCT02853591|Active Comparator|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
11277301|NCT02853591|Experimental|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
11277302|NCT02853591|Experimental|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
11277303|NCT02853591|Experimental|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
11277304|NCT02853578|Experimental|Busonid (budesonide 200mcg and 400mcg)|"It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.
~Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.
~The duration of treatment may be 12 weeks."
11277305|NCT02853565|Experimental|CAN008|CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
11277306|NCT02853539|Experimental|Denosumab|One per 6 months subcutaneous injection of Denosumab (2 doses in total)
11277307|NCT02853539|No Intervention|No Denosumab|No intervention, just observation of HPN patients
11277308|NCT02853526|Experimental|TIPS arm|Transjugular intrahepatic portosystemic shunt(TIPS) is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension.TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (also called p-TIPS or modified TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
11277309|NCT02853526|Active Comparator|conservative treatment arm|Conservative treatment including endoscopic therapy，non-selective beta blockers (propranolol)and anticoagulation therapy (warfarin).
11277310|NCT02853500|Experimental|TACE Procedure With Surefire|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Surefire.
~Patients will undergo structural follow-up for a timeframe of one year post treatment
~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
11277311|NCT02853500|Active Comparator|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.
~Patients will undergo structural follow-up for a timeframe of one year post treatment
~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
11277312|NCT02853487||Cluster headache patients|Episodic cluster headache patients in- and outside of bout will wear an actigraph and fill out a diary for 2 weeks.
11277313|NCT02853487||Control group|Healthy, headache-free controls will wear an actigraph and fill out a diary for 2 weeks.
11277314|NCT02853474|Sham Comparator|Arm A: Chemotherapy (CT) alone|"The medical oncologists (or gastro enterologist physician) are in charge of the patient for CT administration, and for the management of symptoms related to the disease and/or the treatment, in accordance with professional practices. If needed (any time), a PC (Palliative consultation) visit could be performed.
~Interventions are :
~EORTC-QLQ-C30 questionnaire for the assessment of quality of life
~HADS score for anxiety and depression assessment"
11277315|NCT02853474|Experimental|Arm B: CT + Early Palliative care(EPC)|"Standard oncology care as for arm A plus early PC visits.
~Interventions are :
~EORTC-QLQ-C30 questionnaire for the assessment of quality of life
~HADS score for anxiety and depression assessment
~Early palliative care visits"
11277316|NCT02853448|Experimental|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
11277317|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
11277318|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
11277319|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
11277320|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
11277321|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
11277322|NCT02853435|Experimental|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
11277323|NCT02853435|Experimental|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
11277324|NCT02853396|Experimental|Cognitive behavioural therapy|Cognitive behaviour therapy
11277325|NCT02853396|Active Comparator|Psychoeducation|psychoeducation
11277357|NCT02853136|Experimental|Reference Treatment (main phase)|BI 409306 medium or high dose
11277326|NCT02853370|Experimental|Bendamustine and Rituximab|"Induction Phase (Cycle 1 to Cycle 3 ):
~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1**
~Extended Phase (Cycle 4 to Cycle 6):
~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1
~From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles
~*Or days 2-3 according to institutional/patient/physician preference
~**Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)"
11277327|NCT02853357|Sham Comparator|Control|The control group includes randomized participants that will receive a sham manipulation. Participants will also complete the standard set of core strengthening exercises.
11277328|NCT02853357|Experimental|Manipulation|The manipulation group includes randomized participants that will receive a thoracic spine thrust manipulation. Participants will also complete the standard set of core strengthening exercises.
11277329|NCT02853344|Experimental|Cohort A: Clear Cell RCC|Participants with clear cell RCC receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
11277330|NCT02853344|Experimental|Cohort B: Non-clear Cell RCC|Participants with non-clear cell RCC receive pembrolizumab 200 mg IV Q3W for up to 35 doses (approximately 24 months).
11277331|NCT02853331|Experimental|Pembrolizumab+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
11277332|NCT02853331|Active Comparator|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
11277333|NCT02853318|Experimental|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
11277334|NCT02853305|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses.
11277335|NCT02853305|Experimental|Pembrolizumab+Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
11277336|NCT02853305|Active Comparator|Chemotherapy|Participants receive EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
11277337|NCT02853292||amoxicillin crystalluria|
11277338|NCT02853279|Experimental|Interval exercise training|Supervised exercise training undertaking interval exercise twice per week for 30 min each visit over 12 weeks.
11277339|NCT02853279|Active Comparator|Continuous exercise training|Supervised exercise training undertaking continuous exercise twice per week for 30 min each visit over 12 weeks.
11277340|NCT02853266||patients KD|adults with a history of KD in childhood
11277341|NCT02853266||control group|healthy adults volunteers
11277342|NCT02853253|Experimental|SMOF|parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
11277343|NCT02853253|Active Comparator|Medialipide®|parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
11277344|NCT02853240|Experimental|Children with spastic CP receiving toxin injections|Children with spastic cerebral palsy receiving toxin injections
11277345|NCT02853227||BCS|Photographs og consecutive group of 346 patients operated with breast conserving surgery were used to investigate cosmetic outcomes.
11277346|NCT02853227||DIEP|Photographs og consecutive group of 30 patients operated with DIEP-flap were used to assess cosmetic results
11277347|NCT02853214|Experimental|Identification of genetic factors in dysglobulinemia cases|
11277348|NCT02853188|Experimental|cancer of lung|
11277349|NCT02853175||Patients with both CF and ABPA|"Patients with both cystic fibrosis and allergic broncho-pulmonary aspergillosis (ABPA).
~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
11277350|NCT02853175||Patients with CF and no ABPA|"Patients with both cystic fibrosis and no allergic broncho-pulmonary aspergillosis (ABPA).
~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
11277351|NCT02853162|Experimental|ARREST-study|SBRT renal cell carcinoma 5 times 7Gy
11277352|NCT02853149|Experimental|Spinal Cord Injury (SCI)|Experimental: Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) for Spinal Cord injury individuals enrolled with their caregivers, can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
11277353|NCT02853149|Active Comparator|Caregiver Intervention(CCC)|Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
11277354|NCT02853149|Placebo Comparator|Caregiver Control (CC)|Placebo: This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life. The control group intervention will test benefits of exercise alone while controlling for investigator contact.
11277355|NCT02853136|Experimental|Reference Treatment (pilot phase)|BI 409306 low dose
11277358|NCT02853136|Experimental|Test Treatment (main phase)|Fluvoxamin and medium or high dose of BI 40930
11277359|NCT02853123|Experimental|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
11277360|NCT02853123|Active Comparator|Tiotropium|
11277361|NCT02853110|Experimental|Hypo-FLAME|External beam radiotherapy, 5 additional MRI scans, blood sampling
11277362|NCT02853097||Ancillary-Correlative (blood collection)|Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.
11277363|NCT02853084|Experimental|HL2351|
11277364|NCT02853071|Experimental|Estramustine|560 mg per day
11277365|NCT02853071|Active Comparator|Standard practice center|"Standard treatment center choice.
~Excepted: anthracyclines, taxanes, capecitabine and eribulin"
11277366|NCT02853058|Active Comparator|normal PI|Uterine artery PI expresserd in MoM is <95e percentile
11277367|NCT02853058|Active Comparator|pathological PI|Uterine artery PI expressed in Multiple of Mediane (MoM) is >=95e percentile
11277368|NCT02853045|Experimental|period with drug (trade name) then period with generic|Period of 6 weeks.
11277369|NCT02853045|Experimental|period with generic then period with drug (trade name)|Period of 6 weeks.
11277370|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
11277371|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
11277372|NCT02853019|Sham Comparator|Healthy volunteers|Healthy volunteers
11277373|NCT02853019|Experimental|Patients with schizophrenia|Patients with schizophrenia
11277374|NCT02853006|Other|Group 1 lung cancer in stage 1-2|Group 1 : patient with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery
11277375|NCT02853006|Other|Group 2 lung cancer in stage 3-4|Group 2 : patient with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies.
11277376|NCT02853006|Other|Group 3 : control patients|Group 3 control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco.
11277377|NCT02852993||Transfused patients|A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
11277378|NCT02852980||gestational diabetes women|Women who had childbirth in the Hospital center Rene Dubos and who had gestational diabetes.
11277379|NCT02852967|Experimental|KD025 200 mg QD (Once Daily)|Subjects received one KD025 200 mg tablet and one matching placebo tablet in the morning and a matching placebo in the evening
11277380|NCT02852967|Experimental|KD025 200 mg BID (Twice Daily)|Subjects received one KD025 200 mg tablet and one matching placebo tablet in the morning and KD025 200 mg in the evening
11277381|NCT02852967|Experimental|KD025 400 mg QD|Subjects received two KD025 200 mg tablets in the morning and a matching placebo in the evening
11277382|NCT02852967|Experimental|KD025 600 mg/day|Subjects received two KD025 200 mg tablets in the morning and one KD025 200 mg tablet in the evening
11277383|NCT02852967|Placebo Comparator|Placebo|Subjects received two matching placebo tablets in the morning and one matching placebo tablet in the evening.
11277384|NCT02852954||study group1|20 paraffin embedded blocks which was diagnosed endometrial cancer
11277385|NCT02852954||control group|20 paraffin embedded blocks of healthy women
11277386|NCT02852954||study group2|20 paraffin embedded blocks which was diagnosed endometrial hyperplasia
11277387|NCT02852941||Patients after kidney transplantation|The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.
11277388|NCT02852941||Healthy subjects|Medical staff: medical doctors, nurses
11277389|NCT02852915|Experimental|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
11277390|NCT02852915|No Intervention|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
11277391|NCT02852889||fluid responders|Patients whose stroke volume index increase by >10% in response to a 500-ml fluid bolus was defined as fluid responders.
11277392|NCT02852889||fluid non-responders|Patients whose stroke volume index increase by <10% in response to a 500-ml fluid bolus was defined as fluid non-responders.
11277393|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group A (Fasting)|Participants will receive single dose of ASP2151 assigned to Group A on day 1
11277394|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group B (Fasting)|Participants will receive single dose of ASP2151 assigned to Group B on day 1
11277395|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group C (Fasting)|Participants will receive single dose of ASP2151 assigned to Group C on day 1
11277396|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group D (Fasting)|Participants will receive single dose of ASP2151 assigned to Group D on day 1
11277397|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group E (Fasting)|Participants will receive single dose of ASP2151 assigned to Group E on day 1
11277398|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group F (Fasting)|Participants will receive single dose of ASP2151 assigned to Group F on day 1
11277399|NCT02852876|Placebo Comparator|Part 1: Placebo Single Ascending Dose (Fasting)|Participants will receive single dose of matching placebo on day 1
11277400|NCT02852876|Experimental|Part 2: ASP2151 (Fasting)|Participants will receive a single dose of ASP2151 under fasted conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
11277401|NCT02852876|Experimental|Part 2: ASP2151 (Fed)|Participants will receive a single dose of ASP2151 under fed conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
11277402|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group G (Fasting)|Participants will receive single dose of ASP2151 assigned to Group G on day 1
11277403|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group H (Fasting)|Participants will receive single dose of ASP2151 assigned to Group H on day 1
11277404|NCT02852863|Experimental|Ultrasound (case only)|Subjects will fast for a minimum of 8 hours. Ultrasound assessment of gastric volume and content will determine basal conditions. Next, subjects will chew gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
11277405|NCT02852850||Molecular Imaging With IFX-FITC|Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
11277406|NCT02852837|Experimental|Part 1: Dose Escalation Part|Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
11277407|NCT02852837|Experimental|Part 2: Pharmacokinetic (PK) Expansion Part|Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
11277408|NCT02852837|Experimental|Part 3: Safety Expansion Part|Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.
11277409|NCT02852824|Experimental|BI 655130|
11277410|NCT02852824|Placebo Comparator|Placebo|
11277411|NCT02852811|Other|group education|To measure improvement of menopause symptoms and depression all participating women answered a baseline questionnaire and a follow-up questionnaire four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
11277412|NCT02852811|No Intervention|control group|The control group did not obtain any group education or any other intervention. Women answered at baseline questionnaire and four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
11277413|NCT02852785||Asymptomatic volleyball attackers|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
11277414|NCT02852785||Asymptomatic bilateral overhead athletes|Asymptomatic swimmers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
11277415|NCT02852785||Asymptomatic non-athletes|Asymptomatic persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers),
11277416|NCT02852785||Asympt. athletes / scapula dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
11277417|NCT02852785||Symptom. athletes / scapula dyskinesis|Volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis and complaints of shoulder pain and disability
11277418|NCT02852772||PLHIV with microalbuminuria|Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years
11277419|NCT02852772||PLHIV without microalbuminuria (control)|Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years
11277420|NCT02852759|Experimental|intervention group|Add Selective Cold and Electroacupuncture treatment to the existing treatment for patients with insulin resistance.
11277421|NCT02852759|No Intervention|Intensive Care group|continue the existing management of insulin resistance in these patients. They will receive the same follow up, examinations etc as intervention group.
11277422|NCT02852746||Asympt. athletes / scapular dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
11277423|NCT02852746||Symptom. athletes / scapular dyskinesis|Symptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
11277424|NCT02852733||Residents in end-of-life situation|"Residents in end-of-life situation the day of the survey, as determined by the physician coordinator of nursing homes (we will use the definition of terminal condition contained in the guide of the CNSA (coding PATHOS - April 2011))."
11277425|NCT02852733||dead residents|dead residents in the quarter preceding the date of the survey
11277426|NCT02852720|Experimental|Pharmacokinetics|A bilateral TAP block will be performed with 20 ml levobupivacaine 0,25% and epinephrine (5ug/ml). After the blockade, venous blood samples will be taken on predefined times.
11277427|NCT02852707||Unilateral overhead throwing athletes|Volleyball attackers involved in competitive events ≥ 2 years, ≥18 years of age
11277428|NCT02852707||Bilateral overhead athletes|Swimmers involved in competitive events ≥ 2 years, ≥18 years of age
11277429|NCT02852707||Non-athletes|Persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers), ≥18 years of age
11277430|NCT02852694|Active Comparator|High Risk Group|subcutaneous methotrexate versus subcutaneous adalimumab
11277431|NCT02852694|Active Comparator|Low risk group|subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine
11277432|NCT02852694|Other|Ancillary|the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
11277433|NCT02852681|Other|15 mg E4/3 mg DRSP without food|Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).
11277434|NCT02852681|Other|15 mg E4l/3 mg DRSP with food|Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)
11277435|NCT02852668|Experimental|Power Training Group|Physical exercises. Strength training performed quickly
11277436|NCT02852668|Experimental|Strength Training Group|Physical exercises. Strength training performed in moderate speed
11277437|NCT02852668|No Intervention|Control Group|This group maintained the same physical activity level during the intervention period.
11277438|NCT02852655|Experimental|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.
~Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.
~MK-3475 will be administered intravenously"
11277439|NCT02852655|Active Comparator|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.
~Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.
~MK-3475 will be administered intravenously"
11277440|NCT02852642|Experimental|Exercise|Power training model based in the potentiation of the stretch-shortening cycle.
11277441|NCT02852642|No Intervention|Control|Maintaining daily activities
11277442|NCT02852616|Active Comparator|Narrative Exposure Therapy|Participants with a PTSD diagnosis
11277443|NCT02852616|No Intervention|no / standard treatment|Participants with a PTSD diagnosis / other mental health problems / no mental health problems
11277444|NCT02852603||thoracic aortic aneurysm and dissection|Patients with thoracic aortic aneurysm and/or dissection are recruited in the study.
11277445|NCT02852577|Active Comparator|Clonazepam|Treatment with clonazepam
11277446|NCT02852577|Active Comparator|Paroxetine|Treatment with paroxetine
11277447|NCT02852564|Experimental|Enrolled Participants|Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor [TURBT])
11277448|NCT02852551|Experimental|PAT-1251 Single Dose|Oral solution of PAT-1251, 150 - 4000 mg administered once
11277449|NCT02852551|Placebo Comparator|Placebo Single Dose|Matching placebo solution administered once
11277450|NCT02852551|Experimental|PAT-1251 Multiple Dose|Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days
11277451|NCT02852551|Experimental|Placebo Multiple Dose|Matching placebo tablets administered daily for 7 days
11277452|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
11277453|NCT02852525|Other|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
11277454|NCT02852512|Active Comparator|Laparoscopic sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be laparoscopic
11277455|NCT02852512|Active Comparator|Robotic assisted Sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be robotic assisted
11277456|NCT02852499||Mothers|Pregnant women.
11277457|NCT02852499||Fathers|Futur fathers.
11277458|NCT02852499||Children|Children after childbirth.
11277459|NCT02852486|Experimental|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
11277460|NCT02852473|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP) will be administered using FDA-approved equipment.
11277461|NCT02852460|Experimental|Experimental group|rapid recovery
11277462|NCT02852460|No Intervention|Controlled group|non-rapid recovery
11277463|NCT02852434|Experimental|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
11277464|NCT02852434|Active Comparator|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
11277465|NCT02852421|Active Comparator|Multiple injection paravertebral blocks|"Patients in this group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
11277466|NCT02852421|Experimental|Single injection paravertebral block|"Patients in single injection group will receive single injection paravertebral blocks at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections."
11277467|NCT02852408||Study|liver cauterized during laparoscopic cholecystectomy.
11277468|NCT02852408||Control|liver not-cauterized during laparoscopic cholecystectomy.
11277469|NCT02852395|Experimental|Part 1 Single Dose|Part 1 single daytime oral dose of JNJ-48816274 or placebo. Doses of JNJ-48816274 will start at 5 milligram (mg) and increase sequentially to a maximum dose of 250 mg.
11277470|NCT02852395|Experimental|Part 2 Crossover Sleep Study|Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
11277471|NCT02852395|Experimental|Part 3 Repeated Dose (Optional)|Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
11277472|NCT02852382|Active Comparator|scalp block|In this arm, after general anesthesia, before surgery and head pin placement, scalp block will be applied. Scalp block will be performed with bupivacaine (Marcaine 5 mg/mL, 0,5% bupivacaine); nervus supraorbitalis, nervus supratrochlearis, n. auriculotemporalis, nervus zygomaticotemporalis, nervus occipitalis majoris and minoris will be bilaterally blocked with 2-3 ml bupivacaine.
11277473|NCT02852382|Active Comparator|local infiltration|In this arm, after general anesthesia, before surgery, 20 ml 0,5% bupivacaine (Marcaine 5 mg/ml, 0,5% bupivacaine) will be infiltrated to head pin points and skin incision area.
11277474|NCT02852382|Placebo Comparator|control|In this arm, neither scalp block, nor local infiltration will be performed.
11277475|NCT02852369|Experimental|Task Oriented Training|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.
~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
11277476|NCT02852356|No Intervention|Control Incubator|Standard Incubator
11277477|NCT02852356|Experimental|MIRI-TL Timelapse Incubator|Timelapse incubator
11277478|NCT02852356|Experimental|Culture Coin Dish|Culture Coin dish for embryo culture
11277479|NCT02852356|No Intervention|Control dish|Control Dish for embryo culture
11277480|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
11277481|NCT02852317||Spina bifida patient|
11277482|NCT02852317||Patients with multiple sclerosis|
11277483|NCT02852317||Patients with spinal cord injury|
11277484|NCT02852317||Patients with overactive bladder|
11277485|NCT02852291|Experimental|Parents Make the Difference|Parents Make the Difference (Caregivers attend 10 group parent training sessions)
11277486|NCT02852291|Experimental|Parents Make the Difference Plus|Parents Make the Difference Plus (Caregivers attend 10 group parent training sessions and receive 3 home visits)
11277487|NCT02852291|No Intervention|Waitlist Control|No parenting intervention until the end of the study period
11277488|NCT02852265|Experimental|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
11277489|NCT02852239|Experimental|Group 1 - Normal renal function|Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight.
11277490|NCT02852239|Experimental|Group 2 - Severe renal function|Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline.
11277491|NCT02852239|Experimental|Group 3 - End stage renal disease (ESRD)|Subjects with end stage renal disease (ESRD), defined as GFR of <15 mL/min at baseline.
11277492|NCT02852226|Experimental|Study Intervention|Assess PrEP among women in the study. Assess the characteristics of women who enroll in the PrEP study. Assess the referral sources of women who enroll in the PrEP study
11277493|NCT02852213|Experimental|Single treatment arm|"Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency.
~6 subjects will be divided in 2 groups of 3. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes.
~Subjects will be enrolled into 2 dose groups. Group 1 of 3 subjects will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dosing intervals will be 90 days between the first 3 subjects. Group 2 dosing level will be determined by Group 1 results."
11277494|NCT02852200||SEGAm|Elderly community-dwelling people
11277495|NCT02852187|Active Comparator|MOBIS PEEK|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS PEEK Cage
11277496|NCT02852187|Active Comparator|MOBIS II ST|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS II ST Cage
11277497|NCT02852174|Experimental|Mindfulness group|The treatment groups will participate in a mindfulness intervention training that will meet for 2 hours once a week for eight weeks. The 8-week program provides participants with 2-hour weekly instruction designed to teach specific skills and how to apply them during stressful situations (e.g., when caring for or advocating for the veteran).Mindfulness training also requires that participants engage in daily home practice for 30 to 40 minutes. Participants will be required to record the duration of the meditation in log sheets.
11277498|NCT02852174|No Intervention|Control|Participants in the control may receive the mindfulness training after the wait period ends at which point they may receive the treatment as described above.
11277499|NCT02852161|Experimental|MACE|MACE procedure
11277500|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
11277501|NCT02852148|Experimental|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
11277502|NCT02852135|Experimental|LMA Proseal group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Prosealgroup,LMA Proseal was inserted into each patient after anesthesia induction.
11277503|NCT02852135|Experimental|LMA Supreme group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Supreme group,LMA Supreme was inserted into each patient after anesthesia induction.
11277504|NCT02852122|Experimental|C-11 choline|
11277505|NCT02852109||experimental group|patients who was firstly diagnosed as diffuse axonal injury
11277506|NCT02852109||control group|patients negative for magnetic resonance examination with no trauma
11277507|NCT02852096|Experimental|Dual or Multiple Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
11277508|NCT02852096|Active Comparator|One Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
11277509|NCT02852083|Experimental|A: Biomodulatory treatment|treosulfan 250 mg p.o. twice daily, pioglitazone 45 mg p.o. once daily, clarithromycin 250 mg p.o. twice daily until progression or no clinical benefit observed, whichever comes first.
11277943|NCT02848807|No Intervention|without oral nutritional supplements|Dietary advice alone
11277510|NCT02852083|Active Comparator|B: Standard Treatment|Nivolumab, 3 mg per kilogram of body weight every 2 weeks until disease progression according to RECIST 1.1 or unacceptable toxicity
11277511|NCT02852070|Active Comparator|control group|Bronchoscopy examination with 120ml sterile saline solution for bronchoalveolar lavage
11277512|NCT02852070|Experimental|observation group|Bronchoscopy examination with 60ml sterile saline solution for bronchoalveolar lavage
11277513|NCT02852057|Experimental|Subjects Receiving Lenses|All subjects who meet inclusion criteria will receive lenses loaded with timolol maleate and dorzolamide hydrochloride.
11277514|NCT02852044|Active Comparator|Rest|Remain rested prior to the oral glucose tolerance test
11277515|NCT02852044|Experimental|Exercise|Complete exercise prior to the oral glucose tolerance test
11277516|NCT02852031||Hypoplastic Left Heart Syndrome|Infants diagnosed with Hypoplastic Left Heart Syndrome (HLHS)
11277517|NCT02852018||Appropriate treatment|Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
11277518|NCT02852018||No event|Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.
11277519|NCT02852005|Experimental|Group 1: MVA/HIV62B + Placebo|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
11277520|NCT02852005|Experimental|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
11277521|NCT02852005|Experimental|Group 3: MVA/HIV62B + Placebo|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
11277522|NCT02852005|Experimental|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
11277523|NCT02852005|Experimental|Group 5: Placebo + AIDSVAX B/E|Participants will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
11277524|NCT02851992|Other|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
11277525|NCT02851979|Experimental|S0 - S1 - S2|S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
11277526|NCT02851979|Experimental|S0 - S2 - S1|S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
11277527|NCT02851979|Experimental|S1 - S0 - S2|S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
11277528|NCT02851979|Experimental|S1 - S2 -S0|S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
11277529|NCT02851979|Experimental|S2 - S0 - S1|S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
11277530|NCT02851979|Experimental|S2 - S1 - S0|S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation
11277531|NCT02851966|Other|TEX101|This is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
11277532|NCT02851953|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
11277533|NCT02851940|Experimental|A (Rubber Band Ligation)|15 patients
11277534|NCT02851940|Experimental|B (Hypertonic Saline Infusion)|15 patients
11277535|NCT02851927|Experimental|Mini Thoracoscopy|Thoracoscopy procedure shall be performed using the Rigid Mini Thoracoscope
11277536|NCT02851927|Active Comparator|Semirigid Thoracoscopy|Thoracoscopy procedure shall be performed using the SemiRigid Thoracoscope
11277537|NCT02851914|Active Comparator|Arm 1 - TCA|"The Tricyclic Antidepressant (TCA) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
11277538|NCT02851914|Active Comparator|Arm 2 - SSRI|"The Selective Serotonin Reuptake Inhibitor (SSRI) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
11277539|NCT02851888|Experimental|Iliac Fascia Block (Ropivacaine)|These patients will receive a preoperative iliac fascia block performed as a single shot in the standard fashion prior to hip arthroscopy with general anesthesia.
11277540|NCT02851888|Sham Comparator|Control (Normal Saline Sham Injection)|These patients will receive a preoperative sham block of normal saline in the same fashion as a standard singl shot iliac fascia block prior to hip arthroscopy with general anesthesia.
11277541|NCT02851862||Late Onset GM2 Gangliosidosis|10-15 subjects with Late Onset GM2 Gangliosidosis
11277542|NCT02851849|Active Comparator|LGD-6972-5 mg|5 mg LGD-6972 QD
11277543|NCT02851849|Active Comparator|LGD-6972-10 mg|10 mg LGD-6972 QD
11277544|NCT02851849|Active Comparator|LGD-6972-15 mg|15 mg LGD-6972 QD
11277545|NCT02851849|Placebo Comparator|Placebo|Placebo QD
11277546|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
11277581|NCT02851498|Sham Comparator|Control pasta and cereal|Commercial gluten-free pasta (Barcilla orzo and fusilli; %energy: 13/24/63 for protein/fat/carbohydrate) and commercial flaked cereal (Post Honey Bunches of Oats; %energy: 6/18/76 for protein/fat/carbohydrate) were used as the control foods. The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as experimental foods.
11277582|NCT02851485|Experimental|GLPG1972 600 mg oral solution fasted|600 mg GLPG1972 administered as oral solution after overnight fasting
11277547|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
11277548|NCT02851797|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
11277549|NCT02851797|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
11277550|NCT02851784|Active Comparator|MWA only|The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
11277551|NCT02851784|Experimental|MWA combined with immunotherapy|The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
11277552|NCT02851771|Experimental|Pneumonia Patients|Patient admitted at hospital with pneumonia, who need a microbiological diagnosis
11277553|NCT02851758|Experimental|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
11277554|NCT02851745|Experimental|Linagliptin|Linagliptin 5 mg daily for 48 weeks
11277555|NCT02851745|Placebo Comparator|Placebo|Placebo 5 mg daily for 48 weeks
11277556|NCT02851732|No Intervention|Control|"Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: Admission, 06 months, and 12 months. Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes."
11277557|NCT02851732|Experimental|Intervention|Educational multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Health care professionals from each institution one being a physician (acting as a local leader) and the other being a research nurse (acting as a case manager) must attend the training course for high cardiovascular risk patients that will take place at HCor.
11277558|NCT02851719|Experimental|BF group|24 outpatient sessions of the PFMT (twice a week) using manometric-based BF equipment and daily home PFMT exercises.
11277559|NCT02851719|Active Comparator|PFMT group|24 outpatient sessions (twice a week) of PFMT without BF and daily home PFMT exercises.
11277560|NCT02851706||1-Patients with CNS Tumors|Patients with CNS tumors (or a history) including those with undiagnosed imaging abnormalities in the CNS; and patients with known genetic syndromes at high risk of developing CNS Cancers.
11277561|NCT02851693|Experimental|Optical Coherence Tomography (OCT)|
11277562|NCT02851680|Experimental|Fongitell test|
11277563|NCT02851680|Active Comparator|serum galactomannan|
11277564|NCT02851667|Experimental|Training group|Resident training programs such as talks, day camp and thematic activities were delivered in training group.
11277565|NCT02851654||Dry eye syndrome|Meibomian gland dysfunction responsible of moderate to severe dry eye syndrome
11277566|NCT02851641||Nasolacrimal duct obstruction|
11277567|NCT02851628|Experimental|Alternative sizing model trial mask|In this arm participants who are randomized to the alternative sizing model based mask will be given the alternative sizing model based mask to use in home for the duration of this arm.
11277568|NCT02851628|Active Comparator|Prototype Full Face Mask (PFFM)|In this arm, participants who are randomized to the PFFM will be given the PFFM to use in-home for the duration of this arm.
11277569|NCT02851615|Other|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
11277570|NCT02851615|No Intervention|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
11277571|NCT02851602|Experimental|Obese|
11277572|NCT02851602|Placebo Comparator|control|
11277573|NCT02851589|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
11277574|NCT02851576|Experimental|Infusion of ADV specific T cells|This one arm study consists in ADV-specific T cell infusion after HSCT from a (M)MUD or, for the first time, from a haploidentical donor for patients having undergone previous UCB transplantation, in the event of refractory ADV infection or disease. Specific anti-ADV immune reconstitution was observed in all patients, and viral load clearance in all but one.
11277575|NCT02851524|Experimental|posturography|
11277576|NCT02851511|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
11277577|NCT02851511|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
11277578|NCT02851511|Experimental|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
11277579|NCT02851511|Experimental|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
11277580|NCT02851498|Experimental|Novel high-protein pasta and cereal|High-protein pasta (orzo and fusilli) enriched with gluten and egg white protein (%energy: 27/30/43 for protein/fat/carbohydrate) and high-protein flaked breakfast cereal enriched with gluten (%energy: 30/35/35 for protein/fat/carbohydrate) were manufactured by Zone Inc.(Boston, MA). The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as control meals.
11277583|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fasted|600 mg GLPG1972 administered as oral tablet after overnight fasting
11277584|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fed|600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast
11277969|NCT02848547||Control - Standard Care|Participants in the control group received standard one time advice at entry in the study.
11277585|NCT02851472|Experimental|Inhaled Nitric Oxide|iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
11277586|NCT02851472|Active Comparator|Placebo|Placebo gas (nitrogen) will be given continuous, via inhalation at the same ppm, before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
11277587|NCT02851459|Experimental|Morally Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations.
11277588|NCT02851459|Experimental|Morally Non-Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations.
11277589|NCT02851459|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
11277590|NCT02851446||DS|
11277591|NCT02851446||no DS|
11277592|NCT02851433|Experimental|Sevoflurane Group|
11277593|NCT02851433|Active Comparator|Propofol Group|
11277594|NCT02851420|Placebo Comparator|control|
11277595|NCT02851420|Experimental|patient|
11277596|NCT02851407|Experimental|Defibrotide|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT
11277597|NCT02851407|Other|Best Supportive Care|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable
11277598|NCT02851394|Active Comparator|Levobupivacaine group|
11277599|NCT02851394|Experimental|Levobupivacaine + tramadol group|
11277600|NCT02851381|Other|FG-3019|Treatment of Pancreatic Cancer with FG-3019
11277601|NCT02851368|Other|Near Infrared Fluorescence Imaging with Indocyanine Green|Patients will receive an injection of indocyanine green (ICG) 1 day prior to surgery. Near infrared fluorescence imaging (NIFI) will be used to identify pulmonary nodules during the surgical biopsy and/or resection procedure.
11277602|NCT02851342||MS|patients with multiple sclerosis
11277603|NCT02851342||CO|matched control subjects
11277604|NCT02851316|Experimental|Whole Body Vibration|The WBV intervention consists of 6 bouts of 60 seconds vibration with 2 minutes of rest in between (30Hz, 2g acceleration) while participants stand on a vibrating platform with their knees bent.
11277605|NCT02851316|No Intervention|Control|The control intervention consists of 6 bouts of 60 seconds with 2 minutes of rest in between while participants stand with their knees bent (no vibration applied).
11277606|NCT02851303|Active Comparator|Morphine|"Dose given q 3 - 4 hrs with feeds; do not exceed 4 hrs between doses Morphine (0.04mg/0.1ml)
~Score Dose For Initiation 0-8 0 None 9-12 0.04 mg/dose 13-16 0.08 mg/dose 17-20 0.12 mg/dose 21-24 0.16 mg/dose 25 or above 0.20mg/dose
~Morphine Maintenance/Escalation
~Maintain dose if score 0-8
~Increase dose by 0.02 if score is 9-12 (rescore before dosing) • Increase dose by 0.04 if score 13-16
~Increase score by 0.06 if score 17-20
~Weaning Instructions:
~Maintain on dose 48 hrs before starting weaning
~Wean 0.02 mg morphine every day for a score is 0-8 • Defer wean for score 9-12
~Re-escalation
~If neonate scores 9-12 re-score as described for initiation,
~If second score is in 9-12 increase morphine 0.01 mg q3-4 hrs • If 2 consecutive scores 13-16, increase 0.02 mg q3-4 hrs
~If 2 consecutive scores in 17-20, increase 0.04 mg q3-4 hrs etc"
11277607|NCT02851303|Active Comparator|Methadone|Step 1: 0.7 mgs/Kg/24 hrs. divided by into six doses (q 4 hrs) is starting dose Step 2: Decrease dose by half, which is 50% of starting dose, EVERY 4 hours. Step 3: Same dose which is 50% of starting dose EVERY 6 hours. Step 4: Same dose which is 50% of starting dose EVERY 8 hours. Step 5: Same dose which is 50% of starting dose EVERY 12 hours. Step 6: Decrease dose by half, which is 25% of starting dose EVERY 12 hours. Step 7: Same dose which is 25% of starting dose q 24 hours
11277608|NCT02851290|Experimental|Caudal block|Local anesthetic will be administered into the caudal space
11277609|NCT02851290|Active Comparator|Dorsal penile nerve block|Local anesthetic will be administered around the dorsal penile nerve
11277610|NCT02851277|Experimental|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
11277611|NCT02851277|Experimental|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
11277612|NCT02851277|Placebo Comparator|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
11277613|NCT02851277|Experimental|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
11277614|NCT02851277|Placebo Comparator|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
11277615|NCT02851264||Optical enhancement technology examination|After routine examination by white-light endoscopy,the imaging mode will be switched to optical enhancement.Suspicious area will be recorded in detail. Then all enrolled patients will have their esophagus sprayed with iodine solution. Suspicious area will be also recorded in detail.After that biopsy specimens will be obtained respectively by forceps from each suspicious lesion recorded for histologic diagnosis.
11277616|NCT02851238|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 6mL/kg of ideal body weight and positive end expiratory ventilation of 5cmH2O during one-lung ventilation
11277617|NCT02851238|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
11277618|NCT02851225|Experimental|telemedicine transmission|telemedicine transmission of biological results in the treatment of transfusion supportive care
11277619|NCT02851225|No Intervention|without telemedicine transmission|no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care
11277643|NCT02851082|Experimental|Haemophilia A patients|Patients will perform endurance training program on 6 consecutive weeks
11279385|NCT02838602|Experimental|Carbon ions therapy|Radical and exclusive carbon ions radiotherapy
11277620|NCT02851212|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with two Extended Release (XR) tablets of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 Extended Release (XR) fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin XR two tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277621|NCT02851212|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277622|NCT02851212|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277623|NCT02851212|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277624|NCT02851199|Active Comparator|study group 1|1. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the prone position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. Finally the participants will performed additional 3 minutes of hyperventilation in the sitting position
11277625|NCT02851199|Active Comparator|study group 2|2. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the sitting position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. . Finally the participants will performed additional 3 minutes of hyperventilation in the
11277626|NCT02851186|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|Subjects in the treatment group will receive EA combined with AA two hours before operation, immediately post-operation and once a day for the subsequent 5 days.
11277627|NCT02851186|Sham Comparator|Sham acupuncture|Subjects in the control group will receive non-invasive sham procedure in the same schedule as the treatment group.
11277628|NCT02851173|Experimental|LLLT|Six weekly sessions of LLLT. The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each laser stimulation session will consist of total 8 min, with eight 1 min/cycle treatments alternating between two locations on the right forehead.
11277629|NCT02851173|Active Comparator|Placebo|The control group will undergo the same procedure as the treatment group, but will receive brief (5-s) stimulation to the intended site on the forehead, followed by 55 s of no stimulation, for each 1-min cycle. Thus the control group will receive approximately 1/12th of the cumulative energy density as the treatment group. This is sufficient to provide a brief sensation of slight heat (as active placebo) at the onset of each one-minute cycle, using a fraction of the energy received by the experimental group.
11277630|NCT02851160||Patients requiring lung cancer chemotherapy|30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment having a semi-structured interview conducted by a clinical psychologist
11277631|NCT02851160||Family of lung cancer patients receiving chemotherapy|30 Family of lung cancer patients receiving chemotherapy having a semi-structured interview conducted by a clinical psychologist
11277632|NCT02851160||doctors caring for lung cancer patients receiving chemotherapy|15 doctors caring for lung cancer patients receiving chemotherapy 15 have a semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
11277633|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
11277634|NCT02851134||Crohn disease subject|Crohn disease affected subject
11277635|NCT02851134||family control subject|family control unaffected subject
11277636|NCT02851121|Other|Healthy volunteers|
11277637|NCT02851108|Experimental|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
11277638|NCT02851108|Active Comparator|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
11277639|NCT02851095|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with two Extended Release (XR) tablet of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D of (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and 1 metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with 2 metformin (XR) tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277640|NCT02851095|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277641|NCT02851095|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277642|NCT02851095|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11277644|NCT02851069||Participants with Hepatitis C Virus Genotype 1 (HCV + GT1)|ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] with or without dasabuvir [250 mg twice daily]), and with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks in HCV + GT1 participants.
11277645|NCT02851056|Experimental|Survivin Vaccine and Autologous HCT|Dendritic Cell Survivin Vaccine (DC:AdmS) and Autologous Hematopoietic Cell Transplantation (HCT). Participants will receive 1 pre-transplant survivin vaccine, 7-30 days prior to stem cell apheresis collection. After the first survivin vaccination, participants will be mobilized with Granulocyte-colony Stimulating Factor (G-CSF). A second survivin vaccine will be administered on day +21 (between day+20 and +34) after HCT. All participants will be co-immunized with Prevnar 13 at each time they receive the survivin vaccine.
11277646|NCT02851043|Experimental|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
11277647|NCT02851043|No Intervention|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
11277648|NCT02851030|Experimental|Move, Play, Learn! Intervention|This arm will receive the 10-week Move, Play, Learn! intervention immediately.
11277649|NCT02851030|No Intervention|Waitlist Control|This arm will receive the 10-week intervention once follow-up measures on the primary outcome have been collected for both groups.
11277650|NCT02851017|Experimental|Exergaming group (XBOX Kinect|Kinect™ exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total).
11277651|NCT02851017|Experimental|Traditional gym based exercise group|Traditional gym based (TGB) exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total). Those in the TGB group performed exercises that were matched for sequence, intensity, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading as required in the Kinect™ group.
11277652|NCT02851004|Experimental|BBI608 + Pembrolizumab|BBI608 and Pembrolizumab
11277653|NCT02850991|Experimental|High-dose|"concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.
~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
11277654|NCT02850991|Active Comparator|Standard-dose|"concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.
~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
11277655|NCT02850978||Spiolto|Patient with COPD to received Spiolto
11277656|NCT02850965|Experimental|BI 695501|
11277657|NCT02850965|Active Comparator|Humira|
11277658|NCT02850952|Experimental|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
11277659|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
11277660|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
11277661|NCT02850926|Experimental|Soccer head gear|Subjects who are wearing soccer head gear during the practices and games during the soccer season.
11277662|NCT02850926|No Intervention|Control|Subjects who are not wearing soccer head gear during the practices and games during the soccer season.
11277663|NCT02850913|Active Comparator|Doxycycline|"115 participants will be randomized to oral Doxycycline 100 mg daily for six weeks.
~Each capsule contains doxycycline hyclate equivalent to 100 mg of doxycycline base.
~Treatment will be initiated in hospital but will be continued at home.
~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
11277664|NCT02850913|Placebo Comparator|Placebo|"115 participants will be randomized to the placebo arm for matching capsules containing no active ingredients daily for six weeks.
~Placebo will be initiated in hospital but will be continued at home.
~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
11277665|NCT02850900|Experimental|Internet Survey|Subject will receive an electronic survey weekly to complete
11277666|NCT02850900|No Intervention|No Survey|No intervention
11277667|NCT02850887|Active Comparator|general endotracheal anesthesia|an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
11277668|NCT02850887|Active Comparator|deep sedation without endotracheal intubation|local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.
11277669|NCT02850874|Experimental|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
11277670|NCT02850874|Other|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
11277671|NCT02850861|Experimental|The experimental group|In this group, the condylar reductor was applied in the surgical treatment of mandibular condylar fractures.
11277738|NCT02850341|Experimental|Intervention group|Patients receive a pedometer and instructions how to raise their physical activity
11277672|NCT02850861|No Intervention|The control group|In this group, traditional surgical instruments were applied in the surgical treatment of mandibular condylar fractures.
11277673|NCT02850848|Experimental|Entigin Film Coated Tablet 0.5mg|Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets
11277674|NCT02850848|Active Comparator|Baraclude 0.5mg Tablets|Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets
11277675|NCT02850835|Experimental|Video Decision Aid|This group will be shown a video decision aid along with their standard of care.
11277676|NCT02850835|No Intervention|Standard Care|This group will not see the video decision aid and will only receive standard of care.
11277677|NCT02850822||Therapy pre-transplantation|Chemotherapy regimen and/or demethylation drugs(such as decitabine) were given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
11277678|NCT02850822||No Therapy pre-transplantation|No therapy (chemotherapy or demethylation drugs) was given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
11277679|NCT02850809||patients|Treated by percutaneous image-guided radiofrequency for renal tumor
11277680|NCT02850796|Experimental|Kg-Free|Kg-free is a manualized acceptance, mindfulness & compassionate-based group intervention for women struggling with their weight. It comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups (ranging from 10 to 12 participants).
11277681|NCT02850796|Other|Treatment as Usual (TAU)|nutritional treatment for weight loss in primary care units and Hospitals from Coimbra's district that includes dietary and physical activity support
11277682|NCT02850783|Experimental|SLN identification with 89-zirconium-nanocoll|Submucosal injection of 2.5 mBq, 0.4 ml 89-Zirconium-Nanocoll and subsequently SLN identification
11277683|NCT02850770|Other|Control|Pedometers and walking logs
11277684|NCT02850770|Experimental|Phone Messaging|Phone Messaging
11277685|NCT02850770|Experimental|Phone Messaging + Family/Friend Support|Phone Messaging + Family/Friend Support
11277686|NCT02850757|Experimental|U shaped Guedl's airway|
11277687|NCT02850757|Experimental|Modified William's airway(Fekry airway )|
11277688|NCT02850744|Other|Single-arm|Open label, single arm including patients with progressive glioblastoma during or after temozolomide chemotherapy obtaining PQR309 80mg capsules.
11277689|NCT02850731|Experimental|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
11277690|NCT02850731|No Intervention|supervision by a therapist|an adapted physical activity program under supervision of a therapist
11277691|NCT02850718|Experimental|Period 1: Sublingual wafer|Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.
11277692|NCT02850718|Active Comparator|Period 2: Oral comparator|Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.
11277693|NCT02850692|Experimental|Cystic fibrosis with portal hypertension|Mucoviscidosis with portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
11277694|NCT02850692|Experimental|Muco without portal hypertension|Mucoviscidosis without portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
11277695|NCT02850692|Experimental|Portal hypertension without muco|Portal hypertension without Mucoviscidosis. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
11277696|NCT02850692|Experimental|Healthy volunteers|Healthy volunteers. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®).
11277697|NCT02850666|Experimental|Interdisciplinary Process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
11277698|NCT02850653|Other|Endophthalmitis sufferers|Patients hospitalized for diagnostic and therapeutic evaluation of a post-operative acute endophthalmitis.
11277699|NCT02850653|Other|Healthy control patient|Patients hospitalized in the context of a scheduled surgery with sampling of aqueous humour.
11277700|NCT02850627|Experimental|Tongguan capsule|Tongguan capsule (0.5 g tid. for 6 months)
11277701|NCT02850627|Placebo Comparator|placebo capsule|same volume/day of placebo capsule (0.5 g tid. for 6 months)
11277702|NCT02850614|Active Comparator|Control|Fifty participants in the control condition will each receive a FitBit to track their physical activity. Instead of interfacing with a gaming app on their Chromebooks to track physical activity, control condition participants will interface with a minimalist activity tracker showing them only how many minutes of MVPA they've done over the course of the day. It is expected that after several weeks of baseline use, control condition participants will no longer find the FitBit novel. In order to encourage control condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
11277703|NCT02850614|Experimental|Intervention|Fifty participants will be randomized to the intervention condition, which will use a gaming application to encourage physical activity, as physical activity goal achievement will translate into rewards in the game. Physical activity will be tracked using a FitBit activity monitor and in order to encourage intervention condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
11277704|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
11277705|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
11277706|NCT02850588||TCAR treatment|All high risk surgical patients undergoing transcarotid revascularization with a carotid stent during carotid artery flow reversal in hospitals that participate in the Carotid Artery Stent Registry of the Society for Vascular Surgery Patient Safety Organization
11277707|NCT02850588||CEA treatment|All patients undergoing carotid endarterectomy in hospitals that participate in the Carotid Endarterectomy Registry of the Society for Vascular Surgery Patient Safety Organization
11277739|NCT02850341|No Intervention|Control group|Patients receive treatment-as-usual
11277708|NCT02850562|Active Comparator|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
11277709|NCT02850562|Experimental|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
11277710|NCT02850549|Other|physical therapy|Physical Therapy intervention provided by therapists in phase one without training in following a neck classification system and in phase two after being trained to follow a neck pain classification system.
11277711|NCT02850536|Experimental|anti-CEA CAR-T cells|Three infusions of gene-modified anti-CEA T cells over the course of 3 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2.
11277712|NCT02850523|Experimental|Experimental|After an initial assessment, the experimental group will receive 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety (n=6 per group) for perinatal anxiety. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
11277713|NCT02850523|No Intervention|Waitlist Control|After an initial assessment, the wait-list control group will not receive any treatment for 6 weeks. They will then be re-assessed after 6 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety
11277714|NCT02850510|Experimental|Brief Incredible Years parent training|Parent training
11277715|NCT02850510|No Intervention|No parent training|No parent training
11277716|NCT02850497|Active Comparator|CRE8 stent|Treatment with CRE8 stent implantation and evaluated with optical coherence tomography at 6 months
11277717|NCT02850497|Active Comparator|Biomatrix stent|Treatment with Biomatrix stent implantation and evaluated with optical coherence tomography at 6 months
11277718|NCT02850497|Active Comparator|patients treated with Xience stent|Treatment with Xience stent implantation and evaluated with optical coherence tomography at 6 months
11277719|NCT02850484|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
11277720|NCT02850484|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
11277721|NCT02850484|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
11277722|NCT02850471|Experimental|TEAS group|Before anesthesia, patients in this group treated with Transcutaneous Electric Acupoint Stimulation (TEAS) which is an electroacupuncture on Feishu, Hegu, Chize half an hour before the surgery, using the device Hua Tuo SDZ-II Acupoint Stimulator. The stimulus parameters set as 2/100Hz, 2V, 30min.
11277723|NCT02850471|No Intervention|controlled group|Patients in controlled group treated without TEAS or other placebo.
11277724|NCT02850458||implant retained-overdentures with the attachment of bar|patients treated with implant-retained overdentures,and the attachment is bar
11277725|NCT02850458||implant retained-overdentures with the attachment of magnet|patients treated with implant-retained overdentures,and the attachment is magnet
11277726|NCT02850445|Experimental|Integrated Treatment|
11277727|NCT02850445|Active Comparator|antipsychotic medication alone treatment|
11277728|NCT02850432|Active Comparator|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
11277729|NCT02850432|Active Comparator|Conservative treatment|rehabilitation with medical therapy
11277730|NCT02850419|Experimental|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
11277731|NCT02850406|Experimental|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:
~Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)
~Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)
~Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)
~Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)"
11277732|NCT02850393|Experimental|patients with obsessive compulsive disorder|Functional magnetic resonance imaging behavioral measures physiological measurements
11277733|NCT02850393|Experimental|healthy participants|Functional magnetic resonance imaging behavioral measures physiological measurements
11277734|NCT02850380|Other|spatial orientation in weightlessness|"subjects will be asked to flip a series of switches into the off position. On Earth, the off position corresponds to down in all three reference frames: the visual allocentric, the non-visual allocentric as well as the egocentric frames. We expect that flip direction will be dominated by visual allocentric cues when those are available, will be delayed and more variable when confirmatory gravitational cues are absent, and will be biased towards the egocentric reference when tactile cues are added"
11277735|NCT02850367|Active Comparator|Acute intake|Evaluation after acute intake of the food supplement.
11277736|NCT02850367|Active Comparator|Chronic intake|Evaluation before and after chronic intake of the food supplement.
11277737|NCT02850354|Experimental|anti-g maneuvers|"Before the first parabola, pulmonary function will be evaluated. Then during each weightlessness period the subject will be instructed either to stay at rest (control condition) or to perform anti-g maneuvers (4 times each): intermittent exhalation on exertion, lower limbs and abdomen muscular contraction, combined maneuver ('intermittent exhalation on exertion' + 'muscle contraction'). Before, the exhalation on exertion, the subject will close the airway after the mouthpiece by pushing on a button actuating a pneumatic valve.
~Each subject will be tested during 15 parabola where the anti-g maneuvers will be performed in randomized order. After the 15th parabola, pulmonary function will be again evaluated."
11277740|NCT02850328|Other|high-load resistance training for long term space flights|"Short duration electrical will be delivered and the resulting EMG will be recorded. Intensity of electrical stimulation will be progressively increased until we observed a maximal EMG response.
~Finally an ultrasound probe (similar to that used for prenatal diagnostic imaging) will be fixed behind your calf in order to visualize muscle."
11277741|NCT02850302|Other|FDG PET + exome analysis before treatment and after|Participants will performed one PET with FDG an tumor exome analysis before treatment is started.After 6 cycles of chemotherapy a second PET with FDG and a second tumor exome analysis will be performed
11277742|NCT02850289||Pegylated Interferon (PEG-IFN) alfa-2a and Ribavirin|Participants with hepatitis C who were to be treated with combination of pegylated interferon (PEG-IFN) alfa-2a and ribavirin, within 7 days of baseline, with ongoing management at investigator's discretion.
11277743|NCT02850276|Experimental|Pyridostigmine|30mg PO three times a day
11277744|NCT02850263||Cohort 1 / Anti-VEGF treatment naïve patients|Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
11277745|NCT02850263||Cohort 2 / Anti-VEGF treatment non-naïve patients|Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
11277746|NCT02850263||Cohort 3 / Total study population|Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
11277747|NCT02850224|Experimental|Motivational interviewing to elicit PCO in pediatrics|"Providers will be randomized into a patient-centered outcomes (PCO) education course or standard of care. The PCO education course will educate and test providers on patient-centered outcomes of interest and appropriate methods to deliver PCO care.
~Providers randomized into the intervention arm will be required to take a brief, one-hour, webinar describing the background, problem, results from focus groups we conducted, and a training program on motivational interviewing. After completing the course, providers will be required to complete an evaluation."
11277748|NCT02850224|No Intervention|No Intervention|Standard care
11277749|NCT02850211|Experimental|Celecoxib|1 capsule of 200mg Celebrex twice a day for 14 days
11277750|NCT02850211|Active Comparator|Traditional NSAIDs|1 tablet of 385mg Ibuprofen twice a day for 14 days
11277751|NCT02850211|Active Comparator|Opioid drug|1 tablet of 50mg Tramadol twice a day for 14 days
11277752|NCT02850198|Experimental|Scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
11277753|NCT02850198|Sham Comparator|Sham scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. with shame electroacupuncture. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
11277754|NCT02850185|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
11277755|NCT02850185|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
11277756|NCT02850172|Experimental|Walk, eat, & breathe group|"Participants in the experimental group will receive Walk, Eat, & Breathe at initiation of CCRT and ends before curative surgery."
11277757|NCT02850172|No Intervention|Control group|Participants in the control group received usual care.
11277758|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
11277759|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
11277760|NCT02850146|Experimental|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 4 time points over a 4.5 year period.
11277761|NCT02850133|Experimental|Spinal cord injury|Cardio-pulmonary exercise testing and aerobic exercise training
11277762|NCT02850120||Unconfounded|"All hospital admissions including Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with:
~no concomitant procedures,
~any concomitant procedures which were considered unlikely to have an effect on outcomes from their mesh insertion, or
~only other concomitant procedures which were considered likely to be rescue procedures treating complications caused by the mesh insertion procedure itself."
11277763|NCT02850120||Confounded|All hospital admissions for insertion of Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with concomitant procedures likely to affect outcomes.
11277764|NCT02850107|Other|Non-randomized|"Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects.
~DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™.
~Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU.
~Medtronic IN.PACT® Admiral® DCB will be used after DA.
~Volcano Visions® PV .014 IVUS catheter required to assess lesion in each procedure.
~Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required."
11277970|NCT02848508|Experimental|moderate impairment, CKD stage 3a|(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day
11277765|NCT02850094|Experimental|Financial Bonuses|For two weeks following enrollment, subjects are monitored via their FitBit accelerometer to monitor their pre-intervention physical activity levels. For a twenty-four week period following the observational period, participants are eligible for financial bonuses based on their increased activity. Participants enroll as teams and are eligible for additional financial bonuses based on their team's performance.
11277766|NCT02850081|No Intervention|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.
11277767|NCT02850081|Experimental|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin <40mg without amlodipine and <20mg with amlodipine; Atorvastatin (<80mg) or Rosuvastatin (<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.
11277768|NCT02850081|Experimental|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA
11277769|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
11277770|NCT02850055|Experimental|Specific Manual Therapy Group|Conventional Physiotherapy and Specific manual therapy, six one hour treatment sessions. An hour for week.
11277771|NCT02850055|Active Comparator|Multimodal Group|Conventional Physiotherapy, six one hour treatment sessions. An hour for week.
11277772|NCT02850042|Experimental|Occupation-based practice|Occupation-based intervention (OBP) is a form of activity-based therapy consisting of client-directed occupations that match client-identified goals. OBP group will participate in activities such as wood working, scrap booking, higher level dressing (don/doffing a bra, zipping coat), hair care, opening doors, using bathroom stalls, typing, cooking, tying shoes, washing dishes, carrying dirty dish carts, clearing dirty dishes and raking. Repetition of the tasks are not the focus in the OBP group. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
11277773|NCT02850042|Active Comparator|Modified-constraint induced therapy|Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
11277774|NCT02850029||critically ill patients|Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.
11277775|NCT02850016|Experimental|Group A|Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
11277776|NCT02850016|Experimental|Group B|Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .
11277777|NCT02850003|Experimental|IDP-120 Gel|Gel
11277778|NCT02849990|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
11277779|NCT02849977||Cohort 1|If the subject has a history of hyperphagia, early onset obesity and/or clinical characteristics known to be related to mutations in the MC4R pathway and related to obesity (1.4 times 95th percentile in children).
11277780|NCT02849977||Cohort 2|If the subject has exponentially high BMI (≥50 to 59), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.5 - 1.6 times 95th percentile in children).
11277781|NCT02849977||Cohort 3|If the subject has exponentially high BMI (≥60), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.6 times 95th percentile in children).
11277782|NCT02849977||Cohort 4|If the subject has had or is undergoing bariatric surgery, who represents a refractory population of severely obese individuals whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.4 times 95th percentile in children and adolescents aged 12 and older).
11277783|NCT02849964||First time renal replacement therapy|Patients beginning renal replacement therapy by renal dialysis or preemptive kidney transplant.
11277784|NCT02849951|Experimental|LT-02|1.6 g PC in LT-02 BID
11277785|NCT02849951|Placebo Comparator|LT-02 Placebo|0 g PC in LT-02 Placebo BID
11277786|NCT02849938|No Intervention|Control Group|Usual care
11277787|NCT02849938|Experimental|Telemedicine Group|TytoCare Device
11277788|NCT02849925|Experimental|Glass Ionomer Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
11277789|NCT02849925|Active Comparator|Resin Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of resin sealant, Clinpro (3M-ESPE) in first permanent molars
11277790|NCT02849899|Active Comparator|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
11277791|NCT02849899|Placebo Comparator|Placebo|Group 2 will be treated with placebo according to the same dosage.
11277792|NCT02849886|Experimental|LT icasp9 ΔCD19 (cohort1)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 Gene Modified Cells (GMC)/kg).
11277971|NCT02848508|Experimental|moderate impairment, CKD stage 3a)|(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day
11277793|NCT02849886|Experimental|LT iCASP9 ΔCD19 & GvHD (cohort2)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 GMC/kg). Patients who develop GVHD after administration of Gene Modified Cells (GMC) will be treated with dimerizer drug (AP1903)
11277794|NCT02849873|Experimental|IDp-123 Lotion|Lotion
11277795|NCT02849873|Active Comparator|Tazorac Cream|Cream
11277796|NCT02849860|Experimental|IDP-121 Lotion|Lotion
11277797|NCT02849834|Active Comparator|healthy volunteers|
11277798|NCT02849834|Experimental|Patients with resistant pain|
11277799|NCT02849821|Other|hypobaric pressure chamber|The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
11277800|NCT02849808||Keratoplasty patients|All patients who underwent one or more keratoplasties since january 1983.
11277801|NCT02849795|Experimental|Psoriasis and arthritic psoriasis|additional blood sample for biological analyses bone densitometry questionnaires
11277802|NCT02849782|Experimental|Fampridine responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).
~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner."
11277803|NCT02849782|Active Comparator|Fampridine non responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).
~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner."
11277804|NCT02849769||Patients implanted with an MR-conditional Tachy device system|Patients implanted with an MR-conditional Tachy device system in the routine care
11277805|NCT02849756||older in intensive care unit|older (age superior at 85 years) hospitalized in intensive care unit. A follow-up until 6 months after hospitalization will determine the evolution of the quality of life and others secondary outcomes.
11277806|NCT02849743|Experimental|Syntocinon (= Oxytocin), then Placebo|"Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
~Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks) *Dose Escalation, as appropriate, at 2 Weeks"
11277807|NCT02849743|Experimental|Placebo, then Syntocinon (= Oxytocin)|"Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
~Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)"
11277808|NCT02849730||Young adults|Patients aged 20 to 39 who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
11277809|NCT02849730||Elderly patients|Patients aged 70 and over who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
11277810|NCT02849717|No Intervention|Standard Care|Subjects are advised to maintain their normal level of activity
11277811|NCT02849717|Active Comparator|Home-Based Exercise|Progressive walking and resistance exercise treatment
11277812|NCT02849704|Experimental|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.
~Subjects will take Creon36™ for 9 days.
~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
11277813|NCT02849704|No Intervention|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
11277814|NCT02849691||Quartile 1|Quartile 1 of plasma DPP4 activity
11277815|NCT02849691||Quartile 2|Quartile 2 of plasma DPP4 activity
11277816|NCT02849691||Quartile 3|Quartile 3 of plasma DPP4 activity
11277817|NCT02849691||Quartile 4|Quartile 4 of plasma DPP4 activity
11277818|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.
~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
11277819|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
11277972|NCT02848508|Experimental|severe impairment|(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day
11277820|NCT02849665|Experimental|Kangaroo Position|The newborn remains in a vertical position, with limbs flexed, dressed in light clothes, maintaining skin-to-skin contact and the face on the adult's thorax.
11277821|NCT02849665|No Intervention|Not Kangaroo Position|The newborns will be not placed in the position Kangaroo.
11277822|NCT02849652|Experimental|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
11277823|NCT02849652|Other|Usual Care|Usual Care is the typical guideline based smoking cessation intervention
11277824|NCT02849639|Placebo Comparator|Placebo|"Participants enrolled into this arm will only receive educational materials, but will not receive specific recommendations to make changes to the medications they are taking.
~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
11277825|NCT02849639|Active Comparator|Medication Therapy Management (MTM)|"Participants enrolled into this arm will receive educational materials and will have their medications assessed; recommendations for changes in the medications taken will be made when appropriate.
~Cognitive testing at the beginning and the end of the study will be done with and without a scopolamine patch to reveal cognitive reserve."
11277826|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
11277827|NCT02849613|Experimental|Adipose derived Stem Cells ADSC|ADSC, single IV, 1.106 cells/kg
11277828|NCT02849613|Sham Comparator|Vehicle media|IV infusion of cell excipients, 1ml/kg
11277829|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will receive cannabis with placebo THC
11277830|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will receive cannabis with 5.9% THC
11277831|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will receive cannabis with 13.4% THC
11277832|NCT02849561|Active Comparator|Favourable neurological evolution after cardiac arrest|MGOS 4-5
11277833|NCT02849561|Active Comparator|Unfavourable neurological evolution after cardiac arrest|MGOS 1-3
11277834|NCT02849548|Experimental|suvorexant|10 to 20 mg to be administered after an evening written trauma narrative exposure session.
11277835|NCT02849548|Placebo Comparator|Placebo pill|A pill without active ingredients
11277836|NCT02849535|Experimental|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
11277837|NCT02849535|No Intervention|Standard of care|In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.
11277838|NCT02849522||PAE patients|Men who have undergone PAE and are in the UK ROPE Register
11277839|NCT02849522||Comparator treatment patients|Men who have undergone TURP, Open Prostatectomy or laser ablation/enuclation of the prostate, and are on the UK ROPE Register.
11277840|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
11277841|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
11277842|NCT02849496|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II.
11277843|NCT02849496|Experimental|Arm II (olaparib, atezolizumab)|Patients receive olaparib as Arm I and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11277844|NCT02849483|Experimental|Ramosetron|2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
11277845|NCT02849483|Placebo Comparator|Control|dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA
11277846|NCT02849470|Active Comparator|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
11277847|NCT02849470|Active Comparator|ARM 2|"Experimental: HD-PRP + Emulsified AD-tSVF;
~Intervention:
~Platelet Rich Plasma
~Adipose Derived Stem/Stromal Cells
~Intradermal injections of hair loss"
11277848|NCT02849470|Experimental|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss
~Platelet Rich Plasma
~Adipose Derived Stem/Stromal Cells
~Stem/Stromal Cell Isolation
~Intradermal injections of hair loss"
11277849|NCT02849457|Placebo Comparator|Vigabatrin or Placebo|Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
11277850|NCT02849457|Other|Vigabatrin|Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
11277851|NCT02849457|No Intervention|Control Group|Enrolled subjects who never develop EEG abnormalities or clinical seizures
11277852|NCT02849444||Moderate kidney failure|30 ≤ CrCl < 50 mL/min/1.73 m2
11277853|NCT02849444||Severe kidney failure|CrCl < 30 mL/min/1.73 m2
11277854|NCT02849431|Experimental|Mindfulness-based intervention|
11277885|NCT02849223|Sham Comparator|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
11277855|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
11277856|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
11277857|NCT02849405|Other|Arteriosclerosis|Hyperspectral camera for arteriosclerosis Diagnostic
11277858|NCT02849405|Other|Healthy controls|Hyperspectral camera for healthy control Diagnostic
11277859|NCT02849392|Experimental|Pistachio|Pistachio added 20% of kcals to diet
11277860|NCT02849392|No Intervention|No Pistachio|No pistachios in diet (control)
11277861|NCT02849379|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277862|NCT02849379|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277863|NCT02849366|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277864|NCT02849366|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277865|NCT02849353|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277866|NCT02849353|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277867|NCT02849340|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277868|NCT02849340|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277869|NCT02849327|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277870|NCT02849327|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277871|NCT02849314|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277872|NCT02849314|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277873|NCT02849301|Experimental|Cervical pessary|Arabin cervical pessary
11277874|NCT02849301|No Intervention|Standard care|No treatment
11277875|NCT02849288|Experimental|Intervention|Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
11277876|NCT02849275|Placebo Comparator|Lactose free 1% milk|Diet will be recorded with a 7-day diet record and participants will include an isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
11277877|NCT02849275|Experimental|Probiotic treatment|Diet will be recorded with a 7-day diet record and participants will include an isocaloric fermented milk (probiotic), consumed once daily, over 4-5 weeks.
11277878|NCT02849262|Experimental|Omiganan (CLS001)|CLS001 Topical Gel, 2.5%
11277879|NCT02849262|Placebo Comparator|Vehicle|Vehicle Topical Gel
11277880|NCT02849249|Active Comparator|One day schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in one day schedule. The maintenance dose (0.5 mL) is reached in one day.
11277881|NCT02849249|Active Comparator|Rapid schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in a rapid Schedule.The initation phase includes 3 weekly increasing doses till the maintenance dose of 0.5 mL is reached.
11277882|NCT02849236|Placebo Comparator|Control group|PECS block performed with Saline solution instead of local anesthetic
11277883|NCT02849236|Experimental|PECS group|PECS block performed with Ropivacaine 3.75mg/mL
11277884|NCT02849223|Experimental|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
11277886|NCT02849210|Experimental|Allergovac depot|Allergovac depot with Olea europaea pollen extract
11277887|NCT02849197||Primary Closure|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.
~Technique: primary closure. Technical details: An elliptical incision was made, and the excision included sinus openings at the median line and extended down to the pre-sacral fascia. One suction drain was placed in the wound cavity. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and skin was closed with interrupted 2-0 silk suture."
11277888|NCT02849197||Limberg Flap Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.
~Technique: Limberg Flap Technique. Technical details: A rhomboid incision was made as to include all sinus openings, and an excision was made down to the pre-sacral fascia. A bisector drawn in the rhombohedron was extended laterally to a length similar to that of a corner of the rhombohedron. Then, the flap was prepared by removing gluteal muscle with its fascia. One suction drain was placed at the wound cavity. The base of the flap was approximated with the presacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable sutures, and the skin was closed with interrupted 3-0 prolene suture."
11277889|NCT02849197||Modified Limberg Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.
~Technique: Modified Limberg Flap Technique. Technical details: As in Limberg flap technique, a rhomboid incision was made. Upper and lower corners of the excision were lateralized 2 cm away from the midline in order to keep the suturing line at the inferior from overlapping the midline. An excision was made down to the pre-sacral fascia. One suction drain was placed at the wound cavity, and the base of the flap was approximated with the pre-sacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and the skin was closed with 3-0 prolene."
11277890|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
11277891|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
11277892|NCT02849171|Experimental|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
11277893|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
11277894|NCT02849145|Experimental|Biological/Vaccine|
11277895|NCT02849132|Experimental|Treatment group|entecavir oral，0.5mg daily for 5 years
11277896|NCT02849119|Experimental|Transperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through transperitoneal approach
11277897|NCT02849119|Experimental|Retroperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through retroperitoneal approach
11277898|NCT02849106|Experimental|biopsy to obtain a chemogram|
11277899|NCT02849093||Dry Eye Syndrome Patients|Patients who have been diagnosed clinically with Sjögren's will have an OCT image of their lacrimal glands and buccal mucosa taken. Imaging from patients found to have Sjögren's clinically diagnosed following examination of buccal mucosa under the microscope will be compared with images from patients without dry eye syndrome to see of any obvious differences can be identified.
11277900|NCT02849093||Epiphora Patients|Pre and post-operative OCT images of patients undergoing punctoplasty or conjunctivoplasty will be compared to images of the same structures in people without watery eyes.
11277901|NCT02849093||Asymptomatic Patients|OCT images will be captured of the cornea, conjunctiva, lacrimal gland and buccal mucosa to establish normal appearance in asymptomatic patients.
11277902|NCT02849080|Experimental|Semaglutide flexible dosing (3, 7 or 14 mg)|
11277903|NCT02849080|Active Comparator|Sitagliptin 100 mg|
11277904|NCT02849067|Experimental|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
11277905|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
11277906|NCT02849054|Experimental|4, 5, 6ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 5ml/kg, 6ml/kg. Measurement of PTPdi
11277907|NCT02849054|Experimental|4, 6, 5ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 6ml/kg, 5ml/kg. Measurement of PTPdi
11277908|NCT02849054|Experimental|5, 4, 6ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 4ml/kg, 6ml/kg. Measurement of PTPdi
11277909|NCT02849054|Experimental|5, 6, 4ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 6ml/kg,4ml/kg. Measurement of PTPdi
11277910|NCT02849054|Experimental|6, 5, 4ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 5ml/kg, 4ml/kg. Measurement of PTPdi
11277911|NCT02849054|Experimental|6, 4, 5ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 4ml/kg, 5ml/kg. Measurement of PTPdi
11277912|NCT02849041|Experimental|Screening program|Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
11277913|NCT02849028||TBI Patients with sleep disorder|All the patients should be diagnosed by polysomnographic (PSG)
11277914|NCT02849028||health people|The people have a normal sleep
11277941|NCT02848820|Active Comparator|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
11277915|NCT02849015|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive liver cryosurgery first to destroy big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277916|NCT02849015|Active Comparator|Cryosurgery|In this group, the patients will receive liver cryosurgery to destroy big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11277917|NCT02849002|Experimental|Interventional Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the brain motion caused by pulsatile blood flow from the cardiac cycle.
~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile blood flow. The system is powered by rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
11277918|NCT02848989|Experimental|Qigong Mind-Body Exercise (QMBE)|"After the screening procedures confirm that you are eligible to participate in the research study:
~Breast cancer survivors with persistent post-surgical pain (PPSP) into a 12-week program of Qigong mind-body exercise (QMBE).
~Outcome assessments related to pain, function, and quality of life"
11277919|NCT02848976||IA group|EDSS (Expanded Disability Status Scale) below 6 with RE
11277920|NCT02848976||IB group|EDSS (Expanded Disability Status Scale) below 6 with no RE
11277921|NCT02848976||IIA group|EDSS (Expanded Disability Status Scale) betwin 6 and 8 with RE
11277922|NCT02848976||IIB group|EDSS (Expanded Disability Status Scale) below 6 with RE
11277923|NCT02848963|Active Comparator|ketamine-propofol mixture 5/1|Ketamine-propofol mixture will be compare for every groups.
11277924|NCT02848963|Active Comparator|ketamine-propofol mixture 10/1|Ketamine-propofol mixture will be compare for every groups.
11277925|NCT02848963|Active Comparator|Ketamine-propofol mixture 6,7/1|Ketamine-propofol mixture will be compare for every groups
11277926|NCT02848950|Active Comparator|treatment|drug: metformin
11277927|NCT02848950|No Intervention|control|without metformin
11277928|NCT02848937||Bath with citrate|"Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM.
~•Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study"
11277929|NCT02848937||Bath with citrate and Ca_eq|"Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials:
~Filter high permeability (Kuf> 20ml/mmHg);
~Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.
~All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study."
11277930|NCT02848911|Experimental|AFM11|IV (intravenous) infusion, dose escalation
11277931|NCT02848898|Experimental|Equistasi Group|arm treated with application of devices
11277932|NCT02848898|Placebo Comparator|Placebo Group|arm treated with application of inactivated devices
11277933|NCT02848885|Experimental|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
11277934|NCT02848885|Experimental|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
11277935|NCT02848872||NSCLC patients|Resected patients
11277936|NCT02848859|Active Comparator|Intervention: Go! to Sleep|We are using a web-based cognitive behavioral therapy program called Go! to Sleep. Go! to Sleep is an interactive online program developed by specialists in Cleveland Clinic's Wellness Institute and Sleep Disorders Center. The program is a 6 week self-help program that uses cognitive behavioral therapy techniques that have been proven to be effective in decreasing symptoms of insomnia.
11277937|NCT02848859|Placebo Comparator|General Sleep Hygiene Education|General Sleep Hygiene Education is the first step in the treatment of any sleep disorder. Both arms will have access to a Harvard sleep education web site that provides general information about sleep as well as sleep hygiene.
11277938|NCT02848846|Experimental|Robotic Hand|The two patient enrolled will perform the task requiring the use of the robotic hand.
11277939|NCT02848833||JARDIANCE|T2DM with JARDIANCE
11277940|NCT02848820|Experimental|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:
~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.
~Pain medication according to national protocol."
11277942|NCT02848807|Active Comparator|NUTRIDRINK Compact Protein|NUTRIDRINK Compact Protein Oral nutritional supplement Dietary advice
11277944|NCT02848794|Experimental|Apatinib+Irinotecan|Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
11277945|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
11277946|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
11277947|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
11277948|NCT02848742|Experimental|Treatment with cryotherapy device|To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
11277949|NCT02848729|Experimental|Treatment A: Oral Acetaminophen|Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
11277950|NCT02848729|Experimental|Treatment B: IV Acetaminophen|Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
11277951|NCT02848716|Active Comparator|Standard of care arm|Standard chemoradiation based on FluoroDeoxyGlucose-Positon Emission Tomography (FDG-PET) imaging status of the pelvic nodes
11277952|NCT02848716|Experimental|Experimental arm|Pretherapeutic paraaortic lymphadenectomy followed by tailored chemoradiation. Pretherapeutic lymphadenectomy will be performed via the laparoscopic extraperitoneal or transperitoneal approach
11277953|NCT02848703|Experimental|healthy volunteers|
11277954|NCT02848690|Experimental|Educational Intervention Group|Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
11277955|NCT02848690|Sham Comparator|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
11277956|NCT02848677|Active Comparator|intervention group|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
11277957|NCT02848677|Sham Comparator|control group|usual care of hypertensive patients.
11277958|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
11277959|NCT02848651|Experimental|Atezolizumab|Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
11277960|NCT02848625|Experimental|Group A|Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
11277961|NCT02848625|No Intervention|Group B|Patients who are not randomized to yoga sessions will continue with their usual care and usual activities
11277962|NCT02848599|Active Comparator|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
11277963|NCT02848599|Active Comparator|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
11277964|NCT02848586|Active Comparator|ECIGS|Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
11277965|NCT02848586|Active Comparator|Usual brand|Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
11277966|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
11277967|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
11277968|NCT02848547||Intervention - SMS|Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period.
11280257|NCT02832531|Active Comparator|Aspirin (ASA)|Aspirin 100 mg od (n~1000)
11277973|NCT02848482|Active Comparator|Control group|Plastic curette will be used to perform the mechanical debridement. Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
11277974|NCT02848482|Experimental|Test group|Plastic curette will be used to perform the mechanical debridement. Then, the addition photodynamic therapy (PDT) will be performed. This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
11277975|NCT02848469|Active Comparator|Omega-3 fatty acids|Subjects will receive food supplements in the form of 200ml juice drinks, containing either the active component, 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid, or matching placebo for a duration of six months. Neither the active nor the placebo food supplements taste of fish, so the subject will be blind to whether he/she is receiving the active intervention or placebo.
11277976|NCT02848469|Placebo Comparator|placebo 200ml juice drinks|200ml juice drinks
11277977|NCT02848456|Active Comparator|Spinal Manipulation SM|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
11277978|NCT02848456|Active Comparator|Max Voluntary Isometric Contraction MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
11277979|NCT02848456|Active Comparator|SM+MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
11277980|NCT02848443|Experimental|S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)|
11277981|NCT02848430|Experimental|Humulus lupulus|Spent hop extract; 2 gelatin capsules (59.5 mg extract) per day for 14 days
11277982|NCT02848417|Experimental|Curcumin|12 weeks 400mg orally twice a day
11277983|NCT02848417|Experimental|Liposomal Glutathione|12 weeks 630mg orally twice a day
11277984|NCT02848417|Experimental|Placebo Liquid or Capsules|"Placebo liquid for Glutathione 120 ml per/ bottle 420 mg/5 ml
~Placebo capsules for Curcumin 60 capsules per bottle 400 mg /cap"
11277985|NCT02848404|Experimental|Categorical Language Fluency Smartphone Application|Smartphone game application specifically aimed at training categorical language fluency
11277986|NCT02848391|Experimental|healthy subjects|three hour flight simulation
11277987|NCT02848391|Experimental|COPD normocapnic|three hour flight simulation
11277988|NCT02848391|Experimental|COPD hypercapnic|three hour flight simulation
11277989|NCT02848378||Chronic periodontitis group|Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression
11277990|NCT02848378||Gingivitis group|Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at >50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis
11277991|NCT02848378||Periodontally healthy group|Subjects who have no sites with PD >3mm and CAL >0 mm, a BOP score of <15% at the examination and no alveolar bone loss.
11277992|NCT02848365|Active Comparator|Glidescope|
11277993|NCT02848365|Active Comparator|Macintosh laryngoscope|
11277994|NCT02848365|Active Comparator|Bonfill's rigid scope|
11277995|NCT02848365|Active Comparator|Air traq|
11277996|NCT02848365|Active Comparator|C -Mac scope|
11277997|NCT02848365|Active Comparator|flexible fiberoptic scope|
11277998|NCT02848352|Experimental|Positive placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
11277999|NCT02848352|Experimental|Negative placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
11278000|NCT02848352|Placebo Comparator|Placebo control group|Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
11278001|NCT02848352|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
11278002|NCT02848326|Placebo Comparator|Placebo|Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
11278003|NCT02848326|Experimental|Atogepant 10 mg QD|Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
11278004|NCT02848326|Experimental|Atogepant 30 mg QD|Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
11278005|NCT02848326|Experimental|Atogepant 30 mg BID|Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
11278006|NCT02848326|Experimental|Atogepant 60 mg QD|Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
11278007|NCT02848326|Experimental|Atogepant 60 mg BID|Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
11278008|NCT02848313|Experimental|Intermediate AMD - HRD without GA|"Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy [GA]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen.
~Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
11278009|NCT02848313|Experimental|Intermediate AMD with NCGA|"Participants had 1 eye with intermediate AMD with noncentral geographic atrophy [NCGA]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area[DA]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography [SD-OCT]).
~Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
11280258|NCT02832518||patients under hemodialysis|
11278010|NCT02848300|Experimental|All Participants|Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
11278011|NCT02848287|Placebo Comparator|Normal Saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
11278012|NCT02848287|Experimental|Ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
11278013|NCT02848261|Experimental|Developmental Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
11278014|NCT02848261|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
11278015|NCT02848261|Experimental|Remote Monitoring|Optimize the use of remote monitoring by focusing on situational demands and problem solving.
11278016|NCT02848261|Experimental|Fear of Hypoglycemia|Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
11278017|NCT02848261|Placebo Comparator|No Intervention|Serves as the control group comparator. No intervention provided.
11278018|NCT02848248|Experimental|SGN-CD123A|SGN-CD123A every 3 weeks
11278019|NCT02848235|No Intervention|Group 1 (Standard of Care)|Participants in group 1 will receive the standard of care for the Prevention of Mother to Child Transmission (PMCTC) of HIV from the clinic's Mentor Mothers.
11278020|NCT02848235|Experimental|Group 2 (Standard of Care + EMMA)|Participants in group 2 will receive the standard of care for Prevention of Mother to Child Transmission (PMCTC) of HIV plus study-specific enhanced care interventions from the clinic's Mentor Mothers.
11278021|NCT02848222|Experimental|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
11278022|NCT02848222|Experimental|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
11278023|NCT02848222|Sham Comparator|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
11278024|NCT02848209|No Intervention|Control|No peeling applied on the skin flap
11278025|NCT02848209|Experimental|Drug: TCA 20% Peeling|Trichloroacetic acid 20% applied on the skin flap until even frosting for 2-4 minutes.
11278026|NCT02848209|Experimental|Drug: TCA 40% Peeling|Trichloroacetic acid 40% applied on the skin flap until even frosting for 2-4 minutes.
11278027|NCT02848209|Experimental|Drug: Phenol/croton oil Peeling|Phenol/croton oil applied on the skin flap occluded with silicone tape for 24 hours and not neutralized.
11278028|NCT02848196|Experimental|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
11278029|NCT02848183|Experimental|Pediatric de novo acute myeloid leukemia|"I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide
~II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning"
11278030|NCT02848170|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks
11278031|NCT02848170|Active Comparator|olmesartan medoxomil|olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks
11278032|NCT02848157|Experimental|DR|dexmedetomidine 0.3mcg/kg and 0.25% ropivacaine 0.3ml/kg
11278033|NCT02848157|Placebo Comparator|PR|0.25% ropivacaine 0.3ml/kg
11278034|NCT02848144|Other|Children with infectious shock|Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
11278035|NCT02848144|Other|Control group: healthy children|Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
11278036|NCT02848131|No Intervention|Group 1: Observational|Observational Only
11278037|NCT02848131|Active Comparator|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
11278038|NCT02848118|Experimental|A nasal-oral cannula of capnography|Start bronchoscopy when the nasal-oral capnography shows hypoventilation during bronchoscopic sedation.
11278039|NCT02848118|Active Comparator|Sedation scale|Start bronchoscopy when Observer Assessment of Alertness and Sedation scale (OAAS)=3~2 during bronchoscopic sedation.
11278040|NCT02848105|Experimental|VPA+Methyl|VPA added to standard methylpredisonlone treatment for aGVHD
11278041|NCT02848092|Experimental|FOCAL+Training|
11278042|NCT02848092|Sham Comparator|Rules of the Road Training|
11278043|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|Combination treatment with TAS-102 and oxaliplatin
11278044|NCT02848066||Gastric Cancer patients|This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.
11278045|NCT02848066||Cancer-free healthy volunteers|This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.
11278046|NCT02848053||Tianqi group|used Tianqi Capsule in the REDUCES study
11278047|NCT02848053||Placebo group|used placebo in the REDUCES study
11278048|NCT02848040|Experimental|Single Arm|All patients will receive the same interventions. Single are only
11278049|NCT02848027|Experimental|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
11278050|NCT02848014|Experimental|Expectation|Participants are asked to think and write about ways how they can positively influence/control the stress during stress induction. They also can think of strategies they used in their past. The purpose of this arm is to improve participants' personal control expectations.
11278051|NCT02848014|Experimental|Emotion|Participants in this group are asked to write a gratitude-letter to a person they want to thank. The purpose of this arm is to foster positive emotions.
11278052|NCT02848014|Active Comparator|Control|Participants in this group are asked to do a neutral writing task. The task is to write a protocol of yesterday's to-dos.
11278053|NCT02848001|Experimental|CC-90009 - Part A|Will be administered intravenously per dosing schedule in a 28-day cycle.
11278054|NCT02848001|Experimental|CC-90009 - Part B - AML and MDS patients|Relapsed or refractory AML and MDS subjects. IP will be administered intravenously per dosing schedule determined in Part A
11278055|NCT02847988|Active Comparator|Neuro-muscular electrical stimulation|"Intervention:Neuromuscular electrical stimulation (NMES)
~NMES stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering NMES"
11278056|NCT02847988|Sham Comparator|Sham stimulation|"Intervention: sham stimulation
~Sham stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering sham-NMES"
11278057|NCT02847975|Experimental|Sodium nitrate|Sodium nitrate will be administered orally and functional sympatholysis assessed before and after treatment
11278058|NCT02847962|No Intervention|Control (No FBF)|FBF provided after the intervention period
11278059|NCT02847962|Active Comparator|Corn Soy Blend Plus (CSB+)|Consumed Corn Soy Blend Plus (CSB+)
11278060|NCT02847962|Experimental|Corn Soy Blend 14 (CSB14)|Consumed Corn Soy Blend 14 (CSB14)
11278061|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 1|Consumed White Sorghum Cowpea Blend Variety 1
11278062|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 2|Consumed White Sorghum Cowpea Blend Variety 2
11278063|NCT02847962|Experimental|Red Sorghum Cowpea Blend|Consumed Red Sorghum Cowpea Blend
11278064|NCT02847962|Experimental|White Sorghum Soy Blend|Consumed White Sorghum Soy Blend
11278065|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
11278066|NCT02847936|Active Comparator|VICRYL PLUS|triclosan-coated sutures
11278067|NCT02847936|Active Comparator|VICRYL|non antibacterial coated sutures
11278068|NCT02847923|Experimental|Group Experimental|All the volunteers will use the software and then answer the questionnaire. They will be familiar with the software interface, performs an initial test to learn how to use the software, run a test script and answer the questionnaire.
11278069|NCT02847910|Experimental|experimental group|device： High-tech disposable tissue suction set for uterine cavity tissue is produced by Xi'an Mejiajia Medical Equipment Company ; The participants will be use the disposable tissue suction set during the induced abortion procedure.
11278070|NCT02847910|Experimental|control group|device： Traditional metal instruments for induced abortion procedure; The participants will be use traditional metal instruments during induced abortion procedure.
11278071|NCT02847897|Experimental|CO2 AcuPulse Laser treatment|Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
11278072|NCT02847871|Other|Multimodal Intervention|The multimodal intervention on mobility will consist of the implementation of a care pathway dedicated in primary care. It will include awareness and training of general practitioners for easy identification, a care associating a dedicated geriatric consultation to rule out underlying pathology, teaching exercises by MAPA (+/- taken care in the presence of MAPA) and nutritional counseling by a dietician. Close collaboration between general practitioners, geriatrician, MAPA and dietician will be established.
11278073|NCT02847871|No Intervention|Non interventional|Patients received treatment as part of their standard care: at the discretion of the general practitioner patients
11278074|NCT02847858|Experimental|Health-E You App Participants|
11278075|NCT02847858|No Intervention|Control Group|
11278076|NCT02847845|Experimental|Red ginseng powder capsule|People in this group take a red ginseng powder capsule.
11278077|NCT02847845|Placebo Comparator|Placebo powder capsule|People in this group take a placebo powder capsule.
11278078|NCT02847819||Vocal cords movement assessment by airway USG.|Preoperatively patients undergoing thyroid surgery will be scanned by airway ultrasound and graded for vocal cord movement, the same group of patients will be again scanned and graded by airway ultrasound at 4th post operative hours.
11278079|NCT02847806|Experimental|Estradiol|dosage used in the study: 1 patch / 3-4 days dosed at 25, 37.5 or 50 mg / 24h titration according to the plasma level, with the objective of a physiological level of estradiol (25-40 pg / ml ) - During 4 weeks
11278080|NCT02847806|Experimental|Testosterone|dosage used : from 25 to 75 mg / day of testosterone (ie 2.5 to 7.5 g / day transdermal gel) according to the plasma level, with the goal of a physiological level of testosterone (5-8 ng / ml) - During 4 weeks
11278081|NCT02847806|Experimental|Testosterone + Estradiol|Testosterone + Estradiol During 4 weeks
11278082|NCT02847793|Active Comparator|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial
11278083|NCT02847793|Placebo Comparator|Placebo intervention|Using a matching procedure (i.e., yoked control group), participants are required to maintain their gaze in a given picture (e.g., a happy face), for the same average time that their counterparts in the Gaze training group (i.e. Experimental group)
11278084|NCT02847780|Active Comparator|C-Mac video laryngoscope.|Active Comparator: C-Mac Videolaryngoscope for vocal cord movement assessment.
11278085|NCT02847780|Experimental|Airway Ultrasound|Experimental: Airway Ultrasound for vocal cord movement assessment.
11278086|NCT02847767|Experimental|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.
11278119|NCT02847598|Placebo Comparator|Part B: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
11278120|NCT02847585|Experimental|Open label|water-soluble ubiquinol
11278087|NCT02847754|Experimental|A|A patients in arm A carry out daily physical Training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home. exercise tailored isometric physical exercise
11278088|NCT02847754|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min progressive muscle relaxation starting from day one of radiotherapy.
11278089|NCT02847741|Other|Major depressive episode|Depressive patients will be assessed by interview (psychiatrists), questionnaires and blood sampling, as the inpatients's routine care
11278090|NCT02847728||Single Arm Design|The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
11278091|NCT02847715|No Intervention|Audit phase|In the audit-phase, a group of 59 patients will be recruited and followed over a 12 month period. Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
11278092|NCT02847715|Experimental|Intervention (pilot-phase)|In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
11278093|NCT02847702|Experimental|VM902A 200 mg|VM902A 200-mg Capsules
11278094|NCT02847702|Experimental|VM902A 400 mg|VM902A 400-mg Capsules (2 x 200-mg capsules)
11278095|NCT02847702|Active Comparator|Naproxen|Naproxen 500-mg Capsules
11278096|NCT02847702|Placebo Comparator|Placebo|Placebo
11278097|NCT02847689|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
11278098|NCT02847689|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
11278099|NCT02847676||No previous surgery, adhesions present.|Patients have had no previous abdominal surgery. Inspection shows peritoneal adhesions.
11278100|NCT02847676||No previous surgery, no adhesions present.|Patients have had no previous abdominal surgery. Inspection shows no peritoneal adhesions.
11278101|NCT02847676||Previous surgery, adhesions present.|Patients have had previous abdominal surgery. Inspection shows peritoneal adhesions.
11278102|NCT02847676||Previous surgery, no adhesions present.|Patients have had previous abdominal surgery. Inspection shows no peritoneal adhesions.
11278103|NCT02847663|Experimental|Whole-body cryotherapy|The effects of whole-body cryotherapy (-135°C for 2 minutes) are investigated after a muscle damage protocol.
11278104|NCT02847663|Other|Cold-water immersion|The effects of cold-water immersion (10°C for 15 minutes) are investigated after a muscle damage protocol.
11278105|NCT02847650|Placebo Comparator|Placebo|
11278106|NCT02847650|Experimental|PF-06649751|
11278107|NCT02847637|Experimental|A: Emicizumab 1.5 mg/kg/week|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
11278108|NCT02847637|Experimental|B: Emicizumab 3 mg/kg/2 weeks|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 3 mg/kg/2 weeks emicizumab subcutaneously until the end of study (maximum up to 6 years).
11278109|NCT02847637|Active Comparator|C: No Prophylaxis|Participants who received episodic treatment with FVIII prior to study entry will be randomized to continue episodic FVIII treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.
11278110|NCT02847637|Experimental|D: Emicizumab 1.5 mg/kg/week (Pre-study FVIII Prophylaxis)|Participants who received FVIII prophylaxis prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
11278111|NCT02847624||ADPKD|
11278112|NCT02847611|Experimental|Jamar then Labin|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
11278113|NCT02847611|Experimental|Labin then Jamar|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
11278114|NCT02847598|Experimental|Part A: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with systemic lupus erythematosus [SLE] with active skin manifestations and joint involvement.
11278115|NCT02847598|Placebo Comparator|Part A: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with [SLE] with active skin manifestations and joint involvement.
11278116|NCT02847598|Experimental|Part B: BIIB059 50 mg|BIIB059 50 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active cutaneous lupus erythematosus [CLE] with or without systemic manifestations.
11278117|NCT02847598|Experimental|Part B: BIIB059 150 mg|BIIB059 150 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
11278118|NCT02847598|Experimental|Part B: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
11278121|NCT02847572|Other|Surgery Patient|All patients to be implanted bilaterally with a Tecnis Extended Range Lens in the Dominant eye and a Low Add Multifocal in the non dominant
11278122|NCT02847559|Experimental|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11278123|NCT02847533|Other|resistant depression|patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
11278124|NCT02847533|Other|non resistant depression|patients in remission from unipolar depressive disorder
11278125|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
11278126|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
11278127|NCT02847481|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
11278128|NCT02847481|Placebo Comparator|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
11278129|NCT02847481|Experimental|FMT after antibiotic pretreatment v1|fecal microbiota transplantation after antibiotic pretreatment
11278130|NCT02847481|Experimental|FMT after antibiotic pretreatment v2|fecal microbiota transplantation after antibiotic pretreatment
11278131|NCT02847468|Experimental|FDG and FCH PET|Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.
11278132|NCT02847455|Experimental|5 mg ilaprazole|
11278133|NCT02847455|Experimental|10 mg ilaprazole|
11278134|NCT02847455|Active Comparator|10mg Rabeprazole|
11278135|NCT02847442|Experimental|Opicapone (BIA 9-1067) 50 mg|Total duration of trial participation and treatment: three months. All subjects will start treatment with 50 mg opicapone (OPC) once daily for a 3-month period in addition to their current treatment with levodopa/dopa decarboxylase inhibitor (L-dopa/DDCI)
11278136|NCT02847429|Experimental|Crenolanib Arm|Investigational product (crenolanib)
11278137|NCT02847429|Placebo Comparator|Placebo Arm|Matching placebo
11278138|NCT02847416|Experimental|Inspiratory group|the subjects will be instructed to inspire as deeply as possible with steady flow rate for 3 seconds with end-inspiratory pause for 2-3 seconds through the inspiratory circuit and follow by passive exhalation
11278139|NCT02847416|Experimental|expiratory group|the subjects will be instructed to inspire as deeply as possible through the nose with end-inspiratory pause for 2-3 seconds and partially forced exhalation with reach to 1/3 of expiratory reserve volume (ERV) for at least 3 seconds through expiratory circuit
11278140|NCT02847403|Experimental|exenatide|long-acting exenatide 2 mg subcutaneously once-weekly
11278141|NCT02847403|Placebo Comparator|placebo|no drug assigned
11278142|NCT02847390||Pre-implementation group|"The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes education intervention to our staff over a 6-month time frame from August 2016-January 2017. The investigators will use a before and after study design to assess the impact of the educational intervention on hospital-wide hypoglycemia and hyperglycemia.
~Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/16 to 6/30/16)."
11278143|NCT02847390||Post-implementation group|Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/17 to 6/30/17).
11278144|NCT02847377|Experimental|[18F]-ODS2004436|Two TEP will be performed with the radiotracer [18F]-ODS2004436
11278145|NCT02847364|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
11278146|NCT02847364|No Intervention|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
11278147|NCT02847351|Placebo Comparator|Control Diet (CD)|Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
11278148|NCT02847351|Experimental|Arabinoxylan Diet (AXD)|Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
11278149|NCT02847338|Experimental|Mono-therapy group|"The monotherapy group will be treated with the following treatments:
~A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone
~Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA."
11278150|NCT02847338|Experimental|Dual-therapy arm|"The dual-therapy group will be treated with the following treatments:
~A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg
~Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB."
11278151|NCT02847325|Experimental|AC0058TA|Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA
11278152|NCT02847325|Placebo Comparator|Placebo capsules|Drug: Placebo capsules
11278153|NCT02847312|Active Comparator|High avenanthramide, phenolic acid|66.8g Pepsico Oatmeal + 60g Oat cake
11278154|NCT02847312|Active Comparator|Low avenanthramide, medium phenolic acid|17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast
11278155|NCT02847312|Placebo Comparator|Control|69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast
11278156|NCT02847299|Experimental|Astral ventilator|instrumental increase of cough peak flow with air stacking
11278157|NCT02847299|Experimental|Astral ventilator - mode kiné|instrumental increase of cough peak flow with hyperinsufflation
11278158|NCT02847286|Active Comparator|Treatment A|Dapivirine Ring-004 for 28 days
11278159|NCT02847286|Active Comparator|Treatment B|Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
11278160|NCT02847286|Active Comparator|Treatment C|Clotrimazole, 5 g per day for 7 days
11278161|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
11278162|NCT02847247|Experimental|CCRE|20,000 EU of CCRE (Clinical Center Reference Endotoxin)
11278163|NCT02847208||cystic fibrosis women|It was a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry.
11278164|NCT02847195|Experimental|pediatric intensive care|"When aspiration is planned, pain assessment will be performed thrice :
~3-5 minutes before aspiration, during aspiration, and 3-5 minutes after aspiration.
~Pain assessment will be performed with both methods:
~COMFORT B scale (routinely performed by nurses, and lasts less than one minute)
~Simultaneously pupillometry is assessed using the device (Neurolight) (one measurement per eye, this also lasts less than one minute) These measurements can occur at any time during stay in ICU, and can be repeated."
11278165|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
11278166|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
11278167|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
11278168|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
11278169|NCT02847156|Other|cystic fibrosis infants|1 year follow-up in CF infants
11278170|NCT02847143|Experimental|secure|healthy adult male with secure attachement
11278171|NCT02847143|Experimental|avoidant|healthy adult male with avoidant attachement
11278172|NCT02847143|Experimental|enmeshed/fearfull|healthy adult male with enmeshed/fearfull attachement
11278173|NCT02847143|Experimental|dual style|healthy adult male with dual attachement style
11278174|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia [FN], chemotherapy induced nausea and vomiting [CINV], fertility preservation [FP]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.
~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.
~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
11278175|NCT02847117|Other|Mastiha|
11278176|NCT02847104||dynamic insulin protocol|patients received intravenous insulin infusion according to a dynamic insulin protocol
11278177|NCT02847104||static insulin protocol|patients received intravenous insulin infusion according to a static insulin protocol
11278178|NCT02847091|Experimental|Ipragliflozin Group|Ipragliflozin will be administered orally for 24 weeks.
11278179|NCT02847078|Experimental|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
11278180|NCT02847078|Other|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
11278181|NCT02847039||Early repolarization syndrome|Patients with an aspect of early repolarization syndrome or belonging to a family in which the diagnosis of early repolarization was identified.
11278182|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
11278183|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
11278184|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
11278185|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
11278285|NCT02846363||Patients included in the control region (Isère, France)|
11278186|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
11278187|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
11278188|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
11278189|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
11278190|NCT02847013|Placebo Comparator|Placebo- Tap block w normal saline|After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
11278191|NCT02847013|Experimental|Intervention-Tap block w Liposomal bupivacaine|After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
11278192|NCT02847000|Experimental|Decitabine + Tetrahydrouridine|Tetrahydrouridine (THU) is supplied as 250 mg/capsule, Decitabine (Dec) as 5 mg/capsule.
11278193|NCT02846987|Experimental|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
11278194|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
11278195|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
11278196|NCT02846961||Crohn's disease|Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
11278197|NCT02846961||Ulcerative colitis|Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
11278198|NCT02846948|No Intervention|Non-echo group|Patients get the standard monitoring and treatment based on Good medical practice. Extended monitoring by focused echocardiography is not applied for this group.
11278199|NCT02846948|Experimental|Focussed echocardiography group|The extended cardiac monitoring by focused assessed transthoracic echocardiography is applied.
11278200|NCT02846935|Experimental|Decitabine + Tetrahydrouridine|"oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.
~Treatment on protocol monitoring continues for 52 weeks."
11278201|NCT02846922||catheter ablation group|atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
11278202|NCT02846922||rate control group|atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
11278203|NCT02846909|Active Comparator|Vaginal progesterone group|Will receive progesterone pessaries 400 mg once daily vaginally
11278204|NCT02846909|No Intervention|No progesterone group|Will receive nothing
11278205|NCT02846883|Active Comparator|Intravenous infusion of 1 million allogenic MSC's/Kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
11278206|NCT02846883|Active Comparator|Intravenous infusion of 3 million allogeneic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
11278207|NCT02846883|Placebo Comparator|Intravenous infusion of Plasmalyte A (placebo)|In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
11278208|NCT02846870|Active Comparator|Standard Education|Patients receive standard-of-care prostate cancer radiation oncology consultation.
11278209|NCT02846870|Experimental|Visually Enhanced Education|Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.
11278210|NCT02846857|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
11278211|NCT02846857|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
11278212|NCT02846857|Active Comparator|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
11278213|NCT02846844||Group A|"Whole body vibration training
~manuelle therapy
~exercises for power and coordination
~performance training as needed"
11278214|NCT02846844||Group B|"manuelle therapy
~Exercises for power and coordination
~Performance training as needed"
11278215|NCT02846831|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
11278216|NCT02846831|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
11278217|NCT02846818|Experimental|Low mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
11278218|NCT02846818|Experimental|High mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
11278219|NCT02846805|No Intervention|complete dentures|complete dentures will be provided for all subjects according to the standardized treatment protocol
11278220|NCT02846805|Experimental|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible ,and continue wearing their complete denture in the maxilla
11278221|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11278222|NCT02846779|Active Comparator|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
11278223|NCT02846779|Experimental|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
11278224|NCT02846779|Experimental|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
11278225|NCT02846766|Experimental|Lenvatinib|The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.
11278226|NCT02846753|Experimental|Implantation of Venus P-Valve™|Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
11278227|NCT02846740|Experimental|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
11278228|NCT02846740|Sham Comparator|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
11278229|NCT02846727||Sepsis Group|This group will consist of surgical intensive care patients with diagnosis of sepsis, severe sepsis, or septic shock.
11278230|NCT02846727||Control Group|This group will consist of patients that serve as controls who do not have diagnosis of sepsis, severe sepsis, or septic shock.
11278231|NCT02846714|Experimental|FLARE intervention|All FLARE participants enrolled will receive the intervention
11278232|NCT02846701|Other|patient treated by duloxetine|
11278233|NCT02846675|Experimental|SVF treatment (random knee)|A random knee (left or right) of subjects will be treated with autologous SVF.
11278234|NCT02846675|Placebo Comparator|placebo treatment (the other knee)|The other knee of subjects will be treated with placebo.
11278235|NCT02846662|Experimental|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an applicative for smartphones (CONEMO), which encourages them to be more active and to incorporate more activities in their everyday life.
~Primary care nurses will train participants to use the CONEMO app, monitor patients' adherence to CONEMO, calling patients when they are non-adherent, and give technical support when necessary. They will be supervised by clinical psychologists.
~Primary care teams are informed of participants' depression level and deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication."
11278236|NCT02846662|No Intervention|ENHANCED USUAL CARE|The primary care teams are informed of the participants' depression level and can deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication. This is considered enhanced usual care because the teams are notified about participants' level of depressive symptomatology, which otherwise might go undetected, and then decide about the best way to handle with patients' needs related to their depressive symptomatology.
11278237|NCT02846649|Experimental|PIER Intervention|The program will help participants learn to recognize the presence of craving and how it can be reduced through environmental, self-regulatory and mood management. Each day, the PIER1 program sends (1) a morning reflection focused on positive thinking, (2) two random prompts assessing severity of craving, (3) feedback specific to managing withdrawal symptoms, mood management, and environmental triggers that are affecting craving, (4) evening assessments of drug use with feedback, (5) goal commitment prompt with feedback, and (6) user-triggered craving assessments with feedback
11278238|NCT02846623|Experimental|Cohort I (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.
11278239|NCT02846623|Experimental|Cohort II (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.
11278240|NCT02846610||regional anesthesia|surgical patients (age: 0-100 years) having regional anesthesia along with the procedure and postoperative course
11278241|NCT02846610||systemic analgesia|surgical patients (age: 0-100 years) having systemic analgesia along with the procedure and post procedure course
11278242|NCT02846597|No Intervention|Control|Infants in this group will not receive sustained lung inflation in the delivery room and will be put immediately on CPAP at a pressure of 5 cm H2O.
11278243|NCT02846597|Active Comparator|High pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
11278244|NCT02846597|Active Comparator|High pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
11278245|NCT02846597|Active Comparator|Low pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
11278246|NCT02846597|Active Comparator|Low pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
11278247|NCT02846584|Experimental|CD19 or CD20 CAR T cells briging HSCT|lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.
11278248|NCT02846571|Other|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
11278249|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
11278250|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
11278251|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
11278252|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
11278253|NCT02846545|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).
11278254|NCT02846545|Placebo Comparator|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
11278255|NCT02846532|Experimental|Rivaroxaban|
11278256|NCT02846532|Experimental|Acetylsalicylic Acid|
11278286|NCT02846350|Active Comparator|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
11278257|NCT02846519|Experimental|Esketamine|Participants in Cohort 1 (Han Chinese participants), Cohort 2 (Korean participants) and Cohort 3 (Japanese participants ) will receive 100-microliter (mcL) spray of 14 percent (%) esketamine solution (14 milligram [mg]) into each nostril at Time 0 and 5 minutes later for a total dose of 56 milligram (mg) in Period 1.
11278258|NCT02846519|Experimental|Esketamine+Rifampin|Participants in Cohort 4 (Caucasian participants) will receive a 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 1 followed by rifampin from Day -6 to Day -1 of treatment Period 2 and followed by 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 2.
11278259|NCT02846506|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11278260|NCT02846506|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11278261|NCT02846506|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11278262|NCT02846506|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11278263|NCT02846493|Active Comparator|bromocriptine group|Rectal bromocriptine (2.5 mg, qd) for 7 days
11278264|NCT02846493|Experimental|dexamethasone group|Oral take dexamethasone(3mg,qd)for 7 days
11278265|NCT02846480|Experimental|surgical treatment+behavior therapy+physical therapy|Including POP surgical treatment, and pre- post physical therapy to aim the posture, PFM awareness and the strengthening. They will be also informed and instructed on hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
11278266|NCT02846480|Experimental|surgical treatment+behavior therapy|Including POP surgical treatment, and information and instruction about hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
11278267|NCT02846467|Experimental|Portable video media|Patients who receive informed consent trough portable video media around 10 minutes
11278268|NCT02846467|Active Comparator|Traditional IC|Patients who receive traditional IC (written consent) during 10 to 15 minutes
11278269|NCT02846454|Experimental|inulin|Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
11278270|NCT02846454|No Intervention|non inulin and arabinoxylan|investigating the satiating effects of a control drink (2.6g/d maltodextrin)
11278271|NCT02846454|Experimental|arabinoxylan|Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
11278272|NCT02846428|Active Comparator|5-Fluorouracil + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
11278273|NCT02846428|Experimental|Capecitabine + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
11278274|NCT02846415|Experimental|PID group|Experimental group receiving the Play Intervention for Dementia
11278275|NCT02846415|No Intervention|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
11278276|NCT02846402|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
11278277|NCT02846402|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
11278278|NCT02846402|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
11278279|NCT02846389|Experimental|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
11278280|NCT02846389|No Intervention|Control Group|No exercise
11278281|NCT02846376|Experimental|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34
~Dose level 1: 1 mg/kg
~Dose level 2: 3 mg/kg"
11278282|NCT02846376|Experimental|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16
~Dose level 1: 0.3 mg/kg
~Dose level 2: 1.0 mg/kg
~Dose level 3: 3.0 mg/kg"
11278283|NCT02846376|Experimental|Group C - Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34
~Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16
~Dose level 1: 0.3 mg/kg
~Dose level 2: 0.6 mg/kg
~Dose level 3: 1.0 mg/kg"
11278284|NCT02846363||Patients included in the Rhône region from France|public awareness campaign
11278287|NCT02846350|No Intervention|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
11278288|NCT02846337|Experimental|ULTRAFILTRATION|The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (>1 session per week) or isolated ultrafiltration (>1 session per week). Ultrafiltration technique could change throughout the care
11278289|NCT02846337|Other|ENHANCED MEDICAL TREATMENT|"The control group called enhanced medical treatment will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration). These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration."
11278290|NCT02846324|Experimental|GBT440 600 mg Dose|Parts A and B
11278291|NCT02846324|Experimental|GBT440 900 mg Dose|Part A
11278292|NCT02846324|Experimental|GBT440 1500 mg Dose|Part B
11278293|NCT02846324|Placebo Comparator|Placebo|Parts A and B
11278294|NCT02846311||Group with support that will be usually performed|"During the first phase (before), the assumption will be that usually achieved.
~The doctor continues to support according to information it has and according to good practice and service protocols."
11278295|NCT02846311||Group with a flu test|"During the second phase (after), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.
~The doctor continues to support according to information it has and according to good practice and service protocols."
11278296|NCT02846272|Experimental|Observational cohort|Observing MRI changes in subjects.
11278297|NCT02846246|Experimental|Intervention|The experimental group will be introduced to a person-centred care model that involves shared decision making where the person with home care service and family together with contact nurse prioritise care content and make rearrangements to make sure the provided home care service maximises health.
11278298|NCT02846246|Sham Comparator|Control|A usual care paradigm will guide the control units, i.e. a continuation with practice as usual.
11278299|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
11278300|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
11278301|NCT02846220|Experimental|Health coaching|"Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions
~Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets"
11278302|NCT02846220|No Intervention|Usual care|
11278303|NCT02846207|Experimental|Yiqi huoxue group|Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
11278304|NCT02846207|Experimental|Yiqi group|Astragalus 60g. Oral administration, twice one day, for 12weeks.
11278305|NCT02846207|Experimental|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
11278306|NCT02846207|Placebo Comparator|placebo group|dextrin, Oral administration, twice one day, for 12weeks.
11278307|NCT02846194|Experimental|brief guided imagery|The study group of our research will go through six Brief Guided Imagery sessions. These sessions will be completed within two months and will last one hour each.
11278308|NCT02846194|No Intervention|control group|
11278309|NCT02846181|Experimental|Healthy|
11278310|NCT02846155|Placebo Comparator|clear water group|the patients only drink 1000ml clear water before checking
11278311|NCT02846155|Experimental|simethicone group|the patients drink 950ml clear water and 15ml simethicone before checking
11278312|NCT02846155|Experimental|simethicone combined with pronase group|the patients drink 900ml clear water and 15ml simethicone and 20，000iu pronase before checking
11278313|NCT02846142|Active Comparator|SAD PTI-428|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
11278314|NCT02846142|Placebo Comparator|SAD placebo|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
11278315|NCT02846142|Active Comparator|MAD PTI-428|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
11278316|NCT02846142|Placebo Comparator|MAD placebo|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
11278317|NCT02846142|Experimental|OC (ethinyl estradiol and levonorgestrel) DDI Period A|Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).
11278412|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
11278318|NCT02846142|Active Comparator|OC (ethinyl estradiol and levonorgestrel) DDI Period B|Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
11278319|NCT02846142|Placebo Comparator|OC (ethinyl estradiol and levonorgestrel) DDI|Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
11278320|NCT02846116|Active Comparator|lithium disilicate|The intervention will be: Prosthetic crown
11278321|NCT02846116|Active Comparator|Vita suprinity|The intervention will be: Prosthetic crown
11278322|NCT02846103|Experimental|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.
~Tumor tissues will be collected if available."
11278323|NCT02846090|Experimental|D50 Dexmedetomidine 50 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
11278324|NCT02846090|Experimental|D25 Dexmedetomidine 25 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine + 4.5 ml of 2% lidocaine +0.5ml of 25 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
11278325|NCT02846090|Placebo Comparator|control|peribulbar block was given using 10 ml of a mixture of local anesthetics without Dexmedetomidine. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml with 150 IU hyaluronidase.
11278326|NCT02846077||College students|College students will be monitored and will complete online surveys, install apps on their mobile phones, wear physiological sensors and provide saliva samples for later assay.
11278327|NCT02846064|Other|Ovarian tissue cryopreservation|
11278328|NCT02846051|Other|intensive sport practice|"intensive sport practice
~the subject must practice for more than six months a drive of at least 8 hours / week, intense, above the ventilatory threshold, or 60-70% of maximum consumption oxygen or 70-80% of maximum heart rate, ie beyond a moderate slowdown. If stopping the intensive sport practice, the duration of the stop at the time of the study should be less practice time.
~volunteers,
~from 18 to 80 years,
~free to consent.
~covered by social security.
~reported in the national register of healthy volunteers.
~The intervention is a lower limb venous examination = venous mapping"
11278329|NCT02846051|Other|control group|"&) Volunteers who do not have intensive sport practice as it is defined in the group intensive sport practice 2) from 18 to 80 years, 3) free to consent. 4) covered by social security. 5) reported in the national register of healthy volunteers.
~The intervention is a lower limb venous examination = venous mapping"
11278330|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
11278331|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
11278332|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
11278333|NCT02846025|Other|Folate|diet rich in folate
11278334|NCT02846025|Other|placebo|placebo
11278335|NCT02846025|Other|diet antioxidant|diet antioxidant
11278336|NCT02846025|Other|Hazelnut Oil|hazelnut oil capsule
11278337|NCT02846012|No Intervention|CSCM Control|Control medium
11278338|NCT02846012|Experimental|CSCM2|New Formulation medium
11278339|NCT02845999|Experimental|Allogenic NK cells transfer|Patients will be treated with a conditioning chemotherapy including 60 mg/kg intravenous cyclophosphamide, 25 mg/m2 intravenous fludarabine for 5 consecutive days and cetuximab. A lymphapheresis from an haploidentical related donor will be performed and T cells will be depleted . Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol (three doses with at least three patients per cohort)to define the dose-limiting toxicity (DLT). T
11278340|NCT02845986|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed laparoscopic spleen-preserving No.10 lymph node dissections.After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
11278341|NCT02845973||test cohort|The test cohort was from Fudan University Shanghai Cancer Center (August 2016 to December 2016) and ECRJ-East Campus of Renji hospital (January 2012 to March 2017);
11278342|NCT02845973||validation cohort|The validation cohort was from Shanghai Tenth People's Hospital (October 2015 to November 2016) and WCRJ-West Campus of Renji hospital (July 2016 to March 2017)
11278343|NCT02845960||Experimental group|rapid recovery
11278344|NCT02845960||Controlled group|no rapid recovery
11278345|NCT02845947|Experimental|Music Therapy|Music Therapy to be provided for pediatric patients undergoing extubation readiness trial
11278346|NCT02845947|No Intervention|Control|Patients undergoing standard extubation readiness trial
11278347|NCT02845934|Experimental|Mucormycosis|blood sample
11278348|NCT02845921|Placebo Comparator|Group C Control|Patient will be shifted to operation theatre. Electrocardiography (ECG), pulse oximeter and non-invasive blood pressure (NIBP) monitors will be attached. Baseline vitals will be noted. Intravenous access will be secured and crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs will be neither elevated or wrapped. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube.
11278349|NCT02845921|Experimental|Group E Leg elevation|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs are elevated and supported on a stand making an angle of 30 degree to the horizontal. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Stand will be removed and legs will be brought to horizontal position 10 minutes after intubation.
11278448|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
11278350|NCT02845921|Experimental|Group W Leg wrapping|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.
11278351|NCT02845908|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
11278352|NCT02845908|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
11278353|NCT02845908|Active Comparator|FOLFOX|The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
11278354|NCT02845895||Neuroscience pole|Patient hospitalized in the department of medicine-surgery-obstetric of the neuroscience pole department
11278355|NCT02845895||Respiratory tracts pole|Patient hospitalized in the department of medicine-surgery-obstetric of the respiratory tracts pole department
11278356|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
11278357|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
11278358|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
11278359|NCT02845869|Experimental|Light Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Light Therapy treatment with the THOR laser LX2 system.
11278360|NCT02845869|Sham Comparator|Sham Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Sham Therapy.
11278361|NCT02845856|Experimental|Cetuximab and NK immunotherapy|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278362|NCT02845856|Active Comparator|Cetuximab|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278363|NCT02845843|Experimental|Combination of Lopinavir /Ritonavir and IntErferon Beta 1B|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
11278364|NCT02845843|Placebo Comparator|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
11278365|NCT02845830||Participants in early stage of dementia|Subjects with any type of dementia at an early phase diagnosed in the last 12 months with MMSE score 20-25 points
11278366|NCT02845830||Participants without dementia|Subjects without dementia with MMSE score 26-30 points
11278367|NCT02845817|Other|Qualitative research|Semi-structured interviews
11278368|NCT02845804||Alpine|The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
11278369|NCT02845791|No Intervention|Control|The control participants will not receive the educational intervention but will be provided with a detailed advice leaflet for themselves and their parents/guardians.
11278370|NCT02845791|Other|Intervention|The educational intervention participants will receive the eight 90 minute sessions of an interactive family based lifestyle programme.
11278371|NCT02845778|Experimental|melatonin niosomes oral gel 2.5 mg|apply onto oral mucosa as single use
11278372|NCT02845778|Experimental|melatonin niosomes oral gel 5 mg|apply onto oral mucosa as single use
11278373|NCT02845778|Experimental|melatonin niosomes oral gel 10 mg|apply onto oral mucosa as single use
11278374|NCT02845765||Patients with erectile dysfunction|Patients with erectile dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline and 6 months after therapy with Phosphodiesterase type 5 Inhibitor (PDE5I).
11278375|NCT02845765||Subject healthy volunteers|Patients without erectile dysfunction or ocular disease. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline
11278376|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
11278377|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
11278378|NCT02845739|Experimental|kidney transplanted patient|
11278379|NCT02845726||Patients with temporary ureteral stent|Assessment of patients transiently undergoing ureteral stenting.
11278380|NCT02845713|Active Comparator|Single IDA dose W. bancrofti positive|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
11278381|NCT02845713|Active Comparator|Single IDA dose W. bancrofti negative|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
11278382|NCT02845700|Active Comparator|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
11278383|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
11278384|NCT02845687||Participants|All participants are patients within the Quit at Duke Smoking Cessation Program. This is an observational study with no interventions.
11278385|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
11278386|NCT02845661|Experimental|group 1|patients in group 1, aged 20~60, were accepted an initial dose of 0.9μg/kg dexmedetomidine over 15 min.
11278387|NCT02845661|Experimental|group 2|patients in group 2, aged 20~60, were accepted an initial dose of 1.0μg/kg dexmedetomidine over 15 min.
11278388|NCT02845661|Experimental|group 3|patients in group 3, aged 20~60, were accepted an initial dose of 1.1μg/kg dexmedetomidine over 15 min.
11278389|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
11278390|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
11278391|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
11278392|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
11278393|NCT02845622|Experimental|30g peeled hazelnuts cream|Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
11278394|NCT02845622|Experimental|30g unpeeled hazelnuts cream|Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
11278395|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts|Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
11278396|NCT02845622|Experimental|snack w/ 2.5g cocoa powder|Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
11278397|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts+2.5g cocoa|Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
11278398|NCT02845622|Placebo Comparator|empty snack|Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
11278399|NCT02845609|Experimental|Intervention|Sialic acid-Extended release 2000 mg, three times per day (TID) for 3 months
11278400|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
11278401|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
11278402|NCT02845583||Retrospective cohort|150 oncologic patients belonging to major complexity DRGs
11278403|NCT02845583||Perspective cohort|150 oncologic patients belonging to major complexity DRGs
11278404|NCT02845570|Experimental|68Ga-DOTANOC PET/MRI|Comparison between 68Ga-DOTANOC PET/MRI and 18F-FDG PET/MRI scans
11278405|NCT02845557||Control subjects without diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.
~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;
~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
11278406|NCT02845557||Subjects with type 2 diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.
~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;
~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
11278407|NCT02845544|Experimental|Experimental group - Pilates|A Pilates-based exercises program of 6 weeks' duration
11278408|NCT02845544|No Intervention|Control group - no exercises|
11278409|NCT02845531|Experimental|ICD implantation and optimal medical therapy|
11278410|NCT02845531|Active Comparator|optimal medical therapy|
11278411|NCT02845518|Experimental|cMRI AND RHC|Cardiac Magnetic Resonance Imaging (cMRI) and Right Heart Catheterization (RHC) (the latter being recommended in the current guidelines) in all patients at the baseline visit, at 4-6 months of follow up, at 24 months of follow up and in case of clinical worsening from the baseline visit to 24-month of follow up
11278413|NCT02845492|Experimental|Qigong intervention|Qigong meditative exercise intervention meets three times a week for 10 weeks. The qigong group (n=30) will meet at the Women's Medicine Collaborative, Miriam Hospital (146 W. River St., Providence, RI) for Qigong classes. The lesson will be taught by a validated Qi Gong master with over forty years of experience and the interventional protocol will be validated. Two and a half hours of weekly outside personal practice will also be required of participants.
11278414|NCT02845492|Active Comparator|CHIP healthy wellness-exercise class|The Complete Health Improvement Program is a validated set of weekly classes designed to promote gentle exercise and wellness related activities in a supportive group setting led by an experienced trainer.
11278415|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
11278416|NCT02845466|Experimental|Becaplermin/Promagran Dressing|Topical Becaplermin with a protease inhibitor wound dressing.
11278417|NCT02845466|Active Comparator|Becaplermin/Placebo Dressing|Topical Becaplermin with a placebo wound dressing.
11278418|NCT02845453|Experimental|Quetiapine|Quetiapine
11278419|NCT02845453|Placebo Comparator|Placebo|Placebo
11278420|NCT02845440|Active Comparator|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.
11278421|NCT02845440|Experimental|AD + CHW|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.
~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
11278422|NCT02845440|Experimental|AD Alone|Participants who are randomized to this condition will only not be offered additional Community Health Worker services; however, the participant's primary care clinic will receive Academic Detailing as described above.
11278423|NCT02845427|Active Comparator|A(drain group)|patients of primary THA will have closed suction drain introduced intraoperative at surgical site
11278424|NCT02845427|Placebo Comparator|B(No drain group)|patients of primary THA will have the surgical wound be closed with no suction drain
11278425|NCT02845414|Experimental|Intravenous Infusion of dCD133KDEL|
11278426|NCT02845401|Experimental|HBeAg-CHB patients who stop NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that stop treatment.
~Intervention: Cases will stop antiviral therapy"
11278427|NCT02845401|No Intervention|HBeAg-CHB patients continue NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that continue to stay on treatment.
~Intervention: None. Controls will continue antiviral therapy."
11278428|NCT02845388|Active Comparator|estradiol valerate|estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
11278429|NCT02845388|Active Comparator|Sildenafil citrate and estradiol valerate|Sildenafil citrate 25 mg every 6 hours orally in combination with estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
11278430|NCT02845375|Placebo Comparator|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
11278431|NCT02845375|Other|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
11278432|NCT02845375|Experimental|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
11278433|NCT02845362|Experimental|Dysphagia assessment|
11278434|NCT02845349|Experimental|Drug-Vortioxetine|The treatment group will receive vortioxetine 10 mg per day, which will be increased to 20 mg or decreased to 5 mg, if deemed clinically necessary, at week 4 or 8.
11278435|NCT02845349|Placebo Comparator|Placebo|Matching placebo will be used.
11278436|NCT02845336|Experimental|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
11278437|NCT02845336|Active Comparator|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
11278438|NCT02845323|Experimental|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:
~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
11278439|NCT02845323|Active Comparator|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
11278440|NCT02845310|Experimental|Restricted fluid therapy group|Patients will receive restricted fluid management guided by concomitant SVV monitoring. GDT protocol
11278441|NCT02845310|Placebo Comparator|Control group|Patients will receive standard fluid management.
11278442|NCT02845297|Experimental|Safety Run In Phase (only Cohort 1):|The treatment of relapsed and refractory AML patients.
11278443|NCT02845297|Experimental|Cohort 2|The treatment of newly diagnosed AML patients (≥ 65 years) who are not candidates for intensive induction chemotherapy.
11278444|NCT02845284|No Intervention|Routine Care|Group education/counseling from Antenatal clinic midwives, routine PMTCT, HIV C&T and family planning C&T services on request.
11278445|NCT02845284|Experimental|Routine Care plus group support|Routine Care plus enhanced group support
11278446|NCT02845284|Experimental|Routine Care plus individual support|Routine Care plus enhanced individual support
11278447|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
11278449|NCT02845245|Active Comparator|Standard of Care|Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
11278450|NCT02845245|Experimental|Intervention|A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.
11278451|NCT02845232||Intensive chemotherapy|First group: 68 patients receiving a combination of intermediate-dose cytarabine and an anthracycline. One patient with acute promyelocytic leukaemia (APL) also received all-trans retinoic acid (ATRA).
11278452|NCT02845232||Lower-intensity treatments|The second study group comprised 70 patients who were treated on frontline by lower-intensity treatments [LD-AraC(39 patients), azacitidine (16 patients), decitabine (11 patients),tipifarnib (3 patients), or ATRA (1 patient)]. Patients received LD-AraC 20 mg once or twice daily (according to physician'schoice) by subcutaneous injection for 10 consecutive days. Azacitidine was given at the dose of 75 mg/m2/day for 7 consecutive days by sc injection. Decitabine was administered by intravenous route once daily at 20 mg/m2 for 5 consecutive days. Tipifarnib was given at 600 mg administered orally twice daily for 21 consecutive days in 4-week cycles. ATRA was given at 45 mg/m2until CR achievement followed by maintenance combining 6-mercaptopurine with methotrexate.
11278453|NCT02845232||Best Supportive Care|The last study group comprises 76 patients: 31 patients received supportive care, while 36 patients also received hydroxyurea and 9 patients received 6-mercaptopurine.
11278454|NCT02845219|Experimental|Oral contraceptive/SNAC/Oral Trial drug|
11278455|NCT02845206|Experimental|Patient Specific Cutting Blocks|For the bespoke individualised cutting blocks to be manufactured, the patients will undergo a preoperative CT scan under a set protocol. The CT radiation dose will be considerably less than a conventional diagnostic CT scan.
11278456|NCT02845206|Active Comparator|Conventional Cutting Blocks|The patients in this arm will be operated on using conventional instruments.
11278457|NCT02845193|Experimental|Modified Nasoalveolar molding group|This group will receive nasoalveolar molding appliance in addition to taping for 3 Months with follow-up every 2 weeks.
11278458|NCT02845193|Experimental|Taping group|Tape will be used alone in this group on the upper lip segments for 3 months with follow-up every 2 weeks.
11278459|NCT02845193|No Intervention|Control group|This group will not receive any treatment.
11278460|NCT02845193|Experimental|CAD/NAM group|Computer Aided Designed Nasoalveolar molding and 3D printed.
11278461|NCT02845180|Experimental|3 Mo. Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 3 months.
11278462|NCT02845180|Experimental|6 Month Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
11278463|NCT02845167|No Intervention|Usual-care only|Patients will receive usual-care only during the preoperative period.
11278464|NCT02845167|Experimental|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods.
11278465|NCT02845154|Active Comparator|Control (bolus purge)|The portal vein clamp will be totally released after end of portal vein anastomosis and all graft and portal blood contents are allowed free and complete access to the systemic circulation via the inferior vena cave
11278466|NCT02845154|Experimental|Intermittent Purge|The portal clamp will be released in situ for 5 seconds to allow purge of the graft and portal contents into the systemic circulation, followed by 30 seconds of portal clamping again. This will be followed by another two cycles of 5 seconds declamping and 30 seconds clamping , then, the portal clamp will be completely released.
11278467|NCT02845141|Experimental|Actifuse|Actifuse to fill bone tunnel
11278468|NCT02845141|Active Comparator|bone graft|bone graft to fill bone tunnel
11278469|NCT02845128||HFNC failure|requiring intubation and invasive mechanical ventilation
11278470|NCT02845128||HFNC success|not requiring intubation nor invasive mechanical ventilation
11278471|NCT02845115|Other|control|standard care : usual technique for implanting
11278472|NCT02845115|Experimental|laser velocimetry|optimized implantation of laser velocimetry
11278473|NCT02845102|Experimental|Pre-Post Feasibility Testing|The pre-post feasibility testing/ intervention includes the use of tablet technology and cognitive behavioral therapy (CBT) for depression and self-management education for patients with chronic illness and/or chronic pain and depression. The pre-post feasibility testing phase will include 25 subjects. The total duration of pre-post feasibility testing will be 6 weeks upon the retrieval of the RA-CBT tablet and the inclusion of follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview.
11278474|NCT02845089||Advanced/Metastatic NSCLC patients from UAE and KSA|A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)
11278475|NCT02845076|Active Comparator|Decrease in duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered. When a patient reaches without the presence of any reinstitution criteria, the duration of NIV use as 4 hours per 16 hours during daytime, it will be liberated definitively from NIV.
11278476|NCT02845076|Active Comparator|Decrease in pressure and duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. The level of pressure support will be decreased by 2-4 cmH2O per 4 hours during daytime in patients with good tolerance, with no change at night time. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered, based on the vitals and ABGs recorded at 8 pm (see above), with gradual decrease of at least 2 hrs/night. When a patient reaches without the presence of any reinstitution criteria, the level of PS of 8 cmH20, it will be liberated definitively from NIV.
11278477|NCT02845076|Active Comparator|Abrupt discontinuation of NIV|Patients will be disconnected from NIV and oxygenated with a nasal cannula. Oxygen flow will be limited to a maximum of 5L/min.
11278553|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
11278478|NCT02845063|Experimental|concentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
11278479|NCT02845063|Experimental|eccentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
11278480|NCT02845063|Active Comparator|concentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
11278481|NCT02845063|Active Comparator|eccentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
11278482|NCT02845050|Experimental|Vinflunine+Cisplatin+radical cystectomy|neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
11278483|NCT02845037|Experimental|2 mg or placebo|BIA 5-453 or placebo
11278484|NCT02845037|Experimental|10 mg or placebo|BIA 5-453 or placebo
11278485|NCT02845037|Experimental|20 mg or placebo|BIA 5-453 or placebo
11278486|NCT02845037|Experimental|50 mg or placebo|BIA 5-453 or placebo
11278487|NCT02845037|Experimental|100 mg or placebo|BIA 5-453 or placebo
11278488|NCT02845037|Experimental|200 mg or placebo|BIA 5-453 or placebo
11278489|NCT02845037|Experimental|400 mg or placebo|BIA 5-453 or placebo
11278490|NCT02845037|Experimental|600 mg or placebo|BIA 5-453 or placebo
11278491|NCT02845037|Experimental|900 mg or placebo|BIA 5-453 or placebo
11278492|NCT02845037|Experimental|1200 mg or placebo|BIA 5-453 or placebo
11278493|NCT02845024|Active Comparator|oral doxycycline|Oral capsules of doxycycline 100 mg were used
11278494|NCT02845024|Placebo Comparator|oral placebo capsule|oral placebo capsule were used
11278495|NCT02845011|Experimental|Audiovisual compression feedback|Cardiopulmonary resuscitation according to international guidelines with chest compressions performed with real-time audiovisual feedback using the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) device.
11278496|NCT02845011|Active Comparator|Standard chest compression|Cardiopulmonary resuscitation according to international guidelines with standard manual chest compression
11278497|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
11278498|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
11278499|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
11278500|NCT02844985||Addict Group|In-patient and out-patient adult men and women who meet diagnostic criteria for sexual addiction.
11278501|NCT02844985||Control Group|Individuals from the general community and college student populations who have no history of identifiable psychopathology.
11278502|NCT02844946|Experimental|ACT on Life|One day workshop aimed at providing Veterans with new tools and skills needed to pursue valued goals and directions in the face of life's challenges. Mindfulness, acceptance, values clarification, and goal-setting will be taught.
11278503|NCT02844946|No Intervention|Treatment as Usual|Veterans will continue receiving care as usual.
11278504|NCT02844933|Experimental|Cannabidiol|Cannabidiol oral solution (40 mg/kg/day) divided into two daily doses with a standard meal
11278505|NCT02844933|Placebo Comparator|Placebo|Matching placebo solution divided into two daily doses with a standard meal
11278506|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
11278507|NCT02844907|Experimental|Hyperglycemic clamp + Exendin (9-39)|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
11278508|NCT02844907|Experimental|Dexamethasone|Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
11278509|NCT02844894|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation
11278510|NCT02844894|Experimental|Esmolol|0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
11278511|NCT02844894|Placebo Comparator|Placebo|20 ml normal saline infused in 5 minutes before intubation
11278512|NCT02844881|Experimental|Apatinib+MASCT|Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma
11278513|NCT02844868|Experimental|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
11278514|NCT02844868|Sham Comparator|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
11278515|NCT02844855|Active Comparator|patients with Alzheimer disease|Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
11278516|NCT02844855|Active Comparator|patients with Parkinson disease|Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
11278517|NCT02844855|Sham Comparator|healthy controls|Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
11278518|NCT02844842||1 day initiation schedule|The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.
11278519|NCT02844842||Rapid initiation schedule|The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.
11278520|NCT02844829|Other|MRI and biomarkers|Prostate MRI. Blood and urine biomarkers. Both prior to biopsy. Tissue samples during prostatectomy.
11278521|NCT02844816|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.
11278522|NCT02844803|Other|Active drug-> Placebo|Metformin + S. Baicalensis --> Metformin + Placebo
11278523|NCT02844803|Other|Placebo -> Active drug|Metformin + Placebo --> Metformin + S. Baicalensis
11278524|NCT02844790|Experimental|IDegAsp|
11278525|NCT02844777|Placebo Comparator|Placebo|
11278526|NCT02844777|Experimental|5% VDA-1102|
11278527|NCT02844777|Experimental|10% VDA-1102|
11278528|NCT02844764|Experimental|StroMed + Platelet Rich plasma [PRP]|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product by direct injection to affected joints.
11278529|NCT02844751|Experimental|Cohort 1|Interventions assigned by Principal Investigator
11278530|NCT02844751|Experimental|Cohort 2|Interventions assigned by Principal Investigator
11278531|NCT02844738|Experimental|StroMed + platelet rich plasma (PRP)|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
11278532|NCT02844725|Experimental|VVZ-149 injection|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
11278533|NCT02844725|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
11278534|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
11278535|NCT02844699|Experimental|Mobilan (M-VM3) on both Day 1 and on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
11278536|NCT02844699|Experimental|Placebo on Day 1 and Mobilan (M-VM3) on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
11278537|NCT02844699|Placebo Comparator|Placebo on both Day 1 and Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
11278538|NCT02844686|Experimental|Cardiac Dynamic SPECT|
11278539|NCT02844673|Active Comparator|Standard monitoring (SM) arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) with standard monitoring. Standard monitoring is defined as a follow-up visit two weeks after initiation of therapy and monthly follow-ups thereafter
11278540|NCT02844673|Experimental|mDOT arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) and Mobile Directly Observed Therapy (mDOT) consisting of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Participants will receive alerts on their cell phone at pre-arranged times to remind them to take their medications. Participants will be followed-up at two weeks after initiation of therapy and monthly thereafter.
11278541|NCT02844660|Experimental|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
11278542|NCT02844660|Active Comparator|Standard of Care|Weekly application of moist wound therapy and offloading
11278543|NCT02844647|Experimental|MRI w/ Hyperpolarized Pyruvate (13C)|"Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI."
11278544|NCT02844634|Experimental|Immediate doxycycline 100mg PO daily|"Individuals will receive tenofovir/emtricitabine one tablet daily in an open-label fashion.
~Subjects are randomized to immediate (12 months duration) doxycycline 100mg PO daily."
11278545|NCT02844634|Active Comparator|Deferred doxycycline 100mg PO daily|Individuals will receive daily tenofovir/emtricitabine one tablet daily and will begin doxycycline 100mg PO daily after 6 months for a total duration of 6 months
11278546|NCT02844621|Experimental|Healthy subjects|
11278547|NCT02844608|Other|Quality of Life|Administration of Quality of Life questionnaires
11278548|NCT02844595|Active Comparator|Standard cognitive-behavioural smoking cessation treatment|
11278549|NCT02844595|Active Comparator|Standard smoking cessation treatment and behavioral activation|
11278550|NCT02844595|No Intervention|Control group|It will be a delayed treatment control group for a period of 3 months.
11278551|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11278552|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
11278554|NCT02844556|Other|SMILE surgery|Small incision lenticule extraction (SMILE) has become a novel and effective method for the correction of myopia and myopic astigmatism. It is a micro-invasive and flapless refractive procedure that has been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
11278555|NCT02844556|Other|FS-LASIK surgery|FS-LASIK surgery is femtosecond laser assisted- conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
11278556|NCT02844543|Experimental|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
11278557|NCT02844530|Experimental|RIT|The experimental treatment will consist on 2 injections of 370 MBq/m2 of 90Y-epratuzumab tetraxetan fractionated RIT at day 1 and day 8. The first infusion of 90Y-epratuzumab tetraxetan will be co-injected for the six first patients in Nantes with 111In-epratuzumab tetraxetan for dosimetry purpose.
11278558|NCT02844530|Active Comparator|chemotherapy/ immunotherapy|"chemotherapy/ immunotherapy regimen will be assigned per investigator's choice to one of the following chemotherapy/ immunotherapy regimens:
~FLAG +- anthracycline based regimen For subject's >60 years : idarubicin 5 mg/m2 day 1,3, fludarabine 20 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5.
~Clofarabine or clofarabine based regimens. Clofarabine use as a single agent should follow the recommended prescribing information. Clofarabine combination based regimens should use >=20mg/m2/day for up to 5 days.
~Hyper-C-VAd regimen: hyperfractionated cyclophosphamide 300 mg/m2 intravenously(i.v.) every 12 hours for 6 doses Days 1 to 3 + vincristine 2 mg i.v.Days 4 and 11; doxorubicin 50 mg/m2 i.v. over 24 hours via central venous catheter Day 4; and dexa-methasone 40 mg daily Days 1 to 4 and 11 to 14.
~Blinatumomab (Blincyto®) : 28-day continuous infusion (9µg/d for days 1-7; 28µg/d thereafter, followed by 2 weeks of rest for up to 2 cycles."
11278559|NCT02844517|Experimental|Artificial Pancreas|The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
11278560|NCT02844504|Experimental|Low Intensity Exercise Training 1|Cancer survivors will receive low intensity handgrip exercise training.
11278561|NCT02844504|Experimental|Low Intensity Exercise Training 2|Cancer survivors will receive low intensity handgrip exercise training different than other arm.
11278562|NCT02844504|No Intervention|Control|This group will receive no training.
11278563|NCT02844491||Cohort A|"In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.
~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab
~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab"
11278564|NCT02844491||Cohort B|"For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.
~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage
~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months"
11278565|NCT02844478|Active Comparator|SBP ENGLISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in English
11278566|NCT02844478|Experimental|SBP SPANISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in Spanish
11278567|NCT02844465|Experimental|Treatment|Visualase MRI-guided laser ablation procedure
11278568|NCT02844452|Experimental|Verum Acupuncture 1|The participants with atopic dermatitis in the acupuncture group 1 will attend twelve acupuncture sessions over 4 weeks: 3 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
11278569|NCT02844452|Experimental|Verum Acupuncture 2|The participants with atopic dermatitis in the acupuncture group 2 will attend eight acupuncture sessions over 4 weeks: 2 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
11278570|NCT02844452|Sham Comparator|Sham Acupuncture|The participants in the sham acupuncture group will visit eight acupuncture sessions over 4 weeks. The acupuncture treatment will be conducted on six control points. The acupressure will be applied with ring-sham press tack needles on three control points. Unlike the acupuncture group 2, partially-individualized manual acupuncture according to the patient's symptoms will not be given but the questions about symptoms will be questioned to patients.
11278571|NCT02844452|No Intervention|Healthy Control|The participants will go through the screening test. The included subjects will complete questionnaires and their blood sample will be obtained.
11278572|NCT02844439|Experimental|Glioblastoma|The single arm design assessing PFS-6 in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma, based on PFS-6 rates seen in randomized studies with bevacizumab [Weathers 2015; Taal 2014; Galanis 2015]. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
11278573|NCT02844426|Placebo Comparator|Placebo|patients allowed to take maltodextrin by the experienced doctor.
11278574|NCT02844426|Experimental|synbiotic|patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .
11278575|NCT02844413|Experimental|study group|implementation of aerobic interval training
11278576|NCT02844413|No Intervention|control group|control group
11278577|NCT02844400||Adjuvant and Curative Chemotherapy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
11278578|NCT02844400||Palliative Chemoteraphy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
11278579|NCT02844387|Experimental|Arginine|In the Arginine arm patients will receive 10 mg of L-arginine hydrochloride solution oral supplementation (in 200 ml of flavoured drinking water solution) administered twice a day prior to the radiation therapy fraction
11278580|NCT02844387|Placebo Comparator|Placebo|In the Placebo arm patients will receive 200 ml of flavoured drinking water oral solution administered twice a day prior to the radiation therapy fraction
11278581|NCT02844374|Other|Partial Epilepsy Drug Resistant|Patients with partial Epilepsy Drug Resistant , justifying a SEEG exploration.
11278582|NCT02844361|Experimental|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
11278583|NCT02844361|Active Comparator|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
11278584|NCT02844348|No Intervention|Standard pain control|Classical pain assessment and drug treatment at each dialysis session.
11278585|NCT02844348|Experimental|Hypnosis|Besides the classical pain assessment and drug treatment, hypnosis sessions during 2 periods of one week of dialysis sessions.
11278586|NCT02844335|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278587|NCT02844335|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278588|NCT02844322|Experimental|Bortezomib|Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
11278589|NCT02844322|Experimental|rituximab|Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
11278590|NCT02844309|Experimental|Thalidomide|thalidomide 50-150mg per night
11278591|NCT02844296|Experimental|exercise group|"A free handgrip (strength 15 kg) will be given to the subject and some short-bout exercise will be introduced to the subjects for reliving the cravings for smoking through a short video. After the video, the counselor will install a smartphone application which is about exercise in the subject's mobile phone to set up exercise reminder schedule for 4 weeks. 20-30 reminders on exercise and quitting tips via the App for 4 weeks. Subjects will be requested o record a daily diary on smoking.
~A leaflet with exercise instruction and motivation messages based on the Health Action Process Approach (HAPA) will be given to the participant. 2-month, 6 -month and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
11278592|NCT02844296|Experimental|diet group|"Subjects will view a short video on healthy diet only. After the video, the counselor will also install another smartphone application which is about healthy diet in the subject's mobile phone to set up healthy die reminder schedule for 4 weeks.
~A leaflet on healthy diet will be given to the subjects, and 20-30 reminders on healthy diet and quitting tips via the App for 4 weeks.2-,6- and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
11278593|NCT02844283|Experimental|treatment group|Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery
11278594|NCT02844283|Sham Comparator|control group|0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery
11278595|NCT02844270|Experimental|Galaxy stent|The galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System will be implanted in all subjects.
11278596|NCT02844244|Experimental|training group|Two two-hour training sessions for the participants. It aimed to train lay resident leaders to be peer health promoters. The peer health promoters were taught either to independently implement or to assist social workers to conduct a series of community-based family well-being activities.
11278597|NCT02844231|Other|Sleepwalker, SW episode|Sleepwalker patients undergo single-photon emission computed tomography during a sleepwalking episode.
11278598|NCT02844231|Other|Sleepwalkers, slow wave sleep|Sleepwalker patients undergo single-photon emission computed tomography during slow-wave sleep.
11278599|NCT02844231|Other|Control group|Control subjects undergo single-photon emission computed tomography during slow-wave sleep.
11278600|NCT02844218||Intensive chemotherapy group|Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
11278601|NCT02844218||Lower intensity treatment group|Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
11278602|NCT02844218||personalized treatment group|"Group 3: patients who had received, starting in 2007, more personalized treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician."
11278603|NCT02844179|Experimental|dose escalation|Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally
11278604|NCT02844166|Experimental|viscoelastic group|viscoelastic surface support
11278605|NCT02844166|Active Comparator|pyramidal foam group|pyramidal foam surface support
11278606|NCT02844153||6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)|All patients with type 2 diabetes seen for the first time by a nephrologist.
11278607|NCT02844140|Experimental|Scans|Patients included in the trial will receive DE-CT in stead of SE-CT's.
11278608|NCT02844127|Other|Apex First|Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
11278609|NCT02844127|Other|Septum First|Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
11278610|NCT02844114|Experimental|Ganoderma lucidum spore & Chemotherapy|Ganoderma lucidum spore 1500mg tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
11278611|NCT02844114|Placebo Comparator|Placebo & Chemotherapy|Placebo tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
11278612|NCT02844101|Other|non-blinded group|The non-blinded subjects will be informed that the accelerometer device (GT3X Actigraph accelerometer) is an accelerometer that assessed physical activity levels and patterns
11278613|NCT02844101|Other|blinded group|The blinded subjects will be informed that they will test the reliability of a new device for body posture assessment and these youngsters will not receive any information with regards to physical activity.
11278614|NCT02844088|Experimental|vaccinated group|evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
11278615|NCT02844088|Other|unvaccinate group|Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
11278616|NCT02844075|Experimental|pembrolizumab|
11278617|NCT02844062|Experimental|anti-EGFRvIII CAR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg
11278618|NCT02844049|Active Comparator|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
11278619|NCT02844049|No Intervention|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
11278620|NCT02844036|Experimental|Patients with a pulmonary hypertension|Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.
11278621|NCT02844023|Other|Patient with giant gells arteritis|50 patients with giant gells arteritis
11278622|NCT02844023|Other|Control patients|50 control patients : blood from French national blood service (EFS)
11278623|NCT02844010||patients with pneumonia|
11278624|NCT02843997|Other|Healthy volunteers|Members of a family
11278625|NCT02843984|No Intervention|A - untreated|The patients will be not treated with vaginal lactoferrin
11278626|NCT02843984|Active Comparator|B - 4 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
11278627|NCT02843984|Active Comparator|C - 12 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 12 hours prior to mid-trimester genetic amniocentesis.
11278628|NCT02843971|Experimental|Healthy volunteers|
11278629|NCT02843958|Other|Healthy volunteers and patients under Vitamin K antagonist|
11278630|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
11278631|NCT02843932|Experimental|Psychogenic disorders|Psychogenic movement disorders and seizures
11278632|NCT02843919|Other|Healthy volunteers|Adults healthy volunteers
11278633|NCT02843906|Active Comparator|BD/CD +|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
11278634|NCT02843906|Active Comparator|BD/CD -|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
11278635|NCT02843906|Active Comparator|a-MCI|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
11278636|NCT02843893|Other|Intubated and Mechanically Ventilated Patients|Intubated and Mechanically Ventilated Patients receiving by continuous intravenous an hypnotic sedation (midazolam or propofol) associate with a morphine type drug (fentanyl, sufentanil, rémifentanil, or morphine) since at least 6 hours and for a predictable duration over 24 hours.
11278637|NCT02843880||Septic shock patients|Septic shock patients staying over 3 days mechanically ventilated in the ICU
11278638|NCT02843841|Other|ATG group|"Renal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of polyclonal antilymphocyte globulin (ATG-Fresenius®) as recommended.
~Intervention = blood and fecal sample"
11278639|NCT02843841|Other|Anti-CD25 group|"PRenal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of anti-CD25 monoclonal antibodies (basiliximab SIMULECT®) as recommended.
~Intervention = blood and fecal sample"
11278640|NCT02843828|Experimental|Samsung Hip Assist v1|gait rehabilitation with Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
11278641|NCT02843828|Active Comparator|Conventional gait training|gait rehabilitation without Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
11278642|NCT02843815|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278643|NCT02843815|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278644|NCT02843802|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278645|NCT02843802|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278646|NCT02843789|Experimental|Adiponectin evaluation|Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
11278647|NCT02843763|Other|Renal transplant with 1rst cancer|"Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).
~Intervention : blood sample"
11278648|NCT02843763|Other|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.
~Intervention : blood sample"
11278649|NCT02843763|No Intervention|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
11278650|NCT02843763|Other|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
11278651|NCT02843763|Other|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
11278652|NCT02843763|Other|Rt patients without cancer apparied to RT skin cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.
~Intervention : blood sample"
11278653|NCT02843750|Experimental|Inspiratory Muscle Training-Rehabilitation|Patients will start the IMT-R, following their consent and within 2 weeks of their scheduled surgery: 10 sessions lasting about 90 minutes. Participants who completed their initial IMT greater than 2 weeks prior to surgery will have an additional visit prior to surgery. Participants will receive a Participant Manual demonstrating and explaining the rehabilitation process. Participants will also receive a log for recording their efforts and notes. A DVD of the rehabilitation is available to the participant. Participants will complete questionnaires at baseline and 3 months.
11278654|NCT02843724|Active Comparator|Control (Conventional) Arm|Treatment of Type 2 Diabetes according to the Canadian Diabetes Association guidelines. Participants' other health concerns to be addressed as per usual care by practitioners at Wise-Elephant Family Health Team.
11278655|NCT02843724|Active Comparator|Integrative (Naturopathic + Conventional) Arm|In addition to conventional care, participants will receive free naturopathic care at Brampton Naturopathic Teaching Clinic (located within the Brampton Civic Hospital). Senior student clinicians will provide care under the direct supervision of licensed naturopathic doctors. A naturopathic menu of treatment options have been designed to reflect naturopathic practice and vetted by 3 licensed naturopathic doctors and experts in the field. Participants' other health concerns will be addressed as per naturopathic doctors' discretion.
11278656|NCT02843711||Adenocarcinoma|Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
11278657|NCT02843698|Experimental|Dexmedetomidine group|Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
11278658|NCT02843698|Placebo Comparator|Control group|Patients will receive normal saline
11278659|NCT02843672|Active Comparator|TWO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.
~Triple´s Weil osteotomy is performed."
11278660|NCT02843672|Active Comparator|DMMO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.
~Distal metatarsal minimally invasive osteotomy is performed."
11278661|NCT02843659|Experimental|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
11278662|NCT02843659|Experimental|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
11278663|NCT02843659|Placebo Comparator|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
11278664|NCT02843646|Experimental|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
11278665|NCT02843646|Placebo Comparator|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
11278666|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
11278667|NCT02843620|Placebo Comparator|Placebo|The placebo arm will take a pill each day containing only excipients
11278668|NCT02843620|Experimental|b-2Cool|The b-2Cool arm will take a pill each day containing 40 mg of b-2Cool and excipients
11278669|NCT02843607|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278670|NCT02843607|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
11278671|NCT02843594|Active Comparator|LEEP Intervention C1|Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
11278672|NCT02843594|Active Comparator|LEEP Intervention C2|Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
11278673|NCT02843594|Placebo Comparator|Control Phaco C2|Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
11278674|NCT02843581|Experimental|Cryosurgery and NK immunotherapy|We use comprehensive cryosurgery to destroy big tumors, and use multiple (more than 6 times) NK immunotherapy to destroy small tumors
11278675|NCT02843581|Active Comparator|Cryosurgery|We use comprehensive cryosurgery to destroy big tumors
11278676|NCT02843568|Active Comparator|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.
~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
11278677|NCT02843568|Experimental|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
11278678|NCT02843555||Leukodystrophy of unknown etiology|Subjects who may have an undiagnosed form of leukodystrophy
11278679|NCT02843542|Other|Control Group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT)
11278680|NCT02843542|Other|Study group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT) and in addition will also undergo the PET-MR
11278681|NCT02843529|Experimental|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers
~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
11278682|NCT02843529|Experimental|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers
~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
11278683|NCT02843516||patients with stroke|patients with stroke
11278684|NCT02843516||patients without stroke|patients without stroke
11278685|NCT02843503|Experimental|Arterialized-venous reference YSI|CGM monitoring performance per arterialized venous reference measurement (YSI)
11278686|NCT02843503|Experimental|Venous reference samples YSI|CGM monitoring performance per venous reference measurement (YSI)
11278687|NCT02843490|Experimental|Ranibizumab treatment of nAMD patients|nAMD patients will be treated with Ranibizumab (0.5 mg injection) 3 times within three months followed by individual therapy interval based on the clinical progress (PRN) up to 7 times. Analysis of specific biomarker.
11278688|NCT02843490|No Intervention|healthy subjects|Analysis of specific biomarker.
11278689|NCT02843477||Fluid loading group|Spontaneously breathing patients before induction of general anesthesia who receive fluid loading
11278690|NCT02843464|Experimental|long-term RIPC group|routine treatment + once RIPC/day for a year. Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
11278691|NCT02843464|No Intervention|control group|routine treatment.
11278692|NCT02843451|Experimental|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
11278693|NCT02843451|Placebo Comparator|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
11278694|NCT02843438|Other|Subjects suspected of toxoplasmosis chorioretinitis infection|Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
11278695|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
11278696|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
11278697|NCT02843412||group 1|choose one tumor tissue paraffin blocks
11278698|NCT02843412||group 2|choose two tumor tissue paraffin blocks
11278699|NCT02843399||Exenatide once weekly (EQW)|EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.
11278700|NCT02843399||Insulin Glargine (IG)|IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015
11278701|NCT02843386|Experimental|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
11278702|NCT02843386|Other|B : Surveillance|Intensive surveillance
11278703|NCT02843373||rTMS|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered to the left DLPFC as assessed by either the 5cm rule or F3 site. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
11278704|NCT02843347||Biorepository substudy participants|Participants from the main study who give consent for the genetic testing substudy.
11278705|NCT02843334||Population of adult patients undergoing chronic renal dialysis|Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)
11278706|NCT02843321|Experimental|T-cell infusion|Infusion of donor-derived T cells. Non randomised, prevention study arm
11278707|NCT02843308|Experimental|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
11278708|NCT02843308|Experimental|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
11278709|NCT02843308|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
11278710|NCT02843295|Experimental|Population of the study|3 stratification groups: Group 1: High immunologic risk Patients receiving a ≥ 2nd graft and/or Panel Reactive Antibody ≥ 30% and/or Human Leukocyte Antigen (HLA) mismatches ≥ 4 Group 2: High non-immunologic risk Donors over 60 years of age and/or Donor between 50 to 59 years of age who have died of stroke, or had a history of high blood pressure, or at the time of death had a creatininemia ≥ 135 µmol/L Group 3: Low risk Patients not included in Groups 1 or 2
11278711|NCT02843282|Experimental|Cognitive training|Advanced reasoning training
11278712|NCT02843269|Active Comparator|Multi-component lifestyle intervention 1|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
11278713|NCT02843269|Active Comparator|Multi-component lifestyle intervention 2|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
11278714|NCT02843269|Active Comparator|Multi-component lifestyle intervention 3|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
11278715|NCT02843256||Patients receiving intravenous nutrition|Patients will blow into a bag that will capture 500 mL of their exhaled air daily for 7 days or the length of the parenteral nutrition, whichever is shorter. The Isomark Canary will analyze the air to generate a breath delta value.
11278716|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).
~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.
~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
11278717|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).
~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.
~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
11278718|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).
~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.
~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
11278719|NCT02843217|Experimental|Text Messaging|
11278720|NCT02843204|Experimental|Pembrolizumab and NK immunotherapy|In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278721|NCT02843204|Active Comparator|Pembrolizumab|In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278722|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
11278723|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
11278724|NCT02843178|Experimental|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
11278725|NCT02843178|Active Comparator|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
11278726|NCT02843178|Active Comparator|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
11278727|NCT02843178|Active Comparator|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
11278728|NCT02843165|Experimental|CBI plus SBRT|Checkpoint blockade immunotherapy (CBI) plus stereotactic body radiation therapy (SBRT)
11278729|NCT02843165|Active Comparator|CBI|Checkpoint blockade immunotherapy (CBI)
11278730|NCT02843139||Children group|Children recruiters were categorized into three groups: obesity, overweight and normal control based on World Health Organization child growth standards.
11278731|NCT02843139||Adults group|Adults with type 2 diabetes were defined if the individual had a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L.
11278732|NCT02843126|Experimental|Trastuzumab and NK immunotherapy|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278733|NCT02843126|Active Comparator|Trastuzumab|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278734|NCT02843113|Experimental|4 Your Child Program|Program integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
11278837|NCT02842515||Patients requiring dental avulsion|Patients requiring dental avulsion
11278838|NCT02842502|Experimental|Skin graft pellet|This group concerns patients who are recruited for skin graft procedure leading to the collection of supernumerary biopsies.
11278735|NCT02843113|Experimental|4 Your Child + Case Management|Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
11278736|NCT02843113|No Intervention|Waiting list control|Individuals who are randomly assigned to this condition will receive no treatment for a period of months in parallel with the experimental intervention conditions. Data will be gathered from them, and they will be randomly assigned to a treatment condition when possible.
11278737|NCT02843100|Experimental|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) phases 2 & 3 for 24 weeks
11278738|NCT02843100|Active Comparator|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 24.
11278739|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278740|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278741|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278742|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278743|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278744|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278745|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278746|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278747|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278748|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
11278749|NCT02843074|Experimental|ERd Therapy|"INDUCTION:
~Cycles 1-2: elotuzumab 10mg/kg IV days 1, 8, 15, 22; lenalidomide (len) 25mg orally (PO), once daily (QD) on days 1-21; dexamethasone (dex) 28 mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1, 8, 15, 22.
~Cycles 3-4: elotuzumab 10mg/kg IV days 1 and 15; len 25mg PO QD days 1-21; dex 8mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.
~CONSOLIDATION:
~Four 28-day cycles: elotuzumab 10mg/kg IV days 1 and 15; len 15mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.
~MAINTENANCE:
~After completing consolidation therapy patients without progressive disease will receive, for up to 24 months, 28-day cycles of elotuzumab 20mg/kg IV day 1; len 10mg +/- 5mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes prior to elotuzumab) day 1."
11278750|NCT02843061|Experimental|Rituximab and NK immunotherapy|In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278751|NCT02843061|Active Comparator|Rituximab|In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
11278752|NCT02843048|Experimental|Exercise training|Exercise training plus standard medical follow-up care
11278753|NCT02843048|Active Comparator|Standard medical care|Standard medical follow-up care only
11278754|NCT02843035|Experimental|Adult GD1 participants: No venglustat treatment (Cohort 1)|"Part 1 only (45 days): Biomarker evaluation/screening phase. No venglustat administered.
~During Part 1 participants will continue their routine total monthly Cerezyme dose or, if received another enzyme replacement therapy (ERT) prior to study, will switch to a defined corresponding Cerezyme dose regimen."
11278755|NCT02843035|Experimental|Adult GD3 participants: OL venglustat (Cohort 2)|"Part 1 (45 days): Biomarker evaluation/screening phase. No venglustat administered.
~Part 2: Open label (OL) venglustat administered once a day orally for 12 months.
~Part 3: OL venglustat administered once a day orally for up to 3 years.
~During Parts 1-3 study participants will continue their routine total monthly Cerezyme dose or, if received another ERT prior to study, will switch to a defined corresponding Cerezyme dose regimen."
11278756|NCT02843035|Experimental|Adult/pediatric GD3 participants: DB venglustat (Cohort 3)|"Part 1 (60 days): Biomarker evaluation/screening phase. No venglustat administered.
~Part 2: Double-blind (DB) venglustat administered once a day orally for 12 months.
~Part 3: OL venglustat administered once a day orally for up to 2.5 years.
~During Parts 1-3 study participants will continue their routine total monthly Cerezyme dose or, if received another ERT prior to study, will switch to a defined corresponding Cerezyme dose regimen."
11278757|NCT02843035|Placebo Comparator|Adult/pediatric GD3 participants: DB placebo (Cohort 3)|"Part 1 (60 days): Biomarker evaluation/screening phase. No venglustat administered.
~Part 2: DB placebo administered once a day orally for 12 months.
~Part 3: OL venglustat administered once a day orally for up to 2.5 years.
~During Parts 1-3 study participants will continue their routine total monthly Cerezyme dose or, if received another ERT prior to study, will switch to a defined corresponding Cerezyme dose regimen."
11278758|NCT02843022|Active Comparator|Usual care|Participant will receive the usual care provided by the nursing staff at Catholic Medical Center. A lactation consultant or childbirth educator attempts to call each patient within 2-3 weeks prior to discharge. Only one call is made, and a message left if the patient would like to call back.
11278759|NCT02843022|Experimental|Message Only|Participant will receive the usual care, and in addition, will receive four standardized electronic messages weekly for six months postpartum. These will be one-way messages without the option to respond.
11278760|NCT02843022|Experimental|Message and Nurse|"Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond yes to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week."
11278761|NCT02843009|Placebo Comparator|Safflower Oil plus Resistance Exercise Training|3.0g of safflower oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
11278762|NCT02843009|Active Comparator|Fish Oil plus Resistance Exercise Training|3.0g of fish oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
11278763|NCT02842996||Patient and carer study group|Patients having undergone hip fracture surgery and their care givers.
11278764|NCT02842983|Experimental|Esmolol|After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.
11278765|NCT02842983|No Intervention|Control|Patients received conventional management of septic shock
11278839|NCT02842489|Experimental|left lateral tilt-down position|patients will be positioned on left lateral tilt-down position during colonoscopy until sigmoid-descending junction were examined, and then patients will be positioned on the left lateral horizontal position during colonoscopy
11278766|NCT02842957|Experimental|Lifestyle intervention|Behavioral: The Lifestyle arm is the experimental group that will be exposed to an intensive, individualized approach aimed at assisting these CKD patients to adhere to lifestyle changes that are expected to be beneficial to their health and wellbeing. Patients will receive direction to implement a plant based diet, along with more physical activity in their lives. They will be assisted with the optimal use of their prescribed medications by pharmacy professionals and they will receive behavioral counseling by experts in that area.
11278767|NCT02842957|No Intervention|Usual Care|The Usual Care arm will continue to receive the current standard of care involving all the services provided at a contemporary nephrology practice in Western Massachusetts
11278768|NCT02842944|Experimental|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
11278769|NCT02842944|Active Comparator|Routine care|"Connect and start Beacon with advice disabled
~Standardized routine care"
11278770|NCT02842931|Active Comparator|R-DA-EPOCH-21|Protocol involves 6 cycles.
11278771|NCT02842931|Active Comparator|R-DA-EPOCH-21 + auto-SCT|Protocol involves 6 cycles. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
11278772|NCT02842931|Active Comparator|R-mNHL-BFM-90|"Course A:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 25 mg/m2/day IV 1, 2 days, Vincristine 2 mg IV 1 day, Cytarabine 100 mg/m2/day IV 1 h 4, 5 days.
~Course B:
~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Doxorubicin 25 mg/m2/day IV 4, 5 days, Vincristine 2 mg IV 1 day. Protocol involves 6 cycles : A-B-A-B-A-B. One cycle continues 21 days."
11278773|NCT02842931|Active Comparator|R-mNHL-BFM-90 + auto-SCT|Protocol involves 6 cycles R-mNHL-BFM-90: A-B-A-B-A-B. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
11278774|NCT02842918|Active Comparator|Spinal Manual Therapy|Supine thoracic spine manipulation located between the levels of T4-T7
11278775|NCT02842918|Sham Comparator|Spinal Range of Motion|Supine thoracic spine sham manipulation located between the levels of T4-T7; identical procedure as the active treatment intervention but without the delivery of high velocity low amplitude thrust
11278776|NCT02842905|Active Comparator|Control Group|Fitting Audiologist completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
11278777|NCT02842905|Experimental|Test Group|Participant's physician completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
11278778|NCT02842892|Other|Squat Jump|
11278779|NCT02842892|Other|Drop Jump|
11278780|NCT02842892|Other|Countermovement Jump|
11278781|NCT02842879|Experimental|Outpatient Foley cervix priming|Patients randomized to outpatient cervix priming will have the insertion of the catheter in the same conditions defined by the Department protocol for inpatient cervix priming. They will be discharged after a reassuring cardiotocogram following the introduction of the Foley catheter. When discharged, the patients will be instructed to apply manual traction to the catheter every 6 hours and they will be given a written document with all the information that should bring them back to hospital.
11278782|NCT02842879|No Intervention|Inpatient Foley cervix priming|The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
11278783|NCT02842866|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
11278784|NCT02842866|Active Comparator|Group 2: Menomune® Vaccine|Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
11278785|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 1|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 1a) and adults aged 18 to 55 years (Group 1b) received a single dose of MenACYW conjugate vaccine from lot 1 on Day 0.
11278786|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 2|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 2a) and adults aged 18 to 55 years (Group 2b) received a single dose of MenACYW conjugate vaccine from lot 2 on Day 0.
11278787|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 3|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 3a) and adults aged 18 to 55 years (Group 3b) received a single dose of MenACYW conjugate vaccine from lot 3 on Day 0.
11278788|NCT02842853|Active Comparator|Menactra®|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 4a) and adults aged 18 to 55 years (Group 4b) received a single dose of Menactra® on Day 0.
11278789|NCT02842840|Experimental|Patients based intervention|A multifaceted intervention program will use to improve adherence and clinical outcomes in Stroke patients. This intervention focus on behavioral treatment in the patients.
11278790|NCT02842840|Experimental|Family based intervention|Patients and their families will receive a series of educational/motivational interventions.
11278791|NCT02842840|Active Comparator|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 30 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
11278792|NCT02842827|Experimental|Multiple ascending dose|MAD Cohorts using IMG-7289 alone
11278793|NCT02842827|Experimental|Combination Therapy|IMG-7289 in combination with all-trans retinoic acid (ATRA)
11278794|NCT02842827|Experimental|Ascending duration|Treatment duration extension Cohorts using IMG-7289 alone
11278795|NCT02842814|Experimental|Full withdrawal|Intervention: 'Drug free'.
11278796|NCT02842814|Experimental|GC withdrawal|Intervention: 'HCQ' .
11278797|NCT02842814|Experimental|No withdrawal|Intervention: 'GC+HCQ' .
11278798|NCT02842801|Other|Hip Manipulation|Hip manipulation: high velocity low amplitude thrust mobilization
11278799|NCT02842788||ARDS patients receiving invasive mechanical ventilation in ICU|"ARDS criteria (Berlin definition) fulfilled the day of the study, whatever the ARDS stage. The onset of ARDS could have been established at any time between ICU admission and study day but ARDS criteria must be still present the day of the study. The ARDS criteria are listed below
~Within 1 week of a known clinical insult or new or worsening respiratory symptoms
~Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules
~Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
~PaO2/FIO2 ≤ 300 with Positive end-expiratory pressure (PEEP) ≥ 5 cmH2O
~Age ≥ 18 years
~Intubated or tracheotomized and mechanically ventilated"
11278800|NCT02842775|Experimental|Dynamic balance exercise group|balance perturbation training
11278801|NCT02842775|No Intervention|Control group|No intervention
11278802|NCT02842762|Sham Comparator|Non-paced|"cardiac surgery
~3D TEE measurements of systolic dyssynchrony
~right ventricular epicardial pacemaker lead (off)"
11278803|NCT02842762|Experimental|Paced|"The patient is randomized to the order of measurements taken, and serves as his own control.
~cardiac surgery
~3D TEE measurements of systolic dyssynchrony
~right ventricular epicardial pacemaker lead (on)"
11278804|NCT02842749|Experimental|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
11278805|NCT02842736|Experimental|Endometrial Cryoablation|
11278806|NCT02842723|Experimental|Protontherapy|
11278807|NCT02842710|Experimental|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
11278808|NCT02842697|Experimental|Single arm study|"Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.
~Intervention: Procedure: HVPG measurement"
11278809|NCT02842684|Experimental|Traumacad software|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . The recent TraumaCad system ( Brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric hip parameters
11278810|NCT02842684|No Intervention|without digital planning|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise
11278811|NCT02842671|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the the procedure will serve as our intervention group. The participants will be assigned an Ambassador throughout the procedure and will complete a patient satisfaction survey afterwards. The investigators hope to enroll 25 controls.
11278812|NCT02842671|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
11278813|NCT02842658|Active Comparator|A high-intensity interval exercise group|Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
11278814|NCT02842658|Other|An attention-control group|Patients will receive counseling regarding physical activity during chemotherapy. Patients will receive a weekly phone call to maintain physical activity during chemotherapy and compliance will be verified using physical activity diaries and pedometers.
11278815|NCT02842645||Control|Children born at term and not exposed to drugs during pregnancy
11278816|NCT02842645||Case|Case = Children exposed to drugs during pregnancy
11278817|NCT02842632|Other|A virtual teaching|Group A will be introduced to the virtual TEE online (http://pie.med.utoronto.ca/TEE/)
11278818|NCT02842632|Other|B simulator|Group B will be introduced to the simulator (CAE Vimedix Simulator)
11278819|NCT02842632|Other|C hands on OR|group C will be introduced to the TEE training in the operation room.
11278820|NCT02842619|Experimental|Intervention Arm|1 Arm - IMP treatment arm
11278821|NCT02842606|Experimental|Fiber-enriched pasta|The participants consume whole wheat pasta with added fiber (fiber 12 g fiber/100 g).
11278822|NCT02842606|Active Comparator|Control pasta|The participants consume pasta made from durum wheat semolina (fiber 2.7g/100g).
11278823|NCT02842593|Experimental|Resistance exercise training|Whole-body resistance exercise training 4x/week for 12 weeks. Either 'lower-repetition, heavier-load' or 'higher-repetition, lighter-load' intervention.
11278824|NCT02842593|No Intervention|Non-exercising control|Continue habitual physical activity for 12 weeks.
11278825|NCT02842580|Active Comparator|Standard arm (escalation strategy - arm A)|LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
11278826|NCT02842580|Experimental|Experimental arm (de-escalation strategy -arm B)|(4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine
11278827|NCT02842567|Experimental|TREATED GROUP|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
11278828|NCT02842567|Placebo Comparator|PLACEBO GROUP|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
11278829|NCT02842554|Other|DPA|Drug Placebo Administration
11278830|NCT02842554|Other|C|Control
11278831|NCT02842554|Other|EPT|Evoked Pain Training
11278832|NCT02842541|Experimental|Single dose arm|Subjects will receive a single intravitreal dose of EBI-031
11278833|NCT02842541|Experimental|Repeat dose arm|Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months
11278834|NCT02842528|Experimental|Alcohol-dependent patients|
11278835|NCT02842528|Active Comparator|First-degree relatives of alcohol-dependent probands|
11278836|NCT02842528|Active Comparator|Healthy Controls|
11278840|NCT02842489|Active Comparator|left lateral horizontal body position|patients will be positioned on the left lateral horizontal position during colonoscopy insertion
11278841|NCT02842476||Disposable Sensor|Adhesive based Pulse Oximeter Probes, Model S0136J
11278842|NCT02842476||Reusable Sensor|Reusable Pulse Oximeter Probes, Model S0080D
11278843|NCT02842476||Control Pulse Oximetry|Reference CO-Oximeters ABL80 Flex OSM (Radiometer), # 302125, 307205 IL682 (Instrumentation Laboratories), # 012511B (ILH), #012511A (ILG)
11278844|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.
~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
11278845|NCT02842450||training with typical definitions established + photos|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
11278846|NCT02842450||Training only with definitions|Interns will receive typical definitions of LAP stages
11278847|NCT02842437|Experimental|Dexmedetomidine|25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
11278848|NCT02842437|Placebo Comparator|Placebo|25 patients receive matching placebo （normal saline）
11278849|NCT02842424|Experimental|Ramipril Treatment|6 months treatment with the medication Ramipril
11278850|NCT02842411||chronic constipation|patients with chronic constipation based on Rome Ⅳ
11278851|NCT02842398|Experimental|Balance Master Training|Children receive one weekly Balance Master training session, in addition to their weekly physical therapy sessions. During Balance Master training, children practice balance on a Balance Master device that simulates crossing a city street.
11278852|NCT02842398|Active Comparator|Customary Care|Children received their customary scheduled physical therapy sessions, without Balance Master training
11278853|NCT02842385|Active Comparator|Nonsubmerged thick group|Nonsubmerged type of implants placed with thick (>3 mm) soft tissue
11278854|NCT02842385|Active Comparator|Nonsubmerged thin group|Nonsubmerged type of implants placed with thin (<3 mm) soft tissue
11278855|NCT02842385|Active Comparator|Submerged thick group|Submerged type of implants placed with thick (>3 mm) soft tissue
11278856|NCT02842385|Active Comparator|Submerged thin group|Submerged type of implants placed with thin (<3 mm) soft tissue
11278857|NCT02842372||Ectoin Dermatitis Cream 7%|Cream for symptomatic treatment and relief of skin redness and itching experienced with various types of inflammatory dermatoses.
11278858|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
11278859|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
11278860|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
11278861|NCT02842333|Experimental|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).
~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
11278862|NCT02842320|Experimental|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
11278863|NCT02842307|Active Comparator|A(senior acupuncturists)|Manual acupuncture implemented by senior acupuncturists (clinical experience >15 years)
11278864|NCT02842307|Active Comparator|B(junior acupuncturists)|Manual acupuncture implemented by junior acupuncturists (clinical experience <5 years)
11278865|NCT02842307|Active Comparator|C(P6 points)|Manual acupuncture on P6 points by junior acupuncturists (clinical experience <5 years)
11278866|NCT02842307|No Intervention|D(no acupuncture)|No acupuncture treatment
11278867|NCT02842294||irinotecan based chemotherapy|patients having a 1st line doublet chemotherapy including irinotecan
11278868|NCT02842294||oxaliplatin based chemotherapy|patients having a 1st line doublet chemotherapy including oxaliplatin
11278869|NCT02842294||triplet chemotherapy|patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
11278870|NCT02842281|Active Comparator|Fructan|Fructans will be provided for 72 hours.
11278871|NCT02842281|Placebo Comparator|Maltodextrin|Maltodextrin will be provided for 72 hours.
11278872|NCT02842268|Experimental|BAY987517|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams.Subject should sweat profusely.
11278873|NCT02842255|Experimental|Healthy volunteers|
11278874|NCT02842242|Experimental|Open Label|MYK-461
11278875|NCT02842229||Patients with Haematologic Neoplasms|"Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01).
~Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).
~Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01)."
11278876|NCT02842190|Active Comparator|NIPPV|NIPPV after ekstubation
11278877|NCT02842190|No Intervention|BIPAP|BIPAP after ekstubation
11278878|NCT02842177|Active Comparator|Group I (classic method)|
11278879|NCT02842177|Active Comparator|uterine sound sparing group|
11278880|NCT02842164|Other|Foley Catheter Balloon with Tension group|a 16 French transcervical Foley catheter balloon will be advanced to or past the internal os and the balloon will be filled. Then catheter will be placed on gentle traction by taping the distal tip to the medial thigh for maximum 24 hours. To maintain gentle traction, periodic repositioning of the distal tip on the thigh will be necessary.
11278881|NCT02842164|Other|Foley Catheter Balloon without tension group|The Foley catheter balloon will be just supported by simple taping to the thigh.
11278882|NCT02842151|Other|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
11278912|NCT02841982|Active Comparator|IPCA|postoperative IPCA is given alone
11278883|NCT02842138|Experimental|CD19 CAR T cells|A standard dose escalation approach aimed to assess the safety and efficacy of autologous anti-CD19 CAR T cells will be applied.
11278884|NCT02842125|Experimental|Ad-p53 with Xeloda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
11278885|NCT02842125|Experimental|Ad-p53 with Keytruda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
11278886|NCT02842125|Experimental|Ad-p53 with Opdivo 33.3% of patients|Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
11278887|NCT02842112||CD34+ CD38-|A first cell population, which expressed the CD34 antigen and lacked CD38 (CD34+ CD38-), and often contained very few events requiring to be tightly clustered in a forward light scatter /side light scatter (FSC/ SSC) and CD45/SSC plot;
11278888|NCT02842112||CD34+ CD38low|A second population characterized by expression of the CD34 antigen and by a low density of CD38 antigen (CD34+ CD38low)
11278889|NCT02842112||CD34+ CD38+|A third population characterized by a large density of CD38 and CD34 antigens (CD34+ CD38+). Antigens were expressed as percent positively stained cells as well as intensity of the fluorescence signal quantified as mean fluorescence intensity (MFI) from CD34+ gated cells and from CD45low/SSC total immature cells
11278890|NCT02842099|Experimental|TA or TAC plus X|Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
11278891|NCT02842099|Active Comparator|TA or TAC|Standard chemotherapy (TA or TAC) followed by no more chemotherapy
11278892|NCT02842086|Experimental|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
11278893|NCT02842086|Experimental|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
11278894|NCT02842086|Experimental|Open-label Extension|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment in the open-label extension for 48 weeks.
11278895|NCT02842073|Experimental|Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
11278896|NCT02842060|Experimental|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
11278897|NCT02842060|Active Comparator|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
11278898|NCT02842047|Experimental|End of Life Care with Meditation|The intervention has two content components: end of life planning education (using end of life planning videos) and strategies and kindness based meditation (using the Stop, Breathe & Think™ app). The activities comprising these components work together to improve both analytic neural processing (e.g. improving knowledge about goal setting and EOL planning, learning self-monitoring of EOL values and goals of care, and self-regulation skills of monitoring symptoms of distress and anxiety) and emotional neural processing (e.g. teaching participants to experience the moment non-judgmentally and directing thoughts to think positive thoughts and feel positive feelings like kindness and compassion.
11278899|NCT02842047|Active Comparator|Meditation Only|This arm has the single content component of kindness based meditation delivered by using the Stop, Breathe & Think™ application. This group will also be instructed to view 3 caregiver wellness videos.
11278900|NCT02842034|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
11278901|NCT02842034|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
11278902|NCT02842021|Active Comparator|S2G6T-1|Topical cream
11278903|NCT02842021|Active Comparator|S2G6T-2|Topical Cream
11278904|NCT02842021|Active Comparator|S2G6T-3|Topical Cream
11278905|NCT02842021|Placebo Comparator|S2G6T-4|Topical Cream
11278906|NCT02842008|Experimental|Exercise group|Wheelchair basketball players participating in home therapeutic exercise program that use the protocol of postural hygiene.
11278907|NCT02842008|No Intervention|Control group|Wheelchair basketball players that not participate in home therapeutic exercise program and use a protocol of postural hygiene provided.
11278908|NCT02841995|Experimental|KD025 200 mg QD|Two 100 mg capsules or one 200 mg tablet (200 mg) of KD025 once daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal.
11278909|NCT02841995|Experimental|KD025 200 mg BID|Two 100 mg capsules or one 200 mg tablet (200 mg) of KD025 twice daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal and 2 capsules or 1 tablet with their evening meal or within 5 minutes of completing a meal.
11278910|NCT02841995|Experimental|KD025 400 mg QD|Four 100 mg capsules or two 200 mg tablets (400 mg) of KD025 once daily. Subjects should take 4 capsules or 2 tablets with their morning meal or within 5 minutes of completing a meal.
11278911|NCT02841982|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
11278913|NCT02841969|Active Comparator|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
11278914|NCT02841969|Experimental|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
11278915|NCT02841956|Experimental|Electronic Screen + Education (Phase 1)|Electronic screening of participants and targeted education of providers according to standard EDAPT model.
11278916|NCT02841956|Active Comparator|Targeted Provider Education (Phase 1)|Targeted education of providers according to standard EDAPT model.
11278917|NCT02841956|Experimental|Community Mobile Engagement (Phase 2)|Clinical intake interviews take place via videoconference at a location in the community convenient for the participant.
11278918|NCT02841956|Active Comparator|Clinic based Engagement (Phase 2)|Clinical intake interviews take place at the EDAPT clinic.
11278919|NCT02841930|Experimental|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
11278920|NCT02841930|No Intervention|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
11278921|NCT02841917||Transcatheter Aortic Valve Replacement|ROS Post TAVR
11278922|NCT02841917||Surgical Aortic Valve Replacement|ROS Post SAVR
11278923|NCT02841904|Other|CLE|CLE assessed by the pathologist
11278924|NCT02841904|Active Comparator|Biopsy|Histology assessed by the pathologist
11278925|NCT02841891|Experimental|Test|Test group will receive Sylys® Surgical Sealant as an adjunct to standard closure of stapled anastomosis in colectomy procedure.
11278926|NCT02841891|Active Comparator|Control|Control group will receive standard of care closure of stapled anastomosis in colectomy procedure without Sylys® Surgical Sealant.
11278927|NCT02841878|Other|analysis on colorectal biopsy|"Proteases activity (cystein and serin proteases)
~Proteases inhibitors genes expression (Serpins A1 / E1)
~Colonic biopsies permeabilityTight junctions genes expression
~Cytokines genes expression (TNFalpha, interleukines)
~Cellularity on histologic sections"
11278928|NCT02841839|Experimental|2-step system|Subjects are to brush with 2-step system for 4 weeks; stannous fluoride
11278929|NCT02841826|Other|Group I: IUD without uterine sound group|Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding.
11278930|NCT02841826|Other|Group II: IUD with uterine sound|Intrauterine contraceptive device inserted by classic method
11278931|NCT02841813||The normal mothers group|No intervention
11278932|NCT02841813||The normal full-term infants group|No intervention
11278933|NCT02841813||The preterm mothers group|No intervention
11278934|NCT02841813||The preterms group|No intervention
11278935|NCT02841800|Experimental|Intra-luminal radiofrequency ablation|Intra-luminal radiofrequency ablation Admission for endoscopic retrograde cholangiopancreatography (ERCP) and stent placement after radiofrequency ablation. ERCP should be performed for 2 times with an interval of two months.
11278936|NCT02841787|Experimental|Individual Internet Intervention (III)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.
~(iCBT for late life depression without social network included.)"
11278937|NCT02841787|Experimental|Internet Intervention+Peer Supp.(II+PS)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.
~(iCBT for late life depression with social network included.)"
11278938|NCT02841787|No Intervention|Waitlist Control (WLC)|Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.
11278939|NCT02841774|Active Comparator|Moderate Intensity Group|pravastatin 40mg daily for 12 weeks
11278940|NCT02841774|Experimental|High Intensity Group|rosuvastatin 20 - 40 mg daily for 12 weeks
11278941|NCT02841761|Experimental|Treatment A (Midazolam)|Single dose of Midazolam 8 mg on Day 1
11278942|NCT02841761|Experimental|Treatment B1 (ACT-132577)|Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.
11278943|NCT02841761|Experimental|Treatment B2 (Midazolam + ACT-132577)|Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6
11278944|NCT02841748|Experimental|Pembrolizumab|200mg, every three weeks, iv, x 1 year
11278945|NCT02841748|Experimental|Placebo|iv, every 3 weeks, x 1 year
11278946|NCT02841735||Smartphone breathalyzer device & app|This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
11278947|NCT02841735||BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
11278948|NCT02841735||Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.
11278949|NCT02841722|Other|Biological samples|Only one arm in this pilot study. All patient will have a follow up and treatment as per standard care for this pathology. Specifically for the study all patients will have 8 additional blood samples to be drawn during the first 2 cycles of treatment (1 cycles is 21 days).
11278950|NCT02841709|Experimental|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
11278951|NCT02841709|Experimental|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
11278952|NCT02841709|Experimental|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
11278953|NCT02841709|Experimental|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
11278954|NCT02841709|Experimental|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
11278955|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
11278956|NCT02841683|Active Comparator|Lifestyle counseling|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
11278957|NCT02841683|No Intervention|Current practices|Current practices of smoking cessation in France
11278958|NCT02841644||Traumatic Arthrotomy|Patient diagnosed with traumatic arthrotomy.
11278959|NCT02841631||Post-Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
11278960|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks
11278961|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks
11278962|NCT02841605|Other|AD group|AD group: rectosigmoidospcopy with biopsies of colon
11278963|NCT02841605|Other|PD group|PD group: rectosigmoidospcopy with biopsies of colon
11278964|NCT02841605|Other|PSP group|PSP group: rectosigmoidospcopy with biopsies of colon
11278965|NCT02841605|Other|Patient eligible for colorectal cancer screening|Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon
11278966|NCT02841592|Active Comparator|Non-rebreather|This group will have a non-rebreather mask applied to the face and they will receive the flush rate oxygen intervention
11278967|NCT02841592|Active Comparator|Bag-valve-mask|With each inspiration from the subject, the ventilation bag will be gently squeezed to provide positive pressure and augment the amount of oxygen that is received by the subject for each breath. This group will receive the flush rate oxygen with assist intervention.
11278968|NCT02841579|Experimental|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.
11278969|NCT02841566||Problem glambers|The group of problem gamblers will consist of patients already included in the cohort EVALADD [favorable opinion of GNEDS 06/09/2012; CNIL authorization No. 912631 of 10.09.2013], and the data will be extracted directly from the database EVALADD
11278970|NCT02841566||Non-problem gamblers|The subjects of this group will be matched on sex, age and education level with the group problem gamblers. They will be recruited over the Internet and using the volunteer base [normal declaration with the CNIL: No. 1761543 of 21/05/2014].
11278971|NCT02841540|Experimental|H3B-8800 (escalation and expansion)|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
11278972|NCT02841527|Active Comparator|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
11278973|NCT02841527|Active Comparator|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
11278974|NCT02841527|Active Comparator|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
11278975|NCT02841514|Experimental|treatment group|the operator will administer the Y10 whitening toothpaste in to the attachable mouthpiece and place it in the subject's mouth and turn on the device RF. After treating the patients for 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
11278976|NCT02841514|Placebo Comparator|placebo group|the operator will administer an off the shelf regular toothpaste in to the attachable mouthpiece and place it in the subject's mouth. At this point the operator will switch on the device but the RF will not be activated. After 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
11278977|NCT02841501||Candidemia patients|These patients are included in the study after the reception of a positive blood culture for Candida sp.
11278978|NCT02841501||Control patients|"These patients are matched on case patients on the following criteria:
~Age+/-5 years
~length of hospitalisation
~type of ward
~type of surgery for surgical patients
~IGS2 for intensive care patients"
11278979|NCT02841488|Active Comparator|Continuous nerve block|Continuous peripheral sciatic nerve block through popliteal perineural catheter with ropivacaine
11278980|NCT02841488|Active Comparator|Systemic analgesia|Intravenous fentanyl patient controlled analgesia device
11278981|NCT02841462|Experimental|Bursitis|Intra-bursal thermal ablation
11278982|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
11279123|NCT02840461|Placebo Comparator|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
11279124|NCT02840448||Case|Subjects with WS/SVAS
11278983|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
11278984|NCT02841436|Experimental|irreversible electroporation (IRE)|IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
11278985|NCT02841423|Experimental|INTRAVENOUS ANESTHESIA|neuropsychological test battery
11278986|NCT02841423|Experimental|CLOSED LOOP ANESTHESIA|neuropsychological test battery
11278987|NCT02841410|Other|Healthy Volunteer|
11278988|NCT02841384|Other|Group taping McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
11278989|NCT02841384|Other|Group placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
11278990|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
11278991|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
11278992|NCT02841358|Other|Psychiatric adults patients presenting psychologic disorders|
11278993|NCT02841345|Other|Bipolar|bipolar patients type I or II (DSM-IV TR), euthymic phase
11278994|NCT02841345|Other|Schizophrenic|schizophrenic loss or paranoid or undifferentiated patients
11278995|NCT02841345|Other|Control|control group (paired in age and sex for patients)
11278996|NCT02841332|Experimental|Patients with glioblastoma|"Patient with histologically proved glioblastoma diagnostic will receive the following interventions :
~Cerebral magnetic resonance imagery
~Tomography emission positron with F-MISO
~Bevacizumab administration
~Clinical examination"
11278997|NCT02841319|Experimental|Intervention|Virtual reality exercises using Hand Tutor for 8 weeks
11278998|NCT02841319|No Intervention|Control|Home exercises for 8 weeks
11278999|NCT02841306|Active Comparator|3-5 hours|Duration between oral UDCA intake and surgery of 3-5 hours.
11279000|NCT02841306|Active Comparator|6-8 hours|Duration between oral UDCA intake and surgery of 6-8 hours.
11279001|NCT02841306|Active Comparator|9-12 hours|Duration between oral UDCA intake and surgery of 9-12 hours.
11279002|NCT02841306|Active Comparator|> 12 hours|Duration between oral UDCA intake and surgery of >12 hours.
11279003|NCT02841306|No Intervention|Control|No medication
11279004|NCT02841293|Experimental|Arm with biological mesh|The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)
11279005|NCT02841293|Active Comparator|Arm with primary perineal wound closure|The intervention consists of perinal reconstruction by primary perineal wound closure
11279006|NCT02841280|Experimental|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
11279007|NCT02841280|Placebo Comparator|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
11279008|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
11279009|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
11279010|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
11279011|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
11279012|NCT02841228|Experimental|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
11279013|NCT02841215|Experimental|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
11279014|NCT02841215|Active Comparator|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
11279015|NCT02841202|Active Comparator|oral contraceptive pills group|healthy women using oral contraceptive pills for only contraception for more than one year was called OCP group
11279016|NCT02841202|No Intervention|control group|The second group was called control group consisting 20 healthy women and using no drug
11279017|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
11279018|NCT02841176|Experimental|Experimental|Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)
11279125|NCT02840448||Controls|Healthy Volunteers
11279383|NCT02838615|Active Comparator|epidural steroid injection|TF epidural steroid (dexamethasone) injection
11279019|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
11279020|NCT02841150|Experimental|Treatment Sequence 1|Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
11279021|NCT02841150|Experimental|Treatment Sequence 2|Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
11279022|NCT02841137|Experimental|progesterone 5 mg|progesterone 5 mg tablet
11279023|NCT02841137|Experimental|progesterone 10 mg|progesterone 10 mg tablet
11279024|NCT02841137|Experimental|progesterone 20 mg|progesterone 20 mg tablet
11279025|NCT02841137|Active Comparator|progesterone 100 mg|progesterone 100 mg capsule
11279026|NCT02841124|Other|Qualitative research|Semi-structured interviews
11279027|NCT02841098|Experimental|Carotid endarterectomy combined with optimal medical therapy|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
11279028|NCT02841098|Active Comparator|Optimal medical therapy (OMT)|Optimal medical therapy (OMT)
11279029|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
11279030|NCT02841059||Laparoscopic subtotal hysterectomy|women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.
11279031|NCT02841059||Laparoscopic CLSH|women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.
11279032|NCT02841059||Laparoscopic AVH|women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.
11279033|NCT02841046|Other|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
11279034|NCT02841046|Experimental|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
11279035|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
11279036|NCT02841020|No Intervention|Control SOC|Standard of care is followed
11279037|NCT02841020|Experimental|Experimental additional biopsy|Additional biopsy
11279038|NCT02841007|Experimental|geko device arm|Patients consenting to take part will receive the geko device prior to surgery to internally fixate their fractured ankle, to reduce and prevent oedema
11279039|NCT02840994|Experimental|CV301 + Pembrolizumab|CV301 + Pembrolizumab (Phase 1b portion of the trial)
11279040|NCT02840994|Experimental|CV301 + Nivolumab|CV301 + Nivolumab (Phase 1b portion of the trial)
11279041|NCT02840955|Active Comparator|Staphefekt SA.100|Staphefekt SA.100 cream, twice daily on (lesional) skin during 12 weeks
11279042|NCT02840955|Placebo Comparator|Placebo|Placebo (Gladskin cream without the Staphefekt protein), twice daily on (lesional) skin during 12 weeks
11279043|NCT02840942|No Intervention|Non-robot|Patients will interact with Child Life as per usual routine, no robot condition
11279044|NCT02840942|Experimental|Coping Robot|Robot will play coping game with children. Robot will speak and child will respond by touching tablet. Child life still present.
11279045|NCT02840942|Experimental|Non-coping Robot|Robot will play distraction only game, in addition to Child Life and routine cares
11279046|NCT02840929|Experimental|Second-look OGD group|"Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.
~OGD will be offered if signs of rebleeding present)"
11279047|NCT02840929|Active Comparator|Standard care group|Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present
11279048|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
11279049|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
11279050|NCT02840903||Setting 1 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
11279051|NCT02840903||Setting 2 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
11279052|NCT02840903||Setting 3 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
11279053|NCT02840903||Setting 4 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
11279054|NCT02840903||Setting 5 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
11279055|NCT02840903||Setting 6 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
11279056|NCT02840903||Setting 7 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
11279057|NCT02840903||Setting 8 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
11279058|NCT02840890|Experimental|experimental|Patients will have a visceral osteopathic technique perform with continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
11279059|NCT02840890|Placebo Comparator|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
11279060|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
11279061|NCT02840864|Experimental|Arm 1|Sonographically assisted breast surgery
11279062|NCT02840864|Active Comparator|Arm 2|Conventional breast surgery
11279063|NCT02840851||Healthy young women|Healthy young women between the age of 20-34 years.
11279064|NCT02840851||Healthy young men|Healthy young men between the age of 20-34 years.
11279065|NCT02840851||Healthy older women|Healthy older women between the age of 50-64 years.
11279066|NCT02840851||Healthy older men|Healthy older men between the age of 50-64 years.
11279067|NCT02840812|Experimental|Renal function impaired|Subject with Severe Impaired Renal Function. Nemonoxacin Malate Capsules 500mg single dose oral
11279068|NCT02840812|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
11279069|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
11279070|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.
~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
11279071|NCT02840786|Active Comparator|Intervention: Stents|Stents group
11279072|NCT02840786|Active Comparator|Intervention: Atherectomy|directional atherectomy group
11279073|NCT02840773|Active Comparator|Test group-baseline|Press-fit implant connection was monitored at baseline
11279074|NCT02840773|Active Comparator|Test group-12 month|Press-fit implant connection was monitored at 12 month after prosthesis delivered.
11279075|NCT02840773|Active Comparator|Control group-baseline|Screw-retained connection was monitored at baseline
11279076|NCT02840773|Active Comparator|Control group-12 month|Screw-retained connection was monitored at 12 month after prosthesis delivered.
11279077|NCT02840760|Active Comparator|tardive dyskinesia group|tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.
11279078|NCT02840760|No Intervention|Healthy control group|
11279079|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
11279080|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
11279081|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
11279082|NCT02840734|Experimental|Kinesio taping|All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
11279083|NCT02840734|Placebo Comparator|Placebo taping|Placebo tapes (3M tape) were applied with same method with Kinesio taping.
11279084|NCT02840734|No Intervention|No taping|In case of the no taping condition, the subject was treated along the same procedure which was closed subject's eyes with eye mask and covered the legs with clothes although applied anything on their legs. It might be able to minimize the error, because the researchers did not realize which condition the subject had.
11279085|NCT02840721|Experimental|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
11279086|NCT02840708|Active Comparator|125mcg|SK-1401 125mcg single inhalation
11279087|NCT02840708|Active Comparator|250mcg|SK-1401 250mcg single inhalation
11279088|NCT02840708|Active Comparator|500mcg|SK-1401 500mcg single inhalation
11279089|NCT02840695||AS patients|Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
11279090|NCT02840669|Other|Friedreich's Ataxia|
11279091|NCT02840669|Other|Healthy Volunteers (Controls)|
11279092|NCT02840656||healthy adult subject|oropharyngeal and rectal swabbing to collect Gram-negative bacilli
11279093|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
11279126|NCT02840435|Active Comparator|North Carolina Quit Line: Quit for Life|Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
11279127|NCT02840435|Experimental|Sit to Quit|Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
11279128|NCT02840409|Active Comparator|Arm A|68 weeks of single agent Vinblastine administered once weekly IV
11279094|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
11279095|NCT02840630|No Intervention|Non-diabetic group|Non-diabetic volunteers will be recruited for baseline data. They will only be required to provide dried blood samples (DBS) samples and information at week 0. They have to collect finger prick DBS, weigh themselves and fill in food frequency questionnaire only at one time point.
11279096|NCT02840630|No Intervention|Diabetic control intervention group|The diabetic control group will provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16. This group will not be receiving tinned mackerel and will be asked to continue with their habitual diet and lifestyle.
11279097|NCT02840630|Active Comparator|Diabetic fish intervention group|This intervention group will receive two 125 g portion of tinned mackerel fish (containing 7.8 g n-3 LCPUFA) per week from week 0 until 16 and a mackerel recipe book each. They will be required to provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16.
11279098|NCT02840617|Experimental|ICG injection group|ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
11279099|NCT02840604||patient with all types of solid malignant tumors not treatable|In the treatment or assessment of metastatic solid tumor malignancies not curable it can be offered to patients to establish the profile of their tumor by next generation sequencing (NGS). This technique permits the sequencing of millions of fragments in parallel in a short time and allows to identify rapidly somatic or constitutional mutations known or yet unknown. The establishment of the genetic profile of the tumor coupled to the available clinical data can help clinicians to predict patient outcome in terms of survival or progression to disease, but may also provide key clues to adapt the management and patient treatment.
11279100|NCT02840591|Experimental|Drug Treatment|"First 5 consecutive subjects: Ramelteon 8 mg daily at 8 pm for 5 days
~Next 5 consecutive subjects: Citicoline 250 mg daily at 8 pm for 2 days, followed by citicoline 500 mg daily at 8 pm for 3 days
~All subjects: Standard medical care"
11279101|NCT02840591|No Intervention|Observation-Only|Standard medical care
11279102|NCT02840565|Experimental|BIA 5-453 25 mg or placebo|Multiple oral doses of BIA 5-453 25 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
11279103|NCT02840565|Experimental|BIA 5-453 50 mg or placebo|Multiple oral doses of BIA 5-453 50 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
11279104|NCT02840565|Experimental|BIA 5-453 100 mg or placebo|Multiple oral doses of BIA 5-453 100 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
11279105|NCT02840565|Experimental|BIA 5-453 200 mg or placebo|Multiple oral doses of BIA 5-453 200 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
11279106|NCT02840565|Experimental|BIA 5-453 400 mg or placebo|Multiple oral doses of BIA 5-453 400 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
11279107|NCT02840565|Experimental|BIA 5-453 600 mg or placebo|Multiple oral doses of BIA 5-453 600 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
11279108|NCT02840552|Experimental|FCH-PET/CT|18F-Fluoromethylcholine (18F-FCH) PET/CT
11279109|NCT02840539|Experimental|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
11279110|NCT02840526|Experimental|PVB group|Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
11279111|NCT02840526|Other|GEN group|Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
11279112|NCT02840513|Experimental|Smartphone app/CO self-monitoring|The app offers a coaching function where users receive personalized messages to encourage smoking cessation and advice for behavioural changes. For the first 4 weeks of the intervention, individuals will also be asked to blow daily into a breath carbon monoxide monitor before going to sleep. Depending on the results of the breath test, individualized messages will be delivered by the Smokelyzer feedback app to either enhance maintenance of abstinence or increase the motivation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at least twice a week until the end of the 6-month study. The app will react with positive feedback in individuals doing well with smoking cessation and messages to encourage individuals with difficulties quitting to smoke.
11279113|NCT02840513|No Intervention|Control|Participants in the control group will be managed according to usual care as regularly provided by their SHCS physicians. Physicians will motivate patients to quit, emphasise the advantage of quitting, and provide patients with an information card that contains short advices how to quit and addresses of stop smoking clinics. The Swiss HIV Cohort Study study nurse will enter past or current use as well as of nicotine replacement therapy or use of other pharmaceutical support to quit smoking in the online study form
11279114|NCT02840500||Breakthrough Cancer Pain|No intervention (Non-interventional study)
11279115|NCT02840487|Experimental|Group 1|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
11279116|NCT02840487|Experimental|Group 2|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
11279117|NCT02840487|Experimental|Group 3|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
11279118|NCT02840487|Experimental|Group 4|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
11279119|NCT02840474|Experimental|Part A|40 mg/kg IV
11279120|NCT02840474|Experimental|Part B|40 mg/kg IV
11279121|NCT02840461|Experimental|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
11279122|NCT02840461|Active Comparator|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
11279129|NCT02840409|Experimental|Arm B|68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
11279130|NCT02840396|Experimental|rTMS|
11279131|NCT02840396|Sham Comparator|Sham rTMS|
11279132|NCT02840383|Active Comparator|Delayed Intervention|Schools not receiving intervention until two years after implementation.
11279133|NCT02840383|Experimental|Intervention|Schools receiving intervention at the beginning of study.
11279134|NCT02840370|Experimental|transcranial direct current stimulation|tDCS
11279135|NCT02840370|Sham Comparator|Sham tDCS|S-tDCS
11279136|NCT02840357|Experimental|Treatment Group|Purple Wheat Convenience Bars The treatment group will consume 4 servings /day of bran-enriched purple wheat convenience bars (40g/ serving)
11279137|NCT02840357|Placebo Comparator|Control Group|Control Wheat Convenience Bars The control group will consume 4 servings /day of bran-enriched ordinary wheat convenience basr (40g/ serving)
11279138|NCT02840344|Experimental|Couples MBSR|"Young breast cancer survivors and their partners take part in an 8-week Couples Mindfulness-Based Stress reduction (C-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor and partner will be asked to watch a video module, together, each week for a total of 8 weeks. The C-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.
~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
11279139|NCT02840344|Active Comparator|Individual MBSR|"Young breast cancer survivors take part in an 8-week Individual Mindfulness-Based Stress reduction (I-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor will be asked to watch a video module each week for 8 weeks in a row. The I-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.
~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
11279140|NCT02840331|Experimental|St. John's Wort & PDD, PDT|St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
11279141|NCT02840318|Experimental|Compassion Intervention|Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
11279142|NCT02840305|Other|Expérience 1|Brain bases of spatial frequencies treatment 30 young adults, 20 old adults 20 children between 4 and 6 years, 20 children between 6 and 12 years and 20 young adults
11279143|NCT02840305|Other|Expérience 2|Brain bases of Computer to Film (CtF) analysis 30 young adults, 20 old adults
11279144|NCT02840305|Other|Expérience 3|Part of parahippocampal gyrus in Computer to Film (CtF) analysis 30 young adults, 20 old adults.
11279145|NCT02840292||Cases|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal hemoglobin < 11gm/dl
11279146|NCT02840292||Controls|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal haemoglobin ≥ 11gm/dl
11279147|NCT02840279|Experimental|BPN14770|An oral dose of BPN14770
11279148|NCT02840279|Placebo Comparator|Placebo|An oral dose of placebo matching BPN14770
11279149|NCT02840253|Experimental|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
11279150|NCT02840240|Experimental|Gabapentin enacarbil|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
11279151|NCT02840240|Placebo Comparator|Placebo|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days
11279152|NCT02840227|Experimental|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
11279153|NCT02840227|Experimental|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
11279154|NCT02840214|Active Comparator|tDCS rescue group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
11279155|NCT02840214|Placebo Comparator|Sham Treatment Group|Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
11279156|NCT02840214|Active Comparator|tDCS prevent group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
11279157|NCT02840188||Radius tilt angle|Children 0-16 years of age positive for distal forearm fracture and positive history of goalkeeper's fracture (to catch a ball).
11279158|NCT02840188||Normal control group|Children 0-16 years of age without radius fracture and no history of catching a ball.
11279159|NCT02840175|Experimental|Experimental|"Day 0 at Weeks 24 : Increase the interval between 2 doses of the biological agent (etanercept, adalimumab, tocilizumab, abatacept)
~Weeks 24 at Weeks 72: Stop the biological agent if inactive disease is maintained."
11279384|NCT02838615|Active Comparator|IL epidural steroid injection|PS interlaminar epidural steroid(dexamethasone) injection
11279160|NCT02840175|Active Comparator|Control|"Day 0 at Weeks 24: Maintain the biological agent (etanercept, adalimumab, tocilizumab, abatacept) at the same dose.
~Weeks 24 at Weeks 48 : Increase the interval between 2 doses of the biological agent.
~Weeks 48 at Weeks 72: Stop the biological agent if inactive disease is maintained."
11279161|NCT02840162|Active Comparator|Celecoxib|Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
11279162|NCT02840162|Placebo Comparator|Placebo|Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth
11279163|NCT02840149|Other|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients
11279164|NCT02840136|Experimental|Standard of care|Sputum is collected from patients receiving standard of care therapy with IV piperacillin-tazobactam, ceftazidime or meropenem
11279165|NCT02840123|Experimental|Autologous dendritic cells|
11279166|NCT02840110||Post-ACTR|Subjects who have previously been treated with an ACTR T cell product
11279167|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
11279168|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
11279169|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
11279170|NCT02840084|Experimental|Treatment Patients|In stage I, 10 women aged 22 years or older who have received silicone or saline breast implants for subglandular or submuscular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.
11279171|NCT02840071|Experimental|Intervention|Psychological therapy.
11279172|NCT02840058|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.
~Peripheral blood mononuclear cells (PBMC) and plasma will be collected.
~Available tumor tissues will be collected."
11279173|NCT02840045|Experimental|Alzheimer patients|Cerebral measurements from high-density electroencephalography are recorded in Alzheimer patients. The same protocol is applied in the 3 arms
11279174|NCT02840045|Experimental|patients with a depressive disorder|Cerebral measurements from high-density electroencephalography are recorded in patients with a depressive disorder. The same protocol is applied in the 3 arms
11279175|NCT02840045|Active Comparator|Healthy controls|Cerebral measurements from high-density electroencephalography are recorded in healthy controls
11279176|NCT02840019|Experimental|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.
~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
11279177|NCT02840019|Experimental|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.
~The research MRI sequences will also be tested during the add-on research MRI scan."
11279178|NCT02840006|Active Comparator|General anesthesia only|Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1
11279179|NCT02840006|Active Comparator|General anesthesia associated spinal anesthesia|spinal anesthesia using bupivacaine 0,5% hyperbaric 20 mg, morphine 200 mcg, set trendeleburg for 10 minutes, sensitive test in T1. Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1.
11279180|NCT02839993|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
11279181|NCT02839993|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
11279182|NCT02839980||orthopedics (gr1) surgery|parient admitted to the orthopedics (gr1) surgery ward for an elective or semi-emergent surgical procedure.
11279183|NCT02839980||thoracic (gr2) surgery|parient admitted to the thoracic (gr2) surgery ward for an elective or semi-emergent surgical procedure.
11279184|NCT02839980||abdominal (gr3) surgery|parient admitted to the abdominal (gr3) surgery ward for an elective or semi-emergent surgical procedure.
11279185|NCT02839980||ICU (gr4)|patients admitted to the ICU with an antcipated length of stay of 3 days or more
11279186|NCT02839967|Experimental|Photobiomodulation group|For the purposes of photobiomodulation is used a portable cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), and 1 905 nm diode LASER, 4 875 nm LED diodes and 4 670 nm diodes LED, 4 cm2 beam, emitting an energy of 39.27 J.
11279187|NCT02839967|Placebo Comparator|Photobiomodulation placebo group|"To provide the blinding of the participants of the study we will use two identical photobiomodulation equipment supplied by the manufacturer, being an active and another a placebo, but both have identical light and sound device (do not send energy and heat, non-coherent light without biological effect). The devices are named in X and Y for a researcher who does not participate in treatment and assessments."
11279188|NCT02839954|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
11279189|NCT02839941|Experimental|experiment|
11279190|NCT02839941|Sham Comparator|Control|
11279191|NCT02839928|Experimental|Treatment|The experimental arm consists of children given intranasal Ketamine 1 mg/kg, once
11279243|NCT02839538|Active Comparator|local Infiltration|"Induction of General Anesthesia with Propofol(2mg/Kg) and Atracurium(0,5mg/Kg) . Pulmonary ventilation with laryngeal mask and Propofol infusion ( 100mcg/Kg/min.) After , Infiltration of 0.75% ropivacaine (10 ml) each side block injection of local anesthetic at perianal.
~If necessary, fentanyl endovenous injection (50 mcg)."
11279192|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take one capsule, twice a day. Once in the morning and once in the evening (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start with 10 mg capsule once a day for Days1-13). Dosing will start at 10-20 mg/day, based on subject's weight, and increase to 30-50 mg/day over four weeks. Primary caregiver will be contacted by telephone on Weeks 2, 6 and 10. Follow up visits at Weeks 4, 8 and 12 (end of Double-blind phase). After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
11279193|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take one capsule, twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start with capsule once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. Primary caregiver will be contacted by telephone on Weeks 2, 6 and 10. Follow up visits at Weeks 4, 8 and 12 (end of Double-blind phase). After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
11279194|NCT02839902|Experimental|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
11279195|NCT02839902|Experimental|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
11279196|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
11279197|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
11279198|NCT02839876|Experimental|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
11279199|NCT02839876|Active Comparator|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
11279200|NCT02839850|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty
11279201|NCT02839837|Experimental|Depressed and non-depressed controls|All participants will participate in three different conditions: Low intensity aerobic exercise and paired associative stimulation, high intensity aerobic exercise and paired associative stimulation, no exercise control and paired associative stimulation. The order of conditions will be randomized.
11279202|NCT02839811|Experimental|immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
11279203|NCT02839798|Experimental|sTMS active|Treatment with the NEST Device
11279204|NCT02839785|Experimental|Ibuprofen|Active ibuprofen
11279205|NCT02839785|Placebo Comparator|Placebo|Placebo of ibuprofen
11279206|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
11279207|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
11279208|NCT02839759|Experimental|TELLYHealth Group|Subjects will receive the standard of care in hearing aid education and the TELLYHealth intervention for use over an 8 to12-week period and will be followed by their audiologist for 8 to 12 weeks.
11279209|NCT02839759|No Intervention|Standard of Care Group|Subjects will receive the standard of care in hearing aid education and will be followed by their audiologist for 8 to 12 weeks.
11279210|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
11279211|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
11279212|NCT02839733||Healthy Volunteers|Children and young adults healthy volunteer
11279213|NCT02839720|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
11279214|NCT02839707|Experimental|Arm I (PLD, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15.
11279215|NCT02839707|Experimental|Arm II (PLD, bevacizumab, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15.
11279216|NCT02839707|Active Comparator|Arm III (PLD, bevacizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15.
11279217|NCT02839694|Experimental|Dose escalation cohort|dose escalation cohort
11279218|NCT02839694|Experimental|Expansion cohort|expansion cohort at MTD
11279219|NCT02839694|Active Comparator|expansion cohort with celecoxib|expansion cohort at MTD with celecoxib
11279220|NCT02839681|Experimental|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
11279221|NCT02839681|Experimental|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansine at the recommended phase 2 dose (dose level 1 if no more than 1 dose limiting toxicity (DLT) occurred in the safety run-in arm, or at dose level -1 otherwise)
11279222|NCT02839668|Experimental|Sevoflurane|The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
11279244|NCT02839538|Other|Subarachnoidal block|"Sedation with midazolam 2 mg. After , Spinal block with 10 mg of hyperbaric 0.5% bupivacaine. Injection of anesthetic at subarachnoidal space with Quincke needle 27G.
~If pain, local infiltration with lidocaine 1% (5 ml) in wound."
11279223|NCT02839668|Active Comparator|Sevoflurane+Lidocaine|The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
11279224|NCT02839668|Experimental|TIVA-TCI|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.
11279225|NCT02839668|Active Comparator|TIVA-TCI+lidocaine|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.
11279226|NCT02839655|Experimental|Da Vinci Xi|
11279227|NCT02839642|Active Comparator|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.
~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
11279228|NCT02839642|Placebo Comparator|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
11279229|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
11279230|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
11279231|NCT02839590||HiFu (ultrasound)|Manufacturer Name Eyehope Principle intended use Surgical treatment of uncontrolled glaucoma and OHT The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study.
11279232|NCT02839590||Baerveldt implant|"Manufacturer Name Abbott Medical Optics Inc., Abbott Laboratories Inc., Abbott Park, Illinois, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
11279233|NCT02839590||Ahmed Implant|"Manufacturer Name New World Medical, Inc., 10763 Edison Court, Rancho Cucamonga, CA 91730, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
11279234|NCT02839590||STARflo|"Manufacturer Name iSTAR Medical SA, Parc Créalys, Rue Phocas Lejeune, Bâtiment Regain 25/3, 5032 Isnes, Belgium.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
11279235|NCT02839590||Hydrus Microstent implant|"Manufacturer Name Ivantis, Inc., 38 Discovery, Suite 150, Irvine, CA 92618, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
11279236|NCT02839590||iStent implant|"Manufacturer Name Glaukos Corporation, 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, USA.
~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT
~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
11279237|NCT02839590||Kahook Dual Blade|Manufacturer: New World Medical. Inc. Single use, ophthalmic blade Utilizes ab interno approach through a clear cornea micro incision Dual blades positioned for precise parallel incisions of the trabecular meshwork with minimal residual leaflets Maintains natural physiologic outflow pathways
11279238|NCT02839577|Active Comparator|High Volume injection (HVI) with corticosteroid|"10 mls 0.5% bupivacaine hydrochloride
~20 mg of Depomedrol (40 mg/ml methylprednisolonacetat)
~40 mls saline (NaCl)
~HVI with corticosteroid is injected one time at baseline and compared to HVI without corticosteroid."
11279239|NCT02839577|Active Comparator|High Volume injection (HVI) without corticosteroid|"10 mls 0.5% bupivacaine hydrochloride
~40 mls saline (NaCl)
~HVI with corticosteroid is injected one time at baseline and compared to HVI with corticosteroid."
11279240|NCT02839564|Experimental|Adhesiolysis group|Patients underwent laparoscopic adhesiolysis
11279241|NCT02839564|Placebo Comparator|Placebo group|Patients underwent diagnostic laparoscopy alone
11279242|NCT02839551|Experimental|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
11279245|NCT02839525|Placebo Comparator|Omega 3|"3000mg of olive oil
~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
11279246|NCT02839525|Placebo Comparator|Isolate whey protein|"23g of maltodextrin
~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
11279247|NCT02839525|Placebo Comparator|Omega 3 and Isolate whey protein|"3000mg of olive oil and 23g of maltodextrin
~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
11279248|NCT02839512|Experimental|Jejunal to Ileal Diversion|All subjects who receive jejunal to ileal diversion endoscopic procedure
11279249|NCT02839499|Experimental|mixed food|experimental group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
11279250|NCT02839499|Other|normal texture food|control group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
11279251|NCT02839486||vancomycin and cefoxitin pharmacokinetics|This is surgical prophylaxis and cefoxitin/vancomycin have to be administered to each patient of the study, before surgery
11279252|NCT02839473|Experimental|Hydrosorb® arm|Hydrogel Hydrosorb®
11279253|NCT02839473|Placebo Comparator|Placebo arm|Castalie water spray
11279254|NCT02839460||subjects with sarcopenia|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)
~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)
~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
11279255|NCT02839460||healthy, physically-active controls|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)
~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)
~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
11279256|NCT02839447||Normal Semen|"Semen that meet the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
11279257|NCT02839447||Abnormal Semen|"Semen that fail to achieve one or more of the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
11279258|NCT02839434||Treated with oral anticoagulants|Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.
11279259|NCT02839421|Experimental|Scaling and Root Planing plus moxifloxacin|The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.The experimental treatment group consist of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days.One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the MOX group will be extensively informed about the intake of the prescribed medication.
11279260|NCT02839421|Active Comparator|Scaling and Root Planing plus amox-metro|"The active comparator is Scaling and Root Planing (SRP) combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days. The active comparator group consist of SRP combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days.
~One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the amox-metro group will be extensively informed about the intake of the prescribed medication."
11279261|NCT02839421|Placebo Comparator|Scaling and Root Planing plus placebo|Scaling and Root Planing (SRP) + placebo once daily for 7 days. The placebo comparator group consist of SRP combined with systemically administered placebo once daily for 7 days. One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The placebo agent will start at the SRP visit. Subjects in the placebo group will be extensively informed about the intake of the prescribed medication.
11279262|NCT02839408|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
11279263|NCT02839408|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months.
11279264|NCT02839408|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500mg Azithromycin
11279265|NCT02839395|Active Comparator|base line|First night is the base line- no exposure to computer screen illumination.
11279266|NCT02839395|Experimental|Acute|Second night is the acute exposure to computer screen illumination.
11279267|NCT02839395|Experimental|Chronic|Chronic is the effect after five nights of exposure to computer screen light illumination.
11279268|NCT02839382|Active Comparator|Coaching|External facilitation by a practice coach for 15 months
11279269|NCT02839382|Active Comparator|Educational Outreach|Academic detailing phone calls to support implementation of a cardiovascular risk calculator/estimator in each clinic
11279270|NCT02839382|Active Comparator|Site Visit|"Site visits made by practices to 'exemplar practices to learn innovative approaches to quality improvement"
11279271|NCT02839382|Active Comparator|Educational Outreach and Site Visit|In this arm of the study, practices will be offered both educational outreach and an opportunity for a site visit
11279272|NCT02839369||children|post Traumatic Brain Injury With Cerebral Palsy Typically developed
11279273|NCT02839356|Experimental|Drug: epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
11279274|NCT02839356|Placebo Comparator|Drug: normal saline|20-mL irrigation with physiological saline over the entire papilla
11279275|NCT02839343|Experimental|mFOLFIRINOX + surgery + FOLFOX|Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
11279276|NCT02839343|Experimental|mFOLFIRINOX + radiation + surgery + FOLFOX|Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.
11279277|NCT02839330|Experimental|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
11279278|NCT02839330|Experimental|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
11279279|NCT02839330|Experimental|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
11279280|NCT02839330|Placebo Comparator|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
11279281|NCT02839317||Biological in pediatric CD|75 pediatric-onset CD Biological
11279282|NCT02839317||Biological in pediatric controls|75 pediatric controls matched on gender, age and area of residence Biological
11279283|NCT02839317||Biological in elderly CD|75 elderly-onset CD Biological
11279284|NCT02839317||Biological in elderly controls|75 elderly controls matched on gender, age and area of residence Biological
11279285|NCT02839304|Experimental|Catheter Ablation Treatment|Cryoablation System: Atrial Fibrillation Ablation
11279286|NCT02839291|Experimental|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
11279287|NCT02839278|Experimental|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
11279288|NCT02839265|Experimental|SBRT + FLT3 Ligand Immunotherapy|"Patients will be treated with stereotactic body radiotherapy (SBRT) to a single pulmonary or extrapulmonary lesion as well as FLT3 immunotherapy.
~FLT3 Ligand Therapy (CDX-301)
~Daily subcutaneous injections of CDX-301 (75 ug/kg) will be administered for 5 days, beginning on the first day of SBRT.
~Additional cycles of SBRT (to distinct lesions) and CDX-301 may be administered every 2-4 months to subjects who demonstrate evidence of clinical benefit (lack of treatment-related toxicity and no disease progression).
~Study therapy will be discontinued in cases of treatment-related toxicity or disease progression."
11279289|NCT02839252|Experimental|Intervention Group|After the baseline tools have been completed, the child will be given the Iggy Comic Book and trading cards. Parents and their children will then watch a 12-minute Iggy Video. At the completion of the video and prior to going home, the child and parent will complete the same 2 measures on asthma knowledge and self-efficacy. At 1-month after this clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
11279290|NCT02839252|No Intervention|Control Group|After the baseline tools have been completed, the parent and child will go home. At 1-month after the initial study clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
11279291|NCT02839239|Experimental|Drops with lactobacilli and vitamin D3|Exclusive breast feeding plus L. rhamnosus 19070-2 and L. reuteri DSM 12246 in a dose of 125 x 106 CFU (both strains) with 1,667 mg fructooligosaccharides and 2,5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
11279292|NCT02839239|Placebo Comparator|Drops with vitamin D3|Exclusive breast feeding plus 2.5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
11279293|NCT02839226|Active Comparator|AR/101|AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
11279294|NCT02839226|Placebo Comparator|Placebo|placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
11279295|NCT02839213|Active Comparator|group A (Hyoscine Butyl bromide group)|The women will be given Hyoscine Butyl bromide
11279296|NCT02839213|Active Comparator|group B (Saline group)|The women will be given saline
11279297|NCT02839200|Experimental|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
11279298|NCT02839200|Experimental|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
11279299|NCT02839200|Experimental|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
11279300|NCT02839200|Experimental|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
11279301|NCT02839200|Active Comparator|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
11279302|NCT02839200|Placebo Comparator|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
11279303|NCT02839187|Experimental|Patients with Alzheimer Disease|Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography
11279304|NCT02839187|Active Comparator|Controls patients|Controls will have neuroimaging by AV45-positron emission tomography
11279305|NCT02839161|Experimental|Low-dose (0,2,4 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
11279381|NCT02838654||cervical epidural injection group|cervical epidural injection group
11279382|NCT02838628|Experimental|KX2-391 Ointment|
11279306|NCT02839161|Experimental|Low-dose (0,2,6 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
11279307|NCT02839161|Experimental|Medium-dose (0,2,4 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
11279308|NCT02839161|Experimental|Medium-dose (0,2,6 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
11279309|NCT02839161|Experimental|High-dose (0,2,4 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
11279310|NCT02839161|Experimental|High-dose (0,2,6 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
11279311|NCT02839161|Active Comparator|Comparator (0,2,4 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
11279312|NCT02839161|Active Comparator|Comparator (0,2,6 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.
11279313|NCT02839148|Experimental|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
11279314|NCT02839148|Experimental|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
11279315|NCT02839135|Experimental|Reformulated scopolamine patch|Participants will receive reformulated scopolamine Transdermal Delivery System (TDS) patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
11279316|NCT02839135|Active Comparator|Marketed scopolamine patch|Participants will receive currently marketed scopolamine TDS patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area, with delivery of approximately 1.0 mg over 72 hours.
11279317|NCT02839122|Experimental|Dutasteride, Tadalafil|
11279318|NCT02839122|Experimental|Tadalafil, Dutasteride|
11279319|NCT02839096|Other|Once Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and placebo in the evening
11279320|NCT02839096|Other|Twice Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and 325mg of ferrous sulfate in the evening
11279321|NCT02839083|Placebo Comparator|Thoracic Paravertebral group|Ultrasound guided thoracic paravertebral block
11279322|NCT02839083|Active Comparator|Pecs II group|Ultrasound guided Pecs II block
11279323|NCT02839070|Experimental|Regular Schedule|Participant will be on a regular sleep/wake schedule
11279324|NCT02839070|Experimental|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
11279325|NCT02839057||Surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated with surgical fracture stabilisation
11279326|NCT02839057||Non-surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated non-surgically
11279327|NCT02839044|Experimental|Vitamin K|One group receives tablets of 360 microgram menaquinone-7 daily
11279328|NCT02839044|Placebo Comparator|Placebo|One group receives placebo tablets daily
11279329|NCT02839031|Experimental|"CBT group"|
11279330|NCT02839031|Sham Comparator|Control group|
11279331|NCT02839018||Central nervous system (CNS) group|n=50 patients with presumed low prevalence of ICU-AW
11279332|NCT02839018||Severe sepsis/shock group|n=50 patients with presumed high prevalence of ICU-AW
11279333|NCT02839005|Active Comparator|suture with polyglecaprone 25|
11279334|NCT02839005|Active Comparator|suture with polyamide (nylon)|
11279335|NCT02838992|Experimental|ATG, Cy and cord blood transfusion group|"ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.
~Intervention:
~Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion"
11279336|NCT02838992|Active Comparator|ATG and CSA group|ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA
11279337|NCT02838979|Experimental|Oral L-Glutamine (0.4mg/kg/day)|Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses. Duration 2 weeks
11279338|NCT02838979|Placebo Comparator|Maltodextrin|Identical appearing maltodextrin powder.
11279339|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 1|1 can per day for 5 days prior to surgery
11279340|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 2|2 cans per day for 5 days prior to surgery
11279341|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 3|3 cans per day for 5 days prior to surgery
11279342|NCT02838966|Active Comparator|Nestle Boost High Protein Drink - Control Arm|4 cans per day for 5 days prior to surgery
11279343|NCT02838953|Experimental|COPD patients|COPD patients submitted to Pulmonary Rehabilitation according to the ATS/ERS statement.
11279344|NCT02838953|No Intervention|Control|"Healthy individuals who will undergo the same COPD's evaluation protocol. As healthy individuals they will not participate to the Pulmonary Rehabilitation."
11279345|NCT02838940|Experimental|cesarean in different indications|Women that are about to undergo an elective cesarean in different indications.
11279346|NCT02838927||Hypoparathyroidism|No intervention.
11279347|NCT02838914|Experimental|patients with AF|Before radiofrequency ablation (RFCA)
11279348|NCT02838914|Experimental|Assigned Comparisons|After radiofrequency ablation (RFCA)
11279349|NCT02838901|Experimental|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
11279350|NCT02838901|Placebo Comparator|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
11279351|NCT02838888||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
11279352|NCT02838875|Experimental|Pregnant women at risk population|women who arrived to the delivery room at Lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because of their affiliation to the at-risk population.
11279353|NCT02838862||Response to Therapy|
11279354|NCT02838862||No therapy response|
11279355|NCT02838849|Sham Comparator|Fiber|Participants were treated with 2 sachets of fiber orally a day for 14 days, after baseline characterization of bowel habit and stool features.
11279356|NCT02838849|Active Comparator|Fiber and Water|Participants were treated with 2 sachets of fiber orally a day and ingested 2 liters of water a day for 14 days, after baseline characterization of bowel habit and stool features.
11279357|NCT02838836||Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
11279358|NCT02838823|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
11279359|NCT02838810|Experimental|Experimental|CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1000 IU/mL and Hepatitis B virus DNA <100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
11279360|NCT02838810|Other|Control|Patients do not need to change their NAs treatment.
11279361|NCT02838797|Placebo Comparator|Placebo|"For the single ascending dose study, subjects will receive a single dose of oral acetate buffer on a single day.
~For the multiple ascending dose study, subjects will receive a single daily dose of oral acetate buffer each day for 14 days."
11279362|NCT02838797|Experimental|RQ-00000010|"For the single ascending dose study, subjects will receive a single dose of either:
~2 micrograms, 50 micrograms or 200 micrograms of RQ-00000010 on a single day.
~For the multiple ascending dose study, subjects will receive single daily doses of either 10 micrograms, 50 micrograms or 100 vs. 200 micrograms of RQ-00000010 each day for 14 days."
11279363|NCT02838784|Experimental|Artacent Human Amniotic Membrane|Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
11279364|NCT02838784|Active Comparator|Lower Extremity Ulcer Standard of Care|Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
11279365|NCT02838771|Experimental|Research group participants|"Research group consisted of 171 elderly nursing home residents and 82 outpatients of the Hospital of Lithuanian University of Health Sciences.
~The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening)."
11279366|NCT02838771|Other|Control group participants|Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
11279367|NCT02838758|Experimental|Cryoablation|Ultrasound guided perineural cryoablation. The mechanism of therapeutic cryoablation involves using short and repeated cycles of freezing and thawing to cause axonal degeneration and disrupt neuronal activity without damage to epineurium and perineurium.
11279368|NCT02838758|Active Comparator|Lidocaine|Ultrasound guided perineural lidocaine injection. Under ultrasound guidance, roughly 3cc of 2% lidocaine will be injected near the neuroma.
11279369|NCT02838758|Placebo Comparator|Saline|Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
11279370|NCT02838745|Experimental|Pemetrexed and Cisplatin|• Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
11279371|NCT02838732|Experimental|vegetarian|oral L-carnitine for one month
11279372|NCT02838732|Sham Comparator|omnivore|oral L-carnitine for one month
11279373|NCT02838719|Experimental|Perineural group|Group 1: perineural dexamethasone acetate added to bilateral transverse abdominis plane block with levobupivacaine
11279374|NCT02838719|Active Comparator|Intravenous group|Group 2: Intravenous dexamethasone acetate added with bilateral transverse abdominal plane block with levobupivacaine
11279375|NCT02838706||Elderly with hip fracture|The subjects are patients age ≥ 65 years requiring surgery for a hip fracture
11279376|NCT02838693||APT-2D (Normoglycemic)|800 Normoglycemic
11279377|NCT02838693||APT-2D (Pre-Diabetic)|1,500 Pre-Diabetic
11279378|NCT02838680|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
11279379|NCT02838667|No Intervention|Standard of Care|If participants are randomized into the non-intervention group, the participants' information during the study period will be collected. Participants will be managed by a care provider as per the standard of care. Participants may receive nephrology consultation as indicated clinically.
11279380|NCT02838667|Experimental|Standard of Care plus Nephrology Care|If participants are randomized into the intervention group, participants' information will be checked by the study investigators daily for 7 days (2 days pre-op and 5 days post-op). When appropriate, investigators may give suggestions to minimize the participants' risk(s) for AKI. Participant's primary care providers may take the suggestions into consideration. Participants' primary care providers are not obligated to carry out the suggestions that are given.
11279386|NCT02838602|Active Comparator|Conventional radiotherapy|Radical radiotherapy by Xrays and / or protons
11279387|NCT02838589|Active Comparator|Byetta|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
11279388|NCT02838589|Placebo Comparator|Isotonic saline|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
11279389|NCT02838576|Experimental|Conjugated Equine Estrogen|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.
~The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.
~During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug."
11279390|NCT02838576|Placebo Comparator|Placebo|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.
~The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.
~During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo."
11279391|NCT02838563||Patient living in nursing home|Patient with an Alzheimer Disease or related disorder living in nursing home.
11279392|NCT02838550|Experimental|MOI and PEDOMETER|Accessing to a motivational online intervention and wearing an unblinded pedometer (in order to receive feedback of the steps taken).
11279393|NCT02838550|Experimental|MOI (without PEDOMETER)|Accessing to a motivational online intervention and wearing a blinded pedometer (in order to not receive feedback of the steps taken).
11279394|NCT02838550|No Intervention|CONTROL|Wearing a blinded pedometer (in order to not receive feedback of the steps taken).
11279395|NCT02838537||Triptan Arm|"Users of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
11279396|NCT02838537||Ergot Arm|"Users of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
11279397|NCT02838511||Non-cardiac surgery|Hopkins Frailty Score (HFS) or Modified Frailty Index (MFI) will be obtained during during pre anesthesia evaluation
11279398|NCT02838498|Experimental|Intensive EMS training group|"Device: ERCP mechanical simulator training EMS group was coached (by JWL) on how to use the EMS, and then practiced with supervision by a senior surgeon biliary endoscopist (WBM). Trainees practiced for a total of 20 hours performing basic maneuvers including scope insertion 2 hours, scope positioning 6 hours, selective guide wire cannulation of common bile duct (CBD) stricture or pancreatic duct (PD) 10 hours and placement of a biliary stent 2 hours.
~All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over."
11279399|NCT02838498|No Intervention|Routine ERCP training group|Other: Routine ERCP training group All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over.
11279400|NCT02838485|Experimental|Amputees|The subjects will receive both mirror and imagery treatments in a cross-over design.
11279401|NCT02838446|Experimental|Cognitive Therapy|Graded motor imagery program was applied in only intervention group for 8 weeks.
11279402|NCT02838446|Active Comparator|Control|Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
11279403|NCT02838433|Experimental|Biological samples|"Blood samples will be collected :
~at baseline,
~6 months after the first-line therapy or at disease progression (if occurs first).
~In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected :
~at baseline
~3 months after the initiation of immunotherapy or targeted therapy
~at disease progression Tumor tissues will be collected if available."
11279404|NCT02838420|Experimental|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
11279405|NCT02838420|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
11279406|NCT02838407|Other|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
11279407|NCT02838394|Experimental|Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
11279408|NCT02838394|Sham Comparator|Sham Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.
11279409|NCT02838381|Other|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.
~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
11279500|NCT02837770|Active Comparator|Oral Diclofenac and Diclofenac Eye Drops|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
11279410|NCT02838355|Active Comparator|Standard Respiration Monitoring|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring throughout their stay in the ICU.
11279411|NCT02838355|Experimental|Standard Respiration Monitoring + Continuous ETCO2-NC|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring and continuous end-tidal capnography monitoring via nasal cannula (ETCO2-NC) throughout their stay in the ICU.
11279412|NCT02838342|Experimental|Metronomic cyclophosphamide and interferon-alpha|
11279413|NCT02838329|Active Comparator|room temperature - RT|Ropivacaine used for Epidural top-up administered at room temperature
11279414|NCT02838329|Experimental|body temperature BT|Ropivacaine used for Epidural top-up administered warmed to body temperature
11279415|NCT02838316|Experimental|150 x 106 dosage|10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR
11279416|NCT02838316|Experimental|300 x 106 dosage|10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR
11279417|NCT02838303|Other|Group A|Initial spray session: organophosphate. Crossover spray session: placebo
11279418|NCT02838303|Other|Group B|Initial spray session: placebo. Crossover spray session: organophosphate
11279419|NCT02838290|Experimental|Induction|
11279420|NCT02838290|Other|Control group|
11279421|NCT02838277||Lipedema|Women with all stages of lipedema
11279422|NCT02838277||Dercum's disease|Men and women with nodular, mixed and diffuse Dercum's disease
11279423|NCT02838277||Control|Sex, age and BMI matched controls.
11279424|NCT02838277||Familial Multiple Lipomatosis|Women and men with multiple lipomas and/or angiolipomas
11279425|NCT02838277||Madelung's disease|Men and women with different types of Madelung's disease.
11279426|NCT02838264|Experimental|Cohort 1|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
11279427|NCT02838264|Experimental|Cohort 2|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
11279428|NCT02838264|Experimental|Cohort 3|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
11279429|NCT02838264|Experimental|Cohort 4|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive the highest safe dose (mg) of PF-06463922 as a single-dose Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
11279430|NCT02838238|Experimental|X|Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
11279431|NCT02838238|Placebo Comparator|Placebo|Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
11279432|NCT02838225|Experimental|DA|docetaxel 75 mg/m², iv, day 1, doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1, every 3 weeks for 6 cycles
11279433|NCT02838225|Active Comparator|DAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
11279434|NCT02838212||Drug-related deaths|fatal adverse drug reactions
11279435|NCT02838212||non drug-related deaths|deaths for other causes different as drugs
11279436|NCT02838199|Experimental|TAVR|Transcatheter aortic valve replacement with SAPIEN 3
11279437|NCT02838199|Active Comparator|SAVR|Surgical aortic valve replacement
11279438|NCT02838186|Active Comparator|right colon in retroflexion|"polyp/adenoma detection
~feasibility"
11279439|NCT02838186|Active Comparator|right colon in forward view|polyp/adenoma detection
11279440|NCT02838173|Experimental|SPB|Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision
11279441|NCT02838173|Active Comparator|tissue infiltration|tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision
11279442|NCT02838160|Experimental|booklet Group|
11279443|NCT02838160|Experimental|Oral presentations group|
11279444|NCT02838160|Experimental|Clinical teaching in bedside Group|
11279445|NCT02838147|Experimental|Normal OGTT (Oral Glucose Tolerance Test)|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
11279446|NCT02838147|Experimental|Pathological OGTT - 1 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
11279447|NCT02838147|Experimental|Pathological OGTT - 2 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
11279448|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
11279449|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
11279450|NCT02838121|Experimental|Aclasta|Aclasta IV once annual for 2 years
11279451|NCT02838121|Placebo Comparator|Placebo|Placebo group
11279452|NCT02838108||patients with COPD|
11279453|NCT02838095|No Intervention|No nap|After each night with a 5-hour sleep opportunity, participants did not have a daytime nap opportunity, but instead watched documentaries.
11279454|NCT02838095|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants had the chance to take a daytime nap from 14:00 to 15:00.
11279455|NCT02838082|Experimental|Sleep Hygiene Protocol|Participants in this arm will undergo a 4 week sleep hygiene protocol
11279456|NCT02838082|Active Comparator|Standard of Care Protocol|Participants will undergo 4 weeks of current inpatient standard of care procedures in a rehabilitation facility
11279501|NCT02837770|Placebo Comparator|Pacebo pill and Artificial Tears|Pacebo pill will be administered 4 hours before the IVI and one drop Artificial Tears will be instilled 45' prior to the IVI.
11279457|NCT02838069|Experimental|2x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
11279458|NCT02838069|Experimental|10x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
11279459|NCT02838069|Placebo Comparator|Placebo|0.5% glucose in saline with 4.5% albumin
11279460|NCT02838056|Experimental|epidural injection|epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
11279461|NCT02838043|Experimental|Participant|All participants will be experimental and receive Probio'Stick.
11279462|NCT02838030|Experimental|acetylsalicylic acid and L-arginine|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
11279463|NCT02838030|Placebo Comparator|acetylsalicylic acid and placebo|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
11279464|NCT02838017|Experimental|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
11279465|NCT02838017|Active Comparator|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
11279466|NCT02838004|Experimental|Single arm receiving Mini WELL Ready IOL|IOL implantation for cataract
11279467|NCT02837991|Experimental|CDX-014|"During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
~The planned dose of CDX-014 depends on the cohort assigned at enrollment."
11279468|NCT02837978|Experimental|Tacrolimus group|RA patients treated with tacrolimus, without MTX
11279469|NCT02837978|Active Comparator|Tacrolimus + MTX group|RA patients treated with tacrolimus and MTX
11279470|NCT02837965||diagnosed bullous pemphigoid|
11279471|NCT02837952|Active Comparator|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
11279472|NCT02837952|Placebo Comparator|Placebo|Placebo
11279473|NCT02837939|Experimental|Active|Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.
11279474|NCT02837939|Placebo Comparator|Control|Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm
11279475|NCT02837926|Experimental|women attending for cervical cancer screening|
11279476|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
11279477|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
11279478|NCT02837900|Placebo Comparator|Previous LT TX knee and right placebo|Previous left treated knee will have placebo treatment in this protocol.
11279479|NCT02837900|Placebo Comparator|Previous RT TX knee and left placebo|Previous right treated knee will have placebo treatment in this protocol.
11279480|NCT02837900|Active Comparator|Both TX with Active|Both knees with receive Active
11279481|NCT02837887|Experimental|Group I (immediate treatment)|Patients undergo computerized cognitive behavior therapy consisting of 45-60 minute sessions once per week for 8 weeks. Patients also complete the PHQ-9 and GAD7 at weeks 1, 3, 5, 7 and 8 and complete other questionnaires for 15-30 minutes each that assess psychosocial and physical symptoms.
11279482|NCT02837887|Experimental|Group II (wait-list)|Patients are placed on an 8-week wait-list and then undergo computerized cognitive behavior therapy and receive questionnaires as in Group I.
11279483|NCT02837874|Active Comparator|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
11279484|NCT02837874|Experimental|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
11279485|NCT02837861|Experimental|Experimental Group|Routine Nutritional Support plus supplemental IV amino acids, to begin within 24h of injury. (Target approximately 1.5-2g protein/kg/day)
11279486|NCT02837861|Active Comparator|Control Group|Routine Nutritional Support (i.e. enteral nutrition as tolerated, to begin as early as medically feasible)
11279487|NCT02837848|Experimental|Coactivation strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
11279488|NCT02837848|Active Comparator|Regular strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
11279489|NCT02837835|Experimental|continuous administration of ceftazidime|
11279490|NCT02837835|Experimental|intermittent administration of ceftazidime|
11279491|NCT02837822|Active Comparator|Stimulation Off|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn Off during the experiment."
11279492|NCT02837822|Active Comparator|Stimulation On|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn On during the experiment."
11279493|NCT02837809|Experimental|Intervention|Low Dose CT, annual or biennial, associated with primary prevention and pulmonary function test evaluation.
11279494|NCT02837809|No Intervention|Control|Program of primary prevention with pulmonary function test evaluation
11279495|NCT02837796|Active Comparator|inside-outside group|inside-out transobturator tape approach
11279496|NCT02837796|Active Comparator|outside-inside group|outside-in transobturator tape approach
11279497|NCT02837783|Experimental|290 μg linaclotide|Linaclotide Oral, once daily
11279498|NCT02837783|Placebo Comparator|Matching Placebo|Matching Placebo Oral, once daily
11279499|NCT02837770|Active Comparator|Pacebo pill and Diclofenac Eye Drops|Pacebo pill will be administered 4 hours before the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
11280331|NCT02831985|Experimental|general practice follow-up|post-surgery follow-up by general practitioner
11279502|NCT02837757|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.
~Available tumor tissues samples will be collected."
11279503|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
11279504|NCT02837731|Experimental|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of < 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
11279505|NCT02837731|No Intervention|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
11279506|NCT02837718|Other|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
11279507|NCT02837705||carriers of a mutation in the Prion gene|Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status.
11279508|NCT02837705||family members of carriers of a mutation in the Prion gene|Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
11279509|NCT02837692|Experimental|Cohort 1|Participants assigned to Cohort 1 group A (elderly non-Asian), group B (young healthy non-Asian) and group C (healthy Japanese) will receive JNJ-42847922 10 mg, 3 hours after completing dinner.
11279510|NCT02837692|Experimental|Cohort 2|Participants assigned to Cohort 2 group A, group B and group C will receive JNJ-42847922 20 mg, 3 hours after completing dinner.
11279511|NCT02837692|Experimental|Cohort 3|Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
11279512|NCT02837692|Experimental|Cohort 4|Participants assigned to Cohort 4 group B will receive JNJ-42847922 60 or 80 mg, 3 hours after completing dinner.
11279513|NCT02837679|Experimental|Intervention|Geriatric follow up
11279514|NCT02837679|No Intervention|Control|Usual care
11279515|NCT02837666|Active Comparator|Exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group with exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
11279516|NCT02837666|Active Comparator|No exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group without exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
11279517|NCT02837653|Experimental|Experimental|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home, and a personalized Physical Activity Counseling based on the Cardiovascular Risk of Each Patient
11279518|NCT02837653|Active Comparator|Control|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home.
11279519|NCT02837640|Experimental|Treatment|"This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.
~patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months."
11279520|NCT02837614|Active Comparator|Group A (intramuscular dexamethasone)|In Group A patients, 1 ml of dexamethasone (4mg) administered in the deltoid muscle before commencement of surgical procedure
11279521|NCT02837614|Experimental|Group B (submucosal dexamethasone)|In Group B patients, 1 ml of dexamethasone was administered in submucosa after local anesthesia
11279522|NCT02837614|Placebo Comparator|Group C (control)|Group C patients continued without receiving any preoperative medication.
11279523|NCT02837601|Other|LOW AIS Pressure AirSeal®|AIS with an insufflation pressure target of 9mmHg ±1mmHg
11279524|NCT02837601|Other|HIGH AIS Pressure AirSeal®|AIS with an insufflation pressure target of 15mmHg ±1mm
11279525|NCT02837588|Active Comparator|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
11279526|NCT02837588|No Intervention|CONTROL|No intervention with radiofrequency treatment, only evaluation to usual drug treatment
11279527|NCT02837575|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses
11279528|NCT02837575|Placebo Comparator|Phosphate-buffered saline, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses
11279529|NCT02837562||Interventional Cardiology/Cath Lab Staff|"This is considered to be the case or group under study. These are Interventional Cardiology/ Cardiac Cath lab staff that are exposed to radiation as a result of their role as Cardiac Cath lab staff.
~Intervention: Slit lamp eye examination"
11279530|NCT02837562||Non-Interventional Cardiology/ Controls|"This is considered to be the control or comparison group. These are non-interventional cardiology/ non-cardiac cath lab staff that are not exposed to radiation as they do no operate/ work in the Cardiac Cath Lab.
~Intervention: Slit lamp eye examination"
11279531|NCT02837549|Experimental|Occupational therapy treatment|"Participants will undergo the following as appropriate:
~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations
~Application of the Physiotouch (a low-intensity negative pressure device)
~Passive Range of Motion
~Active Range of Motion
~Functional Activities"
11279532|NCT02837536|Active Comparator|Horizontal iCare|In the horizontal iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the horizontal position first and then their IOP measured with the iCare tonometer held in the vertical position.
11280703|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
11279533|NCT02837536|Active Comparator|Vertical iCare|In the vertical iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the vertical position first and then their IOP measured with the iCare tonometer held in the horizontal position.
11279534|NCT02837523||Observation|Patients with a Cystinosis disease or high-grade suspicion for Cystinosis disease
11279535|NCT02837510|Other|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
11279536|NCT02837497|No Intervention|Control|Standard ICU resuscitation practices
11279537|NCT02837497|Experimental|ICU-RESUS CPR Improvement Bundle|ICU-RESUS bundle implementation: 1) point-of-care bedside CPR training; and 2) post-cardiac arrest debriefings.
11279538|NCT02837484|Other|NuTech Affinity™ Membrane|Sharp dissection of the defect will be performed being careful not to violate the subchondral bone sparing the calcified cartilage layer. After hemostasis is reached, the defect will be treated with an Affinity™ patch stabilized with fibrin glue.
11279539|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
11279540|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
11279541|NCT02837458|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11279542|NCT02837458|Sham Comparator|Sham Stimulation|Electrodes are placed over the arm for a 30 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
11279543|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
11279544|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
11279545|NCT02837432|Other|Healthy|Healthy individuals will receive both the placebo and hydrocortisone interventions in a randomized order
11279546|NCT02837432|Other|Depression|Individuals with depression will receive both the placebo and hydrocortisone interventions in a randomized order
11279547|NCT02837406||Doctors|specialists and general practitioners by ich territory
11279548|NCT02837406||Health professionals|"pharmacists
~nurses
~physiotherapists
~Medical and social professionals: social workers, psychologists, educators ..."
11279549|NCT02837406||Medical-social institutes|"Hospital,
~Healthcare structure,
~Local Centre of Information and Gerontological Coordination ..."
11279550|NCT02837393||History of Kidney Stones|Participants with a history of kidney stones who will be undergoing kidney surgery.
11279551|NCT02837393||No History of Kidney Stones|Participants without a history of kidney stones who will be undergoing kidney surgery.
11279552|NCT02837380|Experimental|FF/UMEC/VI|Subjects will receive single combination dose of FF/UMEC/VI 100/62.5/25 mcg via a DPI in the morning for 7 days.
11279553|NCT02837367|Experimental|Adult intervention|"The intervention will consist Administration of supplements containing methyl-donors (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
11279554|NCT02837367|Placebo Comparator|Adult placebo|"The intervention will consist of the Administration of supplements containing methyl-donors (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
11279555|NCT02837367|Experimental|Children intervention|"The intervention will consist of the Administration of supplements containing methyl-donors (as syrup) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
11279556|NCT02837367|Placebo Comparator|Children Placebo|"The intervention will consist of Administration of supplements containing methyl-donors (as syrup) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).
~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
11279557|NCT02837367|No Intervention|Adults genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.
11279558|NCT02837367|No Intervention|Children genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.
11279559|NCT02837341|Other|Volunteers|Monitoring of respiratory rates via camera-based System Monitoring of respiratory rate by Philips®Vital Sign Device - Camera-based system (Prototype) and capnography simultaneously.
11279560|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
11279561|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
11280332|NCT02831985|Active Comparator|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
11279562|NCT02837315|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS was described to participants as the College Adjustment Session and the session was conducted using an MI plus personalized feedback approach."
11279563|NCT02837315|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students were asked about their reaction to the relaxation techniques and were provided with relaxation training handouts.
11279564|NCT02837315|No Intervention|Assessment|Participants fill out a battery of measures and receive no intervention.
11279565|NCT02837302|Active Comparator|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
11279566|NCT02837302|No Intervention|General nutritional support|General nutritional support
11279567|NCT02837289|Other|Treatment|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
11279568|NCT02837289|Other|Placebo|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
11279569|NCT02837263|Experimental|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
11279570|NCT02837250|Experimental|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
11279571|NCT02837250|Active Comparator|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
11279572|NCT02837237|Experimental|KBP-5074|Single oral dose
11279573|NCT02837224||Preimplementation: Situate Locate System|Subjects/surgeries performed before implementation of the Situate Detection System.
11279574|NCT02837224||Implementation|Subjects/surgeries performed after implementation of the Situate Detection System.
11279575|NCT02837211|Experimental|Tapered Diet|
11279576|NCT02837211|Active Comparator|Traditional Low Calorie Diet|
11279577|NCT02837198|Experimental|Uric acid-overproduction Type|FYU-981
11279578|NCT02837198|Experimental|Uric acid- underexcretion Type|FYU-981
11279579|NCT02837198|Experimental|Uric acid-overproduction Type (combination)|FYU-981 , Topiroxostat
11279580|NCT02837198|Experimental|Uric acid- underexcretion Type2|FYU-981
11279581|NCT02837185|Experimental|Cervical Dystonia|'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
11279582|NCT02837185|Other|Healthy controls|No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.
11279583|NCT02837172||Parkinson's disease from UAB|MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, Diffusion Weighted Imaging (DWI), and neurological examination.
11279584|NCT02837172||Parkinson's disease from PPMI dataset|Obtain retrospective and prospective de-identified data from the The Parkinson's Progression Markers Initiative (PPMI) dataset on Parkinson's disease (PD) subjects that have the following characteristics: within 2 years of diagnosis, positive DaTscan, and not (at study entry) on any PD related medication.
11279585|NCT02837172||Controls from PPMI dataset|Obtain retrospective and prospective de-identified DTI imaging and data from the PPMI dataset
11279586|NCT02837159|Experimental|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
11279587|NCT02837159|No Intervention|Usual care|Usual care
11279588|NCT02837146|Experimental|Tocilizumab (TCZ) + Methotrexate (MTX)|"Induction phase:
~From week 0 to week 24, all subjects will receive TCZ and MTX
~Maintenance phase:
~From week 24 to week 54, all subjects will receive MTX"
11279589|NCT02837133|Experimental|other techniques group|theory and practice of pair massage with tapping, stretching of the ankle and neck, and autogenic training
11279590|NCT02837107|Active Comparator|Supplement|The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
11279591|NCT02837107|Placebo Comparator|Placebo|A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
11280362|NCT02831751|Active Comparator|FluLaval® Tetra (15 µg/strain)|
11279592|NCT02837094|Experimental|C19-A3 GNP (Gold Nanoparticles)|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold. Solution For Injection The dose given will be equivalent to 10ug of C19A3 peptide at 3 dispensing visits, which are 4 weeks apart. Total 30ug.
11279593|NCT02837081|Active Comparator|Preauthorization group|Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.
11279594|NCT02837081|Experimental|Prospective audit|Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
11279595|NCT02837068|Experimental|Wheelchair handrail compensator|When a patient sitting on the wheelchair, the physiotherapist put the paralysis upper limb on the handrail compensator and keep the limb in normal position for at least 60 minutes one day.
11279596|NCT02837068|Active Comparator|Ordinary wheelchair|When a patient sitting on the wheelchair, the paralysis upper limb was put on the ordinary handrail for at least 60 minutes one day.
11279597|NCT02837055|Experimental|VivaSight intubation|Patients are intubated with the VivaSight-SL endotracheal tube
11279598|NCT02837055|Active Comparator|conventional intubation|Patients are intubated with a conventional endotracheal tube
11279599|NCT02837042|Experimental|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
11279600|NCT02837029|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11279601|NCT02837016|Experimental|Experimental 1|Wearable biofeedback device + Relaxation Training
11279602|NCT02837016|Active Comparator|Experimental 2|Relaxation Training only
11279603|NCT02837003||Experimental: Aspirin|Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
11279604|NCT02837003||Experimental: Thienopyridine|Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
11279605|NCT02836990|Active Comparator|Prevena|Prevena Incision Management System for vascular surgical groin wounds
11279606|NCT02836990|Active Comparator|Dermabond|Dermabond for vascular surgical groin wounds
11279607|NCT02836977|Experimental|maintenance therapy|Patients will receive oral tegafur-uracil 400mg/day (100mg/Cap., 2 capsules each time, twice a day), combined with oral folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day), and continue for one year.
11279608|NCT02836977|Active Comparator|observation arm|Patients will be observed following adjuvant oxaliplatin-based regimen.
11279609|NCT02836964|Active Comparator|Loading of Dental Implants after 4 weeks|"A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar. for this group.
~After 4 weeks definitive crown will be placed."
11279610|NCT02836964|Active Comparator|Loading of Dental Implants after 3 months|A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar for this group. After 3 months definitive crown will be placed
11279611|NCT02836951||Patient|This group consists of patients that are hospitalized due to a head injury. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
11279612|NCT02836951||Healthy controls|This group consists of healthy volunteers. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
11279613|NCT02836938||Severe|Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
11279614|NCT02836938||Mild|Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
11279615|NCT02836938||Control|Bronchiolitis obliterans syndrome (BOS), stage 0
11279616|NCT02836925|Experimental|Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir|The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
11279617|NCT02836912|No Intervention|Regular education|Regular education for COPD, including percussion and posture drainage.
11279618|NCT02836912|Experimental|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group.
11279619|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
11279620|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
11279621|NCT02836886||Sézary syndrome|Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
11279622|NCT02836873|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
11279623|NCT02836873|Placebo Comparator|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
11279624|NCT02836860|Other|Healthy Controls|Effects of tactile stimulation on lumbar multifidus activation in healthy adults without LBP.
11279625|NCT02836860|Other|Low Back Pain|Effects of tactile stimulation on lumbar multifidus activation in adults with LBP.
11279626|NCT02836847|Experimental|target therapy|The patients wil receive conventional chemotherapy(GEMOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
11279627|NCT02836847|Other|GEMOX|The patients wil receive conventional chemotherapy(GEMOX).
11279628|NCT02836834|Experimental|Dose Escalation Cohort|JS001
11279629|NCT02836834|Experimental|Expanded cohort 1|The subjects of expanded cohort 1 will use repeated doses every 2 weeks like multiple dose cohorts
11279630|NCT02836834|Experimental|Expanded cohort 2|The subjects of expanded cohort 2 will use repeated doses every 2 weeks like multiple dose cohorts
11279631|NCT02836821|Experimental|Apatinib|subjects receiving a single 750 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then rifampicin capsules 600 mg/day orally for 10 days with a single 750 mg oral dose of apatinib mesylate tablets co-administered on day 8 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
11279632|NCT02836808|No Intervention|Control|Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area
11279633|NCT02836808|Experimental|CAIPaDi|Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day
11279634|NCT02836795|Experimental|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
11279635|NCT02836782||Naive patients|Patients who begin their first antiretroviral regimen. Blood sample withdrawal
11279636|NCT02836782||Experienced patients|"Patients with a history of antiretroviral treatment, switching to a new regimen.
~Blood sample withdrawal"
11279637|NCT02836769|Experimental|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
11279638|NCT02836743|Experimental|Circadin 2mg|low-dose (2mg) slow-release melatonin for 1 month.
11279639|NCT02836743|Experimental|Circadin 6mg|high-dose (6mg) slow-release melatonin for 1 month.
11279640|NCT02836743|Placebo Comparator|Placebo|Administer placebo pills with identical morphology
11279641|NCT02836730||Lumbar disc herniation|Patients with surgery for lumbar disc herniation;
11279642|NCT02836730||Spinal stenosis|Patients with surgery for lumbar spinal stenosis
11279643|NCT02836730||No surgery|Patients with no surgery for lumbar disc herniation; patients with no surgery for lumbar spinal stenosis;
11279644|NCT02836704|Active Comparator|Standard initial dose of insulin glargine|Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
11279645|NCT02836704|Experimental|Higher initial dose of insulin glargine|Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
11279646|NCT02836691|Active Comparator|EKG to Control subjects|healthy controls without asthma or other respiratory disease.
11279647|NCT02836691|Active Comparator|EKG monitoring Mild asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
11279648|NCT02836691|Active Comparator|EKG monitoring severe control asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
11279649|NCT02836691|Active Comparator|EKG monitoring severe uncontrolled asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
11279650|NCT02836678|Active Comparator|Control group|Ridge splitting, immediate implantand PRF.
11279651|NCT02836678|Experimental|Test group|Ridge splitting, immediate implant, Nanobone with PRF.
11279652|NCT02836665|No Intervention|A: Control group|Patients of group A wait routinely until the dermatological investigator in charge arrives at the emergency room. Once the dermatological investigator is on site, he gives a diagnosis and proposes a therapy.
11279653|NCT02836665|Experimental|B: Telemedicine for dermatological emergency patients|"For Patients of group B study-related photographs of the skin lesion and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal."
11279654|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
11279655|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
11279656|NCT02836639|Experimental|Busulfan, Etoposide, Bendamustine|All patients will receive the conditioning regimen followed by autologous stem cell transplantation.
11279657|NCT02836626|Experimental|Deep Fascial Mobilization|
11279658|NCT02836626|Experimental|Superficial Fascial Mobilization|
11279659|NCT02836613|Active Comparator|Galcanezumab Reference|Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
11279660|NCT02836613|Experimental|Galcanezumab Test|Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
11279661|NCT02836600|Experimental|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
11279662|NCT02836587|Experimental|interventional|Experimental group will undergo balance training for 8 weeks.
11279663|NCT02836587|No Intervention|control|Control group will have no assigned intervention.
11279664|NCT02836574|Experimental|Immediate Treatment|Neo-Kidney Augment (NKA) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of NKA as soon as NKA product is made available.
11279665|NCT02836574|Active Comparator|Delayed Treatment|Neo-Kidney Augment (NKA) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after NKA product is made available before receiving 2 injections of NKA.
11279666|NCT02836561|Experimental|Intervention Message|Participants who are randomized to the intervention message will receive contraception information in advance of their appointment that may be helpful in their decision-making.
11279667|NCT02836561|No Intervention|Control Message|Participants who are randomized to the control message will receive appointment logistic information that may be a helpful reminder.
11279668|NCT02836548|Experimental|vorinostat|Vorinostat 360 mg once daily
11279669|NCT02836535||patients with complications|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential. The interview will examine the impact of complications utilizing a semi-structured script specific to each group
11279670|NCT02836535||patients without Complications (control group)|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential.
11279671|NCT02836509|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
11279672|NCT02836509|Experimental|Ibuprofen group|Second Group: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
11279673|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
11279674|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
11279675|NCT02836483|Experimental|Group 1|LCB01-0371 800mg, QD
11279676|NCT02836483|Experimental|Group 2|LCB01-0371 400mg, BID
11279677|NCT02836483|Experimental|Group 3|LCB01-0371 800mg, BID
11279678|NCT02836483|Active Comparator|Group 4|Tubes 3~5Tablet, QD
11279679|NCT02836483|Active Comparator|Group 5|Zyvox 600mg, BID
11279680|NCT02836483|Experimental|Group 6|LCB01-0371 1200mg, QD
11279681|NCT02836470|Experimental|LB1148|Active
11279682|NCT02836470|Placebo Comparator|Placebo|Placebo
11279683|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
11279684|NCT02836431|Experimental|DEX 1 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
11279685|NCT02836431|Experimental|DEX 2 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
11279686|NCT02836431|Experimental|DEX 1 mcg/kg Intravenous|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
11279687|NCT02836418|Experimental|ATYR1940|All patients will receive ATYR1940 at the highest tolerated dose received in the parent study for 12-weeks. After 12 weeks, if the patient is demonstrating good tolerability, theATYR1940 dose may be increased on a patient-specific basis at the Investigator's discretion, in consultation with the Sponsor and Medical Monitor. ATYR1940 dose increases to >3.0 mg/kg are not permissible.
11279688|NCT02836405||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder (ASD) will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
11279689|NCT02836405||Healthy Control|Typically developing individuals without a history of autism will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
11279690|NCT02836379||Breakthrough Cancer Pain|No intervention (Non-interventional study)
11279691|NCT02836353|No Intervention|Observational only|Oral glucose tolerance test, neurocognitive questionnaire tasks only.
11279692|NCT02836353|Experimental|Somatostatin|Oral glucose tolerance test after 100mcg Somatostatin
11279693|NCT02836353|Experimental|Antibiotics|Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth
11279694|NCT02836340|Experimental|2-Iminobiotin|Increasing dosage of study drug
11279695|NCT02836327||Multiple sclerosis|Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
11279696|NCT02836327||Neuromyelitis optica spectrum disorders|Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
11279697|NCT02836327||Health control|Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.
11279698|NCT02836314|Experimental|PRF and ABBM|Intervention: Anorganic Bovine Bone Mineral and Platelet Rich fibrin is applied to the periodontal intrabony defects
11279699|NCT02836314|Active Comparator|Anorganic Bovine Bone Mineral|Intervention: Anorganic Bovine Bone Mineral is applied to the periodontal intrabony defects
11279700|NCT02836301|Active Comparator|Testimonials-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
11279701|NCT02836301|Active Comparator|Testimonials-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
11279702|NCT02836301|Active Comparator|Testimonials-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
11279703|NCT02836301|Experimental|Documentary-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
11279762|NCT02835859|Experimental|Group 1- Oral solution|Participants will be randomly assigned to drink two oral solutions made of different combinations of saccharin, lactisole, acetaminophen, 3-O-methyl glucose, or glucose.
11279704|NCT02836301|Experimental|Documentary-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
11279705|NCT02836301|Experimental|Documentary-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
11279706|NCT02836288|Experimental|Ketamine|Oral ketamine 1.0 mg/kg mixed with syrup
11279707|NCT02836288|Placebo Comparator|Placebo|Oral placebo (syrup)
11279708|NCT02836288|Experimental|Ketamine after placebo|Optional oral Ketamine 1.0 mg/kg mixed with syrup for patients on placebo arm after 12 week treatment is completed.
11279709|NCT02836275|Experimental|Perfusion and diffusion-weighted MRI|
11279710|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
11279711|NCT02836249|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
11279712|NCT02836249|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
11279713|NCT02836249|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
11279714|NCT02836236|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
11279715|NCT02836236|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
11279716|NCT02836236|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
11279717|NCT02836223|Experimental|Interdental device|Water Flosser
11279718|NCT02836223|Other|Toothbrush|Control
11279719|NCT02836210|Active Comparator|Angled incision|Patients in this arm will undergo 27-gauge vitrectomy wound construction using angled (tunnel-like) incisions for trocar entry.
11279720|NCT02836210|Active Comparator|Straight Incision|Patients in this arm undergo 27-gauge vitrectomy wound construction using straight (perpendicular) incisions for trocar entry.
11279721|NCT02836197|Experimental|Experimental group|This group of 30 physicians will immediately attend the intervention communication skills training program (experimental group).For this experimental group, the first assessment will take place before the first training session and the second recording after the last session. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
11279722|NCT02836197|No Intervention|Waiting-list group|This group of 30 physicians will attend the intervention communication skills training in a delayed manner (control group). For this control group, the first and the second recording will take place with a four-month interval. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
11279723|NCT02836184|Active Comparator|control group|Group treated with calcium carbonate for 6 weeks first,then switch to nicotinic acids treatment after 2 week of wash-out.
11279724|NCT02836184|Experimental|nicotinic acids group|Group treated with nicotinic acids for 6 weeks first,then switch to calcium carbonate treatment after 2 week of wash-out.
11279725|NCT02836171|Experimental|Treatment|subjects receiving a single 250 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then Itraconazole capsules 100 mg/day orally for 6 days with a single 250 mg oral dose of apatinib mesylate tablets co-administered on day 4 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
11279726|NCT02836158|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
11279727|NCT02836132|Active Comparator|Weight Watchers Online|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform.
11279728|NCT02836132|Experimental|Weight Watchers Online + Experience Success|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
11279729|NCT02836106|Experimental|Healthy|Lean subjects (BMI<25) with a waist circumference of <94 cm for men and<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
11279730|NCT02836106|Experimental|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
11279731|NCT02836093||evaluations/assessments|
11279732|NCT02836080|Experimental|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services [EMYS]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
11279733|NCT02836080|Active Comparator|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.
~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
11279734|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:
~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
11279735|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:
~Questionnaires Blood Draw Bronchoscopy"
11279736|NCT02836054|Other|Patients with cognitive disorders|lumbar punction + brain MRI
11279737|NCT02836054|Other|Patients without cognitive disorders|lumbar punction + brain MRI
11279763|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
11279827|NCT02835378||Bilateral upper limb amputation|Bilateral upper limb amputees, with amputation from the short transverse hand (hand completely non-functional) to complete arm, whatever their age
11279738|NCT02836041||Pediatrics cancer patients|Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.
11279739|NCT02836028|Experimental|talazoparib|Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
11279740|NCT02836028|Active Comparator|talazoparib + temozolomide|Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
11279741|NCT02836015|Experimental|Shared Medical Visit Groups|All patients will be enrolled in the experimental group and will be involved in shared medical visits.
11279742|NCT02836002|Experimental|Group 1 - SP low/SP high|"Group 1 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.
~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).
~Group 1 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
11279743|NCT02836002|Experimental|Group 2 - SP low/Pip high|"Group 2 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.
~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).
~Group 2 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
11279744|NCT02836002|Experimental|Group 3 - Pip low/Pip high|"Group 3 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.
~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).
~Group 3 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
11279745|NCT02836002|Experimental|Group 4 - Pip low/SP high|"Group 4 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.
~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).
~Group 4 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
11279746|NCT02835989|Experimental|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.
~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
11279747|NCT02835989|No Intervention|Control|Usual Care
11279748|NCT02835976|Experimental|Olesoxime|Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
11279749|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
11279750|NCT02835937|No Intervention|Transfuse|Patients will receive a transfusion under standard care
11279751|NCT02835937|Experimental|No-Transfuse|Patients will not receive a transfusion
11279752|NCT02835924|Active Comparator|Arm A|160 mg/day 3w on/1w off
11279753|NCT02835924|Experimental|Arm B|120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
11279754|NCT02835924|Experimental|Arm C|160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
11279755|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
11279756|NCT02835898||Test Group|Patients with periodontal disease that need conventional periodontal treatment
11279757|NCT02835898||Control Group|Periodontally-healthy individuals.
11279758|NCT02835885|Experimental|Active tVNS Stimulation|Stimulating electrode will be placed on left tragus of subject. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied.The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
11279759|NCT02835885|Sham Comparator|Sham tVNS Stimulation|Stimulating electrode will be placed on left ear lobe of subject for sham tVNS stimulation condition. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied. The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
11279760|NCT02835872|Placebo Comparator|Cellulose control|3 g Insoluble Fiber (Cellulose)/d contained within drinks and crackers
11279761|NCT02835872|Active Comparator|Soluble fiber treatment|3 g soluble dietary fiber test ingredient contained within drinks and crackers
11280363|NCT02831751|Active Comparator|Fluzone® High-Dose (60 µg/strain)|
11279764|NCT02835833|Experimental|Nintedanib 150 mg + Bevacizumab 15 mg/kg|"The first three patients on study will be treated with 150 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
~If one dose limiting toxicity occurs in the first cohort, then three more patients will be treated at that same starting dose and assessed for toxicity after cycle two. If two or more patients have dose limiting toxicity, then dose escalation will end and the maximum tolerated dose will be reached."
11279765|NCT02835833|Experimental|Nintedanib 200 mg + Bevacizumab 15 mg/kg|If no patients experience dose limiting toxicity, then three additional patients will be treated with 200 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
11279766|NCT02835820|Experimental|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
11279767|NCT02835820|No Intervention|Patient Choice Diet|Control.
11279768|NCT02835807|Experimental|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
11279769|NCT02835807|Active Comparator|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
11279770|NCT02835794|Experimental|Arm 1|Omacetaxine - escalating doses subcutaneous twice daily on Days 1-5 and 8-12 Azacitidine 50 mg/m2 subcutaneous/intravenous daily on Days 8-12 G-CSF 5mcg/kg subcutaneous daily on Days 15-19 and 22-26
11279771|NCT02835781||Acellular dermal matrix arm|The females undergoing breast reconstruction surgery after breast removal because of breast cancer. The breast reconstruction will be performed using acellular dermal matrix implantation.
11279772|NCT02835768|Experimental|Intervention|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Participants will be given an additional leaflet about the domestic safety website with address link and brief introductory information.
11279773|NCT02835768|No Intervention|Control|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Only this booklet serves as the anticipatory guidance to mothers about domestic safety.
11279774|NCT02835755|Active Comparator|Group I (Control)|Patients receive standard information about HPV and HPV vaccine, such as the VIS, on a mobile-friendly website study portal.
11279775|NCT02835755|Experimental|Group II (mHealth HPV vaccine)|Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail.
11279776|NCT02835742|Active Comparator|Group1|Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
11279777|NCT02835742|Placebo Comparator|Group2|Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
11279778|NCT02835729|Experimental|Phase 1a|"Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
~All current subjects will transition from indoximod freebase capsules over to indoximod HCL F2 tablets. All new subjects enrolled will also receive indoximod HCL F2 tablets."
11279779|NCT02835729|Experimental|Phase 1b (CLOSED TO ACCRUAL)|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL F1 formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
11279780|NCT02835703|Active Comparator|Deep hypothermic arrest|Surgical repair of coarctation of aorta under deep hypothermic circulatory arrest
11279781|NCT02835703|Active Comparator|Selective antegrade cerebral perfusion|Surgical repair of coarctation of aorta using selective antegrade cerebral perfusion
11279782|NCT02835703|Active Comparator|Double arterial cannulation|Surgical repair of coarctation of aorta using cerebral antegrade perfusion with descending aortic cannulation
11279783|NCT02835690|Experimental|Pembrolizumab 2 mg/kg|Participants receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
11279784|NCT02835690|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
11279785|NCT02835690|Experimental|Pembrolizumab 200 mg Fixed Dose|Participants receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
11279786|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
11279787|NCT02835664|Experimental|Nicotinamide Riboside|Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
11279788|NCT02835664|Placebo Comparator|Placebo|Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
11279789|NCT02835651|Experimental|Palmitic acid|Diet rich in palmitic acid
11279790|NCT02835651|Experimental|Stearic acid|Diet rich in stearic acid
11279791|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)
~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
~Women selected for further assessment (positive screening exam) will be recalled."
11279792|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
11279793|NCT02835612|Experimental|Early stimulation|skin-to skin care by mother (kangaroo care) plus massage therapy by mothers.
11279794|NCT02835612|Active Comparator|Conventional care|skin-to skin care by mother (kangaroo care).
11279795|NCT02835586|Experimental|paclitaxel delivery in femoropopliteal artery|
11279796|NCT02835573||Sepsis-induced myocardial injury group|Patients admitted to the hospital with the diagnosis of Sepsis-induced myocardial injury
11279797|NCT02835573||Blank control group|Patients admitted to the hospital without the diagnosis of Sepsis-induced myocardial injury
11279798|NCT02835560|Experimental|Experimental|Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid
11279799|NCT02835560|Active Comparator|Active Comparator|"Esoprazole
~Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid"
11279800|NCT02835547||Systemic lupus erythematosus|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
11279801|NCT02835547||Rheumatoid arthritis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
11279802|NCT02835547||Psoriasis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
11279803|NCT02835547||Scleroderma|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
11279804|NCT02835547||Hematopoietic stem cells transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
11279805|NCT02835547||Kidney transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
11279806|NCT02835534|Experimental|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
11279807|NCT02835534|Active Comparator|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
11279808|NCT02835521|Experimental|Intervention Group|Patients will receive the reception treatment before the joint injection
11279809|NCT02835521|Active Comparator|Control Group|patient will receive a joint injection
11279810|NCT02835508|Experimental|Treatment A|Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
11279811|NCT02835508|Experimental|Treatment B|Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets*60 mg) on Day 1.
11279812|NCT02835508|Experimental|Treatment C|Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets*60 mg) on Day 1.
11279813|NCT02835495|Experimental|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention
~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
11279814|NCT02835495|Active Comparator|Enhanced Usual Care|"Behavioral: Individual Education Program
~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
11279815|NCT02835482|Experimental|Patient with glaucoma|Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
11279816|NCT02835482|Other|Patient without glaucoma|Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.
11279817|NCT02835469||Menopur® Multidose|Treatment according to routine clinical practice.
11279818|NCT02835456|Active Comparator|Group A: Sharklet Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
11279819|NCT02835456|Active Comparator|Group B: Silicone Foley Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
11279820|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
11279821|NCT02835430|Experimental|Coronally advanced flap and PRF with DFDBA|Coronally advanced flap and platelet-rich fibrin membrane with demineralized freeze-dried bone allograft.
11279822|NCT02835430|Active Comparator|Coronally advanced flap and PRF without DFDBA|Coronally advanced flap and Platelet-rich fibrin membrane without demineralized freeze-dried bone allograft.
11279823|NCT02835404|Experimental|Concurrent radiochemotherapy Group|Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
11279824|NCT02835404|Active Comparator|Radiotherapy Group|patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.
11279825|NCT02835391|Active Comparator|PerClot|PerClot® Polysaccharide Hemostatic System (PerClot) is a medical device composed of absorbable polysaccharide particles (AMPs) and delivery applicators. Investigators will have the option to choose 3g or 5g dependent on the requirements of the patient
11279826|NCT02835391|Active Comparator|Usual Care|Usual care will consist of any other haemostat the Investigator would normally use in the control of bleeding i.e arista, Floseal, surgical, surgiflo. If the Investigator would not normally use a haemostat to control bleeding then electrocautery or diathermy may be used in this arm
11280364|NCT02831738|Experimental|Active Treatment|Polydextrose 12 g
11279828|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
11279829|NCT02835352|Experimental|Essential oils then oil massages|Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
11279830|NCT02835352|Experimental|Oil then essential oils massages|Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days
11279831|NCT02835339|Active Comparator|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
11279832|NCT02835339|Experimental|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
11279833|NCT02835326|Experimental|Exercise and Dietary Weight Loss|For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
11279834|NCT02835326|Active Comparator|Walk with Ease|The Arthritis Foundation's (AF) WWE is a self-management program for symptoms of arthritis (pain, fatigue, stiffness,etc.) through exercise. It is a 6 week program involving 3 sessions per week each lasting about 60 minutes. The WWE sessions are comprised of walking, stretching and strengthening exercises, and health education lectures. These group classes will be lead by an AF instructor. Each participant will complete 2 consecutive WWE classes for a total of 12 weeks in the program. During the final week of the program, participants will be trained and transitioin to the self-directed version of WWE for maintenance of exercise. To aid in retention efforts, phone contacts are provided to participants on a monthly basis from 4-12 months and bi-monthly from 12 to 24 months
11279835|NCT02835313|Experimental|FAST+SAM|Subjects participate in fast walking training in combination with a step activity monitoring program
11279836|NCT02835313|Active Comparator|FAST|Subjects participate in fast walking training
11279837|NCT02835313|Active Comparator|SAM|Subjects participate in a step activity monitoring program
11279838|NCT02835300|Experimental|CampAir Intervention|Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
11279839|NCT02835300|Active Comparator|Information and Referral Control|Adolescents assigned to the information-and-referral control condition will be provided access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will receive access to CampAir.
11279840|NCT02835287|Experimental|Protocol-based Integrated Care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
11279841|NCT02835287|Active Comparator|Enhanced Control|A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
11279842|NCT02835274|Experimental|Ring mode followed by Unrestricted mode|omni-directional stimulation followed by unrestricted Mode stimulation
11279843|NCT02835274|Active Comparator|Unrestricted mode followed by ring mode|Unrestricted Mode stimulation followed by omni-directional stimulation
11279844|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
11279845|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
11279846|NCT02835248||Primary|Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/).
11279847|NCT02835235|Experimental|NNC9204-0530|Dose-escalation within the cohort before reaching final dose
11279848|NCT02835235|Placebo Comparator|Placebo|
11279849|NCT02835222|Experimental|Arm 2 (Selinexor) cytarabine, daunorubicin and selinexor|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2, and selinexor PO twice weekly. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3, and selinexor PO twice weekly from day 1. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Have had a response, completed all planned consolidation, have not gone to transplant receive selinexor on Days 1 and 8 for cycle 1 only, then Day 1 for cycles 2-4; Day 1 of every 4th cycle. Treatment continues until progression or unacceptable toxicity."
11279911|NCT02834767|Experimental|Group 3 Primary OSA Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
11279850|NCT02835222|Active Comparator|Standard of Care - Cytarabine and daunorubicin|"INDUCTION: Cytarabine IV on days 1-7, daunorubicin hydrochloride IV on days 1-3. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Disease has not responded receive cytarabine IV on days 1-5, daunorubicin hydrochloride IV on days 1-2. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: In remission receive cytarabine IV every 12 hours for a total 6 doses days 1-3. Treatment repeats every 42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
11279851|NCT02835209||Work of breathing during SBT|Ventilated premature infants born 24 to 34+6 weeks gestational age.
11279852|NCT02835196||Optical Elastography Assessment of Skin Thickness|
11279853|NCT02835196||Visual Assessment of Skin Thickness|
11279854|NCT02835183|Experimental|Insulin pump followed by iDECIDE|Participants will be randomly assigned to 4 weeks of using their insulin pump to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing.
11279855|NCT02835183|Experimental|iDECIDE followed by insulin pump|Participants will be randomly assigned to 4 weeks of using iDECIDE to receive recommendations for insulin dosing and then 4 weeks of using their insulin pump to decide insulin boluses.
11279856|NCT02835170|Experimental|Autologous immunoglobulin|Intramuscular injection of autologous immunoglobulin (IgG)
11279857|NCT02835170|Placebo Comparator|Placebo|Intramuscular injection of normal saline
11279858|NCT02835157|Experimental|Balanced salt solution or study group|After enrollment, a fluid bolus comprising of 'balanced saline' solution at a dose of 20 ml/kg over 15-20 minutes with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. A second bolus would be repeated with the same fluid at 20 ml/kg over 15-20 minutes in case therapeutic end points are not reached. After this the management protocol will be as per recommendations of the surviving sepsis campaign guidelines for septic shock in children.
11279859|NCT02835157|Active Comparator|Normal saline or control group|After enrollment, a fluid bolus comprising of 'normal saline' solution at a dose of 20 ml/kg over 15-20 minutes with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. A second bolus would be repeated with the same fluid at 20 ml/kg over 15-20 minutes in case therapeutic end points are not reached. After this the management protocol will be as per recommendations of the surviving sepsis campaign guidelines for septic shock in children.
11279860|NCT02835144|Experimental|TIQAAM_therapy|Individuals in this group will receive units from the TIQAAM treatment program
11279861|NCT02835144|Active Comparator|active_control|Individuals in this group will receive units of psychoeducation
11279862|NCT02835118|Experimental|Surotomycin 0.5 g|Two oral doses of 0.25 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
11279863|NCT02835118|Experimental|Surotomycin 1 g|Two oral doses of 0.5 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
11279864|NCT02835118|Experimental|Surotomycin 2 g|Two oral doses of 1 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
11279865|NCT02835118|Placebo Comparator|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
11279866|NCT02835105|Experimental|Surotomycin 0.5 g|A single oral dose of 0.5 g surotomycin in hard gelatin capsules
11279867|NCT02835105|Experimental|Surotomycin 1 g|A single oral dose of 1 g surotomycin in hard gelatin capsules
11279868|NCT02835105|Experimental|Surotomycin 2 g|A single oral dose of 2 g surotomycin in hard gelatin capsules
11279869|NCT02835105|Experimental|Surotomycin 4 g|A single oral dose of 4 g surotomycin in hard gelatin capsules
11279870|NCT02835105|Placebo Comparator|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
11279871|NCT02835092|Active Comparator|Self-directed Control|
11279872|NCT02835092|Experimental|Take Shape For Life Program|
11279873|NCT02835092|Experimental|Medifast Direct Program|
11279874|NCT02835079|Other|open label study|one arm open label study
11279875|NCT02835066||Ancillary-Correlative (HRQOL, fitness and psychosocial health)|Patients scheduled for surgery, radiation therapy, or chemotherapy complete the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-core 30 (C30) and QLQ-Lung Cancer 13 (LC13) in addition to psychosocial health and smoking status questions from baseline up to 2 weeks prior to the start of treatment, 5-6 weeks after treatment begins, and 5-6 months from the start of treatment. During the same time points, patients also undergo function/fitness assessments including standard health measurements, short physical performance battery (SPPB), 6 minute walk test (6MWT), and a grip strength test.
11279876|NCT02835053||Emergency General Surgery|All patients having emergency general surgery procedures as defined by Scott et al (JAMA Surgery 2016)
11279877|NCT02835040|Experimental|CAP Service|
11279878|NCT02835040|Active Comparator|Usual care|
11279879|NCT02835014||Adolescents with T1DM|Adolescents with type I Diabetes Mellitus diagnosed for at least one year will be screened for mental health symptoms with the PHQ9, SCARED and UCLA PTSD. Self-efficacy regarding self-care and diabetes management will be assessed by using the SEDM. Parenting styles will be assessed by administering the Parenting Styles and Dimensions Questionnaire (PSDQ).
11279880|NCT02835001|Other|Patient with severe emphysema|Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
11279881|NCT02834988||SLND Patients|Patients scheduled to have their sentinel lymph nodes removed, as part of standard of care.
11279882|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:
~Pembrolizumab 200mg intravenously (IV);
~Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);
~Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);
~Carboplatin IV area under the curve (AUC) of 6."
11279883|NCT02834962|Experimental|single bundle ACLR|patients undergo single bundle ACL reconstruction
11279884|NCT02834962|Active Comparator|double bundle ACLR|patients undergo double bundle ACL reconstruction
11279978|NCT02834325||exit|HFNC with no need for mechanical ventilation
11279885|NCT02834949|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the College Adjustment Session and the session will be conducted using an MI plus personalized feedback approach."
11279886|NCT02834949|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
11279887|NCT02834949|No Intervention|Assessment|Participants will fill out a battery of measures and receive no intervention.
11279888|NCT02834936|Experimental|pyrotinib treatment|
11279889|NCT02834923|Active Comparator|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change. CTH utilizes web-based interactive behavior change technology, based on a logic model of behavior and maintenance that is informed by social-cognitive and social ecological theories. Prior to diabetes visits with a clinician, health educator, or care manager, patients complete a pre-visit CTH assessment at their practice through a tablet computer or computer kiosk. CTH assesses multiple diabetes management behaviors (diet, physical activity, medication adherence, alcohol and tobacco use, stress, mood) using brief assessment measures, each with cut-points highlighting areas of deficit. Action planning plays a central role, through a web-based platform that allows the patient and health care team to select and set goals collaboratively.
11279890|NCT02834923|Experimental|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
11279891|NCT02834910||Case group|patients with Extended-Spectrum Beta-lactamase producing Enterobacteriaceae carrying a qnr gene isolate
11279892|NCT02834910||control-group|patients with Enterobacteriaceae isolate without qnr gene
11279893|NCT02834897|Experimental|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
11279894|NCT02834884||all tumor types|Pathologically confirmed selected tumor types, including rare tumors. The SPECTA Steering Committee will decide on project basis which tumor types and stages to include at any particular time during the study.
11279895|NCT02834871|Other|patients with cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients with cervical dystonia
11279896|NCT02834871|Other|patients without cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients without cervical dystonia
11279897|NCT02834858|Experimental|Umbilical Cord Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells Infusion.
11279898|NCT02834858|Placebo Comparator|saline|saline injection
11279899|NCT02834845|Experimental|Sevoflurane|
11279900|NCT02834845|Experimental|Desflurane|
11279901|NCT02834832||Control|The patients will be given removable dentures with no coatings. These dentures are part of the standard of care to treat their edentulism.
11279902|NCT02834832||PECVD Coatings|The patients will be given removable partial dentures with PECVD coatings on both the tissue surface of the dentures and the acrylic denture teeth.
11279903|NCT02834819|Experimental|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
11279904|NCT02834819|No Intervention|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
11279905|NCT02834806|Experimental|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
11279906|NCT02834793|Experimental|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.
~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
11279907|NCT02834793|Placebo Comparator|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.
~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
11279908|NCT02834780|Experimental|H3B-6527 (escalation and expansion)|Hepatocellular Carcinoma
11279909|NCT02834767|Experimental|Group 1 Primary Snoring Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
11279910|NCT02834767|Placebo Comparator|Group 2 Primary Snoring Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
11279912|NCT02834767|Placebo Comparator|Group 4 Primary OSA Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
11279913|NCT02834754|Experimental|Vedolizumab|Vedolizumab infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
11279914|NCT02834754|Placebo Comparator|placebo|Placebo infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
11279915|NCT02834741|Placebo Comparator|SAD Phase|"Up to 36 subjects: 50 - 1200 mg NYX-2925, Up to 12 subjects: placebo
~6 additional subjects will receive a fed dose of NYX-2925, 2 additional subjects will receive a fed dose of placebo (Food Effect Cohort)
~6 additional subjects will receive 1 dose of 50 mg NYX-2925 followed by a lumbar puncture at 1 and 4 (3 subjects) or 2 and 8 (3 subjects) hours post dose"
11279916|NCT02834741|Placebo Comparator|MAD Phase|"Up to 24 subjects : 150 - 600 mg NYX-2925 daily for 7 days, up to 6 subjects : placebo daily for 7 days
~6 additional subjects will receive 300 mg NYX-2925 daily for 7 days and undergo lumbar puncture on Day 6 in order to have two CSF samples taken (CSF Cohort)."
11279917|NCT02834728||Frail elderly people|A group of elderly people hospitalised in medical wards via emergency department
11279918|NCT02834715|Experimental|Stevia|Once-daily oral intake of 240 mg of Stevia liquid extract for 30 days as food supplement.
11279919|NCT02834715|No Intervention|Control|No intervention, similar follow up as experimental arm to control for trial effect
11279920|NCT02834702|Experimental|Sinew acupuncture|Sinew acupuncture
11279921|NCT02834702|Sham Comparator|Sham acupuncture|Sham acupuncture
11279922|NCT02834689|Experimental|Walking|Walking on a treadmill at 3.5 metabolic equivalents (METS) for 50 minutes
11279923|NCT02834689|Experimental|Seated Control|Sitting for 50 minutes
11279924|NCT02834676||Chemonucleolysis by Gelified Ethanol|Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy. Written informed consent was obtained from all participants.
11279925|NCT02834663|Experimental|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
11279926|NCT02834650|Experimental|Group 1a|Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
11279927|NCT02834650|Experimental|Group 1b|"Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.
~A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County."
11279928|NCT02834650|Experimental|Group 2|Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.
11279929|NCT02834650|Experimental|Group 3|Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.
11279930|NCT02834637|Active Comparator|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
11279931|NCT02834637|Active Comparator|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
11279932|NCT02834637|Active Comparator|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
11279933|NCT02834637|Active Comparator|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
11279934|NCT02834637|Active Comparator|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
11279935|NCT02834637|Active Comparator|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
11279936|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
11279937|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
11279938|NCT02834611|Experimental|Ceramide NanoLiposome|Dose escalation of Ceramide NanoLiposome
11279939|NCT02834598|Experimental|Rocking movement|Participant is lying in a hammock with a rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
11279940|NCT02834598|Active Comparator|Lying position|Participant is lying in a hammock with no rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
11279941|NCT02834598|Active Comparator|Seated position|Participant is sitting on a chair. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
11279942|NCT02834585||Ultrasound|Patients undergoing Ultrasound
11279943|NCT02834585||Magnetic Resonance Imaging|Patients undergoing Magnetic Resonance Imaging
11279944|NCT02834572|Experimental|All About Me|assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach
11279945|NCT02834572|Active Comparator|Control|HIV testing information
11279946|NCT02834559|Active Comparator|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
11279947|NCT02834559|Placebo Comparator|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
11279948|NCT02834546||Patients with HCC treated with sorafenib|
11279949|NCT02834533|Active Comparator|column heading in tables.|The group 1 (G1, n=20) underwent Lokomat-Nanos training. Each patient underwent 40 1h-training sessions (for 3 times a week). Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
11279950|NCT02834533|Active Comparator|row and column in table|The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions. The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
11279951|NCT02834520||oral lichen planus|30 patients suffering from reticular, erosive and atrophic oral lichen planus
11279952|NCT02834520||control subjects|30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.
11279953|NCT02834507|Placebo Comparator|Placebo|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
11279954|NCT02834507|Experimental|Nebicapone 75 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
11279955|NCT02834507|Experimental|Nebicapone 150 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
11279956|NCT02834507|Active Comparator|Entacapone 200 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
11279957|NCT02834494|Other|3D Shear Wave Elastography (SWE)|
11279958|NCT02834481|Other|: ventilated children|ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE
11279959|NCT02834468|Experimental|Treatment group|DEX Combined With RTX, CSA and IVIG All patients are assigned to receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
11279960|NCT02834455|Active Comparator|CE-CT scanning|Contrast-enhanced CT scan of the thorax and abdomen.
11279961|NCT02834455|Active Comparator|PET-CT scanning|Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
11279962|NCT02834442|Experimental|Single ascending dose, MT-7117 or Placebo|
11279963|NCT02834442|Experimental|Multiple ascending dose, MT-7117 or Placebo|
11279964|NCT02834429||endoscopy patients|We will recruit patients (n=1000) from the endoscopy department at the Royal Hallamshire Hospital, Sheffield, United Kingdom (UK).
11279965|NCT02834416|Experimental|Group-Supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
11279966|NCT02834416|Experimental|Home-Based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
11279967|NCT02834403|Experimental|Experimental|"Phase Ib: L-NMMA and docetaxel will be given for 6 21-day cycles. L-NMMA at doses of 5, 7.5 (starting dose), 10, 12.5, 15, 17.5, and 20 mg/kg will be administered IV on Days 1-5. For 5-15 mg/kg L-NMMA doses, docetaxel will be administered at 75 mg/m2. For 17.5 and 20 mg/kg L-NMMA doses, docetaxel will be administered at 100 mg/m2. Docetaxel will be administered IV 15 min after the Day 1 L-NMMA infusion. Amlodipine (10 mg) will be orally administered daily for 6 days, starting 24 hours before the Day 1 L-NMMA infusion. Enteric-coated aspirin (81 mg) will be orally administered once daily during the 6 21-day cycles. Pegfilgrastim (6 mg) will be administered subcutaneously 24 h after docetaxel.
~Phase II: L-NMMA starting dose will be the RP2D determined in the Phase Ib portion of the study."
11279968|NCT02834390|Experimental|Arm 1|"Quizartinib and Cytarabine to be used in both the Induction period and the Consolidation period.
~And either Idarubicin or Daunorubicin to be used in the Induction period."
11279969|NCT02834377|Experimental|Treatment algorithm|Patients allocated to the study group will be connected to a cardiac output monitor. An initial haemodynamic assessment will be performed at the beginning of surgery and at regular time intervals (every 15 minutes) during surgery. The personal cardiac output value is targeted.
11279970|NCT02834377|No Intervention|Standard of Care|Patients allocated to the control group will receive the standard care of the hospital.
11279971|NCT02834364|Experimental|single arm|Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
11279972|NCT02834351|Active Comparator|Peripheral artery diseased group|pad Patients referred for femoro popliteal bypass Muscle biopsy during surgery
11279973|NCT02834351|Sham Comparator|Cardiac group|Patients referred for saphenous withdrawal for coronary bypass Muscle biopsy during surgery
11279974|NCT02834338|No Intervention|Laparoscopic surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
11279975|NCT02834338|Active Comparator|Laparoscopic surgery, intervention|activity tracking for autofeedback
11279976|NCT02834338|No Intervention|Open surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
11279977|NCT02834338|Active Comparator|Open surgery, intervention|activity tracking for autofeedback
11279985|NCT02834299|Experimental|DBT Guided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and receive six brief therapy sessions via video-calling."
11279986|NCT02834299|Experimental|DBT Unguided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and asked to follow the manual on their own."
11279987|NCT02834299|Active Comparator|Self-Esteem-Focused Unguided Self-Help|"Participants will be provided with the self-help manual Self-Esteem by McKay & Fanning (2016) as asked to follow the manual on their own."
11279988|NCT02834286|Experimental|Rituximab, eltrombopag and dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4
11279989|NCT02834273|Experimental|Therapeutic Workshop|Therapeutic Workshop (patients following therapeutic education workshops during their hospitalization)
11279990|NCT02834273|No Intervention|Usual care|
11279991|NCT02834260|Experimental|ozurdex group|Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
11279992|NCT02834247|Experimental|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
11279993|NCT02834247|Experimental|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If >=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
11279994|NCT02834247|Experimental|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
11279995|NCT02834247|Experimental|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
11279996|NCT02834247|Experimental|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
11279997|NCT02834234||Peritoneal mesothelioma specimens|"The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.
~The CGH arrays will be realized on frozen samples (for the comparative genomic analysis)."
11279998|NCT02834221|Experimental|Real-time ultrasound-guided puncture|Cannulate each femoral veins with two wires with real-time ultrasound-guided method.
11279999|NCT02834221|Other|Anatomical landmark guided puncture|Cannulate each femoral veins with two wires with the anatomical landmark guided method.
11280000|NCT02834208|Experimental|Schizophrenia subjects|35 patients suffering from schizophrenia
11280001|NCT02834208|Other|Healthy siblings|35 healthy siblings of the patients suffering from schizophrenia
11280002|NCT02834208|Other|Healthy controls|"35 healthy controls patients"
11280003|NCT02834182|Experimental|Bipolar Disorder patients and Schizophrenic patients|
11280004|NCT02834182|Active Comparator|Healthy Controls|
11280005|NCT02834169||pseudomyxoma peritonei|Data from pseudomyxoma peritonei cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280259|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).
~No intervention but only observational."
11280006|NCT02834169||peritoneal mesothelioma|Data from peritoneal mesothelioma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280007|NCT02834169||desmoplastic small round cell tumor|Data from desmoplastic small round cell tumor cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280008|NCT02834169||psammocarcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280009|NCT02834169||primary peritoneal serous carcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280010|NCT02834169||diffuse peritoneal leiomyomatosis|Data from diffuse peritoneal leiomyomatosis cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280011|NCT02834169||appendiceal mucinous neoplasms|Data from appendiceal mucinous neoplasms cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
11280012|NCT02834156|Other|LP in a seated position then LP in a lying position|Patients will have first a lumbar puncture (LP) in a seated position then a LP in a lying position
11280013|NCT02834156|Other|LP in a lying position then LP in a seated position|Patients will have first a lumbar puncture (LP) in a lying position then a LP in a seated position
11280014|NCT02834130|Other|children from 2 to 10 years with haemophilia or allied HBD, wh|
11280015|NCT02834117|Other|Natural cycle|Ovulation is not induced by drugs
11280016|NCT02834117|Experimental|Moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
11280017|NCT02834104|Experimental|Myocardial fibrosis|
11280018|NCT02834078|Experimental|BGG|Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
11280019|NCT02834078|Placebo Comparator|Placebo|Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
11280020|NCT02834065|Active Comparator|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
11280021|NCT02834065|Active Comparator|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
11280022|NCT02834065|Active Comparator|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
11280023|NCT02834052|Experimental|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:
~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)
~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg
~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.
~Participants may receive treatment for 1 year (~17 cycles)."
11280024|NCT02834052|Experimental|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.
~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (~17 cycles)."
11280025|NCT02834039|Active Comparator|Tidal volume 6 ml/kgBW|Tidal volume 6 ml/kgBW was given to patients after endotracheal tube was inserted properly
11280026|NCT02834039|Active Comparator|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to patients after endotracheal tube was inserted properly.
11280027|NCT02834026|Experimental|Intervention|The intervention group held two months of training in hemodialysis a physical therapy protocol with cycle ergometer
11280028|NCT02834026|Experimental|Control|The control group was reassessed after two months of the initial evaluation
11280029|NCT02834013|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who complete 17 cycles (2 years) of therapy, may continue receiving the same treatment with nivolumab and ipilimumab, or receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) per physician discretion in the absence of disease progression or unacceptable toxicity. Patients who stop treatment prior to the completion of 17 cycles of therapy may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity.
11280030|NCT02834013|Experimental|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. After 17 cycles (2 years) of therapy, patients may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity.
11280031|NCT02834000|No Intervention|Standard Care|We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. The control group will compose of patients supervised in a standard way.
11280032|NCT02834000|Experimental|LiDCO rapid™ CNAP monitoring|Young, healthy adult patients (ASA I and II) undergoing elective orthopaedic surgery under general anaesthesia will be included in to this study. We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. We will use in the LiDCO rapid™ CNAP monitoring group, the continuous real time haemodynamic monitoring through non-invasive arterial pressure waveform. The monitor LiDCO rapid™ CNAP permits, through analysis the arterial blood pressure trace, to acquire information about CO, SVR, HR variability, SV and BIS.
11280186|NCT02832986||Patients in frailty consultation|Patients consulting in frailty consultation, at this occasion they will complete a medical questionary for the collection of study data
11280033|NCT02833987||Treated with direct oral anticoagulants (DOACs)|Patients who received a new prescription for a DOAC (apixaban, dabigatran, or rivaroxaban) in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
11280034|NCT02833987||Treated with warfarin|Patients who received a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
11280035|NCT02833974|Experimental|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
11280036|NCT02833974|Placebo Comparator|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
11280037|NCT02833961|Experimental|ISCHEMIC STROKE|ischemic stroke admitted in the Pitié Salpêtrière Stroke unit in Paris
11280038|NCT02833961|Active Comparator|HEALTHY SUBJECTS|Age and gender-matched healthy volunteers
11280039|NCT02833948|Active Comparator|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
11280040|NCT02833948|Experimental|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
11280041|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
11280042|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
11280043|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
11280044|NCT02833909|Experimental|HS|
11280045|NCT02833909|Experimental|Controls|
11280046|NCT02833896||endometrial cancer|
11280047|NCT02833896||Control|
11280048|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
11280049|NCT02833870|Experimental|Musical intervention|
11280050|NCT02833870|Experimental|Non-musical (cooking) intervention|
11280051|NCT02833870|Active Comparator|Control with no intervention|
11280052|NCT02833857|Experimental|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
11280053|NCT02833844|Experimental|Double-Blind Placebo SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks
11280054|NCT02833844|Placebo Comparator|Double-Blind EvoMab 420 mg SC QM|Double-blind Repatha (evolocumab) SC injection QM for 24 weeks
11280055|NCT02833844|Experimental|Open Label EvoMab 420 mg SC QM|Open label Repatha (evolocumab) SC injection QM for 24 weeks
11280056|NCT02833831|Experimental|Part 1: Group 1|Participants will receive Treatment A (a single dose of ALS-008176 1,500 mg) or Treatment B (a single dose of placebo) under fasted conditions.
11280057|NCT02833831|Experimental|Part 1: Group 2|Participants will receive Treatment C (a single dose of ALS-008176 2,500 mg) or Treatment D (a single dose of placebo) under fasted conditions.
11280058|NCT02833831|Experimental|Part 1: Group 3|Participants will receive Treatment E (a single dose of ALS-008176 3,000 mg) or Treatment F (a single dose of placebo) under fasted conditions.
11280059|NCT02833831|Experimental|Part 2: Sequence GHI|Participants will receive Treatment G (a single dose of ALS-008176 3,000 mg + a single dose of moxifloxacin placebo under fasted conditions) then Treatment H (a single dose of ALS-008176 placebo + a single dose of moxifloxacin 400 mg under fasted conditions) then Treatment I (a single dose of ALS-008176 placebo + a single dose of moxifloxacin placebo under fasted conditions). There will be a washout period of at least 14 days between subsequent treatments.
11280060|NCT02833831|Experimental|Part 2: Sequence HIG|Participants will receive Treatment H then Treatment I and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
11280061|NCT02833831|Experimental|Part 2: Sequence IGH|Participants will receive Treatment I then Treatment G and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
11280062|NCT02833831|Experimental|Part 2: Sequence IHG|Participants will receive Treatment I then Treatment H and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
11280063|NCT02833831|Experimental|Part 2: Sequence HGI|Participants will receive Treatment H then Treatment G and then Treatment I. There will be a washout period of at least 14 days between subsequent treatments.
11280064|NCT02833831|Experimental|Part 2: Sequence GIH|Participants will receive Treatment G then Treatment I and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
11280187|NCT02832973|Experimental|Spironolactone, Furosemide Amiloride|Spironolactone 25 mg qd, Furosemide 20 mg qd, Furosemide 40 mg qd, Amiloride 5 mg qd
11280065|NCT02833818|Experimental|CAKE-intervention|Increased nutrition and dietary consultations. Growth rate followed by clinical nutritionists that supply high protein and energy if growth rate deviates from 17g/kg/day
11280066|NCT02833818|Active Comparator|CAKE-control|nutrition according to established procedures in the neonatal intensive care unit (NICU)
11280067|NCT02833805|Experimental|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
11280068|NCT02833792|Experimental|Stem Cells|Stem cells
11280069|NCT02833792|Placebo Comparator|Placebo|Lactated Ringer's Solution
11280070|NCT02833779|Active Comparator|Group Therapy Exercises|Patients will be taught exercises in groups of six persons, on a daily basis for twelve sessions.
11280071|NCT02833779|Active Comparator|Individual Manual Therapy Exercises|Patients will be taught the same exercises as in a Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering
11280072|NCT02833766|Experimental|anti-EGFR-IL-dox|Metastatic, non resectable, EGFR positive TNBC patients treated in first-line
11280073|NCT02833753|Experimental|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.
~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients will receive dose level 3. The fourth cohort of 3 patients will receive dose level 2."
11280074|NCT02833740|Other|Click-MUAC & regular MUAC tape screening|"Each child will have nutritional status classified 11 times:
~3 times with each of the 3 Click-MUAC prototypes by the mother/caregiver
~1 time with a regular MUAC tape by the mother/caregiver
~3 times with each of the 3 Click-MUAC prototypes by the case-finding/programme staff
~1 time with a regular MUAC tape by the case-finding/programme staff
~3 times with a regular MUAC tape by the data collection team (gold standard)"
11280075|NCT02833727||Asthmatic smokers (AS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) < 8 mg/ml with a diagnosis of asthma made by a respirologist.
~Smokers or ex smokers will be defined by a smoking history of ≥ 10 pack/year."
11280076|NCT02833727||Asthmatic non-smokers (ANS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a PC20 < 8 mg/ml with a diagnosis of asthma made by a respirologist.
~Never smokers will have a life-long history without smoking."
11280077|NCT02833701|Experimental|Treatment (bevacizumab and ascorbic acid)|Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11280078|NCT02833688|Experimental|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
11280079|NCT02833688|Placebo Comparator|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
11280080|NCT02833675||bradykinin angioedema|Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
11280081|NCT02833675||Histaminergic angioedema|Allergic and non allergic angioedema
11280082|NCT02833675||Control group|Patients with abdominal pain
11280083|NCT02833662|Other|Patients suspected to present a Sleep Apnea Syndrom|"Record nocturnal respiratory and cardiac parameters before and after surgery :
~Severity of sleep respiratory disorders and relationship with cardiac rhythm abnormalities will be assessed in patients suspected to present Sleep Apnea, before and after surgery under general anesthesia."
11280084|NCT02833649|Experimental|Toric Implantable contact Lens|The Visian implantable collamer lens (Staar Surgical AG, Nidau, Switzerland), is a monoblock single-piece plate haptic lens made of collamer (an extremely hydrophilic and highly biocompatible flexible collagen copolymer with a refractive index of 1.452 that is permeable to oxygen and nutrients
11280085|NCT02833636||Successful CTO-PCI group|low ACEF score <1.215 (n = 79), intermediate ACEF score from 1.215 to 1.493 (n=70), and high ACEF score≥1.493 (n=72)
11280086|NCT02833636||Failed/non-attempted CTO-PCI group|low ACEF score<1.215 (n=45), intermediate ACEF score from 1.215 to 1.493 (n=57), and high ACEF score≥1.493 (n=54).
11280087|NCT02833623|Experimental|Short-message-based Re-education group|"Patients receive oral and written education before H. pylori eradication therapy at first, then they receive short message re-education twice per day during therapy.
~Both the content of the oral and written education and the short message re-education are same."
11280088|NCT02833623|Active Comparator|conventional education group|Patients only receive oral and written education before H. pylori eradication therapy.
11280089|NCT02833610|Experimental|Denosumab Injection|Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.
11280090|NCT02833584|Experimental|Paracetamol|Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
11280091|NCT02833584|Placebo Comparator|Placebo|Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
11280092|NCT02833558|Experimental|PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
11280093|NCT02833558|Other|Standard Electrocautery|Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
11280094|NCT02833545|Experimental|OZONE|injection of ozone gas
11280095|NCT02833545|Active Comparator|control|injeciton of steroids intra articularly
11280096|NCT02833532|Experimental|Volus|Maxium: 22ml
11280097|NCT02833532|Active Comparator|Powerfill|Maxium: 22ml
11280098|NCT02833519|No Intervention|control group|Standard care, mentally vulnerable women
11280099|NCT02833519|Active Comparator|group exercise|Supervised Group training
11280100|NCT02833506|Active Comparator|Cohort I (NY-ESO-1 protein with MIS416)|Patients receive NY-ESO-1 protein with MIS416 vaccine SC on days 1, 15, 29, 57, 85, and 113 in the absence of disease progression or toxicity.
11280101|NCT02833506|Experimental|Cohort II (NY-ESO-1 protein with MIS416, sirolimus)|Patients receive NY-ESO-1 protein with MIS416 vaccine as in Cohort I. Patients also receive sirolimus PO daily for 2 weeks followed by 2 weeks off starting on days 1, 29, 57, and 85.
11280102|NCT02833480|Experimental|Fluticasone group|Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
11280103|NCT02833480|Experimental|Budesonide group|Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
11280104|NCT02833480|Active Comparator|Formoterol group|Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
11280105|NCT02833454|Active Comparator|direct insertion single bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using single bundle technique.
11280106|NCT02833454|Experimental|anatomical double bundle ACLR|Patients with ACL rupture undergo double bundle anterior cruciate ligament reconstruction.
11280107|NCT02833454|Experimental|anatomical single bundle ACLR|Patients with ACL rupture undergo single bundle anterior cruciate ligament reconstruction.
11280108|NCT02833454|Active Comparator|direct insertion double bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using double bundle technique.
11280109|NCT02833441|Experimental|Peer Support Intervention|Adolescents/young adults in the Peer Support Intervention arm will be referred to a Peer Support Intervention support group within their own or nearby community. This support group will meet monthly and will be facilitated by a professional HIV counsellor together with a Peer Support Intervention counselor. The Peer Support Intervention counsellors will provide regular counselling to their allocated participants through home visits and SMS messages. Each participant will be visited once a week in their home. Whatsapp messages will be delivered daily to each participant by the Community Adolescent Treatment Supporters. The agreed messages will briefly enquire about the participant's well-being without specifically making reference to HIV or ARVs. In addition, participants' caregivers will be invited to a 3-session intervention to build knowledge, skills and confidence to better support their adolescents.
11280110|NCT02833441|No Intervention|Standard of Care Practice|"Participants in the standard of care group will receive adherence evaluations and counseling at the clinic as per the current standard of care. Current procedures involve a group counseling session given on Monday morning during which topics are discussed that are relevant to adolescents. In general children aged between 13-19 years attend these sessions. After the group counseling, adolescents also receive an individual counseling session before being evaluated by the clinic doctor. Youth are also encouraged to complete a self reported adherence questionnaire and may periodically undergo pill counts by the clinic counselors.
~The adolescents may belong to peer support groups in their communities, however these activities are not part of the clinic program. No interventions are typically targeted at their caregivers."
11280111|NCT02833428|Experimental|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
11280112|NCT02833415|Experimental|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
11280113|NCT02833415|Placebo Comparator|Placebo|Placebo one tablet daily for 3 months
11280114|NCT02833402||UUI patients undergoing SNM|Urine specimens, questionnaire, and medical data will be collected from subjects that have UUI and are undergoing InterStim placement (SNM).
11280115|NCT02833389|Experimental|Cohort A - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 1|Participants with 0.8-6.0 centimeters square (cm^2) index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 1 for 12 weeks (a total of 4 doses).
11280116|NCT02833389|Experimental|Cohort B - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
11280117|NCT02833389|Experimental|Cohort C - UTTR1147A, 0.8-6.0 cm^2, Mild Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
11280118|NCT02833389|Experimental|Cohort D - UTTR1147A, 1.5-6.0 cm^2, Mild Infection - Dose 2|Participants with 1.5-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
11280119|NCT02833389|Experimental|Cohort E - UTTR1147A, 0.8-6.0 cm^2, No infection - Dose 3|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 3 for 12 weeks (a total of 4 doses).
11280120|NCT02833389|Placebo Comparator|Placebo|Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).
11280121|NCT02833376|Experimental|Alcohol group|Patients allocated to this group will receive skin antisepsis with alcohol 70% prior spinal anesthesia
11280122|NCT02833376|Experimental|Chlorhexidine group|Patients allocated to this group will receive skin antisepsis with alcoholic solution of chlorhexidine 0.5% prior spinal anesthesia
11280123|NCT02833363||patients with non-atrophic gastritis|
11280124|NCT02833363||Patients with gastritis|
11280125|NCT02833363||Patients with intestinal metaplasia|
11280126|NCT02833363||Patients with intrepithelial neoplasia|
11280127|NCT02833363||Patients with non-cardia gastric cancer|
11280144|NCT02833246|Active Comparator|usual care|This includes physician and nursing assessment and intervention for any identified AEs. Of note, there is not currently standard follow-up that patients receive from nursing or physician staff while on an OAM treatment. Patients are encouraged to call their physician's office with any questions or changes in their medical status but are not called routinely by MSK staff.
11280188|NCT02832973|Active Comparator|Ramipril, Bisoprolol|Ramipril 5 mg qd, Ramipril 10 mg qd, Bisoprolol 5 mg qd, Bisoprolol 10 mg qd
11280330|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
11280128|NCT02833350|Experimental|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280129|NCT02833350|Experimental|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280130|NCT02833350|Experimental|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280131|NCT02833350|Active Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280132|NCT02833350|Placebo Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280133|NCT02833350|Experimental|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280134|NCT02833350|Placebo Comparator|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
11280135|NCT02833324|Experimental|Fitbit with ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. In addition to being educated on the importance of postoperative ambulation, this arm will have 5 alarms every day reminding them to ambulate.
11280136|NCT02833324|Active Comparator|Fitbit without ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. Participants will be educated on the importance of postoperative ambulation but will not have ambulation reminder alarms.
11280137|NCT02833311|Active Comparator|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
11280138|NCT02833311|Active Comparator|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
11280139|NCT02833311|Active Comparator|Standard Treatment Control Group|Participants are prescribed an exercise program and given information on healthy eating.
11280140|NCT02833298|Experimental|Automated reminders|Patient will be contacted for automated reminders within one month before the six-month interval indicating they are due for HCC screening.
11280141|NCT02833298|Experimental|Patient navigation|The patient navigator will coordinate with the provider and subject to schedule the appropriate office visit and imaging for HCC screening as needed within one month before the test is due.
11280142|NCT02833272|Experimental|EMPOWER Educational Brochure|This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.
11280143|NCT02833246|Experimental|SMS/MMS text messaging|Patients will be able to tailor their SMS/MMS reminders with respect to when (i.e., what time of day) they wish to receive the reminders, as well as how often the messages are sent (e.g., morning and evening).
11280255|NCT02832544|Active Comparator|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n ~ 2250); VKA titrated to achieve an INR of 2.0-3.0
11280145|NCT02833233|Experimental|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
11280146|NCT02833220||Healthy volunteers|"Healthy adults between the ages of 18-65 are eligible.
~Participants will receive non-invasive brain stimulation by way of single-pulse transcranial magnetic stimulation to the motor cortex"
11280147|NCT02833207|Experimental|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
11280148|NCT02833207|Experimental|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
11280149|NCT02833207|Experimental|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
11280150|NCT02833207|Experimental|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
11280151|NCT02833194||Leiden Group|Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
11280152|NCT02833194||aP1Ab-positive|"Inclusion in the aP1Ab Group:
~Initially positive for aP1Ab
~Second positive aP1Ab test six months later"
11280153|NCT02833194||Thrombophilia-negative|Women with completely negative thombophilia screening results.
11280154|NCT02833181||Awake patients|Awake patients
11280155|NCT02833181||Sedated patients|
11280156|NCT02833181||Sedated and curarized patients|
11280157|NCT02833168||1|Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.
11280158|NCT02833168||2|Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.
11280159|NCT02833168||3|Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.
11280160|NCT02833155|Experimental|Entinostat and Exemestane|"Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.
~Exemestane wil be orally administered once daily for up to six months."
11280161|NCT02833142|Experimental|BIIB033-A|Staggered single dosing schema
11280162|NCT02833142|Experimental|BIIB033-B|Staggered single dosing schema
11280163|NCT02833116|Experimental|Group Betamethasone|One ampule containing 12 mg of betamethasone in a syringe of 10 ml
11280164|NCT02833116|Active Comparator|Group Dexamethasone|One ampule containing 4 mg of dexamethasone in a syringe os 10 ml
11280165|NCT02833103|Experimental|Pinaverium Bromide group|Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
11280166|NCT02833103|Active Comparator|Danshu group|Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
11280167|NCT02833090|Other|Group 1|Control group had biomarkers.
11280168|NCT02833090|Experimental|Group 2|Biomarkers
11280169|NCT02833090|Experimental|Group 3|Biomarkers
11280170|NCT02833090|Experimental|Group 4|Biomarkers
11280171|NCT02833077|Experimental|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
11280172|NCT02833077|Other|No Treatment then JUVÉDERM VOLUMA® XC|No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
11280173|NCT02833064||Acute Liver Failure|"biological sampling
~MRI scanning for patients with paracetamol induced acute liver failure"
11280174|NCT02833064||Acute Liver Injury|- biological sampling
11280175|NCT02833064||Acute on Chronic Hepatic Injury|- biological sampling
11280176|NCT02833064||Stable Cirrhotics|- biological sampling
11280177|NCT02833064||Non-cirrhotic liver disease|- biological sampling
11280178|NCT02833038|Experimental|Magnesium group|Intravenous administration of Magnesium Sulfate
11280179|NCT02833038|Placebo Comparator|Control group|Intravenous administration of normal saline
11280180|NCT02833012|Experimental|Group 1|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
11280181|NCT02833012|Experimental|Group 2|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
11280182|NCT02833012|Experimental|Group 3|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
11280183|NCT02833012|Experimental|Group 4|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
11280184|NCT02832999|Experimental|sub cutaneous liraglutide|once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
11280185|NCT02832999|Active Comparator|Oral Vildagliptin|Once daily oral 100mg of Vildagliptine for two weeks
11280256|NCT02832531|Experimental|Rivaroxaban (15 mg)|Rivaroxaban 15 mg od (n ~ 1000)
11280189|NCT02832960|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
11280190|NCT02832960|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
11280191|NCT02832947|Other|Rivaroxaban Arm|
11280192|NCT02832934|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
11280193|NCT02832934|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
11280194|NCT02832921|Experimental|VR cognitive tasks + treadmill|This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.
11280195|NCT02832921|Active Comparator|VR cognitive tasks - treadmill|This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.
11280196|NCT02832921|Sham Comparator|scientific TV documentary + treadmill|This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.
11280197|NCT02832921|No Intervention|Passive control|This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.
11280198|NCT02832908|Other|Patients + parents|Patients with severe head trauma
11280199|NCT02832895|Experimental|Transcranial Doppler examination|Transcranial Doppler examination
11280200|NCT02832882|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
11280201|NCT02832882|Active Comparator|Conventional tumor puncture RFA arm|Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
11280202|NCT02832869|Experimental|short message service|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
11280203|NCT02832869|Experimental|Wechat|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
11280204|NCT02832869|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
11280205|NCT02832856|Placebo Comparator|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
11280206|NCT02832856|Experimental|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks.
11280207|NCT02832856|Experimental|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
11280208|NCT02832843||NTM lung disease|Patients with NTM lung disease satisfying American Thoracic Society guidelines
11280209|NCT02832843||Healthy control|The age-, sex-matched control subjects without pulmonary diseases
11280210|NCT02832830|Experimental|A|intensity modulated radiotherapy (IMRT) 10 x 3 Gy
11280211|NCT02832830|Active Comparator|B|fractionated conventional external beam RT 10×3 Gy
11280212|NCT02832804|Experimental|anodal stimulation|10 person The patients treated by anodal stimulation (2mA) for 20 minutes
11280213|NCT02832804|Active Comparator|cathodal stimulation|10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
11280214|NCT02832804|Sham Comparator|sham stimulation|10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
11280215|NCT02832791|Active Comparator|QUADRICEPS TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING QUADRICEPS TENDON
11280216|NCT02832791|Active Comparator|HAMSTRING TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING HAMSTRING TENDON
11280217|NCT02832778|Experimental|Stage 1 London|"Stage 1, London:
~Phase 1 (2 weeks): tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily
~Phase 2 (12 weeks): tenofovir/emtricitabine or tenofovir /lamivudine or zidovudine/lamivudine) plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)"
11280218|NCT02832778|Experimental|Stage 2 Kampala|Tenofovir/emtricitabine or lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥ 50 kg or rifampicin 450 mg and isoniazid 300 mg if <50kg).
11280219|NCT02832765|Experimental|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions
11280220|NCT02832765|Experimental|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis
11280221|NCT02832765|Experimental|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions
11280222|NCT02832765|Experimental|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis
11280223|NCT02832752|Active Comparator|ECPR Region|The ECPR region has incorporated ECPR therapy into the out-of-hospital cardiac arrest algorithm. Within the ECPR Protocol, full standard advanced cardiac life support treatments will continue up until the time of ECMO initiation. The anticipated enrolment in this group is 70 patients. All eligible patients in the region will be enrolled, regardless of whether the ECPR protocol is activated or whether the patient is actually treated with ECPR.
11280224|NCT02832752|No Intervention|Control Region|"The control region will continue usual care as per current protocols which include standard advanced cardiac life support. Patients will be enrolled in the control region group at the same juncture of study eligibility. The anticipated enrolment in this group is 350 patients.
~Within BCEHS practice, transport to hospital without prior return of spontaneous circulation is rare. Termination of resuscitation must be approved by an on-call physician and cannot occur prior to 30 minutes of resuscitation efforts."
11280225|NCT02832739|Experimental|SENACA - self-management support system|Use of enhanced SENACA - ICT based self-management support system prototype by study participants at home for 75-100 days
11280226|NCT02832726|Active Comparator|cyano-hydroxo B12|Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given.
11280227|NCT02832726|Active Comparator|Cyano-B12 doses|Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given.
11280228|NCT02832713|Experimental|Intra-articular injection of botulinum toxin A|
11280229|NCT02832713|Active Comparator|Intra-articular injection of hyaluronic acid|
11280230|NCT02832700|Active Comparator|Casein glycomacropeptide (CGMP)|During 4 weeks a daily oral intake of CGMP-protein-shake.
11280231|NCT02832700|Placebo Comparator|Placebo|During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.
11280232|NCT02832687|Active Comparator|normal saline|Patients will receive 100 milliliters of normal saline with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses in 24 hours. Blinded medication will be prepared by research pharmacist.
11280233|NCT02832687|Experimental|acetaminophen|Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients <50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline
11280234|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
11280235|NCT02832648|Experimental|selenase 200mcg|selenium as selenase 200mcg once daily, oral
11280236|NCT02832648|Experimental|selenase 50mcg|selenium as selenase 50mcg once daily, oral
11280237|NCT02832648|Placebo Comparator|placebo|matched placebo, once daily, oral
11280238|NCT02832635|Experimental|WBRT|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
11280239|NCT02832635|Experimental|WBRT with avoidance of hippocampus|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
11280240|NCT02832635|Experimental|WBRT with TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.
11280241|NCT02832635|Experimental|WBRT with avoidance of hippocampus and TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.
11280242|NCT02832622||MPP Group|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
11280243|NCT02832622||Treatment Strategy (BiV/MPP) Group|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., Biventricular (BiV) pacing ON at some point in months 1-9 and MPP ON for months 10-12)
11280244|NCT02832622||BiV Group|MPP OFF at the 12-month study visit and for at least three continuous months prior to 12-month assessment (i.e., BiV pacing ON for months 10-12)
11280245|NCT02832622||Other Pacing Group|Other pacing schemes not covered above (Retrospective categorization implemented based on the usage of MPP or BiV pacing for 12 months)
11280246|NCT02832609|No Intervention|sitting position|measurement in the sitting position
11280247|NCT02832609|Active Comparator|supine position|measurement in the sitting position
11280248|NCT02832596|No Intervention|Control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
11280249|NCT02832596|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
11280250|NCT02832583|Experimental|Mesotherapy of PRP-HA into the cheeks|Three sessions of PRP-HA prepared with RegenKit BCT-HA Cellular Matrix into each cheek separated by 1 month interval.
11280251|NCT02832570|Experimental|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
11280252|NCT02832570|Placebo Comparator|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
11280253|NCT02832557||MCHAT-R Positive|Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
11280254|NCT02832544|Experimental|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n ~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
11280365|NCT02831738|Placebo Comparator|Control Treatment|No polydextrose
11280260|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).
~No intervention but only observational."
11280261|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).
~No intervention but only observational."
11280262|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
11280263|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
11280264|NCT02832453|Other|Lifestyle counseling|This group will receive lifestyle counselling but not supervised exercise training sessions
11280265|NCT02832453|Experimental|Aerobic interval training|This group will receive lifestyle counselling plus supervised high intensity (80%VO2max) interval exercise training sessions
11280266|NCT02832453|Active Comparator|Traditional continous training|This group will receive lifestyle counselling plus supervised moderate intensity (60%VO2max) continous exercise training sessions
11280267|NCT02832440|Other|Intradialytic exercise|Exercise during hemodialysis
11280268|NCT02832440|Other|Home-based exercise|Exercise at home
11280269|NCT02832414|No Intervention|Regular program|
11280270|NCT02832414|Active Comparator|Intensive weight loss program|
11280271|NCT02832401|Active Comparator|Caffeine|200 mg of caffeine powder administered in capsules
11280272|NCT02832401|Placebo Comparator|Placebo|Cellulose powder administered in capsules
11280273|NCT02832388||PA-patients for MRI|A subgroup of PA-patients perform a coronary MRI, including stress-testing with adenosine, and are compared to a sex- and age-matched group of healthy Controls who perform the same MRI-procedure
11280274|NCT02832388||Healthy controls|Healthy Controls that are age-and sex-matched to the subgroup of PA-patients performing coronary MRI, perform MRI including adenosine as stress-test during MRI
11280275|NCT02832388||PA-patients diagnosed from 2013 onwards|All PA-patients diagnosed at Haukeland University from 2013 onwards are asked for inclusion in the main observational PA-study.
11280276|NCT02832375|Experimental|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million [ppm] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
11280277|NCT02832375|Active Comparator|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
11280278|NCT02832362|Experimental|Carbomer 980|Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
11280279|NCT02832362|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
11280280|NCT02832349|Experimental|EA group (Educational Actions)|Epileptic patients participating to the educational actions program
11280281|NCT02832349|No Intervention|Control group|Epileptic patients with standard follow-up
11280282|NCT02832336|Experimental|Caffeine|"Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.
~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants."
11280283|NCT02832336|Placebo Comparator|Fiber|Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
11280284|NCT02832323|Other|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
11280285|NCT02832297|Other|Vectra DA (Arm A)|Treatment intensification with non-biologic DMARDS guided by Vectra DA
11280286|NCT02832297|Other|Usual care (Arm B)|Treatment intensification by usual care without using Vectra DA
11280287|NCT02832284|Experimental|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
11280288|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
11280289|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
11280290|NCT02832258||Children with urinary tract infection due to E-ESBL|In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with E-ESBL UTI (febrile UTI or cystitis) were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. We used the Kaplan-Meier method to estimate the time to apyrexia and length of hospital stay, and Log-rank test to assess equality of survivor functions. We also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
11280291|NCT02832232|Experimental|Mobilization Group|translational dorsal glide mobilization technique grade III and Protocolized Physiotherapy
11280292|NCT02832232|Experimental|Maintained pressure Group|pressure maintained suboccipital inhibition technique and Protocolized Physiotherapy
11280293|NCT02832232|Other|Control Group|Protocolized Physiotherapy
11280294|NCT02832219|Experimental|Molecular hydrogen|Molecular hydrogen, tablet, 2 g/day, 4 weeks
11280295|NCT02832219|Placebo Comparator|Placebo|Cellulose, tablet, 2 g/day, 4 weeks
11280296|NCT02832206||hybrid ablation|60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation
11280297|NCT02832193||Study group|"POCD data of study patients of the following studies:
~Phydelio - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 ReCosa - EA1/056/13 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 Pain-Long-EA2/041/17 PCI - EA2/024/18 Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
11280298|NCT02832193||Control group I|"POCD data of prospective control subjects/patients (ASA I+II+III) and POCD data of control subjects/patients of the following studies:
~Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 Phydeliostudie - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 BioCog-Studie - EA2/092/14 REACT-Studie - EA2/091/15 PAINLONG-Studie - EA2/041/17 PCI - EA2/024/18 Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
11280299|NCT02832180|Experimental|Daily single dose of OC containing EE and NET|Daily single dose of OC Containing EE and NET alone.
11280300|NCT02832180|Experimental|Daily single dose of OC in combination with BMS-986142|Daily single dose of OC containing EE and NET in combination with BMS-986142.
11280301|NCT02832167|Experimental|Nivolumab|
11280302|NCT02832154|Experimental|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
11280303|NCT02832141||Group A|Group A: immediate effects: T0, Grade 3 central thoracic mobilization from posterior-to-anterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
11280304|NCT02832141||Group B|Group B: immediate effects: T0, 3 central thoracic mobilization from anterior-to-posterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
11280305|NCT02832128|Experimental|AUT00063 - Placebo|AUT00063 (800 mg/day) for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with placebo
11280306|NCT02832128|Experimental|Placebo - AUT00063|Placebo for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with AUT00063 (800 mg/day)
11280307|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
11280308|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
11280309|NCT02832102||Retrospective cohort|"A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.
~Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN."
11280310|NCT02832102||Prospective cohort|"A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.
~Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments."
11280311|NCT02832089|Experimental|active arm|single arm study with one group given oral carvedilol.
11280312|NCT02832076|Experimental|group a|This arm will receive subcutaneous negative suction drain for the midline wound for 10 days.
11280313|NCT02832076|Active Comparator|group b|This arm will receive closure of the midline wound without a subcutaneous drain.
11280314|NCT02832063|Active Comparator|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
11280315|NCT02832063|Placebo Comparator|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
11280316|NCT02832050|Experimental|Intervention|"The play therapy intervention consists of a standard of care delivered by a play specialist. The play specialist delivers interventions aimed in assisting the child through the process of undergoing procedures. The intervention is semi-structured in order to facilitate a systematic approach which remains individualised and child-centred.
~The intervention requires patients to be classified as 'high risk' or 'low risk' for procedure-related anxiety. This is assessed for all patients at baseline based on parent and clinician opinion. The play specialist may re-classify patients at the initial assessment or at any point whilst working with the child. If this occurs, clear documentation of the rationale for this will be recorded. Patients classified as high risk receive additional preparation sessions as detailed in the standard of care."
11280317|NCT02832050|Placebo Comparator|Comparator|The comparator group will receive standard care of patients having blood tests within the Trust, which does not include the specific intervention of a play therapist routinely. As part of standard care if a child becomes particularly distressed a clinician may make a decision to refer the child for play therapy. If this occurs during the study period the child will be referred to the play specialist delivering the intervention for the study. The child will then receive play therapy as in the described intervention. They will be excluded from the main analysis but data will still be collected and analysed descriptively.
11280318|NCT02832037|Experimental|BI 425809 dose 1|
11280319|NCT02832037|Experimental|BI 425809 dose 2|
11280320|NCT02832037|Experimental|BI 425809 dose 3|
11280321|NCT02832037|Experimental|BI 425809 dose 4|
11280322|NCT02832037|Placebo Comparator|Placebo|
11280323|NCT02832024|Active Comparator|Intervention: Stents|Stents group
11280324|NCT02832024|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
11280325|NCT02832024|Active Comparator|Intervention: Balloon|Balloon group
11280326|NCT02832011|Active Comparator|olive oil|After randomization, Investigators will give human milk fortiﬁed with olive oil
11280327|NCT02832011|Active Comparator|Eoprotin|After randomization, Human milk fortiﬁed with Eoprotin according to the recommendations of the manufacturer (1g per 30ml milk)
11280328|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
11280329|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
11280333|NCT02831972|Experimental|Period 1|A single oral dose of AG-120 will be administered at Hour 0 followed by PK sampling for 504 hours (21 days).
11280334|NCT02831972|Experimental|Period 2|In Period 2, multiple oral doses of itraconazole will be administered once daily (QD) for 18 consecutive days (Days -4 to 14) with a single oral dose of AG-120 coadministered at Hour 0 on Day 1. PK sampling for AG-120 will be taken for 504 hours (21 days) following AG-120 dosing on Day 1. PK sampling will also be collected for itraconazole and its metabolite, hydroxy-itraconazole, from Day -2 up to Day 13.
11280335|NCT02831959|Experimental|NovoTTF-100M device|Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-100M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
11280336|NCT02831959|Active Comparator|Best Standard of Care|Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
11280337|NCT02831946|Experimental|MODIFIED VICRYL PLUS|The intra-cuticular layer will closed with with VICRYL PLUS suture
11280338|NCT02831946|Experimental|DERMABOND GLUE|The intra-cuticular layer will closed with with DERMABOND GLUE
11280339|NCT02831933|Experimental|Experimental|"ADV/HSV-tk (5 x 1011 viral particles) in a 2-mL total volume will be injected intratumorally on day 0 of the study.
~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days. Valacyclovir treatment will be administered 24 hours after the gene vector injection from day 1 to day 15 of the study.
~SBRT of 30 gray (Gy; 6 Gy X 5 fractions) will be administered over 2 weeks from day 2 to day 16 of the study.
~Nivolumab (480 mg) will be administered intravenously over 30 minutes every 4 weeks starting on day 17 of the study and continuing until disease progression, unacceptable toxicity, or up to 12 months in patients without disease progression."
11280340|NCT02831920|Experimental|Single Arm|every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies. Every patient is therefore its own control.
11280341|NCT02831907||Cardiac surgery patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
11280342|NCT02831894|Sham Comparator|0% Hypnotic Medication Taper|In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
11280343|NCT02831894|Active Comparator|25% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
11280344|NCT02831894|Active Comparator|10% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.
11280345|NCT02831868|Experimental|EXP|Implantation of a HAVAI device to correct HVA without osteotomy
11280346|NCT02831855|Experimental|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
11280347|NCT02831855|Placebo Comparator|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
11280348|NCT02831842||mCRC Participants|Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.
11280349|NCT02831829|Active Comparator|Water-based exercise training group|"Intervention: Patients randomized to the water-based exercise training group will undergo water-based exercise training. The immersed exercise will include two session of aerobic (water-based) and calisthenic exercise per day, six days of a week, each lasting 30 minutes."
11280350|NCT02831829|Active Comparator|Land-based exercise training group|"Patients randomized to the land-based exercise training group will undergo exercise training which will include two aerobic and calisthenic exercise session per day, six days of a week, lasting 30 minutes"
11280351|NCT02831829|No Intervention|Control group (usual care)|Control group: patients randomized in control group will have usual care with no exercise
11280352|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
11280353|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
11280354|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
11280355|NCT02831803|Experimental|Intervention|All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
11280356|NCT02831790|Experimental|Educational Intervention|Participants in the intervention group will have access to the 3 teaching videos, ~3:30-5:00 minutes in duration each, beginning several weeks prior to the preadmission clinic (as soon as written consent is obtained).
11280357|NCT02831790|No Intervention|Usual Care|Participants in the usual care will not be offered an intervention and will not be made aware of the existence of the teaching videos.
11280358|NCT02831764|Experimental|DTG + 3TC (50 mg+300 mg|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
11280359|NCT02831764|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
11280360|NCT02831751|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
11280361|NCT02831751|Experimental|60 µg/strain of Quadrivalent VLP Vaccine|
11280371|NCT02831686|Experimental|Selinexor (KPT-330), Ixazomib, and Dexamethasone|"Patients with relapsed and/or refractory MM will be treated with ixazomib, selinexor, and dexamethasone, all of which will be administered orally.Ixazomib will be given on Days 1, 8, and 15 on a 28 day cycle.
~Selinexor will be given twice weekly for three weeks, then there will be 1 week off (Days 1,3, 8,10, 15, 17) This study will follow a 3-by-3 dose escalation design.
~Dexamethasone will be given on all days of Selinexor but will also be given on the week off from Selinexor (Days 1, 3, 8, 10,15, 17, 22, 24)."
11280372|NCT02831673|Experimental|DTG + 3TC (50 mg+300 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
11280373|NCT02831673|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
11280374|NCT02831660|Experimental|idarucizumab|
11280375|NCT02831647|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PRAGUE for a period of 9 days.
11280376|NCT02831634|Other|Blood sampling|
11280377|NCT02831621|Active Comparator|diet (usual care)|All participants will receive a hypocaloric diet based on the individual resting metabolic rate. Resting metabolic rate (RMR) will be estimated using the WHO formula or measured using indirect calorimetry. Total energy expenditure will be calculated by multiplying RMR with a physical activity level (PAL). The used physical activity level will be 1.3. A hypocaloric diet with an energy deficit of 500 kcal/day will be prescribed. Participants will see a skilled dietician two-weekly the first month and on a monthly basis the next five months to discuss problems and solutions or coping strategies. The first consultation will have a duration of 60 minutes, the next consultations will have a duration of approximately 30 minutes. Each visit, nutritional compliance will be recorded on a 0 to 10 numeric rating scale. The usual care group will be asked to continue with their normal physical activity during the six-month intervention period.
11280378|NCT02831621|Experimental|diet+exercise|"For participants of this group, usual care will be supplemented with a prescribed exercise program. For this exercise program the participants will be referred to a local fitness club near home, free of charge. Aerobic training will be done at an intensity of 90-95% of the heart rate achieved at the RCP. Aerobic training will have a duration of 30 to 45 minutes, according to the training stage. Cardio training will be performed on different cardio devices and strength training will be done on isotonic strength training devices. Each training day, core stability training will be completed with four strength exercises for large muscle groups. Each exercise will be done in two sets of 15 repetitions with the goal to achieve better muscular strength endurance.
~This combined training will be done individually during six months, three times/week.
~In this study, an effort is made to reach a uniform manner of guidance to the physical activity program."
11280379|NCT02831608|Experimental|Drug: influenza vaccine|Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
11280380|NCT02831608|Placebo Comparator|Drug: placebo|Saline administered as a deep subcutaneous injection at one occasion per subject.
11280381|NCT02831595||Patients undergoing unilateral TKA|
11280382|NCT02831582|Active Comparator|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid supplementation PO QD for 6 months.
11280383|NCT02831582|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
11280384|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
11280385|NCT02831556||Emergency Department Subjects|Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.
11280386|NCT02831556||Non-patient volunteers|Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.
11280387|NCT02831543|Experimental|Motireb 5/100 mg t.i.d|Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
11280388|NCT02831543|Active Comparator|Mosapride citrate t.i.d|Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d
11280389|NCT02831543|Placebo Comparator|Placebo t.i.d|Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
11280390|NCT02831530|Experimental|Abemaciclib|Patients randomized to the treatment arm will start treatment from 15 days before the surgery (day 1 of the study) to receive the last dose of treatment the day before the surgical procedure (day 14 of the study). Abemaciclib will be taken orally at a dose of 150 mg/ twice a day (Every 12h +/- 2h) on day 1 to day 14. The treatment should be taken in the morning and evening with a big glass of water (250ml) at approximately the same time.
11280391|NCT02831530|No Intervention|No treatment|
11280392|NCT02831517|Experimental|Part 1|48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
11280393|NCT02831517|Experimental|Part 2|16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
11280394|NCT02831504||Myotonic Dystrophy type 1 (DM1) patients|Natural History Study
11280395|NCT02831491|Experimental|Ramucirumab + Docetaxel|Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.
11280396|NCT02831478|Experimental|BAY987517|2/3 of subjects testing the test article
11280397|NCT02831478|Active Comparator|Sunscreen Lotion|1/3 of subjects testing the marketed control
11280398|NCT02831465|Experimental|healthy subjects|Subjects with normal lung function between 40 and 70 years old.
11280399|NCT02831452||non-pregnant nulliparous|nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
11280704|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
11280400|NCT02831452||primigravid on 1º trimester|"nulliparous women on her first pregnancy and gestational age until 13 weeks and 6 days.
~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
11280401|NCT02831452||primigravid on 2º trimester|"nulliparous women on her first pregnancy and gestational age between 14 weeks and 27 weeks.
~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
11280402|NCT02831452||primigravid on 3º trimester|nulliparous women on her first pregnancy and gestational age above 28 weeks. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
11280403|NCT02831439|Experimental|Intervention|Participating health systems in Wisconsin. Interventions include: Basic public reporting and the enhanced intervention (app)
11280404|NCT02831439|Other|Control|Health systems in comparison states. Control includes: Cost savings comparison
11280405|NCT02831426|Active Comparator|ADM two-stage reconstruction|Two-stage with Acellular Dermal Matrix (CELLIS® Breast). Tissue Expander A, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by ADM
11280406|NCT02831426|Experimental|TCPM two-stage reconstruction|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra). Tissue Expander B, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by TCPM
11280407|NCT02831413|Placebo Comparator|Control|Control group members will receive an alternate curriculum that is not related to relationship education. Family Bridges has identified a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
11280408|NCT02831413|Experimental|RS+|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
11280409|NCT02831413|Experimental|RS+ with enhanced facilitator support|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
11280410|NCT02831400|Experimental|IFABP assessment (1 study group)|30 elderly volunteers
11280411|NCT02831387|Experimental|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
11280412|NCT02831387|Placebo Comparator|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
11280413|NCT02831374|Experimental|Use of platelet rich plasma (Group A)'|Local anesthesia, surgical extraction of impacted third molar, Preparation of PRP gel, Placing platelet Rich plasma and suturing, Postoperative medication
11280414|NCT02831374|Placebo Comparator|surgical extraction (Group B)|Local anesthesia, surgical extraction of impacted third molar, Suturing, Postoperative medication
11280415|NCT02831361|Experimental|Gemigliptin 50mg|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
11280416|NCT02831361|Placebo Comparator|Gemigliptin 50mg placebo|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
11280417|NCT02831348||Uncontrolled asthma|Indicated by an asthma control test (ACT) score of <20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
11280418|NCT02831348||Controlled asthma|Indicated by an ACT score of >19, or spirometry results within 10% of year's best value (based on FEV1).
11280419|NCT02831348||Pneumonia|Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
11280420|NCT02831348||Controlled allergic rhinitis|Indicated by a rhinitis control assessment test (RCAT) score of >= 21.
11280421|NCT02831348||Uncontrolled allergic rhinitis|Indicated by an RCAT score of <21.
11280422|NCT02831348||Cystic fibrosis (exacerbated)|Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
11280423|NCT02831348||Cystic fibrosis (stable)|Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
11280424|NCT02831348||Control|Indicated by a negative history of any of the conditions characterizing the other groups.
11280425|NCT02831335||Group 1|normal 21-35 years old participants
11280426|NCT02831335||Group 2|normal 36-50 years old participants
11280427|NCT02831335||Group 3|normal 51-65 years old participants
11280428|NCT02831335||Group 4|normal 66- 80 years old participants
11280429|NCT02831322|Experimental|radial artery occlusion|Radial artery occlusion was the absence of a flow signal by Doppler ultrasound examination.
11280430|NCT02831322|Other|radial artery normal|Radial artery normal was blood flow signal by Doppler ultrasound
11280431|NCT02831309|Sham Comparator|Sedentary Condition|Forty minutes of screen time. Standardized meals provided.
11280432|NCT02831309|Active Comparator|Light-Intensity Condition|Forty minutes of light-intensity activity. Standardized meals provided.
11280433|NCT02831309|Active Comparator|Moderate-Intensity Condition|Forty minutes of moderate-intensity activity. Standardized meals provided.
11280434|NCT02831309|Active Comparator|High-Intensity Condition|Forty minutes of high-intensity activity. Standardized meals provided.
11280435|NCT02831296||Affected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)
~The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy."
11280436|NCT02831296||Unaffected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger who are not affected with SMA
~The unaffected group will undergo the same assessments as the affected group."
11280437|NCT02831296||Unaffected Family Members|"Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.
~The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy."
11280438|NCT02831296||Affected Subjects >36 Mos. of Age|"Children and adults >36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.
~The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects."
11280439|NCT02831283|Experimental|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
11280440|NCT02831283|Active Comparator|No cognitive impairment|Normal aging
11280441|NCT02831270||Control Group|Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB
11280442|NCT02831270||Active Comparator: Acute normovolemic hemodilution group|Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
11280443|NCT02831257|Experimental|AZD2014|"18 patients will be enrolled in this study in a single stage.
~AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.
~One cycle will consist of 28 days (1 cycle = 28 days)."
11280444|NCT02831244|Other|Agili-CTM|Intervention
11280445|NCT02831231|Active Comparator|Xanomeline plus placebo|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
11280446|NCT02831231|Experimental|Xanomeline plus trospium|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
11280447|NCT02831218|Experimental|QCA and Aspirin alone|
11280448|NCT02831218|Experimental|QCA and Clopidogrel alone|
11280449|NCT02831218|Active Comparator|Imaging guided and Aspirin alone|
11280450|NCT02831218|Active Comparator|Imaging guided and Clopidogrel alone|
11280451|NCT02831205|Experimental|ABSORB BVS|
11280452|NCT02831205|Active Comparator|XIENCE EES|
11280453|NCT02831192|Experimental|MST（microtransplantation）|
11280454|NCT02831179|Experimental|Treatment (capecitabine, temozolomide, veliparib)|Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
11280455|NCT02831166|Active Comparator|Transradial approach|Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=125).
11280456|NCT02831166|Active Comparator|Transfemoral approach|Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=125).
11280457|NCT02831153|Active Comparator|normal coronary anatomy|coronary angiography will be performed by transfemoral or transradial route.
11280458|NCT02831153|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
11280459|NCT02831153|Active Comparator|slow coronary flow|coronary angiography will be performed by transfemoral or transradial route.
11280460|NCT02831153|Active Comparator|nonobstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
11280461|NCT02831153|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
11280462|NCT02831140|Other|Common arm : for both groups :|"In preoperative phase
~In peroperative phase
~In postoperative phase"
11280463|NCT02831140|Experimental|FTR protocol group (A)|"A. Experimental : FTR protocol group :
~Early exercises after a thoracic surgery : removing urinary probe and all catheters as well as alimenting ."
11280464|NCT02831140|No Intervention|Control group (B)|Traditional, conventional care group with first get up and alimentation permission in 24 hours at the postoperative.
11280465|NCT02831127|Experimental|short message service group|Patients in this arm received conventional instructions plus short message reminder.
11280466|NCT02831127|Active Comparator|conventional group|Patients in this arm just received conventional instructions.
11280467|NCT02831114|Experimental|Intervention|The nine participants in the intervention arm will receive 18 acupuncture treatments over the course of 12 weeks (2 treatments per week for 6 weeks and 1 treatment per week for 6 weeks). They will undergo assessments at baseline, 6 weeks, and 12 weeks through the use of questionnaires and blood tests. The participants will also be allowed to continue their conventional therapy for TIPN.
11280468|NCT02831114|No Intervention|Control|The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
11280469|NCT02831101|Experimental|Sufentanil|Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study
11280470|NCT02831101|Other|Placebo|Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study
11280471|NCT02831101|No Intervention|Propofol|Open administration using a separate target controlled infusion system and the PK/PD model by Schnider. Initial effect-site concentration 0.5 mcg/ml increased by 0.5 mcg/ml until LOC
11280472|NCT02831088|Experimental|Neu2000KWL High-dose group|
11280473|NCT02831088|Experimental|Neu2000KWL Low-dose group|
11280474|NCT02831088|Placebo Comparator|Placebo|
11280475|NCT02831075|Experimental|Adipose-derived stem cell|Mesenchymal stem cells derived from adipocyte transplantation
11280476|NCT02831075|Placebo Comparator|saline|saline injections
11280477|NCT02831062|No Intervention|ad lib diet|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients will be asked to continue on their regular diet and the protein and caloric ingestion will be recorded at each visit.
11280545|NCT02830516||Lung elastance - transpulmonary pressure|Lung elastance and transpulmonary pressure measured by tidal esophageal pressure variations and by performing a PEEP step
11280478|NCT02831062|Experimental|Low Protein Diet + Ketosteril|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients in this arm will be prescribed a low protein diet (LPD) and +Ketosteril supplementation, containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose). Protein and caloric ingestion will be recorded.
11280479|NCT02831049|Experimental|1|alcohol retrieval/alcohol extinction
11280480|NCT02831049|Active Comparator|2|soft-drink retrieval/alcohol extinction
11280481|NCT02831049|Active Comparator|3|alcohol retrieval/soft-drink extinction
11280482|NCT02831036|Experimental|trial group|subjects in trial group will be following the experimental protocol (VO2max tests and spatial orientation tests) while performing a training program during the trial (3 months).
11280483|NCT02831036|Other|control group|following the experimental protocol (VO2max tests and spatial orientation tests)without performing additional exercise.
11280484|NCT02831023|Active Comparator|SP-AQ only|Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
11280485|NCT02831023|Experimental|SP-AQ plus PQ|Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
11280486|NCT02831023|Active Comparator|DP only|Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
11280487|NCT02831023|Experimental|DP plus MB|Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).
11280488|NCT02831010||encephalopathy of prematurity|infants with encephalopathy of prematurity showed on MRI at term-equivalent age
11280489|NCT02831010||no encephalopathy of prematurity|infants with no encephalopathy of prematurity showed on MRI at term-equivalent age
11280490|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
11280491|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
11280492|NCT02830984|Experimental|EST+LBD+ENBD group|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
11280493|NCT02830984|Active Comparator|EST+LBD group|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
11280494|NCT02830971|Other|Clinical specific education|Providing clinical skills conditions
11280495|NCT02830958|Experimental|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
11280496|NCT02830958|Placebo Comparator|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
11280497|NCT02830945|Other|Control Brochure Arm|Control Arm households receive a culturally tailored Stroke and CVD brochure for prevention.
11280498|NCT02830945|Experimental|Motivational Interviewing Intervention Arm|The MI intervention households receive three aspects of the intervention: digital stories, motivational interviewing talking circle and the option to receive text messages to adhere to the action plan.
11280499|NCT02830932|Experimental|VXA-RSV-f Tablets (high dose)|Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
11280500|NCT02830932|Experimental|VXA-RSV-f Tablets (low dose)|Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
11280501|NCT02830932|Placebo Comparator|VXA Placebo Tablets|Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
11280502|NCT02830919|Experimental|Glucosamine and chondroitin sulfate combination (Eurofarma)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
11280503|NCT02830919|Active Comparator|Glucosamine and chondroitin sulfate combination (Zodiac)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
11280504|NCT02830906|Experimental|ramosetron group|Patients received 0.3 mg of intravenous ramosetron before spinal anesthesia and intrathecal morphine
11280505|NCT02830906|Active Comparator|ondansetron group|Patients received 8 mg of intravenous ondansetron before spinal anesthesia and intrathecal morphine
11280506|NCT02830893|Experimental|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
11280507|NCT02830893|Active Comparator|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
11280508|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
11280509|NCT02830854|Experimental|Molecular Hydrogen|Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks
11280546|NCT02830503|Experimental|Intervention|Feeding tube daily replacement
11280547|NCT02830503|No Intervention|Control|Feeding tubes replaced as normal practice in the department (normally once a week).
11280548|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
11280510|NCT02830841|Experimental|DR-RIPC (donor and recipient RIPC group)|Both donors and recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm(donor) or right lower limb(recipient) and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
11280511|NCT02830841|Sham Comparator|S-RIPC (sham RIPC)|Patients had a deflated cuff placed on the right upper arm or right lower limb for 30 min
11280512|NCT02830841|Experimental|R-RIPC (recipient RIPC group)|Recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right lower limb and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
11280513|NCT02830841|Experimental|D-RIPC (donor RIPC group)|Donors receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
11280514|NCT02830828||Patients|Patients fulfilling inclusion/exclusion criteria referred to the PI with suspected carpal tunnel syndrome.
11280515|NCT02830828||Controls|"Healthy volunteers fulfilling inclusion/exclusion criteria with no symptoms of carpal tunnel syndrome.
~Mid-study, it was elected to also match patients to their own contralateral disease-free hand to act as a control."
11280516|NCT02830802|Experimental|Group A|Active Agent
11280517|NCT02830802|Placebo Comparator|Group B|Placebo
11280518|NCT02830789|Experimental|Calcium Carbonate|1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3
11280519|NCT02830789|Experimental|Calcium Citrate|2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3
11280520|NCT02830776|Experimental|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
11280521|NCT02830763|Experimental|Medium-chain Fatty Acid (CNT-02)|
11280522|NCT02830737|Active Comparator|Traditional RFA|Using Traditional RFA for the treatment of small hepatocellular carcinoma
11280523|NCT02830737|Experimental|No-touch RFA|Using No-touch RFA for the treatment of small hepatocellular carcinoma
11280524|NCT02830724|Experimental|1/Phase I|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
11280525|NCT02830724|Experimental|2/Phase II|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
11280526|NCT02830685|Active Comparator|Direct-To-Implant A|DTI with Acellular Dermal Matrix (CELLIS® Breast), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of an Acelluar Dermal Matrix (ADM)
11280527|NCT02830685|Experimental|Direct-To-Implant B|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of a titanium coated polypropylene mesh
11280528|NCT02830672|Active Comparator|Open surgical release A1 Pulley|
11280529|NCT02830672|Active Comparator|Ultrasound guided close release A1 pulley|
11280530|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC
11280531|NCT02830633|Experimental|LNTME|Laparoscopy-assisted nerve-preserved TME (LNTME) is conducted in rectal cancer patients
11280532|NCT02830633|Active Comparator|OTME|Open TME (OTME) is conducted in rectal cancer patients
11280533|NCT02830620|Other|groupe1|cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines
11280534|NCT02830620|Other|groupe2|cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines
11280535|NCT02830620|Other|groupe3|pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines
11280536|NCT02830620|Other|groupe4|unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines
11280537|NCT02830607|Experimental|Xiaomi Mi Band|participants will wear Xiaomi Mi Band .the device measures their daily steps number before and after epidural steroid injection for treatment of low back pain.
11280538|NCT02830594|Experimental|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Cycles repeat every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity."
11280539|NCT02830568||couples kidney living donor - receiver|"Three groups for each technique of taking of kidney :
~open donor nephrectomy
~standard and hand-assisted laparoscopic donor nephrectomy
~laparoscopic robotic-assisted nephrectomy"
11280540|NCT02830542|Experimental|SER-262|SER-262 [Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs]
11280541|NCT02830542|Placebo Comparator|Placebo|Placebo
11280542|NCT02830529|Experimental|MAD DASH|Mindfulness based stress reduction and diet education delivered in 8 sessions lasting 2.5 hours each. Mindfulness conducted by a certified trainer. Participants were given homework and meditation CD. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
11280543|NCT02830529|Experimental|DASH diet education|Dietary approaches to stop hypertension sessions were delivered by a registered dietitian in 8 sessions lasting 1 hour each. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
11280544|NCT02830529|No Intervention|Usual Care-DASH Pamphlet Only|Dietary approaches to stop hypertension pamphlet was mailed to each participant. They continued receiving usual care from their health care provider.
11280549|NCT02830438|Experimental|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
11280550|NCT02830412|Experimental|PONV Reminder|After patient has non-cardiac surgery, the subject will have Post-Operative Nausea and Vomiting Reminder display
11280551|NCT02830412|No Intervention|No PONV Reminder|After patient has non-cardiac surgery, the subject will not have Post-Operative Nausea and Vomiting Reminder display
11280552|NCT02830399|Active Comparator|active rTMS-ECT|5 active high frequency rTMS before 5 bilateral ECT
11280553|NCT02830399|Placebo Comparator|sham rTMS-ECT|5 sham rTMS before 5 bilateral ECT
11280554|NCT02830386||LVIS stents group|The patients with ruptured intracranial saccular aneurysm wil be treated with a LVIS stent without coils.
11280555|NCT02830373||LVIS stents group|patients with unruptured intracranial saccular aneurysms which located in the internal carotid artery or vertebra-basilar artery will be treated with a LVIS stent with coils
11280556|NCT02830360|Active Comparator|VT catheter ablation|Catheter ablation of ventricular tachycardia
11280557|NCT02830360|Active Comparator|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
11280558|NCT02830347||Amoxicillin|No randomization is performed. Patients who are prescribed antibiotics by the clinician performing the tooth extraction ( based on case complexity and intra operative judgement) are recruited into this group.The principal investigator is not involved in the decision to prescribe antibiotics or not.
11280559|NCT02830347||No Amoxicillin|Patients who do not receive antibiotics after extractions are recruited into this group.
11280560|NCT02830321||case|"Pregnant women who suffered from hyperemesis gravidarum and admitted in the hospital
~Age: 18-40 years old
~Gestational age: less than 16 weeks confirmed by pelvic u/s
~Excessive pregnancy - related nausea and /or vomiting that prevent adequate intake of food and fluids.
~All pregnant (case and control) were asked to bring a stool sample in a clean container. Collected samples were tested in a laboratory (Ain Shams Univerisity hospital).
~Stool samples were be tested by using one step H.pylori stool antigen test (CER TEST BIOTEC) for the detection of H. pylori antigen."
11280561|NCT02830321||control|Control patients which are selected from pregnant women presenting to the outpatient clinics for routine antenatal care of the same gestational age, same age range and same socioeconomic standard as cases.
11280562|NCT02830308||Adults with known or suspected endocrine or metabolic dissorde|Adults with known or suspected endocrine or metabolic dissorders
11280563|NCT02830295|Experimental|Basic Body Awareness Therapy|The Basic Body Awareness Therapy is usual therapy of physiotherapy in health mental in nord of europe. BBAT is based in twelve movements and massage that improve the movement quality of patient, also BBAT improves others movement qualities like biomechanical, physiologic, socio-cultural and existential.
11280564|NCT02830295|No Intervention|control|the patients which below receive the treatment as usual, according the clinic guidelines of Health government
11280565|NCT02830243|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
11280566|NCT02830243|Experimental|Desflurane|Anesthesia was maintained with desflurane.
11280567|NCT02830230|Experimental|Intervention group/Case|"women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.
~women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.A cervico-vaginal swab shall be taken for Lab diagnosis of RTIs along with HPVDNA test on day 1.Women shall be treated with Tab Azithromycin 1gm and Tab Cefixime 400mg stat along with barrier contraception advised.The women will be followed up after 7-14 days .A repeat cervicovaginal swab and HPVDNA shall be repeated."
11280568|NCT02830230|No Intervention|Control group|Women without signs and symptoms of cervicitis or cervico-vaginitis.No intervention will be done in this group
11280569|NCT02830217||STEMI patients having primary PCI|Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
11280570|NCT02830204|Experimental|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
11280571|NCT02830178||Any Paracetamol|Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
11280572|NCT02830178||Ibuprofen|Participants with age 18 and over who received a first prescription of single-ingredient ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
11280573|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
11280574|NCT02830152|Experimental|Left Atrial Appendage Occlusion (LAAO)|The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
11280615|NCT02829892|Other|Light therapy|Innovative ambient lighting
11280616|NCT02829879|Experimental|arginine|25 volunteers with dentin sensitivity
11280617|NCT02829879|Active Comparator|potassium nitrate|25 volunteers with dentin sensitivity
11280575|NCT02830152|Active Comparator|Medical Therapy|The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
11280576|NCT02830139|Sham Comparator|Radical colorectal resection without HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and postoperative chemotherapy (XELOX)
11280577|NCT02830139|Experimental|Radical colorectal resection with HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (XELOX)
11280578|NCT02830126|No Intervention|Anesthesiology Control Tower Control|Patients managed by anesthesia teams without feedback alerts from the ACT
11280579|NCT02830126|Experimental|Anesthesiology Control Tower Feedback|Patients managed by anesthesia teams with feedback alerts from the ACT
11280580|NCT02830113|Experimental|non-surgical periodontal treatment|One session of non-surgical periodontal treatment consisting of a complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution.
11280581|NCT02830100|Other|Healthy volunteers|
11280582|NCT02830087|Active Comparator|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
11280583|NCT02830087|Active Comparator|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
11280584|NCT02830087|Active Comparator|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
11280585|NCT02830087|Active Comparator|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
11280586|NCT02830087|Active Comparator|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
11280587|NCT02830087|Active Comparator|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
11280588|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the ?BEST? program (Best practices PAP + patient Education + ongoing Support and Training)
11280589|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
11280590|NCT02830061||TYAC|Teenagers and young adults who have received a cancer diagnosis which puts them at moderate-to-high risk of fertility impairment. Semi-structured interviews will take place with each individual participant.
11280591|NCT02830048|Experimental|Glibenclamide dose titration|Increasing doses of glibenclamide oral suspension from 0.3mg/day to 6mg/day.
11280592|NCT02830035|Active Comparator|Anatomical Landmark Technique|Traditional anatomical landmark technique based paramedian spinal anesthesia
11280593|NCT02830035|Active Comparator|Real-time Ultrasound-guided Technique|Ultrasound-guided paramedian spinal anesthesia Intervention: Ultrasound-guided Technique
11280594|NCT02830022|Experimental|Patients|Children from 8 to 18 years with autism without without intellectual disabilities (IQ > 70), verbals and responding to classification CIM 10-DSM IV.
11280595|NCT02830022|Experimental|Healthy volunteers|Paired for age, gender, IQ and and the practice of a physical activity strictly within the school context.
11280596|NCT02830009|Other|Primary Hyperoxaluria patient|
11280597|NCT02830009|Other|Primary Hyperoxaluria patient's siblings|
11280598|NCT02830009|Other|Idiopathic hypercalciuria patients|
11280599|NCT02830009|Other|Healthy volunteers|
11280600|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
11280601|NCT02829996|Experimental|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
11280602|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
11280603|NCT02829996|Active Comparator|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
11280604|NCT02829996|Active Comparator|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
11280605|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
11280606|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
11280607|NCT02829970|Experimental|SUCCEEDS Program|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will be engaged about personalized alcohol feedback and identify life values and specific activities important to those values.
11280608|NCT02829970|Active Comparator|Living a Healthy College Lifestyle|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
11280609|NCT02829957|Active Comparator|Rivaroxaban|
11280610|NCT02829957|Active Comparator|Apixaban|
11280611|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
11280612|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
11280613|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.
~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
11280614|NCT02829918|Experimental|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
11280618|NCT02829853||sporadic cases (SP)|Sporadic cases are defined as patients diagnosed for sarcoidosis, for which the familial history did not reveal any other cases, whatever the relative degree is: 1, 2, 3 or 4. The clinical follow-up and the genetic studies performed in the frame of this project are the same as for the familial group. During the regular follow-up, patients are regularly questioned about the putative occurrence of the disease in their family, and if such a situation occurred, the patient (and his relative) may change from the SP to the familial (FAM) group. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
11280619|NCT02829853||familial cases (FAM)|Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
11280620|NCT02829840|Experimental|Cohort #1|"Cohort #1: Participants with no previous leukemia therapy (including no previous FLT3 inhibitor therapy) for either: a) front-line treatment of elderly (age 65 and greater) FLT3-mutated AML patients, or b) patients unable or unwilling to receive standard intensive therapy.
~Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.
~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
11280621|NCT02829840|Experimental|Cohort #2|"Cohort #2: Participants with relapsed/refractory FLT3-mutated AML that have not received prior FLT3 inhibitor therapy.
~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.
~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
11280622|NCT02829840|Experimental|Cohort #3|"Cohort #3: Participants with relapsed/refractory FLT3-mutated AML, that have received previous FLT3 inhibitor therapy (including, but not limited to, quizartinib, crenolanib, sorafenib, other FLT3 inhibitors).
~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant will continue on to Part 2 of study.
~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
11280623|NCT02829827|Experimental|Radiprodil|Each subject will enter an individualized dose titration schedule.
11280624|NCT02829814|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
11280625|NCT02829814|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
11280626|NCT02829801|Experimental|AAT arm|AAT and cognitive stimulation and rehabilitation of social tie.
11280627|NCT02829801|Other|control group|Cognitive stimulation and rehabilitation of social tie.
11280628|NCT02829788||Digestive peritoneal carcinomatosis staging|All patients underwent laparoscopic followed by laparotomic surgical staging.
11280629|NCT02829775|Experimental|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
11280630|NCT02829762|Experimental|Interventional arm PS-DR|The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
11280631|NCT02829762|No Intervention|Reference Arm|In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.
11280632|NCT02829749|Experimental|NeoChord DS1000 Artificial Chordae Delivery System|Subjects randomized to the experimental group will undergo the NeoChord implantation
11280633|NCT02829749|Other|Control|traditional mitral valve repair performed under cardiac arrest
11280634|NCT02829736|Active Comparator|Chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard post-operative chest tube.
11280635|NCT02829736|Experimental|No chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
11280636|NCT02829723|Experimental|BLZ945 single agent|
11280637|NCT02829723|Experimental|BLZ945 + PDR001|
11280638|NCT02829710||group 1 : pre implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between January 2013 and December 2013.
~Prior to implementation of the protocol, analgesia and sedation were managed by the attending physician's order."
11280639|NCT02829710||group 2 : post implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between May 2014 and March 2015.
~Nurses managed analgesia and sedation following an algorithm, including COMFORT-B scale."
11280640|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 2.5 mL|Perineural injection of ropivacaine 0.2 %, 2,5 mL
11280641|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
11280642|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
11280643|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
11280644|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
11280645|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
11280646|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
11280647|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
11280648|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
11280649|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 30 mL|Perineural injection of ropivacaine 0.2 %, 30 mL
11280650|NCT02829671|Other|Patients with major depressive disorders|
11280651|NCT02829658||Psychiatric patients group|Patient groups were composed with: BPD, other PD and assessed Psychologic test
11280652|NCT02829658||Control group|Matched controls (age, sex) composed the 3rd and 4th group (BPD control and other PD control). They were randomly chosen in the health database insurance previously used. They had no intervention.
11280653|NCT02829645|Other|Eating disorders|
11280654|NCT02829632|Experimental|Experimental: Group Sessions|Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
11280655|NCT02829632|Experimental|Active Comparator: Self-Monitoring|Active Comparator: Self-monitoring Participants will record diet, activity and weight as described above in the participant's smartphone app to assist the participant in losing weight.
11280656|NCT02829632|Experimental|Experimental: Feedback|"Participants will be sent via the participant's smartphone between
~1 and 4 feedback messages a day about whether the participant has been self monitoring, or the amount of calories, fat or sugar the participant has consumed."
11280657|NCT02829606|Active Comparator|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
11280658|NCT02829606|Active Comparator|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
11280659|NCT02829593|Experimental|type 1 diabetes|type 1 diabetes >5 years duration
11280660|NCT02829593|Placebo Comparator|healthy controls|
11280661|NCT02829580|Experimental|Sickle group|Children with major sickle cell syndrome will have an usual Echocardiography
11280662|NCT02829580|Active Comparator|Control group|Children recruited in a previous study and who had an usual Echocardiography
11280663|NCT02829567|Experimental|Oral hygiene counseling and motivational interviewing|This group will receive a session of oral hygiene counseling and a single session of motivational interviewing to increase the readiness of change.
11280664|NCT02829567|No Intervention|Oral hygiene counseling|
11280665|NCT02829554||Respondents|US residents recruited to an on-line questionnaire through Amazon mTurk.
11280666|NCT02829541|Experimental|Cohorts 1|6 participants randomized (4:2) to receive a single-ascending dose (SAD) administered orally in tablet
11280667|NCT02829541|Experimental|Cohort 2|6 participants randomized (4:2) to receive a SAD administered orally in tablet(s)
11280668|NCT02829541|Experimental|Cohort 3|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
11280669|NCT02829541|Experimental|Cohort 4|8 participants randomized (6:2) to receive a SAD administered orally in tablet
11280670|NCT02829541|Experimental|Cohort 5|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
11280671|NCT02829541|Experimental|Cohort 6|14 participants (all active) to receive a SAD administered orally in tablet(s)
11280672|NCT02829528|Experimental|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
11280673|NCT02829502|Active Comparator|Byetta|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
11280674|NCT02829502|Placebo Comparator|Normosaline|"Pre- and post treatment investigations:
~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler
~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)
~Endothelial function/response by the methods:
~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)
~EndoPAT2000
~Ankle-brachial index"
11280675|NCT02829476|Experimental|patients with AIS|Patients will have 'Osteoblast sample'
11280676|NCT02829476|Experimental|control patients|
11280677|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
11280678|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
11280679|NCT02829450||PD|"Patients with CHF and chronic renal disease which started the treatment with peritoneal ultrafiltration.
~The patients will be follow up every 3 months for assesment of symptoms, QOL questionary, routine blood and urine tests and also for assesment of residual renal function and peritoneal membrane function: monitoring of clinical symptoms of fluid overload, hospital admissions, UF rate, peritoneal membrane damage parameters (cell-free DNA in peritoneal effluent, peritoneal equilibration test) and residual renal function markers (eGFR creatinine or cystatin C based , KT/V, urinary markers) at the start of the treatment, each 3 months during the treatment and at each change of prescription. Complications of all kinds will be recorded."
11280680|NCT02829450||Control|Patients with CHF and chronic renal disease which preferred to continue their regular treatment or choose other then peritoneal ultrafiltration type of renal replacement therapy (data from medical records): clinical symptoms of fluid overload, hospital admissions, urine volume,residual renal function markers (eGFR creatinine)
11280681|NCT02829437||Retrospective Observational Group|Patients who received treatment for EST Patients with EST diagnosis prior August 2016
11280682|NCT02829437||Prospective Observational Group|Patients who will receive treatment for EST Patients with EST diagnosis after August 2016
11280683|NCT02829424|Active Comparator|Experimental group|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the control group and according to the Summary of Product Characteritics (SmPC) MTX: 15 mg a week orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX will be initiated within 7 days after the start of the anti TNF alpha agent
11280684|NCT02829424|Placebo Comparator|Control group|"Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent
~All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the experimental group and according to the SmPC Placebo-MTX orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX-placebo will be initiated within 7 days after the start of the anti TNF alpha agent"
11280685|NCT02829411|Active Comparator|Employment Services only|'Workforce Readiness Program'. job readiness workshop, organized into ten daily sessions over two weeks. The main content of these sessions will be a program-developed workforce readiness training, developed with funding from a DOL Career Pathways Bridge grant.
11280686|NCT02829411|Experimental|Employment Services with HMRE content|'Workforce Readiness Program supplemented with Relationship Education': job readiness workshop, organized into ten daily sessions over two weeks. Program will add approximately 17 hours of content from the Within My Reach relationship education curriculum to the two-week job readiness workshop - and add up to eight additional one-hour relationship skills education sessions that customers can attend in the five weeks after completing the initial two-week job readiness workshop
11280687|NCT02829398|Experimental|Patients with subarachnoid hemorrhage|Patients with subarachnoid hemorrhage will have CerebroSpinal fluid and plasma sample.
11280688|NCT02829398|Active Comparator|Control subjects|healthy controls from a previous study with a CerebroSpinal fluid and plasma sample
11280689|NCT02829385|Experimental|Apatinib combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)
~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
11280690|NCT02829372|Experimental|GBR 1302|Dose escalation
11280691|NCT02829359|Experimental|Entecavir therapy|Patients who received entecavir (zhengda Tianqing Co., Ltd, Lianyungang, Jiangsu Province, China; 0.5 mg/d) were submitted to antiviral group. Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month. No immunological therapy in perioperative period will be submitted to any included patients.
11280692|NCT02829359|No Intervention|No antiviral therapy|Patients who did not receive any antiviral therapies were submitted as non-antiviral group. Patients in the non-antiviral group who underwent HBV reactivation will receive entecavir therapy. No immunological therapy in perioperative period will be submitted to any included patients.
11280693|NCT02829346|Experimental|Peri-articular group|Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
11280694|NCT02829346|Active Comparator|Intravenous group|Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.
11280695|NCT02829333|Other|Group GA|22 patients receive general anesthesia and patient controlled intravenous analgesia
11280696|NCT02829333|Other|Group SA|22 patients receive spinal anesthesia and continuous postoperative epidural analgesia
11280697|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
11280698|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
11280699|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
11280700|NCT02829281|Experimental|Botulinum toxin group|Patients will receive a intervention with joint injection of 100 units of botulinum toxin
11280701|NCT02829281|Active Comparator|Corticosteroid group|Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
11280702|NCT02829281|Placebo Comparator|Saline Group|Patients will receive a joint injection of 2ml of normal saline
11280705|NCT02829255|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
11280706|NCT02829242||Prostatic Surgery|Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
11280707|NCT02829242||Colorectal Surgery|Patient scheduled for a robotic assisted laparoscopic colorectal surgery.
11280708|NCT02829229|No Intervention|Usual care (UC)|Usual postpartum WIC care
11280709|NCT02829229|Experimental|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
11280710|NCT02829203||No-Frailty|Patients without frailty score submitted to a cardiac surgery
11280711|NCT02829203||Pre-Frailty|Patients with pre-frailty score submitted to a cardiac surgery
11280712|NCT02829190|Experimental|Healthy volunteers|Magnetic Resonance Imaging (MRI)
11280713|NCT02829190|Experimental|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
11280714|NCT02829190|Experimental|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
11280715|NCT02829190|Experimental|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
11280716|NCT02829177|Active Comparator|Allopurinol|400 mg once daily, tablet treatment
11280717|NCT02829177|Placebo Comparator|Placebo|Identical tablet treatment
11280718|NCT02829151|Experimental|Triple antiplatelet therapy group|Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol
11280719|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) A|Patient group with dual antiplatelet therapy using aspirin and clopidogrel
11280720|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) B|Patient group with angioplasty using aspirin and cilostazol
11280721|NCT02829138|Placebo Comparator|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
11280722|NCT02829138|Experimental|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
11280723|NCT02829099|Experimental|JNJ-64457107|In Part 1, the first cohort will receive JNJ-64457107 at a starting dose of 75 microgram per kilogram (mcg/kg). The proposed treatment schedule is intravenous (IV) dosing every 14 days. JNJ-64457107 doses will be escalated following a modified Continual Reassessment Method (mCRM); the JNJ-64457107 dose will be increased by not more than half-logarithmical (3.2-fold) dose increments. Dose escalation will continue until the maximum tolerated dose (MTD) and/or RP2D of JNJ-64457107 are defined or the maximum-administered dose (MAD) has been reached. In Part 2, subjects will receive JNJ-64457107 at the RP2D and regimen determined in Part 1.
11280724|NCT02829086|Experimental|Group I|Participants in Group I will receive the following interventions: Intro to Relationship Enhancement (8 hours), Family Stress and Conflict Management (8 hours), and case management
11280725|NCT02829086|Experimental|Group II|Participants in Group II will receive the following interventions: Intro to Relationship Enhancement (8 hours), RE & Financial Management (8 hours), and case management
11280726|NCT02829086|No Intervention|Group III|Participants in Group III will receive the the standard care of all participants, case management ONLY
11280727|NCT02829073|Experimental|Oasis™ device|Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.
11280728|NCT02829073|Placebo Comparator|Placebo device|Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.
11280729|NCT02829060|Active Comparator|1a: Indwelling drains (48 hr)|"This group has indwelling urinary tubes/drains and a negative urine culture
~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
11280730|NCT02829060|Active Comparator|1b: Indwelling drains (7d)|"This group has indwelling urinary tubes/drains and a negative urine culture
~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
11280731|NCT02829060|Active Comparator|2a: +UCx with Oral Options (48hr)|"This group has a positive pre-operative urine culture with oral antibiotic options
~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery
~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
11280732|NCT02829060|Active Comparator|2b: +UCx with Oral Options (7d)|"This group has a positive pre-operative urine culture with oral antibiotic options
~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery
~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
11280733|NCT02829060|Active Comparator|3a: +UCx No Oral options (48hr)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities
~48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)
~Gentamicin (80 mg) preferred if sensitive
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
11280734|NCT02829060|Active Comparator|3b: +UCx No Oral options (7d)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities
~7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)
~Gentamicin (80 mg) preferred if sensitive
~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
11280735|NCT02829047|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
11280736|NCT02829034|Active Comparator|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
11280737|NCT02829034|Placebo Comparator|Placebo|Placebo by mouth twice per day
11280738|NCT02829021|Other|Thermography and mammography|"All participants will be examined with
~Dynamic infrared thermography (FLIR ThermaCAM P-65)
~Mammography, clinical examination and if necessary breast tissue biopsy to diagnose breast cancer."
11280739|NCT02829008|Experimental|low-dose-bevacizumab/Pemetrexed|Low-dose-bevacizumab is given at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and every three weeks are a treatment cycle .Pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too. The pretreatment of pemetrexed should be conducted within the study.
11280740|NCT02829008|Active Comparator|Treatment of physician' choice|Treatment of physician's choice can be any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. It can be drugs like taxanes,capecitabine, gemcitabine, cisplatin, everolimus or even nutrient solution,et al.
11280741|NCT02828995||Comprehensive Diabetes Stigma Survey|Participants in the END STIGMA study will be adult patients who have been receiving diabetes-related medical care for a minimum of 12 months in the Vanderbilt University Medical Center Diabetes Clinic and who take at least 1 medication to manage their diabetes.
11280742|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
11280743|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
11280744|NCT02828969|Other|Children and adolescents with conduct disorders|Girls and boys having less than 18 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
11280745|NCT02828943|Active Comparator|IMT with Low Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. For the comparator group, EMT will be set to 5 cm H2O, the lowest setting on the device. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with low resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training.
11280746|NCT02828943|Experimental|IMT with High Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. EMT training loads in the experimental group will be set to 30% of maximal expiratory pressure. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with high resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training. At two weeks, participants will have a follow-up office visit to monitor progress and those that have completed 80% of their training sessions will increase their training to 40% of maximum inspiratory and expiratory pressures as tolerated.
11280747|NCT02828930|Experimental|Idasanutlin|On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg [14C]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of [13C]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
11280748|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
11280749|NCT02828904||Primary Cases|"Primary cases are women
~aged 15 to 49 years
~with a new VTE diagnosis within the study period
~current user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
11280750|NCT02828904||Secondary Cases|"Secondary cases are women
~aged 15 to 49 years
~with a new VTE diagnosis within the study period
~using any HC other than CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg, or not using any HC at all"
11280751|NCT02828904||Primary Controls|"Primary controls are women
~aged 15 to 49 years
~matched to a primary case by age (+/- 1 year) and region of residence
~current or recent past user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
11280752|NCT02828904||Secondary Controls|"Secondary controls are women
~aged 15 to 49 years
~matched to a primary case by age (+/- 1year) and region of residence
~current or recent past user of other COCs (not containing CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg)"
11280753|NCT02828891|Experimental|Experimental|Intervention: transcranial Doppler device will be utilized to measure CSF pressure.
11280754|NCT02828878|Experimental|ApoGraft|ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
11280755|NCT02828865|Experimental|irreversible electroporation (IRE)|irreversible electroporation (IRE) (AngioDynamics, NY) To use 2 to 6 unipolar electrodes of IRE in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
11280756|NCT02828852|Experimental|Pregnancy|Blood sample
11280757|NCT02828852|Experimental|No pregnancy|Blood sample
11280795|NCT02828566|Active Comparator|IV ketamine and IN saline|Ketamine, single dose, 1 to 1.5 mg/kg (0.02 to 0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 120 mg (2.4 mL) AND 0.9% normal saline (NS) 0.1 mL/kg delivered intranasally using an atomizer and divided to both nares, to a maximum of 8 mL
11280758|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
11280759|NCT02828826|Experimental|telephone coaching|"Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.
~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.
~Data from the telephone coaching will be recorded in the eCRF."
11280760|NCT02828826|No Intervention|Without telephone coaching|
11280761|NCT02828813||Normal|healthy subjects
11280762|NCT02828813||CogImpair|persons with cognitive impairments
11280763|NCT02828813||MotorDeficits|persons with motor deficits
11280764|NCT02828787|Experimental|Urticaria|15 patients with urticaria
11280765|NCT02828787|Experimental|Psoriasis|15 patients with psoriasis
11280766|NCT02828787|Other|healthy|15 healthy control subjects
11280767|NCT02828761|Experimental|Coronary Calcium Scoring|Coronary calcium scoring by multidetector row computed tomography (MDCT).
11280768|NCT02828761|Active Comparator|Standard Care|Standard evaluation of chest pain patient which often includes immediate non-invasive imaging.
11280769|NCT02828748|Experimental|active UC|patients with clinically active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
11280770|NCT02828748|Experimental|remission UC|patients with clinically non active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
11280771|NCT02828748|Experimental|active CD|patients with clinically active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
11280772|NCT02828748|Experimental|remission CD|patients with clinically non active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
11280773|NCT02828735|Other|Respiration assessment|
11280774|NCT02828722|Experimental|Controlled light, noise and nutrition|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the nutrition protocol corresponding to the daily rhythm will be applied.
11280775|NCT02828722|Experimental|Controlled light and noise|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the continuous nutrition (in accordance with the clinical trial site's standard practice) will be applied.
11280776|NCT02828722|No Intervention|Control|The treatment of the study subject will be performed based on the clinical trial site's standard practice without environmental simulation or changes in the nutrition protocol.
11280777|NCT02828709|Experimental|Irreversible electroporation (IRE)|"IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called nanopores, resulting in increased permeability of the cell and subsequent cell death."
11280778|NCT02828696|Other|No prep|"No prep treatment of worn dentition with CAD-CAM composite (PICN)"
11280779|NCT02828683|Experimental|Ultimaster, Drug Eluting Stent|Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster
11280780|NCT02828683|Active Comparator|Kaname, Bare metal stent|Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname
11280781|NCT02828670||patient|
11280782|NCT02828670||control|
11280783|NCT02828644|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
11280784|NCT02828644|Active Comparator|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
11280785|NCT02828631|Active Comparator|Macintosh laryngoscope|Nasotracheal intubation by Macintosh laryngoscope
11280786|NCT02828631|Experimental|McGrath videolaryngoscope|Nasotracheal intubation by McGrath videolaryngoscope
11280787|NCT02828631|Experimental|Pentax videolaryngoscope|Nasotracheal intubation by Pentax videolaryngoscope
11280788|NCT02828618|Active Comparator|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
11280789|NCT02828618|Experimental|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
11280790|NCT02828605|No Intervention|Control Group|Only receive surveys.
11280791|NCT02828605|Experimental|Experimental Group|Receive VIP Transplant App and surveys.
11280792|NCT02828592|Experimental|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
11280793|NCT02828579||Group 1|Patient with morbid obesity defined as a BMI above 40kg/m2 or 35kg/m2 with comorbidities who are qualified for bariatric surgery.
11280794|NCT02828566|Experimental|IN ketamine and IV saline|Ketamine, single dose, 10 mg/kg (0.1 mL/kg) of 100 mg/mL solution delivered intranasally using an atomizer and divided to both nares to a maximum of 800 mg (8 mL) AND 0.9% normal saline (NS) 0.02 to 0.03 mL/kg delivered intravenously to a maximum of 2.4 mL
11280879|NCT02827903|Active Comparator|Group III|Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
11280796|NCT02828553||Control Group - Usual Care|At the start of the study, subjects will be enrolled in usual care when admitted to the heart failure unit following standard protocols.
11280797|NCT02828553||Intervention Group - Aggressive Ambulation|After a washout period and transition to a new aggressive ambulation protocol, subjects will be enrolled to usual care + aggressive planned ambulation with a trained mobility aide.
11280798|NCT02828540|Experimental|HT047 High-dose group|three times a day dosing schedule 3 tablets per dose
11280799|NCT02828540|Experimental|HT047 Low-dose group|three times a day dosing schedule 3 tablets per dose
11280800|NCT02828540|Placebo Comparator|Placebo|three times a day dosing schedule 3 tablets per dose
11280801|NCT02828501|Experimental|Lumbar manipulation group|Spinal Manipulation
11280802|NCT02828501|Experimental|Cervical manipulation group|Spinal Manipulation
11280803|NCT02828501|No Intervention|Control group|This group will receive a 2 minute supine rest between measurements
11280804|NCT02828475||CALYPSO-augmented|Patients' postoperative care will be augmented with the CALYPSO platform.
11280805|NCT02828475||Historical Control|Patients' postoperative care was performed using standard practice, before adopting the CALYPSO platform
11280806|NCT02828462||Experimental|Patients using the device
11280807|NCT02828462||Control|Patients not using the device
11280808|NCT02828449|Experimental|therapeutic education program|therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer
11280809|NCT02828436|Experimental|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
11280810|NCT02828436|Other|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
11280811|NCT02828423|Active Comparator|Control group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) alone
11280812|NCT02828423|Experimental|Test group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) and Biphasic Calcium phosphate (BC)
11280813|NCT02828410|Experimental|SBI|Serum bovine immunoglobulin protein isolate (SBI)
11280814|NCT02828397|Experimental|Reference Drug|REGN2222 Reference Formulation
11280815|NCT02828397|Experimental|Test Drug|REGN2222 Test Formulation
11280816|NCT02828384|Active Comparator|low fodmap diet|Subjects receive formalized teaching in low fodmap diet by a dietician
11280817|NCT02828384|Active Comparator|psyllium|subjects receive 7.1 g of psyllium daily
11280818|NCT02828371|Experimental|Erigo|Single daily sessions of verticalization, using a tilt table with an integrated robotic stepping device (Erigo. Hocoma AG, Switzerland) located in the ICU room. Sessions were performed five times per week (Monday-Friday) for three consecutive weeks (a total of 15 sessions per patient). On the same days the patients received conventional physiotherapy for 30 minutes a day. Before the verticalization period the experimental group received conventional in-bed physiotherapy for 60 minutes a day.
11280819|NCT02828371|Active Comparator|Conventional|treated with conventional in-bed physiotherapy for 60 minutes a day, from Monday to Friday, throughout the ICU stay.
11280820|NCT02828358|Experimental|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
11280821|NCT02828332|Other|Patient with autism disorder|Interview with a psychologist who do Vineland II (VABS -II) and evaluate Quality of life and comorbidities
11280822|NCT02828319|Experimental|Z-213|
11280823|NCT02828306||Patients with skull defects|Patients with skull defects after craniotomy for example tumor resection, head trauma, stroke which need a Patient Specific Implant.
11280824|NCT02828293||GMK Sphere|Patients who underwent total knee replacement using GMK Sphere implants. Patients underwent surgery before the inclusion in the study.
11280825|NCT02828293||GMK PS Fixed Bearing|Patients who underwent total knee replacement using GMK PS Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
11280826|NCT02828293||GMK UC Fixed Bearing|Patients who underwent total knee replacement using GMK UC Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
11280827|NCT02828280||NuMask|Pt's randomized to Numask first will be ventilated for 10 breaths with the NuMask device first, followed by 10 breaths with the traditional face mask
11280828|NCT02828280||Traditional mask|patients randomized to traditional mask first will receive 10 breaths by traditional mask, followed by 10 breaths with NuMask
11280829|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
11280830|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-10 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
11280831|NCT02828267|Active Comparator|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive a 5-10 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
11280832|NCT02828267|Active Comparator|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-10 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
11280833|NCT02828241|Experimental|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
11280834|NCT02828241|Placebo Comparator|Placebo Ointment|Placebo Ointment
11280835|NCT02828228|Experimental|Vitamin D 1200 IU|Supplementation with vitamin D (1200 IU) once a day for 26 weeks
11280836|NCT02828228|Placebo Comparator|Placebo|Placebo once a day for 26 weeks
11280837|NCT02828189|Active Comparator|Physical Exercise|"The protocol consists in:
~Physical Exercise according to their preferences.
~Therapeutic Education related to Health Habits and Physical Exercise."
11280978|NCT02827162||Case D1|Subject having experienced a Virologically confirmed dengue infection, from the first injection until the end of the active phase, excluding Case D3 subjects
11280838|NCT02828189|Experimental|Therapeutic Exercise-Physiotherapy|"The protocol consists in:
~Cardiovascular exercise.
~Force-Resistance Exercises of the principals muscle groups of the lower limbs, upper limbs and trunk.
~Muscle Stretches.
~Therapeutic Education related to Health Habits and Physical Exercise."
11280839|NCT02828163|Experimental|Autologous Platelet rich plasma|Autologous platelet-rich plasma (PRP) is autologous plasma that has platelet concentration above the baseline. 1 millilitre of autologous platelet-rich plasma will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
11280840|NCT02828163|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide is an effective treatment for oral erosions of pemphigus vulgaris patients. 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
11280841|NCT02828150|Experimental|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements
11280842|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
11280843|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
11280844|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
11280845|NCT02828124|Experimental|Dose Escalation Monotherapy|
11280846|NCT02828124|Experimental|Dose Expansion Monotherapy|
11280847|NCT02828124|Experimental|Dose Escalation Combination Therapy|
11280848|NCT02828124|Experimental|Dose Expansion Combination Therapy|
11280849|NCT02828111|Experimental|Patidegib gel 2% - Cohort 1|Patidegib gel 2%, applied topically, once daily for 12 weeks (Cohort 1)
11280850|NCT02828111|Experimental|Patidegib gel 4% - Cohort 2|Patidegib gel 4%, applied topically, once daily for 12 weeks (Cohort 2)
11280851|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 1|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 1)
11280852|NCT02828111|Experimental|Patidegib gel 2% - Cohort 3|Patidegib gel 2%, applied topically, twice daily for 12 weeks (Cohort 3)
11280853|NCT02828111|Experimental|Patidegib gel 4% - Cohort 4|Patidegib gel 4%, applied topically, twice daily for 12 weeks (Cohort 4)
11280854|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 2|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 2)
11280855|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 3|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 3)
11280856|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 4|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 4)
11280857|NCT02828098|Experimental|Part 1: BO-112 IT|BO-112 dose 1 (starting dose) intratumoral injection. BO-112 dose 2, 3 and 4 are expected to be tested, upon confirmation of the safety profile of the starting dose.
11280858|NCT02828098|Experimental|Part 2: BO-112 IT|"Combination treatment of BO-112 intratumoral injections with standard of care nivolumab intravenous treatment
~Or Combination treatment of BO-112 intratumoral injections with standard of care pembrolizumab intravenous treatment"
11280859|NCT02828085|Other|Infective Pericarditis|In patient prescribed with a pericardite kit for an etiological diagnosis of a pericardial syndrome, an additional nasal swab will be performed in order to perform a specific diagnosis with PCR technique.
11280860|NCT02828072|Experimental|Sky|Sky treatment foe 15 days
11280861|NCT02828072|Sham Comparator|control|standard medical therapy
11280862|NCT02828046|Placebo Comparator|Placebo|Placebo
11280863|NCT02828046|Experimental|M281|M281
11280864|NCT02828033|Experimental|Rilonacept|A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
11280865|NCT02828020|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
11280866|NCT02828020|Experimental|Ubrogepant 100 mg|2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
11280867|NCT02828020|Placebo Comparator|Placebo|2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
11280868|NCT02828007|Experimental|Treatment/Intervention|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
11280869|NCT02827994|Experimental|Education and exercise|The intervention included neurophysiology of pain education and exercises.
11280870|NCT02827994|No Intervention|No intervention|This group received no intervention as participants were students that were not seeking treatment for their pain.
11280871|NCT02827968|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1, 2.5, 5 and 10 mg/kg weekly.
11280872|NCT02827955|Experimental|bilateral thalamotomy radiosurgery|Gamma Knife radiosurgery bilateral
11280873|NCT02827942|Experimental|Dual therapy|Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
11280874|NCT02827942|Active Comparator|Triple therapy|Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
11280875|NCT02827929|Experimental|educated group|Subjects who is diagnosed as COPD or asthma by their physicians were recruited from 43 primary clinic and had been visiting each primary clinic over one year or more will be provided education of 3 times for one months about disease, inhaler use technics and action plans about exacerbation
11280876|NCT02827916|Experimental|All patients|Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
11280877|NCT02827903|Experimental|Group I|Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
11280878|NCT02827903|Active Comparator|Group II|Metformin + placebo, Dosing to Type II DM with Dyslipidemia
11280880|NCT02827890|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Januvia Tab. 100mg)*1T/day for 5 days, QD, PO.
~Period 2: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.
~Each treatment period was separated by a washout period of at least 10 dyas."
11280881|NCT02827890|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.
~Period 2: Treatment A(Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO.
~Each treatment period was separated by a washout period of at least 10 dyas."
11280882|NCT02827877|Experimental|Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)|Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
11280883|NCT02827864|Experimental|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1 lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
11280884|NCT02827864|Experimental|apply tDCS concurrently|"For the participants in the CON group, sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS.
~Similar to the SEQ group, the participants will also practice functional tasks for 30 minutes after MT."
11280885|NCT02827864|Sham Comparator|MT with sham tDCS|For the SHAM group, the training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
11280886|NCT02827851|Experimental|SVF injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
11280887|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
11280888|NCT02827812|Experimental|Participants Telemedicine Care (PTE)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).
~B. Physical Intervention at home for 60 minutes 3 days/week for three months
~C. Home-Based telemedicine program:"
11280889|NCT02827812|Active Comparator|Participants Usual Care (PUC)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).
~B. Physical Intervention at home for 60 minutes 3 days/week for three months"
11280890|NCT02827799|Placebo Comparator|Heart Failure Self-Management Education|This treatment includes participation in 4 one hour biweekly face-face sessions of education on heart failure self-management, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
11280891|NCT02827799|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
11280892|NCT02827786|Experimental|Electromagnetic Acoustic Imaging|
11280893|NCT02827773|Experimental|Received Talking Pill Bottles|Patients received anti-hypertensives over 90 day period in Talking Pill Bottle which contained summary of pharmacy counselling session.
11280894|NCT02827773|No Intervention|Usual Care|Patients received oral summary of pharmacy counselling session.
11280895|NCT02827760|Placebo Comparator|Maltodextrin DE19|Placebo
11280896|NCT02827760|Active Comparator|Prebiotic Synergy1|Effective prebiotic
11280897|NCT02827747|Placebo Comparator|Placebo with Dietary Sources of Vitamins|Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.
11280898|NCT02827747|Active Comparator|Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum|Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.
11280899|NCT02827747|Active Comparator|Antioxidants (Vitamins A,C, E) plus GSH|Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.
11280900|NCT02827747|Active Comparator|Placebo plus Centrum|Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.
11280901|NCT02827734||interstitial lung disease|patients with known or suspected ILD such as idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, sarcoidosis, granulomatosis with polyangiitis
11280902|NCT02827734||pulmonary healthy controls|patients without known or suspected pulmonary disease
11280903|NCT02827721||COPD|Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
11280904|NCT02827721||pulmonary healthy controls|Patients without known or suspected pulmonary disease
11280905|NCT02827708|Experimental|Semaglutide|
11280906|NCT02827708|Placebo Comparator|Placebo|
11280907|NCT02827695|Experimental|SMASK|Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.
11280908|NCT02827695|Other|EnhancedSC|Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.
11280909|NCT02827682|Experimental|study group|Using Angel-6000D Multiparameter Anesthesia Monitor to maintain the Hemodynamic stability during surgery. Keep IoC1 40 to 60 while IoC2 30-50.Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when IoC1<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when IoC2>50 but was decreased by 1 ng/ml per adjustment when IoC2<30, with the maintenance value between 30 and 50.
11280910|NCT02827682|Placebo Comparator|control group|Using BIS VISTA Monitor to maintain the Hemodynamic stability during surgery. Keep BIS 40 to 60.The doses of propofol and remifentanil were adjusted by the anesthetists according to BIS. Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when BIS<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when BIS>60 but was decreased by 1 ng/ml per adjustment when BIS<40, with the maintenance value between 40 and 60.
11280911|NCT02827669|Experimental|One Drop Experts Program|Participants will be able to use the One Drop mobile app and One Drop Experts program on their smartphones. The One Drop mobile app is a diabetes management platform that allows users to track and log their blood glucose levels, medications, food, and activities. One Drop Experts is a diabetes education and coaching program delivered entirely through the One Drop mobile application.
11280912|NCT02827669|Experimental|One Drop Experts Program + Apple Watch|An Apple Watch will be provided to study participants in this arm. In addition to using the One Drop mobile app and One Drop Experts program on their smartphones, participants will also be able to engage with the app and program on their Apple Watch.
11280913|NCT02827656|Experimental|Decapeptyl support|S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
11280914|NCT02827656|Active Comparator|hCG luteal support|S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
11280915|NCT02827643|Active Comparator|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
11280916|NCT02827643|Other|TDF/3TC or FTC/EFV|the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
11280917|NCT02827630|Active Comparator|DH-4|Subjects will use Proteus Discover, the digital health offering (DH) for 4 weeks
11280918|NCT02827630|Active Comparator|DH-12|Subjects will use Proteus Discover, the digital health offering (DH) for 12 weeks
11280919|NCT02827630|Other|Usual Care|Subjects received usual medical care including all normal interventions such as medication titration, adherence counseling, lifestyle coaching, and additional clinic visits per their providers' discretion.
11280920|NCT02827617||TP53 mutated CLL|
11280921|NCT02827578|Experimental|Tamsulosin + Solifenacin|Tamsulosin and Solifenacin
11280922|NCT02827578|Active Comparator|Tamsulosin + Solifenacin Placebo|Tamsulosin and Solifenacin placebo
11280923|NCT02827565|Experimental|CircuLOR-1|KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
11280924|NCT02827552|Other|ARPEGE BioM|N/A (not a randomized study)
11280925|NCT02827539|Other|Research|If the patient is randomized to the Research Arm, the physician will begin the procedure utilizing LessRay enhanced fluoroscopic images.
11280926|NCT02827539|Other|Control|For patients in the control arm standard fluoroscopy will be used with the C-arm set to the conventional full dose setting
11280927|NCT02827526|Active Comparator|Ketamine|Patients in the ketamine arm will receive an intraoperative and postoperative infusion of ketamine
11280928|NCT02827526|Placebo Comparator|Control|Patients in the control arm will receive an intraoperative and postoperative infusion of dextrose
11280929|NCT02827513|Experimental|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
11280930|NCT02827513|Experimental|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
11280931|NCT02827513|Experimental|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
11280932|NCT02827513|Experimental|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
11280933|NCT02827500|Active Comparator|ivabradine|Active Comparator: ivabradine
11280934|NCT02827500|Placebo Comparator|usual care|Placebo Comparator: usual care
11280935|NCT02827487|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
11280936|NCT02827487|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
11280937|NCT02827487|Placebo Comparator|Placebo 1|Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
11280938|NCT02827474||Patient Participants|Patient participants will participate in two patient interviews.
11280939|NCT02827474||Physician Participants|Provider participants will participate in one provider interview.
11280940|NCT02827461||MZ|Monozygotic twins
11280941|NCT02827461||DZ|Dizygotic twins
11280942|NCT02827435|Experimental|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
11280943|NCT02827409|Active Comparator|Short Delay Cord Clamping|Subject will have umbilical cord clamped and cut by 1 minute of life.
11280944|NCT02827409|Active Comparator|Extended Delay Cord Clamping|Subject will have umbilical cord clamped and cut after at least 5 minutes of delayed cord clamping. Duration of cord clamping after 5 minutes will depend on if the subject is breathing and/or if the cord has stopped pulsating
11280945|NCT02827396|Experimental|Psycho-social intervention|Experimental group: The intervention group will get Psycho social Training Intervention which will be developed during the third phase of the study.
11280946|NCT02827396|No Intervention|TAU intervention|Wait-list (controlled) group: The waiting list (control) group will continue getting the general health education (TAU) that is done at disability clinics in the existing sites.
11280947|NCT02827383|Experimental|Stair Climbing 4x/day|Participants use the stair climber 4 times per day, for 4 minutes at a time. Total dose = 16 minutes.
11280948|NCT02827383|Experimental|Stair Climbing 8x/day|Participants use the stair climber 8 times per day, for 2 minutes at a time. Total dose = 16 minutes.
11280949|NCT02827370|Experimental|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
11280950|NCT02827344||Stage IV non-small cell lung cancer|"Intervention to be done are :
~- Blood sample collection for CTC and MDSC analysis"
11280951|NCT02827331||Patients exposed to benzodiazepines|"Data to be collected are :
~Administrative and medical data
~Exposition to hypnotics or anxiolytics benzodiazepines"
11280952|NCT02827331||Patients not exposed to benzodiazepines|"Data to be collected are :
~Administrative and medical data
~Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics"
11280953|NCT02827331||Control group|"Data to be collected are :
~Administrative and medical data
~Medical consultation without prescription of interest"
11280954|NCT02827318|Active Comparator|75g glucose|75g of glucose dissolved in 500ml provided in a clear plastic tumbler.
11280955|NCT02827318|Experimental|75g isomaltulose|75g of isomaltulose dissolved in 500ml provided in a clear plastic tumbler.
11280956|NCT02827318|Placebo Comparator|Sweetened water|500ml water sweetened with sucralose provided in a clear plastic tumbler.
11280957|NCT02827305|Experimental|group 1|scaling and Gotukola mouthwash intervention- 1.Scaling 2.Gotukola mouthwash , 10ml twice daily to be rinsed for 60 seconds
11280958|NCT02827305|Active Comparator|group 2|Scaling
11280959|NCT02827305|Active Comparator|group 3|Intervention- Gotukola mouthwash only is advised to be used two times a day, each time 10ml rinsed for 60 seconds (morning and evening ) after the food.
11280960|NCT02827292|Experimental|Laparoscopic Surgery without music|Intervention: Headphones without music (Silent). A headphone will be applied peroperatively but no music will be played. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
11280961|NCT02827292|Experimental|Laparoscopic Surgery with music|Intervention: peroperative music via head phones. A headphone will be applied peroperatively and music will be played for the entire duration of the surgical procedure. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
11280962|NCT02827279|Other|Patients|Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
11280963|NCT02827279|Other|Healthy volunteers|Mesure of emotional induction by eye tracking on People without disorders
11280964|NCT02827266|Experimental|Epoetin beta|Participants will receive epoetin beta over an 8-week correction phase and a 4-week extension or continuation phase, for a total exposure of up to 12 weeks.
11280965|NCT02827253||Predialysis|Patients with CKD (4 and 5 stages by KDOQI guidelines) underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A MRI 6 months after starting haemodialysis will be performed to analyze changes in gray and white matter of the brain.
11280966|NCT02827253||Haemodialysis|Patients with end stage of renal disease (ESRD) in haemodialysis underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A one year follow up MRI will be performed to analyze the changes in gray and white matter of the brain.
11280967|NCT02827240|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
11280968|NCT02827240|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
11280969|NCT02827240|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
11280970|NCT02827227||Primary HIV- Infected patients|Primary HIV- Infected patients with a minimum of 2 years of effective cART.
11280971|NCT02827214||Surgical treatment|"Several surgical treatments exist to treat the fractures included in the study. The following section describes the different surgical treatment modalities in more detail
~Approaches:
~Open short segment surgical fixation (1 level above and below the fracture level) with or without posterior decompression
~Open long segment posterior fixation (2 or more levels above, 2 or more levels below) with or without posterior decompression
~Posterior short or long fixation with posterolateral corpectomy and reconstruction
~Anterior alone instrumentation
~Combined Anterior Posterior (AP) instrumentation
~Percutaneous posterior fixation combined with anterior instrumentation
~Percutaneous posterior fixation with or without vertebroplasty"
11280972|NCT02827214||Non-surgical treatment|"Non-surgical treatment is defined as bed rest followed by immobilization with:
~Custom-molded or prefabricated total body contact thoracolumbosacral orthosis (TLSO)
~Thermoplastic removable brace
~Jewett hyperextension braces
~Anterior hyperextension brace (ASH)
~Taylor-Knight brace
~Plaster of Paris (POP)"
11280973|NCT02827201|Experimental|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :
~2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)
~follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
11280974|NCT02827201|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
11280975|NCT02827188|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
11280976|NCT02827188|No Intervention|Control-waitlist group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
11280977|NCT02827175|Experimental|fevers of the travelers|
11281218|NCT02825537|Other|Without use of compression stocking|No use of compression stocking during 3 consecutives days
11280979|NCT02827162||Case D3|Subject having experienced a Virologically confirmed dengue infection, from 28 days after the third injection until the end of the Active Phase of the proof of concept (PoC) efficacy study
11280980|NCT02827162||Control I|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and belonging to the PoC efficacy study immunogenicity subset
11280981|NCT02827162||Control E|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and not belonging to the PoC efficacy study immunogenicity subset
11280982|NCT02827136|Experimental|Patch group|Lidocaine patch and Hypafix
11280983|NCT02827136|Placebo Comparator|Control group|Just Hypafix
11280984|NCT02827123|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
11280985|NCT02827123|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
11280986|NCT02827110|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope
11280987|NCT02827110|Experimental|fiberoptic bronchoscope with pentax-AWS|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope with pentax-AWS
11280988|NCT02827097|Experimental|Rectus sheath block group|"administration of denogan
~rectus sheath block with 0.375% ropivacaine"
11280989|NCT02827097|Placebo Comparator|Control group|just administration of denogan
11280990|NCT02827084|Experimental|Kinesio Taping|Apply the Kinesio Taping with tension in the vatus mediallis
11280991|NCT02827084|Placebo Comparator|Placebo|Apply the Kinesio Taping without tension in the vatus mediallis
11280992|NCT02827084|No Intervention|Control|It will not apply Kinesio.
11280993|NCT02827071||Retina abnormalities|Subjects with various retina vascular disorders
11280994|NCT02827058|Experimental|G25 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
11280995|NCT02827058|Active Comparator|G27 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle
11280996|NCT02827045||Depressive phase|Vestibular test
11280997|NCT02827045||Maniac phase|Vestibular test
11280998|NCT02827045||Euthimic phase|Vestibular test
11280999|NCT02827045||Healthy subject|Vestibular test
11281000|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
11281001|NCT02827006|Active Comparator|Bone graft|Bone graft from iliac crest as gapfiller
11281002|NCT02827006|Experimental|Calcium phosphate bone cement|CaP bone cement as gapfiller
11281003|NCT02826993|Experimental|CCE in incomplete Colonoscopies|Patients in which colonoscopy is not possible are invited for CT colonography and those patients are examined by Camera Capsule Endoscopy the day before the CT colonography and the two different examinations are compared.
11281004|NCT02826967|Experimental|Colonic Irrigation|A designated health professional will administer to the patient the colonic irrigation procedure -using the Hydro-San Plus colon therapy system, an FDA approved and ISO certified device for colonic irrigation and cleansing before endoscopic procedures (FDA #2027347).
11281005|NCT02826954||COPD patients|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.
~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
11281006|NCT02826954||Healthy subjects|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.
~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
11281007|NCT02826941|Experimental|Hypothermia|If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.
11281008|NCT02826941|Placebo Comparator|Normothermia|If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.
11281009|NCT02826928|Experimental|patients with small-intestine neuroendocrine tumors|
11281010|NCT02826928|Experimental|control subjects with irritable bowel syndrome|
11281011|NCT02826902|Active Comparator|TIVA group|
11281012|NCT02826902|Active Comparator|Inhalation anesthesia group|
11281013|NCT02826889|Experimental|Fluid loading group|
11281014|NCT02826876|Placebo Comparator|Ropivacaine|Topical use of Ropivacaine
11281015|NCT02826876|Placebo Comparator|Placebo|Topical use of placebo
11281016|NCT02826863|Experimental|Experimental: ZX008 - 0.8 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
11281017|NCT02826863|Experimental|Experimental: ZX008 - 0.2 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 0.2 mg/kg/day ZX008 will be administered twice a day (BID) in equally divided doses with food.
11281018|NCT02826863|Placebo Comparator|Placebo Comparator: Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
11281019|NCT02826850|Sham Comparator|Genicular nerves|Neurotomy by radiofrequency of genicular nerves knee guided by fluoroscopy
11281020|NCT02826850|Active Comparator|Saphenous Nerve|Neurotomy of saphenous nerve by radiofrequency on the distal third of the thigh, guided by ultrasound
11281214|NCT02825563|Experimental|Anlotinib(In the fasting state)|In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
11281021|NCT02826837|Experimental|LEAC-102 and FOLFOX+Bevacizumab/Cetuximab|"The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.
~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.
~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day
~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
11281022|NCT02826798|Experimental|VBI-1501A: 0.5µg with adjuvant|0.5µg CMV vaccine with adjuvant
11281023|NCT02826798|Experimental|VBI-1501A: 1.0µg with adjuvant|1.0µg CMV vaccine with adjuvant
11281024|NCT02826798|Experimental|VBI-1501A: 2.0 µg with adjuvant|2.0 µg CMV vaccine with adjuvant
11281025|NCT02826798|Experimental|VBI-1501: 1.0µg without adjuvant|1.0µg CMV vaccine without adjuvant
11281026|NCT02826798|Placebo Comparator|Placebo|Buffer/sucrose used for VBI-1501 suspension
11281027|NCT02826785|Experimental|Cognitive strategy training|The cognitive strategy training intervention consists of 6 weekly ~1 hour sessions. It is delivered in an individual, face-to-face format in the client's home. It is a behavioral intervention that teaches people metacognitive, problem-solving and other compensatory strategies to address self-identified cognitive performance problems, and it uses practice and homework to promote strategy learning, retention and transfer.
11281028|NCT02826772|Experimental|Phase 1 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
11281029|NCT02826759||serum sphingolipid metabolites in healthy subjects|Healthy subjects are classified according to BMI into three subgroups: healthy normal weight subjects, healthy overweight subjects and healthy subjects with obesity. Age and sex are matched among three subgroups. serum sphingolipid metabolites including sphingosine-1-phosphate will be compared.
11281030|NCT02826759||serum sphingolipid metabolites in diabetic subjects|Diagnosed diabetic patients are divided into three subgroups: diabetic patients with normal weight, overweight and obesity. age and sex are matched.
11281031|NCT02826759||serum sphingolipid metabolites in the progression of diabetes|serum sphingolipid metabolites are compared among three age-, sex- and body mass index-matched subgroups: healthy subjects, subjects with pre-diabetes, subjects with diabetes
11281032|NCT02826759||serum sphingolipid metabolites and HbA1c|diabetic subjects are divided by HbA1c level. the cut-offs are 7% and 9%. serum sphingolipid metabolites will be tested among diabetic patients with HbA1c <7%, 7%-9% and >9%
11281033|NCT02826759||serum sphingolipid metabolites in insulin-resistant subjects|comparison of serum sphingolipid metabolites in newly diagnosed insulin-resistant subjects and age-, sex- and BMI-matched healthy controls.
11281034|NCT02826746|Experimental|Magnesium group|intravenous administration of Magnesium Sulfate
11281035|NCT02826746|Placebo Comparator|Control group|intravenous administration of normal saline
11281036|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).
~EEG NIRS MRI"
11281037|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .
~EEG NIRS MRI"
11281038|NCT02826720||HP+|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
11281039|NCT02826720||HP-|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
11281040|NCT02826720||NP+|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
11281041|NCT02826720||NP-|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
11281042|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
11281043|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
11281044|NCT02826694|Other|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
11281045|NCT02826694|Other|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
11281046|NCT02826681|Active Comparator|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
11281047|NCT02826681|Placebo Comparator|Normal Saline|Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.
11281048|NCT02826668|No Intervention|Control|Baseline ultrasound only, with no markings placed. No ultrasound prior to epidural placement.
11281049|NCT02826668|Experimental|Ultrasound|Baseline and pre-puncture ultrasound with markings placed.
11281050|NCT02826655|Active Comparator|Healthy Controls|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
11281219|NCT02825524|Experimental|Endobiliary radiofrequency|
11281051|NCT02826655|Experimental|Subjects with diabetic retinopathy|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
11281052|NCT02826642|Experimental|Arm 1: Medically fit for induction|IDH305 + Standard of care for patients that are medically fit for induction.
11281053|NCT02826642|Experimental|Arm 2 Medically unfit for induction|IDH305 + Standard of care for patients that are medically unfit for induction.
11281054|NCT02826629|Other|Schizophrenia|40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
11281055|NCT02826629|Other|Healthy sibling|25 healthy siblings
11281056|NCT02826629|Other|Ultra high risk for developing Schizophrenia|15 patients with ultra high risk for developing Schizophrenia
11281057|NCT02826629|Other|Controls|-25 age and gender-matched healthy controls
11281058|NCT02826616|Experimental|Trimetazidine group|Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery
11281059|NCT02826616|No Intervention|The control group|placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery
11281060|NCT02826603|Experimental|Secukinumab|Secukinumab
11281061|NCT02826603|Active Comparator|Ustekinumab|Ustekinumab
11281062|NCT02826590|Experimental|Neck passive mobilizations|Neck passive mobilizations
11281063|NCT02826590|Placebo Comparator|Manual contact|Manual contact
11281064|NCT02826577|Active Comparator|Pregnenolone 175mg|- Single dose of 175mg
11281065|NCT02826577|Active Comparator|Pregnenolone 400mg|- Single dose of 400mg
11281066|NCT02826577|Placebo Comparator|Placebo|- Single dose of placebo
11281067|NCT02826577|No Intervention|Matched healthy controls|- No intervention
11281068|NCT02826564|Experimental|Sequential|Stereotactic body radiotherapy prior to pembrolizumab treatment
11281069|NCT02826564|Experimental|Concurrent|Stereotactic body radiotherapy concurrent with pembrolizumab treatment
11281070|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.
~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
11281071|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.
~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
11281072|NCT02826538|Experimental|patient specific guides|fracture fixation with 3D planning and use of patient-specific instruments
11281073|NCT02826538|Active Comparator|standard procedure|standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments
11281074|NCT02826525|Experimental|Treatment|Subjects in this arm will receive AZD4076
11281075|NCT02826525|Placebo Comparator|Control|Subjects in this arm will receive placebo
11281076|NCT02826512|Experimental|Niraparib|niraparib 300 mg QD continuously
11281077|NCT02826499|Active Comparator|Fluoroscopy|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy.
11281078|NCT02826499|Experimental|Fluoroscopy and Pediguard|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy, with the Pediguard system.
11281079|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.
~Combination therapy period begins following monotherapy treatment and consists of:
~Pembrolizumab 200mg once every three weeks.
~Beginning on Day 10, BL-8040 three times a week"
11281080|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®) plus Onivyde chemo|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.
~Combination therapy period begins following monotherapy treatment and consists of:
~IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.
~Pembrolizumab 200mg once every three weeks.
~Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
11281081|NCT02826473|Experimental|Intervention-Group|
11281082|NCT02826473|No Intervention|Control-Group|
11281083|NCT02826460||Liver Transplant Recipients|
11281084|NCT02826447||Patients|500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
11281085|NCT02826447||Healthcare workers|50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
11281086|NCT02826434|Experimental|PVX-410 and Durvalumab|"Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.
~The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections.
~The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions."
11281087|NCT02826421|Experimental|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
11281088|NCT02826421|Active Comparator|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
11281089|NCT02826421|Active Comparator|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
11281090|NCT02826421|Active Comparator|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
11281091|NCT02826408|Active Comparator|Active group|Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)
11281092|NCT02826408|Placebo Comparator|Placebo group|Will receive Folic acid 5 mg once daily
11281093|NCT02826382|Experimental|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
11281094|NCT02826382|Experimental|Whole body dosimetry group|Determination of human dosimetry of the investigation drug [68Ga]P15-041
11281095|NCT02826369|Experimental|3.0 Tesla in Magnetic Resonance Imaging|
11281096|NCT02826343|Other|COPD Advair|"Subjects will undergo hyperpolarized xenon MRI with perfusion imaging, before and after a 90 day course of Adair.
~All subjects belong to one arm and will receive same treatment. Then they are compared at baseline and 3 month post intervention (described below) for within same-subject changes.
~Subjects will be administered with
~Hyperpolarized Xenon129 inhalation during MRI twice (at baseline and post 3 month Advair)
~Gadolinium intravenous contrast during MRI twice (at baseline and post 3 month Advair)
~Advair diskus: strength 250mcg/50mcg, one puff twice a day for 3 months."
11281097|NCT02826330||case Crohn disease|60 cases with Crohn's Disease
11281098|NCT02826330||first relative healthy|2 healthy relatives per CD case (total 120)
11281099|NCT02826330||controls|60 controls matched on gender and age with CD cases
11281100|NCT02826304|Active Comparator|VH|Vaginal Hysterectomy for uteri larger than 280gm
11281101|NCT02826304|Active Comparator|LAVH|Laparoscopic assisted vaginal hysterectomy for uteri larger than 280gm
11281102|NCT02826291||RD-100i, OSNA|SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging
11281103|NCT02826278||Healthy female newborns|Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
11281104|NCT02826265||pulmonary disease|patients with known or suspected pulmonary disease
11281105|NCT02826252||Ventavis|The study will be conducted in patients who are enrolled in the German Ventavis patient support program Ventaplus.
11281106|NCT02826239||pulmonary healthy controls|patients without known pulmonary disease
11281107|NCT02826239||pulmonary disease|patients with known or suspected pulmonary disease
11281108|NCT02826226||obstructive ventilation disorder|patients with known or suspected obstructive ventilation disorder and clinical indication for bronchodilator testing
11281109|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
11281110|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
11281111|NCT02826200|Experimental|Group 1 (SOC+OAT)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving single antiplatelet therapy plus oral anticoagulant therapy.
11281112|NCT02826200|Active Comparator|Group 2 (SOC)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving standard of care therapy.
11281113|NCT02826187||Patients with acetabular implant|"Data to be collected are :
~Early complications data related to implant or procedure of implantation
~Late stage complications data
~Efficacity of treatment with HIP score
~Patient satisfaction
~Radiographic evaluation during standard follow-up"
11281114|NCT02826174|Experimental|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
11281115|NCT02826174|Active Comparator|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
11281116|NCT02826174|Other|Anti-Rejection Agents|Anti-Rejection Agents for both groups
11281117|NCT02826174|Other|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
11281118|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
11281119|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
11281120|NCT02826148|Other|Patients with autism disorder|The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
11281121|NCT02826135|Experimental|Pediatric patients with hypovolemic state|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
11281122|NCT02826122|Active Comparator|FitBit APP|FitBit Zip APP registers and give feed-back on number of steps per day, distance and calories burned.
11281123|NCT02826122|Experimental|Pai APP|Mio Pai APP registers duration and intensity of the Activity and give feed back as activity Points.
11281124|NCT02826109|Experimental|Interventional: Cyanoacrylate Application|Application of cyanoacrylate adhesive to one quadrant of mouth
11281125|NCT02826109|No Intervention|Control: Absence of Cyanoacrylate Application|No application of cyanoacrylate adhesive to the other quadrant of mouth
11281126|NCT02826096|Experimental|biofeedback group|biofeedback therapy
11281127|NCT02826096|No Intervention|medication group|only medication treament
11281128|NCT02826083|Experimental|XXS|
11281129|NCT02826083|Placebo Comparator|Placebo|
11281130|NCT02826070|Other|Off-treatment|Patients who had stopped treatment during EFFORT extension study could receive 2-year off-treatment follow-up. All the patients in Part I will be followed up at the interval of 12 weeks. For these patients, if they have hepatitis flare during follow-up, they will be re-treated with telbivudine combined with adefovir for the left study period ( the total study period is 2 years) and followed up at the interval of 12 weeks. Hepatitis flare is defined as HBV DNA>4 Log10 copies/mL with either ALT≥5 times upper limit of normal (ULN) or TBIL≥2×ULN，or 2 ≤ALT ≤5 ×ULN (at two consecutive visits at least 2 weeks apart) and total bilirubin (TBIL) <2×ULN.
11281131|NCT02826070|Other|On-treatment|Patients with continuous treatment during EFFORT extension study will continue treatment, without off-treatment rule in the further extension study. The treatment strategy is depended on the HBV DNA level of each individual, that is, for patients with negative HBV DNA level (defined as HBV DNA <20 IU/mL) will continue their previous treatment strategy; and for patients with positive HBV DNA level (defined as HBV DNA>=20 IU/mL) will receive the combination therapy of telbivudine and adefovir, irrespective of their previous treatment strategy. All the patients in Part II will be followed up at the interval of 24 weeks until they complete the 2-year on-treatment follow-up. Patients will be conducted liver biopsy at the sixth year of treatment. All the patients with telbivudine monotherapy will be switched to telbivudine plus adefovir once confirmed HBV DNA breakthrough developed.
11281132|NCT02826057|Active Comparator|24 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
11281133|NCT02826057|Experimental|48 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
11281134|NCT02826044|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
11281135|NCT02826044|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
11281136|NCT02826044|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
11281137|NCT02826031|Experimental|Sodium Hyaluronate Injection + DICL-SR|"Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group.
~From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID） daily"
11281138|NCT02826031|Active Comparator|DICL-SR|From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID daily）. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.
11281139|NCT02826018|Active Comparator|ALN-HBV|
11281140|NCT02826018|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11281141|NCT02826005|Experimental|cirrhotic patients|if positive for 3 bio-markers- will be followed by MRI for HCC diagnosis
11281142|NCT02826005|No Intervention|non cirrhotic patients|control group - 3 bio-markers will be measured only
11281143|NCT02825992|Other|AcQMap System|All patients who underwent catheter ablation using the AcQMap System
11281144|NCT02825979|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
11281145|NCT02825979|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
11281146|NCT02825966|Other|LifeVest|Assigned to wear the LifeVest overnight
11281147|NCT02825953|Active Comparator|Nebulized surfactant|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV), and than premature babies with RDS breathing spontaneously will be administered surfactant by nebulizer.
11281148|NCT02825953|Active Comparator|Endotracheal bolus application|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The investigators will administer surfactant via fundamental method.
11281149|NCT02825953|Active Comparator|Minimally invasive surfactant therapy|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). After randomisation, the investigators will administer surfactant via minimally invasive surfactant therapy (MIST) method which is recently very popular method
11281150|NCT02825940|Experimental|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
11281151|NCT02825940|Experimental|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
11281152|NCT02825927|Experimental|Intervention group|Intensive training with oral screen for 5 weeks.
11281153|NCT02825927|No Intervention|Control group|The control group is not offered any intervention.
11281154|NCT02825914|Active Comparator|Casein glycomacropeptide (CGMP)|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.
11281155|NCT02825914|Placebo Comparator|Placebo|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.
11281156|NCT02825901|Active Comparator|Djulis-Buckwheat & Placebo|Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
11281157|NCT02825901|Active Comparator|Buckwheat & Placebo|Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
11281158|NCT02825901|Experimental|Djulis-Buckwheat & Buckwheat|Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
11281159|NCT02825888||Non-obese|Body Mass index less than 30 kg/m2
11281160|NCT02825888||Obese|Body Mass index more than 30 kg/m2
11281161|NCT02825875||adenocarcinoma of the prostate|
11281162|NCT02825862|No Intervention|Replication group|Replication group - this group will complete the entire questionnaire, in order to replicate the findings of O'Carroll et al (2011)
11281295|NCT02824939|No Intervention|Control group|
11281163|NCT02825862|Active Comparator|Omit affective attitudes|Omitting affective attitudes The intervention is the omission of all questions on affective attitudes. This group will complete a similar questionnaire to the replication group, with the same number of questionnaire items, but affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
11281164|NCT02825862|Active Comparator|Omit negatively-worded items|Omitting negatively-worded affective attitudes. This intervention is the omission of a subset of negatively-worded affective attitudinal items. This group will complete a similar questionnaire to the replication group, with the same number of items, but all negatively-worded affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
11281165|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
11281166|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
11281167|NCT02825836|Experimental|M7583 80/160 mg QD|Participants received M7583 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by M7583 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
11281168|NCT02825836|Experimental|M7583 300 mg QD|Participants received M7583 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
11281169|NCT02825836|Experimental|M7583 600 mg QD|Participants received M7583 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
11281170|NCT02825836|Experimental|M7583 300 mg BID|Participants received M7583 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
11281171|NCT02825836|Experimental|M7583 900 mg QD|Participants received M7583 900 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
11281172|NCT02825823|Experimental|Ketone Salts|Acute dose of beta-hydroxybutyrate potassium/sodium salt (0.2g beta-hydroxybutyrate/kg, 0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
11281173|NCT02825823|Placebo Comparator|Placebo|Acute dose of taste-matched placebo (0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
11281174|NCT02825810|Experimental|Cervical motor control group|
11281175|NCT02825810|No Intervention|Control group|
11281176|NCT02825797|Experimental|Group 1A|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
11281177|NCT02825797|Experimental|Group 1B|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
11281178|NCT02825797|Experimental|Group 1C|HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
11281179|NCT02825797|Experimental|Group 2|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
11281180|NCT02825797|Experimental|Group 3|HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.
11281181|NCT02825784|Experimental|Renastart|"Compared to cows' milk and/or standard pediatric enteral feeds, Renastart has the following additional nutritional features that are beneficial in children with CKD: lower phosphorus, calcium and vitamin A. The powder presentation allows flexibility with dilutions to facilitate the provision of adequate energy and protein to support growth in children with CKD.
~For each subject, the recommended daily intake of Renastart is determined by the dietitian in collaboration with the local PI and primary nephrologist based on individual nutritional requirements, specifically dietary intake of potassium and serum potassium levels.
~Renastart is to be given by the clinician and based on clinical and nutritional needs. Standard preparation guidelines can be found on the Renastart label."
11281182|NCT02825771|Experimental|Usual Care + Caring Contacts messages|Usual care services plus caring contacts messages
11281183|NCT02825771|Active Comparator|Usual Care|Usual care services provided in that community following identification of suicidal ideation or behavior.
11281184|NCT02825758|Experimental|ZestiVits|"Supplement for use in ketogenic and restricted therapeutic diets, from the age of 11.
~Daily use for 7 days. Daily intake level for each subject will be determined and prescribed by a dietitian."
11281185|NCT02825745|Other|Betashot|"Children:will take Betashot as a proportion of their daily energy requirements calculated from the dietary information obtained during Visit A for up to 12 weeks.
~Adults:will introduce Betashot and increase the amount taken in ml incrementally for up to 12 weeks."
11281186|NCT02825719|Experimental|Ulipristal|Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
11281187|NCT02825719|Placebo Comparator|Placebo|Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
11281215|NCT02825563|Experimental|Anlotinib(In the high fat diet state)|In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
11281216|NCT02825550|Experimental|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
11281296|NCT02824926|Experimental|Dapaconazole|(cream; 2%; topical)
11281188|NCT02825706|Experimental|Experimental group|The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding. Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved. In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week. The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk. Low-intensity exercises with 20-25 repetitions were included.
11281189|NCT02825706|No Intervention|Control group|The patients in the control group did not receive any educational sessions and did no exercise at all at home.
11281190|NCT02825693|Active Comparator|Femtosecond laser cataract surgery|Cataract surgery with femtosecond laser treatment for corneal incisions, astigmatic keratotomies, capsulotomy and nuclear fragmentation
11281191|NCT02825693|Active Comparator|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery
11281192|NCT02825680|Active Comparator|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
11281193|NCT02825680|Experimental|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
11281194|NCT02825667|Experimental|Experimental group|"Patients included in this group will receive treatment over a period of three weeks, receiving 3 physiotherapy sessions lasting approximately 30 minutes each.
~The treatment program includes 8 maneuvers that must be administered bilaterally: maneuver longitudinal sliding on the fascial surface plant, maneuver induction of the plantar fascia, maneuver longitudinal surface sliding on the anterolateral compartment of the leg, induction maneuver ankle anterior compartment, maneuver pressure and sliding on the posterior region of the leg, technical release of the popliteal fascia, maneuver induction sural triceps, and lower extremity telescopic technique."
11281195|NCT02825667|No Intervention|Control group|Patients included in this group will not receive any physiotherapy treatment. However, will be evaluated under the same conditions that patients in the experimental group (pretreatment evaluation, post-treatment and follow-up).
11281196|NCT02825654||Post-9/11 Gulf War Era Veterans|Military personnel who deployed to Central Asia, Southwest Asia, and Africa during the Post-9/11 Gulf War Era
11281197|NCT02825641|Active Comparator|Expectant Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with Dinoprostone after 24 hours of waiting depending on obstetric history and cervical conditions."
11281198|NCT02825641|Active Comparator|Expectant Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with oxytocin after 24 hours of waiting depending on obstetric history and cervical conditions."
11281199|NCT02825641|Experimental|Active Management-Dinoprostone|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with Dinoprostone on presentation depending on obstetric history and cervical conditions."
11281200|NCT02825641|Experimental|Active Management-Oxytocin|"Women with premature rupture of membranes who are not in active labor and have an unfavorable cervix (Bishop score<6).
~Labor induction will be initiated with oxytocin on presentation depending on obstetric history and cervical conditions."
11281201|NCT02825628|Experimental|Osteodex 3.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
11281202|NCT02825628|Experimental|Osteodex 6.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
11281203|NCT02825628|Experimental|Osteodex 9.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
11281204|NCT02825615|Active Comparator|Conventional method (CM)|Radial artery cannulation has been done using the conventional method. Cannulation failure with this technique were tried with USG technique secondarily.
11281205|NCT02825615|Experimental|Ultrasound guided method (USG)|Radial artery cannulation is done with ultrasound guidance for this group of patients. Cannulation failure with this technique were tried with Conventional technique secondarily.
11281206|NCT02825602||Vietnam War Theater Veterans|Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
11281207|NCT02825602||Blue Water Navy Vietnam Veterans|Blue Water Navy Veterans are defined as Veterans who served aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975 and who never served ashore or on inland waterways of Vietnam.
11281208|NCT02825602||Vietnam era Veterans|Vietnam era Veterans served in locations around the world OTHER than on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos or aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975.
11281209|NCT02825602||Non-military U.S. public|Non-military U.S. public are individuals who were born before 1958, never served in the U.S. military, and are age- and gender-matched (by the study investigators) to Vietnam War Theater Veterans.
11281210|NCT02825589|Experimental|BIA-guided|Assessment of target dry weight guided by using bioelectrical impedance analysis (BIA).
11281211|NCT02825589|No Intervention|Standard clinical guided|Assessment of target dry weight guided by clinical evaluation eg. jugular venous pressure, blood pressure, edema etc.
11281212|NCT02825576|Active Comparator|Sugammadex group|Sugammadex 2mg/kg intravenously at completion of surgery.
11281213|NCT02825576|Active Comparator|Neostigmine/Glycopyrrolate group|Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.
11281217|NCT02825537|Experimental|With use of compression stocking|Use of compression stocking during 3 consecutives days
11281220|NCT02825511||A cohort of basal cell carcinoma|A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
11281221|NCT02825498|Experimental|Operator guided by contact force|Operator has full access to contact force parameters including force time integral (FTI).
11281222|NCT02825498|No Intervention|Operator blinded to contact force|Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
11281223|NCT02825485|Other|Control Group|The control patients will be the patients with antenatal hydronephrosis who get a routine VCUG to evaluate for vesicoureteral reflux, as part of routine care.
11281224|NCT02825485|No Intervention|Observation Group|Receives no intervention
11281225|NCT02825472|Active Comparator|Exercise training program|Six-months sports participation, three times per week for 30 minutes in the target heart rate zone
11281226|NCT02825472|No Intervention|No exercise training program|no exercise training program, usual care
11281227|NCT02825459|Experimental|Abstinence from e-cigarettes|Participants abstain from e-cigarettes and other nicotine/tobacco products for 6 days
11281228|NCT02825459|No Intervention|E-cigarette use|Participants use e-cigarettes and continue to abstain from tobacco/nicotine products as they normally would.
11281229|NCT02825446|Active Comparator|angioplasty tibial arteries|
11281230|NCT02825446|Experimental|radio frequency denervation popliteal artery by the use|"radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon"
11281231|NCT02825433||Patients receiving procedural sedation|The investigators collected ventilation data for each breath (respiratory rate, tidal volume, and end-tidal CO2) for all patients receiving procedural sedation for endoscopy.
11281232|NCT02825407|Experimental|main study|
11281233|NCT02825394||apixaban initiation|N=20
11281234|NCT02825394||apixaban on-treatment|N=20
11281235|NCT02825394||dabigatran initiation|N=20
11281236|NCT02825394||dabigatran on-treatment|N=20
11281237|NCT02825394||rivaroxaban initiation|N=20
11281238|NCT02825394||rivaroxaban on-treatment|N=20
11281239|NCT02825394||edoxaban initiation|N=20
11281240|NCT02825394||edoxaban on-treatment|N=20
11281241|NCT02825368|Experimental|Homeopathic vaccine group|"Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.
~Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo."
11281242|NCT02825368|Active Comparator|Conventional vaccine group|"One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)
~One subcutaneous dose of MMR (measles, mumps, rubella)
~Sugar pellets as placebo."
11281243|NCT02825368|Placebo Comparator|Control group|"Sugar pellets oral dose
~Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo"
11281244|NCT02825355||Patients with cervical cancer|All patients receive sentinel node mapping as the conventional treatment.
11281245|NCT02825355||Patients with endometrial cancer|All patients receive sentinel node mapping as the conventional treatment.
11281246|NCT02825342|No Intervention|GERD with PPI's therapy|Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
11281247|NCT02825342|Active Comparator|PPI's and SSRI's therapy|Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
11281248|NCT02825342|Active Comparator|SSRI's therapy|Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks
11281249|NCT02825316|Experimental|Group A|Patients with active Crohn's disease that will be allocated to the Mediterranean diet group.
11281250|NCT02825316|Experimental|Group B|Patients with active Crohn's disease that will be allocated to the low residue diet group.
11281251|NCT02825303|Experimental|Novel workplace - first half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
11281252|NCT02825303|Experimental|Novel workplace - second half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the second half of the study. Traditional workstation within the frist half of the study.
11281253|NCT02825303|No Intervention|Control group|Control group subjects did not encounter any changes in their regular office environments. Traditional workstation for both halves of the study.
11281254|NCT02825290|Experimental|Study group|hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer & GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.
11281255|NCT02825290|No Intervention|Control group|The usual progesterone only luteal phase support.
11281256|NCT02825277|Other|pathological group|pregnant women with preeclampsia and/or IUGR pregnancy with a planned or semi-urgent caesarean section or vaginal delivery will be recruited into this study.
11281257|NCT02825277|Other|physiological group|pregnant women with normal pregnancy with a planned caesarean section or vaginal delivery will be recruited into this study
11281258|NCT02825264||STARflo|Patients who have been implanted with STARflo implant
11281259|NCT02825251|Experimental|Faster-acting insulin aspart CSII|
11281260|NCT02825251|Active Comparator|NovoRapid® CSII|
11281261|NCT02825238|No Intervention|Control|Control group, did not undergo intervention.
11281262|NCT02825238|Experimental|Exercise group|Experimental, exercise group, underwent intervention
11281263|NCT02825225|Experimental|20 core-biopsy fragments|Patients submitted to experimental intervention (extended sextant biopsy with 20 cores) compared to current standard biopsy protocol (extended sextant biopsy with 12 cores) guided by transrectal ultrasound.
11281264|NCT02825225|Experimental|Base and apex local anesthesia|Patients submitted to experimental intervention in prostate-biopsy anesthetic protocol (prostate base and prostate apex bilateral local anesthetic injection) compared to participants submitted to current standard anesthetic protocol in institution (prostate base bilateral local anesthesia) guided by transrectal ultrasound. guided by transrectal ultrasound.
11281265|NCT02825212|Experimental|Harvoni|90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.
11281297|NCT02824926|Active Comparator|Ketoconazole|(cream; 2%; topical)
11281266|NCT02825199|Experimental|Caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
11281267|NCT02825199|Placebo Comparator|Non caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received placebo capsule (maize starch). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
11281268|NCT02825186|Experimental|Loteprendol|Topical Loteprendol used after strabismus surgery
11281269|NCT02825186|Experimental|Dexamethasone|Topical Dexamethasone used after strabismus surgery
11281270|NCT02825173|Experimental|Seal-G|A surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
11281271|NCT02825160||Ventavis|Ventavis treatment group
11281272|NCT02825147|Experimental|MESA|stage I/II: methotrexate 1000mg/m2,d1 dexamethasone 40mg,d2-d4 etoposide 100mg,d2-d4 pegaspargase 2500U/m2,d5 a cycle of every 21 days with totally 4 cycles Radiotherapy at least 50Gy in dose for the involved local focus is sandwiched after 2 cycles.
11281273|NCT02825134|Experimental|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
11281274|NCT02825134|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
11281275|NCT02825121|Experimental|Monitoring Neuromuscular Blockade|Monitoring Neuromuscular Blockade the Flexor Hallucis and adductor of the thumb.
11281276|NCT02825108|Experimental|experimental group|The patients who receive 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
11281277|NCT02825108|Placebo Comparator|placebo group|The patients who receive only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
11281278|NCT02825108|Other|control group|The patients for whom the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups
11281279|NCT02825095|Active Comparator|Talc Pleurodesis|"For patients in this group, chest tube type PIGTAIL 10 - 14 Fr will be inserted by by chest ultrasound guided and under local anesthesia, allowing good draining of the hemithorax, in case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed, chest tube will be removed 24 - 48 hours later on. the patient will be admitted in the hospital during the whole procedure course.
~If the patient developed non expanded - trapped lung post chest tube insertion, or if he had persistence high chest tube output for more than 10 days, then the patient will remain with the PIGTAIL as an Indwelling Pleural Catheter."
11281280|NCT02825095|Active Comparator|Indwelling Pleural Catheter|"All patients from this group will have Indwelling Pleural Catheter insertion type PLEURAX inserted by ultrasound guided and under local anesthesia.
~the patient and his/her family will be instructed and educated about the proper way of using the catheter, and how to perform pleural draining at home.
~the duration of treatment with the Pleurax depends on the rate and amount of pleural effusion draining."
11281281|NCT02825069|Experimental|Intervention group|Early introduction of solid foods starting at the age of 4 months, with foodstuff from all major groups in diet by the age of 6 months (vegetables and fruits, wheat and other grains, meat, fish, egg, dairy products). Babies presenting with mild symptoms are encouraged to continue the symptom-eliciting food.
11281282|NCT02825069|No Intervention|Control group|Families are advised to follow the official Finnish Nutrition Recommendations, including exclusive breastfeeding until the age of 6 months.
11281283|NCT02825056|Active Comparator|Bupivacaine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%).
11281284|NCT02825056|Experimental|Bupivacaine + Morphine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%) and 250 microgram of preservative free Morphine (VERMOR).
11281285|NCT02825043|Experimental|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
11281286|NCT02825030|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281287|NCT02825017|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281288|NCT02825004|Experimental|Psychological Intervention|All the professionals workers involved in the experimental group will attend three intensive psychological meetings about emotional exhaustion, depersonalisation, low personal accomplishment and how to improve coping skills.
11281289|NCT02825004|No Intervention|Control Group|There is not any intervention.
11281290|NCT02824991|Experimental|Deep Dry Needling|"Deep Dry Needling (DN) with the purpose of obtaining local twitch responses (LTRs). Description: Latent MTrPs were identified in both MG using according the presence of a palpable taut band and hypersensitive spot in the palpable taut band as diagnostic criteria.
~The deep DN was administered by a physical therapist with three years of experience in the technique. The ultrasound video (SonoSite Titan; Sonosite, Bothell, WA, USA) was recorded at 60 frames per second captured through an external capture device from Epiphan Systems Inc. (Ottawa, Ontario, Canada). According to the perception of the physical therapist and the ultrasound assessment, the filament needle was inserted into the MTrP to achieve three LTRs. Posterior to DN application, the ROMs of the MG and HA were measured"
11281291|NCT02824965|Experimental|Pembrolizumab+1x10^9 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
11281292|NCT02824952|Experimental|Tagrisso 80 mg|80 mg of Tagrisso(AZD9291) will be given every day for 6 or 12 weeks.
11281293|NCT02824939|Experimental|Transversus Abdominis Plane group|
11281294|NCT02824939|Experimental|Quadratus Lumborum group|
11281298|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
11281299|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
11281300|NCT02824900|Experimental|Vibration stimuli to neck|Vibration stimuli to contralesional neck muscles, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
11281301|NCT02824900|Active Comparator|Vibration stimuli to hand|Vibration stimuli to contralesional hand, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
11281302|NCT02824887||Exposed group|Long term curative effect of electroacupuncture treatment of lumbar intervertebral disc herniation in exposure group
11281303|NCT02824887||control group|Long term efficacy of conventional treatment of lumbar disc herniation in the control group
11281304|NCT02824874|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO
~Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO
~Each treatment period was separated by a washout period of at least 10 dyas."
11281305|NCT02824874|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO
~Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO
~Each treatment period was separated by a washout period of at least 10 dyas."
11281306|NCT02824861|Experimental|Text Intervention|Participants receive text messages to a personal cell phone over 8 weeks, wear a fitbit to monitor physical activity, and communicate with a health coach intermittently over 2 weeks
11281307|NCT02824861|Active Comparator|Active Control|Participants receive and wear a fitbit only for 8 weeks
11281308|NCT02824848|Active Comparator|Passive Stretching|Passive Stretching intervention components include static passive stretching, active assistive range of motion, assisted stretching of the involved cervical musculature, and associated strengthening activities aimed to elicit head righting in developmentally appropriate positions and during developmentally appropriate movement transitions. Intervention is progressed by increasing head tilt angles, duration of head righting, and frequency and number of repetitions.
11281309|NCT02824848|Active Comparator|Perception-Action Approach|P-A Approach intervention components include environmental set-up for activity and participation in play, and manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions. Both components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing environmental supports provided to the infant's body parts, and by removing the therapist's hands from the infant's body to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
11281310|NCT02824835||adenoma group|Patients with adenoma. Biopsies are taken before endoscopic resection.
11281311|NCT02824835||cancer group|Patients with colorectal cancer. Biopsies are taken before surgical resection.
11281312|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
11281313|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
11281314|NCT02824796|Experimental|Schema Parent Behavioral Training|An enhanced protocol which combines a Schema Focused Therapy (SFT) and Behavioral Parent Training (PBT)
11281315|NCT02824796|Active Comparator|Parent Behavioral Training|Usually medication & The usual PBT treatment
11281316|NCT02824770|Active Comparator|Usual Care|After a major abdominal surgery, the control group will receive the usual postoperative care including continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) in the surgical intensive care unit.
11281317|NCT02824770|Experimental|Dimming of lights and decreasing noise|After a major abdominal surgery, the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed and will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) as in the control group. The study intervention will include dimming of lights and decreasing noise. The lights will be dimmed to 40 lux. The doors of the side-rooms will be closed decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m.
11281318|NCT02824757||known diabetes|Participants have been diagnosed diabetes.
11281319|NCT02824757||known prediabetes|Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.
11281320|NCT02824757||normal glucose tolerance|Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.
11281321|NCT02824757||unclear glucose tolerance condition|Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.
11281322|NCT02824744|Active Comparator|treatment by 2l/min/kg in HFNC|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
11281323|NCT02824744|Experimental|treatment by 3l/min/kg in HFNC|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
11281324|NCT02824731|Active Comparator|supratentorial, grade III/IV, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
11281325|NCT02824731|Experimental|supratentorial, grade III/IV, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
11281326|NCT02824731|Active Comparator|supratentorial, grade I/II, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
11281327|NCT02824731|Experimental|supratentorial, grade I/II, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.
11281328|NCT02824731|Active Comparator|infratentorial, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
11281329|NCT02824731|Experimental|infratentorial, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
11281330|NCT02824731|Active Comparator|pre-radiation, photon|> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
11281331|NCT02824731|Experimental|pre-radiation, proton|> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
11281332|NCT02824718|Experimental|rh PTH(1-34)|40 µg/day rhPTH(1-34) (teriparatide or FORSTEO® 20 µg twice daily) over 7 to 8 weeks (52±3 days).
11281333|NCT02824718|Active Comparator|Thiazide + potassium sparing diuretic|hydrochlorothiazide 25 mg/day (ESIDREX®) + amiloride 5 mg/day (MODAMIDE®) + 0.5 µg/day alfacalcidol (ALFACALCIDOL®) over 7 to 8 weeks (52±3 days).
11281334|NCT02824679|Active Comparator|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
11281335|NCT02824679|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
11281336|NCT02824679|Placebo Comparator|Saline|They received two ml of normal saline intravenously as a placebo
11281337|NCT02824666|Experimental|0.5 mg/kg|• Cohort 1: ATI-9242 - Single IV bolus dose of 0.5 mg/kg
11281338|NCT02824666|Experimental|ATI-9242 1.0 mg/kg|• Cohort 2: ATI-9242 - Single IV bolus dose of 1.0 mg/kg
11281339|NCT02824653|Experimental|Mesenchymal Stem Cells|The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells
11281340|NCT02824640|Active Comparator|Patient Navigation|"The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
~Health Promotion Sessions: PNs will deliver 4 standardized health promotion sessions to all patients either individually or within a group.
~Optional Weekly Support Groups: Subjects randomized to the PN arm will be offered weekly support groups led by Peers."
11281341|NCT02824640|Active Comparator|modified Directly Observed Therapy|"OAT clinic setting: Observation of HCV medications will be linked to methadone visits among patients receiving methadone. Patients will be receiving methadone as part of routine clinical care for opioid addiction and not as an intervention related to this study. The schedule of five days per week will be considered modified DOT (mDOT). Subjects will initiate HCV treatment on Mondays if feasible. Take home medications will be packed in a weekly electronic blister pack.
~Community health clinic setting: This intervention is considered modified DOT (mDOT) since between 3-5 weekly doses will be directly observed. A minimum of one dose will be observed in person by clinic/study staff. For the remaining observed doses, the research staff and provider will present the participant with a menu of options and determine what will work best for that participant."
11281342|NCT02824627|Experimental|Oxytocin|Subjects weighing >40kg will receive a total of 24 IU of oxytocin delivered as 2- 6 IU puffs to each nostril once daily. Subjects weighing < 40kg will receive a total of 12 IU of oxytocin delivered as 1- 6 IU puff to each nostril daily. Subjects will receive 14 to 21 days of daily oxytocin administration.
11281343|NCT02824627|Placebo Comparator|Placebo|Subjects weighing>40kg will 2 puffs of placebo to each nostril daily. Subjects weighing <40kg will receive 1 puff per day. Subjects will receive 14-21 days of placebo administration.
11281344|NCT02824614|No Intervention|Control|20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
11281345|NCT02824614|Active Comparator|E967-Xylitol|20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
11281346|NCT02824614|Active Comparator|E968-Erythritol|20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
11281347|NCT02824601|Experimental|One-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
11281348|NCT02824601|Experimental|Two-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. In the following, 14-day inter-appointment medication with Ca(OH)2 + SSL was placed in the root canal. After 14 days with intracanal medication, the tooth was isolated for surgery and disinfection, including removal of provisional restoration. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
11281349|NCT02824588|Experimental|Intervention|Working Memory Training
11281350|NCT02824588|Active Comparator|Control|Internet use
11281351|NCT02824575|Experimental|Arm A1-2: Paclitaxel plus Rebastinib.|"Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.
~Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
11281352|NCT02824575|Experimental|Arm B1-2: Eribulin plus Rebastinib.|"Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.
~Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
11281353|NCT02824562|Other|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
11281354|NCT02824562|Other|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
11281355|NCT02824536|Experimental|Group 1|Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
11281356|NCT02824536|Experimental|Group 2|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
11281357|NCT02824536|Experimental|Group 3|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
11281358|NCT02824523||High-dose aspirin|
11281359|NCT02824510|Active Comparator|Patients under insulin pump therapy.|Patients under insulin pump therapy. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart).
11281360|NCT02824510|Active Comparator|Patients under MDI.|Patients under multiple daily injection regimen. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart and glargine or detemir).
11281361|NCT02824484|Experimental|Guided Written Disclosure Protocol|GWDP consists of three 20-minutes writing sessions. Participants write every two weeks at home following the specific instructions for each session.
11281362|NCT02824484|Placebo Comparator|Control|Control condition consists of three 20-minutes writing sessions. Participants write every two weeks at home following the instructions. Their task is constructed to be emotionally neutral.
11281363|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
11281364|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
11281365|NCT02824458|Experimental|Gefitinib + Apatinib|"(Part A) Phase I, Open-label, Dose-escalation Study Escalating doses(500mg, 750mg, or 250mg) of Apatinib in combination with 250mg Gefitinib daily orally. Participants may continue to receive treatment until progress or intolerable.
~(Part B)Multicenter, Randomized, Double-Blind Study Apatinib (dose determined from Part A of study) in combination with 250mg Gefitinib."
11281366|NCT02824458|Placebo Comparator|Gefitinib + Placebo|"(Part A) Not Applicable
~(Part B) Placebo in combination with 250mg Gefitinib. Participants may continue to receive treatment until progress or intolerable."
11281367|NCT02824445|Sham Comparator|Sham|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
11281368|NCT02824445|Experimental|Treatment|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
11281369|NCT02824432|Experimental|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered once a day immediately after meal.
11281370|NCT02824432|Experimental|TAK-085 4g|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered twice a day immediately after meal.
11281371|NCT02824419|Experimental|C11-methionine|To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
11281372|NCT02824419|Experimental|68Ga-Dotanoc|To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
11281373|NCT02824406||Patients|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
11281374|NCT02824406||Controls|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
11281375|NCT02824393|Experimental|Mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
11281376|NCT02824393|No Intervention|Control patients|The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.
11281377|NCT02824380|Experimental|Sequence A|Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)
11281378|NCT02824380|Experimental|Sequence B|Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)
11281379|NCT02824367|Other|Parkinsonian|Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
11281380|NCT02824367|Other|Dystonic|Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
11281381|NCT02824354|Placebo Comparator|placebo|"The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side."
11281382|NCT02824354|Experimental|Nalmefene|"Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate).
~Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.
~The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food."
11281383|NCT02824341|Other|Parkinson's disease patients with RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
11281384|NCT02824341|Other|Parkinson's disease without RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
11281385|NCT02824341|Other|Healthy volunteers|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
11281386|NCT02824315|Experimental|AL-335+Simeprevir (SMV)+Odalasvir (ODV)|Participants will receive AL-335 800 milligram (mg) once daily from day 1-3; SMV 75 mg once daily from Day 4-13; loading dose of ODV 150 mg on Day 14, followed by ODV 50 mg once daily from Day 15 to 23; ODV 50 mg once daily + AL-335 800 mg once daily from day 24-26; ODV 50 mg once daily + SMV 75 mg once daily from Day 27-33 and ODV 50 mg once daily + SMV 75 mg once daily + AL-335 800 mg once daily from Day 34 to 36.
11281387|NCT02824289|Experimental|Sun Safe Workplaces Program|Program promoting the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers and in-person training of outdoor workers by research staff over two years.
11281388|NCT02824289|Active Comparator|Attention Control|Program promoting occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff.
11281389|NCT02824276|Experimental|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
11281390|NCT02824276|Placebo Comparator|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
11281391|NCT02824263|No Intervention|CPAP|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
11281392|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
11281393|NCT02824250|Experimental|MBSR + Usual Care|8-week standard Mindfulness-Based Stress Reduction (MBSR) course + standard of care
11281394|NCT02824250|No Intervention|Usual Care|Standard of care
11281395|NCT02824237|Experimental|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
11281396|NCT02824224|Experimental|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
11281397|NCT02824224|Placebo Comparator|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
11281398|NCT02824211|Experimental|Right Dose System|Use of automated oxygen titration during exertion
11281399|NCT02824198|Experimental|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
11281400|NCT02824198|Placebo Comparator|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
11281401|NCT02824185|Experimental|FCH-PET/MRI|FCH-PET/MRI exam performed in addition to the usual examinations for monitoring hepatocellular carcinoma.
11281402|NCT02824172|Experimental|Cast immobilization|36 patients in the experimental cast immobilization
11281403|NCT02824172|Active Comparator|complete sport rest|36 patients in the complete sport rest group
11281404|NCT02824159||Patient with haematologic malignancies|"Interventions to be administrated are :
~Clinical examinations
~Biological statement
~Blood samples for pharmacokinetics exploration
~Imagery with positron emission tomography scan or resonance magnetic imagery
~Saliva samples for genetics analyses
~Blood samples for treatment mutation resistance search
~Quality of life scale questionary
~Detection of adverse events"
11281405|NCT02824146|No Intervention|Control group|Patients received standard protective mechanical ventilation during all surgery, with tidal volumen 6 ml/kg and positive end-expiratory pressure (PEEP) level of 5 (centimeter of water) cmH2O.
11281406|NCT02824146|Experimental|Recruitment maneuver group|"Patient received a lung recruitment maneuver after pneumoperitoneum insufflation.
~The recruitment maneuver consists in 10 breaths at 30/15 cmH2O of plateau pressure and PEEP, respectively. Then, the ventilatory settings back to protective ventilation but adding 8 cmH2O of PEEP to keep the lungs open."
11281407|NCT02824133|Experimental|AZD4547|AZD4547: intake of 80mg bd (160mg/day), on a continuous schedule.
11281408|NCT02824120|Experimental|Comedy|patients in this group will watch a comedy film that will not exceed 30 minutes
11281409|NCT02824120|Experimental|Documentary|patients in this group will watch a documentary film that will not exceed 30 minutes.
11281410|NCT02824107|Experimental|patients with myocardial infarction|
11281411|NCT02824107|Experimental|patients with stroke|
11281412|NCT02824081|Other|Depressive patients|Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
11281438|NCT02823951||Tecfidera - early discontinuation cohort - disease activity|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
11281439|NCT02823912|Experimental|Capsaicin|75 mg capsaicin every 12 hours for 90 days
11281413|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 15 mg; then RO5545965 5mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
11281414|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 5 mg; then RO5545965 15 mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
11281415|NCT02824055|Experimental|RO5545965 15 mg first; then Placebo; then RO5545965 5 mg|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
11281416|NCT02824055|Experimental|RO5545965 15 mg first; then RO5545965 5 mg; then Placebo|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
11281417|NCT02824055|Experimental|RO5545965 5 mg first; then Placebo; then RO5545965 15 mg|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
11281418|NCT02824055|Experimental|RO5545965 5 mg first; then RO5545965 15 mg; then Placebo|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
11281419|NCT02824042|Experimental|Anetumab ravtansine|The evaluation of multiple ECG parameters and the drug-drug interaction (DDI) potential of anetumab ravtansine parameters when administered alone and together with itraconazole 100 mg oral capsules will be conducted in 2 sequential parts. On Cycle 1 Day 1, anetumab ravtansine will be given alone at a dose of 6.5 mg/kg in Part 1 and Part 2. On Cycle 2 Day 1, anetumab ravtansine will be given together with itraconazole at a dose of 0.6 mg/kg in Part 1, and at a dose of 6.5 mg/kg (planned) in Part 2.
11281420|NCT02824029|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11281421|NCT02824016|Active Comparator|with supraclavicular irradiation|Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
11281422|NCT02824016|Active Comparator|without supraclavicular irradiation|Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
11281423|NCT02824003|Experimental|ISIS-GCGRRx|ISIS-GCGRRx once weekly dosing for 13 weeks
11281424|NCT02824003|Placebo Comparator|Placebo|once weekly dosing for 13 weeks
11281425|NCT02823990|Experimental|Treatment TG4010 + nivolumab|Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11281426|NCT02823977|Experimental|Ketamine / Dexmedetomidine|Ketamine 0.25 mg/kg bolus followed by 0.5 mg/kg per hour AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
11281427|NCT02823977|Placebo Comparator|Placebo / Dexmedetomidine|Normal saline, as a 500 mL infusion bag, to represent placebo AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
11281428|NCT02823964|Experimental|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
11281429|NCT02823951||Rebif - 1 year MRI cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline and at 12 months
11281430|NCT02823951||Rebif - 1 year clinical cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline
11281431|NCT02823951||Rebif - early discontinuation cohort - tolerability|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
11281432|NCT02823951||Rebif - early discontinuation cohort - adverse events|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
11281433|NCT02823951||Rebif - early discontinuation cohort - disease activity|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
11281434|NCT02823951||Tecfidera - 1 year MRI cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline and at 12 months
11281435|NCT02823951||Tecfidera - 1 year clinical cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline
11281436|NCT02823951||Tecfidera - early discontinuation cohort - tolerability|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
11281437|NCT02823951||Tecfidera - early discontinuation cohort - adverse events|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
11281440|NCT02823912|Placebo Comparator|Control|75 mg magnesia calcinada every 12 hours for 90 days
11281441|NCT02823899|Experimental|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
11281442|NCT02823899|Active Comparator|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
11281443|NCT02823886|Experimental|STEMI patients|
11281444|NCT02823873||Normotensive|Normotensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
11281445|NCT02823873||Hypertensive|Hypertensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
11281446|NCT02823860|Other|Biospecimens and Quality of Life (QoL)|Only if patient's consent is obtained, biospecimens, including tumor and/or peripheral blood are collected.
11281447|NCT02823847|Experimental|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
11281448|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
11281449|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
11281450|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
11281451|NCT02823808|Experimental|ALO+PIO|Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.
11281452|NCT02823808|Active Comparator|GMPD+MET|Group who takes Glimepiride 2mg+Metformin 500mg, once daily.
11281453|NCT02823795|Experimental|sPATH|Motivational Interviewing in five sessions post hospital discharge
11281454|NCT02823795|No Intervention|Control|Care as usual
11281455|NCT02823782|Experimental|Laminar HP|Structural and functional MRI markers
11281456|NCT02823782|Experimental|Complex HP|Structural and functional MRI markers
11281457|NCT02823782|Experimental|ADHD|Structural and functional MRI markers
11281458|NCT02823782|Other|Control|Structural and functional MRI markers
11281459|NCT02823769|Experimental|SI-R21204 resin composite|Fillings made with a new dental filling material
11281460|NCT02823769|Active Comparator|Nanohybrid resin composite|Fillings made with nanohybrid resin composite (Clearfil Majesty)
11281461|NCT02823756|Experimental|Physical Therapy|Treatment arm: manipulation, exercise, and education
11281462|NCT02823743|Experimental|Low dose aspirin|75 mg aspirin orally daily from gestational week 7-35
11281463|NCT02823743|Placebo Comparator|Placebo|Placebo pill orally daily from gestational week 7-35
11281464|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
11281465|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
11281466|NCT02823691|Experimental|Lanreotide and Metformin|"Dose and Treatment Regimen:
~LANREOTIDE ATG 120 mg/28 days (equivalent to 1 cycle), deep subcutaneous injection (SC) in combination with METFORMIN 2550 mg daily (maximum dose), oral administration (OS).
~Metformin starting dose 850 mg/day to be increased up to 1700 mg/day at day 14, 2550 mg/day at day 28, (maximum dose), if well tolerated."
11281467|NCT02823678||Pancreatectomy|Patients scheduled to undergo a pancreatectomy
11281468|NCT02823665|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
11281469|NCT02823665|Experimental|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
11281470|NCT02823652|Experimental|Group I (internet-based intervention)|Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
11281471|NCT02823652|Active Comparator|Group II (usual care control)|Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
11281472|NCT02823652|Experimental|Group III (genetic counseling)|Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.
11281473|NCT02823639|Active Comparator|Transcranial direct current stimulation|tDCS with varying intensity, location and polarity
11281474|NCT02823639|Placebo Comparator|Sham stimulation|Double blind sham stimulation with sham mode of neuroConn device
11281475|NCT02823626||Intervention|Spironolactone and patiromer
11281476|NCT02823613|Experimental|Healthy male test subjects 1-5|High salt diet followed by low salt diet
11281477|NCT02823613|Experimental|Healthy male test subjects 6-10|Low salt diet followed by high salt diet
11281478|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
11281479|NCT02823587|Experimental|Bronchiectasis Pulmonary Rehabilitation|The volunteers will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
11281480|NCT02823587|Experimental|Healthy Pulmonary Rehabilitation|In this arm, the volunteers healthy will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
11281481|NCT02823587|Sham Comparator|Bronchiectasis Group Control|The volunteers with bronchiectasis will be informed only about the benefits of physical activities
11281482|NCT02823587|Sham Comparator|Healthy Group Control|Volunteers healthy will be informed only about the benefits of physical activities
11281483|NCT02823574|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
11281484|NCT02823574|Active Comparator|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
11281485|NCT02823561|Active Comparator|Garcinia mangostana (treatment group)|Balanced low-calorie diet and regular exercise in combination with integration
11281486|NCT02823561|Other|Control group|balanced low-calorie diet and regular exercise
11281487|NCT02823548|Experimental|Droglican|Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.
11281488|NCT02823548|Placebo Comparator|Placebo|Patients take one sacchet of Placebo once a day during 6 months.
11281489|NCT02823535|Experimental|Iwin: Individual Well-Being Navigator|Iwin intervention during 6-month intervention period plus study assessments at baseline, 6, and 9 months.
11281490|NCT02823535|No Intervention|Control group|Study assessments at baseline, 6 months, and 9 months, plus two short surveys unrelated to the study behaviors at 4 and 5 months.
11281491|NCT02823509|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281492|NCT02823496|Experimental|Arm 1|All subjects are patched with the same product
11281493|NCT02823483|Experimental|Arm 1|All subjects are patched.
11281494|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
11281495|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
11281496|NCT02823457|Other|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
11281497|NCT02823444||Peripheral Vascular Disease|Gender distribution will be approximately equal. The age range is 18-95, with increased prevalence in the elderly population.
11281498|NCT02823444||Control|In the initial sequence optimization stage, healthy volunteers will also be recruited.
11281499|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
11281500|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
11281501|NCT02823418||No neuraxial labor analgesia|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
11281502|NCT02823418||Neuraxial labor analgesia|For patients who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
11281503|NCT02823405|Experimental|X4P-001 + Pembrolizumab|X4P-001 alone, then adding pembrolizumab
11281504|NCT02823379|Experimental|Physical Activity|A culturally relevant physical activity promotion program delivered using a Smartphone application.
11281505|NCT02823379|Active Comparator|Wellness Contact Control|A wellness contract control condition delivered using a Smartphone application.
11281506|NCT02823366|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
11281507|NCT02823366|Active Comparator|Monotherapy|UDCA alone
11281508|NCT02823353|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
11281509|NCT02823353|Active Comparator|Monotherapy|UDCA alone
11281510|NCT02823340|Experimental|Fractional Microneedle Radiofrequency Treatment|Fractional Microneedle Radiofrequency Treatment
11281511|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
11281512|NCT02823314|Experimental|Intervention group|One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes.
11281513|NCT02823314|Placebo Comparator|Placebo group|Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area.
11281514|NCT02823301|Experimental|VAMOS group|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
11281515|NCT02823301|No Intervention|Control group|Group that will not receive the VAMOS program as intervention.
11281516|NCT02823288|Experimental|Sonke CHANGE intervention condition|This arm (n=9 clusters) will receive the Sonke CHANGE intervention for 12 months.
11281517|NCT02823288|No Intervention|Control condition|In this arm (n=9 clusters), no activities will take place during the trial period outside of data collection.
11281518|NCT02823275|Active Comparator|Functional mobilisation|
11281519|NCT02823275|Experimental|plaster cast fixation|
11281582|NCT02822898|Active Comparator|Hypotonic Maintenance Fluid|Hypotonic Maintenance Fluid
11281738|NCT02821741|Active Comparator|Ear Lobe|Mild electrical stimulation is applied to the earlobe of the left ear.
11281520|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation
~Including background questionnaire and randomization into Decision Aid Group or Control Group:
~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.
~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.
~Assessment at One week after participants surgical consultation and five months after surgical consultation"
11281521|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation
~Including background questionnaire and randomization into Decision Aid Group or Control Group:
~Participant will receive Usual Care assistance when making treatment decisions.
~Assessment at One week after participants surgical consultation and five months after surgical consultation"
11281522|NCT02823249|Active Comparator|1.56 g L-Tryptophan|"1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
11281523|NCT02823249|Active Comparator|1.56 g L-Leucine|"1.56 g L-Leucine in 300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
11281524|NCT02823249|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water given via nasogastric tube
11281525|NCT02823249|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water given via nasogastric tube
11281526|NCT02823249|Placebo Comparator|75 g Glucose and mixed liquid meal|"75 g Glucose in 300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
11281527|NCT02823249|Placebo Comparator|Tap water and mixed liquid meal|"300 mL tap water given via nasogastric tube
~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
11281528|NCT02823236|Active Comparator|Intralesional Triamcinolone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
11281529|NCT02823236|Experimental|Topical Pirfenidone|Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
11281530|NCT02823236|Experimental|Triamcinolone + Pirfenidone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
11281531|NCT02823223|Experimental|ELVR with Endobronchial Valves|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Endobronchial Valves (Zephyr valve) inserted into the target lobe of the lung with the aim of complete lobar exclusion.
11281532|NCT02823223|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice
11281533|NCT02823197|Experimental|active transport lesson|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations.
11281534|NCT02823197|Experimental|active transport lesson and Facebook group|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
11281535|NCT02823197|No Intervention|control group|Participants in the control group do not receive the active transport lesson or the Facebook group.
11281536|NCT02823184||Patients|ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available
11281537|NCT02823171|Experimental|Sequence I|Sequence I: treatment A/B
11281538|NCT02823171|Experimental|Sequence II|Sequence II: treatment B/A
11281539|NCT02823158|Experimental|GPi DBS and best medical treatment|
11281540|NCT02823158|Active Comparator|Best medical treatment|
11281541|NCT02823145|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
11281542|NCT02823132||patients who develop a fungal infection|
11281543|NCT02823132||patients without fungal infection|
11281544|NCT02823119|Experimental|Mini-hysteroscopy|A rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm.
11281545|NCT02823119|Active Comparator|Conventional Office Hysteroscopy|A rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm
11281546|NCT02823106|Experimental|Verapamil and Citicoline|10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
11281547|NCT02823106|Placebo Comparator|Placebo|The control group will receive saline only.
11281548|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
11281549|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
11281550|NCT02823067||Nursing home patients|Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
11281551|NCT02823054|No Intervention|Standard group|bi lung ventilation usual practice
11281552|NCT02823054|Experimental|EZ-Blocker group|one lung ventilation 'EZ-Blocker'
11281553|NCT02823041|Experimental|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
11281554|NCT02823041|Active Comparator|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
11281555|NCT02823028|Active Comparator|NRT + Web Guide|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges)
11281556|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Coed|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group
11281557|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Women|Experimental: NRT + Web Guide + Tweet2Quit-Women NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a women-only Tweet2Quit group
11281558|NCT02823015||Study population|The study population consists of adult surgery patients, scheduled for breast cancer surgery at St-Luc University Hospital.
11281559|NCT02823002|Experimental|Slow, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
11281560|NCT02823002|Experimental|Rapid, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
11281561|NCT02823002|Experimental|Slow, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
11281562|NCT02823002|Experimental|Rapid, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
11281563|NCT02823002|Experimental|Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
11281564|NCT02823002|Placebo Comparator|Non-Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
11281565|NCT02822989|Active Comparator|Vagus Nerve Stimulation|Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
11281566|NCT02822989|Sham Comparator|Sham Vagus Nerve Stimulation|Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
11281567|NCT02822976||Critically Ill Patient HbA1c<6.5|Patients admitted to an intensive care unit with a HbA1c <6.5.
11281568|NCT02822976||Critically Ill Patient HbA1c≥6.5|Patients admitted to an intensive care unit with a HbA1c ≥6.5.
11281569|NCT02822963||A|Non anticoagulant and/or antiplatelet users.
11281570|NCT02822963||B|Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
11281571|NCT02822963||C|Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
11281572|NCT02822950|Other|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
11281573|NCT02822937|Experimental|Placebo, Methylphenidate, Triazolam|The participants will receive placebo on the first day, 40mg Methylphenidate on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
11281574|NCT02822937|Experimental|Placebo, Triazolam, Methylphenidate|The participants will receive placebo on the first day, 0.375mg Triazolam on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
11281575|NCT02822937|Experimental|Methylphenidate, Placebo, Triazolam|The participants will receive 40mg Methylphenidate on the first day, placebo on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
11281576|NCT02822937|Experimental|Methylphenidate, Triazolam, Placebo|The participants will receive 40mg Methylphenidate on the first day, 0.375mg Triazolam on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
11281577|NCT02822937|Experimental|Triazolam, Placebo, Methylphenidate|The participants will receive 0.375mg Triazolam on the first day, placebo on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
11281578|NCT02822937|Experimental|Triazolam, Methylphenidate, Placebo|The participants will receive 0.375mg Triazolam on the first day, 40mg Methylphenidate on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
11281579|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
11281580|NCT02822911|Other|Alcohol Used Disorders Identification Test (AUDIT C)|Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
11281581|NCT02822898|Active Comparator|Isotonic Maintenance Fluid|Isotonic Maintenance Fluid
11281583|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
11281584|NCT02822872||infertile couples|"couples addressing IVF treatment due to known infertility will fill questionnaire in order to assess their stress level (as mentioned above), after filling the questionnaire scalp hair sample will be taken to assess chronic cortisol secretion.
~during the IVF treatment the stress level will be assessed every 3 month by using the same system (in order to find match between the stress level and cortisol secretion with the fertility treatment"
11281585|NCT02822859|Active Comparator|Wright|Methacholine challenge performed using the Wright nebulizer
11281586|NCT02822859|Active Comparator|Bennett-Twin|Methacholine challenge performed using the Bennett-Twin nebulizer
11281587|NCT02822859|Active Comparator|Aeroneb Solo|Methacholine challenge performed using the Aeroneb Solo nebulizer
11281588|NCT02822833|Experimental|Sentinel lymph node mapping|Sentinel lymph node mapping with indocyanine green injection to cervix in endometrial cancer patients operated laparoscopically
11281589|NCT02822820|Active Comparator|Advanced bipolar (Ligasure-Covidien)|Devices with advanced bipolar energy (Ligasure-Covidien) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
11281590|NCT02822820|Active Comparator|Conventional bipolar (RoBi forceps-Karl Storz)|Devices with conventional bipolar energy (RoBi rotating bipolar forceps-Karl Storz) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
11281591|NCT02822807|Other|Q fever without valvular disease|Q fever without valvular disease
11281592|NCT02822807|Other|Q fever with valvular disease|Q fever with valvular disease
11281593|NCT02822807|Other|Q fever infective endocarditis|Q fever infective endocarditis
11281594|NCT02822807|Other|Other Coxiella burnetii infections (including pregnant women)|Other Coxiella burnetii infections (including pregnant women)
11281595|NCT02822794|Experimental|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
11281596|NCT02822794|Experimental|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
11281597|NCT02822768|Active Comparator|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
11281598|NCT02822768|Placebo Comparator|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
11281599|NCT02822755|Experimental|Video Recording Group|The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
11281600|NCT02822755|Active Comparator|Conventional Printed Group|The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs
11281601|NCT02822742|Other|DE-117 ophthalmic solution and Latanoprost|DE-117 is Experimental. Latanoprost is Active Comparator.
11281602|NCT02822729|Experimental|DE-117 ophthalmic solution (Group1)|Monotherapy
11281603|NCT02822729|Experimental|DE-117 ophthalmic solution (Group2)|Monotherapy
11281604|NCT02822729|Other|DE-117 ophthalmic solution + Timolol (Group3)|Concomitant Use
11281605|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
11281606|NCT02822703|Experimental|Active 20Hz|The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil. Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds. In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
11281607|NCT02822703|Sham Comparator|Sham|The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device. There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil. In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
11281608|NCT02822690||University Medical Center Groningen|all patients that died on one of the wards with the exception of children; on several wards the Hospice care will be introduced as an intervention
11281609|NCT02822690||Martini Ziekenhuis|all patients that died on one of the wards with the exception of children
11281610|NCT02822690||Ommelander ZorgGroep|all patients that died on one of the wards with the exception of children
11281611|NCT02822664|Other|Pedophiles patients|Adults diagnosed with pedophilia
11281612|NCT02822664|Other|Healthy subjects|Healhy subjects (not diagnosed with pedophilia)
11281613|NCT02822651|Experimental|Vitamin D status|The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.
11281614|NCT02822638||STEMI PATIENT Cohort|STEMI PATIENT Cohort
11281615|NCT02822625|Experimental|arm 1|Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.
11281616|NCT02822625|Active Comparator|arm 2|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.
~Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message"
11281617|NCT02822625|Placebo Comparator|arm 3|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.
~Patients will receive QUTENZA® according to standard procedure with a music therapy"
11281618|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
11281619|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
11281620|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
11281621|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
11281622|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
11281623|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
11281624|NCT02822586|Experimental|Cohort A (Stage IB and Stage IIA to IIIB [if N0-1])|"(Eligible patients with Stage IB, IIA, IIB, and IIIA [if N0-1])
~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.
~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week."
11281625|NCT02822586|Experimental|Cohort B(Stage IIA to IIIB; IVA;transformed CTCL)|"(Eligible patients with Stage IIA, IIB, IIIA [if N2-3]; IIIB; Stage IVA; and transformed CTCL)
~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.
~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week.
~Continuation of brentuximab every 3 weeks until disease progression or unacceptable toxicity or for up to 2 years as a study participant, (whichever occurs first)."
11281626|NCT02822573|Active Comparator|Donepezil|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
11281627|NCT02822573|Placebo Comparator|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
11281628|NCT02822560|Active Comparator|pEVAR|percutaneous femoral access using a suture-mediated closure system
11281629|NCT02822560|Active Comparator|open femoral access|cutdown to femoral artery and surgical closure
11281630|NCT02822547|Experimental|Peginterferon alfa-2a|
11281631|NCT02822534|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
11281632|NCT02822534|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
11281633|NCT02822534|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
11281634|NCT02822521|Experimental|Mobile Application + Population Manager|This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
11281635|NCT02822521|No Intervention|No Mobile Application|This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.
11281636|NCT02822508|Experimental|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
11281637|NCT02822508|Experimental|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
11281638|NCT02822508|Experimental|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
11281639|NCT02822508|Placebo Comparator|BLI801 Placebo|BLI801 Placebo
11281640|NCT02822482|Experimental|Copanlisib + Cetuximab|All patients will be treated by Copanlisib in association with Cetuximab.
11281641|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
11281642|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
11281643|NCT02822456|Experimental|Individual 3D-printed guided tube|IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat
11281644|NCT02822456|Active Comparator|traditional IOE tube|classic IOE tube feeding using nelaton tube only whenever they eat
11281645|NCT02822456|Active Comparator|nasogastric tube|nasogastric tube feeding using levin tube always
11281646|NCT02822443|Experimental|TAU - EFT|This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions. 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
11281647|NCT02822443|Experimental|TAU - SR|This arm focuses on the training of self-regulation strategies (SR; Carver & Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU). 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
11281648|NCT02822430||Patients|"Patients with psychiatric disorders will be assessed using five evaluation of pain scales :
~Visual analogic scale pain
~Pain behaviour scale
~Short-FormHealth Survey (SF-36)
~Global Clinical Impression (GCI) for severity and improvement
~Mini International Neuropsychiatric Interview (MINI)"
11281649|NCT02822417||patients after general anesthesia|Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia
11281650|NCT02822404|Experimental|Urinary and blood sample|Urinary and blood samples for cystatin C dosage
11281651|NCT02822391||Stroke-group|Screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 15. They were excluded if they presented with acute pain in the oro-facial sphere (nominal question) or an additional neuro-muscular disease.
11281652|NCT02822391||Control-group|Similar to stroke group in regard to age, gender and dental state. no stroke
11281653|NCT02822378|Experimental|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
11281654|NCT02822378|Experimental|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
11281655|NCT02822378|Experimental|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
11281656|NCT02822365||Diagnostic (PET/CT)|Patients undergo a PET/CT scan as part of their standard clinical care. While still positioned for the clinical scan, patients undergo additional research PET/CT scans in a smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single bed position CTAC.
11281657|NCT02822352|No Intervention|High Definition White Light|Surveillance colonoscopy using High Definition White Light alone
11281658|NCT02822352|Active Comparator|High Definition Virtualchromoendoscopy|High Definition Virtualchromoendoscopy
11281659|NCT02822339|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281660|NCT02822326|Experimental|CD19-CAR-T2 T Cells|The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells). These CD19-CAR-T2 T cells will be infused over 10-15 minutes on days Day 1, 2 and 3 tentatively according to the response to infusion.
11281661|NCT02822313|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281662|NCT02822300|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281663|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
11281664|NCT02822274|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281665|NCT02822261|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281666|NCT02822248|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11281667|NCT02822235||Crohn's Disease|Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
11281668|NCT02822235||Ulcerative Colitis|Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
11281669|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
11281670|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
11281671|NCT02822209|Experimental|Coordinating nurse added to the personalized care program|"The coordinating nurse (CN) is dedicated to the newly diagnosed patient to optimize their personalized care program.
~The CN is the connection between the medical team and the patient. They act according to the instructions from the multidisciplinary staff in charge of bronchopulmonary cancer patients.:
~e.g. Schedule an exam or an hospitalization, collect and share results of useful information to correct treatment's side effects etc
~Main contact of the patient, the general practitioner and the patient's relatives, they give practical information for the patient's case
~Quality of life questionnaires - EORTC QLQ-C30 and EORTC QLQ-LC13 - completed by the patient throughout the study.
~2 Satisfaction questionnaires completed :
~satisfaction questionnaire - patient,
~satisfaction questionnaire - general practitioner or home nurse"
11281729|NCT02821806||Cohort 1|Healthy Volunteers
11281730|NCT02821793||Elderly patient (70 years and older)|
11281731|NCT02821793||Young patient (18 years - 69 years)|
11281732|NCT02821767||1|Individuals with various diagnosed and undiagnosed ocular conditions
11281733|NCT02821754|Experimental|1/A1|Durvalumab + Tremelimumab
11281734|NCT02821754|Experimental|2/A2|Durvalumab + Tremelimumab + TACE
11281672|NCT02822209|Active Comparator|Personalized care program as routine practice|"A personalized care program is decided for the newly diagnosed patient by the multidisciplinary team in charge of lung cancer.
~The care provided will be organized by the medical team, and besides the oncologist, no principal coordinating contact will be in charge of the patient.
~The quality of life questionnaire - EORTC QLQ-C30 and QLQ-LC13 - will be completed by the patient throughout the study.
~2 Satisfaction questionnaires completed :
~satisfaction questionnaire - patient,
~satisfaction questionnaire - general practitioner or home nurse"
11281673|NCT02822196|Experimental|Serratus Anterior Muscle Plane Block|The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi, teres major and serratus muscles will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.
11281674|NCT02822196|Active Comparator|Thoracic Paravertebral Block|The spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down.The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.
11281675|NCT02822170|Experimental|IV amino acids and in-bed cycle ergometry|"Beginning within 96 hours of ICU admission, participants will receive the following combined intervention:
~IV amino acids (15% solution) delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day.
~In-bed cycle ergometry exercise delivered in 45-minute sessions 5 days per week according to a detailed specific protocol that includes a safety check and gradual increases in resistance if the participant is actively cycling."
11281676|NCT02822157|Experimental|Olaparib|olaparib 300mg oral tablets twice daily for 28 days in 28-day cycles
11281677|NCT02822157|Active Comparator|Chemotherapy|physician's choice chemotherapy
11281678|NCT02822144|Experimental|general anesthesia|General anesthesia with etomidate, succinylcholine, propofol and remifentanil
11281679|NCT02822144|Experimental|sedation|Sedation with remifentanil and local anesthesia with lidocaine
11281680|NCT02822131|Other|low phosphate|low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.
11281681|NCT02822131|Other|high phosphate|high phosphate diet will be induced by oral supplementation with sodium phosphate.
11281682|NCT02822118|Experimental|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe for 8 weeks.
11281683|NCT02822118|Placebo Comparator|Placebo|Patients in this group were administered the placebo for 8 weeks.
11281684|NCT02822105|Experimental|H3N2 M2SR monovalent influenza vaccine|This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
11281685|NCT02822105|Experimental|placebo|This group will receive saline administered intranasally.
11281686|NCT02822092||Patients with Psychotic Disorders taking Risp. or Arip.|Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
11281687|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
11281688|NCT02822066|Experimental|IRE for refractory neoplasms in liver and pancreas|To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
11281689|NCT02822053|Experimental|US-guided laser ablation for refractory neoplasms|The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50*10E9/L and PT ≤ 20s. Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
11281690|NCT02822040||Experimental group|All patients who have initial and final records qualify in the experimental group.
11281691|NCT02822027|Experimental|human gamma globulin|human gamma globulin for infants with encephalopathy of prematurities
11281692|NCT02822027|Active Comparator|non-human gamma globulin|non-human gamma globulin for infants with encephalopathy of prematurities
11281693|NCT02822014|Other|FDG-PET/CT arm|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical evolution of patients.
11281694|NCT02821988|Experimental|Nonstress test|"Subjects will undergo weekly nonstress tests beginning at 32 weeks until delivery in addition to monitoring fetal kick counts.
~A nonstress test is a test in which an external fetal monitor is placed on the mother to defect the fetal heart rate for 20 to 40 minutes. A test is considered reactive if there are more than 2 accelerations in fetal heart rate defined as an increase of at least 15 beats per minute lasting at least 15 seconds in a 20 minute period."
11281735|NCT02821754|Experimental|3/A3|Durvalumab + Tremelimumab+ RFA
11281736|NCT02821754|Experimental|4/A4|Durvalumab + Tremelimumab+ Cryo
11281737|NCT02821741|Experimental|Cymba Conchae|Mild electrical stimulation is applied to the cymba conchae of the left ear.
11281739|NCT02821728|Experimental|Normal diet|No dietary intervention
11281695|NCT02821988|Experimental|Biophysical profile|Subjects will undergo weekly biophysical profile testing beginning at 32 weeks until delivery in addition to monitoring fetal kick counts. A Biophysical profile is a test using real time ultrasonography to determine the presence of absence of certain components of fetal well being. There components include: an episode of fetal breathing lasting at least 30 seconds, 3 or more discrete body movements, 1 or more episodes of extension of a fetal extremity with return to flexion, and determination of amniotic fluid volume to detect a maximum vertical pocket of >2cm. The duration of this test is no more than 30 minutes.
11281696|NCT02821988|No Intervention|Kick counts only|Subjects will monitor fetal kick counts only.
11281697|NCT02821975|Experimental|Cognitive computer training|This is the intervention group receiving cognitive computer training three times a week for three months.
11281698|NCT02821975|No Intervention|cogntrol group|The control group do not receive cognitive computer training for three months
11281699|NCT02821962|Experimental|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
11281700|NCT02821962|No Intervention|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
11281701|NCT02821949||Patients|Patients with Non Small Cells Lung Cancer PCT dosage
11281702|NCT02821936|Experimental|Parametric Imaging|"one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy.
~Two PET scans at 3 months and one year after inclusion"
11281703|NCT02821923|No Intervention|Control|no treatment
11281704|NCT02821923|Active Comparator|E967-Xylitol|24g xylitol/d
11281705|NCT02821923|Active Comparator|E968-Erythritol|36g erythritol/d
11281706|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
11281707|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
11281708|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
11281709|NCT02821897|Experimental|Target-controlled Intravenous Anaesthesia|Patients have a target controlled intravenous anaesthesia to implant the spinal cord stimulation lead with active cooperation during the surgery.
11281710|NCT02821897|Active Comparator|Total anesthesia|Patients have a total anaesthesia to implant the spinal cord stimulation lead without active cooperation during the surgery.
11281711|NCT02821884|Experimental|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes.
11281712|NCT02821884|Active Comparator|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation.
11281713|NCT02821884|Sham Comparator|Combination of sham tDCS and sham NMES|"Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Shame tDCS is started in a ramp-like fashion but fade out slowly after 30 seconds.
~Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation."
11281714|NCT02821871|Active Comparator|SP2086|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
11281715|NCT02821871|Other|high fat diet|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
11281716|NCT02821858|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) 50 milligram (mg) (n=8) or placebo (n=2) on Day 1.
11281717|NCT02821858|Experimental|Panel 1: Treatment B|Participants will receive ODV 100 mg (n=8) or placebo (n=2) on Day 1.
11281718|NCT02821858|Experimental|Panel 1: Treatment C|Participants will receive ODV 300 mg (n=8) or placebo (n=2) on Day 1.
11281719|NCT02821858|Experimental|Panel 2: Treatment D|Participants will receive AL-335 400 mg (n=8) or placebo (n=2) on Day 1 of Period 1. Each treatment period will be separated by a washout period of 7 days.
11281720|NCT02821858|Experimental|Panel 2: Treatment E|Participants will receive AL-335 800 mg (n=8) or placebo (n=2) on Day 1 of Period 2. Each treatment period will be separated by a washout period of 7 days.
11281721|NCT02821858|Experimental|Panel 2: Treatment F|Participants will receive AL-335 1,200 mg (n=8) or placebo (n=2) on Day 1 of Period 3. Each treatment period will be separated by a washout period of 7 days.
11281722|NCT02821845|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
11281723|NCT02821845|No Intervention|Unexercised SCI Hip|"Individuals with spinal cord injury who have been discharged from a locomotor training programs at least 6 months prior to enrollment in this study. This group will serve as unexercised controls for the Trained SCI Hip group."
11281724|NCT02821845|Experimental|Trained SCI Hip|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will focus specifically on rehabilitation of the hip joint.
11281725|NCT02821832|Other|Arm A|Expected high risk of relapse
11281726|NCT02821832|Active Comparator|Arm B|Expected low risk of relapse
11281727|NCT02821832|Experimental|Arm C|Expected low risk of relapse
11281728|NCT02821819|Experimental|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
~Interventions:
~Random start ovarian stimulation
~Gonadotrophins: Urinary FSH 150-225 IU/d
~GnRH antagonists: Cetrorelix 0,25 mg/d
~GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
11281740|NCT02821728|Experimental|Dietary intervention|3 portions of broccoli soup per week
11281741|NCT02821715|Active Comparator|Modafinil + placebo|3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks
11281742|NCT02821715|Experimental|THN102 300/3|3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks
11281743|NCT02821715|Experimental|THN102 300/27|3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks
11281744|NCT02821702|Experimental|Post surgery and embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
11281745|NCT02821702|Active Comparator|Control group|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
11281746|NCT02821702|Active Comparator|Post surgery with accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
11281747|NCT02821702|Active Comparator|Post surgery without accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
11281748|NCT02821702|Active Comparator|Normal Vaginal Delivery - no suspected accreta|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
11281749|NCT02821689|Experimental|pirfenidone|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
11281750|NCT02821689|No Intervention|Blank|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
11281751|NCT02821676|Experimental|PEC1/SPB Block|
11281752|NCT02821676|Active Comparator|Intercostal Block|
11281753|NCT02821663|Experimental|Vocal intervention|Vocal intervention
11281754|NCT02821650|Experimental|Intervention|Intervention arm will be administered with improved cook stoves (TEJ- Traditional stove to Efficient stove in Jhuggi).
11281755|NCT02821650|No Intervention|control|control arm will continue using traditional cook stoves (chulha) or a combination of the traditional stove and the kerosene/diesel stove.
11281756|NCT02821637|Other|Effort rehabilitation program|"An effort rehabilitation program designed for obese and overweight children or teens : 13 weekly sessions of 1hour30 then 1 session 2 months, 6 months and 12 months later.
~This program is part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse.
~Child Health Questionnaire (CHQ) of quality of life are completed by parents and children on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session.
~Eurofit tests of Physical Fitness performed on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session."
11281757|NCT02821624|Experimental|Cohort 1|G1T38 or placebo
11281758|NCT02821624|Experimental|Cohort 2|G1T38 or placebo
11281759|NCT02821624|Experimental|Cohort 3|G1T38 or placebo
11281760|NCT02821624|Experimental|Cohort 4|G1T38 or placebo
11281761|NCT02821624|Experimental|Cohort 5|G1T38 or placebo
11281762|NCT02821624|Experimental|Cohort 6|G1T38 or placebo
11281763|NCT02821624|Experimental|Cohort 7|G1T38 or placebo
11281764|NCT02821624|Experimental|Cohort 8|G1T38 or placebo
11281765|NCT02821624|Experimental|Cohort 9 - Food Effect|G1T38
11281766|NCT02821624|Experimental|Cohort 10|G1T38 or placebo
11281767|NCT02821624|Experimental|Cohort 11|G1T38 or placebo
11281768|NCT02821624|Experimental|Cohort 12|G1T38 or placebo
11281769|NCT02821611|Experimental|Meditation Group|Participants in the experimental group are practicing a mantra-based meditation twice daily for 20 minutes over the 8 week intervention period to reduce stress and blood pressure and enhance quality of sleep.
11281770|NCT02821611|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
11281771|NCT02821598|Experimental|Upper limb pattern|Upper Limb pattern with flexion - abduction - external rotation
11281772|NCT02821598|Experimental|Lower limb pattern 1|Lower Limb pattern with flexion - adduction - external rotation with knee flexion;
11281773|NCT02821598|Experimental|Lower limb pattern 2|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion;
11281774|NCT02821598|Experimental|Lifting to the right|
11281775|NCT02821598|Active Comparator|Sit to Stand|Sit to Stand task
11281776|NCT02821585|Active Comparator|Mediterranean Diet|Participants will receive nutritional lessons on the principles of the Mediterranean diet. This type of diet is defined with a carbohydrate intake of 45-55% of total energy intake, 15-20% of proteins, 30-35% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
11281777|NCT02821585|Placebo Comparator|Low Fat Diet|Participants will receive nutritional lessons on the principles of the low fat diet. This type of diet is defined with a carbohydrate intake greater than 45% of total energy intake, 15-20% of proteins, less than 30% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
11281778|NCT02821572||patient|
11281779|NCT02821572||control|
11281780|NCT02821559|Experimental|triweekly then biweekly|The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).
11281781|NCT02821559|Experimental|biweekly then triweekly|The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.
11281782|NCT02821546|Placebo Comparator|standard hydration|Patients underwent first-time ERCP to receive standard fluid hydration with Lactated Ringer's solution at a rate calculated by the Holliday-Segar method given peri-procedurally starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
11281847|NCT02820974||Perimenopause|Women at the age of 40-54 with irregular cycles filling in th criteria of perimenopause.
11281783|NCT02821546|Active Comparator|aggressive hydration|Patients underwent first-time ERCP to receive aggressive fluid hydration with Lactated Ringer's solution at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
11281784|NCT02821533|Other|TACE using a high dose of cisplatin|Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.
11281785|NCT02821520|Experimental|Initial PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.
~PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.
~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.
~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
11281786|NCT02821520|Active Comparator|Delayed PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.
~PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.
~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.
~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
11281787|NCT02821507|Experimental|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
11281788|NCT02821494|Experimental|Hespecta|Four dose groups of Hespecta
11281789|NCT02821481|Experimental|Beta-alanine and muscular endurance exercise|Receive 3.2 g/day beta-alanine and 3 days per week of endurance resistance training for 12 weeks
11281790|NCT02821481|Experimental|Beta-alanine without muscular endurance training|Receive 3.2 g/day beta-alanine with no endurance resistance training for 12 weeks
11281791|NCT02821481|Placebo Comparator|Placebo and muscular endurance exercise|Receive similar dextrose placebo and 3 days per week of endurance resistance training for 12 weeks
11281792|NCT02821481|Placebo Comparator|Placebo without muscular endurance training|Receive similar dextrose placebo with no endurance resistance training for 12 weeks
11281793|NCT02821468|Experimental|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
11281794|NCT02821468|Experimental|Control|Untreated arm
11281795|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
11281796|NCT02821442|Experimental|Acupuncture|Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).
11281797|NCT02821442|Sham Comparator|Sham Acupuncture|Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.
11281798|NCT02821429||Patient with mechanical ventilation|Patient will be followed with combined Thoracic Echography Record
11281799|NCT02821416|Experimental|Benralizumab|Benralizumab administered subcutaneously
11281800|NCT02821416|Placebo Comparator|Placebo|Placebo administered subcutaneously
11281801|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
11281802|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
11281803|NCT02821390|Active Comparator|Nepafenac 0.1% Eye Drops|One drop of Nepafenac 0.1% Eye Drops will be instilled to the eye's cul de sac prior to the intravitreal injection.
11281804|NCT02821390|Placebo Comparator|Artificial Tears|One drop of Artificial Tears will be instilled to the eye's cul de sac prior to the intravitreal injection.
11281805|NCT02821377|Experimental|intravenous furosemide|intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix
11281806|NCT02821377|Experimental|intravenous hypertonic saline solutions|small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified
11281807|NCT02821377|Active Comparator|seriated paracentesis|no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge
11281808|NCT02821364|Other|Advanced Life Support|ALS providers are trained and able to perform certain procedures such as intubation with endotracheal tubes and placement of intravenous catheters. Endotracheal intubation is often performed by pre-hospital providers in critically ill trauma patients because it is believed that it allows for protection of the airway and better delivery of oxygen. However, most studies actually show that intubation does not provide a survival advantage to this patient population and actually could result in worse outcomes. Intravenous catheter placement and administration of intravenous fluids is also routinely performed however, studies have shown that it is also not helpful.
11281809|NCT02821364|No Intervention|Basic Life Support|Subjects randomized to the study group will receive basic life support (BLS) level care. This means that pre-hospital procedures such as endotracheal intubation and intravenous fluid administration will not be carried out. However, passive oxygen and needle thoracostomy, if required for tension pneumothorax, will be permitted if medically necessary.
11281810|NCT02821351|Experimental|DiamondTemp|Bilateral pulmonary vein isolation by RF ablation using DiamondTemp temperature controlled catheter and RF generator/pump system
11281811|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
11281848|NCT02820974||Menopause|Women at the age of over 55 without normal cycles filling in th criteria of menopause.
11281812|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
11281813|NCT02821325||MRI|Radiology
11281814|NCT02821312|Active Comparator|Active in Group A1~A7|In each of Groups A1 to A7, 8 subjects will receive DA-8010.
11281815|NCT02821312|Placebo Comparator|Placebo in Group A1~A7|In each of Groups A1 to A7, 2 subjects will receive placebo.
11281816|NCT02821312|Active Comparator|Active in Group B1~B4|In each of Groups B1 to B4, 8 subjects will receive DA-8010.
11281817|NCT02821312|Placebo Comparator|Placebo in Group B1~B4|In each of Groups B1 to B4, 2 subjects will receive placebo.
11281818|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
11281819|NCT02821273|Experimental|Modified INSURE|Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
11281820|NCT02821273|Active Comparator|INSURE|INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant.
11281821|NCT02821247||Aflibercept|Adult wet Age Related Macular degeneration (AMD) treatment naïve partcipants were treated with intravitreal aflibercept injection
11281822|NCT02821234|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
11281823|NCT02821234|Experimental|Control group|Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
11281824|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
11281825|NCT02821182|Experimental|Anti-PD1 treatment in combination with SBRT|Patients receiving anti-PD1 treatment will be treated with high-dose radiotherapy to one lesion in 3 fractions prior to the second cycle of systemic therapy.
11281826|NCT02821169|Placebo Comparator|saline solution 0.9%|injection of saline solution in the sphenopalatine area in both nasal fossa
11281827|NCT02821169|Active Comparator|ropivacaine (2mg/ml)|injection of ropivacaine in the sphenopalatine area in both nasal fossa
11281828|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
11281829|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
11281830|NCT02821130||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis
11281831|NCT02821117|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
11281832|NCT02821104||Healthy Adolescents|
11281833|NCT02821091|No Intervention|Control young adults|Healthy adults, age between 20 to 59 yeas old
11281834|NCT02821091|No Intervention|Control old adults|Healthy adults, age between 60 to 80 yeas old
11281835|NCT02821091|Experimental|Exercise old adults|Healthy adults, age between 60 to 80 yeas old received interactive dynamic balance training
11281836|NCT02821078|Experimental|Participants|"In addition to the standard clinical MR protocol, 2 added sequences:
~4D flow imaging sequence
~standard 2D-PhaseContrast at portal trunk level as reference"
11281837|NCT02821065|Experimental|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse receives and reviews the data electronically and will follow-up with the patient.
11281838|NCT02821052||insulin degludec/insulin aspart|
11281839|NCT02821026|Experimental|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
11281840|NCT02821013|Active Comparator|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
11281841|NCT02821013|Active Comparator|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
11281842|NCT02821000|Experimental|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
11281843|NCT02820987|Active Comparator|MEROPENEM|After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.
11281844|NCT02820987|Active Comparator|PIPERACILLIN-TAZOBACTAM|After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
11281845|NCT02820987|Active Comparator|CEFEPIME|After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
11281846|NCT02820974||Healthy control|Healthy women of child bearing age (25-39) with regular cycles.
11281849|NCT02820961|Active Comparator|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
11281850|NCT02820961|Active Comparator|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
11281851|NCT02820948|Experimental|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
11281852|NCT02820948|No Intervention|No Vitamin E ointment application|No vitamin E ointment was performed.
11281853|NCT02820935|Experimental|Part 1, Period 1: CC-220|Single dose of 0.6mg CC-220
11281854|NCT02820935|Experimental|Part 1, Period 2: itraconazole with CC-220|Multiple does of 200 mg itraconazole alone, with a single dose of 0.6 mg CC-220 plus itraconazole
11281855|NCT02820935|Experimental|Part 2, Period 1: CC-220|Single dose of 0.6mg CC-220
11281856|NCT02820935|Experimental|Part 2, Period 2: rifampin with CC-220|Multiple doses of 600 mg rifampin alone, with a single dose of 0.6 mg CC-220 plus rifampin
11281857|NCT02820922||Orthopedic emergency surgery|Patients of all ages who have undergone emergency orthopedic surgery The analysis of medical data with regard to age, sex, the American Society of Anesthesiologists (ASA) score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
11281858|NCT02820909|Experimental|Ultrasound guidance|46 patients in the experimental ultrasound group
11281859|NCT02820909|Active Comparator|Anatomical guidance|46 patients in the anatomical group
11281860|NCT02820896|Placebo Comparator|Multiple Dose Placebo IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses.
11281861|NCT02820896|Experimental|Multiple Dose RO7105705 IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses.
11281862|NCT02820896|Experimental|Single Dose RO7105705 SC|Healthy participants will receive a single dose of RO7105705 SC on Day 1.
11281863|NCT02820896|Placebo Comparator|Single dose Placebo IV|Healthy participants will receive a single dose of placebo IV on Day 1.
11281864|NCT02820896|Experimental|Single dose RO7105705 IV|Healthy participants will receive a single dose of RO7105705 IV on Day 1.
11281865|NCT02820883|Experimental|High dosage vaccine|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
11281866|NCT02820883|Experimental|Middle dosage vaccine|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
11281867|NCT02820883|Experimental|Low dosage vaccine|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
11281868|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
11281869|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
11281870|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
11281871|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
11281872|NCT02820844|Experimental|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
11281873|NCT02820844|Placebo Comparator|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
11281874|NCT02820805|Experimental|Meal skipping|No meal given
11281875|NCT02820805|Experimental|Mashed potatoes|Carbohydrate Test Meal (50 g of available carbohydrates)
11281876|NCT02820805|Experimental|French fries|Carbohydrate Test Meal (50 g of available carbohydrates)
11281877|NCT02820805|Experimental|Hash browns|Carbohydrate Test Meal (50 g of available carbohydrates)
11281878|NCT02820805|Experimental|Rice|Carbohydrate Test Meal (50 g of available carbohydrates)
11281879|NCT02820805|Experimental|Beans|Carbohydrate Test Meal (50 g of available carbohydrates)
11281880|NCT02820792|Active Comparator|LMA ProtectorTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
11281881|NCT02820792|Active Comparator|Ambu AuraGainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
11281882|NCT02820779|Experimental|WILLIS|Patients undergo WILLIS intracranial covered stent interventional treatment
11281883|NCT02820766||Journey II BCS Knee|Physical Therapy Observational
11281884|NCT02820766||All Other Posterior Stabilized Knees|Physical Therapy Observational
11281885|NCT02820753|No Intervention|Enhanced Usual Care|Patients will receive EHR tools (patient-friendly MedSheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles).
11281886|NCT02820753|Active Comparator|EHR + Text|Patients receive EHR tools, as well as text reminders telling them to take their medicine. Texts will be set to patients' personal schedules and will have a standard length of time before patients then can opt back in to continue.
11281887|NCT02820753|Active Comparator|EHR + Portal|Patients receive EHR tools, as well as enrollment into their clinic's portal. Patients will be prompted every other week to fill out an online survey, asking if they filled their medication, about any side effects, or concerns. Any concerns or questions will be followed up by a nurse, providing a feedback loop for patients.
11281888|NCT02820753|Active Comparator|EHR + Text + Portal|Patients in this arm will receive all interventions - EHR tools, text reminders, and portal communication.
11281889|NCT02820740|Other|NeuroBlate LITT Treatment|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
11281890|NCT02820714|Experimental|BLI801 Laxative|BLI801 oral laxative
11281891|NCT02820701|No Intervention|Control|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
11281892|NCT02820701|Experimental|Treatment|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. Participants in the Treatment group will receive OMT to address sacral base asymmetry after the initial ultrasound assessment.
11281893|NCT02820688|Active Comparator|Concentrated|Infraclavicular nerve block under guidance of ultrasonography will be performed using an undiluted solution of 45mg bupivacaine and 180mg prilocaine (bupivacaine 0.25% and prilocaine 1%, 18mL in total) to patients in this group
11281894|NCT02820688|Active Comparator|Diluted by 33%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 33% (bupivacaine 0.167% and prilocaine 0.66%, 27mL in total) to patients in this group
11281895|NCT02820688|Active Comparator|Diluted by 50%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 50% (bupivacaine 0.125% and prilocaine 0.5%, 36mL in total) to patients in this group
11281896|NCT02820675|Other|intervention|all hospitals participating in the icosmos trial will be supported in implenatation of the two main interventions.
11281897|NCT02820662|Experimental|RETCAM|
11281898|NCT02820649|Experimental|Exercise training|7 weeks of exercise training
11281899|NCT02820649|Sham Comparator|Control|Sedentary group
11281900|NCT02820636|Experimental|InVita|Participants receive the Socio-Cognitive Behavior Therapy (S-CBT) treatment.
11281901|NCT02820636|Active Comparator|Treatment as Usual|Intensive outpatient therapy of standard care for adolescents and their parents
11281902|NCT02820623|Experimental|Self-report|Therapists randomized to this condition will complete a brief self-report measure, the Therapy Process Observational Coding System for Child Psychotherapy Strategies Scale-Self Report version (TPOCS-SR) for each of the recorded clinical encounters with enrolled youth. The TPOCS-SR will be a self-report version of the Therapy Process Observational Coding System for Child Psychotherapy-Strategies Scale (TPOCS-S) and will be created in collaboration with the instrument developer (McLeod). In this condition, the investigators will (a) provide an operational definition for each item on the TPOCS-SR (e.g., cognitive education: teaches client the cognitive model (e.g., thoughts influence behavior)/identifies how the cognitive model applies to a specific aspects of the client's life), and (b) provide therapists with a 30-minute training session that includes sample vignettes of particular behaviors and information about how those vignettes should be rated.
11281903|NCT02820623|Experimental|Chart Stimulated Recall|"Therapists randomized to this condition will be asked to bring the charts of three enrolled youth to the chart-stimulated recall interview. A trained interviewer will ask the therapists how well they recall the encounter (rating of memory quality) followed by an open-ended question (Talk me through your last session with your client. Tell me what you did.). While the therapists are speaking, the interviewer will note any elements that represent a prescribed CBT strategy. The interviewer will go through a list of cognitive-behavioral strategies based upon the TPOCS-S and probe to determine if the therapists completed any of the strategies. Follow-up questions will be used to explore to what degree an element was used and how skillfully and responsively the strategies were used."
11281904|NCT02820623|Experimental|Behavioral Rehearsal|"Therapists randomized to this condition will be asked to engage in role-plays demonstrating the CBT strategies used with the three enrolled youth. The investigators will provide therapists with a list of the TPOCS-S CBT strategies and ask them to identify the CBT strategies used in their recorded encounter. The investigators will randomly select one of the strategies they report for each role-play. The investigators will then tell them, Please role-play how you used this strategy in session with your client, with the trained actor in front of you. Later, an independent rater will rate therapists' adherence and skill based on established scoring criteria."
11281905|NCT02820610|Active Comparator|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
11281906|NCT02820610|Active Comparator|Magnesium sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
11281907|NCT02820610|Placebo Comparator|Control group|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
11281908|NCT02820597|Experimental|Intervention|Cryoablation with the ClariFix device
11281909|NCT02820584|Experimental|GSC-loaded autologous dendritic cells|DC-GSC immunotherapy. Six vaccinations are envisaged. The first three vaccinations will be performed every two weeks; subsequent three vaccinations every month. The first vaccination will be performed using 20 million DC, the second and third with 10 million DC; and from the 4th vaccine 5 million DC
11281910|NCT02820558|Experimental|Substance P - 1nmol/kg|Substance P 1nmol/kg intra-celiac artery, single treatment
11281911|NCT02820558|Experimental|Substance P - 5nmol/kg|Substance P 5nmol/kg intra-celiac artery, single treatment
11281912|NCT02820558|Experimental|Substance P - 15nmol/kg|Substance P 15nmol/kg intra-celiac artery, single treatment
11281913|NCT02820558|Experimental|Substance P - 45nmol/kg|Substance P 45nmol/kg intra-celiac artery, single treatment
11281914|NCT02820545||Sociological interview|Patients will take a sociological interview with a sociologist during their hospital stay
11281915|NCT02820545||Self-administrated questionnaire|Patients will take a self-administrated questionnaire at the end of their hospital stay and one week after they left hospital
11281916|NCT02820532|Other|Tracking|The volunteers will be placed on the treatment couch. Their respiratory motion will be measured and the treatment couch will be moved accordingly. During the couch motion experiment the heartbeat, the skin humidity, the respiratory characteristics and the pupil motion will be additionally measured.
11281917|NCT02820519|Experimental|Loxapine|Loxapine Capsules 10 mg Day 1- 14: 10 mg b.i.d Day 15-28: 10 mg t.i.d Day 29-42: 20 mg b.i.d. Day 43-56: 20 mg t.i.d. Dosages will be escalated according to analgesic efficacy and tolerability.
11281918|NCT02820506|Other|High risk endometrial cancer|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
11281919|NCT02820506|Other|Cervical cancer tumor size 2-4 cm|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
11281920|NCT02820493|Other|single arm study|Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.
11281921|NCT02820480||Patients/health professionals|Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
11281922|NCT02820467|Experimental|patients with suspicion of CLI|patients presenting with peripheral artery disease and suspicion of critical limb ischemia as assessed by TASK II consensus 30 patients will be enrolled and will benefit of measures of TcPO2, too systolic blood pressure and skin perfusion pressure and in the same time angiography with fluorescence (Indocyanine grey 0.05 mg/kg by intravenous injection
11281923|NCT02820454|Experimental|AGuIX and radiotherapy|"Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.
~Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg"
11281924|NCT02820441|Experimental|ZOPICLONE|Zopiclone 3.5 mg capsule by mouth daily for 2 weeks
11281925|NCT02820441|Placebo Comparator|PLACEBO|Placebo 3.5 mg capsule by mouth daily for 2 weeks
11281926|NCT02820428|Other|Healthy participants|Submission of the scale 'Evaluation of behaviour in Parkinson's Disease' to healthy subjects
11281927|NCT02820415||infertile couples undergoing ICSI for PGS/PGT|patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).
11281928|NCT02820389||Optical colonoscopy|Patients with suspected colorectal cancer will undergo optical colonoscopy as the initial imaging modality.
11281929|NCT02820389||CT Colonography|Patients with suspected colorectal cancer will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan.
11281930|NCT02820376|Other|All patients|"Differential renal function assessment by 4D CT:
~All patients will undergo both CT and SPECT assessment of differential renal function; each patient will be his own comparator"
11281931|NCT02820363|Experimental|Test|"Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s)."
11281932|NCT02820363|Active Comparator|Control|Tibial fracture fixation with IM nail.
11281933|NCT02820337||non comparative|Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal
11281934|NCT02820324|Experimental|Treatment 1 Oliceridine|
11281935|NCT02820324|Experimental|Treatment 2 Oliceridine|
11281936|NCT02820324|Experimental|Treatment 3 Oliceridine|
11281937|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
11281938|NCT02820324|Active Comparator|Treatment 5 Morphine|
11281939|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
11281940|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
11281941|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
11281942|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
11281943|NCT02820298|Experimental|Group 1 - Bexagliflozin with food|"Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
~Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast."
11281944|NCT02820298|Experimental|Group 2 - Bexagliflozin without Food|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
11281945|NCT02820285|Other|Morbid obese patients|
11281946|NCT02820285|Other|Control patients|
11281947|NCT02820285|Other|Patients with overweight, steatosis and steatohepatitis|
11281948|NCT02820272|Experimental|NPWT with cold water|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change.
11281949|NCT02820272|Active Comparator|NPWT with normal saline room temp|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change.
11281950|NCT02820272|Placebo Comparator|NPWT without other intervention|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was no injection of any liquids into sponge before dressing change.
11281951|NCT02820246||hospitalised patients|all patients present in a hospital ward during the morning shift
11281952|NCT02820220||Patient/patient attendants|"Study subjects will be females.
~Age at enrolment should be more than 18 years.
~Attending Department of Paediatrics OPD/emergency/well-baby clinics/immunisation clinics OR Department of Gynaecology and Obstetrics OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.
~Written informed consent to participate in the study."
11281953|NCT02820220||Students,nursing|"Pursuing Bsc Nursing(in their final year) or intern of college of nursing LHMC
~Written informed consent to participate in the study"
11281954|NCT02820220||In-service nurses|"Posted in Department of Paediatrics indoor/OPD/well-baby clinics/immunisation clinics or Department of Gynaecology and Obstetrics indoor/OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.
~Written informed consent to participate in the study."
11281955|NCT02820207||Vulnerable plague|The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
11281956|NCT02820194|Active Comparator|Stereotactic body radiation therapy|Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
11281957|NCT02820194|Active Comparator|Microwave Ablation|Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.
11281958|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
11281959|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
11281960|NCT02820155|Placebo Comparator|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
11281961|NCT02820155|Experimental|RGN1016_50mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
11281962|NCT02820155|Experimental|RGN1016_100mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
11281963|NCT02820155|Experimental|RGN1016_200mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
11281964|NCT02820155|Experimental|RGN1016_400mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
11281965|NCT02820155|Experimental|RGN1016_800mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
11281966|NCT02820142||Bacteremia with Sepsis group|Patients aged 20 years or older with a diagnosis of bacteremia will be eligible for inclusion in the study.
11281967|NCT02820129|Experimental|Wallet Card Group|"The intervention arm is comprised of:
~Patients from the TAPER study who receive a medication wallet card with their medications and medical conditions listed."
11281968|NCT02820129|Placebo Comparator|Control Group|"Standard of care as well as wait list control. These participants will receive a reminder wallet card which states, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
11281969|NCT02820116|Experimental|Icotinib|Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
11281970|NCT02820103|Active Comparator|Information leaflet (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
11281971|NCT02820103|Experimental|Text+Visual BCT-based intervention (Intervention Group 1)|Participants in the visual intervention group will receive the control condition specified above PLUS a specifically developed Text+Visual BCT-based intervention, comprising the 12 BCTs identified earlier in a Systematic Review and expert consensus study. The BCTs are Problem solving; Action planning; Social support (practical); Social support (emotional); Instruction on how to perform the behaviour; Information about health consequences; Salience of health consequences; Prompts/cues; Credible source; Pro's & Con's; Comparative imagining of future outcomes; Mental rehearsal of successful performance
11281972|NCT02820103|Experimental|Text-only BCT-based intervention (Intervention Group 2)|Information leaflet (usual care) plus text-only BCT-based intervention (Intervention group 2) Participants in the text-only BCT-based intervention group will receive the control condition specified above plus a text-only BCT-based intervention. This was developed in the same way as the text+visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen instead.
11281973|NCT02820090||Success with SBT|The patient have a success in SBT.
11281974|NCT02820090||Success with mechanical ventilation|Weaning from mechanical ventilation is successful
11281975|NCT02820090||failure with SBT|The patient have a failure in SBT.
11281976|NCT02820090||failure with mechanical ventilation|Weaning from mechanical ventilation is failed
11281977|NCT02820077|Experimental|Hemospray|Patients treated with hemostatic powder
11281978|NCT02820077|No Intervention|Clinical support|Patients treated with optimal clinical management, as it is been advised by the latest guidelines
11281979|NCT02820064|Other|only one arm|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
11281980|NCT02820051|Active Comparator|Midazolam|"In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
~Intervention: Transcutaneous CO2 monitor"
11282010|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
11282011|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
11282116|NCT02819245|Other|Age before and after 18 years old|Surgical treatment before and after skeletal maturity
11281981|NCT02820051|Experimental|Propofol|"In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
~Intervention: Transcutaneous CO2 monitor"
11281982|NCT02820038|Active Comparator|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
11281983|NCT02820038|Experimental|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
11281984|NCT02820038|Experimental|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
11281985|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
11281986|NCT02820025|Experimental|doxapram group|the doxapram group iv doxapram 1mg/kg,
11281987|NCT02820025|Placebo Comparator|Controlled group|the controlled group given equal volume of saline with the doxapram group.
11281988|NCT02820012|Other|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.
~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.
~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .
~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
11281989|NCT02819999|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
11281990|NCT02819999|Experimental|Rovalpituzumab Tesirine followed by Cisplatin, Etoposide|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion
11281991|NCT02819999|Experimental|Rovalpituzumab Tesirine with Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion
11281992|NCT02819999|Experimental|Rovalpituzumab Tesirine following Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
11281993|NCT02819986|Experimental|Progressive Goal Attainment Program|10 one hour weekly therapy sessions focused on behavioural interventions
11281994|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
11281995|NCT02819973|Experimental|Educational Video 2|Caucasian Video
11281996|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
11281997|NCT02819960|Active Comparator|active probiotic formula|"Intervention: Probiotic formula PROBIO-FIX INUM® will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.
~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
11281998|NCT02819960|Placebo Comparator|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).
~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
11281999|NCT02819934|Experimental|Arm1|experimental group
11282000|NCT02819921|Experimental|Desvenlafaxine succinate 100mg|Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
11282001|NCT02819921|Experimental|Desvenlafaxine succinate 50mg|50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
11282002|NCT02819921|Placebo Comparator|Placebo|50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.
11282003|NCT02819908|Active Comparator|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
11282004|NCT02819908|Active Comparator|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
11282005|NCT02819895|Experimental|Intervention|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive their usual care (an immunization card). In addition they will received automated text, calls and emails (if applicable) reminders through a customized windows® software application when their child's immunization visit is due.
11282006|NCT02819895|No Intervention|Control|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive usual care (an immunization card)
11282007|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
11282008|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
11282009|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
11282012|NCT02819869|Experimental|Taking both statin and metformin Group|The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.
11282013|NCT02819869|No Intervention|Non- taking both statin and metformin Group|Non- taking both statin and metformin.
11282014|NCT02819856|Placebo Comparator|SPI-1000 Capsule 0mg Ebselen Placebo|0mg Ebselen SPI-1000 bid po x 21d
11282015|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x1|200mg SPI-1005 bid po x 21d Low Dose Arm
11282016|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x2|400mg SPI-1005 bid po x 21d Mid Dose Arm
11282017|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x3|600mg SPI-1005 bid po x 21d High Dose Arm
11282018|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.
11282019|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
11282020|NCT02819830|Experimental|Intervention group|"Participants, who have been randomly assigned to the intervention group, will take part in a six-week supervised exercise training programme. This programme takes place in a rehabilitation gymnasium. The exercise programme consists of two group sessions per week (scheduled for evenings, after typical working hours, approximately 12 patients per session). Each session lasts for approximately 70 minutes and includes a 5 minute warm up, 30 minutes of aerobic cycling exercise, 30 minutes of strength training, and a 5 minute cool down.
~Participants will also perform a 30 minute walk each weekend as part of the intervention."
11282021|NCT02819830|No Intervention|Control group|Participants who have been randomly assigned to the control group will not undertake the exercise intervention. These participants are instructed to maintain their usual lifestyle.
11282022|NCT02819817|Experimental|Aloe Vera Gel|Experimental gel placed in identical opaque tube as placebo gel.
11282023|NCT02819817|Placebo Comparator|Ultrasound Gel|Placebo placed in identical opaque tube as experimental gel.
11282024|NCT02819817|No Intervention|Standard care|Standard care
11282025|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11282026|NCT02819791|Active Comparator|Control group|
11282027|NCT02819791|Experimental|Intervention group|
11282028|NCT02819778|Other|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
11282029|NCT02819778|Other|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
11282030|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
11282031|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
11282032|NCT02819739|Experimental|normoxia|During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
11282033|NCT02819739|Active Comparator|hyperoxia|During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
11282034|NCT02819726|Experimental|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
11282035|NCT02819726|Active Comparator|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
11282036|NCT02819726|Active Comparator|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
11282037|NCT02819713|Placebo Comparator|ultrasound gel|
11282038|NCT02819713|Active Comparator|Instillagel|
11282039|NCT02819687|Experimental|RDX5791 10mg QD (SAD phase)|10mg of RDX5791 administered once daily PO fasting
11282040|NCT02819687|Experimental|RDX5791 50mg QD (SAD phase)|50mg of RDX5791 administered once daily PO fasting
11282041|NCT02819687|Experimental|RDX5791 150mg QD (SAD phase)|150mg of RDX5791 administered once daily PO fasting
11282042|NCT02819687|Experimental|RDX5791 450mg QD (SAD phase)|450mg of RDX5791 administered once daily PO fasting
11282043|NCT02819687|Experimental|RDX5791 900mg QD (SAD phase)|900mg of RDX5791 administered once daily PO fasting
11282044|NCT02819687|Experimental|RDX5791 3mg QD (MAD phase)|3mg of RDX5791 administered once daily PO fasting
11282045|NCT02819687|Experimental|RDX5791 10mg QD (MAD phase)|10mg of RDX5791 administered once daily PO fasting
11282046|NCT02819687|Experimental|RDX5791 30 mg QD (MAD phase)|30mg of RDX5791 administered once daily PO fasting
11282047|NCT02819687|Experimental|RDX5791 100 mg QD (MAD phase)|100mg of RDX5791 administered once daily PO fasting
11282048|NCT02819674||early-onset hypertension|early-onset hypertension patients recruited in Chinese multiple centers
11282115|NCT02819258|Other|Endodontic treatment for a tooth with a periapical pathology|
11282337|NCT02817685||5|ultrasound-difficult patient
11282049|NCT02819661|Active Comparator|women BMI<30 POD 1|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
11282050|NCT02819661|Active Comparator|women BMI≥30 POD 1|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
11282051|NCT02819661|Active Comparator|women BMI<30 POD4|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
11282052|NCT02819661|Active Comparator|women BMI≥30 POD 4|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
11282053|NCT02819648|Experimental|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France); administered 30 minutes before endodontic treatment
11282054|NCT02819648|Placebo Comparator|Control|Milk tablet administered 30 minutes before endodontic treatment
11282055|NCT02819635|Placebo Comparator|Placebo|Administered once daily.
11282056|NCT02819635|Experimental|Updacitinib (ABT-494) Dose A|Administered once daily.
11282057|NCT02819635|Experimental|Updacitinib (ABT-494) Dose B|Administered once daily.
11282058|NCT02819635|Experimental|Updacitinib (ABT-494) Dose C|Administered once daily.
11282059|NCT02819635|Experimental|Updacitinib (ABT-494) Dose D|Administered once daily.
11282060|NCT02819622||Control group|control (no disease)
11282061|NCT02819622||central serous retinopathy group|Central serous retinopathy (with CSCR disease) by exam and OCT
11282062|NCT02819609||Myomectomy|Women with uterine fibroids who underwent myomectomy as their index procedure as part of their routine clinical care
11282063|NCT02819609||Endometrial ablation|Women with uterine fibroids who underwent endometrial ablation as their index procedure as part of their routine clinical care
11282064|NCT02819609||Uterine artery embolization|Women with uterine fibroids who underwent uterine artery embolization as their index procedure as part of their routine clinical care
11282065|NCT02819609||MRI-guided focused ultrasound ablation|Women with uterine fibroids who underwent MRI-guided focused ultrasound ablation as their index procedure as part of their routine clinical care
11282066|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
11282067|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
11282068|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
11282069|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
11282070|NCT02819583|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
11282071|NCT02819570|Experimental|cefuroxime|I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days
11282072|NCT02819570|Active Comparator|ampicillin|I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days
11282073|NCT02819557|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
11282074|NCT02819544|Active Comparator|Ropivacaine|Ropivacaine 7.5 mg/mL administration
11282075|NCT02819544|Placebo Comparator|Sodium chloride|NaCl 0.9% administration
11282076|NCT02819531|Active Comparator|Rotational atherectomy|RA protocol: After IVUS protocol, patients who are randomized to RA will undergo coronary wiring of the target lesion and subsequent advancement of the RA burr. The RA system is performed using standard technique under intravenous infusion of heparin. The atherectomy burr size will be determined by the operator.
11282077|NCT02819531|Active Comparator|Orbital atherectomy|OAS protocol: After IVUS protocol, patients who are randomized to OAS will undergo coronary wiring of the target lesion and subsequent advancement of the OAS according to the manufacturer's guidelines.
11282078|NCT02819531|Active Comparator|Scoring balloon system|SBS protocol: After IVUS protocol, patients who are randomized to SBS will undergo coronary wiring of the target lesion and balloon inflation with SBS performed by standard technique under intravenous infusion of heparin. SBS will be used according to the manufacturer's guidelines.
11282079|NCT02819518|Experimental|Part 1: Pembrolizumab + Nab-paclitaxel|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
11282080|NCT02819518|Experimental|Part 1: Pembrolizumab + Paclitaxel|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle.
11282081|NCT02819518|Experimental|Part 1: Pembrolizumab + Gemcitabine/Carboplatin|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an Area Under the Curve (AUC) 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
11282082|NCT02819518|Experimental|Part 2: Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS one of three chemotherapy regimens: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
11282083|NCT02819518|Active Comparator|Part 2: Placebo + Chemotherapy|Participants receive placebo (normal saline) IV on Day 1 of each 21-day cycle PLUS one of three chemotherapy regimens: 1) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, 2) paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 of each 28-day cycle, OR 3) gemcitabine/carboplatin 1000 mg/m^2 (gemcitabine) and an AUC 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.
11282084|NCT02819505|Experimental|Beta-alanine supplementation|Participants will be supplemented with 6.4g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets four times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
11282085|NCT02819505|Placebo Comparator|Placebo supplementation|Participants will be supplemented with 6.4g·d-1 placebo (maltodextrin; NAI, USA).
11282086|NCT02819492||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
11282087|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
11282088|NCT02819466||volunteers|Healthy volunteers over the age of 18 years employed by Amiens University Hospital 3D echography
11282089|NCT02819453|Experimental|Corticosteroid group|Patients with acute respiratory distress syndrome were treated with corticosteroid, which determined by two clinicians.
11282090|NCT02819440|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
11282091|NCT02819440|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
11282092|NCT02819427||epilepsy|children with absence epilepsy presenting either typical or atypical seizures
11282093|NCT02819414|Placebo Comparator|Control Group|Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
11282094|NCT02819414|Active Comparator|Treatment Group|Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
11282095|NCT02819388|Experimental|Intervention|Contraceptive counseling
11282096|NCT02819388|No Intervention|Control|Control group without counseling
11282097|NCT02819375|Active Comparator|Group Propofol|anesthesia will induced 1 mg/kg propofol
11282098|NCT02819375|Active Comparator|Group propofol/remifentanil|anesthesia will induced 0.5 mg/kg propofol and 1 µg/kg remifentanil
11282099|NCT02819375|Active Comparator|Group propofol/ketamine|anesthesia will induced propofol 0.5 mg/kg and ketamine 0.5 mg/kg
11282100|NCT02819362||Prospective cohort - MRI|Patients with pathological nipple discharge
11282101|NCT02819349|Experimental|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. The intervention will include an online interface for clinicians and an automated text messaging program for patients. Firstly, patients and providers will meet in an intake session, to identify the patient's personal early warning signs from a pre-identified list. Using the online interface, providers will enter additional warning signs or personalize the wording of the messages as requested by the patient. The patient also will determine the threshold at which the provider will be alerted about a possible relapse and whether additional contact people should be alerted.
11282102|NCT02819349|No Intervention|Treatment-As-Usual Control|The control group will be a treatment as usual comparison group. For the majority of individuals with schizophrenia/SAD in care at JHCPP, this involves meeting with their therapist every 2 to 4 weeks and meeting with their psychiatrist at least once every 90 days or more frequently as clinically indicated. All routine appointments are scheduled, but individuals can walk in or call if they do not feel well between sessions.
11282103|NCT02819336|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions within 21 days)
~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)
~20 minutes duration with middle frequency (30 Hz) of electrical stimulation
~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
11282104|NCT02819336|Sham Comparator|Park sham (PS) group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions within 21 days)
~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)
~20 minutes duration with undelivered electrostimulation of middle frequency (30 Hz)
~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
11282105|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
11282106|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
11282107|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
11282108|NCT02819310|Experimental|BLI400 Laxative|BLI400 Laxative
11282109|NCT02819297|Experimental|BLI400 Laxative|BLI400 Laxative
11282110|NCT02819297|Placebo Comparator|Placebo|BLI400 placebo
11282111|NCT02819284|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
11282112|NCT02819284|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
11282113|NCT02819271|Experimental|CXL-1427 (BMS-986231)|Experimental
11282114|NCT02819271|Placebo Comparator|Placebo|Placebo
11282117|NCT02819232|Other|Patient with a prescription of a microbiologic diagnostic of|Patient with a prescription of a microbiologic diagnostic of keratitis
11282118|NCT02819219|Placebo Comparator|Placebo|Participants will receive a flavored water placebo supplement. Part of the supplemental intervention. This, and all groups, simultaneously took part in the exercise intervention.
11282119|NCT02819219|Experimental|ElevATP|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
11282120|NCT02819219|Experimental|ElevATP w/Caffeine|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts), a 180 mg blend of caffeine (caffeine anhydrous, pterostilbene-bound caffeine), and 38mg B vitamins. Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
11282121|NCT02819206|Other|Uveitis|Patient with a prescription of a microbiologic diagnostic of uveitis
11282122|NCT02819193||exposed group : early raw mother's own milk|"The use of raw MOM is considered as early when it begins before day 7."
11282123|NCT02819193||unexposed group : no use of raw mother's own milk|Neonates who receive, or not, raw MOM before day 7.
11282124|NCT02819180||Healthy adults group|Healthy men and women between 18 and 59 years of age.
11282125|NCT02819180||Elderly group|Elderly over 60 years old.
11282126|NCT02819167|Other|neurologic and neuropsychological evaluation|
11282127|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
11282128|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
11282129|NCT02819128|Other|Homeless people|Populations of homeless households in Marseille.
11282130|NCT02819115||Healthy adults group|Healthy adults aged 18 to 59 years
11282131|NCT02819115||Elderly group|Elderly over 60 years old.
11282132|NCT02819102|Experimental|Metabolic Probes and BCX7353|"Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.
~Day 2: a single oral dose of 2 mg midazolam. Days 3 to 9: 350 mg BCX7353 once a day. Day 10: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, 30 mg dextromethorphan and 350 mg BCX7353, orally.
~Day 11: a single oral dose of 2 mg of midazolam along with 350 mg BCX7353."
11282133|NCT02819089|Active Comparator|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
11282134|NCT02819089|Placebo Comparator|NSS|NSS loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
11282135|NCT02819076||Painless Children|30 children
11282136|NCT02819076||Painful Children|70 children
11282137|NCT02819050|Experimental|Sprinting|Take off NCPAP twice daily for 3hours (day 1), Take off NCPAP twice daily for 6hours (day 2), Take off NCPAP twice daily for 9hours (day 3), Placed back on NCPAP for 24hours (day 4), Switch to nasal cannula at a flow rate of 1.5-2 L/min (day 5)
11282138|NCT02819050|Active Comparator|Non-Sprinting|"If the infant was on NCPAP 6, Infant was weaned down to CPAP 5 for 96 hours. If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC.
~If the infant was on NCPAP 5, the infant was continued on CPAP 5 for 96 hours If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC."
11282139|NCT02819037|Experimental|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
11282140|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
11282141|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
11282142|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
11282143|NCT02818998|Experimental|Aflibercept 2 mg fixed|Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
11282144|NCT02818998|Experimental|Aflibercept 2 mg flexible|Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
11282145|NCT02818998|Experimental|Aflibercept 2 mg PRN|Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
11282146|NCT02818985|Active Comparator|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
11282147|NCT02818985|Active Comparator|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
11282148|NCT02818985|Placebo Comparator|Control|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
11282149|NCT02818972|Experimental|RelayPro|Endovascular treatment with the investigational device.
11282150|NCT02818959|Experimental|Transcatheter Aortic Valve Replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.
11282151|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
11282152|NCT02818933||Aim 1|This group follows a crossover design where adolescents 12-17 years old (n=10) complete a diet recall using one of the two methods (interviewer-administered vs web-based), and then does another diet recall using the other method about a week later. Participants are randomly assigned to the order in which they complete each method of diet recall.
11282153|NCT02818933||Aim 2, interviewer-administered recall|This group of adolescents 12-17 years old (n=10) completes an interviewer-administered diet recall once a week for 6 weeks.
11282338|NCT02817685||6|ultrasound-difficult patient
11282154|NCT02818933||Aim 2, web-based recall|This group of adolescents 12-17 years old (n=10) completes a web-based self-administered diet recall once a week for 6 weeks.
11282155|NCT02818920|Experimental|Pembrolizumab prior to and after surgery|
11282156|NCT02818907|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.
~Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.
~Tumor tissue will be collected during surgery."
11282157|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
11282158|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
11282159|NCT02818881|Experimental|High-speed then low-speed yoga|Subjects received a single session of High-speed yoga and within one week a single session of Low-speed yoga
11282160|NCT02818881|Experimental|Low-speed then high-speed yoga|Subjects received a single session of Low-speed yoga and within one week a single session of High-speed yoga
11282161|NCT02818855|Experimental|Collagen Matrix plus coronally advanced flap (CAF)|A new collagen matrix (Mucograft) associated to coronally advanced flap
11282162|NCT02818855|Active Comparator|Subepithelial connective tissue graft plus CAF|Subepithelial connective tissue graft associated to coronally advanced flap
11282163|NCT02818842||Pregnant Women|"Medical and personal data will be collected for all the pregnant women who want to participate.
~The source of data are :
~Primary Health Insurance Fund data
~Prenatal Diagnostic Center of Toulouse University Hospital data
~Mother and child protection data collection
~Medicalisation Program of Information Systems data"
11282164|NCT02818829||Cohort|Collection of biological samples
11282165|NCT02818816|Experimental|Brimonidine Tartrate 0.2% (2mg/mL)|One (I) drop of brimonidine tartrate 0.2% (2mg/mL) will be placed in the randomized eye preoperatively thirty minutes before robotic-assisted radical laparoscopic prostatectomy (RALP)
11282166|NCT02818816|Placebo Comparator|Carboxymethylcellulose Eye Drops|One drop of Carboxymethylcellulose eye drops will be placed in the randomized eye half an hour before RALP
11282167|NCT02818803|Experimental|Propolis|Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days
11282168|NCT02818803|Active Comparator|Miconazole|Miconazole 20mg/g oral gel,3 times a day, for 14 days
11282169|NCT02818790|No Intervention|Group 1. Control|
11282170|NCT02818790|Experimental|Group 2. Intervention 1|
11282171|NCT02818790|Experimental|Group 2. Intervention 2|
11282172|NCT02818777|Experimental|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).
~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
11282173|NCT02818764||Delirium|"Subjects undergoing elective total joint arthroplasty determined to have delirium by post operative 3D-CAM.
~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.
~CSF collected for biomarkers. Blood colelcted for biomarkers."
11282174|NCT02818764||Non-delirium|"Subjects undergoing elective total joint arthroplasty determined not to have delirium by post oeprative 3D-CAM.
~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.
~CSF collected for biomarkers. Blood colelcted for biomarkers."
11282175|NCT02818751|Experimental|Escitalopram|Patients being randomized to receive escitalopram, at an initial dose of 5 mg (oral) daily for 2 days. On day 3, escitalopram will be increased to 10 mg daily and continued for 7 days. Then, on day 10, escitalopram will be increased to 15 mg. At the week 4 visit, the dose of escitalopram may be increased to 20 mg, based on the investigator's clinical judgment and if significant anxiety symptoms are still present.
11282176|NCT02818751|Placebo Comparator|Placebo|Patients will receive placebo (sugar pill) at an initial dose of 5 mg daily for 2 days. On day 3, placebo will be increased to 10 mg daily and continued for 7 days to match the experimental group.
11282177|NCT02818751|No Intervention|Healthy Controls|Healthy adolescents will receive fMRI scans at the same time points, which will provide assessments of the stability of neurophysiologic measures and will be used to adjust and interpret comparisons within the patients (i.e., whether patient values are changing toward or away from those of healthy adolescents).
11282178|NCT02818738|Experimental|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
11282179|NCT02818738|Placebo Comparator|Placebo|matching verum
11282180|NCT02818725|Active Comparator|Chemotherapy|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin
11282181|NCT02818725|Experimental|Arm B: chemotherapy + panitumumab|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab
11282182|NCT02818712||Patients with IPF|
11282183|NCT02818699|Placebo Comparator|Placebo Capsule|Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
11282184|NCT02818699|Experimental|EMIQ Capsule|Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
11282185|NCT02818686|Experimental|TD-1473 low dose|10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days
11282186|NCT02818686|Experimental|TD-1473 mid dose|10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days
11282187|NCT02818686|Experimental|TD-1473 high dose|10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days
11282188|NCT02818686|Placebo Comparator|Placebo|10 subjects will be randomized to receive placebo orally daily for 28 days
11282189|NCT02818673|Experimental|Ascites in Patients With Cirrhosis|Patients will be further classified according to the refractory or sensitive ascitis
11282190|NCT02818660|Experimental|Synacthen|The patient get Synacthen to stimulate the adrenals to produce cortisol
11282191|NCT02818647|Active Comparator|COLD-DISSECTION|Cold Dissection Technique
11282192|NCT02818647|Active Comparator|HOT-DISSECTION|Needle Electrocautery Dissection Technique
11282193|NCT02818634|Active Comparator|Muscle-sparing|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
11282194|NCT02818634|Active Comparator|Muscle-cutting|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were cut with Monopolar electrocautery at (25 watts).
11282195|NCT02818621|Active Comparator|Group Dex|"The Dex group received 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure.
~Interventions:
~◦Drug: Dexmedetomidine"
11282196|NCT02818621|Placebo Comparator|Group Placebo|"The Placebo group received equal amount of normal saline.
~Interventions:
~◦Drug: Normal saline"
11282197|NCT02818608|Active Comparator|Functional electrical stimulation (FES)|Chronic stroke patients submitted to functional electrical stimulation (FES).
11282198|NCT02818608|Experimental|Combination of transcranial direct current stimulation and FES|Chronic stroke patients submitted to transcranial direct current stimulation (tDCS) and functional and to functional electrical stimulation (FES).
11282199|NCT02818595|Experimental|Normal children|Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological
11282200|NCT02818595|Experimental|Abnormal children|Every child meet the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological as intraventricular hemorrhage .
11282201|NCT02818582|Active Comparator|1|Active
11282202|NCT02818582|Placebo Comparator|2|Placebo
11282203|NCT02818569|Experimental|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
11282204|NCT02818569|Experimental|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
11282205|NCT02818556|Other|Restylane Right, Belotero Left|Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)
11282206|NCT02818556|Other|Restylane Left, Belotero Right|Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)
11282207|NCT02818543|Experimental|Cohort 1|LYC-30937 25 mg single oral dose
11282208|NCT02818543|Experimental|Cohort 2|LYC-30937 100 mg single oral dose
11282209|NCT02818530|Experimental|IOP by tomoneter and ultrasound|Intraocular pressure will be measured by electronic tomometer (tonopen) at different point of time after induction of anaesthesia in patients undergoing robotic assisted surgery under steep Trendelenberg position. Anterior chamber depth will be measured by ultrasound at the same time intervals.
11282210|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
11282211|NCT02818504|Experimental|Repeatability and reproducibility study|"Monitoring of system (Wize MIrror) measurements with changes in environmental conditions (fasting state, light, temperature)"
11282212|NCT02818504|Experimental|Validation study|"Longitudinal monitoring of cardiometabolic risk factors through an user---friendly, unobtrusive, personalized system for lifestyle self---management (the Wize Mirror)"
11282213|NCT02818491|Placebo Comparator|Control group|Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls
11282214|NCT02818491|Active Comparator|Dex 1|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls
11282215|NCT02818491|Active Comparator|Dex 2|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls
11282216|NCT02818491|Active Comparator|Dex 3|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls
11282217|NCT02818491|Active Comparator|Dex 4|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls
11282218|NCT02818478|Other|RA; at home first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
11282219|NCT02818478|Other|RA; outpatient clinic first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
11282220|NCT02818478|Other|AxSpa; at home first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
11282221|NCT02818478|Other|AxSpa; outpatient clinic first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
11282222|NCT02818465|Experimental|Patients|
11282223|NCT02818452|Experimental|Oatmeal containing beta-glucan|27 g oatmeal
11282224|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 1|27.72g oatmeal
11282225|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 2|28.43g oatmeal
11282226|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 3|29.86g oatmeal
11282227|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 4|32.72g oatmeal
11282228|NCT02818452|Placebo Comparator|Hot Cereal - Cream of Rice|20g oatmeal
11282229|NCT02818426|Experimental|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.
~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
11282520|NCT02816619|Other|APA-|APA- : patients will do free practice of physical activity during 3 months.
11282230|NCT02818413||U.S. Olympic Team and elite athletes|Biospecimens will be collected from and questionnaires will be administered to U.S. Olympic team members and other elite athletes
11282231|NCT02818400|Experimental|Composite tissue allotransplantation|
11282232|NCT02818387|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
11282233|NCT02818387|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
11282234|NCT02818387|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by midazolam 0.015 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.
~Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary."
11282235|NCT02818374|Experimental|Disabled People with behavioral trouble|
11282236|NCT02818361|Experimental|topical TwHF gel group|Topical TwHF gel recipe composes Tripterygium wilfordii Hook F, Mangxiao (Mirabilite), Chuanxiong (Rhizoma Ligustici), Ruxiang (Olibanum), Moyao (M yrrh) (prescription proportion is 4:4:2:2:1).Each gel is 20 gram(g). TwHF gel is applied for 1st to 5th metacarpophalangeal joints, 1st to 5th proximal interphalangeal joints, wrists, knees and ankles 20g for 1 hour, once per day from week 0 through week 4 and 10g for 1 hour, once per day from week 5 through week 8.
11282237|NCT02818361|Placebo Comparator|placebo group|Placebo recipe composes viscous agent which matches by the sucrose. The usage and dosage of topical TwHF and placebo are the same.
11282238|NCT02818348|Experimental|DRV cohort|Darunavir/Cobicistat 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
11282239|NCT02818348|Experimental|ETR cohort|Etravirine 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
11282240|NCT02818335|Experimental|LY3023414 Reference Fasted|Single oral dose of LY3023414 (Reference) on day one fasting.
11282241|NCT02818335|Experimental|LY3023414 Test Fasted|Single oral dose of LY3023414 (Test) on day one fasting.
11282242|NCT02818335|Experimental|LY3023414 Test Fed|Single oral dose of LY3023414 (Test) on day one after a meal.
11282243|NCT02818322|Experimental|telemedical monitoring ( T)|Home care by a nurse trained in the management of diabetic foot lesions with transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion every week
11282244|NCT02818322|Active Comparator|classic monitoring|Home care by a nurse trained in the management of diabetic foot lesions without transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion
11282245|NCT02818309|Experimental|Lesogaberan|Lesogaberan
11282246|NCT02818309|Placebo Comparator|Placebo|Placebo
11282247|NCT02818296|Experimental|Active IU CBM-I|This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
11282248|NCT02818296|Sham Comparator|Control CBM-I|This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.
11282249|NCT02818283|Experimental|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
11282250|NCT02818283|Active Comparator|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
11282251|NCT02818283|Placebo Comparator|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
11282252|NCT02818270|Experimental|Drug depositions|Aerosol drug deposited delivered on the inhaled and exhaled filters and protective filters were evaluated. Salbutamol and Acetylcysteine were delivered by a jet nebulizer through a mechanical ventilator.
11282253|NCT02818257|Experimental|Strip A (wet)|Six strips of Strip A are applied on skin wetted with two different buffers (3 strips each)
11282254|NCT02818257|Experimental|Strip A (dry)|Six strips of Strip A are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
11282255|NCT02818257|Experimental|Strip B (wet)|Six strips of Strip B are applied on skin wetted with two different buffers (3 strips each)
11282256|NCT02818257|Experimental|Strip B (dry)|Six strips of Strip B are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
11282257|NCT02818257|Experimental|Strip C (wet)|Six strips of Strip C are applied on skin wetted with two different buffers (3 strips each)
11282258|NCT02818257|Experimental|Strip C (dry)|Six strips of Strip C are applied on skin that is either dry (3 strips) or wetted with buffer (3 strips)
11282259|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
11282260|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
11282261|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
11282262|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
11282263|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
11282264|NCT02818231||NON EXPOSED|"Male, >50 years, unexposed to wood dust, without any nasal pathology, without known tumor
~-> Brushing of the olfactory cleft"
11282265|NCT02818231||EXPOSED|"Male, >50 years, exposed to wood dust, without any nasal pathology, without known tumor
~-> Brushing of the olfactory cleft"
11282266|NCT02818205||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation
11282267|NCT02818205||Typically Developing Children|Typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
11282268|NCT02818179|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures
11282269|NCT02818166|Experimental|Endoaortic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and endoaortic balloon clamp
11282270|NCT02818166|Active Comparator|Transthoracic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and transthoracic clamp.
11282271|NCT02818153|Experimental|questionnaire for allergic rhinitis control|Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
11282272|NCT02818140|Active Comparator|Ropivacaine TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
11282273|NCT02818140|Placebo Comparator|Placebo TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%
11282274|NCT02818127|Active Comparator|normal coronary artery|coronary angiography will be performed by transfemoral or transradial route.
11282275|NCT02818127|Active Comparator|coronary slow flow|coronary angiography will be performed by transfemoral or transradial route.
11282276|NCT02818127|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
11282277|NCT02818127|Active Comparator|non-obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
11282278|NCT02818127|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
11282279|NCT02818114|Experimental|PEET|Peer support interventions as an adjunct to prolonged exposure
11282280|NCT02818101|No Intervention|Control group|No hypnosis session before the coronary angiography
11282281|NCT02818101|Experimental|Hypnotised group|Hypnosis session before the coronary angiography
11282282|NCT02818088|Experimental|Cognitive Training|Cognitive Training - n Back.
11282283|NCT02818075|Experimental|Mobile Phone Based Peer Support|Mobile phone-based peer support (MPPS)
11282284|NCT02818075|Active Comparator|Usual Care|Standard community prenatal and postpartum support services
11282285|NCT02818062||Endophthalmitis|The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound).
11282286|NCT02818062||Cataract (Control)|Controls were patients who underwent cataract surgery.
11282287|NCT02818049|Experimental|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
11282288|NCT02818036|Experimental|naltrexone|single 50mg dose of naltrexone
11282289|NCT02818036|Placebo Comparator|sugar pill|single sugar pill
11282290|NCT02818023|Experimental|Pembrolizumab plus vemurafenib and Cobimetinib|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.
~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
11282291|NCT02818010||exposed = patient practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire)
~A patient is defined as practicing physical activity (exposed) when he meets one of the conditions following:
~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week
~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week
~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.
~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
11282292|NCT02818010||unexposed = patient not practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire(Global Physical Activity Questionnaire)
~A patient is defined as unexposed if he does not fulfill any of these conditions :
~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week
~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week
~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.
~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
11282293|NCT02817984|Experimental|Treatment Group|Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.
11282339|NCT02817672|Active Comparator|PRIME 1.0|8 weeks use of PRIME 1.0 (current version). Mobile application designed to improve psychosocial functioning and motivational deficits.
11282582|NCT02816177|Active Comparator|Usual care alone|Usual care during12 months.
11282294|NCT02817971|Experimental|Enhanced feedback|"Monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators
~Two-monthly written feedback on multiple quality of paediatric care indicators
~Clinical network promoting clinical leadership linked to mentorship and peer to peer support
~Improved use of health information on service delivery"
11282295|NCT02817971|Active Comparator|Standard feedback|"Two-monthly written feedback on multiple quality of paediatric care indicators
~Clinical network promoting clinical leadership linked to mentorship and peer to peer support
~Improved use of health information on service delivery"
11282296|NCT02817958|Experimental|A-Adjuvant Chemotherapy TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days
11282297|NCT02817958|Experimental|B-Neoadjuvant Chemotherapy TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
11282298|NCT02817945|Experimental|68Ga-NOTA-3P-TATE-RGD PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-3P-TATE-RGD in one dose intravenously and underwent PET/CT scan 45-60 min later.
11282299|NCT02817932|Experimental|Group 1 (Korean, 375 mg)|Group 1 (Korean, 375 mg): Ranolazine PR 375 mg
11282300|NCT02817932|Experimental|Group 2 (Korean, 500 mg):|Group 2 (Korean, 500 mg): Ranolazine PR 500 mg
11282301|NCT02817932|Experimental|Group 3 (Korean, 750 mg):|Group 3 (Korean, 750 mg): Ranolazine PR 750 mg
11282302|NCT02817932|Experimental|Group 4 (Caucasian, 375mg)|Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg
11282303|NCT02817932|Experimental|Group 5 (Caucasian, 750mg)|Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg
11282304|NCT02817906|Experimental|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks
11282305|NCT02817906|Placebo Comparator|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
11282306|NCT02817880|Experimental|rTMS (repetitive transcranial magnetic stimulation)|rTMS (repetitive transcranial magnetic stimulation)
11282307|NCT02817880|Experimental|tDCS (transcranial direct-current stimulation)|tDCS (transcranial direct-current stimulation)
11282308|NCT02817880|Experimental|tsDCS (transcutaneous spinal Direct Current Stimulation)|tsDCS (transcutaneous spinal Direct Current Stimulation)
11282309|NCT02817867|Active Comparator|tDCS|Patients who will be treated with Transcranial direct-current stimulation (tDCS) in the ipsilesional motor cortex.
11282310|NCT02817867|Active Comparator|rTMS|Patients who will be treated with Magnetic brain stimulation (rTMS) in the contralesional motor cortex.
11282311|NCT02817867|Experimental|tDCS + rTMS|Patients who will be treated with the association between Transcranial direct-current stimulation (tDCS) and magnetic brain stimulation (rTMS), in the ipsilesional and contralesional motor cortex, respectively.
11282312|NCT02817854||Patients with acute diverticulitis|Patients admitted in emergency setting for acute diverticulitis
11282313|NCT02817841|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
11282314|NCT02817828|Experimental|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
11282315|NCT02817815|Active Comparator|Group 1|Volunteers
11282316|NCT02817815|Experimental|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
11282317|NCT02817815|Experimental|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
11282318|NCT02817815|Experimental|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
11282319|NCT02817815|Experimental|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
11282320|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
11282321|NCT02817789|Active Comparator|Standard group|154 patients
11282322|NCT02817789|Experimental|Ticagrelor group|154 patients
11282323|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
11282324|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
11282325|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
11282326|NCT02817750|Experimental|zolpidem hemitartarate (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
11282327|NCT02817750|Experimental|zolpidem hemitartarate (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
11282328|NCT02817737||CT|Measured with computed tomography
11282329|NCT02817737||plain Radiography|Measured with plain Radiography
11282330|NCT02817724|Active Comparator|m-Health group|BENECA System: The m-health group will use the BENECA app for 8 weeks.
11282331|NCT02817724|Experimental|Integral Group|BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
11282332|NCT02817698|Experimental|Drug of dependence|There is only one arm to the study. All subjects will receive their drug of dependence in this study. Nicotine dependent subjects will receive tobacco cigarettes, cannabis dependent subjects will receive cannabis cigarettes, and cocaine dependent subjects will receive IV cocaine.
11282333|NCT02817685||1|Chronic Hepatitis B patient
11282334|NCT02817685||2|Chronic Hepatitis B patient
11282335|NCT02817685||3|cirrhotic patient
11282336|NCT02817685||4|cirrhotic patient
11282340|NCT02817672|Experimental|PRIME 2.0|8 weeks use of PRIME 2.0 (version with the NLP-powered dashboard). Mobile application designed to improve psychosocial functioning and motivational deficits.
11282341|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
11282342|NCT02817646||Intensive care patients|Patients admitted to the intensive care unit for 4 days or more with a computed tomography scan made for clinical reasons early during intensive care stay and who receive enteral and/or parenteral nutrition as per hospital protocol
11282343|NCT02817633|Experimental|Part 1a: TSR-022 monotherapy|Part 1a (monotherapy dose escalation) will evaluate TSR-022 at ascending weight-based doses. TSR-022 will be administered intravenously (IV).
11282344|NCT02817633|Experimental|Part 1b: TSR-022 in combination with nivolumab|Participants in Part 1b will receive nivolumab at the standard dose in combination with ascending doses of TSR-022. The starting dose of TSR-022 will be the Part 1a dose at which less than or equal to (<=)1 of 6 participants experienced dose-limiting toxicity (DLTs).
11282345|NCT02817633|Experimental|Part 1c: TSR-022 in combination with TSR-042|Participants in Part 1c will receive escalating doses of TSR-022 in combination with TSR-042.
11282346|NCT02817633|Experimental|Part 1d: TSR-022 in combination with TSR-042 and TSR-033|Part 1d will initially evaluate TSR-022 and TSR-033, at ascending doses in combination with TSR-042 at a constant dose. At each dose escalation step, only 1 drug will be escalated, either TSR-022 or TSR-033.
11282347|NCT02817633|Experimental|Part 1e: TSR-022 in combination with TSR-042|Part 1e will evaluate TSR-022 in combination with TSR-042 in participants with select cancer types who have not received prior treatment with anti-PD-L1.
11282348|NCT02817633|Experimental|Part 1f: TSR-022 in combination with TSR-042 and Docetaxel|Part 1f will evaluate the triple combination therapy of TSR-022, TSR-042 , and docetaxel, Q3W, for safety. The starting dose of docetaxel will be 75 mg/m^2.
11282349|NCT02817633|Experimental|Part 2: Cohort A (Melanoma) (TSR-022 as monotherapy)|Participants with advanced or metastatic melanoma will be enrolled in Cohort A and will receive treatment with TSR-022 at RP2D as monotherapy.
11282350|NCT02817633|Experimental|Part 2: Cohort A (Melanoma) (TSR-022 with TSR-042)|Participants with advanced or metastatic melanoma will be enrolled in Cohort A and will receive treatment with TSR-022 at RP2D in combination with TSR-042.
11282351|NCT02817633|Experimental|Part2:CohortB Non-small cell lung cancer (TSR-022-monotherapy)|Participants with advanced or metastatic Non-small cell lung cancer (NSCLC) will be enrolled in Cohort B and will receive treatment with TSR-022 at RP2D as monotherapy.
11282352|NCT02817633|Experimental|Part2:CohortB Non-small cell lung cancer(TSR-022 with TSR-042)|Participants with advanced or metastatic NSCLC will be enrolled in Cohort B and will receive treatment with TSR-022 at RP2D in combination with TSR-042.
11282353|NCT02817633|Experimental|Part2:CohortC Colorectal cancer (TSR-022 as monotherapy)|Participants with advanced/metastatic Colorectal cancer (CRC) will be enrolled in this arm and will receive treatment with TSR-022 at RP2D as monotherapy.
11282354|NCT02817633|Experimental|Part2:CohortC Colorectal cancer (TSR-022 with TSR-042)|Participants with advanced/metastatic CRC will be enrolled in Cohort C and will receive treatment with TSR-022 at RP2D in combination with TSR-042.
11282355|NCT02817633|Experimental|Part 2: Cohort D (TIM-3 selected NSCLC)|Participants with advanced or metastatic NSCLC having a positive TIM-3 expression will be enrolled in Cohort D. Participants will be administered TSR-022 at RP2D in combination with TSR-042.
11282356|NCT02817620|Experimental|Spirulysat®|Food supplement packaged in 10 ml vials called Spirulysat®. This product is a phycocyanin concentrated fresh spirulina water extract (Spirulina Platensis). 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
11282357|NCT02817620|Placebo Comparator|Placebo|Placebo with the same characteristics, appearance, packaging and composition as the active formula except for active ingredient (Spirulina) replaced by a classical blue food colorant used to colour desserts. 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
11282358|NCT02817607|Experimental|Surgery|
11282359|NCT02817594||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
11282360|NCT02817568||Aggressive Periodontitis (case)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention.(Drawing Blood)
11282361|NCT02817568||Healthy (Control)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention. (Drawing Blood)
11282362|NCT02817555|Active Comparator|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
11282363|NCT02817555|Active Comparator|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.
~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.
~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
11282364|NCT02817542||STEMI TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention with TA
11282365|NCT02817542||STEMI without TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention without TA
11282366|NCT02817529|Experimental|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
11282367|NCT02817529|Active Comparator|RC-Cornet|The RC-Cornet is a device that provides oscillatory positive expiratory pressure (OPEP) therapy for the detachment and removal of pulmonary secretions. Through variable pressure settings and optional aerosolized medication delivery, patients realize maximum efficacy specific to their unique clinical needs.The RC-Cornet uses the patient's full expired air volume to produce pressure and oscillatory vibrations. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
11282368|NCT02817516|Experimental|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter [mg/mL] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
11282369|NCT02817516|Experimental|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
11282370|NCT02817516|Experimental|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
11282371|NCT02817516|Experimental|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
11282372|NCT02817516|Experimental|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
11282373|NCT02817516|Experimental|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
11282374|NCT02817516|Placebo Comparator|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
11282375|NCT02817516|Placebo Comparator|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
11282376|NCT02817503|Experimental|Standard BP control|"SBP within 140 - <150 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.
~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
11282377|NCT02817503|Active Comparator|Moderate BP control|"SBP within 130 - <140 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.
~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
11282378|NCT02817503|Active Comparator|Intensive BP control|"SBP <130 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.
~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
11282379|NCT02817490||Patients with hypermobility type Ehlers-Danlos Syndrome|Patients with hypermobility type Ehlers-Danlos Syndrome participating to one out of the three patient education sessions included in the study.
11282380|NCT02817490||Caregivers|Caregivers participating to one out of the three patient education sessions included in the study.
11282381|NCT02817477|Experimental|IN Ketamine|A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
11282382|NCT02817477|Active Comparator|IM Morphine|A single administration of 0.15 mg/kg intramuscular morphine
11282383|NCT02817477|Active Comparator|IV Morphine|A single administration of 0.1 mg/kg slow intravascular bolus of morphine.
11282384|NCT02817464|Experimental|TV-46046 - 1|
11282385|NCT02817464|Experimental|TV-46046 - 2|
11282386|NCT02817464|Experimental|TV-46046 - 3|
11282387|NCT02817451|Experimental|Study Group A|HIV exposed and infected infants
11282388|NCT02817451|Experimental|Study Group B|HIV exposed and uninfected infants
11282389|NCT02817438|Experimental|Online Intervention|Participants randomized to the online intervention arm will be given access to the Good Days Ahead program for 12 weeks.
11282390|NCT02817438|No Intervention|Waitlist|Participants randomized to the waitlist arm will wait for 12 weeks without doing an online intervention.
11282391|NCT02817425|Active Comparator|SOX Sequential S-1 Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 6 months and sequential S-1 for 6 months"
11282392|NCT02817425|Active Comparator|SOX Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 12 months"
11282393|NCT02817425|Experimental|TEGAFOX Sequential S-1|"Patients received chemotherapy with TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)  for 6 months and sequential S-1 for 6 months"
11282394|NCT02817412|Experimental|Go/No-Go Training|In the go/no go training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. They are told to press response keys as quickly as possible to indicate the side of presentation (go-trials). On half of the trials, the rectangular frame surrounding the image is not solid but hatched, which is a signal for them to withhold their response (no-go trials). This training is divided into 4 blocks of 50 trials.
11282395|NCT02817412|Experimental|Stop-Signal Training|In the stop signal training, participants are shown images in either a dark blue or light gray border. They are told to press the space bar as quickly as possible when the border is blue (go trials) and to withhold a response when the border is gray (no-go trials). This training is divided into 20 blocks of 32 trials.
11282396|NCT02817412|Experimental|Dot-Probe Training|In the dot-probe training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. Immediately after the images disappear, a small dot probe appears in the location of one of the images. Participants are told to press response keys as quickly as possible to indicate whether a visual probe appeared behind the left or right image during the trials. The probe appears in the location occupied by a high-calorie food image 10% of the time and in the location occupied by a low-calorie food image 90% of the time. This training is divided into 6 blocks of 40 trials.
11282397|NCT02817412|Placebo Comparator|Generic Training|In the generic training, participants complete a generic go/no-go training that uses images of flowers and office supplies instead of the images of high-calorie and low-calorie food images. This generic go/no go training is identical in duration and contact time to the go/no-go food training.
11282398|NCT02817399|Active Comparator|Neuro-muscular electrical stimulation|Active exercises & Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
11282399|NCT02817399|Experimental|Functional electrical stimulation|Active exercises & Functional electrical stimulation while walking.
11282400|NCT02817386||POD and Non-POD;|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The assessment of post deliriu (POD) was performed once per day between 8:00 AM to 10:00 AM. Patient notes were not reviewed for episodes of delirium which could occur outside the time of assessment. The clinical research assistants who performed the delirium assessments in this study had good training and went through quality control procedures. We used state-of-the-art delirium detection methods, which tend to report a higher incidence of delirium. The interview included the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS).
11282401|NCT02817373|Other|transvaginal ultrasound study|Patients with a well established infertility requiring IVF treatment and who are <40. Cohort will consist of patients going through a fresh day 5 transfer with a planned transfer of a single good quality embryo. Patients will go thorough a Ultrasound scan performed through a vaginal probe on the morning of the embryo transfer.
11282402|NCT02817360|Experimental|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
11282403|NCT02817360|Other|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
11282404|NCT02817347|Experimental|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
11282405|NCT02817347|Experimental|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
11282406|NCT02817347|Experimental|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
11282407|NCT02817347|Experimental|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
11282408|NCT02817347|Experimental|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
11282409|NCT02817334|Experimental|indocyanine green|"As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
~Intervention: Drug: indocyanine green"
11282410|NCT02817321|Experimental|Single-injection TPVB +continuous TPVB|Single-injection of TPVB is given preoperatively followed with continuous infusion+ postoperative IPCA.
11282411|NCT02817321|Active Comparator|IPCA|postoperative IPCA is given alone
11282412|NCT02817308|Experimental|Patients|"Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.
~intervention: samples of blood, saliva and urine"
11282413|NCT02817308|Other|Control|"Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.
~intervention: samples of blood, saliva and urine"
11282414|NCT02817295||elderly|patients underwent bariatric surgery and are above 65 years old
11282415|NCT02817295||non-elderly|patients underwent bariatric surgery and are below 65 years old
11282416|NCT02817282|Other|Hand hygiene implementation strategy|The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).
11282417|NCT02817269|Experimental|Manual palpation group|For the manual palpation group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut band tried to elicit local twitch response and referred pain in the infraspinatus area. First, three attempts will be made to elicit an local twitch response (LTR) using snapping palpation if a response will be obtained. After LRT, referred pain could also be evoked by palpation.
11282418|NCT02817269|Experimental|Deep dry needling group|For the deep dry needling group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut before making the needle insertion. Sterile stainless steel needles (length 40mm/caliber 0.32 with a cylindrical plastic guide) will be used.
11282419|NCT02817256|Active Comparator|Group A, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.
~Ergocalciferol 300,000 IM - Every 3 months Oral Vitamin B12 tablets daily (500mcg) Calcium /D Tab 600-200mg Centrium -1 Tablet Daily
~Mineral:
~Iron preparation - Daily (47mg)"
11282420|NCT02817256|Active Comparator|Group B, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.
~Centrium - 1 Tablet daily Ergocalciferol 50000 IU once every two weeks Vitamin B12 1000mcg IM every three months Calcium /D Tab 600-200mg
~Minerals:
~Iron preparation - Daily (47mg)"
11282421|NCT02817243|Other|SP2086 and Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
11282422|NCT02817230||Patients|Patients referred to the out-patient clinic with LDL levels >4.9 mmol/l
11282423|NCT02817230||Controls|Matched normocholesterolemic control subjects
11282424|NCT02817217|Other|SP2086 and Valsartan|
11282425|NCT02817204|Experimental|Aerobic Exercise group|Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
11282426|NCT02817204|Other|Health Education Group|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise
11282427|NCT02817191|Experimental|Hylo-Comod|The patients used Hylo-Comod eye drop after phaco+IOL in this group.
11282428|NCT02817191|Experimental|Tears Naturale Forte|The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
11282429|NCT02817178|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, at 1 month, at 3 months, and 1 month after surgery (if applicable).
~Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected. Tissue tumor is collected during surgery if applicable."
11282430|NCT02817165|Experimental|Probiotic (BioK+)|Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
11282431|NCT02817165|Placebo Comparator|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
11282432|NCT02817152|Sham Comparator|Periodontal ultrasonic debridement|Periodontal pockets received ultrasonic periodontal debridement intervention.
11282433|NCT02817152|Active Comparator|Low-level laser therapy|Periodontal pockets received ultrasonic periodontal debridement plus low-level laser therapy intervention.
11282434|NCT02817139|Active Comparator|active tDCS over primary motor cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
11282435|NCT02817139|Experimental|active tDCS over prefrontal cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
11282436|NCT02817139|Placebo Comparator|sham tDCS over primary motor cortex|Duration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
11282437|NCT02817126|Experimental|Robot-assisted surgery|Patients undergo robot-assisted resections.
11282438|NCT02817126|Active Comparator|Laparoscopic surgery|Patients undergo laparoscopic resections.
11282439|NCT02817113|Experimental|NC-6004, Cetuximab and 5-FU|Cetuximab will be administered before the start of chemotherapy at a loading dose of 400 mg/m2 given, followed by a subsequent weekly doses of 250 mg/m2; NC-6004 will be administered on Day 1 every 3 weeks, and 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
11282440|NCT02817100|Experimental|BAY1817080|Study Part 1: Dose 1 to 7 of BAY1817080 (increasing dose levels; redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]); Study part 2: Dose 1 to 4 of BAY1817080 together with an American breakfast (increasing dose levels; redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
11282441|NCT02817100|Placebo Comparator|Placebo|Study Part 1: Placebo Dose 1 to 7 of BAY1817080; Study Part 2: Placebo Dose 1 to 4 of BAY1817080
11282442|NCT02817087|Active Comparator|repetitive Transcranial Magnetic Stimulation -On|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.
11282443|NCT02817087|Sham Comparator|repetitive Transcranial Magnetic Stimulation -Off|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.
11282444|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
11282445|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
11282446|NCT02817061|Experimental|NIR brain stimulation|"An Omnilux device will be used to put NIR light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.
~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
11282447|NCT02817061|Sham Comparator|Sham|"An Omnilux Device will be used at a safe wavelength not associated with photobiomodulation, putting sham light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.
~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
11282448|NCT02817048|Active Comparator|Tubeless|Interventions: VATS without chest tube placement
11282449|NCT02817048|Active Comparator|Chest tube|VATS with chest tube placement
11282450|NCT02817035|Experimental|noninvasive mechanical ventilation|To investigate the change of the neural inspiratory time and expiratory delay noninvasive mechanical ventilation ,in comparison to spontaneous breathing
11282451|NCT02817022|Other|developmentally supportive care|enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B
11282452|NCT02817009|No Intervention|Nutrition Group|This group will go through standard of care and visit the nutritionist on a monthly basis for the three months that they are a part of the study.
11282453|NCT02817009|Experimental|Healthy Families Group|Participants and their families will attend a weekly nutrition session, social support session and physical activity session for 12 weeks.
11282454|NCT02816996|Experimental|Hand-holding|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
11282455|NCT02816996|Experimental|Stress Ball|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
11282456|NCT02816996|No Intervention|Nothing|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
11282457|NCT02816983||SBRT for oligometastatic prostate cancer|
11282458|NCT02816970|Experimental|A Test|Test drug (Gliptus) 1 tablet contains 50 mg vildagliptin
11282459|NCT02816970|Active Comparator|B Reference|Reference drug (Galvus) 1 tablet contains 50 mg vildagliptin
11282460|NCT02816957|Active Comparator|patients receiving Nigella|40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
11282461|NCT02816957|No Intervention|patients not received nigella as controls|40 patients in the control group will not receive nigella sativa and continued on the usual chelators
11282462|NCT02816944|Experimental|EUS-guided laser ablation for refractory neoplasms|
11282463|NCT02816918|Experimental|Extraluminal use of Univent Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .
~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
11282464|NCT02816918|Experimental|Innerluminal use of Univent Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
11282465|NCT02816905|Active Comparator|Group A|20 eyes that received topical 0.1% Dexamethasone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
11282466|NCT02816905|Active Comparator|Group B|20 eyes that received topical 0.1 % Fluorometholone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
11282467|NCT02816905|Active Comparator|Group C|40 eyes that received topical 1% Rimexolone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
11282468|NCT02816892||Rupture group|Rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity.
11282469|NCT02816892||Covert rupture group|Covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities.
11282470|NCT02816892||Acute dissection group|Acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed.
11282471|NCT02816892||Chronic dissection group|Chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations.
11282472|NCT02816892||Ectatic aneurysm group|Ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal
11282473|NCT02816879|Experimental|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
11282474|NCT02816866|Experimental|empowered primary care model|"patients receive an individualized prescription for survivorship care prepared by a cancer survivor specialist to be implemented by the primary care doctor"
11282475|NCT02816866|Experimental|specialty survivor clinic|patient attends a specialty survivor clinic at Yale for survivorship care
11282476|NCT02816853|Experimental|Sequence 1|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
11282477|NCT02816853|Experimental|Sequence 2|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
11282516|NCT02816645|Experimental|Between 10 and 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
11282517|NCT02816645|Experimental|> 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
11282518|NCT02816632|Experimental|healthy volunteers|
11282519|NCT02816619|Experimental|APA+|APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)
11282478|NCT02816853|Experimental|Sequence 3|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
11282479|NCT02816853|Experimental|Sequence 4|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
11282480|NCT02816840|Experimental|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
11282481|NCT02816840|Experimental|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
11282482|NCT02816840|No Intervention|Computed Tomography|Patients in this arm take radiotherapy positioning with CT.
11282483|NCT02816827|Experimental|E-AG-01|550 mg of 2 capsules having AG-01 and AG-07 will be administered orally twice daily for one day.
11282484|NCT02816827|Experimental|E-AG-02|550 mg of 2 capsules having AG-05 and AG-06 will be administered orally twice daily for one day.
11282485|NCT02816827|Experimental|E-AG-03|550 mg of 2 capsules having AG-01 and AG-05 will be administered orally twice daily for one day.
11282486|NCT02816827|Experimental|E-AG-04|550 mg of 2 capsules having AG-06 and AG-07 will be administered orally twice daily for one day.
11282487|NCT02816814|Active Comparator|Love Diet|Overweight females (BMI > 25) in menopause
11282488|NCT02816814|Experimental|LωVE diet|Overweight females (BMI > 25) in menopause
11282489|NCT02816801|Experimental|Intervention|Access to Butler-Program 2.0
11282490|NCT02816801|No Intervention|Waitlist|
11282491|NCT02816788|Experimental|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
11282492|NCT02816775|Active Comparator|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
11282493|NCT02816775|Active Comparator|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
11282494|NCT02816762|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
11282495|NCT02816762|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
11282496|NCT02816749|Experimental|Maggot debridement therapy(MDT)|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
11282497|NCT02816749|Active Comparator|Conventional Dressing Therapy(CDT)|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
11282498|NCT02816736|Active Comparator|LCZ696 (Entresto) + placebo|LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
11282499|NCT02816736|Active Comparator|valsartan + placebo|valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
11282500|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
11282501|NCT02816723|Active Comparator|Brain Health|Brain Health education class
11282502|NCT02816710|Experimental|IVC Preoperative group|Conbercept injection before vitrectomy
11282503|NCT02816710|Experimental|IVC Postoperative group|Conbercept injection at the end of vitrectomy
11282504|NCT02816710|Experimental|IVC Pre- and Post-operative group|First conbercept injection before vitrectomy and second at the end of operation.
11282505|NCT02816697|Active Comparator|Cease-Aim 1|"Cease Implementation
~100 Patients after CEASE Implementation
~Exit Interview and Tobacco Use Survey"
11282506|NCT02816697|Active Comparator|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)
~Tobacco Use Survey (Baseline,1- 6 Months)
~Biochemical verification"
11282507|NCT02816697|Experimental|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)
~Tobacco Use Survey (Baseline,1- 6 Months)
~Biochemical verification"
11282508|NCT02816697|Active Comparator|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services
~100 patients in usual care
~Exit Interview and Tobacco Use Survey"
11282509|NCT02816697|No Intervention|Clinician and Staff Survey|- Interview clinicians and support staff (40)
11282510|NCT02816684|Active Comparator|SET-C|Social Effectiveness Therapy for Children (SET-C; Beidel et al., 2000) includes social skills training, peer generalization experiences, and in vivo exposure.
11282511|NCT02816684|Experimental|Pegasys-VR|SET-C SST and individual exposure sessions are the same as the active comparator. Peer generalization sessions are replaced by a virtual environment, known as Pegasys School. children engage with artificially intelligent avatars throughout the school.
11282512|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
11282513|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
11282514|NCT02816645|Experimental|<5 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
11282515|NCT02816645|Experimental|Between 5 and 10 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:
~< 5 years
~Between 5 and 10 years
~Between 10 and 15 years
~> 15 years"
11282521|NCT02816606||Standard Reconstruction Technique|ACL reconstruction using hamstring autograft Using 30-degree arthroscope Using rigid femoral tunnel reamer (Rigid Reamers)
11282522|NCT02816606||Alternative Reconstruction Group|ACL reconstruction using hamstring autograft Using 30-degree and 70-degree arthroscopes Using flexible femoral tunnel reamer (Flexible Reamers)
11282523|NCT02816593|Experimental|Group 1 - HP 6%|Group 1: Experimental: Office; hydrogen peroxide 6%,
11282524|NCT02816593|Experimental|Group 2 - HP 15%|Group 2: Experimental: Office; hydrogen peroxide 15%,
11282525|NCT02816593|Active Comparator|Group 3 - CP 10%|Group 3: Control: Homemade; Carbamide Peroxide 10%,
11282526|NCT02816580|Experimental|elderly subjects|
11282527|NCT02816567|Experimental|NMBA group|
11282528|NCT02816567|Placebo Comparator|placebo group|
11282529|NCT02816554|Experimental|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1.0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12days
11282530|NCT02816554|Experimental|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
11282531|NCT02816554|Experimental|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
11282532|NCT02816554|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
11282533|NCT02816541|Experimental|Pelvis Retroverted|Pilates-based therapeutic exercises performed with a posterior pelvic tilt
11282534|NCT02816541|Experimental|Pelvis in Neutral Position|Pilates-based therapeutic exercises performed with a neutral position of the pelvis
11282535|NCT02816541|Active Comparator|Control Group|Aerobic exercise performed on a treadmill
11282536|NCT02816528||Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
11282537|NCT02816528||Nothing|Not Trained Physicians
11282538|NCT02816515||Ectoin® mouth wash|The treatment will be started on the first day of radio- and/or chemotherapy, before development of mucositis
11282539|NCT02816515||Ectoin mouth wash|The treatment will be started after oral mucositis development in patients receiving radio- and/or chemotherapy
11282540|NCT02816515||Supersaturated electrolyte mouth rinse|The treatment will be started after oral mucositis development in patients receiving radio and/or chemotherapy
11282541|NCT02816502|Experimental|Stress Management Skill Building Program A|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
11282542|NCT02816502|Active Comparator|Stress Management Skill Building Program B|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
11282543|NCT02816489|Experimental|Group I|"will be treated using passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA).
~Intervention: Device: passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA)."
11282544|NCT02816489|Experimental|Group II|"will be treated using conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA).
~Intervention: Device: conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA)."
11282545|NCT02816476|Experimental|Daratumumab|Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
11282546|NCT02816463|Experimental|Ambu AuraGain (Group A)|Laryngeal mask Ambu AuraGain will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
11282547|NCT02816463|Active Comparator|LMA Supreme (Group S)|Laryngeal mask Supreme will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
11282548|NCT02816450|Experimental|HIGH|Increase water intake to 2.5 liters per day for 4 days
11282549|NCT02816450|Experimental|LOW|Decrease water intake to 0.5 liter per day for 4 days
11282550|NCT02816437|Experimental|OpenBiome FMT retention enema|OpenBiome Fecal Microbiota Transplantation retention enema, one rectal application.
11282551|NCT02816424|Experimental|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
11282552|NCT02816424|No Intervention|Control|
11282553|NCT02816411|Experimental|Protein|Milk protein isolate supplementation: orally, 20g of protein immediately post-exercise and then 20g every 3h on 3 occasions (+3, +6, +9), on the exercise day. The remaining 8 days, 20g daily with breakfast.
11282554|NCT02816411|Active Comparator|Placebo|Placebo administration: orally 500 ml, immediately post-exercise as well as at +3, +6 and +9 hours, on the exercise day. The remaining 8 days, 500 ml daily with breakfast.
11282555|NCT02816398|Experimental|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
11282556|NCT02816385|Active Comparator|Antegrade Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
11282557|NCT02816385|Experimental|Retrograde Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
11282558|NCT02816372|Experimental|Tidal volume 4 ml/kg Predicted Body Weight (PBW)|
11282559|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
11282583|NCT02816164|Active Comparator|Neupogen for 5 days|Neupogen injection for 5 days
11282560|NCT02816346|Experimental|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
11282561|NCT02816346|Experimental|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
11282562|NCT02816346|Experimental|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
11282563|NCT02816346|Experimental|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
11282564|NCT02816346|Experimental|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).
~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.
~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
11282565|NCT02816333||Type B aortic dissection|Patients with Type B aortic dissection requiring TEVAR
11282566|NCT02816320||Inpatient stays|All patients who were hospitalized in participating hospitals in France during the study period were eligible for inclusion.
11282567|NCT02816307|Experimental|Infective endocarditis|
11282568|NCT02816294|Experimental|Housing Prescription|Participants in the intervention group will be referred to the Care Coordinator at Project Hope, who will conduct case management with the family to stabilize their housing. The Care Coordinator will refer families all families to benefit maximization services and complete Problem Solving Education. The Care Coordinator will also refer families as necessary to Medical-Legal Partnership Boston for pro-bono legal services and/or the Boston Housing Authority for priority on a subsidized housing waitlist.
11282569|NCT02816294|No Intervention|Resource List|At present, for families facing housing insecurity, Children's HealthWatch offers paper resources with contact information for local social service agencies that may assist with housing stability.
11282570|NCT02816281||Reasons of case cancellation|"will be recorded and categorized into 6 groups including
~patient issue such as surgery refusal, no show on the day of surgery, transport problems
~facility such as equipment needs, improper estimate case time, case bumps
~Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively
~anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error
~medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure
~miscellaneous."
11282571|NCT02816268|Other|Conventional Pulmonary vein isolation|Conventional pulmonary vein isolation was gained by using an irrigated tip ablation catheter
11282572|NCT02816268|Other|Contact force pulmonary vein isolation|Contact force was meassured by using the SMART-Touch ablation catheter (Biosense-Webster®)
11282573|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
11282574|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
11282575|NCT02816242|Experimental|intervention|teaching anatomy by concept map
11282576|NCT02816242|Sham Comparator|placebo|teaching anatomy by traditional method
11282577|NCT02816229|Experimental|Insertion of endobronchial valve|Patients in this group will have one or more EBV inserted into the relevant lung regions to manage the haemoptysis via flexible bronchoscopy.
11282578|NCT02816229|No Intervention|Best care|Patients will receive best medical care.
11282579|NCT02816216|Other|End User Iterative Testing - CampAir|To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability.
11282580|NCT02816203|Experimental|Primary Hemostatic Intra-Uterine suction cup|Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
11282581|NCT02816177|Experimental|Telemedicine|Usual care and telemedicine consultations during12 months.
11282584|NCT02816164|Active Comparator|Neupogen for 7 days|Neupogen injection for 7 days
11282585|NCT02816164|Active Comparator|Neupogen for 10 days|Neupogen injection for 10 days
11282586|NCT02816151|Experimental|Group 1|
11282587|NCT02816151|Experimental|Group 2|
11282588|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
11282589|NCT02816125|Active Comparator|Habitual supplemented|habitual diet with 1.2 g EPA+DHA in capsule form/day.
11282590|NCT02816125|Experimental|Low-fat supplemented|Reduce dietary fat to less than 20% energy, add 1.2 g EPA+DHA in capsule form/day.
11282591|NCT02816112|Active Comparator|Ciprofloxacin|Oral tablet taken twice a day at home starting 5 days after chemotherapy for 14 days for every cycle of TC
11282592|NCT02816112|Active Comparator|G-CSF|Daily injection at home for the number of days as chosen by the treating physician
11282593|NCT02816099|Experimental|Type-1 diabetes patients|
11282594|NCT02816099|Other|Controls|
11282595|NCT02816086|No Intervention|Standard care|The study participants receives standard care in the ward, this does not include a pharmacist.
11282596|NCT02816086|Experimental|Intervention|Interdisciplinary collaboration structure
11282597|NCT02816073|Active Comparator|1,700|Patients receive 1,700 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
11282598|NCT02816073|Active Comparator|2,500|Patients receive 2,500 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
11282599|NCT02816060|Experimental|neural tensionner exercise|This group will receive a specific tensionner nerve exercise to provide mechanical stress across the median nerve. This technique have two positions, start and end. It consists on going from one to the other position constantly, controlling the speed of the technique to be constant. In the start position, the subject will be supine lying on a couch with the following parameters: contralateral cervical side bending, shoulder depression, shoulder abduction and external rotation to 90°, elbow flexion to 90º, and forearm supination. In the final position, the therapist will perform full elbow extension while maintaining all the joints previously situated as described above until the patients feel tension, then return to the start position.
11282600|NCT02816060|Placebo Comparator|sham neural tensionner exercise|The control group will receive a sham technique (ST) with minimal mechanical stress across the median nerve. Patients will be placed in neutral cervical spine position with no shoulder depression, shoulder abduction and external rotation to 45°, 45° of elbow extension, and forearm pronation.. This technique will be passively repeated from elbow flexion to extension in the same way than the NTE group
11282601|NCT02816034|Experimental|Experimental Explicit|Cannabis user performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
11282602|NCT02816034|Active Comparator|Control Explicit|Healthy subject performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
11282603|NCT02816034|Experimental|Experimental Implicit|Cannabis user performs visuo-motor rotation tasks without being informed of the explicit strategy
11282604|NCT02816034|Active Comparator|Control Implicit|Healthy subject performs visuo-motor rotation tasks without being informed of the explicit strategy
11282605|NCT02816021|Experimental|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.
~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
11282606|NCT02816021|Experimental|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.
~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
11282607|NCT02816008|Experimental|Cognitive rehabilitation group|Cognitive rehabilitation training with RGS in the clinic.
11282608|NCT02816008|Active Comparator|Passive control group|Passive/conventional cognitive training at home.
11282609|NCT02815995|Experimental|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.
~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
11282610|NCT02815995|Experimental|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.
~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
11282611|NCT02815995|Experimental|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
11282612|NCT02815995|Experimental|Synovial Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
11282699|NCT02815436|Active Comparator|SMS reminder|Subjects in this arm will receive a SMS reminder
11283030|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
11282613|NCT02815995|Experimental|Osteosarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
11282614|NCT02815995|Experimental|Other Sarcomas Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).
~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.
~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
11282615|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
11282616|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
11282617|NCT02815969||Healthy volunteers|If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
11282618|NCT02815969||Patients|Patients are asked for a vena punction and urine collection, if not already done because of medical care.
11282619|NCT02815956|Experimental|percutaneous tibial nerve stimulation (ST)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.
~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.
~The protocol of stimulation is the same, that the one performed for fecal incontinence."
11282620|NCT02815956|Placebo Comparator|placebo (P)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.
~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.
~The device delivers ineffective impulses."
11282621|NCT02815943|Other|Before DBP-DS surgery|
11282622|NCT02815943|Experimental|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
11282623|NCT02815943|Other|Before SG surgery|
11282624|NCT02815943|Experimental|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
11282625|NCT02815930||HCUs|Newly incident seniors with annual total healthcare expenditures in the top 5% of Ontarians
11282626|NCT02815930||Non-HCUs|Seniors with annual total healthcare expenditures below the top 5% of Ontarians
11282627|NCT02815917|Experimental|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
11282628|NCT02815917|Experimental|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
11282629|NCT02815917|Experimental|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic [18F]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
11282659|NCT02815722|Active Comparator|Simvastatin and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from B stage to A stage.
11282660|NCT02815709|Experimental|Treatment 1 Oliceridine|
11282630|NCT02815917|Experimental|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the [18F]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.
~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
11282631|NCT02815904|Experimental|Yakson touch and Kinesthetic stimulation|"Yakson touch (YT) The therapist will relax arms and shoulder muscles for 1 minute and will do deep breathing to accumulate Ki energy on the palms. The Therapist will apply Yakson on the neonate.
~Kinesthetic stimulation (KS) For giving kinesthetic stimulation the neonate will be placed in supine position. There will be six passive flexion and extension movements. Each of the movement will each last for approximately 10 seconds. The movements will be performed in the following order -right arm, left arm, right leg, left leg, both legs simultaneously"
11282632|NCT02815904|Active Comparator|Conventional Handling and KMC|"Conventional Handling (CH) The neonates in control group will receive developmental positioning(positioning of preterm infants for optimal physiological development) for 20 minutes per hour for 5 days.
~Kangaroo mother care (KMC) Holding the neonate skin to skin by mother for one hour a day"
11282633|NCT02815878|Experimental|Group 1: Intervention with Disability|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
11282634|NCT02815878|Active Comparator|Group 2: Intervention without Disability|Participants without a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
11282635|NCT02815878|No Intervention|Group 3: No intervention|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older complete pre and post outcome assessments.
11282636|NCT02815865|Active Comparator|Foley catheter and pitocin|Intervention: Foley catheter and pitocin Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
11282637|NCT02815865|Active Comparator|Foley catheter and dinoprostone|Intervention: Foley catheter and dinoprostone Foley catheter will be inserted through the cervix and inflated with 80 ml saline dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
11282638|NCT02815865|Active Comparator|Dinoprostone|Intervention: Dinoprostone 3 mg will be inserted to the posterior fornix
11282639|NCT02815839|Experimental|Cohort 1|2.5-mg SHR4640 or placebo
11282640|NCT02815839|Experimental|Cohort 2|5-mg SHR4640 or placebo
11282641|NCT02815839|Experimental|Cohort 3|7.5-mg SHR4640 or placebo
11282642|NCT02815839|Experimental|Cohort 4|10-mg SHR4640 or placebo
11282643|NCT02815839|Experimental|Cohort 5|20-mg SHR4640 or placebo
11282644|NCT02815826||Barefoot training|16 weeks of progressive barefoot running training
11282645|NCT02815813|Experimental|PeerFIT|PeerFIT is a group-based lifestyle intervention enhanced by mobile health technology and social media designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
11282646|NCT02815813|Active Comparator|BEAT|BEAT involves basic education in fitness and nutrition supported by a wearable activity tracking device designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
11282647|NCT02815800|Experimental|ETHNODYNE VISIO|Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease
11282648|NCT02815787|Active Comparator|SP2086 and Glyburide|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days. In this group,the subjects was given the drugs from A sequence to the B sequence.
11282649|NCT02815787|Active Comparator|Glyburide and SP2086|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days.In this group,the subjects was given the drugs from B sequence to the A sequence.
11282650|NCT02815774|Active Comparator|health volunteers|this group patients were given SP2086 50mg only one time.
11282651|NCT02815774|Active Comparator|mild renal insufficiency|this group patients were given SP2086 50mg only one time.
11282652|NCT02815774|Active Comparator|moderate renal insufficiency|this group patients were given SP2086 50mg only one time.
11282653|NCT02815774|Active Comparator|severe renal insufficiency|this group patients were given SP2086 50mg only one time.
11282654|NCT02815774|Active Comparator|end-stage renal insufficiency|this group patients were given SP2086 50mg only one time.
11282655|NCT02815748|Other|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
11282656|NCT02815735|Experimental|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
11282657|NCT02815735|Active Comparator|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
11282658|NCT02815722|Active Comparator|SP2086 and Simvastatin|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from A stage to B stage.
11282661|NCT02815709|Experimental|Treatment 2 Oliceridine|
11282662|NCT02815709|Experimental|Treatment 3 Oliceridine|
11282663|NCT02815709|Placebo Comparator|Placebo|
11282664|NCT02815709|Active Comparator|Morphine|
11282665|NCT02815696|Experimental|lumbar spine segmental instability|Patients with a segmental instability of the lumbar spine having undergone surgery. Lumbar spine instability diagnosis is based on imaging (Magnetic resonance imaging, standard radiography, and EOS imaging). Surgical treatment is indicated if the pain is relieved by wearing a brace during at least three months.
11282666|NCT02815670|Experimental|Idarucizumab|
11282667|NCT02815657|Active Comparator|SP2086 and Valsartan|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.
11282668|NCT02815657|Active Comparator|Valsartan and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from B stage to A stage.
11282669|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
11282670|NCT02815631|Experimental|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.
~First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.
~Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.
~Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.
~The patients involvement will then be finished in the study and will be cared for as per clinical practice.
~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
11282671|NCT02815631|Active Comparator|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:
~A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.
~Maximal hyperaemia FFR will be recorded during adenosine infusion.
~An FFR ratio of <0.80 will be regarded as a positive result."
11282672|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
11282673|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
11282674|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
11282675|NCT02815592|Experimental|Experimental Arm 1|BMS-986012/Cisplatin/Etoposide
11282676|NCT02815592|Experimental|Experimental Arm 2|BMS-986012/Carboplatin/Etoposide
11282677|NCT02815592|Experimental|Experimental Arm 3A|BMS-986012/Platinum/Etoposide
11282678|NCT02815592|Active Comparator|Active Comparator Arm 3B|Platinum/Etoposide
11282679|NCT02815579|Experimental|Intervention|The Shamba Maisha Intervention includes: a) a microcredit loan (~$140) from a well-established Kenyan bank for purchasing agricultural implements and commodities; b) agricultural implements to be purchased with the microcredit loan including the KickStart treadle pump, seeds, fertilizers and pesticides; and c) education in financial management and sustainable farming practices occurring in the setting of patient support groups.
11282680|NCT02815579|No Intervention|Control|Participants in the control arm will receive the standard of care.
11282681|NCT02815566|Experimental|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
11282682|NCT02815566|Active Comparator|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
11282683|NCT02815553|Experimental|Cardiac tumors|
11282684|NCT02815540|Other|Observational|This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
11282685|NCT02815527||Fresubin Intensive|Adult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
11282686|NCT02815514||Aortic valve procedures|"percutaneous transfemoral aortic valve implantation
~percutaneous transapical aortic valve implantation
~percutaneous transaortic aortic valve implantation
~aortic valve valvuloplasty
~surgical aortic valve replacement
~conservative treatment"
11282687|NCT02815501||women|"attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery
~Blood samples"
11282688|NCT02815488|Experimental|CHF6297 Active|
11282689|NCT02815488|Placebo Comparator|Placebo|
11282690|NCT02815475|Placebo Comparator|Placebo|Starch filled capsule
11282691|NCT02815475|Experimental|Curcumin|400mg of Curcumin via capsule to be consumed every other day
11282692|NCT02815475|Active Comparator|Turmeric powder|2 teaspoons of dried turmeric powder to be consumed every other day
11282693|NCT02815462|Experimental|Intervention|FAM-FACE-SG risk score + decision making algorithm
11282694|NCT02815462|Active Comparator|Control|Usual Care
11282695|NCT02815449|Experimental|Low stabilizer level|Meals prepared with iron fortified cube with low stabilizer level
11282696|NCT02815449|Experimental|Medium stabilizer level|Meals prepared with iron fortified cube with medium stabilizer level
11282697|NCT02815449|Experimental|High stabilizer level|Meals prepared with iron fortified cube with high stabilizer level
11282698|NCT02815436|Active Comparator|Telephone reminder|subjects in this arm will receive a telephone reminder
11282700|NCT02815436|No Intervention|No reminder|usual care, where no additional intervention will be offered
11282701|NCT02815423|Experimental|UCMSCs|Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.
11282702|NCT02815423|Placebo Comparator|Placebo|The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.
11282703|NCT02815410|Other|Levetiracetam|Newly diagnosed histologically proven supratentorial glioblastoma patients received levetiracetam during and after their CCRT
11282704|NCT02815397|Experimental|Single arm, open label|Metformin added to standard of care treatment for all patients
11282705|NCT02815371|Experimental|Needle Acupuncture|Sterile, disposable needles were inserted into specific acupoints until Deqi sensation was elicited. The needles were retained for 25 minutes before and after embryo transfer.
11282706|NCT02815371|Experimental|Laser Acupuncture|Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
11282707|NCT02815371|Sham Comparator|Sham Laser Acupuncture|However, support staff uninvolved in the design of the trial or analysis of the data disarmed the machine, such that no laser irradiation was emitted. This system created an illusion for both the patient and the acupuncturist, and allowed for a truly double blinded control group.
11282708|NCT02815371|No Intervention|No Treatment|This control group was not exposed to any additional physical contact or acupuncture related protocol. They were only exposed to dim light and calming music before and after embryo transfer, mimicking the natural waiting room and procedure room setting for all patients undergoing embryo transfer.
11282709|NCT02815358|Experimental|Segmental Stabilization Group|Patients receiving segmental stabilization exercises.
11282710|NCT02815358|Active Comparator|Control Group|Patients receiving home exercises.
11282711|NCT02815345|Experimental|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.
~Some included neonates will also have rhinomanometry measurements."
11282712|NCT02815332|Placebo Comparator|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
11282713|NCT02815332|Experimental|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
11282714|NCT02815332|Experimental|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
11282715|NCT02815319|Active Comparator|Standard of care|Physician's treatment recommendation for dexamethasone premedication
11282716|NCT02815319|Active Comparator|8mg PO dexamethasone|8mg PO dexamethasone premedication
11282717|NCT02815306|Experimental|Brace goup|The infants who were brace group treated by braces which were designed and made by us.
11282718|NCT02815293|Experimental|AGN-195263|
11282719|NCT02815293|Placebo Comparator|Vehicle|
11282720|NCT02815280|Experimental|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
11282721|NCT02815280|Placebo Comparator|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
11282722|NCT02815267|Experimental|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
11282723|NCT02815267|Placebo Comparator|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
11282724|NCT02815254|Active Comparator|Low dose exercise intervention|
11282725|NCT02815254|Experimental|High dose exercise intervention|
11282726|NCT02815241|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11282727|NCT02815228|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11282728|NCT02815215|Experimental|Intervention group|Minimally Invasive Carroll's Technique
11282729|NCT02815215|Active Comparator|Control group|Ponseti method
11282730|NCT02815202|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11282731|NCT02815189|Experimental|Post operative Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg taken a week after. Incidence of flare ups after a single vs multiple visits root canal treatments.
11282732|NCT02815189|Experimental|Flare up|Acetaminophen 325 mg for Flare Up. Taken second day after. Incidence of Post operative pain after root canal treatment in one vs two visits.
11282733|NCT02815176||Central serous chorioretinopathy|De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
11282734|NCT02815176||Polypoidal choroidal vasculopathy|De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
11282735|NCT02815176||Epiretinal membrane|Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
11282736|NCT02815163|No Intervention|comparison group|The CG received no extra care; they could receive the usual routine care for THR in the unit as they had before participation in the study. The routine care included oral instruction by nurses follow by the handout. Also, a brochure was provided of the structure of hip, the risk factors of THR, care before and after THR, complications, care of discharge, and demonstration of rehabilitation with pictures) of THR designed by researchers in this study. Five orthopedics health care experts independently reviewed and rated each item in the brochure on a five-point Likert-type scale in terms of relevance, representativeness, specificity, and clarity.
11282865|NCT02814253||Acute Admissions Group|Patients who are admitted to hospital with an acute exacerbation of COPD. These patients are potentially eligible for the acute admission group.
11282737|NCT02815163|Experimental|Empowerment education group|"The 5 times total, 12-week EE intervention was aimed to empower older patients with THR to develop their own self-management program to meet their needs. This empowerment education intervention based on 6 empowerment components: Partnership, listening, dialogue, reflection, action, feedback and 5-step empowerment strategies: motivating patients self-awareness, assessing the causes of the problem, goal setting, individual self-care plan development, and checking whether goals or plans have been achieved who modified from Freire's 3-stage methodology. The difference between this program and the other health educations for patients with THR are that this program encourages them to explore their needs and worries, their own ability and power to meet their needs, and their capacity to seek and use their social support and resources etc."
11282738|NCT02815150|Experimental|Treatment group|Preoperative oral carbohydrate drink: patients drink 5% glucose solution 250ml 2-3 hours before surgery.
11282739|NCT02815150|No Intervention|Control group|Patients undergo 6-8 hours of preoperative fasting.
11282740|NCT02815137|Other|XPO1 E571K mutation detection|Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy
11282741|NCT02815124|Active Comparator|Standard of Care|Cochlear Implant programming using standard of care
11282742|NCT02815124|Experimental|Image-Guided Cochlear Implant Programming|Cochlear Implant programming using Image-Guided Cochlear Implant Programming
11282743|NCT02815111||Control Group|Intensivists will proceed with analgesia utilizing conventional opioid based pain order sets.
11282744|NCT02815111||Study Group|The investigators plan to study an analgesic regimen of Ketamine and lidocaine as infusions with Neurontin and Acetaminophen delivered orally for postoperative analgesia and the subsequent effect on ventilator days and ICU stay.
11282745|NCT02815085|Experimental|RecoverLINK technology|RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.
11282746|NCT02815059|Experimental|Ibrutinib, Dasatinib and prednisone, all patients|
11282747|NCT02815033|Other|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
11282748|NCT02815020|Other|Boot Camp Translation|"Boot Camp Translation is rolled out in a stepped wedge design across participating PBRNs to assist practices with SMS implementation. The Boot Camp Translation intervention initiates practices to review and begin uptake and implementation of tools from the AHRQ Self-Management Support tool library."
11282749|NCT02815007|Experimental|Chidamide with EGFR-TKI|"Chidamide: Per Os, 30mg (5mg*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast.
~EGFR-TKI:
~Taken according to the instruction book"
11282750|NCT02814994|Experimental|tidal volume guided by respiratory system compliance|effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
11282751|NCT02814994|Experimental|low tidal volume|Ventilated patients with low tidal volume
11282752|NCT02814968|Experimental|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
11282753|NCT02814955||referred for paroxysmal atrial fibrillation with fluindione|
11282754|NCT02814955||referred for paroxysmal atrial fibrillation with previscan|
11282755|NCT02814955||referred for paroxysmal atrial fibrillation with apixaban|
11282756|NCT02814955||referred for paroxysmal atrial fibrillation with rivaroxaban|
11282757|NCT02814955||referred for paroxysmal atrial fibrillation with dabigatran|
11282758|NCT02814942||Heart Failure receiving CRT|Heart failure patients with QRS > 120ms receiving CRT
11282759|NCT02814929||Demographic and Prenatal Characteristics|Gender, multiple pregnancy antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis will be compared among infants with and without ROP
11282760|NCT02814929||Neonatal Characteristics of infants|Neonatal characteristics: GA, BW, SGA, resuscitation in delivery room, RDS, duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant PDA, early/late sepsis, NEC, number of blood transfusions, BPD, breastfeeding and weight gain at postnatal 28th day will be compared among infants with and without ROP.
11282761|NCT02814929||Incidence of any ROP and severe ROP|Incidence of any ROP, severe ROP and its treatment in relation to BW and GA will be evaluated. The same parameters will also be evaluated in preterm babies of refugees.
11282762|NCT02814916|Experimental|Dalbavancin, single dose|
11282763|NCT02814916|Experimental|Dalbavancin, two doses|
11282764|NCT02814916|Active Comparator|Comparator|
11282765|NCT02814903||Planned cardiac surgery. POAF occurence or not|The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) < 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.
11282766|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
11282767|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
11282768|NCT02814864|Experimental|Mesenchymal Stromal Cell (MSC)|Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)
11282769|NCT02814851|Experimental|Non valvular cardiac surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
11282770|NCT02814838|Experimental|Ladarixin|Ladarixin oral capsule
11282771|NCT02814838|Placebo Comparator|Placebo|Placebo oral capsule
11282866|NCT02814240|Experimental|Pituitary gland failure|
11282772|NCT02814825||ViviGen|Patients undergoing a two or three level ACDF using ViviGen Cellular Bone Matrix in conjunction with cervical allograft spacers and DePuy Synthes anterior cervical plate systems.
11282773|NCT02814812|Experimental|pancreatic surgery|
11282774|NCT02814799||bone donors|
11282775|NCT02814786|Experimental|Equinus cohort|"15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.
~Interventions: MRI scanner and gait analysis"
11282776|NCT02814786|Experimental|Control cohort|"In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.
~Interventions: MRI scanner and gait analysis"
11282777|NCT02814773||AD group|group suffering from Alzheimer-type dementia (mild to moderate dementia)
11282778|NCT02814760||Pre-intervention group (Control group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.
~Patients of this group are included before the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
11282779|NCT02814760||Post-intervention group (Training course group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.
~Patients of this group are included after the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
11282780|NCT02814747|Experimental|quantitive study: 500 patients likely to be candidates for HTS|quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.
11282781|NCT02814747|Experimental|qualitative study: 30 patients who have benefited from HTS and|qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.
11282782|NCT02814721|No Intervention|Standard cannulation|The standard cannulation protocol of the center was defined as using 17 gauge needles for the first 3 dialysis sessions, followed by 16 gauge for the next 3, and finally 15 gauge for subsequent sessions.
11282783|NCT02814721|Active Comparator|Ultrasound guided cannulation|The study protocol involved similar up titration of needle size over a 3-week period, except that a pre-cannulation evaluation of the fistula was performed using the Sonic Window ultrasound device. The device was used to evaluate and identify the optimal site of cannulation (image 1). Depending upon the cannulator's preference, real-time guidance could be employed during cannulation (image 2, 3). The cannulations were performed by 4 selected personnel trained in device use and successfully completed a competency evaluation on simulator models and a mature dialysis fistula.
11282784|NCT02814708|Experimental|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
11282785|NCT02814708|Experimental|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
11282786|NCT02814708|Experimental|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
11282787|NCT02814708|Experimental|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
11282788|NCT02814708|Experimental|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
11282789|NCT02814708|Experimental|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
11282790|NCT02814708|Placebo Comparator|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
11282791|NCT02814695|No Intervention|Control|First fraction was control, 0.1ml of liquefied semen mixed with 0.1ml Ham's F10 medium and incubated at 37o C for 30 minutes.
11282792|NCT02814695|Experimental|Vit E|2nd, 3rd, 4th fractions (Vit. E 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (1, 2, 5 mg/ml) Vitamin E respectively and incubated at 37o C for 30 minutes.
11282793|NCT02814695|Experimental|YE|5th, 6th, 7th parts fractions ( YE 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (10, 20, 50 mg/ml) Yeast extraction and incubated at 37o C for 30 minutes.
11282794|NCT02814695|Experimental|Vit C|8th, 9th, 10th fractions (Vit. C. 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02, 0.04, 0.06 mg/ml) Vitamin C respectively and incubated at 37o C for 30 minutes.
11282795|NCT02814669|Experimental|Cohort 1: ATZ + R-223-D (Concurrent)|Participants will receive concurrent radium-223 dichloride and atezolizumab for a single-cycle, 28-day dose limiting toxicity (DLT) assessment. If the combination is initially found to be safe and tolerable, additional participants will be randomized to Arms A, B, and C.
11282796|NCT02814669|Experimental|RT Arm A: ATZ + R-223-D (Concurrent)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm (randomized treatment [RT]) to receive concurrent radium-223 dichloride and atezolizumab.
11282797|NCT02814669|Experimental|RT Arm B: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
11282798|NCT02814669|Experimental|RT Arm C: ATZ + R-223-D (Staggered, 28-Day ATZ Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive atezolizumab in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
11282799|NCT02814669|Experimental|Cohort 2: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is not tolerable, Arms A, B, and C will not be introduced and additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab in Cycle 2. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward). If, at Cycle 2, Cohort 2 regiment is not tolerable, additional participants will be enrolled in Cohort 3.
11282821|NCT02814578|Active Comparator|IntraVascular UltraSound|Intravascular ultrasound guidance has been associated with improved event-free survival compared with angiographic guidance after DES placement.
11282822|NCT02814565|Experimental|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
11282823|NCT02814565|Placebo Comparator|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
11282800|NCT02814669|Experimental|Cohort 3: ATZ + R-223-D (Staggered, 56-Day R-223-D Run-In)|If Cohort 2 regimen is not tolerable, additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab in Cycle 3. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab from Cycle 3 onward). If, at Cycle 3, Cohort 3 regiment is not tolerable, no additional participants will be enrolled in this study.
11282801|NCT02814656|Experimental|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
11282802|NCT02814656|Experimental|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
11282803|NCT02814656|Experimental|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
11282804|NCT02814643|Experimental|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
11282805|NCT02814643|Placebo Comparator|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
11282806|NCT02814630|Other|Open-label Xolair|"The patients will receive one subcutaneous injection of omalizumab at a dose of 300 mg on Days 1, 30, and 60.
~There is no control drug."
11282807|NCT02814617|Experimental|Cordyceps sinensis mycelium culture extract|Cordyceps sinensis mycelium culture extract 1.68 g
11282808|NCT02814617|Placebo Comparator|Placebo|Placebo
11282809|NCT02814604|Experimental|Traffic Light|"Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.
~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
11282810|NCT02814604|Experimental|Health Star Rating System|"Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall healthy rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.
~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
11282811|NCT02814604|No Intervention|Control|Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.
11282812|NCT02814604|Experimental|High-in Warning Label|"Participants in this group will download an app which features the nutrition information of the selected product in a 'high-in' warning label format (i.e. stop signs for each of saturated fat, sugar, and sodium; according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.
~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
11282813|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
11282814|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
11282815|NCT02814591||Cohort 3: Patients with osteoarthritis (OA)|40 patients with OA. Patients must have been clinically diagnosed with OA. Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database.
11282816|NCT02814591||Cohort 4: Patients with osteoporosis (OI)|40 patients with OI receiving treatment with bisphosphonates. Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment. 20 Adults and 20 Children. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed.
11282817|NCT02814591||Cohort 5: Patients with osteoporosis (OP) (2 treatment groups)|Patients must have been clinically diagnosed with OP. The first group will have been prescribed with bisphosphonate anti-resorptive treatment; the second with anabolic agents. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed. Bone mineral density (BMD) will be confirmed with DXA. Where possible measurements will be acquired prior to the start of treatment and then up to 4 follow up visits at flexible time points to allow scheduling to coincide with hospital appointments. Minimum time between vistis should be 2 months.
11282818|NCT02814591||Cohort 6: Patients with rickets and osteomalacia|10-15 participants with rickets and 10-15 participants with osteomalacia. Patients must have been clinically diagnosed with rickets/osteomalacia. Blood tests for 25-hydroxyvitamin D should be less than or equal to 25 nmol/L. Once participants are on treatment further measurements will be made 6 months afterwards. Participants for rickets and osteomalacia groups will be recruited to give a total of 10 complete sets of data per group.
11282819|NCT02814591||Cohort 7: 5 patients with suspected bone infection.|Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
11282820|NCT02814578|Experimental|Optical coherent tomography|Optical coherent tomography provides more detailed information about the morphology of scaffolds, microstructures and coronary vasculature based on tissue characteristics as compared to conventional IVUS. In spite of angiographic success in BVS placement, further scaffold optimization was required in over a quarter of cases based on OCT findings due to malapposition or scaffold under expansion.
11282824|NCT02814552|Other|High Blood Pressure Consented|Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples. Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
11282825|NCT02814552|No Intervention|De-identified historical data|De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications. The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
11282826|NCT02814539||congenital heart disease|children with severe congenital heart disease who undergo open heart surgery during infancy
11282827|NCT02814539||healthy controls|
11282828|NCT02814526|Experimental|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
11282829|NCT02814526|Active Comparator|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
11282830|NCT02814513|Experimental|ANDAGO|ANDAGO
11282831|NCT02814500|Experimental|A group|Amlodipine and Rosuvastatin, DP-R212
11282832|NCT02814500|Experimental|B group|DP-R212, Amlodipine and Rosuvastatin
11282833|NCT02814474|Placebo Comparator|SALINE|Infusion of saline (0.9 %)
11282834|NCT02814474|Experimental|KETONE|Infusion of Na-3-Hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
11282835|NCT02814461|Experimental|Axitinib|Combined axitinib and radiotherapy (fixed strength)
11282836|NCT02814448|Active Comparator|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
11282837|NCT02814448|Active Comparator|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
11282838|NCT02814448|Active Comparator|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
11282839|NCT02814448|Active Comparator|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
11282840|NCT02814448|Experimental|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
11282841|NCT02814435||Patients|Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.
11282842|NCT02814435||Normal controls|Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.
11282843|NCT02814409|Active Comparator|Alteplase - standard care|Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
11282844|NCT02814409|Experimental|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
11282845|NCT02814383||ELBW Infants|This study seeks to collect data on premature ELBW infants (less than or equal to 2.2 lbs) at high risk of developing brain injury.
11282846|NCT02814357|Placebo Comparator|Control (market standard)|100 g wheat flour (atta)
11282847|NCT02814357|Active Comparator|High fibre 1|81% wheat flour (atta) + 15% chickpea + 4% guar gum
11282848|NCT02814357|Active Comparator|High fibre 2|80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley
11282849|NCT02814357|Active Comparator|High fibre 3|77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley
11282850|NCT02814344||pregnant women not in labour|"from 24 weeks of gestation until term, provided that they are not in labour
~Electrohysterography"
11282851|NCT02814344||women in labour|Electrohysterography
11282852|NCT02814331||symptomatic partial epilepsy|whose brain MRI is abnormal multimodal high-resolution EEG-NIRS
11282853|NCT02814331||not symptomatic partial epilepsy|whose brain MRI is normal multimodal high-resolution EEG-NIRS
11282854|NCT02814318||IV Vancomycin|GBS positive laboring women who are allergic to penicillin and clindamycin and are treated using IV vancomycin.
11282855|NCT02814318||IV Penicillin|GBS positive laboring women who are not allergic to penicillin and are treated using IV penicillin.
11282856|NCT02814305|No Intervention|Control|Patient receives neither educational nor financial interventions
11282857|NCT02814305|Experimental|Financial intervention only|Patient receives financial (pharmacy offer) intervention only
11282858|NCT02814305|Experimental|Educational intervention only|Patient receives educational (narrative) intervention only
11282859|NCT02814305|Experimental|Both interventions|Patient receives both educational and financial interventions
11282860|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
11282861|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
11282862|NCT02814266|Other|difficult intubation|Intubation difficulty score >5
11282863|NCT02814266|Other|Easy intubation|Intubation difficulty score >5
11282864|NCT02814253||Community Based Group|Patients who regularly present with exacerbations of COPD and have chronically-elevated CO2 levels. These patients are supported intensively in an out-patient setting (case-managed) and are potentially eligible for the community-based group.
11282867|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
11282868|NCT02814214||ECG+IEGM|Surface ECG and intracardiac electrogram recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy settings
11282869|NCT02814201||Parkinson best-On|two hours after taking two tablets of 125 mg dispersible Modopar®
11282870|NCT02814201||Parkinson worst-off|after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)
11282871|NCT02814201||Huntington|
11282872|NCT02814201||Control|Data collected from the existing database
11282873|NCT02814188|Experimental|Carbohydrate Beverage|
11282874|NCT02814188|Placebo Comparator|Placebo Beverage|
11282875|NCT02814175|Active Comparator|Part 1: MTX Escalated Dose|Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
11282876|NCT02814175|Experimental|Part 1: ADA + MTX|Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
11282877|NCT02814175|Active Comparator|Part 2: MTX Escalated Dose|Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
11282878|NCT02814175|Active Comparator|Part 2: ADA + MTX Escalated Dose|Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
11282879|NCT02814175|Experimental|Part 2: ADA|Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
11282880|NCT02814175|Experimental|Part 2: ADA ew + MTX|Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
11282881|NCT02814149|Active Comparator|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
11282882|NCT02814149|Active Comparator|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
11282883|NCT02814136|Active Comparator|WACA|wide area circular ablation
11282884|NCT02814136|Active Comparator|EWACA|extra-wide area circular ablation
11282885|NCT02814123|Active Comparator|Rapid Insulin-alone closed-loop delivery|Rapid Insulin will be delivered by subcutaneous infusion. Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine)
11282886|NCT02814123|Experimental|Rapid Insulin-plus-pramlintide closed-loop delivery|"Rapid insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).
~Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine) Drug: Pramlintide"
11282887|NCT02814123|Experimental|Regular Insulin-plus-pramlintide closed-loop delivery|"Regular insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).
~Interventions: 24-hour inpatient intervention Drug: Regular Insulin (humulin R) Drug: Pramlintide"
11282888|NCT02814110|Other|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy
11282889|NCT02814097|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
11282890|NCT02814097|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
11282891|NCT02814084|Active Comparator|Bilateral Internal Mammary Artery grafts|Standard care wound dressings used as part of coronary artery bypass graft operation
11282892|NCT02814084|Experimental|Prevena|Prevena dressing used as part of coronary artery bypass graft operation.
11282893|NCT02814071|No Intervention|Fasting with intravenous fluids|The child will be kept fasted. Intravenous fluids will be at a rate and type as directed by the treating clinician. A low fat oral diet will be commenced once abdominal pain resolves and serum amylase/lipase levels decrease from the peak levels as per treating clinician. In the event that the patient is unable to tolerate oral feeding, tube feeding or parenteral nutrition may be commenced based on the clinical decision of the treating clinician(s). This will be recorded as an adverse event. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled as per treating clinician's discretion
11282894|NCT02814071|Experimental|Early enteral feeding|Patients will commence on an unrestricted oral diet within 24 hours of presentation, meeting 50% of EER with a regular diet and no fat restriction for the first 24 hours of enteral feeding. A 75-100% EER is targeted ≥ 24 hours of enteral feeding.If the targeted EER is not met orally, a nasogastric tube will be inserted to provide bolus feeds of a standard formula with standard fat content. If the patient fails to tolerate both oral and bolus nasogastric tube feeding, continuous nasogastric tube feeding will be provided. If all fails, enteral nutrition by nasojejunal tube feeding or parenteral nutrition may be commenced based on the clinical decision. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled.
11282895|NCT02814058|Experimental|Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
11282896|NCT02814058|Experimental|Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
11282897|NCT02814045||Alzheimer with OSA|Alzheimer with OSA after PSG
11282898|NCT02814045||Alzheimer without OSA|Alzheimer without OSA after PSG
11282899|NCT02814032||PTC group 1|papillary thyroid carcinoma patients with cervical lymph node metastasis
11282900|NCT02814032||PTC group 2|papillary thyroid carcinoma patients without cervical lymph node metastasis
11282901|NCT02814032||Positive control group|benign disease
11282902|NCT02814032||Negative control group|histologically normal
11282903|NCT02814019|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
11282904|NCT02814019|Placebo Comparator|placebo|matching placebo tablets
11282905|NCT02814006|Experimental|every other day|participants will visualize educational video with timed intercourse as recommended by NICE and ASRM
11282906|NCT02814006|Experimental|fertile window|participants will visualize educational video with timed intercourse as recommended by well-know evidence of better conception rates when using this strategy
11282907|NCT02814006|No Intervention|CG|participants will respond to questionnaire with no knowledge of intervention
11283028|NCT02813278|No Intervention|empty control|Patients only receive best support care.
11282908|NCT02813993|Experimental|Intervention Group|A five-minute video concerning age-related fertility decline, fertility risk factors, success of infertility treatments and emotional consequences of childlessness
11282909|NCT02813993|No Intervention|Control|No intervention
11282910|NCT02813980||High SUDEP-7 score|Patients with epilepsy who have a high SUDEP-7 score
11282911|NCT02813980||Low SUDEP-7 score|Patients with epilepsy who have a low SUDEP-7 score
11282912|NCT02813967|Experimental|chemoradiotherapy|Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
11282913|NCT02813967|Active Comparator|Radiotherapy 60 Gy|Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.
11282914|NCT02813954|Experimental|Study Group|Neonates with respiratory distress
11282915|NCT02813954|No Intervention|Control Group|Healthy Infants
11282916|NCT02813941|Experimental|Alternative GRADE SoF table|Two SoF tables (alternative GRADE SoF table and EPC SoF table) will be used in this randomized controlled non-inferiority trial as an intervention. The alternative GRADE SoF table format will be developed from a user-testing survey.
11282917|NCT02813941|Experimental|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published.
11282918|NCT02813941|Active Comparator|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
11282919|NCT02813928|Experimental|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
11282920|NCT02813915||Use of Cheetah medical NICOM|For those who consent to the study, the Cheetah NICOM will be used to obtain cardiac output, stroke volume, and fluid responsiveness.
11282921|NCT02813902|Active Comparator|Heliocare|240 mg administered orally daily
11282922|NCT02813902|Placebo Comparator|Sugar pill|a sugar pill matching the Heliocare tablet in look and weight will be administered orally daily
11282923|NCT02813889|Experimental|Infants|Two populations will be involved in testing in the SmarToyGym: 1. Infants exhibiting typical development between 3 months and 11 months of age 2 . Infants exhibiting atypical development (at-risk for neuromotor delay) between 3 months and 11 months of age.
11282924|NCT02813876|Experimental|Enhanced recovery|Enhanced recovery protocol for nursing, diet and analgesic regimen
11282925|NCT02813876|No Intervention|Standard care|Standard care arm
11282926|NCT02813863|Experimental|SP2086 and Metformin|In the first day,the subject takes metformin 1000mg once,and from Day 4 to Day 7 they need to take SP2086 100mg everyday. In Day 8,they will be given SP2086 100mg and metformin 1000mg.
11282927|NCT02813850|No Intervention|control|standard medical care
11282928|NCT02813850|Experimental|oxygen therapy|
11282929|NCT02813837|Experimental|single arm|Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
11282930|NCT02813824|Active Comparator|Aspirin300|Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
11282931|NCT02813824|Placebo Comparator|Placebo300|Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
11282932|NCT02813824|Active Comparator|Aspirin100|Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
11282933|NCT02813824|Placebo Comparator|Placebo100|Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
11282934|NCT02813798|Experimental|Mild Renal Impairment|A single dose of IV Rivipansel over 20 minutes
11282935|NCT02813798|Experimental|Moderate Renal Impairment|A single dose of IV Rivipansel over 20 minutes
11282936|NCT02813798|Experimental|Severe Renal Impairment|A single dose of IV Rivipansel over 20 minutes
11282937|NCT02813798|Experimental|Normal Renal Functions|A single dose of IV Rivipansel over 20 minutes
11282938|NCT02813785|Experimental|Atezolizumab|Participants will receive atezolizumab until loss of clinical benefit and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
11282939|NCT02813785|Active Comparator|Docetaxel|Participants will receive docetaxel until disease progression per standard RECIST v1.1 criteria or unacceptable toxicity and will thereafter enter survival follow-up until death, loss to follow-up, withdrawal, or study end.
11282940|NCT02813772|Experimental|group 1|Patients with infantile colics who will receive the milk formula NAN Sensitive, Nestlè
11282941|NCT02813772|Active Comparator|group 2|Patients with infantile colics who will receive the milk formula NAN Optipro, Nestlè
11282942|NCT02813759|Experimental|Sucralose|14 mg sucralose (Zero K sucralose powder, IANSA®) an 200 mL of water
11282943|NCT02813759|Placebo Comparator|Water|200 mL of water
11282944|NCT02813746||Obese non smoker vs Normoweight non smoker|Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO). Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9 kg/m2). The modifications in the miRNAs expression will be studied. After the weight loss, new EF will be collected from these patients.
11282945|NCT02813746||Normoweight smoker vs Normoweight non-smoker|EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
11282946|NCT02813733||Thyroid surgery|All patients who underwent a thyroid procedure in 5 high volume referral centers in France were eligible for inclusion.
11282947|NCT02813720||Patients with peripheral PsA|
11282948|NCT02813720||Patients with psoriatic nail onycholysis|
11282949|NCT02813720||Patients with PsO only|
11282950|NCT02813720||Healthy match control subjects|
11282951|NCT02813694|Experimental|lefamulin|oral lefamulin, 600mg
11282952|NCT02813694|Active Comparator|Moxifloxacin|oral moxifloxacin, 400mg
11282953|NCT02813681|Active Comparator|US-epidural SVD|US-epidural SVD group - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
11282954|NCT02813681|Sham Comparator|(US sham- epidural SVD)|US sham- epidural SVD group- participants who received US examination process but with the monitor turned off.
11282955|NCT02813681|Placebo Comparator|SVD without an Epidural|Spontaneous vaginal delivery without an Epidural group The purpose of the control group is to serve as a baseline.
11282956|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
11282957|NCT02813655|Experimental|Experimental arm|Tetracosactide (Synacthène®)
11282958|NCT02813655|Placebo Comparator|Control arm|placebo saline (0.9% NaCl)
11282959|NCT02813642|Experimental|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
11282960|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
11282961|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
11282962|NCT02813629|Active Comparator|SS-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
11282963|NCT02813629|Sham Comparator|SS-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
11282964|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
11282965|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
11282966|NCT02813629|Active Comparator|SC-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
11282967|NCT02813629|Sham Comparator|SC-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
11282968|NCT02813603||Study Product (19-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
11282969|NCT02813603||Control Intervention (22-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
11282970|NCT02813590||Patients with liver cirrhosis and with SBP|
11282971|NCT02813590||Patients with liver cirrhosis and without SBP|
11282972|NCT02813577|Other|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
11282973|NCT02813564|Experimental|Training group|This group of children will receive the software based intervention program (CAVINS) and will train at home during the training phase.
11282974|NCT02813564|No Intervention|Control group|This group of children will play video-games-as-usual and return in about 3 weeks for their next assessment appointment.
11282975|NCT02813564|Experimental|fMRI-training group|"This sub-group of children from the Training group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and train on CAVINS (the intervention) during the training phase."
11282976|NCT02813564|No Intervention|fMRI-Control group|"This sub-group of children from the Control group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and play video-games-as-usual until their next assessment appointment (after about 3 weeks)."
11282977|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
11282978|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
11282979|NCT02813538||IGC and thromboelastometry|Patients that have hyper, normo o hypcoagulability measured by tromboelastometry and anticoagulant proteins levels early after major liver resection and clinical evolution and patients with liver funcion impairment or without it, measured by indocyanine green clearance early after surgery and clinical evolution
11282980|NCT02813525||IUGR group|estimated fetal weight <10th percentile associated with an abnormal umbilical artery Doppler with IP>95th percentile or a confirmation of placental vascular disease by histological examination
11282981|NCT02813525||CONTROL group|non IUGR fetuses for gestational age (normal for weight, Doppler, and structural analyse)
11282982|NCT02813512|Experimental|GXNPC1|Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.
11282983|NCT02813499||CARE Rule|Evaluation of the clinical suspicion of myocardial infarction and calculation of CARE rule.
11282984|NCT02813486|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
11282985|NCT02813486|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
11282986|NCT02813460|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.
11282987|NCT02813460|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.
11282988|NCT02813460|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.
11282989|NCT02813460|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.
11282990|NCT02813460|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.
11282991|NCT02813460|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.
11282992|NCT02813460|Experimental|Session 2: Sequence 1|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).
11282993|NCT02813460|Experimental|Session 2: Sequence 2|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).
11282994|NCT02813460|Experimental|Session 2: Sequence 3|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).
11282995|NCT02813460|Experimental|Session 2: Sequence 4|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).
11282996|NCT02813460|Experimental|Session 2: Sequence 5|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).
11282997|NCT02813460|Experimental|Session 2: Sequence 6|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).
11282998|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
11282999|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
11283000|NCT02813434|Experimental|Florbetapir|
11283001|NCT02813421|Experimental|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
11283002|NCT02813421|No Intervention|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
11283003|NCT02813408||Participants with Prostate Cancer (abiraterone acetate)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.
11283004|NCT02813408||Participants with Prostate Cancer (enzalutamide)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.
11283005|NCT02813395|No Intervention|Control group|Volunteers remained at rest before and after the fatigue protocol.
11283006|NCT02813395|Placebo Comparator|Placebo group|Volunteers were subjected to laser application simulation for approximately four minutes with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
11283007|NCT02813395|Experimental|Laser before|Volunteers received effective application of laser before fatigue protocol.
11283008|NCT02813395|Experimental|Laser after|Volunteers received effective application of laser after fatigue protocol.
11283009|NCT02813382||B-group|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
11283010|NCT02813382||C-group|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
11283011|NCT02813382||P-group|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
11283012|NCT02813369||naloxegol|patients exposed to naloxegol
11283013|NCT02813369||non-PAMORA laxative|patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
11283014|NCT02813356||naloxegol|patients exposed to naloxegol
11283015|NCT02813356||non-PAMORA|patients exposed to non-peripherally acting mu-opioid antagonist
11283016|NCT02813343|Experimental|Immediate Treatment Group|The Immediate Treatment group will receive access to the study intervention - BlueStar app, immediately after consenting for a total duration of 6 months.
11283017|NCT02813343|Other|Delayed Treatment Group|The Delayed Treatment group will receive access to the study intervention - BlueStar app, 3 months after consenting for a total duration of 3 months.
11283018|NCT02813330|Experimental|Sterile Water injection|Subcutenous injection at low back portion during labor pain
11283019|NCT02813330|Experimental|saline injection|Subcutenous injection at low back portion during labor pain
11283020|NCT02813304|Experimental|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
11283021|NCT02813304|Active Comparator|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap and a towel cloth. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
11283022|NCT02813291|Experimental|Stimulation group (Young Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
11283023|NCT02813291|Experimental|Stimulation group (Elderly Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
11283024|NCT02813291|Sham Comparator|Sham group (Young Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
11283025|NCT02813291|Sham Comparator|Sham group (Elderly Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
11283026|NCT02813278|Experimental|simo decoction and acupuncture with vitamin B1|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection for 5 days or until flatus.
11283027|NCT02813278|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection for 5 days or until flatus.
11283031|NCT02813252||JCAR015-treated|Patients who received previous treatment with JCAR015
11283032|NCT02813239||HCG triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG when at least 2 follicles had a mean diameter of 17 mm.
11283033|NCT02813239||HCG + GnRH agonist triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG and GnRH agonist when at least 2 follicles had a mean diameter of 17 mm.
11283034|NCT02813226|Other|Imaging|Molecular Imaging
11283035|NCT02813213|Active Comparator|Standard skin graft|"This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard tie over dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day."
11283036|NCT02813213|Experimental|Skin micro graft|"This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use Xpansion micro-autografting system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution."
11283037|NCT02813200|Experimental|Group 1|
11283038|NCT02813200|Experimental|Group 2|
11283039|NCT02813200|Experimental|Group 3|
11283040|NCT02813174|Experimental|Automated online Compassionate Mind Training|
11283041|NCT02813135|Experimental|ARM A. Ribociclib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
11283042|NCT02813135|Experimental|ARM C. AZD1775 + Carboplatin|AZD1775 capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
11283043|NCT02813135|Experimental|ARM D. Olaparib + Irinotecan|Olaparib tablets orally BID on Day 1-10 of a 21 day cycle; Irinotecan iv QD Day 4-8 of a 21 day cycle.
11283044|NCT02813135|Experimental|Arm I. Enasidenib|Enasidenib orally on a continuous dosing once daily (QD) per 28 day cycle.
11283045|NCT02813135|Experimental|Arm J. Lirilumab + Nivolumab|Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Lirilumab iv QD every 4 weeks of a 28 day cycle (Day 1)
11283046|NCT02813122||with x-ray|patients underwent bariatric surgery and underwent x-ray
11283047|NCT02813122||without x-ray|patients underwent bariatric surgery and did not underwent x-ray
11283048|NCT02813096|Experimental|folfox4 chemotherapy regimen|"details in the Intervention Description"
11283049|NCT02813096|Placebo Comparator|Placebo|"details in the Intervention Description"
11283050|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
11283051|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
11283052|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
11283053|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
11283054|NCT02813057|Active Comparator|Stoppa repair|Stoppa inguinal hernia repair
11283055|NCT02813057|Experimental|TEP repair|Total extraperitoneal inguinal hernia repair
11283056|NCT02813044|Experimental|TIVA group|Anesthesia is maintained with propofol during surgery
11283057|NCT02813044|Active Comparator|inhalation anesthesia group|Anesthesia is maintained with sevoflurane during surgery
11283058|NCT02813031|Experimental|Functional meat products with healthy lipids from olive oil|Healthy people consuming 300g/week of functional meat products with high diglyceride lipid from olive oil
11283059|NCT02813031|Placebo Comparator|Traditional meat products|Healthy people consuming the same amount of traditional meat products
11283060|NCT02813018|Experimental|preemptive group|Group who will be received ropivacaine bolus and continous infusion 5 minutes before skin incision.
11283061|NCT02813018|Placebo Comparator|saline group|Group who will be received saline bolus and continous infusion 5 minutes before skin incision
11283062|NCT02813005|Experimental|Jet ventilation/ group A|Frequency : 120-200/min Pressure : 1-2 bars Inspiratory fraction of oxygen : 100% and 50% if Expiratory pressure : 5 -10 cmH2O
11283063|NCT02813005|Sham Comparator|Standard ventilation/ group B|Apnea made by the anesthesiologist to the request of the radiologist.
11283064|NCT02812992|Active Comparator|GO-GO arm|Nab-paclitaxel 125 mg/m^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m^2 on days D1, D8, D15 of a 28-day cycle.
11283065|NCT02812992|Active Comparator|SLOW-GO arm|Gemcitabine 1000 mg/m^2 i.v. on days D1, D8, D15 of a 28-day cycle.
11283066|NCT02812992|Active Comparator|FRAIL arm|Best supportive care as determined by the investigator.
11283067|NCT02812979|Experimental|Airvo2 with Aerogen Solo|"AIRVOTM2 will be set to deliver air (21% oxygen concentration ) at a rate of 30 L / min at 100 % relative humidity at 37 ° C.
~Nebulization of salbutamol will be effected by means of a nebulizer to the vibrating screen (Aerogen® Solo, Aerogen , Galway, Ireland ) which is a nebulizing device for single use, commonly used in invasive and non invasive mechanical ventilation.
~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
11283068|NCT02812979|Active Comparator|Mask|"During nebulization in the usual way ( oral facial mask ) , it will be used a pneumatic nebulizer powered by a 6 L / min air flow rate ( usual method ).
~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
11283069|NCT02812979|Placebo Comparator|arm control Airvo2 without nebulization of salbutamol|control procedure is to be placed under humidified high flow nasal alone
11283070|NCT02812966|Active Comparator|Lutonix DCB|Lutonix 035 Drug coated Balloon PTA Catheter
11283071|NCT02812966|Active Comparator|IN.PACT DCB|IN.PACT Admiral Paclitaxel-Coated PTA Balloon Catheter
11283072|NCT02812940|Experimental|Everolimus as part of GvHD prophylaxis after allogeneic SCT|Everolimus from day +5 to day +100
11283073|NCT02812927|Other|Standard infusion line|The standard insulin infusion system consisted in regular human insulin administration through a six-stopcock manifold connected to the distal line of a multilumen central venous catheter by 150 cm tubing. Insulin was systematically infused by syringe pump on the patient proximal port of the manifold. Carrier was infused via pump through the manifold. All others medicines were infused through the other five stopcocks.
11283074|NCT02812927|Experimental|Optimised infusion line|The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
11283075|NCT02812914|Experimental|Phase 1|In Phase I, 25 pregnant women will receive a low-cost gas stove and will be taught by peer educators in group classes how to safely use gas stoves and how to reduce exposure to air pollution.
11283076|NCT02812914|Experimental|Phase 2|In Phase 2, the investigators will assess a more resource-intensive behavioral intervention approach with a different group of 25 women who will follow the same study procedures described in Phase I.
11283077|NCT02812901|Other|morning group|cardiac surgery scheduled in the morning
11283078|NCT02812901|Other|afternoon group|cardiac surgery scheduled in the afternoon
11283079|NCT02812888||Hyperthyroid Patients|Patients with hyperthyroidism
11283080|NCT02812888||NC group|Normal control subjects
11283081|NCT02812875|Experimental|CA-170|Taken orally in a once or twice daily schedule.
11283082|NCT02812862||treatment group|"50 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.
~Ultibro/ Breezhaler combination therapy"
11283083|NCT02812862||control group|50 male and female patients suffering from chronic heart failure but not COPD and NOT receiving LAMA/ LABA
11283084|NCT02812849||Suspected cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
11283085|NCT02812849||Known cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
11283086|NCT02812849||Other inflammatory cardiac disease|Cu-64 DOTATATE PET/CT or PET/MRI
11283087|NCT02812836|Other|Manometry|All patients will be investigated by anorectal manometry and after the procedure with balloon expulsion test as previously described.
11283088|NCT02812823|Other|High resolution anorectal manometry|All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
11283089|NCT02812810|Experimental|active rTMS|
11283090|NCT02812810|Placebo Comparator|placebo rTMS|
11283091|NCT02812771|Experimental|Efinaconazole|Efinaconazole
11283092|NCT02812758||patients|All sedated, intubated, mechanically ventilated adult patients admitted for elective cardiac surgery, monitored for sedation depth (with the BIS) and for preload dependence indices (SVV, PPV and PVI) transthoracic echocardiography
11283093|NCT02812745||patients|"patients presenting an indication for general anaesthesia during elective cardiac surgery and being monitored for sedation depth
~recording of cardiac output
~other parameters"
11283094|NCT02812732|Other|Intervention|Providers at each clinic will receive the intervention (DOSE HPV) on a rolling basis. Vaccination rates will be compared pre- and post-intervention at each clinic, and changes in rates will be compared across clinics.
11283095|NCT02812719|Active Comparator|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.
~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
11283096|NCT02812719|Experimental|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.
~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
11283097|NCT02812706|Experimental|Isatuximab|Isatuximab will be administered intravenously (IV) once every week (QW) for 4 weeks followed by once every other week (Q2W)
11283098|NCT02812693|Experimental|Treatment (pembrolizumab, imatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and imatinib mesylate orally PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11283099|NCT02812680||Esophageal Cancer Patients - Blood Draw|Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.
11283100|NCT02812680||Healthy volunteers - Blood Draw|Comparators for the esophageal cancer group
11283101|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
11283102|NCT02812654|Experimental|Doxorubicin, Ifosfamide, radiotherapy|Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
11283103|NCT02812641|Experimental|BPF-CCRT (Run-in Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil
~Chemotherapy:
~Bevacizumab(B): 10 mg/kg on day 1
~Cisplatin(P): 75 mg/m2 on day 1
~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4
~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
11283104|NCT02812641|Experimental|BPF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil
~Chemotherapy:
~Bevacizumab(B): 10 mg/kg on day 1
~Cisplatin(P): 75 mg/m2 on day 1
~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4
~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
11283105|NCT02812641|Active Comparator|PF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Cisplatin and 5-fluorouracil
~Chemotherapy:
~Cisplatin(P): 75 mg/m2 on day 1
~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4
~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
11283106|NCT02812628|Active Comparator|Conventional LAPR|Patients undergoing conventional laparoscopic abdominoperineal resection (LAPR).
11283107|NCT02812628|Experimental|LAPR-TILT|Patients undergoing LAPR with transabdominal individualized levator transection (TILT).
11283108|NCT02812615|Experimental|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
11283109|NCT02812602|Experimental|Lidocaine patch|The patients was randomly assigned to experimental group or placebo group. In this arm, lidocaine patches will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
11283110|NCT02812602|Placebo Comparator|Placebo|The patients was randomly assigned to experimental group or placebo group. In this arm, a placebo patch will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
11283111|NCT02812589|Experimental|Diffusion tensor imaging (DTI) in breast MRI|
11283112|NCT02812550|Other|full-spectrum colonoscopy|Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)
11283113|NCT02812550|Other|standar forward-viewing colonoscopy|Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)
11283114|NCT02812537||patients with conduct disorders|Girls and boys having less than 16 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
11283115|NCT02812524|Experimental|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
11283116|NCT02812511|Experimental|Skin biopsy|
11283117|NCT02812498|Experimental|Teleconsultation|Teleconsultation for patients affected by type 1 diabetes mellitus
11283118|NCT02812498|Other|Control|Standard visit in outpatient clinic for the same type of patients
11283119|NCT02812472|Experimental|treadmill training with functional electrical stimulation|Subjects in the experimental group received additional treadmill training with functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
11283120|NCT02812472|Active Comparator|treadmill training without functional electrical stimulation|Subjects in the control group received additional treadmill training without functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
11283121|NCT02812459|Experimental|Kinesio taping plus exercise|Kinesio taping application for low back plus back exercises.This protocol will be administered three a week for 4 weeks.
11283122|NCT02812459|Active Comparator|Electrical stimulation plus exercise|Electrical stimulation for control pain applied in low back plus exercises.This protocol will be administered three a week for 4 weeks.
11283123|NCT02812446||IAI patients group|patients with Staphylococcus aureus of implant-associated infections
11283124|NCT02812446||control group|patients with Staphylococcus aureus nasal carriage
11283125|NCT02812433|Active Comparator|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
11283126|NCT02812433|Placebo Comparator|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
11283127|NCT02812420|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1 of weeks 1 and 4. Beginning 4-6 weeks after the last infusion, patients undergo cystectomy with pelvic lymph node dissection surgery.
11283128|NCT02812407|Experimental|Mucosal Impedance|"Patient's having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.
~During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it."
11283129|NCT02812394|Experimental|CVT-301|"CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.
~CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.
~Sinemet® (carbidopa/levodopa)"
11283130|NCT02812381|Active Comparator|SCS (Jones tecnique)|18 patients were treatment with straincounterstrain
11283131|NCT02812381|Sham Comparator|KT Kinesiotaping|18 patients were treatment with neuromuscular bandage
11283132|NCT02812368|Experimental|Clonidine|Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
11283133|NCT02812368|Placebo Comparator|Placebo (for clonidine)|Taken once a day at bedtime
11283134|NCT02812355|Experimental|half heparinization|heparin I.V. 150 U/kg
11283135|NCT02812355|Active Comparator|full heparinization (300 U/kg)|heparin I.V. 300 U/kg
11283136|NCT02812342|Experimental|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
11283137|NCT02812329|Experimental|HIV prevention videogame|Participants will play PlayForward on a tablet computer for 1 hour, two times per week for 3 weeks.
11283138|NCT02812316|Experimental|Scleral lenses|Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.
11283190|NCT02811991|Active Comparator|Experimental:Paracetamol Injection|325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment
11283139|NCT02812303||Population Health Coordinator Support|"8 practices received the support of central population health coordinators (PHCs). PHCs utilized a population health management (PHM) information technology (IT) tool and performed administrative tasks including appointment scheduling, ordering overdue laboratory testing, chart reviews, and obtaining outside tests/labs. In addition, PHCs regularly met with physicians to review those patients who required clinical intervention to develop an action plan.
~The network did not have sufficient resources to implement a PHC in all of the 18 network practices. So PHCs were allocated by responses from the practice leader, baseline quality scores, size of the practice, nature of the practice (health center vs not), and location of the practice. These decisions were made in a way that sought to equitably distribute available PHC resources within the practice network as a way to get network buy-in and maximize the impact of the program, both for practices with and without PHCs."
11283140|NCT02812303||No Population Health Coordinator Support|Ten practices without PHC support were provided training on how to use the PHM IT tool. The staff in these practices remained primarily responsible for managing administrative tasks.
11283141|NCT02812277||Anastrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted anastrozole therapy with the completed follow-up data.
11283142|NCT02812277||letrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted letrozole therapy with the completed follow-up data.
11283143|NCT02812264|Experimental|API App|use of API weight loss mobile application for 12 months, plus fitness tracker and scale.
11283144|NCT02812264|Active Comparator|Attention Control|use of non-API app for weight loss over 12 months, plus fitness tracker and scale.
11283145|NCT02812251|Experimental|Part 1: Cohort 1|Participants will receive 1 milligram (mg) JNJ-61393215 or placebo.
11283146|NCT02812251|Experimental|Part 1: Cohort 2|Participants will receive 5 mg JNJ-61393215 or placebo.
11283147|NCT02812251|Experimental|Part 1: Cohort 3|Participants will receive 15 mg JNJ-61393215 or placebo.
11283148|NCT02812251|Experimental|Part 1: Cohort 4|Participants will receive 30 mg JNJ-61393215 or placebo.
11283149|NCT02812251|Experimental|Part 1: Cohort 5|Participants will receive 45 mg JNJ-61393215 or placebo.
11283150|NCT02812251|Experimental|Part 1: Cohort 6|Participants will receive 60 mg JNJ-61393215 or placebo.
11283151|NCT02812251|Experimental|Part 1: Cohort 7|Participants will receive 90 mg JNJ-61393215 or placebo.
11283152|NCT02812251|Experimental|Part 1: Cohort 8|Participants will receive 120 mg JNJ-61393215 or placebo.
11283153|NCT02812251|Experimental|Part 2|Participants will receive JNJ-61393215 (dose to be determined).
11283154|NCT02812251|Experimental|Part 3|Participants will receive JNJ-61393125 (dose to be determined) or placebo under fed conditions.
11283155|NCT02812238|Experimental|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
11283156|NCT02812238|Experimental|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
11283157|NCT02812225|Experimental|BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
11283158|NCT02812212|Experimental|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
~Diuretic renography to measure the cortical transit time"
11283159|NCT02812199|Experimental|pilot study group 1|Patients in pilot study group 1 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in pilot study group scheduled for 6 follow up visits at 1,2,3,4,6 and 12 weeks after implantation and for tampon removal at day 2 - 3 after FESS surgery. Stent will be removed between 14 and 28-day implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
11283160|NCT02812199|Experimental|study group 2|Patients in study group 2 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in 2nd study group scheduled for 4 follow up visits at 2, 4, 6 and 12 weeks after implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
11283161|NCT02812199|No Intervention|control group 3|control group patients will undergo post-FESS bilateral Standard of Care (tampon) placement into middle meatus as standard of care. Frontal tampon will be placed to stop bleeding. Patients in control group scheduled for 3 follow up visits at 2, 6 and 12 weeks after surgery and for tampon removal at day 2 - 3 after FESS surgery.
11283162|NCT02812186|Other|Deep to Moderate NMB|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
11283163|NCT02812186|Other|Moderate to Deep NMB|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
11283164|NCT02812173|Active Comparator|suprapubic tube ex 2 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 2th day after the surgery
11283165|NCT02812173|Active Comparator|suprapubic tube ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 5th day after the surgery
11283166|NCT02812173|Active Comparator|transurethral catheter ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a transurethral catheter, which was withdrawn on the 5th day after the surgery
11283167|NCT02812160|Active Comparator|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
11283168|NCT02812160|No Intervention|Control|Dietary and Exercise counselling
11283191|NCT02811991|Placebo Comparator|Placebo:Normal Saline Injcetion|32.5mLor 50mL iv q6h according to assignment.
11283277|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
11283169|NCT02812147|Active Comparator|L-DOPS|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
11283170|NCT02812147|Placebo Comparator|Placebo|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
11283171|NCT02812134||anorexic|
11283172|NCT02812121|Experimental|Group MSC-1|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.
11283173|NCT02812121|Experimental|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.
11283174|NCT02812121|No Intervention|Group Control|Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis).
11283175|NCT02812108||HARET|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
11283176|NCT02812095|Experimental|The refeeding group|Refeeding is initiated when 120mL/kg/day of enteral feed reaches or stoma loss exceeds more than 40ml/kg/day after operation.
11283177|NCT02812095|No Intervention|The control group|
11283178|NCT02812082|Experimental|video web-based patient education application|This is a single-arm design. Development of the web-based application will occur over a 6 month period. Patient accrual will not occur until development of the program is complete. Controlled usability testing during the development/design process of the computer program will not be employed as we do not aim to assess the mechanics of patient use, but rather overall time spent interacting with the application in an uncontrolled environment. Following completion of the tool, patient accrual will occur over a six month time period in order to meet our target sample size of up to 50 participants. Participants will be directed to complete a pre-test questionnaire at the time of accrual and will have 3 months to use the program before being directed to complete the post-test questionnaire.
11283179|NCT02812069|Other|minor to moderate surgical procedure|The ThermaZone® Device will be used for 30 minutes to warm the cervical spine during
11283180|NCT02812056|Experimental|Alisertib + TAK-228|"Dose Escalation Phase:
~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.
~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.
~Dose Expansion Phase:
~Alisertib and TAK-228 taken at the maximum tolerated dose from Dose Escalation Phase."
11283181|NCT02812043|Experimental|Amorolfine|This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month
11283182|NCT02812043|Experimental|Long-pulsed Nd:YAG|This group of patients will receive only the long-pulsed Nd:YAG (Cynergy®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
11283183|NCT02812043|Experimental|Amorolfine+Long-pulsed Nd:YAG|This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
11283184|NCT02812030||aflibercept in real world|Patients receiving aflibercept for diabetic macular oedema at Bristol Eye Hospital or Gloucestershire Hospitals NHS Foundation Trust
11283185|NCT02812017|Experimental|1 - Intervention|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the Thirty Million Words-Well Baby intervention, which consists of educational, multimedia modules at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
11283186|NCT02812017|Placebo Comparator|2 - Neutral|The Neutral Video group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the neutral videos about car safety at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
11283187|NCT02812017|No Intervention|3 - Usual care|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will receive care as usual at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
11283188|NCT02812004|Experimental|Study Eye|Ultra Q Reflex YAG laser (Ellex)
11283189|NCT02812004|Sham Comparator|Contralateral Eye|Short light impulse is simulated
11283236|NCT02811731|Experimental|CKD-330|CKD-330 16/5mg - B, PO, 1days or 22days
11283192|NCT02811978|Experimental|Group 1 : Intravenous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib intravenously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
11283193|NCT02811978|Experimental|Group 2 : Subcutaneous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib subcutaneously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
11283194|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
11283195|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
11283196|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
11283197|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
11283198|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
11283199|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
11283200|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
11283201|NCT02811952||study group|Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
11283202|NCT02811952||control group|Patients that need cystoscopy due to others reasons than malignancy.
11283203|NCT02811939|Experimental|Active THC and Placebo Pregnenolone|
11283204|NCT02811939|Experimental|Active THC and Active Pregnenolone|
11283205|NCT02811939|Experimental|Placebo THC and Active Pregnenolone|
11283206|NCT02811939|Placebo Comparator|Placebo THC and Placebo Pregnenolone|
11283207|NCT02811926||Ileostomy or colostomy|Patients with a ileostomy or colostomy in the Capital Region of Denmark
11283208|NCT02811913|Other|High frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 5 Hz rTMS
11283209|NCT02811913|Other|Low frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 1 Hz rTMS
11283210|NCT02811913|Other|Sham rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was sham rTMS
11283211|NCT02811887|Active Comparator|Usual care|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic
11283212|NCT02811887|Experimental|SMS-messages|12 weeks of supervised physical exercise followed by usual care in the outpatient liver cirrhosis rehabilitation clinic + regular text messages via SMS over a 12-week period
11283213|NCT02811874|Experimental|diabetes education|Four community health workers receive a one-month diabetes education program (intervention group, patients n= 62)
11283214|NCT02811874|Active Comparator|education in other areas|Four community health workers receive an education course in other health issues (control group, patients n= 56).
11283215|NCT02811861|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily
11283216|NCT02811861|Experimental|Lenvatinib 20 mg plus pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks
11283217|NCT02811861|Active Comparator|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment
11283218|NCT02811848||Barbers|Barbers that service African American clientele mainly will be recruited for this study; there is no intervention.
11283219|NCT02811835||Renal Transplant Recipients|Renal Transplant Recipients that were more than 1 year post-transplantation
11283220|NCT02811835||Healthy Controls|Healthy subjects being evaluated as potential living kidney donors
11283221|NCT02811822|Experimental|Dose 1|
11283222|NCT02811822|Experimental|Dose 2|
11283223|NCT02811822|Experimental|Dose 3|
11283224|NCT02811822|Experimental|Dose 4|
11283225|NCT02811809|Experimental|Apalutamide + IHT|Participants will be treated with 240 mg (4-60 mg tablets) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently.
11283226|NCT02811809|Active Comparator|IHT only|Participants will receive 22.5 mg 3-month depot intramuscular leuprolide until PSA progression, then they will crossover to Apalutamide + IHT
11283227|NCT02811796||angio-based FFR estimation|The investigators will include all patients receiving successful coronary stent implantation. In these patients the investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
11283228|NCT02811783|Active Comparator|Naloxone Hydrochloride Lotion, 0.5%|Naloxone Hydrochloride Lotion 0.5%
11283229|NCT02811783|Placebo Comparator|Placebo Lotion|Placebo Lotion
11283230|NCT02811770||children with HSN|
11283231|NCT02811757|Experimental|tenodesis|
11283232|NCT02811757|Active Comparator|tenotomy|
11283233|NCT02811744|Experimental|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
11283234|NCT02811744|Other|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and LP and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
11283235|NCT02811731|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
11283237|NCT02811718|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
11283238|NCT02811718|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
11283239|NCT02811705||PFAPA group|Life quality for PFAPA patient report by themselves or parent
11283240|NCT02811705||FMF group|Life quality for FMF patient report by themselves or parent
11283241|NCT02811692||BAY86-5321|Anti-Vascular Endothelial Growth Factor (VEGF) - naive patients starting intravitreal Aflibercept injection treatment for Neovascular age-related macular degeneration (AMD), macular edema following Branch Retinal Vein Occlusion (BRVO), macular edema following central retinal vein occlusion (CRVO), and diabetic macular edema (DME)
11283242|NCT02811679|Experimental|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
11283243|NCT02811666|Experimental|Patients operated for liver or pancreas cancer|
11283244|NCT02811653|Experimental|Alzheimer disease|Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
11283245|NCT02811653|Active Comparator|control|"Healthy age- and gender-matched volunteers will be recruited into the study from the general population.
~Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation"
11283246|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
11283247|NCT02811627|Experimental|Memantine and Magnetic Resonance Imaging|"Subjects will be started on memantine post the imaging session.
~Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills). Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks."
11283248|NCT02811614|Experimental|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
11283249|NCT02811614|Experimental|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
11283250|NCT02811614|Active Comparator|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
11283251|NCT02811601|Experimental|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery
11283252|NCT02811588||Screening phase: normocapnic group|Normocapnic COPD patients
11283253|NCT02811588||Screening phase: hypercapnic group|Hypercapnic COPD patients
11283254|NCT02811588||Treatment phase: control group|Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.
11283255|NCT02811588||Treatment phase: non-invasive ventilation group|Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.
11283256|NCT02811575||Patients with diabetes|Patients with type 2 diabetes will have biopsy during coloscopy.
11283257|NCT02811575||Control|Patients without type 2 diabetes will have biopsy during coloscopy.
11283258|NCT02811562|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in manikin using fiberoptic bronchoscope
11283259|NCT02811562|Experimental|fiberoptic bronchoscope with pentax-airwayscope|Tracheal intubation in manikin using fiberoptic bronchoscope with pentax-airwayscope
11283260|NCT02811549|Experimental|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults who have severe to profound sensorineural hearing loss in one ear, and up to moderate sensorineural hearing loss in the other ear (asymmetric hearing loss).
11283261|NCT02811536||Diabetic retinopathy|Patients with various degrees of diabetic retinopathy
11283262|NCT02811536||Retinal detachment|Patients with a history of retinal detachment
11283263|NCT02811536||Retinal vein occlusion|Patients with a history of retinal vein occlusion
11283264|NCT02811536||Arterial hypertension|Patients with a history of arterial hypertension
11283265|NCT02811536||Carotid artery occlusion|Patients with a history of carotid artery occlusion
11283266|NCT02811536||Age related macular degeneration|Patients with a history of Age related macular degeneration
11283267|NCT02811536||Macroaneurysms|Patients with a history of retinal macroaneurysms
11283268|NCT02811536||Central serous chorioretinopathy|Patients with a history of central serous chorioretinopathy
11283269|NCT02811523|Experimental|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283270|NCT02811523|Experimental|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283271|NCT02811523|Experimental|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283272|NCT02811523|Experimental|Doxorubicin 11 mcg/ml|Doxorubicin 11mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283273|NCT02811523|Experimental|Doxorubicin 13 mcg/ml|Doxorubicin 13mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283274|NCT02811523|Experimental|Doxorubicin 15 mcg/ml|Doxorubicin 15mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283275|NCT02811523|Experimental|Doxorubicin 17 mcg/ml|Doxorubicin 17mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283276|NCT02811523|Experimental|Doxorubicin 20 mcg/ml|Doxorubicin 20mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
11283278|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
11283279|NCT02811497|Experimental|Azacitidine and Durvalumab|"Azacitidine will be given by mouth at a fixed dose of 300 mg daily for 14 consecutive days of every 28 day cycle for 3 cycles.
~Durvalumab will be given intravenously (by vein) at a fixed dose of 1500 mg (over 1 hour) on Day 1 of every 28 day cycle for 12 months or until disease progression."
11283280|NCT02811484|Other|Group 1|Insulin titration and behavioral therapy.
11283281|NCT02811484|Placebo Comparator|Group 2|Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.
11283282|NCT02811484|Experimental|Group 3|Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.
11283283|NCT02811458|Experimental|Transdiagnostic CBT|Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012)
11283284|NCT02811458|No Intervention|Treatment-as-usual|Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up.
11283285|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
11283286|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
11283287|NCT02811432|Experimental|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
11283288|NCT02811432|Active Comparator|Standard care|Incubator or radiant warmer
11283289|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
11283290|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
11283291|NCT02811406|Experimental|Receives IV albumin infusion|IV albumin 20% 50 mL for every 1L of ascitic fluid drained
11283292|NCT02811406|Placebo Comparator|Do not receive IV albumin infusion|No IV albumin infusion
11283293|NCT02811393||Bariatric surgery|Women who have been submitted to a Roux-en-Y Gastric Bypass Surgery for at least 2 years
11283294|NCT02811393||Unoperated|Women with similar characteristics to control group (age, body mass index, physical activity level), but they have not been submitted to bariatric surgery
11283295|NCT02811380|Experimental|BIP CVC|Bactiguard Infection Protection Central Venous Catheter
11283296|NCT02811380|Placebo Comparator|Uncoated standard CVC|Uncoated standard Central Venous Catheter
11283297|NCT02811367|Experimental|HPV self-test|Women will perform the HPV self-test.
11283298|NCT02811354|Experimental|AZD9291|Patient will be treated with AZD9291 at a starting dose of 80mg once a day until the patient completes the study, withdraws from the study or closure of the study. A cycle of treatment is defined as 28 days of once daily AZD9291 treatment. Patients may continue to receive AZD9291 until objective disease progression (determined by RECIST 1.1) or if the subject is no longer receiving clinical benefit in the Investigator's opinion.
11283299|NCT02811341|Placebo Comparator|A group|Using normal saline before pcle examination
11283300|NCT02811341|Experimental|B group|Using Scopolamine Hydrobromide before pcle examination
11283301|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
11283302|NCT02811289|Experimental|Mirabegron|Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.
11283303|NCT02811289|Active Comparator|Cold exposure|Cold exposure protocol using a water-conditioned cooling suit will be applied
11283304|NCT02811276|No Intervention|Control Group|Those assigned to the Control Group will receive a eucaloric diet (a diet designed to meet the person's energy needs and maintain body weight) composed of 55% of carbohydrate, 15% of protein, and 30% of lipid.
11283305|NCT02811276|Experimental|High-Protein Diet Group|Those assigned to the High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®).
11283306|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
11283307|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
11283308|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
11283309|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
11283310|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
11283311|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
11283312|NCT02811237|Other|HESTIA group|
11283313|NCT02811237|Other|sPESI group|
11283314|NCT02811224||Ovarian Cancer|
11283315|NCT02811224||Benign Neoplasm|
11283316|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
11283317|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
11283318|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
11283319|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
11283320|NCT02811185|Other|PET/CT Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
11283321|NCT02811185|Other|PET Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
11283322|NCT02811172||Healthy pregnant women|Healthy pregnant women
11283323|NCT02811172||Risk pregnant women|Hypertensive, obese and diabetic women
11283324|NCT02811159|Experimental|Telapristone Acetate 12 mg|Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).
11283325|NCT02811146|Experimental|Cardiopulmonary exercise testing|Assess whether people who wore noninvasive ventilation during aerobic exercise have greater functional capacity than those who did not wear.
11283326|NCT02811146|Experimental|ADL Glitre test|Check that people who wore noninvasive ventilation during aerobic exercise have greater submaximal functional capacity than those who did not wear. Compare a ventilatory metabolic response of the ADL Glitre test with an six-minute walk test. .
11283327|NCT02811146|Experimental|Minnesota Living with Heart Failure|Check if people undergoing heart rehabilitation has improved quality of life.
11283328|NCT02811146|Experimental|Bioimpedance balance|Check if people undergoing heart rehabilitation has improved the body composition.
11283329|NCT02811146|No Intervention|Six-minute walk test|Compare a ventilatory metabolic response of the six-minute walk test with an ADL Glitre test.
11283330|NCT02811146|Experimental|Metabolic ventilatory response|"To verify if non-invasive ventilation during aerobic exercise modifies the ventilatory metabolic response in patients with heart failure.
~Check the metabolic ventilatory response during the Glittre ADL test and six-minute walk test."
11283331|NCT02811133|Experimental|Inositol|Subjects will receive inositol
11283332|NCT02811120||single arm|single venepuncture
11283333|NCT02811107||Patients in preoperative area|Patients in preoperative area before surgery or interventional procedure will complete questionnaires on tablet computers
11283334|NCT02811094|Other|Adult patients with Systemic LupusErythematosus (SLE)|Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.
11283335|NCT02811081|Experimental|Control|Passive deflation of residual carbon dioxide
11283336|NCT02811081|Experimental|Normal Saline Instillation|Instillation of isotonic normal saline in the sub-diaphragmatic region
11283337|NCT02811081|Experimental|Combined Intervention|Normal Saline Instillation + Pulmonary Recruitment
11283338|NCT02811068||Venepuncture|Collection of single blood sample to assess antibody persistence over time
11283339|NCT02811055|Experimental|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
11283340|NCT02811055|Placebo Comparator|Administration of placebo|Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
11283341|NCT02811042|Active Comparator|Oropharyngeal leak pressure|Ambu AuraOnce
11283342|NCT02811042|Experimental|Fiberoptic position|Ambu AuraGain
11283343|NCT02811029|Experimental|premature infants less than 32 weeks of age|measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
11283344|NCT02811016|Experimental|budesonide 200|inhaled budesonide 200 µg bid
11283345|NCT02811016|Experimental|budesonide 800|inhaled budesonide 800 µg bid
11283346|NCT02811016|Placebo Comparator|placebo|inhaled placebo bid
11283347|NCT02811003|Experimental|Treatment|Treatment with Rotation Medical Bioinductive Implant
11283348|NCT02810990|Experimental|Bosutinib treatment|
11283349|NCT02810964|Experimental|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
11283350|NCT02810964|Placebo Comparator|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
11283351|NCT02810951|Experimental|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.
~In Phase II the study will target enrolling subjects (aged seven (7) or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.
~All subjects will receive FCX-007 into intact skin as well as to one or more paired target wounds at least one time during the study with a possible second administration pending laboratory results.
~One wound in each target wound pair will be used as control for efficacy and safety evaluations. FCX-007 administered wounds will be compared within paired target wounds to untreated wounds."
11283352|NCT02810925|Experimental|PENS T6 and 1200 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
11283353|NCT02810925|Active Comparator|PENST6 + Normocaloric 2000 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a normocaloric 2000 Kcal/day diet.
11283354|NCT02810925|Placebo Comparator|TENS T11/ T12 + 1200 Kcal/day diet|Patients undergo 12 sessions of transcutaneous electrical stimulation of dermatomes T11-T12 , weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
11283355|NCT02810925|Active Comparator|1200 Kcal/day diet|Patients follow only a hypocaloric 1200 Kcal/day diet.
11283356|NCT02810912||Supraglottic airway device-based anesthesia|Investigators planned to enroll 200 cases who will receive scheduled surgery under supraglottic airway device-based general anesthesia.
11283357|NCT02810899|Experimental|Dexmedetomidine group|A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
11283358|NCT02810899|Placebo Comparator|Control group|Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
11283359|NCT02810886|Experimental|Single, arm exploratory|Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
11283360|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
11283450|NCT02810236|Active Comparator|Ultrasound|Ultrasound recommended.
11283361|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
11283362|NCT02810860|Other|Open Label|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
11283363|NCT02810847|Experimental|I-BiT Plus|6 weeks of I-Bit treatment plus (at least 30 mins/day, 6 days/week)
11283364|NCT02810847|No Intervention|Control|Refractive adaption or observation
11283365|NCT02810834|Experimental|Walking/Running Program|Walking/running/jogging program; school-based.
11283366|NCT02810834|Experimental|Classroom activity break program|Classroom physical activity break program; school-based.
11283367|NCT02810834|No Intervention|Control|Control/Delayed Intervention
11283368|NCT02810821||male|
11283369|NCT02810821||female, premenopause|Women with regular menstrual cycles in normal range (22-35 days) for the previous three cycles.
11283370|NCT02810821||female, perimenopause|Women with variability in menstrual cycle length, defined as a persistent difference of 7 days or more in the length of consecutive cycles, or amenorrhea of at least 60 days but no longer than 12 months.
11283371|NCT02810821||female, postmenopause|Women with amenorrhea of at least 12 consecutive months.
11283372|NCT02810808|Experimental|Ranibizumab 0.5 mg 1+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab
11283373|NCT02810808|Active Comparator|Ranibizumab 0.5 mg 3+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.
11283374|NCT02810782|Experimental|Phenobarbital|Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
11283375|NCT02810782|Active Comparator|Chlorpromazine|Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
11283376|NCT02810782|Active Comparator|Morphine|Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
11283377|NCT02810769|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
11283378|NCT02810769|Experimental|Juiced berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
11283379|NCT02810769|Experimental|Powdered berry drink|Berry drink made up from a powdered concentrate. each drink will be standardised to contain 500mg of polyphenols
11283380|NCT02810756|Experimental|Treated patients|
11283381|NCT02810743|Active Comparator|ddAC-CP-Olaparib|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle
~CP; carboplatin/paclitaxel (CP) consisting of carboplatin (AUC 6) on day 1 and paclitaxel (80 mg/m2) on day 1,8 and 15 of a 21 days cycle. In total 4 courses of CP will be administered.
~Olaparib will be administered in Dutch centers only, as monotherapy for one year at a dose of 300 mg BID, starting 3 weeks after adjuvant radiotherapy, or, if radiotherapy is not indicated, 3-5 weeks after the last CP cycle.
~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
11283382|NCT02810743|Active Comparator|ddAC-mini CTC|"ddAC; doxorubicin 60 mg/m² as an i.v. bolus and cyclophosphamide 600 mg/m² as an i.v. bolus on day 1 every 2 weeks ddAC must be supported with prophylactic pegfilgrastim 6 mg s.c. given 24-48 hours after completion of administration of EVERY chemotherapy cycle
~intensified alkylating 'mini' CTC (2x) cyclophosphamide 3000 mg/m2 day 1 mesna 500 mg (push) + 2000 mg in 24 hours day 1 carboplatin (400 mg/m2; (or AUC=5 in patients with a calculated creatinine-clearance of <100 ml/min)) days 1,2 thiotepa 250 mg/m2 day 2
~Patients without a (near) pCR will receive adjuvant capecitabine at a starting dose of 1000-1250 mg/m2, twice a day, on days 1-14 every 3 weeks for eight cycles."
11283383|NCT02810730|Other|Single arm|Pancreatic MRI in the 6 months following the first consultation
11283384|NCT02810717|Experimental|active TBS|40 patients with TRD will receive active theta-burst stimulation using a MagPro X1000 between the two PET measurements
11283385|NCT02810717|Sham Comparator|sham TBS|40 patients with TRD will receive sham stimulation using a MagPro X1000 between the two PET measurements. After the second PET scan they will receive active TBS
11283386|NCT02810704|Experimental|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
11283387|NCT02810704|Experimental|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
11283388|NCT02810704|Experimental|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
11283389|NCT02810691|Active Comparator|Soluble fiber, dose #1|Soluble fiber supplementation with dose #1 (smaller dose) of psyllium fiber.
11283390|NCT02810691|Active Comparator|Soluble fiber, dose #2|Soluble fiber supplementation with dose #2 (bigger dose) of psyllium fiber.
11283391|NCT02810691|Placebo Comparator|Placebo|A 250 ml placebo solution of orange-flavored water will be drink at breakfast.
11283392|NCT02810678|No Intervention|Control|No Intervention: Program runs as per usual. Minimal interference and visits from study staff. Main study outcomes evaluated in first and last 6 months of trial. Minimal visits to collect information on costing at control sites.
11283491|NCT02809885|Experimental|Transplanted patients|All patients included are in the same arm.
11283393|NCT02810678|Active Comparator|Intervention|Latent Tuberculosis Infection program evaluation & diagnosis: In intervention health facilities the current Latent Tuberculosis Infection program will be evaluated and gaps in the Latent Tuberculosis Infection cascade of care will be identified. Gaps in the current cascade will be quantified and solution proposed that are unique to the problems identified in each site. In phase 2 of the study low cost solutions will be implemented and the Latent Tuberculosis Infection program scaled up and improved. Study outcomes are evaluated in the first and last 6 months of trial. Costing evaluations are done throughout the trial.
11283394|NCT02810665||Normal vision group|Individuals with VA 20/20 to 20/25
11283395|NCT02810665||Impaired vision group|Individuals with impaired vision: VA of 20/32 to 20/200 due to either cataract, diabetic macular edema, or age-related macular degeneration
11283396|NCT02810652|Experimental|Perioperative Geriatrics Intervention|Evaluation with a board-certified geriatric clinician, both pre- and post-operatively.
11283397|NCT02810652|Active Comparator|Standard Care|Usual care participants will not meet with a geriatric clinician perioperatively, but may receive a geriatric consult upon request or at the discretion of their treating clinician(s).
11283398|NCT02810626|No Intervention|Control|Control Group (surgical standard of care): Subjects 18 years and younger diagnosed with a pediatric brain tumor, and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
11283399|NCT02810626|Other|Interventional|Interventional Group (involvement of all BrightMatter™ products): Subjects 18 years and younger diagnosed with a pediatric brain tumor and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol and will be sent to the interventional technology (BrightMatter Bridge) for quality control. The QC'ed images will then be sent to a pre-operating planning software (BrightMatter Plan) for planning the surgical approach. Surgery will be carried out with guidance from the exported plan and the intra-operative neuro-navigation software, BrightMatter Guide, with the use of post-processing DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
11283400|NCT02810587||Topical antibiotics group|Those who receive topical antibiotics after intravitreous injection as home medication for 7 days.
11283401|NCT02810587||No topical antibiotics group|Those who does NOT receive topical antibiotics after intravitreous injection as home medication.
11283402|NCT02810574|Active Comparator|Active noninvasive brain stimulation and cognitive training|In active condition, subject will receive stimulation during all the 30-minute stimulation period combined with cognitive training.
11283403|NCT02810574|Sham Comparator|Sham noninvasive brain stimulation|In sham condition, subject will receive stimulation only during the first 30 seconds of the 30-minute stimulation period combined with cognitive training.
11283404|NCT02810548|Placebo Comparator|OFD alone|Control group: including 15 defects that will receive open flap debridement (OFD).
11283405|NCT02810548|Active Comparator|PRF + OFD|Test group (1): including 15 defects that will receive platelet rich fibrin (PRF) with open flap debridement (OFD).
11283406|NCT02810548|Active Comparator|Bone + OFD|Test group (2): including 15 defects that will receive nanohydroxyapatite bone graft with open flap debridement OFD).
11283407|NCT02810548|Active Comparator|PRF + Bone + OFD|Test group (3): including 15 defects that will receive nanohydroxyapatite bone graft with platelet rich fibrin (PRF) after open flap debridement (OFD).
11283408|NCT02810535|Active Comparator|Allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and positive prick test for house dust mite
11283409|NCT02810535|Experimental|Non-allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and negative prick test for house dust mite
11283410|NCT02810535|Other|Healthy Control|Clinical observation of 20 subjects without nasal symptoms and with negative prick test
11283411|NCT02810509||Short-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)
~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
~TTR evaluable days < 90 days"
11283412|NCT02810509||Long-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)
~long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment
~TTR evaluable days ≥ 90 days"
11283413|NCT02810496|Experimental|patient|
11283414|NCT02810483|Experimental|Arm 1: Topiramate|Topiramate Arrow 50 mg hard capsules
11283415|NCT02810483|Placebo Comparator|Arm 2: Placebo Comparator|50 mg hard capsules with the same shape, color and taste than the active product
11283416|NCT02810470|Experimental|Cream appreciation tests|
11283417|NCT02810470|Experimental|Beverages appreciation tests|
11283418|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:
~15 mg/kg IV infusion on Day 1 of each 21-day cycle.
~Drug: Paclitaxel:
~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
~Drug: Carboplatin:
~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
11283419|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|"Drug: Avastin:
~15 mg/kg IV infusion on Day 1 of each 21-day cycle.
~Drug: Paclitaxel:
~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.
~Drug: Carboplatin:
~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
11283420|NCT02810444|Experimental|BT595|Patients will receive BT595 according to their usual regime treatment every 3 or 4 weeks
11283421|NCT02810418|Experimental|Arm A1 (Phase 1, short infusion)|MTD determination in patients with pancreaticcancer receiving short infusion LMB-100+nabpaclitaxel
11283422|NCT02810418|Experimental|Arm A2 (Phase 2, short infusion)|efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel
11283644|NCT02808871|Experimental|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
11283423|NCT02810418|Experimental|Arm B1 (Continuous infusion single agent leadin)|MTD determination in patients with pancreatic cancer receiving contious infusion LMB-100 as single agent
11283424|NCT02810418|Experimental|Arm B2 (continous infusion combination therapy)|Up to 6 subjects with pancreatic cancer meeting nab- paclitaxel eligibility criteria, followed by an additional 4 subjects if safety is established.
11283425|NCT02810405||Patient Samples|Patients treated at NCI with available tissue samples
11283426|NCT02810392|Active Comparator|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
11283427|NCT02810392|Placebo Comparator|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
11283428|NCT02810379|Placebo Comparator|written informed consent|participants read the written informed consent documents befor ERCP
11283429|NCT02810379|Experimental|video+written informed consent|participants watch a video about the ERCP and read the written informed consent documents before ERCP
11283430|NCT02810366|Active Comparator|Physician Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the electronic Verbal Autopsy (eVA) instrument.
~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a short checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness, followed by a free-text narrative.
~Cause of death for these VAs will be assigned by trained physicians using the MDS physician coding system; this includes dual, independent coding of VA records, disagreements resolved by reconciliation, and remaining cases by adjudication by a third physician. The assignment of cause of deaths will be in line with the international classification of disease version 10 (ICD-10)."
11283431|NCT02810366|Experimental|Computer Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the Extended Symptom List (ESL) VA instrument.
~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a long checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness. This VA instrument does not contain a free-text narrative.
~The cause of death for these VAs will be independently assigned by five leading computer-coding VA algorithms. The assignment of cause of deaths will be in line with 17 broad cause of death categories."
11283432|NCT02810353|Experimental|Expander with differential opening group|The experimental group will comprise 25 patients who will be submitted to rapid maxillary expansion using the expander with differential opening. The expander will be composed by two 11-mm screws, one anteriorly and the other posteriorly positioned on the palate (Great lakes Orthodontics Ltd, NY, EUA).
11283433|NCT02810353|Active Comparator|Hyrax group|The control group will be comprised by 25 patients who will undergo rapid maxillary expansion using the conventional Hyrax expander. The expander will be composed by one 11-mm screw centrally positioned on the palate (Dentaurum, Ispringen, Germany).
11283434|NCT02810340|Experimental|MCV-5 with adjuvant|MCV-5 adjuvanted with Alum administered as a single IM injection, each dose contains 5 micrograms of each of meningococcal polysaccharide A, C, Y, W, and X, along with 125 micrograms of Alum adjuvant
11283435|NCT02810340|Experimental|MCV-5 without adjuvant|MCV-5 without adjuvant administered as a single IM injection, each dose contains 5 micrograms of each of meningococcal polysaccharide A, C, Y, W, and X
11283436|NCT02810340|Active Comparator|Menactra|Menactra administered as a single IM injection, each dose contains 4 micrograms of each of meningococcal polysaccharide A, C, Y, and W
11283437|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
11283438|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
11283439|NCT02810314|Experimental|Clinical measures|MS patients recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works for each group and all MS patients will also complete a comprehensive neuropsychological battery including cognitive and behavioural tests of interest in MS
11283440|NCT02810314|Other|Control measures|Healthy participants recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works
11283441|NCT02810301|Experimental|Treatment (Probiotic ES1)|Capsules containing 1 billion CFU of B. longum ES1 per capsule. One capsule taken before and after consuming 2 slices of bread for 7 days.
11283442|NCT02810301|Placebo Comparator|Placebo|Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
11283443|NCT02810288||Expert|Anaesthesiologist with large paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
11283444|NCT02810288||Non-experts|Anaesthesiologist with little paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
11283445|NCT02810275|Experimental|Folinic Acid|Folinic acid group received 5 mg daily during four weeks
11283446|NCT02810275|Placebo Comparator|Placebo|Placebo group received a tablet daily during four weeks
11283447|NCT02810262||First bone metastasis of adenocarcinoma lung cancer|Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.
11283448|NCT02810249||African American YMSM|
11283449|NCT02810236|Active Comparator|No ultrasound|No ultrasound recommended. Discussion with radiologist.
11283451|NCT02810223|Experimental|Single dose of CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
11283452|NCT02810210||Cohort 1|Monitoring of children born without congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
11283453|NCT02810210||Cohort 2|Monitoring of children born with congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
11283454|NCT02810210||Cohort 3|Monitoring of children born without congenital anomalies to mothers with no biologically confirmed ZIKV's infection during the pregnancy
11283455|NCT02810197|Experimental|Exposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
11283456|NCT02810197|Experimental|unexposed group|Psychopathological assessment Neuropsychological assessment Functional magnetic resonance imaging (fMRI)
11283457|NCT02810184|Other|CBCT arm|all participating patients receive an additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
11283458|NCT02810171|Active Comparator|Cognitive Behavioral Therapy|
11283459|NCT02810171|Other|Relaxation Therapy|
11283460|NCT02810171|No Intervention|No Intervention: Healthy youth only|Healthy control participants, matched to gender and age with anxiety patients, will be enrolled. These healthy participants will be scanned with fMRI before and after ~16 weeks, but without any intervention (i.e., no therapy).
11283461|NCT02810158||Patients with suspected OSA|Persons with clinical suspicion of obstructive sleep apnoea syndrome (OSA)
11283462|NCT02810145||TBI with GCS <or= 8|Adult patients admitted to the surgical intensive care unit with traumatic brain injury and a Glasgow coma score less than or equal to 8.
11283463|NCT02810132|Active Comparator|Metformin|Drug: Metformin Target dose: 1000 mg x 2 (if eGFR 30-60 ml/min: 500 mg x 2) Other name: Glucophage XR 500
11283464|NCT02810132|Placebo Comparator|Placebo|Drug: Placebo
11283465|NCT02810119|Experimental|LO2A|Sodium Hyaluronate
11283466|NCT02810119|Placebo Comparator|Placebo-Controlled Saline|Placebo
11283467|NCT02810093||Breast cancer patients between 2000 and 2016|Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
11283468|NCT02810067|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
11283469|NCT02810067|Experimental|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
11283470|NCT02810054|Sham Comparator|Control Group (MIST without EMD)|Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .
11283471|NCT02810054|Experimental|Test Group (MIST with EMD)|Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .
11283472|NCT02810041|Experimental|yoghurts enriched with XXS|
11283473|NCT02810041|Placebo Comparator|yoghurts non enriched with XXS|
11283474|NCT02810028|Experimental|ACT + Standard Medical Care (SMC)|This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
11283475|NCT02810028|No Intervention|Standard Medical Care (SMC)|All participants will receive SMC. As such, they will receive all the treatment and support they would otherwise receive outside of a research trial including a personalised assessment from the physiotherapist.
11283476|NCT02810015|Experimental|Botulinum Toxin A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
11283477|NCT02810002|Experimental|DEFINITE-REGULATOR|Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel
11283478|NCT02810002|Active Comparator|modified Belleville 390 TROP|Standard issue infantry boot
11283479|NCT02809989||Ovaleap®|Single group prospective treatment cohort
11283480|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
11283481|NCT02809963|Active Comparator|Eplerenone|Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
11283482|NCT02809963|Placebo Comparator|placebo|sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
11283483|NCT02809950|Experimental|oral carbohydrate beverage group|
11283484|NCT02809950|Placebo Comparator|control group|
11283485|NCT02809937|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
11283486|NCT02809937|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
11283487|NCT02809924|Experimental|Simulation-based just-in-time training|Viewing a short video showing the neonatal glottis of similar gestational age to the patient that is being intubated followed by practice on a mannequin (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada) with supervision and feedback from a senior provider (low fidelity simulation).
11283488|NCT02809924|Active Comparator|Video training|5 minutes video regarding endotracheal intubation
11283489|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
11283490|NCT02809911|Other|Active Provant|Active Provant Treatment
11283645|NCT02808871|Placebo Comparator|Placebo|Placebo for 52 weeks
11283492|NCT02809872||Study Group|Study Group with Pleural effusion for any cause and receiving chest CT scan and thoracic Ultrasounds.
11283493|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
11283494|NCT02809846|Active Comparator|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
11283495|NCT02809846|Sham Comparator|Sham Quell Device|Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.
11283496|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
11283497|NCT02809820|Active Comparator|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
11283498|NCT02809820|Active Comparator|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
11283499|NCT02809807|Experimental|Baseline|Without a gas mask. We measure baseline respiratory index, parameters and the comfort.
11283500|NCT02809807|Experimental|Assessment with gas mask and canister A|With a gas mask, the measurement have been done with a high resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
11283501|NCT02809807|Experimental|Assessment with gas mask and canister B|With a gas mask, the measurement have been done with a low resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
11283502|NCT02809794|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
11283503|NCT02809781|Experimental|Intravenous infusion of MSCs|Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
11283504|NCT02809781|Active Comparator|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
11283505|NCT02809768|Experimental|Avatrombopag plus fluconazole|Part A: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, fluconazole (400-mg) will be administered once daily on Days 1 to 16, and a single dose of avatrombopag (20-mg) on Day 7 in Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
11283506|NCT02809768|Experimental|Avatrombopag plus itraconazole|Part B: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, itraconazole (200-mg) will be administered twice daily on Day 1 and 200-mg once daily on Days 2 to 16. A single dose of avatrombopag (20-mg) will be administered on Day 7 of Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
11283507|NCT02809768|Experimental|Avatrombopag plus rifampin|Part C: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, rifampin (600-mg) will be administered once daily on Days 1 to 16. In order to avoid a food-effect on rifampin absorption, each dose will be administered 1 hour before participants consume a meal. On Day 7 of Treatment Period 2, rifampin (600-mg) and avatrombopag (20-mg) will be administered 1 hour before meal and 30 minutes after starting meal consumption.
11283508|NCT02809755|Experimental|4% lidocaine|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
11283509|NCT02809755|Placebo Comparator|Placebo Saline|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
11283510|NCT02809742||Epidural group|Epidural : automatic intermittent boluses ( 8-12 mL per hour) + patient controlled bolus (4 mL evrey 20 min) using ropivacaine
11283511|NCT02809729|Placebo Comparator|placebo|The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction
11283512|NCT02809729|Active Comparator|cefazolin|The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction
11283513|NCT02809716||Ancillary-Correlative (blood and tumor tissue collection)|Patients undergo collection of blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo and tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including, whole-genome CNV profiles, protein expression, and cell morphology.
11283514|NCT02809690|Experimental|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
11283515|NCT02809677|Other|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
11283516|NCT02809651|Experimental|Ischemic stroke|patients suffering from ischemic stroke diagnosed by clinical examination and CT-scan
11283517|NCT02809651|Experimental|Brain tumor|patients diagnosed with a brain tumor diagnosed by clinical examination and CT-scan or MRI
11283518|NCT02809651|Experimental|Brain surgery|patients that have undergone brain surgery
11283519|NCT02809651|Active Comparator|Intracranial hemorrhage|patients with intracranial hemorrhage diagnosed by clinical examination and CT-scan
11283520|NCT02809651|Experimental|Headache|patients with headache complaints and a normal CT-scan of the brain
11283521|NCT02809651|Experimental|Headtrauma|patients with head trauma and a normal CT-scan of the brain
11283522|NCT02809638||DVT of the lower limbs|patients with first suspected episode of unprovoked DVT of the lower limbs and patients with episode of unprovoked DVT of the lower limbs at third month of follow-up
11283553|NCT02809378|Experimental|Sevoflurane|anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
11283523|NCT02809612|Experimental|Internet-based intervention|"Patients randomized to the internet-based intervention will be given access to the information in the internet-based platform directly after randomization. During the first 6 weeks, information will be offered in a structured way, with a theme changing weekly. After this time-point, the patients will have the possibility to navigate through all information. The platform encompasses internet-based training including information on the disorder, psycho-education and information of simple self-implemented intervention strategies cope with vulvodynia and ameliorate dyspareunia. The platform will also include videos where team members will describe their role in treating patients with the disorder, but also short videos from former patients willing to share their individual stories."
11283524|NCT02809612|No Intervention|Control group|Patients randomized to the control group through the platform will immediately be informed about the fact that there is available information and resources on the internet and that they will be called for a visit to the physiotherapist-midwife at due time, according to the present guidelines of care followed in the respective clinic (Uppsala, Falun, Gävle).
11283525|NCT02809599|No Intervention|Pre-intervention|Patients in hospitals that have not received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess BPPV processes at the ED Index visit. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
11283526|NCT02809599|Experimental|Post-intervention|Patients in hospitals that have received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess the main study outcome, behavior change in medical providers. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
11283527|NCT02809586|Active Comparator|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
11283528|NCT02809586|Active Comparator|SMI|A Social Media Intervention (SMI) condition
11283529|NCT02809586|No Intervention|Control|An Attention-Control E-News (CONTROL) condition
11283530|NCT02809573|Experimental|study drugs|Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.
11283531|NCT02809560|Experimental|Asthmatic children|Induced sputum method using hypertonic serum
11283532|NCT02809560|Sham Comparator|Control children|Induced sputum method using hypertonic serum
11283533|NCT02809547|Active Comparator|In Clinic monitoring|70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
11283534|NCT02809547|Experimental|At Home monitoring|30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.
11283535|NCT02809534|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11283536|NCT02809521|Other|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
11283537|NCT02809508|Experimental|Oily fish|
11283538|NCT02809508|Experimental|Poultry (control)|
11283539|NCT02809495||Patients who will use the clinical application|
11283540|NCT02809495||Patients who do not make use of clinical application|
11283541|NCT02809482|Other|Eucaloric Feeding|
11283542|NCT02809482|Other|Overfeeding|
11283543|NCT02809469|Experimental|Dose reduction|Eligible patients with apixaban levels persistently above 170ng/mL on two occasions, 2 weeks apart, will undergo apixaban dose reduction.
11283544|NCT02809456|Experimental|Nicorandil|Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral. Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
11283545|NCT02809456|Active Comparator|observation|regular radiotherapy as our protocol
11283546|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
11283547|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
11283548|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
11283549|NCT02809417||LICORNE platform|
11283550|NCT02809417||Control|
11283551|NCT02809391|Active Comparator|Orthotic|Recruited participants will be asked to wear the customizable foot orthotic, from baseline testing to a follow-up at 6 weeks post-baseline. Outcome measures at 6 weeks will be compared to those at baseline.
11283552|NCT02809391|Active Comparator|Orthotic+Textured Top Cover|At 6 weeks post-baseline, participants will received a different orthotic which has a textured material used as its top cover. Testing at 6 weeks post-baseline will determine if acute changes occur as a result of wearing the orthotic with textured top cover. Testing at 12 weeks post-baseline will determine if long-term changes occur as a result of the orthotic with textured top cover.
11283554|NCT02809378|Experimental|sevoflurane, remifentanil, and propofol|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
11283555|NCT02809378|Experimental|Sevoflurane, remifentanil, propofol, and palonosetron|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
11283556|NCT02809365|Other|Libre|FreeStyle Libre users: FreeStyle Libre Flash Glucose Monitoring System is an interstitial glucose monitoring system intended to be replacement for the capillary blood glucose measurement. The system contains several features that distinguish it from exiting sensor technology including no user calibration during 14 days of wear. The sensor is applied to the upper arm of the patient and the hand-held reader is used to scan the sensor to receive glucose result along with historic results with a 15 min frequency for up to 8 hours.
11283557|NCT02809365|Other|SMBG|Self monitoring blood glucose: patients in this arm will measure blood glucose with personal glucometer
11283558|NCT02809352||women tested positive for hrHPV|All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
11283559|NCT02809339||Epithelial ovarian cancer|
11283560|NCT02809326|Experimental|17 week Trauma Management Therapy (TMT)|TMTconsists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups. Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy. Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
11283561|NCT02809326|Experimental|3 week Trauma Management Therapy (TMT)|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
11283562|NCT02809326|Active Comparator|17 week Exposure Therapy Control Arm|The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
11283563|NCT02809313|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct probiotic containing one sachet Lactobacillus rhamnosus per day during 3 month
11283564|NCT02809313|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct placebo containing one sachet placebo (talc power) per day during 3 month
11283565|NCT02809300|Experimental|ankylosing spondylarthritis|
11283566|NCT02809287||study group|patients with left lateral position plus jackknife posture when perform laparoscopic hepatectomy
11283567|NCT02809274||Patients with PV, not newly diagnosed|"Patients with clinically overt PV treated with watchful waiting (with or without aspirin), Phlebotomy (PHL), Hydrea or any other treatment.
~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
11283568|NCT02809274||Newly diagnosed patients with PV|"Patients with clinically overt PV, newly diagnosed, before any treatment and before phlebotomy initiation.
~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
11283569|NCT02809261|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
11283570|NCT02809261|Placebo Comparator|Perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.
11283571|NCT02809248|Active Comparator|coated stent|the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
11283572|NCT02809248|Active Comparator|uncoated stent|the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
11283573|NCT02809235|Experimental|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
11283574|NCT02809222|Other|Patients with MDS at diagnosis|The intervention, specific to the study, is to take blood samples on patients with MDS at diagnosis. A quality of life questionnaire will also be used to monitor patients
11283575|NCT02809222|Other|Patients with MDS in treatment|The intervention, specific to the study, is to take blood samples on patients with MDS receiving treatment. A quality of life questionnaire will also be used to monitor patients
11283576|NCT02809222|Other|Healthy volunteers|The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
11283577|NCT02809196|Active Comparator|1: Tailored, friend and mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Friend and mother are invited to participate."
11283578|NCT02809196|Active Comparator|2: Standardized, friend and mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Friend and mother are invited to participate."
11283622|NCT02808988|Active Comparator|group B|periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection
11284576|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of D5W
11283579|NCT02809196|Active Comparator|3:Tailored, friend and not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Friend is invited to participate but not mother."
11283580|NCT02809196|Active Comparator|4: Standardized, friend and not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Friend is invited to participate but not mother."
11283581|NCT02809196|Active Comparator|5:Tailored, mother and not friend|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Mother is invited to participate but not friend."
11283582|NCT02809196|Active Comparator|6: Standardized, mother and not friend|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Mother is invited to participate but not friend."
11283583|NCT02809196|Active Comparator|7:Tailored, not friend, not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.
~Neither friend nor mother is invited to participate."
11283584|NCT02809196|Active Comparator|8: Standardized, not friend, not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.
~Mother is invited to participate but not friend. Neither friend nor mother is invited to participate."
11283585|NCT02809196|Other|9: No SMS program|Control Group; no SMS-based educational program
11283586|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
11283587|NCT02809183|Experimental|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
11283588|NCT02809183|Experimental|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
11283589|NCT02809183|Experimental|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
11283590|NCT02809183|Experimental|TRC101 (6g QD)|Administered once daily (QD) for 14 days
11283591|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
11283592|NCT02809170|Active Comparator|Arginine|Endothelial function will be assessed before and after arginine supplementation
11283593|NCT02809170|Active Comparator|Citrulline|Endothelial function will be assessed before and after citrulline supplementation
11283594|NCT02809144|Other|Nerve block|One novel nerve block combination
11283595|NCT02809131|Experimental|Saline irrigation|Saline irrigation
11283596|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
11283597|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
11283598|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
11283599|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
11283600|NCT02809105|Experimental|Part I ASP0456|ASP0456 will be administered orally for 4 weeks.
11283601|NCT02809105|Placebo Comparator|Part I Placebo|Placebo will be administered orally for 4 weeks.
11283602|NCT02809105|Experimental|Part II ASP0456|ASP0456 will be administered orally.
11283603|NCT02809092|Experimental|NK Cells + Chemotherapy Starting|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.
~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
11283604|NCT02809079|Experimental|Mycophenolate mofetil plus prednisone|Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd
11283605|NCT02809066|Experimental|Interventional group|8-week follow- up with dietary sufficient calcium intake
11283606|NCT02809066|No Intervention|Control group|8-week follow- up with no specific diet
11283607|NCT02809053|Experimental|SAIT101|
11283608|NCT02809053|Active Comparator|MabThera®|
11283609|NCT02809040||Hypertensive Heart Disease|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
11283610|NCT02809040||Volunteer subjects|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
11283611|NCT02809040||Diagnosed Hypertension|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
11283612|NCT02809027|Active Comparator|Ginger|Ginger capsule (500 mg), oral form, 2 capsules 3 time after meal for 3 days
11283613|NCT02809027|Sham Comparator|Placebo|Placebo capsule, oral form, 2 capsules 3 time after meal for 3 days
11283614|NCT02809014|Placebo Comparator|Placebo|Dentifrice without fluoride and tara gum.
11283615|NCT02809014|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
11283616|NCT02809014|Placebo Comparator|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
11283617|NCT02809014|Experimental|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
11283618|NCT02809014|Experimental|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
11283619|NCT02809001|Experimental|Experimental: Fat grafting|Autologous fat graft transplantation subdermally to expanded skin.
11283620|NCT02809001|No Intervention|Control|Expansion was discontinued until the early signs of complication disappeared.
11283621|NCT02808988|Active Comparator|group A|periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
11284668|NCT02801682||Bacterial Sepsis (Bacteremia)|
11283623|NCT02808988|Active Comparator|group C|no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
11283624|NCT02808988|Active Comparator|group D|no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection
11283625|NCT02808975|Placebo Comparator|Placebo|"Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week
~Period B: Weeks 13-14- 1 SC injection each week
~Period C: Weeks 15-23- 1 SC injection each week"
11283626|NCT02808975|Active Comparator|Adalimumab|"Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week
~Period B: Weeks 13-14- 1 SC 40 mg injection each week
~Period C: Weeks 15-23- 1 SC 40 mg injection each week"
11283627|NCT02808962|Other|Cooled Radiofrequency Ablation|"This is a single arm, prospective observational study. All subjects enrolled are patients that meet the inclusion criteria, as deemed by a physician.
~Typical standard of care for these patients is an initial visit followed by two diagnostic blocks ((0.5ml) of 1% Lidocaine per level). Subjects are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve."
11283628|NCT02808949|Experimental|Age Groups|Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
11283629|NCT02808936|Experimental|RIPC group|remote ischemic conditioning group with three cycles of ischemia (5 min) / reperfusion (5 min) of upper or lower limb available with automated RIPC machine using blood pressure cuff
11283630|NCT02808936|Sham Comparator|Control group|No remote ischemic conditioning, but blood pressure cuff applied to the upper or lower limb available
11283631|NCT02808923|Experimental|Foam rolling|"Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6 diameter x 36 length."
11283632|NCT02808923|Experimental|Static stretching|Participants in the static stretching group will perform sustained static hamstring stretching for 2 repetitions of 1 minute bouts for the same leg before switching sides using moderate pressure in supine against the wall. Subjects will rest for 15 seconds between repetitions and adjust distance from the wall to perceive moderate intensity.
11283633|NCT02808923|No Intervention|Control|The control group will perform their regular baseline activities without the addition of a specific lower extremity flexibility program. If the subjects are currently performing stretching of any mode at baseline, they will be allowed to continue with that activity.
11283634|NCT02808910|Experimental|Salt nudge|The following changes will be made in the cafeteria: Salt will be placed in a corner of the buffet, rather than on each dining table. Other spices, without sodium, will be provided on the table. A sign will be placed on the table that nudges participants to try the other spices. Food in the buffet that is high in salt will be labeled with a negative-appearing symbol, and food in the buffet that is low in salt will be labeled with a positive symbol.
11283635|NCT02808910|Experimental|Vegetable nudge|The following changes will be made in the cafeteria: Names of the vegetable dishes in the buffet will be made more attractive. Signs will be placed with reminders to eat more vegetables. Signs will be placed with a visual indication of the percentage of a meal that should consist of vegetables.
11283636|NCT02808910|Experimental|Portion size nudge|The following changes will be made in the cafeteria: Smaller plates will replace the regular plates. Verbal and visual nudges to reduce portion size will be given. Utensils for self-serving calorie-dense foods in the buffet will be smaller than normal.
11283637|NCT02808910|Experimental|Combined nudge|All three nudges are combined in this intervention.
11283638|NCT02808910|No Intervention|Control groups|No changes are made to the cafeteria, compared to the pre-study situation. One control group participates after each of the nudges to control for effects of time of the year.
11283639|NCT02808897|Active Comparator|Standard drainage|The control arm consist of consecutively enrolled cardiac surgery patients receiving < four (4) commercially available standard chest tubes.
11283640|NCT02808897|Experimental|Active Clearance Technology drainage|The test arm consists of consecutively enrolled cardiac surgery patients receiving < two (2) PleuraFlow® chest tubes with Active Clearance Technology® and < two (2) other commercially available standard chest tubes.
11283641|NCT02808884|Experimental|Circulating tumor DNA assay- First test - Negative result|Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
11283642|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Negative result|Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
11283643|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Positive result|Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.
11283646|NCT02808845||microalbuminuria with eGFR≥60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
11283647|NCT02808845||normal-albuminuria group with eGFR≥60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
11283648|NCT02808845||microalbuminuria group with eGFR<60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
11283649|NCT02808845||normal-albuminuria group with eGFR<60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
11283650|NCT02808832|Experimental|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
11283651|NCT02808832|No Intervention|Usual care|Usual care
11283652|NCT02808819|Other|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
11283653|NCT02808819|Other|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
11283654|NCT02808806|Active Comparator|real-time audio-visual feedback|real-time audio-visual feedback to caregivers (i.e. both in- and outside the hospital) bringing the patient to the location where IVT/IAT is administered . The real time audio-visual feedback consists in information on the actual TSD for a particular patient and whether or not this exceeds pre-set median time delay. The feedback is provided by handhelds in the ambulance and by pre-set monitors on different locations in the participating hospitals.
11283655|NCT02808806|No Intervention|regular care|no real-time audio-visual feedback
11283656|NCT02808793|Experimental|AK002|IV dose of AK002
11283657|NCT02808780||Simponi-exposed cohort|Participants receiving Simponi at enrollment and are still receiving Simponi after participation in a therapeutic trial or participants scheduled to receive Simponi within 30 days after enrollment. Participants in this cohort may be receiving Simponi alone or in combination with thiopurines but must not be receiving other approved biologics or investigational agents at enrollment. Participants may have received other approved biologics or investigational agents prior to enrollment.
11283658|NCT02808780||comparator cohort|Participants currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry. Participants must not be receiving approved biologic agents, including Simponi, or investigational agents at enrollment. These patients may have received biologics other than Simponi or investigational agents prior to enrollment.
11283659|NCT02808767|Experimental|Patients treated with Prasugrel|Prasugrel Loading dose: 60 mg Maintenance dose: 10 mg once-daily; patients >75 years of age or < 60 kg of weight receive a maintenance dose of 5 mg o.d.
11283660|NCT02808767|Experimental|Patients treated with ticagrelor|Ticagrelor Loading dose: 180 mg Maintenance dose: 90mg twice-daily
11283661|NCT02808754|No Intervention|Usual Care|Patients in the usual care arm will undergo CEA without RIPC.
11283662|NCT02808754|Experimental|Remote Ischemic Preconditioning|Patients in the RIPC arm will undergo CEA with RIPC.
11283663|NCT02808741|Experimental|F901318 SDD|Liquid formulation
11283664|NCT02808741|Experimental|F901318 IR|Solid formulation
11283665|NCT02808741|Experimental|F901318 IR Fasting|Fasting solid formulation
11283666|NCT02808741|Experimental|F901318 IR Fed|Fed solid formulation
11283667|NCT02808728|Active Comparator|Pain Cocktail with Ropivacaine|"patients given the standard intra-articular pain cocktail injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
~given in one single dose"
11283668|NCT02808728|Experimental|Pain Cocktail with Exparel|"patients given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel, 20cc of 1.3% Exparel, to total 100cc.
~given in one single dose"
11283669|NCT02808702|Experimental|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
11283670|NCT02808689|Active Comparator|Asthma Center|"Use of Currently Accepted Asthma Care Guidelines:
~Assessment and monitoring: the use of objective measures of lung function to assess severity of asthma and to monitor the course of therapy,
~Control of factors contributing to symptom exacerbation: environmental control measures to avoid or eliminate factors that precipitate asthma symptoms or exacerbations,
~Pharmacotherapy: comprehensive pharmacologic therapy for long-term management, and
~Education for partnership in care: patient education that fosters a partnership among the patient, his/her family, and clinicians."
11283671|NCT02808689|Active Comparator|Asthma Center plus Functional Medicine|"All the factors in the Asthma Center Arm plus:
~Address lifestyle factors such as nutrition and exercise that influence long-term health and chronic diseases. The intention is to reduce ongoing biologic imbalances from deficiencies in dietary oxidants/antioxidants via vitamin supplementation, hormonal imbalances through evaluation and management, and the need for medications with unwarranted side effects that compound the chronic medical conditions and adverse effects (e.g. excess use of antibiotics), and to systematically evaluate intolerances to certain foods and additives."
11283672|NCT02808676|Experimental|Exercises+CognitiveTraining+Vitamin D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks."
11283673|NCT02808676|Experimental|Exercises+CognitiveTraining+Placebo D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks."
11283674|NCT02808676|Experimental|Exercises+Control CogTraining+Vitamin D3|Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
11283675|NCT02808676|Experimental|Exercises+Control CogTraining+Placebo D3|Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
11284669|NCT02801682||ICU patients without infectious disease|
11283676|NCT02808676|Placebo Comparator|Placebo exercise+Control Cog+Placebo D3|This will be the comparator arm with control/placebo activities.
11283677|NCT02808663|Experimental|Severe Alcoholic Hepatitis|
11283678|NCT02808650|Experimental|Treatment (prexasertib)|Patients receive prexasertib IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11283679|NCT02808637|Experimental|Manual Pressure|
11283680|NCT02808637|Experimental|Rapid Injection without Aspiration|
11283681|NCT02808637|Experimental|Manual Pressure + Rapid Injection without Aspiration|
11283682|NCT02808637|Experimental|Control|
11283683|NCT02808624|Experimental|Treatment group|this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
11283684|NCT02808624|No Intervention|Control group|This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
11283685|NCT02808611|Active Comparator|Propranolol|Propranolol is a beta-blocker
11283686|NCT02808611|Placebo Comparator|Placebo|Placebo
11283687|NCT02808598|Experimental|Clinical Trials Education Program|Breast Cancer Clinical Trials Education program is offered to women in the experimental arm. This program was designed to promote increased clinical trials literacy among African American and Hispanic American women. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among these two groups of women who are traditionally underrepresented in breast cancer clinical trials.
11283688|NCT02808598|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of African American and Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
11283689|NCT02808585|Experimental|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
11283690|NCT02808585|Experimental|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
11283691|NCT02808585|Experimental|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
11283692|NCT02808585|Experimental|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
11283693|NCT02808585|Placebo Comparator|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
11283694|NCT02808572|Experimental|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
11283695|NCT02808559|Experimental|Bodystudio ATBM|The PASI of the patients will be evaluated by two dermatologists then by the bodystudio ATBMs.
11283696|NCT02808546||Case Group|All the patients who were diagnosed as gallbladder stone disease with definite clinical symptoms and underwent cholecystectomy in Cheju Halla General Hospital, Jeju, Korea during 2009-2013
11283697|NCT02808546||Control Group|Control group was determined as 1:1 age-sex matched subjects selected from the participants without GBS among Health Promotion Center in the same institute and periods.
11283698|NCT02808533|Experimental|Topiramate|Topiramate will be dispensed on a biweekly basis, and pill counts conducted at each visit.
11283699|NCT02808533|Placebo Comparator|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
11283700|NCT02808520||Hodgkin-lymphoma|Children and adolescents aged 10-18 years
11283701|NCT02808507|Experimental|Facility-based screening|This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
11283702|NCT02808507|Experimental|Contact screening|"This arm is comprised of two sub-arms:
~In the household contact screening sub-arm, a mobile field team visits the household of each consenting newly diagnosed pulmonary TB index case. Each visit consists of a household census, consent of all eligible household members for TB screening, administration of a brief questionnaire, sputum collection for testing with Xpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) and the offer of HIV testing.
~In the incentive-based contact screening sub-arm, all consenting newly diagnosed active TB cases are provided with 10 coupons for free TB screening to give to close contacts. When a contact presents at clinic with a coupon, they and the index case each receive a small amount of money. If the contact is diagnosed with active TB and starts treatment, the index case receives an additional larger amount of money. Each contact receives a brief questionnaire, TB symptom screen, optional HIV testing, and sputum sample collection for Xpert MTB/RIF."
11283703|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia or fetal growth restriction.
11283704|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia or fetal growth restriction.
11283705|NCT02808468|Active Comparator|Brief Cognitive Intervention|One in person session (90 minutes) of trauma focused cognitive therapy followed by 4 weekly coaching calls (20 minutes each) with the same study therapist
11283706|NCT02808468|No Intervention|Assessment Only|Assessment session followed by weekly completion of assessment measures
11283707|NCT02808455|Experimental|Sequence I: A/B|Treatment A: pacritinib 400 mg capsule
11283708|NCT02808455|Experimental|Sequence II: B/A|Treatment B: pacritinib 80 mg solution
11283709|NCT02808442|Experimental|UCART19|
11283710|NCT02808429|Experimental|Placebo|
11283711|NCT02808429|Experimental|Atacicept 25 mg|
11283712|NCT02808429|Experimental|Atacicept 75 mg|
11283713|NCT02808416|Experimental|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
11283714|NCT02808403||Evolocumab exposed|Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.
11283715|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
11283716|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
11283717|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
11283718|NCT02808377|Active Comparator|SPOP|This arm will have the soft silicone pessary inserted post operatively and it will remain in-situ for 3 weeks.
11283719|NCT02808377|No Intervention|Non Intervention|Routine post operative care
11283720|NCT02808364|Experimental|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
11283721|NCT02808351|Experimental|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
11283722|NCT02808351|No Intervention|Blank control|Blank control of berberine administration
11283723|NCT02808338|Active Comparator|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.
~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
11283724|NCT02808338|Experimental|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
11283725|NCT02808338|Active Comparator|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:
~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
11283726|NCT02808338|Active Comparator|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:
~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
11283727|NCT02808325|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
11283728|NCT02808325|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
11283729|NCT02808312|Experimental|Mild Hepatic Impairment (Cohort 1)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of cilofexor 30 mg (3 x 10 mg tablets) on Day 1.
11283730|NCT02808312|Experimental|Moderate Hepatic Impairment (Cohort 2)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of cilofexor 30 mg (3 x 10 mg tablets) on Day 1.
11283731|NCT02808312|Experimental|Severe Hepatic Impairment (Cohort 3)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of cilofexor 10 mg (1 x 10 mg tablet) on Day 1.
11283732|NCT02808299||all the antigen and antibody of HBV are negative|Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.
11283733|NCT02808299||HBV infection history|One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.
11283734|NCT02808299||HBV carriers|One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.
11283735|NCT02808286|Experimental|Hybrid|"The hybrid emotion-focused treatment consists of 10-15 individual 1/1,5 hour sessions. It includes the following stages (examples of methods in parathesis)
~Stage I. Analysis of emotions and pain (Validation, Compassion, Chain analysis, Values & goals).
~Stage II. Developing skills (Dialectics, Self-validation, Self-compassion, emotion regulation skills).
~Stage III. Exposure training (Exposure for emotionally sensitive stimuli, exposure in vivo for avoided movements).
~Stage IV. Maintenance (Identifying key elements, Planning for flare-ups)."
11283736|NCT02808286|Active Comparator|internet Cognitive Behavior Therapy (iCBT)|CBT pain treatment, delivered via the internet consists of 8, weekly, modules and includes topics such as pain education, pain coping strategies (e.g. pacing), relaxation, cognitive restructuring, problem solving, stress and sleep management, conflict resolution. Patients read materials included in each module and do homework tasks on which they report back to the therapist via the internet. The therapist gives written feedback and guidance after each module. See reference for details.
11283737|NCT02808273||Retrospective control|Patients who had received enoxaparine as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
11283738|NCT02808273||Prospective Cohort|Patients who will receive bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
11283739|NCT02808247|Experimental|Experimental arm (arm A): Nintedanib|Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.
11283740|NCT02808247|Active Comparator|Standard arm (arm B): Ifosfamide|Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.
11283741|NCT02808234|Other|Nucel treatment group|One or two level lumbar interbody fusion surgery with Nucel
11283742|NCT02808208|Experimental|Group 1 AMSC Treatment|Patients have tissue biopsy and Adipose Derived Mesenchymal Stem Cells (AMSC) treatment.
11283743|NCT02808208|No Intervention|Group 2 No Treatment|Patients receive standard of care.
11283744|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
11283745|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
11283746|NCT02808182|Other|A0: PET/scan with [11C] palmitate|A bolus of 180 MBq of [11C]-acetate at time 90min and PET acquisition
11283747|NCT02808182|Other|A1: PET/scan with [11C] palmitate|A bolus injection of 180 MBq of [11C]-acetate at time 90min, followed by PET acquisition
11283748|NCT02808182|Other|B0: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.
11283749|NCT02808182|Other|B1: PET/scan with [18F]-FTHA|At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA followed by a PET acquisition at time 90 min.
11283750|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
11283751|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
11283752|NCT02808143|Experimental|Treatment (pembrolizumab, BCG solution)|"PRE-INDUCTION PHASE: Patients receive pembrolizumab intravesically once on day -14.
~INDUCTION PHASE: Patients receive BCG solution intravesically once weekly for 6 weeks at weeks 0-5 and pembrolizumab intravesically every 2 weeks at weeks 0, 2, and 4.
~MAINTENANCE PHASE: Beginning 2 weeks after the last dose of BCG solution, patients receive pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then receive pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses."
11283753|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
11283754|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
11283755|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
11283756|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
11283757|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
11283758|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.
~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
11283759|NCT02808117||Targeted initially|Children who were in the Haiti villages and targeted by the MFI program with MNP delivery initially.
11283760|NCT02808117||Targeted later|Children who were in the Haiti villages and not targeted by the MFI program with MNP delivery until later.
11283761|NCT02808104|Experimental|Mazindol Controlled Release|Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
11283762|NCT02808104|Placebo Comparator|Placebo|Matching placebo
11283763|NCT02808091|Experimental|Early stage (IB or bulky disease - II)|who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
11283764|NCT02808091|Experimental|Advanced stage (III - IV)|will receive only chemotherapy alone
11283765|NCT02808078|Experimental|Augmented reality training|Gait training with augmented reality
11283766|NCT02808078|Active Comparator|Standard training|Gait training without augmented reality
11283767|NCT02808065||Tacrolimus + Mycophenolate mofetil|
11283768|NCT02808052|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
11283769|NCT02808039||DAPT patients|Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.
11283770|NCT02808026|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
11283771|NCT02808013|Experimental|NDS-446|NDS-446
11283772|NCT02808013|Placebo Comparator|Placebo|Placebo
11283773|NCT02808000|Active Comparator|Group 1 (also called Group A )|Group 1/A will use standard catheter during the first ~6 months (observational period 1). Then the patients in this group will switch to the noble metal alloy urinary catheter (BIP Foley catheter of latex or silicone produced by Bactiguard AB) and be observed for another ~6 months (the second observational period).
11283820|NCT02807714||Obstructive CAD (non-ACS) Group|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have obstructive CAD requiring intervention.
11283774|NCT02808000|Experimental|Group 2 (also called Group B)|Group 2/B will use the BIP Foley (latex or silicone) during the first ~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another ~6 months (the second observational period).
11283775|NCT02807987|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
11283776|NCT02807974|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
11283777|NCT02807961|Placebo Comparator|Placebo|Placebo comparator arm
11283778|NCT02807961|Active Comparator|Active treatment|ELX-02, active comparator
11283779|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
11283780|NCT02807935|Other|OCT imaging of surgical/pharmacological/laser branch|"to evaluate the effect on the conventional outflow pathway, and specifically on the Schlemm's canal (SC) anatomy in the surgical branch:
~Before and after trabeculotomy
~Before and after cataract surgery
~Before and after vitrectomy surgery
~Before and after XEN™ Gel Stent implant
~pharmacological branch-
~Before and during the treatment with prostaglandins analogs
~Before and during the treatment with alpha blockers
~Before and during the treatment with beta blockers
~Before and during the treatment with carbonic anhydrase inhibitor
~laser branch-
~Before and after trabeculoplasty
~Before and after laser iridotomy
~Before and after yag capsulotomy laser"
11283781|NCT02807922|Active Comparator|Zopiclone|Zopiclone six nights
11283782|NCT02807922|Placebo Comparator|Placebo|Placebo six nights
11283783|NCT02807909|Experimental|BMS-986177 and Itraconazole|Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days
11283784|NCT02807909|Experimental|BMS-986177 and Diltiazem|Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days
11283785|NCT02807896||pancreatic cancer|pancreatic cancer 88
11283786|NCT02807896||bile duct cancer|bile duct cancer 101
11283787|NCT02807896||stomach cancer|stomach cancer 9
11283788|NCT02807896||colon cancer|colon cancer 5
11283789|NCT02807896||normal group|normal group 29
11283790|NCT02807883|Experimental|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
11283791|NCT02807870|Experimental|Methylphenidate-psychoeducational group|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
11283792|NCT02807870|Experimental|Parental training-placebo pill|Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
11283793|NCT02807870|Placebo Comparator|Psychoeducational group-placebo pill|Weekly psychoeducational groups for parents and placebo pill during 8 weeks.
11283794|NCT02807857|Other|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
11283795|NCT02807844|Experimental|Pancreatic cancer|Pancreatic adenocarcinoma who did not receive prior anti-PD-1/PD-L1 treatment
11283796|NCT02807844|Experimental|Triple Negative Breast cancer|TNBC who did not receive anti-PD-1/PD-L1 treatment
11283797|NCT02807844|Experimental|Endometrial Carcinoma|Endometrial carcinoma who did not receive Prior anti-PD-1/PD-L1 treatment
11283798|NCT02807844|Experimental|Melanoma|Melanoma who progressed on Prior PD-1 and PD-L1 directed therapies
11283799|NCT02807831|Experimental|Executive functions training|
11283800|NCT02807831|Experimental|Language skills training|
11283801|NCT02807831|Active Comparator|Regular school curriculum|
11283802|NCT02807818|Experimental|Nurse home visits|Nurse biweekly home visit.
11283803|NCT02807818|No Intervention|Usual care|Usual care.
11283804|NCT02807805|Experimental|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11283805|NCT02807792|Experimental|Perianal access device|
11283806|NCT02807779|Experimental|Dexamethasone|Patients randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).
11283807|NCT02807779|Active Comparator|Drug Coated Balloon|Patients randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.
11283808|NCT02807766|Experimental|Sensory Integration Training|Behavior modification and Sensory Integration Training
11283809|NCT02807766|Experimental|applied behavioral analysis|Behavior modification and applied behavioral analysis.
11283810|NCT02807766|Experimental|TEACCH|Behavior modification and TEACCH.
11283811|NCT02807766|Other|Behavior modification|Behavior modification.
11283812|NCT02807766|No Intervention|healthy control group|No intervention.
11283813|NCT02807753||Severe Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every 6 months.
~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
11283814|NCT02807753||Mild/Moderate Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every year.
~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
11283815|NCT02807740|Experimental|Virtual Reality|Patients will be treated with a virtual reality rehabilitation program
11283816|NCT02807740|Other|Conventional Rehabilitation Program|Patients will be treated with a conventional rehabilitation program.
11283817|NCT02807727|Active Comparator|Intralipid 20%|Intravenous single bolus of 1.5 ml/kg of Intralipid 20% over 3 minutes.
11283818|NCT02807727|Placebo Comparator|Modified Ringers Lactate|Intravenous single bolus of 1.5 ml/kg of MRL over 3 minutes.
11283819|NCT02807714||No CAD|Patients scheduled for elective cardiac catheterization for evaluation of suspected CAD that are found to not have CAD
11283847|NCT02807584|Experimental|ELECT|Adhesive Foam Dressing
11283821|NCT02807714||Stable CAD, no intervention required|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have non-obstructive CAD not requiring intervention.
11283822|NCT02807714||Acute Coronary Syndrome (ACS)|Patients who undergo an emergent cardiac catheterization for evaluation of known or suspected STEMI, NSTEMI, Unstable Angina (UA).
11283823|NCT02807701|Active Comparator|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy Under general anesthesia, the patient is placed in a supine position with the legs abducted. Carbon dioxide pneumoperitoneum is established using an open technique through a 10-mm trocar over the umbilicus. A 30 telescope is inserted to examine the peritoneal cavity, liver, stomach, and mesentric vessels.Then 4 to 6 more trocars are inserted under direct vision in the epigastrium and upper quadrants
~dissection
~reconstruction"
11283824|NCT02807701|Active Comparator|Open pancreaticoduodenectomy|"Open pancreaticoduodenectomy Abdomen is opened from the Bilateral Subcostal incision. (Chevron's Incision) 2. Abdominal cavity is explored for metastasis especially in liver, base of mesentary, mesocolon and pelvis.
~Dissection Reconstruction Pancreaticogastrostomy Hepaticojejunostomy is next- Done in single layer and can be performed in interrupted or continuous fashion.
~Gastrojejunostomy is the final step of reconstruction."
11283825|NCT02807688|Experimental|Intervention|"Health Promotion Intervention package including elements of psychoeducation on healthy lifestyles and practical sessions of physical activity, with the use of motivational techniques."
11283826|NCT02807688|No Intervention|Control|Control subjects receive treatment as usual at the Community Mental Health Services of the Department of Mental Health.
11283827|NCT02807675|Experimental|CVT-301, levodopa inhalation powder (LIP)|designed to deliver l-dopa to the lung using the CVT-301 inhaler.
11283828|NCT02807675|Placebo Comparator|Placebo|Administered in the same way as the investigational product, except that it does not contain l-dopa.
11283829|NCT02807662|Experimental|Experimental|Intervention mothers receive adapted Seeking Safety intervention delivered by prenatal care advocate over 8 sessions
11283830|NCT02807662|No Intervention|No intervention|Treatment as usual mothers receive usual services of a prenatal care advocate
11283831|NCT02807649|Placebo Comparator|Placebo|Placebo: Methyl cellulose and dextrose
11283832|NCT02807649|Active Comparator|Low dose|This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day
11283833|NCT02807649|Active Comparator|High dose|This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day
11283834|NCT02807636|Experimental|Atezolizumab+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
11283835|NCT02807636|Placebo Comparator|Placebo+Gemcitabine+Carboplatin/Cisplatin|Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
11283836|NCT02807636|Experimental|Atezolizumab Monotherapy|Eligible participants will receive open-label atezolizumab as monotherapy.
11283837|NCT02807623|Experimental|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
11283838|NCT02807623|Placebo Comparator|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
11283839|NCT02807623|Experimental|Compound Exercise of Push-ups|Randomized study participants assigned to Group C will perform an exercise intervention of push-ups immediately after influenza vaccine receipt.
11283840|NCT02807610|Experimental|IV Propofol and IV Etomidate lipuro|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group P Patients received IV Propofol 2mg kg-1 slowly over 60 seconds till Entropy of 40 as a comparator agent in patients undergoing Medical termination of pregnancy(MTP) and Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP
11283841|NCT02807610|Active Comparator|IV Etomidate Lipuro and Placebo|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP and placebo group received normal saline
11283842|NCT02807597|Experimental|Phase I Dose Level 1: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
11283843|NCT02807597|Experimental|Phase I Dose Level 2: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
11283844|NCT02807597|Experimental|Phase I Dose Level 3: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
11283845|NCT02807597|Experimental|Phase I Dose Expansion: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)
~9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
11283846|NCT02807597|Experimental|Phase II: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)
~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
11283848|NCT02807558|Experimental|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6mg/m2/day orally divided into twice a day dosing.
11283849|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with azacitidine|"SY-1425 days 8-28 of a 28-day cycle at 6mg/m2/day orally divided into twice a day dosing.
~Azacitidine 75 mg/m2/day IV or SC days 1-7 of a 28-day cycle in combination with SY-1425."
11283850|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with daratumumab|"SY-1425 during a 7-day lead-in and days 1-28 of a 28 day cycle at 6mg/m2/day orally divided into twice a day dosing.
~Daratumumab at 16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425."
11283851|NCT02807545|Experimental|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.
~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.
~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
11283852|NCT02807545|No Intervention|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
11283853|NCT02807532||atrial fibrillation group|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
11283854|NCT02807532||non-atrial fibrillation group|Patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
11283855|NCT02807519||Oncological patients|Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy . Collection of salivary cytokines will be performed in this group.
11283856|NCT02807519||Control group|Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel. Collection of salivary cytokines will be performed in this group.
11283857|NCT02807506|Experimental|Clinicians, Caregivers and Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept, 2nd mobile base, and 3rd mobile base with arm in daily supportive tasks
11283858|NCT02807493|Experimental|Occlusal Support Device|Support device for women in labor
11283859|NCT02807493|Placebo Comparator|Control|No device given for women in labor
11283860|NCT02807480|Experimental|Exposure-based therapy|Participants will complete 10, 90-minute sessions of Exposure-based therapy, conducted using a group format. Each group will include 8-12 participants. Exposure-based therapy seeks to increase abilities to manage anxiety through repeated practice in facing the situations or thoughts that are the focus of worry or fear. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
11283861|NCT02807480|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen negative mood. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
11283862|NCT02807467|Experimental|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
11283863|NCT02807467|Active Comparator|Propofol|Standard therapy for ICU delirium.
11283864|NCT02807454|Experimental|Daratumumab Plus Durvalumab Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle
~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
11283865|NCT02807454|Experimental|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle
~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward
~oral POM at 4mg/day on days 1 to 21
~oral/IV dex at 40mg/day (>75 years old) or 20mg/day (>75 years old) on days 1, 8, 15 and 22"
11283866|NCT02807441|No Intervention|No aspirin|Patients will not be given any Acetylsalicylic acid in the perioperative period.
11283867|NCT02807441|Experimental|Low-dose aspirin|Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.
11283868|NCT02807441|Experimental|High-dose aspirin|Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.
11283869|NCT02807428|Experimental|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
11283870|NCT02807428|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
11283871|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
11283872|NCT02807389|Experimental|MSC Fistula plug: Single Treatment Group|All patients received treatment of a stem cell coated fistula plug.
11283873|NCT02807376|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
11283874|NCT02807376|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
11283875|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
11283876|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
11283877|NCT02807363|Active Comparator|Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
11283878|NCT02807363|Experimental|Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
11283879|NCT02807350|Experimental|Overminus Treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
11283880|NCT02807350|Active Comparator|Non-overminus Treatment|spectacles with full cycloplegic refraction without overminus
11283881|NCT02807337|Experimental|Caphosol rinse group|Caphosol consists of two solutions (A and B) which are mixed immediately before use. Caphosol mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
11283882|NCT02807337|Active Comparator|0,9% NaCl group.|0,9% NaCl consists of two solutions (A and B). Two vials of 0.9% NaCl will be mixed to maintain blinding. The study mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
11283883|NCT02807324||Controls|Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)
11283884|NCT02807324||Early PE with IUGR|These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
11283885|NCT02807324||Early PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
11283886|NCT02807324||Late PE with IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
11283887|NCT02807324||Late PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
11283888|NCT02807324||HELLP syndrome|Cases consist of women (18 years or older) with HELLP syndrome in the current pregnancy (defined as (1) the presence of microangiopathic hemolytic anemia with abnormal blood smear, low serum haptoglobin and elevated lactate dehydrogenase (LDH) levels, (2) aspartate transaminase (ASAT) above 70 IU/L and lactate dehydrogenase (LD) above 600 IU/L or bilirubin more than 1.2 mg/dL, (3) platelet count below 100 x 10^9 L-1 )
11283889|NCT02807298|Active Comparator|2% Lignocaine (lidocaine)|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine (adrenaline)
11283890|NCT02807298|Experimental|4% Articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine (adrenaline)
11283891|NCT02807272|Experimental|Tipifarnib, Oral|Single arm
11283892|NCT02807259|Experimental|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
11283893|NCT02807259|Other|Control|The intervention will rolled out to all participating villages after 24 months.
11283894|NCT02807246|Active Comparator|Probiotic|Experimental: Breast milk+ Probiotics(Maflor®, Mamsel Pharmaceuticals, Turkey) The study group will be fed with probiotics at a dose of 1x109 CFU/day (Lactobacillus rhamnosus GG 109colony ). Probiotic is in a liquid drop form at a dose of 5 drops a day and is used orally for 10 days.
11283895|NCT02807246|Active Comparator|Saline|Active Comparator: Breast milk+five drops of saline The control group will be given Breast milk without the addition of probiotics
11283896|NCT02807220|Experimental|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
11283897|NCT02807207|Experimental|Sequence I|treatment sequence: A/B/C
11283898|NCT02807207|Experimental|Sequence II|treatment sequence: A/C/B
11283899|NCT02807207|Experimental|Sequence III|treatment sequence: B/A/C
11283900|NCT02807207|Experimental|Sequence IV|treatment sequence: B/C/A
11283901|NCT02807207|Experimental|Sequence V|treatment sequence: C/A/B
11283902|NCT02807207|Experimental|Sequence VI|treatment sequence: C/B/A
11283903|NCT02807194|Experimental|general anesthesia|'lumbar disc herniation'
11283904|NCT02807194|Experimental|spinal anesthesia|'lumbar disc herniation'
11283905|NCT02807181|Active Comparator|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
11284670|NCT02801669|Experimental|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
11283906|NCT02807181|Experimental|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
11283907|NCT02807168|No Intervention|Usual care|Control Group
11283908|NCT02807168|Experimental|Usual care plus NT-proBNP|Experimental Group
11283909|NCT02807155|No Intervention|Non-Intervention Control|No intervention will be delivered.
11283910|NCT02807155|Experimental|Continuity Group|"Continuity Group participants aged 20-21 (i.e. the last year of the LEAP Program) will be seen at one of the 2 study centers - 1) the newly established LAC+USC Diabetes Transition Clinic; or 2) Children's Hospital Los Angeles Pediatric Endocrinology Clinic, and will receive the full 1-year Transition Empowerment Program - Continuity Group"
11283911|NCT02807155|Experimental|Rescue Group|"Rescue Group participants aged 21-25 will be connected to a diabetes healthcare home (medical clinic or doctor's office) in Los Angeles County based on geography and personal preference. Those individuals connected to the LAC+USC Diabetes Transition Clinic will receive the full 1-year Transition Empowerment Program - Rescue Group (TEP-RG). Those assigned to other providers in LA County will have access to the web-based curriculum."
11283912|NCT02807142|Experimental|NC 1 cell therapy|All patients will be treated with the same treatment: NC1 cell therapy
11283913|NCT02807129|Experimental|patients|
11283914|NCT02807116|Experimental|Pacritinib and Rifampin|On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Days 8 through 17, following a 7-day washout period, 600-mg oral doses of rifampin were administered QD. It was anticipated that steady-state concentrations of rifampin would be achieved by Day 17. On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
11283915|NCT02807103|Experimental|Rituximab with FFS=0|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.
~Patients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment"
11283916|NCT02807103|Placebo Comparator|Conventional therapy with FFS=0|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.
~Patients with FFS=0 will receive placebo-rituximab at day 1 and day 15."
11283917|NCT02807103|Experimental|Rituximab with FFS≥1|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.
~Patients with FFS≥1 will receive a total of 9 pulses :
~1 gram of rituximab at day 1 and day 15 as induction treatment
~placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.
~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
11283918|NCT02807103|Active Comparator|Conventional therapy with FFS≥1|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.
~Patients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
11283919|NCT02807090|Experimental|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
11283920|NCT02807090|Experimental|Circular Dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
11283921|NCT02807077|Experimental|Subjects with mild renal impairment|Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
11283922|NCT02807077|Experimental|Subjects with moderate renal impairment|Group 2, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
11283923|NCT02807077|Experimental|Subjects with severe renal impairment|Group 3, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
11283924|NCT02807077|Experimental|Subjects with ESRD|Group 4, will consist of patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.
11283925|NCT02807077|Experimental|Healthy subjects|Group 5, will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.
11283926|NCT02807064|Active Comparator|Bifidobacteria mixture 0.5 ml|Bifidobacteria 0.5 ml per os all days for 2 months
11283927|NCT02807064|Placebo Comparator|placebo|Placebo 0.5 ml per os all days for 2 months
11283928|NCT02807051|Experimental|Pacritinib and Clarithromycin|Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
11283929|NCT02807038|Experimental|Lung function test|Pregnant women performed one spirometry at each trimester of pregnancy
11283930|NCT02807025||Idiopathic Pulmonary Fibrosis(IPF)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
11283931|NCT02807025||Sarcoidosis|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
11283932|NCT02807025||Tuberculosis(TB)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
11283933|NCT02807025||Chronic Obstructive Pulmonary Disease|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
11283934|NCT02807025||Asthma|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
11283935|NCT02807025||Healthy|Nasal, tracheal and bronchial sampling of MLF in patients from healthy controls for comparative data.
11283936|NCT02807012|Experimental|Nursing educational intervention|The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
11283937|NCT02807012|No Intervention|Usual care|The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.
11283938|NCT02806999|Experimental|Berberine; Insulin|"Follow the previous administration program，participants will continue to receive intensive insulin therapy; Besides injecting insulin, participants will receive 500mg berberine twice a day for 8 days.
~Drug: Berberine; Insulin"
11283939|NCT02806999|Active Comparator|Insulin|"Besides receiving intensive insulin therapy, participants will take a placebo twice a day for 8 days.
~Drug: Insulin"
11283940|NCT02806986|Experimental|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
11283941|NCT02806973|Experimental|Nasal Glucagon (NG) - Treatment 1|One dose of 3 milligram (mg) NG administered in one of four study periods.
11283942|NCT02806973|Experimental|NG - Treatment 2|Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.
11283943|NCT02806973|Experimental|NG - Treatment 3|Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.
11283944|NCT02806973|Experimental|NG - Treatment 4|Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.
11283945|NCT02806960|Experimental|Treatment 1|Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).
11283946|NCT02806960|Experimental|Treatment 2|Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.
11283947|NCT02806960|Experimental|Treatment 3|Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.
11283948|NCT02806960|Experimental|Treatment 4|Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.
11283949|NCT02806947|Experimental|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
11283950|NCT02806947|Active Comparator|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
11283951|NCT02806921|Active Comparator|ZenLens with Low limbal clearance|Scleral contact lens designed to provide approximately 25 microns of limbal clearance.
11283952|NCT02806921|Active Comparator|ZenLens with High limbal clearance|Scleral contact lens designed to provide approximately 80 microns of limbal clearance.
11283953|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
11283954|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
11283955|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
11283956|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
11283957|NCT02806882|Experimental|Ceftaroline fosamil|600mg 1 hour intravenous infusion ZINFORO
11283958|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
~Washout period of at least 7 days
~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
11283959|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
~Washout period of at least 7 days
~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
11283960|NCT02806856|Active Comparator|Active tDCS|
11283961|NCT02806856|Sham Comparator|Sham|
11283962|NCT02806843|Experimental|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
11283963|NCT02806830|Experimental|Optive after the second anti-VEGF injection|Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)
11284671|NCT02801669|Placebo Comparator|Placebo group|Placebo orally administered once daily.
11283964|NCT02806817|Experimental|Bevacizumab + ME-344|"Bevacizumab single dose (15 mg/kg infused IV) on day 1. ME-344 will be administered at 10 mg/kg infused IV over 30 minutes on days 8, 15 and 22 (arm 1).
~ME-344 will be suspended in 250 mL sterile saline."
11283965|NCT02806817|Placebo Comparator|Bevacizumab + normal saline|Bevacizumab single dose (15 mg/kg infused IV) on day 1. Placebo: will be administered normal saline 250 mL infused IV over 30 minutes on days 8, 15 and 22 (arm 2).
11283966|NCT02806804|Experimental|one dose test vaccine|One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
11283967|NCT02806804|Experimental|one dose commercially available trivalent influenza vaccine|One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
11283968|NCT02806804|Experimental|One dose quadrivalent influenza virus vaccine|One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
11283969|NCT02806778||Hypoxic brain injury|Consecutive out-of-hospital, post-cardiac arrest patients who remain comatose after successful resuscitation, admitted on ICU of University Hospital Ostrava. The patients will undergo BIS monitor-guided sedation and jugular bulb catheterisation.
11283970|NCT02806765|Experimental|Dietary Supplement|This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol below the upper tolerable limit
11283971|NCT02806765|Experimental|Control|This experimental arm reflects administration of placebo in softgel capsule
11283972|NCT02806752|Experimental|Ranibizumab + Triamcinolone Acetonide|intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg
11283973|NCT02806752|Active Comparator|Ranibizumab|intravitreal injection: Ranibizumab 0.5mg
11283974|NCT02806739|Experimental|Soy Group (Soy Protein + Isoflavones)|"Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones.
~Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet."
11283975|NCT02806739|Placebo Comparator|Control Group (Minimize Soy Intake)|Control Group will avoid soy supplements and minimize intake of soy foods.
11283976|NCT02806726|Experimental|iDesign 1.3-PRESBY|iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
11283977|NCT02806726|Active Comparator|iDesign 1.3|iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
11283978|NCT02806713|Placebo Comparator|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
11283979|NCT02806713|Experimental|phenazopyridine|Patients receiving phenazopyridine
11283980|NCT02806700|No Intervention|Twitter Diabetes Control|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys
11283981|NCT02806700|Experimental|Twitter Diabetes Intervention|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys. This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
11283982|NCT02806687|Experimental|Gene Therapy product CYL-02|Two EUS-guided intratumor injections of CYL-02 at one month interval plus Gemcitabine (3 weeks/month) during two months followed by four months Gemcitabine alone (3 weeks/month) or until progression.
11283983|NCT02806687|Active Comparator|Standard of care|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
11283984|NCT02806674|Experimental|Successful treatment|
11283985|NCT02806674|Experimental|Refractory infection of H.pylori|
11283986|NCT02806661|Experimental|VPRDG for AGC|Vagus nerve-preserving Robot-assisted distal subtotal gastrectomy (VPRDG) with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11283987|NCT02806661|Active Comparator|CRDG FOR AGC|Conventional Robot-assisted distal subtotal gastrectomy (CRDG) with D2 lymphadenectomy without preserving vagus nerve will be performed for the treatment of patients assigned to this group.
11283988|NCT02806648|Experimental|Palbociclib|Palbociclib
11283989|NCT02806635|No Intervention|Waitlist|Participants are assessed start, during, and end wait list; however, no active intervention is given.
11283990|NCT02806635|Experimental|OurRelationship|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s).
11283991|NCT02806635|Experimental|PREP Online|The PREP Online program is based on the in-person Prevention and Relationship Enhancement Program. The PREP Online program consists of seven sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour.
11283992|NCT02806622||Division II Collegiate Athletes|Student athletes (18-45) currently enrolled and participating on a sports team.
11283993|NCT02806609|Other|Group 1|Cold water immersion, with 10 degrees, for 10 minutes
11283994|NCT02806609|Other|Group 2|immersion in water at room temperature
11283995|NCT02806609|Other|Group 3|active recovery - running
11283996|NCT02806609|Other|Group 4|rest in the chair
11285418|NCT02796443||Elective laparoscopic cholecystectomy|Biliary colic with no acute cholecystitis
11283997|NCT02806596|Other|sevoflurane|"induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde)
~intervention : titration of inspired sevoflurane concentration until targeted bispectral index"
11283998|NCT02806583|Experimental|intervention|telephone based structured support groups
11283999|NCT02806583|No Intervention|control|Active Comparator: Usual care (intervention as experimental group after 3 month (after T1)
11284000|NCT02806570|Experimental|AccuCinch® Ventricular Repair System|
11284001|NCT02806557||High risk group|"Defined as risk of severe neutropenia >20% or risk of neutropenic infective complications >10%, with severe neutropenia defined as absolute neutrophil count <1.0 x10^9/L.
~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
11284002|NCT02806557||Frequently given regimens|"Defined as high number of cases of neutropenia, but risk of severe neutropenia <5%.
~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
11284003|NCT02806557||Prophylactic GCSF|"Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).
~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
11284004|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
11284005|NCT02806531|Experimental|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
11284006|NCT02806518||Women scheduled for DIEP|Women scheduled for DIEP breast reconstruction after mastectomy due to breast cancer are examined with DIRT, hand-held Doppler and CTA
11284007|NCT02806505|Experimental|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
11284008|NCT02806505|Experimental|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
11284009|NCT02806492|Experimental|Patient for cardiac surgery|All patient undergo the 5 different intervention in a randomised matter.
11284010|NCT02806479||Case: Hypertrophic cardiomyopathy|HCM patients at high risk for ventricular arrhythmia
11284011|NCT02806479||Control I: Healthy|Healthy Controls
11284012|NCT02806479||Control II: Post-MI with arrhythmogenic substrate|Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy
11284013|NCT02806479||Control III: VT/VF-free ischemic cardiomyopathy|Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life
11284014|NCT02806466|Active Comparator|Asthmatic children|
11284015|NCT02806466|Sham Comparator|Non-asthmatic children|
11284016|NCT02806453|Active Comparator|Group A|Group A: Mg alginate/thickened formula
11284017|NCT02806453|Active Comparator|Group B|Group B: thickened formula/Mg alginate
11284018|NCT02806440|Active Comparator|Low dose naltrexone|Low dose naltrexone 4.5 mg/tablet, 1 tablet a day for 21 days
11284019|NCT02806440|Placebo Comparator|Placebo|"Placebo tablet
~1 tablet a day for 21 days"
11284020|NCT02806427||enterally fed adults|Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days.
11284021|NCT02806414|Experimental|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
11284022|NCT02806401|Experimental|landmark|landmark method_subclavian venous cannulation
11284023|NCT02806401|Active Comparator|US_Ax|ultrasound guided axillary venous cannulation
11284024|NCT02806388||tumor tissue for molecular profiling|
11284025|NCT02806375|Experimental|PTCy and ruxolitinib|
11284026|NCT02806362|Experimental|Ombitasvir/paritaprevir/ritonavir (12 weeks)|Ombitasvir/paritaprevir/ritonavir (25/50/100mg once daily) for 12 weeks
11284027|NCT02806349|Placebo Comparator|Control|3g/d Cornstarch and 14g/d wheat bran control
11284028|NCT02806349|Experimental|K-GB&AG|3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend
11284029|NCT02806336|Experimental|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
11284030|NCT02806336|Active Comparator|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
11284031|NCT02806323|Experimental|Yoga Practice|12 week yoga intervention; 45 minutes/weekly practice Participants will be encouraged to practice their prescribed program of yoga at home, daily, for 20 minutes each day.
11284032|NCT02806310||Prospective|Group A: Patients with known BAV who are scheduled to have a cardiac MRI.
11284033|NCT02806310||Historic|Group B: Patients with known BAV who have already had an MRI within the past year
11284034|NCT02806297|Experimental|Early cholecystectomy with IOC|The experimental arm will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
11284035|NCT02806297|Active Comparator|Late cholecystectomy with IOC|The comparator will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
11284036|NCT02806284|Active Comparator|Neurotrauma|Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
11284099|NCT02805881|Experimental|Neurolief System treatment|Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks
11284037|NCT02806284|Active Comparator|Neurosurgery|Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
11284038|NCT02806284|Active Comparator|Control|All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
11284039|NCT02806271|Experimental|Worry Postponement|Two weeks of daily worry postponement
11284040|NCT02806271|Active Comparator|Worry Monitoring|Two weeks of daily worry monitoring
11284041|NCT02806271|No Intervention|Assessment Only Control|No intervention, participants will complete three assessment time points
11284042|NCT02806258|Active Comparator|Arm A|6-8 cycles of Primary systemic therapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
11284043|NCT02806258|Experimental|Arm B|The patients will receive 3D conformal or other modality (eg IMRT, VMAT) APBI during their PST sequence. APBI will be planned sequentially between the Primary systemic therapy cycles, 2 weeks after the 3rd/6 or the 4th/8 cycle of PST.
11284044|NCT02806245|Experimental|Biventricular pacing|Patients will be randomized pre-operatively to either the pacing group or to the control group. Patients randomized to receive pacing will 1st undergo an acute pacing phase where the order of the pacing mode will be randomized and then will continue to an extended pacing phase of biventricular pacing.
11284045|NCT02806245|No Intervention|Control|Controls will receive standard of care treatment consisting of placement of 2 pacing leads (right atrial and right ventricular), monitoring of the study outcomes, monitoring of oxygen consumption and echocardiography, but no pacing.
11284046|NCT02806232|Experimental|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
11284047|NCT02806232|Experimental|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
11284048|NCT02806232|Experimental|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
11284049|NCT02806232|Experimental|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
11284050|NCT02806232|Experimental|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
11284051|NCT02806232|Experimental|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
11284052|NCT02806232|Experimental|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
11284053|NCT02806232|Experimental|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
11284054|NCT02806232|Experimental|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
11284055|NCT02806219|Active Comparator|Certolizumab Pegol injection by prefilled syringe|
11284056|NCT02806219|Experimental|Certolizumab Pegol injection by e-Device|
11284057|NCT02806206|Experimental|Drug: Prucalopride|A single 2 mg dose of prucalopride before ingesting the capsule endoscopy pill.
11284058|NCT02806206|Placebo Comparator|Drug: Placebo|A placebo pill just before ingesting the capsule endoscopy pill.
11284059|NCT02806193||Cardiovascular Magnetic Resonance Imaging|Cardiovascular imaging techniques (other subsidiary techniques such as CT and ECG will also be followed)
11284060|NCT02806180|Experimental|Single-Operator|For the 'Single Operator Ultrasound Guided IV placement' arm the RN operator will use the ultrasound probe to identify the target vein, and continue to hold and adjust the probe while placing the IV.
11284061|NCT02806180|Experimental|Dual-Operator|For the 'Dual Operator Ultrasound Guided IV placement' arm the RN operator will use the US to identify the target vein, at which time the study coordinator will hold the ultrasound probe in position. The RN operator will then place the IV.
11284062|NCT02806167|Experimental|Clinical algorithm|This is a single arm study. All eligible patients will be subject to our clinical algorithm.
11284063|NCT02806154||Elderly cancer patients|Elderly cancer patients treated with chemotherapy will have DEXA
11284064|NCT02806141|Experimental|Aerosolized plus intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
11284065|NCT02806141|Active Comparator|Intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
11284066|NCT02806128|Experimental|Treatment group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .
~Patients need to complete laboratory tests within a specified time."
11284067|NCT02806128|Experimental|Control group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .
~Patients need to complete laboratory tests within a specified time."
11284068|NCT02806115|Experimental|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
11284131|NCT02805634|Other|Control group|Control group without neurological pathology
11284132|NCT02805621||Subject|Patients with know or suspected coronary artery disease, who underwent both CT angiography and invasive coronary angiography including invasive FFR measurements.
11285638|NCT02795091|Other|Manual clean|clean the rag and floor towel manually
11284069|NCT02806102||High-risk|"Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:
~Age ≥ 65 years
~Diabetes mellitus requiring medication
~Documented history of a second prior presumed spontaneous MI (>1 year ago)
~Documented history of angiographic evidence of multivessel coronary artery disease
~Chronic, non-end stage renal dysfunction"
11284070|NCT02806102||Low-risk|Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
11284071|NCT02806089|Experimental|Muscle strength|"single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by Voorrips score questionnaire), inflammatory and nutritional status."
11284072|NCT02806076|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
11284073|NCT02806076|Active Comparator|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
11284074|NCT02806063|Other|Intraoperative samples|During this study of health care procedure evaluating microbiological setting in PJI prior prosthesis implantation with one stage surgery, 3 additional perioperative samples will be performed prior prosthesis implantation for every patient.
11284075|NCT02806050|Experimental|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
11284076|NCT02806024|Experimental|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
11284077|NCT02806024|Placebo Comparator|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
11284078|NCT02806011||no Intervention|Long-term follow up of no intervention group
11284079|NCT02806011||1-time injection group|Long-term follow up of 1-time injection group
11284080|NCT02806011||2-time injection group|Long-term follow up of 2-time injection group
11284081|NCT02805998|Experimental|Web-based CBT-I|Sleepio delivers CBT-I through 6 weekly web-sessions (www.sleepio.com). Treatment content is based on CBT for insomnia manuals (Espie et al., 2007, 2008) and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
11284082|NCT02805998|Other|Treatment as Usual|Our control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy. Use of non-study treatment will be tracked.
11284083|NCT02805985|Experimental|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
11284084|NCT02805972|Experimental|Naloxone|4 mg / 0.1 ml naloxone
11284085|NCT02805972|Placebo Comparator|Placebo|0.1 ml saline
11284086|NCT02805959||Constipated, Elderly|Investigation with MTS for motility
11284087|NCT02805959||Constipation, Young|Investigation with MTS for motility
11284088|NCT02805959||Normal Bowel, Elderly|Investigation with MTS for motility
11284089|NCT02805959||Normal Bowel, Young|Investigation with MTS for motility
11284090|NCT02805946|Other|intravenous followed by oral|"Start with posaconazole IV 300mg BID on the first day. Posaconazole will be infused over a period of 90 minutes.
~Days 2-7 patients will receive posaconazole IV 300mg QD.
~Days 8-12 patients will receive posaconazole PO 300mg QD.
~Days 13-16 patients will receive posaconazole PO 200mg QD.
~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
11284091|NCT02805946|Other|oral followed by intravenous|"Start with posaconazole PO 300mg BID on the first day.
~Days 2-7: patients will receive posaconazole PO 300mg QD.
~Days 8-12: patients will receive posaconazole IV 300mg QD. Posaconazole will be infused over a period of 90 minutes.
~Days 13-16 patients will receive posaconazole IV 200mg QD.
~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
11284092|NCT02805920|Active Comparator|GROUP 1 : G20|Postoperative pain for ACLR : G20 : received ACB with 20 ml 0.25% Bupivacaine
11284093|NCT02805920|Active Comparator|GROUP 2 : G25|Postoperative pain for ACLR : G25: received ACB with 25 ml 0.25% Bupivacaine
11284094|NCT02805920|Active Comparator|GROUP 3 : G30|Postoperative pain for ACLR : G30 received ACB with 30 ml 0.25% Bupivacaine
11284095|NCT02805907|Experimental|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
11284096|NCT02805907|Placebo Comparator|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
11284097|NCT02805894|Experimental|NBTXR3 activated by IMRT only|"Part I Dose Escalation
~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:
~- EBRT delivered as 45 Gy in 25 fractions of 1.8 Gy each; to the prostate and seminal vesicles, followed by 34.2 Gy in 19 fractions to the prostate and proximal seminal vesicles , over 9-10 weeks, utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT A)"
11284098|NCT02805894|Experimental|NBTXR3 activated by Brachytherapy & IMRT|"Part I Dose Escalation
~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:
~- Brachytherapy Boost and EBRT delivered as a single fraction of 15 Gy in one day to the prostate by High Dose Rate Brachytherapy followed by EBRT (initiated within 2-4 weeks after completion of Brachytherapy), delivered as 45 Gy in 25 fractions of 1.8 Gy to the prostate and seminal vesicles utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT B)"
11284293|NCT02804360|Experimental|therapy|Dexamethasone injection
11284100|NCT02805868|Experimental|Treatment (siltuximab)|Patients receive siltuximab IV over 60 minutes on day 1. Patients also undergo bone marrow biopsy and aspiration at baseline and at the end of treatment (within 30 days of last siltuximab dose) or as clinically indicated. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are responding after 6 courses may receive additional siltuximab treatment for up to 1 year at the discretion of the study doctor.
11284101|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
11284102|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
11284103|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
11284104|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
11284105|NCT02805842|Active Comparator|Tacrolimus BID|20 patients receiving twice daily (BID) Tacrolimus
11284106|NCT02805842|Active Comparator|Advagraf QD|40 patients randomized to receive once daily (QD) Advagraf
11284107|NCT02805829|Experimental|Trastuzumab + NK cells|"On Cycle 1,day -2, patients will receive IV loading dose 8mg/Kg trastuzumab, followed by collection blood on day 0. After NK expansion and verification that the resulting NK cells meet release criteria, NK cells were washed and resuspended in isotonic sodium chloride for intravenous transfusion on day 14.
~NK cellular therapy conduct 2 cycles per year. The maintenance dose of trastuzumab monotherapy is 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress."
11284108|NCT02805816||Study group|Children with suspicion of CD based on positive serology (TG2 >2 times upper limit of normal) and classical clinical manifestations or belonging to high risk groups, who underwent gastroscopy with intestinal biopsies.
11284109|NCT02805816||Control group|Children without suspicion of CD who underwent gastroscopy and duodenal biopsies for other reasons (abdominal pain, failure to thrive, vomiting, eg)
11284110|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:
~SF12
~Beck
~WOMAC"
11284111|NCT02805790|Experimental|Elamipretide, Then Placebo|Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.
11284112|NCT02805790|Placebo Comparator|Placebo, Then Elamipretide|Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.
11284113|NCT02805764|Experimental|Homeoblock functional dental appliance|Removable functional dental appliance to be used at during sleep for one year.
11284114|NCT02805751|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have weight-bearing as tolerated from day 0. They are also instructed to perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
11284115|NCT02805751|Experimental|Early loading|The patients in the early loading group are also allowed to have weight-bearing as tolerated from day 0 and perform tendon strain exercises 3 times each day from 2 weeks after the rupture. The patients in this group will also remove the walker twice a day and use a special training pedal for 5 weeks (until walker removal).
11284116|NCT02805738|Experimental|Experimental Group|once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
11284117|NCT02805738|Active Comparator|Active comparator Group|once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
11284118|NCT02805725|Experimental|Phase 1: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
11284119|NCT02805725|Experimental|Phase 2: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
11284120|NCT02805712|Active Comparator|Control|Participant will receive usual care for Heart Failure patients, which include standard written material on Advanced Care planning and supportive cardiology/palliative care consult if ordered by attending.
11284121|NCT02805712|Experimental|Verbal Information and Discussion|Participants will participate in a guided goals of care conversation and the support of a Palliative Care Social Worker who is working closely with the patients' primary cardiology team. Social worker has ongoing clinical review of participants with a Palliative Care physician who will provide a full medical consult if appropriate.
11284122|NCT02805699|Experimental|Baofeikang Granule|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,cough,give BaoFeikang Granules(by Beijing KangRentang Pharmaceutical Co., Ltd.), 1 bag, twice each day.
11284123|NCT02805699|Placebo Comparator|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,coughand give Chinese medicine placebo (by Beijing Kang Rentang Pharmaceutical Co., Ltd., requirements and Chinese medicine BaoFeikang Granules in appearance and taste similar),1bag，twice each day.
11284124|NCT02805686|Experimental|"En face OCT (C-scan)"|
11284125|NCT02805673|Experimental|OSTEO group|usual medical treatment + 6 osteopathic interventions
11284126|NCT02805673|No Intervention|witness group|usual medical treatment
11284127|NCT02805660|Experimental|Mocetinostat and Durvalumab|Mocetinostat oral capsules, three times weekly along with durvalumab intravenously administered in 28 day cycles
11284128|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
11284129|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
11284130|NCT02805634|Experimental|Multiple sclerosis|Patients with multiple sclerosis, followed by Dr Dachy within the CHU Brugmann Hospital.
11284133|NCT02805608|Experimental|uPAR PET/CT and FDG PET/MR|One injection of 68Ga-NOTA-AE105 followed by PET/CT and on a separate day one injection of 18F-FDG followed by PET/MRI. Both scans will be evaluated for possible regional lymph node metastases.
11284134|NCT02805595|Experimental|Hypertonic Saline|23.4% Hypertonic Saline injection(s) with a maximum of 0.6cc per treatment. If necessary every two weeks, with a maximum of three treatments.
11284135|NCT02805595|Placebo Comparator|Saline (Placebo)|"If a patient has two active HS sites with fistulas or sinus tracts, patients will be their own control.
~Injection with normal saline (placebo) in one site randomly allocated by side. The subject and ultrasound operator will be blinded to the treatment allocation."
11284136|NCT02805582|Active Comparator|Anterior musculus serratus block|"Proximal nerve block above the second intercostal space between Musculus serratus anterior and Musculus pectoralis minor.
~Intervention: 10ml ropivacain 0.5%"
11284137|NCT02805582|Active Comparator|Subpectoral block|"Distal nerve block under the Musculus pectoralis major at the medial border of the axillary triangle.
~Intervention: 10ml ropivacain 0.5%"
11284138|NCT02805569|Active Comparator|Group A|articulating stylet
11284139|NCT02805569|Active Comparator|group C|conventional stylet
11284140|NCT02805556|Experimental|Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529|Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529
11284141|NCT02805543||diabetes group|34 T2DM patients without vascular complications as diabetes group
11284142|NCT02805543||control group|32 healthy people were recruited as control group
11284143|NCT02805530|Experimental|single arm|"Patients with synchronous metastases at Central Nervous System (CNS), evaluated in less than one week by the Multidisciplinary Committee at National Cancer Institute of Mexico to define the initial treatment. Patients with metastases at other sites than CNS will receive first line systemic treatment, in those EGFR-mutated with tyrosine kinase inhibitors (TKI) and in patients without a driver mutation with first line duplet of chemotherapy based on platin. The type of TKI or chemotherapy will be at discretion of the treating physician.
~After 4 cycles of treatment, patients with stable disease or partial response will be evaluated by de Multidisciplinary Committee to establish the type of radical treatment to the primary and to the metastases, radiation therapy and chemoradiotherapy."
11284144|NCT02805517|Experimental|PEAL laparoscopic nephrectomy|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy using 3 mm instruments.
11284145|NCT02805504|Experimental|Exparel|This arm will receive intraoperative local Liposomal Bupivacaine injection (Exparel) at the port placement site.
11284146|NCT02805504|Active Comparator|Marcaine|This group will receive will local bupivacaine HCl (Marcaine) injection at the port placement site.
11284147|NCT02805491||with hypospadias|parent-child triads as cases (male newborns with hypospadias)
11284148|NCT02805491||without hypospadias|parent-child triads as controls (male newborns without hypospadias)
11284149|NCT02805465|Experimental|HBP Group|CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.
11284150|NCT02805465|Active Comparator|BiVP Group|CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.
11284151|NCT02805452|Experimental|Succinate of Solifenacin|1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.
11284152|NCT02805452|Placebo Comparator|Placebo of Succinate of Solifenacin|1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.
11284153|NCT02805439|Experimental|S47445 15mg|
11284154|NCT02805439|Experimental|S47445 50mg|
11284155|NCT02805439|Placebo Comparator|Placebo|
11284156|NCT02805426|Experimental|Tranexamic acid|1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
11284157|NCT02805426|Placebo Comparator|Placebo|oral placebo + 800 mcg sublingual misoprostol
11284158|NCT02805413|Other|DETERMINATION OF BLOOD PRESSURE|"determination and comparison of blood pressure by/with :
~Pulse Curve Analysis
~Inert gas re-breathing
~Central blood pressure device
~Vascular ultrasound device
~Thoracic Impedance (ICG) - Electrocardiography (ECG) - Phonocardiography (Phono) - Carotid plethysmography (Pneumo)"
11284159|NCT02805400|Other|Neurocognitive performance|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.
~For these methods only commercially available CE marked devices will be used."
11284160|NCT02805387|No Intervention|no treatment|Dystocic women where no bicarbonate was given
11284161|NCT02805387|Experimental|Treatment|Dystocic women where bicarbonate was ingested
11284162|NCT02805374|Experimental|ASP1517 fasting then fed|Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
11284163|NCT02805374|Experimental|ASP1517 fed then fasting|Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
11284164|NCT02805348||Chronic kidney disease|Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
11284165|NCT02805335|No Intervention|Control group|Group with the sutureless device actually used
11284166|NCT02805335|Experimental|Innovative group|Group with the new device ( KTFIX PLUS)
11284167|NCT02805322|Experimental|Temporal Temperature Measurement|Infrared Temporal Temperature Measurement using the ARC InstaTemp MD in three different age groups with a specified percentage reporting as febrile.
11284168|NCT02805322|Active Comparator|Tympanic and/or Sublingual Temperature|"Tympanic and/or Sublingual Temperature Measurement using one or both of two widely used reference clinical thermometers in three different age groups with a specified percentage reporting as febrile.
~Choice between Tympanic and/or Sublingual is determined based on standard of care in study site
~Reference Thermometer 1 - Covidien Genius 2 Tympanic Thermometer
~Reference Thermometer 2 - Welch Allen SureTemp Plus Sublingual Thermometer"
11284516|NCT02802579|Active Comparator|A: standard protocol|Standard dual-source computed tomography coronary angiography protocol
11284169|NCT02805309|Experimental|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
11284170|NCT02805309|Experimental|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
11284171|NCT02805309|Active Comparator|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
11284172|NCT02805296|Active Comparator|Double light|"High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below.
~Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm"
11284173|NCT02805296|Active Comparator|Single light|High-intensity phototherapy with blue LED light from above. Intervention: Light irradiance: 66 µW/cm2/nm
11284174|NCT02805283||Dapagliflozin, dapagliflozin/met ER|Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
11284175|NCT02805283||Sulfonylurea|Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
11284176|NCT02805270|Experimental|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
11284177|NCT02805270|No Intervention|usual care|Usual care provided by ward pharmacist, nurses and doctors in the ward
11284178|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
11284179|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
11284180|NCT02805244|Experimental|JTZ-951, 14C-JTZ-951|Single oral administration on Day 1; 10 mg JTZ-951, 100 μCi of 14C-JTZ-951
11284181|NCT02805231||primary open-angle glaucoma patients|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
11284182|NCT02805231||randomly age-matched people|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
11284183|NCT02805218|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
11284184|NCT02805205|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
11284185|NCT02805192|Other|one Arm: size measurement by Smart phone App|
11284186|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
11284187|NCT02805166|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
11284188|NCT02805153|Experimental|Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
11284189|NCT02805153|Active Comparator|Active Comparator/rhG-CSF|patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day. Injections on day 3 after chemotherapy and continued daily until an ANC of at least 10.0 X 10^9/L was documented after the expected nadir, or for a maximum of 14 days
11284190|NCT02805140|Experimental|Virtual exercise and mobile apps|Participants randomized to the intervention arm will join a virtual group convenient for them. They will plan and participate in 8 weeks (every week day) of virtual exercise sessions. Sessions will all be under 30 minutes and include a brief check in amongst participants. The investigators will provide links to information on physical activity and links to online resources for being active.
11284191|NCT02805140|Active Comparator|Exercise resources and information|The investigators will provide links to information on physical activity and links to online resources for being active. Women will be invited to join the exercise groups at the end of the 8 weeks.
11284192|NCT02805127||Patients with COPD and Asthma .|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.
~All clinical diagnoses and treatments will be performed according to the department's protocols.
~This is an observational study with no interventions"
11284193|NCT02805114||Asthma and COPD patients|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken from the subjects with at least two minutes recording before the first spirometry assessment.
~All clinical diagnoses and treatments will be performed according to the department's protocols.
~This is an observational study with no interventions"
11284194|NCT02805101|Experimental|Biodentine|The perforation area of the root is going to be covered by Biodentine
11284195|NCT02805101|Active Comparator|MTA|The perforation area of the root is going to be covered by MTA.
11284196|NCT02805088|Experimental|Bipolar Disorder patients|
11284197|NCT02805088|Experimental|Schizophrenia patients|
11284198|NCT02805088|Experimental|Healthy Volunteers|
11284199|NCT02805075|Experimental|Supportive care (Fructooligosaccharide)|Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
11284200|NCT02805062||Pleural Effusion|Malignant pleural effusion patients requiring investigation with thoracoscopy.
11284201|NCT02805049|Experimental|The study population|The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).
11284517|NCT02802579|Experimental|B: enhanced protocol|enhanced dual-source computed tomography coronary angiography protocol
11285639|NCT02795091|Other|machine clean|clean the rag and floor towel by machine
11284202|NCT02805036||30 cmH20 for 30 seconds|"plateau pressure is hold on at 30 cmH20 pour 30 seconds. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.
~echocardiography - arterial oximetry"
11284203|NCT02805036||10 cmH20 above|"plateau pressure is hold on at 10 cmH20 above. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.
~echocardiography - arterial oximetry"
11284204|NCT02805023|Placebo Comparator|Placebo|Intramuscular injection of control medium only
11284205|NCT02805023|Experimental|BGC101|Intramuscular injection of BGC101 (autologous EnEPC preparation)
11284206|NCT02805010|Experimental|Subcutaneous(SC) Abatacept|
11284207|NCT02805010|Placebo Comparator|Placebo|
11284208|NCT02804984||ICUS|idiopathic cytopenia of undetermined significance (ICUS)
11284209|NCT02804958||STEMI treated with primary PCI|Patients diagnosed with acute ST-segment elevation myocardial infarction and treated with primary percutaneous coronary intervention were consecutively registered.
11284210|NCT02804945|Experimental|Mesenchymal Stem Cells|"Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).
~Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
11284211|NCT02804932|Experimental|Beetroot crystals (nitrate)|Participants will receive a nitrate rich beetroot powder (10g/day) for 8 weeks.
11284212|NCT02804932|Placebo Comparator|Placebo (beetroot powder, no nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 8 weeks.
11284213|NCT02804919|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
11284214|NCT02804906|Experimental|Home-Based Physical Therapy|
11284215|NCT02804906|Active Comparator|Control-30-minute counseling session|Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge.
11284216|NCT02804893|Active Comparator|VATS GROUP|VATS lobectomy or segmentectomy
11284217|NCT02804893|Active Comparator|RATS GROUP|Robotic lobectomy or segmentectomy
11284218|NCT02804880|Experimental|Group A|HAR + AWARD + Referral Card + A4 leaflet
11284219|NCT02804880|Experimental|Group B|LTM + AWARD + Referral Card + A4 leaflet
11284220|NCT02804880|Active Comparator|Group C|Brief advice + 12-page booklet
11284221|NCT02804867||Depression|
11284222|NCT02804867||Bipolar disorder|
11284223|NCT02804867||Control|
11284224|NCT02804854|Experimental|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
11284225|NCT02804841|Experimental|Intervention|Healthy, Community Dwelling; Aged 60-80 years; Cholecalciferol -Vitamin D3, 4000 international units (IU) on alternating days.
11284226|NCT02804841|Placebo Comparator|Placebo|Healthy, Community Dwelling; Aged 60-80 years; Placebo -gel capsule containing no vitamin D on alternating days.
11284227|NCT02804828|Active Comparator|Arm 1|
11284228|NCT02804828|Sham Comparator|Arm 2|
11284229|NCT02804815|Active Comparator|Aspirin 100mg|Aspirin 100mg
11284230|NCT02804815|Placebo Comparator|Placebo 100mg|100mg Placebo
11284231|NCT02804815|Active Comparator|Aspirin 300mg|Aspirin 300mg
11284232|NCT02804815|Placebo Comparator|Placebo 300mg|300mg Placebo
11284233|NCT02804776|Experimental|Gefitinib|Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery
11284234|NCT02804763|Placebo Comparator|Placebo|Placebo in a specified sequence for a total of 24 weeks
11284235|NCT02804763|Experimental|DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
11284236|NCT02804763|Experimental|DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
11284237|NCT02804763|Experimental|DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
11284238|NCT02804750|Experimental|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
11284239|NCT02804750|Experimental|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
11284240|NCT02804737||Web Group|Patients given web site (aiddly) instructions for colonoscopy
11284241|NCT02804737||Paper Group|Patients given paper instructions for colonoscopy
11284242|NCT02804724||Newly diagnosed individuals with HIV|Individuals newly diagnosed with HIV in Grampian between January 2009 and December 2014
11284243|NCT02804711|Experimental|Four doses of low dose vaccine|four doses of 15µg/0.6ml per dose
11284244|NCT02804711|Experimental|Four doses of middle dose vaccine|four doses of 30µg/0.6ml per dose
11284245|NCT02804711|Experimental|Four doses of high dose vaccine|four doses of 60µg/0.6ml per dose
11284246|NCT02804711|Experimental|Three doses of low dose vaccine and one dose of placebo|three doses of 15µg/0.6ml per dose and one dose of placebo
11284247|NCT02804711|Experimental|Three doses of middle dose vaccine and one dose of placebo|three doses of 30µg/0.6ml per dose and one dose of placebo
11284248|NCT02804711|Experimental|Three doses of high dose vaccine and one dose of placebo|three doses of 60µg/0.6ml per dose and one dose of placebo
11284249|NCT02804711|Placebo Comparator|Four doses of placebo|four doses of placebo
11284250|NCT02804698|Experimental|Meta Salud Diabetes-Intervention|"Attend the thirteen weekly educational classes and physical activity group (prior physician approval) that are part of the Meta Salud Diabetes program.
~Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.
~Respond to a survey about your nutrition and physical activity habits on three separate occasions (at the start of the 13-week program, just after you finish the program, and nine months after you finish the program).
~You may also be invited to participate in a follow-up interview, where you will be asked about your experience during and after the Meta Salud Diabetes program."
11284518|NCT02802579|Experimental|C: enhanced obesity protocol|enhanced obesity-mode dual-source computed tomography coronary angiography protocol
11284251|NCT02804698|No Intervention|Meta Salud Diabetes-Comparison Group|"Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.
~Respond to a survey about your nutrition and physical activity habits on three separate occasions (you will answer the first survey as soon as you finish reading and agree to participate by signing this form, the second survey will be three months from now, and the third survey will be 12 months from now)."
11284252|NCT02804685|No Intervention|Control|It consists on only a regular training performance
11284253|NCT02804685|Experimental|Experimental|It consists on performing the protocol which includes 6 strength, agility and balance exercises together with the regular training. The exercise program has to be performed twice a week during 6 weeks
11284254|NCT02804646|Experimental|endostar and chemotherapy group|recombinant human endostatin(endostar) injection was continuous intravenous transfusion for 7 days,with the dose of 15mg/m2 per one day,every 21 days of a cycle,combined with pemetrexed plus cisplatin or carboplatin.
11284255|NCT02804646|Active Comparator|chemotherapy group|pemetrexed injection was intravenous with the dose of 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin,without recombinant human endostatin.
11284256|NCT02804633|Active Comparator|IV acetaminophen group|In addition to PCA (morphine or hydromorphone) all patients receive 1 gram of IV acetaminophen (100 ml ) 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge.
11284257|NCT02804633|Placebo Comparator|Placebo Group|In addition to PCA (morphine or hydromorphone) all patients received placebo (100 ml normal saline) given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge
11284258|NCT02804620|Experimental|PLEASED|The PLEASED intervention arm will receive peer leader who is patients with diabetes that has been gone through our trainings. Also, they will receive three free health screenings (baseline, 3 months, 12 months) and monetary compensation for their time and effort.
11284259|NCT02804620|No Intervention|Wait List|The wait list will receive three free health screening (at baseline, 3months, 12 months) and monetary compensation for their time and effort.
11284260|NCT02804607||skin lesion|severe skin traumatism occurring during childhood and which had required an initial graft.
11284261|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
11284262|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
11284263|NCT02804581|Experimental|Gum Arabic|Oral intake of 30 gram of Gum Arabic daily for 12 weeks
11284264|NCT02804568|Experimental|Group 1|Olanzapine/samidorphan 10 mg/10 mg
11284265|NCT02804568|Experimental|Group 2|Olanzapine/samidorphan 20 mg/10 mg
11284266|NCT02804555|Active Comparator|Oxygen support|5 liter / minute oxygen has given to the mothers on face mask.
11284267|NCT02804555|No Intervention|Room air|Oxygen support has not given to the mothers.
11284268|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
11284269|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
11284270|NCT02804529|Experimental|Meng's Point entry|Meng's entry involved a 0.2 cm horizontal or vertical incision using the Veress needle in the cross of lateral border of the left rectus abdominis and rib arch.
11284271|NCT02804529|Experimental|Palmer's Point entry|Palmer's entry involved a 0.2 cm horizontal or vertical incision with the Veress needle in the left midclavicular line approximately 3 cm caudal to the 10th rib
11284272|NCT02804529|Experimental|Periumbilllicus entry|Periumbilllicus entry involved a 0.2 cm horizontal or vertical midline incision using the Veress needle in the lower or uper border of the umbilicus.
11284273|NCT02804516|Experimental|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
11284274|NCT02804516|Experimental|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
11284275|NCT02804503|Experimental|Calorie Labels|A menu with rank ordered calorie labels and a statement on the energy needs per meal.
11284276|NCT02804503|Experimental|Exercise Labels|A menu with rank ordered exercise labels showing minutes of brisk walking necessary to burn the food calories.
11284277|NCT02804503|Active Comparator|No Labels|A menu with no labels
11284278|NCT02804490|Placebo Comparator|White maize|Conventional maize flour
11284279|NCT02804490|Experimental|Biofortified maize|Provitamin A carotenoid biofortified maize flour
11284280|NCT02804490|Active Comparator|Fortified maize|Retinyl palmitate fortified maize flour
11284281|NCT02804451|Experimental|Intubation without chest compression|normal airway, without chest compression during intubation.
11284282|NCT02804451|Experimental|Intubation with uninterrupted chest compression|normal airway, with continuous chest compressions
11284283|NCT02804425|Experimental|"actor-spectator group"|actor at least once during the immersive simulation session
11284284|NCT02804425|No Intervention|"spectator-only group"|observer during the whole one-day session but participation in the debriefing part of the four scenarios
11284285|NCT02804412|Active Comparator|Control group|Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
11284286|NCT02804412|Experimental|CIAT-group|Patients received constraint-induced aphasia therapy.
11284287|NCT02804412|Active Comparator|communication treatment group (CTG)|Patients received aphasia group therapy without constraints
11284288|NCT02804399|Experimental|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
11284289|NCT02804386|Experimental|treatment|Sofosbuvir, 400 mg OD for 6 months
11284290|NCT02804373|Placebo Comparator|placebo daily|daily administration of placebo during 28 days : placebo continuous
11284291|NCT02804373|Active Comparator|24 IU of oxytocin daily|24 IU of daily oxytocin administration during 28 days : oxytocin continuous
11284292|NCT02804373|Active Comparator|24 IU of oxytocin every 3 days|24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days
11284294|NCT02804347||Patient|Patients will be receiving either ECT or iTBS as a depression management. Olfactory functioning will be assessed at pre-treatment and 6 weeks later at post-treatment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
11284295|NCT02804347||Control|Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
11284296|NCT02804334||Healthy Volunteers|Participants with no current or lifetime psychiatric disorders
11284297|NCT02804334||Untreated Bipolar Disorder|Participants who meet criteria for current bipolar disorder but who are not currently taking any psychotropic medications
11284298|NCT02804308|No Intervention|Group Control with breast cancer and without breast cancer|Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months
11284299|NCT02804308|Experimental|Combined Training with breast cancer and without breast cancer|Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
11284300|NCT02804295|Other|Collaborative Care Intervention|All enrolled participants received the collaborative care intervention over 6 months.
11284301|NCT02804282|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
11284302|NCT02804269||Healthy Volunteer|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
11284303|NCT02804269||Dilated Cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
11284304|NCT02804269||Hypertrophic cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
11284305|NCT02804269||Ischemic heart disease with reduced EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
11284306|NCT02804269||Ischemic heart disease with normal EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
11284307|NCT02804243|Active Comparator|nasal high flow therapy|In this group, patients have undergone rehabilitation under the nasal high flow therapy (FiO2 100%, oxygen flow from 30 to 60 L/min) during four weeks.
11284308|NCT02804243|No Intervention|oxygen therapy|In this group, patients have undergone rehabilitation under the oxygen therapy via a nasal canula (6 L/min) during four weeks.
11284309|NCT02804230|Experimental|MRgFUS Ablation of Epileptic Foci|MR-Guided Focused Ultrasound
11284310|NCT02804204||Anti-TNF|
11284311|NCT02804191|Experimental|LO2A|Sodium Hyaluronate
11284312|NCT02804191|Placebo Comparator|Placebo-Controlled|Saline.
11284313|NCT02804178|Experimental|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth BID up to 1000 mg BID.
11284314|NCT02804165|Other|Target high-risk subjects or subpopulations for T1D|Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
11284315|NCT02804152|Other|CBT for Chronic Pain|single arm open-label design
11284316|NCT02804139|Active Comparator|Standard care|Standard Care after C-section with no additional physical therapy.
11284317|NCT02804139|Experimental|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization
11284318|NCT02804126|Experimental|TAP (transversus abdominis plane)|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
11284319|NCT02804126|Experimental|QL (quadratus lumborum)|Ultrasound-guided quadratus lumborum block at the end of cesarean section
11284320|NCT02804113|Experimental|Supera Peripheral Stent System|
11284321|NCT02804087|Experimental|MobiusHD Implantation|
11284322|NCT02804087|Sham Comparator|Sham Implantation|Sham
11284323|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
11284324|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
11284325|NCT02804061|Active Comparator|Full NELIP|This group will receive the full Nutrition and Exercise Lifestyle Intervention Program (two behavior changes) from enrollment until birth and serves as the comparator control (Group A).
11284326|NCT02804061|Experimental|Nutrition followed by Exercise (N+E)|Intervention - Nutrition component only (one behaviour) until 24 week assessment, then the addition of the second behavior change (Exercise component) at 25 weeks, with both behaviours followed until birth (Group B).
11284327|NCT02804061|Experimental|Exercise followed by Nutrition (E+N)|Intervention - Exercise component only (one behaviour) until 24 week assessment, after which there will be the addition of the second behaviour change (Nutrition component), with both behaviours followed until birth (Group C).
11284328|NCT02804048|Experimental|Pelvic Floor Muscle Training|"superficial heat pelvic floor muscle intra vaginal manual therapy. PERFECT scale is applied in 5 sessions and based on the result of each assessment is performed the treatment plan with exercises of the pelvic floor muscles.
~It is performed manual therapy in iliopsoas, diaphragm and piriformis. From the fourth session, initiate treatment with electromyographic biofeedback based on the result of PERFECT scale."
11284329|NCT02804048|Placebo Comparator|Low back|superficial heat low back Manual therapy in piriform, lumbar, iliopsoas and diaphragm.
11284519|NCT02802566|Experimental|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
11284330|NCT02804035|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
11284331|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
11284332|NCT02803996|Active Comparator|Part A- Single Dose- 400 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
11284333|NCT02803996|Active Comparator|Part A- Single Dose- 600 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
11284334|NCT02803996|Placebo Comparator|Part A-Single Dose-Placebo|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
11284335|NCT02803996|Active Comparator|Part B-Multiple Dose-400 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
11284336|NCT02803996|Active Comparator|Part B-Multiple Dose-600 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
11284337|NCT02803996|Placebo Comparator|Part B-Multiple Dose-Placebo|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
11284338|NCT02803983||Pediatric hip plate|The children were treated with pediatric hip plate.
11284339|NCT02803983||Cannulated screw|The children were treated with cannulated screw.
11284340|NCT02803957|Experimental|Treatment Group|Subjects with degenerative mitral valve insufficiency treated with artificial chordae implanted using the NeoChord DS1000
11284341|NCT02803957|Active Comparator|Control Group|Subjects with degenerative mitral valve insufficiency treated with standard surgical mitral valve repair
11284342|NCT02803944||Cystic fibrosis patients taking azithromycin|Cystic fibrosis patients taking azithromycin continuously for two years.
11284343|NCT02803931|Experimental|Cardiogoniometry|Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI. The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
11284344|NCT02803931|Active Comparator|12-lead ECG|For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
11284345|NCT02803918|Experimental|Lixisenatide|Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
11284346|NCT02803918|Placebo Comparator|Placebo|Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
11284347|NCT02803905|Active Comparator|standard procedure: intrahepatic|Liver infusion: the islet mixture is delivered slowly via injection through a syringe attached to the catheter in the portal vein or portal vein tributary. Access to the portal vein is achieved by percutaneous transhepatic access under fluoroscopic, ultrasonographic, or real-time CT guidance. Alternatively access to a mesenteric or omental venous tributary of the portal vein can be obtained by mini-laparotomy under general anesthesia (transplant site preference or in the extremely rare circumstance that percutaneous access cannot be achieved). At a minimum, portal pressure will be monitored before and after infusion of the islet product. Portal pressure measurements will be documented in the medical record. Gel foam plugs and/or collagen/thrombin paste will be used to embolize the entire peripheral catheter tract immediately before the catheter is withdrawn, to reduce the chances of bleeding.
11284348|NCT02803905|Experimental|experimental procedure: omentum|Omentum infusion: briefly, islets are spread in the surface of the omentum, in a single omental pouch site. Transplanting in a single site will reduce risks. A single dose of at least 5000 IEQ/KG will be transplanted. The investigators should be able to achieve a meaningful metabolic improvement and prevention of severe hypoglycemia, as previously seen in experience with intraportal islet transplants. Recombinant human thrombin is added to the islets placed on the omentum to promote formation of a gel clot and facilitate adherence to the surface of the omentum. A pouch is then created by folding the omentum. The pouch is secured inn place with stitches.
11284349|NCT02803892|Placebo Comparator|Group 1: Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks
11284350|NCT02803892|Experimental|Group 2: Rapamycin plus Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks
11284351|NCT02803892|Experimental|Group 3: Rapamycin plus Vildagliptin|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks
11284352|NCT02803879|Experimental|Cardiogoniometry (CGM)|All patients attending clinic for follow up appointments following the implantation of a CRT device will be eligible for inclusion in the study. If they consent for enrolment in the study each patient will undergo a series of 4 CGM recordings whilst in their follow up appointment. They will undergo each of these during different pacemaker settings. These are: 1) No pacing, 2) Paced from the right ventricular lead; 3) Paced from the left ventricular lead and 4) Paced from both ventricular leads. After this has been done the participants involvement in the study will have finished.
11284353|NCT02803866||Parents of preterm newborns (25-32 weeks of gestation)|Parents (mother or mother+father) of preterm newborns admitted at the Gregorio Marañón Hospital from birth, recruited during the first 10 days of preterm newborn hospitalization and receiving the training program CAP-PREM
11284354|NCT02803853|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
11284355|NCT02803853|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
11284356|NCT02803840|Other|Experimental|DLBCL patients with indication for palliative radiotherapy
11284357|NCT02803827|Experimental|Rapid diagnostics and probiotic|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
11284358|NCT02803827|Other|Rapid diagnostics and placebo|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.
11284359|NCT02803827|Other|No rapid diagnostics and probiotic|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
11284360|NCT02803827|Placebo Comparator|No rapid diagnostics and placebo|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.
11284361|NCT02803814|Experimental|Superior mesenteric artery approach|Initial approach of the superior mesenteric artery to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
11284362|NCT02803814|Active Comparator|Classic approach|Classic approach to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
11284363|NCT02803801|Experimental|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
11284364|NCT02803788|Active Comparator|Group O|this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.
11284365|NCT02803788|Experimental|Group R|this group will receive inj. ramosetron 0.3mg iv stat just before extubation.
11284366|NCT02803775|Active Comparator|Paced|Paced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
11284367|NCT02803775|Active Comparator|Sensed|Sensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
11284368|NCT02803762|Experimental|Investigational: [14C] Pacritinib|All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg [14C]pacritinib (containing 100 μCi radioactivity).
11284369|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
11284370|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
11284371|NCT02803736|Experimental|Real acupuncture group|Patients in the real acupuncture group will receive true acupuncture 3 times a week for 4 weeks (12 sessions). A standardized prescription of six acupuncture points is used unilaterally. Needles are inserted and manipulated manually until needling sensation (de qi) is obtained, and are retained for 20 minutes with manual manipulation at 10 minutes. Acupuncturists are trained to inquire about specific needle sensations when providing true acupuncture.
11284372|NCT02803736|Sham Comparator|Sham acupuncture group|Patients in the sham acupuncture group will receive sham acupuncture 3 times a week for 4 weeks (12 sessions).
11284373|NCT02803723|Experimental|Holding-cuddling + Sucrose|The Holding-cuddling is started 5 minutes before and the sucrose administration is started 2 minutes before blood sampling.
11284374|NCT02803723|Active Comparator|Sucrose alone|The sucrose administration is started 2 minutes before blood sampling.
11284375|NCT02803710||Case group|patients with decreased susceptibility to carbapenems Enterobacteriaceae isolate
11284376|NCT02803710||Control-group|patients with Enterobacteriaceae isolate without decreased susceptibility to carbapenems
11284377|NCT02803697||Patients|All patients who underwent surgery for a NFPA in Reims university hospital between 01/01/1991 and 31/12/2004
11284378|NCT02803684|Experimental|Single arm|Whole cohort
11284379|NCT02803671|Experimental|patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
11284380|NCT02803671|Experimental|without patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
11284381|NCT02803671|Experimental|patent ductus arteriosus + cardiac or respiratory therapy|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
11284382|NCT02803658|Experimental|infertile couples|smoking behavior
11284383|NCT02803658|Active Comparator|Fertile couples|smoking behavior
11284384|NCT02803645|Experimental|healthy|blood sample
11284385|NCT02803632|Experimental|suicide attempt|questionnaires actigraphic recording
11284386|NCT02803606||hypothermia|Preterm neonates less than 32 weeks of gestational age admitted at birth to the Neonatal Medicine unit
11284387|NCT02803593|No Intervention|Control|165 Asian American breast cancer survivors (55 per sub-ethnic group) who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS). Participants are asked to use the online ACS resources for 3 months.
11284388|NCT02803593|Experimental|Intervention (TICAA)|165 Asian American breast cancer survivors (55 per sub-ethnic group) who use the intervention (TICAA) and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors. Participants are asked to use the TICAA program for 3 months.
11284389|NCT02803567|Experimental|Intervention|Those in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education on substance use. Content in the intervention will focus on health promotion and will deliver positive messages about health.
11284390|NCT02803567|No Intervention|Control|Those in the control arm will receive treatment as usual.
11284391|NCT02803554|Experimental|Young donor plasma|An infusion of plasma derived from donors aged 25 years or younger
11284392|NCT02803541|Experimental|12 day mainstream summer camp experience|The 12 day mainstream camp experience involves increased exercise from baseline at home. Can this exercise and peer contact improve physical endurance as measured by the 6 minute walk test and self concept as measured by a modified Harter scale
11284393|NCT02803528|Experimental|Biodentine|The exposed area of the pulp is going to be covered with Biodentine.
11284394|NCT02803528|Active Comparator|MTA|The exposed area of the pulp is going to be covered with MTA
11284395|NCT02803515|Experimental|Patient with HIPEC|
11284396|NCT02803515|Sham Comparator|Patient without HIPEC|
11284397|NCT02803502|Experimental|hemophilia|Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII
11284398|NCT02803489|Experimental|medical device intervention|
11284399|NCT02803476||Cases|Polycystic ovary syndrome (PCOS) female patients. 20-35 years of age.
11284400|NCT02803476||Controls|Non-PCOs female subjects. 20-35 years of age.
11284401|NCT02803463|Active Comparator|Peritoneal Closure|open appendectomy with peritoneal closure
11284402|NCT02803463|Active Comparator|Peritoneal Non Closure|open appendectomy without peritoneal closure
11284403|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Needle|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via epidural needle followed by catheter placement.
~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.
~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
11284404|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Catheter|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via the epidural catheter administration following catheter placement.
~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.
~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
11284405|NCT02803450|Active Comparator|Low Volume, High Concentration via Epidural Catheter|"Standard of Care Epidural Administration Epidural loading: Participants will receive 10ml of 0.125% bupivacaine with fentanyl 2mcg/ml in 5 ml increments 5 minutes apart via the epidural catheter following epidural catheter placement, per standard of care.
~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.0625% bupivacaine with 2mcg/ml fentanyl. The infusion rate will be set at 10ml/hr basal rate and 4ml every 15 minutes on demand with lockout of 26ml/hr.
~For inadequate analgesia: One additional 5ml boluses of the standard 0.125% bupivacaine with 2mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
11284406|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
11284407|NCT02803424|Experimental|Volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
11284408|NCT02803424|Active Comparator|Autoflow-volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, Autoflow-volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
11284409|NCT02803398|Experimental|Patient at risk of venous thrombosis|
11284410|NCT02803385|Active Comparator|Continous Epidural Analgesia|Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes
11284411|NCT02803385|Active Comparator|Patient Controlled Epidural Analgesia|Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .
11284412|NCT02803372|Experimental|Intervention group|In addition to routine monitoring, invasive LiDCOrapid is used to monitor mean arterial pressure (MAP), stroke volume variation (SVV) and cardiac index (CI). Intraoperative goal-directed circulatory management is performed, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery.
11284413|NCT02803372|Active Comparator|Control group|Routine monitoring is performed, which includes invasive blood pressure and urine output. Intraoperative routine circulatory management is performed, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h.
11284414|NCT02803359|Experimental|Planned Procedure|Endoscope will be connected to a camera and monitor. Needle electrodes will then be positioned into the false vocal fold mucosa bilaterally, under direct visualization of the needle tip on the monitor, but the needles will be passed trans-orally in the operating room. For those participating during an open-neck surgery, the surgery will commence as planned and once exposure of the superior laryngeal nerve is obtained, the surgeon will insert the electrodes directly into the nerve trunk for the purposes of recording. In Surgery or cervical lymphadenectomy, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold.
11284415|NCT02803359|Experimental|Routine Laryngoscopy|Nasolaryngoscopy will be performed in the office in the standard fashion with the use of oxymetazoline for topical decongestion of the nasal mucosa, In both settings, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold
11284416|NCT02803346||septic shock patients|
11284417|NCT02803333||Data Capture Participants|This is a prospective observational cohort study of advanced non-small cell lung cancer patients (stage 3b/4) receiving treatment at the Moffitt Cancer Center (MCC) or The Ohio State Comprehensive Cancer Center (OSUCCC) to assess treatment impact at monthly intervals from baseline to 6 months post-enrollment.
11284418|NCT02803320|Experimental|SPF 50 Y65 110|All subjects received baseline skin evaluation and 1 day of sun exposure.
11284419|NCT02803307|Experimental|6 mg TLC599|6 mg DSP with 50 μmol PL
11284420|NCT02803307|Experimental|12 mg TLC599|12 mg DSP with 100 μmol PL
11284421|NCT02803294|Experimental|Aortic Stenosis/regurgitation|Transcatheter aortic valve replacement
11284422|NCT02803281||Lung Cancer - Frialty Assessment|Patients who will undergo surgery for lung cancer
11284423|NCT02803281||Esophageal Cancer - Frailty Assessment|Patients who will undergo esophagectomy for esophageal cancer
11284424|NCT02803268|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
11284425|NCT02803268|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
11284426|NCT02803268|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
11284427|NCT02803255|Experimental|Assist-As-Needed Control|"Subjects in this group will interact with a robotic exoskeleton, the MAHI Exo-II, programmed with an adaptive mode. In this mode, the robot will continuously assist motion along pre-defined trajectories, but will employ an assist-as-needed protocol.
~Here, the amount of assistance provided by the robot will not be always the 100% of that required to complete the task (as in the position control mode), but only a fraction of it. The robot will continuously estimate the residual movement capabilities of the subject, depending on the specific joint addressed in the movement, and will estimate the remaining contribution needed to complete the movement following a predefined trajectory, thus avoiding to over-support motion."
11284428|NCT02803255|Active Comparator|Subject-Triggered Control|Subjects in group B will interact with a robotic exoskeleton, the MAHI Exo-II, controlled via the subject-triggered mode, as in a previous clinical trial with the MAHI Exo II robotic system. In the subject triggered mode, the MAHIExo II is commanded to regulate joints motion following a position-control control scheme, and using as desired trajectories standardized single-joints profiles that require motion of one of the axes of the exoskeleton (i.e. elbow flexion and extension, forearm pronation and supination, wrist radial and ulnar deviation, wrist flexion and extension). The switch to position control of the exoskeleton is triggered by the application of sufficient force by the subject, in a previous phase where the robot implements a virtual wall.
11284429|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
11284430|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
11284431|NCT02803216|Experimental|standard triple region|The patients in this group were given 10-day standard triple therapy.
11284432|NCT02803216|Active Comparator|standard triple region +2-week TCM|The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.
11284433|NCT02803216|Active Comparator|standard triple region +4-week TCM|The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.
11284434|NCT02803203|Experimental|osimertinib and bevacizumab|"Phase 1:
~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks
~Phase 2:
~Use MTD determined during phase 1"
11284435|NCT02803190|Experimental|ICG- integrated care group|Integraded Care Group
11284436|NCT02803190|Experimental|MTG- muscle training group|Muscle Traing Group
11284437|NCT02803177|Experimental|BMC2012 + beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical standard, filled with a clinically established scaffold (beta-TCP Chronos® Synthes), and loaded with 1.3 x 10E6 BMC/ml TCP per 1 ml beta-TCP in situ.
11284438|NCT02803177|Placebo Comparator|beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical Standard and filled with a clinically established scaffold (beta-TCP Chronos® Synthes).
11284439|NCT02803164|Other|Intervention|Treatment of wound with Vacuum-assisted dressing.
11284440|NCT02803151|Experimental|Stereotactic ablative radiotherapy|Image-guided stereotactic ablative radiotherapy
11284441|NCT02803138||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
11284442|NCT02803125|Active Comparator|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
11284443|NCT02803125|Placebo Comparator|Support group control|This is the comparison group
11284444|NCT02803099|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284445|NCT02803086||1|To date, around 700 patients, who were treated with Radiotherapy for Prostate Cancer, have been enrolled. 34% of them underwent radiotherapy with radical intent, whereas the others were post-prostatectomy patients (29% adjuvant, 37% salvage). Various techniques of irradiation were used (1% 3DCRT, 6% SF-IMRT, 52% VMAT, 41% Tomotherapy) in conventional (42%, 1.7-2.0 Gy/fr.) and hypofractionated (58%, 2.1-2.7 Gy/fr.) settings. EQD2(alpha/beta=3) to prescribed PTV ranged between 64 and 93 Gy. Limph nodes were treated in the 98% of cases.
11284446|NCT02803073|Experimental|Testosterone Replacement|The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.
11284447|NCT02803073|Placebo Comparator|Control|Patients in the control group will receive intramuscular normal saline injections.
11284448|NCT02803060|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284520|NCT02802566|Active Comparator|Control|Standard prenatal vitamin provided by the study
11284449|NCT02803047|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284450|NCT02803034|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284451|NCT02803021|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284452|NCT02803008|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284453|NCT02802995|Experimental|Treatment arm|Subjects receiving the study drug which is PRP/thrombin mixture
11284454|NCT02802995|No Intervention|Control arm|Subjects receiving the standard of care for chronic venous wounds
11284455|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
11284456|NCT02802956|Experimental|intervention group|Daily Life Promotion Program
11284457|NCT02802956|Experimental|control group|general rehabilitation treatment
11284458|NCT02802943|Experimental|Peptide Vaccine MRD +|MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
11284459|NCT02802943|Experimental|Peptide Vaccine MRD-|MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow <10-4 6-10 weeks after the end of first line treatment)
11284460|NCT02802930|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products (SPF 50 Y65 110,SPF 50 Y51 002, and SPF 15 V27 l 04 compared to that of a negative control [0.9% NaCl]) were tested simultaneously on each subject.
11284461|NCT02802917|Experimental|SPF 50 Y49 091|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
11284462|NCT02802917|Experimental|SPF 50 X15 158|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
11284463|NCT02802917|Experimental|SPF 50 X15 160|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
11284464|NCT02802917|Experimental|SPF 50 X57 162|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
11284465|NCT02802904|Experimental|Palm olein IV 64|Palm olein IV 64, n= 15, 4 weeks intervention
11284466|NCT02802904|Experimental|Cocoa butter|Cocoa butter, n= 15, 4 weeks intervention
11284467|NCT02802904|Experimental|Virgin olive oil|Virgin olive oil, n= 15, 4 weeks intervention
11284468|NCT02802891||Recruitment group|"Group of individuals (aged 6 to 18 years old) recruited for the JOIN project. Consent was obtained from legal guardians for individuals under 18.
~Exclusion criteria:
~Individuals who refused to partake in the clinical assessment, despite the legal guardians consent.
~Individuals who provided an insufficient amount of sample (ex: low volume of EBC)"
11284469|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.
~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
11284470|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
11284471|NCT02802865|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
11284472|NCT02802865|Experimental|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
11284473|NCT02802852|Experimental|Calf Compression, Filgrastim injection|All patients enrolled in the study will undergo pneumatic calf compression though use of the Art Assist device as well as stem cell mobilization through administration of Filgrastim 10 mcg/kg subcutaneously, every 3rd day for 30 days.
11284474|NCT02802839|Experimental|Sperimental|The patient will be shown the headset for VR and a selection of age appropriate virtual realities to immerge in by the nurse not performing the procedure. There will be two lists of VRs to choose from, one for age 6 to 12 and one for age 12 to 18 with the following themes: amusement rides /carousel, space rides, zoo, safari, dinosaurs, city touring, landscapes, caverns. Once the patient is ready to wear the headset the application will start and 120 seconds later the procedure will take place. The nurse performing venipuncture will be a different one than the one handling distraction. Once the procedure ends the video will last for one more minute or up to the child' s desire. Only the first venipuncture attempt will be observed.
11284475|NCT02802839|No Intervention|Observational|Control intervention When arriving to the CF centre for routine visit that implies also the taking of blood samples, after having obtained the informed consent, a trained nurse of the CF Centre, will apply to each child recruited -in the presence of the parent, who may hold the child- the anesthetic cream. Only the first venipuncture attempt will be observed.
11284573|NCT02802241|Experimental|double-blind peppermint oil|
11284476|NCT02802826|Experimental|Tailored Exercise Prescription|"Participants will have a discussion on the 'My Exercise Prescription' booklet on the benefits of increasing levels of physical activity. They will be encouraged to read this in more detail and guided through its completion. The participant will receive an exercise prescription using the Pre-Intervention Assessment Tool (PIAT) and following discussion with the participant on a realistic and achievable starting point.
~The booklets provided will guide participants through the exercise programme which is a graduated walking-based activity intervention. Both booklets provide participants with a suggested starting point for walking distance per week based on their PIAT score as well as motivational and behaviour change strategies to encourage participation."
11284477|NCT02802826|No Intervention|Standard Care|No sham or placebo conditions will be used in the study. At visit 1 standard care participants will be given the Standard Care Information Sheet and asked to simply continue with standard care.
11284478|NCT02802813|Active Comparator|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
11284479|NCT02802813|Placebo Comparator|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
11284480|NCT02802800|Experimental|Water|Plyometric Training in water, twice per week for 6 weeks.
11284481|NCT02802800|Experimental|Land|Plyometric training on land, twice per week for 6 weeks.
11284482|NCT02802787|Experimental|Camp Discovery|One week activity based camp
11284483|NCT02802774|Active Comparator|Plaster Splint|
11284484|NCT02802774|Active Comparator|Velcro Brace|
11284485|NCT02802774|Active Comparator|Soft Dressing|
11284486|NCT02802748|Experimental|Metronomic Vinorelbine + Letrozole|"Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
~Letrozole: 2.5mg daily, for 3 weeks"
11284487|NCT02802748|Active Comparator|Letrozole alone|Letrozole: 2.5mg daily, for 3 weeks
11284488|NCT02802748|Active Comparator|Metronomic Vinorelbine alone|Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
11284489|NCT02802735|Experimental|Part 1: Apremilast 20mg|A single oral dose of 20 mg (1 tablet) apremilast
11284490|NCT02802735|Experimental|Part 1: Apremilast 30mg|A single dose of oral 30 mg (1 tablet) apremilast
11284491|NCT02802735|Experimental|Part 1: Apremilast- 40mg|A single dose of oral 40 mg (2 x 20 mg tablets) apremilast
11284492|NCT02802735|Experimental|Part 2: Apremilast 60mg or matching placebo|A daily dose of 60 mg oral apremilast (one 30 mg tablet orally in the morning and one 30 mg tablet orally in the evening) or matching placebo will be administered to subjects since this is the targeted therapeutic dosing regimen for the indications of PsA and psoriasis.
11284493|NCT02802722|Active Comparator|Immediate supplementation|Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
11284494|NCT02802722|Placebo Comparator|Delayed supplementation|Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
11284495|NCT02802709|Experimental|SB-061|SB-061
11284496|NCT02802709|Placebo Comparator|Placebo|Placebo
11284497|NCT02802696|Experimental|Furosemide|Diuretic
11284498|NCT02802696|Placebo Comparator|Placebo|Normal saline
11284499|NCT02802683|Experimental|"BUPI,P"|patients who received hyperbaric bupivacaine and continous infusion of phenylephrine
11284500|NCT02802683|Placebo Comparator|"BUPI,N"|patients who received hyperbaric bupivacaine and continous infusion of normal saline
11284501|NCT02802683|Experimental|"LEVO,P"|patients who received isobaric levobupivacaine and continous infusion of phenylephrine
11284502|NCT02802683|Active Comparator|"LEVO,N"|patients who received isobaric levobupivacaine and continous infusion of normal saline
11284503|NCT02802670|Experimental|GDC-0810|GDC-0810 300-mg dose administered as oral solution, containing approximately 100 microcuries of [14C]-labeled GDC-0810.
11284504|NCT02802657|Experimental|Conbercept 0.5mg Treat-and-Extend regimen|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and Treat-and-Extend Regimen of the same dose guided by BCVA stabilization and optical coherence tomography (OCT) in the extension treatment period.
~Intervention: Drug: Conbercept"
11284505|NCT02802657|Active Comparator|Conbercept 0.5mg Pro Re Nata|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period.
~Intervention: Drug: Conbercept"
11284506|NCT02802644|Experimental|DPP-4 Inhibitor|Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
11284507|NCT02802644|Active Comparator|Non DPP-4 Inhibitor|Oral anti-diabetic medication except DPP-4 inhibitor
11284508|NCT02802631|Experimental|Minocin for Injection (minocycline)|Minocin (minocycline for injection) for will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg. Within each cohort, subjects will receive a single dose on Day 1, followed by 7 days of multiple-doses (Days 4-10, given every 12 hours), followed by a single dose on Day 11.
11284509|NCT02802631|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo is in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection USP). Dosing is to the same schedule as subjects randomized to Minocin (minocycline) for Injection.
11284510|NCT02802618|Experimental|Interactive 3D visualization technique|"The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with 3D technique.
~Patients randomized into education by 3D technique."
11284511|NCT02802618|No Intervention|Conventional technique|The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with conventional technique. Patients randomized into education by conventional technique.
11284512|NCT02802605|Experimental|Bemiparin|Bemiparin 3.500 U, once a day during hospitalization
11284513|NCT02802605|No Intervention|No drug|Clinical practice as usual
11284514|NCT02802592|Active Comparator|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
11284515|NCT02802592|Placebo Comparator|Normal Saline|250 ml normal saline infused over 1 hr
11284521|NCT02802553|Experimental|Integrated Imaging Goggles|Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle. Viewed by Smart Googles and compare lesions detected by SPY Elite in addition to those detected by gamma probe and blue dyes.
11284522|NCT02802540|Experimental|Nabilone|Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.
11284523|NCT02802540|Placebo Comparator|placebo|Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.
11284524|NCT02802527|Other|Bronchoscopy Guided|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
11284525|NCT02802527|Other|Direct Laryngoscopy|Performing percutaneous tracheostomy by placing the tube higher up, near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
11284526|NCT02802514|Experimental|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
11284527|NCT02802514|Experimental|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
11284528|NCT02802514|Experimental|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
11284529|NCT02802514|Experimental|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
11284530|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
11284531|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
11284532|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
11284533|NCT02802488|Experimental|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
11284534|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
11284535|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
11284536|NCT02802462|Experimental|High intensity-interval (HIT)|
11284537|NCT02802462|Experimental|moderate intensity-continuous (MCT)|
11284538|NCT02802462|No Intervention|control (CTL)|
11284539|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
11284540|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
11284541|NCT02802436|Experimental|Extraction with socket graft and GEM21|"Intervention - Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Test site (active arm) will be injected with Bioactive Agent (PDGF - Platelet derived growth factor). At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd.
~Bioactive agent - GEM21S (Growth factor enhanced matrix) Dosage - one cup containing 0.5 cc of ß-TCP particles (0.25 to 1.0 mm); and one syringe containing a solution of 0.5 mL rhPDGF-BB (0.3 mg/mL)"
11284542|NCT02802436|Other|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Normal saline will be used and no growth factor to maintain the volume in control sites
11284543|NCT02802423|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
11284544|NCT02802410|Experimental|IQ-Tape|IQ-application on leg muscles muscles
11284545|NCT02802410|Experimental|Kinesiotape|Kinesiotape application on leg muscles
11284546|NCT02802410|Experimental|No-Tape|No-Tape on leg muscles
11284574|NCT02802241|No Intervention|no additional treatment|
11284575|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
11284547|NCT02802397|Other|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.
~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
11284548|NCT02802397|Other|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.
~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
11284549|NCT02802384||Cases|People with active Paget's Disease of Bone
11284550|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
11284551|NCT02802371|No Intervention|control group|Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.
11284552|NCT02802371|Active Comparator|Psychosocial intervention|Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
11284553|NCT02802371|Experimental|Pharmaceutical care and psychosocial support|Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
11284554|NCT02802358||Hip fracture|Patients with a hip fracture due to an accidental fall
11284555|NCT02802358||Wrist fracture|Patients with a wrist fracture due to an accidental fall
11284556|NCT02802345|Experimental|Nintedanib + placebo matching sildenafil|
11284557|NCT02802345|Active Comparator|Nintedanib + Sildenafil|
11284558|NCT02802332|Active Comparator|Footlength Card|Pregnant women will receive a card that enables them to measure the length of their baby's foot. The card contains a phone number to pre-recorded message that provides basic information/advice regarding care of preterm and/or low birth weight babies
11284559|NCT02802332|No Intervention|No Footlength Card|Women in this group do receive any footlength card.
11284560|NCT02802319|Experimental|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
11284561|NCT02802319|Active Comparator|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
11284562|NCT02802306|Experimental|Tack Implant|Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.
11284563|NCT02802293|Active Comparator|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
11284564|NCT02802293|Active Comparator|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
11284565|NCT02802293|Active Comparator|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
11284566|NCT02802280|Other|Cardiovascular risk in HCV patients|"Intervention:
~The only intervention to be carried out along the study will consist of a complete evaluation of cardiovascular risk of HCV patients both at baseline (pre-treatment) and after HCV treatment, through performing different tests (see below)
~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied at different times before and after the end of the treatment.
~The participation in the study will not influence neither the indication to treat nor the treatment used.
~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
11284567|NCT02802267|Experimental|inecalcitol|Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.
11284568|NCT02802267|Placebo Comparator|placebo|Two tablets of placebo 2mg each (total 4mg) taken orally every other day
11284569|NCT02802254|Experimental|Pedometer+physical-activity-feedback|At cardiac consultation patients receive a patient-targeted individual physical-activity-feedback.
11284570|NCT02802254|Active Comparator|Pedometer-only|Patients use a Pedometer in order to measure their daily step number
11284571|NCT02802241|Experimental|open-label placebo|
11284572|NCT02802241|Experimental|double-blind placebo|
11284577|NCT02802215|Active Comparator|Metformin group|40 women will receive metformin in dose of 1500 mg per day orally (500 mg every 8 hrs in the middle of meal) starting from 12th week of gestation till delivery.
11284578|NCT02802215|Placebo Comparator|control group|40 women will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet.
11284579|NCT02802202||Fibromyalgia|Individuals who met the criteria for a diagnosis of FM based upon the ACR diagnostic criteria.
11284580|NCT02802202||Myofascial Pain Syndrome|Individuals with a diagnosis of MPS that does not meet the American College of Rheumatology (ACR) diagnostic criteria for FM.
11284581|NCT02802202||Control|Individuals with no current or prior diagnosis consistent with MPS or FM.
11284582|NCT02802189|Experimental|exercise and INIT group|The first group (experimental) followed the exersice programme in combination with the integrated neuromuscular inhibition technique (INIT).
11284583|NCT02802189|Active Comparator|exercise group|"The protocol for this group was identical to the previous group with the sole difference that the application of INIT was not included.
~At the end of the exercise programme, relaxing breathing exercise and gentle stretching was applied for 15 min"
11284584|NCT02802176|Experimental|Intra-vaginal culture - INVOcell device|3 day intra-vaginal incubation using the INVOcell device
11284585|NCT02802176|Active Comparator|Traditional IVF culture|3 day traditional IVF incubation
11284586|NCT02802163|Experimental|Combination Therapy|Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
11284587|NCT02802150|Active Comparator|Zanthoxylum schinifolium seed Oil|Zanthoxylum schinifolium seed Oil 100% (4g/day)
11284588|NCT02802150|Placebo Comparator|soy bean oil|soy bean oil 99.9%, edible dyes 0.01% (4g/day)
11284589|NCT02802137|Active Comparator|Tafluprost drops|Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
11284590|NCT02802137|Active Comparator|Tafluprost and dorzolamide/timolol drops|Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
11284591|NCT02802124|Experimental|carbon-ion radiotherapy for tumor away from GI|For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels [55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx] are planned within the Phase I part.
11284592|NCT02802124|Experimental|carbon-ion radiotherapy for tumor adjacent to GI|"For tumor location which is adjacent to gastrointestine (less than 1 cm).We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.
~Three dose levels (carbon 60GyE/15Fx, carbon 67.5GyE/15Fx, carbon 75GyE/15Fx) are planned within the Phase I part."
11284593|NCT02802111|Experimental|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
11284594|NCT02802111|Experimental|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
11284595|NCT02802098|Experimental|Bevacizumab + Durvalumab|Treatment with DURVALUMAB 10 mg/kg Q2W IV infusion plus Bevacizumab 10 mg/ Kg Q2W, IV infusion for a maximum duration of treatment of 12 months. Study treatment should be discontinued prior to 12 months if there is confirmed PD (unless the investigator considers the subject to continue to receive benefit from treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue study treatment occur.
11284596|NCT02802085||Knee Arthroplasty|Vega Knee Arthroplasty
11284597|NCT02802072|Experimental|Enterprise stent implantation group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive Enterprise stent implantation in combination with antiplatelet medication for carotid artery stenosis.
11284598|NCT02802072|Experimental|Only aspirin medication group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive only antiplatelet medication for carotid artery stenosis.
11284599|NCT02802059|Experimental|EcN-Suspension|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension
11284600|NCT02802059|Placebo Comparator|Placebo|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo
11284601|NCT02802046||FFR≦0.8|FFR is a score of 0 to 1, FFR < 0.75, has proved almost always accompanied by myocardial ischemia.
11284602|NCT02802046||FFR>0.8|FFR > 0.80 almost never associated with myocardial ischemia.
11284603|NCT02802020|Experimental|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
11284604|NCT02802007|Experimental|Elipse Intragastric Balloon|Patients seeking weight loss received the Elipse Intragastric Balloon.
11284605|NCT02801994|Experimental|Ventilator settings, PAV|"A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.
~The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min."
11285640|NCT02795065|Active Comparator|Enoxaparin 40 mg subcutaneous once daily|
11284606|NCT02801981|Experimental|Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
11284607|NCT02801981|Experimental|Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
11284608|NCT02801981|Experimental|Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg|Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
11284609|NCT02801981|Experimental|Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg|Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
11284610|NCT02801968|Experimental|Tap block|Tap block with ropivacaine 2 mg/kg at the end of cesarean delivery. Postoperative analgesia with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
11284611|NCT02801968|Active Comparator|control group|Postoperative analgesia after cesarean delivery with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
11284612|NCT02801955||tumor marker|serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
11284613|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
11284614|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
11284615|NCT02801929|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11284616|NCT02801916|Other|Study subjects|Each healthy subject will receive each of the interventions in randomized order.
11284617|NCT02801903|Experimental|SB204 4%|Topically Once Daily (AM)
11284618|NCT02801890|Experimental|AD-MSC|The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
11284619|NCT02801890|Placebo Comparator|Placebo|The patients with ultra filtration failure (UFF) underwent Placebo injection.
11284620|NCT02801877|Experimental|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
11284621|NCT02801877|Experimental|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
11284622|NCT02801877|Experimental|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
11284623|NCT02801877|Experimental|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
11284624|NCT02801864|Experimental|Combined real tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. The stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. For the experimental group, the stimulation will be ramped up for 45 seconds and stay there for 20 min. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
11284625|NCT02801864|Sham Comparator|Combined sham tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. For the sham group, the stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. The stimulation will be ramped up for 45 seconds and then ramp down after the initial 45 seconds. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
11284626|NCT02801851|Experimental|Intervention SCREEN-ED|This is the arm that will receive the SCREEN-ED. SCREEN-ED is an innovative, yet practical intervention that combines screening with informing clinicians of the results and provides a checklist for delirium management that is tailored to the time-limited ED setting.
11284627|NCT02801838|Experimental|Ventilator settings, morphine titration|First, ventilator settings optimization and when the clinician judges necessary (remains discomfortable), opioid titration with a maximum of 10mg of morphine
11284628|NCT02801825|Experimental|Axillary artery.|Cannulation of the axillary artery.
11284629|NCT02801825|Experimental|Femoral artery.|Cannulation of the femoral artery.
11284630|NCT02801812||Systemic Lupus Erythematosus|patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.
11284631|NCT02801812||Healthy controls|subjects ≥18 years fulfilling the definition proposed in the protocol.
11284632|NCT02801799|Active Comparator|Infusion group 1|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 12 mL/h. This infusion rate is normal clinical practice when administering a perineural infusion of ropivacaine."
11284633|NCT02801799|Experimental|Infusion group 2|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 60 mL/h. This infusion rate is experimental."
11284634|NCT02801799|Experimental|Infusion group 3|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 300 mL/h. This infusion rate is experimental."
11285641|NCT02795065|Experimental|Bemiparin 3500 IU subcutaneous once daily|
11284635|NCT02801799|Experimental|Infusion group 4|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 600 mL/h. This infusion rate is experimental."
11284636|NCT02801799|Active Comparator|Infusion group 5|"Intervention:
~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.
~Infusion rate will be 1800 mL/h. This infusion rate is normal clinical practice when administering a perineural bolus of ropivacaine."
11284637|NCT02801786|Placebo Comparator|Placebo|Five capsules containing placebo
11284638|NCT02801786|Experimental|Tamoxifen|Five capsules containing 20mg of tamoxifen.
11284639|NCT02801786|Experimental|Lidocaine|One sachet containing lidocaine gel at 4%
11284640|NCT02801773|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and adjunct probiotic one lozenge containig Lactobacillus reuteri per day during 3 month
11284641|NCT02801773|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and one lozenge containig placebo (mint lozenge) per day during 3 month
11284642|NCT02801760||Subjects Currently or Previously Enrolled in ATN 110/ATN 113|Younger and older YMSM and transgender women who have sex with men, ages 15 through 22 years, inclusive, at the time of consent into the ATN 110 or ATN 113 study.
11284643|NCT02801760||Sub-Sample of Subjects to Complete Qualitative Interview|A sub-sample of subjects who completed the web-based survey and indicated willingness to complete the qualitative interview.
11284644|NCT02801747|Experimental|Condition 1|Receives a core intervention session and the navigation intervention component (long duration; that is, up to 6 months).
11284645|NCT02801747|Experimental|Condition 2|Receives a core intervention session, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
11284646|NCT02801747|Experimental|Condition 3|Receives a core intervention session, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
11284647|NCT02801747|Experimental|Condition 4|Receives a core intervention session, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
11284648|NCT02801747|Experimental|Condition 5|Receives a core intervention session, the pre-adherence preparation component, and the navigation intervention component (short duration, that is, up to 3 months).
11284649|NCT02801747|Experimental|Condition 6|Receives a core intervention session, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
11284650|NCT02801747|Experimental|Condition 7|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
11284651|NCT02801747|Experimental|Condition 8|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
11284652|NCT02801747|Experimental|Condition 9|Receives a core intervention session, the Motivational Interviewing sessions component, and the navigation intervention component (short duration, that is, up to 3 months).
11284653|NCT02801747|Experimental|Condition 10|Receives a core intervention session, the Motivational Interviewing sessions component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
11284654|NCT02801747|Experimental|Condition 11|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
11284655|NCT02801747|Experimental|Condition 12|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
11284656|NCT02801747|Experimental|Condition 13|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, and the navigation intervention component (long duration, that is, up to 6 months).
11284657|NCT02801747|Experimental|Condition 14|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
11284658|NCT02801747|Experimental|Condition 15|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
11284659|NCT02801747|Experimental|Condition 16|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
11284660|NCT02801734|Experimental|Intervention|"Participants in the EQUIP intervention group will individually receive four face-to-face sessions with a palliative care nurse.
~For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate."
11284661|NCT02801734|No Intervention|Control|For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate.
11284662|NCT02801721|Active Comparator|Stimulation|Stimulation group received psycho social stimulation. In the stimulation there were anemic and non anemic children. All anemic children received iron(syrup) supplementation.
11284663|NCT02801721|No Intervention|No stimulation|No stimulation group did not receive any stimulation. In the no stimulation group there were anemic and non anemic children. All anemic children received iron (syrup) supplementation
11284664|NCT02801695|Experimental|L-Citrulline|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
11284665|NCT02801695|Placebo Comparator|Lactose|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
11284666|NCT02801682||Healthy Controls|
11284667|NCT02801682||Invasive Candidiasis|
11284672|NCT02801656|Experimental|Fecal Microbiota Transplantation|Oral, encapsulated fecal microbiota transplantation
11284673|NCT02801656|Active Comparator|Vancomycin|125 mg po qid x 10 days
11284674|NCT02801630|Sham Comparator|Sham Crossover|"After the enrollment and lead in period, subjects will be given a sham device to sleep with every night for a month. They will be asked to fill out their pain and analgesic use logs, and undergo the bi weekly assessments. After a month they will be crossed over to an active Painshield SAW patch device and will continue to complete their pain and analgesic use logs as well as undergo biweekly assessments for months two and 3."
11284675|NCT02801630|Active Comparator|Active Device|After the enrollent and lead in period, subjects will be given an active PainSHield SAW Patch device to sleep with every night. They will be asked to fill out their pain and analgesic use logs, and undergo bi weekly assessments. They will continue to use the device while completing their logs and undergoing assessments for 3 months.
11284676|NCT02801617|Experimental|Sequence 1 (PRO-067)|"study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
~Washout period: 21 hours"
11284677|NCT02801617|Active Comparator|Sequence 2 (GAAP Ofteno®)|"study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
~Washout period: 21 hours"
11284678|NCT02801591||GH AQ|
11284679|NCT02801578|Experimental|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.
~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
11284680|NCT02801565|Experimental|GH AQ|Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
11284681|NCT02801552|Experimental|Regenerative Endodontic Procedure + PRF|Visit 1: root canal dressing with triple antibiotic paste. Visit 2: a 5 ml sample of whole blood was drawn intravenously from the patient's forearm. The blood sample is centrifuged at 400 g for 10 min. The prepared PRF membrane is cut into segments, the fragments are placed into the canal space. The coronal is sealed mineral trioxide aggregate and composite resin.
11284682|NCT02801552|No Intervention|Regenerative Endodontic Procedure|Regenerative Endodontic Procedure Visit 1: root canal dressing with triple antibiotic paste. Visit 2: Blood clot formation is induced in the root canal after disinfection. No PRF was used in this group. Then the canal access is sealed with mineral trioxide aggregate and composite resin.
11284683|NCT02801539|Experimental|Respiratory muscle training (RMT)|Subjects in the experimental arm will be given an inspiratory and expiratory RMT device to use during Duke-based and home-based RMT therapy.
11284684|NCT02801539|Sham Comparator|Sham-RMT|Subjects in control arm will be given an inspiratory and expiratory sham-device and will complete Duke-based and home-based sham-RMT therapy.
11284685|NCT02801526|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
11284686|NCT02801526|Experimental|CKD-330|CKD-330 16/5mg - A, PO, 1days or 22days
11284687|NCT02801513|Experimental|Brief Mindfulness Training|The brief mindfulness training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to engage in formal meditation practice for about 25 minutes twice per day on six out of seven days of each week using recorded guided meditations. Practices were shorter in duration than the practices in Mindfulness-Based Cognitive Therapy (MBCT, Segal et al., 2002) in order to allow for more flexibility in scheduling the practices, but followed the standard sequence of mindfulness-based interventions.
11284688|NCT02801513|Active Comparator|Resting Control Training|The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
11284689|NCT02801500|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
11284690|NCT02801500|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
11284691|NCT02801487|Experimental|CIRT with concurrent chemo arm|Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m^2, weekly).
11284692|NCT02801474|Experimental|direct reduction|Intervention: The posterior and lateral malleoli were accessed via a posterolateral approach with the patients in prone position. The fibular fracture was exposed and reduced anatomically in the first place. The posterior malleolus was then exposed between the fiexor halluces longus and peroneus longus interval. The posterior malleolar fragment was then reduced with reference to the typical metaphyseal-diaphyseal spike of the posterior malleolus. One-third tubular plate, reconstruction plate, or distal radius plate were applied spanning the fracture in a buttress mode. Cannulated screws could also be used.
11284693|NCT02801474|Experimental|indirect reduction|Intervention: After open reduction and internal fixation of lateral and medial malleolar fractures, the posterior malleolus was then reduced through ligamentotaxis with the ankle in dorsiflexion. One or two 4.0 mm cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
11284694|NCT02801461|Experimental|Three-sessions of ESWT|ESWT was given once a week for 3 weeks.
11284695|NCT02801461|Active Comparator|One-session of ESWT|Single ESWT was given.
11284696|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
11284697|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
11284728|NCT02801305|Experimental|Diltiazem Gel 2%|About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
11284698|NCT02801435|Experimental|Cohort 1-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284699|NCT02801435|Placebo Comparator|Cohort 1-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284700|NCT02801435|Experimental|Cohort 2-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284701|NCT02801435|Placebo Comparator|Cohort 2-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284702|NCT02801435|Experimental|Cohort 3-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284703|NCT02801435|Placebo Comparator|Cohort 3-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284704|NCT02801435|Experimental|Cohort 4-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284705|NCT02801435|Placebo Comparator|Cohort 4-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
11284706|NCT02801422||Cannabis Dependence|ages 18-40
11284707|NCT02801422||Healthy control subjects|socio-demographically matched
11284708|NCT02801409|Active Comparator|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
11284709|NCT02801409|Experimental|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
11284710|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
11284711|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
11284712|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
11284713|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
11284714|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
11284715|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
11284716|NCT02801383|Active Comparator|Treatment group|received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
11284717|NCT02801383|Placebo Comparator|controlled group|received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
11284718|NCT02801370|Experimental|OTO-201|
11284719|NCT02801370|Sham Comparator|Control|
11284720|NCT02801357|Experimental|lofexidine with tapering buprenorphine|Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
11284721|NCT02801344|Experimental|Normal protein intake|participants will receive the controlled-diet containing 0.8 g protein /kg/day and the test drink containing 0.14 g protein/kg/d.
11284722|NCT02801344|Experimental|Moderate protein intake|participants will receive the controlled-diet containing 1.20 g protein /kg/day and the test drink containing 0.40 g protein/kg/d.
11284723|NCT02801344|Experimental|High protein intake|participants will receive the controlled-diet containing 1.83 g protein /kg/day and the test drink containing 1.03 g protein/kg/d.
11284724|NCT02801331|Experimental|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth. SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed). Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
11284725|NCT02801331|No Intervention|Treatment as Usual (TAU)|Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS. Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
11284726|NCT02801318|Other|Polysomnography|
11284727|NCT02801305|Placebo Comparator|Vaseline|About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
11285708|NCT02794649||healthy|Individuals without a history of kidney or bowel disease
11284729|NCT02801305|Experimental|Nitroglycerin Ointment 2%|About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
11284730|NCT02801292|Other|administering of ketamine|adjuvant to standard of care
11284731|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
11284732|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
11284733|NCT02801266|Experimental|Intervention|The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.
11284734|NCT02801266|No Intervention|No intervention|The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.
11284735|NCT02801240|Experimental|Nutrition Support Product|Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
11284736|NCT02801227|Experimental|Oxytocin|
11284737|NCT02801227|Experimental|Prostaglandin E2|
11284738|NCT02801214||Recreational Cannabis Use|ages 18-40
11284739|NCT02801214||Healthy control subjects|socio-demographically matched
11284740|NCT02801201|Active Comparator|sedation|Midazolam : 0,10 mg/kg
11284741|NCT02801201|Active Comparator|spinal anesthesia|Bupivacain 10 mg
11284742|NCT02801188|Placebo Comparator|Bupivacaine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
11284743|NCT02801188|Active Comparator|Mixture of bupivacaine and dexmedetomidine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
11284744|NCT02801175||RF|Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation
11284745|NCT02801175||Cryoballoon|Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation
11284746|NCT02801162|Active Comparator|Conventional ABG analyser|
11284747|NCT02801162|Experimental|Proxima 3® arterial blood gas|
11284748|NCT02801149|No Intervention|No further imaging|Patients randomised to this group will receive standard care, i.e. will not undergo additional imaging scans at A&E/Urgent Care Centre.
11284749|NCT02801149|Experimental|Wrist Magnetic Resonance Imaging (MRI)|Patients randomised to this group will undergo an additional 3-sequence wrist MRI during the initial A&E/Urgent Care Centre episode.
11284750|NCT02801136|Experimental|CBT for PNES|CBT-PNES consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
11284751|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
11284752|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires.
11284753|NCT02801123|Experimental|Preference: MBCR (im)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to immediate treatment
11284754|NCT02801123|Experimental|Preference: TCQ (im)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to immediate treatment
11284755|NCT02801123|Active Comparator|Preference: MBCR (wl)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to waitlist
11284756|NCT02801123|Active Comparator|Preference: TCQ (wl)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to waitlist
11284757|NCT02801123|Experimental|No Preference: MBCR (im)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - immediate
11284758|NCT02801123|Experimental|No Preference: TCQ (im)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - immediate
11284759|NCT02801123|Active Comparator|No Preference: MBCR (wl)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - waitlist
11284760|NCT02801123|Active Comparator|No Preference: TCQ (wl)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - waitlist
11284761|NCT02801097|Experimental|RRx-001 + Irinotecan|Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.
11284762|NCT02801084|Experimental|Float|One arm only: restricted environmental stimulation
11284763|NCT02801071|Experimental|L-citrulline|15 g L-citrulline p.o. per day (3x 5g) for 24 weeks
11284764|NCT02801071|Placebo Comparator|Placebo|L-citrulline Placebo 3 times daily p.o. for 24 weeks
11284765|NCT02801058|No Intervention|Control|Simple observation
11284766|NCT02801058|Sham Comparator|Shame|Light touch manipulative simulation
11284767|NCT02801058|Experimental|Treatment|Osteopathic manipulative techniques on the abdominal diaphragm
11284768|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
11284769|NCT02801032|Active Comparator|Active Treatment|Tadalafil 20 mg Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
11284770|NCT02801032|Placebo Comparator|Control|Placebo Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
11284771|NCT02801019|Experimental|E-XLPE|E-poly
11284772|NCT02801019|Active Comparator|C-XLPE|ArComXL
11284773|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
11284774|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
11284775|NCT02800980||Drainage and sclerotherapy.|Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.
11284776|NCT02800980||Drainage alone.|Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.
11284777|NCT02800967|Active Comparator|Pure Aronia juice|Participants will consume 100 ml of pure Aronia juice per day for 28 days
11284778|NCT02800967|Active Comparator|Aronia juice-based beverage|Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
11284779|NCT02800967|Placebo Comparator|Placebo beverage|Participants will consume 100 ml of Placebo beverage per day for 28 days
11284780|NCT02800954|Experimental|multiple myeloma group|case group = patients with multiple myeloma
11284781|NCT02800954|Experimental|MGUS group|monoclonal gammopathy of undetermined significance
11284782|NCT02800954|Other|healthy control group|control group = healthy subjects
11284783|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
11284784|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
11284785|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
11284786|NCT02800915|Experimental|Intervention, telemedicine and interdisciplinary cooperation|The intervention group will be offered regular interdisciplinary outpatient follow-up via telemedicine.
11284787|NCT02800915|Active Comparator|Control, interdisciplinary guidance on request.|The control group will receive guidance based on existing routines, and based on initiative taken by the local healthcare service/ patient/ next of kin.
11284788|NCT02800902|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
11284789|NCT02800902|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
11284790|NCT02800902|Active Comparator|group 3|SRP followed by 1.2% Atorvastatin (ATV) gel
11284791|NCT02800889|Experimental|Treatment: Pixantrone|Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment. At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts. The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity. During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced. Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
11284792|NCT02800876||asymptomatic not ruptured aneurysm|Patients with asymptomatic not ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
11284793|NCT02800876||symptomatic not ruptured aneurysm|Patients with symptomatic aortic aneurysms greater than 3 cm who received a clinical indicated CT
11284794|NCT02800876||symptomatic ruptured aneurysm|Patients with symptomatic ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
11284795|NCT02800876||patients with small aneurysms|Patients with small aortic aneurysms approximately 5.5 cm, ruptured and not ruptured, who received a clinical indicated CT
11284796|NCT02800863||Dorsal Root Ganglion (DRG) Stimulation|
11284797|NCT02800850|Experimental|Bright Light Group|Bright Light Exposure
11284798|NCT02800850|Placebo Comparator|Control Group|Placebo Light Exposure
11284799|NCT02800824|Experimental|Budesonide rectal foam|
11284800|NCT02800824|Active Comparator|Uceris rectal foam|
11284801|NCT02800811|Experimental|Part 1: Cohort A, Group 1, FR104|Dose: single 0.005 mg/kg.
11284802|NCT02800811|Experimental|Part 1: Cohort A, Group 2, FR104|Dose: single 0.05 mg/kg.
11284803|NCT02800811|Experimental|Part 1: Cohort A, Group 3, FR104|Dose: single 0.2 mg/kg.
11284804|NCT02800811|Experimental|Part 1: Cohort A, Group 4, FR104|Dose: single 0.5 mg/kg.
11284805|NCT02800811|Placebo Comparator|Part 1: Cohort A, placebo|Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).
11284806|NCT02800811|Experimental|Part 1: Cohort B, Group 7, FR104|Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
11284807|NCT02800811|Experimental|Part 1: Cohort B, Group 8, FR104|Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
11284808|NCT02800811|Experimental|Part 1: Cohort B, Group 9, FR104|Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
11284809|NCT02800811|Experimental|Part 1: Cohort B, Group 9 bis, FR104|Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.
11284810|NCT02800811|Placebo Comparator|Part 1: Cohort B, placebo|placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)
11284811|NCT02800811|Experimental|Part 2: Group 10, FR104|Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.
11284812|NCT02800811|Experimental|Part 2: Group 11, FR104|Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.
11284813|NCT02800811|Placebo Comparator|Part 2: placebo|placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.
11284814|NCT02800798||High risk for OSA|High risk OSA defines as Stop-bang score ≥ 3
11284815|NCT02800798||Low risk for OSA|Low risk OSA defines as Stop-bang score < 3
11284816|NCT02800785|Active Comparator|Antibiotics Therapy Arm|Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
11285414|NCT02796456||Obese women with gestational diabetes|BMI more than 30 kg/m2 and with gestational diabetes
11284817|NCT02800785|Active Comparator|Appendectomy Arm|Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.
11284818|NCT02800772|Experimental|acetic acid|spray 50ml acetic acid to duodenal bulb
11284819|NCT02800772|Placebo Comparator|saline|spray 50ml saline to duodenal bulb
11284820|NCT02800759|Active Comparator|100% of JOINTRUS®|After randomization, 100% dose of JOINTRUS® is taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
11284821|NCT02800759|Active Comparator|80% of JOINTRUS®|After randomization, 80% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
11284822|NCT02800759|Active Comparator|62.4% of JOINTRUS®|After randomization, 62.4% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
11284823|NCT02800759|Placebo Comparator|Starch 100%|After randomization, starch 100% was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
11284824|NCT02800746|Experimental|Experimental group|Ferric carboxymaltose
11284825|NCT02800746|Placebo Comparator|Control Group|Placebo
11284826|NCT02800733|Experimental|saffron|450 mg of saffron capsule once a day for 6 weeks
11284827|NCT02800733|Placebo Comparator|placebo|placebo capsule once a day for 6 weeks
11284828|NCT02800720|Experimental|Meditation Awareness Training|"Target Intervention Arm:
~8-week meditation intervention"
11284829|NCT02800720|Active Comparator|Cognitive Behavioural Therapy for Groups|"Active Comparator Arm:
~8-week CBT-based intervention"
11284830|NCT02800707|Active Comparator|Sucralose|Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
11284831|NCT02800707|Active Comparator|Stevia|Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
11284832|NCT02800681||Asperger syndrome|"Expert panel evaluation for identification of participants with typical symptoms
~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum
~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being
~Other general interviewer ratings for assessing functioning and severity of psychopathology"
11284833|NCT02800681||Schizotypal disorder|"Expert panel evaluation for identification of participants with typical symptoms
~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum
~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being
~Other general interviewer ratings for assessing functioning and severity of psychopathology"
11284834|NCT02800668||DJBL implant-group|"T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.
~The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR <50 ml/min), pregnancy or breast feeding."
11284835|NCT02800655|Experimental|DHFS with IS-ARV|Digital Health Feedback System (DHFS) with either IS- Odefsey®, IS- Genvoya®, IS-Biktarvy®, IS- Tivicay® and Truvada® or IS- Tivicay® and Descovy ® (IS-co-encapsulated with ingestion sensor) -1 or 2 capsules daily (QD), depending on the treatment regimen, administered orally for 16 weeks.
11284836|NCT02800642|Experimental|Intravitreal (IVT) aflibercept|Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
11284837|NCT02800629|Active Comparator|Intervention|Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
11284838|NCT02800629|Placebo Comparator|Control|Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
11285059|NCT02798835|Active Comparator|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
11284839|NCT02800616|Experimental|Full intervention group|The full intervention ('The Healthy Primary School of the Future') is implemented in two schools involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years.
11284840|NCT02800616|Experimental|Partial intervention group|The partial intervention ('The Physical Activity School') is implemented in two other schools: involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years. Hence, this intervention only differs from the full intervention on the absence of nutritional intervention. Instead, children bring their own food from home, as they normally do.
11284841|NCT02800616|No Intervention|Control group|Four primary schools will function as control schools. The control schools have a representative Dutch school environment in terms of lifestyle education, school hours and amount of Physical Education (PE) lessons.
11284842|NCT02800603|Experimental|Family Check Up|FCU Intervention: All 280 participants will undergo screening and a baseline FCU assessment before randomization. Once randomized, the FCU group (n=140) will be provided with a feedback visit and up to 6 optional sessions of the EDP curriculum over 16 weeks.
11284843|NCT02800603|No Intervention|Community Control|The Community Control group (n=140) will receive general information that includes a list of all the relevant services available in Hamilton. As such, the community control group would be provided with all the information needed to obtain standard care.
11284844|NCT02800590|Experimental|ABP-700 30 μg/kg/min|Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
11284845|NCT02800590|Experimental|ABP-700 40 μg/kg/min|Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
11284846|NCT02800590|Experimental|ABP-700 45 μg/kg/min|Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
11284847|NCT02800577|Other|All participants|Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
11284848|NCT02800564|Experimental|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months plus interactive voice response systems (IVRS) and monthly open community meetings.
11284849|NCT02800564|Experimental|Passive mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months
11284850|NCT02800551|Experimental|SBRT (Arm A)|"dose-intensified image-guided SBRT using simultaneous integrated boost:
~in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.
~In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively."
11284851|NCT02800551|Active Comparator|Conventional Radiation Therapy (Arm B)|"External 3-dimensional conformal radiotherapy (3D-CRT):
~Homogeneous irradiation of the affected vertebra delivering either
~20 Gy in 5 fractions or
~30 Gy in 10 fractions."
11284852|NCT02800551|Experimental|SBRT (prospective observational)|Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.
11284853|NCT02800538|Experimental|Lauric acid|the nutrient that can be widely found in daily food.
11284854|NCT02800538|Experimental|Palmitic acid|the nutrient that can be widely found in daily food.
11284855|NCT02800538|Experimental|Capric acid|the nutrient that can be widely found in daily food.
11284856|NCT02800538|Placebo Comparator|Saline|physiological salt water
11284857|NCT02800525|Experimental|Picosecond laser|"The pigmented lesions on this half-side of the face would be treated with picosecond laser.
~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.
~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
11284858|NCT02800525|Active Comparator|Q-switched Nd:YAG laser|"The pigmented lesions on this half-side of the face would be treated with q-switched Nd:YAG laser.
~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.
~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
11284859|NCT02800512|Active Comparator|Sacrocolpopexy|Robotic sacrocolpopexy
11284860|NCT02800512|Active Comparator|HUSLS|Vaginal high uterosacral ligament suspension
11284861|NCT02800499||KOCOSS|The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional observational study within the Korean COPD patients
11284862|NCT02800486|Experimental|Intra-arterial Cetuximab with Re-Irradiation|Mannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
11284863|NCT02800473|Other|Experimental|"Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.
~Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.
~24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects"
11284864|NCT02800460|Other|Deep brain stimulation with fMRI-3T|Patients will have a 3T-fMRI before their usual MRI-1,5T
11284865|NCT02800447|Experimental|Treatment|baseline BEACOPP regimen
11284866|NCT02800447|Active Comparator|controlled group|ABVD regimen
11284867|NCT02800434|Experimental|hand allograft|
11284868|NCT02800421||no organ damage|no evidence of HLI and CI-AKI
11284869|NCT02800421||CI-AKI only|CI-AKI, but no HLI
11284870|NCT02800421||HLI only|HLI, but no CI-AKI
11284871|NCT02800421||combined CI-AKI and HLI|Both CI-AKI and HLI
11284872|NCT02800408|Experimental|Whole grain high-BCX maize|Whole grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
11284873|NCT02800408|Experimental|Refined grain high-BCX maize|Refined (degermed) grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
11284874|NCT02800408|Placebo Comparator|Whole grain white maize|Whole grain, white maize (low in beta-cryptoxanthin) will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
11284875|NCT02800395|Other|Nutritional evaluation|
11284876|NCT02800382|Other|Lung Malignancy|"Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
~The samples (fine-needle aspiration biopsy and fine-needle aspiration cytology) were diagnosed by pathological examination."
11284877|NCT02800382|Other|Lung bening Diseases|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
11284878|NCT02800369|Experimental|ZFN-603 and ZFN-758|Subjects will receive suppository with ZFN-603 or ZFN-758
11284879|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
11284880|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
11284881|NCT02800343||Cardiovascular surgery|All adult patients undergoing elective or emergency cardiovascular surgery at the study site
11284882|NCT02800330|Other|Arm A (e.g. sequence phase A-B-C)|In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
11284883|NCT02800330|Other|Arm B (e.q. sequence phase C-B-A)|In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
11284884|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
11284885|NCT02800265|Experimental|Avmacol during week 2 for 3 days|"Buccal cells line the inner cheek, and will be collected from the inner right cheek with a cytobrush (a q-tip like swab) by a trained investigator.
~During the second week the participant will take 8 Avmacol tablets every evening for 3 evenings (Day 2, 3, 4), and record the time of each dose in the provided diary. Research blood collection: on days 1 and 5. Overnight urine collection."
11284886|NCT02800252|Placebo Comparator|Control Group|Full-mouth periodontal debridement and placebo
11284887|NCT02800252|Active Comparator|Test 1|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
11284888|NCT02800252|Active Comparator|Test 2|omega-3 plus aspirin before periodontal therapy
11284889|NCT02800239|Experimental|Active, adolescent females|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
11284890|NCT02800226|Experimental|10Hz|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
11284891|NCT02800226|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
11284892|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
11284893|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
11284894|NCT02800200|Experimental|Platelet rich plasma|The ultrasoud-guided injection with Platelet rich plasma (3cc) was perfomed in both groups.
11284895|NCT02800200|Experimental|Active shock wave|One-session active shock wave 2 weeks later after PRP injection was performed in intervention group.
11284896|NCT02800200|Placebo Comparator|Sham shock wave|One-session sham shock wave 2 weeks later after PRP injection was performed in control group.
11284897|NCT02800187|Experimental|three-sessions of ESWT|Active three-sessions of ESWT ( once a week for 3 weeks) was given.
11284898|NCT02800187|Active Comparator|one-session of ESWT|One-session of ESWTactive ESWT was given.
11284899|NCT02800187|Active Comparator|Night splint|The night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study. Another 3 sessions of sham ESWT was given.
11284900|NCT02800174|Experimental|Smart nitinol stent implantation group|The Smart nitinol stent system was used (import product registration number YZB/USA 0115-2008; Nitinol stent system, trade name SMART Control). The stent system comprises a self-expanding stent and a delivery system. The self-expanding stent is composed of a nickel titanium alloy and the ends of the stent are equipped with tantalum radiopaque markers. The Smart nitinol stent system is sterilized with ethylene oxide gas and is intended for single use only.
11284901|NCT02800174|Active Comparator|Antiplatelet drug group|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
11284902|NCT02800161|Active Comparator|Trehalose|Trehalose 70g/die
11284903|NCT02800161|Placebo Comparator|Placebo|Maltose 70g/die
11284904|NCT02800148|Experimental|Azelaic acid foam|
11284905|NCT02800148|Active Comparator|Finacea Foam|
11284906|NCT02800148|Placebo Comparator|Placebo Foam|
11284907|NCT02800135|Experimental|Furosemide stress test|
11284908|NCT02800122||Patients with acute dyspnea|"Patients with acute dyspnea treated by a medical team of emergencies of CHRU of Nancy.
~All patients admitted to the emergencies in the last 5 years matching the inclusion criteria will be evaluated. About 4,000 patients will be affected, including more than 800 patients with acute heart failure. (Figures based on export of ICD X codes (R06.0: Dyspnea) of patients cared in extra-hospital for acute dyspnea (diagnosis Dyspnea + Heart Failure) over the last 5 years)."
11285172|NCT02798042||Patient population|Patients undergoing bariatric surgery
11284909|NCT02800096|Active Comparator|Gambling Internet intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
11284910|NCT02800096|Experimental|Gambling Internet intervention + MoodGYM|The G+MH intervention condition will consist of the G-only intervention and an online intervention for depression and anxiety. The mental health intervention chosen is MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
11284911|NCT02800083|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
11284912|NCT02800083|Placebo Comparator|Placebo|placebo
11284913|NCT02800070|Experimental|Treatment Arm|Patients will receive Health Canada approved transduced autologous CD34+ cell product.
11284914|NCT02800044|Experimental|Wearing glucose sensor|The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..
11284915|NCT02800031|Experimental|Participants|"Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).
~Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method.
~Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes.
~Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy.
~All specimens will be examined histopathologically."
11284916|NCT02800005|Other|BMI group (Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
11284917|NCT02800005|Experimental|AFA group(Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.
11284918|NCT02799992|Active Comparator|Half Dose Photodynamic Therapy|Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
11284919|NCT02799992|Experimental|689 nm Laser Treatment|A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
11284920|NCT02799979||Case|Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months
11284921|NCT02799979||Control|Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline
11284922|NCT02799966|Other|Early Treatment Group|Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury
11284923|NCT02799966|Other|Late Treatment Group|Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury
11284924|NCT02799953|Experimental|Technology-based self-management model|Participants randomized to the intervention group will be given a tablet-based, interactive touch-screen self-monitoring system free of charge to perform disease self-monitoring in their homes.
11284925|NCT02799953|No Intervention|Conventional self-management|Participants randomized to the usual care group will not be provided access to tablet computers but a 2-in-1 blood pressure and blood glucose monitor and a paper-based log book to perform conventional self-monitoring.
11284926|NCT02799940||Computed tomography in acute respiratory distress syndrome|The lung on computed tomography (CT) in patients with acute respiratory distress syndrome (ARDS) has revealed a heterogeneous pattern of lung injury, with areas of normal lung interspersed with altered regions: ground-glass opacification and consolidation among the most frequent. It has been performed quantitative assessments of ARDS by means of CT, thus enabling a correlation of such pathologic details with physiologic, clinical parameters and with patient outcomes. Therefore, the primary objective of the study is to determine the correlation between the extent of oxygenation (PaO2/FiO2) and the degree of consolidation (total CO) in the CT. The secondary objectives are to determine: the correlation between the driving pressure, ventilator variables and the total CO; the independent variables associated with total CO; differences in the CT with respect to the total lung-disease score (total CO plus total value of ground-glass opacification) between survivors and nonsurvivors.
11284927|NCT02799927|Experimental|Biodentine|"Biodentine (Septodont, Saint-Maur-des-Fosses, France) has been recently introduced and marketed as a bioactive dentin substitute. The Biodentine powder contains tricalcium silicate, dicalcium silicate and calcium oxide, while its liquid consists of calcium chloride and a carboxylate-based hydrosoluble polymer (water-reducing agent).
~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the preparation of Biodentine liner (a mix of powder and liquid), following the manufacturers' instructions, and its placement over the remanent carious dentin layer."
11284928|NCT02799927|Active Comparator|Ultra-Blend plus (Calcium hydroxide)|"Ultra-Blend plus® (Ultradent Products Inc., South Jordan, UT, USA). This material is a light-activated calcium hydroxide based-liner. Calcium hydroxide has demonstrated to reduce and promote immediate deactivation of the residual microorganisms after IPT.
~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the placement of Ultra-Blend plus liner over the remanent carious dentin layer, using a dycal metallic applicator. Finally, the liner is cured through light exposure during 20 seconds ."
11284929|NCT02799901|Experimental|Patient|patient with Advanced melanoma
11284930|NCT02799888|Experimental|Maraviroc + standard GVHD prophylaxis|Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.
11284931|NCT02799875|Active Comparator|Higher permissive hypercapnia|Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 75mmHg; pH < 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
11284932|NCT02799875|Active Comparator|Lower permissive hypercapnia|Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 55mmHg; pH < 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
11284933|NCT02799849|Other|Narcoleptic patients|
11284934|NCT02799849|Other|hypersomnic patients|
11284935|NCT02799836|Experimental|Light deprived study subjects|Study subjects who are blindfolded for 48 hours
11284936|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
11284937|NCT02799797|Active Comparator|short axis (SAX) placement of adductor canal catheters|Procedure: Ultrasound guided short axis (SAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a PAJUNK Contiplex S catheter along the short axis of the middle part of adductor canal
11284938|NCT02799797|Experimental|long axis (LAX) placement of adductor canal catheters|Procedure: Ultrasound guided long axis (LAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a catheter along the long axis of the middle part of adductor canal
11284939|NCT02799784|Experimental|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
11284940|NCT02799784|Experimental|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
11284941|NCT02799758|Experimental|NK-104-CR|NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.
11284942|NCT02799758|Active Comparator|Livalo® IR|Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.
11284943|NCT02799745|Active Comparator|Enzalutamide|Taken once daily
11284944|NCT02799745|Other|Active Surveillance (AS)|AS arm will not receive any study drug
11284945|NCT02799706|Active Comparator|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.
~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.
~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
11284946|NCT02799706|Experimental|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.
~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
11284947|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
11284948|NCT02799680|Experimental|allogeneic CART-33|infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
11284949|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
11284950|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
11284951|NCT02799641|Placebo Comparator|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
11284952|NCT02799641|Experimental|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
11285173|NCT02798029|Experimental|Treatment (FFSRT)|Patients undergo FFSRT daily over 30 minutes for 3-5 days.
11284953|NCT02799628|Active Comparator|intervention|"Give the physical therapy of low back pain educational video + therapist introduction and recommendation video, at the first time of clinic visit.
~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
11284954|NCT02799628|Placebo Comparator|placebo|"Give the physical therapy of low back pain educational video, at the first time of clinic visit.
~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
11284955|NCT02799602|Experimental|BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel|Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel
11284956|NCT02799602|Placebo Comparator|Placebo + standard ADT + Docetaxel|Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel
11284957|NCT02799589|Experimental|Remifentanil-dexmedetomidine and caudal|Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
11284958|NCT02799576|Experimental|Curved needle|This will utilize the curved block needle of performance of regional block
11284959|NCT02799576|No Intervention|Traditional needle|This will utilize the traditional block needle of performance of regional block
11284960|NCT02799563|Experimental|Cohort A: Coach, Preselected number of cases|Cohort A completed the DKA simulator cases during two one-hour coached sessions. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
11284961|NCT02799563|Experimental|Cohort B: Coach, Self-selected number of cases|Cohort B completed the DKA simulator cases during two one-hour coached sessions. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
11284962|NCT02799563|Experimental|Cohort C: No coach, Preselected number of cases|Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
11284963|NCT02799563|Experimental|Cohort D: No coach, Self-selected number of cases|Cohort D completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
11284964|NCT02799550|Experimental|allogeneic CART-19|infusions of allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
11284965|NCT02799537|Experimental|Intervention|Participants in the intervention arm complete the Stanford letter advance directive
11284966|NCT02799537|Active Comparator|Control|Participants in the control arm complete the California state traditional advance directive
11284967|NCT02799511|Other|protein expression|
11284968|NCT02799498|Active Comparator|A-etanercept (ENBREL®) by auto-injector|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
11284969|NCT02799498|Other|B-etanercept (ENBREL®) by Manual injection|Single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
11284970|NCT02799485|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
11284971|NCT02799472|Experimental|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
11284972|NCT02799472|Placebo Comparator|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
11284973|NCT02799459||General anaesthesia|this group will allow us to compare the results like it is the treatment used in current practice ie general anesthesia.
11284974|NCT02799459||Hypnosis in conization|This group is the treatment being tested , where hypnosis is used in the conization
11284975|NCT02799446|Experimental|Reslizumab|Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
11284976|NCT02799446|Placebo Comparator|Placebo|Matching placebo.
11284977|NCT02799433|Active Comparator|Usual Services|This group of child care centers receives standard services from the San Francisco Department of Public Health Child Care Health Program. CCHP offers services to child care centers annually. The standard services include nurse consultation, health education, monitoring of nutrition and physical activity resource need, vision, hearing, oral health, and height and weight screenings.
11284978|NCT02799433|Experimental|Usual services + HAP|This group of child care centers receives all the standard services plus invitation to participate in the voluntary Healthy Apple Program (HAP). The Healthy Apple program involves child care provider self-assessment, followed by an iterative process of goal setting, technical assistance/training, and re-assessment.
11284979|NCT02799420|Experimental|pCLE group|The intervention group
11284980|NCT02799420|Active Comparator|WLE group|The control group
11284981|NCT02799407|No Intervention|Traditional Long Form Consent|Participants will receive the traditional long-form consent form.
11284982|NCT02799407|Experimental|ResearchKit Consent|Participants will receive the Apple ResearchKit consent form.
11284983|NCT02799394|Experimental|Activity modification, exercises and gradual return to sport|
11284984|NCT02799381|Active Comparator|Optimized Medical Treatment (OMT)|Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
11285017|NCT02799082|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
11284985|NCT02799381|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
11284986|NCT02799368|Experimental|CJ Plasma Solution A Injection|Before contrast media administration : CJ Plasma Solution A Injection (3mL/kg for 1 hour) After contrast media administration : CJ Plasma Solution A Injection (1.5 mL/kg/h for 4 hours)
11284987|NCT02799368|Active Comparator|CJ 0.9% Normal Saline Injection|Before contrast media administration : CJ 0.9% Normal Saline Injection (3mL/kg for 1 hour) After contrast media administration : CJ 0.9% Normal Saline Injection (1.5mL/kg/h for 4 hours)
11284988|NCT02799316|Other|rheumatic disease with HBs-ag positive|• HBV core antibodies testing. • Real time PCR testing.
11284989|NCT02799303|Experimental|Multi-parametric MRI|Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
11284990|NCT02799303|Active Comparator|PSA Only|"Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.
~Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician."
11284991|NCT02799290|No Intervention|CONTROL|No intervention
11284992|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
11284993|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
11284994|NCT02799277|Experimental|Testosterone|14mg testosterone will be administered intranasally in a 1milliliter aqueous solution
11284995|NCT02799277|Placebo Comparator|Placebo|1ml blank (containing no drug) aqueous solution will be administered intranasally
11284996|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence AB (fasted followed by fed)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive a single tablet of cabotegravir 30 mg,(micronized 500 mg core weight) orally under fasted condition with at least 10 hours of prior fast. In Period 2, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
11284997|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence BA (fed followed by fasted)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. In Period 2, eligible subjects will receive a single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally under fasted condition with at least 10 hours of prior fast. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
11284998|NCT02799251||Collection of plasma cell rate|Post operative infections and their association with lymphopenia are assessed in this study for patients over 18 years of age undergoing digestive or thoracic cancer surgery under general anesthesia.
11284999|NCT02799238|Active Comparator|Radiotherapy in combination with Temozolomide (TMZ)|radiotherapy combined with TMZ treatment followed by adjuvant TMZ
11285000|NCT02799238|Experimental|ALECSAT + Radiotherapy in combination with TMZ|3 doses of ALECSAT /4 weeks followed by ALECSAT every 3 months
11285001|NCT02799225||Enterobacteria|
11285002|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
11285003|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
11285004|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
11285005|NCT02799173|Experimental|Systemic lupus erythematosus|RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
11285006|NCT02799147|Experimental|280 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.
11285007|NCT02799147|Experimental|200 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv
11285008|NCT02799147|Experimental|140 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4: Bendamustine 70 mg/m2/day iv.
11285009|NCT02799134|Experimental|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
11285010|NCT02799134|Placebo Comparator|group2|take Vitamin C at 22:00 on the first day, 0.5mg
11285011|NCT02799134|Other|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
11285012|NCT02799121|Experimental|ReGenerCell™|Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading
11285013|NCT02799108|Experimental|patients|children with drug-resistant partial epilepsy, in whom preoperative assessment is indicated
11285014|NCT02799095|Experimental|ALKS 4230|
11285015|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
11285016|NCT02799082|Placebo Comparator|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
11285058|NCT02798835|Active Comparator|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
11285018|NCT02799069|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
11285019|NCT02799069|Active Comparator|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
11285020|NCT02799069|Placebo Comparator|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
11285021|NCT02799043|Active Comparator|Standard PVI|Standard catheter ablation including pulmonary vein isolation (PVI) procedure.
11285022|NCT02799043|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by PVI.
11285023|NCT02799030|Placebo Comparator|BF-200 ALA 0%|Topical application of matched placebo gel without containing 5-ALA. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
11285024|NCT02799030|Experimental|BF-200 ALA 1%|Topical application of BF-200 ALA gel containing 0.78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
11285025|NCT02799030|Experimental|BF-200 ALA 3%|Topical application of BF-200 ALA gel containing 3.8 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
11285026|NCT02799030|Experimental|BF-200 ALA 10%|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
11285027|NCT02799017|Experimental|Intensive Phonology Treatment|"The participants in the experimental group will receive an hour of phonology treatment, an hour of group therapy, and an hour of reading. They will work on writing, generative naming during group time focusing on self-cueing with the sounds they learn during the individual session. They will be read to or read aloud depending on their level.
~The participants in the experimental group will be taught all consonants and vowels over the course of 16 weeks."
11285028|NCT02799017|Active Comparator|Intensive SFA Treatment|The participants in the control group will receive an hour of individual therapy, an hour of reading and an hour of group therapy in a traditional setting. They will work on writing, generative naming during group time following the semantic feature analysis to retrieve the name.They will be read to or read aloud depending on their level.
11285029|NCT02799004||Patients in acute pain|
11285030|NCT02798991|Experimental|10 mg of GSK3179106 QD-Cohort 1|Eligible six subjects will receive 10 mg oral dose once daily for 14 days
11285031|NCT02798991|Experimental|50 mg of GSK3179106 QD-Cohort 2|Eligible six subjects will receive 50 mg oral dose once daily for 14 days
11285032|NCT02798991|Experimental|200 mg of GSK3179106 QD-Cohort 3|Eligible six subjects will receive 200 mg oral dose once daily for 14 days
11285033|NCT02798991|Experimental|400 mg of GSK3179106 QD-Cohort 4|Eligible six subjects will receive 400 mg oral dose once daily for 14 days
11285034|NCT02798991|Experimental|25 mg of GSK3179106 BID-Cohort 5|Eligible six subjects will receive 25 mg oral dose twice daily for 14 days
11285035|NCT02798991|Experimental|200 mg of GSK3179106 BID-Cohort 6|Eligible six subjects will receive 200 mg oral dose twice daily for 14 days
11285036|NCT02798991|Placebo Comparator|Matching placebo QD-Cohort 1, 2, 3, 4|Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days
11285037|NCT02798991|Placebo Comparator|Matching placebo BID-Cohort 5, 6|Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days
11285038|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
11285039|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
11285040|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
11285041|NCT02798965|Other|Control|patients with goiter or nodule
11285042|NCT02798965|Experimental|Graves' disease|patients with Graves' disease
11285043|NCT02798952|Experimental|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
11285044|NCT02798939||cirrhotic patients|
11285045|NCT02798926||with the use of a polyethylene bag|
11285046|NCT02798926||without the use of a polyethylene bag|
11285047|NCT02798913|Experimental|Short DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
11285048|NCT02798913|Experimental|Long DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
11285049|NCT02798900|Experimental|Functional task-training and Ultrasound|This group will receive 16 sessions of functional task-training program and therapeutic ultrasound will be applied prior to functional task-training.
11285050|NCT02798900|Active Comparator|Functional task-training|This group will receive 16 sessions of functional task-training program.
11285051|NCT02798887|Experimental|Ridge preservation membrane|Positive control Patients will receive ridge preservation intrasocket allograft and overlay xenograft resorbable with membrane
11285052|NCT02798887|Experimental|Ridge preservation no membrane|test patients will receive ridge preservation intrasocket allograft and overlay xenograft with no membrane
11285053|NCT02798874|Experimental|Ticagrelor Group|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
11285054|NCT02798874|Active Comparator|Clopidogrel Group|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
11285055|NCT02798861||CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
11285056|NCT02798848|Experimental|Assistive technology: tablet computer|iPad tablet computers
11285057|NCT02798848|Active Comparator|Standard optical low vision devices|standard optical devices including magnifiers, telescopes, CCTV
11285060|NCT02798835|Active Comparator|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
11285061|NCT02798822|Active Comparator|RME on upper first permanent molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 35 ± 6 days for Gr6, and the average treatment time was 12 ± 1.3 months.
11285062|NCT02798822|Active Comparator|RME on upper second deciduous molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 41 ± 8 days, and the average treatment time was 12 ± 1.3 months.
11285063|NCT02798809||GeOrGS cohort|Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy)
11285064|NCT02798796|Experimental|MRI Group|MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
11285065|NCT02798796|No Intervention|Control Group|Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
11285066|NCT02798783||Diagnosed with EVA|Self-reported Enlarged Vestibular Aqueduct (EVA), or, when available, radiological diagnosis of EVA will be used to define the cohort.
11285067|NCT02798770||Stroke Center Basel|
11285068|NCT02798757|Experimental|Dapagliflozin|All patients will take dapagliflozin, the intervention does not refer to a drug or device but to the specific 1HNMR test spectroscopy
11285069|NCT02798744|Experimental|Empagliflozin 25mg once daily|Empagliflozin (Jardiance™) 25mg once daily (orally)
11285070|NCT02798744|Experimental|Empagliflozin 25mg once daily + diet|Empagliflozin (Jardiance™) 25mg once daily (orally) + energy restriction diet
11285071|NCT02798744|Placebo Comparator|Placebo once daily|Placebo once daily (orally)
11285072|NCT02798744|Active Comparator|Placebo once daily + diet|Placebo once daily (orally) + energy restriction diet
11285073|NCT02798718|Active Comparator|lactose digesters|Participants in arm 1 are grouped as lactose digesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is less than 20 ppm.
11285074|NCT02798718|Active Comparator|lactose maldigesters|Participants in arm 2 are also grouped as lactose maldigesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is not less than 20 ppm.
11285075|NCT02798692|Active Comparator|Low dose HB-101 group|Intervention:Three administrations of a low dose of HB-101
11285076|NCT02798692|Active Comparator|Medium dose HB-101 group|Intervention:Three administrations of a middle dose of HB-101.
11285077|NCT02798692|Active Comparator|High dose HB101 group|Intervention:Three administrations of a high dose of HB-101.
11285078|NCT02798692|Placebo Comparator|Placebo group|Intervention:Three administrations of placebo (diluent)
11285079|NCT02798666|Experimental|High intensity exercise training|The participants exercised for 40 minutes, twice a week, under supervision of two physiotherapists for in total 10 weeks. Each training session included a warming up, a sprint interval block [10 minutes], continuous aerobic exercise [10 minutes], another sprint interval block [10 minutes] and cooling down. For the first 5 weeks, each sprint interval block consisted of 10 sprint bouts [>100 r/min] of 15 seconds at a cycling resistance matching with the ventilatory threshold [VTR], alternated with 45 seconds relative rest [50 r/min at VTR]. Starting from week 6 until week 10, the intensity of sprinting and relative rest was increased up to 110% of VTR.
11285080|NCT02798666|Active Comparator|Continuous exercise training|The comparative group performed a continuous aerobic training [CAT] for 10 weeks, twice a week and 40 minutes per session [volume and frequency is equal to HIIT]. The protocol of the CAT group consisted of warming up [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes], continuous aerobic exercise training [3 times 10 minutes] and cooling down [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes]. During the continuous aerobic protocol [cycling or stepping] participants exercised for 10 minutes at a HR similar to the HR at VT [60 r/min], which was increased to 110% of VT from week 6 onwards.
11285081|NCT02798653|Experimental|Choriomon®|subjects receive 1,500 IU of hCG (Choriomon®; IBSA) intramuscular (IM) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
11285082|NCT02798653|Experimental|Choriomon®+Endometrin ®|patients will receive 1,500 IU of hCG (Choriomon®; IBSA) (IM) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
11285083|NCT02798653|Experimental|Endometrin ®|patients will receive only Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
11285084|NCT02798640|Active Comparator|Active|Subject wearing Celliant garment
11285085|NCT02798640|Placebo Comparator|Control|Subject wearing non-celliant control garment
11285086|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
11285087|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
11285088|NCT02798614|Active Comparator|10-day cast|Removal of plaster cast 10 Days after reduction
11285089|NCT02798614|No Intervention|1-month cast|Removal of plaster cast 1 month after reduction
11285709|NCT02794649||primary hyperoxaluria|Patients diagnosed with type I PH by genetic testing
11285090|NCT02798601|Experimental|Hypernatremia|Serum sodium between 150 - 155 milliequivalent/L. 7,5% sodium chloride (2 ml/kg every 4 hours), with controls of serum sodium every 4 hours, to achieve a goal of serum sodium between 150 - 155 milliequivalent/L. If after 4 doses of 7.5% sodium chloride the serum sodium is below the target, a bolus of 1 ml/kg of 12% sodium chloride will be used every 4 hours. The goal of serum sodium will be maintained for 48 hours.
11285091|NCT02798601|No Intervention|Normonatremia|Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
11285092|NCT02798588|Experimental|Comatose patients in ICU|
11285093|NCT02798562|Experimental|Native and dynamic contrast-enhanced CT|Patients will undergo a native high-resolution and a dynamic contrast-enhanced CT, both sides respectively.
11285094|NCT02798549|Other|Viraemic|
11285095|NCT02798549|Other|Remission|
11285096|NCT02798536|Experimental|A1/LMB-100 dose escalation (closed)|De-escalating doses of LMB-100 in up to 18 subjects
11285097|NCT02798536|Experimental|A2/LMB-100 dose expansion (closed)|Fixed dose of LMB-100 as determined in Arm A1 in up to 16 subjects
11285098|NCT02798536|Experimental|B1/LMB-100+ nab- paclitaxel dose escalation|De-escalating doses of LMB-100 + fixed dose of nab-paclitaxel in up to 12 subjects
11285099|NCT02798536|Experimental|B2/LMB-100+ nab- paclitaxel dose expansion|Fixed dose of LMB-100 as determined in Arm B1 + fixed dose of nab-paclitaxel in up to 16 subjects
11285100|NCT02798523|Experimental|Group A|Following collection of a 3-mm skin punch biopsy sample and a preinfusion whole-blood sample, volunteers will receive a single intravenous dose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes, and a single application of topical methylprednisolone 0.1% to a small area (2 x 2 cm) of the skin. Whole blood samples will then be obtained serially, at 2 and 4 hours after the start of drug administration. A second skin punch biopsy will be performed 4 hours after the start of drug administration, in the area of skin where topical methylprednisolone was applied.
11285101|NCT02798523|Experimental|Group B|Following collection of a pre-infusion whole- blood sample, volunteers will receive a single intravenousdose of 250 milligrams (mg) of methylprednisolone sodium succinate infused over 15 minutes. Whole-blood samples will then be obtained serially, at 1 and 2 hours after the start of drug administration.
11285102|NCT02798510|Experimental|Arm 1|Patients in arm 1 will receive adjuvant chemotherapy followed by concurrent chemoradiotherapy. Patients will receive four cycles of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330mg/m2 per day) and radiotherapy (50.4Gy/28fx to regional lymphatics with or without tumor bed)
11285103|NCT02798510|Active Comparator|Arm 2|Patients in arm 2 will receive six cycles chemotherapy of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days
11285104|NCT02798497|Other|staphylococcus aureus PVL-|patients with staphylococcus aureus PVL-
11285105|NCT02798497|Other|staphylococcus aureus PVL+|patients with staphylococcus aureus PVL+
11285106|NCT02798484|Experimental|Breast cancer|Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.
11285107|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.
~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
11285108|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
11285109|NCT02798458|Experimental|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
11285110|NCT02798458|Experimental|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
11285111|NCT02798445|Experimental|tapirs|this group will have surgery with endovascular laser treatment (EVLT) in the axial vein and foam sclerotherapy echo-guided in perforator veins and veins in relation with the ulcer, after the surgery the patients will have conventional wound care plus juxta cure system that give a continuous compression in the leg.
11285112|NCT02798445|Active Comparator|multilayer bandage|multilayer bandage and conventional wound care (grade 1A) recommendation in management of vein ulcers. gold standard
11285113|NCT02798432|Experimental|Hybrid NEXGEN LPS|Noncemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
11285114|NCT02798432|Sham Comparator|Cemented NEXGEN LPS|Cemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
11285115|NCT02798419|Experimental|DFD05 Cream|DFD05 Cream
11285116|NCT02798419|Active Comparator|Active01 Cream|Active01 Cream
11285117|NCT02798406|Experimental|DNX-2401 + pembrolizumab|Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.
11285118|NCT02798393|Sham Comparator|HL-Sham|The placebo device (also referred to as the HL-SHAM device) will have an identical appearance to the HL-NIR device. Though the HL-NIR device will be applied, there will be no treatment administered.
11285174|NCT02798016|Experimental|Platelet-Rich Plasma alone|The scars will be injected with Platelet-Rich Plasma alone.
11285119|NCT02798393|Experimental|HL-NIR|The device referred to as the HL-NIR device includes both a podiatric or foot and leg component, similar to a loose fitting boot, that is easily applied to all subjects (one size fits all). Application of the device is snug but comfortable without risk for constriction of soft tissue.
11285120|NCT02798380|Experimental|HTS-519 Insert|Active treatment
11285121|NCT02798367|Experimental|CBT-I plus Melatonin 3 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 3mg. Melatonin 3mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.
~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
11285122|NCT02798367|Experimental|CBT-I plus Melatonin 5 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 5mg. Melatonin 5mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.
~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
11285123|NCT02798367|Other|CBT-I plus placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo. The participants shall administer the placebo tablets to enable the double-blind study. Placebo will be dispensed to 65 (first stage) and 56 (second stage) participants of this group and shall administer 01 tablet orally every 24 hours one hour before bedtime for 21(±2) days.
~Sleep hygiene is a psychoeducational intervention that teaches patients to prevent external or environmental factors generate adverse effects and harmful to sleep. The stimulus control technique is based on five instructions that encourages the patient to establish a proper sleep-wake rhythm and strengthens the links between the way for a quick and well consolidated sleep. The CBT-I guidelines are standardized in clinical protocol."
11285124|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.
~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
11285125|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.
~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
11285126|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.
~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
11285127|NCT02798328||Reference Range|Healthy Subjects
11285128|NCT02798328||DOAC Pivotal|DOAC Eligible Subjects
11285129|NCT02798315||Participants With Hepatitis C Virus (HCV) Genotype 1 or 4|"Participants with HCV genotype 1 or 4 receiving paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
11285130|NCT02798302|Active Comparator|Non rebreather|
11285131|NCT02798302|Active Comparator|Bag valve mask without leak|
11285132|NCT02798302|Active Comparator|Bag valve mask with simulated mask leak|
11285133|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
11285134|NCT02798276|Experimental|AGTP-treatment|Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.
11285135|NCT02798276|Other|Control|Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
11285136|NCT02798263|Experimental|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
11285137|NCT02798263|Experimental|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
11285138|NCT02798263|Experimental|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
11285139|NCT02798250|Active Comparator|Dual-hormone CL with overestimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
11285140|NCT02798250|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 35g of carbohydrates.
11285175|NCT02798016|Active Comparator|Platelet-Rich Plasma with micro-needling|The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma
11285176|NCT02798003||Cachectic cancer patients|Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
11285141|NCT02798237|Experimental|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.
~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
11285142|NCT02798237|Sham Comparator|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program.
11285143|NCT02798224|Experimental|e-assist: Colon Health (treatment arm)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
11285144|NCT02798224|Active Comparator|Healthwise Educational Program (active control)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
11285145|NCT02798224|No Intervention|Usual care control (observational only)|There will be no participant contact in this arm. We will use existing data sources only (e.g., EHRs) to obtain information on participants in this arm (i.e., an observational data review only).
11285146|NCT02798211|Active Comparator|Group 1|secukinumab 300mg
11285147|NCT02798211|Active Comparator|Group 2|secukinumab 150 mg
11285148|NCT02798211|Placebo Comparator|Group 3|Placebo
11285149|NCT02798198||Diabetes group|37 T2DM adults (diabetes group) without DKD
11285150|NCT02798198||Control group|33 healthy adults (control group)
11285151|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
11285152|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
11285153|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
11285154|NCT02798172|Experimental|Alogliptin+metformin|Alogliptin (alogliptin benzoate) is the most recent DPP-4 inhibitor; it entered the market in 2006. It is a potent and highly selective DPP-4 inhibitor with oral antidiabetic activity; Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
11285155|NCT02798172|Experimental|metformin|Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
11285156|NCT02798159|Experimental|Part A- Arm 1|Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
11285157|NCT02798159|Experimental|Part A- Arm 2|Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
11285158|NCT02798159|Experimental|Part A- Arm 3|Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
11285159|NCT02798159|Experimental|Part A- Arm 4|Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
11285160|NCT02798159|Experimental|Part B- Arm 1|"Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.
~Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month"
11285161|NCT02798159|Active Comparator|Part B- Arm 2|Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month
11285162|NCT02798146|Other|hormonal levels|Blood samples are collected for analysis of LH, E2, hCG and progesterone.
11285163|NCT02798133|Experimental|OLA|recruitment maneuver + individualized PEEP
11285164|NCT02798133|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
11285165|NCT02798120|Experimental|SB204 4%|SB204 4% once daily
11285166|NCT02798107||All patients treated with idarucizumab|
11285167|NCT02798094||Depressed Participants|No intervention
11285168|NCT02798094||Healthy Control Participants|No intervention
11285169|NCT02798081|Experimental|Single arm study|A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
11285170|NCT02798068|Active Comparator|Solu - Medrol|Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
11285171|NCT02798068|Placebo Comparator|Placebo|NaCl 0,9% 100ml IV once single administration
11285177|NCT02798003||Non-cachectic cancer patients|Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
11285178|NCT02798003||Cachectic COPD patients|Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
11285179|NCT02798003||Non-cachectic COPD patients|Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
11285180|NCT02797977|Experimental|Standard-Dose Triplet Combination|SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
11285181|NCT02797977|Experimental|Low-Dose Gemcitabine Combination|SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
11285182|NCT02797964|Experimental|Open label|
11285183|NCT02797951|Experimental|Galcanezumab|Galcanezumab given subcutaneously (SQ) up to once a month.
11285184|NCT02797938|Experimental|Taper guard tube|Taper guard tube was intubated in 26 patients
11285185|NCT02797938|Active Comparator|Cylindrical tube|Cylindrical tube was intubated in 26 patients
11285186|NCT02797925||Tendinopathy|Long slow strength training for 3 months that are performed at home or gym. Participants receive initial guidance to the exercises from a physiotherapist assigned to Bispebjerg H.
11285187|NCT02797925||Healthy|No intervention. No training
11285188|NCT02797912||CF children and young people|Observational study involving clinical procedures: lung function testing, respiratory muscle strength testing, body composition analysis & exercise tolerance.
11285189|NCT02797899|Active Comparator|Palatal donor site received PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and received platelet rich fibrin and periodontal pack as assigned randomly by a flip of coin during the screening visits.
11285190|NCT02797899|Active Comparator|Palatal donor site NOT receiving PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and sutured followed by periodontal pack application.
11285191|NCT02797886|Experimental|FES+VOL|Electrical stimulation (FES) in concert with volitional effort. The subject is visually cued to initiate the movement and when they begin the movement (as ascertained by EMG response), the stimulation is immediately applied until the completion of the trial.
11285192|NCT02797886|Active Comparator|FES|Electrical stimulation alone. The subject is asked to do nothing as electrical stimulation initiates and completes the movement for them.
11285193|NCT02797886|Active Comparator|VOL|Volitional effort alone. When cued, the subject initiates and completes the movement on their own until the completion of the trial. There is no electrical stimulation in this group.
11285194|NCT02797873|Experimental|EIP|"Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.
~Interventions:
~fMRI - Stroop task
~fMRI - MID task
~Stop Signal task
~Structural T1 MRI scan
~Structural T2 MRI scan
~DTI MRI scan
~Resting state MRI scan
~FEFA 2
~SCID-II
~SDQ
~ASRS
~AQ
~TAS-20
~Raven's SPM
~Reading ability
~Ishihara's tests for colour deficiency
~Additional questionnaire
~Brown-ADD
~MFQ
~STAI-T
~BIS
~DAWBA
~STAI-S
~Sleepiness rating x 6
~Motivation rating x 6"
11285195|NCT02797873|Experimental|Healthy controls|"Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).
~Interventions:
~fMRI - Stroop task
~fMRI - MID task
~Stop Signal task
~Structural T1 MRI scan
~Structural T2 MRI scan
~DTI MRI scan
~Resting state MRI scan
~FEFA 2
~SCID-II
~SDQ
~ASRS
~AQ
~TAS-20
~Raven's SPM
~Reading ability
~Ishihara's tests for colour deficiency
~Additional questionnaire
~Brown-ADD
~MFQ
~STAI-T
~BIS
~DAWBA
~STAI-S
~Sleepiness rating x 6
~Motivation rating x 6"
11285196|NCT02797860||transabdominal cervicoisthmic cerclage|Second Stage of Labor pregnant women who are scheduled for transabdominal cervicoisthmic cerclage due to incompetent internal os of cervix
11285197|NCT02797860||control|women of childbearing age between 20 and 45
11285198|NCT02797847|Active Comparator|ALN-TTRSC02|
11285199|NCT02797847|Placebo Comparator|Sterile normal saline 0.9% for SC administration|
11285200|NCT02797834||Patients Endometrial Fluid|"Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days).
~This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30)."
11285201|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
11285202|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
11285203|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
11285204|NCT02797808|Experimental|OCD|
11285205|NCT02797808|Active Comparator|Healthy Controls|
11285206|NCT02797795|Experimental|NEV801|"Part A - Dose escalation and de-escalation for the determination of the Maximum tolerated dose. All subjects will receive NEV801 intravenously on days 1, 8, 15 and 22 during each 28-day cycle.
~Part B - Subjects will receive NEV801 at or below the highest tolerable dose from Part A."
11285207|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
11285208|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
11285209|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
11285210|NCT02797756||Case|CC/GER+ presence of chronic cough and presence of GER evidenced by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
11285211|NCT02797756||Control|CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
11285212|NCT02797743||Whole blood from all ages and gender|- Ages from 0 to Adults (18 yrs of age or older)
11285213|NCT02797730|Experimental|art-therapy sessions|Caregivers will receive 6 art-therapy sessions
11285214|NCT02797730|No Intervention|no art-therapy sessions|Caregivers will not receive 6 art-therapy sessions during the evaluation period
11285215|NCT02797717|Other|"A-COPDAC-28"|"standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.
~drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8."
11285216|NCT02797717|Experimental|"B- DECOPDAC-21"|"DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.
~Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:
~Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1"
11285217|NCT02797704|Experimental|SC Aflibercept|The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
11285218|NCT02797691|Experimental|CaCBT plus Treatment As Usual|"Receiving CaCBT intervention in addition to the Treatment as usual"
11285219|NCT02797691|Active Comparator|Treatment As Usual (TAU)|Receiving Treatment as usual
11285220|NCT02797678|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week. Participants will then be crossed over and will wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week
11285221|NCT02797678|Sham Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week. Participants will then wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week.
11285222|NCT02797665|Active Comparator|Steroids group|The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
11285223|NCT02797665|Active Comparator|Stent group|The patients will be treated with oral corticosteroids and biliary stent.
11285224|NCT02797652||Neoadjuvant chemotherapy|ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
11285225|NCT02797652||Surgery|ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
11285226|NCT02797639|Experimental|Co-PID|Eight collaborative consultation meetings between occupational therapist to each teacher in purpose of enhancing participation of students in class
11285227|NCT02797639|Active Comparator|In-service|Three in- service meetings to all homeroom teachers together, in purpose of enhancing participation of students in class
11285228|NCT02797626|Other|Primary RPNLD|
11285229|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
11285230|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
11285231|NCT02797600||ARM I|Woman residing in Appalachian counties who have prevalent invasive cervical cancer. Invasive cervical cancer cases participants will include women previously and currently treated for ICC during the past 10 years. Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. Biological samples will be collected during a scheduled visit with the research staff.
11285232|NCT02797600||ARM II|Woman residing in Appalachian counties who are newly diagnosed with invasive cervical cancer(ICC). Newly diagnosed with ICC, and currently being treated for ICC. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected during a scheduled clinic visit.
11285233|NCT02797600||ARM III|Healthy controls (women without a diagnosis of any type of cancer. Healthy controls will be women who are coming into one of the participating clinic or physician practice for a routine Pap test. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected at the time of the clinical Pap smear.
11285234|NCT02797587|Active Comparator|Varenicline + Nicotine Replacement Therapy placebo|Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
11285235|NCT02797587|Placebo Comparator|Varenicline placebo + Nicotine Replacement Therapy|Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
11285236|NCT02797587|Active Comparator|Cytisine + Nicotine Replacement Therapy placebo|Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
11285304|NCT02797158|Experimental|Interventional Arm|
11285237|NCT02797587|Placebo Comparator|Cytisine placebo + Nicotine Replacement Therapy|Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
11285238|NCT02797574|Active Comparator|Vitiligo Diagnosed Group|Clinically diagnosed with non-segmental vitiligo
11285239|NCT02797574|Active Comparator|Healthy Control Group|20 normally pigmented control subjects who are between the ages of 18 and 50
11285240|NCT02797561||Tandem lesion evaluated by FFR|
11285241|NCT02797548|Experimental|Aspirin only|
11285242|NCT02797548|Active Comparator|No antiplatelet therapy|
11285243|NCT02797535|Other|GI fluids samples collection|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
11285244|NCT02797522|Experimental|NHV Participants: Cohort 1|NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.
11285245|NCT02797522|Experimental|NHV Participants: Cohort 2|NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.
11285246|NCT02797522|Experimental|NHV Participants: Cohort 3|NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.
11285247|NCT02797522|Experimental|NHV Participants: Cohort 4|NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.
11285248|NCT02797522|Experimental|NHV Participants: Cohort 5|NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.
11285249|NCT02797522|Experimental|NHV Participants: Cohort 6|NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.
11285250|NCT02797522|Placebo Comparator|NHV Participants: Placebo|NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.
11285251|NCT02797522|Experimental|CHB Participants: Cohort 3b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
11285252|NCT02797522|Experimental|CHB Participants: Cohort 4b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
11285253|NCT02797522|Experimental|CHB Participants: Cohort 3c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.
11285254|NCT02797522|Experimental|CHB Participants: Cohort 4c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.
11285255|NCT02797509|Experimental|Psychosocial Skills-Based Intervention|Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.
11285256|NCT02797509|No Intervention|Minimally Enhanced Usual Care (MEUC)|Those in the MEUC will continue with their current care. This may include meeting with nurses, physical therapist, medical doctors, and other members of the stroke patient's medical team. Treatment as usual may also involve administration of Selective Serotonin Reuptake Inhibitors (SSRIs) to those patients with motor problems. They will also received a pamphlet with educational information on stroke and recovery
11285257|NCT02797496|Experimental|Asymmetric Motor Strengthening|
11285258|NCT02797496|Active Comparator|Conventional Therapy|
11285259|NCT02797483|Experimental|Test Fat Blue|16 weeks interventions
11285260|NCT02797483|Experimental|Test Fat Green|16 weeks interventions
11285261|NCT02797483|Experimental|Test Fat Red|16 weeks interventions
11285262|NCT02797470|Experimental|Treatment (anti-HIV gene transduced CD34+ cells)|Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.
11285263|NCT02797457|Other|Allograft|Bilateral allograft of the hands and forearms.
11285264|NCT02797457|Other|Prostheses|Prosthetic forehands
11285265|NCT02797431|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
11285266|NCT02797431|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
11285267|NCT02797431|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
11285268|NCT02797418|Experimental|Cognitus and Me|Cognitus & Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
11285269|NCT02797418|Active Comparator|control group|the control management that involves fine motor skills and research computer information,management control is usually done
11285270|NCT02797405|Other|Standard treatment|The patients will receive standard treatment according to international recommendations depending on their type of cancer.
11285305|NCT02797145|Active Comparator|Intensive Group|Dose adjusted digoxin by the recommended range for the serum digoxin: 0.5-0.9 nanogram/mL
11285306|NCT02797145|Placebo Comparator|Conventional|Use digoxin as recommended by the guidelines.
11285415|NCT02796443||Early laparoscopic cholecystectomy (ELC)|Operation within 72 hours after onset of symptoms
11285271|NCT02797392|Experimental|Lifestyle intervention|All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
11285272|NCT02797379|Other|Immediate start|This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later.
11285273|NCT02797379|Other|Delayed start|This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8.
11285274|NCT02797366|Other|Proton radiotherapy|Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
11285275|NCT02797353|Experimental|Intervention Arm|Antenatal Care, Post natal care, Skilled birth attendance, recognition and referrals of complicated cases, immunization
11285276|NCT02797353|No Intervention|Control|This arm will receive the standard MNCH services as outlined in the MNCH policy of Government of Pakistan
11285277|NCT02797340|Experimental|Interventional|All participants
11285278|NCT02797314|Other|Type 2 diabetic population|Bone biopsies
11285279|NCT02797314|Other|Non-diabetic control population|Bone biopsies
11285280|NCT02797301|Experimental|synthetic test & computerised test|Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
11285281|NCT02797301|Experimental|computerised test & synthetic test|Sixteen preschool children (G2), with no motor impairments, from a private school. The children in G2 performed the computerised test before the synthetic test.
11285282|NCT02797301|Experimental|computerised test|Seven volunteers (G3), two males and five females, with moderate mobility impairment, patients from the Physical Therapy and Rehabilitation Clinic.
11285283|NCT02797275|Experimental|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
11285284|NCT02797275|Experimental|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
11285285|NCT02797262|Experimental|Intervention|"Building on the available Proteus devices, the investigators will design and create a Proteus digital health feedback (PDHF) system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
~The investigators will test overall utility (including feasibility, acceptability and sustainability) of the PDHF system, its accuracy for measuring adherence and its impact on enhancing patients' level of adherence and the effect on virologic and clinical outcomes (exploratory), the retention of its impact on keeping up with adherence and improvement of plasma HIV RNA and CD4 cell count after the 16-week usage of the PDHF system."
11285286|NCT02797262|No Intervention|Control|UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment. Eligible patients will be randomized to one of the two conditions using a stratified urn randomization procedure to increase the likelihood of balanced allocation of prognostic variables at baseline.
11285287|NCT02797249|Experimental|aspirin|Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
11285288|NCT02797249|Other|blank|Routine examination during pregnancy.
11285289|NCT02797236|Experimental|vaccine dose 1|SF2a-TT15 vaccine, 2 μg
11285290|NCT02797236|Experimental|vaccine dose 1+ adjuvant|SF2a-TT15 vaccine, 2 μg + alum
11285291|NCT02797236|Experimental|vaccine dose 2|SF2a-TT15 vaccine, 10 μg
11285292|NCT02797236|Experimental|vaccine dose 2 + adjuvant|SF2a-TT15 vaccine, 10 μg + alum
11285293|NCT02797236|Placebo Comparator|Placebo|Tris buffer
11285294|NCT02797236|Placebo Comparator|Placebo + adjuvant|Tris buffer + Alum
11285295|NCT02797210|Experimental|Sham then Active Stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
11285296|NCT02797210|Experimental|Active then Sham Stimulation|Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
11285297|NCT02797197|Experimental|patient undergoing to chemotherapy during 6 months|
11285298|NCT02797184|Experimental|Aim 1. KNO3 dose response|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
11285299|NCT02797171|Experimental|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
11285300|NCT02797171|Experimental|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
11285301|NCT02797171|Experimental|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
11285302|NCT02797171|Experimental|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
11285303|NCT02797171|Experimental|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
11285307|NCT02797132|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A (<14 kg): Participants weighing less than (<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.
~Part A (>=14 kg): Participants weighing greater than or equal to (>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.
~Part B (<14 kg): Participants weighing <14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.
~Part B (>=14 kg): Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B."
11285308|NCT02797119|Experimental|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.
~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
11285309|NCT02797119|Experimental|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
11285310|NCT02797119|Placebo Comparator|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
11285311|NCT02797119|No Intervention|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
11285312|NCT02797106||health care professionals|health care professionals potentially involved in assessment and/or treatment of drooling in children with Cerebral Palsy.
11285313|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
11285314|NCT02797080|Experimental|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
11285315|NCT02797067|Experimental|Indomethacin|Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
11285316|NCT02797067|Placebo Comparator|Glycerin|Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.
11285317|NCT02797054|Experimental|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
11285318|NCT02797054|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
11285319|NCT02797054|Other|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
11285320|NCT02797028|Placebo Comparator|Placebo capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule
11285321|NCT02797028|Experimental|Anthocyanidins capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.
11285322|NCT02797028|Experimental|Allopurinol|The experimental group taking allopurinol.
11285323|NCT02797015|Experimental|1 mg RPC1063|1 mg RPC1063 oral capsule daily
11285324|NCT02797015|Experimental|0.5 mg RPC1063|0.5 mg RPC1063 oral capsule daily
11285325|NCT02797002||Chronic non specific neck pain|Experiencing neck pain for at least 3 months in the last year
11285326|NCT02797002||Without neck pain (asymptomatic)|No history of neck pain
11285327|NCT02796989|Active Comparator|Healthy - Wheat Bran|Wheat bran 20 g each day
11285328|NCT02796989|Placebo Comparator|Healthy - Placebo|Placebo 20 g each day
11285329|NCT02796989|Active Comparator|Obese - Wheat bran|Wheat bran 20 g each day
11285330|NCT02796989|Placebo Comparator|Obese - Placebo|Placebo 20 g each day
11285331|NCT02796976|No Intervention|healthy older active|only cross-sectional
11285332|NCT02796976|No Intervention|healthy older sedentary|only cross-sectional
11285333|NCT02796976|Active Comparator|older sedentary at risk|cross-sectional and training or control condition
11285334|NCT02796963|Experimental|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
11285335|NCT02796963|Experimental|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
11285336|NCT02796950|Experimental|Acipimox|Administration of acipimox 250 mg p.o.
11285337|NCT02796950|No Intervention|Control|No intervention.
11285338|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
11285339|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
11285340|NCT02796911|No Intervention|Corticotomy alone|Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
11285341|NCT02796911|Experimental|Corticotomy + xenograft|group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
11285342|NCT02796911|Experimental|Corticotomy + bioactive glass|group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
11285343|NCT02796898|Experimental|Treated Group|"SM88 is a combination therapy consisting of 4 agents. One agent, the tyrosine isomer will be increased in each of 2 dose cohorts as follows:
~Cohort 1:
~Tyrosine isomers - 230 mg qd
~Phenytoin - 50 mg qd.
~Methoxsalen - 10 mg qd
~Sirolimus - 0.5 mg qd
~Cohort 2:
~Cohort 2 has increasing tyrosine isomer from q.d. to b.i.d.
~Expansion Cohort:
~The optimum dose will be expanded in 2nd stage of the study to 30 subjects."
11285344|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
11285345|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
11285346|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
11285347|NCT02796872|Placebo Comparator|mother's breast milk.|mother's breast milk.
11285348|NCT02796872|Active Comparator|other GOS|Commercial infant formula containing 4% w/w FOS:GOS (1:3)
11285349|NCT02796872|Experimental|B-GOS 3%|Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
11285350|NCT02796872|Experimental|B-GOS 2%|Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
11285351|NCT02796859|Active Comparator|Treatment Group|Subjects in the siltuximab group will receive an 11 mg/kg infusion at baseline, and weeks 3 and 6, as per the recommended dosing for multicentric Castleman's disease
11285352|NCT02796859|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the siltuximab group) at baseline, and weeks 3 and 6.
11285353|NCT02796846||CPAP prescription group|Patients with a CPAP prescription (both compliant and noncompliant)
11285354|NCT02796846||Without a CPAP prescription|Patients without a CPAP prescription to satisfy our primary goals/objectives.
11285355|NCT02796833|Other|SMOF/Intralipid|"Patients that are randomized to receive for the first 6 months SMOF as a lipid emulsion in their PN, and for the next 6 month (after 28 days of active washout on Intralipid) Intralipid, which is the standard lipid emulsion used in the hospital. SMOF is approved by Health Canada.
~The parenteral nutrition bags are compounded individually for each patient based on their specific needs."
11285356|NCT02796833|Other|Intralipid/SMOF|Patients that are randomized to receive Intralipid, which is the standard lipid emulsion used in the hospital for the first 6 months, and for the next 6 month (after 28 days of active washout on Intralipid) SMOF as a lipid emulsion in their PN. SMOF is approved by Health Canada.The parenteral nutrition bags are compounded individually for each patient based on their specific needs.
11285357|NCT02796820|Experimental|Huaier Granule|Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
11285358|NCT02796820|No Intervention|Regular follow-up observation|Regular follow-up observation after surgery.
11285359|NCT02796807|Experimental|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
11285360|NCT02796794|Active Comparator|Genistein|Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
11285361|NCT02796794|Other|control|Control group are the patients receiving enteral nutrition
11285362|NCT02796781|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
11285363|NCT02796768||Participants|"Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:
~BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.
~FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,
~1 2D US scanning session of right and left hip by Specialist 1,
~1 2D US scanning session of right and left hip by Specialist 2."
11285364|NCT02796755|Experimental|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
11285365|NCT02796755|Placebo Comparator|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
11285366|NCT02796742||Group MSSA|
11285367|NCT02796742||Group MRSA|
11285368|NCT02796742||Group PVL-negative strains|
11285369|NCT02796742||Group PVL-positive strains|
11285370|NCT02796729|Experimental|dynamic glucose enhanced MRI after D-glucose injection|"IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.
~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.
~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec."
11285371|NCT02796703|Placebo Comparator|Control Group|Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
11285372|NCT02796703|Active Comparator|Treatment Group|"Dietary Supplement: Heat Inactivated Probiotics
~1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula."
11285373|NCT02796690||Group Methicillin susceptible Staphylococcus aureus (MSSA)|
11285374|NCT02796690||Group methicillin resistant Staphylococcus aureus (MRSA)|
11285375|NCT02796677|Experimental|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
11285376|NCT02796677|Experimental|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
11285377|NCT02796677|Experimental|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
11285378|NCT02796677|Experimental|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
11285379|NCT02796664|Active Comparator|Ginseng|2grams twice per day (0.5gram/capsule, 2capsules twice a day) for 12months
11285380|NCT02796664|Placebo Comparator|Placebo|Placebo has the same appearance (same size and color) of the real drug. 2grams twice per day (0.5gram/capsule, 2capsules twice a day) for 12months
11285416|NCT02796443||Intermediate cholecystectomy (ILC)|Operation within 14 days after onset of symptoms
11285381|NCT02796651|Experimental|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
11285382|NCT02796651|Experimental|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
11285383|NCT02796651|Experimental|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
11285384|NCT02796651|Placebo Comparator|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
11285385|NCT02796651|Experimental|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
11285386|NCT02796651|Experimental|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
11285387|NCT02796638|Experimental|Minute Ventilation Adaptive Servo-Ventilation plus SOC|Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
11285388|NCT02796638|No Intervention|Standard of Care (SOC)|Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
11285389|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
11285390|NCT02796612|Active Comparator|No intervention|Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
11285391|NCT02796612|Experimental|Intervention group|"Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
~Additionally, delivery of a take-home brochure to the patients during the first visit is planned. The biopsy is explained to the patient and performed by a psychological trained physician. Patient care by a psychologically trained physician is performed in the sense that patients are informed about their biopsy result by a specifically trained physician."
11285392|NCT02796599|Experimental|CWLT with facial mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
11285393|NCT02796599|Experimental|CWLT with nasal mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
11285394|NCT02796586|Placebo Comparator|Individual Contraceptive Counseling|Performed by a medical provider and planned to simulate a typical clinic visit addressing contraception.
11285395|NCT02796586|Experimental|Group Contraceptive Counseling|Performed by a bicultural study staff member who speaks the primary languages of participants and had been formally trained in contraception counseling.
11285396|NCT02796573|Experimental|B-CBT|6 face-to-face consultations plus 6 online modules.
11285397|NCT02796573|Active Comparator|Face-to-Face CBT|12 face-to-face consultations.
11285398|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
11285399|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
11285400|NCT02796547|Experimental|Levobupivacaine|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with Levobupivacaine. This is the only intervention specific to the study, as compared to the standard of care.
11285401|NCT02796547|Placebo Comparator|Placebo|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with physiological serum.This is the only intervention specific to the study, as compared to the standard of care.
11285402|NCT02796521|Other|control group|The control group will receive usual dietary counseling for enrichment.
11285403|NCT02796521|Other|workshop group|The workshop group will have informations about interest of foods. They will enrich a meal with foods which can easily be added without cooking.
11285404|NCT02796508|Experimental|Non-action video game training|Experimental: Non-action video game training 16 1-hour training sessions with 10 non-action video game training selected games from Lumosity.
11285405|NCT02796508|Active Comparator|Non-cognitive video game training|Active Control: Non-cognitive social video game training 16 1-hour training sessions with non-cognitive video game training with social games from The Sims.
11285406|NCT02796495|Experimental|Operation of hand prosthesis with direct nerve stimulation|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in one or two amputees:
~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)
~TIME-4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)
~Sensorized Hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)
~Prosthetics sensorized hand for amputees DLR/HIT Hand II (Wessling Robotics)
~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand
~The EPIONE Psychophysical Testing Platform software for stimulator control"
11285407|NCT02796482|Other|EnergieShake 1.5 kcal Complete Intervention|Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
11285408|NCT02796469||Pentoxifylline + Corticosteroid|Association of treatment by pentoxifylline and corticosterone during 28 days
11285409|NCT02796469||Corticosteroid|treatment by corticosteroid during 28 days
11285410|NCT02796469||Pentoxifylline|treatment by pentoxifylline during 28 days
11285411|NCT02796469||Placebo|
11285412|NCT02796456||Normal weight women|BMI between 18.5 and 25 kg/m2 and without gestational diabetes
11285413|NCT02796456||Obese women without gestational diabetes|BMI more than 30 kg/m2 and without gestational diabetes
11285419|NCT02796430||Mechanically ventilated patients|Ease of use will be assessed by analysing the time needed to start indirect calorimetry measurement, and results of indirect calorimetry measurements by both the new indirect calorimeter and the currently used calorimeters at each study center.
11285420|NCT02796417|Experimental|Rehacop group|Cognitive rehabilitation
11285421|NCT02796417|Active Comparator|Control group|Occupational activities
11285422|NCT02796404|Experimental|Homebased cardiac rehabilitation program|Homebased Cardiac rehabilitation program with monitoring vest and mixed surveillance.
11285423|NCT02796404|Other|Traditional cardiac rehabilitation|Multidisciplinary program in a cardiac rehabilitation gym. Routine clinical practice
11285424|NCT02796391|Experimental|Study 1: Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mb nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction.
~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
11285425|NCT02796391|Experimental|Study 1: Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).
~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
11285426|NCT02796391|Experimental|Study 2: Targeted/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
11285427|NCT02796391|Experimental|Study 2: Targeted/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
11285428|NCT02796391|Experimental|Study 2: Generic/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
11285429|NCT02796391|Experimental|Study 2: Generic/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).
~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
11285430|NCT02796378|Active Comparator|Training+Simvastatin+Q10-placebo|Training+Simvastatin+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day and Q10-placebo.
11285431|NCT02796378|Placebo Comparator|Training+Simvastatin-placebo+Q10-placebo|Training+Simvastatin-placebo+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week, Simvastatin-placebo and Q10-placebo.
11285432|NCT02796378|Active Comparator|Training+Simvastatin+Q10|Training+Simvastatin+Q10. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day in combination with 400 mg of oral supplementation with Q10.
11285433|NCT02796365|Experimental|Exercise|Patients will participate in a 10 week outpatient cardiac rehabilitation program. Exercise will consist of 3 days per week of interval training on a treadmill or bike at an intensity between 50-90% of heart rate reserve. Additionally patients will perform resistance exercises 1-2 days per week and attend 8 nutrition and lifestyle classes.
11285434|NCT02796365|No Intervention|Usual care|Control group will not be instructed on exercise, but encouraged to follow standard medical advice.
11285435|NCT02796352|Experimental|High dose bolus interleukin-2 (HD IL2)|
11285436|NCT02796339|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
11285437|NCT02796339|Placebo Comparator|Placebo|This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
11285438|NCT02796326|Experimental|Dilatation|Patients undergoing tracheal dilatation with the study device
11285439|NCT02796313|Experimental|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $30 credit for groceries.
11285440|NCT02796313|Active Comparator|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $30 credit for groceries.
11285441|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
11285442|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
11285443|NCT02796287|Experimental|Patients with Ictus amnesic|Patients admitted in the hospital as part of their medical care with amnesic Ictus episode
11285444|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
11285445|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
11285446|NCT02796235|Other|Spinal cord injury (SCI) patient|
11285447|NCT02796222||Hemophilia A patients on rFVIIIFc|Patients with hemophilia A who switch from on-demand or prophylactic treatment with rFVIII to rFVIIIFc
11285448|NCT02796222||Hemophilia A patients on rFVIII|Patients with hemophilia A who remain on on-demand or prophylactic treatment with rFVIII
11285449|NCT02796222||Hemophilia B patients on rFIXFc|Patients with hemophilia B who switch from on-demand or prophylactic treatment with rFIX to rFIXFc
11285450|NCT02796222||Hemophilia A patients on rFIX|Patients with hemophilia B who remain on on-demand or prophylactic treatment with rFIX
11285451|NCT02796209|Experimental|Atomexetine|Following the dose optimization phase, investigators will stratify the treatment assignment by Atomexetine dose (10mg or 19mg twice a day)
11285452|NCT02796209|Placebo Comparator|Placebo|The placebo capsules will be of identical color, size, and approximate weight to provide an authentic blinded effect. The capsule contents will be a microcrystalline cellulose, NF (PH-105), which should not produce any adverse effects. It is a common pharmaceutical capsule filler used in the industry.
11285453|NCT02796196||Supportive care (monitoring device, medical chart review)|Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
11285454|NCT02796183|Other|Diabetic macular edema|Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
11285455|NCT02796170|Active Comparator|Dapagliflozin|This arm will undergo either 6 weeks of Dapagloflozin then 6 weeks of placebo, or 6 weeks of placebo then 6 weeks of Dapagloflozin
11285456|NCT02796170|Other|Sulfonylurea|This arm will be open label, participants will receive usual care for 6 weeks, then be provided a sulfonylurea medication for 6 weeks.
11285457|NCT02796157|Active Comparator|absorb arm|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
11285458|NCT02796157|Experimental|Xience arm|PCI with Xience everolimus-eluting metallic stent
11285459|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
11285460|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
11285461|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
11285462|NCT02796131|Experimental|30 mg bid|30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).
11285463|NCT02796131|Experimental|30 mg tid|30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).
11285464|NCT02796131|Experimental|60 mg bid|60 mg of RDX5791 administered two times daily (120 mg total dose/day).
11285465|NCT02796131|Experimental|15 mg bid|15 mg of RDX5791 administered two times daily (30 mg total dose/day).
11285466|NCT02796131|Experimental|30 mg QD|30 mg of RDX5791 administered once daily (30 mg total dose/day).
11285467|NCT02796131|Experimental|Escalating dose bid|15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.
11285468|NCT02796131|Experimental|30 mg bid with psyllium|30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).
11285469|NCT02796118|Experimental|ASP2151 Low dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
11285470|NCT02796118|Experimental|ASP2151 High dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
11285471|NCT02796118|Experimental|ASP2151 Low dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
11285472|NCT02796118|Experimental|ASP2151 High dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
11285473|NCT02796118|Placebo Comparator|Placebo in non-elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
11285474|NCT02796118|Placebo Comparator|Placebo in elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
11285475|NCT02796105|Experimental|Progevera|Progevera 10 mg
11285476|NCT02796105|Active Comparator|Orgalutran|Orgalutran 0.25 mg
11285477|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
11285478|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
11285479|NCT02796079|Experimental|Autologous Bone Marrow Stem Cell|Mesenchymal stem cells derived from bone marrow infusion
11285480|NCT02796079|Placebo Comparator|saline|saline injections
11285481|NCT02796066|Placebo Comparator|Vehicle|Vehicle gel
11285482|NCT02796066|Experimental|Low Dose Active|Low Dose of TSN2898
11285483|NCT02796066|Experimental|Mid Dose Active|Mid Dose of TSN2898
11285484|NCT02796066|Experimental|High Dose Active|High Dose of TSN2898
11285485|NCT02796053|Placebo Comparator|Placebo|Placebo to TAB08
11285486|NCT02796053|Experimental|TAB08 Dose 1|Drug: TAB08 biologic
11285487|NCT02796040|Experimental|patients with ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
11285488|NCT02796040|Other|patients without ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
11285489|NCT02796027|Experimental|Experimental: BRIDGE|Subjects assigned to this arm would receive an integrated HIV service model
11285490|NCT02796027|No Intervention|Pre-implementation|Subjects assigned to this arm would receive standard care (treatment as usual) and would not be exposed to the integrated HIV service model.
11285491|NCT02796001|Active Comparator|RV16|volunteers re-challenged with RV16
11285492|NCT02796001|Active Comparator|RV39|volunteers re-challenged with RV39
11285493|NCT02795988|Experimental|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
11285494|NCT02795988|Experimental|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
11285495|NCT02795988|Experimental|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
11285496|NCT02795962|Active Comparator|Transfer to an Endovascular Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center.
11285497|NCT02795962|No Intervention|Transfer to the Local Stroke Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol.
11285498|NCT02795949|Experimental|Antipseudomonal beta-lactam antibiotic|"Ampicillin 2g IV/6h
~Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h
~Cefuroxime 750-1000 mg IV/8h
~Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h
~Amoxicillin/clavulanate 1000/125 mg IV/8h
~Ciprofloxacin 400 mg IV/12h
~Ertapenem 1-2g/24h."
11285499|NCT02795949|Active Comparator|De-escalation(short-spectrum antibiotic)|"Piperacillin/tazobactam 4/0.5 g IV/8h
~Meropenem 1-2 g IV/8h
~Imipenem 0.5 g IV/6h - 1g IV/6h
~Aztreonam 1-2 g IV/8h
~Ceftazidime 1-2 g IV/8h
~Cefepime 2 g IV/8-12h"
11285500|NCT02795936|Active Comparator|Institutional based rehabilitation|Conduct cardiac rehabilitation exercise protocol within the hospital
11285501|NCT02795936|Active Comparator|Home based rehabilitation|Conduct cardiac rehabilitation exercise protocol at home
11285502|NCT02795936|Placebo Comparator|Observational arm|No prescribed exercises, followed up monthly
11285503|NCT02795910|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions
11285504|NCT02795910|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will receive no outreach education training.
11285505|NCT02795884|Experimental|Intercalation arm|"Intercalation phase (Duration: 3wks x 4 cycles = 12 wks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Erlotinib 150mg D8-21 q3wks
~Maintenance phase (Duration: 1 year) Erlotinib 150mg D1-28"
11285506|NCT02795884|Active Comparator|Chemotherapy alone arm|Duration: 3wks x 4 cycles = 12 wks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3wks
11285507|NCT02795871|Experimental|Group D+ 1|Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
11285508|NCT02795871|Experimental|Group D+ 2|Girls and boys affected by CAH and treated in utero by Dexamethasone.
11285509|NCT02795871|Active Comparator|: Group D - 1|Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
11285510|NCT02795871|Active Comparator|Group D - 2|Girls and boys affected by CAH and not treated in utero by Dexamethasone.
11285511|NCT02795871|Other|Group D - 3|Girls and boys enrolled in school closed to Lyon
11285512|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with Ramucirumab at a pre-determined dose intravenously every 14 days of a 28-day treatment cycle.
~Patients will receive treatment with a Somatostatin Analog at a pre-determined dose.
~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
11285513|NCT02795845|Experimental|Primary prevention- probiotic capsules|"patients with normal vaginal flora in the experimental arm will be treated with Probiotic capsules (containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus, Bifidobacterium bifidum and B. Lactis).
~one capsule twice a day until delivery."
11285514|NCT02795845|Placebo Comparator|Primary prevention - Placebo|patients with normal vaginal flora in the placebo arm will be treated with a capsule without active ingredient, one capsule twice a day until delivery.
11285515|NCT02795845|Experimental|Secondary prevention - probiotic capsules|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given probiotic capsules.
11285516|NCT02795845|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given placebo without active ingredient.
11285517|NCT02795832|Experimental|Cohort 1a|ZPL-5212372 1% w/w Ointment BID
11285518|NCT02795832|Placebo Comparator|Cohort 1b|Placebo Ointment BID
11285519|NCT02795832|Experimental|Cohort 2a|ZPL-5212372 1% w/w Ointment BID
11285520|NCT02795832|Placebo Comparator|Cohort 2b|Placebo Ointment BID
11285521|NCT02795832|Experimental|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
11285522|NCT02795832|Placebo Comparator|Cohort 3b|Placebo Ointment BID
11285523|NCT02795819|Experimental|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
11285524|NCT02795819|Experimental|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
11285525|NCT02795819|Experimental|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
11285526|NCT02795819|Experimental|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
11285527|NCT02795819|Experimental|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
11285528|NCT02795819|Experimental|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
11285529|NCT02795819|Experimental|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
11285530|NCT02795806||1|Everybody for whom a clinical narrative report is created.
11285531|NCT02795793|Experimental|Non-operative management group (NOM)|Children in the NOM group will receive intravenous Piperacillin with Tazobactam (Tazocin) 100mg/kg/dose every 8 hours for at least 24 hours, and they will be observed and reassessed within 24 hours after randomisation. A further 24 hours of intravenous Piperacillin with Tazobactam therapy will be offered to children in invariable condition. A clinical decision will be made by the attending surgeon to offer OM if a patient's condition deteriorates at any time, or if a patient has failed to improve after 48 hours of intravenous antibiotic therapy. Once the patient is clinically improving and tolerating oral intake, the antibiotic regimen will be changed to oral Amoxicillin plus Clavulanic acid (Augmentin) 22.5mg/kg/dose twice per day to complete a total seven day course of antibiotics. Oral Ciprofloxacin 15mg/kg/dose twice daily and oral Metronidazole 10mg/kg/dose twice daily will be offered to children who are known to have an intolerance or allergy to Amoxicillin or Clavulanic acid.
11285532|NCT02795793|Active Comparator|Appendectomy group (Operative management, OM)|Children allocated to OM may receive preoperative antibiotic prophylaxis as clinically indicated. Appendicectomy will be performed laparoscopically, or via open surgery according to the surgeon's standard practice. Postoperative antibiotic treatment will be determined on the basis of intraoperative findings in accordance with the institutional practice. The appendix specimen will be examined by a paediatric pathologist, and the formal histopathology report will be recorded.
11285533|NCT02795780|Experimental|Follow-up Flortaucipir PET Scan|
11285534|NCT02795767|Experimental|Cohort A: Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
11285535|NCT02795767|Experimental|Cohort B: Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
11285536|NCT02795767|Experimental|Cohort C: Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
11285537|NCT02795754|Experimental|GSK2838232 PIB (50 mg+100 mg+200 mg)+Placebo|During Part 1A, subjects will receive QD single dose of either GSK2838232 50 mg, 100 mg or 200 mg or placebo in each of the four visits (one treatment per visit).Subjects will also receive RTV along with all the doses and QD RTV for 48hours (2 doses) before all doses of GSK2838232 and placebo.
11285538|NCT02795754|Experimental|GSK2838232 PIB+IR1+IR2|During Part 1B, subjects will receive either GSK2838232 PIB, GSK2838232 IR1 or IR2 in each of the three visits (one treatment per visit) after at least 10 hours fasting and IR1 or IR2 after fat meal at visit 4.
11285539|NCT02795754|Experimental|GSK2838232 PIB (20mg/50 mg/100 mg/200 mg)/Placebo|During Part 2, subjects will receive repeated QD doses of either GSK2838232 (20 mg, 50 mg, 100 mg or 200 mg) or placebo for 11 days. Subjects will also receive RTV along with all the doses of GSK2838232 and placebo.
11285540|NCT02795741|Experimental|Cooling Bolero|All participants will use the Cooling Bolero for one month
11285541|NCT02795728|Experimental|Experimental arm|Fuji type VII is a GIC based sealant with an additional property of high fluoride release
11285542|NCT02795728|Active Comparator|Resin based sealant|Helioseal F is a resin based sealant
11285543|NCT02795715|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
11285544|NCT02795715|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
11285545|NCT02795702|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
11285546|NCT02795702|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
11285547|NCT02795676|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 infusion every 2 weeks
11285548|NCT02795676|Active Comparator|agalsidase beta|agalsidase beta infusion every 2 weeks
11285549|NCT02795663|Experimental|parkinson's patient stimulated at STN level|15 parkinson's disease patients stimulated at STN level NIRS EEG HR recording
11285550|NCT02795663|Experimental|non STN|5 Parkinson's Disease patients who received stimulation in another target that the STN NIRS EEG HR recording
11285551|NCT02795663|Experimental|control|20 control patients undergoing DBS for the treatment of OCD NIRS EEG HR recording
11285552|NCT02795650|Experimental|Experimental arm|Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.
11285553|NCT02795650|Active Comparator|Control|Investigators are allowed to chose the best option of standard treatment for patients.
11285554|NCT02795637|Experimental|dasotraline|dasotraline 8mg capsule/day
11285555|NCT02795624||Flight attendants|Flight attendants
11285556|NCT02795611|Experimental|Treatment group|Patients who receive 'family-centered occupational therapy' in our hospital
11285557|NCT02795611|Active Comparator|Control group 1|Patients who receive regular occupational therapy in our hospital
11285558|NCT02795611|Other|Control group 2|Patients who don't receive intervention in our hospital
11285559|NCT02795598|Active Comparator|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
11285560|NCT02795598|Active Comparator|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
11285561|NCT02795585||QFR group|Patients with stable angina pectoris and indication for FFR.
11285710|NCT02794649||enteric hyperoxaluria|Patients with Roux-en-Y-gastric-bypass.
11285562|NCT02795572|Experimental|Intervention Group|The intervention group will receive a daily dose of Vitamin D 2000 IU, Vitamin B6 100 mg, Vitamin B12 100 mcg and Omega-3 Fatty Acids 2700 mg [900 mg TID (600 mg EPA, 300 mg DHA)].
11285563|NCT02795572|No Intervention|Reference Group|Reference group will receive usual care.
11285564|NCT02795559|Other|Lean|Subjects within the range of desirable body weight (BMI<25)
11285565|NCT02795559|Other|OWO|Subjects who are overweight or obese (BMI between 25 and 40)
11285566|NCT02795546|Experimental|Test group|400µg Alendronate sodium+ β-TCP + saline. 400µg alendronate sodium is combined with beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
11285567|NCT02795546|Active Comparator|Control group|β-TCP + saline Beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
11285568|NCT02795533||Clinical follow-up|As part of the regular follow-up of aSAH patients at Oslo University Hospital patients with as aSAH in 2011-2012 will be invited to a clinical interview, medical examination and neuropsychological test. Patients will also be asked to answer Quality of Life Questionnaires.
11285569|NCT02795520|Experimental|OTS167IV|
11285570|NCT02795507|Experimental|Device with feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in this specialized motion control apparatus which allows movement of the non involved hand while receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).
~5 days per week for 3 weeks, 1 hour per day."
11285571|NCT02795507|Active Comparator|Device without feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in a specialized motion control apparatus which allows movement of the non involved hand but without receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).
~5 days per week for 3 weeks, 1 hour per day."
11285572|NCT02795494||Perthes Group|Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
11285573|NCT02795494||Fracture Control Group|Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
11285574|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
11285575|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
11285576|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
11285577|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
11285578|NCT02795481||Traumatic brain injury patients|10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.
11285579|NCT02795468|Active Comparator|Palpation group|The operator will use the pulsation of the radial artery as a guide for the cannulation.
11285580|NCT02795468|Experimental|Ultrasound group|The ultrasound guided technique will be used to find a radial artery and insert a radial arterial catheter.
11285581|NCT02795455|Experimental|Interoceptive Exposure (IE)|IE is an exposure-based intervention that involves consuming a food in session and tolerating uncomfortable feelings around eating.
11285582|NCT02795455|Active Comparator|Family Based Therapy-Weight Gain Control (FBT-WG)|Family-based therapy uses parent(s) to help modify disordered eating and develop contingencies to motivate eating.
11285583|NCT02795455|No Intervention|Healthy Controls (HC)|HC participants will only participate in the pre and post-intervention visits and not in the intervention sessions.
11285584|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
11285585|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
11285586|NCT02795429|Experimental|INC280+PDR001|PDR001 + INC280 treatment in Phase II
11285587|NCT02795429|Experimental|PDR001 single agent|PDR001 single agent treatment in Phase II
11285588|NCT02795416|Experimental|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.
~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
11285589|NCT02795403|Experimental|Viraemic|
11285590|NCT02795403|Experimental|responder group|
11285591|NCT02795390|Experimental|Chinese herbal medicine|MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
11285592|NCT02795390|Placebo Comparator|Placebo|Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.
11285593|NCT02795377||male subjects with arterial hypertension|Measurements will be taken at baseline.
11285594|NCT02795377||male subjects without arterial hypertension and no CAD|Measurements will be taken at baseline.
11285595|NCT02795377||male subjects with hypertensive crises|Measurements will be taken before and after 4 hours and normalization of arterial blood pressure by urapidil.
11285596|NCT02795377||male subjects with stable CAD|Measurements will be taken before and after transfemoral coronary diagnostic angiography.
11285597|NCT02795364|Active Comparator|Structural Image Guidance|In this arm, the patients will receive maximum resection of the tumor with the MRI T1W-enhanced image guidance, in addition to the standard therapy
11285780|NCT02794220|Active Comparator|Nicorette Inhalator 15 mg|"15 mg strength
~- Administration once every hour for a total of 4 hours."
11285598|NCT02795364|Experimental|Metabolic Image Guidance|In this arm, the patients will receive quantitative resection of the tumor with both the MRI T1W-enhanced and the MRS Cho-to-NAA index (CNI) image guidance, in addition to the standard therapy.
11285599|NCT02795351|Experimental|Active|Sildenafil 100 mg single dose
11285600|NCT02795351|Placebo Comparator|Placebo|Placebo capsule
11285601|NCT02795325|Experimental|PH Patients|
11285602|NCT02795325|Experimental|Healthy Volunteers|
11285603|NCT02795312|Experimental|Smoking Cessation Training Program|Participants will take part in a 9-week Smoking Cessation Program class curriculum consisting of weekly 2.5 hour classes and complete pre and post questionnaires
11285604|NCT02795299|Active Comparator|Gerilimzumab 5/2 mg/Methotrexate/folate|• 5 mg gerilimzumab loading dose followed by 2 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
11285605|NCT02795299|Active Comparator|Gerilimzumab 10/5mg/Methotrexate/folate|• 10 mg gerilimzumab loading dose followed by 5 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
11285606|NCT02795299|Active Comparator|Gerilimzumab 20/10mg/Methotrexate/folate|• 20 mg gerilimzumab loading dose followed by 10 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
11285607|NCT02795299|Placebo Comparator|Placebo/Methotrexate/folate|• Placebo every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
11285608|NCT02795286|Experimental|ASIST A|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
11285609|NCT02795286|Experimental|ASIST B|Artis Haemodialysis Machine w/ ASIST Software - Isotonic
11285610|NCT02795286|Active Comparator|Conventional HD|Artis Haemodialysis Machine w/o ASIST Software
11285611|NCT02795273|Experimental|Grass-SPIRE|Eight intradermal injections of Grass-SPIRE
11285612|NCT02795273|Placebo Comparator|Placebo|Eight intradermal injections of Placebo
11285613|NCT02795260|Experimental|ESAT6-CFP10 in the right arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.
11285614|NCT02795260|Experimental|ESAT6-CFP10 in the left arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.
11285615|NCT02795247|Active Comparator|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
11285616|NCT02795247|Active Comparator|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
11285617|NCT02795247|Active Comparator|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
11285618|NCT02795234|Other|Participants with Vitamin D deficiency|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
11285619|NCT02795234|Other|Participants with sufficient Vitamin D Level|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
11285620|NCT02795208|No Intervention|Control group|Patients received standard protective ventilation along the protocol.
11285621|NCT02795208|Experimental|Recruitment maneuver group|Patient received a lung recruitment maneuver after cardiopulmonary bypass. The recruitment maneuver consists in 10 breaths at 40/20 cmH2O of plateau pressure and PEEP, respectively. Then, the .ventilatory settings back to protective ventilation but adding 10 cmH2O of PEEP to keep the lungs open.
11285622|NCT02795195|Experimental|CIRT Arm (3GyE per fraction)|Patients included in this arm were treated with carbon ion radiotherapy with a fraction size of 3GyE.
11285623|NCT02795182|Other|BGB-3111 and BGB-A317|Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tiselisumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
11285624|NCT02795156|Experimental|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
11285625|NCT02795156|Experimental|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
11285626|NCT02795156|Experimental|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
11285627|NCT02795156|Experimental|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
11285628|NCT02795143|Experimental|Isotretinoin|"Isotretinoin will be given at the following dosage:
~Dosing will be as listed on the table below.
~Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg"
11285629|NCT02795143|Placebo Comparator|Placebo|Subjects will be given placebo capsules twice a day.
11285630|NCT02795130|Experimental|8-0 polyglactin 910|
11285631|NCT02795130|Experimental|6-0 plain gut suture|
11285632|NCT02795117|Experimental|Test product|
11285633|NCT02795117|Active Comparator|Reference product|
11285634|NCT02795117|Placebo Comparator|Placebo product|
11285635|NCT02795104|Experimental|ARM I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
11285636|NCT02795104|Experimental|ARM II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
11285637|NCT02795104|Experimental|ARM III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
11285642|NCT02795052|Active Comparator|Arm 1 - Intravenous BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously.
11285643|NCT02795052|Active Comparator|Arm 2- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
11285644|NCT02795039|Experimental|Fulvestrant 50mg/mL (Fresenius Kabi)|5 mL intramuscular injection
11285645|NCT02795039|Active Comparator|Fulvestrant 50 mg/mL (Faslodex®)|5 mL intramuscular injection
11285646|NCT02795026|Active Comparator|Manual therapy|Intervention to be administered is manual therapy with myofascial release of trigger points for pelvic floor muscles, pelvis and abdominal musculature.
11285647|NCT02795026|Active Comparator|Dry needling & manual therapy|Intervention to be administered is Trans-perineal trigger point dry needling, done externally to target the trigger points in the pelvic floor muscles along with dry needling of the pelvis and abdominal musculature.Manual therapy will only be used in areas difficult to reach with the acupuncture needles.
11285648|NCT02795013||Participants with Hodgkin Lymphoma|Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.
11285649|NCT02795013||Family Members without Hodgkin Lymphoma|Those unaffected by HL will serve as a control group to compare with those with HL.
11285650|NCT02795000||Primary Ovarian insufficiency group|"amenorrhea one year or more than one year
~amenorrhea more than 4 months and FSH≥40IU/L
~≤42 years old and AMH≤0.071"
11285651|NCT02795000||The normal group|"normal regular menorrhea
~≤42 years old
~normal FSH and AMH level"
11285652|NCT02794987||Classification group|Group of endoscopists that will use the previous classification to select the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes
11285653|NCT02794987||No classification group|Group of endoscopists that will classified the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes without using the classification.
11285654|NCT02794974|Experimental|with perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
11285655|NCT02794974|Experimental|without perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
11285656|NCT02794961|Experimental|CD22 CAR-T|Enrolled patients will receive three escalating doses of autologous CAR-T.
11285657|NCT02794948|Experimental|Chinese Medicine intervention|Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months
11285658|NCT02794948|Active Comparator|Western intervention|DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.
11285659|NCT02794935|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
11285660|NCT02794935|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
11285661|NCT02794922|Experimental|Interventional|Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
11285662|NCT02794922|Placebo Comparator|Placebo|Capsule containing 250mg corn starch
11285663|NCT02794909|Experimental|CPUS group|The group of patients in the CPUS group will be those who receive a cardiopulmonary ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has received specific training in the CPUS protocol.
11285664|NCT02794909|No Intervention|Control group|The group of patients in the control group will be those who do not receive an ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has not received specific training in the CPUS protocol.
11285665|NCT02794896|Experimental|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
11285666|NCT02794896|Experimental|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
11285667|NCT02794883|Active Comparator|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11285668|NCT02794883|Active Comparator|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
11285669|NCT02794883|Experimental|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11285670|NCT02794870|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
11285671|NCT02794870|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
11285672|NCT02794857|Experimental|NP001|NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
11285673|NCT02794857|Placebo Comparator|Placebo|Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
11285674|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.
~No other ARM will be studied."
11285675|NCT02794831||patient|Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
11285676|NCT02794831||control|Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site
11285677|NCT02794818||Participating Patients|Participating patients will receive a prescription for weekly CSA produce boxes with nutritional education
11285678|NCT02794818||Participating Providers|Participating providers will be surveyed at the end of the pilot to evaluate their perceived program efficacy, the benefit of the program to their patients, and elicit program feedback.
11285679|NCT02794805|Experimental|HCC positive|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
11285680|NCT02794805|Experimental|HCC negative|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
11285681|NCT02794792|Active Comparator|Metformin and placebo|Participants will receive daily dosage of Metformin and Placebo as single tablets.
11285682|NCT02794792|Experimental|Metformin and Ipragliflozin|Participants will receive daily dosage of Metformin and Ipragliflozin (2 dose strengths) as single tablets.
11285683|NCT02794792|Other|Metformin, placebo and Ipragliflozin|Participants will receive daily dosage of Metformin, placebo and Ipragliflozin (1 dose strength) as single tablets.
11285684|NCT02794779|Experimental|Rule of three|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
11285685|NCT02794779|Active Comparator|Continuous infusion|Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.
11285686|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
11285687|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
11285688|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
11285689|NCT02794753|Experimental|True intervention|Working memory training on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
11285690|NCT02794753|Active Comparator|Active control|Similar time spent playing on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
11285691|NCT02794740|Experimental|X0002 First Dose|Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.
11285692|NCT02794740|Experimental|X0002 Second Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
11285693|NCT02794740|Placebo Comparator|Placebo Second Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
11285694|NCT02794740|Experimental|X0002 Third Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
11285695|NCT02794740|Placebo Comparator|Placebo Third Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
11285696|NCT02794740|Experimental|X0002 Fourth Dose|8 Subjects,Single Dose,Once,Double-Blind.
11285697|NCT02794740|Placebo Comparator|Placebo Fourth Dose|2 Subjects,Single Dose,Once,Double-Blind.
11285698|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
11285699|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
11285700|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
11285701|NCT02794714|Experimental|deep neuromuscular blockade|Rocuronium will be administered to achieve PTC 1-2 throughout surgery.
11285702|NCT02794714|Active Comparator|moderate neuromuscular blockade|Rocuronium will be administered to achieve TOFC 2 throughout surgery
11285703|NCT02794701||people with silicosis|
11285704|NCT02794688||Ductal lavage group|The patients will receive ductal lavage therapy every other day for two weeks, and will be followed up for one year.
11285705|NCT02794675|Experimental|Cesium 131 brachytherapy|Cesium 131 is the radioactive isotope in the protocol. The prescribed dose will range from 50-80 Gy at maximal delivery. It comes in 0.5 cm seeds that will be placed in the tumor resection bed at 1cm intervals. They are implantable seeds that do not require removal.
11285706|NCT02794662|Experimental|Oxygen Environment|Blended oxygen delivered by servo-controlled incubator
11285707|NCT02794662|Active Comparator|Nasal cannula oxygen|Blended oxygen delivered by nasal cannula
11285711|NCT02794649||calcium oxalate stone formers|History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment.
11285712|NCT02794636||IFN Treatment|Adult (age ≥ 18 years) patients identified as having stage III melanoma and no other primary or secondary cancer who initiated treatment with IFN between 1/1/2007 and 12/31/2011. Patients are required to have continuous pharmaceutical benefit enrollment for 180 days before (pre-index) and after (post-index) IFN initiation and no evidence of treatment with systemic chemotherapy during the pre- or post-index period
11285713|NCT02794623|Experimental|Cochlear Implant Recipients|
11285714|NCT02794610|Experimental|Topical tacrolimus|Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.
11285715|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
11285716|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
11285717|NCT02794584|Active Comparator|Off-pump hybrid closure|Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.
11285718|NCT02794584|Placebo Comparator|Control|Control group: Conventional closure of ventricular septal defects was aided with cardiopulmonary bypass.
11285719|NCT02794571|Experimental|Phase Ia Dose-Escalation Stage: MTIG7192A|Cohorts of at least 3 participants each will be treated with escalating doses of MTIG7192A.
11285720|NCT02794571|Experimental|Phase Ia Dose-Expansion Stage: MTIG7192A+Atezolizumab|Participants will be treated with MTIG7192A at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.
11285721|NCT02794571|Experimental|Phase Ib Q3W Dose-Escalation Stage: MTIG7192A+Atezolizumab|A minimum of 3 participants will be treated for each dose level of MTIG7192A in combination with a fixed dose of atezolizumab.
11285722|NCT02794571|Experimental|Phase Ib Q3W Dose-Expansion Stage: MTIG7192A+Atezolizumab|Participants will be treated every 3 weeks (Q3W) with MTIG7192A at or below the MTD or MAD in combination with a fixed dose of atezolizumab.
11285723|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A|In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and MTIG7192A IV infusion. During induction phase, participants will receive atezolizumab and MTIG7192A in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and MTIG7192A in combination with pemetrexed on Day 1 of each 21-day cycle.
11285724|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B|In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and MTIG7192A IV infusion. During induction phase, participants will receive atezolizumab and MTIG7192A in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and MTIG7192A on Day 1 of each 21-day cycle.
11285725|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C|In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and MTIG7192A IV infusion. During induction phase, participants will receive atezolizumab and MTIG7192A in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and MTIG7192A on Day 1 of each 21-day cycle.
11285726|NCT02794571|Experimental|Phase Ib Q4W Dose-Expansion Stage: MTIG7192A + Atezolizumab|Participants will be treated every 4 weeks (Q4W) with fixed doses of MTIG7192A and atezolizumab
11285727|NCT02794558|Experimental|Treatment Arm|Subjects in this arm are treated once with MRgFUS device
11285728|NCT02794545|Experimental|Recent infection patient|The patient who infected with HIV-1 and screened out by P24 ELISA, and they would receives early cART course.
11285729|NCT02794532|No Intervention|Pre oxygenation with 100% oxygen via tight fitting mask|Pre Oxygenation will be done using a tight mask
11285730|NCT02794532|Experimental|Pre oxygenation with 100% oxygen in high-flow nasal cannula|Pre Oxygenation will be done using high-flow nasal canula
11285731|NCT02794519|Experimental|Sirukumab 50 mg/mL administered subcutaneously every 4 weeks|Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
11285732|NCT02794519|Placebo Comparator|Placebo administered subcutaneously every 4 weeks|Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
11285733|NCT02794506|Experimental|Propolis|400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
11285734|NCT02794506|Placebo Comparator|Placebo|Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
11285735|NCT02794493|Experimental|Arm I|Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
11285736|NCT02794493|Placebo Comparator|Arm II|Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
11285737|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
11285781|NCT02794220|Active Comparator|Cigarette|"Subjects will all smoke the same brand.
~- Administration once every hour for a total of 4 hours."
11285738|NCT02794480|Experimental|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
11285739|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
11285740|NCT02794480|Experimental|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
11285741|NCT02794467|Experimental|Epelsiban 75 mg|Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration
11285742|NCT02794467|Experimental|Epelsiban 200 mg|Approximately 24 subjects will receive 200 mg of epelsiban TID via oral administration
11285743|NCT02794467|Placebo Comparator|Placebo|Approximately 24 subjects will receive a matching placebo TID via oral administration
11285744|NCT02794454|Active Comparator|HeezOn Ultra-1|HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
11285745|NCT02794454|Active Comparator|HeezOn Ultra-2|HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
11285746|NCT02794454|Placebo Comparator|Placebo|Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
11285747|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
11285748|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
11285749|NCT02794428|Active Comparator|Eflornithine|
11285750|NCT02794428|Placebo Comparator|Eflornithine Placebo|
11285751|NCT02794415|Other|Community-based exercise|
11285752|NCT02794402|Active Comparator|Bydureon|s.c. once Weekly
11285753|NCT02794402|Placebo Comparator|Placebo|s.c. once Weekly
11285754|NCT02794389|Experimental|N-acetyl cysteine|1200mg for 2 days 2400mg for 7 days
11285755|NCT02794389|Placebo Comparator|Placebo|Magnesium stearate capsules
11285756|NCT02794376|Experimental|Immediate Treatment Group|Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments.
11285757|NCT02794376|Other|Delayed Treatment Group|Waiting period plus Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments after the waiting period has finished.
11285758|NCT02794363|Other|Autologous platelet rich plasma|Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms
11285759|NCT02794350||Cohort|
11285760|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
11285761|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
11285762|NCT02794324|Experimental|Voluntary deep-inspiratory breath hold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
11285763|NCT02794324|Active Comparator|Active-breathing-controlled deep-inspiratory breathhold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
11285764|NCT02794324|Active Comparator|Prone treatment|Stage 1B: Optimised supine DIBH vs prone position
11285765|NCT02794298|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
11285766|NCT02794298|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
11285767|NCT02794298|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
11285768|NCT02794285|Experimental|Anifrolumab|Anifrolumab
11285769|NCT02794285|Placebo Comparator|Placebo|Placebo
11285770|NCT02794272|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
11285771|NCT02794272|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
11285772|NCT02794272|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
11285773|NCT02794259|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
11285774|NCT02794259|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
11285775|NCT02794259|Sham Comparator|Sham tDCS|Sham stimulation during resting state fMRI
11285776|NCT02794246|Experimental|Single Arm|
11285777|NCT02794233|Experimental|PD patients with implanted DBS|Impedance measurements at different time points.
11285778|NCT02794220|Experimental|CN Electronic cigarette 10 mg|"10 mg strength
~- Administration once every hour for a total of 4 hours."
11285779|NCT02794220|Experimental|CN Electronic cigarette 15 mg|"15 mg strength
~- Administration once every hour for a total of 4 hours."
11285782|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
11285783|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
11285784|NCT02794194|No Intervention|Control group|No intervention
11285785|NCT02794194|Experimental|Vibration group|Proprioceptive training on a whole body vibration platform. Participants in the Vibration group trained with a BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
11285786|NCT02794194|Experimental|Non-vibration group|Proprioceptive training with the BOSU® on the floor. Participants in the Non-Vibration group trained with a BOSU® on the floor.
11285787|NCT02794168|Experimental|VAS203 (Ronopterin)|Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg
11285788|NCT02794168|Placebo Comparator|Saline|Intravenous infusion of physiological saline over 48 hours
11285789|NCT02794155|Experimental|Test Group|HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period
11285790|NCT02794155|Active Comparator|Control Group|Insulin Lispro subcutaneous, Pre-prandial dosing, 26 week treatment period
11285791|NCT02794142|Experimental|HD patient|
11285792|NCT02794129|Experimental|Bipolar Disorder patients|
11285793|NCT02794129|Experimental|Healthy Controls|
11285794|NCT02794116|Active Comparator|Control group: Sound teeth|"20 first permanent molars sound, that not affected by MIH will be included.
~The teeth were treated with conventional sealants to prevent caries lesion"
11285795|NCT02794116|Experimental|Test: Hypomineralized teeth|"20 first permanent molars affected by MIH will be included.
~The MIH teeth were treated with a resin sealants."
11285796|NCT02794103|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
11285797|NCT02794090|Active Comparator|Usual care, individual visits|Usual care according to regular treatment routines at the clinic during 18 months. The Child and parent(s) at regular visits to the nurse at the clinic.
11285798|NCT02794090|Active Comparator|Telephone coaching|Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
11285799|NCT02794077|Experimental|Cyclophosphamide|Patients receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progression or unacceptable toxicity.
11285800|NCT02794064|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes. Imaging time: Approximately 30 minutes
11285801|NCT02794051|Experimental|Unified Protocol for Children|Child participants with behavior problems between the ages of 8-12 and their caregivers will participate in a transdiagnostic group therapy protocol.
11285802|NCT02794038|Active Comparator|Soberlink Cellular Device|BAC reading with Soberlink Cellular Device
11285803|NCT02794038|Active Comparator|BACtrack S80 Pro|BAC reading with BACtrack S80 Pro
11285804|NCT02794025|Experimental|esmolol group|patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
11285805|NCT02794025|Sham Comparator|control group|Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
11285806|NCT02794012||At-Risk Rheumatoid Arthritis subjects|
11285807|NCT02794012||Early Rheumatoid Arthritis subjects|
11285808|NCT02794012||Healthy Controls|
11285809|NCT02794012||Non-Rheumatoid Arthritis Autoimmune Controls|
11285810|NCT02793986|Experimental|dexmedetomidine sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h.
11285811|NCT02793986|Experimental|propofol sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
11285812|NCT02793973|Active Comparator|80% discrepancy lift height correction|Each participant will be given 80% discrepancy shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
11285813|NCT02793973|Experimental|optimal lift height correction|Each participant will be given the optimal shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
11285814|NCT02793960|Experimental|Topical BPM31510 3.0% Cream|Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
11285815|NCT02793947|Experimental|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
11285816|NCT02793947|No Intervention|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
11285817|NCT02793934||1st phase|"In the 1st phase of the study the staff of the medical organizations continue to work in the familiar old scheme, but using the set of scales."
11285909|NCT02793310|Active Comparator|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
11285818|NCT02793934||2nd phase|"In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program ICF-reader will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales."
11285819|NCT02793921|Experimental|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
11285820|NCT02793921|No Intervention|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
11285821|NCT02793908|Experimental|Pleyris|Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days
11285822|NCT02793908|Active Comparator|Crinone8|Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days
11285823|NCT02793895|Experimental|Enhanced cardiac rhythm monitoring|Subjects in this group will receive up to 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
11285824|NCT02793895|Active Comparator|Usual care|Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
11285825|NCT02793869||Total cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
11285826|NCT02793869||Anterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
11285827|NCT02793869||Interior cataracts group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
11285828|NCT02793869||Posterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
11285829|NCT02793856|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
11285830|NCT02793856|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
11285831|NCT02793856|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
~A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
11285832|NCT02793843|Active Comparator|Ondansetron|
11285833|NCT02793843|Experimental|Ondansetron+ dexamethasone|
11285834|NCT02793830|Experimental|Mobile App Group|Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
11285835|NCT02793830|Active Comparator|Control Group|The control group will receive the same educational materials, but no daily reminder.
11285836|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
11285837|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
11285838|NCT02793804|No Intervention|Control|All HIV testing and counselling services will be conducted as currently.
11285839|NCT02793804|Experimental|HIV Self-Testing|Community-based distribution agents (CBDA), including Voluntary Male Medical Circumcision (VMMC) mobilisers, will deliver OraQuick® HIV Self-Tests (Orasure Technologies, Thailand). The kits will also be available at the health facility.
11285840|NCT02793791|Experimental|Ablation|
11285841|NCT02793791|No Intervention|Observation|
11285842|NCT02793778|Experimental|CROWN|CROWN: A nutritionally based therapy with a high protein content, formulated as a powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
11285843|NCT02793778|Placebo Comparator|CROWN Placebo|Placebo: An appearance and volume matched formulated powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
11285844|NCT02793765|Experimental|Docetaxel & Sipuleucel-T|75 mg/m2 docetaxel IV over 1-hour every 21 days x 6 cycles; 28 day rest then Sipuleucel-T IV over 1-hour every 14 days for 3 doses
11285845|NCT02793752||Mitochondrial Activity of Cumulus Cells|One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
11285846|NCT02793752||Competence to Blastocyst|The percentage of fertilized eggs that develop to the blastocyst stage.
11285847|NCT02793739|Experimental|20 subjects|20 subjects will be enrolled to take part in this study and followed for a period of 12 months. Subjects will receive hyaluronic acid filler injection in the dorsal fingers (2-4 syringes) at the initial visit for volume restoration. If warranted, subjects will receive touch-up of hyaluronic acid at day 14 (1-2 syringes). The investigators expect volume restoration to last 9-12 months.
11285848|NCT02793726||Symptomatic|Patients with pain and or other sign of prothesis failure
11285849|NCT02793726||Asymptomatic|Patients with regular clinical and radiographic evolution of the implant. No pain
11285850|NCT02793687|Experimental|Mexidol|"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.
~The use of the study drug is held with basic therapy."
11285851|NCT02793687|Placebo Comparator|Placebo|"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.
~The use of a placebo is held with basic therapy."
11285852|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
11285853|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
11285854|NCT02793661|Experimental|RenalGuard Arm|In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.
11285855|NCT02793661|Active Comparator|Control Arm|Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.
11285856|NCT02793648|Experimental|Treatment|Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks
11285857|NCT02793648|Placebo Comparator|Placebo|colloidal Silica 200mg twice a day for twelve weeks
11285858|NCT02793635|Experimental|SCI Patients|"10 subjects with complete or incomplete SCI (> 1 year post-injury) with preserved LE function will be recruited.
~No control group"
11285859|NCT02793622|Active Comparator|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
11285860|NCT02793622|Active Comparator|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
11285861|NCT02793609|Other|Outpatient group|After insertion of double balloon induction catheter of labor, women are discharged overnight to home. Intervention is to let patient to go home.
11285862|NCT02793609|Other|Inpatient group|After insertion of double balloon induction catheter of labor, women are observed in the prenatal ward. Intervention is to observe women in the ward.
11285863|NCT02793596|Experimental|Obstetrical patients|Obstetrical patients requiring epidural analgesia for delivery
11285864|NCT02793583|Experimental|TGR-1202 + Ublituximab|TGR-1202 oral daily dose in combination with Ublituximab intravenous administration
11285865|NCT02793583|Experimental|TGR-1202|TGR-1202 oral daily dose
11285866|NCT02793583|Experimental|TGR-1202 + Ublituximab + Bendamustine|TGR-1202 oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
11285867|NCT02793557|Placebo Comparator|Placebo|Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.
11285868|NCT02793557|Experimental|FOL-005: Solution 1|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
11285869|NCT02793557|Experimental|FOL-005: Solution 2|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
11285870|NCT02793557|Experimental|FOL-005: Solution 3|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
11285871|NCT02793557|Experimental|FOL-005: Solution 4|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
11285872|NCT02793544|Active Comparator|Regimen A (RIC: Flu/Cy/TBI)|"Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2
~Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
~Total Body Irradiation (TBI) 200cGy on Day -1
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
11285873|NCT02793544|Active Comparator|Regimen B 2a (FIC: Bu/Cy)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)
~Cyclophosphamide 50mg/kg/day IV on Days -2,-1
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
11285874|NCT02793544|Active Comparator|Regimen B 2b (FIC: Bu/Flu)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)
~Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
11285875|NCT02793544|Active Comparator|Regimen C (FIC: Cy/TBI)|"Cyclophosphamide 50mg/kg/day IV on Days -5,-4
~Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
~Infusion of non-T-cell depleted bone marrow on Day 0
~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
11285876|NCT02793531|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
11285877|NCT02793531|Experimental|Cancer subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
11285878|NCT02793518|Experimental|Bipolar Disorder patients|
11285879|NCT02793518|Experimental|Healthy Controls|
11285880|NCT02793505||Pregnant patient exposed to metformin|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)).
11285881|NCT02793505||Reference group|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to any drug not known as a major teratogen or fetotoxicant and different than metformin, insulin or any other hypoglycaemic agent.
11285882|NCT02793492|Experimental|Misago® RX Self-expanding Stent|Eligible participants will undergo stent implantation with the Misago® RX Self-expanding Stent
11285883|NCT02793479||BE|Patients presenting Barrett's Esophagus as a complication of a gastroesophageal reflux disease.
11285884|NCT02793466|Experimental|Durvalumab; MEDI4736|Open label
11285885|NCT02793453|Other|Diseased|Patients suffering of moderate to severe chronic periodontitis
11285886|NCT02793453|Other|Healthy|Healthy Patients not suffering of any periodontal disease a
11285887|NCT02793440|Active Comparator|cortivazol|anti-inflammatory therapy and epidural
11285888|NCT02793440|Experimental|Traction arm|Medical treatment associated with 5 lumbar traction sessions
11285889|NCT02793427|Experimental|Type 1 diabetes|
11285890|NCT02793427|Experimental|control|
11285891|NCT02793414||Malaria patients|
11285892|NCT02793414||Febrile controls|
11285893|NCT02793401|Active Comparator|HILT group|71 of the patients were in the HILT group
11285894|NCT02793401|Active Comparator|US Group|70 of the patients were in the US group.
11285895|NCT02793388|Active Comparator|Supervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure. Supervision of primaquine is done on alternate days at home (attended by a home visitor) or at the health centre.
11285896|NCT02793388|Active Comparator|Unsupervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure for self administration.
11285897|NCT02793375|Placebo Comparator|Control|Patients receiving placebo preoperatively (blinded)
11285898|NCT02793375|Experimental|Study group|Patients receiving montelukast preoperatively (blinded)
11285899|NCT02793362||Normal subjects without stroke|"subjects who can walk independent without any difficult
~subjects without history of CNS or PNS lesion
~Modified ranking scale (MRS) <=2
~Functional ambulation category (FAC) >=2"
11285900|NCT02793362||Post stroke patients with sarcopenia(by sarcopenia index)|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
11285901|NCT02793362||Post stroke patients without sarcopenia(by sarcopenia index)|patients who do not satisfy the value of DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
11285902|NCT02793362||Post stroke patients with sarcopenia(by lean body mass)|Existence of sarcopenia will be determined by DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
11285903|NCT02793362||Post stroke patients without sarcopenia(by lean body mass)|patienst who do not satisfy the value of DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
11285904|NCT02793349|Experimental|Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
11285905|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
11285906|NCT02793323|Experimental|Superficial cervical block|Patients will receive superficial cervical nerve block in which we inject 5 ml of local anaesthetic mixture. Each 17 ml of the mixture contain: 6 ml lidocaine 2%, 6 ml lidocaine 2% with adrenaline 5 µg/ml, and 5 ml bupivacaine 0.5. Patients will also receive 100 ml IV saline.
11285907|NCT02793323|Placebo Comparator|NSAID|Patients will receive 100 mg (100 ml) IV NSAIDs (Profenid) before induction of anesthesia. Superficial cervical nerve block containing 5 ml placebo will be performed.
11285908|NCT02793310|Active Comparator|DMEK|The intervention group will receive cornea transplantation by DMEK
11285910|NCT02793297|Experimental|refined wheat crisp bread|refined wheat crisp bread was served as part of a complete standardized breakfast
11285911|NCT02793297|Experimental|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread was served as part of a complete standardized breakfast
11285912|NCT02793297|Experimental|unfermented rye crisp bread|Unfermented rye crisp bread was served as part of a complete standardized breakfast
11285913|NCT02793284|Experimental|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
11285914|NCT02793271|Active Comparator|PRIME|The behavioral intervention will be the PRIME/mhGAP training. This is standard mental health training for prescribers (primary care workers who can prescribe psychotropic medication, e.g., health assistants) and non-prescribers (primary care workers who cannot prescribe medications, e.g., auxilliary nurse midwives). For prescribers, training includes introduction to psychosocial techniques and mhGAP. For non-prescribers, training includes psychosocial techniques.
11285915|NCT02793271|Experimental|PRIME+RESHAPE|The behavioral intervention will be the PRIME/mhGAP training plus the RESHAPE training adjunct. This is the PRIME training plus social contact component in which mental health service users participate as training co-facilitators. The intended goal of the additional component is to reduce stigma against persons with mental illness.
11285916|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.
~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
11285917|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.
~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
11285918|NCT02793245|Experimental|Studied population|Patients will be questioned about their main characteristics (age, gender, height, weight, smoking), they will also perform a simplified a pulmonary function test (if possible).
11285919|NCT02793232|Experimental|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
11285920|NCT02793232|Experimental|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
11285921|NCT02793232|Experimental|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
11285922|NCT02793219|Experimental|Sipuleucel-T then Docetaxel|Sipuleucel-T IV over 1-hour every 14 days for 3 doses; 28 day rest; 75 mg/m2 docetaxel IV over 1-hour every 21 days for 6 cycles
11285923|NCT02793193|Experimental|Active (rifaximin/B.longum 1714)|
11285924|NCT02793193|Experimental|Placebo|
11285925|NCT02793167|No Intervention|Usual care|patients will receive standard clinical care by the doctor in charge.
11285926|NCT02793167|Experimental|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
11285927|NCT02793154|Experimental|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
11285928|NCT02793154|Experimental|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
11285929|NCT02793154|Active Comparator|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.
~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
11285930|NCT02793141||ICU Nosocomial Pneumonia|Nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ward patients (= or > 48 hours after hospital admission) that due to deterioration are subsequently admitted to ICU or nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ICU patients (= or >48 hours after hospital admission) or ventilator-associated pneumonia with onset = or > 48 hours after intubation. No intervention will be administered.
11285931|NCT02793128|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
11285932|NCT02793115|Experimental|Arm 1|Disclosure Letter-RISKS
11285933|NCT02793115|Experimental|Arm 2|Disclosure Letter-BENEFITS
11285934|NCT02793115|Experimental|Arm 3|Disclosure Letter-RISKS AND BENEFITS
11285935|NCT02793115|Experimental|Arm 4|Disclosure Letter-NO RISKS OR BENEFITS
11285936|NCT02793115|Placebo Comparator|Arm 5|Letter-APPOINTMENT REMINDER
11285937|NCT02793102|Experimental|Olfactory workshop + Somesthesia workshop|Olfactory workshop, Twenty odorants. Somesthesia workshop, time for moving the body, Talk Time
11285938|NCT02793102|Experimental|Auditory workshop + Somesthesia workshop|Auditory workshop, Twenty extracts of music tracks. Somesthesia workshop, time for moving the body, Talk Time
11285939|NCT02793089||First quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
11285940|NCT02793089||Second quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
11285941|NCT02793089||Third quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
11285942|NCT02793089||Fourth quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
11285943|NCT02793076|Experimental|Bollywood Dance|Bollywood dance is a routine that doubles as both physical and mental exercise.
11285944|NCT02793063||BBD Consortium Contact Registrants|Osteogenesis Imperfecta patients who have self-registered at the Brittle Bone Disorders Consortium (BBD) Consortium Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
11285945|NCT02793050||Trabectedin|Trabectedin give according the market authorization for advanced soft tissue sarcoma
11285946|NCT02793037|Experimental|A proof of concept of using zirconia bonded bridge|
11285947|NCT02793024|Experimental|Arm 1 - Intervention|Counties will be randomized to receive the intervention or act as a delayed control. Students in the intervention arm will receive the 12-week intervention to improve shopping choices.
11285948|NCT02793024|No Intervention|Arm 2 - Intervention|Control adolescents will not receive the intervention and will receive routine information normally distributed through schools.
11285949|NCT02793011|Experimental|Dexamethasone|Liquid or capsule dexamethasone - to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
11285950|NCT02793011|Placebo Comparator|Placebo|Placebo liquid or capsule to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
11285951|NCT02792998|Experimental|IW-1701|IW-1701 tablets administered orally in multiple ascending dose.
11285952|NCT02792998|Placebo Comparator|Placebo|Matching placebo tablets administered orally.
11285953|NCT02792985|Experimental|Multisensory stimulation protocol|The Experimental group will follow an intervention protocol.
11285954|NCT02792985|Active Comparator|Control protocol|The Control group will follow the current protocol for patients in PTA at the Institut Guttmann.
11285955|NCT02792972|Active Comparator|Acmella oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers 3 minutes before the venipuncture
11285956|NCT02792972|Placebo Comparator|alcohol 70%|70% alcohol were used in the volunteers 3 minutes before the venipuncture
11285957|NCT02792959|Experimental|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
11285958|NCT02792946|Experimental|Sulfolase CR (200mg, QD)|for 7 days with or without meal
11285959|NCT02792946|Active Comparator|Sulfolase Capsule (100mg, BID)|for 7 days with or without meal
11285960|NCT02792933|Active Comparator|air in epidural space|When the ALOR epidural localization technique will be used, an intermittent pressure with fast movements will be exerted on the plunger of the syringe while the Tuohy needle will be inserted until loss of resistance was felt.
11285961|NCT02792933|Experimental|saline in epidural space|When the SLOR technique is used, a continuous pressure will be exerted on the plunger of the Tuohy needle until loss of resistance was felt.
11285962|NCT02792920|Other|CoCr-EES|
11285963|NCT02792907|Experimental|Compressive Stockings group|Patients with compressive stockings at the operated foot for 4 weeks
11285964|NCT02792907|No Intervention|No compressive stockings group|Patients with no compressive stockings at the operated foot
11285965|NCT02792894|No Intervention|Enhanced Usual Care (EUC)|Enhanced Usual Care comprises of normal routine visits conducted by the local community health workers / Lady Health Workers (LHWs). Care is enhanced in 2 ways: (a) LHWs in the EUC arm will receive training in identifying children with developmental disorders and delays, as well as making referrals to their primary care physicians for treatment using the WHO mhGAP training program for developmental disorders and (b) The primary care physicians will receive the training in WHO mental health GAP(mhGAP) program developmental disorders module, by WHO Collaborating Center in Rawalpindi, Pakistan.
11285966|NCT02792894|Experimental|Family Networks program|Intervention is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO Parent Skills Training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
11285967|NCT02792881|Experimental|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
11285968|NCT02792868||patient|patient with cardiovascular risk (moderate)
11285969|NCT02792855|Experimental|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
11285970|NCT02792855|Experimental|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
11285971|NCT02792842|Experimental|ART-123 (High Frequency)|
11285972|NCT02792842|Experimental|ART-123 (Low Frequency)|
11285973|NCT02792842|Placebo Comparator|Placebo|
11285974|NCT02792829|Experimental|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:
~Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)
~Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
11285998|NCT02792686|Experimental|ABX464|50, 100, 150 or 200 mg once a day / Single Administration
11285999|NCT02792673|Active Comparator|"Embryo Glue®"|Hyaluronan-enriched medium
11286000|NCT02792673|Active Comparator|"Global Total®"|30% Protein-supplemented Culture Medium
11286001|NCT02792673|Experimental|Autologous Follicular Fluid|a novel technique
11286002|NCT02792660|Experimental|Injeq IQ-Needle|Lumbar puncture is performed using Injeq IQ-Needle
11286003|NCT02792647|Placebo Comparator|Placebo|Placebo
11286192|NCT02791334|Experimental|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
11285975|NCT02792829|Experimental|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:
~Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE
~Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER
~Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE
~Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
11285976|NCT02792829|Experimental|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:
~Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation
~Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
11285977|NCT02792816||Kawthaung Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Kawthaung is one of the sentinel site and located at the Southern Myanmar.
11285978|NCT02792816||Myawaddy Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Myawaddy is one of the sentinel site and located at the northern part of the Southern Myanmar.
11285979|NCT02792816||Thanbyuzayat Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Thanbyuzayat is one of the sentinel site and located at the northern part of the Southern Myanmar.
11285980|NCT02792816||Shwegyin Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Shwegyin is one of the sentinel site and located at the southern part of the central Myanmar.
11285981|NCT02792816||Magway Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Magway is one of the sentinel site and located at the middle part of the central Myanmar.
11285982|NCT02792816||Rakhine Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Rakhine is one of the sentinel site and located at the western Myanmar.
11285983|NCT02792803|Experimental|Xalatan --> Apo-/Co-Latanoprost|Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
11285984|NCT02792803|Experimental|Apo-/Co-Latanoprost --> Xalatan|Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
11285985|NCT02792790||Patients with carpal tunnel syndrome.|Patients undergoing carpal tunnel release surgery.
11285986|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
11285987|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
11285988|NCT02792764||Port|Subjects receiving chemotherapy through a port
11285989|NCT02792764||Peripheral Intravenous (PIV) Lines|Subjects receiving chemotherapy through a peripheral IV
11285990|NCT02792751|Active Comparator|Group R (Ramsey)=25 patients|Propofol infusion was administered to provide Ramsey Sedation Scale 3-4 in Group R
11285991|NCT02792751|Experimental|Group B (BIS)=25 patients|Propofol infusion was given to maintain the Bispectral index monitorisation (BIS) levels between 60 and 85 in Group B.
11285992|NCT02792738|Experimental|hypnosis, visual distraction|"This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction.
~For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used.
~For visual distraction, subject will be watching the movie la marche des empereurs"
11285993|NCT02792712|Experimental|STEMI_MRI_Ticagrelor|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm
11285994|NCT02792712|Active Comparator|STEMI_MRI_Clopidogrel|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm
11285995|NCT02792699|Experimental|ABP 798 / ABP 798|Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
11285996|NCT02792699|Active Comparator|Rituximab (US) / ABP 798|Participants received rituximab (United States [US] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
11285997|NCT02792699|Active Comparator|Rituximab (EU) / Rituximab (EU)|Participants received rituximab (European Union [EU] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
11286004|NCT02792647|Experimental|Experimental: IX-01|2 different dose groups 1,600 mg and 2,400 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
11286005|NCT02792621|Experimental|active oral supplement|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
11286006|NCT02792621|Placebo Comparator|placebo supplement|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
11286007|NCT02792608|Experimental|Mindfulness-based Therapy|5 week, manual-based group MBI treatment for depression
11286008|NCT02792595|Sham Comparator|Negative Control|Untreated area will be irradiated using a sun simulator with UV irradiation increment of 1.25 to detect MED of the unprotected skin.
11286009|NCT02792595|Active Comparator|Positive Control|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, positive control will be applied. The dose of positive control will be measured in accordance to the application volume (2 milligram (mg)/centimeter (cm)^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Positive control will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 seconds (s). After waiting for 15 to 30 minutes (min), the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the SPF of positive control, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286010|NCT02792595|Experimental|Test Product A|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286011|NCT02792595|Experimental|Test Product B|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286012|NCT02792595|Experimental|Test Product C|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286013|NCT02792595|Experimental|Test Product D|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286014|NCT02792595|Experimental|Test Product E|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286015|NCT02792595|Experimental|Test Product F|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286163|NCT02791516|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a month for 6 months.
11286016|NCT02792595|Experimental|Test Product G|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286017|NCT02792595|Experimental|Test Product H|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
11286018|NCT02792582|Active Comparator|Tumor-Surgery|"Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups.
~If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups."
11286019|NCT02792582|Active Comparator|Tumor-No Surgery|Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
11286020|NCT02792569|Experimental|Biopsy at Right side|Biopsy of ovarian cortical tissue (50% right side)
11286021|NCT02792569|Experimental|Biopsy at Left side|Biopsy of ovarian cortical tissue (50% left side)
11286022|NCT02792556||patient having a drug abortion|Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
11286023|NCT02792543|Active Comparator|parenteral nutrition|Parenteral nutrition consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
11286024|NCT02792543|Experimental|chyme reinfusion|Chyme reinfusion consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
11286025|NCT02792530|Other|arm 1|Unuric hemodialytic patients who accumulate above 2.5 (4%) in intradialytic intervals before the nutritional intervention.
11286026|NCT02792517|Experimental|Erenumab + Estrogen/Progestin Contraceptive|"Participants received a combination oral contraceptive for 3 28-day cycles during the study.
~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider."
11286027|NCT02792491|Experimental|Reduced dose R-CHOP|"Reduced dose R-CHOP is regimen including Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
~In this study, Rituximab 375 mg/m2, Cyclophosphamide 600 mg/m2, Doxorubicin 30 mg/m2 and Vincristine fixed dose of 1mg will be administrated through intravenous on day 1. and Prednisone 40mg will be administrated orally on day 1-5. This chemotherapy will be repeated every 21 days."
11286028|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.
11286029|NCT02792478||Patient RAS WT|As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.
11286030|NCT02792465|Experimental|Cohort A|CFI-402257 capsules will be taken orally, once a day, every day.
11286031|NCT02792465|Experimental|Cohort B|CFI-402257 capsules will be taken orally, once a day, every day.
11286032|NCT02792465|Experimental|Cohort C|CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
11286033|NCT02792426|Active Comparator|Group 1 AB|Smoker subject's own brand of combustion cigarette
11286034|NCT02792426|Active Comparator|Group 1 BA|Smoker subject's own brand of combustion cigarette
11286035|NCT02792426|Active Comparator|Group 2|E-cigarette user's own brand of electronic nicotine delivery system (ENDS)
11286036|NCT02792413|Experimental|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
11286037|NCT02792413|Placebo Comparator|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
11286038|NCT02792400|Placebo Comparator|A1: GRA-placebo + MEAL + DPP4-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo
11286039|NCT02792400|Placebo Comparator|A2: GRA-active + MEAL + DPP4-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo
11286040|NCT02792400|Active Comparator|A3: GRA-placebo + MEAL + DPP4-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
11286041|NCT02792400|Active Comparator|A4: GRA-active + MEAL + DPP4-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
11286042|NCT02792400|Placebo Comparator|B1: GRA-placebo + MEAL + SGLT2-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
11286043|NCT02792400|Placebo Comparator|B2: GRA-active + MEAL + SGLT2-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
11286044|NCT02792400|Active Comparator|B3: GRA-placebo + MEAL + SGLT2-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
11286045|NCT02792400|Active Comparator|B4: GRA-active + MEAL + SGLT2-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
11286046|NCT02792374||Dental patients group|Psychological measurement is done when they refer to a dental clinic.
11286047|NCT02792374||Control group|Psychological measurement is done when they refer to a dental clinic.
11286048|NCT02792361|No Intervention|Control Group|Subjects who did not have a suction drain placed post-operatively following a Pterional Craniotomy.
11286049|NCT02792361|Experimental|Treatment Group|Subjects who did have a suction drain placed post-operatively following a Pterional Craniotomy at the location of surgical incision.
11286050|NCT02792348||children with congenital urine flow impairment|this group contain children with an unilateral urinary tract dilatation diagnosed by prenatal ultrasonography
11286051|NCT02792348||control group|this group contains children, between 1 and 3 months of age, without nephrological or urological anomaly
11286052|NCT02792335||patients naive to oral anticoagulant treatment|NVAF patients naïve to oral anticoagulant treatment (Naïve)
11286053|NCT02792335||patients with prior warfarin therapy|NVAF patients with prior warfarin therapy (Warfarin treated)
11286054|NCT02792322|Other|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
11286055|NCT02792309|Experimental|MotherWise Programming|Three components: (1) 18 hours of core workshop sessions using the Within My Reach relationship education curriculum supplemented with content on mother-infant relationships; (2) case management services; and (3) optional relationship education workshops for couples.
11286056|NCT02792309|No Intervention|Control|No program services
11286057|NCT02792296|Experimental|Daily measurement|This arm will be asked to use the Project: EVO Monitor once a day for four weeks..
11286058|NCT02792296|Experimental|Multiple times per day measurement|This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.
11286059|NCT02792296|Experimental|Weekly measurement|This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.
11286060|NCT02792283|Experimental|patients undergoing hemodialysis|
11286061|NCT02792270|Experimental|Caloric Restriction Diet|"Patients will meet with the Registered Dietitian to discuss calorie, protein and fluid needs.The dietitian will calculate calorie needs.
~Calorie needs will then be reduced to 30%.
~Protein needs will be estimated based on 0.8g/kg BW and then reduced by 70%.
~Dietitian will educate participants on electrolytes and fluid intake based on the reduced food intake."
11286062|NCT02792270|No Intervention|Normal Diet|Participant will follow a normal diet.
11286063|NCT02792257|Experimental|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
11286064|NCT02792257|Placebo Comparator|Placebo|Placebo medication will be administered twice daily.
11286065|NCT02792231|Experimental|OMG 20 mg|"Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1
~,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily"
11286066|NCT02792231|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
11286067|NCT02792218|Experimental|OMB 20 mg|Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
11286068|NCT02792218|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
11286069|NCT02792192|Experimental|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
11286070|NCT02792192|Experimental|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
11286071|NCT02792192|Experimental|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
11286072|NCT02792192|Experimental|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
11286073|NCT02792179|Experimental|[18F]RO6958948|Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
11286074|NCT02792166|Active Comparator|BPD-DS|BPD-DS involves creating a sleeve gastrectomy and creation of a Roux-en-Y bypass involving a Roux limb (150cm) which is anastomosed to the transected first-stage of the duodenum and a short common channel (100cm).
11286075|NCT02792166|Experimental|SADI-S|SADI-S involves creating a sleeve gastrectomy but simplifies the bypass part of the BPD-DS by a single anastomosis of a loop of jejunum at 250cm from the ileocecal valve (longer common channel) to the transected first-stage of the duodenum instead of the Roux-en-Y construct.
11286076|NCT02792153|Experimental|Estrogen|AN participants receive a course of transdermal estradiol treatment.
11286077|NCT02792140|No Intervention|Baseline|reporting of dreams
11286078|NCT02792140|Experimental|Naltrexone|daily administration of 50mg Naltrexone, reporting of dreams
11286079|NCT02792140|Placebo Comparator|Placebo|daily administration of Placebo, reporting of dreams
11286080|NCT02792127|Experimental|Experimental|These participants will be given access to a six-month online program for social anxiety.
11286081|NCT02792127|No Intervention|Wait List Control|These participants will not be given an intervention until after they have completed the study.
11286082|NCT02792114|Experimental|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen & diphenhydramine, & administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
11286083|NCT02792088|Experimental|Besifovir|Besifovir 150 mg q.d.
11286084|NCT02792088|Active Comparator|Tenofovir|Tenofovir 300 mg q.d.
11286085|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
11286086|NCT02792075||OCT|Patients with Optical coherence tomography
11286087|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
11286088|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
11286089|NCT02792062|Experimental|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
11286090|NCT02792062|Experimental|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
11286091|NCT02792062|Experimental|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
11286092|NCT02792062|Experimental|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
11286093|NCT02792062|Experimental|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
11286094|NCT02792062|Experimental|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
11286095|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
11286096|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
11286097|NCT02792036|Experimental|Treatment|"Participants with retinoblastoma that is refractory or has relapsed inside the eye.
~Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy."
11286098|NCT02792023|Other|Colonoscopy followed by upper endoscopy|In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination
11286099|NCT02792023|Other|Upper endoscopy followed by colonoscopy|In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination
11286100|NCT02792010|Experimental|T1rho MRI|Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
11286101|NCT02791997|Experimental|Brain-damaged patients|
11286102|NCT02791997|Experimental|Control participants|
11286103|NCT02791997|Experimental|Migraine patients|
11286104|NCT02791984|Experimental|Fluid challenge with 250 ml of Ringer Lactate|
11286164|NCT02791516|Experimental|Romosozumab|Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
11286105|NCT02791971|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
11286106|NCT02791971|Active Comparator|Alcohol Control Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.
~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
11286107|NCT02791958|Experimental|CV Fixed Dose Combination Pill AAR|Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
11286108|NCT02791958|Active Comparator|Atorvastatin|Atorvastatin 40 mg (Lipitor®).
11286109|NCT02791958|Active Comparator|Ramipril|Ramipril 10 mg (Altace®).
11286110|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
11286111|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
11286112|NCT02791932|Experimental|Exercise|The intervention will last 8-10 months depending on when during pregnancy the participant is randomized. The intervention will consist of three components (i.e., telephone, print materials, and exercise log/goal setting) designed to increase exercise. Social Cognitive Theory (SCT) and Self-Determination Theory will guide the exercise intervention. The counseling sessions will be a collaboration between the counselor and participants on how to best integrate exercise into the participant's daily routine. Participants will receive 15 intervention phone calls lasting approximately 15-20 minutes each. There will be a one-month intensive phase (weekly contacts), followed by bi-weekly contacts for two months, and then monthly until delivery. Beginning at 6 weeks postpartum, bi-weekly contacts will resume through 3 months postpartum.
11286113|NCT02791932|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard of care as suggested by their healthcare provider. Participants will complete the same assessments and incentives as the active interventions but will not receive the exercise counseling sessions. Following completion of the nine-month follow-up, the usual care arm can choose to receive a six-month version of the exercise intervention.
11286114|NCT02791919|Experimental|Treatment (AZD1775, FLAG chemotherapy)|Patients receive filgrastim IV or SC daily, fludarabine intravenously IV over 30 minutes, cytarabine IV over 1-3 hours and wee1 kinase inhibitor AZD1775 PO on days 1-5. Patients who meet criteria for CR, CRp or PR may receive a second course of therapy. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11286115|NCT02791906|Experimental|ISMN Only|Patients receive only ISMN
11286116|NCT02791906|Experimental|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
11286117|NCT02791893|Experimental|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
11286118|NCT02791893|Placebo Comparator|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
11286119|NCT02791880||TAVR patients|The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
11286120|NCT02791867|Active Comparator|Active|AphoelineBrake administration
11286121|NCT02791867|Placebo Comparator|Placebo|Placebo Administration
11286122|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
11286123|NCT02791841|Experimental|RRT|Rhythmic Reading Training, administered for 13 hours over 9 days (two 45-minute training sessions per day).
11286124|NCT02791841|Experimental|VHSS+AVG|Visual Hemispheric-Specific Stimulation + Action Video Games, administered for 13 hours over 9 days (two 45-minute training sessions per day).
11286125|NCT02791841|Experimental|AVG|Action Video Games only, administered for 13 hours over 9 days (two 45-minute training sessions per day).
11286126|NCT02791815|Experimental|Sequence AB|Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
11286127|NCT02791815|Experimental|Sequence BA|Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
11286128|NCT02791802||Group A: Lipoprotein apheresis subjects|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.
~Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP)."
11286191|NCT02791334|Experimental|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
11286129|NCT02791802||Group B: Control group|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.
~The control group will not undergo a sham apheresis procedure. It is an open trial."
11286130|NCT02791789|Other|Autism Spectrum Disorder|clinical exam, speech and language therapy and neuropsychological evaluations, Training to the SEMATIC serious game
11286131|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.
~collection of patient's radiographic and clinical parameters"
11286132|NCT02791763|Experimental|Daprodustat in ND participants|Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams [mg] as recommended) dose once daily for 52 weeks.
11286133|NCT02791763|Active Comparator|Epoetin beta pegol in ND participants|Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram [µg] as recommended) dose once every 2 or 4 weeks for 52 weeks.
11286134|NCT02791763|Experimental|Daprodustat in PD participants|Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
11286135|NCT02791750||Observational|Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
11286136|NCT02791737|Experimental|Supportive care (otago exercise programme)|Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
11286137|NCT02791724|Experimental|Desiconnect|Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
11286138|NCT02791724|Active Comparator|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
11286139|NCT02791711|Other|High Flow Nasal Cannula|Use of High Flow Nasal Cannula
11286140|NCT02791685||Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
11286141|NCT02791685||Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
11286142|NCT02791685||Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
11286143|NCT02791672||Same Day Discharge|Following a Latissimus Dorsi flap reconstruction patients will be offered discharge at 24 hours. Patients successfully discharged within 24 hours of their surgery will be included in the cohort group.
11286144|NCT02791659|Active Comparator|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
11286145|NCT02791659|Experimental|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
11286146|NCT02791646|Experimental|PCST-Full|PCST-full will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
11286147|NCT02791646|Experimental|PCST-Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
11286148|NCT02791620|Experimental|A nanofractional radiofrequency device|
11286149|NCT02791581|Experimental|Breast Cancer Patients|"Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.
~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.
~Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment."
11286150|NCT02791581|Experimental|Non-Cancer Controls|"Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.
~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities."
11286151|NCT02791568||Pilot Study|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection"
11286152|NCT02791568||Main Study- Control Group|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection"
11286153|NCT02791568||Main Study- Study Group|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection"
11286154|NCT02791568||Main Study- Ferumoxytol Group|"Ultrasound Scan
~MRI Scan
~Blood/Urine collection
~Ferumoxtyol Infusion"
11286155|NCT02791555||Pradaxa|20 men and 20 women on Pradaxa for non valvular atrial fibrillation
11286156|NCT02791555||Warfarin|20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
11286157|NCT02791542||Asthma|Participants with a history of asthma
11286158|NCT02791542||Healthy controls|Participants without a history of asthma
11286159|NCT02791542||Asthma Bronchoscopy sub-group|Participants with a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
11286160|NCT02791542||Healthy Bronchoscopy sub-group|Participants without a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
11286161|NCT02791529|Active Comparator|Scalpel|Skin incision performed by scalpel
11286162|NCT02791529|Experimental|Electrocautery|Skin incision performed by electrocautery
11286420|NCT02789631||chronic neck pain|experiencing neck pain for at least 3 months in the last year
11286165|NCT02791503|Experimental|IRE group|FOLFIRINOX + IRE For patients diagnosed with LAPC, a combination of chemotherapy plus local tumor destruction using irreversible electroporation (IRE), a novel tumor ablation technique, has recently shown great promise. IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
11286166|NCT02791503|Active Comparator|SABR group|FOLFIRINOX + SABR Focal therapy using external beam radiation therapy (EBRT) may further improve survival, but outcome remains poor. Stereotactic ablative radiotherapy (SABR) is a form of EBRT that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
11286167|NCT02791490|Experimental|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day [b.i.d.]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
11286168|NCT02791490|Placebo Comparator|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
11286169|NCT02791477|Other|Attune FB PS|Attune FB PS knee arthroplasty
11286170|NCT02791464|No Intervention|wait list control|Waitlist control subjects interested in learning the TM program will be asked to wait for 4 months before learning if they were randomly assigned to this comparison group. Controls will receive usual medical care during 4 month intervention period.
11286171|NCT02791464|Experimental|Transcendental Meditation|The TM technique is a simple, effortless, mental technique to reducing stress which allows the mind to experience finer levels of the thinking process to achieve a state of restful alertness. The Transcendental Meditation program will be taught as a standard seven-step program over five consecutive days.
11286172|NCT02791451|Experimental|Telemonitoring|Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.
11286173|NCT02791438|Experimental|Azilsartan 2.5 - 20 mg (Weight < 50 kg)|Following a 2-week placebo run-in period, azilsartan 2.5 mg (titrated as needed to the highest dose of 20 mg) was administered orally once daily before or after breakfast, for the participants weighing < 50 kg.
11286174|NCT02791438|Experimental|Azilsartan 5 - 40 mg (Weight ≥ 50 kg)|Following a 2-week placebo run-in period, azilsartan 5 mg (titrated as needed to the highest dose of 40 mg) was administered orally once daily before or after breakfast, for the participants weighing ≥ 50 kg.
11286175|NCT02791425|Experimental|Brain Computer Interface (BCI) device|The patient uses the Brain Computer Interface (BCI) device in the ICU for communication for 2 hours a day for 3 consecutive days. The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
11286176|NCT02791412||unprotected left main|undergone percutaneous coronary intervention or coronary artery bypass graft
11286177|NCT02791399|No Intervention|Control|Treatment as usual
11286178|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
11286179|NCT02791386||Chinese Patients With CHB and Drug Resistance to NA Therapy|
11286180|NCT02791373|Active Comparator|Mobilisation Chemotherapy: Vinorelbine|Vinorelbine is given at a standard dose of 35mg/m2 i.v. at day 1 as an infusion over 10 minutes, on an ambulatory basis.
11286181|NCT02791373|Experimental|Mobilisation Chemotherapy: Gemcitabine|Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
11286182|NCT02791360|Other|MRI evaluation|Patient pretreated for brain tumor and witness
11286183|NCT02791347|No Intervention|Control|"Upon discharge from the medical center, patients would be advised on a qualitative, neutropenic diet. Participants' quality of life, physical activity level, functional and nutritional status would be assessed at days +30, +60 and +100 post transplantation.
~These participants will not receive nutritional counseling by the dietitian as outpatients except if referred by the medical team."
11286184|NCT02791347|Experimental|Nutrition Intervention Group|"Upon discharge from the medical center, NIG patients will receive tailored nutrition counseling with the provision of patient education material and oral nutritional supplements if needed. Patients will be advised on a diet high in energy and proteins and tailored to their medical condition in the hospital before discharge.
~Patients will be followed up at days +30, +60 and +100 post transplantation. Compliance will be measured at each visit by comparing patients caloric and protein needs to their actual protein and energy intake. Compliance will be reinforced to meet patients' goals using nutritional tips, oral supplementation, and artificial nutrition use."
11286185|NCT02791334|Experimental|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
11286186|NCT02791334|Experimental|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
11286187|NCT02791334|Experimental|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
11286188|NCT02791334|Experimental|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
11286189|NCT02791334|Experimental|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
11286190|NCT02791334|Experimental|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
11286193|NCT02791334|Experimental|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
11286194|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
11286195|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
11286196|NCT02791334|Experimental|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
11286197|NCT02791321|Other|Patients with ADS-MR|Patients presenting Autism Spectrum Disorder and mental retardation who are evaluated for their ADS severity, their adaptative and intellectual functioning, psychiatric and somatic comorbidities
11286198|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
11286199|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
11286200|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
11286201|NCT02791295|Experimental|Diet and physical activity program|Diet and physical activity program with individual coaching
11286202|NCT02791295|No Intervention|control|standard care
11286203|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Patients with clinical suspicion for CTEPH, scheduled for SPECT
11286204|NCT02791269|Experimental|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
11286205|NCT02791269|Experimental|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
11286206|NCT02791256|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day [mg/day] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.
11286207|NCT02791243|Experimental|Finasteride 0.25%|approximately 0.2 ml of P-3074 (0.25% finasteride)
11286208|NCT02791243|Placebo Comparator|Placebo for Finasteride 0.25%|approximately 0.2 ml of the vehicle cutaneous solution
11286209|NCT02791243|Other|Negative Control|approximately 0.2 ml of 0.9% aqueous NaCl
11286210|NCT02791230|Experimental|Tafamidis|Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg
11286211|NCT02791217||Diffused Large B cell Lymphoma|
11286212|NCT02791217||Follicular Lymphoma|
11286213|NCT02791217||Multiple Myeloma|
11286214|NCT02791217||Hodgkin Lymphoma|
11286215|NCT02791217||Healthy individuals|
11286216|NCT02791204|Experimental|Participants with PAD|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
11286217|NCT02791204|Active Comparator|Controls|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
11286218|NCT02791191|Experimental|Dose 1 LY3202626|3 mg LY3202626 given orally once daily for 52 weeks.
11286219|NCT02791191|Experimental|Dose 2 LY3202626|12 mg LY3202626 given orally once daily for 52 weeks.
11286220|NCT02791191|Experimental|Placebo|Placebo given orally once daily for 52 weeks.
11286221|NCT02791178||STEMI patients|"The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.
~All patients to do Optical Coherence Tomography (OCT), Index of Microcirculatory Resistance (IMR) and Cardiac MRI."
11286222|NCT02791139||Control|Healthy Volunteers will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Hand-Grip Strength Measurement Body Fat Mass Analysis
11286223|NCT02791139||Ageing|"Ageing cohort will undergo the following studying procedures:
~Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Body Fat Mass Analysis"
11286224|NCT02791126||Heart Failure|"Patients presented to hospital with a primary diagnosis of Heart Failure or are attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either resulted in a hospital admission (primary diagnosis) or was treated in out-patient clinic.
~Cardiovascular Magnetic Resonance and Echocardiogram will be performed."
11286225|NCT02791100|No Intervention|No promotion of chicken eggs|The community receives no chickens and therefore has no additional eggs or egg shell powder for children
11286226|NCT02791100|Experimental|Promotion of Chicken eggs for children|The community receives chickens so that each study child receives 2 eggs a day and also receives some egg shell daily (1/4 bottle cap which provides 500 mg Ca). The community receives information on using the egg and eggshell, and has help in caring for the chickens.
11286227|NCT02791087||Coronary Artery Disease for CABG|Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.
11286228|NCT02791087||Stable/Unstable Angina|Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.
11286229|NCT02791074||Control|"Healthy Volunteers will undergo the following studying procedures:
~Echocardiography Arterial tonometry"
11286230|NCT02791074||Heart Failure Patients|"Patients will undergo the following studying procedures:
~NTproBNP Echocardiography Arterial tonometry"
11286231|NCT02791061||Control|"Healthy Volunteers will undergo the following studying procedures:
~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
11286232|NCT02791061||Congenital Disease|"Patients will undergo the following studying procedures:
~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
11286233|NCT02791048|Experimental|Experimental Group|Music therapy for up to 45 minutes twice a week for three weeks, in addition to usual care from the hospice multidisciplinary team.
11286234|NCT02791048|No Intervention|Control Group|Usual care only from the hospice multidisciplinary team. The dose and frequency of usual care will be as deemed appropriate by the hospice practitioner in charge of their treatment.
11286235|NCT02791035|Experimental|Ipragliflozin|Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks
11286236|NCT02791009||Diagnosed Heart Failure [Prior]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
11286237|NCT02791009||Control [Prior]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
11286238|NCT02791009||Control [New]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
11286239|NCT02791009||Diagnosed Heart Failure [New]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
11286240|NCT02790996|Experimental|Vancomycin - Optimised Regimen|"A single loading dose of 25 mg/kg followed by a maintenance dose of:
~Postmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly"
11286241|NCT02790996|Active Comparator|Vancomycin - Standard Regimen|Postmenstrual age < 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly
11286242|NCT02790970|Experimental|PReDicT Test|To determine whether use of the PReDicT Test to direct antidepressant treatment results in an increased proportion of depressed patients showing a response to treatment at week 8
11286243|NCT02790970|Placebo Comparator|Treatment as usual|Treat patients as usual without using the predict test to determine treatment.
11286244|NCT02790957|Experimental|Plerixafor|Single subcutaneous injection of Plerixafor (0.24 mg/kg)
11286245|NCT02790957|Placebo Comparator|Placebo|Single injection of an equal volume of NaCl solution
11286246|NCT02790931|Experimental|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months.
11286247|NCT02790931|No Intervention|Control Group|Patients will not receive any exercise treatment, will not have acess to the software, but they will keep their recommended clinical treatment.
11286248|NCT02790918||Diagnosed Pulmonary Hypertension|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
11286249|NCT02790918||Healthy Volunteer|Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
11286250|NCT02790892|Other|Art therapy - pre and post test measures|20 young adults aged 15-24 years with diabetes (10 with type 1 diabetes and 10 with type 2 diabetes) receiving 12 weeks of group art therapy. Participants serve as their own controls.
11286251|NCT02790879||Transition|Patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.
11286252|NCT02790866|Experimental|LuCaS Decision Aid|Access to LuCaS, a web-based lung cancer screening decision aid
11286253|NCT02790866|Active Comparator|NCI Website|Access to NCI website on lung cancer screening
11286254|NCT02790853|Experimental|Diagnostic (multimodal imaging, biopsy)|Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
11286255|NCT02790840|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days
11286256|NCT02790827|Experimental|CETA|Participants in the experimental arm will receive the CETA intervention. The intervention period will last for approximately 4 months with weekly sessions. There will be separate groups for men, women, and children. Each group will have approximately six participants. Individuals who cannot attend group therapy (e.g., conflicting work schedules) may be offered the therapy individually.
11286257|NCT02790827|Active Comparator|Treatment as usual|There is no standard of care for domestic violence or alcohol use problems in Zambia. We will track any treatment or care that families receive during the course of the study. The active comparator arm will not receive any formal services provided by the study.
11286258|NCT02790814|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
11286259|NCT02790814|Active Comparator|Hand-held fetoscope|Intermittent fetal heart rate monitoring
11286260|NCT02790801||1 group|observation of patients with chronic heart failure and atrial fibrillation
11286261|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
11286262|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
11286263|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 1|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1
11286264|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 2|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2
11286265|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 3|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3
11286421|NCT02789631||without neck pain (asymptomatic)|no history of neck pain
11286266|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 4|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4
11286267|NCT02790762|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
11286268|NCT02790749|Experimental|PAO with adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) with adjunctive hip arthroscopy.
11286269|NCT02790749|Active Comparator|PAO WITHOUT adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) WITHOUT adjunctive hip arthroscopy.
11286270|NCT02790736|Experimental|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
11286271|NCT02790736|Placebo Comparator|placebo capsule|Placebo capsule, given once after fear activation procedure
11286272|NCT02790723|Experimental|Low Dose Group|Subjects will receive a single intra-articular 10mL injection consisting of 10{11} viral genomes.
11286273|NCT02790723|Experimental|Medium Dose Group|Subjects will receive a single intra-articular 10mL injection consisting of 10{12} viral genomes.
11286274|NCT02790723|Experimental|High Dose Group|Subjects will receive a single intra-articular 10mL injection consisting of 10{13} viral genomes.
11286275|NCT02790710|Experimental|Propanolol|Propranolol 40 mg capsule, given once after fear reactivation procedure
11286276|NCT02790710|Placebo Comparator|Placebo capsule|Placebo capsule, given once after fear reactivation procedure
11286277|NCT02790697||Mechanically ventilated ICU patient|Indirect calorimetry measurements will be conducted using the new calorimeter and the mass spectrometer system at the same time for all enrolled patients.
11286278|NCT02790684|Experimental|DS-8500a|
11286279|NCT02790671|Experimental|single study arm|DS-8500a and itraconazole
11286280|NCT02790658|Other|Grumixama Juice|"Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight.
~The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice."
11286281|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
11286282|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
11286283|NCT02790645|Other|Group 1b. Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
11286284|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).
11286285|NCT02790632|Experimental|EG-1962 Group|"1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg
~Up to 21 days of placebo capsules/tablets"
11286286|NCT02790632|Active Comparator|Enteral Nimodipine Group|"1 dose of intraventricular normal saline
~Up to 21 days of oral nimodipine capsules/tablets"
11286287|NCT02790619|Active Comparator|Meditation and Active Stimulation 1|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 1 milliamp(mA) stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
11286288|NCT02790619|Active Comparator|Meditation and Active Stimulation 2|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 2 mA stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
11286289|NCT02790619|Sham Comparator|Meditation and Sham Stimulation|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.The participants in the sham study will receive Sham tDCS (no stimulation) with Anode over F8 and cathode over left supraorbital area with intervention administration delivered by Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
11286290|NCT02790606|Experimental|Covera(TM) Vascular Covered Stent|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
11286291|NCT02790593|Experimental|Juxta-Cures™|Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
11286292|NCT02790593|Active Comparator|Standard compression|Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
11286293|NCT02790580|Active Comparator|Dose-dense doxorubicin/cyclophosphamide|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after doxorubicin/cyclophosphamide
11286294|NCT02790580|Experimental|Dose-dense doxorubicin/cyclophosphamide + sunitinib|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide, Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0), Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
11286295|NCT02790567||HIT study group|The HIT study group will include all patients admitted in our surgical intensive care unit (ICU) during the study period if the clinician in charge of the patient suspects the diagnosis of HIT. The HEP score, the 4Ts score, the immuno-diffusion particle gel immunoassay (ID-PaGIA) and the HIT-Ab(PF4-H) test will be done for each patient the day the diagnosis of HIT will be suspected.
11286296|NCT02790554|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
11286297|NCT02790554|Active Comparator|Hand-held Doppler|Intermittent fetal heart rate monitoring
11286298|NCT02790541|Experimental|Treatment|Hyperbaric Oxygen Therapy: 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
11286299|NCT02790541|Other|Control/Crossover|Hyperbaric Oxygen Therapy: 3 months control period (no treatment) followed by 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
11286300|NCT02790528|Experimental|Atorvastatin|20mg QD
11286301|NCT02790528|Placebo Comparator|Placebo|
11286302|NCT02790515|Experimental|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.
~Cells for infusion are prepared using the CliniMACS System."
11286303|NCT02790502|Other|Intervention|Intervention Group
11286304|NCT02790489|Experimental|Valedia|Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses
11286305|NCT02790476|Experimental|Letter intervention|The intervention arm will involve letters sent to prescribers in San Diego County.
11286306|NCT02790476|No Intervention|Control|The control group will involve prescribers not receiving letters
11286307|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
11286308|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
11286309|NCT02790450|Experimental|Benzbromarone|1x200mg Benzbromarone
11286310|NCT02790437|Experimental|Treatment IdeS|IdeS intravenous infusion
11286311|NCT02790424|Experimental|Patients|Imaging devices
11286312|NCT02790411|Experimental|healthy volunteers|Imaging devices New Non Invasive Devices
11286313|NCT02790398|Experimental|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol.
11286314|NCT02790398|Active Comparator|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol that includes a component aimed at the regulation of PA.
11286315|NCT02790385|Experimental|NPWT|subjects will undergo negative pressure wound therapy
11286316|NCT02790385|Active Comparator|Standard Gauze|standard method of using gauze and dressing will be utilized
11286317|NCT02790372|No Intervention|Control nursing homes|Nursing homes carries out usual care
11286318|NCT02790372|Active Comparator|Intervention nursing homes|Nursing homes that carries out regularly case conferencing
11286319|NCT02790359|Active Comparator|Patient group 1|Air
11286320|NCT02790359|Active Comparator|Patient group 2|Carbon dioxide
11286321|NCT02790346|Experimental|arthrodesis talonavicular|arthrodesis talonavicular in addition to tendon gestures
11286322|NCT02790346|Active Comparator|tendon gestures|tendon gestures only
11286323|NCT02790333|Experimental|Tri-Staple reloads|Tri-Staple reloads were used for pancreatic stump texture
11286324|NCT02790333|Active Comparator|traditional reloads|the traditional reloads were used for pancreatic stump texture
11286325|NCT02790320||Patients with locally recurrent or metastatic breast cancer|Patients received 1.4 mg/m2 eribulin, administered intravenously on day 1 and 8 of each 21 day cycle until disease progression or unmanageable toxicity, per routine clinical practice.
11286326|NCT02790307|Experimental|Daily stimulation (30mins/day)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
11286327|NCT02790307|Experimental|Weekly stimulation (30mins/week)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
11286328|NCT02790294|Experimental|Postoperative Magnetic Resonance Imaging|Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
11286329|NCT02790268||Lens Subluxation|Pediatric eyes with lens subluxation undergoing Cionni Ring Bag fixation with in-the-bag IOL Implantation
11286330|NCT02790255|Experimental|Cold air|Subjects to be seated in an airtight chamber at an ambient temperature between 16 to 20 degrees Celsius for 1 hour.
11286331|NCT02790255|Experimental|Cold water|Subjects to be seated in an airtight chamber at an ambient temperature of 24 degrees Celsius, with their hands and feet fully immersed in cold water for 5 minutes.
11286332|NCT02790229|Experimental|anti-gravity treadmill arm|Treatment with anti-gravity treadmill (alter G®)
11286333|NCT02790229|Other|control arm|Treatment with standardized physiotherapy
11286334|NCT02790216||Brachytherapy|men eligible for monotherapy seed implant brachytherapy
11286335|NCT02790203|Experimental|Celecoxib|"Celecoxib will be given orally to patients participating in the study and allocated to the treatment group, for an intervention period of 6 days, starting from the day of surgery.
~Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses, a dose which is within the recommended and a widely used dosage and is expected to induce a significant inhibition of prostaglandin synthesis by the COX2 pathway. Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses."
11286336|NCT02790203|Placebo Comparator|Placebo|"Placebo will be given orally to patients participating in the study and allocated to the control group that will receive placebo, for an intervention period of 6 days, starting from the day of surgery.
~Placebo will be given throughout the intervention period of the study orally in capsules that resemble the drug, twice a day."
11286337|NCT02790190|Experimental|Individualized Adaptive radiotherapy|GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.
11286338|NCT02790190|No Intervention|Conventional radiotherapy|2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.
11286339|NCT02790177|Experimental|HiB|This group will receive the compound for the reduction of adhesions
11286340|NCT02790177|Placebo Comparator|Normal saline|This group will just receive normal saline to ensure blinding.
11286494|NCT02789267|No Intervention|Control|"Group of patients with standard of care: the nutritional support is conducted by physicians.
~No systematic dietary support"
11286341|NCT02790164|Experimental|Rocuronium|Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.
11286342|NCT02790164|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
11286343|NCT02790151|Active Comparator|Standard Therapy|Learning and practicing memory strategies
11286344|NCT02790151|Experimental|Experimental Intervention|Computerbased working memory training and Recollection training
11286345|NCT02790138|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
11286346|NCT02790138|Placebo Comparator|Placebo|Vedolizumab placebo-matching IV infusion, once at Weeks 0, 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
11286347|NCT02790125|Experimental|Dose Panel 1|"BMS-986166 or Placebo matching BMS-986166
~Single oral dose of solution as specified"
11286348|NCT02790125|Experimental|Dose Panel 2|"BMS-986166 or Placebo matching BMS-986166
~Single oral dose of solution as specified"
11286349|NCT02790125|Experimental|Dose Panel 3|"BMS-986166 or Placebo matching BMS-986166
~Single oral dose of solution as specified"
11286350|NCT02790125|Experimental|Dose Panel 4|"BMS-986166 or Placebo matching BMS-986166
~Multiple ascending solid dose formulation as specified"
11286351|NCT02790125|Experimental|Dose Panel 5a/b/c|"BMS-986166
~Single oral solid dose formulation under fasting/fed/fasting with famotidine conditions"
11286352|NCT02790112|Other|GnRHas - Not GnRHas patients|Compared long term outcome of treated and untreated patients with idiopathic central precocious puberty : hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
11286353|NCT02790112|Other|GnRHas - controls patients|Compared long term outcome of treated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
11286354|NCT02790112|Other|Not GnRHas - Controls patients|Compared long term outcome of untreated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
11286355|NCT02790099|Experimental|Rectus sheath block only|Patient will be given surgical rectus sheath block postoperatively with 40ml of bupivacaine (2.5mg/mL) and 0.1ml of normal saline will be injected intrathecally at time of spinal anaesthesia.
11286356|NCT02790099|Active Comparator|Intrathecal morphine group|0.1mg preservative free morphine will be injected intrathecally at time of spinal anesthesia and 40ml of normal saline will be injected as rectus sheath block.
11286357|NCT02790099|Active Comparator|Both intervention|Patient will be given 0.1mg preservative free morphine intrathecally at time of spinal anaesthesia and surgical rectus sheath block with 40ml of bupivacaine (2.5mg/ml).
11286358|NCT02790073|Other|SNF472|SNF472 for calciphylaxis
11286359|NCT02790047|Active Comparator|Home-base exercise|"Patients will receive intervention as following
~A home-base exercise program
~Health education
~Breathing strategies for self secretion clearance
~The medication following the COPD GOLD guidelines (2015)"
11286360|NCT02790047|Experimental|Home-base exercise with a PEP mask|"Patients will receive intervention as following
~A home-base exercise program with using a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise
~Health education
~Breathing strategies for self secretion clearance
~The medication following the COPD GOLD guidelines (2015)"
11286361|NCT02790034|Active Comparator|Sarizotan|Between 2 to 10 mg bid based on age and weight criteria.
11286362|NCT02790034|Placebo Comparator|Placebo|Placebo bid respectively
11286363|NCT02790021|No Intervention|Complex decongestive therapy|Group A will continue complex decongestive therapy consisting of skin care, manual lymphatic drainage, and compression therapy using compression stockings.
11286364|NCT02790021|Experimental|Lymphaticovenous anastomosis (LVA)|Group B will undergo an LVA procedure under local anesthesia in surgical daycare setting. Patients are not allowed to wear compression stockings or have decongestive therapy for four weeks after the surgery.
11286365|NCT02790008||Aortic valve disease|Patients with aortic stenosis referred to surgery. Exclusion criteria are concomitant heart valve disease, congenital heart disease, hemodynamic instability, previous cardiac surgery, history of myocardial infarction and coronary artery disease.
11286366|NCT02789995|Experimental|Patients with and without sepsis|"Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.
~Human biological samples collected for research :
~Blood sample
~Muscle biopsy
~Bone marrow sample (mesenchymal stem cells)"
11286367|NCT02789982|Experimental|Reconsolidation blockade|β-adrenergic blocker propranolol 1 mg / kg to each of the 6 treatment sessions
11286368|NCT02789982|Active Comparator|Treatment as usual|Treatment as usual like SSRIs, psychotherapy, ...
11286369|NCT02789969|Experimental|Hydromorphone 15mcg/kg IV|Patient randomly assigned to hydromorphone
11286370|NCT02789969|Experimental|Fentanyl 1.5 mcg/kg IV|Patient randomly assigned to fentanyl
11286371|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
11286372|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
11286373|NCT02789917|Experimental|Dual therapy (incl. NOAC)|Apixaban plus Clopidogrel
11286374|NCT02789917|Active Comparator|Triple therapy (incl. VKA)|Phrenprocoumon plus Clopidogrel plus ASA
11286375|NCT02789904||Chest pain patients in DEM|Recruitment done at SGH DEM. Blood taking will be done at 0, 1 and 2 hr.
11286376|NCT02789891|Experimental|D2 Lymphadenectomy including No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
11286377|NCT02789891|Active Comparator|D2 lymphadenectomy excluding No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
11286378|NCT02789878|Experimental|ADT and Abiraterone|"Goserelin 10.8 mg, single dose, subcutaneously.
~Abiraterone 1,000 mg, once daily, orally for 3 months.
~Prednisone 5 mg, once daily, orally for 3 months."
11286379|NCT02789878|Experimental|ADT, Abiraterone and Apalutamide|"Goserelin 10.8 mg, single dose, subcutaneously.
~Abiraterone 1,000 mg, once daily, orally for 3 months.
~Prednisone 5 mg, once daily, orally for 3 months.
~Apalutamide 240 mg, once daily, orally for 3 months."
11286380|NCT02789865|Active Comparator|Antibiotic therapy group|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
11286381|NCT02789865|Experimental|ERAT group|The patients will receive emergent endoscopic retrograde appendicitis therapy (ERAT).
11286382|NCT02789865|Active Comparator|Appendectomy group|The patients will receive laparoscopic appendectomy according to standard routines.
11286383|NCT02789852|Experimental|Orthosis Group|Will use the night orthosis for interphalangeal in the treatment of OA hand.
11286384|NCT02789852|No Intervention|Control Group|wait for treatment
11286385|NCT02789839|Experimental|Healthy volunteer|Blood test Medullar test
11286386|NCT02789826|Experimental|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
11286387|NCT02789826|Active Comparator|Open gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group
11286388|NCT02789813|Experimental|Valproic Acid and fear reactivation|This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.
11286389|NCT02789813|Active Comparator|Valproic Acid and no fear reactivation|This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.
11286390|NCT02789813|Placebo Comparator|Placebo and fear reactivation|This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.
11286391|NCT02789813|Placebo Comparator|Placebo and no fear reactivation|This group will receive once Placebo (oral solution) before exposure therapy.
11286392|NCT02789800|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
11286393|NCT02789800|No Intervention|Group B|Control group (n = 163)
11286394|NCT02789800|No Intervention|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
11286395|NCT02789787||Maxillary protraction|Early adolescents (11 - 14 yrs) with cleft lip and palate and Cl III malocclusion
11286396|NCT02789787||Orthognathic surgery|Late adolescents to young adults (16-21 years) with cleft lip and palate and Cl III malocclusion
11286397|NCT02789774|Experimental|Surgical treatment|Stabilization of odontoid fracture with posterior fusion C1-C2
11286398|NCT02789774|Active Comparator|Conservative treatment|External stabilization of odontoid fracture with a rigid cervical collar for 3 months.
11286399|NCT02789761|Active Comparator|High-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
11286400|NCT02789761|Placebo Comparator|Low-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately <1 mg of (-)-epicatechin for 2-weeks (14 days)
11286401|NCT02789748|Experimental|Treatment ON|Kinesthetic stimulation administered during one night
11286402|NCT02789748|No Intervention|Treatment OFF|NO kinesthetic stimulation administered during one night
11286403|NCT02789735|Active Comparator|Device: LiteCure LCT-1000®|Treatment with 10 J/cm²
11286404|NCT02789735|Sham Comparator|Device: Sham LiteCure|Sham i.e. visible red light
11286405|NCT02789722|Experimental|Yerba Mate Extract 750 mg|Yerba Mate Extract - Capsules: daily dose of 2.250 g, distributed in 3 doses of 750 mg, for 28 days.
11286406|NCT02789722|Placebo Comparator|Placebo|Starch - Capsules: 3 times daily for 28 days.
11286407|NCT02789709||Non metastatic colon cancer patients|Consecutive patients undergoing elective surgery for non-metastatic colon or rectal cancer with curative intent.
11286408|NCT02789696|Other|Acromegaly|Diagnosis of acromegaly
11286409|NCT02789683|Experimental|Fine emulsion|Emulsion with small lipid droplet size served together with white bread
11286410|NCT02789683|Experimental|Coarse emulsion|Emulsion with large lipid droplet size served together with white bread
11286411|NCT02789683|Experimental|Control|Non-emulsified oil and water served together with white bread
11286412|NCT02789670||MS patients|MS patient group is composed by 20 Individuals with inflammatory brain lesions seen in MRI (Radiologically Isolated syndrome) 20 patients with only one clinically isolated syndrome (CIS) 20 patients with relapsed remittent Multiple sclerosis (RRMS) 20 patients with primary progressive Multiple Sclerosis (PPMS)
11286413|NCT02789670||Control group patients|"Control patient cohort is composed by 20 patients suffering from inflammatory neurological disease other than MS Devic syndrome, Neurosarcoidosis, Neurobehcet... (autoimmune disease control group with neurological disease) 20 patients with systemic sclerosis (autoimmune disease control group) without neurological disease)
~40 healthy subjects"
11286414|NCT02789657|Experimental|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
11286415|NCT02789657|Experimental|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
11286416|NCT02789657|Experimental|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
11286417|NCT02789657|Experimental|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
11286418|NCT02789644|Experimental|Ursodeoxycholic acid 400mg|Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
11286419|NCT02789644|Experimental|Ursodeoxycholic acid 800mg|Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
11286422|NCT02789618|Active Comparator|A01|Toothpaste containing calcium silicate and Sodium Monofluorophosphate (1450ppm F) and a gel containing sodium fluoride (1450ppm F)
11286423|NCT02789618|Active Comparator|B99|Toothpaste containing Stannous Fluoride and a dentinal bonding agent
11286424|NCT02789618|Placebo Comparator|M89|Toothpaste containing sodium fluoride (1450ppm F)
11286425|NCT02789605|Experimental|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months
11286426|NCT02789605|Placebo Comparator|Placebo|Patient receiving placebo, orally taken, 4 times a day, during 3 months
11286427|NCT02789592|Experimental|Group 1|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
11286428|NCT02789592|Experimental|Group 2|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
11286429|NCT02789592|Experimental|Group 3|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
11286430|NCT02789592|Experimental|Group 4|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
11286431|NCT02789592|Experimental|Group 5|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
11286432|NCT02789592|Experimental|Group 6|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
11286433|NCT02789579|Experimental|levofloxacin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 3 days before Minimally invasive upper tract lithotomy.
11286434|NCT02789579|Experimental|nitrofurantoin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 3 days before Minimally invasive upper tract lithotomy.
11286435|NCT02789579|Experimental|cefuroxime group|There are 150 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and does not receive oral antibiotics 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
11286436|NCT02789579|Experimental|levofloxacin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 7 days before Minimally invasive upper tract lithotomy.
11286437|NCT02789579|Experimental|nitrofurantoin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 7 days before Minimally invasive upper tract lithotomy.
11286438|NCT02789566|Experimental|Regimen|Primaquine (PQ) 30 mg base single dose
11286439|NCT02789553|Experimental|Meal with glucose syrup|Meal with glucose syrup : 30g of glucose mixed with 150 mL of water and dived into three 50 mL portions. It will be consumed in 15 minutes
11286440|NCT02789553|Experimental|Starch meal|Starch meal with 30g mixed in 120 mL of water. It will be consumed in 15 minutes and it represents 30g of glucose
11286441|NCT02789527|Experimental|Healthy volunteers in Ethiopia|Phenotype and genotype of enzymes involved in drug metabolism in Ethiopia population
11286442|NCT02789527|Experimental|Healthy volunteers in Oman|Phenotype and genotype of enzymes involved in drug metabolism in Oman population
11286443|NCT02789527|Experimental|Healthy volunteers in the Czech Republic|Phenotype and genotype of enzymes involved in drug metabolism in Czech Republic population
11286444|NCT02789527|Experimental|Healthy volunteers in Greece|Phenotype and genotype of enzymes involved in drug metabolism in Greek population
11286445|NCT02789514||children|Investigators give observation to the patients who need esophagogastroduodenoscopic procedures.
11286446|NCT02789501|Active Comparator|Control|Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
11286447|NCT02789501|Experimental|Test|"TauroLock™ based lock solution regimen:
~Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval).
~TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin.
~TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase."
11286448|NCT02789488|Other|Furocyst|Furocyst one caps BID
11286449|NCT02789475|Experimental|amplodipine group|Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days
11286450|NCT02789475|Experimental|rosuvastatin group|Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days
11286451|NCT02789462||Patients undergoing laser-assisted PCI|Patients of VAMC centers who undergone laser-assisted percutaneous coronary interventions.
11286452|NCT02789449||precapillary|patients with PH and PAWP<12mmHg
11286453|NCT02789449||postcapillary|patients with PH and PAWP>18mmHg
11286454|NCT02789436|Experimental|L. reuteri Prodentis® lozenges|"15 subjects
~Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). Probiotic lozenges are used twice daily for 28 days."
11286455|NCT02789436|Placebo Comparator|Placebo lozenges|"15 subjects
~Placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.Placebo lozenges are taken twice daily for 28 days."
11286456|NCT02789423|Active Comparator|Dycal|Intervention: drug: Dycal, Other names: Calcium Hydroxide. Intervention Description:DPC using Dycal for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria evaluated were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility. Radiographic criteria:Defective restoration/Recurrent caries,Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
11286457|NCT02789423|Active Comparator|Biodentine|Intervention: drug: Biodentine, Other names: Calcium Silicate. Intervention Description:DPC using Biodentine for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility.Radiographic criteria:Defective restoration/Recurrent caries, Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
11286458|NCT02789410|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
11286459|NCT02789410|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
11286460|NCT02789397|Active Comparator|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
11286461|NCT02789397|Placebo Comparator|Placebo|IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
11286462|NCT02789384|Experimental|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
11286463|NCT02789371|Other|Arm A|the first pass is made with 5ml suction technique
11286464|NCT02789371|Other|Arm B|the first pass is made with modified wet suction technique
11286465|NCT02789358|Active Comparator|Control Arm|"Conventional protocol for cryoablation:
~At least 2 applications of 180s each"
11286466|NCT02789358|Experimental|Study Arm|"Experimental protocol for cryoablation:
~Time to effect + 1 minute and a bonus application of 120s"
11286467|NCT02789345|Experimental|Ramucirumab + Osimertinib|"Dose Finding: Ramucirumab given intravenously (IV) on day 1 every 2 weeks (Q2W) and osimertinib given orally daily during each 14 day cycle.
~Expansion: Ramucirumab given IV on day 1 Q2W and osimertinib given orally daily during each 14 day cycle."
11286468|NCT02789345|Experimental|Necitumumab + Osimertinib|"Dose Finding: Necitumumab given IV on days 1 and 8 every 3 weeks (Q3W) and osimertinib given orally daily during each 21 day cycle.
~Expansion: Necitumumab given IV on days 1 and 8 Q3W and osimertinib given orally daily during each 21 day cycle."
11286469|NCT02789332|Active Comparator|Paclitaxel with Carboplatin (PwCb)|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
11286470|NCT02789332|Experimental|Paclitaxel with Olaparib (PwO)|"paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)
~followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery."
11286471|NCT02789319|Other|FreeStyle Lite|Blood Glucose Meter type
11286472|NCT02789319|Other|Contour Next|Blood Glucose Meter type
11286473|NCT02789319|Other|OneTouch Ultra2|Blood Glucose Meter type
11286474|NCT02789319|Other|ACCU-CHEK AVIVA Plus|Blood Glucose Meter type
11286475|NCT02789319|Other|Prodigy Auto Code|Blood Glucose Meter type
11286476|NCT02789319|Other|Walmart ReliOn Prime|Blood Glucose Meter type
11286477|NCT02789319|Other|Embrace|Blood Glucose Meter type
11286478|NCT02789319|Other|True Result|Blood Glucose Meter type
11286479|NCT02789319|Other|True Track|Blood Glucose Meter type
11286480|NCT02789319|Other|Walmart ReliOn Confirm|Blood Glucose Meter type
11286481|NCT02789319|Other|Advocate Redi-Code +|Blood Glucose Meter type
11286482|NCT02789319|Other|CVS Advanced|Blood Glucose Meter type
11286483|NCT02789319|Other|OneTouch Verio|Blood Glucose Meter type
11286484|NCT02789319|Other|Contour|Blood Glucose Meter type
11286485|NCT02789319|Other|Accu-Chek Nano|Blood Glucose Meter type
11286486|NCT02789319|Other|Walmart ReliOn Ultima|Blood Glucose Meter type
11286487|NCT02789319|Other|Gmate Smart|Blood Glucose Meter type
11286488|NCT02789319|Other|SolusV2|Blood Glucose Meter type
11286489|NCT02789306||Peri-implantitis|"Peri-implantitis' - Loss radiographic bone beyond the biological bone remodeling at baseline (after prosthesis delivery) from the implant neck
~Early:> 4 mm probing depth; <25% radiographic bone loss
~Moderate:> 6mm probing depth; <50% radiographic bone loss
~Severa:> 8 mm probing depth; > 50% radiographic bone loss"
11286490|NCT02789306||Healthy|No signs of inflammation and otherwise no bone loss beyond the biological bone remodeling
11286491|NCT02789293|Experimental|Focused Ultrasound treatment|Ultrasound ciliary pasty (UCP) using focused ultrasound
11286492|NCT02789280|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
11286493|NCT02789280|Active Comparator|Wait List|Participants will be asked to wait for a week until they receive the behavioral activation condition
11286528|NCT02788968|Experimental|Young adults|MRI 19-25 years
11286495|NCT02789267|Experimental|Regular dietary support|Group of patients will benefit from a systematic and regular dietary support. Patients will be followed by a dietitian 1 month and 3 month after radiotherapy in hospital. Then, dietitian will realize a telephon interview 2 and 5 months after radiotherapy
11286496|NCT02789254|Experimental|Experimental: FLYSYN|IV infusion over a 3-hr duration
11286497|NCT02789241|Experimental|Endotoxin (LPS)|The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
11286498|NCT02789241|Placebo Comparator|Placebo|The trial will consist of 4 groups each group will have 2 subjects receiving Placebo (normal saline)].
11286499|NCT02789228|Experimental|Tumor associated antigen lymphocytes (TAA-CTL)|"Tumor associated antigen lymphocytes (TAA-CTL). Three different dosing schedules will be evaluated.
~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2
~Patients will receive cells due to the presence of refractory disease and/or high risk for disease relapse and/or residual detectable disease following conventional therapy at the time of the infusion. Ideally, patients should not receive other systemic antineoplastic agents for at least 6 weeks after infusion of TAA CTL (for purposes of evaluation), although such treatment may be added if deemed critical for patient care by the attending physician."
11286500|NCT02789215|Experimental|Intervention|Receive new CACFP menu pattern
11286501|NCT02789215|No Intervention|Control|Follow existing CACFP menu pattern
11286502|NCT02789202|Experimental|Silver Diamine Fluoride|Control treatment
11286503|NCT02789202|Active Comparator|Fluoride Varnish|Test treatment
11286504|NCT02789189|Experimental|nedaplatin combined with gemcitabine|
11286505|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They were contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They were asked to take part in all prospective follow up surveys at 12, 18, & 24 months of age.
11286506|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, & completed the follow surveys at 12, 18, & 24 months of age.
11286507|NCT02789150|Experimental|MAP 65-70|Goal MAP of 65-70
11286508|NCT02789150|Active Comparator|MAP greater than or equal to 85|MAP greater than or equal to 85
11286509|NCT02789124|Experimental|Carotid Artery Flow Time|Patients with radial aline and flotrac vigileo will have carotid dopper measured for carotid flow time and a passive leg raise
11286510|NCT02789111|Active Comparator|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
11286511|NCT02789111|Placebo Comparator|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
11286512|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
11286513|NCT02789085|No Intervention|Control|without tens stimulation
11286514|NCT02789085|Experimental|Test|with tens stimulation
11286515|NCT02789072|Other|Microgravity|effect of microgravity on central aortic blood pressure.
11286516|NCT02789059|Experimental|muscle oxygenation|assesment of muscle oxygenation and gas exchanges
11286517|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
11286518|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
11286519|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
11286520|NCT02789020|Experimental|Rasagiline|This group will receive a 1 mg rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
11286521|NCT02789020|Placebo Comparator|Placebo|This group will receive a placebo tablet in the same forum as the rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
11286522|NCT02789007|Other|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
11286523|NCT02788994|Experimental|Endovis BA2 Nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.
~The system has been designed to allow:
~stable fracture synthesis for fast rehabilitation and early mobilization
~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)
~This is a one off surgical fixation."
11286524|NCT02788994|Active Comparator|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.
~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
11286525|NCT02788981|Experimental|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
11286526|NCT02788981|Placebo Comparator|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
11286527|NCT02788968|Other|Adolescents|MRI 11-15 years
11286529|NCT02788955|Active Comparator|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
11286530|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
11286531|NCT02788942|No Intervention|Umbilical|The cholecystectomy material will be removed from umbilical port as usual. This will be control group. Port site infection rates will be measured.
11286532|NCT02788942|Experimental|Epigastric|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured.
11286533|NCT02788929|Active Comparator|Fitbit Charge HR|"Use of the Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
~All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback."
11286534|NCT02788929|No Intervention|No Device|No Fitbit used and no feedback on exercise goal adherence. All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback.
11286535|NCT02788916||Cohort 1|Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
11286536|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
11286537|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
11286538|NCT02788903||COVID-19|This cohort of patients will be defined as patients age 18 and older who have received a diagnosis of COVID-19.
11286539|NCT02788890|Active Comparator|Control Group (T0)|The supragingival scaling without LA
11286540|NCT02788890|Experimental|Test Group 1 (T1)|The simple restoration under LA
11286541|NCT02788890|Experimental|Test Group 2 (T2)|The simple exodontia under LA
11286542|NCT02788877|Experimental|treat-and-extend|Aflibercept 2mg is injected into the vitreous cavity. An injection is given every 4 weeks five times and then the Treat-and-Extend process begins. If 1mm central subfield macular thickness (CSMT) improved (10% or more reduction) compared to the previous visit, the next treatment will be performed at the same interval. If CSMT is maintained (less than 10% changes), the next interval will be extended by two weeks (up to 12 weeks). If CSMT is worsened (10% or more increase), the next interval will be shortened by two weeks (minimum 4 weeks). If CSMT is stable two times at 12 weeks-interval, the injection will be deferred, and the next visit will be 8 weeks later. These process will be continued for 2 years.
11286543|NCT02788864|Active Comparator|Arterakine|Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
11286544|NCT02788864|Placebo Comparator|Placebo|Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
11286545|NCT02788851|Active Comparator|Medication only|Stimulant or non-stimulant medication only - Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine. Investigators will be using a product approved for clinical use in Canada), with dose optimized for each participant based on report of efficacy and side effects. Once on an optimal dose of stimulant or non-stimulant medication they will attend 8 weekly education sessions about ADHD.
11286546|NCT02788851|Experimental|Aerobic Exercise only|Participants attend a structured aerobic exercise class, twice a week for 8 weeks.
11286547|NCT02788851|Active Comparator|Combination Group|Participants assigned to this group will be optimally medicated (either stimulant or non-stimulant medication - approved for clinical use in Canada) and will attend a structured aerobic exercise class, twice a week for 8 weeks.
11286548|NCT02788812|Active Comparator|Open modified Lichtenstein repair|
11286549|NCT02788812|Active Comparator|Laparoscopic TAPP inguinal hernia repair|
11286550|NCT02788799||Control|
11286551|NCT02788799||Intervention|
11286552|NCT02788786|Experimental|chlorhexidine|0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks
11286553|NCT02788786|Experimental|cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks
11286554|NCT02788786|Active Comparator|Salt and Water|Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks
11286555|NCT02788786|No Intervention|No oral rinse|No rinse provided in this group
11286556|NCT02788773|Experimental|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
11286557|NCT02788773|Experimental|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
11286558|NCT02788760|Other|6 weeks|This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
11286559|NCT02788760|Other|12 weeks|This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)
11286560|NCT02788747|Experimental|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
11286561|NCT02788747|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
11286562|NCT02788747|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
11286563|NCT02788734||INC Contact Registry|INC Contact Registry will complete the online questionnaires
11286564|NCT02788721|Experimental|GLPG2451 single dose|Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order
11286565|NCT02788721|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension
11286566|NCT02788708|Experimental|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11286567|NCT02788695||Group 1 - aged 20-90 years|25 participants from each decade from 20-90. Those from 50+ will be recruited from the NICOLA study and retinal/lens images assessed to confirm normality.
11286568|NCT02788695||Group 2: aged 60 years|Group 2: 250 participants NICOLA participants aged 60 will be invited to participate; only those whose ocular images confirm normality will be included.
11286569|NCT02788682||Patients|WT+ Diplotype
11286570|NCT02788682||Controls|WT- Diplotype
11286571|NCT02788656|Experimental|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
11286572|NCT02788656|Active Comparator|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.
~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
11286573|NCT02788630|Experimental|Intervention group|Arm: Experimental: Intervention group Field workers trained in sleep hygiene counseling will advice the mothers randomly allocated to the intervention group. The intervention will be delivered at the child household and will include information on: Normal sleep behaviors during the first year of life; ideal conditions to promote sleep onset like environmental improvements that ensure restful sleep (no screen media, low noise and light); calming naptime routines and avoiding stimulating or stressing children just before naptime; practices that promote child self-regulation of sleep, including putting infants to sleep drowsy but awake; and how to handle nighttime awakenings. A booklet with the intervention content to aid the mother in implementing the intervention will be used.
11286574|NCT02788630|No Intervention|Control group|Mothers randomly allocated to the control group will be visited at home following the same schedule as the intervention group. The control group will receive a written material describing the advantages of breastfeeding over maternal and child health. No advice in relation to child sleep hygiene will be delivered to the mothers from the control group.
11286575|NCT02788617||Non treatment group|This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.
11286576|NCT02788604|Experimental|Experimental Group|Participants in this arm will have a summary of their family's psychosocial risk factors provided to the treatment team. This will occur twice: once shortly after diagnosis (within 2-4 weeks) and once approximately 6 months following diagnosis.
11286577|NCT02788604|Active Comparator|Control Group|Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
11286578|NCT02788591|Other|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
11286579|NCT02788591|Other|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
11286580|NCT02788552|Active Comparator|Acute Symptomatic WKS- 300mg|Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
11286581|NCT02788552|Active Comparator|Acute Symptomatic WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
11286582|NCT02788552|Active Comparator|Acute Symptomatic WKS - 1500mg|Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
11286583|NCT02788552|Active Comparator|High-risk subclinical WKS- 100mg|Thiamine Hydrochloride 100mg once daily for 3 days.
11286584|NCT02788552|Active Comparator|High-risk subclinical WKS- 300mg|Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
11286585|NCT02788552|Active Comparator|High-risk subclinical WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
11286586|NCT02788539|No Intervention|Science Cafe|One time event, Group discussion for 30 participants who are chronic pain stakeholders on pain in their community.
11286587|NCT02788539|Experimental|Cohort 1- Pilot OWL Study|Participants will pilot test a website- Our Whole Lives website for nine weeks in order to determine if it will help with their chronic pain management.
11286588|NCT02788526|Experimental|Adjuvant TACE|Adjuvant TACE were performed 4-6 weeks after surgery
11286589|NCT02788526|Other|Follow-up|Routine follow-up were performed instead of adjuvant TACE
11286590|NCT02788513|Experimental|BI 425809 dose 1|
11286591|NCT02788513|Experimental|BI 425809 dose 2|
11286592|NCT02788513|Experimental|BI 425809 dose 3|
11286593|NCT02788513|Experimental|BI 425809 dose 4|
11286594|NCT02788513|Placebo Comparator|Placebo|
11286595|NCT02788500||Swedish para-athletes|The total population of athletes in the Swedish Paralympic program, which covers candidates for the Paralympic Summer or Winter Games, will be invited by mail to participate in the study and report their incidence of sports-related injuries and illnesses
11286596|NCT02788487|Active Comparator|CPAP1 use and TRD 2use|Wash-in period 1 week and Continuous positive airway pressure (CPAP) is used for 3 weeks then wash-out 1 week and Tongue retaining device (TRD) is used for another 3 weeks
11286597|NCT02788487|Experimental|TRD1 use and CPAP2 use|Wash-in period 1 week and Tongue retaining device (TRD) is used for 3 weeks then Wash-out period 1 week and Continuous positive airway pressure (CPAP) is used for another 3 weeks
11286598|NCT02788474|Placebo Comparator|placebo|
11286599|NCT02788474|Experimental|nintedanib|
11286600|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
11286601|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
11286602|NCT02788448|Experimental|VIVASURE CLOSURE DEVICE|Large hole closure device
11286603|NCT02788435|No Intervention|Control|Patients in the control arm will undergo a graduated prescription of voice use immediately following surgery.
11286604|NCT02788435|Experimental|Absolute Voice Rest|Patients in the experimental arm will undergo 7 days of absolute voice rest following surgery.
11286605|NCT02788422|Experimental|Video|Video discharge instructions developed using Easy Sketch Pro3TM software (Easy Sketch Pro, United Kingdom). It was created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
11286606|NCT02788422|Active Comparator|Standard of care|This is a one-page paper handout created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
11286607|NCT02788409||Medicare CRPC|Men in the US older than 65 years old having CRPC
11286608|NCT02788370|Sham Comparator|Sham-PEP breathing|Patients will perform a constant work load cycling test with sham-positive expiratory pressure breathing util symptom limit.
11286609|NCT02788370|Experimental|Conical-PEP breathing|Patients will perform a constant work load cycling test with positive expiratory pressure breathing using a conical positive expiratory pressure device until symptom limit.
11286610|NCT02788357|Experimental|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
11286611|NCT02788357|Placebo Comparator|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
11286612|NCT02788331||Hospitals with increasing activity|Hospitals experiencing an increase in the volume of surgical procedures over the study period
11286613|NCT02788331||Hospitals with decreasing activity|Hospitals experiencing a decrease in the volume of surgical procedures over the study period
11286614|NCT02788331||Hospitals with stable activity|Hospitals experiencing no change in the volume of surgical procedures over the study period
11286615|NCT02788318||diagnostic of SUDEP|patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.
11286616|NCT02788318||Control 1|Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.
11286617|NCT02788318||Control 2|Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.
11286618|NCT02788305||non obese|BMI<30. Misoprostol is given for induction of labour according to Bishop score
11286619|NCT02788305||obese|BMI>30. Misoprostol is given for induction of labour according to Bishop score
11286620|NCT02788292|Experimental|Acetylcysteine (NAC)|NAC added to tumescent solution for liposuction and eventual fat grafting.
11286621|NCT02788292|No Intervention|Control|Just tumescent solution for liposuction and fat grafting.
11286622|NCT02788279|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
11286623|NCT02788279|Experimental|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
11286624|NCT02788279|Active Comparator|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
11286625|NCT02788266|Active Comparator|connective tissue graft+composite resin|connective tissue graft plus composite resin
11286626|NCT02788266|Active Comparator|connective tissue graft+ glass ionomer|connective tissue graft plus resin modified glass ionomer cement
11286627|NCT02788266|Active Comparator|connective tissue graft+giomer|connective tissue graft plus giomer
11286628|NCT02788240|Experimental|Peg GCSF with standard medical therapy|
11286629|NCT02788240|Active Comparator|Placebo with standard medical therapy|
11286630|NCT02788227|Experimental|Boosted Group|Group randomized at Month 18 to receive booster vaccination
11286631|NCT02788227|Experimental|Non-boosted Group|Group randomized to no booster at Month 18
11286632|NCT02788214||Intestinal metaplasia|Patients with advanced intestinal metaplasia
11286633|NCT02788214||Non-atrophic gastritis|Patients with non-atrophic gastritis
11286634|NCT02788201|Experimental|Treatment Regimen|Treatment regimen selected by CO eXpression ExtrapolatioN (COXEN) model
11286635|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
11286636|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
11286637|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
11286638|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
11286639|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
11286640|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
11286641|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
11286642|NCT02788175|Experimental|HIV-infected Adults on cART|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia
11286709|NCT02787733|Experimental|Citrus flavonoid|Citrus peel extract containing >90% flavonoids
11286643|NCT02788162|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11286644|NCT02788149|Experimental|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
11286645|NCT02788149|Active Comparator|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
11286646|NCT02788136|Experimental|Klinefelter syndrome|13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)
11286647|NCT02788136|Active Comparator|Control|12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)
11286648|NCT02788123|Experimental|bismuth tripotassium dicitrate and pantoprazole|Participants will receive bismuth tripotassium dicitrate (twice daily) and pantoprazole (once daily) as single tablets
11286649|NCT02788123|Active Comparator|pantoprazole|Participants will receive pantoprazole (once daily) as single tablet
11286650|NCT02788110|Other|NIV NAVA then NIPPV|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
11286651|NCT02788110|Other|NIPPV then NIV NAVA|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIPPV then NIV NAVA.
11286652|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
11286653|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
11286654|NCT02788084||B cell Non-Hodgkin Lymphoma|18 years of age or older with new diagnosis of non-Hodgkin lymphoma with FFPE specimen demonstrating enough tissue for elucidation of lymphoma specific variant and immunoglobulin clonotype, willing to provide baseline and follow up bloodwork to look for presence of variant and clonotype.
11286655|NCT02788071|Experimental|FMT capsules|FMT capsules
11286656|NCT02788071|Placebo Comparator|FMT placebo|Placebo capsules
11286657|NCT02788058|Experimental|EGFR-TKI|Patients take EGFR-TKI alone till tumor progression
11286658|NCT02788058|Active Comparator|EGFR-TKI+hypofractionated radiotherapy|After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
11286659|NCT02788045|Experimental|Group 1A: Ad26.Mos.HIV|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
11286660|NCT02788045|Placebo Comparator|Group 1B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
11286661|NCT02788045|Experimental|Group 2A: Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 years or 5 years Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events [SAEs]).
11286662|NCT02788045|Placebo Comparator|Group 2B: Placebo|Participants will receive placebo at Weeks 0, 12, 24 and 48.
11286663|NCT02788032|Other|EnergieShake Intervention|Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
11286664|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
11286665|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
11286666|NCT02788006|Experimental|Regorafenib 160 mg|
11286667|NCT02787993|Active Comparator|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
11286668|NCT02787993|No Intervention|Treatment as usual|Treatment as usual
11286669|NCT02787980|Other|Patients = premature newborns|"Patients will consist of all premature babies (<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood"
11286670|NCT02787980|Other|"Controls = children born full term"|"For controls the participation to research would be proposed to parents of children born full term, just after each patient child included.
~Additional taking blood"
11286671|NCT02787967|Experimental|NEXThaler® 35/4µg|CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg
11286672|NCT02787967|Active Comparator|Reference treatment|Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
11286673|NCT02787954||Transcatheter Chemoembolization or TACE|A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.
11286710|NCT02787733|Placebo Comparator|Placebo|Identical looking placebo
11286711|NCT02787720|Experimental|Family centered empowerment model|The Family-Centered Empowerment Model (FCEM)
11286712|NCT02787720|Experimental|Continuous care model|The Continuous Care Model
11286674|NCT02787954||Yittrium 90 or Y-90|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.
11286675|NCT02787954||Microwave Ablation or MWA|Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
11286676|NCT02787954||electroporation|Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.
11286677|NCT02787941|Experimental|Intervention group|The intervention group will receive the pharmacist-delivered multifaceted intervention with two counselling sessions in addition to usual care.
11286678|NCT02787941|No Intervention|Control group|The control group will receive usual care without the pharmacist-delivered multifaceted intervention.
11286679|NCT02787928|Experimental|Intrathecal Dilaudid|This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
11286680|NCT02787915|Experimental|dendritic cell vaccine|DC1-CTL cellular therapy
11286681|NCT02787902|Experimental|Communication|Behavioral weight loss program with communication skills training
11286682|NCT02787902|Active Comparator|Standard|Standard behavioral weight loss program
11286683|NCT02787889|Experimental|Uneven Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks.Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
11286684|NCT02787889|Experimental|Even Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks. Each participant will consume 33% of total protein consumed each meal
11286685|NCT02787876|Experimental|Chemotherapy induced neutropenia|Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle
11286686|NCT02787863|Experimental|COPD with Prevenar-13 (1)|33 patients with COPD. Standard therapy with Prevenar-13.
11286687|NCT02787863|Experimental|Asthma with Prevenar 13 (2)|34 patients with asthma. Standard therapy with Prevenar 13.
11286688|NCT02787863|Experimental|COPD with Pneumo-23 (3)|25 patients with COPD. Standard therapy with Pneumo-23.
11286689|NCT02787863|Experimental|Asthma with Pneumo-23 (4)|25 patients with asthma. Standard therapy with Pneumo-23.
11286690|NCT02787863|Experimental|COPD with Pneumo-23/Prevenar-13 (5)|32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).
11286691|NCT02787863|Experimental|Asthma with Pneumo-23/Prevenar-13 (6)|18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
11286692|NCT02787863|Experimental|COPD with Prevenar-13/Pneumo-23 (7)|25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
11286693|NCT02787863|Experimental|Asthma with Prevenar-13/Pneumo-23 (8)|27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
11286694|NCT02787850|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen with a new applicator design.
11286695|NCT02787837||Abiraterone Acetate|Abiraterone Acetate 1000 mg/24h plus Prednisone 5mg/12h
11286696|NCT02787824|Experimental|continuous iv administration of iron sucrose|Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).
11286697|NCT02787824|Active Comparator|intermittent iv administration of iron sucrose|Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
11286698|NCT02787811|Active Comparator|Pregnant|women with positive serum beta HCG done 14 days after Intrauterine insemenation
11286699|NCT02787811|Active Comparator|Nonpregnant|women with negative serum beta HCG done 14 days after Intrauterine insemenation
11286700|NCT02787798|Experimental|Entresto|"Stop of all angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor during 2 days.
~valsartan/sacubitril 100 mg tablets (51 and 49 mg) during 2 to 4 weeks twice a day.
~valsartan/sacubitril 200 mg tablets (103 and 97 mg) during 2 to 4 weeks twice a day.
~Microneurography recording of sympathetic activity in muscle destiny (MSNA)"
11286701|NCT02787798|Placebo Comparator|Control|"Hearth failure treatment as usual (angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor)
~Microneurography recording of sympathetic activity in muscle destiny (MSNA) will be done"
11286702|NCT02787785|No Intervention|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
11286703|NCT02787785|Active Comparator|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
11286704|NCT02787772|Experimental|Elective Hernia Repair|Elective abdominal wall hernia surgery was performed in randomized cirrhotic patients.
11286705|NCT02787772|No Intervention|Clinical follow up|"Cirrhotic patients were kept in clinical follow up concerning their abdominal wall hernia.
~If a complication occured at the hernia site (such as skin rupture, bowel strangulation,..) the patient underwent emergency hernia repair."
11286706|NCT02787759|Active Comparator|Hands-Free Walking|Body-weight supported treadmill training
11286707|NCT02787759|Experimental|Challenge Based plus Hands-Free|9 different balance and locomotor challenges applied during walking while not holding onto anything
11286708|NCT02787746|Other|donepezil|This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.
11286713|NCT02787707|Active Comparator|intervention|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
11286714|NCT02787707|Placebo Comparator|control|2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.
11286715|NCT02787694|Experimental|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
11286716|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
11286717|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat. During the first two weeks of the intervention,
11286718|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
11286719|NCT02787655|Experimental|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
11286720|NCT02787655|Active Comparator|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
11286721|NCT02787642|Experimental|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
11286722|NCT02787629|Experimental|Simultaneous|Simultaneous Intubation with GlideScope and ETT inserted simultaneously
11286723|NCT02787629|Active Comparator|Control Standard|Standard Intubation with GlideScope inserted first and ETT inserted after the GlideScope view is obtained
11286724|NCT02787616||Rosacea Group|
11286725|NCT02787616||Non-Rosacea Group|
11286726|NCT02787603|Experimental|group A|Interruption of antibiotic treatment due to PCT measurement
11286727|NCT02787603|No Intervention|group B|Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.
11286728|NCT02787590|Active Comparator|Simvastatin|A one month low dose phase of 40mg oral simvastatin daily will be followed by a 23 month high dose phase of 80mg oral simvastatin daily and a final two month phase off trial medication
11286729|NCT02787590|Placebo Comparator|Matched Placebo|A one month low dose phase of 40mg matched placebo daily will be followed by a 23 month high dose phase of 80mg matched placebo daily and a final two month phase off trial medication
11286730|NCT02787577|Experimental|Sleep Lengthening|The intervention group will receive a personalised sleep consultation session to lengthen sleep by 1-1.5 hours per night by targeting sleep hygiene using behaviour change techniques for 4 weeks.
11286731|NCT02787577|No Intervention|Control|The control group will be asked to resume their normal lifestyle.
11286732|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
11286733|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
11286734|NCT02787551|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.
~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
11286735|NCT02787551|Active Comparator|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily [BID], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
11286736|NCT02787538|Experimental|US-ANSWER-2 decision aid|The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
11286737|NCT02787538|Active Comparator|Control group (Online medication guide)|The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
11286738|NCT02787525||A: patients on anticoagulation|Questionnaire to patients with non-valvular atrial fibrillation on OAC or NOAC
11286739|NCT02787525||B: patients treated by LAA-Closure|Questionnaire to patient with non-valvular atrial fibrillation who underwent LAAC between 2009 and 2014 at the University hospitals Bern or Zurich
11286740|NCT02787512|Active Comparator|Plastic stent|10 Fr plastic stent (Percuflex Amsterdam® or C-flex pigtail® or Advanix® Biliary stent)
11286741|NCT02787512|Experimental|Uncovered metal stent|Uncovered metal stent (WallFlex® Biliary RX stent)
11286861|NCT02786680|Experimental|stroop test in condition DBS off|Condition 1 : On Med /Off Stim
11286742|NCT02787499|No Intervention|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load <1,000 copies/mL at repeat testing will be retained on first-line therapy.
11286743|NCT02787499|Experimental|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
11286744|NCT02787486||Aneuploidy Arm|Includes pregnant women at high risk for fetal chromosome aneuploidy for serum screening
11286745|NCT02787486||TORCH Arm|Infectious disease arm: Toxoplasmosis, other viruses, rubella, cytomegalovirus, and herpes simplex virus (TORCH). Includes pregnant women at low-risk for fetal aneuploidy that may be at increased risk for fetal infection for serum screening
11286746|NCT02787473|Experimental|pemetrexed+carboplatin/cisplatin+radiation therapy->docetaxel|Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.
11286747|NCT02787460|Experimental|Behavioral Text Messages|Couples assigned to a treatment group will receive weekly behavioral theory-based messages encouraging them to attend the sessions.
11286748|NCT02787460|No Intervention|Simple Reminder Text Messages|"Couples in the control group will receive simple reminder text messages that include the date, time, and location of their next group session"
11286749|NCT02787447|Experimental|1|After 3 mos TKI, patients showed stable disease take TKI, radiotherapy and thymosin alpha 1 till tumor progression.
11286750|NCT02787434|Experimental|PCSPrep decision aid|All participants recruited to the trial will receive the decision aid. This a one-group study with a quasi-experiemental pre/post evaluation design.
11286751|NCT02787421|Experimental|Functional Rhinoplasty|Participants undergoing functional rhinoplasty for nasal valve compromise and obstruction at the Emory Aesthetics Center.
11286752|NCT02787408|Experimental|EW Tricuspid Transcatheter Repair System|Edwards (EW) Tricuspid Transcatheter Repair System
11286753|NCT02787395|Experimental|Milch|modified Milch technique for self reduction
11286754|NCT02787395|Experimental|Boss Holtzach|Boss Holtzach technique for self reduction
11286755|NCT02787395|Experimental|Stimson|Stimson technique for self reduction
11286756|NCT02787382|Experimental|Pregnant women with CMV infection|"An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).
~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography)."
11286757|NCT02787382|Experimental|Pregnant women with suspected CMV infection|"The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).
~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group."
11286758|NCT02787369|Experimental|Combination of ACY-1215 With Ibrutinib|ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
11286759|NCT02787369|Experimental|Combination of ACY-1215 With Idelalisib|ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
11286760|NCT02787356|Experimental|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic with trained skin graders and images of skin
11286761|NCT02787356|Experimental|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD with trained skin graders and images of skin
11286762|NCT02787330|Active Comparator|Control Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
11286763|NCT02787330|Experimental|Experimental Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program which focuses on education, therapeutic problem solving, and social support. Each intervention session is structured by theme relevant to the cancer experience and themes are addressed through fun activities, games, arts, and crafts.To maximize the therapeutic effect of the intervention fun work (homework) will be assigned after each session. Training for the EG facilitators requires reading and studying the manual to become fully familiarized with the intervention approaches, observing group sessions through a one-way mirror prior to participation as a group facilitator, and participating as a group facilitator assistant for the intervention program.
11286764|NCT02787317|Active Comparator|heparin|For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.
11286765|NCT02787317|Experimental|not prolong infusion Bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .
11286766|NCT02787317|Experimental|prolong infusion bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.
11286767|NCT02787304|Experimental|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
11286768|NCT02787304|Experimental|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
11286769|NCT02787304|Experimental|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
11286770|NCT02787304|Placebo Comparator|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
11286862|NCT02786680|Active Comparator|stroop test in condition DBS on|Condition 2 : On Med /On Stim
11286771|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
11286772|NCT02787278|Experimental|SP-8203 High dose group|SP-8203 160mg (80mg/dose twice a day for three days)
11286773|NCT02787278|Experimental|SP-8203 Low dose group|SP-8203 80mg (40mg/dose twice a day for three days)
11286774|NCT02787278|Placebo Comparator|Placebo group|Placebo group: twice a day for three days
11286775|NCT02787265||spinal cord stimulation|Failed back surgery syndrome patients will receive high density spinal cord stimulation
11286776|NCT02787252|Experimental|HF DRG|HF DRG Implants
11286777|NCT02787239|Experimental|HLX01|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
11286778|NCT02787239|Active Comparator|Rituximab|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
11286779|NCT02787226|Active Comparator|TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
11286780|NCT02787226|Active Comparator|Reverse TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
11286781|NCT02787226|Active Comparator|TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
11286782|NCT02787226|Active Comparator|Reverse TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.
11286783|NCT02787213||Women with preterm delivery|
11286784|NCT02787213||Women without preterm delivery|
11286785|NCT02787187|Active Comparator|Standard resection|Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
11286786|NCT02787187|Experimental|Extended resection|Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
11286787|NCT02787174|No Intervention|Control|Participants will receive routine clinical treatment care.
11286788|NCT02787174|Experimental|Intervention|Participants will receive interactive tailored asthma medication adherence education on an iPad.
11286789|NCT02787161|Active Comparator|Hemodialysis|Patients who are treated with high flux hemodialysis will continue the same treatment with high flux hemodialysis.
11286790|NCT02787161|Experimental|Hemodiafiltration|Patients who are treated with high flux hemodialysis will be switched to hemodiafiltration for 6 months.
11286791|NCT02787148|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for Major Depression
11286792|NCT02787148|No Intervention|Waitlist group|Waitlist group to control for repeated physiological measures and fluctuations over time
11286793|NCT02787135|Active Comparator|CBTd-E|Experimental: emotion-oriented Cognitive Behavior Therapy focused on delusions for patients with schizophrenia-spectrum disorders and delusions. The therapeutical intervention follows a treatment-manual consisting of two modules. Patients work on two modules every week for 25 weeks in a row. Module I comprises psychoeducation on emotions, training radical acceptance of emotions and mindfulness, cognitive and behavioral strategies in order to change negative emotions and in order to foster positive emotions and suggestions for life-style changes (positive activities, sports, stress reduction). In the second module, the focus is on self-acceptance. Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
11286794|NCT02787135|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait-list receive treatment as usual (regular visits to a physicist every third month and antipsychotic medication). After six month the waiting list patients receive the treatment specified above.
11286795|NCT02787122|Active Comparator|CBT-E|"Emotion-focussed Cognitive behavior therapy:
~Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy. Interventions are behavioral activation, training of emotion regulation strategies, improvement of self-esteem and relapse prevention."
11286796|NCT02787122|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait list are required to wait for half a year, while they receive standardized care (antipsychotic medication). After half a year, they receive CBT-E, as well.
11286797|NCT02787109|Experimental|CTH522-CAF01|"CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)
~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
11286798|NCT02787109|Experimental|CTH522-Al(OH)3|"CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)
~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
11286799|NCT02787109|Placebo Comparator|Placebo|Saline for IM and In administrations
11286800|NCT02787096|Experimental|laxIRM|Patients will have dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
11286801|NCT02787083|Experimental|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
11286802|NCT02787083|Placebo Comparator|Placebo|These patients will receive placebo tablets daily for 12 weeks.
11286803|NCT02787070|Active Comparator|Primaquine supervised|14 days of supervised primaquine treatment (0.5mg/kg/day).
11286804|NCT02787070|Active Comparator|Primaquine unsupervised|14 days of unsupervised primaquine treatment (0.5mg/kg/day).
11286805|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
11286806|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
11286807|NCT02787044|Experimental|High Dose Influenza Vaccine|High Dose Influenza Vaccine
11286808|NCT02787044|Active Comparator|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
11286809|NCT02787031||Neuraxial anesthesia|Participants in this group will be those who had a spinal or epidural anesthetic without concurrent general anesthesia
11286810|NCT02787031||General anesthesia|Participants in this group will be those who had general anesthesia, including those who had a general plus a concurrent spinal or epidural anesthetic.
11286811|NCT02787018|Placebo Comparator|Block with Ropivacaine and Normal saline|Patients will receive brachial plexus block with 20 ml 0.5% ropivacaine with 1ml normal saline: Total volume 21 ml
11286812|NCT02787018|Active Comparator|Block with Ropivacaine and Dexamethasone|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 4mg (1ml) dexamethasone: Total volume 21 ml
11286813|NCT02787018|Experimental|Block with Ropivacaine and Dexmedetomidine|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 50mcg (1ml) dexmedetomidine: Total volume 21 ml
11286814|NCT02787005|Experimental|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
11286815|NCT02787005|Experimental|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
11286816|NCT02787005|Experimental|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
11286817|NCT02787005|Experimental|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
11286818|NCT02787005|Experimental|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
11286819|NCT02786992|Active Comparator|Misoprostol + Oxytocin|400 ug sublingual misoprostol + 10 IU Oxytocin IVI
11286820|NCT02786992|Active Comparator|Carbetocin|100 ug Carbetocin IV
11286821|NCT02786979|Experimental|Beraprost sodium tablet and Aspirin combination group|Oral
11286822|NCT02786979|Experimental|Aspirin Group|Oral
11286823|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
11286824|NCT02786953|Experimental|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
11286825|NCT02786953|No Intervention|Usual Care|Usual Care
11286826|NCT02786940|Experimental|Live Remote Cardiac Monitoring|Patients in this arm will receive the Cardiophone device, a live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
11286827|NCT02786940|Active Comparator|Usual Care|Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
11286828|NCT02786927|Experimental|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
11286829|NCT02786927|Experimental|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
11286830|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
11286831|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
11286832|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
11286833|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
11286834|NCT02786901|Placebo Comparator|Vehicle Gel|Vehicle
11286835|NCT02786888||conventional needle|conventional needle used
11286836|NCT02786888||fenestrated needle|fenestrated needle used
11286837|NCT02786875|Experimental|Group A (high intensity program):|"Diet: low glycemic index (GI) Mediterranean diet. All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
~Moderate physical activity: brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
~Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D."
11286838|NCT02786875|Active Comparator|Group B (lower intensity program)|"Diet: general recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
~Basic physical activity: general recommendations to avoid sedentary behaviour. Vitamin D supplement (cholecalciferol) will be given only if vitamin D insufficiency is detected to reach blood levels of 30 ng/ml of 25(OH)D."
11286863|NCT02786667|Experimental|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
11286864|NCT02786667|Placebo Comparator|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
11286865|NCT02786641|Active Comparator|Group A|low risk NPC treated with concurrent chemoradiotherapy
11286839|NCT02786862|Experimental|Ventilation|Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
11286840|NCT02786849|Experimental|Group of high frequency and intensity|Group realized high frequency and intensity neuromuscular electrical stimulation
11286841|NCT02786849|Experimental|Group of low frequency and intensity|Group realized neuromuscular electrical stimulation of low frequency and intensity
11286842|NCT02786836|Experimental|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness <26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
11286843|NCT02786823|Experimental|Folic acid|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
11286844|NCT02786823|Experimental|Vitamin B12|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
11286845|NCT02786823|Experimental|"Folic acid and Vitamin B12"|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
11286846|NCT02786823|Active Comparator|Control|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation
11286847|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
11286848|NCT02786797|Experimental|MBSR(BC) 6 Week Program|Participants who are randomized to MBSR(BC) program will receive of educational material; group practice of mindfulness meditation (MM) and homework assignments; and group processes related to the practice of MM and supportive group interaction. Participants who receive MBSR will receive training in (1) sitting meditation anchored to the breath; (2) body scan (observing body sensations from the toes to the head); (3) Gentle Yoga (postures and stretches that increase awareness and balance; and (4) walking meditation. Through this arm of the study the goal is to enhance executive cognition through training in self-regulation of attention and acceptance of experience.
11286849|NCT02786797|Active Comparator|BCES Education Support Program|Participants who are randomized to the BCES program will be scheduled for 6 weekly, 2-hour sessions. BCES compared to MBSR(BC) meets the following criteria: (1) professional contact and group support time matched equally to the MBSR(BC) program; and (2) the content or activities of the BCES program does not include meditation or attention, relaxation, yoga, body scan, or walking meditation. This program is as an active control condition that accounts for nonspecific effects related to attention from the leader and favorable outcome expectancy, the educational materials provided and supportive interaction between group members and is matched for homework activity time over the 6 months. This group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
11286850|NCT02786797|No Intervention|Usual Care|Participants who are randomized to the Usual Care (UC) or control group will continue to receive standard post-treatment medical and nursing clinic visits that will not be modified by study participation. The UC participants will participate in their standard care appointments and will not be required to alter their UC regimen; however, they will be asked not to initiate a mindfulness program during the study period. The UC group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
11286851|NCT02786784|Other|healthy control|patients with patellofemoral pain
11286852|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
11286853|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
11286854|NCT02786732|Experimental|210mg Brodalumab|Administered by subcutaneous injection until Week 12
11286855|NCT02786732|Experimental|140mg Brodalumab|Administered subcutaneous injection until Week 12
11286856|NCT02786732|Active Comparator|Ustekinumab|Administered subcutaneous injection until Week 52
11286857|NCT02786732|Placebo Comparator|Placebo|Administered subcutaneous injection until Week 12
11286858|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
11286859|NCT02786706|Other|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
11286860|NCT02786693||FUO and SII patients|Patients with fever > 38,3°C for more than a week, OR CRP> 5mg/L, without diagnosis after a first step clinical examination and paraclinical exams.
11286866|NCT02786641|Active Comparator|Group B|high risk NPC treated with concurrent chemoradiotherapy
11286867|NCT02786641|Experimental|Group C|high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy
11286868|NCT02786628||Solid tumor malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
11286869|NCT02786628||Hematologic malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
11286870|NCT02786628||Hematopoietic cell transplantation|15 patients. Will participate in physical performance testing and patient-generated health data.
11286871|NCT02786615|Experimental|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
11286872|NCT02786615|No Intervention|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
11286873|NCT02786589|Experimental|Blood-stage infection of P. vivax|This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.
11286874|NCT02786576||Participants receiving adalimumab|Hidradenitis Suppurativa (HS) participants receiving adalimumab
11286875|NCT02786563||Participants with RA receiving adalimumab|This group contains participants in China with RA receiving adalimumab
11286876|NCT02786550|Experimental|Botulinum Toxin|"Immediately after lower blepharoplasty surgery 3 injections of 2.5U of botulinum toxin over lateral part of orbicularis oculi muscle.
~Intervention: Botulinum toxin injection"
11286877|NCT02786550|Placebo Comparator|Normal saline|"Immediately after lower blepharoplasty surgery 3 injections of same amount of normal saline over lateral part of orbicularis oculi muscle.
~Intervention: Normal saline injection"
11286878|NCT02786537|Active Comparator|elbasvir/grazoprevir tablet with RBV|Subjects will take elbasvir/grazoprevir tablet tablet once daily with Ribavirin (RBV) for 12 to 16 weeks (provider discretion)
11286879|NCT02786537|Active Comparator|elbasvir/grazoprevir tablet|Subjects will take elbasvir/grazoprevir tablet tablet once daily without RBV for 12 to 16 weeks (provider discretion)
11286880|NCT02786537|Active Comparator|sofosbuvir/ledipasvir with Ribavirin|Subjects will take 1 tablet sofosbuvir/ledipasvir orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (per discretion of provider)
11286881|NCT02786537|Active Comparator|sofosbuvir/ledipasvir|Subjects will take 1 tablet sofosbuvir/ledipasvir orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
11286882|NCT02786537|Active Comparator|ombitasvir/paritaprevir/ritonavir & dasabuvir & Ribavirin|Two ombitasvir/paritaprevir/ritonavir once daily and dasabuvir twice daily for 12 to 24 weeks and Ribavirin (use and dosage at provider discretion)
11286883|NCT02786537|Active Comparator|ombitasvir/paritaprevir/ritonavir & dasabuvir (Phase 1 only)|Two ombitasvir/paritaprevir/ritonavir once daily and dasabuvir twice daily for 12 to 24 weeks without Ribavirin (at provider discretion)
11286884|NCT02786524|No Intervention|Standard of Care|Patients randomized to this arm receive standard symptom management care by their primary gynecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each visit, every 3-4 weeks.
11286885|NCT02786524|Experimental|Symptom Management and Supportive Care|Patients randomized to this arm are referred to a specialized symptom management and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recommended by the symptom management providers, and at each visit they will complete the ESAS-r and NCCN distress thermometer and return their responses either in person or by mail to the study team in a pre-addressed postage paid envelope.
11286886|NCT02786511||Subjects with multiple myeloma|Subjects treated with ex vivo gene therapy in a bluebird bio sponsored trial who agree to participate in this study.
11286887|NCT02786498|Experimental|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
11286888|NCT02786498|Experimental|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
11286889|NCT02786498|Experimental|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
11286890|NCT02786498|Placebo Comparator|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
11286891|NCT02786485|Experimental|Rivogenlecleucel & Rimiducid|"All subjects will receive 3 courses of rivogenlecleucel (BPX-501 T cells) infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.
~Escalating doses of rimiducid (AP1903) (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after rivogenlecleucel infusion."
11286892|NCT02786472|Active Comparator|Haven|"Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are personalized and reflective and incorporate the student's unique perspectives and experiences. This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training."
11286893|NCT02786472|Active Comparator|AlcoholEdu|Online Substance Abuse Training or AlcoholEdu provides confidential substance abuse education course which uses a science-based approach to educate students about alcohol and its effects. Whether the student drinks or not, the course will help them make informed decisions about alcohol and better deal with drinking behavior that may occur around them. AlcoholEdu is used by more than 500 colleges nationwide through EVERFi.
11286894|NCT02786472|Experimental|ConnectEd|In-person Combination Training provides Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming to develop ConnectED. The intentional coordination between substance abuse and violence prevention programming would include in-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystander behaviors and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; and, in-depth skill building activities to prepare participants to safely intervene in problem situations.
11286947|NCT02786095||Code-AF registry|
11286895|NCT02786472|Experimental|GreenDot|"In-person Bystander Training provides Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions. While a Popular Opinion Leader strategy has been used in prior training, for this trial all incoming students randomized to this condition will be offered intensive bystander training.
~NOTE: Green Dot Speeches will be supplemental to Intensive Green Dot Bystander training. These speeches will continue to occur as usual. As the aim of this study is to compare bystander intensive training, we will not attempt to limit participation to Green Dot Speeches."
11286896|NCT02786459|Experimental|Post Radical Prostatectomy|"Up to n=30 evaluable male patients, between ages 30-75, who were previously diagnosed with PCa, have undergone a RP at least 6 months before imaging and who experience rising PSA (biochemical failure). The RP group (n=30) will be stratified into PSA subgroups <0.005, 0.005-<0.2, >0.2.
~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI."
11286897|NCT02786459|Active Comparator|Active Surveillance|"Up to n=10 men, between ages 30-75, on active surveillance with known prostate adenocarcinoma diagnosis and multiple positive biopsies.
~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
11286898|NCT02786459|Experimental|Multiple Negative Biopsies|"Up to n=20 men, between ages 30-75, who have previously undergone one/or multiple negative biopsies, with elevated PSA (≥4 ng/mL) and/or an abnormal digital rectal exam suspicious for prostate cancer with a planned sextant prostate biopsy but who do not have a definitive PCa diagnosis.
~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
11286899|NCT02786446|Active Comparator|Lidocaine gel|20 grams Lidocaine gel 2 % will be applied to corresponding lumber area of the patients 30 minutes before undergoing ESWL for renal stone.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
11286900|NCT02786446|Active Comparator|Naproxen Sodium|Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
11286901|NCT02786446|Active Comparator|Lidocaine Gel and Naproxen Sodium|Oral Naproxen sodium 55o mg and locally applied 2 % lidocaine gel to patients before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
11286902|NCT02786433|Active Comparator|GROUP CONTROL|"Participants in the control group only underwent conventional physiotherapy. Conventional therapy includes stretching and strengthening exercises with cane aid, leggings , elastic band and overball for upper and lower limbs , in addition to gait and balance training.
~The intervention for the control group was applied for five weeks with sessions of 60 minutes twice a week"
11286903|NCT02786433|Experimental|EXPERIMENTAL GROUP|The subjects in the experimental group underwent conventional physiotherapy (The same applied in the control group) associated with virtual reality , performed with the console X -Box Kinect® of Microsoft. Durante the achievement of the virtual reality practice, Kinect and Kinect games Adventures® Dance® demanded the anterior movements players -posterior and lateral , as well as jumps and squats to get rid of the game obstacles. They Kinect Dance® game were all required movements of the previous game more dance . The intervention lasted five weeks , with two weekly sessions lasting 30 minutes to conventional therapy and 30 minutes to virtual reality.
11286904|NCT02786420||Observational|Pregnant women
11286905|NCT02786407|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
11286906|NCT02786407|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
11286907|NCT02786394|Experimental|REACH Participant Course|This study will run twice a week over 8 weeks with 6 REACH sessions 8 optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
11286908|NCT02786368|Other|Control group|For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
11286909|NCT02786368|Experimental|EHFP group|Households will receive training and inputs for an Enhanced Homestead Food Production (EHFP) package. Participants will also receive educational components through inter-personal behavioural change communication on nutrition (Essential Nutrition Actions), Water Sanitation and Hygiene (WASH), gender, and business/marketing.
11286910|NCT02786355|Other|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
11286911|NCT02786355|Other|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
11286912|NCT02786342||Advanced HCC patients treated with sorafenib|
11286913|NCT02786329|Active Comparator|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.
~Interventions: TIVA+lidocaine"
11286914|NCT02786329|Placebo Comparator|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
11286915|NCT02786329|Placebo Comparator|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).
~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
11286916|NCT02786329|Active Comparator|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.
~Intervention: sevoflurane anesthesia+ lidocaine infusion"
11286917|NCT02786316|Experimental|intervention group|Hit program for the rehabilitation of persons with nonspecific chronic low backpain
11286918|NCT02786316|Active Comparator|Control group|a conventional rehabilitation program for persons with nonspecific chronic low backpain
11286919|NCT02786303|Other|arm whole-body MRI|
11286920|NCT02786290|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
11286921|NCT02786277|No Intervention|Usual Care|No alert will be fired
11286922|NCT02786277|Experimental|Alert|An alert informing the provider of acute kidney injury will be fired.
11286923|NCT02786264||Propofol-dominant Sedation|Patients receiving propofol infusion for TAVR as the primary drug for sedation.
11286924|NCT02786264||Dexmedetomidine-dominant Sedation|Patients receiving dexmedetomidine infusion for TAVR as the primary drug for sedation.
11286925|NCT02786264||Fentanyl and/or Midazolam Sedation|Patients receiving fentanyl +/- midazolam as the primary drugs for sedation for TAVR
11286926|NCT02786251|Other|BAT+|Individuals with significant amounts of BAT (>20 ml)
11286927|NCT02786251|Other|BAT-|Individuals with no/minimal amounts of BAT (<20 ml)
11286928|NCT02786238|Active Comparator|Standard Behavioral Treatment (SBT)|For the Standard Behavioral Treatment (SBT) condition, participants will participate in the standard behavioral weight loss programming, which utilizes strategies from existing obesity treatments (e.g., the Diabetes Prevention Program). These features include the following: 1) nutritional education, 2) diet and physical activity, 3) expectations for daily self-monitoring of calorie intake and activity, 4) stimulus control, behavior shaping, behavior analysis, and relapse prevention strategies, and 5) social support.
11286929|NCT02786238|Experimental|Acceptance-Based Treatment (ABT)|"The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., urge-surfing). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430)."
11286930|NCT02786225|Experimental|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a Vanderbilt University Medical Center (VUMC) perinatologist and a Vanderbilt University School of Nursing (VUSN) nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
11286931|NCT02786225|Active Comparator|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
11286932|NCT02786212|Experimental|dexmedetomidine|Patients receiving intraoperative dexmedetomidine infusion. Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
11286933|NCT02786212|Placebo Comparator|control|control group, receiving same volume of normal saline infusion.
11286934|NCT02786199||Hepatocellular carcinoma|patients HCC who are going to receive surgical resection
11286935|NCT02786186||Secikinumab|Patients treated with secukinumab
11286936|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
11286937|NCT02786160|Active Comparator|HMO1|Daily bolus of HMO1
11286938|NCT02786160|Active Comparator|HMO2|Daily bolus of HMO2
11286939|NCT02786160|Placebo Comparator|Dextropur|Daily bolus of Dextropur
11286940|NCT02786147||Patient Initiated|Patients randomized into this group will receive a standard handout explaining their result, which includes information on how to obtain cancer genetics services through Winship. However, neither the patient nor their ordering clinician will be directly contacted regarding the B-RST result.
11286941|NCT02786147||Physician Notification|Patients randomized into this group will also receive the standard handout explaining their result. In addition, their primary care physician or ordering physician will be notified via Emory Electronic Medical Record (EeMR) that the patient screened positive on the B-RST. The note will provide specific instructions on how to refer the patient for cancer genetic counseling services.
11286942|NCT02786147||Automatic Follow-Up By Genetic Counseling Staff|Patients randomized into this group will also receive the standard handout explaining their result. Within 1-2 weeks after their mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment. This call may take up to 10 - 15 minutes.
11286943|NCT02786134|Experimental|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
11286944|NCT02786134|Experimental|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
11286945|NCT02786108|Experimental|left gastric artery embolization|Patients undergoing left gastric artery embolization
11286946|NCT02786108|Active Comparator|healthy diet and exercise|Patients undergoing healthy diet and exercise
11286948|NCT02786082|Experimental|Group I|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group I, half are male and half are female, will take Azilsartan tablet 20mg orally on fasting.
~For Pharmacokinetics Studies of Azilsartan with Multiple-dose oral administration, 12 subjects in group I will take 20mg Azilsartan orally once daily for 7 day (day 3~day 9) after completing the last time blood sample collection (in day 2, 48h) of the first time administration (day 1)"
11286949|NCT02786082|Experimental|Group II|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group II, half are male and half are female, will take Azilsartan tablet 40mg orally on fasting.
~For The effects of diet for pharmacokinetic study: The 12 healthy subjects, in group II (in single-dose administration study), after 7-day washout period after the first administration (at day 1, 40mg) will receive Azilsartan tablet 40mg after high-fat diet at day 8"
11286950|NCT02786069|Experimental|Single arm|
11286951|NCT02786056|Experimental|Lung MRI examination|
11286952|NCT02786043|Experimental|Single arm|
11286953|NCT02786030|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions.
11286954|NCT02786030|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will not receive outreach education training.
11286955|NCT02786017|Sham Comparator|Conventional therapy|
11286956|NCT02786017|Experimental|Injectable Collagen Scaffold + HUC-MSCs|
11286957|NCT02786004|Experimental|Full Field Digital Mammography|2-dimensional breast imaging
11286958|NCT02786004|Experimental|Digital Breast Tomosynthesis|3-dimensional breast imaging
11286959|NCT02785978|Experimental|Parkinson Disease Patients Group #1|PD patients with programmed levodopa challenge
11286960|NCT02785978|Experimental|Parkinson Disease Patients Group #2|PD patients without programmed levodopa challenge
11286961|NCT02785978|Experimental|Healthy volunteers|Healthy volunteers
11286962|NCT02785965|Experimental|acupuncture & lifestyle modification|Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
11286963|NCT02785965|Active Comparator|lifestyle modification|diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
11286964|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11286965|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11286966|NCT02785939|Experimental|Arm I - closed to accrual 09/01/2016 (palbociclib)|Patients receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11286967|NCT02785939|Experimental|Arm II - closed to accrual 12/18/15 (docetaxel)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients may be eligible to re-register to Arm III.
11286968|NCT02785939|Experimental|Arm III - closed to accrual 09/01/2016 (palbociclib re-reg)|Patients in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11286969|NCT02785913|Experimental|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11286970|NCT02785900|Experimental|33A + HMA|33A plus azacitidine or decitabine
11286971|NCT02785900|Active Comparator|placebo + HMA|placebo plus azacitidine or decitabine
11286972|NCT02785887|Experimental|Oncological and geriatrician review|Routine oncological care plus geriatric intervention
11286973|NCT02785887|No Intervention|Oncological care|Routine oncological care only
11286974|NCT02785874|Experimental|Statin(Crestor) taken|Subjects take Statin(Crestor) 10mg per day for a- year
11286975|NCT02785874|No Intervention|non Statin(Crestor) taken|non Statin(Crestor) taken as a reference for experimental group.
11286976|NCT02785861|Experimental|supervised practice|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.
~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.
~Each patient of supervised walking group will meet the student each session"
11286977|NCT02785861|Experimental|distance supervised physical activity|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.
~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.
~Each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions"
11286978|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
11286979|NCT02785822|Active Comparator|Fostipur|
11286980|NCT02785822|Experimental|Meriofert|
11286981|NCT02785796|Experimental|CV4|The practitioner will contact the participant's occiput (lateral to the external occipital protuberances, but medial to the occipital-mastoid suture) with his or her thenar eminences. When no cranial mobility will be found, operators will be free to use any kind of technique to enhance the cranial movement before CV4 procedure. Once the practitioner will detect the CRI, the practitioner will resist the flexion phase of the CRI and exaggerate the extension phase. This compressive pressure will be maintained until the CRI stopped, and the still-point is reached. The still-point will be held until the CRI return, at which point the compressive pressure will be slowly release
11287013|NCT02785614|Experimental|II-1|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:
~R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days."
11286982|NCT02785796|Placebo Comparator|sham technique|"The operator will overlap the hands so that the thumbs formed a V. The operator's thenar eminences will contact the occiput very lightly well below the positioning used in the CV4 procedure but with no pressure on the occiput between the occipitomastoid sutures. Once placement will be achieved, the operator's hands will remain motionless for 10 min. Finally, the practitioner's hands will be gently removed and the participant's head will be placed on the table for both procedures"
11286983|NCT02785796|No Intervention|Control|The control group will not receive ant type of treatment: subject just stay quietly in supine position in ambulatory room for ten minutes
11286984|NCT02785783|Active Comparator|Standard colonoscopy|A standard colonoscope will be used to complete the procedure
11286985|NCT02785783|Active Comparator|EndoRings™|An EndoRings™ device will be placed at the distal end of a standard colonoscope
11286986|NCT02785770|Experimental|PF-04447943 low dose|25 mg of PF-04447943
11286987|NCT02785770|Experimental|PF-04447943 high dose|100 mg of PF-04447943
11286988|NCT02785770|Placebo Comparator|Placebo|Matching placebo for PF-04447943
11286989|NCT02785770|Active Comparator|Moxifloxacin|400 mg of moxifloxacin
11286990|NCT02785757|Experimental|Patients with adenocarcinoma|60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy
11286991|NCT02785744||Patients receiving DEXA Scan|Gaucher patients referred for dual energy X-ray absorptiometry (DEXA scan), who were found to have T-score <-1.0.
11286992|NCT02785731||Women with a pelvic mass|Women diagnosed with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled for a laparotomy or laparoscopy for removal of the pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 60 days prior to surgery.
11286993|NCT02785718|Experimental|Patients with FXI or FXII deficiency|12 patients with FXI deficiency and 6 patients with FXII deficiency
11286994|NCT02785705|Experimental|cIPV-bOPV-bOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two bivalent types 1 and 3 oral poliovirus vaccine sequentially.
11286995|NCT02785705|Experimental|cIPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
11286996|NCT02785705|Experimental|cIPV-cIPV-bOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one bivalent types 1 and 3 oral poliovirus vaccine sequentially.
11286997|NCT02785705|Experimental|cIPV-cIPV-tOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
11286998|NCT02785705|Experimental|cIPV-cIPV-cIPV poliovirus vaccine|Participants would be vaccine with three shots of trivalent conventional inactivated poliovirus vaccine.
11286999|NCT02785705|Experimental|tOPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with three times of trivalent types 1, 2 and 3 oral poliovirus vaccine .
11287000|NCT02785692||Combined Radiation/ Surgery|All patients treated with combined radiotherapy and surgery at Balgrist University Hospital and University Hospital Zurich
11287001|NCT02785679|No Intervention|Exclusive breast feeding|Exclusive breast feeding
11287002|NCT02785679|No Intervention|Exclusive CMF feeding|Exclusive CMF feeding
11287003|NCT02785679|Active Comparator|Breast feeding with small amount of CMF|Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
11287004|NCT02785679|Active Comparator|Breast feeding with one meal of CMF|Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
11287005|NCT02785666|Experimental|Treatment and behavioural intervention:|"Treatment intervention: Patients with a replicating GT 1 and/or 4 HCV infection without or with cirrhosis will be treated with grazoprevir/elbasvir (100mg/50mg) for 12 weeks. GT 1a infected patients with baseline RAV's and GT 4 infected patients with a history of prior HCV treatment failure without or with cirrhosis will be treated with the same regimen for 16 weeks, in combination with weight-adjusted ribavirin.
~Behavioural Intervention: Participants with inconsistent condom use with occasional partners will receive the behavioral Intervention and in addition standard of care written and oral information on prevention of HCV reinfection. Study participants with consistent condom use or those reporting inconsistent condom use with occasional partners but not willing to participate in the intervention will receive standard of care written and oral information on prevention of HCV reinfection only"
11287006|NCT02785653|Experimental|sevoflurane and rocuronium|After induction of general anaesthesia, patients in the sevoflurane group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen with 2% inspired concentration of sevoflurane. After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
11287007|NCT02785653|Active Comparator|rocuronium|After induction of general anaesthesia, patients in the control group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen . After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
11287008|NCT02785640|Experimental|Prompt group|Following feedback on their baseline sitting behaviour and an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered via Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing
11287009|NCT02785640|No Intervention|Control group|The control group will receive the same education session as the prompt group, as well as feedback on their baseline sitting behaviour. However, the will not receive prompts on their PC.
11287010|NCT02785627||Group A: ADT|Men with non-metastatic prostate cancer, about to start or within 2 weeks of starting ADT
11287011|NCT02785627||Group B: ADT + chemotherapy|Men with newly diagnosed hormone sensitive metastatic prostate cancer, starting ADT and who will have chemotherapy
11287012|NCT02785627||Group C: Controls|Healthy age matched men
11287066|NCT02785263|Other|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
11287014|NCT02785614|Experimental|II-2|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:
~T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days."
11287015|NCT02785601|Experimental|I-1|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
11287016|NCT02785601|Experimental|I-2|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
11287017|NCT02785601|Experimental|I-3|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
11287018|NCT02785601|Experimental|I-4|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
11287019|NCT02785588|Other|3.0 T Neonatal MRI scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
11287020|NCT02785575|Active Comparator|HeProCalc|This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.
11287021|NCT02785575|No Intervention|Traditional calculations|This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)
11287022|NCT02785562|Other|Assessment of PDL1 expression|Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.
11287023|NCT02785549|Experimental|Symptomatic treatment with NSAID|1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
11287024|NCT02785549|Active Comparator|Antibiotic+symptomatic treatment with NSAID|875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
11287025|NCT02785536|Active Comparator|Standard Treatment|The standard treatment was a well-established, manual-driven, multicomponent CBT for tobacco dependence that has been delivered in multiple modalities (i.e., group, individual, and telephone), used in numerous studies, and considered intensive, comprehensive, and consistent with the Public Health Service Clinical Practice Guideline.
11287026|NCT02785536|Experimental|RITCh Treatment|The RITCh treatment is an adaptation of the standard treatment which proactively addresses the needs and experiences of a diverse group of lower SES smokers as well as ensures that the treatment is culturally congruent and experientially resonant for African Americans while maintaining the same amount of treatment contact (i.e., six one-hour sessions).
11287027|NCT02785523|Experimental|G. SPORE LIPIDS|"Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy.
~Duration: 6 chemotherapy cycles."
11287028|NCT02785523|Placebo Comparator|Placebo|"Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy.
~Duration: 6 chemotherapy cycles."
11287029|NCT02785497|Experimental|Treatment group|"Chronic ulcer patients will be treated with 50 minutes of the high-voltage current or 10 minutes of the diadynamic current. To burn patients 50 minutes high voltage current in the donor area. For both group the metal electrodes will be sterilized and the negative polarity in the active electrode.
~50 min, 100Hz, intensity according to the sensitivity patient - High Voltage; 10 min, intensity according to the sensitivity patient - Diadynamic"
11287030|NCT02785497|Sham Comparator|Control group|"For the control group the unit is turned on, the time will pass but will not be given intensity
~50min, 100Hz, Intensity according to the sensitivity patient"
11287031|NCT02785484|Experimental|Label with constituent disclosure message|
11287032|NCT02785484|Other|Label with litter message|
11287033|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
11287034|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
11287035|NCT02785458|No Intervention|Usual Care|Subjects will receive the current standard of care.
11287036|NCT02785458|Experimental|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
11287037|NCT02785445|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
11287063|NCT02785276|Experimental|Ropivacaine infusion|Following the insertion of the 2mm fenestrated catheter, the wound catheter will be connected to the 270mL AutoFuser Pain Pump. The intraperitoneal infusion with ropivacaine (0.2%) at 4 mL/hour will start immediately and continue for 68 hours post-operatively uninterrupted.
11287064|NCT02785276|Placebo Comparator|Placebo infusion|In the same manner as described for the ropivacaine infusion arm, 0.9% Normal Saline will be administered over 68 hours.
11287038|NCT02785432|Sham Comparator|Sham low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 0 watts for a total of 0 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint. The contact head applicator will be used if soft tissue contact is tolerable. Otherwise, the non-contact head will be utilized.
11287039|NCT02785432|Active Comparator|Active low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. This equates to standard acceptable dosing of 6-10 j/cm2 over the larger area of treatment. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Areas for administration and contact will otherwise be consistent with the sham group.
11287040|NCT02785419|Experimental|Arm Training with Action Selection|Task-oriented, functional arm training with the addition of action selection cues to practice. All participants receive the same arm training intervention.
11287041|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
11287042|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
11287043|NCT02785393|Placebo Comparator|Sugar Pill|
11287044|NCT02785393|Active Comparator|Doxazosin|
11287045|NCT02785380|Experimental|laparoscopic surgery(LS)|For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
11287046|NCT02785380|Active Comparator|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).
11287047|NCT02785367|Experimental|Cord blood samples|8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml washed with Heparin.
11287048|NCT02785354||NOAC|New oral anticoagulant groups
11287049|NCT02785354||VKA|VKA group
11287050|NCT02785341|Other|Immediate adaptated physical activity (Group A)|"Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.
~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
11287051|NCT02785341|Other|Without immediate adaptated physical activity (Group B)|"Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.
~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
11287052|NCT02785328|Experimental|obstructive sleep apnoea|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from obstructive sleep apnoea syndrome.
11287053|NCT02785328|Experimental|narcolepsy|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from narcolepsy.
11287054|NCT02785328|Experimental|BECTS (Benign epilepsy with centro-temporal spikes)|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from BECTS.
11287055|NCT02785328|Experimental|high intellectual potential|The objective of this task is to evaluate the sleep-dependent consolidation abilities in children with high intellectual potential.
11287056|NCT02785328|Experimental|healthy children|The objective of this task is to evaluate the sleep-dependent consolidation abilities in healthy children.
11287057|NCT02785315|Experimental|rehabilitation & remediation approach|The intervention group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention with various compensatory strategies. Investigators will use group discussion to discuss everyday situations with memory problem and specific strategies (internal and external) related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
11287058|NCT02785315|Active Comparator|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
11287059|NCT02785302||Adolescents and Young Adults:|Behaviorally-infected, HIV-positive, adolescents and young adults enrolled in ATN 125, aged 18 through 24, inclusive who are transition eligible. All subjects with available endpoint data will be included in the analysis.
11287060|NCT02785302||AMTU and Adult Clinic Staff|Clinical staff at the Adolescent Medical Trials Units (AMTUs) and at adult clinics where the AMTUs refer their transitioning patients will be recruited to complete quantitative surveys and semi-structured interviews.
11287061|NCT02785289|Experimental|Flocked|Patients will perform vaginal cell collection beginning with the flocked swab, followed by the coton swab.
11287062|NCT02785289|Experimental|Coton|Patients will perform vaginal cell collection beginning with the coton swab, followed by the flocked swab.
11287065|NCT02785263|Other|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
11287067|NCT02785263|Other|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
11287068|NCT02785250|Experimental|Arm 1|DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)
11287069|NCT02785250|Experimental|Arm 2|DPX-Survivac, Cyclophosphamide (in Phase 2 only)
11287070|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in first lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
11287071|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in first lesion|Patients with Ultimaster® Drug-eluting stent in first lesion
11287072|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in second lesion|Patients with with Ultimaster® Drug-eluting stent in first lesion
11287073|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in second lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
11287074|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
11287075|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
11287076|NCT02785211|Experimental|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
11287077|NCT02785211|Placebo Comparator|control group|"For the control group, participants will receive regular physical examinations and education by village doctors weekly during the 8 week intervention.The weekly visits for every old people whose age above 65 by country doctors are not arranged by our study, it is the country doctors routine work by government health policy. This study was permitted by the local community health center, the director with specific responsibility will inform all country doctors to support our study."
11287078|NCT02785198|No Intervention|Control group|A control group receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
11287079|NCT02785198|Experimental|Passive training group|An Intervention group doing passive exercise for 8 weeks in knee extensor machine, and receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
11287080|NCT02785185|Experimental|IDP-122 Lotion|Lotion
11287081|NCT02785185|Active Comparator|Ultravate Cream|Cream
11287082|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
11287083|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
11287084|NCT02785172|Experimental|IDP-118 Lotion|Lotion
11287085|NCT02785172|Active Comparator|Ultravate Cream|Cream
11287086|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
11287087|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
11287088|NCT02785159|Experimental|IDP-118 Lotion|Lotion
11287089|NCT02785159|Active Comparator|Tazorac Cream|Cream
11287090|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
11287091|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
11287092|NCT02785146|Experimental|mFOLFOX6 + Huaier Granule|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
11287093|NCT02785146|Active Comparator|mFOLFOX6|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).
11287094|NCT02785133|Experimental|Treatment group|Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.
11287095|NCT02785120|Placebo Comparator|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
11287096|NCT02785120|Placebo Comparator|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
11287097|NCT02785120|Placebo Comparator|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
11287098|NCT02785107|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
11287099|NCT02785107|No Intervention|Control|Participants exercised on their own without receiving any instructions.
11287100|NCT02785094||A|Group of High Education level
11287101|NCT02785094||B|Group of Low/Non Education level
11287102|NCT02785094||C|Group has Accessibility to Social Media
11287103|NCT02785094||D|Group has not Accessibility to Social Media
11287104|NCT02785068|Experimental|Phase 1b/2a|"Phase 1b: Safety Evaluation - MM-151 (weekly dosing) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400mg/m2 every two weeks.
~Phase 2a: Expansion - MM-151 (Maximum Tolerated Dose or Recommended Phase 2 Dose) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2."
11287105|NCT02785055|Active Comparator|Ultrasound-Assisted|Ultrasound assisted marking of the thoracic spine on the skin for Thoracic Epidural Placement
11287106|NCT02785055|Active Comparator|Palpation|Palpation marking of the thoracic spine on the skin for Thoracic Epidural Placement
11287107|NCT02785042|Experimental|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
11287108|NCT02785029|Experimental|Normal healthy Volunteers|OCT imaging
11287109|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
11287110|NCT02785003|Experimental|Ketamine Infusion|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the ketamine solution at a calculated dose of 0.25 mg/kg. A continuous infusion of ketamine will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
11287111|NCT02785003|Placebo Comparator|Saline Placebo|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the saline solution at a calculated dose of 0.25 mg/kg. A continuous infusion of saline will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
11287112|NCT02784990||Patient|
11287113|NCT02784977||Obstructive Sleep Apnea (OSA)|Patients with apnea hypopnea index of at least 5 events per hour. Intervention with positive airway pressure, or intraoral device, or uvuloplasty, or conservative treatment.
11287114|NCT02784977||No-OSA|Patients with apnea hypopnea index less than 5 events per hour. No intervention.
11287115|NCT02784964|Experimental|Elixcyte 8mL|ADSC 6.4*10^7 cells, allogeneic injection, one time injection on Day 1
11287116|NCT02784964|Active Comparator|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
11287117|NCT02784964|Experimental|Elixcyte 4mL|ADSC 3.2*10^7 cells, allogeneic injection, one time injection on Day 1
11287118|NCT02784964|Experimental|Elixcyte 2mL|ADSC 1.6*10^7 cells, allogeneic injection, one time injection on Day 1
11287119|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
11287120|NCT02784938|Experimental|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
11287121|NCT02784938|No Intervention|Wait-list Control|Services as usual
11287122|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
11287123|NCT02784899|Experimental|iloprost group|iloprost inhalation group
11287124|NCT02784899|Placebo Comparator|control group|normal saline inhalation group
11287125|NCT02784873|No Intervention|Usual care|"Usual care cardiac rehabilitation with exercise training as per current guidelines
~Warm up: 15 mins, < 40% heart rate reserve (HRR) Cardiovascular component: progress towards 20 - 40 mins continuous cardiovascular exercise at 40-70% HRR.
~Muscular strength and endurance programme. Cool down: 10 mins, < 40% HRR. Initial duration based on participant's previous and current physical activity (PA) levels and cardiopulmonary exercise test (CPEX) performance.
~Duration and workload of cardiovascular component adjusted, as tolerated, within the above parameters, in response to exercising heart rate (HR), participant reported rating of perceived exertion (RPE) and symptoms."
11287126|NCT02784873|Experimental|High intensity interval training|"High intensity interval training within a standard cardiac rehabilitation programme.
~Warm up: 15 mins total, 10 mins <40-70% HRR, 5 mins <70% HRR. Cardiovascular component: exercise bike interval training: 10 x high @ 85-90% peak power output (PPO) from CPEX, 10 x low @ 20-25% PPO (exercise intensity will not to be prescribed from gas exchange data i.e. %VO2 peak). Change in intensity from low to high achieved by altering cadence (rpm).
~Muscular strength and endurance programme. Cool down: 10 mins, <40% HRR. Duration of intervals and total programme duration increased in a standardised fashion.
~Workload increased bi-weekly in response to participant reported RPE (only after the full 10 x 1 protocol has been achieved). If RPE < 17 then workload will be increased."
11287127|NCT02784860|Active Comparator|Lidocaine|Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
11287128|NCT02784860|Placebo Comparator|Placebo|Placebo Administration of normal saline: same volume of saline as lidocaine.
11287129|NCT02784847|Other|treatment arm|pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
11287130|NCT02784834|Experimental|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.
~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.
~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
11287131|NCT02784821|Other|Antibiotics Control|"These neonates have a clinical indication to receive antibiotics, such as maternal chorioamnionitis with fetal tachycardia. The standard of care antibiotics include Ampicillin and Gentamicin or Cefotaxime and as part of standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.
~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
11287162|NCT02784613|Experimental|Ospemifene open label|60 mg ospemifene daily for 20 weeks
11287163|NCT02784600||Partial or full-thickness rotator cuff tear|Rotation Medical bioinductive implant
11287207|NCT02784275|Placebo Comparator|Dose D|Placebo
11288959|NCT02772718|Experimental|Part 2 - multiple doses|Cohort 1
11287132|NCT02784821|Other|No Antibiotics Control|"These neonates show no signs of respiratory distress(RDS) or have no indications of maternal chorioamnionitis. Antibiotics is not indicated for this group as standard of care.
~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins."
11287133|NCT02784821|Other|Randomized to pre-emptive antibiotics|"This group will be randomized to receive standard of care antibiotics which include Ampicillin and Gentamicin or Cefotaxime. Standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.
~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
11287134|NCT02784821|Other|Randomized to no pre-emptive antibiotics|This group will be randomized not to receive standard of care antibiotics. Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins.
11287135|NCT02784808||Biologic DMARDs|Participants who received biologic DMARDs as per standard of care were included in this arm.
11287136|NCT02784808||Non-biological DMARDs|Participants who received non-biologic DMARDs as per standard of care were included in this arm.
11287137|NCT02784795|Experimental|LY3039478 + Taladegib|LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.
11287138|NCT02784795|Experimental|LY3039478 + LY3023414|LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
11287139|NCT02784795|Experimental|LY3039478 + Abemaciclib|LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.
11287140|NCT02784795|Experimental|LY3039478 + Cisplatin/Gemcitabine|LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.
11287141|NCT02784795|Experimental|LY3039478 + Gemcitabine/Carboplatin|LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.
11287142|NCT02784782|Experimental|Orthesis|Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
11287143|NCT02784782|Active Comparator|No Orthesis|"Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol.
~Control: The patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes."
11287144|NCT02784769|Experimental|aneurysm diameter of below 75 mm|
11287145|NCT02784769|Experimental|aneurysm diameter above 75 mm|
11287146|NCT02784756|Other|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
11287147|NCT02784743|Experimental|albendazole and ivermectin|Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).
11287148|NCT02784730|Experimental|Iterative PICC placement|New PICC placement at each chemotherapy cycle (removed after treatment administration)
11287149|NCT02784730|Active Comparator|Long term implantable device|Port-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
11287150|NCT02784717||Rivaroxaban (Xarelto, BAY 59-7939)|Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.
11287151|NCT02784704|Experimental|Eravacycline|
11287152|NCT02784704|Active Comparator|Meropenem|
11287153|NCT02784691|Experimental|Patients|
11287154|NCT02784678|Experimental|closed reduction group|Patients will be assigned to C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws (experimental group).
11287155|NCT02784678|Experimental|open reduction group|Patients will be assigned to open reduction (palmar and dorsal incisions) and internal fixation with titanium plate (control group).
11287156|NCT02784665|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
11287157|NCT02784665|Active Comparator|577-TL|"577nm Traditional laser(577-TL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area."
11287158|NCT02784652|Experimental|RT & Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions, Zoleronic acid: every 4 weeks, 6 times, 4.0 mg iv
11287159|NCT02784639|Other|determination of KRAS mutation|circulating cell free DNA (ccfDNA) plasma analysis
11287160|NCT02784626|Experimental|Dexmedetomidine|Patients who received dexmedetomidine during the operation
11287161|NCT02784626|Experimental|Propofol|Patients who received propofol during the operation
11302256|NCT02684331||T2DM|
11287164|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
11287165|NCT02784561|Experimental|Busulfan/FLAG conditioning regimen|"All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).
~The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously [i.v.], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days
~-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2)."
11287166|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
11287167|NCT02784535|Placebo Comparator|placebo|placebo capsules
11287168|NCT02784535|Active Comparator|atomoxetine|atomoxetine capsules 10 mg or 18 mg
11287169|NCT02784522|Experimental|locking compression plate group|In the experimental group, patients will undergo closed reduction via a lateral approach to the shoulder followed by locking compression plate fixation using a minimally invasive technique.The locking compression plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
11287170|NCT02784522|Active Comparator|conventional locking plate group|Patients in the control group will be subjected to closed reduction via a lateral approach to the shoulder followed by conventional steel plate fixation using a minimally invasive technique. The conventional locking plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
11287171|NCT02784496|Experimental|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
11287172|NCT02784483|Experimental|Atezolizumab (1200mg via IV infusion)|
11287173|NCT02784470|Experimental|gastrojejunostomy arm|
11287174|NCT02784470|Active Comparator|gastroduodenal stent placement|
11287175|NCT02784457|Active Comparator|GnRHant|women who received GnRH antagonist
11287176|NCT02784457|No Intervention|Control|women who did not receive GnRH antagonist
11287177|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
11287178|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
11287179|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
11287180|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
11287181|NCT02784418|Active Comparator|PCI of CTO|Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.
11287182|NCT02784418|Sham Comparator|Sham Procedure|"Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a Sham procedure, wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months."
11287183|NCT02784392|Experimental|Active|Ulimorelin
11287184|NCT02784392|Active Comparator|Comparator|Metoclopramide
11287185|NCT02784379||The breast with mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast with mastalgia.
11287186|NCT02784379||The breast without mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast without mastalgia.
11287187|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
11287188|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
11287189|NCT02784353|Active Comparator|Conventional|No intervention; conventional perioperative management without perioperative rehabilitation program
11287190|NCT02784353|Experimental|Intervention - PReHeBP|conventional perioperative management with preoperative and postoperative rehabilitation program
11287191|NCT02784340|Active Comparator|IV dexamethasone|40 women received 16 mg Dexamethasone IV drip.
11287192|NCT02784340|Active Comparator|Local dexamethasone|40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
11287193|NCT02784340|Placebo Comparator|placebo|Placebo in the form of IV fluids 500 cc saline infusion
11287194|NCT02784327|Experimental|PRF110- oily solution|Post-operative application of new extended release PRF110- oily solution (Ropivacaine)
11287195|NCT02784314|Experimental|Robotic-Assisted Radical Prostatectomy|Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
11287196|NCT02784314|Active Comparator|Laparoscopic Radical Prostatectomy|Standard laparoscopic Radical Prostatectomy
11287197|NCT02784301|Experimental|Belly breathing with biofeedback app|
11287198|NCT02784301|No Intervention|Standard of Care|
11287199|NCT02784301|Active Comparator|Belly breathing without biofeedback app|
11287200|NCT02784301|Active Comparator|Belly breathing + visual distraction|
11287201|NCT02784288|Experimental|Surgery|
11287202|NCT02784288|Experimental|Radiation|
11287203|NCT02784288|Experimental|Radiation and Chemotherapy|
11287204|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
11287205|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
11287206|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
11287208|NCT02784262|Experimental|botox injection|"Preoperative medication: Paracetamol 1,5g oral, diclofenac 50mg (evt ibuprofen 600mg) oral and/or diazepam 5-10 mg oral.
~Skin and tissue inside the projected injection canal will be infiltrated with 5-10ml Marcain-Adrenalin (5mg/ml + 5microg/ml) for local anaesthesia.
~Localization will be confirmed with help of navigation before the medication will be given. Intravascular injection will be prevented by control of aspiration."
11287209|NCT02784249|Experimental|Goniotomy|Procedure: Goniotomy and trabecular excision in combination with planned cataract extraction via Phaco and PCIOL implant.
11287210|NCT02784249|Active Comparator|Trabecular Micro-Bypass Stent|Procedure: Device implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
11287211|NCT02784236|Other|pre-post evaluation|All patients undergo the condition of telemedicine.
11287212|NCT02784223|Experimental|PET-CT with F18-choline|PET-CT with F18-choline examination will be performed before surgery
11287213|NCT02784210|No Intervention|No Treatment|
11287214|NCT02784210|Experimental|Steroids 1|oral steroids
11287215|NCT02784210|Experimental|Steroids 2|intravenous steroids
11287216|NCT02784197|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
11287217|NCT02784184||1 year follow-up group|1 year follow-up group including 6 measurements
11287218|NCT02784184||40 days diaper study subgroup|"Subgroup of the 1 year follow-up group including 15 girls undergoing daily measurement of urinary hormone excretion"
11287219|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
11287220|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
11287221|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
11287222|NCT02784145|Other|RS|Resistant starch supplementation (5 g twice a day)
11287223|NCT02784145|Other|No RS|PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition)
11287224|NCT02784132|Other|Study Arm A|Right eye examined first with video diversion then left eye examined without video diversion
11287225|NCT02784132|Other|Study Arm B|Right eye examined first without video diversion then left eye examined with video diversion
11287226|NCT02784132|Other|Study Arm C|Left eye examined first with video diversion then right eye examined without video diversion
11287227|NCT02784132|Other|Study Arm D|Left eye examined first without video diversion then right eye examined with video diversion
11287228|NCT02784119|Experimental|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
11287229|NCT02784119|No Intervention|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
11287230|NCT02784106|Placebo Comparator|Placebo: Double-Blind Treatment Period|
11287231|NCT02784106|Experimental|M2951: Double-Blind Treatment Period|
11287232|NCT02784106|Experimental|Placebo/M2951: Open Label Extension Period|
11287233|NCT02784106|Experimental|M2951/M2951: Open Label Extension Period|
11287234|NCT02784093|Experimental|Exposure Group|Participants were allocated to receive 100 mL of Gastrograﬁn orally once daily for 6 consecutive days.
11287235|NCT02784093|Placebo Comparator|Control Group|Participants were allocated to receive enemas twice daily for 6 consecutive days.
11287236|NCT02784080||HLA-alloantibodies exposure|Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.
11287237|NCT02784067|Experimental|Treatment|Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
11287238|NCT02784067|Placebo Comparator|Placebo|Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
11287239|NCT02784054|Experimental|Intracranial NGGCT|"Six cycles of chemotherapy with carboplatin, etoposide, bleomycin (CEB) and cyclophosphamide, etoposide, bleomycin (CyEB) regimen.
~Peripheral blood stem cell collection during the first cycle of chemotherapy.
~Surgery, if there is residual tumor after chemotherapy.
~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation (auto-SCT)
~1st HDCT: Carboplatin, thiotepa, etoposide
~2nd HDCT: Cyclophosphamide, melphalan
~Reduced dose of radiotherapy"
11287240|NCT02784041|Experimental|single adductor-canal-block|Patients in this group will receive ultrasound guided single adductor-canal- block with 0.35% ropivacaine 25ml.
11287241|NCT02784041|Experimental|periarticular infiltration|patients in this group will receive periarticular infiltration of local anesthetic.
11287242|NCT02784028|Experimental|SGM-101|6 dose levels of SGM-101 (5mg/patient, 7.5mg/patient, 10 mg/patient, 12.5mg/patient , 15 mg/patient - 24 h prior surgery and 15 mg/patient - 48h prior surgery
11287243|NCT02784015|Experimental|Unresectable localized soft tissue sarcoma|"Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen.
~Surgery, if possible
~Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan)
~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy.
~1st HDCT: carboplatin, thiotepa, etoposide
~2nd HDCT: cyclophosphamide, melphalan"
11287244|NCT02784002|Experimental|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
11287245|NCT02784002|Active Comparator|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
11287417|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
11287419|NCT02782936|Experimental|Baseline|Randomised baseline without and with gas mask.
11287246|NCT02783989|Active Comparator|White wine|Two glasses of a market white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14 g in women). It is estimated that wine will contain about 8-9 mg/l of tyrosol. Therefore the dose of tyrosol ingested in two glasses would be 2-2.5 mg (1-1.25 mg in women).
11287247|NCT02783989|Experimental|White wine plus tyrosol capsules|Two glasses of white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14g in women), in combination with capsules of 25 mg of TYR (each one to be ingested with a glass of wine), two capsules along the day for men (at lunch and at dinner) and one for woman (at lunch).
11287248|NCT02783989|No Intervention|Water|Drinking water along with meals
11287249|NCT02783976||Sovaldi-based regimens|Adult patients with chronic HCV infection living in Mexico who take Sovaldi as part of routine clinical care at a participating clinical site.
11287250|NCT02783963|Other|MI with nonobstructive CAD at coronary angiography|MI with nonobstructive CAD investigated by means of OCT and CMR
11287251|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
11287252|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
11287253|NCT02783937|Active Comparator|Filgrastim arm|Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days
11287254|NCT02783937|Placebo Comparator|Placebo arm|Intervention: Injection of saline SC injection twice daily for five consecutive days.
11287255|NCT02783924|Active Comparator|Cholecalciferol|Vitamin d (as a 20.000 IU capsule) will be given i a dose of 40.000 IU per week for two months
11287256|NCT02783924|Placebo Comparator|Placebo|two capsules (identical looking to the vitamin D capsules) will be given per week for two months
11287257|NCT02783911|Experimental|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (< 1gm) will be placed on pulp orifice once for the life of the primary teeth
11287258|NCT02783911|Experimental|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
11287259|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
11287260|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
11287261|NCT02783872||Loss of control|30 overweight or obese (BMI≥85th %ile) youth endorsing loss of control eating within the past 3 months
11287262|NCT02783872||Overweight control|30 overweight or obese controls without any history of loss of control eating
11287263|NCT02783872||Normal-weight control|15 normal-weight controls without any history of loss of control eating
11287264|NCT02783859|Experimental|Active arm: Amoxicillin-clavulanic Acid|8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)
11287265|NCT02783859|Placebo Comparator|Placebo arm|8 days of oral placebo (equivalent volume as the active arm)
11287266|NCT02783846|Placebo Comparator|Group control|24 eligible patients are received equal volumes of saline intravenously for 10 minutes
11287267|NCT02783846|Active Comparator|Group dexmedetomidine 0.5 µg/kg|24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
11287268|NCT02783846|Active Comparator|Group dexmedetomidine 1.0 µg/kg|25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
11287269|NCT02783833|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
11287270|NCT02783833|Experimental|MMV390048 dose to be determined mg|MMV390048 dose to be determined mg, tablets, single dose
11287271|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
11287272|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
11287273|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
11287274|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
11287275|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
11287276|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
11287277|NCT02783807|Experimental|Eyenez Retinal Camera v200|Retinal images from Eyenez Retinal Camera v200 of healthy and diseased subjects
11287278|NCT02783807|Active Comparator|Volk Pictor Ret 1|Retinal images from Volk Pictor Ret 1 of healthy and diseased subjects
11287279|NCT02783794|Experimental|BP-C1|Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
11287280|NCT02783794|Placebo Comparator|Placebo|Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
11287281|NCT02783781||Cardiac surgery|All patients (planned and urgent) needed cardiac surgery, and agreed to participate
11287490|NCT02782455|Experimental|CDobi|Calcium dobesylate is given in this group
11287282|NCT02783768|Experimental|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
11287283|NCT02783768|Experimental|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
11287284|NCT02783755|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
11287285|NCT02783742|Experimental|Intervention|Providers in this arm will receive a communication coaching intervention immediately post-randomization.
11287286|NCT02783742|Other|Waitlist Control|Providers assigned to this arm will be offered the option of receiving the communication coaching intervention after follow up data collection is complete.
11287287|NCT02783729|Experimental|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
11287288|NCT02783729|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
11287289|NCT02783729|Active Comparator|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
11287290|NCT02783729|Placebo Comparator|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
11287291|NCT02783716|Active Comparator|Cardiac Resynchronization Therapy (CRT)|Participants will be undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure
11287292|NCT02783716|Active Comparator|Control Group|Participants will undergo device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block.
11287293|NCT02783703|Experimental|MCT|Medium chain triglyceride (MCT) oil ingested daily for 6 weeks
11287294|NCT02783690|No Intervention|Conventional Fractionation|50.0 Gy (RBE) in 25 daily fractions
11287295|NCT02783690|Experimental|Hypofractionation|40 Gy (RBE) in 15 daily fractions
11287296|NCT02783677||DM with PAD before angioplasty|Diabetic patients diagnosed with peripheral artery disease via vascular Duplex.
11287297|NCT02783677||DM without PAD|Diabetic patients diagnosed without peripheral artery disease via vascular Duplex.
11287298|NCT02783677||Healthy volunteers|Healthy volunteers
11287299|NCT02783677||DM with PAD after angioplasty|Diabetic patients diagnosed with PAD underwent balloon-angioplasty
11287300|NCT02783664||Questionnaires to Evaluate Patient Stress Levels|
11287301|NCT02783651||No treatment 1|It is planned to have 20-30 sites participating on the trial for chart review of approximately 200-235 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
11287302|NCT02783651||No Treatment 2|Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
11287303|NCT02783638|Experimental|YHD1119 (Pregabalin 300mg)|YHD1119 (Pregabalin 300mg)
11287304|NCT02783638|Active Comparator|Lyrica (Pregabalin 150mg)|Lyrica (Pregabalin 150mg)
11287305|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
11287306|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
11287307|NCT02783612|Experimental|glucose application|Regular high risk pregnancy clinic surveillance in addition to a Smart phone application for registering the Blood glucose levels and submitting via email every 3-5 days to the High risk Doctor involved in the trial.
11287308|NCT02783612|No Intervention|Regular monitoring|Regular high risk pregnancy clinic surveillance
11287309|NCT02783599|Experimental|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle).
~Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle).
~Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles)."
11287310|NCT02783599|Experimental|Olaratumab + Radiotherapy Addendum|"Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy.
~Radiotherapy addendum was not implemented."
11287311|NCT02783586|Experimental|Quadratus Lumborum Block type II|Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
11287312|NCT02783586|Active Comparator|Transversus Abdominalis Plane Block|Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle
11287313|NCT02783573|Experimental|Lanabecestat 20 milligrams (mg)|Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
11287314|NCT02783573|Experimental|Lanabecestat 50 mg|Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156.
11287315|NCT02783573|Experimental|Placebo/ Lanabecestat 20 mg|Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156.
11287316|NCT02783573|Experimental|Placebo/ Lanabecestat 50 mg|Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156.
11287317|NCT02783560|Experimental|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
11287491|NCT02782455|Active Comparator|Flavono|Flavonoids are given in this group
11287318|NCT02783560|Active Comparator|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
11287319|NCT02783547|Experimental|SyB C-1101 and Azacytidine|
11287320|NCT02783534|Experimental|Verum acupuncture|Participants will receive verum acupuncture plus usual care. Participants will receive acupuncture treatment start from the 5th or 7th day before the estimated first day of menstrual cycle, and for each cycle, participants will receive one session of treatment each day for 5 consecutive days, totally be treated with 15 sessions.Verum needles will be inserted into the skin and manipulated manually until deqi occurs. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and manipulates the needles to maintain the intensity of deqi. Participants will receive the same usual care as those in the usual care group.
11287321|NCT02783534|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.
11287322|NCT02783534|Placebo Comparator|Usual care|Participants will not receive acupuncture treatment besides health education as a control group.
11287323|NCT02783521|Experimental|Intervention|Includes changing eating behaviors, increasing physical activity, and attending regular in-person weight loss meetings for 12 weeks. To support additional weight loss/weight maintenance, participants will receive bi-weekly phone calls across a 12 week follow-up.
11287324|NCT02783521|Other|Wait List Control|Wait-list control participants will not receive any intervention for the first 12 weeks. After 12 weeks, participants will receive the weight loss intervention plus mHealth technology support.
11287325|NCT02783508|Active Comparator|IV Meperidine|Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.
11287326|NCT02783508|Active Comparator|Inhaled Nitrous Oxide|Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.
11287327|NCT02783495|Experimental|Device: iPad|Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
11287328|NCT02783482|Experimental|GC5107|GC5107 Immune globulin intravenous (human) solution, 10% liquid
11287329|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
11287330|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
11287331|NCT02783456|Active Comparator|Noise and silence|Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.
11287332|NCT02783456|Active Comparator|silence and noise|Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes
11287333|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
11287334|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
11287335|NCT02783430|Experimental|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
11287336|NCT02783430|Active Comparator|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
11287337|NCT02783417|Experimental|Training with vascular occlusion|Strength Training: intensity of 30% of 1RM, with vascular occlusion pressure in members.
11287338|NCT02783417|Experimental|Traditional strength training|Strength Training: intensity of 80% of 1RM, without vascular occlusion pressure in members
11287339|NCT02783417|No Intervention|Control|Subject untrained.
11287340|NCT02783404|No Intervention|Control|Receiving no prophylaxis
11287341|NCT02783404|Active Comparator|Amoxicillin|"Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation
~Intervention: Drug: Amoxicillin"
11287342|NCT02783404|Experimental|Amoxicillin-Potassium Clavulanate|"Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation
~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
11287343|NCT02783391|Experimental|BRAINSPEAK|Electrocorticographical (ECoG) and intracortical electrodes
11287344|NCT02783378|Other|Gaviscon syrup|"Gaviscon will be given to threat patients with reflux after first 24 hours of oesophagal pH-monitoring.
~This is a syrup and will be given after every meal. dosage depends from age between 1ml and 5ml after every meal"
11287345|NCT02783365|Experimental|Intervention|The intervention uses photo-elicitation and online group support (via Facebook) to improve patients' overall experience of chronic pain and patient-identified areas of function. This intervention was informed by the Photovoice methodology developed by Wang and Burris (1994). Photovoice participants will utilize cameras that enable them to record issues related to their experiences, and subsequently display them in office visits with their physician or mid-level clinician.
11287346|NCT02783365|No Intervention|Control|Patients in the control practices will receive usual care and will be eligible to participate in the intervention after their participation in the study is completed at 12 months.
11287347|NCT02783352|Experimental|treatment group|arthroscopic rotator cuff repair + injection of autologous micro-fragmented adipose tissue (10 mL)
11287348|NCT02783352|Other|control group|arthroscopic rotator cuff repair only
11287994|NCT02779140|Experimental|0.165 mg/kg NTM-1632|N=6 administered 0.165 mg/kg NTM-1632 IV, N=2 administered placebo IV
11287349|NCT02783326|Experimental|COPD Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
11287350|NCT02783326|Active Comparator|Control Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
11287351|NCT02783313|Experimental|PR-plasma-PCs|Pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)
11287352|NCT02783313|Active Comparator|Plasma-PCs|Pooled buffy coat-derived plasma-stored platelet concentrates (plasma-PCs)
11287353|NCT02783300|Experimental|Part 1a: Dose Escalation|In Part 1, participants will receive GSK3326595 12.5 milligram (mg) once daily (QD) and escalate until the maximum tolerated dose (MTD) is reached. Projected daily dose levels are 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg. BID dosing may divide this total daily dose into two equal doses, administered twice daily. Additional doses (either lower than 12.5 mg, higher than 1200 mg, or intermediate doses between those listed above) and schedules may be explored based on emerging safety, PK and PD data. Further enrollment to this cohort is closed.
11287354|NCT02783300|Experimental|Part 2a: Disease-Specific TNBC|This part 2 expansion cohort will enroll participants with triple-negative breast cancer (TNBC). The dose of GSK3326595 will be 400 mg QD. Further enrollment to this cohort is closed.
11287355|NCT02783300|Experimental|Part 2b: Disease-Specific MTCC|This part 2 expansion cohort will enroll participants with metastatic transitional cell carcinoma (MTCC) of the urinary system. The dose of GSK3326595 will be 400 mg QD. Further enrollment to this cohort is closed.
11287356|NCT02783300|Experimental|Part 2c: Disease-Specific recurrent GBM|This part 2 expansion cohort will enroll participants with recurrent glioblastoma multiforme (GBM). The dose of GSK3326595 will be 400 mg QD. Further enrollment to this cohort is closed.
11287357|NCT02783300|Experimental|Part 2d: Disease-Specific NHL p53 mutant|This part 2 expansion cohort will enroll participants with NHL p53 mutant gene. The dose of GSK3326595 was started at 400 mg QD but going forward participants will receive 300 mg QD.
11287358|NCT02783300|Experimental|Part 2e: Disease-Specific NHL p53 wildtype|This part 2 expansion cohort will enroll participants with NHL p53 wild-type gene. The dose of GSK3326595 was started at 400 mg QD but going forward participants will receive 300 mg QD.
11287359|NCT02783300|Experimental|Part 2f: Disease-specific ACC (GSK3326595 capsule)|This part 2 expansion cohort will enroll participants with adenoid cystic carcinoma (ACC) and will receive GSK3326595 capsules. The dose of GSK3326595 will be 400 mg QD. Further enrollment to this cohort is closed.
11287360|NCT02783300|Experimental|Part 2g: Disease-specific ACC (GSK3326595 tablet)|This part 2 expansion cohort will enroll participants with ACC who have not received any systemic therapy for locally advanced or metastatic disease and will receive GSK3326595 tablets. The dose of GSK3326595 will be 300 mg QD.
11287361|NCT02783300|Experimental|Part 2h: Disease specific ER+BC|This part 2 expansion cohort will enroll participants with hormone receptor-positive adenocarcinoma of the breast (ER+BC). The dose of GSK3326595 will be 400 mg QD. Further enrollment to this cohort is closed.
11287362|NCT02783300|Experimental|Part 2i: Disease-specific HPV|This part 2 expansion cohort will enroll participants with human papillomavirus (HPV) positive solid tumors of any histology (including cervical cancer and squamous cell carcinoma of the head and neck [HNSCC]). The dose of GSK3326595 will be 400 mg QD. Further enrollment to this cohort is closed.
11287363|NCT02783300|Experimental|Part 2j: Disease specific p53 wild-type NSCLC|This part 2 expansion cohort will enroll participants with P53 wild-type non small-cell lung cancer (NSCLC) and will receive GSK3326595. The dose of GSK3326595 will be 300 mg QD.
11287364|NCT02783300|Experimental|Part 3: Dose Determination at 100 mg|The participants with NSCLC, melanoma, mTCC, or HNSCC will receive pembrolizumab at the approved dose (200 mg intravenous [IV] every 3 weeks), in combination with GSK3326595 dosed orally at 100 mg QD.
11287365|NCT02783300|Experimental|Part 3: Dose Determination at 200 mg|The participants with NSCLC, melanoma, mTCC, or HNSCC will receive pembrolizumab at the approved dose (200 mg IV every 3 weeks), in combination with GSK3326595 dosed orally at 200 mg QD.
11287366|NCT02783300|Experimental|Part 3: Dose Determination at 300 mg|The participants with NSCLC, melanoma, mTCC, or HNSCC will receive pembrolizumab at the approved dose (200 mg IV every 3 weeks), in combination with GSK3326595 dosed orally at 300 mg QD.
11287367|NCT02783300|Experimental|Part 1b: Food Effect and Relative Bioavailability|Part 1 will include a sub-study that will be an open-label, randomized, single dose, three period, cross over study to investigate the effect of a high-fat, high-calorie meal on the bioavailability of GSK3326595, and compare two formulations of GSK3326595 (capsule versus tablet). The dose of GSK3326595 will be 300 mg QD.
11287368|NCT02783287|Experimental|Medication text message|Once daily text message reminder.
11287369|NCT02783287|Experimental|Exercise text message|4x daily text message reminder.
11287370|NCT02783287|No Intervention|Usual care, medication adherence|Usual care for medication adherence.
11287371|NCT02783287|No Intervention|Usual care, exercise regimen|Usual care for exercise regimen.
11287372|NCT02783274|Other|Actis Total Hip System|The Actis DuoFix Femoral Stem can be used for both a Total and Hemi-hip Replacement
11287373|NCT02783261||Post Y90 hypertrophy measurement|All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
11287374|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.
~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.
~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.
~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.
~Patients in the study will receive an annual monitoring as recommended, independently of the study."
11287418|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
11287375|NCT02783235|Other|cervical cancer|cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
11287376|NCT02783222|Active Comparator|Arm B|Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks
11287377|NCT02783222|Experimental|Arm A|Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
11287378|NCT02783209|Other|Cataract surgery|Patient acts as his own control
11287379|NCT02783196|Experimental|Liraglutide (LIR)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with Liraglutide ( IR) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with placebo (PLA)
11287380|NCT02783196|Placebo Comparator|Placebo (PLA)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with placebo ( PLA) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with Liraglutide ( LIR)
11287381|NCT02783183|Experimental|YHD1119|Pregabalin 300mg
11287382|NCT02783183|Active Comparator|Lyrica|Pregabalin 150mg
11287383|NCT02783170|Other|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
11287384|NCT02783170|Other|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
11287385|NCT02783157|Experimental|Transcutaneous low-level vagal nerve stimulation (LLVNS)|n=100 patients will be randomized to transcutaneous low-level vagal nerve stimulation (LLVNS), via a clip applied to the ear. Stimulation will be delivered throughout the procedure.
11287386|NCT02783157|Sham Comparator|Sham LLVNS|n=100 patients will be randomized to sham LLVNS, with the clip applied but no stimulation delivered.
11287387|NCT02783144|Experimental|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, 4 mg of Dexamethasone are added to 20 ml of 0,375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
11287388|NCT02783144|Placebo Comparator|TAP Block and Saline|After general anesthesia and before the beginning of surgery, 2 ml of saline are added to 20 ml of 0.375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
11287389|NCT02783144|Active Comparator|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, 20 ml of 0,375% Levobupivacaine are used in Ultrasound-guided Tranversus Abdominis Plain Block. In this group 4 mg of dexamethasone are injected intravenously.
11287390|NCT02783131|Experimental|MedNav|Team getting taught to use mednav, and using mednav in simulation managing Post partum Haemorrhage.
11287391|NCT02783131|No Intervention|non MedNav|Team undergoing routine simulation training in Post Partum Haemorrhage.
11287392|NCT02783118|Experimental|Healthy sample, active intervention|Healthy participants will be testing a depression prevention app employing a self administered online CBT intervention, for 4 weeks.
11287393|NCT02783118|No Intervention|Healthy sample, delayed intervention|Healthy participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
11287394|NCT02783118|Experimental|Mild depression, active intervention|Mildly depressed participants will be testing a depression prevention app, employing a self administered online CBT intervention, for 4 weeks.
11287395|NCT02783118|No Intervention|Mild depression, delayed intervention|Mildly depressed participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
11287396|NCT02783105|Experimental|Musical intervention|"Music is provided through headphones: Two 30-min musical sessions per day (one in the morning and one in the evening) beginning at the onset of desedation (Day 0) until day 21.
~Both have inverted U shape."
11287397|NCT02783105|Sham Comparator|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
11287398|NCT02783092|Experimental|Cannabidiol|Concentration unit: 200mg/ml; 5 - 25 mg/Kg/day ; Oral solution
11287399|NCT02783092|Placebo Comparator|Placebo|Oral solution
11287400|NCT02783079|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT)
11287401|NCT02783079|Active Comparator|Arm 2|Mindfulness Based Stress Reduction (MBSR)
11287402|NCT02783066|Experimental|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
11287403|NCT02783053|Other|Metformin use|The investigators compare the use of metformin vs no metformin
11287404|NCT02783053|No Intervention|Lean or Obese|The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
11287405|NCT02783040|Experimental|single dose cocktail (Midazolam, Warfarin, Omeprazole)|
11287406|NCT02783040|Experimental|single dose Midazolam|
11287407|NCT02783040|Experimental|single dose Digoxin|
11287408|NCT02783040|Experimental|multiple dose BI 425809|
11287409|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
11287410|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
11287411|NCT02782988||CMV symptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
11287412|NCT02782988||CMV asymptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
11287413|NCT02782988||Healthy controls|olfactory tests, otoacoustic emissions (OAE)
11287414|NCT02782975|Experimental|aducanumab IV|Infusion of aducanumab over approximately 1 hour
11287415|NCT02782975|Experimental|aducanumab SC|Subcutaneously via injection
11287416|NCT02782962||Cohort|Patients with acute vertigo/unsteadiness
11304574|NCT02669069|Active Comparator|PS2|
11287420|NCT02782936|Experimental|Induced Hypoxemia|Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
11287421|NCT02782936|Experimental|Effort|Randomised effort without and with gas mask
11287422|NCT02782923|Experimental|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
11287423|NCT02782923|Experimental|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
11287424|NCT02782923|Experimental|CDR with STISIM|Cervical disc replacement
11287425|NCT02782923|Experimental|PCLF with STISIM|Posterior laminectomy and fusion
11287426|NCT02782923|Experimental|PCD with STISIM|Posterior cervical decompression procedure
11287427|NCT02782923|Sham Comparator|Control Group with STISIM|
11287428|NCT02782910|Experimental|SBAA+|Upon exceeding pre defined SBAA-threshold limits during the randomisation phase the treating physician is alerted (+) to this signal and required to contact the patient so as to assess the current mental status and collaboratively discuss the potential need for medical/psychiatric treatment with the patient.
11287429|NCT02782910|No Intervention|SBAA|Continuous monitoring will occur analogous to SBAA+. Exceeding the pre defined SBAA-threshold will not result in any action taken.
11287430|NCT02782897|Experimental|IVIg group|Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.
11287431|NCT02782897|Other|Control group|Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.
11287432|NCT02782884||Outpatient general surgery operation|Patients undergoing outpatient general surgical operations They will be given a specified number of narcotic pills based on our retrospective analysis of patient post-operative opioid use
11287433|NCT02782884||Inpatient general surgical patients|Inpatients who are being discharged They will be given a specified number of narcotic pills based on the number of pills they took in the 24 hrs prior to discharge
11287434|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
11287435|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
11287436|NCT02782858|Experimental|Dose 1 GNbAC1|Monthly IV repeated dose
11287437|NCT02782858|Experimental|Dose 2 GNbAC1|Monthly IV repeated dose
11287438|NCT02782858|Experimental|Dose 3 GNbAC1|Monthly IV repeated dose
11287439|NCT02782858|Placebo Comparator|Placebo|Monthly IV repeated dose
11287440|NCT02782845|Experimental|Pegfilgrastim|Participants will receive CT or ICT for 6 cycles on Days 1-6, as per standard of care. Protocol does not specify any choice of CT or ICT drugs. Participants will receive pegfilgrastim at a fixed dose of 6 mg subcutaneously, 24 hours after the last dose of CT or ICT in each treatment cycle. CT or ICT cycles of 21 days, as per standard of care.
11287441|NCT02782819|Placebo Comparator|Crystalloid|Isotonic crystalloid solution resuscitation
11287442|NCT02782819|Active Comparator|Crystalloid plus Colloid|Colloid solution resuscitation
11287443|NCT02782806|Experimental|Test group|All subjects are enrolled into the test group and receive Masimo Rad-67 Pulse Oximeter for measurement of hemoglobin.
11287444|NCT02782793||Patient's with complex colon polyps|
11287445|NCT02782780|Experimental|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
11287446|NCT02782780|No Intervention|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
11287447|NCT02782767|Active Comparator|Epidural catheter infusion|epidural catheter in the thoracic vertebra level to provide local anesthetic infusion
11287448|NCT02782767|Experimental|Wound catheter infusion|A multiorificed wound infusion catheter kept within the incision site to provide continuous local anesthetic infusion
11287449|NCT02782754|Experimental|Intracranial germinoma|"Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen
~Reduced dose of radiotherapy
~Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site
~With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site"
11287450|NCT02782741|Experimental|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
11287451|NCT02782741|Active Comparator|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
11287452|NCT02782728|Active Comparator|TIPS-Basic|Providers receive tailored scripts based on the patient's responses to the questions administered via tablet.
11287453|NCT02782728|Experimental|TIPS-Plus|Patients receive tailored messages in addition to the scripts given to providers.
11287454|NCT02782715|Experimental|Radiotherapy & Microwave Ablation|"3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:
~Dose level I: 6 Gy x 5 fractions
~Dose level II: 8 Gy x 5 fractions
~Dose level III: 10 Gy x 5 fractions
~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.
~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.
~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration)."
11287455|NCT02782702|Experimental|Botulism Toxin treatment|Injection of 50 UI Botulism toxin for the treated zone
11287456|NCT02782689|Experimental|Kit Biflex|The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
11287457|NCT02782689|Active Comparator|Profore|The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.
11287458|NCT02782676|Experimental|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
11288105|NCT02778477|Experimental|Part A_Cohort 4_Active|Multiple ascending dose of PF-06423264
11287459|NCT02782676|Active Comparator|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
11287460|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
11287461|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose B|Open label dose B QD
11287462|NCT02782650||Survey and interviews|"* part one * (quantitative)
~Survey on:
~A) prenatal counseling at the limits of viability, both current and preferred, within three domains of interest:
~organization of prenatal counseling
~content of prenatal counseling
~decision-making in prenatal counseling
~B) treatment options at the limits of viability against the background of the Dutch guideline
~* part two * (qualitative)
~Focus groups interviews (qualitative) to in-depth explore preferences in prenatal counseling
~insight in the specific preferred content of prenatal counseling.
~study influencing factors on preferences in the domains of organization and decision-making."
11287463|NCT02782637||Survey and interviews|"*part one* (quantitative)
~Survey on:
~A. prenatal counseling at the limits of viability, within three domains of interest:
~organization of prenatal counseling
~content of prenatal counseling
~decision-making in prenatal counseling Domains used to evaluate current counseling and counseling preferences
~B. decision-making at the limits of viability: evaluation of the made decision (decisional conflict and regret)
~*part two* (qualitative)
~Individual interviews (qualitative) to in-depth explore preferences in prenatal counseling
~insight in the specific preferred content of prenatal counseling.
~study influencing factors on preferences in the domains of organization and decision-making."
11287464|NCT02782624|Experimental|Treatment A: Empagliflozin|5 mg bid
11287465|NCT02782624|Experimental|Treatment B: Empagliflozin|10 mg qd
11287466|NCT02782611|Experimental|Treatment|ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
11287467|NCT02782611|No Intervention|Waiting Group Control|The waiting group control will complete the same assessments as the experimental group but without receiving the intervention.
11287468|NCT02782598|Experimental|CRT+NAVH|Surface ECG and pressure-volume loop recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings at the device implant procedure
11287469|NCT02782585|Experimental|Experimental group 1|Cervical Manipulation
11287470|NCT02782585|Experimental|Experimental group 2|Cervical lateral glide
11287471|NCT02782585|Placebo Comparator|Control group|Cervical Mobilisation
11287472|NCT02782572|Experimental|Exercise with Non-invasive ventilation|Patients with acute haert failure who performed aerobic exercise with non-invasive ventilation. This group also received conventional medical treatment.
11287473|NCT02782572|Sham Comparator|Exercise|Patients with acute haert failure who performed aerobic exercise with placebo of non-invasive ventilation. This group also received conventional medical treatment.
11287474|NCT02782572|Other|Control|Patients who receiveid only conventional medical treatment and not performed exercise during protocol.
11287475|NCT02782559|Experimental|Sildenafil|Sildenafil 40mg oral tablet three times a day from randomization until delivery
11287476|NCT02782559|Placebo Comparator|Placebo|Matched to oral capsule of active treatment three times a day from randomization until delivery
11287477|NCT02782546|Experimental|Recipient|"Standard of care reduced intensity preparative regimen consisting of fludarabine, cyclophosphamide, and single dose total body irradiation (TBI) on Day -1
~Graft cell infusion on Day 0
~Post-transplant cyclophosphamide on Days +3 and +4
~GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD
~G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines
~The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.
~ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses"
11287478|NCT02782546|Experimental|Donor|"Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.
~Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.
~On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
11287479|NCT02782533|Experimental|DBS V3|Deep Brain Stimulation V3
11287480|NCT02782520|Active Comparator|Ringer Lactate|Ringer Lactate group
11287481|NCT02782520|Experimental|Hypertonic saline|Hypertonic saline group
11287482|NCT02782494||Dialysis group|Patient receiving long term dialysis
11287483|NCT02782481|Experimental|ND0612 High dose (Levodopa/Carbidopa solution)|High dose ND0612 SC infusion over 24 h
11287484|NCT02782481|Experimental|ND0612 Low dose (Levodopa/Carbidopa solution)|Low dose ND0612 SC infusion over 24 h
11287485|NCT02782481|Placebo Comparator|Placebo|Placebo SC infusion over 24 h
11287486|NCT02782468|Experimental|Arm 1, Cohort 1: Pevonedistat 25 mg/m^2|Pevonedistat, 25 milligram per square meter (mg/m^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
11287487|NCT02782468|Experimental|Arm 1, Cohort 2: Pevonedistat 44 mg/m^2|Pevonedistat, 44 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
11287488|NCT02782468|Experimental|Arm 2, Cohort 1: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 10 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
11287489|NCT02782468|Experimental|Arm 2, Cohort 2: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
11287492|NCT02782442|Experimental|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
11287493|NCT02782442|Active Comparator|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
11287494|NCT02782429|Experimental|Ketamine|This group received ketamine in a dose 0.5 mg / in anesthesia, in addition to other drugs used for induction, which will be standardized.
11287495|NCT02782429|Placebo Comparator|Placebo|This group received the equivalent volume of saline, in addition to other drugs used for induction, which will be standardized.
11287496|NCT02782416|No Intervention|Waiting for renal transplant_no screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination but no LTBI check
11287497|NCT02782416|Placebo Comparator|Not waiting for renal transplant|Dialysis patients who are not waiting for renal transplant
11287498|NCT02782416|Other|Status post renal transplant|patients who have received renal transplant
11287499|NCT02782416|Experimental|Waiting for renal transplant_ screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination in addition to LTBI check
11287500|NCT02782403|Experimental|Treatment (alternating therapy)|Patients with chronic phase CML receive either bosutinib PO QD or axitinib PO BID alone for 3 months. Patients then switch to the other drug for 3 months and alternate between the two every 3 months in the absence of disease progression or unacceptable toxicity.
11287501|NCT02782403|Experimental|Treatment (combined therapy)|Patients with accelerated or blastic phase CML receive bosutinib PO QD and axitinib PO BID for 3 months. Courses repeat every 3 months in the absence of disease progression or unacceptable toxicity.
11287502|NCT02782390|Experimental|Hall Technique|single placement of stainless dental crowns on atypical cavities
11287503|NCT02782390|Active Comparator|Composite Resin|single placement of composite resin on atypical cavities
11287504|NCT02782377||Pelvic Floor Dysfunction|Observational study where patients with pelvic floor dysfunction undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed
11287505|NCT02782364||Faecal Incontinence|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 16 patients will undergo fast-fill measurement first and another 16 patients will have step-wise measurement first
11287506|NCT02782351|Experimental|CAR-T|In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.
11287507|NCT02782325|Active Comparator|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
11287508|NCT02782325|Placebo Comparator|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
11287509|NCT02782312|Experimental|ICS+LABA Group|Seretide 250，inhalation，twice daily，one year
11287510|NCT02782312|Active Comparator|Control Group|routine therapy for one year
11287511|NCT02782299|No Intervention|Control|This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
11287512|NCT02782299|Experimental|Decision Aid|This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.
11287513|NCT02782286|Active Comparator|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
11287514|NCT02782286|Active Comparator|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
11287515|NCT02782273|Active Comparator|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
11287516|NCT02782273|Active Comparator|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
11287517|NCT02782260|Experimental|Active|"Dipyridamole eye drops 8.48 mg in 100ml
~1 drop three times a day for 1 year"
11287518|NCT02782260|Placebo Comparator|Placebo|"Fluorescein in Active Vehicle
~1 drop three times a day for 1 year"
11287519|NCT02782247||Short term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who are planning to start antiviral therapy will be enrolled. Patients will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
11287520|NCT02782247||Medium term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who have been successfully treated in the past 3 or 5 years (+/- 3 months). Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
11287521|NCT02782247||Hepatitis B Patients|60 patients with chronic hepatitis B and cirrhosis will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients who have started treatment past 3 or 5 years (+/- 3 months) will also be tested. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
11287522|NCT02782234|No Intervention|not contract management|monthly follow-up phone or family visit completed as regulation, and instruct them proper healthy training.
11287559|NCT02781909|Experimental|Ibuprofen-treated|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines plus ibuprofen (400mg/day/2 months); n=12
11287523|NCT02782234|Experimental|Contract management|In accordance with the contract content, researchers and participants should manage and maintain the liquid balance of the participants. Signed doctors and nurses should undergo the follow-up phone or family visit on time, instruct them proper healthy training, and provided necessary information data. By telephone, SMS, wechat, remind and urge the participants to take the lifestyle and behavior regulate in the contract. Participants should supervise and manage the fluid unbalance (Edema, hypertension, heart failure, and fluid imbalance of intake and output etc.), and feedback the Management and supervision to researchers according to contract.
11287524|NCT02782221|Active Comparator|Growth hormone|Subjects are receiving growth hormone
11287525|NCT02782221|Placebo Comparator|Placebo|Subjects are receiving pegvisomant to block the action of growth hormone
11287526|NCT02782208|Active Comparator|Acipimox/GH substitution|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
11287527|NCT02782208|Active Comparator|Acipimox/GH pause|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
11287528|NCT02782208|Placebo Comparator|Placebo/GH substitution|Drug: Placebo tablets Continue GH substitution as usually.
11287529|NCT02782208|Placebo Comparator|Placebo/GH pause|Drug: Placebo tablets Pause GH substitution to days prior to the study day.
11287530|NCT02782182|Experimental|FOLFIRINOX+surgery|4 cycles of pre-operative FOLFIRINOX, followed by surgery, followed by 2 more cycles of FOLFIRINOX
11287531|NCT02782169|Active Comparator|Pregabalin|
11287532|NCT02782169|Placebo Comparator|Placebo|
11287533|NCT02782130|Active Comparator|Intervention Group|Subjects randomized to the Epic Allies Intervention will download and install the intervention branch of the Epic Allies app and receive a tour of the app guided by site staff. During the 26-week intervention phase, intervention arm subjects will receive daily adherence reminders set up through Epic Allies with tailored feedback for encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all features of Epic Allies and will receive supportive messages from other subjects on the intervention arm.
11287534|NCT02782130|Placebo Comparator|Control Group|Subjects randomized to the control arm will download and install the control branch of the Epic Allies app (phone-based notifications only) and be provided with instructions on using the app. During the 26-week intervention phase, the control arm subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
11287535|NCT02782117|Experimental|Treatment Regimen A|Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.
11287536|NCT02782104|Experimental|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
11287537|NCT02782091|Experimental|Schizophrenia Patient|
11287538|NCT02782091|Experimental|Control Subject|
11287539|NCT02782078|Other|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
11287540|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
11287541|NCT02782052|Experimental|Nebulized ipratropium bromide|Administration in a random order nebulized ipratropium bromide at V3 or V4 or V5
11287542|NCT02782052|Experimental|Nebulized combination ipratropium bromide with salbutamol|Administration in a random order combination Ipratropium bromide and Salbutamol at V3 or V4 or V5
11287543|NCT02782052|Placebo Comparator|Placebo|Administration in a random order placebo at V3 or V4 or V5
11287544|NCT02782026|Experimental|idiopathic PAH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
11287545|NCT02782026|Experimental|heritable PAH with BMPR2 mutation|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
11287546|NCT02782026|Experimental|chronic thromboembolic PH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
11287547|NCT02782026|Experimental|Controls|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
11287548|NCT02782000|Experimental|Long-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
11287549|NCT02782000|Active Comparator|Short-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 3 months.
11287550|NCT02781987||CP group|Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc..
11287551|NCT02781987||BD group|Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct.
11287552|NCT02781974|Experimental|Intervention|Intervention consists of strength and balance exercise in group sessions, twice a week for 12 weeks
11287553|NCT02781974|No Intervention|Control|"Participants allocated in the control group are instructed to live as usual"
11287554|NCT02781948||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
11287555|NCT02781948||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus
11287556|NCT02781922|Experimental|Autologous cardiac stem cells (JRM-001)|
11287557|NCT02781922|No Intervention|Usual care|
11287558|NCT02781909|Active Comparator|Control: Standard of Care TB treatment|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines; n=12
11287560|NCT02781896|Active Comparator|Right ventricular pacing|Rapid pacing during TAVI is provided by a temporary pacing catheter placed in the right ventricle. An additional venous vascular access is required.
11287561|NCT02781896|Experimental|Left ventricular pacing|Rapid pacing during TAVI is provided by the valve delivery guidewire inserted into the left ventricle using two alligator clamps. One clamp is attached directly to the skin at the femoral entry site, the other is attached to the body of the valve delivery guidewire. No additional venous vascular access is required.
11287562|NCT02781883|Experimental|Untreated AML|BP1001 in combination with Ventoclax plus decitabine
11287563|NCT02781883|Experimental|Refractory/Relapsed AML|BP1001 in combination with Ventoclax plus decitabine
11287564|NCT02781883|Experimental|Refractory/Relapsed AML (ventoclax-intolerant or resistant)|BP1001 + decitabine combination in patients who are resistant or intolerant of venetoclax-based treatment, or considered not optimal candidates for a venetoclax-based therapy.
11287565|NCT02781870|Other|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
11287566|NCT02781870|Experimental|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
11287567|NCT02781857||60 patients with lung cancer|"Group A: 30 patients with squamous cell carcinoma eligible for lung cancer surgery
~Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
11287568|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history and lung function testing.
11287569|NCT02781844|Experimental|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
11287570|NCT02781844|Experimental|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
11287571|NCT02781844|Experimental|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
11287572|NCT02781844|Experimental|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
11287573|NCT02781831|Active Comparator|Standard Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation program
11287574|NCT02781831|Experimental|Robot-assisted Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation as well as robot-assisted gait rehabilitation program
11287575|NCT02781818|Experimental|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
11287576|NCT02781818|Experimental|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
11287577|NCT02781818|Placebo Comparator|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
11287578|NCT02781805|Experimental|Alendronate|Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
11287579|NCT02781792|Experimental|Arm 1: Temozolomide morning|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).
~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
11287580|NCT02781792|Experimental|Arm 2: Temozolomide evening|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).
~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
11287581|NCT02781779|Active Comparator|Silverlon®|Subjects randomized to this arm will receive Silverlon® dressing postoperative.
11287582|NCT02781779|Active Comparator|AQUACEL® AG|Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.
11287583|NCT02781766|Other|One arm: patients with severe haemophilia A on prophylaxis|Patients with severe haemophilia A (FVIII < 1 IU/dl), currently on prophylactic therapy , having the same prophylaxis regimen in the last six months, aged between 2 (with a body weight ≥12.5 kg ) and 45 years , with adequate venous access, having patient's diary or equivalent regularly completed and able to give informed consent
11287584|NCT02781753|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.
11287585|NCT02781753|Active Comparator|Pegasys|Peginterferon 180 μg single dose S.C.
11287586|NCT02781740|Active Comparator|CPAP therapy|Continuation of the already established CPAP therapy.
11287587|NCT02781740|Sham Comparator|Sham CPAP therapy|Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
11287588|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
11287589|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
11287699|NCT02780999|Active Comparator|Control group|It is a thumb orthotic that does not include wrist joint neither metacarpophalangeal joint.
11287590|NCT02781714|Experimental|Two-way SMS|Pre-programmed SMS messages by partner track will be delivered twice weekly to participants in participants' preferred languages from enrollment to 6 months postpartum. They will include a question soliciting a response from the participant(s). Interactive SMS communication will be responded to and managed by the study nurse at each site. Content themes will include: general support/encouragement, postpartum visit reminders, postpartum pregnancy risk and benefits of birth spacing, postpartum contraceptive options and side effects, family planning misconceptions, and couple communication.
11287591|NCT02781714|No Intervention|Control|The control arm will receive standard education and counseling provided in antenatal care and in postnatal care.
11287592|NCT02781701|Experimental|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.
~Therefore, participants will work out about 20 minutes a day for 6 weeks."
11287593|NCT02781688|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks.
11287594|NCT02781675|Experimental|Western Diet|Dietary Intervention: 3 wks of a typical Western Diet
11287595|NCT02781675|Experimental|Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet
11287596|NCT02781675|Experimental|Modified Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet including full fat dairy products
11287597|NCT02781662|No Intervention|Control|No Intervention; Control Arm: Receives Written Medication Information
11287598|NCT02781662|Experimental|Intervention|Behavioral: Pharmacist Home-Visit
11287599|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
11287600|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
11287601|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
11287602|NCT02781636|Experimental|Chronic Tibial Implant Arm|StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
11287603|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
11287604|NCT02781610|Other|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
11287605|NCT02781610|Other|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
11287606|NCT02781610|Other|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
11287607|NCT02781610|Other|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
11287608|NCT02781597|Active Comparator|Tranexamic acid|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
11287609|NCT02781597|Placebo Comparator|Placebo|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
11287610|NCT02781584|Experimental|SEL (Cohort 1)|SEL (1 x 18 mg tablet) for 12 weeks
11287611|NCT02781584|Experimental|Firsocostat (Cohort 2)|"Firsocostat (2 x 10 mg capsules) for 12 weeks
~Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1."
11287612|NCT02781584|Experimental|Cilofexor (Cohort 3)|"Cilofexor (3 x 10 mg tablets) for 12 weeks
~Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2."
11287613|NCT02781584|Experimental|SEL+ Cilofexor(Cohort 4)|"SEL (1 x 18 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
~Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3."
11287614|NCT02781584|Experimental|SEL + Firsocostat(Cohort 5)|"SEL (1 x 18 mg tablet) + firsocostat (1 x 20 mg tablet) for 12 weeks
~Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4."
11287615|NCT02781584|Experimental|Firsocostat + Cilofexor(Cohort 6)|"Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
~Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5."
11287616|NCT02781584|Experimental|Firsocostat Cirrhotic (Cohort 7)|"Firsocostat (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)
~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
11287617|NCT02781584|Experimental|Cilofexor Cirrhotic (Cohort 8)|"Cilofexor (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)
~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
11287618|NCT02781584|Experimental|SEL + Firsocostat + Cilofexor (Cohort 9)|"SEL (1 x 18 mg tablet) + Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks
~Enrollment into Cohort 9 will begin upon completion of enrollment for Cohort 6."
11287619|NCT02781584|Experimental|Firsocostat + Fenofibrate 48 mg (Cohort 10)|Pre-treatment with fenofibrate 48 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 48 mg tablet) for 24 weeks
11287620|NCT02781584|Experimental|Firsocostat + Fenofibrate 145 mg (Cohort 11)|Pre-treatment with fenofibrate 145 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 145 mg tablet) for 24 weeks
11287621|NCT02781584|Experimental|Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)|Pre-treatment with Vascepa® (2 x 1 g tablet twice daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + Vascepa® (2 x 1 g tablet twice daily) for 6 weeks
11304575|NCT02669069|Active Comparator|PS3|
11287622|NCT02781584|Experimental|Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)|Pre-treatment with fenofibrate (1 x 145 mg tablet once daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + fenofibrate (1 x 145 mg tablet once daily) for 6 weeks
11287623|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
11287624|NCT02781558|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
11287625|NCT02781558|Experimental|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
11287626|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
11287627|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
11287628|NCT02781506|Experimental|Nivolumab and SABR|Nivolumab alone: IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.
11287629|NCT02781493|Experimental|Prucalopride group|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
11287630|NCT02781493|Placebo Comparator|Placebo group|2 mg Placebo plus 2 L Polyethylene Glycol regimen
11287631|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
11287632|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
11287633|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
11287634|NCT02781467|Experimental|Cyclophosphamide + Fludarabine + PNK-007 + rhIL-2|Fludarabine Day -6 to -2 and Cyclophosphamide Day -5 and -4. On Day 0 PNK-007 at 4 varying dose levels followed by Human recombinant Interleukin-2 (rhIL-2) every other day, Day 0 to Day 10.
11287635|NCT02781454|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
11287636|NCT02781454|Active Comparator|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
11287637|NCT02781454|Placebo Comparator|Placebo|Placebo, by mouth per day for 4 weeks.
11287638|NCT02781441|Active Comparator|Control group|Patients will receive only the education brochure of GFM
11287639|NCT02781441|Experimental|General QPL group|Patients will receive the brochure and the newly developed QPL (general version)
11287640|NCT02781441|Experimental|Targeted QPL group|Patients will receive the brochure and the newly developed QPL (general version)
11287641|NCT02781415|Experimental|Acupuncture|Traditional Acupuncture Session:Patients in this group will benefit from a 30 minutes acupuncture session made by an experimented physician.
11287642|NCT02781415|Active Comparator|Titrated Morphine|Morphine Titration:Patients will receive an intravenous titration of morphine by a qualified nurse.
11287643|NCT02781402|Experimental|4 weeks of Aerobic Training for normal BMI group|4 weeks of aerobic training on treadmill 3 times per week.
11287644|NCT02781402|Experimental|4 weeks of Aerobic Training for overweight BMI group|4 weeks of aerobic training on treadmill 3 times per week.
11287645|NCT02781376|Experimental|CHICA-OSA|Two clinics will be randomized to receive the advanced CHICA-OSA computer decision support system designed to support PCPs in evidence-based identification and management of pediatric OSA. This module includes a snoring identification component (received by the control group).
11287646|NCT02781376|Other|Control|Two clinics will be randomized to receive a control computer decision support system module that automates screening for snoring and alerts the PCP, but does not provide any additional guidance on evidence-based diagnosis or management.
11287647|NCT02781363|Other|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
11287648|NCT02781363|Other|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
11287649|NCT02781350|Placebo Comparator|High fat high carbohydrate (HFHC) meal|Subjects will consume a HFHC meal. HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
11287650|NCT02781350|Experimental|HFHC meal plus Fiber|HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). Subjects will also receive FiberOne Original cereal 14 grams (half cup) before and after the HFHC meal. 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
11287651|NCT02781324|Experimental|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
11287652|NCT02781324|Active Comparator|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
11287653|NCT02781311|Experimental|Setipiprant|Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
11287654|NCT02781311|Placebo Comparator|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
11287655|NCT02781311|Active Comparator|Finasteride|Finasteride 1 mg tablet, orally, once daily for 24 weeks.
11287656|NCT02781298|Experimental|New Infant Cereal|amount ingested according to pediatricians recommendations
11287657|NCT02781298|Active Comparator|Multicereals Infant Cereal|amount ingested according to pediatricians recommendations
11287658|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
11287659|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
11287660|NCT02781285||3group three|patients take no Chinese Medicine
11287661|NCT02781272||Women with a pelvic mass|Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
11287726|NCT02780791|Active Comparator|Transplantation into pelvic wall|Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
11287662|NCT02781259|Experimental|Selective Lymph Node Dissection|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.
11287663|NCT02781246|Active Comparator|saline (Group A)|perineural ropivacaine
11287664|NCT02781246|Active Comparator|0.5 mcg/kg dexmedetomidine (Group B)|(perineural ropivacaine plus 0.5 mcg/kg dexmedetomidine),
11287665|NCT02781246|Active Comparator|1 mcg/kg dexmedetomidine (Group C)|(perineural ropivacaine plus 1 mcg/kg dexmedetomidine)
11287666|NCT02781246|Active Comparator|1.5 mcg/kg dexmedetomidine (Group D)|(perineural ropivacaine plus 1.5mcg/kg dexmedetomidine)
11287667|NCT02781246|Active Comparator|2 mcg/kg dexmedetomidine (Group E)|(perineural ropivacaine plus 2 mcg/kg dexmedetomidine)
11287668|NCT02781233|Experimental|Training group|Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
11287669|NCT02781233|Placebo Comparator|Control group|Usual daily activities
11287670|NCT02781220||Qualifying participants|All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
11287671|NCT02781194|Experimental|forced-air warming blanket|Forced-air warming blanket via 3M™ Bair Hugger™.
11287672|NCT02781194|Experimental|warmed, humidified insufflation|Warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
11287673|NCT02781194|Experimental|forced-air warming blanket & warmed, humidified insufflation|Combination of forced-air warming blanket via 3M™ Bair Hugger™ and warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
11287674|NCT02781181|Other|CAS with CPD|CAS performed under neuroprotection
11287675|NCT02781181|Active Comparator|CAS without CPD|CAS without neuroprotection
11287676|NCT02781168|Experimental|Use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
11287677|NCT02781168|Active Comparator|No use of earmuffs|No use of earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
11287678|NCT02781155|Other|Self administration of moxibustion|Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
11287679|NCT02781142|Experimental|Motor imagery training|Persons with multiple sclerosis
11287680|NCT02781142|No Intervention|Control group|Persons with multiple sclerosis
11287681|NCT02781142|No Intervention|Healthy controls|Healthy participants
11287682|NCT02781129|Experimental|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
11287683|NCT02781103|Experimental|Guided imagery plus active tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
11287684|NCT02781103|Sham Comparator|Guided imagery plus Sham tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
11287685|NCT02781090|Experimental|Positively Smoke Free on the Web+|Subjects will be assigned to the PSFW+ website and social network. They will also be offered a three-month supply of nicotine patches.
11287686|NCT02781090|Placebo Comparator|American Heart Assoc Getting Healthy|Subjects will be assigned to the AHA Getting Healthy website. They will also be offered a three-month supply of nicotine patches.
11287687|NCT02781064|Active Comparator|Atorvastatin 20mg|Atorvastatin to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
11287688|NCT02781064|Placebo Comparator|Placebo - Microcrystalline Cellulose|Placebo to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
11287689|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
11287690|NCT02781038|Experimental|Interventional|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given a teaching intervention and receive another attitude survey.
11287691|NCT02781038|Other|Control|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will receive another attitude survey.
11287692|NCT02781025||Oligometastatic Disease|Patients with oligometastatic cancer, defined as biopsy proven disease involving at least one organ other than the primary tumor organ. Regional lymph node metastases are not considered metastatic.
11287693|NCT02781012||Healthy|Healthy volunteers without any known pancreatic disease
11287694|NCT02781012||Healthy At-Risk|Healthy volunteers with no known benign or malignant pancreatic disease, AND with one first-degree relative with pancreatic cancer, OR two second-degree relatives with pancreatic cancer. These subjects also include those who have undergone surgery for suspected pancreatic cancer, and who are found to have a non-pancreatic cancer pathology upon final local site or central pathology review.
11287695|NCT02781012||Pancreatitis|Subjects diagnosed with acute or chronic pancreatitis
11287696|NCT02781012||Early Stage/Borderline/Locally Advanced|Subjects diagnosed with early stage pancreatic cancer who undergo surgery as standard of care therapy with or without preoperative (neoadjuvant) chemotherapy and/or radiation therapy; subjects diagnosed with borderline pancreatic cancer, or subjects diagnosed with locally advanced pancreatic cancer.
11287697|NCT02781012||Metastatic|Subjects diagnosed with metastatic pancreatic cancer and treated with any standard of care therapy/therapies.
11287698|NCT02780999|Experimental|Experimental group|It is a thumb orthotic that does not include wrist joint but includes the metacarpophalangeal joint.
11292454|NCT02749825|Experimental|Trelstar|Per prescribing information
11287700|NCT02780986|Active Comparator|Female entertainment worker intervention group|The intervention program for the female EE workers aims to increase STI/HIV prevention knowledge and develop their condom negotiation and application skills so as to increase condom use with both casual and paid partners. It consists of a total of 4 sessions: 2 on-site and 2 online sessions. For each on-site session, groups of 4 to 5 female EE workers will be gathered. The 2 on-site sessions would be delivered by peer educators. The 2 online sessions would be conducted via phone and other modes of network communication (e.g. SMS message or WhatsApp message) depending on the preference of each participant. In addition, all the intervention materials and video demonstrations will also be uploaded onto the web portal for the participant to access during their free time.
11287701|NCT02780986|No Intervention|Female entertainment worker control group|"The female EE workers in the control group will receive the same number of 2 onsite and 2 online sessions but covering healthy eating and physical activity.
~The following gives a summarised breakdown and content of each session:
~Session 1 (on-site immediately after baseline survey, 10 minutes):
~The peer educator will share information on healthy eating and physical activity using the educational pamphlets from the Health Promotion Board (HPB) with the participants.
~Session 2 (online 1-2 weeks after baseline survey, 5 minutes):
~The peer educator will share an app on healthy eating with the participants.
~Session 3 (online 3-4 weeks after baseline survey, 5 minutes):
~The peer educator will share an app on physical activity with the participants.
~Session 4 (onsite during follow-up survey, 10 minutes):
~The peer educator will reinforce information on healthy eating and physical activity based on the educational pamphlets from HPB with the participants."
11287702|NCT02780986|Active Comparator|Heterosexual men intervention group|The intervention program for heterosexual men patronising EEs will be a holistic non disease-centric, non-stigmatising and non-judgemental program addressing sexual well-being, avoidance of casual and paid sex if possible and safe sex such as condom use.
11287703|NCT02780986|No Intervention|Heterosexual men control group|There will be a simultaneous programme on healthy eating and physical activity at the control site at Tanjong Pagar. Health promoters will go around Tanjong Pagar and distribute pamphlets and brochures developed by the HPB on healthy eating and physical activity to the heterosexual men who step into or out of the EEs there. These health promoters have been trained to give simple health advice on healthy eating and physical activity if the heterosexual men wish to find out more information.
11287704|NCT02780973||Females|Female volunteers
11287705|NCT02780973||Males|Male volunteers
11287706|NCT02780960|Experimental|HPV self-testing|Patients will perform HPV self-testing at home, prior to their follow-up visit. At the colposcopy visit, the doctor or nurse will also perform HPV testing. This procedure will be repeated at 6 and 12 months following LEEP.
11287707|NCT02780947|Active Comparator|Prophylactic substrate ablation group|Prophylactic substrate ablation group will undergo substrate mapping and ventricular tachycardia substrate ablation
11287708|NCT02780947|No Intervention|Control group|Control group will undergo substrate mapping
11287709|NCT02780934|Active Comparator|Pressure Dressing|Participants randomized to this group will receive the standard post-operative dressing following their Mohs procedure: a pressure dressing consisting of high absorbency gauze and retention tape.
11287710|NCT02780934|Experimental|Simple Adhesive Dressing|Participants randomized to this group will receive the experimental post-operative dressing following their Mohs procedure: a simple adhesive dressing consisting of a non-adherent pad and transparent dressing.
11287711|NCT02780921|Experimental|Prehab Group|In the experimental group (Prehab group) compared to the control group, the main objective will be to demonstrate an improvement of the percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board
11287712|NCT02780921|Other|control group|The control group will be treated according to conventional care; will not receive any specific intervention before surgery except nutritional support and physiotherapy at the surgeon's discretion
11287713|NCT02780908|Experimental|Hypoxia at rest and exercise|The participants will perform a resting test, hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in normoxic condition ((HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m)
11287714|NCT02780908|Placebo Comparator|Normoxia at rest and exercise|The participants will perform a resting test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo)
11287715|NCT02780895|Experimental|Single Arm Study|stereotactic brain surgery of human stem cells (OK99)
11287716|NCT02780882|Experimental|Pasireotide|Each patient will be treated with pasireotide at an initial dose of 600 μg twice daily for one month. The dose will be further increased to 900 μg twice daily for month 2 and 3. After month 3, patients who continue to meet the inclusion and exclusion criteria will be entered into an additional 3 months of treatment.
11287717|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
11287718|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
11287719|NCT02780856|Other|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
11287720|NCT02780843|Experimental|Computerized Tomography|Patients will be examined with Computerized Tomography (CT) at admission
11287721|NCT02780843|Experimental|Magnetic Resonance Imaging|Patients will be examined with Magnetic Resonance Imaging (MRI) at admission
11287722|NCT02780830|Experimental|AZD2014 plus Ibrutinib Combination|AZD2014 and ibrutinib will be dosed together in the morning under fasting conditions. When possible, the morning doses of AZD2014 and ibrutinib should be taken at approximately the same time each day. The morning doses must be taken in a fasted state (water to drink only) from at least 2 hours prior to the dose to at least 1 hour post dose. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
11287723|NCT02780817|Experimental|Error enhancement|Arm reaching rehabilitation training with error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
11287724|NCT02780817|Other|Control group|Arm reaching rehabilitation training without error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
11287725|NCT02780804|Experimental|Treatment (entinostat)|Patients receive entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11287727|NCT02780791|Active Comparator|Transplantation into the ovary|Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies
11287728|NCT02780778|Experimental|Treatment group|Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w
11287729|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
11287730|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
11287731|NCT02780752|Experimental|Hymecromone|Hymecromone 300 mg orally three times per day for 3 months followed by hymecromone 600 mg orally three times per day for an additional 3 months (i.e. total 6 months of drug treatment).
11287732|NCT02780739|Experimental|Cognitive Training - 48 sessions|56 hours of video game training with Mind Frontiers adaptive cognitive training software (48 70-min sessions distributed over 16 weeks)
11287733|NCT02780739|Experimental|Fitness, Cognitive Training, sham tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers adaptive cognitive training software with simultaneous sham tDCS (20 70-min sessions distributed over weeks 5-16)
11287734|NCT02780739|Experimental|Fitness, Cognitive Training, active tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers 1.0 adaptive cognitive training software with simultaneous active tDCS for a total of 10 hrs (20 70-min sessions distributed over weeks 5-16)
11287735|NCT02780739|Active Comparator|Active Control|56 hours of video game training with visual search and change detection tasks using open sesame software (48 70-min sessions distributed over 16 weeks)
11287736|NCT02780739|No Intervention|No Contact Control|Completed no study activities for 16 weeks after pre-assessment, then returned for post-assessment
11287737|NCT02780726|Experimental|ASP1517 Low Dose Group (ESA Untreated)|This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.
11287738|NCT02780726|Experimental|ASP1517 High Dose Group (ESA Untreated)|This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
11287739|NCT02780726|Experimental|ASP1517 ESAs Treated Group|This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
11287740|NCT02780713|Experimental|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.
~Treatment period 1 will assess AZD9496 Variant A: 100mg.
~Treatment period 2 will assess AZD9496 Reference: 100mg.
~Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.
~Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.
~Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
11287741|NCT02780700|Experimental|Nintedanib|
11287742|NCT02780700|Experimental|Nintedanib plus capecitabine|
11287743|NCT02780687|Experimental|Afatinib|
11287744|NCT02780674|Active Comparator|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
11287745|NCT02780674|Placebo Comparator|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
11287746|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
11287747|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
11287748|NCT02780648|Experimental|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
11287749|NCT02780635|Experimental|App + Couples Coach Intervention|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse. Those assigned to this arm will also receive mailed materials that are designed to help increase positive communication strategies.
11287750|NCT02780635|Active Comparator|App Alone|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse.
11287751|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
11287752|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
11287753|NCT02780609|Experimental|Selinexor Plus HDM HCT|The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.
11287754|NCT02780596|Experimental|Items1;3|Caregiver is randomly assigned to receive screening items 1 and 3. Item 1: Does CHILD NAME often wake one or more times during the night? Item 3: Do you think CHILD NAME's sleep is a problem?
11287755|NCT02780596|Experimental|Items1;4|Caregiver is randomly assigned to receive screening items 1 and 4. Item 1: Does CHILD NAME often wake one or more times during the night? Item 4: Does you think CHILD NAME has a sleep problem?
11287756|NCT02780596|Experimental|Items1;5|Caregiver is randomly assigned to receive screening items 1 and 5. Item 1: Does CHILD NAME often wake one or more times during the night? Item 5: Do you have any concerns about CHILD NAME's sleep?
11287757|NCT02780596|Experimental|Items2;3|Caregiver is randomly assigned to receive screening items 2 and 3. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 3: Do you think CHILD NAME's sleep is a problem?
11287758|NCT02780596|Experimental|Items2;4|Caregiver is randomly assigned to receive screening items 2 and 4. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 4: Does you think CHILD NAME has a sleep problem?
11287759|NCT02780596|Experimental|Items2;5|Caregiver is randomly assigned to receive screening items 2 and 5. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 5: Do you have any concerns about CHILD NAME's sleep?
11287760|NCT02780596|Experimental|Items3;5|Caregiver is randomly assigned to receive screening items 3 and 5. Item 3: Do you think CHILD NAME's sleep is a problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
11287761|NCT02780596|Experimental|Items4;5|Caregiver is randomly assigned to receive screening items 4 and 5. Item 4: Does you think CHILD NAME has a sleep problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
11287762|NCT02780583|Placebo Comparator|placebo|methylprednisolone intravenously, placebo shots every 6 hours
11287763|NCT02780583|Experimental|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
11287764|NCT02780570|Active Comparator|GBS patients|Small Volume Plasma Exchange
11287765|NCT02780570|No Intervention|non-GBS|non-GBS patients with central venous catheter
11287766|NCT02780557|Experimental|Contingent Reading Intervention|
11287767|NCT02780557|Other|Book Provision Control|
11287768|NCT02780544|Experimental|skin-to-skin contact + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in skin-to-skin position with a parent (intervention group) and one in the incubator (standard care). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination.
11287769|NCT02780544|Active Comparator|incubator + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in the incubator (standard care) and one in skin-to-skin position with a parent (intervention group). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination
11287770|NCT02780518|Experimental|Airvo|All patients scheduled for elective microlaryngeal surgery under general anaesthesia and subglottic high frequency jet ventilation
11287771|NCT02780505|Active Comparator|vitamin c|vitamin C supplement orally up to 250 mg per day for 6 weeks was prescribed. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study.
11287772|NCT02780505|Placebo Comparator|placebo|ُPlacebo prescribed to Group B. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study
11287773|NCT02780492||Ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
11287774|NCT02780492||Non-ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
11287775|NCT02780492||Healthy volunteers and Disease controls|A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
11287776|NCT02780479|Experimental|Dexamethasone|Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
11287777|NCT02780479|Active Comparator|Prednisone|Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
11287778|NCT02780466||Patients with septic shock|
11287779|NCT02780453|Experimental|Negative pressure dressing|Negative pressure dressing
11287780|NCT02780453|Active Comparator|Standard dressing|Standard wound dressing
11287781|NCT02780440||Control Group|Subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program.
11287782|NCT02780440||Experimental Group 1|Subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program
11287783|NCT02780440||Experimental Group 2|Subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.
11287784|NCT02780427|Active Comparator|1-6 months (Group 1)|
11287785|NCT02780427|Active Comparator|7-12 months (Group 2)|
11287786|NCT02780427|Active Comparator|13-18 months (Group 3)|
11287787|NCT02780427|Active Comparator|19-24 months (Group 4)|
11287788|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
11287789|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
11287790|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
11287791|NCT02780388|Placebo Comparator|Placebo|Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
11287792|NCT02780388|Experimental|VIB4920 75 mg|Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
11287793|NCT02780388|Experimental|VIB4920 500 mg|Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
11287794|NCT02780388|Experimental|VIB4920 1000 mg|Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
11287795|NCT02780388|Experimental|VIB4920 1500 mg|Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
11287796|NCT02780375||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
11287797|NCT02780362|Experimental|A Test|Test drug (Prodactariv)1 tablet contains 60 mg Daclatasvir
11287798|NCT02780362|Active Comparator|B Reference|Reference drug (Clatazev) 1 tablet contains 60 mg Daclatasvir
11287799|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
11287800|NCT02780336||Blepharospasm (BL)|Participants in this group should be diagnosed with blepharospasm, but may have dystonia in other body parts as well.
11287801|NCT02780336||Disease Control Group|Participants in this group should be diagnosed with a disorder affecting their eyes or face, such as hemifacial spasm, facial tics, or apraxia.
11287802|NCT02780336||Normal Control Group|Participants in this group should not have any neurologic problems or other disorders affecting patients eyes or face.
11287803|NCT02780323|Experimental|CELBESTA® and CELEBREX® placebo|CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks
11287804|NCT02780323|Active Comparator|CELEBREX®|CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks
11287805|NCT02780310|Experimental|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
11287806|NCT02780297||Primary Hyperoxaluria Patients|Patients with confirmed diagnosis of Primary Hyperoxaluria.
11287807|NCT02780297||Dent Disease Patients|Patients with confirmed diagnosis of Dent Disease.
11287808|NCT02780297||Cystinuria Patients|Patients with confirmed diagnosis of Cystinuria.
11287809|NCT02780297||APRT deficiency Patients|Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
11287810|NCT02780297||Lowe Syndrome or Dent 2 patients|Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
11287811|NCT02780297||Dent 1 carriers|Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
11287812|NCT02780297||Enteric Hyperoxaluria Patients|Patients with confirmed diagnosis enteric hyperoxaluria.
11287813|NCT02780284|Experimental|Physical activity intervention|Observation phase of usual activity and an intervention phase of regular physical activity
11287814|NCT02780271|Experimental|Arm A|Subjects will receive in-person education plus e-communication AND subjects will receive control intervention
11287815|NCT02780271|Experimental|Arm B|Subjects will receive e-communication alone AND subjects will receive control intervention
11287816|NCT02780271|Experimental|Arm C|Subjects will receive in-person education alone AND subjects will receive control intervention
11287817|NCT02780271|Active Comparator|Arm D|Subjects will receive control intervention
11287818|NCT02780258|Experimental|Restylane Silk Treated Hand|The dorsal aspect of one hand will be injected with Restylane Silk.
11287819|NCT02780258|No Intervention|Control Hand|The dorsal aspect of the hand that is not treated will be used for baseline comparison.
11287820|NCT02780245|Experimental|Group (X) Prophylactic Tranexamic Acid|Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
11287821|NCT02780245|Experimental|Group (Y) Intraoperative Uterine Cooling|Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].
11287822|NCT02780232|Experimental|Internet-based program|"Adolescents in the intervention will receive a tailored online program during 3 months.
~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links."
11287823|NCT02780232|No Intervention|Treatment as usual|-Waiting list control group.
11287824|NCT02780219|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
11287825|NCT02780219|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
11287857|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
11287995|NCT02779140|Experimental|0.33 mg/kg NTM-1632|N=6 administered 0.33 mg/kg NTM-1632 IV, N=2 administered placebo IV
11287826|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
11287827|NCT02780180|Experimental|QGC001|QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
11287828|NCT02780180|Placebo Comparator|Placebo|Placebo, capsule twice daily, for 28 days, oral use
11287829|NCT02780167|Experimental|Cohort 1|10 mg of PF-04965842 QD
11287830|NCT02780167|Experimental|Cohort 2|30 mg of PF-04965842 QD
11287831|NCT02780167|Experimental|Cohort 3|100 mg of PF-04965842 QD
11287832|NCT02780167|Experimental|Cohort 4|200 mg of PF-04965842 QD
11287833|NCT02780167|Placebo Comparator|Cohort 5|placebo QD
11287834|NCT02780154|Experimental|1600 7G8 PfSPZ|N= 7-9 participants will receive 1600 7G8 PfSPZ DVI in a volume of 500mcL
11287835|NCT02780154|Experimental|3200 7G8 PfSPZ|N= 9 participants will receive 3200 7G8 PfSPZ DVI in a volume of 500mcL
11287836|NCT02780154|Experimental|3200 NF54 PfSPZ|N= 5-6 participants will receive 3200 NF54 PfSPZ DVI in a volume of 500mcL
11287837|NCT02780154|Experimental|4800 7G8 PfSPZ|N= 2-3 participants will receive 4800 7G8 PfSPZ DVI in a volume of 500mcL
11287838|NCT02780154|Experimental|800 7G8 PfSPZ|N= 7-9 participants will receive 800 7G8 PfSPZ DVI in a volume of 500mcL
11287839|NCT02780141|Experimental|ASP1517 Low dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
11287840|NCT02780141|Experimental|ASP1517 High dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
11287841|NCT02780128|Other|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
11287842|NCT02780128|Experimental|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.
~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.
~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
11287843|NCT02780115|Experimental|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
11287844|NCT02780115|Experimental|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
11287845|NCT02780115|Experimental|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
11287846|NCT02780115|Experimental|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
11287847|NCT02780115|Experimental|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
11287848|NCT02780102|Experimental|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR): 20 sixty-minute sessions of cognitive-motor rehabilitation
11287849|NCT02780102|Experimental|Ritalin|2 to 3 doses of 10 mg Ritalin tablets per day during 8 week.
11287850|NCT02780102|Active Comparator|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
11287851|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
11287852|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
11287853|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
11287854|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
11287855|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
11287856|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
11287888|NCT02779868|Experimental|Omega-3|Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
11287858|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
11287859|NCT02780076|Experimental|Functional training group|Participation in a functional training program in addition to usual care. The functional training program is initiated by the nurses and consists of walking, sit-to-stands, balance training, weight transfer training, knee squats. The program is performed 4 times a day for 3 weeks while at short-term stays.
11287860|NCT02780076|No Intervention|Control group|Usual care only. No participation in the functional training program while at short-term stays.
11287861|NCT02780063|Experimental|Lenstar Biometry|Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
11287862|NCT02780050|No Intervention|chest compression before physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.
~2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). Researchers record subject's chest compression depth and rate in 1st chest compression."
11287863|NCT02780050|Experimental|after core muscle activation using physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.
~After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.
~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 2nd chest compression."
11287864|NCT02780037|Experimental|Prevention|Regulatory frame: prevention
11287865|NCT02780037|Experimental|Promotion|Regulatory frame: promotion
11287866|NCT02780037|Sham Comparator|Neutral|Regulatory frame: not implied
11287867|NCT02780024|Experimental|Registered one arm study|Two weeks of neo-adjuvant Metformin+Temozolomide followed by accelerated hypofractionation using an IMRT technique+TMZ & Metformin followed by TMZ, and Metformin as adjuvant component.
11287868|NCT02780011|Experimental|Alsertib and Brentuximab Vedotin|Brentuximab vedotin at a fixed dose of 1.8 mg/kg will be administered by intravenous infusion on day 1 of every 21-day cycle. MLN8237 at a dose of 60 mg will be orally administered daily in 2 divided doses (30 mg qAM, 30 mg qPM) from days 1 to 7 of each 21-day cycle. MLN8237 dose will be escalated in 20-mg increments to the maximum dose of 100 mg (Level 2) or de-escalated in a 20-mg decrement to the minimum dose of 40 mg (Level -1).
11287869|NCT02779998|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute in order to maintain peripheral oxygen saturation (SpO2) above 94% during electrophysiology procedure under light sedation.
11287870|NCT02779998|Experimental|non invasive ventilation|non invasive ventilation (NIV) which associated positive end expiratory pressure (PEEP: 5 to 10 cmH2O) and pressure support ventilation (PSV: 5 to 15 cmH2O, to achieve total Pressure bellow 20cmH2O) will be delivered during electrophysiology procedure under light sedation. The patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
11287871|NCT02779985|Experimental|Lycium Barbarum mixed meal|Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
11287872|NCT02779985|Active Comparator|Control mixed meal|Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
11287873|NCT02779972||60's decade|60's decade Echo stress test
11287874|NCT02779972||70's decade|70's decade Echo stress test
11287875|NCT02779972||80's decade|80's decade Echo stress test
11287876|NCT02779959|Experimental|Buccal Prochlorperazine|Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline
11287877|NCT02779959|Active Comparator|Intravenous Prochlorperazine|Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
11287878|NCT02779946||CHD-positive|positive tested for coronary artery disease
11287879|NCT02779946||CHD-negative|negative tested for coronary artery disease
11287880|NCT02779920|Experimental|Per oral pylorotomy|Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
11287881|NCT02779907||Study Population|Children aged 4-6 years resident in Chikwawa District.
11287882|NCT02779894|No Intervention|Hospital group|Patients referred to the sleep unit and randomized to Hospital group. Participants will be diagnosed in the hospital either by Polysomnography , Respiratory Polygraphy or one night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the titration and adjustment of patient's will be accomplished at the hospital. This patient's will be monitored during 3 months of the study at the hospital.
11287883|NCT02779894|Other|ICT group|Patients referred to the sleep unit and randomized to intervention group. Participants will be diagnosed at home by 3 night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the adjustment will be performed at the CPAP supplier center, titration will be performed at home and patient's compliance and treatment will be controlled via remote. During the 3 months of the study patient's will be controlled via phono/video conferences and with a platform designed for the study.
11287884|NCT02779881||Healthy controls|Healthy controls
11287885|NCT02779881||Children at diagnosis of cow's milk allergy|Children at diagnosis of cow's milk allergy
11287886|NCT02779881||Subjects outgrown cow's milk allergy with formula+probiotic|Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
11287887|NCT02779881||Subjects outgrown cow's milk allergy assuming other formulas|Subjects tolerant with other formulas
11324361|NCT02538497|Other|Routine care|
11287889|NCT02779868|Placebo Comparator|Olive oil|Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
11287890|NCT02779855|Experimental|Talimogene laherparepvec + Chemotherapy|Talimogene laherparepvec with Neoadjuvant Paclitaxel Chemotherapy treatment administration on an outpatient basis. Phase I: Dose Escalation to Determine Maximum Tolerated Dose (MTD). Phase II: Treatment at MTD.
11287891|NCT02779842|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11287892|NCT02779829|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11287893|NCT02779816|Experimental|Intervention (pen device)|Subjects will use the pen device when using their commercially available insulin pens
11287894|NCT02779816|No Intervention|Control|Subjects will use the commercially available insulin pens only (no adaptive pen device).
11287895|NCT02779777|Experimental|Tipifarnib, Oral|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
11287896|NCT02779764|Experimental|ASP1517 Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
11287897|NCT02779751|Experimental|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11287898|NCT02779751|Experimental|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11287899|NCT02779751|Experimental|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11287900|NCT02779751|Experimental|HR+, HER2- Locally Advanced or Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11287901|NCT02779738|Experimental|Merestinib Fasted|Single dose of merestinib administered in fasted state in one of three periods
11287902|NCT02779738|Experimental|Merestinib Standard Meal|Single dose of merestinib administered with a standard meal in one of three periods
11287903|NCT02779738|Experimental|Merestinib High-Fat Meal|Single dose of merestinib administered with a high-fat meal in one of three periods
11287904|NCT02779725|Active Comparator|Group 1 SCC/SSR|This arm includes self-care coaching (SCC) message during daily self-reported symptom severity report (SSR) calls to the automated system.
11287905|NCT02779725|Active Comparator|Group 2 NP/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. These alerts are monitored and follow-up care is given by a nurse practitioner.
11287906|NCT02779725|Active Comparator|Group 3 NP/DSS/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. Nurse practitioner follow-up calls utilize the evidenced based SCH decision support system (DSS) when symptoms exceed alert thresholds
11287907|NCT02779725|Active Comparator|Group 4 Full Intervention SSR/SCC/NP/DSS|Complete intervention with all components used in prior efficacy study (Symptom Severity Report (SSR)+Self Care Coaching (SCC) +Nurse Practitioner (NP) +Decision Support System (DSS))
11287908|NCT02779725|Active Comparator|Group 5 SSR/SCC/AT|Symptom severity reporting (SSR), automated self-care coaching (SCC) based on daily symptom reporting plus activity tracker (AT)
11287909|NCT02779712|Active Comparator|Remote Ischaemic Conditioning|Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (20mmHg above systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
11287910|NCT02779712|Sham Comparator|Control|Control: 4 cycles of alternating 5 minutes inflation (up to 30 mmHg) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
11287911|NCT02779699|Experimental|AL2846|AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11287912|NCT02779686||ARMD Free|Patient free of ARMD on clinical examination
11287913|NCT02779686||ARMD Positive|Patients with evidence of ARMD on clinical examination
11287914|NCT02779673|Experimental|Test group|Subjects randomized to the test group consumed yoghurt drink containing 3.4g plant stanol as ester for 1 per day for a period of 4 weeks.
11287915|NCT02779673|Placebo Comparator|Placebo group|Subjects randomized to the placebo group consumed yoghurt drink without plant stanol as ester for 1 per day for a period of 4 weeks.
11287916|NCT02779660|Experimental|RIPC-Group|After randomization patients will undergo 3 sessions of RIPC (Remote ischemic preconditioning) intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
11287917|NCT02779660|Placebo Comparator|Control-Group|After randomization patients will undergo 3 sessions of sham-intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
11287918|NCT02779647|Experimental|Study group|Consisting of 49 children who were recommended a programme of physical activity, play and nutritional advice, for both the children and their parents
11287919|NCT02779647|No Intervention|Control group|49 children, who received only nutritional advice
11287920|NCT02779634|Placebo Comparator|Placebo|Placebo three times daily
11287921|NCT02779634|Active Comparator|Active|Pills of 100 mg ubiquinol three times daily
11287922|NCT02779621|Experimental|Self-sampling|(Self-collecting a vaginal sample with a swab for HPV testing) Women in the experimental arm will have the option of vaginal self-sampling for HPV testing, in addition to the routine screening test. They can choose one of them.
11287993|NCT02779140|Experimental|0.033 mg/kg NTM-1632|N=6 administered 0.033 mg/kg NTM-1632 IV, N=2 administered placebo IV
11287923|NCT02779621|Active Comparator|Routine smear|(Collection of cervical sample for routine cervical screening) Women in the control arm will only receive the routine cervical screening invitation letter.
11287924|NCT02779608|Experimental|intraperitoneal docetaxel and oral S-1|"Docetaxel is diluted in 1litre normal saline and administered intraperitoneal（IP）at a dose of 60 mg/m2 over 1 hour on day 1. S-1 was administered orally twice daily at a dose of 40mg/m2 per day for 14 consecutive days, followed by 7 days of rest.
~Intervention: Drug: Intraperitoneal docetaxel Intervention：Drug：Oral S-1"
11287925|NCT02779595||Lung surgery|26 patients (up to 36) undergoing lung surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
11287926|NCT02779595||Flail chest|8 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
11287927|NCT02779582|Experimental|Progesterone|Oral micronized progesterone, 300 mg po daily, taken as three capsules daily before sleep for three months
11287928|NCT02779582|Placebo Comparator|Placebo|Placebo, each taken as three capsules daily before sleep for three months
11287929|NCT02779569|Experimental|Ultra-low-dose group|decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
11287930|NCT02779569|Active Comparator|Low-dose group|decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
11287931|NCT02779556|Other|Enhanced Usual Care|ADA Living Well with Diabetes Workbook, 15 minute in-person counseling, follow-up every 3 months
11287932|NCT02779556|Other|Intervention|ACP Living with Diabetes Guide, 15 minute in-person counseling , 15 minute follow-up counseling (3, 6, and 9 months), monthly phone calls after 3 months
11287933|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
11287934|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
11287935|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
11287936|NCT02779530|Experimental|Diclofenac|
11287937|NCT02779530|Placebo Comparator|Placebo|
11287938|NCT02779517||Focus groups- Patients|Subjects with or without an upper extremity disability will be asked to observe and interact with the mobile service robot.
11287939|NCT02779517||Focus Groups-clinicians|Clinicians with neuro-rehab experience.
11287940|NCT02779504||Agluna treated METS|Patient implanted with Agluna treated METS
11287941|NCT02779504||Untreated METS|Patient implanted with untreated METS
11287942|NCT02779491|Experimental|Intervention for two weeks|Receipt of the mobile phone application for two weeks
11287943|NCT02779491|No Intervention|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
11287944|NCT02779491|Experimental|Intervention for four weeks|Receipt of the mobile phone application for four weeks
11287945|NCT02779491|No Intervention|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
11287946|NCT02779478||Positive NTM Culture|Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy
11287947|NCT02779478||Negative NTM Culture|Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.
11287948|NCT02779465|Experimental|Vitamin D|Drug: Vitamin D3 800 IU daily besides the anti-virus treatment with nucleos(t)ide medicine
11287949|NCT02779465|No Intervention|Control|chronic hepatitis B patients with long term anti-virus therapy
11287950|NCT02779452||GDM newborns|Newborns from gestational diabetes mellitus pregnancy
11287951|NCT02779452||No GDM newborns|Newborn from a normal pregnancy
11287952|NCT02779439|Experimental|3rd party CTL infusion|Virus specific CTLs
11287953|NCT02779426|Experimental|Text Message Intervention + Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution as well as daily text messages with information about atopic dermatitis and treatment reminders. 1-2 times/week they will receive a message asking if they were able to complete their treatments in the last day. They will respond with 1=yes, 2=no, 3= I have questions about the treatment. Those who respond with 3 will be sent the contact information for the office. No other communications will be sent through text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
11288099|NCT02778477|Experimental|Part A_Cohort 1_Active|Multiple ascending dose of PF-06423264
11287954|NCT02779426|No Intervention|Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution. They will not receive text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
11287955|NCT02779413||Insulin degludec|
11287956|NCT02779400|Experimental|Evaluation of the device perfomance|
11287957|NCT02779387|Experimental|GnRH-a|"patients treated with GnRH-a after surgery and Outpatient guidance
~."
11287958|NCT02779387|No Intervention|non GnRH-a|patients treated with outpatient guidance only.
11287959|NCT02779374|Experimental|Autologous bone marrow transplantation|autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up
11287960|NCT02779361|Experimental|Green tea|Green tea consumption along 7 days.
11287961|NCT02779348|Experimental|Nebicapone plus warfarin|BIA 3-202 200 mg tid + Warfarin 25 mg
11287962|NCT02779348|Experimental|Warfarin|Warfarin 25 mg
11287963|NCT02779335|Other|Enteral formula tube feeding|Enteral fed children, ages 1-13, with establish enteral feeding access
11287964|NCT02779322|Active Comparator|Minigastric bypass|Intervention(s): The patient will have done a Laparoscopic one anastomosis gastric bypass (minigastric bypass) at the time of the surgical procedure.
11287965|NCT02779322|Active Comparator|Gastric bypass|The patient will have a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
11287966|NCT02779309||Development Cohort|437,000 home care recipients who received services from January 1, 2007 to December 31, 2012.
11287967|NCT02779309||Validation Cohort|122,000 home care recipients who received services from January 1, 2013 to December 31, 2013.
11287968|NCT02779296|Experimental|2-Octyl Cyanoacrylate Glue|At the surgical site, a thin layer of cyanoacrylate glue will be applied over the sutures at the time of closure.
11287969|NCT02779296|No Intervention|No Glue|No cyanoacrylate glue will be applied.
11287970|NCT02779283|Experimental|Arm I (AML)|Patients receive cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 30 minutes on days 1-3.Patients receive cyclophosphamide IV over 3 hours twice daily (BID) on days 1-3, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV on day 4, dexamethasone PO on days 1-4 and 11-14, and rituximab IV on day 1 and 11 (day 11 only of course 1). Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
11287971|NCT02779283|Experimental|Arm II (ALL)|Patients receive cytarabine IV over 2 hours BID on days 2-3, methotrexate IV over 2-22 hours on day 1, methylprednisolone sodium succinate IV BID on days 1-3, leucovorin calcium IV every 6 hours until methotrexate level is < 0.05 uM and rituximab IV on days 1 and 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
11287972|NCT02779270|Experimental|BAY987518|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
11287973|NCT02779270|Active Comparator|Sunscreen control|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
11287974|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
11287975|NCT02779244|Experimental|Early Weight Bearing + Cam boot|
11287976|NCT02779244|Active Comparator|Standard Treatment Cam boot|
11287977|NCT02779231|Experimental|Texting group|This group will be enrolled in bi-directional texting to send back blood pressure.
11287978|NCT02779231|No Intervention|Standard of care group|
11287979|NCT02779218|Experimental|Sequence 1|"The patients will receive in order :
~Paired Associative Stimulation
~Paired Associative Stimulation + Motor Imagery exercises
~Placebo Paired Associative Stimulation + Motor Imagery exercises"
11287980|NCT02779218|Experimental|Sequence 2|"The patients will receive in order :
~Paired Associative Stimulation + Motor Imagery exercises
~Placebo Paired Associative Stimulation + Motor Imagery exercises
~Paired Associative Stimulation"
11287981|NCT02779218|Experimental|Sequence 3|"The patients will receive in order :
~Placebo Paired Associative Stimulation + Motor Imagery exercises
~Paired Associative Stimulation
~Paired Associative Stimulation + Motor Imagery exercises"
11287982|NCT02779205|Other|0-1 year old child|Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
11287983|NCT02779205|Other|>1-10 year old child|Adipose tissue sample in >1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
11287984|NCT02779192|Active Comparator|SPI-1005 200 mg|200 mg SPI-1005, capsule, bid, po, x7d
11287985|NCT02779192|Active Comparator|SPI-1005 400 mg|400 mg SPI-1005, capsule, bid, po, x7d
11287986|NCT02779192|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, bid, po, x7d
11287987|NCT02779179|Experimental|Immediate Periodontal treatment group|
11287988|NCT02779179|Active Comparator|Delayed Periodontal treatment Group|
11287989|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
11287990|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
11287991|NCT02779153|Experimental|Acthar low dose (40 U)|
11287992|NCT02779153|Experimental|Acthar high dose (80 U)|
11287996|NCT02779127|Other|Intervention|"Subjects exposed to passive smoking at least 1 hour per day since 1 year, non active smokers, non exposed to passive smoking at home
~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
11287997|NCT02779127|Other|Control|"Subjects non expose to passive smoking at home or at work, non active smokers
~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
11287998|NCT02779114|Other|Control group|After 1:1:1 randomization patients in the control group receive their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during 12 months of the study.
11287999|NCT02779114|Other|Reduction group 1|Patients in reduction group 1 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
11288000|NCT02779114|Other|Reduction group 2|Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
11288001|NCT02779101|Experimental|Single arm|pembrolizumab
11288002|NCT02779088|Experimental|Early exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the AB arm receive exercise and nutrition intervention first, followed by the education course.
11288003|NCT02779088|Active Comparator|Delayed exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the BA arm receive the education course first, followed by exercise and nutrition.
11288004|NCT02779075|Placebo Comparator|Saline|0.9% NaCL (saline) intravenously for 6 hours.
11288005|NCT02779075|Active Comparator|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
11288006|NCT02779049||MAC-LD|patients with MAC-LD Do Blood examination
11288007|NCT02779049||Control|controls without NTM or tuberculosis infection Do Blood examination
11288008|NCT02779049||Tuberculosis infection|patients with tuberculosis infection which diagnosis by culture or typical pathology Do Blood examination
11288009|NCT02779049||MAC colonization|patients with MAC pulmonary colonization by American Thoracic Society guideline Do Blood examination
11288010|NCT02779036|Experimental|Task-oriented Exercise|Structured, progressive, task-oriented, home exercise program
11288011|NCT02779036|Active Comparator|Usual Care|Usual Physiotherapy Care
11288012|NCT02779023|Experimental|ICHP + CBT-I|Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
11288013|NCT02779023|No Intervention|ICHP Only|Participants in this arm will receive the usual care (ICHP program).
11288014|NCT02779010|Experimental|Hand washing with soap|Hand washing with soap and health education every 2 weeks for 6 months
11288015|NCT02779010|No Intervention|Books and pens|Books and pens for every 2 months for 6 months
11288016|NCT02778984|Active Comparator|standard face masks|The standard mask is used in usual care
11288017|NCT02778984|Experimental|QuadraLite face masks|This study will compare tightness of 2 face masks during preoxygenation and after induction of anesthesia with propofol, sufentanil and rocuronium. During preoxygenation, a 10 l.min-1 fresh gas flow and 8 cm H2O PEEP will be applied. After induction of anesthesia, patients will receive pressure-controlled ventilation (fresh gaz flow 3 L.min-1, pressure set to obtain a 7 ml.kg-1 ideal body weight, 10 cpm, peep 5 cm H2O).
11288018|NCT02778971||Qualifying participants|All consented participants referred by a dementia expert physician to receive an amyloid PET scan with [18F]Flutametamol and meeting eligibility criteria will have visual and semi-quantitative software aided scan interpretation, complete care partner questionnaires and providers will document diagnosis, diagnostic confidence, and management plan before and after the scan.
11288019|NCT02778958|Experimental|ibuprofen and morphine|iv ibuprofen 800 mg infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
11288020|NCT02778958|Active Comparator|paracetamol and morphine|iv paracetamol 1 gram infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
11288021|NCT02778945|Experimental|Group D (Deep NMB group)|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
11288022|NCT02778945|Active Comparator|Group I (Intermediate NMB group)|Use NMB as conventional clinical usage Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
11288023|NCT02778932||ITN|General anesthesia including intubation and muscle relaxation
11288024|NCT02778932||LM|General anesthesia including laryngeal mask without muscle relaxation
11288025|NCT02778919|Experimental|KLH-2109, lowest dose|
11288026|NCT02778919|Experimental|KLH-2109, low dose|
11288027|NCT02778919|Experimental|KLH-2109, medium dose|
11288028|NCT02778919|Experimental|KLH-2109, high dose|
11288029|NCT02778919|Placebo Comparator|Placebo|First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
11288030|NCT02778919|Other|Leuprorelin acetate|Active reference
11288031|NCT02778906|Active Comparator|Abatacept|Abatacept 125 mg s.c. weekly
11288032|NCT02778906|Placebo Comparator|Placebo|Placebo (NaCl 0,9%) s.c. weekly
11288100|NCT02778477|Placebo Comparator|Part A_Cohort 1_Placebo|Multiple dose of placebo
11288101|NCT02778477|Experimental|Part A_Cohort 2_Active|Multiple ascending dose of PF-06423264
11288033|NCT02778893|Experimental|Conmana and Thalidomide|"Conmana(Icotinib Hydrochloride Tablets) and Thalidomide:
~Conmana(Icotinib Hydrochloride Tablets) will be administered at 125mg three times a day(TID）continuously; Thalidomide will be administered at 100mg one a day（QD)at night continuously,If can tolerance after 1 weeks to add to 200mg."
11288034|NCT02778880|Experimental|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
11288035|NCT02778880|Active Comparator|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
11288036|NCT02778867|Active Comparator|1-Food Elimination Diet (1FED)|Participants eliminate milk from the diet in Phase 1
11288037|NCT02778867|Active Comparator|6-Food Elimination Diet (6FED)|Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
11288038|NCT02778867|Other|1FED Non-Responders (6FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
11288039|NCT02778867|Other|6FED Non-responders (SGC)|Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2
11288040|NCT02778854||cohort 1|Participants are recruited for diagnostic test
11288041|NCT02778854||cohort 2|participants are recruited for follow-up
11288042|NCT02778841|Experimental|XBox Kinact Exercise|Kinact game intervention group performed three times per week on non-consecutive days for eight weeks
11288043|NCT02778841|Experimental|conventional balance exercises|conventional balance exercises group performed three times per week on non-consecutive days for eight weeks
11288044|NCT02778841|Experimental|concurrent exercise group|Concurrent group performed mixed conventional balance and Xbox Kinact exercises three times per week on non-consecutive days for eight weeks
11288045|NCT02778841|No Intervention|control Group|There is no exercise for this group
11288046|NCT02778828|Experimental|Patients with Multi-Resistant Tb|
11288047|NCT02778815|Experimental|Kindness for Mums|An online self-help course designed to promote self-kindness and self-compassion in new mothers
11288048|NCT02778815|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help intervention once the RCT is complete.
11288049|NCT02778789||Tocilizumab|Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
11288050|NCT02778789||TNF-alpha Inhibitor|Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
11288051|NCT02778776|Experimental|Agave inulin + Metfomin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
11288052|NCT02778776|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
11288053|NCT02778776|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
11288054|NCT02778776|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
11288055|NCT02778763|Experimental|One injection of CBLB612 after Сhemo|One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)
11288056|NCT02778763|Experimental|One injection of CBLB612 prior Сhemo|One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)
11288057|NCT02778763|Placebo Comparator|Placebo|Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)
11288058|NCT02778750||Stable Group|
11288059|NCT02778750||Rapid Decliner Group|
11288060|NCT02778737|Experimental|ACT-based intervention|The Acceptance and Commitment Therapy + MTAU consists of an unpublished manual developed for the purposes of the project (Karekla et al., 2013). The 8, 90-min weekly group sessions focus in fostering psychological flexibility or the capacity to engage or change behaviors based on what a situation affords and an individual's goals, needs, and desires (Hayes et al., 2004). The ACT protocol involves helping patients to engage in values-based behaviors while remain in contact with pain, especially, when efforts to control or reduce it fail or contribute to suffering.
11288061|NCT02778737|Active Comparator|CBT-based intervention|The Cognitive Behavioral group + MTAU consists of an unpublished manual developed by Kalantzi-Azizi & Karademas (2003). It includes 8, 90-min weekly group session and primarily focuses on teaching patients to manage their pain by utilizing various techniques, such as activity pacing, muscle relaxation(i.e., progressive muscle relaxation, diaphragmatic breathing, guided imagery), pain recording, thought challenging, problem solving skills, relapse prevention, etc. The CBT protocol involves helping patients to learn to control their pain and to modify dysfunctional thoughts that accompany it.
11288062|NCT02778711|Experimental|Cosentyx|secukinumab (anti-IL-17)
11288063|NCT02778685|Experimental|Treatment (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11288064|NCT02778672||Infants with potential pneumonia|
11288065|NCT02778659|Experimental|Zolpidem Normoxia|Acute zolpidem intake at sea level
11288066|NCT02778659|Sham Comparator|Placebo Normoxia|Acute placebo intake at sea level
11288067|NCT02778659|Experimental|Zolpidem Hypoxia|Acute zolpidem intake at high altitude
11288068|NCT02778659|Sham Comparator|Placebo Hypoxia|Acute placebo intake at high altitude
11288069|NCT02778646||MINAP Audit|Individuals within this group are those that have been admitted into a United Kingdom (UK) based hospital following a major cardiac event. The FH status of individuals within this group is unknown.
11288070|NCT02778646||BCIS Audit|Individuals within this group are those who have undergone percutaneous coronary intervention in the United Kingdom (UK). The FH status of individuals within this group is unknown.
11288102|NCT02778477|Placebo Comparator|Part A_Cohort 2_Placebo|Multiple dose of placebo
11288103|NCT02778477|Experimental|Part A_Cohort 3_Active|Multiple ascending dose of PF-06423264
11288104|NCT02778477|Placebo Comparator|Part A_Cohort 3_Placebo|Multiple dose of placebo
11288071|NCT02778633||Sepsis|Patients diagnosed with septic shock, admitted to the intensive care unit, with a good left ventricular ejection fraction without significant co-morbidity are highly eligible for this study. Patients must be equipped with a pulse-contour cardiac output (PICCO)-system with a central venous catheter which will be applied by the intensivist on admission.Patients will be subsequently connected to the hemodynamic monitoring device Navigator™. In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
11288072|NCT02778620||Aortic Valve Replacement|Post Anaesthetic Care Unit (PACU) patients treated with aortic valve replacement (AVR) are highly eligible for this study.These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
11288073|NCT02778607||Progressive Supranuclear Palsy|Patients with a current clinical diagnosis of Progressive Supranuclear Palsy (PSP)
11288074|NCT02778607||Multiple System Atrophy|Patients with current clinical diagnosis of Multiple System Atrophy (MSA).
11288075|NCT02778607||Atypical Parkinsonian Syndrome|Atypical Parkinsonian Syndrome (APS) patients who do not fulfil existing criteria for PSP/CBD/MSA, but may represent variant clinical syndromes related to tau pathology including pure akinesia with gait freezing (PAGF), PSP-parkinsonism, overlap syndromes and atypical parkinsonian disorders not meeting clinical diagnostic criteria at entry
11288076|NCT02778607||Controls|Participants unaffected by neurological or psychiatric disease
11288077|NCT02778607||Corticobasal Degeneration|Patients with a current clinical diagnosis of Corticobasal Degeneration (CBD)
11288078|NCT02778594|Placebo Comparator|Placebo|Placebo (4 tablets) Simultaneously with the placebo dose, subjects were administered 1 capsule of Madopar® HBS 125
11288079|NCT02778594|Experimental|Nebicapone 50 mg|Nebicapone 50 mg (1 tablet of 50 mg plus 3 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
11288080|NCT02778594|Experimental|Nebicapone 100 mg|Nebicapone 100 mg (2 tablets of 50 mg plus 2 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
11288081|NCT02778594|Experimental|Nebicapone 200 mg|Nebicapone 200 mg (4 tablets of 50 mg). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
11288082|NCT02778581|Active Comparator|Lipidic Blend 1|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
11288083|NCT02778581|Active Comparator|Lipidic Blend 2|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
11288084|NCT02778581|Placebo Comparator|Placebo|Glass bottle with 45 ml of Olive oil. 1 bottle per day
11288085|NCT02778568|Experimental|Resistance Training|Patients performed resistance exercises
11288086|NCT02778568|Active Comparator|Control|Patients who performed flexibility exercise
11288087|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
11288088|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
11288089|NCT02778555||Sample 3|In Sample 3 (N=318), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14. In addition, assessments of pain, mood, activity, sleep, energy level, and positive affect were administered daily for the 14-day period.
11288090|NCT02778542|Active Comparator|Electronic Pill Bottle|Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication.
11288091|NCT02778542|Active Comparator|Bidirectional Text Messaging|Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
11288092|NCT02778542|No Intervention|Usual Care|Participants in this arm do not receive a medication reminder system.
11288093|NCT02778529|Other|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
11288094|NCT02778516|Active Comparator|Sodium Restriction 1500mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
11288095|NCT02778516|Active Comparator|Sodium Restriction 2400mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
11288096|NCT02778516|No Intervention|Control Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
11288097|NCT02778503|Active Comparator|High Cost|Restoration using a high-cost glass ionomer cement.
11288098|NCT02778503|Experimental|Low Cost|Restoration using a low-cost glass ionomer cement.
11288106|NCT02778477|Placebo Comparator|Part A_Cohort 4_Placebo|Multiple dose of placebo
11288107|NCT02778477|Experimental|Part A_Cohort 5_Active|Multiple ascending dose of PF-06423264
11288108|NCT02778477|Placebo Comparator|Part A_Cohort 5_Placebo|Multiple dose of placebo
11288109|NCT02778477|Experimental|Part A_Cohort 6_Active|Multiple ascending dose of PF-06423264
11288110|NCT02778477|Placebo Comparator|Part A_Cohort 6_Placebo|Multiple dose of placebo
11288111|NCT02778477|Experimental|Part A_Cohort 7_Active|Multiple ascending dose of PF-06423264
11288112|NCT02778477|Placebo Comparator|Part A_Cohort 7_Placebo|Multiple ascending dose of placebo
11288113|NCT02778477|Experimental|Part B_Cohort 1_Active|Multiple doses of PF-06423264
11288114|NCT02778477|Placebo Comparator|Part B_Cohort 1_Placebo|Multiple doses of placebo
11288115|NCT02778477|Experimental|Part B_Cohort 2_Active|Multiple doses of PF-06423264
11288116|NCT02778477|Placebo Comparator|Part B_Cohort 2_Placebo|Multiple doses of placebo
11288117|NCT02778464||Group A: Female IBD and RA (non-pregnant)|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
11288118|NCT02778464||Group B: Female IBD|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
11288119|NCT02778464||Group C: Female - Healthy Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
11288120|NCT02778464||Group D: Female - RA Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
11288121|NCT02778451|Other|Ultrasonography-experienced surgeons|Attending physicians and consultants in head and neck surgery using head and neck Ultrasonography on a daily basis.
11288122|NCT02778451|Other|Ultrasonography novices|Physicians participating in their one-year internship at other surgical or medical departments with no experience with head and neck US or head and neck surgery.
11288123|NCT02778425|No Intervention|Primary prevention-1|Endoscopic therapy
11288124|NCT02778425|No Intervention|Primary prevention-2|beta blockers
11288125|NCT02778425|Experimental|Primary prevention-3|Endoscopic therapy+PSE
11288126|NCT02778425|No Intervention|Control of acute bleeding-1|Endoscopic therapy+ somatostatin
11288127|NCT02778425|Experimental|Control of acute bleeding-2|Endoscopic therapy+ somatostatin+PSE
11288128|NCT02778425|No Intervention|Secondary prevention-1|Endoscopic therapy+ beta blockers
11288129|NCT02778425|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
11288130|NCT02778399|Experimental|OBE2109 dose 1|
11288131|NCT02778399|Experimental|OBE2109 dose 2|
11288132|NCT02778399|Experimental|OBE2109 dose 3|
11288133|NCT02778399|Experimental|OBE2109 dose 4|
11288134|NCT02778399|Experimental|OBE2109 dose 5|
11288135|NCT02778399|Placebo Comparator|Placebo / OBE2109 dose 6|
11288136|NCT02778386|Experimental|Cohort 1|6 subjects, male & female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
11288137|NCT02778386|Experimental|Cohort 2|6 subjects, male & female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
11288138|NCT02778386|Experimental|Cohort 3|8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
11288139|NCT02778386|Experimental|Cohort 4|8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
11288140|NCT02778373|Placebo Comparator|Placebo|Flavored Water
11288141|NCT02778373|Active Comparator|Low Molecular Weight Carbohydrate|low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
11288142|NCT02778373|Experimental|High molecular weight carbohydrate|high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
11288143|NCT02778360|Experimental|Neurofeedback NFT|"Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.
~Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home"
11288144|NCT02778360|Active Comparator|Methylphenidate MPH|"Methylphenidate long acting preparation.
~Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).
~Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day)."
11288145|NCT02778334|No Intervention|patients who return home|
11288146|NCT02778334|Experimental|patients who continued hospitalization in rehabilitation|
11288147|NCT02778321|Other|Uses of SpiderFlash monitor|"The intervention corresponds to the use of Spiderflash as Holter monitor. Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.
~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist."
11288148|NCT02778308|Active Comparator|chemotherapy group|6 cycles of Gemcitabine + Cisplatin as per the following schedule Injection Gemcitabine 1 gm/kgm2 intravenous over 30 min Day1 and Day8 Injection Cisplatin 70 mg/kg m2 intravenous on Day1
11288149|NCT02778308|No Intervention|control group|follow up
11288150|NCT02778295||Observation|Patients with Fabry disease or high-grade suspicion for Fabry disease
11288151|NCT02778282|No Intervention|Standard Care|Standard Care through office-based opioid treatment with buprenorphine/naloxone and weekly urine toxicology screening
11288152|NCT02778282|Experimental|Standard Care + MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents Standard Care plus MySafeRx™.
11288153|NCT02778269|Experimental|Study Treatment|The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
11288154|NCT02778256|Experimental|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
11288155|NCT02778256|Sham Comparator|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
11288156|NCT02778243|Experimental|Bladder cancer|▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
11288157|NCT02778243|Other|benign prostate hyperplasia|▪ Patients with benign prostate hyperplasia who justified a prostatectomy.
11288158|NCT02778230|Experimental|Pea Fiber|Two fiber snacks fortified with 5 g/each of pea fiber (Best Pea Fiber 200) will be consumed each day for a period of two weeks.
11288159|NCT02778230|Other|Control|Two control snacks will be consumed each day for a period of two weeks.
11288160|NCT02778217|No Intervention|Uninterrupted single embryo culture|The same single medium is used throughout the 5-6 days of culture with no replenishment on day 3.
11288161|NCT02778217|Experimental|Interrupted single medium culture|The single step medium is renewed on Day 3 of embryo culture.
11288162|NCT02778204|Experimental|Cohort 1 Stratum 1A|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; without in utero exposure to maternal efavirenz.
11288163|NCT02778204|Experimental|Cohort 1 Stratum 1B|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; with in utero exposure to maternal efavirenz.
11288164|NCT02778204|Experimental|Cohort 2 Stratum 2A|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; without in utero or breast milk exposure to maternal efavirenz.
11288165|NCT02778204|Experimental|Cohort 2 Stratum 2B|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; with in utero and breast milk exposure to maternal efavirenz
11288166|NCT02778191||Concomitant cisplatin|Patients treated with concomitant cisplatin
11288167|NCT02778191||Carboplatin plus 5-FU|Patients treated with carboplatin plus 5-FU
11288168|NCT02778178|Experimental|TAP block with ropivacaine|Bilateral single shot TAP block under ultrasound guidance: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
11288169|NCT02778178|Placebo Comparator|TAP block with placebo|Placebo administration: bilateral single shot TAP block under ultrasound guidance: 20 mL saline 0.9%, per side
11288170|NCT02778165|No Intervention|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
11288171|NCT02778165|Experimental|MyCaRe Android Application|The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Flex before leaving hospital. They will be asked to input data (pain, mood, wounds, activity) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
11288172|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
11288173|NCT02778139||youth smokers|
11288174|NCT02778139||non-smokers|
11288175|NCT02778126|Experimental|[¹⁴C]Prexasertib|170 milligrams (mg) of prexasertib containing approximately 50 μCi [¹⁴C] prexasertib radiotracer administered intravenously (IV) as a 1 hour continuous IV infusion.
11288176|NCT02778126|Experimental|Prexasertib|"105 milligrams per square meter (mg/m²) of prexasertib administered IV as a 1 hour continuous IV infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.
~Treatment for this arm was administered after ¹⁴C administration (¹⁴C was administered during first phase of the study)"
11288177|NCT02778113|Experimental|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
11288178|NCT02778113|Experimental|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
11288179|NCT02778113|Experimental|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
11288180|NCT02778113|Active Comparator|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
11288181|NCT02778100|Experimental|Nasal Glucagon (NG) - Common Cold|Cohort 1 - Nasal Glucagon (NG) administered once in participants with a common cold.
11292455|NCT02749825|Active Comparator|Lupron|Per prescribing information
11288182|NCT02778100|Experimental|Nasal Glucagon (NG) - Symptom-Free|Cohort 1 - NG administered once in participants who have recovered from a common cold.
11288183|NCT02778100|Experimental|NG - Common Cold+Oxymetazoline|Cohort 2 - NG administered once in participants with a common cold who are taking oxymetazoline.
11288184|NCT02778087|Experimental|TAU plus 30 minutes of BT.|Intervention: Subjects randomized to the 30 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently two times per day in addition to their treatment as usual.
11288185|NCT02778087|Experimental|TAU plus 60 minute of BT.|Intervention: Subjects randomized to the 60 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently four times per day in addition to their treatment as usual.
11288186|NCT02778087|Sham Comparator|TAU plus 30 minutes of sham BT.|Intervention: Subjects randomized to the control (sham) group will perform the above Sham Mirror Box Therapy intervention independently two times per day. The control group will be using a mirror box with an opaque surface as opposed to a reflective mirror.
11288187|NCT02778074|Experimental|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
11288188|NCT02778074|Placebo Comparator|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
11288189|NCT02778048||fecal incontinence patients (m/f)|patients suffering from fecal incontinence (m/f) are going to be assessed via MRI, US, FLIP, and HRAM
11288190|NCT02778035|Experimental|60 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 60 min).
11288191|NCT02778035|Experimental|30 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 30 min).
11288192|NCT02778035|Experimental|0 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 0 min).
11288193|NCT02778022|Experimental|Immediate PriCARE|Parent-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
11288194|NCT02778022|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual.
11288195|NCT02778009|Experimental|Fit Physician Group|"Subjects will receive activity monitor and will be required to attend monthly wellness lectures and weekly exercise intervention.
~Every subject will undergo an iDEXA scan to measure body mass composition"
11288196|NCT02778009|Active Comparator|Activity Monitor Only Group|"Subjects will receive an activity monitor without any intervention Every subject will undergo an iDEXA scan to measure body mass composition
~)"
11288197|NCT02778009|Other|Control Group|Subjects will not an activity monitor nor will they receive any intervention Every subject will undergo an iDEXA scan to measure body mass composition
11288198|NCT02777996|Active Comparator|Screening arm|Low Dose Computed Tomography offered at baseline and for 3 repeated rounds
11288199|NCT02777996|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care (in Europe lung cancer screening is not raccomended), according with the GP.
11288200|NCT02777983|Experimental|Education Group|This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
11288201|NCT02777983|No Intervention|Usual Care Group|Subjects randomized to usual care will receive a 1-page generic informational handout on general conditioning recommended for low back pain, in addition to whatever education the subject's PCP decides to provide.
11288202|NCT02777970|Experimental|Tramadol/Dexketoprofen|"One film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single-dose;
~Two tablets of Placebo matching Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single-dose."
11288203|NCT02777970|Active Comparator|Tramadol/Paracetamol|"Two film-coated tablets of Tramadol Hydrochloride/Paracetamol 75 mg/650 mg [2 x 37.5mg/325mg] oral single dose;
~One tablet of Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol oral single dose."
11288204|NCT02777970|Placebo Comparator|Placebo|"One tablet of Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;
~Two tablets of Placebo matching Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
11288205|NCT02777957||mPAP ≥ 25 mmHg|mean pulmonary artery pressure (mPAP) ≥ 25 mmHg (37 patients)
11288206|NCT02777957||mPAP < 25 mmHg|mean pulmonary artery pressure (mPAP) < 25 mmHg (28 patients).
11288207|NCT02777944|Experimental|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
11288208|NCT02777944|No Intervention|Control|Usual Care
11288209|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
11288210|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
11288211|NCT02777918|Experimental|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
11288212|NCT02777918|No Intervention|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
11288213|NCT02777905|Experimental|MBCT intervention|"Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the centre local de services communautaires (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms."
11288214|NCT02777905|No Intervention|Control Group|Patients randomized to the control group will be offered literature on mental health promotion and will receive treatment as usual in the primary care health center setting. After the end of the study, the control group will be offered MBCT.
11288215|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
11288216|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC<70 and FEV1>50%)
11288217|NCT02777879||Control|No obstruction (FEV1/FVC<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
11288218|NCT02777866|Experimental|1: Bupivacaine 0.5%|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
11288219|NCT02777866|Placebo Comparator|2: 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs, who will be infiltrated in the total thickness of the abdominal wall with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound.
11288220|NCT02777853|Experimental|Active (green) tea|Tea to be ingested 3 times per day for 7 days.
11288221|NCT02777853|Placebo Comparator|Placebo tea|Tea to be ingested 3 times per day for 7 days.
11288222|NCT02777840|Active Comparator|Face mask group|Patients will be given oxygen via face mask as per routine practice, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
11288223|NCT02777840|Active Comparator|THRIVE group|Patients will be given oxygen via high flow oxygen in Optiflo, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
11288224|NCT02777827|Experimental|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
11288225|NCT02777827|Experimental|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
11288226|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
11288227|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
11288228|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
11288229|NCT02777827|Placebo Comparator|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
11288230|NCT02777814|Experimental|Prophylactic Entecavir|Entecavir is prophylactically used from the time of chemotherapy initiation at the dose of 0.5 mg p.o daily
11288231|NCT02777814|Active Comparator|Preemptive Entecavir|Entecavir is preemptively used from the time that hepatitis B virus DNA copies are more than 100 IU/ml at the dose of 0.5 mg p.o daily
11288232|NCT02777801|Experimental|Prophylactic Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the initiation of chemotherapy till 6 months after the end of chemotherapy.
11288233|NCT02777801|Active Comparator|Preemptive Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the time that the DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of chemotherapy.
11288234|NCT02777788|Active Comparator|chemotherapy|"Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.
~Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1."
11288235|NCT02777788|Experimental|TCM combined chemotherapy|TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21
11288236|NCT02777762|Experimental|Fun First|Strategies to promote enjoyment of physical activity
11288237|NCT02777762|Active Comparator|Close at Hand|Strategies to promote tracking of physical activity
11288238|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
~Adductor Canal Block (ACB)"
11288239|NCT02777749|Active Comparator|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
11288240|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.
~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
11288241|NCT02777736|Experimental|Arm A - Methotrexate i.v.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).
11288242|NCT02777736|Active Comparator|Arm B - Methotrexate i.t.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).
11288243|NCT02777736|No Intervention|Arm C - no Methotrexate|Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.
11288244|NCT02777723|Experimental|CKD-350|Xenobella
11288245|NCT02777723|Active Comparator|Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
11288246|NCT02777710|Experimental|Combination Pexidartinib-Durvalumab|"DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca
~PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg.
~In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose."
11288247|NCT02777697||cancer patients|
11288248|NCT02777684||knee osteoarthritis|
11288249|NCT02777671|Experimental|Group A|Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide
11288250|NCT02777671|Experimental|Group B|Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide
11288251|NCT02777658||Primary Study Cohort|Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
11288252|NCT02777658||Secondary Study Cohort|Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
11288253|NCT02777645||Study group|Study group(n=50) included CP children with chewing disorder. Growth, feeding evaluation will be done.
11288254|NCT02777645||Control group|Control group(n=35)= healthy children without chewing disorder Growth, feeding evaluation will be done.
11288255|NCT02777632||HCV patients following living donor liver transplantation|single infection episode group
11288256|NCT02777632||patients following living donor liver transplantation|recurrent Infections episode group
11288257|NCT02777619|Placebo Comparator|Propofol and 0.0ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
11288258|NCT02777619|Experimental|Propofol and 0.4ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
11288259|NCT02777619|Experimental|Propofol and 0.6ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
11288260|NCT02777619|Experimental|Propofol and 0.8ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
11288261|NCT02777606|Experimental|Si-Ni-Tang (a Chinese Herbal Formula)|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015. Besides, 150ml of Si-Ni-Tang will be given by p.o. or a nasogastric tube once per day for 3 days in the treatment group.
11288262|NCT02777606|No Intervention|Control|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015.
11288263|NCT02777593|Other|Zone 2 Aortic aneurysm|Zone 2 Aortic Aneurysm
11288264|NCT02777593|Other|Zone 2 Non-aneurysm aortic lesions|Includes dissection, traumatic transection and other isolated lesion types
11288265|NCT02777580|Experimental|Pharmaco-invasive strategy|Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
11288266|NCT02777580|Active Comparator|Standard primary PCI|Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.
11288267|NCT02777554|Experimental|Treatment A: 60mg Apremilast reference IR formulation|One 30 mg Immediate Release oral tablet in the morning and one 30 mg IR oral tablet in the evening of the dosing days) for 7 days under the fed condition.
11288268|NCT02777554|Experimental|Treatment B: 75mg Apremilast Once-daily (QD)|75 mg apremilast QD formulation once daily for 7 days under the fed conditions
11288269|NCT02777554|Experimental|Treatment C: 60 mg reference IR tablet|One 30 mg IR oral tablet administered in the morning in the fasting state and one 30 mg IR oral tablet administered in the evening after a minimum of a 2 hr fast for 1 day.
11288270|NCT02777554|Experimental|Treatment D: Single dose of QD apremilast|Single dose of 75mg apremilast QD administered in the fasting state
11288271|NCT02777554|Experimental|Treatment E: Single dose of QD apremilast|Single dose of 75mg apremilast QD administered approximately 30 minutes after a standard meal
11288272|NCT02777554|Experimental|Treatment F: Single dose of QD apremilast|Single dose of 75mg apremilast QD administered approximately 30 minutes after a high-fat meal
11288273|NCT02777541|Other|Early enteral nutrition|3 hours after PEG implantation
11288274|NCT02777541|Other|Late enteral nutrition|8 hours after PEG implantation
11288275|NCT02777528|Other|Zone 0/1 Aortic aneurysm|Zone 0/1 Aortic aneurysm
11288276|NCT02777528|Other|Zone 0/1 Non-aneurysm aortic lesions|Includes dissection and other isolated lesion types
11288277|NCT02777515|Other|Patients using electronic cigarette|The patients under the age of 35 followed at the consultation of rythmology for a cardiovascular assessment and already smoking the electronic cigarette and this since at least 1 month. The patient will receive a clinical examination, an electrocardiogram, a Holter-ECG and an echocardiogram before and after electronic cigarette consumption for 15 minutes.
11288278|NCT02777489|Experimental|Perindopril Bluepharma 8 mg|Each participant will have an at least 4-week run-in period, followed by a 6 weeks treatment period with Perindopril 8 mg.
11288279|NCT02777476|Experimental|procedure with B-Lite® Light Weight Breast Implant|
11288280|NCT02777450||Block group|Lumbar facet block. Levobupivacaine 0,25% and corticosteroids
11327158|NCT02520245|Experimental|Open-Label|
11288281|NCT02777437|No Intervention|Laparoscopic surgery|Patients with T4 colon cancer receive laparoscopic surgery only.
11288282|NCT02777437|Experimental|Neoadjuvantive chemotherapy + Laparoscopic surgery|Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
11288283|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
11288284|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
11288285|NCT02777411|Experimental|Group A1|3 to 6 years
11288286|NCT02777411|Experimental|Group A2|3 to 6 years
11288287|NCT02777411|Experimental|Group A3|3 to 6 years
11288288|NCT02777411|Experimental|Group A4|3 to 6 years
11288289|NCT02777411|Experimental|Group B2|6 to 35 months
11288290|NCT02777411|Experimental|Group B3|6 to 35 months
11288291|NCT02777411|Experimental|Group B4|6 to 35 months
11288292|NCT02777398|Experimental|Trans-Quadrant Channel Surgery|Patients in the experimental arm (experimental group, i.e. microsurgery through trans-Quadrant channel pathway) will be operated using Quadrant channel system. All the tumor resection will be operated through the Quadrant channel with assistance of microsurgical techniques.
11288293|NCT02777398|Active Comparator|Conventional Open Surgery|Patients in the active comparator arm (control group, i.e. conventional open surgery) will be operated using the conventional open surgery. All the tumor resection will be operated directly with conventional procedures. More posterior structures of spine will be removed.
11288294|NCT02777385|Experimental|Arm 1|Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplating and radiation.
11288295|NCT02777385|Experimental|Arm 2|Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisp/radiation and given every 3 weeks
11288296|NCT02777372|Experimental|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMD group only) on arousal regulation across the menstrual cycle.
11288297|NCT02777359|Experimental|the closure group|In the closure group, the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA, in combination of clopidogrel(50mg/d, 3mon) and aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
11288298|NCT02777359|No Intervention|the medication group|In the medication group, in combination of clopidogrel (50mg/d, 3mon) and aspirin (0.1g/d, 6mon), current medication resumed, including conventional prescription for migraine as β-receptor blockers, calcium-ion antagonists, antiepileptics, antidepressants and non-steroid anti-inflammatory drugs (NSAID).
11288299|NCT02777346|Experimental|Absorbable|Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).
11288300|NCT02777346|Active Comparator|Non Absorbable|Suture material: Polypropylene thread (Prolene®, Ethicon Inc).
11288301|NCT02777333|Experimental|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
11288302|NCT02777333|No Intervention|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
11288303|NCT02777320|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
11288304|NCT02777320|Experimental|Ibuprofen group|Second Group: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
11288305|NCT02777307|Experimental|Hemopatch Sealing Hemostat|
11288306|NCT02777307|No Intervention|No Hemopatch Sealing Hemostat|
11288307|NCT02777294|Experimental|Online intervention|Therapist-facilitated, cognitive behavioral therapy
11288308|NCT02777294|Active Comparator|Psycho-educational website|Self-help, psycho-educational website
11288309|NCT02777281|Other|Shoulder pain and SCI|Manual wheelchair users with SCI
11288310|NCT02777281|Other|Shoulder pain and able bodies|No SCI or wheelchair use but presence of shoulder pain
11288311|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
11288312|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
11288313|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
11288314|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
11288315|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
11288316|NCT02777242|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg [Device: QuickShot® Testosterone (QST)]
11288317|NCT02777229|Experimental|Dolutegravir|Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
11288318|NCT02777229|Active Comparator|Efavirenz|Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
11288319|NCT02777216|Experimental|ConfidenHT system|ConfidenHT system
11288320|NCT02777190|Experimental|Oral misoprostol|oral misoprostol given 25 mcg every 2 hours
11288321|NCT02777190|Active Comparator|Vaginal misoprostol|vaginal misoprostol given 25 mcg every 4 hours
11288322|NCT02777164|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
11288323|NCT02777151|Experimental|Cohort 1|REGN3470-3471-3479 dosing level 1 or placebo
11288324|NCT02777151|Experimental|Cohort 2|REGN3470-3471-3479 dosing level 2 or placebo
11288325|NCT02777151|Experimental|Cohort 3|REGN3470-3471-3479 dosing level 3 or placebo
11288326|NCT02777151|Experimental|Cohort 4|REGN3470-3471-3479 dosing level 4 or placebo
11288350|NCT02777008|Experimental|CTP-543 Multiple Dose|Multiple oral dose for 7 consecutive days
11288351|NCT02776995|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every 5 fraction of radiation, starting prior to the first radiation treatment, periodically, until the end of radiation therapy (a period of several weeks).
11288327|NCT02777138||Young males aged 20-35 years old|"Maintaining a normal daily living lifestyle
~Healthy
~Reasonably active- PAL: 1.4-1.9
~Non-obese- Fat mass index based on DEXA of 4-8kg/m2
~Weight stable for more than 3 months (±3% body mass)
~Non-smoker
~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders
~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription
~No medications that may influence lipid or carbohydrate metabolism or immune system function
~No known negative reaction to lidocaine
~No participation in heavy resistance training"
11288328|NCT02777138||Old males aged 65-85 years old|"Maintaining a normal daily living lifestyle
~Healthy
~Reasonably active- PAL: 1.4-1.9
~Non-obese- Fat mass index based on DEXA of 4-8kg/m2
~Weight stable for more than 3 months (±3% body mass)
~Non-smoker
~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders
~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription
~No medications that may influence lipid or carbohydrate metabolism or immune system function
~No known negative reaction to lidocaine
~No participation in heavy resistance training"
11288329|NCT02777125|Active Comparator|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
11288330|NCT02777125|Active Comparator|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
11288331|NCT02777112|Placebo Comparator|Control|This group will receive generic information about depression and serve as control
11288332|NCT02777112|Experimental|e-mental health program|This group will receive the developed e-mental health program
11288333|NCT02777112|Experimental|e-mental health program and job coaching|This group will receive the developed e-mental health program plus interactive job coaching through telephone.
11288334|NCT02777099|Experimental|RIPostC|Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning
11288335|NCT02777099|Sham Comparator|sham RIPostC|"Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure.
~Intervention:Procedure:Sham Remote Ischemic Postconditioning"
11288336|NCT02777086|Experimental|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
11288337|NCT02777086|No Intervention|Comparison|Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
11288338|NCT02777073|Active Comparator|liraglutide 1.8 mg|single dose of Victoza ( liraglutide) 1.8 mg
11288339|NCT02777073|Experimental|dapagliflozin 10|single dose of Farxiga ( dapagliflozin) 10 mg
11288340|NCT02777073|Placebo Comparator|Placebo|Single dose of placebo
11288341|NCT02777060|Experimental|Exergame|inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback. The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
11288342|NCT02777060|Active Comparator|Home based balance training|The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback. Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
11288343|NCT02777047|Experimental|Intervention|Complex Intervention including focused discharge medication reconciliation; structured handovers to family physician, community pharmacy, patient and family, home care, telehealth providers; virtual visit follow-up focused on anticoagulation monitoring.
11288344|NCT02777047|No Intervention|Control|Usual care. Patients will be provided with the URL to Thrombosis Canada website.
11288345|NCT02777034|Experimental|Enhanced Recovery|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.
~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.
~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
11288346|NCT02777034|Other|Unenhanced Recovery|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.
~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.
~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
11288347|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
11288348|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
11288349|NCT02777008|Experimental|CTP-543 Single Dose|Single oral dose
11288352|NCT02776982|Other|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
11288353|NCT02776956|Experimental|atorvastatin group|atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.
11288354|NCT02776956|Other|non-atorvastatin group|atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..
11288355|NCT02776943|Experimental|Mesenchymal stem cell treatment|Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.
11288356|NCT02776943|Active Comparator|Hyaluronic acid treatment|Administer hyaluronic acid (30 mg) in a single injection
11288357|NCT02776930||Return to Duty after Rehab from Injury|Patients deemed healthy enough to return to full duty without any restrictions after completing a course of rehabilitation for a lumbar/thoracic spine or lower extremity injury.
11288358|NCT02776917|Experimental|Cirmtuzumab + Paclitaxel|"Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
~Paclitaxel 80 mg/m^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle."
11288359|NCT02776904|Other|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
11288360|NCT02776904|Other|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
11288361|NCT02776891|Experimental|Gallium citrate|The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 millicurie (mCi) and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
11288362|NCT02776878|Experimental|Dasatinib|Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.
11288363|NCT02776865|Experimental|physical therapy and suprascapular nerve block|patient received ultrasound-guided suprascapular nerve block as well as physical therapy.
11288364|NCT02776865|Active Comparator|physical therapy only|patient received physical therapy only.
11288365|NCT02776852|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11288366|NCT02776839|Other|Mobile Sensing|This phase of the study is designed to develop the app. due to algorithms the app should lern to detect depressive symptoms
11288367|NCT02776813|Experimental|ACTR087, in combination with rituximab|
11288368|NCT02776800|Experimental|Allevyn Life|Foam Dressing
11288369|NCT02776800|Other|Foam Dressing|Standard Care - Foam Dressing
11288370|NCT02776787||Patients|Patients with diverticulitis
11288371|NCT02776787||Surgeons|Surgeons who perform elective colon resections
11288372|NCT02776761|Experimental|Hantaan Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
11288373|NCT02776761|Experimental|Puumala Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
11288374|NCT02776761|Experimental|Hantaan/Puumala Vaccine|The HTNV and PUUV vaccine will be combined (equal volumes) before use: 1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
11288375|NCT02776748|Other|FTC-TDF|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF
11288376|NCT02776735|Experimental|Sarilumab|Participants will receive one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose regimen once this is identified. Sarilumab will be given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for approximately 72 patients enrolled in dose-finding and second portions and 84 weeks for approximately 28 patients enrolled in third portion)
11288377|NCT02776709||Bile duct Stricture|Patients referred for the evaluation of indeterminate strictures.
11288378|NCT02776709||Common bile duct Stones|Patients referred for the removal of difficult stones.
11288379|NCT02776696|Experimental|Advanced HybridClosed Loop System (AHCL)|Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3 or 5 days in a camp setting and 21 days at home during segment 4.
11288380|NCT02776696|Experimental|Hybrid Closed Loop System (HCL)|"Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:
~36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3"
11288381|NCT02776683|Experimental|All patients|
11288382|NCT02776670|Experimental|SYSTANE BALANCE|Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
11288383|NCT02776670|Active Comparator|REFRESH OPTIVE|Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
11288384|NCT02776657|Active Comparator|Cohort 1 (Stable Angina)|20 patients with stable angina planned to undergo elective coronary angiography will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries.
11288385|NCT02776657|Active Comparator|Cohort 2 (Acute Coronary Syndrome)|20 patients diagnosed with acute coronary syndrome will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries. If thrombus is identified, participants will be asked to undergo a repeat MRI scan at one and three months.
11288386|NCT02776631|Experimental|Pinloc|Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
11288387|NCT02776631|Active Comparator|LIH (Hansson pins)|2 pins. An established method for fixation of femoral neck fractures.
11288388|NCT02776618|Experimental|Polyglactin 910|One half of excision site will be randomly assigned superficial closure with polyglactin 910 suture
11288389|NCT02776618|Experimental|poliglecaprone 25|One half of excision site will be randomly assigned superficial closure with poliglecaprone 25
11288390|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)
~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.
~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.
~HSCT (performed ideally within 1 month from the end of consolidation).
~Post HSCT therapy (MRD monitoring)"
11288391|NCT02776592|Experimental|Experimental|A cow's milk-based formula with added nutrients
11288392|NCT02776592|Active Comparator|Control|A cow's milk-based formula
11288393|NCT02776579|Experimental|Girls-only resistance training|8 weeks of 2-3x/week girls-only resistance training class with a female strength and conditioning specialist.
11288394|NCT02776579|No Intervention|No resistance training|8 weeks of usual activity.
11288395|NCT02776566|Active Comparator|Anticoagulation Clinic|"Usual care through pharmacist managed anticoagulation clinic
~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
11288396|NCT02776566|Experimental|Patient Self-Monitoring|"In home self-monitoring and pharmacist guided education
~Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages."
11288397|NCT02776553|Experimental|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
11288398|NCT02776553|Active Comparator|Control|nutritional intervention
11288399|NCT02776540|Active Comparator|900 mg Clopidogrel|67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
11288400|NCT02776540|Active Comparator|600 mg Clopidogrel|67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
11288401|NCT02776540|Placebo Comparator|400 mg Aspirin|67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
11288402|NCT02776527|Experimental|A group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
11288403|NCT02776527|No Intervention|B group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox
11288404|NCT02776514|Active Comparator|Triamcort (1 ml, 40 mg/ml)|60 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
11288405|NCT02776514|Active Comparator|Platelet-rich-plasma (PRP 3 ml)|60 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
11288406|NCT02776514|Active Comparator|Suplasyn1-shot (60 mg/ ml)|60 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
11288407|NCT02776514|Placebo Comparator|Placebo (Iopamiro 200)|60 patients receive intraarticular injection with contrast media only
11288408|NCT02776501|Experimental|BAY987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11288409|NCT02776488|Experimental|ELI Arm|Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI
11288410|NCT02776488|Placebo Comparator|Placebo|Placebo infusion of normal saline in Part 2 RCT
11288411|NCT02776475|Other|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
11288412|NCT02776462||Potential Traumatic Brain Injury|This group will consist of people admitted to the ER, Trauma Bay, or Neurosurgery for potential traumatic brain injury.
11288413|NCT02776449||Normal Tension Glaucoma|Patients with manifest normal tension glaucoma
11288414|NCT02776436|Experimental|Breast cancer|"Dose of prophylactic dexamethasone will be reduced as follows:
~STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)
~STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)
~STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)
~STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)
~STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)
~STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)"
11288415|NCT02776436|Experimental|Prostate cancer|"Dose of prophylactic dexamethasone will be reduced as follows:
~STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)
~STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)
~STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)
~STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)"
11288416|NCT02776410|Experimental|Intervention group|Group receiving tailored messages promoting sustainable and healthy eating through an mobile-application together with six principles of sustainable healthy eating that will be included in the mobile application,
11288417|NCT02776410|No Intervention|Control group|Group who will not download the mobile application
11288418|NCT02776397|Active Comparator|Hp 2-2 Vitamin E|The Haptoglobin 2-2 group randomised to Vitamin E
11288419|NCT02776397|Placebo Comparator|Hp 2-2 Placebo|The Haptoglobin 2-2 group randomised to placebo
11288420|NCT02776397|Active Comparator|Non Hp 2-2 Vitamin E|The Non Haptoglobin 2-2 group randomised to Vitamin E
11368157|NCT02247141|Experimental|Subgam®|
11288421|NCT02776397|Placebo Comparator|Non Hp 2-2 Placebo|The Non Haptoglobin 2-2 group randomised to placebo
11288422|NCT02776384||chronic heart failure|patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction
11288423|NCT02776371|Experimental|Modified non-clarithromycin triple therapy|H.pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
11288424|NCT02776371|Active Comparator|Sequential therapy|H.pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
11288425|NCT02776358|Experimental|High Fidelity Simulation|Students will receive a 1 hour High fidelity simulation session
11288426|NCT02776358|Experimental|Video Case|Students will receive a 1 hour assisted Video Case learning session
11288427|NCT02776345|Active Comparator|Ultrasound guided Needle Fragmentation|"Ultrasound guided Needle Fragmentation (Intervention):
~Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed."
11288428|NCT02776345|Active Comparator|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
11288429|NCT02776345|Placebo Comparator|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
11288430|NCT02776332|Active Comparator|3 day group|Manual expression for 3 days after delivery Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
11288431|NCT02776332|Active Comparator|7 day group|The 7 day group will manually express for 7 days after delivery. Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery follow up phone call at 5 days to encourage continued manual expression
11288432|NCT02776319|Experimental|Active|Non-invasive brain stimulation (active)
11288433|NCT02776319|Placebo Comparator|Sham/Placebo|Non-invasive brain stimulation (sham)
11288434|NCT02776306|Experimental|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
11288435|NCT02776306|No Intervention|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
11288436|NCT02776293|Active Comparator|Relaxation Group|The relaxation group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to sit undisturbed for 20 minutes.
11288437|NCT02776293|Experimental|Music Group|The music group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to listen to pre-recorded songs specifically composed for pregnancy.
11288438|NCT02776280|Placebo Comparator|Negative control|Meal prepared with non-fluoridated water and salt
11288439|NCT02776280|Experimental|Fluoridated water|Meal prepared with fluoridated water
11288440|NCT02776280|Experimental|Fluoridated salt|Meal prepared with fluoridated salt
11288441|NCT02776267|Experimental|Angiolite stent - 3-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
11288442|NCT02776267|Experimental|Angiolite stent - 6-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
11288443|NCT02776254|Experimental|START|The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing and results, streamlined adherence counseling, and quicker initiation of life-long ART to patients enrolling in HIV care and treatment services.
11288444|NCT02776254|Experimental|FAST Track|In the FAST-TRACK model a pharmacy technician will dispense drugs) and lay health care workers will provide brief symptom screening to identify patients in need of higher-level care. If there is no need of higher-level care, then the clinic visit is over.
11288445|NCT02776254|Experimental|CAG (intervention)|CAG intervention, consists of facilitated groups of six people based on geographic proximity of home address and patient preference. This group of six people, will meet monthly at a designated place in the community to provide support and receive medications. Each month one of the members will rotate visiting the clinic for their routine medical visit and will pick up medications for the entire CAG and bring them back to the community. This rotation schedule will recur every six months. Lay health care workers will provide brief symptom screening to identify patients in the group that need of higher-level care.
11288446|NCT02776254|Active Comparator|CAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
11289186|NCT02771158|Placebo Comparator|placebo|randomization to placebo control
11288447|NCT02776254|Experimental|UAG (intervention)|Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
11288448|NCT02776254|Active Comparator|UAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
11288449|NCT02776241|No Intervention|water restriction|20 patients will be subjected to 3 hours of water restriction following MR scan of the kidneys.
11288450|NCT02776241|Active Comparator|high water intake|20 patients will be subjected to 1 hour of high water intake (20 ml/kg) following MR scan of the kidneys.
11288451|NCT02776228|Experimental|benzodiazepine|The patient which will be in the Experimental arm (after randomization) will receive 0.25 mg of Brotizolam (short acting benzodiazepine) for six weeks from the day of discharge.
11288452|NCT02776228|Placebo Comparator|placebo|The patient which will be in the placebo arm (after randomization) will receive placebo for six weeks from the day of discharge.
11288453|NCT02776215|Experimental|Pharmacokinetic Dosing|Single-dose pharmacokinetics of tasimelteon
11288454|NCT02776202|Experimental|Reduced-intensity conditioning regimen|"The HSCT preparative regimen will consist of
~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5
~Fludarabine: 35 mg/m2/day IV on Days -8 through -4
~Melphalan: 140 mg/m2 IV on Day -3
~Rest on Day -2 and -1
~Day 0 is the day of transplant
~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
11288455|NCT02776189|Experimental|Midazolam & Dexmedetomidine|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
11288456|NCT02776189|Active Comparator|Midazolam & Propofol|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous propofol 2 mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
11288457|NCT02776176|Experimental|ERAS group|Patients receive the Enhanced Recovery After Surgery program during the peri-operative period.
11288458|NCT02776176|Other|Traditional group|Patients receive the Traditional program during the peri-operative period.
11288459|NCT02776163|Experimental|Cisplatin Group|Intensity-modulated radiotherapy+concurrent chemotherapy with cisplatin for squamous carcinoma of salivary gland
11288460|NCT02776163|Experimental|Docetaxel+Cisplatin|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and cisplatin for adenogenous types carcinoma of salivary gland
11288461|NCT02776150||MGIT liquid culture+drug sensitivity test|MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
11288462|NCT02776150||Xpert-MTB/RIF|xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
11288463|NCT02776150||probe melting curve detection|Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.
11288464|NCT02776137|Experimental|Docetaxel Group|Concurrent Chemoradiotherapy With Docetaxel
11288465|NCT02776124|Experimental|ONS group|Individualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
11288466|NCT02776124|No Intervention|control group|Individualized dietary counseling during CRT
11288467|NCT02776111||Healthy Controls|Participants in this group will have a one time blood sample taken.
11288468|NCT02776111||Kidney Transplant Group|Participants in this group have had a kidney transplant and blood samples will be obtained as described in study plan
11288469|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
11288470|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
11288471|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
11288472|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
11292456|NCT02749825|Active Comparator|Zoladex|Per prescribing information
11288473|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
11288474|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
11288475|NCT02776072||dimethyl fumarate (DMF)|Participants who initiated DMF during the specified time period
11288476|NCT02776072||glatiramer acetate (GA)|Participants who initiated GA during the specified time period
11288477|NCT02776072||teriflunomide|Participants who initiated teriflunomide during the specified time period
11288478|NCT02776072||fingolimod|Participants who initiated fingolimod during the specified time period
11288479|NCT02776059|Experimental|prednisolone or pentoxifylline + pegfiltrastim|prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot
11288480|NCT02776059|Active Comparator|prednisolone or pentoxifylline|prednisolone or pentoxifylline for 28 days
11288481|NCT02776046|Experimental|High FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
~Postoperatively 3h with 0.8 FiO2 and individualized CPAP"
11288482|NCT02776046|Active Comparator|Conventional FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.3. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
~Postoperatively 3h with 0.3 FiO2 and individualized CPAP"
11288483|NCT02776033|Experimental|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
11288484|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
11288485|NCT02776033|Experimental|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
11288486|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
11288487|NCT02776020||Propofol sedated patients|Women undergoing a short trans vaginal ovum retrieval (TVOR) will be sedated with propofol , and monitored non-invasively for changes in blood propofol concentration levels. Propofol dosages will be adapted according to patients vital signs and their reaction to noxious stimuli exerted during the trans vaginal ovum retrieval (TVOR) procedure, irrespective to the proposed study in which these participants undergo.Those changes of administered propofol dosages will be observed by the anesthetic drug monitor (ADM). Propfol is administered by the anesthesiologist in a routine manner and according to anesthesiologist discretion .
11288488|NCT02776007|Experimental|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
11288489|NCT02776007|Active Comparator|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
11288490|NCT02775994|Experimental|Treatment Arm|Single dose of Canakinumab 4mg/kg
11288491|NCT02775981|Experimental|Active|RX0041-002
11288492|NCT02775955|Experimental|RX0041-002|Active
11288493|NCT02775942|Experimental|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
11288494|NCT02775942|Experimental|IPOVAC 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
11288495|NCT02775942|Experimental|IPOVAC 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
11288496|NCT02775942|Active Comparator|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
11288497|NCT02775929|Other|PrEP as a bridge to ART|FTC-TDF PrEP for HIV uninfected partners and ART for HIV infected partners
11288498|NCT02775916|Experimental|CDZ173|Capsule
11288499|NCT02775916|Placebo Comparator|Placebo|Capsule matching Placebo
11288500|NCT02775903|Experimental|Azacitidine + Durvalumab|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
11288501|NCT02775903|Active Comparator|Azacitidine Alone|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
11288502|NCT02775890||Eating lead-shot wild game|Hunters that have eaten lead-shot in the past week will have blood lead levels measured.
11288503|NCT02775890||Not eating lead-shot wild game|Hunters that have not eaten lead-shot in the past week will have blood lead levels measured.
11288504|NCT02775877|Experimental|letrozole and clomiphene|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and clomiphene100 mg tablet orally once a day from 11-15 day of menstrual cycle.
11369422|NCT02238756|Experimental|CV8102|
11288505|NCT02775877|Active Comparator|Letrozole and human menopausal gonadotropin (HMG)|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and HMG 75u once a day by intramuscular injection from 11-15day of menstrual cycle
11288506|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
11288507|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
11288508|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
11288509|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
11288510|NCT02775851|Experimental|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab.
11288511|NCT02775851|Active Comparator|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity.
11288512|NCT02775838|Experimental|kidney transplantation|Intravenous injection of Indocyanine Green in patients receiving kidney transplantation
11288513|NCT02775812|Experimental|Treatment (cisplatin, pembrolizumab, IMRT)|Patients receive cisplatin IV over 1-2 hours once weekly for weeks 1-6 and pembrolizumab IV over 30 minutes every 3 weeks in weeks 9, 12, 15, 18, and 21. Patients also undergo IMRT in weeks 1-6. Patients may also receive pembrolizumab IV over 30 minutes in weeks 3, 6, 24, and 27.
11288514|NCT02775786|No Intervention|Healthy Volunteers|Normal volunteers with no pancreas mass or risk factors for pancreas cancer will be recruited for MRI protocol optimization and nothing more. No intravenous contrast will be given. They will be asked to lie in the scanner for up to 1 hour and non-contrast imaging will be performed.
11288515|NCT02775786|Experimental|Pancreatic Mass or Risk Factors Group|Participants with pancreatic adenocarcinoma who are planning to undergo surgical resection. Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis .
11288516|NCT02775773|Experimental|arm A (TXA)|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
11288517|NCT02775773|Active Comparator|arm B (OXY)|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
11288518|NCT02775760|Experimental|Cardiovascular endurance|Participants will undergo cardiovascular endurance training. The trainer-supervised endurance training will involve walking on a treadmill at moderate intensity
11288519|NCT02775760|Active Comparator|Strength, balance, and flexibility|Participants will undergo Strength, balance, and flexibility training.
11288520|NCT02775747|Experimental|platelet rich plasma gel|Injection of Platelet rich plasma (PRP) gel in 64 cases at time of wound closure in women undergoing cesarean section for improving wound healing after fullfit to all the inclusion and exclusion craiteria
11288521|NCT02775747|Placebo Comparator|Saline|64 Controlled Women with recurrent cesarean section and fullfit to all the inclusion and exclusion craiteria will reseve saline injection at time of wound closure
11288522|NCT02775734|Active Comparator|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + LOD
11288523|NCT02775734|Active Comparator|NO N-acetyl-cysteine|Clomiphene citrate + LOD
11288524|NCT02775721|Other|Cohort A|"Head and Neck Cancer patients receiving Radiation Therapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts B and C.
~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.
~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.
~Nutritional therapy education and evaluation is assessed per the attending dietitian.
~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
11288525|NCT02775721|Other|Cohort B|"Head and Neck Cancer patients receiving Chemotherapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and C.
~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.
~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.
~Nutritional therapy education and evaluation is assessed per the attending dietitian.
~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
11288526|NCT02775721|Other|Cohort C|"Head and Neck Cancer patients receiving Chemotherapy and Radiation therapy. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and B.
~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.
~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.
~Nutritional therapy education and evaluation is assessed per the attending dietitian.
~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
11288527|NCT02775708|Experimental|capsule endoscopy|open label arm ; up to 100 subjects indicated for capsule endoscopy (CE) procedure will undergo the CE procedure with the Pillcam endoscopy system
11288528|NCT02775695|Experimental|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
11288529|NCT02775682||patients with epilepsy|
11288530|NCT02775682||normal individuals without epilepsy|
11288531|NCT02775669||intracranial ICP monitoring|invasive intracranial ICP monitoring
11288532|NCT02775669||tranfontanel ICP monitoring|Noninvasive transfontanel ICP monitoring
11288601|NCT02775201|Active Comparator|Plantaris release under ultrasound guidance|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris released under ultrasound guidance by a consultant radiologist
11288533|NCT02775656||Prospective cohort|For a pregnancy to be enrolled in the prospective cohort, the pregnancy outcome cannot be known (ie, no prenatal diagnosis of a fetus with a congenital defect and the pregnancy is still ongoing at the time of consent).
11288534|NCT02775656||Retrospective cohort|For a pregnancy to be enrolled in the retrospective cohort, the pregnancy outcome must already be known (ie, a congenital defect has already been identified at the time of consent into the pregnancy follow-up study, or the pregnancy has been completed at the time of consent).
11288535|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
11288536|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
11288537|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
11288538|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..
~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
11288539|NCT02775604|Other|Home-Based Video|GoPro Camera
11288540|NCT02775604|Other|Paper Checklist|Homeowner Print Checklist
11288541|NCT02775591|Experimental|Motilitone arm|DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
11288542|NCT02775591|Placebo Comparator|Placebo arm|DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks
11288543|NCT02775578|Experimental|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
11288544|NCT02775578|Experimental|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
11288545|NCT02775578|Experimental|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
11288546|NCT02775552|Experimental|A&T intervention areas|
11288547|NCT02775552|Active Comparator|Comparison areas|(Receive standard government services)
11288548|NCT02775539|Active Comparator|Mirabegron|Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.
11288549|NCT02775539|Placebo Comparator|Placebo|Oral placebo, similarly titrated to ensure blindness.
11288550|NCT02775526|Active Comparator|TOT|TOT
11288551|NCT02775526|Active Comparator|TVT|TVT
11288552|NCT02775526|Active Comparator|Burch colposuspension|Burch colposuspension
11288553|NCT02775513||Mutation|Patients with functional mutation in ion channels
11288554|NCT02775513||Control|Matched control
11288555|NCT02775500||Apremilast-Exposed Cohort|Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
11288556|NCT02775500||Diseased Comparison Cohort|Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
11288557|NCT02775500||Healthy Comparison Cohort|Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
11288558|NCT02775500||Apremilast-Exposed Registry Group|Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
11288559|NCT02775487||COPD and air quality|Persons enrolled in the study will have been diagnosed with Stage III or IV COPD and samples of air taken from their home environment.
11288560|NCT02775474|Experimental|Methadone|Methadone used as anesthesia opioid: induction with 0,15 mg / kg intravenous methadone. Boluses of 0,05 mg / kg intravenous methadone as needed intraoperatively
11288561|NCT02775474|Active Comparator|Fentanyl|Fentanyl used as anesthesia opioid: induction with 6 mcg / kg intravenous fentanyl. Boluses of 2 mug / kg intravenous fentanyl as needed intraoperatively
11288562|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
11288563|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
11288564|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
11288565|NCT02775448|Experimental|Diet + exercise + Carduus marianus 6cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
11288566|NCT02775448|Experimental|Diet + exercise + Carduus marianus 12cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
11288567|NCT02775448|Experimental|Diet + exercise + Carduus marianus 30cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
11288568|NCT02775448|Placebo Comparator|Diet + exercise + placebo|Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
11288569|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
11288602|NCT02775201|Active Comparator|Plantaris excision surgically|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris excised in surgery by a consultant orthopaedic surgeon
11288960|NCT02772705||Hyperthyroidism|Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
11372928|NCT02215031|Experimental|BI 44370|
11288570|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
11288571|NCT02775422|Experimental|Pregnant women|Pregnant women
11288572|NCT02775409|Active Comparator|Subcutaneous|Subcutaneous placement of tissue expander
11288573|NCT02775409|Active Comparator|Submuscular|Submuscular placement of tissue expander
11288574|NCT02775396|Experimental|Adult computer user|Wearing each of the two spectacle lens designs for one month in random sequence
11288575|NCT02775383||Longitudinal|Participants with MDS, MDS/MPN overlap disorder, AML <30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities
11288576|NCT02775383||Cross-sectional|Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only
11288577|NCT02775370|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
11288578|NCT02775357|Experimental|Enhanced HIV counseling and testing|In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
11288579|NCT02775357|Active Comparator|Standard HIV testing and counseling|Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
11288580|NCT02775344|Experimental|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
11288581|NCT02775344|No Intervention|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
11288582|NCT02775331|Experimental|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
11288583|NCT02775331|Experimental|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
11288584|NCT02775331|No Intervention|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
11288585|NCT02775318|Other|Stellate Ganglion Block|After diagnosis of vasospasm patients were administered ultrasound guided Stellate Ganglion block using 10 cc of 0.5% Inj Bupivacaine on the same side of vasospasm or the side contralateral to the focal neurological deficit.Patients were then assessed using transcranial Doppler and digital subtraction angiography after 30 minutes
11288586|NCT02775305|No Intervention|Not frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants do not meet criteria for frailty, baseline screening data will be used for comparative analysis as the no intervention arm.
11288587|NCT02775305|Experimental|Frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants meet criteria for frailty participants will be enrolled in the intervention arm. Participants who are ambulatory regardless of co-morbidities will not be excluded from the study.
11288588|NCT02775292|Experimental|Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.
~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.
~NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
~NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28.
~LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses."
11288589|NCT02775279||Acute coronary syndrome group|200 consecutive patients were recruited, who have diagnosed with acute coronary syndrom(ACS) by quantitative coronary angiography.
11288590|NCT02775279||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
11288591|NCT02775266|Active Comparator|ALA + Scaling and Root planing|Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)
11288592|NCT02775266|Placebo Comparator|Scaling and root planing only|Patients will receive scaling and root planning at baseline and 3 months(group A)
11288593|NCT02775253|Experimental|Chronic cold acclimation group|All patients will be conducted a chronic cold acclimation intervention for 33 days.
11288594|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
11288595|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
11288596|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
11288597|NCT02775227|Experimental|Hydrocortisone|
11288598|NCT02775227|Active Comparator|Pasireotide|
11288599|NCT02775214|No Intervention|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
11288600|NCT02775214|Active Comparator|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
11288603|NCT02775188|Experimental|Physical Therapy with InterACTION|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
11288604|NCT02775188|Other|Physical Therapy|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week
11288605|NCT02775175|No Intervention|Fasting as Usual|This group will continue to practice their usual fasting regimen during Ramadan
11288606|NCT02775175|Experimental|Modified Ramadan Fasting|This group will receive an educational intervention providing knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
11288607|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
11288608|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
11288609|NCT02775149||Reflux patients|Patients who are treated at the Clinic for Gastroenterology and Gastrointestinal Oncology and have a 24-hours pH monitoring or impedance measurement performed for medical reasons
11288610|NCT02775136|Experimental|HS-1000 recording|Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
11288611|NCT02775123|No Intervention|Control|Conventional cardio-pulmonary bypass
11288612|NCT02775123|Experimental|Cytosorb|Cytosorb added to cardio-pulmonary bypass
11288613|NCT02775110|Active Comparator|Immediate Discontinuation Group|Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
11288614|NCT02775110|Experimental|Taper-off Group|Patients will be administered two more natalizumab infusion, one at six weeks and the second at eight weeks (14 weeks from study entry), followed by six months natalizumab discontinuation. Another DMT will be initiated within two months after the last natalizumab infusion.
11288615|NCT02775097||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
11288616|NCT02775097||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus.
11288617|NCT02775084|Experimental|Healthy Fish Oil|8 grams fish oil
11288618|NCT02775084|Placebo Comparator|Olive Oil|8 grams olive oil
11288619|NCT02775058||patients|The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.
11288620|NCT02775045||Eosinophil esophagitis|Adult patients (>18 yr) will be recruited from the Gastroenterology clinic following a diagnostic endoscopy for esophageal dysfunction with predominant symptom(s) of solid food dysphagia and/or esophageal food impaction. Patients with esophageal biopsy showing greater than 15 eosinophil/hpf (pathology results typically available within three business days) despite greater than two months use of high dose proton pump inhibitor will be invited to participate and enroll in the study within 1 week of the endoscopy.
11288621|NCT02775019|Active Comparator|Lactobacillus reuteri lonzenges|2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
11288622|NCT02775019|Placebo Comparator|Placebo lozenges|2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
11288623|NCT02775006|Active Comparator|Docetaxel|Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
11288624|NCT02775006|Active Comparator|Docetaxel plus erlotinib|Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.
11288625|NCT02774993|Experimental|Doxycycline|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
11288626|NCT02774993|Placebo Comparator|Placebo|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
11288627|NCT02774967|Active Comparator|extended flap technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.
~Other Names:
~acellular dermal matrix extended flap technique"
11288628|NCT02774967|Experimental|tunnel technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.
~Other Names:
~acellular dermal matrix extended flap technique"
11288629|NCT02774954|Experimental|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
11288961|NCT02772705||Health Humans|Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
11375878|NCT02195505||Synvisc®|
11288630|NCT02774954|Active Comparator|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
11288631|NCT02774941|Active Comparator|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
11288632|NCT02774941|Experimental|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
11288633|NCT02774928||Chronic Obstructive Pulmonary Disease|Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
11288634|NCT02774928||Interstitial lung diseases|Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
11288635|NCT02774928||Obstructive sleep apnea (OSA)|"Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.
~These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
~OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome-also referred to as obstructive sleep apnea-hypopnea syndrome."
11288636|NCT02774902|Experimental|TAK-438 40 mg + Clarithromycin 500 mg|TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.
11288637|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.
~Fall prevention tips
~Fall prevention exercise videos noting technique and safety
~Guest expert videos and communication with expert
~Tools to set exercise goals, reminders and track progress
~Fall prevention specialist for feedback and group activities
~Discussion and messaging (1:1, small and large group)
~Fall prevention resources."
11288638|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
11288639|NCT02774876|Active Comparator|Carbohydrate meal|
11288640|NCT02774876|Active Comparator|Carbohydrate + fat meal|
11288641|NCT02774876|Active Comparator|Carbohydrate + protein meal|
11288642|NCT02774876|Active Comparator|Carbohydrate + fat + protein meal|
11288643|NCT02774863||"Group Maternal and Child Protection"|Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
11288644|NCT02774863||"Group Home passages"|A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.
11288645|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
11288646|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
11288647|NCT02774837|Experimental|combination|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
11288648|NCT02774837|Active Comparator|mono therapy|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
11288649|NCT02774824||CABG patients from protocol 003-03|"Patients who will agree to be followed for an additional 9 months, which include:
~2 phone calls at 6 and 9 months after coronary artery bypass graft surgery
~1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography)"
11288650|NCT02774811|Active Comparator|Selective laser trabeculoplasty|Selective laser trabeculoplasty
11288651|NCT02774811|Active Comparator|Prostaglandin analogue|Prostaglandin analogue topical medical therapy
11288652|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:
~Oxford Grades 1 & 2 - intra-rectal intussusception
~Oxford Grades 3 & 4 - intra-anal intussusception
~Oxford grade 5 - Overt Rectal Prolapse"
11288653|NCT02774785|Experimental|Device Arm|Randomized for MarginProbe device to be used during surgical procedure
11288654|NCT02774785|No Intervention|Control Arm|Randomized for surgical procedure to happen as per standard care
11288655|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.
~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.
~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.
~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
11288711|NCT02774382|Experimental|Vancomycin + rectal bacteriotherapy|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
11288962|NCT02772692|Experimental|Squatting pan|Defecation using a squatting pan
11390937|NCT02096731||LABA + tiotropium|
11288656|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.
~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.
~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
11288657|NCT02774759|Active Comparator|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.
~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.
~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
11288658|NCT02774746|Active Comparator|35-week delivery group|Subjects to be delivered at 35 0/7 weeks through 35 6/7 weeks.
11288659|NCT02774746|Active Comparator|38-week delivery group|Subjects to be expectantly managed to spontaneous delivery, delivered by 38 0/7 weeks through 38 6/7 weeks.
11288660|NCT02774720|Experimental|Centre-based physical activity|People with Mild Cognitive Impairment (MCI) and early dementia will receive centre-based physical activity for one hour each week for three months, plus at-home prescribed exercise.
11288661|NCT02774720|Experimental|Home-based exercise|People with Mild Cognitive Impairment (MCI) and early dementia be prescribed at-home prescribed exercise and will received monthly support phone calls.
11288662|NCT02774694||observational cohort|patients undergoing interventional pain management procedures
11288663|NCT02774681|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
11288664|NCT02774668|Active Comparator|"Grab-and-Go meal plan"|"The intervention of this arm is to use a Grab-and-Go meal plan. This meal plan provides Atkins shakes and bars for breakfast, lunch, and snacks for 2 weeks. For dinner the subject is given a freshly-prepared meal. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
11288665|NCT02774668|Active Comparator|"Jump-Start meal plan"|"The intervention of this arm is to use a Jump Start meal plan. This meal plan provides Atkins frozen meals at breakfast, lunch and dinner for 2 weeks and these meals are supplemented with fresh salads and vegetables. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
11288666|NCT02774655|Experimental|PAI APP|personal activity index application
11288667|NCT02774655|Active Comparator|FitBit APP|
11288668|NCT02774642|Experimental|CBTI-PE|Integrates the core components of CBT-I and PE in 14 90-minute weekly sessions.
11288669|NCT02774642|Active Comparator|Hygiene-PE|Uses non-active sleep hygiene to account for the dose response of experimental condition before starting PE. Uses 14 90-minute weekly sessions.
11288670|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
11288671|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
11288672|NCT02774616|Other|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
11288673|NCT02774603|Active Comparator|Aquatic Locomotor Training|Aquatic Locomotor Training is a Locomotor Training technique utilizing an underwater treadmill to help increase a patient's independence and function. Aquatic Locomotor Training may require up to three people to obtain desirable gait kinematics: one at each of the patient's legs, and one at the patient's pelvis; however, typically with ambulatory patients, only one therapist is utilized. Therapists are highly trained, using their legs and feet to provide properly timed underwater cues throughout the gait cycle.
11288674|NCT02774603|Active Comparator|Land Locomotor Training|Locomotor Training encompasses a variety of interventions ranging from BWSTT to overground gait training to robotic-assisted walk training. Overground Locomotor Training, depending upon the technique used, can require up to four people to complete the intervention (one at each participant's leg, one at the participant's trunk and/or pelvis, and one monitoring the computer and/or treadmill).
11288675|NCT02774590|Experimental|Timolol to split face for 8 weeks|All 24 subjects will receive study drug and everyone will be randomized to which side of the face is treated with study drug first (right half-face versus left half-face). After 8 weeks of split-face treatment every night before bed, the subjects will be instructed to start treating both sides for another 8 weeks. Up to 30 subjects may be enrolled to ensure a target sample size of 24 (12 acne cases, 12 rosacea cases). This is an exploratory study. No part of this protocol will be considered routine care.
11288676|NCT02774577|Experimental|healthy young and elderly|young adults (20 to 30 years) compare to elderly (60 to 74 years)
11288677|NCT02774564|Experimental|Nebicapone 50 mg|1 tablet of 50 mg plus 3 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
11288678|NCT02774564|Experimental|Nebicapone 100 mg|2 tablets of 50 mg plus 2 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
11288679|NCT02774564|Experimental|Nebicapone 200 mg|4 tablets of 50 mg concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
11288680|NCT02774564|Placebo Comparator|Placebo|4 tablets concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
11288712|NCT02774369|Experimental|Physical exercise|A 6-week individualised, aerobic intervention program elaborated by a kinesiologist following a complete assessment of the individual's physical condition.
11288713|NCT02774369|Active Comparator|Cognitive-behavioral therapy|A 6-week self-administered cognitive-behavioral therapy for insomnia composed of a 60-min video (DVD format) and 6 booklets.
11288714|NCT02774356||Native Chinese speakers|
11390938|NCT02096731||LABA mono|
11288681|NCT02774551|Experimental|Physical activity intervention group|The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse. The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
11288682|NCT02774551|No Intervention|Standard care control group|Patients follow their routine daily physical activity.
11288683|NCT02774538|Other|Experimental arm|
11288684|NCT02774525|Active Comparator|Treatment as Usual (TAU)|Outpatient substance-abuse treatment plus drug and alcohol screening plus brief support for personal goal setting
11288685|NCT02774525|Experimental|Contingency Management|Contingency management for drug and alcohol abstinence plus TAU
11288686|NCT02774525|Experimental|Parenting Intervention|Parenting intervention plus TAU
11288687|NCT02774525|Experimental|Parenting Intervention + Contingency Management|Parenting intervention plus contingency management for drug and alcohol abstinence plus TAU
11288688|NCT02774512|Experimental|Nilotinib|A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status. Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days. The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours). When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
11288689|NCT02774499|Experimental|Methadone|Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
11288690|NCT02774499|Placebo Comparator|Placebo|Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
11288691|NCT02774486|Experimental|IQP-AK-102|2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
11288692|NCT02774460|Active Comparator|Zestril® (Lisinopril)|Inhibition of angiotensin converting enzyme (ACE inhibitor). Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
11288693|NCT02774460|Active Comparator|Atacand® (Candesartan)|Angiotensin receptor blocker. Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
11288694|NCT02774460|Active Comparator|Norvasc® (Amlodipine)|Calcium channel blocker. Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
11288695|NCT02774460|Active Comparator|Hydrochlorothiazide® (Hydrochlorothiazide)|Diuretic agent. Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
11288696|NCT02774460|Active Comparator|Repeated treatment X|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.
~The repeated arms will be given with the same duration and dosing as the other arms."
11288697|NCT02774460|Active Comparator|Repeated treatment Y|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.
~The repeated arms will be given with the same duration and dosing as the other arms."
11288698|NCT02774460|Placebo Comparator|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
11288699|NCT02774447||Rectal cancer patients with ileostoma|"In association with anterior resection of rectal cancer these patients obtain loop-ileostoma in order to avoid complications. These are closed within a few months and according to previous studies the admission time is 3-5 days after operation. This study is a single-arm study. The arm include patients having had rectal cancer operation and who have obtained a loop-ileostoma and that meet the inclusion criteria.
~The operation procedure is standardized; shortly described by dissecting the ileostoma from the abdominal wall and everting the stoma ledges, which will be sutured or stapled. The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will be followed up."
11288700|NCT02774434|Experimental|JM-105|Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
11288701|NCT02774421|Experimental|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
11288702|NCT02774421|Experimental|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
11288703|NCT02774408|Other|CPAP|"Infants on CPAP will receive backup breafs whenever the SpO2 <88 % along with
~automated FiO2 controller. In the control period they will receive automated FiO2
~alone"
11288704|NCT02774408|Other|NIMV/NIPPV|"Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate
~of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%
~( max rate 100/min) in the reference period as compared to baseline (automated FiO2
~- control + unchanged SIPPV settings)"
11288705|NCT02774395||endometrioid adenocarcinoma grade I|
11288706|NCT02774395||endometrioid adenocarcinoma grade II|
11288707|NCT02774395||endometrioid adenocarcinoma garde III|
11288708|NCT02774395||healthy endometrioid|obtain after hysterectomia provided for
11288709|NCT02774382|Active Comparator|Vancomycin|"Oral vancomycin according to number of recurrences (Danish guidelines):
~First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days
~≥2 recurrences:
~capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by
~capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by
~capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by
~capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by
~capsule vancomycin 125 mg x 1 p.o. every third day for 14 days"
11288710|NCT02774382|Experimental|Vancomycin + fecal microbiota transplantation|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
11288715|NCT02774356||Native English speakers without experience of a tonal language|
11298395|NCT02710331|Experimental|Active THC and Placebo Ethanol|
11288716|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
11288717|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
11288718|NCT02774330||Minneapolis, Minnesota Customers|"Minneapolis, Minnesota has a policy in place whereby minimum quantities and varieties of healthy food are required for all licensed food stores. The policy is our intervention condition."
11288719|NCT02774330||St. Paul, Minnesota Customers|No policy exists in St. Paul, Minnesota. This is the control condition.
11288720|NCT02774317|Active Comparator|FFP|Patients receive FFP as clinically indicated (INR 1.5 or more)
11288721|NCT02774317|Experimental|FP24|Patients receive FP24 as clinically indicated (INR 1.5 or more)
11288722|NCT02774304|Active Comparator|arterial line|invasive haemodynamic monitoring
11288723|NCT02774304|Experimental|Cheetah®|non-invasive cardiac output
11288724|NCT02774291|Experimental|Treatment (mTCR, aldesleukin)|Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.
11288725|NCT02774278|Experimental|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
11288726|NCT02774265|Active Comparator|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
11288727|NCT02774265|Active Comparator|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
11288728|NCT02774252|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11288729|NCT02774239|Experimental|SC Treatment Period|"Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:
~1st week: 2-3 SCIG infusions of 10ml per site at four sites (total dose 16 to 24g)*
~2nd week: 2-3 SCIG infusions of 15ml per site at four sites (total dose 24 to 36g)*
~3rd week: 2-4 SCIG infusions of 20ml per site at four sites (total dose 32 to 64g)*
~4th week: 2-4 SCIG infusions of 25ml per site at four sites (total dose 40 to 80g)*
~Doses indicated are study recommended. Doses may be adjusted depending on tolerance and total dose required by the patient."
11288730|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline, 4 weeks, 8 weeks, and 12 weeks following, 5mg/kg, 10mg/kg, or 20mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
11288731|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline, 4 weeks, 8 weeks, and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
11288732|NCT02774200|Experimental|test group|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
11288733|NCT02774187|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
11288734|NCT02774187|Active Comparator|Sorafenib alone|Sorafenib alone
11288735|NCT02774174||METS Proximal Humeral system|Implanted with METS Proximal Humerus
11288736|NCT02774161|Experimental|Diagnostic (B-mode ultrasound imaging)|Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.
11288737|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
11288738|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
11288739|NCT02774135||direct occupational therapy intervention|group will be evaluated 4 times: on referral to waiting list for treatment, before and after 9-12 direct individual treatments of 45 minutes, and follow-up after 3 months.
11288740|NCT02774122|Active Comparator|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
11288741|NCT02774122|Experimental|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
11288742|NCT02774109|Experimental|Experimental group|Participants in the experimental group will take fish oil (five 1000mg fish oil soft capsules per day, each capsule containing 350mg EPA and 250mg DHA) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
11288743|NCT02774109|Placebo Comparator|Control group|Participants in the control group will take placebo (five 1000mg sunflower oil soft capsules per day) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
11288744|NCT02774096|No Intervention|Control group（Ascending aorta）|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
11288745|NCT02774096|Experimental|Xenon Post-conditioning|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
11288746|NCT02774083|Active Comparator|Feuerstein Program|The participants of the Intervention Group will participate in the Feuerstein mediated learning cognitive program.
11288747|NCT02774083|Placebo Comparator|Adler Program|The Control Group will participate in the program of the Adler Institute dealing with social and emotional development without specific cognitive skills training.
11288748|NCT02774070|Other|Symptomatic atlantoaxial joint affection|Undergo plain X-ray and magnetic resonance imaging
11288749|NCT02774070|Other|Asymptomatic atlantoaxial joint aff.|Undergo plain X-ray and magnetic resonance imaging
11404572|NCT02005523|Experimental|RNS60|
11288750|NCT02774057|Experimental|Initial therapy with Captafer®|This arm will consist of 10 patients who will begin Captafer® therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Iron Sulfate therapy twice daily for an additional 6 weeks.
11288751|NCT02774057|Experimental|Initial therapy with Iron Sulfate|This arm will consist of 10 patients who will begin Iron Sulfate therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Captafer® therapy twice daily for an additional 6 weeks.
11288752|NCT02774044|Experimental|Cadisurf (goat lung surfactant extract)|Neonates in the intervention group will be intratracheally administered 100 mg/kg of GLSE (CADISURF®).
11288753|NCT02774044|Active Comparator|Survanta (Beractant)|
11288754|NCT02774031|Experimental|Aisys with Et control|the ventilation modus will be pressure control ventilation with volume guarantee (PCV-VG). Settings: tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR) 12 -14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP). Target for end expired desflurane concentration (F A des) is set to 4.2%, and target for end expired oxygen (F AO2) is set to 35%.
11288755|NCT02774031|Active Comparator|Aisys conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Aisys with PCV-VG'
11288756|NCT02774031|Experimental|Flow-i with ACG|the following parameters will be preset: FIO2= 40%; end expired gas concentration (FA des) to 4.2%; speed 6; and ventilation modus = pressure regulated volume control (PRVC) with tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR)12-14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP).
11288757|NCT02774031|Active Comparator|Flow-I conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Flow-i with ACG'
11288758|NCT02774018|Experimental|12 institutionalized elderly people|Mindfulness-Based Stress Reduction program.
11288759|NCT02774005|Experimental|Raxone|
11288760|NCT02773992||The IoT group|
11288761|NCT02773992||The routine management group|
11288762|NCT02773979|Active Comparator|Group 1: PfSPZ 51200 sporozoites/Placebo|Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
11288763|NCT02773979|Active Comparator|Group 2: PfSPZ 102400 sporozoites/Placebo|CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
11288764|NCT02773979|Active Comparator|Group 3: PfSPZ 102400 sporozoites|CQ/PfSPZ Challenge 102400 sporozoites N=9
11288765|NCT02773966|Experimental|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
11288766|NCT02773966|Active Comparator|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
11288767|NCT02773953|Experimental|CPAP + T4PTelemonitoring device|T4P® (Telemonitoring device) is added to CPAP at home. Sleep lab technical staff are connecting to the web portal 2 X/ week. In case of air leaks, persistant significant apnea-hypopnea index, use < 3h on three consecutive days, they have to call the patient .
11288768|NCT02773953|Active Comparator|CPAP standard care|After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
11288769|NCT02773940|Experimental|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
11288770|NCT02773927|Experimental|Agave inulin + Metformin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
11288771|NCT02773927|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
11288772|NCT02773927|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
11288773|NCT02773927|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
11288774|NCT02773914|Experimental|CGA intervention|The CGA intervention will include multidisciplinary teams consisting of physician, nurse (RN), physiotherapist (PT), occupational therapist (OT) and social worker (SW). The team will work according to CGA, and have the primary and continuing responsibility for planning of hospital care and discharge. CGA will include assessment of socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, as well as treatment and planning for discharge and follow-up.
11288775|NCT02773914|No Intervention|Control group|The control group receives usual hospital care, that is care given at an ordinary medical hospital ward, without the specialized multi-disciplinary team approach and CGA.
11288776|NCT02773901|Experimental|HS-1000 recording|ICP monitoring will be done with the HS-1000 to compare to CSF measurement from lumbar puncture (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals last 10 minutes.
11288777|NCT02773888|Experimental|HS-1000 recording|ICP readings will be recorded in parallel from both the invasive ICP monitor, and HeadSense's non-invasive ICP monitor. Each recording session will be done until an aggregate of at least 30 minutes worth of quality data is collected, depending on the patient's clinical condition. For each patient, two recording sessions will be completed for 30-60 minutes each for 120 minutes total.
11288778|NCT02773875|No Intervention|Sensor Augmented Pump (control)|Use sensor augmented pump (SAP) for 3 weeks.
11288779|NCT02773875|Experimental|Artificial Pancreas (intervention)|Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
11288874|NCT02773212|Active Comparator|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
11298396|NCT02710331|Experimental|Active THC and Active Ethanol|
11288780|NCT02773862|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an invasive monitoring device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 48 hours, continuously depending on the patient's clinical condition.
11288781|NCT02773849|Experimental|INSTILADRIN|Intravesical administration of INSTILADRIN into the bladder
11288782|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
11288783|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
11288784|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
11288785|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
11288786|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
11288787|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
11288788|NCT02773823|Active Comparator|Intervention|"Lifestyle intervention includes diet instruction and exercise intervention:
~Diet instruction: The children were asked to increase fruit/vegetables consumption, reduce high fat food, etc.
~Exercise intervention: The children participated sports 60 min/day,5d/week for 8 months."
11288789|NCT02773823|No Intervention|Control|"No intervention in the group with control."
11288790|NCT02773810|Experimental|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
11288791|NCT02773797|Placebo Comparator|IN-DEX 1.0 mcg/kg, intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
11288792|NCT02773797|Placebo Comparator|IN-DEX, 1.5 mcg/kg intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label IN-DEX intranasal 1.5 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
11288793|NCT02773797|Active Comparator|Placebo - Saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Placebo - Saline will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
11288794|NCT02773784||invasive breast cancer|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
11288795|NCT02773771|Placebo Comparator|Placebo + Vital HP|GROUP 1 will receive Placebo (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas.
11288796|NCT02773771|Experimental|B-hydroxy-B-methylbutyrate (HMB) + Vital HP|GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
11288797|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
11288798|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
11288799|NCT02773745|No Intervention|Standard of Care|Participant will receive standard of care and a brochure on healthy eating.
11288800|NCT02773745|Active Comparator|Aquatic Prehabilitation Group|The prehabilitation group will undergo 6-8 weeks of individualized aquatic exercise in a heated pool (60 min/session, 3 times per week). Aquatic equipment maybe used to challenge balance and trunk stabilization.
11288801|NCT02773732|Experimental|Ciprofloxacin and Etoposide|
11288802|NCT02773719|Experimental|True biofield therapist|Subject will have a 40 minutes therapy with a real biofield therapist to treat the wart
11288803|NCT02773719|Placebo Comparator|Fake biofield therapist|Subject will have a 40 minutes therapy with a fake biofield therapist to treat the wart
11288804|NCT02773706|Experimental|Usual Subspecialty Care|"Once a subject is screened positive for anxiety or depression, the subspecialty provider is informed of the positive screen, and left to manage or refer the condition as per usual care by that provider.
~Intervention: Depression / anxiety screen + clinician informed."
11288963|NCT02772692|No Intervention|Toilet|defecation using a standard-sized toilet
11289804|NCT02767076|Experimental|Ultrasound|ultrasound guided paramedian spinal anesthesia
11288805|NCT02773706|Active Comparator|Integrated Psychology Care|"Once a subject is screened positive for anxiety or depression, an automated psychology referral occurs, in addition to any intervention determined by the subspecialty provider.
~Intervention: Depression / anxiety screen + clinician informed + automated psychologist visit."
11288806|NCT02773693|Active Comparator|CPT|Cognitive Processing Therapy-cognitive only version (typically labeled CPT-C, but labeled CPT in this grant for simplicity) is a type of Cognitive Therapy addressing daytime symptoms of PTSD. This arm will have 12 twice-weekly sessions, followed by 6 weekly sessions.
11288807|NCT02773693|Active Comparator|CBTin+CPT|Cognitive Behavioral Therapy of Insomnia and nightmares (CBTin) will be used to address nighttime symptoms of PTSD during 6 weekly sessions, followed by 12 twice-weekly sessions of CPT.
11288808|NCT02773693|Active Comparator|CPT+CBTin|12 twice-weekly sessions of CPT followed by 6 sessions of CBTin.
11288809|NCT02773680|Experimental|Study cohort 1|"electrical impedance tomography"
11288810|NCT02773654||Healthy Volunteers|Asymptomatic subjects: subjects without complaints or history of shoulder pain or obvious movement abnormalities.
11288811|NCT02773654||Symptomatic Volunteers|Symptomatic subjects: subjects with shoulder pain who have active range of motion beyond 120° of elevation.
11288812|NCT02773641|Active Comparator|Botulinum Toxin Type A|50 Allergan units (0.5 ml) injected in m bulbocavernosus twice with 3 months in between treatments
11288813|NCT02773641|Placebo Comparator|Sterile saline solution|0.5 ml of sterile saline injected in m bulbocavernosus twice with 3 months in between treatments
11288814|NCT02773628|Placebo Comparator|control group|stable asthmatics receiving an Acar'up placebo system
11288815|NCT02773628|Active Comparator|treatment group|stable asthmatics receiving Acar'up system
11288816|NCT02773602|Experimental|Dexamethasone|Dexamethasone has been used for adult epidurals and nerve blocks and in spine surgeries. It prolongs the duration of pain relief and causes less sedation. It is commonly administered to children during surgery to help decrease nausea and vomiting after surgery. It is also much cheaper than clonidine The patient will receive Ropivacaine plus 200 μgm/kg of dexamethasone in 1 ml saline
11288817|NCT02773602|Active Comparator|Clonidine|"Clonidine has been added to caudal analgesia for infants and children for many years. It increases the duration of pain relief of ropivicaine by itself, however, it may lead to prolonged sedation following the surgical procedure (an undesired effect) and it is expensive.
~The patient will receive Ropivacaine plus 2 μg/kg of clonidine in 1 ml saline."
11288818|NCT02773602|Placebo Comparator|Normal Saline|The patient only will receive Ropivacaine
11288819|NCT02773589|Experimental|Peroral endoscopic myotomy|
11288820|NCT02773576|Experimental|2x360 mg risperidone implant|2, 360 mg risperidone implants
11288821|NCT02773576|Experimental|3x300 mg risperidone implant|3, 300 mg risperidone implants
11288822|NCT02773563||EUS with CO2 insufflation|Patients undergoing EUS with CO2 insufflation
11288823|NCT02773563||EUS with air insufflation|Patients undergoing EUS with air insufflation
11288824|NCT02773550|Experimental|Velcadito|Bortezomib 1.3 mg/m2 days 1,4,8 and 11 first cycle, the 1.0 mg/m2 days 1 and 4. Melphalan 9 mg/m2 days 1 to 4 Prednisone 60 mg/m2 days 1 to 4 Cycles of 28 days
11288825|NCT02773537|Active Comparator|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
11288826|NCT02773537|Active Comparator|Randomization Group 2|Adductor canal catheter and selective tibial block
11288827|NCT02773537|Active Comparator|Randomization Group 3|Adductor canal catheter only
11288828|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
11288829|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
11288830|NCT02773511|Other|Bone healing|Bone healing in surgical or conservative treatment for children type 1 humeral condyle fracture
11288831|NCT02773511|Other|Fracture displacement|Fracture displacement in surgical or conservative treatment for children type 1 humeral condyle fracture
11288832|NCT02773498|Active Comparator|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
11288833|NCT02773498|Experimental|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
11288834|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
11288875|NCT02773212|Active Comparator|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
11288930|NCT02772874||Passive-predominant|All subjects who report fecal incontinence that is primarily passive-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
11288835|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
11288836|NCT02773472|Experimental|Electroacupuncture Group|In addition to morphine, patients will receive 4 sessions of electroacupuncture after surgery over four days, with each session lasting 30 minutes.
11288837|NCT02773472|Other|Morphine Group|Neither electroacupuncture nor sham acupuncture will be given. Patient use morphine for analgesia.
11288838|NCT02773459|Experimental|Phase 1 part|to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
11288839|NCT02773459|Experimental|Expansion part|to assess the efficacy (PFS) of MEK162+Capecitabine combination
11288840|NCT02773446|Experimental|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
11288841|NCT02773446|Experimental|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
11288842|NCT02773446|Experimental|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
11288843|NCT02773446|Experimental|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
11288844|NCT02773446|Experimental|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
11288845|NCT02773446|Experimental|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
11288846|NCT02773433|Experimental|PAV group|Using Proportional Assist Ventilation after failed Spontaneous Breathing Trial
11288847|NCT02773433|No Intervention|Control group|Using Volume Assist Control mode after failed SBT
11288848|NCT02773420|Experimental|HET application arm|Patients with grade I-II internal hemorrhoids will undergo HET application
11288849|NCT02773407|Active Comparator|Group A|Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)
11288850|NCT02773407|Active Comparator|Group B|Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)
11288851|NCT02773394||Group 1|Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
11288852|NCT02773381|Experimental|Semaglutide 3 mg, 7 mg, 14 mg|
11288853|NCT02773381|Placebo Comparator|Placebo|
11288854|NCT02773368|Experimental|IDegLira|
11288855|NCT02773368|Active Comparator|IGlar|
11288856|NCT02773355||Saxenda®|
11288857|NCT02773342||Pathological findings in chest CT|
11288858|NCT02773329|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive exercise program (game-based exercise) intervention twice a week for 6 weeks.
11288859|NCT02773329|Active Comparator|Intervention without game-based exercise|Subjects will be receiving non-technology based foot and ankle exercise twice a week for 6 weeks
11288860|NCT02773316|Experimental|MR902 50/0.5 mg|MR902 50/0.5 mg PR tablets, single dose oral
11288861|NCT02773316|Experimental|MR902 200/2 mg|MR902 200/2 mg PR tablets, single dose oral
11288862|NCT02773316|Active Comparator|IR morphine sulphate 10 mg/5mL solution|IR morphine sulphate 10 mg/5mL solution, single dose oral
11288863|NCT02773303|Active Comparator|Active|Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
11288864|NCT02773303|Sham Comparator|Control|Children not receiving neurofeedback based therapy, but receiving the Sham therapy
11288865|NCT02773290|Experimental|Romiplostim|Weekly Subcutaneous (SC) administration
11288866|NCT02773277|Experimental|Single intervention arm|All patients will be assigned the intervention arm and will receive head-impulse testing before and in the days after skull base surgery.
11288867|NCT02773264||UltraSound Patients|All patients will undergo next to the clinical indicated conventional US-examination, US Elastography after informed consent. After completion of these three examinations, the participation in the study is completed.
11288868|NCT02773251|Experimental|hyaluronic acid-carboxymethylcellulose treatment group|the HA/CMC treatment group after laparoscopic pelvic surgery
11288869|NCT02773251|No Intervention|control group|the HA/CMC non-treatment group after laparoscopic pelvic surgery
11288870|NCT02773238|Experimental|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or > 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
11288871|NCT02773225|Experimental|Eltrombopag + Ciclosporin A|"Eltrombopag, 75 mg film tablets, starting dose: 2 tablets (150 mg per day), daily, per os
~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
11288872|NCT02773225|Placebo Comparator|Placebo + Ciclosporin A|"Placebo for Eltrombopag 75 mg film tablets, 2 tablets, daily, per os
~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
11288873|NCT02773212|Experimental|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
11288925|NCT02772900|Active Comparator|Beetroot gel (dietary nitrate)|Beetroot-based nutritional gel containing approximately 10.0 mmol of nitrate per dose
11288876|NCT02773199||Cohort 1- Morning Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in morning hours (until 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for 8 hours
11288877|NCT02773199||Cohort 2- Afternoon Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in afternoon hours (after 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for more than 12 hours
11288878|NCT02773173|Experimental|Individualized Pneumoperitoneum Pressure|In Individualized Pneumoperitoneum Pressure (IPP) group, measures to optimize and individualize intra-abdominal pressure (PIA) will be apply.
11288879|NCT02773173|Other|Standard Pneumoperitoneum Pressure|In Standard Pneumoperitoneum Pressure (SPP) group, a conventional operation without optimization measures and PIA preset to 12 mmHg will be conducted.
11288880|NCT02773160|Experimental|Sensor-based postural feedback|Subjects will receive visual feedback on a computer screen while practicing the motor control task. The feedback is based on information from from motion sensors that mointor the movements of the lumbar spine
11288881|NCT02773160|Experimental|Mirror Feedback|Subjects will receive feedback from a mirror while practicing the motor control task
11288882|NCT02773160|Active Comparator|control group|Subjects will receive no feedback while practicing the motor control task
11288883|NCT02773147|Experimental|Triobe|Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
11288884|NCT02773147|No Intervention|Control|
11288885|NCT02773134|Active Comparator|Brace Group|Patients in the brace group will be fitted by an orthotist postoperatively and will be instructed to wear a rigid molded Lumbosacral Orthosis (LSO) full time for 8 weeks except during hygiene and wound care followed by daytime wear for another 4 weeks. All patients will start wearing the brace 48 hours after the surgery following removal of the wound drain. All braces will be molded and fitted by the same experienced orthotist affiliated with the hospital. Self-compliance to brace wear will be noted every day for 3 months by each patient on a specific form.
11288886|NCT02773134|Experimental|Control Group|No brace prescription postoperatively. Patients in this group will be observed and results will be compared to the brace group.
11288887|NCT02773121|Experimental|Physical activity monitoring|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their physical activity level to at least 150 min of moderate-intensity physical activity per week. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
11288888|NCT02773121|Active Comparator|Flexibility and balance|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their balance and flexibility over the 12 week period of the intervention. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
11288889|NCT02773108||Hospitalized|Hospitalized psychiatric patients
11288890|NCT02773108||Daily hospital|
11288891|NCT02773108||Outpatients|
11288892|NCT02773095|Experimental|Intervention counties|In intervention counties, a Novartis Access portfolio of 15 medicines will be sold to local purchasers at a cost of 150 Kenyan Shillings (KES), around US$1.50, per monthly dose.
11288893|NCT02773095|No Intervention|Control counties|Control counties not exposed to the intervention.
11288894|NCT02773082|Experimental|Reclaim™ DBS Therapy|Procedure: Reclaim™ DBS Therapy The DBS lead is stereotactically introduced into the target in the brain (AIC) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region. This is performed by a neurosurgeon skilled in this technique, as the same procedure is routinely performed in patients with other diseases (using other brain targets).
11288895|NCT02773069|Experimental|Weight loss program|Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.
11288896|NCT02773056|Active Comparator|Socket 1 (Ischial Ramus Containment)|This arm included unilateral transfemoral amputees who were assessed while using the Ischial Ramus Containment socket.
11288897|NCT02773056|Active Comparator|Socket 2 (Dynamic Socket IRC)|This arm included unilateral transfemoral amputees who were assessed while using the Dynamic Socket Ischial Ramus Containment socket.
11288898|NCT02773056|Active Comparator|Socket 3 (Sub-Ischial Interface)|This arm included unilateral transfemoral amputees who were assessed while using the Sub-Ischial Interface socket.
11288899|NCT02773043|Other|non invasive imaging technique|
11288900|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
11288901|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
11288902|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
11288926|NCT02772900|Active Comparator|Placebo gel (nitrate-depleted)|Nutritional gel nitrate-depleted
11288927|NCT02772887|Experimental|Citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
11288928|NCT02772887|Placebo Comparator|Placebo|Placebo, 3 grams once per day for 3 weeks.
11288929|NCT02772874||Urge-predominant|All subjects who report fecal incontinence that is primarily urge-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
11288958|NCT02772718|Experimental|Part 1 - single dose|Cohorts A, B, and C
11288903|NCT02773030|Experimental|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA.
~Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
~Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle."
11288904|NCT02773030|Experimental|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.
~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.
~Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle."
11288905|NCT02773030|Experimental|Cohort G1-CC-220 in combination with CFZ and DEX -Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
~Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle
~Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg"
11288906|NCT02773030|Experimental|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
~Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle
~Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg"
11288907|NCT02773030|Experimental|CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle
~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
11288908|NCT02773030|Experimental|CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above).
~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.
~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
11288909|NCT02773030|Experimental|CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle.
~Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.
~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
11288910|NCT02773017|Experimental|Youth female group|patients in the Youth female group, aged 20~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
11288911|NCT02773017|Experimental|Middle-aged female group|patients in the Middle-aged female group, aged 40~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
11288912|NCT02773017|Experimental|Elderly female group|Patient in the elderly female group, aged 65~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
11288913|NCT02773004|Other|EndoPredict (EP)clin testing|Once the patient is registered, the most representative block of the primary tumor from surgery (or 10 paraffin slides) are sent to the central analysis platform for EP clin testing. The EPclin method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.
11288914|NCT02772991|Experimental|Cases|All patients will be submmited to troponin measurements and CCTA. If CCTA shows coronary stenosis ≥ 50%, patient will initiate the ACS treatment and be hospitalized to have coronary cineangiography. If CCTA shows lesions < 50%, the patient will be discharged and monitored for 30 days. A second sampling of the troponin will be obtained from all patients three hours after the first collection in order to evaluate for an increase/decrease of troponin.
11288915|NCT02772978|Experimental|functional MRI arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
11288916|NCT02772965|Experimental|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.
~Folic Acid (1 mg) daily"
11288917|NCT02772965|Placebo Comparator|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.
~Folic Acid (1 mg) daily"
11288918|NCT02772952|Other|Control Group|a control group whose intervention will be to review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
11288919|NCT02772952|Experimental|Experimental Group|Experimental group whose intervention will be a Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program.
11288920|NCT02772939|Experimental|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
11288921|NCT02772926|Placebo Comparator|Placebo|450 g per pill, 2 pills per day to get 900 mg per day
11288922|NCT02772926|Active Comparator|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
11288923|NCT02772913||acute mesenteric ischemia|patients with abdominal pain and acute mesenteric ischemia
11288924|NCT02772913||non-acute mesenteric ischemia|patients with abdominal pain without mesenteric ischemia
11405953|NCT01996163||Male|
11288931|NCT02772861|Experimental|Citrulline|Citrulline is a non-protein amino acid that is present in substantial amounts in watermelon (Citrullus vulgaris), with a mean content of 2.1 mg/g fresh weight, ranging from 0.5 to 3.6 mg/g according to variety. The oral dose can reach 20 g, which was administered orally in the present study in one single dose, followed by a washout period of one week Amino Acid Supplement - One dose
11288932|NCT02772861|Experimental|Glutamine|"L-glutamine is a protein amino acid found in proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient l-glutamine to meet physiological demands. However, there are conditions where the body cannot do so. Recently, l-glutamine has come to be regarded as one of the most important of the amino acids when the body is subjected to such metabolic stress situations as trauma (including surgical trauma), cancer, sepsis and burns. In the present study, glutamine was administered orally in one single dose of 20 g, followed by a washout period of one week.
~Amino Acid Supplement - One dose"
11288933|NCT02772861|Experimental|Arginine|"Arginine was administered orally in 20 g for one single dose, followed by a washout period of 1 week.
~Amino Acid Supplement - One dose"
11288934|NCT02772861|Experimental|3-Methyl-Histidine|"This amino acid is made by methylation of the actin and myosin peptide chains in the muscle. Metabolism after intravenous administration of L-3-methylhistidine involves excretion in the urine of 75% of the administered dose in 24 h and 95% in 48 h.
~3-Methyl-Histidine was administered orally in 120 mg for one single dose, followed by a washout period of 1 week."
11288935|NCT02772861|Placebo Comparator|Placebo|Dextrose (glucose) was used in a dose of 20 g in this study.
11288936|NCT02772835|Active Comparator|nHFOV|Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
11288937|NCT02772835|Active Comparator|nCPAP|Starting treatment mode: nCPAP with Medin-cno. Targeted oxygen saturation of 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the be-ginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A se-cond capillary BGA will be performed at the end of second period.
11288938|NCT02772822|Experimental|Experimental|SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
11288939|NCT02772822|Active Comparator|Active Comparator|Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
11288940|NCT02772809|Other|Stroke survivors with low and moderate motor deficits|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
11288941|NCT02772796|Experimental|SENS-218|2 x 10 mg administered once on Day 1.
11288942|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
11288943|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
11288944|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
11288945|NCT02772770||Non Operative: Rehabilitation, Bracing, Activity Restriction|
11288946|NCT02772770||Operative: Transphyseal|
11288947|NCT02772770||Operative: Partial Transphyseal|
11288948|NCT02772770||Operative: Physeal sparing by Anderson Technique|
11288949|NCT02772770||Operative: Physeal sparing by Micheli/Kocher Technique|
11288950|NCT02772757|Active Comparator|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
11288951|NCT02772757|Experimental|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
11288952|NCT02772757|Experimental|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
11288953|NCT02772744||Group 1: Easy to treat group|"Treatment naïve
~Total serum bilirubin ≤ 1.2 mg/dl
~Serum albumin ≥ 3.5 g/dl
~International normalized ratio ≤ 1.2
~Platelet count ≥ 150000 mm3
~This group will be receiving Sofosbuvir + daclatasvir for 12 weeks."
11288954|NCT02772744||Group 2: Difficult to treat group|"Peg interferon treatment experienced.
~Total serum bilirubin ≥ 1.2 mg/dl
~Serum albumin ≤ 3.5 g/dl
~International normalized ratio ≥ 1.2
~Platelet count ≤ 150000 mm3
~This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks."
11288955|NCT02772744||Group 3: Sofosbuvir resistant cases|This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.
11288956|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
11288957|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
11288964|NCT02772679|Experimental|PolyTregs+IL-2|Patients with type 1 diabetes mellitus will receive ex vivo expanded human autologous polyclonal regulatory T cells plus IL-2
11288965|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
11288966|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
11288967|NCT02772653||Severe trauma patients|"No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:
~Blood Lactate levels
~Blood Base Excess levels
~Blood B-type Natriuretic Peptide levels
~Blood Thromboelastometry (ROTEM) alterations
~Near-infrared spectroscopy alterations
~Sublingual videomicroscopy alterations
~All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission."
11288968|NCT02772640|Active Comparator|Arm I: R+E morning->evening|Rosuvastatin and Ezetimibe morning or evening administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the morning (8:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the evening hours (20:00).
11288969|NCT02772640|Active Comparator|ARM II: R+E evening->morning|Rosuvastatin and Ezetimibe evening or morning administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the evening (20:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the morning hours (8:00).
11288970|NCT02772627|Experimental|Nebicapone 100 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
11288971|NCT02772627|Experimental|Nebicapone 200 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
11288972|NCT02772627|Experimental|Nebicapone 300 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
11288973|NCT02772614|Experimental|Nebicapone (200 mg)|"Each subject was to receive one single dose of 2.5 MBq [14C]-labelled BIA 3-202 (200 mg) together with a total of 250 mL non-carbonated water.
~The study drug was given after an overnight fast of at least 10 hours after the in-house stay. During waking hours on Day 1, subjects had to have a fluid intake of at least 150 mL per hour starting 1 hour before study drug administration."
11288974|NCT02772601|Experimental|All patients|
11288975|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
11288976|NCT02772575||patients with primary liver or liver metastases|A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.
11288977|NCT02772562|Experimental|PROSTVAC-V/F|
11288978|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study all participants are subject to a set of three visual stimulus conditions.
~These are: Low ambient light; Self selected tinted light; White light"
11288979|NCT02772523|Other|Intervention|
11288980|NCT02772510|Experimental|Smart glove system with functional electrical stimulation|game-based virtual reality rehabilitation combined with functional electrical stimulation for upper extremity
11288981|NCT02772510|Active Comparator|Functional electrical stimulation|functional electrical stimulation on upper extremity
11288982|NCT02772497|Experimental|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks
11288983|NCT02772484|Experimental|HS-1000 recording|The recording session should be performed in a quiet environment with no disturbance to the patient for a total of up to 60 minutes.
11288984|NCT02772471|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and invasive ICP monitoring. HS-1000 ICP monitoring intervals will last at least 30 minutes, continuously depending on the patient's clinical condition.
11288985|NCT02772458|Experimental|Crohn's Disease|Active Crohn's Disease
11288986|NCT02772458|Experimental|Healthy|Healthy volunteers
11288987|NCT02772445|Experimental|STROKE-CARE Intervention|In STROKE-CARE, caregivers will learn a problem-solving strategy. Participants will receive approximately 10 sessions by an occupational therapist in the home over a 5 week process.
11288988|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
11289109|NCT02771665||Breast cancer women without recurrences|Breast cancer women without recurrences
11288989|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
11288990|NCT02772419|Experimental|benralizumab A|Subcutaneous (SC) administration
11288991|NCT02772419|Experimental|benralizumab B|SC administration
11288992|NCT02772419|Placebo Comparator|Placebo|Placebo SC administration
11288993|NCT02772406|Experimental|Experimental group|(With LCI endoscopy and 1 month later with white light endoscopy) The patients will be evaluated by Linked Color Imaging and 1 month later evaluated by White Light endoscopy
11288994|NCT02772406|Active Comparator|Control group|(With white light endoscopy and 1 month later with LCI endoscopy) The patients will be evaluated by White Light endoscopy and 1 month later evaluated by Linked Color Imaging
11288995|NCT02772380|Experimental|VT/ VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and termination through use of a defibrillator, will be carried out as the intervention in all subjects undergoing study procedures.
11288996|NCT02772367||Breast Cancer Patients|In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.
11288997|NCT02772354|Experimental|Ablation|Standard radiosurgery ablation of premature ventricular complexes using navigation system.
11288998|NCT02772354|Active Comparator|Control|Antiarrhythmic therapy of premature ventricular complexes according to the guidlines
11288999|NCT02772341|Active Comparator|Salt room with halogenerator|Asthmatic patients sitting in a salt room with salt aerosol produced by a halogenerator.
11289000|NCT02772341|Placebo Comparator|Salt room without halogenerator|Asthmatic patients sitting in a salt room without salt aerosol
11289001|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
11289002|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
11289003|NCT02772315||Hypertensive patients|Diagnostic procedures in patients with hypertension applying omics results
11289004|NCT02772302|Experimental|mindBEAGLE|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
11289005|NCT02772289|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
11289006|NCT02772289|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
11289007|NCT02772289|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
11289008|NCT02772276|Experimental|Normal-CKD Stage 2/QuantumLeap|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may receive different doses.
11289009|NCT02772276|Experimental|CKD Stage 3-4/QuantumLeap|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may receive different doses.
11289010|NCT02772276|Experimental|Normal-CKD Stage 2/Radiance|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289011|NCT02772276|Experimental|CKD Stage 3-5/Radiance|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289012|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance algorithm optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289013|NCT02772276|Experimental|CKD Stage 3-5/Brilliance algorithm optimization|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289014|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Sensor optimization of the Brilliance device will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289015|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor verification|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Verification of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289016|NCT02772276|Experimental|CKD Stage 3-5/Brilliance sensor verification|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Verification of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289110|NCT02771652|Active Comparator|e-training intervention|Resistance and endurance training
11289111|NCT02771652|Other|Control|no exercise
11289112|NCT02771639||Femoral neck fractures|Patients admitted to Sundsvall hospital for a displaced femoral neck fracture and treated with a hip arthroplasty
11289017|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance final algorithm and sensor|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device will be tested. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm will receive two doses of MB-102, 12 hours apart.
11289018|NCT02772276|Experimental|CKD Stage 3-5/Brilliance final algorithm and sensor|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device will be tested. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
11289019|NCT02772263|Experimental|CHAP-EMS Intervention|Participants guided through a 15-20 minute defined risk assessment by a trained paramedic. Risk factors assessed were those related to cardiovascular and diabetes risk (blood pressure, diabetes-risk status, lifestyle factors), and potential for falls. Based on these, the paramedic provided education and developed an individualized action plan directing participants to use available community resources to assist them in addressing their risk factors. They were advised to return to CHAP-EMS sessions regularly for BP monitoring and follow-up. Each participant's information was faxed to his/her family physician once a month.
11289020|NCT02772250|Active Comparator|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by a investigator at 15:00-17:00 on the day before colonoscopy.
11289021|NCT02772250|Experimental|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
11289022|NCT02772237|Active Comparator|Treatment group|Riboflavin 400mg daily
11289023|NCT02772237|Placebo Comparator|Placebo group|Placebo
11289024|NCT02772224|Experimental|Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty
11289025|NCT02772224|Active Comparator|Conventional balloon angioplasty|Conventional balloon angioplasty
11289026|NCT02772211|Experimental|D-cycloserine|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
11289027|NCT02772211|Placebo Comparator|Placebo|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
11289028|NCT02772198|Experimental|Single Arm|All patients will be treated on this single arm
11289029|NCT02772185|Experimental|active tDCS plus real CT|Participants will receive active transcranial direct current stimulation and real cognitive training.
11289030|NCT02772185|Experimental|sham tDCS plus real CT|Participants will receive sham transcranial direct current stimulation and real cognitive training.
11289031|NCT02772185|Experimental|active tDCS plus placebo CT|Participants will receive active transcranial direct current stimulation and placebo cognitive training.
11289032|NCT02772185|Placebo Comparator|sham tDCS plus placebo CT|Participants will receive sham transcranial direct current stimulation and placebo cognitive training.
11289033|NCT02772172|Active Comparator|GuideMia surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
11289034|NCT02772172|Active Comparator|Control surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in control program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
11289035|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
11289036|NCT02772146|Experimental|Device: CLS UF|The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.
11289037|NCT02772133||STEMI patients|
11289038|NCT02772133||Healthy subjects|
11289039|NCT02772133||Unstable angina|
11289040|NCT02772120|Active Comparator|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
11289041|NCT02772120|Active Comparator|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
11289042|NCT02772107|Experimental|BSC group|Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. Radiotherapy was allowed. Follow-up until disease progression.
11289043|NCT02772107|Experimental|TMZ group|"Patients will receive platinum-based first-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cyclesfor the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
~Re-staging will be performed every 2 cycles (every 8 weeks) during the study, radiotherapy was allowed."
11289146|NCT02771457|Experimental|Infliximab at weeks 0,2, and 6|In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.
11405954|NCT01996163||Female|
11289044|NCT02772094|Experimental|Single arm, open-label|"Experimental:
~ADCTA-G total 10 doses, each dose (30+/-5 millions autologous dendritic cells plus 6+/-0.5 millions 100Gy-irradiated short-term cultured autologous GBM tumor cells) divided in 2 halves for subcutaneous injection into both axillar areas, in a course of 6 months (sequential series of weekly injections 4 times, bi-weekly injections twice; then monthly injections 4 times.
~Experimental: ADCTA-G total 10 doses, each dose (similar fore-mentioned numbers of 5:1 ratio of autologous dendritic cells and irradiated short-term cultured autologous GBM tumor cells) divided into 2 injections administered subcutaneously in both axillar areas, in a course of 8 months (sequential series of bi-weekly injections 4 times, then monthly injections 6 times)."
11289045|NCT02772081|Experimental|Curosurf LISA|"Single dose of poractant alfa 200 mg/kg via brief insertion of a thin catheter (CHF 6440) into the trachea in neonates with RDS.
~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.
~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
11289046|NCT02772081|Active Comparator|Curosurf Endotracheal Tube|"Single dose of poractant alfa 200 mg/kg via the conventional intubation with endotracheal tube in neonates with RDS.
~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.
~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
11289047|NCT02772068|Active Comparator|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
11289048|NCT02772068|Experimental|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
11289049|NCT02772055|Experimental|moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
11289050|NCT02772055|Experimental|smoke-free moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants and have a purification device at the top of the moxibustion to remove the moxa smoke.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
11289051|NCT02772042|Experimental|Intervention Group|Investigators will performed traction manipulation of those articulations of upper cervical spine with indication for this treatment. Before manipulation soft tissue techniques will be applied in order to prepare the joint. After manipulation the patient rest in supine position. The intervention will have a duration of 10 minutes.
11289052|NCT02772042|Other|Control Group|The patient of the control group maintain the supine position for 10 minutes.
11289053|NCT02772029|Experimental|Apatinib Mesylate Tablets|Apatinib (Apatinib Mesylate Tablets) 750 mg is administered orally daily, until disease progression or intolerable toxicity.
11289054|NCT02772016|Experimental|Intervention group|Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.
11289055|NCT02772016|No Intervention|Control group|Patients in control groups do not receive any intervention.
11289056|NCT02772003|Experimental|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
11289057|NCT02771990|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
11289058|NCT02771990|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
11289059|NCT02771977|No Intervention|Usual Care|No alert will be fired.
11289060|NCT02771977|Experimental|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
11289061|NCT02771964||All patients|All patients receive both types of quality of life assessment, thus serving as their own controls.
11289062|NCT02771951|Experimental|Special Intervention|Study participants randomized to receive Special Intervention receive a series of 7 group classes taught by trained clinic health educators; a series of phone calls; clinical visits with a mid-level provider; and a series of 6 booster group classes over 1 year.
11289063|NCT02771951|Placebo Comparator|Usual Care|Study participants randomized to receive Usual Care receive up to 2 visits with a usual care health educator over 1 year.
11289064|NCT02771938|Experimental|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
11289065|NCT02771938|Active Comparator|Radiotherapy after surgery|Mastectomy and DIEP flap reconstruction followed by radiotherapy (current standard treatment)
11289066|NCT02771925|Experimental|gabapentin|Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
11289067|NCT02771925|Placebo Comparator|Placebo|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
11289068|NCT02771912|Experimental|Propofol|"Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %).
~Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes.
~Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h."
11289113|NCT02771626|Experimental|CB-839 + Nivolumab Dose Escalation|Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).
11289069|NCT02771912|Placebo Comparator|Intralipid|"Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion.
~Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes."
11289070|NCT02771899|Experimental|EOS + spineEOS software in adults|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
11289071|NCT02771899|Active Comparator|EOS in adults|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
11289072|NCT02771899|Experimental|EOS + spineEOS software in children|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
11289073|NCT02771899|Active Comparator|EOS in children|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
11289074|NCT02771886|Active Comparator|2-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 2nd week in the study. The duration of the study will be 6 weeks."
11289075|NCT02771886|Active Comparator|4-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 4th week in the study. The duration of the study will be 6 weeks."
11289076|NCT02771873|No Intervention|Usual care|Screening for CVD risk factors plus one time education regarding management of risk factors will be provided to all family members.
11289077|NCT02771873|Experimental|Life style Intervention and care coordination|Integrated cardiovascular disease risk management.
11289078|NCT02771860|Active Comparator|Experimental: denosumab|50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline.
11289079|NCT02771860|Placebo Comparator|Comparator|"50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks.
~Calcium and vit D supplementation will be installed at baseline"
11289080|NCT02771834||Experimental|women with osteoporosis
11289081|NCT02771834||Control|women without osteoporosis
11289082|NCT02771821|Experimental|Group Intervention|Individual routine consultation with the Family Health Unit team and participation in operative groups based on methodology of problematization
11289083|NCT02771821|No Intervention|Control Group|Individual routine consultation with the Family Health Unit team
11289084|NCT02771808||diabetic patients|obtain biomarker samples from diabetic patients and examine for 1-1 & 1-2 & 2-2 haptoglobin genotype
11289085|NCT02771795||Herceptin (trastuzumab)|Intravenous administration
11289086|NCT02771795||SB3 (proposed trastuzumab biosimilar)|Intravenous administration
11289087|NCT02771782|Experimental|BCG|Subjects are vaccinated with BCG vaccine (SSI) alone, 0,1ml intradermal
11289088|NCT02771782|Experimental|TDaP-IPV|Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular
11289089|NCT02771782|Experimental|BCG+TDaP-IPV|Subjects are vaccinated with BCG vaccine (SSI) (0.1ml intradermal) and TDaP-IPV vaccine Boostrix Polio (0.5ml intramuscular) simultaneously
11289090|NCT02771756|Experimental|test group|Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.
11289091|NCT02771756|Placebo Comparator|placebo group|Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.
11289092|NCT02771743|Experimental|High risk neuroblastoma|"Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen
~Upfront surgery or surgery after 6 cycles of chemotherapy
~Peripheral stem cell mobilization after 7 cycles of chemotherapy
~Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT)
~Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT
~Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT
~Radiotherapy after tandem HDCT
~Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin"
11289093|NCT02771730|Experimental|Vaccine A|Receive Ad4-mgag three times at 0,2,and 6 months with a boost at 8months
11289094|NCT02771730|Experimental|Vaccine B|Receive Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
11289095|NCT02771730|Experimental|Vaccine A & B|Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
11289096|NCT02771730|Placebo Comparator|Placebo|Receive placebo three times at 0,2,and 6 months with a boost at 8 months
11289097|NCT02771730|Experimental|Vaccine A & B (previously received study vaccine)|People who have previously had a study vaccine: Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
11289098|NCT02771717|Experimental|Budesonide (Pulmicort)|Low dose inhaled corticosteroid.
11289099|NCT02771717|Placebo Comparator|Placebo - dummy inhaler|Placebo - dummy inhaler
11289100|NCT02771704|Experimental|Silver diamine fluoride|Intervention: Silver diamine fluoride will be applied in vivo on carious dentine lesions
11289101|NCT02771704|Experimental|Potassium iodide|Potassium iodide will be applied in vivo on carious dentine lesions.
11289102|NCT02771704|Experimental|Chlorhexidine|Chlorhexidine will be applied in vivo on carious dentine lesions
11289103|NCT02771704|Experimental|Silver diamine fluoride+Potassium iodide|Silver diamine fluoride and potassium iodide mixture will be applied in vivo on carious dentine lesions
11289104|NCT02771704|Experimental|Saline|Sterile physiological saline will be applied in vivo on carious dentine lesions
11289105|NCT02771691|Experimental|MBT therapy plus treatment as usual|Mentalization based group treatment for adolescents plus standard care
11289106|NCT02771691|No Intervention|Treatment as usual alone|Standard care provided by local Child and Adolescent Mental Health Services
11289107|NCT02771678||Asthma|All participants will have an asthma-related crisis event due to an asthma exacerbation that resulted in A&E attendance and/or hospital admission.
11289108|NCT02771665||Breast cancer women with known recurrences|Breast cancer women with known recurrences (locoregional recurrence and distant metastasis)
11414187|NCT01941238||Insulin pump|
11289114|NCT02771626|Experimental|Clear Cell RCC Naïve to Checkpoint Inhibitors|Cohort 1: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one TKI but are treatment naive to checkpoint modulators anti-PD-1/PD-L1, CTLA-4, or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
11289115|NCT02771626|Experimental|Clear Cell RCC Recently Treated with Nivolumab|Cohort 2: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
11289116|NCT02771626|Experimental|Clear Cell RCC with Prior PD-1 Therapy|Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
11289117|NCT02771626|Experimental|Melanoma with Prior PD-1 Therapy|Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
11289118|NCT02771626|Experimental|NSCLC with Prior PD-1 Therapy|Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
11289119|NCT02771613||Active experience feedback|Multi professional, in situ simulation , with scenarios based on the adverse events analyzed in MMR : After analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
11289120|NCT02771613||Passive experience feedback|Large diffusion of information about discussions and decisions of Morbidity Mortality Reviews : after the analysis of adverse effects in Morbidity Mortality reviews, a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out.
11289121|NCT02771613||No experience feedback|MMR will be performed as usual, without any feedback to the medical staff
11289122|NCT02771600|Experimental|Buzzy|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
11289123|NCT02771600|Active Comparator|Standard Care (Maxilene)|Maxilene topical anaesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site
11289124|NCT02771587|Experimental|Alcohol and energy drink|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
11289125|NCT02771587|Active Comparator|Alcohol|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
11289126|NCT02771587|Active Comparator|Energy drink|3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
11289127|NCT02771587|Placebo Comparator|Placebo|"3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
~Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration."
11289128|NCT02771574|Experimental|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
11289129|NCT02771574|Experimental|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
11289130|NCT02771574|Experimental|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
11289131|NCT02771574|Experimental|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
11289132|NCT02771574|Experimental|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
11289133|NCT02771561|Other|Patent Foramen Ovale Closure|All eligible participants undergo a patent foramen ovale closure procedure
11289134|NCT02771548||Anterior Cruciate Ligament Reconstruction|Those who have undergone unilateral anterior cruciate ligament reconstructive surgery in the Sports Surgery Clinic.
11289135|NCT02771548||Control|Healthy volunteers with no previous knee injury, no current lower limb injuries and take part in regular multidirectional team sports.
11289136|NCT02771535|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
11289137|NCT02771535|Active Comparator|Health Training Group|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
11289138|NCT02771522|Other|Active post-othodontic lesions|Imaging with the Calcivis System
11289139|NCT02771509|Active Comparator|ANG-3777|Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
11289140|NCT02771509|Placebo Comparator|Normal Saline|The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
11289141|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
11289142|NCT02771483||Suspected GCA (GCA final diagnosis)|
11289143|NCT02771483||Suspected GCA (alternative final diagnosis)|
11289144|NCT02771470|Experimental|Probiotic|Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
11289145|NCT02771470|Placebo Comparator|Placebo|Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
11289147|NCT02771457|Experimental|Infliximab at weeks 0,4, and 8|In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8
11289148|NCT02771457|Active Comparator|Infliximab at weeks 0, and 8|In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.
11289149|NCT02771444|Experimental|Tomo Assessment|Subjects will have a 4-view tomosynthesis examination with the study device.
11289150|NCT02771431|No Intervention|Standard|Group 1 will consist of patients receiving in-person attending-patient encounters while inpatients.
11289151|NCT02771431|Experimental|Tele-rounding|Group 2 will consist of patients receiving video-conference attending-patient encounters. The intervention is being seen via ipad
11289152|NCT02771418|Sham Comparator|TIVA with propofol|Induction and maintenance of general anesthesia using TIVA with propofol
11289153|NCT02771418|Active Comparator|VIMA with sevoflurane|Induction and maintenance of general anesthesia using VIMA with sevoflurane
11289154|NCT02771405|Experimental|Sofosbuvir +Ribavirin|Sofosbuvir 400 mg/day +ribavirin for 24 weeks
11289155|NCT02771405|Experimental|Sofosbuvir+Simeprevir±Ribavirin|Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
11289156|NCT02771405|Experimental|Sofosbuvir+Daclatasvir±Ribavirin|Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks
11289157|NCT02771405|Experimental|Sofosbuvir+Ledipasvir±Ribavirin|Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks
11289158|NCT02771392|Experimental|Tetracaine Group|Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
11289159|NCT02771392|Placebo Comparator|Normal Saline Group|Patients with the primary diagnosis of corneal abrasion will be treated with normal saline eye drops. Normal saline will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of normal saline. Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
11289160|NCT02771379||Patients who are treated with Raxone®|
11289161|NCT02771366|Experimental|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
11289162|NCT02771366|Placebo Comparator|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
11289163|NCT02771353|Active Comparator|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
11289164|NCT02771353|Active Comparator|VMAT_FB|Volumetric modulated arc therapy in free breathing.
11289165|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
11289166|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
11289167|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
11289168|NCT02771327|Experimental|CPAP plus gas|Treatment with Boussingnac valve CPAP during 6 hour, starting immediately after weaning
11289169|NCT02771327|Active Comparator|Usual treatment(ventimask plus gas)|ventimask
11289170|NCT02771314|Experimental|AZD9291|AZD9291
11289171|NCT02771301|Other|dendritic cell|Patients will receive autolgous IDH1R132H dendritic cells and cytotoxic lymphocytes treatment.
11289172|NCT02771288|Other|Kawasaki disease|
11289173|NCT02771275|Experimental|Harpoon Medical Device TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
11289174|NCT02771249|Experimental|B|Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + RPT and INH once weekly (days 5-19).
11289175|NCT02771236||Affected Participants|Participants with inherited eye diseases
11289176|NCT02771236||Unaffected family members|Family members without eye disease
11289177|NCT02771223||Study group|patients scheduled for prolonged cardiac surgery (over 3 hours anticipated ECC time) with no known coagulation disorders
11289178|NCT02771210|Experimental|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose will be assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
11289179|NCT02771210|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
11289180|NCT02771197|Experimental|Lymphodepletion plus Pembrolizumab|Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
11289181|NCT02771184|Other|Lung-Healthy|Subjects with no diagnosed lung disease. The intervention is the recording of lung sounds with the Lung Sound Recording System.
11289182|NCT02771184|Other|Pneumothorax|Subjects with pneumothorax. The intervention is the recording of lung sounds with the Lung Sound Recording System.
11289183|NCT02771184|Other|Pulmonary Fibrosis|Subjects with pulmonary fibrosis. The intervention is the recording of lung sounds with the Lung Sound Recording System.
11289184|NCT02771171||Age groups|The cohort is divided into on the basis of age
11289185|NCT02771158|Experimental|midodrine|randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
11289187|NCT02771145|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
11289188|NCT02771132|Experimental|Intervention|"12-hour intervention IMPower empowerment self defense course for girls and 12-hour Source of Strength for boys+ 2 refresher sessions (at 2 hrs. per session)"
11289189|NCT02771132|Other|Standard of Care|1-2 hour course based on Ministry of Education life skills course (no refresher sessions)
11289190|NCT02771106||vision dysfunction|This group are subjects with mild TBI who have been diagnosed with profound oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist. These subjects will undergo neuro vision rehabilitation.
11289191|NCT02771106||control|This group are subjects with mild TBI who have no oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist
11289192|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
11289193|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
11289194|NCT02771067|Experimental|Pulse pressure variation|Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
11289195|NCT02771054|Experimental|TAF/emtricitabine (FTC)|All 20 patients will switch their nucleoside backbone, either ABC/3TC or TDF/FTC to TAF/FTC
11289196|NCT02771041|Experimental|Group with D-8 medical consultation|"A medical consultation 8 days before surgery would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
11289197|NCT02771041|No Intervention|Group without D-8 medical consultation|
11289198|NCT02771028|Experimental|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
11289199|NCT02771028|No Intervention|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
11289200|NCT02771015|Active Comparator|Mepilex Border®|Mepilex Border® wound dressing at patients after hip-knee or primary spine surgery
11289201|NCT02771015|Active Comparator|Cosmopor steril®|Standard wound dressing at patients after hip-knee or primary spine surgery
11289202|NCT02771002||septic shock patients|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until normalisation of lactate sonographic assesment of perfusion of solid organs once within 24h after admission
11289203|NCT02771002||patients rewarming after cardiac surgery|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until extubation
11289204|NCT02771002||healthy volunteers|measurements of peripheral perfusion including capillary refill time and peripheral perfusion index in ambient temperature and after cooling of extremity
11289205|NCT02770989|Experimental|Vimecon Laser CAI Cardiac Ablation|Ablation of the cardiac tissue by the use of the Vimecon Laser CAI (Cardiac Ablation Instrument).
11289206|NCT02770976|Experimental|NAVA|Seven increasing and decreasing NAVA levels (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0 and 0.5 cmH2O/uV) will applied to 20 preterm infants each for 10 minutes.
11289207|NCT02770963|Experimental|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.
~Huatuo Brand needle (0.3*75 mm) will be used for BL25 and Huatuo Brand needle (0.3*40mm) will be used for BL23, BL40 and BL57."
11289208|NCT02770963|Sham Comparator|Sham acupuncture|The acupoints will be the same as the acupuncture group. Specially designed sham needles (0.3*25 mm) will be used . The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
11289209|NCT02770950|Active Comparator|High dose group|"High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.
~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day."
11289210|NCT02770950|Active Comparator|Low dose group|"Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.
~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day."
11289211|NCT02770950|Active Comparator|Controlled group|Indometacin Cataplasms will be used topically on the knee for 24h per day
11289212|NCT02770937|Active Comparator|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
11289213|NCT02770937|Active Comparator|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on box trainer.
11289214|NCT02770937|No Intervention|Control|The control group will not receive further training.
11289215|NCT02770924|Experimental|AT LISA TRI TORIC|All patients will be undergo to phacoemulsification with IOL implantation bilateral
11289216|NCT02770924|Experimental|AT LISA TRI|All patients will be undergo to phacoemulsification with IOL implantation bilateral
11289217|NCT02770911|Experimental|"without Dog Ear group"|Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
11289218|NCT02770911|Active Comparator|"with Dog Ear group"|traditional double-stapled anastomosis was used for laparoscopic anterior resection
11289243|NCT02770716|Placebo Comparator|Placebo|"Participants will receive 1 vial of matching placebo intravenously as a bolus injection of 1 vial over 2 minutes every 6 hours (+/- 30 minutes), followed by a saline flush.
~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
11289244|NCT02770703|Experimental|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
11290587|NCT02761928||SIJ injection|Positive response (>50% pain relief) to sacroiliac joint injection
11289219|NCT02770898|Experimental|Brief Intervention|The brief intervention is individual focus and consists of three main components, which include enhancing the individual personal attributes such as participant's knowledge, values, and behaviors related to physical exercise. Second, the intervention will promote changes in behavioral attributes by providing opportunities and experience in goal setting, skills development in physical exercise and self-monitoring. Finally, the brief intervention promotes family relations and well-being by encouraging individuals to share their knowledge and increase physical activities with other family members. The brief intervention will be delivered by the probation officer during regular monthly consultation.
11289220|NCT02770898|Experimental|Combined Intervention|Participants allocated to the combined intervention will receive the individual brief intervention and participate in a community group program. The components in the brief intervention will also be reinforced in the group program. The group nature is designed to create an environment that is supportive of physical exercise, through role models, peer support, and encourages families to exercise with probationers.
11289221|NCT02770898|No Intervention|Care-as-usual|Participants allocated to Care-as-usual arm will receive their usual services. Participants will be offered the combined interventions upon completion of 3-months follow up assessment.
11289222|NCT02770885|Experimental|Verum first|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
11289223|NCT02770885|Placebo Comparator|Placebo first|Placebo: 0.5 ml normal saline (0.9% sodium chloride [0.9% sodium chloride (NaCl)]), injection sc via syringe once weekly for 3 weeks.
11289224|NCT02770872||Obese, normal|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2. Observation of SAA on apoB containing lipoproteins
11289225|NCT02770872||Obese, MetS|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2, blood pressure above 135/80, HDL less than 40 mg/dl, triglycerides greater the 150 mg/dl and fasting blood glucose greater than 100 mg/dl but less than 126 mg/dl. Observation of SAA on apoB containing lipoproteins
11289226|NCT02770872||Obese, diabetic|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2 and physician diagnosed diabetes mellitis. Observation of SAA on apoB containing lipoproteins
11289227|NCT02770846|Experimental|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
11289228|NCT02770846|Active Comparator|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
11289229|NCT02770833|Experimental|Salmon vs. veal and CHO with low or high GI|"In the first clinical study (Study 1), subjects will eat salmon or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:
~Meat balls with salmon served with tomato sauce and other accompaniments with low GI
~Meat balls with salmon served with tomato sauce and other accompaniments with high GI
~Meat balls with veal served with tomato sauce and other accompaniments with low GI
~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
11289230|NCT02770833|Experimental|Cod vs. veal and CHO with low or high GI|"In the second clinical study (Study 2), subjects will eat codfish or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:
~Meat balls with codfish served with tomato sauce and other accompaniments with low GI
~Meat balls with codfish served with tomato sauce and other accompaniments with high GI
~Meat balls with veal served with tomato sauce and other accompaniments with low GI
~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
11289231|NCT02770820|Experimental|Treatment (autologous CD8 T cells)|Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on day 0 and again after a minimum of 3 weeks. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
11289232|NCT02770807|Experimental|EDS-EP dose range of ~5-10 mg DSP/infusion|"Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL.
~Other Names:
~EryDex System end product"
11289233|NCT02770807|Experimental|EDS-EP dose range of ~14-22 mg DSP/infusion|"Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
~Other Names:
~EryDex System end product"
11289234|NCT02770807|Placebo Comparator|Placebo EDS infusion|Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
11289235|NCT02770794|Experimental|All patients|Discontinue infliximab; Receive infliximab when relapse
11289236|NCT02770781|Experimental|Personal Trainer|All subjects will meet a set amount of times with a personal trainer over the course of the study to participate in an exercise regimen.
11289237|NCT02770768|Active Comparator|Flibanserin|"Drug: Flibanserin
~8 weeks
~100mg once daily at bedtime"
11289238|NCT02770768|Placebo Comparator|Placebo|Drug: Matching Placebo Matching placebo capsules taken in same amount of pills as the active medication (for 8 weeks once daily at bedtime)
11289239|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
11289240|NCT02770729|Active Comparator|Intracameral moxifloxacin|Intracameral injection of 0.5% moxifloxacin at conclusion of cataract surgery (150 micrograms)
11289241|NCT02770729|Sham Comparator|No injection of moxifloxacin|No injection of moxifloxacin at conclusion of cataract surgery
11289242|NCT02770716|Experimental|Terlipressin|"Participants will receive terlipressin intravenously as a bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (+/- 30 minutes), followed by a saline flush.
~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
11289245|NCT02770703|Experimental|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
11289246|NCT02770703|Experimental|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
11289247|NCT02770690|Experimental|spray|apply the ethyl chloride spray before propofol injection
11289248|NCT02770690|Active Comparator|lidocaine|apply the lidocaine 0.5 mg/kg under the touniquette state before propofol injection
11289249|NCT02770690|Placebo Comparator|placebo|apply the saline before propofol injection
11289250|NCT02770677|No Intervention|Control group|Control group will be asked to continue their normal daily life without Yoga training
11289251|NCT02770677|Experimental|Yoga group|Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
11289252|NCT02770664|Experimental|LC28-0126 Dose A|
11289253|NCT02770664|Experimental|LC28-0126 Dose B|
11289254|NCT02770664|Experimental|LC28-0126 Dose C|
11289255|NCT02770664|Placebo Comparator|Placebo|
11289256|NCT02770651||Optical Coherence Tomography|To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.
11289257|NCT02770638|Experimental|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
11289258|NCT02770638|Active Comparator|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
11289259|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
11289260|NCT02770612|Other|Post-cesarean delivery mothers|"Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.
~After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)
~The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.
~A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc."
11289261|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
11289262|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
11289263|NCT02770586|Other|Breast PET|Breast PET
11289264|NCT02770573|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense; Kuraray Teethmate™ Desensitizer; Ghimas Dentin Desensitizer.
~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.
~The application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
11289265|NCT02770560||Chronic hemodialysis patients with a tunneled cuffed catheter|In case of thrombotic dysfunction of the dialysis catheter : administration of Urokinase (100 000 units in total) as locking solution in the dead space of the catheter lumen, interdialytic (between two dialysis sessions) or intradialytic (during the dialysis in case of complete obstruction of the dialysis catheter)
11289266|NCT02770547|Active Comparator|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
11289267|NCT02770547|Experimental|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
11289268|NCT02770534||Sickle patients in steady state|Well sickle cell patients attending the outpatient clinic
11289269|NCT02770534||Sickle cell patients admitted in crisis|Inpatients with acute vaso-occlusive crisis
11289270|NCT02770534||Sickle patients on transfusion program|Sickle patients managed on a regualar transfusion program
11289271|NCT02770534||Sickle patients on Hydroxycarbamide|Sickle cell patients managed on hydroxycarbamide and on a stable dose for at least 3 months
11289272|NCT02770534||Health controls|Well age and race matched individuals without a known diagnosis of sickle cell anaemia
11289273|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
11289274|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
11289275|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
11289276|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
11289277|NCT02770508|Experimental|Darunavir/ritonavir plus lamivudine|Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
11289278|NCT02770508|Active Comparator|Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)|Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
11289279|NCT02770495|Experimental|Postoperative endoscopic recurrence|Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection
11289280|NCT02770482|Experimental|AD Patients|
11289281|NCT02770469|Active Comparator|Standard Intervention|The standard intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship.
11289282|NCT02770469|Experimental|Enhanced Intervention|The enhanced intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship as well as cognitive-behavioral stress management.
11289283|NCT02770456|Experimental|High dose fish oil|Women will be offered 4 capsules per day containing fish oil
11289284|NCT02770456|Experimental|Low dose fish oil|Women will be offered 4 capsules per day containing mixed fish oil and olive oil
11289285|NCT02770456|Placebo Comparator|Control|Women will be offered 4 capsules per day containing olive oil
11289286|NCT02770443|Experimental|Treatment|Withdrawal of beta blockers and ACE inhibitors
11289287|NCT02770443|Placebo Comparator|control|no withdrawal, standard of care
11289288|NCT02770430|Active Comparator|conventional treatment|"After randomization, patients will be allocated to receive conventional treatment:
~Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.
~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
11289289|NCT02770430|Experimental|mesenchymal stem cells|Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg
11289290|NCT02770417|Active Comparator|COPD (beta-alanine)|
11289291|NCT02770417|Placebo Comparator|COPD (placebo)|
11289292|NCT02770417|Other|Healthy controls|
11289293|NCT02770404|Experimental|Nafithromycin|"Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.
~Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1"
11289294|NCT02770404|Placebo Comparator|Placebo|Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.
11289295|NCT02770391|Experimental|ARN-509 + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to ARN-509 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. ARN-509 will be continued till the day of RP.
11289296|NCT02770378|Experimental|Temozolomide combined with 9 repurposed drugs|"After enrollment, the subject goes into the induction cycle, which lasts 35 days. The induction cycle consists of a drug-by-drug addition and up-dosing process.
~Hereafter, the subject will enter the treatment cycles (up to 12). During the induction cycle and the first 2 treatment cycles, regimen adjustments (dropping of certain drugs, dose modification of certain drugs) may be executed to accommodate to the patients' individual toxicity reactions that may occur during this period."
11289297|NCT02770365|Experimental|Test Product|estradiol cream
11289298|NCT02770365|Active Comparator|Reference Product|estradiol cream
11289299|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
11289300|NCT02770326|Experimental|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
11289301|NCT02770313|Experimental|Intermittent Fasting|Water-only Intermittent Fasting
11289302|NCT02770313|No Intervention|Control|ad libitum Usual Diet
11289303|NCT02770300|No Intervention|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.
~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
11289304|NCT02770300|Experimental|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
11289305|NCT02770300|Experimental|Automatic personalized robotic rehabilitation with ALEx RS|
11289306|NCT02770287|Experimental|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
11289307|NCT02770274|Experimental|Group Cilostazol|Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.
11289308|NCT02770274|Active Comparator|Group Aspirin|Patients receiving monotherapy with aspirin 100mg once daily for 12 months.
11289309|NCT02770261|Experimental|CR group|DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
11289310|NCT02770261|Active Comparator|CP group|DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
11289311|NCT02770261|Active Comparator|PR group|DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
11289312|NCT02770248|Experimental|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
11289313|NCT02770248|Active Comparator|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
11289314|NCT02770235|Experimental|DE assessment and AGE measurements|To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients
11289315|NCT02770222|Experimental|Part 1, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods.
11289316|NCT02770222|Experimental|Part 1, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
11289317|NCT02770222|Experimental|Part 2, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
11289318|NCT02770222|Experimental|Part 2, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
11289319|NCT02770209|Experimental|the experimental group|Patients in the experimental group will be treated with the biomimetic cartilage matrix combined with autologous chondrocytes. The entire course of treatment includes two surgeries. The first surgery will be performed to observe articular cartilage damage by arthroscopy and assess treatment potential. If the patient's condition meets the surgical requirement, we will extract cartilage from the fossa intercondylar non-weight-bearing area during the first surgery. Chondrocytes will be in vitro-amplified and inoculated into the cartilage scaffold. The fully prepared seeded scaffold will be implanted into the site of injury during the second surgery.
11289320|NCT02770209|Experimental|the control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
11289321|NCT02770196|Experimental|Group One (Two-year Intervention, 2016 Enrollment)|Group one intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2016 and 2017. During the 2016 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
11289322|NCT02770196|Experimental|Group Two (Delayed Two-year Intervention, 2016 Enrollment)|Group two intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2017 and 2018. During the 2017 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
11289323|NCT02770196|Experimental|Group Three (One-year Intervention, 2017 Enrollment)|Group three intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2017 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
11289324|NCT02770196|Experimental|Group Four (Delayed One-year Intervention, 2017 Enrollment)|Group four delayed intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2018 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
11289325|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.
~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
11289326|NCT02770170|Experimental|BI 655064 dose 1|
11289327|NCT02770170|Experimental|BI 655064 dose 2|
11289328|NCT02770170|Experimental|BI 655064 dose 3|
11289329|NCT02770170|Placebo Comparator|Placebo|
11289330|NCT02770157|Experimental|DA-3002|1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
11289331|NCT02770157|Active Comparator|Genotropin®|1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
11289332|NCT02770157|Other|Non-treatment control group|After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
11289333|NCT02770144|Experimental|Financial Coaching & Social Services Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
11289334|NCT02770144|Active Comparator|Access to Referrals to Social Services|Enrollment provides access to referrals to social services to meet basic needs.
11289335|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
11289336|NCT02770118|Experimental|PSR-TSD|Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
11289337|NCT02770118|Experimental|TSD-PSR|Total sleep deprivation (TSD) followed by partial sleep restriction (PSR). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
11289520|NCT02768974|Experimental|OPRX-106 8 mg|Open label, 1:1 randomization ration (up to 10 subjects)
11414188|NCT01941238||MDI|
11289338|NCT02770092|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
11289339|NCT02770092|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
11289340|NCT02770092|Experimental|Congestive Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
11289341|NCT02770079||Gestational diabetes|10 women with gestational diabetes
11289342|NCT02770053|Experimental|Intervention|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with #35 K-files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
11289343|NCT02770053|Active Comparator|Control|In the control group, no foraminal enlargement will be performed.
11289344|NCT02770040|Active Comparator|Intensified Infliximab Induction|Infliximab 10mg/kg at Week 0 and Week 1
11289345|NCT02770040|Active Comparator|Accelerated Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 1 and Week 3
11289346|NCT02770040|Active Comparator|Standard Infliximab Induction|Infliximab 5mg/kg at Week 0, Week 2 and Week 6
11289347|NCT02770027|Placebo Comparator|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11289348|NCT02770027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11289349|NCT02770014|Experimental|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
11289350|NCT02769988||Project SHARE|
11289351|NCT02769975||Case Only|Children ages 0-18 with known or suspected endocrine or metabolism disorders.Family members ages 0-100. They may participate in the DNA part of the study
11289352|NCT02769962|Experimental|Phase I|CRLX101 + olaparib CRLX101 (IV Q 2wks Days 1, 15) + olaparib (PO Days 3- 13* and 17-26*) q 28 days
11289353|NCT02769962|Experimental|Phase II|CRLX101 + olaparib at MTD/RP2DRP2D CRLX101 + olaparib q 28 days
11289354|NCT02769949||Genetic Disorders and family members|subjects with genetic disorders and family members (adult and pediatric; affected and unaffected) may be enrolled for the purpose of determining the molecular lesion(s) responsible for genetic disorders.
11289355|NCT02769936|Placebo Comparator|Healthy Adult - Placebo|Single dose placebo pill in healthy adults
11289356|NCT02769936|Experimental|Healthy Adult - D-cycloserine|Single 100 mg dose D-cycloserine pill in healthy adults
11289357|NCT02769936|Placebo Comparator|Schizophrenia - Placebo|Single dose placebo pill in schizophrenia patients
11289358|NCT02769936|Experimental|Schizophrenia - D-cycloserine|Single 100 mg dose D-cycloserine pill in schizophrenia patients
11289359|NCT02769923|Active Comparator|Arm A|Westpharma ID Adapter
11289360|NCT02769923|Active Comparator|Arm B|Star ID syringe
11289361|NCT02769923|Active Comparator|Arm C|BCG NS
11289362|NCT02769910|Other|Cowhage|Cowhage is used to induce non-histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hours and Qutenza Demo Patch.
11289363|NCT02769910|Other|Histamine|Histamine is used to induce histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hour and Qutenza Demo Patch.
11289364|NCT02769897|Experimental|Intervention group|The exercise program, nutritional counseling and oral health will last for five to six months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC). The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
11289365|NCT02769897|No Intervention|Control group|The control group did not receive the intervention.
11289366|NCT02769884|Experimental|MMPPC arm|Subjects in this arm will wear the experimental MMPPC algorithm artificial pancreas for 72 hours in a hotel/house setting. The study period will involve unannounced meals and exercise
11289367|NCT02769871|Active Comparator|Standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at the participant's initial interview. Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
11289368|NCT02769871|Experimental|Neuroimages of stroke|Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
11289369|NCT02769858|Experimental|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
11289697|NCT02767713|Placebo Comparator|Control|Equal volume of normal saline (placebo) was administered intravenously 10h before surgery
11289370|NCT02769845|Experimental|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
11289371|NCT02769845|Experimental|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
11289372|NCT02769832|Experimental|Nab-Paclitaxel with Gemcitabine|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days; Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
11289373|NCT02769819|Experimental|Intubation with a flexible fiberscope|Following induction of general anesthesia and administration of a neuromuscular blocking agent, intubation will be performed using a flexible fiberscope.
11289374|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
11289375|NCT02769793|Experimental|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
11289376|NCT02769793|Active Comparator|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
11289377|NCT02769767||Cases|Subjects with Relapsing-Remitting Multiple Sclerosis. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
11289378|NCT02769767||Controls|Healthy subjects. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
11289379|NCT02769767||Responders|Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of <1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
11289380|NCT02769767||No responders|Subjects with MS that have more than one relapse per year treated for at least two years, and who had ≥1 relapse(s) or an increase of 1.5 points on the EDSS (if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
11289381|NCT02769754|Placebo Comparator|Control|In the control group (group A) no additional treatment will be applied after performing the usual surgical hemostasis.
11289382|NCT02769754|Experimental|Hemopatch|Hemopatch will be apply in the treatment group (group B), once the standard surgical hemostasis is achieved
11289383|NCT02769741|Other|Crossover 1: Control Diet followed by Active Diet|Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts
11289384|NCT02769741|Other|Crossover 2: Active Diet followed by Control Diet|Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts
11289385|NCT02769728|Experimental|EndoBarrier|EndoBarrier will be implemented for 9 months.
11289386|NCT02769715|Active Comparator|cast removable partial denture|patients received cast removable partial dentures fabricated using traditional lost-wax casting technique.
11289387|NCT02769715|Experimental|laser-sintered removable partial denture|patients received removable partial dentures fabricated using laser-sintering.
11289388|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
11289389|NCT02769689|Experimental|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
11289390|NCT02769689|Placebo Comparator|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
11289391|NCT02769676|Experimental|3-week visit|Participants randomized to this arm will receive an additional visit at 3-weeks postpartum
11289392|NCT02769676|Active Comparator|usual care|Participants randomized to this arm will receive usual postpartum care, including the standard timing for a postpartum visit.
11289393|NCT02769663||OSA|Patients with newly diagnosed obstructive sleep apnea and no medical comorbidity affecting cognition.
11289394|NCT02769663||healthy controls|Participants with no sleep disorder or other medical comorbidity affecting cognition.
11289395|NCT02769650|Experimental|Stress-MRI + Chronic total occlusion PCI|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Coronary angioplasty with stenting of RCA CTO
11289396|NCT02769650|Active Comparator|Stress-MRI + Optimal medicamentous treatment|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Optimal medicamentous treatment
11289397|NCT02769637||ON PPI|Subjects on proton pump inhibitor (PPI) treatment
11289398|NCT02769637||OFF PPI|Subjects off proton pump inhibitor (PPI) treatment
11289399|NCT02769624|Experimental|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
11289400|NCT02769624|Placebo Comparator|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
11289401|NCT02769611|Experimental|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
11289402|NCT02769611|Experimental|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
11289403|NCT02769611|Experimental|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
11289799|NCT02767089|Other|Sequence D|Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg
11298397|NCT02710331|Experimental|Placebo THC and Active Ethanol|
11289404|NCT02769598||ANI Index for Hospitalized children|"Each child will be registered upon arrival in the service and for a period of 24 hours. Registration will finish at the end of 24 hours or when the patient is discharged from the service. A FLACC scale (Face, Legs, Activity, Cry, Consolability scale) will be performed at the patient's input and then once every 4 hours corresponding to the patient's baseline. A FLACC scale will then be performed at each painful episode of the patient and 30 minutes after the end of production of analgesic treatment corresponding to the post-treatment painful condition of the patient.
~A measurement of blood pressure will be performed at each pain rating by the patient assisted by the nurse."
11289405|NCT02769585|Experimental|Self-hypnosis|Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.
11289406|NCT02769585|Active Comparator|CDE training|Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.
11289407|NCT02769572|Experimental|real moxibustion plus placebo gel|In subjects with osteoarthritis of the knee
11289408|NCT02769572|Active Comparator|diclofenac sodium gel plus sham moxibustion|In subjects with osteoarthritis of the knee
11289409|NCT02769559||Patients with macromasty|Female adult patients with symptomatic macromasty selected for elective reduction surgery
11289410|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
11289411|NCT02769507|Experimental|real tDCS|DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
11289412|NCT02769507|Sham Comparator|sham tDCS|"DC Stimulator PLUS (NeuroConn) The sham condition is identical to the real tDCS condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period."
11289413|NCT02769494|Experimental|Mesalazine Group|Mesalazine Sustained-Release Tablets and 0.02L glycerol mixed, 2.5% mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. Daily treatment time of the drug is 8 am,12 pm and 4 pm.
11289414|NCT02769494|Active Comparator|Riboflavin Sodium Phosphate Group|wipe the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. Daily treatment time of the drug is am,12 pm and 4 pm.
11289415|NCT02769481|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
11289416|NCT02769481|Active Comparator|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
11289417|NCT02769468|Active Comparator|The Back|The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.
11289418|NCT02769468|Active Comparator|Chest|The probe is placed on the chest, 1 cm above the left nipple.
11289419|NCT02769468|Active Comparator|Left Axilla|The probe is placed deep in the left axilla
11289420|NCT02769455|No Intervention|Control|The control group will not be exposed to any FOP nutrition labels
11289421|NCT02769455|Experimental|Front-of-pack labelling (Reference Intakes)|The second group will be exposed to a FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are presented in the form of a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
11289422|NCT02769455|Experimental|Front-of-pack labelling (5-CNL)|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.
~The format of the 5-CNL system therefore includes five categories of nutritional quality of food products, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the letter/colour corresponding to the product being enlarged."
11289423|NCT02769442|Experimental|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
11289424|NCT02769442|Active Comparator|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
11289425|NCT02769429||ultrasound-guided CISB|Group 1 will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
11289426|NCT02769429||nerve stimulator-guided CCPVB|Group 2 will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
11289427|NCT02769416||Spinal Cord and Traumatic Brain Injury Subjects|Patients with a history of spinal cord and/or traumatic brain injury will provide data and samples so that they may be queried for interventional studies.
11289428|NCT02769416||Family Members and Healthy Volunteers|Healthy volunteer controls or family members may be enrolled for identification of genetic mutations.
11289429|NCT02769403|Experimental|Treatment|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
11289606|NCT02768337|Experimental|Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.
11289430|NCT02769403|Active Comparator|Control|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The control participants will use it daily only for weeks 7-12. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
11289431|NCT02769390|No Intervention|Bupivacaine 0,166%|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% for hypospadia surgery
11289432|NCT02769390|Active Comparator|Clonidine 1 mcg/Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 1 mcg/ Kg of clonidine for hypospadia surgery
11289433|NCT02769390|Active Comparator|Clonidine 2 mcg/ Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 2 mcg/ Kg of clonidine for hypospadia surgery
11289434|NCT02769390|Active Comparator|Clonidine 3 mcg/Kg|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 3 mcg/ Kg of clonidine for hypospadia surgery
11289435|NCT02769377|No Intervention|Control|patients who decline or unable to do self-monitoring of blood glucose
11289436|NCT02769377|Active Comparator|Breeze2 glucometer|patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone
11289437|NCT02769377|Experimental|Breeze2 glucometer and H2|patients who do self-monitoring of blood glucose and transfer data via mobile-phone
11289438|NCT02769364||Participants treated with eribulin for at least 7 months|
11289439|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
11289440|NCT02769338|Experimental|QI with External Facilitation|Receive external facilitation to support implementation of the quality improvement program
11289441|NCT02769338|No Intervention|Control|Non-Intervention VA Medical Centers
11289442|NCT02769325|Experimental|Atropine|Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia
11289443|NCT02769325|Placebo Comparator|placebo|Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia
11289444|NCT02769312|Sham Comparator|Sham Stimulation|A sham coil is being used to compare against active coil.
11289445|NCT02769312|Active Comparator|Active Stimulation|An active coil is being used to compare against sham coil.
11289446|NCT02769286|Experimental|Osimertinib in cohort 1|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA
11289447|NCT02769286|Experimental|Osimertinib in cohort 2|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA
11289448|NCT02769260|No Intervention|No toothbrushing during experiment and Pyrosequencing|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope) and 16S DNA pyrosequencing.
11289449|NCT02769260|No Intervention|No toothbrushing during experiment|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
11289450|NCT02769260|Active Comparator|Toothbrushing during experiment|48hours-Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
11289451|NCT02769247|Experimental|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
11289452|NCT02769247|Experimental|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
11289453|NCT02769247|Experimental|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
11289454|NCT02769247|Experimental|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
11289455|NCT02769234||Alzheimer's disease|Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
11289456|NCT02769221|Experimental|Optiscope|Endotracheal intubation by rigid video stylet, manufactural named Optiscope.
11289457|NCT02769221|Active Comparator|McGrath|Endotracheal intubation by video laryngoscope, manufactural named McGrath.
11289458|NCT02769208|Active Comparator|Group A: Pre-Filter Only Intervention|Subjects in Group A start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which both the HEPA and ESP are removed, leaving only a pre-filter. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
11289459|NCT02769208|Active Comparator|Group B: Pre-filter + HEPA Intervention|Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
11289460|NCT02769182|Experimental|Monitoring and training using the system|
11289461|NCT02769182|Active Comparator|Standard of care|
11289462|NCT02769169|Experimental|double-dose|"double-dose
~Lucentis® (Raibizumab), 1mg, 3+prn"
11289463|NCT02769169|Active Comparator|regular-dose|"regular-dose
~Lucentis® (Raibizumab), 0.5mg, 3+prn"
11289464|NCT02769143|Experimental|Whole-Body Vibration Group (WBV)|Will be exposed to five minutes on a vibrating platform (Oscillating Platform Semi-Professional Horizontal - Arktus, Cascavel, Brazil), this type of platform vibrates through an anteroposterior axis, causing the right and left sides alternate horizontally denominated: alternating side vibration platforms, will be performed three times per week on alternate days (5 minutes). a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. The volunteers will be guided to stand on the platform with semi-flexed knees, barefoot and apart about hip width.
11289607|NCT02768324||sepsis with diarrhea|
11289608|NCT02768324||sepsis without diarrhea|
11422416|NCT01886300||Cohort|
11289465|NCT02769143|Experimental|Pilates Group (PG)|Will be exposed to 60 minutes, held three times a week on alternate days. Pilates equipment used for the exercises are: Combo Chair, Cadillac Trapeze, Ladder Barrel, Reformer Universal, Step Barrel and Wall Unit. Will be selected for this study, 21 strengthening exercises and stretching to the main body segments. All exercises are performed in a series of ten repetitions with one minute interval between exercises. To determine the level of effort and consequently to changing loads, will be used verbal command according to the Borg CR10 scale. The level of effort will be maintained during the session heavy (Borg between 5 and 6).
11289466|NCT02769143|No Intervention|Control Group (CG)|The control group will be instructed to maintain their usual activities both in relation to their daily activities, dietary habits, failure to use drugs that can influence the increase in bone mass and participate in monthly meetings to address on issues osteoporosis and postmenopausal women. After the end of the interventions with WBV and GP groups, GC volunteers will be invited to also perform whole body vibration for six months. Exposure of vibration will be for five minutes on a vibrating platform, three times per week on alternate days. a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. Likewise which was offered for the WBV group.
11289467|NCT02769130|Experimental|Losartan|"Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.
~Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year."
11289468|NCT02769117|Active Comparator|Ultrasound on fractured bone|An ultrasound technique will be used to record the acoustic response of the fractured bone at each clinical visit until the fracture is healed. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm on either sides of the fracture. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fracture and on the unaffected (contralateral) bone as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
11289469|NCT02769117|Active Comparator|Ultrasound on contralateral intact bone|An ultrasound technique will be used to record the acoustic response of the intact bone as control at each clinical visit. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm or clavicle. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fractured forearm/clavicle and on the unaffected (contralateral) forearm/clavicle as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
11289470|NCT02769104|Experimental|AI+Chemo|aromatase inhibitors (Letrozole 2.5mg po. QD for 5 years) starts at the beginning of neoadjuvant treatment combined with chemotherapy (AC*4-T*4) in patients with postmenopausal hormone receptor-positive breast cancer
11289471|NCT02769104|Active Comparator|Chemo|chemotherapy (AC*4-T*4) as neoadjuvant treatment without aromatase inhibitors in patients with postmenopausal hormone receptor-positive breast cancer
11289472|NCT02769091|Experimental|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
11289473|NCT02769091|Placebo Comparator|Placebo|Matching placebo
11289474|NCT02769078||Patients who received dabigatran|Patients who received dabigatran
11289475|NCT02769078||Patients who received rivaroxaban|Patients who received rivaroxaban
11289476|NCT02769078||Patients who received apixaban|Patients who received apixaban
11289477|NCT02769078||Patients who received warfarin|Patients who received warfarin
11289478|NCT02769065|Placebo Comparator|SRD: Placebo Cohorts 1-6, 18 and 19|TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
11289479|NCT02769065|Experimental|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
11289480|NCT02769065|Experimental|SRD: Cohort 2: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
11289481|NCT02769065|Experimental|SRD: Cohort 3: TAK-071 9 mg|TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
11289482|NCT02769065|Experimental|SRD: Cohort 4: TAK-071 20 mg|TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
11289483|NCT02769065|Experimental|SRD: Cohort 5: TAK-071 40 mg|TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
11289484|NCT02769065|Experimental|SRD: Cohort 6: TAK-071 80 mg|TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
11289485|NCT02769065|Placebo Comparator|MRD: Placebo Cohorts 7-9|TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
11289486|NCT02769065|Experimental|MRD: Cohort 7: TAK-071 3 mg|TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
11289487|NCT02769065|Experimental|MRD: Cohort 8: TAK-071 9 mg|TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
11289488|NCT02769065|Experimental|MRD: Cohort 9: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
11289489|NCT02769065|Placebo Comparator|MRD: TAK-071 Placebo Cohorts 10-12+Donepezil|TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
11289609|NCT02768311|Experimental|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system post-treatment pain after using neolix rotary system
11289800|NCT02767089|Other|Sequence E|Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo
11289490|NCT02769065|Experimental|MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg|TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
11289491|NCT02769065|Experimental|MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg|TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
11289492|NCT02769065|Experimental|MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg|TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
11289493|NCT02769065|Experimental|MRD: Placebo Cohorts 13-15|TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
11289494|NCT02769065|Experimental|MRD: Cohort 13: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
11289495|NCT02769065|Experimental|MRD: Cohort 14: TAK-071 9 mg|TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
11289496|NCT02769065|Experimental|MRD: Cohort 15: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
11289497|NCT02769065|Experimental|Cohort 16|
11289498|NCT02769065|Experimental|Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC|A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
11289499|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence BCA|B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
11289500|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence CAB|C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
11289501|NCT02769065|Experimental|SRD: Cohort 18: TAK-071 120 mg|TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
11289502|NCT02769065|Experimental|SRD: Cohort 19: TAK-071 160 mg|TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
11289503|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil Placebo|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
11289504|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
11289505|NCT02769065|Experimental|SRD: Cohort 20: TAK-071 40 mg+Donepezil|TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
11289506|NCT02769065|Experimental|SRD: Cohort 21: TAK-071 60 mg+Donepezil|TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
11289507|NCT02769065|Experimental|SRD: Cohort 22: TAK-071 80 mg+Donepizil|TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
11289508|NCT02769052|Active Comparator|Follow-up/Treatment Group|Composed of two phases of 8 weeks each (follow-up - treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
11289509|NCT02769052|Active Comparator|Treatment/Follow-up Group|Composed of one phase of 8 weeks (treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
11289510|NCT02769039||Parkinson's Disease participants|People with early Parkinson's disease with mild-to-moderate severity of disease.
11289511|NCT02769039||Control participants|Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
11289512|NCT02769013||S. haematobium positives in Gabon|Asymptomatic volunteers infected with S. haematobium and living in Gabon
11289513|NCT02769013||S. haematobium negatives in Gabon|Volunteers not infected with S. haematobium and living in Gabon
11289514|NCT02769013||S. haematobium positives in Ghana|Asymptomatic volunteers infected with S. haematobium and living in Ghana
11289515|NCT02769013||S. haematobium negatives in Ghana|Volunteers not infected with S. haematobium and living in Ghana
11289516|NCT02769000|Experimental|Subjects 1-30|15 subjects in each RT dose schedule 10 GY in 5 daily fractions 20 GY in 10 daily fractions
11289517|NCT02768987|Experimental|Overweight|Sedentary adolescents with T1D and overweight
11289518|NCT02768987|Experimental|Normal Weight|Sedentary adolescents with T1D and normal weight
11289519|NCT02768974|Experimental|OPRX-106 2 mg|Open label, 1:1 randomization ration (up to 10 subjects)
11289521|NCT02768961|Experimental|Active treatment|"All HCV chronic infected patients will be treated with oral anti-HCV regimens containing sofosbuvir, ledipasvir (associated or not to ribavirin) according to clinical practice as indicated into the current guidelines (1)
~(1)European Association for Study of Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
11289522|NCT02768948|Experimental|telmisartan|treatment with telmisartan at doses of 80 mg / day for 6 months
11289523|NCT02768948|Experimental|losartan|Losartan at a dose of 100 mg / d for 6 months.
11289524|NCT02768935|Other|Diabetes|
11289525|NCT02768935|Other|normoglycaemic|
11289526|NCT02768922|Experimental|Aphasia telerehabilitation|Speech and language therapy is given by telemedicine to improve expressive language function. The therapy will include knowledge based tasks of aphasia rehabilitation including training of language forms and overall functional communication. A special emphasis will be put on naming training. The telerehabilitation will be given in a addition to standard face-to-face aphasia rehabilitation
11289527|NCT02768922|Active Comparator|Control|Control Group receives standard face-to-face aphasia rehabilitation
11289528|NCT02768909|Experimental|Pulmonary TB|"This arm will enroll 100 patients older than 15 years old, from Caracas, with pulmonary TB, culture proved.
~Intervention:
~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.
~Chest X-ray.
~Sputum samples for Ziehl Neelsen smear and Culture in L-J.
~Follow Up 5 days after beginning of Tx
~Follow Up 15 days after beginning of Tx
~Follow Up 30 days after beginning of Tx
~Follow Up 60 days after beginning of Tx"
11289529|NCT02768909|Active Comparator|Non - Pulmonary TB|"This arm will enroll 75 patients older than 15 years old, from Caracas, with non TB pulmonary infections, culture negative.
~Intervention:
~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.
~Chest X-ray.
~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
11289530|NCT02768909|Active Comparator|Healthy Individuals|"This arm will enroll 75 patients older than 15 years old, from Caracas, without any symptom or sign of lower track infection.
~Intervention:
~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.
~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.
~Chest X-ray.
~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
11289531|NCT02768896|No Intervention|Baseline|Patients will walk naturally with EEG measuring brain waves
11289532|NCT02768896|Experimental|Visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
11289533|NCT02768896|Experimental|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
11289534|NCT02768896|Experimental|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
11289535|NCT02768883|Experimental|Clinic + Home + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator
~Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls
~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
11289536|NCT02768883|Experimental|Clinic + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator
~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
11289537|NCT02768883|Experimental|Home + Community|"Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls
~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
11289538|NCT02768883|Active Comparator|Community only|Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook.
11289539|NCT02768870|Experimental|Harpoon Medical Device|This is a prospective, single arm, nonrandomised, multi-center EU study to demonstrate the performance and safety of the Harpoon Medical device in patients with degenerative MR.
11289540|NCT02768857|Experimental|Early sensorimotor reeducation intervention|The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
11289541|NCT02768857|Active Comparator|Traditional sensorimotor reeducation intervention|The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
11289542|NCT02768844|Experimental|SVS vs Control|Prospective, within-subject design. Compare effects of mattress SVS (ON) and Control (SVS OFF) on physiology in opioid-exposed newborns. SVS is alternated in intervals between continuous stimulation (ON) and no stimulation (OFF/Control) throughout inter-feed intervals. The order of the ON-OFF cycles is randomized across subjects and counterbalanced between feeding periods within subjects.
11289543|NCT02768831|Experimental|Cuffed ETT|
11289544|NCT02768818|Experimental|Intervention|Probiotic VIVOMIXX™
11289545|NCT02768818|Placebo Comparator|Control|Placebo
11289546|NCT02768805|Experimental|15 µg/strain of Quadrivalent VLP Vaccine|
11289547|NCT02768805|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
11289548|NCT02768805|Active Comparator|15 µg/strain of the licensed quadrivalent vaccine|
11289610|NCT02768311|Experimental|waveone rotary system (reciprocating system)|Procedure: waveone rotary system post-treatment pain after using waveone rotary system
11289611|NCT02768311|Experimental|hand files k-files|Procedure: hand files post-treatment pain after using hand files
11289549|NCT02768792|Other|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
11289550|NCT02768779||HIV negative and positive individuals|HIV Negative or HIV positive individuals, aged 18 years or older, who have been taking their ARV medication for at least 3 months and are adherent based on blood plasma HIV RNA of <50 copies/mL or HIV negative status. Hair analysis.
11289551|NCT02768766|Experimental|Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles starting at a dose of 125mg. The doses to be studied on a 3 day on, 4 day off schedule are 100mg, 125mg, 150mg, 175mg, 200mg and 225mg as per the time to event continual reassessment (TITE-CRM) design.
11289552|NCT02768753|Experimental|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
11289553|NCT02768753|Experimental|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
11289554|NCT02768740|Active Comparator|200 mg group|Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
11289555|NCT02768740|Experimental|300 mg group|Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
11289556|NCT02768727|Experimental|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
11289557|NCT02768714|Experimental|Eurofarma's pegfilgrastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Eurofarma's pegfilgrastim (subcutaneous injection)
11289558|NCT02768714|Active Comparator|Neulastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)
11289559|NCT02768701|Experimental|Experimental: Single Arm|Subjects will receive a single dose (300 mg/m2) of cyclophosphamide given the day before cycle 1 of pembrolizumab (200 mg), which will be administered every 3 weeks.
11289560|NCT02768688|Experimental|Brain connectivity and physiology|Dexmedetomidine anesthesia on glymphatic flow in human subjects as visualized by diffusion tensor MRI.
11289561|NCT02768675|Experimental|LOADPRO arm|Participants will temporarily receive a LOADPRO device affixed to kyphotic corrective rods. The device will not be implanted and will be removed prior to surgery closure.
11289562|NCT02768662|Experimental|OTO-104|12 mg dexamethasone
11289563|NCT02768649|Experimental|Cohort 1|Eligible subjects received a test dose of 0.25 risperidone prior to dosing with RBP-7000. Fifteen eligible subjects then received low dose RBP-7000
11289564|NCT02768649|Experimental|Cohort 2|After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
11289565|NCT02768649|Experimental|Cohort 3|After safety and tolerability review of the data from Day 1 to Day 15 of the medium dose arm, 3 subjects were dosed in Cohort 3 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
11289566|NCT02768636|Experimental|Before and after omega-3 used|Before and after omega-3 used
11289567|NCT02768623|Active Comparator|Control Group|Patients in the control group will receive standard, dispensing services they currently receive from pharmacists. Control group pharmacists will continue to provide these services in accordance with the standards of practice adopted by the Ontario College of Pharmacists. They will not provide either of the 3 intervention components outlined above. Should a control group patient request additional information and/or services, the pharmacist will comply and provide these as deemed necessary for the particular patient. This could include the full range of educational and drug therapy optimization services outlined for the intervention group. If this occurs then the pharmacists will document all services provided in order for the research team to account for this in the analysis.
11289568|NCT02768623|Experimental|Intervention Group|"Pharmacists in the intervention group will provide patients with a comprehensive disease management program for asthma. The 3 major components of pharmacists' intervention are outlined below. The services delivered will be customized based on each patient's case.
~Medication review and drug therapy optimization
~Patient education
~Improving patient adherence"
11289569|NCT02768610|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine is administered before endotracheal intubation for 10 minutes
11289570|NCT02768610|Placebo Comparator|Normal Saline|
11289571|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
11289572|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
11289573|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
11289574|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
11289612|NCT02768298|Experimental|LCZ696|LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.
11289613|NCT02768298|Active Comparator|Enalapril|"Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.
~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
11289575|NCT02768571|Experimental|Cerebrolysin|"Cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation
~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)
~Rehabilitation
~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day
~5 times/week for 3 weeks
~Duration of Treatment:
~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.
~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
11289576|NCT02768571|Placebo Comparator|Placebo|"Saline 100 ml/day * 21 days with rehabilitation
~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)
~Rehabilitation
~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day
~5 times/week for 3 weeks
~Duration of Treatment:
~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.
~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
11289577|NCT02768558|Experimental|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
11289578|NCT02768558|Placebo Comparator|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
11289579|NCT02768545|Experimental|Liver transplant candidates|Ezetimibe in a dose of 10 mg/d for 12 weeks.
11289580|NCT02768532|Experimental|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
11289581|NCT02768519|Experimental|OTS167IV|Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.
11289582|NCT02768519|Placebo Comparator|Placebo|Cherry syrup
11289583|NCT02768506||Gastric bypass|Subjects submitted to gastric bypass
11289584|NCT02768506||SADI-S|Subjects submitted to SADI-S
11289585|NCT02768493|Experimental|low dose group|Patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block.
11289586|NCT02768493|Active Comparator|high dose group|Patients in the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block.
11289587|NCT02768480|Active Comparator|Primary Care|Patients will be followed by primary care team exclusively.
11289588|NCT02768480|Experimental|Phone Calls Support and Primary Care|Patients will be followed by primary care team and supported by periodic nurse phone calls.
11289589|NCT02768467|Experimental|Tissue Matrix Graft Placement|After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
11289590|NCT02768467|Active Comparator|Without stitches|After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
11289591|NCT02768454||inpatient under broad-spectrum antibiotics|medical review
11289592|NCT02768441|Experimental|Study group|Participants receiving Dexamphetamine 60 mg SR
11289593|NCT02768428|Experimental|Video-Audio Media|watching the entire video in 15 mins
11289594|NCT02768428|No Intervention|Handbooks|study the hand book in 15 mins
11289595|NCT02768415|Experimental|lapatinib+oral vinorelbine|"apatinib 425/500mg qd, 21days/cycle
~oral vinorelbine 60mg/m2 d1, 8, 15 21days/cycle*3cycles, after 3 cycles: 80mg/m2 d1, 8, 15 21days/cycle"
11289596|NCT02768402|Experimental|Treatment Arm|All eligible patients will be in the treatment arm for the 'Caisson TMVR System' (transcatheter mitral valve replacement) procedure. No control or comparator in this study.
11289597|NCT02768389|Experimental|Modified Atkins Diet and Bevacizumab|Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
11289598|NCT02768376|Active Comparator|General anesthesia group|General anesthesia group: Standard anesthetic technique will be applied.Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response. Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
11289599|NCT02768376|Experimental|Spinal anesthesia group|While in sitting position; intrathecal injection using 25 G spinal needle using 3 mls of Bupivacaine 0.5% with 20 mic Fentanyl, at L 2-3 level the patient head will be lowered till sensory blockade of T6 obtained at least.
11289600|NCT02768363|Active Comparator|ProstAtak®|Patients randomized to the ProstAtak arm will receive two courses of aglatimagene besadenovec + valacyclovir
11289601|NCT02768363|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
11289602|NCT02768350|Experimental|Control group|All of the participants in control group will be treated with conventional treatment for 3 days, The conventional treatments consist of: (1) Passive chest mobilization, (2) Positioning, (3) Side lying (good lung down), (4) Vibration. The conventional treatment consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
11289603|NCT02768350|Experimental|Experimental group|All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
11289604|NCT02768337|Other|Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)|No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
11289605|NCT02768337|Experimental|Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.
11289614|NCT02768285|Experimental|Intervention|Endodontic treatment was performed in posterior teeth with necrotic pulp and periapical periodontitis using a reciprocating single-file system (Reciproc). Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 2.5 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 K-files in patency group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills was done. The canals were obturated with gutta-percha and epoxy resin sealer. The treatments were carried out in one-visit.
11289615|NCT02768285|No Intervention|Control|In the control group, apical patency did not maintained.
11289616|NCT02768272|Experimental|Epidural analgesia|Randomized allocation to receive patient controlled epidural analgesia or programed intermittent epidural boluses
11289617|NCT02768272|Experimental|Epidural technique|Randomized allocation to be punctioned a conventional epidural or a combined spinal-epidural technique
11289618|NCT02768246|Active Comparator|Begin with BVGA|The volunteers will be asked to breathe 5 minutes of room air through the BVGA, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the BVGA. Then the same volunteers will be asked to repeat the protocol with the face mask.
11289619|NCT02768246|Active Comparator|Begin with Face-mask|The volunteers will be asked to breathe 5 minutes of room air through the face mask, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the face mask. Then the same volunteers will be asked to repeat the protocol with the BVGA.
11289620|NCT02768233|Experimental|Educational programme|Group 1: Educational programme + standard treatment
11289621|NCT02768233|No Intervention|Standard treatment|Standard treatment
11289622|NCT02768220|Active Comparator|Linagliptin|Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
11289623|NCT02768220|Experimental|Empagliflozin|Eligible patients were randomized empagliflozin 25mg daily for 30 days.
11289624|NCT02768207|Experimental|Treatment Phase: Vemurafenib+Cobimetinib|Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.
11289625|NCT02768194|Experimental|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
11289626|NCT02768194|Active Comparator|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
11289627|NCT02768194|Other|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
11289628|NCT02768181|Experimental|Arm 1: BCC+PNS+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with a lipid-based nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with a lipid-based nutrient supplement for children (CNS) aged 6m to 2 years.
11289629|NCT02768181|Experimental|Arm 2: BCC+PNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
11289630|NCT02768181|Experimental|Arm 3: BCC+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutrient supplement to children (CNS) 6m to 2 years.
11289631|NCT02768181|Experimental|Arm 4: BCC only|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
11289664|NCT02767947|Placebo Comparator|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
11289801|NCT02767089|Other|Sequence F|Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg
11289632|NCT02768181|No Intervention|Arm 5: comparison|No intervention will be provided by the study. The existing services delivered though government health systems will be continued. Government /NGO-led routine counseling and supplementary services available at Upazila and union levels, which include prenatal counseling, exclusive breastfeeding counseling, and maternal iron-folic acid supplementation and vitamin-A supplementation for children will continue. However, assessment of outcomes will be conducted in same frequency and schedule, alike in intervention arms, described in data collection section.
11289633|NCT02768168|Experimental|Group D|40 patients receive dezocine 0.1 mg/Kg
11289634|NCT02768168|Placebo Comparator|Group C|40 patients receive matching placebo （normal saline）
11289635|NCT02768155|Experimental|AF 4.0|Amniotic Fluid 4.0ml dose
11289636|NCT02768155|Experimental|AF 2.0|Amniotic Fluid 2.0ml dose
11289637|NCT02768155|Placebo Comparator|Placebo|Saline Placebo Control
11289638|NCT02768142|Experimental|Natural cesarean delivery|Placing the neonate on maternal chest immediately after the extraction from the uterus, and permitting breastfeeding during surgery.
11289639|NCT02768142|Active Comparator|Standard cesarean delivery|Presentation of the neonate to the mother during the operation.
11289640|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
11289641|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
11289642|NCT02768116|Experimental|ATP technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of non-left-main bifurcation lesion.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
11289643|NCT02768116|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Provisional T stenting technique in the treatment of non-left-main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
11289644|NCT02768103|Experimental|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
11289645|NCT02768090|Experimental|Skin Patch|Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry
11289646|NCT02768077|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
11289647|NCT02768077|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
11289648|NCT02768064|Experimental|Flexible screwed electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a flexible screwed electrode.
11289649|NCT02768064|Active Comparator|Stiff standard electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a stiff standard temporary electrode
11289650|NCT02768051|Experimental|AF Ablation Intervention|Subjects who are scheduled to undergo ablation procedure due to atrial flutter.
11289651|NCT02768025|Experimental|Intervention group|NRT, counselling, traditional & complementary medicine treatment (Body acupuncture, Ear acupuncture and aromatic therapy).
11289652|NCT02768025|Active Comparator|Control group|NRT, counselling
11289653|NCT02768012|Active Comparator|mindfulness-based cognitive therapy|The practice of mindfulness will be followed plus the basics of cognitive therapy given in small group format.
11289654|NCT02768012|No Intervention|waitlist|Women diagnosed with AISD randomised to wait list will receive no active treatment during the trial period.
11289655|NCT02767999|Experimental|Fluoxetine|One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI
11289656|NCT02767999|Placebo Comparator|Placebo|The other group will take a cellulose placebo per day from D0 to D90 and have fMRI
11289657|NCT02767986||Spanish-speaking Latinas|Women who speak Spanish as their primary language
11289658|NCT02767973|Experimental|Woodsmoke Exposure|
11289659|NCT02767960||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
11289660|NCT02767960||NSTEMI group|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
11289661|NCT02767960||UAP group|The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
11289662|NCT02767960||control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.
11289663|NCT02767947|Experimental|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
11289665|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
11289666|NCT02767921|Experimental|Treatment (recombinant EphB4-HSA fusion protein, surgery)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes once weekly for 3 weeks (3 doses) in the absence of disease progression or unacceptable toxicity. Patients who agree may receive the fourth dose after an additional week as determined by the study medical oncologist. Two to four weeks after the last dose of recombinant EphB4-HSA fusion protein, patients undergo robotic-assisted radical cystectomy or robotic-assisted radical or partial nephrectomy.
11289667|NCT02767908|No Intervention|Usual Care|Participants in the usual care group will be offered and, if accepted, provided with smoking cessation support that meets the recommendations of NICE PH48 guidance including pharmacotherapy and behavioural support before leaving hospital, referral to NHS SSS for continued care after discharge, and ascertainment of smoking status at 4 weeks; participants will also be asked to consent to smoking status ascertainment at three months. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation. All will be asked at four weeks and 3 months to list the cessation support, in terms of pharmacotherapy and behavioural support from local or other services, delivered since the last contact.
11289668|NCT02767908|Active Comparator|Intervention|A home visit will be carried out as soon as practicable after discharge and typically within 48 hours, to deliver a multi-component intervention. Intervention components all have an existing evidence base proving or suggesting potential efficacy for smoking cessation and/or relapse prevention, though their feasibility and importance when delivered as a combined package have not been tested.
11289669|NCT02767895|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health
11289670|NCT02767895|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
11289671|NCT02767882|Active Comparator|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
11289672|NCT02767882|Experimental|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
11289673|NCT02767882|Placebo Comparator|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
11289674|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
11289675|NCT02767869|Placebo Comparator|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
11289676|NCT02767856|Experimental|Intense 12-hour IO-therapy Group|Participants wear 12-hour daily IO-therapy glasses for 4 weeks
11289677|NCT02767856|Active Comparator|Standard 4-hour IO-therapy Group|Participants wear 4-hour daily IO-therapy glasses for 12 weeks
11289678|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
11289679|NCT02767830|Experimental|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
11289680|NCT02767817|Sham Comparator|Stereotactic Hematoma Evacuation|
11289681|NCT02767817|Experimental|MSCs Transplantation|
11289682|NCT02767817|Experimental|Injectable Collagen Scaffold with MSCs Transplantation|
11289683|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
11289684|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
11289685|NCT02767791|Active Comparator|Acupuncture|Acupuncture wrist 6
11289686|NCT02767791|Active Comparator|Auriculotherapy|Auriculotherapy
11289687|NCT02767791|Experimental|Auriculotherapy and acupuncture|Auriculotherapy and acupuncture
11289688|NCT02767791|No Intervention|No treatment|No treatment
11289689|NCT02767778|Experimental|REAL Pulsed ELF-MF stimulation|Patients will receive REAL pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
11289690|NCT02767778|Sham Comparator|SHAM Pulsed ELF-MF stimulation|Patients will receive SHAM pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
11289691|NCT02767765|Experimental|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
11289692|NCT02767752|Experimental|T-ChOS + Gemcitabine + Capecitabine|"T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.
~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
11289693|NCT02767752|Placebo Comparator|Placebo + Gemcitabine + Capecitabine|"Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.
~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
11289694|NCT02767739|Experimental|Physical, social and cultural activities|"Physical Activity: The training program will be supervised by a physical activity specialist and will consiste of two aerobic exercise sessions per week, including walking and stretching exercises after walking. Each session will be 60 minutes and the size of groups will be from 15 to 30 participants. Additionally, participants will receive advice about the health benefits of PA and PHC nurses using different strategies to encourage the adherence of participants to the program.
~Social and cultural support activities. Activities will include: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons. These activities will be performed once a month."
11289695|NCT02767739|No Intervention|Control Group|No intervention. We will measure the variables at the begining and after 9 months.
11289696|NCT02767713|Experimental|Dexamethasone|Dexamethasone dose of 0.1 mg/kg was administered intravenously 10h before surgery
11289802|NCT02767089|Other|Sequence G|Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg
11289698|NCT02767687|Experimental|Noninvasive ventilation (NIV)|Noninvasive mechanical ventilation is a resource used to treat respiratory failure or to reestablish respiratory comfort and function. It is commonly used in the ICU with a regular mechanical ventilator and is offered using an interface that connects the machine to the patient. The interface used for adults and in this study, was a silicon facial mask that covers the nose and mouth of the patient, allowing him or her to open the eyes.
11289699|NCT02767674|Experimental|R-GemOx|Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)
11289700|NCT02767674|Active Comparator|R-miniCHOP|Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Epirubicin 35 mg/m2 IV d1 vindesine 2 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)
11289701|NCT02767661|Experimental|Capecitabine+Aromatase inhibitor|Capecitabine, 625mg/m2, orally twice daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
11289702|NCT02767661|Active Comparator|Aromatase inhibitor|Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
11289703|NCT02767648||cholestasis|infant suffering from cholestasis proteomic urine analysis
11289704|NCT02767635|Experimental|Botox-Epic group|20 units of Botox injection into lateral epicondyle in Botox-Epic group
11289705|NCT02767635|Experimental|Botox-Tend group|20 units of Botox injected into tender point of muscles in Botox-Tend group
11289706|NCT02767635|Active Comparator|Steroid group|40mg of triamcinolone acetonide but not Botox injected into lateral epicondyle in Steroid group
11289707|NCT02767622||Patient Group|Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation.
11289708|NCT02767622||Control Group|Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness.
11289709|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
11289710|NCT02767596|Experimental|Lixisenatide|S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
11289711|NCT02767583|Experimental|Non diabetic obese|Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology.
11289712|NCT02767570|Experimental|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
11289713|NCT02767570|Experimental|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
11289714|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:
~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.
~Gemcitabine:
~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
~Nab-Paclitaxel:
~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
11289715|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:
~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.
~Nab-Paclitaxel:
~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
11289716|NCT02767544|Experimental|ropivacaine group|Vaginal wound local analgesia by 10ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
11289717|NCT02767544|No Intervention|Control group|Vaginal wound no local analgesia by 10 ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
11289718|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
11289719|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
11289720|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
11289721|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
11289722|NCT02767505|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
11289723|NCT02767505|Active Comparator|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
11289724|NCT02767492|Experimental|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
11289725|NCT02767492|Active Comparator|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
11289726|NCT02767479|Active Comparator|rabeprazole group|rabeprazole-based regimen. This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
11289727|NCT02767479|Active Comparator|esomeprazole group|'esomeprazole^based regimen. This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
11289728|NCT02767466||G|"All participants were randomly exposed to two different treatments:
~Conventional physical therapy (no specific device used)
~Robotic assisted gait training (Lokomat, Hocoma AG, Switzerland)
~We consider the study as observational, since the both interventions of the study (physical therapy, robotic assisted gait training) did not change in the patients' usual therapy plan, as they received both interventions daily.
~We only added diagnostic interventions to assess the affective responses."
11289729|NCT02767453|Active Comparator|TSA with drain placement|Hemovac drains are placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
11289730|NCT02767453|Active Comparator|TSA without drain placement|Hemovac drains will not be placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
11289731|NCT02767440|Experimental|Families on Track Intervention|This is a pre-post study. Enrolled parents will receive the Families on Track intervention plus usual care at the Healthy Lifestyles clinic at Duke University.
11289732|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
11289733|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
11289734|NCT02767414|Experimental|Respirio Flu Test and eLab Flu Test|"Upper respiratory tract samples from participants will be tested with:
~Respirio Flu Test; eLab Flu Test; and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)"
11289735|NCT02767401|Active Comparator|PCI using stenting or balloon expansion|Opening single CTO lesions using drug-eluting stents (such as Xience V and Prime, Endeavor Resolute, Taxus express and Libete, Excel, Partner, BUMA, YINYI, TIVOLI,Firebird2,FireHawk, and Coroflex) or balloon expansion plus optimal medical therapy. Intravascular ultrasound (IVUS),optimal coherence tomgraphy (OCT) or fractional flow reserve (FFR) is used if they are needed. Optimal medical therapy includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-angina therapy should be used if the patients have symptoms.
11289736|NCT02767401|No Intervention|Optimal medical therapy|Optimal medical therapy. It includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
11289737|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
11289738|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
11289739|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
11289740|NCT02767375|Active Comparator|HAIC treatment group|HAIC treatment after resection Intervention: Drug: Oxaliplatin, 5-fluorouracil (5-FU) Procedure/Surgery: Hepatic arterial catheter implantation
11289741|NCT02767375|No Intervention|No HAIC treatment group|Best support care and follow up
11289742|NCT02767362|Experimental|Single Arm|Patients will undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgery. At the time of hysterectomy and surgical staging, women will undergo repeat endometrial biopsy in the operating room under general anesthesia.
11289743|NCT02767349|Experimental|MNK-155|MNK-155, initial dose of two or three tablets followed by 2 tablets every 12 hours up to a maximum of five doses.
11289744|NCT02767336|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
11289745|NCT02767323|Active Comparator|rTMS over the DLPFC (Aim1a)|excitatory rTMS applied over the DLPFC (fMRI-guided)
11289746|NCT02767323|Sham Comparator|Sham rTMS over the DLPFC (Aim1a)|electrical sham coil applied over the DLPFC (fMRI-guided)
11289747|NCT02767323|Active Comparator|rTMS over the Parietal cortex (Aim1b)|excitatory rTMS applied over the parietal cortex (fMRI-guided)
11289748|NCT02767323|Sham Comparator|Sham rTMS over the Parietal cortex (Aim1b)|electrical sham coil applied over the parietal cortex (fMRI-guided)
11289749|NCT02767323|Active Comparator|rTMS over the DLPFC and the Parietal cortex (Aim 1c)|excitatory rTMS applied over the the DLPFC and the parietal cortex (fMRI-guided)
11289750|NCT02767323|Sham Comparator|Sham rTMS over the DLPFC and the Parietal cortex (Aim 1c)|electrical sham coil applied over the DLPFC and the parietal cortex (fMRI-guided)
11289751|NCT02767310|Experimental|Test Product|Rosuvastatin 20 mg film-coated tablets
11289752|NCT02767310|Active Comparator|Reference product|Crestor 20 mg film-coated tablets
11289753|NCT02767297|Experimental|Part 1: Single dose (cross over)|FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
11289754|NCT02767297|Experimental|Part 2: Multiple dose (dose level 1)|FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
11289755|NCT02767297|Experimental|Part 2: Multiple dose (dose level 2)|FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
11289756|NCT02767297|Experimental|Part 2: Multiple dose (dose level 3)|FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
11289757|NCT02767297|Experimental|Part 3: Single dose|FDL169 test formulation administered as a single dose in CF subjects
11289758|NCT02767284|Experimental|UCST-V1|The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
11289759|NCT02767284|Experimental|UCST-V2|The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
11289760|NCT02767284|Experimental|UCST-V3|The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
11289761|NCT02767284|Experimental|Quick-CSF|The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
11289762|NCT02767284|Active Comparator|Pelli-Robson|The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
11289803|NCT02767076|Active Comparator|Conventional|conventional paramedian spinal anesthesia
11289763|NCT02767284|Active Comparator|Optec 6500|The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
11289764|NCT02767271|Experimental|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
11289765|NCT02767271|Experimental|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
11289766|NCT02767258|Active Comparator|Sham Comparator: Eye drop|Eye drop LACRIBELL® - two drops each eye, two times a day, after eye cleansing.
11289767|NCT02767258|Experimental|VIDISIC® GEL|Ocular gel VIDISIC® GEL applied two times a day at the lower palpebra from medium line to the lateral border.
11289768|NCT02767245|Active Comparator|Thiamine|Thiamine intravenously 100 mg/day for 3 days
11289769|NCT02767245|No Intervention|No thiamine|No thiamine was given to the patient
11289770|NCT02767232|Active Comparator|Standard Anticoagulation Therapy|Anticoagulant therapy will be prescribed in accordance with 2012 ACCP Guidelines for children. Initial therapy generally will consist of low molecular weight heparin (LMWH) or unfractionated heparin (UFH), monitored to achieve and maintain a target anti-Xa activity of 0.5-1.0 IU/mL for LMWH and 0.35-0.7 IU/mL for UFH. Long-term therapy generally will consist of warfarin/coumadin, monitored to achieve and maintain a target INR of 2.0-3.0. The use of novel anticoagulants is permitted based on investigator preference.
11289771|NCT02767232|Experimental|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis (CDT) with intrathrombus delivery of Recombinant tissue plasminogen activator (rt-PA) (maximum allowable total dose 35 mg/24 hours) into the DVT over a period of up to 24 hours. CDT will be initiated within 72 hours of diagnosis. Two methods of initial rt-PA delivery will be used: 1.) AngioJet Thrombectomy System- maximum first-session rt-PA dose 25 mg; or 2.) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole catheter. Before and after CDT, patients will receive standard DVT therapy as in the standard anticoagulation group
11289772|NCT02767219|Other|Dexamethasone and 5-fluorouracil|The control arm consists of current standard therapy of subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of 5-fluorouracil as required for 4 consecutive weeks after entry into the trial.
11289773|NCT02767219|Active Comparator|Dexamethasone and Avastin|Subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of bevacizumab will be given for 4 consecutive weeks from time of entry into trial
11289774|NCT02767206||portal hypertension|Patients with cirrhosis or non-cirrhotic portal hypertension.
11289775|NCT02767193|Experimental|DCV3|Autologus differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus
11289776|NCT02767193|Experimental|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG-INF
11289777|NCT02767193|Placebo Comparator|CD placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded
11289778|NCT02767193|Placebo Comparator|CD placebo + PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG-INF
11289779|NCT02767180||Critical care survivors|Former ICU-patients recruited six months to three years after discharge from the ICU
11289780|NCT02767180||Matched controls|Control patients who have not been critically ill, matched for age and sex.
11289781|NCT02767167|Active Comparator|Milk treatment group|Semi-skimmed cow's milk + normal diet for 12 weeks
11289782|NCT02767167|No Intervention|Control group|Normal diet for 12 weeks
11289783|NCT02767154|Active Comparator|PrimECC|1250 ml of a priming solution based on the colloid Dextran 40 to use for extracorporeal circulation.
11289784|NCT02767154|Active Comparator|Ringer-Acetate/Mannitol|1250 ml of a priming solution based on the crystalloid Ringer-Acetate (1000ml) and Mannitol (250ml).
11289785|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
11289786|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
11289787|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
11289788|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
11289789|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
11289790|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
11289791|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
11289792|NCT02767115|Experimental|GSE mucoadhesive gel|2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
11289793|NCT02767115|Placebo Comparator|Control mucoadhesive gel|GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
11289794|NCT02767102|Experimental|Red wine with Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be enriched with 10 ng mL-1 MLT (MLT+) and used as experimental wine.
11289795|NCT02767102|Placebo Comparator|Red wine without Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be used as placebo treatment (PLC).
11289796|NCT02767089|Other|Sequence A|Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg
11289797|NCT02767089|Other|Sequence B|Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg
11289798|NCT02767089|Other|Sequence C|Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg
11289805|NCT02767063|Experimental|Experimental Arm_ACTOS|"TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
~PIOGLITAZONE (Actos®):
~30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE."
11289806|NCT02767063|No Intervention|controled Arm|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
11289807|NCT02767063|Experimental|Experimental Arm_AVELUMAB|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
11289808|NCT02767050||GROUP 1: CONTROL GROUPS|Patients with no habit history of tobacco are included in group 1.
11289809|NCT02767050||GROUP 2: SMOKING TOBACCO|Patients with a history of tobacco consumption in the form of smoking.
11289810|NCT02767050||GROUP 3: SMOKELESS TOBACCO|Patients with a history of tobacco consumption in the form of chewing.
11289811|NCT02767037|Active Comparator|Parkinson's disease (PD) patients|40 patients will be recruited. All will meet criteria for probable PD, according to the new MDS Clinical Diagnostic criteria. All participants will be 40 or older (young-onset PD includes many genetic causes, which often have normal autonomic function).
11289812|NCT02767037|Active Comparator|parkinsonsism (non-PD) patients|20 patients will also be recruited. These will include patients with progressive supranuclear palsy, multiple system atrophy, 'vascular parkinsonism' or corticobasal syndrome. All patients will have parkinsonism according to UK brain bank criteria, with a diagnosis of one of the above conditions made according to gold-standard expert evaluation. No patient will meet MDS Criteria for probable PD.
11289813|NCT02767037|Active Comparator|idiopathic REM sleep behavior disorder patient|40 patients will be recruited. All patients will have polysomnogram-confirmed RBD according to American Academy of Sleep Medicine Criteria. Patients will be free of parkinsonism and dementia according to neurological examination and will have no untreated sleep apnea, epilepsy, or other abnormalities that could cause dream enactment behavior.
11289814|NCT02767037|Placebo Comparator|Controls|40 controls will be age matched (within 5 years) and sex-matched (with >90% concordance). All controls will have an examination confirming the absence of parkinsonism, and will have no symptoms of REM sleep behavior disorder, as assessed with the RBD1Q and expert interview.
11289815|NCT02767024|Experimental|Sodium Nitroprusside|Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP > 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) > 2.2 L·min-1·m-2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
11289816|NCT02767024|Active Comparator|Dobutamine|Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI > 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
11289817|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
11289818|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
11289819|NCT02766998|Experimental|Preserved umbilical vein|Preserved umbilical vein as shunt/conduit
11289820|NCT02766985||FSHD|Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
11289821|NCT02766972|Experimental|RVP|
11289822|NCT02766959||PAV/PAV Tasters|Individuals homozygous for the taster allele of the TAS2R38 gene, PAV/PAV.
11289823|NCT02766959||AVI/PAV.|Individuals heterozygous for the taster allele of the TAS2R38 gene, AVI/PAV.
11289824|NCT02766959||AVI/AVI|Individuals homozygous for the non-taster allele of the TAS2R38 gene, AVI/AVI.
11289825|NCT02766946|Experimental|Mechanical Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Mechanical Ventilation
~Interventions :
~Ultrasound of the right diaphragm
~Ultrasound of the pectoral muscle
~Neuromyopathy score
~Respiratory performances"
11289826|NCT02766946|Active Comparator|Non-invasive Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Non-invasive Ventilation
~Interventions :
~Ultrasound of the right diaphragm
~Ultrasound of the pectoral muscle
~Neuromyopathy score
~Respiratory performances"
11289827|NCT02766946|Active Comparator|Spontaneous Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Spontaneous Ventilation
~Interventions :
~Ultrasound of the right diaphragm
~Ultrasound of the pectoral muscle
~Neuromyopathy score
~Respiratory performances"
11289828|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
11289829|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
11289830|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
11289831|NCT02766881||Patients with DCIS|Whether patients with DCIS receive radiotherapy based on Oncotype DX DCIS score, radiation oncologist treatment recommendation and patient's decision.
11289832|NCT02766868|Experimental|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
11289833|NCT02766855|Experimental|cysteamine eye drops|Patients used cysteamine eye drops every 2 hours while awake to both eyes.
11289834|NCT02766842|Active Comparator|EUS-FNB with ProCore needle|General anesthesia or conscious sedation will be started and an upper endoscopic ultrasound will be inserted into the participants mouth and advanced to the site of the lesion. The lesion will be punctured by the ProCore needle, then the stylet is completely removed, and negative suction pressure is applied using a 10 ml syringe for 30 seconds while the needle is stationary with the target. Then, the needle is moved back and forth several times within the target, utilizing the fanning technique. Finally, suction is released by closing the lock of the syringe and the needle is removed.
11289835|NCT02766842|Active Comparator|EUS-FNB with SharkCore needle|The procedure will be done in the same manner with same endoscopic technique and method of tissue procurement. The only difference will be using the SharkCore needle to acquire tissue.
11289836|NCT02766829|Experimental|CLSP Group|Those with cross leg sitting position: patients sit with both their knees flexed medially, hip flexed, resulting in pelvic leaning posteriorly and reducing lumbal lordosis.
11289837|NCT02766829|Active Comparator|TSP Group|Those with traditional sitting position: patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion.
11289838|NCT02766816|Experimental|Part 1 Study - BBio bOPV|
11289839|NCT02766816|Active Comparator|Part 1 Study - Licensed bOPV|
11289840|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 1|
11289841|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 2|
11289842|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 3|
11289843|NCT02766816|Active Comparator|Part 2 Study - Licensed bOPV|
11289844|NCT02766803|Active Comparator|Simvastatin + resveratrol|simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily
11289845|NCT02766803|Placebo Comparator|simvastatin+ placebo|simvastatin 20 mg daily Placebo
11289846|NCT02766790|Placebo Comparator|Placebo|Placebo taken once daily in the morning and once daily in the evening
11289847|NCT02766790|Active Comparator|TA-65MD 100 units Dose|TA-65MD 100 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
11289848|NCT02766790|Active Comparator|TA-65MD 250 units Dose|TA-65MD 250 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
11289849|NCT02766790|Active Comparator|TA-65MD 500 units Dose|TA-65MD 500 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
11289850|NCT02766790|Active Comparator|TA-65MD 250 units a.m. and p.m. Dose|Two TA-65MD 250 units capsules; one of them will be taken in the a.m. and one of them will be taken in the p.m.
11289851|NCT02766777|Experimental|Lubiprostone|Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
11289852|NCT02766764|Active Comparator|Study group|Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.
11289853|NCT02766764|Placebo Comparator|Placebo group|Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.
11289854|NCT02766751|Placebo Comparator|Health Education|The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
11289855|NCT02766751|Experimental|HIVPASS|Over 7 sessions, the interventionist and the participant will explore the relationship between pain, depressive symptoms, and HIV. General information about pain, HIV and depression will be discussed, as will avoidance of physical activity. Psychoeducation about these areas will be tied to the participant's stated life goals, and exposure exercises and goal lists will be developed. Later sessions will integrate continued efforts towards reaching goals and reducing avoidance. A release of information will be obtained from the participant to allow study session chart notes to be placed in the medical record at the participant's PCP office and to allow the PCP and the study interventionist to discuss treatment coordination.
11289856|NCT02766738|No Intervention|Control|All participants assigned to the control group will be given the option to engage in other activities that were offered by the facility during the 24-week intervention period. However, no specific resistance exercises were offered in these activities.
11289857|NCT02766738|Experimental|GrACE program|Participants in the exercise group will perform twice weekly training for 24 weeks. In brief, the program will include weight-bearing exercises and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. The following-weight bearing and resistance exercises: chair stands, chair dips, calf raises and hip flexor/abdominal lifts, trunk twists, and bicep curl and shoulder press. In total the sessions will be 45 minutes twice weekly.
11289858|NCT02766738|Experimental|GrACE + gait program|GrACE program as mentioned above plus focus on gait specific training will be one-hour training sessions for 24 weeks. Gait exercises will be a combination of exercises: heel and toe raises, stepping in different directions, single leg stand¬ing, step-ups, and task-specific balance work (e.g. reaching outward from the base of support while standing, sitting, and standing and turning). Gait exercises will be upgraded by: 1) reducing hand support and/or 2) narrowing the base of support, and/or 3) introducing a cognitive challenge (e.g. counting backwards while performing exercise) or perform¬ing exercise with the eyes closed.
11289859|NCT02766725|Experimental|preparation F12 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
11289860|NCT02766725|Active Comparator|preparation F2 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
11289861|NCT02766725|Placebo Comparator|placebo gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
11289981|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
11289982|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
11289983|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
11289862|NCT02766712|Experimental|CA 1st Half of lesion|During each of the 15 pre-specified lesions, pacing will be initiated at a 500ms cycle length from a catheter in the coronary sinus or right ventricle prior to the start of the lesion. Pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Weckebach behavior continues, the pacing catheter will be moved to the right ventricle, which and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
11289863|NCT02766712|Experimental|CA 2nd Half of Lesion|During each of the 15 pre-specified lesions, pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Wenckebach behavior persists, the pacing catheter will be moved to the right ventricle and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
11289864|NCT02766699|Experimental|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10^9 or 8 x 10^9. All subjects will undergo an adapted dose escalation regime in the first cycle of treatment. For subsequent cycles all doses will be administered at full strength (5x10^9 or 8x10^9 EGFR(V)-EDV-Dox). Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
11289865|NCT02766686|Experimental|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
11289866|NCT02766686|Active Comparator|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
11289867|NCT02766686|Other|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
11289868|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
11289869|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
11289870|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
11289871|NCT02766660|Other|Thyroid ophthalmopathy|Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
11289872|NCT02766660|Other|Control|Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
11289873|NCT02766647|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
11289874|NCT02766647|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
11289875|NCT02766634|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
11289876|NCT02766634|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
11289877|NCT02766621|Placebo Comparator|Placebo injection SC/IV|Placebo for injection SC/IV
11289878|NCT02766621|Active Comparator|PF-06823859|Study Drug being used in the study
11289879|NCT02766608|Experimental|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
11289880|NCT02766608|Experimental|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
11289881|NCT02766608|Experimental|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
11289882|NCT02766608|Experimental|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
11289883|NCT02766608|Other|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
11289884|NCT02766595|Other|hyperventilation|Non-drug: performing hyperventilation while sitting up during routine EEG
11289885|NCT02766582|Experimental|Chemotherapy combined with pembrolizumab|"Single arm study:
~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 7 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
11289886|NCT02766556|Active Comparator|arm 1|received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
11289887|NCT02766556|Placebo Comparator|arm 2|received ISB with 8mL of ropivacaine with 1ml of normal saline
11289888|NCT02766543|Experimental|MRI-guided Transurethral Ultrasound Ablation Device|Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue.
11289889|NCT02766530|Experimental|PETMR study|All the study participants will receive PET MR examinations before neoadjuvant chemotherapy and during neoadjuvant chemotherapy (during early cycle as well as during mid-cycle of chemotherapy treatment). There will be two groups of patients after completion of neoadjuvant chemotherapy, that is, responders versus non-responders. We will compare the PET MR imaging parameters before, during neoadjuvant chemotherapy between the two groups of patients.
11289890|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
11289891|NCT02766491|Experimental|Strengthening and stretching|The intervention group will follow a strengthening-stretching program of the calf muscles.
11289892|NCT02766491|Active Comparator|conventional stretching|The control group will receive conventional stretching and strengthening exercises to the upper limb to assure that the same systemic physiological stimuli and a similar number of contact hours is received.
11289893|NCT02766478|Experimental|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
11289894|NCT02766478|Placebo Comparator|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
11289984|NCT02765841|Experimental|Lomitapide|
11289985|NCT02765828||Late-Onset Pompe Disease|
11289986|NCT02765828||Acquired/Hereditary Myopathy|
11289987|NCT02765828||Neuropathy|
11290054|NCT02765373||non-steroidal aromatase inhibitors(AIs)|Letrozole 2.5mg Qd or Anastrozole 1mg Qd for 5 years
11289895|NCT02766465|Experimental|Donor Arm|"Donor Arm patients will undergo hematopoietic cell transplant. Patients with a matched unrelated donor will receive a bone marrow transplant (unless PBSC graft is pre-approved per section 2.5.1 using a preparative regimen with Busulfan, Fludarabine and rabbit ATG. Patients with an HLA-identical sibling donor can receive a transplant using one of three regimens:
~A. Busulfan, Fludarabine, and rabbit ATG using a bone marrow graft (preferred regimen) B. Alemtuzumab/TBI 300 cGy using a peripheral blood graft C. Alemtuzumab, fludarabine, melphalan using a bone marrow graft"
11289896|NCT02766465|Active Comparator|No-Donor Arm|No-donor arm patients will continue with standard of care per their SCD physician.
11289897|NCT02766452|Experimental|Pre-operative educational DVD preparation|"After their pre-assessment clinic (PAC) appointment, parents in the intervention group took the hospital's 20 minute surgical virtual tour in the hospital's family library. Parents in the intervention group also watched the 12 minute DVD entitled, You and Your Child in the RR. This pre-operative educational tool was developed and tested in a previous study (Chartrand 2014). It was designed to enable parents to gain knowledge about the equipment and procedures related to the RR, and about nurses' and parents' roles in supporting their child in the RR. The DVD also focused on potential reactions of children waking up after a general anesthesia and strategies parents can use to support their child in the RR. The DVD included images of RR equipment and positive nurse-family and parent-child interactions."
11289898|NCT02766452|Placebo Comparator|Standard pre-operative preparation|After their PAC appointment, parents in the control groups took the hospital's 20 minute surgical virtual tour in the hospital's family library.
11289899|NCT02766439||Rhupus syndrome, SLE without RA|Rhupus syndrome, SLE without RA
11289900|NCT02766426|Other|Lifestyle change intervention|Overweight/obese pregnant women enrolled in a healthy lifestyle change programm
11289901|NCT02766400|Experimental|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
11289902|NCT02766400|Active Comparator|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
11289903|NCT02766387|Experimental|2 minutes walk test|fast walk test during 2 minutes in first and the 10 meters walk test, the 6 minutes walk test and the 2 kilometers walk test
11289904|NCT02766387|Experimental|6 minutes walk test|comfortable walk test during 6 minutes in first and the 10 meters walk test, the 2 minutes walk test and the 2 kilometers walk test
11289905|NCT02766374|Experimental|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
11289906|NCT02766374|Placebo Comparator|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
11289907|NCT02766361|Experimental|Cognitive Behavioral Rehabilitation|12 sessions of new intervention of cognitive behavior therapy and cognitive rehabilitation
11289908|NCT02766361|Active Comparator|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
11289909|NCT02766348|Experimental|DC-CTL|After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment
11289910|NCT02766348|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
11289911|NCT02766335|Experimental|Arm I (MEDI4736 - closed to accrual 12/2015)|Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
11289912|NCT02766335|Active Comparator|Arm II (docetaxel - closed to accrual 4/2015)|Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
11289913|NCT02766335|Experimental|Arm III (MEDI4736 retreatment)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
11289988|NCT02765815|Active Comparator|Exparel plus multi-drug cocktail|Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.
11289989|NCT02765815|Active Comparator|Multi-drug cocktail alone|Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.
11289914|NCT02766322||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
11289915|NCT02766322||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
11289916|NCT02766322||Sleeve gastrectomy longitudinal|Morbidly obese subjects undergoing sleeve gastrectomy surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight..
11289917|NCT02766322||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
11289918|NCT02766322||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
11289919|NCT02766322||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
11289920|NCT02766322||Non-surgical group|Subjects who are age and body mass index equivalent to gastric bypass (cross-sectional) and Sleeve gastrectomy (cross-sectional) but did not undergo any type of bariatric surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
11289921|NCT02766296|Experimental|Active Emotional Working Memory Training|Each participant will receive 15 sessions (each lasting 20 minutes) over a 5 week. This will be Internet-based cognitive training based on the adaptive dual n-back paradigm.
11289922|NCT02766296|Placebo Comparator|Control Working Memory Training|Participants in this condition will receive 15 sessions (each lasting 20 minutes) over a 5-week period. This will also be home-based training over the Internet. This training will be based on a fixed 1-back training program.
11289923|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
11289924|NCT02766270|Experimental|Chemoradiotherapy with Temozolomide|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses
11289925|NCT02766270|Active Comparator|Radiotherapy alone|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)
11289926|NCT02766257|Other|children undergoing ambulatory surgery|
11289927|NCT02766244|Experimental|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
11289928|NCT02766231||Physica CR|
11289929|NCT02766231||Physica PS|
11289930|NCT02766218||Behavioral: Lifestyle Intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
11289931|NCT02766218||No Intervention: Standard Care|
11289932|NCT02766192|Experimental|TIMBER-Ketamine arm|This arm received TIMBER psychotherapy and ketamine infusion.
11289933|NCT02766192|Placebo Comparator|TIMBER-placebo arm|This arm received TIMBER psychotherapy and placebo (normal saline) infusion.
11289934|NCT02766179|Active Comparator|CPAP Therapy|Continuous Positive Airway Pressure
11289935|NCT02766179|Experimental|Somnoguard|Somnoguard
11289936|NCT02766166||Predictive Monitoring|
11289937|NCT02766166||No Predictive Monitoring|
11289938|NCT02766153||patients|
11289939|NCT02766153||healthy volunteers|intrafamily marrow donors
11289940|NCT02766140|Experimental|SHR1020 plus Docetaxel|
11289941|NCT02766140|Placebo Comparator|Placebo plus Docetaxel|
11289942|NCT02766127|Experimental|Xerostomic Patients|"Patients with evident clinical signs of xerostomia who experienced dentinal hypersensitivity after undergoing radiation therapy due to head and neck cancer.
~The following dental materials will be used following the manufacturers' instructions: Veritise Flow; Universal Dentin Sealant; Clearfil Protect Bond, and Flor-Opal® Varnish. In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.
~the application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
11289990|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
11290409|NCT02762994|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
11289943|NCT02766114|Experimental|Issa1|After local anesthesia, through transverse approach on the middle of dorsal wrist crease the incision is made for 1.5 cm length, then the subcutaneous fat is dissected, soon we see the the palmaris longus tendon or its connection with the carpal ligament , take the ulnar side of the palmaris longus tendon and cut the carpal ligament axillary by scalpel, not going deep with the scalpel to avoid medial nerve injury, soon we see the nerve, we use the scissors to cut the proximal part then the distal part of the carpal ligament by enclosing it between the blades of the scissors, now the full released carpal tunnel most be observed, and one stitch is enough, in this operation most be an assistant exist.
11289944|NCT02766101|Experimental|Aerobic Exergaming PE|Progressive aerobic curriculum utilizing virtual reality exergaming stationary bicycles. Classes held 2 times per week for 30-40 minutes, aerobic exercise beginning at 10 minutes at moderate to vigorous intensity and building to 20 minutes plus.
11289945|NCT02766101|Active Comparator|Standard PE|Traditional PE focused on gross motor skill and sports skill acquisition, and team building. Typically non-aerobic.
11289946|NCT02766088|Experimental|Total Group|Subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia. The study population comprised household members and should include between 30% and 50% of adults (aged 18 years or above) per site.The appropriate recruitment strategy was selected by each participating site. Two approaches might be considered: a school-based approach and a community-based approach without school involvement The expected period for recruiting the target sample size was approximately three months.
11289947|NCT02766075|Experimental|Supervised TAVR Exercise Program (STEP)|Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
11289948|NCT02766075|No Intervention|Standard of Care|Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
11289949|NCT02766062|Active Comparator|propofol group|Patients with metabolic syndrome were randomly assigned to receive propofol anesthesia
11289950|NCT02766062|Active Comparator|sevoflurane group|Patients with metabolic syndrome were randomly assigned to receive sevoflurane anesthesia
11289951|NCT02766049|Active Comparator|(a) DC|Autologous dendritic cells (3x10e7)
11289952|NCT02766049|Active Comparator|(b) DC 10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
11289953|NCT02766049|Active Comparator|(c) DC 10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
11289954|NCT02766036|Active Comparator|Propolis|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
11289955|NCT02766036|Placebo Comparator|Placebo|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.
11289956|NCT02766023|Experimental|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
11289957|NCT02766023|Placebo Comparator|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
11289958|NCT02766010|Experimental|group A TensorTip|Male or female, age > 18
11289959|NCT02765997|Active Comparator|Unmanipulated UCB|Subjects will receive unmanipulated umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
11289960|NCT02765997|Experimental|StemRegenin-1 UCB|Subjects will receive StemRegenin-1 (SR-1) cultured umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
11289961|NCT02765984||normal placental site|women with normal implantation site at early trimester with normal placental site
11289962|NCT02765984||Low placental site|women with low implantation site at early trimester with low placental site
11289963|NCT02765971|Active Comparator|chewing gum group|180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval
11289964|NCT02765971|Active Comparator|laxatives group|180 women will receive laxatives after their operating room discharge by 3 hours
11289965|NCT02765971|Placebo Comparator|control|they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds
11289966|NCT02765958||Healthy|subjects without heart disease or arrhythmia, no evidence of obstructive sleep apnea
11289967|NCT02765958||OSA|obstructive sleep apnea
11289968|NCT02765932|Active Comparator|Placebo Therapy|Dummy Movements
11289969|NCT02765932|Experimental|Psychosensory Therapy|Will involve touch technique, havening.
11289970|NCT02765919|Experimental|Radiation HDR Brachytherapy 9 Gy|High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix
11289971|NCT02765919|Active Comparator|Radiation HDR Brachytherapy 7 Gy|High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix
11289972|NCT02765906|No Intervention|No intervention|No additional education
11289973|NCT02765906|Experimental|Graphic card|Education with graphic card
11289974|NCT02765906|Experimental|Video|Education with video
11289975|NCT02765893|No Intervention|Foley|Patients will have Foley in place overnight after completion of surgery, which is currently standard of care at our institution.
11289976|NCT02765893|Active Comparator|No Foley|Patients will have Foley catheter removed 6 hours post-op.
11289977|NCT02765880|Experimental|Healthy volunteer|
11289978|NCT02765880|Experimental|Patients with schizophrenia|
11289979|NCT02765880|Experimental|Patient with bipolar disorder|
11289980|NCT02765867|Experimental|RBP-6000|A single dose of RBP-6000 will be administered on Study Day 1
11289991|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
11289992|NCT02765789|Experimental|Immunoadsorption|Immunoadsoprtion (Immunosorba). All (anticipated) 8 participants will be treated with immunoadsorption
11289993|NCT02765763|Sham Comparator|Group 1 Sham|Null Formula of the Test System
11289994|NCT02765763|Active Comparator|Group 2 Treated|Full Formulas of Test System
11289995|NCT02765750|Experimental|BIS 40-60|Patient with intraoperative Bispectral Index (BIS) 40-60.
11289996|NCT02765750|Experimental|BIS 20-40|Patient with intraoperative Bispectral Index (BIS) 20-40.
11289997|NCT02765750|Placebo Comparator|Placebo|Placebo group
11289998|NCT02765737|Active Comparator|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
11289999|NCT02765737|Active Comparator|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
11290000|NCT02765724|Experimental|Group 1|Patients with mild hepatic impairment
11290001|NCT02765724|Experimental|Group 2|Patients with moderate hepatic impairment
11290002|NCT02765724|Experimental|Group 3|Patients with severe hepatic impairment
11290003|NCT02765724|Experimental|Group 4|Healthy subjects
11290004|NCT02765711||the use of ticagrelor in hospital|
11290005|NCT02765685|Experimental|ODRA|
11290006|NCT02765685|Active Comparator|usual care|
11290007|NCT02765672|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
11290008|NCT02765672|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
11290009|NCT02765672|Active Comparator|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
11290010|NCT02765672|Active Comparator|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
11290011|NCT02765672|Active Comparator|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
11290012|NCT02765672|Active Comparator|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
11290013|NCT02765659|Other|Community 1|Receives Mzake ndi Mzake T1 immediately after baseline
11290014|NCT02765659|Other|Community 2|Receives Mzake ndi Mzake T2 immediately after Post-T1 evaluation
11290015|NCT02765659|Other|Community 3|Receives Mzake ndi Mzake T3 immediately after Post-T2 Evaluation
11290016|NCT02765633|Experimental|Cangrelor|Cangrelor in up to four (4) dose cohorts consisting of a minimum of five participants in each cohort. One cohort of five participants will be enrolled at a time. Cohort 1 subjects will receive Cangrelor at 0.5 mcg/kg/min. Cohort 2 subjects will receive Cangrelor at 0.25 mcg/kg/min. Subsequent cohort dosing decisions are made at the completion of enrollment in each cohort.
11290017|NCT02765620||drug|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
11290018|NCT02765620||radiation|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
11290019|NCT02765594|Experimental|valsartan only:control group|valsartan (160mg/d)
11290020|NCT02765594|Experimental|hydroxychloroquine with valsartan:study group|valsartan (160mg/d) and Hydroxychloroquine Sulfate ( 400mg/d, twice daily)
11290021|NCT02765581|Experimental|Verum acupuncture (VA)|Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
11290022|NCT02765581|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
11290023|NCT02765581|Placebo Comparator|Usual care (UA)|Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.
11290024|NCT02765568|Experimental|Moderate Intensity Continuous Exercise|Moderate Intensity Continuous Exercise Training
11290025|NCT02765568|Experimental|Nordic Walking|Nordic Walking
11290026|NCT02765568|Experimental|High Intensity Interval Training|High Intensity Interval Training
11290052|NCT02765386|Experimental|Cochlear Implant Recipients|Newly implanted cochlear implant recipients with post-implantation acoustic hearing.
11290053|NCT02765373||steroidal aromatase inhibitors(AIs)|Exemestane 25mg Qd for 5 years
11290027|NCT02765555|Experimental|RBP-7000|All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
11290028|NCT02765542|Experimental|Automated phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
11290029|NCT02765529|Experimental|20-30 years|Blood sampling
11290030|NCT02765529|Experimental|45-55 years|Blood sampling
11290031|NCT02765529|Experimental|70-80 years|Blood sampling
11290032|NCT02765529|Experimental|Control|Blood sampling for standardization of technical procedures
11290033|NCT02765516|Active Comparator|Plant sterols|
11290034|NCT02765516|Placebo Comparator|Placebo|
11290035|NCT02765503|Active Comparator|Control|'Standard' external beam radiotherapy to deliver 66Gy in 33 fractions treating with 6 fractions a week.
11290036|NCT02765503|Experimental|HYPNO|The experimental regimen in which patients receive external beam radiotherapy to deliver 55Gy in 20 fractions treating 5 times a week.
11290037|NCT02765490|Experimental|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
11290038|NCT02765490|Experimental|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
11290039|NCT02765477||Angiogram Cohort w Acute Coronary Occlusion|Inclusion Criteria: Angiogram Cohort. Patients who present 1) directly through the study site Emergency Department (ED) OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1.Underwent urgent or emergent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to chest pain [CP] and/or shortness of breath [SOB]) AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, a group of patients will be identified who had angiographic evidence of ACO, defined as an acute lesion with TIMI flow 0 or 1 when evaluated by an experienced study-site adjudicator.
11290040|NCT02765477||Non-ACO Angiogram Cohort|Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
11290041|NCT02765477||Random ED Sample w Paced Rhythm but No AMI|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.
~Each study site will randomly select 5 unique encounters for every one 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.
~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.
~The primary control group selected from this search will be all patients in this group who do not meet criteria for acute myocardial injury, as defined by 1) all troponins below the 99th percentile or 2) Peak troponin < 3x the upper limit of normal AND no rise and/or fall of > 30%."
11290042|NCT02765477||ED Patients w Paced Rhythm Without AMI excluded|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.
~Each study site will randomly 5 unique encounters for every 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.
~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.
~The secondary control group will include patients in this group in whom Acute MI cannot be excluded because they either have at least 1 troponin > 3x the upper limit of normal or they have at least 1 troponin between 1x and 3x the ULN AND have a rise and/or fall of at least 30%."
11290043|NCT02765451|Active Comparator|A : 1 year of intervention|interventions of Cancéropôle Nord-Ouest during 1 year after an observational period of 2 years.
11290044|NCT02765451|Active Comparator|B : 2 years of intervention|interventions of Cancéropôle Nord-Ouest during 2 years after an observational period of 1 year.
11290045|NCT02765438|Experimental|BOBO|"Playing with the BOBO system."
11290046|NCT02765425|Experimental|Training Group|Subjects will receive the same outcome measures at baseline, after 3 months training and 6 months later. Intervention will comprise of three sessions seated at the AMES device. Each training session will include 15 min of training of each ankle. Training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
11290047|NCT02765425|No Intervention|Control Group|Subjects will receive no intervention. Subjects will receive all outcome measures at baseline and at 3 months post enrollment. Subjects will also receive a fall-incidence reporting form 9 months post enrollment. No other intervention - i.e. no treatment - is given.
11290048|NCT02765412||standard implementation|Webinar, Promotion, Tool Access, academic detailing + Audit and Feedback
11290049|NCT02765412||intensive implementation|Webinar, Promotion, and Tool Access, academic detailing + Audit and Feedback + LEAP
11290050|NCT02765399|Experimental|Liraglutide|"Liraglutide subcutaneous injection once daily with following dose escalation:
~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months."
11290051|NCT02765399|Placebo Comparator|Placebo|"Placebo subcutaneous injection once daily with following dose escalation:
~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months."
11290908|NCT02760043|Experimental|Dexamethasone|LIA mixture with the addition of 8mg Dexamethasone.
11290055|NCT02765360|Experimental|Treatment|Each patient will be assigned to Continuous Positive Airway Pressure (CPAP), Pressure Support Ventilation (PSV) and Pressure Control Ventilation (PCV) modes in a random order with a 10 minute washout period modes.
11290056|NCT02765347|Other|Metformin and Insulin|MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks
11290057|NCT02765347|Other|Insulin|Accept insulin for 24 weeks
11290058|NCT02765334|Experimental|nBETTER and Conventional Therapy|Intervention: nBetter therapy
11290059|NCT02765321|Experimental|Physical activity and healthy eating promotion|
11290060|NCT02765308||Healthy volunteers|healthy age matched with cases volunteers as controls
11290061|NCT02765308||Uveitis with raised IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
11290062|NCT02765308||Uveitis with with normal IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
11290063|NCT02765295|Active Comparator|hydrogen inhalation|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
11290064|NCT02765295|Sham Comparator|oxygen inhalation|Oxygen will be generated by an instrument provided by the sponsor, that would be capable of generating oxygen equivalent to that generated by the MUNHO (3L/min mixed gas containing 33.3% oxygen). Usual care referred to mucolytics [[ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily)/ serrapeptase (10mg thrice daily), or carbocisteine (500mg thrice daily)] alone or in combination with chest physiotherapy.
11290065|NCT02765282|Experimental|DBS-Expert Programming First|These patients will be undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) first and then be programmed by a clinician within five days.
11290066|NCT02765282|Experimental|Traditional Programming First|These patients will be programmed by a clinician first and then undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) within five days.
11290067|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
11290068|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
11290069|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
11290070|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
11290071|NCT02765243|Experimental|effectiveness of Anti-GD2 CART|Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma
11290072|NCT02765217|Experimental|Study group 1|"Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).
~Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days."
11290073|NCT02765217|Placebo Comparator|Study group 2|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.
11290074|NCT02765217|Experimental|Study group 3|Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.
11290075|NCT02765217|Placebo Comparator|Study group 4|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.
11290076|NCT02765204|Experimental|DS-D-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
11290077|NCT02765204|Experimental|DS-DG-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
11290078|NCT02765204|Experimental|D-DG-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
11290079|NCT02765204|Experimental|D-DS-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
11290080|NCT02765204|Experimental|DG-D-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
11290081|NCT02765204|Experimental|DG-DS-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
11290082|NCT02765191|Experimental|Study group|Subjects investigated according to protocol after administration of bolus of Ringer's Acetate
11290410|NCT02762994|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
11290083|NCT02765178||Patients with Tourette Syndrome|The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
11290084|NCT02765178||Patients with Diabetes type 1|The primary caregiver will be asked to fill the Children's motivation Scale. Demographic data will also be collected for each study patient.
11290085|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1a|USL311, intravenous, once per week, starting at 60 mg/m˄2
11290086|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1b|USL311, oral, daily, starting at 40 mg
11290087|NCT02765165|Experimental|Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2|USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks
11290088|NCT02765165|Experimental|Dose-Expansion, USL311, GBM, Part 3|USL311, oral, daily, starting at dose determined in Part 1b
11290089|NCT02765165|Experimental|Dose-Expansion, USL311 with Lomustine, GBM, Part 4|USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2
11290090|NCT02765152|Active Comparator|Conventional Physical Therapy|Usual therapy: joint mobility exercises, stimulating joint movement of the main active components of the upper limb; major muscle groups stretching, especially in the affected muscles by tone impairment; manual resistance training according to the degree of the patient's muscle strength, prioritizing the functional specificity of the upper limb, so the majority of the exercises will be held in open chain; motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks.
11290091|NCT02765152|Experimental|discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
11290092|NCT02765152|Experimental|rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
11290093|NCT02765139|Experimental|EMAP Treatment|Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
11290094|NCT02765139|Other|Control|In the 15 control sites, the male participants will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
11290095|NCT02765126|Active Comparator|Group 1|Diphtheria-tetanus-acellular pertussis vaccine administered day 0, followed by seasonal influenza vaccination four weeks later. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week, 4 weeks, 4 weeks + 24 hours, 5 weeks, 8 weeks and 30 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
11290096|NCT02765126|Active Comparator|Group 2|Seasonal influenza vaccine administered on day 0, to be offered DTP vaccine at week 26. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
11290097|NCT02765126|Active Comparator|Group 3|Seasonal influenza vaccine and DTP vaccine administered together on day 0. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
11290098|NCT02765113|Active Comparator|Facial nerve combing|Facial nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
11290099|NCT02765113|Active Comparator|Facial and Trigeminal nerve combing|Facial nerve combing、trigeminal nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
11290100|NCT02765100|Experimental|Low CRP|Subjects have CRP > 3
11290101|NCT02765100|Experimental|High CRP|Subjects have CRP =/> 3
11290102|NCT02765087|Experimental|Pleural TB|"This group consist of patients with TB pleural effusion.
~Intervention:
~Inform Consent
~Medical History
~E-Nose Device
~Chest CT
~Cytomorphologic & Cytochemistry of pleural Fluid.
~Adenosine Deaminase value of pleural Fluid."
11290103|NCT02765087|Active Comparator|Control|"Patients with pleural effusion with different aetiologies than Tuberculosis.
~Intervention:
~Inform Consent
~Medical History
~E-Nose Device
~Chest CT
~Cytomorphologic & Cytochemistry of pleural Fluid.
~Adenosine Deaminase value of pleural Fluid."
11290104|NCT02765074|Experimental|Roactemra|subcutaneous tocilizumab
11290105|NCT02765048|Experimental|GAIN Program|Subjects randomly assigned to receive the GAIN Program intervention
11290106|NCT02765048|No Intervention|Usual Care|Subjects randomly assigned to receive community-based services as part of their usual care
11290107|NCT02765035|Experimental|C-Leg 4/C-Leg 3|The participants will be firstly fitted with C-Leg 4 and then with C-Leg 3.
11290108|NCT02765035|Experimental|C-Leg 3/C-Leg 4|The participants will be firstly fitted with C-Leg 3 and then with C-Leg 4.
11290109|NCT02765022|Experimental|Clip|Clip closure of mucosal defects after endoscopic mucosal resection.
11290110|NCT02765022|Active Comparator|No clip|No clip closure of mucosal defects after endoscopic mucosal resection. Observation.
11290111|NCT02765009|No Intervention|Control|Usual care provided according to the ward policy. Patients have to be weighed at least on admission (day 0), day 7 and day 14.
11290112|NCT02765009|Experimental|Strategy|Patients have to be weighed every day. Use of an algorithm based on weight changes from day 2 to day 14 in order to reduce weight gain (fluid overload) using diuretics, fluid restriction,albumin, and ultrafiltration (the latter when ongoing renal replacement)
11290411|NCT02762994|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
11290113|NCT02764996|Experimental|Acupuncture for Migraine|Acupuncture treatments will be subject dependent, and points could include the N point (on scalp); various auricular points to include Shen Men, Point Zero, thalamus and Omega-2; body points to include Liver 2, Liver 3, Gall Bladder 20, bladder 10; and surface release over tense areas in the neck or shoulders
11290114|NCT02764983|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Driving safety professional, three x 1 hour sessions to discuss traffic safety, rules of the road, defensive driving, driving under influence, driver attitudes and safety. Additionally, the study will obtain real world driving data from the Department of Motor Vehicles (public records) which will include citations, violations, and recorded collisions/ crashes.
11290115|NCT02764983|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
11290116|NCT02764983|Active Comparator|Caregiver Control Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
11290117|NCT02764983|Active Comparator|Caregiver Experimental Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
11290118|NCT02764983|Other|Focus Group Discussion Interview Guide|This group will comprise of a subset of the control and experimental groups. A focus group with 8 participants (4 with Traumatic Brain Injury/Post Traumatic Stress Disorder and 4 with orthopedic conditions). The focus group will meet once for a discussion which will be guided with a semi-structured interview that will explore the driving behavior prior to war, during war and post-deployment. Responses will be outlined in an intervention matrix.
11290119|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
11290120|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
11290121|NCT02764957|Active Comparator|intervention|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
11290122|NCT02764957|Placebo Comparator|control|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
11290123|NCT02764944|Experimental|Intervention|simple non-exposure EFTR group (single arm study)
11290124|NCT02764931|Experimental|Oat meal 1|A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
11290125|NCT02764931|Placebo Comparator|Placebo meal|A single meal which does not contain oats before ingesting the SmartPill capsule. Dietary intervention: gluten-free oats and gastrointestinal health.
11290126|NCT02764931|Experimental|Oat meal 2|A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
11290127|NCT02764918||Children|
11290128|NCT02764918||Mothers|
11290129|NCT02764905||intensive cognitive-physical rehabilitation group|will include a 2 phase multi-disciplinary intervention. The 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies
11290130|NCT02764892|Experimental|V81444|Single oral dose of V81444
11290131|NCT02764879|Experimental|omega 3 group|scaling and root planing omega3 received 2 times daily-for 6 months
11290132|NCT02764879|Placebo Comparator|control group|scaling and root planing placebo soft gelatin capsules 2 times daily-for 6 months
11290133|NCT02764866|Experimental|Sleep testing|Enrolled patients with lung cáncer will undergo home sleep testing during their initial oncologic evaluation, prior to treatment.
11290134|NCT02764853|Experimental|STEP-AD (10 sessions)|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence."
11290135|NCT02764853|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive 1 session of Lifesteps and appropriate services and referrals as needed, followed by bi-weekly check-ins with a study research assistant.
11290136|NCT02764840|Experimental|experimental group isokinetic dynamometer (GEDI)|Isokinetic Biodex System Pro 4
11290137|NCT02764840|Experimental|experimental group elastic tube (GETE)|elastic tube brand LEMGRUBER 203
11290138|NCT02764814|Active Comparator|Treatment|subjects receiving cryopreserved amniotic membrane
11290139|NCT02764814|No Intervention|Control|no intervention
11290140|NCT02764801|Experimental|Contrast ultrasound arm|Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
11290141|NCT02764788|Experimental|Specific auriculotherapy|Auriculotherapy on specific points with needles
11290142|NCT02764788|Sham Comparator|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
11290143|NCT02764788|Placebo Comparator|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
11290144|NCT02764775|Experimental|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
11290450|NCT02762903|Active Comparator|Osteotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with lesser tuberosity osteotomy technique.
11298398|NCT02710331|Placebo Comparator|Placebo THC and Placebo Ethanol|
11290145|NCT02764762|Experimental|Vedolizumab 300 mg+Adalimumab 160-40 mg+Methotrexate 15 mg|In Triple Combination Therapy Phase, vedolizumab 300 milligram (mg), intravenous infusion, once at Weeks 0, 2, 6, 14 and 22, along with adalimumab 160 mg subcutaneously, once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral Methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg intravenous infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.
11290146|NCT02764749|Experimental|freeze dried powder whole cranberry dissolved in water|Dietary Supplement: freeze dried cranberry powder
11290147|NCT02764749|Placebo Comparator|freeze dried cranberry deprived powder dissolved in water|Placebo comparator: freeze dried cranberry deprived powder
11290148|NCT02764736|Experimental|atorvastatin|Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
11290149|NCT02764723|Active Comparator|Hyperbaric bupivacaine|12.5 mg of 0.5% hyperbaric bupivacaine
11290150|NCT02764723|Experimental|Isobaric ropivacaine|15 mg of 0.5% isobaric ropivacaine
11290151|NCT02764710|Experimental|Short treatment|Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
11290152|NCT02764710|Active Comparator|Long treatment|Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
11290153|NCT02764697|Other|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
11290154|NCT02764684|Experimental|HIV-infected patients|Probiotics (lactobacillus rhamnosus)
11290155|NCT02764671|Experimental|10μg/0.5ml recombinant HBV vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
11290156|NCT02764658|Experimental|Pulmonary recovery on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
11290157|NCT02764658|Other|Routine care on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
11290158|NCT02764658|Other|Routine care on the stable COPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
11290159|NCT02764645|Experimental|CardioGard group|"Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.
~2. The suction cannula of the 'Cardiogard cannula'."
11290160|NCT02764645|Active Comparator|Control group|Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
11290161|NCT02764632|Active Comparator|Didgital group|After induction of anesthesia, and after ensuring muscle relaxation, NGT will be inserted through the selected nostril and advanced for 12 cm then the NGT was advanced according to study group advancing. In control group; NGT was inserted with patient head flexed. In D group, after feeling the NGT in pharynx, with the head in neutral position,the index finger was used to support the NGT with slight direction towards the left side. This will prevent tube kinking at this point in front of the resistance offered by the inflated tube cuff or arytenoids cartilage. Also, this digital support reinforces the tube at the area weakened by its openings
11290162|NCT02764632|No Intervention|Control group|
11290163|NCT02764619|Active Comparator|Aldo group|Fixed dose of spironolactone, Spirix (Takeda Pharma A/S), 25 mg once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
11290164|NCT02764619|Placebo Comparator|Control group|Matched placebo, 1 pill once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
11290165|NCT02764606||Patients with a non-small cell lung cancer|Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
11290166|NCT02764593|Experimental|Arm 1 (Nivolumab + Cisplatin)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
11290167|NCT02764593|Experimental|Arm 2 (Nivolumab + High-dose Cisplatin)|Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
11290168|NCT02764593|Experimental|Arm 3 (Nivolumab + Cetuximab)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
11290169|NCT02764593|Experimental|Arm 4 (Nivolumab + IMRT)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
11290170|NCT02764567|Experimental|Aromatherapy|"The participants randomized to aromatherapy will be offered one of three essential oils, 'applied' to their smell zone via cotton ball that are known to have anti-anxiety effect. These are:
~ginger
~calming
~lavender The participant's choice will be documented in a database. The participant can chose an oil each time (i.e., they are not bound to use only the first choice oil). Pain and anxiety will be measured prior to receiving the essential oils and again after the phlebotomy procedure. Blood pressure and pulse will also be measured post-phlebotomy."
11290451|NCT02762890|Experimental|Deep neuromuscular blockade|Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
11290171|NCT02764567|No Intervention|Standard of Care|The participants randomized to standard of care will proceed to the outpatient phlebotomy room in the Heart Care Clinic as per usual care. Pain, anxiety, blood pressure and pulse will be assessed pre and post-procedure.
11290172|NCT02764554||Lenvatinib 4 milligram (mg) and 10 mg capsule|Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
11290173|NCT02764541|Experimental|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
11290174|NCT02764541|Experimental|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
11290175|NCT02764541|Experimental|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
11290176|NCT02764541|Experimental|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
11290177|NCT02764528|No Intervention|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
11290178|NCT02764528|Experimental|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
11290179|NCT02764528|Experimental|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
11290180|NCT02764528|Experimental|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
11290181|NCT02764515|Experimental|Kunxian capsule group|"Intervention:
~Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo."
11290182|NCT02764515|Active Comparator|Methotrexate group|"Intervention:
~Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks."
11290183|NCT02764502|Experimental|Pressure Gauge Manometer|Tuohy needle is introduced into intervertebral space at the level of L3-L4 up to the interspinous ligaments . The needle is advanced slowly using both hands while monitoring the manometer reading and is stopped when the pressure suddenly dropped ( the pressure usually drops by 5-10 mm Hg when the tip of the needle inters the epidural space ).
11290184|NCT02764489|Experimental|Part 1 Regular then reduced volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA reconstituted in regular volume then FEIBA reconstituted in 50% reduced volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
11290185|NCT02764489|Experimental|Part 1 Reduced then regular volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA Reconstituted in 50% Reduced Volume then FEIBA Reconstituted in Regular Volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
11290186|NCT02764476|Experimental|Virtual Reality Therapy|Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.
11290187|NCT02764476|Active Comparator|Control|Eight 30 minute sessions of virtual reality therapy.
11290188|NCT02764463|Other|FRCFPDs|Fiber reenforced Composite Fixed Partial Dentures
11290189|NCT02764450|Experimental|Astralis 10 HPM|Polymerization High-power mode: 1300 mW/cm2 for 10 s
11290190|NCT02764450|Experimental|Astralis 10 RM|Polymerisation regular mode: 650 mW/cm2 for 20
11290191|NCT02764437|Other|MRI-Bronch, PET-WLAC (Stress vs Control)|Subjects will have a functional MRI scan 24 hours before a bronchoscopy with segmental allergen challenge. 48 hours post segmental allergen challenge, the subject will have another MRI and bronchoscopy. 4-6 weeks later, subjects will have a PET scan and whole lung antigen challenge under a stress condition or control condition. 4-6 weeks later, subject will have another PET scan and whole lung antigen challenge under a stress condition or control condition (whatever they did not have the first time).
11290192|NCT02764424||Preterm or term newborns|Preterm or term newborns, hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France), who have to acute painful stimuli related to their care will be included in the study. This painful stress is made in the patient's usual care and is not modified by the protocol. Their stress due to the painful stimuli will be measured with different scales (2 PIPP (Premature Infant Pain Profile) and DAN (Newborn Acute Pain)) and compared with the index obtained with the NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®).
11290193|NCT02764411|Experimental|Onreltea ( Brimonidine)|All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).
11290194|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
11290195|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
11290196|NCT02764372|Experimental|Serious games|The experimental group received Serious Games-based upper extremity therapy through Kinect
11290197|NCT02764372|Active Comparator|Exergames|The control played the same amount of time with commercial exergames of the Wii
11290198|NCT02764359|Experimental|IV Vancomycin loading dose- higher|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
11290199|NCT02764359|Experimental|IV Vancomycin loading dose- lower|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
11290200|NCT02764346|Experimental|iCanCope app|iCanCope app
11290201|NCT02764346|Active Comparator|Attention control app|Control group: iCanCope attention control app
11290909|NCT02760043|Sham Comparator|Saline|LIA mixture with the addition of 2mL of 0.9% NaCl Saline.
11290202|NCT02764333|Experimental|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
11290203|NCT02764320|Active Comparator|Discontinuation|Immediate discontinuation of the overused medication(s) and migraine preventive therapy
11290204|NCT02764320|Active Comparator|Preventive Therapy Only|Migraine preventive therapy without immediate discontinuation of the overused medication(s)
11290205|NCT02764307|Experimental|Aerosolized drug depositions|Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
11290206|NCT02764294|Active Comparator|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
11290207|NCT02764294|Active Comparator|Stress Ball Group|"Stress ball group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
11290208|NCT02764294|Active Comparator|DVD Group|DVD group was watched a DVD of their choice (documentaries, interesting and amazing videos, comedies) on a ceiling-mounted monitor positioned at a comfortable distance to the participant.
11290209|NCT02764294|No Intervention|Control Group|Participants received usual care from health professionals. They didn't receive any intervention.
11290210|NCT02764281|Experimental|MEDA/Auto-HSCT|Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).
11290211|NCT02764268|Experimental|Apatinib|
11290212|NCT02764255||embryoscope group|cases with embryos continuously monitored by the embryoscope followed by embryo selection based on a multivariable model
11290213|NCT02764255||control group|cases with embyos cultured in the standard incubator and evaluated only by morphology
11290214|NCT02764242|Other|insect sting allergy|"Skin prick tests to local and imported insect sting allergen with different concentration are performed.
~sIgE Measurement (to insect and the recombinant venom)"
11290215|NCT02764229|Experimental|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
11290216|NCT02764216|Experimental|EMI group|Elective mucosal irradiation
11290217|NCT02764203|Experimental|Chocolate consumption|Subjects will consume 50g of dark chocolate for 2 weeks and have their blood pressure compared before chocolate and after chocolate
11290218|NCT02764190|Experimental|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
11290219|NCT02764190|No Intervention|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
11290220|NCT02764177|Experimental|Protein|In this arm the subjects were provided with a PROTEIN drink to consume after exercise. This protein drink contained whey protein isolate that provided 0.3 g/ kg body mass of protein.
11290221|NCT02764177|Experimental|Carbohydrate|In this arm the subjects were provided with a CARBOHYDRATE drink to consume after exercise. This carbohydrate drink was energy matched to the protein drink in the other arm of the experiment.
11290222|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
11290223|NCT02764151|Experimental|PF-06840003|Daily Oral PF-06840003
11290224|NCT02764138|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.
~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
11290225|NCT02764138|No Intervention|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
11290226|NCT02764125|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
11290227|NCT02764125|Experimental|levodopa MR|Levodopa MR/carbidopa/ODM-104
11290228|NCT02764099|Experimental|Life Skills Training|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the intervention condition (n=280) will participate in the LST program concurrently during the weeks when they serve as peer court jurors."
11290260|NCT02763878|Sham Comparator|Billroth II anastomosis|After distal gastrectomy, duodenal stump closure, the investigators first underwent remnant stomach and upper jejunum side anastomosis. Then choose the jejunum about 25cm from Treitz ligament, premenstrual colon using a disposable cutting closure (or tubular stapling) in the rear wall of the stomach and jejunum anastomosis, common opening was closed with the (barbed wire) hand-stitched. After that, steps were same with the group A.
11290452|NCT02762890|Active Comparator|Moderate neuromuscular blockade|Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
11290979|NCT02759562|Placebo Comparator|Placebo (Part 1)|Placebo weekly for 8 weeks
11290229|NCT02764086|Other|Trial Cohort Description|"Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.
~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort
~Cohort is extended to 12pts:
~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level & recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.
~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent & neo-adjuvant/no chemotherapy arms will be escalated independently of each other"
11290230|NCT02764060|Experimental|Tongue scraper|In this group the subjects are explained how to use a plastic loop-formed tongue cleaner (Halita® tongue cleaner (Dentaid, Spain)) to clean their tongues.
11290231|NCT02764060|Experimental|Toothbrush|In this group the subjects are explained how to use a toothbrush (Oral-B® Indicator® medium tooth brush) to clean their tongues.
11290232|NCT02764047|Placebo Comparator|Placebo|Placebo capsule
11290233|NCT02764047|Active Comparator|Probiotic|Probiotic capsule
11290234|NCT02764021|Experimental|1.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
11290235|NCT02764021|Active Comparator|2.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
11290236|NCT02764008|Active Comparator|Low thoracic paravertebral block|T8-T9 Ultrasound guided paravertebral block with 20 ml %0,25 bupivacaine
11290237|NCT02764008|Active Comparator|Peritubal infiltration|Peritubal infiltration with 20 ml %0,25 bupivacaine
11290238|NCT02764008|No Intervention|Control Group|No drug
11290239|NCT02763995|Experimental|Pharmaceutical care|Dader method. Health education for lifestyle modification. Improve adherence. Resolution of negative outcome associated with medication.
11290240|NCT02763982||G1|High or normal left ventricular ejection fraction
11290241|NCT02763982||G2|Moderate left ventricular ejection fraction
11290242|NCT02763982||G3|Reduced left ventricular ejection fraction
11290243|NCT02763969|Experimental|Part A: Single Ascending Dose|BMS-986202 or Placebo specified dose on specified days
11290244|NCT02763969|Experimental|Part B: Multiple Ascending Dose|BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
11290245|NCT02763969|Experimental|Part C: Multiple Ascending Dose-Japanese descent|BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent
11290246|NCT02763969|Experimental|Part D: Relative Bioavailability|BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days
11290247|NCT02763969|Experimental|Part E: Proof of Mechanism|BMS-986202 or Placebo + Ustekinumab specified dose on specified days
11290248|NCT02763956|Experimental|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
11290249|NCT02763956|Placebo Comparator|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
11290250|NCT02763930|Experimental|CONTROL (dairy-free)|6 weeks experimental diet with all meals and foods provided to participants. The diet contain 32% of fat, 11% of saturated fat (SFA), 13% of mono-unsaturated fat (MUFA), 8% of polyunsaturated fat (PUFA) and 15% of proteins.
11290251|NCT02763930|Experimental|MILK (low fat dairy)|6 weeks experimental diet with all meals and foods provided to participants including 3 servings/day of milk (1% fat) per 2500 kcal. The diet contain 32% of fat, 11% of SFA, 13% of MUFA, 8% of PUFA and 15% of proteins.
11290252|NCT02763930|Experimental|GABA-rich cheese (high-fat dairy )|6 weeks experimental diet with all meals and foods provided to participants including 50g/day of GABA-rich cheddar cheese (approximately 32% fat). The diet contain 32% of fat, 13% of SFA, 13% of MUFA, 6% of PUFA and 15% of proteins.
11290253|NCT02763917|Active Comparator|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
11290254|NCT02763917|Placebo Comparator|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
11290255|NCT02763904|Experimental|Intensive nutritional counseling|Dietary counseling + energy dense oral nutritional supplements
11290256|NCT02763904|Active Comparator|Dietary counseling|Dietary counseling
11290257|NCT02763891|Experimental|Intervention group|Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
11290258|NCT02763891|Sham Comparator|Control group|Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
11290259|NCT02763878|Experimental|uncut Roux-en-Y anastomosis|After distal gastrectomy, duodenal stump closure, side to side anastomosis was underwent on the remnant stomach and jejunum,which was 25cm from Treitz ligament. Then underwent side to side anastomosis between jejunum about 35cm distance from gastrojejunostomy and jejunum about 5cm from Triez ligament . close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis by using uncut Closure devices
11290261|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
11290262|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
11290263|NCT02763852|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Madopar 125. BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
11290264|NCT02763852|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
11290265|NCT02763852|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
11290266|NCT02763852|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
11290267|NCT02763852|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
11290268|NCT02763839|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Sinemet 25/100 BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
11290269|NCT02763839|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
11290270|NCT02763839|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
11290271|NCT02763839|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
11290272|NCT02763839|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
11290273|NCT02763826|Experimental|tDCS Application|transcranial direct current stimulation. tDCS currents are applied in increasing strengths and then in different electrode montages.
11290274|NCT02763813|Experimental|Propulsion type appliance (Herbst)|
11290275|NCT02763813|Active Comparator|Retention type appliance (ORM)|Retention type appliance
11290276|NCT02763800|Experimental|Group 1: BIA 3-202 50 mg/placebo|"Group 1: BIA 3-202 50 mg/placebo on Day 1; BIA 3-202 50 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 50 mg/placebo on Day 9.
~50 mg BIA 3-202: 5 x 10 mg BIA 3-202 tablets"
11290277|NCT02763800|Experimental|Group 2: BIA 3-202 100 mg/placebo|"Group 2: BIA 3-202 100 mg/placebo on Day 1; BIA 3-202 100 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 100 mg/placebo on Day 9.
~100 mg BIA 3-202: 1 x 100 mg BIA 3-202 tablet"
11290278|NCT02763800|Experimental|Group 3: BIA 3-202 200 mg/placebo|"Group 3: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.
~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
11290279|NCT02763800|Experimental|Group 4: BIA 3-202 200 mg/placebo|"Group 4: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo t.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.
~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
11290280|NCT02763787|Experimental|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290281|NCT02763787|Experimental|10 mg|1 x 10 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290282|NCT02763787|Experimental|30 mg|3 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290283|NCT02763787|Experimental|50 mg|5 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290284|NCT02763787|Experimental|100 mg|1 x 100 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290285|NCT02763787|Experimental|200 mg|2 x 100 mg BIA 3-202 tablets
11290286|NCT02763787|Experimental|400 mg|4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290287|NCT02763787|Experimental|800 mg|8 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290288|NCT02763787|Experimental|Food Effect (fed/fasted)|400 mg BIA 3-202: 4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
11290340|NCT02763436|No Intervention|"Group immediate cord clamping (ICC)"|The cord will be clamped within the first minute after birth, afterwards the newborn will be placed on the mothers chest/abdomen. This corresponds to the present routine approach in Graz.
11290289|NCT02763774|Experimental|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
11290290|NCT02763774|Experimental|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
11290291|NCT02763774|Experimental|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
11290292|NCT02763761|Experimental|Infliximab + Prednisone|Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days
11290293|NCT02763761|Experimental|Methylprednisolone + Prednisone|Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days
11290294|NCT02763748|Experimental|Laparoscopic surgery|Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.
11290295|NCT02763748|Experimental|laparoscopic and endoscopic|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
11290296|NCT02763748|Experimental|Single-arch laparoscopic and endoscopic|Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
11290297|NCT02763735||Pulmonary Arterial Hypertension|Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging.
11290298|NCT02763735||Subjects without cardiopulmonary disease|Subjects without known cardiopulmonary disease. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging
11290299|NCT02763722|Experimental|Emollient spray product|"Study design
~A 3 visits are planned:
~0 week (first visit) 2nd week (second visit) 4th week (third visit)
~B. During each visit will be made:
~The clinical examination (including an assessment of any adverse effects)
~Evaluation of transepidermal water loss (TEWL) and capacitance of outer areas of the stratum corneum as an indirect assessment of skin hydration,
~fill out questionnaires CDLQI (The Children's Dermatology Life Quality Index)
~will assess VAS (visual analogue scale)
~C. All patients will be instructed to use emollients spray the entire surface of the skin at least twice daily for four weeks."
11290300|NCT02763709||Cases|Children admitted in Pediatric ICU for more than 24 hours with Pediatric Risk of Mortality (PRISM) score III > 20
11290301|NCT02763696||normal women|Composition of Viginal flora of Child-Bearing women in normal woman
11290302|NCT02763696||vaginitis women|Women of childbearing age with vaginitis
11290303|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
11290304|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
11290305|NCT02763670|Other|Interventional|PRETICARD patient care management
11290306|NCT02763670|Other|Control|"Heterogenous as usual patient care management."
11290307|NCT02763657|Experimental|Brain activity during reasoning|
11290308|NCT02763644|Experimental|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
11290309|NCT02763644|Experimental|All SoC first|Standard of Care then LFG316 plus SoC
11290310|NCT02763631|Experimental|Run In Phase|Eligible patients will have 6-Minute Walk Test (6-MWT) on self ventilation and on CPAP
11290311|NCT02763631|Experimental|Treatment|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:
~Treatment arm - Patients will be setup onto portable CPAP during the day"
11290312|NCT02763631|Sham Comparator|Standard Care Arm|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:
~Control Arm - Standard care arm."
11290313|NCT02763618|Active Comparator|Group A: Theta/beta ratio Neurofeedback|"In this condition, participants will receive three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions.
~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
11290314|NCT02763618|Active Comparator|Group B: Theta/beta ratio Neurofeedback|"In this condition, participants will receive nine baseline sessions and continue with eight theta/beta ratio Neurofeedback sessions.
~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
11290315|NCT02763618|Placebo Comparator|Group C: Placebo Neurofeedback training|Three baseline sessions and continue with 14 placebo training sessions. The placebo training will be a previously recorded Neurofeedback session of a participant in group A (receiving 14 real Neurofeedback sessions). Before the participants in group C (placebo trainings) start, they will be matched to a participant in group A, and receive the exact same (prerecorded) feedback per session of their matched participant. In this way, participants in the placebo training are then made to think that the video and EEG feedback is their own, however they are actually not able to influence the continuation of the video.
11290316|NCT02763605||patients diagnosed with acanthamoeba keratitis|"Inclusion Criteria:
~- All patients presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016 with the tissue proven corneal AK will be included.
~Exclusion Criteria
~- Patients with tissue proven corneal AK during from Jun. 1st, 2003 to dec. 30th , 2016, but without in vivo confocal data, or complete chart records."
11290371|NCT02763202|No Intervention|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
11290317|NCT02763592|Experimental|Lidocaine|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
11290318|NCT02763592|Placebo Comparator|placebo|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
11290319|NCT02763579|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
11290320|NCT02763579|Active Comparator|Placebo + Carboplatin + Etoposide|Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
11290321|NCT02763566|Experimental|Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)|Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
11290322|NCT02763566|Experimental|Placebo + NSAI|Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
11290323|NCT02763566|Experimental|Abemaciclib + Fulvestrant|Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
11290324|NCT02763566|Experimental|Placebo + Fulvestrant|Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
11290325|NCT02763553|Experimental|Ketogenic Feed|A low-carbohydrate, high-fat enteral feed (Nutrison KetoCal 4:1) containing 0.4g of carbohydrate and 10g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
11290326|NCT02763553|Active Comparator|Standard Feed|Standard enteral feed (Nutrison ProteinPlus MF 1.28) containing 11.1g of carbohydrate and 3.8g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
11290327|NCT02763540|Other|Lung cryobiopsy|
11290328|NCT02763527|Experimental|Smoking reduction|"Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a booster intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers."
11290329|NCT02763527|Placebo Comparator|Smoking Cessation|"Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and booster intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group."
11290330|NCT02763514|Active Comparator|DHA-enriched oil|3 g PronovaPure 150:500 EE EU
11290331|NCT02763514|Active Comparator|EPA-enriched oil|3 g PronovaPure 500:200 EE EU
11290332|NCT02763514|Placebo Comparator|Placebo|3 g Olive oil
11290333|NCT02763501|Active Comparator|RCT|"patients operated with laparoscopic gastric bypass surgery within a register based RCT from May 1st 2010 until Nov 14th 2011.
~1:1 randomization to closure of mesenteric defects by running, non-absorbable sutures"
11290334|NCT02763501|Active Comparator|non-RCT|"patients operated with laparoscopic gastric bypass surgery outside of the RCT from May 1st 2010 until Nov 14th 2011.
~Intervention of mesenteric defects according to local tradition or choice of surgeon (non-randomized)"
11290335|NCT02763488|Active Comparator|Standard physical therapy|These individuals will conduct physical therapy for 12 sessions as per the institutional standard physical therapy protocol
11290336|NCT02763488|Experimental|Blood flow restriction|These individuals will conduct physical therapy for 12 sessions with the addition of blood flow restriction interventions to their standard physical therapy
11290337|NCT02763475|Experimental|Natural Killer (NK) Cells + Chemotherapy|Starting on day -6, 60mg/Kg cyclophosphamide by vein will be administrated. Day -5 to -1 fludarabine administrated by vein at 25 mg/m2. 24-48 hours after chemotherapy completion, NK cell infusion will be injected (day 0). On day 7 a second NK cell infusion will be administrated. First infusion consist of 5x10^7/kg NK CD3-CD56+ NK cells. The second NK cell infusion will include up to 5x10^8 CD3-CD56+ cells if no treatment related toxicity occurred. Subcutaneous IL-2 (1x10^6 UI/m2) three times a week for two weeks will be administrated after first NK infusion.
11290338|NCT02763449|Experimental|Sedentary|Individuals will reduce their physical activity level for 14-days
11290339|NCT02763449|Experimental|Active|Individuals will increase their physical activity level for 14-days
11290341|NCT02763436|Active Comparator|"Group physiological based cord clamping (PBCC)"|"The newborn will be placed on mother's chest/abdomen with intact cord. After the newborn has established stable breathing efforts (continuous regular breathing pattern and SpO2 values >25th percentile from Dawson et al reference range for oxygen saturation -minute 2>58%, minute 3>67%, minute 4>76%) the cord is clamped. This will need 2 - 4 minutes."
11290342|NCT02763423|Experimental|umbilical cord mesenchymal stem cell|single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients
11290343|NCT02763410||control group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery, with no renal failure at the 48th hour after surgery, based on the RIFLE classification, and regardless of the transfusion received after the H6 assessment.
11290344|NCT02763410||Renal failure group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery and who developed renal failure before H48 with no new transfusion prior to diagnosis of kidney failure.
11290345|NCT02763397|Experimental|NBM-DBS on|DBS is programmed to stimulate the NbM
11290346|NCT02763397|Placebo Comparator|DBS off|DBS is turned off, no stimulation will be exerted
11290347|NCT02763384|Experimental|Arm 1: BL-8040 and Nelarabine|"Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6
~Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5
~Treatment may be repeated every 21 days for up to 4 cycles"
11290348|NCT02763371|Experimental|Dietary: high GI lunch|High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
11290349|NCT02763371|Experimental|Dietary: low GI lunch|Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
11290350|NCT02763358|Other|Bites and Steps displayed|All subjects will be assigned to one arm-daily bites and steps displayed on Bite Counter device
11290351|NCT02763345|Active Comparator|Paper-based CCM (Standard Care)|Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
11290352|NCT02763345|Experimental|SL eCCM App + paper CCM|Health Surveillance Assistants use the Supporting LIFE electronic Community Case Management App (SL eCCM App) deployed on a smartphone and replicating paper-based CCM guidelines to assess and treat children in conjunction with standard care, for a minimum of 2-weeks and maximum of 7-weeks. Clinical data is recorded in both the SL eCCM App and Village Clinic Register.
11290353|NCT02763332|Experimental|Upper trunk group (UTG)|In the UTG, the bandage was applied over the superior fibbers of the trapezious and levator scapulae muscle using a strip in a 'Y' shape. The individuals were asked to remain in an upright sitting position and the base of the strip was attached to the skin beyond the acromion without any tension. Later, we placed the two straps of the bandage with a range of tension from 15 to 25%. The main goal of this shape is achieve muscular relaxation of the trapezius, scapula levator and supraspinatus.
11290354|NCT02763332|Active Comparator|Global trunk group (GTG)|In the GTG the bandage was applied parallel to the paravertebral muscles in a 'C' shape. The individuals were sit in the same position with the head in the neutral position. The strip was pasted with approximately 25% of tension all over the paravertebral musculature. The main goal was procuring a global mechanical correction of the superior part of the trunk.
11290355|NCT02763319|Experimental|Tafasitamab and bendamustine|Tafasitamab and bendamustine
11290356|NCT02763319|Active Comparator|Rituximab and bendamustine|Rituximab and bendamustine
11290357|NCT02763306|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
11290358|NCT02763293|Experimental|Manual Therapy|Cranial therapy (CT). Neuro-lymphatic reflexes treatment (NL) Viscerosomatic reflexes (VR) Induction myofascial Visceral osteopathic therapy (VOT)
11290359|NCT02763293|No Intervention|Control Group|Patients only came to make assessments, without receiving any treatment.
11290360|NCT02763280|Experimental|Ginseng extract 1g|Ginseng extract 1g
11290361|NCT02763280|Experimental|Ginseng extract 3g|Ginseng extract 3g
11290362|NCT02763280|Placebo Comparator|Placebo|Placebo
11290363|NCT02763267||Pregnant Women|Pregnant women with history of GDM or at risk for diabetes mellitus will enter study during first trimester (4-14 weeks) and receive an oral glucose tolerance test (OGTT) at baseline, mid-pregnancy, and at delivery.
11290364|NCT02763267||Nonpregnant Women|Nonpregnant women with a history of GDM will undergo an OGTT at baseline.
11290365|NCT02763254|Experimental|baltaleucel-T|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
11290366|NCT02763241|Experimental|Cleanoze®|"Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
11290367|NCT02763241|Active Comparator|Syringe irrigation|"Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe
~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
11290368|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.
~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
11290369|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.
~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
11290370|NCT02763215||Total|
11290408|NCT02762994|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
11290372|NCT02763202|Experimental|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
11290373|NCT02763189|Active Comparator|Control|Control group will study the learning material independently. 'Self-study'.
11290374|NCT02763189|Experimental|Mentored|Mentored group will study the learning materials and then receive expert mentoring
11290375|NCT02763163||outdoor workers|Subjects with an excessive exposure to the sun on a daily basis
11290376|NCT02763163||office workers|Subjects who spend most of the day in a closed shaded room
11290377|NCT02763150|Experimental|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
11290378|NCT02763150|Active Comparator|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
11290379|NCT02763137|Active Comparator|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
11290380|NCT02763137|Experimental|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
11290381|NCT02763124|Experimental|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
11290382|NCT02763111|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
11290383|NCT02763111|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
11290384|NCT02763111|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
11290385|NCT02763111|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10, 12.
11290386|NCT02763098|Experimental|Remi 0.1|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [(0.1), 0.2, 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
11290387|NCT02763098|Experimental|Remi 0.2|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, (0.2), 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-RoiFrance) for two minutes.
11290388|NCT02763098|Experimental|Remi 0.3|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, 0.2, (0.3) µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
11290389|NCT02763085|Experimental|Basic Filling Material|Fillings made with a new dental filling material.
11290390|NCT02763072|Experimental|Picosecond Q-switched Laser|12 subjects will receive one treatment with a dual wavelength 532 nm KTP and/or 1064 nm Nd: YAG picosecond pulse duration laser.
11290391|NCT02763072|Active Comparator|KTP Laser|12 subjects will receive up to four treatments with a dual wavelength 532nm KTP long pulsed laser and/or 1064 nm Nd: YAG.
11290392|NCT02763059|Active Comparator|Group 1- Received Ibuprofen (N=44)|
11290393|NCT02763059|Active Comparator|Group 2- Received Dexamethasone (N=44)|
11290394|NCT02763059|Placebo Comparator|Group 3 - Received Placebo (N=44)|
11290395|NCT02763046|Experimental|Secukinumab - delayed NSAID tapering|"Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind.
~NSAID tapering allowed from Week 4 (delayed tapering)."
11290396|NCT02763046|Experimental|Secukinumab - early NSAID tapering|"Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind.
~NSAID tapering allowed from Week 4 (early tapering)."
11290397|NCT02763046|Placebo Comparator|Placebo|"Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20).
~NSAID tapering allowed from Week 4."
11290398|NCT02763033|Experimental|Bob's Red Mill®|"Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.
~Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID."
11290399|NCT02763033|Placebo Comparator|Starch Placebo|Patients will receive an iso-caloric, non-resistant starch placebo.
11290400|NCT02763020|Placebo Comparator|Food bar without fruit|snack bar without fruit
11290401|NCT02763020|Experimental|Food bar with cranberry extract (0.5%)|Snack bar with cranberry extract (0.5% total weight)
11290402|NCT02763020|Experimental|Food bar with cranberry extract (1.0%)|Snack bar with cranberry extract (1.0% total weight)
11290403|NCT02763020|Experimental|Food bar w/ dried black raspberry (10%)|Snack bar with freeze-dried black raspberry(10% total weight)
11290404|NCT02763020|Experimental|Food bar w/ dried black raspberry (20%)|Snack bar with freeze-dried black raspberry (20% total weight)
11290405|NCT02763007|Experimental|alogliptin+pioglitazone|A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
11290406|NCT02763007|Active Comparator|alogliptin|A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
11290407|NCT02763007|Active Comparator|pioglitazone|A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
11290412|NCT02762981|Experimental|CORT125134 with nab-paclitaxel|"Part I - Dose Escalation:
~Patients will be treated with CORT125134 in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.
~Part 2 - Dose Expansion:
~Expansion cohorts in the Continuous-Dosing and Intermittent-Dosing Regimens will be enrolled to better characterize the antitumor activity in patients with specific tumor types and to better define the safety profile."
11290413|NCT02762968|Placebo Comparator|Placebo|Placebo capsules similar to the experimental treatments.
11290414|NCT02762968|Experimental|HMB|HMB capsules providing 3 g of calcium HMB per day.
11290415|NCT02762968|Experimental|HMB + BC30|Capsules providing 3 g calcium HMB per day plus Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
11290416|NCT02762955|Experimental|BCD-057 group|"BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.
~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa."
11290417|NCT02762955|Active Comparator|Humira® group|"Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.
~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.
~Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa."
11290418|NCT02762942|Active Comparator|Vaginal misoprostol alone|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols
11290419|NCT02762942|Experimental|Vaginal misoprostol + Foley catheter|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
11290420|NCT02762929|Experimental|Part A Cohort A|200 mg of HTX-011A via closed wound infiltration
11290421|NCT02762929|Experimental|Part A Cohort B|200 mg of HTX 011A via open wound infiltration
11290422|NCT02762929|Experimental|Part A Cohort C|200 mg of HTX-011B via closed wound infiltration
11290423|NCT02762929|Experimental|Part A Cohort D|200 mg of HTX 011B via open wound infiltration
11290424|NCT02762929|Active Comparator|Part A Cohort E|50 mg 0.5% bupivacaine hydrochloride injection via a closed wound infiltration
11290425|NCT02762929|Placebo Comparator|Part A Cohort F|Saline Placebo via a closed wound infiltration
11290426|NCT02762929|Experimental|Part B Cohort A|200 mg HTX 002 via closed wound infiltration
11290427|NCT02762929|Experimental|Part B Cohort B|200 mg HTX 002 via open wound infiltration
11290428|NCT02762929|Placebo Comparator|Part B Cohort C|Saline placebo via a closed and open wound infiltration
11290429|NCT02762929|Experimental|Part C Cohort A|120 mg of HTX-011B via closed wound infiltration
11290430|NCT02762929|Experimental|Part C Cohort B|120 mg of HTX-011B via open wound infiltration
11290431|NCT02762929|Experimental|Part C Cohort C|120 mg of HTX-011B local administration via instillation
11290432|NCT02762929|Placebo Comparator|Part C Cohort D|Saline placebo via open wound infiltration
11290433|NCT02762929|Experimental|Part D Cohort A|60 mg of HTX-011B via closed wound infiltration
11290434|NCT02762929|Experimental|Part D Cohort B|60 mg of HTX-011B via open wound infiltration.
11290435|NCT02762929|Placebo Comparator|Part D Cohort C|Saline placebo via open wound infiltration
11290436|NCT02762929|Experimental|Part E Cohort A|120 mg HTX 002 via closed wound infiltration
11290437|NCT02762929|Experimental|Part E Cohort B|120mg HTX 002 via open wound infiltration
11290438|NCT02762929|Placebo Comparator|Part E Cohort C|Saline placebo via closed and open wound infiltration
11290439|NCT02762929|Experimental|Part F Cohort A|HTX 009 via closed wound infiltration
11290440|NCT02762929|Experimental|Part F Cohort B|HTX 009 via open wound infiltration
11290441|NCT02762929|Placebo Comparator|Part F Cohort C|Saline placebo via closed and open wound infiltration
11290442|NCT02762929|Experimental|Part G Cohort A|30 mg of HTX 011B via closed wound infiltration
11290443|NCT02762929|Placebo Comparator|Part G Cohort B|Saline placebo via closed wound infiltration
11290444|NCT02762929|Experimental|Part H Cohort A|120 mg of HTX-011-056
11290445|NCT02762929|Experimental|Part H Cohort B|60 mg of HTX-011-056
11290446|NCT02762929|Placebo Comparator|Part H Cohort C|4.1 mL of normal saline
11290447|NCT02762916|Experimental|1- Telemedicine arm|"The intervention arm (IA), telehealth control, were followed up by himself helped by CONTECI program. They have to use every three months and if somethings was wrong the patient have to send mail to the doctor.
~The intervention consisted to use the CONTECI program (included test) for the following of the patients."
11290448|NCT02762916|No Intervention|2- Control arm|The Control Arm (CA) were followed up as usual every 6 months in outpatient vascular visits in the clinical hospital. If some patient have a complications or and emergency they have to do usual protocol, go to primary care or emergency.
11290449|NCT02762903|Active Comparator|Tenotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with tenotomy technique.
11290486|NCT02762682||HEALTHY CONTROLS|Developmentally normal child not suffering from any acute or chronic neurological illness
11290453|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
11290454|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
11290455|NCT02762864|Experimental|PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period. For patients in the PRU-target group with PRU ≥234 seconds, rescue medicine (ticagrelor) will be added to keep PRU<234 seconds.
11290456|NCT02762864|Active Comparator|non PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period, regardless the levels of PRU.
11290457|NCT02762851|Experimental|Influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.
11290458|NCT02762851|Placebo Comparator|Placebo vaccine|Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.
11290459|NCT02762838|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
11290460|NCT02762838|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
11290461|NCT02762825|Experimental|Higher Intensity Interval Training (HIIT)|
11290462|NCT02762825|Active Comparator|Moderate Continuous Training (MCT)|
11290463|NCT02762812|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
11290464|NCT02762812|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
11290465|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
11290466|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
11290467|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
11290468|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
11290469|NCT02762786|Experimental|Experimental|Participants in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation. The Music Children Foundation is a non-governmental organization established by a group of professional musicians with the objective of transforming children's lives and instils positive values in the entire community through music. It aims to provide free musical training to low-income children and children with chronic diseases, including those with Down's syndrome, mucopolysaccharidoses, skeletal dysplasia and visual impairment.
11290470|NCT02762786|No Intervention|Wait-list control group|Participants in the waitlist control group will receive the same training after the experimental group had completed the intervention.
11290471|NCT02762773|Experimental|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
11290472|NCT02762773|Placebo Comparator|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
11290473|NCT02762760|Experimental|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
11290474|NCT02762760|Experimental|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
11290475|NCT02762747|Experimental|Drain|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
11290476|NCT02762747|No Intervention|No-drain|No drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
11290477|NCT02762734|Experimental|MEDIA|"The patient will benefit of the usual care with additional text message (SMS or mail or other new media). The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt."
11290478|NCT02762734|No Intervention|CLASSIC|The patient will benefit of the usual care.
11290479|NCT02762708|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Subjects between the ages of 20-65 years of age seen for weight management in the Nutrition Clinic at Mayo Clinic, who have been approved for RYGB.
11290480|NCT02762708|Sham Comparator|Caloric restriction|Subjects between the ages of 20-65 years of age, with diagnosis of Type 2 diabetes mellitus or impaired fasting glucose. Subjects will undergo caloric restriction alone to mimic weight loss seen after gastric bypass surgery.
11290481|NCT02762708|Active Comparator|Exendin-9,39|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
11290482|NCT02762708|Placebo Comparator|Normal Saline|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
11290483|NCT02762695|Experimental|Case Management|
11290484|NCT02762695|Active Comparator|Control|Usual Care at Primary Health Care
11290485|NCT02762682||CASES OF ITS AND PRE ITS|"Either sex, age less than 3 years
~Clinical diagnosis of Infantile Tremor Syndrome as evidenced by the following features:
~[Developmental delay or regression WITH history of exclusive or predominant breast feeding WITH two or more of the following; skin pigmentation, hair depigmentation, tremors] ITS:1 and 2 plus tremors PreITS:1 and 2 without tremors"
11291042|NCT02759198|Placebo Comparator|Placebo|YH23537 Placebo
11290487|NCT02762669|No Intervention|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
11290488|NCT02762669|Active Comparator|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
11290489|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
11290490|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
11290491|NCT02762669|Active Comparator|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
11290492|NCT02762669|Active Comparator|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
11290493|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
11290494|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
11290495|NCT02762656|Active Comparator|Lidocaine|Patients will receive Lidocaine drip during spine surgery
11290496|NCT02762656|Placebo Comparator|Placebo|Patients will receive placebo during spine surgery
11290497|NCT02762643|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
11290498|NCT02762643|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
11290499|NCT02762617|Experimental|TDF IVR group|"The Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core which contains the experimental drug, TDF, and sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).
~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
11290500|NCT02762617|Placebo Comparator|Placebo IVR group|"The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).
~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
11290501|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
11290502|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
11290503|NCT02762578|Experimental|IDegAsp BID|
11290504|NCT02762578|Active Comparator|BIAsp 30 BID|
11290505|NCT02762565|Experimental|breast scanner|
11290506|NCT02762552|Experimental|Transcranial-holter monitoring|Transcranial doppler in patient with ischemic stroke
11290507|NCT02762539|No Intervention|Control group|Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion
11290508|NCT02762539|Experimental|SMOF group|SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.
11290509|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
11290510|NCT02762500|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
11290511|NCT02762500|Placebo Comparator|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
11290512|NCT02762487|Experimental|LINX arm|Previous LSG patient will be treated with the LINX device and serve as their own control
11290513|NCT02762474|Experimental|nab-paclitaxel group|Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
11290514|NCT02762461||Exposed group|Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).
11290515|NCT02762461||Reference group 1|Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).
11290516|NCT02762461||Reference group 2|Women with medically treated endometriosis not undergoing ART.
11290517|NCT02762448||Daclatasvir + Asunaprevir|Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
11290518|NCT02762435|Placebo Comparator|control|No pressure applied to the 3 points
11290519|NCT02762435|Sham Comparator|sham|Light touch applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
11290520|NCT02762435|Experimental|acupressure|Moderate pressure applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
11300495|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
11290521|NCT02762422|Experimental|Phlebotomy plus normal saline|Four serial phlebotomy procedures followed by infusion of normal saline
11290522|NCT02762422|Experimental|Phlebotomy plus intravenous iron|Four serial phlebotomy procedures followed by infusion of intravenous iron sucrose
11290523|NCT02762422|Placebo Comparator|Sham Phlebotomy|Four serial sham phlebotomy procedures followed by infusion of normal saline
11290524|NCT02762409||patients exposed|Patients exposed will be estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015, and in 17 centers of the group control some study IPREA3 during October 2015
11290525|NCT02762409||patients non exposed|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015 and in 17 centers of the interventional group during October 2014"
11290526|NCT02762383|Experimental|Peginterferon Alfa-2a|Participants will receive a low dose of peginterferon alfa-2a for 18 months.
11290527|NCT02762370|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
11290528|NCT02762370|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
11290529|NCT02762357||Novosyn® Quick|episiotomy closure using suture material
11290530|NCT02762344||ACT < 150 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec
11290531|NCT02762344||ACT between 150 and 249 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec
11290532|NCT02762344||ACT >= 250 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec
11290533|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
11290534|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
11290535|NCT02762305|Experimental|RSVP Bone Builder group exercise|A group of older adults who are participating in the RSVP Bone Builder group exercise.
11290536|NCT02762292|Experimental|Patients|
11290537|NCT02762279|Experimental|Patients|"Patient baseline characteristics will be collected.
~Specific nasogastric tube installation: a specific nasogastric tube equipped with pressure transducers (Gaeltec® probe) will be installed.
~Connection of a pressure transducer to the existing chest-tube.
~Simultaneous recordings of PES (Gaeltec®), PPL, PAW, respiratory volume and flow (5 minutes).
~Removal of the Gaeltec® probe, and repositioning of the pre-existing nasogastric tube in the esophagus for PES measurement.
~Simultaneous recordings of PES (feeding tube), PPL, PAW, respiratory volume and flow (5 minutes).
~Repositioning of the nasogastric tube in the stomach, and disconnection of the different recording equipment."
11290538|NCT02762266|Active Comparator|Arm I (TACE)|Patients undergo TACE.
11290539|NCT02762266|Experimental|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
11290540|NCT02762253|Other|Riboflavin drops - epithelium on or off|Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax
11290541|NCT02762240|Active Comparator|DHQP 2016|This group consists of general practices allocated to undergo accreditation scheme in 2016.
11290542|NCT02762240|Placebo Comparator|DHQP 2018|This group consists of general practices allocated to undergo accreditation scheme in 2018.
11290543|NCT02762227|Experimental|gallbladder polyps patients|"All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US, were enrolled in this study.
~Of these patients, we excluded: (1) gallbladder polyp with a diameter less than 10 mm. (2) lesions highly suspected to be cancer due to visible metastasis. (3) allergy to contrast agents and cannot received CT or CEUS examination. (4) women in pregnancy or lactation.
~All patients received transabdominal US, abdominal high resolution CT and contrast-enhanced ultrasonography (CEUS) before the cholecystectomy."
11290544|NCT02762214|Active Comparator|With Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.
11290545|NCT02762214|Experimental|Without Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.
11290546|NCT02762201|Experimental|PASI|PASI dental prosthesis delivery
11290547|NCT02762201|Active Comparator|PAC|PAC dental prosthesis delivery
11290548|NCT02762188|Experimental|wet ARMD patients|Patients with the wet form of ARMD who receive or have received in the past anti VEGF intra vitreal injections. Diagnosis of wet ARMD is made based on clinical data-visual acuity, fundus presence of subretinal fluid and/or haemorrhage and/or hard exudates, fundus photographs -color and red free, optical coherence tomography (SD-OCT), fluorescein angiography and indocyanine green angiography showing the presence and activity of subretinal neovascularisation.
11290549|NCT02762149|Active Comparator|0.1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
11290586|NCT02761928||Medial branch RFA|Positive response (>50% pain relief) to median branch nerve radiofrequency ablation
11290550|NCT02762149|Active Comparator|1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
11290551|NCT02762136|Placebo Comparator|placebo|Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
11290552|NCT02762136|Active Comparator|Xiang-sha-liu-jun granules|Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
11290553|NCT02762123|Experimental|Cohort 1 (BMS-986142: 200 mg)|200mg BMS-986142 administered orally once daily on specified days.
11290554|NCT02762123|Experimental|Cohort 2 (BMS-986142: 350 mg)|350mg BMS-986142 administered orally once daily on specified days.
11290555|NCT02762097|Experimental|intervention|All women would undergo saline sonography with normal saline. Women with endometrial polyps who consent to the removal of polyps will be offered polypectomy
11290556|NCT02762097|Placebo Comparator|control|All women would undergo saline sonography with normal saline. Women with endometrial polyps who do not consent to the removal would serve as controls
11290557|NCT02762084|Experimental|Patidegib gel 2%|Patidegib gel 2%, applied topically, twice daily for 26 weeks
11290558|NCT02762084|Experimental|Patidegib gel 4%|Patidegib gel 4%, applied topically, twice daily for 26 weeks
11290559|NCT02762084|Placebo Comparator|Vehicle gel|Vehicle gel, applied topically, twice daily for 26 weeks
11290560|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
11290561|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
11290562|NCT02762058|Experimental|Experimental Group|Patients receiving Virtual Reality Mirror Therapy
11290563|NCT02762058|Experimental|Control Group|Patients receiving Traditional Mirror Therapy
11290564|NCT02762045|Experimental|Low dose Ad5-gag or Placebo|1ml low dose Ad5-gag(2x10^9VP) or Preservation solution at weeks 0 and weeks 4.
11290565|NCT02762045|Experimental|Medium dose Ad5-gag or Placebo|1ml medium dose Ad5-gag(2x10^10VP) or Preservation solution at weeks 0 and weeks 4.
11290566|NCT02762045|Experimental|High dose Ad5-gag or Placebo|1ml high dose Ad5-gag(2x10^11VP) or Preservation solution at weeks 0 and weeks 4.
11290567|NCT02762032|Active Comparator|Arm 1|15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.
11290568|NCT02762032|Active Comparator|Arm 2|15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.
11290569|NCT02762032|Placebo Comparator|Arm 3|15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.
11290570|NCT02762019|Experimental|Laser therapy|Children are allocated to receive Laser therapy
11290571|NCT02762019|Sham Comparator|Sham therapy|Children are allocated to receive Sham therapy
11290572|NCT02762006|Experimental|Durvalumab + Tremelimumab with Nephrectomy|"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.
~Cohort 1: Durvalumab x 1 dose (n=6)
~Cohort 2: Durvalumab + Tremelimumab x 1 dose (n=6)
~Cohort 2a: Durvalumab + Tremelimumab x 1 dose (n=12)
~Cohort 3: Durvalumab + Tremelimumab x 1 dose (n=9)
~Cohorts 1 and 2: Adjuvant dosing of Durvalumab x 1 beginning 2-8 weeks after surgery.
~Cohort 2a: Durvalumab monotherapy until 1 year after nephrectomy.
~Cohort 3: Adjuvant dosing of durvalumab + tremelimumab x 1 beginning 2-8 weeks after surgery, then durvalumab monotherapy until 1 year after nephrectomy."
11290573|NCT02761993|Active Comparator|Group 1|Group 1: 1XST266 dosed as per regimen 1.
11290574|NCT02761993|Active Comparator|Group 2|Group 2: 1XST266 as per regimen 2.
11290575|NCT02761993|Placebo Comparator|Group 3|Group 3: Placebo dosed as per regimen 1.
11290576|NCT02761980|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
11290577|NCT02761980|Active Comparator|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
11290578|NCT02761980|Active Comparator|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
11290579|NCT02761980|Placebo Comparator|Placebo|Single dose of 2 caplets of Placebo by mouth
11290580|NCT02761967|Experimental|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.
~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
11290581|NCT02761967|No Intervention|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.
~After the postpartum period, the women in the control group did not perform regulated physical activity."
11290582|NCT02761928||Epidural|Positive response (>50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)
11290583|NCT02761928||Selective nerve root block|Positive response (>50% pain relief) to selective nerve root block
11290584|NCT02761928||Facet injection|Positive response (>50% pain relief) to intra-articular facet injection
11290585|NCT02761928||Medial branch block|Positive response (>50% pain relief) to median branch nerve block
11290588|NCT02761928||Lateral branch block|Positive response (>50% pain relief) to lateral branch nerve block for SIJ
11290589|NCT02761928||Greater trochanter injection|Positive response (>50% pain relief) to greater trochanteric bursa injection
11290590|NCT02761928||Piriformis injection|Positive response (>50% pain relief) to piriformis injection
11290591|NCT02761928||Trigger point injection|Positive response (>50% pain relief) to trigger point injection
11290592|NCT02761915|Other|Dose Level 1|Patients in Dose Level1 will receive 1x10^7 1RG-CART/m^2 on Day 0 (intravenously).
11290593|NCT02761915|Other|Dose Level 2|Patients in Dose Level 2 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 on Day 0.
11290594|NCT02761915|Other|Dose Level 3|Patients in Dose Level 3 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 on Day 0.
11290595|NCT02761915|Other|Dose Level 4|Patients in Dose Level 4 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 on Day 0.
11290596|NCT02761915|Other|Dose level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 on Day 0 .
11290597|NCT02761902||Preschool group|3-6 years old
11290598|NCT02761902||school age group|7-12 years old
11290599|NCT02761902||Adolescence group|13-15 years old
11290600|NCT02761889|Experimental|IGRT 45 Gy in 5 fractions of 9 Gy|Patients will be treated using volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
11290601|NCT02761876|Experimental|Intervention (Participatory education)|Participatory education
11290602|NCT02761876|No Intervention|Control|Delayed participatory education
11290603|NCT02761863||CD74 - VEGF arm|
11290604|NCT02761837|Active Comparator|IVR call/text|Identify gaps in care and contact patients by IVR phone call or text
11290605|NCT02761837|Active Comparator|Email|Identify gaps in care and contact patients by email
11290606|NCT02761824|Experimental|Camp Discovery|One week activity based camp.
11290607|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
11290608|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
11290609|NCT02761798||Automated Mobile Interactive Audiometer, Test Retest|Each participant will act as his/her own control. The iPad audiogram will be compared to the audiogram in sound booth or to a second iPad audiogram.
11290610|NCT02761798||Automated Mobile Interactive Audiometer, Validation.|iPad testing will be compared to conventional audiometry in the sound booth.
11290611|NCT02761798||Automated Mobile Interactive Audiometer, Speech Recognition|Testing with NU-6 word lists will be conducted by the iPad and by an audiologist in the sound booth.
11290612|NCT02761798||Automated Mobile Interactive Audiometer, Cochlear Implant|Participants with cochlear implants will be tested using iPad against conventional audiometry (warble tone) in the sound booth.
11290613|NCT02761785||Celiacs with oat-related symptoms|Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats
11290614|NCT02761785||Celiacs without oat-related symptoms|Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats
11290615|NCT02761785||Healthy controls|Healthy controls (without celiac disease) who include oats in their diet
11290616|NCT02761785||Non-celiac gluten sensitive subjects|Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.
11290617|NCT02761772||PEP-A|See detailed description
11290618|NCT02761772||PEP-S|See detailed description
11290619|NCT02761746|Experimental|Intervention Condition (MESA)|MESA involves two sessions (ACASI assessment and intervention), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first MESA session is tailored based on how important and how confident the person feels about taking medications as prescribed. The participant is also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, the participant may engage in goal setting. The second MESA session focuses on adherence behavior over the previous month and the consequences (good or bad) of that behavior.
11290620|NCT02761746|No Intervention|Control Condition (SH)|The SH control condition involves two sessions (ACASI assessment and control condition), one at study entry (prior to beginning ART) and one a month later. Then, participants will complete ACASI assessments only at 3, 6, 9, and 12 months. The first SH session targets healthy eating and physical activity and is matched for dose and length of time of the intervention session. Feedback and education are provided, if desired. Finally, the participants may engage in goal setting for healthy eating and physical activity. The second SH session focuses on the goals set during the first session and behavior over the previous month.
11290621|NCT02761733|Experimental|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
11290622|NCT02761733|No Intervention|Control|Treatment as usual
11290623|NCT02761720||MyPennMedicine (MPM)|Participants assigned to this arm downloaded only the MyPennMedicine mobile app.
11290624|NCT02761720||MPM and Ginger iO|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app.
11290625|NCT02761720||Lottery|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app. They were also given a lottery incentive if they completed 70% of the daily mood ratings.
11290626|NCT02761707||Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Parkinson's Disease. Must be Hoehn and Yahr stage 2 or less with a history of motor symptoms less than two years.
11290720|NCT02761161|No Intervention|Treatment as usual|TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation
11290627|NCT02761707||Alzheimer's Disease|Non-smokers, ages 18-80, diagnosed with Alzheimer's Disease. Must meet the 2011 National Institute on Aging-Alzheimer's Association and the 1984 National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's disease and Related Disorders Association criteria for probable AD.
11290628|NCT02761707||Progressive Supranuclear Palsy|Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
11290629|NCT02761707||Essential Tremor|Non-smokers, ages 18-80, diagnosed with Essential Tremor.
11290630|NCT02761707||Drug-Induced Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Drug-Induced Parkinson's Disease.
11290631|NCT02761707||Myasthenia Gravis|Non-smokers, ages 18-80, diagnosed with Myasthenia Gravis.
11290632|NCT02761707||Multiple System Atrophy|Non-smokers, ages 18-80, who have been diagnosed with Multiple System Atrophy.
11290633|NCT02761707||Diffuse Lewy Body Disease|Non-smokers, ages 18-80, diagnosed with Diffuse Lewy Body Disease. Must meet the Consensus Criteria for the clinical diagnosis of DLBD.
11290634|NCT02761707||Healthy Controls|Non-smokers, ages 18-80, with no neurodegenerative disease, and no first-degree relatives with a neurodegenerative disease.
11290635|NCT02761707||Spinal Cord Injury|
11290636|NCT02761707||Asymptomatic Relatives|
11290637|NCT02761694|Experimental|ARQ 751|Subjects will receive ARQ 751 orally every day. Subjects will receive treatment with ARQ 751 until unacceptable toxicity, disease progression (clinical or radiological), or another of the discontinuation criteria is documented. It is expected that most subjects will receive between one and six cycles of ARQ 751 for a treatment period of 4 to 24 weeks.
11290638|NCT02761694|Experimental|ARQ 751 and fulvestrant|ARQ 751 will be administered orally every day (QD) of a 28-day cycle in combination with fulvestrant, which will be administered intramuscularly on Days 1 & 15 of Cycle 1 and Day 1 of all subsequent cycles. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
11290639|NCT02761694|Experimental|ARQ 751 and paclitaxel|ARQ 751 will be administered orally every day of a 28-day cycle in combination with paclitaxel, which will be administered intravenously on Days 1, 8 & 15 of each cycle. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
11290640|NCT02761681|Experimental|ACT-CL Web-based guided self-help|Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
11290641|NCT02761681|Active Comparator|Control Web-based guided self-help|Behavioral: Control Web-based guided self-help program This intervention will be created for the current study. It will involve psycho-education on how students might get the most out of counseling. Counselors will go through the psycho-education session before inviting students to participate.
11290642|NCT02761668|Experimental|ParS+Ortho 4W|Orthodontic alignment starts 4 weeks post surgical
11290643|NCT02761668|Active Comparator|ParS+Ortho 6M|Orthodontic alignment starts 6 months post surgical
11290644|NCT02761655|No Intervention|Control Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement.
11290645|NCT02761655|Experimental|Intervention Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement. The intervention group will further receive memory strategies training on encoding and retention, retrieval, as well as execution and monitoring.
11290646|NCT02761642|Experimental|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
11290647|NCT02761629|Experimental|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
11290648|NCT02761629|Active Comparator|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
11290649|NCT02761616||eBC treated participants|Participants with metastatic disease after previously being treated for eBC were observed for 24 months.
11290650|NCT02761603|Active Comparator|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
11290651|NCT02761603|Experimental|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
11290652|NCT02761590|Experimental|Circuit training protocol|"The CT protocol will be held in three sessions per week for 14 weeks. The volume of work is defined by the training section of time and intensity of effort by the heart rate response to exercise.
~The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. that concludes in favor of the organization of training adapted to the reality of the public to be trained."
11290721|NCT02761161|Active Comparator|Mianserin|10-30 mg of mianserin af sleep enhancing
11290722|NCT02761161|Active Comparator|Imagery Rehearsal Therapy|Therapy focusing on nightmares
11290723|NCT02761161|Active Comparator|mianserin and Imagery Rehearsal Therapy|Both mianserin and IRT
11290724|NCT02761148||Control|
11290653|NCT02761590|Active Comparator|Strength training protocol|"The strength training protocol was performed in three sessions per week for 14 weeks and divided into three levels.
~The initial load set for each exercise was based on the one repetition maximum test (1 RM). Strengthening exercises were performed in two sets of 15 repetitions, using 25% 1RM for hip adductors and abductors, and 50% 1RM for the quadriceps and hamstrings, using ankle weights. Exercises for the trunk were performed in 3 10-second series, increasing the duration when participants were able."
11290654|NCT02761590|No Intervention|Educational Protocol|In order to provide care, social interaction, and health education, an educational protocol was conducted. This protocol consisted in interactive presentations of 60 minutes, twice a month for 14 weeks, totaling 7 meetings. The topics addressed pathophysiology of osteoarthritis, and American College of Rheumatology (ACR) recommendations on nutrition, posture, and lifestyle.
11290655|NCT02761577|No Intervention|control|perorally 1500 ml water on the day of the procedure
11290656|NCT02761577|Experimental|Sodium bicarbonate|3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
11290657|NCT02761577|Experimental|N-acetylcysteine plus Sodium bicarbonate|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.
11290658|NCT02761564|Experimental|ScVO2 group|Anemia (<9g/dL) requiring blood transfusion Measure of ScvO2 : ScVO2 is measured using the central venous catheter placed in the superior vena cava. Transfusion is performed if the ScVO2 is inferior or equal to 65%.
11290659|NCT02761564|Other|Control group|Anemia (<9g/dL) requiring blood transfusion : Transfusion is performed following national guidelines for red blood cell transfusion
11290660|NCT02761551|No Intervention|Usual Care|Patients in this group will not receive any reminders for influenza vaccine.
11290661|NCT02761551|Experimental|1 notice|Patients in this group will receive one reminder for influenza vaccine across the 2016 influenza season.
11290662|NCT02761551|Experimental|2 notices|Patients in this group will receive up to two reminders for influenza vaccine across the 2016 season.
11290663|NCT02761551|Experimental|3 notices|Patients in this group will receive up to three reminders for influenza vaccine across the 2016 season.
11290664|NCT02761538|Experimental|AVIITAM Group|Utilization of the web platform Aviitam
11290665|NCT02761538|No Intervention|Control group|No utilization of web-platform Aviitam
11290666|NCT02761525|Experimental|gel silver nanoparticles|topic gel silver nanoparticles 12 ppm
11290667|NCT02761525|Placebo Comparator|placebo|topic innocuous gel
11290668|NCT02761512|Experimental|CJ-12420 50 mg QD|CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks
11290669|NCT02761512|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
11290670|NCT02761512|Active Comparator|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks
11290671|NCT02761499||Total Hip Arthroplasty|The United Hip System consist of several components, and for this clinical evaluation it includes the U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem.
11290672|NCT02761486|Active Comparator|Aspirin|The subjects will receive 325 mg of aspirin once a day for 6 weeks followed by a 6-week washout.
11290673|NCT02761486|Placebo Comparator|Placebo|The subjects will receive placebo once a day for 6 weeks followed by a 6-week washout.
11290674|NCT02761473||Patients with Urticaria Pigmentosa|This group will undergo skin biopsy, blood and buccal swab analyses
11290675|NCT02761473||Family members of affected patients|This group will undergo blood and buccal swab analyses
11290676|NCT02761460|Experimental|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy,
11290677|NCT02761447|Experimental|Treatment Traditional and Motor Imaginary Program|"Amputees patients also conservative protocol will undergo physiotherapy techniques work Motor Imaginary Program, based on a system of two videos that allow the patient to recreate the normal way. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases. This protocol will be applied 3 days a week (25-30minutos) for one month."
11290678|NCT02761447|Active Comparator|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
11290679|NCT02761434|Active Comparator|Dehydration|Infusion of 3% sodium chloride for osmotic stimulation of vasopressin
11290680|NCT02761434|Placebo Comparator|Euhydration|Infusion of 0.9% sodium chloride that will induce similar expansion of plasma volume without any significant change in osmolality and vasopressin
11290681|NCT02761421||patients with IOPD|observation all patients with IOPD
11290682|NCT02761395|Experimental|Group 1: ALhijama|20 patients under went Al-hijamah procedure for iron chelation
11290683|NCT02761395|Experimental|Group 2: AL-hijama with deferasirox|20 patients receive deferasirox and Al-hijamah.
11290684|NCT02761395|Active Comparator|Group 3:deferasirox|20 patients already receiving deferasirox
11290685|NCT02761382|Experimental|Mindfulness-based treatment|"The mindfulness-based psychological treatment consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT) and Acceptance and commitment therapy (ACT). The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:
~mindfulness-training (including meditation and yoga),
~therapy based on ACT, and
~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
11290725|NCT02761148||White matter hyperintensity|
11290726|NCT02761135||Side-fire|Using side-fire technique during transrectal ultrasound.
11290727|NCT02761135||End-fire|Using end-fire technique during transrectal ultrasound.
11300956|NCT02693093|Experimental|200 mg NI-03|TID Day for 28 Days
11290686|NCT02761382|Experimental|Non-specific treatment|"The non-specific general psychological treatment is matched the mindfulness-based psychological treatment and consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Client-centered therapy. The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:
~relaxation and physical training,
~therapy based on the non-specific factors of psychological treatment which emphasize a focus on the relation and alliance between the therapist and the client and the therapist being a warm empathic, non-directive and unconditionally accepting support, and
~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
11290687|NCT02761382|No Intervention|Waiting list control|Participants in this arm will be on the waiting list to participate in one of the two experimental treatments after a period of six months. Participants will receive medical treatment as usual in this period.
11290688|NCT02761369|Experimental|A PAS protocol, right-to-left, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the right DLPFC
11290689|NCT02761369|Experimental|A PAS protocol, left-to-right, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the left DLPFC
11290690|NCT02761369|Sham Comparator|A sham PAS protocol, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a sham PAS protocol, starting with the right DLPFC (@ 40% of individual MT)
11290691|NCT02761356||Tc99-MAA and SPECT-CT|26 of the patients were examined with Tc99-MAA and SPECT-C
11290692|NCT02761356||Tc99-MAA , SPECT-CT and PET-CT|24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT.
11290693|NCT02761343|Other|MRI scan|Post ablation MRI scan will be performed for all subjects who are clinically stable.
11290694|NCT02761330|Active Comparator|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
11290695|NCT02761330|Experimental|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
11290696|NCT02761330|Sham Comparator|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
11290697|NCT02761317|Active Comparator|GroupA：standard preparation|Subjects who are randomized into group A receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
11290698|NCT02761317|Experimental|Group B:low-volume preparation|Subjects who are randomized into group B receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure. ( 2L PEG-ELS and 10mg bisacodyl )
11290699|NCT02761317|Experimental|Group C：high-volume preparation|Subjects who are randomized into group C will receive 2L PEG-ELS at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure. (4 L PEG-ELS)
11290700|NCT02761304|Experimental|ultrasound results given to obstetrical practionnair|
11290701|NCT02761304|Other|ultrasound results shaded to obstetrical practionnair|
11290702|NCT02761291|Experimental|gemcitabine dose escalation|In three combined drugs used in nasopharyngeal carcinoma, the valproic acid and valganciclovir administration will be followed by indication to find the maximum tolerance dose of gemcitabine.
11290703|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression Before Polypectomy|A biopsy will taken in infertility patients with endometrial polyp before polypectomy
11290704|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression After Polypectomy|A biopsy will taken in infertility patients with endometrial polyp 1-3 months after polypectomy
11290705|NCT02761265|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
11290706|NCT02761265|Other|Control Group|Gait and balance testing to be administered once in healthy subjects
11290707|NCT02761252|Experimental|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
11290708|NCT02761252|Active Comparator|Bilastine+placebo montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
11290709|NCT02761252|Active Comparator|Montelukast+placebo bilastine|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
11290710|NCT02761239|Other|Cricopharyngeal muscle innervation|The recurrent laryngeal nerve (RLN), vagus nerve, external branch of the superior laryngeal nerve (EBSLN) and pharyngeal plexus were stimulated intraoperatively by the NIM 3.0 Nerve Monitoring System (Medtronic Xomed, Jacksonville, FL, USA). Responses were evaluated by visual observation of the cricopharyngeal muscle and electromyographies via needle electrodes inserted into the cricopharyngeal muscle.
11290711|NCT02761226|Experimental|Group A (Platform Matched Design)|10 Patients with missing tooth in upper posterior area will receive dental implant (implants with the same abutment diameter)
11290712|NCT02761226|Active Comparator|Group B (intervention - Platform Switching Design)|10 patients with missing tooth in upper posterior area will receive dental implant (implants with smaller diameter abutment)
11290713|NCT02761213|Experimental|Oral sulfate solution (OSS)|oral sulfate solution (OSS)
11290714|NCT02761213|Active Comparator|2-L PEG/Asc|low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)
11290715|NCT02761200||volunteer who completion of a recent ATI|
11290716|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
11290717|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
11290718|NCT02761174|Active Comparator|Brimonidine (Mirvaso cream)|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face (control) and 0.5 g of brimonidine (Mirvaso cream) to the randomized side of the face.
11290719|NCT02761174|Other|IPL+air-cooling|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face and IPL+air-cooling (control) are thereby compared to IPL+air-cooling+brimonidine (Mirvaso cream).
11300957|NCT02693093|Experimental|300 mg NI-03|TID Day for 28 Days
11290728|NCT02761122|Experimental|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.
~Human biological samples :
~Blood sample
~Skin or mucosal brushing
~Skin or mucosal biopsy"
11290729|NCT02761096|Experimental|Study group|The acupuncture intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). It will be given in addition to conventional treatments. All interventions will be performed by one Korean Medicine doctor with over 5 years of working experience with a college education of 6 years. This doctor will be trained in the study protocol before the start of the trial.
11290730|NCT02761096|Other|Control group|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery.
11290731|NCT02761083|Experimental|Novosyn® Quick|Eye surgery using suture material
11290732|NCT02761083|Active Comparator|Vicryl® Rapid|Eye surgery using suture material
11290733|NCT02761070|Active Comparator|Bevacizumab (BEV) alone|Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
11290734|NCT02761070|Experimental|Dose Dense Temozolomide Followed by BEV|Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
11290735|NCT02761057|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate PO on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11290736|NCT02761057|Experimental|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11290737|NCT02761057|Experimental|Arm III (crizotinib closed to accrual 12/5/18)|Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11290738|NCT02761057|Experimental|Arm IV (savolitinib closed to accrual 12/5/18)|Patients receive savolitinib PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11290739|NCT02761018|Experimental|Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
11290740|NCT02761018|Experimental|Fitness Tracker with Group Participation|will use a fitness tracker and will be able to see other member's daily and weekly results
11290741|NCT02761005|Experimental|23S rRNA wt|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
11290742|NCT02761005|Experimental|23S rRNA mutation|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains with mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,
11290743|NCT02760992|Active Comparator|Oral Baclofen|Subject will start baclofen at a 5 mg oral dose every 8 hours. Oral baclofen will be increased incrementally and self-administered over 13 days to a maximum dose of 20 mg every 8 hours. Following IV administration, subjects will be changed back to oral baclofen at a 15 mg dose self-administered every 8 hours and tapered off of baclofen over 15 days.
11290744|NCT02760992|Experimental|IV Baclofen|Subjects will be crossed over to 16 mg intravenous baclofen infused over 120 or 150 minutes every 8 hours for 11 doses.
11290745|NCT02760979|Active Comparator|Denosumab|Patients treated with Denosumab
11290746|NCT02760979|Placebo Comparator|Placebo|Patients treated with placebo
11290747|NCT02760966|Experimental|Alcohol 70º|Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
11290748|NCT02760966|Active Comparator|Soap|Umbilical cord care will be carried out using soap at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
11290749|NCT02760953|Experimental|TUR with Cryoablation|Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
11290750|NCT02760953|Active Comparator|TUR with instant instillation|Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
11290751|NCT02760940|Experimental|Oral liposomal iron treatment|Oral liposomal iron - 28 mg per day over 8 weeks
11290752|NCT02760927|Experimental|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
11290753|NCT02760914||Coronary heart disease|Patients with coronary heart disease undergoing planned coronary artery bypass surgery
11290754|NCT02760901|Active Comparator|Mannitol group|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
11290755|NCT02760901|Active Comparator|ACTZ group|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.
11290756|NCT02760901|Active Comparator|NAC group|patients received acetylcysteine NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.
11290757|NCT02760888|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
11290758|NCT02760888|Active Comparator|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
11290759|NCT02760888|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure
11290760|NCT02760875||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
11290832|NCT02760472|Active Comparator|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
11290761|NCT02760875||control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
11290762|NCT02760862|Active Comparator|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
11290763|NCT02760862|Active Comparator|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
11290764|NCT02760849|Experimental|Arm I (ISDO)|Patients undergo ISDO.
11290765|NCT02760849|Active Comparator|Arm II (RRSO)|Patients undergo RRSO.
11290766|NCT02760823|Active Comparator|Alpha Lipoic Acid|Subjects in this arm will receive ALA IV, as a dose of 600 mg/12 hours.
11290767|NCT02760823|Placebo Comparator|Non-Alpha Lipoic Acid|Subjects in this arm will to receive standard treatment only (without Alpha Lipoic Acid, instead they will receive placebo , which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment.
11290768|NCT02760810|Experimental|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
11290769|NCT02760797|Experimental|Part I (Dose-Finding Stage)|Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
11290770|NCT02760797|Experimental|Part II (Dose Expansion Stage)|Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
11290771|NCT02760784||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
11290772|NCT02760784||Control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.
~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
11290773|NCT02760771||with BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve
11290774|NCT02760771||without BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve
11290775|NCT02760758|Experimental|Cohort 1A HV|CDI-31244 20 mg active or placebo single dose (SD)
11290776|NCT02760758|Experimental|Cohort 2A HV|CDI-31244 50 mg active or placebo SD
11290777|NCT02760758|Experimental|Cohort 3A HV|CDI-31244 100 mg active or placebo SD
11290778|NCT02760758|Experimental|Cohort 4A HV|CDI-31244 200 mg active or placebo SD; food effect
11290779|NCT02760758|Experimental|Cohort 5A HV|CDI-31244 400 mg active or placebo SD
11290780|NCT02760758|Experimental|Cohort 6A HV|CDI-31244 200 mg active or placebo multiple dose (MD)
11290781|NCT02760758|Experimental|Cohort 7A HV|CDI-31244 200 mg active or placebo MD
11290782|NCT02760758|Experimental|Cohort 8A HV|CDI-31244 400 mg active or placebo MD
11290783|NCT02760758|Experimental|Cohort 1B HCV genotype (GT) 1|CDI-31244 400 mg active or placebo MD
11290784|NCT02760758|Experimental|Cohort 2B HCV GT 1|CDI-31244 600 mg active or placebo MD
11290785|NCT02760758|Experimental|Cohort 3B HCV GT 1|CDI-31244 800 mg active or placebo MD
11290786|NCT02760745||Febrile Shivering|
11290787|NCT02760745||Fever without Shivering|
11290788|NCT02760732|Experimental|drug eluting balloon group|patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .
11290789|NCT02760732|Experimental|drug eluting stent group|patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R&D Center Co., Ltd. China) implantation.
11290790|NCT02760719|Experimental|hypertonic saline|4 ml of nebulized 3 % hypertonic saline + salbutamol 0,03 ml/kg every 8 hours for the time of hospitalisation and standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
11290791|NCT02760719|No Intervention|supportive care|Standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
11290792|NCT02760693||bipolar patients|unselected admissions of bipolar patients
11290793|NCT02760680|Placebo Comparator|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
11290794|NCT02760680|Active Comparator|Diagnostic Device (WatchPAT 200 (TM))|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
11290875|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
11290795|NCT02760667|Experimental|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
11290796|NCT02760654|Experimental|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
11290797|NCT02760654|No Intervention|Control|Treatment as usual
11290798|NCT02760641|Experimental|Egg-based diet (EBD)|This arm will provide ≤25% energy from CHO, 25% energy from protein, and ≥50% energy from fat. EBD participants will be asked to consume ≥2 eggs per day along with other protein sources including meat, fish, pork, and poultry. Carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day.
11290799|NCT02760641|Placebo Comparator|Carbohydrate-based diet (CBD)|The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
11290800|NCT02760628|Experimental|The First Twenty (TF20)|Participants in TF20 will be provided an online wellness program focused on fitness and nutrition tailored to firefighters. TF20 is interactive and involves health coaching.
11290801|NCT02760628|Placebo Comparator|Life Simple Seven (LS7)|Participants assigned to the LS7 arm will be directed to a website that contains information about health and wellness from the American Heart Association that was developed for the general population. No health coaching is present and the site is not tailored for the fire service.
11290802|NCT02760615|Other|Part 1: UC and CD Participants|Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
11290803|NCT02760615|Other|Part 1: Healthy Participants|Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
11290804|NCT02760615|Experimental|Part 2: Vedolizumab|Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
11290805|NCT02760602|Experimental|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
11290806|NCT02760602|Experimental|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
11290807|NCT02760589||ACL tear - conservative|conservative treatment
11290808|NCT02760589||ACL tear - ACL reconstruction|reconstruction of the ACL with autologous tendons
11290809|NCT02760589||ACL tear - Internal brace|augmentation of the ruptured ACL with Internal brace
11290810|NCT02760589||healthy subjects|control group of healthy subjects with no previous injury
11290811|NCT02760576|Experimental|BAY 987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11290812|NCT02760563|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11290813|NCT02760550||never smokers|who have never smoked at all
11290814|NCT02760550||ex-smokers|formerly smokers but currently do not smoke at all
11290815|NCT02760550||current smokers|current smokers who, at the time of the survey, smoke any tobacco product either daily or occasionally. Social smokers fall into this category and are defined as those who smoke less than one cigarette per week or smoke only in some occasions
11290816|NCT02760537|Experimental|Lay Health Worker Intervention|LHWs conducted phone interventions by reminding participants of a series of vaccinations at months 1, 2, and 5 among those assigned to the intervention group. Those who had health insurance were encouraged to complete vaccinations through their providers. If participants did not have health insurance, LHWs provided resources to help those in the intervention access vaccinations by referring them to free vaccine events in the community.
11290817|NCT02760537|Placebo Comparator|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
11290818|NCT02760524|Experimental|Intervention|Subjects will receive NET intervention treatment immediately
11290819|NCT02760524|Active Comparator|Control|Subjects will receive NET intervention treatment and serve as a wait-list control
11290820|NCT02760511|Placebo Comparator|Control|Intake of placebo capsules
11290821|NCT02760511|Active Comparator|20 mg|Daily intake of 20 mg anthocyanin
11290822|NCT02760511|Active Comparator|40 mg|Daily intake of 40 mg anthocyanin
11290823|NCT02760511|Active Comparator|80 mg|Daily intake of 80 mg anthocyanin
11290824|NCT02760511|Active Comparator|160 mg|Daily intake of 160 mg anthocyanin
11290825|NCT02760511|Active Comparator|320 mg|Daily intake of 320 mg anthocyanin
11290826|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously every 2 weeks.
11290827|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered intravenously every 2 weeks.
11290828|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously every 3 weeks.
11290829|NCT02760498|Experimental|Group 4|Patients with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] Cemplimab administered intravenously every 4 weeks.
11290830|NCT02760498|Experimental|Group 6|Patients with advanced CSCC (metastatic [nodal or distant] or locally advanced). Cemiplimab administered IV every 3weeks.
11290831|NCT02760485|Experimental|itacitinib + ibrutinib|
11290833|NCT02760472|Experimental|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
11290834|NCT02760459|Active Comparator|Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.
11290835|NCT02760459|Placebo Comparator|Placebo|The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
11290836|NCT02760446|Other|CAM-ICU.fr|CAM-ICU and ICDSC evaluation proceed by two investigators and a Neuropsychologist (Speech & language therapist specialized in neuropsychology)
11290837|NCT02760433|Experimental|Arm 1: Olokizumab q4w + Methotrexate|Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral)
11290838|NCT02760433|Experimental|Arm 2: Olokizumab q2w + Methotrexate|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
11290839|NCT02760433|Placebo Comparator|Arm 3: Placebo q2w + Methotrexate|Placebo Subcutaneous q2w + Methotrexate (oral)
11290840|NCT02760420|Experimental|Placebo|250 mg of placebo (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
11290841|NCT02760420|Active Comparator|3 Days|250 mg amoxicillin (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
11290842|NCT02760407|Experimental|Arm 1: Olokizumab q4w + Methotrexate|Experimental, Olokizumab 64mg q4w Subcutaneous + Methotrexate (oral)
11290843|NCT02760407|Experimental|Arm 2: Olokizumab q2w + Methotrexate|Experimental, Olokizumab 64mg q2w Subcutaneous + Methotrexate (oral)
11290844|NCT02760407|Active Comparator|Arm 3: Adalimumab q2w + Methotrexate|Active Comparator, Adalimumab 40mg q2w Subcutaneous + Methotrexate (oral)
11290845|NCT02760407|Placebo Comparator|Arm 4: Placebo q2w + Methotrexate|Placebo Comparator, Placebo q2w Subcutaneous + Methotrexate (oral)
11290846|NCT02760394|Active Comparator|Treated group|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
11290847|NCT02760394|Other|Control group|Following 2 months of follow up the group will be crossed over to receive the same treatment as the treated group
11290848|NCT02760381|Experimental|Routine colonoscopy Cohort|Patients receiving routine colonoscopy receive the intervention: NBI + Acetic Acid (AA)
11290849|NCT02760368|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
11290850|NCT02760368|Experimental|Arm 2: Olokizumab q2w|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
11290851|NCT02760368|Placebo Comparator|Arm 3: Placebo|Placebo Subcutaneous q2w + Methotrexate (oral)
11290852|NCT02760355|Experimental|Active treatment|Ledipasvir 90 mg/Sofosbuvir 400 mg, one tablet once a day + b.w. dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks
11290853|NCT02760342|Experimental|ASP015K and Metformin|Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
11290854|NCT02760329||Chronic airways disease|Patients with suspected or primary diagnosis of asthma or COPD
11290855|NCT02760316|Experimental|AZD9567 oral suspension of 10 mg|Participants will receive oral supension of 10 mg dose strength
11290856|NCT02760316|Experimental|AZD9567 oral suspension of 20 mg|Participants will receive oral suspension of 20 mg dose strength
11290857|NCT02760316|Experimental|AZD9567 oral suspension of 40 mg|Participants will receive oral suspension of 40 mg dose strength
11290858|NCT02760316|Experimental|AZD9567 oral suspension of 80 mg|Participants will receive oral suspension of 80mg dose strength
11290859|NCT02760316|Active Comparator|Prednisolone oral capsules of 20 mg|Participants will receive oral capsules of 5 mg dose strength
11290860|NCT02760316|Experimental|AZD9567 oral suspension of 125 mg|Participants will receive oral suspension of 125 mg dose strength
11290861|NCT02760316|Experimental|AZD9567 oral suspension of 155 mg|Participants will receive oral suspension of 155 mg dose strength
11290862|NCT02760316|Active Comparator|Prednisolone oral capsules of 5 mg|Participants will receive oral capsules of 5 mg dose strength
11290863|NCT02760316|Active Comparator|Prednisolone oral capsules of 40 mg|Participants will receive oral capsules of 5 mg dose strength
11290864|NCT02760303|Experimental|Cognitive Behavioral Therapy|Hains' adaptation of cognitive behavioral therapy for adolescents and young adults with type 1 diabetes
11290865|NCT02760303|Experimental|Mindfulness Based Stress Reduction|Sabinga's adaptation of Mindfulness Based Stress Reduction for adolescents and young adults with type 1 diabetes
11290866|NCT02760303|Active Comparator|Diabetes Support and Education|Investigator developed peer support group and diabetes education
11290867|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
11290868|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
11290869|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
11290870|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
11290871|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
11290872|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
11290873|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
11290874|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
11290876|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
11290877|NCT02760251|Experimental|Romiplostim|Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
11290878|NCT02760238||Patients with a diagnosis of MPN|"Patients with a myeloproliferative neoplasm (MPN) diagnosis:
~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T"
11290879|NCT02760225|Experimental|89Zr-Pembrolizumab PET imaging|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
11290880|NCT02760212|Experimental|Group 1 - Radial Shockwave Therapy Group|Participants in Group 1 will receive RSWT to the most painful spot within each of the 3 most painful regions as described by the participant. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with treatment to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot.
11290881|NCT02760212|Placebo Comparator|Group 2 - Placebo Group|Participants in Group 2 will receive a placebo treatment with a soft rubber cap applied to the applicator, leaving air between the transmitter and the cap and the participant's skin so that no shockwave will be generated nor applied to the participant's skin. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with placebo treatment to the painful areas will be undertaken with 2000 placebo shocks (15 Hz) producing an audible sound but no therapeutic dosage to the most painful spot. Upon completion of the placebo treatment, participant's will be offered the experimental treatment but this data will not be used for comparison and analysis.
11290882|NCT02760199|Experimental|89Zr-AMG211 and 89Zr-AMG211 PET|
11290883|NCT02760186|Experimental|Altitude Exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
11290884|NCT02760173|Experimental|Single intervention arm|This is the only arm in this study, measuring verticality perception after prolonged roll-tilt over 5min.
11290885|NCT02760160|Other|Reconstituted grape powder|Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
11290886|NCT02760147|Other|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
11290887|NCT02760147|Other|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
11290888|NCT02760147|Other|PEEP Over Level|PEEP Level upward by 50%, 2 hours
11290889|NCT02760147|Other|PEEP Under Level|PEEP Level downward by 50%, 2 hours
11290890|NCT02760134|Other|SMP with F14 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F14 suction-evacuation sheath.
11290891|NCT02760134|Other|SMP with F12 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F12 suction-evacuation sheath.
11290892|NCT02760121|Experimental|Acetazolamide|Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
11290893|NCT02760121|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
11290894|NCT02760121|Placebo Comparator|Placebo|Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
11290895|NCT02760108||Index case|Patients with a family history of Parkinson's/parkinsonism, and/or early onset Parkinson's/parkinsonism. The first individual member from a family who is recruited to the study.
11290896|NCT02760108||Affected relatives|Patients with Parkinson's/parkinsonism who are first or second degree relatives of an Index Case.
11290897|NCT02760108||Unaffected relatives|Participants who do not have Parkinson's/parkinsonism and are first or second degree relatives of an Index Case.
11290898|NCT02760095||Children with EED|Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
11290899|NCT02760095||Children without EED|Children are placed in this arm if they screen negative for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
11290900|NCT02760082||Semi-structured interviews|20 participants (anticipated)
11290901|NCT02760082||Questionnaire survey|400 respondents (anticipated)
11290902|NCT02760082||Focus group interviews|3-5 focus group interviews (anticipated)
11290903|NCT02760069|Active Comparator|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
11290904|NCT02760069|Experimental|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
11290905|NCT02760069|Active Comparator|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
11290906|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
11290907|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
11290910|NCT02760030|Experimental|Treatment (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11290911|NCT02760017|Placebo Comparator|placebo|capsules containing placebo for B forticata
11290912|NCT02760017|Experimental|B. forficata|capsules of B. forficata containing 200 mg of plant extracts
11290913|NCT02760004|Experimental|Prism Intervention|PRogram In Support of Moms (PRISM)
11290914|NCT02760004|Experimental|Enhanced Usual Care|Enhanced Usual Care group (Access to MCPAP for Moms)
11290915|NCT02759991|Active Comparator|HEV vaccine|Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
11290916|NCT02759991|Placebo Comparator|HBV vaccine|Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
11290917|NCT02759978||Suspicion NVE|Patients with suspicion of native valve endocarditis, infective endocarditis and no intracardiac prosthetic material in situ
11290918|NCT02759978||Suspicion (PVE)|Patients with a suspicion of prosthetic valve endocarditis (PVE), infective endocarditis and one or more prosthetic valves in situ
11290919|NCT02759978||Suspicion pacemaker/ICD related endocarditis|Patients with a suspicion of infective endocarditis and a pacemaker or implantable cardiac defibrillator (ICD) in situ
11290920|NCT02759939|Experimental|Arm 1|
11290921|NCT02759939|Experimental|Arm 2|
11290922|NCT02759939|Experimental|Arm 3|
11290923|NCT02759939|No Intervention|Arm 4|
11290924|NCT02759926|Active Comparator|Denatonium benzoate intragastric|1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
11290925|NCT02759926|Active Comparator|Quinine hydrochloride intragastric|10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
11290926|NCT02759926|Placebo Comparator|Tap water intragastric|An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.
11290927|NCT02759926|Active Comparator|Denatonium benzoate intraduodenal|1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
11290928|NCT02759926|Active Comparator|Quinine hydrochloride intraduodenal|10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
11290929|NCT02759926|Placebo Comparator|Tap water intraduodenal|An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
11290930|NCT02759913||Amyotrophic lateral sclerosis|Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
11290931|NCT02759913||ALS mimics|Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection
11290932|NCT02759900|Experimental|Non-thermal atmospheric plasma treatment|Device treatment
11290933|NCT02759900|Experimental|Indirect non-thermal atmospheric plasma treatment|A compound of non-thermal atmospheric plasma and medium is used to treat the target by direct application or by on-site generation of the compound
11290934|NCT02759887|Other|DS adult group|Consists of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
11290935|NCT02759887|Other|DS/AD group|Consists of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by DSM-IV criteria. Diagnoses will be by standard consensus review of all cases. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
11290936|NCT02759887|Other|NC adult|Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
11290937|NCT02759874|Experimental|Experimental|Intervention is pregnant women enrolled and using specialized breathalyzer device w face recognition technology linked to a cellphone
11290938|NCT02759874|No Intervention|Control Group|No intervention. No breathalyzer given. Access granted by participant to IHE to collect data from Alberta Health Services (medical records)
11290939|NCT02759861|Experimental|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
11290940|NCT02759848||with history of TB|
11290941|NCT02759848||without history of TB|
11290942|NCT02759835|Experimental|Arm 1|osimertinib followed by LAT followed by osimertinib
11290943|NCT02759835|Experimental|Arm 2|LAT followed by osimertinib
11290944|NCT02759822||Group A: Acute Lymphoblastic Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)
~Preferred conditioning:
~Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)
~Alternative conditionings:
~Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)
~Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)"
11290945|NCT02759822||Group B: Acute Myeloid Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200
~Alternative conditionings:
~Bu9,6 + Flu150 + TBI200
~Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF"
11290946|NCT02759809||Children previously assigned to donor milk in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive donor milk when mother's own breastmilk was unavailable. Donor milk was from a milk bank part of the Human Milk Banking Association of North America (HMBANA).
11290977|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
11290947|NCT02759809||Children previously assigned to formula in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive preterm formula when mother's own breastmilk was unavailable. Preterm formula was either Similac Special Care or Enfamil Premature depending on hospital contract with formula companies.
11290948|NCT02759796|Placebo Comparator|Clinical assessment of flap perfusion|Tailoring the flap according to clinical assessment of flap perfusion
11290949|NCT02759796|Experimental|Angiography assessment of flap perfusion|Tailoring the flap according to ICG Angiography assessment of flap perfusion
11290950|NCT02759783|Active Comparator|Standard of Care|Standard of care (SOC) is at the discretion of the local oncologist.
11290951|NCT02759783|Experimental|Standard of Care + SBRT|Patients randomised to SBRT will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC.
11290952|NCT02759770||ARDS|ARDS patients after cardiac surgery
11290953|NCT02759770||non-ARDS|non-ARDS patients after cardiac surgery
11290954|NCT02759770||propective group|patients of cardiac surgery including ARDS and non-ARDS patients
11290955|NCT02759757|Experimental|Kinesio Taping|"Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a I position bilaterally."
11290956|NCT02759757|Placebo Comparator|Placebo|Patient from this group will receive a 5cm-wide Micropore® tape from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae bilaterally.
11290957|NCT02759757|No Intervention|Control|Patients allocated will not receive any intervention.
11290958|NCT02759744|Experimental|1|ultrasound image-guided focal laser ablation device
11290959|NCT02759731|Experimental|Arm 1|Baricitinib starting at a dose of 2mg daily for 12 weeks. If the response at 12 weeks is a CR and there has not been a DLT, the dose will be remain at 2mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks, the dose will be decreased to 1mg daily, and will continue at this dose as tolerated. If there has been DLT at this dose (1 mg), patients will be taken off treatment.
11290960|NCT02759731|Experimental|Arm 2|If the response is a PR or stable disease (from cohort 1), the dose will be increased to 4mg daily for an additional 12 weeks. If there has been a DLT within the first 4 weeks will have a dose reduction back to 2mg daily. For patients who experience cGVHD progression at any time within the first 12 weeks on 2mg daily, the dose can be increased to 4mg daily until 24 weeks.
11290961|NCT02759718|Experimental|pancreatic neuroendocrine tumor|chromogranin A
11290962|NCT02759692|Active Comparator|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
11290963|NCT02759692|Active Comparator|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
11290964|NCT02759679|Other|Lung cancer|Patients with lung cancer
11290965|NCT02759679|Other|Controls|Controls being either healthy or having other lung disease
11290966|NCT02759666|Experimental|SHR3162|"3 to 6 participants (traditional 3+3 design) will be enrolled in 6 dose levels. SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6."
11290967|NCT02759653||Symptomatic|Symptomatic carotid artery disease
11290968|NCT02759653||Asymptomatic|Asymptomatic carotid artery disease
11290969|NCT02759640|Experimental|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
11290970|NCT02759627|No Intervention|Conventional Training|Conventional physical therapy consisted of neurophysiological concepts such as Bobath and Brunnstrom.Training sessions focused on static and dynamic postural tasks, improving lower and upper extremity range of motion, strengthening and overground walking. During walking training, emphasis was on distance walked than on gait quality. Symmetrical weight distribution was encouraged through verbal and tactile cues and was made more difficult by the addition of arm activities or actions requiring trunk rotation. In an effort to improve rhythmic weight-shifting ability, subjects practiced shifting their weight in forward and backward directions and side to side while performing reaching tasks. A session lasted 45 minutes, for 5 days per week for 6 weeks.
11290971|NCT02759627|Experimental|Robotic-Assisted Gait Training|Lokomat (Hocoma) was used in Robotic-Assisted Gait Training group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait. Robotic-Assisted Gait Training sessions lasted 45-minute sessions, 2 days a week during 6 weeks.
11290972|NCT02759627|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
11290973|NCT02759614|Experimental|Bevacizumab and Erlotinib|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
11290974|NCT02759614|Active Comparator|Erlotinib|Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
11290975|NCT02759601|Other|Tefinostat|"This is an open label, dose escalating, phase I/II study of Tefinostat administered orally, once or twice daily in 28 day cycles of treatment in patients with advanced hepatocellular carcinoma.
~Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II."
11290976|NCT02759588|Experimental|GL-ONC1|
11290978|NCT02759562|Experimental|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
11290980|NCT02759562|Experimental|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
11290981|NCT02759562|Experimental|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
11290982|NCT02759562|Placebo Comparator|Placebo (Part 2)|Placebo weekly for 8 weeks
11290983|NCT02759562|Experimental|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
11290984|NCT02759549|Experimental|eSMART-MH|Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
11290985|NCT02759549|Other|Theater Testing|Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
11290986|NCT02759536|Experimental|Boronophenylalanine and IHNI-based BNCT|
11290987|NCT02759510|Active Comparator|phenylephrine|phenylejphrine (one bolus for 40 ug/ml)
11290988|NCT02759510|Experimental|norepinephrine|norepinephrine (one bolus for 2 ug/ml)
11290989|NCT02759497||Serum amyloid A level in SBP|serum amyloid A level
11290990|NCT02759497||Serum amyloid A level in cirrhosis|Serum amyloid A level
11290991|NCT02759484|Experimental|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
11290992|NCT02759484|Active Comparator|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
11290993|NCT02759471|Experimental|comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
11290994|NCT02759471|Active Comparator|comfilcon A sphere (control)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
11290995|NCT02759458|Experimental|Healicoil|Patients that met the inclusion criteria who were randomly selected to receive the Healicoil anchor for their rotator cuff repair.
11290996|NCT02759458|Active Comparator|Twinfix|Patients that met the inclusion criteria who were randomly selected to not receive the Healicoil anchor for their rotator cuff repair.
11290997|NCT02759432|Experimental|Intervention|Participants in the intervention group will complete a 4-week school-based high-intensity interval exercise training programme. The intervention will take place twice per week, and comprise of 6-8 repetitions of 45 s maximal effort exercise (boxing, running, soccer and basketball drills), each interspersed with 90-s rest. Participants will be encouraged to work maximally during the 45-s repetitions.
11290998|NCT02759432|No Intervention|Control|Participants in the control group will be instructed not to change their lifestyle, dietary or physical activity habits during the intervention period, and maintain their normal school physical education routine
11290999|NCT02759419|Experimental|BAY63-2521|Single-arm, uncontrolled
11291000|NCT02759406|Experimental|Mach-5 Grooved|grooved
11291001|NCT02759406|Experimental|Mach 5 Bare Metal|bare metal
11291002|NCT02759393|Experimental|DEX group|receiving 8-week dexlansoprazole 60 mg per day
11291003|NCT02759393|Active Comparator|Double-dose PPI group|receiving 8-week lansoprazole 30 mg twice daily
11291004|NCT02759380|Experimental|Phytoestrogen-rich foods|"Introduced to the study by a dietitian.
~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).
~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.
~Called one time during the study and perform a 24-hour recall.
~The intervention continues until the day before the surgery (at least 6 weeks).
~The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
11291005|NCT02759380|No Intervention|Control group|"Introduced to the study by a dietitian.
~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).
~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.
~Called one time during the study and perform a 24-hour recall.
~The intervention continues until the day before the surgery (at least 6 weeks)."
11291006|NCT02759367|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
11291007|NCT02759367|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake.
11291008|NCT02759354|Experimental|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
11291009|NCT02759354|Active Comparator|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
11291010|NCT02759354|Experimental|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
11291011|NCT02759354|Active Comparator|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
11291012|NCT02759341|Other|Cardiac X Syndrome (CSX)|patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)
11291013|NCT02759341|Other|Takotsubo Cardiomyopathy (TTC)|Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)
11291014|NCT02759341|Other|Acute myocardial infarction (AMI)|Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)
11291015|NCT02759328|Experimental|Xbox Kinect™ training group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program plus 60 minutes/day, 5 days/week, 4 weeks (20 sessions) Xbox Kinect™ upper extremity training. Two games both of which require using upper extremities, were chosen and each game was played for 30 minutes per session.
11291816|NCT02754024||Total shoulder arthroplasty (TSA)|Replacement of humeral head and glenoid
11291016|NCT02759328|Active Comparator|Conventional rehabilitation group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program only. The treatment protocol was individualized according to the goals which were determined depending on each patient's needs and functional level.
11291017|NCT02759315|Experimental|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
11291018|NCT02759315|Experimental|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
11291019|NCT02759315|Experimental|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
11291020|NCT02759315|Experimental|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
11291021|NCT02759315|Experimental|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
11291022|NCT02759315|Experimental|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
11291023|NCT02759302||Patients with LGMD2N|Five patients over 18 years old with genetically verified LGMD2N
11291024|NCT02759289||Group A|Prediabetes glycohemoglobin test A1c 5.7-6.4%
11291025|NCT02759289||Group B|"T2D glycohemoglobin test= A1c 6.5-7.9% without T2D medications
~T2D glycohemoglobin test=A1c ≥ 8.0% with/without T2D medications"
11291026|NCT02759289||Group C|Control
11291027|NCT02759276||Resistant Hypertension (RH)|uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
11291028|NCT02759276||Stages 1 and 2 Hypertension (MMH)|According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
11291029|NCT02759276||Normotensive (CG)|Blood Pressure <140/90 mmHg and without comorbidities.
11291030|NCT02759263|Experimental|Working Memory Intervention|The group randomized to the Working Memory intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the adolescents' responses, time spent on each task, and evolution curves.
11291031|NCT02759263|No Intervention|Control group - Standard of Care|Adolescents randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, an adolescent in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like adolescents assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
11291032|NCT02759250|Experimental|adjuvant monotherapy|ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
11291033|NCT02759250|Experimental|metastatic/recurrent monotherapy|ARGX-110 5mg/kg once every three weeks until disease progression
11291034|NCT02759250|Experimental|metastatic/recurrent combination therapy|ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
11291035|NCT02759237||Patient Group|Patients identified for treatment of symptomatic aortic sten
11291036|NCT02759224|Other|Arm A (Lafutidine and Irsogladine maleate --> BRI-1501)|Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day
11291037|NCT02759224|Other|Arm B (BRI-1501 --> Lafutidine and Irsogladine maleate)|Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day
11291038|NCT02759211|Active Comparator|Forwards Walking Group (FWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
11291039|NCT02759211|Experimental|Backwards Walking Group (BWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
11291040|NCT02759198|Experimental|YH23537|YH23537 750/1500/3000mg
11291041|NCT02759198|Active Comparator|Celebrex|Celecoxib 200mg
11291043|NCT02759185|Experimental|High THC marijuana|Provided with up to 1.8 g of marijuana with more tetrahydrocannabinol than cannabidiol
11291044|NCT02759185|Experimental|High CBD marijuana|Provided with up to 1.8 g of marijuana per day of marijuana with more cannabidiol than tetrahydrocannabinol
11291045|NCT02759185|Experimental|High THC/high CBD marijuana|Provided with up to 1.8 g per day of marijuana with an approximately equal amount of tetrahydrocannabinol and cannabidiol
11291046|NCT02759185|Placebo Comparator|Placebo marijuana|Provided with 1.8 per day of marijuana with very low levels of tetrahydrocannabinol and cannabidiol
11291047|NCT02759172|Experimental|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
11291048|NCT02759172|No Intervention|Standard Care|Standard Care for pretrial jail detainees is assessment of risk and stabilization to the extent possible during their jail detention. No post-release community follow-up is typically provided. This study will augment standard care with regular assessment and emergency referral post-release, as well as provision of a list of community resources.
11291049|NCT02759159|Experimental|AD-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on AD patients"
11291050|NCT02759159|Sham Comparator|AD-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on AD patients"
11291051|NCT02759159|Experimental|Mild Cognitive Impairment(MCI)-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on MCI patients"
11291052|NCT02759159|Sham Comparator|MCI-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on MCI patients"
11291053|NCT02759146|Experimental|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
11291054|NCT02759146|Experimental|Mindfulness Meditation|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
11291055|NCT02759146|No Intervention|Control|Control - no intervention
11291056|NCT02759133|Active Comparator|A - A standard Localization technique|A standard Localization technique : Metal wire as localization technique for breast cancer surgery
11291057|NCT02759133|Experimental|B - Experimental Localization technique|Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery
11291058|NCT02759120|Experimental|Antimicrobial therapy|Co-trimoxazole OR doxycycline
11291059|NCT02759120|Other|Standard of care|Standard of care for patients with IPF for comparison
11291060|NCT02759107|Experimental|LY3298176 (Part A)|Escalating doses of LY3298176 administered subcutaneously (SC) once in healthy participants.
11291061|NCT02759107|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants.
11291062|NCT02759107|Experimental|LY3298176 (Part B)|Escalating doses of LY3298176 administered SC once weekly for four weeks in healthy participants.
11291063|NCT02759107|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants.
11291064|NCT02759107|Active Comparator|Dulaglutide (Part B)|Dulaglutide administered SC once weekly for four weeks in healthy participants
11291065|NCT02759107|Experimental|LY3298176 (Part C)|Two dose levels of LY3298176 administered SC once weekly for four weeks in participants with T2DM.
11291066|NCT02759107|Placebo Comparator|Placebo (Part C)|Placebo administered SC once weekly for four weeks in participants with T2DM.
11291067|NCT02759094|Experimental|Treatment with RefluxStop device|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ at all time
11291068|NCT02759081|Active Comparator|water exchange|The air was turned off at the beginning of colonoscopy. Water was infused and suctioned at the same time during insertion. The air was turned on when the colonoscope reached the cecum.
11291069|NCT02759081|Experimental|cap-assisted water exchange|Cap was mounted to the tip of the colonoscope when water exchange was performed.
11291070|NCT02759068|Experimental|patients behavior|Behavior (motor reaction) to stimuli (sounds and odors)
11291071|NCT02759068|Active Comparator|healthy volunteers behavior|Behavior (motor reaction) to stimuli (sounds and odors)
11291072|NCT02759055|Experimental|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
11291073|NCT02759055|No Intervention|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
11291074|NCT02759029|Active Comparator|Susceptibility-guided group|Drugs according to antimicrobial susceptibility-guided treatment
11291075|NCT02759029|Sham Comparator|triple therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
11291076|NCT02759029|Sham Comparator|concomitant therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
11291077|NCT02759016|Experimental|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
11291078|NCT02759003|Active Comparator|inpatients group|"In-hospital nightime NIV initiation. For the inpatients Group, NIV was initiated in the respiratory wards of the two hospitals and continued during night for a minimum of 4 hours/night.
~Inpatients had a 24-h availability of health staff care. During the night, they had nurses and physicians available on-hand."
11291628|NCT02755272|Active Comparator|Standard Chemotherapy Alone|Standard chemotherapy alone using carboplatin and gemcitabine.
11291079|NCT02759003|Experimental|outpatients group|"Home nightime NIV initiation. For the outpatients group, diurnal NIV was initiated during a scheduled visit in a hospital dedicated room(at least 4 hours/day of care), the trial proceeded at home during the night with a personal caregiver.
~A minimum of 4 hours/night was required. No support during the night was provided to these patients."
11291080|NCT02758990|Experimental|Predictions: BMI vs. Broccoli|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291081|NCT02758990|Experimental|Predictions: BMI vs. Caffeine|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291082|NCT02758990|Experimental|Predictions: BMI vs. Coffee|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291083|NCT02758990|Experimental|Predictions: BMI vs. Spinach|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291084|NCT02758990|Experimental|Predictions: BMI vs. Vitamin A|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291085|NCT02758990|Experimental|Predictions: BMI vs. Vitamin C|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291086|NCT02758990|Experimental|Predictions: Headache vs. Vitamin B6|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291087|NCT02758990|Experimental|Predictions: Headache vs. Vitamin C|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291088|NCT02758990|Experimental|Predictions: Headache vs. Nicotinamide|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291089|NCT02758990|Experimental|Predictions: Headache vs. Axon Eyewear|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291090|NCT02758990|Experimental|Predictions: Rhinitis vs Broccoli|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291091|NCT02758990|Experimental|Predictions: Rhinitis vs Caffeine|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291092|NCT02758990|Experimental|Predictions: Rhinitis vs Chocolate|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291093|NCT02758990|Experimental|Predictions: Rhinitis vs Coffee|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291094|NCT02758990|Experimental|Predictions: Rhinitis vs Vitamin A|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291095|NCT02758990|Experimental|Predictions: Insomnia vs Axon Eyewear|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291096|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin A|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291097|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin E|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291098|NCT02758990|Experimental|Predictions: Insomnia vs Nicotinamide|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291629|NCT02755259|Experimental|Acetazolamide|Diamox 500mg i.v. (1x)
11291099|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin D3|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291100|NCT02758990|Experimental|Predictions: Joint pain vs Broccoli|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291101|NCT02758990|Experimental|Predictions: Joint pain vs Caffeine|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291102|NCT02758990|Experimental|Predictions: Joint pain vs Coffee|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291103|NCT02758990|Experimental|Predictions: Joint pain vs Spinach|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
11291104|NCT02758977|Experimental|ALPPS|"ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS)
~Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) is performed according to local practice in the respective centers. Preconditions to participation are experience with major liver resections and documentation of having performed at least 5 ALPPS cases prior to participation due to the learning curve with this quite complex procedure.
~The amount of transsection (in-situ split/liver partition) in Step 1 is left to the participating center, no minimal % of transsection is specified."
11291105|NCT02758977|Active Comparator|TWO STAGE HEPATECTOMY|"TWO STAGE HEPATECTOMY (TSH)
~Two-Stage Hepatectomy is defined as:
~Partial resection + portal vein ligation (RES PVL)
~Partial resection + secondary portal vein embolization (RES PVE). Followed by (extended) hemihepatectomy after an interval to induce hypertrophy of the liver.
~Conventional Two- Stage Hepatectomies will be standard procedures of the centers participating in the study."
11291106|NCT02758951|Experimental|Perioperative systemic therapy and CRS-HIPEC|"At the discretion of the treating physician, perioperative systemic therapy consists of either four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by either four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four (FOLFOX/FOLFIRI) neoadjuvant cycles.
~CRS-HIPEC is performed according to the Dutch protocol in all study centres."
11291107|NCT02758951|Active Comparator|Upfront CRS-HIPEC alone|CRS-HIPEC is performed according to the Dutch protocol in all study centres.
11291108|NCT02758938|Experimental|Patient Subjects|Patients that are part of the UW LUTD Program (n=30) will undergo 3 weekly biofeedback sessions each lasting 1 hour. All interactive biofeedback sessions will be conducted by American Family Children's Hospital nurses that are experienced in standard biofeedback techniques. After the patient has completed all of the biofeedback sessions, he/she will complete a feedback form about their satisfaction with the device.
11291109|NCT02758938|Experimental|Biofeedback Nurse Subjects|"The nurses (n=3) involved in the biofeedback portion of the UW LUTD Program will undergo a Nurse Training Session where they will be asked to think aloud while completing an outlined scenario. Their feedback will be used to update the software to make it more user friendly. After the session, they will be asked to complete the System Usability Scale (SUS). Additionally, after guiding patients through biofeedback sessions using the new software, they will be asked to complete the Nurse Feedback Form."
11291110|NCT02758938|Experimental|Biofeedback Physician Subject|The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
11291111|NCT02758938|Experimental|Focus Group Subjects|A Focus Group session will involve the physician involved in this study, an advisor on the project and staff involved in the project as well as three random individuals outside of the project (n=7). These individuals will provide feedback on the software that will be used to improve the software.
11291112|NCT02758925|Experimental|DLBCL patients|they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles
11291113|NCT02758912|Experimental|arm 1, Cardionat®|oral intake of study drug capsules at a dose of 1 g per day for 3 weeks.
11291114|NCT02758912|Experimental|arm 2, Cardionat®|oral intake of study drug capsules at a dose of 2 g per day for 3 weeks.
11291115|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
11291116|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
11291117|NCT02758886|Experimental|Stress reduction method|Participants randomized into the PYSA group engaged in a 10 minute direct interaction with the animals (dogs and cats) of the Pet Your Stress Away program
11291118|NCT02758886|Placebo Comparator|Control|Participants randomized into the Control group watched a 10 minute slide show of dog and cat photos
11291119|NCT02758886|No Intervention|Non-treatment|Participants randomized into the No-treatment group silently waited for 10 minutes without engaging in any physical or electronic social interactions.
11291120|NCT02758886|Placebo Comparator|Observation|Participants randomized into the observation group observed 10 minutes of others in the general PYSA program petting cats and dogs, while they 'waited in line' for there turn.
11291282|NCT02757781|No Intervention|Control Group|Group of healthcare professionals that NOT receive the intervention (community of practice)
11291121|NCT02758873|Experimental|Personalised Medicine|If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.
11291122|NCT02758873|Active Comparator|Standard care|If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.
11291123|NCT02758847|Other|Critical Limb Ischemia (CLI) and Tissue Loss|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent
11291124|NCT02758821|Other|CRP-Control|The health care provider will manage the patient using standard guidelines. No CRP will be measured onsite
11291125|NCT02758821|Other|CRP-A|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
11291126|NCT02758821|Other|CRP-B|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
11291127|NCT02758795|Placebo Comparator|CONTROL|A placebo nutrient drink with no anti-inflammatory bioactivity (measure by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
11291128|NCT02758795|Active Comparator|NUTRIENT|A nutrient drink with confirmed anti-inflammatory bioactivity (measured by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
11291129|NCT02758782|Active Comparator|Golimumab monotherapy|Treatment with 50 mg Golimumab subcutaneous once monthly
11291130|NCT02758782|Active Comparator|Golimumab combined with Celecoxib|Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day
11291131|NCT02758769||ORENCIA with Exposure|ORENCIA with Exposure
11291132|NCT02758756|Active Comparator|Massage|Subjects assigned to Arm 1 will receive two massage treatments approximately two weeks apart.
11291133|NCT02758756|Experimental|Two Reiki Tx|Subjects assigned to Arm 2 will receive two Reiki treatments approximately two weeks apart.
11291134|NCT02758756|Experimental|Four Reiki Tx|Subjects assigned to Arm 3 will receive four Reiki treatments approximately 1 week apart.
11291135|NCT02758743|Experimental|Acetium Lozenge|Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.
11291136|NCT02758743|Placebo Comparator|Placebo|Identical in appearance with Acetium lozenge, placebo lozenges will be used in the same manner as in experimental arm.
11291137|NCT02758730|Experimental|AFFITOPE® PD01A + Adjuvant|3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
11291138|NCT02758730|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks
11291139|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
11291140|NCT02758704|Experimental|High-Stress (HS)|In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
11291141|NCT02758704|Active Comparator|Low-Stress (LS)|In the LS environment, there will be absence of audio (alarms), physical (third-party supervisor, nurse and respiratory therapist) and situational (unstable infant) stressors.
11291142|NCT02758691|Experimental|Intranasal Insulin|Healthy participants will self-administer 20 IU of Humulin® R U-100 with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
11291143|NCT02758691|Placebo Comparator|Saline Placebo|Healthy participants will self-administer a saline solution with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
11291144|NCT02758678||1-patients with operating tumor|"1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin.
~Will be compared concentration of P-selectin in 3 groups of patients.
~Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
11291145|NCT02758678||2-patients with advanced desease.|"2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy);
~In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:
~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above"
11291146|NCT02758678||3-patients with inoperable disease|"In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:
~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
11291147|NCT02758665|Experimental|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
11303491|NCT02676336|Placebo Comparator|Placebo|3mg placebo daily
11291148|NCT02758639|Experimental|W & W Intervention|Wonders & Worries Psychosocial intervention is a 6 week group or individual sessions for children who have a parent with cancer focusing on psycho-educational information about cancer, treatment and its side effects, feelings expression, positive coping strategies, and family communication about the illness.
11291149|NCT02758639|Other|Wait list control|Wait list group will complete baseline, 6 week and 8 week follow up measures and then will be enrolled to receive W & W intervention.
11291150|NCT02758626|Active Comparator|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
11291151|NCT02758626|Active Comparator|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
11291152|NCT02758613|Experimental|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
11291153|NCT02758613|Experimental|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
11291154|NCT02758613|Experimental|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
11291155|NCT02758613|Placebo Comparator|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
11291156|NCT02758600|Experimental|LVEF < 45%|Patients with left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
11291157|NCT02758600|Experimental|LVEF > 45%|Patients without left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
11291158|NCT02758587|Experimental|Dose - escalation|"Does-escalation in an all-comers phase I population, with treatment-refractory advanced solid malignancies, unselected by tumour type. Two cohorts of up to evaluable 6 patients in each:
~Cohort 1: 200mg (IV) pembrolizumab every 3 weeks; plus 200mg (oral) defactinib twice daily
~Cohort 2: 200mg (IV) pembrolizumab every 3 weeks; plus 400mg (oral) defactinib twice daily
~Interventions:
~Drug: Defactinib
~Drug: Pembrolizumab"
11291159|NCT02758587|Experimental|Pancreatic|Pancreatic expansion for response assessment (single arm). Optional paired biopsies prior to treatment and after 14 days of treatment. All would have concurrent therapy with pembrolizumab + defactinib (VS-6063) from the start (c.f. NSCLC & mesothelioma expansions below). 15 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 6
11291160|NCT02758587|Experimental|NSCLC|NSCLC paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and after around 14 days of treatment. 1:1 randomised split of patients having their mandatory on-treatment biopsy after concurrent therapy, or after a defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
11291161|NCT02758587|Experimental|Mesothelioma|Mesothelioma paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and around 14 days of treatment. 1:1 randomised split of patients having thier on-treatment biopsy after concurrent therapy, or after defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
11291162|NCT02758574|Active Comparator|CDT without ultrasound acceleration|Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus
11291163|NCT02758574|Experimental|CDT ultrasound accelerated|Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus
11291164|NCT02758561|No Intervention|Standard of care|Standard of care
11291165|NCT02758561|Experimental|Workshop|90 minute workshop on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (POP)
11291166|NCT02758548|Other|Capillary Blood Sampling|Capillary blood sampling, collected as two fingerprick samples with POCT device and two venous samples
11291167|NCT02758535|Experimental|Core needle biopsy with coaxial method|The patients undergo renal biopsy with a coaxial Tru-Cut needle
11291168|NCT02758535|Experimental|Core needle biopsy with noncoaxial method|The patients undergo renal biopsy with a noncoaxial Tru-Cut needle
11291169|NCT02758522|Active Comparator|Once-daily insulin|60% of total dose of insulin as NPH insulin in the once-daily regimen was administered subcutaneously before breakfast. Also, 40% in rapid insulin before meals (every 8 hours).
11291170|NCT02758522|Active Comparator|Twice-daily insulin|60% of total dose of insulin as NPH insulin in the twice-daily regimen it was given before breakfast and before dinner. Also, 40% in rapid insulin before meals (every 8 hours).
11291171|NCT02758522|Active Comparator|Triple-daily insulin|60% of total dose of insulin as NPH insulin in the triple daily regimen it was administered before each meal. Also, 40% in rapid insulin before meals (every 8 hours).
11291172|NCT02758509||PEG/RBV|Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)
11291173|NCT02758509||PEG/RBV+BOC or TVR|Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)
11291174|NCT02758509||IF-DAAs|"Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)
~Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks
~Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)
~Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks
~Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks"
11291175|NCT02758496||ASD Subjects|Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.
11291176|NCT02758496||Healthy Controls|Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group
11291177|NCT02758483|Other|Test diet|"Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
11291178|NCT02758483|Other|Control diet|"Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
11291179|NCT02758470|Experimental|Acetazolamide|Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
11291180|NCT02758470|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
11291181|NCT02758470|Placebo Comparator|Placebo|Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
11291182|NCT02758457|Active Comparator|metal-based restorations|single crown with a metal framework and pressed ceramic
11291183|NCT02758457|Experimental|zirconia-based restorations|single crown with a zirconia framework and pressed ceramic
11291184|NCT02758444|Active Comparator|Micronutrient Powder (MNP) + 15 mg Zn|1 sachet of Micronutrient Powder (MNP) + 15 mg Zn will be added to a single meal on study day 8
11291185|NCT02758444|Active Comparator|MNP + 10 mg Zn|1 sachet of MNP + 10 mg Zn will be added to a single meal on study day 8
11291186|NCT02758444|Active Comparator|MNP + 5 mg Zn|1 sachet of MNP + 5 mg Zn will be added to a single meal on study day 8
11291187|NCT02758444|Placebo Comparator|MNP without Zn|1 sachet of MNP without Zn will be added to a single meal on study day 8
11291188|NCT02758431|Placebo Comparator|Group 1: Acyline plus placebo (No Testosterone Add-Back)|Acyline plus placebo gel and placebo tablet.
11291189|NCT02758431|Active Comparator|Group 2: Acyline plusTestosterone|Acyline plus transdermal testosterone gel plus placebo tablet.
11291190|NCT02758431|Active Comparator|Group 3: Acyline plus Testosterone plus Arimidex)|Acyline plus transdermal testosterone gel plus Aromatase inhibitor (Arimidex) oral.
11291191|NCT02758418|Experimental|Online Computerized Program group.|"Intervention group that uses TAO program."
11291192|NCT02758418|No Intervention|Waiting list control group.|Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
11291193|NCT02758405|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11291194|NCT02758405|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11291195|NCT02758405|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11291196|NCT02758405|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11291197|NCT02758392|Experimental|Dose 1: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.
11291198|NCT02758392|Experimental|Dose 2: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.
11291199|NCT02758392|Experimental|Dose 3: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.
11291200|NCT02758392|Experimental|Dose 4: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.
11291201|NCT02758392|Experimental|Dose 5: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.
11291202|NCT02758392|Experimental|Dose 6: JNJ-61178104 OR Placebo SC|Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.
11291203|NCT02758379|Experimental|Shockwave Coronary Lithoplasty System|Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
11291204|NCT02758366|Experimental|Doxorubicin|"Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.
~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)
~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).
~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).
~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day."
11291205|NCT02758353|Experimental|Community distribution of SP|All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.
11291283|NCT02757781|Experimental|Intervention group|Group of healthcare professionals that receive the intervention (community of practice)
11291206|NCT02758340|Experimental|M=misoprostol|Patients who would receive Only oral misoprostol{(50 micrograms) tab cytotec ¼ tablets (Searle)}. All patients in this group will be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes). If labor is not established within 4 hours of the administration of the fourth dose, induction will be considered to be failed
11291207|NCT02758340|Experimental|M+F=MISOPROSTOL+FOLEY'S BALLOON CATHETER|All patients in this group will be explained the technique of foley's catheter ballooning and informed consent will be taken. The cervix will be visualized with the help of Cusco's speculum. The balloon will be inflated with about 30 cc of sterile water. The catheter will be pulled down to bring the balloon into the cervical canal and will be tapped around the thigh. Patients will also be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes).
11291208|NCT02758327|Experimental|TheraTears Lubrication Drop|TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
11291209|NCT02758314||Cases / NSCLC patients|"Evaluation of PD-1/PDL-1 expression.
~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 150 NSCLC, free treatment by flow cytometry.
~Evaluate the expression of PD-1 / PD-L1 in tumor tissue obtained by biopsy of patients with NSCLC by immunohistochemistry.
~The patients for the enrollment have to be diagnosed with advanced Non-Small Cell Lung Adenocarcinoma (clinical stages IIIA, IIIB and IV), treated at the Instituto Nacional de Cancerología (INCan) who had not received radiotherapy and / or chemotherapy prior to obtaining samples to analyze. ECOG performance status 0-2 and present evidence of measurable disease."
11291210|NCT02758314||Control / Healthy subjects|"Evaluation of PD-1/PDL-1 expression.
~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 50 samples, by flow cytometry.
~Healthy subjects blood cells will be obtained from the blood bank at the Instituto Nacional de Cancerología (INCan)"
11291211|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
11291212|NCT02758288||New Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach
11291213|NCT02758288||Standard Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach
11291214|NCT02758275|Experimental|Teaching: Individual (5606)|People will receive an education session per month for a period of six months with an average duration of 30 minutes. These will be performed by nurses outside the collection of phase base line and follow-up measurements, previously trained for the purpose.
11291215|NCT02758275|No Intervention|Usual care|People will continue to receive usual care in the health center where they usually assist to medical controls.
11291216|NCT02758262|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the duration of the experimental session.
11291217|NCT02758262|Placebo Comparator|Noninvasive brain stimulation: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of the experimental session.
11291218|NCT02758249|Active Comparator|sevoflurane|patients under sevoflurane anesthesia
11291219|NCT02758249|Active Comparator|propofol|patients under propofol anesthesia
11291220|NCT02758223|Experimental|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
11291221|NCT02758210|Experimental|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
11291222|NCT02758197|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
11291223|NCT02758197|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
11291224|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
11291225|NCT02758184|No Intervention|Control Group|Patients who are randomized not to receive ROTEM
11291226|NCT02758171|Experimental|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
11291227|NCT02758171|Active Comparator|Empagliflozin+Linagliptin single tablets|
11291228|NCT02758158|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
11291229|NCT02758145|Active Comparator|Influenza vaccine information (G1)|During the recruitment visit at the occupational medicine unit between the 04/29/16 and the 10/31/16, the workers in this group (G1) in addition to their recruitment visit, will benefit from a short intervention given by the nurse concerning the flu, the advantages of the flu vaccination, and how they can be vaccinated in the institution. The nurse also transmits an information sheet concerning the benefits of the vaccination. 2 weeks after the beginning of the next flu vaccination campaign, they will receive a reminder letter to encourage vaccination.
11291230|NCT02758145|No Intervention|No information (G2)|Workers in the control group (G2) receive no intervention, only recruitment visit.
11291231|NCT02758132|Active Comparator|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
11291232|NCT02758132|Active Comparator|Standard of Care|Denosumab plus enzalutamide alone
11291471|NCT02756507|Sham Comparator|wait list|The wait-list is a delayed treatment condition.
11291233|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
11291234|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
11291235|NCT02758106|Active Comparator|HFCW oscillation|"HFCWO was performed using a Vest Airway Clearance System Model 105 (Hill-Rom, St. Paul, Minnesota). HFCWO was applied to each subject at a frequency of 10-12 Hz and a pulse pressure setting of 1-2 selected for 15 minutes. The patients receiving HFCWO were placed in a semi-upright sitting position. Following HFCWO, suction was performed immediately via an endotracheal tube.
~Changes to the initial ventilator settings during HFCWO were recorded before and at 5, 10 and 15 minutes. The variables included peak airway pressure, positive-end expiratory pressure, respiratory rate, fraction of inspired oxygen, inspiratory time, and sensitivity settings. Following HFCWO, suction was performed immediately via an endotracheal tube."
11291236|NCT02758106|Placebo Comparator|placebo intervention|the patients undergoing CCPT received cup-hand percussion with the hands positioned 3 inches from the chest, striking the chest with a waving movement while they were placed in right and left decubitus positions for 5-10 minutes each. Following CCPT, suction was performed immediately via an endotracheal tube.
11291237|NCT02758093|Experimental|Speed of Processing Training (10 hours)|Participants randomized to this arm will receive 10 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
11291238|NCT02758093|Experimental|Speed of Processing Training (20 hours)|Participants randomized to this arm will receive 20 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
11291239|NCT02758093|Sham Comparator|Internet Navigational (10 hours)|In this group, participants will receive 10 hours of Internet Navigation Training. Specifically, participants will be given instructional materials and exercises on how to navigate the Internet. For more computer savvy participants, they will be directed to the Thinks.com website. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
11291240|NCT02758080|Experimental|Matched|A molecular profile is identified using next generation sequencing. A participant in this arm is assigned to early clinical trial studying targeted agent, which is anticipated to have the best response rate.
11291241|NCT02758080|Other|Not matched|A participants in this arm is assigned to a clinical trial at physician's choice.
11291242|NCT02758067|Experimental|brexpiprazole|
11291243|NCT02758067|Experimental|risperidone|
11291244|NCT02758054|No Intervention|Usual Care|Participants will experience standard practice for lung cancer early detection.
11291245|NCT02758054|Experimental|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
11291246|NCT02758041|Experimental|Sebacia Microparticles|
11291247|NCT02758028|Other|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.
~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
11291248|NCT02758015|Active Comparator|Standardized Meal|Standardized meal given to patients.
11291249|NCT02758015|Experimental|Beatine PO (by mouth) 1500mg|Betaine (natural supplement)
11291250|NCT02758015|Experimental|Betaine PO (by mouth) 3000mg|Betaine (natural supplement)
11291251|NCT02758015|Experimental|Betaine PO (by mouth) 4500mg|Betaine (natural supplement)
11291252|NCT02758002|Experimental|Firm ablation for transitional AF rotors|All subjects will undergo this ablation, in addition to their standard PVI and Firm ablation for sustained AF rotors.
11291253|NCT02757989|Experimental|Patients with donor|Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling)
11291254|NCT02757989|No Intervention|Patients without donor|Patients without a matched donor
11291255|NCT02757976|Active Comparator|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging
11291511|NCT02756208|Placebo Comparator|0.5 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 0.5 mL placebo on study days 0, 28, 56 and 168.
11291256|NCT02757976|Experimental|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
11291257|NCT02757963|Other|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS >=8 and/or BPE/BPO questionnaire >=3 with a PSA >=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
11291258|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
11291259|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
11291260|NCT02757937|Experimental|Health & Wellness Website|Subjects will receive access to an interactive health & wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
11291261|NCT02757937|Other|Control Arm|Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
11291262|NCT02757924|Experimental|Infant formula supplemented with prebiotics|infant formula powder, feed ad libitum
11291263|NCT02757911|Experimental|open label|X vivo gene therapy
11291264|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
11291265|NCT02757885|Other|Bone Marrow Donor|Participants who are related marrow donors and are 2-4 (out of 8) human leukocyte antigen (HLA) antigen mismatched and towards whom the recipient does not have donor specific antibodies.
11291266|NCT02757885|Experimental|Bone Marrow Recipient|Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) matched donor.
11291267|NCT02757872|Active Comparator|Vitamin D and fish oil|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
11291268|NCT02757872|Active Comparator|Vitamin D and fish oil placebo|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary Supplement: Fish oil placebo Fish oil placebo
11291269|NCT02757872|Active Comparator|Vitamin D placebo and fish oil|"Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
~Dietary Supplement: Vitamin D placebo Vitamin D3 placebo"
11291270|NCT02757872|Placebo Comparator|Vitamin D placebo and fish oil placebo|Dietary Supplement: Vitamin D placebo Vitamin D3 placebo Dietary Supplement: Fish oil placebo Fish oil placebo
11291271|NCT02757859|Active Comparator|Arm I (EIPL-S)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal saline EIPL-S lavage 10 times over 15 minutes.
11291272|NCT02757859|Active Comparator|Arm II (EIPL-D)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal distilled water EIPL-D lavage 10 times over 15 minutes
11291273|NCT02757859|Sham Comparator|ARM III (NO LAVAGE)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
11291274|NCT02757833|Other|Late Life Depressed Arm|Participants in the Late Life Depressed arm will have a confirmed diagnosis of late-life depression.
11291275|NCT02757833|Other|Healthy Control Arm|Participants in the Healthy Control Arm will have no history of mental illness.
11291276|NCT02757820|Active Comparator|LMA classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
11291277|NCT02757820|Active Comparator|I-gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
11291278|NCT02757820|Active Comparator|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
11291279|NCT02757807|Experimental|Utilization of Serenita for Relaxation|Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
11291280|NCT02757794|Active Comparator|Cognitive remediation parents|
11291281|NCT02757794|Placebo Comparator|Remediation standard|
11291630|NCT02755259|Placebo Comparator|Placebo|Placebo Saline injection (1x)
11291284|NCT02757768|Experimental|Mirabegron|Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
11291285|NCT02757768|Placebo Comparator|Placebo|Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
11291286|NCT02757755|Experimental|Cohort 10^8|AB-SA01 (10^8) and Placebo
11291287|NCT02757755|Experimental|Cohort 10^9|AB-SA01 (10^9) and Placebo
11291288|NCT02757742||Non-ischemic cardiomyopathy|Non-ischemic cardiomyopathy patients with baseline cardiac magnetic resonance LVEF≤35%
11291289|NCT02757729|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 8 weeks
11291290|NCT02757729|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 8 weeks
11291291|NCT02757729|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 8 weeks
11291292|NCT02757729|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 8 weeks
11291293|NCT02757716|Other|Sleeve Gastrectomy|Obese patients who undergo sleeve gastrectomy fill in questionnaire
11291294|NCT02757716|Other|Roux-en-Y-Gastric Bypass|Obese patients who undergo roux-en-y-gastric bypass fill in questionnaire
11291295|NCT02757716|Other|One anastomosis-Gastric Bypass|Obese patients who undergo one anastomosis gastric bypass fill in questionnaire
11291296|NCT02757703|Active Comparator|somatostatin group|Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.
11291297|NCT02757703|Placebo Comparator|terlipressin group|Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.
11291298|NCT02757690|Active Comparator|2-dimenasional distal pancreatectomy|device: 2 dimensional laparoscopy of Olympus
11291299|NCT02757690|Experimental|3-dimenasional distal pancreatectomy|device : 3 dimensional laparoscopy of Olympus
11291300|NCT02757677||Longitudinal arm|Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
11291301|NCT02757677||24-h Intraocular pressure (IOP) arm|Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
11291302|NCT02757677||Surgery arm|Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients
11291303|NCT02757664|Active Comparator|Shock wave plus eccentric exercises|Shock wave therapy associated with eccentric exercises rehabilitation program.
11291304|NCT02757664|Placebo Comparator|Placebo plus eccentric exercises|Placebo associated with eccentric exercises rehabilitation program.
11291305|NCT02757651|Experimental|Radiotherapy + radiation sensitizer|Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer
11291306|NCT02757651|No Intervention|Radiotherapy alone|Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone.
11291307|NCT02757638|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
11291308|NCT02757638|Experimental|Obese subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.
~3 study days (one baseline, one pre-surgery, one post-surgery): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
11291309|NCT02757625|Experimental|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
11291310|NCT02757612|Active Comparator|Interventional|"Device Laser diode parameters: spot size of 0.04 mm2, average power (output) of 40 mW and 0.4 J per irradiation point, energy density of 10 J cm2, irradiation time of 10 seconds per point
~1 session per week during 4 session"
11291311|NCT02757612|Sham Comparator|Comparator|"laser probe inactive for similar duration as for the laser diode group; only a beep sound was produced by the laser machine
~1 session per week during 4 session"
11291312|NCT02757599|Other|Top-down (TD)|The group having the transvaginal ultrasound image top-down. During training and transfer test.
11291313|NCT02757599|Other|Bottom-up (BU)|The group having the transvaginal ultrasound image bottom-up. During training and transfer test.
11291314|NCT02757573|Experimental|Hypercarbia|Hypercarbia: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
11291315|NCT02757560|Experimental|SFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
11291316|NCT02757560|Experimental|MUFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
11291631|NCT02755246|Experimental|Polyamine supplementation|
11291317|NCT02757560|Experimental|CARB versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
11291318|NCT02757547|Placebo Comparator|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
11291319|NCT02757547|Active Comparator|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
11291320|NCT02757521|Placebo Comparator|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
11291321|NCT02757521|Experimental|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
11291322|NCT02757508|Active Comparator|Control|Vitamins/minerals-200 mg premix
11291323|NCT02757508|Experimental|Group 1|Vitamins/minerals + Milk Protein (8.75 g)-the milk protein is a skim milk powder with the sugar lactose.
11291324|NCT02757508|Experimental|Group 2|Vitamins/minerals + Milk/plant Protein (8.75g)-the milk protein is a skim milk protein powder and the plant protein is a rice protein concentrate and the sugar lactose.
11291325|NCT02757508|Experimental|Group 3|Vitamins/minerals + Milk Protein (4.38g)-the milk protein is a skim milk protein powder with the sugar lactose.
11291326|NCT02757495|No Intervention|Traditional|This will utilize the traditional method of performance of single dose caudal epidural block
11291327|NCT02757495|Experimental|Caudal dexmedetomidine|In this arm, single dose caudal epidural injection will be done patients in this arm will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%
11291328|NCT02757482|Experimental|intervention|Patient training
11291329|NCT02757482|No Intervention|control|no patient training
11291330|NCT02757469|Experimental|Yasmin|Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.
11291331|NCT02757456|Other|Aerobic Exercise program|Intervention of aerobic exercise
11291332|NCT02757456|Other|Control|no aerobic exercise program
11291333|NCT02757443|Experimental|Phosphocreatine|"Participants randomly assigned to the phosphocreatine arm receive:
~after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);
~together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);
~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;
~immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV"
11291334|NCT02757443|Placebo Comparator|Control|"Participants randomly assigned to the placebo arm receive:
~after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;
~together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);
~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;
~immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes"
11291335|NCT02757417|Active Comparator|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
11291336|NCT02757417|Active Comparator|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
11291337|NCT02757404|Experimental|Ultrasonography guidance|Ultrasonography guidance injection of Meditoxin®.
11291338|NCT02757404|Experimental|Electrical stimulation guidance|Electrical stimulation guidance injection of Meditoxin®.
11291339|NCT02757404|Experimental|Manual needle placement|Manual needle placement injection of Meditoxin®.
11291340|NCT02757391|Experimental|Treatment (CD8 +T cell therapy, pembrolizumab)|Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide IV over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin SC BID on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15.
11291341|NCT02757378|Experimental|Neuroplasticity Education Group|Patients who receive manual physical therapy treatment with a neuroplasticity explanation of the basis for the technique
11291342|NCT02757378|Active Comparator|Biomechanical Education Group|Patients who receive manual physical therapy treatment with a traditional, biomechanical explanation of the basis for the technique
11291343|NCT02757365|Experimental|the NSAIDs group|Patients in the this Group will received the aspirin 100mg qd until the experiment finished
11291344|NCT02757365|Experimental|the antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks
11291345|NCT02757365|Experimental|the NSAIDs+antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks and aspirin 100mg qd until the experiment finished
11291346|NCT02757365|No Intervention|the control group|No treatment
11291347|NCT02757352|Experimental|Q2W Ixekizumab|"Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period.
~Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
11291512|NCT02756208|Experimental|1.0 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 300 mcg (1.0 mL) FLSC on study days 0, 28, 56 and 168.
11291348|NCT02757352|Experimental|Q4W Ixekizumab|"Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period.
~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44."
11291349|NCT02757352|Placebo Comparator|Placebo|"Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period.
~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
11291350|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 140 female patients with either DID or PTSD ages 18-89
11291351|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
11291352|NCT02757326|Experimental|Phase 1b/II|"For Phase 1b, the planned ABC294640 doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.
~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
11291353|NCT02757313|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
11291354|NCT02757313|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
11291355|NCT02757300|Experimental|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.
~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
11291356|NCT02757300|Active Comparator|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.
~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
11291357|NCT02757287|Experimental|FSH-CTP + DESOGESTREL|Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation
11291358|NCT02757261|Experimental|Application of Low-level laser therapy.|The intervention will be twelve sessions (two per week). Laser parameters: wavelength - 786.94 nm; conventional tip; energy density - 25 J/cm²; intensity - 1.675 mW/cm²; output power - 70 mW (0.070 W); and exposure time - 20 seconds per point. The point application method will be used with direct contact with the skin (spot beam of 0.04 cm²), following the protocol suggested by Carvalho et al.50 and Venezian et al.44 A potentiometer will be used to determine the mean power of the laser equipment to ensure the safety of the operator.
11291359|NCT02757261|Experimental|Treatment with Occlusal splint.|The intervention will be a maxillary occlusal splint will be used on the maxilla with palatal and occlusal coverage. Following the protocol established by Hachmann et al., the children will only use the splint at night for two months, with weekly adjustments of a quarter turn.46
11291360|NCT02757261|Active Comparator|Placebo laser|Placebo laser will be performed using the same equipment.
11291361|NCT02757261|No Intervention|Children without bruxism|Control group
11291362|NCT02757248|Experimental|Cohort 1|Volasertib 75mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
11291363|NCT02757248|Experimental|Cohort 2|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
11291364|NCT02757248|Experimental|Cohort 3|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
11291365|NCT02757248|Experimental|Cohort 4|Volasertib 150mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
11291366|NCT02757248|Experimental|Cohort -1|Volasertib 50mg/m2 on days 1 and 8 Romidepsin 10mg/m2 on days 1, 8 and 15
11291367|NCT02757235|Active Comparator|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
11291368|NCT02757235|Active Comparator|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
11291369|NCT02757222|Active Comparator|Standard dose|Patients receive a radiation dose of 66Gy in 30 fractions to the planning target volume 1 (PTV1) and 54 Gy in 30 fractions to the PTV2 concurrent with platinum chemotherapy weekly
11291370|NCT02757222|Experimental|Escalated dose|Patients receive a radiation dose of 73.5 Gy in 30 fractions to the boost target volume (BTV), 63Gy in 30 fractions to PTV1 and 54 Gy in 30 fractions to PTV2 concurrent with platinum chemotherapy weekly
11291371|NCT02757209|Active Comparator|Spiromax Inhaler|"Evaluation of correct use of Spiromax inhaler - DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.
~Additional 8 weeks in one subgroup"
11291372|NCT02757209|Active Comparator|Turbohaler inhaler|"Turbohaler® - Symbicort® 160/4.5 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate). Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week.
~Additional 8 weeks in one subgroup"
11291373|NCT02757209|Active Comparator|Diskus Inhaler|"Diskus® inhaler - Seretide Diskus 50/250 mcg ® or 50/500 mcg (50 mcg salmeterol & 250/500 mcg fluticasone propionate). Dose of one inhalation twice a day for 1 week.
~Additional 8 weeks in one subgroup"
11291374|NCT02757196|Experimental|Rituximab plus methylprednisolone|Combination therapy with rituximab （1000mg IV day1, week 3, week 17 , and week 19）plus short-term methylprednisolone (1mg/kg, oral or IV; reduce to 50% of base dose at week 4, then reduce 8mg every 1 week until stopped).
11291375|NCT02757196|Active Comparator|Methylprednisolone|standard dose methylprednisolone alone (1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks).
11291632|NCT02755246|Placebo Comparator|Placebo|
11306135|NCT02658526||surgery|children with anesthesia / surgery
11291376|NCT02757170|Experimental|I|Thromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
11291377|NCT02757170|Active Comparator|Group II|Thromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
11291378|NCT02757170|Experimental|Group III|Thromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
11291379|NCT02757170|Experimental|Group IV|Thromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
11291380|NCT02757157|Experimental|COPD (normal weight)|People with COPD (BMI 21 kg/m2 to 29 kg/m2)
11291381|NCT02757157|Experimental|COPD (obese)|People with COPD (BMI >/= 30 kg/m2)
11291382|NCT02757144|Experimental|Cohort 1: DWP14012 Amg|DWP14012 Amg, tablets, orally, single dose administration
11291383|NCT02757144|Experimental|Cohort 2: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single dose administration
11291384|NCT02757144|Experimental|Cohort 3: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single dose administration
11291385|NCT02757144|Experimental|Cohort 4: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, single dose administration
11291386|NCT02757144|Experimental|Cohort 5: DWP14012 Emg|DWP14012 Emg, tablets, orally, single dose administration
11291387|NCT02757144|Experimental|Cohort 6: DWP14012 Fmg|DWP14012 Emg, tablets, orally, single dose administration
11291388|NCT02757144|Placebo Comparator|Cohort 1-6: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
11291389|NCT02757144|Active Comparator|Cohort 1-6: Esomeprazole|Nexium® tablets, orally, single dose administration
11291390|NCT02757144|Experimental|Cohort 7: DWP14012 Amg|DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
11291391|NCT02757144|Experimental|Cohort 8: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
11291392|NCT02757144|Experimental|Cohort 9: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
11291393|NCT02757144|Placebo Comparator|Cohort 7-10: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
11291394|NCT02757144|Active Comparator|Cohort 7-10: Esomeprazole|Nexium®, orally, repeated dose administration(for 7days)
11291395|NCT02757144|Experimental|Cohort 9: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
11291396|NCT02757131|Experimental|Intervention|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the Physical Therapy (PT) staff 3 times daily under the supervision of the dedicated ambulator PCNA.
~The ambulator will be trained by the physical therapy team on how to implement the protocol prior to initiation of the study."
11291397|NCT02757131|No Intervention|Control|"The cohort of patients randomized to usual care will not be seen by the dedicated ambulator, but will not otherwise be restricted in nursing's baseline ability to execute nursing specific recommendations placed by the PT team."
11291398|NCT02757118|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11291399|NCT02757118|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11291400|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
11291401|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
11291402|NCT02757092|Experimental|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
11291403|NCT02757092|Active Comparator|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
11291404|NCT02757079|Experimental|NPC-15 Granule|NPC-15 granule 1 mg, 2 mg or 4 mg once a day, administered orally before going to bed.
11291405|NCT02757066|Experimental|NPC-15 Granules Lower Dose|NPC-15 Granules Lower Dose group which is administered 1mg melatonin
11291406|NCT02757066|Experimental|NPC-15 Granules Higher Dose|NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
11291407|NCT02757066|Placebo Comparator|NPC-15 Placebo Granule|NPC-15 Placebo Granules group which is administered placebo melatonin
11291408|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
11291409|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
11291410|NCT02757040|Experimental|Ibrutinib combined with As2O3|Ibrutinib combined with As2O3
11291411|NCT02757040|Active Comparator|Ibrutinib|Ibrutinib only
11291412|NCT02757027|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11291413|NCT02757027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11291414|NCT02757014|Experimental|Coppertone (BAY987517)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11291415|NCT02756988|Experimental|Coppertone (BAY987704)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11291416|NCT02756975|Experimental|transperineal prostate biopsy with coaxial method|The patients undergo transperineal biopsy with a coaxial Tru-Cut needle (18-gauge Core Biopsy Instrument with a 17-gauge Disposable Coaxial Needle).
11291417|NCT02756975|Experimental|transperineal prostate biopsy with noncoaxial method|The patients undergo transperineal biopsy with a noncoaxial 18-gauge needle.
11291418|NCT02756962|Experimental|Cohort A: HiDAC|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced
~Patients who have clearance of their leukemia-associated mutations, defined as a LAM VAF <2.5% will be assigned to the high-dose cytarabine consolidation (HiDAC) arm.
~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles.
~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
11291419|NCT02756962|Experimental|Cohort B: Investigator's choice (HiDAC, AlloSCT)|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced
~Patients who have persistent leukemia-associated mutations, defined as a LAM VAF ≥2.5% will be assigned to the investigator's choice arm.
~Patients assigned to this arm may received either HiDAC or AlloSCT.
~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles.
~The source of stem cell product, donor selection, conditioning regimen, graft-versus-host-prophylaxis, and supportive care will be at the discretion of the treatment physician
~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
11291420|NCT02756949|Experimental|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
11291421|NCT02756949|No Intervention|Standard of care|Participants in this arm are randomised to receive standard of care services.
11291422|NCT02756936|Experimental|A Test|Test drug (Daclatasvir zeta)1 tablet contains 60 mg Daclatasvir
11291423|NCT02756936|Active Comparator|B Reference|Reference drug (Clatazev)) 1 tablet contains 60 mg Daclatasvir
11291424|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
11291425|NCT02756897|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
11291426|NCT02756884|Experimental|LoFU and aADSC|Low Frequency Ultrasound LFUS will be delivered in a non-sterile manner using a custom modified LFUS combined imaging/therapy probe. Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area after the administration of the low frequency ultrasound
11291427|NCT02756884|Active Comparator|Adipose Derived Stem Cells|Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area without the administration of the low frequency ultrasound
11291428|NCT02756871|Experimental|Online guided self-help intervention|CBT based online guided self-help intervention. Intervention can be found at www.overcomingperfectionism.co.uk
11291429|NCT02756871|No Intervention|Control|No intervention.
11291430|NCT02756858|Experimental|ANAVEX2-73 Oral as assigned in ANAVEX2-73-002|
11291431|NCT02756845|Experimental|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to ≤ 21 years). Cohort B1 (age 2 to < 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to ≤ 21 years), Cohort B2 (age 2 to < 12 years).
11291432|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 (T2DM) who received alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) were observed for approximately 6 months.
11291433|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.
11291434|NCT02756806|Experimental|Picosecond Q-switched Laser|Treatment with investigational wavelengths of the Cutera enlighten laser for tattoo removal.
11291435|NCT02756793|Active Comparator|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:
~Continue with current systemic agent(s)
~Observation
~Switch to next-line treatment"
11291436|NCT02756793|Experimental|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
11291513|NCT02756208|Placebo Comparator|1.0 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 1.0 mL placebo on study days 0, 28, 56 and 168.
11291633|NCT02755233||Pulmonary function|Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated
11291437|NCT02756780|Experimental|Tenovus Cancer Choir|Participants will be asked to attend 12 weeks of weekly choir rehearsals lasting approximately 1 hour. Following the first 12 weeks, participants will no longer be asked to attend rehearsals, but are welcome to do so. Whether or not they do and how many they attend will be measured as an outcome variable to assess whether initial 3-month involvement leads to long-term engagement.
11291438|NCT02756780|No Intervention|Control (no choir) Group|If eligible participants are unable to make the dates and times or live too far away but fulfil all the same criteria (including expressing an interest in singing) they will become part of the control group. This will involve the same data collection as the Cancer Choir Group but participants will not sing in a weekly choir.
11291439|NCT02756767||Completed subjects|Subjects will complete patient-reported outcomes assessments during and after radiation therapy.
11291440|NCT02756754|Experimental|Radiofrequency ablation|"Radiofrequency ablation (RFA) is a minimally invasive technique for eliminating both primary tumors and metastases.
~The needles that will be used are monopolar RFA, the LeVeen™ Needle Electrode Family with a generator RF 3000 by Boston Scientific. The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored."
11291441|NCT02756741|Active Comparator|STANDARD DOSE|Albumin 1.5gm/kg on day 1 and 1gm/kg on day 3
11291442|NCT02756741|Placebo Comparator|LOW DOSE|Albumin 20g/d for 5 days
11291443|NCT02756728|Active Comparator|HDM+ASCT|Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
11291444|NCT02756728|Experimental|BI-505|Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation
11291445|NCT02756715|Active Comparator|propofol group|The patient who anesthetized by using propofol.
11291446|NCT02756715|Active Comparator|Desflurane group|The patient who anesthetized by using sevoflurane.
11291447|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
11291448|NCT02756689|Active Comparator|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
11291449|NCT02756689|Active Comparator|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
11291450|NCT02756676|Experimental|Rehabilitative treatment (MIRT)|Rehabilitative treatment MIRT consist in daily sessions of: motor treatment, occupational therapy and language speech therapy
11291451|NCT02756663|Experimental|Arm A: PAN (10mg) + CFZ + Dex|Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
11291452|NCT02756663|Experimental|Arm B: PAN (20mg) + CFZ + Dex|Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
11291453|NCT02756663|Active Comparator|Arm C: CFZ + Dex|Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
11291454|NCT02756650|Experimental|Canakinumab|Canakinumab was administered monthly
11291455|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
11291456|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
11291457|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
11291458|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
11291459|NCT02756611|Experimental|Venetoclax|"Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation.
~In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, determined on a case by case basis."
11291460|NCT02756598|Active Comparator|Sufentanil I|"Randomized arm moderate sufentanil I: bolus 1 microgram/kg propofol I: infusion 0.03 mg/kg/min"
11291461|NCT02756598|Active Comparator|Sufentanil II|"Randomized arm low sufentanil II bolus 0.5 microgram/kg propofol II: infusion 0.06 mg/kg/min"
11291462|NCT02756585|Other|ct perfusion|All participants will undergo the imaging protocol with CTP of head at the time of initial diagnostic imaging upon hospital arrival.
11291463|NCT02756572|Experimental|Treatment (chemotherapy, HCT)|See Detailed Description
11291464|NCT02756559||sepsis, severe sepsis and septic shock|Septic patients were divided into sepsis, severe sepsis and septic shock
11291465|NCT02756546|No Intervention|Control|Healthy volunteers
11291466|NCT02756546|Active Comparator|Patients|SLE patients further divided into mild and severe patients
11291467|NCT02756533|Experimental|Telemonitoring|Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
11291468|NCT02756533|Placebo Comparator|control|"Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.
~Phone calls to patient during the follow-up like false alerts for the blind procedure."
11291469|NCT02756520||Chronic kidney disease (pre-dialysis)|Observational study: supplemented protein-restricted diet
11291470|NCT02756507|Experimental|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
11291472|NCT02756494||Ischemic Stroke in Young Adults|Patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the Department of Beijing Chaoyang Hospital between January 1, 2016 and December 31, 2016. All patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain CT or MRI.
11291473|NCT02756494||matched control subjects|The age-, sex-, and time of enrollment-matched control cohort was randomly identified after eliminating the study subjects and those who had been given a diagnosis of any stroke at any time.
11291474|NCT02756481||NVAF Treatment patterns|"Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit.
~Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected:
~Type of treatment, start & stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable
~Type of therapy utilized (monotherapy/combination therapy)
~Total number of therapy changes or switches through the course of treatment
~Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR)
~Routine care (visits per month) by anticoagulation regimen"
11291475|NCT02756468||pts operated for pancreatic cancer|all pts operated of pancreatic resection for cancer in the involved units
11291476|NCT02756455||gastric cancer pts undergoing surgery|all pts receiving gastric resection for cancer, with anastomosis
11291477|NCT02756442|Experimental|pregnant women with gestational diabetes|
11291478|NCT02756442|Active Comparator|pregnant women without gestational diabetes|
11291479|NCT02756429|Experimental|atrial fibrillation|Patients with atrial fibrillation
11291480|NCT02756429|Experimental|Control|Patients without atrial fibrillation
11291481|NCT02756416|Experimental|ASL MRI and MRA|All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
11291482|NCT02756403|Active Comparator|Azithromycin|500 mg of Azithromycin
11291483|NCT02756403|Active Comparator|Doxycycline|200 mg of Doxycycline
11291484|NCT02756403|Active Comparator|Metronidazole|500 mg of Metronidazole
11291485|NCT02756403|Placebo Comparator|Placebo|Inactive Ingredient
11291486|NCT02756390|Experimental|Arm A (Sleep Hygiene & CBTI-CS)|Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions
11291487|NCT02756390|Other|Arm B (Telehealth Pilot of CBTI-CS)|Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.
11291488|NCT02756377|Active Comparator|cetylpyridinium chloride|mouthwash (cetylpyridinium chloride)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
11291489|NCT02756377|Active Comparator|Chlorhexidine mouthwash|mouthwash ( Alcohol-free chlorhexidine)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
11291490|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Cycle 1 Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent.
11291491|NCT02756364|Experimental|Fulvestrant 500 mg + MLN0128 4 mg|Fulvestrant 500 mg, IM, once on Cycle 1 Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle along with MLN0128 4 mg, capsule, orally, once daily of a 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent.
11291492|NCT02756364|Experimental|Fulvestrant 500 mg + MLN0128 30 mg|Fulvestrant 500 mg, IM, once on Cycle 1 Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle along with MLN0128 30 mg, capsule, orally, once weekly of a 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent.
11291493|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
11291494|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
11291495|NCT02756325|Experimental|MRI|
11291496|NCT02756312|Other|Intravenous anesthesia|Patients will receive total intravenous anesthesia undergoing brain tumor resection.
11291497|NCT02756312|Other|Inhalation anesthesia|Patients will receive volatile inhalational anesthesia undergoing brain tumor resection.
11291498|NCT02756299|Active Comparator|Device and Standard Care|Positive Airway Pressure Device and Standard Support
11291499|NCT02756299|Active Comparator|Device and Educational Care|Positive Airway Pressure Device and Educational Support
11291500|NCT02756286||ADHD: Adults with ADHD|NAT electroencephalography (EEG) test
11291501|NCT02756286||Controls: Healthy adults without ADHD|NAT electroencephalography (EEG) test
11291502|NCT02756273|Experimental|no bridge device|After the ileostomy creation, no bridge device was placed.
11291503|NCT02756273|Active Comparator|bridge device|A bridge device was placed after the stoma creation.
11291504|NCT02756247|Experimental|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.
~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration for 36 cycles, not exceeding 36 months on therapy."
11291505|NCT02756234||Qualifying CTP patients|A convenience sample of all qualifying patients for CTP procedure
11291506|NCT02756221|Experimental|Probiotics|Probiotics capsules, one capsule daily for 90 days.
11291507|NCT02756221|Placebo Comparator|Placebo|Starch capsules, one capsule daily for 90 days
11291508|NCT02756208|Experimental|0.25 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 75 mcg (0.25 mL) FLSC on study days 0, 28, 56 and 168.
11291509|NCT02756208|Placebo Comparator|0.25 mL Placebo Group ENROLLED|Five volunteers will be vaccinated with 0.25 mL placebo on study days 0, 28, 56 and 168.
11291510|NCT02756208|Experimental|0.5 mL FLSC Vaccine Group ENROLLED|Fifteen volunteers will be vaccinated with 150 mcg (0.5 mL) FLSC on study days 0, 28, 56 and 168.
11291514|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
11291515|NCT02756182|Experimental|Urodynamics with AC and WP|Patients underwent a conventional urodynamics study utilizing a single catheter technique
11291516|NCT02756169|Experimental|Intervention|One workshop during pregnancy Support for breastfeeding at immediate postpartum Telephonic support after delivery
11291517|NCT02756169|No Intervention|Control|Standar procedures of neonatal and pregnancy health care at the clinics or hospitals.
11291518|NCT02756143|No Intervention|Control Group|Non- supervised physical exercise program during pregnancy
11291519|NCT02756143|Experimental|Exercise Group|Supervised physical exercise program during pregnancy
11291520|NCT02756130|Experimental|Treatment (birinapant, carboplatin)|Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11291521|NCT02756117|Experimental|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at one study visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of L-lysine (10 g) in 100 ml water. This amount of lysine is equivalent to that which is found in a 10oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of 10 ml/hr to flush the canula prior to each blood draw.
~All subjects will undergo the same procedures and interventions."
11291522|NCT02756104|Other|Volunteers|Healthy People on each collecting blood for phenotyping Tcells
11291523|NCT02756104|Other|Patients with ALS|"Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.
~The patients who are deficient in Vitamin D will have supplementation in vitamin D"
11291524|NCT02756078|Active Comparator|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
11291525|NCT02756078|Active Comparator|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
11291526|NCT02756065||Control|Individuals between 18-30 years old No diagnosis of Bipolar Disorder or Schizophrenia No intervention used
11291527|NCT02756065||Bipolar Disorder|Individuals between 18-30 years old Diagnosis of Bipolar Disorder No intervention used
11291528|NCT02756065||Schizophrenia|Individuals between 18-30 years old Diagnosis of Schizophrenia or Schizoaffective Disorder No intervention used
11291529|NCT02756052|Sham Comparator|Medical Student - Sham tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).
~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
11291530|NCT02756052|Sham Comparator|General Surgery Resident - Sham tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).
~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
11291531|NCT02756052|Experimental|Medical Student - Anodal tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).
~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
11291532|NCT02756052|Experimental|General Surgery Resident - Anodal tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).
~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
11291533|NCT02756026|Experimental|Micronutrient supplementation|"On day 3, all mothers are given a commercial multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
~On day 4, all mothers are given two commercial multiple micronutrient supplements (Nutri-Fem) manufactured by Thorne, containing twice the Recommended Dietary Intake (RDA)."
11291534|NCT02756013|Experimental|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
11291535|NCT02756000|Experimental|complete PCI at initial hospitalization|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session during initial hospitalization for ST elevation myocardial infarction
11291536|NCT02756000|Experimental|complete PCI after 30 days|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session after 30 days from initial hospitalization for ST elevation myocardial infarction
11291537|NCT02756000|Active Comparator|Dobutamine stress testing|Revascularization by PCI or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using Dobutamin stress echocardiography
11291538|NCT02755961|No Intervention|Control group|No intervention was performed
11291539|NCT02755961|Experimental|Education group|Dietary education and education on phosphate binder use. Pharmacists instructed patients about how to take phosphate binders properly. Dietitians educated on dietary phosphate restriction.
11291592|NCT02755584||Healthy Volunteers|between the ages of 20-39 years and 70 years old and older
11308876|NCT02639975|Experimental|600 mg PBF-677|
11291540|NCT02755948|Experimental|RSV A Memphis 37|Half the participants will be inoculated with RSV Memphis 37 10(4) plaque forming units (PFU) in 1 milliliter (mL) 25% sucrose/Dulbecco's Modification of Eagle's Medium (DMEM) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
11291541|NCT02755948|Experimental|Influenza A/California/04/2009|Half the participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
11291542|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
11291543|NCT02755922|Experimental|Fractures with Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.
11291544|NCT02755922|No Intervention|Fractures without Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site.
11291545|NCT02755909|Other|Subjects|Pra-anesthetic education given to the subjects includes the anatomy of a normal heart, normal blood circulation, anatomy and pathophysiology of the disease in the respected subject, surgery procedures needed, anesthetic procedures needed for the surgery, and cardiopulmonary bypass procedures. Education and discussion were given repeatedly until subjects could repeat the materials given correctly.
11291546|NCT02755896|Other|Arm 1 - 600 cGY x 5 fractions|Patients will receive 600 cGY x 5 fractions of radiation therapy over 5 consecutive days.
11291547|NCT02755896|Other|Arm 2 - 800 cGY x 3 fractions|Patients will receive 800 cGY x 3 fractions of radiation therapy every other day for 3 days.
11291548|NCT02755883|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
11291549|NCT02755883|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
11291550|NCT02755870|Experimental|CNM-Au8|"CNM-Au8 is an orally administered, clean-surface gold nanocrystal suspension drug. It is atomically clean-surface elemental nanocrystals, free of any residual surface chemicals or surface-capping agents.
~CNM-Au8 15, 30, 60, 90mg as an oral suspension"
11291551|NCT02755870|Placebo Comparator|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
11291552|NCT02755857|Experimental|Lozanoc|65 mg, capsules, at least 2 capsules twice a day
11291553|NCT02755844|Experimental|Olaparib, metformin and metronomic cyclophosphamide|"Phase 1: Dose escalation scheme: a continual reassessment method (CRM) will be used to guide inclusion of patients in drug dose levels pre-specified based on observations of dose-limiting toxicity.
~Phase 2 (expansion of cohort): once RP2D will be determined, additional patients will be enrolled, in order to obtain preliminary data about efficacy in a 2 stage Simon's design."
11291554|NCT02755831|Experimental|Sleep Study + CPAP group|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
11291555|NCT02755831|Other|Standard Prenatal Care group|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
11291556|NCT02755818||control|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
11291557|NCT02755818||chronic renal disease (CKD3b)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
11291558|NCT02755818||chronic renal disease (CKD4)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
11291559|NCT02755818||chronic renal disease (CKD5)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
11291560|NCT02755805|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
11291561|NCT02755805|Placebo Comparator|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
11291562|NCT02755792|Experimental|Calligraphy Training|This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
11291563|NCT02755792|Active Comparator|iPad Training|This group receives an iPad training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
11291564|NCT02755766||Clubfeet|Babies, ages 0-1, with a diagnosis with clubfoot or clubfeet who are beginning treatment with foot abduction bracing following casting treatment.
11291565|NCT02755766||Adolescent Idiopathic Scoliosis|Patients, ages 10-14, with a diagnosis of AIS who are beginning treatment with TLSO (initial bracing).
11291566|NCT02755766||Guardians (CF babies)|Clubfoot patients' guardians.
11291567|NCT02755753|Experimental|Study Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
~Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
11291568|NCT02755753|Placebo Comparator|Control Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
~Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
11291593|NCT02755558|Experimental|Low energy density, small portion|Low milk energy density and small portion size
11291594|NCT02755558|Experimental|Low energy density, large portion|Low milk energy density and large portion size
11291595|NCT02755558|Experimental|High energy density, small portion|High milk energy density and small portion size
11291596|NCT02755558|Experimental|High energy density, large portion|High milk energy density and large portion size
11308877|NCT02639975|Placebo Comparator|Placebo 100 mg|
11291569|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
11291570|NCT02755727|Experimental|Platelet Rich Plasma injection|"In the outpatient setting a sample of venous whole blood will be taken from the patient (40mls), from the antecubital fossa using standard phlebotomy techniques. The Angel™ system will be in the available also in the outpatient clinic and will be used to separate the blood to yield a PRP sample (approximately 15 minutes preparation time). The PRP sample is then injected into the common extensor origin.
~2 injections will be used per patient over 2 weeks."
11291571|NCT02755727|Active Comparator|Open Surgical Release|Standardised surgical technique based on the Nirschl technique will be used. The patient will then have a small scar centred over the lateral epicondyle and the plane opened between ECRL (Extensor Carpi Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the damaged ECRB (Extensor Carpi Radialis Brevis) tendon. The amount of abnormal tendon will be documented and excised. EDC will also be inspected and any abnormal tissue documented then excised. The footprint of the excised ECRB +/- EDC is cleared of soft tissue and the bone scored with an osteotome to promote bleeding. The interval is closed with suture material and the skin wound closed.
11291572|NCT02755714|No Intervention|No Atrovent ®|NO INTERVENTION: The patient will not receive Ipratropium bromide spray (MDI) 20 μg ,(Atrovent ®) prior to CLE testing
11291573|NCT02755714|Experimental|Atrovent ®|INTERVENTION: Ipratropium bromide spray (MDI) 20 μg (Atrovent ®) prior to CLE testing
11291574|NCT02755701|Experimental|BCAA group|Branched-chain amino acid, 4.15g, Tid
11291575|NCT02755701|Placebo Comparator|Placebo group|Placebo, 4.15g, Tid
11291576|NCT02755688|Experimental|Thoracoscopic surgical ablation|Pulmonary vein isolation, ganglionic plexi ablation, left atrial appendage exclusion
11291577|NCT02755688|Active Comparator|Catheter ablation|Pulmonary vein isolation, linear lines
11291578|NCT02755675|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
11291579|NCT02755662|Active Comparator|Narval O.R.M CC™|First mandibular retention device : Narval O.R.M CC™
11291580|NCT02755662|Active Comparator|Narval O.R.M™ trad|Second mandibular retention device : Narval O.R.M TRAD™
11291581|NCT02755649|Experimental|Placebo QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
11291582|NCT02755649|Experimental|Dupilumab 300 mg Q2W + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
11291583|NCT02755649|Experimental|Dupilumab 300 mg QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
11291584|NCT02755636|Experimental|PCPHC intervention|PCPHC intervention during 6-month intervention period plus study assessments at baseline, 6, and 12 months
11291585|NCT02755636|Active Comparator|Usual care|Usual primary care plus study assessments at baseline, 6, and 12 months
11291586|NCT02755623|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|low-frequency (1 Hertz) rTMS
11291587|NCT02755623|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|sham TMS
11291588|NCT02755610|Experimental|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
11291589|NCT02755610|No Intervention|Control|Standard care
11291590|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
11291591|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Venetoclax 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
11308878|NCT02639975|Placebo Comparator|Placebo 200 mg|
11291597|NCT02755545|Active Comparator|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
11291598|NCT02755545|Active Comparator|Product B (salicylic acid)|Product B applied topically to the affected area of the skin 1 to 3 times daily.
11291599|NCT02755532|Active Comparator|Bupivacaine 0,25%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve) In the group bupicavaine 0.25%, 10 ml of 0.25% bupivacaine was injected into each nerve, for a total of 40 ml per patient.
11291600|NCT02755532|Active Comparator|Bupivacaine 0,5%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve). In the group bupivacaine 0.5% , 5 ml of 0.5% bupivacaine was injected into each nerve, for a total of 20 ml per patient.
11291601|NCT02755519||Primary Aldosteronism|"Those with hypertension, and with or without hypoglycemia;
~Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1"
11291602|NCT02755519||Non-Primary Aldosteronism|"Those with Primary Hypertension;
~Those with adrenal diseases except for Primary Aldosteronism"
11291603|NCT02755506|Experimental|patients with thoracic lesions|Patients with thoracic lesions is going to undergo endobronchial ultrasound elastography followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
11291604|NCT02755493|Experimental|Sleep Deprivation|Sleep deprivation
11291605|NCT02755480|Experimental|ultralow dose research|"An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.
~The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography."
11291606|NCT02755467|Experimental|Laser treatment|Each subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
11291607|NCT02755454|Other|open label|Perfusion CT Imaging
11291608|NCT02755428|Experimental|retinal pigment epithelium transplantation|Subretinal transplantation of human embryonic stem cell derived retinal pigment epitheliums.
11291609|NCT02755415|Active Comparator|Static Standing Table Training|Patients in this group will receive standard hospital based rehabilitation as well as static standing table training
11291610|NCT02755415|Experimental|Robotic Gait Training|Patients in this group will receive standard hospital based rehabilitation as well as robot-assisted gait rehabilitation training
11291611|NCT02755402|Experimental|Rapid evaluation|Transient elastography, Xpert HCV Viral load, medical and nurse visits
11291612|NCT02755389|Placebo Comparator|0 L/min|These participants will receive 0 L/min oxygen via conventional nasal cannulae during the apneic period.
11291613|NCT02755389|Experimental|15 L/min|These participants will receive 15 L/min oxygen via conventional nasal cannulae during the apneic period.
11291614|NCT02755389|Experimental|60 L/min|These participants will receive 60 L/min oxygen via high-flow nasal cannulae during the apneic period.
11291615|NCT02755376|Active Comparator|ACL reconstruction only|only ACL reconstruction without any injection
11291616|NCT02755376|Experimental|ACL reconstruction + Cartistem(TM)|ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.
11291617|NCT02755376|Experimental|ACL reconstruction + Hyaluronic acid|ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy
11291618|NCT02755363|Active Comparator|osteopathic manual therapy (OMT group)|patients who will undergo manual osteopathic therapy.
11291619|NCT02755363|Placebo Comparator|control group (C group)|patients who will undergo manual therapy not aimed to decrease hyperinflation.
11291620|NCT02755350|Experimental|Truvada|Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.
11291621|NCT02755324|Experimental|Intervention|Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
11291622|NCT02755311|Experimental|liver resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
11291623|NCT02755311|Active Comparator|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
11291624|NCT02755298|Experimental|Acetazolamide|Twice a day 250 mg acetazolamide for 5 weeks
11291625|NCT02755298|Placebo Comparator|Placebo|Placebo capsule 250 mg (Mannitol) twice a day 5 weeks
11291626|NCT02755285|Experimental|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
11291627|NCT02755272|Experimental|Pembrolizumab with Standard Chemotherapy|Pembrolizumab plus standard chemotherapy using carboplatin and gemcitabine.
11308879|NCT02639975|Placebo Comparator|Placebo 400 mg|
11291634|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
11291635|NCT02755207||Suspected ACS group|Patients admitted to the hospital with the diagnosis of ACS
11291636|NCT02755207||Blank control group|Patients admitted to the hospital without the diagnosis of ACS
11291637|NCT02755194||Breastfeeding women on the study medications|The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)
11291638|NCT02755181||BPD|Borderline Personality Disorder as diagnosed by DSM-5
11291639|NCT02755181||normal volunteers|normal volunteers
11291640|NCT02755168|Other|External Pop-Out Cesarean Section|
11291641|NCT02755168|Other|Classic technique|
11291642|NCT02755155|Experimental|Continuous low dosage (CLD)|The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
11291643|NCT02755155|Active Comparator|Intermittent high dosage (IHD)|The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%
11291644|NCT02755142|Active Comparator|Dose level 1|0,2 mg/Kg
11291645|NCT02755142|Active Comparator|Dose level 2|2,0 mg/Kg
11291646|NCT02755142|Active Comparator|Dose level 3|20 mg/Kg
11291647|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.
~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:
~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test
~Walking exercises - 4 Meter Gait Speed (4MGS) Test
~Walking Exercises - Five Times Sit to Stand (FTSTS) Test
~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
11291648|NCT02755116|Experimental|Olanzapine|10mg pill
11291649|NCT02755116|Placebo Comparator|Placebo|
11291650|NCT02755103|Experimental|Women receiving MBRP plus TAU|Women will receive the Mindfulness Based Relapse Prevention (MBRP) plus treatment as usual (TAU less trauma focused group).
11291651|NCT02755103|No Intervention|Women receiving TAU|Women will only receive treatment as usual (TAU less trauma focused group).
11291652|NCT02755090|Experimental|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
11291653|NCT02755090|No Intervention|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
11291654|NCT02755077|Experimental|Mask ventilation in rotated head position|Patient's head will be axially rotated 45 degrees to the right
11291655|NCT02755077|No Intervention|Mask ventilation in neutral head position|
11291656|NCT02755064|Experimental|Erythromycin lactobionate IV 2 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
11291657|NCT02755064|Active Comparator|Erythromycin lactobionate IV 3 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
11291658|NCT02755064|Placebo Comparator|Placebo IV|Saline was given as an initial bolus over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
11291659|NCT02755064|Experimental|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
11291660|NCT02755064|Placebo Comparator|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
11291661|NCT02755051|Experimental|CBT-CI-A Therapy|Participants in this group receive Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder (CBT-CI-A)
11291662|NCT02755038||premenopausal and postmenopausal women|One group will include 20 premenopausal women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 postmenopausal women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.
11291663|NCT02755025||Prospective cohort|This group will include ICU patients for the two month period after the automated SOFA score has been activated within the electronic patient care dashboard.
11291664|NCT02755012||Longitudinal|155 women enrolled in 2nd or 3rd trimester of pregnancy, and seen again, with their infant, at 0-6 wk postpartum, and 4-6 mo postpartum
11291665|NCT02755012||Early Postpartum|60 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
11291666|NCT02755012||Later Postpartum|56 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
11291667|NCT02754999|Experimental|SANGUINATE™|As Needed Dosing of SANGUINATE
11291668|NCT02754986|Experimental|measuring Holter electrocardiogram|Hotter ECG will be recorded continuously during hemodialysis
11291669|NCT02754973|Experimental|Experimental group|During hospitalization for cancer treatment, besides receiving usual care, participants in the experimental group will first receive a health education talk Participants will then be taught and encouraged to practice with some stretching and relaxing exercises during their hospitalization. After hospitalization, participants will receive an integrated experiential training program with coaching by nursing students through home visits.
11291670|NCT02754973|Placebo Comparator|Placebo Control group|Since participants in both groups are hospitalized in the same unit, to avoid contamination, participants in the placebo control group will receive the same intervention as those participants in the experimental group during their hospitalization. When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures.
11291671|NCT02754960|Active Comparator|Thalidomide group|Patients were randomly assigned to the thalidomide group and received 100 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
11291672|NCT02754960|Placebo Comparator|Placebo group|Patients were randomly assigned to the placebo group and received 100 mg of thalidomide placebo (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
11291673|NCT02754921|Experimental|Ultra-perc|
11291674|NCT02754921|Experimental|Ciaglia Blue Dolphin|
11291675|NCT02754908|Experimental|Experimental group|In addition to medical follow-up, the subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation. Qualified orchestral performers will provide the musical training. Training will start at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song). The subjects will continue on to the next level if they successfully pass the relevant test; those who do not will be encouraged to repeat test.
11291676|NCT02754908|Placebo Comparator|Placebo Control group|"The subjects will receive medical follow-up according to the schedule of the oncology units.
~They will receive the same amount of time and attention as those in the experimental group but not in a way designed to have any specific effect on the outcome measures. They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks)."
11291677|NCT02754895|Experimental|PP-weekly|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week.
11291678|NCT02754895|Experimental|PP-daily|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day.
11291679|NCT02754895|Experimental|Shortened PP-weekly plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week.
11291680|NCT02754895|Experimental|Shortened PP-daily plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day.
11291681|NCT02754895|Experimental|PP-weekly with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
11291682|NCT02754895|Experimental|PP-daily with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
11291683|NCT02754895|Experimental|Shortened PP-weekly plus MI + boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
11291684|NCT02754895|Experimental|Shortened PP-daily plus MI with boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
11291685|NCT02754882|Active Comparator|Bevacizumab (Avastin)|Avastin® + Carboplatin/Paclitaxel
11291686|NCT02754882|Experimental|SB8 (A proposed bevacizumab biosimilar)|SB8 + Carboplatin/Paclitaxel
11291687|NCT02754869||Control Subject-Drug Study|The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra---patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
11291688|NCT02754869||Dysmotility Subjects-Drug Study|The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1---3 days reducing patient time off medication
11291689|NCT02754869||Reference Range Study|The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
11291773|NCT02754323|Other|apparatus CODESNA|correlation between job stress measurement by the Maslach Burnout INVENTORY and KARASEK questionnaires and measurement of chronic stress by CODESNA tool
11291690|NCT02754869||Desmotility Reversibility Study|The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11---16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes
11291691|NCT02754856|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
11291692|NCT02754843|Active Comparator|Naida Q90-SP|Phonak's commercial power Behind-The-Ear (BTE) device, type 1.
11291693|NCT02754843|Active Comparator|Naida Q90-UP|Phonak's commercial power Behind-The-Ear (BTE) device, type 2.
11291694|NCT02754830|Experimental|LY3303560|Single IV infusion or SC injection of LY3303560 on Day 1
11291695|NCT02754830|Placebo Comparator|Saline Solution|Single IV infusion of saline solution to match LY3303560 on Day 1
11291696|NCT02754817||Insulin degludec/liraglutide|
11291697|NCT02754804||PAD patients|Patients with grade 1 claudication Measurement of biomechanic parameters while walking on treadmill
11291698|NCT02754791|No Intervention|Monthly report|A monthly report will be submitted to department heads describing their departments rate of blood culture contamination and comparing it to blood culture contamination rate in previous months and to blood culture contamination rate of the hospital as a whole
11291699|NCT02754791|Experimental|Steripath|The Steripath device (Magnolia) will be used to take blood cultures in this arm instead of standard methods. This will be in addition to a departmental monthly report (described above).
11291700|NCT02754791|Experimental|Soluprep wipes|In this arm, skin sterilization will be achieved using Soluprep wipes (3M) instead of standard methods (alcohol wipes).This will be in addition to a departmental monthly report (described above).
11291701|NCT02754778|No Intervention|control group|no intervention, regular family life
11291702|NCT02754778|Active Comparator|intervention group|6 month of regular conditional workout 1-3 times a week
11291703|NCT02754765|Experimental|endTB regimen 1 (BeLiMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
11291704|NCT02754765|Experimental|endTB regimen 2 (BeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
11291705|NCT02754765|Experimental|endTB regimen 3 (BeDeLiLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
11291706|NCT02754765|Experimental|endTB regimen 4 (DeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
11291707|NCT02754765|Experimental|endTB regimen 5 (DeCMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
11291708|NCT02754765|Active Comparator|endTB regimen 6 (Control)|endTB regimen 6 is the control regimen.
11291709|NCT02754752|Experimental|Group I (electroacupuncture therapy)|Patients undergo electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions.
11291710|NCT02754752|Placebo Comparator|Group II (sham electroacupuncture therapy)|Patients undergo modified electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. Acupuncture needles are placed in different locations using a different technique than those used for Group I.
11291711|NCT02754752|Active Comparator|Group III (waitlist control)|Patients receive standard of care without any kind of acupuncture therapy.
11291712|NCT02754739|Experimental|Pravastatin|Pravastatin 40mg tablet by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
11291713|NCT02754739|Placebo Comparator|Placebo|Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
11291714|NCT02754739|Other|Open-label control|No medication. Only nutritional education was provided to participants by a nutritionist, and participants were instructed to follow the educated guideline.
11291715|NCT02754726|Other|single arm|open label using combination therapy
11291716|NCT02754713||Patients with acute pericarditis|300 patients with a first episode of acute pericarditis
11291717|NCT02754700|Experimental|Biofeedback Hip|Hip focused biofeedback with neuromuscular training
11291718|NCT02754700|Experimental|Biofeedback Knee|Knee focused biofeedback with neuromuscular training
11291719|NCT02754700|Active Comparator|Neuromuscular Training|Neuromuscular Training component
11291720|NCT02754687|Placebo Comparator|Placebo|Placebo
11291721|NCT02754687|Experimental|11βmethyl nortestosterone dodecylcarbonate|11β-MNTDC in doses of 100 mg, 200 mg, 400 mg, and 800 mg
11291722|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
11291723|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
11291740|NCT02754583|Experimental|Targeted antibiotics arm (TAITU)|Targeted antibiotic treatment: Communities will receive targeted antibiotic treatments for children testing positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21, and 24 months. Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
11291724|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.
~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.
~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
11291725|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.
~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
11291726|NCT02754648|Active Comparator|Group A; laparoscopic ovarian endometrial aspiration|Laparoscopic ovarian endometrial aspiration will be done for thirty patients with ovarian endometriotic cyst. .
11291727|NCT02754648|Active Comparator|group B; laparoscopic ovarian endometrial stripping|Laparoscopic ovarian endometrial stripping will be done for thirty patients with ovarian endometriotic cyst.
11291728|NCT02754648|Active Comparator|Group c laparoscopic ovarian endometrial de-roofing|Laparoscopic ovarian endometrial de-roofing and bed cauterization will be done for thirty patients with ovarian endometriotic cyst.
11291729|NCT02754635|Active Comparator|Induction of labour|Induction of labour at 38-39 weeks
11291730|NCT02754635|Active Comparator|Expectant management|Expectant management until 41 weeks.
11291731|NCT02754622||Observational Group|"2hours before planned physical rehabilitation patients will have their regular ventilator changed to the study ventilator by an ICU Consultant and patients will be clinical stable for 30mins prior to the start of the planned physical rehabilitation.
~Intended physical rehabilitation as planned will continue without change. This session will be observed by a member of the research team to ensure accurate documentation of the exact timing of performance of the physical rehabilitation activity.
~Patients will also undergo an assessment by the Medical Research Council Sum-score and maximal inspiratory pressure (all part of routine physiotherapy assessment).
~Following the physical rehabilitation session, the patient to rate their perceived exertion then patients will also undergo ultrasound assessment of peripheral skeletal muscle architecture.
~Patients return to their original ventilator after 30mins by an ICU Consultant."
11291732|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-10|A total of 40 participants week 0 and week 8 will have low dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 10 L3 in 200 microliter (uL) of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
11291733|NCT02754609|Placebo Comparator|Tabasco® Sauce|A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
11291734|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-20|A total of 10 participants at week 0 and week 8 will have medium dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 20 L3 in 200 uL of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
11291735|NCT02754596|Experimental|Travoprost Intraocular Implant, high elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
11291736|NCT02754596|Experimental|Travoprost Intraocular Implant, low elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
11291737|NCT02754596|Active Comparator|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol, a beta blocker, will be dosed twice daily
11291738|NCT02754583|Experimental|WASH arm (WUHA)|"WUHA I, Behavioral: Water, sanitation, and hygiene (WASH) intervention: Communities will receive the water, sanitation, and hygiene (WASH) intervention including community water point construction, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
~WUHA II, Behavioral and Treatment: WASH intervention communities will continue to receive the water, sanitation, and hygiene (WASH) intervention.
~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline."
11291739|NCT02754583|Other|Standard of care WASH arm (WUHA)|"WUHA I: Standard of care WASH intervention: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.
~WUHA II: Standard of care WASH intervention and treatment: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.
~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
~These communities will receive a WASH package at the conclusion of the SWIIFT II study, including water point construction, hygiene and sanitation promotion, and educational materials."
11291741|NCT02754583|Other|Delayed mass antibiotics arm (TAITU)|Delayed mass antibiotic treatment: Communities will receive no mass azithromycin treatment during the study period. Communities in this treatment group have previously received at least 8 rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program (azithromycin or tetracycline) after the completion of the study.
11291742|NCT02754583|Active Comparator|Mass antibiotics arm (TAITU)|Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all individuals aged 6 months and up (20mg/kg for children; 1 g for adults); those younger than 6 months, pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline.
11291743|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
11291744|NCT02754557|Experimental|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
11291745|NCT02754557|Experimental|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
11291746|NCT02754544|Experimental|Diagnostic (electrocorticography)|Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.
11291747|NCT02754531|Experimental|Subjects|USG was used to measure the internal transversal subglottic diameter on the crichoid cartilago level while the head was in sniffing position. After USG measurement was recorded, Cole formula was used to measure internal diameter of uncuffed endotracheal tube.
11291748|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
11291749|NCT02754505|Other|Early rehabilitation group|Directly after transfer to a general ward the early rehabilitation group started with an early rehabilitation program, as ordered by an experienced physiatrist. The applied intervention (early rehabilitation) is a combination out of different therapeutic modalities (for further information please see interventions).
11291750|NCT02754505|Other|Usual care group|The usual care group received single physical therapy sessions as ordered by the primary care team after transfer from the ICU to the general ward. The applied intervention (usual care) is a combination out of different therapeutic modalities (for further information please see interventions).
11291751|NCT02754492|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
11291752|NCT02754492|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
11291753|NCT02754492|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
11291754|NCT02754479|Experimental|Laser treatments|Each subject will receive a combination of 532 nm KTP and/or 1064 nm Nd:YAG laser treatment
11291755|NCT02754466|Experimental|Deep dentin lesions|Subjective vs objective criteria in selective excavation of carious lesions Group 1: selective carious dentin excavation using subjective criteria (standard protocol in Dentistry) Group 2: selective carious dentin excavation using objective criteria (polymer burs) All restorations performed using high-viscosity glass-ionomer.
11291756|NCT02754466|Experimental|Shallow and medium depth dentin lesion|Glass-ionomer vs Bulk fill composites in the ART approach All cavities excavated using hand-instruments only (ART approach) Group 1: restorations using high-viscosity glass-ionomer Group 2: restorations using self-etch adhesive and bulk fill composite
11291757|NCT02754453|Other|Behavioral|
11291758|NCT02754440|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
11291759|NCT02754440|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
11291760|NCT02754440|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
11291761|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
11291762|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
11291763|NCT02754414|Experimental|Healthy Volunteers|Autologous, cold stored, PAS/plasma suspended platelets stored for various periods (3 to 20 days).
11291764|NCT02754401|Other|group 1|non-periodontitis persons (PSI 0-2)
11291765|NCT02754401|Other|group 2|periodontitis persons (PSI 3-4)
11291766|NCT02754375|Experimental|Patient|Patient with resistant depression treated with rTMS
11291767|NCT02754362|Experimental|Block 1|
11291768|NCT02754362|Experimental|Block 2|
11291769|NCT02754362|Experimental|Block 3|
11291770|NCT02754349|Experimental|Validation|SphygmoCor version 7, AtCor Medical, Sydney, Australia
11291771|NCT02754336|Active Comparator|Cogmed Robomemo, working memory training|Robomemo working memory training, 25 sessions with 8 verbal and non-verbal tasks per session.
11291772|NCT02754336|Active Comparator|Othmer, neurofeedback|Othmer method neurofeedback, 25 sessions a 30 minutes.
11308880|NCT02639975|Placebo Comparator|Placebo 600 mg|
11291774|NCT02754310|Active Comparator|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
11291775|NCT02754310|Experimental|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
11291776|NCT02754297|Experimental|Personalized PRRT (P-PRRT)|"177Lu-Octreotate (LuTate) P-PRRT will be administered as follows:
~Renal absorbed radiation dose will be prescribed for the 4-cycle induction course (23 Gy) and for each subsequent cycle (6 Gy), with a reduction in cases of impaired renal or bone marrow function, or significant toxicity from prior cycles.
~The personalized activity to be administered at each cycle will be derived from renal dose per unit of injected activity that is predicted by patient characteristics or renal dose delivered during prior cycle(s).
~Participants responding to the induction course of P-PRRT will be eligible to receive additional consolidation and/or maintenance cycles.
~Participants with prior PRRT exposure outside the trial may receive less induction cycles, or only consolidation/maintenance cycle(s)."
11291777|NCT02754284|Experimental|Autologous fat transplantation|
11291778|NCT02754284|Experimental|Functional collagen scaffold transplantation|
11291779|NCT02754271|Experimental|Intervention|A research-based film (Fit for Dialysis) and a 16-week exercise program involving activities during dialysis, at home, and in the community.
11291780|NCT02754271|No Intervention|Control|The 16-week exercise program involving activities during dialysis, at home, and in the community.
11291781|NCT02754258|Placebo Comparator|Placebo|60 day oral administration of sugar placebo twice per day before lunch and supper.
11291782|NCT02754258|Experimental|Methylphenidate (MPH)|60 day oral administration of active study drug (methylphenidate) twice per day before lunch and supper.
11291783|NCT02754245||JPS|study sample at JPS included for analysis
11291784|NCT02754245||BUMC Dallas|study sample at Baylor University Medical Center Dallas included for analysis
11291785|NCT02754245||BUMC at Gardin|study sample at Baylor University Medical Center Gardin included for analysis
11291786|NCT02754245||BUMC Waxahachie|study sample at Baylor University Medical Center Waxahachie included for analysis
11291787|NCT02754245||BUMC Carrolton|study sample at Baylor University Medical Center Carrolton included for analysis
11291788|NCT02754245||BUMC McKinney|study sample at Baylor University Medical Center McKinney included for analysis
11291789|NCT02754232|Active Comparator|Telemedical training|Patients in the intervention group will receive telemedical training 21 times, three times weekly for seven weeks. During the first three weeks the regional physiotherapists will be responsible for the training. Municipal occupational -and physiotherapists will manage the last four weeks' training.
11291790|NCT02754232|No Intervention|The usual training or no training|Patients in the control-group will receive no telemedical training. They will be discharged to the municipal sphere with a rehabilitation plan, where they have the possibility to receive training.
11291791|NCT02754219|Experimental|Evogliptin|Hepatic dysfunction, Healthy control
11291792|NCT02754206||Control|Subjects who are collegiate level athletes who do not have a concussion and are currently playing a contact-collision sport.
11291793|NCT02754206||Concussed|Subjects who have recently suffered a sports-related concussion and are currently a collegiate athlete playing a contact-collision sport.
11291794|NCT02754193|Experimental|Moderate hypothermia|Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
11291795|NCT02754193|No Intervention|Normothermia|Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
11291796|NCT02754180|Active Comparator|chemotherapy|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.
11291797|NCT02754180|Experimental|chemotherapy with chemoradiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
11291798|NCT02754167|Experimental|PRS-080#022-DP|Hepcidin antagonist, single administration, ascending doses
11291799|NCT02754167|Placebo Comparator|PRS-080-Placebo#001|Comparator treatment, single administration
11291800|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
11291801|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
11291802|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
11291803|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
11291804|NCT02754141|Experimental|Arm A-Monotherapy|BMS-986179, dose as specified
11291805|NCT02754141|Experimental|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
11291806|NCT02754141|Experimental|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
11291807|NCT02754128|Active Comparator|BeFAST|Motor learning-based program involving athletic lower extremity training of gait-related skills.
11291808|NCT02754128|Active Comparator|BeSTRONG|Lower limb strength training program involving progressive muscle resistance exercises.
11291809|NCT02754102|Experimental|Sunscreen Spray-Liquid|All subjects are patched with the same product
11291810|NCT02754089|Experimental|Rhus|500 mg twice daily after meal for 6 weeks
11291811|NCT02754089|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
11291812|NCT02754076|Experimental|AX 250|In Part 1, patients will receive up to 3 escalating doses of AX 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of AX 250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
11291813|NCT02754063|Active Comparator|ICP Management|
11291814|NCT02754063|Experimental|PbtO2 + ICP Management|
11291815|NCT02754050|Experimental|Polypectomy|When a 6-25mm polyp is identified the Tandem snare will be inserted through the colonoscope, remove and retrieve the polyp.
11291817|NCT02754024||Hemi shoulder arthroplasty (HSA)|Replacement of humeral head only
11291818|NCT02754011|Experimental|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
11291819|NCT02753998|Experimental|Conventional angioplasty + paclitaxel-coated balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with paclitaxel-coated balloon
11291820|NCT02753998|Placebo Comparator|Conventional angioplasty + placebo balloon|Treatment of stenosis of AVF by conventional angioplasty + 1 minute additional angioplasty with placebo balloon.
11291821|NCT02753972|Experimental|Mindful Eating and Living|The goal of the Mindful Eating and Living (MEAL) intervention was to apply mindfulness to apply mindfulness to eating behavior. The content for the MEAL sessions included group discussion, mindfulness meditation, and group eating exercises. The course, based on the work of Kristeller, Baer, & Quillian-Wolever (31), emphasized brief daily meditation and pairing meditation with eating, but was more streamlined in terms of didactic content and course length. Participants examined hunger and satiety cues, the qualities of foods they crave, and emotional and cognitive states associated with eating. Each session included an eating exercise with a variety of foods. The monthly refresher sessions included a brief meditation, a brief eating exercise, and group discussion. (The MEAL curriculum is available from the authors.)
11291822|NCT02753972|Active Comparator|Active Control|The Active Control (CONT) group matched the MEAL group regarding schedule. The agenda for the CONT sessions involved giving each participant the opportunity to discuss issues such as food choices, activity levels, and caloric goals. The sessions began by having the participants check-in about their experiences with eating. Next, the clinical psychology graduate student led the participants in goal setting and finally there was a question and answer period when the registered dietician answered questions about food selection. The monthly refresher sessions had the same agenda as the initial weekly sessions.
11291823|NCT02753959|Experimental|Acute Intervention|Patients will need to be Clinically stable patients with established neuromuscular disease with clinical secretions or cough PEF <270 and history of chest infections. Patients are required to be stable for the preceding 4 weeks with no changes to medications or ventilator settings.
11291824|NCT02753959|Experimental|Stable Intervention|Patients with established neuromuscular disease admitted to either the Lane Fox Respiratory Unit or Critical Care at St Thomas' Hospital with acute respiratory deteriorations and with the need for respiratory physiotherapy for secretion management.
11291825|NCT02753946|Experimental|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
11291826|NCT02753946|Active Comparator|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
11291827|NCT02753933||MRI scan|Direct referral from Primary Care (GPs) to an MRI scan as the initial Secondary Care point of contact.
11291828|NCT02753933||Neurology Appointment|Referral from Primary Care (GPs) to Neurology Services in Secondary Care as the initial Secondary Care point of contact.
11291829|NCT02753920|Active Comparator|Retrograde fill voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.
~Catheter is removed
~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).
~The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).
~If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids <200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
11291830|NCT02753920|Active Comparator|Force of Stream (FAST) voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.
~Catheter is removed
~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).
~The patient will subjectively quantify their force of stream via VAS scale.
~If VAS scale >/=50 (>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR
~If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is <500cc, the patient will be discharged without a catheter; if PVR is >/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
11291831|NCT02753907|Experimental|Low LA (linoleic acid)|Individuals who replaced 10 mL soy oil with one apple
11291832|NCT02753907|No Intervention|Medium LA|Individuals who maintained their usual food intake
11291833|NCT02753907|Experimental|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9 g of soy oil as a supplement
11291834|NCT02753894|Experimental|4.5 g/day group|Three times a day
11291835|NCT02753894|Experimental|6.0 g/day group|Three times a day
11291836|NCT02753894|Experimental|7.5 g/day group|Three times a day
11291837|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
11291838|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
11291839|NCT02753868|Experimental|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
11291840|NCT02753868|Experimental|Hemodialysis with Exercise (1-st hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
11291841|NCT02753868|Experimental|Hemodialysis with Exercise (3-rd hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
11291842|NCT02753855|Experimental|Telavancin Administration|Single dose of telavancin administered as a 1-hour intravenous infusion
11291843|NCT02753842|Experimental|Fitted, Then Thin, Then Standard Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
11291844|NCT02753842|Experimental|Fitted, Then Standard, Then Thin Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
11291845|NCT02753842|Experimental|Thin, Then Fitted, Then Standard Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
11291846|NCT02753842|Experimental|Thin, Then Standard, Then Fitted Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
11291847|NCT02753842|Experimental|Standard, Then Fitted, Then Thin Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
11291848|NCT02753842|Experimental|Standard, Then Thin, Then Fitted Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
11291849|NCT02753829|Experimental|Experimental group 1|Cardiovascular rehabilitation program using Kinect of Xbox, in home care context,virtual format
11291850|NCT02753829|Experimental|Experimental group 2|Cardiovascular rehabilitation program using paper manual, in home care context, conventional format
11291851|NCT02753829|Other|Control Group|Educational component
11291852|NCT02753816|Experimental|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
11291853|NCT02753816|Placebo Comparator|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
11291854|NCT02753803|Experimental|A group|Evogliptin Pioglitazone Evogliptin+Pioglitazone
11291855|NCT02753803|Experimental|B group|Pioglitazone Evogliptin Evogliptin+Pioglitazone
11291856|NCT02753803|Experimental|C group|Evogliptin Evogliptin+Pioglitazone Pioglitazone
11291857|NCT02753803|Experimental|D group|Pioglitazone Evogliptin+Pioglitazone Evogliptin
11291858|NCT02753803|Experimental|E group|Evogliptin+Pioglitazone Evogliptin Pioglitazone
11291859|NCT02753803|Experimental|F group|Evogliptin+Pioglitazone Pioglitazone Evogliptin
11291860|NCT02753790|Experimental|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
11291861|NCT02753764|No Intervention|Normal control|Health volunteers will be recruited as an additional control group.
11291862|NCT02753764|Other|Corticosteroid sensitive (CS) asthmatics|After the initial visit, asthmatics will be given oral prednisone for 1 week and patients will return for the spirometer assessment. Patients will be defined as CR if <10% improvement in FEV1 % predicted is observed and as CS in >12% improvement in FEV1% predicted is observed.
11291863|NCT02753764|Active Comparator|Corticosteroid resistant (CR) asthmatics active|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
11291864|NCT02753764|Placebo Comparator|Corticosteroid resistant (CR) asthmatics placebo|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
11291865|NCT02753751|No Intervention|Usual Care|No alert will be fired.
11291866|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
11291867|NCT02753738|Experimental|SSRI treatment|Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
11291868|NCT02753738|Placebo Comparator|Placebo treatment|Subjects will receive 21 days of placebo treatment while performing learning paradigms.
11291869|NCT02753725|Active Comparator|Fentanyl group|Fentanyl given at a dose of one micro gram per kilogram body weight
11291870|NCT02753725|Placebo Comparator|normal saline group|placebo arm will be given normal saline at a volume equivalent to Fentanyl dose as per body weight.
11291871|NCT02753712|Active Comparator|fluticasone/vilanterol DPI (Relvar Ellipta DPI)|Inhalation powder. 92/22µg, I inhalation od
11291872|NCT02753712|Experimental|Fluticasone/formoterol BAI|Pressurised suspension for inhalation 125/5µg, 2 inhalations bid
11291873|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
11291874|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
11291875|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
11291876|NCT02753686||Cohort 1: Endocrine Therapy (ET)|HR+ HER2- male, female pre/postmenopausal advanced breast cancer patients being treated with endocrine therapy
11291877|NCT02753686||Cohort 2: Endocrine Therapy (ET) plus Targeted Therapy (TT)|HR+ HER2- male, female pre/ postmenopausal advanced breast cancer patients being treated with endocrine therapy in combination with targeted therapy including CDK4/6 inhibitor therapy
11291912|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
11291913|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
11291984|NCT02752971|Experimental|Sodium diclofenac|A dilution of sodium diclofenac 75 mgrs (3ml) and 12 ml of solution 0,9% was infiltrated in surgical wound after close the aponeurosis
11291878|NCT02753673||Breast Cancer|The assessments are all qualitative. The assessments include an in-person, open-ended qualitative interview, during which the interviewer will use an interview guide to ensure that all relevant topics are discussed. Participants will also complete the Patient Expectations with Breast Reconstruction questionnaire using the think-aloud technique in order to identify which questions reflect the expectations of BCT patients, which questions need modification to reflect the expectations of BCT patients and which questions are not appropriate for BCT patients. The responses to the expectations questionnaire for this portion of the interview will not be recorded or analyzed; only the participants' thoughts and opinions about the questions will be recorded.
11291879|NCT02753660|Active Comparator|Traditional sitting position|Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
11291880|NCT02753660|Experimental|Pendant position|Patients sit with both their underarms propped up on a metal prop, thus both arms hanging from the prop before spinal anesthesia begun.
11291881|NCT02753647|Experimental|Chidamide plus R-CHOP|Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Doxorubicin 50mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Chidamide 20mg/d PO d1, 4, 8, 11 Frequency every 21 days for 6 cycles
11291882|NCT02753634|Experimental|Square-stepping exercise Intervention|Participant attend sessions 2 times per week for 24-weeks at a community location. An instructor demonstrated increasingly difficulty walking or stepping patterns across a gridded mat and participants are asked to try and remember and repeat the patterns. Social engagement is encouraged.
11291883|NCT02753634|No Intervention|Usual care wait-list control group|This group will be invited to participate in square-stepping exercise after final assessments are completed.
11291884|NCT02753621|Experimental|Singing Intervention|Twelve weekly group singing classes lasting 60-90 minutes under the direction of a professional choir director and a social worker with a music background.
11291885|NCT02753621|Active Comparator|Discussion/Support Group Intervention|Twelve weekly 60-90 minute discussion groups led by a facilitator trained in discussion group facilitation; occurring at the same time and in the same location (next door) as experimental intervention (group singing).
11291886|NCT02753608|Sham Comparator|No ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients without clinical signs of VAP
11291887|NCT02753608|Experimental|Ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients displaying clinical signs of VAP
11291888|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:
~Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m^2)) or
~Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m^2) or
~Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m^2)
~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed."
11291889|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
11291890|NCT02753595|Experimental|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m^2.
11291891|NCT02753582|Active Comparator|Intervention|SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
11291892|NCT02753582|Placebo Comparator|Placebo|Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
11291893|NCT02753543|Experimental|Chidamide plus previous chemotherapy|Chidamide 20mg/d Biw p.o. on d1,4,8,11 for of each cycle for 3 cycles
11291894|NCT02753530|Experimental|Arimoclomol|Participants will be asked to take 400mg arimoclomol three times a day.
11291895|NCT02753530|Placebo Comparator|Placebo|Participants will be asked to take 400mg placebo three times a day.
11291896|NCT02753517|Other|Extended hepatectomy|Hepatic Scintigraphy
11291897|NCT02753504|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
11291898|NCT02753504|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
11291899|NCT02753504|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
11291900|NCT02753491|Active Comparator|Intervention|In intervention group, three or four motivational short interview made with every participants.
11291901|NCT02753491|No Intervention|Control|non intervention group,
11291902|NCT02753478|Experimental|intracoronary hypothermia group|Patients who will receive intracoronary hypothermia before and during percutaneous coronary intervention
11291903|NCT02753465|Experimental|left colic artery group|Laparoscopic D3 Lymph Node Dissection with preservation of the left colic artery
11291904|NCT02753465|Active Comparator|High ligation group|Laparoscopic D3 Lymph Node Dissection with high ligation
11291905|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
11291906|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
11291907|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
11291908|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
11291909|NCT02753439|Experimental|3rd molar|Drug: Geistlich Bio Oss
11291910|NCT02753426|Other|Doxycycline-Placebo|Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.
11291911|NCT02753426|Other|Placebo-Doxycycline|Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.
11291914|NCT02753400|Experimental|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)
~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)
~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)
~Week 4- Four emixustat HCl tablets (Strength C)
~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
11291915|NCT02753400|Placebo Comparator|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
11291916|NCT02753387|Experimental|CHLORHEXIDINE|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of chlorhexidine
11291917|NCT02753387|Placebo Comparator|NaCl 0.9 %|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of NaCl 0.9%
11291918|NCT02753361|No Intervention|Traditional|This will utilize the traditional method of performance of regional block
11291919|NCT02753361|Experimental|US-guided|In this arm, regional block will be performed under the ultrasound guidance
11291920|NCT02753348||Newborns|Newborns (within 14 days from birth)
11291921|NCT02753335|Experimental|GMI and Desensitization|Left/right judgement, imagine movements of the affected area, mirror treatment and tactile stimulation of the affected limb with different materials.
11291922|NCT02753335|Experimental|Desensitization|Tactile stimulation of the affected limb with different materials.
11291923|NCT02753322|Experimental|Dual-task training group|"Subjects in this group will have 30 minutes of dual-task training with simultaneously performing balance and walking exercise and attention demanding tasks, and 30 minutes of stretching exercises.
~The training program will last for 8 weeks with frequency of 2 sessions a week."
11291924|NCT02753322|Active Comparator|Single-task training group|"Subjects in this group will have single-task training with 30 minutes of balance and walking exercise and 30 minutes of attention demanding task performed separately.
~The training program will last for 8 weeks with frequency of 2 sessions a week."
11291925|NCT02753322|Active Comparator|Limbs exercise group|"Subjects in this group will have stretching and strengthening exercise for 60 minutes.
~The training program will last for 8 weeks with frequency of 2 sessions a week."
11291926|NCT02753309|Active Comparator|Rapamycin 0.5mg|Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
11291927|NCT02753309|Active Comparator|Rapamycin 2.0mg|Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
11291928|NCT02753309|No Intervention|Control|Subject will be apart of the control group and won't take the study drug being tested
11291929|NCT02753283|Experimental|Denosumab, then Zoledronic Acid|Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of Denosumab.
11291930|NCT02753283|Placebo Comparator|Placebo Group, then Zoledronic Acid|Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of placebo.
11291931|NCT02753270|Active Comparator|Short catheter|Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
11291932|NCT02753270|Experimental|Long catheter preceded by tumescence|Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
11291933|NCT02753244|Experimental|Intendu FBT inpatient|Other: Motion Based Cognitive Video Games Software
11291934|NCT02753244|Active Comparator|iPad games|Other: iPad apps
11291935|NCT02753244|Experimental|Intendu FBT community|Other: Motion Based Cognitive Video Games Software
11291936|NCT02753231|Experimental|Low physical activity program|Three Physical Education sessions / week
11291937|NCT02753231|Experimental|High physical activity program|Three Physical Education sessions / week (increased volume)
11291938|NCT02753231|Experimental|Low and High physical activity program|Three Physical Education sessions / week (increased volume and intensity)
11291939|NCT02753231|Active Comparator|Conventional physical activity program|One Physical Education sessions / week
11291940|NCT02753218|Experimental|Midazolam and LEO 32731|
11291941|NCT02753205|Experimental|Control|Infusion of normal saline
11291942|NCT02753205|Active Comparator|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
11291943|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
11291944|NCT02753179|Experimental|Bilateral vestibular hypofunction|Patients suffering from chronic bilateral vestibular hypofunction.
11291945|NCT02753166|Experimental|Dexamethasone|
11291946|NCT02753166|No Intervention|Control|
11291947|NCT02753153|Experimental|Mucograft®, Geistlich Biomaterials|A Mucograft membrane will be used in state of a connective tissue graft. The dimension of the Mucograft® will be previously calculated according to the site dimensions and inserted into buccal pouch and sutured to be stabilized on the buccal aspect. The membrane is then positioned to cover the socket and inserted and sutured in the palatal pouch by the means of vertical interrupted sutures
11291948|NCT02753153|Active Comparator|Soft tissue graft|
11291949|NCT02753140|Experimental|RT concurrent with cetuximab|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.To observe the curative effect of the treatment of the cetuximab
11291950|NCT02753140|Experimental|RT concurrent with TP|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy. To observe the curative effect of concurrent radiotherapy and chemotherapy
11291951|NCT02753127|Experimental|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
11291952|NCT02753127|Active Comparator|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
11291953|NCT02753114|Experimental|Intranasal Ketamine|Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
11291954|NCT02753114|Placebo Comparator|Placebo|"Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered."
11291955|NCT02753101|Experimental|Single Arm|[18F]-FTC-146
11291956|NCT02753088|Experimental|BCD-063 (glatiramer acetate)|Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day
11291957|NCT02753088|Active Comparator|Copaxone-Teva (glatiramer acetate)|Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day
11291958|NCT02753088|Placebo Comparator|Placebo|Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day
11291959|NCT02753075|Experimental|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
11291960|NCT02753075|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
11291961|NCT02753075|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
11291962|NCT02753062|Experimental|bendamustine, rituximab|Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
11291963|NCT02753049|Experimental|Peer led mHealth adherence intervention|Eligible participants enrolled will receive five, weekly-60 minute, 'ACCESS' sessions, delivered by a peer adherence coach via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
11291964|NCT02753036||Chemotherapy Ovarian|patients with ovarian cancer and paclitaxel/ carboplatin combination chemotherapy
11291965|NCT02753036||Control Ovarian|patients with benign gynecological tumors after surgical tumor resection
11291966|NCT02753036||Chemotherapy Breast|patients with breast cancer and epirubicin/cyclophosphamide/paclitaxel combination chemotherapy
11291967|NCT02753036||Control Breast|patients with breast cancer and radiation and/or antihormonal treatment
11291968|NCT02753023||acute coronary syndromes|No intervention related
11291969|NCT02753023||acute decompensated heart failure|No intervention related
11291970|NCT02753023||warfarin intoxication|No intervention related
11291971|NCT02753023||acute pulmonary edema|No intervention related
11291972|NCT02753023||acute aortic dissection|No intervention related
11291973|NCT02753023||chest pain|No intervention related
11291974|NCT02753023||pulmonary embolism|No intervention related
11291975|NCT02753023||syncope|No intervention related
11291976|NCT02753010||Acute hip fracture|Women preoperatively with acute hip fracture with gastric emptying of carbohydrate-rich beverage
11291977|NCT02753010||Elective hip replacement|Women on waiting list for elective hip replacement with gastric emptying of carbohydrate-rich beverage
11291978|NCT02753010||Healthy volunteers|Healthy female volunteers with gastric emptying of carbohydrate-rich beverage
11291979|NCT02752997|Experimental|Intervention|"Discharge medication services included:
~Discharge medication reconciliation
~Identification of medication discrepancies and resolution
~Medication counseling using health coaching techniques with short term goal setting and follow up phone call"
11291980|NCT02752997|No Intervention|Comparator|Current standard of care provided by nursing staff.
11291981|NCT02752984||PICC insertion|Peripherally Inserted Central Catheter insertion
11291982|NCT02752971|Experimental|Bupivacaine|A dilution of Bupivacaine 0,25% , 15 ml was infiltrated in surgical wound after close the aponeurosis
11291983|NCT02752971|Experimental|Bupivacaine, sodium diclofenac|A dilution of Bupivacaine 0,25% and sodium diclofenac 75 mgr, was infiltrated in surgical wound after close the aponeurosis
11292052|NCT02752464|Active Comparator|Feedback report|Feedback report Participants receive a brief printed feedback report
11291985|NCT02752958|Experimental|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
11291986|NCT02752945|Experimental|One-day CBT workshop (+Usual Care)|"One-day CBT-based workshop (DISCOVER), followed by up to three brief telephone contacts to review goals set in workshop."
11291987|NCT02752945|Active Comparator|Usual care|Usual care afforded by local CAMHS services
11291988|NCT02752932|Other|HNSCC -PDX development|Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
11291989|NCT02752932|Other|RMHNSCC -PDX drug testing|Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
11291990|NCT02752919|Experimental|Part A Galunisertib - 1 tablet|Single oral dose of galunisertib in Japanese participants
11291991|NCT02752919|Experimental|Part A Galunisertib - 2 tablets|Single oral dose of galunisertib in Japanese participants
11291992|NCT02752919|Experimental|Part B Galunisertib - 1 tablet|Single oral dose of galunisertib in non-Japanese participants
11291993|NCT02752919|Experimental|Part B Galunisertib - 2 tablets|Single oral dose of galunisertib in non-Japanese participants
11291994|NCT02752906|Experimental|MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine-primed adolescents (greater than or equal to [>=] 15 to less than [< ]18 years) or adults (>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.
11291995|NCT02752906|Active Comparator|Menactra®|Healthy, meningococcal- vaccine-primed adolescents (>= 15 to < 18 years) or adults (>= 18 years) received a single dose of Menactra ® vaccine on Day 0.
11291996|NCT02752880|Experimental|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
11291997|NCT02752880|Placebo Comparator|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
11291998|NCT02752867|Experimental|Jianpi Yishen Huatan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
11291999|NCT02752867|Placebo Comparator|The control group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
11292000|NCT02752854||Group A|Pain threshold measurement in high altitude
11292001|NCT02752854||Group B|Pain threshold measurement in low altitude
11292002|NCT02752841|Experimental|Intervention|Nutritional vitamin D repletion and maintenance
11292003|NCT02752828|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
11292004|NCT02752828|Active Comparator|insulin glargine|"Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
11292005|NCT02752815|Active Comparator|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days
~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
11292006|NCT02752815|Experimental|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days
~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
11292007|NCT02752802|Active Comparator|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
11292008|NCT02752802|Active Comparator|Control|The control group will include standard of care for diagnostic coronary angiograms.
11292009|NCT02752789||Pediatric Heart Transplant Recipients|CTOTC-04 (ClinicalTrials.gov ID NCT01005316) participants who consent to long-term follow-up as part of this study as well as candidates less than 21 years of age who are listed for isolated orthotopic heart transplantation at one of the participating sites
11292010|NCT02752776|Experimental|Secukinumab|All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
11292011|NCT02752763|Experimental|preservative free artificial tear drop|preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.
11292051|NCT02752464|Experimental|Feedback report plus peer counseling|Feedback report plus peer counseling Participants receive 12 sessions of behavioral counseling and a brief printed feedback report
11310176|NCT02631551|Active Comparator|Mometasone furoate NS|
11292012|NCT02752763|Experimental|%40 Autologous serum(AS)|peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.
11292013|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
11292014|NCT02752750||HC_GROUP|Healthy controls
11292015|NCT02752724|Experimental|Ketamine Interventional Arm|1.0 mg/kg IV ketamine (experimental arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
11292016|NCT02752724|Active Comparator|Methohexital Control Arm|1mg/kg of methohexital (standard arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
11292017|NCT02752698|Other|laparotomy group|open surgery
11292018|NCT02752698|Experimental|Micro Hand S robotic group|Micro Hand S robotic surgery group
11292019|NCT02752698|Other|laparoscopic surgery|laparoscopic surgery group
11292020|NCT02752698|Other|da Vinci robotic group|da Vinci robotic robotic group
11292021|NCT02752685||triple negative breast cancer (TNBC)|
11292022|NCT02752685||hormone receptor (HR)-positive cohort|(currently not recruiting for this group)
11292023|NCT02752672||Psoriasis|Psoriasis patients treated with dithranol
11292024|NCT02752672||Non-Psoriasis|Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
11292025|NCT02752659|Experimental|Women with breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
11292026|NCT02752659|Experimental|Women at risk of breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
11292027|NCT02752646|Active Comparator|nepafenac 0.3%|Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
11292028|NCT02752646|Active Comparator|ketorolac 0.5%|Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
11292029|NCT02752633|Experimental|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
11292030|NCT02752620|Experimental|Osteopathic Manipulative Treatment|"We selected two types of osteopathic techniques for this study:
~Technical articulation: rhythmic technique with low speed in which the goal is the full gain range of motion.
~Myofascial techniques (Neuromuscular): techniques involving lateral stretching, linear, deep pressures and pulls of the origins and insertions aiming at a myofascial relaxation.
~Sacroiliac articulatory technique; Dorsal articulatory technique; Lumbar paraspinal muscles stretching technique; Lumbar myofascial technique (inhibitory)."
11292031|NCT02752620|Active Comparator|Exercise Therapy|"2 types of therapeutic exercises techniques were used:
~Stabilization exercises
~Stretches
~Stabilization exercises:
~Bridge on the ball 10 - 15 sec Side plank 10 - 15 sec Front board 10 - 15 sec active mobilization lumbopelvic 3 x 6 rep Squats with the ball on the wall 3 x 8 rep
~Static-passive stretch (2 x 30 sec):
~Paraspinal; Abdominals; Quadratus lumborum; Hip extenders; Hip flexors; Hip abductors; Hip adductors."
11292032|NCT02752594|Experimental|probiotic|2 mg of probiotic powder mixed in 10 ml of distilled water
11292033|NCT02752594|Placebo Comparator|placebo|10 ml of distilled water
11292034|NCT02752581|Other|Drain Group|Suction drain was applied to these patients after arthroscopic knee surgery.
11292035|NCT02752581|Other|Control Group|No suction drain was applied to this group, therefore used as a control group.
11292036|NCT02752568|Active Comparator|Endometrial scratch group|endometrial scratch controlled ovarian hyperstimulation
11292037|NCT02752568|Active Comparator|Assisted hatching group|assisted hatching controlled ovarian hyperstimulation
11292038|NCT02752568|Sham Comparator|ovarian stimulation only group|controlled ovarian hyperstimulation
11292039|NCT02752555|No Intervention|Antioxidant group|In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).
11292040|NCT02752555|Experimental|Antioxidant+modifiable lifestyle factors|In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
11292041|NCT02752542|Experimental|Psychotherapy|Cognitive Behavioral Therapy
11292042|NCT02752542|Experimental|Pharmacotherapy|Antidepressant medication
11292043|NCT02752529|Experimental|Tacrolimus/dose1|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
11292044|NCT02752529|Active Comparator|Tacrolimus/dose2|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
11292045|NCT02752516|Experimental|Anlotinib|
11292046|NCT02752503|Experimental|Nalmafene|
11292047|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
11292048|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
11292049|NCT02752477|Experimental|Opioid-free anesthetic (OFA) group|
11292050|NCT02752477|Active Comparator|Traditional Anesthesia (TA) group|
11292053|NCT02752451|Other|CO|8 subjects who did not undergo arthroscopy simulation training prior to assessment on cadaveric specimens. These served as controls.
11292054|NCT02752451|Experimental|CBAT|8 Subjects who received 4 hours of simulation training on the Cigar Box Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
11292055|NCT02752451|Experimental|AKAT|8 Subjects who received 4 hours of simulation training on the Anatomic Knee Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
11292056|NCT02752438||Survived|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation and survived.
11292057|NCT02752438||Death|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation but died.
11292058|NCT02752425|Experimental|With visual feedback|Session of speech therapy conducted with the additional use of articulatory visual feedback based on ultrasound echography, which allows to visualize the patient's tongue in real time on a computer screen
11292059|NCT02752425|No Intervention|Without visual feedback|Session of speech therapy without use of ultrasound echography
11292060|NCT02752412|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Metformin will be continued."
11292061|NCT02752412|Active Comparator|insulin glargine|"Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.
~Metformin will be continued."
11292062|NCT02752386|Experimental|Biofeedback Training 1|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide pain relief when relaxation is achieved.
11292063|NCT02752386|Active Comparator|Biofeedback Training 2|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide a painful context in which to practice relaxing.
11292064|NCT02752386|Active Comparator|Biofeedback Training 3|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback.
11292065|NCT02752360|Experimental|BSA Group|Patients accept the management of Biodegradable Stenting Anastomoses for reconstruction in the surgery of Intestinal Anastomosis
11292066|NCT02752360|Experimental|DHS Group|Patients accept the management of Double-layer Hand Sutures for reconstruction in the surgery of Intestinal Anastomosis
11292067|NCT02752347|Experimental|unilateral crossbite|unilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
11292068|NCT02752347|No Intervention|control|the surface Electromyography (surface EMG device) device will be used to examine the muscle activities on normal patients
11292069|NCT02752347|Experimental|Bilateral crossbite|Bilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
11292070|NCT02752334|No Intervention|group Bupivacaine|patients will receive 23 mL of Bupivacaine HCL 0.5% (Marcaine, 5 mg per mL; Hospira, USA) in addition to 2 mL normal saline using Ultrasound-guided Supraclavicular Brachial Plexus Block
11292071|NCT02752334|Active Comparator|group Bupivacaine Magnesium|patients will receive 23 mL of Bupivacaine HCL 0.5% in addition to 2 mL (100 mg) Magnesium Sulphate (Magnesium Sulphate 50 %, 500 mg per mL; Hospira, USA) diluted with normal saline. using Ultrasound-guided Supraclavicular Brachial Plexus Block
11292072|NCT02752321|Experimental|eDischarge + Standard Discharge (SDeD)|"Patients in this arm will be enrolled in the eDischarge technology prior to hospital discharge. Upon hospital discharge, these patients will receive a personalized eDischarge, containing text and multimedia information, in addition to receiving the standard discharge process.
~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
11292073|NCT02752321|No Intervention|Standard Discharge (SD)|"Patients in this arm will receive the standard discharge process upon hospital discharge.
~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
11292074|NCT02752308|Active Comparator|General anesthesia + caudal block|Patients who receive general anesthesia plus caudal epidural block and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
11292075|NCT02752308|Active Comparator|General anesthesia only|Patients who receive only general anesthesia and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
11292076|NCT02752295|No Intervention|Waiting list, intervention after EOS|control group / waiting list one week stress-coping intervention planned after end of study (EOS) without one week stress-coping intervention AND without an additional two days follow-up care
11292077|NCT02752295|Active Comparator|Stress-coping week without follow-up|active comparator with one week stress-coping intervention BUT without an additional two days follow-up weekend
11292078|NCT02752295|Active Comparator|Stress-coping week with follow-up|active comparator with one week stress-coping intervention AND with an additional two days follow-up weekend
11292079|NCT02752282|Sham Comparator|Control Video|Participants in this study arm will be assigned to watch a short educational video about new pap screening guidelines for women. Intervention: Cancer Screening Guidelines.
11292080|NCT02752282|Active Comparator|Intervention Video|Participants in this group will be assigned to watch a short educational video providing anticipatory counseling on their LNG-IUS' side effects and expected changes in bleeding. Intervention: Anticipatory Counseling
11292081|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
11292082|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
11292083|NCT02752243|Experimental|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
11292084|NCT02752230|Active Comparator|Exparel (Bupivicaine Liposome)|Patient will have Exparel (Bupivicaine Liposome) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
11292085|NCT02752230|Active Comparator|Marcaine (Bupivicaine)|Patient will have Marcaine (Bupivicaine) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
11292086|NCT02752217|Experimental|Inspiratory Muscle Training (IMT)|"Subjects in the inspiratory muscle training (IMT) group will perform loaded deep breathing exercise at 6 breaths/min using BreatheMaxยฎ device. The IMT protocol at 6 breathing rate (inspiratory time = 4 seconds and expiratory time = 6 seconds) with load at 25 percent of MIP for eighth weeks.
~The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks"
11292087|NCT02752217|Placebo Comparator|Control|Subjects in the control (CON) group will perform breathing exercise with inspiratory load at 2 cmH2O at 6 breathing rate using one BreatheMAXยฎ device. The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks
11292088|NCT02752204|Other|Stage 1|AZD 2014 oral tablets will be given to patients
11292089|NCT02752204|Other|Stage 2|AZD 2014 oral tablets and rituximab infusion will be given to patients
11292090|NCT02752191|Active Comparator|Ferumoxytol|Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
11292091|NCT02752191|Active Comparator|gadofosveset|gadofosveset, 0.03mmol/kg, one time bolus injection
11292092|NCT02752178||DEP+MA+|Incompletely responsive patients (approximately N ~100) who are currently depressed after greater than 6 weeks of treatment with one or more monoaminergic antidepressants
11292093|NCT02752178||DEP-MA+|Responsive patients (approximately N~50) who are not currently depressed after greater than 6 weeks of treatment with a monoaminergic antidepressant
11292094|NCT02752178||DEP+MA-|Untreated patients (approximately N~50) who are currently depressed but have not been treated with monoaminergic antidepressants in the previous 6 weeks
11292095|NCT02752178||DEP-MA-|Healthy volunteers (approximately N~50) who have no personal history of depression requiring treatment with either monoaminergic antidepressants or other clinical interventions including psychotherapy
11292096|NCT02752165|Experimental|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
11292097|NCT02752165|Active Comparator|Enhanced Usual Care|Report of symptoms to primary care physician
11292098|NCT02752152|Experimental|Computer-assisted counseling|Computer-assisted informational/educational interactive session followed by an interactive face-to-face session to discuss personal issues with a counselor as needed
11292099|NCT02752152|Experimental|On-demand counseling|The counselor asks whether the participant has any questions
11292100|NCT02752152|Active Comparator|Standard counseling|Interactive face-to-face counseling session
11292101|NCT02752152|Experimental|Appointment + reminder|Make appointment and send SMS reminder
11292102|NCT02752152|Experimental|Reminder only|Send SMS reminder only
11292103|NCT02752152|Active Comparator|No appointment and no reminder|No appointment and no SMS reminder sent
11292104|NCT02752139||patients with sleep disorders|
11292105|NCT02752139||normal individuals without sleep disorders|
11292106|NCT02752126|Active Comparator|Standard Palliative Radiation|Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
11292107|NCT02752126|Experimental|Esophageal Sparing IMRT|Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
11292108|NCT02752113|Active Comparator|Empagliflozin and Linagliptin|After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
11292109|NCT02752113|Active Comparator|Metformin and Insulin sc|Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
11292110|NCT02752100|Experimental|Interventional Therapy|Percutaneous transluminal angioplasty.
11292111|NCT02752100|No Intervention|Non-Interventional Therapy|
11292112|NCT02752087|Experimental|U-193 LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
11292113|NCT02752087|Active Comparator|U-95 LY900014 Reference|LY900014 reference dose administered via SC injection
11292114|NCT02752074|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
11292115|NCT02752074|Active Comparator|Pembrolizumab + Placebo|Pembrolizumab + Placebo
11292116|NCT02752061|Experimental|Kweneng East District|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in Kweneng East District during study period.
11292117|NCT02752061|No Intervention|All other districts|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in all other districts of Botswana (or Kweneng East prior to implementation of intervention).
11292118|NCT02752048|Experimental|TAS-205（Low dose group）|Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
11292119|NCT02752048|Experimental|TAS-205（High dose group）|High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
11292120|NCT02752048|Placebo Comparator|Placebo|Placebo group: Oral administration of tablets for 24 weeks, BID after meal
11292121|NCT02752035|Experimental|Dose escalation of ASP2215 given with azacitidine|Subjects will be treated with ASP2215 daily (days 1-28) and azacitidine daily for 7 days (days 1-7).
11292122|NCT02752035|Experimental|Arm A: ASP2215|Subjects will be treated daily each 28-day cycle.
11292123|NCT02752035|Experimental|Arm AC: ASP2215 + azacitidine|Subjects will be treated with ASP2215 daily and azacitidine daily for 7 days (days 1-7) each 28-day cycle.
11292124|NCT02752035|Active Comparator|Arm C: azacitidine|Subjects will be treated with azacitidine for 7 days (days 1-7) each 28-day cycle.
11292125|NCT02752022||Heavy smokers|Heavy smokers (continuous smoking of >10 cigarettes per day) for at least 6 months who will give up smoking and switch to nicotine containing e-cigarettes for 28 days to help them quit smoking.
11292126|NCT02752009|Experimental|Axillary Lymph Node Sampling Clip|"Axillary Lymph Node Biopsy
~-- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes.
~Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed.
~Wire-localization of the clipped node on the day of surgery.
~Lymphatic mapping performed with either radiocolloid and/or blue dye.
~Sentinel lymph node biopsy will be performed on the day of surgery.
~--- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen.
~Axillary lymph node dissection as is the standard of care."
11292127|NCT02751996|Active Comparator|Part A Cohort 1: 25mg SB 9200|Part A Cohort 1: 25mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292128|NCT02751996|Placebo Comparator|Part A Cohort 1: 25mg Placebo|Part A Cohort 1: 25mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292129|NCT02751996|Active Comparator|Part A Cohort 2: 50mg SB 9200|Part A Cohort 2: 50mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292130|NCT02751996|Placebo Comparator|Part A Cohort 2: 50mg Placebo|Part A Cohort 2: 50mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292131|NCT02751996|Active Comparator|Part A Cohort 3: 100mg SB 9200|Part A Cohort 3: 100mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292132|NCT02751996|Placebo Comparator|Part A Cohort 3: 100mg Placebo|Part A Cohort 3: 100mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292133|NCT02751996|Active Comparator|Part A Cohort 4: 200mg SB 9200|Part A Cohort 4: 200mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292134|NCT02751996|Placebo Comparator|Part A Cohort 4: 200mg Placebo|Part A Cohort 4: 200mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292135|NCT02751996|Active Comparator|Part B: SB 9200 with tenofovir|Part B: SB 9200 selected dose from Part A administered in combination with tenofovir 300 mg qd. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292136|NCT02751996|Active Comparator|Part B: Tenofovir 300 mg|Part B: Tenofovir 300 mg qd monotherapy. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
11292137|NCT02751983|Experimental|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
11292138|NCT02751983|Active Comparator|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
11292139|NCT02751970|Active Comparator|3 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin.
11292140|NCT02751970|Experimental|2 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of an adhesive/primer step.
11292141|NCT02751970|Active Comparator|2 step SE & Dental restoration|Dental restoration with etching the dental substrates with acidic primer, followed by the application of adhesive resin.
11292142|NCT02751970|Experimental|1 step SE & Dental restoration|Dental restoration with etching and infiltrate the dental substrates with acidic primer/adhesive system.
11292143|NCT02751957|Experimental|Intervention|Receives caregiver coaching version of the Early Start Denver Model (ESDM) intervention, delivered by non-specialist workers. ESDM is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
11292144|NCT02751944|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 2 weeks
11292145|NCT02751944|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 2 weeks
11292146|NCT02751931|Experimental|Children (3 to < 12 Years)|Participants aged 3 to < 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg (milligram) [PED25]) on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50], orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 end-of-study (EOS) or end-of-treatment (EOT).
11292353|NCT02750514|Experimental|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
11292147|NCT02751931|Experimental|Adolescents (12 to < 18 Years)|Participants aged 12 to < 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight [PED25] on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50] orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT.
11292148|NCT02751918|Experimental|Anetumab ravtansine|Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.
11292149|NCT02751905|Experimental|BIIB074|Single oral dose on Day 1
11292150|NCT02751892|Experimental|Active Lifestyle Programme|Supervised exercises for 3 months and motivational interviewing to facilitate physical activity behaviour change. Supervised exercise sessions took place twice per week for the first four weeks. This was tapered off to once per week for the second four weeks. During the last month of the intervention participants continued with the exercise at home and were encouraged to achieve 150min of moderate to vigorous PA per week.
11292151|NCT02751892|No Intervention|Standard Care|Received usual care. Was offered the intervention after the completion of the study.
11292152|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
11292153|NCT02751866|Active Comparator|Active supplement, low carbohydrate|Whole fruit berry powder, low carbohydrate diet
11292154|NCT02751866|Placebo Comparator|Placebo, Control|placebo powder, higher carbohydrate diet
11292155|NCT02751853|Experimental|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
11292156|NCT02751853|Experimental|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
11292157|NCT02751853|Active Comparator|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
11292158|NCT02751840|Experimental|Caffeine|Caffeine capsule (200 mg) is taken prior to RMR measurement
11292159|NCT02751840|Placebo Comparator|Placebo|Placebo (starch) capsule is taken prior to RMR measurement
11292160|NCT02751840|Experimental|Coffee|Black coffee (9 grams) is consumed prior to RMR measurement
11292161|NCT02751840|Placebo Comparator|Decaffeinated|Decaffeinated Black coffee (9 grams) is consumed prior to RMR measurement
11292162|NCT02751827||Prospective cohort - Blood sample|All patients without major violations of the eligibility criteria are included in this population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.
11292163|NCT02751801||Adults and children with hypophosphatasia|Healthcare use interview
11292164|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated long-term opioid therapy or initiated ER/LA opioid therapy
11292165|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than one year
11292166|NCT02751749|Experimental|Unified Protocol|"CBT based Internet delivered treatment targeting transdiagnostic vulnerability and maintaining factors for chronic pain and emotional problems.
~Since this is a new target Group, a replicated single case design was used and participants are their own Control Group (no other treatment arms)."
11292167|NCT02751736|Experimental|Intervention|"2 g sachet (CJLP 243) once a day for 3 weeks
~10 billion lactic acid bacteria(lactobacillus plantarum CJLP243), maltodextrin, glucose(anhydrous)"
11292168|NCT02751736|Placebo Comparator|Control|"2g sachet (near identically appearing placebo) once day for 3 weeks
~maltodextrin, glucose(anhydrous)"
11292169|NCT02751723||lung cancer|validated questionnaires
11292170|NCT02751723||malignant melanoma|validated questionnaires
11292171|NCT02751723||cancer of the hepatobiliary system|validated questionnaires
11292172|NCT02751723||head and neck cancer|validated questionnaires
11292173|NCT02751723||breast cancer|validated questionnaires
11292174|NCT02751723||ovarian carcinoma|validated questionnaires
11292175|NCT02751723||pancreatic cancer|validated questionnaires
11292176|NCT02751723||stomach cancer|validated questionnaires
11292177|NCT02751723||oesophageal cancer|validated questionnaires
11292178|NCT02751723||colorectal cancer|validated questionnaires
11292179|NCT02751710|Experimental|Whole-body FDG PET-CT alone|
11292180|NCT02751710|No Intervention|Conventional breast cancer staging|Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen & pelvis
11292181|NCT02751671|Experimental|POCUS before clean catch sampling|The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is > 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is < 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches > 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
11292182|NCT02751671|Experimental|Standard clean catch sampling|Patients allocated to this arm will have a 20 minute feeding period either being breastfed or provided with formula intake appropriate to the infant's age and weight. If possible, the genital areas of the infant will be cleaned with warm water and soap and dried with sterile gauze prior to the feeding. The parents will let the diaper opened and will be will be ready to collect urine if the child voids during the feeding period. After the feeding, the stimulated clean-catch procedure will be performed without prior ultrasound
11292183|NCT02751658|Other|patients in the Otorhinolaryngology|patients in the Otorhinolaryngology department realization of a levy into the mouth swab on the day of admission to hospital and the day of release
11292184|NCT02751645|No Intervention|Standard of Care Control|This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
11292185|NCT02751645|Experimental|Acute Normovolemic Hemodilution|This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
11292186|NCT02751632|Experimental|Step 1-Regular SPS Therapy|Support and Problem Solving Therapy delivered to all study participants over a six-week period with a minimum of three sessions.
11292187|NCT02751632|Experimental|Responders- Monthly SPS Therapy|Participants are randomised to receive monthly Support and Problem Solving Therapy for up to 12 months.
11292188|NCT02751632|Experimental|Responders- 3-monthly monitoring|Participants are randomised to be monitored for risk every 3 months for up to 12 months.
11292189|NCT02751632|Experimental|Step 2- Regular SPS Therapy|Participants are randomised to receive regular sessions of Support and Problem Solving Therapy, with a minimum of six sessions delivered over an 18-week period.
11292190|NCT02751632|Experimental|Step 2- Regular CBCM|Participants are randomised to receive regular sessions of Cognitive Behavioural Case Management, with a minimum of six sessions delivered over an 18-week period.
11292191|NCT02751632|Experimental|Step 3- Regular CBCM + Fluoxetine|Participants are randomised to receive either Cognitive Behavioural Case Management plus an antidepressant medication for six months .
11292192|NCT02751632|Placebo Comparator|Step 3- Regular CBCM+ placebo|Participants are randomised to receive Cognitive Behavioural Case Management plus placebo medication for six months.
11292193|NCT02751619|Experimental|Lidocaine Group|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, PA, USA) measuring 10 x 14 cm and containing 700 mg of Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
11292194|NCT02751619|Active Comparator|Placebo Patch|A patch, that was identical in appearance to the active patch but did not contain Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
11292195|NCT02751606|Experimental|Breast and rectal cancer|Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.
11292196|NCT02751593|Experimental|dexamethasone|dexamethasone 40mg/d for 4 days
11292197|NCT02751580|Experimental|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
11292198|NCT02751567|Experimental|Arm 1|All subjects are patched with the same product
11292199|NCT02751541|Experimental|BAY987519|All subjects are patched
11292200|NCT02751528|Experimental|ETBX-021|Ad5 [E1-, E2b-]-HER2/neu Vaccine, Suspension for Injection
11292201|NCT02751515|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
11292202|NCT02751502|Experimental|Bimanual-to-unimanual device home training program|
11292203|NCT02751502|No Intervention|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
11292204|NCT02751489|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
11292205|NCT02751476|Active Comparator|standard SAM treatment (control group)|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure.
11292206|NCT02751476|Experimental|SAM treatment + flocculent-disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a flocculent-disinfectant for household level application.
11292207|NCT02751476|Experimental|SAM treatment + chlorine disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a chlorine disinfectant for household level application.
11292208|NCT02751476|Experimental|SAM treatment + ceramic water filter|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a ceramic water filter for household level application.
11292209|NCT02751463|Experimental|BAY987519|All subjects are patched .
11292210|NCT02751450|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
11292211|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
11292212|NCT02751437|No Intervention|Low Arginine unsupplemented|These infants identified as having low blood arginine levels will receive standard care.
11292213|NCT02751437|Experimental|Low Arginine supplemented|These infants identified as having low arginine levels will receive an additional arginine infusion between days 3 and 10 of life.
11292214|NCT02751437|No Intervention|Normal Arginine|These infants identified as having normal arginine levels will receive standard care.
11292215|NCT02751424|Experimental|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
11292354|NCT02750514|Experimental|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
11292216|NCT02751424|Placebo Comparator|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
11292217|NCT02751424|Experimental|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
11292218|NCT02751424|Placebo Comparator|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
11292219|NCT02751411|Experimental|micro-enema with Promelaxin|2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
11292220|NCT02751411|Active Comparator|Macrogol 4000|One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).
11292221|NCT02751398|Experimental|Dapagliflozin|Dapagliflozin 10mg/day
11292222|NCT02751398|Placebo Comparator|Placebo|
11292223|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
11292224|NCT02751372|Experimental|BAY 987517|All subjects are patched .
11292225|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
11292226|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
11292227|NCT02751346||Patients with Pain|Patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
11292228|NCT02751346||Patients without Pain|Patients without pain age and gender matched to patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
11292229|NCT02751333|Active Comparator|FCSEMS with Endostitching (ES)|General anesthesia or conscious sedation will be started and an upper endoscope will be inserted into the participants mouth and advanced into the stomach. Endoscopic stenting with a fully covered self-expanding metal stents (FCSEMS) will then be performed. Once the stent is in place, the endoscope will be withdrawn from the participant to set-up the endostitch device unto the endoscope. Bites are taken separately with the first on the esophageal mucosa followed by a second on the stent itself and finishing with a last bite on esophageal mucosa. A cinch is then used to secure the deployed suture. An attempt at placing 2 sutures will be performed. Stent removal will then be performed at 8-weeks post-stent insertion.
11292230|NCT02751333|Active Comparator|FCSEMS with No Suturing (NS)|The procedure will be done in the same manner with same endoscopic technique, stent deployment, and timing of stent removal. The only difference would be the lack of suturing and naturally the need for suture cutting at stent removal.
11292231|NCT02751320|Experimental|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
11292232|NCT02751320|Experimental|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
11292233|NCT02751320|Experimental|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
11292234|NCT02751320|Placebo Comparator|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
11292235|NCT02751320|Active Comparator|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
11292236|NCT02751320|Active Comparator|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
11292237|NCT02751307|Active Comparator|metformin 500 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
11292238|NCT02751307|Active Comparator|metformin 1000 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, 500 mg of metformin twice a day was administered. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
11310177|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
11292239|NCT02751307|Placebo Comparator|placebo; clozapine 100 mg|In the first week, one pill of placebo was given and in the second week, placebo BID was given. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
11292240|NCT02751294|Experimental|TQ Control+ TQ SIL|Subjects received TQ Control product (2 tablets) and 30 mg TQ SIL solution orally with water after a meal.
11292241|NCT02751294|Experimental|TQ X + TQ SIL|Subjects received 2 tablets of Tafenoquine dissolution profile X and 30 mg TQ SIL solution orally with water after a meal.
11292242|NCT02751281|Active Comparator|pneumatic percutaneous nephrolithotomy|pneumatic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
11292243|NCT02751281|Active Comparator|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
11292244|NCT02751268|Placebo Comparator|Control|placebo for the realization of infraorbital and infratrochlear block
11292245|NCT02751268|Active Comparator|Ropivacaine|ropivacaine for the realization of infraorbital and infratrochlear block
11292246|NCT02751255|Experimental|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
11292247|NCT02751242||Usual Care|All patients will receive a dose of intravenous furosemide.
11292248|NCT02751229|Experimental|Honest Open Proud|"The group program is about disclosure ('coming out') versus secrecy of one's mental illness. The groups are facilitated by peers (young adults with mental illness) and mental health professionals. Each group runs for three weeks, one meeting per week, and two hours per meeting.
~Fidelity to manual: rated by PhD student in each session as proportion of key topics covered"
11292249|NCT02751229|No Intervention|Control Group|treatment as usual (TAU)
11292250|NCT02751216|Experimental|spinal cord stimulation|
11292251|NCT02751203|Experimental|Make Safe Happen App Intervention|Pre- and post-test delivered to online survey panel participants. Instruction to download and use the intervention (Make Safe Happen Mobile App) for 1 week.
11292252|NCT02751203|No Intervention|Make Safe Happen App Control|A subset of online survey panel participants (n=200) will complete a pre- and post-test survey but will receive a non-safety app (e.g. a free recipe app). After the study, participants will be asked to download the intervention app.
11292253|NCT02751177|Experimental|OncoBEAM|KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.
11292254|NCT02751164||Weekday daytime|Admitted to the critical care unit Monday-Friday 08:00-17:59
11292255|NCT02751164||Weekend daytime|Admitted to the critical care unit Saturday-Sunday 08:00-17:59
11292256|NCT02751164||Weekday night|Admitted to the critical care unit Monday-Friday 18:00-07:59 the next day
11292257|NCT02751164||Weekend night|Admitted to the critical care unit Saturday-Sunday 18:00-07:59 the next day
11292258|NCT02751151|Experimental|1|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
11292259|NCT02751138||Isocitrate dehydrogenase - 1 mutated|Immunophenotype of Glioblastoma and correlation with outcome
11292260|NCT02751138||Isocitrate dehydrogenase - 1 wild type|Immunophenotype of Glioblastoma and correlation with outcome
11292261|NCT02751125|Experimental|Augmentation of new alveolar bone|Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
11292262|NCT02751112|Experimental|Couple donor / recipient|"Each couple will be treated the same way :
~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.
~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process."
11292263|NCT02751099||de novo renal transplanted patients|renal transplanted patients
11292264|NCT02751086||Robotic Gastrectomy|Patients who will be treated for gastric cancer with the assistance of the robotic surgical system
11292265|NCT02751086||Laparoscopic Gastrectomy|Patients who will be treated for gastric cancer through laparoscopic devices.
11292266|NCT02751086||Open Gastrectomy|Patients who will be treated for gastric cancer with traditional open surgery.
11292267|NCT02751060||patients with coronary heart disease symptoms|
11292268|NCT02751047|Placebo Comparator|Manual ventilation|During anesthetic induction, facemask ventilation is performed by manual bagging, after setting adjustable pressure limiting (APL) valve at 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
11292269|NCT02751047|Active Comparator|Pressure controlled mechanical ventilation|During anesthetic induction, facemask ventilation is performed with mechanical ventilator by pressure controlled mode, with inspiratory pressure of 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
11292270|NCT02751034|Experimental|Neuramis® Deep Lidocaine|Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
11292271|NCT02751034|Active Comparator|Restylane® PERLANE-L|Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
11292272|NCT02751021|Other|Sleep apnea diagnosis|The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
11292273|NCT02750995|Experimental|Vaccination|Azacitidine + NPMW-peptide vaccine
11292274|NCT02750982|Experimental|Laughter therapy|effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
11292305|NCT02750761|Experimental|Group 2 Cohort 1: Tedizolid IV 6 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 6 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
11292351|NCT02750514|Active Comparator|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
11292275|NCT02750969|Experimental|1. lidoderm patches first|"29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.
~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
11292276|NCT02750969|Experimental|2. tegaderm patches first|"29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.
~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
11292277|NCT02750956||Group 1|Periodontal healthy individuals
11292278|NCT02750956||Group 2|Patients with chronic periodontitis
11292279|NCT02750956||Group 3|the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
11292280|NCT02750943|Experimental|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
11292281|NCT02750943|Active Comparator|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
11292282|NCT02750930|Experimental|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
11292283|NCT02750917|Experimental|GROUP LORNOXICAM|Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours
11292284|NCT02750917|Active Comparator|GROUP ETORICOXIB|Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.
11292285|NCT02750904|Experimental|Experimental therapy|
11292286|NCT02750904|Active Comparator|Control Therapy|
11292287|NCT02750891|Experimental|DSP-7888|
11292288|NCT02750878|No Intervention|Control group|Participants will receive only the standard verbal TOT surgical consent counseling.
11292289|NCT02750878|Other|Intervention group|Participants will receive the standard verbal TOT surgical consent counseling plus a handout describing their surgical intervention
11292290|NCT02750865|No Intervention|Control Usual Care|In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
11292291|NCT02750865|Experimental|Embodied Conversational Agent (ECA)|In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
11292292|NCT02750852||Analysis group|Create an algorithm to predict blood loss using patients data
11292293|NCT02750852||Control group|The algorithm was applied to analyze sensitivity and specificity
11292294|NCT02750839||proximal humerus fracture|Patients with proximal humerus fracture treated with mini-invasive plate.
11292295|NCT02750826|Other|Arm 1: Health Education Program|Patients will receive a standardized intervention focusing on healthy living. This will include mailings at study entry and one year later describing healthy lifestyle behaviors. All participants will also receive a 2-year subscription to a health magazine. In addition, all study participants will be invited to join twice-yearly Webinars/teleconferences that focus on breast cancer and other health topics, such as treatment updates in breast cancer, management of menopausal side effects, general cancer screening, etc. Finally, the study will also provide birthday and holiday greeting cards and a twice-yearly study newsletter with study updates and other general breast cancer news.
11292296|NCT02750826|Other|Arm 2: Health Education Program + Weight Loss Intervention|Patients will receive a standardized intervention focusing on healthy living as described in the Arm 1 (Health Education Program). In addition, patients will utilize a standardized, 2-year, telephone-based weight loss intervention. The intervention will include individual weight loss, caloric restriction, and physical activity goals for each participant. It will be administered through semi-structured phone calls delivered by trained coaches at the BWEL call center and supplemented through print and on-line materials. The intervention will utilize a toolbox approach that will allow for tailoring for the individual participant.
11292297|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
11292298|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
11292299|NCT02750800||Adalimumab and AbbVie Care 2.0|Adalimumab administered via subcutaneous (SC) injection for 12 months according to the approved EMA label and Hungarian financial protocols and supportive services via the AbbVie Care 2.0 patient support program
11292300|NCT02750787|Experimental|Nutritional Study Product|A ready-to-drink peptide-based liquid formula for patients with impaired gastro-intestinal function.
11292301|NCT02750774|Experimental|Low-Glycemic Index Group|Women in the low- glycaemic index group received a dietary intervention based on 3 main meals and 3 snacks, with a precise macronutrient composition, and a physical activity counseling according to the ACOG and ACSM recommendations.
11292302|NCT02750774|Other|Standard Care Group|Women in the Standard Care Group received a simple nutritional booklet regarding lifestyle, which was in agreement with the Italian Guidelines for a healthy diet during pregnancy that included general advice regarding food consumption and physical activity.
11292303|NCT02750761|Experimental|Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 5 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
11292304|NCT02750761|Experimental|Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
11292306|NCT02750761|Experimental|Group 2 Cohort 2: Tedizolid IV 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
11292307|NCT02750761|Experimental|Group 3: Tedizolid oral 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single dose of tedizolid phosphate oral suspension dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
11292308|NCT02750761|Experimental|Group 4: Tedizolid oral 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single dose of tedizolid phosphate oral suspension dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
11292309|NCT02750748|Experimental|4mg Intranasal Naltrexone|Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril
11292310|NCT02750748|Experimental|4mg Intranasal Naltrexone with Intravail|Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril
11292311|NCT02750748|Experimental|2mg Intramuscular Naltrexone|Administer 2 mg formulation intramuscularly
11292312|NCT02750748|Experimental|50mg Naltrexone|Administer 50mg formulation orally
11292313|NCT02750735||Retrospective NCWS patients|The clinical charts of NCWS patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca were retrospectively reviewed. Patients had all been diagnosed with NCWS between January 2001 and June 2011, by a DBPCC method, and included in a previously published study. These charts included specific sections for the presence of associated atopic diseases, including nickel allergy. In this way, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy. Incomplete clinical charts were excluded.
11292314|NCT02750735||Prospective NCWS patients|The investigators also prospectively surveyed adult patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS. The patients were recruited between December 2014 and March 2016 at 3 centers: the two already mentioned and the Gastroenterology Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the patients had been referred due to gastrointestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. Again, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy.
11292315|NCT02750735||Retrospective NCWS control patients|To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
11292316|NCT02750735||Prospective NCWS control patients|As for the retrospective study, to compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 patients with functional gastroenterological symptoms, was selected, with the same criteria adopted for the retrospective study.
11292317|NCT02750722|Experimental|Cycling in combination with Flutter® therapy|Participants perform 30 minutes of moderately intense cycling exercise in 4-min intervals at 75% of their maximal heart rate and interspersed with 2-min resting periods during which 6-8 breathing maneuvers are performed with the Flutter®.
11292318|NCT02750722|Active Comparator|Cycling without Flutter® therapy|Participants perform 30 minutes of continuous moderately intense cycling exercise at 75% of their maximal heart rate without additional Flutter® breathing maneuvers.
11292319|NCT02750709|Experimental|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292320|NCT02750709|Experimental|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292321|NCT02750709|Experimental|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292322|NCT02750709|Experimental|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292323|NCT02750709|Experimental|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292324|NCT02750709|Experimental|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292325|NCT02750696|Active Comparator|Co/ Ac|Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
11292352|NCT02750514|Experimental|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
11310483|NCT02629679||Females athletes|Athletic girls (involved in sports)
11292326|NCT02750696|Experimental|Tr/ Ac|Tramadol/acetaminophen (37.5 mg/325 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of tramadol/acetaminophen (37.5 mg/325 mg) every 4 hours for 3 days.
11292327|NCT02750670|Experimental|GD2P|Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m^2 by IV for 1 hour all for a duration of 3 cycles
11292328|NCT02750657||Patients with advanced pancreatic ductal adenocarcinoma|
11292329|NCT02750644||High-risk|Patients with atherosclerotic carotid disease with (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
11292330|NCT02750644||Standard-risk|Patients with atherosclerotic carotid disease without (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
11292331|NCT02750631|Experimental|Triple Therapy|Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance
11292332|NCT02750618|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
11292333|NCT02750605|Experimental|Drug eluting balloon angioplasty|Intervention with DEB angioplasty in long lesions of crural arteries
11292334|NCT02750605|Active Comparator|Plain old balloon angioplasty|Intervention with plain old balloon angioplasty POBA in long lesions of crural arteries
11292335|NCT02750592|Experimental|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
11292336|NCT02750579|Active Comparator|Control group|control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)
11292337|NCT02750579|Experimental|experimental group|experimental group: early Percutaneous coronary intervention for revascularization intervention (<2 hours)
11292338|NCT02750566|Experimental|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
11292339|NCT02750566|Active Comparator|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
11292340|NCT02750553|Experimental|Pre-test|Three healthy male subjects were randomized in 2:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
11292341|NCT02750553|Experimental|Cohort 1|Eight healthy subjects were randomized in 3:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
11292342|NCT02750553|Experimental|Cohort 2|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 10 mg SHR0534 or matching placebo.
11292343|NCT02750553|Experimental|Cohort 3|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 25 mg SHR0534 or matching placebo.
11292344|NCT02750553|Experimental|Cohort 4|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 50 mg SHR0534 or matching placebo.
11292345|NCT02750553|Experimental|Cohort 5|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 100 mg SHR0534 or matching placebo.
11292346|NCT02750540|Active Comparator|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
11292347|NCT02750540|Active Comparator|Product B dose|Product B will contain tenofovir (TFV) *660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
11292348|NCT02750540|Active Comparator|Product C dose|Product C will contain tenofovir (TFV) *660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
11292349|NCT02750540|Placebo Comparator|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
11292350|NCT02750540|Placebo Comparator|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
11310685|NCT02628275|No Intervention|Control|Continued inactivity
11292355|NCT02750514|Experimental|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
11292356|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
11292357|NCT02750488|Experimental|BAY987517|All subjects are patched with the same product
11292358|NCT02750475|Experimental|Arm 1|All subjects are patched.
11292359|NCT02750462|Experimental|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
11292360|NCT02750462|Active Comparator|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
11292361|NCT02750449|Experimental|Arm 1|All subjects are patched.
11292362|NCT02750436|Experimental|Ultrasound guided|Ultrasound guided sacral lateral branch block
11292363|NCT02750436|Active Comparator|Fluoroscopy guided|Fluoroscopically guided sacral lateral branch block
11292364|NCT02750423|Active Comparator|DHCA+RCP|Participants undergoing ascending aortic and hemiarch replacement will receive deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP).
11292365|NCT02750423|Active Comparator|MHCA+uSACP|Participants undergoing ascending aortic and hemiarch replacement will receive moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA+uSACP).
11292366|NCT02750410|Experimental|Dulaglutide|Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
11292367|NCT02750410|Placebo Comparator|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
11292368|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
11292369|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
11292370|NCT02750384|Experimental|50% SDD granules, fasting|50% spray dried dispersion granules, fasting
11292371|NCT02750384|Active Comparator|25% SDD powder for suspension, fasting|25% spray dried dispersion powder for suspension, fasting
11292372|NCT02750384|Experimental|50% SDD granules, fed|50% spray dried dispersion granules, fed
11292373|NCT02750371|Experimental|Patients with brain tumors treated by radiotherapy|"Patients with:
~- meningioma of the cavernous sinus for which radiotherapy is planned
~Or
~- a pituitary adenoma for which radiotherapy is planned"
11292374|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
11292375|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292376|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292377|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292378|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292379|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292380|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292381|NCT02750332|Experimental|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292382|NCT02750332|Experimental|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
11292383|NCT02750319|Placebo Comparator|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
11292384|NCT02750319|Experimental|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
11292385|NCT02750306|Experimental|Suvorexant|Participants will receive 1 suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' suvorexant dose may be increased to 20 mg if their Clinical Global Impression of Insomnia Severity (CGI-S) is ≥3 and investigators feel they can tolerate the increased dose.
11292386|NCT02750306|Placebo Comparator|Placebo|Participants receive 1 placebo-matching suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' placebo-matching dose can be increased to 20 mg if their CGI-S is ≥3 and investigators feel they can tolerate the increased dose.
11292387|NCT02750293|Active Comparator|cholecalciferol|vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
11292388|NCT02750293|Placebo Comparator|placebo|placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
11292389|NCT02750280|Experimental|Urinary Bladder matrix (UBM)|UBM covered with silicone foam dressing plus total contact cast
11292390|NCT02750280|Active Comparator|Standard Care|Silicone foam dressing plus total contact cast
11292391|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
11292392|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
11292393|NCT02750254|Experimental|Arm 1: Azacitidine|"Treating physician must choose from one of these conditioning regimens (will be given per standard of care)
~fludarabine and fractionated total body irradiation (Flu/FrTBI)
~fludarabine and busulfan (Flu/Bu4)
~fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)
~fludarabine and melphalan (Flu/Mel)
~reduced-intensity fludarabine and busulfan (Flu/Bu2)
~G-CSF from Day -5 through Day -1 per standard of care
~On Day 0, the allograft will be infused per standard of care.
~Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days
~Cyclophosphamide on Days +3 and +4 post-transplant"
11292394|NCT02750241|Experimental|Active video game-based intervention|This arm will receive the active video game-based intervention, which will include attending 12 weekly group sessions at the UTMB Breast Health Clinic, participate in self-paced home session, and monitor daily, weekly, and monthly steps using Wii Fit Meter. All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
11292395|NCT02750241|Active Comparator|Pedometer|This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
11292396|NCT02750215|Experimental|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.
~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
11292397|NCT02750202|Active Comparator|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
11292398|NCT02750202|Sham Comparator|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
11292399|NCT02750189||Mild Group|FEV₁/FVC <70% and FEV₁≥80% direct/indirect cost
11292400|NCT02750189||Moderate Group|FEV₁/FVC <70% and 50%≤FEV₁≤80% direct/indirect cost
11292401|NCT02750189||Severe Group|FEV₁/FVC <70% and 30%≤FEV₁≤50% direct/indirect cost
11292402|NCT02750189||Very Severe Group|FEV₁/FVC <70% and FEV₁<30% direct/indirect cost
11292403|NCT02750176|Experimental|CERCT|Closed chain exercises
11292404|NCT02750150|Experimental|Freezed-dried plasma|transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
11292405|NCT02750150|Active Comparator|Fresh-frozen plasma|transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
11292406|NCT02750124|Active Comparator|HPV self sampling test sent|A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
11292407|NCT02750124|Active Comparator|HPV self sampling test ordered|An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
11292408|NCT02750124|Active Comparator|Nurse navigator contact|An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
11292409|NCT02750124|Placebo Comparator|Control|The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
11292410|NCT02750098|Experimental|Diabetic patients|Diabetic patients planned to undergo elective cataract surgery
11292411|NCT02750085||2-point and 6-point PK sampling|
11292412|NCT02750072|Active Comparator|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
11292413|NCT02750072|Experimental|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
11292414|NCT02750059|Experimental|TDF/3TC/EFV + Telmisartan|The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
11292415|NCT02750059|Active Comparator|TDF/3TC/EFV only|Subjects will receive ART only
11292416|NCT02750046|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
11292453|NCT02749851||Confirmed IUGR|Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy
11292417|NCT02750046|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
11292418|NCT02750033||Basal Cell Carcinoma (BCC)|Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
11292419|NCT02750033||Squamous Cell Carcinoma (SCC)|Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
11292420|NCT02750020||never smokers|Around 1667 never smokers will be required to answer a questionnaire via telephone.
11292421|NCT02750020||ex-smokers|Around 1667 ex-smokers will be required to answer a questionnaire via telephone.
11292422|NCT02750020||current smokers|Around 1667 current smokers will be required to answer a questionnaire via telephone.
11292423|NCT02750007|Experimental|Experimental|Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
11292424|NCT02749994|Active Comparator|R5|Rosuvastatin 5mg
11292425|NCT02749994|Active Comparator|R10|Rosuvastatin 10mg
11292426|NCT02749994|Active Comparator|R20|Rosuvastatin 20mg
11292427|NCT02749994|Experimental|R5/E10|Rosuvastatin 5mg/Ezetimibe 10mg
11292428|NCT02749994|Experimental|R10/E10|Rosuvastatin 10mg/Ezetimibe 10mg
11292429|NCT02749994|Experimental|R20/E10|Rosuvastatin 20mg/Ezetimibe 10mg
11292430|NCT02749981||Cefazolin|patients receiving cefazolin as part of routine clinical care
11292431|NCT02749968|Active Comparator|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
11292432|NCT02749968|Placebo Comparator|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
11292433|NCT02749955|Experimental|PS-PrEP Intervention Group|
11292434|NCT02749955|Active Comparator|PrEPLine Control Group|
11292435|NCT02749955|No Intervention|CDPH Prevention Projects|
11292436|NCT02749942|Active Comparator|AutoRIC: Remote Ischemic Conditioning|Daily cuff treatment of arm with 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG of pressure) on top of standard care.
11292437|NCT02749942|Sham Comparator|AutoRIC: Sham device treatment|Daily sham device treatment of arm, 4 cycles of 5 minute (0 mmHG of pressure) on top of standard care. No ischemia induced.
11292438|NCT02749929|Experimental|Low-Level Laser therapy|"After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the laser to make skin contact. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. The light from the laser is not visible to the eye, and will not give any perceptible stimulus.
~Low-Level Laser therapy (LLLT) will be given according to the recommended dosage from World Association of Laser Therapy (WALT). A LLLT dose of 3.6 Joules will be administered at two points over the fracture site."
11292439|NCT02749929|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the placebo laser to make skin contact. The placebo laser is identical in apperance to a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Since the light from the laser is invisible, neither the participant nor the therapist will know whether the laser is a placebo. The treatment time and number of treated points will be identical to group 1.
11292440|NCT02749916||Patients with acute or recent (within 3months) stroke|
11292441|NCT02749903|Other|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
11292442|NCT02749890|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
11292443|NCT02749890|Active Comparator|lixisenatide|"Lixisenatide (AVE0010) is injected subcutaneously (under the skin) once daily. It will be initiated with Dose 1 for 1 week and then continue with Dose 2 for 1 week followed by the maintenance dose of Dose 3 up to the end of treatment period.
~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
11292444|NCT02749877|Experimental|Cognitive Training|"This group will undergo a working memory training program (Training A). The children will receive individual memory training based on the computer program Cogmed RM and will be supervised by trained neuropsychologists. Its efficacy in the use with children with cancer has been recently published. The children will undergo 25 training sessions online; each session takes about 45 minutes and consists of a selection of various tasks that target the different aspects of working memory."
11292445|NCT02749877|Experimental|Physical Training|This group will receive a physical training that can be executed at home (Training B). The training will be based on xbox Kinect games and comprise games and activities such as jump'n'run games, physical training, and dance activities. One training session will last approximately 45 minutes and will be performed 3 days a week over a period of 8 weeks (in total 25 sessions).
11292446|NCT02749877|Active Comparator|Waiting Control Group|This group will serve as a waiting control group and will receive either the physical or the working memory training program after completion of the Neuropsychological Assessment II
11292447|NCT02749864||A: Age 20-34 yr|No intervention Cohort of subjects aged 20-34 years old.
11292448|NCT02749864||B: Age 35-49 yr|No intervention Cohort of subjects aged 35-49 years old.
11292449|NCT02749864||C: Age 50-79 yr|No intervention Cohort of subjects aged 50-79 years old.
11292450|NCT02749851||Non-smokers|Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.
11292451|NCT02749851||Smokers|Pregnant women that identify as smokers will receive the MRI Imaging intervention.
11292452|NCT02749851||High risk/Non-Smokers|Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.
11292457|NCT02749812|Experimental|Constant Continuous Positive Airway Pressure|
11292458|NCT02749812|Experimental|automatic Continuous Positive Airway Pressure|
11292459|NCT02749799|Experimental|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
11292460|NCT02749786|Other|Control Group|Participants who do not have rosacea (control group)
11292461|NCT02749773|Active Comparator|Oocyte aspiration with 17G needle|Oocyte Aspiration with 17G needle.
11292462|NCT02749773|Active Comparator|Oocyte aspiration with (20-17G) needle|Oocyte Aspiration (20-17G) needle.
11292463|NCT02749760|Other|Minor league pitchers|Minor league pitchers from a single professional baseball organization. Strength tests of the elbows will be administered at spring training and end of season for 5 years. If strength correlates to injury, strengthening and exercise programs may be established to target the stabilizers of the elbows.
11292464|NCT02749747|Active Comparator|Sulpiride use|50mg sulpiride once a day use for 60 days
11292465|NCT02749747|Placebo Comparator|Placebo|50mg placebo once a day use for 60 days
11292466|NCT02749734|Experimental|hESC-RPE|Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums
11292467|NCT02749721|Other|Open-label vortioxetine|
11292468|NCT02749708|Experimental|Dose level 1|IRX5183 50 mg daily
11292469|NCT02749708|Experimental|Dose level 2|IRX5183 75 mg daily
11292470|NCT02749695|Experimental|Group 1 (Melsmon)|20 women used placental extract Melsmon® (Japan), 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
11292471|NCT02749695|Placebo Comparator|Group 2 (placebo)|20 patients used placebo (normal saline solution): 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
11292472|NCT02749682||constipation & hernia group|The effect of constipation on study group whether there is a correlation between subgroups of operated patients on the view of direct and indirect hernias(Nyhuss classification).
11292473|NCT02749682||constipation & normal population|The level of constipation on normal population using constipation severity scale.
11292474|NCT02749669|Other|Qualitative research|Semi-structured interviews
11292475|NCT02749669|No Intervention|Economic evaluation|Questionnaire
11292476|NCT02749656|Experimental|0.25% Desoximetasone cream (Topoxy®)|"0.25% Desoximetasone cream (Topoxy®): apply on scalp psoriasis lesion twice a day for 8 weeks.
~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
11292477|NCT02749656|Active Comparator|0.25% Desoximetasone cream (Topicorte®)|"0.25% Desoximetasone cream (Topicorte®): apply on scalp psoriasis lesion twice a day for 8 weeks.
~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
11292478|NCT02749656|Placebo Comparator|Placebo|Placebo: apply on scalp psoriasis lesion twice a day for 8 weeks. (Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)
11292479|NCT02749643|Experimental|Vibrotactile feedback|Vibrotactile system - comprises of force sensors, attached to the fingertips of the prosthetic hand, and a set of 8 vibration actuators attached to a fabric arm cuff. When the subject applies force on the sensors with his prosthetic hand, he receives a vibration on the skin of his arm. The sensors and actuators are connected to an electronic control board, which transforms the resistance from the sensors to an electric signal that activates the vibration actuators.
11292480|NCT02749630|Experimental|Healthy Volunteer|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
11292481|NCT02749630|Experimental|Ulcerative Colitis|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
11292482|NCT02749630|Experimental|Crohn's Disease|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
11292483|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
11292484|NCT02749604|Active Comparator|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
11292485|NCT02749604|Experimental|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
11292486|NCT02749591|Experimental|Robot-assisted therapy (RT)|After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
11292487|NCT02749591|Experimental|Mirror therapy (MT)|After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
11292488|NCT02749591|Active Comparator|Control Intervention (CI)|After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
11292489|NCT02749578|Other|Treatment|Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
11292490|NCT02749565||asthmatic patients with OSA|
11292491|NCT02749565||asthmatic patients without OSA|
11292492|NCT02749552|Experimental|Acceptance and Commitment Therapy|ACT intervention
11292493|NCT02749539|Experimental|Kinesio tape|The first 3 kinesio tape application was inhibition technique for supraspinatus, deltoid and teres minor muscles. the fourth Kinesio tape was mechanical correction for the shoulder joint. in addition to active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
11292494|NCT02749539|Active Comparator|Physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
11311662|NCT02621892|Placebo Comparator|Placebo|Placebo
11292495|NCT02749526|Experimental|Endostar combined with MPFC|"Chemotherapy regimens (er degree + mPFC) :
~Endostar:
~degrees 30 mg civ24h d0-6;
~Liposo:
~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2
~Gimeracil and Oteracil Potassium (Tegafur):
~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
11292496|NCT02749513|Experimental|Itraconazole|Itraconazole 300 mg po bid for 14-17 days
11292497|NCT02749500|Active Comparator|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
11292498|NCT02749500|Experimental|OT + Device-assisted therapy|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy. The m2 BAT will enable repeated movement of the affected body part without the help of a therapist, providing the opportunity to maintain range-of motion in the affected limb to limit spasticity, contracture and the ensuing deformity, a major goal of rehabilitation therapy and produces movement in the affected limb from activating the patient's own brain, rather than from being acted on by an external powered source such as a robot.
11292499|NCT02749487||cured (c)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
11292500|NCT02749487||Died ( M)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
11292501|NCT02749474||Pregnant women diagnosed with cancer|Any pregnant woman diagnosed with any cancer within 6 weeks prior to their last menstrual period, or up to 6 months after the end of their pregnancy can be enrolled.
11292502|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
11292503|NCT02749435||Standard of Care + digital disease management cohort|Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
11292504|NCT02749435||Standard of Care cohort|Participants will have standard care with no access to the digital disease management tool.
11292505|NCT02749422|Active Comparator|Healthy Subjects|
11292506|NCT02749422|Experimental|Temporal Lobe Epilepsy Patients|
11292507|NCT02749409|Active Comparator|Control group|The control group will be given Morphine prn after admission
11292508|NCT02749409|Experimental|Experimental group|the experimental group will be given parecoxib after admission by intravenous method every 12 hours for 4 days. Then Morphine agent will be given prn usage
11292509|NCT02749396||IFN-β / Cohort 1|Exposure to IFN-β only
11292510|NCT02749396||IFN-β + other MSDMDs / Cohort 2|Women with MS exposed to IFN-β regardless of exposure to other MSDMDs
11292511|NCT02749396||No MSDMDs / Cohort 3|Women with MS exposed with no exposure to any MSDMDs
11292512|NCT02749396||No IFN-β + other MSDMDs / Cohort 4|Women with MS exposed to IFN-β exposure regardless of exposure to other MSDMDs
11292513|NCT02749396||Other MSDMDs / Cohort 5|Women with MS exposed to other MSDMD only excluding IFN-β or glatiramer acetate (Copaxone) or dimethyl fumarate (Tecfidera)
11292514|NCT02749396||Control / Cohort 6|Women from the general population without MS
11292515|NCT02749383|Experimental|PAC-14028 cream 0.3%|Twice daily for 4 weeks
11292516|NCT02749383|Experimental|PAC-14028 cream 1.0%|Twice daily for 4 weeks
11292517|NCT02749383|Placebo Comparator|PAC-14028 cream vehicle|Twice daily for 4 weeks
11292518|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
11292519|NCT02749357|Active Comparator|Control|"Intervention: Control group, with 30 training sessions in robotic orthosis with duration of 30 minutes during 6 weeks.
~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
11292520|NCT02749357|Experimental|Experimental|"Intervention: Experimental group, with 30 training sessions in robotic orthosis with duration of 60 minutes during 6 weeks.
~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
11292521|NCT02749344|Experimental|FET after endometrial preparation|Natural cycle/progesterone fortified endometrial preparation before embryo transfer
11292522|NCT02749331|Experimental|AdVince|"Dose escalation, minimum 3 patients per dose in Phase I. Dose levels:
~10 000 000 000 virus particles
~100 000 000 000 virus particles
~300 000 000 000 virus particles
~1000 000 000 000 virus particles
~Maximum tolerated dose will be confirmed by 12 additional patients treated at this dose level in Phase IIa."
11292523|NCT02749318|Experimental|Experimental Group|Consented patients who complete the initial Experimental Group Questionnaire, receive a prophylaxis, have the IL-1 genetic test for risk of severe periodontitis performed, their dental records monitored for 18 months post-enrollment, and answer a Study Completion Questionnaire 18 months post-enrollment.
11292524|NCT02749318|No Intervention|Usual Care Group|Consented patients who complete the initial Usual Care Group Questionnaire, receive a prophylaxis and have their dental records monitored for 18 months post-enrollment.
11292525|NCT02749305|Other|Preop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures preoperatively and annually postoperatively will occur with all metabolic and bariatric surgery patients scheduled for surgery at a participating center.
11292526|NCT02749305|Other|Postop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures annually postoperatively will occur with all metabolic and bariatric surgery patients who had surgery at a participating center within the preceding 12 months.
11292550|NCT02749097|Experimental|Cohort 1|Single oral dose of 10 mg SHR0534 or matching placebo
11292551|NCT02749097|Experimental|Cohort 2|Single oral dose of 25 mg SHR0534 or matching placebo
11292552|NCT02749097|Experimental|Cohort 3|Single oral dose of 50 mg SHR0534 or matching placebo
11311937|NCT02619916|Experimental|CBT|Cognitive Behavioral Therapy
11292527|NCT02749292|Active Comparator|B cell reconstitution|Subjects will no longer receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months for B cell return. Once peripheral B cells rise to ≥ 10cells/mm3 they will receive rituximab 1000 mg IV x 2 (doses spaced approx. 2-3 weeks apart). Subsequent dosing will be again based on B cell return (≥ 10 B cells/mm3), with patients seen in clinic and B cells monitored every 3 months.
11292528|NCT02749292|Active Comparator|Serologic ANCA flare|Subjects will not receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months in clinic. Re-dosing will occur once the subject's ANCA titer has risen above the predetermined treatment value (MPO treatment value defined as a 5-fold rise from baseline and a level greater than 4 times the cutoff value for the assay; PR3 treatment value defined as a 4-fold rise from baseline and a level greater than 2-fold above the cutoff for the assay). Subjects who meet this criteria will then be re-dosed with rituximab 1000 mg IV x2 (spaced 2-3 weeks apart). If the ANCA titer remains 2-fold above baseline and above a specified threshold (the cutoff value of the assay for PR3 and 4 times the cutoff value for MPO), subjects will then receive rituximab 1000mg IV every 6 months x 2 doses and a new ANCA titer baseline will be established. The cycle will then re-start.
11292529|NCT02749266|Experimental|Chiropractic Activator Adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
11292530|NCT02749266|Sham Comparator|Chiropractic sham adjustment|Participant will receive a sham (simulated) chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
11292531|NCT02749253|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
11292532|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program (Youth Empowerment Seminar, YES!) will be offered to at risk youth participating in programs or resources offered by Youth Opportunities Unlimited. The YES! program will be taught in two phases: (1) an active learning phase which consists of four consecutive days (3 hrs/day) of SEL skills taught in a multi-modality interactive format as well as SKY training, and (2) a reinforcement phase which involves weekly follow up sessions (75-90 mins each) for the 7 weeks following the active phase. Two certified instructors from the Art of Living Foundation (Spencer Delisle and Mark Frye) will deliver this training under supervision of Ronnie Newman (RN). After the initial 4 day training, participants will be asked to practice SKY daily for 20-25 minutes in addition to attending the weekly follow up sessions.
11292533|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
11292534|NCT02749214||Parkinson's Disease (PD)|Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
11292535|NCT02749214||Healthy Control|Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
11292536|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
11292537|NCT02749188|Other|bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes.
11292538|NCT02749175|Experimental|Cricoid force sensor monitor system|Nurse applied cricoid pressure with a sensor guided by monitoring Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons.
11292539|NCT02749175|Sham Comparator|Sham cricoid force sensor monitor system|Nurse applied pressure on a sham sensor with no monitor input. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
11292540|NCT02749175|No Intervention|Current standard|Nurse applied cricoid force according to memory. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
11292541|NCT02749162|Placebo Comparator|Group A|After the spinal anesthesia regressed, the investigators performed a single shot femoral block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
11292542|NCT02749162|Active Comparator|Group B|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg and 4 mg dexamethasone phosphate. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
11292543|NCT02749162|Active Comparator|Group C|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg+ lidocaine 1% 200 mg and 8 mg dexamethasone phosphate.After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
11292544|NCT02749149||Cardiac Surgery|Patients undergoing cardiac surgery: coronary artery bypass graft (CABG); valve replacement/repair; or transcatheter aortic valve implantation (TAVI) surgery
11292545|NCT02749136|Experimental|Perioperative chemotherapy|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles
~Postoperative gemcitabine, every 4 weeks, 3-6 cycles"
11292546|NCT02749123|Active Comparator|Lidocaine5% v Lidocaine3.6%,Menthol1.25%|Daily patch Q12 followed by Q12 of no patch
11292547|NCT02749123|Placebo Comparator|Lidocaine 3.6%, menthol 1.25% v placebo|Daily patch Q12 followed by Q12 of no patch
11292548|NCT02749110|Experimental|Self-sampling for HPV test|Invitation to participate to the screening process by means of the usual care (pap-test) or the provision of a vaginal self-sampling brush (Evalyn Brush°). Self-collected samples are mailed to a central lab for HPV testing.
11292549|NCT02749110|No Intervention|Usual care (Pap test)|Intervention: invitation to participate to the screening process by means of the usual care (pap-test).
11292553|NCT02749097|Experimental|Cohort 4|Single oral dose of 100 mg SHR0534 or matching placebo
11292554|NCT02749097|Experimental|Cohort 5|Single oral dose of 200 mg SHR0534 or matching placebo
11292555|NCT02749084|Experimental|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.
~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.
~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).
~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.
~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).
~Patients in the MTD study should be about 10, according to Fleming."
11292556|NCT02749071|Sham Comparator|Control Group|This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
11292557|NCT02749071|Experimental|Treatment Group|The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
11292558|NCT02749058|Other|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
11292559|NCT02749058|Other|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
11292560|NCT02749045|Other|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
11292561|NCT02749032|Active Comparator|Vildagliptin - stratum diet/exercise|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
~Mixed meal test were performed in the morning after an overnight fast."
11292562|NCT02749032|Active Comparator|Vildagliptin - stratum metformin|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
~Mixed meal test were performed in the morning after an overnight fast."
11292563|NCT02749032|Active Comparator|Sitagliptin - stratum diet/exercise|"The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
~Mixed meal test were performed in the morning after an overnight fast."
11292564|NCT02749032|Active Comparator|Sitagliptin - stratum metformin|"In patients treated with metformin, sitagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening.
~Mixed meal test were performed in the morning after an overnight fast."
11292565|NCT02749032|Placebo Comparator|Placebo - stratum diet/exercise|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
~Mixed meal test were performed in the morning after an overnight fast."
11292566|NCT02749032|Placebo Comparator|Placebo - stratum metformin|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
~Mixed meal test were performed in the morning after an overnight fast."
11292567|NCT02749019|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
11292568|NCT02749006|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
11292569|NCT02749006|Sham Comparator|Sham rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
11292570|NCT02748993|Experimental|PAC-14028 Cream 0.1%|PAC-14028 Cream 0.1%, Twice daily for 4 weeks
11292571|NCT02748993|Experimental|PAC-14028 Cream 0.3%|PAC-14028 Cream 0.3%, Twice daily for 4 weeks
11292572|NCT02748993|Experimental|PAC-14028 Cream 1.0%|PAC-14028 Cream 1.0%, Twice daily for 4 weeks
11292573|NCT02748993|Placebo Comparator|PAC-14028 Cream Vehicle|PAC-14028 Cream Vehicle, twice daily for 4 weeks
11292574|NCT02748980||Non- obstructive coronary artery disease, non- diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed without diabetes.
11292575|NCT02748980||Non- obstructive coronary artery disease, diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed with type 2 diabetes.
11292576|NCT02748967|Experimental|Group 1|Participants with age (greater than or equal to [>=] 20 to less than [<] 50 years) will receive single dose of 0.5 milliliter (mL) of ExPEC4V (4:4:4:4) or placebo on Day 1.
11292577|NCT02748967|Experimental|Group 2|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
11292578|NCT02748967|Experimental|Group 3|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
11292579|NCT02748967|Experimental|Group 4|Participants with age greater than or equal to [>=] 50 will receive single dose of 0.5 mL of ExPEC4V (4:4:4:4) or placebo on Day 1.
11292580|NCT02748967|Experimental|Group 5|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
11292581|NCT02748967|Experimental|Group 6|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
11292582|NCT02748954|Experimental|Thoughts.|"Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week"
11292583|NCT02748954|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
11292584|NCT02748954|Experimental|Assertiveness|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict
11292585|NCT02748954|Experimental|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
11292586|NCT02748954|Active Comparator|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
11292587|NCT02748941|Experimental|symptomatic and asymptomatic patients|
11292588|NCT02748928|Experimental|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.
~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
11292589|NCT02748915|Experimental|Patients using cochlear implants|All patients using cochlear implants included in the study will take electrophysiological and psychoacoustic tests to measure auditive parameters regarding the study objectives : ECAP, EABR, speech recognition and MCL.
11292590|NCT02748915|Experimental|Patients using EAS device|Patients using EAS device for more than 11 months will take electrophysiological and psychoacoustic tests with the implant functioning only with electrical pulses or in bimodal mode to measure ECAP, EABR, speech recognition and MCL ; this will allow to perform bimodal comparison.
11292591|NCT02748915|Experimental|Patients with bilateral cochlear implant|Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
11292592|NCT02748902|Experimental|ingenol mebutate 0.05% gel|Single group, open label. All subjects will receive active product.
11292593|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
11292594|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
11292595|NCT02748876|Experimental|His-Ventricular (HV)-optimised|His-Ventricular (HV) optimised atrioventricular delay
11292596|NCT02748876|No Intervention|Non-optimised|Standard atrioventricular delay
11292597|NCT02748863|Placebo Comparator|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
11292598|NCT02748863|Experimental|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
11292599|NCT02748863|Active Comparator|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
11292600|NCT02748850|Active Comparator|leukemia patients|Patients with acute leukemia and / or refractory anemia with excess blasts and comprising a number of blasts in the blood greater than 5% device.
11292601|NCT02748850|Placebo Comparator|apheresis patients|patients with non-myeloid hematological malignancy
11292602|NCT02748837|Experimental|Dose escalation cohort of ERY974|Dose escalation (DE) will proceed with the dose level increment and the dose cohort size being guided by a safety evaluations during and at the end of each cohort. DE initially utilizes an accelerated titration design (ATD) and once the first dose limiting toxicity (DLT) is observed, DE will continue using a modified continual reassessment method (mCRM) until MTD.
11292603|NCT02748837|Experimental|Cohort expansion in gastric cancer|Patients with GPC3 positive advanced gastric cancer or gastroesophageal junction cancer will receive ERY974 at recommended dose until disease progression.
11292604|NCT02748837|Experimental|Cohort expansion in esophageal carcinoma|Patients with GPC3 positive advanced squamous cell esophageal carcinoma will receive ERY974 at recommended dose until disease progression.
11292605|NCT02748837|Experimental|Cohort expansion in other solid tumors|Patients with other GPC3 positive advanced solid tumors will receive ERY974 at recommended dose until disease progression
11292606|NCT02748811|No Intervention|Control group|The control group receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change in treatment or progression. If the patient has other health problems, those issues will be assessed either by the oncologist or by the general practitioner. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
11292607|NCT02748811|Active Comparator|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. They will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
11292705|NCT02748265|Other|Inhaled Epoprostenol, phenylephrine, sevoflurane|Inhaled Epoprostenol (Flolan), phenylephrine, volatile anesthesia maintenance (Sevoflurane)
11311938|NCT02619916|No Intervention|TAU|Treatment as usual
11292608|NCT02748798|Experimental|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
11292609|NCT02748798|Experimental|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
11292610|NCT02748785|Experimental|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
11292611|NCT02748785|Experimental|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
11292612|NCT02748785|Experimental|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
11292613|NCT02748785|Experimental|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
11292614|NCT02748772|Active Comparator|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
11292615|NCT02748772|Placebo Comparator|Pure chemotherapy（Xelox）|chemotherapy alone for the patients of Advanced Colorectal Cancer
11292616|NCT02748759|Active Comparator|EXP 1: Manual mobilization / CPM|Patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist. After a pause of 5 minutes, the patient was collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension.
11292617|NCT02748759|Active Comparator|EXP 2: CPM / Manual mobilization|Patients were collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension. After a pause of 5 minutes, patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist.
11292618|NCT02748746|Experimental|Surgery no Lymphedema|The inclusion criteria for involving the first group is surgery time. No one will be involved into the first group if surgery was applied 18 months ago before enrollment to this study. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum. Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
11292619|NCT02748746|Experimental|Surgery having Lymphedema|The second group will contain patients who had breast cancer surgery and having upper extremity lymphedema.Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
11292620|NCT02748746|Active Comparator|Healthy Women|The third group will contain healthy women. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
11292621|NCT02748733|Active Comparator|Adapted double mini PET|"PET = Peritoneal Equilibration Test, a test routinely performed to measure peritoneal transport rates of solutes and water in peritoneal dialysis patients. To this end the routinely administered dialysis fluid is infused into the peritoneal cavity. The test will be modified (adapted):
~A short, small cycle (0.6 mL/m² BSA, 30 min) followed by a long, large cycle (1.4 mL/m², 120 min) will be performed in each patient and compared to a standard double mini PET."
11292622|NCT02748733|Placebo Comparator|Standard double mini PET|The Standard double mini PET consists of two identical cycles (fill volume 1 L/m², 75 min of dwell time)
11292623|NCT02748720|Experimental|RFM Visible|Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
11292624|NCT02748720|No Intervention|RFM No Visible|Patients will be randomize in a Group 2, where the parameters of TVe and respiratory flow would not be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). Always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the Spanish Society of Neonatology, based on international recommendations (1-3.5) apply. In turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks
11292625|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
11292626|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
11292627|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
11292628|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
11292629|NCT02748694|Experimental|Part 1: Cohort 1: TAK-041 5-20 mg|TAK-041 5 milligram (mg) and 20 mg suspension or matching placebo, orally, once on Day 1 of treatment periods 1 and 2, respectively. Each treatment period will be separated by a washout period of at least 7 days.
11293681|NCT02741570|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
11292630|NCT02748694|Experimental|Part 1: Cohort 2: TAK-041 10-40 mg|TAK-041 10 mg and 40 mg suspension or matching placebo, orally, once on Day 1 of treatment periods 1 and 2 respectively. Each treatment period will be separated by a washout period of at least 7 days.
11292631|NCT02748694|Experimental|Part 1: Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension or matching placebo, orally, once on Day 1. Although planned, all subsequent doses after the dose of 80 mg for Cohort 3 will be determined based on the emerging safety, tolerability, and PK data from the preceding cohorts.
11292632|NCT02748694|Experimental|Part 1: Cohort 4: TAK-041 TBD|Cohort 4 will participate in a sequential-panel, double-blind study design to evaluate single-rising doses of TAK-041 or matched placebo. The planned dose levels of TAK-041 to be evaluated in Cohorts 4 is 120 mg. Although planned, all subsequent doses after the dose of 80 mg for Cohort 3 will be determined based on the emerging safety, tolerability, and PK data from the preceding cohorts.
11292633|NCT02748694|Experimental|Part 1: Cohort 5: TAK-041 TBD|Cohort 5 will participate in a sequential-panel, double-blind study design to evaluate single-rising doses of TAK-041 or matched placebo. The planned dose levels of TAK-041 to be evaluated in Cohorts 5 is 160 mg. Although planned, all subsequent doses after the dose of 80 mg for Cohort 3 will be determined based on the emerging safety, tolerability, and PK data from the preceding cohorts.
11292634|NCT02748694|Experimental|Part 2: Cohort 1: TAK-041 20mg|TAK-041 20 mg, suspension or matching placebo, orally, initial loading dose on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 1 will be based on emerging safety/tolerability and PK data from Part 1.
11292635|NCT02748694|Experimental|Part 2: Cohort 2: TAK-041 TBD|TAK-041, suspension or matching placebo, initial loading dose on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 2 onwards will be based on emerging safety/tolerability and available PK data from Part 1 and from preceding cohorts in Part 2.
11292636|NCT02748694|Experimental|Part 2: Cohort 3: TAK-041 TBD|TAK-041, suspension or matching placebo, initial loading dose of on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 2 onwards will be based on emerging safety/tolerability and available PK data from Part 1 and from preceding cohorts in Part 2.
11292637|NCT02748694|Experimental|Part 2: Cohort 4: TAK-041 TBD|TAK-041, suspension or matching placebo, initial loading dose of on Day 1 followed by a maintenance dose that is half the initial dose on Days 8, 15, and 22. The dose levels for Part 2 Cohort 2 onwards will be based on emerging safety/tolerability and available PK data from Part 1 and from preceding cohorts in Part 2.
11292638|NCT02748694|Experimental|Part 3: TAK-041 40 mg Tablet Fasted State|TAK-041 40 mg, tablet, orally, once on Day 1 under fasted state.
11292639|NCT02748694|Experimental|Part 3: TAK-041 40 mg Tablet Fed State|TAK-041 40 mg, tablet, orally, once on Day 1 under fed state.
11292640|NCT02748694|Experimental|Experimental: Part 4: TAK-041 TBD|TAK-041 TBD, suspension or TAK-041 placebo-matching suspension administered as an initial loading dose on Day 1 followed by a maintenance dose on Days 8, 15, and 22. The dose levels for Part 4 will be based upon the emerging safety/tolerability and PK data of same dose in healthy participants from Part 2.
11292641|NCT02748681|Active Comparator|Telemedicine Group|Patient group with a telemedicine monitoring system
11292642|NCT02748681|Active Comparator|Standard Group|Patient Group without a telemedicine monitoring
11292643|NCT02748668||ECMO|No intervention. Blood specimen collection.
11292644|NCT02748668||Control|No intervention. Blood specimen collection.
11292645|NCT02748655|Placebo Comparator|Tap water|Oral consumption of tap water
11292646|NCT02748655|Active Comparator|Alkaline ionized water|Oral consumption of alkaline ionized water
11292647|NCT02748642|Experimental|Part A Cohort A: BITS7201A Dose Level 1 Subcutaneous (SC)|Healthy participants will receive a single SC dose of BITS7201A dose Level 1 on Day 1.
11292648|NCT02748642|Experimental|Part A Cohort B: BITS7201A Dose Level 2 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 2 on Day 1.
11292649|NCT02748642|Experimental|Part A Cohort C: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 on Day 1.
11292650|NCT02748642|Experimental|Part A Cohort D: BITS7201A Dose Level 4 Intravenous (IV)|Healthy participants will receive a single IV dose of BITS7201A dose Level 4 on Day 1.
11292651|NCT02748642|Experimental|Part A Cohort E: BITS7201A Dose Level 6 IV|Healthy participants will receive a single IV dose of BITS7201A dose Level 6 on Day 1.
11292652|NCT02748642|Placebo Comparator|Part A: Placebo|Healthy participants will receive a single SC or IV dose of placebo matched to BITS7201A on Day 1.
11292653|NCT02748642|Experimental|Part B Cohort F: BITS7201A Dose Level 3 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 3 every 4 weeks (Q4W) on Days 1, 29, and 57.
11292654|NCT02748642|Experimental|Part B Cohort G: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 Q4W on Days 1, 29, and 57.
11292655|NCT02748642|Experimental|Part B Cohort H: BITS7201A Dose Level 5 SC|Healthy participants will receive SC dose of BITS7201A dose Level 5 Q4W on Days 1, 29, and 57.
11292656|NCT02748642|Experimental|Part B Cohort I:BITS7201A Dose Level 5 SC (Mild Atopic Asthma)|Mild atopic asthma participants will receive SC dose of BITS7201 dose Level 5 Q4W on Days 1, 29, and 57.
11292657|NCT02748642|Placebo Comparator|Part B: Placebo|Healthy participants or mild atopic asthma participants will receive SC doses of placebo matched to BITS7201A Q4W on Days 1, 29, and 57.
11292658|NCT02748629|Active Comparator|ProGrip Mesh Repair|80 patients are randomized to inguinal hernia repair using selfgripping ProGrip Mesh (Covidien Parietex ProGrip Self-Fixating Mesh) - sutureless fixation.
11292659|NCT02748629|Active Comparator|Lichtenstein Operation|80 patients are randomized to inguinal hernia repair using lightweight polypropylene mesh (<40 g/m2) with standard Lichtenstein technique.
11292660|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
11292661|NCT02748603||Patient with non ST Elevation - Acute Coronary Syndrome|
11292662|NCT02748603||Patient with stable Coronary Artery Disease (CAD)|
11292663|NCT02748590|Experimental|Neuromodulation|
11292706|NCT02748265|Other|Inhaled Epoprostenol phenylephrine & Propofol|Inhaled Epoprostenol (Flolan), phenylephrine and intravenous anesthesia maintenance (Propofol)
11292707|NCT02748252||HIV patients|HIV patients admitted in Stroke units for the first occurence of acute stroke
11292664|NCT02748577|Experimental|Migraine|Participants with migraines will complete one study visit where they will complete several questionnaires and will also complete Quantitative Sensory Testing (QST) Pain Measurements. They must be migraine-free during the visit and no migraine within 48 hrs of study visit
11292665|NCT02748577|Active Comparator|Healthy Controls|Healthy Controls will complete one study visit where they will complete several questionnaires and will complete Quantitative Sensory Testing (QST) Pain Measurements.
11292666|NCT02748564|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
11292667|NCT02748551|Experimental|Laparoscopic surgery|Traditional open procedure for patient with locally advanced gastric cancer
11292668|NCT02748551|Active Comparator|Open surgery|Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
11292669|NCT02748538||Face Down|To posture in the face down position for the first 24 hours following surgery.
11292670|NCT02748538||Position to Support the Break|The head is positioned so that the retinal breaks (which caused the retinal detachment) are positioned at the highest point of the eye and well supported by the intra-ocular gas bubble left within the eye at the completion of surgery.
11292671|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
11292672|NCT02748512|Experimental|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
11292673|NCT02748512|Active Comparator|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
11292674|NCT02748499|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
11292675|NCT02748499|Active Comparator|Control|The control group maintains daily activities.
11292676|NCT02748486|Experimental|Jumping To Conculsions|Metacognitive Training Jumping to conclusions module
11292677|NCT02748486|Experimental|Theory of Mind|Metacognitive Training To empathize... module
11292678|NCT02748486|Sham Comparator|Control|group discussion of current events
11292679|NCT02748473|Other|pelvic floor muscle strength|evaluated pelvic floor muscle strength before and after Pilates exercises program on sedentary nulliparous women
11292680|NCT02748473|Other|Device: 3D perineal ultrasound|evaluated the pubovisceral muscle thickness and the levator hiatus area before and after Pilates exercises program on sedentary nulliparous women
11292681|NCT02748460||Patients treated with Esmya|Any patient who was confirmed as receiving one dose of Esmya
11292682|NCT02748447|Experimental|A-FiO2|24 hours in automated FiO2 adjustment to maintain SpO2 within a target range
11292683|NCT02748447|No Intervention|M-FiO2|24 hours in manual adjustment of FiO2 to maintain SpO2 within a target range
11292684|NCT02748434|Other|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
11292685|NCT02748434|Other|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
11292686|NCT02748421|Other|Lumera Microscope with OCT RESCAN|in the group microscope coupled to OCT, patients will undergo retinal surgery using the Lumera microscope with Rescan OCT Zeiss
11292687|NCT02748421|Other|Conventional Microscope|control group without OCT RESCAN
11292688|NCT02748395|Placebo Comparator|Placebo|Injection of 3.5mL of normal saline into the point of maximal tenderness in the abdomen
11292689|NCT02748395|Experimental|Treatment|Injection of 20mg triamcinolone and 1% lidocaine into the point of maximal tenderness in the abdomen
11292690|NCT02748382|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
11292691|NCT02748382|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
11292692|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
11292693|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
11292694|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
11292695|NCT02748343|Active Comparator|allograft bone|traditional allograft bone
11292696|NCT02748343|Experimental|tissue-engineered bone|tissue-engineered bone
11292697|NCT02748330|Experimental|Ticagrelor|Oral ticagrelor 90 mg tablet, twice daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
11292698|NCT02748330|Active Comparator|Clopidogrel|Oral clopidogrel 75 mg tablet, once daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
11292699|NCT02748317|Experimental|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
11292700|NCT02748304|Placebo Comparator|control|just follow up after liver resection in HCC patients
11292701|NCT02748304|Active Comparator|sorafenib|use sorafenib after liver resection in HCC patients
11292702|NCT02748304|Active Comparator|sorafenib and aspirin|use sorafenib and aspirin after liver resection in HCC patients
11292703|NCT02748291|Experimental|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
11292704|NCT02748291|Active Comparator|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
11292708|NCT02748252||non HIV patients|non HIV patients admitted in Stroke units for the first occurence of acute stroke
11292709|NCT02748239|Active Comparator|MEDIAS 2 CT|The MEDIAS CT is a newly developed education program for the initiation of a conventional insulin therapy in type 2 diabetic patients.
11292710|NCT02748239|Placebo Comparator|Current CT program|This program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients.
11292711|NCT02748226||Retrospective cohort|This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals.
11292712|NCT02748226||Prospective cohort|This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals.
11292713|NCT02748213|Experimental|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
11292714|NCT02748213|Experimental|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
11292715|NCT02748200|Experimental|external beam radiotherapy: Dose level 1|57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)
11292716|NCT02748200|Experimental|external beam radiotherapy: dose level 2|60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)
11292717|NCT02748200|Experimental|external beam radiotherapy: dose level 3|62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)
11292718|NCT02748187|Experimental|Intervention|Cognitive Behavioural Analysis System of Psychotherapy
11292719|NCT02748174|Experimental|Episodic Migraine group|100 patients with chronic or episodic migraine
11292720|NCT02748174|Experimental|Chronic Migraine Group|100 patients with chronic or episodic migraine
11292721|NCT02748174|Experimental|Post concussive Headache Group|75 patients
11292722|NCT02748161|Active Comparator|DEB-TACE: Standard Endhole Catheter|Subjects will undergo DEB-TACE using a standard endhole catheter.
11292723|NCT02748161|Active Comparator|DEB-TACE: Surefire Infusion System|Subjects will undergo DEB-TACE using the Surefire Infusion System.
11292724|NCT02748148|Experimental|Medication therapy management|Medication therapy management service that is enhanced by the incorporation of pharmacogenomics and medication risk mitigation factor technology
11292725|NCT02748135|Experimental|TB-403 20mg/kg|
11292726|NCT02748135|Experimental|TB-403 50mg/kg|
11292727|NCT02748135|Experimental|TB-403 100mg/kg|
11292728|NCT02748135|Experimental|TB-403 175mg/kg|
11292729|NCT02748122|Experimental|Adolescents with T2DM|
11292730|NCT02748109|Experimental|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback
11292731|NCT02748109|Active Comparator|Vestibular Rehabilitation|Vestibular rehabilitation
11292732|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
11292733|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
11292734|NCT02748083|Active Comparator|tDCS group|The active tDCS group will be stimulated with transcranial Direct Current Stimulation (tDCS).
11292735|NCT02748083|Sham Comparator|Sham tDCS group|The sham tDCS group will have stimulation with sham transcranial Direct Current Stimulation (tDCS).
11292736|NCT02748070|Experimental|Prednisone|Provided oral steroid and topical steroid
11292737|NCT02748070|Placebo Comparator|Placebo|Provided oral placebo and topical steroid
11292738|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
11292739|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
11292740|NCT02748044|Experimental|Eligible patients for CC-Cruiser test|
11292741|NCT02748031|Experimental|eligible patients group|
11292742|NCT02748018|Experimental|Hybrid Closed Loop Arm|The HCL Arm will use the 670G insulin pump and the fourth generation glucose sensor (i.e. using the Auto Mode feature) for 6 months during the study period.
11292743|NCT02748018|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump). Each cohort (CSII, MDI, or SAP) will be used as the control arm to be compared to the experimental arm (HCL).
11292744|NCT02748005|Experimental|Fenugreek seeds extract 500 mg|Fenugreek seeds extract(Furosap) 500 mg
11292745|NCT02747992||PECS 0|receiving paravertebral block
11292746|NCT02747992||PECS 1|receiving paravertebral block and blocks targeting pectoral musculature
11292747|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA330)|Combination of hemodialysis and hemoperfusion (HA330) therapy All subjects in the study phase will receive hemodialysis plus hemoperfusion(HA330) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
11292748|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA130)|Combination of hemodialysis and hemoperfusion (HA130) treatment All subjects in the study phase will receive hemodialysis and hemoperfusion(HA130) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
11292749|NCT02747979|Active Comparator|hemodialysis only|hemodialysis only All subjects in the study phase will receive regular hemodialysis treatment three times per week.
11292750|NCT02747953|Experimental|afatinib|
11292751|NCT02747940|Experimental|patients with chronic migraine|flunarizine for patients with chronic migraine
11292752|NCT02747940|Experimental|patients with fibromyalgia|pregabalin for patients with fibromyalgia
11292753|NCT02747940|Experimental|patients with chronic migraine and fibromyalgia|flunarizine and pregabalin for patients with chronic migraine and myalgia
11292754|NCT02747927|Experimental|Tetravalent Dengue Vaccine|Tetravalent Dengue Vaccine (TDV) 0.5 mL, subcutaneous (SC) injection on Day 1 and Day 90. Eligible participants will offered TDV, SC injection, on Day 1 in the Booster Phase (Day 1b) based on the randomization on Day 1 of the study.
11292755|NCT02747927|Placebo Comparator|Placebo|Placebo-matching TDV, 0.5 mL, SC injection on Day 1 and Day 90. Eligible participants will be offered a placebo-matching TDV, SC injection on Day 1b in Booster Phase based on the randomization on Day 1 of the study.
11292756|NCT02747914|Experimental|Transcranial magnetic stimulation therapy|Group of patients treated with rTMS low than 5Hz
11292757|NCT02747914|Active Comparator|Conventional exercise treatment|Group of patients treated with conventional exercise
11292758|NCT02747901|Experimental|Kinesiotaping Group|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
11292759|NCT02747901|Active Comparator|Cold Therapy Group|Cold Therapy group received cold pack immediately after operation and following postoperative days.
11292760|NCT02747901|No Intervention|Control Group|Control group have no intervention.
11292761|NCT02747888|No Intervention|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition
~Screening and Enrollment:
~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
~- Sample stored in Biorepository"
11292762|NCT02747888|Experimental|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition
~Screening and Enrollment:
~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.
~- Specimen Testing and Analysis
~•Referral to Genetic Counselor, if indicated"
11292763|NCT02747875|Active Comparator|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
11292764|NCT02747875|Active Comparator|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
11292765|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
11292766|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
11292767|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
11292768|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
11292769|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
11292770|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
11292771|NCT02747823|Experimental|CBT124|CBT124, single dose of 1 mg/kg, IV infusion
11292772|NCT02747823|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 1 mg/kg, IV infusion
11292773|NCT02747823|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 1 mg/kg, IV infusion
11292774|NCT02747810|Experimental|New TENS design|To determine the function and safety of the strap design by evaluating the electrical connection to electrode, 2) the security in the insole and the electronic unit, and 3) facilitating observation and hand access to the top panel for adjusting the stimulation strength. 4) to elicit toe twitching with stimulation of tribal nerve
11292775|NCT02747797|Experimental|Advanced cancer with lucitanib-targeting biomarker(s)|Lucitanib 10 mg orally daily
11292776|NCT02747784|Experimental|Study group experimental|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
11292777|NCT02747784|Active Comparator|Study group active comparator|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Working memory (WOME)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
11292778|NCT02747784|No Intervention|Control group|48 female control subjects aged 18 years or older (24 without surgery, 24 with urogynecological or breast cancer surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
11292779|NCT02747758|Sham Comparator|Control|sham transcranial direct current stimulation (tDCS)
11292780|NCT02747758|Experimental|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
11292781|NCT02747758|Experimental|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
11292782|NCT02747745|No Intervention|Control Group|Group receive no intervention
11292783|NCT02747745|Experimental|Interventional Group|Four risk areas reflecting the great needs of FCGs of PWDs: depressive symptoms, burden, distress to problematic behaviors of PWDs and healthy behaviors.
11292830|NCT02747407||Basic Science Group II (vaccination at 9 months)|Patients undergo standard of care treatment and collection of blood samples as in Group I. Patients then receive hepatitis A and tetanus toxoid vaccinations at month 9.
11292784|NCT02747732|Experimental|one arm|"Therapy initiation 30 days max from screening.
~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
11292785|NCT02747719|Experimental|Light and exercise|Exposure to light with exercise
11292786|NCT02747706|Experimental|Parent Mentoring|1-on-1, phone, SMS/text, and smartphone-based parent-to-parent mentoring.
11292787|NCT02747706|No Intervention|Usual Care|No intervention through study.
11292788|NCT02747680|Other|type 1 diabetes|type 1 diabetes >5 years duration Well controlled (a1c <7.5%)
11292789|NCT02747680|Other|healthy controls|healthy controls
11292790|NCT02747667||Eye with late IOL complication|Alle patients with IOL complication (subgroup: in-the-bag dislocation; out-of-the-bag dislocation; haptic dislocation)
11292791|NCT02747667||Eyes with no late IOl complication|
11292792|NCT02747654|No Intervention|standard dosing|a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight
11292793|NCT02747654|Experimental|Genotype-guided dosing|INH dose determined based on developed model
11292794|NCT02747641|Other|treatment|only one arm
11292795|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
11292796|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
11292797|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
11292798|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
11292799|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
11292800|NCT02747602|Experimental|Group ABC|AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
11292801|NCT02747602|Experimental|Group BCA|caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
11292802|NCT02747602|Experimental|Group CAB|caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
11292803|NCT02747589|Experimental|Treatment Group|Subjects will be implanted to assess the feasibility of stimulating visual cortex to restore vision in blind volunteers.
11292804|NCT02747576||Medulloblastoma Group|Medulloblastoma survivors, 30 between the ages of 12-20 years and 30 between 21-30 years.
11292805|NCT02747576||Control Group|Health comparison group frequency matched on age (30 between the ages of 12-20 years and 30 between 21-30 years), gender and race.
11292806|NCT02747563|Experimental|Active Surveillance|Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
11292807|NCT02747563|Active Comparator|Controls|Patients without known diagnosis of prostate cancer Intervention - PSA measurement
11292808|NCT02747550|Experimental|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
11292809|NCT02747550|Active Comparator|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy.
11292810|NCT02747537|Experimental|Arm 1: Sorafenib and Irinotecan|"Sorafenib is an oral drug which will be administered on an outpatient basis twice a day continuously (every day of a 21-day cycle) at approximately the same times each day. For patients unable to swallow whole pills, an oral suspension may be prepared with tablets.
~Irinotecan will be administered orally (mixed with cranberry type juice) on an outpatient basis once a day on Days 1-5 of a 21-day cycle. Irinotecan should be given at least 1 hour after sorafenib."
11292811|NCT02747524|Experimental|Vita Mamba|Nutrient fortified peanut butter paste for 26 weeks.
11292812|NCT02747524|No Intervention|Control|
11292813|NCT02747511|Active Comparator|Haloperidol|
11292814|NCT02747511|Placebo Comparator|Placebo|
11292815|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
11292816|NCT02747498|Experimental|Linear ablation in addiction to pulmonary vein isolation|Procedure with linear ablation in addiction to pulmonary vein isolation
11292817|NCT02747485|Experimental|organic left-sided regurgitant valve|
11292818|NCT02747472|Placebo Comparator|Placebo|Infusion of saline
11292819|NCT02747472|Active Comparator|GIP(1-42)|Infusion of agonist, GIP(1-42)
11292820|NCT02747472|Experimental|GIP-A|Infusion of GIP-A alone
11292821|NCT02747472|Experimental|GIP-A + GIP(1-42)|Infusion of GIP-A and GIP(1-42)
11292822|NCT02747459|Experimental|SSS Intervention|Sensory Supported Swimming-eight, 30 minute lessons
11292823|NCT02747446|Experimental|Honey|added sugar: diet with 25% acacia honey
11292824|NCT02747446|Experimental|Fructose:glucose mixture|added sugar: Diet with 25% energy as a fructose:glucose mixture
11292825|NCT02747446|No Intervention|control|no intervention: Diet with 45% starch and no honey or added sugars
11292826|NCT02747433|Active Comparator|ALPS + Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
11292827|NCT02747433|Active Comparator|ALPS + Robot + Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
11292828|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
11292829|NCT02747420|Sham Comparator|Sham Group|
11293682|NCT02741570|Active Comparator|Extreme Regimen|Specified dose on specified days
11292831|NCT02747407||Basic Science Groups I (vaccination pre-treatment)|Patients receive standard of care hepatitis A or B vaccine, tetanus toxoid vaccine, and trivalent influenza vaccine and then undergo standard of care treatment external beam radiation therapy and receive standard of care temozolomide. Patients also undergo collection of blood Samples monthly for the first 8 months and then bimonthly for up to 12 months for analysis via flow cytometry, (CFSE) assay, live cell/dead cell distinction assay, and determination of naïve and memory immune response.
11292832|NCT02747394|Experimental|Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of adaptive Cogmed
11292833|NCT02747394|Other|Non-Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of non-adaptive Cogmed
11292834|NCT02747381|Experimental|intervention|receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications
11292835|NCT02747381|No Intervention|control|Asthmatic patients receiving conventional asthma medications
11292836|NCT02747368|Other|Wet age related macular degeneration|Ocusweep system is compared to results of conventional devices.
11292837|NCT02747342|Experimental|SHR3680; SHR3680+SHR3162|In dose esclation and expansion phase, SHR3680 will be administered orally In combination phase, SHR3680 will be administered together with SHR3162
11292838|NCT02747329|Experimental|1st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
11292839|NCT02747329|Active Comparator|1st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 1st month QCA and OCT assessment.
11292840|NCT02747329|Experimental|2st month OCT group implanted BuMA Supreme™ stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of BuMA Supreme™ stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
11292841|NCT02747329|Active Comparator|2st month OCT group implanted Xience V/Prime stent|This group contains 20 subjects. All subjects in this group will undergoing implantation of Xience V/Prime stent. The Primary Endpoint of this group is 2st month QCA and OCT assessment.
11292842|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 18|
11292843|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 28|
11292844|NCT02747303|Active Comparator|Stereotactic Radiosurgery to 2 mm GTV to PTV margins|
11292845|NCT02747303|Experimental|Stereotactic Radiosurgery to 0 mm GTV to PTV margins|
11292846|NCT02747290|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
11292847|NCT02747264|Experimental|eRAPID intervention|Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment online and weekly for 6 weeks post treatment (a total of 12 weeks) and then at 18 & 24 weeks. Hospital staff will be able to review eRAPID reports and use the information during the consultation in clinic, when attending radiotherapy or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.
11292848|NCT02747264|No Intervention|Usual care|The Usual care patients act as a comparison to the patients using eRAPID. They complete a paper-based quality of life questionnaire at baseline and then 6, 12 and 24 weeks after. The researchers will also collect clinical process measures for this group including number of hospital contacts and admissions.
11292849|NCT02747251|Experimental|Strengthen your Shoulder & Usual Care|"Instructions in a home-based intervention consisting of progressive high volume resistance training with an elastic band. Instructions provided 0, 2, 5, and 10 weeks after baseline. Usual care includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
11292850|NCT02747251|Active Comparator|Usual Care|"Includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
11292851|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
11292852|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
11292853|NCT02747199|Active Comparator|Coronary artery implanted with SYNERGY stent|One of the blocked coronary artery of a patient will received SYNERGY stent
11292854|NCT02747199|Active Comparator|Coronary artery implanted with ABSORB scaffold|Another blocked coronary artery of the same patient will received ABSORB scaffold
11292855|NCT02747186|Active Comparator|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.
~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
11292856|NCT02747186|Active Comparator|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.
~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
11292857|NCT02747173||RCC patients with bone metastases|Patients will receive the standard TKI treatment for first line treatment naive metastatic RCC. Sunitinib or pazopanib as decided by the investigator.
11292858|NCT02747160|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a six-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
11292859|NCT02747147|No Intervention|A- Control|Group A will have their PIVs assessed daily and record kept of PIV dislodgement or replacement
11292919|NCT02746770|No Intervention|control group|intervention: The control group will not perform the active exercise that will be applied to intervention group.
11292860|NCT02747147|Experimental|B - Device Intervention|patients will have their PIVs assessed daily and record kept of PIV displodgement or replacement. patients will additionally have a single blood collection attempted using the study device
11292861|NCT02747134|Experimental|Emotion Regulation and Mindfulness skills|A 10 week intervention including emotion regulation and mindfulness skills from dialectical behavioral therapy (DBT) was delivered.
11292862|NCT02747134|Active Comparator|Psychoeducation|Psychoeducation consisted of 5 session in which basic information about depressive symptoms and how to prevent depression relapse was given.
11292863|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
11292864|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
11292865|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
11292866|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
11292867|NCT02747095|Experimental|Spectral CT image|Interventions: IQon Spectral CT
11292868|NCT02747082|Active Comparator|1% sodium hypochlorite (NaOCl)|"Retreatment of root-filled teeth with infection with 1% NaOCl as irrigation solution.
~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
11292869|NCT02747082|Active Comparator|2% chlorhexidine gluconate (CHX)|"Retreatment of root-filled teeth with infection with 2% CHX as irrigation solution.
~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
11292870|NCT02747069||NICU electronic stethoscope|Neonatal patients of any gestation admitted to the neonatal intensive care unit (NICU) and undergoing routine monitoring with ECG and pulse oximetry Heart rate will be evaluated using an electronic stethoscope
11292871|NCT02747069||Newborns <32 weeks and ECG|Neonatal patients <32 weeks gestation Heart rate will be assessed at the time of delivery with both an electronic stethoscope and ECG using a pre placed lead system
11292872|NCT02747056|Experimental|Autism spectrum disorder studyA part1|The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
11292873|NCT02747056|Experimental|Autism spectrum disorder studyA part2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
11292874|NCT02747056|Other|Control adults Study A, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
11292875|NCT02747056|Other|Control adults Study A, part 2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
11292876|NCT02747056|Experimental|Autism spectrum disorder Study B, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
11292877|NCT02747056|Experimental|Autism spectrum disorder Study B, part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements.
11292878|NCT02747056|Other|Control adults, Study B part 1|The subjects will perform clinical, psychological and neuropsychological assessment.The subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
11292879|NCT02747056|Other|Control adults, Study B part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements
11292880|NCT02747043|Experimental|ABP 798|ABP 798 was administered at a dose of 375 mg/m^2 as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
11292881|NCT02747043|Active Comparator|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
11292882|NCT02747030|Experimental|Ocriplasmin intravenously|All subjects included in this phase I study are in the experimental treatment arm and will undergo a vitrectomy augmented with retinal vein cannulation and intravenous Ocriplasmin infusion.
11292883|NCT02747017||CDI patients|Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
11292884|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
11292885|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
11292886|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
11292887|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
11292888|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
11292889|NCT02746978|Active Comparator|Peer directed education|A revised education approach that focuses on problem solving discussions delivered by peers and grounded clinical information is compared to traditional approach of didactic clinician-driven education lectures
11292890|NCT02746978|Other|Patient Engagement Portal|A patient-owned portal to manage injury information is maintained in real-time by patients and families and shared with other care providers after inpatient rehabilitation discharge.
11292891|NCT02746965|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
11292892|NCT02746965|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
11292893|NCT02746952|Experimental|UCART19|
11292894|NCT02746939|No Intervention|Pre-curriculum assessment|Assessments will be administered to 3rd and 4th grade students prior to receiving curriculum training in fitness and nutrition.
11292895|NCT02746939|Experimental|Post-curriculum assessment|Assessments will be administered to 3rd and 4th grade students (matched from pre-curriculum assessment) after receiving 4-6 week InSciEd Out Fitness and Nutrition Curriculum.
11292896|NCT02746926|Experimental|4x20 mg tafamidis meglumine soft gel capsule|
11292897|NCT02746926|Experimental|48.8 mgA tafamidis free acid capsule|
11292898|NCT02746926|Experimental|61 mgA tafamidis free acid capsule|
11292899|NCT02746913|Experimental|Urodynamics, followed by Pessary|
11292900|NCT02746913|Experimental|Pessary, followed by Urodynamics|
11292901|NCT02746900|Experimental|Cervical cerclage|After the woman is placed in the dorsal lithotomy position and the bladder is emptied with a urinary catheter to reduce the chance of bladder injury, surgical preparation with Betadine will be performed. Breisky retractors and Sims retractors will be used to exposure the entire cervix. Sponge ring forceps will be used to optimized visualization of the cervix and provide the necessary countertraction at the suture entry and exit sites. McDonald technique will be performed placing 4-6 bites circumferentially around the cervix. Only one stitch will be used. The suture will be places as high as feasible
11292902|NCT02746900|No Intervention|No intervention|Bed rest will be not recommended.
11292903|NCT02746887||Preterm cohort|Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g
11292904|NCT02746887||Term control cohort|Healthy term infants
11292905|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
11292906|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
11292907|NCT02746861|Experimental|Diabetes Self-Management Support (DSMS)|Patient receives 6-months of DSMS while receiving support from a trained peer mentor (Peer-supported DSMS).
11292908|NCT02746861|No Intervention|Usual Care|Patient continues to receive usual care.
11292909|NCT02746848|Experimental|Patients with cornea injury|Patients with cornea injury who received healing Amniotic Membrane Extract Eye Drop.
11292910|NCT02746835|Experimental|Exercise Protocol|Set of exercises for balance, endurance, muscle strength and flexibility
11292911|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
11292912|NCT02746796|Experimental|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
11292913|NCT02746796|Experimental|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
11292914|NCT02746796|Experimental|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.
~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.
~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
11292915|NCT02746796|Placebo Comparator|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.
~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.
~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
11292916|NCT02746783|Active Comparator|Group 1|Single dose of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
11292917|NCT02746783|Experimental|Group 2|Double dose of MUTAGRIP® (one dose into the right deltoid area and the other one into the left deltoid area) containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
11292918|NCT02746770|Experimental|Cawthorne and Cooksey exercises group|Intervention: Participants allocated in both control and experimental groups were receiving treatment for their specific vestibular disorders. Patients assigned to the experimental group also performed the Cawthorne and Cooksey exercises for vestibular rehabilitation during a six week of treatment period.
11292920|NCT02746757|No Intervention|Ischemia-reperfusion no intervention|Ischemia-reperfusion without intervention
11292921|NCT02746757|Experimental|Ischemia-reperfusion with RIPC|Ischemia-reperfusion with intervention by RIPC
11292922|NCT02746757|Experimental|Ischemia-reperfusion with RIPC and Ex 9-39|Ischemia-reperfusion with RIPC and Ex 9-39
11292923|NCT02746744|Experimental|Rituximab|Infusion of Mabthera/Rituximab every 6 months
11292924|NCT02746744|Active Comparator|Dimethyl Fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
11292925|NCT02746744|Sham Comparator|Sodium Chloride solution|Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)
11292926|NCT02746731|Experimental|Prehabilitation|'Cardiorespiratory and resistance training.
11292927|NCT02746731|Active Comparator|Reference|Usual care.
11292928|NCT02746718|Other|Restrictive Respiratory Failure|A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
11292929|NCT02746705|Active Comparator|Transcranial Direct Current Stimulation (tDCS)|
11292930|NCT02746705|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|
11292931|NCT02746692|Experimental|Intervention|
11292932|NCT02746692|Active Comparator|Comparison|
11292933|NCT02746679|Experimental|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
11292934|NCT02746679|No Intervention|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
11292935|NCT02746666|Experimental|Intervention|Under pharmacist's behavioral intervention
11292936|NCT02746666|No Intervention|Control|No pharmacist's behavioral intervention
11292937|NCT02746653|Experimental|Use of TroClose1200(TM) for access port and closure device|TroClose in 1 port
11292938|NCT02746627|Active Comparator|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
11292939|NCT02746627|Experimental|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
11292940|NCT02746627|Experimental|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
11292941|NCT02746614|Active Comparator|Psychomotor Therapy & Adaptive Behavior|After the initial assessment of adaptive behavior, i.e.., set of skills that each individual with intellectual disability should train to cope with environmental demands, a Psychomotor Intervention Program was designed specifically. The program integrated individual and group sessions during 3 months, and the main goals of the program were related to independent functioning, motor development, economic and professional activities, academic and verbal skills.
11292942|NCT02746614|Active Comparator|Psychomotor Therapy & Motor Proficiency|Motor Proficiency After the initial assessment, a Psychomotor Intervention Program was designed specifically for participants with IDD. This program integrated individual and group sessions during 3 months, and the main goals of the program were related to motor coordination (balance, manual dexterity and coordination, global and fine praxis).
11292943|NCT02746601|Experimental|Risk Assessment, Counselling & Resources|Patients complete an electronic preconception health risk assessment tool. Results from the tool are directly uploaded or scanned into the patients' electronic medical record. A healthcare provider provides behavioural counselling, based on results of the risk assessment. Patients are given a customized handout that includes health recommendations and resources based on the patient's identified risk factors.
11292944|NCT02746575|Experimental|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
11292945|NCT02746562|Experimental|Freeze all|Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle
11292946|NCT02746562|No Intervention|Fresh embryo transfer|Standard procedure
11292947|NCT02746549|Experimental|1.5 Tesla MRI|Measurement of renal perfusion by 1.5 Tesla MRI with arterial spin labelling
11292948|NCT02746549|Experimental|3.0 Tesla MRI|Measurement of renal perfusion by 3.0 Tesla MRI with arterial spin labelling
11292949|NCT02746536|Experimental|Slow chest compression|Patients will receive the slow chest compression for one minute, immediately after 6MST.
11292950|NCT02746536|Placebo Comparator|No slow chest compression|Immediately after 6MST, the patient will not receive the SCC and will remain seated at rest for one minute, without any intervention.
11292951|NCT02746523||Case / Retired NHL Players|"All interventions for this group are described below:
~Sensory Organization Test (SOT): Balance and proprioception test
~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.
~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression
~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders
~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment
~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
11292995|NCT02746211|Experimental|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
11292996|NCT02746211|Experimental|Low titre Influenza Vaccine|Low titre Influenza Vaccine
11292997|NCT02746198|Experimental|Verum|2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
11292998|NCT02746198|Placebo Comparator|Placebo|2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
11312340|NCT02617186|Active Comparator|Robotic Lobectomy|
11292952|NCT02746523||Age Matched Controls|"All interventions for this group are described below:
~Sensory Organization Test (SOT): Balance and proprioception test
~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.
~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression
~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders
~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment
~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
11292953|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
11292954|NCT02746497|Active Comparator|Group E (early intervention)|One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
11292955|NCT02746497|Active Comparator|Group L (late intervention)|After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
11292956|NCT02746484|Experimental|Ability platform program|Multi-domain at home rehabilitation program delivered through the Ability platform.
11292957|NCT02746484|Active Comparator|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
11292958|NCT02746458|No Intervention|Standard of Care Physical Therapy|This group will receive the standard of care physical therapy program for 6 weeks.
11292959|NCT02746458|Experimental|Blood Flow Restriction Plus Standard of Care Physical Therapy|This group will receive the same standard of care physical therapy program for 6 weeks plus blood flow restriction.
11292960|NCT02746445||ASD Subjects|No interventions. This is an observation of subjects who received MeRT utilizing assessment documentation.
11292961|NCT02746432|No Intervention|Control group|Routine intra operative saline infusion to be administered.pre-operation and timed assessment lab set to be obtained.
11292962|NCT02746432|Experimental|Intervention group.Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin (Human regular insulin) ) infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
11292963|NCT02746419|Experimental|Experimental|Subjects will receive renal denervation.
11292964|NCT02746419|Sham Comparator|Control|Subjects will receive all procedures as experimental group but renal denervation system will not be turned on.
11292965|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
11292966|NCT02746393|Experimental|Intervention|Health Advocates Program
11292967|NCT02746393|Active Comparator|211 Arm|211 Information Sheet
11292968|NCT02746380|Experimental|LBAL|Adalimumab
11292969|NCT02746380|Active Comparator|Humira®|Adalimumab
11292970|NCT02746367||MDD|Patients diagnosed with Major Depressive Disorder
11292971|NCT02746367||BPI|Patients diagnosed with bipolar I
11292972|NCT02746367||BPII|Patients diagnosed with bipolar II
11292973|NCT02746354|Experimental|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
11292974|NCT02746354|No Intervention|Usual care|
11292975|NCT02746328|Experimental|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
11292976|NCT02746315|Experimental|Experimental 1|Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.
11292977|NCT02746315|Experimental|Experimental 2|Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.
11292978|NCT02746315|Experimental|Experimental 3|Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.
11292979|NCT02746315|Experimental|Experimental 4|Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.
11292980|NCT02746302|Experimental|HS-20004|One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
11292981|NCT02746302|Placebo Comparator|Placebo|Placebo Injected s.c. (under the skin) once for one subject.
11292982|NCT02746276|Other|Ceftriaxone and metronidazole|Pharmacokinetic study of ceftriaxone and metronidazole in malnourished children
11292983|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
11292984|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
11292985|NCT02746250|Active Comparator|Tension type headache|The investigator measures the muscle soreness and muscle stiffness before the patients starts their prescribed treatment with amitriptyline - and again after they have reached their optimal dosage of amitriptyline.
11292986|NCT02746250|No Intervention|Healthy controls|The investigator measures the muscle soreness and muscle stiffness once.
11292987|NCT02746237|Experimental|KAR5585|KAR5585 Capsules
11292988|NCT02746237|Placebo Comparator|Placebo|Placebo capsules
11292989|NCT02746224|Other|group 1A|the surgical technique initially dissects the inferior mesenteric vein (IMV).
11292990|NCT02746224|Other|group 1B|the surgical technique initially dissects the inferior mesenteric artery (IMA).
11292991|NCT02746224|Other|group 2A|the patients will have a latero-terminal colorectal anastomosis
11292992|NCT02746224|Other|group 2B|the patients will have a termino-terminal colorectal anastomosis.
11292993|NCT02746211|Experimental|High Titre Influenza virus|High Titre Influenza virus
11292994|NCT02746211|Experimental|Medium - High Influenza virus|Medium - High Influenza virus
11292999|NCT02746185|Active Comparator|Low-molecular-weight heparin|dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
11293000|NCT02746185|Experimental|Rivaroxaban|rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
11293001|NCT02746172|Experimental|Cochlear Implant Recipients|cochlear implant recipients
11293002|NCT02746172|No Intervention|Normal Hearing Volunteers|Normal hearing volunteers
11293003|NCT02746146|Experimental|Chronic dialysis patients|"The study population consists of patients over 70 (≥) and under 85 years (<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (<) 7 points (Dusseux et al. 2015).
~Intervention: Systematic use of a prognostic score"
11293004|NCT02746133||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
11293005|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
11293006|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
11293007|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
11293008|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
11293009|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
11293010|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
11293011|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
11293012|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
11293013|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
11293014|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
11293015|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
11293016|NCT02746094|Experimental|The study population|"The study population is comprised of adult men less than 80 years of age who are consulting for ED lasting for over 6 months following a prostatectomy that took place 18 to 60 months ago. The patients are currently in a stable relationship that has been going on for at least 3 months, have an IIEF-EF score between 6 and 25, and have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).
~Intervention: 8 bi-weekly LIESWT sessions"
11293017|NCT02746081|Experimental|BAY1436032|"Dose escalation: Patients with any type of IDH1-R132X-mutant solid tumor may be eligible for enrollment. A minimum of 3 patients per cohort will be treated. If dose limiting toxicities (DLTs) occur, Bayesian dose-DLT modeling will be performed to help guide dosing decisions and to identify the maximum tolerated dose (MTD). If the MTD is not reached, a recommended phase II dose (RP2D) will be chosen based on available safety, tolerability, PK, PD and clinical efficacy data.
~Dose expansion: The dose and schedule that was determined to be most appropriate in the dose escalation part of the study, which may be the MTD and / or the RP2D, will be used. Cohorts will consist of patients with the following IDH-R132X-mutant tumor types: (1) anaplastic glioma; (2) glioblastoma; (3) intrahepatic cholangiocarcinoma; (4) tumor types other than those in Cohorts 1-3."
11293018|NCT02746068|Experimental|AXS-02|Administered orally in the morning for 6 weeks
11293019|NCT02746068|Placebo Comparator|Placebo|Administered orally in the morning for 6 weeks
11293020|NCT02746042|Experimental|Sinupret extract coated tablets|"Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.
~There will be no dose change during the trial."
11293021|NCT02746042|Placebo Comparator|Placebo coated tablets|Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.
11293022|NCT02746029||Children with cardiac murmur|
11293023|NCT02746016|Experimental|Infant Formula supplemented with Oligosaccharides|Ready to feed infant formula ; Feed ad libitum.
11293024|NCT02746003|Other|Managed Aquifer Recharge water|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control at different times.
11293025|NCT02746003|Other|Control|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control arms at different times.
11293026|NCT02745990|Experimental|EPO group|In EPO group, The recombinant human erythropoietin (rhEPO) will be given by 500 U/kg/dose intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
11293027|NCT02745990|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
11293028|NCT02745977|Other|Dairy Free Diet- guaiac + on dairy free diet|Dairy Free Diet x 3 weeks then stool guaiac positive
11293029|NCT02745977|Other|Guaiac negative on dairy free diet|on dairy free diet x 3 weeks, then stool guaiac negative
11293030|NCT02745964|Experimental|LMA supreme|Anesthesia is maintained using LMA supreme during surgery.
11293031|NCT02745964|Active Comparator|I-gel|Anesthesia is maintained using I-gel during surgery.
11293032|NCT02745951|Experimental|Heliox|Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass
11293033|NCT02745951|Active Comparator|Standard of care|Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass
11293034|NCT02745938||Mitochondrial disease|Patients with mitochondrial disease, investigated by blood samples and exercise test.
11293035|NCT02745938||Metabolic myopathy|Patients with metabolic myopathy, investigated by blood samples and exercise test.
11293036|NCT02745938||Muscular dystrophy|Patients with muscular dystrophy, investigated by blood samples and exercise test.
11293037|NCT02745938||Healthy controls|Healthy controls, investigated by blood samples and exercise test.
11293038|NCT02745925|Experimental|normal-weight|normal-weight women
11293039|NCT02745925|Experimental|obesity|obese women
11293040|NCT02745912|Experimental|Metformin + Naltrexone/Bupropion|Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
11293041|NCT02745899|Active Comparator|Soy milk substitute Healthy|Healthy children aged 6-18 will drink 240 ml of soy milk substitute.
11293042|NCT02745899|Active Comparator|Soy milk substitute Asthma|Asthmatic children aged 6-18 will drink 240 ml of soy milk substitute.
11293043|NCT02745899|Experimental|Cow milk Healthy|Healthy children aged 6-18 will drink 240 ml of cow milk.
11293044|NCT02745899|Experimental|Cow milk Asthma|Asthmatic children aged 6-18 will drink 240 ml of cow milk.
11293045|NCT02745886|Experimental|Metformin group|Metformin 0.85 twice daily for 6 months
11293046|NCT02745886|No Intervention|Standard diet group|
11293047|NCT02745886|Other|CR group|Calorie restriction diet will be given to this group.
11293048|NCT02745873|Experimental|Arm A|Ascorbic Acid 250 mg in tablet form was used.
11293049|NCT02745873|Experimental|Arm B|Ascorbic Acid 500 mg in tablet form was used.
11293050|NCT02745860|Experimental|Sequence AB|Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
11293051|NCT02745860|Experimental|Sequence BA|Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
11293052|NCT02745847|Experimental|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
11293053|NCT02745834|Experimental|Chronic Ankle Instability|Soldiers who suffer from chronic ankle instability who had a first major ankle sprain one year or more ago, and did not sustained any major ankle sprain in the last two months, will go through Gait analysis intervention.
11293054|NCT02745834|Experimental|Healthy controls|Healthy soldiers who are not suffering from chronic ankle instability, will go through Gait analysis intervention.
11293055|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
11293056|NCT02745808|Experimental|HUC-MSCs|Intracavernous injection of 15 million HUC-MSCs.
11293057|NCT02745808|Experimental|Injectable Collagen Scaffold + HUC-MSCs|Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
11293058|NCT02745795|Experimental|MIG: Motivational Interview Group|Group submitted to three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
11293059|NCT02745795|Sham Comparator|CIG: Conventional Intervention Group|Group submitted to three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
11293060|NCT02745769|Experimental|Ramucirumab + Merestinib|Ramucirumab intravenously (IV) on day 1 and day 15 in combination with merestinib orally once a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
11293061|NCT02745769|Experimental|Ramucirumab + Abemaciclib|"Ramucirumab IV on day 1 and day 15 in combination with abemaciclib orally twice a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
~On June 21st 2017 the Ramucirumab + Abemaciclib arm was cancelled with no participants enrolled."
11293062|NCT02745756|Experimental|Combined Cell Therapy|Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
11293063|NCT02745743|Experimental|Arm 1|Biomarker-enriched advanced hematological neoplasms
11293064|NCT02745743|Experimental|Arm 2|Other selected advanced hematological neoplasms
11293065|NCT02745730|Active Comparator|Glucose|Shake sweetened with glucose
11293066|NCT02745730|Active Comparator|Fructose|Shake sweetened with fructose
11293067|NCT02745730|Experimental|Sucralose|Shake sweetened with sucralose
11293068|NCT02745730|Experimental|Allulose|Shake sweetened with allulose
11293069|NCT02745717|Experimental|cord blood and IST group|Administration of antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days, Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml, plus one unit of at least 4/6 HLA loci matched cord blood transfusion 24 hours after last dose of ATG.
11293070|NCT02745717|Active Comparator|IST group|Antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days , Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml.
11293071|NCT02745704|Experimental|PEG-IFN group|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.
11293072|NCT02745704|No Intervention|NAs group|Patients do not need to change their NAs treatment.
11293073|NCT02745691||A. Surgery|A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
11293074|NCT02745691||B. Radiochemotherapy|B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
11293075|NCT02745691||C. Targeted therapy|C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
11293076|NCT02745691||D. Immunotherapy|Any new immunotherapy for lung cancer
11293077|NCT02745678|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation.
11293078|NCT02745665||1-Elite Cyclist|"10 symptomatic cyclists with unilateral diagnosis of iliac EF,
~FLOW MEDIATED DILATION Ankle brachial pressure index (ABPI) PULSE WAVE VELOCITY AND AUGMENTATION INDEX Blood pressure RAMP Test"
11293079|NCT02745665||2-Amateur Cyclist|"10 asymptomatic cyclists with no evidence of EF
~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
11293080|NCT02745665||3-Control|"10 age-matched healthy male group
~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
11293081|NCT02745652|Experimental|pulsed electromagnetic field (PEMF)|patients in this group received the pulse electromagnetic field with frequency 50 Hz and intensity 80 gauss for 30 min.The patient was in sitting position, while the forearm was rested on the bed inside the solenoid in supination position
11293679|NCT02741583|Experimental|altitude rehabilitation program|3 weeks rehabilitation program at high altitude (3200m)
11293082|NCT02745652|Experimental|Therapeutic ultrasound (US)|Pulsed mode US was applied over the volar surface of the forearm (the carpal tunnel area) 15 min per session with a frequency of 1 MHz and intensity of 1.0 W/cm2
11293083|NCT02745639|Experimental|VMAT-SIB + XELOX|"A VMAT-SIB technique was used. Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and Organs at risks.
~The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment."
11293084|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
11293085|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
11293086|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
11293087|NCT02745613|Experimental|Family history of T2D|The participants will undergo 8 weeks of combined exercise
11293088|NCT02745613|Experimental|No Family history of T2D|The participants will undergo 8 weeks of combined exercise
11293089|NCT02745600|Other|Software assisted RFA treatment|Non-controlled, prospective, multicenter study arm, to evaluate RFA therapy simulation software.
11293090|NCT02745587|Experimental|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
11293091|NCT02745587|Active Comparator|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
11293092|NCT02745574|Experimental|Combined maneuver|Combined maneuver: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm dihydrogen monoxide (H2O). The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
11293093|NCT02745574|Experimental|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
11293094|NCT02745574|No Intervention|Control group|CO2 was removed by passive exsufflation through the port site.
11293095|NCT02745561|Experimental|Chemoradiotherapy Arm|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
11293096|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
11293097|NCT02745522|Experimental|Oxytocin|Oxytocin nasal spray
11293098|NCT02745522|Placebo Comparator|Placebo|Placebo nasal spray
11293099|NCT02745509|Experimental|Extensive Intraoperative Peritoneal Lavage|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles), followed by complete aspiration of the fluid . The abdomen will be closed as per standard.
11293100|NCT02745509|No Intervention|Standard Treatment|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal lavage will be done < 3 cycles with 3 liters or less of warmed normal saline. The abdomen will be closed as per standard.
11293101|NCT02745496|Other|TRUS Biopsy|Standard of Care Treatment
11293102|NCT02745496|Other|TRUS/FUSION Biopsy|Interventional Treatment
11293103|NCT02745483|Experimental|Separable clustered electrodes|Enrolled patients in the prospective study (RFA using separable clustered electrodes (Octopus®)) for treatment-naive HCC (n=79)
11293104|NCT02745483|No Intervention|Historical control group|Patients who received RFA according to routine protocol in our center (multiple internally-cooled electrodes) for treatment-naive HCC from Jan 2011 to July 2013 in our institution (n=74) .
11293105|NCT02745470|Experimental|Lixisenatide injection|intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI
11293106|NCT02745470|Placebo Comparator|Normal saline|control : normal saline 0.3 cc subcutaneous injection before functional MRI
11293107|NCT02745444|Other|low-calorie formula diet|Donor taking low-calorie formula diet, 50% of basal energy rate, individually calculated with Mifflin-St. Jeor formula.
11293108|NCT02745444|No Intervention|no diet|Donor ingesting food as usual.
11293109|NCT02745444|Other|protein-restricted diet|Donor taking protein-restricted diet according to diet plans of clinical dietetics of University Hospital of Cologne, with unchanged calorie supply, individually calculated with Mifflin-St. Jeor formula.
11293110|NCT02745444|No Intervention|Normal protein supply|Donor taking same dishes as protein-restricted diet group but with customary protein levels, with unchanged calorie supply.
11293111|NCT02745431|Experimental|Oxytocin nasal spray|Oxytocin nasal spray
11293112|NCT02745431|Placebo Comparator|Placebo nasal spray|Placebo nasal spray
11293113|NCT02745405|Experimental|Fat Suit Condition|Participants are randomly assigned to wear a fat suit and then walk across campus.
11293114|NCT02745405|Other|Control Condition|Participants are randomly assigned to wear the same clothing that is on the fat suit but in their own size and then walk across campus.
11293115|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
11293116|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
11293117|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
11293118|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
11293119|NCT02745379|Experimental|BFPSC+|The group receives a combination (DFDBA)+buccal fat pad derived stem cells BFPSC and PRF for sinus augmentation
11293120|NCT02745379|Active Comparator|BFPSC-|The group receives a combination of demineralized freeze-dried bone allografts DFDBA (lacking any cells) and PRF for sinus augmentation
11293121|NCT02745366|Experimental|BFPSC+|The combination of BFPSC+FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure.
11293680|NCT02741583|Active Comparator|rehabilitation program|3 weeks rehabilitation program at low altitude (760m)
11293122|NCT02745366|Active Comparator|BFPSC-|The combination of FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure
11293123|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
11293124|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
11293125|NCT02745340|Active Comparator|Acetate|
11293126|NCT02745340|Experimental|Citrate|
11293127|NCT02745314||>74 years|Older than 74 year-old patients
11293128|NCT02745288|Experimental|Nerve block|This arm will receive inferior alveolar nerve block
11293129|NCT02745288|No Intervention|control|Control arm will not receive inferior alveolar block
11293130|NCT02745275|Experimental|Peer-led Health Education|A single 60 minute interactive workshop led by the trained health coach followed by a series of three one hour discussion groups
11293131|NCT02745275|No Intervention|Control|No intervention
11293132|NCT02745262||Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
11293133|NCT02745262||Non Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
11293134|NCT02745249|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention which focus on improving dietary practices, specifically improved diversity of foods and energy intakes of pregnant women, and improved intake of calcium and iron/folic acid (IFA) supplements.
11293135|NCT02745249|No Intervention|A&T-non intensive|A&T-non intensive aim only receive MNCH services
11293136|NCT02745236|Experimental|Nurse Practitioner Led-Care|"Nurse Practitioner (NP) Intervention Initial Visit and Interventions: An experienced nurse practitioner with extra atrial fibrillation (AF) management training will complete the initial assessment to determine a treatment plan based on current AF Guidelines. The NP will provide patient education on AF management.
~Follow-up: Follow-up will occur at 3 and 6 months from baseline to evaluate the patient's response to treatment and will be modified as required based on AF symptoms, testing results and physical assessment.
~A physician will be consulted for advanced specialty AF management or if a patient requires admission to hospital."
11293137|NCT02745236|Active Comparator|Cardiologist Led-Care|"Standard Care Initial Visit and Intervention: A general cardiologist will manage patients as per their usual practice.
~Follow-up: As per the cardiologist's usual practice. The patient's care will remain with the family physician if no follow-up is required.
~Follow-up: Follow-up will be determined as per the cardiologist's usual practice. If a follow-up appointment is required it will done in the cardiologist's own independent clinic. The patient's care will be referred back to the family physician if no follow-up is required."
11293138|NCT02745223|Experimental|PresbiDrops (CSF-1)|Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.
11293139|NCT02745223|Placebo Comparator|Placebo|Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.
11293140|NCT02745210|Experimental|Experimental|Magnetic resonance (MR) spectroscopy study.
11293141|NCT02745197|Experimental|Nutritional Supplement|2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
11293142|NCT02745197|Placebo Comparator|Placebo|2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
11293143|NCT02745184|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
11293144|NCT02745171|No Intervention|Control group|This group will be evaluated after three months there will be a reassessment, in this case the participating subjects do not perform any kind of therapy.
11293145|NCT02745171|Experimental|Experimental group|There will be an initial evaluation, after a month of physical therapy at the end of the protocol, and twice more after the protocol, both interval a month.
11293146|NCT02745158||FOP Patients|
11293147|NCT02745145|Experimental|Abituzumab 1500 milligram (mg)|
11293148|NCT02745145|Experimental|Abituzumab 500 mg|
11293149|NCT02745145|Placebo Comparator|Placebo|
11293150|NCT02745132|Other|Cognitive evaluation in HCV patients|"Neuropsychological evaluation and Brain MRI
~Intervention: The only intervention to be carried out along the study will consist of complete neuro-psychological tests and MRI studies performed at different times.
~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied: A neuro-psychological battery of tests and brain MRI studies will be performed at different times before and after the end of the treatment. The participation in the study will not influence neither the indication to treat nor the treatment used.
~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
11293151|NCT02745119|Experimental|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
11293152|NCT02745119|Experimental|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
11293153|NCT02745106|Experimental|PADN treatment|"Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:
~Ablation catheter
~Carto 3, Carto RMT, Stereotaxis
~Swan-Ganz catheter"
11293154|NCT02745106|Sham Comparator|Control (Sham)|"Procedure: Right heart catheterization
~Using following device:
~- Swan-Ganz catheter"
11293155|NCT02745093|Experimental|64-84 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-84 days will receive 200 µg mifepristone followed by misoprostol 24-48 hours later.
11293453|NCT02743130|Experimental|Blackcurrant nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
11293156|NCT02745093|No Intervention|57-63 days gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
11293157|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
11293158|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 50.
11293159|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
11293160|NCT02745041|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]
11293161|NCT02745041|Active Comparator|Cryoprecipitate|Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]
11293162|NCT02745028|Other|With monosodium glutamate|Results of one time gastric emptying study with a single dose of monosodium glutamate; 1 g for weight greater than 45 kg, 700mg between 35 and 44,900 kg, 600mg between 25 and 34,900, 500mg between 15 and 25 kg and 250mg in less than 15 kg
11293163|NCT02745015|Experimental|treatment|immediate non-surgical periodontal treatment
11293164|NCT02745015|Other|control|non-surgical periodontal treatment scheduled for the following 3-monthly visit
11293165|NCT02745002|Experimental|navigated bronchoscopy|
11293166|NCT02744989|Experimental|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
11293167|NCT02744989|Sham Comparator|Sham tDCS|
11293168|NCT02744976|Experimental|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
11293169|NCT02744976|Active Comparator|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
11293170|NCT02744963|Experimental|Free and convenient medicine access|Free access to a list of essential medicines. Medicines are either mailed to the patient or dispensed at the point of care.
11293171|NCT02744963|No Intervention|Usual medicine access|Usual access to medicines.
11293172|NCT02744950|Active Comparator|Intermediate/complex repair|This arm will have closures of scalp defects with deep and superficial suture placement.
11293173|NCT02744950|Experimental|Pulley stitches|This arm of the study will have only pulley stitches to close the entire defect.
11293174|NCT02744937|Experimental|A|continuing LDA
11293175|NCT02744937|No Intervention|B|discontinuing LDA
11293176|NCT02744924|Experimental|Physical activity intervention|Participants undergo the community-based physical activity promotion (see Intervention)
11293177|NCT02744911|Experimental|Telemedicine group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device via the internet using the telemedicine application. Also includes speech-language pathologists providing treatment via the telemedicine application.
11293178|NCT02744911|Active Comparator|In person group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device in person. Also includes speech-language pathologists providing treatment in person.
11293179|NCT02744898|Experimental|Carboplatin AUC and Abraxane 100mg/m2|
11293180|NCT02744885|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
11293181|NCT02744885|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
11293182|NCT02744872|Active Comparator|Felodipine|Tablet Felodipin 10 mg x 1 daily
11293183|NCT02744872|Placebo Comparator|Placebo|Identical placebo once daily
11293184|NCT02744859|Experimental|Calorie Label|"Labels will read [lower calorie bound] - [upper calorie bound] calories per container. 2,000 calories a day is used for general nutrition advice but calorie needs vary."
11293185|NCT02744859|Experimental|Warning Label|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay."
11293186|NCT02744859|Experimental|Warning Label with Graphics|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. These labels will also have graphic depictions of each health condition above the corresponding text."
11293187|NCT02744859|No Intervention|No label|We will also have a condition where no labels are presented-- business as usual.
11293188|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:
~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and
~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
11293189|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:
~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and
~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
11293190|NCT02744833|Experimental|GMI-1271|
11293191|NCT02744833|Active Comparator|Enoxaparin Sodium (Lovenox®)|
11293192|NCT02744820|Placebo Comparator|Cohort 1 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
11293228|NCT02744586|Experimental|Strengthening our Vows (SOV) Group|"Participants in the SOV arm will participate in the Together HIV Free and Protecting My Spouse plans."
11293193|NCT02744820|Placebo Comparator|Cohort 2 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
11293194|NCT02744820|Placebo Comparator|Cohort 3 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
11293195|NCT02744820|Placebo Comparator|Cohort 4 (Part 2)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Salt Other: Placebo"
11293196|NCT02744807||non-Chronic endometritis|patients with intrauterine adhesion only
11293197|NCT02744807||Chronic endometritis|patients with intrauterine adhesion as well as Chronic endometritis
11293198|NCT02744794|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
11293199|NCT02744781|Experimental|Lumbar disc degeneration; LDD|The LDD group included subjects with at least 1 abnormal disc from L1-2 to L5-S1 of grade III, IV, or V. The non-LDD group included subjects with 5 normal discs of grade I or II. For further assessment, the most damaged disc of the 5 constituted the highest grade of LDD.
11293200|NCT02744768|Experimental|Treatment|"Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.
~HLA typing will be performed immediately after the diagnosis for eligible patients.
~MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation."
11293201|NCT02744755|Experimental|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
11293202|NCT02744755|Active Comparator|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
11293203|NCT02744742|Experimental|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11293204|NCT02744742|Active Comparator|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
11293205|NCT02744729|Experimental|Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.
11293206|NCT02744716|Experimental|non-balloon group|with aspirin
11293207|NCT02744716|Experimental|balloon group|with aspirin and intrauterine balloon
11293208|NCT02744716|No Intervention|control group|without aspirin and intrauterine balloon
11293209|NCT02744703|Active Comparator|self-etch adhesive|application of self-etch adhesive on cavities.
11293210|NCT02744703|Experimental|CAPE-S|CAPE before self-etch adhesive
11293211|NCT02744703|Active Comparator|total-etch adhesive|total-etch adhesive on cavities.
11293212|NCT02744703|Experimental|CAPE-T|CAPE before total-etch adhesive application
11293213|NCT02744690|Experimental|MMC Injection|Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy
11293214|NCT02744690|Active Comparator|MMC Sponge Application|Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed
11293215|NCT02744677|Experimental|TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN 3 THV
11293216|NCT02744664|Experimental|Experimental|The subject receive Cryotherapy and than receive Icotinib 125mg, 3 times a day, orally administered until disease progression or intolerable toxicity reaction.
11293217|NCT02744651|Active Comparator|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
11293218|NCT02744651|Active Comparator|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
11293219|NCT02744638|Experimental|probiotic yoghurt & Arilin|probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
11293220|NCT02744638|Placebo Comparator|chemically acidified milk & Arilin|chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
11293221|NCT02744625|Active Comparator|Shock lower Mean Arterial Pressure (MAP)|Vasopressor-dependent treated to lower MAP (65 mmHg)
11293222|NCT02744625|Experimental|Shock higher MAP|Vasopressor-dependent treated to higher MAP (75 mmHg)
11293223|NCT02744625|No Intervention|Healthy participant awake|Healthy participant awake
11293224|NCT02744625|Experimental|Healthy participant sedated|Healthy participant Under light sedation
11293225|NCT02744612|Experimental|Treatment (Ibrutinib and Brentuximab Vedotin)|Patients receive ibrutinib PO QD on days 1-21 and brentuximab vedotin IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11293226|NCT02744599|Experimental|Device prompting|
11293227|NCT02744599|No Intervention|Control|Patients receive standard of care
11293414|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
11293229|NCT02744586|Placebo Comparator|Good Health Package Plus (GHPP) Group|Participants in the GHPP arm will receive education on the prevention of helminths, schistosomiasis, hypertension, diabetes, and diarrheal diseases through participatory and interactive group sessions.
11293230|NCT02744573||General Anaesthesia|ANI and SPI values under general anaesthesia
11293231|NCT02744573||Spinal Anaesthesia|ANI and SPI values under spinal anaesthesia
11293232|NCT02744573||Spinal Anaesthesia + Sedation|ANI and SPI values under spinal anesthesia in combination with sedation
11293233|NCT02744573||Control|ANI and SPI values under no anaesthesia
11293234|NCT02744560|Experimental|patients|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
11293235|NCT02744547|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
11293236|NCT02744547|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
11293237|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
11293238|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
11293239|NCT02744521|Experimental|Symptom based screening intervention|
11293240|NCT02744521|No Intervention|control|
11293241|NCT02744508|Active Comparator|P group|Palonosetron group
11293242|NCT02744508|Experimental|PD group|Palonosetron and dexamethasone group
11293243|NCT02744495|Experimental|postoperative nausea and vomiting risk factors|Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.
11293244|NCT02744495|No Intervention|control|No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.
11293245|NCT02744482|Experimental|Risedronate|Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
11293246|NCT02744482|Placebo Comparator|Placebo|Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.
11293247|NCT02744469||New patients|''New tuberculosis patients'' are patients just diagnosed for tuberculosis, and who were never treated for tuberculosis or who are treated for less than 1 month. In total, 1192 new patients will be recruited.
11293248|NCT02744469||Retreatment patients|''Retreatment tuberculosis patients'' are patients just diagnosed for tuberculosis and who were previously treated for tuberculosis (for a duration of 1 month at least). This group includes: patients with treatment relapse, failure and patients who return after default. In total, 298 retreatment patients will be recruited.
11293249|NCT02744456|Other|N-of-1 trial|Patients with hypertension who are taking none or one BP medication will be will be provided with prescriptions for up to 3 BP medications representative of different BP medication classes (i.e., losartan, an angiotensin system blocking agent; amlodipine, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic). Patients will be asked to take each medication for 2 weeks at a low dose, 2 weeks at a medium dose, and then 2 weeks at a high dose; provide health information and identify which medication they prefer to remain on following the N-of-1 trial (i.e., for long-term use).
11293250|NCT02744443|Experimental|Leucine|Leucine supplementation (10 g/d)
11293251|NCT02744443|Placebo Comparator|Placebo|Placebo supplementation (alanine, 10 g/d)
11293252|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
11293253|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
11293254|NCT02744417|Experimental|Smoking cessation therapy|Non-surgical periodontal therapy and concurrent smoking cessation therapy, with Smoking cessation counseling, Nicotine replacement therapy, use of bupropion hydrochloride and varenicline
11293255|NCT02744404||POC EID|Point of Care Early Infant Diagnosis qualitative technologies (Alere q) will be implemented. Sample collection and testing will happen in the same location within the health care facility.
11293256|NCT02744404||Laboratory-based testing|Conventional laboratory-based testing using the Abbott m2000 technology will continue to be used per standard of care in Malawi. Dried blood spot samples will be collected at health care facilities and transported within the national network to centralized laboratories for testing.
11293257|NCT02744391|Experimental|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
11293258|NCT02744378|Active Comparator|Clobetasol Group|clobetasol propionate (0.05%) cream
11293259|NCT02744378|Active Comparator|Tacrolimus Group|tacrolimus (0.1%) cream
11293260|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
11293261|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :
~low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)
~pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
11293262|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
11293263|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
11293264|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
11293265|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
11293266|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
11293267|NCT02744339|Experimental|Riociguat|Riociguat up-titrated to a maximum of 1.5mg TID
11293268|NCT02744339|Placebo Comparator|Placebo|Placebo sham-titrated TID
11293269|NCT02744326|Experimental|Text message reminder group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive text message reminders to attend or schedule a follow-up outpatient referral.
11293270|NCT02744326|No Intervention|Usual Care group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive the usual standard of care.
11293271|NCT02744313||AP Naive|Group followed over 12 weeks to measure fat deposition, insulin resistance, and glucose tolerance.
11293272|NCT02744300|Experimental|BABI-2 Lifestyle Intervention|Participants in this group will take part in the web-based lifestyle intervention which includes access to the lifestyle intervention website and personalized coaching from a Lifestyle Coach.
11293273|NCT02744300|No Intervention|Post-GDM Follow-up Group|Participants in this group will have access to a separate website containing links to information about diabetes prevention.
11293274|NCT02744287|Experimental|Arm 1: Phase 1 Dose Escalation|Participants with advanced pancreas, stomach, or prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
11293275|NCT02744287|Experimental|Arm 2: Phase 2 Dose Expansion|Participants with advanced pancreas, stomach, or prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
11293276|NCT02744274|Experimental|Verum acupuncture|16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
11293277|NCT02744274|Placebo Comparator|Sham acupuncture|16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
11293278|NCT02744248|Active Comparator|IOP Injection|Participants will receive 1 injection of the IOP at Days 1,once time.
11293279|NCT02744248|Placebo Comparator|0.9% normal saline|Participants will receive 1 injection of 0.9% normal saline at Days 1,once time.
11293280|NCT02744235|Other|Patients undergoing Polysomnography|
11293281|NCT02744222|Experimental|BCD-054, 180 mcg, biweekly|Patients of Groups 1 will receive blinded BCD-054 180 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 1 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
11293282|NCT02744222|Experimental|BCD-054, 240 mcg, biweekly|Patients of Groups 2 will receive blinded BCD-054 240 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 2 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
11293283|NCT02744222|Active Comparator|Avonex®, 30 mcg, weekly|Patients of Group 3 (reference group) will receive blinded Avonex® 30 mcgintramuscularly once a week for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive).
11293284|NCT02744222|Placebo Comparator|Placebo, 0,5 ml, weekly|Patients of Group 4 (placebo) will receive blinded placebo once a week for the first 20 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive)
11293285|NCT02744196|Experimental|Acellbia + methotrexate|"106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15.
~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days."
11293286|NCT02744196|Placebo Comparator|Placebo + methotrexate|"53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15.
~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days."
11293287|NCT02744183|Active Comparator|Control Group|Maintain habitual habits
11293288|NCT02744183|Active Comparator|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
11293289|NCT02744183|Experimental|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
11293290|NCT02744170|Experimental|COPD patients with delivery order 1, 2, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
11293291|NCT02744170|Experimental|COPD patients with delivery order 2,3, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
11293292|NCT02744170|Experimental|COPD patients with delivery order 3, 2, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
11293293|NCT02744170|Experimental|COPD patients with delivery order 1, 3, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
11293294|NCT02744170|Experimental|COPD patients with delivery order 2, 1, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
11293295|NCT02744170|Experimental|COPD patients with delivery order 3, 1, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
11293415|NCT02743351|Experimental|ProTmune|
11293416|NCT02743351|Active Comparator|Control Arm|
11293296|NCT02744157|Other|structured lifestyle program|The program consisted of an individual visit to a nurse for a health check-up and lifestyle counseling at baseline, six month and one year. The program also consisted of five group educations which included lectures on nicotine, alcohol, physical inactivity, eating habits, stress, sleeping habits and behavior changes
11293297|NCT02744144||Non-infection|Patients without clinical infection or positive wound culture
11293298|NCT02744144||Infection|Patients with clinical infection and positive wound culture
11293299|NCT02744131|Active Comparator|OCP|Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.
11293300|NCT02744131|Active Comparator|Metformin|Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.
11293301|NCT02744118|Experimental|Marijuana Screening and Brief Counseling|The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
11293302|NCT02744118|Active Comparator|Healthy Internet Use Model|The media screening and brief counseling intervention is based on a media use screening and brief counseling intervention tested as the active comparator for a 5As tobacco cessation randomized control trial (NCT01312480) and the 2010 American Academy of Pediatrics policy statement on children and media.
11293303|NCT02744105|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
11293304|NCT02744105|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
11293305|NCT02744092|Experimental|Randomized Arm 1|Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
11293306|NCT02744092|Active Comparator|Randomized Arm 2|Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
11293307|NCT02744092|Experimental|Preference Cohort|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).
~Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC).
~Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin."
11293308|NCT02744079|Active Comparator|Low carbohydrate diet|45 subjects will receive a very low carbohydrate diet between a positive breast biopsy and surgical tumor removal
11293309|NCT02744079|Active Comparator|Low fat diet|20 subjects will receive a lo fat diet between a positive breast biopsy and surgical tumor removal
11293310|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
11293311|NCT02744053|Experimental|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
11293312|NCT02744040|Other|Early ART initiation|Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
11293313|NCT02744040|Other|Deferred ART initiation|ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)
11293314|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Contrast Imaging|Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
11293315|NCT02744014|Experimental|Early intervention group|The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
11293316|NCT02744014|Other|Late intervention group|This group will receive the same training with a delay of 60-90 days, serving initially as control.
11293317|NCT02744001|Experimental|Low Added Sugar Diet|Menu containing <10% of total daily energy intake from added sugars.
11293318|NCT02743988|Experimental|Low target range|Low oxygen saturation target range: SpO2 85-89%
11293319|NCT02743988|Active Comparator|High target range|High oxygen saturation target range: SpO2 91-95%
11293320|NCT02743975|Experimental|Treatment group|Bevacizumab-800CW
11293321|NCT02743962|Active Comparator|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
11293322|NCT02743962|Experimental|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
11293323|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
11293324|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
11293325|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
11293326|NCT02743936|Experimental|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
11293327|NCT02743936|Active Comparator|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
11293328|NCT02743923|Active Comparator|carboplatin-paclitaxel- bevacizumab|carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg all administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by bevacizumab maintenance every 3 weeks until progression
11293329|NCT02743923|Active Comparator|cisplatin-pemetrexed|pemetrexed 500 mg/m2 administered intravenously on day 1 and cisplatin 75 mg/m2 administered intravenously on day 1 every 3 weeks for 4-6 cycles, followed by maintenance pemetrexed every 3 weeks until progression.
11293330|NCT02743910||Stage II-III breast cancer|Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.
11293331|NCT02743897|Experimental|Direct-acting antiviral treatment for HCV|
11293332|NCT02743884|Experimental|Esophageal Cooling Device|Esophageal cooling
11293333|NCT02743884|Experimental|Esophageal Warming|Esophageal warming
11293334|NCT02743871|Experimental|Cohort 1|10 mg of PF-06817024 or placebo
11293335|NCT02743871|Experimental|Cohort 2|30 mg of PF-06817024 or placebo
11293336|NCT02743871|Experimental|Cohort 3|100 mg of PF-06817024 or placebo
11293337|NCT02743871|Experimental|Cohort 4|300 mg of PF-06817024 or placebo
11293338|NCT02743871|Experimental|Cohort 5|1000 mg of PF-06817024 or placebo
11293339|NCT02743871|Experimental|Cohort 6|2000 mg of PF-06817024 or placebo
11293340|NCT02743871|Experimental|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
11293341|NCT02743871|Experimental|Cohort 8|300 mg of PF-06817024 or placebo
11293342|NCT02743871|Experimental|Cohort 9|IV dose to be determined of PF-06817024 or placebo
11293343|NCT02743871|Experimental|Cohort 10|PF-06817024 or placebo
11293344|NCT02743871|Experimental|Cohort 11|PF-06817024 or placebo
11293345|NCT02743871|Experimental|Cohort 12|PF-06817024 or placebo
11293346|NCT02743871|Experimental|Cohort 13|PF-06817024 or placebo
11293347|NCT02743858||Breast Cancer-Related Lymphedema|Bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder and the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed at baseline (prior to surgery), post-operatively (after surgery) and at scheduled timepoints of 6 months, 12 months, 18 months, and 24 months after surgery for a total of 2 years. For a patient who is diagnosed with lymphedema at ≥ 13 months after surgery, surveillance will continue for an additional 12 months after [lymphedema] diagnosis, and total surveillance time may exceed 2 years. Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. All patients will complete the ULL-27 (upper limb lymphedema) quality-of-life questionnaire at baseline and at each scheduled visit.
11293348|NCT02743832|Experimental|High-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
11293349|NCT02743832|Active Comparator|High-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
11293350|NCT02743832|Experimental|Low-level group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
11293351|NCT02743832|Active Comparator|Low-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
11293352|NCT02743819|Experimental|Treatment|Treatment with the combination of pembrolizumab and ipilimumab.
11293353|NCT02743806|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once every 8 weeks until vedolizumab is commercially available. (Per MM approval, dosing regimen may be modified per physician's decision).
11293354|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:
~An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;
~No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and
~Normal and stable allograft function at screening visit defined as-
~For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)
~For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) > 45 ml/min/1.73 m^2."
11293355|NCT02743780|Experimental|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
11293356|NCT02743780|Placebo Comparator|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
11293357|NCT02743767|No Intervention|Before interventions|Only observational activity for this arm, to record the frequency and triggering factors of airway complications during general anaesthesia.
11293358|NCT02743767|Experimental|After interventions|After introducing five different treating adaptations in airway management we want to record the frequency of airway complications during general anaesthesia.
11293652|NCT02741752|Experimental|test group|decortication group
11293359|NCT02743754|Placebo Comparator|Standard Therapy|Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
11293360|NCT02743754|Active Comparator|Standard Therapy and hyperbaric oxygen|Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
11293361|NCT02743741|Experimental|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
11293362|NCT02743728|Experimental|All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
11293363|NCT02743715|Active Comparator|Active tDCS|Electric current of 2mA delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
11293364|NCT02743715|Sham Comparator|Sham tDCS|In this group, the cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
11293365|NCT02743702|Experimental|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
11293366|NCT02743702|Experimental|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
11293367|NCT02743676||Avian influenza A|Natural history of Avian influenza A, particularly H5N1 strain which has a high potential of causing a global human pandemic, and real-world treatment practices will be observed in this study. This registry program will not require, recommend, or provide any specific treatment or medications.
11293368|NCT02743663||Wheezing subjects|Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
11293369|NCT02743663||Healthy cohort|One study visit will be completed with healthy participants. At this visit, three breathing tests will be performed: multiple-breath washout, forced oscillation technique, and spirometry. As well, an allergy skin test will be performed at the visit.
11293370|NCT02743650|Experimental|Sodium Bicarbonate|"All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).
~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening."
11293371|NCT02743637|Experimental|SDX-7320|Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
11293372|NCT02743624|Other|Pressure Support Titration|The analysis of the diagnostic accuracy of the breathing pattern variables, P 0.1 and the rate of tracheal muscle relaxation.
11293373|NCT02743611|Experimental|Arm 1 Does Escalation|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.
~Rimiducid may be administered in response to treatment-related toxicity."
11293374|NCT02743611|Experimental|Arm 2 Dose Escalation|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.
~Rimiducid may be administered in response to treatment-related toxicity."
11293375|NCT02743611|Experimental|Arm 1 Part 2 Dose Expansion|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701 at the recommended cell dose level.
~Rimiducid may be administered in response to treatment-related toxicity."
11293376|NCT02743611|Experimental|Arm 2 Part 2 Dose Expansion|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701 at the recommended cell dose level.
~Rimiducid may be administered in response to treatment-related toxicity."
11293377|NCT02743598|Experimental|Liraglutide|
11293378|NCT02743585|Experimental|Rapid diagnostic arm|"Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) AND FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen will be performed.
~The Interventions to be administered are the rapid diagnostic tests: FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen.
~Subjects will be recruited 8am-3pm daily, weekdays only. Results of the BCID and Rosco test will be communicated to the managing physicians by phone in real-time."
11293379|NCT02743585|No Intervention|Standard of care (control)|Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) will be used. FilmArray BCID and Rosco Diagnostica ESBL and carbapenemase screen will NOT be performed. Subjects will be recruited 8am-3pm daily, weekdays only.
11293380|NCT02743572|No Intervention|control group|preterm infants of this group with iron-free PN for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
11293381|NCT02743572|Experimental|iron sucrose-1|preterm infants of this group with iron supplementation of 100μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
11293382|NCT02743572|Experimental|iron sucrose-2|preterm infants of this group with iron supplementation of 200μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
11293383|NCT02743572|Experimental|iron sucrose-3|preterm infants of this group with iron supplementation of 300μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
11293384|NCT02743572|Experimental|iron sucrose-4|preterm infants of this group with iron supplementation of 400μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
11293385|NCT02743559|Active Comparator|Vitamin D group|Children born to mothers who received vitamin D during pregnancy will undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform(LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
11293386|NCT02743559|Placebo Comparator|Placebo group|Children born to mothers who received placebo during pregnancy will also undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform (LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
11293387|NCT02743546|Experimental|Dose Optimization:Participant with Certain B-Cell Malignancies|Participants with certain B-cell malignancies (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], or follicular lymphoma [FL]) will receive rising doses of intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met. Dose escalation will continue until the recommended phase 2 dose or maximum tolerated dose is reached.
11293388|NCT02743546|Experimental|Dose Expansion: Participants with DLBCL|Participants with DLBCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
11293389|NCT02743546|Experimental|Dose Expansion: Participants with FL|Participants with FL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
11293390|NCT02743546|Experimental|Dose Expansion: Participants with MCL|Participants with MCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
11293391|NCT02743546|Experimental|Dose Expansion: Participants with CLL|Participants with chronic lymphocytic leukemia (CLL) will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
11293392|NCT02743520|Experimental|Cardiac event monitor|Participants will under go evaluation with a two week cardiac event monitor.
11293393|NCT02743494|Experimental|Nivolumab|
11293394|NCT02743494|Placebo Comparator|Placebo|
11293395|NCT02743468||Healthy Volunteers|Healthy Volunteers
11293396|NCT02743455|Experimental|(Vaccine+Placebo)MVA-BN-YF + ISA 720|MVA-BN-YF + ISA 720 1.0x10^8 TCI50 intramuscularly on day 1(Vaccine)+ day 29(Placebo), 15 subjects
11293397|NCT02743455|Experimental|MVA-BN|MVA-BN 1.0x10^8 TCID50 subcutaneously on days 1 and 29, 15 subjects
11293398|NCT02743455|Experimental|MVA-BN-YF|MVA-BN-YF 1.0x10^8 TCI50 intramuscularly on days 1 and 29, 15 subjects
11293399|NCT02743455|Experimental|MVA-BN-YF + ISA 720|MVA-BN-YF + ISA 720 1.0x10^8 TCI50 intramuscularly on days 1 and 29, 15 subjects
11293400|NCT02743455|Experimental|MVA-BN-YF*|MVA-BN-YF 1.0x10^8 TCI50 intramuscularly on days 1 and 29, 15 subjects* *- Prior receipt of MVA-BN
11293401|NCT02743455|Experimental|YF-Vax|YF-Vax =/ > 4.74 log10 PFU subcutaneously on day 1(Vaccine)+ day 29 (Placebo), 15 subjects
11293402|NCT02743442|Experimental|Transoral surgery|
11293403|NCT02743429|Experimental|Long term infusion of ch14.18/CHO|10 day continuous Infusion of ch14.18/CHO.
11293404|NCT02743416||ECG screening|Will be screened for AF using only one-stop protocol
11293405|NCT02743416||Control group|as per regular standard as of today
11293406|NCT02743403|Active Comparator|Neurodyn Portable TENS|"Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.
~The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.
~The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.
~Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.
~Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject."
11293407|NCT02743403|Placebo Comparator|Placebo TENS- Neurodyn Portable TENS|"Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.
~The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active."
11293408|NCT02743403|No Intervention|Control|"Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.
~The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS."
11293409|NCT02743390|Active Comparator|TNF-alpha inhibitor drug|Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
11293410|NCT02743390|Placebo Comparator|Placebo drug|Saline infusion (250mL)
11293411|NCT02743377|Experimental|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
11293412|NCT02743377|Experimental|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
11293413|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
11293417|NCT02743338|Experimental|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
11293418|NCT02743338|Active Comparator|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
11293419|NCT02743338|Active Comparator|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
11293420|NCT02743338|Active Comparator|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
11293421|NCT02743325|Active Comparator|ALARA protocol|SVT ablation by ALARA protocol
11293422|NCT02743325|Active Comparator|current treatment|SVT ablation by conventional protocol
11293423|NCT02743312|Experimental|Torso Weights then Sham Weights|"No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks.
~Participants wear the Fitbit Flex throughout."
11293424|NCT02743312|Experimental|Sham Weights then Torso Weights|"No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks.
~Participants wear the Fitbit Flex throughout."
11293425|NCT02743299|Experimental|CPR simulation|CPR simulation with and without ventilator
11293426|NCT02743286|No Intervention|Control condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
11293427|NCT02743286|Experimental|Frequent sit-to-stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 15 2-minute standing interruptions, 3 per hour, and a mid-point bathroom break.
11293428|NCT02743286|Experimental|Walking breaks (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 2-minute walking interruptions, 3 per hour, and a mid-point bathroom break.
11293429|NCT02743286|Experimental|Stand More (Protocol D)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 10-minute standing breaks, 1 per hour, and a mid-point bathroom break.
11293430|NCT02743260|Experimental|pitavastatin (OATP1B1)|2 mg pitavastatin single dose
11293431|NCT02743260|Experimental|metformin (MATE1, MATE2K, OCT1, OCT2)|500 mg metformin single dose
11293432|NCT02743260|Experimental|digoxin (intestinal & renal P-glycoprotein)|0.5 mg digoxin single dose
11293433|NCT02743260|Experimental|adefovir dipivoxil (OAT1)|10 mg adefovir dipivoxil single dose
11293434|NCT02743260|Experimental|sitagliptin (OAT3)|100 mg sitagliptin single dose
11293435|NCT02743260|Experimental|cocktail (all substances)|combination of all individual drugs at respective single doses
11293436|NCT02743247|Experimental|Tacrolimus and Mycophenolate mofetil|Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
11293437|NCT02743234|Experimental|FMT|Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
11293438|NCT02743234|Active Comparator|Fidaxomicin|10 days fidaxomicin 200 mg x 2 daily
11293439|NCT02743234|Active Comparator|Vancomycin|10 days vancomycin 125 x 4 daily
11293440|NCT02743221|Experimental|Trifluridine/tipiracil + bevacizumab|"Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.
~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.
~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks."
11293441|NCT02743221|Active Comparator|Capecitabine + bevacizumab|Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks
11293442|NCT02743208|Experimental|Furlong Evolution femoral stem|Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.
11293443|NCT02743208|Active Comparator|Furlong H-A.C. femoral stem|Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.
11293444|NCT02743195|Other|Polyphenol/prebiotic blend|Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
11293445|NCT02743182|Active Comparator|Pegylated interferon alfa-2a|adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
11293446|NCT02743182|No Intervention|Control|HBeAg-negative patients receiving nucleos(t)ide analogues
11293447|NCT02743169||Standard Practice|This group will consist of ambulance calls under the standard practice of Aman Foundation for ambulance placement.
11293448|NCT02743169||Post-Intervention|This group will consist of ambulance calls after the spatially-optimized placement of ambulances.
11293449|NCT02743156|Active Comparator|angiography-guided PCI|angiography-guided percutaneous coronary intervention
11293450|NCT02743156|Experimental|IVUS-guided PCI|intravascular ultrasound guided percutaneous coronary intervention
11293451|NCT02743143|Experimental|Exercise therapy|High aerobic intensity training and maximal strength training 2 times per week in 1 year at the Hospital's Exercise Training Clinic. Patients receive comprehensive support from Trondheim municipal administration to facilitate adherence.
11293452|NCT02743143|Active Comparator|Follow-up care as usual|The usual care (UC) group will receive the usual physical activity offered by the primary health care system. UC includes the traditional physical activity advice from the Health Directorate. The UC group are invited to supervised exercise at the exercise training Clinic after 1 year.
11293454|NCT02743130|Experimental|Lingonberry nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
11293455|NCT02743130|Active Comparator|Reference|Sugar control, contains 17.5 g glucose and 17.5 g fructose in water
11293456|NCT02743117|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
11293457|NCT02743117|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
11293458|NCT02743104|Active Comparator|Ketamine for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.
~This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
11293459|NCT02743104|Active Comparator|Propofol for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.
~This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
11293460|NCT02743078|Experimental|Bevacizumab and TTFields Therapy|Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.
11293461|NCT02743065||Device: HepaSphere Microspheres|HepaSphere Microsphere
11293462|NCT02743039|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
11293463|NCT02743039|No Intervention|Control Standard of CAP|No assignment to participate in the CareerAdvance® program, but given community referrals and resources
11293464|NCT02743026|Experimental|Intervention|participants will complete the FOXY intervention
11293465|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI|with/without Charcoal Block
11293466|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI (replicate)|with/without Charcoal Block
11293467|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI VHC|with/without Charcoal Block with Valved Holding Chamber
11293468|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 1|with/without Charcoal Block
11293469|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 2|with/without Charcoal Block
11293470|NCT02743000||Women ages 18-35|Women ages 18-35 who do and do not engage in binge eating will be included in the study
11293471|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
11293472|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
11293473|NCT02742974|No Intervention|FloTrac™ and EV1000™ pre and post-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the pre and post-operative period in the control arm.
11293474|NCT02742974|Experimental|FloTrac™ and EV1000™ peri-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the perioperative period for the intervention arm
11293475|NCT02742961||Peripheral nerve block|Intervention arm. Participants who receive a peripheral nerve block identified through submission of an appropriate physician billing code
11293476|NCT02742961||No peripheral nerve block|Control arm. Participants who do not receive a peripheral nerve block identified through lack of a submission of an appropriate physician billing code
11293477|NCT02742948|Active Comparator|preoperative antibiotic group|200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
11293478|NCT02742948|Active Comparator|early intraoperative antibiotic group|200 women will receive IV ceftriaxone (2g) immediately with skin incision
11293479|NCT02742948|Active Comparator|post cord clamping antibiotic group|200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
11293480|NCT02742935|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes.
11293481|NCT02742922|Experimental|Culturally adapted therapy (C-MAP)|Culturally adapted manual assisted (C-MAP) brief problem solving therapy
11293482|NCT02742922|No Intervention|Treatment as usual|This arm will receive no intervention only TAٓU.
11293483|NCT02742909|Active Comparator|rhBNP|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received rhBNP.
11293484|NCT02742909|Placebo Comparator|Placebo|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received placebo.
11293485|NCT02742896||Restoration of Erectile dysfunction|The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
11293486|NCT02742883|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
11293487|NCT02742870||Patients with MRI pelvic imaging|Women over 18 years old, having undergone a magnetic resonance imaging of the pelvis within the CHU Brugmann Hospital
11293488|NCT02742857|Experimental|Treatment Group|
11293489|NCT02742844|Experimental|APZ2 application|Topical, single application of APZ2; 500000 cells per square cm;
11293490|NCT02742831|Experimental|Intervention|"The intervention group will receive a one-on-one in-person intervention of 6 sessions, each lasting approximately 60 minutes. The intervention is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. The overview of the 6 sessions is as follows:
~Behavioral chain analysis of episodes where parent felt stressed and episode where things went well. Identification of sources of interpersonal support.
~Stress relief. Development of a detailed crisis plan.
~Problem solving techniques.
~Emotional regulation exercises.
~Positive parenting, review of parenting challenges.
~Reflection, repeat behavioral chain analysis. Update crisis plan."
11293491|NCT02742831|Active Comparator|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
11293492|NCT02742818|Other|Upper body blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
11293493|NCT02742818|Other|Underbody blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
11293494|NCT02742805|Experimental|High Dose Vitamin D|Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
11293495|NCT02742805|Active Comparator|Low Dose Vitamin D|Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
11293496|NCT02742792|Experimental|Resistance training|Resistance training, twice a week during 12 weeks.
11293497|NCT02742792|Other|Advice on lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
11293498|NCT02742779|Experimental|High-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
11293499|NCT02742779|Experimental|High-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 3.
11293500|NCT02742779|Experimental|Low-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
11293501|NCT02742779|Experimental|Low-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
11293502|NCT02742779|Experimental|MD Cohort: PIC (Part 2)|Participants will receive multiple ascending dose administered orally using PIC from Day 1 to Day 13 twice daily (BID) or may even be thrice daily (TID) or four times a day (QD) depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
11293503|NCT02742779|Experimental|MD Cohort: Solution Formulation (Part 4)|Participants will receive multiple ascending dose in fed or fast condition, administered orally using solution from Day 1 to Day 13 BID or may even be TID or QD depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
11293504|NCT02742779|Placebo Comparator|Placebo PIC|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
11293505|NCT02742779|Placebo Comparator|Placebo Solution|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
11293506|NCT02742779|Experimental|SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using PIC on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 1.
11293507|NCT02742779|Experimental|SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using solution formulation on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 3.
11293508|NCT02742766|Experimental|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
11293509|NCT02742766|Experimental|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
11293510|NCT02742766|Experimental|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
11293511|NCT02742753||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
11293512|NCT02742740|No Intervention|Control|Standard of care for chemotherapy treatment.
11293513|NCT02742740|Experimental|Chemo Buddy|Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
11293514|NCT02742727|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
11293515|NCT02742714|Experimental|PillCam SBC|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
11293516|NCT02742688|Experimental|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|
11293517|NCT02742688|Placebo Comparator|Placebo|
11293518|NCT02742675|Experimental|androgen deprivation therapy|Patients will receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide acetate, goserelin acetate, buserelin, or triptorelin) subcutaneously or as an injection AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily).
11293519|NCT02742675|Experimental|androgen deprivation therapy plus definitive treatment|Patients will receive androgen-deprivation therapy as in arm I in addition to definitive treatment including surgery to remove prostate or radiation therapy to the prostate.
11293520|NCT02742662|Experimental|Smart Technology Group|The Smart Technology Group will receive a technology-based lifestyle intervention program which uses wearable technology, smartscales and smartphone applications to track and deliver feedback on caloric expenditure, physical activity, caloric intake and body weight. Participants will receive information through smartphone applications on strategies to make changes to their diet, physical activity, and weight-related behaviors along with standard 3 monthly in-person weight management visits.
11293521|NCT02742662|Other|Standard Weight Management Group|The Standard Weight Management Group will receive 3 monthly in-person weight management visits during which they will receive standard of care lifestyle recommendations in accordance with the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline.
11293522|NCT02742649|Experimental|Fixed Combination (FC) Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one segment of timolol maleate combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
11293523|NCT02742649|Experimental|Bimatoprost Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
11293524|NCT02742649|Experimental|Timolol Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of timolol and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
11293525|NCT02742636|Experimental|Group A (treatment group)|The patients in this group will have their catheter directly removed in the OR after LH.
11293526|NCT02742636|Active Comparator|Group B (control group)|The patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).
11293527|NCT02742623||Rivaroxaban|Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
11293528|NCT02742610|Experimental|Mindfulness with Contingency Management|The intervention (MSI-CM) will involve two individual pre-quit in-person sessions and two post-quit phone counseling sessions, a series of brief mindfulness trainings that will be delivered via smartphone, that prompts participants to practice a mindfulness exercise five times a day while abstinent during the 2-week incentivized abstinence period (using CM) plus an additional 2 weeks (without CM) following the participant's target quit date. The MSI-CM participants will be asked to provide CO video via smartphone twice daily with monetary incentives provided (CM). Participants will receive monetary incentives contingent on each confirmed CO level (less than 7 ppm) for the CM period. We will use CM as an adjunct strategy to enhance the efficacy of mindfulness training.
11293529|NCT02742610|Active Comparator|Active Control|Participants assigned to the control group will receive two individual pre-quit in-person sessions and two post-quit phone counseling sessions, similar to the MSI-CM except for mindfulness introduction/discussion. Participants in the control group will receive the same monetary incentives on average as the participants in the MSI-CM for submitting CO videos, regardless of CO levels (non-abstinent contingent), during the 2-week post-TQD period. Each participant in the group (the non-contingent CO group) will be yoked to a single participant (selected randomly with stratification) in the MSI-CM. The yoked participant receives the same amount of monetary incentives as his or her matched participant in the contingent CO (MSI-CM) group.
11293530|NCT02742597|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting
11293531|NCT02742597|Active Comparator|Group B|Before/After Intervention group (n = 24) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting
11293532|NCT02742597|No Intervention|Group C|Control group (n = 163)
11293533|NCT02742597|No Intervention|Group D|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
11293534|NCT02742584|Experimental|Group A|Cough Stress Test with a comfortably full bladder.
11293535|NCT02742584|Experimental|Group B|Cough Stress Test with an empty bladder after straight catheterization.
11293536|NCT02742584|Experimental|Group C|Cough Stress Test with a bladder infused with 200 cc of saline.
11293537|NCT02742584|Experimental|Group D|Cough Stress Test with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary.
11293538|NCT02742558|Experimental|cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
11293539|NCT02742558|Active Comparator|shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
11293540|NCT02742545|Experimental|MayoExpertAdvisor|Clinicians in care teams assigned to the intervention arm will have access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
11293541|NCT02742545|No Intervention|Usual Care|Clinicians in care teams assigned to the standard of care arm will continue to provide up-to-date, patient-specific guideline-based treatment recommendations as is the standard of care at Mayo Clinic.
11293542|NCT02742532|Experimental|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
11293543|NCT02742532|Placebo Comparator|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
11293544|NCT02742519|Experimental|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
11293545|NCT02742519|Experimental|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
11293546|NCT02742519|Experimental|Part 2: ivacaftor|open label period
11293547|NCT02742506|Experimental|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
11293548|NCT02742506|Active Comparator|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
11293549|NCT02742493|Experimental|0.028 bonded to canines|lower fixed canine and canine retainer and upper removable Hawley (Intervention A)
11293550|NCT02742493|Experimental|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer and upper removable Hawley (Intervention B)
11293551|NCT02742493|Active Comparator|removable Hawley-type|lower hawley-type and upper hawley removable retainer (Control)
11293552|NCT02742480||Dabigatran|300 patients treated with dabigatran under the habitual clinical practice.
11293553|NCT02742480||Acenocoumarol|200 patients treated with acenocoumarol under the habitual clinical practice.
11293554|NCT02742467|Experimental|1|Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
11293555|NCT02742467|Active Comparator|2|Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
11293556|NCT02742467|Active Comparator|3|Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.
11293557|NCT02742454|Active Comparator|Standard 30-60 Seconds Cord Clamping|Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.
11293558|NCT02742454|Experimental|VentFirst 120 Seconds Cord Clamping|Assisted ventilation (face mask Continuous Positive Airway Pressure, CPAP, or Positive Pressure Ventilation, PPV) will be provided prior to cord clamping at 120 seconds.
11293559|NCT02742441|Experimental|122-0551 Foam|"122-0511 Foam, topically applied twice daily
~Intervention: Drug: 122-0551 Foam"
11293560|NCT02742441|Placebo Comparator|Vehicle Foam|"Vehicle Foam, topically applied twice daily
~Intervention: Drug: Vehicle Foam"
11293561|NCT02742428|Experimental|Ascites drainage before surgery.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. An indwelling catheter insertion into abdominal cavity and slow, systematic ascites evacuation for 7 or more days before surgery (if it cannot be scheduled immediately) will be performed. Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
11293562|NCT02742428|Other|Observation.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. A standard of care: observation or acute paracentesis (>5000ml) will be performed while waiting for the surgery (if it cannot be scheduled immediately). Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
11293563|NCT02742415|Experimental|Cancer patients receiving hand massage|Caring Hand massage will be provided to the outpatients undergoing chemotherapy
11293564|NCT02742402|Experimental|Observation|Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
11293565|NCT02742402|Active Comparator|Diagnostic imaging|Patients undergo abdominal ultrasound and if the result is inconclusive or negative for appendicitis patients will have abdominal computed tomography. Laparoscopic appendectomy is done for patients with appendicitis in diagnostic imaging.
11293566|NCT02742389|No Intervention|Standard counseling|This group will receive the standard counseling that all our patients would receive if they are scheduled to have urodynamic testing. This counseling will include a description of the procedure and a handout about urodynamic testing
11293567|NCT02742389|Other|Standard + Preprocedure Telephone Call|The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
11293568|NCT02742376|Other|Soft surface|A soft sponge used for physiotherapy is placed on the floor along a path,
11293569|NCT02742376|Other|Floor|The subject will walk on the floor.
11293570|NCT02742376|Other|Shoes|Special shoes (Kyboot) with air cushions that are meant to relieve pressure will be used.
11293653|NCT02741752|No Intervention|control|without decortication
11293654|NCT02741739|Experimental|Reference Drug|REGN1033 Reference Formulation
11293655|NCT02741739|Experimental|Test Drug|REGN1033 Test Formulation
11293571|NCT02742350|Experimental|IMT+Exercise|The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
11293572|NCT02742350|No Intervention|Exercise Control|Aerobic Exercise and Stretching
11293573|NCT02742337||Test|Newly diagnosed female patients with rheumatoid arthritis who have not previously used a disease modifying anti-rheumatic drug.
11293574|NCT02742337||Control|Female patients not having a diagnosis of rheumatoid arthritis and who have not previously used a disease modifying anti-rheumatic drug.
11293575|NCT02742324|Experimental|Ruxolotinib and peg-IFN alpha -2a|"Phase I
~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly
~Phase II
~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
11293576|NCT02742311|Active Comparator|transforaminal endoscopic discectomy|
11293577|NCT02742311|Active Comparator|interlaminar endoscopic discectomy|
11293578|NCT02742298|Other|QMUS|All patients will undergo serial quantitative muscle ultrasound.
11293579|NCT02742298|Other|EIM|All patients will undergo serial electrical impedance myography measures.
11293580|NCT02742285|Other|Artemether + lumefantrine|One single adult dose of artemether + lumefantrine 80 + 480 mg
11293581|NCT02742272||ED Headache or Migraine Patients|The investigators will perform a prospective cohort study of patients ages 6-18 years presenting to the ED with a complaint of headache or migraine over a 12 month period.
11293582|NCT02742259||Beta Cutoff|Assay
11293583|NCT02742259||Pivotal|Assay
11293584|NCT02742246|No Intervention|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
11293585|NCT02742246|Active Comparator|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
11293586|NCT02742246|Experimental|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
11293587|NCT02742233|Experimental|saxagliptin|"saxagliptin & Regular treatment:
~saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd"
11293588|NCT02742233|Placebo Comparator|placebo|"placebo & Regular treatment:
~placebo, dose: 5mg, po, qd"
11293589|NCT02742220|Experimental|Isometric Handgrip Training Group|Experimental group will perform home-based unilateral handgrip exercise and will be recommended to increase daily physical activity levels.
11293590|NCT02742220|Sham Comparator|Control Group|Control group will be recommended to increase daily physical activity levels.
11293591|NCT02742207||Observational|All comers with Atrial fibrillation
11293592|NCT02742194|Placebo Comparator|Placebo|Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
11293593|NCT02742194|Experimental|Ginger group|Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
11293594|NCT02742181|Experimental|Alvimopan group|In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
11293595|NCT02742181|Other|Control Group|Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.
11293596|NCT02742168|Experimental|Breast Cancer,99mTc-3PRGD2,SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of breast cancer
11293597|NCT02742155|Experimental|Play2Sleep|For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
11293598|NCT02742155|Active Comparator|Comparison|In the comparison group, only standard public health handouts on infant sleep will be reviewed with parents.
11293656|NCT02741726|Experimental|dual acupoint stimulation|The acupoints of dual point group are bilateral Neiguan points(PC6) combined with Danzhong point(RN17), electric stimulation was given through electrode attached to the acupoints.
11313845|NCT02607527|Other|Device Implantation|Transcatheter IRIS placement
11293599|NCT02742142|Placebo Comparator|control|Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
11293600|NCT02742142|Experimental|silver diammine fluoride|the subjects received the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution was painted onto the exposed tooth root surfaces. This treatment was repeated after 12 and 24 months.
11293601|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
11293602|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
11293603|NCT02742103|Experimental|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
11293604|NCT02742103|Placebo Comparator|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
11293605|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
11293606|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
11293607|NCT02742064||MDD-Single Episode|1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
11293608|NCT02742064||MDD-Recurrent|1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
11293609|NCT02742064||Bipolar Disorder|1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
11293610|NCT02742051|Experimental|Everolimus+Letrozole|everolimus 10mg/d,po + letrozole 2.5mg/d,po * 18 weeks
11293611|NCT02742051|Active Comparator|Fluorouracil+epirubicin+cyclophosphamide|Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 * 6 cycles (every 21 days per cycle)
11293612|NCT02742038|Experimental|Fluoride varnish plus education|Biannual fluoride varnish every 6 month/ 24 months plus educational component
11293613|NCT02742038|Placebo Comparator|Placebo varnish plus education|Biannual placebo varnish every 6 month/ 24 months plus educational component
11293614|NCT02742025|Other|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.
~Intervention: Inclusion visit
~Intervention: Coronarography on day 0"
11293615|NCT02742025|Experimental|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.
~Intervention: Inclusion visit
~Intervention: Nurse consultation
~Intervention: Telephone contact
~Intervention: Coronarography on day 0"
11293616|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.
~Intervention: Risk estimation prior to surgery and immediately after the surgery.
~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
11293617|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.
~Intervention: Risk estimation prior to surgery and immediately after the surgery.
~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
11293618|NCT02741973|Experimental|Yoga|Students have 10 weeks yoga instead of school sport.
11293619|NCT02741973|Active Comparator|School sport|Students have 10 weeks regular school sport.
11293620|NCT02741960|Experimental|metformin|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
11293621|NCT02741960|Placebo Comparator|placebo|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
11293622|NCT02741947|Active Comparator|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
11293623|NCT02741947|Experimental|Levodopa Benserazide Teva Italia|Levodopa Benserazide Teva Italia100+25mg and 200+50mg, tablet, tid e qid, for four weeks
11293624|NCT02741934||Preterm cohort|Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled.
11293625|NCT02741934||Term control cohort|The infants who were born from 2008 to 2009 with term gestational age will be enrolled.
11293626|NCT02741921|Experimental|Normal airway|intubation with normal airway Cormack-Lehane classivication I
11293627|NCT02741921|Experimental|difficult airway|intubation with difficult airway Cormack-Lehane classivication III
11293628|NCT02741908|Experimental|Fixed diet plan|Patients received a fixed diet plan to assist in the choice of foods aimed at changing eating behavior. Dietary intake was evaluated by using 3 nonconsecutive 24-hour dietary recalls collected at each visit. Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
11293629|NCT02741908|Experimental|Calorie counting diet|Patients underwent a calorie counting diet, in which each patient has received a table list with equivalent points for food and drinks, and was instructed to record all daily food or drink intake and calculate the total score of points consumed (1 point = 3.6 calories). They were allowed to eat any food but were limited to the recommended amount of points (or calories equivalents). Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
11293630|NCT02741895||Postoperative patients|The target populations for the study are patients undergoing robotic cystectomy, open colectomy, abdominal hysterectomy, esophagectomy, lung lobectomy, gastric bypass, and hip replacement at Cedars-Sinai Medical Center.
11293631|NCT02741882||Cases|Mothers who delivered a baby with microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
11293632|NCT02741882||Controls|Mothers who delivered a baby without microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
11293633|NCT02741869|Experimental|single arm|This is a single arm, open label study. Subjects who meet eligibility criteria will be treated with photodisinfection therapy (MRSAid™).
11293634|NCT02741856|Experimental|Arm 1 (carboplatin/paclitaxel+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1
~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (50Gy/25 fractions)"
11293635|NCT02741856|Experimental|Arm 2 (cisplatin/capecitabine+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14
~Cycles 3 and 4 are given concomitantly with radiotherapy (50Gy/25 fractions). Capecitabine stops on last day of RT."
11293636|NCT02741856|Experimental|Arm 3 (carboplatin/paclitaxel+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1
~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (60Gy/25 fractions)"
11293637|NCT02741856|Experimental|Arm 4 (Cisplatin+Capecitabine+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21
~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14 Cycles 3 and 4 are given concomitantly with radiotherapy (60Gy/25 fractions). Capecitabine stops on last day of RT."
11293638|NCT02741843|Experimental|Patient Education|
11293639|NCT02741843|No Intervention|Control|
11293640|NCT02741830||Uterosacral ligament suspension (USLS)|This group of patients underwent the procedure of native tissue vaginal reconstructive surgery using uterosacral ligament suspension for pelvic organ prolapse.
11293641|NCT02741830||Robotic sacrocolpopexy (RSC)|This group of patients underwent the reconstructive pelvic surgery of robotic sacrocolpopexy using synthetic mesh.
11293642|NCT02741817|Experimental|Aspirin 20mg|Supplied with sachets of 100mg soluble aspirin and training, instructions and equipment will be provided to prepare 20 mg dose twice daily x14 then aspirin 75mg once daily x14
11293643|NCT02741817|Experimental|Aspirin 75mg|This is the standard dose of aspirin the participant will already be taking. The study will require the participants to switch to soluble aspirin for two weeks to enable accurate comparison with the other dose and to take their aspirin dose in the morning. Participants will be provided with a supply of soluble aspirin, along with training, instructions and equipment to help prepare it. They should not take their usual aspirin tablets whilst receiving the study medication, but should continue all other usual medications.
11293644|NCT02741804|Active Comparator|BBH-1001 Brain Health Supplement|Patients will be given supplement containing ingredients all approved by the FDA: Turmeric (125mg), fisetin (16.65mg), green tea leaf extract (17.5mg), EPA (75mg), DHA (150mg) and Vitamin D3 (250IU). Patients will take 4 softgels once per day for entire study duration (18 months).
11293645|NCT02741804|Placebo Comparator|Brain Health Placebo|Patients will be given a pill resembling the study supplement, but instead consisting of Soybean oil (608mg). Patients will take 4 softgels once per day for the entire study duration (18 months).
11293646|NCT02741791|Experimental|AXS-05|
11293647|NCT02741791|Active Comparator|Bupropion|
11293648|NCT02741778|Other|Minimally invasive group|"In this group, all manipulations are finished by laparoscopy and thoracoscopy.
~Horizontal position, undergoing laparoscopy through 5-port method. The sequence: gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes ), gastric tube making, and jejunostomy.
~Left lateral position, undergoing thoracoscopy through 3-port method. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection, gastro-esophageal anastomosis by using CEEA."
11293649|NCT02741778|Other|Open group|"Right lateral position, Traditional thoracotomy through the 7th intercostal incision. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection.
~Then,oped the diaphragm,undergoing gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes), gastric tube making, gastro-esophageal anastomosis by using CEEA. Nasointestinal tube is placed for feeding."
11293650|NCT02741765|Active Comparator|Group 1: Sham Group|Sham group will receive Sham rTMS+Aerobic Exercise
11293651|NCT02741765|Experimental|Group 2: Real Group|rTMS+Aerobic Exercise
11293657|NCT02741726|Experimental|single acupoint stimulation|The acupoints of single point group is bilateral Neiguan points(PC6), Electric stimulation was given through electrode attached to the acupoints.
11293658|NCT02741726|Placebo Comparator|no stimulation|false stimulation group only attach electrodes without electric current.
11293659|NCT02741713|Sham Comparator|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
11293660|NCT02741713|Active Comparator|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
11293661|NCT02741700|Experimental|Gout storytelling video|Patients view a culturally relevant patient storytelling in African-American Veterans' own voices about gout and its treatment.
11293662|NCT02741700|Active Comparator|Video about management of another chronic condition|Patient narrated slide show of roughly the same duration as the experimental arm, summarizing management of a non-gout condition.
11293663|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).
~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.
~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
11293664|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).
~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.
~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
11293665|NCT02741674||Roux-en-y gastric bypass (RYGB)|"Adults and children age ≤79 years at time of surgery
~Had a primary (not revision) Roux-en-y gastric bypass from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)
~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
11293666|NCT02741674||Adjustable gastric banding (AGB)|"Adults and children age ≤79 years at time of surgery
~Had a primary (not revision) adjustable gastric banding procedure from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)
~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
11293667|NCT02741674||Sleeve gastrectomy (SG)|"Adults and children age ≤79 years at time of surgery
~Had a primary (not revision) sleeve gastrectomy from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)
~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
11293668|NCT02741661||Normal coronary arteries|Patients in whom coronary arteriography has demonstrated no significant tortuosity.
11293669|NCT02741661||Tortuous coronary arteries|Patients in whom coronary arteriography has demonstrated tortuous coronary arteries defined as >1 major bend of >45 degrees in a major coronary artery
11293670|NCT02741648||ELBW Infants with Prolonged Irradiation Storage Time|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
11293671|NCT02741648||ELBW Infants without Irradiation Storage|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
11293672|NCT02741648||ELBW Infants with NEC|"Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy."
11293673|NCT02741648||ELBW Infants without NEC|Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
11293674|NCT02741635|Experimental|New Nasal Pillows Mask|Participants to use nasal pillows mask one night in lab overnight polysomnography.
11293675|NCT02741622|Experimental|Exercise|Acute High aerobic intensity training (HIT) and long slow distance training (LSD)
11293676|NCT02741609|Experimental|Early/Late Stage Lyme disease|Have early Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with early stage Lyme disease. Subjects must have a physician-diagnosed erythema migrans (EM) rash and should have systemic symptoms indicative of disseminated infection. Symptoms may include fever, headache, fatigue, myalgias, arthralgias, and stiff neck. Paired acute and convalescent titers will be drawn (first draw at time of initial visit and second draw 4 weeks later). Have late Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with late stage Lyme disease, including but not limited to disseminated rash, arthritis, meningitis, facial palsy, or carditis. Qualified subjects will be administered the Borrelia Diagnostic Test.
11293677|NCT02741596|Experimental|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
11293678|NCT02741596|Experimental|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
11314419|NCT02603653|Experimental|Patients|Virtual radial task in 3D
11293683|NCT02741557|Experimental|DTG/RPV FDC-DTG plus RPV|Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 2 under fed state.
11293684|NCT02741557|Experimental|DTG plus RPV-DTG/RPV FDC|Subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 2 under fed state.
11293685|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
11293686|NCT02741531|Experimental|Intervention|Patients in this group will have their bladder filled with 150 cubic centimeters (cc) of saline solution prior to being moved to the PACU.
11293687|NCT02741531|No Intervention|Control|patients in this group will have their bladders drained completely prior to being moved to the PACU as is the current standard of care.
11293688|NCT02741518|Active Comparator|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
11293689|NCT02741518|Placebo Comparator|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
11293690|NCT02741505|Experimental|Sleep Deprivation followed by Normal Sleep|Subjects will be sleep deprived at the sleep laboratory.
11293691|NCT02741492|Active Comparator|Block Group|Continuous Transversus Abdominis Plane Catheter
11293692|NCT02741492|Sham Comparator|Sham Group|Continuous Sham Catheter
11293693|NCT02741479|Experimental|K Tape Group|
11293694|NCT02741479|Active Comparator|Sham Group|
11293695|NCT02741479|Experimental|No Tape|
11293696|NCT02741466|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
11293697|NCT02741453|Active Comparator|Standard Practice|Placement of a CVC by standard practice
11293698|NCT02741453|Experimental|Bilateral IJ Ultrasound Scanning|Placement of a CVC after mandatory ultrasound scanning of both right and left internal jugular veins
11293699|NCT02741440|Other|Study Arm|participants with SCA7
11293700|NCT02741427|Placebo Comparator|G1 (group 1) - Conventional toothpaste|G1 used a conventional toothpaste in daily oral regimen
11293701|NCT02741427|Experimental|G2 (group 2) - Whitening toothpaste|G2 used a whitening toothpaste containing blue pigment in daily oral regimen
11293702|NCT02741427|Active Comparator|G3 (group 3) - 10 % Carbamide peroxide|G3 made an at-home tooth bleaching with 10 % Carbamide peroxide
11293703|NCT02741414|Experimental|H pylori culture negative group|The patients who have the negative result of H pylori culture were classified into H pylori culture negative group.
11293704|NCT02741414|Experimental|The first successful eradication group|The patients with first eradication therapy of H. pylori infection have the first successful treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and proton pump inhibitors （PPIs) dose selection from CYP2C19 gene sequencing.
11293705|NCT02741414|Experimental|The refractory infection of H. pylori group|The patients with first eradication therapy of H. pylori infection have the two failure treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and PPIs dose selection from CYP2C19 gene sequencing.
11293706|NCT02741401|Active Comparator|Therapy standard|Patients receive usual postoperative care
11293707|NCT02741401|Experimental|Therapy standard + hand-foot massage|Patients receive usual postoperative care and hand-foot massage
11293708|NCT02741388|Experimental|Selinexor + immunochemotherapy|"Selinexor will be administered orally on Day1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy, R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine) or R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin) for 3 cycles (choice of the immunochemotherapy left at the investigator's decision before patient's inclusion).
~Different dose levels of selinexor will be examined sequentially in each group: 20 mg flat (DL-1), 40 mg flat (DL1), 60 mg flat (DL2), 80 mg flat (DL3)."
11293709|NCT02741375||Brain Death Group (BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
11293710|NCT02741375||Non-Brain Death Group (Non BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
11293711|NCT02741362|Experimental|ADSC arm|Single intravenous administration of Stromal Vacsular Fraction (SVF) cells soinating Adipose Derived Stem Cells (ADSC) 6 week baseline data prior to the injection of ADSC will be collected. 6 week, 3 months and 6 months follow up data will be compared against baseline.
11293712|NCT02741336|Experimental|CBT-I Intervention|For those randomized to the CBT-I group, the therapist will initiate telephone-delivered cognitive-behavioral therapy within 2 weeks of baseline assessment. Participants will complete 4 telephone sessions over a period of 8 weeks. Sessions last approximately 45 minutes. CBT-I is a short-term, focused psychotherapy that is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.
11293784|NCT02740985|Experimental|Arm KD|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy-naïve patients with colorectal carcinoma.
11293785|NCT02740985|Experimental|Arm L|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with other solid tumours.
11293713|NCT02741336|Active Comparator|Self-Monitoring Control Group|Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
11293714|NCT02741323|Experimental|Arm 1: Maraviroc (MVC)|Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
11293715|NCT02741323|Placebo Comparator|Arm 2: Placebo|Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
11293716|NCT02741310|Placebo Comparator|Placebo|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
11293717|NCT02741310|Experimental|Erenumab|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
11293718|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
11293719|NCT02741284|Experimental|No Oxygen|Room air
11293720|NCT02741284|Active Comparator|Oxygen|10L oxygen by nonrebreather mask
11293721|NCT02741271|Experimental|MF/F MDI 100/10 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.
11293722|NCT02741271|Active Comparator|MF MDI 100 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.
11293723|NCT02741258|Experimental|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
11293724|NCT02741258|Active Comparator|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
11293725|NCT02741245|Active Comparator|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
11293726|NCT02741245|Active Comparator|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
11293727|NCT02741245|Active Comparator|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
11293728|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
11293729|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
11293730|NCT02741232|Active Comparator|Pectoral nerve block|After induction of general anesthesia and under ultrasound visual guidance, pectoral block is performed with 30 mL total of local anesthetic (1% lidocaine + 1/400000 epinephrine). 10 mL of local anesthetic between pectoralis major muscle and pectoralis minor muscle and 20 mL between pectoralis minor muscle and serratus anterior muscle at the third rib.
11293731|NCT02741232|Sham Comparator|Sham block|No needle or injection will be used
11293732|NCT02741219|Placebo Comparator|Control Group|Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.
11293733|NCT02741219|Experimental|Dex Group|Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.
11293734|NCT02741206|Active Comparator|High Risk PTSD Group 1|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
11293735|NCT02741206|Active Comparator|High Risk PTSD Group 2|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
11293736|NCT02741206|Experimental|Low Risk PTSD Control|Twenty additional women, who are at lower risk and thus not eligible for randomization, will also receive one psycho-education session and usual care (control group 2).
11293737|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
11293738|NCT02741180|Other|Patients with Arrhythmias|
11293739|NCT02741180|Other|Healthy Control|
11293740|NCT02741167||CRS and HIPEC|Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy
11293741|NCT02741154|Experimental|aromataze group|patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
11293742|NCT02741154|Active Comparator|classic group|same protocol for induction without aromataze inhibitor
11293743|NCT02741141|Active Comparator|Classical partograph|Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
11293744|NCT02741141|Experimental|New partograph|The second strategy is based on the partograph developped by Neal and Lowe. An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation. In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
11293745|NCT02741128|Experimental|CYD Dengue vaccine group|Subjects will receive 3 doses of CYD dengue vaccine at 0, 6, and 12 months
11293746|NCT02741128|Placebo Comparator|Placebo vaccine group|Subjects will receive 3 doses of placebo (NaCl, 0.9%) vaccine at 0, 6, and 12 months
11293747|NCT02741115|Experimental|Drug|Udenafil. One tablet twice daily for 26 weeks
11293748|NCT02741115|Experimental|Placebo|Placebo. One tablet twice daily for 26 weeks
11293749|NCT02741102|Experimental|Women with AUFI|Women with AUFI must meet criteria for uterine transplant. In vitro fertilization to obtain 6 (screened) healthy embryos for cryo-preservation precedes uterine transplant from an appropriate donor The recipient will be required to take potent anti rejection medications including Thymoglobulin, Prednisone, Tacrolimus, Mycophenolate Mofetil (MMF) , later substituted with Azathioprine to avoid birth defects. One year later, up to 6 attempts using 1 screened embryo at a time will be tried to achieve pregnancy. During pregnancy, the high risk pregnancy and transplant teams will follow the recipient. The goal is a full term baby and delivery will be by Caesarian section. A second pregnancy may be attempted. Afterward, the uterus will be explanted.
11293750|NCT02741089||Indication for a flexible bronchoscopy|Patients representing to the hospital with the indication for a flexible bronchoscopy
11293751|NCT02741076|Experimental|Structured discontinuation opioid therapy Suboptimal Responder|
11293752|NCT02741076|Experimental|Structured discontinuation opioid therapy Optimal responders|
11293753|NCT02741076|Experimental|Continuation of opioid therapy Suboptimal responders|
11293754|NCT02741076|Experimental|Structured Continuation of opioid therapy Optimal responders|
11293755|NCT02741063|Experimental|high autistic and oxytocin group|subject with high ASQ scores will receive oxytocin treatment
11293756|NCT02741063|Experimental|low autistic and oxytocin group|subject with low ASQ scores will receive oxytocin treatment
11293757|NCT02741063|Placebo Comparator|high autistic and placebo group|subject with high ASQ scores will receive placebo treatment
11293758|NCT02741063|Placebo Comparator|low autistic and placebo group|subject with low ASQ scores will receive placebo treatment
11293759|NCT02741050|Experimental|Tailored Physical Activity Intervention|Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
11293760|NCT02741050|Active Comparator|Standard of Care Control Group|Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.
11293761|NCT02741037|Experimental|Dyadic lifestyle intervention|Mothers and daughters participate in the Unidas partner intervention together.
11293762|NCT02741037|Experimental|Individual lifestyle intervention|Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers.
11293763|NCT02741037|Other|Usual Care|Mothers and daughters receive usual care.
11293764|NCT02741024|Active Comparator|Amodiaquine-Artesunate (ASAQ)|Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
11293765|NCT02741024|Active Comparator|Artemether-Lumefantrine (AL)|Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).
11293766|NCT02741011|Other|Radiological imaging|Mentally handicapped patients underwent sedation anesthesia with IV Propofol and then tomographic images were obtained with NewTom 5G. Orthopantomographies (OPGs) were obtained by processing the raw images and radiological examination of the patients were performed on OPGs.
11293767|NCT02740998||Depo Provera|Ten women ages 18-40 who elect to start a using Depo Provera for contraception.
11293768|NCT02740998||Mirena IUD|Ten women ages 18-40 who elect to start a using a Mirena IUD for contraception.
11293769|NCT02740998||Nexplanon|Ten women ages 18-40 who elect to start a using Nexplanon for contraception.
11293770|NCT02740998||Control: Tubal Sterilization|Five women ages 18-40 who elect to have a tubal sterilization.
11293771|NCT02740985|Experimental|Arm A|AZD4635 monotherapy as nanoparticle suspension 125 mg BID
11293772|NCT02740985|Experimental|Arm B|AZD4635 monotherapy as nanoparticle suspension 75 mg QD
11293773|NCT02740985|Experimental|Arm C|AZD4635 monotherapy as nanoparticle suspension 100 mg QD
11293774|NCT02740985|Experimental|Arm D|AZD4635 as nanoparticle suspension 75 mg QD plus durvalumab
11293775|NCT02740985|Experimental|Arm E|AZD4635 as nanoparticle suspension 100 mg QD plus durvalumab
11293776|NCT02740985|Experimental|Arm EA|AZD4635 as nanoparticle suspension plus enzalutamide
11293777|NCT02740985|Experimental|Arm AA|AZD4635 as nanoparticle suspension plus abiraterone acetate
11293778|NCT02740985|Experimental|Arm F|AZD4635 as nanoparticle suspension plus durvaluamb in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
11293779|NCT02740985|Experimental|Arm G|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
11293780|NCT02740985|Experimental|Arm H|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with other solid tumours.
11293781|NCT02740985|Experimental|Arm I|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
11293782|NCT02740985|Experimental|Arm J|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
11293783|NCT02740985|Experimental|Arm K|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with colorectal carcinoma.
11293786|NCT02740985|Experimental|Arm CA|AZD4635 capsule formulation monotherapy 75 mg, 150 mg, and 200 mg QD. A lower dose of 125 mg or 100 mg may be given. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CA. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycle 1 and Cycle 2 will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
11293787|NCT02740985|Experimental|Arm CB|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
11293788|NCT02740985|Experimental|Arm CC|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus docetaxel. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CC. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycles will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
11293789|NCT02740972|Experimental|NS-065/NCNP-01 40mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
11293790|NCT02740972|Experimental|NS-065/NCNP-01 80mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
11293791|NCT02740972|Placebo Comparator|Placebo|Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment
11293792|NCT02740959|Experimental|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
11293793|NCT02740959|Experimental|Astragalus Polysaccharides 250 mg|PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
11293794|NCT02740946|Experimental|Exercise therapy|Exercise therapy 5 months
11293795|NCT02740933|Experimental|Demeclocycline|"All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.
~The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first."
11293796|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
11293797|NCT02740894||targeted therapy|according to national healthy policy, targeted therapy is the optional therapy
11293798|NCT02740894||traditional chemotherapy|according to national healthy policy, chemotherapy is the first line treatment.
11293799|NCT02740881|Experimental|Training Support System|Participants receive training in Contingency Management and immediately receive the full training support system and quality assurance feedback for 15 months while they provide the treatment.
11293800|NCT02740881|Active Comparator|CM-CAT then TSS|Participants are trained in Contingency Management and use the treatment without training support and quality assurance feedback for 9 months. After 9 months they continue using Contingency Management but now receive the full training support system and quality assurance feedback for 6 months.
11293801|NCT02740868|Active Comparator|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
11293802|NCT02740868|Active Comparator|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
11293803|NCT02740868|Active Comparator|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
11293804|NCT02740842|Active Comparator|Non-intensive group|Essential Health Care (EHC) only This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
11293805|NCT02740842|Experimental|Intensive group|"Interpersonal behavioral change communication This arm will have a behavior change communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
~In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm."
11293806|NCT02740829|Placebo Comparator|Intranasal placebo|placebo comparator
11293807|NCT02740829|Experimental|Intranasal glucagon|active intervention
11293808|NCT02740803|Experimental|NaF - R|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
11293809|NCT02740803|Experimental|NaF - NR|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
11293810|NCT02740803|Experimental|NaMFP- R|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
11293811|NCT02740803|Experimental|NaMFP- NR|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
11293812|NCT02740803|Experimental|SnF + NaF - R|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
11293813|NCT02740803|Experimental|SnF + NaF - NR|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
11293814|NCT02740803|Experimental|NaF + NaMFP - R|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
11293815|NCT02740803|Experimental|NaF + NaMFP - NR|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
11293816|NCT02740803|Experimental|AmF - R|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes followed by rinsing with distilled water.
11293817|NCT02740803|Experimental|AmF - NR|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes not followed by rinsing with distilled water.
11293818|NCT02740803|Experimental|0 Fluoride - R|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes followed by rinsing with distilled water.
11293819|NCT02740803|Experimental|0 Fluoride - NR|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes not followed by rinsing with distilled water.
11293820|NCT02740790|Experimental|HPV vaccine 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
11293821|NCT02740790|Placebo Comparator|Placebo 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
11293822|NCT02740790|Experimental|HPV vaccine 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
11293823|NCT02740790|Experimental|HPV vaccine 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
11293824|NCT02740790|Placebo Comparator|Placebo 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
11293825|NCT02740790|Placebo Comparator|Placebo 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
11293826|NCT02740777|Experimental|2-dose adolescent|300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
11293827|NCT02740777|Experimental|3-dose adolescent|300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
11293828|NCT02740777|Experimental|3-dose adult|300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
11293829|NCT02740764|Experimental|Optimization of drug prescribing|The group with optimization program will have: (i) a medical history of the drug prescribing; (ii) analysis and pharmaceutical recommendations and (iii) preparation of a management plan. Notices will be sent only to referring physicians in this experimental group.
11293830|NCT02740764|No Intervention|No intervention|This group will receive the current management of patients in geriatric or memory consultation, during which the intervention of a clinician pharmacist is not provided. There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital, but the recommendations will not be transmitted to the referring physicians of patients.
11293831|NCT02740751|Active Comparator|Still-Tee|Generic name: galactogoe herbal tee, still-tee Dosage: Three cups (each 200 ml) of tea of Still-Tee galactogogue tea will be used Frequency: Three times in a day Duration: for 4 weeks after birth
11293832|NCT02740751|Placebo Comparator|Placebo|The mothers of the babies will receive placebo tea which does not contain galactogogue herbs
11293833|NCT02740751|No Intervention|Water|The mothers of the babies will receive water
11293834|NCT02740725|Active Comparator|Recommendation of Patching|Patients will receive two hours of patching in the case of one line difference of best corrected visual acuity(BCVA) between two eyes during one month.
11293835|NCT02740725|Active Comparator|Recommendation of Patching and interactive binocular treatment|Patients will receive interactive binocular treatment addition to patch therapy in the least of 4 to 5 days of a week within 20-30 minutes in each day during one month.
11293836|NCT02740712|Other|single arm probe drugs and rucaparib|Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib
11293837|NCT02740699|Other|Moderate to high intensity treatment|Participants will receive 20-40 mg once daily Rosuvatain, or Participants will receive 40-80 mg once daily of Atrovastin.
11293838|NCT02740686||Frequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the frequent exacerbators group based on whether they have had 2 or more hospitalisations for exacerbations or have taken 2 or more courses on steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
11293839|NCT02740686||Infrequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the infrequent exacerbators group based on whether they have had no more than 1 hospitalisation for exacerbations or have not taken more than 1 course of steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
11293840|NCT02740686||Healthy smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and currently smoke.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. A resting blood sample will be taken from these patients and used to compare baseline measurements with the COPD groups.
11293841|NCT02740686||Healthy never smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and have never smoked.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. Resting blood samples will be taken from these patients and used to compare baseline measurements with the COPD groups.
11293842|NCT02740673|Other|Driving simulator|Using the driving simulator for 30 min.
11293985|NCT02739594|Experimental|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
11293843|NCT02740660|Experimental|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
11293844|NCT02740660|Placebo Comparator|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
11293845|NCT02740647|Experimental|Intervention group|Intervention group will be getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery.
11293846|NCT02740647|Placebo Comparator|Control group|the Control group will be getting intra-venous Placebo (0.9% 50 ml of sodium chloride) for 5 days.
11293847|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
11293848|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
11293849|NCT02740621||Patients with coronary heart disease|coronary angiography with finding coronary heart disease currently no cancer 40 years or older
11293850|NCT02740621||control patients|coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older
11293851|NCT02740608|Other|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
11293852|NCT02740595|Experimental|Nicotine|Use an e-cig filled with liquid with nicotine
11293853|NCT02740595|Experimental|no nicotine|Use an e-cig filled with liquid without nicotine
11293854|NCT02740595|Sham Comparator|sham comparator|Use an empty e-cigarette (sham control)
11293855|NCT02740582|Experimental|Tolcapone First, then Placebo|Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
11293856|NCT02740582|Placebo Comparator|Placebo First, then Tolcapone|Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
11293857|NCT02740556|Placebo Comparator|AdhereTech Passive Monitoring|Patients not using the HepCure patient app while AdhereTech passively monitors adherence (no chimes or reminders).
11293858|NCT02740556|Experimental|HepCure Toolkit|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard with AdhereTech passively monitoring adherence (no chimes or reminders).
11293859|NCT02740556|Experimental|HepCure Toolkit and AdhereTech Active Features|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard and with AdhereTech actively monitoring adherence (chimes and reminders enabled).
11293860|NCT02740543|Active Comparator|Irritant-Induced Asthma|
11293861|NCT02740543|Active Comparator|Allergic Asthma|
11293862|NCT02740543|Placebo Comparator|Irritant-Induced Asthma Control|
11293863|NCT02740543|Placebo Comparator|Allergic Asthma Control|
11293864|NCT02740530|Experimental|rTMS Active|High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
11293865|NCT02740530|Placebo Comparator|rTMS Sham|Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex
11293866|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
11293867|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.
~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
11293868|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.
~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
11293869|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to 65) and BMI from 18.5 to 45
11293870|NCT02740491||The study population|The study population consists of adult patients diagnosed with localized breast cancer who have completed adjuvant treatment (chemotherapy, radiotherapy) and who are cared for in the Medical Oncology department of the Nîmes University Hospital.
11293871|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
11293872|NCT02740465|Experimental|COPD Patients|
11293873|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
11293874|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
11293875|NCT02740439|Experimental|Intervention Meal|Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
11293876|NCT02740439|Placebo Comparator|Control Meal|Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
11293877|NCT02740426|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
11293878|NCT02740426|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
11293879|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
11293880|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
11293881|NCT02740400|Experimental|CT-TTNB|patients receive CT-TTNB to diagnose PPLs.
11293882|NCT02740400|Experimental|EBUS-GS|patients receive EBUS-GS to diagnose PPLs.
11293883|NCT02740387|Experimental|OTO-104|12 mg dexamethasone
11293884|NCT02740374|Experimental|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.
~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
11293885|NCT02740374|Active Comparator|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.
~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
11293886|NCT02740361|Experimental|Deprexis|This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
11293887|NCT02740361|Experimental|DeprexisPlus|This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)
11293888|NCT02740361|No Intervention|Waitlist Control|Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.
11293889|NCT02740348|Experimental|ZocDoc Assistance|Research assistant sets up follow-up appointment for subject using ZocDoc.
11293890|NCT02740348|Active Comparator|ZocDoc Information|Research assistance provides subject with written information about ZocDoc.
11293891|NCT02740348|No Intervention|Usual Care|ED staff gives written and verbal discharge instructions to subject.
11293892|NCT02740335|Experimental|Octaplex|Participants to receive1 Octaplex infusion intravenously
11293893|NCT02740335|Active Comparator|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
11293894|NCT02740322|Other|Hum Test|To examine and compare the Hum Test, Weber Test, and audiogram in their ability to detect and identify hearing loss, hearing loss will be simulated with the use of ear plugs (mimicking conductive hearing loss). Subjects will serve as their own control as these tests will be conducted with and without ear plugs.
11293895|NCT02740309|Experimental|Integrated Brief Behavior Therapy (IBBT) Intervention|4-sessions of IBBT for youth anxiety and depression.
11293896|NCT02740309|Active Comparator|Treatment as usual|Treatment as usual
11293897|NCT02740296||Healthy controls|Healthy controls
11293898|NCT02740296||RRMS|Relapsing-Remitting Multiple Sclerosis
11293899|NCT02740296||RRMS+MDD|Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder
11293900|NCT02740296||MDD|Major Depressive Disorder
11293901|NCT02740283|Experimental|Pregnant women|As a diagnostic study, the cohort will recruit 300 pregnant women who meet inclusion and exclusion criteria outlined below. OGTTs will be performed between 18 and 20 gestational weeks (early-OGTT) and 24 to 28 gestational weeks (regular-OGTT). Clinical and laboratory information of the mother and their offspring will be collected for analysis.
11293902|NCT02740270|Experimental|Arm A|
11293903|NCT02740270|Experimental|Arm B|
11293904|NCT02740257||Group 1 Artificial Lesions|Photos will be taken of skin lesion markings using a smartphone
11293905|NCT02740257||Group 2 high risk|A convenience sample of patients will be recruited. This population will consist of patients with known high risk to have new/changing lesions, and who fall within the Fitzpatrick skin types I-IV. High risk patients include, but are not limited to, those with dysplastic nevus syndrome, previous history of melanoma/non-melanoma skin cancer, fair skin, >16 nevi, family history of melanoma, and/or immunosuppressed status. The first photography session will be taken by the research team in all 13 projections. After the first visit, the patient will be instructed to take photographs every month for 12 months using the TBDP app on their smart phone or tablet, and have follow-up research appointments every 6 months.
11293906|NCT02740244|Active Comparator|active iTBS|Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score < 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
11293907|NCT02740244|Sham Comparator|sham iTBS|The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.
11293908|NCT02740231|Active Comparator|Reference product|
11293909|NCT02740231|Experimental|JTA-004 50 (2 ml)|
11293910|NCT02740231|Experimental|JTA-004 50 (4 ml)|
11293911|NCT02740231|Experimental|JTA-004 100 (2 ml)|
11293912|NCT02740218||Psoriasis patients|Single cohort of psoriasis patients treated with OTEZLA (apremilast)
11293913|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
11293914|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
11294111|NCT02738710|Experimental|transumbilical wound|transumbilical incision
11293915|NCT02740192|Experimental|Adductor Canal Block|Patients in this group received local infiltration of bupivacaine in the adductor canal after surgery, in addition to the periarticular injection intra-op.
11293916|NCT02740192|Sham Comparator|Periarticular Injection|Patients in this group received a bandaid at the presumed adductor canal injection site, in addition to the periarticular injection intra-op.
11293917|NCT02740179|Experimental|Eplerenone|Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
11293918|NCT02740179|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
11293919|NCT02740166|No Intervention|Banding ligation group|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
11293920|NCT02740166|Experimental|Propranolol group|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
11293921|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under
~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD, as defined as follows:"
11293922|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under
~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD, as defined as follows:"
11293923|NCT02740153||Primary Caretakers|"Primary caretaker(s) of a patient age 25 and under who has been diagnosed with either CPSD, OTCD, ASD or ALD (typically a parent, but broadly defined as those individuals who are responsible for making the child's treatment decisions and who also provide the majority of the child's physical and emotional care)
~Considered, are currently considering, or opted for, liver transplantation as a treatment for UCD.
~Willing to participate in a 60-minute semi-structured interview and/or a 60-90 minute focus group discussion
~OR
~Health care provider (e.g. metabolic disease physician, liver transplant surgeon, gastroenterologist, genetic counselor, or nurse) that participates in treating patients diagnosed with either CPSD, OTCD, ASD or ALD,
~Willing to participate in a 60-minute semi-structured interview and/or a 60-90 minute focus group discussion"
11293924|NCT02740127|Experimental|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.
~Study staff calls participant about 3 days after surgery."
11293925|NCT02740127|Active Comparator|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.
~Study staff calls participant about 3 days after surgery."
11293926|NCT02740114|Active Comparator|Bupivacaine Group|"Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.
~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
~Participants complete a pill diary every day for 30 days after hospital discharge.
~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
11293927|NCT02740114|Experimental|Liposomal Bupivacaine + Bupivacaine Group|"Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.
~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
~Participants complete a pill diary every day for 30 days after hospital discharge.
~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
11293928|NCT02740101|Experimental|oxytocin nasal spray|subjects administrating oxytocin were divided into experimental group
11293929|NCT02740101|Placebo Comparator|placebo nasal spray|subjects administrating placebo were divided into controlled group
11293930|NCT02740075||Hand-ventilated|This group will be transported from the operating room to the intensive care unit with the anesthesia provider ventilating the patient by hand via Mapleson circuit and supplemental oxygen. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators. The anesthesia provider will be blinded to the end-tidal carbon dioxide levels and respiratory rate.
11293931|NCT02740075||Mechanically ventilated|This group will be transported from the operating room to the intensive care unit with the patient being ventilated by a transport ventilator with controlled tidal volume, respiratory rate, and positive end-expiratory pressure. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators.
11293932|NCT02740062|Active Comparator|Active treatment|Active tDCS treatment
11293933|NCT02740062|Sham Comparator|Sham treatment|Sham tDCS treatment
11293934|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
11293935|NCT02740023|Active Comparator|Phonak Audéo V90-13|The Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
11293936|NCT02740023|Experimental|Successor of Phonak Audéo V90-13|The successor of Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
11293937|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
11293938|NCT02739984|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
11293939|NCT02739984|Experimental|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
11293940|NCT02739971|Active Comparator|Low AGEs diet|Participants randomized to this arm will receive active instruction on reducing dietary AGEs intake, in addition to standard of care dietary guidance for type 2 diabetes.
11293941|NCT02739971|Placebo Comparator|Standard of care dietary guidance|Participants randomized to this arm will only recieve standard of care dietary guidance for type 2 diabetes.
11293942|NCT02739958|Active Comparator|Propofol group|Patients receive only intravenous anesthetics
11293943|NCT02739958|Placebo Comparator|Isoflurane group|Patients receive isoflurane /fentanyl anesthesia
11293944|NCT02739945|Other|Open cubital tunnel release|In situ decompression (MacKinnon and Novak 2005) is made through a 6-10 cm longitudinal incision along the course of the ulnar nerve midway between the medial epicondyle and the olecranon.
11294112|NCT02738710|Active Comparator|infra umbilical wound|infra umbilical incision
11293945|NCT02739945|Other|Endoscopic cubital tunnel release|Endoscopic release follows Hoffmann's technique (Hoffmann 2006) that demonstrated the safety and efficacy of this technique in a cadaveric model and in a clinical study.
11293946|NCT02739906|Experimental|HinsBet®|
11293947|NCT02739906|Active Comparator|Humalog®|
11293948|NCT02739906|Active Comparator|Huminsulin® Normal|
11293949|NCT02739893|Experimental|Scope Guide Assisted|Scope Guide Assist to be utilized during colonoscopy
11293950|NCT02739893|Placebo Comparator|Standard|Colonoscopy completed using current SOC without scopeguide assist.
11293951|NCT02739880|Experimental|The study population|"The study population consists of postmenopausal patients (more than 2 years and less than 10 years) with a body mass index <35 with sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.
~Intervention: Intra-mucosal Injections of Cross-linked Hyaluronic Acid"
11293952|NCT02739867||Unprovoked VTE|Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism
11293953|NCT02739841|Experimental|Ventilator hyperinflation|For the ventilator hyperinflation techniques (VHI), the study consists of three consecutive periods 1) baseline period: 10 minutes rest in side lying by effected lung uppermost with head-up 30 degree 2) Intervention period: Patients were positioned as same as baseline period and 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial 3) recovery period: 10 minutes rest in the same position but reduce VT to initial.
11293954|NCT02739841|Experimental|Chest physical therapy|For the conventional chest physical therapy (CPT), the study will be performed in the similar procedure except the intervention period, the patient will be received vibration and passive of the both upper extremity.
11293955|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
11293956|NCT02739815|Placebo Comparator|Placebo|Will receive a placebo (10 ml of distilled water) in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
11293957|NCT02739815|Active Comparator|T1|Will receive Tranexamic acid 15 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
11293958|NCT02739815|Active Comparator|T2|Will receive Tranexamic acid 20 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
11293959|NCT02739815|Active Comparator|T3|Will receive Tranexamic acid 25 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
11293960|NCT02739802|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
11293961|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
11293962|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
11293963|NCT02739776||A|Pt receiving standard Epidural block care for vaginal delivery
11293964|NCT02739763|Experimental|Plasmodium falciparum sprozoite (PfSPZ) challenge|Challenge agent
11293965|NCT02739737|Experimental|Blinded Reviewers|Subjects receiving randomized sham manuscript for review
11293966|NCT02739737|Experimental|Unblinded Reviewers|Subjects receiving randomized sham manuscript for review
11293967|NCT02739724|Active Comparator|Classic laparoscopy|Patients will undergo laparoscopy surgery with classic laparoscopy technic.
11293968|NCT02739724|Experimental|Laparoscopy single port access|Patients will undergo laparoscopy surgery by single port access technic.
11293969|NCT02739711|Active Comparator|Glycoprotein IIb/IIIa inhibitor|Glycoprotein IIb/IIIa inhibitor administration
11293970|NCT02739711|No Intervention|Standard therapy|No glycoprotein IIb/IIIa inhibitors
11293971|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
11293972|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
11293973|NCT02739685|Experimental|Bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
11293974|NCT02739685|Active Comparator|Stent|Implantation everolimus-eluting stent in chronic total occlusion
11293975|NCT02739672|Experimental|TAH tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet
11293976|NCT02739672|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
11293977|NCT02739659|Experimental|carbon-ion radiotherapy|Four dose levels [59.2 GyE(Gray equivalent)/16Fx, 60.8 GyE/16Fx, 62.4 GyE/16Fx, 64.0 GyE/16Fx] are planned within the Phase I part. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 64 GyE/16Fx are safely delivered, the recommended dose (or 64 GyE/16Fx) will be the prescribed dose in the Phase II part of the study.
11293978|NCT02739646|Experimental|Females|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
11293979|NCT02739646|Experimental|Males|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
11293980|NCT02739633|Experimental|Genexol-PM + Gemcitabine|Genexol-PM125 mg/m2 will be administered in combination with gemcitabine 1,000 mg/m2 weekly for 3 weeks followed by one week of rest. Each cycle is 28 days.
11293981|NCT02739620|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
11293982|NCT02739620|No Intervention|Control|Control group
11293983|NCT02739607|Experimental|Transdiagnostic program|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
11293984|NCT02739607|No Intervention|Wait list control group|This arm represents the wait-list comparison group.
11293986|NCT02739594|Active Comparator|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
11293987|NCT02739581|Experimental|Endoscopic variceal ligation with Non-selective B-blockers|
11293988|NCT02739581|Active Comparator|Endoscopic variceal ligation with Placebo|
11293989|NCT02739568|Experimental|Pitolisant (BF2.6449|Histamine H3 receptor H3R antagonist/ inverse agonist
11293990|NCT02739568|Placebo Comparator|Placebo|Placebo
11293991|NCT02739555|Active Comparator|1: Percutaneous treatment|Percutaneous treatment of OO is a thermal tumor destruction by radiofrequency or laser photocoagulation performed under CT control with strict aseptic approach and most often under general anesthesia. The introductive needle is inserted toward the nidus. Then the optic fiber or the radiofrequency probe is inserted in the nidus center and thermal destruction of the tumor is obtained.When the distance between the nidus and a nerve or the skin is less than 10 mm, infusion of normal saline or CO2 is introduced as spacing agent. When the nidus is in the subchondral bone, cold normal saline is introduced in the joint to protect the cartilage. In addition, a thermocouple is placed in the epidural or foraminal space to continuously monitor the temperature. A procedure typically required between 1 and 2 h from the time the patient entered the CT unit.
11293992|NCT02739555|Experimental|2: Bisphosphonate treatment|"The treatment consists of 3 infusions of zoledronic acid administered at a monthly interval. Bisphosphonate treatment is considered finished 1 month after the third bisphosphonate infusion (V4 visit). In few cases, the analgesic efficacy provided by 3 bisphosphonate infusions cannot be sufficient: 1 to 3 additional infusions could be proposed to the patient.
~Zoledronic acid is supplied as a 4 mg/100 ml solution for infusion. It will be administered as infusion over 30 minutes under the supervision of a nurse. Adults will receive intravenous infusion of 4 mg of zoledronic acid. Children will receive infusion of 0.025 mg/kg of zoledronic acid.
~The investigators propose abacus corresponding to zoledronic acid volume to infuse during 30 minutes for children."
11293993|NCT02739542|Active Comparator|Tecfidera|Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
11293994|NCT02739542|Placebo Comparator|Placebo|Placebo by mouth twice daily.
11293995|NCT02739529|Experimental|Cohort 1|Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
11293996|NCT02739529|Experimental|Cohort 2|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
11293997|NCT02739529|Experimental|Cohort 3|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
11293998|NCT02739516|Active Comparator|Control|In letrozole stimulated cycle: On the day of ovulation trigger the patient received standard dose of Human chorionic gonadotropin (10,000 IU).
11293999|NCT02739516|Experimental|Study|In letrozole stimulated cycle: On the day of ovulation trigger the patient received hCG 10000 IU plus FSH co-trigger (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once .
11294000|NCT02739490|No Intervention|Group control|It does not perform any kind of guided exercise.
11294001|NCT02739490|Experimental|Core Training Group|The training was distributed in four positions defined ventral plank, side plank left, right side board and bridge semiflexion knees, respectively. With time isometric contraction of 30 seconds repeated four times with rest 30 seconds between repetitions. During 10 sessions distributed twice weekly.
11294002|NCT02739477|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
11294003|NCT02739464|Experimental|Exercise + SOC PT/OT|SOC treatment plus a personalized, structured, and quantifiable exercise program (MP10) carried out soon after admission until hospital discharge (including during the BICU stay and time on ventilation.
11294004|NCT02739464|Active Comparator|SOC PT/OT|Only SOC for treating in-patient burn subjects
11294005|NCT02739451|Active Comparator|standard oxygen group|Oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system
11294006|NCT02739451|Experimental|High-flow nasal oxygen (HFNO) group|"Device that delivers humidified and warmed high-flow oxygen at flows greater than 15 L/min.
~HFNO will be initiated at a flow rate of 50 L/min and 100% FiO2. If the target SpO2 is not reached, the flow rate will be increased to 60 L/min. Then, FiO2 will be tapered to target an SpO2≥95. The minimal flow rate will be 45 L/min"
11294007|NCT02739438||E Cigarette users|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months. Total pack years of smoking should be less than 20 for their smoking history, with normal lung function (FEV1 and FEV1/FVC) and no clinical symptoms of airway obstruction/inflammation (cough, dyspnea, sputum and wheeze).
11294008|NCT02739438||Cigarette smokers|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
11294009|NCT02739438||Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
11294010|NCT02739425|Other|Standard Procedure plus use of sentimag|Detection of the nodes carried out using the gamma probe and also the sentimag - all patients receive both diagnostic interventions
11294011|NCT02739412|Experimental|Interleukin-2|IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
11294012|NCT02739399|Other|Patient receiving phenylephrine 2ug/kg|phenylephrine 2ug/kg in case of hypotension
11294013|NCT02739386||Cohort Population|Individuals included in a large US-based administrative medical claims database with underlying autoimmune disorder exposed to ipilimumab for the treatment of melanoma.
11294014|NCT02739373|Experimental|BMS-986189|Specified Dose on Specified Day
11294015|NCT02739373|Placebo Comparator|Placebo|Specified Dose on Specified Day
11294016|NCT02739360|Experimental|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
11294017|NCT02739347|Experimental|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
11294018|NCT02739347|Sham Comparator|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
11294113|NCT02738697|Experimental|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
11294019|NCT02739334|Experimental|ENRICH|The intervention will integrate the Play and Learning Strategies (PALS) program, a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler with Coordinated Approach To Child Health (CATCH), a behaviorally-based school health promotion program based on Social Cognitive Theory (SCT) to increase opportunities for healthy eating and activity.
11294020|NCT02739334|Active Comparator|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
11294021|NCT02739321|Experimental|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.
~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
11294022|NCT02739321|Experimental|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.
~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
11294023|NCT02739308|Experimental|Intervention: Proprioceptive Training|"The intervention will be the implementation of a proprioceptive training program for the fencing athletes in the intervention group.
~In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes, three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes, and preferably one of each category. The categories have exercises with different levels of difficulty and can change the exercises occur by different proposed levels or the complexity of the exercise by changing category. The training program will be implemented by the same evaluator over the 12 weeks."
11294024|NCT02739308|Placebo Comparator|Control|The control group will not make the intervention and will continue with the usual training fencing.
11294025|NCT02739295|Experimental|G-CSF|An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.
11294026|NCT02739295|Placebo Comparator|Placebo|An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.
11294027|NCT02739282|Active Comparator|Systematic therapeutic drug monitoring|"Systematic therapeutic drug monitoring performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring (rescue therapeutic drug monitoring, transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events."
11294028|NCT02739282|No Intervention|"Rescue therapeutic drug monitoring"|"In the rescue therapeutic drug monitoring arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached."
11294029|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
11294030|NCT02739269|Sham Comparator|AFC group|AFC measurement
11294031|NCT02739256|Experimental|voiding trial 4 hours post-op|
11294032|NCT02739256|Active Comparator|voiding trial post-op day 1|
11294033|NCT02739243|Experimental|Tailored group intervention|"Participants take part in the tailored group intervention which consists of five 90-minute group sessions over eight weeks. The sessions are in the form of structured group talk/discussions following specific themes:
~Session 1 - Coping and acceptance: identification of common themes from participants' feedback, provision of information about support services, mindfulness practices
~Session 2 - Distress: introduction of the distress model, identification of resources, breathing practices
~Session 3 - Handling of stressful situations: individual identification in tandems, discussion of common pitfalls in the group
~Session 4 - Self-care: inspection of individual daily routines, group collects positive experiences with windows for self-care
~Session 5 - Feedback and outlook: stabilisation, retrospective reflection on the group experience and its benefits and, if applicable, potential adverse events"
11294034|NCT02739243|Active Comparator|Treatment as usual|Participants are provided with brief information in a leaflet, about the possibilities for individual counselling including referral to the local outpatient cancer counselling centre providing client-centred counselling and financial social work.
11294035|NCT02739230|Active Comparator|Exparel Injection|
11294036|NCT02739230|Active Comparator|On-Q intraarthicual catheter placement|
11294037|NCT02739217|Experimental|PBI-4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
11294038|NCT02739204|Experimental|Celecoxib|Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
11294039|NCT02739191|Experimental|Intervention|Prophylactic negative pressure wound therapy
11294040|NCT02739178|Experimental|GSF Sanitation intervention|This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
11294041|NCT02739178|No Intervention|Comparator|This arm will receive the GSF intervention in 2017 or later.
11294042|NCT02739165|Experimental|ART-123|
11294043|NCT02739165|Placebo Comparator|Placebo|
11294044|NCT02739139|Placebo Comparator|Placebo|Placebo
11294045|NCT02739139|Experimental|AlphaBrain|AlphaBrain(TM)
11294046|NCT02739126|Active Comparator|Thick USS (1.7mm) with use of additional aspiration needle|
11294047|NCT02739126|Active Comparator|Thin USS (1.4mm)|
11294048|NCT02739100|Experimental|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
~Intervention Drug: Triferic"
11294114|NCT02738697|Other|Follow-up|Routine follow-up were performed instead of adjuvant chemotherapy
11294049|NCT02739100|Experimental|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).
~Intervention: Drug: Triferic"
11294050|NCT02739100|Experimental|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).
~Intervention: Drug: Triferic"
11294051|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
11294052|NCT02739061|Active Comparator|cognitive behavioral group therapy|cognitive behavioral group therapy
11294053|NCT02739061|Active Comparator|drug therapy|drug therapy
11294054|NCT02739061|Active Comparator|The combination therapy|cognitive behavioral group therapy and drug therapy
11294055|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
11294056|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
11294057|NCT02739022|Experimental|Early Psychological Support for the Critically Ill (EPSCI)|patients will receive EPSCI in parallel with medical treatment
11294058|NCT02739009|Experimental|MOR106|Single intravenous administration of MOR106
11294059|NCT02739009|Placebo Comparator|Placebo|Single intravenous administration of Placebo
11294060|NCT02739009|Experimental|MOR106 MAD|Multiple intravenous administration of MOR106
11294061|NCT02739009|Placebo Comparator|Placebo MAD|Multiple intravenous adminstration of Placebo
11294062|NCT02738996|Experimental|60-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 30 min
11294063|NCT02738996|Experimental|30-15 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 15 min
11294064|NCT02738996|Experimental|15-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 60 min
11294065|NCT02738996|Experimental|60-15|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 15 min
11294066|NCT02738996|Experimental|30-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 60 min
11294067|NCT02738996|Experimental|15-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 30 min
11294068|NCT02738983|Experimental|Bioradiotherapy|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).
11294069|NCT02738970|Active Comparator|Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
11294070|NCT02738970|Experimental|Part 1-Cohort 2: Pertuzumab 400 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
11294071|NCT02738970|Experimental|Part 1-Cohort 3: Pertuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
11294072|NCT02738970|Experimental|Part 1-Cohort 4: Pertuzumab 1200 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
11294073|NCT02738970|Active Comparator|Part 1-Cohort 5: Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
11294074|NCT02738970|Experimental|Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
11294075|NCT02738970|Experimental|Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
11294076|NCT02738970|Experimental|Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
11294077|NCT02738970|Experimental|Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
11294078|NCT02738970|Experimental|Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
11294079|NCT02738970|Experimental|Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.
11294107|NCT02738736|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
11294108|NCT02738736|No Intervention|Usual Care|Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
11294080|NCT02738957|Other|Prenatal Counseling Group|"Patients in the PCG will receive specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one two midwives involved in the study. The information will include: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models. During the counseling sessions patients will have the opportunity to discuss questions on breastfeeding."
11294081|NCT02738957|No Intervention|Control Group|No breastfeeding counseling during the antenatal period will be provided. The Control Group will receive non-specific counseling with standard orientation regarding breastfeeding after delivery and during their postpartum hospitalization period. This standard orientation will be provided by one of the midwives of the hospital during a single counseling session with brief guidance covering the following topics: starting breastfeeding, hygiene, infants' conditions, colostrum/breast milk, infants' positions, duration of breastfeeding, frequency of feeds, mammary milking, and stopping breastfeeding.
11294082|NCT02738944|Active Comparator|Integrated Care|Telepsychiatry Collaborative Care
11294083|NCT02738944|Active Comparator|Referral Care|Telepsychiatry Enhanced Referral
11294084|NCT02738931|Experimental|Treatment Sequence ABC|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
11294085|NCT02738931|Experimental|Treatment Sequence BCA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
11294086|NCT02738931|Experimental|Treatment Sequence CAB|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
11294087|NCT02738931|Experimental|Treatment Sequence ACB|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
11294088|NCT02738931|Experimental|Treatment Sequence BAC|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
11294089|NCT02738931|Experimental|Treatment Sequence CBA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
11294090|NCT02738918|Experimental|Nulojix|
11294091|NCT02738905|Experimental|Rifaximin|Participants will receive study drug for a period of 7 days.
11294092|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
11294093|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
11294094|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
11294095|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
11294096|NCT02738840|Experimental|Prodigy MRI or Proclaim Elite MR|"The Prodigy MRI system is only MR conditional for scans of the head and extremities (upper except shoulder, lower except hip).
~The Proclaim Elite system is MR conditional for scans of the head, extremities (upper except shoulder, lower except hip), or any other body part."
11294097|NCT02738827|Other|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
11294098|NCT02738814|Experimental|PAED > 13|When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
11294099|NCT02738814|No Intervention|PAED < 14|Caregivers must first try to reassure patients.
11294100|NCT02738801|Experimental|GLPG1690 600 mg once daily (QD)|
11294101|NCT02738801|Placebo Comparator|Placebo QD|
11294102|NCT02738775|Experimental|Ublituximab|Ublituximab IV infusion dose on Day 1, 15 and Week 24
11294103|NCT02738775|Placebo Comparator|Ublituximab Placebo|Placebo IV infusion dose on Day 1 and 15 only
11294104|NCT02738762|Active Comparator|intervention group|enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU
11294105|NCT02738762|No Intervention|control group|patients receive normal treatment, no glutamine supplementation
11294106|NCT02738749|Other|ICD group|Adult patients with newly implanted ICD devices for primary prevention will be enrolled. At baseline, 3-, 6-, 9-, and 12-month followup visit, the medial information and blood samples will be collected.
11294109|NCT02738723|Experimental|GROUP 1|SBRT plus EP
11294110|NCT02738723|Active Comparator|GROUP 2|IMRT plus EP
11294115|NCT02738684||lung cancer|A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
11294116|NCT02738671||Type 1 Diabetes Mellitus|These T1DM patients have late diabetes onset.(latent autoimmune diabetes in adult, LADA)
11294117|NCT02738671||Type 2 Diabetes Mellitus|A subgroup of these T2DM patients are obesity patients who will have the bariatric surgery. These obese T2DM subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain MRI at baseline and 6 months after their surgery.
11294118|NCT02738671||Control|A subgroup of these non-diabetic people are obesity patients who will have the bariatric surgery. These obese subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain fMRI at baseline and 6 months after their surgery.
11294119|NCT02738658|Experimental|Bioresorbable vascular scaffold (BVS)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
11294120|NCT02738658|Active Comparator|Everolimus-eluting stent (EES)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
11294121|NCT02738645||pneumonia in RICU|The patients admit in RICU because of pneumonia.
11294122|NCT02738632|Experimental|Telmisartan/Amlodipine+Hydrochlorothiazide|Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
11294123|NCT02738632|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
11294124|NCT02738619|Active Comparator|vitamin d3|1600 UI
11294125|NCT02738619|Placebo Comparator|placebo|placebo
11294126|NCT02738606|Experimental|Group I (surgery, chemotherapy)|Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
11294127|NCT02738606|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
11294128|NCT02738580|Active Comparator|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
11294129|NCT02738580|Active Comparator|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
11294130|NCT02738567||local anesthesia with adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia with adrenaline
11294131|NCT02738567||local anesthesia without adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia without adrenaline
11294132|NCT02738554|Other|Treatment cessation arm|Cessation of treatment as according to European Association for the Study of the Liver Guidelines for chronic hepatitis B
11294133|NCT02738541|Active Comparator|Group 1|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
11294134|NCT02738541|Placebo Comparator|Group 2|PLACEBO DENTRIFICE WITHOUT PYROPHOSPATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
11294135|NCT02738528|Experimental|Experimental Group|Mental practice and brushing guidance in patients with Parkinson Disease
11294136|NCT02738528|No Intervention|Control group|Brushing guidance in patients without Parkinson Disease
11294137|NCT02738515|Active Comparator|Group 1|Scaling and Root Planing (SRP) with 0.75% BORIC ACID GEL for treating furcation defect
11294138|NCT02738515|Placebo Comparator|Group 2|Scaling and Root Planing (SRP) with PLACEBO GEL for treating furcation defect.
11294139|NCT02738502|Experimental|Single Group|Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
11294140|NCT02738489|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes. Only one arm in this study
11294141|NCT02738463||Group 1 case|This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
11294142|NCT02738463||Group 2 control|This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
11294143|NCT02738450|Active Comparator|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
11294144|NCT02738450|Active Comparator|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
11294145|NCT02738450|Placebo Comparator|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
11294146|NCT02738437|No Intervention|control|Control Group receiving standard treatment
11294147|NCT02738437|Active Comparator|intervention group|Intervention Group receiving the standard treatment and the kryptonite-bone cement
11294148|NCT02738424||3T patients : Calculate the ADC scores|In this group all the patients perform a 3 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS (picture archiving and communication system) Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
11294149|NCT02738424||1.5T patients : Calculate the ADC scores|In this group all the patients perform a 1,5 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
11294150|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
11294151|NCT02738398|Experimental|PET imaging|PET imaging
11294152|NCT02738385|Experimental|High Intensity Interval Training|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
11294153|NCT02738385|Active Comparator|Moderate Intensity Interval Training|Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
11294559|NCT02735694|Placebo Comparator|Placebo|Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose
11294154|NCT02738372||Chronic Shoulder Pain|"Men / women aged between 18 and 70 years.
~Patients suffering from shoulder pain, defined as pain presented or exacerbated by movements in the shoulder, pain intensity ≥ 2 measured by a numerical scale with values from 0 to 10, meaning 0= no pain and 10= the worst pain, will be included in this study, among all these following shoulder pain conditions: (i) Rotator Cuff tendinopathy; (ii) Adhesive Capsulitis; (iii) glenohumeral instability; (iv) SLAP lesion; (v) and/or acromioclavicular pathology. Subjects will not be required to undergo diagnostic imaging (i.e. Magnetic Resonance Imaging) to diagnosis the pathology because of the recruitment will be carried out by clinical findings.
~Duration of symptoms: greater than 3 months."
11294155|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
11294156|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
11294157|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:
~t0: FIT -> if positive : OC; t = 1 year: FIT -> if positive : OC; t = 2 years: FIT -> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
11294158|NCT02738346|Experimental|Arm A : Carboplatin-Etoposide|Intravenous administration of Carboplatin Auc 5 at Day 1 and Intravenous administration of 100 mg / m² / of Etoposide J Day 1 to Day 3 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
11294159|NCT02738346|Active Comparator|Arm B : Topotecan|Per os administration of 2.3 mg / m² of Topotecan Day 1 to Day 5 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
11294160|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
11294161|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
11294162|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
11294163|NCT02738320|Experimental|Intervention|Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected.
11294164|NCT02738320|No Intervention|Usual Care|Control patients will receive the usual care when discharge to a nursing home from the hospital is expected.
11294165|NCT02738307|Experimental|altitude exposure|Altitude Exposure Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
11294166|NCT02738294|Experimental|Suspected EGC group|Participants with suspected EGC from white light endoscopy were enrolled.The endoscopist first used white light endoscopy to identify suspected gastric lesions and assessed lesions carefully with magnifying view, non-magnifying NBI view and ME-NBI view in sequence. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
11294167|NCT02738281||Rett Syndrome|This is a prospective natural history study examining the phenotypic variations of individuals with mutations in MECP2 or meeting the diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome. The overwhelming majority will be female, but males meeting diagnostic criteria will be included. No interventions are planned.
11294168|NCT02738281||MECP2 Duplication|This is a prospective natural history study examining the phenotypic variations of individuals with MECP2 duplications. The majority are expected to be males, but females expressing a duplication will be included. No interventions are planned.
11294169|NCT02738281||RTT related disorders|This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
11294170|NCT02738268|Sham Comparator|Control group|Control group: receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
11294171|NCT02738268|Experimental|Treatment Group|Treatment Group: receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
11294172|NCT02738255|Active Comparator|Polysomnogram with Varnum Mouthpiece|Varnum mouthpiece, similar to a mouth tape with central opening
11294173|NCT02738255|No Intervention|Regular Polysomnogram|Overnight sleep study with no mouthpiece
11294174|NCT02738242|Experimental|Novus system users|Sixteen (16) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be recruit for this study and will receive the Novus system for daily use.
11294175|NCT02738229|Experimental|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:
~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
11294176|NCT02738229|Placebo Comparator|control|placebo pill
11294177|NCT02738216|Experimental|Prenatal Yoga|A 9-week prenatal yoga program
11294178|NCT02738216|Active Comparator|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
11294179|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):
~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
11294180|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):
~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
11294181|NCT02738190|Active Comparator|Albumin|5% Albumin to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and albumin to reach the standard volume administered to these patients (400 ml)
11294182|NCT02738190|Active Comparator|Fresh Frozen Plasma|Fresh Frozen Plasma to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and plasma to reach the standard volume administered to these patients (400 ml)
11294183|NCT02738177|Active Comparator|misoprostol group|30 candidates were receive 2 tablets of misoprostol (PGE1) 200ug (i.e. 400 ug) 4 hrs prior to surgical evacuation
11294184|NCT02738177|Active Comparator|Effox group|30 candidates were received 2 tablets of Effox (Isosorbide mononitrate) 20 mg (i.e 40 mg) 4 hrs prior to surgical evacuation
11294185|NCT02738177|Active Comparator|combination therapy group|30 candidates were received 1 tablets of misoprostol 200ug & 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation.
11294186|NCT02738151|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
11294187|NCT02738151|Active Comparator|Tresiba|Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
11294188|NCT02738138|Experimental|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
11294189|NCT02738138|Experimental|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
11294190|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
11294191|NCT02738099||Arrest from presume Cardiac etiology|Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
11294192|NCT02738086|Experimental|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
11294193|NCT02738086|Experimental|Wait-List Control Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
11294194|NCT02738073|Placebo Comparator|Control|
11294195|NCT02738073|Active Comparator|Interventional|
11294196|NCT02738060|Experimental|Case group|The patients in case group will be received baked milk daily in the form of muffin for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
11294197|NCT02738034|Experimental|Adaptive training group|The intervention group will be composed of hypertensive participants with cognitive decline that will be submitted to the training program (Cogmed) for approximately 10 weeks. Across training, task difficulty was adjusted as a function of individual performance.
11294198|NCT02738034|Active Comparator|Active control Group|In the control group, hypertensive patient will be submitted to a set of online games available on the internet and previously determined. In this way, the control group will receive the same motivation, as well as will be engaged in computerized activities, in the same way as the experimental group. The difference is that these varied games do not provide any type of intense and adaptive training, at the same time as they do not stimulate any specific cognitive function.
11294199|NCT02738021|Experimental|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
11294200|NCT02738008|Experimental|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
11294201|NCT02737995|Experimental|Iron Replacement|
11294202|NCT02737982||IHD Men|Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
11294203|NCT02737982||IHD Women|Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
11294204|NCT02737969||TEE/Angio fusion software|Patients planned to undergo a transcatheter-based structural heart disease procedure that utilizes TEE and fluoroscopic guidance
11294205|NCT02737943|Experimental|Arm1 Mebo|20 : receiving Moist Exposed Burn Ointment (MEBO) at sites of donor graft and recipient at time of operation and in dressing
11294206|NCT02737943|Placebo Comparator|Arm2 Placebo|20 : receiving Standard cream Zagazig University Hospital (Antibiotics & analgesics)
11294207|NCT02737930|Experimental|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
11294208|NCT02737930|Placebo Comparator|Placebo|Matching placebo
11294209|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
11294210|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
11294211|NCT02737904|Active Comparator|Control group|Usual care - conventional, personalised in-patient rehabilitation 4 weeks duration
11294212|NCT02737904|Experimental|Intervention group|Usual care - conventional, personalised in-patient rehabilitation - plus APT cycling programme 4 weeks duration
11294213|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
11294214|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
11294215|NCT02737878|Experimental|Aerobic Training and Resistance Training (A&RT)|The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
11294216|NCT02737878|Experimental|Aerobic Training (AT)|The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
11294560|NCT02735681|Active Comparator|Probing Treatment Right Eye|Meibomian gland will be performed on the right upper eye lid of each participant.
11294217|NCT02737878|Experimental|Resistance Training (RT)|The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
11294218|NCT02737878|Active Comparator|Balance and Tone Program (CON)|The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
11294219|NCT02737865|Experimental|SMI and sonazoid (single arm)|Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line
11294220|NCT02737852|Experimental|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
11294221|NCT02737839|Experimental|Arm 1: STEPPING ON|"Adaptation Waves is to adapt Stepping On to the oncology setting/Pilot Waves is to determine the feasibility & acceptability of the program for older adults receiving cancer care/Gait & Balance Waves is to determine whether the participants experience changes in their gait & balance
~Complete baseline questionnaires about Instrumental Activities of Daily Living, Medical Outcome Study Activities, Karnofsky Performance Status, falls in past 3 months, medications, comorbidities, vision & hearing, The Falls Behavioral Scale, The Falls Efficacy Scale-International, Patient Reported Outcome pain, PRO neuropathy
~7 week STEPPING ON program is multi-component learning environment which has shown to help reduce falls
~A home visit to gather any feedback on the experience of the program
~Follow-up questionnaires up to 3 months after completion of the program
~Participants may elect to participate in a booster session to reinforce concepts 3-6 months after completion of the program"
11294222|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
11294223|NCT02737826|Active Comparator|Phase II - Gabapentin|Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
11294224|NCT02737826|Placebo Comparator|Phase II - Placebo|Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
11294225|NCT02737826|Experimental|Phase II - Buprenorphine taper|Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
11294226|NCT02737813|Experimental|Isobaric Marcaine|Isobaric Marcaine 2.2 mL for spinal block
11294227|NCT02737813|Active Comparator|Hyperbaric Marcaine|Hyperbaric Marcaine 2.2 mL for spinal block
11294228|NCT02737800|Active Comparator|1A endometrioma more than 5cm|Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
11294229|NCT02737800|Sham Comparator|1B endometrioma more than 5cm control|Endometrioma aspiration Standard long stimulation protocol & ICSI
11294230|NCT02737800|Active Comparator|2A endometrioma less than 5cm|Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
11294231|NCT02737800|Sham Comparator|2B endometrioma less than 5cm control|Standard long stimulation protocol & ICSI
11294232|NCT02737787|Experimental|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.
11294233|NCT02737774|Experimental|Icotinib and Pemetrexed/Carboplatin|"Icotinib: Icotinib for 18 weeks, 125mg Tid，PO. Chemotherapy: pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.
~Then continue with Icotinib, 125mg Tid，PO. until disease progression."
11294234|NCT02737761|Experimental|Optimal Adherence|"Participants will all undergo a qualitative interview and adherence measurements at baseline and 12 weeks after hospital discharge.
~In person the participants will receive a MEMSCaps device and an Actigraph accelerometer. They will be asked to begin wearing the accelerometer after their initial interview and to begin using the MEMSCaps device once they arrive at home. Participants will use the MEMSCap throughout the entire study and will wear the Actigraph for 2 weeks at baseline and again at 12 weeks."
11294235|NCT02737748|Experimental|Treatment Group|TWB-103 add-on Tegaderm
11294236|NCT02737748|Placebo Comparator|Control Group|Placebo+Tegaderm
11294237|NCT02737735|Experimental|Chemotherapy combined with compound herbal medicine|Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years，which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
11294238|NCT02737735|Active Comparator|Chemotherapy|The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
11294239|NCT02737722|Experimental|Bisphosphocin Nu-3|Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
11294240|NCT02737722|Placebo Comparator|Placebo|Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
11294241|NCT02737709|Experimental|Paclitaxel and Carboplatin regimen|Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.
11294242|NCT02737696|Active Comparator|Control|Participants in this group will have access to Drug Enforcement Administration's website (JustThinkTwice.gov). The JustThinkTwice website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz. Youth in this group will be informed that they will be prompted (by email and phone; described below) when the next online survey is available to complete. Youth will be asked to use this website for 30 minutes, twice per week (for a total of 60 minutes per week) for about 3-4 weeks.
11294243|NCT02737696|Experimental|Experimental|"Participants assigned to the Web-based prescription opioid prevention for adolescents will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks."
11294244|NCT02737670|Active Comparator|Sulodexide|Sulodexide 25 mg twice per day for 40 days
11294245|NCT02737670|Placebo Comparator|Placebo|1 tablet twice per day for 40 days
11294246|NCT02737657||Cohort 1|Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
11294247|NCT02737657||Cohort 2|Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
11294248|NCT02737644||CHD birth cohort|Cases are identified as those whose newborns screened and confirmed with CHD during the follow-up and four age- and delivery-hospital matched controls are selected for each case from the rest of the cohort.
11294249|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon personal lubricant via occlusive patch"
11294250|NCT02737618|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
11294251|NCT02737605|Experimental|Sequence 1|Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
11294252|NCT02737605|Experimental|Sequence 2|Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
11294253|NCT02737605|Experimental|Sequence 3|Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
11294254|NCT02737605|Experimental|Sequence 4|Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
11294255|NCT02737605|Experimental|Sequence 5|Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
11294256|NCT02737605|Experimental|Sequence 6|Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
11294257|NCT02737592|Experimental|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
11294258|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
11294259|NCT02737566|Experimental|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
11294260|NCT02737566|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
11294261|NCT02737553|Active Comparator|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.
~doi: 10.1097/AOG.0000000000000823.)."
11294262|NCT02737553|Active Comparator|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
11294846|NCT02733874|Active Comparator|control group|Calcipotriol Betamethasone Ointment
11294263|NCT02737540||Major depressive episode|This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
11294264|NCT02737540||Healthy subjects|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
11294265|NCT02737527|Experimental|Ultrasound with Fluoroscope|"This group undergoes lumbar sympathetic block using ultrasound and fluoroscope.
~Preparation: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Ultrasound for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
11294266|NCT02737527|Active Comparator|Fluoroscope only|"This group undergoes lumbar sympathetic block using fluoroscope only.
~Device: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Fluoroscope for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
11294267|NCT02737514|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
11294268|NCT02737514|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
11294269|NCT02737514|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
11294270|NCT02737501|Experimental|Brigatinib|Brigatinib will be administered orally to eligible participants with locally advanced or metastatic ALK+NSCLC naive to ALK inhibitors at a dose of 90 milligram (mg) QD for 7 days, then 180 mg QD, continuously, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death.
11294271|NCT02737501|Active Comparator|Crizotinib|Crizotinib will be administered to eligible participants with locally advanced or metastatic ALK+ NSCLC naive to ALK inhibitors as 250 mg orally BID, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death.
11294272|NCT02737488|Experimental|TST|
11294273|NCT02737488|Active Comparator|TAU Group|
11294274|NCT02737475|Experimental|Part 1: Dose Escalation|"BMS-986178 at specified doses at specified intervals
~Enrollment is closed for this arm"
11294275|NCT02737475|Experimental|Part 2: Dose Escalation and Expansion|"BMS-986178 in combination with Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
11294276|NCT02737475|Experimental|Part 3: Dose Escalation and Expansion|"BMS-986178 in combination with Ipilimumab at specified doses at specified intervals
~Enrollment is closed for this arm"
11294277|NCT02737475|Experimental|Part 4: Dose Schedule and Exploration|"BMS-986178/Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
11294278|NCT02737475|Experimental|Part 5: Dose Schedule and Exploration|"BMS-986178/Ipilimumab at specified doses at specified intervals
~Enrollment is closed for this arm"
11294279|NCT02737475|Experimental|Part 6: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
11294280|NCT02737475|Experimental|Part 7: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
~Enrollment is closed for this arm"
11294281|NCT02737475|Experimental|Part 8: Dose Exploration|"BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval
~Enrollment is closed for this arm"
11294282|NCT02737475|Experimental|Part 9: Dose Exploration|"BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals
~Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]"
11294283|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
11294284|NCT02737436|Experimental|Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
11294285|NCT02737436|Experimental|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
11294286|NCT02737423|Experimental|vitamin D|single IM dose 600,000 IU of cholecalciferol
11294287|NCT02737410|Active Comparator|Treatment|Treatment group obtaining Gut-directed Hypnotherapy
11294288|NCT02737410|No Intervention|Control|Control group
11294289|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
11294290|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
11294291|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
11294292|NCT02737397|Placebo Comparator|placebo|placebo and placebo
11294293|NCT02737384|Experimental|Treatment|
11294294|NCT02737371|Experimental|F901318 Dose level A oral|F901318 adverse events days 1-10
11294295|NCT02737371|Placebo Comparator|Placebo Dose level A oral|Placebo adverse events days 1-10
11294296|NCT02737371|Experimental|F901318 Dose level B oral|F901318 adverse events days 1-10
11294297|NCT02737371|Placebo Comparator|Placebo Dose level B oral|Placebo adverse events days 1-10
11294298|NCT02737371|Experimental|F901318 Dose level C oral|F901318 adverse events days 1-10
11294299|NCT02737371|Placebo Comparator|Placebo Dose level C oral|Placebo adverse events days 1-10
11294300|NCT02737358|Placebo Comparator|Placebo|Matched placebo will be given to half of the study participants.
11294301|NCT02737358|Active Comparator|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
11294302|NCT02737345||Waiting list|Patients on the liver transplant waiting list
11294303|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
11294304|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
11294305|NCT02737319|Experimental|Rosuvastatin|40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.
11294306|NCT02737319|No Intervention|Control|Use of standard therapy in elective angioplasty.
11294561|NCT02735681|Placebo Comparator|Fellow Eye (Left) Untreated|The fellow eye (left) will be used at the untreated control
11294307|NCT02737306|Experimental|PRO 140|up to 60 subjects will be enrolled. PRO 140 will be administered as a 525 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for up to 100±7 days. Subjects will return to the clinic for three Follow-up visits at 2 weeks after the last treatment visit, 30 days after the last treatment visit and one year after the first treatment visit.
11294308|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
11294309|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
11294310|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
11294311|NCT02737280|Active Comparator|Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
11294312|NCT02737280|Experimental|High flow oxygen therapy|High flow nasal cannula oxygen therapy with Airvo (TM, Fisher & Paykel Healthcare) device
11294313|NCT02737267|Experimental|Moderately high protein diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 40% of the energy derived from carbohydrates, 30% of the energy derived from protein and 30% of the energy derived from fat
11294314|NCT02737267|Placebo Comparator|Low fat diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 60% of the energy derived from carbohydrates, 18% of the energy derived from protein and 22% of the energy derived from fat
11294315|NCT02737254|Experimental|Oxytocin and Secure CBM training|
11294316|NCT02737254|Active Comparator|Placebo and Secure CBM training|
11294317|NCT02737254|Active Comparator|Oxytocin and Neutral CBM training|
11294318|NCT02737254|Placebo Comparator|Placebo and Neutral CBM training|
11294319|NCT02737241|Active Comparator|LP-HoLEP|Low power Holmium laser enucleation of the prostate
11294320|NCT02737241|Active Comparator|HP-HoLEP|High power Holmium laser enucleation of the prostate
11294321|NCT02737228|Experimental|CG200745 PPA|CG200745 PPA plus Gemcitabine and Erlotinib
11294322|NCT02737215|Active Comparator|CPAP group|patients will receive CPAP therapy for the first 7 days after extubation from CABG
11294323|NCT02737215|No Intervention|Control Group|Patients will receive usal care
11294324|NCT02737202|Experimental|Saracatinib|Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
11294325|NCT02737189|Experimental|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
~Best Medical Treatment and maximum supportive care"
11294326|NCT02737189|Other|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
11294327|NCT02737176|Experimental|Tobacco cessation intervention|Tobacco cessation intervention is implemented for 12 weeks. The nicotine dependence status is evaluated by the FTND (Fagerstrom Test for Nicotine Dependence) test. The point 3 or more is regarded as a moderate or high tobacco dependence and determining a cessation intervention. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Even if participants fail to abstain from smoking, the oral treatment is continued. In case of the use of the NRTs (nicotine patch and/or gum), the investigators supply it for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
11294328|NCT02737176|No Intervention|Non-tobacco cessation intervention|Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
11294329|NCT02737150|Active Comparator|Self-expandable valve under local anesthesia|CoreValve Evolut R valve under local anesthesia with conscious sedation
11294330|NCT02737150|Active Comparator|Self-expandable valve under general anesthesia|CoreValve Evolut R valve under general anesthesia
11294331|NCT02737150|Active Comparator|Balloon-expandable valve under local anesthesia|Edwards Sapien 3 valve under local anesthesia with conscious sedation
11294332|NCT02737150|Active Comparator|Balloon-expandable valve under general anesthesia|Edwards Sapien 3 valve under under general anesthesia
11294333|NCT02737137|Other|Manual measurement by the anesthetist|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic : Group 1
11294334|NCT02737137|Experimental|Measurement by a pressure gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the injection pressure of the local anesthetic : Group 2
11294335|NCT02737124|Experimental|1000 Mg Acetaminophen|Acetaminophen will be given 24 hours before surgery
11294336|NCT02737124|Active Comparator|Placebo|A sugar pill will be given 24 hours before the scheduled surgery.
11294337|NCT02737098|Active Comparator|Standard Implementation|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
11294338|NCT02737098|Active Comparator|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
11294339|NCT02737085|Experimental|Diffuse Large B Cell Lymphoma(DLBCL)|The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11294340|NCT02737072|Experimental|20 mg LY2510924 + 1500 mg Durvalumab|20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
11294341|NCT02737072|Experimental|30 mg LY2510924 + 1500 mg Durvalumab|30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
11294342|NCT02737072|Experimental|40 mg LY2510924 + 1500 mg Durvalumab|40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
11294343|NCT02737059|Placebo Comparator|Codeine/naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d."
11294344|NCT02737059|Placebo Comparator|Naloxegol/ codeine placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d."
11294345|NCT02737059|Active Comparator|Codeine/ naloxegol|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d."
11294346|NCT02737059|Active Comparator|codeine placebo/ naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.
~Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d."
11294347|NCT02737046|Experimental|Belinostat + Zidovudine|Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
11294348|NCT02737033|Experimental|Rhodiola|Rhodiola rosea 800mg single dose
11294349|NCT02737033|Placebo Comparator|Placebo|placebo 800mg single dose
11294350|NCT02737020|Experimental|Rhodiola|Rhodiola rosea 200mg up to four times a day for 28 days
11294351|NCT02737020|Placebo Comparator|Placebo|Placebo pill manufactured to mimic Rhodiola rosea 200mg, up to four times a day for 28 days
11294352|NCT02737007|Experimental|[14C]-GSK3191607 IV Microdose|Subjects will receive a single microdose of 100 micrograms (mcg) of [14C]-GSK3191607 by intravenous infusion over 15 minutes on Day 1 of the study.
11294353|NCT02736994|Other|Immersion in water|water
11294354|NCT02736994|Active Comparator|Immersion in water + cleansing tablet|Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
11294355|NCT02736994|Experimental|Immersion in water with PIP|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium)
11294356|NCT02736981|Active Comparator|Behavioral Weight Loss (BWL)|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment.
11294357|NCT02736981|Active Comparator|BWL + Autonomous Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
11294358|NCT02736981|Active Comparator|BWL + Extrinsic Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
11294359|NCT02736968|Experimental|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
11294360|NCT02736968|Placebo Comparator|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
11294361|NCT02736968|Experimental|Giardia- Active|N=34, 6mg auranofin daily x 5 days
11294362|NCT02736968|Placebo Comparator|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
11294363|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
11294364|NCT02736942|Active Comparator|Laparoscopic|Laparoscopic TME
11294365|NCT02736942|Experimental|Transanal|TaTME
11294366|NCT02736929|Active Comparator|Cognitive Processing Therapy - Cognitive|Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
11294367|NCT02736929|No Intervention|Waiting Period Control (WP-CON)|WP-CON group will receive minimal attention in the form of weekly telephone calls to assess current emotional state and to provide supportive, nondirective, brief counseling if participants report experiencing a crisis. Any participant assigned to the WP-CON group will be given the opportunity to receive CPT-C after the post-waiting period assessment.
11294368|NCT02736916|Experimental|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
11294369|NCT02736916|Active Comparator|Conventional PCI|LD-SCLC patients with Conventional PCI
11294370|NCT02736903|Active Comparator|Individual intervention|Behavioral: PennFit mobile individual intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their own daily steps and the minutes for vigorous, moderate, and muscle-strengthening exercises that they completed for each day. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening.
11294393|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
11294394|NCT02736708||PSC|Male or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not
11294395|NCT02736695|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
11294371|NCT02736903|Experimental|Online network intervention|Behavioral: PennFit mobile online network intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their exercises. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening. Participants were randomly assigned to 4-person online networks in the PennFit app. Participants in the online networks could see both their own information and the profiles and activity logs of the three other people assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
11294372|NCT02736890|Active Comparator|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
11294373|NCT02736890|Placebo Comparator|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
11294374|NCT02736877|Experimental|Lumera Microscope with OCT RESCAN|In the group microscope coupled to OCT, patients will undergo corneal surgery using the Lumera Microscope WITH RESCAN OCT - ZEISS. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
11294375|NCT02736877|Active Comparator|Conventional Microscope|The control group will undergo corneal transplant with conventional microscope without coupled OCT. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
11294376|NCT02736851|No Intervention|Control group|Usual care
11294377|NCT02736851|Active Comparator|Home-based telemedicine group|Nurse-tutor support at home for 6 months
11294378|NCT02736838|Experimental|Phase I|Interventions: Different positions will be applied to subjects to measure preipheral tissue oxygenation, pressure, and changes in microvascular flow. Subjects will be placed up to 4 hours in each of the standard positions for the experiment: supine decubitus (SD) right lateral decubitus (RLD), left lateral decubitus (LLD). SD measurements will be made at 0, 30 and 45 degrees of inclination to bed. RLD and LLD positions will be evaluated with a body inclination of 30 and 90ª. The subjects will lie down on a memory foam mattress for an articulated bed, as are commonly used at home, residential or hospital care. Between the subject and the mattress will be inserted the pressure measuring surface. Measurements in each position will be made during intervals of 0-4 hours in the same position (SD-RLD-LLD) in each of the inclinations of the bed (0º, 30°, 45 °) or body (30º, 90º), respectively.
11294379|NCT02736825|Active Comparator|Group A, Ulthera System with standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using standard transducers. Energy levels for each transducer will be set to EL2:
~Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line
~DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
11294380|NCT02736825|Experimental|Group B, Ulthera System with prototype 2 simulines transducers|"Subjects randomized to Group B will receive a Ultherapy® treatment with a total minimum pulse count of 336 pulses (+5%) using the prototype 2 simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:
~Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line
~DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
11294381|NCT02736812|Experimental|French Lyophilized Plasma|receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice
11294382|NCT02736812|Active Comparator|Normal Saline Solution|receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice
11294383|NCT02736799|Sham Comparator|Sham vibrating capsule|Sham vibrating capsule
11294384|NCT02736799|Active Comparator|Vibrant Capsule (1 vibration)|1 vibration/min
11294385|NCT02736799|Active Comparator|Vibrant Capsule (3 vibration)|3 vibrations/min
11294386|NCT02736799|Active Comparator|Vibrant Capsule (5 vibration)|5 vibrations/min
11294387|NCT02736773|Experimental|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
11294388|NCT02736760|Experimental|Daylight photodynamic therapy (PDT)|"One intervention in the daylight photodynamic therapy arm:
~Daylight photodynamic therapy using Methylaminolevulinate (MAL) will be performed five times within 18 months (visits 1-5). In the PDT group the patients will apply a chemical sunscreen (SPF 50+) to the whole face and other light-exposed, unprotected areas of the skin. After at least 15 minutes a lesion preparation of AKs (removal of crusts) will be performed and methylaminolevulinate (MAL) will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours."
11294389|NCT02736760|Active Comparator|Cryosurgery|In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
11294390|NCT02736747|Active Comparator|Cryotherapy (ice pack)|A pack with 1000g of crushed ice without air will be placed for 20 consecutive minutes on a pre-delimited rectangular area with dimensions of 25 x 35 cm and will be fixed with a non-compressive elastic band. One strip of plastic paper will encompass the paretic leg of the subjects, avoiding direct contact from the skin with the ice pack.
11294391|NCT02736747|Placebo Comparator|Placebo (sand pack)|"For placebo application, the pack will be filled with 1000g of thin sand, in environmental temperature, so that the pressure exerted will be the same as the ice pack. All other experimental procedures will follow the same protocol as cryotherapy application."
11294392|NCT02736734|Other|CRH condition|All HV first underwent a baseline manometry measurement. After 30 minutes, an intravenous CRH injection was done. The same measurement was repeated but now with CRH administered.
11294465|NCT02736071|Placebo Comparator|Placebo|Women will receive an oral placebo similar to Tramadol and an oral placebo similar to Celecoxib 2 hours before the procedure
11294396|NCT02736682|Experimental|Single dose antibiotic|2g of intra venous Ceftriaxone and 500 mgs Intra venous metronidazole is administered to the mothers as a Single dose pre-operative30-60 minutes before surgery.
11294397|NCT02736682|Active Comparator|multiple dose antibiotic.|Multiple doses of IV Ceftriaxone 1g and metronidazole 500mgs given to the mother during surgery there after Ceftriaxone 1g every day for 3 days and IV metronidazole 500 mgs every 8 hours for 3 days.
11294398|NCT02736669|Active Comparator|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
11294399|NCT02736669|Experimental|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
11294400|NCT02736656|Experimental|Open-Label Treatment|Subjects aged 6-12 years will be treated with SPN-812 ER followed by dose optimization. The subject will be given a choice to extend their participation in the study every 6-months for up to 36 months.
11294401|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
11294402|NCT02736604|Experimental|Air anesthesia|air will be used as carrier agent for maintenance of anesthesia
11294403|NCT02736604|Active Comparator|Nitrous Oxide anesthesia|nitrous oxide will be used as carrier agent for maintenance of anesthesia
11294404|NCT02736591|Active Comparator|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI
11294405|NCT02736591|Active Comparator|Growth hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
11294406|NCT02736578|Experimental|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
11294407|NCT02736578|Experimental|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
11294408|NCT02736565|Experimental|pbi-shRNA™ EWS/FLI1 Type 1 LPX|"Subjects will accrue in 3 to 6-subject escalation cohorts up to a dose of 0.156mg/kg of DNA / single dose.
~An intravenous infusion will be administered twice a week for 4 weeks (e.g. Mon and Thurs, preferred) for a total of 8 infusions of the product per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met."
11294409|NCT02736552|Experimental|S-1 for 6 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection
11294410|NCT02736552|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
11294411|NCT02736539|Experimental|Active|galacto-oligosaccharides
11294412|NCT02736539|Placebo Comparator|Placebo|Placebo
11294413|NCT02736526|Experimental|Surgical treatment|The recession or resection of the horizontal extraocular muscles will be processed in the beginning of the trial.
11294414|NCT02736526|No Intervention|Observation only|
11294415|NCT02736513|Experimental|AZD9291 80 mg - naive patients|naive patients with tumors harbouring either exon 19 deletion, L858R, T790M, or uncommon sensitizing EGFR mutations, will be treated with AZD9291 80 mg/day
11294416|NCT02736513|Experimental|AZD9291 80 mg - previously treated T790M was diagnosed|Patients previously treated with first and second generation EFGR TKIs (either Gefitinib, Erlotinib or Afatinib) in whom T790Mwas diagnosed either in the tumor specimen or in the ctDNA after testing it following the most recent disease progression, will be treated with AZD9291 80 mg/day
11294417|NCT02736513|Experimental|AZD9291 80 mg - previously treated unrelated to T790M|patients advanced NSCLC previously treated with 1st/2nd generation EGFR TKIs (either gefitinib. erlotinib or afatinib) who progressed unrelated to T790M (T790M-). No restriction regarding the number of prior EGFR TKIs or cytotoxic chemotherapy lines of treatment is applied.
11294418|NCT02736500|Experimental|28 GBq 177Lu-DOTATATE|5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) 177Lu-DOTATATE
11294419|NCT02736500|Experimental|22 GBq 177Lu-DOTATATE|6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi) 177Lu-DOTATATE
11294420|NCT02736487|Active Comparator|Group A: True-Washout-Sham|Subjects in group A receives true air filtration intervention, then at least two weeks of washout period, followed by sham air filtration intervention.
11294421|NCT02736487|Active Comparator|Group B: Sham-Washout-True|Subjects in group B receives sham air filtration intervention, then at least two weeks of washout period, followed by true air filtration intervention.
11294422|NCT02736474|Experimental|Naltrexone and Bupropion|Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.
11294423|NCT02736474|Placebo Comparator|Placebo Naltrexone and Bupropion|Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
11294424|NCT02736461||Group 1- With strabismus|Study group with strabismus happening after floor fracture repair
11294425|NCT02736461||Group 2- Without strabismus|No strabismus happening after floor fracture repair
11294426|NCT02736448|Experimental|Arm Lu-PRRT-Cap|Arm Lu-PRRT-Cap: oral low dose of capecitabine in association with Lu-PRRT (at 3.7 Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
11294427|NCT02736448|Experimental|Arm Lu-PRRT|Arm Lu-PRRT: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
11294891|NCT02733562||sweet eaters|Classificated preoperatively
11294428|NCT02736435|Experimental|Fibroid dimension < 8 cm|"Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.
~Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound."
11294429|NCT02736435|Experimental|Fibroid dimension > 8 cm|"Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.
~Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.
~Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc."
11294430|NCT02736422|Other|hyperpolarised xenon|evaluating the sensitivity of pulse sequences for 129Xe magnetic resonance imaging in the lungs, heart and brain and monitoring the transient changes in vital signs during and following the gas inhalation
11294431|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
11294432|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
11294433|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
11294434|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
11294435|NCT02736396||Healthy Controls|Medical History, Neuropsychological tests, clinical assessments, fMRI
11294436|NCT02736396||Cognitive impairment|Medical History, Neuropsychological tests, clinical assessments, fMRI
11294437|NCT02736383||Tranexamic Acid|Patients that receive 2 gm TXA during surgery
11294438|NCT02736383||No Tranexamic Acid|Patients that receive no TXA during surgery
11294439|NCT02736344|Experimental|BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:
~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent
~Delivery System - Rapid Exchange (RX) Coronary System
~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®
~Ridaforolimus drug - CAS Registry Number: 572924-54-0
~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
11294440|NCT02736331|Experimental|Treatment 1 Beverage|Treatment 1
11294441|NCT02736331|Placebo Comparator|Treatment 2 Beverage|Treatment 2
11294442|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
11294443|NCT02736305|Experimental|Regorafenib|Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
11294444|NCT02736292|Experimental|participant|
11294445|NCT02736266|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.
11294446|NCT02736240|Active Comparator|Control Arm|7-valent pneumococcal conjugate vaccine
11294447|NCT02736240|Experimental|Test Arm|13-valent pneumococcal conjugate vaccine
11294448|NCT02736227|Experimental|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
11294449|NCT02736214|Experimental|Lifestyle counseling|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
11294450|NCT02736214|No Intervention|Control group|The control group answered a baseline questionnaire in the waiting room and received standard care.
11294451|NCT02736201|Experimental|IMT+ T-CaRe®on; n = 10|The instrumental manual therapy with the switched on capacitive diathermy electrode
11294452|NCT02736201|Sham Comparator|IMT+ T-CaRe® off; n = 10|The instrumental manual therapy with the switched off capacitive diathermy electrode
11294453|NCT02736188|Experimental|Drug: Aceneuramic Acid Extended-Release Tablets|Participants will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).
11294454|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
11294455|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
11294456|NCT02736162||Perampanel|Participants with a diagnosis of epilepsy who received perampanel as primary or secondary (conversion) monotherapy at any time between 1 Jan 2013 and 15 Oct 2015.
11294457|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.
~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
11294458|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
11294459|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
11294460|NCT02736123|Experimental|Arm A consists of 3 phases or steps|"Induction Phase Nivolumab 3 mg/kg IV infusion every 2 weeks for 3 doses
~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)
~Maintenance Phase (after recovery from surgery) Nivolumab 3 mg/kg IV infusion every 3 weeks"
11294461|NCT02736123|Experimental|Arm B consists of 3 phases or steps|"Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses
~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)
~Maintenance Phase (after recovery from surgery) Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses; then, Nivolumab 3 mg/kg IV infusion every 3 weeks"
11294462|NCT02736084|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
~Exercises:
~Gratitude for positive events Using personal strengths Gratitude letter Enjoyable and meaningful activities Recalling past success Performing acts of kindness Repeating one of the previous exercises."
11294463|NCT02736071|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
11294464|NCT02736071|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
11294892|NCT02733562||snack eaters|Classificated preoperatively
11294466|NCT02736058|Experimental|Participants|the included pregnant females will undergo trans-abdominal sonography as well as trans-vaginal sonography , to diagnose the abnormal placentation and the results will be compared to the intra- operative as well as the pathological examination of the specimen.
11294467|NCT02736045|No Intervention|Control|Sham control. Subjects will be asked to write a journal (per week).
11294468|NCT02736045|Experimental|emWave|Our approach will be to test the impact of a behavioral intervention through a smartphone application, emWave software, which will be provided to all our subjects. The intervention (emWave) is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention.
11294469|NCT02736032|Active Comparator|With GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
11294470|NCT02736032|Active Comparator|Without GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
11294471|NCT02736019|Active Comparator|Celecoxib|Women will receive oral celecoxib 200mg 2 hours before the procedure
11294472|NCT02736019|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
11294473|NCT02736019|Placebo Comparator|Placebo|Women will receive a placebo similar to celecoxib and a placebo similar to Tramadol
11294474|NCT02736006|Experimental|20 meters air dive|
11294475|NCT02735980|Experimental|Prexasertib (Platinum Sensitive Disease)|105 mg/m^2 Intravenous (IV) prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had platinum-sensitive disease (has prior platinum based therapy with subsequent progression greater or less than 90 days after last dose of platinum based therapy).
11294476|NCT02735980|Experimental|Prexasertib (Platinum Resistant Disease)|105 mg/m^2 IV prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had resistant/refractory disease (did not have an objective response to platinum-based therapy or had progression greater than 90 days after the last dose of platinum).
11294477|NCT02735980|Experimental|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|40 mg/m^2 IV prexasertib Day 1, 2, and Day 3 of a 14 day cycle in participants with ED-SCLC platinum sensitive disease.
11294478|NCT02735967|Experimental|Group manual therapy + diadynamic|"Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
~Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient."
11294479|NCT02735967|Active Comparator|Group manual therapy|Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
11294480|NCT02735967|Active Comparator|Group diadynamic|An electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF),4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
11294481|NCT02735954||Marijuana Users|Individuals who use marijuana
11294482|NCT02735954||Combined Marijuana and Tobacco Users|Individuals who use marijuana and also smoke cigarettes
11294483|NCT02735954||Non-Marijuana Users|Individuals who do not use marijuana
11294484|NCT02735941||UC group|Patients with ulcerative colitis (active or remission)
11294485|NCT02735941||CD group|Patients with Crohn's disease (active or remission)
11294486|NCT02735941||Colon cancer group|Patients with colon cancer or metastasis
11294487|NCT02735941||control group|healthy individuals
11294488|NCT02735928|Experimental|PIPAC|PIPAC stands for Pressurized IntraPeritoneal Aerosol Chemotherapies. Enrolled patients will undergo to explorative laparoscopy as usual and PC index will be determined according to Fagotti score (PIV). Pathological response will be determined by serial peritoneal biopsies. Then a pressurized aerosol containing cisplatin followed by doxorubicin will be applied via a nebulizer. The PIPAC procedure can be repeated after 4-6 weeks until progression or limiting toxicity
11294489|NCT02735915|Experimental|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
11294490|NCT02735902|Experimental|vitamin K antagonist or Direct oral anticoagulant treatment|"In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.
~Intervention: anticoagulant"
11294553|NCT02735707|Active Comparator|Eritoran|Patients will receive Eritoran intended to be active against COVID-19
11294554|NCT02735707|Active Comparator|Apremilast|Patients will receive Apremilast intended to be active against COVID-19
11294555|NCT02735707|No Intervention|No antiplatelet|Patients will not receive any antiplatelet agent or NSAID for 14 days while patient remains in hospital
11294491|NCT02735902|Active Comparator|vitamin K antagonist or Direct oral anticoagulant + Aspirin|"In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.
~Intervention: anticoagulant Intervention: Aspirin"
11294492|NCT02735889|Other|No carbonation (control)|No carbonation (NC, control): Potable water + sugar
11294493|NCT02735889|Active Comparator|Low carbonation|Low carbonation (LC): Potable water + sugar + little CO2
11294494|NCT02735889|Active Comparator|High carbonation|High carbonation (HC): Potable water + sugar+ high CO2
11294495|NCT02735876|Experimental|acalabrutinib plus rituximab|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
11294496|NCT02735876|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 200 subjects).
11294497|NCT02735876|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 50 subjects).
11294498|NCT02735863|Experimental|ABX464|Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
11294499|NCT02735863|Placebo Comparator|ABX464 Matching placebo|Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
11294500|NCT02735850|Experimental|Ablative SBRT to all (max 3) sites followed by L19-IL2|Ablative cohort
11294501|NCT02735850|Active Comparator|Ablative SBRT to all (max 3) sites|Ablative cohort
11294502|NCT02735850|Experimental|SBRT 1 site, L19-IL2 and then standard of care|Non-ablative cohort
11294503|NCT02735850|Active Comparator|Standard of care|Non-ablative cohort
11294504|NCT02735837|Active Comparator|doxycycline gel|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
11294505|NCT02735837|Placebo Comparator|placebo gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
11294506|NCT02735824||patients with suspected PID|From included patients with suspected primary immunodeficiency (PID), i.e. patients with recurrent/unusual infection, immune dysregulation and/or susceptibility to malignancies from whom consent to participate was obtained, nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
11294507|NCT02735824||healthy relatives of patients with PID|From healthy relatives of patients with suspected PID from whom consent to participate was obtained, nucleated cells will be used for genetic testing in order to compare their genetic information with the one form their relatives with suspected PID.
11294508|NCT02735824||Healthy volunteers|From healthy volunteers from whom consent to participate was obtained, nucleated blood cells will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement. The data obtained will be compared to age matched patients with suspected PID.
11294509|NCT02735798|Experimental|Single Arm Study - Arm 1|10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
11294510|NCT02735785|Experimental|intervention|behavioral intervention
11294511|NCT02735785|No Intervention|control|control
11294512|NCT02735772|Other|cystocele|"Arm: Patients with paravaginal defect cystocele
~Intervention: transobturator approach for paravaginal repair"
11294513|NCT02735759|Other|Healthy Volunteers|This cohort will consist of ten healthy volunteers. The photoacoustic flow cytometry device will be used to establish device settings. The intervention with the subject will include the PAFC device to establish appropriate device settings.
11294514|NCT02735759|Other|Venous Thromboembolism|This cohort will consist of ten patients with newly diagnosed, non-life threatening acute venous thromboembolism. The intervention with the subjects is to perform the photoacoustic flow cytometry device to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.
11294515|NCT02735746||High fidelity functional lung imaging|High fidelity functional lung imaging (HFFLI) is an improved method of measuring pulmonary function by analyzing 3-Dimensional (3D) motion. Using this technique, we are able to detect and localize pathological changes in the lung with sub-segmental resolution. The approach uses a unique cross-correlation analysis and non-linear optimization to reconstruct lung tissue motion from a small number of standard projections. All participants will undergo standard 4D Computed Tomography (CT), standard Cone Beam CT, research Low-dose Cinefluorography, and additional research Pulmonary Function Tests.
11294516|NCT02735733|Active Comparator|Room temperature arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at room temperature.
11294517|NCT02735733|Experimental|Cold arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at approximately 32 degrees F for the study group.
11294556|NCT02735707|Active Comparator|Aspirin|Patients will receive aspirin for up to 14 days while the patient remains in hospital
11294557|NCT02735707|Active Comparator|P2Y12 inhibitor|Patients will receive either clopidogrel, prasugrel, or ticagrelor (as per site preference).
11294558|NCT02735694|Active Comparator|Cycloserine|Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
11314420|NCT02603653|Experimental|Controls|Virtual radial task in 3D
11294518|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.
~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
11294519|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.
~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
11294520|NCT02735707|Active Comparator|Corticosteroid Domain: fixed-duration Hydrocortisone|The patient will receive IV Hydrocortisone 50 mg every 6 hours for up to 7 days.
11294521|NCT02735707|No Intervention|Corticosteroid Domain:No systemic corticosteroid (no placebo)|The patient will receive no systemic corticosteroid for the treatment of CAP or its direct complications, up until study day 28.
11294522|NCT02735707|Active Comparator|Corticosteroid Domain: shock dependant Hydrocortisone|The patient will receive hydrocortisone (50mg IV every 6 hours) while the patient is in septic shock.
11294523|NCT02735707|Active Comparator|Antibiotic Domain: Ceftriaxone + Macrolide|Ceftriaxone and site preferred macrolide will be administered for empiric antibiotic therapy
11294524|NCT02735707|Active Comparator|Antibiotic Domain: Moxifloxacin or Levofloxacin|Moxifloxacin or levofloxacin will be administered for empiric antibiotic therapy
11294525|NCT02735707|Active Comparator|Antibiotic Domain: Piperacillin-tazobactam + Macrolide|Piperacillin-tazobactam and site preferred macrolide will be administered for empiric antibiotic therapy
11294526|NCT02735707|Active Comparator|Antibiotic Domain: Ceftaroline + Macrolide|Ceftaroline and site preferred macrolide will be administered for empiric antibiotic therapy
11294527|NCT02735707|Active Comparator|Antibiotic Domain: Amoxicillin-clavulanate + Macrolide|Amoxicillin-clavunate and site preferred macrolide will be administered for empiric antibiotic therapy
11294528|NCT02735707|Active Comparator|Macrolide Duration Domain: Standard course macrolide|The patient will receive macrolide therapy for 3-5 days. This arm is nested within the Antibiotic Domain.
11294529|NCT02735707|Active Comparator|Macrolide Duration Domain: Extended course macrolide|The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.
11294530|NCT02735707|No Intervention|No antiviral agent active against influenza (no placebo)|The patient will receive no antiviral agent active against influenza, including oseltamivir.
11294531|NCT02735707|Active Comparator|Five-day course of Oseltamivir|The patient will receive a five-day course of oseltamivir.
11294532|NCT02735707|Active Comparator|10-day course of oseltamivir|The patient will receive a ten-day course of oseltamivir.
11294533|NCT02735707|No Intervention|No antiviral for COVID-19|The patient will receive no antiviral agent intended to be active against SARS-CoV-2 infection.
11294534|NCT02735707|Active Comparator|Lopinavir/ritonavir for COVID-19|Patients will receive lopinavir/ritonavir (kaletra) 400/100mg enterally every 12 hours intended to be active against SARS-CoV-2 infection.
11294535|NCT02735707|Active Comparator|Hydroxychloroquine for COVID-19|Patients will receive hydroxychloroquine intended to be active against SARS-CoV-2 infection.
11294536|NCT02735707|Active Comparator|Hydroxychloroquine + lopinavir/ritonavir for COVID-19|Patients will receive both hydroxychloroquine and lopinavir/ritonavir intended to be active against SARS-CoV-2 infection.
11294537|NCT02735707|No Intervention|No immune modulation for COVID-19|Patients will not receive any immune modulating therapy intended to be active against COVID-19.
11294538|NCT02735707|Active Comparator|Interferon-β1a for COVID-19|Patients will receive Interferon-β1a intended to be active against COVID-19.
11294539|NCT02735707|Active Comparator|Anakinra (interleukin-1 receptor antagonist) for COVID-19|Patients will receive anakinra intended to be active against COVID-19.
11294540|NCT02735707|Active Comparator|Fixed-duration higher dose Hydrocortisone|The patient will receive IV Hydrocortisone 100mg every 6 hours for up to 7 days.
11294541|NCT02735707|Active Comparator|Tocilizumab|Patients will receive Tocilizumab intended to be active against COVID-19
11294542|NCT02735707|Active Comparator|Sarilumab|Patients will receive Sarilumab intended to be active against COVID-19
11294543|NCT02735707|No Intervention|No Vitamin C|Patients will not receive vitamin c (no placebo)
11294544|NCT02735707|Active Comparator|Vitamin C|Patients will receive IV Vitamin C (50mg/kg every 6 hours for 16 doses)
11294545|NCT02735707|No Intervention|Standard Care Thromboprophylaxis|Patients will receive local standard care thromboprophylaxis for 14 days.
11294546|NCT02735707|Active Comparator|Therapeutic Anticoagulation|Therapeutic anticoagulation with IV unfractionated heparin or subcutaneous low molecular weight heparin.
11294547|NCT02735707|No Intervention|No simvastatin|Patients will not receive simvastatin for up to 28 days while the patient remains in hospital.
11294548|NCT02735707|Active Comparator|Simvastatin|Patients will receive simvastatin (80mg enterally once daily) for up to 28 days while the patient remains in hospital.
11294549|NCT02735707|No Intervention|No immunoglobulin against SARS-CoV-2|Patients will not receive any preparation of immunoglobulin intended to neutralise SARS-CoV-2 during the index hospitalisation.
11294550|NCT02735707|Active Comparator|Convalescent plasma|Patients will receive at least one, and not more than two, units of convalescent plasma within 48 hours of randomisation.
11294551|NCT02735707|No Intervention|Clinician-preferred invasive ventilation|Patients will receive invasive mechanical ventilation as determined by the treating clinician.
11294552|NCT02735707|Active Comparator|Protocolised invasive mechanical ventilation strategy|Patient will receive a protocolised invasive mechanical ventilation strategy
11294893|NCT02733549||patient|Patients with sudden onset dizziness (SOD) analysed LFTs
11294562|NCT02735668|Active Comparator|Shoulder Conventional Exercises|"The protocol consists in:
~Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment.
~Therapeutic Education about chronic shoulder pain.
~The treatment duration is 1 day per week during 6 weeks."
11294563|NCT02735668|Experimental|Multimodal Physiotherapy|"The protocol consists in:
~Dry Needling in active myofascial trigger points.
~Neurodynamic techniques.
~Scapular exercises.
~Therapeutic Education about chronic shoulder pain.
~The treatment duration is 1 day per week during 6 weeks."
11294564|NCT02735668|Experimental|Scapular exercises|"The protocol consists in:
~Scapular exercises
~Therapeutic Education about chronic shoulder pain.
~The treatment duration is 1 day per week during 6 weeks."
11294565|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
11294566|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
11294567|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
11294568|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
11294569|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
11294570|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
11294571|NCT02735629|Experimental|CX1739 - 300 mg|Study Drug - low dose
11294572|NCT02735629|Placebo Comparator|Placebo|Placebo
11294573|NCT02735629|Experimental|CX1739 - 600 mg|Study drug - mid Dose
11294574|NCT02735629|Experimental|CX1739 - 900 mg|Study drug - high dose
11294575|NCT02735616||study|"15 CVA patients, 1-3 weeks after their first stroke. The patients will be hospitalized in the neurology department at the geriatric Beit-Rivka hospital at Petah-Tiva, Israel.
~patients with pacemaker or those who use Beta-Blocker drugs, as well as patients with cerebellar injury, will be excluded from the research"
11294576|NCT02735616||control|15 patients from the orthopedic department at the same hospital, matching by age and gender to the study group.
11294577|NCT02735603|Experimental|Nalterxone/Bupropion + Placebo + Moxifloxacin|Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
11294578|NCT02735603|Experimental|Placebo + Moxifloxacin + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
11294579|NCT02735603|Experimental|Moxifloxacin + Naltrexone/Bupropion + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.
11294580|NCT02735603|Experimental|Naltrexone/Bupropion + Moxifloxacin + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.
11294581|NCT02735603|Experimental|Placebo + Naltrexone/Bupropion + Moxifloxacin|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
11294582|NCT02735603|Experimental|Moxifloxacin + Placebo + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
11294583|NCT02735590|Experimental|Open-label 3HP|Participants in the Treatment Arm will receive high dose INH (15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg) with Pyridoxine supplementation (25mg), and Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months. Dispensing of IP and Directly Observed Treatment (DOT) field visits in Treatment Arm participants will be performed by staff members not involved in TB symptom screening or investigation. Participants receiving 3HP who develop symptoms of hepatotoxicity will be evaluated by an Investigator.
11294584|NCT02735590|No Intervention|Baseline Screening; Active Surveillance|Adult volunteers living in TB hyperendemic communities of South Africa will be consented and screened. Individuals with HIV infection and conditions likely to affect the performance of the COR assay, or the safety and/or efficacy of the 3HP investigational regimen, will not be enrolled. Active surveillance for TB disease (Observation Arm), including regular symptom screening and symptom-targeted TB investigation (all participants) will be conducted on this Arm.
11294585|NCT02735577|Experimental|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
11294586|NCT02735564|Experimental|RYGB|Bariatric Surgery:Roux-en-y
11294587|NCT02735564|Experimental|SG|Bariatric Surgery: Sleeve Gastrectomy
11294588|NCT02735564|Placebo Comparator|Control|BMI matched control
11294589|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
11294590|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
11294591|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
11294592|NCT02735538||osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
11294593|NCT02735538||osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
11294594|NCT02735525|Experimental|Smartphone monitoring|Intervention arm
11294595|NCT02735512||Group I|Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
11294596|NCT02735512||Group II|Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
11294597|NCT02735512||Group III|Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.
11294598|NCT02735499|Experimental|Treatment with Botox|Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.
11294599|NCT02735486|Experimental|Ginger drink|Experimental: Ginger drink (300 ml) to be consumed during the study visit
11294600|NCT02735486|Placebo Comparator|Placebo: Super pure water|Super Pure water low in nitrate content
11294601|NCT02735473|Experimental|Choline bitartrate|Powdered drink mix containing choline bitartrate 19 mg. per kg.
11294602|NCT02735473|Placebo Comparator|Placebo|Powdered drink mix containing matching placebo
11294603|NCT02735460|Experimental|Treatment arm|In this arm the Andago V2.0 is used.
11294604|NCT02735434|Experimental|Internet-based ACT|Brief clinical psychiatric assessment to determine eligibility (video-based).
11294605|NCT02735434|Active Comparator|Internet-based discussion forum|Brief clinical psychiatric assessment to determine eligibility (video-based).
11294606|NCT02735421|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening on half of the face (determined by randomization)
11294607|NCT02735421|Placebo Comparator|Vehicle gel|Vehicle gel, once daily in the evening on half of the face (determined by randomization)
11294608|NCT02735408|Experimental|100% KT Tension|100% KT Tension
11294609|NCT02735408|Experimental|50% KT Tension|50% KT Tension
11294610|NCT02735408|Experimental|0% KT Tension|0% KT Tension
11294611|NCT02735408|No Intervention|Control (Without KT)|Control (Without KT)
11294612|NCT02735395|Placebo Comparator|Control|Scaling and root planing (SRP) + two placebo pills thrice a day (TID) for 14 days (control group)
11294613|NCT02735395|Active Comparator|MTZ 250 (7 days)|SRP + MTZ (250mg/TID) + AMX, for 7 days and placebos for another 7 days
11294614|NCT02735395|Active Comparator|MTZ 400 (7 days)|SRP + MTZ (400mg/TID) + AMX, for 7 days and placebos for another 7 days
11294615|NCT02735395|Active Comparator|MTZ 250 (14 days)|SRP +MTZ (250mg/TID) + AMX for 14 days
11294616|NCT02735395|Active Comparator|MTZ 400 (14 days)|SRP +MTZ (400mg/TID) + AMX for 14 days
11294665|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
11294894|NCT02733549||control|The control group with 98 healthy volunteer analysed LFTs
11294617|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.
~Intervention: Behavioral: Tobacco quitline EHR referral"
11294618|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.
~Intervention: Behavioral: Tobacco quitline Fax referral"
11294619|NCT02735382|Experimental|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
11294620|NCT02735382|Active Comparator|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
11294621|NCT02735369|Placebo Comparator|Placebo|Placebo Comparator
11294622|NCT02735369|Experimental|2% OC-10X|2% OC-10X
11294623|NCT02735356|Experimental|Treatment (itraconazole and placebo)|Patients apply itraconazole topically BID and placebo topically BID for 12 weeks.
11294624|NCT02735343|Active Comparator|Standard treatment arm|compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
11294625|NCT02735343|Experimental|Research arm|Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
11294626|NCT02735330|Active Comparator|GROUP 1|68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol
11294627|NCT02735330|Placebo Comparator|GROUP 2|68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
11294628|NCT02735317|Experimental|FORRAD group|"This group of patients will receive Oral Ulcer Gargle (FORRAD®) during study for prevention and treatment of acute radiation-induced oral mucositis (OM).
~This is the experimental group."
11294629|NCT02735317|Active Comparator|Quadruple mixture group|"This group of patients will receive quadruple mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, during study for prevention and treatment of acute radiation-induced oral mucositis (OM).
~This is the active comparator group."
11294630|NCT02735304|Other|Innovation treatment 3M ESPE materials|"The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment during the Impression intervention.
~Materials to be used all 3M ESPE - Astringent Retraction Paste, Imprint™ 4 Preliminary, Imprint™4 VPS, Imprint™ 4 Bite, Intra-oral syringes, Impression Tray,"
11294631|NCT02735304|Other|standard clinical practice treatment|"The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment during the Impression intervention
~Materials as per the operating dentist's choice to be recorded on CRF"
11294632|NCT02735291|Experimental|Single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
11294633|NCT02735265|Experimental|Virtual reality group|45 min standard treatment plus 45 min virtual reality balance training used by Kinect for Xbox game. Game choosed based on motor learning principle. Training task such as reach or stepping in various direction, squat, stand up, upper trunk forward or lateral bench.
11294634|NCT02735265|Active Comparator|Standard treatment only group|90 min standard treatment. Depended on patient's ability, principle used by motor learning, sensory process, motor control, task oriented training, symmetry w't bearing.
11294635|NCT02735252|Experimental|Group A: Androgen Signaling Inhibition|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving treatments that inhibit androgen signaling to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294636|NCT02735252|Experimental|Group B: Immunotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving immunotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294637|NCT02735252|Experimental|Group C: Radiotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving radiotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294638|NCT02735252|Experimental|Group D: Targeted Therapy Not Otherwise Specified|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving targeted therapy and investigational therapeutics to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294639|NCT02735252|Experimental|Group E: DNA Damage Response|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294640|NCT02735252|Experimental|Group F: Aggressive Variant Disease|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients with variants of disease that display aggressive behavior to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294664|NCT02735135|Experimental|SENTRY 1200 First|"Patients randomized to this arm will be placed on a SENTRY 1200 mattress for day 0. They will then be switched to an AIRSOFT DUO mattress until the end of month 1.
~Intervention: SENTRY 1200 for 1 day Intervention: AIRSOFT DUO for 1 month"
11294895|NCT02733536|Experimental|Scenario A|manikin with normal standard airway
11294641|NCT02735252|Experimental|Group G1: Castration Sensitive, ADT naïve and ADT < 3 months|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294642|NCT02735252|Experimental|Group G2:Castration Sensitive,Pre-treated w/ sub-optimal PSA|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294643|NCT02735252|Experimental|Group R: Advanced Renal Cell Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294644|NCT02735252|Experimental|Cohort U: Advanced Urothelial Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.
~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.
~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
11294645|NCT02735239|Experimental|Durvalumab and standard of care chemotherapy|Phase 1 will evaluate the safety of durvalumab alone (Cohort A1) administered before chemotherapy (oxaliplatin + capecitabine) in subjects with metastatic or locally advanced Oesophageal Cancer + Chemotherapy
11294646|NCT02735239|Experimental|Durvalumab + tremelimumab and standard of care chemotherapy|Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy (Cohort A2).
11294647|NCT02735239|Experimental|Recommended combination of doses from Cohort A1 or A2|Subjects in Cohort B are subjects with metastatic/locally advanced Oesophageal Cancer. Subjects in Cohort B will receive the recommended combination dose from Cohort A1 (durvalumab alone administered before chemotherapy (oxaliplatin + capecitabine)) or A2 (Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy) and Chemotherapy.
11294648|NCT02735239|Experimental|Durvalumab, surgery and standard of care chemotherapy|Durvalumab 750mg + Chemotherapy (Cohort C)
11294649|NCT02735239|Experimental|Durvalumab, surgery, standard of care chemo and radiotherapy|Durvalumab 750mg + Chemotherapy Radiotherapy (Cohort D)
11294650|NCT02735239|Experimental|Durvalumab, surgery, new standard of care chemotherapy C-FLOT|Durvalumab 750mg + Chemotherapy (Cohort C-FLOT)
11294651|NCT02735226||Acute Stroke patient|Patients who are presented to hospital within 7days from onset. The key measurement of clinical quality controlled in patients with acute stroke managment and inhouse stroke care were record automatically
11294652|NCT02735213|Experimental|577-MPL|"577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
11294653|NCT02735213|Active Comparator|TLT|"Traditional laser will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
11294654|NCT02735200|Experimental|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
11294655|NCT02735200|Active Comparator|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
11294656|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
11294657|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
11294658|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:
~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
11294659|NCT02735161|Experimental|Exercise training|"Four exercise training sessions. Two endurance training sessions, one with high intensity interval training and one session of moderate intensity of longer duration. Two strength training session; one with high load and few repetitions and one with low load and many repetitions.
~Fatigue and lactate will be measured before, after and 24 hours post-exercise. Trainings sessions will be randomized."
11294660|NCT02735148|No Intervention|Conventional Training|Conventional training sessions generally consisted of exercises which aimed to improve range of motion, strength, and movement quality in upper and lower extremity as an in-patient rehabilitation protocol. Also developing static and dynamic postural control and increasing walking distance were the other aims of training. Duration of the Conventional Training is 45 minute per session, 3 days a week for 6 weeks.
11294661|NCT02735148|Experimental|Body Weight Supported Treadmill Training|"Body weight supported treadmill training (BWSTT) was composed of outpatients who were undertaken only BWST training with 45-minute sessions, 2 days a week during 6 weeks.
~BWST Training
~Locomat (Hocoma) was used in BWSTT group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait pattern."
11294662|NCT02735148|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
11294663|NCT02735135|Experimental|Airsoft Duo First|"Patients randomized to this arm will be placed on an AIRSOFT DUO mattress for day 0. They will then be switched to a SENTRY 1200 mattress until the end of month 1.
~Intervention: AIRSOFT DUO for 1 day Intervention: SENTRY 1200 for 1 month"
11295114|NCT02731859||EndoBarrier|All patients with EndoBarrier treatment
11294666|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
11294667|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
11294668|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
11294669|NCT02735109|Other|description|photographies and biopsy on normal area
11294670|NCT02735096|Experimental|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
11294671|NCT02735083|Experimental|UCART19 follow-up|
11294672|NCT02735070|Experimental|Corisitina D|The patient will use the medication 4 times a day - orally The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine. Coristina® d is indicated as an analgesic, antipyretic, antiallergic, and nasal congestion for the treatment of the symptoms of influenza and common cold.
11294673|NCT02735070|Active Comparator|Resfenol|The patient will use the medication 4x / day - orally Resfenol® drug acts against the symptoms of colds and flu, such as nasal congestion, runny nose, fever, headache, muscle pain and other symptoms. The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.
11294674|NCT02735057|Experimental|Phase I|"for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)
~for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
11294675|NCT02735044|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter [U/mL]) Subcutaneous(SC) injection once daily for 12 months.
11294676|NCT02735044|Active Comparator|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
11294677|NCT02735031|Active Comparator|EXENATIDE|"Exenatide
~week 1-2: 5 µg twice daily
~week 3-6: 10 µg twice daily (if tolerated)"
11294678|NCT02735031|Placebo Comparator|PLACEBO|"Placebo matched to exenatide
~week 1-2: 5 µg twice daily
~week 3-6: 10 µg twice daily (if tolerated)"
11294679|NCT02735018|Experimental|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
11294680|NCT02735018|Experimental|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
11294681|NCT02735005|Experimental|SMAF assessment|"Face to face interview for the Functional Autonomy Measurement System (SMAF) tool questionnaire For disabled patients living at home, the Social SMAF questionnaire is used in addition.
~Data related to care consumption of each enrolled patients are collected too."
11294682|NCT02734992|Other|Acceptance and Commitment therapy + MTAU|"The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou & Karekla, 2015). The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness.
~Participants will be asked to remain stable on their pharmacotherapy during this study. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions.
~Participants will complete questionnaires at pre-, post-treatment, and at 3-month follow-up. The WL group will enter treatment at the 3-month follow-up of the ACT-group."
11294683|NCT02734992|Other|MTAU/ Wait-list Control Gr|"The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment. Participants will complete the same questionnaires at three different time points: pre-, post-treatment, and at 3-month follow-up.
~Participants will be asked to remain stable on their pharmacotherapy during this study and inform the researchers of any changes. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Excluded participants will be referred to appropriate services."
11294684|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
11294685|NCT02734966|Experimental|arm 1|lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
11294686|NCT02734966|Experimental|arm 2|higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
11294687|NCT02734966|Active Comparator|Tiopronin Injection|Tiopronin Injection 200mg OD for 4 weeks
11294688|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
11294689|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.
~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
11294728|NCT02734680|Experimental|Stereotactic Radiotherapy(SBRT) Group|Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
11294729|NCT02734667|Experimental|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
11294730|NCT02734667|No Intervention|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
11294690|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
11294691|NCT02734927|Active Comparator|schizophrenia group|Schizophrenia patients suffering
11294692|NCT02734927|Sham Comparator|control group|subjects showing no psychological or neurological disorder
11294693|NCT02734914|Experimental|SF-URS with automatic control of RPP|Participants in SF-URS with automatic control of renal pelvic pressure (RPP) group undergo ureteroscopy using the intelligent pressure control device (Medical irrigation and suctioning platform with pressure feedback function, and suctioning ureteral access sheath with function of pressure measuring).
11294694|NCT02734914|Active Comparator|conventional F-URS|Participants in conventional F-URS group undergo ureteroscopy using the classic flexible ureteroscope.
11294695|NCT02734901|Active Comparator|400 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
11294696|NCT02734901|Active Comparator|200 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
11294697|NCT02734901|Placebo Comparator|Placebo control|Raspberry deprived supplement Acute intake of 600 mL (1x daily)
11294698|NCT02734888|Other|Healthy control|"Will undergo PET scan as a negative control"
11294699|NCT02734888|Other|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
11294700|NCT02734888|Other|E-cigarette user|Will undergo PET scan
11294701|NCT02734875|Experimental|Intervention|Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy. Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
11294702|NCT02734875|No Intervention|Usual Care|Primary care providers will provide usual care.
11294703|NCT02734862|Experimental|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.
~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
11294704|NCT02734862|Active Comparator|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).
~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
11294705|NCT02734862|Experimental|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.
~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
11294706|NCT02734849|Experimental|AK001 low dose|A low dose of AK001 will be administered in multiple doses
11294707|NCT02734849|Experimental|AK001 high dose|A high dose of AK001 will be administered in multiple doses
11294708|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients
11294709|NCT02734836|Experimental|Zilver PTX Stent|Diagnostic assessment of the lesion after implantation of drug eluting stent with Balloon Angioplasty and placement of the Zilver PTX Stent with Optical Coherence Tomography (OCT)
11294710|NCT02734823||Ancillary-Correlative (ovary imaging, hormonal analysis)|Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.
11294711|NCT02734810|Experimental|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
11294712|NCT02734810|Experimental|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to <7 years
11294713|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
11294714|NCT02734784|Experimental|Photodynamic Therapy and SRP|
11294715|NCT02734784|Sham Comparator|SRP and Sham Photodynamic Therapy|
11294716|NCT02734771|Experimental|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
11294717|NCT02734758||Atrial fibrillation stroke|
11294718|NCT02734758||Non-atrial fibrillation Stroke|
11294719|NCT02734745|Experimental|flash glucose monitoring|Patients will use a device: Freestyle Libre for 14 days
11294720|NCT02734732|Active Comparator|Ciprofloxacin|T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy
11294721|NCT02734732|Active Comparator|Trimethoprim/Sulfamethoxazole|Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy
11294722|NCT02734719|Experimental|the group treated with electrical stimulation|
11294723|NCT02734706|Experimental|LRC™ capsule|
11294724|NCT02734706|Placebo Comparator|Placebo capsule|
11294725|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
11294726|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
11294727|NCT02734680|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
11294731|NCT02734654|No Intervention|Control group|patients do not receive remote preconditioning prior to lung lobectomy
11294732|NCT02734654|Experimental|RIPC group|patients receive remote preconditioning prior to lung lobectomy
11294733|NCT02734641||intravenous (IV) iron therapy|"Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects.
~20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested."
11294734|NCT02734641||healthy volunteer|healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks.
11294735|NCT02734628|Experimental|Dexpanthenol|A squeeze of ointment, approximately 0.5 cm in length corresponding to an amount of about 0.3 g of ointment, which is equal to 15 mg dexpanthenol , twice daily (once in the morning and once in the evening) over a period of 14 days was applied topically under occluded conditions
11294736|NCT02734628|Placebo Comparator|Placebo|Subjects received applications of placebo corresponding to verum
11294737|NCT02734615|Experimental|Arm A|Patients will get LSZ102 single agent during dose escalation.
11294738|NCT02734615|Experimental|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
11294739|NCT02734615|Experimental|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
11294740|NCT02734615|Experimental|Arm 1|Patients will get LSZ102 single agent during dose expansion
11294741|NCT02734615|Experimental|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
11294742|NCT02734615|Experimental|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
11294743|NCT02734615|Experimental|Arm 4|Patient will get LSZ102 in combination with BYL719 during dose expansion
11294744|NCT02734602|Other|Cognitive Testing|Subjects will take part in verbal assessments as well as computer testing.
11294745|NCT02734602|Active Comparator|Magnetic Resonance Imaging|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. We will acquire the following: structural MRI, resting state MRI, diffusion tensor imaging data (DTI), and arterial spin labeling (ASL). We may also ask subjects to complete an emotional capture task.
11294746|NCT02734602|Active Comparator|Positron Emission Tomography|Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.
11294747|NCT02734589|Active Comparator|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
11294748|NCT02734589|Experimental|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
11294749|NCT02734589|Active Comparator|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
11294750|NCT02734576|Experimental|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
11294751|NCT02734563||Multiple hernia group|Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed.
11294752|NCT02734563||Control group|Males without any history or presence of hernias
11294753|NCT02734550|Active Comparator|Control|Diagnosis of invasive candida infection according to standard of care.
11294754|NCT02734550|Experimental|(1,3)-β-D-glucan guidance|Treatment according to BDG-result
11294755|NCT02734537|Experimental|Arm A (IMRT)|Patients undergo IMRT QD 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
11294756|NCT02734537|Experimental|Arm B (IMRT, cisplatin)|Patients undergo IMRT QD 5 days a week and receive cisplatin IV over 1-2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
11294757|NCT02734524|Experimental|NK infusion+chemotherapy|Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.
11294758|NCT02734524|Active Comparator|chemotherapy|Receive the same taxol and carboplatin in experimental arm without NK cell infusion.
11294759|NCT02734511|Experimental|Drug: sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
11294760|NCT02734498|Active Comparator|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
11294761|NCT02734498|Active Comparator|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
11294762|NCT02734498|No Intervention|Control group|No ECT treatment for control group.
11294791|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
11294763|NCT02734485|Active Comparator|active Deep Tms|Each DTMS session consisted in two consecutive stimulations: a first low-frequency (1 Hz) stimulation in the motor cortex (110% of the motor threshold, for 15 minutes)and a second high-frequency (10Hz) one in the prefrontal cortex (100% motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).The coil contains two symmetric devices, perfectly designed to rouse both hemispheres at the same time.
11294764|NCT02734485|Sham Comparator|sham deep tms|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an inactive DTMS coil.
11294765|NCT02734472||Hanzhong cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
11294766|NCT02734472||Mei county cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
11294767|NCT02734459|Experimental|tobramycin and dexamethasone ophthalmic test ointment|The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
11294768|NCT02734459|Active Comparator|TobraDex® ointment|The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
11294769|NCT02734446|Active Comparator|Reuterin D3 drops|Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)
11294770|NCT02734446|Placebo Comparator|Placebo|The patients will receive 5 drops/day of placebo for 3 months
11294771|NCT02734433|Experimental|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
11294772|NCT02734420|Experimental|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs; Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up: Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
11294773|NCT02734420|Experimental|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette; Follow up; Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
11294774|NCT02734407|Experimental|Open-Label Arm|"2mg Aflibercept, as needed, intravitreal administration.
~All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.
~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.
~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
11294775|NCT02734394|Experimental|Cardiovascular and strength training exercise|24 sessions (~12 weeks) exercise
11294776|NCT02734368||Healthy non-smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
11294777|NCT02734368||Asymptomatic smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
11294778|NCT02734368||COPD subjects|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
11294779|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
11294780|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
11294781|NCT02734342|Experimental|Exercise, Kinesiophobia and Knee Osteoarthritis|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. During the hour, participants will complete a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improve aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted.
11294782|NCT02734329|Experimental|Zero Ischemia group|Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
11294783|NCT02734329|Active Comparator|Conventional group|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
11294784|NCT02734303||Potentially Exposed NM Residents|residents of the state of New Mexico (NM) potentially exposed to radioactive fallout fromthe Trinity nuclear test conducted in 1945
11294785|NCT02734290|Experimental|Arm A|pembrolizumab + weekly paclitaxel
11294786|NCT02734290|Experimental|Arm B|pembrolizumab + capecitabine
11294787|NCT02734277||Group 1: Detectable C-peptide by MMTT|"Participants with detectable C-peptide at their:
~Last Immune Tolerance Network (ITN) T1DM week 104 study visit,
~Last AbATE (NCT00129259) follow-up visit, or
~Last ITN066AI T1DES visit
~Detectable C-peptide is defined as a value above the lower limit of detection."
11294788|NCT02734277||Group 2:Undetectable C-peptide by MMTT|"Participants without detectable C-peptide at their:
~Last ITN T1DM week 104 study visit,
~Last AbATE follow-up visit, or last
~ITN066AI T1DES visit
~Undetectable C-peptide is defined as a value below the lower limit of detection."
11294789|NCT02734251|Placebo Comparator|Placebo|Dietary Supplement: Placebo
11294790|NCT02734251|Experimental|Relora|Dietary Supplement: Relora, 750 mg/day
11294792|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
11294793|NCT02734225|Experimental|EXPERIMENTAL|Functional recovery Balance training
11294794|NCT02734225|Active Comparator|CONTROL|Functional recovery Balance training Dynamometric Platform training
11294795|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
11294796|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
11294797|NCT02734199||Enrollment Period 1 Cohort|Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
11294798|NCT02734199||Enrollment Period 2 Cohort|Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
11294799|NCT02734199||Enrollment Period 3 Cohort|Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
11294800|NCT02734186|Experimental|Sh|Mono infected with Schistosoma haematobium
11294801|NCT02734186|Experimental|ShMp|Coinfected with Schistosoma haematobium andMansonella perstans
11294802|NCT02734173|Active Comparator|Genotype 1a Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
11294803|NCT02734173|Active Comparator|Genotype 1b Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin
11294804|NCT02734173|Active Comparator|Genotype 1a/1b Compensated Cirrhotic Arm|• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
11294805|NCT02734160|Experimental|Galunisertib + Durvalumab|(Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).
11294806|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
11294807|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
11294808|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
11294809|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
11294810|NCT02734121|Experimental|Educational group intervention|The pre-consultation educational group intervention will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
11294811|NCT02734121|No Intervention|Standard Care|Routine pre-consultation education
11294812|NCT02734108|Experimental|Transcranial direct current stimulation|10 patients will be stimulated twice a day for two weeks or 20 sessions. 2 milli ampere stimulation will be applied for 25 min respecting a period of four hours between sessions.
11294813|NCT02734095|Experimental|Intravascular Ultrasound data|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
11294814|NCT02734082||Elevated Troponin and pathological EC|Patients with acute ischemic stroke with elevated Troponin
11294815|NCT02734082||No elevated Troponin or pathological EC|Patients with acute ischemic stroke without elevated Troponin
11294816|NCT02734082||Elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography
11294817|NCT02734082||No elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography
11294818|NCT02734069||Sarcopenic|Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
11294819|NCT02734069||Non Sarcopenic|Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
11294820|NCT02734056|Experimental|Music|The intervention to be administered is music
11294821|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
11294822|NCT02734030||Control Group|"Knee pain-free females with no history of lower limb injuries serving as a control group.
~."
11294823|NCT02734030||Anterior Knee Pain Group|Females with anterior knee pain syndrome were enrolled in this group.
11294824|NCT02734017|Other|standard course|group not receiving medication review
11294845|NCT02733874|Experimental|test group|Compound Clobetasol Propionate Ointment
11294825|NCT02734017|Other|pharmacist-led standardized medication review|"pharmacist-led standardized medication review including :
~Medical and pharmaceutical admission medication reconciliation and treatment review
~Medical and pharmaceutical medication reconciliation at discharge and treatment review
~Medication Liaison Service"
11294826|NCT02734004|Experimental|Arm 1|Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1
11294827|NCT02734004|Experimental|Arm 2|Includes 2nd stage cohorts (modules 5&7) and 3rd stage cohorts (modules 8&9): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1
11294828|NCT02734004|Experimental|Arm 3|Includes 2nd stage cohort (module 6) and 3rd stage cohort (module 10): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1
11294829|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
11294830|NCT02733991|Active Comparator|Control|MiniMed™640G alone
11294831|NCT02733978|Experimental|ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
11294832|NCT02733978|No Intervention|non-ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
11294833|NCT02733965|Other|standard course|"The patients in the control group will have a classic course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.
~Group workshops entitled Disease and drugs, Dietary and sports activity, Psychology Workshop during which the patient will be able to participate in order to get all the information he needs.
~Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.
~Moreover, in the control arm, a systematic short pharmaceutical interview with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):"
11294834|NCT02733965|Other|Long Pharmaceutical Consultations|The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
11294835|NCT02733952|Active Comparator|tranexamic acid|"bolus intravenous injection of tranexamic acid 10mg/kg (maximum1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1L of saline for 10 h (maximum
~1 g/10 h)"
11294836|NCT02733952|Active Comparator|Pericervical Tourniquet|The tourniquet method will be used where the urinary bladder will be dissected downwards from the lower uterine segment, and then a perforation will be made in the posterior leaflet of the broad ligament bilaterally at the level of uterine isthmus. A tourniquet (using 16- inch Foley catheter) will be passed through the perforation encircling the uterine arteries bilaterally. The Fallopian tubes and the ovaries will be carefully excluded from the line of the tourniquet to avoid direct compression and necrosis. The tourniquet will be released intermittently (at about 30 minutes interval) during the surgery and ﬁnally removed after the repair of the uterus
11294837|NCT02733939|Experimental|Technology intervention|Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
11294838|NCT02733939|No Intervention|Usual care|"Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality (Biståndshandläggaren) where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues."
11294839|NCT02733926|No Intervention|City kindergarten|Children living in a normal city kindergarten that hardly has vegetation in backyards
11294840|NCT02733926|Experimental|adding of vegetation into the backyards.|"Children living in a normal city kindergarten that has plenty of vegetation in backyards.
~Intervention: adding of vegetation into the backyards."
11294841|NCT02733926|No Intervention|Nature kindergarten|Children living in a city kindergarten where children go regularly into a natural forest
11294842|NCT02733900|Experimental|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
11294843|NCT02733900|Other|Control group|Patients with coxarthrosis
11294844|NCT02733887|Experimental|lymphoma|The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
11294847|NCT02733848|Experimental|DIET|A registered dietician (RD) will meet with and thoroughly review the patients diet. The patient will be counseled on a diet lower in refined carbohydrates and higher in protein.
11294848|NCT02733848|Active Comparator|Creon|Subjects will be provided Creon at a dose of 500 units/kg of lipase to be taken with meals and snacks to see if this decreases frequency and severity of hypoglycemia.
11294849|NCT02733848|Placebo Comparator|Placebo|Subjects will be provided placebo and advised to take it with meals and snacks to provide.
11294850|NCT02733835|Experimental|Remifentanil|Remifentanil Patient Controlled Analgesia
11294851|NCT02733822|Experimental|IMP: buccal naloxone (single dose)|0.8 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
11294852|NCT02733822|Experimental|IMP: buccal naloxone (double dose)|1.6 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
11294853|NCT02733822|Active Comparator|Intramuscular (IM) reference|0.8 mg IM injection of 1 mg/ml Naloxone Hydrochloride Injection
11294854|NCT02733822|Active Comparator|Intravenous (IV) reference|0.8 mg IV injection of 1 mg/ml Naloxone Hydrochloride Injection
11294855|NCT02733809|Experimental|Sorafenib|Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.
11294856|NCT02733783|Experimental|septorhinoplasty patients|Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
11294857|NCT02733770|Active Comparator|Sleeve gastrectomy|US DOopler for Patient with BMI of 40 or more than 35 with co-morbidities underwent Sleeve gastrectomy
11294858|NCT02733770|Active Comparator|Mini Gastric Bypass|US DOopler for Patient with BMI of 40 or more than 35 wtih co-morbidities underwent mini gastric bypass
11294859|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
11294860|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
11294861|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
11294862|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
11294863|NCT02733744|Experimental|Fecal Microbiota Transplant|"Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards.
~Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water."
11294864|NCT02733731|Experimental|Chinese Herbal Compound Ointment|This kind of CHCO composed of several chinese herbs,dong quai,angelica,resina draconis and lithospermum.The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks.
11294865|NCT02733731|Active Comparator|Estriol|The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks in two groups.
11294866|NCT02733718|Other|Group 1: no enteral feeding|intervention: NIRS (near-infrared spectroscopy)
11294867|NCT02733718|Other|Group 2: Feeding is reduced by %50|intervention: NIRS (near-infrared spectroscopy)
11294868|NCT02733718|Other|Group 3: Feeding will be continued|intervention: NIRS (near-infrared spectroscopy)
11294869|NCT02733705|Placebo Comparator|Control|normal saline IV plus propofol infusion
11294870|NCT02733705|Active Comparator|Fentanyl|0.5 mcg/kg ideal body weight IV plus propofol infusion
11294871|NCT02733692|Experimental|GURHL Code Smartphone application|Experimental arm will receive the 'Understanding Reproductive Health for Ladeez (GURHL) Code 'app' (application) for their smartphone with sexual health information. The intervention is embedded in the smart phone application. This includes sexual and reproductive health knowledge, plus access to a National Planned Parenthood health educator, and directions to other nearby clinics. Participants will be assessed using A-CASI at 3 months after enrollment.
11294872|NCT02733692|No Intervention|Control|"The control arm will receive usual care. That is, they will receive a web-based flyer. This flyer will include a list of clinics and other trusted available resources, but without hyperlinks.
~Participants will be assessed using A-CASI at 3 months after enrollment."
11294873|NCT02733679|Experimental|Ataxia Telangiectasia|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
11294874|NCT02733679|Active Comparator|Healthy controls|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
11294875|NCT02733666|Experimental|Absorbable screw group|One absorbable screw was used for fixation in the experimental group
11294876|NCT02733666|No Intervention|K-wires group|two 1.8-mm K-wires were used for the fixation in the control group. The K-wires were the most common used by the orthopaedic surgeon.
11294877|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
11294878|NCT02733640|Active Comparator|Pantoprazole|Drug: Pantoprazole 40 mg once-daily
11294879|NCT02733640|Experimental|Ranitidine|Drug: Ranitidine 150 mg twice-daily
11294880|NCT02733627|Experimental|BI 1467335 low dose|
11294881|NCT02733627|Experimental|BI 1467335 medium dose|
11294882|NCT02733627|Experimental|BI 1467335 high dose|
11294883|NCT02733627|Placebo Comparator|Placebo|
11294884|NCT02733614|Experimental|SRX246|SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks
11294885|NCT02733614|Placebo Comparator|Placebo|oral administration, capsules, daily for 8 weeks
11294886|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
11294887|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
11294888|NCT02733575|Other|Compassion Focused Therapy|Intervention
11294889|NCT02733562||Binge eaters|Classificated preoperatively
11294890|NCT02733562||Volume eaters|Classificated preoperatively
11294896|NCT02733536|Experimental|Scenario B|Cervical immobilization using a standard Patriot cervical extraction collar (Oessur Americas, Foothill Ranch, CA, USA), applied to the manikin's neck by an instructor.
11294897|NCT02733536|Experimental|Scenario C|Cervical immobilization using a vacuum mattress (Ferno-Washington, Inc. Wilmington, OH, USA), applied to the manikin's neck by an instructor
11294898|NCT02733523|Experimental|"Program Sentirnos bien"|"The intervention Program Sentirnos bien is based around a group dynamic, held once a week during 3 months, aimed at:
~Promoting the uptake of self-care healthy habits
~Promoting social capital at individual level:
~Promoting health literacy"
11294899|NCT02733523|No Intervention|Control arm|The control arm will receive no intervention. Once the trial is finished, i.e. after the last follow-up evaluation, this arm will receive the intervention (waiting-list approach).
11294900|NCT02733510||subclinical rejection group|patients whose protocol biopsy outcome is subclinical rejection and treat with steroid pulse therapy (methylprednisolone)
11294901|NCT02733510||No rejection group|patients whose protocol biopsy outcome is normal
11294902|NCT02733497|Active Comparator|Sympathectomy Group|Excision of ganglia at T3 level
11294903|NCT02733497|Active Comparator|Sympathicotomy Group|Resection of sympathetic chain at T3 level
11294904|NCT02733484|Experimental|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
11294905|NCT02733484|Placebo Comparator|Placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
11294906|NCT02733471|Experimental|Lidocaine|Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.
11294907|NCT02733471|Placebo Comparator|Control|Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy
11294908|NCT02733458|Experimental|GELAD/Radiation|Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
11294909|NCT02733445||dasatinib cohort|Patients with CML receiving dasatinib
11294910|NCT02733445||nilotinib cohort|Patients with CML receiving nilotinib
11294911|NCT02733432|Experimental|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
11294912|NCT02733432|Experimental|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
11294913|NCT02733432|Active Comparator|Cohort 3|Oral fluconazole (150mg) administered on day 1.
11294914|NCT02733419|Experimental|Enfuvirtide + OB (Not Randomized)|Participants will receive enfuvirtide 90 milligram (mg) twice daily (b.i.d.) and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants not meeting the randomization criteria will receive enfuvirtide 90 mg b.i.d and OB for next 24 weeks (up to Week 52).
11294915|NCT02733419|Experimental|Enfuvirtide + OB (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive enfuvirtide 90 mg b.i.d. and OB for next 24 weeks (up to Week 52).
11294916|NCT02733419|Experimental|OB alone (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive OB alone for next 24 weeks (up to Week 52).
11294917|NCT02733406|Other|Target Controlled Infusion|This group of patients will have their anaesthesia induced with Target Controlled Infusion (TCI)
11294918|NCT02733406|Other|Velocity Controlled Infusion|This group of patients will have their anaesthesia induced with Velocity Controlled Infusion (VCI)
11294919|NCT02733393|Experimental|SPG Block|
11294920|NCT02733380|Experimental|Chidamide combined with VDDT regimen|Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles
11294921|NCT02733367|Experimental|Infacort|Infacort® granules
11294922|NCT02733354||Control Group|Control Group:perform routine oral education.Both groups were asked to complete kidney disease knowledge questionnaire before education.
11294923|NCT02733354||Intervention Group|Intervention Group ：On the basis of Control Group, watching video demonstration of each type of dialysis. The videos were based on real cases, showing patients with peritoneal and hemodialysis life modes, lasting for 20 minutes respectively for each type of dialysis. Both groups were asked to complete kidney disease knowledge questionnaire before education.
11294924|NCT02733341|Active Comparator|Oral Ticagrelor|Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
11294925|NCT02733341|Active Comparator|Intravenous Cangrelor|Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
11294926|NCT02733328||AKI Patients|Patients with AKI
11294927|NCT02733328||Non-AKI Patients|Patients without AKI
11294928|NCT02733315|Experimental|DCMP|
11294929|NCT02733302|Experimental|Hope theory|
11294930|NCT02733276|Experimental|Electroacupuncture|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: 6 needles in each lower limb, 8 abdominal, 3 in upper extremity and 3 on the front
11294931|NCT02733276|Sham Comparator|Electroacupuncture sham|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: needles on each forearm on nonselective points
11294932|NCT02733276|No Intervention|Control|Initially no intervention. In a second period in this group we will perform EAP
11294933|NCT02733263|Experimental|Group 1|Participants will first consume in the the order of 0 g RMD, 15 g RMD, 25 g RMD for 3 weeks each
11294934|NCT02733263|Experimental|Group 2|Participants will first consume RMD in the the order of 0 g RMD, 25 g RMD, 15 g RMD for 3 weeks each
11294935|NCT02733263|Experimental|Group 3|Participants will first consume RMD in the the order of 15 g RMD, 0 g RMD, 25 g RMD for 3 weeks each
11294936|NCT02733263|Experimental|Group 4|Participants will first consume RMD in the the order of 15 g RMD, 25 g RMD, 0 g RMD for 3 weeks each
11294937|NCT02733263|Experimental|Group 5|Participants will first consume RMD in the the order of 25 g RMD, 15 g RMD, 0 g RMD for 3 weeks each
11294938|NCT02733263|Experimental|Group 6|Participants will first consume RMD in the the order of 25 g RMD, 0 g RMD, 15 g RMD for 3 weeks each
11294939|NCT02733250|Other|Pembrolizumab + Nab-Paclitaxel|"Phase I will determine the recommended Phase II dose (RP2D) of nab-paclitaxel when given in combination with pembrolizumab. Escalation for nab-paclitaxel will be conducted following a 3+3 design. First cohort of 3 patients will receive nab-paclitaxel on Days 1 and 8 at a dose of 100 mg/m2 intravenous (IV) in combination with pembrolizumab at 200 mg IV every 3 weeks. If no dose limiting toxicities (DLT) occur, the dose of nab-paclitaxel will be escalated to 100 mg/m2 on Days 1, 8 and 15 every 3 weeks. The dose of pembrolizumab will remain the same. If no DLTs occur, dose level 2 will be defined as the RP2D. In the Phase II, pembrolizumab will be administered at 200 mg IV every 3 weeks and nab-paclitaxel will be administered at the RP2D."
11294940|NCT02733237|Experimental|male oxytocin group|male subjects with oxytocin treatment
11294941|NCT02733237|Experimental|female oxytocin group|female subjects with oxytocin treatment
11294942|NCT02733237|Placebo Comparator|male placebo group|male subjects with placebo treatment
11294943|NCT02733237|Placebo Comparator|female placebo group|female subjects with placebo treatment
11294944|NCT02733211|Experimental|Closed Loop System|MD-Logic automated insulin delivery system - all subjects wearing the study system during nights over 4 weeks
11294945|NCT02733211|Active Comparator|Sensor augmented pump therapy|Sensor augmented pump therapy - all subjects are using sensor augmented pump therapy over 4 weeks
11294946|NCT02733198|Experimental|Prognosis-guided|Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
11294947|NCT02733198|No Intervention|Standard medical therapy|Duration of bed rest and duration of length of stay will be decided by the attending physician.
11294948|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
11294949|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
11294950|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
11294951|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
11294952|NCT02733159|Experimental|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
11294953|NCT02733146||cardiac arrest patients|Patients who has suffered a cardiac arrest
11294954|NCT02733133|Experimental|Uncovered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and cover the area before engaging in contact with the female partner.
11294955|NCT02733133|Experimental|Covered|Half of the male partners in each cohort will apply the Testagen® TDS Testosterone 5% HypoSpray® and will not cover the area before engaging in contact with the female partner.
11294956|NCT02733120|Experimental|Healthy matched controls|Study Day: The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
11294957|NCT02733120|Experimental|Adults with Autism Spectrum Disorder|The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
11294958|NCT02733107|Other|Apatinib+Etoposide|Apatinib combined with Etoposide
11294959|NCT02733094|Experimental|Open-label|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.
11294960|NCT02733081|No Intervention|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
11294961|NCT02733081|Experimental|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
11294962|NCT02733068|Experimental|HPV-16/18 vaccine|Including 6000 participants who received the HPV-16/18 vaccine 0.5ml.
11294963|NCT02733068|Placebo Comparator|HPV-16/18 placebo|Including 6000 participants who received the HPV-16/18 placebo 0.5ml.
11294964|NCT02733055|Experimental|subjects|participant undergoing posturographic evaluation
11294965|NCT02733042|Experimental|Arm A: Durvalumab + Lenalidomide ± Rituximab|"Participants assigned to Arm A will receive:
~Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and
~Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of:
~Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or
~All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL
~Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5.
~All treatment cycles were 28 days."
11294966|NCT02733042|Experimental|Arm B: Durvalumab + Ibrutinib|"Participants assigned to Arm B will receive:
~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13
~Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason.
~All treatment cycles were 28 days."
11294967|NCT02733042|Experimental|Arm C: Durvalumab + Rituximab ± Bendamustine|"Participants assigned to Arm C will receive:
~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13
~Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose)
~Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6.
~All treatment cycles were 28 days."
11294968|NCT02733042|Experimental|Arm D: Durvalumab Monotherapy|Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
11294969|NCT02733029|Experimental|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
11294970|NCT02733029|No Intervention|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
11294971|NCT02733003|Experimental|Women's Health CoOp (WHC)|This is an adapted behavioral intervention for women in South Africa, who use alcohol and other drugs and are living with HIV or at risk of acquiring HIV.
11294972|NCT02732990|Experimental|Exercise training - Whole body exercise|Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks
11294973|NCT02732990|Experimental|Exercise training - One-legged exercise|Control subjects will train high intense one-legged exercise for 6 weeks
11294974|NCT02732990|Experimental|Exercise training - 2-legged cycling CHF|CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks
11294975|NCT02732990|Experimental|Exercise training - CHF|CHF Patients will train high intense one-legged exercise for 6 weeks
11294976|NCT02732977|Other|expert system|System for predicting patients heart failure, that can predict response to a personalized treatment from the analysis of a set of data (images, physiological data , treatment outcomes ) .
11294977|NCT02732964|No Intervention|Control|baseline hemodynamics and anxiety screen; no music
11294978|NCT02732964|Experimental|Pandora Music|A study investigator will create a station in the Pandora® music application based on the patient's preferred music genre or artist.
11294979|NCT02732964|Experimental|Mozart Music|A study investigator will turn on a playlist of pre-selected Mozart music.
11294980|NCT02732951|Experimental|BI 1026706|
11294981|NCT02732951|Active Comparator|Placebo|
11294982|NCT02732938|Experimental|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing
~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
11294983|NCT02732925|Sham Comparator|Arm 1 - Sham Procedure|"Sham Procedure & Conservative Treatment
~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.
~Below is a list of the conservative management they will be managed by their Doctor:
~Bisphosphonates
~Pain relief
~Systemic chemotherapy for Myeloma disease
~Bed rest
~Radiotherapy
~Physiotherapy
~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used."
11294984|NCT02732925|Active Comparator|Arm 2 - Balloon Kyphoplasty|"Balloon Kyphoplasty & Conservative Treatment - Interventional Arm
~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.
~Below is a list of the conservative management they will be managed by their Doctor:
~Bisphosphonates
~Pain relief
~Systemic chemotherapy for Myeloma disease
~Bed rest
~Radiotherapy
~Physiotherapy
~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used."
11294985|NCT02732912|Active Comparator|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
11294986|NCT02732912|Experimental|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
11294987|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
11294988|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
11294989|NCT02732886|Experimental|Betafoam®|Brand name: Betafoam® Generic term: Wound dressing with 3% povidone iodine
11294990|NCT02732886|Active Comparator|Medifoam®|Brand name: Medifoam® Generic term: Wound dressing
11294991|NCT02732873|Experimental|FibroFix|
11294992|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
11294993|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
11295354|NCT02730169|Experimental|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
11294994|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
11294995|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 30)
~After the screening procedures confirms patient eligibility:
~Molecular Profiling will be performed on clinical sample
~pPDX generation for in vivo drug testing
~In vitro organoid culture generation (if sufficient fresh tissue available)
~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
11294996|NCT02732847|Other|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
11294997|NCT02732847|Other|Usual|usual date
11294998|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
11294999|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
11295000|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
11295001|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
11295002|NCT02732821||Gastric Per Oral Endoscopic Myotomy|All patients presenting with Gastroparesis will undergo Per oral endoscopic gastric myotomy
11295003|NCT02732808|Experimental|poor ovarian responder|The women with diagnose of poor ovarian responder after IVF/ICSI treatments underwent ovulation stimulation and egg collection in the same IVF/ ICSI cycle ( Shanghai protocol)
11295004|NCT02732795|Experimental|Morphine dosing|Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
11295005|NCT02732782|Experimental|Isometric exercise|Isometric exercise (90% maximum voluntary contraction (MVC), 12 weeks, 4 times a week, 5 sets of 4 repetitions a 3 seconds)
11295006|NCT02732782|Active Comparator|Eccentric exercise|"Eccentric training (Alfredson approach, 12 weeks, 2 sets per day with extended and two sets per day with bended knee, 15 repetitions per set)"
11295007|NCT02732782|No Intervention|Control|Control, no intervention
11295008|NCT02732769|Active Comparator|Group treated by radiosurgery with stereotaxic frame|Subjects will receive a radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)
11295009|NCT02732769|Experimental|Group treated by radiosurgery with the thermoformed mask|Subjects will receive a radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®
11295010|NCT02732756|Experimental|Sleep Restriction|The Sleep Restriction condition will allow 6.5 hours in bed, which in previous research results in an average of 6.1-6.3 hours of nightly sleep. This condition reflects a realistic dose of sleep restriction (similar to the school-night sleep of 15-20% of healthy adolescents) that has been shown to be feasible and to induce daytime sleepiness, inattention, and irritability/moodiness in typically developing adolescents.
11295011|NCT02732756|Experimental|Sleep Extension|The Sleep Extension condition will allow adolescents to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep), which (a) is how long adolescents sleep during controlled trials of sleep satiation and naturally on non-school nights, (b) has been shown to result in a well-rested state, and (c) matches clinical recommendations for adolescents.
11295012|NCT02732743|Other|Food Supplement Physiomanna® Baby|Dosage: 1g/kg body
11295013|NCT02732730|Experimental|PrEP Acceptor|"For those women who choose to accept PrEP (Truvada), the following adherence support package will be provided:
~Cognitive Behavioral Theory adherence support sessions
~Two-way SMS communications
~Optional monthly adherence support clubs Drug level counseling for those randomized to that extra intervention (1:1)"
11295014|NCT02732730|No Intervention|PrEP Decliner|Standard of care
11295015|NCT02732717||abnormal ultrasound index|twin pregnancy with abnormal ultrasound index
11295016|NCT02732717||normal ultrasound index|twin pregnancy with normal ultrasound index
11295017|NCT02732704|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System
11295018|NCT02732691|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
11295019|NCT02732678|Experimental|Cohort of a dose of Propranolol 80 mg/day|
11295020|NCT02732678|Experimental|Cohort of a dose of Propranolol 120 mg/day|
11295021|NCT02732678|Experimental|Cohort of a dose of Propranolol 160 mg/day|
11295022|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
11295023|NCT02732626|Active Comparator|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
11295024|NCT02732626|Experimental|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
11295025|NCT02732613|Experimental|Actual weight Group|Patients in Actual weight Group: The selection of Laryngeal Mask Airway classic will be based on actual body weight, followed the recommendations of manufacturer (size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
11295026|NCT02732613|Experimental|Ideal weight Group|Patients in Ideal weight Group: The selection of Laryngeal Mask Airway classic will be based on ideal body weight, followed the recommendations of manufacturer ( size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
11295027|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
11295028|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
11295029|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
11295030|NCT02732574|Experimental|OPEP Device Treatment|Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
11295031|NCT02732574|Sham Comparator|SHAM Device|Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
11295032|NCT02732561|Sham Comparator|Sham Device|Sham device
11295033|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
11295034|NCT02732548|Active Comparator|NPWT Only|Study subjects who are randomized to the control arm will be treated with Negative Pressure Wound Therapy (NPWT) and additional standard care treatments. No cellular or acellular biological tissue scaffold will be allowed for subjects in this study arm for the first 6 weeks of the study. Subjects who are randomized to this arm and who do not experience at least a 50% surface area reduction of the study wound by the 6 week study visit will have the option to cross over into the NPWT + MIRODERM treatment arm.
11295035|NCT02732548|Experimental|NPWT + MIRODERM|Subjects in this arm will receive NPWT and standard care, plus application(s) of the MIRODERM product.
11295036|NCT02732522|Experimental|Misoprostol sublingual|
11295037|NCT02732522|Active Comparator|Misoprostol vaginal|
11295038|NCT02732509||Lean|Body mass index less than 25 kg/m2
11295039|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
11295040|NCT02732496|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
11295041|NCT02732496|Placebo Comparator|Youth Appropriate Online Games|Engaging games not designed to improve cognition
11295042|NCT02732483|Experimental|Endo-Clot(TM)|
11295043|NCT02732470|Experimental|Qi Gong|The effect of Qi Gong training on quality of life in patients with systemic lupus erythematosus
11295044|NCT02732444||COPD and APD patients in LTOT|• COPD and APD patients in LTOT
11295045|NCT02732444||Healthy Control|• Patients without significant cardiorespiratory disease, matched for age and body mass index with the other group.
11295046|NCT02732431|Other|trisomy 21|Parents will complete two sleep symptom questionnaires (PSQ-SRBD and CSHQ) and children will be evaluated by a paediatric pulmonologist and allergist with skin allergy test. An Ear, Nose and Throat specialist will complete two questionnaires (CAS-15 and SCR) carrying a nasopharyngoscopy. Then, children will perform an overnight polysomnography in the Department of Paediatric Functional Investigations of University Hospital in Nice.
11295047|NCT02732418|Experimental|Depo-Provera CI 45 mg|a single subcutaneous (SC) injection of 45 mg/0.3 mL
11295048|NCT02732418|Experimental|Depo-Provera CI 75 mg|a single subcutaneous (SC) injection of 75 mg/0.5 mL
11295049|NCT02732418|Experimental|Depo-Provera CI 105 mg|a single subcutaneous (SC) injection of 105 mg/0.7 mL
11295050|NCT02732418|Active Comparator|Depo-subQ 104|a single subcutaneous (SC) injection of 104 mg/0.65 mL
11295051|NCT02732405|Experimental|MK5172 /MK8742|
11295052|NCT02732392|Experimental|lymphadenectomy|
11295053|NCT02732379|Experimental|Lavender Aromatherapy|Aromatherapy with lavender essential oil.
11295054|NCT02732379|Experimental|Rose Aromatherapy|Aromatherapy with rose essential oil
11295055|NCT02732379|Experimental|Ginger Aromatherapy|Aromatherapy with ginger essential oil
11295056|NCT02732379|Placebo Comparator|Placebo Aromatherapy|Aromatherapy with pure water
11295057|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
11295058|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
11295059|NCT02732353|Active Comparator|Minced beef|Minced beef
11295060|NCT02732353|Experimental|Hydrolyzed beef|Hydrolyzed beef
11295061|NCT02732340|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
11295062|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
11295063|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
11295064|NCT02732314|Experimental|Investigational OTC Cream|Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
11295065|NCT02732314|Placebo Comparator|Placebo Cream|Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
11295066|NCT02732314|Active Comparator|Cosmetic Eczema Cream|Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
11295067|NCT02732314|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor.
~Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions."
11295068|NCT02732288|Experimental|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
11295069|NCT02732288|Experimental|Healthy volunteers|Melatonin 3mg, orally, at 8pm
11295070|NCT02732275|Experimental|DS-3201b|
11295071|NCT02732262|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
11295072|NCT02732262|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
11295073|NCT02732262|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
11295074|NCT02732249|Active Comparator|Triple regimen group|Esomeprazole 20mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
11295075|NCT02732249|Experimental|Low metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg bid for 14 days
11295076|NCT02732249|Experimental|High metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
11295077|NCT02732223|Experimental|Functional treatment|Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.
11295078|NCT02732223|Placebo Comparator|Control treatment|Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets
11295079|NCT02732197||Sedation (S)|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
11295080|NCT02732197||No sedation (NS)|Parturients who did not receive any sedative agent after the spinal anesthesia performance.
11295081|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
11295082|NCT02732171|Other|Screening Bone Marrow Aspirate|All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs).
11295083|NCT02732158|Experimental|Nutrition Products|Two servings per day of the sachet study product mixed with water; 1 carotenoid capsule per day
11295084|NCT02732145|Placebo Comparator|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
11295085|NCT02732145|Placebo Comparator|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
11295086|NCT02732145|Placebo Comparator|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
11295355|NCT02730169|Placebo Comparator|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
11295087|NCT02732145|Active Comparator|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).
~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
11295088|NCT02732132|Active Comparator|Ketamine and Midazolam|ketamine 1 mg/kg midazolam 0.1 mg/kg
11295089|NCT02732132|Experimental|Propofol and Fentanyl|propofol 1 mg/kg fentanyl 1 mcg/kg
11295090|NCT02732119|Experimental|ribociclib + everolimus + exemestane|ribociclib with everolimus and exemestane daily
11295091|NCT02732093|Active Comparator|stellate block|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml of lidocaine 2% after routine induction of general anesthesia and before endotracheal intubation
11295092|NCT02732093|Placebo Comparator|control|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml normal saline (Na.Cl 0.9%) (control group) after routine induction of general anesthesia and before endotracheal intubation
11295093|NCT02732080|Experimental|Deferred coronary stenting|In this arm, after establishing TIMI -3 flow in infarct related artery with balloon angioplasty, patients will undergo stent implantation when coronary autoregulatory function was recovered (initial hyperemic flow was subsided and baseline resistance was increased). Recovery of the auto regulatory function will be determined by measuring microvascular flow and resistance. After stenting microvascular flow / resistance will continue to be monitored using pressure/flow sensor tipped guide wire until the completion of 1 hour follow up period.
11295094|NCT02732080|Active Comparator|Immediate stenting|In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
11295095|NCT02732054|Active Comparator|HIV-Group 1|Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, and 6
11295096|NCT02732054|Experimental|HIV-Group 2|Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, 2, and 6
11295097|NCT02732015|Experimental|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
11295098|NCT02732015|Active Comparator|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
11295099|NCT02732002|Experimental|OCBRA group.|This group of patients will follow the proposed methodological approach for work related injuries rehabilitation.
11295100|NCT02731989||study group|The surgeon will estimate the size difference between the undescended and the normally located testis. Independently the ultrasonographer will measure the true size of both testes in the study group.
11295101|NCT02731989||Control group|The same measurments will be done by the surgeon and the ultrasonographer on boys without cryptorchism.
11295102|NCT02731976|Experimental|GFD|After instruction of a dietician, participants adhered to a gluten-free diet for 4 weeks.
11295103|NCT02731963|Experimental|Mechanical bowel preparation|80 Patients who received mechanical bowel preparation with 4 packets of polyethylene glycol in 4 liters of water, 4 hours before intervention.
11295104|NCT02731963|No Intervention|No mechanical bowel preparation|81 Patients who received clear liquid diet 1 day before intervention.
11295105|NCT02731950|Active Comparator|A magnesium|"Consists of 20 patients:
~Each receive bupivacaine 0.125% with 5% magnesium sulfate by infusion through a small diameter multi-hole soft catheter generally used for epidural analgesia positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 hours postoperative. A bolus of 5 ml of the study solution will be injected in the catheter after aspiration test before connection to infusion pump that delivers continuous infusion pump that delivers continuous infusion at a fixed rate of 5 ml/h.
~postoperative : 25 µg fentanyl for breakthrough pain. placebo will be given in same intravenous instead of paracetamol and ketorolac of group B , to keep the investigator blinded"
11295106|NCT02731950|No Intervention|B control|"Consists of 20 patients:
~saline as placebo infusion through a small diameter multi-hole soft catheter positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 Postoperative pain control will be managed with 1gm paracetamol /6 hr, Ketorolac 30 mg every 8-12 hour .25 µg fentanyl for breakthrough pain."
11295107|NCT02731937|Other|GE Healthcare CT Revolution (CT scanner)|Each subject will be scanned twice: the first time will be the subjects' clinically indicated CT exam and the second scan will be performed on the GE Healthcare CT Revolution (CT scanner) both scans will will be obtained.
11295108|NCT02731924||Ultrasound for Appendicitis|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected appendicitis
11295109|NCT02731911||Ozurdex® (dexamethasone intravitreal implant)|Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
11295110|NCT02731885|Experimental|Fasted Conditions|50mg of ABX464 (two 25mg capsules) /Fasted
11295111|NCT02731885|Experimental|Fed Conditions|50mg of ABX464 (two 25mg capsules) /Fed
11295112|NCT02731872|Experimental|High Flow humidification system|In addition to their usual oxygen apparatuses, the treatment group will have an Airvo humidifier system installed in the home. The supplied oxygen flow will be entrained along with room air through the Airvo humidification system. this combined respiratory gas will then be warmed and humidified and delivered to the patient via a nasal cannula. The total respiratory gas flow rate will be between 20-25 l/min, depending on participant´s preference. Then the oxygen fraction is adjusted until the subjects target oxygen saturation levels are achieved.
11295113|NCT02731872|No Intervention|Standard oxygen therapy|The control group will continue receiving the standard oxygen therapy prescribed by the department
11295115|NCT02731846|Experimental|FF/UMEC/VI (100/62.5/25 mcg) + placebo|Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
11295116|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg|Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
11295117|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + placebo|Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
11295118|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
11295119|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
11295120|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
11295121|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
11295122|NCT02731807|Experimental|Dose A, B, C, D, E|All participants will receive all doses throughout the course of the study.
11295123|NCT02731807|Experimental|Dose D, E, C, B, A|All participants will receive all doses throughout the course of the study.
11295124|NCT02731807|Experimental|Dose C, D, E, A, B|All participants will receive all doses throughout the course of the study.
11295125|NCT02731807|Experimental|Dose E, D, C, B, A|All participants will receive all doses throughout the course of the study.
11295126|NCT02731794|Experimental|LVA group|LVA group: left ventricular assist group.
11295127|NCT02731794|Active Comparator|BiVA group|BiVA group: Biventricular assist group.
11295128|NCT02731768|Active Comparator|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively. They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
11295129|NCT02731768|Experimental|Social support-enhanced|Participants will receive the same intervention components as the Standard group, as well as two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
11295130|NCT02731755|Active Comparator|Oat intervention|67.7g oatflake and 22.5g oatbran concentrate - single intake (mixed with water)
11295131|NCT02731755|Placebo Comparator|Control|39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder, 6.5g cellulose and mixed with water
11295132|NCT02731742|Experimental|Dose A MK-1966 + Dose A SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
11295133|NCT02731742|Experimental|Dose A MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
11295134|NCT02731742|Experimental|Dose B MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
11295135|NCT02731742|Experimental|Dose C MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
11295136|NCT02731742|Experimental|Part B Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
11295137|NCT02731742|Experimental|Part C Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
11295138|NCT02731729|Experimental|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
11295139|NCT02731729|Experimental|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
11295140|NCT02731716|Experimental|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
11295141|NCT02731716|Experimental|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
11295468|NCT02729428||Exercise trained older adults|Exercise trained older adults between the age of 55-75 years.
11295142|NCT02731716|Experimental|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
11295143|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
11295144|NCT02731690|Experimental|Open Label UX001, 6g/day|
11295145|NCT02731677|Experimental|Experimental|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
11295146|NCT02731677|No Intervention|Control|The control group no suffered intervention.
11295147|NCT02731664|Experimental|GLP-1|Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
11295148|NCT02731664|Placebo Comparator|Control|Intravenous saline
11295149|NCT02731651|Active Comparator|Open Hysterectomy|Open hysterectomy was performed with taking one of the ovaries at the beginning and the other ovary was removed at the end of the surgery.
11295150|NCT02731651|Active Comparator|LaparoscopicAssistedVaginalHysterectomy|Surgery in Group 2 (LAVH): Laparoscopic Assisted Vaginal Hysterectomy was performed with taking one of the ovary at the beginning of the procedure and the other ovary was removed at the end of the surgery.
11295151|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
11295152|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
11295153|NCT02731625|Experimental|Kettlebell Training|Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
11295154|NCT02731625|Active Comparator|Army Physical Readiness Training|Army Physical Readiness Training (PRT) per Army Field Manual 7-22
11295155|NCT02731612|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
11295156|NCT02731612|Placebo Comparator|Placebo|Placebo added to current treatment for 6 weeks
11295157|NCT02731599|Experimental|treadmill training|20-minutes treadmill training per day, 6 times a week, for 4 weeks
11295158|NCT02731586|Experimental|osseointegration using Allogenic MSC's|Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA.
11295159|NCT02731573|Experimental|Treatment arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.
11295160|NCT02731573|Other|Control arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.
11295161|NCT02731560|Other|Single Arm|Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs
11295162|NCT02731547|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
11295163|NCT02731547|No Intervention|Control group|
11295164|NCT02731534|Experimental|Z-213|
11295165|NCT02731534|Active Comparator|Saccharated Ferric Oxide|
11295166|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
11295167|NCT02731508|Experimental|True stimulation|True repetitive bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, daily 20 minutes for 10 sessions
11295168|NCT02731508|Sham Comparator|Sham stimulation|Repetitive bihemispheric transcranial direct current stimulation, as the experimental stimulation condition but only for 30 seconds
11295169|NCT02731495|Experimental|EGCG|Participants were randomly divided based on age, sex and severity of TBI in two groups. Randomization lists was computer-generated by a statistician and participants, project managers and employees at the clinic are completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients received EGCG supplement was in the form of 400 mg oral capsules with a purity of 80% catechin. EGCG powder of each capsule was dissolved in 10 ml deionized water and given to patients via gavage (1 capsule per day) for a week.
11295170|NCT02731495|Placebo Comparator|Placebo|Placebo group only received 10 ml of deionized water via gavage for a week.
11295171|NCT02731482|Experimental|Training Group|Patients with bronchiectasis in home-based pulmonary rehabilitation
11295172|NCT02731482|Active Comparator|Control Group|Patients with bronchiectasis in usual care and recommendations for performing exercises
11295173|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
11295174|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
11295175|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
11295176|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
11295177|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
11295178|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
11295179|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
11295180|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
11295181|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
11295182|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
11295183|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
11295184|NCT02731456|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude.
11295185|NCT02731443||ESx|Epilepsy patients undergoing elective surgical resection of brain tissue; study group: epilepsy surgery=ESx.
11295186|NCT02731443||DE|Epilepsy patients undergoing elective depth electrodes insertion in general anesthesia; control group: depth electrodes=DE.
11295187|NCT02731430|Active Comparator|group I: morphine group|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
11295188|NCT02731430|Placebo Comparator|group II: control group|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
11295189|NCT02731417|Experimental|Urinary retention-group 1|For women with post partum urinary retention designated for experimental treatment.
11295190|NCT02731417|Active Comparator|Urinary retention-group 2|For women with post partum urinary retention designated for current departmental protocol treatment.
11295191|NCT02731404|Other|IPPV ventilation|standard intermittent positive pressure ventilation in patients undergoing laparoscopic cholecystectomy
11295192|NCT02731404|Other|HFJV ventilation|high frequency jet ventilation in patients undergoing laparoscopic cholecystectomy
11295193|NCT02731391|Experimental|Mesh repairment|patients undergoing pelvic floor Reconstruction using mesh
11295194|NCT02731391|Active Comparator|Tradition Neoplasty|patients undergoing traditional surgical approaches
11295195|NCT02731378|Experimental|EPO plus sustained iron dextran|Group 1, EPO treatment at the original dose plus IV iron dextran 200 mg every three weeks (Q3W) for 15 weeks
11295196|NCT02731378|Experimental|EPO plus aggressive iron dextran|Group 2, EPO treatment at the original dose plus IV iron dextran 100 mg, twice a week (BIW) for five weeks
11295197|NCT02731378|Active Comparator|Double EPO|Group 3, the control group, doubling the EPO dose without preplanned iron supplementation
11295198|NCT02731365|Experimental|DBS LFP Activa PC+S|The study aims at testing a slightly modified device (battery) that is similar to the approved system that has the potential of offering future patients a closed loop system with automatic adjustments of stimulation. The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming.
11295199|NCT02731352|Experimental|iodine-131 Refractory/Resistant Differentiated Thyroid Cancer|iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer
11295200|NCT02731339|Experimental|Women with Urinary incontinence|
11295201|NCT02731339|Experimental|Women without Urinary incontinence|
11295202|NCT02731326|Experimental|iHEART|Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
11295203|NCT02731326|No Intervention|Usual Care|Participants will continue with usual care with their physician.
11295204|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
11295205|NCT02731300|Active Comparator|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
11295206|NCT02731300|Sham Comparator|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
11295207|NCT02731287|Experimental|Timolol|Timolol maleate 0.5% topical solution; 50% of the patients treated (randomized)
11295208|NCT02731287|Placebo Comparator|Placebo|Saline topical solution; 50% of the patients treated (randomized)
11295209|NCT02731274|Experimental|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
11295210|NCT02731274|No Intervention|Control|
11295211|NCT02731261|Experimental|Experimental|
11295212|NCT02731261|No Intervention|Control|
11295213|NCT02731235|Other|Control|Prophylactic stroke medication and recommendations for lifestyle changes
11295214|NCT02731235|Active Comparator|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
11295215|NCT02731209|Experimental|catheter insertion for 2 weeks|50 randomized patients that will do urodynamic urinary examination and will be inserted urinary catheter for 2 weeks
11295216|NCT02731209|No Intervention|follow up|50 randomized patients that will do urodynamic urinary examination and will be regularly followed by nephrologist
11295217|NCT02731196|Experimental|Early exercise intervention group|Education, stabilization and neurodynamic level one exercises will be provided to the intervention group within one to two weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will be provided with education, stabilization and neurodynamic level two exercises and a pedometer to monitor step count between week 4 and week 10 following the surgery.
11295218|NCT02731196|Active Comparator|Late exercise intervention group|Education, stabilization and neurodynamic level one and two exercises will be provided to the active comparator group within 4-6 weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will also be given instructions and a pedometer to monitor step count between week 4 and week 10 following the surgery.
11295219|NCT02731183|Experimental|FMT|Patients included will receive standard FMT, and then will be followed up for 8 weeks.
11295220|NCT02731170|Experimental|rehabilitation treatment (MIRT)|MIRT consists of a 4-week physical therapy. daily sessions are subdivided in: motor treatment (2 hour), occupational therapy (1 hour) and speech Therapy (1 hour)
11295253|NCT02730975|Experimental|AA reduced dose-fat diet (B)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a fat breakfast
11295221|NCT02731157|Experimental|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
11295222|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
11295223|NCT02731144|Experimental|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
11295224|NCT02731144|Active Comparator|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
11295225|NCT02731131|Experimental|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
11295226|NCT02731131|Experimental|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
11295227|NCT02731118|Experimental|Placebo and Salovum|6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
11295228|NCT02731118|Experimental|Salovum and placebo|6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14
11295229|NCT02731105|Active Comparator|Arm 1|Acnatac® Gel on left face and Epiduo® Gel on right face once daily for three weeks
11295230|NCT02731105|Active Comparator|Arm 2|Epiduo® Gel on left face and Acnatac® Gel on right face once daily for three weeks
11295231|NCT02731092|Experimental|Lactoferrin 100 mg/kg|100 mg/kg enteral administration daily for 30 days
11295232|NCT02731092|Experimental|Lactoferrin 200 mg/kg|200 mg/kg enteral administration daily for 30 days
11295233|NCT02731092|Experimental|Lactoferrin 300 mg/kg|300 mg/kg enteral administration daily for 30 days
11295234|NCT02731079|Active Comparator|Covidien|Group that will have sleeve gastrectomy performed using the Covidien iDrive powered stapler with absorbable polymer membrane staple line reinforcement.
11295235|NCT02731079|Active Comparator|Ethicon|Group that will have sleeve gastrectomy performed using the Ethicon Echilon powered stapler with absorbable polymer membrane staple line reinforcement.
11295236|NCT02731066|Experimental|High pro, carbo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
11295237|NCT02731066|Experimental|Standard pro, carbo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
11295238|NCT02731066|Experimental|High pro, placebo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
11295239|NCT02731066|Experimental|Standard pro, placebo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
11295240|NCT02731053|Experimental|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
11295241|NCT02731053|No Intervention|Control|Participants will receive a brochure describing the nature, causes, and consequences of depression, as well as available prevention/treatment options
11295242|NCT02731040||Controls|Women who are/have been on bisphosphonate therapy for osteoporosis who have not suffered an atypical femoral fracture
11295243|NCT02731040||Fracture Group|Women who are/have been on bisphosphonate therapy for osteoporosis who have suffered an atypical femoral fracture
11295244|NCT02731027||Healthy Controls|
11295245|NCT02731027||Participants with Spinal Cord Injury|
11295246|NCT02731014|Experimental|Dry Needling Group|Dry Needling, Manual Therapy, and Exercise.
11295247|NCT02731014|Sham Comparator|Sham Dry Needling Group|Sham Dry Needling, Manual Therapy, and Exercise.
11295248|NCT02731001|Experimental|Proton therapy|Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.
11295249|NCT02731001|Active Comparator|Photon therapy|Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.
11295250|NCT02730988|Experimental|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 & 2 & 1 Plan™, a 1200 calorie, high protein diet targeting ~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
11295251|NCT02730988|Active Comparator|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
11295252|NCT02730975|Experimental|AA Reduced dose-normal diet (A)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a standard breakfast
11314421|NCT02603640|Experimental|epileptic patient|
11295254|NCT02730975|Active Comparator|AA normal dose-fasting conditions (C)|Abiraterone acetate at approved dose of 1000 mg po daily in cycles of 28 days administered in fasting conditions
11295255|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
11295256|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
11295257|NCT02730949|Experimental|1 g D-chiro-Inositol + 400 mcg Folic Acid|1 g D-chiro-Inositol + 400 mcg folic acid once daily
11295258|NCT02730949|Active Comparator|400 mcg folic|400 mcg folic acid only once daily
11295259|NCT02730936|Experimental|Antimicrobial Hernia Repair Device|Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields.
11295260|NCT02730923|Experimental|Arm A: AZD2014 plus anastrozole|
11295261|NCT02730923|Active Comparator|Arm B: anastrozole alone|
11295262|NCT02730910|Experimental|Purple Wheat Crackers|Bran-enriched purple wheat wholegrain crackers served in 120 g portion.
11295263|NCT02730910|Experimental|Purple Wheat Granola Bars|Bran-enriched purple wheat wholegrain granola bars served in 160 g portion.
11295264|NCT02730897||VATS|Patients operated by means of minimal invasive technique (VATS or roboticVATS)
11295265|NCT02730897||Open|Patients operated by means of open thoracotomy
11295266|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
11295267|NCT02730871|Experimental|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
11295268|NCT02730871|Placebo Comparator|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
11295269|NCT02730858|Experimental|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;
~-- Standard oncology care with palliative care."
11295270|NCT02730858|Active Comparator|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;
~-- Standard oncology care"
11295271|NCT02730845|Active Comparator|Intra-articular dexmedetomidine|Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
11295272|NCT02730845|Placebo Comparator|Intravenous dexmedetomidine|patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
11295273|NCT02730832|Experimental|Patients with schizophrenia|
11295274|NCT02730819|Experimental|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
11295275|NCT02730806|Experimental|NLP PTSD intervention protocol|Behavioral intervention (NLP) - intervention method will be 5 weekly personal therapy and counseling sessions with a certified therapist specializing in NLP, implementing the NLP PTSD protocol, such as Visual Kinesthetic Dissociation (VKD) behavioral technique for PPPTSD cases
11295276|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
11295277|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
11295278|NCT02730780|Other|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
11295279|NCT02730780|Other|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
11295280|NCT02730767|Experimental|Intervention Group|Partially supervised exercise intervention: Survivors in the intervention group will be asked to add at least 2.5 hours of intense physical activities per week. These should include at least 30 min of strength building exercises and 2 hours of aerobic exercises per week. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
11295281|NCT02730767|No Intervention|Control Group|The control group will keep their physical activity level constant over the 1 year of the study. Thereafter, they will have the opportunity to receive the same intervention than the intervention group had received (off-trial) to benefit in the same way from an active lifestyle.
11295282|NCT02730741|Experimental|Lcr restituo® sachet and placebo|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening) and the placebo at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening).
11295283|NCT02730741|Experimental|Lcr restituo® sachet|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
11295284|NCT02730741|Placebo Comparator|Placebo|The placebo at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
11295351|NCT02730182|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
11295285|NCT02730728|Active Comparator|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
11295286|NCT02730728|Active Comparator|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
11295287|NCT02730728|Active Comparator|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
11295288|NCT02730715||Thymoglobulin|blood specimen collection
11295289|NCT02730715||Basiliximab|blood specimen collection
11295290|NCT02730689|Experimental|A group|DP-R207 >> rosuvastatin+ezetimibe
11295291|NCT02730689|Active Comparator|B group|rosuvastatin+ezetimibe >> DP-R207
11295292|NCT02730676||Electronic Cigarette #1|VUSE® Original Digital Vapor Cigarettes (29 mg nicotine)
11295293|NCT02730676||Electronic Cigarette #2|VUSE® Menthol Digital Vapor Cigarettes (29 mg nicotine)
11295294|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
11295295|NCT02730650|Experimental|Platelet Rich Therapy|Each subject will receive six injections of Platelet Rich Plasma (PRP) at designated points on each side of their face (twelve total). Injection points are spaced evenly across the inferior border of the cheek and mid-cheek, and are consistent on each patient. Patients will receive a post-injection phone call within 48 hours of the procedure. Photographs will be taken at two time points as part of the research to serve as a point of comparison before and after platelet rich plasma. Patients will receive the Global Aesthetic Improvement Scale amd tje Face-Q Questionnaire 1 month post-op
11295296|NCT02730637|No Intervention|Standard care|Patients with elevated biomarkers receive a standard treatment.
11295297|NCT02730637|Active Comparator|Interventional care|Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.
11295298|NCT02730624|Experimental|piperacillin/tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h
11295299|NCT02730611||Patients|Patients with morbid obesity and vertical sleeve gastrectomy
11295300|NCT02730598|Experimental|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
11295301|NCT02730598|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
11295302|NCT02730585||Acute appendicitis|all patients admitted to our hospital with a clinically suspected acute appendicitis.
11295303|NCT02730572||Concerta to authorized generic (AG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to AG formulation will be observed.
11295304|NCT02730572||Concerta to equivalent generic (EG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to EG formulation will be observed.
11295305|NCT02730559|Experimental|Intervention Group|Group A (Parent-adolescent dyads)
11295306|NCT02730559|Active Comparator|Control Group - Active Comparator|Group B (Adolescents only)
11295307|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
11295308|NCT02730533|Active Comparator|Control group|No PPI treatment should given after the initial allocation. Patient will be admitted, and ESD will be performed. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
11295309|NCT02730533|Experimental|Esomeprazole group|Esomeprazole should start as soon as possible after the initial allocation. During the 7 days of p.o. treatment, patient will be admitted, and ESD will be performed as soon as completing the p.o. treatment. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
11295310|NCT02730520||Immuno-allergology patients|Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.
11295311|NCT02730507|Experimental|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
11295312|NCT02730507|Active Comparator|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
11295313|NCT02730494|Active Comparator|Lcr Regenerans® vaginal capsule|Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
11295314|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 3 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
11295315|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 4 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
11295316|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 5 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
11295317|NCT02730481|Experimental|ORAXOL|"Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules
~Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
11295318|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
11295319|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
11295352|NCT02730169|Experimental|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
11295320|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
11295321|NCT02730442|Experimental|Single dose F901318 with fluconazole|AUC0-t for F901318 will be assessed before and after 5 days of treatment with fluconazole oral
11295322|NCT02730429|Placebo Comparator|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.
~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
11295323|NCT02730429|Experimental|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.
~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.
~Letrozole is administered as standard of care in both study arms."
11295324|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
11295325|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
11295326|NCT02730403||Opioid Use Disorder Patients|
11295327|NCT02730390||Probucol Tablets|Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).
11295328|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
11295329|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
11295330|NCT02730364|Experimental|Theraflu night powder|Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
11295331|NCT02730364|No Intervention|No Treatment|Participants in this arm will not receive any medication
11295332|NCT02730351|Experimental|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
11295333|NCT02730351|Experimental|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
11295334|NCT02730338|Active Comparator|Arm A: Supervised exercise group|Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support
11295335|NCT02730338|Other|Arm B: Self directed exercise group|Self directed exercise and psychosocial support group
11295336|NCT02730325|Active Comparator|SBI 10 g BID|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams twice per day
11295337|NCT02730325|Placebo Comparator|Placebo BID|Placebo
11295338|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
11295339|NCT02730299|Experimental|NiCord® (omidubicel)|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:
~ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))
~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.
~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
11295340|NCT02730299|Active Comparator|Unmanipulated CBU(s)|
11295341|NCT02730273|Experimental|Trial Nasal Mask|Participants to use nasal mask in-home for a week and one night in lab overnight polysomnography.
11295342|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
11295343|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
11295344|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
11295345|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
11295346|NCT02730221||Patients admitted during measurement 1|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period before the implementation of a new electronic patient data management system
11295347|NCT02730221||Patients admitted during measurement 2|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period after the implementation of a new electronic patient data management system
11295348|NCT02730208|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
11295349|NCT02730208|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
11295350|NCT02730195|Experimental|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
11295353|NCT02730169|Experimental|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
11295356|NCT02730156|Experimental|Altitude exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
11295357|NCT02730143|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure after 6 days at low altitude
11295358|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
11295359|NCT02730117|Experimental|Early renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, starting within 12 hours after randomization
~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
11295360|NCT02730117|Placebo Comparator|Conventional renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, after the patients reached at least one of the following criteria;
~pH < 7.15 or serum HCO3 < 15 mEq/L
~serum K >= 6 mEq/L
~Signs of volume overload or P/F ratio < 200
~BUN > 60 mg/dL
~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
11295361|NCT02730104||Cohort A: Patients with small bowel NET|Patients with small bowel NET (including appendiceal NETs)
11295362|NCT02730104||Cohort B: Patients with gastric NET|Patients with gastric NET (gastroduodenal)
11295363|NCT02730104||Cohort C: Patients with pancreatic NET|
11295364|NCT02730104||Cohort D: Patients with colorectal NET|Patients with colorectal NET (this includes mid-gut)
11295365|NCT02730104||Cohort E: Unknown primary tumor|
11295366|NCT02730091|Active Comparator|Letrozole or anastrozole|Letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
11295367|NCT02730091|Experimental|Vinorelbine + Anastrozole or letrozole|Oral vinorelbine 50 mg (1 soft capsule of 30 mg and 1 soft capsule of 20 mg) three times a week every ( Monday, Wednesday and Friday) before lunch and letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
11295368|NCT02730078|Active Comparator|Attention-meetings (AG)|Attention-control
11295369|NCT02730078|Experimental|VEMOFIT (VG)|Personal value exploration, disease education, emotional skills and goal setting.
11295370|NCT02730065|Active Comparator|Structured Aerobic Dance Training Group|Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
11295371|NCT02730065|Placebo Comparator|Stretching plus education|Participants in the control group will receive a weekly 3-hour group-based (group of 5 participants) programme containing stretching exercise, stress reduction and health education on dementia and stroke prevention for 6 months. The programme consists of low-intensity seated stretching, psychoeducation on stress management, various relaxation methods with practice as well as education on the causes, identification, treatment and prevention of stroke and dementia. Benefits of physical exercise will also be discussed but will its weight will be evenly balanced with other forms of evidence-based preventive strategies.
11295372|NCT02730052|Active Comparator|Omron 9200T without Telemonitoring|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
11295373|NCT02730052|Experimental|Omron 9200T plus Telemonitoring|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
11295374|NCT02730039||Cancer Care Providers|"Provider will attend a MCPT two-day intensive workshop that will include:
~Didactic Components
~Experiential Exercises
~Simulated patient role plays with actors
~Provider completes MCPT Workshop Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)
~MCP Core Competency Trainer rated Assessment
~MCP Pre & Post Workshop Knowledge Assessment
~MCPT Session Evaluation Assessment Provider will participate in training follow-up calls & webinars for approximately 6 -12 months following completion of MCPT workshop.
~Provider will have ongoing access to MCPT Website with a discussion board, training resources and materials for clinical care.
~Provider will complete follow-up assessment at 3, 6, 9, & 12 months post-training
~Training Update
~Goal Evaluation Form
~MCP Core Competency Self-Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)"
11295375|NCT02730026|Experimental|Surgery with Ketoprofen|Fifty healthy volunteers underwent removal one of lower third molar, will be treated to control pain, swelling and trismus with ketoprofen 100 mg
11295376|NCT02730026|Experimental|Surgery with Ketoprofen and Omeprazole|Fifty healthy volunteers underwent removal the other lower third molars, will be treated to control pain, swelling and trismus with ketoprofen 200 mg associated with Omeprazole 20 mg
11295377|NCT02730013|Experimental|Square Stepping Exercise|Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
11295378|NCT02730013|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
11295379|NCT02730000|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
11295380|NCT02730000|Experimental|ART with Riva Self Cure|Occlusal-proximal restoration in primary molars using Riva Self Cure from SDI, encapsulated, pre-dosed and mechanized handling.
11295381|NCT02729987|Experimental|Minimum Support Group (MSG)|Intervention group with 8 week access to the online stress management programme with minimal support from a coach (WorkGuru).
11295382|NCT02729987|Experimental|Discussion Group|Intervention group with 8 week access to the online stress management programme with minimal support from a coach, plus access to an online facilitated messaging board (WorkGuru).
11295383|NCT02729987|No Intervention|Waiting List Control (WLC)|Control group with access to the intervention after 16 weeks
11295384|NCT02729974|Experimental|ROTEM|Participants randomized to this arm will have rapid testing of hematocrit and clotting function every 30 minutes during the hysterectomy portion of their surgery for placenta accreta, with transfusion of blood products based on defined abnormalities in these tests.
11295385|NCT02729974|Active Comparator|Standard treatment|Participants randomized to this arm will have standard visual assessment of blood loss and standard laboratory studies to assess blood count and clotting function when indicated during the hysterectomy portion of their surgery for placenta accreta. Transfusion of blood products will be based on abnormalities of these test results.
11295386|NCT02729961|Experimental|Treatment (brentuximab vedotin, ceritinib)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive ceritinib PO QD on days 8-21 of course 1 and on days 1-21 for all subsequent courses. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11295387|NCT02729948|Experimental|Screening (TCE)|Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
11295388|NCT02729935|Experimental|Parecoxib|40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
11295389|NCT02729935|Placebo Comparator|Placebo|An equal volume of saline
11295390|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
11295391|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
11295392|NCT02729896|Experimental|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
11295393|NCT02729896|Experimental|Expansion Phase|For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1 and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months (during maintenance treatment for FL participants).
11295394|NCT02729896|Experimental|Safety Run-In Phase|For DLBCL, during the induction treatment Cycles 1-6 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1.
11295395|NCT02729883|Experimental|Supportive care (Take the Fight)|Patients receive patient navigation via strategists from the Take the Fight for 8 weeks. Patients also complete interviews regarding perceived physical, logistical, psychosocial, and informational challenges experienced prior to meeting with strategists/navigators and how challenges were addressed by navigator or others, perceived benefits or limitations of navigator assistance. Strategists also complete interviews regarding their perceptions on how patients benefited from participation, challenges patients experienced that were directly or indirectly related to their cancer diagnosis and treatment, how these concerns were addressed, barriers to addressing these concerns, and patient health literacy.
11295396|NCT02729870||Oral Glucose Gel|This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
11295397|NCT02729870||Oral Placebo Gel|The group will consist of participants ages 1 - 7. The subjects who are less than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3- 7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
11295398|NCT02729857|Experimental|Familial hypercholesterolemia|Subjects diagnosed with familial hypercholesterolemia receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
11295399|NCT02729857|Active Comparator|Healthy|Subjects with no chronic diseases receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
11295400|NCT02729844||Neolifes Heart|All premature infants, admitted at the neonatal intensive care unit (NICU) of the University Medical Centre Groningen, born <30 weeks or birth weight < 1000 gram, who participate in NeolifeS
11295401|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
11295402|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
11295403|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
11295404|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
11295405|NCT02729805|Placebo Comparator|Saline|A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
11295406|NCT02729805|Active Comparator|Ketamine 0.5mg/kg|A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
11295407|NCT02729805|Experimental|Ketamine 0.75mg/kg|A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
11295408|NCT02729792|Experimental|Single site rTMS|"Each treatment session will consist of:
~1200 pulses of iTBS over a posterior target location followed by a 60 minute interval, then 1200 pulses of iTBS over an anterior target location."
11295469|NCT02729428||Sedentary older adults|Sedentary older adults between the age of 55-75 years.
11315716|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
11295409|NCT02729792|Active Comparator|Dual site rTMS|"Each treatment session will consist of:
~600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location followed by a 60 minute interval, then 600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location."
11295410|NCT02729779|Experimental|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
11295411|NCT02729779|Active Comparator|Aerobic Group|The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
11295412|NCT02729766|Active Comparator|Empagliflozin 25mg Tbl|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
11295413|NCT02729766|Placebo Comparator|Placebo P-Tablet|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
11295414|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
11295415|NCT02729753|Other|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
11295416|NCT02729740|Other|Penumbra Smart System|
11295417|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
11295418|NCT02729714|Active Comparator|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
11295419|NCT02729714|Placebo Comparator|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
11295420|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
11295421|NCT02729688|Active Comparator|ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
11295422|NCT02729688|Active Comparator|customized pressure guide bandage|Bandaging was applied by spiral methods. Three customized pressure guide elastic bandage were applied by stretching until the elliptical shape marker in the bandage turned into circular shape with 50% overlapping from foot to just below knee level.
11295423|NCT02729675|Experimental|Access Intervention|Worksites in this condition received weekly Fruit and Vegetable markets
11295424|NCT02729675|Experimental|Enhanced Intervention|Worksites in this condition received weekly Fruit and Vegetable markets and Educational Interventions including Campaigns, Newsletters, DVDs, A Website, and Chef Demonstrations
11295425|NCT02729675|Active Comparator|Comparison Intervention|Worksites in this condition received Stress and Physical Activity Interventions
11295426|NCT02729662|Other|Patients with ADPKD|This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.
11295427|NCT02729649|Experimental|ArmAssist therapy|The group will be treated with ArmAssist robot therapy.
11295428|NCT02729649|Active Comparator|Conventional therapy|The group will be treated with conventional therapy.
11295429|NCT02729649|Active Comparator|Extended Conventional therapy|The group will be treated with extended conventional therapy.
11295430|NCT02729636|Experimental|FES:a|The group will be treated with multipad electrical stimulation device.
11295431|NCT02729636|Active Comparator|control|The group will be treated with conventional treatment.
11295432|NCT02729623|Experimental|Single CannaHALER dose 10 ± 0.1 mg|Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
11295433|NCT02729623|Experimental|Single CannaHALER dose 15 ± 0.1 mg|Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
11295434|NCT02729623|Experimental|Single CannaHALER dose 20 ± 0.1 mg|Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
11295435|NCT02729623|Experimental|Single CannaHALER dose 25 ± 0.1 mg|Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
11295436|NCT02729610|Active Comparator|DLT group|In this arm, patient will be intubated with a double lumen endotracheal tube
11295437|NCT02729610|Experimental|BB group|In this arm, patient will be intubated with an endobronchial blocker
11295438|NCT02729597||Myotonic dystrophy type 1 patients|"Patients with myotonic dystrophy type 1 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.
~To be assessed at baseline and follow-up:
~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
11295439|NCT02729597||Myotonic dystrophy type 2 patients|"Patients with myotonic dystrophy type 2 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.
~To be assessed at baseline and follow-up:
~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
11295440|NCT02729597||Controls|"Healthy control subjects who meet all inclusion and exclusion criteria for healthy controls.
~To be assessed at baseline and follow-up:
~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
11295441|NCT02729584||Normal weight|
11295442|NCT02729584||Obese|
11295443|NCT02729571|Experimental|MTBVAC Group 1|Intervention: MTBVAC live vaccine (low dose)
11295444|NCT02729571|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose)
11295445|NCT02729571|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose)
11295446|NCT02729571|Active Comparator|BCG Control Group|Intervention: commercially available BCG live vaccine
11295447|NCT02729558|No Intervention|observation|Watchful waiting
11295448|NCT02729558|Active Comparator|local stereotactic radiotherapy (SRT)|local SRT in three fractions of 8 Gy to the surgical cavity
11295449|NCT02729545|Experimental|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
11295450|NCT02729545|Active Comparator|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
11295451|NCT02729532||Xpert cohort|HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)
11295452|NCT02729532||Standard of Care cohort|HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)
11295453|NCT02729519|Other|Group A|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
11295454|NCT02729519|Experimental|Groupe B|standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
11295455|NCT02729506|Active Comparator|Arm A|"Intervention:
~Yttrium-90 Transarterial Radioembolization
~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).
~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.
~Patients must not be less than 18 and not more than 80 and can be either gender.
~Patients must have a performance status of ECOG score equal to or less than 2.
~Child-Pugh's A or Early B, score 8 and above"
11295456|NCT02729506|Active Comparator|Arm B|"Intervention:
~Trans-arterial chemo-embolization using Drug-eluting beads
~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).
~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.
~Patients must not be less than 18 and not more than 80 and can be either gender.
~Patients must have a performance status of ECOG score equal to or less than 2.
~Child-Pugh's A or Early B, score 8 and above"
11295457|NCT02729493|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
11295458|NCT02729480|Experimental|Continued Stimulation Group|Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
11295459|NCT02729480|Active Comparator|Delayed Continuation Group|Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
11295460|NCT02729467|Experimental|Panel 1|Participants will receive a single 250 milligram (mg) dose of JNJ-53718678 on Day 1 and 200 mg itraconazole once a day on Days 4 to 11 along with a single 250-mg dose of JNJ-53718678 on Day 9.
11295461|NCT02729467|Experimental|Panel 2|Participants will receive a single 500-mg dose of JNJ-53718678 on Day 1; a single 600-mg dose of rifampicin along with a single 500-mg dose of JNJ-53718678 on Day 4 and 600 mg rifampicin once daily on Days 5 to 11 along with a single 500-mg dose of JNJ-53718678 on Day 9.
11295462|NCT02729454|Active Comparator|Exclusively physical therapy|The patients will be submitted to 15 therapeutical sessions two times per week with length of 40 minutes for motor physiotherapy . Each session of the motor physiotherapy will be constituted of exercises that include stretching (emphasizing the front of the torso), reinforcement (with emphasis in inferior members extensores); active exercises as transference (for example, to put into motion it bed or uprising of a chair), to reach and to grasp and training of balance and march.
11295463|NCT02729454|Experimental|Mental Practice And Physical Therapy|In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
11295464|NCT02729441|Active Comparator|Ramipril|"Maximal recommended dose of ramipril Altace® (10 mg/d) given as an active comparator for 12 week."
11295465|NCT02729441|Experimental|Perindopril|"Perindopril Coversyl® at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks."
11295466|NCT02729428||Exercise trained young adults|Exercise trained young adults between the age of 18-35 years.
11295467|NCT02729428||Sedentary young adults|Sedentary young adults between the age of 18-35 years.
11295470|NCT02729415|Experimental|Stromal Vascular Fraction Cells (SVF Cells)|The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.
11295471|NCT02729402|Experimental|Older Cochlear Implant Subjects|We will assign the study participants to a diagnostic intervention (cognitive testing) before and after their cochlear implant.
11295472|NCT02729389|Experimental|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
11295473|NCT02729389|Experimental|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
11295474|NCT02729376|Experimental|Single dose of [14C]-galeterone|[14C]-galeterone will be supplied as 325 mg capsules (powder in capsule [PIC]). The treatment to be administered will be 2600 mg (~500 µCi) (8 x 325 mg capsules).
11295475|NCT02729363|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline visit to determine the immediate effects of guided relaxation intervention on stress and pain in outpatients with sickle cell disease.
11295476|NCT02729363|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients talk about their sickle cell disease experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
11295477|NCT02729350|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.
11295478|NCT02729350|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
11295479|NCT02729337|Experimental|ITG (In This Together)|This will be a multi-week behavioral intervention delivered daily via text messaging. Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
11295480|NCT02729337|No Intervention|Control Group|Given the preliminary nature of the intervention development, the control group will be inactive but blinded. They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk. Messages will be didactic and not driven by the IMB model.
11295481|NCT02729324|Experimental|FORRAD group|This group of patients will receive Medical Radiation Protectants (FORRAD®) during study for prevention and treatment of acute radiation-induced dermatitis. This is the experimental group.
11295482|NCT02729324|Active Comparator|Biafine group|This group of patients will receive Trolamine (Biafine) during study for prevention and treatment of acute radiation-induced dermatitis. This is the active comparator group.
11295483|NCT02729311|Experimental|Group 1|Paired PLIÉ Program, immediate start
11295484|NCT02729311|Other|Group 2|Paired PLIÉ Program, delayed start
11295485|NCT02729298|Experimental|Advanced Solid Tumors|"Phase 1a Single daily dose of TP-0903 by oral administration on Days 1-21 of a 28 day cycle
~AND
~Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle."
11295486|NCT02729298|Experimental|EGFR+ NSCLC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
11295487|NCT02729298|Experimental|BRAF-, KRAS-, or NRAS-Mutated CRC|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
11295488|NCT02729298|Experimental|Persistent/Recurrent Ovarian Cancer|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
11295489|NCT02729298|Experimental|BRAF-Mutated Melanoma|Phase 1b - Upon confirmation of MTD, will receive single oral daily doses of a flat dose of TP-0903 based on the average of the dose administered in the MTD expansion safety cohort on Days 1-21 of each 28 day cycle.
11295490|NCT02729285|Experimental|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
11295491|NCT02729285|Placebo Comparator|placebo|On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.
11295492|NCT02729272|Experimental|Ultrasonic ESD|Laparoscopic colpotomy by ultrasonic ESD (Harmonic Synergy Hook Blade; Ethicon Endo-Surgery) during total laparoscopic hysterectomy.
11295493|NCT02729272|Active Comparator|Monopolar ESD|Laparoscopic colpotomy by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany) during total laparoscopic hysterectomy.
11295494|NCT02729259|Other|Virtual Reality Snowworld|The subjects will receive Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
11295495|NCT02729259|Other|Virtual Reality slides of nature|The subjects will see several slides of the nature through virtual reality goggles during their wound care. The nurse will be doing the wound care.
11295496|NCT02729259|Other|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
11295497|NCT02729246|No Intervention|Control Group|
11316186|NCT02592148||Health subjects|Male and female
11295498|NCT02729246|Other|Surgery Group|The patients in this group will undergo Laparoscopic Gastric Bypass surgery
11295499|NCT02729233|Other|patients receiving biopsies|UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
11295500|NCT02729220|Other|Healthy controls|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
11295501|NCT02729220|Other|Smokers|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
11295502|NCT02729220|Other|COPD rapid decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
11295503|NCT02729220|Other|COPD slow decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
11295504|NCT02729207|Active Comparator|Esflurbiprofen 1.5% Hydrogel Patch|One patch per 24hr for 7 days
11295505|NCT02729207|Placebo Comparator|Placebo comparator|Placebo One patch per 24hr for 7 days
11295506|NCT02729194|Experimental|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
11295507|NCT02729168|Experimental|Human rabies vaccines|Five doses 0.5 mL vaccine INDIRAB® on D0, D3, D7, D14, D28 using administered intramuscularly.
11295508|NCT02729155|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
11295509|NCT02729155|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
11295510|NCT02729155|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
11295511|NCT02729155|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
11295512|NCT02729142|Experimental|Tibial cortical density evaluation|
11295513|NCT02729129|Experimental|Commercially available highly-efficient facemask|
11295514|NCT02729129|Sham Comparator|Sham facemask|
11295515|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
11295516|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
11295517|NCT02729103||Treatment patterns, healthcare resource utilization and costs|Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
11295518|NCT02729103||Mortality|Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
11295519|NCT02729090|Experimental|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks
11295520|NCT02729090|Active Comparator|Device: treadmill Train_Comb_aerobic|strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series.
11295521|NCT02729077||Increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry. Patients in this arm will be especially evaluated for hypoxemia and other complications.
11295522|NCT02729077||Not increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry.
11295523|NCT02729064|Experimental|Intranasal 40|Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
11295524|NCT02729064|Experimental|Intranasal 80|Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
11295525|NCT02729064|Placebo Comparator|Placebo|Patients will receive intranasal normal saline via a metered nasal dispenser
11295526|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11295527|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
11295528|NCT02729038|Experimental|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
11295529|NCT02729038|Experimental|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
11295530|NCT02729038|Experimental|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
11295531|NCT02729038|Experimental|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
11295532|NCT02729038|Experimental|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
11295533|NCT02729038|Experimental|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
11295534|NCT02729025|Placebo Comparator|Placebo|Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
11295535|NCT02729025|Experimental|Evolocumab 420 mg QM|Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
11295536|NCT02729012|Active Comparator|Case|Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
11295537|NCT02729012|Placebo Comparator|Control|Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
11295538|NCT02728999|Other|Group A|Steep Trendelenburg
11295539|NCT02728999|Experimental|Group B|Decreased Trendelenburg
11295540|NCT02728986|Active Comparator|Compression1|Multilayer compression bandage (Profore)
11295541|NCT02728986|Experimental|Compression2|Coban2 compression system
11295542|NCT02728973||ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
11295543|NCT02728973||conventional treatment program|conventional treatment
11295544|NCT02728960|Experimental|Traumatic Brain Injury|Documented history of Traumatic Brain Injury
11295545|NCT02728960|Active Comparator|Normal Controls|No prior history of concussion, TBI, blast exposure, stroke, or other major neurological disorder
11295546|NCT02728960|Active Comparator|Sequence Development Volunteers|
11295547|NCT02728947|Active Comparator|2mg|1 week on 2mg/24 hr patch
11295548|NCT02728947|Active Comparator|4mg|1 week on 4mg/24hr patch
11295549|NCT02728947|Active Comparator|6mg|1 week on 6mg/24hr patch
11295550|NCT02728947|Active Comparator|8mg|1 week on 8mg/24hr patch
11295551|NCT02728934||Golimumab Intravenous (IV)|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Golimumab IV.
11295552|NCT02728934||Infliximab|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Infliximab.
11295553|NCT02728921|Active Comparator|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
11295554|NCT02728921|Experimental|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
11295555|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
11295556|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
11295557|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
11295558|NCT02728882|Experimental|single arm|"Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days，the first day,the fourth day,the seventh day,28 days,31 days,34 days.
~Duration:Total seven times."
11295559|NCT02728869|Experimental|Heat Stable Rotavirus (HSRV) Vaccine|25 healthy adults who will be administered a single dose of test HSRV vaccine
11295560|NCT02728869|Placebo Comparator|Placebo for Heatstable Rotavirus vaccine|25 healthy adults who will be administered a single dose of placebo
11295561|NCT02728869|Experimental|Heat Stable Rotavirus Vaccine|25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
11295562|NCT02728869|Active Comparator|RotaTeq|25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals
11295563|NCT02728856|Experimental|Sun Protection Factor (SPF) 50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
11295564|NCT02728856|Experimental|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
11295565|NCT02728843|Experimental|Deferiprone 300 mg|One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg
11295566|NCT02728843|Experimental|Deferiprone 600 mg|One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg
11295567|NCT02728843|Experimental|Deferiprone 900 mg|One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg
11295568|NCT02728843|Experimental|Deferiprone 1200 mg|Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg
11295569|NCT02728843|Placebo Comparator|Placebo|Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day
11295570|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.
~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.
~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
11317690|NCT02582216|Experimental|Open label|3D augmented reality
11295571|NCT02728817|Active Comparator|arteriovenous fistula (AVF)|Patient receiving a traditional arteriovenous fistula at the wrist (end-cephalic vein to side-radial artery)
11295572|NCT02728817|Experimental|RADAR|Patient receiving an arteriovenous fistula at the wrist using the Radial Artery Deviation And Reimplantation technique (end-radial artery to side-cephalic vein)
11295573|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
11295574|NCT02728778|Active Comparator|Botulinum toxin A|Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.
11295575|NCT02728778|Other|Acupuncture|Patients will receive four facial acupuncture treatments every two weeks.
11295576|NCT02728765|Active Comparator|auto CPAP|Each patient will be interviewed by the physician on duty and invited to participate in the overnight hospital based auto continuous positive airway pressure (CPAP) titration study for 1 night and then commencement of auto CPAP treatment for 6 months.
11295577|NCT02728765|Placebo Comparator|Subtherapeutic CPAP|Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
11295578|NCT02728752|Placebo Comparator|Placebo|Subjects eligible after screening, randomized to placebo arm, will receive 4 infusions of placebo every 4 weeks during the First Period (16 weeks). In case of deterioration at or after Week 6, subjects will be crossed-over to the alternate treatment, and will not drop-out before the primary endpoint assessment at Week 16 to keep the blind unless they deteriorate also on the alternate IMP after starting it at least 6 weeks before. After response assessment at Week 16, patients will be unblinded. From Week 16 onwards, all subjects, except subjects randomized to Octagam 10% who deteriorate in the First Period and who will drop-out, will enter the open-label Extension Period. In the Extension Period they will receive six infusions of 2.0 g/kg Octagam 10% every 4 weeks (± 4 days). At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator.
11295579|NCT02728752|Experimental|Octagam10%|Subjects eligible after screening, randomized to Octagam10% arm, will receive 4 infusions of Octagam10% every 4 weeks during the First Period (16 weeks). In case of deterioration at or after Week 6, subjects will be crossed-over to the alternate treatment, and will not drop-out before the primary endpoint assessment at Week 16 to keep the blind unless they deteriorate also on the alternate IMP after starting it at least 6 weeks before. After response assessment at Week 16, patients will be unblinded. From Week 16 onwards, all subjects, except subjects randomized to Octagam10% who deteriorate in the First Period and who will drop-out, will enter the open-label Extension Period. In the Extension Period they will receive six infusions of 2.0 g/kg Octagam 10% every 4 weeks (± 4 days). At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator.
11295580|NCT02728739|Experimental|Acute Heart Failure Patients|Acute Heart Failure patients with elevated levels of BNP ( >30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.
11295581|NCT02728726|Experimental|Treatment group|study drug (sugammadex) administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and patient is extubated.
11295582|NCT02728726|Placebo Comparator|Control group|placebo administered intravenously after routine reversal of anesthesia is performed and patient is extubated.
11295583|NCT02728713|Experimental|Cranial manipulation|"Assessment for cranial strain patterns, followed by indirect cranial manipulation to treat dysfunctions found on assessment, followed by reassessment.
~Repeated for a total of eight visits no less than one week apart."
11295584|NCT02728713|Sham Comparator|Sham/placebo|Assessment for cranial strain patterns, followed a laying on of hands, followed by reassessment. Repeated for a total of eight visits no less than one week apart.
11295585|NCT02728700|Experimental|Treatment (sirolimus, HSCT, MMF)|Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.
11295586|NCT02728687|Experimental|Mannitol and menthol cream|Mannitol and menthol cream (Water, Mannitol, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the menthol cream will be applied to the participant's feet. Whether the mannitol and menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
11295587|NCT02728687|Active Comparator|Menthol cream|Cream containing menthol (Water, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the mannitol and menthol cream will applied to the participant's feet. Whether the menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
11295588|NCT02728674|Other|Man+Breathlessness|Person in the case is a male. Symptom in the case is breathlessness.
11295589|NCT02728674|Other|Man+Pain|Person in the case is a male. Symptom in the case is pain.
11295590|NCT02728674|Other|Woman+Breathlessness|Person in the case is a female. Symptom in the case is breathlessness.
11295591|NCT02728674|Other|Woman+Pain|Person in the case is a female.Symptom in the case is pain.
11295689|NCT02728011|Experimental|Intervention|Scientific Brain Training (SBT)
11295690|NCT02728011|Placebo Comparator|Controle|Tetris
11295592|NCT02728661|Experimental|PACE|PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
11295593|NCT02728661|Experimental|Delayed PACE|After being notified of their randomized condition at baseline (up to 6 weeks prior to surgery), Delayed PACE participants will not have contact with coaches until 12 weeks after surgery. At 12 weeks after surgery, Delayed PACE participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks. Further, participants may opt to receive regular text messages or emails from coaches if they prefer.
11295594|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
11295595|NCT02728635|Active Comparator|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
11295596|NCT02728635|Active Comparator|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
11295597|NCT02728635|Active Comparator|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
11295598|NCT02728622|Experimental|Tamoxifen|Tamoxifen 40 mg is given orally once daily until progression
11295599|NCT02728622|Active Comparator|Chemotherapy|Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression
11295600|NCT02728609||Blue towel: vacuum pack device|Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
11295601|NCT02728609||ABThera abdominal closure|Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
11295602|NCT02728596|Experimental|Clinic group 1 (clinic with automated system)|Patients with a high risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSFs not be used for drugs that have a low risk of FN.
11295603|NCT02728596|Experimental|Clinic group 2 (clinic with no automated system)|Patients receive CSF based on clinical practice guidelines.
11295604|NCT02728596|Experimental|Clinic group 3 (clinic with automated system)|Patients with a high or moderate risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSFs not be used for drugs that have a low risk of FN.
11295605|NCT02728596|Active Comparator|Clinic group 4 (clinic with automated system)|Patients with a high risk of developing FN receive CSF based on the automated system recommendations. The automated system suggests that CSF not be used for drugs that have a moderate risk of FN.
11295606|NCT02728583|Active Comparator|Margarine enriched with plant sterols and fish oil|Low-fat margarine (25 g per day) with added plant sterols and Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) from fish oil
11295607|NCT02728583|Placebo Comparator|Placebo margarine|Low-fat margarine (25 g per day) without added plant sterols and EPA + DHA
11295608|NCT02728570|Experimental|Low Flavonoids then High Flavonoids|Participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks.
11295609|NCT02728570|Experimental|High Flavonoids then Low Flavonoids|Participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks.
11295610|NCT02728557|Experimental|Supportive psychotherapy|Participants will receive supportive therapy.
11295611|NCT02728557|Experimental|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
11295612|NCT02728544|Experimental|Prader Willi syndrome|16 (8 males) PWS adolescents and young adults
11295613|NCT02728544|Active Comparator|Obese controls|16 - sex, age, and BMI-matched controls
11295614|NCT02728531|Experimental|Bendamustine, Rituximab, Cytarabine|"Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.
~In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.
~On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.
~Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.
~Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).
~Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
11295615|NCT02728518|Experimental|Nebulized Amikacin|patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam
11295616|NCT02728518|Active Comparator|Amikacin Intravenous|patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam
11295617|NCT02728505|Active Comparator|SinuSurf irrigation twice daily|This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
11295618|NCT02728505|Placebo Comparator|NeilMed Sinus rinse irrigation twice daily|This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
11295619|NCT02728492|Experimental|Quisinostat 8 mg & Paclitaxel & Carboplatin|Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
11295620|NCT02728492|Experimental|Quisinostat 10 mg & Paclitaxel & Carboplatin|Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
11295621|NCT02728492|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
11295622|NCT02728492|Experimental|Quisinostat 8 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
11295623|NCT02728492|Experimental|Quisinostat 10 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
11295624|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
11295625|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1250 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
11295626|NCT02728466|Active Comparator|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
11295627|NCT02728466|Active Comparator|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
11295628|NCT02728466|Placebo Comparator|Flavanols and procyanidins deprived supplement|Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
11295629|NCT02728453|Experimental|Empagliflozin|25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
11295630|NCT02728453|Active Comparator|Glimepiride|2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.
11295631|NCT02728440||Hypogonadotropic hypogonadism patients|30 patients with idiopathic hypogonadotrophic hypogonadism
11295632|NCT02728427|Experimental|Suprapubic Catheterization|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.
11295633|NCT02728427|Active Comparator|Transurethral Catheterization|Transurethral catheterization using Foley catheter will be performed for patients in this group.
11295634|NCT02728414|Experimental|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
11295635|NCT02728414|Other|placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
11295636|NCT02728401||INSI|Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
11295637|NCT02728401||CSSS|Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
11295638|NCT02728401||Viral|The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
11295639|NCT02728388|Experimental|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.
~16 to 24 hours post study drug treatment, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
11295640|NCT02728375|Experimental|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 45 minutes,three times per week for sixteen weeks
11295641|NCT02728375|Active Comparator|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength. The exercises will be performed 45 minutes, three times per week for sixteen weeks
11295642|NCT02728349|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
11295643|NCT02728336|Active Comparator|Heart Failure Patients|patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony
11295644|NCT02728336|Active Comparator|Control|20 matched control subjects
11295645|NCT02728323|Active Comparator|Levobupivacaine 100 mg, USG TAP Block|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
11295646|NCT02728323|Placebo Comparator|Placebo|20 ml of Saline (for 100 mg Levobupivacaine) intramuscularly, at the end of surgery
11295647|NCT02728310|Active Comparator|Levobupivacaine infusion|1500 mg of Levobupivacaine by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
11295648|NCT02728310|Placebo Comparator|Saline infusion|300 ml of Saline (for Levobupivacaine as placebo) by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
11295649|NCT02728297|Experimental|Staged ETS|Video-assisted endoscopic sympathicotomy from level of T3 to level of T12 on one side
11295650|NCT02728284|Active Comparator|Normal Cardiovascular System|70 with a history of heart or lung disease
11295651|NCT02728284|Active Comparator|Abnormal Cardiovascular System|30 without any history of heart or lung disease
11295760|NCT02727517|Active Comparator|Delayed cord clamping|Delayed (≥ 180 seconds) cord clamping
11295652|NCT02728271|Experimental|HPC cell infusion|Autologous HPC will be infused within 24 hours of completing the chemotherapy. A total of 5 x 106/kg CD34+ HPC will be infused. The remaining HPC will be stored as back-up, to be used in case of graft failure.
11295653|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11295654|NCT02728245|Placebo Comparator|Control group|"Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.
~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
11295655|NCT02728245|Experimental|Case group|"Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.
~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
11295656|NCT02728232|Experimental|Internal Iliac artery ligation group|in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure
11295657|NCT02728232|Active Comparator|Hysterectomy only|in this group patients will undergo cesarean hysterectomy only
11295658|NCT02728219|Experimental|hepatectomy|Comparison of Treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion
11295659|NCT02728219|Active Comparator|TACE|
11295660|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
11295661|NCT02728193|Experimental|RFA|Radiofrequency ablation
11295662|NCT02728193|Experimental|MWV|Microwave ablation
11295663|NCT02728193|Experimental|PEI|Percutaneous ethanol injection
11295664|NCT02728180|Experimental|Xingnaojing and standard care|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
11295665|NCT02728180|Active Comparator|Standard care only|Subjects will receive guidelines-based standard care only.
11295666|NCT02728167|Experimental|Pre-coagulation by HIFU-AR|Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
11295667|NCT02728167|No Intervention|Standard liver resection|Standard liver resection
11295668|NCT02728154||Normal control|The subjects in the normal heart function group will provide a blood sample and stool sample.
11295669|NCT02728154||heart failure|The subjects in history of heart failure group will provide a blood sample and stool sample.
11295670|NCT02728154||pre-HFpEF|The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
11295671|NCT02728141|Placebo Comparator|Water|Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
11295672|NCT02728141|Active Comparator|Sucrose|Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
11295673|NCT02728128||Low cardiac output syndrome|Patients who experience low cardiac output syndrome
11295674|NCT02728128||No low cardiac output syndrome|Group that does not experience low cardiac output syndrome.
11295675|NCT02728115|Experimental|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells/weight range per administration of Cellavita HD (n= 3) .
11295676|NCT02728115|Experimental|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells/weight range per administration of Cellavita HD (n= 3).
11295677|NCT02728102|Experimental|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
11295678|NCT02728102|Active Comparator|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
11295679|NCT02728102|Active Comparator|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
11295680|NCT02728089|Experimental|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
11295681|NCT02728076|Experimental|Radiation Therapy followed by Lumpectom|Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
11295682|NCT02728063|Experimental|Single arm|Supplementation with Lactibiane Tolerance
11295683|NCT02728050|Experimental|Treatment (sorafenib, G-CLAM)|See Detailed Description.
11295684|NCT02728037|Experimental|Magnesium-Based Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
11295685|NCT02728037|Active Comparator|Lidocaine-Only Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
11295686|NCT02728037|No Intervention|Wait-Listed Patients|This arm is a non-randomized, no-treatment arm consisting of women who are on the waiting list for the chronic pain clinic.
11295687|NCT02728024||A|Complete the questionnaires with personal aid
11295688|NCT02728024||B|questionnaires are completed by patients alone
11295691|NCT02727998|Experimental|Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
11295692|NCT02727998|Active Comparator|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
11295693|NCT02727985|Experimental|Pharmacist weaning schedule|The Neuromodulation clinic pharmacist will develop a weaning schedule for these patients. Schedules will be individualized taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
11295694|NCT02727985|No Intervention|Self/Family Physician weaning schedule|Patients will wean off their opioids by themselves or with their family physician without the assistance of a prepared schedule.
11295695|NCT02727972|Other|Cognitive Testing|Cognitive assessments
11295696|NCT02727972|Active Comparator|Magnetic Resonance Imaging|All subjects will have one MRI with a possibility of one functional MRI (fmri).
11295697|NCT02727972|Active Comparator|Positron Emission Tomography|All subjects will have PET scan using FPEB or ABP688.
11295698|NCT02727959||Patients newly diagnosed with IBD|
11295699|NCT02727959||Symptomatic non IBD-controls|Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
11295700|NCT02727946|Other|optimal resuscitation|This group of multiple trauma patients will be resuscitated with crystalloids, analgesics, blood products as needed. Then follow up of the difference between arterial and venous CO2 to difference between arterial and venous oxygen tension, serum lactate, renal function, other organ affection along over the short hospital stay period
11295701|NCT02727920|Experimental|Experimental|drink containing pyridoxine, folate; B12); taurine, choline, glucuronic acid; tyrosine, phenylalanine*, malic acid, and caffeine administered one time.
11295702|NCT02727920|Placebo Comparator|Placebo drink|Placebo drink administered one time.
11295703|NCT02727907|Experimental|BCD-033|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
11295704|NCT02727907|Active Comparator|Rebif|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
11295705|NCT02727907|Placebo Comparator|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
11295706|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
11295707|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
11295708|NCT02727881|Experimental|Squalamine solution, 0.2% BID|Squalamine lactate ophthalmic solution, 0.2% bis in die (BID) + ranibizumab every 4 weeks
11295709|NCT02727881|Placebo Comparator|Placebo solution BID|Placebo ophthalmic solution BID + ranibizumab every 4 weeks
11295710|NCT02727868|Other|exclusive breast irradiation group|to assess the impact of irradiation areas
11295711|NCT02727868|Other|breast and sternal irradiation group|to assess the impact of irradiation areas
11295712|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
11295713|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
11295714|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
11295715|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
11295716|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
11295717|NCT02727803|Experimental|Myeloablative regimen 1|"Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3.
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.
~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
11295718|NCT02727803|Experimental|Non-myeloablative regimen 2|"Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s).
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.
~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
11295719|NCT02727803|Experimental|Reduced intensity regimen 3|"Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2.
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.
~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
11295720|NCT02727790|Experimental|PES Treatment|Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System
11295956|NCT02726191|Experimental|Lumosity|
11295721|NCT02727790|No Intervention|Control|Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System
11295722|NCT02727777|Experimental|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group
~Participants take TAK-228 1 time every day of a 28 day cycle.
~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.
~Participant checks blood sugar every day before TAK-228 dose."
11295723|NCT02727777|Experimental|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group
~Participants take TAK-228 1 time every day of a 28 day cycle.
~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.
~Participant checks blood sugar every day before TAK-228 dose."
11295724|NCT02727777|Experimental|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group
~Participants take TAK-228 1 time every day of a 28 day cycle.
~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.
~Participant checks blood sugar every day before TAK-228 dose."
11295725|NCT02727764|Experimental|Cohort I|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e12 vg/ MCP joint, 0.6x10e12 vg/ PIP joint or 0.3x10e12 vg/ DIP joint single intra-articular injection
11295726|NCT02727764|Experimental|Cohort II|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint single intra-articular injection
11295727|NCT02727764|Experimental|Cohort III|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint ART-I02 or maximum Tolerated Dose (MTD) as assessed in cohorts I and II: single intra-articular injection
11295728|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
11295729|NCT02727738|Experimental|Methimazole plus selenium|Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days
11295730|NCT02727738|Active Comparator|Methimazole|Methimazole 5-30 mg daily for 90 days
11295731|NCT02727725|Experimental|Traminer MRI Sequence|The TRAMINER MRI sequence implementation to be tested allows the acquisition of high resolution MR images in the free-breathing patient, by combining multiple averages and motion correction with the TRAMINER preparation.
11295732|NCT02727712|Experimental|TPVB T2/3+T5/6+GA|the group A of patients has been received bilateral thoracic paravertebral block (TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4), before general anesthesia management
11295733|NCT02727712|Experimental|TPVB T3/4+GA|the group Bof patients has been received bilateral thoracic paravertebral block (TPVB 3/4) by ropivacaine(0.3%,10ml*4), before general anesthesia management Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
11295734|NCT02727712|Placebo Comparator|GA|group C under control (without TPVB)program Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
11295735|NCT02727699|Experimental|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
11295736|NCT02727699|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
11295737|NCT02727686|Experimental|Water Load (WL) Post-Operative Day 1|All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
11295738|NCT02727673||healthy volunteers|matched group
11295739|NCT02727673||hepatitis cirrhosis|negative group
11295740|NCT02727673||hepatocellular carcinoma|patients with primary HCC
11295741|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
11295742|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
11295743|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
11295744|NCT02727647|Experimental|Arm 1|FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
11295745|NCT02727647|Experimental|Arm 2|FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months
11295746|NCT02727634|Other|Postoperative elective CABG patients|Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.
11295747|NCT02727621|Active Comparator|Dexmedetomidine group|
11295748|NCT02727621|Active Comparator|Propofol group|
11295749|NCT02727608|Experimental|Eculizumab|Intravenous infusion
11295750|NCT02727595|Experimental|CyclaPlex Implant|Implant device for reduction of the inter metatarsal angle (IMA) without osteotomy.
11295751|NCT02727569||Feasibility Study|10 subjects. Subjects will performed two different versions of the new visual field algorithm with DLS (differential light sensitivity) strategies. Two repeats of each strategy will be performed.
11295752|NCT02727569||Clinical evaluation study|100 subjects. Subjects will performed a visual field assessment with the new visual field algorithm with MMDT (Moorfields Motion Displacement Test) and DLS -like stimuli and a commercial available SITA algorithm (DLS-like strategy). Two repeats of each strategy will be performed.
11295753|NCT02727556|Experimental|Functional dyspepsia patient|Visual stimuli of food and non-food images will be presented to patients. Non-food images include positive, neutral, negative emotional pictures.
11295754|NCT02727556|Experimental|Healthy|Visual stimuli of food and non-food images will be presented to participants. Non-food images include positive, neutral, negative emotional pictures.
11295755|NCT02727543|No Intervention|Control|Participants randomized to this arm will not receive the intervention.
11295756|NCT02727543|Experimental|Intervention|Participants randomized to this arm will receive the intervention, Medisafe, a smartphone application.
11295757|NCT02727530|Experimental|GROUP RECEIVING VISCERAL MANUAL THERAPY-ADVICES|Subjects will receive 2 manual therapy sessions and advices.
11295758|NCT02727530|Experimental|GROUP RECEIVING ADVICES|Subjects will receive advices.
11295759|NCT02727517|Active Comparator|Early (≤ 60 seconds) cord clamping|Early (≤ 60 seconds) cord clamping
11295761|NCT02727504||Patient with aortic valve stenosis|"115 patients will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.
~Then will be performed :
~An electrocardiogram
~2D and 3D echocardiography
~Dobutamine stress echocardiography
~Blood tests : blood electrolytes, creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-ProBNP), C reactive protein (CRP), soluble suppression of tumorigenicity-2 (ST-2)
~A cardiac MRI
~A cardiac scanner
~A 6-minutes walking test
~An evolution of the Duke Activity Score"
11295762|NCT02727491|Experimental|dextromethorphan|1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy
11295763|NCT02727491|Placebo Comparator|Placebo|30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group
11295764|NCT02727478|Experimental|Balance training group|1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
11295765|NCT02727478|No Intervention|Control group|Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.
11295766|NCT02727465||meningitis cases|any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged <16 years) or next-of-kin (for non-survivors)
11295767|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
11295768|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
11295769|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
11295770|NCT02727439|Experimental|Sedentary Subjects|Healthy lean sedentary subjects.
11295771|NCT02727439|Experimental|Athletes|Active athletes.
11295772|NCT02727426|Experimental|low salt diet|All subjects will be instructed to maintain a low-sodium (LS) diet, with an intake of less than 2.3 g of salt per day (DASH eating plan; US Department of Health and Human Services, 2006) for 7 days (washout period).
11295773|NCT02727426|Experimental|high salt diet|After washout period, all subjects will be instructed to maintain a high-sodium (HS) diet, with an intake of 11.2 g of salt per day for 7 days.
11295774|NCT02727413||Infective endocarditis|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with infective endocarditis in accordance with Duke criteria and scheduled for valve surgery
11295775|NCT02727413||Valvular heart disease|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with valvular heart disease, with no signs of infection, scheduled for valve replacement surgery
11295776|NCT02727400||advanced maternal age|Infertile women due to advanced maternal age
11295777|NCT02727400||Young patients|women under 35 undergoing infertility treatments
11295778|NCT02727387|Experimental|TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL|2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for<14 years old ,800 mg/die for>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for<14 years old, 50 mg/m2 for>14 years old)
11295779|NCT02727374|Experimental|EXPERIMENTAL|Physiotherapy intervention, plus cognitive-behavioural intervention
11295780|NCT02727374|Active Comparator|CONTROL|Physiotherapy intervention
11295781|NCT02727361|Experimental|Cholinergic striatal imaging|Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer
11295782|NCT02727348|Experimental|Sciatic block with or without femoral block|Sciatic block with or without femoral block performed on the patient with 3mg/kg of ropivacaine
11295783|NCT02727348|Active Comparator|Spinal anaesthesia|Spinal anaesthesia will be performed on the patient with heavy marcaine 0.5% up to 3mls
11295784|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
11295785|NCT02727322|Active Comparator|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
11295786|NCT02727322|Placebo Comparator|Placebo|Receives matching placebo
11295787|NCT02727309|Experimental|apatinib|Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.
11295788|NCT02727296|Active Comparator|propofol|Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
11295789|NCT02727296|Active Comparator|sevoflurane|Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
11295790|NCT02727283|Experimental|Cohort 1|Subjects will receive 1 placebo and 3 escalating doses in one of the four treatment periods. The planned dose range is 10 mg to 200 mg. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
11295791|NCT02727283|Experimental|Cohort 2|Cohort 2 will proceed after completion of the treatment periods in Cohort 1. Subjects assigned to Cohort 2 will participate in up to 4 dosing periods which include up to 2 escalating doses and placebo in Periods 1 and 2, and a pilot food effect in Periods 3 and 4. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
11295792|NCT02727270||Parkinson's - High Stress|Parkinson's disease patients with self-reported high strain/stress.
11295793|NCT02727270||Parkinson's - Low Stress|Parkinson's disease patients with self-reported low strain/stress.
11295794|NCT02727270||Controls - High Stress|Healthy controls (no neurological disease) with self-reported high strain/stress.
11295795|NCT02727270||Controls - Low Stress|Healthy controls (no neurological disease) with self-reported low strain/stress.
11295796|NCT02727270||Huntington's - High Stress|Huntington's disease patients with self-reported high strain/stress.
11295797|NCT02727270||Huntington's - Low Stress|Huntington's disease patients with self-reported low strain/stress.
11295798|NCT02727257|Experimental|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. All the exercises are aerobic. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
11295799|NCT02727257|No Intervention|healthy controls|we assessed the attentive Reaction Times in healthy controls, that don't receive rehabilitative treatment
11295800|NCT02727231|Experimental|day and night closed loop control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
11295801|NCT02727231|Active Comparator|usual insulin pump therapy management|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (FreeStyle Navigator CGM)
11295802|NCT02727218|Experimental|chest tube removal after 3 hours|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal after 3 hours.
11295803|NCT02727218|Active Comparator|delayed chest tube removal|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal according to the department's protocol, most probably post operative day 1 (POD1)
11295804|NCT02727205|Experimental|Single Arm|One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.
11295805|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
11295806|NCT02727192|No Intervention|Control group|No sleep apnea treatment
11295807|NCT02727179|Experimental|Laparoscopic group|Liver resection performed by laparoscopic approach
11295808|NCT02727179|Active Comparator|Open group|Liver resection performed by open approach
11295809|NCT02727166|Experimental|Inulin 8 g/d|Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
11295810|NCT02727166|Placebo Comparator|maltodextrine 8 g/d|
11295811|NCT02727153|Experimental|"Ultra E.R.A.S."|Discharge patients on Post Operative Day 2
11295812|NCT02727153|Active Comparator|Classic E.R.A.S.|Discharge patients on Post Operative Day 4
11295813|NCT02727140|Experimental|Yoga with Asana (yoga postures)|
11295814|NCT02727140|Experimental|Yoga without Asana (yoga postures)|
11295815|NCT02727140|No Intervention|Wait-list control group|
11295816|NCT02727127||Healthy Volunteers|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
11295817|NCT02727127||Bipolar Patients|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
11295818|NCT02727114||participants aged 8 weeks to 3 years|"Echographic measurement of skin thickness at the proximal forearm, the deltoid region and medial thigh (till age of 2 years) in participants aged 8 weeks to 3 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
11295819|NCT02727114||participants aged 3 to 6 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 3 to 6 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
11295820|NCT02727114||participants aged 6 to 12 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 6 to 12 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
11295821|NCT02727114||participants aged 12 to 18 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 12 to 18 years.
~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
11295822|NCT02727101|Active Comparator|phenobarbital|"After 12 weeks of baseline observation on phenobarbital medication, the treatment with perampanel will introduced as add on medication."
11295823|NCT02727101|Active Comparator|valproate|"After 12 weeks of baseline observation on valproate medication, the treatment with perampanel will introduced as add on medication."
11295824|NCT02727101|Active Comparator|lamotrigine|"After 12 weeks of baseline observation on lamotrigine medication, the treatment with perampanel will introduced as add on medication."
11295825|NCT02727101|Active Comparator|levetiracetam|"After 12 weeks of baseline observation on levetiracetam medication, the treatment with perampanel will introduced as add on medication."
11295826|NCT02727101|Active Comparator|zonisamide|"After 12 weeks of baseline observation on zonisamide medication, the treatment with perampanel will introduced as add on medication."
11295827|NCT02727101|Active Comparator|pregabalin|"After 12 weeks of baseline observation on pregabaline medication, the treatment with perampanel will introduced as add on medication."
11295828|NCT02727101|Active Comparator|lacosamide|"After 12 weeks of baseline observation on lacosasmide medication, the treatment with perampanel will introduced as add on medication."
11295829|NCT02727101|Active Comparator|clobazam|"After 12 weeks of baseline observation on clobazam medication, the treatment with perampanel will introduced as add on medication."
11295830|NCT02727101|Active Comparator|ezogabine|"After 12 weeks of baseline observation on ezogabine medication, the treatment with perampanel will introduced as add on medication."
11295831|NCT02727101|Active Comparator|eslicarbazepine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
11295984|NCT02725970||Western Human Nutrition Research Center|Survey, no intervention.
11295832|NCT02727101|Active Comparator|topiramate|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
11295833|NCT02727101|Active Comparator|tiagabine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
11295834|NCT02727088|Active Comparator|Pulpectomy : root canal treatment|Pulpectomy : ablation of the whole dental pulp, preparation and filling of the whole root canal system
11295835|NCT02727088|Experimental|Pulpotomy : Conservative pulp management|Pulpotomy : ablation of the coronal part of the pulp
11295836|NCT02727062|Experimental|OM Pain Smartphone Application|This study examines whether the smartphone OM Pain App is a feasible and valid tool to assess pain from radiation-induced oral mucositis.
11295837|NCT02727049|Experimental|injured athlete for OMM|Participating athletes who sustain an injury will receive standard of care with the Intervention osteopathic manipulative medicine (OMM)
11295838|NCT02727049|No Intervention|injured athlete no OMM|Participating athletes who sustain an injury will receive standard of care withOUT osteopathic manipulative medicine (OMM)
11295839|NCT02727036|Experimental|Pumpkin seed oil|Pumpkin seed oil (1g) capsules - 2 capsules per day for 12 weeks
11295840|NCT02727036|Active Comparator|Pumpkin seeds|Packet of pumpkin seeds (4.1 grams /~0.15ounces) - 1 pack per day for 12 weeks
11295841|NCT02727023|Experimental|Osteopathic Manipulative Medicine|The thoracic inlet release, The Miller Thoracic Pump, Pedal Pump will be performed. These techniques are gentle and would be rhythmic in motion.
11295842|NCT02727010||mothers with motor impairment due to a rare disease|20 Women with motor impairment due to a rare disease
11295843|NCT02727010||mothers with motor impairment not related to a rare disease|controls, 20 women with motor impairment not related to a rare disease
11295844|NCT02726997|Experimental|Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)|"NEOADJUVANT CHEMOTHERAPY: Before debulking surgery, patients receive durvalumab and carboplatin IV over 1 hour on day 1, and paclitaxel IV over 3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo debulking surgery.
~SURGERY: After 3 courses of chemotherapy, patients undergo debulking laparoscopic surgery.
~ADJUVANT THERAPY: Beginning after debulking surgery, patients receive carboplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on days 1, 8, and 15, and durvalumab IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive durvalumab IV over 1 hour on day 1 and 15. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity."
11295845|NCT02726984|Experimental|case|Patients with carotid plaque ≥ 50% symptomatic (ischemic stroke on CT or MR) during the last 15 days
11295846|NCT02726984|Experimental|control|Patients with asymptomatic carotid plaque ≥ 50%
11295847|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.
~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
11295848|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.
~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
11295849|NCT02726958||group M|patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure
11295850|NCT02726958||group T|other patients
11295851|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
11295852|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
11295853|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
11295854|NCT02726919|Other|Clobazam treatment|This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
11295855|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
11295856|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
11295857|NCT02726893||patients undergoing colonoscopy|patients undergoing colonoscopy were observed in terms of the bowel preparation quality which is measured by Boston Bowel Preparation Scale (BBPS).
11295858|NCT02726880|Active Comparator|Referral for care|
11295859|NCT02726880|Experimental|Behavioral therapy|
11295860|NCT02726867|Active Comparator|levetiracetam|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 4000 mg levetiracetam.
11295861|NCT02726867|Active Comparator|lacosamide|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 600 mg lacosamide.
11295862|NCT02726867|Active Comparator|ketamine|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 2.5 mg/kg ketamine.
11295863|NCT02726867|Active Comparator|phenobarbital|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin (PHT) with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after PHT loading will receive intravenously (i.v.) phenobarbital 15 mg/kg.
11295864|NCT02726854|Experimental|Apatinib|Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
11295865|NCT02726841|Experimental|Hybrid TAAD repair|The group includes patients who underwent open thoracoabdominal aortic repair + abdominal stenting.
11295866|NCT02726841|Active Comparator|Conventional TAAD repair|The group includes patients who underwent classic thoracoabdominal aortic repair with dacron prosthesis.
11295867|NCT02726828|Active Comparator|group I: morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
11295868|NCT02726828|Active Comparator|group II: ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
11295869|NCT02726828|Active Comparator|group III: morphine + ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
11295870|NCT02726802|Experimental|Physical Therapy route of entry|The subject will see a physical therapist as their initial encounter into the healthcare system
11295871|NCT02726802|Active Comparator|Primary Care Provider rout of entry|The subject will see a primary care provider as their initial encounter into the healthcare system
11295872|NCT02726789|Experimental|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
11295873|NCT02726776|Experimental|Suspension without prior climbing|Free Suspension in a harness after baseline measurements and without prior climbing
11295874|NCT02726776|Experimental|Suspension with prior climbing|Free Suspension in a harness after baseline measurements and after climbing in moderate intensity for 10 minutes
11295875|NCT02726763|Experimental|tDCS with cognitive training|We will collect: 1) self-reported demographic information (~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (~10min) [60]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (~5 min)
11295876|NCT02726750||Observational (biospecimen collection)|Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
11295877|NCT02726737|Experimental|sodium bicarbonate|0.7 mL of 8.4% sodium bicarbonate & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
11295878|NCT02726737|Active Comparator|Non-sodium bicarbonate|Sterile distilled water & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
11295879|NCT02726724|Experimental|Condition B|An audience of 5 people with at least 2 neonatologists will be present with the operator during the intubation of the mannequin.
11295880|NCT02726724|Experimental|Condition A|Only the staff will be present with the operator during the intubation of the mannequin.
11295881|NCT02726711|Experimental|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.
~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.
~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
11295882|NCT02726711|Placebo Comparator|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.
~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.
~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
11295883|NCT02726685|Experimental|RT (respiratory training) group|Besides traditional rehabilitation therapy, subjects also receive 12-week respiratory training.
11295884|NCT02726685|Sham Comparator|Control group|Besides traditional rehabilitation therapy, subjects receive 12-week sham training unrelated to respiratory function.
11295885|NCT02726672|Experimental|Respiratory rehabilitation|Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
11295886|NCT02726672|No Intervention|control group|No respiratory rehabilitation
11295887|NCT02726659|Experimental|Celecoxib|Adjunct celecoxib in 6 week treatment
11295888|NCT02726659|Placebo Comparator|Placebo|Adjunct placebo in 6 week treatment
11295889|NCT02726646|Placebo Comparator|Debridement|mechanical debridement in one session and application of 1 mg placebo microspheres in two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
11295890|NCT02726646|Experimental|Debridement plus Doxycycline|mechanical debridement in one session associated with the application of 1 mg of microspheres loaded with doxycycline per periodontal pockts, two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
11295891|NCT02726620|Experimental|Hypotension decision support|"The intervention period. Several decision support elements are implemented to notify anesthesia providers: attending anesthesiologists and in-room anesthesia providers of intraoperative hypotension (threshold of a mean arterial pressure below 60 mmHg). Two types of decision support will be implemented: near real-time decision support and feedback emails.
~Near real-time decision support elements will notify the anesthesia providers of a blood pressure drop below the threshold and display the associated increased risk of acute kidney injury. The notification is presented through the pager system for attending anesthesiologists and through the anesthesia information management system for the in-room anesthesia provider.
~All providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension that is associated with an increased risk of organ injury due to organ ischemia."
11295892|NCT02726620|Active Comparator|Usual care group|The 'before' period - or historic control group - during which no decision support for intraoperative hypotension was being used, also known as 'usual care'. This is the three year period prior to the intervention period (the 'Intraoperative hypotension decision support' arm).
11295985|NCT02725970||Human Nutrition Research Center On Aging|Survey, no intervention.
11295893|NCT02726607|Experimental|HITSystem 2.0|Pregnant women who are eligible for PMTCT services will be enrolled in the HIV Infant Tracking System 2.0 (HITSystem 2.0) intervention during their first PMTCT appointment and followed until 12 weeks postpartum.
11295894|NCT02726607|Active Comparator|Standard of PMTCT Care|Pregnant women who are eligible for PMTCT services will receive standard of care PMTCT services at the control hospital. The records of women enrolled during their first PMTCT appointment will be used to assess outcomes during the same follow-up period.
11295895|NCT02726594||Patients|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
11295896|NCT02726594||Subjects|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district ETH / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
11295897|NCT02726581|Experimental|Investigational Arm|"Nivolumab, Pomalidomide and Dexamethasone
~Enrollment is closed for this arm"
11295898|NCT02726581|Active Comparator|Control Arm|"Pomalidomide and Dexamethasone
~Enrollment is closed for this arm"
11295899|NCT02726581|Experimental|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone
~Enrollment is closed for this arm"
11295900|NCT02726568|Experimental|Icotinib 375mg Tid|The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.
11295901|NCT02726555|Experimental|Red yeast rice and atorvastatin|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
11295902|NCT02726555|Active Comparator|Atorvastatin alone|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
11295903|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
11295904|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
11295905|NCT02726529|Experimental|Brighter Bites|Children of families in the intervention group will also receive the Coordinated Approach to Child Health (CATCH) school-based curriculum in addition to families receiving fresh fruits and vegetables to take home from school once a week along with nutrition education for 8 weeks in Fall and 8 weeks in Spring semesters of the school year.
11295906|NCT02726529|Active Comparator|Comparison|
11295907|NCT02726516|Experimental|Treated|Treated volunteers will be administered one dose of PRJ-205 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of PRJ-205 for 4 days for the chronic testing.
11295908|NCT02726516|Placebo Comparator|Placebo|Placebo volunteers will be administered one dose of placebo 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of placebo for 4 days for the chronic testing.
11295909|NCT02726503|Experimental|Treatment Arm|
11295910|NCT02726490|Active Comparator|Glyburide|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
~The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.
~The dose of glyburide will be increased as needed to a maximum of 20mg /day.
~Antenatal testing will be initiated at 28 weeks
~Patients will receive monthly growth scans"
11295911|NCT02726490|Active Comparator|Glucovance|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.
~The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.
~Patients will receive monthly growth scans
~Antenatal testing will be initiated at 28 weeks."
11295912|NCT02726477|Experimental|Wuling San|"This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.
~A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry."
11295913|NCT02726477|Placebo Comparator|placebo|A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.
11295914|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
11295915|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
11295916|NCT02726438|Experimental|Debio 1450|"Participants will receive 3 oral administrations of Debio 1450 at a dose of 240 mg approximately 12 hours apart. The last dose should be given approximately 2, 4, 6 or 12 hours prior to surgery with 3 patients each to be dosed at each of these time points.
~If the surgery is delayed by more than 12 hours postdose, the patients could receive up to 2 additional administrations (approximately 12 hours apart) to ensure that the last dose is administered between 2 and 12 hours before the surgery."
11295917|NCT02726438|No Intervention|Calibration|A single participant will not receive the study drug, providing data to be used as calibration.
11295918|NCT02726425|Experimental|Second Life Participants|Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)
11295919|NCT02726425|Active Comparator|Face-to-Face Participants|The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.
11295920|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
11295921|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 1|Regimen 1 of ND0612 continuous SC infusion over 24 hrs
11295922|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 3|Regimen 3 of ND0612 continuous SC for over 16 hrs
11295923|NCT02726373|Experimental|Intermittent walking training|
11295924|NCT02726373|Active Comparator|Continuous Walking Training|
11295925|NCT02726360||Oncology physician|Physicians (MD or DO) in the oncology departments of participating hospitals will complete a survey. Non-English language proficiency will be assessed by self-assessment using Interagency Language Roundtable (ILR) scale, which the PI has previously used. The physician survey is collected among treating physicians of patients enrolled to MSK IRB approved protocols 12-099 and 12-223 at some of the participating hospitals. For physicians who already completed this survey as part of participation in protocol 12-099 or 12-223, data will be extracted from the respective study's REDCap database.
11295926|NCT02726360||patients|Audio record the initial visits between patients and their treating physician. Analyze 48 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
11295927|NCT02726347|Active Comparator|Smokers between the ages of 19-80|current smokers between the ages of 19 and 80
11295928|NCT02726347|Active Comparator|elderly individuals (over age 50)|elderly individuals, defined as subjects age 50 years or older, without a history of frequent infections, COPD, or asthma
11295929|NCT02726347|Active Comparator|COPD subjects|COPD subjects between the age of 19 and 80, without history of recurrent bacterial infections.
11295930|NCT02726347|Active Comparator|Asthmatics subjects|Asthmatics between the ages of 19 and 80
11295931|NCT02726347|Active Comparator|Subjects with recurrent bacterial infections|Individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
11295932|NCT02726334|Experimental|Group/Stream 1 - Monotherapy|"Patient group: Patients who have failed at least two lines of chemotherapy for metastatic disease.
~Treatment: BNC101 administered via intravenous infusion over 60 minutes weekly.
~Patients with stable disease or a response at or after day 56 (2 cycles) will be allowed to continue to receive weekly doses of BNC101 until disease progression."
11295933|NCT02726334|Experimental|Group/Stream 2 - Combination Chemo|"Patient Group: Patients who have failed at least one line of chemotherapy for metastatic disease.
~Treatment: BNC101 administered in combination with FOLFIRI
~Participants will be treated until disease progression, intolerable toxicity, withdrawal of consent, or study termination by the Sponsor, whichever occurs first."
11295934|NCT02726308|Active Comparator|Dexamethasone Group|I.V. Dexamethasone 5 mg just before induction plus intra-operative 10 ml/kg Ringer's lactate solution.
11295935|NCT02726308|Active Comparator|Dexamethasone and super-hydration Group|I.V. Dexamethasone 5 mg just before induction of anesthesia plus intraoperative 30 ml/kg Ringer's lactate solution
11295936|NCT02726295|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.
11295937|NCT02726295|Placebo Comparator|Matched placebo|Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).
11295938|NCT02726269|Active Comparator|CLA (Clarithro+Lanso+Amoxi)|Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
11295939|NCT02726269|Experimental|PLA (Panto+Levoflox+Azithro)|Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
11295940|NCT02726256||Diabetes and Impaired glucose Tolerance (G-CREDIT)|Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
11295941|NCT02726243||IBD without CRC|
11295942|NCT02726243||IBD with CRC|
11295943|NCT02726243||IBD with dysplasia|
11295944|NCT02726243||non IBD without CRC|
11295945|NCT02726243||non IBD with CRC|
11295946|NCT02726243||IBD-PSC without CRC|
11295947|NCT02726243||IBD-PSC with CRC|
11295948|NCT02726243||IBD-PSC with dysplasia or healthy subjects|IBD-PSC with dysplasia or healthy subjects for whom a colonoscopy is scheduled
11295949|NCT02726230|Experimental|Ananya Intervention|"Strengthen enumeration and mapping of areas to ensure reach of front line workers (FLWs: auxiliary nurse midwives- ANMs; community health workers- ASHAs; anganwadi workers- AWWs).
~Convene monthly FLW meetings to build skills and get trained in job kits to increase the quantity and quality of household visits.
~Train FLWs on communication skills and use of mobile kunji, a job-aid tool, to improve FLWs' communication with households.
~A mass media campaign inclusive of street theatre, tv and radio, and a mobile van.
~Community mobilization linking mass media efforts with self-help groups.
~Quality improvement activities at public health facilities.
~Facility-based skills training to staff delivering infants to improve quality of care"
11295950|NCT02726230|No Intervention|Control Condition|standard of care public health services in India
11295951|NCT02726217|Experimental|CareSmarts Intervention|Participants in the program receive text messages about diabetes self-care
11295952|NCT02726217|Active Comparator|Control|Standard of Care reminders and assessments for individuals with Diabetes
11295953|NCT02726204|Active Comparator|Healthy Subjects|Seven healthy patients will serve as controls based on preliminary data in healthy volunteers using CAREX with gravity elimination alone versus gravity elimination plus path assistance.
11295954|NCT02726204|Active Comparator|Chronic Post Stroke Right Side Hemiparesis|Radiologically verified unilateral stroke patients with at least 4 months previously.
11295955|NCT02726191|Experimental|Posit Science|
11295957|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.
~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
11295958|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.
~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
11295959|NCT02726152|Experimental|Polymer clips|Patients will be randomised to polymer clips for closure of the appendiceal stump
11295960|NCT02726152|Active Comparator|Endoloops|Patients will be randomised to endoloops for closure of the appendiceal stump
11295961|NCT02726139||Emory University|Samples obtained at and shipped from Emory University
11295962|NCT02726139||University of Michigan|Samples obtained at and shipped from University of Michigan
11295963|NCT02726126||C group, (n=25)|C group, (n=25) each patient received transdermal placebo patch
11295964|NCT02726126||TDF group, (n=25)|TDF group, (n=25) each patient received transdermal therapeutic system-fentanyl 50μg/h
11295965|NCT02726126||TDM group, (n=25)|TDM group, (n=25) each patient received transdermal therapeutic system containing 7 mg of melatonin
11295966|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
11295967|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
11295968|NCT02726100|Experimental|Intervention arm|Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.
11295969|NCT02726100|No Intervention|Control arm|"Control group doesn't use SMARTHealth Diabetes.The usual-care in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance."
11295970|NCT02726087|Experimental|ministernotomy|"Minimally invasive aortic valve replacement with Partial J upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice."
11295971|NCT02726087|Active Comparator|full sternotomy|Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.
11295972|NCT02726074|Experimental|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
11295973|NCT02726061|Experimental|Internet Based psychological support|The internet-based psychological support intervention (PATH) is an internet based Problem Solving Therapy, stress management training and conflict management training program.
11295974|NCT02726048|Experimental|Full face/Nasal masks|Simplus/Eson
11295975|NCT02726035|Experimental|Group 1 A-ABAB|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 1 will receive oral naltrexone 50 mg daily during weeks 5-7 (3 weeks). They will switch to placebo for weeks 8-10, then return to naltrexone for weeks 11-13, then placebo for weeks 14-16 (i.e., A-ABAB double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
11295976|NCT02726035|Experimental|Group 2 A-BABA|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 2 will receive oral placebo once daily during weeks 5-7. They will then be switched to oral naltrexone 50 mg daily for weeks 8-10, then return to placebo for weeks 11-13, then naltrexone for weeks 14-16 (i.e., A-BABA double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
11295977|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
11295978|NCT02726009|Experimental|Degarelix|
11295979|NCT02725996|Experimental|curative therapy+NK infusion|Adjuvant adoptive immune therapy using NK cell 4 times after curative therapy
11295980|NCT02725996|Other|curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation[RFA]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
11295981|NCT02725983|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015). Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
11295982|NCT02725983|Active Comparator|No Intra Oral camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015) and considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon was not used.
11295983|NCT02725970||Children's Nutrition Research Center|Survey, no intervention.
11295986|NCT02725970||Delta Obesity Prevention Research Center|Survey, no intervention.
11295987|NCT02725970||Beltsville Human Nutr Research Center|Survey, no intervention.
11295988|NCT02725970||Grand Forks Human Nutr Research Center|Survey, no intervention.
11295989|NCT02725957|Experimental|Trehalose 9%|Single dose administration of Trehalose 9% for IV infusion.
11295990|NCT02725957|Placebo Comparator|Saline 0.9%|Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)
11295991|NCT02725944||Patients with cryptogenic stroke and TIA|Implantation of ICRM in all participants.
11295992|NCT02725931|Experimental|Activity group|Pulmonary rehabilitation plus physical activity intervention
11295993|NCT02725918|Experimental|Pem mono|Patients in arm B will receive pemetrexed (500 mg/m2, d1) every 3 weeks until PD or intolerable toxicities.
11295994|NCT02725918|Active Comparator|Pem+Cis|Patients in arm A will receive 4 cycles of cisplatin (75 mg/m2, d1) and pemetrexed (500 mg/m2, d1) every 3 weeks, those without disease progression (PD) and being tolerable judged by investigator will continue single-agent pemetrexed (500 mg/m2, d1) every 3 weeks as maintenance until progression or intolerable toxicities.
11295995|NCT02725905|Experimental|Multi-Modal Education (MME)|1) The MME is a three year multi-modal educational intervention including a series of interactive learning components and interventions focused on integrated weight management counseling. Prior to its launch, each component of the curriculum will be refined using a school participatory approach to help ensure feasibility and acceptability.
11295996|NCT02725905|Active Comparator|Traditional Education (TE)|2) The TE arm of the study includes the school's current curriculum which may include topics related to the treatment of weight management and obesity.
11295997|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
11295998|NCT02725879||HASIMOTO's PATIENTS (HT)|Children and Adolescents diagnosed with Hashimoto's clinical hypothyroidism.
11295999|NCT02725879||CONTROL GROUP (C)|Healthy individuals matched for gender and age
11296000|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
11296001|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
11296002|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
11296003|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
11296004|NCT02725840||Proton beam radiation therapy|The participants in this group will be receiving proton therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
11296005|NCT02725840||X-ray based radiation therapy|The participants in this group will be receiving X-ray radiation therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
11296006|NCT02725827|Active Comparator|HA group|One the day of frozen-thawed embryo transfer, frozen embryos will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife), a hyaluronan-enriched embryo transfer medium, will be used as embryo transfer medium. EmbryoGlue contains a higher concentration of hyaluronan than the control medium.
11296007|NCT02725827|Active Comparator|Control group|For women allocated to the control group, the usual transfer medium used in the study centers will be used and will serve as control. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.
11296008|NCT02725814|Experimental|Sucrose|
11296009|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
11296010|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
11296011|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
11296012|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
11296013|NCT02725775|Active Comparator|100% OJ|240ml 100% Florida Orange Juice consumed on a daily basis for 10 weeks.
11296014|NCT02725775|Placebo Comparator|Equicaloric Orange Drink|An equicaloric placebo orange drink (containing equivalent dose of sucrose, glucose, fructose, vitamin C and citric acid for flavour) consumed daily for 10 weeks.
11296015|NCT02725762|Experimental|Photobiomodulation Treatment|Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
11296016|NCT02725762|Sham Comparator|Sham Treatment|Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
11296017|NCT02725749|Experimental|Laser|
11296018|NCT02725749|Experimental|Exercise|
11296019|NCT02725749|Experimental|Laser and Exercise|
11296020|NCT02725736|Experimental|Atosiban|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Atosiban group.
11296021|NCT02725736|Experimental|Nifedipine|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Nifedipine group.
11296022|NCT02725723|Experimental|Subject after epidural injection|Subjects are patients from the clinic who have been diagnosed with Lumbar spinal stenosis and determined eligible for receiving steroidal epidural injection for pain management
11296023|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
11296024|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
11296025|NCT02725697||TCM treatment|TCM treatment (e.g. acupuncture, Tuina massage, Chinese herbal medicine, moxibustion, electroacupuncture, ear acupuncture)
11296026|NCT02725684||Glioblastoma|Observational study, no intervention
11296027|NCT02725671|Other|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
11296028|NCT02725658|Other|DOSI|
11296029|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
11296030|NCT02725632|No Intervention|Control|"An age-matched control group will be enrolled and consented. A Data Collection Sheet will be used to document data from the subject's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.
~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. Another blood drawn will be collected after one month. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
11296031|NCT02725632|Active Comparator|OSA|"Newly diagnosed OSA patients will be enrolled and consented. A Data Collection Sheet will be used to document data from the patient's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.
~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. The patients on CPAP treatment will be followed-up for 1 month. Another blood drawn will be collected after one month of CPAP treatment. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
11296032|NCT02725619|Experimental|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
11296033|NCT02725619|Active Comparator|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
11296034|NCT02725606|Active Comparator|Pegylated Recombinant Human G-CSF|100ug/kg 6 subjects (2 subjects per GW003 cohort)
11296035|NCT02725606|Experimental|GW003 300ug/kg|6-8 subjects
11296036|NCT02725606|Experimental|GW003 650ug/kg|6-8 subjects
11296037|NCT02725606|Experimental|GW003 850ug/kg|6-8 subjects
11296038|NCT02725593|Experimental|Dapagliflozin|
11296039|NCT02725593|Placebo Comparator|Dapagliflozin placebo|
11296040|NCT02725580|Experimental|Open Label|Subjects with diagnosis of vLINCL6 Batten disease will receive a single intrathecal injection into the lumbar spinal cord region of AT-GTX-501.
11296041|NCT02725567|Experimental|Part A|"Group 1: Participants 12 to < 24 months
~Group 2: Participants 6 to < 12 months (enrollment begins after an assessment of data from Group 1)
~Group 3: Participants 3 to < 6 months (enrollment begins after an assessment of data from Group 2)
~Group 4: Participants 0 to < 3 months (enrollment begins after an assessment of data from Group 3)"
11296042|NCT02725567|Experimental|Part B|"Group 5: Participants 12 to < 24 months (enrollment begins after an assessment of data from Part A, Group 1
~Group 6: Participants 6 to < 12 months (enrollment begins after an assessment of data from Part A, Group 2
~Group 7: Participants 0 to < 6 months (enrollment begins after an assessment of data from Part A, Group 3, and also enrollment for subjects < 3 months begins after review of data from Part A Group 4)"
11296043|NCT02725554|Active Comparator|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
11296044|NCT02725554|Experimental|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
11296045|NCT02725541|Experimental|Experimental|Trastuzumab emtansine at a dose of 3.6 mg/kg will be administered via intravenous infusion for 6 weeks (two 21-day cycles).
11296046|NCT02725528|Active Comparator|collagenase injection|This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.
11296047|NCT02725528|Active Comparator|limited palmar fasciectomy|The Dupuytren's cord will be excised under local anesthesia in a minor procedure room setting or main operating room under local or general anesthetic depending on the complexity of the disease and the surgeon's routine. As this is a pragmatic study comparison of collagenase injections (novel intervention) to limited palmar fasciectomy as it is actually presently performed in all settings academic or community (local in minor room or general/local anesthetic in the main operating room) will be examined. Surgery will be performed according to the operating surgeon's preferred technique i.e. zig-zag Brunner incision or straight incision with z-plasty closure of the skin.
11318566|NCT02576457|Other|Placebo|Placebo on specified days
11296048|NCT02725515|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
11296049|NCT02725515|Placebo Comparator|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
11296050|NCT02725502|Active Comparator|Linagliptin treatment group|Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin
11296051|NCT02725502|Placebo Comparator|Placebo group|Group will receive placebo for 3 months in addition to their insulin
11296052|NCT02725489|Experimental|Part 1 Cohort 1: 1x10^6 cells Vigil|The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
11296053|NCT02725489|Experimental|Part 1 Cohort 2: 1x10^7 cells Vigil|Cohort 2 will receive Vigil at 1x10^7 cells/ID injection and durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
11296054|NCT02725489|Experimental|Part 1 Cohort -1: 1x10^5 cells Vigil|If needed, Cohort -1 will be used which will receive Vigil at 1x10^5 cells/ID injection and Durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
11296055|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
11296056|NCT02725463|Experimental|vestibular implant|Up to 30 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
11296057|NCT02725450|Experimental|Motor Imagery + Psychomotor Battery of fine motor skills|Application of Motor Imagery together with normal practice improves fine motor skills in disabled individuals.
11296058|NCT02725437|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
11296059|NCT02725437|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
11296060|NCT02725437|Placebo Comparator|Placebo (accelerated schedule)|
11296061|NCT02725437|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
11296062|NCT02725437|Experimental|High-dose C. difficile Vaccine (non-accelerated schedule)|
11296063|NCT02725437|Placebo Comparator|Placebo (non-accelerated schedule)|
11296064|NCT02725424|Active Comparator|Her2 Positive with SOX|Her-2 Positive patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin 130 mg/m2, iv, d1 S-1 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), po,Bid， d1-14 Every 3weeks
11296065|NCT02725424|Experimental|Her2 Positive with SOXT|Her-2 positive patients treated with Oxaliplatin plus S-1 and Trastuzumab Oxaliplatin : As Above S-1: As Above Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks
11296066|NCT02725424|Active Comparator|Her2 Negative with SOX|Her2 Negative patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin As Above S-1 As Above Every 3 weeks
11296067|NCT02725424|Experimental|Her2 Negative with DOS|Her-2 Negative patients treated with Docetaxel plus Oxaliplatin and S-1（DOS） Docetaxel 60 mg/m2, iv, d1 Oxaliplatin 100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks
11296068|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
11296069|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
11296070|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
11296071|NCT02725398|Experimental|Buscopan group|First to use standard white light to observe, to record spasm score, to observe the lesion.Buscopan (BSP, 20mg) is administered by endoscopic nurse, recorded blindly.
11296072|NCT02725398|Active Comparator|Scopolamine group|First to use standard white light to observe, to record spasm score, to observe the lesion.Scopolamine is administered by endoscopic nurse, recorded blindly.
11296073|NCT02725398|Placebo Comparator|physiological saline group|First to use standard white light to observe, to record spasm score, to observe the lesion. Physiological saline is administered by endoscopic nurse, recorded blindly.
11296074|NCT02725385||Ancillary-Correlative (stress and coping)|"PART I:
~Participants complete a questionnaire that measures several psychological constructs including stress, anxiety, depression, coping mechanisms, uncertainty, positive and negative emotions, and life satisfaction over 15-30 minutes.
~PART II:
~Participants undergo a Trier Social Stress Test during a laboratory session over 1.5 hours."
11296075|NCT02725372|Experimental|Inhaled Nitric Oxide 75mcg/KgIBW/Hr|"Part 1:
~15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.
~Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment (Open Label Treatment - All Subjects)"
11296076|NCT02725372|Placebo Comparator|Placebo|"Part 1:
~Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period"
11296077|NCT02725359|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
11296078|NCT02725359|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
11296079|NCT02725359|Active Comparator|Bupivacaine|Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
11296080|NCT02725346|Experimental|Computer-assisted planning|Acromioplasty with planification
11296081|NCT02725346|Active Comparator|No planning|Acromioplasty without planification
11296082|NCT02725333|Other|Shoulder Stabilization|Anteroposterior and superoinferior translations were assessed in patients, before and after shoulder stabilization, through a dedicated patient-specific measurement technique based on optical motion capture and computed tomography.
11296083|NCT02725320||Female Rotator Cuff Surgical Group|Females, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
11296084|NCT02725320||Male Rotator Cuff Surgical Group|Males, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
11296085|NCT02725294||COPD patients|Veterans with COPD who are cared for at VA Puget Sound Health Care System (Seattle, WA) or VA Eastern Colorado (Denver, CO) who are at high risk for a COPD exacerbation based on an exacerbation treated with prednisone or antibiotics in the year preceding enrollment.
11296181|NCT02724605|Other|Group B|Red blood cells unit age more than 14 days
11296086|NCT02725294||Informal Caregiver for COPD patients|Informal caregiver (ie. family member, friend, etc.) for the patient with COPD who is participating in the COPD patients cohort.
11296087|NCT02725281|No Intervention|Control group|"The patients in Group-I were not interfered by researchers before and during lithotripsy."
11296088|NCT02725281|Active Comparator|Stress ball|"The patients in Group II were given stress ball into their both palms as a before the lithotripsy and told to squeeze the ball whenever they would like."
11296089|NCT02725281|Active Comparator|Music|"The patients in Group-III were listened to the music chosen by them with a headset as a nonpharmacological method during lithotripsy."
11296090|NCT02725268|Experimental|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligrams per square meter (mg/m^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
11296091|NCT02725268|Experimental|Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg|Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
11296092|NCT02725268|Experimental|Sapanisertib 30 mg|Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
11296093|NCT02725268|Experimental|Sapanisertib 4 mg + MLN1117 200 mg|Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
11296094|NCT02725255|Experimental|Papaya seed porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
11296095|NCT02725255|Active Comparator|Albendazole and Plain porridge|Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
11296096|NCT02725255|Placebo Comparator|Plain porridge|arm receiving 300ml plain porridge daily (without papaya seeds)
11296097|NCT02725242|Experimental|Once-daily budesonide/formoterol (160/4.5 μg/d)|once-daily budesonide/formoterol (160/4.5 μg/d)
11296098|NCT02725242|Active Comparator|Twice-daily Budesonide (200μg)|twice-daily Budesonide (400μg/d)
11296099|NCT02725229|Active Comparator|parasternal block group|Patients in this group will be randomized to receive an parasternal block and PCA.
11296100|NCT02725229|Active Comparator|TENS group|Patients in this group will be randomized to receive an TENS and PCA.
11296101|NCT02725229|Active Comparator|control group|Patients in this group will be randomized to receive an PCA.
11296102|NCT02725203|Experimental|Intervention: Activate intervention|Participants in the intervention arm will visit their primary care nurse four times in a three-month period for structured and comprehensive support in achieving an improved level of physical activity.
11296103|NCT02725203|No Intervention|Control|Patients in the control arm will receive care as usual.
11296104|NCT02725190|Other|Group 1|Normal sleep night.
11296105|NCT02725190|Other|Group 2|Sleepless night.
11296106|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
11296107|NCT02725164|Placebo Comparator|Uncuffed tracheal tubes|After tracheal intubation with an uncuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
11296108|NCT02725164|Active Comparator|Cuffed tracheal tubes|After tracheal intubation with a cuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
11296109|NCT02725138|Experimental|Probiotic|subjects will be treated with probiotic containing Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
11296110|NCT02725138|Placebo Comparator|Placebo|subjects will be treated with placebo without Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
11296111|NCT02725125|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0days,the first day,the second day,28 days,29 days Duration:total five times
11296112|NCT02725112|Experimental|Pregabalin ER- Target Release 330mg|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
11296113|NCT02725112|Experimental|Pregabalin ER - Slow Release 330mg|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
11296114|NCT02725112|Experimental|Pregabalin ER - Fast Release 330mg|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
11296115|NCT02725112|Experimental|Pregabalin IR - 300mg|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
11296116|NCT02725112|Experimental|Pregabalin ER - Target Release 82.5mg|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
11296117|NCT02725112|Experimental|Pregabalin ER - Aberrant Fast 330mg|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
11296118|NCT02725099|Active Comparator|Oral Ticagrelor|
11296119|NCT02725099|Experimental|Chewing Ticagrelor|
11296120|NCT02725086|Experimental|Part 1; Filgrastim 5 ㎍/kg|Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
11296121|NCT02725086|Experimental|Part 2; Filgrastim 10 ㎍/kg|Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
11296122|NCT02725073|Experimental|photodynamic therapy|Photodynamic therapy with a novel photosensitizer and flexible laser catheter
11296182|NCT02724592|Experimental|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
11296183|NCT02724592|Active Comparator|control|control group, only Fluoride varnish (Duraphat®)
11296123|NCT02725060|Experimental|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:
~Posture study with blood samples for autoantibody testing
~24-hour heart rhythm and blood pressure monitoring
~autonomic function tests
~Quantitative Axonal Sudomotor Reflex Testing
~Total blood volume assessment
~Pharmacologic testing with phenylephrine
~Pharmacologic testing with isoproterenol
~Cardiac output with rebreathing
~Assessment of splanchnic capacitance
~Microneurography"
11296124|NCT02725047|Experimental|TREATMENT - CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
11296125|NCT02725047|Placebo Comparator|PLACEBO - SAND|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
11296126|NCT02725034|Active Comparator|Group 1|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
11296127|NCT02725034|Experimental|Group 2|High definition endoscopy with Optic Enhancement targeted biopsies for gastric intestinal metaplasia.
11296128|NCT02725021|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
11296129|NCT02725021|No Intervention|Control group|
11296130|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
11296131|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
11296132|NCT02724969|Experimental|MILK intervention group|Semi-automated text messages sent to participants' cellular phones 3-5 times per week beginning Week 25 of pregnancy, through 8 weeks postpartum, specific to breastfeeding support and prevention of perceived insufficient milk supply.
11296133|NCT02724969|Active Comparator|Text4Baby control intervention group|Text4Baby automated texts sent to participants' cellular phones 3-5 times per week from Week 25 of pregnancy through the postpartum period from the national Text4Baby system. Messages provide general prenatal and postpartum support, including breastfeeding.
11296134|NCT02724956|Experimental|Ambu AuraGain|"SGAD placement using Ambu AuraGain
~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.
~Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.
~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.
~Inflate cuff and remove aScope."
11296135|NCT02724956|Experimental|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector
~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.
~Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.
~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.
~Inflate cuff and remove aScope."
11296136|NCT02724943|Experimental|TX CORD Intervention|TX CORD Intervention. The intervention entailed: (1) BMI screening, (2) Next Steps brief counseling materials for the healthcare provider, (3) a 3-month intensive Mind Exercise Nutrition Do It! and Coordinated Approach To Child Health (MEND/CATCH) phase, which included the Mind Exercise Nutrition Do it! ( MEND) programs for preschool (ages 2-5) and school-aged (ages 6-12) children coupled with adapted CATCH activities, and (5) a 9-month transition MEND/CATCH Transition phase, which offered monthly reinforcement sessions for parents and children, and twice weekly Young Men's Christian Association (YMCA) sports for children. Community Health Workers (CHWs) serve as program liaisons and assist in delivering all intervention group sessions as well as tracking families. Electronic Health Record (EHR) changes supported the screening and Next Steps delivery.
11296137|NCT02724943|Active Comparator|Brief Clinic Comparison|Next Steps brief clinical intervention. The comparison program was a 12-month clinic-based program conducted at twelve partner healthcare clinics and entailed (1) EHR changes to support childhood obesity clinical visits; (2) BMI screening, (3) Next Steps brief counseling materials for the healthcare provider, and (4) Next Steps self-paced booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity.
11296138|NCT02724930|No Intervention|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
11296139|NCT02724930|Experimental|Implementation Facilitation|"Enhanced facilitation of COPES implementation.
~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
11296140|NCT02724917|Experimental|APN1125, Low Dose|APN1125, Low Dose
11296141|NCT02724917|Experimental|APN1125, Mid Dose|APN1125, Mid Dose
11296142|NCT02724917|Experimental|APN1125, High Dose|APN1125, High Dose
11296143|NCT02724917|Placebo Comparator|Placebo|Placebo to match
11296144|NCT02724904|Experimental|Allogeneic Stem Cell Transplantation|Patients will undergo reduced intensity conditioning (fludarabine and thiotepa) followed by fully matched related or unrelated allogeneic stem cell transplantation. Afterwards, patients will receive standard post-transplant care (Methotrexate).
11296145|NCT02724891||Arm 1 paper form first|paper questionnaires first then web/smart phone questionnaires after a 2-week washout period
11296146|NCT02724891||Arm 2 web/smartphone form first|web/smart phone questionnaires first then paper questionnaires after a 2-week washout period
11296147|NCT02724878|Experimental|Bevacizumab And Atezolizumab Combination|Patients will be administered a pre-determine dose of Bevacizumab and Atezolizumab intravenously every 3 weeks. Patients will be evaluated clinically every 3 weeks and will undergo disease assessments with imaging every 6 weeks.
11296148|NCT02724865|Active Comparator|Oral appliance therapy; Somnodent®|Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
11296149|NCT02724865|Active Comparator|Oral appliance therapy; Herbst®|Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
11296214|NCT02724358|Experimental|Rg3|20mg, BID, maintained though Month 12
11296150|NCT02724852|Active Comparator|HIV-infected adults|"Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.
~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
11296151|NCT02724852|Experimental|HIV-uninfected adults|"Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.
~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
11296152|NCT02724839|Experimental|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
11296153|NCT02724839|Experimental|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
11296154|NCT02724839|Experimental|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
11296155|NCT02724826|Experimental|Qigong therapy|The qigong treatment was done according to medical qigong, and is a way of affecting and directing qi (energy) for medical benefit. Each qigong practice included body posture adjustment, gentle movement, meditation, relaxation, breathing regulation practices and massage. The qigong was practiced in groups of ten to 15 participants. Each qigong session started with information about the philosophy and a general warm-up with soft movements and 14 selected qigong exercises according to the Biyun method.
11296156|NCT02724826|Active Comparator|Exercise therapy|Exercise therapy was carried out individually, adjusted for each participant. A physiotherapist instructed the participant with focused on the cervical and shoulder/thoracic regions. Each training session included stationary bicycle for ten minutes, 40 minutes of dynamic exercises. These exercises consisted of active movements in all neck directions and muscle exercises aimed to maintain/increase circulation, endurance and strength. The load at the muscle exercises was to achieve between 30 and 70% of maximum muscle capacity and was gradually increased as endurance and strength were gained.
11296157|NCT02724813|Experimental|Intervention arm|Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
11296158|NCT02724813|Active Comparator|Wait-list arm|Participant in this arm will receive therapy 8 weeks after initial assessment. Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
11296159|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
11296160|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
11296161|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
11296162|NCT02724774|Experimental|Promoting First Relationships® (PFR)|10 week home visiting program
11296163|NCT02724774|No Intervention|Parent Information Packet|A packet is mailed to the families, including handouts related to child development, health, and local resources.
11296164|NCT02724761|Experimental|Experimental: Racemic Epinephrine|Over the Counter (OTC) - 0.5 mL Nebulized Racemic Epinephrine
11296165|NCT02724761|Placebo Comparator|Placebo: 0.9% Normal Saline|0.5 mL 0.9% Normal Saline
11296166|NCT02724748|Experimental|Educational intervention|Beside usual care the intervention will encourage collaborative practices between staff, patients and family members to adopt more human patient-centred approach on the unit. The intervention is designed to impact on treatment culture and thereby treatment practices on the study wards.
11296167|NCT02724748|No Intervention|Treatment as usual|Wards allocated to comparison wards continue with their usual care. No restrictions on how nursing staff works in these wards, although participation in corresponding projects is not supported.
11296168|NCT02724735||Longitudinal Observational Cohort|Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189.
11296169|NCT02724722|Experimental|Intervention|a simple flyer in one empty bag with face-to-face health education
11296170|NCT02724722|Placebo Comparator|No Intervention|a simple flyer in one empty bag with no face-to-face health education
11296171|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
11296172|NCT02724670|Other|Radiation|IGRT 5x 2Gy/week, total dose: 78 Gy
11296173|NCT02724657|Experimental|Buteyko Method|Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
11296174|NCT02724657|No Intervention|Control|Asthma education.
11296175|NCT02724644|Experimental|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
11296176|NCT02724644|Placebo Comparator|EN3835 Placebo|Placebo
11296177|NCT02724631|Experimental|TubeClear® (Phase I)|To determine feasibility and tolerability, 15 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
11296178|NCT02724618|Experimental|Curcumin plus RT|120mg/day nanocurcumin during RT course
11296179|NCT02724618|Placebo Comparator|Placebo plus RT|120mg/day placebo of nanocurcumin during RT course
11296180|NCT02724605|Other|Group A|Red blood cells unit age 14 days or less
11319857|NCT02568085|No Intervention|2|Thyroidectomy
11296184|NCT02724579|Experimental|Treatment (reduced radiation therapy and chemotherapy)|"RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks.
~MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
11296185|NCT02724566|Other|Apelin then Placebo|First clamp during which an apelin infusion will be administered followed by a wash-out period and then, a second clamp in which a placebo infusion will be administered
11296186|NCT02724566|Other|Placebo then Apelin|First clamp during which a placebo infusion will be administered followed by a wash-out period and then, a second clamp in which an apelin infusion will be administered
11296187|NCT02724553|Other|Vertical orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the vertical position during routine cataract surgery
11296188|NCT02724553|Other|Horizontal orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the horizontal position during routine cataract surgery
11296189|NCT02724540|Experimental|Arm 1 - BE|Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.
11296190|NCT02724540|Experimental|Arm 2 - TACE|Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
11296191|NCT02724540|Experimental|Arm 3 - DEB - CLOSED|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.
11296192|NCT02724527|Placebo Comparator|Placebo|Matching capsule (BID administration Q12H)
11296193|NCT02724527|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) at 400 mg dose (100 mg x 4 capsules) (BID administration Q12H)
11296194|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
11296195|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
11296196|NCT02724475|Experimental|LA group|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated.
11296197|NCT02724475|Experimental|3D-CRT group|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times.
11296198|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
11296199|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
11296200|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
11296201|NCT02724436|Experimental|TACE|transcatheter arterial chemoembolization
11296202|NCT02724436|Experimental|TACE+radioembolization|TACE plus radioembolization with Y-90: 100
11296203|NCT02724423|Experimental|NRL-1|A single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
11296204|NCT02724410|Active Comparator|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages <13; age 13 or greater, then 1 gm daily)
11296205|NCT02724410|Experimental|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
11296206|NCT02724397|Experimental|Experimental group|(White endoscopy and then LCI/BLI) The patients will be evaluated by Standard White Light and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI).
11296207|NCT02724397|Active Comparator|Control group|(LCI/BLI then white endoscopy) The patients will be evaluated by Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy.
11296208|NCT02724384|Experimental|Group 1|Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly
11296209|NCT02724384|Experimental|Group 2|Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly
11296210|NCT02724384|Experimental|Group 3|Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly
11296211|NCT02724371|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
11296212|NCT02724371|Experimental|Revision Breast Reconstruction|participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
11296213|NCT02724358|Experimental|TACE|iodized oil (5ml) + Pirarubicin (20mg)
11296215|NCT02724358|Experimental|TACE + Rg3|the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
11296216|NCT02724358|Experimental|Control|standard liver protective therapy
11296217|NCT02724345||CK18 positive|HCC patients with CK18 high expression levels in tumor tissue.
11296218|NCT02724345||CK18 negative|HCC patients with CK18 high expression levels in tumor tissue.
11296219|NCT02724332|No Intervention|control group|Patients will be treated with radical hepatectomy only.
11296220|NCT02724332|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE
11296221|NCT02724319||Left heart catheterization patients|Patients presenting to the UF Health Jacksonville cardiac catheterization laboratory for left heart catheterization for suspected coronary artery disease and intent to undergo percutaneous coronary intervention will be targeted for enrollment and will be genotyped by SpartanRX
11296222|NCT02724306|Experimental|Active Lifestyle Programme|ALP will receive supervised exercise sessions twice per week for three months and once per week for the following three months. Participants will also take part in biweekly physical activity workshops for the period of the intervention. Each session consists of a warm-up (5-10min), aerobic (20-30min) and resistance exercises (15-20), and cool-down (5-10)stretches lasting in total 60min. The intensity of exercises will be at 65-85% of maximum heart rate as determined by maximal fitness test. Exercise will take place in small groups of two to five people. Behaviour change workshops to aid the uptake and maintenance of physical activity will be delivered every fortnight throughout the whole intervention period totalling 12 workshops. Workshops will also take place in small groups.
11296223|NCT02724306|No Intervention|Standard Care|The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
11296224|NCT02724293|Placebo Comparator|Group I (placebo)|patients received placebo.
11296225|NCT02724293|Active Comparator|Group II (pregabaline 300 once)|patients received pregabalin 300 mg 2 hours preoperatively.
11296226|NCT02724293|Active Comparator|Group III (pregabaline 300 twice)|patients received pregabalin 300 mg 2 hours preoperatively and 12 hours after the preoperative dose.
11296227|NCT02724293|Active Comparator|Group IV (pregabaline 600)|patients received pregabalin 600 mg 2 hours preoperatively
11296228|NCT02724280|Active Comparator|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
11296229|NCT02724280|Placebo Comparator|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
11296230|NCT02724267|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE only.
11296231|NCT02724267|Experimental|internal radiation group|Patients will be treated with TACE combined with internal radiation.
11296232|NCT02724254|Experimental|AP611074 5% gel|100 mg twice daily doses of AP611074 5% gel
11296233|NCT02724254|Placebo Comparator|Placebo|AP611074 matching placebo gel
11296234|NCT02724241|Experimental|nicotine|use of an e-cigarette filled with liquid with nicotine
11296235|NCT02724241|Experimental|no nicotine|Use of an e-cigarette filled with liquid without nicotine
11296236|NCT02724241|Sham Comparator|sham comparator|Use of empty e-cigarette (sham control)
11296237|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study. BMN 111 will be administered in one of the following daily dosing regimens: 15 μg/kg or 30 μg/kg daily.
11296238|NCT02724215||Patients with Sleep Apnea|Patients with increased apnea-hypopnea-index (>5/h)
11296239|NCT02724215||Patients without Sleep Apnea|Patients with normal apnea-hypopnea-index (5/h and below)
11296240|NCT02724202|Experimental|Open Label|All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
11296241|NCT02724189||Patients attending the preoperative assessment clinic|Patients in preoperative assessment clinic
11296242|NCT02724176|Experimental|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
11296243|NCT02724163|Active Comparator|Mitoxantrone|"Course 1
~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).
~Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).
~Course 2
~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).
~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
11296244|NCT02724163|Experimental|Liposomal daunorubicin|"Course 1
~Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).
~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).
~Course 2
~Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).
~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
11296245|NCT02724163|Experimental|Gemtuzumab Ozogamicin Dose Finding Study|"Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.
~Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.
~Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10."
11296246|NCT02724163|Active Comparator|High dose cytarabine|Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
11296247|NCT02724163|Experimental|Fludarabine & cytarabine|"Two courses of:
~Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).
~Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion"
11296248|NCT02724163|Active Comparator|Myeloablative conditioning|"Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).
~Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses)."
11296249|NCT02724163|Experimental|Reduced intensity conditioning|"Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).
~Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses)."
11296250|NCT02724150|Active Comparator|Omeprazole High dose|Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
11296251|NCT02724150|Experimental|Omeprazole Low Dose|Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
11296252|NCT02724137|Experimental|Physical Therapy Rehab and Fitbit®|Standard outpatient physical therapy rehabilitation after total knee replacement with the addition of a Fitbit® to promote physical activity.
11296253|NCT02724137|Active Comparator|Physical Therapy Rehab|Standard outpatient physical therapy rehabilitation after total knee replacement.
11296254|NCT02724124|Experimental|static stretching|group of 11 volunteers (gSS)
11296255|NCT02724124|Experimental|warm up -|group of 11 volunteers (gWU)
11296256|NCT02724124|Experimental|static stretching + warm up|(group of 11 volunteers - SS+WU)
11296257|NCT02724124|Experimental|warm up+static stretching|(group of 11 volunteers - WU+SS)
11296258|NCT02724124|Other|Control Group|No intervention - athletes rested
11296259|NCT02724111|Experimental|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade [NMB] (train-of-four [TOF] count 0, post-tetanic count [PTC] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
11296260|NCT02724111|Active Comparator|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade [NMB] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change [a prone position]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
11296261|NCT02724098|Active Comparator|intravenous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
11296262|NCT02724098|Active Comparator|subcutaneous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.
11296263|NCT02724085|Active Comparator|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296264|NCT02724085|Active Comparator|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296265|NCT02724085|Active Comparator|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296266|NCT02724085|Active Comparator|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296267|NCT02724085|Active Comparator|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296268|NCT02724085|Active Comparator|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296269|NCT02724085|Active Comparator|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
11296270|NCT02724072|Experimental|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
11296271|NCT02724059|Experimental|Patients with mediastinal lesions|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA
11296272|NCT02724046|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
11296273|NCT02724046|Active Comparator|Household prophylaxis|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
11296274|NCT02724046|Active Comparator|Village prophylaxis|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
11296275|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
11296276|NCT02724033|Active Comparator|Group B|Group B - antiemetic
11296277|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
11296278|NCT02724020|Active Comparator|Everolimus 10 mg|Everolimus 10 milligram (mg), capsules, orally, once daily in a 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program or up to 24 months.
11296279|NCT02724020|Experimental|MLN0128 30 mg|MLN0128 30 mg, capsules, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program or up to 24 months.
11296280|NCT02724020|Experimental|MLN0128 4 mg + MLN1117 200 mg|MLN0128 4 mg, capsules, orally, once daily for 3 days per week and MLN1117 200 mg, capsules, orally, once daily for 3 days per week on Days 1-3, 8-10, 15-17 and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program or up to 24 months.
11296281|NCT02724007||All participants|
11296282|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
11296283|NCT02723981|Experimental|COMBO-Stent|Implantation of COMBO-Stent and medication with (N)OAC and clopidogrel for 3 months followed by (N)OAC alone
11296284|NCT02723981|Active Comparator|Any Drug eluting or bare metal stent|Implantation of any drug eluting oder bare metal stent combined with anticoagulant medication according to ESC guidelines
11319858|NCT02568085|Experimental|3|Thyroidectomy with neck + Arista
11296285|NCT02723968|Other|Continuous glucose monitoring system|OGTT followed by continuous glucose monitoring system and finally IGTT and HbA1C dosage
11296286|NCT02723955|Experimental|Part 1A: Dose escalation GSK3359609|Participants will receive GSK3359609 as an intravenous (IV) infusion administered once every 3 weeks (Q3W) continuously at a dose level dependent on to which dose level the participant is accrued.
11296287|NCT02723955|Experimental|Part 1B: Expansion GSK3359609|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously at a dose level chosen for further exploration in dose expansion cohorts.
11296288|NCT02723955|Experimental|Part 2A: Dose escalation (GSK3359609+pembrolizumab)|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with 200 milligram (mg) of pembrolizumab as an IV infusion administered once Q3W continuously.
11296289|NCT02723955|Experimental|Part 2A: Dose escalation (GSK3359609+GSK3174998)|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with GSK3174998 as an IV infusion administered once Q3W.
11296290|NCT02723955|Experimental|Part 2A: Safety run-in (GSK3359609+chemotherapy)|Participants participating in Part 2A chemotherapy combination cohorts will receive GSK3359609 in combination with chemotherapy at doses and schedules based on standard of care practice.
11296291|NCT02723955|Experimental|Part 2A: Dose escalation (GSK3359609+ dostarlimab)|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with dostarlimab administered as an IV infusion at 500 mg Q3W for 4 cycles followed by 1000 mg Q6W.
11296292|NCT02723955|Experimental|Part 2A: Dose escalation (GSK3359609+dostarlimab+cobolimab)|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with dostarlimab administered as an IV infusion at 500 mg Q3W for 4 cycles followed by 1000 mg Q6W plus cobolimab administered as an IV infusion at 300 mg Q3W.
11296293|NCT02723955|Experimental|Part 2A: Dose escalation (GSK3359609+bintrafusp alfa)|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with bintrafusp alfa administered as an IV infusion at 2400 mg Q3W.
11296294|NCT02723955|Experimental|Part 2B: Expansion-GSK3359609|Participants will receive GSK3359609 as an IV infusion administered Q3W continuously in combination with 200 mg of pembrolizumab as an IV infusion administered once Q3W continuously.
11296295|NCT02723955|Experimental|Part 2B: Expansion-GSK3359609 (Q6W)|Participants will receive GSK3359609 as an IV infusion administered once every 6 weeks (Q6W) continuously in combination with 400 mg of pembrolizumab as an IV infusion administered Q6W continuously.
11296296|NCT02723942|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
11296297|NCT02723942|No Intervention|no intervention|no intervention
11296298|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
11296299|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
11296300|NCT02723916|Experimental|Intervention: ezParent Program|
11296301|NCT02723916|Active Comparator|Control: Health-e Kids App|
11296302|NCT02723903|Other|with CAD and somatic symptom|Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
11296303|NCT02723903|Other|without CAD, with somatic symptom|Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
11296304|NCT02723903|No Intervention|without CAD, without somatic symptom|Have neither coronary artery disease nor somatic symptom, continue follow-up.
11296305|NCT02723903|Other|with CAD, without somatic symptom|Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
11296306|NCT02723890|Experimental|Tyto Device|examination with Tyto device carried out by a nurse and sent online to the principle and co-investigators for remote analysis.
11296307|NCT02723877|Experimental|Eribulin and PQR309|PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing.
11296308|NCT02723864|Experimental|1|VX-970 will be administered IV on Days 2 and 9 of each 21-day cycle; Veliparib will be administered orally twice a day (BID) Days 1-3 and 8-10 of each cycle; Cisplatin will be administered at 40 mg/m2 IV Day 1 (and Day 8 from DL3 onwards) of each cycle
11296309|NCT02723851||Acute MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
11296310|NCT02723851||Non-MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
11296311|NCT02723825|Placebo Comparator|Less or equal to 2mm|the residual displacement is less than or equal to 2mm
11296312|NCT02723825|Placebo Comparator|Between 2-4mm|the residual shift is between 2-4mm, manual reset once again, as still between 2-4mm
11296313|NCT02723825|Active Comparator|Greater than 4mm|the residual displacement is greater than 4mm
11296314|NCT02723812|Experimental|GCFLU® Influenza vaccine (Split virion, Inactivated)|One dose 0.5 mL vaccine GCFLU® administered intramuscularly.
11296315|NCT02723799|Experimental|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
11296316|NCT02723799|Other|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
11296354|NCT02723500|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
11296355|NCT02723487|No Intervention|Group A|Control
11296317|NCT02723786|Experimental|GSK1070806 3 mg/kg IV|Subjects received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Subjects also received a combination immunosuppression comprized of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.
11296318|NCT02723773|Experimental|LTFU Group|Long-Term Follow-Up of the subjects who received at least one dose of the HZ/su vaccine in the primary studies ZOSTER-006/022
11296319|NCT02723773|Experimental|Additional Dose Group (1AdD Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 1 additional dose of the HZ/su vaccine in the current study.
11296320|NCT02723773|Experimental|Revaccination Group (Rev Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 2 additional doses of the HZ/su vaccine in the current study on a 0, 2 Month schedule (N=60).
11296321|NCT02723773|Sham Comparator|Control Group (Ctrl Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive no additional doses of the HZ/su vaccine in the current study and will control for the 1-Additional and Revaccination groups
11296322|NCT02723760|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of rheumatoid arthritis
11296323|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
11296324|NCT02723734||African-American Men (AAM)|AAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
11296325|NCT02723734||Non-African American Men (NAAM)|NAAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
11296326|NCT02723721|Experimental|Picato gel|application on1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
11296327|NCT02723708|Experimental|Self activation of VTA bold signal|Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
11296328|NCT02723695|Experimental|Patients|Surgery (cochlear implantation)
11296329|NCT02723695|Active Comparator|Controls|Asymptomatic subjects
11296330|NCT02723669|Experimental|AR10|AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g)
11296331|NCT02723669|Active Comparator|acetylcysteine|acetylcysteine solution; oral 20% (200 mg/mL)
11296332|NCT02723656|Active Comparator|Proactive mailed care coordination|
11296333|NCT02723656|Active Comparator|Proactive telephone care coordination.|
11296334|NCT02723630|Experimental|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
11296335|NCT02723630|Experimental|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
11296336|NCT02723630|Experimental|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
11296337|NCT02723630|Experimental|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
11296338|NCT02723630|Experimental|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
11296339|NCT02723630|Experimental|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
11296340|NCT02723617|Other|MED 0.5|
11296341|NCT02723617|Other|MED 2.5|
11296342|NCT02723617|Other|MED 5.5|
11296343|NCT02723617|Other|AAD 2.5|
11296344|NCT02723604|Experimental|Experimental: Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
11296345|NCT02723591|Active Comparator|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
11296346|NCT02723591|Active Comparator|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
11296347|NCT02723578|Experimental|Pemetrexed and Erlotinib|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and Erlotinib 150 mg PO once daily on days 1-21 every 21 days
11296348|NCT02723552|No Intervention|Control|Control participants undergo no intervention.
11296349|NCT02723552|Experimental|Exercise|Exercise group participants will undergo 16 weeks of 3x/week supervised aerobic exercise of at least 40 minutes per session. After the supervised exercise phase, they will be monitored and supported to maintain an increased physical activity level for eight months.
11296350|NCT02723539|Experimental|MBN-101|MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
11296351|NCT02723539|Placebo Comparator|Vehicle|MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate
11296352|NCT02723526||Single arm|
11296353|NCT02723513|Experimental|Preterm Adults|All enrolled preterm adults will undergo non-contrast enhanced MRI (using ultra-short echo time methods), hyperpolarized noble gas MRI (using hyperpolarized xenon-129), x-ray computed tomography (CT), pulmonary function tests, and questionnaires in a single visit.
11296356|NCT02723487|Active Comparator|Group B|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.125%), 0.5 ml/kg on each side.
11296357|NCT02723487|Active Comparator|Group C|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.25%), 0.5 ml/kg on each side.
11296358|NCT02723474|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.
11296359|NCT02723461|Active Comparator|pulsatile oxytocin|Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
11296360|NCT02723461|Active Comparator|continuous oxytocin|Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
11296361|NCT02723448|Other|Single Arm Study|Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant [Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients]. There is no maximum number of cycles.
11296362|NCT02723435|Experimental|Midostaurin|Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11296363|NCT02723422|Experimental|Prehabilitation Visit/Increased Physical Therapy post-TAVR|
11296364|NCT02723422|Active Comparator|Control|Standard of care physical therapy post-TAVR
11296365|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
11296366|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
11296367|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
11296368|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
11296369|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
11296370|NCT02723396||Parkinson|Prospective observation of a cohort of consecutive patients with idiopathic PD in an ecological setting.
11296371|NCT02723396||Healthy|The same assessments will be performed in a subgroup of age- and sex-matched healthy volunteers.
11296372|NCT02723383|Experimental|BACLOFEN|patient will receive baclofen caps
11296373|NCT02723383|Placebo Comparator|PLACEBO|patient will receive placebo caps (lactose)
11296374|NCT02723370|Experimental|Initial Intervention|Staff will receive the intervention during the initial intervention period.
11296375|NCT02723370|Experimental|Delayed Intervention|Staff will receive the intervention during the replication study.
11296376|NCT02723357|Experimental|Financial Coaching & Access to Services|Participants in this arm will receive monthly financial coaching and access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
11296377|NCT02723357|Active Comparator|Access to Services|Participants in this arm will receive access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
11296378|NCT02723344|Experimental|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
11296379|NCT02723344|Placebo Comparator|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
11296380|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
11296381|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
11296382|NCT02723318|Experimental|Financia Coaching & Social Services Referrals|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
11296383|NCT02723318|Active Comparator|Social Services|Enrollment in the control arm offers access to social services referrals.
11296384|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
11296385|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.
~+topical testosterone treatment for >1 year"
11296386|NCT02723292|Experimental|Experimental group services|This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
11296387|NCT02723292|Active Comparator|Control group services|Youth in the control arm will receive a work readiness training curriculum focused on competencies to secure employment. This will include such topics as building customer service skills, clear and direct communication, and creating a work portfolio.
11296388|NCT02723279|Experimental|EPNS group|
11296389|NCT02723279|Active Comparator|TT group|
11296390|NCT02723266|Experimental|Intervention|Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
11296391|NCT02723266|No Intervention|Control|Control does not receive the intervention.
11296392|NCT02723253|Experimental|Radiotherapy plus Tom-Ox|Patients received concomitant boost RT (55 Gy/5 weeks) with concurrent Tom-Ox chemotherapy. The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
11296393|NCT02723240|Other|Part 1|"NUC-3373 IV Infusion on Day 1, Day 8, Day 15, Day 22, (28 day cycle)
~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
11296394|NCT02723240|Other|Part 2|"NUC-3373 IV Infusion on Day 1, Day 15 (28 day cycle)
~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
11296395|NCT02723227|Experimental|Financial Coaching & Social Service Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
11296396|NCT02723227|Active Comparator|Social Services Referral|Enrollment provides for access to referrals to social services.
11296397|NCT02723214|Active Comparator|Frame-based stereotactic brain biopsy|Brain biopsy
11296398|NCT02723214|Active Comparator|Frameless fiducial-less brain biopsy|Brain biopsy
11296399|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
11296400|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
11296401|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
11296402|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
11296403|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
11296404|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
11296405|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
11296406|NCT02723188|Sham Comparator|Sham|Sham electrical stimulation
11296407|NCT02723188|Experimental|DC: Direct current|Direct current electrical stimulation
11296408|NCT02723188|Experimental|AC: Alternating current|Alternating current electrical stimulation
11296409|NCT02723175|Experimental|Sham tDCS Stimulation|"30 minutes of the sham transcranial Direct Current Stimulation
~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
11296410|NCT02723175|Experimental|Anodal tDCS Stimulation of DLPFC|"30 minutes of the active transcranial Direct Current Stimulation (tDCS)
~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
11296411|NCT02723162|Experimental|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
11296412|NCT02723162|Active Comparator|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
11296413|NCT02723162|Active Comparator|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
11296414|NCT02723162|Placebo Comparator|PBO+PBO|Double placebo taken for 28 days
11296415|NCT02723149|Experimental|Approach Avoidance Training Condition|The AAT group will push away the joystick from marijuana pictures 90% of the trials and pull towards the marijuana pictures 10% of the trials.
11296416|NCT02723149|Sham Comparator|Sham Condition|The sham group will undergo the same procedures, except the ratio for marijuana pictures will be 50% push and 50% pull.
11296417|NCT02723136|Experimental|Smartphone application|Participants allocated to this arm will receive a smartphone application developed to assist and guide the study of internal medicine and its subspecialties. The application will provide feedback to participants regarding their overall performance in terms of correct answers and the overall time required to solve a clinical vignette.
11296418|NCT02723136|No Intervention|Usual care|Students allocated to this arm will not receive any further assistance in studying for this trial's tests.
11296419|NCT02723123|Experimental|CPAP|CPAP will be provided for a approximately 45 minutes.
11296420|NCT02723123|Experimental|NIPPV|NIPPV will be provided for a approximately 45 minutes.
11296421|NCT02723123|Experimental|NIV-NAVA|NIV-NAVA will be provided for a approximately 45 minutes.
11296422|NCT02723110||rs78408340 heterozygous carriers|
11296423|NCT02723110||homozygous non-risk allele carriers|
11296424|NCT02723097|Experimental|Relaxation Response Resiliency Program (3RP)|
11296425|NCT02723084|Experimental|Arm A|Co-formulated ABT-493/ABT-530 (300 mg/120 mg) administered once daily (QD) for 8 weeks in HCV genotype (GT) 2 -infected, DAA treatment-naïve participants without cirrhosis.
11296426|NCT02723084|Active Comparator|Arm B|sofosbuvir (400 mg) QD co-administered with weight based ribavirin (RBV) 600-1000 mg divided twice daily (BID) for 12 weeks in HCV GT2 -infected, DAA treatment-naïve participants without cirrhosis.
11296427|NCT02723071|Experimental|Cohort A: Ocrelizumab 200 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
11296428|NCT02723071|Experimental|Cohort B: Ocrelizumab 375 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
11296429|NCT02723071|Experimental|Cohort C: Ocrelizumab 375/750 mg/m^2|Participants will receive first infusion of ocrelizumab 375 mg/m^2 followed by 7 infusions of 750 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
11296430|NCT02723058|Experimental|ICMHM|ICMHM mothers receive services of a primary care clinician (PCP) and a care manager both trained in depression care management in a shelter-based primary care clinic.
11296431|NCT02723058|No Intervention|Treatment as Usual|Treatment as Usual mothers receive usual services of a PCP and case manager from a shelter-based primary care clinic. .
11296432|NCT02723045|Active Comparator|Open modified Lichtenstein repair|Patients will undergo open repair of their inguinal hernias
11296433|NCT02723045|Active Comparator|Laparoscopic TEP inguinal hernia repair|Patients will undergo laparoscopic repair of their inguinal hernias
11296434|NCT02723032|Other|Healthy Subjects and patients|Validation of SpO2 sensor in healthy subjects as a first step. Validation of SpO2 sensor in patients as a second step.
11296435|NCT02723019|Experimental|Intervention Group|Volunteer Peer Mentor + Behavioral Health Nurse
11296436|NCT02723019|No Intervention|Control|Care as Usual
11296437|NCT02723006|Experimental|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
11296438|NCT02723006|Experimental|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
11296439|NCT02723006|Experimental|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
11296440|NCT02722993|Active Comparator|Probiotics|
11296441|NCT02722993|Placebo Comparator|Placebo|
11296442|NCT02722980|Placebo Comparator|Placebo|Capsules
11296443|NCT02722980|Active Comparator|Active|Capsules.
11296444|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
11296445|NCT02722954|Experimental|Demcizumab and Pembrolizumab|Demcizumab will be administered prior to pembrolizumab
11296446|NCT02722941|Active Comparator|Cohort A: Maintenance Therapy|Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
11296447|NCT02722941|Active Comparator|Cohort B: Maintenance Therapy|Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.
11296448|NCT02722928|No Intervention|Conventional 1:1 oxygen/air gas mixture|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
11296449|NCT02722928|Experimental|Pure oxygen ventilation|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture (60% oxygen concentration) during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with 100% (pure) oxygen concentration
11296450|NCT02722915|Experimental|fMRI Neurofeedback up-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
11296451|NCT02722915|Experimental|fMRI Neurofeedback down-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
11296452|NCT02722902|Experimental|LIPID + Carnitor|"intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion
~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.
~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
11296453|NCT02722902|Placebo Comparator|LIPID + PLAC|"Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)
~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
11296454|NCT02722902|Placebo Comparator|PLAC|"Infusion of saline (no IntraLipid and no carnitor)
~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h."
11296455|NCT02722889||Healthy controls|Healthy control patients
11296456|NCT02722889||Type A dissection|Patients with proven type A dissection,
11296457|NCT02722876|Experimental|Contralateral rehabilitation|8-weeks of resistance training of the non-operative limb following ACL reconstruction
11296458|NCT02722876|Placebo Comparator|Placebo flexibility exercise|8-weeks of 'placebo' flexibility training of the upper limb
11296459|NCT02722850|Experimental|ALIVE - Physical Activity|PA CONDITION: The goal of the PA condition is to encourage participants to gradually increase moderate to vigorous PA to 150 minutes per week and to increase resistance training to a total of 15 minutes per day twice per week.
11296460|NCT02722850|Experimental|ALIVE - Dietary Modification|DIET CONDITION: The goal of the dietary condition includes increasing intake of fruit and vegetable to 5-servings per day. The program also encourages participants to increase the consumption of colorful fruits and vegetables. The fat goals consist of reducing saturated fats to <10% of total kilocalories per day, trans fats to <3 grams per day, and added sugar to <50 grams per day.
11296461|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11296462|NCT02722824|Placebo Comparator|Placebo|Wearable stimulators will be placed on the patients and controls without stimulation for 20 minutes
11296463|NCT02722824|Experimental|Active Stimulation|Instrinsic auricular muscles will be stimulated for 20 minutes
11296464|NCT02722824|Sham Comparator|Sham|An area out of the instrinsic auricular muscles region will be stimulated with the same parameters of the active group for 20 minutes
11296465|NCT02722824|No Intervention|Passive Control|Only the electrodes of the wearable stimulators will be inserted but there will not be electrostimulation for 20 minutes
11296466|NCT02722811|Experimental|Etanercept treatment group|Subcutaneous injection etanercept of 50 mg/w and Health education, exercise and diet guidance; treatment: 8 weeks
11296467|NCT02722811|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 8 weeks
11296468|NCT02722798|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 44
11296469|NCT02722785|No Intervention|Usual Care Observation Group|Patients allocated to usual care control will receive the standard patient care program as provided by the department of surgical gastroenterology, Rigshospitalet
11296470|NCT02722785|Experimental|Aerobic and Resistance Exercise Training|Patients allocated to this group will receive usual care plus a supervised aerobic and resistance exercise program at CFAS' facilities consisting of 2 weekly sessions of approximately 60 minutes.
11296471|NCT02722772|Experimental|Etanercept treatment group|Intra-articular injection of etanercept of 25 mg/w/joint and Health education, exercise and diet guidance; treatment: 5 weeks (If both knees are involved, the more significant symptomatic side is chosen for injection by etanercept)
11296472|NCT02722772|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 5 weeks
11296473|NCT02722759|Other|hemoglobin measurement arm|"In this arm hemoglobin measurement is done by four different devices
~device Radical-7 for non-invasive measurement of SpHb
~device HemoCue for taking capillary and venous blood for measurement of HcHb
~device ABL 800 for measurement of BGAHb
~device Siemens ADVIA for measurement of labHb
~For measurement of haemoglobin by the devices the following interventions have to be done:
~venous or arterial puncture (routine)
~capillary puncture
~placing of the Radical 7 sensor"
11296474|NCT02722746|Placebo Comparator|Ropivacaine only Control group|The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.
11296475|NCT02722746|Active Comparator|Ropivacaine + 2 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.
11296476|NCT02722746|Active Comparator|Ropivacaine + 5 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.
11296477|NCT02722733|Active Comparator|G-CSF (filgrastim)|1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.
11296478|NCT02722733|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|"Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).
~G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis."
11296479|NCT02722720|Experimental|Carotid stenting, Transradial approach|Internal carotid artery stenting using transradial arterial approach
11296480|NCT02722720|Active Comparator|Carotid stenting, Transfemoral approach|Internal carotid artery stenting using transfemoral arterial approach
11296481|NCT02722694|Experimental|Subcutaneous(SC) Abatacept|
11296482|NCT02722694|Placebo Comparator|Placebo|
11296483|NCT02722681||Symptomatic spinal lipoma patients|Spinal lipoma patients undergoing surgery due to symptomatic lipoma. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intraoperatively and usually discarded, some will be kept for research.
11296484|NCT02722681||Asymptomatic spinal lipoma patients|Spinal lipoma patients who remain asymptomatic. Routine blood and urine samples will be taken as part of routine clinical care, some will be kept for research.
11296485|NCT02722681||Non-lipoma spinal conditions|Patients undergoing spinal surgery for a non-lipoma related condition. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intra-operatively and usually discarded, some will be kept for research.
11296486|NCT02722668|Experimental|No ATG|Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
11296487|NCT02722668|Experimental|ATG|Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
11296488|NCT02722655||Type 1 diabetes mellitus|Sudden onset of symptoms and non-overweight/obese
11296489|NCT02722655||Type 2 diabetes mellitus|Insidious onset of symptoms and overweight/obese
11296490|NCT02722655||Type 1.5 diabetes mellitus|Overlap of type 1 and type2 diabetes mellitus clinical characteristics
11296491|NCT02722655||Other types of diabetes mellitus|According American Diabetes Association criteria
11296492|NCT02722642|Experimental|Bronchial basal cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
11296493|NCT02722629|Experimental|Aspiration in COPD patients|All COPD patient will be evaluated systematically by FEESST (Flexible Endoscopic Evaluation of Swallowing with Sensory Testing) with direct evaluation of aspiration by direct observation.
11296494|NCT02722616|Active Comparator|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
11296495|NCT02722616|Active Comparator|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.
~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
11296496|NCT02722616|Other|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
11296497|NCT02722603|Experimental|gabapentin / placebo tramadol|gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
11296498|NCT02722603|Active Comparator|tramadol / placebo gabapentin|tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.
11296499|NCT02722590||Fycompa tablets 2/4/6/8/10/12 mg|Participants who are prescribed Fycompa film-coated tablets 2/4/6/8/10/12 milligrams (mg) per approved prescribing information in a normal clinical practice setting.
11296500|NCT02722564|Experimental|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
11296501|NCT02722551|Experimental|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
11296502|NCT02722538|Experimental|Residual Tumor following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
11296503|NCT02722538|Experimental|No Residual Tumor Following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
11296504|NCT02722525|Experimental|Diagnostic (cardiac MRI, skeletal muscle PMRS)|Patients undergo a treadmill stress CMR focused on cardiac muscle comprised of resting MRI over 10-15 minutes followed by treadmill exercise until peak stress. Patients then undergo MRI and gadopentetate dimeglumine perfusion imaging immediately after exercise and after a 6-8 minute recovery period. Within 24 hours of treadmill CMR exam, patients also undergo skeletal muscle PMRS while at rest, during, and in the recovery phase of resistive lower extremity exercise which patients complete over 30 seconds. Both procedures are performed before initiation of ADT treatment (baseline) and 4-7 months after initiation of ADT treatment.
11296505|NCT02722512|Experimental|Newly Diagnosed High Grade Glioma (HGG)|Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
11296506|NCT02722512|Experimental|Recurrent HGG and Ependymoma|On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.
11296507|NCT02722499|Experimental|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
11296508|NCT02722499|Experimental|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
11296509|NCT02722499|Experimental|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
11296510|NCT02722486|Active Comparator|Standard Vestibular Rehabilitation|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions of an hour each). During these sessions, standard balance training exercises will be done at the discretion of the physical therapists.
11296511|NCT02722486|Experimental|Vestibular Rehabilitation/Balance Belt|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions). They will undergo standard balance training exercises with the physical therapists like the control group, but will also undergo an additional 15 minutes of Balance Belt exercises during each session.
11296512|NCT02722473|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5°C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5°C for 24 hours.
11296513|NCT02722473|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5°C for 48 hours
11296514|NCT02722447|Active Comparator|Rivaroxaban|Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)
11296515|NCT02722447|Experimental|Placebo|Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)
11296516|NCT02722434|Experimental|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
11296517|NCT02722434|Active Comparator|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
11296518|NCT02722421|Experimental|Efavirenz group|HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.
11296551|NCT02722174||BED|Binge Eating Disorder
11296552|NCT02722174||ADHD|Attention Deficit Hyperactivity Disorder
11296519|NCT02722408|Experimental|Gemcabene|Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84. Participants were followed until Day 112.
11296520|NCT02722395||Single arm cohort study|
11296521|NCT02722382|No Intervention|Usual Nephrology Care|Nephrology care at Geisinger Health System.
11296522|NCT02722382|Active Comparator|Patient-Centered Kidney Transitions Care|Health system intervention which will implement informatics tools (including a disease registry, predictive modeling, and advance directives) and a disease specific care manager who will provide services and navigate patients through kidney disease transitions.
11296523|NCT02722369|Active Comparator|Control Arm|"IV carboplatin AUC5 (area under curve) on Day1
~IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3"
11296524|NCT02722369|Experimental|Investigational Arm|"IV gemcitabine 1200mg/m2 on Day 1 and Day 8
~IV carboplatin AUC5 on Day 1
~Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)"
11296525|NCT02722356|Experimental|Oxytocin|Oxytocin administered according to proposed protocol
11296526|NCT02722356|Active Comparator|Standard Practice|Oxytocin administered according to standard practice at facility
11296527|NCT02722343|Experimental|Tenofovir intravaginal ring|The tenofovir intravaginal ring (TFV IVR) is 55.0 mm in diameter, consisting of a single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. The IVR delivers 8-10mg/day of TFV.
11296528|NCT02722343|Active Comparator|Truvada oral tablets|"The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg). The tablets are commercially available as Truvada. The tablets are blue, capsule-shaped, film-coated, debossed with GILEAD on one side and with 701 on the other side"
11296529|NCT02722330|Experimental|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:
~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
11296530|NCT02722304|Experimental|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
11296531|NCT02722304|Experimental|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
11296532|NCT02722304|Experimental|GLASSIA 60 mg/kg|60 mg/kg body weight/week
11296533|NCT02722304|Experimental|GLASSIA 120 mg/kg|120 mg/kg body weight/week
11296534|NCT02722304|Placebo Comparator|Placebo|Human Albumin 2%
11296535|NCT02722291|Experimental|presbyopia|All participants perform all exams under 3 conditions, that is baseline, with out pinhole glasses, and with multiple pinhole glasses
11296536|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
11296537|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
11296538|NCT02722265|Experimental|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
11296539|NCT02722252||Embryoscope group|
11296540|NCT02722252||Embryo culture without incorporated camera group|
11296541|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
11296542|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
11296543|NCT02722226|Experimental|Simulation based sedation learning (Intervention Group)|The program includes online learning. It is followed by development of interactive presentations, based on simulated cases or simulated patients (actors), low fidelity simulation for specific technical skills as well as high fidelity scenarios of complications related to sedation.
11296544|NCT02722226|No Intervention|Control Group|
11296545|NCT02722213|Experimental|Mindfulness-Based Stress Reduction|"The intervention is an 8-week Mindfulness-Based Stress Reduction (MBSR) course, with 8 weekly 2.5-hour group sessions, and 1 all-day (6.5 hours) retreat, taught per standard protocol in a group setting. The course includes instruction and practice of meditation, breathing techniques, gentle yoga and Tai Chi poses, with shared discussion, brief readings and home practice between sessions. Participants will continue with usual care and receive standard educational materials on healthy lifestyles and stress management.
~Note: This study will recruit patients eligible for exercise-based cardiac rehabilitation (CR). Randomization to either MBSR or control (no MBSR) condition will occur within two strata (CR; no CR) will occur based on current enrollment in CR at time of study enrollment."
11296546|NCT02722213|No Intervention|Control (No MBSR)|"Those randomized to the control condition will continue with usual care and receive standard educational materials on healthy lifestyles and stress management. At the end of the study control participants will receive a compact disc and workbook on MBSR.
~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
11296547|NCT02722200|Experimental|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
11296548|NCT02722200|Placebo Comparator|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
11296549|NCT02722187|Experimental|microsurgery|40 patients will undergo subinguinal microscopic varicocelectomy
11296550|NCT02722187|Active Comparator|laparoscopy|20 patients will undergo laparoscopic varicocelectomy
11296553|NCT02722174||SUD, cocaine subtype|Stimulant Use Disorder, cocaine subtype
11296554|NCT02722174||BPD|Borderline Personality Disorder
11296555|NCT02722174||BPD, Cohort 2|Borderline Personality Disorder, Cohort 2
11296556|NCT02722174||HC|Healthy Controls
11296557|NCT02722161|Experimental|[14C]BI 1482694|
11296558|NCT02722148|Experimental|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
11296559|NCT02722135|Experimental|Volasertib|
11296560|NCT02722122|Experimental|AIR DNase™ 2.5 mg|2.5 mg of AIR DNase™ administered once daily via inhalation for 28 days
11296561|NCT02722096|Experimental|Axillary block anesthesia|Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery
11296562|NCT02722096|Active Comparator|Local anesthesia|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
11296563|NCT02722083|Experimental|BAY X002134|Subjects will be given BAY X002134
11296564|NCT02722083|Placebo Comparator|Placebo|Subjects will be given a placebo
11296565|NCT02722070||Healthy Controls|Age matched control for the various clinical groups
11296566|NCT02722070||Neurodegenerative patients|
11296567|NCT02722070||Stroke patients|
11296568|NCT02722070||Neuropsychiatric patients|
11296569|NCT02722057||Cohort 1 - Interventional|The Interventional cohort will not be utilized.
11296570|NCT02722057||Cohort 2 - Non Interventional|A Non-Interventional Cohort comprising pediatric (<18 years of age) and adult R117H-CFTR patients treated with commercially-available Kalydeco.
11296571|NCT02722057||Cohort 3 - Historical|A Historical Cohort comprising data from an earlier time period for pediatric (<18 years of age) and adult patients with the R117H-CFTR mutation who have never been exposed to Kalydeco and matched on age, gender, and lung function to patients in the Non-Interventional Cohort.
11296572|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
11296573|NCT02722018|Experimental|Part 1: GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
11296574|NCT02722018|Experimental|Part 2 (Optional): GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of two Phase III prototype tablets (Prototype 4 or 5) in a crossover fashion.
11296575|NCT02722018|Experimental|Part 3: GDC-0810 dose level B - Low Fat Meal/Fasted|Participants will receive a single dose of GDC-0810 dose level B on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal or under fasted condition either as Phase II tablet (with low fat meal) or as the Phase III prototype tablet selected from Parts 1 or 2 (with low fat meal or under fasted conditions), in a crossover fashion.
11296576|NCT02722005|Experimental|Financial Coaching & Access to Services|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
11296577|NCT02722005|Active Comparator|Access to Services|Participants will have access to a host of referrals to social services (this is the intervention for this group)
11296578|NCT02721992||Graves' Disease|Patients with Graves' disease, without Graves' Orbitopathy
11296579|NCT02721992||Graves' Orbitopathy|Patients with Graves' disease, with Graves' Orbitopathy
11296580|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
11296581|NCT02721966|Experimental|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
11296582|NCT02721966|Experimental|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
11296583|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
11296584|NCT02721953|Experimental|Hypocaloric diet plus butyrate|Hypocaloric diet plus butyrate
11296585|NCT02721953|Placebo Comparator|Hypocaloric diet plus placebo|Hypocaloric diet plus placebo
11296586|NCT02721940|Experimental|Treatment group|In the treatment group, patients will be given local injection of enriched autologous mononuclear cells and zoledronic acid into the necrotic area following core decompression by drilling.
11296587|NCT02721940|Experimental|Control group|In the control group, core decompression will be performed, but no treatment will be given.
11296588|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Subjects will receive 4 massotherapy sessions and 4 of HYPOPRESSIVE ABDOMINAL GYMNASTIC (HAG).
11296589|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
11296590|NCT02721914|Experimental|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
11296591|NCT02721901|Experimental|iEAT Manual Intervention|Caretakers of 10 children will be randomized to participate in the integrated Eating Aversion Treatment (iEAT) intervention. iEAT is a technology-based manual which aims to increase the child's food consumption.
11296592|NCT02721901|Active Comparator|Control group|Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
11296593|NCT02721888|Experimental|Main study|
11296594|NCT02721875|Experimental|Volasertib monotherapy|
11296595|NCT02721875|Experimental|Volasertib + azacitidine combination|
11296596|NCT02721862|Experimental|Experimental|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
11296597|NCT02721862|Placebo Comparator|Control|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
11296598|NCT02721849|Experimental|adolescent yoga / parent control|The adolescent will receive an 12 week yoga course, while one parent will only answer the questionnaires.
11296599|NCT02721849|Experimental|adolescent waitlist / parent yoga|One parent will participate in an 12 week yoga course, while the adolescent will receive the intervention after the follow-up period.
11296600|NCT02721849|Experimental|adolescent yoga / parent yoga|Both adolescent and parent will participate in an 12 week yoga course at the same time.
11296601|NCT02721849|No Intervention|adolescent waitlist / parent control|The adolescent will receive the intervention after the follow-up period, while one parent will only answer the questionnaires.
11296602|NCT02721836|Experimental|Yoga|12 week yoga course, two times a week 75 minutes each time
11296603|NCT02721836|Active Comparator|Nutrition|3 counselling sessions within 12 weeks
11296604|NCT02721823|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
11296605|NCT02721823|Active Comparator|control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
11296606|NCT02721810|No Intervention|Control|Prompts standard to rounds or electronic medical records.
11296607|NCT02721810|Experimental|Prompting Intervention|Prompting consideration of 3-month functional outcome.
11296608|NCT02721797||Skin|Patients with EDS diagnosis having surgery, have debrided skin retained for this research
11296609|NCT02721797||Tendon|Patients with EDS diagnosis having surgery, have debrided tendon retained for this research
11296610|NCT02721797||Uterine tissue|Patients with EDS diagnosis having surgery, have debrided uterine tissue retained for this research
11296611|NCT02721797||Vaginal tissue|Patients with EDS diagnosis having surgery, have debrided vaginal tissues retained for this research
11296612|NCT02721797||Ligaments|Patients with EDS diagnosis having surgery, have debrided ligaments retained for this research
11296613|NCT02721784|Other|Pre- and Post- Radiotherapy MRI|"mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:
~Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy
~External Beam Radiotherapy to be given after 3 months of androgen deprivation"
11296614|NCT02721758|Experimental|Brief Motivational Intervention|Single, 60-minute, manualized behavioural intervention designed to support cardiac rehabilitation enrollment, informed by principles of motivational interviewing
11296615|NCT02721758|No Intervention|Usual Care|Standard encouragement to enroll in cardiac rehabilitation, and meeting with a researcher to complete study questionnaires
11296616|NCT02721745|Experimental|Natural Fatigue|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
11296617|NCT02721745|Experimental|tDCS anodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
11296618|NCT02721745|Experimental|tDCS cathodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
11296619|NCT02721745|Experimental|tDCS sham|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
11296620|NCT02721745|Experimental|inhibitory TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
11296621|NCT02721745|Experimental|Sham TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
11296622|NCT02721732|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
11296623|NCT02721719||Healthy Adults|[Not receiving Vedolizumab] Healthy adults who have not donated blood within the past two months and who have no history of blood-borne diseases.
11296624|NCT02721719||Adults with no Inflammatory Bowl Disease|[Not receiving Vedolizumab] Adult patients undergoing endoscopy for indications other than Inflammatory Bowel Disease or other inflammatory conditions of the bowel (such as colon cancer screening or polypectomy)
11296625|NCT02721719||Donors with Ulcerative Colitis|[Set to receive Vedolizumab] Adults with an established diagnosis of UC (≥ 6 months preceding involvement in study) who are both scheduled for an endoscopy and are about to receive Vedolizumab treatment (standard of care).
11296626|NCT02721706|Experimental|CIPA screening tool|Patients are evaluated by CIPA nutritional screening tool
11296627|NCT02721706|No Intervention|usual hospital clinical care|Patients are not subject of CIPA screening tool, and continue the usual hospital clinical care
11296628|NCT02721693|Experimental|Treadmill exercise test|Patients are subjected to an incremental Cardiopulmonary Exercise Test to exhaustion
11296629|NCT02721680|Experimental|Healthy Subjects- Awareness Training Group 1|Subjects in this arm will undergo an internal awareness training program.
11296630|NCT02721680|Experimental|Healthy Subjects - Awareness Training Group 2|Subjects in this arm will undergo an external awareness training program.
11296650|NCT02721524|Active Comparator|Group R (ring)|Patients in Group R will undergo tricuspid ring annuloplasty
11296651|NCT02721524|Active Comparator|Group S (suture)|Patients in Group S will undergo De Vega's suture annuloplasty
11296704|NCT02721173|Experimental|Tazarotene group|This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
11296631|NCT02721667|No Intervention|Enhanced Usual Care|"Participants receive a home BP monitor, are taught how to measure home BP and are encouraged to take BP readings to appointments with their providers. In addition, they will be reminded to perform a home BP series each quarter for study outcome purposes, which will encourage self-monitoring.
~Home BP readings will be teletransmitted for data collection purposes but neither participants nor providers will have access to the these readings. High BP levels that trigger safety alerts to research personnel are the only exception - participants and their primary care providers will be made aware of these."
11296632|NCT02721667|Active Comparator|Telemonitoring and Case Management|"Home BP series mean, trends and individual readings will be generated for use by the case manager. Participants in this arm will each be assigned a pharmacist case manager who holds full prescribing privileges and who will:
~Administer health behaviour modification counselling, teach BP self-monitoring, and monitor medication adherence;
~Review telemonitored health portal BP summaries and make medication regimen adjustments according to guideline-concordant study protocol;
~Fax a summary of these adjustments to the participant's primary care provider (to make them aware of treatment changes); and
~Facilitate communication between participants and providers."
11296633|NCT02721654|Experimental|Plasma-Lyte 148®|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
11296634|NCT02721654|Active Comparator|0.9% sodium chloride|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
11296635|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
11296636|NCT02721628|Experimental|Epi-keratoplasty Group|Epi-keratoplasty Group: Reversible keratoplasty performed with only the removal of corneal epithelium of the host cornea. A donor graft is transplanted on the recipients' eye locating on the Bowman's layer.
11296637|NCT02721628|Active Comparator|Collagen Cross-Linking Group|Collagen Cross-Linking: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
11296638|NCT02721615|Active Comparator|Laminectomy|Comparison of bone decompression versus no decompression for reducing intra spinal pressure
11296639|NCT02721615|Active Comparator|Duraplasty|Expansion duraplasty versus no duraplasty for reducing intraspinal pressure
11296640|NCT02721615|Active Comparator|Hypothermia|Localised hypothermia for reducing intra spinal pressure and improving spinal cord metabolism
11296641|NCT02721602|Experimental|Intervention Group|Families in the Families Preventing Diabetes Together intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
11296642|NCT02721602|No Intervention|Measurement Only|No intervention only measurements
11296643|NCT02721589|Experimental|Injection SHR-1210|200mg/vial
11296644|NCT02721576|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T>40Gy/20f,week 1->5"
11296645|NCT02721563|Active Comparator|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
11296646|NCT02721563|Placebo Comparator|Control Group|"Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
11296647|NCT02721550|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4"
11296648|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
11296649|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
11319859|NCT02568085|No Intervention|4|Thyroidectomy with neck
11296652|NCT02721511|Experimental|Furosemide injection solution 8mg/mL|8mg/mL (total dose=80mg) of furosemide injection solution administered subcutaneously as 30mg over the first hour and then as 12.5 mg per hours over the subsequent 4 hours.
11296653|NCT02721498|Active Comparator|Visit A|Rest period for 30-60 minutes
11296654|NCT02721498|Active Comparator|Visit B|Airway clearance session utilising the Active Cycle of Breathing techniques (ACBT) supervised by a specialist physiotherapist for 30-60 minutes.
11296655|NCT02721485|Other|Normal Saline|Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Ringer's Lactate following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
11296656|NCT02721485|Other|Ringer's Lactate|Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Normal Saline following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians in for the final 90-day test period.
11296657|NCT02721472|Other|sickle cell disease patients|Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) < 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).
11296658|NCT02721459|Experimental|Dose Escalation|Escalating Doses of XL888 with Vemurafenib plus Cobimetinib.
11296659|NCT02721446|Other|VHA Cohort|Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if > 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
11296660|NCT02721446|Other|Eskenazi Health System Cohort|Investigators will use EHR data from Indiana Network for Patient Care (INPC) to identify a cohort of live patients with at least one primary care visit in the prior 12 months. Investigators will use identical methods to construct Framingham risk score variables from the EHR data.
11296661|NCT02721433|Active Comparator|4 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
11296662|NCT02721433|Active Comparator|12 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
11296663|NCT02721420|Other|Drug + short message(SMS) reminder|dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course
11296664|NCT02721420|Other|Drug + no short message(SMS) reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.
11296665|NCT02721420|Other|Drug+ Health worker reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.
11296666|NCT02721420|Other|Drug at hospital + SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.
11296667|NCT02721420|Other|Drug at Hospital+no SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course
11296668|NCT02721407|Experimental|Anti-CD22 CAR-T|Administrated with CD22.CAR-T cells on day 0,1,2 in the lympho-depleted patients
11296669|NCT02721394|Experimental|Researcher Implemented FCT|Children receive functional communication training. Assessment and initial intervention sessions are completed by the researcher and family carers are trained to continue the intervention at home.
11296670|NCT02721394|Experimental|Family Carer Implemented FCT 1|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher in person.
11296671|NCT02721394|Experimental|Family Carer Implemented FCT 2|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher via videoconferencing and support from a family carer assistant in person.
11296672|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
11296673|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
11296674|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
11296675|NCT02721368|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
11296676|NCT02721368|Active Comparator|Comparator medical device|Juvederm® Voluma® with Lidocaine
11296677|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
11296678|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
11296679|NCT02721342||Ramipril, Irbesartan and Atorvastin treatment|A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.
11296680|NCT02721329|Active Comparator|APAP without SensAwake|Auto CPAP delivered from the ICON+ CPAP device.
11296681|NCT02721329|Experimental|APAP with SensAwake|Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
11296682|NCT02721316|Experimental|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
11296683|NCT02721316|No Intervention|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
11296684|NCT02721303|Active Comparator|obese older aged, aged 65-85, BMI 30-40|Older aged patients who are obese and between the ages of 65-85 with a BMI between 30-40.
11296685|NCT02721303|Active Comparator|normal weight older aged, aged 65-85, BMI 18-25|Older aged patients who are of normal weight and between the ages of 65-85 with a BMI between 18-25.
11296686|NCT02721303|Active Comparator|obese younger aged, aged 21-45, BMI 30-40|Younger aged patients who are obese and between the ages of 21-45 with a BMI between 30-40 .
11296687|NCT02721290|Active Comparator|Femoral nerve block using Ultrasound and neurostimulator|Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.
11296688|NCT02721290|Experimental|Femoral nerve block using femoral artery target|Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.
11296689|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
11296690|NCT02721264|Experimental|Fecal Microbiota Transplantation (FMT)|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.
11296691|NCT02721264|Active Comparator|Standard Treatment Care|
11296692|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
11296693|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
11296694|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
11296695|NCT02721238|Active Comparator|Resuscitation with 30ml/kg plasmalyte|
11296696|NCT02721238|Experimental|Resuscitation with 20% Albumin|
11296697|NCT02721225|Active Comparator|Fructooligosaccharide|"One kind of prebiotics agent defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
11296698|NCT02721225|Placebo Comparator|Pocari-Sweat|Commercially produced isotonic solution by Otsuka Pharmaceutical Co., Ltd., Tokyo,Japan
11296699|NCT02721212|Experimental|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.
~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
11296700|NCT02721212|Active Comparator|Control Group|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).
~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.
~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
11296701|NCT02721199||Prospective Cohort|Neural Respiratory Drive Automated EMGpara assessment
11296702|NCT02721186|Experimental|MDA with DHAp and SLD Primaquine|MDA will be conducted at two time points with an approximate four-week interval. All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
11296703|NCT02721186|No Intervention|Control|The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms. This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
11296705|NCT02721173|Active Comparator|Adapalene group|This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.
11296706|NCT02721160|Experimental|Nutrition PBF|45 health centres are assigned to this group. The intervention consists in a performance based financing scheme applied to nutrition services.
11296707|NCT02721160|No Intervention|Control|45 health centres are in the control group. Health centres in this group are not incentivized, but they receive an equivalent funding to the one received by the intervention group. The main difference is that this payment is not based on their own performance.
11296708|NCT02721147|Experimental|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
11296709|NCT02721147|Active Comparator|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
11296710|NCT02721134|Other|additional blood tubes|
11296711|NCT02721121|Active Comparator|circumferential pulmonary vein isolation|circumferential pulmonary vein isolation
11296712|NCT02721121|Experimental|Linear ablation in addiction to pulmonary vein isolation|Linear ablation in addiction to pulmonary vein isolation
11296713|NCT02721108|Experimental|Mindfulness: Group A|Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
11296714|NCT02721108|Active Comparator|Relaxation: Group B|Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
11296715|NCT02721108|No Intervention|Treatment as usual: Group C|No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.
11296716|NCT02721095|Experimental|0.9%NaCl|KCl plus 0.9%NaCl
11296717|NCT02721095|Active Comparator|0.45%NaCl|KCl plus 0.45%NaCl
11296718|NCT02721082|Experimental|Opt Out|"Participants in this arm will be first enrolled to receive cessation treatment and will only not receive it by opting out. Participant will receive a Opt Out treatment program. Participants will receive counseling and nicotine replacement therapy."
11296719|NCT02721082|Active Comparator|Opt In|"Traditional approach to tobacco treatment program. Participants must first indicate they are ready to quit smoking by opting in to receive Opt In treatment program."
11296720|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
11296721|NCT02721056|Experimental|NBTXR3, IL or IA injection +SBRT|"Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 42% of the baseline tumor volume, activated by SBRT.
~Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT."
11296722|NCT02721043|Experimental|Personalized Genome Vaccine 001|"PGV-001 (peptides + Poly-ICLC)
~Peptides: 100mcg per peptide per dose.
~Poly-ICLC (Hiltonol®, Oncovir): 1.4mg (0.7mL, 2mg/mL)"
11296723|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
11296724|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
11296725|NCT02721004||Rheumatoid arthritis participants|Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
11296726|NCT02720991|Experimental|Mifepristone and sublingual misoprostol|200 mg mifepristone and 400 ug sublingual misoprostol
11296727|NCT02720978|Experimental|Intravenous oxytocin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.
~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:
~Verification rupture of membranes and gestational age.
~Choosing the treatment group Intravenous oxytocin from red envelope, randomly.
~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
~Induction according to departmental protocol of each delivery way.
~Data collecting after the delivery."
11296728|NCT02720978|Experimental|vaginal prostaglandin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.
~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:
~Verification rupture of membranes and gestational age.
~Choosing the treatment group vaginal prostaglandin from red envelope, randomly.
~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
~Induction according to departmental protocol of each delivery way.
~Data collecting after the delivery."
11296729|NCT02720965|Experimental|Electronic pump|Continuous nerve blocks Remote-controlled perineural local anesthetics delivery
11296730|NCT02720965|No Intervention|single injection|single injection
11296731|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).
~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
11296732|NCT02720939||ASD group|ASD patients who met the diagnostic criteria of either autistic disorder or Asperger's disorder defined by the DSM-IV criteria
11296733|NCT02720939||TD group|Typically development controls without lifetime diagnosis with ASD or any psychiatric disorders
11296734|NCT02720926|Experimental|TKI258 combined with Xeloda/Oxaliplatin|TKI258 200 mg once a day (OD) 5 days on/2 days off Capecitabine (Xeloda) 2000 mg/m2 bid d1-14 Oxaliplatin 130mg/m2 d1 q21days
11296735|NCT02720913|Experimental|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
11296736|NCT02720913|Active Comparator|Standard Suture Tying|Standard Suture Tying
11296737|NCT02720900|Placebo Comparator|Maltodextrin|powder, 1.8g/day
11296738|NCT02720900|Active Comparator|B-GOS|powder, 1.8g/day
11296739|NCT02720887||pregnant woman|Patient to receive an amniocentesis for medical reasons other than study and who will have a measure of nanoparticles load
11296740|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
11296741|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
11296742|NCT02720861||non embolic ischemic stroke|acute ischemic stroke from atherosclerosis or lacunar stroke
11296743|NCT02720848|Experimental|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
11296744|NCT02720848|Active Comparator|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
11296745|NCT02720822|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
11296746|NCT02720822|Experimental|Morphine Sulfate (0, 0, 8 mg)|Placebo on weeks one and two. Morphine 8 mg/day on week three.
11296747|NCT02720822|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo on week one. Morphine 8 mg/day on weeks two and three.
11296748|NCT02720822|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo on week one. Morphine 8 mg/day on week two. Morphine 16 mg/day on week three.
11296749|NCT02720822|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg/day on weeks one, two and three.
11296750|NCT02720822|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
11296751|NCT02720822|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on weeks two and three.
11296752|NCT02720822|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on week two. Morphine 24 mg/day on week three.
11296753|NCT02720822|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg/day on weeks one, two and three.
11296754|NCT02720822|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg/day on weeks one and two. Morphine 24 mg/day on week three.
11296755|NCT02720822|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on weeks two and three.
11296756|NCT02720822|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on week two. Morphine 32 mg/day on week three.
11296757|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
11296758|NCT02720783|Experimental|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg|One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
11296759|NCT02720783|Active Comparator|Placebo plus Econazole nitrate 150 mg|One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days
11296760|NCT02720783|Active Comparator|Placebo plus Benzydamine HCl 6 mg|One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
11296761|NCT02720783|Placebo Comparator|Placebo|One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days
11296762|NCT02720770|Experimental|norditropine simplex|
11296763|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
11296764|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
11296765|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
11296766|NCT02720731||children|aged from 1 to 18 years with motor disorder
11296767|NCT02720731||adults|aged from 18 to 80 years with motor disorder
11296768|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
11296769|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
11296770|NCT02720705|Active Comparator|DEX I|active comparator receive 0.5µg/kg dexmedetomidine orally half an hour before operation
11296771|NCT02720705|Placebo Comparator|Saline Control|2ml oral 0.9%saline half an hour before operation
11296772|NCT02720705|Active Comparator|DEX II|active comparator receive,1µg/kg dexmedetomidine orally half an hour before operation
11296773|NCT02720692|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
11321501|NCT02557126|Experimental|URC102|URC102
11296774|NCT02720692|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 7 doses.
11296775|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
11296776|NCT02720666|Experimental|Group A:K-001 2700mg/d (1350mg BID)|K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
11296777|NCT02720666|Experimental|Group B: K-001 3240mg/d (1620mg BID)|K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
11296778|NCT02720666|Experimental|Group C: K-001 3780mg/d (1890mg BID)|K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
11296779|NCT02720666|Experimental|Group D: K-001 4320mg/d (2160mg BID)|K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
11296780|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
11296781|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
11296782|NCT02720640|Experimental|Implant 'on' vs implant 'off'|Intra-individual comparison of implant 'on' vs implant 'off'
11296783|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
11296784|NCT02720614|Experimental|Hypofractionated radiation/chemotherapy|"Hypofractionated radiation：Patients receive accelerated hypofractionated radiation: three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks.
~Chemotherapy: Regimen 1 is as follows: vinorelbine (NVB) was administered by intravenous infusion at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and carboplatin (CBP) is administered at a concentration-time curve (AUC) of 5 mg/ml on d8. This treatment was repeated every 28 days. One cycle of chemotherapy is performed concurrently with the radiotherapy.
~Chemotherapy: Regimen 2 is as follows: paclitaxel at 30 mg/m2 and cisplatin at 20 mg/m2 (TP) are administrated every week for 5 weeks continuously."
11296785|NCT02720601|Experimental|Irinotecan & Capecitabine|"Irinotecan at 120 mg/m2 intravenously every three weeks + Capecitabine at 1500 mg/m2/day orally twice per day for a total of 14 days.
~The treatment cycle is once every 21 days."
11296786|NCT02720588||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
11296787|NCT02720588||Sibling group|Sex-matched unaffected siblings of ASD probands
11296788|NCT02720588||TD group|Typically developing controls without lifetime ASD or a family history of ASD
11296789|NCT02720575|Active Comparator|A|50,000 IU of crystalline D2 in 5 capsules.. Vitamin D2 in its natural state consumed orally via capsule
11296790|NCT02720575|Active Comparator|B|50,000 IU of crystalline D3 in 5 capsules.. Vitamin D3 in its natural state consumed orally via capsule
11296791|NCT02720575|Active Comparator|C|50,000 IU of vitamin D2 from vitamin D2 yeast in 5 capsules. Vitamin D generated in yeast. Acts as a comparator to the yeast in bread.
11296792|NCT02720575|Active Comparator|D|50,000 IU of vitamin D2 from yeast cell walls in 5 capsules. Yeast cell walls rich in Vitamin D. Acts as a comparator to the yeast in bread.
11296793|NCT02720575|Experimental|E|50,000 IU of vitamin D2 from 2 slices of bread made from bread. Bread raised with yeast rich in vitamin D. Main experimental arm.
11296794|NCT02720575|Experimental|F|50,000 IU of vitamin D2 from 2 slices of bread. Bread raised with yeast and yeast cell walls rich in vitamin D.
11296795|NCT02720562||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
11296796|NCT02720562||TD group|Typically development controls without lifetime diagnosis with ADHD
11296797|NCT02720549|Experimental|post-ischemic conditioning group|
11296798|NCT02720549|Placebo Comparator|valvular surgery with bypass group|
11296799|NCT02720536|Experimental|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
11296800|NCT02720523|Experimental|Placebo / Upadacitinib 7.5 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.
~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks."
11296801|NCT02720523|Experimental|Placebo / Upadacitinib 15 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
11296802|NCT02720523|Experimental|Placebo / Upadacitinib 30 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
11296803|NCT02720523|Experimental|Upadacitinib 7.5 mg / Upadacitinib 7.5 mg|"Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks."
11296804|NCT02720523|Experimental|Upadacitinib 15 mg / Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
11296805|NCT02720523|Experimental|Upadacitinib 30 mg / Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.
~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
11296806|NCT02720510|Active Comparator|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
11296807|NCT02720510|Active Comparator|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
11296808|NCT02720497|Experimental|60-minute Prolonged Exposure|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
11296809|NCT02720497|Active Comparator|90-minute Prolonged Exposure|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
11296914|NCT02719925|Active Comparator|Water low in magnesium|- 1,5 L per day of mineral water containing 50 mg/L of magnesium
11296810|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
11296811|NCT02720471|Active Comparator|Locoregional anesthesia|Classical locoregional analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh will be performed in patients of this arm
11296812|NCT02720471|Experimental|Peroperative infiltration|Peroperative infiltration of local anesthetics (IAL) will be performed in patients of this arm
11296813|NCT02720458|Experimental|Standardized hypnotic taper and self-help program|
11296814|NCT02720458|Active Comparator|Standardized hypnotic taper only|
11296815|NCT02720445|Experimental|Nicotine Transdermal Patch|150 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment
11296816|NCT02720445|Placebo Comparator|Placebo Patch|150 participants will wear matching placebo patches during waking hours.
11296817|NCT02720432|Experimental|CIMT|"A soft splint or restraint will be posed to best functioning hand of the infant only during the therapy session. Parents will be educated to perform the therapy, which consists of stimulation of reaching and grasping with the hemiplegic arm.
~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform CIMTfor 30 minutes, 6 days a week."
11296818|NCT02720432|Experimental|HABIT|"No restraint will be implemented and instead of promoting unilateral grasping, bimanual grasping will be stimulated. Toys will be precisely selected to stimulate progressed bimanual grasping. The approach of the therapist and parents remain equal.
~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform HABIT for 30 minutes, 6 days a week."
11296819|NCT02720432|Sham Comparator|Baby-massage|3 sessions of baby-massage will be given by a qualified instructor
11296820|NCT02720419||Synergy stent|
11296821|NCT02720406|Active Comparator|Intravenous ketamine0.5mg/kg|intravenous ketamine 0.5 mg/kg given after induction of anesthesia and before surgery.
11296822|NCT02720406|Active Comparator|Nebulized ketamine 1mg/kg|nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.
11296823|NCT02720406|Active Comparator|Nebulized ketamine 2mg/kg|nebulized ketamine group received 2mg/kg ketamine by nebulzation before induction of anesthesia.
11296824|NCT02720406|Placebo Comparator|control group|control group received placebo nebulization
11296825|NCT02720393|Placebo Comparator|Regular diet|Meals and snacks will contain carrageenan in the amount consumed in the typical daily diet and will be selected by the study dietician and distributed to study subjects randomized to the regular diet study arm.
11296826|NCT02720393|Experimental|No-carrageenan diet|No-carrageenan diet will be composed of meals and snacks selected by the study dietician and distributed to study participants who are randomized to the no-carrageenan diet study arm.
11296827|NCT02720380|Experimental|Buteyko|Children in the intervention group will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
11296828|NCT02720380|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
11296829|NCT02720367|Experimental|7-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
11296830|NCT02720367|Experimental|21-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.
11296831|NCT02720354|Experimental|A single Intravenous bolus injection|A single Intravenous bolus injection of 11C[DMDPA]
11296832|NCT02720341|Experimental|ARMin|Therapy on ARMin robotic device
11296833|NCT02720328|Other|DOAC-treated patients|Concerning patients taking DOACs, blood samples are drawn to evaluate DOAC plasma concentration. One EDTA tube is also drawn to extract DNA and determine the genetic profile of genes involved in the metabolism of DOACs. The aim will be to assess if genetic determinants can explain the observed interindividual variability in plasma concentrations.
11296834|NCT02720315|Experimental|Intensive cryotherapy|Application of ice in a plastic bag wrapped to the patient's site of pain, and kept in place for 20min.
11296835|NCT02720315|No Intervention|Control|Existing pain control practice of physicians and nurses, which includes application of a chemical cold pack.
11296836|NCT02720302|Experimental|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.
~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.
~At each consultation with the overweight child and his/her biological parents there are two therapists present."
11296837|NCT02720302|Experimental|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3)."
11296838|NCT02720289|Experimental|Video-based social learning|Video-based social learning class
11296839|NCT02720289|Active Comparator|Traditional didactic|Traditional didactic class
11296840|NCT02720276|Experimental|Training after acute stroke|Intervention: Outdoor walking and strength training.
11296841|NCT02720263|Experimental|Double-Blind ASP4345 Multiple Dose Levels|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered under fasting conditions. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions.
11296842|NCT02720263|Placebo Comparator|Double-Blind Placebo Multiple Dose|Matching placebo capsules will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, matching placebo capsules will be administered with food. On days 2-6 and 8-13, matching placebo will be administered under fed conditions.
11296915|NCT02719912|Experimental|Valve Replacement|Mitral valve replacement
11296843|NCT02720263|Experimental|Open-Label ASP4345|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered with food. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions. This is an optional cohort where subjects will be enrolled to further characterize pharmacodynamics in the event a higher sample size is necessary to determine changes in electrophysiological biomarkers.
11296844|NCT02720250|Experimental|Omega-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
11296845|NCT02720250|Experimental|Regular|Intake of 3 regular chicken eggs per day for three weeks.
11296846|NCT02720237|Experimental|Brief Intervention|Brief Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the ART clinic
11296847|NCT02720237|Experimental|MET+CBT Intervention|MET+CBT Intervention (6 in-person sessions and 3 optional group sessions), study assessment visits, and standard of care from providers at the ART clinic
11296848|NCT02720237|No Intervention|Assessment-Only Control|Study assessment visits and standard of care from providers at the ART clinic
11296849|NCT02720224|Experimental|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol ([14C]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
11296850|NCT02720211|Active Comparator|Gray tinted spectacle lenses|Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
11296851|NCT02720211|Experimental|Thin-Film spectacle lenses|Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength
11296852|NCT02720198|Active Comparator|Levomilnacipran|Levomilnacipran ER is switched from SSRI.
11296853|NCT02720198|Active Comparator|Quetiapine|Quetiapine XR is added in addition to current SSRI.
11296854|NCT02720185|Experimental|Dasatinib 100mg|Dasatinib 100mg for 7-10 days until day prior to surgery
11296855|NCT02720172|Experimental|Early Home Exercise Program|The early home exercise program is an exercise-based self-management program for patients immediately after cervical spine surgery.
11296856|NCT02720172|Other|Usual Care|Usual postoperative care.
11296857|NCT02720159|Experimental|TREATMENT|
11296858|NCT02720146||Artificital tear|The epitheliotrophic ability in cell and animal model
11296859|NCT02720146||Human peripheral serum|The epitheliotrophic ability in cell and animal model
11296860|NCT02720146||Human platelet lysate|The epitheliotrophic ability in cell and animal model
11296861|NCT02720133||Patients with cardiovascular risk factors who fast Ramadan|Stable clinical and biochemical parameters before Ramadan fasting
11296862|NCT02720120|Experimental|Part 1: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
11296863|NCT02720120|Experimental|Part 1: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
11296864|NCT02720120|Experimental|Part 1: Ocrelizumab 2000 mg|Participants will receive single IV infusion of ocrelizumab 2000 mg.
11296865|NCT02720120|Experimental|Part 1: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
11296866|NCT02720120|Placebo Comparator|Part 1: Placebo|Participants will receive single IV infusion of placebo matched to ocrelizumab.
11296867|NCT02720120|Experimental|Part 2: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
11296868|NCT02720120|Experimental|Part 2: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
11296869|NCT02720120|Experimental|Part 2: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 mg.
11296870|NCT02720107|Experimental|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
11296871|NCT02720094|Experimental|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
11296872|NCT02720094|Experimental|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
11296873|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
11296874|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
11296875|NCT02720068|Experimental|Part A: MK-4280 Dose A|Participants receive MK-4280 Dose A intravenous (IV) infusion on Day 1 of each 21-day cycle.
11296876|NCT02720068|Experimental|Part A: MK-4280 Dose B|Participants receive MK-4280 Dose B IV infusion on Day 1 of each 21-day cycle.
11296877|NCT02720068|Experimental|Part A: MK-4280 Dose C|Participants receive MK-4280 Dose C IV infusion on Day 1 of each 21-day cycle.
11296878|NCT02720068|Experimental|Part A: MK-4280 Dose D|Participants receive MK-4280 Dose D IV infusion on Day 1 of each 21-day cycle.
11296879|NCT02720068|Experimental|Part A: MK-4280 Dose E|Participants receive MK-4280 Dose E IV infusion on Day 1 of each 21-day cycle.
11296880|NCT02720068|Experimental|Part A: MK-4280 Dose A+Pembro|Participants receive MK-4280 Dose A IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296881|NCT02720068|Experimental|Part A: MK-4280 Dose B+Pembro|Participants receive MK-4280 Dose B IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296916|NCT02719899||1|Healthy Volunteers
11297295|NCT02717338|Experimental|Autonomy|Participants will be assigned to receive a brief telephone interview.
11296882|NCT02720068|Experimental|Part A: MK-4280 Dose C+Pembro|Participants receive MK-4280 Dose C IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296883|NCT02720068|Experimental|Part A: MK-4280 Dose D+Pembro|Participants receive MK-4280 Dose D IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296884|NCT02720068|Experimental|Part A: MK-4280 Dose E+Pembro|Participants receive MK-4280 Dose E IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296885|NCT02720068|Experimental|Part B: MK-4280 Monotherapy Dose|Participants receive MK-4280 monotherapy dose IV infusion on Day 1 of each 21-day cycle.
11296886|NCT02720068|Experimental|Part B: MK-4280 Dose F+Pembro|Participants receive MK-4280 Dose F IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296887|NCT02720068|Experimental|Part B: MK-4280 Dose G+Pembro|Participants receive MK-4280 Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296888|NCT02720068|Experimental|Part B: MK-4280 Dose H+Pembro|Participants receive MK-4280 Dose H IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle.
11296889|NCT02720068|Experimental|Part B: MK-4280 Dose G+Pembro+mFOLFOX7|Participants receive MK-4280 Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS mFOLFOX7 (oxaliplatin 85 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and fluorouracil [5-FU] 2400 mg/m^2 IV over 46 to 48 hours every 2 weeks [Q2W]).
11296890|NCT02720068|Experimental|Part B: MK-4280 Dose G+Pembro+FOLFIRI|Participants receive MK-4280 Dose G IV infusion on Day 1 of each 21-day cycle PLUS pembrolizumab IV administered sequentially on Day 1 of each 21-day cycle PLUS FOLFIRI (irinotecan 180 mg/m^2 IV, leucovorin [calcium folinate] 400 mg/m^2 IV and 5-FU 2400 mg/m^2 IV over 46 to 48 hours Q2W).
11296891|NCT02720068|Experimental|Part B: MK-4280A|Participants receive MK-4280A (MK-4280 and pembrolizumab administered as a co-formulation) IV infusion on Day 1 of each 21-day cycle.
11296892|NCT02720068|Experimental|Part B: MK-4280 Dose G+Pembro+Lenvatinib|Participants receive MK-4280 Dose G IV infusion on Day 1 of each 21 day cycle PLUS pembrolizumab IV infusion administered sequentially on Day 1 of each 21-day cycle PLUS oral lenvatinib (20 mg) each day of 21-day cycle.
11296893|NCT02720055|Experimental|Psychological Workbook|Psychological work book containing information and activities aimed at improving outcomes.
11296894|NCT02720055|Active Comparator|Basic information workbook|Basic information which represents current practice
11296895|NCT02720042|Experimental|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
11296896|NCT02720029|Experimental|pH/impedance monitor|
11296897|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
11296898|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
11296899|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
11296900|NCT02720003|Experimental|LTX DCB|Patients treated with Bard Lutonix DCB
11296901|NCT02719990|Experimental|Somavaratan in adults with GHD|Cohort 1: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult subjects with GHD irrespective of age and gender
11296902|NCT02719990|Experimental|Somavaratan in women on estrogen|Cohort 2: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult female subjects with GHD on oral estrogen (regardless of age)
11296903|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
11296904|NCT02719964|Experimental|A: UCR Games→SP-Directed Therapy|Participants in Arm A will first participate in Visual Attention Program (UCR Games) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
11296905|NCT02719964|Experimental|B: Lumosity→SP-Directed Therapy|Participants in Arm B will first participate in General Cognitive Rehabilitation Games (Lumosity) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
11296906|NCT02719964|Experimental|C: SP-Directed Therapy→UCR Games|Participants in Arm C will first participate in Speech Pathologist-Directed Therapy followed by Visual Attention Program (UCR Games) with assessment sessions prior to and following each treatment intervention.
11296907|NCT02719964|Experimental|D: SP-Directed Therapy→Lumosity|Participants in Arm D will first participate in Speech Pathologist-Directed Therapy followed by General Cognitive Rehabilitation Games (Lumosity) with assessment sessions prior to and following each treatment intervention.
11296908|NCT02719951|Experimental|autistic patients|[18F]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
11296909|NCT02719951|Experimental|FXS patients|[18F]FPEB PET imaging MRI Biological samples
11296910|NCT02719951|Experimental|Healthy subjects|[18F]FPEB PET imaging MRI Biological samples
11296911|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
11296912|NCT02719938|No Intervention|Control|Usual care.
11296913|NCT02719925|Experimental|Mineral water rich in magnesium|- 1,5 L per day of mineral water containing 160 mg/L of magnesium
11296917|NCT02719886|Experimental|Fetal growth ultrasound every 2 weeks|Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
11296918|NCT02719886|Active Comparator|Fetal growth ultrasound every 4 weeks|Ultrasound to measure fetal growth every 4 weeks (i.e. 28, 32 and 36 weeks gestation). Usual Care.
11296919|NCT02719873||control group|the group with normal BMI
11296920|NCT02719873||study group|The group with the BMI more than 24.9 kg per meter square to study the impact of maternal obesity in pregnancy outcome
11296921|NCT02719860|Experimental|Green tea|
11296922|NCT02719860|Experimental|Black tea|
11296923|NCT02719860|Placebo Comparator|Placebo tea|
11296924|NCT02719847|Experimental|EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
11296925|NCT02719834||Acetaminophen, then placebo|Participants in this group will receive acetaminophen for the first four weeks, then placebo for the next four weeks.
11296926|NCT02719834||Placebo, then acetaminophen|Participants in this group will receive placebo for the first four weeks, then acetaminophen for the next four weeks.
11296927|NCT02719821|Experimental|Intervention|Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
11296928|NCT02719808||Tenofovir1|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.
11296929|NCT02719808||Tenofovir2|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.
11296930|NCT02719808||Tenofovir3|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one week after delivery.
11296931|NCT02719808||Tenofovir4|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one month after delivery.
11296932|NCT02719808||Group without any treatment|100 patients don't receive any blockade therapies
11296933|NCT02719795|Experimental|Ropivacaine|Ropivacaine hydrochloride injection； Generic name：Naropin； Dosage form：Liquid、Injectable formulation； Dosage：105mg；30ml； Frequency：Once.
11296934|NCT02719795|Placebo Comparator|Normal saline|Medical Normal saline Generic name：Normal saline； Dosage form：Liquid、Injectable formulation； Dosage：30ml； Frequency：Once.
11296935|NCT02719782|Experimental|HBV/TCR T cell Infusion|"This is a single-arm study.
~Patients will receive a total of 2 cycles, in which first 28-day treatment cycle consists of escalating doses of TCR-T on Day 1, Day 8, Day 15 and Day 22, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of second (final) cycle. A one month treatment break will be given between the cycles."
11296936|NCT02719756|Experimental|Metformin & Dapagliflozin|Metformin stable dose tablets and Dapagliflozin 10 mg tablets by mouths, once daily in morning for 3 months
11296937|NCT02719756|Active Comparator|Metformin up-titration|Metformin tablets up-titration by mouths, for 3 months
11296938|NCT02719743|Active Comparator|H5N1 Formulation 1 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.
11296939|NCT02719743|Experimental|H5N1 Formulation 2 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
11296940|NCT02719743|Experimental|H5N1 Formulation 3 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
11296941|NCT02719743|Experimental|H5N1 Formulation 4 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
11296942|NCT02719743|Experimental|H5N1 Formulation 5 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
11296943|NCT02719730|Experimental|Reimbursement arm|Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
11296944|NCT02719730|No Intervention|Control arm|Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.
11296945|NCT02719717|Experimental|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
11296946|NCT02719704|Experimental|"MEXA-SE"|Intervention on physical fitness, eating habits and body image
11296947|NCT02719704|No Intervention|Control|School of the control group carried out one semester with the regular and traditional activities. The control school had three physical educations lessons per week, similar of experimental schools.
11296948|NCT02719704|Experimental|"Espelho, espelho meu"|School-based intervention on body image
11296949|NCT02719691|Experimental|Dose-Escalation of Alisertib and MLN0128|This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.
11296950|NCT02719691|Experimental|Dose-Expansion of Alisertib and MLN0128|"Group 1:
~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.
~Group 2:
~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.
~Pancreatic Cancer Cohort:
~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
11296951|NCT02719678|Experimental|Intervention group|Invitation to up to three general health checks over a 10-year period
11296952|NCT02719678|No Intervention|Control group|Control group
11296953|NCT02719665|Experimental|Phase 1a (OMEGA-SPM-DOSE)|PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
11296954|NCT02719665|Active Comparator|SPM - Phase 1b (OMEGA-SPM-DOSE)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
11296955|NCT02719665|Placebo Comparator|Placebo - Phase 1b (OMEGA-SPM-PLACEBO)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
11296956|NCT02719652||symptomatic ICAD|symptomatic intracranial atherosclerosis diseases
11296957|NCT02719652||asymptomatic ICAD|asymptomatic intracranial atherosclerosis diseases
11296958|NCT02719613|Experimental|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
11296959|NCT02719600|Experimental|Down Syndrome Group|Group with Down Syndrome
11296960|NCT02719600|Active Comparator|Typical Development Group|Control group with typical development
11296961|NCT02719587|Placebo Comparator|control group|Control group (8 males, 7 females; 42.54±5.82 years) (SRP): SRP followed by administration of a placebo. The placebo was identical except for the fish oil.
11296962|NCT02719587|Active Comparator|test group|Test group (8 males, 7 females; 40.87±9.7 years) (SRP+omega-3 PUFAs): SRP followed by omega-3 PUFAs supplementation. The test drug contained omega-3 PUFAs including 6.25 mg EPA and 19.19 mg DHA obtained from the Atlantic salmon Salmo salar.Both test and placebo drugs were taken twice a day by the patients for six months. Subjects came to the clinic every 4 weeks during the 6 month course of the experiment to replenish their medication. Remaining medications were checked for compliance. At each evaluation visit (1, 3 and 6 months), oral soft and hard tissue examinations and adverse-event evaluations were performed.
11296963|NCT02719574|Experimental|PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)|
11296964|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine|
11296965|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine|
11296966|NCT02719574|Experimental|PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent|Relapsed or Refractory (R/R) AML
11296967|NCT02719574|Experimental|PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent|AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
11296968|NCT02719574|Experimental|PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent|R/R AML/MDS, previously treated with an IDH1 inhibitor
11296969|NCT02719574|Experimental|PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
11296970|NCT02719574|Experimental|PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
11296971|NCT02719574|Experimental|PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have been previously treated with single-agent IDH1 inhibitor therapy as their last therapy prior to study enrollment
11296972|NCT02719574|Experimental|PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent|Treatment naïve AML for whom standard treatments are contraindicated
11296973|NCT02719574|Experimental|PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine|Treatment naïve AML who are candidates for azacitidine first line treatment
11296974|NCT02719561|Experimental|Fatigue intervention|Fatigue Intervention is to be co-designed by participants, and likely to include education, energy conservation and activity promotion. Participants will also decide the name of the Fatigue Intervention
11296975|NCT02719548|Experimental|Breastshield treatment group A|"Participants will be treated with the following three breast shields:
~Soft edge oval - Hard oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
11296976|NCT02719548|Experimental|Breastshield treatment group B|"Participants will be treated with the following three breast shields:
~Modified PF breast shield - Soft edge oval - Hard oval Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
11296977|NCT02719548|Experimental|Breastshield treatment group C|"Participants will be treated with the following three breast shields:
~Hard oval - Soft edge oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
11296978|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
11296979|NCT02719509||Observational Cohort|All emergency department patients who had a cardiac ultrasound performed as part of their diagnostic workup
11296980|NCT02719496|Experimental|IBEROGAST|Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.
11296981|NCT02719483|Active Comparator|rESWT + traditional conservative therapy|Radial extracorporeal shock wave therapy (rESWT) performed with the Swiss DolorClast device (EMS Electro Medical Systems, Nyon, Switzerland) plus traditional conservative therapy.
11296982|NCT02719483|Other|Traditional conservative therapy|Traditional conservative therapy alone.
11296983|NCT02719470|Experimental|normal cognition|Group 1: patients with normal cognitive profile, assessed with MMSE (27 ≤ correct score ≤ 30) undergoing MIRT
11296984|NCT02719470|Experimental|mildly impaired cognition|Group 3: patients with middle cognitive decline, assessed with MMSE (20 ≤ correct score < 27) undergoing MIRT
11296985|NCT02719470|Experimental|moderately-severely impaired cognition|Group 2: patients cognitive decline, assessed with MMSE (correct score < 20) undergoing MIRT
11296986|NCT02719470|Experimental|patients with normal executive functions|Group 4: patients with pathological executive functions, assessed with FAB (FAB ≥ 13.8) undergoing MIRT
11296987|NCT02719470|Experimental|pathological executive functions|Group 5: patients with pathological executive functions, assessed with FAB (FAB < 13.8) undergoing MIRT
11296988|NCT02719457|Other|6 minute walk test (6 MWT)|patients will be perform the six minute walk test (6 mwt) to evaluate their exercise capacity.
11296989|NCT02719457|Other|spot marching test (SMT)|patients will be perform the spot marching test (SMT) to evaluate their exercise capacity.
11296990|NCT02719431|Other|Warfarin/Warfarin + K-877|
11296991|NCT02719418||Tinzaparin|Hospitalized patients with chronic renal insufficiency (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin 3500 or 4500 unit sub-cutaneous once daily.
11296992|NCT02719405|Placebo Comparator|Amino Acid Formula|
11296993|NCT02719405|Active Comparator|EHCF|Extensively Hydrolyzed Casein Formula
11296994|NCT02719405|Active Comparator|EHCF + LGG|Extensively Hydrolyzed Casein Formula + Lactobacillus GG
11296995|NCT02719392|Active Comparator|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
11296996|NCT02719392|Active Comparator|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
11296997|NCT02719392|Active Comparator|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
11296998|NCT02719392|Placebo Comparator|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
11296999|NCT02719379|Experimental|Asthmatics|19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response
11297000|NCT02719379|Active Comparator|Non-asthmatics|19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers)
11297001|NCT02719379|Other|Asthmatics - Serum Stored|Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community.
11297002|NCT02719366|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
11297003|NCT02719366|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
11297004|NCT02719353|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
11297005|NCT02719353|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
11297006|NCT02719327|Experimental|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
11297007|NCT02719327|Placebo Comparator|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
11297008|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
11297009|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
11297010|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
11297011|NCT02719301||Men/Women between 18 & 85|Accepting both healthy and non-healthy subjects. A portion of the subjects will have a fluid management issue or heart failure.
11297012|NCT02719288|Experimental|CLARIX® CORD 1K|Applied in addition to standard of care tendon repair surgery.
11297013|NCT02719288|No Intervention|Standard of care tendon repair surgery only|
11297014|NCT02719275||Suicidal Behaviour|
11297015|NCT02719275||Suicidal Ideation|
11297016|NCT02719275||Other Mental Health|
11297017|NCT02719275||Other Health|
11297018|NCT02719262|Experimental|Intervention|installing ventilation in the workplace
11297019|NCT02719249||Men with ESRD on dialysis or transplant|
11297020|NCT02719236|Active Comparator|Direct anterior approach|Primary total hip arthroplasty using a direct anterior approach
11297021|NCT02719236|Active Comparator|Direct lateral approach|Primary total hip arthroplasty using a direct lateral approach
11297022|NCT02719223|Experimental|High Flux Hemodialysis|
11297023|NCT02719223|Experimental|OL-HDF|
11297024|NCT02719210|Experimental|High Volume Plasma Exchange with Standard Treatment|
11297025|NCT02719210|Active Comparator|Standard Treatment|"Standard Treatment is defined as anti raised Intra-cranial pressure
~Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).
~Mannitol
~Hypertonic 3% Saline"
11297026|NCT02719197|Experimental|AC-083, Single Ascending Dose|AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
11297027|NCT02719197|Placebo Comparator|Placebo, Single Ascending Dose|Matched placebo administered as single ascending doses in parallel to AC-083
11297028|NCT02719184||Healthy volunteers|
11297029|NCT02719184||COPD GOLD I|Chronic obstructive pulmonary disease
11297030|NCT02719184||COPD GOLD II|Chronic obstructive pulmonary disease
11297031|NCT02719184||COPD GOLD III|Chronic obstructive pulmonary disease
11297032|NCT02719184||A1AT Deficiency|Alpha one anti-trypsin deficiency
11297033|NCT02719171|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
11297034|NCT02719171|Experimental|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
11297035|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
11297036|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
11297037|NCT02719171|Experimental|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
11297038|NCT02719158|Experimental|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
11297039|NCT02719158|Experimental|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
11297040|NCT02719158|Sham Comparator|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
11297041|NCT02719145||Control group (group 1)|10 healthy volunteer subjects.
11297042|NCT02719145||Asthma group (group 2)|10 asthmatic patients.
11297043|NCT02719145||COPD group (group 3)|10 COPD patients.
11297044|NCT02719132|Experimental|Arm 1|Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)
11297045|NCT02719132|Active Comparator|Arm 2|Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)
11297046|NCT02719119|Experimental|monthly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation monthly.
11297047|NCT02719119|Experimental|bi-weekly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation bi-weekly.
11297048|NCT02719106||Ultimaster stent|
11297049|NCT02719093|Experimental|recombinant FSH|recombinant FSH 150UI daily
11297050|NCT02719067||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV and ICD-10 criteria
11297051|NCT02719067||TD group|Typically developing controls without lifetime ASD or a family history of ASD
11297052|NCT02719054|Experimental|stimulation|Cognitive behavioral therapy for mother and play stimulation for children aged 6 to 12 months
11297053|NCT02719054|No Intervention|Mother child dyad|
11297054|NCT02719041||Tissue samples|Tissue samples taken from women treated for ovarian cancer will be stained.
11297055|NCT02719028|Placebo Comparator|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
11297056|NCT02719028|Experimental|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
11297057|NCT02719028|Experimental|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
11297058|NCT02719028|Experimental|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
11297091|NCT02718781|Experimental|Talk and leaders|This group will comprise of health talk and regular contact with community leaders.
11297059|NCT02719015|Experimental|rAd.CD40L + Pembrolizumab|"The dose escalation phase will include rAd.CD40L dose escalation and increase in the number of injected sites/lesions. Once patients tolerate dose level 1 (1 injection site and 1x1011vp-MTD) in Dose Escalation cohort, Expansion cohort will open with same maximum number of injection sites at maximum tolerated dose from Dose Escalation cohort.
~All participants receive same dosage of Pembrolizumab in both phases."
11297060|NCT02719002|Experimental|OCT C-scan|
11297061|NCT02718989|Experimental|10 Kilohertz (KHz)|"Transcutaneous application of 10 Kilohertz (KHz) current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11297062|NCT02718989|Experimental|Transcutaneous Electrical Stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 100 Hz and pulse width 100 microseconds"
11297063|NCT02718989|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
11297064|NCT02718976|Experimental|Shamrock guided by US/MR image fusion|Use of US/MR image fusion guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
11297065|NCT02718976|Other|Shamrock guided by US|Use of US guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
11297066|NCT02718963|Experimental|Control group|"control group(N=10): who does not have dysphagia symptom
~apply Synchronized Electrical Stimulation Device
~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function
~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
11297067|NCT02718963|Experimental|Experimental group|"experimental group(N=10): who have dysphagia symptoms
~apply Synchronized Electrical Stimulation Device
~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function
~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
11297068|NCT02718950|Experimental|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks.
11297069|NCT02718937|Experimental|BTA-C585|BTA-C585 100 mg oral capsule
11297070|NCT02718937|Placebo Comparator|Placebo|Matching placebo capsule
11297071|NCT02718924||morbidly obese pregnant|Term pregnant women with BMI more than 40
11297072|NCT02718924||non obese pregnant|Term pregnant women with BMI less than 30
11297073|NCT02718911|Experimental|LY3022855 + Durvalumab (Dose Escalation)|LY3022855 given intravenously (IV) in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
11297074|NCT02718911|Experimental|LY3022855 + Tremelimumab (Dose Escalation)|LY3022855 given IV in combination with tremelimumab given IV. Treatment may continue until disease progression or discontinuation.
11297075|NCT02718911|Experimental|LY3022855 + Durvalumab (Expansion)|LY3022855 given IV in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
11297076|NCT02718898|Experimental|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.
~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
11297077|NCT02718898|Placebo Comparator|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.
~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
11297078|NCT02718885|Sham Comparator|Maltodextrin|Maltodextrin
11297079|NCT02718885|Active Comparator|Inulin|Inulin-type fructans
11297080|NCT02718872|Experimental|Tobacco cessation online training|Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
11297081|NCT02718859|Active Comparator|irreversible electroporation (IRE)|Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
11297082|NCT02718859|Experimental|IRE & NK cells|Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
11297083|NCT02718846|Experimental|Meniace and Isobide|co-administration Isobide solution and Meniace tablets
11297084|NCT02718846|Active Comparator|Meniace|single administration Meniace tablets
11297085|NCT02718833|Experimental|Elotuzumab, pomalidomide, bortezomib, dex|"Each cycle is 28 days.
~Elotuzumab will be administered by intravenous infusion. For cycles 1-2, elotuzumab will ge given weekly. For cycles 3-8, elotuzumab will be given every other week. For cycles 9+, elotuzumab will be given on day 1.
~Pomalidomide will be given orally on days 1-21.
~Bortezomib will be given weekly subcutaneously on days 1, 8, 15.
~Dexamethasone will be given as a combination orally and intravenously."
11297086|NCT02718820|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression.
11297087|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
11297088|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
11297089|NCT02718794|Experimental|Simulation training first|A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment.
11297090|NCT02718794|Experimental|Problem-based learning first|Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
11297092|NCT02718781|Experimental|Talk, leaders and equipment|This group will comprise of health talk and regular contact with community leaders. Moreover, a home-based equipment (handgrip) will be delivered to them
11297093|NCT02718781|Active Comparator|Talk|This group will comprise of a health talk only.
11297094|NCT02718755|Experimental|Fludarabine + Cytarabine + Erwinase|"Induction Phase: Participants receive 1-2 cycles during the Induction phase.
~Participants receive 1-2 cycles during the Induction phase.
~Participants receive Fludarabine by vein on Days 1-5 and Cytarabine by vein.
~Participants receive Erwinase by vein or as an injection into the muscle on Days 1-7.
~Consolidation Phase: Participants receive up to 3 cycles during the Consolidation phase.
~Participants receive Fludarabine by vein on Days 1-4 and Cytarabine by vein.
~On Day 1 and then every other day for 15 days (3, 5, 7 and so on), participant receives Erwinase by vein or as an injection into the muscle."
11297095|NCT02718742|Experimental|Treatment (nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11297096|NCT02718729|Other|Rectal cancer patients|All patients who will fulfill the inclusions criteria. Patients will undergo formal curative radical Laparoscopic resection for rectal cancer
11297097|NCT02718716|Experimental|UCB7665 dose 1|Subjects in this Arm will receive 5 subcutaneous (sc) doses of UCB7665 at 1-week intervals
11297098|NCT02718716|Experimental|UCB7665 dose 2|Subjects in this Arm will receive 3 subcutaneous (sc) doses of UCB7665 dose 2 at 1-week intervals
11297099|NCT02718716|Experimental|UCB7665 dose 3|Subjects in this Arm will receive 2 subcutaneous (sc) doses of UCB7665 dose 3 at 1-week intervals
11297100|NCT02718716|Experimental|UCB7665 dose 4|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 4
11297101|NCT02718716|Experimental|UCB7665 dose 5|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 5
11297102|NCT02718703|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
11297103|NCT02718690|Experimental|Transcutaneous nerve stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11297104|NCT02718690|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
11297105|NCT02718677||1. Refacto AF (NIS)|Non-Interventional Study
11297106|NCT02718664|No Intervention|A (fasting)|Fasting condition
11297107|NCT02718664|Experimental|B (fed)|Fed condition (test meal)
11297108|NCT02718638|Other|physical exercises group|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.
11297109|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
11297110|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
11297111|NCT02718599|Active Comparator|Terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
11297112|NCT02718599|Placebo Comparator|CONTROL|Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).
11297113|NCT02718573||Non-liver transplants with HCV|
11297114|NCT02718573||Liver transplants with HCV|
11297115|NCT02718560|Experimental|Group 1 - Writing with 1 cm cue|This group uses to write space of 1 cm size
11297116|NCT02718560|Experimental|Group 2 - Writing with 1.5 cm cue|This group uses to write space of 1.5 cm size
11297117|NCT02718560|Experimental|Group 3 - Writing without cue|This group writes without using cues
11297118|NCT02718560|No Intervention|Group 4 - no writing|This group do not write. Only wrist mobilization is performed.
11297119|NCT02718547|Experimental|Participants receiving Combigan drops in order to reduce IOP|All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
11297120|NCT02718534||ERTAS-1|first limb rehabilitation therapy took place within 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
11297121|NCT02718534||ERTAS-2|first limb rehabilitation therapy took place after 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
11297122|NCT02718521|Experimental|Hydration Therapy Combined With Isosorbide Dinitrate|Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography
11297123|NCT02718521|Active Comparator|Conventional hydration group|normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography
11297124|NCT02718508|No Intervention|Standard Care|All enrolled adolescents will continue to receive standard trauma center care, a brief intervention during their hospitalization by a trauma center social worker which is required by institutional policy.
11297125|NCT02718508|Experimental|Standard Care plus e-Parenting Group|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
11297126|NCT02718495|Placebo Comparator|Part A|Part A consists of two treatment groups, SAD and MAD. Both treatment groups will consist of 3 cohorts. In SAD, subjects will receive a single dose of PTI-428 or placebo. In MAD, subjects will receive once daily dosing of PTI-428 or placebo for 7 days.
11297205|NCT02717988|Experimental|SKI-O-703 800 mg|SKI-O-703 capsule (4x200 mg)
11297127|NCT02718495|Placebo Comparator|Part B|Part B will consist of 2 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
11297128|NCT02718495|Placebo Comparator|Part C|Part C will consist of 3 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
11297129|NCT02718482|Experimental|Gemcitabine and Docetaxel|Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
11297130|NCT02718482|Experimental|Ifosfamide|Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks
11297131|NCT02718469|Experimental|Ebola Vaccine - low dose|Low Dose Zaire Ebola Vaccine
11297132|NCT02718469|Experimental|Ebola Vaccine - mid dose|Mid Dose Zaire Ebola Vaccine
11297133|NCT02718469|Experimental|Ebola Vaccine - high dose|High Dose Zaire Ebola Vaccine
11297134|NCT02718469|Placebo Comparator|Placebo|Placebo
11297135|NCT02718456|No Intervention|Standard of care|Standard HIV counseling and referral to care
11297136|NCT02718456|Experimental|CD4 testing|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week.
11297137|NCT02718456|Experimental|CD4 testing plus peer counseling|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
11297138|NCT02718443|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
11297139|NCT02718430|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
11297140|NCT02718417|Active Comparator|Arm A|Chemotherapy followed by observation
11297141|NCT02718417|Experimental|Arm B|Chemotherapy followed by avelumab in maintenance
11297142|NCT02718417|Experimental|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
11297143|NCT02718404|Experimental|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.
~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.
~During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
~Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI."
11297144|NCT02718391|Experimental|Arm A: Autologous Dendritic Cell vaccine|Daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days starting from the second day after each vaccine dose. Vaccine doses will be given intradermally in two sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis.The first dose (WK1) will consist of freshly prepared vaccine, whereas for all the further doses cryopreserved aliquots will be utilized. The remaining 5 doses will be administered every 4 weeks to complete six months of therapy (six vaccines).
11297145|NCT02718391|No Intervention|Arm B: follow up|Arm B: Patients will undergo laboratory and clinical assessment, tumor re-staging, blood collection for immunological biomarkers every 12 weeks until relapse.
11297146|NCT02718378|Placebo Comparator|No added active|placebo without estetrol
11297147|NCT02718378|Active Comparator|estetrol dose level 1|estetrol given in dose level 1
11297148|NCT02718378|Active Comparator|estetrol dose level 2|estetrol given in dose level 2
11297149|NCT02718378|Active Comparator|estetrol dose level 3|estetrol given in dose level 3
11297150|NCT02718365|Experimental|Group A|Wedge resection
11297151|NCT02718365|Active Comparator|Group B|Segmentectomy
11297152|NCT02718339|Experimental|Intensive counseling by a pulmonologist|Counselor visit during hospitalization, telephone follow up for 4 weeks and a follow up visits.
11297153|NCT02718339|No Intervention|Usual care|
11297154|NCT02718326|Experimental|Dosing regimen 1|Participants will receive IVT aflibercept dosing regimen 1
11297155|NCT02718326|Experimental|Dosing regimen 2|Participants will receive IVT aflibercept dosing regimen 2
11297156|NCT02718326|Sham Comparator|Dosing regimen 3|Participants will receive matching sham injections
11297157|NCT02718313||Intraventricular conduction delay|Transthoracic echocardiography will be performed to investigate whether the patients have the cardiac disease or not. The transthoracic echocardiography will be performed after the induction of general anesthesia and before the start of surgery.
11297158|NCT02718300|Experimental|Part 1: Ruxolitinib + Parsaclisib|Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
11297159|NCT02718300|Experimental|Part 2: Ruxolitinib + Parsaclisib|Part 2 will compare 2 doses of parsaclisib .
11297160|NCT02718300|Experimental|Part 3: Ruxolitinib + Parsaclisib|Part 3 will compare 2 different long term dosing strategies.
11297161|NCT02718300|Experimental|Part 4: Ruxolitinib + Parsaclisib|Part 4 will compare 2 different daily dosing strategies.
11297162|NCT02718287|Experimental|Treatment:|Home visiting with PCCSF
11297163|NCT02718287|Experimental|Control|Home visiting no PCCSF
11297164|NCT02718274|No Intervention|Control|Standard of care.
11297165|NCT02718274|Active Comparator|Self-testing|Community-Based Distribution Agents (CBDAs) in the HIV Self-Testing (HIVST) Arm villages will be trained to provide HIVST services as well as reproductive health services.
11297166|NCT02718274|Active Comparator|Self-testing + home HIV care home initiation|CBDAs will be trained to provide HIV Self-Testing plus offer home assessment and HIV care initiation (first assessment and first 14 days of HIV care medications), with this additional intervention aimed at facilitating linkage into care.
11297167|NCT02718261|Experimental|Verum (pantoprazole)|
11297168|NCT02718261|Placebo Comparator|Placebo|0.9% saline
11297206|NCT02717988|Placebo Comparator|Placebo|Placebo capsule
11297262|NCT02717572|Experimental|FDG-PET/CT and FDG-PET/MR|"10 mCI fludeoxyglucose IV bolus approximately 60 minutes before first PET/CT
~Immediately following PET/CT scan, the participant will be moved to PET/MR scanner
~The scans will take place at baseline and also one more time point between Day 1 and Day 7. There needs to be at least 24 hours between the baseline and repeat imaging"
11297169|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
11297170|NCT02718235||Overall survival HCCIS low risk|HCCIS 2 points
11297171|NCT02718235||Overall survival HCCIS medium risk|HCCIS 1 point
11297172|NCT02718235||Overall survival HCCIS high risk|HCCIS 0 point
11297173|NCT02718222|Experimental|3-9 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 3 months.
~Nepal and Sri Lanka: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 9 months."
11297174|NCT02718222|Experimental|9-15 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 9 months.
~Nepal and Sri Lanka: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 15 months."
11297175|NCT02718209|Experimental|Frozen section|Frozen sections taken from women operated on for possible gynecologic malignancies.
11297176|NCT02718196|Experimental|Application Users|English-speaking parents of children ages 6-24 months who are interested in starting sleep training within the next month.
11297177|NCT02718183|Experimental|PH|Hydrogen peroxide 35% to intracoronal bleaching in discoloration teeth eith endodontic treatment
11297178|NCT02718183|Experimental|PC|Carbamide peroxide 37% to intracoronal bleaching in discoloration teeth eith endodontic treatment
11297179|NCT02718170|Experimental|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
11297180|NCT02718170|Active Comparator|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
11297181|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
11297182|NCT02718144|Experimental|estetrol|3 + 3 design with inter-patient dose escalation
11297183|NCT02718131|Active Comparator|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
11297184|NCT02718131|Placebo Comparator|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
11297185|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
11297186|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
11297187|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
11297188|NCT02718092|Active Comparator|Plastic Stent|Three 7 Fr OR two 10 Fr Plastic Stents will be used
11297189|NCT02718092|Active Comparator|Axios FCSEMS|15 mm Axios Fully Covered Self Expanding Metal Stent
11297190|NCT02718079|Experimental|Standard medical therapy with Plasma Exchange|Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
11297191|NCT02718079|Active Comparator|Standard medical therapy alone|Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
11297192|NCT02718066|Experimental|HBI-8000 in combination with nivolumab|HBI-8000 dose escalation 20mg, 30mg, 40mg, orally, twice weekly; in combination with Nivolumab 240mg intravenous infusions every 2 weeks for Phase 1b and in accordance with the manufacturer package insert and institution's prescribing practice for Phase 2.
11297193|NCT02718053||spasticity|patients affected by spasticity of the lower limbs
11297194|NCT02718053||controls|healthy subjects
11297195|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
11297196|NCT02718027||Participants with Alport Syndrome|Participants diagnosed with Alport syndrome aged between 2 months and 50 years
11297197|NCT02718014|Other|pre menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
11297198|NCT02718014|Other|post menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
11297199|NCT02718001|Experimental|Treatment|Treatment with the Edwards EVOQUE transcatheter mitral valve replacement system
11297200|NCT02717988|Experimental|SKI-O-703 50 mg|SKI-O-703 capsule (2x25 mg)
11297201|NCT02717988|Experimental|SKI-O-703 100 mg|SKI-O-703 capsule (4x25 mg)
11297202|NCT02717988|Experimental|SKI-O-703 200 mg|SKI-O-703 capsule (1x200 mg)
11297203|NCT02717988|Experimental|SKI-O-703 400 mg|SKI-O-703 capsule (2x200 mg)
11297204|NCT02717988|Experimental|SKI-O-703 600 mg|SKI-O-703 capsule (3x200 mg)
11297207|NCT02717975|Active Comparator|Without valve|"Trial removal of catheter without catheter valve in patients with urinary retention. These are those patients who have catheter on free drainage, attend the clinic for catheter removal and bladder to be filled naturally ( which may take upto 4-5 hours). After removal of catheter they will be asked to drink plenty of fluids while waiting for the bladder to fill up.
~This is the traditional method of catheter removal."
11297208|NCT02717975|Experimental|With valve|"Trial removal of catheter in patients with urinary retention with closed catheter valve. These patients will be asked to close the valve 3-4 hours before attending the clinic prior to catheter removal. Here the intervention is catheter valve that allows bladder to be comfortably full by the time patient arrives in the clinic. By this intervention the investigators hypothesise that the investigators can save the clinic time as the patient will not need to wait for natural bladder filling which generally takes 4-5 hours.
~Intervention: Urinary catheter valve"
11297209|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
11297210|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
11297211|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
11297212|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
11297213|NCT02717936|Other|Immunohistochemistry|Patients are investigated using immunohistochemistry with Pancytokeratin
11297214|NCT02717923|Experimental|Maintenance Treatment|A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.
11297215|NCT02717910|Experimental|Health game group|Participants in this arm will receive the health game intervention including both 20 minutes guided training session at school and 2 weeks free usage of the health game during free time.
11297216|NCT02717910|Sham Comparator|Web page group|Participants in this arm will receive the web page intervention including both 20 minutes guided training session at school and 2 weeks free usage of the web page during free time.
11297217|NCT02717910|No Intervention|Group with no intervention|The participants in this arm will receive no intervention.
11297218|NCT02717884|Experimental|TCP, ATRA, Cytarabine|"Phase I part:
~The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.
~Intervention: Four dose levels of TCP (20 mg, 40 mg**, 60 mg**, 80 mg** on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.
~**TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment"
11297219|NCT02717871|Experimental|Treatment (PACK-CXL)|Photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL)
11297220|NCT02717871|Active Comparator|Antimicrobial therapy|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.
~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):
~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).
~OR
~1b. a Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
~2. Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
~3. Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium"
11297221|NCT02717858|Experimental|Liraglutide|
11297222|NCT02717858|Placebo Comparator|Placebo|
11297223|NCT02717845|Experimental|CT scan Ellipse|New medical device for high tibial osteotomy
11297224|NCT02717845|Active Comparator|CT scan Tomofix|Established medical device for high tibial osteotomy
11297225|NCT02717832|Experimental|Insulin Sensitivity|
11297226|NCT02717819|Experimental|Resistance training and protein|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
11297227|NCT02717819|Placebo Comparator|Resistance training and placebo|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
11297228|NCT02717806|Experimental|PATHway|"Patients allocated to the PATHway intervention will be given a 4 week run-in period as an outpatient to get acquainted with the system. During this run-in period, the PATHway system will also be installed in each participant's home. They will be provided with a training manual and a quick set up guide for getting started with PATHway in the home.
~After this 4 week run-in period, the PATHway system will be set up for each individual patient including a patient specific exercise prescription. The patient will then exercise with the PATHway platform for 6 months."
11297229|NCT02717806|No Intervention|Usual care|Patients randomized to the control group will receive usual care.
11297230|NCT02717793|Experimental|isometric muscle strength|"isometric muscle strength was measured with a digital hand-held dynamometer. The digital hand-held dynamometer was held by the therapist against the flexor aspect of the distal forearm of the subject, on the wrist joint. Subject was asked to maintain the position and a break test was done with progressive loading of 5 seconds given by the tester. The peak isometric strength was recorded by a second tester at the end of 5 seconds. A standardised instructions and verbal encouragement was given to the subject for motivation. Subject as well as the tester was blinded to the values recorded on the digital hand-held dynamometer. An average of three measurements (with a rest period of 4 minutes in between each trial session) was recorded for the analysis. After each trial session, the rate of perceived exertion (RPE) was asked to the subject using the 1-10 Borg rating of perceived exertion scale"
11297263|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
11297231|NCT02717793|Experimental|1RM measurement of muscle strength|1RM measurement was done using the Brzycki 1RM prediction equation. In first testing session, subject was instructed to perform a general warm up for 5 minutes. Thereafter, the subject was asked to perform 10 repetitions of the movement using the amount of resistance that the subject felt she will be able to lift for only less than 10 times. The selection of the weight is made based on a list of weights provided (1kg to 10kg). When the subject performed the movement for 10 times or more, then the resistance was increased 1kg at a time, until the subject can perform only 9 or fewer repetitions of the movement correctly throughout the range of motion. A 3 minutes rest period was given to the subject before the new attempt was done with the increased weight. A standardized verbal encouragement was provided for motivation
11297232|NCT02717780|Active Comparator|SEVO-FENTA|Patients scheduled for lower limb surgery will receive a balanced anesthesia with fentanyl and sevoflurane.
11297233|NCT02717780|Experimental|DES-REMI|Patients scheduled for lower limb surgery will receive a balanced anesthesia with remifentanil and desflurane.
11297234|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
11297235|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
11297236|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
11297237|NCT02717741|Experimental|tafetinib|tafetinib administered daily for 2 weeks, followed by a 1-week off period
11297238|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses
~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter
~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
11297239|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)
~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter
~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
11297240|NCT02717715|Experimental|Intervention group|Stroke patients from the intervention group will be, on top of usual care, offered a holistic home based and semi-supervised stroke rehabilitation program followed by a period of tele-supervision.
11297241|NCT02717715|No Intervention|Control group|The participants in the control group will only receive usual care.
11297242|NCT02717702||ACS Patients|Subjects will be patients presenting to the Emergency Department for evaluation of ACS.
11297243|NCT02717689|Experimental|Biomarker arm|Biomarker based adjustment of corticosteroid dose.
11297244|NCT02717689|No Intervention|Standard care|The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function
11297245|NCT02717676|Experimental|Group A|Episiotomy
11297246|NCT02717676|No Intervention|Group B|no episiotomy
11297247|NCT02717663|Experimental|Static goals with delayed incentives|Participants will receive static physical activity goals with delayed, non-contingent incentives
11297248|NCT02717663|Experimental|Adaptive goals with delayed incentives|Participants will receive adaptive physical activity goals with delayed, non-contingent incentives
11297249|NCT02717663|Experimental|Static goals with immediate rewards|Participants will receive static physical activity goals with immediate rewards
11297250|NCT02717663|Experimental|Adaptive goals with immediate rewards|Participants will receive adaptive physical activity goals with immediate rewards
11297251|NCT02717650|Experimental|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
11297252|NCT02717650|Experimental|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
11297253|NCT02717650|Active Comparator|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
11297254|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
11297255|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
11297256|NCT02717624|Experimental|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
11297257|NCT02717611|Experimental|ACP-196 (acalabrutinib)|
11297258|NCT02717598|Experimental|CSP|Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
11297259|NCT02717598|Experimental|HSP|Hot snare polypectomy, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp,then use Electrocoagulation until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
11297260|NCT02717585|No Intervention|Control Group|For the no intervention group (Control), patients will only receive standardized treatment for FM at the Pain Clinic. All patients will receive a multifaceted tailored regimen that incorporates one or more lines of pharmacological and/or non-pharmacological therapy. All assessment and management will be performed according to evidence-based therapeutic recommendations put forward by the Canadian Rheumatology Association and Canadian Pain Society.
11297261|NCT02717585|Active Comparator|Treatment Group (CPAP)|In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
11297449|NCT02716311|Other|Afatinib|Afatinib 40 mg/d until progression
11297264|NCT02717533||blood volume|dry weight adjusted according to ideal blood volume obtained from absolute blood volume measurement (Daxor)
11297265|NCT02717520|Experimental|All study participants|One permanent molar with an approximal and occlusal carious lesion restored with EQUIA Forte, and one permanent molar with an approximal and occlusal carious lesion restored with Tetric EvoCeram
11297266|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
11297267|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
11297268|NCT02717494|Experimental|Arm 1A (PPV-23)|In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
11297269|NCT02717494|Experimental|Arm 1B (PCV-10)|In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
11297270|NCT02717494|Placebo Comparator|Arm 1C (placebo)|In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
11297271|NCT02717494|Experimental|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
11297272|NCT02717494|Experimental|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
11297273|NCT02717494|Experimental|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.
11297274|NCT02717481||Patients with known aortic aneurysm|"Patients with known abdominal aortic aneurysm diagnosed in clinical follow-up or after an invasive procedure to repair it.
~US-CT Fusion examination"
11297275|NCT02717455|Experimental|Treatment (STRATUM 1)|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
11297276|NCT02717455|Experimental|Treatment (STRATUM 2)|Patients with non-progressed DIPG will be enrolled. All patients will take the study drug panobinostat (LBH589).
11297277|NCT02717442|Experimental|OTO-104|12 mg dexamethasone
11297278|NCT02717442|Placebo Comparator|Placebo|
11297279|NCT02717429|Experimental|Mindfulness Meditation Training (MMT)|Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration. The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness. In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
11297280|NCT02717429|Active Comparator|Computerized Cognitive Training|The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group. Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
11297281|NCT02717429|No Intervention|Wait-List Control Group|This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
11297282|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
11297283|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip therapy.
11297284|NCT02717403|Experimental|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
11297285|NCT02717403|Experimental|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
11297286|NCT02717403|Experimental|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
11297287|NCT02717390|Experimental|Bright By Three (BB3) Intervention|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years
11297288|NCT02717390|Active Comparator|Texts for Child Safety (TCS) Intervention|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
11297289|NCT02717377|No Intervention|Uninterrupted sitting|Subjects remained seated all day except to rise from the chair to void.
11297290|NCT02717377|Active Comparator|Sitting + one bout of activity|Subjects remained seated all day, except to rise from the chair to void, and to perform one bout of 30-minutes moderate-intensity walking. Physical activity was performed at 0800, after measures of vitals and basal questionnaire assessments, but before breakfast.
11297291|NCT02717377|Experimental|Sitting + microbursts of activity|Subjects rose from the seated position every hour for 6-hours from 0910 to 1430 to complete 5-minute bouts of moderate-intensity walking, yielding a total activity time of 30-minutes.
11297292|NCT02717364||Population With Yervoy Exposure|Population With Yervoy Exposure
11297293|NCT02717351|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11297294|NCT02717338|Experimental|Competence|Participants will be assigned to review our donor coping website.
11297296|NCT02717338|Experimental|Relatedness|Participants will be asked to join a closed Facebook group for one month.
11297297|NCT02717338|Experimental|Competence + Autonomy|Participants will be assigned to the web site review, followed by the brief telephone interview.
11297298|NCT02717338|Experimental|Competence + Relatedness|Participants will be assigned to the web site review, followed by the one-month Facebook group membership.
11297299|NCT02717338|Experimental|Autonomy + Relatedness|Participants will be assigned to the brief telephone interview, followed by the one-month Facebook group membership.
11297300|NCT02717338|Experimental|Competence + Autonomy + Relatedness|Participants will be assigned to the web site review, brief telephone interview, and one-month Facebook group membership.
11297301|NCT02717338|No Intervention|Treatment-as-Usual Control|Participants will receive the standard communications that New York Blood Center has with all first-time donors.
11297302|NCT02717325|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
11297303|NCT02717299|Experimental|Sensor Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The surgeon will use this data to intraoperatively align the knee according to the indications of the data.
11297304|NCT02717299|Placebo Comparator|Surgeon Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The computer displaying the data will be turned away from the surgeon, so that he is not able to use the sensor data, and must balance the knee with feel and visual estimation of balance.
11297305|NCT02717286|Sham Comparator|Control|"20 first permanent molars from children aged between 6 to 12 years old presenting MIH will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the European Academy of Pediatric Dentistry (EADP) criteria.
~Intervention of Control: The restorative treatment using a total-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
11297306|NCT02717286|Experimental|Test|"20 first permanent molars from children aged between 6 to 12 years old presenting Molar Incisor Hypomineralization will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the EAPD criteria.
~Intervention of test: the restorative treatment using a self-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), air jet (5 s), adhesive application (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
11297307|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
11297308|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.
~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
11297309|NCT02717260|Sham Comparator|Sham transcranial noise stimulation|subjects are stimulated 3 times with sham transcranial random noise stimulation (tRNS) (Starstim) with a 30 seconds offset
11297310|NCT02717260|Active Comparator|1 Active transcranial random noise stimulation|subjects are stimulated 1 time with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes and 2 times with sham tRNS
11297311|NCT02717260|Active Comparator|3 Active transcranial random noise stimulation|subjects are stimulated 3 times with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes
11297312|NCT02717247|Experimental|Active tRNS treatment|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).
~100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days"
11297313|NCT02717247|Sham Comparator|Placebo tRNS treatment|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
11297314|NCT02717234|Active Comparator|Impact Advanced Recovery|Oral nutrition supplement intended for consumption at 3 servings per day
11297315|NCT02717234|Experimental|Impact Advanced Recovery-R|Oral nutrition supplement intended for consumption at 3 servings per day
11297316|NCT02717221|Experimental|18F-MPG:EGFR+|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
11297317|NCT02717221|Experimental|18F-MPG:post-TKI EGFR+|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.
11297318|NCT02717221|Experimental|18F-MPG:post-chemo EGFR+|Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
11297319|NCT02717221|Experimental|18F-MPG:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
11297320|NCT02717221|Experimental|18F-MPG:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
11297321|NCT02717221|Experimental|18F-MPG:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
11297322|NCT02717208|Active Comparator|HL036 0.5mg/ml|Administration : 2 times per day for one day
11297323|NCT02717208|Active Comparator|HL036 5mg/ml|Administration : 2 times per day for one day
11297324|NCT02717195|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
11297325|NCT02717195|Experimental|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
11297326|NCT02717195|Experimental|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
11297327|NCT02717195|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
11297328|NCT02717169|Other|Biometrical Tracker|The participants are equipped with an wrist watch. The activity tracker measures biometrical information like, steps, sleep duration and heart rate.
11297329|NCT02717156|Experimental|Treatment (EphB4-HSA and pembrolizumab)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, and 15 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11297330|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:
~prolonged chest pain > 10 minutes,
~recent infectious context <7 days
~young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion
~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.
~This is an observational study that does not affect the management of patients."
11297331|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
11297332|NCT02717117|Experimental|Feeding|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
11297333|NCT02717091|Experimental|FOLFIRINOX|4 course of FILFIRINOX before surgery
11297334|NCT02717091|Experimental|GEM + nab-PTX|2 course of GEM + nab-PTX before surgery
11297335|NCT02717078|Experimental|LoBAG Diet|Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks.
11297336|NCT02717078|Active Comparator|Control Diet|Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks.
11297337|NCT02717065|Experimental|Characterization, Audiovisual|"Characterization: Tinnitus characterization tools (Minimal Masking Level, Tinnitus Functional Index, Tinnitus Handicap Inventory, and Subjective rating scale) are assessed in an individual over time to determine baseline variability.
~Audiovisual: The individual will watch a series of silent videos of a person speaking, both with and without a tone matched to their tinnitus as well as videos of a still face with and without the matched tone."
11297338|NCT02717052|Experimental|(S)-ketamine|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)
~all patients and 10 HC (randomized, double blind)
~Interventions:
~Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2"
11297339|NCT02717052|Placebo Comparator|Placebo|"0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
~10 HC (randomized, double blind)
~Interventions:
~Drug: Placebo Other: Main study: PET1 Other: Main study: PET2"
11297340|NCT02717052|Experimental|(S)-ketamine (Pilot Study II, 5 subj.)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
~Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.
~Pilot-study II is cross-over design!
~Interventions:
~Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
11297341|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study II, 5 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
~Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.
~Pilot-study II is cross-over design!
~Interventions:
~Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
11297342|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study I, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)
~Interventions:
~Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2"
11297343|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study III, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
~Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes
~Interventions:
~Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2"
11297344|NCT02717039||Blood Draw|A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
11297345|NCT02717013|Placebo Comparator|Placebo Diet Restriction|
11297346|NCT02717013|Placebo Comparator|Placebo No Diet Restriction|
11297347|NCT02717013|Active Comparator|HMB Diet Restriction|
11297348|NCT02717013|Active Comparator|HMB No Diet Restriction|
11297349|NCT02717000||NASH|
11297350|NCT02717000||No NASH|
11297450|NCT02716311|Experimental|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
11297351|NCT02716987|Experimental|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with [18F] ([18F]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
11297352|NCT02716987|Experimental|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
11297353|NCT02716987|Experimental|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
11297354|NCT02716987|Experimental|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
11297355|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
11297356|NCT02716974|Experimental|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
11297357|NCT02716961|No Intervention|Monotherapy|Barely epirubicin was instilled after TURBT. Epirubicin was immediately instilled in 24h after TURBT. Instillation was conducted regularly for a year: once in a week for 8 times, once in two weeks for 8 times, once in a month for 6 times.
11297358|NCT02716961|Experimental|Combination|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. Intervention: GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
11297359|NCT02716948|Experimental|Treatment (nivolumab, stereotactic radiosurgery)|Patients receive nivolumab IV over 60 minutes on day 1. Patients then undergo stereotactic radiosurgery on day 8 per standard of care. Courses with nivolumab repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11297360|NCT02716935|Experimental|Fortified lipid based nutrient supplement|lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin
11297361|NCT02716935|Active Comparator|lipid based nutrient supplement|lipid based nutrient supplement (Nutributter)
11297362|NCT02716935|No Intervention|non intervention group|This group will not be supplemented
11297363|NCT02716922|Experimental|Cervical cerclage|Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
11297364|NCT02716922|No Intervention|No intervention|No cerclage Women randomized to not receive cerclage represent the control arm
11297365|NCT02716909|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
11297366|NCT02716909|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
11297367|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
11297368|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
11297369|NCT02716883|No Intervention|Non AMT|"Freshly prepared fortified eye drops (cefazolin 50 mg/mL and amikacin 14 mg/mL) were applied as starting treatment. In the first 3 days, eye drops are applied round the clock followed by drops every 2 h during waking hours until results of laboratory investigation were available.
~After preparation of the culture results, the antimicrobial treatment was narrowed according to bacterial sensitivity. Also topical betamethasone 0.1% four times a day on a tapering weekly dosage until 3-4 weeks is used for all patients. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented"
11297370|NCT02716883|Active Comparator|AMT|"This group (case group) received above mentioned routine antibiotic therapy followed by double-layer amniotic membrane transplantation 2-5 days after the start of medications and the second group (control group) only received routine antibacterial therapy.
~The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented."
11297371|NCT02716857|Experimental|Oxycodone extended-release|Egalet ADER oxycodone tablet
11297372|NCT02716857|Placebo Comparator|Placebo of Oxycodone extended-release|Egalet ADER oxycodone placebo tablet
11297373|NCT02716844|Experimental|Exercise Group,|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
11297374|NCT02716844|No Intervention|Control Group|Nothing given to control group, told to continue their normal life for 6 weeks.
11297693|NCT02714829|Active Comparator|ExcelOS-inject|ExcelOS-inject without rhBMP-2
11297375|NCT02716831|Experimental|Counseling & Acceptance-based Therapy|Nutritional Counseling & Acceptance-based Therapy (N-CAAT) incorporates acceptance-based behavioral strategies and nutritional counseling designed to encourage willingness to tolerate distress and the ability to pursue chosen values in an adaptive manner despite distressing internal experiences. In addition to these skills, a principal focus of the treatment will be on identifying, practicing, and achieving behavioral goals, such as normalization of eating, reduction of maladaptive dietary restraint and restriction, and elimination of compensatory behaviors.
11297376|NCT02716831|Active Comparator|Cognitive Therapy for Eating Disorders|Participants in the Cognitive Behavioral Therapy for Eating Disorders (CBT) condition will receive 20-sessions of standard CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn and published in his book Cognitive Behavioral Therapy and Eating Disorders.
11297377|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
11297378|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
11297379|NCT02716805|Experimental|Cohort 1|"Subjects received Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
11297380|NCT02716805|Experimental|Cohort 2|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
11297381|NCT02716805|Experimental|Cohort 3|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
11297382|NCT02716805|Experimental|Cohort 4|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
11297383|NCT02716792|Experimental|Ibandronate 15-Minute Infusion|Participants will receive ibandronate IV infusions over a 15-minute interval.
11297384|NCT02716792|Active Comparator|Ibandronate 60-Minute Infusion|Participants will receive ibandronate IV infusions over a 60-minute interval.
11297385|NCT02716779|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
11297386|NCT02716779|Placebo Comparator|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
11297387|NCT02716779|Experimental|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
11297388|NCT02716766|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
11297389|NCT02716766|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily from Day 1 to 14
11297390|NCT02716753|Experimental|Seminal plasma|Half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
11297391|NCT02716753|Placebo Comparator|Physiological NaCL solution|An amount of physiological NaCL solution equal to half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
11297392|NCT02716740|Experimental|Leucine-enriched amino acid : 2.16g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
11297393|NCT02716740|Experimental|Leucine-enriched amino acid : 4g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
11297394|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
11297395|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
11297396|NCT02716714|Active Comparator|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
11297397|NCT02716714|Active Comparator|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
11297398|NCT02716701|Experimental|Exercise Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will be asked to increase their activity level, with a goal of at least doubling their average daily activity (steps)
11297399|NCT02716701|Active Comparator|Control Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will not be encouraged to increase their activity level
11297400|NCT02716688|Experimental|Radiotherapy and S-1 arm|Radiotherapy will be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy. Preplanned concurrent S-1 (70mg/m²/day) will be administered on Day 1 for 14 days, every 3 weeks. After dCRT, maintenance S-1 will be given up to two cycles.
11297451|NCT02716298|Active Comparator|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
11297401|NCT02716675|Experimental|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
11297402|NCT02716675|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
11297403|NCT02716675|Placebo Comparator|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
11297404|NCT02716662|Experimental|Open Label|Axona
11297405|NCT02716649||All participants|No intervention
11297406|NCT02716636|No Intervention|Fast placement|Placement of the tenaculum quickly and without avoiding ratchet
11297407|NCT02716636|Experimental|Slow placement of the tenaculum|Placement of the tenaculum over a 7-10 second time frame and not allowing the tenaculum to ratchet audibly.
11297408|NCT02716623|Experimental|CR Diet and Exercise|Participants will be asked to follow specific diet intervention and exercise regimen.
11297409|NCT02716610|Experimental|INH 69 U (low)|single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
11297410|NCT02716610|Experimental|INH 69 U (high)|single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
11297411|NCT02716610|Experimental|INH 139 U|single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
11297412|NCT02716610|Experimental|INH 208 U|single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
11297413|NCT02716610|Active Comparator|LIS 18 U|single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
11297414|NCT02716597|Experimental|25% Albumin|25% albumin 75 grams IV over 1 hour once.
11297415|NCT02716597|Placebo Comparator|Placebo|0.9% normal saline 200mL IV over 1 hour once.
11297416|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
11297417|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
11297418|NCT02716571|Other|Healthy Donors|Healthy Donors will given white blood cell and plasma
11297419|NCT02716558|Experimental|Moisture tolerant resin sealant|Moisture resistant sealant (wet bond sealant)
11297420|NCT02716558|Active Comparator|ART sealant|Glass inomer based sealant
11297421|NCT02716545|Experimental|Endoscopic Intervention Group|Endoscopic therapy
11297422|NCT02716532|Other|Peptamen AF|over 7 days
11297423|NCT02716519|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks
11297424|NCT02716519|Active Comparator|Standard Card|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
11297425|NCT02716506||Symptomatic POP|POP surgery in year 2015
11297426|NCT02716493|Experimental|Telerehabilitation group|Patients with unresectable thoracic neoplasia receiving chemotherapy treatment
11297427|NCT02716480|Experimental|Mobility Coaching|"45 patients undergoing bariatric surgery received a monthly mobility coaching session of 20 to 30 min by phone during 6 months."
11297428|NCT02716480|Experimental|Diet Coaching|"45 patients undergoing bariatric surgery received a monthly diet coaching session of 20 to 30 min by phone during 6 months."
11297429|NCT02716467|Experimental|intercessory prayer group|Patients in the experimental group receive prayer of intercession during radiotherapy treatment.
11297430|NCT02716467|Active Comparator|Radiotherapy Treatment|Patients in the radiotherapy group not receive prayer of intercession during radiotherapy treatment.
11297431|NCT02716454|Experimental|Early Surgery - ES|Early laparoscopic ileocaecal resection
11297432|NCT02716454|No Intervention|Step-up therapy - STUP|Treatment with step-up conservative approach according to good clinical practice.
11297433|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
11297434|NCT02716428|Experimental|Cohort 1|12 weeks of Faldaprevir plus TD-6450 plus Ribavirin
11297435|NCT02716428|Experimental|Cohort 2|12 weeks of Faldaprevir plus TD-6450
11297436|NCT02716415|Active Comparator|Calmoseptine Ointment|Calmoseptine Ointment as part of a structured skin care regimen.
11297437|NCT02716415|Active Comparator|Destin Maximum Strength 40% Zinc|Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
11297438|NCT02716402|Other|Cyanotic congenital heart disease|Patients who previously have been examined with cerebral MRI and V/Q SPECT/CT will be re-examined with cerebral MRI and V/Q SPECT/CT
11297439|NCT02716389|Other|Mask on|
11297440|NCT02716389|Other|Mask off|
11297441|NCT02716376|Experimental|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
11297442|NCT02716376|No Intervention|No treatment|Observation: No treatment.
11297443|NCT02716363|Experimental|Device : Rotablator|We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
11297444|NCT02716350|Experimental|B-GOS|powder, 3.5g/day
11297445|NCT02716350|Placebo Comparator|Maltodextrin|powder, 3.5g/day
11297446|NCT02716337|Other|Intervention group|In the intervention group VLBW infants were fed target fortified human milk Growth and safety were compared to a historical group of VLBW infants fed with standard fortified human milk
11297447|NCT02716324|Active Comparator|ADHD Portal|In this arm, the ADHD Portal was used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
11297448|NCT02716324|Experimental|ADHD Portal plus Care Manager (CM)|In this arm, the ADHD Portal was combined with the CM. Clinicians, teachers, and parents used the ADHD Portal as standard of care. In addition, clinicians, teachers, parents, and any external mental health providers interacted with a CM, who had access to information contained in the ADHD Portal.
11297452|NCT02716298|Active Comparator|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
11297453|NCT02716285|Experimental|Ileocolonic release peppermint oil|Colon-targeted-delivery capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
11297454|NCT02716285|Experimental|Small intestinal release peppermint oil (Tempocol®)|Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
11297455|NCT02716285|Placebo Comparator|Placebo|Capsule containing microcrystalline cellulose, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
11297456|NCT02716272|Experimental|MONOTHERAPY ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
11297457|NCT02716272|Experimental|COMBINATION ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
11297458|NCT02716259|Experimental|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and oral antiseptics (clorhexidine 0.12% rinse),
11297459|NCT02716259|Placebo Comparator|Supragingival prophylaxis|Two sessions of supragingival prophylaxis under local anesthesia and an oral rinse with no antiseptic properties.
11297460|NCT02716246|Experimental|Cohort 1 Low Dose|Dose of 0.5 X 10^13 vg/kg
11297461|NCT02716246|Experimental|Cohort 2 Mid Dose|Dose of 1 X 10^13 vg/kg
11297462|NCT02716246|Experimental|Cohort 3 High Dose|Dose of 3 X 10^13 vg/kg
11297463|NCT02716233|Active Comparator|Arm 1|pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
11297464|NCT02716233|Experimental|Arm 2|pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
11297465|NCT02716220|Experimental|'Percutaneous Coronary Intervention' /Scaffold Implantation|PCI for enrolled subjects: implantation of the DREAMS 2G Drug-Eluting Coronary Scaffold System
11297466|NCT02716207|Experimental|Maximal tolerated dose with CyberKnife|SBRT will be delivered in 5 fractions within 1 to 2 weeks by the following schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5 with BED10 in correspondence to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy respectively while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is four weeks between each dose level. In case patient presents III/IV GI toxicity, three additional patients will be included at the same dose level. The Maximal Tolerated Dose will be defined as the dose for which at least 2 patients in 3, or at least 3 patients in 9, will present with a limiting toxicity.
11297467|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
11297468|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
11297469|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
11297470|NCT02716181|Active Comparator|"Атопик phase 1"|"For the first phase of the study, subjects will be randomized to receive treatment with Атопик Soothing Cream."
11297471|NCT02716181|Placebo Comparator|Placebo - phase 1|For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.
11297472|NCT02716181|Active Comparator|"Атопик phase 2"|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
11297473|NCT02716181|Placebo Comparator|Placebo - phase 2|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
11297474|NCT02716168|Experimental|Video consultation|Video consultation between cancer patient, general practitioner and oncologist at the start of chemotherapy treatment
11297475|NCT02716168|No Intervention|usual care|Usual care. The patients General Practitioner will receive standard discharge summary and ambulant notes from the oncologist specialist
11297476|NCT02716142|Experimental|Group A|rectal misoprostol 400 microgram
11297477|NCT02716142|Active Comparator|Group B|sublingual misoprostol 400 microgram
11297478|NCT02716129|Active Comparator|Group 1|Morphine group
11297479|NCT02716129|Active Comparator|Group 2|Morphine plus Nalbuphine group
11297480|NCT02716116|Experimental|Dose Escalation Cohort|TAK-788 treatment for participants with advanced NSCLC.
11297481|NCT02716116|Experimental|Expansion Cohort 1|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI), and who have no active, measurable central nervous system (CNS) metastases.
11297482|NCT02716116|Experimental|Expansion Cohort 2|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
11297483|NCT02716116|Experimental|Expansion Cohort 3|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
11297484|NCT02716116|Experimental|Expansion Cohort 4|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations), without active CNS metastases.
11297485|NCT02716116|Experimental|Expansion Cohort 5|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.
11297620|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
11297486|NCT02716116|Experimental|Expansion Cohort 6|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions, who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases
11297487|NCT02716116|Experimental|Expansion Cohort 7|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.
11297488|NCT02716116|Experimental|Extension Cohort|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.
11297489|NCT02716103||Initial Cohort: feasibility|Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
11297490|NCT02716103||2nd Cohort - pre-treatment|If feasibility is determined with initial cohort, bone marrow collection and peripheral blood collection from 20 patients with untreated AL amyloidosis who are scheduled to undergo antineoplastic therapy will be evaluated to isolate a plasma cell clone. An additional 3 teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving therapy. For those who complete therapy and achieve complete response or very good partial response, subsequent samples of bone marrow and peripheral blood will be sent for minimal residual disease detection (based on the previously identified cancer clone) at 6 to 12 months post treatment.
11297491|NCT02716090|Experimental|Dalap Duo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.
11297492|NCT02716090|Active Comparator|Epiduo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.
11297493|NCT02716064|Experimental|TAP-CM Intervention|Patients in this arm will be encouraged to complete the Healthy Lifestyle App modules and use McMaster PHR to self manage their chronic disease. Participants will also be completing the health and life goals using the App. The TAPESTRY-CM reports generated will then be reviewed by the clinic huddle teams
11297494|NCT02716051|Experimental|MRI|Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
11297495|NCT02716051|Active Comparator|PET|At day 1 , in the morning, patient will undergo an PET analysis
11297496|NCT02716038|Experimental|MPDL3280A, Carboplatin, Nab-paclitaxel|"Subjects with advanced or recurrent cancers receiving:
~MPDL3280A every 21 days for up to 84 days
~Carboplatin every 21 days for up to 84 days
~Nab-paclitaxel every 7 days for up to 84 days"
11297497|NCT02716025||Case Group|
11297498|NCT02716025||Control Group|
11297499|NCT02716012|Experimental|MTL-CEBPA|
11297500|NCT02715999|Active Comparator|Quadratus Lumborum Block|Quadratus Lumborum block group (QL) patients will receive unilaterally Quadratus Lumborum block using Bupivacaine 0.2 %
11297501|NCT02715999|Active Comparator|Transversus abdominis plane block|Transversus abdominis plane block (TAP) patients will receive unilaterally TAP block using Bupivacaine 0.2 %
11297502|NCT02715986|Experimental|Severly depressed patients|Recruitment of twenty depressive subjects will be conducted within the hospital service adult psychiatry.These patients are referred for indication of ECT sessions for severe resistant depression. Four MRI evaluations (3T MRI examination) are programmed in such patients to analyze structural changes in the hippocampus.
11297503|NCT02715973|Experimental|Nutritional Supplement|"Diet Counseling (Energy=200 kcal/kg/day, (present weight) protein =3-4 gm/kg/day)
~Nutritional supplement (Providing extra 40 kcal/kg/day)"
11297504|NCT02715973|Active Comparator|Standard nutritional treatment|"Diet counselling only (Energy=200 kcal/kg/day (present weight) protein =3-4 gm/kg/day).
~Standard nutritional treatment"
11297505|NCT02715960|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
11297506|NCT02715947|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
11297507|NCT02715934|Experimental|Glucose to Goal|Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
11297508|NCT02715934|Other|Control Group|Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
11297509|NCT02715921|Experimental|Cystic fibrosis patients|Receive tele-exercise training and undergo pulmonary function testing and exercise testing
11297510|NCT02715908|Experimental|LBEC0101|Etanercept 50mg
11297511|NCT02715895|Experimental|Friso|Friso formula feeding
11297512|NCT02715895|Experimental|Wyeth|Wyeth formula feeding
11297513|NCT02715895|Active Comparator|Breast milk|Breast milk feeding
11297514|NCT02715882|Experimental|1 injection of CBLB502 0.35 μg/kg|One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
11297515|NCT02715882|Experimental|1 injection of CBLB502 0.45 μg/kg|One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
11297516|NCT02715882|Experimental|2 injections of CBLB502 0.35 μg/kg|Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
11321502|NCT02557126|Placebo Comparator|Placebo|Placebo
11297517|NCT02715882|Experimental|2 injections of CBLB502 0.45 μg/kg|Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
11297518|NCT02715869|Active Comparator|A pharmacologic cardiac preconditioning|Sevoflurane as a pharmacologic preconditioner for the heart
11297519|NCT02715869|Active Comparator|B ischeamic preconditioning|ischemic preconditioning by inflation the cuff of blood pressure
11297520|NCT02715856|Active Comparator|Group I (standard follow up, physical activity measurement)|Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.
11297521|NCT02715856|Experimental|Group II (mobile surveillance)|Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.
11297522|NCT02715830|Experimental|One Artery|In this arm after obtain the good result after the angioplasty of one artery the procedure stops
11297523|NCT02715830|Experimental|More than one artery|In this arm, after obtain a good result of the angioplasty of one artery, we continue trying one or two more arteries
11297524|NCT02715817|Active Comparator|Virtual Rehabilitation - VR|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.
~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
11297525|NCT02715817|Active Comparator|Conventional Therapeutic Exercises - CTE|A program of conventional therapeutic exercises (G1) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1: 30 minutes of upper limb PNF diagonal exercise (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes of scapula PNF diagonal exercise (anterior and posterior elevation); b) protocol 2: 20 minutes of lower limb PNF diagonal exercise (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes of pelvis PNF diagonal exercise (anterior and posterior depression), and 10 minutes gait cycle training;
11297526|NCT02715817|Experimental|VR and CTE|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
11297527|NCT02715804|Experimental|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
11297528|NCT02715804|Placebo Comparator|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
11297529|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of study will receive access to the Healthy Lifestyle App and the McMaster PHR
11297530|NCT02715791|Other|TAP-HC-DM|Patients randomized to the intervention group will get TAP-HC-DM intervention from time zero
11297531|NCT02715778||Adult Participants|
11297532|NCT02715778||Child Participants|
11297533|NCT02715765|Sham Comparator|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
11297534|NCT02715765|Experimental|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
11297535|NCT02715765|Experimental|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
11297536|NCT02715752||Herpes Simplex Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
11297537|NCT02715752||Human Papillomavirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
11297538|NCT02715752||Epstein-Barr Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
11297539|NCT02715752||Cytomegalovirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
11297540|NCT02715752||Varicella Zoster Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
11297541|NCT02715739||All participants|
11297542|NCT02715726|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
11297543|NCT02715726|Experimental|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was >=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter [mmol/L]) at Week 8.
11297544|NCT02715713||testosterone deficiency group|Men between the ages of 40 to 80-years-old with testosterone deficiency
11297545|NCT02715713||prostate cancer group|Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
11297829|NCT02713867|Active Comparator|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
11297546|NCT02715700|Experimental|Maintenance Methadone and MK-1439|Participants maintained on a stable methadone regimen (20 to 200 mg once daily) for ≥14 days prior to Day 1 will continue to receive methadone maintenance once per day on Days 1 to 7. From Day 2 to 6, participants will also receive doravirine 100 mg once daily.
11297547|NCT02715687|Placebo Comparator|Placebo|Will receive 30 days treatment with oral placebo of 200mg
11297548|NCT02715687|Active Comparator|Interventional|Will receive 30 days treatment with oral Amiodarone of 200mg
11297549|NCT02715674|Placebo Comparator|control group|take 4lt/min oxygen with Plasti-med oxygen therapy mask
11297550|NCT02715674|Active Comparator|IS group|in postoperatively, patients will carry out Plasti-med TRIFLO 5 min per hour for 6 hours.
11297551|NCT02715674|Active Comparator|CPAP group|in postoperatively, patients will carry out 10 cmH2O noninvasive continuous positive airway pressure with BIPAP VISION 5 min per hour for 6 hours.
11297552|NCT02715661|Active Comparator|Coronary artery disease|those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .
11297553|NCT02715661|Active Comparator|Metabolic Syndrome|Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)>130 and/or Diastolic Blood Pressure (DBP)>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference >102cm in males;>88cm in females), Fasting triglycerides > 1.695 mmol/L, Low HDL cholesterol: Males < 1.04 mmol/L; Females < 1.29 mmol/L, Fasting glucose >5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
11297554|NCT02715661|Active Comparator|Health Control|Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
11297555|NCT02715648|No Intervention|No Phenazopyridine before cystoscopy|This group will not receive phenazopyridine prior to cystoscopy
11297556|NCT02715648|Experimental|Phenazopyridine before cystoscopy|This group will receive 200mg of phenazopyridine prior to cystoscopy
11297557|NCT02715635|Active Comparator|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®
~Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate"
11297558|NCT02715635|Placebo Comparator|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®
~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
11297559|NCT02715622||Open Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia open repair surgical procedure
11297560|NCT02715622||Laparoscopic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia laparoscopic repair surgical procedure
11297561|NCT02715622||Robotic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia robotic-assisted laparoscopic repair surgical procedure
11297562|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ (dose escalation)|"DSF (dose level (DL) 1=125mg, DL 2=250mg, DL 3=375 mg, DL 4=500mg). DSF starts at DL 2 and escalated using the Time-to-Event Continual Reassessment Method
~3 day lead-in of oral DSF once daily (QD) prior to surgery (optional)
~2 mg Cu gluconate 3 times daily (TID) on days when DSF is given (optional pre-surgery)
~Surgery performed per routine clinical care.
~After surgery, evaluation to confirm the final pathological diagnosis as GBM (if not the patient will not continue with the 2nd part of the study).
~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.
~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.
~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose
~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles."
11297563|NCT02715609|Experimental|DSF, Cu, Surgery, RT, TMZ (dose expansion)|"Surgery performed per routine clinical care.
~RT 4-6 weeks following surgery at 60 Gy in 30 daily fractions.
~TMZ from Day 1 of RT to the last day of RT at a daily oral dose for a maximum of 49 days as per standard clinical care.
~DSF QD and Cu TID during chemoradiotherapy as per preoperative dose
~4-6 weeks after completion of chemoradiotherapy, adjuvant TMZ may be administered for 6 cycles. TMZ on Days 1-5 of every 28-day cycle. Daily DSF of 500mg will be continued with adjuvant TMZ for up to 6 cycles.
~If a patient develops recurrent tumor during follow-up and plans to undergo another resection, he/she may opt for an optional preoperative DSF study prior to salvage surgery."
11297564|NCT02715596|Experimental|Intervention A|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
11297565|NCT02715596|Placebo Comparator|Intervention B|Placebo supplementation in a 15 cc emulsion stick-pack
11297566|NCT02715570|Experimental|Single dose - healthy volunteers|
11297567|NCT02715570|Experimental|Repeat dose - healthy volunteers|
11297568|NCT02715570|Experimental|Single dose - asthmatic patients|
11297569|NCT02715557|Experimental|Full Access to the relapse prevention program|The participants will receive access to the relapse prevention program throughout the entire 6-week trial period.
11297570|NCT02715557|Experimental|TAU|The participants will receive treatment as usual (TAU) for 6-weeks, and will receive access to the relapse prevention program after the completion of the 6 month follow-up.
11297571|NCT02715544|Experimental|Intervention group|The group will receive healthy lifestyle intervention
11297572|NCT02715544|Active Comparator|control group|Other: physical activity and dietary guidelines
11297573|NCT02715531|Experimental|Arm A (Hepatocellular Carcinoma [HCC], All subtypes)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior treatment are non-randomized and will receive atezolizumab and bevacizumab, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.
11297621|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
11297622|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
11297623|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
11297574|NCT02715531|Experimental|Arm B (Gastric Cancer)|Participants with previously untreated human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) are non-randomized and will receive atezolizumab, bevacizumab, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil [FU]), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered as maintenance therapy without oxaliplatin instead of infusional 5-FU and leucovorin, and biologic therapy may be given every 3 weeks (q3w). In the event that a patient experiences unacceptable toxicity after replacement of infusional 5-FU and leucovorin with capecitabine, the patient may be allowed to switch back to 5-FU and leucovorin following investigator discussion with the Medical Monitor.
11297575|NCT02715531|Experimental|Arm C (Metastatic Pancreatic Cancer)|Participants with previously untreated metastatic pancreatic cancer are non-randomized and will receive atezolizumab q2w starting on Day 1, Cycle 1 (each cycle of 28 days). Administration of nab-paclitaxel followed by gemcitabine will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.
11297576|NCT02715531|Experimental|Arm E (Randomized Metastatic Esophageal Cancer)|Participants with squamous metastatic esophageal cancer (mEC) will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab and FOLFOX, q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab followed by cisplatin and 5-FU q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.
11297577|NCT02715531|Experimental|Arm F (Randomized HCC)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior systemic treatment will be randomized (1:1) into Group F1 and Group F2. Participants will receive atezolizumab alone (Group F2) or combined with bevacizumab (Group F1) on a q3w schedule, with dosing on Day 1 of each 21 day Cycle. Treatment with atezolizumab with or without bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator. Participants who are randomly assigned to Group F2 (atezolizumab monotherapy) and experience investigator-assessed unequivocal radiographic progression as per RECIST v1.1 will also be given the option to cross over to atezolizumab and bevacizumab combination therapy, provided they meet the criteria for crossover and Medical Monitor approval is obtained.
11297578|NCT02715518|Active Comparator|FFR-guided strategy arm|FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis > 90%, we will judge FFR value of ≤ 0.80.
11297579|NCT02715518|Active Comparator|Angiography-guided strategy arm|"Non-IRA stenosis with > 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.
~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
11297580|NCT02715505|Experimental|HSC835|HSC835 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation
11297581|NCT02715492|Active Comparator|Transarterial Chemoembolization|1st group: included 20 patients with HCC treated by TACE only.
11297582|NCT02715492|Experimental|TACE and LMWH|2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).
11297583|NCT02715479|Experimental|Treatment A|Single DTG tablet under fed conditions for a specified period
11297584|NCT02715479|Experimental|Treatment B|Two BMS955176 tablets under fed conditions for a specified period
11297585|NCT02715479|Experimental|Treatment C|Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period
11297586|NCT02715466|Experimental|Gelatine|Balanced gelatine solution
11297587|NCT02715466|Active Comparator|Electrolyte|Balanced electrolyte solution
11297588|NCT02715453|Experimental|Intervention on frailty|Intervention on frailty in addition to the usual care by the cardiologist. A multidisciplinary team (physicians, nurses and physiotherapists and nutritionists) will carry out the intervention on frailty
11297589|NCT02715453|No Intervention|Control|Conventional strategy consisting only of the usual care by the cardiologist
11297590|NCT02715440|Experimental|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs : 25% reduction of the benzodiazepines dose or related drugs every 2 weeks during nine weeks in order to stop the treatment .
11297591|NCT02715440|No Intervention|Delayed intervention|usual care without intervention
11297592|NCT02715427|Active Comparator|Conventional care|"Preoperative consultation Information support conventional perioperative No bowel preparation
~Day before surgery Normal diet until midnight No carbohydrate loading Premedication with anxiolytic
~Operative day Conventional general anaesthesia Classic management perfused volumes Conventional use of drains at the operative site Standard nasogastric drainage Conventional analgesia protocol
~Postoperative time Mobilization from J1 Progressive refeeding Progressive removal of venous, arterial and urinary catheters. Gradual recovery of the usual treatment from J1 Breathe physiotherapy depending on the clinical course No stimulation of intestinal transit"
11297593|NCT02715427|Experimental|Enhanced recovery|"Preoperative consultation Specific information about the enhanced rehabilitation No bowel preparation Immunonutrition for the 7 preoperative days
~Day before surgery Minimal preoperative fasting No premedication Carbohydrate loading
~Operative day Optimized general anesthesia Reduced volumes perfused Limiting use of drains at the operative site Reduced doses of morphine Local anesthetic usage No standard use of nasogastric drainage
~Postoperative time Stimulation mobilization from D0 Refeeding on demand  from D0 Early removal of venous, arterial and urinary catheters. J1 recovery from the majority of the usual treatment Breathe physiotherapy from D0 to D5 Ileus prevention by chewing gum"
11297594|NCT02715414|Active Comparator|Multiple Family Group (MFG)|A multiple family group (MFG) is a 12-week, family-centered, group delivered intervention consists of six to eight families (caregiver/child dyads). Groups meet for approximately two hours per week, and sessions focus on targeting family-level factors that are associated with child problem behaviors. Specifically, eight of the 12 sessions are devoted to establishing rules (family organization, consistent discipline), responsibilities (inter-connectedness, expectancies), relationships (family warmth, within family support), respectful communication (family communication and conflict). An additional four sessions are focused on factors that impact the ability of families to incorporate new behaviors (family stress and social support).
11297595|NCT02715414|Experimental|MFG + Clinic Implementation Team|This condition consists of service providers, directors, and clinic staff who will create site-specific plans to enhance uptake and implementation of MFG. CITs address potential barriers to implementation and adjust the format and structure of MFG as needed in order to be implemented as part of clinic care.
11297596|NCT02715414|No Intervention|Standard Care|Standard Care consists of services including outpatient individual and family therapy, which are offered as part of clinic care.
11297597|NCT02715401|Experimental|Sequence 1|"T → R
~T : HCP1303 R : HGP1201 + HIP1402"
11297598|NCT02715401|Experimental|Sequence 2|"R → T
~T : HCP1303 R : HGP1201 + HIP1402"
11297599|NCT02715388|Experimental|Silicon oil removal 3D visualization|
11297600|NCT02715375|Experimental|Device: CREON2000A|Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
11297601|NCT02715375|Sham Comparator|Device: Sham Comparator|Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
11297602|NCT02715362|Experimental|TAI-GPC3-CART cells|A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
11297603|NCT02715349|Experimental|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
11297604|NCT02715349|No Intervention|Control|Family and patient do not receive psychoeducation, but still receive standard hospital services for schizophrenia.
11297605|NCT02715336|Experimental|Study group: High Responders|1000 units hCG
11297606|NCT02715336|No Intervention|Control group: High Responders|1000 units hCG
11297607|NCT02715336|Experimental|Study group: Normal Responders|5000 units hCG
11297608|NCT02715336|No Intervention|Control group: Normal Responders|5000 units hCG
11297609|NCT02715336|Experimental|Study group: Low Responders|10000 units hCG
11297610|NCT02715336|No Intervention|Control group: Low Responders|10000 units hCG
11297611|NCT02715297|Experimental|Arm A: SRT to the resection cavity|Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
11297612|NCT02715297|No Intervention|Arm B: Observation|Observation without adjuvant radiotherapy.
11297613|NCT02715284|Experimental|Part 1: Participants receiving dostarlimab|Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
11297614|NCT02715284|Experimental|Part 2A: Participants receiving dostarlimab|In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.
11297615|NCT02715284|Experimental|Part 2B: Cohort A1 dMMR/MSI-H|Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >= IIIB) disease.
11297616|NCT02715284|Experimental|Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer|Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >=IIIB) disease.
11297617|NCT02715284|Experimental|Part 2B: Cohort E NSCLC|Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
11297618|NCT02715284|Experimental|Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers|Participants with recurrent or advanced dMMR/MSI-H solid tumors or polymerase ɛ mutated (POLE -mut) solid tumors , except endometrial cancers, that have progressed following up to 2 prior lines of systemic therapy for recurrent or advanced (>=Stage IIIB) disease and who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
11297619|NCT02715284|Experimental|Part 2B: Cohort G PROC without known BRCA|Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
11297624|NCT02715245|Experimental|Experimental Group|Patients with multiple chronic disease referred to Mobile Rehabilitation and Physical therapy team (MRPTT) and Nurse-led case Management in the province of Almeria that comply the inclusion criteria; as well as their caregivers.
11297625|NCT02715245|No Intervention|Control Group|Patients with multiple chronic disease and their caregivers belonging to health centers or areas where there is no figure MRPTT or Nurse-led case Management to reach this population
11297626|NCT02715232|Experimental|Female-to-Males|Female-to-Male Transsexuals receiving Testosterone treatment
11297627|NCT02715232|Experimental|Male-to-Females|Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment
11297628|NCT02715232|No Intervention|Female Controls|Female Controls receiving no intervention
11297629|NCT02715232|No Intervention|Male Controls|Male controls receiving no intervention
11297630|NCT02715219|Experimental|intervention group|Subjects in intervention group will be given an appointment date to attend the an Asthma Education Programme.
11297631|NCT02715219|No Intervention|control group|Subjects in control group will routinely go for the normal follow up in Respiratory Clinic without receive any intervention.
11297632|NCT02715206|Experimental|Control|middle schools not receiving keepin' it REAL; continue their own programs if any.
11297633|NCT02715206|Experimental|keepin' it REAL classic|middle schools will implement keepin' it REAL classic drug prevention curriculum
11297634|NCT02715206|Experimental|keepin' it REAL rural|middle schools will implement the keepin' it REAL rural curriculum
11297635|NCT02715193|Experimental|REMD-477 Treatment A|Administered as a single SC dose in subjects with Type 1 Diabetes
11297636|NCT02715193|Placebo Comparator|Matching placebo|Administered as a single SC dose in subjects with Type 1 Diabetes
11297637|NCT02715180|Other|Chest computed tomography|Low dose chest computed tomography during expiration and inspiration
11297638|NCT02715167|Active Comparator|Group Budesonide|Inhaled corticoids
11297639|NCT02715167|Placebo Comparator|Group Placebo|Placebo by inhalation
11297640|NCT02715154|Active Comparator|Dexmedetomidine 0.5 µg/kg/h|Solution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
11297641|NCT02715154|Placebo Comparator|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
11297642|NCT02715128|Active Comparator|real tDCS|anode over electrode position F3, cathode over F4, 20 min, 2mA intensity
11297643|NCT02715128|Sham Comparator|sham tDCS|frequency and duration correspondent active tDCS, ramp in and ramp out periods only without intermittent stimulation
11297644|NCT02715115|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
11297645|NCT02715115|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
11297646|NCT02715089||Precise treatment|All patients should accept next-generation sequencing (NGS) test before treatment.
11297647|NCT02715076|Experimental|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
11297648|NCT02715076|Experimental|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
11297649|NCT02715076|Experimental|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
11297650|NCT02715076|Experimental|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
11297651|NCT02715076|Experimental|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
11297652|NCT02715076|Experimental|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
11297653|NCT02715063|Experimental|High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
11297654|NCT02715063|Active Comparator|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
11297655|NCT02715063|Active Comparator|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
11297656|NCT02715063|Placebo Comparator|Usual clinical care|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
11297657|NCT02715050|Experimental|Group A - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
11297690|NCT02714842|Active Comparator|Voltaren|Single dose of enteric coated diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
11297691|NCT02714842|Experimental|Radiolabelled diclofenac tablet C|Single dose of delayed release diclofenac sodium (25 mg) tablet radiolabelled with 4 MBq 99mTc
11297658|NCT02715050|Experimental|Group B - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
11297659|NCT02715050|Experimental|Group C - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
11297660|NCT02715050|Experimental|Group D - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group D, received program 2 before strength training, and program 2 after training."
11297661|NCT02715037||Acute tonsillitis|Patients referred to the tertiary care center with severe acute tonsillitis but without peritonsillar cellulitis, infectious mononucleosis, or abscess formation.
11297662|NCT02715037||Peritonsillar cellulitis|Patients referred to the tertiary care center with severe acute tonsillitis and peritonsillar cellulitis but without abscess formation.
11297663|NCT02715037||Infectious mononucleosis|Patients referred to the tertiary care center with acute tonsillitis and biochemical or serological signs of infectious mononucleosis but without abscess formation.
11297664|NCT02715037||Controls|Patients treated for conditions not related to the throat and without signs or symptoms of recent throat disease.
11297665|NCT02715024|Experimental|Tamsulosin alone|
11297666|NCT02715024|Experimental|Tamsulosin + solifenacin|
11297667|NCT02715011|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-63709178 in Part 1 (in different cohorts). Each subsequent cohort will receive JNJ-63709178 at an increased dose level. Ascending doses may be given initially to minimize or prevent cytokine release syndrome. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
11297668|NCT02715011|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-63709178 at the recommended Phase 2 dose(s) (RP2D) determined in dose expansion phase.
11297669|NCT02714998|Active Comparator|Methotrexate only|Single dose of systemic Methotrexate administered to 55 patients.
11297670|NCT02714998|Active Comparator|Salpingectomy only group|Laparoscopic unilateral salpingectomy performed to 61 patients.
11297671|NCT02714998|Active Comparator|Salpingectomy following Methotrexate|15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
11297672|NCT02714985||confirmed chikungunya cases|cases with confirmed chikungunya fever and included for follow-up as per protocol
11297673|NCT02714972|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
11297674|NCT02714972|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
11297675|NCT02714959|Experimental|Proleukin|Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9
11297676|NCT02714946|Active Comparator|LA Arm|Percutaneous Laser Ablation
11297677|NCT02714946|Active Comparator|RFA Arm|Percutaneous Radiofrequency Ablation
11297678|NCT02714933|Experimental|MRI sequence Advanced ZTE|
11297679|NCT02714920|Other|DNA Repair enzyme signature|Tumor biopsies and blood samples performed specifically to determine DNA Repair enzyme signature biomarkers profiles (CHEMRAD assay)
11297680|NCT02714907|Experimental|AF assessed from Cortrium C3 data|Atrial fibrillation assessed from Cortrium C3 device data
11297681|NCT02714907|Experimental|AF assessed from Holter data|Atrial fibrillation assessed from Holter data
11297682|NCT02714894||Clozapine Responders (Non-URS)|"Definition of non-URS
~(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment."
11297683|NCT02714894||Clozapine Non-Responders (URS)|"Definition of URS
~Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.
~CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items."
11297684|NCT02714894||Healthy Controls|Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.
11297685|NCT02714881|Other|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
11297686|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
11297687|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
11297688|NCT02714842|Experimental|Radiolabelled Diclofenac tablet A|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
11297689|NCT02714842|Experimental|Radiolabelled diclofenac tablet B|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
11297692|NCT02714829|Experimental|Inject BMP|ExcelOS-inject containing rhBMP-2
11297694|NCT02714803|Experimental|Connective tissue massage group|Connective tissue massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
11297695|NCT02714803|Active Comparator|Classic massage group|Classic massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
11297696|NCT02714803|Sham Comparator|Sham massage group|Sham massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
11297697|NCT02714777||Pediatric population from 4 to 8 years-old|Description of the Autonomic nervous system activity (parasympathetic activity)
11297698|NCT02714751|No Intervention|Observational group|
11297699|NCT02714751|Other|Group after information intervention|Control group after daily information to healthcare team
11297700|NCT02714738|Experimental|Infraclavicular Block|The patient will be positioned supine. The operating limb may be positioned abducted or adducted by side depending on operator preference and patient factors. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. Local anaesthetic (lidocaine 2% with epinephrine 1:200.000) will be injected posterior to the artery with the intention achieving the U shape, cranio-postero-caudal spread. Local anaesthetic will be deposited to the lateral and medial cords as well, if required. The total dose of the local anaesthetic will be 20-30 ml, as clinically indicated.
11297701|NCT02714738|Experimental|Axillary Brachial Plexus Block|The patient will be positioned supine with the operative upper limb extended, flexed at the elbow, rested on a pillow to expose the axilla. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. All four nerves in the axillary region are being blocked. The local anesthetic (lidocaine 2% with epinephrine 1:200.000, 15-25 ml) will be divided among the four nerves as clinically indicated by the spread, but at least 3 ml applied to each nerve.
11297702|NCT02714725|Placebo Comparator|Control group (Group C)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
11297703|NCT02714725|Active Comparator|Group Dexmedetomidine (Group DEX)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
11297704|NCT02714712||HCV group (Peginterferon alfa-2a)|A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
11297705|NCT02714712||Control Group|There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.
11297706|NCT02714699|Experimental|diclofenac potassium|oral diclofenac potassium
11297707|NCT02714699|Active Comparator|hyoscine butyl bromide|oral hyoscine butyl bromide
11297708|NCT02714699|Placebo Comparator|placebo|oral placebo
11297709|NCT02714686|Experimental|Radio Mass Media Family Planning Campaign|Clusters receive a three-year mass media campaign on family planning in an attempt to reduce cognitive barriers to contraception
11297710|NCT02714686|No Intervention|Control group|
11297711|NCT02714673||ADELC|Cohort of patients on long term anticoagulation and undergoing a primary hip or knee replacement.
11297712|NCT02714673||CONTROL|Cohort of patients not on long term anticoagulation and undergoing a primary hip or knee replacement.
11297713|NCT02714660||Participants with Type 2 Diabetes|Adults with type 2 diabetes will be enrolled in this mixed methods observational study.
11297714|NCT02714647|Experimental|Experimental|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on accuracy over speed prior to practicing the motor task. Participants will also have extended deadlines (750 ms) throughout the task to ensure an accuracy preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
11297715|NCT02714647|Sham Comparator|Control|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on speed over accuracy prior to practicing the motor task. Participants will also have short deadlines (250 ms) throughout the task to ensure a speed preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
11297716|NCT02714634|Experimental|methotrexate + biologic group|"Methotrexate +
~biologic chosen by investigator"
11297717|NCT02714634|Active Comparator|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
11297718|NCT02714621|No Intervention|Feasibility of MR-HIFU for painful gynaecological metastases|Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.
11297719|NCT02714621|Experimental|Treatment using MR-HIFU of painful gynaecological metastases|Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)
11297720|NCT02714608|Experimental|Ginsenoside H dripping pills|Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
11297721|NCT02714608|Experimental|Ginsenoside H dripping pills+Placebo|Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
11297722|NCT02714608|Placebo Comparator|Placebo|Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
11297723|NCT02714595|Experimental|S-649266|Participants will receive S-649266 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days
11297724|NCT02714595|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days.
11321559|NCT02556671||Normal renal function Patients Undergoing PCI|
11297725|NCT02714582|Experimental|Bedside shift report|"The experimental group (nurses and patients) will:
~develop a tailored BSR-intervention by use of co-design, diagnostic interviews, and pilot testing
~use the tailored BSR-intervention, with participation of the patient, instead of the regular nurse shift report"
11297726|NCT02714582|No Intervention|No bedside shift report|The control group will not use bedside shift report, but will use the regular nurse shift report without participation of the patient
11297727|NCT02714569|Experimental|Part A: LY3202328|A single ascending dose of LY3202328 orally, in 2 periods while fasting, and up to one period while fed.
11297728|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
11297729|NCT02714569|Experimental|Part B: LY3202328|A multiple ascending dose of LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
11297730|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
11297731|NCT02714543|Experimental|aloevera group|aloevera juice twice daily for 3 months. aloevera gel one scoop to be applied 3-4 times daily for 3 months
11297732|NCT02714543|Active Comparator|steroid group|intralesional injection of hydrocortisone 100mg and injection hyaluronic acid 1500IU once a week for 6 weeks with Capsules SM Fibro once daily for 3 months.
11297733|NCT02714530|Experimental|Radiotherapy combined with erlotinib|Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
11297734|NCT02714530|Active Comparator|Radiotherapy alone|Radiotherapy 3 Gy x 10 alone
11297735|NCT02714517|Experimental|hydrotherapy|patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks
11297736|NCT02714517|Active Comparator|controls|patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks
11297737|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
11297738|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
11297739|NCT02714491|Active Comparator|Music|Erigo + Music: During each stepping verticalization session the patient receives auditory stimulation (earphones) with previously preferred music
11297740|NCT02714491|Active Comparator|Metronome|Erigo + Metronome: During each stepping verticalization session the patient receives auditory stimulation (earphones) with a metronome (rhythmic with the stepping movement)
11297741|NCT02714491|Active Comparator|Silence|Erigo + Silence: During each stepping verticalization session the patient does note receive any auditory stimulation.
11297742|NCT02714478|Experimental|treatment|"3 Equistasi devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
11297743|NCT02714478|Placebo Comparator|controls|"3 placebo devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
11297744|NCT02714465|Experimental|Hyperbaric oxygen therapy|All patients underwent radiosurgery with clinical and instrumental signs of cerebral radionecrosis
11297745|NCT02714452|Other|Intervention|Person-centred care
11297746|NCT02714452|No Intervention|Control|Conventional care
11297747|NCT02714439|Experimental|High-Resolution Microendoscopy (HRME)|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
11297748|NCT02714426|Active Comparator|Brain Health|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
11297749|NCT02714426|Experimental|Mindfulness-inspired Treatment/Testing|"Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
11297750|NCT02714413|Placebo Comparator|Sucrose 50g + placebo|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
11297751|NCT02714413|Experimental|Sucrose 50g + D-allulose 2.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
11297752|NCT02714413|Experimental|Sucrose 50g + D-allulose 5.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
11297753|NCT02714413|Experimental|Sucrose 50g + D-allulose 7.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
11297754|NCT02714413|Experimental|Sucrose 50g + D-allulose10.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
11297755|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
11297756|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
11297757|NCT02714387||ICU patients|Patients with Non Traumatic Neuro-Vascular Diseases. Medical data concerning ICU stay will be collected.
11297758|NCT02714374|Experimental|GL-ONC1|Cohort 3, 5, 7, 8, 9
11297759|NCT02714361|Active Comparator|Vitamin D3 supplement|Participants will be asked to take 1 capsule of vitamin D3 supplement (1500 IU) (37.5ug) daily for a total duration of 8 weeks.
11297760|NCT02714361|Placebo Comparator|Placebo|Participants will be asked to take 1 capsule of placebo (65% olive oil) daily for a total duration of 8 weeks.
11297761|NCT02714322|Experimental|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
11321931|NCT02554240|Experimental|DA-5202 High dose|- DA-5202 20mg
11297762|NCT02714322|Active Comparator|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
11297763|NCT02714309|Experimental|Control Trial|A mixed macronutrient breakfast meal is consumed without additional protein, following a period of rest. An ad libitum lunch meal is subsequently consumed.
11297764|NCT02714309|Experimental|Exercise No Preload Trial|Following an exercise bout a mixed macronutrient breakfast meal is consumed without additional protein. An ad libitum lunch meal is subsequently consumed.
11297765|NCT02714309|Experimental|Exercise With Preload Trial|Following low/moderate intensity exercise bout, whey protein (20g) administered prior to consumption of mixed macronutrient breakfast meal. An ad libitum lunch meal is subsequently consumed.
11297766|NCT02714296|Active Comparator|Group Nutridrink 200ml|50 patients: two days before the investigation is assigned to a diet with the use of specialized clinical nutrition Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
11297767|NCT02714296|Active Comparator|Group Nutridrink compact protein|two days before the study is assigned diet with the addition of specialized clinical nutrition Nutridrinc compact protein 125 ml 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
11297768|NCT02714296|No Intervention|Group control|only diet without receiving specialized nutrition
11297769|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
11297770|NCT02714270|Active Comparator|modified partograph|routine modified partograph
11297771|NCT02714270|Active Comparator|paperless partograph|paperless partograph with no graph paper
11297772|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
11297773|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
11297774|NCT02714231|Experimental|diclofenac|oral diclofuhenac sodium
11297775|NCT02714231|Active Comparator|hyoscine|oral hyoscine butyl bromide
11297776|NCT02714218|Experimental|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV|Specified dose on specified days
11297777|NCT02714218|Experimental|Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV|Specified dose on specified days
11297778|NCT02714218|Experimental|Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg|Specified dose on specified days
11297779|NCT02714205|Experimental|Transdermal Nitroglycerin|Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr. Dose escalation up to 0.6 mg/hr.
11297780|NCT02714205|Placebo Comparator|Placebo|Daily transdermal placebo patch.
11297781|NCT02714192|Experimental|BCTT|Participants received an standardized exercise stress test within 7 days of concussive injury. Stress test is stopped when participant experiences any exacerbation of symptoms. Heart rate at time of symptom exacerbation is referred to as the threshold heart rate (THR). Stress test is known as the Buffalo Concussion Treadmill Test.
11297782|NCT02714192|No Intervention|No BCTT|All participants in the no intervention arm did not get assessed using the BCTT until they had fully recovered or when they had their second clinic visit fourteen days after their first visit.
11297783|NCT02714179|Active Comparator|Group Preemptive (Group PE),|Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
11297784|NCT02714179|Active Comparator|Group Preventive (Group PV),|Group II: i.V. paracetamol 1 g (100 ml) was given before the end of surgery.
11297785|NCT02714166|Experimental|Sunscreen lotion Sun Protection Factor 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
11297786|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
11297787|NCT02714153|Experimental|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
11297788|NCT02714140|Experimental|Group A: More preferred Existing + Common|Group A participants will be offered the common option and 3 currently available testing options that are targeted at the distribution of preferences among participants.
11297789|NCT02714140|Experimental|Group B: More preferred Enhanced + Common|"Group B participants will be offered the common option and 3 preference-informed enhanced testing options, which include combinations of features that may not yet be available in the study area."
11297790|NCT02714140|Active Comparator|Group C: Less preferred + Common|Group C participants will be offered the common option and 3 predicted less-preferred options. With the common option being the best option in Group C, this group is effectively a non-PB-HCT comparison group.
11297791|NCT02714127||Cases|"Women (25-64 years old) with abnormal cytology results and/or (high risk) HPV infection refered for colposcopy, and hence possibly diagnosed with an (high risk) HPV infection and/or cervical (pre)cancerous lesions.
~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
11297828|NCT02713880||Patients with Transthyretin-Related Familial|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
11297792|NCT02714127||Controls|"Healthy women (25-64 years old), falsely diagnosed with abnormal cytology and/or (high risk) HPV infection, but referred for colposcopy, are included as negative controls. Based on a specificity of 76.14% of the HPV type-specific PCR (polymerase chain reaction) used, an estimated 24 out of these 100 participants will be incorrectly scheduled for colposcopy and serve as the control group.
~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
11297793|NCT02714114||Cases: HPV vaccinated group|"Women (18-26 years old) whom are previously vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.
~No clinical evaluations will be performed."
11297794|NCT02714114||Controls: HPV unvaccinated group|"Women (18-26 years old) whom are not vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.
~No clinical evaluations will be performed."
11297795|NCT02714101|Experimental|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
11297796|NCT02714088|Experimental|Intervention|Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach >90% of their maximal heart rate.
11297797|NCT02714088|No Intervention|Control|Participants will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
11297798|NCT02714075|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
11297799|NCT02714062|Placebo Comparator|Placebo|Days 1-56: Placebo
11297800|NCT02714062|Experimental|VI-0521 Mid Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
~Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
11297801|NCT02714062|Experimental|VI-0521 Top Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
~Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
~Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
~Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
11297802|NCT02714049|Experimental|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
11297803|NCT02714049|Experimental|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
11297804|NCT02714036|Experimental|MN-166 (ibudilast)|MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.
11297805|NCT02714023|Active Comparator|Normal Saline|Patients were randomized to receive normal saline as an irrigation solution during appendectomy.
11297806|NCT02714023|Active Comparator|Sterile Water|Patients were randomized to receive sterile water as an irrigation solution during appendectomy.
11297807|NCT02714023|No Intervention|No irrigation used|Patients who do not receive any irrigation at time of operation.
11297808|NCT02714010|Experimental|Arm 1|Patients take EGFR-TKI alone till tumor progression
11297809|NCT02714010|Active Comparator|Arm 2|Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI
11297810|NCT02713997|No Intervention|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
11297811|NCT02713997|Experimental|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
11297812|NCT02713997|Experimental|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
11297813|NCT02713984|Experimental|HER2 positive cancers|Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells
11297814|NCT02713971|Experimental|Gamepad|Biofeedback rehabilitation with Gamepad system.
11297815|NCT02713971|Active Comparator|Control|Conventional physiotherapy.
11297816|NCT02713958|Experimental|Tele rehabilitation|Telerehabilitation:The subjects in the study group will receive two treatments in Telerehabilitation and one treatment in the clinic weekly . At home they will be asked practice daily active exercises with the Meditouch Ltd. system.
11297817|NCT02713958|Active Comparator|rehabilitation|Traditional Occupational Therapy:The subjects in this group will receive three treatments in the clinic every week. At home they will be asked to practice daily active exercises in the same level of difficulty and duration as the study group but without the Meditouch Ltd. system
11297818|NCT02713945|Experimental|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
11297819|NCT02713945|Placebo Comparator|Control|Placebo administrated orally once daily in the morning
11297820|NCT02713932||Transcatheter aortic valve implantation|
11297821|NCT02713919|Experimental|Intervention Group|Adapted German PRO-SELF© Plus Pain Control Program
11297822|NCT02713919|No Intervention|Control Group|No intervention
11297823|NCT02713906|Experimental|X-Ray Knee Guide group|Total knee arthroplasy using Materialise X-Ray Knee Guides
11297824|NCT02713893|Experimental|Econazole nitrate 1% plus Benzydamine HCl 0.12%|5 grams of Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days
11297825|NCT02713893|Active Comparator|Placebo plus Econazole nitrate 1%|5 grams of Placebo plus Econazole nitrate 1% intravaginal cream, once daily for 15 consecutive days
11297826|NCT02713893|Active Comparator|Placebo plus Benzydamine HCl 0.12%|5 grams of Placebo plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days.
11297827|NCT02713893|Placebo Comparator|Placebo|5 grams of Placebo intravaginal cream, once daily for 15 consecutive days.
11297830|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
11297831|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
11297832|NCT02713841|Experimental|Inhaled insulin (LOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)
11297833|NCT02713841|Experimental|Inhaled insulin (MOM1)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
11297834|NCT02713841|Experimental|Inhaled insulin (MOM2)|repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
11297835|NCT02713841|Experimental|Inhaled insulin (HOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)
11297836|NCT02713841|Active Comparator|subcutaneous insulin lispro (LIS)|single 6 unit dose of insulin lispro administered subcutaneously
11297837|NCT02713828|Experimental|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
11297838|NCT02713828|Experimental|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
11297839|NCT02713815|Sham Comparator|control group|sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
11297840|NCT02713815|Active Comparator|rTMS group|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
11297841|NCT02713802|Experimental|Test product|Propofol solution (1% [10 mg/mL]), via intravenous injection
11297842|NCT02713802|Active Comparator|Reference product|Propofol emulsion (1% [10 mg/mL]), via intravenous injection
11297843|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
11297844|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
11297845|NCT02713776|Experimental|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
11297846|NCT02713776|Placebo Comparator|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
11297847|NCT02713763|Experimental|Sunitinib|Sunitinib 37.5 mg/day
11297848|NCT02713750||HIV female adolescents|sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status
11297849|NCT02713737|Experimental|HFNC group|HFNC: Heated humidified high-flow nasal cannula.
11297850|NCT02713737|Active Comparator|NIV group|NIV: Noninvasive ventilation.
11297851|NCT02713724|Active Comparator|DAPS-group|Physical exercise
11297852|NCT02713724|Active Comparator|Standard-group|Limited physical exercise
11297853|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
11297854|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
11297855|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
11297856|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
11297857|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
11297858|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
11297859|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
11297860|NCT02713685|Experimental|Subarachnoid block|Subarachnoid block will be given in lateral position
11297861|NCT02713685|Active Comparator|Peripheral nerve block|Combined Femoral and Sciatic nerve block will be given using nerve stimulation technique
11297862|NCT02713672|Experimental|Intervention group|Psychiatric patients with a CYP2D6 or CYP2C19 PM or IM genotype, using antidepressants or antipsychotics metabolized by CYP2D6 or CYP2C19
11297863|NCT02713672|No Intervention|Control group|Psychiatric patients with a CYP2D6 or CYP2C19 EM genotype using antidepressants or antipsychotics
11297864|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
11297865|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
11297866|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
11297867|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
11297868|NCT02713620|Placebo Comparator|Healthy|"the Healthy group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
11297869|NCT02713620|Active Comparator|HIV-Group1|"the Standard doses group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
11297870|NCT02713620|Active Comparator|HIV-Group 2|"the Four doses group receiving four intramuscular doses of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
11297871|NCT02713620|Active Comparator|HIV-Group 3|"the Four double doses group receiving four intramuscular double doses (40 μg) of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
11297872|NCT02713607|Experimental|doxycycline|Given doxycycline and assessment of gut, blood and skin
11297873|NCT02713607|No Intervention|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
11297874|NCT02713594|Placebo Comparator|Control|Counseling from WTQL
11297875|NCT02713594|Experimental|Incentive|Counseling from WTQL; Financial incentive to participate
11297876|NCT02713581||Women with proximal VTE|"Patients will correspond to cases of proximal venous thromboembolism. They will be recruited during consultations conducted for the chronic management of a history of proximal venous thromboembolism or thrombophilia following a recent history of proximal venous thromboembolism. Venous thromboembolism, outside of acute phase episodes, has good symptom stability over time; no difference is to be expected between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease.
~Intervention: Blood sampling"
11297877|NCT02713581||Women with >1 healthy pregnancy|"This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy.
~Intervention: Blood sampling"
11297878|NCT02713568|Active Comparator|Ultrasound|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.
~An Ultrasound scan to estimate the fetal weigth will be carried out during the 36th week of gestation."
11297879|NCT02713568|Experimental|Magnetic Resonance|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.
~A Magnetic Resonance examination to estimate the fetal weigth will be carried out during the 36th week of gestation."
11297880|NCT02713555|Experimental|Roux-en-Y Gastric Bypass group|Morbidly obese patients with type 2 diabetes mellitus will be examined before and after the Roux-en-Y Gastric Bypass procedure
11297881|NCT02713555|Experimental|Gastric sleeve group|Morbidly obese patient with type 2 diabetes Mellitus will be examined before and after the Gastric Sleeve procedure
11297882|NCT02713555|No Intervention|Method /control group|Healthy normal weight participants matched by age and gender to the intervention study will be examined with the same methods as the intervention groups and serve as participants in a method study and as a metabolic normal reference group.
11297883|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
11297884|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
11297885|NCT02713529|Experimental|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
11297886|NCT02713516|Experimental|Single Arm|The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.
11297887|NCT02713503||Healthy Drivers|Driving Observation and VisionCoach
11297888|NCT02713490|Active Comparator|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
11297889|NCT02713490|Active Comparator|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
11297890|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 1 Test 1|Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
11297891|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 2 Test 2|Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
11297892|NCT02713477|Placebo Comparator|Placebo - Reference 1|Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
11297893|NCT02713477|Other|Insulin glargine (Lantus) - Reference 2|Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition
11297894|NCT02713464|Active Comparator|maternal education|Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.
11297895|NCT02713464|No Intervention|Historic control|Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.
11297896|NCT02713464|No Intervention|No intervention|Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.
11297897|NCT02713451|Active Comparator|Liberal Oxygenation (LO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
11297898|NCT02713451|Experimental|Conservative Oxygenation (CO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
11297923|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
11297899|NCT02713438|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.
~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
11297900|NCT02713438|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the child. The parent is actively participating in forming plans by the child.
~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
11297901|NCT02713438|Experimental|Collaborative Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (child and parent). Physical activity may be performed jointly by both persons in the dyad.
~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
11297902|NCT02713438|Active Comparator|Education|The education group received extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
11297903|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
11297904|NCT02713412|Experimental|Glucose|75g glucose and 150mg C13-acetate in 300ml water
11297905|NCT02713412|Placebo Comparator|Control|300ml water
11297906|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
11297907|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
11297908|NCT02713386|Active Comparator|Arm I (paclitaxel and carboplatin)|See Detailed Description.
11297909|NCT02713386|Experimental|Arm II (ruxolitinib, paclitaxel, and carboplatin)|See Detailed Description.
11297910|NCT02713373|Experimental|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
11297911|NCT02713360|Experimental|Cognitive therapy|The intervention consists of 3 steps. 1: Consultation with a nurse that aims of identifying what the anxiety consist of and how the patient experiences his or her life situation with an ICD. A plan is made to structure the treatment. 2: Participation in an individualized intervention based on anxiety type specific protocols. 3. The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
11297912|NCT02713360|No Intervention|Usual care|The control group will receive usual care which consists of control of ICD, disease control and treatment, and at one of the sites an offer of a group information meeting where experiences and events with ICD are discussed. The meeting takes place at Rigshospitalet every other month.
11297913|NCT02713347|Experimental|ADAPT Intervention|"The intervention includes 3 components:
~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.
~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.
~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.
~The nurse and social worker visits are in-person or by phone."
11297914|NCT02713347|No Intervention|Enhanced usual care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referrals to and ongoing care from cardiology, pulmonary, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of baseline depression surveys if they screen positive for depression, and patients will be given an information sheet that outlines self-care for CHF or COPD.
11297915|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
11297916|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
11297917|NCT02713308||Group1-CRT|Patients with RV-to-LV delay≥80ms, CRT standard programming (single-point)
11297918|NCT02713308||Group2-MPP|Patients with RV-to-LV delay<80ms, CRT programming with MPP (multi-point)
11297919|NCT02713295||Subjects with Moderate to Severe Plaque Psoriasis|Subjects with Moderate to Severe Plaque Psoriasis in Greece
11297920|NCT02713282|Experimental|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
11297921|NCT02713269|Experimental|Treatment (thermal ablation, SSRS)|Patients undergo thermal ablation and CT-guided SSRS via intensity-modulated radiation therapy on different dates within a 1-14 day window. The order of treatment is at the doctor's discretion.
11297922|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
11321932|NCT02554240|Experimental|DA-5202 Low dose|- DA-5202 10mg
11297924|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
11297925|NCT02713230|Active Comparator|EXPAREL 133 mg|EXPAREL (bupivacaine liposome injectable suspension) 133 mg in 10 mL expanded with 10 mL of normal saline for a total volume of 20 mL.
11297926|NCT02713230|Placebo Comparator|Placebo|Normal saline in 20 mL.
11297927|NCT02713217||Pre-Implementation Cohort|Eligible patients will be recruited and enrolled prior to implementation of the blended integrated care model in each study site. They will be exposed to care as usual in the CBOCs.
11297928|NCT02713217||Post-Implementation Cohort|"Eligible patients will be recruited and enrolled following implementation of the blended integrated care model in each study site. These participants are thus exposed to the intervention model."
11297929|NCT02713204|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
11297930|NCT02713204|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
11297931|NCT02713204|Experimental|Aflibercept (IAI) 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
11297932|NCT02713191|Experimental|Dexmedetomidine|Dexmedetomidine + fentanyl before, and dexmedetomidine infusion during, procedure
11297933|NCT02713191|Active Comparator|Midazolam|Midazolam + fentanyl before, and matching saline infusion during, procedure
11297934|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
11297935|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
11297936|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
11297937|NCT02713165|Experimental|Raisins Enhanced Diet|Participants will be provide with a Raisin Enhanced Diet over a short term period of time.
11297938|NCT02713152||Patients with OAG|Patients with a diagnosis of Open Angle Glaucoma
11297939|NCT02713152||Controls|Controls without a diagnosis of Open Angle Glaucoma
11297940|NCT02713139|Experimental|Colpistatin 5DT|
11297941|NCT02713139|Active Comparator|Gynecological Flagyl|
11297942|NCT02713139|Active Comparator|Gino-Canesten 3|
11297943|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer
11297944|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer
11297945|NCT02713113|Active Comparator|group 1|patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
11297946|NCT02713113|Active Comparator|group II|patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
11297947|NCT02713113|Active Comparator|group III|patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
11297948|NCT02713087|Active Comparator|Ephedrine|
11297949|NCT02713087|Active Comparator|Phenylephrine|
11297950|NCT02713074|Active Comparator|Group A|povidone-iodine group
11297951|NCT02713074|Active Comparator|Group B|Normal saline group
11297952|NCT02713061|Experimental|TAK-850 0.5 mL|TAK-850 0.5 mL (15 µg of hemagglutinin [HA] antigen per strain), subcutaneous injection, once on Day 1.
11297953|NCT02713048||Acute coronary syndrome culprit coronary lesion|
11297954|NCT02713048||Stable obstructive coronary artery disease|
11297955|NCT02713048||Non-obstructive coronary artery disease|
11297956|NCT02713035|No Intervention|Usual|Receive standard medical therapy for eczema
11297957|NCT02713035|Experimental|Treatment|Receive standard medical therapy for eczema plus behavioral self help intervention
11297958|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
11297959|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
11297960|NCT02713009|Experimental|Treatment 1|Pregnancy multivitamin + vitamin D daily from ~Week 12 gestation until delivery
11297961|NCT02713009|Placebo Comparator|Treatment 2|Pregnancy multivitamin + placebo daily from ~Week 12 gestation until delivery
11297962|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
11297963|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
11297964|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)
11297965|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP/PBO|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
11297966|NCT02712983|Placebo Comparator|Cohort A (3 capsules o.d.): PBO|Cohort A (3 capsules o.d.): Inhaled placebo (PBO)
11297967|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)
11297968|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP/PBO|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
11297969|NCT02712983|Placebo Comparator|Cohort B (5 capsules o.d.): PBO|Cohort B (5 capsules o.d.): inhaled placebo (PBO)
11297970|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)
11297971|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP/PBO|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
11297972|NCT02712983|Placebo Comparator|Cohort C (4 capsules b.i.d.): PBO|Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)
11297973|NCT02712970||stage-I|Single pit in the midline, no lateral extension. Pit-picking technique will be performed.
11297974|NCT02712970||Stage-II|>1 pits in the midline, no lateral extension. Pit-picking and Bascom cleft lift techniques will be performed.
11297975|NCT02712970||Stage-III|Midline pit/pits plus lateral extension in one direction. Bascom cleft lift technique will be performed.
11297976|NCT02712970||Stage-IV|Midline pit/pits plus lateral extension in both directions. Rhomboid excision with the Limberg Flap will be performed.
11297977|NCT02712970||Stage-R|Recurrent PSD following any type of treatment. Other flap techniques such as V-Y advancement flap, Z-Plasty will be performed.
11297978|NCT02712957|Experimental|NEO6860|NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
11297979|NCT02712957|Placebo Comparator|Placebo|In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).
11297980|NCT02712957|Active Comparator|Naproxen|Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.
11297981|NCT02712944|Active Comparator|Testosterone|Testosterone intramuscular every 2 weeks
11297982|NCT02712944|Placebo Comparator|Saline|Saline intramuscular every 2 weeks
11297983|NCT02712918|Experimental|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.
11297984|NCT02712918|Placebo Comparator|Standard care|Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.
11297985|NCT02712905|Experimental|INCB059872|
11297986|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:
~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.
~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML
~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.
~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
11297987|NCT02712866||Patients treated with vedolizumab|
11297988|NCT02712853||Autism Spectrum Disorder (ASD)|"Age at enrollment: 18 months to 6 years with established DSM-5 diagnosis of autism spectrum disorder. Exclusion criteria include:
~wards of the state syndromic autism (attributed to a known genetic mutation) active periodontal infection active upper respiratory infection"
11297989|NCT02712853||Control|"Age 18 months to 6 years without autism spectrum disorder (may have typical development or developmental delay without autism - as defined by negative MCHAT-R or negative ADOS-II evaluation)
~Exclusion criteria include:
~wards of the state active periodontal infection active upper respiratory infection"
11297990|NCT02712840|Experimental|Freeze-All Protocol|Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
11297991|NCT02712840|Active Comparator|Fresh Protocol|Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.
11297992|NCT02712827|Experimental|Progrip|The Progrip group is the intervention group. Patients will undergo laparoscopic total extraperitoneal repair of inguinal hernia. The surgeon will use a self-gripping mesh to repair the hernia. No fixation is required for the mesh.
11297993|NCT02712827|Active Comparator|Non-Progrip|"The Non-Progrip group is the control group.
~Operation is performed under general anesthesia. A standard three-trocar technique is used: one infra-umbilical camera trocar (1cm) and two 5mm trocars placed at midline between the umbilicus and pubic bone (or one at the side of inguinal hernia). A laparoscope is inserted to the preperitoneal space through the incision. The space is insufflated with carbon dioxide. Dissection is performed, hernia content (if any) is reduced.
~A non self-gripping synthetic mesh is placed. Fibrin glue is used for fixation."
11297994|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender
~The pain began while taking hormonal contraceptive
~Secondary PVD
~On exam, atrophic vestibular tissue (dry and thin)"
11297995|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender
~Primary PVD
~There may be sensitivity to palpation of the umbilicus
~Normal appearing vestibule"
11297996|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender
~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.
~Normal appearing vestibule"
11297997|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule
~Pelvic floor muscles are tight and tender
~Primary or Secondary PVD"
11297998|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule
~Primary PVD
~There may be sensitivity to palpation of the umbilicus
~Normal appearing vestibule
~Pelvic floor muscles are tight and tender"
11297999|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule
~The pain began while taking hormonal contraceptive
~Secondary PVD
~On exam, atrophic vestibular tissue (dry and thin)
~Pelvic floor muscles are tight and tender"
11298000|NCT02712801|Experimental|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
11298066|NCT02712359|Other|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
11298001|NCT02712801|Active Comparator|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
11298002|NCT02712788|Active Comparator|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
11298003|NCT02712788|Placebo Comparator|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
11298004|NCT02712775|Experimental|Minocycline|Experimental group will receive an infusion of minocycline, the investigational drug, through a needle in a vein in the arm at the dose of 200 mg at 1 h prior to transplantation and 100 mg 12 h and 24 h after transplantation. In addition, the donated liver will be flushed with 200 mg minocycline 1 h prior to transplantation.
11298005|NCT02712775|Placebo Comparator|Saline|Placebo group will receive an infusion of saline, a placebo, through a needle in a vein in the arm according to the same schedule. In addition, the donated liver will be flushed with saline 1 h prior to transplantation.
11298006|NCT02712749|Experimental|Group A : Sound with Binaural Beats|"Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz through generated by the software Gnaural in stereo option"
11298007|NCT02712749|Active Comparator|Group B : Sound without Binaural Beats|"Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the software Gnaural in mono option"
11298008|NCT02712736|Other|Survey respondents|The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.
11298009|NCT02712723|Active Comparator|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
11298010|NCT02712723|Experimental|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
11298011|NCT02712723|Experimental|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
11298012|NCT02712710|Experimental|wear a functional knee brace|20 subjects with symptomatic medial compartment knee OA, with grade 2 to 4 on Kellgren and Lawrence scale, and showing willing to wear a functional knee brace. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
11298013|NCT02712710|No Intervention|no wear a functional knee brace|Another 20 subjects with comparable body height, weight, and sex. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
11298014|NCT02712697|Experimental|WM Group|Shentong Granules, two packs, bid, P.O., 48weeks; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
11298015|NCT02712697|Placebo Comparator|Hormone Group|Placebo ; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
11298016|NCT02712671||Enrolled subjects|Subjects attending the Ian Charleson Centre and agreeing to be tested for latent, subclinical and active tuberculosis using Chest radiograph, Blood interferon gamma release assay, Tuberculin skin testing, Sputum induction for mycobacterial microscopy and culture with spirometry, and Mycobacterium tuberculosis polymerase chain reaction testing.
11298017|NCT02712658|Active Comparator|terbutaline|terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
11298018|NCT02712658|Placebo Comparator|Placebo|placebo is administered as isotonic saline (10 ml)
11298019|NCT02712619|Experimental|metformin 250mg|metformin 375/250 mg
11298020|NCT02712619|Experimental|metformin 1000mg|metformin 1000/1000 mg
11298021|NCT02712593|Experimental|Niagen™ 100|
11298022|NCT02712593|Experimental|Niagen™ 300|
11298023|NCT02712593|Experimental|Niagen™ 1000|
11298024|NCT02712593|Experimental|Placebo|
11298025|NCT02712580|Active Comparator|First investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light."
11298026|NCT02712580|Active Comparator|Second investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light."
11298027|NCT02712580|Placebo Comparator|ES Wetling W200 with white light|Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
11298028|NCT02712580|Placebo Comparator|ES Wetling W200 with red light|Placebo device - 'ES Wetling W200 Placebo with red light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
11298029|NCT02712554|Experimental|Treatment A:CL-108 22.5mg/975mg/37.5mg|CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
11298030|NCT02712554|Experimental|Treatment B:CL-108 37.5mg/1625mg/62.5mg|CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
11298031|NCT02712554|Active Comparator|Treatment C:M366 22.5mg/975mg|M366 22.5 mg/975 mg tablet by mouth
11298032|NCT02712554|Active Comparator|Treatment D: M366 37.5mg/1625mg|M366 37.5 mg/1625 mg tablet by mouth
11298033|NCT02712554|Placebo Comparator|Treatment E: Placebo|Placebo 0 mg tablet by mouth
11298034|NCT02712528|Active Comparator|remifentanil-based|remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
11298035|NCT02712528|Placebo Comparator|sevoflurane-sufentanil balanced|balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen
11322117|NCT02553148||United Kingdom|One of the 23 countries studied
11298036|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
11298037|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
11298038|NCT02712502||Study group (OG).|"50 patients c and acute exacerbation of chronic bacterial rhinosinusitis in the study group (OG).
~The treatment regimen in the study group.
~Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.
~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
11298039|NCT02712502||Control group (CG).|"50 patients c and acute exacerbation of chronic rhinosinusitis in the control group (CG).
~The treatment regimen of the control group. Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.
~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
11298040|NCT02712489||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-003"
11298041|NCT02712476|Active Comparator|Mannitol,furosemide|Mannitol 0.5mg/kg and furosemide 0.5mg/kg IV is compared with mannitol 1mg/kg and furosemide 0.5mg/kg
11298042|NCT02712476|Placebo Comparator|Mannitol, placebo|Mannitol 0.5mg/kg and placebo is compared with mannitol+forosemide
11298043|NCT02712463||Participants with Schizophrenia|This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
11298044|NCT02712450||Control group|"Patients included from January 2016 to August 2016
~Before regulating doctors training course"
11298045|NCT02712450||Experimental group|"Patients included from January 2017 to August 2017
~After regulating doctors training course"
11298046|NCT02712437|Experimental|PROSPECT|Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for >30 days with an insomnia severity index score of >14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.
11298047|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
11298048|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
11298049|NCT02712411|Experimental|Sequence 1|"T → R
~T : HCP1303 R : HGP1201 + HIP1402"
11298050|NCT02712411|Experimental|Sequence 2|"R → T
~T : HCP1303 R : HGP1201 + HIP1402"
11298051|NCT02712398|Experimental|Phasix™ ST|Subjects treated with Phasix™ ST mesh
11298052|NCT02712385|No Intervention|Control - usual care|Usual post-TIA/minor stroke care as per current healthcare system protocol will be given to patients in control group and details will be recorded.
11298053|NCT02712385|Active Comparator|Manual|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual'.
11298054|NCT02712385|Active Comparator|Manual + pedometer, 1|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a General Practitioner.
11298055|NCT02712385|Active Comparator|Manual + pedometer, 2|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a Stroke nurse.
11298056|NCT02712372|Experimental|Part 1, Dose Level 1|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
11298057|NCT02712372|Experimental|Part 1, Dose Level 2|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
11298058|NCT02712372|Experimental|Part 1, Dose Level 3|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
11298059|NCT02712372|Experimental|Part 1, Dose Level 4|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
11298060|NCT02712372|Experimental|Part 1, Dose Level 5|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
11298061|NCT02712372|Experimental|Part 1, Dose Level 6|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
11298062|NCT02712372|Experimental|Part 2, Dose Level 1|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
11298063|NCT02712372|Experimental|Part 2, Dose Level 2|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
11298064|NCT02712372|Experimental|Part 2, Dose Level 3|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
11298065|NCT02712372|Placebo Comparator|AZD4831 Placebo|"Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
~Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12"
11298096|NCT02712190|Experimental|Low - High frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 250/min and respiratory rate 500/min
11298067|NCT02712359|Other|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
11298068|NCT02712359|Other|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
11298069|NCT02712359|Other|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
11298070|NCT02712346|Experimental|Treatment|Ambrisentan 5 mg PO daily
11298071|NCT02712346|Placebo Comparator|Placebo|One inactive pill PO daily
11298072|NCT02712333|Experimental|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
11298073|NCT02712333|Sham Comparator|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
11298074|NCT02712320|Experimental|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
11298075|NCT02712307|Experimental|5 days|Phenoxymethylpenicillin 800 mg x 4 for 5 days
11298076|NCT02712307|Active Comparator|10 days|Phenoxymethylpenicillin 1000 mg x 3 for 10 days
11298077|NCT02712294|No Intervention|Control Group (GC)|The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
11298078|NCT02712294|Experimental|NMES Group (GE)|Receiving the usual care and guidance on their illness, underwent 30 minute NMES sessions twice a week for two months using an electrostimulator. Specifically, 5 cm adhesive surface electrodes in four alternate channels on the Rectus Femoris (two channels the right and two on the left) were used to deliver two-phase symmetrical currents, with a rectangular pulse wave at a frequency of 35 Hz and pulse duration of 250 μ. The time of ascent and descent was one second, contraction time was four seconds and relaxation was eight seconds.
11298079|NCT02712281|Experimental|Autism MEAL Plan|Parents of eligible children who are randomized to the Autism Managing Eating Aversions and Limited variety (MEAL) Plan will participate in group-based parent training sessions (4 parents per group).
11298080|NCT02712281|Active Comparator|Parent Education|Parents of eligible children who are randomized to the Parent Education Arm will receive group-based parent education (PE). Each group includes 4 parents.
11298081|NCT02712268|Other|After introduction of the checklist|Review of medications of all consecutive admitted patients during the study period using a checklist
11298082|NCT02712255|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.
~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
11298083|NCT02712255|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the patient. The partner is actively participating in forming plans by the patient.
~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning"
11298084|NCT02712255|Experimental|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (the patient and the partner). Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
11298085|NCT02712255|Active Comparator|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
11298086|NCT02712242|Experimental|Platelet Rich Fibrin|PRF was laid directly on the palatal wound immediately after harvesting the tissue graft and stabilized
11298087|NCT02712242|Active Comparator|Butyl cyanoacrylate|Butyl cyanoacrylate was directly applied on the palatal wound after harvesting the tissue graft
11298088|NCT02712242|Placebo Comparator|Wet Gauze|Wet Gauze was placed for 1 minute on the palatal wound after harvesting the tissue graft
11298089|NCT02712229|Experimental|CONNECT Intervention|At clinics randomized to the CONNECT intervention, oncology nurses will be selected by a nurse advisory panel to receive standardized primary palliative care training. A multi-step deployment strategy will be employed to orient oncologists and implement CONNECT processes. CONNECT nurses will administer CONNECT to enrolled patients and caregivers. An intervention fidelity monitoring and maintenance plan will be implemented to ensure high quality and consistent delivery of the intervention.
11298090|NCT02712229|No Intervention|Usual Care Control|At clinics randomized to Usual Care, enrolled patients and caregivers will continue to receive supportive oncology care according to usual practice.
11298091|NCT02712216|Other|Trocar Insertion Sites|Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
11298092|NCT02712203||12 months|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age
11298093|NCT02712203||13 months|MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age
11298094|NCT02712203||14 months|MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age
11298095|NCT02712203||15 months or more|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older
11298097|NCT02712190|Experimental|High - Low frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 500/min and respiratory rate 250/min
11298098|NCT02712177||Coadministration B_RV246|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
11298099|NCT02712177||Coadministration B_RV234|Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
11298100|NCT02712177||Coadministration B_MMRV12|Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
11298101|NCT02712177||Separate administration B246_RV357|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
11298102|NCT02712177||Separate administration B12_MMRV13|Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
11298103|NCT02712177||Routine vaccines only at 2, 3 and 4 months of age (RV234)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
11298104|NCT02712177||Routine vaccines only at 2, 4 and 6 months of age.(RV246)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
11298105|NCT02712164|Experimental|Experimental: Modified NPWT dressing|In the experimental group, a microporous silver-impregnated foam with a thin silicone contact layer (Mepilex Ag) will be applied. A macroporous foam layer (V.A.C. GranuFoam) and an occlusive dressing (V.A.C. Drape) will then be applied to cover the foam, plus 3-5cm border of intact skin. The occlusive dressing will then be pinched and a 2cm hole will be cut to apply the SensaT.R.A.C. Pad that supplies pressure from the NPWT unit. NPWT will be applied at 125mmHg throughout treatment using KCI's InfoV.A.C. Therapy Unit. The donor site dressing will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
11298106|NCT02712164|Active Comparator|Control: Tegaderm|In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
11298107|NCT02712151|Active Comparator|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
11298108|NCT02712151|Active Comparator|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
11298109|NCT02712125|Active Comparator|isosorbide mononitrate|Received 20 mg isosorbid mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily until delivery
11298110|NCT02712125|Placebo Comparator|Control|Received placebo vaginal tablets once daily until delivery
11298111|NCT02712112|Experimental|Intermittent dosing arm|one-week on and one-week off schedule(Imatinib Mesylate, 400 mg once daily, oral)
11298112|NCT02712112|Sham Comparator|Continuous dosing arm|continuous dosing without off-treatment schedule(Imatinib Mesylate, 400 mg once daily, oral)
11298113|NCT02712086|No Intervention|usual dietary management|Control group: usual dietary management Following the intervention, the stomach of patients underwent many changes
11298114|NCT02712086|Experimental|care of with usual dietary protein supplementation|Intervention group: Usual dietary management with protein supplementation (30g) in addition to the usual inputs
11298115|NCT02712073||patients undergoing colonoscopy|
11298116|NCT02712060||EDS patients|Patients with the diagnosis of Ehlers-Danlos syndrome
11298117|NCT02712060||controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
11298118|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
11298119|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
11298120|NCT02712034|Placebo Comparator|Medication-assisted treatment (MAT)|Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.
11298121|NCT02712034|Experimental|MAT + A-CHESS|Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.
11298122|NCT02712021|Experimental|Cerebral Palsy-Study group|The intervention consisted of wearing a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.
11298123|NCT02712021|Active Comparator|Cerebral Palsy-Control Group|Children with clinical characteristics similar to the study group; they will be assessed using the same protocol but with no use of lycra garments
11298124|NCT02712008|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
11298125|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
11298126|NCT02712008|Active Comparator|Aflibercept 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
11298175|NCT02711722|Active Comparator|NAVA60%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 60% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA60% for 30min.
11298127|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
11298128|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
11298129|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
11298130|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
11298131|NCT02712008|Experimental|Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
11298132|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
11298133|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
11298134|NCT02711982|Active Comparator|Optic nerve decompression|Optic canal and optic nerve sheath decompression within 5 days from trauma occur.
11298135|NCT02711982|Active Comparator|methylprednisolone|a maximum daily dose of 1 g of methylprednisolone
11298136|NCT02711969|Experimental|Apatinib mesylate|
11298137|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.
~Patients are either enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria or are currently receiving enzalutamide who have experienced prostate-specific antigen (PSA) progression by PCWG2 criteria in the absence of radiographic and/or clinical progression. For the latter, patients may or may not have experienced prior progression on abiraterone."
11298138|NCT02711917|Experimental|SP1- sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
11298139|NCT02711917|Experimental|SP2- Sevoflurane MAC 0.75|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
11298140|NCT02711917|Experimental|SP3 -Sevoflurane MAC 1.0|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.
11298141|NCT02711917|Experimental|SP4- Sevoflurane MAC 0.5|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
11298142|NCT02711917|Experimental|SP5- Sevoflurane MAC 0.75|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
11298143|NCT02711917|Experimental|SE1- Sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
11298144|NCT02711917|Experimental|SE2- Sevoflurane 0.75|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
11298145|NCT02711917|Experimental|SE3- Sevoflurane MAC 1.0|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
11298146|NCT02711904|Active Comparator|Extubation U|Remifentanil concentration between 2 - 3 ng/ml.
11298147|NCT02711904|Experimental|Extubation T|Remifentanil concentration between 3 - 4 ng/ml
11298176|NCT02711722|Active Comparator|PScli2|Patients return to PS ventilation, according to the Clinical settings as in PScli1 for 30min.
11298148|NCT02711891|Experimental|5% Loperamide gel|Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
11298149|NCT02711891|Placebo Comparator|Placebo gel|Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
11298150|NCT02711878|Experimental|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
11298151|NCT02711878|Active Comparator|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
11298152|NCT02711865||MK-0646|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
11298153|NCT02711865||Control|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
11298154|NCT02711852|Experimental|Drug: Duvelisib (IPI-145)|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg.
11298155|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
11298156|NCT02711839|Experimental|Treatment Group|White sweet potato formula
11298157|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|"Standard of care
~(N=15 participants in this group)"
11298158|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10^6). After receiving at least 300X10^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.
~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.
~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.
~(N=15 participants in this group)"
11298159|NCT02711813|Placebo Comparator|Placebo|Placebo to TAB08
11298160|NCT02711813|Experimental|TAB08 Dose 1|
11298161|NCT02711813|Experimental|TAB08 Dose 2|
11298162|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
11298163|NCT02711787|Experimental|Experimental group|Robotic device Gloreha (Gloreha, Idrogenet, Italy) and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
11298164|NCT02711787|Active Comparator|Control group|Physiotherapy, occupational therapy and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
11298165|NCT02711761|Experimental|15 cm|The depth of guide wire will be 15 cm from puncture site of skin prior to tissue dilation during central venous catheterization
11298166|NCT02711761|Experimental|17.5 cm|The depth of guide wire will be 17.5 cm from puncture site of skin prior to tissue dilation during central venous catheterization
11298167|NCT02711761|Active Comparator|20 cm|The depth of guide wire will be 20 cm from puncture site of skin prior to tissue dilation during central venous catheterization
11298168|NCT02711748|Experimental|Bradycardia|Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
11298169|NCT02711748|Experimental|PEA|In case of bradycardia. The patient unconscious, not breathing, the ECG - bradycardia 30 / min - no pulse. Pulseless electrical activity
11298170|NCT02711735|Active Comparator|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
11298171|NCT02711735|Placebo Comparator|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
11298172|NCT02711722|Active Comparator|PScli1|Patients are ventilated in Pressure support (PS) according to the Clinical settings for 30min.
11298173|NCT02711722|Active Comparator|NAVAcli|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to match to respiratory muscle unloading reached with PScli1. Patients are ventilated in NAVAcli for 30min.
11298174|NCT02711722|Active Comparator|NAVA40%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 40% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA40% for 30min.
11298177|NCT02711709|Other|Intra-abdominal sepsis|Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
11322118|NCT02553148||United States|One of the 23 countries studied
11298178|NCT02711696|Active Comparator|A, GCED cohort|GCED, Gluten Contamination Elimination Diet
11298179|NCT02711696|No Intervention|B, time cohort|Cohort B consisted of patients on long term follow-up that accepted a repeated biopsies 60 or more months later the first control biopsy.
11298180|NCT02711683||DL-3-n-butylphthalide group|using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
11298181|NCT02711683||donepezil group|only using donepezil treatment in patients with mild to moderate AD
11298182|NCT02711670|Experimental|thiazide|Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating
11298183|NCT02711657|Experimental|Fibrocyte measurement and lung function test|All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.
11298184|NCT02711644|Experimental|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
11298185|NCT02711644|Active Comparator|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
11298186|NCT02711631|No Intervention|Control: Standard therapy|Participants in this arm of the study will receive standard therapy.
11298187|NCT02711631|Experimental|MedBIKE|Participants in this arm will be using the new MedBIKE system as their method of rehabilitation.
11298188|NCT02711618|Experimental|UltraShape Contour I V3 treatment|Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28
11298189|NCT02711605|Experimental|Unilateral UltraShape treatment|One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
11298190|NCT02711605|Experimental|Bilateral UltraShape treatment|Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
11298191|NCT02711592|Other|Genetic Panel for Analgesics|Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.
11298192|NCT02711579|Experimental|Celecoxib for electroencephalography|Electroencephalography will be performed before and after celecoxib administration
11298193|NCT02711579|Placebo Comparator|Placebo for electroencephalography|Electroencephalography will be performed before and after placebo administration
11298194|NCT02711579|Experimental|Celecoxib for motor evoked potential|Motor evoked potential will be measured before and after celecoxib administration
11298195|NCT02711579|Placebo Comparator|Placebo for motor evoked potential|Motor evoked potential will be measured before and after placebo administration
11298196|NCT02711566|Active Comparator|Sensorimotor training|"Patients in this arm were assigned to the 'Physioassistant: Haptic training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation.
~All participating centers used the exact same apparatus and experimental set-up."
11298197|NCT02711566|Experimental|Haptic training|Patients in this arm were assigned to the 'Physioassistant: Sensorimotor training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation. All participating centers used the exact same apparatus and experimental set-up.
11298198|NCT02711553|Experimental|Ramucirumab|"A1: Ramucirumab plus cisplatin and gemcitabine intravenously (IV) on Days 1 and 8, every 21 days.
~A2: Placebo plus cisplatin and gemcitabine IV on Days 1 and 8, every 21 days."
11298199|NCT02711553|Experimental|Merestinib|"B1: Merestinib orally each day, plus cisplatin and gemcitabine IV on Days 1 and 8, every 21 days.
~B2: Placebo orally each day, plus cisplatin and gemcitabine IV on Days 1 and 8, every 21 days."
11298200|NCT02711540||Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
11298201|NCT02711540||No Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did not receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
11298202|NCT02711527|Active Comparator|Acupunture group A|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total) Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation , all needles will be retained for 30 minutes."
11298203|NCT02711527|Active Comparator|Acupunture group B|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total). Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes."
11298204|NCT02711501|Experimental|Laser irradiation|laser-assisted surgery with the following parameters: Wavelength:810 nanometer, power: 3 W, pulse mode,pulse length 100 µs, pulse interval 200 µs
11298205|NCT02711501|Experimental|blade|conventional surgery by blade
11298206|NCT02711488|Experimental|Intervention group|Combine primary prevention activities at the school level with secondary prevention at the household level
11298207|NCT02711488|No Intervention|Control group|No intervention
11298208|NCT02711462|Other|Cohort 1|Subjects will receive 2mg of PF 06687234 or placebo via the SC route
11298209|NCT02711462|Other|Cohort 2|Subjects will receive 20mg PF 06687234 or placebo via the SC route
11298210|NCT02711462|Other|Cohort 3|This is an optional cohort that may be added anytime during the study. In this cohort, subjects will receive PF 06687234 or placebo via the SC route
11298211|NCT02711462|Other|Cohort 4|Subjects will receive 40mg of PF 06687234 or placebo via the SC route
11298212|NCT02711462|Other|Cohort 5|Subjects will receive 80mg of PF 06687234 or placebo via the SC route
11298213|NCT02711462|Other|Cohort 6|Subjects receive a single dose of PF 06687234 or placebo via the IV route
11298214|NCT02711462|Other|Cohort 7|This is an optional cohort where Japanese subjects will receive PF 06687234 or placebo via the SC route
11298215|NCT02711462|Other|Cohort 8|Subjects in this cohort may receive 20 mg of PF 06687234 or placebo via the SC route every week with a total of 5 doses
11298216|NCT02711462|Other|Cohort 9|Subjects in this cohort may receive 40 mg of PF 06687234 or placebo via the SC route every two weeks with a total of 3 doses
11298217|NCT02711462|Other|Cohort 10|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
11298218|NCT02711462|Other|Cohort 11|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
11298219|NCT02711449|Experimental|Methylprednisolone|125 mg Methylprednisolone intravenously approximately 30 minutes prior to skin incision
11298220|NCT02711449|Placebo Comparator|Placebo|0.9% Saline intravenously approximately 30 minutes prior to skin incision
11298221|NCT02711436|Active Comparator|Computed Tomography Scan|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with Computed Tomography scan.
11298222|NCT02711436|Active Comparator|Fast Magnetic Resonance Imaging|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with T1/T2-weighted MRI.
11298223|NCT02711423|Experimental|Part I (Dose Escalation): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1.
11298224|NCT02711423|Placebo Comparator|Part I (Dose Escalation): Placebo|Participants will receive a single SC dose of matching placebo on Day 1.
11298225|NCT02711423|Experimental|Part II (PK Extension): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.
11298226|NCT02711397||Celiac patients|Celiac patients following a GFD for at least one year prior to the inclusion in the study.
11298227|NCT02711397||Positive controls|Healthy children and adults on an unrestricted gluten containing diet.
11298228|NCT02711397||Negative controls|Healthy infants who were exclusively fed with infant formula specifically labelled as gluten-free.
11298229|NCT02711371||Cannabis Dependence|Cannabis dependent individuals according to DSM 4 criteria, aged 18-40 years
11298230|NCT02711371||Healthy|Healthy controls, socio-demographically matched
11298231|NCT02711358|Experimental|indomethacin|indomethacin suppositories
11298232|NCT02711358|Placebo Comparator|placebo|placebo suppositories
11298233|NCT02711345|Experimental|Escalation|
11298234|NCT02711345|Experimental|Expansion Group 1|
11298235|NCT02711345|Experimental|Expansion Group 2|
11298236|NCT02711345|Experimental|Expansion Group 3|
11298237|NCT02711345|Experimental|Expansion Group 4|
11298238|NCT02711332||Degree of Haemolysis|Each subject will have four capillary blood sampling on different fingers. A reference venous blood sampling will be conducted.
11298239|NCT02711319|Active Comparator|active (real) rTMS (ACTIVE GROUP)|"The patients were randomly distributed in two study groups: real or sham rTMS group.
~For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes."
11298240|NCT02711319|Sham Comparator|sham rTMS (SHAM GROUP)|For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
11298241|NCT02711306|Experimental|GMN Diet|In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.
11298242|NCT02711306|Placebo Comparator|PN Diet|In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.
11298243|NCT02711293|Experimental|ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard plus enhanced nutrition counseling.
11298244|NCT02711293|Experimental|ART home delivery + no enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard counseling.
11298245|NCT02711293|Experimental|No ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home to provide enhanced nutrition counseling. Participants will not receive ART home delivery.
11298246|NCT02711293|No Intervention|Standard of care|Participants in this arm receive facility-based ART care and no enhanced nutrition counseling. They receive community health worker visits as per the standard of care in Dar es Salaam.
11298247|NCT02711280|Experimental|Sevoflurane General anesthesia|Anesthesia was induced with 8% sevoflurane with 8L/min oxygen. Anesthesia was maintained with 1-3% sevoflurane in oxygen/air mixture.
11298248|NCT02711280|Experimental|Propofol General anesthesia|Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
11298249|NCT02711267|Experimental|Phase 1: Optimization Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump). On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream. The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other. Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
11298250|NCT02711267|Experimental|Phase 2: Formulation Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. Different topical 5% acyclovir formulations currently available on the market will be tested. One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application. The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
11298251|NCT02711267|Experimental|Phase 3: Pilot BE study|4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
11298252|NCT02711267|Experimental|Phase 4: Main BE Study|20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
11298253|NCT02711241|Active Comparator|Dipyrone|
11298254|NCT02711241|Active Comparator|Papaverine|
11298255|NCT02711228|Experimental|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
11298256|NCT02711202|Active Comparator|Sirolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at post-operative day (POD) 14, they were randomized to sirolimus monotherapy.
11298257|NCT02711202|Active Comparator|Tacrolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at POD 14, they were randomized to tacrolimus monotherapy.
11298258|NCT02711189|Active Comparator|Oxytocin|Intranasal oxytocin will be delivered on twice daily basis in this crossover trial.
11298259|NCT02711189|Placebo Comparator|Placebo|Within Subject Design
11298260|NCT02711176|Experimental|Tavanex & Nexium & Tinafas|"Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days"
11298261|NCT02711176|Active Comparator|Lanzol & Klacid &Iramox|Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days
11298262|NCT02711163|Experimental|Extensively hydrolyzed formula|Feeding extensively hydrolyzed formula
11298263|NCT02711163|Placebo Comparator|Amino acid formula|Feeding amino acid formula
11298264|NCT02711150|Experimental|EPD Measurements|"Intervention:
~PLL Length Measured through US will be done with the subject placed on the Epidural Positioning Device."
11298265|NCT02711150|Active Comparator|Flexed Position Measurements|"Intervention:
~PLL Length Measured through US will be done with the subject placed in a flexed lumbar spine position."
11298266|NCT02711137|Experimental|INCB057643|
11298267|NCT02711137|Experimental|INCB057643 + Standard of Care (SOC) agents|
11298268|NCT02711124||Group with hemoglobin A1c < 7|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
11298269|NCT02711124||Group with hemoglobin A1c ≥ 7%|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
11298270|NCT02711111|Experimental|orthodontic bone anchor|new bone anchor device, which creates anterior traction on the upper jaw. Placed on the chin-region intra-orally.
11298271|NCT02711111|Active Comparator|face mask protraction|control group, conventional treatment method. Face mask creates anterior traction on the upper jaw
11298272|NCT02711098|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
11298273|NCT02711098|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
11298274|NCT02711085||Acute trauma|Those within the first 3 weeks of a non-catastrophic injury affecting the musculoskeletal system, including but not limited to whiplash or other road-traffic collisions, sports injuries, work-related injuries, sprains, strains, slips and falls and non-displaced fractures that don't require surgical correction.
11298275|NCT02711072|Placebo Comparator|control group|
11298276|NCT02711072|Active Comparator|infiltration group|
11298277|NCT02711059|Active Comparator|parathyroidectomy|change in insulin resistance
11298278|NCT02711059|No Intervention|control|the study participant will be examined parallel with the active comparator
11298279|NCT02711046|Experimental|single stage nasolabial flap|single staged nasolabial flap as an interpositional material after surgical resection of fibrous band in oral submucous fibrosis
11298280|NCT02711033|Experimental|Laparoscopic-assisted total gastrectomy|Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.
11298281|NCT02711033|Active Comparator|Open total gastrectomy|Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
11298282|NCT02711020|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy delivered in individual format.
11298283|NCT02711020|Experimental|Personal Construct Therapy|Personal Constructs Therapy delivered in individual format.
11298284|NCT02711007|Experimental|apatinib|apatinib 750mg tablet or 500mg tablet by mouth, Qd half an hour after dinner
11298285|NCT02710994|Experimental|CDFR0209, Then Losec|Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
11298286|NCT02710994|Experimental|Losec, Then CDFR0209|Subjects first received Losec 40 mg each morning in a fasting state for 7 days. After a washout period of 14 days, they then received CDFR0209 in a fasting state each morning for 7 days.
11298287|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
11298288|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
11298399|NCT02710318|Experimental|Immunization Alert on|Children with visits seen when the immunization alert is on
11322119|NCT02553148||Zimbabwe|One of the 23 countries studied
11298289|NCT02710968|Experimental|11540KE and Balt Goldbal 2 balloon|"Patients meeting inclusion criteria will receive fetoscopic tracheal occlusion using the fetoscopy sheath 11540 KE and the Balt Goldbal2 detachable balloon.
~Participants with an O/E LHR 25% (severe group) will have FETO completed at 27 weeks + 0 days to 29 weeks + 6 days gestation. Balloon removal is 4-5 weeks after that.
~Participants with an O/E LHR 25 - <30% (less severe group) will have FETO completed at 30 weeks + 0 days to 31 weeks + 6 days gestation. Balloon removal is 3 - 4 weeks after that."
11298290|NCT02710955|Experimental|Thickened infant formula|
11298291|NCT02710942|Experimental|SPHERE intervention|It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
11298292|NCT02710942|Experimental|PRISM intervention|It is a targeted self-guided Internet-based CBT intervention. PRISM was built upon the myWHI diary, an electronic headache diary. PRISM helps users discover their headache triggers by analyzing the inputted diary data using association rule mining. Once one or multiple headache triggers are identified the application uses an algorithm to provide the user with a few personalized recommendations to help them to cope with these triggers. The algorithm is based on the opinion of clinical experts (e.g., medical health professionals, psychologists). The user chooses recommendations to follow and sets goals in the application to follow them. To support the process, the application checks in with users about their goals and tracks goal completion.
11298293|NCT02710942|No Intervention|Usual care|Participants can continue doing what they usually do to deal with their migraines.
11298294|NCT02710929||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
11298295|NCT02710929||TD group|Typically development controls without lifetime diagnosis with ADHD
11298296|NCT02710916|Sham Comparator|perimetric glaucoma patients|
11298297|NCT02710916|Active Comparator|preperimetric glaucoma patients|
11298298|NCT02710916|Sham Comparator|perimetric glaucoma control patients|
11298299|NCT02710903|Experimental|Healthy with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with probing depths (PD) ≤4mm, no evidence of inter proximal clinical attachment loss (CAL), and <20% of sites with bleeding on probing (BOP).
11298300|NCT02710903|Experimental|Periodontal Disease with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
11298301|NCT02710903|Experimental|Healthy with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with PD ≤4mm, no evidence of interproximal CAL, and <20% of sites with BOP.
11298302|NCT02710903|Experimental|Periodontal Disease with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
11298303|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years. For Cohort 2 every attempt will be made to enroll 20 subjects >= 4 to < 8 years of age, 12 subjects >= 2 to < 4 years of age and 12 subjects >= 1 month to < 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
11298304|NCT02710877|Experimental|Programmed Intermittent bolus (PIEB)|Intervention: epidural analgesia through administration of a mixture of levobupivacaine 0,0625% and sufentanil 4 mcg. Intermittent bolus of 10 ml mixture every 75 minutes. Patient controlled bolus of 5 ml same mixture, lock-out 15 minutes.
11298305|NCT02710877|Active Comparator|Manuale epidural bolus (TOP-UP)|Intervention: manual epidural bolus of 15 ml levobupivacaine 0,0625% and sufentanil 5 mcg on maternal request.
11298306|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
11298307|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
11298308|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
11298309|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
11298310|NCT02710838|Experimental|Cancer group|All patients receive the infrared endoscopy after injecting indocyanine green（ICG） intravenously.
11298311|NCT02710838|Other|Non-cancer group|All patients receive the infrared endoscopy after injecting ICG intravenously.
11298312|NCT02710825|Experimental|Osteopathic treatment|
11298313|NCT02710825|Placebo Comparator|Simulated osteopathic treatment|
11298314|NCT02710812||Rectum sparing group|"Patients who have all of the following requirements:
~Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy);
~Written informed consent (after 2nd restaging).
~Note: They will be subject to wait-and-see approach only patients with cCR."
11298315|NCT02710799|Active Comparator|Control|Referrals will be evaluated through the state's protocols
11298316|NCT02710799|Experimental|Intervention|Referrals will be evaluated through the state's protocols associated with telephone-based teleconsultations.
11298317|NCT02710786||Gastric bypass|Patients undergoing gastric bypass
11298318|NCT02710773|Experimental|Backward Walking Treadmill Training|The subjects will perform a backward walking training on treadmill device
11298319|NCT02710773|Active Comparator|Treadmill training|The subjects will perform a walking training on treadmill device
11298320|NCT02710760|No Intervention|Control|Households in the control group receive no special treatment.
11298359|NCT02710552|Active Comparator|Three antihypertensive Drugs|Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
11298400|NCT02710318|No Intervention|Immunization Alert off|Children with visits seen when the alert is off
11298321|NCT02710760|Experimental|Adoption Encouragement Treatment|"Households in the Adoption Encouragement Treatment group were visited between March and April 2015 and offered child nutrition focused adoption encouragement. Both the male household head and the primary female caregiver were invited to attend these meetings (though the household head is the primary target), where the nutritional benefits of Quality Protein Maize (QPM) adoption for children were emphasized along with the agronomic properties. In addition, the fact that only small amounts of QPM are necessary to nourish children was highlighted and small seed bag sizes were offered. During the adoption encouragement visit, we offered the option to order up to three 2 kg bags of QPM for free."
11298322|NCT02710760|Experimental|Consumption Encouragement Treatment|In addition to receiving the Adoption Encouragement Treatment, households in the Consumption Encouragement Treatment group received additional information, targeted to the caregiver, and tools for separating Quality Protein Maize and targeting it to young children in the household in August 2015. They will additionally receive further guidance in February 2016.
11298323|NCT02710747|Experimental|Genetic Group|Dose (mg/week) = [5.6044 - 0.02614 × Age [in years] + 0.0087 × Height [cm] + 0.0128 × Weight [kg] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 *1/*2 - 0.9357 × CYP2C9 *1/*3 - 1.0616 × CYP2C9 *2/*2 - 1.9206 × CYP2C9*2/*3 - 2.3312 × CYP2C9 *3/*3 - 0.1092 × Asian race - 0.5503 × amiodarone ]2
11298324|NCT02710747|No Intervention|Control Group|Dose for the first three days after operation will be 4.5mg/d.
11298325|NCT02710734|Experimental|CRT|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3
11298326|NCT02710734|Experimental|Surveillance|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance
11298327|NCT02710734|Experimental|Intravesicle therapy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3
11298328|NCT02710734|Experimental|Radical Cystectomy|Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy
11298329|NCT02710721|Experimental|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
11298330|NCT02710721|Active Comparator|Control|mediterranean diet
11298331|NCT02710708|Experimental|Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)|Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
11298332|NCT02710695|Active Comparator|Control|This group will receive a 10 minute discussion
11298333|NCT02710695|Active Comparator|Intervention|This group will receive a 10 minute standardized discussion
11298334|NCT02710682|Active Comparator|Mini-open surgery|Surgery
11298335|NCT02710682|Experimental|Ultrasound-guided Tendon fenestration|Tendon fenestration
11298336|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
11298337|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
11298338|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
11298339|NCT02710656|Experimental|Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
11298340|NCT02710656|Active Comparator|Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
11298341|NCT02710643|No Intervention|MRD - BEFORE RT|Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
11298342|NCT02710643|No Intervention|MRD + BEFORE RT AND MRD - AFTER RT|Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
11298343|NCT02710643|Experimental|MRD + BEFORE RT AND MRD + AFTER RT|"Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).
~Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated."
11298344|NCT02710630|Active Comparator|Dabigatran etexilate capsule|
11298345|NCT02710630|Experimental|Dabigatran etexilate tablet A1|
11298346|NCT02710630|Experimental|Dabigatran etexilate tablet B1|
11298347|NCT02710630|Experimental|Dabigatran etexilate tablet C1|
11298348|NCT02710630|Experimental|Dabigatran etexilate tablet D1|
11298349|NCT02710630|Experimental|Dabigatran etexilate tablet E1|
11298350|NCT02710604|Active Comparator|CMX157 5mg versus TDF|CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days
11298351|NCT02710604|Active Comparator|CMX157 10mg versus TDF|CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days
11298352|NCT02710604|Active Comparator|CMX157 25mg versus TDF|CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days
11298353|NCT02710604|Active Comparator|CMX157 50mg versus TDF|CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days
11298354|NCT02710604|Active Comparator|CMX157 100mg versus TDF|CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days
11298355|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.
~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
11298356|NCT02710578|Active Comparator|Alcohol|Alcohol
11298357|NCT02710578|Placebo Comparator|Placebo|Tonic water
11298358|NCT02710565|Other|Cohort|"Participants who are scheduled to have an endo bronchial ultrasound (EBUS) trans bronchial needle aspiration (TBNA) will provide additional samples. These samples will then be sent to Imperial College London to see whether a cell line can be grown.
~If growth is successful then the samples will be returned to our pathology department to see if grading is possible and then to compare these results with the previous diagnostic samples.
~The cell line samples will not be used for patient diagnosis."
11298360|NCT02710552|Active Comparator|Two antihypertensive drugs|Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
11298361|NCT02710539|Active Comparator|Free combination|Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy
11298362|NCT02710539|Active Comparator|Tripliam|fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily
11298363|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
11298364|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
11298365|NCT02710526|Experimental|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
11298366|NCT02710513|Experimental|Beta-glucans|2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)
11298367|NCT02710500|Experimental|Cohort 1 (Low Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10^12 in one muscle.
~Intervention Drug: rAAVrh.MHCK7.DYSF.DV"
11298368|NCT02710500|Experimental|Cohort 2 (High Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10^12 vg in one muscle.
~Intervention Drug: rAAVrh74.MHCK7.DYSF.DV"
11298369|NCT02710487|Experimental|REM Sleep Awakening (REMSA)|The investigators will actively awaken each subject from nocturnal REM sleep in a sleep laboratory setting, in the hour preceding her/his habitual wake time.
11298370|NCT02710487|Experimental|NREM Sleep Awakening (NREMSA)|Awakening from the NREM sleep stage N2 will be the control intervention.
11298371|NCT02710474|Active Comparator|Standard Care|Preterm infants will receive current Standard Care (SC) in the NICU.
11298372|NCT02710474|Experimental|Intervention|Preterm infants will receive Family Nurture Intervention (FNI) in addition to current Standard Care (SC) in the NICU. Specifically, staff will support the parents and facilitate contact between mother and infant during the NICU stay.
11298373|NCT02710474|Active Comparator|Term Controls|Full term infants will receive current Standard Care (SC) in the NICU. Term Controls (TC)
11298374|NCT02710474|Active Comparator|Chart Review|Chart review will be conducted to acquire a comparison group to determine if our study participants differ from the non-study population.
11298375|NCT02710461|Experimental|Subjects with abdominal obesity|Intervention with grape pomace and pomegranate pomace
11298376|NCT02710448|Experimental|Metformin|Metformin in patients with renal failure
11298377|NCT02710435||Arm 1 - Prospective|Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Neovasc Reducer System implant procedure
11298378|NCT02710435||Arm 2 - COSIRA|Includes subjects who were previously enrolled and treated with the Neovasc Reducer System during the COSIRA study and agree to participate in this long term follow up study
11298379|NCT02710435||Arm 3 - CE Mark|"Includes subjects who received a Neovasc Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study
~Arm 3 has been closed to enrollment-June 2017"
11298380|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
11298381|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
11298382|NCT02710409|Experimental|Quadrivalent influenza vaccine|
11298383|NCT02710409|Active Comparator|Trivalent influenza vaccine A|Active Comparator A
11298384|NCT02710409|Active Comparator|Trivalent influenza vaccine B|Active Comparator B
11298385|NCT02710396|Experimental|Cohort 1|Subjects will receive single agent pembrolizumab 200 mg IV will be administered every 3 weeks for up to 2 years.
11298386|NCT02710396|Experimental|Cohort 2|Subjects will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of nab-paclitaxel and carboplatin administered with cycles 1 and 2.
11298387|NCT02710396|Experimental|Cohort 3|Subject will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of pemetrexed and carboplatin administered with cycles 1 and 2.
11298388|NCT02710383||Participants genetically diagnosed with Cystic fibrosis|Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years
11298389|NCT02710370||Controls|Patients who meet criteria for gastric bypass surgery, and do not have a documented history of Type 1 or Type 2 Diabetes.
11298390|NCT02710370||Participants with Type 2 Diabetes|Patients who meet criteria for gastric bypass surgery, and have a documented history of Type 2 Diabetes.
11298391|NCT02710357|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
11298392|NCT02710357|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 4 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
11298393|NCT02710344|No Intervention|Usual Care|Usual care at community mental health care provider
11298394|NCT02710344|Experimental|Telehealth|Usual care at community mental health care provider PLUS psychiatric telehealth program with remote monitoring.
11298401|NCT02710305|Active Comparator|Group A|oral hyoscine butyl bromide tablets plus lidocaine cream
11298402|NCT02710305|Placebo Comparator|Group B|oral placebo tablets plus placebo cream
11298403|NCT02710292|Other|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
11298404|NCT02710292|Other|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
11298405|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
11298406|NCT02710266|Placebo Comparator|Placebo group|hepatectomy without Gabexate Mesilate
11298407|NCT02710266|Experimental|Preoperative Gabexate Mesilate group|Gabexate Mesilate administered from the preoperative day
11298408|NCT02710266|Experimental|Intraoperative Gabexate Mesilate group|Gabexate Mesilate administered from the operative day
11298409|NCT02710253|Experimental|Treatment (SBRT or EBRT)|Patients undergo either 4 fractions of SBRT or 5-15 fractions of EBRT to any site of metastatic disease daily for any time between 4 days and 3 weeks as determined by the treating radiation oncologist. Patients with at least SD after the second imaging evaluation may undergo additional SBRT in 4 fractions or EBRT in 3 fractions.
11298410|NCT02710227||liver cirrhosis|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
11298411|NCT02710227||control|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
11298412|NCT02710214|Experimental|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
11298413|NCT02710214|Placebo Comparator|Placebo|Placebo pill daily for 8 weeks.
11298414|NCT02710201|No Intervention|Control|No feedback on progress of other participants.
11298415|NCT02710201|Experimental|Descriptive Social Norm|Average physical activity of other participants in study conveyed to this group.
11298416|NCT02710201|Experimental|Descriptive-plus-Injunctive Social Norm|Average physical activity of other participants in study and message of approval or disapproval (depending on how one is faring compared to others) conveyed to this group.
11298417|NCT02710188|Experimental|HTL0009936 modified release (MR) Formulation|Intervention: 5 different modified release formulations of HTL0009936, as a single dose
11298418|NCT02710188|Active Comparator|HTL00009936 immediate release (IR) fasted|Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state
11298419|NCT02710162|Experimental|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
11298420|NCT02710149|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD20-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
11298421|NCT02710136|Experimental|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.
~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
11298422|NCT02710123|Experimental|Aerobic Exercise|Participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during the Buffalo Concussion Treadmill Test (BCTT). The script will ask the participant to exercise one a day for 20 minutes at 80% of HRT. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Sub-Threshold exercise prescription
11298423|NCT02710123|Placebo Comparator|Stretching Exercise|Participants will receive a prescription for stretching exercises that they will be asked to do daily. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Structured stretching exercise prescription.
11298424|NCT02710110|Experimental|Active Respiratory Trainer|Participants enrolled in this arm will be given the PowerLung trainer. The adjustable spring allows for discrete and calibrated changes to the valve, which in turn blocks air until sufficient inspiratory or expiratory pressure is applied by an individual. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
11298425|NCT02710110|Sham Comparator|Sham Trainer|Participants enrolled in this arm will be given the PowerLung trainer; however, the adjustable spring allows for discrete and calibrated changes to the valve and these will not have any resistance. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
11298426|NCT02710097|Experimental|Active THC and Placebo Ethanol|
11298427|NCT02710097|Experimental|Active THC and Active Ethanol|
11298428|NCT02710097|Experimental|Placebo THC and Active Ethanol|
11298429|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
11298430|NCT02710084|Experimental|Oxytocin|The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
11298509|NCT02709668|Experimental|enlyte|gel cap of B vitamins brand Enlyte
11298431|NCT02710084|Placebo Comparator|Saline|During the first phase, patients randomized to the placebo group will receive intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants will receive oxytocin, in identical doses.
11298432|NCT02710071|Experimental|Placebo, Nebivolol, Hydrochlorothyazide|Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
11298433|NCT02710071|Experimental|Placebo, Hydrochlorothyazide, Nebivolol|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
11298434|NCT02710058||Arab American Women with Breast Cancer|We conducted a study using an evaluation assessment survey to assess the impact of the AMBER support groups on quality of life parameters, compliance with treatment appointments, and patient/family support. After reviewing preliminary results, we identified several recurrent themes, such as the need for health information, discrepancies around the extent of family support and disease disclosure, and an overall satisfaction with the support groups. To further examine these themes, we are initiating a qualitative research study using an in-depth interview guide. A trained interviewer bilingual in Arabic and English will conduct 10-15 in-depth interviews, to saturation, with AMBER's support group participants over a 6 month period.
11298435|NCT02710045|Active Comparator|MV at 9 months|"Measles Vaccine at 9 months of age. Measles Vaccine at 18 months of age. All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.
~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
11298436|NCT02710045|Active Comparator|DTP + MV at 9 months|Measles Vaccine at 9 months of age. DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
11298437|NCT02710045|Active Comparator|DTP at 9 months|DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
11298438|NCT02710032|Experimental|Intervention|Social Network-Based Adherence Intervention
11298439|NCT02710032|No Intervention|Control|Control
11298440|NCT02710019|Experimental|Psychoeducational video games|Participants in this group will play the Back to Reality Series video games: (1) Harry's Journey which delivers experiential knowledge about psychosis and marijuana use; (2) Harry's Journal which challenges their understanding of 12 psychiatric symptoms associated with psychosis and (3) the PathwaysToCare Map which uses colourful 3D images and voice-overs to depict actual mental health and addictions services for youth available in Hamilton. These in
11298441|NCT02710019|Other|Control video game|The control video game is a spelling/memory quiz involving with themes from pop culture. The control game will not provide any education about mental health and addictions issues It should be noted that all participants will play both sets of games during their initial and only visit. Participants are randomized to determine which game they will play first during this visit. This is not an RCT or a crossover design. There is no follow up or clinical assessments.
11298442|NCT02710006|Experimental|SonoHysteroAVC|Three-dimensional sonohysterography is the first point for uterine cavity volume estimation, and it is going to be performed in all participants. The investigators are going to fill the uterine cavity twice by saline solution during single sonohysterography procedure, and acquise the volumetric datasets of uterus for offline analysis. The 3D dataset containing the entire uterine cavity will by analyzed using a personal computer and/or the ultrasound machine with specific softwere.
11298443|NCT02709993|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
11298444|NCT02709980|Placebo Comparator|Sleep Education|6 sessions of sleep education.
11298445|NCT02709980|Active Comparator|Cognitive Behavior Therapy for Insomnia|6 sessions of cognitive behavioral therapy for insomnia (CBT-I).
11298446|NCT02709967|Active Comparator|Material support|Writing materials
11298447|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
11298448|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
11298449|NCT02709954|Experimental|Active THC and Placebo Ethanol|
11298450|NCT02709954|Experimental|Active THC and Active Ethanol|
11298451|NCT02709954|Experimental|Placebo THC and Active Ethanol|
11298452|NCT02709954|Placebo Comparator|Placebo THC and Placebo Ethanol|
11298453|NCT02709941|Active Comparator|IMST Training Group|Subjects in inspiratory muscle strength training group will complete 30 breaths against a resistance set at 75% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
11298454|NCT02709941|Placebo Comparator|Placebo Training Group|Subjects in placebo training group will complete 30 breaths against a resistance set at 15% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
11298455|NCT02709928|Experimental|TD-0714|Capsule formulation
11298456|NCT02709928|Placebo Comparator|Placebo|Capsule formulation
11298457|NCT02709915|Experimental|Breakfast Diet (Bdiet)|The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
11298510|NCT02709655|Experimental|Vortioxetine 10 mg/day|
11298511|NCT02709655|Experimental|Vortioxetine 20 mg/day|
11298458|NCT02709915|Active Comparator|6 small meals diet (6Mdiet)|The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
11298459|NCT02709902|Experimental|Adapalene/BP gel, 0.3%/2.5%|Topical, once daily, for 84 days.
11298460|NCT02709902|Active Comparator|EPIDUO® FORTE|Topical, once daily, for 84 days.
11298461|NCT02709902|Placebo Comparator|Placebo|Topical, once daily, for 84 days.
11298462|NCT02709889|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
11298463|NCT02709876|Experimental|Stem Cells|Intravitreal Injection of bone marrow derived CD34+, CD133+, CD271+ stem cells.
11298464|NCT02709863|Active Comparator|Sevoflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
11298465|NCT02709863|Active Comparator|Desflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
11298466|NCT02709863|Active Comparator|Propofol|6-10 mg/kg/h, iv infusion, during operation
11298467|NCT02709850|Placebo Comparator|Cohorts A, D: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
11298468|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 20 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 20 milligrams (mg) subcutaneously on Day 1.
11298469|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 120 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 120 mg subcutaneously on Day 1.
11298470|NCT02709850|Placebo Comparator|Cohorts B, C: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
11298471|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 40 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 40 mg subcutaneously on Day 1.
11298472|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 80 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 80 mg subcutaneously on Day 1.
11298473|NCT02709850|Placebo Comparator|Cohorts AA-DD: Placebo|Participants received IONIS ANGPTL3-LRx-matching placebo subcutaneously once per week for 6 weeks.
11298474|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 10 mg|Participants received IONIS ANGPTL3-LRx 10 mg subcutaneously once per week for 6 weeks.
11298475|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 20 mg|Participants received IONIS ANGPTL3-LRx 20 mg subcutaneously once per week for 6 weeks.
11298476|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 40 mg|Participants received IONIS ANGPTL3-LRx 40 mg subcutaneously once per week for 6 weeks.
11298477|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 60 mg|Participants received IONIS ANGPTL3-LRx 60 mg subcutaneously once per week for 6 weeks.
11298478|NCT02709837|Active Comparator|Poorly cooked meat-Good chewing|Meat cooked 10min at 75°C, chewing without appliance
11298479|NCT02709837|Active Comparator|Highly cooked meat-Good chewing|Meat cooked 45min at 90°C, chewing without appliance
11298480|NCT02709837|Active Comparator|Poorly cooked meat-Bad chewing|Meat cooked 10min at 75°C, chewing with appliance
11298481|NCT02709837|Active Comparator|Highly cooked meat-Bad chewing|Meat cooked 45min at 90°C, chewing with appliance
11298482|NCT02709824|Active Comparator|Chlorhexidine gluconate with ADS|Chlorhexidine 0.12% plus Anti-Discoloration System Mouthwash
11298483|NCT02709824|Active Comparator|Chlorhexidine gluconate without ADS|Chlorhexidine 0.12% Mouthwash
11298484|NCT02709811|Experimental|electrochemotherapy|
11298485|NCT02709798|Experimental|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
11298486|NCT02709798|Placebo Comparator|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
11298487|NCT02709785|Experimental|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
11298488|NCT02709785|Experimental|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
11298489|NCT02709785|Placebo Comparator|Group 3 Placebo|28 subjects with plaque and gingival inflammation
11298490|NCT02709772|Active Comparator|Provider Alert|This arm is the intervention arm. This arm will receive the Electronic Record Alert.
11298491|NCT02709772|No Intervention|No Provider Alert|This arm is the control arm.
11298492|NCT02709759|Active Comparator|MI|Motivational interviewing focused on reducing alcohol use, delivered by videoconferencing.
11298493|NCT02709759|Active Comparator|BA|Brief Advice to reduce drinking delivered by videoconferencing
11298494|NCT02709759|Active Comparator|MI + ITM|Motivational intervention to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
11298495|NCT02709759|Active Comparator|BA + ITM|Brief Advice to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
11298496|NCT02709759|Active Comparator|MI + ITM + EI|Participants in this arm receive MI delivered by videoconferencing and ITM over 9 months rather than 1
11298497|NCT02709759|Active Comparator|BA + ITM + EI|Participants in this arm receive BA delivered by videoconferencing and ITM over 9 months rather than 1
11298498|NCT02709759|Active Comparator|BA + EI|Participants in this arm receive BA delivered by videoconferencing over 9 months rather than 1
11298499|NCT02709759|Active Comparator|MI + EI|Participants in this arm receive MI delivered by videoconferencing over 9 months rather than 1
11298500|NCT02709746|Experimental|Vortioxetine 10 mg/day|
11298501|NCT02709746|Experimental|Vortioxetine 20 mg/day|
11298502|NCT02709746|Active Comparator|Fluoxetine 20 mg/day,|
11298503|NCT02709746|Placebo Comparator|Placebo|
11298504|NCT02709733|Experimental|VR Motivation Training|Weekly training sessions with a VR motivation treatment 1 hour per week for 8 weeks.
11298505|NCT02709720|Experimental|1|2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy
11298506|NCT02709707||Patients with diabetes|
11298507|NCT02709681||SCD patients|Patients followed in 32 Italian Centers.
11298508|NCT02709668|Placebo Comparator|placebo|gel cap with placebo
11298512|NCT02709655|Active Comparator|Fluoxetine 20 mg/day,|A decision has been taken to stop recruitment into this treatment arm.
11298513|NCT02709655|Placebo Comparator|Placebo|
11298514|NCT02709642|No Intervention|Control|Control Participants will complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight.
11298515|NCT02709642|Experimental|Deposit Contract|The deposit contract group will also complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight. In addition, the deposit contract group will be asked to make a deposit of at least $100 each 10-week period over the course of one year (50 weeks). Each week, they will recoup 1/10 of their 10-week deposit if they are within two pounds of their baseline weight or lower. If they are more than two pounds above their baseline weight, they will forfeit 1/10 of their 10-week deposit. The money they forfeited for that week will go into a collective pool to be divided up at the end of each 10-week period by all deposit contract participants who successfully maintained their weight loss at the end of the 10-week period.
11298516|NCT02709629|Experimental|Individualized and adaptive computerised cognitive training|Training in this group is individualized using a computer algorithm which assigns tasks (from a pool of 33 training tasks) on the basis of cognitive strengths and weaknesses as determined by the training program. In addition, task difficulty is adaptive and responsive to performance level. Participants are able to see feedback on their progress each training session in the form of a session-score. A range of behavior change techniques are used throughout the training period (delivered via scheduled monitoring phone calls, and email contact with participants) to support the compliance and adherence of participants. These include a range of motivation and confidence building strategies, based on a theoretical framework. Participants are required to train for approx. 30 min., 3 times per week, for 8 weeks.
11298517|NCT02709629|Active Comparator|Active control|"Training in this group is generic, and tasks (from the same pool of 33 training tasks) are randomly selected by the training program. In addition, task difficulty is fixed, such that irrespective of performance, each time a participant is presented with a given task, the level of difficulty returns to the basic level. Participants in this arm do not receive feedback on their progress at the end of each training session. The same protocol of behavior change techniques is used in this intervention arm.
~Participants are also required to train for approx. 30 min., 3 times per week, for 8 weeks."
11298518|NCT02709616|Experimental|Personalized cellular vaccine|DC based cellular vaccine
11298519|NCT02709603|Experimental|Group A|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
11298520|NCT02709603|Placebo Comparator|Group B|oral 2 tablets (PLACEBO) 30 minutes before the procedure
11298521|NCT02709590|Experimental|Group A|oral diclofenac potassium plus lidocaine anesthetic cream placed into their cervix immediately before HSG
11298522|NCT02709590|Placebo Comparator|Group B|oral placebo tablets plus placebo cream placed into their cervix immediately before HSG
11298523|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
11298524|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
11298525|NCT02709564|Placebo Comparator|Group A|400 mg placebo
11298526|NCT02709564|Active Comparator|Group B|400 microgram misoprostol
11298527|NCT02709551|Experimental|HRV-Bfb|HRV biofeedback, training about 30 minutes/day
11298528|NCT02709551|Experimental|MBI|Mindfulness based intervention, training about 30 minutes/day
11298529|NCT02709551|Other|MBI_HRV-Bfb|Mindfulness based HRV biofeedback. Wait list control group for the interventions HRV-Bfb and MBI, after the main phase intervention with combined method.
11298530|NCT02709538|Experimental|GSP 301 NS|
11298531|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
11298532|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7.0|
11298533|NCT02709525|Experimental|hyaluronic acid|Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
11298534|NCT02709525|Placebo Comparator|Blood clot|Immediately after the extractions, the other side socket was naturally filled with blood clot.
11298535|NCT02709512|Experimental|Drug: ADI-PEG 20 plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
~In Combination With:
~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
11298536|NCT02709512|Placebo Comparator|Drug: Placebo plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study
~In Combination With:
~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
11298537|NCT02709499|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
11298538|NCT02709499|Experimental|6J LLLT|The Laser radiation will be made with 4J by spot
11298539|NCT02709486|Experimental|Low dose|Investigational product
11298540|NCT02709486|Experimental|High dose|Investigational product
11298541|NCT02709486|Placebo Comparator|Placebo|Investigational product
11298542|NCT02709473|Active Comparator|propofol|Propofol arm includes patients that induction of general anesthesia started with propofol and followed by remifentanil and rocuronium administration
11298543|NCT02709473|Active Comparator|remifentanil|Remifentanil arm include patients that induction of general anesthesia started with remifentanil and followed by propofol and rocuronium administration
11298544|NCT02709460|Experimental|Lateral occlusion|Women included in this arm is randomized to lateral occlusion of the uterine artery
11298545|NCT02709460|Active Comparator|cervical occlusion|Women included in this arm is randomized to occlusion of the uterine artery at cervical entry
11298546|NCT02709447|Experimental|Date SMART|Group based prevention
11298547|NCT02709447|Active Comparator|Health Promotion|Group based prevention
11298548|NCT02709434|Active Comparator|Intervention group|Patients with quiescent IBD who are randomized to receive the active intervention of the psychoeducational programme
11298549|NCT02709434|Placebo Comparator|Control group|Randomized to standard care
11298635|NCT02708901|Active Comparator|GI Vivomixx®|25 children with GI symptoms
11298550|NCT02709421||Indomethacin Group|"All the patients with high risks of PEP received administration of one single dose of 100mg rectal indomethacin after ERCP.
~Patients were considered high risk of PEP if they met one of the following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, cannulation time≥10 minutes; pneumatic dilatation of an intact biliary sphincter, ≥3 inadvertent pancreatic duct cannulation, opacification of pancreatic acini, or the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush or forceps."
11298551|NCT02709408||Carbapenem-resistant Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-resistant Enterobacteriaceae
11298552|NCT02709408||Carbapenem-resistant A. baumannii|Patients with bloodstream infections due to carbapenem-resistant Acinetobacter baumannii
11298553|NCT02709408||Susceptible Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-susceptible Enterobacteriaceae matched to carbapenem-resistant ones by centre, type of ward, infection type, acquisition and previous duration of hospitalisation.
11298554|NCT02709408||Admitted control patients|Patients without infection due to Enterobacteriaceae matched to carbapenem-resistant Enterobacteriaceae cases according to centre, ward and previous length of hospitalisation.
11298555|NCT02709395|Experimental|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
11298556|NCT02709382|Experimental|FEP-TAZ|Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)
11298557|NCT02709369|Experimental|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
11298558|NCT02709356|Experimental|Alzheimer's disease|"Patients with mild Alzheimer's disease.
~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
11298559|NCT02709356|Experimental|Controls|"Healthy elderly people
~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
11298560|NCT02709343|Experimental|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
11298561|NCT02709343|Placebo Comparator|Placebo|Placebo product manufactured to look like MSCs
11298562|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:
~LunaRich X Capsules (12 capsules per day)
~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)
~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)
~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
11298563|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
11298564|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
11298565|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
11298566|NCT02709304|Placebo Comparator|Standard Gel|Standard gel not containing local anesthetic used to insert urinary catheters.
11298567|NCT02709304|Experimental|Lidocaine Gel|lidocaine containing gel uses to insert urinary catheters
11298568|NCT02709291|Other|Community Health Workers|Community health workers will complete a 5-day interventionist training to deliver a behavioral parent training intervention.
11298569|NCT02709291|Other|Parent-Child Dyads|Parents and children will receive a behavioral parent training intervention delivered by community health workers.
11298570|NCT02709278|Other|Group 1A: low dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^3 cfu by the aerosol inhaled route, followed by bronchoscopy.
11298571|NCT02709278|Other|Group 1B: medium dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
11298572|NCT02709278|Experimental|Group 1C: standard dose aerosol BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
11298573|NCT02709278|Experimental|Group 1D: standard dose intradermal BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
11298574|NCT02709278|Other|Group 2A: lower than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
11298575|NCT02709278|Other|Group 2B: close to the standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^5 cfu by the aerosol route, followed by bronchoscopy.
11298576|NCT02709278|Other|Group 2C: higher than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^6 cfu by the aerosol inhaled route, followed by bronchoscopy.
11298636|NCT02708901|Placebo Comparator|GI Placebo|25 children with GI symptoms
11298577|NCT02709278|Experimental|Group 2D: close to or higher than standard aerosol BCG|9 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
11298578|NCT02709278|Experimental|Group 2E: close to or higher than standard intradermal BCG|12 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
11298579|NCT02709265|Experimental|Cohort 1|amikacin/fosfomycin (30/12 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
11298580|NCT02709265|Experimental|Cohort 2|amikacin/fosfomycin (60/24 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
11298581|NCT02709265|Experimental|Cohort 3|amikacin/fosfomycin (90/36 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
11298582|NCT02709265|Experimental|Cohort 4|amikacin/fosfomycin (90/36 mg) delivered via the PARI LC Sprint Nebulizer (single dose)
11298583|NCT02709265|Experimental|Cohort 5|amikacin/fosfomycin (Dose and Nebulizer to be chosen based on results from Cohorts 1 - 4)
11298584|NCT02709252|Experimental|Cohort|Only one cohort is included with comparisons of two different hemodynamic parameters
11298585|NCT02709239|Active Comparator|DHA 200mg|Participants will receive 200mg DHA to take per day. Participants will be asked to take four capsules containing 50mg DHA each.
11298586|NCT02709239|Experimental|DHA 800mg|Participants will receive 800mg DHA to take per day. Participants will be asked to take four capsules containing 200mg DHA each.
11298587|NCT02709226|Experimental|I/Radiation|Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned reirradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
11298588|NCT02709213||Patients with CT-diagnosed acute colitis|Patients with symptomatic colitis (fever and/or pain and/or diarrhea) proven by computed tomography
11298589|NCT02709200||Dexmedetomidine|Patients that received dexmedetomidine during open heart surgery.
11298590|NCT02709200||No dexmedetomidine|Patients that didn't receive dexmedetomidine during open heart surgery.
11298591|NCT02709187|Experimental|RT group|combination dose of Candesartan and Rosuvastatin and DP-R208 in order
11298592|NCT02709187|Experimental|TR group|DP-R208 and combination dose of Candesartan and Rosuvastatin in order
11298593|NCT02709174||pregnant with pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
11298594|NCT02709174||pregnant without pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
11298595|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
11298596|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
11298597|NCT02709148|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
11298598|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
11298599|NCT02709122|Experimental|With Tension pneumothorax|evaluation of the patient with the existing tension pneumothorax during a simulated CPR - breathing
11298600|NCT02709122|Experimental|Without Tension pneumothorax|evaluation of the patient without the existing tension pneumothorax during a simulated CPR - breathing
11298601|NCT02709109|Experimental|VX-371 + Saline , then Saline|Participants receive VX-371 + Saline during Treatment Period 1 followed by Saline during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
11298602|NCT02709109|Experimental|Saline, then VX-371 + Saline|Participants receive Saline during Treatment Period 1 followed by VX-371 + Saline during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
11298603|NCT02709109|Experimental|VX-371 + Placebo, then Placebo|Participants receive VX-371 + placebo (saline) during Treatment Period 1 followed by placebo (saline) during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
11298604|NCT02709109|Experimental|Placebo, then VX-371 + Placebo|Participants receive placebo (saline) during Treatment Period 1 followed by VX-371 + placebo (saline) during Treatment Period 2. A washout period of 28 Days will be maintained between the two treatment periods. All subjects must be receiving stable treatment with Orkambi before the first dose of study drug and throughout the duration of the study.
11298605|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
11298606|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
11298780|NCT02707939||Controls|Patients with no developmental diagnoses
11298607|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
11298608|NCT02709070|Active Comparator|resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
11298609|NCT02709070|Experimental|highly-purified CTL|Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective participants who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Participants in the immunotherapy group received a number up to 5×10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. Participants were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving resection, followed by 6-9 treatments during 6 months to 2 years after receiving resection.
11298610|NCT02709057|Active Comparator|Life-style intervention 1|Life-style intervention in participants with low genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
11298611|NCT02709057|Active Comparator|Life-style intervention 2|Life-style intervention in participants with high genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
11298612|NCT02709057|No Intervention|Control 1|No intervention in participants with low genetic risk score
11298613|NCT02709057|No Intervention|Control 2|No intervention in participants with high genetic risk score
11298614|NCT02709044|Experimental|Ringer lactate 20 mL/kg|This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
11298615|NCT02709044|Experimental|Ringer lactate 40 ml/kg|This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
11298616|NCT02709031|Active Comparator|Cicletanine|Patients will take escalating doses of cicletanine
11298617|NCT02709031|Experimental|Cicletanine + magnesium|Patients will take escalating doses of cicletanine; patients will in addition take magnesium
11298618|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
11298619|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
11298620|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
11298621|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
11298622|NCT02708992|Experimental|Cefixime/Azithromycin|Eight participants will receive three oral doses of 800 mg cefixime (q 8 hours) on Day 1, followed by three oral doses of 800 mg cefixime (q 8 hours)+ one oral dose of 1000 mg azithromycin (with first dose of cefixime) on day 10
11298623|NCT02708979|Active Comparator|University Exam Period|This visit takes place the week before an exam at the university assuming that this will induce a stress response. Measurements (see description elsewhere) are being taken within 1-2 weeks prior to an university exam.
11298624|NCT02708979|Placebo Comparator|University Non-exam Period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period. Measurements (see description elsewhere) are being taken in a control-period without exams (at least 4 weeks after and 4 weeks prior to an exam)
11298625|NCT02708966|Experimental|Gymnema Sylvestre|Patients with IGT
11298626|NCT02708966|Placebo Comparator|Placebo|Patients with IGT
11298627|NCT02708953|Experimental|Treatment (thoracic manipulation)|Patients in the initial manipulation group will attend physical therapy two sessions per week for 3 weeks for a total of 6 sessions. Each treatment session will last for a total of 15 minutes. After the initial manipulation group receives 3 weeks of treatment they will wait for 1-week, be retested, and then crossover into the other group.
11298628|NCT02708953|Active Comparator|Wait-list (thoracic manipulation)|When individuals are assigned to the wait-list control group they will serve as the control for 3 weeks while the initial manipulation group receives treatment. After serving as the wait-list control condition for 3 weeks, this group will then return for testing and will receive the manipulation package as described below at 4 weeks.
11298629|NCT02708940|Active Comparator|Usual care|Control arm - these patients will get usual care as part of the PHP and IOP programs at UCLA. They will not receive mobile support messages.
11298630|NCT02708940|Active Comparator|Participatory technology development|Intervention - Patients will have access to a website that allows them to co-create mobile support messages with their therapist to support their care as part of the PHP and IOP programs at UCLA.
11298631|NCT02708927|Experimental|patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
11298632|NCT02708927|Experimental|Control|healthy subject
11298633|NCT02708914|Other|UB-851|
11298634|NCT02708914|Other|Eprex then UB-851|
11298637|NCT02708901|Active Comparator|NGI Vivomixx®|25 children without GI symptoms
11298638|NCT02708901|Placebo Comparator|NGI placebo|25 children without GI symptoms
11298639|NCT02708888|Experimental|Trunk training|Exercises: Core stability training
11298640|NCT02708888|Sham Comparator|Cognitive exercises|Exercises: The RevArte Visual Search Test (RVST) of Lafosse et al (2013) and the Visuospatial Neglect Test Battery (VNTB) of Vaes et al. (2015)
11298641|NCT02708875|Experimental|Mixed Meal Challenge|Participants will consume a liquid mixed meal (~300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
11298642|NCT02708875|Active Comparator|Glucose Challenge|Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
11298643|NCT02708862|Experimental|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
11298644|NCT02708849|Experimental|Ketamine plus lamotrigine|
11298645|NCT02708849|Placebo Comparator|ketamine plus placebo|
11298646|NCT02708836|Active Comparator|ETT only|Endotracheal tube intubation after induction of anesthesia. Ventilation with ETT until emergence.
11298647|NCT02708836|Experimental|Combined ETT/LMA technique|Placement of LMA after induction of anesthesia. Intubation of trachea with ETT via LMA with fiberoptic bronchoscope. Ventilation with ETT throughout case. Removal of ETT while deeply anesthetized. Ventilation with LMA until emergence.
11298648|NCT02708810|Other|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
11298649|NCT02708797|Other|Migraine with aura Patients|Patients with migraine with aura will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
11298650|NCT02708797|Other|Controls|Control group with healthy volunteers will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
11298651|NCT02708784||Pompe disease|Patients will perform muscle strength measurement with dynamometer and MR-imaging. After 8 months the investigations will be repeated.
11298652|NCT02708784||Myotonic Dystrophy|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
11298653|NCT02708784||Healthy controls|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
11298654|NCT02708771|Experimental|Intervention|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
11298655|NCT02708771|Placebo Comparator|Control|Capsules of similar appearance and flavor without active drug
11298656|NCT02708758|Active Comparator|Treatment group|Medical nutrition therapy plus self monitoring capillary glucose levels and if necessary drug therapy (metformin or insulin) when goals are not met.
11298657|NCT02708758|No Intervention|Routine care group|Prenatal routine care without medical nutrition therapy and without self monitoring capillary glucose levels and drug therapy specific for GDM.
11298658|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
11298659|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
11298660|NCT02708732||DLBCL Participants|A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
11298661|NCT02708719|Other|Pulmonary rehabilitation|multimodal pulmonary Rehabilitation program (3 weeks Duration)
11298662|NCT02708706|Experimental|physical therapy and hyaluronic acid|patient received ultrasound-guided steroid injection via rotator interval
11298663|NCT02708706|Active Comparator|physical therapy only|patient received ultrasound-guided steroid injection via posterior recess
11298664|NCT02708693|Experimental|experimental: steroid injection and splinting|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine) and a customized volar thermoplastic wrist splint
11298665|NCT02708693|Active Comparator|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
11298666|NCT02708680|Active Comparator|Entinostat plus Atezolizumab|Patients in this arm will receive entinostat at the RP2D in combination with atezolizumab
11298667|NCT02708680|Placebo Comparator|Placebo plus Atezolizumab|Patients in this arm will receive placebo in combination with atezolizumab
11298668|NCT02708654|Experimental|Intervention|Participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.(5) Research coordinators to remotely monitor weight gain thresholds and add alert into the participant's electronic health record for verified weight gain
11298669|NCT02708654|No Intervention|Control|Participants will receive usual care.
11298670|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
11298671|NCT02708628|Active Comparator|Patients using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin two times in a day.
11298672|NCT02708628|Active Comparator|Patients not using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will not use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin.
11298673|NCT02708615|Other|Vertical rotation|Vertical insertion and 90 degree rotation of speculum in vagina
11323395|NCT02544828|Placebo Comparator|Control Group|placebo
11298674|NCT02708615|Other|Straight horizontal insertion|Straight horizontal insertion of speculum with no rotation in vagina
11298675|NCT02708602||β2AR Arg16Arg (AA group)|People with β2AR Arg16Arg genotype.
11298676|NCT02708602||β2AR Arg16Gly (AG group)|People with β2AR Arg16Gly genotype.
11298677|NCT02708602||β2AR Gly16Gly (GG group)|People with β2AR Gly16Gly genotype.
11298678|NCT02708602||β2AR Gln27Gln (CC group)|People with β2AR Gln16Gln genotype.
11298679|NCT02708602||β2AR Gln27Glu (CG group)|People with β2AR Gln27Glu genotype.
11298680|NCT02708602||β2AR Glu27Glu (GG group)|People with β2AR Glu27Glu genotype.
11298681|NCT02708589|Active Comparator|probiotic|the probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic (fructooligosaccharide).
11298682|NCT02708589|Placebo Comparator|Placebo|Placebo capsules have identical appearance to probiotic capsules and contain Maltodextrin.
11298683|NCT02708576|Experimental|NGM313|Administration of active NGM313
11298684|NCT02708576|Placebo Comparator|Placebo|Administration of placebo comparator
11298685|NCT02708563|Experimental|Immediate intubation|These infants will have immediate endotracheal suctioning after delivery. They will then have resuscitation per Neonatal Resuscitation Program guidelines.
11298686|NCT02708563|Experimental|Immediate resuscitation|These infants will have immediate resuscitation per the Neonatal Resuscitation Program guidelines without endotracheal suctioning.
11298687|NCT02708550|Experimental|Participatory Organizational Intervention|Participatory intervention (workshops) with workers, consultants and leaders. The workshops will find solutions for increased use of assistive devices
11298688|NCT02708550|No Intervention|Control|This group will go through the same baseline and follow-up tests as the intervention group, but will not receive any intervention.
11298689|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
11298690|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
11298691|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
11298692|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
11298693|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
11298694|NCT02708511|Experimental|Diagnostic (Cu 64 DOTA-B-Fab)|Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT 60 minutes post-injection and 24 hours post-injection
11298695|NCT02708498|Experimental|Kronoberg Educational Intervention|The educational intervention is provided to ten nursing homes.
11298696|NCT02708498|No Intervention|Skåne Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
11298697|NCT02708498|Experimental|Skåne Educational Intervention|The educational intervention is provided to ten nursing homes.
11298698|NCT02708498|No Intervention|Kronoberg Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
11298699|NCT02708485|No Intervention|Control group|No intervention
11298700|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
11298701|NCT02708472|Experimental|Open-label|"Subjects who qualify will receive daily active synchronized Transcranial Magnetic Stimulation (sTMS) treatments. Treatment will be initiated on Day 1 of the study. Subjects will come to the clinic for 5 daily treatment sessions for a total of 4 treatment weeks (20 treatment sessions). Treatment will be discontinued at the end of Week 4. Subjects will be clinically evaluated for safety and efficacy at the end of each of the four weekly treatment courses.
~At the end of Week 4, subjects who have not met the endpoint of 50% reduction in Hamilton Anxiety Rating Scale (HAM-A) score will be eligible to be considered for 2 additional weeks of daily treatment in an extended phase (for a total of 30 treatment sessions)."
11298702|NCT02708459|Active Comparator|Control|Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
11298703|NCT02708459|Active Comparator|Bupevecaine group|Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
11298704|NCT02708459|Active Comparator|Dex group|catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
11298705|NCT02708446|Active Comparator|Sublingual misoprostol|200mg mifepristone + 400mcg sublingual misoprostol q3h
11298706|NCT02708446|Active Comparator|Buccal misoprostol|200mg mifepristone + 400mcg buccal misoprostol q3h
11298707|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.
~In week two the alternate anesthetic would be administered.
~Mandibular molar and canine tested for pulpal anesthesia"
11298708|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.
~Mandibular molar and canine tested for pulpal anesthesia"
11298709|NCT02708420|Other|Glidescope intubation|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
11298710|NCT02708420|Other|Macintosh Laryngoscope|This standard technique involves laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
11298812|NCT02707692|Other|Arm 4: Pneumovax, Placebo, Flu|Arm 4: Pneumovax, Placebo, Flu
11298711|NCT02708407|Experimental|Peritoneal Dialysis Group|These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
11298712|NCT02708407|No Intervention|Control Group|These participants will continue to receive standard HF care.
11298713|NCT02708394|Experimental|olanzapine|Atypical antipsychotic
11298714|NCT02708394|Placebo Comparator|placebo|Placebo comparator
11298715|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
11298716|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
11298717|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
11298718|NCT02708355|Experimental|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
11298719|NCT02708355|Experimental|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
11298720|NCT02708355|Placebo Comparator|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
11298721|NCT02708329|Active Comparator|CTO coronary angioplasty +T-provisional stenting|Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.
11298722|NCT02708329|Experimental|CTO coronary angioplasty + Mini-crush stenting|Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.
11298723|NCT02708316||schizophrenia group|schizophrenia patients in the group
11298724|NCT02708316||control group|healthy population
11298725|NCT02708303||Foregut Surgery|Foregut surgery includes conditions of the esophagus, stomach and proximal small intestine. More specifically foregut surgery includes surgery for gastroesophageal reflux disease, hiatal hernias, and paraesophageal hernias.
11298726|NCT02708290||Test arm|The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
11298727|NCT02708290||Control arm|The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.
11298728|NCT02708277|Experimental|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
11298729|NCT02708277|Experimental|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
11298730|NCT02708264|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
11298731|NCT02708264|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
11298732|NCT02708251|Experimental|glyceryl trinitrate cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
11298733|NCT02708251|Experimental|lidocaine cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
11298734|NCT02708251|Placebo Comparator|placebo cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
11298735|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
11298736|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
11298737|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
11298738|NCT02708225|Experimental|interventional - with a medical clown|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test with a medical clown present
11298739|NCT02708225|No Intervention|non interventional|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test without a medical clown present
11298740|NCT02708212|Active Comparator|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
11298741|NCT02708212|Active Comparator|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
11298742|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
11298743|NCT02708186|Placebo Comparator|Placebo|Placebo
11298744|NCT02708173|Experimental|One dose Vaccine in aged 18-60 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.
11298745|NCT02708173|Experimental|One dose Vaccine in aged 3-17 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.
11298746|NCT02708160|Placebo Comparator|Fluoride Free toothpaste|Fluoride free (0%), silica based toothpaste
11298747|NCT02708160|Experimental|1.1% Fluoride toothpaste|Prevident 5000 Plus, silica based toothpaste
11298748|NCT02708160|Active Comparator|0.243% Fluoride Toothpaste|silica based fluoride toothpaste
11298749|NCT02708147|Sham Comparator|Conventional treatment|"Conventional treatment means that there will be only contact with physician/paediatrician and maybe drugs prescription.
~Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after."
11298750|NCT02708147|Experimental|Physiotheraphy + Conventional treatment|Apart Conventional treatment a Physiotherapy protocol (techniques and education) will be performed on 5 sessions and evaluations will be made after each session as well as on baseline and on the 3th, 5th and 21st days and an interview 30 days after.
11298751|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
11298752|NCT02708121|Experimental|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
11298753|NCT02708121|Active Comparator|Comparator Arm|Participant receives access to weight loss treatment alone.
11298754|NCT02708108|Experimental|Obesity Intervention|Personalized 28-day Dietary Intervention and Activity and Exercise Intervention with the goal to reduce fat gain and lean muscle loss while inducing an overall negative energy balance.
11298755|NCT02708095|Experimental|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
11298756|NCT02708095|Experimental|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
11298757|NCT02708095|Placebo Comparator|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
11298758|NCT02708082||Glaucoma|Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry
11298759|NCT02708069|Other|e-Unstuck condition|Parents in the e-Unstuck condition will be asked to complete each of the e-Unstuck modules (one per week) over the course of the nine-week intervention, in addition to reading the UOT manual.
11298760|NCT02708069|Other|In-Person condition|Parents participating in the in-person condition will be asked to attend two in-person trainings (approximately 125 and 100 minutes respectively) on the Unstuck and On Target (UOT) curriculum, in addition to reading the UOT manual.
11298761|NCT02708056|Other|Sugammadex, Bridion|Drug were given intravenously by a anesthesiologist at the end of surgery
11298762|NCT02708043|Other|F-LMA group|LMA were placed to 814 patients for adenoidectomy surgery. Researchers evaluated flexible laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.
11298763|NCT02708030|Active Comparator|Ketogenic Diet|Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
11298764|NCT02708030|Experimental|Modified Atkins Diet|Modified Atkins Diet (MAD) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
11298765|NCT02708030|Experimental|Low Glycemic Index Therapy|Low Glycemic Index Therapy (LGIT) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
11298766|NCT02708017|Active Comparator|S-TAP block|ultrasound guided bilateral subcostal TAP block
11298767|NCT02708017|Active Comparator|P-TAP block|ultrasound guided bilateral Posterior TAP block
11298768|NCT02708004|Experimental|ACT-132577|3 different dose levels
11298769|NCT02708004|Placebo Comparator|Placebo|Matching active drug
11298770|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
11298771|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
11298772|NCT02707978|Experimental|Experimental F 18 T807|
11298773|NCT02707965|Active Comparator|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
11298774|NCT02707965|Active Comparator|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
11298775|NCT02707952|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
11298776|NCT02707952|Active Comparator|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
11298777|NCT02707952|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
11298778|NCT02707952|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
11298779|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
11298781|NCT02707913|Experimental|BF-Amlodipine Tablet 10mg|During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours
11298782|NCT02707913|Active Comparator|Norvasc Tablet 10mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours
11298783|NCT02707900|Experimental|Vorinostat + AGS-004|"Vorinostat (VOR) 400 mg PO - two paired doses at Step 2 (Enrollment) - Only participants demonstrating an in vivo response to the 2nd of the paired VOR doses will proceed to the AGS-004 manufacturing and treatment in Steps 3 through 7.
~Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal (ID) injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses."
11298784|NCT02707887|Placebo Comparator|Treatment as Usual|Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.
11298785|NCT02707887|Active Comparator|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.
11298786|NCT02707887|Active Comparator|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
11298787|NCT02707874|Active Comparator|CI 0.2% ropivacaine|"Patients in Group Continuous Infusion (CI) will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.
~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.
~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.
~3) Oral acetaminophen 1,000 mg 6 hourly."
11298788|NCT02707874|Active Comparator|PIB 0.2% ropivacaine|"Patients in Group programmed intermittent boluses (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.
~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.
~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.
~3) Oral acetaminophen 1,000 mg 6 hourly."
11298789|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):
~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial
~OR
~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial
~Administered for 48 weeks, or until ibalizumab becomes commercially available"
11298790|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):
~800 mg once every two weeks for qualifying patients who have never received ibalizumab
~Administered for 48 weeks, or until ibalizumab becomes commercially available"
11298791|NCT02707835|Active Comparator|control group|self massage, skin care education, manual lymph drainage exercise, compression garment
11298792|NCT02707835|Active Comparator|manual lymph drainage group|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
11298793|NCT02707835|Experimental|experimental group|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
11298794|NCT02707822||kidney or liver transplantation|Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.
11298795|NCT02707809|No Intervention|Control|Routine anesthesia care for kidney transplant
11298796|NCT02707809|Experimental|Dexmedetomidine|Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine
11298797|NCT02707796|Experimental|Hemicolectomy|Oxygen reserve index and partial oxygen pressure will be noted for patients undergoing hemicolectomy
11298798|NCT02707783||Bioresorbable vascular scaffold (BVS) implantation|Patients with un/stable angina that require coronary revascularization undergoing the BVS implantation
11298799|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
11298800|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
11298801|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
11298802|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
11298803|NCT02707744||sinus rhythm|patients with heart failure and sinus rhythm
11298804|NCT02707744||atrial fibrillation|patients with heart failure and atrial fibrillation
11298805|NCT02707731|Experimental|Hydrokinesiotherapy in preterm|Salivary cortisol samples, pain applying the Neonatal Infant Pain Scale Scale, heart rate, respiratory rate and oxygen saturation were collected before and after hydrokinesiotherapy
11298806|NCT02707705|Experimental|: Auricular Acupuncture (needle patch) group A|Needle patch: Patients receiving the auricular acupuncture protocol with needles inserted on adhesive tape.
11298807|NCT02707705|Placebo Comparator|Needle-free patch: group P.|Patients who received the auricular acupuncture protocol with adhesive tape without needles.
11298808|NCT02707705|No Intervention|No intervention: group C|Patients without any device or intervention.
11298809|NCT02707692|Other|Placebo, Flu, Pneumovax|"Each subject will take Influenza (Fluarix®, GSK), Pneumococcal (Pneumovax®23, Merck), and placebo. Randomization will determine the order in which the subjects receive the injections. There are six potential study arms, one for each order in which someone could receive the injections:
~Arm 1: Placebo, Flu, Pneumovax"
11298810|NCT02707692|Other|Arm 2: Placebo, Pneumovax, Flu|Arm 2: Placebo, Pneumovax, Flu
11298811|NCT02707692|Other|Arm 3: Flu, Placebo, Pneumovax|Arm 3: Flu, Placebo, Pneumovax
11324397|NCT02538367|Experimental|YH12852 DR1 4mg|Once daily
11298813|NCT02707692|Other|Arm 5: Pneumovax, Flu, Placebo|Arm 5: Pneumovax, Flu, Placebo
11298814|NCT02707692|Other|Arm 6: Flu, Pneumovax, Placebo|Arm 6: Flu, Pneumovax, Placebo
11298815|NCT02707679|Other|Effects of Mulligan's Mobilization|The patients in this arm (n=18) received two techniques pertaining to Mulligan's Mobilization with movement approach (Mulligan's Straight Leg-Raise with Traction and Tibial Gliding) along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed before the treatment, 45 minutes after the initial treatment, at the end of the 4-session-treatment during 2-week period and 6 weeks later.
11298816|NCT02707679|Other|Effects of Kinesiotaping|Patients in this arm were applied kinesiotaping on quadriceps and hamstring muscle along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. The same assessment parameters was conducted on this arm too.
11298817|NCT02707666|Experimental|Pembrolizumab+Surgery+Chemotherapy|Neoadjuvant pembrolizumab, followed by surgery, followed by adjuvant pemetrexed and cisplatin
11298818|NCT02707653|Other|Miso|Misoprostol 400 s/l
11298819|NCT02707640|Placebo Comparator|Matching Placebo|
11298820|NCT02707640|Experimental|N-Acetylcysteine|
11298821|NCT02707640|Other|Pirfenidone|Background therapy
11298822|NCT02707627||Laser Therapy|Participants will receive laser therapy for the treatment of their hypertrophic burn scars. Laser treatment decisions will be tailored to meet the needs of the patient.
11298823|NCT02707614||Robotic vs open prostastectomy|One group is operated by open prostatectomy the other by robotic assistance
11298824|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.
~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
11298825|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.
~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
11298826|NCT02707588|Experimental|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
11298827|NCT02707588|Active Comparator|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
11298828|NCT02707575|Experimental|Ranibizumab|Intravitreal Ranibizumab
11298829|NCT02707562|Experimental|GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
11298830|NCT02707549|Active Comparator|Normal Saline Group|the patients included in this group will receive normal saline solution (0.9% sodium chloride) during surgery and in the first 24 hours after ICU admission.
11298831|NCT02707549|Experimental|Balanced Crystalloid Solution Group|the patients included in this group will receive balanced crystalloid solution during surgery and in the first 24 hours after ICU admission.
11298832|NCT02707536|No Intervention|No socket grafting|Extraction with normal socket healing
11298833|NCT02707536|Active Comparator|Socket grafting with platelet rich fibrin (PRF) alone|Extraction with socket grafting with platelet rich fibrin (PRF) alone.
11298834|NCT02707536|Active Comparator|Socket grafting with bone grafting alone|Extraction with socket grafting using bone graft (xenograft).
11298835|NCT02707536|Active Comparator|Socket grafting with PRF and bone grafting|Extraction with socket grafting using PRF combined with bone graft (xenograft).
11298836|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
11298837|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
11298838|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
11298839|NCT02707510|Experimental|Intervention Arm|Patients in the intervention group will be provided with all programmatic materials (including copies of power point presentations, copies of reading texts, and audio CDs) and classes will be held in group format, with a maximum of 9 participants per group. Classes will meet weekly, in a group, and at a set time. All classes will be facilitated jointly by the two Co-PIs. All participants will complete surveys before class, during class, at the end of class, 1 month after the end of class, 6 months after the end of class and 1 year after the end of the class. Additionally, those randomized to the intervention group will be asked to attend a 1 time focus group 1 week after the end of the class.
11298840|NCT02707510|No Intervention|Control Arm|Patients in the control group will be asked to complete surveys at: baseline, 6 weeks after baseline (T1), and 1 month after T1. After T1, the control group will off study and will be permitted to attend the next available GRACE course.
11298841|NCT02707497|Experimental|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
11298842|NCT02707497|Placebo Comparator|placebo|The control group will not use any platelet-increased drugs.
11298843|NCT02707484|Experimental|Thalidomide Group（100mg）|
11298844|NCT02707484|Experimental|Thalidomide Group（50mg）|
11298845|NCT02707484|Placebo Comparator|placebo -controlled Group|
11298846|NCT02707471|Experimental|SM-AET|a self-management intervention for enhancing skills to improve adherence and reduce symptom interference (SM-AET) (active intervention group)
11298847|NCT02707471|Other|general health education Intervention|general health education Intervention (control group)
11298876|NCT02707237|Other|Verbal, pictorial, written counseling|Parents with threatened delivery will receive verbal counseling supplemented with pictorial and written information
11298877|NCT02707224|Experimental|Group A|combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
11298878|NCT02707224|Experimental|Group B|DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
11298879|NCT02707211|Experimental|Anti-oxLDL IgM antibodies|administration Anti-oxLDL IgM antibodies
11298848|NCT02707458|Experimental|Single arm|All subjects will receive probucol, starting with a fixed dose of 600 mg daily following the evening meal. The variable plasma concentrations achieved and the resulting modification in concentration of CSF apoE will suggest an ideal range of plasma concentrations for use of the drug as an inducer of increased availability of apoE in the CSF. The known dose-proportionality of the drug in plasma will then be used to estimate an ideal individualized dose for each participant. The effects of such individualized dosage will be tested over 1 year of follow-up observations, searching for treatment effects on CSF apoE and for evidence of other treatment effects, particularly including adverse effects.
11298849|NCT02707445|Experimental|GENIUS|All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months
11298850|NCT02707432|Experimental|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
11298851|NCT02707432|Experimental|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
11298852|NCT02707419|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
11298853|NCT02707419|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
11298854|NCT02707406|Experimental|NEOX®CORD 1K|Intervention Other: hct/p human cell or tissue product: NEOX®CORD 1K Intervention other: human tissue application of of NEOX®CORD 1K on subject wound
11298855|NCT02707406|Active Comparator|Standard of Care|Intervention Other: standard of care alone Other intervention of Standard dressing with a non-adherent wound contact layer, a classic foam pad or gauze for moderately draining wounds, a secondary bandage, and institution of an investigator-approved off-loading device
11298856|NCT02707393|Experimental|single arm|Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A
11298857|NCT02707380|Active Comparator|Group 1 Resistance Training Group|Participants will perform 3 exercises, one of which will be a series of 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
11298858|NCT02707380|Active Comparator|Group 2 Standard of Care|Participants will perform 3 exercises that do not include the 7 muscle-strengthening exercises + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
11298859|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 1|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include two pre-tests and two post-tests, building in an observation period that is not present in Wave 2.
11298860|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 2|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include one pre-test and three post-tests.
11298861|NCT02707354|Experimental|Probe based confocal laser endomicroscopy (Cellvizio)|intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console.
11298862|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
11298863|NCT02707328|Experimental|A|"Chemotherapy:
~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle
~Radiation:
~20-55 GY over 5 fractions
~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy."
11298864|NCT02707315|Experimental|A|"Chemotherapy:
~Gemcitabine 1000 mg/m2 weekly x 3 on 28 day cycle
~Radiation:
~25 Gy over 5 fractions
~Surgery:
~surgical resection of pancreas
~treatment plan:
~1 cycle of chemotherapy, followed by stereotactic radiosurgery, followed by an additional 6 cycles of chemotherapy or surgical resection"
11298865|NCT02707302|Experimental|Iodophor-impregnated adhesive drapes|"In the iodophor-impregnated adhesive drapes group, routine disinfection will be carried out and bacteria samples will be harvested 1 cm from the wound site using sterilized swabs prior to use of the surgical adhesive drapes, and again at the end of surgery before skin suturing, for preoperative bacterial culture. The packaging of the 3M™ iodophor-impregnated adhesive drapes will be opened and the aseptic adhesive drapes unfolded until the stop instruction. The adhesive drapes will then be pasted to the surgical wound and smoothed using an aseptic cloth, taking care to avoid air bubbles."
11298866|NCT02707302|Experimental|Iodophor-free adhesive drapes|Patients in the iodophor-free adhesive drapes group will undergo the same procedures, but with iodophor-free drapes.
11298867|NCT02707276|Experimental|Active LFMS|Active Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
11298868|NCT02707276|Sham Comparator|Sham LFMS|Sham Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
11298869|NCT02707263|Active Comparator|Intravenous continuous infusion of heparin (IV UFH)|Heparin will be administered intravenously.
11298870|NCT02707263|Active Comparator|Subcutaneous heparin|Heparin will be subcutaneously administered.
11298871|NCT02707250|Placebo Comparator|Placebo|Oblique subcostal tap block with normal sterile saline ,20 ml, bilateral, single shot,24h
11298872|NCT02707250|Active Comparator|Bupivacaine|Oblique subcostal tap block with bupivacaine 0,25% ,20 ml, bilateral, single shot,24h
11298873|NCT02707250|Active Comparator|Pethidine|Oblique subcostal tap block with pethidine 1% ,10 ml,bilateral,single shot,24h
11298874|NCT02707250|Active Comparator|Pethidine Local Infiltration (L.I.)|Local infiltration of pethidine 1% at trocar insertion sites, 5ml /site, 24h compared with Tap Block with pethidine 1%
11298875|NCT02707237|Other|Verbal counseling|Parents with threatened delivery will receive verbal counseling only
11299029|NCT02706314||Healthy volunteers|Healthy volunteers with neither critical illness nor CIP
11298880|NCT02707198|No Intervention|Group A|Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
11298881|NCT02707198|Active Comparator|Group B|Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
11298882|NCT02707198|Active Comparator|Group C|Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
11298883|NCT02707185|Other|Physicians|"Physician in training:
~All internal medicine (IM), emergency medicine (EM), anesthesia (A), surgery (S) residents and all hospital ICU nurses."
11298884|NCT02707185|Other|Nurses|Nurses in Training
11298885|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.
~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
11298886|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.
~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
11298887|NCT02707159|Experimental|Nab paclitaxel / gemcitabine|Patients will receive 125 mg per m2 nab-paclitaxel and 1000 mg per m2 on days 1, 8 and 15 followed by one week of rest before new treatment cycle.
11298888|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
11298889|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
11298890|NCT02707120|Experimental|PRGF-Endoret eye-drops|
11298891|NCT02707120|Active Comparator|Artificial tears eye-drops|
11298892|NCT02707107|Active Comparator|3 g of zidebactam (1 g q8h) and 6 g of cefepime (2 g q8h) or 6|administered as IV infusions every q8h, over a period of 60 minutes.
11298893|NCT02707107|Placebo Comparator|Placebo|administered as IV infusions every q8h, over a period of 60 minutes.
11298894|NCT02707094|Other|Usual Care (Medication + Exercise)|Usual Care: Participants will receive guidance on over-the-counter and prescribed pain medications to use to treat their chronic low back pain symptoms. The Research Coordinator (RC) will provide instructions for low back pain stretching and strengthening exercises. The Licensed Provider (LP) will determine if any exercises should be excluded based on their physical limitations. Participants enrolled in the usual care treatment arm will track the frequency of their back stretching and strengthening exercise sessions on the Pain Medication & Exercise Diary. For the purpose of this study, treatment compliance will be met if participants complete the exercises a minimum of three times per week.
11298895|NCT02707094|Experimental|Biomodulator + Usual Care|Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).
11298896|NCT02707081|Placebo Comparator|Placebo control group|Saline was given both intraperitoneally and intravenously during caesarean section
11298897|NCT02707081|Active Comparator|Intraperitoneal instillation group|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.
11298898|NCT02707081|Active Comparator|Intravenous injection group|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding
11298899|NCT02707068|Experimental|QOLITI|"Intervention group receives the QOLITI (Quality Of LIfe Tool for IBD) manual immediately to work with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.
~Participants will be invited to discuss their experiences after the end of the actual study. These interviews are no obligatory part of the QOLITI study."
11298900|NCT02707068|No Intervention|Waitlist Control group (WLC)|Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions.
11298901|NCT02707055|Experimental|Active Drug|Ghrelin Receptor Inverse Agonist
11298902|NCT02707055|Other|Counseling Support|Counseling support
11298903|NCT02707055|Other|MI-VF|Motivational Interviewing with Video Feedback
11298904|NCT02707055|Placebo Comparator|Placebo|Placebo
11298905|NCT02707042|Other|Group A|Control
11298906|NCT02707042|Other|Group B|Amoxicillin
11298907|NCT02707042|Other|Group C|
11298908|NCT02707029||Persons, with or without pain disorders|Adults and adolescents with or without pain disorders.
11298909|NCT02707016|Other|High dose sevoflurane|"Inhaled sevoflurane 8% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).
~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.
~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
11298940|NCT02706873|Active Comparator|Placebo Upadacitinib and Methotrexate|"Period 1: Participants will receive Upadacitinib placebo once daily and methotrexate once weekly for 48 weeks.
~Period 2: Participants will continue on Upadacitinib placebo once daily and methotrexate once weekly followed by methotrexate alone once weekly."
11300756|NCT02694380||Prostate|Subjects with prostate cancer receiving radiation therapy.
11298910|NCT02707016|Other|Low dose sevoflurane|"Inhaled sevoflurane 5% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).
~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.
~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
11298911|NCT02707003||AZ PACU|Observation of standard of care with capnography blinded
11298912|NCT02707003||TWH PACU|Observation of standard of care with capnography blinded
11298913|NCT02706990|Other|Physica KR|Patients who have received a Physica KR total knee implant.
11298914|NCT02706990|Other|Physica PS|Patients who have received a Physica PS total knee implant.
11298915|NCT02706977|Experimental|Diabetes Group - Low Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
11298916|NCT02706977|Experimental|Diabetes Group - High Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
11298917|NCT02706977|Other|Diabetes Group - No Electroretinogram (ERG) Delays|Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
11298918|NCT02706977|Other|Age-Matched Controls|Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.
11298919|NCT02706964|Experimental|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
11298920|NCT02706951|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive Upadacitnib 30 mg once daily and Methotrexate once weekly for 14 weeks.
~Period 2: Participants receive Upadacitinib 30 mg once daily until participants begin to receive 15 mg once daily."
11298921|NCT02706951|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive Upadacitnib 15 mg once daily and methotrexate once weekly for 14 weeks.
~Period 2: Participants receive Upadacitinib 15 mg once daily."
11298922|NCT02706951|Experimental|Methotrexate followed by Upadacitinib 30 mg|"Period 1: Participants receive Methotrexate once weekly and Upadacitinib Placebo once daily for 14 weeks.
~Period 2: Participants receive Upadacitinib 30 mg once daily until participants begin to receive 15 mg once daily."
11298923|NCT02706951|Experimental|Methotrexate followed by Upadacitinib 15 mg|"Period 1: Participants receive Methotrexate once weekly and Upadacitinib Placebo for 14 weeks.
~Period 2: Participants receive Upadacitinib 15 mg once daily."
11298924|NCT02706938|Other|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
11298925|NCT02706938|Other|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
11298926|NCT02706925|Experimental|BI 443651|
11298927|NCT02706925|Placebo Comparator|Placebo|
11298928|NCT02706912|Experimental|VOTA Group|All enrolled subjects are in this arm. After pre-assessment subjects have an 8-week waiting period, after which a mid-assessment takes place. Subject then participate in VOTA therapy for 8 weeks, followed by a post-assessment . The pre-/mid-assessment difference is used to control for spontaneous recovery. The mid-/post-assessment difference is used to ascertain efficacy.
11298929|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
11298930|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
11298931|NCT02706886|Placebo Comparator|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
11298932|NCT02706886|Experimental|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
11298933|NCT02706886|Experimental|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
11298934|NCT02706886|Experimental|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
11298935|NCT02706886|Experimental|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
11298936|NCT02706886|Placebo Comparator|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
11298937|NCT02706886|Experimental|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
11298938|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
11298939|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
11298941|NCT02706873|Experimental|Upadacitinib 7.5 mg and Placebo Methotrexate (Japan-only)|"Period 1: Participants will receive Upadacitinib 7.5 mg once daily and methotrexate placebo once weekly for 48 weeks.
~Period 2: Participants will continue on Upadacitinib 7.5 mg once daily and methotrexate placebo once weekly followed by Upadacitinib 7.5 mg once daily without methotrexate placebo once the treatment assignment is unblinded to sites and participants."
11298942|NCT02706873|Experimental|Upadacitinib 15 mg and Placebo Methotrexate|"Period 1: Participants will receive Upadacitinib 15 mg once daily and methotrexate placebo once weekly for 48 weeks.
~Period 2: Participants will continue on Upadacitinib 15 mg once daily and methotrexate placebo once weekly followed by Upadacitinib 15 mg once daily without methotrexate placebo once the treatment assignment is unblinded to sites and participants."
11298943|NCT02706873|Experimental|Upadacitinib 30 mg and Placebo Methotrexate|"Period 1: Participants will receive Upadacitinib 30 mg once daily and methotrexate placebo once weekly for 48 weeks.
~Period 2: Participants will continue on Upadacitinib 30 mg once daily and methotrexate placebo once weekly until participants begin to receive Upadacitinib 15 mg once daily without methotrexate placebo once the treatment assignment is unblinded to sites and participants."
11298944|NCT02706860|Experimental|"80 mg atorvastatin for 2 days regimen"|80 mg atorvastatin/ day for 2 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
11298945|NCT02706860|Experimental|"40 mg atorvastatin for 5-9 days preoperative regime"|40 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
11298946|NCT02706860|Experimental|"80 mg atorvastatin for 5-9 days preoperative regime"|80 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
11298947|NCT02706847|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive Upadacitinib 15 mg once daily for 24 weeks.
~Period 2: Participants will continue on Upadacitinib 15 mg once daily."
11298948|NCT02706847|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive Upadacitinib 30 mg once daily for 24 weeks.
~Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
11298949|NCT02706847|Experimental|Placebo and Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by Upadacitinib 15 mg once daily for 12 weeks.
~Period 2: Participants will continue on Upadacitnib 15 mg once daily."
11298950|NCT02706847|Experimental|Placebo and Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by Upadacitinib 30 mg once daily for 12 weeks.
~Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
11298951|NCT02706834|Experimental|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11298952|NCT02706834|Experimental|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11298953|NCT02706834|Experimental|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11298954|NCT02706834|Experimental|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11298955|NCT02706834|Experimental|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11298956|NCT02706834|Experimental|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11298957|NCT02706834|Experimental|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
11299028|NCT02706314||Critically ill patients without CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 without CIP
11298958|NCT02706834|Experimental|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
11298959|NCT02706834|Experimental|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
11298960|NCT02706834|Experimental|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
11298961|NCT02706834|Experimental|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
11298962|NCT02706821|Active Comparator|Treatment sequence 1|PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
11298963|NCT02706821|Active Comparator|Treatment sequence 2|Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
11298964|NCT02706808|Experimental|resistance starch for CKD|- Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
11298965|NCT02706808|Experimental|cross-over period|intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
11298966|NCT02706795|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
11298967|NCT02706782|Experimental|TAI-meso-CART|A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions. The dose is 1-10x106/kg meso-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. Patients will undergo cannula--DSA radiography--CAR-T cells perfusion. The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
11298968|NCT02706769|Active Comparator|Paracetamol|Participants will take blinded Paracetamol (as they were taking before entering the study)
11298969|NCT02706769|Placebo Comparator|Placebo|Participants will take blinded Paracetamol
11298970|NCT02706756|Experimental|Education, exercise and manual therapy|"One group will receive education and advice, manual therapy that is applied toward the impairments of the subject, a prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Subjects will be seen twice weekly for 4 to 6 weeks, depending on the progression.
~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
11298971|NCT02706756|Active Comparator|Education and exercise|"Group will receive a prescriptive intervention designed to strengthen the hip and surrounding regions as well as improve flexibility of the lower extremity. This group will not receive additional physiotherapy management but will be schedule bi-weekly to review the home exercises and to receive appropriate educational support.
~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
11298972|NCT02706756|Placebo Comparator|Supervised neglect|"Group will receive supervised neglect. We will monitor this group for changes or emergent situations but no formal care will be provided.
~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
11298973|NCT02706730|Experimental|OTO-104|12 mg dexamethasone
11298974|NCT02706717|Active Comparator|Visbiome Extra Strength|
11298975|NCT02706717|Placebo Comparator|Placebo for Visbiome Extra Strength|
11298976|NCT02706704|Active Comparator|Intravitreal|Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
11298977|NCT02706704|Active Comparator|Systemic|Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
11298978|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
11298979|NCT02706678|Experimental|Tacrolimus sustained-release capsule group|Oral
11298980|NCT02706652||all patients|all eligible patients
11298981|NCT02706639||SVAS group|Children or adults must:be between the ages of 0-85;have clinical features of SVAS;SVAS- like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
11298982|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85 have a presumed or confirmed diagnosis of WS; and have a parent/guardian available to provide consent and assist in answering medical questions
11298983|NCT02706626|Experimental|Brigatinib|Experimental: Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent
11298999|NCT02706535|Experimental|Part 1 Cohort 2|Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
11298984|NCT02706613|Other|Face to Face Pulmonary Rehabilitaton|6 week incremental pulmonary rehabilitation (PR) programme. Participants will attend 12 sessions over the 6 week period. The components of the PR programme will include an exercise programme. Education sessions will also be provided and include anatomy of the lungs and what is COPD, anxiety and depression, self management, managing breathlessness, medications and treatments, managing exacerbations of COPD and chest infections, clearing sputum and the Active Cycle of Breathing Technique, nutrition, pacing, smoking cessation. Participants on the face to face arm will also be instructed to carry out the pulmonary rehabilitation exercises an additional three times a week at home.
11298985|NCT02706613|Active Comparator|Online Pulmonary Rehabilitation|Those randomised to receive the online programme will be given log-in details and a password, and instructions to begin the 6 week programme at home. The online programme mirrors the conventional face-to-face PR programme and the exercise and educational components are given by means of instructional videos. Participants will be instructed to exercise five times a week. Participants in the online arm will receive during the PR course telephone contact to record any adverse or serious adverse events.
11298986|NCT02706600|Other|Written Self Management|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
11298987|NCT02706600|Active Comparator|Online Self Management|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.
~Medication and symptom diaries. Appointment diary, pulmonary rehabilitation videos to promote and support exercises that can be done in the home.
~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.
~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
11298988|NCT02706587|Experimental|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
11298989|NCT02706587|Sham Comparator|Sham Control|No electrostimulation
11298990|NCT02706574||Isolated Traumatic Brain Injury|This group will present to our Level 1 Trauma Center with a Traumatic Brain Injury and no other associated injuries. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
11298991|NCT02706574||Isolated Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient with no injury to their head. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
11298992|NCT02706574||Combined Traumatic Brain Injury and Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient that had injuries to both their head and body. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
11298993|NCT02706574||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
11298994|NCT02706561|Experimental|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
11298995|NCT02706561|Experimental|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
11298996|NCT02706548|Experimental|Occupational Therapy Intervention Group|Thirty-minute intervention in which the participant and interventionist discuss past medication taking performance, medication-related goals, and strategies to meet goals. Intervention is enhanced with motivational interviewing and therapeutic use of self.
11298997|NCT02706548|Active Comparator|Standard Care Intervention Group|Thirty-minute educational intervention in which the participant and interventionist review a pamphlet on adherence to medication.
11298998|NCT02706535|Experimental|Part 1 Cohort 1|Subjects will receive a single dose of GSK525762 10 mg on Day 1 followed by 200 mg Itraconazole two times a day (BID) on Day 3. On Day 4 to Day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On Day 7 subjects will receive a single dose of GSK525762 5 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
11299027|NCT02706314||Critically ill patients with CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 with CIP
11299000|NCT02706535|Experimental|Part 2|Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
11299001|NCT02706522|Experimental|Allocated to Carbohydrated group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Carbohydrated group
~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
11299002|NCT02706522|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Placebo group
~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
11299003|NCT02706509|Active Comparator|oral tramadol|Patients will receive oral Tramadol 50 mg capsules (n=50)' . After an hour, Jaydess intrauterine device will be inserted.
11299004|NCT02706509|Sham Comparator|verbal anesthesia|'verbal anesthesia' (n=50) After an hour, Jaydess intrauterine device will be inserted
11299005|NCT02706496||young adults (20-35yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
11299006|NCT02706496||middle age(45-60yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
11299007|NCT02706496||elderly(65-74yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
11299008|NCT02706483|Experimental|Plecanatide|Plecanatide 6.0 mg tablets
11299009|NCT02706470|Experimental|Cyclosporin A|Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.
11299010|NCT02706470|Active Comparator|Dydrogesterone|Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.
11299011|NCT02706457||cohort 2012 - 2014|all patients admitted for > 48 hours on the Intensive Care Unit in 2012, 2013 and 2014
11299012|NCT02706444|Active Comparator|Conventional Balloon Angioplasty|Conventional balloon angioplasty. After fistulogram, full expansion of conventional balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
11299013|NCT02706444|Active Comparator|Drug-Coated Balloon Angioplasty|Drug-coated balloon angioplasty. After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
11299014|NCT02706431|No Intervention|Normoventilation|The patients will be normoventilated before anesthesia
11299015|NCT02706431|Experimental|Hyperventilation|Prior to anesthesia, the patients will hyperventilate during 2 mins or until symptoms from the central nervous system (e.g. dizziness).
11299016|NCT02706418|Other|Clinical Massage Therapy|
11299017|NCT02706405|Experimental|Group I (JCAR014, durvalumab)|Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
11299018|NCT02706405|Experimental|Group II (durvalumab, JCAR014)|Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
11299019|NCT02706392|Experimental|Treatment (ROR1 CAR-specific autologous T-lymphocytes)|Patients receive chemotherapy comprising fludarabine phosphate and cyclophosphamide as determined by the referring physician in consultation with the protocol PI. Beginning within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive ROR1 CAR-specific autologous T-lymphocytes IV over 20-30 minutes. Patients may receive a second infusion of ROR1 CAR-specific autologous T-lymphocytes with or without additional cytoreductive therapy at the same (for those that received the highest cell dose) or up to the next highest dose level and there is persistent disease, there were no toxicities attributed to the first infusion, and the patient is at least 21 days from the first T cell infusion.
11299020|NCT02706379|Experimental|Local cerebral oxygen saturation|use NIRS technical to detect local cerebral oxygen saturation of both sides of brain
11299021|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:
~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.
~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
~Dose Expansion Phase:
~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.
~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
11299022|NCT02706340||Vaginal delivery|Women who have had a copper IUD placed within 10 minutes of a vaginal delivery of at least 34 weeks 0 days gestation.
11299023|NCT02706340||Cesarean delivery|Women who have had a copper IUD placed within 10 minutes of a cesarean delivery of at least 34 weeks 0 days gestation.
11299024|NCT02706327|Experimental|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
11299025|NCT02706327|Experimental|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
11299026|NCT02706327|Placebo Comparator|Control|8-week follow-up with placebo insole and home based exercise program
11299030|NCT02706301|Experimental|Telephone-Based Coping Skills Training (CST)|The CST condition will receive 5 sessions of a cognitive behavior theory-based protocol that teaches coping skills (e.g., relaxation, activity pacing/planning, cognitive restructuring) relevant to managing pain as well as psychological distress.
11299031|NCT02706301|No Intervention|Standard care control|The standard care control condition will receive resources and referrals related to survivorship health. This information will be provided to the participant during their initial survivorship care consult.
11299032|NCT02706288|Experimental|Weight loss with diet with exercise|Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after 7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until 7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
11299033|NCT02706275|Experimental|Warming Group|External warming via forced air warming
11299034|NCT02706275|No Intervention|Control Group|Standard of care body temperature management
11299035|NCT02706262|No Intervention|Metabolically normal lean - Baseline testing only|"Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
~Dietary intervention - None."
11299036|NCT02706262|No Intervention|Metabolically normal obese - Baseline testing only|"Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
~Dietary intervention - None."
11299037|NCT02706262|Experimental|Metabolically abnormal obese - Mediterranean diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.
~Dietary intervention - A nutritionally balanced diet that includes fruits, vegetables, fish, beans, whole grains, and olive oil with approximately 50% of daily calories coming from complex carbohydrates, 30% of calories from fat, and 20% of calories from protein."
11299038|NCT02706262|Experimental|Metabolically abnormal obese - Low carbohydrate ketogenic diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.
~Dietary intervention - A very-low-carbohydrate, adequate protein, high-fat diet containing 20 grams of carbohydrate or less per day (about 5% of calories), derived mainly from vegetables."
11299039|NCT02706262|Experimental|Metabolically abnormal obese - Plant-based very-low-fat diet|"Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver.
~Dietary intervention - A plant-based diet high in complex carbohydrates and low in fat, protein, and sodium, with approximately 70% of daily calories from carbohydrates, 15% from fat, and 15% from protein."
11299040|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.
~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
11299041|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.
~On study Enoxaparin will be administered for up 14 days during hospitalization."
11299042|NCT02706236|Active Comparator|Intervention Arm|Pancreatic enzyme replacement (Pancrelipase) with meals and snacks daily, for 4 weeks.
11299043|NCT02706236|Placebo Comparator|Placebo Arm|Lactose placebo tablets with meals and snacks, for 4 weeks.
11299044|NCT02706223|Experimental|Pharmacist Led|This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
11299045|NCT02706223|Experimental|Nurse Led|This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
11299046|NCT02706210||vascular cognitive disorders pre-dementia (VCD-P)|
11299047|NCT02706210||amnestic mild cognitive impairment (aMCI)|
11299048|NCT02706197|Experimental|IA No treatment except standard-of-care (SOC) surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
11299049|NCT02706197|Experimental|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
11299050|NCT02706184|Experimental|Intervention|Patients receive E. coli Nissle suspension
11299051|NCT02706184|Placebo Comparator|Control|Patients receive placebo
11299052|NCT02706171|Experimental|A: pre-operative|"Radiation- CyberKnife:
~35-40 Gy over 5 fractions
~Surgery:
~Surgical resection of sarcoma"
11299053|NCT02706171|Experimental|B: Post-operative|"Radiation- CyberKnife:
~40 Gy over 5 fractions"
11299054|NCT02706171|Experimental|C: Non-resectable|"Radiation- CyberKnife:
~50 Gy over 5 fractions"
11299055|NCT02706158|Experimental|supplement and balanced diet|"Woman at high risk of pre-eclampsia:
~supplements. 1500 mg Calcium and 1200 IU Vitamin D for 2 months. balanced diet."
11299056|NCT02706158|No Intervention|women without nutrition or supplement intervention|usual follow-up in the gynecology out patient clinic, without nutrition or supplement intervention.
11299057|NCT02706145|Experimental|Intervention Group (West Louisville)|This group will be exposed to the social norming campaign via traditional, mass, and social media over the three-year intervention period.
11299058|NCT02706145|No Intervention|Control Group (East Nashville)|This group will serve as the control group, and measures of social norms and attitudes toward violence will be compared between this group and the intervention group.
11299059|NCT02706132|Experimental|The MSCs group|The group of patients receive allogeneic MSCs therapies.
11299280|NCT02704559|Experimental|Study effect of DWC20156 on DWC20155 PK|To study effect of DWC20156 on DWC20155 PK
11299281|NCT02704559|Experimental|Study effect of DWC20155 on DWC20156 PK|To study effect of DWC20155 on DWC20156 PK
11299060|NCT02706119|Experimental|Glargine insulin|Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
11299061|NCT02706119|Active Comparator|Regular insulin|Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
11299062|NCT02706106|Experimental|Knee brace with a hole|Patients will be prepared to receive the device of knee brace with a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
11299063|NCT02706106|Placebo Comparator|Knee brace without a hole|Patients will be prepared to receive the device of knee brace without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
11299064|NCT02706093|Other|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
11299065|NCT02706093|Other|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
11299066|NCT02706093|Other|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
11299067|NCT02706093|Other|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
11299068|NCT02706080||Antithrombotic agents|We propose to realize a single-center prospective registry of patient under Antithrombotic agent who came to the emergency unit for any reason.
11299069|NCT02706067|Experimental|Orlistat|Participants will receive intermittent orlistat for up to 4 years, with the dose determined according to body weight changes.
11299070|NCT02706054|Placebo Comparator|C-group|patients receiving an IM saline injection near the nerve root (periradicular)
11299071|NCT02706054|Experimental|M-group|patients receiving an IM Meloxicam injection near the nerve root (periradicular)
11299072|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
11299073|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
11299074|NCT02706028|Active Comparator|ultrasound group|Patients in the ultrasound group received underwater US therapy to both hands and wrists for 7 minutes with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
11299075|NCT02706028|Sham Comparator|control group|The control group received sham treatment (the ULTRON home OE-302® device was not turned on) during 10 sessions for 7 minutes per session.
11299076|NCT02706015|Experimental|Cefaliv® & Placebo|Dihydroergotamine mesylate+ dipyrone sodium + caffeine
11299077|NCT02706015|Active Comparator|Neosaldina® & Placebo|Isometheptene mucate + dipyrone sodium + anhydrous caffeine
11299078|NCT02706002|Active Comparator|hip prosthesis under fluoroscopy|implantation of femoral stem of hip prosthesis in this group of patients are under fluoroscopic guidance for stem size and stem alignment and last rap before original stem implantation will be checked for alignment , lateral and vertical offsets parameters.
11299079|NCT02706002|Sham Comparator|hip prosthesis without fluoroscopy|in this group of patients rasping of femoral canal during hip prosthesis is made via anatomic landmarks which confirmed by to senior surgeons and than original stem implanted.
11299080|NCT02705989|Placebo Comparator|Single Ascending Dose (SAD)|Single ascending dose of BMS-986195 or Placebo matching BMS-986195
11299081|NCT02705989|Placebo Comparator|Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
11299082|NCT02705989|Placebo Comparator|Japanese-Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
11299083|NCT02705989|Experimental|Relative Bioavailability with Food Effects (Open Label)|
11299084|NCT02705976|Active Comparator|self-managing warfarin|self-managing warfarin patients who are educated in dosing warfarin to achieve target INR value
11299085|NCT02705976|Experimental|algorithm-suggested warfarin dosing|algorithm-suggested warfarin dosing, where the participants are provided with a dosage suggestion of their warfarin dosage (calculated dose) to achieve target INR
11299086|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
11299087|NCT02705950|Active Comparator|intrathecal baclofen bolus|In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
11299088|NCT02705950|Placebo Comparator|placebo|In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
11299089|NCT02705937|Experimental|Dairy product|The product will be taken for 14 days
11299090|NCT02705937|Active Comparator|Aequasyal mouth spray medical device|The spray will be taken for 14 days
11299382|NCT02703870|Active Comparator|Verum tDCS|Verum group receiving complete treatment of tDCS
11299091|NCT02705924|Experimental|Psychoeducational intervention|group participating to the first psychoeducational intervention: it consists in a week-end session in a SPA center including several conferences about HBOC familial risk, cancer prevention, prophylactic possibilities (surgery), recommendations about nutrition and physical activity a risk modulators, assisted medical procreation and embryo selection, social support...). Besides conferences, Moreno role games and group sharing are organized under the supervision of a psychotherapist.
11299092|NCT02705924|Other|Waiting list|delayed intervention: group participating to the second psychoeducational intervention (6 months later). Intervention is same as in the intervention arm but it is delayed. Because questionnaires are completed before this second intervention in both arms and allocation to arms are randomized, it represents an adequate control group.
11299093|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
11299094|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
11299095|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
11299096|NCT02705898|Experimental|LPA+Fitbit|A 12-week LPA+Fitbit intervention for depressed women in intensive alcohol treatment. This will include: 1) a single in-person physical activity (PA) counseling orientation session; 2) 6 brief, phone-based PA counseling sessions focused on increasing PA and strategically using bouts of PA to cope with affect and alcohol cravings; 3) use of the Fitbit fitness tracker for physical activity goal-setting and daily self-monitoring; and 4) weekly supportive messages delivered by email.
11299097|NCT02705898|Active Comparator|Health Education Contact Control (HEC)|The HEC condition will include: 1) an in-person orientation session, 2) 6 telephone-delivered health education sessions, and 3) weekly health-related e-mails. A variety of health and lifestyle topics will be addressed including the following: Session 1 (week 1) - Nutrition-What to Eat and What Not to Eat; Session 2 (week 2) - Sleep Problems and Sleep Hygiene; Session 3 (week 4) - Alcohol Use among Women; Session 4 (week 6) - Relaxation training; Session 5 (week 8) - Time Management and Assertiveness; and Session 6 (week 10) - Being a Smart Patient when Coordinating your Healthcare.
11299098|NCT02705885|Experimental|Gingipain IgY|Participants consume lozenges containing IgY against gingipains of Porphyromonas gingivalis
11299099|NCT02705885|Placebo Comparator|Placebo IgY|Participants consume lozenges containing placebo IgY
11299100|NCT02705872|Experimental|Programmed intermittent boluses|Epidural analgesia performed with programmed intermittent boluses.
11299101|NCT02705872|Active Comparator|Continuous perfusion|Epidural analgesia performed with a continuous perfusion.
11299102|NCT02705859|Other|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.
~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
11299103|NCT02705846||BRCA1 mutation carriers|Men with a known pathogenic germline BRCA1 mutation
11299104|NCT02705846||BRCA2 mutation carriers|Men with a known pathogenic germline BRCA2 mutation
11299105|NCT02705846||BRCA1 controls|Men known not to carry a pathogenic germline BRCA1 mutation
11299106|NCT02705846||BRCA2 controls|Men known not to carry a pathogenic germline BRCA2 mutation
11299107|NCT02705833||Population with R/M SCCHN|Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection
11299108|NCT02705820|Experimental|single arm study|experimental treatment with maintenance pembrolizumab
11299109|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
11299110|NCT02705781|Experimental|General|One arm study: smARTrack Feeding Tube System.
11299111|NCT02705768|No Intervention|Healthy control|Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
11299112|NCT02705768|Experimental|Carbamazepine group|Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
11299113|NCT02705768|Experimental|Oxcarbazepine group|Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
11299114|NCT02705755|Experimental|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
11299115|NCT02705755|Experimental|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
11299116|NCT02705755|Experimental|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
11299117|NCT02705742|Other|stem cells group|mesenchymal stem cells only
11299118|NCT02705729|Active Comparator|Ketac Universal|Simplified glass ionomer tooth filling
11299119|NCT02705729|Active Comparator|Ketac Molar Quick|Glass ionomer tooth filling
11299120|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
11299121|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
11299383|NCT02703870|Sham Comparator|sham tDCS|Sham group receiving sham tDCS
11299384|NCT02703870|Active Comparator|real VRT|Real Vision Restoration Training
11299122|NCT02705703|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
11299123|NCT02705677||Rett syndrome|This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.
11299124|NCT02705677||MECP2 Duplication disorder|This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.
11299125|NCT02705677||Rett-related disorders: CDKL5, FOXG1|This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
11299126|NCT02705664|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 7 weeks on all affected toenails of one foot
11299127|NCT02705664|Active Comparator|Urea Ointment + Bifonazole Cream|"On the opposite foot:
~Urea 40% ointment to be applied once a day under occlusion for 2-3 weeks depending on the achievement of optimal diseased toenail plates removal)
~Bifonazole 1% cream to be applied for 4 weeks on affected toenails (after the maximum 3-week treatment period with Urea ointment)"
11299128|NCT02705651|Experimental|Somatostatin-Analog|A long acting somatostatin analog will be applied.
11299129|NCT02705651|No Intervention|No treatment|This arm will be be the observational control according to the endpoints of the study. No intervention will be made.
11299130|NCT02705638|Experimental|Rituximab and Lenalidomide|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
11299131|NCT02705625|Experimental|MIV-711:1|MIV-711 for a total of 26 w
11299132|NCT02705625|Experimental|MIV-711:2|MIV-711 for a total of 26 w
11299133|NCT02705625|Placebo Comparator|Placebo|Placebo for a total of 26 w
11299134|NCT02705612|Other|control group|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
11299135|NCT02705612|Experimental|experimental group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group. Patients also receive nimotuzumab during the external radiotherapy.
11299136|NCT02705586|Experimental|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
11299137|NCT02705573|Experimental|Mannitol 20%|Mannitol 1g/ kg BW
11299138|NCT02705573|Placebo Comparator|Nacl 0.9%|NaCl 0.9% 5ml/ kg BW
11299139|NCT02705560|Experimental|Cow´s milk (3.9% fat, pasteurized)|Cow´s milk (3.9% fat, pasteurized) Single dose, 600 ml milk
11299140|NCT02705560|Experimental|Hard, yellow cheese|"Hard, yellow cheese Single dose, 100 g cheese
~+ 500 ml water"
11299141|NCT02705560|Active Comparator|Soy based drink|Soy based drink Single dose, 600 ml soy drink (soy drink + plant based cream)
11299142|NCT02705547|Experimental|Rosuvastatin (Crestor)|This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
11299143|NCT02705534|Experimental|Treatment|Subjects will receive sofosbuvir, ledipasvir and ribavirin
11299144|NCT02705521|No Intervention|Treatment as usual group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). They will be assessed for progression and be provided with a home exercise program. Range of motion in their shoulder will be collected on a weekly basis using the MIRA technology. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
11299145|NCT02705521|Experimental|Treatment as usual plus Exergames group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). Rather than use a home exercise program patients will be provided with a laptop computer and kinect sensor. they will use the new technology to play 'Exergames' each program will be tailored to the patients progress and patients can play the system as often as they wish. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
11299146|NCT02705508|Experimental|PEG group|Treatment PEG dosages were as follows: days 1 and 8,30min intravenous infusion of 1000mg/m2 gemcitabine;day1,4h intravenous infusion of 100mg/m2 etoposide,day1-3,deep intramuscular injection of 2500U/m2 Pegaspargase at three different sites.The regimen was repeated every 3 weeks.Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved-field radiation (IFRT) dose was 50-56 Gy.Stage IIIE/IVE patients were given for a maximum of six cycles.
11299147|NCT02705495|Active Comparator|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
11299148|NCT02705495|Other|Control|Recommendation for use of cranberry products only
11299149|NCT02705482|Experimental|Arm A: MEDI0562 and durvalumab|MEDI0562 and durvalumab
11299150|NCT02705482|Experimental|Arm B: MEDI0562 and tremelimumab|MEDI0562 and tremelimumab
11299151|NCT02705469|Experimental|Dose Escalation and Dose Confirmation - ZEN003694 Single Agent|ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
11299152|NCT02705456|Experimental|HA-Tooth Paste|"Tooth Brushing HA
~Cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite twice daily over the duration of the study (24 weeks).
~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
11299153|NCT02705456|Active Comparator|FL-Tooth Paste|"Tooth Brushing FL
~Cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste twice daily over the duration of the study (24 weeks).
~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
11299154|NCT02705443||Tissue w/ Thermographic Anomaly|"Visibly undamaged tissue with anomaly identified by the thermographic image
~No intervention
~Standard of care"
11299155|NCT02705443||Tissue w/o Thermographic Anomaly|"Visibly undamaged tissue with no anomaly identified by the thermographic image
~No intervention
~Standard of care"
11299156|NCT02705443||Tissue w/ Visible Anomaly|"Visibly damaged tissue
~No intervention
~Standard of care"
11299157|NCT02705430|No Intervention|A|Group A will continue their actual therapy (control).
11299158|NCT02705430|Experimental|B|Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study
11299159|NCT02705430|Experimental|C|Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study
11299160|NCT02705430|Experimental|D|Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study
11299161|NCT02705417||Group A|Patients in whom selection of vascular access relied upon physical examination and medical history, during pre-operative surgical assessment
11299162|NCT02705417||Group B|Patients who underwent vascular mapping using color Doppler Ultrasonography in addition to physical examination and history during pre-operative evaluation.
11299163|NCT02705378|Active Comparator|Polyethylene glycol|17g power qday; reconstituted in water for naso/orogastric tube administration
11299164|NCT02705378|Experimental|naloxegol|25mg qday; crushed pill reconstituted in water for naso/orogastric tube administration
11299165|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
11299166|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
11299167|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
11299168|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
11299169|NCT02705339|Experimental|Arm 1: Rociletinib|"Rociletinib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg twice per day during each 28-day cycle.
~After completion of cycle 1, patients who tolerate the 500 mg twice per day dose without significant adverse effect may increase dosing to 625 mg twice per day at the discretion of the investigator"
11299170|NCT02705326|Experimental|Opti-Speech|Speech treatment will be guided by Opti-Speech's visual feedback of tongue movement during speech
11299171|NCT02705300|Experimental|Chemotherapy plus tocotrienol|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.
~Daily: Tocotrienol 300 mg x 3 daily"
11299172|NCT02705300|Placebo Comparator|Chemotherapy plus placebo|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.
~Daily: Placebo x 3 daily"
11299173|NCT02705287||Vitamin D dynamics-pregnant|Pregnant women recruited to measure Vitamin D dynamics during pregnancy.
11299174|NCT02705287||Vitamin D dynamics-nonpregnant|Non-pregnant women recruited to measure Vitamin D dynamics.
11299175|NCT02705287||Delivery-placental transfer|Pregnant women planning to deliver by scheduled c-section who will be dosed with vitamin D3 in late gestation (week 36-38).
11299176|NCT02705287||Delivery-Vitamin D|Pregnant women will be dosed with vitamin D3 at term when they come in for their pre-surgical appointments prior to their scheduled c-section
11299177|NCT02705287||Delivery-25(OH) Vitamin D|Pregnant women will be dosed with 25(OH)D3 when they come in for their pre-surgical appointments
11299178|NCT02705274|Active Comparator|Prompt Panretinal Photocoagulation|PRP= Panretinal Photocoagulation. PRP alone.
11299179|NCT02705274|Experimental|Bevacizumab with deferred PRP|Bevacizumab = Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
11299180|NCT02705261|Experimental|Cognitive-behavior therapy|Cognitive-behavior therapy to teach parents the skills to help their children. Participants will have access to the program as often as they wish and have the post assessment at week 12.
11299181|NCT02705248||Group A|(Group A) case group: 40 pregnant females at 6- 13wks presenting with a history of recurrent pregnancy loss (two or more failed clinical pregnancies as documented by ultrasonography or histopathology examination according to the American Society of Reproductive Medicine) (ASRM, 2008).
11299182|NCT02705248||Group B|control group: 40 pregnant females at 6- 13wks with no history of abortion.
11299183|NCT02705222|Active Comparator|D&C group|Women will undergo D&C
11299184|NCT02705222|Active Comparator|Hysteroscopy group|Women will undergo hysteroscopy
11299185|NCT02705209|Active Comparator|Treatment|
11299186|NCT02705209|Placebo Comparator|Control|
11299213|NCT02705027|Experimental|Freka®-EasyIn|The other half of the patients will receive a Freka®-EasyIn probe which is directly placed in the small intestine inserted over the endoscope, after endoscopy was initially pushed - as far as possible - into the small intestine.
11299678|NCT02701920||Newborns needing stabilisation|Newborn infants requiring resuscitation or stabilisation following birth.
11299187|NCT02705196|Experimental|Arm 1 Intratumoral LOAd703|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment.
~The following LOAd703 doses will be evaluated:
~Dose level 1: 5 X 10^10 viral particles per treatment Dose level 2: 1 X 10^11 viral particles per treatment Dose level 3: 5 X 10^11 viral particles per treatment"
11299188|NCT02705196|Experimental|Arm 2: Intratumoral LOAd703 + atezolizumab|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment. A fixed dose of atezolizumab 1680 mg will be given every 4 weeks on day 1 of each chemotherapy cycle.
~Patients will be assigned to the following LOAd703 doses:
~Dose level 1: 1 X 10^11 viral particles per treatment Dose level 2: 5 X 10^11 viral particles per treatment"
11299189|NCT02705183|Active Comparator|A: Surgery & Post-operative radiotherapy|Surgery & Post-operative radiotherapy
11299190|NCT02705183|No Intervention|B: Surgery only|Surgery only
11299191|NCT02705170||left ventricle dilatation|The subjects of the investigation will be patients with recent diagnosis of unknown left ventricle dilatation. These subjects received coronary artery angiography as exam suggested by guidelines to discriminate the cause of left ventricle dilatation. In subjects without documentation of coronary artery lesions, the Authors will assess the index of microvascular resistance.
11299192|NCT02705157||Bone metastasis of the long bone|Patients with bone metastases of the long bone(s) receiving surgical stabilisation of a pathologic or impending fracture or receiving radiotherapy for a painful metastasis.
11299193|NCT02705144||biopsies from lung tissue affected by emphysema|analysis of the number of stem cell niches
11299194|NCT02705144||biopsies from lung tissue affected by interstitial fibrosis|analysis of the number of stem cell niches
11299195|NCT02705144||biopsies from normal appearance lung tissue|analysis of the number of stem cell niches
11299196|NCT02705131|Experimental|Balance Chiropractic Therapy(BCT)|patients are in the sitting position and receive the Balance Chiropractic Therapy(BCT) .1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.The patients will received BCT 1 time every other day, 20min each time. a total of 10 times in 20 days.
11299197|NCT02705131|Active Comparator|Traction Therapy(TT)|patients will receive the Traction Therapy(TT):The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
11299198|NCT02705118|Experimental|Automatic registration arm|"Automatic registration for fusion imaging of US and MRI will be performed.
~Automatic Imaging fusion of ultrasonography and MRI"
11299199|NCT02705118|Active Comparator|Manual registration arm|"Manual registration for fusion imaging of US and MRI will be performed.
~Manual Imaging fusion of ultrasonography and MRI"
11299200|NCT02705105|Experimental|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab
~If >1 patient has a DLT at first dose level, then the following cohort will be enrolled:
~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
11299201|NCT02705105|Experimental|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab
~Subjects will be separated further into cohorts by tumor type"
11299202|NCT02705092|Experimental|Subliminal priming with subliminal reward stimuli|"This intervention consisted of five presentations [three cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal priming (displayed for 17 ms), and positive words as subliminal reward (displayed for 17 ms)].
~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
11299203|NCT02705092|Experimental|Subliminal priming with supraliminal reward stimuli|"This intervention consisted of four presentations [two cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal prime (displayed for 17 ms), and positive words as supraliminal reward (displayed for 150 ms)].
~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
11299204|NCT02705066|Placebo Comparator|Placebo (Cellulose)|
11299205|NCT02705066|Experimental|Cognizin 250 mg/day|
11299206|NCT02705066|Experimental|Cognizin 500 mg/day|
11299207|NCT02705053|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 2)|The subjects' Sensor-Augmented Pump Open-Loop Care for the second week of the study before any adjustments to pump settings, using a CGM and Insulin Pump.
11299208|NCT02705053|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on CGM glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device. Algorithmic adjustment of carbohydrate ratios prior to closed-loop initiation, and continued basal rate and carbohydrate ratio algorithmic optimization during closed-loop use will occur.
11299209|NCT02705040||Normal|bone mineral density T>=-1.0
11299210|NCT02705040||Osteopenia|bone mineral density -1.0>T>=-2.5
11299211|NCT02705040||Osteoporosis|bone mineral density T<-2.5
11299212|NCT02705027|Active Comparator|Standard|"After randomization one half of the patients receive a Freka®-Trilumina probe, which is inserted in nasogastric route an then pushed  using a small forceps which is inserted through the endoscope into the small intestine."
11299279|NCT02704572|Active Comparator|2years to 5years after shingles|Patients will be vaccinated with Zostavax from 2 years to 5 years after zoster illness.
11324398|NCT02538367|Experimental|YH12852 DR2 8mg|Once daily
11299214|NCT02705014|Experimental|treatment group|patients were administered with pulsatile gonadotropin-releasing hormone (GnRH )therapy for 12 months at an interval of 90 minutes.The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L.
11299215|NCT02704988|Active Comparator|Colon Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
11299216|NCT02704988|Active Comparator|Colon Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
11299217|NCT02704988|Active Comparator|Rectal Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
11299218|NCT02704988|Active Comparator|Rectal Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
11299219|NCT02704975|Experimental|Rehabilitation and Dry Needling|Standard Rehabilitation Protocol following shoulder stabilization surgery and Dry Needling to the Shoulder girdle 1 time a week for 4 weeks between weeks 4 and 8 post operatively
11299220|NCT02704975|Active Comparator|Rehabilitation|Standard Rehabilitation Protocol following shoulder stabilization surgery alone
11299221|NCT02704962|Experimental|trifluoperazine plus olanzapine|trifluoperazine 5mg/day + olanzapine 5mg/day
11299222|NCT02704962|Active Comparator|full-dose olanzapine|olanzapine 10mg/day
11299223|NCT02704949|Experimental|Low-dose|The intervention is to use 1/4 fluoroscopy dose while the ureteroscopy is being performed
11299224|NCT02704949|Active Comparator|Full-dose|The intervention is to use full fluoroscopy dose while the ureteroscopy is being performed
11299225|NCT02704936||Male donor|42 samples of semen from male donor attached to a donation program Normal sperm count as WHO 2010.
11299226|NCT02704936||IUI positive pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and have obtained positive pregnancy in any of the first 4 treatments IUI
11299227|NCT02704936||IUI unsuccessful pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and after undergoing maximum 4 cycles have unsuccessfully IUI indication of IVF / ICSI.
11299228|NCT02704923|Active Comparator|Atropine|
11299229|NCT02704923|Placebo Comparator|Placebo|
11299230|NCT02704910|Placebo Comparator|Voluntary subject|Patient without parkinson disease, without deep brain stimulation
11299231|NCT02704910|Active Comparator|Patients|Subthalamic stimulation
11299232|NCT02704897|Experimental|Intervention Arm|"Wound assessment tool - delivered via a smartphone. A link will be sent to participants on discharge, which can be accessed at any point should they have concerns about their wound.
~They will also be sent the tool at 3 additional time-points."
11299233|NCT02704897|No Intervention|Control Arm|Normal Post-operative Care
11299234|NCT02704884|Experimental|probiotic soy milk|consume a diet containing 200 ml/day probiotic soy milk in intervention group
11299235|NCT02704884|Active Comparator|soy milk|200 ml/day soy milk in the control condition
11299236|NCT02704858|Experimental|NEO100|Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose. Followed by treatment of total of 25 patients at maximum tolerated dose
11299237|NCT02704845||Ankylosing Spondylitis|
11299238|NCT02704845||Chronic non-specific low back pain|
11299239|NCT02704832|No Intervention|Arm A|"Arm A Standard oncological care: patients will be treated according to daily oncological practices as defined for each type of cancer, in the Management protocol of Oncology written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months."
11299240|NCT02704832|Experimental|Arm B|"Arm B Geriatrician Intervention: patients will be treated according to the same Management protocol of Oncology than patients in the arm Standard oncological care.
~Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the Management protocol of Geriatrics.
~The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months."
11299241|NCT02704819|Experimental|Non-specialist doctor +DSS|"Patients allocated to +DSS group will receive the following intervention:
~V1: appointment with a non-specialist doctor with the support of the DSS
~V2: appointment with an overseeing expert
~V3: DSS Customised Vestibular Physiotherapy
~V4: follow-up visit with the overseeing expert"
11324399|NCT02538367|Active Comparator|Prucalopride 2mg|Once daily
11299242|NCT02704819|Active Comparator|Non-specialist doctor -DSS|"Patients allocated to -DSS group will receive the following intervention:
~V1: appointment with a non-specialist doctor without the support of the DSS
~V2: appointment with an overseeing expert
~V3: Standard Physiotherapy Practice
~V4: follow-up visit with the overseeing expert"
11299243|NCT02704793|Experimental|Bilateral 1 Hz Cerebellar rTMS|Patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days.
11299244|NCT02704793|Sham Comparator|Sham (electrical stimulation)|Sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS.
11299245|NCT02704780|Active Comparator|400 Microgram Misoprostol|Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group
11299246|NCT02704780|Active Comparator|800 Microgram Misoprostol|Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group
11299247|NCT02704767|Placebo Comparator|TarceP|Tarceva with Placebo
11299248|NCT02704767|Experimental|TarceA|Tarceva with Apatinib
11299249|NCT02704754|Experimental|suvorexant|10 to 20 mg to be administered before bedtime
11299250|NCT02704754|Placebo Comparator|Placebo pill|A pill without active ingredients
11299251|NCT02704741|Experimental|all subjects|"Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.
~Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).
~Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic."
11299252|NCT02704728|Experimental|Thetanix|In Part A, 8 subjects will receive a single dose and in Part B, 8 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules
11299253|NCT02704728|Placebo Comparator|Placebo|In Part A, 2 subjects will receive a single dose and in Part B, 2 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules.
11299254|NCT02704715|Other|general anesthesia,orbital operation|"diagnosed as orbital disease and ocular tumor
~over 16 years old
~orbital operation under general anesthesia"
11299255|NCT02704702|Other|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)
~There will be a washout of at least 7 days between the each period."
11299256|NCT02704702|Other|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)
~There will be a washout of at least 7 days between the each period."
11299257|NCT02704702|Other|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)
~There will be a washout of at least 7 days between the each period."
11299258|NCT02704702|Other|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)
~There will be a washout of at least 7 days between the each period."
11299259|NCT02704702|Other|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)
~There will be a washout of at least 7 days between the each period."
11299260|NCT02704702|Other|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)
~There will be a washout of at least 7 days between the each period."
11299261|NCT02704689|Experimental|AccuLIF|
11299262|NCT02704676||control patients|normal pregnant women, 3rd trimester
11299263|NCT02704676||mild pre-eclampsia|patients with albuminuria +1 and blood pressure >140/90 and <160/110
11299264|NCT02704676||sever pre-eclampsia|patients diagnosed as sever pre-eclampsia according to criteria done by ACOG
11299265|NCT02704663|Experimental|Transumbilical route|Transumbilical removal of benign adnexal masses via laparoscopy.
11299266|NCT02704663|Active Comparator|Lateral abdominal route|Lateral transabdominal removal of benign adnexal masses via laparoscopy.
11299267|NCT02704650|Experimental|Vaginal fluid of healthy patient|vaginal fluid sample from healthy patients
11299268|NCT02704650|Experimental|Vaginal fluid of ovary cancer patients|vaginal fluid sample from patients with ovary cancer
11299269|NCT02704637|Experimental|HS-1000 recording|Each non-invasive recording session with the HS-1000 device will be done for 10 consecutive uninterrupted minutes. Patients will be recorded once daily for the duration of their time in ICU or for up to 14 days total. In the case the PI or a member of the study team positively confirms vasospasm based on clinical assessment or follow-up care during the monitoring period, the patient will be recorded twice daily for up to 14 consecutive days or for their duration in the ICU.
11299270|NCT02704624|Active Comparator|Vitamin D|Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
11299271|NCT02704624|Placebo Comparator|Placebo|The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
11299272|NCT02704611|Active Comparator|Group I|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week).
11299273|NCT02704611|Sham Comparator|Group II|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
11299274|NCT02704598|Active Comparator|Rivaroxaban|Patients with deep venous thrombosis using Rivaroxaban for 6 months, and then will be evaluated with DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
11299275|NCT02704598|Active Comparator|Warfarin|Patients with deep venous thrombosis using Warfarin for 6 months, and then will be evaluated wiht DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
11299276|NCT02704585|Other|Nellcor|Connection to Nellcor pulse oximeter for measuring oxygen saturation after birth
11299277|NCT02704585|Other|Masimo|Connection to Masimo pulse oximeter for measuring oxygen saturation after birth
11299278|NCT02704572|Experimental|6months to 2years after shingles|Patients will be vaccinated with Zostavax from 6 months to 2 years after zoster illness.
11299679|NCT02701920||Parental feedback|Parental feedback of babies recruited into HeartLight will be sought.
11299282|NCT02704546|Experimental|Methylphenidate|In experimental days taking MPH, subjects will take 20mg Ritalin® (Novartis AG) in two tablets of 10mg, by swallow 1 hour prior to performing the physical test.
11299283|NCT02704546|Placebo Comparator|Placebo|In experimental days with placebo subjects will be asked to ingest 2 capsules identical to Ritalin® capsules, by swallow 1 hour prior to performing the physical test.
11299284|NCT02704533|Experimental|Optimization Phase - Group A|"n=6; three times 9x10^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.
~If >75% efficacious, the treatment will be simplified to two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 (Group B1).
~If <75% efficacious, the treatment will be increased to three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)"
11299285|NCT02704533|Experimental|Optimization Phase - Group B1|"n=6; two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.
~If >75% efficacious, the treatment will be simplified to one injection 2.7x10^6 PfSPZ Vaccine (Group C1).
~If <75% efficacious, the treatment will be increased to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2)."
11299286|NCT02704533|Experimental|Optimization Phase - Group B2|"n=6; three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.
~If >75% efficacious, the treatment will be simplified to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).
~If <75% efficacious, the treatment will be increased to three times 2.7x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3)."
11299287|NCT02704533|Experimental|Optimization Phase - Group C1|"n=6; one time 2.7x10^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.
~If Group C1 gets vaccinated, study will proceed to verification phase after completion."
11299288|NCT02704533|Experimental|Optimization Phase - Group C2|"n=6; two times 2.7x10^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.
~If Group C2 gets vaccinated, study will proceed to verification phase after completion."
11299289|NCT02704533|Experimental|Optimization Phase - Group C3|"n=6; three times 2.7x10^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.
~In case C3 shows <75% efficacy, verification phase will not be done."
11299290|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D1|"n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI.
~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
11299291|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D2|"n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI.
~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
11299292|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D3|"n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI.
~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
11299293|NCT02704533|Experimental|Verification Phase - Group V1|"n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides >75% protection (5/6) against homologous CHMI (V1).
~Optimal & maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2).
~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8."
11299294|NCT02704533|Experimental|Verification Phase - Group V2|"n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2).
~Optimal & maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides >75% protection (5/6) against homologous CHMI (V1).
~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.
~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
11299295|NCT02704533|Placebo Comparator|Verification Phase - Group P1|"n=6; normal saline as placebo. This group will follow the regimen selected for Group V1.
~Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
11299296|NCT02704533|Placebo Comparator|Verification Phase - Group P2|"n=6; NS as placebo. This group will follow the regimen selected for Group V2.
~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.
~Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart.
~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
11300757|NCT02694380||Breast|Subjects with breast cancer receiving radiation therapy.
11299297|NCT02704520|Other|Control arm|Patients in the control arm will undergo surgery and then receive a course of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil) and follow-up assessments as standard i.e. standard clinical practice
11299298|NCT02704520|Experimental|Intervention arm|Patients in the intervention arm will be split into one of two groups according to their response to chemoradiotherapy. Patients who show a good response (mrTRG I&II) will be offered deferral of surgery and receive the standard course of chemotherapy. Patients who show a poor response (mrTRG III-V) will receive 12 weeks of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil), undergo repeat restaging, and then continue to surgery or defer surgery. Depending on chemotherapy regimen received patients may then receive a further 12 weeks of chemotherapy.
11299299|NCT02704507|Experimental|Topical steroid|Topical retinoid plus topical steroid applied daily to half of the face for 4 weeks, followed by 4 weeks of topical tretinoin. Patients will be randomized to which side receives the topical steroid.
11299300|NCT02704507|Placebo Comparator|Topical emollient|Topical retinoid plus topical emollient applied daily to the opposite half of the face for 4 weeks, followed by 4 weeks of topical tretinoin.
11299301|NCT02704494|Experimental|Resveratrol|Resveratrol + Losartan
11299302|NCT02704494|Placebo Comparator|Placebo|Placebo + Losartan
11299303|NCT02704481|Experimental|Mifepristone-misoprostol|Women randomized to receive 200 mg mifepristone to take on Day 1, 800 mcg buccal misoprostol to take 24-48 hours after later, and four placebo misoprostol pills to take a further 3-12 hours later.
11299304|NCT02704481|Experimental|Misoprostol-misoprostol|Women randomized to receive a placebo mifepristone pill to take on Day 1 and two doses of 800 mcg buccal misoprostol, the first of which should be taken 24-48 hours after the placebo and the second of which should be taken 3-12 hours after the first misoprostol dose.
11299305|NCT02704468||CAVI and FGF-21|renal transplant patients for more than 1 month measured FGF-21 and CAVI
11299306|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up
11299307|NCT02704416|No Intervention|Control arm|Control arm - continued implanted cardioverter defibrillator therapy
11299308|NCT02704416|Active Comparator|Intervention Arm|ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy
11299309|NCT02704416|Other|Single Cross Over Arm|these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine
11299310|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
11299311|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
11299312|NCT02704390|Experimental|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
11299313|NCT02704377|Experimental|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
11299314|NCT02704364|Experimental|NGM282 Dose 1|NGM282 Dose 1
11299315|NCT02704364|Experimental|NGM282 Dose 2|NGM282 Dose 2
11299316|NCT02704364|Active Comparator|Placebo|Placebo
11299317|NCT02704351||Sugammadex group|sugammadex to reverse neuromuscular blockade following cardiac surgery
11299318|NCT02704338|Experimental|Regulatory T cells|CD4(cluster of differentiation)+CD25+CD127- T cells isolated from peripheral blood mononuclear cells were be expanded with GMP(Good Manufacturing Practice) anti-CD3/CD28 coated beads in the presence of IL-2 and all-trans retinoid acid.
11299319|NCT02704325|Experimental|GALGT2 Viral Vector|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
11299320|NCT02704325|Experimental|Saline|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
11299321|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
11299322|NCT02704299|Experimental|Autologous T cells-Based Immunotherapy|Surgery Chemotherapy Autologous T cells-Based Immunotherapy
11299323|NCT02704286|Sham Comparator|Generic Osteoarthritis Risk Information|Participants in this arm received generic osteoarthritis information that was not personalized.
11299324|NCT02704286|Experimental|Personalized Osteoarthritis Risk|Participants in this arm obtained their personalized osteoarthritis risk from the internet-based Osteoarthritis Risk Calculator.
11299325|NCT02704260|Experimental|GENETIC ANALISYS|GENETIC ANALYSIS AND RESEARCH OF GENETIC BLOOD SAMPLE
11299326|NCT02704247|Experimental|Testing CARDIOSPACE System|Healthy volunteers have to test CARDIOSPACE System
11299327|NCT02704234|Experimental|Active Acupuncture|Active Acupuncture 2 times per week for 5 weeks
11299328|NCT02704234|Placebo Comparator|Placebo|Placebo Acupuncture 2 times per week for 5 weeks
11299329|NCT02704221|Active Comparator|Behavioral Parent Training (BPT)|The control group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks and 2) attend 12 weekly BPT training sessions.
11324400|NCT02538367|Placebo Comparator|Placebo|Once daily
11299330|NCT02704221|Experimental|BPT + Contingency Management (BPT+CM)|The experimental group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks, 2) attend 12 weekly BPT training sessions, and 3) receive monetary rewards for achieving weekly step-count goals.
11299331|NCT02704208|Experimental|Behavioral: Thrive With Me Intervention|Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
11299332|NCT02704208|Placebo Comparator|Behavioral: Thrive With Me Control|Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
11299333|NCT02704195|Active Comparator|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
11299334|NCT02704195|Experimental|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
11299335|NCT02704182|Active Comparator|Real tDCS|Direct current stimulation using anodal electrode, 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
11299336|NCT02704182|Sham Comparator|Sham tDCS|Sham direct current stimulation, 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
11299337|NCT02704169|Experimental|Spatially registered endoscopy for H&N cancer|
11299338|NCT02704156|Experimental|Five-fraction SBRT|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive five-fraction SBRT/cyberknife as the initial treatment
11299339|NCT02704143|Experimental|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
11299340|NCT02704130|Experimental|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
11299341|NCT02704130|Active Comparator|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
11299342|NCT02704117|Experimental|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
11299343|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
11299344|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
11299345|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
11299346|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
11299347|NCT02704078|Active Comparator|EBUS-TBNA|Mediastinal lymph node aspiration shall be performed transtracheally.
11299348|NCT02704078|Experimental|EUS-B-FNA|Mediastinal lymph node aspiration shall be performed transesophageally
11299349|NCT02704065||Recurrent AA amyloidosis|Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
11299350|NCT02704065||Control group 1|Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
11299351|NCT02704065||Control group 2|Renal transplant recipients whose primary diseases are other than amyloidosis
11299352|NCT02704052|Active Comparator|Standard enoxaparin dose|We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion-the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
11299353|NCT02704052|Experimental|Real time enoxaparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time enoxaparin dose adjustment and will receive followup steady state peak and trough aFXa levels. aFXa monitoring will be discontinued when in range peak levels are obtained, when enoxaparin prophylaxis is discontinued at surgeon discretion, or when the patient is discharged. Patients may be continued on enoxaparin prophylaxis after discharge per attending surgeon discretion but aFXa levels will not be followed in the outpatient environment.
11299354|NCT02704026||Inflammatory Bowel Disease|Patients 6-18 of age at the time of enrolment who have IBD at any stage of disease activity, on any or no treatment
11299355|NCT02704026||Control|Age- and sex-matched healthy controls
11299356|NCT02704013|Other|Intervention|Patients with overactive bladder will receive anticholinergic therapy: oral oxybutynin in daily dose 0.2-0.5 mg/kg divided in two daily doses for 3 to 6 months depending on treatment outcome assessed 3 months after start of intervention.
11299357|NCT02704000|No Intervention|Control|No interventions - only baseline and endline assessments to be conducted at children's home.
11299358|NCT02704000|Experimental|Home visits by CDAs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained child development agents (CDAs). CDAs will implement the Jamaica curriculum intervention during the home visits..
11299680|NCT02701920||Healthcare provider feedback|Healthcare professionals caring for babies recruited into HeartLight will have their feedback on the device sought.
11299359|NCT02704000|Experimental|Home visits by CHWs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained community health workers (CHWs) trained on delivering the intervention. CHWs will implement the Jamaica curriculum intervention during the home visits..
11299360|NCT02703987|Experimental|Group I|Fermented infant milk formula
11299361|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
11299362|NCT02703974|Experimental|Early handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and nudges built after Phase II data collection.
11299363|NCT02703974|Experimental|Late handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations and nudges built at the same time, after Phase II data collection.
11299364|NCT02703974|Active Comparator|Early handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and will receive a Hand hygiene education-based program, after Phase II data collection is complete.
11299365|NCT02703974|Active Comparator|Late handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after Phase II data collection is complete, when the Hand hygiene education-based program will commence.
11299366|NCT02703961|Experimental|experimental|"concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.
~During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.
~After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;
~The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
~docetaxel 75mg/m2, d43,d64."
11299367|NCT02703961|Other|control|"standard chemoradiotherapy with weekly cisplatin.
~Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.
~Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy."
11299368|NCT02703948|Other|Restylane Silk with Lidocaine|
11299369|NCT02703935|Experimental|health talk and adventure-based training|Participate will join a four-day adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 12 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
11299370|NCT02703935|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
11299371|NCT02703922|Other|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
11299372|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
11299373|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
11299374|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
11299375|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
11299376|NCT02703896|Placebo Comparator|Group C (placebo)|"Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)
~Group C (placebo)"
11299377|NCT02703896|Active Comparator|Either PPIs or H2RAs|"Drug Intervention Two doses at 8.00 pm and then at 6.00 am
~Group L (lansoprazole 15 mg)
~Group E(esomeprazole 20 mg)
~Group P (pantoprazole 20 mg)
~Group R (rabeprazole 10 mg)
~Group O (omeprazole 20 mg)
~Group T (cimetidine 200 mg)
~Group F (famotidine 20 mg)
~Group N (nizatidine 150 mg)
~Group Z (ranitidine 150 mg)
~Group S (lafutidine 10 mg)"
11299378|NCT02703896|Active Comparator|Either PPIs or H2RAs+prokinetics|"Drug intervention Two doses at 8.00 pm and then at 6.00 am
~Group L D (lansoprazole 15 mg+ domperidone 10 mg)
~Group EM (esomeprazole 20 mg+metoclopramide 10 mg)
~Group PD (pantoprazole 20 mg+domperidone 10)
~Group RM (rabeprazole 10 mg+metoclopramide 10 mg)
~Group OD (omeprazole 20 mg+domperidone 10)
~Group TD (cimetidine 200 mg+domperidone 10)
~Group FM (famotidine 20 mg+metoclopramide 10 mg)
~Group NM (nizatidine 150 mg+metoclopramide 10 mg)
~Group ZD (ranitidine 150 mg+ domperidone 10 mg)
~Group SD (lafutidine 10 mg+domperidone 10 mg)"
11299379|NCT02703896|Active Comparator|Either PPIs or H2RAs+Prokinetic|Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
11299380|NCT02703896|Other|Intervention Orogastric intubation|After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
11299381|NCT02703883|Experimental|Body Weight Support|Treatment protocol consisted of 18 training sessions on the BWST, three times a week, every session included three sets of six minutes of locomotion with rest intervals of 2 min of rest.
11324533|NCT02537457|Active Comparator|BAY59-7939 Rivaroxaban tablet|
11299385|NCT02703844|Active Comparator|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 12 weeks, 7 days a week, twice daily for 20 minutes.
11299386|NCT02703844|Sham Comparator|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 12 weeks in the same manner as the active arm: 7 days a week, twice daily for 20 minutes.
~Individuals allocated to this arm will be later crossed over, in unblinded fashion. to the active arm if the treatment shows evidence of efficacy and safety."
11299387|NCT02703831|Active Comparator|Dual attending|Two attending spine surgeons during the critical portions of the surgery
11299388|NCT02703831|Placebo Comparator|Single attending|One spine attending and an assistant during the critical portions of the surgery, The assistant can be a spine fellow, a resident or a physician's assistant.
11299389|NCT02703818|Experimental|Senza|Spinal Cord Stimulation for UEP
11299390|NCT02703805|Experimental|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors.
11299391|NCT02703805|Active Comparator|Standard YMCA membership|A 12 week standard YMCA membership.
11299392|NCT02703792||Care home staff|Care home staff working in the homes in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
11299393|NCT02703792||NHS staff|GPs supporting residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
11299394|NCT02703792||Service user representatives|Service or carers of an older person with dementia attending and Age UK carers group
11299395|NCT02703792||Relatives of residents|Relatives of residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
11299396|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).
~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
11299397|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.
~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
11299398|NCT02703766|Active Comparator|Lean|"Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.
~Overfeeding induced weight gain and subsequent weight loss"
11299399|NCT02703766|Experimental|Obese|"obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.
~Overfeeding induced weight gain and subsequent weight loss"
11299400|NCT02703753|Experimental|Intervention group|The intervention is an integral and multidisciplinary lifestyle intervention consisting of a healthy diet, appropriate physical activity and, if applicable, smoking cessation, customised to the needs of the women.
11299401|NCT02703753|No Intervention|Control group|The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
11299402|NCT02703740|Experimental|HA 20 mg/mL|
11299403|NCT02703740|Experimental|HA 24 mg/mL|
11299404|NCT02703727||OAC|Patients on oral anticoagulation therapy (OAC) will receive a pharmacists led medication review with a focus on anticoagulation therapy (extended polymedication check)
11299405|NCT02703714|Experimental|Treatment|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
11299406|NCT02703701||Usual Care|Group enrolled during normal emergency department operating procedures (without a physician present at triage).
11299407|NCT02703701||Physician at Triage|Group enrolled while a physician is present at triage.
11299408|NCT02703688|Experimental|Healthy Homes|Behavioral Intervention
11299409|NCT02703688|Active Comparator|Usual Care|Counseling session delivered by pediatrician
11299410|NCT02703675|Experimental|adult healthy volunteer|Adult healthy volunteers will be recruited from staff in Dept. Neurology, medical students. They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
11299411|NCT02703675|Experimental|adult normothermic patient|"Adult normothermic patients will be recruited from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.
~They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours."
11299412|NCT02703675|Experimental|adult sick febrile patient|"Adult sick febrile patients will be enrolled from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.
~Five of the patients will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
~Other five patients will received 2 rounds of cooling process each 2 hours long"
11299413|NCT02703662|Active Comparator|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
11299414|NCT02703662|Experimental|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
11299415|NCT02703649|Experimental|Single dose|Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.
11299416|NCT02703649|Active Comparator|Daily dose|Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
11299417|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
11299509|NCT02703077|Active Comparator|2: ERCP + Balloon Dilation|This group after the diagnosis of difficult bile duct stones, will be submitted to Balloon dilation of the papilla
11299418|NCT02703623|Experimental|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
11299419|NCT02703623|Experimental|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
11299420|NCT02703623|Active Comparator|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
11299421|NCT02703610|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
11299422|NCT02703610|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
11299423|NCT02703597|Experimental|ASPIRE Group|"A Smoking Prevention Interactive Experience (ASPIRE) Group contains participants with and without intent to use tobacco. Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 to 5 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
~At baseline, after 2 sessions, following the last session of the intervention, and one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Also, baseline survey again completed."
11299424|NCT02703597|Experimental|GSA-ASPIRE-Network Group|"GSA-ASPIRE-Network Group contains participants with and without intent to use tobacco. In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 to 5 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
~At baseline, after 2 sessions, following the last session of the intervention, and one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Also, baseline survey again completed."
11299425|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
11299426|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
11299427|NCT02703571|Experimental|Advanced or metastatic solid tumors|Patients in the Phase I portion of the study who have advanced or metastatic solid tumors
11299428|NCT02703558|No Intervention|No dye|Participants will not receive a preoperative or intraoperative dye prior to their intraoperative concomitant cystoscopy.
11299429|NCT02703558|Active Comparator|Phenazopyridine|Participants will receive a single 200mg oral dose of phenazopyridine with a sip of water 30 minutes prior to their surgery which involves an intraoperative concomitant cystoscopy.
11299430|NCT02703558|Active Comparator|Fluorescein|Participants will receive 0.25cc of 10% intravenous sodium fluorescein administered by anesthesia during their surgery, immediately prior to their intraoperative concomitant cystoscopy.
11299431|NCT02703545||Peutz-Jeghers syndrome|
11299432|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family
~first degree relative and 1 second degree relative(1st degree link) or
~first degree relatives or
~1 first degree relative and 2 or more second degree relatives"
11299433|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
11299434|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
11299435|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
11299436|NCT02703532|Experimental|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
11299437|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
11299438|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
11299439|NCT02703532|Active Comparator|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
11299440|NCT02703519|No Intervention|1 cesarean section|control group
11299441|NCT02703519|No Intervention|2 cesarean sections|control group
11299442|NCT02703519|Experimental|resection of uterine scar tissue|2 cesarean sections with resection of uterine scar tissue from first cesarean section
11299443|NCT02703506|Experimental|Experimental. Pain Education Program|Ten group sessions of treatment with a patient education pain for chronic neck pain (biopsychosocial approach). The group sessions of 60-120 minutes twice a week with a maximum of 10 participants.
11299444|NCT02703506|Active Comparator|Control|"The control group: individualized session of physical therapy (TENS and exercise).
~Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises ."
11299445|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
11299510|NCT02703064|Experimental|Furocyst|Furocyst 500mg capsule, BD
11299511|NCT02703051|Experimental|GMI-1271|GMI-1271
11299512|NCT02703051|Active Comparator|Filgrastim|Filgrastim
11299446|NCT02703480|Experimental|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
11299447|NCT02703480|Experimental|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
11299448|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
11299449|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
11299450|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
11299451|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
11299452|NCT02703441|Experimental|Intervention: Tablet computer|Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
11299453|NCT02703441|No Intervention|Control group|Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
11299454|NCT02703415|Active Comparator|Bupivacaine|caudal Bupivacaine
11299455|NCT02703415|Active Comparator|Tramadol|caudal Tramadol
11299456|NCT02703402|Experimental|Exercise protocol|Will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA
11299457|NCT02703402|Experimental|Manual of exercises|Treatment Group: will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises.
11299458|NCT02703389|Experimental|Video|An innovative video will be developed to explain the nature of non-severe acute otitis media and the rationale for watchful waiting and antimicrobial stewardship. This video will be viewed at recruitment and will be available online for further viewing later.
11299459|NCT02703389|Active Comparator|Pamphlet|Informative pamphlet containing the same information as the video.
11299460|NCT02703389|No Intervention|No intervention|This is the reference standard currently.
11299461|NCT02703376|Other|Patients after esophageal surgery|Oral Prednisone for 12 weeks
11299462|NCT02703363|Experimental|Minocycline with TAU|
11299463|NCT02703363|Experimental|Celecoxib with TAU|
11299464|NCT02703363|Experimental|Minocycline and celecoxib with TAU|
11299465|NCT02703363|Active Comparator|Placebo with TAU|
11299466|NCT02703350|Experimental|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
11299467|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
11299468|NCT02703350|Experimental|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
11299469|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
11299470|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
11299471|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
11299472|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
11299473|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
11299474|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
11299475|NCT02703324|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
11299476|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
11299477|NCT02703298|Experimental|TRX-818|
11299478|NCT02703285|Experimental|questionnaire|task of the participants in the study to determine the chest sound based on specific sounds
11299513|NCT02703051|Experimental|GMI-1271 with Filgrastim|GMI-1271 with Filgrastim
11299514|NCT02703038||Cardiogenic shock|Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
11299515|NCT02703025|Experimental|GCB 70 administered group|Green coffee bean extract capsule 500mg, BD
11300758|NCT02694380||Lung|Subjects with lung cancer receiving radiation therapy.
11299479|NCT02703272|Experimental|Part 1: Ibrutinib|The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
11299480|NCT02703272|Experimental|Part 2: Ibrutinib|Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
11299481|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:
~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
11299482|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:
~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
11299483|NCT02703246|Active Comparator|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
11299484|NCT02703246|Active Comparator|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
11299485|NCT02703233|Active Comparator|Nitrous Oxide|Patients receive nitrous oxide via mask.
11299486|NCT02703233|Placebo Comparator|Placebo (Oxygen)|Patients receive oxygen via mask.
11299487|NCT02703220|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.
11299488|NCT02703220|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
11299489|NCT02703220|Experimental|Finasteride|Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.
11299490|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
11299491|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
11299492|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
11299493|NCT02703194|Experimental|Prednisone|Prednisone mono-therapy
11299494|NCT02703194|Experimental|Prednisone and Leflunomide|Prednisone and Leflunomide combination therapy
11299495|NCT02703181|Experimental|Cohort 1(600 mg Epelsiban or placebo[every 8 hours])|Each subject will receive 200 mg of epelsiban administered TID (every 8 hours) (total daily dose of 600 mg) or a matching placebo administered every 8 hours.
11299496|NCT02703168||Immediate loading|Patients were allocated to treatment group in the core study. Immediate loading was defined as follows: Implant(s) will be restored with a temporary restoration on the day of surgery
11299497|NCT02703168||Early loading|Patients were allocated to treatment group in the core study. Early loading was defined as follows: Healing caps will be placed on the implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
11299498|NCT02703155|Other|Home Oral Glucose tolerance test kit|Providing children with Cystic Fibrosis between 10 and 17 years of age with Home Oral glucose tolerance test kit to screen Cystic fibrosis related Diabetes.
11299499|NCT02703142||Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
11299500|NCT02703129|Experimental|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
11299501|NCT02703116|Experimental|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
11299502|NCT02703116|Active Comparator|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
11299503|NCT02703103|Experimental|Standard cardiopulmonary resuscitation|standard CPR (30:2) according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
11299504|NCT02703103|Experimental|asynchronous cardiopulmonary resuscitation|asynchronuos CPR according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
11299505|NCT02703090|Placebo Comparator|Placebo|Normal saline infusion
11299506|NCT02703090|Active Comparator|Drug lower dose|Remifentanil infusion
11299507|NCT02703090|Active Comparator|Drug higher dose|Remifentanil infusion
11299508|NCT02703077|Active Comparator|1: ERCP + Spyglass + EHL|This group after the diagnosis of difficult bile duct stones, will be submitted to spyglass cholangioscopy + EHL (electrohydraulic lithotripsy)
11299516|NCT02703012|Experimental|Adjustment of ventilator settings by EIT|Individual Adjustment of Ventilator settings using an algorithm based on electrical impedance tomography.
11299517|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
11299518|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
11299519|NCT02702986|Experimental|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
11299520|NCT02702973||Observe the fundus characteristics|Observe the fundus characteristics after high doses of interferonα-2b therapy in patients with melanomas of the skin.
11299521|NCT02702960|Experimental|part. liver transplant and BMT|"Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.
~Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).
~If eligible, patients will begin:
~Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.
~Patients followed up through post transplant day 60, then weekly following discharge."
11299522|NCT02702947|Experimental|Prunus Domestica|Prunus domestica extract capsules, 100mg, BD
11299523|NCT02702934|Experimental|High-amylose rusks|Test meal with 100g of carbohydrates coming from high-amylose rusks
11299524|NCT02702934|Active Comparator|Control rusks|Test meal with 100g of carbohydrates coming from regular rusks used as control
11299525|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
11299526|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
11299527|NCT02702908||mPC|Prostate cancer patients with bone metastases (mPC)
11299528|NCT02702908||mCRPC|Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
11299529|NCT02702895||Phase 1|Former ASPIRE participants
11299530|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
11299531|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
11299532|NCT02702882|Other|Fenugreek seeds extract 500 mg|Fenugreek seeds extract ( Furosap) one caps once a day
11299533|NCT02702869||uCL(A)|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
11299534|NCT02702869||uCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, or Veau-III).
11299535|NCT02702869||bCL(A)|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
11299536|NCT02702869||bCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
11299537|NCT02702869||CP|Children with cleft secondary palate only, but intact lip and alveolus. Subgroup analysis by severity (submucous, Veau-I, or Veau-II).
11299538|NCT02702856||Men screened for prostate cancer|
11299539|NCT02702843|Active Comparator|Xenon Light|Laparoscopic cholecystectomy with Xenon Light
11299540|NCT02702843|Experimental|Near infrared light|Laparoscopic cholecystectomy with Near infrared light
11299541|NCT02702830||Diagnostic (MRI and CPET)|Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart. Patients also undergo MRI before and within 60 seconds after exercising.
11299542|NCT02702817|Active Comparator|naproxen|naproxen sodium tablets 220 mg twice daily for two years
11299543|NCT02702817|Placebo Comparator|placebo|tablets identical in appearance to naproxen tablets twice daily for two years
11299544|NCT02702804|Experimental|High Intensity Interval Training|Participants will attend two sessions per week for the 6 week intervention. Each session will consist of 6-10 sets of 60 second high intensity intervals interspersed with 60 seconds recovery. The workload during each interval will be set at 80-90% of peak power achieved during the VO2peak test. This is predicted to elicit 85-95% heart rate reserve in the participants. After each interval the participant's heart rate and rate of perceived exertion (RPE) will be collected. After each session a researcher will complete an Adverse Event form to record if an event occurred or not. Additionally the participant will complete a physical activity enjoyment (Perceived activity enjoyment scale) after one session per week.
11299545|NCT02702791|Experimental|Intervention|Telecoaching - feasible goal setting and feedback to enhance patient's motivation and commitment - in addition to pulmonary rehabilitation.
11299546|NCT02702791|Other|Usual care|includes only general advices regarding physical activity.
11299547|NCT02702778|Active Comparator|4mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 4mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
11299548|NCT02702778|Active Comparator|7mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 7mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
11299549|NCT02702778|Active Comparator|10mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 10mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
11299550|NCT02702765|Experimental|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
11299614|NCT02702297||Single arm|daily multimodal monitoring during pregnancy after PPROM, Analysis of neonatal routine parameters and histologic examination of placenta
11299726|NCT02701569|Experimental|Rebound exercise|Repeated jumping on a mini trampoline was performed with feet slightly apart
11299551|NCT02702752|Other|DYNASDY|The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
11299552|NCT02702752|Active Comparator|Control group|A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
11299553|NCT02702739|Active Comparator|Group I (<65 years)|Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
11299554|NCT02702739|Active Comparator|Group II (>65 years)|Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
11299555|NCT02702726|No Intervention|Congee and juice only|Control breakfast providing 50g carbohydrate
11299556|NCT02702726|Active Comparator|Congee and juice with coconut gel|Control breakfast, plus 25g coconut oleogel (solid)
11299557|NCT02702726|Active Comparator|Congee and juice with coconut oil|Control breakfast, plus 25g coconut oil (liquid)
11299558|NCT02702726|Active Comparator|Congee and juice with sunflower gel|Control breakfast, plus 25g sunflower oleogel (solid)
11299559|NCT02702726|Active Comparator|Congee and juice with sunflower oil|Control breakfast, plus 25g sunflower oil (liquid)
11299560|NCT02702713|Active Comparator|Dairy BEF + egg placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo
11299561|NCT02702713|Active Comparator|Egg BEF + dairy placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo
11299562|NCT02702713|Active Comparator|Bakery BEF + dairy placebo + egg placebo|200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo
11299563|NCT02702713|Placebo Comparator|All placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo
11299564|NCT02702700|Experimental|Lipoplatin/Visudyne-mediated photodynamic therapy|200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
11299565|NCT02702687|Experimental|PEF Feedback|This group will have 9 visits across 15 months.
11299566|NCT02702687|Active Comparator|Control Feedback|This group will have 9 visits across 15 months.
11299567|NCT02702674|Active Comparator|propranolol plus oxytocin|121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.
11299568|NCT02702674|Placebo Comparator|placebo plus oxytocin|121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.
11299569|NCT02702661|Experimental|Procedure - FICB|Fascia Iliaca Block following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
11299570|NCT02702661|Active Comparator|Procedure - LAI|Local Anaesthetic Infiltration following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
11299571|NCT02702648|Experimental|AC-082, Single Ascending Dose|Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level
11299572|NCT02702648|Placebo Comparator|Placebo, Single Ascending Dose|Subjects receive a single dose of the matched placebo
11299573|NCT02702648|Experimental|AC-082, Multiple Ascending Dose|Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level
11299574|NCT02702648|Placebo Comparator|Placebo, Multiple Ascending Dose|Subjects receive the matched placebo for 4 days
11299575|NCT02702635|Experimental|All Subjects|All recruited subjects
11299576|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
11299577|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
11299578|NCT02702596|Experimental|MBIC + DEF|Measurement-Based Integrated Care with Depression Education Fotonovela
11299579|NCT02702596|Experimental|MBIC + SE|Measurement-Based Integrated Care + Standard Education
11299580|NCT02702570|Other|CASA intervention|Each participant serves as his/her own control. Measures administered before and after an intervention.
11299581|NCT02702557|Other|Elastic Band Exercises|Unsupervised Elastic band exercises performed once a day until the patient is discharged from the hospital. One exercise for the upper extremity (row exercise level 1-3) and one exercise for the lower extremity (knee extension level 1-3). The two exercises are both performed as 3 sets of 10 repetitions.
11299582|NCT02702544|Experimental|neutral position|the patient is in the neutral position, located on his back on a flat surface
11299583|NCT02702544|Experimental|legs raised for 20 degrees|patient is placed on a flat surface, legs raised for 20 degrees, supported around ankles
11299584|NCT02702544|Experimental|legs raised for 30 degrees|patient is placed on a flat surface, legs raised for 30 degrees, supported around ankles
11299585|NCT02702544|Experimental|legs raised for 45 degrees|patient is placed on a flat surface, legs raised for 45 degrees, supported around ankles
11299586|NCT02702544|Experimental|legs raised for 60 degrees|patient is placed on a flat surface, legs raised for 60 degrees, supported around ankles
11299587|NCT02702531|Experimental|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
11299588|NCT02702531|Experimental|Water + Povidone-iodine Solution|Clearify Visualization with Water + Povidone-iodine Solutionused during laparoscopic surgery
11299589|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
11299590|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
11299677|NCT02701920||Newborns and surgical delivery|Well term newborn infants following birth by cesarean section.
11299591|NCT02702505|Experimental|NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time. The new formulation has received the Food and Drug Administrations 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).19
11299592|NCT02702505|Other|ProRoot MTA|Control group. This group will receive the old formulation of MTA in the pulpotomy and the tooth will receive a full coverage stainless steel crown restoration.
11299593|NCT02702492|Experimental|KPT-9274|"Part A: [CLOSED TO ENROLLMENT]
~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
11299594|NCT02702492|Experimental|KPT-9274 & Niacin Extended Release (ER)|"Part B:[CLOSED TO ENROLLMENT]
~500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
11299595|NCT02702492|Experimental|KPT-9274 + Nivolumab|"Part C:
~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.
~Nivolumab 480 mg IV administered Day 1 during each 28 day cycle."
11299596|NCT02702466|Experimental|Immediate SPA Therapy|6 day immediate SPA treatment (soon after randomization) and written information with physical exercises adapted to their pathology and also a program of healthcare at the USB key
11299597|NCT02702466|Active Comparator|Late SPA Therapy|Written information with physical exercises adapted to their pathology and a program of healthcare at the USB key and late 6 day SPA treatment
11299598|NCT02702453|Experimental|Development and Testing|Develop an online interactive, tailored intervention to address the needs of men and partners interested in sexual recovery after treatment for localized prostate cancer during the first 6 months after treatment. The intervention will undergo content testing through 4 focus groups with prostate cancer survivors and partners and usability testing with 5 survivors and partners
11299599|NCT02702427|Experimental|ARM 1|Patients with Adenovirus or CMV infection after HSCT and no reduction of viral disease or stable disease with 10E6 viral copies within 2 weeks of antiviral treatment will receive a single infusion of virus-specific T-Cells
11299600|NCT02702414|Experimental|Prior Systemic Therapy|Participants with previously systemically treated HCC receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
11299601|NCT02702414|Experimental|Systemic Therapy Naive|Participants with HCC who had not received treatment for systemic disease receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
11299602|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
11299603|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
11299604|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
11299605|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
11299606|NCT02702362|Active Comparator|anodal stimulation|"Patients received anodal tDCS (on the precuneus ) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS.
~A final CRS-R is performed 5 days after the end of the session to assess the potential long term effects of the tDCS."
11299607|NCT02702362|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed 5 days after the end of the session.
11299608|NCT02702349|Other|1|penicillin test and challenge
11299609|NCT02702336|Experimental|EYTO-Kids Intervention Group|Adolescents will receive 16h of training (2h healthy lifestyle training, social marketing and communication, 6h to design activities, 2h session together with all intervention high-schools, 6h to practice and standardize activities) and 4h (1h/activity) to implement 4 activities in schools. The scholars will receive 4 activities designed by adolescents, focusing on: 1) increasing fruit consumption, 2) increasing vegetable consumption, 3) increasing physical activity practice and to reduce sedentary lifestyles and, 4) decreasing sugary drinks and fast-food consumption.
11299610|NCT02702336|No Intervention|Control Group|The control group will not receive any kind of intervention (only the assessment).
11299611|NCT02702323|Experimental|Apatinib & TACE|Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
11299612|NCT02702323|Active Comparator|TACE|TACE therapy one times every 4-6 weeks.
11299613|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
11299615|NCT02702284|Other|Adequate health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
11299616|NCT02702284|Experimental|Adequate health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
11299617|NCT02702284|Other|Limited health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
11299618|NCT02702284|Experimental|Limited health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
11299619|NCT02702271|Experimental|WATCHMAN FLX|WATCHMAN FLX implant: This is a single arm study
11299620|NCT02702258|Experimental|MB-BP|This is the primary intervention tested in this single arm trial.
11299621|NCT02702245|Placebo Comparator|Placebo comparator: Control|OGTT without thylakoids.
11299622|NCT02702245|Experimental|Experimental: Thylakoids 5 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 5 g. Intervention: OGTT at one occasion.
11299623|NCT02702245|Experimental|Experimental: Thylakoids 10 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 10 g. Intervention: OGTT at one occasion.
11299624|NCT02702232||Parkinson's disease|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex- and age-matched normal subjects with be recruited from the public. These patients will be evaluated by ultrasonography for shoulder.
11299625|NCT02702232||Normal|Normal controls who will be evaluated by ultrasonography for shoulder
11299626|NCT02702219|Experimental|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
11299627|NCT02702219|Active Comparator|Static stretching|Static stretching of the hamstrings muscles to be performed every day
11299628|NCT02702206|Experimental|corticosteroids SASD injection|under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
11299629|NCT02702206|Experimental|hyaluronic acid (ARTZ) SASD injection|under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
11299630|NCT02702206|Placebo Comparator|normal saline SASD injection|under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine
11299631|NCT02702193|Experimental|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
11299632|NCT02702193|No Intervention|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
11299633|NCT02702180|Experimental|molgramostim continuously|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg once daily for 24 weeks
11299634|NCT02702180|Experimental|molgramostim intermittently|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg for seven days and placebo nebuliser solution for seven days for 24 weeks (12 cycles)
11299635|NCT02702180|Placebo Comparator|placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
11299636|NCT02702167|Experimental|High-frequency rTMS|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
11299637|NCT02702167|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
11299638|NCT02702167|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
11299639|NCT02702154|Experimental|High-frequency rTMS|20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
11299640|NCT02702154|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
11299641|NCT02702154|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
11299642|NCT02702141|Experimental|SGN-CD19B|
11299643|NCT02702128|Active Comparator|Tranexamic acid|1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
11299644|NCT02702128|Placebo Comparator|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
11299645|NCT02702115|Experimental|Cohort 1: SB-318: Starting Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11299646|NCT02702115|Experimental|Cohort 2: SB-318 at Next Ascending Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11299647|NCT02702115|Experimental|Cohort 3: SB-318 at Next Ascending Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
11299648|NCT02702102|Experimental|11C-PBR28 PET scans|Participants will receive one IV injection of up to 20 millicuries of 11C-PBR28.
11299649|NCT02702089||IAPE|Intersphincteric AP excision
11299650|NCT02702089||HP|Hartmann's procedure
11299651|NCT02702076|Experimental|Apomorphine|This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
11299652|NCT02702076|Placebo Comparator|Placebo|This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
11299653|NCT02702063|Other|TTE vs. EC + calibration group|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.
~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial."
11299654|NCT02702063|Other|Right heart catheterisation|Twenty five patients undergoing routine right heart catheterization (RHC) at the department of cardiology for the evaluation of suspected pulmonary hypertension or heart failure will be included in this trial. EC measurements will be obtained during RHC, and a TTE (for measuring LVOT-area) will be performed immediately before undergoing RHC. Inclusion and exclusion criteria are similar as described above.
11299655|NCT02702063|Other|Passive leg raising test|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.
~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial.
~SV and CO will be measured using TTE and EC. Patient's legs will then be raised by 45degree, and SV and CO measurements will be repeated after 1 minute. Changes in SV and CO observed with both methods will be compared."
11299656|NCT02702050|Active Comparator|Conventional treatment group|Conventional treatment group will receive an educational session before commencement of the program. Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises will be provided within a 6-week period (i.e., two sessions per week) to all subjects. No mechanical stimulation will be given.
11299657|NCT02702050|Experimental|Mechanical stimulation group|A 10 minute mechanical stimulation program - 'Mechanical stimulation (LPG system; Cellu M6 Integral I), will be provided after each of the twelve sessions of conventional treatment.
11299658|NCT02702037|Experimental|Intervention|"The participants will be supported to perform the sit-to-stand exercise at least four times per day during 12 weeks (7 days/week).
~The participants will also be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week)."
11299659|NCT02702037|No Intervention|Control|Standard care
11299660|NCT02702011|Experimental|empagliflozin low dose|
11299661|NCT02702011|Experimental|empagliflozin medium dose|
11299662|NCT02702011|Experimental|empagliflozin high dose|
11299663|NCT02702011|Placebo Comparator|placebo|
11299664|NCT02701998|Experimental|mHealth-Enhance Physical Activity Intervention|Tech-PAI participants will be given 3 goals: 1) to increase their average baseline daily walking exercise by 30 minutes at week 12; 2) to increase their average baseline daily steps by 4,000 at week 12; and 3) to get up and walk for at least 2 minutes after every 60 minutes of sitting. Participants will receive instruction on how to gradually and safely increase their bout-related walking exercise and steps over the 12 week period. In addition to goal setting, Tech-PAI participants will receive a commercially available activity tracker and accompanying that provides real-time monitoring of steps, activity minutes, and issues a text-based prompt after 60 minutes of sitting to get up and move. Also, participants will receive a weekly e-mail feedback message from research staff on goal progress and will be asked to view weekly Internet-based video lessons that will provide behavioral strategies to increase MPA and steps and decrease SB during the first 6 weeks of the intervention period.
11299665|NCT02701998|Active Comparator|Physical Activity Intervention|PAI participants will be given the same goals as Tech-PAI intervention participants and receive a pedometer and related print materials to assist them in recording and increasing daily steps and bout-related MPA (but no activity tracker, access to video-based skills training lessons, or weekly feedback).
11299666|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
11299667|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
11299668|NCT02701972|Experimental|Control and Test|Pre-implantation and Post-implantation of BACE device
11299669|NCT02701959|Placebo Comparator|Low nitrate lettuce|50g of low nitrate lettuce (placebo) on single occasions
11299670|NCT02701959|Active Comparator|High nitrate lettuce|50g of high nitrate lettuce (intervention) on single occasions
11299671|NCT02701946|Experimental|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US).
11299672|NCT02701946|Placebo Comparator|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
11299673|NCT02701933|Other|Ketamine-Saline|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, ketamine is administered on the first assessment and placebo (saline) is administered on the second assessment.
11299674|NCT02701933|Other|Saline-Ketamine|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, placebo (saline) is administered on the first assessment and ketamine is administered on the second assessment.
11299675|NCT02701920||NICU infants and hat|Newborn infants of any gestation on the neonatal intensive care unit (NICU).
11299676|NCT02701920||NICU infants and sensor|Newborn infants of any gestation requiring heart rate monitoring on the neonatal intensive care unit.
11299681|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
11299682|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.
~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
11299683|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
11299684|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
11299685|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
11299686|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
11299687|NCT02701881|Experimental|Long stenting group|
11299688|NCT02701881|Active Comparator|Short stenting group|
11299689|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the PBRC Demonstration Kitchen over the course of approximately 3 months.
11299690|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
11299691|NCT02701855||Hypertension and progressive MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
11299692|NCT02701855||Hypertension and stable MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
11299693|NCT02701855||Hypertension, without MCI|60 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
11299694|NCT02701842|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
11299695|NCT02701842|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points.
11299696|NCT02701829|Experimental|Health Fairs (HF)|Drivers will undergo U&C Health Fair follow-up either Regular or Urgent Follow-up: Timeline is determined by health status, with regular follow-up continuing for at least two weeks and urgent follow-up continuing for at least a month
11299697|NCT02701829|Experimental|HF + text messaging + home BP monitoring|Drivers will receive: U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months A home BP monitoring equipment with instructions to self-monitor BP for nine months
11299698|NCT02701829|Experimental|HF +Tech + social network support (SNS).|"Drivers will receive:
~U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months and home BP monitoring equipment with instructions to self-monitor BP for nine months A social network support intervention in which selected family/peers encourage drivers to maintain healthy behaviors for nine months"
11299699|NCT02701816||K-INNOVA|Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).
11299700|NCT02701777|Active Comparator|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
11299701|NCT02701777|Active Comparator|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
11299702|NCT02701777|Active Comparator|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
11299703|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
11299704|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
11299705|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
11299706|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
11299707|NCT02701712|Experimental|Magnetic resonance - guided radiation therapy (MRgRT)|Magnetic resonance (MR) - guided radiation therapy
11299708|NCT02701699|Experimental|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
11299727|NCT02701569|No Intervention|Control|No exercise was administered but participants continued with routine medical care
11299728|NCT02701556|Experimental|Bausch & Lomb (B&L) NNR06 Multi-Purpose Solution (MPS)|B & L investigational NNR06 used as a rub care regimen (Test)
11299729|NCT02701556|Active Comparator|COMPLETE MPS|B&L Multi-Purpose Solution as a rub care regimen (Control)
11299709|NCT02701686|Experimental|quit immediately (QI)|Subjects in the QI group will receive a smoking cessation booklet plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit now, as quitting can greatly reduce risks, (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention during each telephone follow-up. The whole intervention will be limited to less than 1 min or slightly longer if necessary. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the counsellor will congratulate to the subjects who successfully quit smoking, while deliver the same brief intervention as a booster for those who continue to smoke.
11299710|NCT02701686|Experimental|cut down to quit (CDTQ)|Subjects in the CDTQ group will also receive the smoking cessation booklet plus a brief intervention using the AWARD model. Instead of asking them to quit immediately, they will be advised gradually cutting down on their cigarette consumption. Also, the subjects will be provided with an education card that contains reduction strategies and a suggested plan to reduce smoking. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the nurse counsellor will repeat the warning message that one out of two smokers will be killed by smoking, and remind the subjects of their next reduction target. The counsellor will congratulate subjects who quit or reduce smoking on their success. When subjects fail to quit or reduce their cigarette consumption, the counsellor will reinforce the health hazards of continued smoking and the benefits of quitting, and encourage them to try again immediately or in the near future.
11299711|NCT02701673|Experimental|Belinostat/Gem/Bu/Mel + AutoSCT|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1.
~Caphosol oral rinses 30 mL four times a day used from Day -8. Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
~Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1. Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2. Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2. Participants with cluster of differentiation antigen 20 (CD20+) tumors receive Rituximab 375 mg/m2 by vein on Day -9.
~Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
~Melphalan 60 mg/m2/d by vein on Day -2. Stem cell transplant by vein given on Day 0."
11299712|NCT02701660|Experimental|electronic medication dispenser|An Automatic Tablet Dispensing and Packaging System is used to repack all solid oral prescription medications for each participant into unit-of-dose pouches. Every participant receives a roll with pouches for 14-28 days loaded into a dispenser installed at their homes. The electronic medication dispenser is a remote controlled, electronic medication management aid reminding the patients with acoustic alerts to take their medication.
11299713|NCT02701647|Experimental|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
11299714|NCT02701647|Experimental|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
11299715|NCT02701647|Sham Comparator|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
11299716|NCT02701634|Experimental|ENTO|ENTO 400 mg or 200 mg tablet twice daily for 48 weeks
11299717|NCT02701634|Placebo Comparator|Placebo|Placebo to match tablet twice daily for 48 weeks
11299718|NCT02701621|Active Comparator|MIRT Group|Individuals underwent Multidisciplinary Intensive Rehabilitation Treatment. It consists of 4 weeks of physical therapy in a hospital setting with four daily sessions for five days and one hour of physical exercise on the sixth day.The duration of each session is about one hour. The first session comprises cardiovascular warm-up activities, relaxation and muscle-stretching. The second session includes aerobic exercises and the use of different devices: a stabilometric platform, treadmill plus, crossover, cycloergometer. The third is a session of occupational therapy. The last session includes one hour of speech therapy. The rehabilitation program can also include: robotic-assisted walking training, virtual reality training and meetings with a Psychologist.
11299719|NCT02701621|Experimental|MIRT-AT|"Patients underwent land-based therapy in association with aquatic therapy, three times per week for four weeks.
~The land-based activities included the second and the third session of MIRT.
~The water sessions were divided in 3 phases:
~i) Warm Up Exercises. This phase lasted 10 minutes and comprised walking performances.
~ii) Central session Training. This phase lasted 30-45 minutes and comprised trunk mobility exercises in standing position and sitting on a floating device, static and dynamic exercises. The successive balance training exercises comprised: maintaining balance with closed eyes; balance control with one leg resting on a step; postural control changing the support base.
~iii) Cool-down. This phase lasted 5 minutes and comprised general stretching exercises and gentle walking."
11299720|NCT02701608|Experimental|Oral switch treatment|Oral switch to the combination of levofloxacin and rifampicin
11299721|NCT02701608|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of staphylococci IE (European guidelines 2015)
11299722|NCT02701595|Experimental|Oral switch treatment|Oral switch to amoxicillin
11299723|NCT02701595|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)
11299724|NCT02701582|Experimental|Goal Directed Therapy|Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
11299725|NCT02701582|Active Comparator|Control Group|FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
11324534|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
11299730|NCT02701543|Active Comparator|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
11299731|NCT02701543|Active Comparator|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
11299732|NCT02701530|Experimental|Targeted smoking cessation|"Smoking cessation program tailored in cooperation with the target group; smokers with low education.
~Peer-based anti-relapse strategy. Recruitment strategy: peer-driven, written invitations and posters."
11299733|NCT02701530|No Intervention|Control|No smoking cessation program.
11299734|NCT02701517|Active Comparator|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
11299735|NCT02701517|Experimental|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
11299736|NCT02701504||Sleep apnea group|The patients who are found to have sleep apnea based on the results of the portable sleep study
11299737|NCT02701504||Non sleep apnea group|The patients who are found to have no sleep apnea based on the results of the portable sleep study
11299738|NCT02701491|Experimental|Ginger|Ginger
11299739|NCT02701491|Placebo Comparator|Placebo|Placebo-no intervention
11299740|NCT02701478|Other|N2O exposure|"There is only one arm in this study. All patients under General Anesthesia are exposed to 4 different doses or concentrations of inhaled N2O that is combined with the anesthetic desflurane. Each patient will be submitted to the standard nociceptive stimulus when inhaled N2O is at 0, 50, 25, and finally back to 0%. ANI and NoL Indices variations between before stimulus and after stimulus at each N2O concentration will be assessed and compared. This will allow to demonstrate an analgesic effect (less variations of ANI and NoL) when inhaled N2O is high (50%) testifying for the analgesic effect of this gas N2O."
11299741|NCT02701465|Experimental|Intervention group|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
11299742|NCT02701465|Active Comparator|Control group|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
11299743|NCT02701452|Experimental|COAGO|All patients undergoing antagonist protocol and at high risk of OHSS (estradiol level ≥ 3000 pg/mL and/or more than 20 follicles ≥ 11mm on the day of triggering) were triggered by GnRH agonist.
11299744|NCT02701439||HIV-infected|"Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.
~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
~Abbreviated demographic and clinical evaluation
~TB history and evaluation
~Obtain three sputum samples - one early morning sample and two spot samples
~HIV testing (and CD4 if positive)
~Chest radiograph
~Small membrane filtration intervention"
11299745|NCT02701439||HIV negative|"Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.
~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
~Abbreviated demographic and clinical evaluation
~TB history and evaluation
~Obtain three sputum samples - one early morning sample and two spot samples
~HIV testing (and CD4 if positive)
~Chest radiograph
~Small membrane filtration intervention"
11299746|NCT02701426|Experimental|participant|agree to participate to the program combining physical activity and nutritional counseling
11299747|NCT02701426|No Intervention|no participant|disagree to participate to the program
11299748|NCT02701413|Experimental|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
11299749|NCT02701413|Sham Comparator|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
11299750|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
11299751|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
11299752|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
11299753|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
11299754|NCT02701374|Experimental|1:TRK-700|high dose
11299755|NCT02701374|Experimental|2:TRK-700|low dose
11299756|NCT02701374|Placebo Comparator|3:Placebo|Placebo
11299757|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
11299758|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
11299759|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
11299760|NCT02701335|Experimental|Experimental group|Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
11299761|NCT02701335|Active Comparator|Control group|Gloreha device and standardized exercise. 12 sessions over 4 weeks (3 sessions per week).
11299762|NCT02701322|Experimental|Medical Clown|the study group will be accompanied by a medical clown from the arrival to the premise, through the actual examination and after exiting the exam room. The medical clown will explain about the upcoming examination and will induce a less stressed atmosphere. After the examination the clown will close the session for the patient.
11299763|NCT02701322|No Intervention|Control|The control group will do the same videofluoroscopic procedure but without a medical clown.
11299764|NCT02701309||Non-invasive Iron detection|Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.
11299765|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
11299766|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
11299767|NCT02701283|Experimental|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of Aortic Stenosis with the Medtronic CoreValve System Transcatheter Aortic Valve Implantation (TAVI) device or the Medtronic Corevalve Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
11299768|NCT02701283|Active Comparator|Surgical Aortic Valve Replacement (SAVR)|Treatment of Aortic Stenosis with commercial Surgical Aortic Valve Replacement (SAVR)
11299769|NCT02701270|Experimental|Experimental Dietary Fibre 1|
11299770|NCT02701270|Experimental|Experimental Dietary Fibre 2|
11299771|NCT02701270|Active Comparator|Polydextrose|
11299772|NCT02701270|Active Comparator|Dextrose control|
11299773|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
11299774|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
11299775|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
11299776|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
11299777|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
11299778|NCT02701244||Permanent Breast Seed Implant (PBSI)|Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
11299779|NCT02701231|Sham Comparator|Sham control|Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
11299780|NCT02701231|Experimental|Low-frequency Rotating Magnetic Therapy|Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
11299781|NCT02701218|Experimental|Single cycle|single cycle of canalith repositioning procedure
11299782|NCT02701218|Experimental|multiple cycles of CRP|multiple cycles of canalith repositioning procedure CRP will be stopped if 1) no nystagmus and vertigo in all positions 2) complications exited 3) stable nystagmus in the 2 last cycles
11299783|NCT02701205|Experimental|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
11299784|NCT02701205|Experimental|etanercept (half dose)|One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
11299785|NCT02701205|Placebo Comparator|Placebo|Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24
11299786|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
11299787|NCT02701179|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
11299788|NCT02701179|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
11299789|NCT02701166|Experimental|Bezafibrate|Bezalip retard 400mg tablet
11299790|NCT02701166|Placebo Comparator|Placebo|Placebo 400mg tablet
11299791|NCT02701153|Experimental|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
11299792|NCT02701140|Active Comparator|Ticagrelor|Ticagrelor will be given in a loading dose of 180 mg followed by a dose of 90 mg twice daily.
11299793|NCT02701140|Active Comparator|Clopidogrel|Clopidogrel will be given in a loading dose of 600 mg followed by a dose of 75 mg once a day.
11299794|NCT02701127|Active Comparator|Niacinamide 1 gram|Oral niacinamide, 1 gram daily
11299795|NCT02701127|Active Comparator|Niacinamide 3 grams|Oral niacinamide, 3 grams daily
11299796|NCT02701127|Placebo Comparator|Placebo|Oral placebo pill
11299797|NCT02701114|Active Comparator|Proximal|Proximal Adductor Canal Block
11299798|NCT02701114|Active Comparator|Distal|Distal Adductor Canal Block
11299833|NCT02700841|Active Comparator|Arm II (vaccine, stem cell transplant)|Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.
11299834|NCT02700828|Active Comparator|Hydrocortisone|Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
11299799|NCT02701101|Other|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:
~Risk Assessment (standard of care; Braden, Waterlow, or Norton)
~Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)
~SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
11299800|NCT02701088|Experimental|Concomitant chemotherapy and radiotherapy|Chemoradiotherapy with two cycles of 5FU and Mitomycin-C plus radiotherapy by SIB-IMRT (for simultaneous integrated boost intensity modulated radiation therapy) day 1 to day 50 in 36 fractions
11299801|NCT02701075|Experimental|MC5-A Scrambler Therapy|MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
11299802|NCT02701075|Sham Comparator|MC5-A Scrambler Therapy Sham Device|The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
11299803|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
11299804|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
11299805|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
11299806|NCT02701036||sporadic adult onset ataxia|SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
11299807|NCT02701036||cerebellar multiple system atrophy|Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.
11299808|NCT02701010|Active Comparator|Group 1|Structured training and leaflet
11299809|NCT02701010|Active Comparator|Group 2|Structured training
11299810|NCT02701010|Active Comparator|Group 3|Leaflet
11299811|NCT02701010|Sham Comparator|Group 4|Control group
11299812|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
11299813|NCT02700984|Experimental|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
11299814|NCT02700984|Active Comparator|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
11299815|NCT02700971|Experimental|Cutaneous Biopsy for microarray analysis|To determine whether outcomes improve as a function of anti-tumor immunity which may enable the use of this technique as a predictive biomarker of treatment response.
11299816|NCT02700958|Experimental|Remote ischemic preconditioning|Remote Ischemic Preconditioning (RIPC) is performed by inflating blood pressure cuff for 5-minutes at 200 mmHg, or if patients systolic blood pressure is higher than 200 mmHg 20 mmHg above systolic pressure, alternated with 5-minute deflation for 4 times.
11299817|NCT02700958|Sham Comparator|SHAM remote ischemic preconditioning|SHAM Remote Ischemic Preconditioning (RIPC-SHAM) is accomplished by alternating 4 cycles of 5-minute inflation with 5-minute deflation. Blood pressure cuff will be inflated to 10-20 mmHg. RIPC-SHAM is performed with standard blood pressure cuff on upper-arm.
11299818|NCT02700945|Active Comparator|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
11299819|NCT02700945|No Intervention|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
11299820|NCT02700932|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
11299821|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
11299822|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
11299823|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
11299824|NCT02700906|Active Comparator|Corticosteroid injection|For corticosteroid injection, triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
11299825|NCT02700906|Active Comparator|Lidocaine injection|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
11299826|NCT02700893|Experimental|Atropine + propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
11299827|NCT02700893|Active Comparator|Atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
11299828|NCT02700880||Heart failure patients with LifeVest|Subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator
11299829|NCT02700867|Experimental|Proximal tibia|Assumption of intraosseous access into the proximal tibia. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
11299830|NCT02700867|Experimental|Proximal humerus|Assumption of intraosseous access into the proximal humerus. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
11299831|NCT02700854|Experimental|5% carbon-dioxide inhalation|5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
11299832|NCT02700841|Experimental|Arm I (vaccine, CD34 transplant, DLI)|ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.
11299835|NCT02700828|Placebo Comparator|Placebo|Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
11299836|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
11299837|NCT02700815|Active Comparator|Diclofenac|
11299838|NCT02700815|Active Comparator|Capsaicin|
11299839|NCT02700815|Placebo Comparator|Placebo|
11299840|NCT02700802|Experimental|Feed1st: Face-to-face provider delivered referral|In this arm of the study, caregivers will receive usual care and a brief face-to-face referral to the Feed1st program delivered by the provider.
11299841|NCT02700802|Experimental|Feed1st: Text message delivered referral|In this arm of the study, caregivers will receive usual care and an automated brief text message referral to the Feed1st program from the health care provider. The text message referral will align as closely as possible with the face-to-face referral.
11299842|NCT02700802|No Intervention|Standard of Care|Usual care includes passive delivery of information from nursing staff about all available food options in the hospital including the self-serve food pantries in the standard Caregiver FYI Admissions Packet.
11299843|NCT02700789||Pregnant women|Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures.
11299844|NCT02700776||COHORT I-BIRADS 1 or 2,|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0 and 6-12.
11299845|NCT02700776||COHORT II -BIRADS 3|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0, 3-6, and 6-12.
11299846|NCT02700776||COHORT III-BIRADS 4-6|SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
11299847|NCT02700763|Experimental|[18F]dabrafenib molecular imaging|A [18F]dabrafenib PET scan will be performed at baseline (7 days or less before the start of treatment with oral dabrafenib).
11299848|NCT02700750|Other|OCT exam|OCT exam No Arm No Intervention
11299849|NCT02700737|Active Comparator|Group A|"Interventional cardiologists presented with limited dataset including only information that is available from imaging parameters currently recommended by clinical practice guidelines."
11299850|NCT02700737|Experimental|Group B|Interventional cardiologists presented with the full dataset, including imaging parameters currently recommended by clinical practice guidelines and image-based simulation modelling.
11299851|NCT02700724|Other|Observation|Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
11299852|NCT02700724|Other|Immediate Surgery|Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
11299853|NCT02700711|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance.
11299854|NCT02700711|Experimental|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance.
11299855|NCT02700698||Healthy lean|Healthy lean women, 25-35 years
11299856|NCT02700698||Obese IR|Obese, insulin resistant women, 25-35 years
11299857|NCT02700685|Experimental|Pycnogenol|"Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
~Subjects < 30 kg body weight: 20 mg Pycnogenol/day Subjects >= 30 kg body weight: 40 mg Pycnogenol/day"
11299858|NCT02700685|Placebo Comparator|Placebo|Placebo treatment (identical capsules containing excipients only)
11299859|NCT02700685|Active Comparator|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release. Subjects < 30 kg body weight: 20 mg methylphenidate once per day Subjects >= 30 kg body weight: 30 mg methylphenidate once per day
11299860|NCT02700672||Institutionalized older adults|Observational study
11299861|NCT02700672||Non-institutionalized older adults|Observational study
11299862|NCT02700659||UC monitoring patients|"Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations.
~All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder.
~No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes."
11299863|NCT02700646|No Intervention|standard care|Standard care comparison
11299864|NCT02700646|Experimental|inpatient|Inpatient recommendations to parents regarding infant motor activities
11299865|NCT02700646|Experimental|inpatient/outpatient|Inpatient and outpatient recommendations to parents regarding infant motor activities
11299866|NCT02700633||Those with pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
11299867|NCT02700633||Those without pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
11299868|NCT02700620|Experimental|Treatment group|Internet-delivered CBT
11299869|NCT02700620|No Intervention|Control group|Waitlist control
11299870|NCT02700607|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11299871|NCT02700607|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
11299872|NCT02700594|Active Comparator|Hip mobilization|Prone posterior-to-anterior Grade IV hip joint mobilization: The subject will be placed in prone on a treatment table. The intervening physical therapist will place the heel of his hand on the greater trochanter of the femur on the involved side provide rhythmic anterior-directed force. The subject will receive 3 bouts of 30 seconds of continuous mobilizations with 10 seconds rest in between bouts. For the prone posterior-to-anterior Grade IV hip joint mobilization, the intervening therapist will perform all 3 bouts in the same position.
11299902|NCT02700399|Other|Traditional first|"Traditional Tilt table 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Erigo® 0 - 60 degrees
~Step frequency on Erigo® = 48"
11299873|NCT02700594|Active Comparator|Spine mobilization|Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization: The subject will be placed in prone on the treatment table. The intervening physical therapist will place his thumbs on the transverse process, on the affected side, of the L3, L4 or L5 vertebrae and provide a rhythmic anterior-directed force. Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization, the intervening therapist will perform 1 bout on each of L3, L4 and L5 for a total of 3 bouts
11299874|NCT02700581|Active Comparator|low PEEP conventional ventilation|PEEP 2 mmHg tidal volume 10ml/kg
11299875|NCT02700581|Experimental|moderate PEEP conventional ventilation|PEEP 7 mmHg tidal volume 10ml/kg
11299876|NCT02700581|Experimental|low PEEP protective ventilation|PEEP 2 mmHg with tidal volume 6 ml/kg
11299877|NCT02700581|Experimental|moderate PEEP protective ventilation|PEEP 7 mmHg tidal volume 6ml/kg
11299878|NCT02700568|Experimental|axitinib|Patients will receive axitinib.
11299879|NCT02700542|Active Comparator|Intervention|"Participants randomly assigned to the intervention group will receive the Integrated Pest Management (IPM) treatment 2-4 weeks of completion of the baseline assessment.The IPM protocol for this research will focus on pest control in the bathrooms and kitchen and will include an assessment of the pest problem, thorough cleaning, patching of small holes, identification and referral of any necessary large repairs, and targeted application of safe pesticides as needed. In cases of severe infestation, a second treatment visit might be required in the home.
~In addition to the intervention, the family will be provided with basic information about good pest-control practices, such as appropriate food storage, and be given a set of food storage containers."
11299880|NCT02700542|Placebo Comparator|Control|Participants randomly assigned to the control group will be offered the equivalent intervention, information, and food storage containers after completion of their 12-month assessment.
11299881|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
11299882|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
11299883|NCT02700516||Recurrent GN|Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
11299884|NCT02700516||Non-recurrent GN|Renal transplant recipients with non-recurrent primary glomerulonephritis.
11299885|NCT02700516||Non-GN|Renal transplant recipients with etiologies other than primary glomerulonephritis.
11299886|NCT02700503|Experimental|Intervention|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
11299887|NCT02700490|Active Comparator|Specialist|Assessment and treatment of common mental disorders by a clinical psychologist in primary care facilities.
11299888|NCT02700490|Experimental|Enhanced Usual Care|Assessment and treatment of common mental disorders by a general practitioner and nurse practitioner, who have been trained in the WHO mhGap manual, in primary care facilities.
11299889|NCT02700477|Active Comparator|Fenugreek seed extract|Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks
11299890|NCT02700477|Placebo Comparator|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
11299891|NCT02700464|Experimental|Bladder EpiCheck Urine Test|Bladder EpiCheck Urine Test
11299892|NCT02700464|Active Comparator|Gold Standard|Cystoscopy and pathology
11299893|NCT02700451|Placebo Comparator|Intravenous (IV) Placebo|IV Placebo arm
11299894|NCT02700451|Experimental|IV Ketorolac|IV Ketorolac arm
11299895|NCT02700451|Experimental|IV Acetaminophen|IV Acetaminophen arm
11299896|NCT02700438|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
11299897|NCT02700438|Experimental|Urgent PC Neuromodulation System®|The Urgent PC Neuromodulation System® (Uroplasty, Minnetonka, MN, USA) was used for percutaneous posterior tibial nerve stimulation. Subjects underwent one 30-min session 2 days per week for 8 consecutive weeks in an outpatient clinic. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion. PPTNS was undertaken at the highest amplification (0-20 mA) at a frequency of 20 Hz, causing neither a motor response nor pain.
11299898|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
11299899|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
11299900|NCT02700412|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).
~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
11299901|NCT02700399|Other|Erigo® First|"Erigo® 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Traditional Tilt table 0 - 60 degrees
~Step frequency on Erigo® = 48"
11299956|NCT02700009|Active Comparator|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
11299903|NCT02700386|Experimental|Adjuvant Hypofractionated Radiation|"Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a boost or conedown) to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions."
11299904|NCT02700373|Experimental|PDC-APB|"PDC-APB Intra-Muscular (IM)
~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
11299905|NCT02700373|Placebo Comparator|Placebo|"Placebo
~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
11299906|NCT02700360|Experimental|Part 1(1,000mg dose): group 1|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; cross-over period: 7 days
11299907|NCT02700360|Experimental|Part 1(1,000mg dose): group 2|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; cross-over period: 7 days
11299908|NCT02700360|Experimental|Part 2(500mg dose): group 3|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; cross-over period: 7 days
11299909|NCT02700360|Experimental|Part 2(500mg dose): group 4|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
11299910|NCT02700360|Experimental|Part 2(2,000mg dose): group 5|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, after high-fat diet intake; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; cross-over period: 7 days
11299911|NCT02700360|Experimental|Part 2(2,000mg dose): group 6|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
11299912|NCT02700347|Experimental|Low dose pyrazinamide|Day 0: Pyrazinamide 10mg/kg, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 10mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
11299913|NCT02700347|Experimental|Standard dose pyrazinamide|Day 0: Pyrazinamide 25mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 25mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
11299914|NCT02700347|Experimental|High dose pyrazinamide|Day 0: Pyrazinamide 35mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 35mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
11299915|NCT02700334|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
11299916|NCT02700334|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
11299917|NCT02700321|Experimental|High Flow nasal cannula oxygen (HFNC)|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/Airvo® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
11299918|NCT02700321|Active Comparator|STANDARD high flow Face Mask (HFFM)|"Patients randomized in Standard face mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
11299919|NCT02700308|Active Comparator|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
11299920|NCT02700308|Experimental|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
11299921|NCT02700295||Orthokeratology contact lens group|
11299922|NCT02700282|Experimental|Cystic Fibrosis children|"Children with Cystic Fibrosis will experience lung function measurement while backpack carrying.
~Aerobic Capacities will also be assessed during treadmill gait."
11299923|NCT02700282|Active Comparator|Healthy Children|"Healthy Children will experience lung function measurement while backpack carrying.
~Aerobic Capacities will also be assessed during treadmill gait."
11299924|NCT02700256||Patients undergoing a procedure|Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third & final call for that day will be placed at 11:00am.
11299925|NCT02700243|Experimental|Fitbit|Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
11299926|NCT02700243|No Intervention|Usual Care|Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
11299927|NCT02700230|Experimental|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies.
11299928|NCT02700217|Experimental|Spinal Anaesthesia|2.5ml of heavy 0.5% Bupivacaine, 400mg of Diamorphine (Spinal Anaesthesia) & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
11300339|NCT02697214|Active Comparator|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
11299929|NCT02700217|Active Comparator|Rectus Sheath Injection|50ml of 0.25% I-Bupivacaine max 2mg/kg (IV block Anaesthesia) injected into rectus sheath bilaterally & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
11299930|NCT02700204|Experimental|PicoWay 532nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 532nm hand-piece
11299931|NCT02700204|Experimental|PicoWay 1064nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 1064nm hand-piece
11299932|NCT02700191|No Intervention|Control|For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.
11299933|NCT02700191|Experimental|uCor|For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.
11299934|NCT02700178|Experimental|Biofeedback|Participants will be asked to participate in all or a subset of daily activities for wheelchair users. The intervention will consist of visual and/or auditory cues to guide their movement while performing the tasks during one to two sessions.
11299935|NCT02700165|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the submandibular submental (chin), can be reduced.
11299936|NCT02700152|Experimental|all subjects|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape device according to the study protocol and user manual.
~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
11299937|NCT02700139|Experimental|Aspheric lens|An aspheric lens which is supposed to slow myopic progression in children by unique asphericity (proprietary information)
11299938|NCT02700139|No Intervention|Single vision spheric/toric lenses|Control: single vision spheric/toric lenses
11299939|NCT02700126||undergoing propofol based TIVA for clip|This study is an observational study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm. We will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
11299940|NCT02700113||ASD|There is only one group; minimally verbal individuals with Autism Spectrum Disorder aged 4 to 17 years.
11299941|NCT02700100|Experimental|Pulmonary Valved Conduit (PV-001)|Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.
11299942|NCT02700087|Placebo Comparator|H2 blocker versus placebo|"The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily).
~Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo."
11299943|NCT02700087|Active Comparator|Treatment arm|Patients who develop severe airway symptoms while they are in the H2 blocker versus placebo arm will then cross over to the treatment arm of the study. These patients will exit randomization and be unblinded. These patients will all be given H2 blockers, and the effects of the H2 blockers will be monitored and studied. Alternatively, patients' families may also elect to undergo surgery to treat laryngomalacia.
11299944|NCT02700074||Minimally Verbal|Minimally verbal adolescents with Autism Spectrum Disorder
11299945|NCT02700074||Verbal Impaired|Language impaired adolescents with ASD
11299946|NCT02700074||Verbal Normal|Language normal adolescents with ASD
11299947|NCT02700074||Typically Developing|Typically developing adolescent controls
11299948|NCT02700061|Experimental|Induced Constraint Therapy - ICT|Physical rehabilitation with Induced Constraint Therapy as part of the occupational therapy. Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
11299949|NCT02700061|Experimental|Robotic occupational therapy|Physical rehabilitation with Robotic occupational therapy. Robotic Occupational Therapy three times a week for twelve weeks.
11299950|NCT02700048|Placebo Comparator|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
11299951|NCT02700048|Experimental|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
11299952|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We will employ an experimental randomized block (RB) design; blocked on reservation where 300 families will be assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention we will complete a pre-test with families in the experimental group. Following the program, we will complete post-tests and 6 month follow-ups for a period of 36 months.
11299953|NCT02700035|No Intervention|BZDDD Prevention Program Control|We will employ a randomized block (RB) design; blocked on reservation, 300 families will be randomly assigned to the control condition. We will complete pre-tests, post-tests, and 6 month follow-ups for 36 months.
11299954|NCT02700022|Experimental|Alisertib combined with R-EPOCH|Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
11299955|NCT02700009|Experimental|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
11299957|NCT02699996|Experimental|self-management + peer mentoring|Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
11299958|NCT02699983|Experimental|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.
~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.
~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.
~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
11299959|NCT02699983|Active Comparator|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
11299960|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.
~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
11299961|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
11299962|NCT02699944|Experimental|CRT sub-optimal responder|Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still <50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.
11299963|NCT02699931|Experimental|Electric3D|3D electric toothbrush (Oral-B) with orthodontic head.
11299964|NCT02699931|Active Comparator|Manual|Manual orthodontic toothbrush (Oral-B).
11299965|NCT02699918|Experimental|screening oxymetry|nocturnal oxymetry to screen for sleep apnea
11299966|NCT02699905||Sepsis|Patients with the diagnosis of sepsis or septic shock
11299967|NCT02699905||Control|Healthy control with no evidence of active infection, or recent infection in the past 4 weeks.
11299968|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
11299969|NCT02699879||Pirfenidone|Participants will receive pirfenidone orally according to the physician discretion.
11299970|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
11299971|NCT02699853|Experimental|Arm I (RRC)|Patients undergo RRC at day 0.
11299972|NCT02699853|Experimental|Arm II (ORC)|Patients undergo ORC at day 0.
11299973|NCT02699840||Menactra Study Group 1|Participant aged 2 through 11 years at vaccination
11299974|NCT02699840||Menactra Study Group 2|Participant aged 12 through 17 years at vaccination
11299975|NCT02699840||Menactra Study Group 3|Participant aged 18 through 55 years at vaccination
11299976|NCT02699827|Active Comparator|Magnesium sulphate group|Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate
11299977|NCT02699827|Placebo Comparator|Placebo group|Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%
11299978|NCT02699814|Experimental|H3 Parent/Child Dyads|A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99 years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem. For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
11299979|NCT02699801|Active Comparator|Propofol|Patients received propofol for post-operative sedation
11299980|NCT02699801|Active Comparator|Dexmedetomidine|Patients received dexmedetomidine for post-operative sedation
11299981|NCT02699788|Experimental|Multifunction Cardiogram|non-invasive computerized, multiphase, resting electrocardiogram analysis device
11299982|NCT02699775||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
11299983|NCT02699762|Experimental|experimental group|self rehabilitation of upper limb in experimental group + BTI + usual physiotherapy
11299984|NCT02699762|No Intervention|control group|BTI + usual physiotherapy
11299985|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.
~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.
~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
11299986|NCT02699736||Cohort I|Enrolled from August 1994. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11300157|NCT02698553|Experimental|Bupropion XL once daily|Healthy subjects will receive Bupropion XL 150milligram (mg) once daily for 5 days (Day 1 to Day 5) and then Bupropion XL 300 mg once daily from Day 6 to Day 14.
11299987|NCT02699736||Cohort II|Enrolled from January 1996. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299988|NCT02699736||Cohort III|Enrolled from February 1997. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299989|NCT02699736||Cohort IV|Enrolled from March 1999. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). The eligibility criteria of a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion has been removed for patients joining the study in 1999 and beyond, since the intention of the study is to include most patients eligible for antiretroviral therapy. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299990|NCT02699736||Cohort V|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299991|NCT02699736||Cohort VI|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299992|NCT02699736||Cohort VII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299993|NCT02699736||Cohort VIII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299994|NCT02699736||Cohort IX|Enrolled from December 2011. Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299995|NCT02699736||Cohort X|All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment >2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
11299996|NCT02699736||Cohort XI|"HIV-1 positive persons ≥18 years of age, not already enrolled in EuroSIDA, are eligible for inclusion. Participants should be enrolled consecutively in one of the following two groups:
~Participants who have started integrase inhibitor (INSTI) based antiretroviral therapy (ART) after 1/1/2012 and have a CD4 cell count and HIV-RNA available in the 12 months prior to starting INSTI or within 3 months after starting INSTI
~If participants have not started INSTI, they should be included providing they have a CD4/HIV-RNA in the 12 months prior to baseline or within 3 months after baseline.
~For all patients enrolled and under follow up, laboratory, therapeutic, clinical and demographic data, date on pregnancy and data on hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually."
11299997|NCT02699723|Experimental|Treatment (arsenic trioxide, itraconazole)|Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
11299998|NCT02699710|Experimental|Part 1: GDC-0853, Rabeprazole (Fasting State)|Participants will receive single dose of GDC-0853 (200 milligrams [mg]) in a crossover design as either the capsule or tablet formulation in the fasted state with the final fixed treatment consisting of the tablet formulation administered in the fasted state after prior administration of rabeprazole (20 mg twice daily [BID]) for 3 days.
11299999|NCT02699710|Experimental|Part 2: GDC-0853, Rabeprazole (Fasting or Fed State)|Participants will receive single dose of GDC-0853 (200 mg) tablet formulation in the fasted or fed state in a crossover design with the final fixed treatment consisting of the tablet formulation administered in the fed state after prior administration of rabeprazole (20 mg BID) for 3 days.
11300000|NCT02699710|Experimental|Part 3: GDC-0853, Methotrexate|Participants will receive single dose of methotrexate (7.5 mg) under fasting conditions on Day 1 (5 mg folic acid will be administered the following day [Day 2]) and then GDC-0853 (200 mg) tablet formulation twice daily (BID) under fasting conditions (an overnight fast for the morning dose and a 2 hour fast for the evening dose) from Days 15 to 20 after washout period from Days 2 to 14. On Day 21, participants will receive single dose of methotrexate (7.5 mg) with single dose of GDC-0853 (200 mg) tablet formulation under fasting conditions, and folic acid (5 mg) will be administered on Day 22.
11300001|NCT02699697|Experimental|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
11300002|NCT02699697|Experimental|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
11300003|NCT02699684|Other|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
11300004|NCT02699684|Other|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
11300005|NCT02699671||acute myocardial infarction|
11300006|NCT02699658|Experimental|levofloxacin in healthy|
11300007|NCT02699645|Experimental|Triple Pill (active treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
11300008|NCT02699645|Placebo Comparator|Placebo|received via blinded study capsules
11300009|NCT02699619|Active Comparator|2 Hansson pins without plate|Patients with undisplaced femoral neck fractures operated with 2 isolated Hansson pins.
11300010|NCT02699619|Active Comparator|3 Hansson pins interlocked in a plate|Patients with undisplaced femoral neck fractures operated with 3 Hansson pins interlocked in plate (Pinloc).
11300011|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
11300012|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
11300013|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
11300014|NCT02699580|Experimental|Biodegradable collagen implant|Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.
11300015|NCT02699580|Active Comparator|Without biodegradable collagen implant|Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.
11300016|NCT02699567||Lean AA|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
11300017|NCT02699567||Obese AA|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
11300018|NCT02699567||Lean GG|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
11300019|NCT02699567||Obese GG|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
11300020|NCT02699554||Orthopaedic surgery|
11300021|NCT02699541|Experimental|Intervention group|Intervention group participants will receive the educational intervention based on the Information, Motivational, Behavioral change model.
11300022|NCT02699541|No Intervention|Control group|Control group participants will receive usual care treatment and referral to diabetes educational consultation if required.
11300023|NCT02699515|Experimental|MSB0011359C (M7824)|
11300024|NCT02699502|Experimental|patients with osteoporotic hip fractures|The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.
11300025|NCT02699489|Experimental|Laparoscopic donor nephrectomy arm|This group will undergo laparoscopic donor nephrectomy
11300026|NCT02699489|Active Comparator|Open donor nephrectomy arm|This group will undergo open donor nephrectomy
11300027|NCT02699476|Active Comparator|Individual + Computer A|Daily activities involve playing one hour of computer games (e.g., hangman, boggle, word scramble, chess; computer cognitive training A (CCA)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
11300028|NCT02699476|Experimental|Individual + Computer B|Daily activities involve playing an alternative set of computer games (computer cognitive training B (CCB)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
11300029|NCT02699476|Active Comparator|Group + Computer B|Daily activities involve group and individual cognitive therapy discussions on health, nutrition, and other topics and computer cognitive training B (CCB).
11300030|NCT02699463|Active Comparator|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
11300031|NCT02699463|Placebo Comparator|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
11300032|NCT02699450|Active Comparator|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
11300158|NCT02698527|Active Comparator|Non-Buffered Lidocaine|Vulvar biopsy conducted using non-buffered lidocaine as anesthesia
11300159|NCT02698527|Experimental|Buffered Lidocaine|Vulvar biopsy conducted using buffered lidocaine as anesthesia
11300033|NCT02699450|Experimental|Arm B: 1.5 mg Faricimab|Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
11300034|NCT02699450|Experimental|Arm C: 6 mg Faricimab|Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
11300035|NCT02699437||Pregnant women with preeclampsia|Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.
11300036|NCT02699424|Other|Radiotherapy|
11300037|NCT02699411|Active Comparator|dry needling|Dry needling on the vastus is performed in patients undergoing ACL fortnight after the intervention and then evaluated. REL dry needling while supplies last twenty insertions before treatment, at midnight, a week and five weeks.
11300038|NCT02699411|Active Comparator|Stability and propioception|Proprioception and stability exercises in patients undergoing ACL fortnight after the intervention and then evaluates performed before treatment, at midnight, a week and five weeks.
11300039|NCT02699398|Experimental|VR-based therapy|3 weeks of home-based treatment for motor training using a virtual reality rehabilitation setup.
11300040|NCT02699398|Active Comparator|Control|3 weeks of home-based occupational therapy for motor training.
11300041|NCT02699385|Experimental|Oral Rehydration Therapy (ORT) + Domperidone|Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
11300042|NCT02699385|Experimental|Oral Rehydration Therapy + Placebo|Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.
11300043|NCT02699372|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.
11300044|NCT02699372|Experimental|RO6889450: Part 1 Single Ascending Dose (SAD)|Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram [mg] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.
11300045|NCT02699372|Experimental|RO6889450: Part 2 Multiple Ascending Dose (MAD)|The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
11300046|NCT02699359|Experimental|HS-1000 recording|Study participants will receive HS-1000 ICP readings for a continuous 16 minute interval in a 30 degree supine position. Recordings will be obtained in one session. When possible, these recordings will be obtained at their initial examination and all follow-up visits. Sports Medicine staff will coordinate the HS-1000 device earplug insertion and recordings so as not to interfere with, nor marginally delay the patient's normal, routine clinical evaluation.
11300047|NCT02699346|Experimental|HS-1000 recording|Eligible patients and healthy subjects will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears. HS-1000 monitoring intervals will last from 20 minutes continuously. Following completion of data collection, HS-1000 will be removed.
11300048|NCT02699333||Microscopic colitis cases|Patients found to have microscopic colitis based on colonic biopsies.
11300049|NCT02699333||Controls|Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.
11300050|NCT02699320||"Asymptomatic"|"Asymptomatic meaning patients showed well tolerance to parenteral nutrient (PN) administration and there were no complications occurred within two months (n=7);"
11300051|NCT02699320||CLABSI|with central catheter-related blood stream infections (CLABSI) meaning patients had fever, increased neutrophils, documented positive catheter blood culture but exclude other source of infection (n=5)
11300052|NCT02699320||PNALD|with parenteral nutrient associated liver disease (PNALD), meaning SBS patients showed elevated liver enzymes and bilirubin (n=14).
11300053|NCT02699320||healthy controls|Seven healthy infants who had added complementary were served as controls (n=7).
11300054|NCT02699307|Experimental|Intervention|OT-led counseling based on home activity pattern
11300055|NCT02699294|Experimental|Contract-relax PNF stretch|A contract-relax PNF stretching techniques of the pectoralis minor muscle including latent trigger points will be applied by Group 1 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
11300056|NCT02699294|Experimental|Z-stretch|The Z- stretch of the pectoralis minor muscle including latent trigger points will be applied by Group 2 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
11300057|NCT02699294|Experimental|Manual pressure release|The single intervention of manual pressure release will be only applied to Group 3 according to the techniques describe by Simons et al. (1999).
11300058|NCT02699294|No Intervention|Control|This is a control group.
11300059|NCT02699281|Experimental|Ultra-micronized Palmitoylethanolamide|Ultra-micronized Palmitoylethanolamide 600 mg twice a day
11300060|NCT02699281|Placebo Comparator|Placebo|Placebo tab twice a day
11300061|NCT02699268||Infants (term borns and preterm borns)|Intervention: simultaneous lung function measurement using VoluSense Pediatrics and a mask-based method with an ultrasonic flowmeter (EcoMedics Exhalyzer)
11300062|NCT02699242|Experimental|Simulator arm|In the Simulation arm group the subjects will be trained on the virtual reality bronchoscopic simulator (ORSIM simulator) for up to 60 minutes as active intervention, before they undertake the 2nd Fiber optic intubations.
11300063|NCT02699242|No Intervention|Control arms|The control arm will be exposed only to the didactic teaching. The subjects will not undergo simulator training before undergoing 2nd fiber optic intubations.
11300064|NCT02699229||Malignant|Tissue sample
11300065|NCT02699229||Benign|Tissue sample
11300066|NCT02699229||Normal|Tissue Sample
11300067|NCT02699216|Experimental|Phase 1 Active Treatment|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
11300160|NCT02698514|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
11300068|NCT02699216|Placebo Comparator|Phase 1 Sham Treatment|Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
11300069|NCT02699216|Experimental|Phase 2 Open Label|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
11300070|NCT02699203|Experimental|High-carbohydrate meal|High carbohydrate breakfast meal consisting of oatmeal and berries.
11300071|NCT02699203|Experimental|Low-carbohydrate meal|Low carbohydrate breakfast meal consisting of eggs and avocado.
11300072|NCT02699190||Prospective Study Cohort|This cohort comprises recently identified individuals for whom a clinical decision has been made to pursue whole genome sequencing (WGS) as a first-line diagnostic test. The cohort also includes each subject's biological parents.
11300073|NCT02699190||Historical Study Cohort|This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
11300074|NCT02699177||Suspected PCD but negative|"CBF measurements:
~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.
~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.
~The two methods will be compared."
11300075|NCT02699177||Suspected PCD but positive|"CBF measurements:
~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.
~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.
~The two methods will be compared."
11300076|NCT02699164|Experimental|combine group|"Conventional physiotherapy applied 15 sessions of treatment. In addition to conventional physiotherapy non-surgical spinal decompression therapy applied.
~First 10 sessions of treatment non-surgical decompression therapy applied and last 5 sessions spinal stabilization exercise applied."
11300077|NCT02699164|Experimental|conventional physiotherapy|conventional physiotherapy applied 15 sessions of treatment. Conventional physiotherapy consisted hotpack, Transcutaneal Electric Nerve Stimulation(TENS) and Ultrasound Currents. Spinal stabilization exercises applied last five sessions of therapy.
11300078|NCT02699138|Experimental|Trazodone|To determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
11300079|NCT02699138|Placebo Comparator|Placebo|To compare placebo outcomes against administration of trazodone
11300080|NCT02699125|Placebo Comparator|guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
11300081|NCT02699125|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
11300082|NCT02699099|Experimental|Coad group|Children randomized to receive Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects will receive a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
11300083|NCT02699099|Experimental|RTS,S group|Children randomized to receive Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects will receive a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
11300084|NCT02699099|Experimental|Control group|Children randomized to receive Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children will receive SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
11300085|NCT02699086|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
11300086|NCT02699086|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsules, trice daily, p.o. after meal for 28 days
11300087|NCT02699073|Experimental|Regorafenib|dose of regorafenib : 160mg once daily
11300088|NCT02699047|Experimental|Fish oil|3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
11300089|NCT02699047|Placebo Comparator|Control group|3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
11300090|NCT02699034|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
11300091|NCT02699008|Active Comparator|HPR-Ticagrelor row|ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
11300092|NCT02699008|Active Comparator|HPR-Clopidogrel row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
11300093|NCT02699008|Active Comparator|unHPR row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
11300161|NCT02698514|Experimental|Desflurane|Anesthesia was maintained with desflurane.
11301126|NCT02691988|Active Comparator|Usual care|Optimization of bronchodilator treatment
11300094|NCT02698995|Placebo Comparator|Group A|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+1 ml saline=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
11300095|NCT02698995|Active Comparator|Group B|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+2 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
11300096|NCT02698995|Active Comparator|Group C|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+4 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
11300097|NCT02698982|Experimental|Monitoring|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring accessible to the anesthesia provider.
11300098|NCT02698982|Sham Comparator|Sham|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring blinded to the anesthesia provider
11300099|NCT02698982|No Intervention|Control|elderly non scheduled for surgery
11300100|NCT02698969|Experimental|Sugammadex|patients enrolled who will receive sugammadex 2 mg*kg-1 at the end of surgery
11300101|NCT02698969|Active Comparator|Nestigmine, Atropine|patients enrolled who will receive neostigmine 50 mcg*kg-1 and atropine 15 mcg*kg-1 at the end of surgery
11300102|NCT02698943||Study Group|Participants who underwent phacoemulsification surgery and implantation of the Envista MX-60 IOL
11300103|NCT02698930|Experimental|dexmedetomidine group|
11300104|NCT02698930|Placebo Comparator|Control group|
11300105|NCT02698917|Active Comparator|Group 1|Low normal PaCO2, low normal PaO2, low normal MAP
11300106|NCT02698917|Active Comparator|Group 2|High normal PaCO2, low normal PaO2, low normal MAP
11300107|NCT02698917|Active Comparator|Group 3|Low normal PaCO2, high normal PaO2, low normal MAP
11300108|NCT02698917|Active Comparator|Group 4|High normal PaCO2, high normal PaO2, low normal MAP
11300109|NCT02698917|Active Comparator|Group 5|Low normal PaCO2, low normal PaO2, high normal MAP
11300110|NCT02698917|Active Comparator|Group 6|High normal PaCO2, low normal PaO2, high normal MAP
11300111|NCT02698917|Active Comparator|Group 7|Low normal PaCO2, high normal PaO2, high normal MAP
11300112|NCT02698917|Active Comparator|Group 8|High normal PaCO2, high normal PaO2, high normal MAP
11300113|NCT02698904|Experimental|Guided Relaxation Technique|Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.
11300114|NCT02698904|Sham Comparator|Documentary movie|"Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes documentary movie.
~Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes documentary movie (listening via headphone. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes."
11300115|NCT02698891|Experimental|Neulasta|"After the screening procedures confirm participation in the research study:
~Completion of 4 cycles of dose dense Adjuvant Doxorubicin Cyclophosphamide (AC)
~Paclitaxel via IV, once every 2 week x 4 cycles
~Neulasta™ (Pegfilgrastim) will be administered in Paclitaxel cycles, if:
~The patient experiences a prior episode of fever and neutropenia.
~If the patient has an active infection this decision will be at provider discretion.
~If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
11300116|NCT02698878|Active Comparator|Control Group|Control Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
11300117|NCT02698878|Experimental|Intervention Group|Intervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
11300118|NCT02698865|Experimental|MONOVISC|MONOVISC High Molecular Weight Hyaluronan
11300119|NCT02698865|Placebo Comparator|Saline|Physiologic saline
11300120|NCT02698852|Experimental|BuMA Supreme group|Totally 1000 subjects combined the 220 subjects from randomized controlled trial(RCT) group
11300121|NCT02698839|Experimental|BuMA Supreme group|This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
11300122|NCT02698839|Active Comparator|BuMA™ group|This group contains 220 subjects.
11300123|NCT02698826|Experimental|Adult patients resuscitated from cardiac arrest|Rapid FiO2 optimization protocol
11300124|NCT02698813|Experimental|UCMSCs-HA|Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).
11300125|NCT02698813|Active Comparator|Control|Procedure: Transdermal injection of hyaluronic acid only.
11300126|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
11300127|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
11300340|NCT02697214|Active Comparator|Mio Fuse|Mio Fuse heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
11300128|NCT02698761|No Intervention|Standard of Care|Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
11300129|NCT02698761|Experimental|Comprehensive Care Plan|Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.
11300130|NCT02698748|Experimental|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
11300131|NCT02698748|Placebo Comparator|Placebo|Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.
11300132|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
11300133|NCT02698735|Placebo Comparator|Placebo|Vehicle control
11300134|NCT02698722|No Intervention|Control|This group will receive verbal education about dialytic and non-dialytic therapies via a standardized script.
11300135|NCT02698722|Experimental|Intervention|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
11300136|NCT02698709||Healthy corneas (C)|Corneas of normal candidates to refractive surgery who did not develop any sign of corneal ectasia after laser in situ keratomileusis during a two year follow-up period were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
11300137|NCT02698709||Overt keratoconus (Kc)|Whether both eyes manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers. Such eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
11300138|NCT02698709||Forme fruste keratoconus (FFKc)|Whether only one eye manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers, and the fellow eye seemed unaffected. Such unaffected eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
11300139|NCT02698696|Experimental|ECo program|Objective: to inform the patient about cognitive impairments and their repercussions; to train the patient in problem-solving skills through exercises; to implement strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises, tools (tokens, cards, maps, chessboard) Modules: Psychoeducation, Attention, Memory, Executive Functions, Functional Impairments
11300140|NCT02698696|Experimental|CRT program|Objective: problem-solving skills training through exercises, in order to use strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises Modules: Cognitive Flexibility, Working Memory, Planning
11300141|NCT02698696|Active Comparator|Supportive psychotherapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' cognitive and functional impact, social skills, and the regulation of sleep and daily activities.
11300142|NCT02698683||malnourished|low zinc, low albumin, anthropometric measures lower than percentile 5 lymphocyte count
11300143|NCT02698683||well nourished|normal zinc, normal albumin, anthropometric measures higher than percentile 5 lymphocyte count
11300144|NCT02698657|Experimental|ASP5094 Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
11300145|NCT02698657|Placebo Comparator|Placebo Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
11300146|NCT02698644|Experimental|isoamyl2cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
11300147|NCT02698631|Active Comparator|Conventional AF ablation.|A standard radiofrequency AF ablation procedure will be carried out without LGE information.
11300148|NCT02698631|Experimental|LGE-MRI guided AF ablation.|Fibrosis information obtained from post-processed LGE-MRI will be used to guide AF ablation procedures.
11300149|NCT02698618|Experimental|Ticagrelor|A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)
11300150|NCT02698618|Active Comparator|Clopidogrel|A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg
11300151|NCT02698605|Experimental|Usability test study of the MirrorPath|This study was a one-arm study and all subjects used the device and received usability test.
11300152|NCT02698592|Active Comparator|CelsiusTMDS® 8 mm catheter|50 patients underwent ablation with CelsiusTMDS® 8 mm catheter.
11300153|NCT02698592|Active Comparator|Thermocool® 3.5 mm irrigated catheter|50 patients underwent ablation with Thermocool® 3.5 mm catheter of irrigated tip.
11300154|NCT02698592|Experimental|Thermocool® SF catheter|50 patients underwent ablation with Thermocool® SF catheter.
11300155|NCT02698579||Subjects treated with Lenti-D|Subjects who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304.
11300156|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
11300162|NCT02698501|Experimental|MEDI9929|MEDI9929 is a human monoclonal antibody immunoglobulin IgG2λ directed against TSLP. MEDI9929 binds with human TSLP and prevents its interaction with thymic stromal lymphopoietin receptor (TSLPR).
11300163|NCT02698501|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP.
11300164|NCT02698488|Active Comparator|Embryo Selection by Morphology|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study
11300165|NCT02698488|Active Comparator|Embryo Selection by Morphology and Mass Spectroscopy|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study. After dilution, embryo culture media will be analyzed by electrospray ionization quadrupole time-of-flight (ESI-QTOF) MS. The spectra will be collected in the negative ion mode. Abundance of ions in each spectrum will be further analyzed.
11300166|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
11300167|NCT02698462|Other|FIT and Questionnaire|Six thousand persons eligible for the national CRC screening program will be selected. They will be selected from four areas that are considered representative of the Netherlands. All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
11300168|NCT02698449|Experimental|cognitive rehabilitation + transcranial stimulation|specific cognitive rehabilitation combined to transcranial direct current stimulation
11300169|NCT02698449|Experimental|cognitive rehabilitation + stimulation sham|specific cognitive rehabilitation combined to transcranial direct current stimulation sham
11300170|NCT02698449|Experimental|placebo rehab + transcranial stimulation|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation
11300171|NCT02698449|Experimental|placebo rehab + stimulation sham|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation sham
11300172|NCT02698436|Experimental|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
~Other Names: Cleanser is marketed while the device is not marketed"
11300173|NCT02698436|Active Comparator|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.
~Other names: Both products are marketed"
11300174|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
11300175|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
11300176|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.
~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
11300177|NCT02698371|Active Comparator|FBDC-SE (G1; Control)|Futurabond DC (single dose blister) will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; FBDC drying layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20s.
11300178|NCT02698371|Active Comparator|FBDC-SE-EE (G2; Control )|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute. The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of Futurabond DC (FBDC) as self-etch mode simultaneously in dentin and enamel, and the light-cured (LED light; 1000mW/cm2), during 20s.
11300179|NCT02698371|Other|FBU-ER (G3)|FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
11300180|NCT02698371|Other|FBU-SE (G4)|FuturabondU® (FBU) apply in enamel and dentin as SE mode. Activating FBU SingleDose. FBU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20 seconds.
11300181|NCT02698371|Other|ADU-ER (G5)|Adhese®Universal (ADU) apply by etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15 seconds in dentin and 30 seconds in enamel); Etch agent rinse with water for 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Adhesive ADU will be scrubbed into the tooth surface (enamel and dentin) for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2 for 20s.
11300209|NCT02698176|Experimental|MK-8628 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received MK-8628 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received MK-8628 in continuous cycles up to 24 months.
11300491|NCT02696239|Active Comparator|Vicryl suture|Vicryl suture by Ethicon
11300182|NCT02698371|Other|ADU-SE (G6)|Adhese®Universal (ADU)apply by self-etch (SE) mode. Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with ADU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 20 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2.
11300183|NCT02698358||K-EPIC|Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
11300184|NCT02698345||K-POP|Patients with isolated popliteal artery disease undergoing endovascular therapy using drug-eluting balloon (In.PACT Admiral, Medtronic)
11300185|NCT02698332|Active Comparator|Algorithm for UTI|Practices in this groups receives a diagnostic algorithm for UTI by post
11300186|NCT02698332|No Intervention|Control|Practices in this group does not receive anything in addition to instructions in the observational registration.
11300187|NCT02698319|No Intervention|Conventional Triage|Conventional triage using Danish Emergency Process Triage (DEPT).
11300188|NCT02698319|Experimental|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is used as triage form in the ED. The Copenhagen Triage Algorithm consists of a few vital parameters and a clinical assessment from the ED nurse.
11300189|NCT02698306|Experimental|Dexamethasone|Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days
11300190|NCT02698306|Active Comparator|Diclofenac Sodium|Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days
11300191|NCT02698293|Experimental|Cohort 1|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
~Total duration of drug product administration (including any open-label lead-in, if applicable).
~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
11300192|NCT02698293|Experimental|Cohort 2|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).
~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
11300193|NCT02698293|Experimental|Cohort 3|"5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration. There will be two levels of light dose: 50 and 100 J/cm2. Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT Total duration of drug product administration (including any open-label lead-in, if applicable).
~Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
~None This is a phase I dose escalation study, with two levels of light dose. The design is cohorts of 3s. Light at 50 Joules and Light at 100 joules There are pre-defined DLTs."
11300194|NCT02698280|Experimental|Treatment|Patients are treated with bevacizumab and nimustine. Every 6 weeks is defined as one therapeutic cycle. Adverse effect is evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Hematologic toxicity is evaluated every 2 weeks. Liver function, renal function, and electrolytes are assessed every 4-6 weeks. Platelet should be no less than 100*10^9/L and neutrophil count should be no less than 1.5*10^9/L.
11300195|NCT02698267|Experimental|BIIB074|Administered orally on Day 1 and Day 11
11300196|NCT02698254|Experimental|Arm I (conventional fractionation)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11300197|NCT02698254|Active Comparator|Arm II (conventional fractionation, bevacizumab)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11300198|NCT02698241|Other|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
11300199|NCT02698228|Sham Comparator|Standard of Care|Intravenous injection of 0.1mg/kg of morphine. Injection of 5cc of 0.9% normal saline into the subcutaneous tissue of the thigh.
11300200|NCT02698228|Active Comparator|Femoral nerve block|Intravenous injection of 0.1mg/kg of morphine. Injection of 20cc of 0.5% bupivacaine into the fascia iliaca space using standard anatomic landmarks.
11300201|NCT02698228|Active Comparator|Ultra-sound guided femoral nerve block|Intravenous injection of 0.1mg/kg of morphine.Injection of 20cc of 0.5% bupivacaine around their femoral nerve under direct ultrasound guidance
11300202|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
11300203|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
11300204|NCT02698202|Experimental|Digital Breast Tomosynthesis|to the experimental arm will be offered twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
11300205|NCT02698202|No Intervention|standard mammography|to the control arm the usual 2D standard mammography exam will be offered
11300206|NCT02698189|Experimental|MK-8628 20 mg AML Cohort|Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
11300207|NCT02698189|Experimental|MK-8628 20 mg DLBCL Cohort|Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
11300208|NCT02698176|Experimental|MK-8628 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received MK-8628 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received MK-8628 in continuous cycles up to 24 months.
11301127|NCT02691975|Experimental|SHR3680|Tablet
11300210|NCT02698176|Experimental|MK-8628 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received MK-8628 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received MK-8628 in continuous cycles up to 24 months.
11300211|NCT02698176|Experimental|NMC Cohort-Part B|Participants (up to 30) in Part B will receive MK-8628 at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive MK-8628 at the RP2D. Participants will continue receiving MK-8628 at an assigned/adjusted dose level for continuous cycles up to 24 months.
11300212|NCT02698163|Active Comparator|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
11300213|NCT02698163|Experimental|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
11300214|NCT02698150||Remote monitoring|Active group of patients undergoing daily remote monitoring using sensors and wearables
11300215|NCT02698150||Control|Control group of patients undergoing standard follow up wth no remote monitoring
11300216|NCT02698124||Decitabine|"Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.
~Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression."
11300217|NCT02698111|Experimental|Donafeinib|donafenib 200mg,bid
11300218|NCT02698098||Compulsory Drug Detention Center|Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
11300219|NCT02698098||Voluntary Treatment Center|Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.
11300220|NCT02698085|Experimental|Intervention Goup|Actual Diacutaneous Fibrolysis
11300221|NCT02698085|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis
11300222|NCT02698072|Experimental|Exercise and dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).
~6 dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using Hong's fast-in and fast-out technique with multiple rapid needle insertion."
11300223|NCT02698072|Active Comparator|Exercise and sham dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).
~6 sham dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using a park sham device consists of a base with a hole in the centre and sticky tape on the bottom. From the top of the base extends a double tube, continuing the central hole in the base."
11300224|NCT02698059|Experimental|Treated|iNAP® Sleep Therapy System Treatment
11300225|NCT02698059|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline
11300226|NCT02698046|Experimental|Ferrous sulfate|
11300227|NCT02698046|Placebo Comparator|Placebo|
11300228|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
11300229|NCT02698020|No Intervention|Control|High level of supplemental inspired oxygen
11300230|NCT02698020|Experimental|Room-air|Supplemental oxygen only provided if oxygen saturation below target
11300231|NCT02698007|No Intervention|without lma|standard fiberoptic bronchoscopy without lma
11300232|NCT02698007|Experimental|with lma|fiberoptic bronchoscopy with the use of lma
11300233|NCT02697994|Experimental|Sterile Water Injection|Participants randomised to the intervention group received 4 intracutaneous injections of 0.1 ml sterile water into the skin surrounding the Michaelis rhomboid over the sacral area.
11300234|NCT02697994|Placebo Comparator|Dry Injection|Participants in the control group received 4 dry injections in the same region using an insulin needle .
11300235|NCT02697981|Experimental|intervention group|Pregnant post bariatric surgery women will receive nutritional counseling from a specialist dietitian, to ensure a healthy balanced diet including adequate daily servings from all food groups, intake of essential nutrient during pregnancy such as iron and folic acid and limitation of high-sugar and fatty foods. Patients will also be advised concerning eating at scheduled times (e.g., 4-6 times daily), supplements, preference of water. Advice concerning healthy cooking methods will also be given, as well as advised to avoid soft drinks, drinking during meals, grazing and emotional eating, and fast foods. Subject of lifestyle in general - encouraged to incorporate suitable physical activity on most days, refraining from alcohol, and smoking. intervention: nutrition counseling
11300236|NCT02697981|No Intervention|control group|The control group is comprised of healthy pregnant women, of similar age, smoking behavior and background. No treatment will be given, just follow-up data collection.
11300237|NCT02697968|Experimental|Electroacupuncture|
11300238|NCT02697955|Experimental|Bupivacaine-epinephrine|10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
11300239|NCT02697955|Placebo Comparator|Placebo|10 ml normal saline water (sodium chloride solution, 0,9%)
11300240|NCT02697942|No Intervention|Standard of care|Participants randomized to the standard of care arm will not receive any intervention.
11326164|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
11300241|NCT02697942|Experimental|Cognitive training (CT)|"Participants randomized to the CT arm will be given a tablet with connection to Lumosity®, which is a web-based brain game. Participants will use the tablets to play brain games at each dialysis session."
11300242|NCT02697942|Active Comparator|Exercise training (ET)|Participants randomized to ET arm will be given a stationary foot peddler. This foot peddler will be situated at a comfortable distance from the dialysis chair so that the patient can comfortably reach the peddler. Participants will use the foot peddlers at each dialysis session.
11300243|NCT02697929|Active Comparator|sugammadex|at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
11300244|NCT02697929|Active Comparator|neostigmine|at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation
11300245|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
11300246|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
11300247|NCT02697903|Experimental|9 elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Natural Pomegranate Juice supplementation during and 48h following the first weightlifting training session."
11300248|NCT02697903|Placebo Comparator|9elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Placebo Juice supplementation during and 48h following the second weightlifting training session."
11300249|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:
~Procedure: Ridge preservation procedure"
11300250|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:
~Device: Mucograft® seal Procedure: Ridge preservation procedure"
11300251|NCT02697877||Patients with known or suspected coronary artery disease.|Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.
11300252|NCT02697864|Experimental|48.8 mgA tafamidis free acid tablet|
11300253|NCT02697864|Experimental|58 mgA tafamidis free acid tablet|
11300254|NCT02697864|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
11300255|NCT02697851|Experimental|Group 1|Microgynon 30® for 21 days, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Evotaz® for 14 days
11300256|NCT02697851|Experimental|Group 2|Evotaz® for 14 days followed by 7 days wash-out, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Microgynon 30® for 14 days (participants may chose to complete a 21 day pack). The total duration of the study is 57 days (+screening and follow up visits) and patients will have 3 intensive pharmacokinetic days on days 14, 35 and 56
11300257|NCT02697838|Experimental|Experimental: Apatinib plus chemotherapy|
11300258|NCT02697825|Other|changes in eye|Changes in both intraocular pressure and optic nerve sheath diameter will be correlated in robotic surgeries to find out any statistical relation existing between two.
11300259|NCT02697812|Experimental|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
11300260|NCT02697812|No Intervention|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
11300261|NCT02697799|Experimental|High-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
11300262|NCT02697799|Experimental|Mid-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
11300263|NCT02697799|No Intervention|No modified recruitment strategy|Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
11300264|NCT02697786|Active Comparator|AVR preformed with full sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.
~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
11300265|NCT02697786|Experimental|AVR preformed with minimal invasive sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.
~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
11300266|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
11300267|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
11300268|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
11300269|NCT02697747||Ultrasound education|Training in the use of ultrasound to identify the L3-L4 interspace
11300270|NCT02697734|Experimental|osilodrostat Group|Participants in this arm are receiving the study drug, osilodrostat and are randomized in a 2:1 ratio to treatment with study drug (osilodrostat or placebo, respectively),
11300271|NCT02697734|Placebo Comparator|osilodrostat Placebo Group|Participants in this arm are receiving osilodrostat placebo and are randomized in a 2:1 ratio to treatment with study drug (osilodrostat or placebo, respectively)
11300272|NCT02697721|Experimental|Powerful Tools for Caregivers|A 6-week psycho-educational program
11300273|NCT02697721|Other|Control group, delayed intervention|Control group with delayed intervention
11300274|NCT02697708|Placebo Comparator|Control Diet|Control (no additional potassium added to diet): Arm will consist of a 16 day balance period with a basal diet set at ~2340mg K/day; based on average American intake.
11300338|NCT02697214|Active Comparator|Apple Watch|Apple Watch heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device .
11300275|NCT02697708|Active Comparator|Potassium Supplement Diet|Potassium gluconate: Arm will consist of a 16 day balance period with the basal (control) diet plus the addition of 1000mg of K/day from potassium gluconate (12 tablets).
11300276|NCT02697708|Experimental|Potato Diet|Potato diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg of K/day from white potatoes.
11300277|NCT02697708|Experimental|French fries Diet|French fry diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg K/day from French fries.
11300278|NCT02697695||laparoscopic sleeve gastrectomy|patients who underwent laparoscopic sleeve gastrectomy (LSG) due to obesity and/or metabolic syndrome
11300279|NCT02697695||laparoscopic Roux-en-Y- gastric bypass|patients who underwent laparoscopic Roux-en-Y- gastric bypass (LRYGB) due to obesity and/or metabolic syndrome
11300280|NCT02697695||laparoscopic omega-loop gastric bypass|patients who underwent laparoscopic omega-loop gastric bypass (LOLGB) due to obesity and/or metabolic syndrome
11300281|NCT02697682|Experimental|Intervention|All patients are recieving the treatment.
11300282|NCT02697656|Active Comparator|Treatment as usual + self-help|Interdisciplinary treatment as usual at the outpatient pain clinic + an additional self-help binder with resources about pain management and employment advice.
11300283|NCT02697656|Experimental|Treatment as usual + IPS|Individual job support (IPS) as an integrated part of the interdisciplinary treatment at the outpatient pain clinic.
11300284|NCT02697643|Experimental|BHCDS-based recommendations|The Experimental condition will use the BH-CDS tool and receive tailored recommendations in addition to treatment as usual.
11300285|NCT02697643|Placebo Comparator|Non-tailored recommendations|The Control condition will use the BH-CDS tool and receive non-tailored recommendations in addition to treatment as usual.
11300286|NCT02697630|Experimental|Pembrolizumab and Entinostat|
11300287|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
11300288|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
11300289|NCT02697591|Experimental|INCAGN01876|
11300290|NCT02697565|Experimental|Train-the-Trainers Arm|Intervention Arm receives the Healthy Caregivers- Healthy Children Toolkit (healthy lifestyle role modeling intervention) via a nutritional gate keeper. The toolkit reinforces center health and activity policy standards.
11300291|NCT02697565|Other|Attention Control Arm|Control Arm that receives an attention control safety curriculum.
11300292|NCT02697552|Experimental|HBI-8000|HBI-8000 at the assigned dose twice weekly.
11300293|NCT02697539|Placebo Comparator|AmF/SnF2 group|Patients in this arm were adviced to use a standart dentifrice over the course of the study (AmF/SnF2, Meridol®, GABA, Lörrach, Germany).
11300294|NCT02697539|Active Comparator|mHA group|Patients in this arm were adviced to use the new dentifrice over the course of the study (mHA, BioRepair®, Wolff, Bielefeld, Germany).
11300295|NCT02697526|Other|Terumo|Patients in this arm will receive Terumo after catheterization
11300296|NCT02697526|Other|Tensoplast|Patients in this arm will receive Tensoplast after catheterization
11300297|NCT02697513|No Intervention|Before Period|Collection of patient-related data without interventions being made
11300298|NCT02697513|Active Comparator|After Period|Implementation of a simple infection management protocol as well as a 'Sepsis First Aid' kit to assist in the management of patients with acute infection
11300299|NCT02697487||No Treatment|This is a longitudinal observational study involving individuals who are depressed, depressed with other comorbidities and non-depressed individuals. The primary aim of this study is to describe the longitudinal course of illness and real world treatment outcomes for depressed patients receiving routine care from their providers. Health outcomes and biospecimens along with the functional and economic burden of depression will be characterized and compared amongst three groups: (1) depressed patients, (2) depressed patients with comorbid illnesses, and (3) non-depressed patients.
11300300|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
11300301|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
11300302|NCT02697461|Experimental|Intrinsic Foot Arm|In arm 1, a randomized control trial will be used in the investigation of validity and reliability comparing multisegmented foot motion, clinical joint physiological and accessory motion, and morphologic foot measurements, and the effect of intrinsic foot strengthening on multisegmented foot function.
11300303|NCT02697461|Experimental|Joint Mobilization Arm|In arm 2, the investigation of group differences in clinical and laboratory measures of multisegmented foot motion and kinetics will use a case control design. A randomized controlled trial will be conducted in the study investigating joint mobilization, with the researcher performing the assessments and the provider performing the treatments blinded to group allocation
11300304|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
11300305|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
11300306|NCT02697435|Experimental|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
11300307|NCT02697435|Placebo Comparator|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
11300308|NCT02697422|Experimental|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
11300309|NCT02697422|No Intervention|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
11300310|NCT02697409|Experimental|Intervention group|The intervention group receives two school-based modules taking less than two hours each delivered by medical students in the schools.
11300311|NCT02697409|No Intervention|Control group|
11300312|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
11300313|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
11300314|NCT02697383|Experimental|Ixazomib (MLN9708) and Dexamethasone|Patients with high risk SMM will be enrolled on the pilot study and treated with 2 drug combination (Cycles 1-12 Ixazomib at 4 mg weekly on days 1, 8 and 15, and dexamethasone on days 1, 8, 15 and 22 of 28 day cycle); the dexamethasone dose will be 40 mg/week the first 4 cycles, thereafter 20 mg/week.
11300315|NCT02697370|Other|Pharmacokinetic based factor VIII dosage|Patient's routine prophylactic factor VIII concentrate infusion will be given in the morning and the exact time (hours and minutes) and dose recorded. There is no wash out so the date, time and dose of the previous 2 prophylactic doses must be accurately known. Samples will be collected that afternoon, the following morning and the following afternoon. Samples can be taken at any convenient time but the exact time must be recorded. Factor VIII levels will be measured and this pharmacokinetic data will be used to calculate the dose of factor VIII (to be infused on alternate days) required to maintain a predicted factor VIII ≥1.5 IU/dL at all times(this will be rounded up to the nearest full 250 IU vial)
11300316|NCT02697357||Caregivers|This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
11300317|NCT02697344|Experimental|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11300318|NCT02697331|Active Comparator|progesterone|74 patients will receive progesterone pessary 200mg twice daily
11300319|NCT02697331|Placebo Comparator|Placebo|74 patients will receive placebo
11300320|NCT02697318|Other|Professional Administration|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
11300321|NCT02697318|Other|Self-Administration (new method)|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
11300322|NCT02697305|Experimental|IV BCAA test|IV application of BCAA solution
11300323|NCT02697305|Experimental|ORAL BCAA test|At once oral ingestion of BCAA capsules
11300324|NCT02697305|Placebo Comparator|ORAL PLACEBO test|At once oral ingestion of placebo capsules
11300325|NCT02697292|Placebo Comparator|Placebo/Normal Saline Group|Subjects will receive placebo for 4 infusions. After completion of the blinded phase, subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
11300326|NCT02697292|Active Comparator|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
11300327|NCT02697279|Active Comparator|Traditional Incision and Drainage|Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
11300328|NCT02697279|Experimental|Loop drainage|Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.
11300329|NCT02697266||Post-call anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
11300330|NCT02697266||Regular-shift anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
11300331|NCT02697253|Experimental|Successful drug|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.
~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
11300332|NCT02697253|Experimental|Unsuccessful drug|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered Sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.
~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
11300333|NCT02697253|Placebo Comparator|Success placebo|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.
~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
11300334|NCT02697253|Placebo Comparator|Unsuccess placebo|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.
~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.
~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
11300335|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
11300336|NCT02697227|Active Comparator|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
11300337|NCT02697227|Active Comparator|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
11300492|NCT02696239|Active Comparator|Lapra-Ty II|Lapra-Ty II, Absorbable Suture Clip, by Ethicon
11300341|NCT02697214|Active Comparator|Basis Peak|Basis Peak heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
11300342|NCT02697201|Experimental|Intralipid Infusion, then Saline|Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
11300343|NCT02697201|Sham Comparator|Saline Infusion, then Intralipid|Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
11300344|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
11300345|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
11300346|NCT02697175|Experimental|Live Video-Colposcopy|Women are able to observe their colposcopic examination in real-time watching a flat screen in front of them
11300347|NCT02697175|Active Comparator|No Live Video-Colposcopy|Women are not able to observe their colposcopic examination in real-time
11300348|NCT02697162|Experimental|Antiseptic-coated catheter|Hydrophilic intermittent urinary catheter coated with octenidine chloride
11300349|NCT02697162|Placebo Comparator|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
11300350|NCT02697149||intervention|patients undergoing nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
11300351|NCT02697149||control|patients undergoing standard endoscopic retrograde cholangiopancreatography
11300352|NCT02697136|Experimental|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
11300353|NCT02697136|Placebo Comparator|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
11300354|NCT02697123||antepartum and postpartum|This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
11300355|NCT02697110|Experimental|A: Edutainment based intervention|This group receives the usual routine immunization at 6, 10, 14 weeks and 9 months and an Edutainment intervention package of limited group (i.e., 3-5 women) drama based video session (Edutainment) followed by a Question and Answer session with mothers on early brain development, parenting skills, communication and negotiating skills at 6 weeks. Mothers will be encouraged to train fathers and other caregivers at home with reinforcement of key messages at subsequent clinic visits. Key messages will be delivered through the use of flip charts at 14 weeks and given to mothers as take home for use in engaging the fathers partners and other caregivers for their child. Reinforcement of key messages at subsequent visits will be through the use of videos and flip chart.
11300356|NCT02697110|No Intervention|B|This group receives routine immunization care (usually includes group health talk) at 6, 10, 14 weeks and 9 months.
11300357|NCT02697097||Control Arm Group|Participants aged 18-30, Male and Female (10 participants each). Control group must have normal range of movement and no evidence of femoro-acetabular impingement (FAI) on clinical examination (negative impingement test, no symptoms). Other exclusions for Control Group include previous surgery to hip joint/s, history of arthritis, family history of FAI, patients who have had symptoms of hip pain in the preceding 1 year or may have other conditions which may affect the hip joint or hip muscle strength including neurological conditions or muscular dystrophy.
11300358|NCT02697097||FAI Arm Comparison Group|Participants aged 18-30, Male and Female (10 participants each). Participants with femoro-acetabular impingement as diagnosed clinically and on radiological imaging for the comparison group (MRI).
11300359|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
11300360|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
11300361|NCT02697058|Experimental|Part 1: Safety and PK|BAX2398 in combination with 5-FU/calcium levofolinate
11300362|NCT02697058|Experimental|Part 2: Safety, PK, Efficacy|BAX2398 in combination with 5-FU/calcium levofolinate
11300363|NCT02697058|Active Comparator|Part 2: 5-FU/calcium levofolinate alone|5-FU/calcium levofolinate
11300364|NCT02697045|Other|ARIPIPRAZOLE|ABILIFY MAINTENA 400 MG LAI Aripiprazole 400mg, IM, Once a month
11300365|NCT02697032|Experimental|Patients|At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.
11300366|NCT02697019|Experimental|Internet-delivered ERITA|
11300367|NCT02696993|Experimental|Group A (nivolumab, SRS)|Patients receive nivolumab IV over 90 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
11300368|NCT02696993|Experimental|Group B (nivolumab, WBRT)|Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
11300369|NCT02696993|Experimental|Group C (nivolumab, ipilimumab, SRS)|Patients receive nivolumab as in Group A and ipilimumab IV over 90 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
11300370|NCT02696993|Experimental|Group D (nivolumab, ipilimumab, WBRT)|GROUP D: Patients receive nivolumab as in Group A and ipilimumab as in Group C. Patients undergo WBRT once daily for 10 days.
11300371|NCT02696980|Experimental|Rescue|Intervention: Positive expiratory pressure (PEEP) 10 will be applied after the administration of methacholine
11300372|NCT02696980|Experimental|Prophylaxis|Intervention: Positive expiratory pressure (PEEP) 10 will be applied during the administration of methacholine
11300373|NCT02696980|Placebo Comparator|No PEEP|Intervention: Positive expiratory pressure (PEEP) 0 will be applied during the administration of methacholine
11300374|NCT02696967|Experimental|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
11300375|NCT02696967|Placebo Comparator|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
11300376|NCT02696954|Experimental|Group A|
11300377|NCT02696954|Experimental|Group B|
11300493|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
11300378|NCT02696941|Experimental|Metformin|Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.
11300379|NCT02696941|Experimental|SGLT2|Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.
11300380|NCT02696928|Other|Artemeter-Lumefantrine (combination therapy)|"33 patients
~(standard of care)"
11300381|NCT02696928|Active Comparator|Artemeter-Lumefantrine and Primaquine (combination therapy)|33 patients
11300382|NCT02696928|Experimental|Artemeter-Lumefantrine and MB (combination therapy)|33 patients
11300383|NCT02696915|Placebo Comparator|Placebo|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.
11300384|NCT02696915|Active Comparator|Bupivacaine|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.
11300385|NCT02696902|Active Comparator|MEDI3902|
11300386|NCT02696902|Placebo Comparator|Placebo|
11300387|NCT02696889|Experimental|ROSE-1 Protocol|Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
11300388|NCT02696876|Active Comparator|Control group|Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.
11300389|NCT02696876|Experimental|Intervention group|Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space.
11300390|NCT02696863||filling a questionnaire and interview|"The questionnaire is tracking occupational carcinogens. It consists of 30 questions , fills an average of 3 minutes and includes three response categories: yes, no and do not know. A questionnaire will be added social and professional issues.
~Interviews will be conducted with the patient to identify obstacles and facilitating elements"
11300391|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
11300392|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
11300393|NCT02696837|Active Comparator|ETT & Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and Muscle Relaxant
11300394|NCT02696837|Active Comparator|ETT & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and No Muscle Relaxant
11300395|NCT02696837|Active Comparator|Proseal LMA & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and NO Muscle Relaxant
11300396|NCT02696837|Active Comparator|Proseal LMA & Subparalytic Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and subparalytic dose Muscle Relaxant
11300397|NCT02696824|Experimental|CBT-AD|Those assigned to the CBT-AD [cognitive behavioral therapy for adherence and depression) condition, will have up to 8 additional sessions delivered by the study clinic nurse. Additionally, those assigned to CBT-AD will have the procedures available to those assigned to ETAU.
11300398|NCT02696824|No Intervention|ETAU|"Participants in both conditions receive usual care plus the following procedures below.
~All participant will have the benefit of the psychosocial assessment, and the clinic nurse will provide feedback to the participant and to their clinic doctor about their depression. Additionally, all participants will undergo standard of care second line treatment adherence counseling in the clinic . The clinic doctor will not be restricted in terms of referral or treatment of depression for their patient with respect to antidepressant medications or other interventions available."
11300399|NCT02696811|Placebo Comparator|Oat biscuits|Participants will eat 3 oat biscuits per day for 6 weeks
11300400|NCT02696811|Experimental|White Carrots|Participants will eat 100g (cooked weight) of white carrots per day for 6 weeks
11300401|NCT02696798|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
11300402|NCT02696798|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
11300403|NCT02696798|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.
~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
11300404|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
11300405|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
11328469|NCT02511210|Active Comparator|general anesthesia|intubated patients
11300406|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
11300407|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.
~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
11300408|NCT02696772|Experimental|Energy balance|Intervention day diet containing 100% of estimated energy requirements
11300409|NCT02696772|Experimental|Energy restriction|Intervention day diet containing 25% of estimated energy requirements
11300410|NCT02696759|Other|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
11300411|NCT02696746||Pain related conditions|Subjects with painful or painless conditions (observational study, no interventions)
11300412|NCT02696733|Experimental|UG - ONB|Patients with the bladder tumor located on the lateral wall, with the high risk of adductor muscles contraction during TURBT under spinal anesthesia.
11300413|NCT02696720|Experimental|Lidocaine|During a period of six weeks, a lidocaine patch will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
11300414|NCT02696720|Sham Comparator|Sham|During a period of six weeks, a visually identical patch (sham) will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
11300415|NCT02696707|Active Comparator|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
11300416|NCT02696707|Active Comparator|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
11300417|NCT02696694||P25-P75|serum progesterone between 25 and 75 percentile
11300418|NCT02696694||<P25 ó >P75|serum progesterone <25 or >75 percentile
11300419|NCT02696681|Experimental|Cognitive Behavioral Therapy|Integrating CBT for any substance use or mental health problems with CBT for adherence/self-care
11300420|NCT02696668|Active Comparator|modified FaME|Participants in the modified FaME group will receive a 16 weeks falls rehabilitation programme which will be tailored and progressed according to their abilities and their needs by the physiotherapist / instructor providing the rehabilitation at the hospital.
11300421|NCT02696668|Experimental|Multisensory|Participants in the multisensory group will receive balance exercises training which will be tailored and progressed to their abilities and needs.
11300422|NCT02696655|Experimental|liver transplant patients|Patients will use a behavioural intervention to assess its usability
11300423|NCT02696642|Experimental|Control group|Anetumab ravtansine was given at 6.5 mg/kg body weight (BW) as a 1 hour intravenous (IV) infusion once every 3 weeks (Q3W) for subjects with adequate hepatic and renal function.
11300424|NCT02696642|Experimental|mild HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with mild hepatic impairment (HI).
11300425|NCT02696642|Experimental|moderate HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate hepatic impairment (HI).
11300426|NCT02696642|Experimental|moderate RI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate renal impairment (RI).
11300427|NCT02696629||Education and follow up|Participants who refuse or fail to have PAP treatment or Oral appliance or other treatments for sleep apnea. They also refuse or have counter-indication for surgical treatment. The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
11300428|NCT02696629||Upper airway surgery|Participants who undergo uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery.
11300429|NCT02696629||Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
11300430|NCT02696616|Experimental|BI 655088|
11300431|NCT02696616|Placebo Comparator|Placebo|
11300432|NCT02696603|Experimental|Participants with Parkinson disease|People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
11300433|NCT02696603|Experimental|Participants without Parkinson disease|People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
11300434|NCT02696590|Experimental|MS patients injectable Vitamin D3|MS patients who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
11300435|NCT02696590|Experimental|MS patients orally Vitamin D3|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
11300436|NCT02696590|Active Comparator|Healthy groups Injectable Vitamin D3|who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
11300437|NCT02696590|Active Comparator|Healthy groups Vitamin D3 orally|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
11300438|NCT02696577|Active Comparator|Low dose aspirin|Received aspirin 81mg once daily for 6 weeks
11300439|NCT02696577|Active Comparator|Low dose aspirin plus omega 3 group|Received aspirin 81mg and omega 3 once daily for 6 weeks.
11300440|NCT02696564|Active Comparator|Losartan|At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
11300494|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
11300441|NCT02696564|Placebo Comparator|placebo|At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.
11300442|NCT02696551|Experimental|Interventional hospital|Interventional hospital, which will receive 3-month medical education
11300443|NCT02696551|No Intervention|Non-interventional hospital|Non-interventional hospital, which will not receive 3-month medical education.
11300444|NCT02696538|Experimental|Experimental|All participants included in this group and will complete all three outcomes assessment
11300445|NCT02696512|Experimental|IBRF ACP/MCP Group 1|The Treatment group will be receiving a combination of pharmaceuticals (polypharmacy using FDA-approved products) and nutraceuticals (Nutraceutical supplementation) and median nerve stimulation (MNS)
11300446|NCT02696512|Other|Standard of Care Group 2|Standard of Care only
11300447|NCT02696499|Experimental|PA101B|
11300448|NCT02696499|Placebo Comparator|Placebo|
11300449|NCT02696486|Experimental|Exercise Training|
11300450|NCT02696473|Experimental|High Carrot Dose|The volunteer will eat 250g carrot for breakfast with 2 slices of bread and 10g butter
11300451|NCT02696473|Experimental|Low Carrot Dose|The volunteer will eat 100g of carrot for breakfast with 2 slices of bread and 10g butter
11300452|NCT02696460|Active Comparator|N2O/O2 analgesia|Wound debridement under analgesia with N2O/O2 premix.
11300453|NCT02696460|Active Comparator|Lidocaine/Prilocaine analgesia|Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
11300454|NCT02696447||Cancer treated by radiotherapy|Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
11300455|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
11300456|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
11300457|NCT02696421||Non diabetic, non obese|
11300458|NCT02696421||Non diabetic obese|
11300459|NCT02696421||Diabetic|
11300460|NCT02696408|Experimental|Laser treatment|preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)
11300461|NCT02696408|Placebo Comparator|laser-off|daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)
11300462|NCT02696395|Active Comparator|DePuy Tri-Lock®|Total hip replacement with DePuy Tri-Lock® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
11300463|NCT02696395|Active Comparator|DePuy Corail®|Total hip replacement with DePuy Corail® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
11300464|NCT02696382|Active Comparator|Usual Care (UC)|"Participants in the Usual Care (UC) group will receive standard, low-intensity physical therapy following discharge from acute hospitalization."
11300465|NCT02696382|Experimental|Progressive High Intensity Therapy|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization."
11300466|NCT02696369|Experimental|2% Lidocaine HCL:Epinephrine inj.|2% Lidocaine HCL with epinephrine 1:200,000
11300467|NCT02696369|Active Comparator|2% Lidocaine HCL:Epinephrine inj. (3M)|2% Lidocaine HCl with epinephrine 1:80,000
11300468|NCT02696356|Experimental|Cohort 1|0.1mg GRN-1201
11300469|NCT02696356|Active Comparator|Cohort 2|1.0mg GRN-1201
11300470|NCT02696356|Experimental|Cohort 3|3.0mg GRN-1201
11300471|NCT02696343|Experimental|EPI experimental|Preterm infants randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
11300472|NCT02696343|Sham Comparator|EPI control|Preterm infants randomized to receive the Sham (blind pacifier) during tube feedings.
11300473|NCT02696330|Active Comparator|clopidogrel|50 patients undergoing ICSI
11300474|NCT02696330|Active Comparator|enoxaparin|50 patients undergoing ICSI
11300475|NCT02696330|Placebo Comparator|placebo|50 patients undergoing ICSI
11300476|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
11300477|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
11300478|NCT02696304|Other|TBI for childhood leukemia|Patients with a metabolic syndrom who received TBI.
11300479|NCT02696304|Other|No TBI for childhood leukemia|Patients with a metabolic syndrom without previousTBI
11300480|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
11300481|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
11300482|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
11300483|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
11300484|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
11300485|NCT02696278|Experimental|Hummus and vegetables|Children will receive a lesson about vegetables and hummus and vegetables as part of their daily snack.
11300486|NCT02696278|Experimental|Vegetables only|Children will receive a lesson about vegetables and vegetables as part of their daily snack.
11300487|NCT02696265|Active Comparator|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
11300488|NCT02696265|Active Comparator|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
11300489|NCT02696252||CGM Users|
11300490|NCT02696239|Active Comparator|V-lock suture|V-lock absorbable Wound Closure Device, by Covidien
11300496|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
11300497|NCT02696213|Experimental|SCOOT Immediate|This group will receive SCOOT immediately
11300498|NCT02696213|Other|SCOOT Delayed|This group will receive SCOOT after 6 weeks
11300499|NCT02696200|Experimental|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
11300500|NCT02696200|No Intervention|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
11300501|NCT02696187|Experimental|KOLwebben|Patients in the experimental group will be introduced to KOL-webben during their ordinary visits to the primary care center. All patients will receive a pedometer
11300502|NCT02696187|No Intervention|Control group|Other than receiving a pedometer the patients in the control group will not receive any intervention.
11300503|NCT02696174|Experimental|Health Microinsurance Scheme|Households owning the HMI package, entitling them to visit and receive treatment from the selected primary care clinic
11300504|NCT02696174|No Intervention|Out-Of-Pocket|Households who visit the selected primary care clinic, but pay by Out-Of-Pocket
11300505|NCT02696161|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
11300506|NCT02696161|Placebo Comparator|5% dextrose|5% dextrose for hydrodissection
11300507|NCT02696148|Experimental|Liraglutide|
11300508|NCT02696148|Placebo Comparator|Placebo|
11300509|NCT02696135||Hypertrophic cardiomyopathy|Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
11300510|NCT02696122|Experimental|Local Group|Local infiltration under general anesthesia via laryngeal mask
11300511|NCT02696122|Experimental|Spinal Group|Spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine
11300512|NCT02696109|Experimental|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
11300513|NCT02696109|Active Comparator|Treatment as Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
11300514|NCT02696096|Other|All Participants|FMRI Suboxone
11300515|NCT02696083|Experimental|Active Treatment|
11300516|NCT02696070|Other|Sham of Provant|Sham of Provant
11300517|NCT02696070|Other|Active Treatment|Active Provant Treatment
11300518|NCT02696057|Active Comparator|Manual technics|Manual technics was consisted of soft tissue technics, muscle energy technics, joint mobilization.
11300519|NCT02696057|Active Comparator|Exercise|Spinal stabilization exercises were applied all the patients in this group accompanied by physiotherapist.
11300520|NCT02696044|Experimental|Participants aged 0 months to 3 years|Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.
11300521|NCT02696044|Experimental|Participants aged 4 to 6 years|Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.
11300522|NCT02696044|Experimental|Participants aged 7 to 9 years|Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.
11300523|NCT02696044|Experimental|Participants aged 10 to 14 years|Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.
11300524|NCT02696044|Experimental|Participants aged 15 to 20 years|Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.
11300525|NCT02696044|Experimental|Participants aged 21 years and older|Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.
11300526|NCT02696031|Experimental|Secukinumab|Secukinumab 150 mg s.c.
11300527|NCT02696031|Placebo Comparator|Placebo|Placebo s.c.
11300528|NCT02696031|Experimental|Experimental|Secukinumab 150 mg s.c. no load
11300529|NCT02696018||Critically ill patients|Ultrasonography in critically ill patients in weaning from mechanical ventilation
11300530|NCT02696005||Group I|15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
11300531|NCT02696005||Group II|15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
11300532|NCT02695992|Active Comparator|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
11300533|NCT02695992|Active Comparator|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
11300534|NCT02695979||Patients undergoing OLT|Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).
11300535|NCT02695940|Active Comparator|LEO 124249 ointment 30 mg/g|Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day
11300536|NCT02695940|Placebo Comparator|LEO 124249 ointment vehicle|LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day
11300537|NCT02695927|Experimental|Chronic|Crossover study on the benefits of computer rehabilitation glasses on chronic sufferers of hemispatial neglect
11300538|NCT02695927|Experimental|Acute|Randomized, controlled study on the benefits of computer rehabilitation glasses on acute sufferers of hemispatial neglect
11300539|NCT02695927|Experimental|Optimization|Study to identify optimal operating parameters of computer rehabilitation glasses
11300540|NCT02695927|Active Comparator|Duration|Study to determine duration of effect of computer rehabilitation glasses
11300541|NCT02695914||Control group|Conventional treatment methods will be given to cases in control group.
11300542|NCT02695914||Experiment group|On the base of control group, Compound Qingre Granule will be added to in experiment group.
11300543|NCT02695901|Experimental|Chlorhexidine gluconate (0,12%)|Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).
11300544|NCT02695901|Experimental|M. alternifolia oil (Nanoparticle solution)|Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).
11300545|NCT02695888|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
11300546|NCT02695888|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
11300547|NCT02695875|Experimental|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
11300548|NCT02695875|Other|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
11300549|NCT02695862|Experimental|Bolus Terlipressin|Injection terlipressin after 2 mg bolus it will be given 2 mg QID
11300550|NCT02695862|Active Comparator|Terlipressin continuous(4mg/24hours)|Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)
11300551|NCT02695849||NSCLC Participants|Participants with non-squamous NSCLC will be enrolled in this study.
11300552|NCT02695836|Active Comparator|Standard feedback|Facilities in this arm will receive an initial face-to-face dissemination workshop that includes feedback of research data on modifiable aspects of their microsystem context but no goal setting.
11300553|NCT02695836|Experimental|Basic assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive a face-to-face goal setting workshop focused on modifiable areas of their microsystem context and two virtual support workshops at six month intervals.
11300554|NCT02695836|Experimental|Enhanced assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive an additional face-to-face goal setting workshop focused on modifiable areas of their microsystem context, two additional face-to-face support workshops at six month intervals plus on-demand email and telephone support.
11300555|NCT02695823|Experimental|Patients undergoing liver transplantation|
11300556|NCT02695810|Experimental|Dapagliflozin|Dapagliflozin, 10 mg per day
11300557|NCT02695810|Active Comparator|Metformin|Metformin, 2 x 850 mg per day
11300558|NCT02695810|Active Comparator|Exercise|Exercise, interval training
11300559|NCT02695810|No Intervention|Control|No intervention
11300560|NCT02695797|Experimental|Immunotherapy|Intravenous immunoglobulin (IVIG) and oral prednisolone. IVIG and oral prednisolone are administered simultaneously: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day).
11300561|NCT02695797|No Intervention|Control|No immunotherapy.
11300562|NCT02695784|Experimental|Probiotic continuation|This Group will Continue probiotics Beyond 34 weeks corrected Gestational agent standard practice
11300563|NCT02695784|No Intervention|Standard treatment Group|This group will continue current standard practice of stopping probiotics at 34 weeks corrected gestational age
11300564|NCT02695771|Experimental|Mitomycin C|Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
11300565|NCT02695771|Active Comparator|Gemcitabine|Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
11300566|NCT02695771|No Intervention|No intervention|Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.
11300567|NCT02695758|Active Comparator|interscalene brachial plexus block|Direct interscalene nerve block injection via brachial plexus
11300568|NCT02695758|Active Comparator|Bupivacaine extended-release liposome injection|Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
11300569|NCT02695745|Experimental|V116517|V116517 aqueous suspension; 300 mg
11300570|NCT02695745|Active Comparator|Celecoxib|Celecoxib capsules; 400 mg (2 capsules of 200 mg each)
11300571|NCT02695745|Placebo Comparator|Placebo|Placebo
11300572|NCT02695732|Experimental|Carvedilol|Carvedilol，6.25mg-12.5mg/d,oral,6-36 months
11300573|NCT02695732|Active Comparator|endoscopy|endoscopy，every 4 weeks until eradication of varices
11300574|NCT02695719|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
11300575|NCT02695719|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
11300576|NCT02695706|Experimental|Laboratoires Mercurochrome Reparador|A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.
11300577|NCT02695693|Experimental|TeachTown|Students in kindergarten-through-second-grade autism support classrooms in this arm receive access to TeachTown, an online academic and pre-academic intervention designed for students with autism. Their teachers also receive coaching in the use of TeachTown, as well as coaching in other evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
11300578|NCT02695693|Active Comparator|Control|Teachers in kindergarten-through-second-grade autism support classrooms in this arm receive coaching in evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
11300579|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
11300580|NCT02695667||OSAS subjects|CPAP Referral OSAS
11300581|NCT02695667||Risk-Free subjects|paired normal control subjects
11300582|NCT02695654||Chronic pain in knee osteoarthritis|Ultrasound guided single shot Adductor canal block with 0,25% Levobupivacaine 14 ml and 100 mcg Clonidine
11300583|NCT02695641|Experimental|Stage 1 - Low dose administration|Ten hemodialysis patients will receive IV infusion treatment with 1.25mg bevacizumab and undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and pharmacokinetic/dynamic (PK/PD) data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcomes are met in stage 1, the study will be terminated, otherwise the study will progress to stage 2.
11300584|NCT02695641|Experimental|Stage 2 - Dose escalation|If outcomes are not met in stage 1, Ten additional hemodialysis patients will receive IV infusion treatment with 2.50mg bevacizumab treatment. They will undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and PK/PD data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcome is not met, the study will be terminated.
11300585|NCT02695628|Experimental|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
11300586|NCT02695602|Experimental|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
11300587|NCT02695602|Experimental|Submucous Resection (SMR)|Turbinoplasty using non-powered instruments
11300588|NCT02695576|Experimental|Surgery|Lumbar fusion surgery Physiotherapy Cognitive behavioral therapy
11300589|NCT02695576|Active Comparator|Non-surgery|Physiotherapy Cognitive behavioral therapy
11300590|NCT02695563|No Intervention|controls|The patients will be not treated with vaginal lactoferrin
11300591|NCT02695563|Active Comparator|Lactoferrin|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
11300592|NCT02695550|Experimental|CT-707|ALK-positive non-small cell lung cancer resistant to Crizotinib treatment
11300593|NCT02695537|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).
~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
11300594|NCT02695524|Active Comparator|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
11300595|NCT02695524|Experimental|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
11300596|NCT02695511|Experimental|25% CR|25% caloric restriction
11300597|NCT02695511|No Intervention|CO (control)|healthy lifestyle recommendation
11300598|NCT02695498|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a standardized course in mindfulness mediation and yoga.
11300599|NCT02695498|Experimental|Migraine/stress Education|This course will educate participants about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
11300600|NCT02695485|Other|sensate flap|the donor nerve harvested with the flap
11300601|NCT02695472|Placebo Comparator|Placebo Arm|One Placebo tablet, twice daily
11300602|NCT02695472|Experimental|40 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet and 1 placebo tablet per day
11300603|NCT02695472|Experimental|80 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet twice per day
11300604|NCT02695459|Experimental|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
11300605|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
11300606|NCT02695433|Experimental|Active treatment (AT) diet plan|1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period
11300607|NCT02695433|Placebo Comparator|Control (CT) diet plan|at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period
11300608|NCT02695420|Placebo Comparator|Placebo BID|Participants will receive placebo BID.
11300609|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
11300610|NCT02695420|Experimental|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
11300611|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
11300612|NCT02695407|Experimental|3 days cannulation|radial artery cannula removed after 3 days
11300613|NCT02695407|Experimental|5 days cannulation|radial artery cannula removed after 5 days
11300614|NCT02695394||MS / CIS|
11300615|NCT02695394||Healthy controls|
11300616|NCT02695381|Experimental|Etodolac-lidocaine Topical Patch|Therapy with experimental drug
11300617|NCT02695381|Placebo Comparator|Placebo|Therapy with placebo
11300618|NCT02695368|Experimental|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:
~regular operating theater
~ultra-Clean operating theaters"
11300619|NCT02695368|Experimental|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
11300620|NCT02695368|Experimental|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
11301128|NCT02691962|Experimental|Xen Matrix AB|Subjects treated with Xen Matrix AB
11300621|NCT02695355|Experimental|ADHD medication effects|Single dose methylphenidate (Ritalin tablets); 10 mg for ages 8-13; 15 mg for ages 13-17
11300622|NCT02695342|Experimental|Home balance exercise program|The home-based exercise program will be tailored to address the underlying balance deficits in COPD and individualized according to each participant's ability. Physiotherapists will teach the program in four home visits over the first 6 weeks of the study; in the event of an exacerbation, a fifth visit will be provided to modify the program. Participants will be given an exercise DVD (with portable player), and will be instructed to perform the program 3 times/week for 6 months. Therapists will provide bi-monthly telephone support.
11300623|NCT02695329|Active Comparator|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
11300624|NCT02695329|No Intervention|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
11300625|NCT02695316|Other|Migrant Women|Focus Group Discussion in native Language with n=20
11300626|NCT02695316|Other|Health Care Professionals|Focus Group Discussion with n=20 Health Care Professionals
11300627|NCT02695316|Other|Interpreters|One-to-one Interviews with n=4 intercultural Interpreters
11300628|NCT02695316|Other|Telephone Interpreting Protocols|Retrospective quantitative analysis of n=50 Telephone Interpreting Protocols (questionnairs)
11300629|NCT02695303|Experimental|BAY 987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11300630|NCT02695290|Experimental|Afatinib|
11300631|NCT02695277|Experimental|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
11300632|NCT02695277|Active Comparator|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
11300633|NCT02695264|Experimental|HS-1000 recording|ICP readings will be recorded from both the invasive and HeadSense non-invasive ICP monitor for an aggregate of 30 minutes. During the recording sessions, a webcam will take periodic snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other clinical parameters that are displayed on screen, with a focus on blood pressure and heart rate (HR). Recording sessions will be done until an aggregate of at least 30 minutes of data are collected, depending on the patient's clinical condition. Recording sessions may be repeated over several days until the 30 minute target is reached.
11300634|NCT02695251|Experimental|Low AGE meal|Renal functional parameters are measured at baseline and after a low AGE (eggs) meal
11300635|NCT02695251|Experimental|High AGE meal|Renal functional parameters are measured at baseline and after a high (mixed nuggets) AGE (eggs) meal
11300636|NCT02695238|Experimental|prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, prophylactic manual rotation will be performed.
11300637|NCT02695238|No Intervention|No prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, expectant management for delevery will be performed
11300638|NCT02695225|Other|Lay-led tobacco abstinence|Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
11300639|NCT02695225|Other|Lay-led promotion of Ohio Quit Line|Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
11300640|NCT02695212|Experimental|Apremilast ( open label)|"Investigational Product: Apremilast
~Doses: Period A:
~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6
~Period B:
~30mg Twice per day, day #7 through week #24
~Period C:
~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
11300641|NCT02695199|Experimental|laparoscopic varicocelectomy|laparoscopic Doppler ultrasound assisted laparoscopic varicocelectomy group
11300642|NCT02695199|Sham Comparator|microscopic varicocelectomy|conventional Microscopic Subinguinal varicocelectomy group
11300643|NCT02695186||A/IM alone|Patients with intestinal metaplasia who undergo gastroscopy and blood sample analysis
11300644|NCT02695186||B/IM and MS|Patients with intestinal metaplasia and metabolic syndrome who undergo gastroscopy and blood sample analysis
11300645|NCT02695186||C/Healthy controls|Healthy controls without intestinal metaplasia or metabolic syndrome who undergo gastroscopy and blood sample analysis
11300646|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
11300647|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
11300648|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
11300649|NCT02695147||TAVI via Subclavian approach|Any TAVI procedure using any valve type performed via the subclavian approach
11300650|NCT02695147||TAVI via Direct Aortic approach|Any TAVI procedure using any valve type performed via the direct aortic approach
11300651|NCT02695134|Other|Intervention Group|This group will receive 6 Healing Touch treatments over 3 weeks
11300652|NCT02695134|No Intervention|Control Group[|This group will continue with their usual medical treatments but receive NO Healing Touch
11300653|NCT02695108|Experimental|classical approach for neck pain|patients in this arm received classical approaches for neck pain. Cervical manual therapy was performed on patients in this arm and they were also instructed to to perform cervical endurance, strength and stretching exercises. Rehabilitation period was lasted for 6 weeks. Pain, quality of life and scapular kinematics were assessed before and after rehabilitation program.
11300654|NCT02695108|Experimental|scapular exercise on neck pain|patients in this arm received cervical manual therapy and cervical exercises too. Apart from cervical manual therapy and cervical exercises,patients also performed scapular stabilization exercise targeting trapezius, serratus anterior and rhomboid muscles. Rehabilitation period was lasted for 6 weeks. The same assessment parameters was conducted on this arm too.
11300655|NCT02695069|Experimental|All Participants|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
11300656|NCT02695043|Experimental|MMPET Group|This group of subjects will be comprised of a subset of culturally diverse patients admitted to the Bellevue the Traumatic Brain Injury Unit at Bellevue. Treatment will focus on improving awareness and comprehension of TBI and its long-term consequences, fostering increased trust in the TBI rehabilitation team, and conveying the importance of continued TBI follow up to maximize recovery.
11300657|NCT02695043|Active Comparator|Control Group|The Control Group will be comprised of equally diverse subset of patients who will receive Standard of Care Treatment.
11300658|NCT02695017|Experimental|Iso inertial|Subjects should do 12 exercise repetition with Iso inertial machine
11300659|NCT02695017|Experimental|Conventional machine|Subjects should do 12 exercise repetition with conventional machine
11300660|NCT02695004|Experimental|Donepezil 35 mg|Donepezil 35 mg or placebo
11300661|NCT02695004|Experimental|Donepezil 70 mg|Donepezil 70 mg or placebo
11300662|NCT02695004|Experimental|Donepezil140 mg|Donepezil 140 mg or placebo
11300663|NCT02695004|Experimental|Donepezil 210 mg|Donepezil 210 mg or placebo
11300664|NCT02695004|Experimental|Donepezil 280 mg|Donepezil 280 mg or placebo
11300665|NCT02694991|Experimental|OMT Group|Osteopathic Manipulative Treatment 15 minutes once a day for 8 days
11300666|NCT02694991|No Intervention|Control Group|No intervention, only usual care
11300667|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
11300668|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
11300669|NCT02694965||Stage IV/Unresectable Stage III Melanoma|Observational - Eligible patients with stage IV/unresectable stage III melanoma selected to undergo treatment with an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a combination of an anti-CTLA-4 antibody/anti-PD-1 antibody will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.
11300670|NCT02694965||Stage III/IV Adjuvant Melanoma|Observational - 1) Patients either undergoing resection of stage III or stage IV melanoma or have previously undergone resection and who are considered candidates for adjuvant anti-PD-1 antibody immunotherapy. 2) Patients who previously underwent resection of stage III or stage IV melanoma and received prior adjuvant anti-PD-1 antibody immunotherapy and have subsequently developed recurrent melanoma.
11300671|NCT02694952|Active Comparator|FAV-Africa|FAV-Africa infusion at enrollment, and then at two and six hours after enrollment, if necessary. To be given as unblinded rescue dose at twelve hours if fourth dose of antivenom necessary.
11300672|NCT02694952|Experimental|EchiTabPlus-ICP|EchiTabPlus-ICP infusion at enrollment, and then at two and six hours after enrollment, if necessary.
11300673|NCT02694939|Experimental|STAND|Receives STAND intervention delivered in community mental health setting.
11300674|NCT02694939|Active Comparator|Usual Care|Receives usual care from community therapists.
11300675|NCT02694926|Other|adrenal insufficiency|
11300676|NCT02694900|Experimental|Resuscitation on the flor|2 min asynchronous cardiopulmonary resuscitation. The patient lies on the floor
11300677|NCT02694900|Experimental|Resuscitation on the stretcher|2 min asynchronous cardiopulmonary resuscitation. The patient lies on a stretcher
11300678|NCT02694874|Experimental|Rosiglitazone|Participants will receive rosiglitazone 0.045mg/kg/dose twice daily dosing, for 4 days
11300679|NCT02694874|Placebo Comparator|Placebo|Participants will receive placebo (grounded placebo powder) at a dose of 0.045mg/kg/dose twice daily for 4 days
11300680|NCT02694861||Registry Group|Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
11300681|NCT02694861||Prospective Group|A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
11300682|NCT02694848|Other|Salvianolate injection group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
11300683|NCT02694848|Active Comparator|Aspirin group|Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
11300684|NCT02694848|Experimental|Salvianolate injection and aspirin group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
11300685|NCT02694835|Experimental|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
11300686|NCT02694835|Active Comparator|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
11300687|NCT02694822|Experimental|AGEN1884|anti-CTLA-4 antibody
11300688|NCT02694809|Experimental|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
11300689|NCT02694809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
11300759|NCT02694367||Recurrent miscarriage group|Women with previous history of RM, defined as two or more consecutive miscarriages
11300760|NCT02694367||Control group|Women with no history of RM
11300761|NCT02694354|Experimental|BI 685509|
11300690|NCT02694796|Experimental|Intervention|The 'Physical activity program after a balneotherapy' intervention involves providing a workshop during a balneotherapy about physical activity and use of automated physical activity program including website, mobile app and connected devices, and after the balneotherapy, the access to the automated program during 12 months.
11300691|NCT02694796|No Intervention|Control|Patients included in the control arm will receive a booklet including informations about physical activity recommendations and practice.
11300692|NCT02694783|Experimental|Treatment Arm|ex vivo generated polyomavirus-specific T cells from HLAmatched donor
11300693|NCT02694770|Experimental|Neihulizumab|Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.
11300694|NCT02694770|Active Comparator|"Conventional Treatment"|Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.
11300695|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
11300696|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
11300697|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
11300698|NCT02694731|Experimental|Mobile application intervention|Participants receive a mobile app with a 5-week mindful eating program and ongoing tools for coping with cravings
11300699|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
11300700|NCT02694705|Experimental|CPAP|3 minutes of preoxygenation with a portable ventilator providing Continuous Positive Airway Pressure (CPAP) at 5 cmH20 and an FiO2 of 100%.
11300701|NCT02694705|Experimental|BVM|3 minutes of preoxygenation with a bag-valve-mask (BVM) device and oxygen flow rate of 15 litres / minute.
11300702|NCT02694705|Experimental|NRM|3 minutes of preoxygenation with a non-rebreather mask (NRM) device and oxygen flow rate of 15 litres / minute.
11300703|NCT02694692||Follow-up|No further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care & Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
11300704|NCT02694679|No Intervention|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
11300705|NCT02694679|Active Comparator|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
11300706|NCT02694679|Active Comparator|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
11300707|NCT02694679|Active Comparator|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
11300708|NCT02694679|Active Comparator|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
11300709|NCT02694679|Active Comparator|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
11300710|NCT02694679|Active Comparator|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
11300711|NCT02694679|Active Comparator|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
11300712|NCT02694679|No Intervention|Friendship 0|CBNH 0% of population targeted
11300713|NCT02694679|Experimental|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
11300714|NCT02694679|Experimental|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
11300715|NCT02694679|Experimental|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
11300716|NCT02694679|Experimental|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
11300717|NCT02694679|Experimental|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
11300718|NCT02694679|Experimental|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
11300719|NCT02694679|Experimental|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
11300720|NCT02694666|Experimental|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
11300721|NCT02694666|Placebo Comparator|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
11300722|NCT02694653|Active Comparator|Drug Arm|Acetaminophen 1000 mg in 100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
11300723|NCT02694653|Placebo Comparator|Placebo Arm|100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
11300762|NCT02694354|Placebo Comparator|Placebo|matching placebo
11300724|NCT02694640|Experimental|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
11300725|NCT02694640|Experimental|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
11300726|NCT02694640|Experimental|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
11300727|NCT02694627|Experimental|Intervention|See intervention description
11300728|NCT02694627|No Intervention|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but do not receive any intervention.
11300729|NCT02694614|Experimental|smartphone-assisted dietary coaching|
11300730|NCT02694601|Experimental|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
11300731|NCT02694588|Active Comparator|Infliximab|5 mg/kg body weight, week 0/2/6, then every 8 weeks
11300732|NCT02694588|Active Comparator|Vedolizumab|300 mg, week 0/2/6, then every 8 weeks
11300733|NCT02694575||Other|Other - currently on other treatment (i.e., non-incretin based therapies)
11300734|NCT02694575||GLP-1|Currently on GLP-1 analogue therapy
11300735|NCT02694575||DPP-4|Currently on DPP-4 inhibitor therapy
11300736|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
11300737|NCT02694549|Experimental|CaveoVasc|
11300738|NCT02694536|Experimental|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
11300739|NCT02694523|Active Comparator|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
11300740|NCT02694523|Experimental|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
11300741|NCT02694510|Active Comparator|Light-protection|Light-protection of TPN solutions. TPN bags and infusion sets will be protected from light by aluminum foils throughout the study period.
11300742|NCT02694510|Active Comparator|Light-exposure|TPN bags and infusion sets will be exposed to light throughout the study period.
11300743|NCT02694484|Other|Healthy volunteers|For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit
11300744|NCT02694471|Experimental|Old group|16 old participants (55-65 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
11300745|NCT02694471|Active Comparator|Young group|7 young participants (18-30 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
11300746|NCT02694458|Experimental|Modeling arm|Early vancomycin monitoring and bayesian dosage adjustment
11300747|NCT02694458|Sham Comparator|Control arm|Usual vancomycin dose and monitoring strategy
11300748|NCT02694432|Active Comparator|GOALS|Participants will use for approximately four months an online platform, GOALS, consisting of weekly lessons designed to enhance blood pressure control. Recommended lifestyle changes for hypertension, including a low-sodium diet, physical activity, weight loss (if appropriate) and behavioral self-management skills will be offered. Attention to medication adherence and pharmacist support as well as that of a dedicated online health coach and ongoing collaboration with the primary care physician are also provided.
11300749|NCT02694432|Experimental|Minding GOALS|Participants in this arm will also use the GOALS standard tools for blood pressure control. To further maximize success, they will receive additional online behavioral training throughout the 4-month intervention that focuses on mind-body approaches. Weekly topics, for example, will include meditation lessons, mindfulness-based stress reduction and mindfulness-based eating awareness.
11300750|NCT02694419||obese/PCO|Women with PCOS who are overweight\obese with BMI ≥ 25 kg/m2.
11300751|NCT02694419||normal weight/PCO|Women with PCOS who are normal weight with BMI < 25 kg/m2.
11300752|NCT02694419||Obese/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are overweight\obese with BMI ≥ 25 kg/m2.
11300753|NCT02694419||normal weight/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are normal weight with BMI < 25 kg/m2.
11300754|NCT02694393|Experimental|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
11300755|NCT02694380||Head and Neck|Subjects with head and neck cancer receiving radiation therapy.
11300763|NCT02694341|Active Comparator|Bakri Balloon with abdominal traction stitch|bakri balloon will be inserted with abdominal traction stitch
11300764|NCT02694341|Experimental|Bakri Balloon without abdominal traction stitch|bakri balloon will be inserted with no performance of abdominal traction stitch
11300765|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
11300766|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
11300767|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
11300768|NCT02694302|Experimental|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
11300769|NCT02694302|Active Comparator|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
11300770|NCT02694289|Other|Metformin|Continue Metformin while admitted to hospital
11300771|NCT02694289|Other|Subcutaneous (sliding scale) Insulin|Discontinue Metformin upon admission and be placed on sliding scale subcutaneous insulin treatment while admitted to hospital
11300772|NCT02694276|Experimental|Internet-based cognitive behavior therapy|10 sessions of ICBT during 10 weeks.
11300773|NCT02694263|Experimental|Canagliflozin + Metformin|Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
11300774|NCT02694263|Active Comparator|Repaglinide + Metformin|Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
11300775|NCT02694263|Active Comparator|Pioglitazone + Metformin|Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
11300776|NCT02694263|Active Comparator|Gliclazide + Metformin|Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
11300777|NCT02694263|Active Comparator|Glimepiride + Metformin|Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.
11300778|NCT02694250|Other|DTRAX Cervical Cervical Cage with DTRAX Bone Screw|
11300779|NCT02694237|Active Comparator|Verbal|This group will only receive a verbal discussion based on the same script used for all three groups. This is the control group.
11300780|NCT02694237|Active Comparator|Verbal + Model|This group will receive a verbal discussion aided with an anatomic model intervention that group participants will be able to touch throughout the discussion.
11300781|NCT02694237|Active Comparator|Verbal + Video|This group will receive a verbal discussion aided with a knee anatomy video intervention that will be played on silent an orated by an interviewer.
11300782|NCT02694224|Experimental|vismodegib plus chemotherapy|Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)
11300783|NCT02694224|Active Comparator|chemotherapy|Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses
11300784|NCT02694211|Experimental|Intervention group ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
11300785|NCT02694211|No Intervention|Control group|No intervention, business as usual
11300786|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
11300787|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
11300788|NCT02694172|No Intervention|Lean non diabetic|Lean and healthy subjects receiving no intervention
11300789|NCT02694172|Experimental|Overweight non diabetic|fiber rich cereal bars, two bars a day for 4 weeks
11300790|NCT02694172|Experimental|Overweight diabetic|fiber rich cereal bars, two bars a day for 4 weeks
11300791|NCT02694146|Experimental|PRP (platelet rich plasma)|"37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.
~For PRP administration:
~The injection should be performed at room temperature.
~The administration should be carried out under aseptic conditions.
~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
~The PRP is injected into the synovial space."
11300792|NCT02694146|Active Comparator|Hylan G-F 20 (Synvisc-One ®)|"37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).
~It is necessary to remove synovial fluid before injecting Hylan G-F 20.
~The injection should be performed at room temperature.
~The administration should be carried out under aseptic conditions.
~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
~The Hylan G-F 20 is injected into the synovial space.
~After injecting Hylan G-F 20 the patient should stand 5 minutes."
11300793|NCT02694133|Experimental|Aphasia group|Aphasia
11300794|NCT02694120||colonoscopy population|
11300795|NCT02694107|Experimental|Proprioceptive exercises|Proprioceptive exercises performed 3 sessions per week for 4weeks
11300796|NCT02694107|No Intervention|Control|Without any exercises
11300797|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
11300798|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
11300799|NCT02694081|Experimental|Uncut Roux-en-Y Reconstruction|Uncut Roux-en-Y Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
11300800|NCT02694081|Active Comparator|Billroth II Reconstruction|Billroth II Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
11300801|NCT02694068||Discovery for Aim One|2173 subjects will be involved in the discovery cohort.
11300802|NCT02694068||Replication for Aim One|1673 subjects will comprise the replication cohort.
11300803|NCT02694068||Discovery for Aim Two|824 subjects will be involved in the discovery cohort.
11300804|NCT02694068||Replication for Aim Two|538 subjects will comprise the replication cohort.
11300805|NCT02694055|Experimental|Proactive Community Case Management (ProCCM)|Villages assigned to the experimental arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing proactive case detection in addition to integrated Community Case Management (ProCCM).
11300806|NCT02694055|Active Comparator|integrated Community Case Management (iCCM)|Villages assigned to the active comparator arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing passive integrated Community Case Management (iCCM) exclusively at a fixed health post to patients who initiate their own care-seeking.
11300807|NCT02694042|Experimental|Mission is Remission® Group|Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
11300808|NCT02694042|No Intervention|Control Group|Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
11300809|NCT02694029|Active Comparator|Radiation with ABC|Active Breathing Coordinator to assist radiation therapy
11300810|NCT02694029|Active Comparator|Radiation with VisionRT|VisionRT-based deep inspiration breath-hold to assist radiation therapy
11300811|NCT02694016|Experimental|Remote ischemic preconditioning|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
11300812|NCT02694016|No Intervention|Control group|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis
11300813|NCT02694003|Experimental|Intervention|The intervention arm will receive access to the BNBD-NDD Intervention.
11300814|NCT02694003|No Intervention|Usual Care|The usual care arm does not receive the BNBD-NDD intervention. This arm is free to access other resources while enrolled in the study. After the 6-month follow up time point, the usual care arm will be able to access the intervention.
11300815|NCT02693990|Experimental|Grade II (Atypical) Meningiomas, STR|Patient will be treated at the starting dose of Intensity Modulated Proton Therapy (IMPT) which is pre-determined.
11300816|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, GTR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
11300817|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, STR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
11300818|NCT02693964||Postmenopausal women with T1D|Postmenopausal between 45-70 years of age and having T1D for at least 10 years
11300819|NCT02693964||Postmenopausal women without diabetes|Postmenopausal between 45-70 years of age without diabetes
11300820|NCT02693951|Experimental|the prophylactic use of antibiotics group|Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
11300821|NCT02693951|No Intervention|Control|Routine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment
11300822|NCT02693938|Experimental|luteal phase clamp|Luteal euglycemic clamp administered during luteal phase of menstrual cycle.
11300823|NCT02693938|Active Comparator|follicular phase clamp|Follicular euglycemic clamp administered during follicular phase of menstrual cycle.
11300824|NCT02693912||acute lung injury|Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
11300825|NCT02693912||control|Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
11300826|NCT02693886||A group|Experience of endoscopist: >2000 cases
11300827|NCT02693886||B group|Experience of endoscopist:between 1000 and 2000 cases
11300828|NCT02693886||C group|Experience of endoscopist:between 500 and 1000 cases
11300829|NCT02693886||D group|Experience of endoscopist:<500 cases
11300830|NCT02693873|Other|Single Arm Study:|All participants will receive GLA:D Canada, an education and neuromuscular exercise program
11300831|NCT02693860|Experimental|huJ591 followed by 89Zr-J591|Subjects will receive two infusions of unlabeled huJ591 on days 1 and 15 (+/- 1 day). 89Zr-J591 will be administered on day 22 (+/- 1 day) and 5-8 days later. PET/CT will be performed followed by repeat imaging of the prostate. Radical prostatectomy with or without lymph node dissection is performed 2 to 4 weeks after the second dose of J591.
11300832|NCT02693834|Experimental|PLS AFO first then DA AFO|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
11300833|NCT02693834|Experimental|DA AFO first then PLS AFO|Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week
11300834|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
11300835|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
11300836|NCT02693808|Active Comparator|Autologous fat injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
11300954|NCT02693093|Placebo Comparator|placebo|TID Day for 28 Days
11300837|NCT02693808|Active Comparator|Hyaluronic acid injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
11300838|NCT02693795|Experimental|Baduanjin exercise group|"The participants randomized to Baduanjin exercise will collectively practice at cardiac rehabilitation centre in Guangdong Provincial Hospital of Chinese Medicine. A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
11300839|NCT02693795|Active Comparator|usual exercise control group|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
11300840|NCT02693782|Placebo Comparator|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
11300841|NCT02693782|Active Comparator|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
11300842|NCT02693769|Experimental|fluticasone/formoterol BAI|To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
11300843|NCT02693769|Active Comparator|Ultibro Breezhaler|Ultibro Breezhaler 85/43 µg (1 puff o.d.)
11300844|NCT02693756|No Intervention|Control|Participants will be allowed to perform all usual activities but should refrain from performing the motor imagery exercises.
11300845|NCT02693756|Experimental|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:
~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
11300846|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
11300847|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
11300848|NCT02693730||Healthy Control|Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
11300849|NCT02693730||Irritable Bowel Syndrome (IBS)|Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
11300850|NCT02693730||Ulcerative Colitis (UC)|Clinically and histologically confirmed diagnosis of ulcerative colitis
11300851|NCT02693717|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11300852|NCT02693704|Experimental|Normal hearing|People showing no hearing loss (< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
11300853|NCT02693704|Experimental|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).
~Introduction of speech signal via the DAI of two hearing aids among:
~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
11300854|NCT02693704|Experimental|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).
~Introduction of speech signal via the DAI of two hearing aids among:
~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
11300855|NCT02693704|Experimental|Profound hearing impaired|"Patients showing profound hearing loss (> 80 dB HL).
~Introduction of speech signal via the DAI of two hearing aids among:
~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
11300856|NCT02693691|Experimental|CardioMEMS HF System|Subjects will collect pulmonary artery pressure measurements daily which will be used by health care professionals to adjust cardiac medications.
11300857|NCT02693678|Experimental|Massage|10 min massage therapy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
11300858|NCT02693678|Experimental|Diathermy|10 min diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
11300859|NCT02693678|Sham Comparator|Sham diathermy|10 min sham diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
11300955|NCT02693093|Experimental|100 mg NI-03|TID Day for 28 Days
11300860|NCT02693665|Experimental|FACE-TC Intervention|Adolescent/family dyads randomized to the experimental condition receive Family Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention - 3 sessions scheduled one week apart of approximately 60 minutes duration each. Session 1 - Lyon Advance Care Planning Survey-Adolescent & Surrogate versions. Session 2 - Respecting Choices Interview facilitated by trained/certified facilitator with adolescent and family. Focuses on patient's understanding of their illness, possible complications, goals of care and treatment preferences in 3 bad outcome situations; and the Session 3 - Five Wishes an advance directive.
11300861|NCT02693665|No Intervention|Treatment As Usual (TAU)|Adolescent/family dyads randomized to the treatment as usual (TAU) condition receive written information on advance care planning, but no active intervention.
11300862|NCT02693652|Experimental|CVI-HBV-002 (20ug, 3 shots)|"HBV surface antigen 20ug/dose
~Intramuscular injection at 0, 1, 2 month"
11300863|NCT02693652|Experimental|CVI-HBV-002 (20ug, 6 shots)|"HBV surface antigen 20ug/dose
~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
11300864|NCT02693652|Experimental|CVI-HBV-002 (40ug, 3 shots)|"HBV surface antigen 40ug/dose
~Intramuscular injection at 0, 1, 2 month"
11300865|NCT02693652|Experimental|CVI-HBV-002 (40ug, 6 shots)|"HBV surface antigen 40ug/dose
~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
11300866|NCT02693639||liver transplantation grafts|
11300867|NCT02693626|Experimental|intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per day for the time leading up to the quit day and the following 12 weeks.
~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
11300868|NCT02693626|No Intervention|No cessation message intervention|Control group participants only will receive one text message every week, thanking them for being in the study, providing study center contact details, and reminding them of the time until their free month at the end of follow up. Another one to two messages will be sent per week until the end of the 24 week. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points.
11300869|NCT02693626|Experimental|Not intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per week for the time leading up to the quit day and the following 12 weeks.
~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
11300870|NCT02693613|Experimental|Group 1|Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
11300871|NCT02693613|Experimental|Group 2|Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
11300872|NCT02693600|Active Comparator|Partial Trapeziectomy (PT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with with ligamentoplasty and partial trapeziectomy.
11300873|NCT02693600|Active Comparator|Total Trapeziectomy (TT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with ligamentoplasty and total trapeziectomy.
11300874|NCT02693587||Misodel group in Holbæk|Misodel for induction of labour in Holbæk
11300875|NCT02693587||Angusta group in Roskilde and Næstved|Angusta for induction of labour in Roskilde and Næstved
11300876|NCT02693574|Active Comparator|Clarithromycin|Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days
11300877|NCT02693574|Experimental|Levofloxacin|Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days
11300878|NCT02693561|Active Comparator|Deep Breathing Exercises|Technical Deep Breathing.
11300879|NCT02693561|Active Comparator|Self-Help Book|Reading the self-help book.
11300880|NCT02693561|Active Comparator|Deep Breathing Exercises and Book|"Technical Deep Breathing and Reading the self-help book.
~Reading the self-help book and will be trained by the physical therapist to perform deep breathing."
11300881|NCT02693561|No Intervention|Control|Not suffer any intervention
11300882|NCT02693548||Familial hypercholesterolaemia patients|Index cases with genetic diagnosis of FH and their relatives over 15 years old with a genetic diagnosis of FH.
11300883|NCT02693548||Unaffected relatives|Relatives of FH patients without FH (genetically defined)
11300884|NCT02693535|Other|Group 3 (ALK, ROS1, MET)|Participants receive crizotinib - dosage, frequency and duration per label; acceptable genomic matches include ALK fusion or mutation, ROS1 fusion, MET amplification or mutation, MET exon 14 alteration, RON amplification or mutation
11300885|NCT02693535|Other|Group 4 (CDKN2A, CDK4, CDK6)|Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications
11300886|NCT02693535|Other|Group 5 (CSF1R,PDGFR,VEGFR)|Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
11300887|NCT02693535|Other|Group 6 (mTOR, TSC)|Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
11300888|NCT02693535|Other|Group 8 (ERBB2)|Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, overexpression, and specific mutations
11300889|NCT02693535|Other|Group 9 (BRAF V600E/D/K/R)|Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
11300890|NCT02693535|Other|Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)|Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
11300891|NCT02693535|Other|Group 14 (BRCA1/2; ATM)|Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
11300892|NCT02693535|Other|Group 15 (POLE, POLD1, high mutational load)|Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations, tumor mutational burden as defined in protocol
11300893|NCT02693535|Other|Group 16 (MSI-H, high mutational load and others)|Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
11300894|NCT02693535|Other|Group 17 (CDKN2A, CDK4, CDK6)|Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications
11300895|NCT02693535|Other|Group 18 (NRG1)|Participants receive afatinib - dosage, frequency and duration per label; acceptable genomic matches include NRG1 fusions
11300896|NCT02693535|Other|Group 19 (BRCA1/2, PALB2)|Participants receive Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
11300897|NCT02693522|Experimental|somatropin|Subcutaneous injection
11300898|NCT02693522|Active Comparator|Eutropin|Subcutaneous injection
11300899|NCT02693483|Active Comparator|povidone iodine|153 cases undergoing cesarean sections will have preoperative vaginal cleansing with 10% povidone iodine
11300900|NCT02693483|No Intervention|no vaginal cleansing|153 cases undergoing cesarean sections
11300901|NCT02693470|Other|single-arm study|"50 patients with severe psoriasis who received Stelara(ustekinumab) at 0 and 1 month. The investigators check microparticles level at baseline and 4 months later.
~50 patients without psoriasis: the microparticles are checked at baseline."
11300902|NCT02693457|Active Comparator|Drain|Intra-articular drain will be placed at closure of randomized knee for 24 hours
11300903|NCT02693457|Experimental|No Drain|No intra-articular will be placed in the contralateral knee of the same patient. A placebo drain will be placed so patient is unaware of which knee contains working drain.
11300904|NCT02693444|Active Comparator|Subacromial Lidocaine Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of lidocaine, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
11300905|NCT02693444|Placebo Comparator|Subacromial Saline Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of saline, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
11300906|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
11300907|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
11300908|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
11300909|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
11300910|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
11300911|NCT02693405|Experimental|child and adult survivors of brain tumor|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.
~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
11300912|NCT02693405|Experimental|healthy controls|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.
~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
11300913|NCT02693392|Active Comparator|Control|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.
11300914|NCT02693392|Experimental|Fenugreek|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.
11300915|NCT02693379|Experimental|D-VIA|HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
11300916|NCT02693366|Experimental|Autologous Cell Therapy|We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
11300917|NCT02693353||Study Group|Patients with diagnosed epiretinal membrane undergoing cataract surgery.
11300918|NCT02693353||Control Group|Patients without epiretinal membrane undergoing cataract surgery.
11300919|NCT02693327||Mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
11300920|NCT02693327||Non-mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
11300921|NCT02693314|Experimental|Jarro-Dophilus EPS® Group|Jarro-Dophilus EPS® (5 billion CFU/capsule) probiotic formulation capsule for 28 days
11300922|NCT02693314|Experimental|Jarro-Dophilus EPS® High Potency Group|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule) probiotic formulation capsule for 28 days
11300923|NCT02693314|Placebo Comparator|Placebo Group|Placebo capsule for 28 days
11300924|NCT02693301|No Intervention|Control|Children who follow the recommendations of their pneumologist
11300925|NCT02693301|Experimental|Experimental|A two month intervention program 3 days/week will be carried out. The session will last ~60 minutes, and will consist of a combined training (aerobic training ~30 min, and strength ~30 min of 7 whole body exercises (3 sets x 10 repetitions).The load was gradually increased as the strength of each child improved, i.e., from 40% of five-repetition maximum (5RM) lifting ability at the start of the program to 60% of 5RM at the end of the program. All sessions were individually supervised by trained professionals.
11300926|NCT02693288|No Intervention|Ultrasound-guided nerve block|
11300927|NCT02693288|Experimental|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaine 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
11300928|NCT02693275|Other|Quotient® System iPad Test|The Quotient® System iPad Test is a test specifically designed to provide clinicians with objective measures in ability to maintain seated stillness, sustained attention to a monotonous task and inhibiting incorrect impulsive responses. The attention task with motion analyses provides a number of objective measures for detailed assessment of the subject's movements and attentiveness.
11300929|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
11300930|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
11300931|NCT02693236|Experimental|adenovirus-transfected autologous DC vaccine plus CIK cells|
11300932|NCT02693210|Active Comparator|Group A: Methotrexate|Participants will receive methotrexate at dosage >=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.
11300933|NCT02693210|Experimental|Group B: Rituximab Monotherapy|Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
11300934|NCT02693210|Experimental|Group C: Rituximab and Cyclophosphamide|Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.
11300935|NCT02693210|Experimental|Group D: Methotrexate and Rituximab|Participants will receive >=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.
11300936|NCT02693197|Experimental|Cohort 1:T-817MA|Mild hepatic impairment subjects
11300937|NCT02693197|Experimental|Cohort 2:T-817MA|Healthy subjects matched to subjects in Cohort 1
11300938|NCT02693197|Experimental|Cohort 3:T-817MA|Moderate hepatic impairment subjects
11300939|NCT02693197|Experimental|Cohort 4:T-817MA|Healthy subjects matched to subjects in Cohort 3
11300940|NCT02693197|Experimental|Cohort 5 :T-817MA|Severe hepatic impairment subjects
11300941|NCT02693197|Experimental|Cohort 6:T-817MA|Healthy subjects matched to subjects in Cohort 5
11300942|NCT02693184||Fragility Fracture Case|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
11300943|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
11300944|NCT02693145|No Intervention|standard of care (SOC) arm|Individuals found to be out of HIV medical care will receive standard of care to re-engage. This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
11300945|NCT02693145|Experimental|Intervention arm|Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
11300946|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
11300947|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
11300948|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
11300949|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution
11300950|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution
11300951|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU)
11300952|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU)
11300953|NCT02693106|Experimental|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.
~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
11300958|NCT02693080|Experimental|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent
11300959|NCT02693067|Experimental|PV-10|Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
11300960|NCT02693054|Experimental|Hybrid Fractional Laser Treatment|Halo (1470nm and 2940 nm) laser
11300961|NCT02693041|Active Comparator|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
11300962|NCT02693041|Placebo Comparator|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
11300963|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
11300964|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
11300965|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
11300966|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
11300967|NCT02693028|Active Comparator|probiotic lozenge|Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
11300968|NCT02693028|Active Comparator|Probiotic capsule|Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
11300969|NCT02693028|Active Comparator|Probiotic chewing gum|The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
11300970|NCT02693028|Placebo Comparator|Placebo lozenge|Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
11300971|NCT02693028|Placebo Comparator|Placebo capsule|Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
11300972|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
11300973|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
11300974|NCT02692976|Experimental|Myeloid dendritic cells (mDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
11300975|NCT02692976|Experimental|Plasmacytoid dendritic cells (pDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
11300976|NCT02692976|Experimental|mDC and pDC vaccinations|Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.
11300977|NCT02692963|Experimental|BCG vaccination|
11300978|NCT02692963|No Intervention|Control|
11300979|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
11300980|NCT02692937|Experimental|Surgery and exercise|Neurolysis of peripheral nerves in the back of the head and/or neck. Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
11300981|NCT02692937|Active Comparator|Exercise, Active Comparator|Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
11300982|NCT02692924||1|analysis of stored ultrasound data collected from the NICHD Fetal Growth Studies Singletons and NICHD Fetal Growth Studies Dichoronic Twins
11300983|NCT02692911||Women with gallstones|Women aged 50-74 with gallstones
11300984|NCT02692898||1|Archived CNS neoplasm specimens, in which primary diagnostic studies are complete, and for which there is excess tissue for analysis in the form of unstained slides or paraffin blocks
11300985|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
11300986|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically, indicated surgeries
11300987|NCT02692872||1|We plan to perform genetic screening of up to 2,000 individuals of African ancestry, an ethnic group with a high prevalence of alpha thalassemia.
11300988|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
11300989|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
11300990|NCT02692846||Control participants with connective tissue disease|Not have a diagnosis of WS. Have a clinical or molecular diagnosis of connective tissue disease, between the ages of 1 and 70 years old
11300991|NCT02692846||Unaffected Control participants|Not have a diagnosis of WS or other connective tissue disease, between the ages of 1 and 70 years old
11300992|NCT02692846||WS participants|Have diagnosis of WS, between the ages of 5 and 70 years old. Be able to tolerate blood pressure measurements.
11300993|NCT02692833||AKI Patients|Patients who develop acute kidney injury within the first 5 days following their cardiac surgical operation.
11300994|NCT02692833||Non-AKI patients|Patients who do not develop acute kidney injury within the first 5 days following their cardiac surgical operation.
11300995|NCT02692820|Experimental|Probiotic|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of probiotics (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (each at 2.5 x 109 colony forming units (CFUs)). The product contains freeze-dried bacteria and excipients in a gelatin capsule.
11300996|NCT02692820|Placebo Comparator|Placebo|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of the placebo containing excipients alone in a gelatin capsule
11300997|NCT02692807|Active Comparator|Hip arthroscopy surgical procedures (HIPARTI Study)|Surgery is performed under general anaesthesia. Traction and joint access is controlled by fluoroscopy. A diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented. Any labral, chondral and bony pathology (cam or pincer) is treated. Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum is secured with suture anchors. Pincer and cam resection is performed using an arthroscopic burr. Cartilage lesions maybe left untreated or treated with debridement or microfracture.
11300998|NCT02692807|Placebo Comparator|Sham surgery (HIPARTI Study)|The same arthroscopic procedures as stated above are preformed, but no surgical interventions related to Cam, Pincer, or labral tear are performed, only diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented.
11300999|NCT02692807|Active Comparator|Prospective Cohort (HARP Study)|Those that are not willing to be included in the RCT (HIPARTI Study), will be asked if they are willing to be included in the prospective cohort, or ongoing in countries were ONLY the surgery is performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).
11301000|NCT02692781|Experimental|Dose Cohort 1|20mg MOD-6031 / Placebo
11301001|NCT02692781|Experimental|Dose Cohort 2|50mg MOD-6031 / Placebo
11301002|NCT02692781|Experimental|Dose Cohort 3|100mg MOD-6031 / Placebo
11301003|NCT02692781|Experimental|Dose Cohort 4|150mg MOD-6031 / Placebo
11301004|NCT02692781|Experimental|Dose Cohort 5|200mg MOD-6031 / Placebo
11301005|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
11301006|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
11301007|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
11301008|NCT02692755|Experimental|Single ARM|Palbociclib + Letrozole or Fulvestrant
11301009|NCT02692742|Experimental|Myelo001|Myelo001 100 mg QD
11301010|NCT02692742|Placebo Comparator|Placebo|Matching Placebo QD
11301011|NCT02692729|Experimental|supraumbilical transverse|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis. Above the panniculus, the fatty tissues are not particularly thick. A transverse opening of the aponeurosis and of the parietal peritoneum was done. Then the approach to the lower uterine segment was easy. A Ricard retractor was put in place.
11301012|NCT02692729|Active Comparator|pfannenstiel|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
11301013|NCT02692716|Experimental|Oral semaglutide|
11301014|NCT02692716|Placebo Comparator|Placebo|
11301015|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
11301016|NCT02692690|Experimental|before-after|TENS stimulation neck and thigh
11301017|NCT02692677|Experimental|JNJ-42756493|Each participant will receive a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493 at Pre-dose,0.5,1,2,3,4,8,12 hour post-dose(pd) on Day 1;24,36 h pd on Day 2;48 h pd on Day 3,72 h pd on Day 4; 96 h pd on Day 5;192 h pd on Day 9,216 h pd on Day 10,240 h pd on Day 11,264 h pd on Day 12,288 h pd on Day 13 and 312 h pd on Day 14
11301018|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
11301019|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
11301048|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
11328534|NCT02510781|Experimental|A group|docetaxel+carboplatin+trastuzumab
11301020|NCT02692638|Experimental|Early laparoscopic enterolysis|Patient randomized to the early laparoscopy arm will undergo diagnostic laparoscopy within 24 hours of admission (depending on surgeon and operating room availability). Standard laparoscopy will be performed including supine positioning, sequential compression devices, and appropriate pre-incision antibiotics. Trocar placement will be at the surgeon's discretion and as appropriate for the patient's previous incisions. The necessity for conversion will be left to the discretion of the attending surgeon. Post operative management will conform to the standards of care. Nasogastric tubes will not be routinely placed.
11301021|NCT02692638|Active Comparator|trial of nonoperative management|Patients randomized to the trial of nonoperative management arm will undergo standard therapy including nil per os (NPO), nasogastric decompression only if actively vomiting, intravenous fluids while awaiting return of bowel function. Patients who do not achieve return of bowel function within 72 hours of admission will undergo attempted laparoscopic enterolysis with the understanding that conversion to open procedure may be necessary.
11301022|NCT02692625|Experimental|Group A|"Group A (test group): This group consist of 80 children receiving the probiotic lozenges.
~The Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). The probiotic lozenge is used twice daily for two months."
11301023|NCT02692625|Placebo Comparator|Group B|"Group B (control group): This group consist of 80 children receiving the placebo lozenges.
~The placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.The placebo lozenges is used twice daily for two months."
11301024|NCT02692612||Young|
11301025|NCT02692612||Middle-Aged|
11301026|NCT02692612||Old|
11301027|NCT02692599|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;
~Intervention: investigational live attenuated mumps vaccine;"
11301028|NCT02692599|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;
~Intervention: control live attenuated mumps vaccine;"
11301029|NCT02692586|Experimental|FlowTriever System|
11301030|NCT02692573|Experimental|prone|Prone positioned after delivery
11301031|NCT02692573|Active Comparator|supine|Supine positioned after delivery
11301032|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
11301033|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
11301034|NCT02692547|Other|Hybrid-logic closed loop system|All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.
11301035|NCT02692534||Cocaine negative|Patients with preoperative urine cocaine negative results
11301036|NCT02692534||Cocaine positive|Patients with preoperative urine cocaine positive results
11301037|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
11301038|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
11301039|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
11301040|NCT02692482|Active Comparator|standard care|
11301041|NCT02692469|Active Comparator|Duodenal Switch Surgical Intervention|a DS procedure involves creating a sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel
11301042|NCT02692469|Experimental|Single Anastomosis Duodenal-Ileal Bypass|The SADI defers from the DS in that after the duodenum is separated from the stomach, preserving the pylorus, a loop of bowel 200 cm from the ileo-cecal valve is anastomosed with the pylorus, thus requiring only one anastomosis
11301043|NCT02692456|Active Comparator|Double needle celiac neurolysis (DNCN)|Patients were subjected to CT guided celiac neurolysis using 2 needle antero-crural technique on each side with patient in prone position and both needles will be lateral to the aorta
11301044|NCT02692456|Placebo Comparator|Single needle celiac neurolysis (SNCN)|Patients were subjected to CT guided celiac neurolysis using a single needle antero-crural approach from left side to be just in the front of the aorta near the origin of celiac trunk with patient in lateral position with his left side up then after the injection the patient were kept to his right side up for more homogenous spread of the dye.
11301045|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
11301046|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
11301047|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
11301084|NCT02692170|Experimental|CVI-HBV-001 (10 μg)|"HBV surface antigen 10 μg/dose
~Intramuscular injection at 0, 1, 6th month"
11328972|NCT02507856||control group|vitamin k antagonist (vka)
11301049|NCT02692404||Hospital Birth|Healthy nulliparous participants, planning spontaneous vaginal or induced vaginal delivery, and planning delivery at a hospital woman-care birth center (Magee-Womens Hospital of UPMC) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to utilize labor epidural analgesia for pain control during labor.
11301050|NCT02692404||Midwife Center Birth|Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
11301051|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
11301052|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
11301053|NCT02692378|Active Comparator|Treatment|"Standard haemodialysis treatment thrice weekly (using a standard dialysate containing bicarbonate at a concentration of 35mmols/L) with the addition of oral sodium bicarbonate 500mg capsules for 12 weeks (weeks 5-16 of the study).
~The dosage will be titrated to individual blood levels. Starting dose will be 1g twice daily and if predialysis bicarbonate levels remain <22mmols/L the dose will be increased by 0.5g twice daily each week. The maximum dose would be 3g twice daily.
~The oral sodium bicarbonate may be withheld on dialysis days, when bicarbonate will be supplemented through the dialysate. This will be assessed on a case by case basis."
11301054|NCT02692378|No Intervention|Control|Standard haemodialysis treatment thrice weekly using a standard dialysate containing bicarbonate at a concentration of 35mmols/L.
11301055|NCT02692365|Experimental|Calcium channels|Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
11301056|NCT02692365|Experimental|Tumor perfusion|Magnetic Resonance + hemodynamic + infusion of gadolinium
11301057|NCT02692352|Experimental|Experimental|8 sessions of Goal Management Training
11301058|NCT02692352|Active Comparator|Active control group|8 sessions of Brain Health Workshop
11301059|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
11301060|NCT02692326|Experimental|Intervention: Cyclic parenteral nutrition Cohort|All newborn who were included in the study to receive cyclic parenteral nutrition (within 24 hours). The parenteral nutrition was stopped for one hour the first day until 4 hours in preterm infants and 6 hours in term neonates.
11301061|NCT02692326|No Intervention|Control: Continuous parenteral nutrition|All newborn who were included in the study to receive continuous parenteral nutrition (24 hours). The parenteral nutrition was given by a central line in 24 hours with a basal flow
11301062|NCT02692313|Placebo Comparator|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
11301063|NCT02692313|Experimental|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
11301064|NCT02692313|Experimental|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
11301065|NCT02692313|Experimental|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
11301066|NCT02692300|No Intervention|Control Group|Patients will undergo standard anesthesia and will be blinded to EEG-based data, as per standard of care in this patient population.
11301067|NCT02692300|Experimental|EEG-Guided Group|Practitioners will follow the EEG-Guided protocol to limit the incidence of EEG burst suppression by decreasing administration of anesthesia. The EEG-guided protocol is suggestive rather than prescriptive, and practitioners will exercise judgment depending on the clinical situation.
11301068|NCT02692287|Other|Use of the PPH Butterfly|The PPH Butterfly will be inserted into the vagina of a healthy postnatal woman
11301069|NCT02692274||Primary Health care clinics|A survey of 100 primary Health care clinics was carried out
11301070|NCT02692274||Pregnant and breast feeding women|208 patients were recruited from nine clinics that participated in the survey for evaluation of the accuracy of results produced by the HIV rapid test.
11301071|NCT02692261|Active Comparator|Hyalossᵀᴹ matrix|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation
11301072|NCT02692261|Active Comparator|Apatos alone xenograft|Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation
11301073|NCT02692248|Experimental|Ibrutinib -R-GEMOX-Dexa|"Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:
~Induction phase:
~Rituximab 375 mg/m2 IV day 1
~Gemcitabine 1000 mg/msq IV on day 1 or 2 (at investigator discretion).
~Oxaliplatine 100 mg/msq on day 1 or 2 (after Gemcitabine administration);
~Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.
~Ibrutinib 560 mg daily for 14 days.
~Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.
~Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity."
11301074|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
11301075|NCT02692235|Placebo Comparator|placebo|24 weeks isonitrogenous supplementation
11301076|NCT02692222||PPV|This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output.
11301077|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
11301078|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
11301079|NCT02692196|Experimental|Neurofeedback Training|Neurofeedback training - neurofeedback of fronto-limbic functional connectivity.
11301080|NCT02692196|Sham Comparator|Sham Control|Sham training - feedback that is not related with fronts-limbic connectivity (motor connectivity)
11301081|NCT02692183||Parkinson Disease (PD) tremor patients|Patients with PD before and after MRI guided Focused ultrasound thalamotomy
11301082|NCT02692183||Essential tremor (ET) patients|Patients with ET before and after MRIFocused ultrasound guided thalamotomy
11301083|NCT02692170|Experimental|CVI-HBV-001 (5 μg)|"HBV surface antigen 5 μg/dose
~Intramuscular injection at 0, 1, 6th month"
11301085|NCT02692170|Experimental|CVI-HBV-001 (20 μg)|"HBV surface antigen 20 μg/dose
~Intramuscular injection at 0, 1, 6th month"
11301086|NCT02692170|Experimental|CVI-HBV-001 (40 μg)|"HBV surface antigen 40 μg/dose
~Intramuscular injection at 0, 1, 6th month"
11301087|NCT02692170|Active Comparator|Conventional Hepatitis B vaccine (20 μg)|"HBV surface antigen 20 μg/dose
~Intramuscular injection at 0, 1, 6th month"
11301088|NCT02692157|Placebo Comparator|Placebo|Placebo Comparator: Placebo - During this arm, Placebo medication will be administered orally each evening at 8pm.
11301089|NCT02692157|Active Comparator|NT-814 50 mg|Active Comparator: NT-814 50 mg - During this arm, 50 mg NT-814 will be administered orally each evening at 8pm.
11301090|NCT02692157|Active Comparator|NT-814 100 mg|Active Comparator: NT-814 100 mg - During this arm, 100 mg NT-814 will be administered orally each evening at 8pm.
11301091|NCT02692157|Active Comparator|NT-814 200 mg|Active Comparator: NT-814 200 mg - During this arm, 200 mg NT-814 will be administered orally each evening at 8pm.
11301092|NCT02692144|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
11301093|NCT02692144|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
11301094|NCT02692144|Placebo Comparator|White-bread|47g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
11301095|NCT02692131||Speckle strain|All adult patients undergoing on pump CABG Surgery.
11301096|NCT02692131||Tissue doppler strain|All adult patients undergoing on pump CABG Surgery
11301097|NCT02692118||sepsis|Patients with septic shock admitted to ICU
11301098|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
11301099|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.
~HDR brachytherapy is also accomplished as an out-patient."
11301100|NCT02692092||Total Arthroplasty Patients|Any patient who has received a total hip or total knee arthroplasty at a healtheast acute care hospital.
11301101|NCT02692079|Experimental|T-PRF+Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Test group sites were treated with T-PRF+allograft
11301102|NCT02692079|Experimental|Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Control group sites were treated with only allograft
11301103|NCT02692066||Healthy Controls|Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
11301104|NCT02692066||Children with Chronic Liver Disease|Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
11301105|NCT02692053|Experimental|Patients with septic shock|
11301106|NCT02692053|Other|Blood samples from a historical cohort of healthy volunteers|
11301107|NCT02692040|Experimental|1.5 mg dose of G3215|1.5 mg G3215 single dose, subcutaneous injection
11301108|NCT02692040|Experimental|4 mg dose of G3215|4 mg G3215 single dose, subcutaneous injection
11301109|NCT02692040|Experimental|8mg dose of G3215|8 mg G3215 single dose, subcutaneous injection
11301110|NCT02692040|Experimental|10 mg dose of G3215|10 mg G3215 single dose, subcutaneous injection
11301111|NCT02692040|Experimental|12 mg dose of G3215|12 mg G3215 single dose, subcutaneous injection
11301112|NCT02692040|Experimental|16 mg dose of G3215|16 mg G3215 single dose, subcutaneous injection
11301113|NCT02692040|Experimental|32 mg dose of G3215|32 mg G3215 single dose, subcutaneous injection
11301114|NCT02692040|Experimental|48 mg dose of G3215|48 mg G3215 single dose, subcutaneous injection
11301115|NCT02692040|Experimental|24 mg (B1) dose of G3215|"G3215 multiple dose, subcutaneous injection:
~5 doses over a 4 week treatment period at escalating doses to a max of 24 mg."
11301116|NCT02692040|Experimental|10 mg (B2) dose of G3215|"G3215 multiple dose, subcutaneous injection:
~5 doses over a 4 week treatment period at escalating doses to a max of 10 mg."
11301117|NCT02692040|Experimental|16 mg (B3) dose of G3215|"G3215 multiple dose, subcutaneous injection:
~5 doses over a 4 week treatment period at escalating doses to a max of 16 mg."
11301118|NCT02692040|Experimental|3.2 mg (Part C) dose of G3215|G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo [saline]).
11301119|NCT02692040|Placebo Comparator|Placebo - saline|0.9% saline
11301120|NCT02692027|Active Comparator|Standard of care|Standard of care in Lesotho. ART-initiation after at least two clinic visits for pre-ART counseling and monthly follow-up visits at the clinic thereafter.
11301121|NCT02692027|Experimental|Same-day ART initiation with less frequent follow-up visits|Proposition of same-day ART initiation with less frequent follow-up visits thereafter.
11301122|NCT02692014||coronary heart disease|2,400 patients who are diagnosed with CHD and have received more than 2 times of coronary angiography within 12-24 months.
11301123|NCT02692001|No Intervention|Current MealTrain menu|This is the current menu being employed for food ordering in the pediatric inpatient wards.
11301124|NCT02692001|Experimental|Intervention MealTrain menu|The intervention menu included child-friendly labeling (attractive characters, fun food names and traffic light system) to encourage healthier choices.
11301125|NCT02691988|Experimental|ICS withdrawal|Guided ICS withdrawal combined with optimization of bronchodilator treatment
11329455|NCT02504567|Other|Laser ablation|Ablation with laser catheter
11301129|NCT02691949|Experimental|Mycophenolate mofetil standard|mycophenolate mofetil 250mg 2# twice per day (BID)
11301130|NCT02691949|Experimental|Mycophenolate sodium low|mycophenolate mofetil 250mg 1# twice per day (BID)
11301131|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
11301132|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
11301133|NCT02691923|Active Comparator|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
11301134|NCT02691923|Experimental|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
11301135|NCT02691910|Active Comparator|CONCURRENT CHLOROQUINE+PRIMAQUINE|"The infected individuals were treated with the standard chloroquine (CQ)+primaquine(PQ) regimen to malaria caused by Plasmodium vivax.
~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.
~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
11301136|NCT02691910|Experimental|CHLOROQUINE|"The infected individuals were initially treated with chloroquine (CQ) alone and the primaquine(PQ) was introduced on day 28.
~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.
~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 28 of CQ treatment. Total dose, 3.5mg/kg.
~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
11301137|NCT02691897|Experimental|Melatonin|Melatonin 3mg once daily at bedtime
11301138|NCT02691897|Placebo Comparator|Placebo|Placebo 1 tablet once daily at bedtime
11301139|NCT02691884||Patients before/after Pressure Exertion|100 pregnant patients at term in low risk pregnancies, undergoing a routine cardiotocography, will experience different amounts of manual pressure on their abdomen. The amount of pressure applied will be recorded and the fetal heart rate will be compared before and at the time of maternal abdominal pressure.
11301140|NCT02691871|Experimental|Apatinib + Docetaxel|Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
11301141|NCT02691858|Experimental|Hydrocortisone|Hydrocortisone IV 10 mg/kg with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
11301142|NCT02691858|Placebo Comparator|Saline|Saline IV 100 ml with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
11301143|NCT02691845|Other|BA|Brief advice to exercise. This serves as a control condition.
11301144|NCT02691845|Active Comparator|BA + SHE + HE|Brief advice to exercise + supervised & home-based exercise + health education
11301145|NCT02691845|Experimental|BA + SHE + CBEX|Brief advice to exercise + supervised & home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
11301146|NCT02691832|Experimental|research arm|"the trial contains one group which will undergo the described protocol three times:
~connected to rectal thermistor and to the double sensor
~connected to rectal thermistor, double sensor and cooling system of Icetron Technologies Ltd.
~connected to rectal thermistor and to the double sensor integrated into a helmet."
11301147|NCT02691806|Experimental|research arm|Each of the 14 participants will undergo the same 2 days experimental protocol, separated by at least 2 days rest.
11301148|NCT02691793|Experimental|sunitinib|sunitinib 50 mg will be administered orally daily
11301149|NCT02691780|Experimental|Sorafenib|Sorafenib 200mg bid will be administered orally daily every 3weeks
11301150|NCT02691767|Experimental|pazopanib|pazopanib 800 mg will be administered orally daily every 3weeks
11301151|NCT02691754|Experimental|free paracetamol|the General Practitioners can prescribe paracetamol for free (covered by NHS). Patients can receive monthly dose at the local hospital
11301152|NCT02691754|No Intervention|standard drug prescription|"Paracetamol is not included in the list of drugs than can be prescribed in charge of National Health System by General Practitioners.
~The General Practitioners can prescribe other drugs or recommend paracetamol payed by the patient (out of pocket) at the chemistry."
11301153|NCT02691741|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
11301154|NCT02691741|Active Comparator|839MP|AT LISA® tri IOL, bilateral implantation
11301155|NCT02691728|Experimental|Treatment Arm|12 Week treatment with LDV/SOF FDC
11301156|NCT02691715|Experimental|Endometrial saline plus curettage|5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant.
11301157|NCT02691715|Active Comparator|Endometrial curettage|Only routine endometrial curettage performed
11301158|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
11301159|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
11301160|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
11301161|NCT02691689|Other|Patients with ASD or VSD and PAH|
11301162|NCT02691676|Experimental|Plasmalyte|Arm 1: Plasmalyte in 5% glucose infusion solution (PL), manufactured by Baxter Healthcare as slightly alkalizing (Na+ 140; K+ 5.0; Mg2+ 1.5; Cl- 98; acetate 27; gluconate 23)
11301163|NCT02691676|Active Comparator|Ringerfundin|Arm 2: Ringerfundin infusion solution (RF), manufactured by B. Braun as acid-base neutral (Na+ 145; K+ 4.0; Mg2+ 1.0; Ca2+ 2.5; Cl- 127; acetate 24; malate 5.0).
11301164|NCT02691663|Active Comparator|Oral bicarbonate supplementation group|0.3 meq/kg/day NaHCO3 capsules
11301165|NCT02691663|Placebo Comparator|Placebo group|Methylcellulose capsules
11301166|NCT02691650||polytrauma patients|Patients with severe traumatic injury, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
11301167|NCT02691650||burns patients|Patients with burns trauma, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
11301168|NCT02691637||H. pylori eradication group|Patients who have had H. pylori infection. After diagnosis of H. pylori infection, the patients who subsequently received successful H. pylori eradication treatment according to appropriate indication.
11301169|NCT02691637||Control Group|Patients who still have H. pylori infection. The patients of control group do not have successful H. pylori eradication result or do not received eradication treatment for any reason.
11301170|NCT02691624||sentinel lymph node biopsy|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive sentinel lymph node biopsy
11301171|NCT02691624||axillary lymph node dissection|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive axillary lymph node dissection
11301172|NCT02691611||Alpha-1 Antitrypsin|All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy
11301173|NCT02691611||Healthy Control|Healthy controls with no lung diseases
11301174|NCT02691598|Experimental|Group A|Dexmedetomidine Hydrochloride 4ug/ml；0.05ml/kg.h infusion for 24hours
11301175|NCT02691598|Placebo Comparator|Group B|Normal Saline 0.05ml/kg.h infusion for 24hours
11301176|NCT02691585|Experimental|Music intervention group 1|Raga 1 will be given
11301177|NCT02691585|Experimental|Music intervention group 2|Raga 2 will be given
11301178|NCT02691585|Experimental|Music intervention group 3|Raga 3 will be given
11301179|NCT02691585|No Intervention|Control Group 4|No raga. Just collection of electrophysiological parameters will be done.
11301180|NCT02691572|Active Comparator|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
11301181|NCT02691572|Experimental|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
11301182|NCT02691559|Active Comparator|maternal inflammation group|Amniotic fluid analysis by blood gas device: evaluate the possible association between maternal inflammation and amniotic fluid pH two groups will be designed. One group will consist of infants born to mothers with infection/inflammation whereas the control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
11301183|NCT02691559|Active Comparator|normal pregnancy group|Amniotic fluid analysis by blood gas device: The control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
11301184|NCT02691546||Subjects aged 75 years or older|
11301185|NCT02691533|Experimental|ω3 PUFA(10% Omegavan 100 ml)|
11301186|NCT02691533|Experimental|ω6 PUFA (20% Intralipid 50 ml)|
11301187|NCT02691533|Placebo Comparator|Placebo Arm|No Lipid Emulsion will be given in this arm
11301188|NCT02691520||Taiwan Participants with Treatment Resistant Depression|Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.
11301189|NCT02691507|Active Comparator|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
11301190|NCT02691507|Experimental|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
11301191|NCT02691494|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
11301192|NCT02691494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
11301193|NCT02691494|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
11301194|NCT02691481|Active Comparator|Oatmeal breakfast|consuming 200 kcal of plain cooked oatmeal for breakfast
11301195|NCT02691481|Active Comparator|Glucerna formula|consuming 200 kcal of Glucerna shake for breakfast
11301196|NCT02691481|Active Comparator|Ultra Glucose Control formula|consuming 200 kcal of Ultra Glucose Control shake for breakfast
11301197|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.
~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .
~The second set of measurements is taken in lateral position after position change.
~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
11301198|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.
~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .
~The second set of measurements is taken in lateral position after position change.
~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
11301199|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt
~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
11301200|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
11301201|NCT02691442|Active Comparator|Ropivacaine 0.75%|The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space
11301202|NCT02691442|Active Comparator|Levobupivacaine 0.5%|The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space
11301203|NCT02691442|Active Comparator|Levobupivacaine 0.5% + epinephrin|The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space
11301204|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 10%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
11301205|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 25%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).
~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
11301206|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
11301207|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
11301208|NCT02691403|Sham Comparator|Placebo QL block|30 ml single shot QL block with saline 0.9%
11301209|NCT02691403|Active Comparator|Active QL block|30 ml single shot QL block with 0.25% levo-bupivacaine
11301210|NCT02691390|Experimental|study group|alcoholics - dTMS group
11301211|NCT02691390|Sham Comparator|control group|alcoholics - sham group
11301212|NCT02691377|Experimental|Acupuncture group|Participants will receive acupuncture for 8 weeks. In particular, acupuncture will be performed three times a week in earlier 4 weeks and twice a week in later 4 weeks.
11301213|NCT02691377|Sham Comparator|Sham Acupuncture group|Participants will receive sham acupuncture for 8 weeks. The procedure is the same as the acupuncture arm.
11301214|NCT02691364||Healthy|Healthy women
11301215|NCT02691364||Preeclamptic|Pregnant women with preeclampsia
11301216|NCT02691351||non-Hodgkin T-cell Lymphoma|
11301217|NCT02691338||patients undergoing thrombectomy|20 anesthetized patients undergoing intra-arterial catheterization for thrombectomy after CVA. The patients will be recruited at the Rambam Health Center, Haifa, Israel. The patients will undergo EEG recording for 5 minutes at the begining of the procedure, after initiating the anesthesia (general or sedation - according to the patient's clinical status). At the end of the procedure, while the patient is still anesthetized, he will undergo another EEG recording for 5 minutes.
11301218|NCT02691338||Control - healthy individuals|15 health individuals under sedation for other procedures. They will undergo EEG recording for 5 minutes during the procedure, while they are under sedation, to validate the sensitivity of the EEG to the effect of the anaesthetic medications.
11301219|NCT02691325|Experimental|Part A (Sequence 1) - Placebo, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 matching placebo (one inhalation) in treatment period 1, and single dose of GSK2269557 200 microgram (mcg) (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
11301220|NCT02691325|Experimental|Part A (Sequence 2) - GSK2269557 100 mcg, Placebo|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 matching placebo (two inhalations) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
11301221|NCT02691325|Experimental|Part A (Sequence 3) - GSK2269557 100 mcg, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
11301222|NCT02691325|Experimental|Part B- GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) once daily via the ELLIPTA DPI for 10 days. Doses of GSK2269557 may be modified based on emerging data from Part A.
11301223|NCT02691325|Experimental|Part B- GSK2269557 matching Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo (2 inhalations) once daily via the ELLIPTA DPI for 10 days.
11301224|NCT02691325|Experimental|Part C- GSK2269557 200 mcg with and without activated charcoal|Subjects will receive a single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) via the ELLIPTA DPI with activated charcoal in one treatment period and without ingestion of activated charcoal in another treatment period. The washout period between each dosing day will be at least 14 days. Dose of GSK2269557 may be modified based on emerging data from Part A.
11301225|NCT02691312||Type 1 diabetes (T1D)|Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
11301226|NCT02691299|Active Comparator|Treatment Arm|All subjects will receive study treatment in 4-week cycles: Fruquintinib, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.
11301227|NCT02691299|Placebo Comparator|Control Arm|All subjects will receive study treatment in 4-week cycles: Placebo, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease
11301228|NCT02691286||Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
11301435|NCT02689830|Experimental|Bead Block microspheres|Prostate embolization
11301229|NCT02691286||No Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock
11301230|NCT02691273|Experimental|breathing technique|this arm includes learning breathing technique using the patient's smartphone.
11301231|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
11301232|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
11301233|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
11301234|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
11301235|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
11301236|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
11301237|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
11301238|NCT02691234|Experimental|Extracorporeal Shockwave Therapy and debridement|The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
11301239|NCT02691234|Active Comparator|debridement and cleansing.|The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
11301240|NCT02691221|Other|Participants with previous suicide attempt or ideation|Participants will complete daily tasks assigned for completion through a downloaded application on their mobile device and completing six 2-hour long outcome assessment sessions including rater-lead scales over the course of six months.
11301241|NCT02691208|Experimental|Group I Kinesiotherapy|women with pain treated with a predefinided exercises protocol of 30 minutes.
11301242|NCT02691208|Experimental|Group II Acupuncture|women with pain treated with a predefinided exercises protocol of 30 minutes followed by 30 minutes of acupuncture, used in predefined points
11301243|NCT02691195|Placebo Comparator|group control|group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
11301244|NCT02691195|Experimental|group SPB|group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
11301245|NCT02691182|Experimental|Open-label treatment with SPN-810|Subjects aged 6-12 years will be treated with SPN-810 starting day 1 of Visit 1 of the study. The subjects will be given a choice of extending their participation in the study every 6-month period for up to 36 months. The clinician will be able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability.
11301246|NCT02691169|Experimental|18F-DCFPyL Injection|The subjects will receive the 18F-DCFPyL Injection (less than or equal to 9 mCi (333 MBq)) at visits 2 and 3.
11301247|NCT02691156||Premature Infants|Premature infants GA 24 to ≤34 wks at risk for hyperbilirubinemia will have BBC, ETCOc, and COHbc measured during 0-7 days of life.
11301248|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
11301249|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
11301250|NCT02691130|Experimental|A: M-001 0.5mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine
~Two administrations of non adjuvanted M-001, 0.5mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
11301251|NCT02691130|Experimental|B: M-001 1.0mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine
~Two administrations of non adjuvanted M-001, 1.0mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
11301252|NCT02691130|Placebo Comparator|C: Saline & H5N1 influenza vaccine|"Biological/Vaccine: Two saline administrations followed by H5N1 influenza vaccine
~Two administrations of saline followed by 3mcg Alum/H5N1 influenza vaccinated intervals of 19-23 days"
11301253|NCT02691117|Experimental|Garlic concentrate|Garlic gel concentrate- once a day topical application
11301254|NCT02691104|Experimental|Intervention|"Use of the app and Fitbit alongside 5-7 week pulmonary rehabilitation programme (plus goal-setting help from physiotherapist), and then app and Fitbit plus intermittent contact with physiotherapist for 8 weeks after pulmonary rehabilitation
~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
11301255|NCT02691104|Other|Control|"Attend 5-7 week pulmonary rehabilitation programme (usual care) and wear blinded Fitbit during pulmonary rehabilitation and for 8 weeks afterwards
~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
11301256|NCT02691078|Experimental|Adult patients with neuroendocrine tumors|
11301257|NCT02691065|Experimental|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
11301258|NCT02691065|No Intervention|Protease inhibitor|Continuation of protease-inhibitor based regimen
11301259|NCT02691052||Pts receiving nab-paclitaxel/gemcitabine|Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.
11301569|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
11301260|NCT02691026|Experimental|Pembrolizumab|200 mg pembrolizumab, i.v. infusion every 3 weeks for up to 10 cycles
11301261|NCT02691013|Placebo Comparator|Placebo|Patients will receive a Placebo tablet every evening.
11301262|NCT02691013|Active Comparator|Ramelteon|Patients will receive Ramelteon 8mg every evening.
11301263|NCT02691000|Experimental|Bright White Light (BWL) Litebook|Participants will be instructed to use the BWL Litebook for an hour every day for 8 weeks.
11301264|NCT02691000|Placebo Comparator|Dim Red Light (DRL) Litebook|Participants will be instructed to use the DRL (comparison condition) Litebook for an hour every day for 8 weeks.
11301265|NCT02690987|Experimental|Overweight/obese subjects|Overweight/obese volunteers with BMI 28.0-50.0 kg/m2, otherwise healthy. This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design.
11301266|NCT02690987|Experimental|Ex-smokers|"Abstinent tobacco dependent individuals who score at least moderately on tobacco dependence as measured retrospectively using the Fagerström Test for Nicotine Dependence (FTND), and who have been in stable tobacco abstinence for at least 6 weeks.
~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
11301267|NCT02690987|Experimental|Ex-alcohol dependent subjects|"Abstinent alcohol dependent individuals who score at least moderately alcohol dependent as measured retrospectively using the Severity of Alcohol Dependence Questionnaire (SADQ), and who have been abstinent for at least 6 weeks.
~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
11301268|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
11301269|NCT02690961|Experimental|Kukoamine B Mesilate 0.06mg/kg|Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11301270|NCT02690961|Experimental|Kukoamine B Mesilate 0.12mg/kg|Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11301271|NCT02690961|Experimental|Kukoamine B Mesilate 0.24mg/kg|Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11301272|NCT02690961|Experimental|Placebo 0.06mg/kg|Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11301273|NCT02690961|Experimental|Placebo 0.12mg/kg|Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11301274|NCT02690961|Experimental|Placebo 0.24mg/kg|Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11301275|NCT02690948|Experimental|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11301276|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11301277|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH
~Impregnated on lactose saccharose globules (380 mg/capsule)"
11301278|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
11301279|NCT02690922|Experimental|ph+ ALL with dasatinib|patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.
11301280|NCT02690909|Experimental|Redy™ Renal Denervation System|Renal Denervation System
11301281|NCT02690896|Experimental|UCF Behavioral Intervention Group|The intervention group will be the UCF Caregiver Support. Participants will receive a 90 minute group session, once a week, for a period of 6 consecutive weeks.
11301282|NCT02690896|Active Comparator|Community Comparison Group|Comparison group members will come from potential local support groups include, but are not limited to, the support group at the Faith Assembly of God church, the caregiver support group at the First Baptist Church of Orlando, and the caregiver support group at the Alzheimer's and Dementia Resource Center.
11301283|NCT02690883|Active Comparator|Lispro|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
11301284|NCT02690883|Experimental|Exenatide|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
11301285|NCT02690870|Experimental|tamoxifen|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
11301305|NCT02690740|Experimental|open label|"test/retest of a titrated quantitative CPT (TqCPT) with outcomes: CPT-scoring system and correlation with digital photo analysis.
~in all patients: 1 Arm = CPT test/re-test, no comparator
~No intervention of a new drug (CPT-solution registered (ALK- Abelló, Hørsholm, Denmark));"
11301306|NCT02690727|Experimental|RP6530 in fast condition|A single dose of RP6530 following fast condition
11301307|NCT02690727|Experimental|RP6530 in fed condition|A single dose of RP6530 following fed condition
11329456|NCT02504567|Other|RF ablation|Ablation with RF catheter
11301286|NCT02690870|Active Comparator|clomiphene|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
11301287|NCT02690857|Experimental|Docosahexaenoic acid|"Each capsule of DHA contains 100 mg DHA in triglycerides from algal oil, 0.125 mg alpha-tocopherol and 0.125 mg ascorbic acid.
~Subjects receive an orally and daily ingestion of DHA capsules (5mg/kg for 15 days followed by 10 mg/kg for another 15 days without interruption between the 2 periods)."
11301288|NCT02690857|Placebo Comparator|Sunflower oil|Placebo capsules contain the same quantities of antioxidants and triglycerides of sunflower oil. Subjects receive an orally and daily ingestion of placebo capsules for 28 days.
11301289|NCT02690844|Active Comparator|Clonazepam|Clonazepam (Klonopin®) treatment arm - 1 mg clonazepam (Klonopin® tablet) TID, dissolved in mouth for 3 minutes then expectorated
11301290|NCT02690844|Placebo Comparator|Mucolox® alone|Mucolox® only - 5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated
11301291|NCT02690844|Experimental|Mucolox® and clonazepam|Mucolox® and clonazepam - 1mg Clonazepam/5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated.
11301292|NCT02690831|Active Comparator|Inspiratory Muscle training (IMT)|"The IMT program consisted of supervised and domiciliary exercises:
~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 6 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:
~First week: 30% Maximum Inspiratory Pressure (MIP)
~Second week: 40% MIP
~Third week: 50% MIP
~Fourth week: 50% MIP
~Fifth week: 60% MIP
~Sixth week: 60% MIP
~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen."
11301293|NCT02690831|Experimental|IMT + Manual Therapy and Motor Control Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:
~- MT:
~Upper cervical region mobilization in flexion
~Lower cervical postero-anterior mobilization + maintained traction
~Costovertebral joint postero-anterior mobilization
~Thrust dorsal
~Cervical postero-anterior mobilization
~- MCE:
~Isometric contraction of the deep neck flexors.
~Isometric contraction of the neck extensors.
~Neural self-mobilization.
~Cervical retraction with theraband.
~Sphinx.
~Scapular adduction exercises in prone.
~Scapular adduction exercises in sitting position with theraband."
11301294|NCT02690818|Experimental|Behavioral intervention arm|"Regularly scheduled medication reminder text messages
~Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.
~Standard of care: Monthly reminder call and clinic visit"
11301295|NCT02690818|No Intervention|Control group receiving standard care|Standard of care: Monthly reminder call and clinic visit
11301296|NCT02690805||Breast cancer patients receiving neoadjuvant chemotherapy|One arm: Combined MRI-SMM Imaging
11301297|NCT02690792|Placebo Comparator|NAFLD/NASH - Placebo|"In NAFLD/NASH Group: Identically appearing Placebo capsules given as double-blinded, randomized intervention as a comparator to Vitamin E intervention.
~Dosage: Placebo capsules. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
11301298|NCT02690792|Active Comparator|NAFLD/NASH - Vitamin E|"In NAFLD/NASH Group: Vitamin E capsules given as double-blinded, randomized intervention as a comparator to Placebo capsules intervention.
~Dosage: Vitamin E 200 IU/capsule. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
11301299|NCT02690779|Experimental|Patients watching educational video|The educational intervention will consist of a 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration. This video will be posted on YouTube. Group 1 will consist of 30 subjects who will be instructed to view this video prior to beginning their colonoscopy preparation. Information to access the YouTube video will be provided to the patients by endoscopy nurse assessment staff when contacting the patients as per standard practice to review appointment scheduling and procedure-day logistics.
11301300|NCT02690779|Sham Comparator|Patients not watching educational video|Group 2 will consist of 30 subjects who will not receive instructions to view the video. They will be given routine care instructions for bowel prep.
11301301|NCT02690766|Other|Physical Activity Group|The Success Study's Standard Behavioral Weight Change Intervention consists of 75 minute group sessions held monthly which include 30 minutes of physical activity with a licensed Physical Activity Instructor. Web Lessons that include information on Physical Activity, Nutrition and Healthy Behaviors will also be provided to participants on the study's website.
11301302|NCT02690753|Experimental|Tailored repositioning + Standardised incontinence care + TAP|A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
11301303|NCT02690753|Experimental|Standard repositioning + Standardised incontinence care + TAP|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
11301304|NCT02690753|No Intervention|Usual care|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care. Instead of using comfort Shield® barrier cream cloths, incontinence care will be given to patients using the standard procedure on the ward. Instead of using the turn and position system, patients will be turned according to the standard procedure on the ward.
11301433|NCT02689843|Active Comparator|Metformin|Metformin 1500 mg daily
11301308|NCT02690714|Experimental|6.6 mg/kg Plasminogen (Human) Intravenous|6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion for 48 weeks (Norway) and longer until product licensing or study termination by the Sponsor (US).
11301309|NCT02690701|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
11301310|NCT02690701|Placebo Comparator|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.
~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
11301311|NCT02690688||Pneumoperitoneum|Patients scheduled for laparoscopic (minimal invasive) abdominal surgery supported by pneumoperitoneum. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
11301312|NCT02690688||Open Surgery|Patients scheduled for conventional (open) abdominal surgery. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
11301313|NCT02690675|Experimental|Intervention high-iron fortified milk|This group received a high dose of iron by formula milk (1.2mg/100mL) between 6 and 12 months of age.
11301314|NCT02690675|Experimental|Intervention low-iron fortified milk|This group received a low dose of iron by formula milk (0.4mg/100mL) between 6 and 12 months of age.
11301315|NCT02690662|Experimental|Obese with kidney stones|Hypocaloric diet for 3 months
11301316|NCT02690649|Experimental|Health Messaging (Non-Procedural)|PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.
11301317|NCT02690649|No Intervention|No Health Messaging|No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.
11301318|NCT02690636|Active Comparator|Conventional|The patients will receive adjuvant radiotherapy conventionally fractionated 5000 cgy fractionated by 200cgy daily fractions, five fractions per week over 5 weeks with an additional 200cgy daily for five days as boost for patients with breast conservative surgery.
11301319|NCT02690636|Experimental|Hypofractionated|The patients will receive adjuvant radiotherapy hypofractionated 266cgy daily fractions, five fractions per week for total 16 fractions and an additional five daily fractions will be added as boost for patients with breast conservative surgery.
11301320|NCT02690623|Experimental|Pediatric hospitalist program|As currently planned, hospitalist services will involve an in-house hospitalist at all hours. The attending hospitalist on each hospitalist service will make morning rounds on weekdays and be present supervising the residents or providing care throughout the day. A different hospitalist will cover at night. On weekends, one hospitalist will cover up to 2 services each day. None will work for more than 25 hours at a stretch.
11301321|NCT02690623|Active Comparator|General Pediatric Inpatient Services|The attending pediatrician on each service conducts daily morning rounds on weekdays, supervises the students and house staff and is available to the residents by phone or in person during the day. On some afternoons the attending physician may be responsible for supervising care in a pediatric clinic. On weeknights, an on-call pediatrician is available to the residents by phone. On weekends two on-call pediatricians make rounds, supervise the residents, and take call from home for the 4 services. Each service usually maintains 10-20 patients at a time and generally accepts 8-12 new admissions per admitting day. This approach on the General Pediatric Services will not be changed materially as hospitalists assume responsibility for one or more of the 4 services.
11301322|NCT02690610|Experimental|Patients with mediastinal lesions|EBUS TBNA of mediastinal lesions or lymph nodes
11301323|NCT02690597|Other|Patient|"State-trait anxiety inventory Y-A form (STAI Y-A form)
~Anxiety visual analog scale evaluation(A-AVS)."
11301324|NCT02690584|Experimental|Metacognitive therapy|Metacognitive therapy, one 45-60 min session weekly during 10 weeks.
11301325|NCT02690571|Sham Comparator|Filtered air exposure|One hour exposure to filtered air during intermittent exercise in controlled chamber, 6 hours after exposure bronchoscopy is performed.
11301326|NCT02690571|Experimental|Biodiesel exhaust exposure|One hour exposure to biodiesel exhaust (generated at same running conditions as earlier studies with diesel exhaust at approximate particle matter concentration 300 mcg/m3) during intermittent exercise in controlled chamber. Six hours after exposure bronchoscopy is performed.
11301327|NCT02690558|Experimental|pembrolizumab, gemcitabine and cisplatin|There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
11301328|NCT02690545|Experimental|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10^8 cells/m2 and 2x10^8 cells/m^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10^8 cells/m^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10^8 cells/m^.
~Phase II: The study team planning to enroll 31 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
11301329|NCT02690532||High risk group|Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
11301330|NCT02690532||Non-celiac group|Children who are self-diagnosed with non-celiac gluten sensitivity.
11301331|NCT02690532||Control Group|Healthy control group (matched for age and gender).
11301332|NCT02690519|Experimental|GLPG1837 dose 1 and GLPG1837 dose 2|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
11301333|NCT02690506|Placebo Comparator|Group C|Oral placebo pill was administered 2 hours before anesthesia
11301334|NCT02690506|Active Comparator|Group P|Oral pregabalin 150 mg was administered 2 hours before anesthesia
11301335|NCT02690493|Active Comparator|Acupuncture Only|Patients will be treated with acupuncture only.
11301336|NCT02690493|Active Comparator|Functional Taping Only|Patients will be treated with taping only.
11301337|NCT02690493|Experimental|Acupuncture and Functional Taping|Patients will be treated with both acupuncture and taping at the same session.
11301434|NCT02689843|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily
11301338|NCT02690480|Experimental|PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)|Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
11301339|NCT02690480|Active Comparator|Placebo+fulvestrant(FaslodexTM)|Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
11301340|NCT02690467|Experimental|Insupen G34x3,5mm|Needle for insulin pen 3,5 mm long and with a diameter of 34 gauge
11301341|NCT02690467|Active Comparator|Insupen G32x4mm|Needle for insulin pen 4 mm long and with a diameter of 32 gauge
11301342|NCT02690441|Experimental|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
11301343|NCT02690441|Active Comparator|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
11301344|NCT02690428|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
11301345|NCT02690415||Antibiotics Given|Patients who's treating physician prescribed antibiotics following incision and drainage of their abscess.
11301346|NCT02690415||Antibiotics Not Given|Patients who's treating physician did not prescribed antibiotics following incision and drainage of their abscess.
11301347|NCT02690402|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
11301348|NCT02690389|No Intervention|Control|standard procedure is used
11301349|NCT02690389|Sham Comparator|Flumazenil only group|flumazenil is given
11301350|NCT02690389|Active Comparator|control with acupuncture|control with acupuncture
11301351|NCT02690389|Active Comparator|control with acupuncture and flumazenil|control with acupuncture and flumazenil
11301352|NCT02690376|Other|Magnetic Assisted Capsule Endoscopy|There is only one arm and its does not reach criteria for other options
11301353|NCT02690350|Experimental|Cohort 1 U3-1784 2.5 mg/kg|U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
11301354|NCT02690350|Experimental|Cohort 2 U3-1784 3.75 mg/kg|U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
11301355|NCT02690350|Experimental|Cohort 3 U3-1784 5.6 mg/kg|U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
11301356|NCT02690337|Experimental|DS-1123|This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.
11301357|NCT02690324|Experimental|Major depressive disorder|DSM-5 major depressive disorder HAMD-17 > 16
11301358|NCT02690324|Active Comparator|panic disorder|DSM-5 panic disorder PDSS>7
11301359|NCT02690324|Active Comparator|normal control|age >20, healthy adults HAMD-17<17 PDSS<7
11301360|NCT02690311|Sham Comparator|LED with bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
11301361|NCT02690311|Experimental|LED without bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
11301362|NCT02690285|Other|Part 1: glutathione transferase zeta 1 (GSTZ1) haplotyping|The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
11301363|NCT02690285|Experimental|Part 2: Dichloroacetate (DCA) Kinetics|Eight study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will complete a DCA kinetic study on day 5, at the Clinical Research Clinic (CRC).
11301364|NCT02690272|Experimental|Psychic processes|Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant
11301365|NCT02690259|Experimental|Sentinel node procedure|Enrolling all eligible endometrial cancer patient to the Sentinel node concept using indocyanine green.
11301366|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
11301367|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
11301368|NCT02690220|Other|surgical mesh implantation|Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.
11301369|NCT02690207|Experimental|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
11301370|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PLACEBO THERAPY SESSION
~Post-Placebo therapy/Pre-procedure
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PROCEDURE
~Post-procedure -Rate pain level of procedure"
11301371|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~BUDDHIFY THERAPY SESSION
~Post-Buddhify therapy/Pre-procedure
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PROCEDURE
~Post-procedure -Rate pain level of procedure"
11301372|NCT02690194|No Intervention|Control Group|"Pre-Procedure
~Blood pressure, pulse, and respiration rate
~State-Trait Anxiety Inventory
~PROCEDURE
~Post-procedure -Rate pain level of procedure"
11301373|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
11301374|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
11301375|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
11301376|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
11301377|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
11301378|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
11301379|NCT02690168||Healthy Men|
11301380|NCT02690155||Rivaroxaban|NVAF patients who were initiated on rivaroxaban for stroke prevention
11301381|NCT02690155||VKA (Vitamin K antagonist)|NVAF patients who were initiated on VKA for stroke prevention
11301382|NCT02690142|Experimental|ABY-035 i.v.|Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
11301383|NCT02690142|Experimental|ABY-035 s.c.|Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
11301384|NCT02690142|Experimental|ABY-035 i.v. in psoriasis patients|Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
11301385|NCT02690142|Experimental|ABY-035 s.c. in psoriasis patients|Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
11301386|NCT02690129|Active Comparator|Group I (Progesterone Group)|"Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.
~Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.
~If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .
~Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation."
11301387|NCT02690129|Placebo Comparator|Group II ( Control group)|Will follow the same plan of management without progesterone support.
11301388|NCT02690116|Experimental|Qigong/Tai Chi Easy|The Qigong/Tai Chi Easy (QG/TCE) intervention has been standardized, manualized, and has a formal training program for instructors from the Institute of Integral Qigong and Tai Chi (IIQTC).
11301389|NCT02690116|Sham Comparator|Sham Qigong|This active control group uses a gentle movement intervention, with similar types of movements with the same energy expenditure, but without the meditative states and breath focus as QG/TCE (validated in the pilot study using the Meditative Movement Inventory).
11301390|NCT02690116|Active Comparator|Educational Support|The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
11301391|NCT02690103|Active Comparator|Group 1|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
11301392|NCT02690103|Experimental|Group 2|Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.
11301393|NCT02690090||enoxaparin|enoxaparin prophylaxis as directed by treating Intensivist
11301394|NCT02690077|Active Comparator|Method 1 by Preference 1|Delivery through the Family-Centered Cesarean for patients with known Family-Centered preference.
11301395|NCT02690077|Active Comparator|Method 1 by Preference 2|Delivery through the Family-Centered Cesarean for patients with known Traditional Cesarean preference.
11301396|NCT02690077|Active Comparator|Method 2 by Preference 1|Delivery through the Traditional Cesarean for patients with known Family-Centered preference.
11301397|NCT02690077|Active Comparator|Method 2 by Preference 2|Delivery through the Traditional Cesarean for patients with known Traditional Cesarean preference.
11301398|NCT02690064|Experimental|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral 1) antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) 2) Resveratrol (1500 mg) 3) Mitoquinol (10 mg) or placebo on two days separated by at least 72 hours.
11301399|NCT02690064|Experimental|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following one of the following: 1) an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day, 2) 1500 mg Resveratrol once a day or 3) 10 mg Mitoquinol once a day.
11301400|NCT02690051|Experimental|BeSmooth Peripheral Stent system|Patients treated with the BeSmooth Peripheral Stent System
11301401|NCT02690038|Experimental|Intervention Arm 1: Treatment|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).
~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
11301402|NCT02690038|Active Comparator|Intervention Arm 2: Control|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).
~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
11301403|NCT02690025|Experimental|ZP1848 High dose|s.c. administration of high dose
11301404|NCT02690025|Experimental|ZP1848 Medium dose|s.c. administration of medium dose
11301405|NCT02690025|Experimental|ZP1848 Low dose|s.c. administration of low dose
11301406|NCT02690012|Active Comparator|Drug Magnesium oxide|Participants will be given standard dose levels of Magnesium oxide according to the level of magnesium in blood.
11301407|NCT02690012|Active Comparator|Drug Magnesium citrate|Participants will be given standard dose levels of Magnesium citrate according to the level of magnesium in blood.
11301408|NCT02689999|Experimental|Dexrabeprazole 10 mg Enteric-Coated Tablets|Dexrabeprazole 10 mg Enteric-Coated Tablets / once daily
11301409|NCT02689986|Experimental|Treatment arm|Bendamustine, Rituximab
11301410|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
11301411|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.
~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
11301412|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
11301413|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
11301414|NCT02689960|Other|vaginal administration first|Intervention first visit: vaginal administration of 100mg prednisone suppository, Intervention second visit: rectal administration of 100mg prednisone suppository
11301415|NCT02689960|Other|rectal administration first|Intervention first visit: rectal administration of 100mg prednisone suppository, Intervention second visit: vaginal administration 100mg prednisone suppository
11301416|NCT02689947|Experimental|Restylane Silk|open label no placebo control
11301417|NCT02689934|Experimental|Lactoflorene colesterolo|Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day
11301418|NCT02689934|Placebo Comparator|Placebo Lactoflorene colesterolo|placebo, powder form, 1 packet per day
11301419|NCT02689921|Experimental|Neoadjuvant Biological Therapy|"Subjects will receive an aromatase inhibitor for the duration of the study [exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).
~Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).
~Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)"
11301420|NCT02689908|Other|The patients underwent thorax CT|The patients refered to radiology service underwent thorax computed tomography without contrast material for the evaluation of various complaints such as dyspnea, hemoptysis and pulmonary infections.
11301421|NCT02689895|Other|Intervention|Research assistants visit participants at home, and send SMS texts on scheduled days for 3 months to encourage adherence to ART. Pill charts, visit charts and text charts are completed. this is called modified directly administered anti-retroviral therapy (mDAART). In addition to the intervention, participants receive standard care at their usual clinic which comprises 3 monthly doctor reviews and adherence counseling at each review visit.
11301422|NCT02689895|No Intervention|Control|Participants get usual care at their clinic, which comprises 3 monthly doctor review visits and adherence counseling at each visit.
11301423|NCT02689882|Experimental|pharmacokinetic study|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
11301424|NCT02689869|Experimental|Ibrutinib and GA 101|"Initial therapy 6 cycles of Ibrutinib:
~Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.
~1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).
~Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:
~Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.
~In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months."
11301425|NCT02689856|Placebo Comparator|Vehicle cream|Placebo control base cream
11301426|NCT02689856|Experimental|3% hydrocortisone|3% Hydrocortisone acetate cream
11301427|NCT02689856|Experimental|0.5% hydrocortisone|0.5% Hydrocortisone acetate cream
11301428|NCT02689856|Experimental|5% lidocaine|5% Lidocaine hydrochloride cream
11301429|NCT02689856|Experimental|1% lidocaine|1% Lidocaine hydrochloride cream
11301430|NCT02689856|Experimental|3% Hydro 5% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 3% and 5% cream
11301431|NCT02689856|Experimental|0.5% Hydro 1% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 0.5% and 1% cream
11301432|NCT02689843|Active Comparator|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily
11301436|NCT02689817|Experimental|Monitoring patch, no display|Participants in this condition will receive a padded bandage that monitors pressure over time. In this arm, healthcare providers will not be able to view the pressure data collected.
11301437|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
11301438|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
11301439|NCT02689791|No Intervention|Control (SWF)|Standard Wheat Flour (SWF) Muffins
11301440|NCT02689791|Experimental|Resistant Starch Type 4|Resistant Wheat Starch Muffins
11301441|NCT02689778|Experimental|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
11301442|NCT02689778|Placebo Comparator|Placebo|Oral placebo with breakfast and with dinner for 12 months.
11301443|NCT02689765|Experimental|Anthocyanins|Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
11301444|NCT02689765|Placebo Comparator|Control|A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
11301445|NCT02689752|Experimental|fruquintinib|fruquintinib suspension, 5 mg （100 mCi）oral taken once
11301446|NCT02689739||Obese Pregnant cohort|Women will be consented to participate and then separated into a study group of obese women (BMI >/= 30).
11301447|NCT02689739||Non-obese Pregnant cohort|This will be the control group of non-obese women (BMI <30).
11301448|NCT02689726|Experimental|GTL001 + Aldara, 5% imiquimod cream|2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
11301449|NCT02689713|Experimental|Topical Voriconazole Study Drug Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Voriconazole study drug placed on graft site.
11301450|NCT02689713|Placebo Comparator|Topical Sterile Water Placebo Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Sterile Water Placebo placed on graft site.
11301451|NCT02689700||HCMV antibody-transfer|Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
11301452|NCT02689700||VZV antibody-transfer|Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation
11301453|NCT02689687|Experimental|Intervention|All participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.
11301454|NCT02689661||Obese participants|Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.
11301455|NCT02689661||Lean participants|Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.
11301456|NCT02689635|Active Comparator|Sodium Restricted Diet|Low Salt (cardiac) diet
11301457|NCT02689635|Active Comparator|Regular Diet|Non-Cardiac diet
11301458|NCT02689622|Experimental|Evaluation of disease prognostic factors|Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
11301459|NCT02689609||Single arm|All patients will receive intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy as standard of care. They will have baseline pre-treatment and post-IMRT serum thyroid function test at least yearly after IMRT.
11301460|NCT02689596|Active Comparator|OT|Oxytocin
11301461|NCT02689596|Placebo Comparator|Placebo|Placebo
11301462|NCT02689583|Experimental|Successful treatment|The patients with H. pylori infection have successful treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
11301463|NCT02689583|Experimental|refractory infection|The patients with H. pylori infection have failed treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
11301464|NCT02689570||type 1 diabetic patients|Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
11301465|NCT02689557|Other|measures of the volumes|Measures of the volumes of the lower limbs. A measure to rest, a measure of effort (walk) and a measure recovery. Intervention.
11301466|NCT02689544|Experimental|static stretching|Group of 15 volunteers (gSS)
11301467|NCT02689544|Experimental|dynamic stretching|Group of 15 volunteers (gDS)
11301468|NCT02689544|Other|control|Group of 15 volunteers (gC)
11301469|NCT02689531||High-Risk (Adult =>18 years old)|"Treated with one or more of the following respiratory modalities for at least 12 continuous hours, either currently or within the prior 7 days:
~Invasive mechanical ventilation
~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)
~High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.
~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.
~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
11301470|NCT02689531||Other-ICU/Standard Risk|Patients do not fulfill high-risk criteria, but, are receiving an antibiotic for treatment of lower respiratory tract infection or undifferentiated sepsis.
11301471|NCT02689531||High-Risk (Pediatric ≥120 days old and <18 years old)|"Currently treated with one or more of the following respiratory modalities for at least 24 hours:
~Invasive mechanical ventilation via endotracheal intubation
~New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy
~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)
~High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM
~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM
~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
11301472|NCT02689531||High-Risk (Pediatric <120 days old)|Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days
11301473|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
11301474|NCT02689505|Experimental|BI 836880|
11301475|NCT02689466||cervical dystonia|clinically documented cervical dystonia (focal cervical or segmental with neck involvement)established by history and physical/neurological examination, at least 18 years old.
11301476|NCT02689466||healthy volunteers|age and sex matched healthy volunteers, atleast 18 years old.
11301477|NCT02689453|Experimental|1A|IL-15 for 10 doses over two weeks followed byalemtuzumab for 4 weeks per dosing schema to determine the maximum tolerated dose (MTD)
11301478|NCT02689453|Experimental|1B|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks at the maximum tolerateddose (MTD)
11301479|NCT02689440|Experimental|Treatment (dasatinib, venetoclax)|Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
11301480|NCT02689427|Experimental|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Cycles repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
11301481|NCT02689414|Experimental|Remote ischaemic preconditioning|Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
11301482|NCT02689414|Sham Comparator|Control to RIPC|Four episodes of 5 minutes during which the pressure in the cuff is equal to venous pressure are performed. Between all the episodes there is a 5-minute pause.
11301483|NCT02689401|Experimental|Ferumoxtyol (Feraheme) with MRI|Patients will undergo a pre-contrast MRI followed by a pre determined dose of of IV Ferumoxyto. Post-contrast MRI imaging will be performed immediately following Ferumoxytol infusion and 48 hours after Ferumoxytol administration with subsequent image analysis.
11301484|NCT02689388|Active Comparator|General Anesthesia with nerve block|Femoral Nerve Block
11301485|NCT02689388|No Intervention|General Anesthesia no nerve block|No femoral Nerve Block
11301486|NCT02689375|Experimental|Patients to receive spinal cord stimulator|
11301487|NCT02689362|Experimental|Evogliptin 2.5mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
11301488|NCT02689362|Experimental|Evogliptin 5.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
11301489|NCT02689362|Experimental|Evogliptin 10.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
11301490|NCT02689362|Active Comparator|Sitagliptin 100mg+Placebo Evogliptin|SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
11301491|NCT02689349|Experimental|Esteem Implant|Implantation of Esteem
11301492|NCT02689336|Experimental|Erlotinib and Temozolomide|"Erlotinib is an oral drug that will be administered on an outpatient basis at a dose of 85 mg/m^2/dose once a day continuously (every day of a 28-day cycle)
~Temozolomide is an oral drug that will be administered on an outpatient basis at a dose of 180mg/m2/dose once a day on Days 1-5 of a 28-day cycle."
11301493|NCT02689323|Experimental|Open label|Participants will undergo 5 sessions of active rTMS
11301494|NCT02689310|Other|Standard Care - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
11301495|NCT02689310|Experimental|Honey Treatment - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
11301496|NCT02689310|Other|Standard Care - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
11301497|NCT02689310|Experimental|Honey Treatment - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
11301498|NCT02689297|Other|group A|Mouthwash (chlorine dioxide 12ml two times per day, for three weeks)
11301499|NCT02689297|Other|group B|Small toothbrush for tongue cleaning two times per day for three weeks
11301500|NCT02689284|Experimental|Margetuximab plus pembrolizumab|margetuximab administered in combination with pembrolizumab
11301501|NCT02689258|Experimental|Part A Cohort A|200 mg of HTX-011A by infiltration
11301502|NCT02689258|Placebo Comparator|Part A Cohort B|Saline Solution by infiltration
11301503|NCT02689258|Experimental|Part A Cohort C|200 mg of HTX-011B by infiltration
11301504|NCT02689258|Experimental|Part A Cohort D|400 mg of HTX-011B by infiltration
11301505|NCT02689258|Experimental|Part A Cohort E|600 mg of HTX-011B by infiltration
11301506|NCT02689258|Experimental|Part B Cohort A|Subjects will be enrolled in Part B following completion of enrollment in Part A to evaluate HTX-011 and HTX-002, with or without saline solution.
11301507|NCT02689258|Experimental|Part C Cohort A|Subjects will be enrolled in Part C following completion of Part B to evaluate 400 mg HTX-011B via instillation, bupivacaine HCl 100 mg via injection and saline placebo via injection
11301508|NCT02689258|Experimental|Part D Cohort A|Up to 300 mg of HTX-011B
11301509|NCT02689258|Placebo Comparator|Part D Cohort B|Saline Solution
11301510|NCT02689245|Experimental|Tenofovir + Fecal Microbiota Transplantation (FMT)|
11301511|NCT02689245|Active Comparator|Tenofovir|
11301512|NCT02689232|Experimental|Thromboelastography (TEG) level|
11301513|NCT02689232|Active Comparator|Coagulation Profile|
11301514|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
11301515|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
11301516|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
11301517|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
11301518|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
11301519|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
11301520|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
11301521|NCT02689193||Salmonella|Patients for whom blood cultures grew Salmonella species.
11301522|NCT02689193||No pathogen|Patients for whom blood cultures did not grow a pathogen and no pathogen was detected using other routine care diagnostics (e.g. malaria with the use of a malaria rapid test).
11301523|NCT02689193||Another pathogen|Patients for whom blood cultures grew with another pathogen or a pathogen was detected using other routine care diagnostics (e.g. malaria with the use of malaria rapid test).
11301524|NCT02689193||Healthy controls|Healthy controls. Patients without fever but from whom blood is drawn for another reason (e.g. check of cholesterol).
11301525|NCT02689180|Placebo Comparator|Withdraw of furosemide|Withdraw of of 40 or 80 mg of furosemide per day
11301526|NCT02689180|Active Comparator|Maintenance of furosemide|Maintenance of 40 or 80 mg of furosemide per day
11301527|NCT02689167|Active Comparator|Arm A 4/6|"Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks on  alternating with 2 weeks off "
11301528|NCT02689167|Experimental|Arm B 2/3|"Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks on  alternating with 1 week off "
11301529|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
11301530|NCT02689141|Experimental|Bendamustine + Ofatumumab + Ibrutinib|Bendamustine: 70mg/m² i.v. Ofatumumab: 1000 mg i.v. Ibrutinib: 420 mg po
11301531|NCT02689115||Clinical activity|Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) > 3.6.
11301532|NCT02689115||Clinical remission|Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) < 2.4.
11301533|NCT02689102||ILD patients|ILD patients scheduled for diagnostic bronchoscopy with biopsy and/or broncho-alveolar lavage will undergo additional imagaing with probe based optical techniques.
11301534|NCT02689089|Other|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
11301535|NCT02689076|Experimental|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
11301536|NCT02689076|Active Comparator|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
11301537|NCT02689076|No Intervention|Usual Care (No HIE Notification and No Care Coordination)|Absence of VA provider notification of non-VA hospitalization via HIE plus Absence of post-hospital geriatric care transitions intervention [Usual Care]
11301538|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
11301539|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
11301540|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
11301541|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
11301568|NCT02688868|Experimental|new specifications (Diameter 2.25mm)of Firehawk stent|Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
11333447|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
11301542|NCT02689050||Patients with lymphadenopathy|Patients ≥ 18 years of age, with (suspected) NSCLC or suspected sarcoidosis, and at least one suspected mediastinal/hilar lesion that are scheduled for standard diagnostic endosonographic workup will undergo additional needle based confocal laser endomicroscopy (nCLE) measurements of suspected lesions.
11301543|NCT02689037|Experimental|stenting+medical treatment|Patients in PTAS+MT group will receive Percutaneous transluminal angioplasty and stenting and medical treatment (aspirin 100mg daily and clopidogrel 75mg daily)
11301544|NCT02689037|Active Comparator|Aspirin plus clopidogrel|Patients in aspirin plus clopidogrel group will receive aspirin 100mg daily and clopidogrel 75mg daily for 90 days.
11301545|NCT02689024|Experimental|Continuous FICB with local anesthetics|"With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.
~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores."
11301546|NCT02689024|Active Comparator|Traditional care with systemic analgesia|"Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.
~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required."
11301547|NCT02689011|Experimental|Group F|Femoral nerve Block Group
11301548|NCT02689011|Active Comparator|Group E|Epidural Group
11301549|NCT02688998|Active Comparator|Venous access PORT or PICC|Participants will receive a central line placement either a PORT or a PICC prior to the initiation of chemotherapy.
11301550|NCT02688998|No Intervention|No intervention|Participants will only receive a central line if required once chemotherapy has been initiated.
11301551|NCT02688985|Experimental|RMS Cohort Arm 1: Ocrelizumab + LP at Weeks 1 and 12|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
11301552|NCT02688985|Experimental|RMS Cohort Arm 2: Ocrelizumab + LP at Weeks 1 and 24|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
11301553|NCT02688985|Experimental|RMS Cohort Arm 3: Ocrelizumab + LP at Weeks 1 and 52|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
11301554|NCT02688985|Experimental|RMS Cohort Arm 4: Ocrelizumab + LP at Week -12 and Week 1|Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
11301555|NCT02688985|Experimental|PPMS Cohort: Ocrelizumab + LP at Weeks 1 and 52|Participants with PPMS will receive ocrelizumab 600 mg as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
11301556|NCT02688972|Experimental|cold water immersion|
11301557|NCT02688972|Other|control|13 volunteers
11301558|NCT02688959|Experimental|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
11301559|NCT02688959|Active Comparator|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
11301560|NCT02688959|No Intervention|Control|Participants in the control arm will not attend a class and not be given a video.
11301561|NCT02688933|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
11301562|NCT02688933|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
11301563|NCT02688920||With T2DM|Subjects with type 2 diabetes.
11301564|NCT02688920||Without T2DM|Subjects without type 2 diabetes
11301565|NCT02688907|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
11301566|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
11301567|NCT02688881|Experimental|sirolimus|sirolimus 1mg will be administered orally daily
11301570|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
11301571|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
11301572|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
11301573|NCT02688816||Women undergoing cervical cancer screening|"HIV-infected women will undergo a cervical cancer screening examination using the VIA method. A digital photograph of the cervix will also be taken to aide visual screening. This is known as digital cervicography, and it is currently standard of care within cervical cancer screening clinics in Zambia.
~Cervical samples will be collected for molecular testing using Xpert HPV, and OncoE6. Cervical biopsy samples will also be obtained for confirmatory histopathologic diagnosis."
11301574|NCT02688803|Active Comparator|Dose dense AC-P|Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
11301575|NCT02688803|Active Comparator|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
11301576|NCT02688803|Active Comparator|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
11301577|NCT02688790|Experimental|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
11301578|NCT02688790|Experimental|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
11301579|NCT02688790|Experimental|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
11301580|NCT02688777|Experimental|Immediate Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training immediately following baseline assessment.
11301581|NCT02688777|Active Comparator|Delayed Backward Walking Training|Individuals will participate in 18 sessions of Backward Walking training at 1-year post-strokeD
11301582|NCT02688764|Experimental|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron
~PA21 (Velphoro®), chewable tablets 250 mg iron
~PA21 (Velphoro®), powder for oral suspension 500 mg iron
~PA21 (Velphoro®), powder for oral suspension 250 mg iron
~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
11301583|NCT02688764|Active Comparator|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
11301584|NCT02688738|No Intervention|Control|Standard of care
11301585|NCT02688738|Active Comparator|Treatment|Oral doxycycline
11301586|NCT02688725|Experimental|Ultrasound|post mastectomy ultrasound
11301587|NCT02688712|Experimental|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
11301588|NCT02688699|Experimental|EndoClot|spraying of Endoclot powder after EMR or ESD
11301589|NCT02688699|No Intervention|control|
11301590|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
11301591|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
11301592|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
11301593|NCT02688647|Experimental|KD025 Daily|Two 200mg tablets (400 mg) KD025 once daily (QD). Subjects should take 2 Tablets with their morning meal or within 5 minutes of completing a meal.
11301594|NCT02688647|Other|Best Supportive Care|Best Supportive Care (BSC) which is a treatment/drug determined by each subject's prescribing physician.
11301595|NCT02688634||Treatment|Participants in this group are randomize to receive post-operative antibiotic of Amoxicillin x7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
11301596|NCT02688634||Non-Treatment|Participants in this group will be randomize to no post-operative antibiotic. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
11301597|NCT02688621|Active Comparator|Internet only|Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
11301598|NCT02688621|Experimental|Internet + Incentives|Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.
11301599|NCT02688608|Experimental|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
11301600|NCT02688595|Experimental|Seldinger|Use a 23 gauge introducer needle for ultrasound-guided central venous catheterization
11301601|NCT02688595|Experimental|Modified Seldinger|Use a 22 gauge Angiocath Plus catheter for ultrasound-guided central venous catheterization
11301602|NCT02688582|Experimental|TCI group|Patients who receive cefepime based on TCI for a maximum of 5 days with a target concentration of cefepime of 16 mg/L.
11301603|NCT02688569|Experimental|CBT-CWP|Participants in this condition will receive Cognitive Behavioral Therapy for Chronic Widespread Pain (CBT-CWP)
11336566|NCT02457104||obese individuals not taking PPI|
11301604|NCT02688569|No Intervention|Control|Participants in the Control condition will not receive CBT-CWP. They will however, continue completing the weekly assessments.
11301605|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
11301606|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
11301607|NCT02688543|Experimental|RF treatment|Patients treated with radio frequency of the genicular nerves
11301608|NCT02688530|Placebo Comparator|0mg IV Dexamethasone|0mg IV Dexamethasone
11301609|NCT02688530|Experimental|4mg IV Dexamethasone|4mg IV Dexamethasone
11301610|NCT02688530|Experimental|6mg IV Dexamethasone|6mg IV Dexamethasone
11301611|NCT02688530|Experimental|8mg IV Dexamethasone|8mg IV Dexamethasone
11301612|NCT02688517|Other|Ancillary-Correlative (genomic analysis)|Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.
11301613|NCT02688504||serious road accidents|Drivers involved in serious road accidents (hospitalization > 24 hours)
11301614|NCT02688504||non-serious road accidents|drivers involved in non-serious road accidents (hospitalization < 24 hours).
11301615|NCT02688491|Experimental|A (Intervention group,sunitinib)|Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks
11301616|NCT02688491|No Intervention|B(observation group)|Patients with radical nephrectomy are observed without intervention
11301617|NCT02688478|Active Comparator|Filtered air|Exposure for 3 hours to filtered air followed by subject specific inhaled allergen challenge
11301618|NCT02688478|Experimental|Phthalate|Exposure for 3 hours to dibutyl phthalate followed by subject specific inhaled allergen challenge
11301619|NCT02688465|Experimental|Apomorphine pump|
11301620|NCT02688452|Active Comparator|Group 1|Young Healthy Adults
11301621|NCT02688452|Active Comparator|Group 2|Young Healthy Adults
11301622|NCT02688439|Active Comparator|Leg in a neutral position|Sciatic nerve block, with leg kept in a neutral position after anesthesia (control group)
11301623|NCT02688439|Experimental|Leg raised 30°|Sciatic nerve block, with leg raised 30° by placing the back of the foot over a support placed on the OR table and maintained in that position for 15 min
11301624|NCT02688439|Experimental|Distal tourniquet placed on the lower part of the leg|Sciatic nerve block, and distal tourniquet placed on the lower part of the leg (upper part of the tourniquet being about 4-6 inches from the ankle) with the leg in a neutral position.
11301625|NCT02688426|Sham Comparator|0J LLLT|The sham treatment is performed in the same way as treatment with LBP, however, with the apparatus switched off
11301626|NCT02688426|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
11301627|NCT02688413|Experimental|MindMotionPRO|MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
11301628|NCT02688413|Active Comparator|Self-Directed Prescribed Exercises|Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
11301629|NCT02688400|Experimental|Diacerein|One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
11301630|NCT02688400|Active Comparator|Celecoxib|One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
11301631|NCT02688387|Experimental|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
11301632|NCT02688387|Experimental|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
11301633|NCT02688387|Experimental|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
11301634|NCT02688374|Other|Treatment A:Treatment B:Treatment C|Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
11301635|NCT02688374|Other|Treatment B:Treatment C:Treatment A|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
11301636|NCT02688374|Other|Treatment C:Treatment A:Treatment B|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
11301637|NCT02688374|Other|Treatment A: Treatment C:Treatment B|Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
11301638|NCT02688374|Other|Treatment B:Treatment A: Treatment C|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
11301701|NCT02687945|Active Comparator|No outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of self-guided physiotherapy exercises
11301702|NCT02687932|Experimental|LCZ696|LCZ696 for 12 months
11301703|NCT02687932|Active Comparator|Valsartan|Valsartan for 12 months
11301639|NCT02688374|Other|Treatment C:Treatment B:Treatment A|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
11301640|NCT02688361|Experimental|Fluimucil® (reference) then Acetylcysteine (test) 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Acetylcysteine (test).
11301641|NCT02688361|Experimental|Acetylcysteine (test) 2% solution then Fluimucil® (reference)|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Fluimucil® (reference).
11301642|NCT02688348|Other|Ancillary-Correlative (late toxicity and QOL)|Patients complete the EORTC QLQ-BLM-C30 at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
11301643|NCT02688335|Experimental|Cloud9 Snoring Treatment|Snoring participants will be instructed to use the device as much as possible for 2 weeks.
11301644|NCT02688322|Experimental|2 g q12 of sulbactam, 1 h infusion|2 g of sulbactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 1 h every 12 h.
11301645|NCT02688309|Experimental|Clinic Patients|"Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis.
~Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an anterior chamber (AC) tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection."
11301646|NCT02688309|Placebo Comparator|OR Patients|Patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macular hole. Surgical patients who agree to participate will have an anterior chamber (AC) tap at the beginning of surgery.
11301647|NCT02688296||Pilon Fractures|Patients who are implanted with Fibulock and have a Pilon fracture
11301648|NCT02688296||High Risk Patients|Patients who are implanted with Fibulock and are at high risk of complications from ankle surgery due to conditions such as diabetes, advanced age or osteoporosis
11301649|NCT02688296||Otherwise Healthy Patients|Patients implanted with Fibulock who are healthy other than their ankle fracture
11301650|NCT02688283|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
11301651|NCT02688283|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
11301652|NCT02688283|Placebo Comparator|White-bread|45g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
11301653|NCT02688270|Experimental|Vascana® (0.9% nitroglycerin cream)|
11301654|NCT02688270|Placebo Comparator|Vehicle cream|
11301655|NCT02688244|Active Comparator|Irrigation|Irrigation of the area with at least 300ml normal saline using the power suction/irrigator
11301656|NCT02688244|Active Comparator|No irrigation|Only suction with the power suction/irrigator without saline attached
11301657|NCT02688231|Experimental|High intensity group|
11301658|NCT02688231|Experimental|Low intensity group|
11301659|NCT02688231|Active Comparator|Control group - conventional treatment|
11301660|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
11301661|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
11301662|NCT02688205||Shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
11301663|NCT02688205||Without shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
11301664|NCT02688192|Active Comparator|Arm I (Intervention)|"Assessment including
~Wear an electronic accelerometer
~Quality of life assessment
~Physical fitness evaluation
~Participate in a fitness program which includes:
~8 group meetings of 90 minutes weekly
~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
11301665|NCT02688192|Active Comparator|Arm II (Waitlist Control [WLC])|"Assessment including
~Wear an electronic accelerometer
~Quality of life assessment
~Physical fitness evaluation
~After waiting 6 months they will begin the fitness program as described in Arm I"
11301666|NCT02688179||Cardiac surgery patients|
11301667|NCT02688166||Breast Cancer|Breast cancer patients who are undergoing internal mammary lymph node radiation
11301668|NCT02688166||Lung Cancer|Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy
11301669|NCT02688153|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
11301670|NCT02688153|Active Comparator|Stented aortic bioprostheses|Stented aortic bioprostheses
11301671|NCT02688140|Experimental|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).
~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.
~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
11336567|NCT02457104||obese individuals taking PPI|
11301672|NCT02688140|Active Comparator|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7, oral tretinoin twice daily on day 1-28 (max. up to day 60).
~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.
~Consolidation I:
~IDA 5 mg/m2 i.v. day 1-4 Ara-C 1000 mg/m2/3h i.v. day 1-4 ATRA 45 mg/m2 p.o. day 1-15
~Consolidation II:
~MTZ 10 mg/m2 i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15
~Consolidation III:
~IDA 12 mg/m2 i.v. day 1 Ara-C 150 mg/m2 every 8h i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15
~Maintenance (duration 7 cycles = 2 years; one cycle lasts 106 days):
~6-MP 50 mg/m2 p.o. Cycle 1-7: day 1-91 (followed by 15 days of ATRA on days 92-106)
~MTX 15mg/m2 i.m./p.o. Cycle 1-7: once weekly for 91 days (followed by 15 days of ATRA on days 92-106)
~ATRA 45 mg/m2 p.o. Cycle 1-6: day 92-106 Cycle 7: without ATRA Administration
~(treatment break of 6-MP and MTX during ATRA administration)"
11301673|NCT02688127|Experimental|tranexamic acid group|tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section
11301674|NCT02688127|Placebo Comparator|placebo group|the control group will receive 500 cc of ringer lactate 20 minute before cesarean section
11301675|NCT02688114|Experimental|Barrett's Esophagus Treatment|All participants are in the treatment arm. Patients with Barrett's esophagus will undergo baseline surveillance endoscopy, be treated with radiofrequency ablation, and undergo follow up endoscopy 1, follow up endoscopy 2, and follow up endoscopy 3.
11301676|NCT02688101|Experimental|DpC|DpC capsules, administered orally
11301677|NCT02688088|Active Comparator|Drug Cocktail|Single dose of drug cocktail (caffeine, warfarin, dextromethorphan, and midazolam) administered orally on Day 1 of Period 1.
11301678|NCT02688088|Experimental|Abemaciclib + Drug Cocktail|Abemaciclib administered orally every 12 hours on Days 1 - 12 of Period 2 with a single dose of drug cocktail administered orally on Day 8 of Period 2.
11301679|NCT02688088|Experimental|Abemaciclib - Period 3|Abemaciclib administered orally every 12 hours on Days 13 to 28 of Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
11301680|NCT02688088|Experimental|Abemaciclib - Period 4|Abemaciclib administered orally every 12 hours on Days 1 to 28 of Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
11301681|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
11301682|NCT02688062|Experimental|NeuroRegen Scaffold with BMMCs transplantation|
11301683|NCT02688062|Experimental|Surgical intradural decompression and adhesiolysis|
11301684|NCT02688049|Experimental|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.
11301685|NCT02688049|Experimental|NeuroRegen scaffold/neural stem cells transplantation|Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury.
11301686|NCT02688036|Experimental|hypofractionated CRT|hypofractionated concurrent chemoradiotherapy
11301687|NCT02688036|Active Comparator|conventionally fractionated CRT|conventionally fractionated concurrent chemoradiotherapy
11301688|NCT02688023|Experimental|single-arm Irinotecan-Oxaliplatin-5-Fluorouracil/leucovorin|Irinotecan,oxaliplatin and 5-fluorouracil/leucovorin(5-fluorouracil/leucovorin can be substituted with Capecitabine or S-1)
11301689|NCT02688010|No Intervention|Control|No specific noise reduction strategies to restrict noise exposure less than 45 dB combined with either continuous bright light or continuous near darkness or unstructured combination of the two during the hospitalization.
11301690|NCT02688010|Experimental|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
11301691|NCT02687997|Experimental|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
11301692|NCT02687997|No Intervention|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
11301693|NCT02687984|Experimental|RBP-7000 PLGH A|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
11301694|NCT02687984|Experimental|RBP-7000 PLGH B|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
11301695|NCT02687984|Active Comparator|RBP-7000 PLGH C|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
11301696|NCT02687971|Active Comparator|Thermotherapy alone|"Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30 applications will be used. Depending on the size of the lesion, more than one application may be administered."
11301697|NCT02687971|Experimental|Thermotherapy plus Miltefosine|"In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.
~The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day)."
11301698|NCT02687958|Experimental|A Everolimus 10mg (every cycle) until PD|Patients with stable disease, partial response or complete response after 4- 6 cycles of induction chemotherapy with Cisplatin or Carboplatin plus Etoposide or alternative first line chemotherapy according with local practice will receive maintenance therapy with Everolimus 10mg every cycle (28days) until PD or unacceptable toxicity.
11301699|NCT02687958|No Intervention|B Observational|Patients in this arm will meet observation criteria
11301700|NCT02687945|Active Comparator|Outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of outpatient physiotherapy with 2-3 weekly sessions
11341157|NCT02426905|No Intervention|Retrospective|
11301704|NCT02687919|Experimental|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
11301705|NCT02687919|No Intervention|Usual Care|Typical physician recommendations for MS.
11301706|NCT02687906|Experimental|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours
~The starting dose for Cohort 1 (ages 12 to <18 years) was 40 mg/kg meropenem and 40 mg/kg vaborbactam, or 2 g meropenem 2 g vaborbactam for subjects ≥50kg in weight. Following completion of Cohorts 1 and 2 an independent DSMB assessed the PK, safety and tolerability data and determined that the new starting dose for Cohort 3 (ages 2 to < 6 years) would be 60 mg/kg or 2 g meropenem 2 g vaborbactam for subjects >33 kg in weight."
11301707|NCT02687893|Experimental|Aerobic Exercise Week|Subjects will complete 45 minutes of aerobic exercise twice during a 7 day period. Exercise will be graded based on the participant's relative capacity determined at the screening visit. Each exercise session will be followed by 60 minutes of monitored resting recovery.
11301708|NCT02687893|Experimental|Resistance Exercise Week|Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
11301709|NCT02687893|No Intervention|No Exercise Week|Subjects will perform no exercise during this week.
11301710|NCT02687880||All Subjects|"All subjects will undergo a surgical procedure (Testicular biopsy) to harvest their testicular tissue. In most cases, this will be done as part of their routine care but it is possible the subject may elect to have the procedure as part of a research only biopsy."
11301711|NCT02687867||Dabigatran|Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.
11301712|NCT02687867||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
11301713|NCT02687854||Apixaban|Non-valvular atrial fibrillation patients who were initiated on apixaban for stroke prevention
11301714|NCT02687854||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on Vitamin K antagonist for stroke prevention
11301715|NCT02687841|Experimental|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
11301716|NCT02687841|Active Comparator|PTX|Pentapentoxifylline 400mg QD for 10 days
11301717|NCT02687828||Subjects receiving adalimumab|The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.
11301718|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
11301719|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
11301720|NCT02687802||Mechanical ventilation|Patients under mechanical ventilation for more than 24h
11301721|NCT02687789|Experimental|Medical Device: WO3191|The vaginal suppository is used for the reduction and/or inhibition of vaginal biofilms that were shown to be related to recurrent bacterial vaginosis.
11301722|NCT02687789|Active Comparator|Medical Device: Vagisan® Lactic Acid|It is used for the maintenance and restoration of a natural pH level in the vagina. The acidification of the vaginal milieu with lactic acid promotes the growth of typical vaginal flora (lactic acid bacteria) and is unfavourable for the growth of pathogens in the vagina. Vagisan® Lactic Acid is used in the post-treatment of bacterial vaginosis.
11301723|NCT02687763|Experimental|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
11301724|NCT02687750|Experimental|MRI|"Eppendorf tubes containing 10% fluorine-19 diluted in agar were taped to the upper thigh of participants. Investigational device was used to image the phantom with Magnetic resonance imaging (MRI). Imaging was performed for anatomical (proton) and fluorine (agent detection). Total scan time was under 1 hour.
~Objectives:
~Verify RF coil functionality
~Obtain preliminary detection threshold limits using a human coil loading"
11301725|NCT02687737|Experimental|Exercise|The participants will have the following tests performed: Maximum Expiratory Pressure (MEP), insertion of a fine-wire electromyography (EMG) electrode into the mid-line base of the tongue, will complete swallowing tasks and breathing tasks under Videofluoroscopy (fluoroscopy on only during the actual task)
11301726|NCT02687724|Active Comparator|Standard treatment as per SmPC|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
11301727|NCT02687724|Experimental|Intervention Arm|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
11301728|NCT02687698|Experimental|Ketogenic diet|Patients will be suggested to follow a ketogenic diet for 8 weeks.
11301729|NCT02687698|No Intervention|Control|Usual diet.
11301730|NCT02687685|Experimental|Skin to skin contact immediate|At birth, the baby will be placed and dried on the breast of his mother where thermoregulation manoeuvres will be applied and once the cord clamping procedure has taken place; the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least one hour or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, it will be allowed again after these interventions. During immediate SSC, mother and baby receive continuous monitoring by the health staff
11301759|NCT02687464|Active Comparator|Appendectomy group|Laproscopic appendectomy within 18 hrs of randomization. IV antibiotics given from time of randomization and continued post-operatively per the standardized treatment regimen: children with visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue IV antibiotics for a minimum of 3 days and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
11301731|NCT02687685|Active Comparator|skin to skin contact early|At birth, the baby will be dried and placed on the abdomen and chest of his mother where thermoregulation manoeuvres are applied once there is an indication that the cord clamp procedure has been completed. At this time the baby will go to the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby who has 60 minutes of life, will proceed with the initiation of SSC for at least one hour or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC the mother and baby will receive monitoring by health personnel
11301732|NCT02687672|Experimental|Stem Cell Transplantation|Injection of leukapheresis-derived, purified, autologous CD34+and CD133+ stem cells
11301733|NCT02687672|Experimental|Stem Cells|Injection of bone marrow-derived, purified, autologous CD34+and CD133+ stem cells.
11301734|NCT02687659|Experimental|Study group using TEMIS system|using TEMIS system during physical exercises: walking, biking, running
11301735|NCT02687646|Experimental|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
11301736|NCT02687633|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
11301737|NCT02687633|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
11301738|NCT02687620||AS patients receiving Anti-TNF treatment|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
11301739|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
11301740|NCT02687594||single group|sucroferric oxyhydroxide
11301741|NCT02687581|Experimental|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
11301742|NCT02687581|Active Comparator|6-hour patching|wear the eye patch for 6-hour
11301743|NCT02687555|Experimental|Intervention|Computerized Cognitive Bias Modification of Appraisals (CBM-App), developed from that used by Woud et al. (2012,2013). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
11301744|NCT02687555|Sham Comparator|Control|Computerized Peripheral Vision Task (PVT), developed from that used by Calkins et al. (2015). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
11301745|NCT02687542|Placebo Comparator|Placebo|Placebo
11301746|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
11301747|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
11301748|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
11301749|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
11301750|NCT02687529||Low Risk|Tested with CST001
11301751|NCT02687529||Known Risk|Tested with CST001
11301752|NCT02687516|Experimental|Family-based behavioral social facilitation therapy.|The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
11301753|NCT02687516|Active Comparator|Treatment as usual|The TAU condition involves an assessment day with the multidisciplinary team (pediatrician, dietician, physical therapist and psychologist) at the hospital obesity clinic. Further a session with the nurse at the hospital clinic making a plan for behavioral lifestyle changes followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital clinic every third month for 12 months. After 12 months they will be offered treatment by family-based behavioral social facilitation therapy (as in the other treatment arm).
11301754|NCT02687503|Other|Daily dose of probiotic|All children enrolled into the study will receive a daily dose of probiotic
11301755|NCT02687490|Experimental|Abraxane|Abraxane: 125 mg/m2, D1, D8, D15 every 28 days
11301756|NCT02687477|Sham Comparator|Sham procedure|Patients in the sham group will take sham procedure like PADN.
11301757|NCT02687477|Experimental|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
11301758|NCT02687464|Experimental|Non-operative treatment group|IV fluids, minimum 12 hrs IV antibiotics, minimum 12 hrs clear PO fluids only, regular clinical review. Discharge within 24 hrs after randomization, if study criteria met. If stable but not adequate improvement for discharge, non-operative management continues. If not improved by 48 hrs, appendectomy will be done. Discharge home once vital signs are within normal limits, light oral diet tolerated, adequate oral pain relief and mobile. Total 10 days of antibiotics (IV and oral) following randomization will be given. Antibiotics used vary between centers and will be current standard of care in that center; improving study feasibility and increased generalization of results.
11341158|NCT02426905|Other|Prospective|
11301760|NCT02687451|Experimental|Oxymorphone HCl Open-Label Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; open-label, single-dose, dose selection phase.
11301761|NCT02687451|Experimental|Oxymorphone HCl Multiple-Dose Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; placebo controlled, randomized, double-blinded multiple-dose phase.
11301762|NCT02687451|Placebo Comparator|Placebo|Sodium Chloride 0.9% solution; comparator for multiple-dose phase.
11301763|NCT02687438|Experimental|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
11301764|NCT02687425|Experimental|pioglitazone|The patients under the long-term treatment of imatinib mesylate acquire pioglitazone additionally.
11301765|NCT02687412|Experimental|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
11301766|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.
~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
11301767|NCT02687399|Experimental|TT-173|It will be sprayed using this syringe and a nozzle tip couplet to it one time over the surgical lesion surfaces on the exposed tissues of the knee
11301768|NCT02687399|Placebo Comparator|placebo|It will be sprayed over the surgical lesion surfaces on the exposed tissues of the knee
11301769|NCT02687386|Experimental|Mitoxantrone packaged EDV|Mitoxantrone packaged EDV (EnGeneIC Dream Vector)
11301770|NCT02687373|Experimental|Part 1: Grp 1A - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination."
11301771|NCT02687373|Placebo Comparator|Part 1: Grp 1A - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination."
11301772|NCT02687373|Experimental|Part 1: Grp 1B - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301773|NCT02687373|Placebo Comparator|Part 1: Grp 1B - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301774|NCT02687373|Experimental|Part 1: Grp 1C - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301775|NCT02687373|Placebo Comparator|Part 1: Grp 1C - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301776|NCT02687373|Experimental|Part 1: Grp 2A - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
11301777|NCT02687373|Placebo Comparator|Part 1: Grp 2A - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
11301778|NCT02687373|Experimental|Part 1: Grp 2B - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
11301779|NCT02687373|Placebo Comparator|Part 1: Grp 2B - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
11301780|NCT02687373|Experimental|Part 1: Grp 2C - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
11301781|NCT02687373|Placebo Comparator|Part 1: Grp 2C - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
11301782|NCT02687373|Experimental|Part 1: Grp 2D - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301837|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
11301838|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
11301783|NCT02687373|Placebo Comparator|Part 1: Grp 2D - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301784|NCT02687373|Experimental|Part 1: Grp 2E - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301785|NCT02687373|Placebo Comparator|Part 1: Grp 2E - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301786|NCT02687373|Experimental|Part 1: Grp 3A - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
11301787|NCT02687373|Placebo Comparator|Part 1: Grp 3A - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
11301788|NCT02687373|Experimental|Part 1: Grp 3B - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
11301789|NCT02687373|Placebo Comparator|Part 1: Grp 3B - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
11301790|NCT02687373|Experimental|Part 1: Grp 3C - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
11301791|NCT02687373|Placebo Comparator|Part 1: Grp 3C - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
11301792|NCT02687373|Experimental|Part 1: Grp 3D - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301793|NCT02687373|Placebo Comparator|Part 1: Grp 3D - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301794|NCT02687373|Experimental|Part 1: Grp 3E - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301795|NCT02687373|Placebo Comparator|Part 1: Grp 3E - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.
~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
11301796|NCT02687373|Experimental|Part 2: Group 1 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose."
11301797|NCT02687373|Experimental|Part 2: Group 2 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose."
11301798|NCT02687373|Experimental|Part 2: Group 3 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose."
11301799|NCT02687373|Placebo Comparator|Part 2: Group 4 - Normal Saline|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
~N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals."
11301800|NCT02687360|Active Comparator|Active rTMS stimulation|This arm will receive high-frequency rTMS pulses directed at the medial prefrontal and anterior cingulate cortices.
11301801|NCT02687360|Sham Comparator|Sham rTMS stimulation|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil and to produce activation of facial muscles similar to the effect of active rTMS without stimulating the brain itself.
11301802|NCT02687347|Experimental|study arm|low dose methadone (1-10mg daily)
11301803|NCT02687347|Active Comparator|control arm|low dose morphine (1-10 mg/day)
11301804|NCT02687334||Standard general anesthesia induction|Patients scheduled for elective surgery at the First Hospital of China Medical University will be recruited for the study beginning in February 2016.We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia
11301839|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
11301805|NCT02687321||Advanced ovarian cancer patients|Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study. The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence. In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
11301806|NCT02687308|Active Comparator|1Retrograde radical prostatectomy RRP|This opem surgical prostatectomy techniques described by Patrick Walsh is made through prostatic dissection, from apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
11301807|NCT02687308|Experimental|2Anterograde radical prostatectomy RRP2A|This opem surgical prostatectomy techniques dissect the prostate, bladder neck and the neurovascular bundle, in an antegrade way, from bladder neck to the apex. With careful bladder neck dissection and preservation, careful nervesparing procedures with meticulous retroprostatic dissection of the posterior layer of Denonvilliers' fascia, and urethrovesical anastomosis performed through a monofilament running suture.
11301808|NCT02687295|Placebo Comparator|Control group|Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
11301809|NCT02687295|Active Comparator|Thylakoid group|Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.
11301810|NCT02687269|Experimental|Ranolazine|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, Ranolazine at a dose of 375 mg twice daily.
11301811|NCT02687269|Placebo Comparator|Placebo|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, placebo twice daily.
11301812|NCT02687256|Experimental|Protocol 1: Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
11301813|NCT02687256|Experimental|Protocol 1: Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
11301814|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 1|Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
11301815|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 2|Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
11301816|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 3|Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
11301817|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 4|Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
11301818|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 5|Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
11301819|NCT02687256|Experimental|Protocol 2 (Part 2): Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
11301820|NCT02687256|Experimental|Protocol 2 (Part 1): Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
11301821|NCT02687243|Experimental|Interactive Virtual Application|Online application
11301822|NCT02687243|No Intervention|Standard of Care|No intervention and Hospital Standard of Care
11301823|NCT02687230|Experimental|Cohort 1|Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
11301824|NCT02687230|Experimental|Cohort 2|Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
11301825|NCT02687230|Experimental|Cohort 3|Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
11301826|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
11301827|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
11301828|NCT02687204|Active Comparator|Enoxaparin prophylaxis|All enrolled patients will receive twice daily enoxaparin prophylaxis. Patients with identified out of range peak anti-Xa levels will receive real time dose adjustment and will be considered as the experimental arm.
11301829|NCT02687204|Experimental|Real time dose adjustment|Patients with identified out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment
11301830|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
11301831|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
11301832|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
11301833|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
11301834|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
11301835|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
11301836|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
11301840|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
11301841|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
11301842|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
11301843|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
11301844|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
11301845|NCT02687178|Active Comparator|Canrenone 50 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
11301846|NCT02687178|Active Comparator|Canrenone 100 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
11301847|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
11301848|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
11301849|NCT02687152|Experimental|Arginase inhibition|N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min
11301850|NCT02687139|Experimental|18F-DCFPyL PET/CT|
11301851|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
11301852|NCT02687113|Other|CT/US fusion|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.
~Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
11301853|NCT02687100|Experimental|Beclomethasone|Patients will receive beclomethasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning. The solution will be aspirated 15 minutes after the instillation.
11301854|NCT02687100|Placebo Comparator|Placebo|Patients will receive 8 mL of saline without any drug.
11301855|NCT02687087|Experimental|Visco-ease|Visco-ease is a suspension of multilamellar vesicles comprising lipids in ratios which mimic the lipidic composition of endogenous extra-alveolar lamellar bodies. Visco-ease is suspended in physiological saline (0.9% NaCl) to provide a final dose concentration of 19.6 mg/mL. Visco-ease is a white to off-white turbid suspension. The device under evaluation in this clinical investigation is Visco-ease at a concentration of 19.6 mg/mL.
11301856|NCT02687087|Placebo Comparator|RIX-Placebo|Physiological Saline (sodium chloride 0.9% (w/v)
11301857|NCT02687074|Experimental|Intubation rate on 28 days|patients with respiratory failure treat with HFNC or NIV and intubation rate on 28 days
11301858|NCT02687061||Chronic hepatitis B|Patients diagnosed with chronic hepatitis B
11301859|NCT02687061||Chronic hepatitis C|Patients diagnosed with chronic hepatitis C
11301860|NCT02687048|Active Comparator|EX protocol|Participants will receive a revised version of the Otago exercise program (OEP) - an individualized home-based exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week. The exercises are for strength and balance and are gradually progressed over the course of the study to meet the individual's abilities.
11301861|NCT02687048|Experimental|EX Plus protocol|"These participants will receive mindful meditation coaching via 6 one-hour small group sessions with an experienced meditation instructor. They will also be expected to practice mindful meditation at home following online audio recordings (free of charge from University of California, Los Angeles; http://marc.ucla.edu/body.cfm?id=22) and written instructions a minimum of five times per week for 30 minutes. Participants will complete a meditation log to record their practice.
~These participants will also receive the same revised version of the Otago exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week."
11301862|NCT02687035|Experimental|SAPIEN 3|Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system
11301863|NCT02687022|Experimental|Myopia (Peramis)|Peramis aberrometry: 30 consecutive LASIK candidates with myopia and regular astigmatism who agree to participate in the study will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer.
11301864|NCT02687022|Active Comparator|Myopia (iDesign)|iDesign aberrometry: The same 30 consecutive LASIK candidates scanned in the Myopia (Peramis) arm will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
11301865|NCT02687022|Experimental|Irregular astigmatism (Peramis)|Peramis aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer
11301866|NCT02687022|Active Comparator|Irregular astigmatism (iDesign)|iDesign aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
11301867|NCT02687009|Experimental|Niclosamide|
11301868|NCT02686996|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (2 tablets twice daily) for 14 weeks
11301869|NCT02686996|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of identical placebo tablets ( 2 tablets twice daily) for 14 weeks
11301870|NCT02686983|Experimental|Active|Betamethasone and local anesthetic.
11301871|NCT02686983|Placebo Comparator|Placebo|Saline with local anesthetic.
11301872|NCT02686957||women closed|"This cohort will include women who underwent repair for obstetric fistula at three fistula repair hospitals in Guinea and who had a closed fistula at hospital discharge.
~no intervention will be done."
11301991|NCT02686047|Active Comparator|The Synvisc-One group|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
11302257|NCT02684318|Experimental|Dose Level 1|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 100 mg BID
11301873|NCT02686944|Experimental|Intuvax (ilixadencel)|"Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12).
~Max 10 000 000 allogeneic dendritic cells/ml per injection."
11301874|NCT02686931||Control|Control: Normal developmental children with orthopedic disease
11301875|NCT02686931||Experimental|Experimental: Developmental delayed children
11301876|NCT02686918|Experimental|consultation by Advanced Practice Nurse.|During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
11301877|NCT02686905|Experimental|Topical vitamin patch|Dietary Supplement: PatchMD Vitamin D3/Calcium Patch Dietary Supplement: PatchMD Multivitamin Patch Dietary Supplement: PatchMD B12 Energy Plus Patch
11301878|NCT02686905|Experimental|Oral vitamins|Dietary Supplement: Chewable Multivitamin with Iron Dietary Supplement: Chewable Calcium Dietary Supplement: Quick Dissolve B12
11301879|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
11301880|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
11301881|NCT02686879|No Intervention|Natural progession|Following the natural progression of axial growth and refractive error.
11301882|NCT02686879|Experimental|Anisohyperopes - intervention eye|The more hyperopic eye will be fitted with a centre-near multifocal contact lens
11301883|NCT02686879|Experimental|Hyperopes|Both eyes will be fitted with centre-near multifocal contact lenses.
11301884|NCT02686879|Experimental|Anisohyperopes - fellow eye|The less hyperopic eye will be fitted with a single vision contact lens if required.
11301885|NCT02686866|Experimental|Body composition measurement|All patients will undergo body composition measurement with dual-energy X-ray absorptiometry and bioelectrical impedance analysis methods. Hand grip strength will also be performed.
11301886|NCT02686853|Experimental|Intrathecal administration group|
11301887|NCT02686840|Experimental|sublingual misoprostol|Group A (100 patients): will be treated with sublingual misoprostol
11301888|NCT02686840|Active Comparator|vaginal misoprostol|Group B (100 patients): will be treated with vaginal misoprostol
11301889|NCT02686827|Experimental|Paricalcitol (Vitamin D3)|paricalcitol, (Zemplar® 5 μg/ml Abbvie), will be administered via the subcutaneous route 4 times at 0.5 ml (registered dose of 5 μg/ml, thus 2.5 μg per sub-cutaneous injection). The minimum time interval between two injections is 4 days, which is a significantly lower frequency than the prescribed maximum of 3 times a week or every other day.
11301890|NCT02686827|Active Comparator|Placebo|Placebo, the same constituents as Zemplar (propylene glycol 30% (v/v) alcohol 20% (v/v)) but no paricalcitol, same dosage as verum-arm.
11301891|NCT02686814|Experimental|MDT-2215|17mm MDT-2215 aortic valve bioprosthesis
11301892|NCT02686788|Experimental|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
11301893|NCT02686775|Experimental|Patient coach|Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
11301894|NCT02686775|Active Comparator|Standard treatment|Standard care.
11301895|NCT02686762|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
11301896|NCT02686762|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
11301897|NCT02686762|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
11301898|NCT02686749|Active Comparator|AF catheter Ablation|Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
11301899|NCT02686749|Active Comparator|FDA approved anti arrhythmic drug|FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.
11301900|NCT02686736|Other|Internet-based educational intervention|The Internet-based educational intervention will include four educational sessions that will be provided during a four-week period. The follow up will last three-months.
11301901|NCT02686736|No Intervention|Control group|In the control group, teens will continue the usual school provided sexual education and will be invited to answer the internet-based self-applied questionnaire at the same time as the intervention group.
11301902|NCT02686723|Experimental|ACL injury|Subjects who has ACL injury repaired and who were allowed to return to sport
11301903|NCT02686723|Active Comparator|Healthy subjects|Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)
11301904|NCT02686710|Active Comparator|VIMA|Patiens receiving volatile induction and maitenance of anesthesia
11301905|NCT02686710|Active Comparator|TIVA|Patiens receiving total intravenous anesthesia based on propofol
11301906|NCT02686710|Active Comparator|Combi|Patiens receiving total intravenous induction and volatile anesthesia
11301907|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
11301908|NCT02686697|Placebo Comparator|Placebo|matching placebo
11301909|NCT02686684||Dimethyl Fumarate|MS patients who started treatment with dimethyl fumarate
11301910|NCT02686684||Healthy Control|
11301911|NCT02686658|Experimental|Dose Group 1|Zimura Dose Administration 1
11301912|NCT02686658|Experimental|Dose Group 2|Zimura Dose Administration 2
11301913|NCT02686658|Sham Comparator|Dose Group 3|Sham Administration 1
11301914|NCT02686658|Experimental|Dose Group 4|Zimura Dose Administration 3
11301915|NCT02686658|Experimental|Dose Group 5|Zimura Dose Administration 4
11301916|NCT02686658|Sham Comparator|Dose Group 6|Sham Administration 2
11301917|NCT02686645|Experimental|Fecal Microbiota Therapy|Vancomycin 125 mg po qid for 7 days or metronidazole 500 mg po tid for 7 days pre-treatment. Loperamide 4 mg po after morning prep and 2 mg post treatment. The route of administration fecal microbiota will be by retention enema via a rectal tube.
11301918|NCT02686632|Experimental|Palate Brushing|"In this group the intervention is palatal brushing, performed by the participants following each meal for a period of 6 months. This will be performed using the provided toothbrush (device). The results will determine if brushing the palate in an efficient intervention for reducing the microbial count and inflammation associated with denture stomatitis."
11301919|NCT02686632|No Intervention|Regular Oral Hygiene|The participants in this study arm will not be prescribed or allocated any intervention. The participants will be asked to continue with the regular hygiene and denture maintenance practices for the duration of the trial.
11301920|NCT02686619|Active Comparator|Mycophenolate Mofetil + Cyclosporine|Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.
11301921|NCT02686619|Experimental|Mycophenolate Mofetil + Sirolimus|Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
11301922|NCT02686606|Experimental|Vital 1.5|200ml orally over 30 minutes
11301923|NCT02686606|Active Comparator|Ensure Plus|200ml orally over 30 minutes
11301924|NCT02686606|Experimental|Elemental 028|200ml orally over 30 minutes
11301925|NCT02686606|Active Comparator|water|200ml orally over 30 minutes
11301926|NCT02686593|Other|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
11301927|NCT02686580|Experimental|Collagen paste|Injection of Permacol Collagen paste into the fistula tract.
11301928|NCT02686567|Active Comparator|with TDT|with TDT
11301929|NCT02686567|Active Comparator|without TDT|without TDT
11301930|NCT02686554||AD patients|
11301931|NCT02686554||AD patients immunized|
11301932|NCT02686528|Experimental|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
11301933|NCT02686528|Active Comparator|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
11301934|NCT02686515|Active Comparator|Single-task balance training group|Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
11301935|NCT02686515|Experimental|Dual-task balance training group|Participants in the dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks. They will perform a cognitive task or motor task concurrently with the balance/gait task. The framework of progressive balance exercises in the dual-task training group will be progressed from simple to more complex tasks as outlined for the single-task training group. In addition, a variety of added tasks will be progressively integrated into the dual-task balance training program.
11301936|NCT02686502|No Intervention|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
11301937|NCT02686502|Active Comparator|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
11301938|NCT02686502|Active Comparator|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
11301939|NCT02686489|Experimental|Heated humidification (HH)|Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
11301940|NCT02686489|Active Comparator|Cool bland aerosol (LVN)|Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.
11301941|NCT02686476|Active Comparator|Empagliflozin dose group|Patient Receive Standard of Care with Empagliflozen
11301942|NCT02686476|No Intervention|Standard dose group|Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin
11301943|NCT02686463|Experimental|the laparoscopy group|Patients who are randomized to the laparoscopy group.
11301944|NCT02686463|Experimental|the laparotomy group|Patients who are randomized to the laparotomy group.
11301945|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:
~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
11301946|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
11301947|NCT02686411||Participant in Palliative Care Unit (PCU)|"Participants complete 2 questionnaires after being transferred to the PCU.
~Two (2) weekdays after completion of first set of questionnaires, 2 more questionnaires completed."
11301948|NCT02686411||Caregiver of Participant in Palliative Care Unit (PCU)|"Caregiver of participant complete 2 questionnaires after participant transferred to the PCU.
~Two (2) weekdays after completion of first set of questionnaires, 2 questionnaires completed."
11301949|NCT02686398|Active Comparator|Fluad|88 CKD patients were vaccinated with Fluad.
11301950|NCT02686398|Active Comparator|Agrippal|86 CKD patients were vaccinated with Agrippal.
11301992|NCT02686034|Active Comparator|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
11301951|NCT02686385|Experimental|Prednisolone + N-Acetylcysteine|Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
11301952|NCT02686385|Active Comparator|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
11301953|NCT02686372|Experimental|HBV/TCR-T cell|Biological: HBV antigen specific TCR redirected T cell infusion.
11301954|NCT02686359|Experimental|Burning Mouth Syndrome Patients|saliva, blood and urinary samples
11301955|NCT02686359|Active Comparator|controls|saliva, blood and urinary samples
11301956|NCT02686346|Experimental|BV-ICE|"Phase I:
~4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;
~Phase II:
~4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4"
11301957|NCT02686333|Experimental|Meditation Intervention Arm|10-15 minute meditation practices (brief silent meditations, guided meditations, body scans, gentle arm movement exercises). Before each session, the interventionist will perform a brief check in, and may discuss the patient's experience with them for 1-2 minutes after the intervention. Patients will be encouraged to practice the techniques at home between sessions. Patients will also be offered literature on mental health promotion.
11301958|NCT02686333|No Intervention|Control Group (No Meditation Exposure)|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as Usual in the dialysis setting.
11301959|NCT02686320||Rheumatoid arthritis >65 years old|
11301960|NCT02686320||Rheumatoid arthritis <50 years old|
11301961|NCT02686307||ICD Implant|All patients receiving a dual chamber ICD
11301962|NCT02686294|Experimental|T-R|First period : administration of test drug Second period : administration of reference drug
11301963|NCT02686294|Experimental|R-T|First period : administration of reference drug Second period : administration of test drug
11301964|NCT02686281|Experimental|Cohort A (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Other: Placebo"
11301965|NCT02686281|Experimental|Cohort B (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo
~Interventions:
~Drug: GMC-252-L-Lysine Other: Placebo
~The dose administered in Part A (fed) was based on the outcome of Part A (fasted)."
11301966|NCT02686268||Individuals diagnosed with known positive C9ORF72 ALS|Individuals diagnosed with known positive C9ORF72 ALS
11301967|NCT02686255||Children 0-18 months post heart surgery|complete blood count for all children 0-18 months going through cardiac surgery
11301968|NCT02686242||spinal anesthesia|patients receive spinal anesthesia before general anesthesia
11301969|NCT02686242||general anesthesia|patients receive general anesthesia
11301970|NCT02686216|Experimental|F-18 THK-5351|F-18 THK-5351 imaging
11301971|NCT02686203|Experimental|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).
~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment."
11301972|NCT02686190|Experimental|Luxtherapy|Luxtherapy exposition
11301973|NCT02686190|No Intervention|Not luxtherapy|Not luxtherapy exposition
11301974|NCT02686177|Experimental|1: Liraglutide|Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
11301975|NCT02686177|Active Comparator|2: Add on oral antidiabetic medication|Metformin or sulfonylurea depending on monotherapy
11301976|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
11301977|NCT02686151|Active Comparator|letrozole|2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
11301978|NCT02686151|Other|Polygeline Injection|500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days
11301979|NCT02686138|Experimental|50mg BID|Tenapanor, 50mg BID (100mg total)
11301980|NCT02686138|Placebo Comparator|Placebo|Placebo
11301981|NCT02686099|Experimental|SternaLock 360|Sternal closure performed with SternaLock 360 as a primary closure system
11301982|NCT02686099|Active Comparator|Wire Cerclage|Sternal closure performed with standard wire cerclage as a primary closure system
11301983|NCT02686086|Placebo Comparator|Standard hospital jet nebuliser|"Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser.
~Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation."
11301984|NCT02686086|Active Comparator|Vibrating mesh nebuliser|Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
11301985|NCT02686073||Group A|Underweight participants whose body mass index is less than 18.5 kg/m2
11301986|NCT02686073||Group B|Control group, in which the participants belong to the normal body mass index range , from 18.5 to 29.9 kg/m2
11301987|NCT02686073||Group C|Obese participants whose body mass index is more than or equal to 30 kg/m2.
11301988|NCT02686060|Experimental|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
11301989|NCT02686060|No Intervention|without in-line filters.|
11301990|NCT02686047|Experimental|the HYAJOINT Plus group|the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
11302258|NCT02684318|Experimental|Dose Level 2|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 150 mg BID
11301993|NCT02686034|Sham Comparator|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
11301994|NCT02686021|Experimental|Metamizole and Ibuprofen|all patients (n=42) will receive metamizol and ibuprofen in one session. In the other session half will receive metamizol and placebo (n=21) and the other half will receive ibuprofen and placebo. The order will be randomized (balanced).
11301995|NCT02686021|Active Comparator|Metamizole and Placebo|"This is one of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
11301996|NCT02686021|Active Comparator|Ibuprofen and Placebo|"This is the second of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
11301997|NCT02686008|Experimental|HPV negative tumors|10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
11301998|NCT02686008|Experimental|HPV positive tumors|10 patients with HPV positive tumors: p16 positive and HPV positive tumors
11301999|NCT02685995|Active Comparator|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
11302000|NCT02685995|Active Comparator|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
11302001|NCT02685982|Experimental|Rhythmic Sensory Stimulation|Participants in this group will undertake 30 minutes of daily Rhythmic Sensory Stimulation, for 5 day per week, for a total of 5 weeks. The stimulation consists of specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range. The intervention is conducted at the participant's home using a portable device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit. This device is a low-voltage consumer product device that has built in low frequency (subwoofer-type) speakers. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration that is synchronized with the relaxing musical track.
11302002|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol & 18F-FDG PET scans.
11302003|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
11302004|NCT02685943|Experimental|CAMS treatment|Psychotherapy using the Collaborative Assessment and Management of Suicidality framework
11302005|NCT02685943|Active Comparator|Treatment as usual|Ordinary treatment for suicidal patients
11302006|NCT02685930||Pneumonia without ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Antibiotic choice and duration of therapy will not be influenced by the dedicated ICU stewardship team.
11302007|NCT02685930||Pneumonia with ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Recommendations for antibiotic choice and duration of therapy will be provided by the dedicated ICU stewardship team (consisting of pulmonary fellows and ICU pharmacists)
11302008|NCT02685917|Experimental|Microfracture with Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
11302009|NCT02685917|Active Comparator|Microfracture without Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
11302010|NCT02685904|Experimental|ENIA11|25 mg of ENIA11 subcutaneously administered twice weekly
11302011|NCT02685904|Placebo Comparator|Placebo|25 mg of Placebo subcutaneously administered twice weekly
11302012|NCT02685891|Active Comparator|playing tones|During slow-wave sleep short tones (50ms, 50dB) will be played
11302013|NCT02685891|Sham Comparator|Playing no tones|During slow-wave sleep no tones will be played
11302014|NCT02685865|Active Comparator|FCSEM Stent|WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
11302015|NCT02685865|Active Comparator|Plastic Stents|WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
11302016|NCT02685852|Active Comparator|Arm 1: Exenatide (5mcg)|Exenatide at a dose of 5 mcg
11302017|NCT02685852|Active Comparator|Arm 2: Exenatide (5mcg) + Acarbose (25mg)|Exenatide (5mcg) + Acarbose (25mg)
11302018|NCT02685852|Placebo Comparator|Arm 3: Placebo|Placebo
11302019|NCT02685839|Active Comparator|Traditional rehabilitation|"Each subject will do traditional rehabilitation work two times per week and one hour at a time
~, lasting 24 weeks."
11302020|NCT02685839|Experimental|Power rehabilitation|Each subject will do Power rehabilitation work with motion tracking and biofeedback recording two times per week and one hour at a time, lasting 24 weeks.
11302021|NCT02685826|Experimental|Cohort A: High risk, TNE|"High risk, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were administered
~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle
~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle
~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
11302022|NCT02685826|Experimental|Cohort B: >=65 years old, TNE|">= 65 years old, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered
~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle
~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle
~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
11302023|NCT02685826|Experimental|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:
~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle
~Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
11302024|NCT02685813||Pregnant women in Denmark|Pregnant women in Denmark participating in prenatal screening. This counts for approximately 50000 pregnancies/year and covers >95% of all pregnancies nationally.
11302025|NCT02685787|Experimental|Psychosocial Intervention|Every caregiver in this arm will be assigned to a permanent counselor.
11302026|NCT02685787|Active Comparator|Educational Intervention on AD|The caregiver enrolled in this arm will not be assigned to a counselor but will participate to group sessions on AD education.
11302027|NCT02685774|Other|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
11302028|NCT02685774|Other|TR group|T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
11302029|NCT02685761|No Intervention|Low Transverse|Patients in this arm will undergo their cesarean section using the standard low transverse skin incision location
11302030|NCT02685761|Experimental|Midline Vertical|Patients in this arm will undergo their cesarean section using a midline vertical skin incision
11302031|NCT02685761|Experimental|High Transverse|Patients in this arm will undergo their cesarean section using a high transverse skin incision, above the pannus
11302032|NCT02685748|Experimental|Aspirin & pantoprazole|"Aspirin 1000 mg/pd per os in two doses
~Pantoprazole 40 mg/pd per os in two doses for gastric protection"
11302033|NCT02685748|Placebo Comparator|Placebo|"Two pills in the morning and two in the evening
~All pills (aspirin, pantoprazole an placebo) will be the same looking- in the same capsules."
11302034|NCT02685735|Active Comparator|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
11302035|NCT02685735|Placebo Comparator|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
11302036|NCT02685722|Experimental|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
11302037|NCT02685722|Experimental|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
11302038|NCT02685709|Experimental|Run-in phase|Oral octreotide capsules
11302039|NCT02685709|Experimental|RCT phase - Oral|Oral octreotide capsules
11302040|NCT02685709|Active Comparator|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
11302041|NCT02685709|Experimental|Combination phase (sub-study)|Octreotide capsules plus cabergoline
11302042|NCT02685696|Experimental|Alexis O Retractor|Group 1 received the Alexis-O-Retractor at thet time of first Caesarean Section
11302043|NCT02685696|Active Comparator|Metal Retractor|Group 2 received the traditional self retaining metal Retractor at thet time of first Caesarean Section
11302044|NCT02685683|Experimental|GED-0301 Induction (160mg) followed by intermittent 160 mg|"GED-0301 160 mg by mouth (PO) daily (QD) for 12 weeks, followed by alternating GED 0301 160 mg QD for 4 weeks and no IP for 4 week, up to Week 100"
11302045|NCT02685670|Experimental|Mixed CD19CAR transfer|All subjects will be infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number
11302046|NCT02685657|Experimental|AC followed by Docetaxel with Selumetinib|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle, 75 mg of SELUMETINIB twice a day PO on days 1-21 of every 3 week cycle
11302047|NCT02685657|Active Comparator|AC followed by Docetaxel|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle
11302048|NCT02685644||Laparoscopic removal|Patients with endometrioma who will undergo laparoscopic removal of cysts.
11302049|NCT02685631||Observational/data registry collection|Patients receiving Yttrium-90 resin microspheres as part of care
11302050|NCT02685618|Experimental|Iloprost + M1006B offset by -10 mmHg|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg
~Intervention: Drug: Iloprost + M1006B offset -10mmHg"
11302051|NCT02685618|Experimental|Iloprost + M1006B, No offset|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset
~Intervention: Drug: Iloprost + M1006B, No offset"
11302052|NCT02685618|Placebo Comparator|Placebo + M1006B offset by -10 mmHg|"Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg
~Intervention: Drug: Placebo + M1006B offset -10mmHg"
11302053|NCT02685618|Placebo Comparator|Placebo + M1006B, No offset|"Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset
~Intervention: Drug: Placebo + M1006B, No offset"
11302054|NCT02685605|Experimental|Experimental Arm (A)|Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
11302055|NCT02685605|Active Comparator|Control Arm (B)|Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
11302056|NCT02685592|Experimental|Lentigo maligna patients|All the participants with histologically confirmed lentigo maligna will receive photodynamic therapy three times with 2 weeks' intervals. The borderline of treatment area is delineated with Wood's lamp and hyperspectral imaging system using 5 millimeter margins. Before applying the 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) light sensitizing gel the skin of treatment area is prepared with fractional ablative CO2-laser to enhance absorption. Ameluz® is spread as a 1 millimeter thick layer on the skin. After light sensitizer absorption the treatment area is illuminated with artificial red light (Aktilite CL128 lamp) using a light dose of 90 J/cm2. Finally 4 weeks after the last PDT treatment LM is excised surgically using 5 mm margins.
11302057|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
11302058|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
11302059|NCT02685553|Experimental|1|Use of NIR
11302060|NCT02685514|Experimental|HIFU Graves|Applying the High intensity Focused Ultrasound treatment to the relapsed Graves' disease Patients.
11302061|NCT02685501||Combat women soldiers|Women soldiers in combat units
11302062|NCT02685501||Non combat women soldiers|Women soldiers in non-combat units
11302063|NCT02685488|Active Comparator|Transcranial Ultrasound Power|Transcranial Ultrasound Power
11302064|NCT02685488|Sham Comparator|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
11302065|NCT02685475||Diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
11302066|NCT02685475||Non-diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
11302067|NCT02685462|Active Comparator|Group 1 (Rosuvastatin)|Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.
11302068|NCT02685462|Active Comparator|Group 1 (Digoxin)|Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.
11302069|NCT02685462|Active Comparator|Group 1 (Caffeine)|Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.
11302070|NCT02685462|Active Comparator|Group 2 (Atorvastatin)|Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.
11302071|NCT02685462|Experimental|Cenicriviroc|"Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12.
~Subjects in Group 3 will receive Cenicriviroc on Days 2-12."
11302072|NCT02685462|Active Comparator|Group 3 (Simvastatin)|Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.
11302073|NCT02685449|Placebo Comparator|group A|"On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal.
~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
11302074|NCT02685449|Active Comparator|group B|"On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal.
~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
11302075|NCT02685436|Other|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
11302076|NCT02685423|Experimental|Visual Deprivation - 10 days|10 days of visual deprivation followed by vision training
11302077|NCT02685423|Active Comparator|Vision Training Only|Vision training without visual deprivation
11302078|NCT02685410|Experimental|One Night Stan Pilot Testing Group|The pilot testing of the One Nigh Stan prototype intervention will utilize 20 young black women aged 18-24 as participants.
11302079|NCT02685397|Active Comparator|LHRH agonist + Enzalutamide|Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)
11302080|NCT02685397|Experimental|LHRH agonist + Enzalutamide + SBRT|Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment
11302081|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
11302082|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
11302083|NCT02685371||Breathing effort type|Current known criteria for constrictive pericarditis will be test under: 1- spontaneous breathing 2- Breathing with a negative pressure of -15 to - 30 cm of water 3- Breathing with a negative pressure of more than - 30 cm of water.
11302259|NCT02684318|Experimental|Dose Level 3|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 200 mg BID
11302084|NCT02685358|Experimental|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consisted of 4 brief sessions over 8 weeks.
11302085|NCT02685358|Active Comparator|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
11302086|NCT02685345|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days
11302087|NCT02685345|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days
11302088|NCT02685345|Placebo Comparator|placebo|placebo tablets, orally, once daily for up to 28 days
11302089|NCT02685332|Experimental|Stereotactic Radiation|Single Fraction Stereotactic Radiation. Cohort 1: 22.5 Gy Cohort 2: 25 Gy Cohort 3: 27.5 Gy Cohort 4: 30 Gy
11302090|NCT02685319|Experimental|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
11302091|NCT02685306|Active Comparator|Taxane|Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
11302092|NCT02685306|Experimental|Bavituximab plus Taxane|Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
11302093|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
11302094|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
11302095|NCT02685280|Experimental|DBS for psychiatric disorders patients|Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention
11302096|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
11302097|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
11302098|NCT02685254|Experimental|Initial group therapy|'Structural skills training group' - Start up with weekly structured skills training group for 14 weeks supplemented by homework training
11302099|NCT02685254|Other|Initial control condition|Treatment as usual/clinical management the first 15 weeks pending deferred start of group therapy (partially cross-over)
11302100|NCT02685241||General population|General population
11302101|NCT02685228|Experimental|decitabine & gemcitabine|"This group was treated by low dose decitabine combinated with gemcitabine regimen. decitabine: 5mg/m2 d1-d5; gemcitabine: 1.0g/m2,d8,d15,d22. 28days for one cycle.
~every 28days for one cycle"
11302102|NCT02685228|Active Comparator|gemcitabine|This group was treated by gemcitabine only. Gemcitabine: 1.0g/m2, d8,d15,d22; 28 days for one cycle. every 28days for one cycle
11302103|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
11302104|NCT02685189||0.75 mg/kg Previous exposure to stannsoporfin|Previous exposure 0.75 mg/kg
11302105|NCT02685189||1.5 mg/kg Previous exposure to stannsoporfin|Previous exposure 1.5 mg/kg
11302106|NCT02685176|Experimental|No Heat|No active heating will be provided post cooling
11302107|NCT02685176|Experimental|Head|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the head following cooling
11302108|NCT02685176|Experimental|Torso|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the torso following cooling
11302109|NCT02685163|Experimental|Antioxidant Ice-cream|Natural antioxidant Ice-cream
11302110|NCT02685163|Placebo Comparator|Control Ice-cream|Natural control ice-cream
11302111|NCT02685150|Experimental|Functional dyspepsia|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice and those who fulfill with Rome III criteria for functional dyspepsia are to be classified into this group.
11302112|NCT02685150|Experimental|Acid reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice. Participants with acid reflux are to confirmed by Omeprazole test, one kind of proton-pump inhibitor (PPI) tests.
11302113|NCT02685150|Experimental|Bile reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging and Analysis of gastric juice. Participants with bile reflux are to be confirmed by Analysis of gastric juice.
11302114|NCT02685150|Experimental|Health volunteers|Health volunteers for routine checkup. Participants are to undergo Endoscopic Tri-Modal Imaging as well as Analysis of gastric juice and those who show no abnormal findings are to be classified into this group.
11302115|NCT02685137|Experimental|Active drug-Stannsoporfin|"Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice
~20 mg/mL 1.5 mL/vial"
11302116|NCT02685137|Sham Comparator|Reference Therapy-Sham|Sham Injection, no injection followed by a Band-Aid to thigh
11302117|NCT02685124|Experimental|Bahia orange juice|250 ml twice daily for 7 days
11302118|NCT02685124|Experimental|Cara Cara orange juice|250 ml twice daily for 7 days
11302119|NCT02685124|Placebo Comparator|Isocaloric control drink|250 ml twice daily for 7 days
11302120|NCT02685111|Active Comparator|A. Pegfilgrastim|D2 once a cycle pegfilgrastim arm
11302121|NCT02685111|Experimental|B. Filgrastim|Intermittent Every Other Days of 5 Shot (D3-11) filgrastim arm
11302122|NCT02685098|Experimental|Active/Treatment Group|Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.
11302123|NCT02685098|No Intervention|Observation Group 1|Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.
11302124|NCT02685098|No Intervention|Observation Group 2|"Tissue Collection Group:
~Amputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation."
11302260|NCT02684318|Experimental|Dose Level 4|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 250 mg BID
11302125|NCT02685098|No Intervention|Observation Group 3|Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.
11302126|NCT02685098|No Intervention|Control Group 4|Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur.
11302127|NCT02685085|Experimental|Misoprostol|in this group misoprostol 25 ug will be administrated for induction of labor every 6 hours
11302128|NCT02685085|Experimental|Foley's catheter|In this group foley's catheter 30 cc will be used for induction of labor
11302129|NCT02685085|Experimental|Combined|Both misoprostol 25 ug and foley's catheter will be used for induction
11302130|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
11302131|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
11302132|NCT02685059|Experimental|MEDI4736|part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks
11302133|NCT02685059|Placebo Comparator|Placebo|part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks
11302134|NCT02685059|Active Comparator|Taxane|Nab-Paclitaxel 125 mg/m² weekly for 12 weeks
11302135|NCT02685059|Active Comparator|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
11302136|NCT02685059|Active Comparator|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
11302137|NCT02685046|Experimental|Intervention|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
11302138|NCT02685033|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was < 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
11302139|NCT02685033|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
11302140|NCT02685020|Experimental|Group 1A|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
11302141|NCT02685020|Placebo Comparator|Group 1B|Participants will receive placebo at weeks 0, 12, 24 and 48.
11302142|NCT02685020|Experimental|Group 2A|Participants will receive Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 0, 12 and 24.
11302143|NCT02685020|Placebo Comparator|Group 2B|Participants will receive placebo at weeks 0, 12 and 24.
11302144|NCT02685020|Experimental|Group 3A|Participants will receive Ad26.Mos.HIV vaccine at Week 0; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 8 and 24.
11302145|NCT02685020|Placebo Comparator|Group 3B|Participants will receive placebo at weeks 0, 8 and 24.
11302146|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
11302147|NCT02684994|Other|Cognitive Processing Therapy|Cognitive Processing Therapy
11302148|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
11302149|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
11302150|NCT02684968|Experimental|Colorectal Surgery with QL block having anesthetic|Bilateral QL catheter with local anesthetic infusion + intravenous patient controlled narcotic medication
11302151|NCT02684968|Placebo Comparator|Colorectal Surgery with QL block having saline|Bilateral QL catheter with normal saline infusion + intravenous patient controlled narcotic medication
11302152|NCT02684955||Cerebral spectroscopy + pupillometry|During CPR, rSO2 will be monitored continuously as well as quantitative measurements of the pupillary light reaction every 5 minutes.
11302153|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
11302154|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
11302155|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
11302156|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
11302157|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
11302158|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
11302159|NCT02684929|Experimental|vegan|Vegan subjects interveinted with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
11302160|NCT02684929|Active Comparator|omnivor|Omnivorous subjects iterveined with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
11302161|NCT02684916|Experimental|Chiropractic treatment|Visit with active treatment.
11302162|NCT02684916|Placebo Comparator|Placebo|Visit without active treatment.
11302163|NCT02684903|No Intervention|Services As Usual (SAU)|Participants receive all the usual services provided by DHS- Children's Services.
11302164|NCT02684903|Experimental|Parent Child Interaction Therapy (PCIT)|"Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.
~."
11302165|NCT02684890||Tinnitus patients|Patients with tinnitus lasting over 3 months
11302166|NCT02684890||Non-tinnitus patients|Patients without tinnitus
11302167|NCT02684877||Intensive care survivors|Observational study
11302168|NCT02684851|Placebo Comparator|Placebo|Inactive
11302169|NCT02684851|Active Comparator|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
11302170|NCT02684825|Experimental|Continuous plus standard cardiac monitoring|Continuous cardiac monitoring by Reveal LINQTM- LNQ11 Internal Loop Recorder (ILR) plus standard cardiac monitoring
11302171|NCT02684825|No Intervention|Standard cardiac monitoring|Routine cardiac monitoring with follow-up at the same frequency, but with no Implantable Loop Recorder
11302172|NCT02684812|Active Comparator|Tranexamic Acid|Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.
11302173|NCT02684812|No Intervention|Control|Standard care
11302174|NCT02684799|Experimental|Part 1 Group 1 (Cenicriviroc)|Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
11302175|NCT02684799|Active Comparator|Part 1 Group 1 (Omeprazole)|Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
11302176|NCT02684799|Experimental|Part 1 Group 2 (Cenicriviroc)|Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
11302177|NCT02684799|Active Comparator|Part 1 Group 2 (Famotidine)|Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
11302178|NCT02684799|Experimental|Part 2 (Cenicriviroc)|Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
11302179|NCT02684799|Active Comparator|Part 2 (Omeprazole)|Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
11302180|NCT02684786|Experimental|Prior right heart catheterization|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status.
11302181|NCT02684786|Experimental|Scheduled for right heart catheterization|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
11302182|NCT02684773||Incentre Nocturnal Hemodialysis|These are patients who converted to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week) from conventional hemodialysis (4 hours/session, 3 sessions/week) at the inception of this study and are eligible for the long-term follow-up phase of the study.
11302183|NCT02684773||Conventional Hemodialysis|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elected to remain on this dialysis schedule at the inception of this study and are eligible for the long term follow-up phase of the study.
11302184|NCT02684760|Experimental|Cohort 1: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
11302185|NCT02684760|Experimental|Cohort 2: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
11302186|NCT02684760|Experimental|Cohort 3: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
11302187|NCT02684760|Experimental|Cohort 4: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
11302188|NCT02684760|Experimental|Cohort 5: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
11302189|NCT02684760|Experimental|Cohort 6: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
11302190|NCT02684747|Experimental|Treatment - Autologous Transfusion|Participants will be randomized to the treatment group (autologous transfusion)
11302191|NCT02684747|Placebo Comparator|Control - Normal Saline (Placebo)|Participants will either be randomized to the control group (saline transfusion)
11302192|NCT02684734||Patients on no immunosuppressant|This includes patients on no medication or mesalamine.
11302218|NCT02684578|No Intervention|Observe|This arm will maintain standard of care for dry AMD, which is observation. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
11302193|NCT02684734||Patients on immunosuppressants|This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.
11302194|NCT02684721|No Intervention|Control group|Patients in the control group receive usual care as a minimum. This includes 3-5 days of hospitalisation where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
11302195|NCT02684721|Experimental|Exercise group|8-week home-base exercise programme: Patients in the intervention group receive the same usual care as patients in the control group. In addition the patients participate in an 8 week home-based exercise programme, including follow-up telephone calls with the physiotherapist after 1 week, 2 weeks and 4 weeks. Briefly put, the patients are required to exercise for a minimum of 3 times per week for 30-60 minutes, and with 3-4 intervals of approximately 1 minute at a high intensity level. Total exercise time and intervals increase during the 8 week programme. The patients can choose whatever type of exercise they prefer, and they are generally encouraged to choose something they already do, or something that they have previously had positive experiences doing.
11302196|NCT02684708|Active Comparator|COPDAC-28|cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3
11302197|NCT02684708|Experimental|DECOPDAC-21|patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
11302198|NCT02684695||Group A|Patients with enthesitis-related arthritis
11302199|NCT02684695||Group B|Patients with other forms of juvenile idiopathic arthritis (extended oligoarticular JIA and polyarticular JIA)
11302200|NCT02684682|Other|12h Group|Intervention 'Frequency of mechanical control of plaque (12h)'
11302201|NCT02684682|Other|24h Group|Intervention 'Frequency of mechanical control of plaque (24h)'
11302202|NCT02684682|Other|48h Group|Intervention 'Frequency of mechanical control of plaque (48h)'
11302203|NCT02684669|Experimental|High-dose naloxone|naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration.
11302204|NCT02684669|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
11302205|NCT02684656|Active Comparator|Hemodialysis|Intervention: Patients will be switch to hemodialysis and basal plasma oxalate levels as well as oxalate removal by hemodialysis will be determined after two weeks of treatment.
11302206|NCT02684656|Active Comparator|Hemodiafiltration|Intervention: Patients will be switch back to hemodiafiltration and basal plasma oxalate levels as well as oxalate removal by hemodiafiltration will be determined after two weeks of treatment.
11302207|NCT02684643|Experimental|enhanced individualised therapy|Patients' dialysis dosage, medication as well as dietary plan will be modified.
11302208|NCT02684643|Experimental|non-enhanced individualised therapy|Patients' medication as well as dietary plan will be modified without alteration of dialysis dosage.
11302209|NCT02684643|Experimental|regular intervention|Phosphate binders and calcitriol will be prescribed and adjusted without altering patients' diet habit.
11302210|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
11302211|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
11302212|NCT02684617|Experimental|Pembrolizumab and Dinaciclib|During the Dose Evaluation phase of the study, 12 participants will receive an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7mg/m^2 on Cycle 1 Day 1 and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants will then receive an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14mg/m^2 on Day 1 and infusion of dinaciclib 14mg/m^2 alone on Day 8 on Cycles 2 through 35. The study design will be revised based on the number of DLTs in Cycle 1 and Cycle 2. If ≤4 DLTs occur, 30 participants per disease type will be enrolled in the Signal Detection Phase. If >5 DLTs occur, a lower dose will be evaluated in up to 24 additional participants.
11302213|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
11302214|NCT02684604||Fertile women|44 fertile women
11302215|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.
~Intervention: Aramchol"
11302216|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
11302217|NCT02684578|Experimental|Metformin|This arm will be receiving the study drug, Metformin, for the duration of the 18 month study. They will begin this drug on a low dose of Metformin, increasing the dosage in a step-wise fashion to avoid unwanted gastrointestinal discomfort, a common side effect when patients begin taking Metformin. During the 18 month study, subjects assigned to this arm will have 3 follow-up exams after the initial enrollment exam, at 6 month intervals.
11302219|NCT02684565|Active Comparator|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
11302220|NCT02684565|Active Comparator|BCAA Low Protein Supplement|Subjects will be randomly assigned to take low BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
11302221|NCT02684552|Experimental|Non invasive ventilation|Patients perform physical test with non invasive ventilation
11302222|NCT02684552|Active Comparator|Oxygen|Patients perform physical test with oxygen with mask
11302223|NCT02684539|Experimental|tilt table Erigo®|observation of physiological parameters, tilting table with onset of syncope
11302224|NCT02684526|Active Comparator|Eovist Contrast agent|To determine if Eovist contrast agent induces a transient abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans.
11302225|NCT02684526|Active Comparator|Non Eovist Contrast agents|To determine if using non-Eovist contrast agents produce the same abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans. Determine if this event is exclusive to Eovist contrast.
11302226|NCT02684513|Active Comparator|Oral Carbohydrate Beverage Group|Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
11302227|NCT02684513|Active Comparator|Rehydration Beverage Group|Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
11302228|NCT02684513|No Intervention|Fasted Controls|Subjects assigned to this group will fast for ≥8 hours prior to surgery.
11302229|NCT02684500||aneurysmal subarachnoid hemorrhage|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) for a aneurysmal subarachnoid hemorrhage in subjects undergoing hypertensive therapy for cerebral vasospasm in SAH, to justify the withholding of enteral nutrition.
11302230|NCT02684487|Active Comparator|vitamin D3|Patients will be given single dose of vitamin D3 within 24 hours of new-onset severe sepsis, followed by weekly doses of vitD3 (25,000 IU) up to 90 days to assess clinical outcomes and key biomarkers.
11302231|NCT02684487|Sham Comparator|Placebo|Patients will be given placebo intervention within 24 hours of new onset severe sepsis followed by or placebo for up to 90 days to assess clinical outcomes and key biomarkers.
11302232|NCT02684461|Active Comparator|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
11302233|NCT02684461|Active Comparator|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
11302234|NCT02684461|Active Comparator|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
11302235|NCT02684448||Robotic-Assisted Inguinal Hernia Repair|Subjects who have undergone robotic-assisted (da Vinci) inguinal hernia repair from the initiation of robotic-assisted hernia repair at site through December 2015.
11302236|NCT02684448||Open Inguinal Hernia Repair|Subjects who have undergone open inguinal hernia repair from the day prior to initiation of robotic-assisted hernia repair through 5 years prior to initiation.
11302237|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
11302238|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.
~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
11302239|NCT02684409|Experimental|PROT-CL-NP101-015.01|
11302240|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
11302241|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
11302242|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
11302243|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
11302244|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
11302245|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
11302246|NCT02684383|Experimental|rDEN3∆30 vaccine|Participants will receive the rDEN3∆30 vaccine at Day 0.
11302247|NCT02684383|Placebo Comparator|Placebo|Participants will receive placebo at Day 0.
11302248|NCT02684370|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11302249|NCT02684370|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11302250|NCT02684370|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11302251|NCT02684357|Placebo Comparator|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11302252|NCT02684357|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11302253|NCT02684357|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
11302254|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:
~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery
~education about signs and symptoms of urinary retention"
11302255|NCT02684344|Active Comparator|Education Group|"Subjects will receive:
~1) education about signs and symptoms of urinary retention"
11302261|NCT02684318|Experimental|Dose Level 5|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 250 mg BID
11302262|NCT02684318|Experimental|Dose Level 6|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 300 mg BID
11302263|NCT02684318|Experimental|Dose Level 7|PM01183 + olaparib PM01183 3 mg/m² IV olaparib 300 mg BID
11302264|NCT02684305|Experimental|Administration of Propess|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:
~1.Administration of Propess for additional 24 hours."
11302265|NCT02684305|Experimental|Intravenous oxytocin infusion + balloon|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:
~2. Intravenous oxytocin infusion combined with intracervical balloon administration, inflated with 60cc of saline."
11302266|NCT02684292|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
11302267|NCT02684292|Active Comparator|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
11302268|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
11302269|NCT02684266|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen
11302270|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
11302271|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).
~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
11302272|NCT02684240|Experimental|Nitazoxanide|Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.
11302273|NCT02684240|Other|Control|Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.
11302274|NCT02684227|Experimental|Treatment (enzalutamide, paclitaxel, carboplatin)|Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
11302275|NCT02684214|Experimental|Food secure families|high and marginal household food security
11302276|NCT02684214|Experimental|Food insecure families|low and very low household food security
11302277|NCT02684201|Experimental|Boston Scientific cord stimulator lead|"A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance."
11302278|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
11302279|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
11302280|NCT02684175|Active Comparator|In-Person CI Counseling Session|Participants (n=6) randomized to receive an in-person CI counseling session will receive what normally occurs with patients pursuing cochlear implantation. The counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, an explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
11302281|NCT02684175|Experimental|Remote CI Counseling Session|Participants (n=6) randomized to receive a remote CI counseling session will be receiving the counseling session remotely. The participants will be counseled remotely by the audiologist located in Lexington, KY via the telemedicine system (intervention). This counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
11302282|NCT02684162|Experimental|Treatment (guadecitabine, DLI)|Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
11302283|NCT02684149|Experimental|A|Relational touch before the first arterial puncture and the second arterial puncture without relational touch
11302284|NCT02684149|Experimental|B|First arterial puncture without relational touch and relational touch before the second arterial puncture
11302285|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
11302286|NCT02684136|Placebo Comparator|placebo|9 nights placebo
11302287|NCT02684123|Active Comparator|Apremilast|Apremilast 30mg twice daily
11302288|NCT02684123|Placebo Comparator|Placebo|Placebo pills twice daily
11302289|NCT02684097|Active Comparator|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
11341298|NCT02426034|Experimental|Apatinib(ATAN)|apatinib 850 mg qd p.o.
11302290|NCT02684097|Placebo Comparator|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
11302291|NCT02684084|Active Comparator|Combination group (RBZ+DEX)|30 eyes will receive an intravitreal Lucentis (0.5 mg) injection followed by Ozurdex implant (0.7 mg) injection within 0 to 8 days.
11302292|NCT02684084|Active Comparator|Monotherapy group (DEX only)|30 eyes will receive Ozurdex implant (0.7 mg) injection only
11302293|NCT02684071|Experimental|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
11302294|NCT02684058|Experimental|HGG cohort: Dabrafenib and trametinib|HGG cohort: All patients in the HGG cohort will receive DRB+TMT
11302295|NCT02684058|Active Comparator|LGG cohort: Carboplatin with vincristine|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
11302296|NCT02684058|Experimental|LGG cohort: Dabrafenib and trametinib|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
11302297|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
11302298|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
11302299|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
11302300|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
11302301|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
11302302|NCT02684032|Experimental|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
11302303|NCT02684019|Active Comparator|Dexmedetomidine|1microgram/kilogram loading dose followed by 0.5 microgram/kilogram/hour IV
11302304|NCT02684019|Active Comparator|Magnesium sulphate|40milligram/kilogram loading dose followed by 10milligram/kilogram/hour IV
11302305|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
11302306|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
11302307|NCT02683993|Experimental|Stone breaking|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with low frequency parameters.
11302308|NCT02683993|Experimental|Stone dusting|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with high frequency parameters.
11302309|NCT02683980|Experimental|Ablation of the prostate|ablation of the prostate will be performed using the study device: Lumenis Pulse P120H Holmium Laser
11302310|NCT02683967|Active Comparator|Acupuncture|These patients received acupuncture during the follicular development phase and on the day of egg collection.
11302311|NCT02683967|No Intervention|Control|Patients received standard care, no acupuncture.
11302312|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
11302313|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
11302314|NCT02683941|Experimental|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
11302315|NCT02683941|Placebo Comparator|Placebo|120mg every 28 days until disease progression, death, or unacceptable toxicity then patient may enter open-label treatment with Lanreotide
11302316|NCT02683928|Experimental|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
11302317|NCT02683928|Placebo Comparator|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
11302318|NCT02683915||Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
11302319|NCT02683915||Non-cooled group|Infants in the non-cooled group received the current standard of care and will be placed under radiant heaters or in incubators, which are servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.
11302320|NCT02683902|Active Comparator|Active tDCS + Diet|The participants will receive active tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
11302321|NCT02683902|Sham Comparator|Sham tDCS + Diet|The participants will receive sham tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
11302322|NCT02683889|Experimental|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
11302323|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
11302324|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
11302325|NCT02683863|Other|Group 1|"There will be 4 CSF sampling groups at the Week 6 visit for PK assessment:
~1. Four subject for CSF samples 3 hours after dosing"
11302326|NCT02683863|Other|Group 2|2. Four subjects for CSF samples 5 hours after dosing
11302327|NCT02683863|Other|Group 3|3. Four subjects for CSF samples 7 hours after dosing
11302328|NCT02683863|Other|Group 4|4. Four subjects for predose CSF samples
11302397|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
11302398|NCT02683343||carpal tunnel syndrome|No intervention
11302399|NCT02683343||normals|no intervention
11302400|NCT02683330|Experimental|Mindfulness-based intervention (MBI)|Participants randomly assigned to the MBI group will receive 8 sessions over an 8-week period. The sessions will last 1 hour and will be held via video-conference through Skype, an online application.
11302329|NCT02683850|Experimental|Omega-3 SPM|"Intervention: Study participants will be instructed to take 3 Omega-3 SPM™ softgel supplements in the morning and 3 Omega-3 SPM™ soft gel supplements in the evening for two weeks.
~At weeks two participants whose PROMIS-43 Pain Intensity score indicates a reduction in pain levels weeks, will take 2 Omega-3 SPM™ soft gel supplements in the morning and 2 in the evening for the remaining 2 weeks of the study.
~Participants whose PROMIS-43 Pain Intensity score remained the same after two weeks, or increased will take 4 Omega-3 SPM™ soft gel supplements in the morning and 4 SPM™ softgels in the evening for the remaining two weeks of the study."
11302330|NCT02683837|Active Comparator|Standard practice|"Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure).
~Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane."
11302331|NCT02683837|Experimental|Pupillometry|Remifentanil infusion guided by changes in pupillary diameter. Anesthesia maintenance with sevoflurane.
11302332|NCT02683824|Experimental|pancreatic cancer patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
11302333|NCT02683824|Experimental|healthy patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
11302334|NCT02683811|Experimental|Intervention group|Diario della Salute (DDS-2), a school-based program aimed to promote psychological well-being and to prevent cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity in preadolescents aged 11-13 years. The program is composed by 5 highly standardised interactive units led by previously trained teachers during school hours (15 hours total). Units focus on emotional and social issues related to adolescent developmental tasks. The goal is to promote the adolescent emotional and social skills.
11302335|NCT02683811|No Intervention|Control group|No intervention aimed at preventing cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity and promoting emotional and social well-being is administered at school by teachers.
11302336|NCT02683798|Active Comparator|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
11302337|NCT02683798|Experimental|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
11302338|NCT02683785|Experimental|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
11302339|NCT02683785|Placebo Comparator|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
11302340|NCT02683772|Experimental|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
11302341|NCT02683772|Active Comparator|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
11302342|NCT02683759|Active Comparator|Treatment Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
11302343|NCT02683759|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
11302344|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
11302345|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
11302346|NCT02683733|Active Comparator|Treatment Arm|"Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
~Starting dose: 50 mg BID of Bio-enhanced Curcumin Soft Gelatin Capsule Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
11302347|NCT02683733|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
11302348|NCT02683720|Experimental|ONS1|new product
11302349|NCT02683720|Active Comparator|ONS2|usual care
11302350|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
11302351|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
11302352|NCT02683694|Other|study arm|iOCT is performed
11302353|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
11302354|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
11302401|NCT02683330|No Intervention|Wait-list control (WLC)|Participants randomly assigned to the WLC group will be discouraged from any new mindfulness related activities during the trial. The WLC group will be offered the opportunity to take part in the MBI at the end of the 20-week follow-up.
11302402|NCT02683317|Experimental|DHA group|Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.
11302472|NCT02682836|Experimental|single arm|Walk with Ease physical activity intervention
11344157|NCT02407496||Control|Healthy individuals without ADHD
11302355|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
11302356|NCT02683655|Experimental|Apatinib 500mg qd p.o.|Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
11302357|NCT02683655|Experimental|Apatinib 750mg qd p.o.|Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
11302358|NCT02683629|Experimental|NTCELL|NTCELL Implantation
11302359|NCT02683629|Sham Comparator|Sham Surgery|Sham Surgery
11302360|NCT02683616|Experimental|OSA + T2DM|CPAP treatment
11302361|NCT02683616|Experimental|OSA no T2DM|CPAP treatment
11302362|NCT02683616|No Intervention|T2DM no OSA|Standard care
11302363|NCT02683616|No Intervention|Healthy controls no ÓSA|no intervention
11302364|NCT02683603|Active Comparator|aerosolised (AS) colistin group|"the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume <8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break > 20%."
11302365|NCT02683603|Active Comparator|intravenous (IV) colistin goup|"the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day."
11302366|NCT02683590|Experimental|sternum by a ceramic implant|The replacement of the sternum by a ceramic implant
11302367|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
11302368|NCT02683564|Experimental|BOW015|Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
11302369|NCT02683564|Active Comparator|Remicade|Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
11302370|NCT02683551||Ligasure|Patients underwent to Sutureless Thyroidectomy with Ligasure SmallJaw
11302371|NCT02683551||Harmonic|Patients underwent to Sutureless Thyroidectomy with Harmonic FOCUS
11302372|NCT02683538|Experimental|Separable cluster electrode|radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
11302373|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
11302374|NCT02683499|Experimental|Ultrasonic tips|Prepared surfaces will be finished with ultrasonic tips
11302375|NCT02683499|No Intervention|Conventional|Prepared surfaces will be finished with ordinary burs
11302376|NCT02683486|Experimental|Activities of daily living on iO2t|Patients will complete simulated activities of daily living on intelligent oxygen therapy (an auto-titrating oxygen system)
11302377|NCT02683486|Active Comparator|Activities of daily living on LTOT|Patients will complete activities of daily living on their usual long-term oxygen therapy.
11302378|NCT02683473||Infants|Infants aged 1-3 months
11302379|NCT02683460|Experimental|patella resurfacing group|Procedure: Patellar component Resurfacing with onlay technique
11302380|NCT02683460|Active Comparator|patella retention|Procedure: patellar retention Trimming of osteophytes when appropriate
11302381|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
11302382|NCT02683434|Experimental|KT|Kinesio Taping Application
11302383|NCT02683434|No Intervention|CONTROL|
11302384|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
11302385|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
11302386|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
11302387|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
11302388|NCT02683408|Experimental|diosmiplex|diosmiplex 630 mg BID administered orally
11302389|NCT02683408|Placebo Comparator|placebo|placebo BID administrered orally
11302390|NCT02683395|Experimental|Treatment Group A|Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
11302391|NCT02683395|Experimental|Treatment Group B|Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
11302392|NCT02683382|Experimental|Moisturizing Eye Product (product in development)|Moisturizing eye product in liquid form (medical device product in development). Part 1 of the study: Administered to both eyes 4 times/day for 1 day. Part 2: to one eye 4 times/day for 9 days. Part 3: to one eye 4 times/day for 45 days. Parts 2 & 3: treatment eyes randomized.
11302393|NCT02683382|Active Comparator|Moisturizing Eye Product, Comparison|Moisturizing eye product in liquid form (medical device CE-marked). Part 2 of the study: Administered to one eye 4 times/day for 9 days. Treatment eyes randomized.
11302394|NCT02683382|No Intervention|No treatment|Part 3 of the study: other eye is a control eye with no treatment for 45 days.
11302395|NCT02683369|Experimental|Iron Supplement|Participants will consume one tablet of Blood Builder®/Iron Response®, once per day, every day, for 8 weeks.
11302396|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
11302403|NCT02683317|Sham Comparator|Control group|"Control group will receive sunflower oil, the excipient of the DHA in our intervention.
~They will receive it once a day, administered by enteral feeding throughout 14 days."
11302404|NCT02683304|Experimental|The study population|The study population consists of consecutive headache patients (visual analogue scale > 3) presenting at the emergency department of the Nîmes University Hospital
11302405|NCT02683291|Active Comparator|Tacrolimus + Mycophenolate|"The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.
~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
11302406|NCT02683291|Experimental|Tacrolimus + Sirolimus|"The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).
~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
11302407|NCT02683278|Experimental|Cognitive-Behavioral Therapy|Group-based cognitive-behavioral manualized treatment
11302408|NCT02683278|Experimental|Mindfulness-acceptance Therapy|Group-based mindfulness-acceptance manualized treatment
11302409|NCT02683278|Active Comparator|Education|Group-based manualized pain education
11302410|NCT02683265|Experimental|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg Aptensio XR)
11302411|NCT02683265|Placebo Comparator|Placebo comparator|Placebo capsules
11302412|NCT02683252|Experimental|Normal patients|Patients with normal bone appearance on conventional MR images
11302413|NCT02683252|Experimental|Carpal osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the carpal bones on conventional MR images (hypointensity on T1 weighted sequences, no contrast enhancement).
11302414|NCT02683252|Experimental|Femoral head osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the femoral head on conventional MR images (fat containing signal anomalies with geographic contours in the femoral epiphysis).
11302415|NCT02683252|Experimental|Pseudarthrosis|Patients presenting a non consolidated macroscopic bone fracture for over 6 months (clinical history and imaging findings).
11302416|NCT02683252|Experimental|Compartment syndrome|Patients with a confirmed compartment syndrome on intra-compartment pressure assessement
11302417|NCT02683239|Experimental|Fasinumab dosing regimen 1|
11302418|NCT02683239|Experimental|Fasinumab dosing regimen 2|
11302419|NCT02683239|Experimental|Placebo|
11302420|NCT02683226|Experimental|metformin and alogliptin|Vipdomet 12.5 mg/1000 mg tablets
11302421|NCT02683226|Experimental|pioglitasone and alogliptin|Incresync 12,5 mg/30 mg tablets
11302422|NCT02683213|Active Comparator|Fluoxetine|One capsule Fluoxetine 20mg once daily for 6 months.
11302423|NCT02683213|Placebo Comparator|Placebo|One matching capsule placebo once daily for 6 months.
11302424|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
11302425|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
11302426|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
11302427|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
11302428|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
11302429|NCT02683148|Experimental|Arm 1: DHEA Dose Level 1|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
11302430|NCT02683148|Experimental|Arm 2: DHEA Dose Level 2|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
11302431|NCT02683148|Experimental|Arm 3: DHEA Dose Level 3|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
11302432|NCT02683148|Experimental|Arm 4: DHEA Phase II|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
11302433|NCT02683135|Active Comparator|High-carbohydrate diet|
11302434|NCT02683135|Experimental|Low-carbohydrate diet|
11302435|NCT02683135|Experimental|Low-carbohydrate diet with post-meal walking|
11302436|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
11302437|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
11302438|NCT02683096||SGA Infants|
11302439|NCT02683096||Failed Hearing Screen Infants|
11302440|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
11302441|NCT02683070|Experimental|The PNB group|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) will be performed after the completion of surgery before extubation.
11302442|NCT02683070|Active Comparator|The TRAM group|Intravenous tramadol of 1.5mg/kg will be administrated after the completion of surgery before extubation.
11302469|NCT02682862|Active Comparator|Striverdi Respimat|olodaterol 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
11302470|NCT02682849||Retrospective cohort|
11302443|NCT02683057||IPAQ HIgh|Excessive physical activity:IPAQ quantifying the activity physical according vigorous intensity activities at least 3 days per week adding a minimum total physical activity of at least 1500MET-minutes / week or 7 or more days any combination of walking, moderate intensity or vigorous intensity activities a total minimum of physical activity of at least 3,000 MET-minutes / week
11302444|NCT02683057||IPAQ Moderate|Ideal Physical activity: IPAQ quantifying the activity physical according 3 days or more of vigorous intensity physical activity at least 20 minutes per day or 5 or more days of moderate intensity and / or walk at least 30 minutes per day or 5 or more days of any combination of walking, moderate-intensity activity and activity vigorous intensity for a total minimum of physical activity of at least 600 MET-minutes / week.
11302445|NCT02683057||IPAQ Low|IPAQ quantifying the activity physical according Insufficient physical activity: Individuals who can not put on the criteria of the above categories.
11302446|NCT02683044|Experimental|Li-ESWT 5 weeks|Consists of five sessions of Low-Intensity Extracorporeal Shock Wave Therapy , one per week, with 3000 pulses at 0,15 mg/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 2000 pulses to the body of the penis and 1000 pulses at its base. Total duration: 5 weeks.
11302447|NCT02683044|Active Comparator|Li-ESWT 3 weeks|Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
11302448|NCT02683031|No Intervention|Without Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
11302449|NCT02683031|Experimental|With Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
11302450|NCT02683018|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 Smoked Cannabis High CBD/low THC cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
11302451|NCT02683018|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
11302452|NCT02683005|Experimental|Ledipasvir/Sofosbuvir|Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.
11302453|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
11302454|NCT02682979||Geriatric patients|100 consecutive geriatric patients admitted in the Emergency Department of the Brugmann Hospital, Horta site, from 01/04/2015.
11302455|NCT02682966||PMI|Postoperative Myocardial injury, postoperative troponin levels ≥ 60 ng/L
11302456|NCT02682966||Control|postoperative troponin levels < 60 ng/L
11302457|NCT02682953|Experimental|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
11302458|NCT02682940|Other|Usual Care Patients on MDI or CSII|Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
11302459|NCT02682927|Experimental|ZX008 - 0.8 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
11302460|NCT02682927|Experimental|ZX008 - 0.2 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
11302461|NCT02682927|Placebo Comparator|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
11302462|NCT02682901|Active Comparator|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
11302463|NCT02682901|Placebo Comparator|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
11302464|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
11302465|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
11302466|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
11302467|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
11302468|NCT02682862|Experimental|Spiolto Respimat|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
11302471|NCT02682849||Prospective PleuralFlow cohort|
11302473|NCT02682823|Experimental|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
11302474|NCT02682823|Experimental|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
11302475|NCT02682823|Experimental|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
11302476|NCT02682823|Other|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
11302477|NCT02682823|Other|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
11302478|NCT02682810|Active Comparator|DNA PCR HIV diagnostic test|SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.
11302479|NCT02682810|Experimental|Alere Q POC nucleic acid-based platform|POC test to provide same-day diagnosis
11302480|NCT02682797||1|At all study visits a complete ophthalmic examination, visual acuity and refractive error, Spectralis OCT, Cirrus OCT, Topcon OCT, PS-OCT, Optomap Fundus photography will be performed.
11302481|NCT02682784|Experimental|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
11302482|NCT02682784|Active Comparator|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
11302483|NCT02682784|Experimental|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
11302484|NCT02682784|Active Comparator|Placebo/Control|Healthy controls who are randomized to placebo.
11302485|NCT02682771|Active Comparator|Control|Individuals were treated with Conventional Respiratory Physiotherapy (CRP), twice in immediate postoperative day and three times in first postoperative day.
11302486|NCT02682771|Experimental|Bilevel positive airway pressure|Individuals were treated with positive pressure, in the BIPAP mode (bilevel positive airway pressure, with inspiratory pressure:12 cmH20 and expiratory pressure: 8 cmH20) twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each
11302487|NCT02682771|Experimental|Load inspiratory breathing exercises|Individuals were treat with PowerBreathe, a device for inspiratory muscle, with 40% maximal inspiratory pressure, measured at preoperative, twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each.
11302488|NCT02682758|Other|Patients of normal weight|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index of less than 30.
11302489|NCT02682758|Other|Obese patients|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index equal to or more than 30.
11302490|NCT02682745|Experimental|R-T1-T2|First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll
11302491|NCT02682745|Experimental|R-T2-T1|First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l
11302492|NCT02682745|Experimental|T1-T2-R|First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug
11302493|NCT02682745|Experimental|T1-R-T2|First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll
11302494|NCT02682745|Experimental|T2-R-T1|First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l
11302495|NCT02682745|Experimental|T2-T1-R|First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug
11302496|NCT02682732|Experimental|FDG-PET/CT|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be performed at diagnosis and at the end of induction chemotherapy (like cytarabine and daunorubicin). Then, patients will be followed to assess their response, and imaging-guided bone marrow sampling will be repeated in the likely event of disease relapse.
11302497|NCT02682719|Experimental|Valsartan/Sacubitril (LCZ696)|"Valsartan/Sacubitril (LCZ696) plus placebo to Valsartan. Standard dosing regime: LCZ696 100mg twice daily for two weeks then increased to 200mg twice daily for the remainder of the study.
~Lower dosing regimen (for patients not taking an ARB or ACE inhibitor, subjects previously taking low doses of these agents and for subjects with a systolic BP of ≥100mm to 110mmHg at screening or baseline): LCZ696 50mg twice daily for two weeks then increased to 100mg twice daily for two weeks then further increased to 200mg twice daily for the remainder of the study."
11302498|NCT02682719|Active Comparator|Valsartan|"Valsartan plus placebo to Valsartan/Sacubitril (LCZ696). Standard dosing regime: Valsartan 80mg twice daily for two weeks then increased to 160mg twice daily for the remainder of the study.
~Lower dosing regimen (for patients not taking an ARB or ACE inhibitor, subjects previously taking low doses of these agents and for subjects with a systolic BP of ≥100mm to 110mmHg at screening or baseline): Valsartan 40mg twice daily for two weeks then increased to 80mg twice daily for two weeks then further increased to 160mg twice daily for the remainder of the study."
11302499|NCT02682693|Experimental|Denosumab|Denosumab every 4 weeks for 6 cycles.
11302500|NCT02682693|Experimental|nab-Paclitaxel weekly|nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.
11302573|NCT02682303|Placebo Comparator|Non-standardized tape (NST)|In the NST group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used.
11302731|NCT02681224|Placebo Comparator|Placebo Gel with Occlusion|Placebo Gel with Silon Bandage
11302501|NCT02682693|Experimental|nab-paclitaxel 2 of 3 weeks|nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.
11302502|NCT02682693|Experimental|EC every two weeks or every three weeks|Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
11302503|NCT02682680|Experimental|Colesevelam|Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks
11302504|NCT02682680|Active Comparator|Ezetimibe|Ezetimibe 10 mg once daily for 24 weeks
11302505|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency.
11302506|NCT02682654|Experimental|Ankle/Knee brace|Dr. Scholl's Prototype Ankle or Knee Brace
11302507|NCT02682641|Experimental|IBRUTINIB + RITUXIMAB|"Subjects will receive the ibrutinib in combination with rituximab according to the following schedule:
~Ibrutinib 560 mg daily po until disease progression or unacceptable toxicity. In case of sustained negative MRD (at least for 6 months) after 2 years of continuous therapy, ibrutinib will be discontinued.
~Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1). Rituximab 375 mg/m2 iv, day one of every cycle 3, 5, 7 and 9."
11302508|NCT02682628|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
11302509|NCT02682615||requirement of norepinephrine|requirement of norepinephrine <0,1 µg/kgKG/min versus ≥0,1 µg/kgKG/min
11302510|NCT02682602||Diseased Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
11302511|NCT02682602||Normal Hip|Subjects will have a normal hip.
11302512|NCT02682602||Implanted Group|All subjects from the Diseased Hip group were implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA
11302513|NCT02682589|Active Comparator|Open surgery|Patients undergo open CME. A standard midline incision carefully protected is made through the abdominal wall and the abdominal cavity is explored. A colectomy with CME is performed with the removal of the afflicted colon and its accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia.
11302514|NCT02682589|Experimental|Laparoscopic surgery|Patients undergo laparoscopic CME. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with carbon dioxide to allow access and visualization. The abdominal cavity is explored. A colectomy with CME is performed using laparoscopic-assisted techniques. A 6-8cm midline auxiliary incision is made for specimen extraction and anastomosis.
11302515|NCT02682576|Experimental|Brachial artery ultrasound imaging|Brachial artery ultrasound imaging is a non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery using high resolution continuous electrocardiogram-gated B-mode (2D) ultrasound imaging during reactive hyperemia.
11302516|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
11302517|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
11302518|NCT02682550||Ctrl|healthy volunteers, sex- and age matched Blood drawing at one time point: 20 ml
11302519|NCT02682550||PT|"polytrauma patients fulfilling the following criteria:
~injury severity score ≥25
~age ≥ 18 Blood drawing at admission to the emergency room, 8 h, 24h, 48 h, 120 h and 240 h post trauma: 20 ml"
11302520|NCT02682537||Female, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 Years
11302521|NCT02682537||Female, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
11302522|NCT02682537||Female, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
11302523|NCT02682537||Female, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
11302524|NCT02682537||Female, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
11302525|NCT02682537||Female, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
11302526|NCT02682537||Female, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
11302527|NCT02682537||Female, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
11302528|NCT02682537||Female, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
11302529|NCT02682537||Male, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 years
11302530|NCT02682537||Male, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
11302531|NCT02682537||Male, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
11302532|NCT02682537||Male, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
11302533|NCT02682537||Male, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
11302534|NCT02682537||Male, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
11302535|NCT02682537||Male, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
11302536|NCT02682537||Male, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
11302537|NCT02682537||Male, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
11302538|NCT02682524|Active Comparator|test|
11302539|NCT02682524|Active Comparator|reference|
11302540|NCT02682511|Experimental|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
11302541|NCT02682511|Experimental|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
11302542|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
11302543|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
11302732|NCT02681224|Placebo Comparator|Placebo Gel without Occlusion|Placebo Gel without Silon Bandage
11302544|NCT02682485|Experimental|Cipro, metronidazole, neomycin combo|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
11302545|NCT02682485|Placebo Comparator|Saline|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
11302546|NCT02682472|Experimental|SettleIN|SettleIN - Adjustment to care programme intervention
11302547|NCT02682459|Experimental|Lisinopril|Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.
11302548|NCT02682459|No Intervention|No intervention|Patients will receive only the standard immunosuppressive therapy.
11302549|NCT02682446||Negative H. pylori group|The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
11302550|NCT02682446||Previous H. pylori infection group|The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
11302551|NCT02682446||Eradicated H. pylori group|The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
11302552|NCT02682446||Persistent H. pylori group|The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
11302553|NCT02682433|Experimental|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same position, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
11302554|NCT02682433|Experimental|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same positionabdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
11302555|NCT02682420|Other|endoAVF|
11302556|NCT02682407|Experimental|OMS721 (narsoplimab)|Administration of OMS721 (narsoplimab)
11302557|NCT02682381|Experimental|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
11302558|NCT02682381|Experimental|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
11302559|NCT02682381|Active Comparator|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
11302560|NCT02682368||POCUSS Trial-1 Acute Biliary Disease|Patients with suspected biliary pathology which will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
11302561|NCT02682368||POCUSS Trial-2 Acute Diverticulitis|Patients with suspected diverticulitis will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
11302562|NCT02682368||Radiology Report|Departmental imaging and reports.
11302563|NCT02682368||Surgical diagnostic|Intraoperative findings of patients that undergo emergency surgery.
11302564|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of pneumonia and/or bloodstream infection
11302565|NCT02682342||Healthy Subjects|Healthy subjects meeting inclusion criteria will be administered a 75 g glucose solution one time (orally). Subjects will be ages 21-70 years with no evidence of diabetes, hypertension, metabolic syndrome, or high cholesterol at the time of screening. Potential subjects with a history of atherosclerotic disease, chronic renal insufficiency (plasma creatinine > 1.5 men, > 1.5 women), liver enzymes > 2.5x normal, pregnant at the time of screening will be excluded
11302566|NCT02682329|Active Comparator|CP 10% + HP 40%|Carbamide Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. CP at home and HP at office
11302567|NCT02682329|Active Comparator|CP 15% + HP 40%|Carbamide Peroxide 15% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
11302568|NCT02682329|Active Comparator|CP 20% + HP 40%|Carbamide Peroxide 20% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
11302569|NCT02682329|Active Comparator|HP 10% + HP 40%|Hydrogen Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. HP at Home and HP at office
11302570|NCT02682316|Active Comparator|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
11302571|NCT02682316|Experimental|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
11302572|NCT02682303|Experimental|elastic bandage|In this study, Idealplast C® (6cm*2.5m) was used.
11302574|NCT02682290|Other|rheological measurement of sputum|"patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.
~Then all participants will have an induced expectoration with hypertonic salin solution."
11302575|NCT02682277|Active Comparator|Medical device polyglucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
11302576|NCT02682277|Placebo Comparator|Placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
11302577|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
11302578|NCT02682251|Experimental|Heart Failure Patients with CRT-CIED|PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
11302579|NCT02682238|Experimental|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
11302580|NCT02682238|Placebo Comparator|Vehicle|Vehicle (placebo) gel
11302581|NCT02682225|Experimental|Sequence 1: Qualification Session|Participants will receive Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 1 and Treatment B (0.5 milligram per kilogram (mg/kg) of intravenous racemic ketamine and intranasal placebo concurrently) on Day 2.
11302582|NCT02682225|Experimental|Sequence 2: Qualification Session|Participants will receive Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo concurrently) on Day 1 and Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 2.
11302583|NCT02682225|Experimental|Sequence 3: Treatment Phase|Participants in Sequence 3 will receive Treatment A (intravenous placebo and intranasal placebo) on Day 1 of period 1, Treatment D (intravenous placebo and intranasal 112 milligram (mg) of esketamine as 4 devices, each with 28 mg esketamine) on Day 1 of period 2, Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo) on Day 1 of period 3, Treatment C (intravenous placebo and intranasal 84 mg esketamine as 3 devices, each with 28 mg esketamine followed by 1 device with placebo) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
11302584|NCT02682225|Experimental|Sequence 4: Treatment Phase|Participants in Sequence 4 will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
11302585|NCT02682225|Experimental|Sequence 5: Treatment Phase|Participants in Sequence 5 will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment D on Day 1 of period 3, Treatment A on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
11302586|NCT02682225|Experimental|Sequence 6: Treatment Phase|Participants in Sequence 6 will receive Treatment D on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment B on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
11302587|NCT02682212|Experimental|Physiotherapy intervention|Intensive pelvic floor muscle training (PFMT) given by a physiotherapist with vaginal/rectal pressure feedback once a week for 12 weeks.
11302588|NCT02682212|No Intervention|No intervention|Standard care
11302589|NCT02682199||Whole Brain Radiation|Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy.
11302590|NCT02682186|No Intervention|Control group (1)|The PECS Blocks are not (1) performed.
11302591|NCT02682186|Experimental|PECS group (2)|The PECS Blocks are performed (2): A single injection of Ropivacaine after dilution with sodium chloride 0.9% per fascial plane and per side.
11302592|NCT02682173|Active Comparator|Laparoscopic gastric bypass|MR Abdomen in morbidly obese patients receiving gastric bypass
11302593|NCT02682173|Active Comparator|Laparoscopic sleeve gastrectomy|MR Abdomen morbidly obese patients receiving sleeve gastrectomy
11302594|NCT02682160|Other|Use of Protein Assistant|patients can use the Protein Assistant during 2 months to evaluate the quantity of protein's intake.
11302595|NCT02682147|Experimental|Hypoxia Administration study group|40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
11302596|NCT02682147|Experimental|Hyperoxia Administration study group|40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
11302597|NCT02682147|Experimental|Sildenafil|40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
11302598|NCT02682134|Experimental|"Xylocaine X"|Patients received xylocaine gel as lubricant on endotracheal tube
11302599|NCT02682134|Experimental|"Dexamethasone D"|Patients were given dexamethasone 8 mg intravenously
11302600|NCT02682134|Experimental|"xylocaine and dexamethasone XD"|Patients were given both xylocaine gel and dexamethasone 8 mg intravenously
11302601|NCT02682121|Placebo Comparator|Placebo|Patients on placebo.
11302602|NCT02682121|Active Comparator|Active drug|Patients on Metformin, 850mg twice daily for 6mos.
11302632|NCT02681900|Experimental|Self-affirmation|Participants in the self-affirmation arm write about their most important value, reasons why is important and an example of when they enacted that value. This is the Self-affirmation manipulation task as described in the intervention.
11302800|NCT02680717|Active Comparator|Treatment 3|Tacrolimus 0.1% ointment
11302603|NCT02682108|Other|Diffusion-weighted imaging|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
11302604|NCT02682095||Patients: achieved BP control|Patients who have achieved blood pressure control (≤140/90 mmHg)
11302605|NCT02682095||Patients: not achieved BP control|Patients who have not achieved blood pressure control (>140/90 mmHg)
11302606|NCT02682095||Individual interviews|Hypertensive patients who have considered changing lifestyle regarding one or more of the areas of tobacco, alcohol, diet, physical activity or stress.
11302607|NCT02682095||Focus-group interviews|Hypertensive patients
11302608|NCT02682082|Experimental|Neurolysis without Bupivacaine|Experimental Group: Endoscopic ultrasound guided celiac plexus Neurolysis without Bupivacaine so only with Absolute Alcohol 20 mL
11302609|NCT02682082|Active Comparator|Neurolysis with Bupivacaine|Endoscopic ultrasound guided celiac plexus Neurolysis with Bupivacaine (0.5% Bupivicaine 20mL + Absolute Alcohol 20 mL)
11302610|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
11302611|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
11302612|NCT02682043|Experimental|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
11302613|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
11302614|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
11302615|NCT02682017|Placebo Comparator|Treatment 1|Pork meat from pigs feed with a standard feed
11302616|NCT02682017|Experimental|Treatment 2|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
11302617|NCT02682004||Women with postpartum depression|
11302618|NCT02682004||Women without postpartum depression|
11302619|NCT02681991|Experimental|test|Renamezin capsule 2g, tid, PO
11302620|NCT02681978|Active Comparator|Ivabradine group|Ivabradine 5 mg twice daily + standard medical therapy
11302621|NCT02681978|Other|Control group|Standard medical therapy
11302622|NCT02681965|Experimental|LEAN|Participants randomized to the weight loss program will initially receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity. Written instructions in the LEAN book will include recording daily diet and exercise in the logs. At the end of the study, participants will return, via a stamped addressed envelope, the logs to the study office so compliance can be assessed.
11302623|NCT02681965|No Intervention|Waitlist Control|Participants randomized to the waitlist control study arm will be mailed the six-month questionnaires, which will include reporting of weight. On return of the 6-month questionnaires each woman will be provided with the entire weight loss program packet.
11302624|NCT02681952|Active Comparator|Renamezin->Kremezin|
11302625|NCT02681952|Active Comparator|Kremezin->Renamezin|
11302626|NCT02681939|Experimental|Tulsi|One capsule of Tulsi (Ocimum sanctum) orally, every morning and evening in empty stomach for 60 days regularly.
11302627|NCT02681939|No Intervention|No Tulsi|No intervention
11302628|NCT02681926||Average force group|A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. In the Average Force group, the operators decided to use the mean contact force as target parameter indicating a good lesion.
11302629|NCT02681926||Force Time Integral group|In the Force Time Integral (FTI) group, the operators decided to use the FTI as target parameter indicating a good lesion.
11302630|NCT02681913|No Intervention|standard cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.
~The cardioplegic maintenance solution consists of a 500 ml normal saline (0.9% NaCl) infusion bag. Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.
~This arms receives standard intermittent 20:1 diluted warm blood cardioplegic solution.
~Intervention: n/a"
11302631|NCT02681913|Experimental|adenosine enriched cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.
~The cardioplegic maintenance solution consists of a 1000 mg = 500 ml adenosine infusion bag (2 mg/ml). Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.
~This arms receives adenosine enriched, intermittent 20:1 diluted warm blood cardioplegic solution.
~Intervention: Drug: Adenosine"
11302633|NCT02681900|Active Comparator|Control|Participants in this arm complete a control equivalent of the self-affirmation task, where they write about their least important value, reasons why is may be important to someone else and an example of when another person may have enacted that value. This is the Control task as described in the intervention.
11302634|NCT02681887|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 12 weeks
11302635|NCT02681887|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
11302636|NCT02681874|Experimental|Group A (Treatment Arm)|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Sessions are 90 minutes. Groups consist of a maximum of five parents. Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions. Parent Leaders receive a week-long leadership training to deliver the program and will be supervised by the PI who is a licensed clinical psychologist.
11302637|NCT02681874|Active Comparator|Group B (Control Arm)|Parents in the control condition will receive the Smart and Secure Children (SSC) program's written handouts. Handouts include didactic curriculum content and instruct parents to write goals and document goal progress.
11302638|NCT02681861|Experimental|Part 1: ASP6294 Single Ascending Intravenous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo intravenously. If no dose limiting toxicities are observed escalation to the next higher dose is planned approximately every 3 weeks. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
11302639|NCT02681861|Experimental|Part 2: ASP6294 Single Ascending Subcutaneous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
11302640|NCT02681835|Experimental|Position 1|Standard position during intubation. Intubator is behind head of the victim, propped up on both elbows
11302641|NCT02681835|Experimental|Position 2|Intubator is behind head of the victim, lies on the left side
11302642|NCT02681835|Experimental|Position 3|Intubator stands astride the victims, intubated using the face-to-face
11302643|NCT02681822||Healthy young subjects|Healthy young Chinese Han subjects aged 18-30
11302644|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
11302645|NCT02681809|Experimental|Ocriplasmin 0.125mg|
11302646|NCT02681809|Sham Comparator|Sham injection|
11302647|NCT02681796|Experimental|Study: Bupivacaine Epidural + standard of care pain regimen|-The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
11302648|NCT02681796|No Intervention|Control: Standard of care pain regimen|-The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
11302649|NCT02681783|Active Comparator|neovascular AMD group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
11302650|NCT02681783|Experimental|CSR group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
11302651|NCT02681783|Experimental|iPCV group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
11302652|NCT02681783|No Intervention|cataract patients|Patients diagnosed with cataracts requiring cataract surgery will serve as study controls. No intervention will be applied to these patients.
11302653|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
11302654|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
11302655|NCT02681744|No Intervention|Control Group|These participants will be instructed to maintain their habits during 24 weeks. Before and after the aforementioned period, they will be asked to perform body composition and strength assessments, using DXA and isokinetic dynamometer, respectively.
11302656|NCT02681744|Experimental|Experimental group|Participants from the experimental group will assign to the resistance training program undergo physician screening at rest and under cardiopulmonary exercise test conditions before starting the program. Following a three-week familiarization process, participants undergo one repetition maximum (1-RM) testing for each of the exercises of the training program. This procedure intended to determine exercise load and will be systematically repeated in four-week intervals. Volunteers will train thrice per week during 24 weeks. The training program will involve the following exercises: chest press, lat pulldown, knee extension, hamstrings curl, leg press, hip abduction.
11302657|NCT02681718|Experimental|Community Health Worker education|During a six-month intervention period, the CHWs will conduct six home-based visitations and provide individualized diabetes education using an intensive diabetes lifestyle curriculum called Diabetes Learning Circle (DLC), developed and used by the Sinai Diabetes Education Program. At each visit, lasting for approximately one hour, the participants will be motivated to set SMART behavioral goals for diabetes self-management. At each visit after the initial visit, CHWs will follow-up with each participant to check their progress on their behavioral SMART goals. In addition, the CHWs will conduct intermittent phone calls (at least one monthly) and home visits as needed.
11302658|NCT02681718|Experimental|Cell phone text messaging|The participants in the text messaging group will receive weekly text messages through CareMessage. Each participant will receive 3-4 text messages per week for 6 months.
11302659|NCT02681718|No Intervention|Control|The participants in the control group will receive education as determined by the hospital's diabetes educator, dietitian, physician, or the participant's managed care provider. No additional education will be provided by the research team.
11302660|NCT02681705|Experimental|Study Treatment|All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with Temozolomide. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as Temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
11302661|NCT02681692|Active Comparator|MEI colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system
11302662|NCT02681692|No Intervention|Standard colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) without the assistance of magnetic scope navigation system
11302663|NCT02681692|Active Comparator|MEI colon model Group|"Colonoscopist would be randomized to perform colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part.
~All force variation data would be recorded by a image storage device."
11302664|NCT02681692|No Intervention|Standard colon model Group|Colonoscopist would be randomized to perform conventional colonoscopy on a colon model without an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
11302665|NCT02681679|Experimental|0.1% bromfenac ophthalmic solution|Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.
11302666|NCT02681679|Placebo Comparator|control physiological normal saline|Patients received control physiological normal saline twice a day for 3 days before surgery.
11302667|NCT02681666|Active Comparator|FODMAPs CONTROL arm|Dietary intervention in this cohort with irritable bowel syndrome will be administered a low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet by a dietician.
11302668|NCT02681666|Experimental|MB-IBS-EAT INTERVENTION STUDY arm|Irritable Bowel Syndrome eating awareness training intervention will be started in a comprehensive 8 weekly sessions of Mindfulness eating training.
11302669|NCT02681653|Active Comparator|Statin|Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
11302670|NCT02681653|Placebo Comparator|Placebo|Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
11302671|NCT02681640|Experimental|uPAR PET|One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions
11302672|NCT02681627|Active Comparator|endometrial scratch|Patient will be randomised to the intervention arm which is the luteal phase endometrial scratch
11302673|NCT02681627|Sham Comparator|touching cervix|Patient will have a speculum examination and cleaning of the cervix with cotton tip with saline but no scratch
11302674|NCT02681614|Experimental|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation.
~All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
11302675|NCT02681601|Active Comparator|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
11302676|NCT02681601|Active Comparator|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
11302677|NCT02681588|Experimental|Obese group|
11302678|NCT02681588|Active Comparator|Normal Weight group|
11302679|NCT02681575|Experimental|Cog-Fun A|Metacognitive-Functional occupational therapy intervention (Cog-Fun - A) includes enhancing self awareness in occupational context, acquiring executive strategies and skills and implementation across multiple occupational domains.
11302680|NCT02681562|Experimental|Olaparib triple negative|Olaparib short administration in triple negative breast cancer
11302681|NCT02681562|Experimental|Olaparib BRCA mutated|Olaparib short administration in BRCA mutated patients
11302682|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
11302683|NCT02681536|Experimental|Minidose long protocol|Down-regulation started on day 20 of the previous cycle by GnRH agonist triptorelin (0.5 µg Decapeptyl; Ferring). On the second day of menstruation, when down regulation was confirmed (as evidenced by endometrial thickness <5 mm and/or E2 levels <50 pg/mL) using transvaginal sonography (TVS) by Voluson 730 Pro (GE, Fairfield, CT) apparatus, gonadotropin (Merional; IBSA) was commenced at an initial dose of 300-450 IU/day for the first 5 days followed by individual adjustment in Gn dose according to ovarian response and the dose of Decapeptyl 50µg/day was continued until day of HCG administration.
11302684|NCT02681536|Experimental|microdose flare protocol|OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.
11302685|NCT02681523|Experimental|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
11302686|NCT02681510|Experimental|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
11302730|NCT02681224|Active Comparator|Active Product without Occlusion|TR987 without Silon Bandage
11302687|NCT02681484|Experimental|Hypertensive|Patients diagnosed with hypertension (I10, either on drug therapy or verified by 24h blood pressure measurements) administered to anthroposophic speech therapy (intervention).
11302688|NCT02681484|Active Comparator|Normotensive|Patients diagnosed with tension headache (G 44.2) or anxiety disorders (F41) administered to anthroposophic speech therapy (intervention).
11302689|NCT02681471|Active Comparator|Monopolar TURP|Patients in Group M (Monopolar) were used monopolar resectoscope (Karl Storz, Tottling, Germany) and 5% Mannitol as an irrigation fluid.
11302690|NCT02681471|Active Comparator|Bipolar TURP|Patients in Group B (Bipolar) were used bipolar resectoscope TURis (OLYMPUS, Tokyo, Japan) and 0,9% Sodium chloride as an irrigation fluid.
11302691|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
11302692|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
11302693|NCT02681445||Group 1 Healthy Non Smokers|No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray Non-Smoker
11302694|NCT02681445||Group-2 Smokers|No TB History No TB Symptoms No TB History Negative Mantoux test Smoker 10 + Cigarettes/day
11302695|NCT02681445||HIV Positive|"No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray HIV Positive
~CD4 count >200"
11302696|NCT02681445||TB Suspect Group|WHO Screening Recommendation Protocls Unexplained Cough Sputum production Fever Weight Loss or loss of appetite Night Sweats
11302697|NCT02681445||Lower Respiratory Track Infection|TB Lab test Negative Ab Normal Chest X-ray HIV Negative
11302698|NCT02681432|Experimental|HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
11302699|NCT02681432|Active Comparator|No HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
11302700|NCT02681419|Active Comparator|Needle fenestration|Needle fenestration
11302701|NCT02681419|Active Comparator|Suture wick|suture wick using 10-0 vicryl
11302702|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
11302703|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
11302704|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
11302705|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
11302706|NCT02681393|Experimental|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
11302707|NCT02681393|Active Comparator|Brochure Only|Participants will receive the Aerobic Exercise After Stroke educational brochure only.
11302708|NCT02681380|Experimental|Relation learning|Participants of this group will benefit form a specific learning on relation, Balint like. They will have 7 sessions during 3 months.
11302709|NCT02681380|Placebo Comparator|Control group|Participants of this group will have no learning related to relation with patient.
11302710|NCT02681367|No Intervention|fresh embryo transfer|Patient with RIF underwent ICSI cycle followed by Day 5 fresh embryo transfer.
11302711|NCT02681367|Experimental|Freeze all|Patient with RIF. All of them underwent ICSI cycle, all their embryos were cryopreserved at Day 5 and transferred in a consecutive natural cycle.
11302712|NCT02681354|Experimental|A additional BioRescue training|Using a playful rehabilitation, BioRescue
11302713|NCT02681354|No Intervention|Regular training|
11302714|NCT02681328||Afirma GEC|single molecular test GEC of collected tissue
11302715|NCT02681328||ThyroSeq v.2|single molecular test ThyroSeq v.2 of collected tissue
11302716|NCT02681328||Afirma GSC|single molecular test GSC of collected tissue
11302717|NCT02681328||ThyroSeq v.3|single molecular test ThyroSeq v.3 of collected tissue
11302718|NCT02681315|Experimental|6 liter/min group|Infants will be extubated to a HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) at ﬂow rate of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
11302719|NCT02681315|Active Comparator|3 liter/min group|Infants will be extubated to HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) a ﬂow rate of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
11302720|NCT02681302|Experimental|All Participants|"Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
~Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
11302721|NCT02681289|Experimental|physiotherapy group|Early goal directed neuromotor therapy applied by physiotherapist
11302722|NCT02681289|Experimental|family group|Early goal directed neuromotor therapy applied by family
11302723|NCT02681276|Experimental|Irrigation with 3% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 3 % NaOCl irrigation during instrumentation. If the patient's first visit was on an uneven date the concentration of the irrigant was 3 %.
11302724|NCT02681276|Active Comparator|Irrigation with 0.5% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 0.5 % NaOCl irrigation during instrumentation. If the patient's first visit was on an even date the concentration of the irrigant was 0.5 %.
11302725|NCT02681263|Experimental|Temocillin|"Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
~Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients)."
11302726|NCT02681250|Experimental|Titanium-zirconium|Patients receiving titanium-zirconium implants
11302727|NCT02681250|Active Comparator|Titanium|Patients receiving titanium implants
11302728|NCT02681237|Experimental|Cediranib and Olaparib|"Cediranib will be given by mouth, at a dose of 20 mg, once a day, everyday.
~Olaparib will given by mouth, at a dose of 300 mg, twice a day, every day."
11302729|NCT02681224|Active Comparator|Active Product with Occlusion|TR987 Gel with Silon Bandage
11302733|NCT02681211|Experimental|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
11302734|NCT02681211|Active Comparator|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
~Ketorolac 0.5mg/kg, max 30mg
~Metoclopramide 0.1 mg/kg, max 10mg
~Diphenhydramine 1mg/kg, max 50mg
~Normal saline fluid bolus 20mL/kg, max 1000mL"
11302735|NCT02681198|Experimental|Lofexidine and paroxetine|Lofexidine in the presence of paroxetine
11302736|NCT02681185|Experimental|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
11302737|NCT02681185|Active Comparator|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
11302738|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.
~The applied florbetaben radioactive dose will be ± 20%."
11302739|NCT02681146|Experimental|Group1|Educational advice + physiotherapist treatment
11302740|NCT02681146|Experimental|Group2|Educational advice + physiotherapist treatment
11302741|NCT02681146|Experimental|Group3|Educational advice + physiotherapist treatment
11302742|NCT02681146|Experimental|Group4|Educational advice + physiotherapist treatment
11302743|NCT02681146|Experimental|Group5|Educational advice + physiotherapist treatment
11302744|NCT02681146|Experimental|Group6|Educational advice + physiotherapist treatment
11302745|NCT02681146|Experimental|Group7|Educational advice + physiotherapist treatment
11302746|NCT02681146|Experimental|Group8|Educational advice + physiotherapist treatment
11302747|NCT02681133||patients with knee pain|
11302748|NCT02681120||High risk/BMI > 30|Women at elevated risk for breast cancer will have imaging (MRI and mammogram) pre-bariatric surgery and 1 year post-bariatric surgery, and blood and tissue collection (blood draw and biopsy) pre-bariatric surgery, 2 weeks post-bariatric surgery, and 1 year post-bariatric surgery.
11302749|NCT02681120||Women with normal BMI|Deidentified samples that were donated to the IU Komen Tissue Bank will be used for comparison to the high risk/BMI > 30 cohort.
11302750|NCT02681107|Experimental|Single Arm|Single cohort to receive Accelerated Partial Breast Irradiation (APBI) 27Gy in 5 fractions
11302751|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
11302752|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
11302753|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
11302754|NCT02681081|Other|Control|For sessions 2 through 4, maintain normal eating patterns.
11302755|NCT02681081|Active Comparator|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
11302756|NCT02681081|Active Comparator|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
11302757|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
11302758|NCT02681042|Experimental|SentreHeart Lariat|Left atrial appendage closure with SentreHeart Lariat device
11302759|NCT02681029|Experimental|Blastocyst transplantation|The infertile women who underwent intra- uterus transferring of blastocyst from thawed cleavage embryo
11302760|NCT02681029|Placebo Comparator|Control|The infertile women who underwent intra- uterus transferring of thawed cleavage embryo.
11302761|NCT02681016|Experimental|"Sirolimus-eluting stent Calypso"|"Commercially approved coronary stent system Calypso (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm."
11302762|NCT02681016|Active Comparator|"Everolimus-eluting stent Xience Prime"|Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.
11302763|NCT02680990|Active Comparator|Exercise Education|Distribution of exercise education materials
11302764|NCT02680990|Experimental|Band Together|A strength-training and walking program with or without an exercise partner throughout neoadjuvant therapy.
11302765|NCT02680977|Experimental|MP-Equivalent; MP-Low; MP+DDCI|"MP-Equivalent: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI (for example 100mg of Madopar corresponds to 500mg of Levodopa in MP).
~MP-Low: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 350mg of Levodopa in MP) MP+DDCI: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 100mg of Levodopa in MP plus 25mg of Benserazide)"
11302766|NCT02680977|Active Comparator|LD+DDCI; LD-DDCI|"LD+DDCI: Levodopa plus Benserazide (dispersible formulation). The dose is calculated as 3.5mg per kg of body weight.
~LD-DDCI: Levodopa without any dopa decarboxylase inhibitor (galenic formulation). The dose is 5-fold than LD+DDCI."
11302767|NCT02680977|Placebo Comparator|Placebo|Powder of groundnuts
11302768|NCT02680951|Experimental|Dose Level 1|"Study participants #1 - #6 receive dose level 1 of dasatinib (60/mg/m2/day) in addition to the standard treatment, for up to 2 courses. Each treatment course is 29 days.
~Treatment course 1 consists of:
~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5
~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5
~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5
~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines
~Dasatinib orally, once daily on days 6-29
~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
11302769|NCT02680951|Experimental|Dose Level 2|"Study participants # 7 - # 12 receive dose level 2 of dasatinib (80/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 1 did not experience intolerable side effects. Each treatment course is 29 days.
~Treatment course 1 consists of:
~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5
~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5
~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5
~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines
~Dasatinib orally, once daily on days 6-29
~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
11302770|NCT02680951|Experimental|Dose Level 3|"Study participants # 13 - # 18 receive dose level 3 of dasatinib (100/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 2 did not experience intolerable side effects. Each treatment course is 29 days.
~Treatment course 1 consists of:
~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5
~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5
~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5
~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines
~Dasatinib orally, once daily on days 6-29
~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
11302771|NCT02680938|Active Comparator|oxytocin group|10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
11302772|NCT02680938|Placebo Comparator|control group|1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
11302773|NCT02680925|Placebo Comparator|Conventional ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
11302774|NCT02680925|Active Comparator|Lung protective ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 6 ml/kg with PEEP 6 cmH2O during two-lung ventilation and TV of 4 ml/kg PEEP 6 cmH2O during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
11302775|NCT02680912|Experimental|Warm needle acupuncture|"Warm needle acupuncture (wenzhen; 温针) is where moxa cones are placed on the handle of the needle, after the needle has been inserted. Once lit, heat transmits along the shaft of the needle to the acupuncture point.
~Moxa refers to the herb mugwort (Artemisia vulgaris) that is burnt to warm specific parts of the body, including acupuncture points."
11302776|NCT02680912|Active Comparator|Basic needle acupuncture|Basic needle acupuncture is the use of acupuncture needles alone, without other methods of stimulation.
11302777|NCT02680899|Experimental|Curricular Intervention|The intervention is a novel science education curriculum in mental health and addiction called My Mind, My Body.
11302778|NCT02680886||Novosyn® Quick|Skin closure using rapid absorbable suture material
11302779|NCT02680873|Other|SASI bypass|sleeve gastrectomy done and gastro-ileum anastomosis 2.5 meter from the ileocecal valve . the anastomosis is less than 3cmm in diameter . the concept to push undigested food early to the ileum to stimulate intestinal hormones secretion to control diabetes .
11302780|NCT02680847|Experimental|ALO-02|One arm, open label, active
11302781|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
11302782|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
11302783|NCT02680821|Other|Isolated ACL-revision|The standard operation with an isolated Anterior cruciate ligament.
11302784|NCT02680821|Other|Combined ACL and ALL surgery|An operation with an Anterior cruciate ligament combined with an anterolateral ligament.
11302785|NCT02680808|Experimental|midazolam with F901318|Pharmacokinetic profile of midazolam 2 mg orally when given after dosing with F901318 to steady state.
11302786|NCT02680795|Experimental|Wild Type UGT1A1|Cohort A: Open for Enrollment Wild Type UGT1A1, Belinostat IV
11302787|NCT02680795|Experimental|Heterozygous UGT1A1*28|Cohort B: Closed For Enrollment Heterozygous UGT1A1, Belinostat IV
11302788|NCT02680795|Experimental|Homozygous UGT1A1*28|Cohort C: Open For Enrollment Homozygous UGT1A1, Belinostat IV
11302789|NCT02680782|Experimental|X4P-001 QD|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
11302790|NCT02680782|Experimental|X4P-001 BID|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
11302791|NCT02680769|Experimental|Magnesium|300 mg of citrate Mg/daily
11302792|NCT02680769|Placebo Comparator|Placebo|placebo group
11302793|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
11302794|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
11302795|NCT02680743|Experimental|Intervention Group|"Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.
~They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.
~Intervention:Education of parents to pursue prompt hearing screening."
11302796|NCT02680730|Experimental|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
11302797|NCT02680730|Experimental|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
11302798|NCT02680717|Active Comparator|Treatment 1|Calcipotriene 0.005% ointment
11302799|NCT02680717|Active Comparator|Treatment 2|Clobetasol 0.05% ointment
11302801|NCT02680704|Other|PEEP Titration Arm|PEEP titrated mechanical ventilation
11302802|NCT02680691|Experimental|Robot, then conventional training|Robot assisted gait training 4 weeks after conventional gait training
11302803|NCT02680691|Active Comparator|Conventional, then robot training|Conventional gait training 4 weeks after robot assisted gait training
11302804|NCT02680678|Active Comparator|Colloid preload|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) 15 minutes before spinal anesthesia.
11302805|NCT02680678|Active Comparator|Colloid Co-load|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) beginning with spinal anesthesia.
11302806|NCT02680678|Active Comparator|Crystalloid Preload|20 patients each patient receives 20 ml/kg of Ringer's lactate solution 15 minutes before spinal anesthesia.
11302807|NCT02680678|Active Comparator|Crystalloid Co-load|20 patients each patient receives 20 ml/kg of Ringer's lactate solution beginning with spinal anesthesia.
11302808|NCT02680652||CVID|Patients with a diagnosis of Common Variable Immune Deficiency
11302809|NCT02680652||Healthy Controls|age matched healthy controls
11302810|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
11302811|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
11302812|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
11302813|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
11302814|NCT02680626|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
11302815|NCT02680626|Active Comparator|Non-magnesium|Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks
11302816|NCT02680613|Experimental|Motivational SMS|This arm will receive 15 motivational SMS about cervical cancer and screening.
11302817|NCT02680613|Experimental|Travel Voucher|This arm will receive a voucher covering return transport from the screening clinic. This arm will also receive identical 15 motivational SMS about cervical cancer and screening as the Motivational SMS arm.
11302818|NCT02680613|No Intervention|Control|This arm will receive standard sensitization during study period (church announcements, screening promotion by key community leaders and posters in community, as well as sensitization by the research assistants conducting the door-to-door household recruitment) during the study and follow-up period. They will also receive one SMS message with the location of screening services during the study period. At the conclusion of the study, participants in the arm will receive identical motivational SMS as the other two arms.
11302819|NCT02680600|Experimental|Study arm|"Cefepime dosing
~Blood sampling
~Urine sampling
~Determination of renal markers
~Population pharmacokinetic modeling
~Covariate screening
~Monte Carlo simulations"
11302820|NCT02680587|Placebo Comparator|Observational (no SBRT)|Evaluating men with oligometastatic prostate cancer lesions randomized to observation
11302821|NCT02680587|Experimental|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
11302822|NCT02680587|Experimental|DCFPyL-PET/MRI|DCFPyL-PET/MRI or -PT/CT Estimate the proportion of DCFPyL-PET/MRI or -PET/CT positive sites that are positive for new or progressive metastatic disease by bone scan at 6-months from SBRT and vice versa
11302823|NCT02680574|Experimental|vadadustat|
11302824|NCT02680574|Active Comparator|darbepoetin alfa|
11302825|NCT02680561|Experimental|Treatment A: Fp MDPI|Single inhalation dose of Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
11302826|NCT02680561|Experimental|Treatment B: FS MDPI|Single inhalation dose of Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
11302827|NCT02680561|Active Comparator|Treatment C: Comparator|Single inhalation dose of fluticasone propionate/salmeterol (ADVAIR DISKUS) on Day 1 into 1 of 6 treatment sequences (ABC, BCA, CAB, ACB, BAC, or CBA)
11302828|NCT02680548|Active Comparator|0.9% saline (salt water)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
11302829|NCT02680548|Active Comparator|local anesthetic (freezing)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
11302830|NCT02680548|Active Comparator|local anesthetic (freezing) and steroid|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
11302831|NCT02680535|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to ultrasound-guided laser irradiation using a FDA cleared laser and an interstitial optical fiber.
11302832|NCT02680522|Active Comparator|Control Group|composed of healthy volunteers who underwent training with virtual reality. Exercises with game through virtual reality
11302833|NCT02680522|Experimental|Parkinson's Group|composed of patients with Parkinson's disease and who underwent training with virtual reality. exercises with game through virtual reality
11302834|NCT02680509|Experimental|All|All patient will undergo a unilateral sympathicotomy R3. After this left and right will be compared
11302835|NCT02680496|Experimental|Lokomat - Treadmill - Overground|Walking order: lokomat walking, treadmill walking, overground walking
11302836|NCT02680496|Experimental|Lokomat - Overground - Treadmill|Walking order: lokomat walking, overground walking, treadmill walking
11302837|NCT02680496|Experimental|Treadmill - Lokomat - Overground|Walking order: treadmill walking, lokomat walking, overground walking
11302838|NCT02680496|Experimental|Treadmill - Overground - Lokomat|Walking order: treadmill walking, overground walking, lokomat walking
11302839|NCT02680496|Experimental|Overground - Lokomat - Treadmill|Walking order: overground walking, lokomat walking, treadmill walking
11302840|NCT02680496|Experimental|Overground - Treadmill - Lokomat|Walking order: overground walking, treadmill walking, lokomat walking
11302841|NCT02680483||AF cohort|AF consecutive patients
11302842|NCT02680470|Experimental|Virtual Observed Therapy|Intervention = Virtual observed therapy of participants taking TB therapy
11302843|NCT02680457|Active Comparator|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
11302844|NCT02680457|Active Comparator|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
11302845|NCT02680444|Experimental|Reappraisal-Only Intervention|Participants were instructed to independently practice the Self-Administered Reappraisal-Only Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the positive reappraisal instructions available online. This involved thinking about how one could grow, learn or benefit from the negative event in any way possible.
11302846|NCT02680444|Experimental|Mindful-Reappraisal Intervention|Participants were instructed to independently practice the Self-Administered Mindful-Reappraisal Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the Mindful-Reappraisal instructions available online. This involved thinking about the negative event in an objective, non-judgmental way, then following the Reappraisal-Only instructions, and closing off with a brief mindfulness breathing technique.
11302847|NCT02680444|Active Comparator|Event Recall Active Control|Participants were instructed to independently practice the Self-Administered Event Recall Exercise in the evening for five days. In this condition, participants were only instructed to recall a negative event from that day with no reappraisal exercise.
11302848|NCT02680431||Neurofibromatosis 1|10 mL venous blood sample taken from patients with type 1 neurofibromatosis
11302849|NCT02680431||Control|10 mL venous blood sample taken from age- and gender-matched healthy controls
11302850|NCT02680418|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
11302851|NCT02680418|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
11302852|NCT02680418|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
11302853|NCT02680418|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
11302854|NCT02680418|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
11302855|NCT02680418|Experimental|Multiple dose|Repeat doses of FDL169 to be administered at a dose level to be determined
11302856|NCT02680405||Atopic Dermatitis|Subjects with Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
11302857|NCT02680405||Non Atopic Dermatitis|Subjects with no Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
11302858|NCT02680392|Experimental|Pulsed and Continuous Radiofrequency|In this group of patients undergoing total knee arthroplasty (allocation of patients is randomized), Pulsed radiofrequency (PRF) is applied to the saphenous nerve of the knee, associated to Continuous Radiofrequency (TRF) applied to the genicular nerves of the knee . A sham catheter is inserted in the mid-tigh to simulate a continuous adductor canal block, and connected to an infusion of normal saline (assessor and patient blinded to the treatment)
11302859|NCT02680392|Active Comparator|Continuous adductor canal block|"Continuous Adductor Canal Block
~Continuous adductor canal block is performed in this group of patients, with a catheter infusing ropivacaine 0.2% in the first 48 hours after surgery.
~The solutions bags are labelled in order to make assessor and patients, blinded to the treatment (Ropivacaine vs Normal Saline)"
11302860|NCT02680379|Experimental|Minocycline, then Minocycline/Lovastatin|Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
11302861|NCT02680379|Experimental|Lovastatin, then Minocycline/Lovastatin|Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months
11302862|NCT02680366|Experimental|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
11302863|NCT02680366|Active Comparator|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
11302864|NCT02680353|Active Comparator|Study group|Patients received bilateral superficial cervical plexus block before operation
11302865|NCT02680353|No Intervention|Control group|Patients received no intervention before operation
11302866|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
11302867|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
11302868|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
11302869|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
11302870|NCT02680288|Placebo Comparator|Oral Placebo|Oral inert treatment
11302871|NCT02680288|Experimental|Active Treatment, Low-Dose|Lorcaserin 10 mg, single dose
11302872|NCT02680288|Experimental|Active Treatment, High-Dose|Lorcaserin 20 mg, single dose
11302873|NCT02680275|Experimental|Doxycycline,Dead Sea Peloid Gel,placebo|"Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally
~Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally"
11302874|NCT02680262|Experimental|Intervention group 1|HPV self-sampling kit mailed directly
11302875|NCT02680262|Experimental|Intervention group 2|HPV self-sampling kit on demand
11302876|NCT02680262|Experimental|Intervention group 3|second reminder
11302877|NCT02680249|Experimental|CTP-656 Fed, low fat|Single dose of CTP-656 150 mg administered after a low-fat breakfast
11302878|NCT02680249|Experimental|CTP-656 Fasted|Single dose of CTP-656 150 mg administered fasted
11302879|NCT02680249|Experimental|CTP-656 Fed, high fat|Single dose of CTP-656 150 mg administered after a moderate-fat breakfast
11302964|NCT02679742|Experimental|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program
11302880|NCT02680236||Breast Cancer Patients|"This pilot study proposes to explore the effect of art therapy on breast cancer patients' perception of pain, and its impact on daily functioning by offering four sessions of individual art therapy, spaced between one to three weeks apart.
~The study will be open to breast cancer patients over the age of 18, who have been assessed by the Royal Marsden (RM) Pain Team, and who report having persistent post treatment pain of at least moderate intensity for the preceding two weeks despite having been optimally treated for their pain already, and who fulfil the inclusion criteria."
11302881|NCT02680223|Active Comparator|Precision tinted lenses|Precision tinted lenses will be provided for one month.
11302882|NCT02680223|Sham Comparator|Non-beneficial tinted lenses|Tinted lenses at a colour different from but not easily distinguishable from the precision tinted will be provided for one month.
11302883|NCT02680210|Other|cognitive measures and questionnaires|the material of the study will consist of cognitive measures and questionnaires in order to (1) compare the cognitive performances and behavioral manifestations between patients with TBI and volunteers without neurological disorders and (2) to analyze the links between cognitive and behavioural measures in the TBI population
11302884|NCT02680197|Experimental|CHF5259 12.5 μg total daily dose|"CHF5259 or Placebo administration:
~Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
11302885|NCT02680197|Experimental|CHF5259 25 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
11302886|NCT02680197|Experimental|CHF5259 50 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
11302887|NCT02680197|Experimental|CHF5259 100μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day
~Interventions :
~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
11302888|NCT02680197|Placebo Comparator|CHF5259 matched Placebo BID|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day
~Interventions :
~Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram
~Day 14: pre-dose spirometry
~Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
11302889|NCT02680184|Experimental|Part 1: Dose-Escalation - CMP-001 and Pembrolizumab|Participants will receive up to 5 escalating dose levels (1 milligram [mg], 3 mg, 5 mg, 7.5 mg and 10 mg) of CMP-001 via intratumoral injection according to one of 2 schedules (Schedule A: once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued; Schedule B: once weekly for 2 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule.
11302890|NCT02680184|Experimental|Part 1: Dose-Expansion - CMP-001 and Pembrolizumab|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
11302891|NCT02680184|Experimental|Part 2: CMP-001 Monotherapy and Crossover to Combination|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses <10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
11302892|NCT02680171|Experimental|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
11302893|NCT02680171|Sham Comparator|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
11302894|NCT02680158|Experimental|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
11302895|NCT02680158|Experimental|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
11302965|NCT02679742|Placebo Comparator|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program
11302896|NCT02680158|Experimental|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
11302897|NCT02680158|Experimental|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
11302898|NCT02680158|Experimental|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
11302899|NCT02680158|Experimental|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
11302900|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
11302901|NCT02680132|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
11302902|NCT02680132|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
11302903|NCT02680119|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
11302904|NCT02680119|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
11302905|NCT02680106|Experimental|SPINNER|All patients in this arm will be treated with the SPINNER dressing.
11302906|NCT02680106|Active Comparator|JELONET|All patients in this arm will be treated with JELONET dressing, regarded as the standard of current care for split-skin donor-site wounds.
11302907|NCT02680093||Cervical length in pregnant women.|"Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up. will be followed while coming to routine monitoring.
~physiological parameter of cervical length will be measured as the differential predictor to determine their due date."
11302908|NCT02680080|Active Comparator|Positive control group|"subjects will receive a single 400 mg tablet of Moxifloxacin - the most commonly used positive control in thorough QTc (TQT) studies. Subjects will be continuously recorded by a Holter monitor for 24 hours"
11302909|NCT02680080|Active Comparator|Grapefruit group|subjects will drink one liter of fresh pink-grapefruit juice as fast as possible. The pink-grapefruit juice will be squeezed in the morning of the experiment in the cardiology department. ECG will be performed immediately pre dose and at 1, 2, 3, 4, 6, 8, 12, 24 after fresh pink-grapefruit juice administration. In addition, subjects will be continuously recorded by a Holter monitor for 24 hours
11302910|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
11302911|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
11302912|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
11302913|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
11302914|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
11302915|NCT02680041|Experimental|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
11302916|NCT02680028|Active Comparator|Standard length intramedullary nail|220mm intramedullary nail
11302917|NCT02680028|Experimental|Short length intramedullary nail|175mm intramedullary nail
11302918|NCT02680015|Experimental|Experimental Group|Immediate enrollment in the PEERS group.
11302919|NCT02680015|No Intervention|Waitlist Group|Research measures while waiting for PEERS; will receive PEERS within one year.
11302920|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
11302921|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
11302922|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
11302923|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
11302924|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
11302925|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
11302926|NCT02679989|Experimental|Intermittent Energy Restriction|Weight loss intervention: Intermittent Energy Restriction
11302927|NCT02679989|Active Comparator|Continuous Energy Restriction|Weight loss intervention: Continuous Energy Restriction
11302928|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
11302929|NCT02679963|Experimental|Maintenance Olaparib|Olaparib (experimental arm): 600 mg daily (2 doses of 300 mg (2*2 tablets of 150 mg) taken approximately 12 hours apart) po, administered until disease progression or toxicity requiring its interruption. Olaparib has to be started no later than 6 weeks after the last administration of induction chemotherapy, and no later than 3 weeks after the CT scan confirming response to induction chemotherapy
11302930|NCT02679963|Placebo Comparator|Placebo|Placebo (control arm): 2 doses of 300 mg per day (2*2 tablets of 150 mg) taken approximately 12 hours apart
11302931|NCT02679950||Initial diagnosis|The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
11302932|NCT02679950||Late relapse|"The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse.
~Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department."
11302933|NCT02679937|Experimental|Fit4Duty|6-week weight gain prevention group
11302934|NCT02679937|Active Comparator|Nutrition Education|Two, 50 minute educational videos.
11302935|NCT02679924|Experimental|Restylane Silk|Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
11302936|NCT02679924|Sham Comparator|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
11302937|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
11302938|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
11302939|NCT02679898|No Intervention|Lean Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
11302940|NCT02679898|No Intervention|Overweight/Obese Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
11302941|NCT02679898|Experimental|Unloaded-Whole Body Vibration (WBVT)|Lower-body exercise training on a vibration platform
11302942|NCT02679898|Experimental|Loaded-Whole Body Vibration (WBVT)|Externally loaded lower-body exercise training on a vibration platform
11302943|NCT02679872||VATS team 1|Video-assisted thoracoscopic surgery team, from institution/hospital 1.
11302944|NCT02679872||VATS team 2|Video-assisted thoracoscopic surgery team, from institution/hospital 2.
11302945|NCT02679872||VATS team 3|Video-assisted thoracoscopic surgery team, from institution/hospital 3.
11302946|NCT02679872||VATS team 4|Video-assisted thoracoscopic surgery team, from institution/hospital 4.
11302947|NCT02679859|Experimental|B-type natriuretic guided medical therapy optimisation|B-type natriuretic guided medical therapy optimisation
11302948|NCT02679859|No Intervention|Normal medical management|
11302949|NCT02679846|Experimental|Standardized protocol of AEDs withdrawal|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
11302950|NCT02679846|No Intervention|Current practice|Centers will continue their current practice
11302951|NCT02679833|Placebo Comparator|Placebo|A toothpaste, with the same matrix, all components, and appearance like the active arm but not containing vitamin B12.
11302952|NCT02679833|Active Comparator|Cyanocobalamin|A toothpaste with cyanocobalamin 100 µg cyanocobalamin per 1 g.
11302953|NCT02679820|Experimental|PostPlacental IUD insertion|Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries.
11302954|NCT02679820|No Intervention|Control|IUD will be offered as a method of contraception after puerperium
11302955|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
11302956|NCT02679807|Placebo Comparator|Placebo|sucrose
11302957|NCT02679794|Experimental|Egg consumption|Consuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
11302958|NCT02679794|Placebo Comparator|Control|Consuming sautéed vegetables and 3g canola oil without eggs
11302959|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
11302960|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
11302961|NCT02679768|Active Comparator|Circadian Reinforcement Therapy|Circadian reinforcement therapy
11302962|NCT02679768|Placebo Comparator|Standard treatment|Standard treatment
11302963|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
11302966|NCT02679729|Experimental|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302967|NCT02679729|Experimental|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302968|NCT02679729|Experimental|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302969|NCT02679729|Experimental|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302970|NCT02679729|Experimental|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302971|NCT02679729|Experimental|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302972|NCT02679729|Experimental|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
11302973|NCT02679729|Experimental|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
11302974|NCT02679716|Other|study group|MRI of the cerebral arteries ist performed
11302975|NCT02679703|Experimental|High voltage|The applied parameters of high voltage electrical stimulation are medium voltage of 100 volts, an increase in the course of the session, frequency of 10 Hz, with application in the donor areas of thigh or scalp for 40 minutes, 25% above of level engine daily until complete epithelialization, and removal of the dressing type rayon.
11302976|NCT02679703|Experimental|Neuromuscular transcutaneous electrical stimulation (TENS)|10 Hz, 40 min, 200 μs and 25% above of motor level
11302977|NCT02679703|Experimental|Control Group|There will be no intervention
11302978|NCT02679690|Experimental|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
11302979|NCT02679690|Experimental|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
11302980|NCT02679677|Sham Comparator|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
11302981|NCT02679677|Experimental|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
11302982|NCT02679664|Experimental|Treatment group|20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
11302983|NCT02679664|No Intervention|Control group|Standard medical care only. No rosuvastatin group.
11302984|NCT02679651||Control group|Healthy Adults without foot pain
11302985|NCT02679651||DIsease group|Adults diagnosed with fat pat atrophy and report symptoms of foot pain and have participated in clinical trial to treat fat pad atrophy.
11302986|NCT02679638||Kaplan Hospital|Breast cancer survivors recruited at the Kaplan Medical Center
11302987|NCT02679638||Rambam Hospital|Breast cancer survivors recruited at the Rambam Medical Center
11302988|NCT02679638||Sheba|Breast cancer survivors recruited at the Sheba Medical Center
11302989|NCT02679638||Barzilai|Breast cancer survivors recruited at the Barzilai Medical Center
11302990|NCT02679599|Other|Cardiac rehabilitation as usual|Participants will receive cardiac rehabilitation as usual (i.e., as offered in the clinical setting).
11302991|NCT02679599|Experimental|Cardiac rehabilitation plus B-MOBILE-CARDIAC smartphone app|Participants will receive cardiac rehabilitation as usual, plus access to the B-MOBILE-CARDIAC smartphone application through 4 weeks post-rehabilitation.
11302992|NCT02679586|Experimental|Diffusion weighted MRI Group|"All patients will receive a double baseline diffusion weighted MRI (performed on the same day as the Baseline MRI).
~Patients participating in Part I will receive another MRI approximately 1 week (day 8-11) after the first dose of Chemotherapy (chemotherapy will be determined by the treating physician and is not assigned as part of this trial).
~Patients participating in Part II will receive a single MRI 1-2 weeks after the first dose of Chemotherapy A (chemotherapy will be determined by the treating physician and is not assigned as part of this trial). A second MRI will be repeated within 2 weeks prior to the start of Chemotherapy B."
11302993|NCT02679573|Experimental|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
11302994|NCT02679573|Active Comparator|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
11302995|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
11302996|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
11302997|NCT02679547||Appendicitis|The patients with appendicitis
11302998|NCT02679547||Control|The participants without appendicitis
11302999|NCT02679534|Experimental|hand massage|"Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice do not disturb, and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand."
11303030|NCT02679313|Experimental|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit).
11303000|NCT02679534|Active Comparator|hand holding|The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
11303001|NCT02679534|Other|rest group|The passive control group will have a 20 minutes rest period including the same environmental adjustments as the massage and hand holding groups in addition to the standard care administered in the ICU. The standard care includes the pharmacological and non-pharmacological treatments used to promote recovery and symptom relief. In the study ICU, cardiac surgery patients are automatically prescribed a pain management protocol that includes the regular administration of morphine, unless extraordinary patient circumstances require different prescriptions. Patients might equally receive breakthrough doses of analgesia in addition to regular opioids. Of the existing non-pharmacological interventions, repositioning and back rubs are commonly employed in the study ICU to provide patient comfort.
11303002|NCT02679521|Active Comparator|rESWT|Radial extracorporeal shock wave therapy (rESWT).
11303003|NCT02679521|Placebo Comparator|Placebo|Placebo treatment.
11303004|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
11303005|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
11303006|NCT02679495|Active Comparator|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
11303007|NCT02679495|No Intervention|No intervention|No meassures are taken to change life style of enrolled patients.
11303008|NCT02679482||Selective laser trabeculoplasty (SLT)|Patients who underwent to Selective laser trabeculoplasty
11303009|NCT02679482||Pattern laser trabeculoplasty (PLT)|Patients who underwent to Pattern laser trabeculoplasty
11303010|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
11303011|NCT02679456|Active Comparator|Treatment Group 1 (Fluconazole)|Fluconazole
11303012|NCT02679456|Experimental|Treatment Group 2: (SCY-078)|Dose regimen 1
11303013|NCT02679456|Experimental|Treatment Group 3 (SCY-078)|Dose regimen 2
11303014|NCT02679443|No Intervention|Delayed Arm|Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
11303015|NCT02679443|Experimental|Immediate Arm|Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
11303016|NCT02679430|Other|Prostate Arterial Embolization|"Intervention: Patients will undergo prostatic artery embolization.
~The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms."
11303017|NCT02679417|Active Comparator|aerobic exercise|Each participant reach a minimum of 50 minutes of some form of aerobic exercise including running on a treadmill 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
11303018|NCT02679417|Active Comparator|resistant exercise|Each participant reach a minimum of 50 minutes of some form of strength training involving repetitions of a resistance training exercise for each major muscle group at an intensity for at least 60% of a one-repetition max, 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
11303019|NCT02679391||A|69 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2011. All post weight loss. , 96% female, BMI by the time of operation 26, mean age 41 (SD 9.5). Their mean weight loss in BMI units: 17.8 (SD 5.12).
11303020|NCT02679391||B|70 consecutive operated patients by plastic surgeons at Karolinska University Hospital 2010-2012. All post weight loss. 86% female, BMI by the time of oepration 26, mean age 38.6 (SD 11.4). Their mean weight loss in BMI units: 17.4 (SD 4.8).
11303021|NCT02679391||C|70 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2013-2014. All post weight loss. 90% female, BMI by the time of operation 26, mean age 46.8 (SD 10.1). Their mean weight loss in BMI units: 16.3 (SD 5.11)
11303022|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
11303023|NCT02679365|Experimental|group a|This arm will have lower segment cesarean section done with double locking technique for closure of Rectus Sheath.
11303024|NCT02679365|Active Comparator|group b|This arm will have lower segment cesarean section done with continuous non-locking technique for closure of rectus sheath.
11303025|NCT02679352|Experimental|SMR stemless|Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
11303026|NCT02679339|Experimental|CNTX-2022 (lidocaine gel, 40%)|Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
11303027|NCT02679339|Placebo Comparator|Placebo|Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
11303028|NCT02679326|Experimental|study group|will receive stretching guidance and high level active Ultrasound
11303029|NCT02679326|Placebo Comparator|control group|will receive stretching guidance and very low level of Ultrasound
11303208|NCT02678182|Experimental|Arm A4: Rucaparib|600mg PO twice daily
11303031|NCT02679300|Experimental|Virtual reality group|During a single intervention session, participants will perform 2 sets of 2 minutes of pelvic tilt exercises using serious games. These serious games have to be controlled by pelvic tilts. Patients will perform the exercises in a standing position in front a TV-screen, on which the games will be displayed. Wireless motion sensors will be mounted to the patient's spine and pelvis to track the movements of the pelvis.
11303032|NCT02679300|Active Comparator|Control group|During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
11303033|NCT02679287|Experimental|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
~SAP=sensor-augmented pump only
~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
11303034|NCT02679287|Experimental|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
~SAP=sensor-augmented pump only
~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
11303035|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
11303036|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
11303037|NCT02679261|Experimental|Atorvastatin|Oral administration Atorvastatin 20 mg per day
11303038|NCT02679261|Placebo Comparator|Control|Oral administration of Placebo
11303039|NCT02679248|Experimental|Neo40 Daily®|
11303040|NCT02679248|Experimental|Placebo|
11303041|NCT02679235|Experimental|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
11303042|NCT02679222|Experimental|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
11303043|NCT02679209|Experimental|Bone allograft|commercially available demineralized bone matrix putty allograft will be used to fill in the defect after opening a periodontal flap
11303044|NCT02679209|Experimental|Amnion chorion membrane|Amnion chorion commercially available allograft bioresorbable membrane as a guided tissue regeneration technique will be used to in the defect after opening a periodontal flap
11303045|NCT02679196|Experimental|KA2237|Open label treatment with KA2237
11303046|NCT02679183|Placebo Comparator|Control 0|No Intervention. This group received Premature Milk Formula. This group did not receive any Medically-Graded Honey.
11303047|NCT02679183|Experimental|Group 1|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 5 gram/day) for 2 weeks
11303048|NCT02679183|Experimental|Group 2|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 10 gram/day) for 2 weeks
11303049|NCT02679183|Experimental|Group 3|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 15 gram/day) for 2 weeks
11303050|NCT02679170||Routine clinical practice group (NSCLC ALK+)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+
11303051|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
11303052|NCT02679131|Experimental|Cohort A|Normal Renal function, Belinostat IV, Dose A
11303053|NCT02679131|Experimental|Cohort B|Mild Impairment, Belinostat IV, Dose A
11303054|NCT02679131|Experimental|Cohort C|Moderate Impairment, Belinostat IV, Dose B
11303055|NCT02679131|Experimental|Cohort D|Severe Impairment, Belinostat IV, Dose B
11303056|NCT02679118|Experimental|Sentire|The patients will undergo their laparoscopic gastric bypass, during the operative period at pre-defined time points, a small amount of gas from the abdomen will be withdrawn and analyzed for the device. The laparoscopic gastric bypass will proceed without interference or effect from the device.
11303057|NCT02679105|Placebo Comparator|ALK diluent|Human albumin
11303058|NCT02679105|Active Comparator|ALK Alutard birch or 5-grasses|Grass pollen suspension or birch pollen suspension
11303059|NCT02679092|Active Comparator|Dilapan (14wks 0days-15wks, 6days)|The clinician will place 1 to 2 osmotic cervical dilators (Dilapan-S) (4mm x 65mm) the day before the participant's procedure.
11303060|NCT02679092|Active Comparator|Dilapan (16wks 0days-18wks, 6days)|The clinician will place 3 to 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
11303061|NCT02679092|Experimental|Mifepristone (14wks 0days-15wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
11303062|NCT02679092|Experimental|Mifepristone (16wks 0days-18wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
11303063|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
11303064|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
11303065|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
11303066|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
11303067|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
11303260|NCT02677792|Experimental|Behavioral Family Intervention (BFI)|
11345218|NCT02400372|No Intervention|3. Comparison group|Polymem dressing
11303068|NCT02679053|Experimental|Exercise (IG)|Aerobic exercise three times per week on indoor bicycles at 60 to 75% of maximal heartrate aiming at a weekly total of 17.5kcal/kg bodyweight for 6 consecutive weeks. The exercise will take place under supervision. At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
11303069|NCT02679053|Placebo Comparator|Control (CG)|Basic stretching and mobilisation program 3 times per week each for approx. 40 minutes, also under supervision for 6 consecutive weeks. At the end of every week physical fitness is evaluated by the queens step test.At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
11303070|NCT02679040|Experimental|Immediate Mammary Reconstruction|Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction
11303071|NCT02679027|Active Comparator|Easy intubation|Intubation difficulty score <5
11303072|NCT02679027|Active Comparator|Difficult intubation|Intubation difficulty score >5
11303073|NCT02679014|Placebo Comparator|Placebo|Participants will receive placebo capsules (2 capsules) twice daily for 28 days.
11303074|NCT02679014|Experimental|RO5459072|Participants will receive RO5459072 100 milligrams (mg) capsules (2*50 mg capsules) twice daily for 28 days.
11303075|NCT02679001||RA participants treated with a TNF inhibitor or TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.
11303076|NCT02678988|Experimental|A1: Tocilizumab AI followed by PFS-NSD in abdomen|Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
11303077|NCT02678988|Experimental|A2: Tocilizumab AI followed by PFS-NSD in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
11303078|NCT02678988|Experimental|A3: Tocilizumab AI followed by PFS-NSD in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
11303079|NCT02678988|Experimental|B1: Tocilizumab PFS-NSD followed by AI in abdomen|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
11303080|NCT02678988|Experimental|B2: Tocilizumab PFS-NSD followed by AI in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
11303081|NCT02678988|Experimental|B3: Tocilizumab PFS-NSD followed by AI in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
11303082|NCT02678975|Active Comparator|Control|Alkylating chemotherapy
11303083|NCT02678975|Experimental|Experimental|Alkylating chemotherapy + disulfiram + copper
11303084|NCT02678962|Active Comparator|SN6AD1 group|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
11303085|NCT02678962|Active Comparator|SBL-3 group|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
11303086|NCT02678962|Active Comparator|LS-313 MF30 group|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
11303087|NCT02678962|Active Comparator|AT LISA tri 839 MP group|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
11303088|NCT02678962|Active Comparator|ART group|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
11303089|NCT02678962|Active Comparator|LS-313 MF30T group|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
11303090|NCT02678949|Experimental|Inhaled Fluticasone 50 mcg/twice day|Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
11303091|NCT02678949|Experimental|Inhaled Fluticasone 100 mcg/twice day|Group 3;Inhaled fluticasone. 100 mcg/twice day for a period of 4 weeks
11303092|NCT02678949|Experimental|Inhaled Albuterol|Group 2 and group 3, inhaled albuterol one dose of 400 mcg.
11303093|NCT02678936|Experimental|PRP|The operation will be performed with application of platelet rich plasma
11303094|NCT02678936|No Intervention|non-PRP|The operation will be performed without addition of platelet-rich plasma
11303095|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
11303096|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
11303097|NCT02678910|Experimental|Ovarian Cryopreservation|Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use.
11303098|NCT02678897|No Intervention|Pain management in early pregnancy MTOP|Patients in early pregnancy (pregnancy weeks <9weeks) undergoing medical termination of pregnancy gets Ibuprofen (tbl 600mg 3 times a day) and Paracetamol (tbl 1000mg 3 times a day).
11303099|NCT02678897|Experimental|Patient controlled analgesia (PCA)|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.
~Patients get pain medication (Oxynorm) via PCA"
11303100|NCT02678897|Active Comparator|Oxynorm on-demand|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.
~Patients get extra pain medication (Oxynorm) on-demad from the nurse."
11303101|NCT02678884|Experimental|HNSCC Patients receiving RT|
11303102|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
11303261|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
11303103|NCT02678858|Experimental|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) shall target expressive and interactional behavior skills together with those social cognitive domains (facial and prosodic affect recognition, social perception, theory-of-mind) known to be most impaired (Savla, 2012) and most closely associated with functional outcome (Fett, 2012) in schizophrenia.
11303104|NCT02678858|Active Comparator|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Therapy (NCRT) shall target impairments in attention, memory, and executive functions as an active comparator to the ISST.
11303105|NCT02678845|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
11303106|NCT02678845|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
11303107|NCT02678832||Cancer patients|
11303108|NCT02678832||Physicians|
11303109|NCT02678832||Oncology nurses|
11303110|NCT02678819|Experimental|Digital Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid during anesthesia and intensive care crises management.
11303111|NCT02678819|No Intervention|No digital aid|Anesthesia and intensive care crises managed without any cognitive aid.
11303112|NCT02678806|Experimental|Postoperative radiotherapy group|Patients hospitalized in Affiliated Tumor Hospital of Guangxi Medical University from 1st November 2017, who were diagnosed as BCLC-A stage hepatocellular carcinoma, accepted hepatocellular carcinoma resection, pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule < 1cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction were selected and received margin postoperative radiotherapy.
11303113|NCT02678806|Active Comparator|Postoperative TACE group|
11303114|NCT02678793|Other|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
11303115|NCT02678780|Experimental|Cohort A|"Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.
~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)"
11303116|NCT02678780|Experimental|Cohort B|Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
11303117|NCT02678767|Experimental|HIV+ with neurocognitive disorder|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
11303118|NCT02678767|Active Comparator|HIV+ without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
11303119|NCT02678767|Active Comparator|HIV- without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
11303120|NCT02678741|Active Comparator|No clinical response|No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy
11303121|NCT02678741|Active Comparator|Develop PD|Develop PD after initial clinical response to CPI monotherapy
11303122|NCT02678741|Active Comparator|Stable Disease|Stable disease for at least 6 months on CPI monotherapy
11303123|NCT02678728|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12hr of aortic cross clamp off
11303124|NCT02678728|Placebo Comparator|Normal saline|IV loading and infusion of same volume of normal saline after induction until 12hr of aortic cross clamp off
11303125|NCT02678715|Experimental|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
11303126|NCT02678715|Experimental|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
11303127|NCT02678715|Experimental|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
11303128|NCT02678715|Experimental|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
11303129|NCT02678715|Experimental|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
11303130|NCT02678715|Experimental|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
11303131|NCT02678702|Experimental|CBT-I|Behavioral intervention: CBT-I
11303132|NCT02678702|Active Comparator|Treatment as usual|Intervention: Control group receiving treatment as usual
11303133|NCT02678689|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|An age-appropriate dose of BMN 190 administered via intracerebroventricular (ICV) infusion every other week (qow) for a duration of 144 weeks.
11303134|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
11303135|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
11303136|NCT02678663|Experimental|Injection-assisted cold snare polypectomy (I-CSP)|Polyps in this group will be resected with the cold snare technique after pre-lift of the lesion with a submucosal injection of methylene blue-tinted normal saline solution. The polyp and a small rim of normal tissue will be then snared closely and removed in a single piece without the use of electrocautery.
11303137|NCT02678663|Active Comparator|Endoscopic mucosal resection (EMR).|"Polyps in this group will be removed in a single piece by using an inject-and-cut EMR technique. Methylene blue-tinted normal saline solution will be injected into the submucosal space followed by the application of snare cautery for lesion resection."
11303138|NCT02678650|Experimental|volatile anesthetics group|10min after intubation, begin to sevoflurane wash-in / wash-out operation: sevoflurane administration was interrupted for at least 10 min, by washout with a high fresh gas flow (10 l/min) to achieve a MAC value below 0.2. Following the interruption, sevoflurane was again washed in with a high fresh gas flow (6 l/min) to achieve 1 MAC end-tidal concentration as soon as possible, and repeated twice periods of 10 minutes. Discontinuation of the halogenated agent for at 15 minutes during the last wash out time.
11303139|NCT02678650|Placebo Comparator|propofol intravenous anesthesia group|propofol infusion 3-5μg / kg / h
11303140|NCT02678624|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
11303141|NCT02678624|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
11303142|NCT02678611|Experimental|Basis 250|
11303143|NCT02678611|Experimental|Basis 500|
11303144|NCT02678611|Placebo Comparator|Placebo|
11303145|NCT02678598||Micafungin group|
11303146|NCT02678585|Active Comparator|Nalbuphine|53 patients received intravenous regional lidocaine plus Nalbuphine
11303147|NCT02678585|Other|Control group|53 patients received intravenous regional lidocaine
11303148|NCT02678572|Experimental|Melphalan/HDS|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
11303149|NCT02678559|Experimental|TEE monitory system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
11303150|NCT02678559|Experimental|mini-invasive monitoring system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
11303151|NCT02678546||patients in outpatients departments|patients from outpatients departments in teaching hospital
11303152|NCT02678546||General|participants from center of continuing education in China Medical University
11303153|NCT02678533|Experimental|Fanconi anemia|G-CSF and Plerixafor
11303154|NCT02678520|Experimental|3-D conformal radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using a 3-D conformal radiation technique (3-D CRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
11303155|NCT02678520|Active Comparator|Intensity modulated radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using intensity modulated radiation therapy (IMRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
11303156|NCT02678507||Patients with chronic pain on opioids|
11303157|NCT02678494|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
11303158|NCT02678481|Experimental|MR-targeted biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.
11303159|NCT02678481|Experimental|TRUS-guided biopsy|Patients of arm B receive a saturation TRUS-guided prostate biopsy.
11303160|NCT02678468||high-risk group|children with birth history of pre-term, low birth weight children with develop delay
11303161|NCT02678468||normal group|children with normal birth history and normal development
11303162|NCT02678455|Experimental|TV005 vaccine|Participants will receive one dose of TV005 vaccine at study entry (Day 0).
11303163|NCT02678455|Placebo Comparator|Placebo|Participants will receive one dose of placebo at study entry (Day 0).
11303164|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
11303165|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
11303166|NCT02678429|Active Comparator|DBS programming, standard of care|DBS settings determined from the standard Neurologist symptomatic response, first
11303167|NCT02678429|Experimental|DBS progamming from Atlas|DBS settings determined from the a functional atlas only,first
11303168|NCT02678416|Experimental|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
11303169|NCT02678416|Experimental|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
11303170|NCT02678416|Experimental|Placebo|All participants receive placebo as one of 4 interventions in random sequence
11303171|NCT02678416|Experimental|Morphine|All participants receive morphine as one of 4 interventions in random sequence
11303262|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
11303172|NCT02678403|Experimental|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
11303173|NCT02678403|Sham Comparator|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
11303174|NCT02678390|Experimental|Healthy women|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.
~Interventions:
~A control day with no MCT and no aerobic exercise.
~A 5 day consecutive MCT intake of 30 g/day.
~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.
~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
11303175|NCT02678390|Experimental|Women with prediabetes|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.
~Interventions:
~A control day with no MCT and no aerobic exercise.
~A 5 day consecutive MCT intake of 30 g/day.
~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.
~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
11303176|NCT02678377|Active Comparator|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
11303177|NCT02678377|Sham Comparator|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
11303178|NCT02678364|Placebo Comparator|Control egg group|Two or less control (non-biofortified) eggs per week
11303179|NCT02678364|Active Comparator|Vitamin D3-eggs group|Seven vitamin D3-biofortified eggs per week
11303180|NCT02678364|Active Comparator|25-Hydroxyvitamin D-eggs group|7 25-hydroxyvitamin D-biofortified eggs per week
11303181|NCT02678351|Experimental|Diagnostic (68Ga-PSMA PET/MRI)|Patients receive 68Ga-PSMA IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
11303182|NCT02678338|Experimental|Hu5F9-G4|Dose Escalation: CD47 blocking antibody Hu5F9-G4
11303183|NCT02678325|Active Comparator|Standardized normal protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 20% of the total caloric intake
11303184|NCT02678325|Experimental|Standardized high protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 33% of the total caloric intake
11303185|NCT02678312|Experimental|Part 1: LCZ696 open label|LCZ696 open label either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril or standard of care for heart failure treatment, if patient consents to participate in Part 2.
11303186|NCT02678312|Active Comparator|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose).
11303187|NCT02678312|Experimental|Part 2:LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight.
11303188|NCT02678299|Experimental|Treatment|
11303189|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
11303190|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
11303191|NCT02678273|Experimental|Intervention group|Intervention
11303192|NCT02678273|No Intervention|Control group|Standard care when patient is in the hospital. At discharge, patients may be referred to community services as deemed necessary by the hospital team. This is not restricted.
11303193|NCT02678260|Experimental|PDR001|PDR001 will be administered i.v. every two weeks until a patient experiences unacceptable toxicity, progressive disease as per irRC and/or treatment is discontinued at the discretion of the investigator or the patient. The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and evaluations, a treatment cycle will consist of 28 days. During the study, cohorts of patients will be treated with PDR001 until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
11303194|NCT02678247|Active Comparator|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
11303195|NCT02678247|Active Comparator|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
11303196|NCT02678234|Experimental|Theraflu Aktiv powder for oral solution|Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
11303197|NCT02678234|No Intervention|No Treatment|Participants in this arm will not receive any medication
11303198|NCT02678221|Active Comparator|Sildenafil citrate with Aspirin|will receive sildenafil citrate 20mg ̸ 8hours plus low dose aspirin 150mg/day
11303199|NCT02678221|Other|placebo with Aspirin|will receive placebo plus low dose aspirin 150mg/day
11303200|NCT02678208|Active Comparator|Tranexamic acid|received tranexamic acid containing 1 g/10mL tranexamic acid diluted with 20 mL of 5% glucose over a 5 minute period
11303201|NCT02678208|Other|placebo|received 30 mL of 5% glucose over the same period of time.
11303202|NCT02678195|Experimental|3 days amoxicillin + 2 days placebo|3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
11303203|NCT02678195|Active Comparator|5 days amoxicillin|5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
11303204|NCT02678182|No Intervention|A1: Surveillance|Patients in this Arm will follow current UK standard of care for this setting and will be reviewed every 4 weeks
11303205|NCT02678182|Experimental|Arm A2: Capecitabine Maintenance|1250 mg/M2/DAY on days 1-21
11303206|NCT02678182|Experimental|Arm A3: MEDI4736 (Durvalumab)|IV treatment on day 1 +15, on a 28 day cycle.
11303207|NCT02678182|Active Comparator|Arm B1: Trastuzumab Maintenance|6mg/kg on day 1 every 21 days
11303209|NCT02678182|Experimental|Arm A5: Capecitabine and Ramucirumab|capecitabine 1250 mg/m2/day PO in two divided doses continuously from days 1-21 of each 21 day cycle (see section 12) and ramucirumab 8mg/kg IV day 1 and day 8
11303210|NCT02678169||Penumbra Aspiration System|Penumbra Aspiration System with the ADAPT technique
11303211|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
11303212|NCT02678143|Experimental|Recipients|"The recipient of one antigen mismatch unrelated HSCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 300 cGy of total body irradiation (TBI) on Day -2.
~The recipient of haplo-SCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, fludarabine on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 400 cGy of TBI on Day -2.
~For both types of HSCT, the frozen peripheral blood stem cells will be thawed and infused on Day 0 per institutional guidelines. GVHD prophylaxis will consist of cyclophosphamide on Days +3 and + 4, mycophenolate mofetil (MMF) three times a day on Days +5 through +35 then tapered off over 1 week provided there is no evidence of GVHD, and sirolimus starting on Day +5 and continuing for one year. Sirolimus can be tapered at one year only if donor T-cell chimerism reaches more than 50% in the absence of GVHD."
11303213|NCT02678130|Active Comparator|InterFuse Group|Patients are randomized based on last digit (odd) of social security number to be treated with an InterFuse T device
11303214|NCT02678130|Active Comparator|Control Group: Standard of care TLIF|treated with a standard of care TLIF (Transforaminal Lumbar Interbody Fusion) device (e.g. Stryker's AVS Unilif)
11303215|NCT02678117|Active Comparator|Pregabalin & placebo|: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
11303216|NCT02678117|Active Comparator|Magnesium sulphate & Placebo|will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
11303217|NCT02678117|Active Comparator|Pregabalin & Magnesium sulphate|: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
11303218|NCT02678117|Placebo Comparator|Placebo|will receive placebo medications at the same time and route of administration of other groups.
11303219|NCT02678104|Experimental|Chlorhexidine mouth wash|Tooth extraction. The patients will start using Chlorhexidine mouthwash on 2nd day of extraction twice daily for 7 days.
11303220|NCT02678104|Experimental|Manuka Honey|intra-alveolar application of Manuka Honey after tooth extraction.
11303221|NCT02678091|Experimental|Patients|Patients with an orbital mass
11303222|NCT02678065|Experimental|InPact Admiral|Patients treated with the InPact Admiral balloon for popliteal lesions
11303223|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
11303224|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
11303225|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.
~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
11303226|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.
~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
11303227|NCT02678026|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early).
~Women will receive pessary soon after UIC"
11303228|NCT02678026|No Intervention|No intervention|No treatment
11303229|NCT02678013|Experimental|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
11303230|NCT02678013|Active Comparator|RFA+CTL|RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
11303231|NCT02678000|Experimental|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.
~For Part 2, patients will receive LHW090 once daily for 4 weeks."
11303232|NCT02678000|Placebo Comparator|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
11303233|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
11303234|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
11303235|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
11303236|NCT02677948|Experimental|Pacritinib and Ibrutinib|"Phase I: Patients will receive Pacritinib 100-200 mg twice daily along with Ibrutinib 420mg/day.
~Phase II Lead-In: Pacritinib at MTD daily continuous x 2 months followed by Pacritinib at MTD twice daily along with Ibrutinib 420mg/day."
11303237|NCT02677935|Experimental|Intervention|community support program
11303238|NCT02677922|Experimental|Oral AG-120 + Subcutaneous (SC) azacitidine|Subjects with an IDH1 mutation will receive AG-120 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
11303239|NCT02677922|Experimental|Oral AG-221 + Subcutaneous (SC) azacitidine|Subjects with an IDH2 mutation will receive AG-221 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
11303240|NCT02677922|Experimental|Subcutaneous (SC) azacitidine|Subjects with either an IDH1 or IDH2 mutation will receive azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
11303241|NCT02677896|Experimental|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received enzalutamide orally once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
11303242|NCT02677896|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
11303243|NCT02677883|Experimental|Arm I: Manometry-guided thoracentesis|Intervention Group - Patients undergo fine needle- aspiration, called therapeutic thoracentesis, to drain fluid accumulated around the lung. Unlike Arm II, the intervention group will have their pleural pressure monitored during the procedure.
11303244|NCT02677883|Active Comparator|Arm II: Symptom-guided thoracentesis|Comparison Group - Patients undergo symptom-guided thoracentesis, the current standard-of-care is to drain fluid until 1) it is all gone or 2) a symptom occurs that indicates the lung may take longer to fully re-expand and drainage should be stopped.
11303245|NCT02677870|Other|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
11303246|NCT02677870|Active Comparator|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
11303247|NCT02677870|Experimental|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
11303248|NCT02677857|Active Comparator|Lifestyle|Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship. The goal will be to increase MVPA to > 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals. Initially, participants will be encouraged to complete MVPA > 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention). Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., > 10 min in length). Any MVPA in bouts of > 10 min in length will be counted towards the MVPA goal. Participants will self-monitor their MVPA using the Polar® Loop tracking system.
11303249|NCT02677857|Active Comparator|Lifestyle + SB|Participants will receive everything that is described in Lifestyle. Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk. The goal will be to reduce sedentary time by > 2 hrs/day or > 14 hrs/wk. Participants will shape towards the goal. Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day. For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day. To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention. Participants will self-monitor their SB using the Polar® Loop tracking system.
11303250|NCT02677857|No Intervention|Newsletter|Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors. This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
11303251|NCT02677844|Experimental|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
11303252|NCT02677844|Placebo Comparator|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
11303253|NCT02677844|Active Comparator|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
11303254|NCT02677844|Experimental|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
11303255|NCT02677844|Active Comparator|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
11303256|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
11303257|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
11303258|NCT02677805|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
11303259|NCT02677805|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
11303263|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
11303264|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
11303265|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
11303266|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
11303267|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
11303268|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
11303269|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|"Patients with early stage breast cancer receiving 4 cycles of doxorubicin-based chemotherapy (doxorubicin:60 mg/m² and cyclophosphamide: 600 mg/m²) at about 2 week intervals followed by paclitaxel.
~Patients will undergo 99mTc-rhAnnexin V-128 scans at 60 min and 2 hrs and a Cardiac Magnetic Resonance Imaging at baseline, after the 2nd cycle of chemotherapy, after the 4th cycle of chemotherapy and 12 weeks after the last cycle of chemotherapy."
11303270|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
11303271|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
11303272|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
11303273|NCT02677675|Experimental|Intervention (reminder module)|"A reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants)"
11303274|NCT02677675|No Intervention|Control (standard care)|Control group received standard care only (routine adherence counselling and paper-based appointment scheduling)
11303275|NCT02677662|Sham Comparator|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise or rest.
11303276|NCT02677662|Experimental|Diesel exhaust exposure|2 hour exposure to dilute diesel exhaust (approximate PM10 (particulate matter<10um) concentration 300 mcg/m3) during intermittent exercise or rest.
11303277|NCT02677649|Active Comparator|cranberry|30 grams/day freeze dried whole cranberry powder added to a basal diet comprising meats, dairy products, simple sugars, and stevia
11303278|NCT02677649|Placebo Comparator|placebo|30 grams/day placebo powder [made with maltodextrin (CPC Maltrin M-180), citric acid, artificial cranberry flavor (Lorann oils), fructose, red color (Lorann oils), and grape shade] added to a basal diet comprising meats, dairy products, simple sugars, and stevia
11303279|NCT02677636|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
11303280|NCT02677636|Placebo Comparator|Placebo Comparator|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
11303281|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral
~Dose: 200 mg PO with small sip of water
~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps
~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
11303282|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous
~Dose: 25 mg
~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,
~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
11303283|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy
~Dose: 300cc during cystoscopy to visualize the ureters
~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection
~Contraindications when used as a genitourinary irrigation solution: anuria"
11303284|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy
~Dose: 300cc
~Known adverse events: no known significant adverse events
~Contraindications: none"
11303285|NCT02677610|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
11303286|NCT02677610|Placebo Comparator|Vehicle|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
11303287|NCT02677597|Experimental|Cisplatin Combined With S-1|Cisplatin 75mg/m2 ivgtt d1 S-1 BSA<1.5 50mg bid，BSA≥1.5 60mg bid po d1-14
11303288|NCT02677597|Experimental|Cisplatin Combined With Paclitaxel|Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h
11303362|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303289|NCT02677584|Active Comparator|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
11303290|NCT02677584|Active Comparator|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
11303291|NCT02677571|Experimental|PVB|51 patients receiving US guided homolateral paravertebral thoracic block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
11303292|NCT02677571|Experimental|PECS|51 patients receiving US guided pectorals nerve block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
11303293|NCT02677558||CFOP obese|"Transthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study.
~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia."
11303294|NCT02677558||CFOP control|"Transthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study.
~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia"
11303295|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
11303296|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
11303297|NCT02677532|Active Comparator|Epidural infusion|Thoracic epidural bolus of 10 ml levobupivacaine 0.25% plus sufentanil 0.15 mcg/kg before end of surgery, followed by continuous epidural infusion of 0.12% levobupivacaine plus 0.4 mcg/ml at 5 ml/h infusion rate for 48 hours.
11303298|NCT02677532|Experimental|Wound infusion plus morphine bolus|Intravenous slow bolus of 10 mg morphine, wound infiltration with 10 ml levobupivacaine 0.5%, followed by pre-peritoneal continuous wound infusion of levobupivacaine 0.25% at 4 ml/h infusion rate for 48 hours.
11303299|NCT02677519|Experimental|10 mg Aptensio XR|10 mg methylphenidate, extended release
11303300|NCT02677519|Experimental|15 mg Aptensio XR|15 mg methylphenidate, extended release
11303301|NCT02677519|Experimental|20 mg Aptensio XR|20 mg methylphenidate, extended release once daily
11303302|NCT02677519|Experimental|30 mg Aptensio XR|30 mg methylphenidate, extended release
11303303|NCT02677519|Experimental|40 mg Aptensio XR|40 mg methylphenidate, extended release
11303304|NCT02677519|Experimental|50 mg Aptensio XR|50 mg methylphenidate, extended release
11303305|NCT02677519|Experimental|60 mg Aptensio XR|60 mg methylphenidate, extended release
11303306|NCT02677506|Experimental|Supraclavicular|Supraclavicular brachial plexus block will be done.
11303307|NCT02677506|Active Comparator|Infraclavicular|Infraclavicular brachial plexus block block will be done.
11303308|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
11303309|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
11303310|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
11303311|NCT02677480|Active Comparator|Test group, probiotic tablets and gel|Test group, probiotic tablets and gel: tablets with probiotic bacteria (10exp8/tablet) and pH-rising components and gel (with probiotic bacteria and pH-rising components) in trays on the teeth once a week.
11303312|NCT02677480|Placebo Comparator|Placebo group, placebo tablets and gel|Placebo group, placebo tablets and gel: placebo tablets without probiotic bacteria and pH-rising components and gel (with no probiotic bacteria but with pH-rising components) in trays on the teeth once a week.
11303313|NCT02677467||Spontaneous epistaxis|A participant enroll if their age is over 18 with spontaneous epistaxis and their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs immediately treatment for hypertensive urgency. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
11303314|NCT02677467||Bleeding of wound|A participant enroll if their age is over 18 with bleeding of wound and their cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds' condition is serious or their pain is much severe. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
11303315|NCT02677454|Experimental|Flash Glucose Monitor|"Each patient with Type 1 diabetes will have a subcutaneous tissue FGM sensor inserted. The sensor will produce a maximum of 1440 tissue fluid glucose measurements per 24 hours and 20160 measurements during the 14 day study. The FGM data (Abbott Freestyle Libre) will be compared to the time-matched reference blood glucose measurements.
~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose 6 to 10 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study."
11303316|NCT02677441|Experimental|Conservative management|Conservative management includes a sling for 10 days, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
11303317|NCT02677441|Active Comparator|Surgery|Surgical fixation of ACJD with coracoclavicular and acromioclavicular fixation, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
11303486|NCT02676362|Experimental|the 2nd day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 10., 30., 5.
11303318|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
11303319|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
11303320|NCT02677415|Other|Local anesthesia|local anesthesia and spontaneous breathing will be maintained.
11303321|NCT02677415|Other|General anesthesia|Intravenous anesthetics and controlled ventilation will be used .
11303322|NCT02677402|Experimental|cold water immersion|Participants immersed their lower limbs in water of ~12°C
11303323|NCT02677402|Experimental|contrast water therapy|Participants immersed their lower limbs in water : alternated every 2 min between ~12°C and ~35°C for CWT
11303324|NCT02677402|Experimental|thermo neutral immersion|Participants immersed their lower limbs in water of ~35°C
11303325|NCT02677389|Experimental|Arm I (Enhanced SCP)|See Detailed Description
11303326|NCT02677389|Active Comparator|Arm II (SCP)|"Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on Healthy Habits at 1, 2, 4, and 8 weeks. Specific topics in emails include positive self-talk, daily relaxation breathing techniques, better sleep, and ways to find pleasure."
11303327|NCT02677363|Experimental|Older adults|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
11303328|NCT02677350|Experimental|Pilot|Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.
11303329|NCT02677337|No Intervention|No intervention|
11303330|NCT02677337|Other|Educational Program|chart abstraction will be conducted post education intervention component.
11303331|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
11303332|NCT02677311|Other|Cases|Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
11303333|NCT02677311|Other|Controls|Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
11303334|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
11303335|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
11303336|NCT02677285||Skin graft|The bioimpedance measurement is done with a purpose built patch that has electrodes in contact with the wound and reference electrodes.
11303337|NCT02677285||Operation wound|The bioimpedance measurement is done with commercial electrodes places in healthy skin surrounding the wound.
11303338|NCT02677259|Experimental|Estradiol + Standard Luteal Phase Support|"17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation
~Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation"
11303339|NCT02677259|Active Comparator|Standard Luteal Phase Support|1. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
11303340|NCT02677246|Experimental|Denosumab|Phase 1, 3+3 design with inter-patient dose escalation from 1mg/kg/dose to 2mg/kg/dose, and possibility of a dose de-escalation of 0.5mg/kg/dose, A modification of 3+3 design is implemented to take into account the achievement of bone resorption blockade by Denosumab. CTX is a biologic marker of bone resorption. Provided a decrease of CTX blood level will be observed under the lower limit (2,5th percentile) for age and sex, or under 20% of the pre-treatment level, there will be no reason to continue escalating the dose. This modified 3+3 design prevents exposure of children to dose escalations that would not be needed regarding the medical and biological aims of this trial.
11303361|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11347642|NCT02383771|Experimental|Single Anti-platelet Treatment|Ticagrelor
11303341|NCT02677233||preeclamptic group|"Blood pressure: greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after 20 weeks of gestation (Roberts et al., 2013).
~Proteinuria: protein/creatinine ratio greater than or equal to 0.3
~In the absence of proteinuria, a new-onset hypertension with new onset of the following:
~thrombocytopenia: platelet count less than 100.000/microliter
~renal insufficiency: serum creatinine greater than 1.1 mg/dl
~impaired liver function: elevated concentration of liver transaminases
~pulmonary edema
~cerebral or visual symptoms
~Severe right upper quadrant or epigastric pain unresponsive to medication."
11303342|NCT02677233||non preeclamptic group|All are normotensive with blood pressure <140/90 with no proteinuria.
11303343|NCT02677220|Experimental|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
11303344|NCT02677207|Experimental|JNJ-39393406|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
11303345|NCT02677207|Placebo Comparator|Placebo|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
11303346|NCT02677194|Experimental|Exposition LED|The patient is his own witness. This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm. Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act : exposition to LED 590nm (4 or 12sec) or 630nm(4min30 or 15 min) or 830 nm (6 or 12 min).
11303347|NCT02677194|Other|Control|Device without any LED exposition : This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm or control (1 mini-zone)
11303348|NCT02677181|Experimental|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).
~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
11303349|NCT02677181|Active Comparator|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
11303350|NCT02677168|Experimental|cNEP|Subjects with OSA will be treated with cNEP (continuous negative external pressure) at home for three weeks
11303351|NCT02677155|Experimental|Intranodal immunotherapy and anti-PD1|"Induction phase: 3 cycles of sequential intranodal immunotherapy (SIIT), every second week:
~Radiotherapy 8 Gy single dose day 2, Rituximab 5 mg intranodal day 1 and 3, Autologous dendritic cells 1x 10 e8 intranodal day 4 and 5, GM-CSF 50 ug subcutaneously day 4 and 5, Pembrolizumab 200 mg intravenous day 5,
~Consolidation phase:
~Pembrolizumab 200 mg intravenous every third week for 8 cycles"
11303352|NCT02677142|Active Comparator|Attention Control Group (CG)|Behavioural: CG: Social Skills Activities: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific social skill and activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
11303353|NCT02677142|Experimental|Experimental Group (EG)|Behavioral: Structured social skills training program, SSIP. Participants in this arm will experience an 8-week manualized intervention program that addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion). Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
11303354|NCT02677129|Experimental|home-based exercise intervention|"home-based exercise intervention:
~Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems."
11303355|NCT02677129|No Intervention|Waiting control group|The wait list control group receives usual care over the study period. Usual care depends on the hospital guidelines as well as oncologists' and physicians' consideration.
11303356|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303357|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303358|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303359|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303360|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.
~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303489|NCT02676349|Active Comparator|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
11303363|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303364|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.
~All cycles are 21 days."
11303365|NCT02677103|Experimental|RSWT group|The RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder. RSWT will be performed once per week, and will be continued for 3 weeks.
11303366|NCT02677103|Experimental|USNP group|All needle punctures will be guided by ultrasound (US). The puncture needle is a 3.8cm 22# needle attached on a 5ml syringe. Before puncture, the skin of the puncture site will be sterilized with better iodine, and the transducer will be covered with a sterilized plastic bag. After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by ultrasound to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff.
11303367|NCT02677103|Experimental|RSWT plus USNP|In this group, each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs
11303368|NCT02677090|Placebo Comparator|Placebo|Placebo
11303369|NCT02677090|Active Comparator|Dose 1 - Promitor®|Investigational product Dose 1
11303370|NCT02677090|Active Comparator|Dose 2 - Promitor®|Investigational product Dose 2
11303371|NCT02677090|Active Comparator|Dose 3 - Promitor®|Investigational product Dose 3
11303372|NCT02677077||Czech Republic|Approximately 230 participants with RRMS receiving commercial natalizumab in Czech Republic
11303373|NCT02677077||Belgium|Approximately 70 participants with RRMS receiving commercial natalizumab in Belgium
11303374|NCT02677064||patients with acute leukemia (AML or ALL)|
11303375|NCT02677051|Placebo Comparator|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
11303376|NCT02677051|Experimental|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in ~ 50 µmol sulforaphane.
~Body weight Dose of sulforaphane 34 kg ~ 50 µmol 68 kg ~ 100 µmol 102 kg ~ 150 µmol"
11303377|NCT02677038|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11303378|NCT02677025|Experimental|Young Women's Health CoOp (YWHC)|This is an adapted behavioral intervention for young women in Cape Town South Africa who dropped out of school, who use alcohol and other drugs and are at risk for HIV.
11303379|NCT02677025|Active Comparator|HIV Counseling/Testing|Provide age and gender appropriate standard HIV counseling and testing.
11303380|NCT02677012||Arm I (RESOLVE TM)|Patients undergo AFG reconstructive surgery comprising washing and low velocity spinning using a commercially available system that washes the lipoaspirate with lactated Ringer's solution separates non-fat material from the fat with gentle centrifugal force and suction.
11303381|NCT02677012||Arm II (Cytori PureGraft TM)|Patients undergo AFG reconstructive surgery comprising gravity filtration using a commercially available system in which the lipoaspirate is rinsed with lactated RL and the non-fat material is filtered through mesh.
11303382|NCT02677012||Arm III (Coleman technique)|Patients undergo AFG reconstructive surgery comprising standard centrifugation at 3200 rpm for 3 minutes with the resulting oil and aqueous layers discarded.
11303383|NCT02676986|Active Comparator|Cohort I (ER positive cohort)|Approximately 180 patients with ER positive breast cancer will be randomised 2:1 in favour of enzalutamide to receive enzalutamide plus exemestane or exemestane alone.
11303384|NCT02676986|Active Comparator|Cohort II (AR positive, TNBC cohort)|55 patients with AR positive, TNBC will receive single agent treatment with enzalutamide.
11303385|NCT02676973|Active Comparator|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
11303386|NCT02676973|Active Comparator|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
11303387|NCT02676973|Active Comparator|Apical Transvaginal Mesh Repair|Uphold™ LITE
11303388|NCT02676947|Experimental|Open Label|Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months
11303389|NCT02676934|Experimental|Et group|applying end tidal concentration as a control target for delivery of sevoflurane
11303390|NCT02676934|No Intervention|FGF group|using Fresh gas control for sevoflurane delivery
11303391|NCT02676921||GROUP 1|Ten samples of sinus membrane where harvested from fifteen patients during a surgical nasal approach for treatment of chronic rhinosinusitis.
11303392|NCT02676908|No Intervention|4 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for four weeks (usual care)
11303393|NCT02676908|No Intervention|4 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for four weeks (usual care)
11303394|NCT02676908|Experimental|2 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for two weeks (trial group)
11303395|NCT02676908|Experimental|2 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for two weeks (trial group)
11303396|NCT02676895|Experimental|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
11303397|NCT02676895|Experimental|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
11303398|NCT02676895|Active Comparator|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
11303487|NCT02676362|Experimental|the 3rd day|Gingival crevicular fluid collection with filter paper the length of sampling time in second: 30., 5., 10.
11303488|NCT02676349|Experimental|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
11303399|NCT02676882|Other|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score </= 10.
11303400|NCT02676882|Other|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score >/= 15.
11303401|NCT02676869|Experimental|IMP321 dose escalation|IMP321 administered fortnightly in addition to SOC pembrolizumab.
11303402|NCT02676856|Experimental|CR group|For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
11303403|NCT02676856|Experimental|Non-CR group|For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
11303404|NCT02676843|Experimental|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
11303405|NCT02676830|Experimental|K-312|
11303406|NCT02676817||Group 1|Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
11303407|NCT02676817||Group 2|Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.
11303408|NCT02676804|Experimental|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
11303409|NCT02676791|Experimental|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
11303410|NCT02676791|No Intervention|B (Control)|Esophageal resection will be performed without esophageal washout.
11303411|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
11303412|NCT02676765|Experimental|Allergen|Subjects will be administered either Timothy Grass or Short Ragweed sublingual allergen tablets, depending on their individual allergic sensitization.
11303413|NCT02676765|Placebo Comparator|Placebo|Subjects will be administered placebo sublingual tablets
11303414|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
11303415|NCT02676739|Placebo Comparator|Placebo|Capsule with no active medical ingredients to be taken orally once a day for 12 weeks.
11303416|NCT02676739|Active Comparator|Adderall XR 10mg|10mg Adderall XR capsule to be taken orally once a day for 12 weeks.
11303417|NCT02676739|Active Comparator|Adderall XR 20mg|20mg Adderall XR capsule to be taken orally once a day for 12 weeks.
11303418|NCT02676726|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
11303419|NCT02676726|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
11303420|NCT02676713|Experimental|TCM Sequential Treatment|"After conservative surgery, patients start to take pre-ovulation decoction for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found LUFS or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles.
~Pre-ovulation decoction is HuoXueXiaoYi decoction, and post-ovulation decoction is BuShenZhuYun decoction. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.
~All drugs are tcm formula granules, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
11303421|NCT02676713|Placebo Comparator|Placebo|"After conservative surgery, patients start to take pre-ovulation decoction(placebo) for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found luteinized unruptured follicle syndrome (LUFS) or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction(placebo) for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.
~Pre-ovulation decoction and post-ovulation decoction is placebo, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
11303458|NCT02676505||1|"Group (I)(Coached group):
~It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds."
11303490|NCT02676336|Active Comparator|Violet™ Iodine|3mg molecular iodine (I2) daily
11303422|NCT02676700|Active Comparator|Pelvic floor muscle training and Kaatsu|"Participants are instructed in the PFMT program by primary investigator and instructed in Kaatsu training by a research nurse. The Kaatsu training is performed 4 times a week before PFMT. The program includes 2 x 15 knee extensions with partly occlusion of the blood supply to the thigh. Training level is >12 RM. Training is performed sitting on a chair and rubber bands are used to increase resistance. Training adherence and bother with the training is reported in a training diary. At week 6 the research nurse adjusts the training program.
~The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.
~Training adherence and any bother with the training is reported in a training diary."
11303423|NCT02676700|Active Comparator|pelvic floor muscle training|"Participants perform the same PFMT program as the intervention group. The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.
~Training adherence and any bother with the training is reported in a training diary."
11303424|NCT02676687|Active Comparator|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
11303425|NCT02676687|Experimental|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
11303426|NCT02676674|Experimental|Dose 1|Three topical applications of 100,000 units for a total of 300,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
11303427|NCT02676674|Experimental|Dose 2|Three topical applications of 300,000 units for a total of 900,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
11303428|NCT02676661||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
11303429|NCT02676661||peri-implant disease|The subjects who suffered from peri-implant disease.
11303430|NCT02676648|Experimental|Experimental: Condition 1|1) core program; 2) breath meter; 3) text messages; 4) diet-appropriate food and cookbooks
11303431|NCT02676648|Experimental|Experimental: Condition 2|1) core program
11303432|NCT02676648|Experimental|Experimental: Condition 3|1) core program; 2) breath meter
11303433|NCT02676648|Experimental|Experimental: Condition 4|1) core program; 2) text messages
11303434|NCT02676648|Experimental|Experimental: Condition 5|1) core program; 2) diet-appropriate food and cookbooks
11303435|NCT02676648|Experimental|Experimental: Condition 6|1) core program; 2) breath meter; 3) text messages
11303436|NCT02676648|Experimental|Experimental: Condition 7|1) core program; 2) breath meter; 3) diet-appropriate food and cookbooks
11303437|NCT02676648|Experimental|Experimental: Condition 8|1) core program; 3) text messages; 4) diet-appropriate food and cookbooks
11303438|NCT02676635|Experimental|Ergonomics Training Only|Participants in this arm receive Ergonomics training only
11303439|NCT02676635|Experimental|Ergonomics and Safety Voice Training|Participants in this arm receive training on both Ergonomic principles and Safety Voice training
11303440|NCT02676635|No Intervention|Control Group|Participants in this arm will receive no additional Ergonomics or Safety Voice training
11303441|NCT02676622|Experimental|Stem-cell mobilization and Leukapheresis|"Stem-cell mobilisation will be achieved using Cyclophosphamide (CY) 4g/m² (2g/m2 on 2 consecutive days) followed 5 days later by filgrastim (G-CSF) 10 mg/kg injection. This will be done daily until the day before the last day of leukapheresis. The PBSCs will be harvested usually between day +9 and +11 of completing CY.
~Leukapheresis will be performed to a target cell dose of 3-8 x106 CD34+ cells/kg Approximately 1 month later patients will undergo HSCT"
11303442|NCT02676609|Active Comparator|Use of smart phone application (device glucal)|"Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio.
~During the first month, then during the second month they'll use as usual their traintement and meal without the apllication"
11303443|NCT02676609|Active Comparator|Use of smart phone application (second month)|"During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin.
~Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio."
11303444|NCT02676596|Other|Cohort 1|Japanese and Non-Japanese subjects receiving K-312 50 mg QD
11303445|NCT02676596|Other|Cohort 2|Japanese and Non-Japanese subjects receiving K-312 100 mg QD
11303446|NCT02676596|Other|Cohort 3|Japanese and Non-Japanese subjects receiving K-312 200 mg QD
11303447|NCT02676596|Other|Cohort 4|Japanese and Non-Japanese subjects receiving K-312 400 mg QD
11303448|NCT02676596|Other|Cohort 5|Japanese and Non-Japanese subjects receiving K-312 25 mg QD
11303449|NCT02676596|Other|Cohort 6|Japanese and Non-Japanese subjects receiving K-312 10 mg QD
11303450|NCT02676583|Active Comparator|Billateral tonsil fossa closure|tonsillectomy
11303451|NCT02676583|Active Comparator|No closure of tonsil fossa|tonsillectomy
11303452|NCT02676583|Active Comparator|Unilateral tonsil fossa closure|tonsillectomy
11303453|NCT02676557||LASIK|
11303454|NCT02676544|Experimental|Embosphere microspheres|Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.
11303455|NCT02676531|Experimental|Walking Meditation|"Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound Budd and Dha and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week."
11303456|NCT02676531|No Intervention|No Walking meditation|keep regular activities, sedentary life style.
11303457|NCT02676518||polycystic ovary syndrome women|PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
11303459|NCT02676505||2|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth.
11303460|NCT02676492||Tic Disorder|Boys with a diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD) aged 11-14 years
11303461|NCT02676492||Control|Boys aged 11-14 years without a diagnosis of TS/CTD (i.e. typically developing)
11303462|NCT02676479|Experimental|Uterine Lavage Group|"The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene.
~The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure (Previvo Uterine Lavage System™, CA, U.S.A.) to recover preimplantation embryos."
11303463|NCT02676466|Experimental|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
11303464|NCT02676466|Placebo Comparator|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
11303465|NCT02676466|Active Comparator|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
11303466|NCT02676466|Placebo Comparator|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
11303467|NCT02676466|Active Comparator|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
11303468|NCT02676466|Other|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
11303469|NCT02676466|Other|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
11303470|NCT02676466|Other|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
11303471|NCT02676453|Experimental|Intervention|Dental hygienist support
11303472|NCT02676453|No Intervention|control|Care as usal
11303473|NCT02676440|Other|Treatment|Toothpaste containing 1.11% Fluoride as Sodium Monofluorophosphate and Zinc Citrate Trihydrate Serum containing 0.17% Fluoride as Sodium Monofluorophosphate and Zinc Sulphate Heptahydrate
11303474|NCT02676440|Other|Comparator|Silica toothpaste 1350ppm F as Sodium Fluoride
11303475|NCT02676414|Other|Education program|"Group of patients participating in the interactive hypertension education program of the DHL© My blood pressure - OK!"
11303476|NCT02676414|No Intervention|Controls|"Group of patients not participating in the interactive hypertension education program of the DHL© My blood pressure - OK! (usual care)"
11303477|NCT02676401|Experimental|MT-3995 Low|
11303478|NCT02676401|Experimental|MT-3995 Middle|
11303479|NCT02676401|Experimental|MT-3995 High|
11303480|NCT02676388|Experimental|Freeze-dried, Capsulized FMT|Patients included will receive bowel lavage and subsequent Freeze-dried, Capsulized FMT, and then will be followed up for 3 months.
11303481|NCT02676388|Experimental|Fresh FMT|Patients included will receive bowel lavage and subsequent Fresh FMT, and then will be followed up for 3 months.
11303482|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
11303483|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
11303484|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
11303485|NCT02676362|Experimental|the first day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 5., 10., 30.
11303492|NCT02676336|Active Comparator|Cross-over|Subjects on placebo will be offered 3 months of active post-treatment
11303493|NCT02676323|Experimental|Treatment|Participants will be given panobinostat in combination with fludarabine and cytarabine. Treatment consists of one course of therapy given over 12 days. Participants will also receive intrathecal triples and leucovorin
11303494|NCT02676310|Experimental|Cohort 1: Bimatoprost 0.3% (Formulation B)|0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
11303495|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation A)|0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.
11303496|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation B)|0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
11303497|NCT02676310|Experimental|Cohort 3: Bimatoprost 1% (Formulation B)|1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
11303498|NCT02676310|Experimental|Cohort 4: Bimatoprost 3% (Formulation B)|1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
11303499|NCT02676297|Experimental|Test product A|tiotropium
11303500|NCT02676297|Experimental|Test product B|tiotropium
11303501|NCT02676297|Active Comparator|reference product|tiotropium
11303502|NCT02676284|Experimental|Durolane SJ|single dose injection
11303503|NCT02676258|Experimental|Si-Hy soft contact lens|olifilon B daily disposable soft contact lens
11303504|NCT02676258|Active Comparator|Vistakon soft contact lens|narafilcon A daily disposable soft contact lens
11303505|NCT02676245|Experimental|Viewing NBS + DBS Educational Movies|Group A: pregnant women who will view the NBS and residual specimen movies and printed materials during one visit between 30 and 40 weeks gestation.
11303506|NCT02676245|Experimental|Viewing NBS Educational Movie only|Group B: pregnant women who will view the NBS movie only and printed materials at one visit between 30 and 40 weeks. The movies will be presented on a tablet PC.
11303507|NCT02676245|No Intervention|No Educational Interventions|Control Group: pregnant women who will receive no experimental intervention during pregnancy or the postpartum period but will receive whatever information is routinely provided by their OB clinic and/or delivery center.
11303508|NCT02676232|Experimental|Intervention|Participants in this arm will follow DARWeb: an online psychosocial intervention for children with recurrent abdominal pain and their parents. This is composed by 7 units for parents and 7 units for children, that have been developed from the cognitive-behavioral model, including setting goals, relaxation and distraction techniques, changing maladaptive thoughts and assertive communication training. The team under the program only contact with families for sending reminders and to answer potential technical problems or doubts
11303509|NCT02676232|No Intervention|Control|Participants allocated in this arm will not receive intervention. However, they will be invited to participate once the families allocated to the experimental group complete the program.
11303510|NCT02676219|Experimental|RS01|oral care product containing containing sodium monofluorophosphate and sodium fluoride
11303511|NCT02676219|Placebo Comparator|Water|Water
11303512|NCT02676206|Experimental|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
11303513|NCT02676206|No Intervention|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
11303514|NCT02676193|Experimental|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
11303515|NCT02676193|Experimental|Blank Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using blank packaging for three months. Blank packaging will indicate participants brand and will not have any brand-related images or labels.
11303516|NCT02676193|No Intervention|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
11303517|NCT02676167|Other|Intervention|
11303518|NCT02676154|Other|Fesoterodine|Open-Label
11303519|NCT02676128|Experimental|Mobile Health ART Adherence Application (mARTAA)|mARTAA will use a smartphone-delivered application developed by Twine Health, Inc.
11303520|NCT02676128|Active Comparator|Face-to-Face ART Adherence Intervention|A single face-to-face ART adherence intervention will be administered.
11303521|NCT02676115|Active Comparator|Control Group|Standard Post Operative Skin Care
11303522|NCT02676115|Experimental|Treatment Group|Medipore Tape will be applied to ACL reconstruction Incision
11303523|NCT02676102|Active Comparator|Control Group|Participant will watch an educational video produced in partnership with the community of black men including customers, employers and owners of BOBs.
11303524|NCT02676102|Active Comparator|Targeted Intervention|Participants will watch an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
11303525|NCT02676102|Active Comparator|Tailored Intervention|Participants will watch videos with content individualized to participant's pre-intervention ODBI scores representing their organ donation beliefs
11303526|NCT02676089|Experimental|CHF 5993 200/6/12.5 µg|"Treatment A:
~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB"
11303527|NCT02676089|Active Comparator|CHF 1535 200/6 µg|"Treatment B:
~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF"
11303528|NCT02676089|Active Comparator|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|"Treatment C (open-label arm):
~CHF 1535 200/6 µg: 2 inhalations bid
~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio"
11303529|NCT02676076|Experimental|CHF 5993 100/6/12.5 µg|"Treatment A:
~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB"
11303530|NCT02676076|Active Comparator|CHF 1535 100/6 µg|"Treatment B :
~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF"
11303531|NCT02676063||neonatal Hypoxic Ischemic encephalopathy|moderate or severe HIE among term and late preterm newborn
11303532|NCT02676050|Experimental|Imaging agents and imaging devices|All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be <100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
11303533|NCT02676024|No Intervention|Control|Resuscitation teams will participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR without being provided cognitive aids. Participants in this group will be allowed to use any cognitive aid that they happen to keep with them and would normally use in their practice, for example, flash cards or smart phone apps.
11303534|NCT02676024|Experimental|Knowledge-based cognitive aid|"Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. However, they will be trained in using a knowledge-based cognitive aid, which will be used by a dedicated team member (the cognitive aid reader)."
11303535|NCT02676024|Experimental|Cognitive aids with roles defined (CARD)|Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. Participants will be trained to use the cognitive aids with roles defined (CARD) system. However, they will not be given knowledge-based cognitive aids and there will be no dedicated cognitive aid reader in the team.
11303536|NCT02676024|Experimental|Integrated cognitive aids|Participants will be trained to use the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid, which will be used by a dedicated cognitive aid reader.
11303537|NCT02676011|Active Comparator|Group A|Intramuscular (IM) atropine (0.01 mg/kg) (1 ml) 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
11303538|NCT02676011|Active Comparator|Group B|1 ml normal saline IM 30 minutes before induction of anesthesia, intravenously (IV) atropine (0.01 mg/kg) in 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
11303539|NCT02676011|Active Comparator|Group C|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and 1mg/kg atropine mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
11303540|NCT02676011|Placebo Comparator|Group D|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
11303541|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
11303542|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
11303543|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
11303544|NCT02675998|Placebo Comparator|Placebo|Placebo
11303545|NCT02675985|Experimental|Intervention arm|Early intensive physical therapy will be the intervention arm. There is not a control group.
11303546|NCT02675972||patient with poor outcome|modified Rankin scale≥3
11303547|NCT02675972||patients with favorable outcome|modified Rankin scale<3
11303548|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
11303549|NCT02675946|Experimental|CGX1321 alone and with pembrolizumab|"Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle
~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle.
~Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).
~Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
11303550|NCT02675933|No Intervention|Standard of Care|"The control arm participants will receive only a satisfaction survey once disposition is determined by the physician provider. The satisfaction survey will be collected by the research associated and kept in a protected location, along with all other study materials.
~All patients will receive standard of care, which at this institution is the help of Child Life Specialists, when they are available and requested by the physician. Physicians will be instructed to request Child Life Specialists with the same discretion as with all patients."
11303551|NCT02675933|Active Comparator|Questionnaire|"Participants who are randomized to the questionnaire arm will receive a patient-centered questionnaire at the beginning of their visit. This single page document will ask questions about their child including, but not limited to, diagnoses, suggestions for distraction, sensory issues that may affect their visit, and method to best administer medications. The research associate will ask them to fill it out to the best of their ability and will collect the questionnaire prior to a physician provider seeing the patient. At least one physician provider must review the questionnaire prior to seeing the patient.
~Once disposition is determined, the satisfaction survey will be distributed by the research associate along with an envelope for the parent to seal their survey within."
11303552|NCT02675920||High risk group of HCC|"known high risk group of HCC according to AASLD guideline. And patients whose risk index is equal to or higher than 2.33.
~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive).
~Patients undergo ultrasonography and LDCT using non-ionic monomer iodinated CT contrast media biannually and the interval between ultrasound and LDCT is within 30 days."
11303553|NCT02675907|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
11303554|NCT02675907|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
11303555|NCT02675894|Active Comparator|RFA with cooled-wet electrode|RFA is performed using three cool-wet electrodes in switching bipolar mode under the fused US guidance.
11352427|NCT02351739|Other|Pembrolizumab|Arm 1: pembrolizumab monotherapy
11303556|NCT02675894|Active Comparator|RFA with separable clustered electrode|RFA using separable clustered electrode in switching monopolar mode under the fused US guidance
11303557|NCT02675881|Active Comparator|RFA DSM|Eligible patients who undergo RFA using DSM and separable clustered electrodes.
11303558|NCT02675881|No Intervention|RFA SSM|Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
11303559|NCT02675868|Experimental|Norepinephrine|The noradrenaline group: a group of 10 subjects that will receive noradrenaline 0.05 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
11303560|NCT02675868|Active Comparator|Vasopressins|The vasopressin group: a group of 10 subjects that will receive vasopressin 0.04 IU/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
11303561|NCT02675868|Active Comparator|Phenylephrine|The phenylephrine group: a group of 10 subjects that will receive phenylephrine 0.5 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
11303562|NCT02675868|Placebo Comparator|Placebo|The placebo group: a group of 10 subjects that will receive NaCl 0.9% infusion for 5 hours, starting 60 minutes before endotoxin administration.
11303563|NCT02675855|Experimental|GrafixPRIME®|GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices
11303564|NCT02675855|Active Comparator|Active Comparator|Wound cover, Dressing Application Patients will be fitted with off-loading devices
11303565|NCT02675842|Active Comparator|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
11303566|NCT02675842|Placebo Comparator|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
11303567|NCT02675829|Experimental|Lung cancers, HER2 mutant|
11303568|NCT02675829|Experimental|Lung cancers, HER2 amplified|
11303569|NCT02675829|Experimental|Bladder and urinary tract cancers, HER2 amplified|
11303570|NCT02675829|Experimental|Other solid tumor cancers, HER2 amplified|
11303571|NCT02675816|Other|Inspire® (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
11303572|NCT02675803|Experimental|VAY736|VAY736 active
11303573|NCT02675803|Placebo Comparator|Placebo|VAY736 placebo
11303574|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
11303575|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
11303576|NCT02675777|Experimental|Quality Improvement Intervention|"Quality improvement intervention: 4 months during which a practice facilitator supports the clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs (see Intervention) as part of behavioral health integration."
11303577|NCT02675777|No Intervention|Usual Care|Care received after 2/2016 but before active implementation begins, which includes passive access to tools in the EHR and 2 months of preparation in each clinic (team building and local pretesting by a local implementation team supported by the external practice facilitator).
11303578|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
11303579|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.
~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.
~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
11303580|NCT02675751|Experimental|wavefront-guided PRK with iDesign|wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser
11303581|NCT02675725||Post cardiac surgery|Patients after cardiac surgery with signs of decreased organ perfusion and the need of fluid therapy.
11303582|NCT02675712||Adults with acute mood disorders|Adults aged over 18 diagnosed with an acute episode of a mood disorder using DSM-V criteria
11303583|NCT02675699|Experimental|Optimisation + HENRY|
11303584|NCT02675699|Active Comparator|HENRY as standard|
11303585|NCT02675673|Active Comparator|GJ-Tube arm|Patients randomized to his arm would usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made into the stomach through the frozen skin. The feeding tube is placed through this puncture into the stomach and the tube tip is placed in the small bowel. Once the GJ-tube has been inserted, the tube in the nose is removed.
11303586|NCT02675673|Active Comparator|G-Tube arm|Patients who are randomized to this arm will usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made through the frozen skin. A small guiding tube or catheter is placed through this puncture into the stomach, and is advanced up the esophagus and out of the mouth. The feeding tube is then pulled into the mouth, down the esophagus, and positioned through the abdomen with its inside tip in the stomach.
11303587|NCT02675660|Experimental|L-Homoarginine|125 mg of L-homoarginine
11303588|NCT02675660|Placebo Comparator|Placebo|placebo capsules
11303589|NCT02675647|Experimental|Intervention group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients.
~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB."
11303625|NCT02675465|Experimental|ATB200|In Stage 1, safety, tolerability, and PK will be evaluated following sequential single ascending doses of intravenously infused ATB200 for 3 dosing periods.
11303590|NCT02675647|Active Comparator|Control group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients.
~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB."
11303591|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
11303592|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
11303593|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
11303594|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
11303595|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
11303596|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
11303597|NCT02675621|Placebo Comparator|Control|Mix 1 flavored still beverage
11303598|NCT02675621|Active Comparator|Phenolic beverage 1|Mix 2 flavored still beverage with a high dose phenolic extract
11303599|NCT02675621|Active Comparator|Phenolic beverage 2|Mix 3 flavored still beverage with a high dose phenolic extract1 and a fruit extract
11303600|NCT02675621|Active Comparator|Phenolic beverage 3|Mix 4 flavored still beverage with a low dose phenolic extract3 and a fruit extract
11303601|NCT02675608||Year 1 Group 1|They are between 18-65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
11303602|NCT02675608||Year 1 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
11303603|NCT02675608||Year 1 Group 3|They are between 18-65 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
11303604|NCT02675608||Year 1 Group 4|They are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
11303605|NCT02675608||Year 1 Group 5|They are between 35-50 years of age, meet the criteria listed above for non-diabetic subjects in Group 1, with the exception of chronic HIV with or without hepatitis B or C infection, and have current medical history of CD4 T-cell counts 300-800.
11303606|NCT02675608||Year 2 Group 1|They are between 18-64 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
11303607|NCT02675608||Year 2 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
11303608|NCT02675608||Year 2 Group 3|If they are between 18-64 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
11303609|NCT02675608||Year 2 Group 4|If they are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
11303610|NCT02675582|Placebo Comparator|Control|Mix 1 flavored still beverage
11303611|NCT02675582|Experimental|Herbal beverage 1|Mix 2 flavored still beverage with a botanical extract(1)
11303612|NCT02675582|Experimental|Herbal Beverage 2|Mix 3 flavored still beverage with a botanical extract(2)
11303613|NCT02675582|Experimental|Combined Herbal Beverage|Mix 4 flavored still beverage with 2 botanical extracts (1,2)
11303614|NCT02675569|Active Comparator|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
11303615|NCT02675569|Experimental|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
11303616|NCT02675556|Experimental|Allogeneic hMSCs|Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
11303617|NCT02675556|Placebo Comparator|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
11303618|NCT02675556|Experimental|Pilot - Allogeneic hMSCs|Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
11303619|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
11303620|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
11303621|NCT02675530|Experimental|healthy control|Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.
11303622|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines
11303623|NCT02675491|Experimental|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
11303624|NCT02675478|Experimental|AC220|This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.
11303626|NCT02675465|Experimental|ATB200 + AT2221|In Stage 2, safety, tolerability, and PK will be evaluated following single- and multiple-ascending dose combinations of ATB200 co-administered with AT2221 (Miglustat) In Stage 3, long term safety and efficacy will be assessed following 24 month treatment of ATB200 co-administered with AT2221 (Miglustat)
11303627|NCT02675452|Experimental|AMG 176 - Part 1a|Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.
11303628|NCT02675452|Experimental|AMG 176 - Part 1b|Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
11303629|NCT02675452|Experimental|AMG 176 - Part 3a|Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.
11303630|NCT02675452|Experimental|AMG 176 - Part 3b|Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
11303631|NCT02675452|Experimental|AMG 176 - Part 3c|Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
11303632|NCT02675452|Experimental|AMG 176 - Part 4|Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break, in combination with azacitidine.
11303633|NCT02675439|Experimental|Dose escalation monotherapy|ADU-S100 administered intratumorally on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxicity, progressive disease and/or treatment is discontinued; starting dose 50 micrograms
11303634|NCT02675439|Experimental|Dose escalation combination|ADU-S100 administered intratumorally on Days 1 and 8 of each 21-day cycle (starting dose 200 micrograms) and ipilimumab, i.v., (3 mg/kg) on day 1 of each 21-day cycle for the first 4 cycles. Dosing is continued until unacceptable toxicity, progressive disease and/or treatment is discontinued
11303635|NCT02675426|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive Upadacitinib 15 mg once daily for 12 weeks.
~Period 2: Participants will continue on Upadacitinib 15 mg once daily."
11303636|NCT02675426|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive Upadacitinib 30 mg once daily for 12 weeks.
~Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
11303637|NCT02675426|Experimental|Placebo and Upadacitinib 15 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.
~Period 2: Participants will receive Upadacitinib 15 mg once daily."
11303638|NCT02675426|Experimental|Placebo and Upadacitinib 30 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.
~Period 2: Participants will receive Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
11303639|NCT02675413|Experimental|Dimethyl Fumarate|Open label dimethyl fumarate (Tecfidera) at the US approved dose of 120mg BID for 7 days and then 240mg BID thereafter for 12 months.
11303640|NCT02675400|Active Comparator|Medication Arm|Vyvanse Arm: 3-week open-label titration beginning at 20 mg Vyvanse (a class II drug), and be increased weekly during the titration period until an optimal response is obtained and then continue for 5 weeks. Optimal response is defined as a clinician Clinical Global Impression-Improvement score (CGI-I) ≤ 2 with minimal associated adverse events. Fathers will remain on optimal dose through the course of the study. In cases of poor tolerability or loss of efficacy the dose can be changed. If an optimal response is not achieved a trial with a long acting methylphenidate will be initiated based upon the Texas algorithm for stimulant medication. The study physician will be available by phone 24 hours/day; participants will be instructed to call with any safety concerns.
11303641|NCT02675400|Active Comparator|Behavioral Parent Training Arm|"Behavioral Parent Training (BPT) Arm: Fathers in the BPT group will receive weekly parent training sessions based on the Barkley manual, Defiant Children, Third Edition. The child participants will also come to several sessions at the clinician's and supervisor's discretion."
11303642|NCT02675387|Active Comparator|Traditional Group|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine
11303643|NCT02675387|Experimental|Buzzy|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine after sensitizing the area with a vibrating device
11303644|NCT02675374|Experimental|Treatment group|24 patients
11303645|NCT02675374|Placebo Comparator|Control group|24 patients
11303646|NCT02675361|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
11303647|NCT02675361|No Intervention|Comparison group|"Participants allocated to this group will receive usual care, which includes follow-up visits according to the complexity of the congenital heart disease. Usual care can vary across clinics, however, they all include meeting with a nurse and a physician.
~This is established as a comparison group since there is the risk of contamination in this group."
11303648|NCT02675361|No Intervention|Control group|"Participants in this group will receive usual care. Follow-up visits will depend on the complexity of the disease.
~Five clinis comprise this section of the study and will be part of an longitudinal, observational study, which investigators will use as a control group."
11303649|NCT02675348|Experimental|Dietary Supplement: Beef Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.
~Intervention will last for 10 weeks. Participants will ingest 20g of beef protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
11303650|NCT02675348|Experimental|Dietary Supplement: Whey Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.
~Intervention will last for 10 weeks. Participants will ingest 20g of whey protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
11303713|NCT02674880|Experimental|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
11303651|NCT02675348|Active Comparator|Dietary Supplement: CHO|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.
~Intervention will last for 10 weeks. Participants will ingest 20g of maltodextrin powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
11303652|NCT02675335|Active Comparator|Sitagliptin|Sitagliptin tablets, 100mg per day, 12 weeks treatment
11303653|NCT02675335|Placebo Comparator|Placebo|Placebo tablets, 1 tablet per day, 12 weeks treatment
11303654|NCT02675322|Experimental|Danlou Tablets|Danlou tablets (4.5 g oral dose taken once daily) for 90 days
11303655|NCT02675322|Placebo Comparator|placebo|matching placebo for 90 days
11303656|NCT02675309|Experimental|MT-8554, rosuvastatin and simvastatin|Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
11303657|NCT02675283|Other|coeliac disease point of care test|Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
11303658|NCT02675270|Experimental|Phonological, Orthographic, Untrained|
11303659|NCT02675270|Experimental|Semantic, Lexical, Untrained|
11303660|NCT02675257|Experimental|Cognitive-behavioural group treatment|"Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control.
~Interventions:
~Diabetes-related affective problems analysis
~Goal setting towards improvement of glycaemic control
~Diabetes-specific problem-solving therapy
~Interventions to increase diabetes treatment motivation
~Activation of personal and social resources
~Reduction of barriers to self-care/glycaemic control
~Cognitive restructuring of diabetes-related problems
~Goal definition regarding self-care/glycaemia/well-being"
11303661|NCT02675257|Active Comparator|Treatment-as-usual|"Standard diabetes education.
~Interventions:
~Health care and specific topics (e. g. blood pressure)
~Healthy foods, cooking recommendations, recipes
~Sports, activities and exercise
~Foot care: exercises, care & control, injuries, neuropathy
~Diabetes complications
~Social aspects of living with diabetes"
11303662|NCT02675244|Active Comparator|MVS Alone|Participants will undergo mitral valve surgery alone.
11303663|NCT02675244|Active Comparator|MVS + TV Annuloplasty|Patients will undergo mitral valve surgery and tricuspid valve annuloplasty.
11303664|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
11303665|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
11303666|NCT02675231|Active Comparator|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
11303667|NCT02675218||Patients with rheumatoid arthritis.|Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.
11303668|NCT02675205|Active Comparator|clopidogrel-aspirin|clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.
11303669|NCT02675205|Experimental|ticagrelor-aspirin|Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery
11303670|NCT02675192||Proof cohort : muscular assessment|"Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...
~Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...
~Urinary collection : metabolome tests
~Maximal voluntary quadriceps strength (MVC)
~Checking muscle functional skills
~Muscular biopsy"
11303671|NCT02675179|Experimental|EOS + Spiral CT pelvimetry|Women with an indication of pelvimetry will be included in this study. They will be their own control because they will benefit from the two methods of diagnosis : EOS new technique, and spiral CT (usual technique).
11303672|NCT02675166||Pediatric cancer young adult survivors|544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
11303673|NCT02675153|Experimental|Upper gastrointestinal strictures|Patients with upper gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
11303674|NCT02675153|Experimental|Lower gastrointestinal strictures|Patients with lower gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
11303675|NCT02675140|Experimental|ZENTEL|Children in intervention group 1 was received 400 mg single-dose albendazole administration, by mouth, for once.
11303676|NCT02675140|Experimental|ZENTEL and Vitamin A Soft Capsules|Children in intervention group 2 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially, by mouth.
11303677|NCT02675140|No Intervention|No drug adminitrated|Children in this Group were received no intervention as control group
11303678|NCT02675127|Experimental|A Test|Test drug (Daktavira, European Egyptian Pharmaceutical Industries)1 tablet contains 60 mg Daclatasvir
11303679|NCT02675127|Active Comparator|B Reference|Reference drug (Daklinza, (Bristol-Myers Squibb Pharma, UK)) 1 tablet contains 60 mg Daclatasvir
11303680|NCT02675114|Active Comparator|Surgical aortic valve replacement (SAVR)|
11303681|NCT02675114|Experimental|Edwards SAPIEN 3 THV|
11303682|NCT02675101|Active Comparator|Whole nuts|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
11303683|NCT02675101|Experimental|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 18 g olestra/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Fat free Pringles will be provided to participants for the duration of the study.
11303684|NCT02675101|Placebo Comparator|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
11303685|NCT02675088|Experimental|high-dose TRT|high-dose thoracic radiotherapy X-ray RT
11303686|NCT02675088|Active Comparator|standard-dose TRT|standard-dose thoracic radiotherapy XRT
11303687|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
11303688|NCT02675049|Placebo Comparator|0.9% saline|Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
11303689|NCT02675049|Experimental|dexmedetomidine 1 µg.kg-1|Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
11303690|NCT02675049|Experimental|dexmedetomidine 1.5 µg.kg-1|Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
11303691|NCT02675049|Experimental|dexmedetomidine 2 µg.kg-1|Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
11303692|NCT02675036|Experimental|Primary canine tooth|Extraction of primary canine tooth
11303693|NCT02675036|Experimental|Primary canine and primary molar teeth|Extraction of primary canine and primary first molar teeth
11303694|NCT02675023|Experimental|Auto-injector (AI)|M923 administered via AI
11303695|NCT02675023|Experimental|Prefilled syringe (PFS)|M923 administered via PFS
11303696|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES|ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
11303697|NCT02674997||Study participants|Participants with Hemophila A
11303698|NCT02674971|Active Comparator|INCREASE|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) per day.
11303699|NCT02674971|Active Comparator|COMBINATION|This condition will be identical to the INCREASE condition, except it will also have a goal regarding the number of high-ED foods to consume and substituting low-ED foods for high-ED foods. Thus, this condition will have ED goals to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day. Foods with an ED >1.0 kcal/g but < 3.0 kcal/g will be unlimited; however, lower ED foods will be strongly encouraged. Furthermore, additions to beverages (i.e., sugar, cream) will count toward the > 3.0 kcal/g goal if the additions meet that ED criteria.
11303700|NCT02674958|Active Comparator|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
11303701|NCT02674958|No Intervention|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
11303702|NCT02674945||Wireless Activity tracker: Fitbit|Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.
11303703|NCT02674932|Experimental|Signature Strengths|"Patients will complete the Values in Action Youth Survey (VIA-Youth) and will receive a list of his/her top character strengths (signature strengths). The patient will then participate in the Identifying and Using Signature Strengths Intervention."
11303704|NCT02674932|Active Comparator|Coping Skills + Memory Aid|Patients will complete the VIA-Youth but will not receive any results. The patient will then participate in the Identifying and Writing Down Coping Skills Intervention.
11303705|NCT02674932|Other|Coping Skills (Treatment as Usual)|Patients will complete the VIA-Youth but will not receive any results. After completing the VIA-Youth, the study team member and patient will have a treatment-as-usual discussion about coping skills. (This is equivalent to treatment as usual that is already provided on the psychiatric unit-doctors and nurses on the unit already have this a discussion about coping skills with patients).
11303706|NCT02674919|Experimental|Nordic Hamstring|The Nordic Hamstring group performs a progressive strengthening program (Mjolsnes et al., 2004) comprising of the Nordic Hamstring exercise during a period of 10 weeks. The training load increases from one session per week in week 1 to 3 sessions per week in week 3-10. Number of sets and repetitions progressively increase from 2 to 3 and 5 to 12, respectively. The exercise program is performed in the end of a regular football training session.
11303707|NCT02674919|Other|Control|The control group are asked not to perform the exercise or any other specific strength training for the hamstring muscles and to continue to play football as usual.
11303708|NCT02674906|Active Comparator|citrate|A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
11303709|NCT02674906|Active Comparator|heparin|A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
11303710|NCT02674893|Experimental|type 2 diabetics treated with GLP1 analogue|
11303711|NCT02674893|Active Comparator|Type 2 diabetics not treated with incretins|
11303712|NCT02674893|Other|Healthy subjects|
11303714|NCT02674880|Placebo Comparator|Placebo|5 ml of saline via nebulizer b.i.d.
11303715|NCT02674867|Experimental|Early treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART before 6 months-of-age (early treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
11303716|NCT02674867|Other|Late treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART after 24 months-of-age (late treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
11303717|NCT02674854|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
11303718|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
11303719|NCT02674854|Active Comparator|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
11303720|NCT02674841|Experimental|Feedback group|Receives live feedback on TUT and pulling force during exercises.
11303721|NCT02674841|Active Comparator|Control group|Receives no feedback on TUT but on pulling force during exercises.
11303722|NCT02674828|Experimental|Reinforcement treatment|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
11303723|NCT02674828|Active Comparator|Standard Treatment|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
11303724|NCT02674815|Experimental|Intervention|Patients within this arm will perform two weeks of high intensity interval training prior to colorectal/thoracic surgery. Exercise intensity will be 100% of the peak power output (PPO) during maximal cardiopulmonary exercise testing. Patients will exercise for 15 seconds at 100% PPO and rest for 15 seconds (passive) for 30 minutes or until exhaustion. This will be performed 5 days a week for 2 weeks.
11303725|NCT02674802||Retrospective study|People who has successfully eradicated helicobacter pylori more than six months detected helicobacter pylori by the C-urea breath test in order to evaluate the reinfection.
11303726|NCT02674802||Prospective study|People who has infected helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6 months detected helicobacter pylori by the C-urea breath test in order to prospect the reinfection .
11303727|NCT02674789|Experimental|Exercise day|Behavioral intervention: 90min bike ergometer test at 70% of VO2max. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
11303728|NCT02674789|No Intervention|Non exercise day (Rest day)|No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
11303729|NCT02674776|Experimental|HuZhen Capsule|The main elements of HuZhen Capsule include Polygonum cuspidatum, Ligustrum lucidum etc.
11303730|NCT02674776|Placebo Comparator|Placebo Capsule|Placebo appearance, content color and taste should be consistent with HuZhen Capsule.
11303731|NCT02674763|Experimental|Dose Escalation Schedule A|IMGN779 administered on days 1 and 15 of a 28-day cycle
11303732|NCT02674763|Experimental|Dose Escalation Schedule B|IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle
11303733|NCT02674763|Experimental|Dose Escalation Schedule C|IMGN779 administered on days 1 and 8 of a 21-day cycle
11303734|NCT02674763|Experimental|Dose Expansion Cohort|Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.
11303735|NCT02674750|Experimental|CUDC-907|RR-DLBCL, including with MYC alterations detected by FISH or by >=40% MYC by IHC
11303736|NCT02674737|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both sedative and analgesic(dexmedetomidine, tramadol and flurbiprofen) are applied to this group of patients.
11303737|NCT02674737|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(tramadol and flurbiprofen) are applied to this group of patients.
11303738|NCT02674724|Experimental|Gym Group|With gym equipments, twice per week for 12 weeks.
11303739|NCT02674724|Active Comparator|Free Weights Group|With dumbbells, elastics, twice per week for 12 weeks.
11303740|NCT02674724|Placebo Comparator|Control Group|The control group will be instructed to perform stretching exercises at home in the same 12-week period, according to an illustrated booklet.
11303741|NCT02674711|Experimental|Educational Video|Evidence-based video: Best Advice for People Taking Opioid Medication
11303742|NCT02674711|No Intervention|Usual Care|Usual care education provided at time of pre-operative appointment.
11303743|NCT02674698|Other|VA Integrated Service Networks Group 1|Access to the CNH Dashboard Step 1
11303744|NCT02674698|Other|VA Integrated Service Networks Group 2|Access to the CNH Dashboard Step 2
11303745|NCT02674698|Other|VA Integrated Service Networks Group 3|Access to the CNH Dashboard Step 3
11303746|NCT02674698|Other|VA Integrated Service Networks Group 4|Access to the CNH Dashboard Step 4
11303747|NCT02674672|Experimental|VenaTech Retrievable arm|VenaTech Retrievable arm
11303748|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
11303749|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
11303750|NCT02674646|Experimental|Group A: Verum Acupuncture|Group A: Verum Acupuncture (Needle Acupuncture) Needlepoints Bilateral PC 6, S 36, L 8, L 9 Unilateral R4, R 6 Acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
11303751|NCT02674646|Sham Comparator|Group B: Sham Acupuncture|Group B: Sham Acupuncture (Needle Acupuncture) Needlepoints 8 needles in the medioaxillary line below the 6th rib, bilateral 2 needles unilateral Sham-acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
11303752|NCT02674633|Active Comparator|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
11303753|NCT02674633|Active Comparator|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
11303754|NCT02674620|No Intervention|Conservative|Standard conservative care of concussion
11303755|NCT02674620|Experimental|Treadmill|Aerobic exercise treatment for concussion
11303756|NCT02674607|Experimental|patients|thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
11303757|NCT02674607|No Intervention|controls|thirty healthy children of matched age and sex
11303758|NCT02674594||Patient treated with Dabigatran|
11303759|NCT02674594||Patient treated with Rivaroxaban|
11303760|NCT02674594||Patient treated with Apixaban|
11303761|NCT02674594||Patient treated with Warfarin|
11303762|NCT02674581|Experimental|Healthy Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
11303763|NCT02674581|Experimental|Mild Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
11303764|NCT02674581|Experimental|Moderate Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
11303765|NCT02674581|Experimental|Severe Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
11303766|NCT02674581|Experimental|End Stage Renal Disease Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
11303767|NCT02674568|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine administered intravenously on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for 2 cycles. An additional 2 cycles of rovalpituzumab tesirine (retreatment) was permitted for eligible participants.
11303768|NCT02674555|Experimental|ASP8273|Two Parts - Part A: 14C-radio labeled; Part B: non radio labeled (optional)
11303769|NCT02674529|Active Comparator|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
11303770|NCT02674529|Placebo Comparator|Placebo|A placebo pill will be taken over an 8-week period.
11303771|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
11303772|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
11303773|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
11303774|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
11303775|NCT02674490|Experimental|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
11303776|NCT02674490|Sham Comparator|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
11303777|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
11303778|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
11303779|NCT02674464|Active Comparator|Standard of Care Plus|The standard of care plus arm will include audit and feedback of blood pressure control rates at the provider level along with web-based training about: 1) barriers to blood pressure and cardiovascular disease (CVD) risk factors management in at-risk patient populations; 2) strategies to address healthcare disparities in clinical settings; and 3) appropriate blood pressure (BP) measurement techniques for all clinical staff. The Hopkins research team will help clinics develop audit and feedback mechanisms if they are lacking and will provide all blood pressure measurement and web-based training.
11303780|NCT02674464|Experimental|Collaborative Care/Stepped Care (CC/SC)|The CC/SC arm includes: -BP training -Audit and feedback dashboard, data stratified by race, ethnicity, payor status -A 4 hour workshop for organizational leaders in quality improvement and disparities reduction, with follow up meetings for problem-solving and support, and web-based, patient-centered communication skills training program for providers and staff -Support and guidance in establishing collaborative care model (CCM): team-based care targeting health behaviors and medication adherence. The primary care provider (PCP), care manager, CHW, and specialists in: medication management, psychosocial/behavioral, and self-management will make up the CCM team -Community health workers (CHW) working on contextualized patient interactions focused on problem-solving skills and patient self-management. CHWs will visit their patients in their homes and communities -Provider access to on-call specialists for help with patients who do not achieve BP control under the CC/SC
11303781|NCT02674451|Active Comparator|RIPC|Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
11303782|NCT02674451|Sham Comparator|Controls|Participants will have routine blood pressure measurements will be obtained.
11303783|NCT02674438|Experimental|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic
~Intervention #1 - Clinical algorithm: the EHMRG 7-day and EHMRG30-ST risk scores, which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation, or emergency department discharge.
~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
11303784|NCT02674438|No Intervention|Control|Usual care without access to the EHMRG/EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
11303785|NCT02674425||Young adults (18-40)|Healthy adult volunteers, aged between 18 and 40, with no prior/current eye problems or family history of genetic eye diseases and good general health.
11303786|NCT02674425||Older adults (50-70)|Healthy adult volunteers, aged between 50 and 70, with no prior/current eye problems or family history of genetic eye diseases and good general health.
11303787|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
11303788|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
11303789|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
11303790|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
11303791|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
11303792|NCT02674373||Localized gastric cancer|resectable tumor receiving a curative intent treatment.
11303793|NCT02674373||advanced gastric cancer|unresectable tumor treated with palliative chemotherapy
11303794|NCT02674360|Active Comparator|SDM Online Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of a web-based SDM online Training (intervention group I). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The SDM online training works on the modeling principle.
11303795|NCT02674360|Active Comparator|Face-to-Face SDM Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of an individualized, context-based SDM individual face-to-face training at the workplace of the participants (intervention group II). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The individual training works on the coaching principle.
11303796|NCT02674360|No Intervention|Control Group|The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
11303797|NCT02674347|Experimental|Cohort 1: 3 g or 6 g of Zidebactam|"Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours [q8h]) (n=8) IV infusions administered over 60 minutes.
~Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes."
11303798|NCT02674347|Placebo Comparator|Placebo|"Cohort 1: Placebo every 8 hours [q8h] (n=2) IV infusions administered over 60 minutes.
~Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes."
11303799|NCT02674334|Active Comparator|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
11303800|NCT02674334|Active Comparator|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
11303801|NCT02674321|Experimental|SD-809|• SD-809 tablets taken once or twice daily for 8 weeks, includes a dose titration period and a maintenance period.
11303802|NCT02674308||Vedolizumab|
11303803|NCT02674308||Other Biologic Agents|
11303804|NCT02674295|Experimental|Cohort 1|50 milligram (mg) of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration.
11303805|NCT02674295|Experimental|Cohort 2|20 mg of intravenous esketamine in 30 milliliter (mL), fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
11303806|NCT02674282|Experimental|ACL-injured|ACL injured professional soccer players submitted to ACL reconstruction.
11303807|NCT02674282|No Intervention|Control|Healthy professional soccer players
11303808|NCT02674269|Experimental|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
11303809|NCT02674269|Experimental|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
11303810|NCT02674269|Placebo Comparator|TC-3 Gel|One intravesical instillation of 60 ml TC-3 gel
11303811|NCT02674256|Active Comparator|CRH injection|Intervention: intravenous injection of CRH 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together then the solution will be injected IV over the course of 1 minute
11303812|NCT02674256|Placebo Comparator|placebo injection|"Intervention: intravenous saline injection
~1mL of saline will be injected intravenously over the course of 1 minute"
11303813|NCT02674243|Experimental|Iodopovidone group|Patients who will be randomized for using iodopovidone solution for pleurodesis.
11303814|NCT02674243|Active Comparator|Talc group|Patients who will be randomized for using Talc for pleurodesis.
11303815|NCT02674230||Extreme obesity|BMI ≥35kg/m2
11303816|NCT02674230||Obesity|BMI 24-34.9kg/m2
11303817|NCT02674230||Normal subjects|BMI <24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
11303818|NCT02674217|Experimental|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS) or primary progressive (PPMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
11303819|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
11303820|NCT02674204|Placebo Comparator|Control|One matching placebo daily
11303821|NCT02674191|Experimental|Group 1|Device: mini-plates supported molar intrusion (Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence Procedure/Surgery: Application of ULTRACARE benzocaine 20%, topical anesthesia (Ultradent Products, Inc) Procedure/Surgery: Administration of , Mepivacaine-l local anesthesia Procedure/Surgery: BETADINE povidone-iodine 10% a local disinfectant Drug: (150g Clindamycin/tds) for 1 week Postoperative antibiotic Drug: (Cataflam 25mg), are prescribed post-operatively an analgesic
11303822|NCT02674191|No Intervention|Group 2|hyperdivergent adolescence with no intervention
11303823|NCT02674178|Active Comparator|Age <35|< 35 years old included 201 women who are further subdivided according o FSH/LH ratio into G1A (201 patients) with FSH/LH ratio <2 and G1B (37 patients) with FSH/LH ratio ≥2.
11303824|NCT02674178|Active Comparator|Age ≥ 35|. Group 2 ≥ 35 years old included 34 women who are further subdivided according o FSH/LH ratio into G2A (25 patients) with FSH/LH ratio <2 and G2B (9 patients) with FSH/LH ratio ≥2
11303825|NCT02674165|Experimental|Intervention|"The pregnancy prevention intervention to be tested is an adaptation of Becoming a Responsible Teen (BART), an evidence-based (proven to work by research) HIV prevention curriculum designed primarily for African American adolescents, ages 14-18, in community-based settings.
~The culturally-adapted version HART consists of nine sessions, lasting about 2 hours each, and includes interactive group discussions and role plays that are -performed by adolescents. Unlike BART, one PTSD awareness session has been added to address what happens to people who have been exposed to mental trauma and natural disasters."
11303826|NCT02674165|No Intervention|Control or nutrition|Nutrition/fitness curriculum will teach students about ingredients in food that are good for the body and will keep it in good health
11303827|NCT02674152|Experimental|BI 836880|
11303828|NCT02674139|Active Comparator|IUD insertion 6 Weeks after delivery|Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
11303829|NCT02674139|Experimental|Immediate Post-placental insertion|Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
11303830|NCT02674126|Placebo Comparator|Control group|Control group
11303831|NCT02674126|Active Comparator|Maternal sound group|Maternal sound
11303832|NCT02674113|Active Comparator|regional anesthesia bupivacaine|regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy
11303833|NCT02674113|Placebo Comparator|regional anesthesia placebo|subcutaneous injection procedure placebo (0.9% sodium chloride in water)
11303834|NCT02674087||Expectant women|
11303835|NCT02674074|Experimental|measurement of corneal temperature by infrared thermography|
11303836|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year).
11303837|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year)
11303838|NCT02674035|Active Comparator|Device: 2-0 monofilament nylon suture|Plication of the anterior rectus sheath (correction of diastasis of the rectus abdominis muscles) was performed in two layers with Device 2-0 monofilament nylon suture (control group). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
11303839|NCT02674035|Active Comparator|Device: Single layer 2-0 monofilament|Single layer with a Device 2-0 monofilament nylon suture (correction of diastasis of the rectus abdominis muscles) (group I). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
11303865|NCT02673866|Placebo Comparator|Placebo|Placebo
11303866|NCT02673866|Active Comparator|Pregabalin|Pregabalin
11303867|NCT02673840|Experimental|Ketotifen|
11303868|NCT02673840|Placebo Comparator|Placebo|
11303840|NCT02674035|Active Comparator|Device: Barbed suture Quill Nylon 1|Using a continuous Device Barbed suture Quill Nylon 1 (correction of diastasis of the rectus abdominis muscles) (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
11303841|NCT02674022|Active Comparator|Mothers of Children with ASD|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
11303842|NCT02674022|Active Comparator|Mothers of Typically Developing Children|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
11303843|NCT02674009||laBCC Participants|Participants with laBCC who received at least one dose of Vismodegib in routine clinical practice for 32 months (between 02 Aug 2013 and 31 Mar 2016).
11303844|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
11303845|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
11303846|NCT02673983|Experimental|Patients undergoing endoscopic full-thickness biopsy|
11303847|NCT02673970||observational arm|From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab
11303848|NCT02673957||Blood pressure cuff protocol|All participants receive a baseline control blood test, and all participants receive the blood pressure cuff inflation protocol and blood sampling following the cuff protocol.
11303849|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
11303850|NCT02673931|Experimental|GLP-1|"270 patients will be randomized to GLP-1, that will be administered as follows:
~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin added 25 microg Byetta (Lilly, Exenatide).
~The study drug infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes. A set dose of 17.4 microg will be given."
11303851|NCT02673931|Placebo Comparator|Placebo|"20% Human Albumin is given as placebo. 270 patients will be randomized to placebo, that will be administered as follows:
~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin.
~The placebo infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes at the same rate as the study drug."
11303852|NCT02673931|Experimental|Restrictive Oxygenation|"The intervention is FiO2 of 50%, given as 'Conoxia (AGA, oxygen)'. 270 patients will be randomized to a FiO2 of 50% as long as the arterial O2 saturation (Sa02) remains above 91% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after
~a maximum of 1 hours of intervention or
~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
11303853|NCT02673931|Active Comparator|Liberal Oxygenation|"The intervention is a FiO2 of 100%, given as 'Conoxia (AGA, oxygen)'. 270 patients will be randomized to a FiO2 of 100% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after
~a maximum of 1 hours of intervention or
~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
11303854|NCT02673918|Experimental|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
11303855|NCT02673918|Experimental|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
11303856|NCT02673905|Experimental|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
11303857|NCT02673905|Experimental|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
11303858|NCT02673892|Experimental|PODS intervention|The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
11303859|NCT02673892|No Intervention|Usual Care|Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.
11303860|NCT02673879|Active Comparator|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
11303861|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated.
11303862|NCT02673866|Experimental|DS-1971a 400 mg TID|DS-1971a 400 mg three times per day (TID)
11303863|NCT02673866|Experimental|DS1971a 400 mg BID|DS1971a 400 mg twice per day (BID)
11303864|NCT02673866|Experimental|DS1971a 100 mg BID|DS1971a 100 mg BID
11303869|NCT02673827|No Intervention|Group control|Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
11303870|NCT02673827|Experimental|experimental group|"Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation.
~They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation."
11303871|NCT02673814|Experimental|Arm A (durvalumab)|10 mg/kg durvalumab alone every two weeks
11303872|NCT02673814|Experimental|Arm B (bavituximab + durvalumab)|3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks
11303873|NCT02673814|Experimental|Arm C (bavituximab + durvalumab)|3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks
11303874|NCT02673801||Patient referred to orthopedic clinic|Orthopedic assessment in the outpatient clinic as well as a new algorithm (using patient-reported symptoms and radiographic evaluation) will be applied
11303875|NCT02673775|Placebo Comparator|Clean Air|Subjects will be exposed to clean air for 3 hours.
11303876|NCT02673775|Experimental|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
11303877|NCT02673762||Normal glucose metabolism|Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
11303878|NCT02673762||Pre-diabetes|Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
11303879|NCT02673762||Type II diabetes|Hemoglobin A1c 6.5% or greater, fasting blood glucose >125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
11303880|NCT02673749|Experimental|RP-G28 Dose 1|
11303881|NCT02673749|Experimental|RP-G28 Dose 2|
11303882|NCT02673749|Placebo Comparator|Placebo|
11303883|NCT02673736|Experimental|PLX73086|"Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.
~Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease)."
11303884|NCT02673723|Experimental|Dezocine|Dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
11303885|NCT02673723|Placebo Comparator|Controlled|The same amount of saline is given for 10 seconds after surface anesthesia
11303886|NCT02673710||Participants with metastatic colorectal cancer|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
11303887|NCT02673697|Experimental|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
11303888|NCT02673697|Active Comparator|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
11303889|NCT02673684|Sham Comparator|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
11303890|NCT02673684|Experimental|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
11303891|NCT02673671||Subjects with unknown POI status consented pre-surgery|Up to 100 subjects may be consented prior to surgery who are planned to undergo gastrointestinal surgery or a planned surgery that does not involve the abdominal cavity. The investigator does not change the routine medical care of study participants.
11303892|NCT02673671||Subjects with known/unknown POI status consented post-surgery|Up to 50 subjects who have undergone gastrointestinal surgery or surgery not involving the abdominal cavity may be consented post- operatively during their hospital stay for this study.The investigator does not change the routine medical care of study participants.
11303893|NCT02673658|Active Comparator|Motor + problem solving|This method focuses on spontaneous movement (rather than facilitated movement). Self-initiated, functionally directed movement is emphasized. Intervention includes guidance and cues, which gently call the child's attention to the support surface, and a set-up of the environment for small increments of movement so that the child can solve a movement problem. Passive movements are not used. Each small increment of movement to advance sitting skill or other motor skills is paired with a specific object or toy that challenges a cognitive concept for spatial problem solving. In this approach, the parent will adjust toys and supports to encourage changes of position from sitting, to transitions in and out of sitting to crawling or standing, but will not assist the child physically.
11303894|NCT02673658|Active Comparator|Body weight support training|In this approach, infants will be supported physically by their parents to take steps, sit, crawl, or reach, in practice sessions focused simply on the motor skill. Toys or problem solving will not be part of this intervention, but the child will be assisted (lifted by the parent) through movement to improve strength and learn specific movements and new positions. The child will be able to perform as much of the movement as possible, but the parents will initiate the activity if the child does not initiate, and the parent will lift the child passively through the task if the child is unable to move.
11303895|NCT02673645|No Intervention|Control group|These youth will receive standard mathematics instruction and support, but not the intensive tutoring offered through the intervention.
11303896|NCT02673645|Experimental|SAGA Innovations|These youth will receive the intensive mathematics tutoring by SAGA Innovations, with students randomized to tutors.
11303897|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
11303898|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
11303899|NCT02673606|Experimental|Estradiol 2mg Dose|2mg dose of estradiol (oral administration)
11303900|NCT02673606|Experimental|Estradiol 4mg Dose|4mg dose of estradiol (oral administration)
11303901|NCT02673606|Placebo Comparator|Placebo|placebo (oral administration)
11303902|NCT02673593|Placebo Comparator|Placebo|Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
11303903|NCT02673593|Experimental|DS102 100mg Single Dose|Taken orally once by Cohort 1
11303904|NCT02673593|Experimental|DS102 500mg Single Dose|Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
11303905|NCT02673593|Experimental|DS102 1000mg Single Dose|Taken orally once by Cohort 3
11303906|NCT02673593|Experimental|DS102 2000mg Single Dose|Taken orally once by Cohort 4
11303907|NCT02673593|Experimental|DS102 500mg Multiple Dose|Taken orally once a day for 28 days by Cohort 5
11303908|NCT02673593|Experimental|DS102 1000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 6
11303909|NCT02673593|Experimental|DS102 2000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 7
11303910|NCT02673580|Other|Open Access telePRO|Intervention: In open access, contact to the outpatient clinic is initiated by the patient by filling in a PRO questionnaire.
11303911|NCT02673580|Other|Standard telePRO|No intervention: In standard telePRO, outpatient follow-up activity is determined by a clinician and patients receive a questionnaire at fixed intervals.
11303912|NCT02673567|Experimental|TEV-48125 - 1|Dose Regimen 1
11303913|NCT02673567|Experimental|TEV-48125 - 2|Dose Regimen 2
11303914|NCT02673567|Experimental|TEV-48125 - 3|Dose Regimen 3
11303915|NCT02673567|Placebo Comparator|Placebo|Matching Placebo
11303916|NCT02673554|Experimental|Oral glucose tolerance test|An oral glucose challenge (75 g)
11303917|NCT02673554|Active Comparator|GIP Bolus|Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
11303918|NCT02673554|Active Comparator|GIP Infusion|Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
11303919|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
11303920|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
11303921|NCT02673528||Directly underwent TLA|Patients with the diagnosis who underwent directly total laparoscopic appendectomy
11303922|NCT02673528||Lap Assisted App|Patients with the diagnosis of acute appendicitis who underwent a successful laparoscopic assisted appendectomy
11303923|NCT02673528||Advanced to TLA|Patients with the diagnosis of acute appendicitis in whom laparoscopic assisted appendectomy attempted; however, because it fail advanced to total laparoscopic appendectomy.
11303924|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
11303925|NCT02673515|No Intervention|control group|control group
11303926|NCT02673502|Experimental|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
11303927|NCT02673502|Experimental|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery.
11303928|NCT02673489|Experimental|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
11303929|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
11303930|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
11303931|NCT02673463|Experimental|Spironolactone|Spironolactone 25 mg once daily for 2 years
11303932|NCT02673463|Placebo Comparator|Placebo|Matched placebo once daily for 2 years
11303933|NCT02673437||Rivaroxaban group|Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
11303934|NCT02673437||Alternative dual antiplatelet therapy|Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
11303935|NCT02673424|Active Comparator|FFR-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by FFR-guided strategy.
11303936|NCT02673424|Active Comparator|IVUS-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by IVUS-guided strategy.
11303937|NCT02673398|Experimental|Treatment (neratinib)|Patients receive neratinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11303938|NCT02673385||Brazelton scale|Procurement across Brazelton scale
11303939|NCT02673385||No test|usual care
11303940|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
11303941|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
11303942|NCT02673359|Active Comparator|Progesterone group|Vaginal progesterone suppositories will be given
11303943|NCT02673359|Active Comparator|Cerclage group|Cervical cerclage will be performed.
11303944|NCT02673346||employees|YKHC employees
11303945|NCT02673333|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
11303946|NCT02673320|Experimental|Early surgery|Early surgery within 48 hours
11303947|NCT02673320|Other|Delayed surgery|Delayed surgery at 15 days
11303948|NCT02673307|No Intervention|Controle|The volunteer does not chew gum during the study period
11303949|NCT02673307|Experimental|Chewing gum|The volunteer chews gum during the first 45 min after ingestion of 250 ml water
11303950|NCT02673294|Experimental|intervention (6-12 months)|Participants with a chronicity between 6-12 months
11303951|NCT02673294|Experimental|Intervention (12-24 months)|Participants with a chronicity between 12-24 months
11303952|NCT02673294|Experimental|Intervention (>24 months)|Participants with a chronicity >24 months
11303953|NCT02673281|Experimental|Walnut shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
11303954|NCT02673281|Placebo Comparator|Placebo shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
11303955|NCT02673268|Experimental|Patients with breast cancer|
11303956|NCT02673255|Experimental|Sanofi Pasteur (Tenivac)|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
11303957|NCT02673255|Experimental|MassBiologics|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: MassBiologics, Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
11303958|NCT02673242|No Intervention|Control|No treatment other than medical
11303959|NCT02673242|Experimental|Intervention|Inspiratory muscle training
11303960|NCT02673229|Active Comparator|Collagenase Santyl|Applied topically (2 mm thickness once daily)
11303961|NCT02673229|Sham Comparator|Bacitracin|Applied topically (2 mm thickness) once daily
11303962|NCT02673216||Spontaneous abortion|Women attending for suspected spontaneous abortion
11303963|NCT02673216||Normal pregnant women|Normal pregnant women attending for nuchal translucency scan
11303964|NCT02673203|Active Comparator|Lean Healthy Control|(BMI <25 kg/m2)
11303965|NCT02673203|Active Comparator|Obese non-diabetic subject|BMI > 30 kg/m2
11303966|NCT02673177|Experimental|Robot-assisted total mesorectal excision|Robot-assisted total mesorectal excision (RTME) for rectal cancer. Two different RTME procedures were chose to personalized patients. Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
11303967|NCT02673177|Active Comparator|Laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed. The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
11303968|NCT02673164|Active Comparator|CSCC_ASC|Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)
11303969|NCT02673164|Placebo Comparator|Placebo|Saline
11303970|NCT02673151|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11. Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA 11 Beginning 50-100 minutes later, a low dose CT will be obtained from vertex to mid thighs; followed by a static PET emission scan over the same .
11303971|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
11303972|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
11303973|NCT02673125|Experimental|Double embryo transfer|Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
11303974|NCT02673112|Experimental|STEP-mhc + LS|Subjects will be asked to perform exercise at 80% of the heart rate threshold determined using the Balke protocol for 5 minutes greater than their measured minutes of MVPA/day at baseline (Subthreshold exercise program). They will also be given a light stretching protocol (5 stretches). The exercise intervention will last for 6 weeks and will be supported by weekly health coaching.
11303975|NCT02673112|Active Comparator|LS alone|Subjects will be given a light stretching program alone (5 stretches). The exercise program will last for 6 weeks.
11303976|NCT02673099|Other|HDF online|All patients were started on HF (high-flux) hemodialysis. After 6 months they were then treated by HDF online.
11303977|NCT02673086|Active Comparator|coracoid approach|Patients in this group will be randomized to receive an coracoid approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
11303978|NCT02673086|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
11303979|NCT02673073|Placebo Comparator|Control_Education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
11303980|NCT02673073|Experimental|Intervention_Diary|All patients will receive patient's information/education booklet on the heart failure including life style modification. In addition, patients also receive a patient's diary for self-recording of 6 parameters: body weight, blood pressure, heart rate, number of remaining pills, degree of pitting edema, and degree of dyspnea.
11303981|NCT02673060|Experimental|dose escalation of MBC-11|MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
11303982|NCT02673047||Botox®|Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
11303983|NCT02673021|Experimental|Microwave Ablation|Microwave Ablation
11303984|NCT02673008|Experimental|MRD-directed DLI|For patients with MRD+ and without grade II/>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.
11303985|NCT02672995|Experimental|Single arm dose-escalation|"Fractionated stereotactic radiosurgery:
~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.
~Concurrent bevacizumab:
~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
11303986|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
11303987|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
11303988|NCT02672969|Experimental|Smoke evacuation uses|Smoke evacuation uses means using RapidVac Smoke Evacuator with electrosurgical unit during coagulation and cutting surgery. (Experimental group)
11303989|NCT02672969|No Intervention|no smoke evacuation uses|No smoke evacuation uses means using only the regular electrosurgical unit during coagulation and cutting surgery. (Control group)
11303990|NCT02672956|Experimental|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
11303991|NCT02672956|Experimental|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
11303992|NCT02672956|Experimental|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
11303993|NCT02672943|No Intervention|Normal|30 normal volunteers with age, sex and BMI-match as control group
11303994|NCT02672943|Active Comparator|treatment group|The Rehabilitation treatment group will receive rehabilitation training once per day, 3 days per week, for 12 weeks. The duration of each session is about 1 hour. Participants will first receive relaxation exercises, positioning and self-stretch exercises (emphasizing on spinal mobility and flexor muscle groups of limbs and trunk) for 15 minutes. Then they will have balance training for 20 minutes. The investigators will use goal-directed tasks, such as different types of ball games, for balance training. At the end, participants will receive walking exercise for 20 minutes, and cool down exercises for 5 minutes.
11303995|NCT02672943|Sham Comparator|non-treatment group|The group will not receive non-rehabilitation treatment, before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
11303996|NCT02672917|Experimental|MVT-5873 Dose Escalation|Initial to maximum tolerated dose (MTD)
11303997|NCT02672904|Active Comparator|CO2 laser|Patients undergoing endoscopic treatment with CO2 laser
11303998|NCT02672904|Active Comparator|KTP laser|Patients undergoing endoscopic treatment with KTP laser
11303999|NCT02672891|Experimental|Device|condom balloon catheter which is composed of a latex condom (SURE natural latex condom, Shanghai) and a 16-20 F, 2 ways silicon coated Foley catheter (Egypt). The catheter was introduced inside the condom and tied over tightly several times with a silk suture, to prevent air escape.
11304000|NCT02672878|Experimental|BVS implantation in patients with ISR|
11304001|NCT02672865|Experimental|HIPEC|The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.
11304002|NCT02672852|Experimental|Risankizumab|Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).
11304003|NCT02672852|Placebo Comparator|Placebo|Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).
11304004|NCT02672839|Experimental|Period 1 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
11304005|NCT02672839|Experimental|Period 1 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
11304006|NCT02672839|Experimental|Period 2 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
11304007|NCT02672839|Experimental|Period 2 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
11304008|NCT02672826|Experimental|adipose tissue surgery|The adipose tissue surgery (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated.
11304009|NCT02672813|Experimental|Pectoral Nerve I and II block|Under Ultrasound guidance, Pectoral nerve I block is given for every breast surgery using 10ml of 0.25 % Ropivacaine ( without added preservatives). Similarly Pectoral nerve II block is also given using 20 ml of 0.25% Ropivacaine ( without added preservative) in same group of patient.
11304010|NCT02672813|No Intervention|No block|Pectoral nerve block is not given in this group of patients undergoing breast surgery
11304011|NCT02672800|Experimental|Writing intervention|
11304012|NCT02672800|No Intervention|Control|
11304013|NCT02672787|Active Comparator|ED usual care plus education|ED usual care plus education
11304014|NCT02672787|Experimental|Intervention|Subjects will receive the ED-based behavioral intervention
11304015|NCT02672774|Other|Gastric cancer|Consecutive patients with gastric cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
11304016|NCT02672774|Other|Colorectal cancer|Consecutive patients with colorectal cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
11353115|NCT02347007|Active Comparator|Cereal Bar|
11304017|NCT02672761|Experimental|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
11304018|NCT02672761|Experimental|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
11304019|NCT02672761|Active Comparator|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
11304020|NCT02672761|Placebo Comparator|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
11304021|NCT02672748|Experimental|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
11304022|NCT02672748|No Intervention|Control|The control families receive a garden as a delayed intervention after two years.
11304023|NCT02672735|Experimental|Corrective Exercise Program|Participants in the Corrective Exercise Program (CEP) group (n = 28) will be given a four-week corrective exercise programming intervention.
11304024|NCT02672735|No Intervention|Control|The participants in the Control (CON) group (n = 28) will have their four-week corrective exercise programming intervention deferred for 4 weeks, and as such, will serve as the comparative group for the CEP group.
11304025|NCT02672722|Experimental|Healthy Test Subjects|We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
11304026|NCT02672709|Experimental|Anticoagulation|Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.
11304027|NCT02672696|Experimental|FluoroMap group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).
~In this group, the surgeon will use the FluoroMap 3D reconstruction system (Stryker Inc) with the standard fluoroscopy to help him place the cephalic screw in the femoral head."
11304028|NCT02672696|No Intervention|Test group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).
~In this group, the surgeon will use only the standard fluoroscopy to help him visualize the position of the cephalic screw in the femoral head."
11304029|NCT02672670|Experimental|Coping-oriented supportive programme|Coping-oriented supportive programme: education of the SCI disease information, learning from role model by watching a well-established DVD, discussion about how to break down stressors and used appropriate coping strategies (problem-solving training, cognitive re-constructing, relaxation exercises, and activity scheduling) to manage the stressors relating to SCI. Social skills training and ways of maintaining and improving social support will also be discussed and practiced in the COSP.
11304030|NCT02672670|Active Comparator|A didactic group|Usual rehabilitation care--routine inpatient rehabilitation care and brief education in groups (structured by both the rehabilitation nurses and the researcher), which will consist of similar professional contacts as the intervention (COSP) group, and thus can balance between the two study groups for the effect of social contacts and attention to SCI patients during group sessions. The intervention in the comparison group will be conducted by a rehabilitation nurse in the SCI wards. The knowledge/didactic education presented to the patients in the comparison group will be the basic health education and relevant information provided by the rehabilitation nurses in their routine care (mainly including knowledge of SCI, nutritional needs, skin care, bowel and bladder training, and other physical and psychological care of patients with SCI provided by the inpatient rehabilitation wards).
11304031|NCT02672644|Experimental|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
11304032|NCT02672644|Experimental|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
11304033|NCT02672631||Median Nerve injury hand|Participants will be randomly called; and that 10 participants which had unilateral median nerve transection totally and repaired primely in our clinic at 2014. In the sample, correlations between physical examination (Tinnel Test, motor strength assessment (Medical Research Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW) monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test), ENMG with the DTI results will be assessed.
11304034|NCT02672631||Healthy Hand|Control group will be taken from patients other hand which had not injured before. And we will compare with first group's results.
11304035|NCT02672618||chronic heart failure|18-85years old,having symptoms of heart failure,New York Heart Association（NYHA） class II or above American College of Cardiology/American Heart Association（ACC/AHA） class B, C, including hypertensive heart disease, rheumatic heart disease, ischemic cardiomyopathy and idiopathic cardiomyopathy
11304036|NCT02672618||normalCardiac function|18-85years old,no symptoms of heart failure,NYHA class I or above ACC/AHA class A, including controled hypertension,stability coronary heart disease and rheumatic heart disease
11304037|NCT02672618||healthy volunteers|18-85years old,Without basic cardiovascular diseases
11304038|NCT02672605|No Intervention|Control|Participant completes a survey measuring abortion stigma prior to receiving the mandatory Pennsylvania State consent for their abortion.
11304039|NCT02672605|Experimental|Investigational|Participant completes a survey measuring abortion stigma after receiving the mandatory Pennsylvania State consent for their abortion.
11304040|NCT02672592|Active Comparator|Anakinra|Anakinra//Kineret® 100mg s.c. bid
11304041|NCT02672592|Placebo Comparator|Placebo|Sodium Chloride 0.9% s.c. bid
11304042|NCT02672579||Children 4-7 years|Pediatric subjects between the ages of 4 and 7 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
11304043|NCT02672579||Children 8-17 years|Pediatric subjects between the ages of 8 and 17 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
11304074|NCT02672358|Experimental|Dabrafenib +Trametinib|Oral Dabrafenib plus Oral Trametinib
11304044|NCT02672579||Parents|Parents of pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of their child's severity of pruritus.
11304045|NCT02672579||Clinicians|Clinicians treating pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of the child's severity of pruritus.
11304046|NCT02672566|Experimental|Experimental group : enoxaparin|Experimental group will take enoxaparin (4000 Ui / Day) and will benefit from the usual care.
11304047|NCT02672566|Active Comparator|Control group|The control group will only benefit from the usual care.
11304048|NCT02672553|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
11304049|NCT02672553|Active Comparator|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
11304050|NCT02672540|Experimental|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
11304051|NCT02672540|Placebo Comparator|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
11304052|NCT02672527|Experimental|TRA|"At Day 1 (D1), premedication with dexamethasone (20 mg) and a 5-HT3 receptor antagonist anti-emetic agent will be intravenously administered 30 minutes prior to trabectedin administration. Trabectedin will be administered through a central venous catheter at a starting dose of 1.5 mg/m² over 24 hours, diluted in at least 500 mL of normal saline solution or of glucose 5% injectable solution.
~Each treatment cycle will last 21 days. Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal, or toxicities.
~In case of disease progression, the further treatments will be based on investigator's judgement."
11304053|NCT02672527|No Intervention|BSC|"Treatment:
~Patients will receive the best supportive care (BSC) in order to alleviate their symptoms and improve their Quality of Life (QoL).
~Antineoplastic agents (including surgery, radiotherapy, thermotherapy, chemotherapy, immunotherapy, hormonal treatment or antibodies-based treatments) are prohibited.
~Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal.
~In case of disease progression, a treatment with trabectedin will be proposed (cross-over). In case of patient refusal, the further treatments will be based on investigator's judgement."
11304054|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.
~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
11304055|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.
~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
11304056|NCT02672501|Experimental|anti-CD19-CAR-T cells|patients receive chemotherapy(CF, cyclophosphamide and Fludarabine) on day -6 to day -1, then infusied with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity.
11304057|NCT02672488|Experimental|Sorafenib and Metformin|Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day
11304058|NCT02672488|Active Comparator|Sorafenib Alone|Sorafenib 400μg tablet by mouth, twice per day
11304059|NCT02672475|Experimental|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11304060|NCT02672462|Experimental|Renal denervation|
11304061|NCT02672449|Experimental|External beam radiotherapy|A total of 65 consecutive newly diagnosed prostate cancer patients with 2013 NCCN high risk category will be consecutively enrolled in a prospective phase II trial on Carbon Ions Boost Followed by Pelvic Photon Radiotherapy .
11304062|NCT02672436|Experimental|ENERGI-F703|ENERGI-F703, topical application, 2 times daily for 12 weeks
11304063|NCT02672436|Placebo Comparator|Placebo|ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
11304064|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
11304065|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
11304066|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
11304067|NCT02672397|Experimental|Hispanic Intervention|Hispanic subjects that receive additional epidural education [44 patients]
11304068|NCT02672397|No Intervention|Hispanic Control|Hispanic subjects that receive standard of care [44 patients]
11304069|NCT02672397|Experimental|Non-Hispanic Intervention|Non-Hispanic subjects that receive additional epidural education [44 patients]
11304070|NCT02672397|No Intervention|Non-Hispanic Control|Non-Hispanic subjects that receive standard of care [44 patients].
11304071|NCT02672384|Experimental|patients in ICU|"Dental examination will be performed to diagnose CP based on the Centre for Diseases Control definition.
~A point of care P. gingivalis test (Denka Seiken Co (Japan) ) on saliva and detection of antibodies against P. gingivalis in sera will be performed.
~In case of discrepancies between both diagnoses methods, RT-PCR for identification of P. gingivalis and other pathogens will be performed on samples of periodontal pocket performed in routine."
11304072|NCT02672371|Experimental|active eMNS|Subjects with receive active eMNS for 20 minutes.
11304073|NCT02672371|Sham Comparator|sham eMNS|Subjects with receive sham eMNS for 20 minutes.
11353116|NCT02346994|Experimental|Melt test blend 3.2|
11304075|NCT02672345||Sevoflurane Group|Group of patients receiving sevorane during extracorporeal circulation period.
11304076|NCT02672345||Not Sevoflurane Group|Group of patients who did not receive the sevorane during extracorporeal circulation period.
11304077|NCT02672332|Experimental|SB204 4%|SB204 4% topically once daily
11304078|NCT02672332|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
11304079|NCT02672319|Experimental|EUS-guided glue injection|Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
11304080|NCT02672319|No Intervention|Historical control|A historical control group of HCC patients with gastroesophageal variceal bleeding who underwent conventional cyanoacrylate injection by OGD for index variceal bleeding based on de-identified data from an existing prospective GI bleed database from 2009-2013 would also be included to allow a more meaningful interpretation of the rebleeding rate from gastroesophageal varices from this study.
11304081|NCT02672306|Experimental|UCMSCs|Subjects with Alzheimer's Disease Intervention: UCMSCs
11304082|NCT02672306|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
11304083|NCT02672293|Experimental|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
11304084|NCT02672280|Experimental|Medical Collagen Membrane with MSC|Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).
11304085|NCT02672280|Active Comparator|Medical Collagen Membrane|Application of medical collagen membrane only.
11304086|NCT02672267|Experimental|Stem Cells|Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells
11304087|NCT02672267|Placebo Comparator|Placebo|Lactated Ringer's Solution
11304088|NCT02672254||Shams|Samples without any type of treatment
11304089|NCT02672254||Samples with 1 treatment|These samples will be treated with only one therapy: chemical agents such as cisplatin or other metallic compounds, or with superficial radiotherapy. These results will help us understand the effectiveness of each treatment by itself on cSCC cells.
11304090|NCT02672254||Samples with 2 treatments|These samples will be treated with both, chemical agents followed by superficial radiotherapy. These results will provide us information concerning the effectiveness of both treatments, wich is expected to be enhanced by the concomitant effects.
11304091|NCT02672241|Experimental|radio-chemotherapy plus nimotuzumab|Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
11304092|NCT02672228|Experimental|MalariaSense device|This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR
11304093|NCT02672215|Experimental|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
11304094|NCT02672215|Active Comparator|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
11304095|NCT02672215|No Intervention|control group|A waitlist control condition and received the generic intervention after completing all measurements
11304096|NCT02672202|Active Comparator|Duloxetine|Treatment
11304097|NCT02672202|Active Comparator|Pregabalin|Treatment
11304098|NCT02672202|Placebo Comparator|Placebo|
11304099|NCT02672189|No Intervention|Waiting list control group|Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.
11304100|NCT02672189|Experimental|EVA-Online guided group|"The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).
~Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support."
11304101|NCT02672189|Experimental|EVA-Online self-management group|The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.
11304102|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
11304133|NCT02671942|Active Comparator|roflumilast:500μg|Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
11304103|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
11304104|NCT02672163|Experimental|AACD-Therapy group|6 patients are recruited to the AADC-therapy group. Autologous atrial appendage derived cells (AADCs) are harvested from the appendage tissue removed during the venal cannulation of bypass. The cells and their extracellular matrix are placed with tissue clue to Cormatrix-sheet and further on top of the myocardium in the area of infarction scar. The procedure is done simultaneously with CABG surgery. The patients will be carefully monitored after the operations and cardiac MRI and echocardiogram will be performed previously to surgery as well as during the follow ups.
11304105|NCT02672163|Active Comparator|Control group|20 patients are recruited to form the control group. They are patients scheduled for elective CABG surgery and they meet the same inclusion and exclusion criteria as the therapy group. There patients are followed as the hospital protocol with out any additional imagination or blood tests.
11304106|NCT02672150|No Intervention|Control|During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 & 3 to document what practice was before the study.
11304107|NCT02672150|Active Comparator|Core|"In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.
~these principles to their improvement efforts during the implementation phase."
11304108|NCT02672150|Experimental|Enhanced|While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
11304109|NCT02672137|Experimental|knowledge translation|knowledge translation 12-month multi-facet intensive knowledge translation measures that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
11304110|NCT02672137|No Intervention|Usual care|no intervention
11304111|NCT02672111|Experimental|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)
~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
11304112|NCT02672111|Experimental|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
11304113|NCT02672098|Experimental|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
11304114|NCT02672085|Experimental|PRP infiltration|Supraspinatus interstitial lesion needling and infiltration with PRP
11304115|NCT02672085|Active Comparator|Needling|Supraspinatus interstitial lesion needling and infiltration with NaCl
11304116|NCT02672072||Control group|5-day specific training with dedicated scenario done by an ICU expert simulation team after the period of the study
11304117|NCT02672072||Simulation group|5-day specific training with dedicated scenario done by an ICU expert simulation team
11304118|NCT02672059||Peripheral Neuropathy|Patients with peripheral neuropathy (observational study, no interventions)
11304119|NCT02672046||Patients with knee injuries|Patients referred to assessment at the Clinic of Sports Injuries
11304120|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
11304121|NCT02672020|Experimental|patients with adrenal tumor|
11304122|NCT02672007|Other|Included patients|All included patients will have respiratory rates measured by a research assistant using a criterion standard approach, by the SensiumVitals device and by the ward staff.
11304123|NCT02671994|Experimental|A (experimental group)|Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
11304124|NCT02671994|No Intervention|B (control group)|Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
11304125|NCT02671968|Experimental|CGM group|
11304126|NCT02671968|No Intervention|Control group|
11304127|NCT02671955|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
11304128|NCT02671955|Experimental|Part 2: Biomarker Evaluation|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
11304129|NCT02671955|Experimental|Part 3: Dose Expansion|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
11304130|NCT02671955|Experimental|Part 4: Dose Expansion|Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
11304131|NCT02671942|Active Comparator|roflumilast:250μg|Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
11304132|NCT02671942|Active Comparator|roflumilast:375μg|Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
11304134|NCT02671942|Placebo Comparator|placebo|Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
11304135|NCT02671929|Experimental|self-help program + feedback|Patients in this arm receive access to the internet-based self-help program and get feedback on their progress in the program.
11304136|NCT02671929|Active Comparator|self-help program|Patients in this arm receive access to the internet-based self-help program and don't get any therapeutic feedback
11304137|NCT02671916||all patients|questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU
11304138|NCT02671903|Active Comparator|Pacemaker: AV optimised, His pacing|Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.
11304139|NCT02671903|No Intervention|No pacing|Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.
11304140|NCT02671890|Experimental|Arm I (chemotherapy and disulfiram)|Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
11304141|NCT02671890|Active Comparator|Arm II (chemotherapy and placebo)|Patients receive chemotherapy at the discretion of the treating oncologist and placebo PO on days 1-28 or days 1-35.
11304142|NCT02671890|Experimental|Cohort I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
11304143|NCT02671864|Other|1: incretin-based therapy|Patients with incretin-based therapy
11304144|NCT02671864|Other|2: other antidiabetic|Patients with other antidiabetic
11304145|NCT02671851||Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs at the level of T3-T4 with 20 mL bupivacaine 0.375% as an adjunct to general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
11304146|NCT02671851||IV metamizole sodium, paracetamol|Patients received only standardized general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
11304147|NCT02671838|Other|Musculoskeletal ultrasound program|Participants will receive the musculoskeletal ultrasound program
11304148|NCT02671838|No Intervention|Control|Participants will not be receiving the musculoskeletal ultrasound program.
11304149|NCT02671825|Experimental|PUR0217a|PUR0200 formulation 1
11304150|NCT02671825|Experimental|PUR0228a|PUR0200 formulation 2
11304151|NCT02671825|Experimental|PUR0228b|PUR0200 formulation 3
11304152|NCT02671825|Experimental|PUR0228c|PUR0200 formulation 4
11304153|NCT02671825|Experimental|PUR0230c|PUR0200 formulation 5
11304154|NCT02671825|Active Comparator|Reference Product 1|Reference Product formulation with active charcoal
11304155|NCT02671825|Active Comparator|Reference Product 2|Reference Product without active charcoal
11304156|NCT02671799|Experimental|VenTouch System Implant|The VenTouch System is indicated for patients who have moderately severe or severe functional mitral regurgitation (grade 3 or 4 MR).
11304157|NCT02671786|Experimental|Intervention Arm|"Intervention area: Provision of community based health care to severely malnourished children 6 months age in 16 tribal villages by trained semi-literate village health workers.
~Treatment of severely malnourished children through MAHAN RUTF & MAHAN Vit-Min mix
~Growth monitoring of all children below the age of 5 years
~Treatment of associated diseases like Diarrhea, Pneumonia, Malaria, etc.
~Management of resistant or relapsed severely malnourished cases by pediatrician.
~Intensive behavior change communication of parents of children below the age of 5 years for proper nutrition.
~Dose: 46 gms of proteins/kg/day & 100170 calories/kg/day with gradual escalation with micro nutrient supplementation Route: Oral Frequency: 4 times a day Duration: 12 weeks"
11304158|NCT02671786|No Intervention|Control Arm|Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
11304159|NCT02671773||BTS Step 2 Asthmatic patients|Group of 20 asthmatic patients on British Thoracic Society (BTS) treatment step 2 - regular low dose inhaled corticosteroids (dose of <400 micrograms/day BDP equivalent)
11304160|NCT02671773||BTS Step 4 Asthmatic patients on treatment with fluticasone|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled fluticasone (dose of >500 micrograms/day)
11304161|NCT02671773||BTS Step 4 Asthmatic patients on treatment with budesonide|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled budesonide (dose of >800 micrograms/day)
11304162|NCT02671760|Experimental|Treatment|SM-1
11304163|NCT02671760|Active Comparator|Comparator|2-drug combination
11304164|NCT02671760|Placebo Comparator|Placebo|Placebo
11304165|NCT02671747|Experimental|Pilot workshop|Participants attend intervention. No control arm
11304166|NCT02671734|No Intervention|control|Subjects in this arm received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
11304167|NCT02671734|Active Comparator|intervention|Subjects in this arm viewed a video detailing key elements of informed consent. Subjects in this arm also received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
11304168|NCT02671721|No Intervention|Conventional Strategy|Patients will receive usual and prudent PEEP and tidal volume settings.
11304169|NCT02671721|Experimental|Maximal Compliance Strategy|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
11304170|NCT02671721|Experimental|Transpulmonary Pressure Strategy|Personal PEEP titration using transpulmonary pressures obtained from a naso/orogastric tube containing an esophageal balloon port
11304171|NCT02671708|Experimental|IDA+BUCY|For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
11304172|NCT02671708|Active Comparator|BUCY|"For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days
~-3 and -2."
11304173|NCT02671695|Experimental|Group 1|chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
11304174|NCT02671695|Experimental|Group 2|chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months
11304175|NCT02671682|Experimental|Immunoadsorption|Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume
11304176|NCT02671682|Active Comparator|Plasmapheresis|Plasmapheresis on 5 consecutive days with 2l plasma exchange
11304177|NCT02671669|Active Comparator|Usual Care (UC)|
11304178|NCT02671669|Active Comparator|Movn application (MVN)|
11304179|NCT02671630|No Intervention|Control group|Patients receive only usual hospital care
11304180|NCT02671630|Experimental|Experimental group|Patients receive only usual hospital care and community-based computerized cognitive training program
11304181|NCT02671617|No Intervention|Control|Control: This group of patients will receive 'current best practice' as per UK NHS recommendations for their specific cancer management prior to surgery.
11304182|NCT02671617|Experimental|High intensity interval training|"Exercise: Participants in this group will attend 3-4 times per week to complete HIIT training during the period from diagnosis to surgery.
~High intensity interval training (HIIT)"
11304183|NCT02671591|Experimental|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP. The control condition is a one-hour, theory-based, one-to-one session that will help YBMSM think more about using condoms consistently and correctly with every sex partner.
11304184|NCT02671591|Active Comparator|control|"This condition will include the provision of free condoms and lubricants - selected from a buffet of condoms and lubricants designed to offer men a broad selection of high quality products that can optimize the fit and feel of condoms during sex."
11304185|NCT02671578|Experimental|Nitrous oxide|Nitrous oxide sedation
11304186|NCT02671565||Hyaluronic acid (HA) injection users|Patients with at least one procedure claim for intra-articular administration of hyaluronic acid (procedure codes: J7320, J7322, J7325, Q4084, J7317, Q4083, J7321, Q4085, J7323, Q4086, J7324, J7327, J7326) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as HA users.
11304187|NCT02671565||Corticosteroids (CS) injections users|Patients with at least one procedure claim for intra-articular administration of corticosteroids (procedure codes: J1020, J1030, J1040, J1094, J1100, J2920, J2930, J0702, J0704, J3300, J3301, J3302, J3303, J1700, J1710, J1720, J2650, J2920, J2930) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as CS users.
11304188|NCT02671565||HA non-users|Patients who do not have any claims for procedural or surgical intervention including HA and CS injections in first 90 days after their first specialist visit will be considered as HA non-users
11304189|NCT02671552|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren protein-type A microspheres IV and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during Magnetic Resonance Imaging (MRI) or computed tomography (CT) follow up.
11304190|NCT02671539|Experimental|open label injection of rAAV2.REP1|This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison
11304191|NCT02671526|Experimental|Computerized Plasticity-based Adaptive Cognitive Training|
11304192|NCT02671513|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.
11304193|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
11304194|NCT02671487|Experimental|Mind-Body Skills Groups|Mind-body skills groups will be administered for 2 hours once a week for 10 weeks and then once a month for 10 months.
11304195|NCT02671487|No Intervention|Wait List Control|No intervention will be administered. Students will have the opportunity to receive the intervention at the end of the study.
11304196|NCT02671461|Experimental|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
11304197|NCT02671461|Experimental|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
11304198|NCT02671461|Placebo Comparator|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
11304199|NCT02671448||Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care.
11304200|NCT02671435|Experimental|Part 1 -Dose escalation with 5 dose escalation cohorts|Durvalumab and monalizumab
11304201|NCT02671435|Experimental|Part 2 - Dose expansion with 4 dose expansion cohorts|Durvalumab with monalizumab
11304202|NCT02671435|Experimental|Part 3 -Dose Exploration with 10 dose exploration cohorts.|Durvalumab and monalizumab and standard of standard of care systemic therapy with or without a biologic agent and monalizumab in combination with biologic agent in CRC.
11304203|NCT02671409|Placebo Comparator|Control group|The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
11304204|NCT02671409|Experimental|MOB Group|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
11304205|NCT02671396|Experimental|Virtual reality based intervention|Virtual reality based balance training
11304206|NCT02671396|Active Comparator|Conventional intervention|Conventional balance training
11304207|NCT02671383|Active Comparator|Darunavir|Darunavir/Ritonavir 400/100mg once daily
11304208|NCT02671383|Active Comparator|Lopinavir|Lopinavir/Ritonavir 400/100mg twice daily
11304209|NCT02671357||ERAMIP with EEN|Minimally invasive pancreaticoduodenectomy (MIPD) with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory with EEN
11304210|NCT02671344||IAD group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
11304211|NCT02671344||FIV group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
11304212|NCT02671344||ICSI group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
11304213|NCT02671318|Active Comparator|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
11304214|NCT02671318|Active Comparator|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
11304215|NCT02671305|Experimental|placental circulation intact|preterm newborns assisted bedside with placental circulation intact
11304216|NCT02671305|Active Comparator|cord milking|preterm newborns who receive cord milking before assistance performed in a routine setting
11304217|NCT02671292|Experimental|Interpersonal Psychotherapy (IPT-WG)|IPT-WG targets the difficult social functioning and stressful events that are associated with loss of control eating and that are highly relevant to the adolescent children of military personnel.
11304218|NCT02671292|Active Comparator|Health Education (HE)|HE improves knowledge on various health topics including, alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
11304219|NCT02671279|Other|Low calorie diet|Dietary intervention group
11304220|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
11304221|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
11304222|NCT02671240||- Patients with behavioral addiction|
11304223|NCT02671240||- Patients with no behavioral addiction|
11304224|NCT02671227|Active Comparator|intrathecal bupivacaine + Mg sulfate|intrathecal bupivacaine 15 mg + intrathecal Mg sulfate 50 mg. in gynecologic laparoscopic surgeries.
11304225|NCT02671227|Active Comparator|intrathecal bupivacaine|intrathecal bupivacaine 15 mg in gynecologic laparoscopic surgeries.
11304226|NCT02671214|Placebo Comparator|Control|100 g high fibre flour
11304227|NCT02671214|Active Comparator|Active 1|85 g high fibre flour + 15 g legume flour
11304228|NCT02671214|Active Comparator|Active 2|98 g high fibre flour + 2 g guar gum
11304229|NCT02671214|Active Comparator|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
11304230|NCT02671214|Active Comparator|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
11304231|NCT02671214|Active Comparator|Active 5|96 g high fibre flour + 4 g guar gum
11304232|NCT02671214|Active Comparator|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
11304233|NCT02671214|Active Comparator|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
11304234|NCT02671214|Active Comparator|Active 8|94 g high fibre flour + 6 g guar gum
11304235|NCT02671214|Active Comparator|Active 9|98 g high fibre flour + 2 g konjac mannan
11304236|NCT02671214|Active Comparator|Active 10|96 g high fibre flour + 4 g konjac mannan
11304237|NCT02671214|Active Comparator|Active 11|100 g low fibre flour
11304238|NCT02671201||Group A|Theoretical training will be scheduled for 2 hours with lectures in basics of emergency ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 4 hours.
11304239|NCT02671201||Group B|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
11304240|NCT02671201||Group C|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound.
11304241|NCT02671188|Experimental|GSK3050002 100 mg/mL|Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
11304242|NCT02671188|Placebo Comparator|Placebo|Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.
11304243|NCT02671175|Active Comparator|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
11304244|NCT02671175|Placebo Comparator|dihydroartemisinin-piperaquine Placebo|Placebo comparator (matching tablets containing no active ingredients)
11304245|NCT02671162|Placebo Comparator|Wheat|Placebo capsule/ 2 capsule 3 times per day
11304246|NCT02671162|Active Comparator|Fumaria|Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.
11304247|NCT02671149|Experimental|Drink water|Participants will receive two 150ml drinks of water during the dehydration protocol
11304248|NCT02671149|No Intervention|Drink nothing|Participants will drink nothing during the dehydration protocol
11304249|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
11304250|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
11304251|NCT02671123|Active Comparator|Coronary PCI with OCT with Co-Registration|Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
11304252|NCT02671123|Placebo Comparator|Coronary PCI with OCT without Co-Registration|"Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted.
~I"
11304253|NCT02671110|Experimental|Transforming Your Life|The TYL program emphasized: 1) helping participants develop and maintain healthy habits and disrupt unhealthy habits, 2) enabling participants to create a personal food and exercise environment that increases exposure to healthy eating and physical activity and encourages automatic responding to goal-related cues, and 3) facilitating participants' weight loss motivation.
11304254|NCT02671110|Active Comparator|Diabetes Prevention program|The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
11304255|NCT02671097|Experimental|BAY1841788 (ODM-201) + Rosuvastatin|All subjects will receive a single dose BAY1841788 (ODM-201) (600 mg) followed by multiple doses BAY1841788 (ODM-201) (600 mg BID) as well as 2 times a single dose rosuvastatin (5 mg), once alone and once in combination with BAY1841788 (ODM-201).
11304256|NCT02671084|Experimental|Sevoflurane Group|Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
11304257|NCT02671084|Placebo Comparator|Control Group|Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
11304258|NCT02671058|Active Comparator|Cortenema|Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
11304259|NCT02671058|Experimental|Hydrocortisone acetate|Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
11304260|NCT02671045||A - Genomic profile by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
11304261|NCT02671045||B - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
11304262|NCT02671045||C - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
11304263|NCT02671045||D - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
11304264|NCT02671045||E - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
11304265|NCT02671045||F - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
11304266|NCT02671045||G - No genomic profiling|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.
11304267|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
11304268|NCT02671019|Experimental|Internet-based treatment|A five-module Internet-based treatment program for harmful alcohol use (including therapist support) based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
11304269|NCT02671019|Active Comparator|Face-to-face treatment|Same treatment content as in the Internet-based treatment delivered via face-to-face treatment sessions in specialized addiction treatment.
11304270|NCT02671006||Patients|Patients with an active Chronic Urticaria according to the EAACI criteria will be included. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
11304271|NCT02671006||Volunteers|Volunteers must no have history of immediate allergy (patients under medical follow up for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched). Controls should have no history of atopy, urticaria or immediate allergy declared (rhinitis, urticaria, asthma) at the time of the test. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
11304272|NCT02670993|Experimental|Control group : Singing sessions.|Patients will participate to singing working sessions. They will continue to take their usual treatments during the study period.
11304273|NCT02670993|Active Comparator|Control group : Painting sessions.|Patients will continue to participate to painting work sessions, and to take their usual treatments during the study.
11304274|NCT02670980|Experimental|Retina Implant|Intelligent Retinal Implant System
11304275|NCT02670954|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both routine analgesic and sedation(dexmedetomidine,tramadol and flurbiprofen) are applied for this group of patients.
11304276|NCT02670954|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(Tramadol and flurbiprofen) is applied for this group of patients.
11304277|NCT02670941|Experimental|Ginger|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
11304278|NCT02670941|Experimental|Lavender|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
11304279|NCT02670941|Experimental|Orange|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
11304280|NCT02670941|Placebo Comparator|Jojoba|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
11304281|NCT02670928|Active Comparator|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
11304282|NCT02670928|Experimental|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
11304283|NCT02670915|Experimental|Meal-time faster-acting insulin aspart and insulin degludec|
11304284|NCT02670915|Active Comparator|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
11304285|NCT02670915|Experimental|Post-meal faster-acting insulin aspart and insulin degludec|
11304286|NCT02670902|Experimental|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
11304287|NCT02670902|Active Comparator|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus three telephone recovery check-up calls post-discharge.
11304288|NCT02670876|Experimental|Anti-bullying intervention|An anti-bullying intervention target to perpetrators of school bullying was conducted. The program consisted of 8 sessions over 4 weeks and was conducted by a board-certified psychiatrist and a therapist with previous training in psychosocial treatments. The intervention was based on cognitive-behavioral therapy (CBT) principles and addressed various factors that have been associated with perpetrators of school bullying, including impulse control, perspective taking (empathy), and the enhancement of communication skills.
11304289|NCT02670863|Experimental|Experimental Infant Formula|Experimental Infant Formula containing a prebiotic
11304290|NCT02670863|Active Comparator|Standard Infant Formula|Standard bovine milk-based term infant formula
11304291|NCT02670850|No Intervention|Control group|Patients received only routine hospital care
11304292|NCT02670850|Experimental|Intervention group|Patients received regular hospital routine care and model-based intervention program
11304293|NCT02670837|Experimental|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
11304294|NCT02670837|Experimental|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
11304295|NCT02670824|Experimental|CN-105 Active Drug|"The CN-105 drug administered via IV at an escalating scale of mg/kg.
~A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg"
11304296|NCT02670824|Placebo Comparator|Placebo|Normal Saline
11304297|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
11304298|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
11304299|NCT02670798|No Intervention|Control|Standard of care hematologic management in the operating room
11304300|NCT02670798|Experimental|Study|Standard of care hematologic management plus additional monitoring with the intervention of Thromboelastography laboratory testing and use of a thromboelastography-guided transfusion protocol.
11304301|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.003 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
11304302|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.01 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
11304303|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.02 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
11304304|NCT02670785|Placebo Comparator|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
11304305|NCT02670772|Active Comparator|Stavudine|Stavudine 20mg twice daily for 96 weeks
11304306|NCT02670772|Active Comparator|Tenofovir Disoproxil Fumarate|Tenofovir 300mg once daily for 96 weeks
11304307|NCT02670759|Experimental|Paravertebral analgesia|A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
11304308|NCT02670759|Active Comparator|Intercostal analgesia|An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.
11304309|NCT02670746||Nab-paclitaxel in combination with gemcitabine (AG)|The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).
11304310|NCT02670733||high responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, intracranial pressure (ICP) increases above the median for the study population.
11304311|NCT02670733||low responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, the level of intracranial pressure (ICP) increases below the median for the study population.
11304312|NCT02670720|Experimental|avoralstat|Five avoralstat capsules (100 mg) to be taken three times daily by mouth
11304313|NCT02670707|Experimental|"Cytarabine (experimental) arm"|On this arm, patients will receive single therapy with cytarabine.
11304314|NCT02670707|Experimental|"Vinblastine/prednisone (standard) arm"|On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.
11304315|NCT02670694||Rett Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
11304316|NCT02670694||Angelman's Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Angelman's Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
11304317|NCT02670694||Prader-Willi Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Prader-Willi Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
11304318|NCT02670694||Control|Siblings of RTT, AS and PW subjects will serve as control subjects.
11304319|NCT02670681|Active Comparator|Aerobic Exercise Mild Intensity|The subjects engage in aerobic exercise training (8 weeks) of mild intensity (continuous). The intensity is controlled by a corresponding heart rate at anaerobic threshold.
11304320|NCT02670681|Active Comparator|Aerobic Exercise Moderate Intensity|The subjects engage in aerobic exercise training (8 weeks) of moderate intensity (continuous). The intensity is controlled by a corresponding heart rate between anaerobic threshold and respiratory compensation point.
11304321|NCT02670681|Active Comparator|Aerobic Exercise High Intensity|The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
11304322|NCT02670668|Experimental|Mutation analysis- NACwith PCR|consisting of 50 patients undergoing NACwith pathological compete response
11304323|NCT02670668|Experimental|Mutation analysis-NAC with SD/PD.|consisting of 50 patients undergoing NAC with SD/PD
11304324|NCT02670655|Experimental|Group A (short-time iontophoresis group)|Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h)
11304325|NCT02670655|Active Comparator|Group B (short-time conventional group)|Group B was treated with conventional AFL-PDT with a short incubation time (2 h)
11304326|NCT02670655|Active Comparator|Group C (long-time conventional group)|Group C was treated with conventional AFL-PDT with a standard incubation time (3 h)
11304327|NCT02670642|Experimental|On demand 20 mg esomeprazole|On demand treatment with 20-mg esomeprazole once daily when needed
11304328|NCT02670642|Active Comparator|Continuous 20 mg esomeprazole|Continuous treatment with 20 mg esomeprazole once daily
11304329|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.
~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
11304330|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.
~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
11304331|NCT02670616|Experimental|ibrutinib in combination with r-CHOP|Ibrutinib560 mg daily on day 1-21 per each cycle ,Rituximab375 mg/m2, Cyclophosphamide750 mg/m2, doxorubicin 50 mg/m2, vincristine1.4 mg/m2 on day 1; Prednisolone 100mg per day on day 1-5 ,cycle length: 21 days ,Six cycles of treatment
11304332|NCT02670603|Experimental|Experimental arm|In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
11304428|NCT02670018|Active Comparator|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets
11353117|NCT02346994|Active Comparator|Corn Oil|
11304333|NCT02670603|Other|Control arm|"In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.
~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm."
11304334|NCT02670590|Experimental|NAFLD|diet
11304335|NCT02670577||stage I or II HR-positive, HER2-negative|"Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive & HER2 negative
~& Axillary lymph node status: 0-3 involved"
11304336|NCT02670577||HER2+|"Histologically proven invasive T1a or T1b breast cancer
~& Hormone receptor negative or positive
~& HER2 positive
~& Axillary lymph node status: 0-1 involved"
11304337|NCT02670577||Triple Negative|"Histologically proven invasive T1a or T1b breast cancer
~& Hormone receptor negative
~& HER2 negative
~& Axillary lymph node status: 0-1 involved"
11304338|NCT02670577||Neoadjuvant|Stage I or II patients receiving neoadjuvant therapy.
11304339|NCT02670564|Experimental|Total body irradiation (TBI)|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.
~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
11304340|NCT02670564|Experimental|Busulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.
~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
11304341|NCT02670564|Experimental|Treosulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.
~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
11304342|NCT02670551|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
11304343|NCT02670551|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
11304344|NCT02670551|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
11304345|NCT02670538|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
11304346|NCT02670538|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
11304347|NCT02670538|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
11304348|NCT02670525|Experimental|Relapsed/Refractory leukemia|"Cohort 1: Relapsed/refractory leukemia
~Acute lymphoblastic leukemia, first or greater relapse
~Acute myeloid leukemia, first or greater relapse
~Leukemia refractory to induction chemotherapy
~Other recurrent leukemia
~Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy
~After the screening procedures confirms patient eligibility:
~Leukemia Profiling will be performed
~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
11304349|NCT02670525|Experimental|New diagnosis|"Cohort 2: New diagnosis
~Acute myeloid leukemia, new diagnosis (excluding acute promyelocytic leukemia (APL))
~New diagnosis infant MLL-rearranged ALL or low hypodiploid (<40 chromosomes) ALL
~Rare leukemia- e.g., JMML, leukemia of ambiguous lineage
~Secondary leukemia
~Myelodysplastic syndrome (MDS) not eligible for stem cell transplant
~After the screening procedures confirms eligibility:
~Leukemia Profiling will be performed
~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
11304350|NCT02670512|Experimental|Telehome Monitoring|Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment reminders, educational content).
11304351|NCT02670512|No Intervention|Standard of Care|Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone communication and using pen and paper log to track their treatments and supplies.
11304352|NCT02670499|Experimental|GAP-FLEX|Study Device will be used up to 6 times per day for up to 6 minutes to aid in the recovery and improve the degree of flexion from TKR
11304353|NCT02670499|Active Comparator|CPM|Control Device will be used up to 2 hours per day for up to 3 times per day to aid in the recovery and improve the degree of flexion from TKR and be compared to the Study Device
11304354|NCT02670486|No Intervention|standard of care|Usual urodynamics with no intervention.
11304355|NCT02670486|Active Comparator|Audiovisual intervention|Audiovisual stimulus during urodynamic testing.
11304356|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
11304357|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
11304358|NCT02670460|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left subclavian vein.
11304359|NCT02670447||First episode of psychosis patients|Patients with schizophrenia will be studied in this clinical trial, and that have never received anti-psychotic treatment. They will perform an MRI.
11304360|NCT02670434|Experimental|NK-104-CR|Controlled release NK-104
11304361|NCT02670434|Placebo Comparator|Placebo|Livalo Placebo
11304362|NCT02670434|Active Comparator|Livalo® Immediate Release IR|Immediate Release Livalo®
11304363|NCT02670421|Active Comparator|Face to face Heart SMART program|Stress management program presented in a face to face meeting of 90-100 minutes with daily printed program instructions to follow over the next 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
11304364|NCT02670421|Active Comparator|Online Heart SMART program|Stress management program in the form of 10- minute videos completed weekly by participant on-line for 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
11304429|NCT02670018|Experimental|C|Combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets
11304576|NCT02669056|Experimental|preterm babies|preterm babies (less than 28 weeks)
11304365|NCT02670395|Experimental|JNJ-54416076|Participants will receive single dose of JNJ-54416076 (in ascending dose) in Part 1 and 2 doses of JNJ-54416076 (one dose in the fasted state and an identical dose in the fed state) in Part 2. The dose selected for Part 2 will be selected based on the preliminary safety and PK data in Part 1.
11304366|NCT02670395|Experimental|Placebo|Participants will receive single dose of placebo in Part 1.
11304367|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
11304368|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
11304369|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
11304370|NCT02670369|Experimental|Sitting time prompt|All participants will receive a prompting device (one-arm intervention).
11304371|NCT02670356|Experimental|Fish oil|fish oil, 1500 mg/day, EPA:DHA ratio of 4:1, each capsule containing 750 mg total EPA+DHA, 2 capsules/day for 10 weeks
11304372|NCT02670356|Experimental|krill oil|krill oil, 300 mg/day, each capsule containing 74 mg total EPA+DHA , 1 capsule/day for 10 weeks
11304373|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
11304374|NCT02670330|Experimental|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
11304375|NCT02670317|Experimental|G CHOP 21 + Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
11304376|NCT02670304|Experimental|letrozole|letrozole for the first day after ovum picked up at least for 5 days.
11304377|NCT02670304|Active Comparator|aspirin|asprin for the first day after ovum picked up at least for 5 days.
11304378|NCT02670291|Active Comparator|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
11304379|NCT02670291|Sham Comparator|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
11304380|NCT02670278||US-Washington, Idaho|healthy breastfeeding women and their infants
11304381|NCT02670278||US-California|healthy breastfeeding women and their infants
11304382|NCT02670278||Sweden|healthy breastfeeding women and their infants
11304383|NCT02670278||Spain|healthy breastfeeding women and their infants
11304384|NCT02670278||Peru|healthy breastfeeding women and their infants
11304385|NCT02670278||Kenya|healthy breastfeeding women and their infants
11304386|NCT02670278||Ethiopia-rural|healthy breastfeeding women and their infants
11304387|NCT02670278||Ethiopia-urban|healthy breastfeeding women and their infants
11304388|NCT02670278||The Gambia-rural|healthy breastfeeding women and their infants
11304389|NCT02670278||The Gambia-urban|healthy breastfeeding women and their infants
11304390|NCT02670278||Ghana|healthy breastfeeding women and their infants
11304391|NCT02670265|Active Comparator|Parenteral nutrition|Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
11304392|NCT02670265|Placebo Comparator|Isotonic fluid|Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
11304393|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
11304394|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
11304395|NCT02670239||EVLP group|All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
11304396|NCT02670226|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
11304397|NCT02670226|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
11304398|NCT02670213||NovoThirteen®|
11304399|NCT02670200|Experimental|intervention arm / verum arm|Participants can work on ten modules specialized cognitive behavior treatments to learn and deal with mindfulness, acceptance and commitment. They should learn to handle their emotions, to accept the situation and to get in an active future. The participants can direct contact a psychotherapist via email, Chat or Skype/tokbox. The modules based on Cognitive Behavior Therapy.
11304400|NCT02670200|Active Comparator|non-intervention arm / control group|Participants can work on six modules with information und education goals for learning something about their possibilities to become a better mood, better psychovegetative or psychosocial situation as cancer patient. This modules are based on Cognitive Behavior Therapy. The non-intervention arm will only allow contact to the platform, no direct contact to a psychotherapist (in opposite to the intervention arm) is available.
11304401|NCT02670187|Experimental|GLS-5300|GLS-5300 at 0.67 mg DNA/dose
11304402|NCT02670187|Experimental|GLS-5300 at 2 mg DNA/dose|GLS-5300 at 2 mg DNA/dose
11304403|NCT02670187|Experimental|GLS-5300 at 6 mg DNA/dose|GLS-5300 at 6 mg DNA/dose
11304404|NCT02670174|Active Comparator|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
11304405|NCT02670174|Experimental|Separate kinetic chain training|A home exercise program consisting of traditional training exercises as well as separate exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
11304568|NCT02669121|Placebo Comparator|Placebo|NoV vaccine placebo-matching solution, intramuscularly (IM), once, on Day 1.
11304406|NCT02670174|Experimental|Integrated kinetic chain training|A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
11304407|NCT02670161|Active Comparator|Treatment A (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
11304408|NCT02670161|Active Comparator|Treatment B (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
11304409|NCT02670161|Active Comparator|Treatment C (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
11304410|NCT02670148|Experimental|Chiropractic Care (CC)|Participants in the CC group will receive evaluation and treatment (chiropractic manipulative therapy) from a doctor of chiropractic over a 4 week period.
11304411|NCT02670148|No Intervention|Waitlist control group (WC)|Participants allocated to the waitlist control group will not receive any chiropractic treatment during the active study period. These individuals will be scheduled for one additional study visit following allocation. This final study visit will be scheduled 4 weeks after allocation (± 7 days). WC participants are not restricted from receiving any other healthcare during study participation. However, participants in the WC group will be asked not to receive any chiropractic care or spinal manipulation by any other provider during the 4 week intervention period. After WC participants complete the final study visit, they will be offered chiropractic care. This treatment will not be part of the study and no data will be collected at these visits.
11304412|NCT02670135|Placebo Comparator|triclosan free toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
11304413|NCT02670135|Active Comparator|Triclosan containing toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
11304414|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
11304415|NCT02670109|Experimental|Unique|"Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.
~Then they will undergo an Autologous Hematopoietic Stem Cell Transplantation."
11304416|NCT02670096|Experimental|Reference therapy|"Baseline evaluation of subjects without acetazolamide administration
~Follow up evaluation of subjects one hour after acetazolamide administration"
11304417|NCT02670083|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
11304418|NCT02670083|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
11304419|NCT02670070|Active Comparator|Coadministration of G+R|Coadministration of gemigliptin 50mg and rosuvastatin 20mg
11304420|NCT02670070|Experimental|Combination G/R|Combination of gemigliptin 50mg / rosuvastatin 20mg
11304421|NCT02670057|Experimental|Transnasal SPG block|
11304422|NCT02670044|Experimental|Dose-Escalation, Arm A (Venetoclax + Cobimetinib)|Participants will receive Venetoclax daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib daily on Days 1-21 of each 28-day treatment cycle.
11304423|NCT02670044|Experimental|Dose-Escalation, Arm B (Venetoclax + Idasanutlin)|Participants will receive Venetoclax on Days 1-28 of each 28 day treatment cycle and Idasanutlin daily or twice daily on Days 1-5 of each 28 day treatment cycle.
11304424|NCT02670044|Experimental|Dosing Schedule Optimization, Arm B (Venetoclax+Idasanutlin)|Participants will receive Venetoclax on Days 1-21 or Days 1-14 of each 28-day treatment cycle and Idasanutlin daily on Days 1-5 of each 28 day treatment cycle.
11304425|NCT02670031||Newly Diagnosed Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
11304426|NCT02670031||Well-Controlled Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
11304427|NCT02670031||Resistant Essential Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
11354710|NCT02336477|Experimental|2|Placebo / Mexiletine
11304430|NCT02670005||FFR-PCI group|patients with ST-segment elevation myocardial infarction (STEMI) who received fractional flow reserve (FFR)-guided selective percutaneous coronary intervention (PCI)
11304431|NCT02670005||angiography-PCI group|patients with STEMI who received angiography-guided selective PCI
11304432|NCT02669992|Experimental|Stapled anastomosis|Stapled anastomosis by the use of commercially available linear stapler device
11304433|NCT02669992|Active Comparator|Hand-sewn anastomosis|Hand-sewn by the use of a resorbable monofilament suture
11304434|NCT02669992|Experimental|Abdominal wall mesh closure|Closure by the use of a mesh low-weight net device
11304435|NCT02669992|Active Comparator|Abdominal wall suture closure|Closure by the use of slowly absorbing monofilament suture
11304436|NCT02669979|Experimental|Intervention|"Intervention in the research groups is professional oral care with tooth brush, ordinary fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month."
11304437|NCT02669979|No Intervention|Control|Care as usual. Common oral hygiene help administered by nursing staff.
11304438|NCT02669966|Experimental|Study Arm|Donor candidates with their intended recipients who meet criteria will be enrolled into this, the sole arm of our study. Donor-recipient pairs will be screened to meet criteria, and will proceed to kidney transplantation and post-transplant monitoring
11304439|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;
~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
11304440|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
11304441|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
11304442|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
11304443|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
11304444|NCT02669914|Experimental|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
11304445|NCT02669914|Experimental|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
11304446|NCT02669914|Experimental|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
11304447|NCT02669901|Other|Patients with opioid substance abuse disorders|All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
11304448|NCT02669888|Experimental|Indigo naturalis ointment|"Form: ointment
~Dose: each gram of ointment contains 200µg of indirubin
~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
11304449|NCT02669888|Placebo Comparator|Placebo|"Form: ointment
~Dose: vehicle
~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
11304450|NCT02669875|Active Comparator|Serelaxin|IV infusion of serelaxin (RLX030) for 2 hours
11304451|NCT02669875|Placebo Comparator|Placebo|IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours
11304452|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
11304453|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
11304454|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
11304455|NCT02669849|Placebo Comparator|Placebo|
11304456|NCT02669849|Experimental|VX-210|
11304457|NCT02669836|Experimental|Posterior fossa decompression surgery|The bone is surgically removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected
11304458|NCT02669836|Experimental|Dural augmentation surgery|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
11304459|NCT02669823||Children <15y|no intervention
11304460|NCT02669823||Adults >=15y|no intervention
11304461|NCT02669810|Experimental|PROTHERACYTES|The interventional investigators will perform the ProtheraCytes® endocardiac injections using the HELIX® catheter introduced via the femoral route up to the left ventricle cavity.
11304462|NCT02669810|Active Comparator|Standard of Care|Patients will undergo standard of care procedure (PTCA Percutaneous Transluminal Coronary Angioplasty and stent(s) implantations)
11304463|NCT02669797|Experimental|EMI|EMI (Arm 1): (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; and (2) a 8-week maintenance phase with EMI tips delivered on high stress days.
11304464|NCT02669797|Experimental|EMI + HV|"EMI + HV (Arm 2) includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) a 8-week maintenance phase with EMI tips delivered on high stress days."
11304465|NCT02669797|Experimental|EMI + HV + Video feedback|"EMI + HV + Video Feedback (Arm 3) includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
11304466|NCT02669784|Active Comparator|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
11304467|NCT02669784|Active Comparator|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
11304468|NCT02669771||Enzalutamide group|oral
11304469|NCT02669758|Experimental|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
11304470|NCT02669745||Women of Chinese Descent|Females of Chinese descent, aged 18 year to 70 year, diagnosed with Stage 1 or Stage 2 (excluding those involving more than 3 lymph nodes) breast cancer.
11304471|NCT02669732|Experimental|DS-8500a 75 mg once daily (QD)|tablets, orally, once daily for up to 28 days
11304472|NCT02669732|Placebo Comparator|Placebo|tablets, orally, once daily for up to 28 days
11304473|NCT02669719|Experimental|chemotherapy followed dendritic cells|pemetrexed and carboplatin chemotherapy followed dendritic cells infusion from Cycle 3
11304474|NCT02669719|Active Comparator|chemotherapy|pemetrexed and carboplatin chemotherapy only
11304475|NCT02669706||IV pentamidine|Pentamidine 4mg/kg IV every month (maximum 300mg)
11304476|NCT02669693|Placebo Comparator|bread without olives|Intervention (no olives): Subjects will consume a meal of 109 g white bread and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
11304477|NCT02669693|Active Comparator|bread with olives|Intervention (olives 100 g): Subjects will consume a meal of 109 g white bread, 100 g of olives and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
11304478|NCT02669680|Experimental|G-CSF + Standard therapy|Standard care of acute-on-chronic liver failure and application of G-CSF
11304479|NCT02669680|Active Comparator|Standard therapy|Standard care of acute-on-chronic liver failure
11304480|NCT02669667|Experimental|Cohort 1|single dose of MEDI9314 or placebo
11304481|NCT02669667|Experimental|Cohort 2|single dose of MEDI9314 or placebo
11304482|NCT02669667|Experimental|Cohort 3|single dose of MEDI9314 or placebo
11304483|NCT02669667|Experimental|Cohort 4|single dose of MEDI9314 or placebo
11304484|NCT02669667|Experimental|Japanese Cohort|single dose of MEDI9314 or placebo
11304485|NCT02669667|Experimental|Cohort 5|single dose of MEDI9314 or placebo
11304486|NCT02669654|Experimental|Day-care management of Severe Pneumonia|management in Day-care clinic
11304487|NCT02669654|No Intervention|Existing Treatment Centre (ETC)|Severe Pneumonia management in Existing Treatment Centre
11304488|NCT02669641|Experimental|Steatosis|Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline
11304489|NCT02669628||Surgical technique|Laparoscopic ovarian cystectomy
11304490|NCT02669628||Alcohol sclerotherapy|US-aspiration and alcohol sclerosis
11304491|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
11304492|NCT02669602||No intervention|No Intervention
11304493|NCT02669589|Active Comparator|heparin anticoagulation|"Systemic anticoagulation of the continuous renal replacement therapy with heparin.
~Dose will be titrated to maintain aPTT (activated partial thromboplastin time) between 45-60s)"
11304494|NCT02669589|Experimental|citrate anticoagulation|"Regional anticoagulation of the continuous renal replacement therapy with citrate.
~Target posthemofilter ionized calcium level: 0.25-0.35 mmol/l"
11304495|NCT02669576|Experimental|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
11304496|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
11304497|NCT02669563|Experimental|Stage 1|"Subjects (n = 4 to 10) will be injected once with 20 mCi of [13N]ammonia and receive a 20 minute PET scan. They will then be injected once with 6.5 mCi of one of the two new drugs under study, [18F]4F-MHPG or [18F]3F-PHPG, and receive a 60 minute PET scan.
~On a second visit to the clinic, subjects will be injected once with 6.5 mCi of [18F]3F-PHPG or [18F]4F-MHPG (whichever was not used for the first visit) and receive a 60 minute PET scan."
11304498|NCT02669563|Experimental|Stage 2|"Subjects (n = 20 to 26) will be injected with 20 mCi of [13N]ammonia and receive a 20 minute PET scan.
~They will then be injected once with 6.5 mCi of [18F]4F-MHPG or [18F]3F-PHPG (whichever was chosen based on Stage 1 of the study) and receive a 60 minute PET scan. On a second visit to the clinic, subjects will be injected once with 20 mCi of [11C]HED and receive a 40 minute scan."
11304499|NCT02669550|Experimental|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
11304577|NCT02669056|Other|term babies|term babies with blood test prescription
11304500|NCT02669550|Experimental|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
11304501|NCT02669537|Experimental|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
11304502|NCT02669537|No Intervention|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
11304503|NCT02669537|Experimental|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
11304504|NCT02669537|No Intervention|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
11304505|NCT02669524|Active Comparator|T2D + OGTT + LY2409021|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
11304506|NCT02669524|Placebo Comparator|T2D + OGTT + placebo|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.
11304507|NCT02669524|Active Comparator|T2D + IIGI + LY2409021|Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
11304508|NCT02669524|Placebo Comparator|T2D + IIGI + placebo|Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.
11304509|NCT02669524|Active Comparator|T2D + MEAL + LY2409021|Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.
11304510|NCT02669524|Placebo Comparator|T2D + MEAL + placebo|Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.
11304511|NCT02669524|Active Comparator|CTRL + OGTT + LY2409021|Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
11304512|NCT02669524|Placebo Comparator|CTRL + OGTT + placebo|Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.
11304513|NCT02669524|Active Comparator|CTRL + IIGI + LY2409021|Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
11304514|NCT02669524|Placebo Comparator|CTRL + IIGI + placebo|Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.
11304515|NCT02669524|Active Comparator|CTRL + MEAL + LY2409021|Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.
11304516|NCT02669524|Placebo Comparator|CTRL + MEAL + placebo|Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.
11304517|NCT02669511|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
11304518|NCT02669498|Active Comparator|Surgery with fallopian tube removal|Patients receiving routine fallopian tube removal during pelvic surgery after randomization.
11304519|NCT02669498|No Intervention|Surgery without fallopian tube removal|Fallopian tubes are not removed during pelvic surgery after randomization.
11304520|NCT02669485|Experimental|ICG|Administering indocyanine green during surgery and the use of ICG fluorescence imaging to assess bowel perfusion during surgery
11304521|NCT02669472|Experimental|F&V Intervention|Housing complexes randomized to the intervention arm received a multicomponent intervention comprised of a year-round, discount, mobile fresh fruit and vegetable market ('Fresh To You') that was paired with nutrition education interventions including educational newsletters, recipe cards, campaigns, taste-testings and videos in both English and Spanish.
11304522|NCT02669472|Experimental|Control Intervention|Housing complexes randomized to the comparison arm received a year-long intervention on physical activity and stress reduction including educational campaigns and materials in both English and Spanish.and a YMCA membership for those who joined the campaigns.
11304523|NCT02669459|Active Comparator|LLETZ|LLETZ (Large Loop excision of the transformation zone) treatment conform current guidelines, which is also the current gold standard in the Netherlands
11304524|NCT02669459|Other|Imiquimod 5% cream|intervention group
11304525|NCT02669446||Ectoin containing Lozenges|treatment with Ectoin containing lozenges
11304526|NCT02669446||Hyaluronic acid containing lozenges|treatment with hyaluronic acid containing lozenges
11304527|NCT02669446||Saline solution for gargling|Subjects in were requested to gargle with salt water
11304528|NCT02669433|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
11304529|NCT02669433|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
11304530|NCT02669433|Placebo Comparator|Placebo|Placebo
11304531|NCT02669420|Experimental|extra amniotic misoprostol|misoprostol dissolved in warm saline , become dissolute misoprostol saline solution(200 microgram every 4 hours)
11304532|NCT02669420|Experimental|vaginal misoprostol|misoprostol tablet soaked with distilled water and inserted in the posterior fornix of the vagina( 200 microgram every 4 hours)
11304533|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
11304569|NCT02669108|Other|PET/MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
11304570|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
11304571|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
11304572|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
11304573|NCT02669069|Active Comparator|PS1|
11304534|NCT02669394|Experimental|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.
~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
11304535|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
11304536|NCT02669381|Other|Experimental: phenylalanine intake|Dietary supplement: phenylalanine intake
11304537|NCT02669368|Active Comparator|Standard dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
11304538|NCT02669368|Active Comparator|Low dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
11304539|NCT02669368|Active Comparator|Low dose Rocuronium + Magnesium Sulfate|Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
11304540|NCT02669342|Active Comparator|Group A: Sharklet Catheter for 2 weeks first|"Arm A will have catheters inserted according to the schedule below:
~Sharklet catheter inserted for 2 weeks
~Standard catheter inserted for 2 weeks
~Sharklet catheter inserted for 4 weeks
~Standard catheter inserted for 4 weeks"
11304541|NCT02669342|Active Comparator|Group B: Sharklet Catheter for 4 weeks first|"Arm B will have catheters inserted according to the schedule below:
~Sharklet catheter inserted for 4 weeks
~Standard catheter inserted for 4 weeks
~Sharklet catheter inserted for 2 weeks
~Standard catheter inserted for 2 weeks"
11304542|NCT02669329|Experimental|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
11304543|NCT02669303|Experimental|platelet-rich plasma group|Autologous platelet-rich plasma subacromial injection
11304544|NCT02669303|Active Comparator|Methylprednisolone group|Methylprednisolone subacromial injection
11304545|NCT02669290|Experimental|Guided|Guided LV lead placement for CRT.
11304546|NCT02669290|Active Comparator|Non-Guided|Non-guided LV lead placement for CRT.
11304547|NCT02669277|No Intervention|group A|no platelet enhancing therapy
11304548|NCT02669277|Active Comparator|group B|Standard IVIG single dose 1.0 gm /kg/dose
11304549|NCT02669277|Experimental|group C|minipool IVIG product single dose 1.0 gm /kg/dose
11304550|NCT02669264|Experimental|Part 1: ADCT-402 dose escalation|"Weekly administration - Participants will receive an intravenous (IV) infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.
~3-week administration - Participants will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.
~The dose escalation will be conducted according to a 3+3 design."
11304551|NCT02669264|Experimental|Part 2: ADCT-402 expansion|All participants will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee
11304552|NCT02669251|Experimental|Phase 1b|Phase Ib dose escalation
11304553|NCT02669251|Experimental|Phase 2|MTD po bid on days 1-28
11304554|NCT02669238|Experimental|Implant|Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
11304555|NCT02669238|Active Comparator|Oral treatment|Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)
11304556|NCT02669225|Experimental|Rested Wakefulness|RW PET/MR Scanning Sessions
11304557|NCT02669225|Experimental|Sleep Deprivation|SD PET/MR Scanning Sessions
11304558|NCT02669212|Other|1|MRI RadiofrequencyCoils, TMS
11304559|NCT02669199|Experimental|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
11304560|NCT02669186|Experimental|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
11304561|NCT02669186|Active Comparator|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
11304562|NCT02669173|Experimental|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
11304563|NCT02669160|Experimental|Experimental|Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
11304564|NCT02669160|Other|Control|Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.
11304565|NCT02669134|Active Comparator|SonR optimization|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
11304566|NCT02669134|Placebo Comparator|Fixed settings|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed Off)."
11304567|NCT02669121|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine intramuscularly (IM), once, on Day 1.
11304578|NCT02669043|Experimental|Ketamine|All participants receive open-label ketamine
11304579|NCT02669030|Experimental|Suvorexant|suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
11304580|NCT02669030|Placebo Comparator|Placebo|no augmentation of FDA-approved antidepressant treatment
11304581|NCT02669017|Experimental|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
11304582|NCT02669017|Experimental|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.
~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
11304583|NCT02669004|Active Comparator|Intermittent bolus epidural morphine|"Patients who received epidural morphine with patient- controlled intermittent bolus epidural analgesia (PCIEA) represented Group 1. Epidural catheter was inserted by surgeon under direct visualization at the midpoint of the incision and advanced 5-6 cm cephalad to thoracic 4-5 before surgical closure.
~Patients received morphine 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion."
11304584|NCT02669004|Active Comparator|Continuous epidural morphine|epidural morphine with patient- controlled continuous epidural analgesia (PCCEA) represented Group 2. Infusion the following initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
11304585|NCT02668991||Cohort 1|It will consist of planned 100 children and adults with Autism Spectrum Disorder (ASD) aged 6 years and older with no requirements regarding concurrent therapies or treatments.
11304586|NCT02668991||Cohort 2|It will consist of planned 50 children and adults aged 6 and older who, as part of their standard care, happen to be beginning a behavioral intervention within 2 weeks after the baseline visit of the study. This intervention can be an applied behavior analysis (ABA) program or similar or a social skills program or a school-based autism program and must be intended to last at least throughout the duration of the study.
11304587|NCT02668991||Cohort 3|It will consist of planned 30 normally developing children and adults. These participants will only have a single visit wherein they will undergo a single session with the task battery and biosensors. There should be 5 participants aged 6-9 years, 5 aged 10-12 years, 5 aged 13-17 years, and 5 aged 18 years and older. This cohort should approximate the male:female ratio in Cohorts 1 & 2, with approximately 1 female for every 5 males.
11304588|NCT02668978|Experimental|Hemopatch™|Hemopatch™ sealing hemostat
11304589|NCT02668978|Active Comparator|Control|Standard surgical technique
11304590|NCT02668965|No Intervention|control|intrauterine infusion with standard embryo culture media 10 microliters before embryo transfer
11304591|NCT02668965|Experimental|intrauterine hCG|intrauterine infusion with hCG (500 IU) 10 microliters before embryo transfer
11304592|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
11304593|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
11304594|NCT02668926|Experimental|Lisdexamfetamine, d-amphetamine, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
11304595|NCT02668926|Experimental|d-amphetamine, Placebo, Lisdexamfetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
11304596|NCT02668926|Experimental|Placebo, Lisdexamfetamine, d-amphetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
11304597|NCT02668913|Experimental|Diagnostic Analysis|This arm will be subject to Caris Molecular profiling.
11304598|NCT02668900|Experimental|Decision support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
11304599|NCT02668900|No Intervention|Usual care|The control group will not receive the decision support intervention prior to consultation with the physician.
11304600|NCT02668874|Active Comparator|Isolite® technique Device|The Isolite® technique differs in that it utilizes a flexible plastic dental adapter to separate the teeth from the cheek and tongue. The resident dentist will show the child the Isolite® before it is placed in the mouth. The resident with whom the child is scheduled will then apply the sealants.
11304601|NCT02668874|Active Comparator|cotton roll technique Device|The resident dentist with whom the child is scheduled with apply the sealants after the cotton roll technique has been placed.
11304602|NCT02668861|Experimental|Vitamin D+Budesonide Nasal Spray|Vitamin D 4000IU/day for 8 weeks + Budesonide Nasal Spray 128ug/d for 8 week
11304603|NCT02668861|Placebo Comparator|placebo+Budesonide Nasal Spray|Placebo for 8 weeks + Budesonide Nasal Spray128ug/d for 8 week
11304831|NCT02667327|Active Comparator|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
11304604|NCT02668848|Experimental|urine monitoring group|Patients of urine monitoring group will be checked for urine specific gravity (USG) once between 6a.m. to 12 m.d. in the first 5 days after admission. Patients will be advised to have water according to the level of USG.
11304605|NCT02668835||Cohort 1|Idiopathic Parkinson's Disease as defined by the UK brain bank criteria and history of resting tremor.
11304606|NCT02668835||Cohort 2|Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist
11304607|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
11304608|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
11304609|NCT02668809|Experimental|Experimental Group 1|consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence.
11304610|NCT02668809|Experimental|Experimental group 2|Consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence, varnish application
11304611|NCT02668809|Placebo Comparator|Control Group|Consent,clinical exam, microbiological sampling, questionnaires
11304612|NCT02668796|Experimental|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
11304613|NCT02668796|Active Comparator|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
11304614|NCT02668796|Placebo Comparator|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
11304615|NCT02668783|Experimental|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
11304616|NCT02668783|Placebo Comparator|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
11304617|NCT02668770|Experimental|Dose Escalation Group: MGN1703 + Ipilimumab|"Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment."
11304618|NCT02668770|Experimental|MTD Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.
~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long."
11304619|NCT02668770|Experimental|MTD Group: MGN1703 (intratumoral injection) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.
~MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long."
11304620|NCT02668770|Experimental|MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.
~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.
~Each cycle is 21 days long."
11304621|NCT02668757|Other|HeartHab application arm|Patients in the HeartHab application arm will receive the mobile application during study period.
11304622|NCT02668744|Experimental|Intervention|TX Sprouts
11304623|NCT02668744|Placebo Comparator|Control|Delayed Intervention
11304624|NCT02668718|Other|Adjuvant radiotherapy|Patients who were randomized to adjuvant radiotherapy following radical prostatectomy
11304625|NCT02668718|No Intervention|Watchful waiting|Patients who were randomized to watchful waiting following radical prostatectomy
11304626|NCT02668705|No Intervention|Human RA|A sham research informed consent form will be explained by a research assistant
11304627|NCT02668705|Experimental|ECA|A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
11304628|NCT02668705|Experimental|ECA + Human RA|A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant
11304629|NCT02668692|Experimental|LEO 80185 gel|
11304630|NCT02668692|Active Comparator|Dovobet ® ointment|
11304631|NCT02668679|Active Comparator|Children and their parents with the presence of Dream Doctors|The DD will use various methods for entertaining the child and alleviate stress . The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
11304632|NCT02668679|Placebo Comparator|Children and their parents without the presence of DD|No DD during the gastroscopy. The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
11304633|NCT02668666|Experimental|Investigational Treatment|"71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.
~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
11304634|NCT02668653|Experimental|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib
~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant
~Continuation: up to 36 cycles with the experimental drug quizartinib"
11355389|NCT02332044|Experimental|Erdosteine 300mg|
11304635|NCT02668653|Active Comparator|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo
~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant
~Continuation: up to 36 cycles with placebo"
11304636|NCT02668640||Participants with RA receiving adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks
11304637|NCT02668614|Experimental|WR-22 model microwave sensor|
11304638|NCT02668601||GDM Exposed|Children exposed to gestational diabetes in utero
11304639|NCT02668601||Non-GDM Exposed|Children not exposed to gestational diabetes in utero
11304640|NCT02668588|Experimental|LF-PB 30 mg|extended release of octreotide
11304641|NCT02668588|Placebo Comparator|Placebo|extended release of placebo
11304642|NCT02668575|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality CF care provided to all patients at the UPMC CF Center.
11304643|NCT02668575|Experimental|Supportive Care Intervention|Patients randomized to the intervention arm will receive a protocolized supportive care intervention from a palliative care nurse practitioner.
11304644|NCT02668562|Experimental|Early CABG|Patients to undergo early CABG
11304645|NCT02668562|Active Comparator|Delayed CABG|Patients to undergo delayed CABG
11304646|NCT02668549||Patients with Opioid dispensings|Patients receiving two or more opioid dispensings within 18 months
11304647|NCT02668549||Patients with Diuretic dispensings (neg control)|Patients receiving two or more Diuretics dispensings within 18 months will serve as negative control
11304648|NCT02668536|Experimental|UV Filter + BNP|A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
11304649|NCT02668536|Sham Comparator|BNP only|A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
11304650|NCT02668536|Active Comparator|Standard|As the active comparator, participants will have 5 sites on their torso where they will have standard sunscreen applied.
11304651|NCT02668536|No Intervention|Control|Participants will have 5 sites on their torso where no agent will be applied.
11304652|NCT02668523|Experimental|Raindrop|A single arm study to evaluate the effectiveness of a 2mm Raindrop Near Vision Inlay for the treatment of presbyopia in pseudophakic subjects. This corneal inlay is placed under a LASIK flap or in a corneal pocket, and is designed to change the anterior curvature of the cornea, resulting in the ability to reduce spectacle dependency for near and intermediate tasks.
11304653|NCT02668510|Experimental|Platelet Rich Plasma Injection Group|shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin
11304654|NCT02668510|Placebo Comparator|Placebo injection group|shockwave therapy with placebo normal saline injection
11304655|NCT02668497|Experimental|De-novo PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
11304656|NCT02668497|Experimental|L-dopa PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
11304657|NCT02668484|Experimental|repositionable valve prosthesis|Lotus
11304658|NCT02668484|Active Comparator|balloon-expandable valve prosthesis|Sapien
11304659|NCT02668471|Experimental|Ultrasound guided|Radial artery catheters will be placed with the assistance of bedside ultrasound.
11304660|NCT02668471|Active Comparator|traditional method|Radial artery catheters will be placed by the palpation technique only.
11304661|NCT02668458|Experimental|NIV|NIV group, preoxygenation by NIV: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, PEEP of 5 cm H2O and FiO2 at 100%.
11304662|NCT02668458|Active Comparator|HFNC|High-flow nasal canula oxygen therapy. NHFC group, preoxygenation by NHFC: oxygen flow rate of 60 L / min and 100% FiO2
11304663|NCT02668445|Experimental|Low carbohydrate|Subjects will eat a low carbohydrate diet
11304664|NCT02668445|Experimental|High carbohydrate|Subjects will eat a high carbohydrate diet
11304665|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
11304666|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
11304667|NCT02668419|Active Comparator|Usual Care|Patients in this group were subject to regular Physical Therapy Sessions in the hospital and each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise.
11304668|NCT02668419|Experimental|Neuromuscular Electrical Stimulator|Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
11304669|NCT02668406||Burkholderia pseudomallei|Patients for whom blood cultures grew Burkholderia pseudomallei
11304670|NCT02668406||No pathogen|Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis
11304671|NCT02668406||Another pathogen|Patients for whom blood cultures grew another pathogen
11304672|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
11304673|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
11304674|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
11304675|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
11304676|NCT02668380||Apatinib|Apatinib Tablets: 850 mg,po, once daily , 28 days for a cycle
11304677|NCT02668367|Active Comparator|BTA-C585 oral capsules|100 mg capsules; Multiple ascending doses (MAD) from 100 mg to 600 mg
11304678|NCT02668367|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
11304679|NCT02668341||psoriasis patients in Denmark|non-interventional survey study in psoriasis patients in daily practice care
11304680|NCT02668341||psoriasis patients in Spain|non-interventional survey study in psoriasis patients in daily practice care
11304681|NCT02668341||psoriasis patients in Poland|non-interventional survey study in psoriasis patients in daily practice care
11304682|NCT02668341||psoriasis patients in Germany|non-interventional survey study in psoriasis patients in daily practice care
11304683|NCT02668328|Experimental|Behavioral Intervention|The proposed study involves a 2-phase randomized clinical trial in adults with recently diagnosed T2D. Participants will be randomized to a wait-list Control group, BI, or Tailored-BI. In Phase 1, wait-list Control participants will receive 6 months of standard care; BI and Tailored-BI participants will receive 6 months of Active Intervention. In Phase 2, wait-list Control group participants will cross-over to the delayed Tailored-BI, and the BI and Tailored-BI participants will enter a 6-month observation phase to examine maintenance effects of the intervention.
11304684|NCT02668315|Experimental|Cohort 1|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9 x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
11304685|NCT02668315|Experimental|Cohort 2|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9 x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
11304686|NCT02668315|Experimental|Cohort 3|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9 x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
11304687|NCT02668302|Experimental|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
11304688|NCT02668302|Active Comparator|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
11304689|NCT02668289|Other|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
11304690|NCT02668276|Placebo Comparator|Standard NCCN counseling|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
11304691|NCT02668276|Experimental|Standard NCCN counseling and Oncotype DX results|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.
11304692|NCT02668263|Active Comparator|Surgery and Drain|Group 1 will be allocated to receive a drain intra-operatively.
11304693|NCT02668263|Other|Surgery alone|Group 2 will not receive a drain and no further intervention.
11304694|NCT02668263|Experimental|Surgery and quilting sutures|Group 3 will not receive a drain but will receive quilting sutures
11304695|NCT02668250|Experimental|Experimental group : OPTI-AGED|The OPTI-AGED group will receive a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia.
11304696|NCT02668250|Active Comparator|Control Group :|The control group will not benefit from the OPTI-AGED intervention but patients will receive the usual care.
11304697|NCT02668237|Experimental|Experimental group|The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.
11304698|NCT02668237|Active Comparator|Control Group|The children will benefit from the usual care : an antibiotic prevention treatment.
11304699|NCT02668224|Experimental|Vibrasens : Test group|Training programme: vibration training 3/week from Day 1 to Day 60 + Usual activities from day 60 to Day 75.
11304700|NCT02668224|Active Comparator|Control group|Control: Usual activities from day 1 to Day 75.
11304701|NCT02668211|Other|PROFEMUR Preserve RSA|Single cohort of subjects prospectively implanted with PROFEMUR® Preserve Classic femoral components
11304702|NCT02668198|Experimental|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
11304703|NCT02668185|Experimental|Active drug|NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks
11304704|NCT02668185|Placebo Comparator|Placebo|Placebo - 40mg bd - for 4 weeks
11304832|NCT02667327|Placebo Comparator|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
11304833|NCT02667327|No Intervention|Standard of Care|Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.
11355390|NCT02332044|Experimental|Bepotastine besilate 10mg|
11304705|NCT02668172|Experimental|Pasireotide LAR 60 mg monotherapy week 12|"After enrollment, acromegaly patients on combination treatment will half their regular weekly dose of pegvisomant (PEGV) for 12 weeks (run-in period).
~When insuline-like growth factor 1 (IGF-I) remains within the age adjusted normal limits after 12 weeks, PEGV and the LA-SSA (Octreotide Long Acting Release (LAR) or Lanreotide Autogel) with Pegvisomant (PEGV) are discontinued and patients are switched to pasireotide LAR 60 mg for 12 weeks."
11304706|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 12|When IGF-I rises above the adjusted normal limits after 12 weeks (run-in period), these subjects will switch their LA-SSA to Pasireotide LAR 60 mg every 4 weeks and continue with the reduced PEGV dose of the run-in period, for the remaining 12 weeks.
11304707|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 24|"Between week 12 and 24 dose adaptations of PEGV are not permitted unless IGF-I drops below the age adjusted normal limits, then the dose of PEGV will be decreased stepwise with 20 mg weekly until IGF-I is within the age adjusted normal limits.
~At week 24, efficacy will be assessed, as the number of patients with a normal IGF-I in the two different groups; the combination Pasireotide LAR 60 mg / PEG V dose and monotherapy Pasireotide LAR 60 mg.
~From week 24 patients will continue with Pasireotide LAR 60 mg monotherapy, or Pasireotide LAR will be combined with 50% of the original dose of PEGV, or with an increasing dose of PEGV every 8 weeks depending on the treatment arm."
11304708|NCT02668159|Experimental|Fish peptide|
11304709|NCT02668159|Experimental|Vitamin D|
11304710|NCT02668159|Experimental|Fish peptide + Vitamin D|
11304711|NCT02668159|Placebo Comparator|Control|
11304712|NCT02668146|Experimental|perampanel|Perampanel administration
11304713|NCT02668146|Placebo Comparator|placebo|Placebo administered to subjects.
11304714|NCT02668133|Active Comparator|lipid-based nutrient supplement SQ-LNS|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution
~1 mg isotopically enriched 68Zn intravenously"
11304715|NCT02668133|Experimental|lipid-based nutrient supplement SQ-LNS with phytase|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution
~1 mg isotopically enriched 68Zn intravenously"
11304716|NCT02668120||Cases|Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
11304717|NCT02668120||Low-risk pregnancy|Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
11304718|NCT02668120||High-risk pregnancy|Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.
11304719|NCT02668107|Active Comparator|Intervention Group (Hammock positioning)|Babies in the intervention group (IG), will be positioned supine in a hammock in the incubator, with the appropriate postural adjustments.
11304720|NCT02668107|No Intervention|Control Group|Those selected for the control group (CG) will be placed in the incubator following the service routine.
11304721|NCT02668094|Active Comparator|Group L|Lidocaine 40mg was given intravenously before injection of propofol
11304722|NCT02668094|Active Comparator|Group LP|Pregabalin 75 mg was given orally 2 hour before surgery
11304723|NCT02668094|Active Comparator|Group HP|Pregabalin 150 mg was given orally 2 hour before surgery
11304724|NCT02668081|Experimental|Endoscopic papillary balloon dilation|For EPBD group, after selective cannulation of the common bile duct by the catheter, cholangiography will be performed to confirm the diagnosis of bile duct pathology. A 0.025-0.035-inch guidewire will then be inserted into the bile duct through the catheter. A dilating balloon (The controlled radial expansion (CRE) balloon dilation catheter, CRE balloon 5.5 cm (centimeter) in length, 1-1.2 cm/1.2-1.5 cm/1.5-2.0 cm in diameter) will be passed via the pre-positioned guidewire into the bile duct. Using fluoroscopic and endoscopic guidance, the balloon will be inflated with contrast medium up to the optimal size and duration (normally 5min (minutes)) after the waist on the balloon disappeared according to the patients' condition and tolerance.
11304725|NCT02668081|Active Comparator|Endoscopic sphincterotomy|"For EST group,endoscopic sphincterotomy(EST) will be done as large as possible with a pull type sphincterotome (The TRUEtome, Biliary sphincterotomy sphincterotome, Single-use sphincterotome CleverCut2V)
~Other interventions: surgical intervention, endoscopic stenting, percutaneous transhepatic cholangiogram with balloon dilation"
11304726|NCT02668068|Active Comparator|Control Group|Large volume whole-lung lavage (WLL) only
11304727|NCT02668068|Experimental|Experimental Group|Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
11304728|NCT02668055|Experimental|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells in wound, stick with wound edge skin suture, with vaseline gauze bandaging, controlled side not adding slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes
11304729|NCT02668042|Experimental|liveness tissue skin|
11304730|NCT02668029|Experimental|oxygen|oxygen administered through a nasal cannula at a personalized, fixed flow
11304731|NCT02668029|Placebo Comparator|medical air|Medical air administered through a nasal cannula at the same flow
11304732|NCT02668016|Experimental|Atorvastatin 20mg Daily|Atorvastatin 20mg daily for 1 month
11304733|NCT02668016|Placebo Comparator|Placebo|Placebo daily for 1 month
11304734|NCT02668016|No Intervention|No Treatment|No Atorvastatin or placebo for 1 month
11304735|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
11304834|NCT02667314|Experimental|Jigsaw Puzzle Group|Jigsaw puzzles & Cognitive health counseling
11304835|NCT02667314|Active Comparator|Cognitive Health Counseling Group|Cognitive health counseling only
11304885|NCT02667015|No Intervention|Control Group|Receives only treatment as usual
11305467|NCT02663050|Active Comparator|NSAID treatment group|only NSAIDs taking group
11304736|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
11304737|NCT02667990|Experimental|orthopaedic stilettoe|orthopaedic stilettoe will be compared to standard stilettoe and comfy trainer
11304738|NCT02667977|Active Comparator|Group 1|These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids
11304739|NCT02667977|Active Comparator|Group 2|These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids
11304740|NCT02667964|Other|Healthy controls|Spiroergometry
11304741|NCT02667964|Other|Patients with T2DM|Spiroergometry
11304742|NCT02667964|Other|Patients with T1DM|Spiroergometry
11304743|NCT02667951|No Intervention|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
11304744|NCT02667951|Experimental|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
11304745|NCT02667938|Experimental|Treatment 1|HCP1303 capsule 5/0.2mg + HCP1303 capsule 5/0.4mg placebo+ HGP1201 placebo
11304746|NCT02667938|Experimental|Treatment 2|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg + HGP1201 placebo
11304747|NCT02667938|Active Comparator|Active Comparator|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg placebo+ HGP1201
11304748|NCT02667925|Experimental|Intervention arm|Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
11304749|NCT02667912|Experimental|Distal renal denervation|Endovascular denervation of segmental branches of renal artery
11304750|NCT02667912|Active Comparator|Conventional renal denervation|Endovascular denervation of main trunk of renal artery
11304751|NCT02667899|Active Comparator|DBS group|Besides routine treatment, Doc patients in this group will accepted deep brain stimulation treatment.
11304752|NCT02667899|Active Comparator|TMS group|Besides routine treatment, Doc patients in this group will accepted transcranial magnetic stimulation treatment.
11304753|NCT02667899|Placebo Comparator|Control group|This Doc patients will accepted routine treatment.
11304754|NCT02667886|Experimental|Part A|X4P-001 + axitinib dose escalation
11304755|NCT02667886|Experimental|Part B|"Randomized assignment to one of two regimens:
~X4P-001 at the Part A maximum tolerated dose (MTD), in combination with axitinib
~X4P-001 at 0.5x Part A MTD, in combination with axitinib"
11304756|NCT02667886|Experimental|Part C|X4P-001 monotherapy
11304757|NCT02667873|Experimental|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
11304758|NCT02667860|Experimental|Intracorporeal anastomosis|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
11304759|NCT02667860|Active Comparator|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
11304760|NCT02667847||Preoperative patients|Preoperative patients were asked to verbally rate their anxiety 1=on a scale from 0-10 and 2=using the new smiley scale
11304761|NCT02667834|Experimental|Social Cognition and Interaction Training (SCIT)|SCIT Social cognition and interaction training program.
11304762|NCT02667834|Active Comparator|Therapeutic education program (ETP)|Therapeutic education program
11304763|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
11304764|NCT02667808||Focus Group|Participants with HIV and receiving antiretroviral therapy (ART) will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
11304765|NCT02667808||Questionnaire|Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
11304766|NCT02667795|Experimental|Monitored walking based exercise|Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
11304767|NCT02667795|No Intervention|Control|No intervention
11304882|NCT02667041|Active Comparator|Blood biomarkers|Investigation of pre- and post-treatment protein biomarkers
11304883|NCT02667028||patients receiving PCI|patients receiving percutaneous coronary intervention(PCI)
11304915|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
11304768|NCT02667782|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is developed by Jon Kabat-Zinn in 1979 (Kabat-Zinn, 1990). It is an eight-week Program that includes practices such as gentle mindful movement (awareness of the body), a body scan (to systematically nurture awareness of the body region by region), and sitting meditation (awareness of the breath to include the four foundations of mindfulness, namely, body, feeling tone, mental state, and mental content) (Cullen, 2011).
11304769|NCT02667782|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, & Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
11304770|NCT02667769|Other|Fasting day without any food|Complete fasting: On a fast day under this Protocol no solid food may be eaten unless it is solid, medically prescribed part of a bedtime snack just before falling asleep (which must sometimes be to prevent nocturnal hypoglycaemia with injection of basal insulin before going to sleep) , Otherwise, the patient have ad libitum access to mineral water and unsweetened tea (possibly a fluid intake restriction should be considered for other diseases).
11304771|NCT02667769|Other|Fasting day with calorie- & carbohydrate-free food|During a fasting day for this protocol, patients may calories in unlimited quantity and (with calorie-free dressing) Take carb food like tomatoes, cucumbers, lettuce to be, both during meal periods and in between, if desired.
11304772|NCT02667743|Experimental|Paclitaxel Micelles for Injection + Cisplatin|"In the First Period, 230 mg/m2 of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
~In the Second Period, 300 mg/㎡ of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device to patients whose minimum neutrophil ≥1.0 × 109 /L and minimum platelet count ≥80 × 109 /L and with no hematologic toxicity of grade II to IV occurred in the First Period. Then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment."
11304773|NCT02667743|Active Comparator|Paclitaxel Injection + Cisplatin|175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
11304774|NCT02667730|Placebo Comparator|Physiotherapy only|This group will receive non-pharmacological advice and physiotherapy only
11304775|NCT02667730|Experimental|Acetaminophen + physiotherapy|This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy
11304776|NCT02667730|Experimental|Naproxen + physiotherapy|This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy
11304777|NCT02667730|Experimental|Celecoxib + physiotherapy|This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy
11304778|NCT02667717|Experimental|Experimental group : Mirror Therapy|Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
11304779|NCT02667717|Active Comparator|Control group : Usual care|The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.
11304780|NCT02667704|Experimental|Nintedanib|
11304781|NCT02667704|Experimental|Bosentan|
11304782|NCT02667691|Experimental|SODB Dimpless-caloric restriction|This arm receives daily two capsules of SODB Dimpless 40mg containing 480 UI of superoxide dismutase (SOD), associated with a moderate caloric restriction.
11304783|NCT02667691|Placebo Comparator|Placebo-caloric restriction|This arm receives daily two capsules Placebo containing excipients only, associated with a moderate caloric restriction.
11304784|NCT02667678|Experimental|Cohort HIVOL, patients infected by HIV|Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
11304785|NCT02667665||Alzheimer's Disease Dementia|
11304786|NCT02667665||non-Dementia|
11304787|NCT02667652|Active Comparator|short biliarypancreatic limb|short biliarypancreatic limb
11304788|NCT02667652|Active Comparator|long biliarypancreatic limb|long biliarypancreatic limb
11304789|NCT02667639|Active Comparator|Treatment|A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
11304790|NCT02667639|Placebo Comparator|Placebo|A single 0.9% sodium chloride injection will be administered subcutaneously.
11304791|NCT02667626|Experimental|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.
~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
11304792|NCT02667626|Active Comparator|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.
~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
11304793|NCT02667613|Experimental|HABIT-ILE|HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
11304794|NCT02667613|Active Comparator|Control|A two weeks period of usual customary care.
11304795|NCT02667600||Cesarean Section Group|Patients undergoing cesarean section
11304884|NCT02667015|Experimental|Anxiety Sensitivity Intervention|Group receives the 3-week, 6-session Anxiety Sensitivity Intervention. This is a 6-session psychotherapy occurring twice weekly (60-90 minutes) for three weeks. This psychotherapeutic treatment is focused on reducing anxiety sensitivity and includes many components, but primarily consists of psychoeducation about the relationship between anxiety and substance use disorders, interoceptive exposures, in vivo exposures, and cognitive challenging.
11304796|NCT02667587|Experimental|Nivolumab + Temozolomide + Radiotherapy|Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeks
11304797|NCT02667587|Placebo Comparator|Nivolumab placebo + Temozolomide + Radiotherapy|Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks
11304798|NCT02667574|Other|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
11304799|NCT02667561|Experimental|Testosterone gel 1% 2.2 mg|Testosterone gel 1% Topical use 2.2 mg (220 mg of gel) once daily duration of treatment: 28 days
11304800|NCT02667561|Experimental|Testosterone gel 1% 4.4 mg|Testosterone gel 1% Topical use 4.4 mg (440 mg of gel) once daily duration of treatment: 28 days
11304801|NCT02667561|Experimental|Testosterone gel 1% 8.8 mg|Testosterone gel 1% Topical use 8.8 mg (880 mg of gel) once daily duration of treatment: 28 days
11304802|NCT02667561|Placebo Comparator|Placebo of Testosterone Gel 1%|Placebo of Testosterone Gel 1% Topical use Approximately 550 mg of gel Once daily duration of treatment: 28 days
11304803|NCT02667548||patients receiving PCI|patients receiving PCI
11304804|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% healthy|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
11304805|NCT02667535|Experimental|Isosorbide Mononitrate 0.5% anal fissure|Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
11304806|NCT02667535|Experimental|Isosorbide Mononitrate 1.0% anal fissure|Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
11304807|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% anal fissure|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
11304808|NCT02667522|Experimental|Parenting Intervention|Parenting Intervention: Parent-Child Interaction Therapy (PCIT)
11304809|NCT02667522|No Intervention|Waitlist Control|Waitlist Control Condition
11304810|NCT02667496|Experimental|Leukine|"Administered SC in treatment cycles up to 24 weeks
~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
11304811|NCT02667496|Placebo Comparator|Placebo|"Administered SC in treatment cycles up to 24 weeks
~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
11304812|NCT02667483|Experimental|DS-5141b|"DS-5141b, Subcutaneous injection
~Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.
~Level 1: 0.1 mg/kg
~Level 2: 0.5 mg/kg
~Level 3: 2.0 mg/kg
~Level 4: 6.0 mg/kg
~Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.
~Part 2-Extension: Two doses, 2.0 mg/kg or 6.0 mg/kg, of DS-5141b will be administered subcutaneously once a week for 48 weeks."
11304813|NCT02667470|Experimental|Solifenacin|
11304814|NCT02667457|Experimental|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
11304815|NCT02667457|Experimental|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
11304816|NCT02667444|Experimental|SB204 4%|SB204 4% topically once daily
11304817|NCT02667444|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
11304818|NCT02667418|Other|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
11304819|NCT02667418|Other|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
11304820|NCT02667418|Other|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
11304821|NCT02667405|Experimental|Whirlpool|Immersion in Whirlpool during therapy
11304822|NCT02667405|Active Comparator|Hot Pack|Hot Pack Application during therapy.
11304823|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
11304824|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
11304825|NCT02667379|Other|Diagnostic skin testing|Diagnostic skin testing with cat dander samples on volar forearms.
11304826|NCT02667366|Experimental|Tel-PT|Tel-PT receives a manualized short-term CBT. Treatment consists of one initial face-to-face appointment and 8-12 subsequent telephone sessions between patient and licensed therapist. Each telephone contact lasts between 20 and 30 minutes and take place on a weekly and later biweekly basis.
11304827|NCT02667366|Active Comparator|TAU and text messages|Control Group receives treatment as usual and additionally weekly text messages containing general information about depression.
11304828|NCT02667353|Other|electroconvulsive therapy|only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
11304829|NCT02667340|Experimental|Superstarch|Supplementation with Superstarch before a simulated soccer game
11304830|NCT02667340|Placebo Comparator|Placebo|Supplementation with placebo before simulated soccer game.
11355922|NCT02328599||Non-surgical|Medical / Lifestyle management
11304836|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:
~The patient is subjected to tympanometry test on the specific ear,
~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,
~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
11304837|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
11304838|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
11304839|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
11304840|NCT02667262||Extended Release and/or Long-Acting Opioids|
11304841|NCT02667249||check list|clinical pathway using a paper based check-list
11304842|NCT02667249||integrated clinical pathway|clinical pathway in form of a clinical pathway integrated into the paper based medical treatment and nursing documentation
11304843|NCT02667236|Active Comparator|A-101 Solution|A-101 Solution 40% administered once
11304844|NCT02667236|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
11304845|NCT02667223|Experimental|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
11304846|NCT02667223|Active Comparator|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered subcutaneously to healthy volunteers
11304847|NCT02667223|Experimental|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
11304848|NCT02667223|Experimental|Cohort 5: bococizumab 450 mg + rHUPH20|bococizumab 450 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
11304849|NCT02667223|Experimental|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to subjects with hypercholesterolemia receiving a statin
11304850|NCT02667210||No shopping behavior|
11304851|NCT02667210||Minimal shopping behavior|
11304852|NCT02667210||Marked shopping behavior|
11304853|NCT02667210||Extensive shopping behavior|
11304854|NCT02667197||Opioid overdose and poisoning|
11304855|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 1|Low FODMAP Oral Nutrition Supplement
11304856|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 2|Low FODMAP Oral Nutrition Supplement
11304857|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 3|Low FODMAP Oral Nutrition Supplement
11304858|NCT02667184|Experimental|FOS Supplement|Supplement containing fructooligosaccharides
11304859|NCT02667171|Active Comparator|Control group|The control group will receive standardized conventional supervised COPD rehabilitation, delivered in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks.
11304860|NCT02667171|Experimental|Online COPD rehabilitation|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
11304861|NCT02667158||No shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
11304862|NCT02667158||Minimal shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
11304863|NCT02667158||Marked shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
11304864|NCT02667158||Extensive shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
11304865|NCT02667145|Experimental|Intervention|Self care program focusing on the assistive device, For 4 weeks (1 to week lasting 90 minutes).
11304866|NCT02667145|No Intervention|Control group|receive only a brochure with orientations of joint protection.
11304867|NCT02667132||medical treatment|In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate
11304868|NCT02667132||surgical treatment|lumpectomy, mastectomy, abscess drainage
11304869|NCT02667132||surgical+medical treatment|first medical, after surgical treatment or first surgical, after medical treatment
11304870|NCT02667119|Experimental|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
11304871|NCT02667119|Active Comparator|Standard Care|Standard substance abuse treatment services
11304872|NCT02667106|Experimental|Single-dose, open label RX0041-2|Active Drug
11304873|NCT02667080|Active Comparator|Ejaculate 1|Semen sample after 2-7 days of sexual abstinence
11304874|NCT02667080|Active Comparator|Ejaculate 2|Semen sample after 2 hours of sexual abstinence
11304875|NCT02667067|Other|Ant cervical discectomy & fusion (ACDF)|
11304876|NCT02667067|Experimental|Simplify Disc|Simplify Disc
11304877|NCT02667054|Active Comparator|Active 4%|One dose of 4mL of RX0041 4% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
11304878|NCT02667054|Placebo Comparator|Placebo|One dose of 4mL of RX0041 placebo for one day in the mucous membrane prior to a diagnostic or surgical procedure.
11304879|NCT02667054|Active Comparator|Active 8%|One dose of 4mL of RX0041 8% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
11304880|NCT02667041|Experimental|rTMS treatment (Monophasic vs. biphasic)|Safety and efficacy
11304881|NCT02667041|Active Comparator|EEG/ERP biomarkers|Investigation of pre- and post-treatment cognitive biomarkers
11304886|NCT02667002|Experimental|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
11304887|NCT02667002|Experimental|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
11304888|NCT02667002|Active Comparator|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
11304889|NCT02666989|Active Comparator|open placebo|8 weeks of open placebo treatment
11304890|NCT02666989|No Intervention|waitlist group|4 weeks of waiting list followed by 4 weeks of open placebo treatment
11304891|NCT02666976|Experimental|ilaprazole group|ilaprazole 20mg once daily for 4 weeks.
11304892|NCT02666963|Experimental|RTA 901 10 mg or 40 mg or Placebo|RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose. Group 1: RTA 901 10 mg or matching placebo Group 2: RTA 901 20 mg or matching placebo Group 3: RTA 901 ≤ 40 mg or matching placebo Group 4: RTA 901 ≤ 80 mg or matching placebo Group 5: RTA 901 ≤ 160 mg or matching placebo Group 6: RTA 901 ≤ 320 mg or matching placebo Group 7: RTA 901 ≤ 640 mg or matching placebo Dose selection will be based on the safety, tolerability and available pharmacokinetics observed in prior study groups.
11304893|NCT02666963|Experimental|RTA 901 Dose TBD or Placebo|RTA 901 capsules, Dose TBD mg or placebo taken orally once daily for 14 days. Group 8: RTA 901 X mg or matching placebo Group 9: RTA 901 ≤Y mg or matching placebo Group 10: RTA 901 ≤Z mg or matching placebo The actual doses for Arm 2 will be selected based on the safety and available pharmacokinetic data obtained from Arm 1.
11304894|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
11304895|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
11304896|NCT02666937||ICU-patients (prospective)|Critically ill patients (18 years and older) on mechanically ventilation who have an arterial line and require bloodgasanalysis for medical reasons
11304897|NCT02666937||Emergency Department (prospective)|Patients (18 years and older), who are presented to the Emergency Department, and require bloodgasanalysis for medical reasons
11304898|NCT02666937||Pulmonary department (prospective)|Patients (18 years and older) who visit the outpatient clinic of the pulmonary department for different pulmonary functional test and require bloodgasanalysis for medical reasons
11304899|NCT02666937||Pulmonary department (retrospective)|Patients (18 years and older) who visited the outpatient clinic of the pulmonary department in the past of the VU medical centre in Amsterdam or the Medical Centre Alkmaar for different pulmonary functional test and required bloodgasanalysis for medical reasons
11304900|NCT02666924|Experimental|Cooking class|The addition of diabetes cooking educational classes to standard diabetes education classes. Cooking classes are a series of four, four-hour sessions. These cooking classes will be led by a registered dietitian, a registered nurse and a chinese chef. Conducted in Mandarin or Cantonese. The cooking education focus is culturally specific teaching for Chinese-Canadian persons living with diabetes.
11304901|NCT02666924|Active Comparator|Control|Type 2 diabetes educational classes, consisting of two sessions, one week apart, four-hour classes. These classes are taught by a registered dietitian and nurse, in Mandarin or Cantonese.
11304902|NCT02666911|Experimental|4D Ultrasound|4D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. The same patients will be imaged with both 2D and 4D transducers.
11304903|NCT02666911|Active Comparator|2D ultrasound|2D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury.The same patients will be imaged with both 2D and 4D transducers.
11304904|NCT02666898|Experimental|Obinutuzumab and Ibrutinib CLL treatment|"3 parts
~PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:
~GA101:
~C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v
~Ibrutinib:
~D3 Month 1 to Day 30 Month 15: 420mg daily PO
~PART 2: 4 cycles / 28 days
~After evaluation at D1 month 9:
~patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
~patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
~Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
~Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
~Ibrutinib 420mg/day PO
~PART 3 (only in GAI-FC+Ibru arm) :
~After evaluation at D1 of M16:
~patients CR with BM MRD< 10-4, treatment stopped
~patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative."
11304905|NCT02666885|Experimental|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
11304906|NCT02666872|Experimental|Motivational interviewing on vaccination|An educational strategy based on motivational interviewing of approximately 15 minutes to promote vaccination, in maternity ward.
11304907|NCT02666872|No Intervention|Brochure about vaccines for infants|Parents in the control group only received a brochure about vaccines for infants. This brochure is given to all fathers and mothers giving birth to the CHUS, participating or not at our study.
11304908|NCT02666859|Experimental|Unilateral Transradial Amputation|This group includes people with a unilateral transradial amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
11304909|NCT02666859|Experimental|Unilateral Transhumeral Amputation|This group includes people with a unilateral transhumeral amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
11304910|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
11304911|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
11304912|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
11304913|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
11304914|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
11304916|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
11304917|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
11304918|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
11304919|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
11304920|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
11304921|NCT02666820|Active Comparator|Large balloon dilatation|Patients underwent clearance of common bile duct stones using a papillary large balloon dilatation.
11304922|NCT02666820|Active Comparator|Mechanical lithotripsy|Patients underwent clearance of common bile duct stones using a mechanical lithotripsy.
11304923|NCT02666807|Experimental|Ginger|Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
11304924|NCT02666807|Placebo Comparator|Placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily
11304925|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 10 micrograms sufentanil, followed by the placement of the epidural catheter
11304926|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
11304927|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
11304928|NCT02666768|Experimental|gamma interferon-1b|Gamma interferon-1b 100 mcg SC 3 times weekly for 12 months
11304929|NCT02666742|Experimental|Apixaban|Participants will be asked to take 5 milligrams by mouth twice per day.
11304930|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
11304931|NCT02666729||AF Ablation Procedure|Patients with AF who are schedule for a first time pulmonary vein isolation (PVI) for AF using the TactiCath catheter. Patients will have four pulmonary veins ablated during procedure. The researcher will perform AF Ablation with contact force information on two veins. The research will perform AF Ablation without contact force information on the other two veins.
11304932|NCT02666703|Experimental|Study (CytoSorb)|In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
11304933|NCT02666703|No Intervention|Control|In the control group (20 patients) no filter will be installed on the CPB.
11304934|NCT02666703|Active Comparator|Corticosteroid|In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
11304935|NCT02666690|Experimental|Patients with metastatic cancer treated with anti angiogenics|
11304936|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
11304937|NCT02666664|Placebo Comparator|Placebo|Placebo control
11304938|NCT02666651|Experimental|Test group|Administration of oral tolvaptan (15-60mg PO titration) during admission for decompensated heart failure
11304939|NCT02666651|Other|Control group|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority
11304940|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
11304941|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
11304942|NCT02666625||Patients treated for cancer in childhood|
11304943|NCT02666612|Other|Patients with metastatic cancer|
11304944|NCT02666599|Experimental|18F-FDG PET/CT|18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''
11304945|NCT02666586|Placebo Comparator|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
11304946|NCT02666586|Experimental|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
11304947|NCT02666586|Experimental|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
11304948|NCT02666586|Experimental|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
11304949|NCT02666586|Experimental|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
11304950|NCT02666573|Experimental|Photodynamic therapy protocol|In addition to scaling and root debridement, test sites received PDT according to manufacturer's instructions.
11304951|NCT02666573|Other|SRP|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
11304952|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
11304953|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
11304954|NCT02666547|Other|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
11304955|NCT02666534|Experimental|AFL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
11304956|NCT02666534|Active Comparator|MAL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
11304957|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
11358820|NCT02309034|Experimental|Aquatic exercise|Hydrogimnastic.
11304958|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
11304959|NCT02666482|Experimental|Stop Smoking SF Web App - baseline|"Online Study 1 will test the data gathering aspects of the proposed web app using a baseline, usual care intervention consisting of a static smoking cessation guide, the Guía para Dejar de Fumar, tested in printed form in the Muñoz et al. (1997) study. The print version of the guide yielded an 11% quit rate at 3 months. The investigators will utilize the content of the guide as the main element of the baseline app, so it will serve to estimate baseline utilization and quit rates when this already tested intervention is provided in a web app format. Participants can join the study online by going to: https://stopsmokingsf.org"
11304960|NCT02666469|Active Comparator|Group A Hyperbaric Oxygen Therapy and Exercise Program|Group A: Hyperbaric Oxygen Therapy (HBOT) and Exercise with HBOT sessions for 90 minutes, once daily, 5 times a week for 8 consecutive weeks. HBOT will be provided with 100% oxygen at 2.0 ATA. Patients will exercise in the multiplace hyperbaric chamber while receiving hyperbaric oxygen.
11304961|NCT02666469|Active Comparator|Group B Exercise Program|Group B: Exercise Program in the hyperbaric medical unit without exposure to HBOT
11304962|NCT02666456||Cross-sectional cohort|Patients with chronic peripheral neuropathic pain
11304963|NCT02666456||Longitudinal cohort|Painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, Operation)
11304964|NCT02666443|Placebo Comparator|Control (C)|Control intervention (no dexamethasone)
11304965|NCT02666443|Experimental|Peri-neural (N)|Peri-neural Dexamethasone 1 mg
11304966|NCT02666443|Experimental|Intravenous|Intravenous Dexamethasone 1 mg
11304967|NCT02666430|Experimental|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
11304968|NCT02666430|Active Comparator|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
11304969|NCT02666417|Active Comparator|MNP+iron and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as FeFum and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
11304970|NCT02666417|Active Comparator|MNP+iron+GOS and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
11304971|NCT02666404|Experimental|Volume Resuscitation|We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
11304972|NCT02666391|Experimental|UCMSCs|Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)
11304973|NCT02666391|No Intervention|controls|Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion
11304974|NCT02666378|Experimental|CMR/ECHO|"Prior to starting chemotherapy treatment, the participant will undergo the following procedures:
~Cardiac Magnetic Resonance Imaging (CMR)
~Echocardiogram (ECHO) in patients with no clinically indicated scans
~Each imaging procedure will be repeated at predetermined times during the protocol
~Simple blood collection for plasma biomarker analysis"
11304975|NCT02666365|Active Comparator|Bolus infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion
11304976|NCT02666365|Active Comparator|Continuous Infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion
11304977|NCT02666352|Experimental|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
11304978|NCT02666352|Experimental|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
11304979|NCT02666352|Experimental|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
11304980|NCT02666339|Experimental|Hortitherapy group|Hortitherapy + Usual care
11304981|NCT02666339|Active Comparator|Control group|Usual care
11304982|NCT02666326|No Intervention|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.
~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
11304983|NCT02666326|Experimental|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
11304984|NCT02666300|Experimental|TaperGuard ETT|tracheal intubation with the TaperGuard ETT，the ETT cuff is Taper-shangped.
11305041|NCT02665910|Placebo Comparator|SHR0302 placebo comparator|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)
11304985|NCT02666287|Experimental|Sequence 1|"Each subject will receive all the 9 treatment regimens in the following order: A,G/B/F/C,H/E/D,I with a washout period of 7 days between each treatment period administered via the ELLIPTA inhaler. Where Treatment A= BAT/FF 900/300 microgram (mcg) (3 inhalations of 300/100 mcg).
~Treatment B= BAT 900 mcg (3 inhalations of 300 mcg) concurrently with FF (lactose) 300 mcg (3 inhalations of 100 mcg) from separate inhalers.
~Treatment C= BAT 900 mcg (3 inhalations of 300 mcg). Treatment D= FF (lactose) 300 mcg (3 inhalations of 100 mcg). Treatment E= FF (magnesium stearate [MgSt]) 300 mcg (3 inhalations of 100 mcg). Treatment F= FF/VI 300/75 mcg (3 inhalations of 100 mcg/25 mcg). Treatment G= 7-day repeat doses: BAT/FF 300/100 mcg (1 inhalation). Treatment H= 7-day repeat doses: BAT 300 mcg (1 inhalation). Treatment I= 7-day repeat doses: FF (lactose) 100 mcg (1 inhalation)."
11304986|NCT02666287|Experimental|Sequence 2|Each subject will receive all the 9 treatment regimens in the following order: B/C,H/A,G/D,I/F/E with a washout period of 7 days between each treatment period.
11304987|NCT02666287|Experimental|Sequence 3|Each subject will receive all the 9 treatment regimens in the following order: C,H/D,I/B/E/A,G/F with a washout period of 7 days between each treatment period.
11304988|NCT02666287|Experimental|Sequence 4|Each subject will receive all the 9 treatment regimens in the following order: D,I/E/C,H/F/B/A,G with a washout period of 7 days between each treatment period.
11304989|NCT02666287|Experimental|Sequence 5|Each subject will receive all the 9 treatment regimens in the following order: E/F/D,I/A,G/C,H/B with a washout period of 7 days between each treatment period.
11304990|NCT02666287|Experimental|Sequence 6|Each subject will receive all the 9 treatment regimens in the following order: F/A,G/E/B/D,I/C,H with a washout period of 7 days between each treatment period.
11304991|NCT02666274||RK Group|participants colonised with Klebsiella spp. resistant to either 3GC or carbapenems (RK cohort of index carriers of Resistant Klebsiella)
11304992|NCT02666261||Breast Cancer Pathology Samples|Data on the epidemiology and HER2 testing of breast cancer will be collected from pathology routine diagnostics.
11304993|NCT02666235|Active Comparator|Remote ischaemic conditioning|Intermittent inflation of a forearm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a curtain.
11304994|NCT02666235|Sham Comparator|Control group|Sham intervention: Arm cuff placement but without inflation during a 40 minute period. A curtain will obscure the patient from the clinical team during this time. Arm cuff placement, no inflation.
11304995|NCT02666196|Experimental|DAA-I 6mg|Subjects given solid compound in vials containing 6mg per vial
11304996|NCT02666196|Experimental|DAA-I 50mg|Subjects given solid compound in vials containing 50mg per vial
11304997|NCT02666196|Experimental|DAA-I 110mg|Subjects given solid compound in vials containing 110mg per vial
11304998|NCT02666196|Placebo Comparator|Placebo|Subjects given 25ml placebo dissolved in 200ml water
11304999|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
11305000|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
11305001|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
11305002|NCT02666170|Experimental|therapy with alpha-lipoic acid daily for six months|
11305003|NCT02666157|Active Comparator|Dabigatran|oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
11305004|NCT02666157|Active Comparator|Rivaroxaban|oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
11305005|NCT02666157|Active Comparator|Apixaban|oral apixaban 5 mg (2.5 mg in specific population) bid for entire study period
11305006|NCT02666144||Glaucoma|
11305007|NCT02666144||Normal|
11305008|NCT02666118|Active Comparator|Preemptive Interscalene Block - Single Shot|
11305009|NCT02666118|Active Comparator|Postoperative Interscalene Block - Single Shot|
11305010|NCT02666118|Active Comparator|Preemptive Interscalene Block - Cathether|
11305011|NCT02666118|Active Comparator|Postoperative Interscalene Block - Catheter|
11305012|NCT02666105|Experimental|Exemestane Therapy|
11305013|NCT02666092||Fish allergy|"51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited.
~Interventions will include:
~A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations
~A detection of anti-Anisakis and anti-fish antibodies"
11305042|NCT02665897||Eclampsia|pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
11305014|NCT02666092||Control|"51 subjects presenting no allergic manifestations after contact with fish.
~Interventions will include:
~A questionnaire on domestic exposure to fish
~A detection of anti-Anisakis and anti-fish antibodies"
11305015|NCT02666079|Experimental|Treatment arm|Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.
11305016|NCT02666053|Experimental|Treatment A|Single BMS-663068 tablet under fasted conditions
11305017|NCT02666053|Experimental|Treatment B|Single BMS-663068 tablet with a high fat meal
11305018|NCT02666053|Experimental|Treatment C|Single BMS-663068 tablet after a single famotidine tablet under fasted conditions
11305019|NCT02666040|Experimental|U - ULTRAPRO|Inguinal Hernia Surgery with ULTRAPRO® meshes, a new ULTRAPRO® mesh will be implanted in patients in the group (AG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment.
11305020|NCT02666040|Active Comparator|P - Prolene|"Inguinal Hernia Surgery with Prolene® meshes, the conventional mesh in polypropylene Prolene® will be implanted in patients in the control group (CG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment."
11305021|NCT02666027|Experimental|FIVA ON|The FIVA will be turned on for cases randomized to an even number. The ON light will be covered by tape. Routine induction and maintenance of anesthesia and rate and manner of delivery of IV fluid will be administered at the discretion by the anesthesiologist. The FIVA monitor will only monitor the first IV fluid bag since the study will be unblinded once the FIVA monitor alarm is triggered. When the IV bag is empty and the FIVA alarm is triggered, the anesthesiologist will turn off the FIVA and change the IV bag. The following will be recorded by the anesthesiologist: Type of surgical procedure; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA during the procedure; VAS assessment of ease of use of the FIVA; Loudness of audial alarm of the FIVA.
11305022|NCT02666027|Placebo Comparator|FIVA OFF|The FIVA will be off for cases randomized to odd numbers. The indicator lights will be covered by tape. Routine induction and maintenance of anesthesia and rate/manner of delivery of IV fluid will be administered at the discretion of the anesthesiologist. The IV bag may run dry with or without being noticed by the anesthesiologist. When they detect the empty bag, it will be changed after the removal of the FIVA. The anesthesiologist will record the presence or absence of air in the IV tubing following the termination of the study. The following will be recorded by the anesthesiologist: Type of surgery; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA device; VAS assessment of ease of use of the FIVA; Assessment of audial alarm of the FIVA.
11305023|NCT02666014|Active Comparator|Sugammadex group|"Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.
~The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding."
11305024|NCT02666014|Active Comparator|Neostigmine group|"Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.
~Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.
~Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered."
11305025|NCT02666001|Experimental|Part 1 (BMS-663068+methadone)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone
11305026|NCT02666001|Experimental|Part 2 (BMS-663068+buprenorphine and norbuprene)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine
11305027|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
11305028|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
11305029|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
11305030|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
11305031|NCT02665962|Other|Calorie Restricted (CR) program|The intervention will provide individualized CR program, meal replacement products and nutritional counseling sessions.
11305032|NCT02665936|Active Comparator|group L|Epidural levobupivacaine 0.125% (Chirocaine) in normal saline in a total volume of 10 ml will be administered epidurally in active stage of labor
11305033|NCT02665936|Active Comparator|group LD4|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 4 mg in a total volume 10 ml
11305034|NCT02665936|Active Comparator|group LD8|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 8 mg in a total volume 10 ml
11305035|NCT02665923||Newborn (gastric emptying)|30 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
11305036|NCT02665923||Newborn|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
11305037|NCT02665923||Infants (1-12mos)|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
11305038|NCT02665923||Children (2-7yrs)|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
11305039|NCT02665923||Older children and adolescents (≥7yrs)|Patients will undergo one ultrasound prior to their elective procedure after induction of general anesthesia to assess antral volume.
11305040|NCT02665910|Experimental|SHR0302|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets
11359052|NCT02307487|Experimental|Cohort C2|160 mg MMC in 90ml gel
11305043|NCT02665897||severe preeclampsia|pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
11305044|NCT02665897||healthy|matched normotensive pregnant women.
11305045|NCT02665884||Glaucoma EX-PRESS|Glaucoma patients who underwent glaucoma surgery between the years 2014-2015 and had diurnal intraocular pressure measurements over 24 hours.
11305046|NCT02665884||Control Group|Glaucoma patients who had been treated with anti-glaucoma drops and had diurnal intraocular pressure measurements over 24 hours.
11305047|NCT02665871|Experimental|one dose of Influenza Vaccine in aged 18 years and older|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
11305048|NCT02665871|Experimental|One dose of Influenza Vaccine in aged 3-17 year|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
11305049|NCT02665871|Placebo Comparator|placebo in aged 18 years and older|placebo in 10 subjects aged 18 years and older on day 0
11305050|NCT02665871|Placebo Comparator|placebo in aged 3-17 years|placebo in 10 subjects aged 3-17 years on day 0
11305051|NCT02665858|Active Comparator|IIH Patients|Patients diagnosed with Idiopathic Intracranial Hypertension who undergo OCT imaging
11305052|NCT02665858|Active Comparator|Control Group|Patients diagnosed with headache with ruled out Idiopathic Intracranial Hypertension who undergo OCT imaging
11305053|NCT02665845|Experimental|5-ASA group|Patients will receive corticosteroids with optimized 5-ASA.
11305054|NCT02665845|Active Comparator|Control group|Patients will receive corticosteroids alone.
11305055|NCT02665832|Experimental|AB|Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
11305056|NCT02665832|Experimental|BA|DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
11305057|NCT02665819||Pediatric cancer women survivors|Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
11305058|NCT02665806|Experimental|Ciclesonide|
11305059|NCT02665806|Active Comparator|Fluticasone|
11305060|NCT02665793|Experimental|DBPCFC to peanut cookie, then single-dose DBPCFC x 2|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):
~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit
~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions"
11305061|NCT02665793|Experimental|Single dose DBPCFC x 2, then DBPCFC to peanut cookie|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):
~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions
~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit"
11305062|NCT02665780|Experimental|Treatment|Periodontal debridement, tongue cleaning, mouth rinsing with 20ml Cetylpyridium Chloride daily for 24 weeks
11305063|NCT02665767|No Intervention|On-site sonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert.
11305064|NCT02665767|Active Comparator|Smartphone-based Telesonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an offsite expert.
11305065|NCT02665754|Experimental|Active group|In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
11305066|NCT02665754|Placebo Comparator|Placebo group|In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
11305067|NCT02665741|Other|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
11305068|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
11305069|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
11305070|NCT02665728|Experimental|BLI400|BLI400 Laxative
11305071|NCT02665715|Experimental|Low carbohydrate/Standard carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
11305072|NCT02665715|Experimental|Standard carbohydrate/Low carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
11305073|NCT02665702|Experimental|Endostar Combined With NVB and DDP|Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
11305074|NCT02665689|Active Comparator|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
11305075|NCT02665689|Experimental|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.
~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
11305076|NCT02665663|Other|healthy volunteers|"Constitution of a control group consisting of 20 healthy volunteers, matched for age and sex to establish a normal pressure force of the language depending on the age and sex value"
11305077|NCT02665663|Other|Patients with Amyotrophic Lateral Sclerosis|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis (ALS), included at diagnosis of the disease on clinical and electromyographic arguments addressed in speech pathology consultation without a complaint swallowing.
11305078|NCT02665663|Other|patients with Amyotrophic Lateral Sclerosis and swallowi|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis ( ALS) and swallowing disorders clinically objectified in the ENT consultation.
11305079|NCT02665650|Experimental|AFM13 + Pembrolizumab|Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.
11305080|NCT02665637|Active Comparator|CT-P6|Trastuzumab
11305081|NCT02665637|Active Comparator|US-licensed Herceptin|Trastuzumab
11305082|NCT02665624|Active Comparator|Stewed apricot juice + senna group|68 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. Additional one liter of stewed apricot juice (made with dried apricot) were told to be drunken until 2 h before colonoscopy.
11305083|NCT02665624|Active Comparator|senna alone group|60 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. 1 patient was dropped out due to obstructive sigmoid colon cancer.
11305084|NCT02665611|Experimental|intervention group|"intervention for improvement of treatment adherence Intervention group- This group will be followed by the MOMA call center (By the MOMA nures every couple weeks and by the study coordinatore and the treating Doctor at special visits as the study required.) The group will be monitored according to number of parameters, including treatment Adherence."
11305085|NCT02665611|Experimental|control group|"treatment as usual Control group- Treatment will continue as usual by the Doctor.(This group will allso be followed by the Study Coordinator at the same visits as the Intervention group.The group will be monitored according to number of parameters, including treatment Adherence."
11305086|NCT02665585|Experimental|C-Guard carotid stent|Carotid stenting procedure by C-Guard stent implantation (InspireMD, Boston, MA, USA)
11305087|NCT02665585|Active Comparator|Wallstent carotid stent|Carotid stenting procedure by Wallstent implantation (BostonScientific, Marlborough, MA, USA)
11305088|NCT02665572|No Intervention|renal transplant without bladder recycling|the patients allocated to this arm and met inclusion criteria will undergo renal transplant without prior recycling of the bladder
11305089|NCT02665572|Active Comparator|renal transplantation with bladder recycling|the patients allocated in this arm will undergo bladder recycling prior to renal transplantation
11305090|NCT02665559||Hypogonadism group|a cross-sectional and prospective study, in HIV-infected men less than 50 years old, with HIV-RNA ≤ 50 cop/mL under ART who had never presented AIDS
11305091|NCT02665546||Case|Patients with diagnosis of LCH based on histopathological or clinical and radiological findings.
11305092|NCT02665546||Controls|Current or ex smokers matched with cases for age, gender and smoking history.
11305093|NCT02665533|Active Comparator|Dexamethasone|Dexamethasone 8 mg, one capsule single preoperative dose.
11305094|NCT02665533|Experimental|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg, one capsule single preoperative dose.
11305095|NCT02665520|Active Comparator|stem cells injection in penis|Treatment Injection of adipose derived cells into penis experimental;randomised
11305096|NCT02665520|No Intervention|controled arm|
11305097|NCT02665507|Active Comparator|LLLI|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition LLLI (low level laser irradiation) treatment performed with Gallium-Aluminium-Arsenide 808 nm laser ( GaAlAs 808nm laser ).
11305098|NCT02665507|Sham Comparator|Sham|Subjects from this group will receive 6 biweekly physiotherapy treatment and in addition sham LLLI treatment
11305099|NCT02665481|Experimental|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
11305100|NCT02665481|Experimental|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
11305101|NCT02665481|Experimental|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.
~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
11305102|NCT02665481|Active Comparator|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
11305103|NCT02665468|Other|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
11305104|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
11305105|NCT02665455|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
11305106|NCT02665442|Experimental|Stylet|This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
11305107|NCT02665442|No Intervention|Non-Stylet|This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
11305108|NCT02665429|No Intervention|Control|Providers who are subject only to the routine implementation of clinical practice guidelines without additional experimental intervention
11305109|NCT02665429|Experimental|Intervention|"Providers who are subject to routine clinical practice guideline implementation AND receive provider's own individual prescribing data profile intervention (Individual prescribing data profile and self-assessment)"
11305143|NCT02665208|Active Comparator|Text Message Intervention|Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
11305110|NCT02665416|Experimental|Part I: Selicrelumab, Vanucizumab/Bevacizumab|Participants will receive a fixed dose of vanucizumab, 2 grams via IV infusion on Days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC in ascending dose levels on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (expected 24 months). Due to the discontinuation of Vanucizumab development, Participants ongoing in Part I will switch from Vanucizumab to Bevacizumab. All the dose escalation has been performed using Vanucizumab.
11305111|NCT02665416|Experimental|Part II: Selicrelumab, Bevacizumab|Bevacizumab will be administered via IV infusion on days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC after the Bevacizumab infusion at the dose determined in the Part I of the study on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (expected 18 months).
11305112|NCT02665403|Experimental|play intervention|30 minutes of hospital play interventions
11305113|NCT02665403|Placebo Comparator|control|usual care
11305114|NCT02665390|Experimental|treatment|Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.
11305115|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
11305116|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
11305117|NCT02665364|Experimental|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
11305118|NCT02665364|Placebo Comparator|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
11305119|NCT02665351|Active Comparator|Peramivir 300mg Q12H|Peramivir 300 mg, administered intravenously, twice daily (every 12 hours)
11305120|NCT02665351|Active Comparator|Peramivir 600mg Q24H|Peramivir 600 mg, administered intravenously, once daily (every 24 hrs)
11305121|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
11305122|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
11305123|NCT02665325||TSHsuppressive therapy group|TSH-suppressive therapy group: newly diagnosed differentiated thyroid carcinoma and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
11305124|NCT02665325||Negative control group|Healthy volunteers (normal T3,T4,FT3,FT4,TSH, TG-ab,TPO-ab,TG) are recruited to match the patients with age, gender, education level, ect.
11305125|NCT02665325||Positive control group|Newly diagnosed nodular goiter and undergone thyroidectomy according to the China thyroid association guidelines for the management of thyroid nodule and thyroid cnacer; followed by L-T4 replacement therapy 6/12 months.
11305126|NCT02665286|Placebo Comparator|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
11305127|NCT02665286|Active Comparator|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
11305128|NCT02665286|Active Comparator|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
11305129|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
11305130|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
11305131|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
11305132|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
11305133|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
11305134|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
11305135|NCT02665247|Experimental|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
11305136|NCT02665247|Other|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
11305137|NCT02665234|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
11305138|NCT02665234|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
11305139|NCT02665221|Placebo Comparator|Control group|
11305140|NCT02665221|Experimental|Treatment group|
11305141|NCT02665208|Active Comparator|Treatment As Usual (TAU)|Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
11305142|NCT02665208|Active Comparator|Nicotine Replacement Therapies|Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
11305468|NCT02663050|Active Comparator|Combination treatment group|NSAIDs plus Kinesio taping group
11305144|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
11305145|NCT02665182|Experimental|Up-positioning of the testes|Patients receive standard medical therapy and supportive therapy
11305146|NCT02665182|No Intervention|Medical therapy only|Patients receive standard medical therapy only
11305147|NCT02665169|Experimental|Exercise intervention group|Supervised exercise intervention of 12 months. One Taiji and one gym training per week for first six months followed by 6 months free independent use of municipal facilities, including gym, swimming hall and weight room. Written and oral health counselling provided.
11305148|NCT02665169|Active Comparator|Control group|Control group, without any induced exercise intervention. Written and oral health counselling provided.
11305149|NCT02665156|Experimental|Robotic Stapled orthotopic neobladder|Intracorporeal stapled neobladder using robotic staplers: Partly stapled orthotopic neobladder: robotic staplers applied to create the neobladder neck and to suture the left side of the posterior aspect of neobladder. Right side of the posterior aspect of neobladder and the anterior aspect of the neobladder hand sewn.
11305150|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
11305151|NCT02665130|Active Comparator|Tai-Chi group|Tai-Chi exercise plus Indacaterol 150ug/day
11305152|NCT02665130|Placebo Comparator|Pulmonary rehabilitation group|Conventional exercise plus Indacaterol 150ug/day
11305153|NCT02665117|Active Comparator|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
11305154|NCT02665117|Active Comparator|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
11305155|NCT02665104||patients without neurological symptoms|carotid endarterectomy patients who dont'have any neurological symptoms after carotid clamping
11305156|NCT02665104||patients with neurological symptoms|carotid endarterectomy patients who have new neurological symptoms after carotid clamping
11305157|NCT02665091|Experimental|Peer Education Group|Group was self compared after the intervention
11305158|NCT02665078||Thoracoscopic Ultrasound|Patients who undergo lobectomy or an anatomical segmental resection for malignant lung tumors will be enrolled in the study. After lung resection, the lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross section with maximum diameter. The ultrasound image with size measurement of the tumor will be recorded using an ultrasound scanner (EU-Y0008, OLYMPUS MEDICALSYSTEMS CORP., Tokyo, Japan). After ultrasound evaluation, the specimen will be delivered directory to the pathology laboratory and the actual tumor size and histological diagnosis will be determined. In addition, we will evaluate the differences between US image and pathological morphology using HE slides of lung tumor.
11305159|NCT02665065|Experimental|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
11305160|NCT02665065|Active Comparator|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
11305161|NCT02665052|Experimental|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
11305162|NCT02665052|Experimental|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
11305163|NCT02665052|Placebo Comparator|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
11305164|NCT02665039|Experimental|Vinflunine + gemcitabine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:
~280 mg/m2 in patients with GFR 40-60 ml/min
~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min
~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
11305165|NCT02665039|Active Comparator|Carboplatin + gemcitabine|"Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
11305166|NCT02665026|Experimental|stoma closure at different times|choose different times to do stoma closure after surgery for rectal cancer
11305167|NCT02665013|Experimental|Tailored|Participants will complete surveys at each intervention time point. Based on survey responses, they will receive vaccine information on the study website tailored to their vaccine concerns and values
11305168|NCT02665013|Placebo Comparator|Untailored|Participants will complete surveys at each intervention time point and receive vaccine information on the study website. The vaccine information will NOT be tailored to their concerns and values.
11305169|NCT02665013|No Intervention|Usual Care|Participants will complete surveys at each intervention time point. They will receive vaccine information sheets that are provided in the well child visits at enrollment in the study.
11305170|NCT02665000|Experimental|Study arm: Structured training programme|"The participants in study arm will undergo 5 days training program in laparoscopic appendectomy using the Box and Wet Trainer as intervention. Each training session will take up to 2 hours. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.
~After the above training, they will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and graded based on a validated GOALS scoring system 6. The Primary Outcome will be the difference of the GOALS results between the 2 groups. Secondary outcomes will include OSAT score, patient outcome, residents' feedback score as well as conversion rates to open surgery."
11305171|NCT02665000|No Intervention|Control arm: non-training|"Participant in study arm will not receive any additional training during the training week. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.
~They will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and then graded based on a validated GOALS scoring system 6"
11305172|NCT02664987||Patients receiving cancer pain treatment|
11305173|NCT02664974|Experimental|HEN group|Home Enteral Nutrition
11305174|NCT02664974|Active Comparator|Control group|Dietary Counseling
11305175|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
11305176|NCT02664948|Experimental|Intervention group|Early geriatric follow-up after discharge from hospital in the patient's home
11305177|NCT02664948|No Intervention|Control group|Usual care with follow-up home-visits conducted by home care and the GP after discharge, if they consider it as necessary
11305178|NCT02664935|Experimental|Arm A: AZD4547|"AZD4547 - FGFR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20 & 80mg Trial Dose & Schedule: 80 mg BD, Continuous dosing, 21 day cycle
~Closed to recruitment."
11305179|NCT02664935|Experimental|Arm B: Vistusertib (AZD2014)|Vistusertib (AZD2014) - MTORC1/2 Inhibitor Route & Formulation: Oral, Tablets Strengths: 25mg Trial Dose & Schedule: 125 mg BD, Intermittent dosing (2 continuous days in 7), 28 day cycle.
11305180|NCT02664935|Experimental|Arm C: Palbociclib|Palbociclib - CDK4/6 Inhibitor Route & Formulation: Oral, Capsules Strengths: 75, 100 & 125mg Trial Dose & Schedule: 125 mg OD, Intermittent dosing (21 days on, 7 days off), 28 day cycle.
11305181|NCT02664935|Experimental|Arm D: Crizotinib|Crizotinib - ALK Inhibitor Route & Formulation: Oral, Capsules Strengths: 200 & 250mg Trial Dose & Schedule: 250 mg BD, Continuous dosing, 21 day cycle.
11305182|NCT02664935|Experimental|Arm E: Selumetinib & Docetaxel|"AZD6244 (Selumetinib) - MEK Inhibitor Route & Formulation: Oral, Capsules Strengths: 25mg Trial Dose & Schedule: 75 mg BD, Continuous dosing, 21 day cycle.
~Docetaxel - Chemotherapy Route & Formulation: IV infusion over 30-60 minutes, concentrate for solution for infusion.
~Trial Dose & Schedule: 75 mg/m2, 3-weekly, 21 day cycle."
11305183|NCT02664935|Experimental|Arm F: AZD5363|"AZD5363 - AKT Inhibitor Route & Formulation: Oral, Tablets Strengths: 80 & 200mg Trial Dose & Schedule: 480 mg BD, Intermittent dosing (4 days on, 3 days off), 28 day cycles.
~Closed to recruitment."
11305184|NCT02664935|Experimental|Arm G: Osimertinib (AZD9291)|"Osimertinib (AZD9291) - EGFRM+ and T790M+ Inhibitor Route & Formulation: Oral, Tablets Strengths: 80mg Trial Dose & Schedule: 80 mg OD, Continuous dosing, 21 day cycles
~Closed to recruitment."
11305185|NCT02664935|Experimental|Arm NA: Durvalumab (MEDI4736)|"Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 200mg Trial Dose & Schedule: 10 mg/kg IV, 2-weekly.
~Closed to recruitment."
11305186|NCT02664935|Experimental|Arm H: Sitravatinib|"Sitravatinib - VEGFR Inhibitor Route & Formulation: Oral, Capsules Strengths: 10 & 40mg Trial Dose & Schedule: 120 mg OD, Continuous dosing, 21 day cycles
~Closed to recruitment."
11305187|NCT02664935|Experimental|Arm J: AZ6738 & Durvalumab|"AZD6738 - ATR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20mg, 80mg, 100mg Trial Dose & Schedule: 240 mg twice daily (BD) on days 15-28 of 28 day cycle.
~Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 500mg Trial Dose & Schedule: 1500mg on day 1 of each 28 day cycle"
11305188|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
11305189|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
11305190|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
11305191|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
11305192|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
11305193|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
11305194|NCT02664896||Knee Osteoarthritis Cohort|Subjects with knee osteoarthritis will be asked to participate in the knee osteoarthritis testing session. This group will participate in 1 three hour testing session.
11305195|NCT02664896||Healthy Subject Cohort|Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
11305196|NCT02664883||Group I (no cancer or hematuria)|Patients with no evidence of cancer and no hematuria undergo collection of blood and urine samples at baseline and 2 months for analysis via the Flow Cytometry MDSC Clinical Assay
11305197|NCT02664883||Group II (localized RCC)|Patients diagnosed with localized renal cell carcinoma undergo collection of blood and urine samples at baseline and after nephrectomy for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI within 30 days after nephrectomy.
11305198|NCT02664883||Group III (metastatic RCC)|Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
11305199|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
11305200|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
11305201|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
11305202|NCT02664857|Active Comparator|vitamin D|After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
11305203|NCT02664857|Sham Comparator|Placebo|Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
11305204|NCT02664844|Experimental|Obese adolescent|
11305205|NCT02664818||Heart failure|Hospitalized patients with primary discharge diagnosis of heart failure and who were aged 18 years or older.
11305206|NCT02664805|Active Comparator|LEO 124249 ointment|Twice daily cutaneous application for 8 weeks
11305207|NCT02664805|Placebo Comparator|LEO 124249 ointment vehicle|Twice daily cutaneous application for 8 weeks
11305208|NCT02664792|Experimental|Diagnosis or suspicion of non-small cell lung carcinoma|SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
11305209|NCT02664779|Experimental|Arrhythmia diagnosis with the 10 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias.
11305210|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 6 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
11305211|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 4 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
11305212|NCT02664766|No Intervention|Control condition|Control condition with no intervention. Participants will be recording their daily alcohol consumption. No lifestyle modification during this period.
11305213|NCT02664766|Experimental|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
11305214|NCT02664753|Experimental|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.
~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
11305215|NCT02664753|Placebo Comparator|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).
~Intervention: 10 days of intravenous placebo (isotonic saline)"
11305216|NCT02664740|Experimental|Phage therapy|"Patients randomized to this arm will have phage therapy.
~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
11305217|NCT02664740|Placebo Comparator|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.
~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
11305218|NCT02664727|Experimental|Heavy drinkers|The effects of acute exercise in heavy drinkers. Participants will cycle on ergometer for 30 min at 50-60% of Heart Rate Reserve (HRR).
11305219|NCT02664727|Experimental|Alcoholic patients|The effects of acute exercise in alcoholic patients. Participants will cycle on ergometer for 30 min at 55-60% of Heart Rate maximal (HRmax).
11305220|NCT02664714|Active Comparator|PFMT Individualized|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s) 4(5s/10s), 5(5s/5s), 6(5s/5s), 7(6s/6s),8(6s/6s), 9(8s/8s) 10(8s/8s), 11(10s/10s),12(10s/10s)
11305221|NCT02664714|Experimental|PFMT individualized with group|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
11305222|NCT02664714|Active Comparator|12 group PFMT|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
11305223|NCT02664701|Active Comparator|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.
~Intervention: Baseline evaluation with a psychiatrist
~Intervention: Individual supportive therapy
~Intervention: Evaluations with a psychiatrist"
11305224|NCT02664701|Experimental|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.
~Intervention: Baseline evaluation with a psychiatrist
~Intervention: Cognitive behavioural group therapy
~Intervention: Evaluations with a psychiatrist"
11305225|NCT02664688|Experimental|Lumbar stabilization exercises|Home exercise program to perform daily for 6 months
11305226|NCT02664688|Active Comparator|Flexor Exercises|Home exercise program to perform daily for 6 months
11305227|NCT02664675||Periimplantitis|"patients formerly treated with a non surgical procedure without antibiotics with at least one functional dental implant with at least on pocket deeper than 5 mm with bleeding on probing and radiographical alveolar bone loss.
~These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis."
11305228|NCT02664675||Periodontitis|patients formerly treated with a non surgical procedure without antibiotics for a generalized severe chronic periodontitis (in accord to Armitage 2009) and needing a resective surgical procedure (periodontal pockets deeper than 5 mm with bleeding on probing) These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis.
11305229|NCT02664675||Healthy patient|healthy patients needing crown lengthening allowing collection of gingival explants
11305230|NCT02664662|Experimental|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
11305231|NCT02664662|No Intervention|standard education|Only provide one paper of post operation and give education of rehabilitated exercise
11305232|NCT02664649|Experimental|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].
~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
11305233|NCT02664649|Active Comparator|Standard of care|VKA or Antiplatelet therapy
11305234|NCT02664636|Experimental|The study population|"The study population consists of patients 20 and 75 years of age who have had a supra-tentorial ischemic or hemorrhagic stroke. The study covers consulting or hospitalized patients at the neurological rehabilitation service (NHS) of Grau du Roi Medical Center, part of the Nîmes University Hospital. Most patients originate from a 2-4 week stay in the neurological acute care, cardiac or polyvalent departments of the University Hospitals of Montpellier or Nîmes.
~Intervention: Physiotherapy
~Intervention: Occupational therapy
~Intervention: Functional near-infrared spectroscopy"
11305235|NCT02664623|Experimental|Dietary advice sheet|"Patients in this arm will receive a dietary advice sheet at the beginning of the study.
~Intervention: Dietary advice sheet"
11305236|NCT02664623|Experimental|Dietary advice sheet + consults with dietician|"In addition to receiving a dietary advice sheet at the beginning of the study, patients randomized to this arm will have individual consultations with a dietician at inclusion, month 1 and month 3.
~Intervention: Dietary advice sheet Intervention: Individual dietary consultations"
11305237|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
11305238|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
11305239|NCT02664597|Sham Comparator|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
11305240|NCT02664597|Experimental|ADNEXMR SCORING|In the intervention group, patients will undergo a pelvic MR imaging as routinely performed, including morphological sequences and functional sequences. Prospectively, the radiologist will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score.
11305241|NCT02664584||Cross-sectional cohort|Cohort who took part in the cross-sectional study (n=5186)
11305242|NCT02664584||Cross-sectional cohort + follow-up|Cohort who took part in both the cross-sectional and follow-up study (planned n=500 (on-going))
11305299|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
11305243|NCT02664571|Other|ACA with isolated hemosiderosis|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis.
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
11305244|NCT02664571|Other|ACA with lobar hematoma(s)|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s).
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
11305245|NCT02664571|Other|Alzheimer's without ACA|"This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA).
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
11305246|NCT02664571|Other|Healthy volunteers|"This group is composed of healthy volunteers.
~Intervention: Pet scan with FBB
~Intervention: MRI scan
~Intervention: APO E genotyping"
11305247|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
11305248|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
11305249|NCT02664545|Experimental|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into.
11305250|NCT02664545|Active Comparator|Tendon Graft|ACL reconstruction is when a tendon graft (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee) is taken and used to replace the torn ACL.
11305251|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
11305252|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
11305253|NCT02664519|Experimental|Exercise training followed by no exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
11305254|NCT02664519|Experimental|No exercise training followed by exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
11305255|NCT02664519|No Intervention|Normal Control|Control subjects without CKD will undergo baseline assessment as above.
11305256|NCT02664506|Experimental|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
11305257|NCT02664493|Experimental|SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.
~Methylprednisolone 0.5 g daily for 3 days will be administered in (Steroid pulse therapy) SPT group."
11305258|NCT02664493|No Intervention|non-SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.
~Steroid pulse therapy (SPT) will not be applied and no additional treatment will be added in non-SPT group"
11305259|NCT02664480||study group|Reproductive age women with polycystic ovary syndrome and irregular menses (Salivary Alpha-amylase Levels of 3rd and 24th day of menstrual cyclus)
11305260|NCT02664480||control group|Reproductive age women with regular menses (Salivary Alpha-amylase level of 3rd and 24th day of menstrual cyclus)
11305261|NCT02664467|Experimental|Bright light therapy (BLT)|Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
11305262|NCT02664467|Placebo Comparator|Placebo dim light|Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
11305263|NCT02664454|Experimental|Systematic nurse-led GA|Interactive educational seminar for GPs and nurses, and focused on geriatric assessment in primary care combined with Systematic nurse-led GA and dedicated hotline for GPs seeking geriatric advice
11305264|NCT02664454|Experimental|GP-led GA on a case-by-case basis, as decided by the GP|Interactive educational seminar for GPs, and focused on Geriatric assessment in primary care combined with a GP-led GA on a case-by-case basis, as decided by the GP, and a dedicated hotline for GPs seeking geriatric advice
11305265|NCT02664454|No Intervention|No intervention|No educational seminar Usual care
11305266|NCT02664441|Active Comparator|Exenatide once weekly extended-release|Injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (Bydureon®) for 36 weeks in randomized intervention followed by 18 weeks open label exenatide once weekly extended-release.
11305267|NCT02664441|Placebo Comparator|Matching placebo|Weekly injections of placebo for 36 weeks followed by 18 weeks open label exenatide once weekly extended-release.
11305268|NCT02664428|Active Comparator|PREBIOIL TEST|Product tests prepared with olives flour, buckwheat flour, pea flour, chestnut flour, oil chemical leavening agents, salt, sucrose. Baked
11305269|NCT02664428|Placebo Comparator|CONTROL|Product control prepared with wheat flour, oil, chemical leavening agents, salt, sucrose. Baked
11305270|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
11305271|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
11305272|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
11305273|NCT02664389|Experimental|Genetic analysis of patient with early-onset breast cancer|Sequencing of 200 selected genes in patient with early-onset breast cancer without genomic alterations of BRCA1, BRCA2 or TP53
11305300|NCT02664168|Active Comparator|Aquacel Ag Surgical Dressing|
11305301|NCT02664168|Active Comparator|Single-Use Negative Pressure Wound Therapy (PICO)|
11305274|NCT02664389|Experimental|Genetic analysis of patient with early-onset ovarian cancer|Sequencing of 200 selected genes in patient with early-onset ovarian cancer without genomic alterations of BRCA1, BRCA2
11305275|NCT02664389|Experimental|Genetic analysis of patient with pediatric cancer|Sequencing of 200 selected genes in patient with pediatric cancer without genomic alteration of TP53
11305276|NCT02664389|Experimental|Genetic analysis of patient with early-onset colorectal cancer|Sequencing of 200 selected genes in patient with early-onset colorectal cancer without genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation or without genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
11305277|NCT02664389|Experimental|Genetic analysis of patient with multiple primary tumors|Sequencing of 200 selected genes in patient with Multiple primary malignant tumors without syndromic presentation
11305278|NCT02664376||Geriatric ward population|Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
11305279|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
11305280|NCT02664350|Experimental|Genotype Arm|Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
11305281|NCT02664350|Active Comparator|Traditional Arm|Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
11305282|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
11305283|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
11305284|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
11305285|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
11305286|NCT02664285|Other|closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section.
11305287|NCT02664285|Other|No closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will not sutured after cesarean section.
11305288|NCT02664259|Experimental|UTB-VBN-EBUS group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
11305289|NCT02664259|Active Comparator|UTB-VBN-EBUS-X-ray group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
11305290|NCT02664233|Experimental|Connected group|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
11305291|NCT02664233|No Intervention|Usual diabetes education and care|Participants will receive standard diabetes education and care; each of the recruiting clinics offers diabetes self-management education programs.
11305292|NCT02664220|Experimental|Povidone-iodine irrigation|
11305293|NCT02664220|Active Comparator|No irrigation|
11305294|NCT02664207|Experimental|Fetal Surgery in Women with ex|"Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:
~a BMI greater than 35 (but less than or equal to 40 kg/m2)
~(minor) Fetal structural abnormality
~(well-controlled) Diabetes
~Previous preterm delivery (followed by a full term delivery)
~Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).
~Intervention: Open Fetal Repair of Myelomeningocele"
11305295|NCT02664194|Active Comparator|Control Group|Primary percutaneous coronary intervention only
11305296|NCT02664194|Experimental|03 Hours Hypothermia Group - Proteus® Cooling System|03 hours of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
11305297|NCT02664194|Experimental|01 Hour Hypothermia Group - Proteus® Cooling System|01 hour of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
11305298|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
11305302|NCT02664155|Experimental|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:
~Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months
~Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
11305303|NCT02664155|Active Comparator|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
11305304|NCT02664142|Experimental|BIS Group|"BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)
~GA induction (Phase 1):
~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
~anaesthesia (Phase 2, Phase 3):
~hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
11305305|NCT02664142|Experimental|Non-BIS Group|"BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)
~GA induction (Phase 1):
~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or
~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)
~anaesthesia (Phase 2, Phase 3):
~hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)
~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)
~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
11305306|NCT02664129|Experimental|Experimental group with video|30 patients will watch the video of them in acute decompensation phase
11305307|NCT02664129|Sham Comparator|Control group without video|30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales
11305308|NCT02664116|Experimental|Cambia|Diclofenac postassium powder for oral solution and placebo injection
11305309|NCT02664116|Active Comparator|ketorolac|ketorolac intramuscular injection and placebo oral solution
11305310|NCT02664103|Experimental|SAR439281(Cohort 1)|Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
11305311|NCT02664103|Experimental|SAR439281(Cohort 2)|Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
11305312|NCT02664103|Experimental|SAR439281(Cohort 3)|Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
11305313|NCT02664077|Experimental|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
11305314|NCT02664077|Placebo Comparator|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
11305315|NCT02664064|Experimental|online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants receive online curriculum, access to a live health coach, interactive group message forums, and connected weight and activity monitoring devices.
11305316|NCT02664064|No Intervention|Matched Control|A de-identified dataset of control subjects matched on age, gender, prediabetes diagnosis, body mass index, comorbidities and socioeconomic status will be cultivated for comparison to the active intervention arm.
11305317|NCT02664051|Placebo Comparator|placebo|mannitol
11305318|NCT02664051|Active Comparator|disodium cromoglycate|disodium cromoglycate
11305319|NCT02664038|Experimental|CRT+IDC|Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling
11305320|NCT02664038|Active Comparator|Computer Game Play+IDC|Computer arcade games for 13 weeks plus Individual Drug Counseling
11305321|NCT02664025|Active Comparator|simulation group|Interns will carry out 10 VE on a simulator
11305322|NCT02664025|No Intervention|Control group|Interns who will not perform any simulated VE
11305323|NCT02664012|Active Comparator|Own Brand Menthol Cigarette|Own Brand Menthol Cigarette
11305324|NCT02664012|Experimental|Electronic Menthol Cigarette #1|VUSE® (menthol flavor, 14 mg nicotine)
11305325|NCT02664012|Experimental|Electronic Menthol Cigarette #2|VUSE® (menthol flavor, 29 mg nicotine)
11305326|NCT02664012|Experimental|Electronic Menthol Cigarette #3|VUSE® (menthol flavor, 36 mg nicotine)
11305327|NCT02664012|Active Comparator|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
11305328|NCT02663999|Experimental|diazepam nasal spray (AB)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
11305329|NCT02663999|Experimental|diazepam nasal spray (BA)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
11305330|NCT02663986|Experimental|Organizational Skills Training (OST) Intervention|"To improve children's organizational functioning, OST focuses on four key skills.
~Tracking Assignments
~Managing Materials
~Time Management
~Task Planning"
11305331|NCT02663960|Experimental|fixed citrate doses protocol|Fixed citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which was set to meet a circuit citrate concentration of 4 mmol/l (duration: the maximum time is 72 hrs).
11305369|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
11305552|NCT02662452|Placebo Comparator|Placebo multiple doses|Multiple doses of placebo oral suspension
11305332|NCT02663960|Active Comparator|adjusted citrate doses protocol|Adjusted citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which the starting infusion rate be set 2.5 % of blood flow ( dosage range: 160-250ml/h) and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l (duration: the maximum time is 72 hrs. )
11305333|NCT02663947||ultrasound group|ultrasonographic measure for optic nerve sheath diameter
11305334|NCT02663934|Experimental|Exercise (EXS)|All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity & duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.
11305335|NCT02663934|Active Comparator|Social Interaction Stretching (SIS)|This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.
11305336|NCT02663921|Experimental|Healthy volunteers|Healthy volunteers without cutaneous disorders associated with pigmentary changes
11305337|NCT02663908|Experimental|Degarelix|
11305338|NCT02663908|Active Comparator|Leuprolide|
11305339|NCT02663895|Experimental|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
11305340|NCT02663882|Experimental|smoking-related self control task|self control practice - smoking related task
11305341|NCT02663882|Active Comparator|Non-smoking-related self control task|self control practice - non-smoking related task
11305342|NCT02663869||HIV Aging-Young|200 patients
11305343|NCT02663869||HIV Aging-Old|200 patients
11305344|NCT02663869||controls|1200 patients
11305345|NCT02663843|Experimental|i-gel airway|I-gel inserted for the low skill fibreoptic intubation technique
11305346|NCT02663843|Experimental|air-Q airway|Air-Q inserted for the low skill fibreoptic intubation technique
11305347|NCT02663830|Experimental|(Sildenafil & clomiphene citrate group)|105 Patients will receive 25 mg sildenafil citrate 6 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
11305348|NCT02663830|Active Comparator|clomiphene only|105 patients will receive only clomiphene citrate 100mg/day (day 2 to 6) orally (2 tablets at same time daily).
11305349|NCT02663817|Experimental|IMRT|Study participants being treated according to the standard of care with intensity modulated radiotherapy (IMRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
11305350|NCT02663804|Active Comparator|Implant design 1|Journey II, BCS, Smith&Nephew
11305351|NCT02663804|Active Comparator|Implant design 2|Persona, Zimmer
11305352|NCT02663804|Active Comparator|Implant design 3|Unity, Corin
11305353|NCT02663778|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
11305354|NCT02663778|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
11305355|NCT02663752|Other|Deferasirox|All patients are already on commercial deferasirox before entering the study.
11305356|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
11305357|NCT02663726|Experimental|Yoga intervention group|10 weekly 75-min sessions of specialised yoga plus written advice about physical activity for older adults
11305358|NCT02663726|Active Comparator|Waiting list control group|Usual care plus written advice about physical activity for older adults
11305359|NCT02663713|Experimental|Ticagrelor|Ticagrelor 60 mg twice daily
11305360|NCT02663713|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily
11305361|NCT02663700|Experimental|1.8x10^6 sporozoites 2 doses|To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 3 and 11. n=8
11305362|NCT02663700|Experimental|2.7x10^6 sporozoites 2 doses|To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 5 and 13. n=8
11305363|NCT02663700|Experimental|2.7x10^6 sporozoites 3 doses|Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80
11305364|NCT02663700|Experimental|4.5x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 4.5x10^5 sporozoites on study weeks 1 and 9. n=8
11305365|NCT02663700|Experimental|9x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 9x10^5 sporozoites on study weeks 1 and 9. n=8
11305366|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
11305367|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
11305368|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
11305370|NCT02663661|Other|Autoantibody negative subjects|Subjects who are relatives of persons with T1DM and have tested negative for autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test.
11305371|NCT02663661|Other|One autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for one autoantibody will have a Metabolic Challenge Admission followed by a CGM home test..
11305372|NCT02663661|Other|Two or more autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for two or more autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test..
11305373|NCT02663635|Other|Single Arm|
11305374|NCT02663622|Active Comparator|CD24Fc|"CD24Fc will be given in three dose cohorts. CD24Fc in 240 mg as intravenous (IV) infusion at Day -1 CD24Fc in 480 mg as intravenous (IV) infusion at Day -1 CD24Fc (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) as intravenous infusion.
~All cohorts + Tacrolimus (begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT)."
11305375|NCT02663622|Placebo Comparator|Placebo|Placebo (saline IV injection solution) + Tacrolimus (begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT)
11305376|NCT02663622|Active Comparator|CD24Fc Expansion|CD24Fc (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT)
11305377|NCT02663596|Experimental|Vancomycin|Patients with vancomycin mixed in the CRRT solution(s)
11305378|NCT02663583||Intensity-Modulated Proton Therapy or( IMPT) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.
~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.
~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
11305379|NCT02663583||TransOral Robotic Surgery (TORS) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.
~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.
~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
11305380|NCT02663570|Experimental|open|therapy with melatonin 2 mg daily for six months
11305381|NCT02663557||non-hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP<140 mmHg; 2. Systolic blood pressure-coefficient variation (SBP-CV) < Median SBP-CV
11305382|NCT02663557||non-hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP< 140 mmHg; 2. SBP-CV > Median SBP-CV
11305383|NCT02663557||hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV < Median SBP-CV
11305384|NCT02663557||hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV > Median SBP-CV
11305385|NCT02663544|Active Comparator|Limited dairy diet|Three 8 oz. servings per week of non-fat milk. Participants will otherwise eat their usual diet, but will be asked not to consume any dairy products not provided by the study.
11305386|NCT02663544|Experimental|Low-fat dairy diet|3.3 daily servings of non-fat and low-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
11305387|NCT02663544|Experimental|Full-fat dairy diet|3.3 daily servings of full-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
11305388|NCT02663531|Experimental|Mild cognitive impairment|Patients with mild cognitive impairment
11305389|NCT02663531|Experimental|Alzheimer Disease|Patients with Alzheimer Disease
11305390|NCT02663531|Experimental|Healthy|Healthy volunteers
11305391|NCT02663518|Experimental|TTI-621 Escalation Phase|The Escalation Phase will include multiple doses of TTI-621
11305392|NCT02663518|Experimental|Indolent B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
11305393|NCT02663518|Experimental|Aggressive B-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
11305394|NCT02663518|Experimental|T-Cell Lymphoma|Monotherapy expansion cohort with TTI-621
11305395|NCT02663518|Experimental|Hodgkin Lymphoma|Monotherapy expansion cohort with TTI-621
11305396|NCT02663518|Experimental|Chronic Lymphocytic Leukemia|Monotherapy expansion cohort with TTI-621
11305397|NCT02663518|Experimental|Acute Lymphoblastic Leukemia|Monotherapy expansion cohort with TTI-621
11305398|NCT02663518|Experimental|Multiple Myeloma|Monotherapy expansion cohort with TTI-621
11305399|NCT02663518|Experimental|Acute Myeloid Leukemia|Monotherapy expansion cohort with TTI-621
11305400|NCT02663518|Experimental|Myelodysplastic Syndrome|Monotherapy expansion cohort with TTI-621
11305401|NCT02663518|Experimental|Myeloproliferative Neoplasms|Monotherapy expansion cohort with TTI-621
11305402|NCT02663518|Experimental|Small Cell Lung Cancer|Monotherapy expansion cohort with TTI-621
11305403|NCT02663518|Experimental|Rituximab Combination|Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies
11305404|NCT02663518|Experimental|Nivolumab Combination|Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma
11305405|NCT02663518|Experimental|Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion cohort with TTI-621
11305406|NCT02663518|Experimental|Peripheral T-Cell Lymphoma (PTCL)|Monotherapy expansion cohort with TTI-621
11305407|NCT02663518|Experimental|Part 4: Cutaneous T-Cell Lymphoma (CTCL)|Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621
11305408|NCT02663505||Group 1|Patients receiving either elective or emergency surgery.
11305463|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
11305409|NCT02663492|Experimental|TEAS group|Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
11305410|NCT02663492|Active Comparator|Medication group|On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
11305411|NCT02663492|No Intervention|Control group|The patients of control group receive routine nursing care, including (1) to be observed the changes in patient condition, (2) to eat high-calories, high-protein, high-vitamin, easy-to-digest foods during chemotherapy, (3) to be treated by psychological care, (4) to be prevented against the occurrence of phlebiti, and (5) to use Ondansetron and Omeprazole as direction.
11305412|NCT02663479|Experimental|Cardiopressin|A 5 capsule proprietary blend of herbal extracts and nutrients
11305413|NCT02663479|Placebo Comparator|Placebo|A 5 capsule placebo matched in color and size to the Experimental supplement
11305414|NCT02663466||Recurrent Group|Patients with clinically confirmed recurrence of sacrococcygeal pilonidal sinus following Limberg flap surgery were eligible (recurrent group, RG). They were evaluated for erroneous off-midline closures as an exposure variable.
11305415|NCT02663466||Nonrecurrent Group|Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
11305416|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
11305417|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
11305418|NCT02663440|Experimental|IMRT|Hypofractionated IMRT With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor
11305419|NCT02663427|Experimental|PG(-) and Hp(-) Group|PG negative （pepsinogen（PG）Ⅰ > 70ng/ml or PGⅠ/PGⅡ >7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
11305420|NCT02663427|Experimental|PG(-) and Hp(+) Group|PG negative and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
11305421|NCT02663427|Experimental|PG(+) and Hp(-) Group|PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0) and Hp negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
11305422|NCT02663427|Experimental|PG(+) and Hp(+) Group|PG positive and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
11305423|NCT02663414|Experimental|Atlas device|Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
11305424|NCT02663401|No Intervention|Control|Control situation in campus cafeterias where no labelling of food is proposed
11305425|NCT02663401|Experimental|Front-of-pack labelling (5-CNL)|Introduction of the 5-CNL front-of-pack nutrition label on shelf display tags for every food and beverage sold in the campus cafeteria. Communication campaigns accompanying the introduction of the label
11305426|NCT02663375||ACURATE TA™ Transapical Aortic Biorposthesis|Patients implanted with ACURATE TA™ Transapical Aortic Biorposthesis and Delivery System
11305427|NCT02663349|Experimental|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One hour group sessions will be offered twice a week for 12 weeks. In addition, one hour of individual training will be provided weekly by an instructor.
11305428|NCT02663336||CKD patients|Patients with chronic kidney disease, with diagnosed arterial hypertension and normal blood pressure during office blood pressure measurement. Comparison of ambulatory blood pressure (ABPM) with office blood pressure measurements (OBPM).
11305429|NCT02663323|Experimental|MeRes100 - BRS|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
11305430|NCT02663310|Experimental|Surgery with Rehabilitation|Surgically removed cysts, and collected intracystic fluids and cerebrospinal fluid for histological and molecular analyses. Samples will be collected during the surgery and will be cryo-protected for further analyses. All subjects will enroll for intensive rehabilitation 60 days after surgery.
11305431|NCT02663310|Active Comparator|Rehabilitation|All subjects will enroll for intensive rehabilitation everyday as instruction.
11305432|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.
~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
11305433|NCT02663284|Experimental|Perineural block|Perineural block with Ropivacaine 0.5%
11305464|NCT02663063|Experimental|SSP treatment group|Case on SSP treatment
11305465|NCT02663063|Sham Comparator|Non-SSP treatment group|Sham SSP treatment
11305466|NCT02663050|Experimental|Kinesio taping group|only Kinesio taping treatment group
11359053|NCT02307487|Experimental|Cohort A|120 mg MMC in 60ml gel
11305434|NCT02663271|Experimental|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
11305435|NCT02663271|Other|Historical Controls|Historical controls treated with continuous bevacizumab alone or in combination with standard chemotherapy will be compared with the Optune arm. Information will be collected: Bevacizumab or additional chemotherapy, physical examination and quality of life questionnaires performed and brain MRI.
11305436|NCT02663258|Experimental|Pembrolizumab arm|All participants treated with Pembrolizumab, 200mg iv, 3weekly
11305437|NCT02663245|Experimental|Intervention 1|Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
11305438|NCT02663245|Experimental|Intervention 2|Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
11305439|NCT02663245|No Intervention|Control group|No intervention. Data of the control groups will be retrieved from the SIDIAP.
11305440|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
11305441|NCT02663219|Experimental|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
11305442|NCT02663219|No Intervention|Control|Standard of care
11305443|NCT02663206|Other|Botulinum toxin injection|"Drug/Device: Botulinum toxin injection; Endoscopic Botulinum toxin (BTX) injection at lower esophagus; Upper endoscopy with Botulinum toxin injection.
~The procedure will be performed as an outpatient basis by an endoscopist. Sedation can be in form of conscious sedation, monitored anesthesia care or general anesthesia. An upper endoscope will be inserted into the patient's mouth and advanced into lower esophagus. Botulinum toxin (Botox@) 100 units 8-10 (25 units/mL) will be injected in 1-ml portion in each of four quadrants about 1 cm above the Z-line (the LES region).
~At 1 month follow-up, patients who do not response to the first botox injection (Eckardt score > 3) will receive the second botox injection.
~At 3-month follow-up, POEM will be offered as a rescue therapy to both non-responders (Eckardt score > 3 at 3-month follow-up after the procedure) and relapsers (Eckardt score ≤ 3 at 3-month follow-up but becomes > 3 during the follow-up)"
11305444|NCT02663206|Other|peroral endoscopic myotomy|"Procedure/Surgery: peroral endoscopic myotomy.
~The procedure will be performed by an endoscopist (gastroenterologist or surgeon). General anesthesia will be started and upper endoscope will be inserted into the patient's mouth and advanced into the stomach. Endoscopic myotomy will be performed. Mucosal entry will then be closed using endoscopic clips or endoscopic suturing.
~All patients will recover from their procedures according to standard practice. They will remain nothing per oral (NPO) the night after the procedure and started on intravenous proton pump inhibitors. A gastrografin esophagram will be obtained the next day and if no evidence of leak, the diet will be advanced to a soft diet for two weeks. The patients will be evaluated by study coordinator/PI on a daily basis during their hospitalization."
11305445|NCT02663193||Enzalutamide Group|Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
11305446|NCT02663193||Abiraterone Acetate plus Prednisone group|Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
11305447|NCT02663180|Experimental|Intervention group|they will be enrolled in an educational program and video contact.
11305448|NCT02663180|No Intervention|Control group|No intervention
11305449|NCT02663167|Experimental|Internet-delivered Cognitive-Behavioral Therapy|
11305450|NCT02663154|Experimental|Aromatherapy|Aromatherapy inhaler (QueaseEASE, Soothing Scents Inc, Enterprise, AL) applied to nauseous post surgical paediatric patients in the postanesthetic care unit
11305451|NCT02663154|Placebo Comparator|Placebo|Saline inhaler applied to nauseous post surgical paediatric patients in the postanesthetic care unit
11305452|NCT02663141|Experimental|Losartan|Oral losartan 50 mg daily for 6 months
11305453|NCT02663141|Placebo Comparator|Placebo|Oral placebo daily for 6 months
11305454|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
11305455|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
11305456|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
11305457|NCT02663115||Arm 1|Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy
11305458|NCT02663115||Arm 2|Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF>50%)
11305459|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
11305460|NCT02663089|Experimental|[14C]-GSK961081 IV+GSK961081 inhalation; [14C]-GSK961081 oral|On Day 1 of Treatment Period 1, after an overnight fast of at least 8 hours, each subject will receive [14C] GSK961081 4 micrograms (mcg) by IV infusion over 1 hour. Within 5 minutes after the start of infusion, subjects will take 1200 mcg non-radiolabelled GSK961081 by inhalation. After Treatment Period 1, there will be a washout of at least 2 weeks. On Day 1 of Treatment Period 2, after an overnight fast of at least 8 hours, each subject will take 200 mcg [14C]-GSK961081 as an oral solution.
11305461|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
11305462|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
11305469|NCT02663037||1|"Subjects will be recruited from a pool of elderly patients who present to the Emergency Department.
~To be eligible for participation in the study, patients must meet ALL of the following criteria:
~Age ≥ 55 years old
~Triaged as P2 or P3 in the Emergency Department
~Singapore citizen or Permanent Resident
~Provision of Informed consent
~Not previously already enrolled in this study"
11305470|NCT02663024|Experimental|Arm 1|0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
11305471|NCT02663024|Experimental|Arm 2|1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
11305472|NCT02663024|Experimental|Arm 3|1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
11305473|NCT02663024|Active Comparator|Arm 4|0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
11305474|NCT02663011||5YR boy|
11305475|NCT02663011||5YR girl|
11305476|NCT02663011||4YR boy|
11305477|NCT02663011||4YR girl|
11305478|NCT02663011||3YR boy|
11305479|NCT02662985|Active Comparator|Group 1|"In Treatment Period-1:
~Patients in this group will be administered secukinumab with 12 weeks of treatment from baseline.
~In Treatment Period-2:
~Patients will continue to receive the same active dose of secukinumab every 4 weeks until Week 24
~In Treatment Period 3 (extension period):
~the extension period is to allow responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
11305480|NCT02662985|Placebo Comparator|Group 2|"In Treatment Period-1:
~Patients will receive placebo at baseline and same time points as secukinumab until Week 8.
~In Treatment Period-2:
~Patients will commence open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12
~In Treatment Period-3:
~Open-label secukinumab will continue to be assigned to patients"
11305481|NCT02662972|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards the sphenopalatine ganglion in the affected side (ipsilateral to the pain)
11305482|NCT02662959|Experimental|Irinotecan|In the experimental arm, patients receive single agent of irinotecan as third line treatment in metastatic gastric cancer.
11305483|NCT02662946|Experimental|ICG- angiography|"Colonic resection margins and colo-rectal anastomosis are intraoperatively assessed using fluorescence angiography to evaluate colonic perfusion. If perfusion at the resection margin is judged insufficient the colon is re-resected to obtain a satisfactory perfusion"
11305484|NCT02662946|Active Comparator|No angiography|Subjective measures are employed to determine anastomotic perfusion
11305485|NCT02662933|Experimental|Bedside Assessment Measures|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.
~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
11305486|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
11305487|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
11305488|NCT02662894|Experimental|Valsartan 160mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.
11305489|NCT02662894|Experimental|Valsartan 320mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.
11305490|NCT02662894|Active Comparator|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
11305491|NCT02662894|Active Comparator|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
11305492|NCT02662855|Active Comparator|Control|WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
11305493|NCT02662855|Experimental|Treatment|WHO-recommended therapies plus oral administration of Favipiravir
11305494|NCT02662842||FlowSmart Infusion set, then current set|Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
11305495|NCT02662829|Experimental|Community-based intervention (CBI)|"Nurse training and mentorship in TB prevention using clinical algorithm based on national guidelines.
~Health education using a treatment literacy curriculum for parents and guardians.
~Community outreach by trained village health workers."
11305548|NCT02662465|Experimental|mucositis grade 3, laser 790|Group 3 included patients with oral mucositis grade 3 Sera used laser diode AsGaAl operating in continuous mode, with a wavelength of 790 nm, power of 100mW and fluency of 8 J / cm².
11305549|NCT02662452|Experimental|GLPG2222 single dose|Single dose of GLPG2222 oral suspension
11305550|NCT02662452|Placebo Comparator|Placebo single dose|Single dose of placebo oral suspension
11305551|NCT02662452|Experimental|GLPG2222 multiple doses|Multiple doses of GLPG2222 oral suspension
11305496|NCT02662829|Active Comparator|Standard of Care (SOC)|At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
11305497|NCT02662816|Experimental|glutathion|The study will validate the detection and the quantification of glutathione in muscle and liver using 1H MRS
11305498|NCT02662803|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
11305499|NCT02662803|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
11305500|NCT02662790|Experimental|Preterm|
11305501|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
11305502|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
11305503|NCT02662751|Active Comparator|Routine Imaging|"Patients randomized to this arm will have routine post-stroke/TIA imaging assessments.
~Intervention: Routine Imaging Assessment"
11305504|NCT02662751|Experimental|LDWBA first|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.
~Intervention: LDWBA first followed by Routine Imaging Assessment if required."
11305505|NCT02662738|Active Comparator|A wheat product|A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
11305506|NCT02662738|Placebo Comparator|Control|A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
11305507|NCT02662738|Other|Glucose solution|A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
11305508|NCT02662725|Experimental|ipilimumab + Stereotactic Radiosurgery|ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
11305509|NCT02662712|Experimental|Part 1: Single Dose Escalation|The single dose escalation phase of the study will consist of 6 dosing sessions (Sessions I to VI) evaluated in 2 panels (Panels 1 and 2). The dose of JNJ-56136379 will be consecutively escalated over 5 levels, alternating between the 2 panels. Panel 1 will receive 3 single doses (SD1, SD3 and SD3fed) in Sessions I, III and V, respectively. Panel 2 will receive 3 single doses (SD2, SD4 and SD5) in Sessions II, IV and VI, respectively. There will be a washout period of at least 14 days between consecutive JNJ-56136379/placebo dosing in each individual participant.
11305510|NCT02662712|Experimental|Part 1: Multiple dose session|After completion of the fifth single dose session another panel of healthy participant (panel 3) receive multiple doses of JNJ-56136379 at one dose level (MDx) or placebo for 12 or 19 consecutive days (Session VII) in fed or fasted conditions.
11305511|NCT02662712|Experimental|Part 2: Multiple dose escalation|Multiple dose levels will be given in Panel 4 in Session VIII (European sites), Sessions IX and X (European and/or Asian sites) Session XI (Asian sites) for 28 consecutive days in fed conditions. Optional Sessions A-B-C (Panel 4) used for further dose evaluations at European and/or Asian sites. Per session, participants will receive JNJ 56136379 or placebo. Dose progression to the next multiple dose level may be adapted based on the emerging safety and PK outcome of the previous dosing levels.
11305512|NCT02662686|Active Comparator|Control|Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).
11305513|NCT02662686|Experimental|MitoScore|Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.
11305514|NCT02662673|Other|Localized prostate cancer, Focal treatment.|
11305515|NCT02662660|Experimental|Port-sites infiltration:Bupivacaine0,25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
11305516|NCT02662660|Experimental|Epidural analgesia:Levobupivacaine0.125%|"Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.
~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours."
11305517|NCT02662660|Active Comparator|Metamizole and Acetaminophen iv|Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
11305518|NCT02662647|Experimental|DCAG plus HLI|Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion.
11305519|NCT02662647|Experimental|DCAG|Patient will be treated with decitabine combining modified CAG regimen without other treatments.
11305520|NCT02662634|Experimental|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
11305521|NCT02662634|Experimental|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.
~Platinum-doublet chemotherapy can be any of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
11305522|NCT02662634|Experimental|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).
~Radiation therapy per PI"
11305523|NCT02662634|Experimental|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.
~Platinum-doublet chemotherapy choice of the following determined by PI
~Carboplatin/Abraxane:
~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.
~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.
~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.
~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).
~Radiation therapy per PI."
11305524|NCT02662621|Other|ill patient|Patient with a cancer disease
11305525|NCT02662621|Other|Healthy volunter|Subject without any cancer pathology
11305526|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
11305527|NCT02662595|No Intervention|Control|
11305528|NCT02662595|Active Comparator|Text message|Subjects in this arm will receive a text message reminder in due time for measles vaccination.
11305529|NCT02662595|Active Comparator|Text message and voice call|Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
11305530|NCT02662582|Experimental|CK-2127107 1000 mg, then placebo|Participants will first receive CK-2127107 (500 mg twice daily [1000 mg daily total]) for 14 days. After a washout period of 14 days, participants will then receive matching placebo for 14 days.
11305531|NCT02662582|Experimental|Placebo, then CK-212710 1000 mg|Participants will first receive placebo for 14 days. After a washout period of 14 days, participants will then receive matching CK-2127107 (500 mg twice daily [1000 mg daily total]) for 14 days.
11305532|NCT02662569|Active Comparator|Atorvastatin (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
11305533|NCT02662569|Active Comparator|Atorvastatin (QM)|Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
11305534|NCT02662569|Experimental|Evolocumab Q2W + Atorvastatin|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
11305535|NCT02662569|Experimental|Evolocumab QM + Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
11305536|NCT02662556|Experimental|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
11305537|NCT02662543||Hospitalized AGE patients|Children less than 18-years-old hospitalized due to acute gastroenteritis to seven Estonian hospitals participating in this study
11305538|NCT02662530|Active Comparator|Botulinum toxin type A clinical|Initial and optimization of BoNT-A injection parameters will be conducted by clinical visual assessment
11305539|NCT02662530|Active Comparator|Botulinum toxin type A kinematic|Initial and optimization of BoNT-A injection parameters will be conducted by kinematic assessment
11305540|NCT02662504|Experimental|multimodal treatment + intrapleural PDT|"surgery of the MPM: extended pleurectomy/decortication (eP/D)
~intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.
~then:
~prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray)
~adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation"
11305541|NCT02662491|Experimental|vitamin D and calcium|daily oral vitamin D(3) (2000 IU) and calcium (600 mg) for 6 months
11305542|NCT02662491|Experimental|Calcium supplement|daily oral calcium (600 mg) for 6 months
11305543|NCT02662491|Experimental|vitamin D supplement|daily oral vitamin D(3) (2000 IU) for 6 months
11305544|NCT02662491|Placebo Comparator|Placebo|daily placebo tablet for 6 months
11305545|NCT02662478||primary gastric GIST|Consisted of all consecutive cases of primary gastric stromal tumors (PGST) that underwent laparoscopic surgery (LS).
11305546|NCT02662465|Experimental|mucositis grade 1, laser 660|Group 1 will include patients with oral mucositis grade 1. Sera used wavelength of 660nm, power 100mW and lluencia of 4 J / cm².
11305547|NCT02662465|Experimental|mucositis grade 2, laser 660|Group 2 included patients with oral mucositis grade 2. Sera used with a wavelength of 660nm, power 100mW and lluencia of 8 J / cm².
11305553|NCT02662439|Experimental|BCM group|The patients are measured by Body Composition Monitor (BCM) and both the patient and the physician know the results and adjust the diuretic therapy accordingly.
11305554|NCT02662439|Placebo Comparator|Control group|The patients are measured by Body Composition Monitor (BCM) but neither the patient nor the physician know the results, the physician adjusts the diuretic therapy as usual, according to the protocols.
11305555|NCT02662426|Experimental|Drugs for experimental group|Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
11305556|NCT02662426|Active Comparator|Drugs for positive control group|Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day.Drugs must be used on the day of fever and last for five days continuously.
11305557|NCT02662426|Placebo Comparator|Drugs for placebo control group|Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
11305558|NCT02662400|Experimental|MNCs GROUP|Patients with Type 2 Diabetes mellitus
11305559|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
11305560|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
11305561|NCT02662374|Active Comparator|Control|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid
11305562|NCT02662374|Experimental|Group 1|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Extra soft toothbrush, brushing with saline bd
11305563|NCT02662374|Experimental|Group 2|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Supersaturated Calcium Phosphate Spray, 5ml qid
11305564|NCT02662361||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
11305565|NCT02662361||peri-implant disease|The subjects who suffered from peri-implant disease.
11305566|NCT02662348|Experimental|Interleukin-2 Transfusion|Patients receive low-dose Recombinant Human Interleukin-2 SC daily beginning 3 days before the first HER2Bi armed T cell infusions infusion.
11305567|NCT02662348|Experimental|T Cells Transfusion|Patients receive HER2Bi-Armed T Cells IV weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11305568|NCT02662335|Experimental|Arm I (computer-assisted cognitive training)|Patients complete a computerized working memory training program (Cogmed) over 35 minutes a day, 5 times a week for 6 weeks.
11305569|NCT02662335|Active Comparator|Arm II (wait-list)|Patients undergo standard follow-up care for 6 weeks. Following standard follow-up care, patients may complete Cogmed as in the Intervention Group in weeks 7-13.
11305570|NCT02662322|Experimental|HYPNOSIS|hypnotic communication, confusion procedure during peripheral intravenous catheterization
11305571|NCT02662322|Active Comparator|NOCEBO|negative connotation communication during peripheral intravenous catheterization
11305572|NCT02662322|Placebo Comparator|NEUTRAL|neutral connotation communication during peripheral intravenous catheterization
11305573|NCT02662309|Experimental|MPDL3280A|Patients receive 2x 3-weekly cycles of MPDL3280A (one infusion on the first day of each cycle) prior to cystectomy surgery.
11305574|NCT02662296|Experimental|Treatment (ibrutinib or idelalisib)|Patients receive ibrutinib PO QD on days 1-28 or idelalisib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11305575|NCT02662283|Active Comparator|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
11305576|NCT02662283|Experimental|Reh-acteoside|Oral take reh-acteoside (0.4g bid) for 8 weeks
11305577|NCT02662283|Experimental|Reh-acteoside+Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) and reh-acteoside (0.4g bid) for 8 weeks
11305578|NCT02662270||Cases|Patients with a fibromyalgia diagnosis established according to the American College of Rheumatology current criteria by a trained physician.
11305579|NCT02662270||Controls|Healthy subjects paired by age and gender to the subjects in the cases group.
11305580|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
11305581|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
11305582|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
11305583|NCT02662218||Patients with superficial wounds|A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible.
11305584|NCT02662205|Active Comparator|Traditional Group|Traditional process psychotherapy group
11305585|NCT02662205|Experimental|Yoga Therapy Group|Psychotherapy group integrating yoga and process dialogue
11305586|NCT02662205|Active Comparator|Yoga Class|Yin yoga class
11305587|NCT02662192|Experimental|Intervention|Exercise + health education + auditory rehabilitation 10 weeks of exercise, interactive health education, socialization and auditory rehabilitation program
11305588|NCT02662192|Active Comparator|Auditory rehabilitation alone|"auditory rehabilitation alone
~1 hour of group auditory rehabilitation once a week for 10 weeks"
11305589|NCT02662179||Elderly patients with solid tumors|The group will include elderly patients with a malignant solid tumor: ovary cancer, breast cancer, digestive cancer (colo-rectal, pancreas), lung cancer or urinary tract cancer (including bladder cancer).
11305590|NCT02662166|Experimental|MRI and biomarkers in bladder cancer|Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity
11305591|NCT02662153||Long-term opioid-use cohort|Persons who have received 70 or more days of Schedule II opioid dispensed in a 90-day period, after at least 183 days with no opioid dispensing.
11305592|NCT02662153||IR/SA to ER/LA Switchers|Persons who have switched to or added on an ER/LA product after stable use of an IR/SA opioid regimen.
11305593|NCT02662153||IR/SA to IR/SA Switchers|Persons who have switched to or added on a new IR/SA opioid after stable use of a different IR/SA opioid regimen.
11305594|NCT02662140|Experimental|Mobile Health Application Group|"emobile health application will enhance the existing evidence informed curriculum of a Multiple Family Group model (called 4 Rs and 2 Ss for Strengthening Families Model) for families with children who have disruptive behavior disorders. This mobile application consists of two primary components that will support engagement and integration of the model's core concepts in family life. The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
11305595|NCT02662127|Experimental|SIGVARIS®. Class 2 - RAL: 23-32|Graduated elastic compression stockings
11305596|NCT02662114||Tresiba®|
11305597|NCT02662101|Experimental|Single arm, exsalt application|
11305598|NCT02662088||Laparoscopic-lavage|Patients with colonic diverticulitis submitted to laparoscopic lavage
11305599|NCT02662075|Experimental|E-cigarette/tobacco Smoking Exposure|
11305600|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
11305601|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
11305602|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
11305603|NCT02662023|Experimental|Bolus|ropivacaine 0.2% administration as repeated, scheduled (one/3 h) bolus doses (24 mL) x 6 h
11305604|NCT02662023|Active Comparator|Basal|ropivacaine 0.2% administration as a continuous basal infusion (8 mL/h) x 6 h
11305605|NCT02661997|Experimental|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
11305606|NCT02661997|Active Comparator|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
11305607|NCT02661984||Healthy (no pulmonary disease)|Healthy children 4 - 6 years old with no pulmonary disease and not exhibiting respiratory illness or sinusitis.
11305608|NCT02661984||Asthmatic (physician diagnosed)|Asthmatic children 4 - 6 years old not exhibiting acute asthma symptoms, respiratory illness or sinusitis.
11305609|NCT02661971|Active Comparator|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
~Docetaxel 50 mg/m², d1
~Oxaliplatin 85 mg/m², d1
~Calciumfolinat 200 mg/m², d1
~5-Fluorouracil 2600 mg/m², d1"
11305610|NCT02661971|Experimental|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab
~Ramucirumab 8mg/kg, d1
~Docetaxel 50 mg/m², d1
~Oxaliplatin 85 mg/m², d1
~Calciumfolinat 200 mg/m², d1
~5-Fluorouracil 2600 mg/m², d1"
11305611|NCT02661958|Experimental|S6G5T-3|topical cream
11305612|NCT02661958|Experimental|S6G5T-1|topical cream
11305613|NCT02661958|Active Comparator|S6G5T-5|topical cream
11305614|NCT02661958|Active Comparator|S6G5T-7|topical cream
11305615|NCT02661958|Active Comparator|S6G5T-6|topical cream
11305616|NCT02661958|Placebo Comparator|S6G5T-8|topical cream
11305617|NCT02661945|Experimental|Near focus with narrow band imaging|Near focus with narrow band imaging is used for marking the tumor margin.
11305618|NCT02661945|No Intervention|Indigo carmin|After indigo carmine was sprayed over the lesion, marking is performed.
11305619|NCT02661932|Experimental|Letrozole associated COS|"Breast cancer patients undergo fertility preservation with letrozole associated COS for oocyte collection.
~Letrozole is administered orally (5mg/day) during the entire stimulation protocol until ovulation triggering."
11305620|NCT02661919|Experimental|Emfit mattress sensor|
11305742|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to <60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
11305621|NCT02661906|Experimental|SKY Pre|Sudarshan Kriya Yoga is provided to all the enrolled participants. The baseline characteristics of patient is compared with that of their characteristics after yoga intervention. All the participants were provided with yoga training for 6 days and then asked to perform the SKY at home daily till 12 week. The questionnaire on anxiety, depression and quality of life were administered at the baseline and at the end of 6 days of yoga. Biochemical parameters such as HbA1c, lipid profile, fasting glucose and post meal glucose were measured at baseline and after 12 week of intervention.
11305622|NCT02661906|Active Comparator|SKY post|The enrolled participants were provided with SKY intervention and their pre and post data were recorded.
11305623|NCT02661893|Experimental|JNJ-42847922 and Rifampin|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ-42847922 on Day 1; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed with one oral dose of rifampin 600 mg (2*300 mg) on Day 5; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed on Day 12, following once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5-12.
11305624|NCT02661880|Experimental|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
11305625|NCT02661867||VD|Vaginal delivery group - women who gave birth of offspring through the vagina without the use of special instruments such as forceps or a vacuum extractor (instrumental vaginal delivery)
11305626|NCT02661867||CS|Cesarean section group - women delivered by surgical procedure in which one or more incisions are made through a mother's abdomen and uterus to deliver a baby. Cesarean section is performed when a vaginal delivery would put the baby's or mother's life or health at risk.
11305627|NCT02661854|Experimental|MM09 Mannosylated 5.000 subcutaneous|5.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11305628|NCT02661854|Experimental|MM09 Mannosylated 10.000 subcutaneous|10.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11305629|NCT02661854|Experimental|MM09 Mannosylated 30.000 subcutaneous|30.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11305630|NCT02661854|Experimental|MM09 Mannosylated 50.000 subcutaneous|50.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11305631|NCT02661854|Experimental|MM09 Mannosylated 5.000 sublingual|5.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11305632|NCT02661854|Experimental|MM09 Mannosylated 10.000 sublingual|10.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11305633|NCT02661854|Experimental|MM09 Mannosylated 30.000 sublingual|30.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11305634|NCT02661854|Experimental|MM09 Mannosylated 50.000 sublingual|50.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11305635|NCT02661854|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
11305636|NCT02661841|Experimental|LI-Guided Therapy|One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.
11305637|NCT02661841|Active Comparator|Control|One hundred and fifty chronic heart failure patients treated based on guidelines only.
11305638|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
11305639|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
11305640|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
11305641|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
11305642|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
11305643|NCT02661815|Experimental|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
11305644|NCT02661802|Experimental|Oxygen Supplementation|Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source.
11305645|NCT02661789|Active Comparator|GnRHa|Goserelin 3.6 mg implant
11305646|NCT02661789|Placebo Comparator|Placebo|Injection of saline
11305647|NCT02661763||Schoolchildren in Zambia|Schoolchildren in grades 7-12 in fifteen randomly selected schools in Lusaka area
11305648|NCT02661750||Step 1|Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
11305649|NCT02661750||Step 2|Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
11305650|NCT02661750||Step 3|Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
11305651|NCT02661750||Step 4|Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
11305652|NCT02661750||Step 5|Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.
11305653|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
11305654|NCT02661724|Experimental|Take Charge Burn - Pain (TCBR-Pain)|The TCBR-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress.
11305743|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m^2 to <30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
11305655|NCT02661724|No Intervention|Education attention control|The attention group receives an educational materials that is matched to the TCBR-Pain intervention in terms of session length and time on the web-based program. The web-based Education attention condition includes 7 sessions delivered over 7 weeks. The Education Attention Control is education materials commonly employed in rehabilitation centers and has been successfully used in several studies as a comparison to active rehabilitation interventions
11305656|NCT02661711|Experimental|Aflibercept (Eylea)|All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
11305657|NCT02661698|Placebo Comparator|Placebo 1|"Placebo
~All participants will be given a placebo for the first visit. The other 3 arms will be randomised in a counterbalanced order."
11305658|NCT02661698|Placebo Comparator|Placebo 2|Placebo
11305659|NCT02661698|Active Comparator|DHA rich oil|Omega-3 oil: DHA enriched
11305660|NCT02661698|Active Comparator|EPA rich oil|Omega-3 oil: EPA enriched
11305661|NCT02661685|Experimental|autologous IKDC-like cell|Received autologous IKDC-like cells
11305662|NCT02661672|Experimental|Patients with Brain Hemorrhage|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo or Artemis System for clot evacuation.
11305663|NCT02661659|Other|Weekly Vaccination|Maintenance multipeptide vaccine (S-588210) administered every week
11305664|NCT02661659|Other|Every other Week Vaccination|Maintenance multipeptide vaccine (S-588210) administered every other week
11305665|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
11305666|NCT02661633||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
11305667|NCT02661633||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
11305668|NCT02661607|Other|Point of care echocardiography after central venous catheter|Point of care echocardiography plus chest radiography
11305669|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
11305670|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
11305671|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
11305672|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
11305673|NCT02661581|Experimental|Peer Support|Peer support intervention group: During the first 3 months of DSME, participants in the DSMS intervention group will be invited to attend 6 lifestyle change sessions delivered a 2-person peer leader team and conducted bi-weekly. Immediately following the 3 months of DSME, participants are invited to attend 9 months of weekly DSMS sessions (60-minutes per session) delivered by a Peer Leader. These sessions are designed to sustain the self-management gains achieved in the 3 months of DSME.
11305674|NCT02661581|No Intervention|Wait-list Control|Immediately following the 6 bi-weekly DSME sessions, participants randomized to the Wait-list control group will have completed their participation in the study.
11305675|NCT02661568||Population with condition and with exposure|
11305676|NCT02661555|Experimental|Aerobic exercise|Aerobic exercise two times per week for 24 weeks.
11305677|NCT02661555|No Intervention|Habitual lifestyle|Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.
11305678|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305679|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305680|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305681|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305682|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305683|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305830|NCT02660541|Active Comparator|Betafoam|Brand name: Betafoam® This is a medicated device (dressing) consisting of 3% povidone iodine.
11305684|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305685|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305686|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305687|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305688|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
11305689|NCT02661529|Active Comparator|Transesophageal Echocardiogram|Patients undergoing an Transesophageal Echocardiogram (TEE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
11305690|NCT02661529|Active Comparator|Transthoracic Echocardiogram|Patients undergoing an Transthoracic Echocardiogram (TTE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
11305691|NCT02661516||Vitamin K Antagonists|Vitamin K Antagonists dose as specified
11305692|NCT02661503|Active Comparator|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
11305693|NCT02661503|Experimental|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
11305694|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
11305695|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
11305696|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
11305697|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
11305698|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
11305699|NCT02661477|Other|pegylated interferon + placebo|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.
11305700|NCT02661477|Other|placebo + pegylated interferon|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).
11305701|NCT02661464|Experimental|Exposed to Ad26.ZEBOV and/or MVA-BN Filo|Safety Data will be collected from participants who received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies in 6-month intervals up to 60 months after prime vaccination, including the duration in the participant's original study (Cohort 1). Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Safety Data for live born children to female participants will be followed up to 60 months after birth (Cohort 3).
11305702|NCT02661451|Experimental|TAVR (with SAPIEN 3 THV) and OHFT|Transcatheter heart valve and Optimal Heart Failure Therapy
11305703|NCT02661451|Active Comparator|OHFT|Optimal Heart Failure Therapy
11305704|NCT02661438|Other|Placebo to Ciprofloxacin DPI|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
11305705|NCT02661425||Standard of Care|
11305706|NCT02661425||EnteraGam|
11305707|NCT02661386|Other|Manometry Device|"During the last 10 minutes of subjects waking up from anesthesia, the motility procedure will be performed."
11305708|NCT02661373|Experimental|Treatment Arm|Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
11305709|NCT02661360|Experimental|Starting condition of swaddled|
11305710|NCT02661360|Experimental|Starting Condition of Unswaddled|
11305831|NCT02660541|Active Comparator|Allevyn Silver dressing|Brand name: Allevyn® Silver
11305832|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
11305711|NCT02661347|Active Comparator|Active comparator: tDCS & Risperidone|In the active arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2 milliampere (mA) for 20 minutes, twice a day for five consecutive days, for a total of 10 sessions.
11305712|NCT02661347|Sham Comparator|Sham comparator: tDCS & Risperidone|In the sham arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2mA for 1 minute, twice a day for five consecutive days, for a total of 10 sessions.
11305713|NCT02661334|Placebo Comparator|Placebo|30g white rice flour
11305714|NCT02661334|Experimental|Low dose|5g/day Creatine Monohydrate (25g white rice flour) for 28 days
11305715|NCT02661334|Experimental|Loading dose|Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
11305716|NCT02661334|Experimental|High dose|High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period
11305717|NCT02661308|Experimental|Systematic bright light exposure|Systematic bright light exposure for 30 min. for 4 weeks
11305718|NCT02661308|Active Comparator|Systematic dim light exposure|Systematic dim light exposure for 30 min. for 4 weeks
11305719|NCT02661295|Other|Ferric Citrate|Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.
11305720|NCT02661282|Experimental|Arm I (temozolomide, CMV-specific T cells, surgery)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer IV over 1-5 minutes on day 22. Patients undergo surgery on day 30 of cycle 1. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-21. Treatment repeats every 42 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11305721|NCT02661282|Active Comparator|Arm II (temozolomide, CMV-specific T cells)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11305722|NCT02661269||Septic patients|Septic patients with fluid overload (fluid balance + 4 L)
11305723|NCT02661269||Post-cardiac surgery patients|Patients after cardiac surgery, at arrival on ICU.
11305724|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
11305725|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
11305726|NCT02661243|Other|Dentate Sjogren's syndrome arm|30 human adults affected by SS with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
11305727|NCT02661243|Other|Dentate healthy controls arm|30 healthy human adults with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
11305728|NCT02661243|Other|Edentulous Sjogren's syndrome arm|30 human edentulous adults affected by SS with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
11305729|NCT02661243|Other|Edentulous healthy controls arm|30 healthy human edentulous adults with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
11305730|NCT02661230|Experimental|COGNIPLUS|Exercise-Gaming
11305731|NCT02661217|Other|Pre-discharge treatment initiation|Patients randomized to Pre-discharge treatment initiation could receive first dose of LCZ696 at any point after the investigator deemed the patient to be stable for at least 24 h, relatively to the ongoing acute HF-therapy.
11305732|NCT02661217|Other|Post-discharge treatment initiation|Patients randomized to Post-discharge treatment initiation could receive the first LCZ696 dose at any point between the day after discharge and up to 14 days after Discharge.
11305733|NCT02661204||Population A|Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
11305734|NCT02661204||Population B|Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
11305735|NCT02661204||Population C|Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
11305736|NCT02661204||Population D|Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
11305737|NCT02661191|Other|asthma severity and disease exacerbation|intramuscular cholecalciferol 100,000 IU, followed by oral cholecalciferol 5000 IU weekly plus 400 IU daily for one year
11305738|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
11305739|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
11305740|NCT02661152|Experimental|Radio-/Chemoradiotherapy + nimorazole|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole but receiving the drug, which is normal standard radiotherapy of HNSCC in Denmark.
11305741|NCT02661152|No Intervention|Radio-/Chemoradiotherapy|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole and not receiving the drug, that is normally part of standard radiotherapy of HNSCC in Denmark.
11305744|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
11305745|NCT02661100|Experimental|CDX-1401 + Poly-ICLC + Pembrolizumab followed by Pembrolizumab|Patients receive CDX-1401, Poly-ICLC and Pembrolizumab for 4 cycles (Q 3 weeks) followed by Pembrolizumab alone (Q 3 weeks) until disease progression.
11305746|NCT02661087|Experimental|Bipolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy
11305747|NCT02661087|Active Comparator|Monopolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy
11305748|NCT02661074||Fishermen|"Fisherman followed by the Service de Santé des Gens de Mer of Boulogne-sur-Mer, France (occupational exposure to fish).
~A questionnaire will be completed."
11305749|NCT02661074||Fish processing factories|"Workers of fish processing factories who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France (occupational exposure to fish).
~A questionnaire will be completed."
11305750|NCT02661074||Control|"Workers who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France, but do not work in fish processing factories.
~A questionnaire will be completed."
11305751|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
11305752|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
11305753|NCT02661048|Experimental|Open label|Non-randomized, open label clinical trial that intends to treat 10 subjects with refractory ventricular tachycardia with the CyberHeart system using standard radiosurgical techniques.
11305754|NCT02661035|Experimental|Reduced Intensity Conditioning|Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
11305755|NCT02661022|Experimental|SL-401/Pomalidomide/ Dexamethasone|SL-401 in combination with Pomalidomide and Dexamethasone
11305756|NCT02661009||Plasma and tissue matching|
11305757|NCT02661009||predicting clinical efficacy|
11305758|NCT02660983|Placebo Comparator|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
11305759|NCT02660983|Experimental|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
11305760|NCT02660983|Experimental|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
11305761|NCT02660970|Active Comparator|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
11305762|NCT02660970|Placebo Comparator|Placebo-band|Children will have to wear a 'placebo-wristband'
11305763|NCT02660970|Active Comparator|Iberogast|Children will have to take Iberogast drops
11305764|NCT02660970|Placebo Comparator|Placebo-drops|Children will have to take placebo-drops
11305765|NCT02660957|Experimental|self-determination smoking cessation|Subjects in the intervention group will be allowed to select their own schedules of quitting after discussing their situation with the counsellor (quit immediately (QI), or quit progressively (QP) with the ultimate goal of completing cessation over an acceptable period). Subjects in the intervention group will receive a self-help quitting leaflet published by the Hong Kong Council on Smoking and Health plus a series of brief interventions using the AWARD model.
11305766|NCT02660957|Placebo Comparator|health life|Subjects in the placebo control group will receive a smoking cessation leaflet published by the Hong Kong Council on Smoking and Health (COSH), as will the intervention group. Moreover, subjects in the placebo control group will undergo a similar schedule of telephone follow-up as those in the intervention group. They will receive a 'placebo' intervention with a 'placebo booster' of the same duration on increasing physical activity and fruit and vegetable intake.
11305767|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
11305768|NCT02660944|Placebo Comparator|Placebo|Saline placebo
11305769|NCT02660931|Experimental|AKI Risk Notification|Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.
11305770|NCT02660931|No Intervention|Usual Care|These patients will receive usual clinical care, with no acute kidney injury risk notification.
11305771|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
11305772|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
11305773|NCT02660905|Experimental|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
11305774|NCT02660892|Experimental|Protein Intake|Threonine intake - Dietary supplement
11305775|NCT02660879|Placebo Comparator|Written Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given written educational materials, and given 5 minutes to read these materials. They were then re-taped for their inhaler technique.
11305776|NCT02660879|Experimental|Online Video Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.
11306636|NCT02655120|Placebo Comparator|Drilling|Group I: a simple drill is practiced
11305777|NCT02660866|Placebo Comparator|SMT+APT+Placebo|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min
~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy."
11305778|NCT02660866|Active Comparator|SMT+APT+Vorapaxar|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min
~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy.
~Vorapaxar: Vorapaxar 2.08mg/day"
11305779|NCT02660853|Other|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
11305780|NCT02660840|Experimental|0.5 mg Test, then 0.5 mg reference|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)
11305781|NCT02660840|Experimental|0.5 mg reference, then 0.5 mg Test|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)
11305782|NCT02660840|Experimental|1 mg Test, then 1 mg reference|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)
11305783|NCT02660840|Experimental|1 mg reference, then 1 mg Test|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)
11305784|NCT02660840|Experimental|5 mg Test, then 5 mg reference|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)
11305785|NCT02660840|Experimental|5 mg reference, then 5 mg Test|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)
11305786|NCT02660827|Experimental|Hybrid closed loop|All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
11305787|NCT02660814|Placebo Comparator|Healthy periodontium without obesity|"GCF samples were taken at baseline
~Intervention: Gingival crevicular fluid collection"
11305788|NCT02660814|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
11305789|NCT02660814|Placebo Comparator|Healthy periodontium with obesity|"GCF samples were taken at baseline
~Intervention: Gingival crevicular fluid collection"
11305790|NCT02660814|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
11305791|NCT02660801|Experimental|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
11305792|NCT02660801|Experimental|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
11305793|NCT02660788|Active Comparator|Control Arm|Mail
11305794|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
11305795|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
11305796|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
11305797|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
11305798|NCT02660762|Experimental|Modified MRCUKALLⅫ/ECOGE2993 Regimen|"All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate
~,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis."
11305799|NCT02660736|Experimental|Regimen AB|"Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.
~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.
~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.
~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
11305886|NCT02660203|Experimental|forced expiration|2 daily sessions of forced expiration on ipsilateral decubitus from day 1 after surgery until chest tube removal
11305887|NCT02660203|No Intervention|control|No session of forced expiration
11305800|NCT02660736|Experimental|Regimen BA|"Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.
~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.
~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.
~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
11305801|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
11305802|NCT02660710|Experimental|R-CHOP|We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks
11305803|NCT02660697|Active Comparator|Test - Extraction site development group|In the test group 29 healthy patients presenting 33 single rooted teeth scheduled for extraction with Extraction Defect Sounding (EDS) Class 3-4 type buccal bony dehiscences were included. 29 maxillary single rooted teeth and 4 single rooted teeth in the mandible (27 incisors, 2 canines and 4 premolars) were removed and treated by the novel extraction site development method. Pre- and postoperative ConeBeam Computer Tomography (CBCT) data were collected for further analysis.
11305804|NCT02660697|No Intervention|Control - Spontaneous healing group|In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
11305805|NCT02660684|Experimental|Prograf + MTX|
11305806|NCT02660684|Active Comparator|Cyclosporine + MTX (historical control)|
11305807|NCT02660671|Active Comparator|Usual care|Email outreach
11305808|NCT02660671|Experimental|Active choice|Email outreach + active choice
11305809|NCT02660671|Experimental|Financial incentive + Active choice|Email outreach + active choice + financial incentive
11305810|NCT02660658|Other|Intrathecal dexmedetomidine|"Up-down sequential allocation
~The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance"
11305811|NCT02660645||Blue Light Cystoscopy with Cysview®|Bladder cancer patients who have undergone Blue light cystoscopy with Hexaminolevulinate hydrochloride (Cysview®) 100mg in 50 milliliters (mL) reconstituted solution instilled intravesically into bladder prior to cystoscopy in operating room (OR). Retention time: 1-3 hours. The Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is used for the cystoscopy procedure at the OR examination.
11305812|NCT02660632|Placebo Comparator|Thoracic epidural analgesia (TEA)|Patients who will be subjected for midline laparotomy, will receive epidural analgesia through an inserted thoracic epidural catheter before induction of general anesthesia
11305813|NCT02660632|Active Comparator|Rectus sheath catheter block|After insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected on each side, then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
11305814|NCT02660619||Low-risk patients|These will be patients with a prescription for opioids for chronic pain for at least 30 days, recruited from university-affiliated pain and rehabilitation medicine clinics that routinely employ precautions to avoid prescribing such medication to individuals seeking it for non-therapeutic reasons
11305815|NCT02660619||High-risk patients|These patients will be in treatment for addiction to opioids and have (or have had) a prescription of opioids to treat pain.
11305816|NCT02660606||Group 1: Opioid abusers|
11305817|NCT02660606||Group 2: Abusers of other substances|
11305818|NCT02660606||Group 3: Non-opioid abusers|
11305819|NCT02660606||Group 4: Non-opioid users|
11305820|NCT02660593|Experimental|SanGrow|Patients will be given SanGrow Decoction 150 ml per day for 3 months.
11305821|NCT02660580|Experimental|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
11305822|NCT02660580|Active Comparator|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
11305823|NCT02660580|Experimental|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
11305824|NCT02660580|Active Comparator|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
11305825|NCT02660580|Experimental|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
11305826|NCT02660567|Experimental|Amr Maneuver|Active management of third stage plus Amr's maneuver
11305827|NCT02660567|No Intervention|Active management alone|Active management of third stage alone
11305828|NCT02660554|No Intervention|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
11305829|NCT02660554|Experimental|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
11305888|NCT02660190|Experimental|PDD|PDD at flexible cystoscopy
11305833|NCT02660515|Active Comparator|ORIF|The operation has to be performed within 3 weeks after the initial trauma. According to the current standard, antibiotic prophylaxis (Cefazoline, 1000 milligram intravenous) will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis and the arteria radialis. After the fracture site is exposed, the fracture will be reduced and an appropriate volar locking plate will be positioned. The type and brand of the plate are at discretion of the treating surgeon. When a dorsal approach is deemed necessary the distal radius will be approached between the third and fourth dorsal extensor tendon compartments. To evaluate the quality of articular reduction, fluoroscopic images will be obtained. Wound closure will be performed using standard techniques.
11305834|NCT02660515|Active Comparator|ORIF with additional wrist arthroscopy|Surgery will be performed by a certified trauma surgeon, with experience in wrist arthroscopy. A delay of minimal 5 days before performing arthroscopy is mandatory to enable visualisation due to the organisation of the hematoma. During wrist arthroscopy, the forearm will be positioned upright and in neutral position, the elbow flexed by 90° and axial traction of 4-6 kg will be performed. Four portal entrees are created by superficial stab incisions and blunt preparation through the joint capsule; one midcarpal radiair and one midcarpal ulnar portal and the 3-4 and 6-R portal. A shaver is used for removal of fracture haematoma and osteocartilaginous debris. Cartilage damage will be graded using the Outerbridge classification system. With the 1 mm hook probe assessment of the quality of reduction and ligamentous injuries (TFCC, scapholunate and lunotriquetral) will be performed. Wound closure will be performed using standard techniques.
11305835|NCT02660502|Experimental|BioChaperone insulin lispro 0.1 U/kg|
11305836|NCT02660502|Experimental|BioChaperone insulin lispro 0.2 U/kg|
11305837|NCT02660502|Experimental|BioChaperone insulin lispro 0.4 U/kg|
11305838|NCT02660502|Active Comparator|Humalog®|
11305839|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
11305840|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
11305841|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
11305842|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
11305843|NCT02660450|Experimental|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
11305844|NCT02660450|Experimental|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
11305845|NCT02660450|Experimental|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
11305846|NCT02660437|Active Comparator|Effect of PR in MCI-group|Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of MCI-Group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR). Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques.
11305847|NCT02660437|Placebo Comparator|Effect of PR in control-group|"Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of control-group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR).
~Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques."
11305848|NCT02660424|Experimental|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
11305849|NCT02660424|Experimental|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
11305850|NCT02660411|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.
~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
11305851|NCT02660411|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.
~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
11305852|NCT02660398|No Intervention|Controls|Our control group will consist of an observational cohort of 40 patients in whom we will make quantitative assessments of the Train-of-four ratio (TOF ratio). This is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
11305853|NCT02660398|Other|Intervention|The intervention consists of a protocol for intraoperative management of neuromuscular blockade with rocuronium and reversal with neostigmine. A train-of-four count of 4 at the thumb will be confirmed prior to administration of an adjusted dose of neostigmine. TOF ratio is measured in the same manner as for the Control group, it is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
11305889|NCT02660190|Experimental|WL|WL only at flexible cystoscopy
11305890|NCT02660177|Experimental|metamizole|single IV metamizole (10mg/kg) administration
11305891|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
11305854|NCT02660385|Experimental|Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
11305855|NCT02660385|Active Comparator|Heart Failure Self-Management Education|Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
11305856|NCT02660372|Experimental|Imonogas|Imonogas 120 mg, 1 capsule three times daily for 8 weeks
11305857|NCT02660372|Active Comparator|Espumisan|Espumisan 40 mg, 2 capsules four times daily for 8 weeks
11305858|NCT02660359|Experimental|600 U Dysport® Group|
11305859|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
11305860|NCT02660359|Experimental|800 U Dysport® Group|
11305861|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
11305862|NCT02660346|Active Comparator|Group A - Daptomycin or Vancomycin|Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.
11305863|NCT02660346|Experimental|Group B - Daptomycin with Ceftaroline|Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.
11305864|NCT02660333|Placebo Comparator|Placebo|Maltodextrin
11305865|NCT02660333|Active Comparator|Prebiotic|Fructooligosaccharide
11305866|NCT02660333|Active Comparator|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
11305867|NCT02660320|Active Comparator|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
11305868|NCT02660320|Placebo Comparator|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
11305869|NCT02660307|Experimental|PROGRESS group|this group received the intervention based in meditation in the first 8 weeks. They were instructed to practice at least 5 times a week for up to half an hour a day. During the second 8 week period this group were left to manage their practice on their own.
11305870|NCT02660307|Other|control group|this group received no intervention in the first 8 weeks. During the second 8 week period, this group received the same intervention based in meditation that received PROGRESS group.
11305871|NCT02660294|Experimental|Platlet rich plasma|For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity
11305872|NCT02660294|No Intervention|Hormone replacement therapy|Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity
11305873|NCT02660281|Other|Full Intensity TBI-based Conditioning|Total Body Irradiation 1200 cGy of 150 cGy over 4 or 5 days, days -5 or -4 to -1 Fludarabine 30 mg/m2/day x 3 days, days -6, -5, -4 Stem Cell Infusion, day 0 Post- Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Mesna 50 mg/kg/day x 2 days, days +3 and +4
11305874|NCT02660281|Other|Full Intensity Chemo-Only Conditioning|Fludarabine 25 mg/m2/day x 5 days, days -6, -5, -4, -3, -2 Busulfan 130 mg/m2/day x 4 days, days -6, -5, -4, -3 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell Infusion Mesna 14.5 mg/kg/day x 2 days, days -3 and -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, days +3 and +4
11305875|NCT02660281|Other|Reduced Intensity Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
11305876|NCT02660281|Other|Non-Myeloablative Conditioning|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Pre-Stem Cell Infusion Cyclophosphamide 14.5 mg/kg/day x 2 days, days -3 and -2 Pre-Stem Cell InfusionMesna 14.5 mg/kg/day x 2 days, days -3 and -2 Total Body Irradiation 200 cGy, day -1 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, day +3 and +4 Post-Stem Cell Infusion Mesna 50 mg/kg/day x 2 days, day +3 and +4
11305877|NCT02660281|Other|Reduced Intensity Conditioning with Addition of Thiotepa|Fludarabine 30 mg/m2/day x 5 days, days -6 to -2 Thiotepa 8 mg/kg, day -3 Melphalan 140 mg/m2/day x 1 day, day -2 Stem Cell Infusion, day 0 Post-Stem Cell Infusion Cyclophosphamide 50 mg/kg/day x 2 days, days +3 and +4 Post-Stem Cell InfusionMesna 50 mg/kg/day x 2 days, days +3 and +4
11305878|NCT02660268|Experimental|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
11305879|NCT02660268|No Intervention|Control|Patients in the control group will receive standard care
11305880|NCT02660242|No Intervention|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
11305881|NCT02660242|Active Comparator|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
11305882|NCT02660242|Active Comparator|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
11305883|NCT02660242|Experimental|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
11305884|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
11305885|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
11305892|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
11305893|NCT02660151|Experimental|Treatment A-B|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
11305894|NCT02660151|Experimental|Treatment B-A|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
11305895|NCT02660138|Experimental|600 U Dysport® Group|
11305896|NCT02660138|Placebo Comparator|600 U Dysport® Placebo Group|
11305897|NCT02660138|Experimental|800 U Dysport® Group|
11305898|NCT02660138|Placebo Comparator|800 U Dysport® Placebo Group|
11305899|NCT02660125|Active Comparator|endometrial scratch injury|endometrial scratch done before ICSI cycle
11305900|NCT02660125|No Intervention|control|IcSI cycle without prior endometrial injury
11305901|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
11305902|NCT02660099|Experimental|Internet-delivered CBT|12 weeks of internet-delivered cognitive behavior therapy provided through a secure internet platform and online clinician contact
11305903|NCT02660086|Experimental|Personalized feedback|Emails and letters providing personalized nutrition feedback about food choices and health, social norms, and financial incentives for healthy food choices
11305904|NCT02660086|No Intervention|Control|Monthly letters with general nutrition information
11305905|NCT02660073|Experimental|NMES+FES group|NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
11305906|NCT02660073|Experimental|Control+FES group|Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
11305907|NCT02660060|Experimental|Pramipexole Dexa Medica|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
11305908|NCT02660060|Active Comparator|Pramipexole Boehringer Ingelheim Pharma|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
11305909|NCT02660047|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.
~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.
~Duration: 26 weeks"
11305910|NCT02660047|Placebo Comparator|Liraglutide - Placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.
~Dose: same as Liraglutide
~Duration: 26 weeks"
11305911|NCT02660034|Experimental|Phase 1A|Approximately 50 participants for the dose escalation until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
11305912|NCT02660034|Experimental|Phase 1B|Approximately 180 participants for expansion in eight selected arms with nine cohorts.
11305913|NCT02660008|Experimental|ZP4207|ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.
11305914|NCT02660008|Active Comparator|GlucaGen|GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.
11305915|NCT02659956||Individuals without known CNS disease|Family members of patient participants
11305916|NCT02659956||Patient Controls|a target population of 20 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
11305917|NCT02659956||Patients with multiple sclerosis|Up to 100 adults (age greater than or equal to 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
11305918|NCT02659943|Experimental|1|Dose escalation for patients who never had an alloHSCT
11305919|NCT02659930|Experimental|1/Group 1|Pomalidomide and liposomal doxorubicin given at escalating doses to patients with KS requiring systemic therapy
11305920|NCT02659930|Experimental|2/ Group I; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
11305921|NCT02659930|Experimental|3/Group II|Pomalidomide with liposomal doxorubicin given at escalating doses in to patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS requiring systemic therapy
11305922|NCT02659930|Experimental|4/Group II; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS or KS with concurrent KSHVassociated MCD or KICS requiring systemic therapy
11305923|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer|Pit and fissure sealing using conventional glass-ionomer cement
11305924|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement|Pit and fissure sealing using conventional glass-ionomer cement
11305925|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer -|Restoration using conventional glass-ionomer cement
11305926|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement -|Restoration using conventional glass-ionomer cement
11305927|NCT02659904|Active Comparator|Less than 2 mm|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: Less than 2 mm remaining palatal tissue thickness
11305928|NCT02659904|Active Comparator|2 mm or more|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: 2 mm or more remaining palatal tissue thickness
11305929|NCT02659891|Active Comparator|Group 1 (Treatment)|Intravenous immune globulin (IVIg; Privigen®) 1g/kg monthly for 2 months with immunosuppression reduction.
11306774|NCT02654236|No Intervention|Non-drinking Controls|Non-drinking healthy controls
11305930|NCT02659891|Placebo Comparator|Group 2 (Control)|Placebo infusion monthly for 2 months with immunosuppression reduction
11305931|NCT02659865|Placebo Comparator|Part A: Placebo|Single oral dose of placebo administered in one of three study periods
11305932|NCT02659865|Experimental|Part A: LY3039478 new formulation|Escalating single oral dose of LY3039478 administered in two of three study periods
11305933|NCT02659865|Experimental|Part B: LY3039478 original formulation|Single oral dose of LY3039478 administered in one of two study periods
11305934|NCT02659865|Experimental|Part B: LY3039478 new formulation|Single oral dose of LY3039478 administered in one of two study periods
11305935|NCT02659852|Experimental|Side by side group|
11305936|NCT02659852|Active Comparator|Stent in stent group|
11305937|NCT02659839||Cancer patients admitted to the ICU|Patients with cancer admitted to the ICU. No intervention will be administered.
11305938|NCT02659826|Experimental|anodal tsDCS and gait training|Volunteers will be submitted to anodal transcutaneous spinal cord stimulation and gait training
11305939|NCT02659826|Experimental|cathodal tsDCS and gait training|Volunteers will be submitted to cathodal transcutaneous spinal cord stimulation and gait training
11305940|NCT02659826|Sham Comparator|sham tsDCS and gait training|Volunteers will be submitted to sham transcutaneous spinal cord stimulation and gait training
11305941|NCT02659826|Experimental|High frequency rTMS and gait training|Volunteers will be submitted to high frequency transcranial magnetic stimulation and gait training
11305942|NCT02659826|Experimental|Low frequency rTMS and gait training|Volunteers will be submitted to low frequency transcranial magnetic stimulation and gait training
11305943|NCT02659826|Sham Comparator|sham rTMS and gait training|Volunteers will be submitted to sham transcranial magnetic stimulation and gait training
11305944|NCT02659813|Experimental|Firewire|Experimental Group 1. Novel orthodontic archwire.
11305945|NCT02659813|Experimental|CNiTi|Experimental Group 2. Current best available orthodontic archwire
11305946|NCT02659800|Experimental|Arm A - Low Dexamethasone (LD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation
~Laboratory Biomarker Analysis Correlative Studies"
11305947|NCT02659800|Experimental|Arm B High Dexamethasone (HD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation
~Laboratory Biomarker Analysis Correlative Studies"
11305948|NCT02659800|Experimental|Arm A1 (LD) Control - Placebo|"Patients receive single dose Placebo IM (blinded). Patients also on Dexamethasone </=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot
~Laboratory Biomarker Analysis Correlative Studies"
11305949|NCT02659800|Experimental|Arm A2 (LD) MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm A (Blinded) . Patients also on Dexamethasone <=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot
~Laboratory Biomarker Analysis Correlative Studies"
11305950|NCT02659800|Experimental|Arm B1 HD MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm B (Blinded) . Patients also on Dexamethasone >= 4mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot
~Laboratory Biomarker Analysis Correlative Studies"
11305951|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
11305952|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
11305953|NCT02659774|Experimental|Group A|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
11305954|NCT02659774|Placebo Comparator|Group B|Face to Face counseling (Motivational intervention) + Booklet + SMS
11305955|NCT02659774|Placebo Comparator|Group C|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
11305956|NCT02659774|Placebo Comparator|Group D|Phone counseling (Motivational intervention) + booklet + SMS
11305957|NCT02659761|Experimental|dolutegravir/abacavir/lamivudine|All study subjects will receive triumeq (600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine) single tablet that will be taken orally, once daily, during 96 weeks
11305958|NCT02659748|Experimental|Milk fat|A 21-day low-fat (E%) experimental diet including milk fat with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single (bioactive) fatty acids.
11305959|NCT02659748|Experimental|Control Fat|A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
11305960|NCT02659735|Experimental|Panel 1: Treatment ADBC|Participants will receive Treatment A (600 milligram [mg] JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 1; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 2; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 3; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
11305961|NCT02659735|Experimental|Panel 1: Treatment BACD|Participants will receive Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 1; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 2; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 3; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
11305962|NCT02659735|Experimental|Panel I: Treatment CBDA|Participants will receive Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 1; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 2; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 3; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
11305963|NCT02659735|Experimental|Panel I: Treatment DCAB|Participants will receive Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 1; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 2; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 3; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
11305964|NCT02659735|Experimental|Panel 2: Treatment EFG|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
11305965|NCT02659735|Experimental|Panel 2: Treatment FGE|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
11305966|NCT02659735|Experimental|Panel 2: Treatment GEF|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
11305967|NCT02659735|Experimental|Panel 2: Treatment GFE|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
11305968|NCT02659735|Experimental|Panel 2: Treatment FEG|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
11305969|NCT02659735|Experimental|Panel 2: Treatment EGF|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
11305970|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
11305971|NCT02659683|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
11305972|NCT02659683|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
11305973|NCT02659657|Experimental|Interleukin-2 interventions|Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).
11305974|NCT02659644|Experimental|Oral citrulline|
11305975|NCT02659631|Experimental|PF-06671008|
11305976|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
11305977|NCT02659605|Experimental|Delayed cord clamping above the perineum|
11305978|NCT02659605|Active Comparator|Delayed cord clamping below the perineum|
11305979|NCT02659592|Experimental|infertile cancer survivors|infertile cancer survivors who seek to conceive and had frozen ovarian tissue when diagnosed years before
11305980|NCT02659579|Experimental|The Reader Organisation's Shared Reading Programme|In the Reader Organisation's Shared Reading Programme, parents and children will attend The Reader Organisation's weekly shared reading programme for 8 weeks. The programme consists of two different modules. Parents will attend 'Magical Storytimes' with their children, in which a collection of shared book reading sessions are led by a project worker. Parents will also attend sessions on their own ('Stories for you and Yours') in which they will be informed how to choose books and read interactively with their child.
11305981|NCT02659579|Active Comparator|Shared Reading control|In the Shared Reading control parents and children will attend a weekly shared reading group at a library for 8 weeks where parents/children will read in a shared reading group which will be coordinated by a group facilitator.
11305982|NCT02659553||mild steatosis|5% - 30% of hepatocytes have fatty infiltration
11305983|NCT02659553||moderate steatosis|30% - 60% of hepatocytes have fatty infiltration
11305984|NCT02659553||No steatosis|No or less than 5% of hepatocytes have fatty infiltration
11306006|NCT02659384|Experimental|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
11306073|NCT02658890|Experimental|Combination Therapy (Dose Expansion)|BMS 986205 + Nivolumab specified dose at specified intervals.
11306244|NCT02657811|Active Comparator|Time Lapse Incubation - Modified|These embryos will be randomized to the bench incubator.
11305985|NCT02659540|Experimental|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
11305986|NCT02659540|Experimental|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
11305987|NCT02659527|Active Comparator|standardized needle biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.
~According to the randomization, the standardized 12 core TRUS (TransRectal UltraSound)-guided biopsy is performed without knowledge of imaging findings by the urologist. If the biopsy is negative patients will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
11305988|NCT02659527|Experimental|image-guided biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.
~Patients will have a standardized 12 core TRUS-guided biopsy without knowledge of imaging findings by the urologist. Patients randomized in this arm will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
11305989|NCT02659514|Experimental|Poziotinib, oral tablets|
11305990|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
11305991|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
11305992|NCT02659488|Other|Lisdexamfetamine|During the Treatment Phase, subjects will be evaluated after 1, 2, 3, 4, 6, 8, 10, and 12 weeks (see Figure 2). The morning after completing the first fMRI scan, LDX will be started at 30 mg q AM (Baseline). After 1 week, LDX will then be increased to 50 mg q AM (Visit 1); after another week, LDX will be increased to 70 mg q AM (Visit 2). A single downward dose titration to 50 mg is allowed during week 3 if 70 mg/d is not tolerated. LDX dose at week 4 (50 or 70 mg/d) will be maintained for the next 8 weeks. Patients who do not tolerate 50 or 70 mg/day will be terminated. For patients who complete the 12-week treatment phase, LDX will be stopped at week 12 visit.
11305993|NCT02659475|Experimental|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
11305994|NCT02659462||patients post Fontan palliation for single ventricular hear|Cardio Pulmonary Exercise Testing
11305995|NCT02659462||Subjects post surgical correction of congenital heart disease|Cardio Pulmonary Exercise Testing
11305996|NCT02659462||Healthy patients|Cardio Pulmonary Exercise Testing
11305997|NCT02659436|Active Comparator|Verbal-linguistic CBT|Participants will receive 4 sessions of verbal cognitive restructuring and exposure therapy delivered in an individual therapy format.
11305998|NCT02659436|Experimental|Imagery-based CBT|Participants will receive 4 sessions of imagery-based cognitive work and behavioural experiments delivered in an individual therapy format.
11305999|NCT02659423||Green Dot BIC 1|"Bystander Intervention Components Clusters will include at least a component of Green Dot.
~E.g. Comparisons will be made across schools that have Green Dot versus those that don't have Green Dot. (BIC 1)"
11306000|NCT02659423||Online BIC 2|"Bystander Intervention Components Clusters will include at least a component of online bystander training.
~E.g. Comparisons will be made across schools that have online bystander training versus those that do not. (BIC 2)"
11306001|NCT02659423||Alternative programs BIC 3|"Bystander Intervention Components Clusters will include at least a component of Green Dot.
~E.g. Comparisons will be made across schools that have alternative program versus those that do not. (BIC 3)"
11306002|NCT02659410|Experimental|Heat stress|4h exposure to heat stress alone or in combination with different solvents. Solvent concentrations are equal to their TLV. Heat conditions are 21, 25 and 30°C (WBGT). Inhalation exposure for all solvents and demal exposure for toluene.
11306003|NCT02659397|Experimental|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
11306004|NCT02659397|Placebo Comparator|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
11306005|NCT02659384|Experimental|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
11306071|NCT02658903|Other|Control-arm with commercial catheter|The control group is treated with a commercial urinary catheter. The intervention is the insertion of the control urinary catheter (foley) into the bladder,
11306007|NCT02659384|Experimental|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
11306008|NCT02659371|Experimental|Low energy diet|Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d.
11306009|NCT02659358||Biosensor + Patient Reported Outcomes (PRO)|Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
11306010|NCT02659345|Experimental|Art Therapy|The art therapy intervention will be executed by an art therapist at the Cancer Center. The same art therapy practices that are utilized in daily practice will be employed in this study. The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities. Sessions will conclude with processing of the art and supportive counseling as appropriate. Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist. Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
11306011|NCT02659332|Experimental|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
11306012|NCT02659319|Experimental|Family Lifestyle (FL; n = 117)|This arm includes the Family Food & Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
11306013|NCT02659319|Experimental|FL + Family Dynamics (FL+FD; n = 88)|This arm includes the Family Food & Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food & Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
11306014|NCT02659319|Experimental|FL + Peer Group (FL+PG; n = 124)|This arm includes the Family Food & Lifestyle intervention plus the 12-session, Peer Group intervention.
11306015|NCT02659319|Experimental|FL + FD + Peer Group (FL+FD+PG; n = 130)|This arm includes the Family Food & Lifestyle intervention plus the Family Dynamics Intervention plus the Peer Group intervention.
11306016|NCT02659319|No Intervention|Control (n = 82)|Non-intervention control group
11306017|NCT02659306|Experimental|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
11306018|NCT02659293|Active Comparator|Lenalidomide (Control)|Treatment with lenalidomide only
11306019|NCT02659293|Experimental|Experimental Combination Regimen|Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
11306020|NCT02659280|Active Comparator|Standard of Care Therapy|Home Health or Outpatient Physical therapy services (a minimum of 1x/week).
11306021|NCT02659280|Experimental|Adjunct Therapy|"Home Health or Outpatient Physical therapy services (a minimum of 1x/week) with an adjunct Home Exercise Program given up to 1x/wk via Store and Forward tele-health through the Hudl Technique app."
11306022|NCT02659267|Experimental|Interventions Group=|Group of change behavior including physical activity and healthy eating habits promotion.
11306023|NCT02659267|No Intervention|Control Group=|Group that will not receive the VAMOS program as intervention, only participate in the Health Academy Program Activities.
11306024|NCT02659254|Experimental|Firesorb Implantation|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）in patients with coronary artery lesions.
11306025|NCT02659241|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5. Patients then undergo standard of care laparoscopy. Patients may also receive adavosertib PO QD on days 8-12, 15-19, and 22-26 for up to 28 days based on surgery schedule.
11306026|NCT02659228|Placebo Comparator|Control 1 (negative control)|Individuals with a diagnosis of UWS without neural markers of consciousness
11306027|NCT02659228|Active Comparator|Control 2 (positive control)|Individuals with a diagnosis of MCS, who are behaviourally responsive and who present neural markers of consciousness
11306028|NCT02659228|Experimental|Target Population|Individuals with a clinical diagnosis of UWS, but who possess some neurophysiological signatures of conscious awareness
11306029|NCT02659215|Experimental|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
11306030|NCT02659215|Active Comparator|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
11306031|NCT02659202|Experimental|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
11306032|NCT02659176|Active Comparator|Transperineal repair with PIS|transperineal repair of anterior rectocele with limited internal sphincterotomy
11306033|NCT02659176|Active Comparator|Transperineal repair without PIS|transperineal repair of anterior rectocele only
11306034|NCT02659163|Experimental|intervention|Intervention subjects will receive feedback on their health behaviors along with clinical recommendations.
11306035|NCT02659163|Active Comparator|control|Control subjects will receive feedback on their health behaviors for self-guided care.
11306036|NCT02659150|Other|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
11306037|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
11306038|NCT02659111|Experimental|High-intensity physical exercise, HIFE|
11306039|NCT02659111|Active Comparator|Physical training advice|
11306040|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
11306072|NCT02658890|Experimental|Combination Therapy (Dose Escalation)|BMS 986205 + Nivolumab specified dose at specified intervals.
11306133|NCT02658526||control|children without anesthesia / surgery
11306041|NCT02659085|Active Comparator|Electroconvulsive Therapy (ECT)|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly. Each participating clinic decides for each patient whether the treatment is given uni- or bilateral, as well as the exact stimulation parameters. Choice of anesthetic drug (e.g. thiopental of propofol) and muscle relaxant is done by local anesthesiologist. The procedure differs in no way from how a given patient would have been treated if he or she were not included in the study.
11306042|NCT02659085|Experimental|Ketamine IV Infusion|Ketamin intra venous infusions of racemic ketamine (0.5mg/kg), delivered over a period of 40 minutes thrice weekly, as ECT (Monday, Wednesday and Friday).
11306043|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1
~Specified Dose on Specified Days"
11306044|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2
~Specified Dose on Specified Days"
11306045|NCT02659046||FH30|Patients treated by Pirkanmaa physician-staffed emergency medical service (EMS) unit
11306046|NCT02659046||FH10|Patients treated by Helsinki and Uusimaa physician-staffed emergency medical service (EMS) unit
11306047|NCT02659033|Active Comparator|ceftriaxone|healthy volunteer who receive ceftriaxone
11306048|NCT02659033|Active Comparator|cefotaxime|healthy volunteer who receive cefotaxime
11306049|NCT02659020|Experimental|Olaratumab + Gemcitabine + Docetaxel (Dose Escalation)|Olaratumab intravenously (IV) on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.
11306050|NCT02659020|Experimental|Olaratumab + Gemcitabine + Docetaxel|Olaratumab IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.
11306051|NCT02659020|Placebo Comparator|Placebo + Gemcitabine + Docetaxel|Placebo IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.
11306052|NCT02659007|Experimental|yoga|yoga, 2 times a week for 8 weeks
11306053|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
11306054|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
11306055|NCT02658981|Experimental|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study
~Laboratory Biomarker Analysis"
11306056|NCT02658981|Experimental|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity
~Pharmacological Study
~Laboratory Biomarker Analysis"
11306057|NCT02658981|Experimental|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study
~Laboratory Biomarker Analysis"
11306058|NCT02658981|Experimental|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)
~Pharmacological Study
~Laboratory Biomarker Analysis"
11306059|NCT02658981|Experimental|Intratumoral Studies|"Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.
~(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)"
11306060|NCT02658968|Experimental|Betalutin|10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
11306061|NCT02658955|Experimental|Short stitch|Patients in which abdominal wall is closed by short stitch technique
11306062|NCT02658955|No Intervention|Large stitch|Patients who didn't receive properly closure according with the protocol
11306063|NCT02658942|Active Comparator|Ureteroscopy|Intervention: Flexible ureteroscopy for removal of lower calyceal stones using holmium:YAG laser lithotripsy
11306064|NCT02658942|Active Comparator|Shockwave lithotripsy|Intervention: Shockwave lithotripsy for lithotripsy of lower calyceal stones using Siemens Lithostar Lithotriptor
11306065|NCT02658929|Experimental|bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
11306066|NCT02658916|Experimental|Panel 1: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
11306067|NCT02658916|Experimental|Panel 2: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
11306068|NCT02658916|Experimental|Panel 3: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
11306069|NCT02658916|Experimental|Panel 4: BIIB092 (Expansion Panel)|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
11306070|NCT02658903|Experimental|Study arm with Oxys-Cathter|The study group is treated with a modified urinary catheter, which delivers electromagnetic therapy to prevent and treat bacterial colonization during the study period. The intervention is the insertion of the study urinary catheter (foley) into the bladder.
11306074|NCT02658890|Experimental|Combination Therapy 2 (Dose Expansion)|BMS 986205 + both Nivolumab and ipilimumab specified dose at specified intervals
11306075|NCT02658877|Experimental|Omalizumab|
11306076|NCT02658877|Placebo Comparator|Placebo|
11306077|NCT02658864|Experimental|10-mg group|Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state.
11306078|NCT02658864|Experimental|20-mg group|Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state.
11306079|NCT02658864|Experimental|40-mg group|Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state.
11306080|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
11306081|NCT02658838|Experimental|full amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with full amount low molecular weight heparin until they leave hospital.
11306082|NCT02658838|Experimental|half amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with half amount low molecular weight heparin until they leave hospital.
11306083|NCT02658838|Experimental|No low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with no low molecular weight heparin.
11306084|NCT02658825|Experimental|Panel 1: Dose level 1|Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B [(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1].
11306085|NCT02658825|Experimental|Panel 1: Dose level 2|Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D [placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1].
11306086|NCT02658825|Experimental|Panel 2: Treatment EFG|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
11306087|NCT02658825|Experimental|Panel 2: Treatment FGE|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
11306088|NCT02658825|Experimental|Panel 2: Treatment GEF|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
11306089|NCT02658825|Experimental|Panel 2: Treatment GFE|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
11306090|NCT02658825|Experimental|Panel 2: Treatment FEG|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
11306091|NCT02658825|Experimental|Panel 2: Treatment EGF|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
11306092|NCT02658812|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
11306093|NCT02658799|Experimental|diclofenac potassium|"Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen.
~Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.
~To promote compliance, each patient was recalled monthly."
11306094|NCT02658799|Active Comparator|placebo|"or placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.
~Administration of placebo was undertaken from baseline to 2 months, no drug (placebo) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.
~To promote compliance, each patient was recalled monthly."
11306095|NCT02658786||Hepatitis B patients|Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years
11306096|NCT02658786||Hepatitis C patients|Biopsy proven Hepatitis C virus infected cases will be followed for the period of 5 years
11306097|NCT02658786||Non Alcoholic Fatty liver Disease patients|Biopsy proven Non Alcoholic Fatty liver Disease patients cases will be followed for the period of 5 years
11306098|NCT02658773|Active Comparator|lidocaine-Prilocaine cream|lidocaine-Prilocaine anesthetic cream placed into their cervix prior to having the IUD inserted
11306099|NCT02658773|Placebo Comparator|placebo cream|an inert placebo cream placed into their cervix
11306100|NCT02658760|Experimental|Bupivacaine|30cc of 0.25% bupivacaine
11306101|NCT02658760|Active Comparator|Dexmedetomidine and bupivacaine|30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
11306102|NCT02658747||Cohort Docetaxel|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)
11306103|NCT02658734|Experimental|Trastuzumab emtansine|
11306134|NCT02658526||anesthesia|children with anesthesia for diagnostic reason
11306104|NCT02658721|Experimental|lidocaine+adjunct tramadol|In the first group (LDC+TRA group), IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation.
11306105|NCT02658721|Experimental|lidocaine+systemic tramadol|In the second group (LDC+SysTRA group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation.
11306106|NCT02658721|Active Comparator|lidocaine|In the third group (LDC group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL.
11306107|NCT02658708|Experimental|Arm 1: Bright blue-green light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, -21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
11306108|NCT02658708|Active Comparator|Arm 2: Dim red light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, 21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 days randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
11306109|NCT02658695||Group 1|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) <10 mm.
11306110|NCT02658695||Group 2|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) >10 mm.
11306111|NCT02658682|Experimental|ABM +|Attention Bias Modification
11306112|NCT02658682|Sham Comparator|ABM -|Sham Attention Bias Modification
11306113|NCT02658669|Experimental|Cognitive-Behavioral Therapy for Insomnia|6-week manualized treatment designed to improve symptoms of chronic insomnia.
11306114|NCT02658669|Active Comparator|Sleep Education|6-week manualized treatment designed to provide information regarding traumatic brain injury and its relationship to sleep disturbance, which incorporates training in sleep hygiene to help improve nighttime sleep and daytime functioning.
11306115|NCT02658656|Active Comparator|Exoskeleton + SOC|Patient will receive exoskeletal-assisted walking device for in home use for 4 months
11306116|NCT02658656|No Intervention|SOC|Patient will receive standard of care (wheelchair use)
11306117|NCT02658643|Experimental|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
11306118|NCT02658643|Active Comparator|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
11306119|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
11306120|NCT02658617||patients|20 patients were enrolled. Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire). 1-2 days after the imaging patients started the treatment with duloxetine: 30mg for the first three days, then 60-90mg.
11306121|NCT02658617||healthy controls|Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire).
11306122|NCT02658604||Home visit by pharmacist|Patients of participating pharmacies age 65 or older, who are on 5 or more chronic prescription medications, and who have a need for, and agree to, a home visit by a pharmacist for a medication review.
11306123|NCT02658591|Active Comparator|Control|Crackers/pasta with no faba bean fraction
11306124|NCT02658591|Experimental|Faba bean protein concentrate|Crackers/pasta with added faba bean protein concentrate
11306125|NCT02658591|Experimental|Faba bean protein isolate|Crackers/pasta with added faba bean protein isolate
11306126|NCT02658591|Experimental|Faba bean flour|Crackers/pasta with added faba bean flour
11306127|NCT02658591|Experimental|Faba bean starch|Crackers/pasta with added faba bean starch
11306128|NCT02658578|Active Comparator|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
11306129|NCT02658578|Placebo Comparator|Sham PNS|In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
11306130|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
11306131|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
11306132|NCT02658552|Experimental|HIFU treatment|To collect the data after HIFU treatment
11306136|NCT02658513||All Patients|"All patients will undergo both of the following interventions:
~Lancet blood sampling Standard intravenous blood sampling"
11306137|NCT02658500|Experimental|Infant Formula|200 newborns just consume the infant formula from 0-42 days to six months age.
11306138|NCT02658500|Other|Breast Milk|100 newborns were just fed with breast milk from after birth to six months age.
11306139|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
11306140|NCT02658474|Experimental|ACT-group|Group based Acceptance and Commitment Therapy. The patients will attend to three sessions which last for three days. Between the sessions the patients will train at home on ACT related topics. The whole intervention will last for three months.
11306141|NCT02658474|No Intervention|Primary care|Treatment in a primary care setting.
11306142|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
11306143|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
11306144|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
11306145|NCT02658448|Experimental|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
11306146|NCT02658435|Experimental|Tafenoquine 300 milligram (mg) single dose|Participants will receive single dose of TQ (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
11306147|NCT02658435|Placebo Comparator|Matched Placebo 300mg single dose|Participants will receive single dose of matched placebo (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
11306148|NCT02658422|Experimental|Sequence A-B (Test Montelukast then Reference Montelukast)|Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
11306149|NCT02658422|Experimental|Sequence B-A (Reference Montelukast then Test Montelukast)|Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
11306150|NCT02658409|Experimental|GC3106(quadrivalent)|0.5ml, intramuscular, a single dosing
11306151|NCT02658409|Active Comparator|Fluarix™tetra Syringe Inj.(Quadrivalent)|0.5ml,intramuscular,a single dosing
11306152|NCT02658396|Experimental|GO-203-2C|"Patients who fulfill eligibility criteria will be entered into the trial to receive Bortezomib and GO-203-2C.
~After the screening procedures confirm participation in the research study:
~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
~Bortezomib
~GO-203-2C"
11306153|NCT02658383|Experimental|Cleaner cookstove received after visit 2|This arm receives the cleaner cookstove earlier in the study (after visit 2 which is approximately after 6 months)
11306154|NCT02658383|Experimental|Cleaner cookstove received after visit 4|This arm receives the cleaner cookstove later in the study (thus acting as a control arm until after visit 4 which is after approximately 1 yr and 6 months)
11306155|NCT02658370|Experimental|animated home-based exercises (Wii-fit)|using the Wii game console by Nintendo
11306156|NCT02658370|Active Comparator|conventional home-based exercise program|by using a compilation with 31 exercises especially for rheumatoid arthritis patients
11306157|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
11306158|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
11306159|NCT02658344|Experimental|Jointstem|Autologous Adipose Tissue derived MSCs
11306160|NCT02658344|Placebo Comparator|Saline solution|Sodium chloride
11306161|NCT02658318||Pierre Robin Syndrome (PRS)|Cleft palate patients with the Pierre Robin Syndrome.
11306162|NCT02658318||non-PRS|Cleft palate patients without the Pierre Robin Syndrome.
11306163|NCT02658305||transoral group|orthognathic patients that were treated with a transoral surgical approach
11306164|NCT02658305||transbuccal group|orthognathic patients that were treated with a transbuccal surgical approach
11306165|NCT02658292|Active Comparator|NAFT900|NAFT900 (Naftifine hydrochloride foam, 3%)
11306166|NCT02658292|Placebo Comparator|Vehicle|Vehicle Foam
11306167|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
11306168|NCT02658266|Experimental|Resistance training|Home based resistance training 12 weeks home based resistance training 3 times per week, 10-12 reps, 2 sets
11306169|NCT02658266|No Intervention|Control group|No instructed exercise training. Continue with habitual physical activity.
11306170|NCT02658253|Experimental|Group A1:Primvac 20 µg +alhydrogel|"Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
11306391|NCT02656719|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
11306171|NCT02658253|Experimental|Group A2:Primvac 20 µg +GLA-SE|Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
11306172|NCT02658253|Experimental|Group B1:Primvac 50 µg +alhydrogel|"Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
11306173|NCT02658253|Experimental|Group B2:Primvac 50 µg +GLA-SE|Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
11306174|NCT02658253|Experimental|Group C1:Primvac 50 µg +alhydrogel|"Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
11306175|NCT02658253|Experimental|Group C2: Primvac 50 µg +GLA-SE|"Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE
~Vaccination schedule: D0, D28 and D56"
11306176|NCT02658253|Placebo Comparator|Group C3: Placebo|"Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)
~Vaccination schedule: D0, D28 and D56"
11306177|NCT02658253|Experimental|Group D1:Primvac 100 µg +alhydrogel|"Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®
~Vaccination schedule: D0, D28 and D56"
11306178|NCT02658253|Experimental|Group D2: Primvac 100 µg +GLA-SE|"Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE
~Vaccination schedule: D0, D28 and D56"
11306179|NCT02658253|Placebo Comparator|Group D3: placebo|"Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)
~Vaccination schedule: D0, D28 and D56"
11306180|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
11306181|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
11306182|NCT02658214|Experimental|Cohort 1|ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
11306183|NCT02658214|Experimental|Cohort 2|Small-cell lung cancer (SCLC)
11306184|NCT02658214|Experimental|Cohort 3|Triple-negative breast cancer (TNBC)
11306185|NCT02658214|Experimental|Cohort 4|Triple-negative breast cancer (TNBC)
11306186|NCT02658214|Experimental|Cohort 5|Gastric/gastro-esophageal junction (GEJ)
11306187|NCT02658214|Experimental|Cohort 6|Pancreatic ductal adenocarcinoma (PDAC)
11306188|NCT02658214|Experimental|Cohort 7|Esophageal squamous cell carcinoma (ESCC)
11306189|NCT02658201|Other|MRI group|Ultrafast MRI
11306190|NCT02658188|Experimental|ASP8825 group|
11306191|NCT02658175|Experimental|Volanesorsen|
11306192|NCT02658162|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
11306193|NCT02658162|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
11306194|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
11306195|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
11306196|NCT02658136|Other|1 arm study: CCT estimated right ventricular function.|
11306197|NCT02658123|Active Comparator|Group A: Standard of care|"Standard of care pre-operative education
~Standard of care home health visits
~Standard of care follow-up post-operative visits with surgeon and CWOCN
~At 30-days post hospital discharge, the participant will:
~See the physician
~Turn in Patient Data Collection Form
~Turn in Healthcare Utilization Form
~Complete The City of Hope QOL Survey for Ostomy Patients
~Ostomy assessment with a CWOCN, including photo of ostomy site"
11306198|NCT02658123|Experimental|Group B: Phone call|"Standard of care pre-operative education
~Standard of care home health visits
~Standard of care follow-up post-operative visits with surgeon and CWOCN
~Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.
~At 30-days post hospital discharge, the participant will:
~See the physician
~Turn in Patient Data Collection Form
~Turn in Healthcare Utilization Form
~Complete The City of Hope QOL Survey for Ostomy Patients
~Ostomy assessment with a CWOCN, including photo of ostomy site"
11306199|NCT02658110|Sham Comparator|Non Protein Trial|Mixed Macronutrient Breakfast Meal and Mixed Macronutrient Lunch Meal served without additional whey protein
11306200|NCT02658110|Experimental|Preload Trial|Whey protein (20g) administered 15 minutes prior to Mixed Macronutrient Breakfast Meal
11306201|NCT02658110|Experimental|With Meal Trial|Whey protein (20g) administered alongside Mixed Macronutrient Breakfast Meal
11306202|NCT02658110|Experimental|Post Meal Trial|Whey protein (20g) administered 15 minutes after Mixed Macronutrient Breakfast Meal
11306203|NCT02658097|Experimental|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
11306204|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
11306205|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
11306206|NCT02658058|Active Comparator|Landmark technique|As intervention, patients in this group are administered landmark guided midline spinal anesthesia.
11306207|NCT02658058|Experimental|Ultrasound-guided paramedian technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided paramedian technique using parasagittal oblique view
11306208|NCT02658058|Experimental|Ultrasound-guided midline technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided midline technique using transverse median view
11306209|NCT02658045||Normal healthy volunteers|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in healthy volunteers during 6 min walking test
11306210|NCT02658045||COPD patients|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in COPD patients during 6 min walking test
11306211|NCT02658032|Other|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
11306212|NCT02658032|Other|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
11306213|NCT02658032|Other|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
11306214|NCT02658032|Experimental|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
11306215|NCT02658019|Experimental|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
11306216|NCT02658006||Cardiac surgical patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
11306217|NCT02657993|Experimental|Hypnosis|The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
11306218|NCT02657993|Active Comparator|Attention Control (Non-Hypnosis)|The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
11306219|NCT02657980|Experimental|YBand(YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (total of 10 applications)
11306220|NCT02657980|Sham Comparator|Sham-Yband(YDT-201N)|sham-tDCS application 5 days a week for 2 weeks (total of 10 applications)
11306221|NCT02657954|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training
11306222|NCT02657954|Active Comparator|Holistic Cognitive Education (HCE)|Holistic Cognitive Education
11306223|NCT02657941|Experimental|Motivational group|psycho-education program inspired by motivational interviewing and behavioral psychotherapy
11306224|NCT02657941|Active Comparator|educational group|exclusively informative psycho-education program
11306225|NCT02657928|Experimental|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11306226|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
11306227|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
11306228|NCT02657902||Gamma 3 Nail|Fractures that were treated with a Gamma 3 nail
11306229|NCT02657902||Gamma 3 Nail + U-Blade|Fractures that were treated with a Gamma 3 nail and additional with antirotation U-blade lag screws.
11306230|NCT02657889|Experimental|niraparib plus pembrolizumab|"Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle
~Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle"
11306231|NCT02657876|Experimental|ExpressGraft-C9T1 Skin Tissue|Enrolled participants receive one application of ExpressGraft-C9T1 skin tissue
11306232|NCT02657863||Healthy volunteer|Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
11306233|NCT02657863||Prostate cancer patients being treat with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
11306234|NCT02657863||Prostate cancer patients being treated with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
11306235|NCT02657850||control cohort - study subject self-reporting|Participants who have another cancer (not head and neck cancer) and undergoing treatment will self-report their dysphagia symptoms.
11306236|NCT02657850||study cohort - study subject self-reporting|Participants who have head and neck cancer and undergoing treatment will self-report their dysphagia symptoms.
11306237|NCT02657850||study cohort - provider reporting|Participants who have head and neck cancer and undergoing treatment will have their dysphagia symptoms reported by the provider.
11306238|NCT02657837||Cystic Fibrosis|Children 2.5 to 18 years old with confirmed diagnosis of cystic fibrosis
11306239|NCT02657837||Children with other respiratory disease|Children 2.5 to 18 years old with confirmed diagnosis of respiratory disease including but not limited to asthma, transplant, and sickle cell anemia.
11306240|NCT02657837||Healthy Children|Children and adults 2.5 to 30 years old with no history of chronic disease
11306241|NCT02657824||measuring ejection fraction|ejection fraction in an acute dyspneic patients
11306242|NCT02657811|Active Comparator|Bench Incubation|These embryos will be randomized to the bench incubator.
11306243|NCT02657811|Active Comparator|Time Lapse Incubation|These embryos will be randomized to the Time Lapse Incubator.
11306245|NCT02657798||Depressed patients taking sertraline|Patients with depression who have been randomised to the sertraline arm in the PANDA trial
11306246|NCT02657798||Depressed patients taking placebo|Patients with depression who have been randomised to the placebo arm in the PANDA trial
11306247|NCT02657798||Healthy controls|Healthy participants with no history of depression
11306248|NCT02657785|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
11306249|NCT02657759|Experimental|CARDICHOL|Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.
11306250|NCT02657759|Placebo Comparator|Placebo|"placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.
~2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch."
11306251|NCT02657746|No Intervention|usual care|Usual care comprises existing services for hypertension control in the community without any additional training
11306252|NCT02657746|Experimental|multi-component interventions|: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
11306253|NCT02657733|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and Nellcor Bedside Respiratory Patient Monitoring System
11306254|NCT02657720|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and PTAF2 (flow meter)
11306255|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
11306256|NCT02657694||Sofosbuvir+Ledipasvir|Following patients treating with Sofosbuvir+Ledipasvir
11306257|NCT02657694||Sofosbuvir+Daclatasvir|Following patients treating with Sofosbuvir+Daclatasvir
11306258|NCT02657694||Sofosbuvir+Velpatasvir|Following patients treating with Sofosbuvir+Velpatasvir
11306259|NCT02657681|Experimental|tSMS|30 min of tSMS, one session per day, for 9 days over 2 weeks
11306260|NCT02657681|Placebo Comparator|sham|30 min of sham, one session per day, for 9 days over 2 weeks
11306261|NCT02657668|Experimental|Treatment Group|Emotion focused therapy: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
11306262|NCT02657668|No Intervention|Control Group|Control group: For control group interactions to be effective in therapeutic outcomes, the psycho-educational group was assigned as control group. The Psycho-educational group was conducted in four sessions (without pretest and posttest sessions). They became familiar with etiology and role of psychological factors in IBS, without any psychotherapy. Eight members were removed (because of being absent more than three sessions).
11306263|NCT02657655|Experimental|Kinesia 360 Users|Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
11306264|NCT02657642||Cohort 1 (exposed)|cohort 1: patients who will receive the OMAGE-P transitional care in geriatric or internal medicine departement of the Eaubonne Hospital
11306265|NCT02657642||Cohort 2 (non exposed)|Cohort 2: : patients included in the usual care arm of the OMAGE RCT study in 2007-2008
11306266|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
11306267|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
11306268|NCT02657616||No anticoagulation with VKA/NOAC|No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
11306269|NCT02657616||Anticoagulation with vitamin-k-antagonists|The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
11306270|NCT02657616||Anticoagulation with novel oral anticoagulants|The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
11306271|NCT02657603|Active Comparator|LAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the adductor canal
11306272|NCT02657603|Active Comparator|SAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the contralateral adductor canal
11306273|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
11306274|NCT02657551|Experimental|Regorafenib|Regorafenib tablets orally, once daily at predetermined dosage for 21 days per cycle
11306275|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
11306276|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
11306671|NCT02654873||Malign|Malign group includes the conditions such as detecting mass or irregularities in the gallbladder wall.
11306277|NCT02657512|Experimental|Arm A|"Period  rivaroxaban alone
~Washout period (at least 6 days)
~Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration"
11306278|NCT02657512|Experimental|Arm B|". Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period  rivaroxaban alone
~Washout period (at least 6 days)
~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration"
11306279|NCT02657512|Experimental|Arm C|". Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration
~Washout period (at least 6 days)
~Period  rivaroxaban alone"
11306280|NCT02657499||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
11306281|NCT02657499||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
11306282|NCT02657486|Experimental|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
11306283|NCT02657473|Active Comparator|TIS 300mg once daily|Tobramycin inhalation solution (TIS) 300mg once daily for at least 9 months and up to 12 months
11306284|NCT02657473|Placebo Comparator|Placebo once daily|Saline 0.9% inhalation solution 300mg once daily for at least 9 months and up to 12 months
11306285|NCT02657460|Experimental|MTX-ATMPs|methotrexate-autologous tumor derived microparticles
11306286|NCT02657460|Sham Comparator|cisplatin|Cisplatin is a traditional treatment for lung cancer
11306287|NCT02657447|Experimental|Arm 1: Betalutin with lilotomab dose 1|Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
11306288|NCT02657447|Experimental|Arm 2: Betalutin with lilotomab dose 2|Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
11306289|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
11306290|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
11306291|NCT02657408|Experimental|BI 1026706|
11306292|NCT02657408|Experimental|Placebo|
11306293|NCT02657395|Experimental|PriMatrix|Use of PriMatrix as a substitute for a subepithelial connective tissue graft under a coronal positioned flap for root coverage.
11306294|NCT02657382|Experimental|Heart Rate Variability (HRV) Biofeedback (BF)|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests. Participants in this group will also participate in heart rate variability (HRV) biofeedback (BF) during the first six weeks of the study.
11306295|NCT02657382|Experimental|Waitlist Control|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests.Participants in this group will receive the heart rate variability (HRV) biofeedback (BF) intervention between the week 6 and week 12 study visits.
11306296|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
11306297|NCT02657356|Placebo Comparator|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
11306298|NCT02657356|Experimental|Bardoxolone methyl capsules|Bardoxolone methyl capsules will be administered orally once a day for 24 weeks. Starting dosage is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
11306299|NCT02657343|Experimental|Cohort A|Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time.
11306300|NCT02657343|Experimental|Cohort B|Ribociclib will be given orally once day continuously for a 21-day cycle of treatment (except at Dose Level -2, when Ribociclib is given Days 1-14 of a 21 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose.
11306301|NCT02657343|Experimental|Cohort C|Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care.
11306302|NCT02657330|Experimental|SBP-101|SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
11306303|NCT02657317|Experimental|FORT-A|"has been labeled FORT-A. FORT-A is provided on an outpatient basis and includes 12 daily group pain management and physical therapy sessions spanning three weeks. Group interventions are supplemented by individual psychotherapy, biofeedback, and case staffings. CBT sessions were decreased in favor of CAM components. FORT-A participants will receive 270 minutes (4½ hours) of intervention a day for 12 days over 3 weeks."
11306392|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
11306304|NCT02657317|Active Comparator|VA Treatment As Usual|"Treatment As Usual (TAU) represents usual VA Care based on as usual appointments and referrals from VA providers. TAU can include active medical interventions, psychosocial intervention, and other rehabilitation strategies."
11306305|NCT02657304|Experimental|Coaching group|PPC + Coaching
11306306|NCT02657304|Active Comparator|Control group|PPC
11306307|NCT02657291|Experimental|Costoclavicular|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the costoclavicular approach
11306308|NCT02657291|Active Comparator|Paracoracoid|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the paracoracoid or standard approach
11306309|NCT02657278|Other|Symptomatic Peripheral arterial disease|Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication.
11306310|NCT02657265|Experimental|SpineJack® system|Spine fracture management
11306311|NCT02657265|Active Comparator|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
11306312|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
11306313|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
11306314|NCT02657239|Experimental|MOVE UP Intervention|Subjects will participate in a healthy lifestyle weight management intervention focused on healthy eating and increasing physical activity
11306315|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
11306316|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
11306317|NCT02657213|Experimental|Minimed 640G with smartguard activated|"Group SmartGuard On: Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640G insulin pump with SmartGuard activation"
11306318|NCT02657213|Active Comparator|Minimed 640G with smartguard off|"Group SmartGuard Off Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640 insulin pump without SmartGuard activation"
11306319|NCT02657187|Experimental|rocuronium 1|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
11306320|NCT02657187|Experimental|rocuronium 2|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
11306321|NCT02657187|Experimental|rocuronium 3|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
11306322|NCT02657187|Experimental|rocuronium 4|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
11306323|NCT02657174|Experimental|G1- experimental active comparator group|G1 - (Experimental) 40 third molars surgeries will be performed in a conventional manner. At the end of surgery low level laser in auricular acupuncture points will be applied for prevention of inflammation and pain in a split-mouth design.
11306324|NCT02657174|Placebo Comparator|G2- control group|G2 - (Control) 40 third molars surgeries will be performed in the conventional manner, identically to the G1. At the end of surgery low level laser device off in auricular acupuncture points will be applied. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1, with split-mouth design.
11306325|NCT02657161|Active Comparator|Group A|"Comparator vaccine RABIPUR®
~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
11306326|NCT02657161|Experimental|Group B|"PIKA Rabies vaccine
~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
11306327|NCT02657161|Experimental|Group C|"PIKA Rabies vaccine with an accelerated regimen
~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)"
11306328|NCT02657148||Immediate postpartum Nexplanon|Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.
11306329|NCT02657148||Control|Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
11306330|NCT02657135|Experimental|History of Traumatic Brain Injury|All participants have a history of TBI. At study outcome participants are provided treatment recommendations that are the result of a consensus meeting of all physician investigators. Follow up care is not provided by this clinical trial.
11306331|NCT02657122|Experimental|TD-1473 for SAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
11306332|NCT02657122|Placebo Comparator|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
11306333|NCT02657122|Experimental|TD-1473 for MAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
11306334|NCT02657122|Placebo Comparator|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
11306335|NCT02657109|Active Comparator|Control|Participants are submitted to cardiac rehabilitation protocol of the hospital where it will be conducted the study, which consists in respiratory exercises of 3 series Inspirations Maximum Sustained for 10 reps, 3 sets of 20 repetitions metabolic exercises with dorsiflexion and plantar flexion and ankle and wrist extension and fingers of the upper limbs. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of postoperative and on the fifth postoperative day
11359054|NCT02307487|Experimental|Cohort B|140 mg MMC in 60ml gel
11306336|NCT02657109|Active Comparator|Early mobilization|Participants performed exercise in cycle ergometer of lower Limbs, pedaling for 20 consecutive minutes at a moderate level with Heart Rate Assessment and the Borg scale to evaluate the Voluntary Comfort. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of oepratório post and on the fifth postoperative day
11306337|NCT02657096|Experimental|Hybenx treatment|Both quadrants included maxillary teeth 11-16 and 21-26. Each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional SRP + desiccant (Hybenx). In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the marginal gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
11306338|NCT02657096|Sham Comparator|Scaling and Root Planing|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
11306339|NCT02657083|Experimental|Glucose control using DreaMed MD-AID|In this group the subjects use a closed loop system (DreaMed Substance Administration Device) that combines glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™), which provides real-time interstitial glucose values, with a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) and computer algorithm, which directs insulin delivery in response to glucose sensor data.
11306340|NCT02657083|Active Comparator|Glucose control using SAP|In this group the subjects use a standard treatment (Sensor Augmented Pump), characterised by glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™) which provides real-time interstitial glucose values and a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) without computer algorithm decisions.
11306341|NCT02657070|Experimental|Experimental Group|Virtual reality based therapy with augmented visuomotor feedback.
11306342|NCT02657070|Active Comparator|Control Group|Virtual reality based therapy without augmentation.
11306343|NCT02657057|Experimental|Transcutaneous Tibial Nerve Stimulation|TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
11306344|NCT02657057|Active Comparator|Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
11306345|NCT02657044|Active Comparator|EMR|In the EMR-arm, endoscopic resection will be performed using the (p)EMR technique.
11306346|NCT02657044|Active Comparator|ESD|In the ESD-arm, endoscopic resection will be performed using the (h)ESD technique.
11306347|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
11306348|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
11306349|NCT02657018|Experimental|Intervention|MOBIGAME group
11306350|NCT02657018|Active Comparator|Control|Lifestyle counseling group
11306351|NCT02657005|Experimental|TK216 treatment|Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
11306352|NCT02656992|Experimental|High-IMT group|Intervention group receive supervised training sessions three times per week for 8 weeks. Each sessions lasted 21 minutes and comprised seven cycles of 2 minutes of breathing on an inspiratory threshold device followed by 1 minute of rest. High-IMT was performed at the maximal load tolerable for each 2-minute work interval and was progressively increased over the training period.
11306353|NCT02656992|Sham Comparator|Control group|Control group was prescribed at 10% of baseline maximal inspiratory pressure, and remained at this level during all training sessions for 8 weeks.
11306354|NCT02656979|Other|Blood flow pre&post IOP lowering|After measurement of blood flow with MRI and measurements of ocular parameters the patient receives the IOP lowering eye drop latanoprost once daily in one eye for approximately one week and then the measurements are are repeated in the same manner.
11306355|NCT02656979|No Intervention|Blood flow|The subjects will do blood flow measurements with MRI and measurements of ocular parameters only once. No intervention with IOP lowering drops.
11306356|NCT02656966|Active Comparator|Auricular acupuncture + standard therapy|Patients, who will wish acupuncture, will receive this intervention, in addition to standard therapy
11306357|NCT02656966|No Intervention|Standard therapy alone|Patients who do not wish acupuncture will be asked if they will fill in the study questionnaire
11306358|NCT02656953|Experimental|VDU lenses|VDU lenses provide a clear vision of the intermediate zone at a distance of approximately 70 centimeters, which is closer than distant vision at a distance of more than 2 meters (e.g. driving), but further than near vision at a distance of 40 centimeters (e.g. reading), so the computer screen is seen clear without the need for excessive focusing effort or bad postures. In this study Zeiss® Officelens Plus lenses with a Silhouette® frame were used.
11306359|NCT02656953|Active Comparator|Progressive lenses|Progressive lenses or multifocal lenses provide a continuous range of focal power between near and far distances.Progressive lenses have some lens power for the intermediate zone as well, but this zone might not be large enough for comfortable and ergonomic computer work. In this study Zeiss® Multifocal Precision Plus lenses with a Silhouette® frame were used.
11306393|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
11359055|NCT02307487|Experimental|Cohort C|160 mg MMC in 60ml gel
11306360|NCT02656940|Experimental|Group 1 - diet rich in n-3 and n-6 PUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.
~Group 1 received diet rich in n-3 and n-6 polyunsaturated fatty acids (PUFA). The volunteers were asked to consume daily a mixture of virgin olive oil and soybean oil, totaling 35.2g to 52.8g, and 2 g of fish oil."
11306361|NCT02656940|Experimental|Group 2 - diet rich in MUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.
~Group 2 received diet rich in monounsaturated fatty acids (MUFA). The volunteers were asked to consume daily virgin olive oil, totaling 35.2g to 50.6g, and 1 capsule of 1g of soybean oil."
11306362|NCT02656940|Experimental|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming 1 sachet of 2g of soybean oil and 1 capsule of 1g of soybean oil by day.
11306363|NCT02656927|Experimental|Yoga Condition|
11306364|NCT02656927|Placebo Comparator|Wait-list Control Condition|
11306365|NCT02656914|Experimental|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
11306366|NCT02656914|Placebo Comparator|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
11306367|NCT02656901|Active Comparator|Auto Total endovenous anesthesia|The closed loop delivering as already approved by ClinicalTrials.gov Identifier: NCT00392158
11306368|NCT02656901|Sham Comparator|Manual Desflurane anesthesia|The anesthesia will be maintained with desflurane to target the BIS of 50.
11306369|NCT02656901|Sham Comparator|Manual sevoflurane anesthesia|The anesthesia will be maintained with sevoflurane to target the BIS of 50.
11306370|NCT02656901|Sham Comparator|Manual total endovenous anestesia|In ManualTIVA group, the anesthesia will be maintained with propofol to target the BIS of 50
11306371|NCT02656888|Experimental|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
11306372|NCT02656888|Placebo Comparator|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
11306373|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.
~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
11306374|NCT02656849|Experimental|BAY 1000394|"After the screening procedures confirm eligibility to participate in the research study:
~Each treatment cycle lasts 4 weeks.
~Participants will take the study drug orally at predetermined times and dosage per cycle."
11306375|NCT02656823|Other|ANKYLOS C/X 6.6 mm implants|ANKYLOS C/X 6.6 mm implants
11306376|NCT02656810|Experimental|Sequence A|Single subcutaneous injection of two teriparatide products (PF708 and Forteo)
11306377|NCT02656810|Experimental|Sequence B|Single subcutaneous injection of two teriparatide products (Forteo and PF708)
11306378|NCT02656797|Experimental|AM-B|Topical Amphotericin-B 0.4% liposomal gel
11306379|NCT02656797|Placebo Comparator|Placebo|Placebo gel preparation
11306380|NCT02656784|Experimental|Trial-Based Cognitive Therapy (TBCT)|"Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach, based on the work of Franz Kafka The Trial and developed by Professor Irismar Reis de Oliveira at Federal University of Bahia, Brazil. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All individuals in the group will be submitted to MRI"
11306381|NCT02656784|Experimental|Behavioral Therapy (ERP)|The Behavioral Therapy is an intervention of first choice for treatment of OCD , which employs the technique of Exposure and Response Prevention (ERP) , considered the gold standard to the disorder. The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All individuals in the group will be submitted to MRI
11306382|NCT02656784|No Intervention|Control Group|The control group consisted of individuals without OCD, matched with the experimental group in terms of gender,age and education. In this group are not included in individuals in psychotherapeutic care and with a history of neurological or psychiatric disorder; however, all them will be submitted to MRI .
11306383|NCT02656771|Active Comparator|Echo Bi-Metric THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.
~It is a relatively new implant that is now in routine clinical use. The stem uses many of the features of the known and used Integral® and Bi-Metric® hip stems while integrating new design features to further enhance clinical performance such as a reduced neck geometry to allow for increased ROM and decreased risk of neck impingement, a polished neck designed to reduce debris should impingement occur and a polished bullet-shape distal tip to reduce distal stresses."
11306384|NCT02656771|No Intervention|Bi-Metric Porous Primary THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.
~It was introduced in 1984 and have shown good clinical results and excellent stem survival in register studies"
11306385|NCT02656758|Experimental|Executive function training|the experimental group will receive 12 sessions of intensive Executive function training weekly immediately
11306386|NCT02656758|Other|the waitlist group|the waitlist group will wait 12 weeks before receiving intensive executive function training for comparison.
11306387|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
11306388|NCT02656732|Experimental|coronally advanced flap with amnion chorion membrane|coronally advanced flap was reflected and amnion chorion allograft membrane was placed under the flap as a guided tissue regeneration barrier.
11306389|NCT02656732|Active Comparator|subepithelial connective tissue graft|coronally advanced flap was reflected and subepithelial connective tissue graft was harvested from the palate and placed under the flap.
11306390|NCT02656719|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
11306394|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
11306395|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
11306396|NCT02656680|Experimental|FB+Friends|FB+Friends is a Facebook-delivered weight loss intervention. In wave 1, participants will be able to invite their friends who are also interested in losing weight. In wave 2, the study team will keep recruitment open for this condition to allow enrollment through week 8.
11306397|NCT02656680|Active Comparator|FB Only|FB Only Facebook-delivered weight loss intervention including only study participants.
11306398|NCT02656667|Experimental|neuromuscular electrical stimulation|conventional pulmonary rehabilitation including exercise training on treadmill and neuromuscular electrical stimulation with a medical device for quadriceps muscle strengthening
11306399|NCT02656667|Experimental|cycle ergometer training|conventional pulmonary rehabilitation including exercise training on treadmill and quadriceps strenghthening on cycle-ergometer
11306400|NCT02656641|No Intervention|Control|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will not complete any scales during other sessions.
11306401|NCT02656641|Experimental|Continuous Client Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will review and discuss their results and at the beginning of each session.
11306402|NCT02656641|Experimental|Continuous Self Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will not have access to these results.
11306403|NCT02656628||Fractures of humerus femur tibia|Dynamic Locking Screw 3.7mm and 5.0mm
11306404|NCT02656615|Experimental|Abiraterone|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
11306405|NCT02656602|No Intervention|Nurse Counseling|A trained endoscopy nurse provided patients with all information on their scheduled colonoscopy.
11306406|NCT02656602|Experimental|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI.All elements of informed consent for colonoscopy (risks, alternatives) were included.
11306407|NCT02656589||Herceptin probable sensitive group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable sensitive group
11306408|NCT02656589||Herceptin probable resistant group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable resistant group
11306409|NCT02656576|Other|patient with suspected lesions of the tonsillar region|patients will have a tonsil biopsy and a smear
11306410|NCT02656563|Experimental|Radium 223 Arm|Radium 223 Dichloride (Xofigo®)
11306411|NCT02656563|No Intervention|Non Treatment Arm|Control Arm
11306412|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
11306413|NCT02656537|Experimental|EnSite™ HD Grid Catheter AF/AT Mapping|
11306414|NCT02656524||Cohort1/Regorafenib|All patients with at least 1 treatment with regorafenib
11306415|NCT02656511|Experimental|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
11306416|NCT02656498|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
11306417|NCT02656498|Experimental|MCI Subjects|MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
11306418|NCT02656498|Experimental|AD Subjects|AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
11306419|NCT02656498|Experimental|Subjects with other neurodegenerative disease|Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
11306420|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
11306421|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
11306422|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
11306423|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
11306424|NCT02656472|Active Comparator|Tranexamic Acid Arm|TXA arm will include 10 subjects who will receive TXA for duration of surgery.
11306425|NCT02656472|Active Comparator|Epsilon Aminocaproic Acid Arm|EACA arm will include 10 subjects who will receive EACA for the duration of surgery.
11306426|NCT02656433|Placebo Comparator|Placebo Group|Receive treatment with physiotherapy
11306427|NCT02656433|Experimental|Experimental or tRNS Group|Receive treatment with physiotherapy plus Transcranial Random Noise Stimulation (tRNS)
11306428|NCT02656420|Placebo Comparator|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
11306429|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
11306768|NCT02654275|Active Comparator|Proprioceptive Intervention|Strength training on a non-stable surface
11306430|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
11306431|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
11306432|NCT02656407|Experimental|Ultrasensitive Doppler|Intraoperative ultrasensitive Doppler acquisitions by using an ultrasound device for functional area detection
11306433|NCT02656394|Active Comparator|GL101|GL101 topical gel
11306434|NCT02656394|Placebo Comparator|Placebo|Placebo topical gel
11306435|NCT02656381||Anterior Uveitis|Participants with AU at entry
11306436|NCT02656381||Intermediate Uveitis|Participants with IU at entry
11306437|NCT02656381||Other|Participants not fitting above criteria
11306438|NCT02656381||Posterior/Pan Uveitis|Participants with non-infectious posterior or pan-uveitis
11306439|NCT02656368|Experimental|Interventional, open label, Safety/Efficacy Study|SEBORRHEAMEDIS Face Cream Interventional 30
11306440|NCT02656355|No Intervention|Stage 1:Healthy people|To establish baseline and reliability.
11306441|NCT02656355|No Intervention|Stage 2:Healthy people|To establish stage 3 training protocol.
11306442|NCT02656355|No Intervention|Stage 2:PD people|To establish stage 3 training protocol.
11306443|NCT02656355|Experimental|Stage 3:PD APA training group|Weight shift training and APA feedback.
11306444|NCT02656355|Experimental|Stage 3:PD Balance training group|Weight shift training without APA feedback.
11306445|NCT02656355|No Intervention|Stage 3:PD Control group|Control group
11306446|NCT02656342|Experimental|250 mg DCS|64 patients receive 250 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
11306447|NCT02656342|Experimental|100 mg D-Cycloserine|64 patients receive 100 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
11306448|NCT02656342|Active Comparator|Placebo|32 patients receive placebo two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
11306449|NCT02656329|Experimental|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
11306450|NCT02656329|Experimental|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
11306451|NCT02656316|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
11306452|NCT02656316|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
11306453|NCT02656303|Experimental|Ublituximab + TGR-1202|Ublituximab IV treatment + TGR-1202 oral daily dose
11306454|NCT02656290|Experimental|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
11306455|NCT02656277|Experimental|Decision tool|The decision tool includes a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention.
11306456|NCT02656277|Active Comparator|Information on Shoulder Dislocation|Subjects in this arm will receive the standard of care information available to patients to make this treatment decision.
11306457|NCT02656251|Active Comparator|0.12% Clorhexidine with alcohol|0.12% Clorhexidine with alcohol, 15ml every 12 hour for 4 days
11306458|NCT02656251|Experimental|0.12% Clorhexidine without alcohol|0.12% Clorhexidine without alcohol, 15ml every 12 hour for 4 days
11306459|NCT02656251|Placebo Comparator|control|placebo 15ml every 12 hour for 4 days
11306460|NCT02656225|Experimental|Ejiao compound|The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
11306461|NCT02656225|Active Comparator|Niferex|The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
11306462|NCT02656212|Experimental|(+)-epicatechin 30mg|10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin
11306463|NCT02656212|Placebo Comparator|placebo|5 subjects will be randomized to a placebo
11306464|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
11306465|NCT02656186|Experimental|Single-arm pretest-posttest|In this study, the subjects served as their own controls. Subjects who were eligible based on inclusion criteria first entered into a 2-week pre-intervention period, during which they received nutrition counseling to keep their routine dietary habits. This was followed by an intervention period, during which an oral nutritional supplement was used over a period of 2 weeks.
11306466|NCT02656173|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
11306467|NCT02656173|Experimental|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
11306468|NCT02656160|Placebo Comparator|Placebo|
11306469|NCT02656160|Active Comparator|Dalfampridine|
11306470|NCT02656147|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
11306471|NCT02656147|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
11306472|NCT02656147|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
11306473|NCT02656121|Experimental|Vitamin D|1st subgroup will be tested and treated with vitamin D together with Clomiphene Citrate for induction of ovulation
11306474|NCT02656121|Active Comparator|control|2nd subgroup will be treated with Clomophene Citrate only
11306475|NCT02656108|Experimental|omiited controlled cord traction|neither controlled cord traction nor fundal pressure will be applied. The placenta will be delivered physiologically and signs of placental separation will be awaited
11306476|NCT02656108|Active Comparator|controlled cord traction|the cord will be held in one hand and the other hand will be placed just above the woman's pubic boneto stabilize the uterus during cord traction
11306477|NCT02656082|Experimental|Etanercept|Intradermal injection of etanercept. The dosage is determined based on discoid lesion radius. Weekly injection up to 12 weeks.
11306478|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
11306479|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
11306480|NCT02656056|Experimental|Lean Adults|Adults with a BMI between 21-25 will consume 8 oz of the fermented soybean beverage, twice daily.
11306481|NCT02656056|Experimental|Obese Adults|Adults with a BMI between 32-37 will consume 8 oz of the fermented soybean beverage, twice daily.
11306482|NCT02656043|Active Comparator|XPF-005|Active treatment: XPF-005 Gel
11306483|NCT02656043|Placebo Comparator|Vehicle gel|Placebo: XPF-005 Vehicle Gel
11306484|NCT02656030|Experimental|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise 2 times/week, 6 weeks duration
11306485|NCT02656030|Experimental|cranio-cervical flexion exercise|cranio-cervical flexion exercise 2 times/week, 6 weeks duration
11306486|NCT02656030|Active Comparator|usual care|Usual care 2 times/week, 6 weeks duration
11306487|NCT02656017|Experimental|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:
~Increase to 500mg twice daily at week 2
~Increase to 1000mg qAM, 500mg qPM at week 4
~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).
~Increased titrations based on tolerability"
11306488|NCT02656017|Placebo Comparator|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:
~Increase to 500mg twice daily at week 2
~Increase to 1000mg qAM, 500mg qPM at week 4
~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).
~Increased titrations based on tolerability"
11306489|NCT02656004|Experimental|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
11306490|NCT02656004|Experimental|Control|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
11306491|NCT02655991|Experimental|Telephone Case Monitoring|Telephone care management augmenting treatment as usual
11306492|NCT02655991|Active Comparator|Treatment as Usual|Case management, psychotherapy, and pharmacotherapy as usual
11306493|NCT02655978||Healthy Volunteers|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
11306494|NCT02655978||Medically Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
11306495|NCT02655978||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).
11306496|NCT02655965|Experimental|Ropivacaine + Clonidine|"A pecs block of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior.
~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
11306497|NCT02655965|Placebo Comparator|Sodium Chloride|"A pecs block of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior).
~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
11306498|NCT02655952|Experimental|Foxy-5|"Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.
~There will be a maximum of 8 dose cohorts. Cohorts 1-4 will be conducted in the United Kingdom and Denmark whereas cohorts 5-8 will only be conducted in Denmark. As doses in cohort 1 and 2 have been investigated in the previous phase I study, cohorts 1+2 and 3 can be run in parallel with dose escalation approved by the DSMB at all times.
~DK+UK: Cohort 1: 0.8 mg/kg DK+UK: Cohort 2: 1.3 mg/kg DK+UK: Cohort 3: 1.8 mg/kg DK+UK: Cohort 4: 2.3 mg/kg DK only: Cohort 5: 3.0 mg/kg DK only: Cohort 6: 4.0 mg/kg DK only: Cohort 7: 5.3 mg/kg DK only: Cohort 8: 7.0 mg/kg"
11306499|NCT02655939|Active Comparator|Reflex Plus|Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
11306500|NCT02655939|Placebo Comparator|Placebo|Placebo Sachets to be taken once in a day Before breakfast for the study duration
11306501|NCT02655926|Active Comparator|STN Arm|Participants would only have STN deep brain stimulation switched at optimal settings for that participant on for 12 weeks.
11306502|NCT02655926|Active Comparator|VC/VS Arm|Participants would only have VC/VS deep brain stimulation switched on at optimal settings for that participant for 12 weeks.
11306503|NCT02655913|Experimental|vitamin C+ mEHT+ supportive care|"Patients will be allocated into 3 Vitamin C infusion dosage groups:
~1g/kg.d,1.2g/kg.d,1.5g/kg.d;3 times a week for 8 weeks(25 infusions);concurrent with Modulated Electro-Hyperthermia (mEHT): 150W x 60 min/session,3 times a week for 8 weeks (25 sessions);together with supportive care."
11306769|NCT02654275|No Intervention|No Proprioceptive Intervention|Conventional strength training
11306504|NCT02655913|Placebo Comparator|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
11306505|NCT02655887|Experimental|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
11306506|NCT02655874|Experimental|Six-monthly influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
11306507|NCT02655874|Active Comparator|Annual influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
11306508|NCT02655861||Ichthyosis|
11306509|NCT02655848|Active Comparator|@ Cuff repair with LHB tenodesis|In case of pathologic changes of the long Head Biceps tendon, a tenodesis is performed in adjunct to performing an arthroscopic rotator cuff repair.
11306510|NCT02655848|Active Comparator|@ cuff repair with LHB tenotomy|In case of pathologic changes of the long Head Biceps tendon, a tenotomy is performed in adjunct to performing an arthroscopic rotator cuff repair.
11306511|NCT02655835|Experimental|Internet Mindfulness Meditation Intervention|Six-week internet mindfulness meditation training program including handouts and daily guided meditations
11306512|NCT02655835|Experimental|Access|Written information handouts on mindfulness meditation and access to guided daily meditations
11306513|NCT02655822|Experimental|Cohort 1 - Closed|Ciforadenant
11306514|NCT02655822|Experimental|Cohort 2 - Closed|Ciforadenant
11306515|NCT02655822|Experimental|Cohort 3 - Closed|Ciforadenant
11306516|NCT02655822|Experimental|Cohort 4|Ciforadenant + atezolizumab
11306517|NCT02655822|Experimental|Cohort 5 - Closed|Ciforadenant
11306518|NCT02655809|Other|Physica KR|Patients who have received a Physica KR total knee implant.
11306519|NCT02655796|Experimental|Moderate/High Risk|Participants assessed as moderate/high risk of falling according to the CDC Algorithm for Fall Risk Assessment
11306520|NCT02655796|Experimental|Low Risk|Participants assessed as low risk of falling according to the CDC Algorithm for Fall Risk Assessment
11306521|NCT02655783|Active Comparator|control|normal saline, 250 ml/h, until expulsion of placental
11306522|NCT02655783|Experimental|intervention|normal saline + 5% dextrose, 250 ml/h, until expulsion of placental
11306523|NCT02655770|Active Comparator|Liraglutide arm|Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
11306524|NCT02655770|Placebo Comparator|Placebo arm|Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
11306525|NCT02655757|Active Comparator|Sitagliptin|Sitagliptin 100mg QD
11306526|NCT02655757|Placebo Comparator|Placebo|Placebo
11306527|NCT02655744||newly-diagnosed patients with primary CNS lymphoma|
11306528|NCT02655731|Other|Treatment|PVI with HeartLight
11306529|NCT02655718|Other|Patients with ACS|Patients with ACS who underwent coronary angiography within 72 hours from the onset of disease. In identifying nonobstructive coronary atherosclerosis , patients underwent cardiac contrast MRI.
11306530|NCT02655705|Active Comparator|Cyclosporine A|Cyclosporine 200 mg/day (male) and 150 mg/day (female) orally, divided twice daily for 16 weeks
11306531|NCT02655705|Active Comparator|Methotrexate|Methotrexate was started with 10 mg/week orally as a single dose, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
11306532|NCT02655692|Placebo Comparator|Placebo|Saline dose
11306533|NCT02655692|Experimental|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
11306534|NCT02655692|Experimental|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
11306535|NCT02655679|Experimental|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
11306536|NCT02655679|Experimental|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
11306537|NCT02655679|Placebo Comparator|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
11306538|NCT02655679|Experimental|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
11306539|NCT02655679|Placebo Comparator|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
11306540|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
11306541|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
11306542|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
11306543|NCT02655640||Lupus|Characteristics of patients with Systemic Lupus Erythematosus. No interventions will be administered. Patients will be asked to complete questionnaires.
11306544|NCT02655640||Scleroderma|Characteristics of patients with Systemic Sclerosis. No interventions will be administered. Patients will be asked to complete questionnaires.
11306545|NCT02655627|Experimental|Group A|Usual Care Group: A brochure which emphasis the importance of physical activity and exercise in Type 2 DM will be given to the patients in this group after the evaluation.
11306546|NCT02655627|Experimental|Group B|Supervised Clinical Exercise Training Group: Patients in this group will continue group exercise training includes aerobic and resistance training, 1 hour in a day, 3 times in a week for 8 weeks with the supervision of a researcher physiotherapist.
11306547|NCT02655627|Experimental|Group C|Internet Based Exercise Training Group. the patients to this group will be a member of the web site named www.diyabetvehareket.com. The participation of the patients will be provided with the videos directing them to 1 hour in a day, 3 times in a week for 8 week both aerobic and resistance exercise training from the researcher physiotherapist.
11306599|NCT02655315|Active Comparator|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
11361754|NCT02289027|Placebo Comparator|Not deployed volunteers - Group 5|
11306548|NCT02655614|Experimental|SAD Stage: GDC-0134|Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).
11306549|NCT02655614|Placebo Comparator|SAD Stage: Placebo|Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.
11306550|NCT02655614|Experimental|MAD Stage: GDC-0134|Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
11306551|NCT02655614|Placebo Comparator|MAD Stage: Placebo|Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
11306552|NCT02655614|Other|Open-Label Safety Expansion (OSE)|Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.
11306553|NCT02655601|Experimental|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
11306554|NCT02655601|Active Comparator|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide [TMZ]). A total of 80 subjects will be in this study arm.
11306555|NCT02655588|Experimental|ImbPST|"ImbPST Arm: Participants in this arm will interact with imbPST program which provides a simulated therapy session based on the Problem Solving Treatment-Primary Care (PST-PC) treatment manual used in depression clinical trials . imbPST via a virtual therapist (presented via audio and video) provides programmed instructions on the steps and skills of problem solving, emotional support, and tailored feedback to the user's input."
11306556|NCT02655588|No Intervention|Control Group|Control Arm: Participants in this group will not receive any treatment for their depression and their depressive symptoms will be monitored for 6 to 9 weeks
11306557|NCT02655575|Experimental|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.
~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
11306558|NCT02655575|Active Comparator|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
11306559|NCT02655562|Experimental|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
11306560|NCT02655562|Placebo Comparator|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
11306561|NCT02655549|Experimental|Cohort 1 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
11306562|NCT02655549|Experimental|Cohort 2 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
11306563|NCT02655549|Experimental|Cohort 3 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
11306564|NCT02655536|Experimental|bevacizumab plus erlotinib|bevacizumab 15mg/kg every 3 weeks plus erlotinib 150mg per day
11306565|NCT02655536|Active Comparator|erlotinib|erlotinib 150mg per day
11306566|NCT02655523|Active Comparator|Bupivacaine+Triamcinolone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 40 mg of triamcinolone.
11306567|NCT02655523|Active Comparator|Bupivacaine+Dexamethasone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 4 mg of dexamethasone.
11306568|NCT02655523|Placebo Comparator|Bupivacaine+Saline|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL of preservative free normal saline.
11306569|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
11306570|NCT02655497|Experimental|Cognitive Training|Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
11306571|NCT02655497|Active Comparator|Psychosocial education|The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The control group will receive brain-health education.
11306600|NCT02655315|Placebo Comparator|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
11306601|NCT02655302|Other|Bacterial exacerbations|Patients with at least 10^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.
11306602|NCT02655302|Other|Non-bacterial exacerbations|Patients without detected bacteria or below 10^7 UFC/ml in sputum during their first COPD exacerbation.
11306603|NCT02655289|Experimental|Modulated TENS|
11306604|NCT02655289|Placebo Comparator|Placebo TENS|
11361828|NCT02288481|Experimental|Cohort 2 25 mg TBA-354|
11306572|NCT02655484|Other|COPD patients|Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.
11306573|NCT02655471|Experimental|HTLV-1 plus Tropical Spastic paraparesis|"Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of Raltegravir and Zidovudine during 48 weeks"
11306574|NCT02655458|Experimental|autologous PBMC reconstitution, Elotuzumab, Lenalidomide|Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
11306575|NCT02655445|Active Comparator|Mini-craniotomy|"Intervention: Bone flap > 30mm and replaced, placement of Jackson-Pratt drain
~A linear incision located over the biggest bulk of the hematoma is made. Dura is opened and a wide opening of the pseudomembrane is done. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
11306576|NCT02655445|Active Comparator|Twist Drill Craniostomy|"Intervention: twist drill burr hole <5mm, placement of Integra basket-type drain
~A stab incision to the scalp is made, at the approximate location of the thickest diameter of hematoma. The twist-drill hole <5mm is placed obliquely to the surface of the skull, at an angle of about 45° until perforation of the dura. No irrigation is performed. A basket-type drain (Integra) is placed in the subdural space and tunneled underneath the skin"
11306577|NCT02655445|Active Comparator|Burr Hole Craniostomy|"Intervention: 2 Burr Holes >5mm and <30mm, placement of Jackson-Pratt drain
~First burr hole at the site of maximal diameter, second anterior and superior to that point. The scalp incisions are so planned that they can be incorporated into a craniotomy if necessary. Visible membranes are opened with a sharp hook until the pia is visualized. Gentle irrigation is performed and continued until the returning liquid is clear. Two burr holes are placed to facilitate drainage. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
11306578|NCT02655432||Spot photoscreener|Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.
11306579|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
11306580|NCT02655406|Active Comparator|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
11306581|NCT02655406|No Intervention|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
11306582|NCT02655393|Experimental|AMAZ-02 250 mg single dose|single dose of AMAZ-02 soft gel capsules at 250 mg dose, n=8 subjects (6 Active, 2 Placebo)
11306583|NCT02655393|Experimental|AMAZ-02 500 mg single dose|single dose of AMAZ-02 soft gel capsules at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
11306584|NCT02655393|Experimental|AMAZ-02 1000 mg single dose|single dose of AMAZ-02 soft gel capsules at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
11306585|NCT02655393|Experimental|AMAZ-02 2000 mg single dose|single dose of AMAZ-02 soft gel capsules at 2000 mg dose, n=8 subjects (6 Active, 2 Placebo)
11306586|NCT02655393|Experimental|AMAZ-02 500 mg single dose-Food Effect|single dose of AMAZ-02 admixed in yoghurt at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
11306587|NCT02655393|Experimental|AMAZ-02 1000 mg single dose-Food Effect|single dose of AMAZ-02 admixed in yoghurt at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
11306588|NCT02655393|Experimental|AMAZ-02 250 mg multiple dose|Repeated 28 day dosing of AMAZ-02 soft gel capsules at 250 mg dose, n=12 subjects (9 Active, 3 Placebo)
11306589|NCT02655393|Experimental|AMAZ-02 500 mg multiple 28 day dose|Repeated 28 day dosing of AMAZ-02 soft gel capsules at 500 mg dose, n=12 subjects (9 Active, 3 Placebo)
11306590|NCT02655393|Experimental|AMAZ-02 1000 mg multiple 28 day dose|Repeated 28 day dosing of AMAZ-02 soft gel capsules at 1000 mg dose, n=12 subjects (9 Active, 3 Placebo)
11306591|NCT02655380|Experimental|ketamine 1|Anesthesia induction with ketamine 1 mg followed by remifentanil.
11306592|NCT02655380|Experimental|ketamine 2|Anesthesia induction with ketamine 2 mg followed by remifentanil.
11306593|NCT02655367|Experimental|Milled followed by flaked oats|Participant consumes test meal consisting of porridge made from milled oats on study day 1, followed by porridge made from flaked oats on study day 2
11306594|NCT02655367|Experimental|Flaked followed by milled oats|Participant consumes test meal consisting of porridge made from flaked oats on study day 1, followed by porridge made from milled oats on study day 2
11306595|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
11306596|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
11306597|NCT02655341||Consecutive STEMI Patients|All patients with AMI referred for primary PCI in a single centre
11306598|NCT02655328|Experimental|athlete under asthma treatment|athlete suffering from asthma blood sample urine sample
11306635|NCT02655120|Experimental|Bone Marrow +BMP7|The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
11306605|NCT02655276|Experimental|100 mg microencapsulated Glycine and then Placebo tablets|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.
11306606|NCT02655276|Experimental|Placebo tablets and then 100 mg microencapsulated Glycine|Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.
11306607|NCT02655263|No Intervention|Control|12 hours of fasting
11306608|NCT02655263|Experimental|GH infusion|12 hours of fasting
11306609|NCT02655263|Experimental|GH and ketone bodies infusion|12 hours of fasting
11306610|NCT02655237|Experimental|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
11306611|NCT02655237|Active Comparator|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
11306612|NCT02655224|Experimental|Relugolix 40 mg|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix 40 mg, tablet, orally once daily before breakfast for 12 weeks.
11306613|NCT02655224|Placebo Comparator|Placebo|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix placebo-matching tablet, orally once daily before breakfast for 12 weeks.
11306614|NCT02655211|Active Comparator|CO2-CO2-Med|Participants will receive two blocks of CO2 laser treatment, followed by one block of usual care.
11306615|NCT02655211|Active Comparator|Med-CO2-CO2|Participants will receive one block of usual care, followed by two blocks of CO2 laser therapy.
11306616|NCT02655211|Active Comparator|CO2-Med-CO2|Participants will receive one block of CO2 laser therapy, one block of usual care, and finally one more block of CO2 laser therapy.
11306617|NCT02655211|Active Comparator|PDL-PDL-MED|Participants will receive two blocks of PDL laser therapy, followed by one block of usual care.
11306618|NCT02655211|Active Comparator|Med-PDL-PDL|Participants will receive one block of usual care, followed by two blocks of PDL laser therapy.
11306619|NCT02655211|Active Comparator|PDL-Med-PDL|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
11306620|NCT02655211|Active Comparator|PDL-CO2-Med|Participants will receive one block of PDL laser therapy, followed by one block of CO2 laser therapy, followed by one block of usual care.
11306621|NCT02655211|Active Comparator|CO2-PDL-Med|Participants will receive one block of CO2 laser therapy, followed by one block of PDL laser therapy, followed by one block of usual care.
11306622|NCT02655211|Active Comparator|Med-PDL-CO2|Participants will receive one block of usual care, followed by one block of PDL laser therapy, followed by one block of CO2 laser therapy.
11306623|NCT02655211|Active Comparator|Med-CO2-PDL|Participants will receive one block of usual care, followed by one block of CO2 laser therapy, followed by one block of PDL laser therapy.
11306624|NCT02655211|Active Comparator|PDL-Med-CO2|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of CO2 laser therapy.
11306625|NCT02655211|Active Comparator|CO2-Med-PDL|Participants will receive one block of CO2 laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
11306626|NCT02655198|Experimental|fenfluramine|"Experimental : one armed open label study :
~Add-on fenfluramine in refractory Lennox Gastaut patients. Starting dose 0.2mg/kg/day. In non-responders (<50% seizure frequency decrease), dose will be uptitrated every 4 weeks from 0,2 to 0,4 and max 0,8 mg/kg/day (max 30 mg). Total duration study and max exposure to the drug 20 weeks"
11306627|NCT02655185||Heart failure|
11306628|NCT02655172|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
11306629|NCT02655172|Active Comparator|Control group|healthy patients who will perform cognitive tasks
11306630|NCT02655159||Abraxane® treatment in patients with metastatic breast cancer|Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
11306631|NCT02655146|Experimental|GnRHa protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 (Progynova) 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2.In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .A single dose of Triptorelin 0.1mg is administrated on the 3rd day after embryo implanted with routine luteal phase support.
11306632|NCT02655146|Other|routine luteal phase protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
11306633|NCT02655133|Active Comparator|Pentaglobin®|Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).
11306634|NCT02655133|Placebo Comparator|Physiologic Solution|Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)
11306637|NCT02655081|Experimental|Dietary supplement|Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
11306638|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.
~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
11306639|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.
~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
11306640|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
11306641|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
11306642|NCT02655042||RCT-01|Participants in previous clinical trial that received blinded injection of RCT-01
11306643|NCT02655042||Placebo|Participants in previous clinical trial that received blinded injection of placebo
11306644|NCT02655016|Experimental|Niraparib|Administered once daily continuously during a 28 day cycle.
11306645|NCT02655016|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle
11306646|NCT02655003|Experimental|INH (Intervention Nursing Homes)|TIME consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of NPS. The staff, physicians and nursing home managers in the intervention nursing homes will receive a one-day education program. Three nurses from each unit will receive further education including practical and theoretical training for three hours.
11306647|NCT02655003|Active Comparator|CNH (Control Nursing Homes)|A brief two hours education-only intervention about dementia and NPS will be given to the staff in for the control nursing homes (CNH). The staff and physicians in the control nursing homes continue practice as usual.
11306648|NCT02654990|Experimental|Arm A - 20mg PAN TIW|20mg panobinostat three times a week, 2 weeks on/1week of in combination with s.c. bortezomib and p.o. dexamethasone
11306649|NCT02654990|Experimental|Arm B - 20mg PAN BIW|20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
11306650|NCT02654990|Experimental|Arm C - 10mg PAN TIW|10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
11306651|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
11306652|NCT02654964|Experimental|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:
~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
11306653|NCT02654951|Experimental|Visual + Force Feedback|Participants will complete a set of trials while receiving visual feedback only. After finishing, participants will continue to a new set of trials while receiving force feedback only.
11306654|NCT02654951|Experimental|Force + Visual Feedback|Participants will complete a set of trials while receiving force feedback only. After finishing, participants will continue to a new set of trials while receiving visual feedback only.
11306655|NCT02654938|Experimental|Mobilan (M-VM3)|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Investigational Drug Product
11306656|NCT02654938|Placebo Comparator|Placebo|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Placebo (Glucose 5%)
11306657|NCT02654925||Young Men|men 21-40 years of age
11306658|NCT02654925||Young Women|women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.
11306659|NCT02654925||Older Men|men 55-100 years of age
11306660|NCT02654925||Older Women|women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).
11306661|NCT02654912|Experimental|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
11306662|NCT02654912|No Intervention|Reactive Focal Test and Treat|This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).
11306663|NCT02654899|Experimental|Part 1_Cohort 1_Active;|Single ascending dose of PF-06815345
11306664|NCT02654899|Placebo Comparator|Part 1_Cohort 1_Placebo;|Single dose of placebo
11306665|NCT02654899|Experimental|Part 1_Cohort 2_Active|Single ascending dose of PF-06815345
11306666|NCT02654899|Placebo Comparator|Part 1_Cohort 2_Placebo|Single dose of placebo
11306667|NCT02654899|Experimental|Part 2|Single dose of solid dosage formulation (test) versus liquid dosage formulation (reference) of PF-06815345
11306668|NCT02654886|Experimental|Resistance Exercise Training|Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
11306669|NCT02654873||Benign|Benign pathology specimens with macroscopically
11306670|NCT02654873||Suspicious|Suspicious group includes the conditions such as increasing of the gallbladder wall thickness, having calcifications or polyps in the gallbladder.
11306672|NCT02654860|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
11306673|NCT02654860|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
11306674|NCT02654860|Experimental|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
11306675|NCT02654860|Placebo Comparator|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
11306676|NCT02654847|Active Comparator|Norepinephrine 3 micrograms/mL|1mL of a solution of norepinephrine, containing 3 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
11306677|NCT02654847|Active Comparator|Norepinephrine 4 micrograms/mL|1mL of a solution of norepinephrine, containing 4 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
11306678|NCT02654847|Active Comparator|Norepinephrine 5 micrograms/mL|1mL of a solution of norepinephrine, containing 5 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
11306679|NCT02654847|Active Comparator|Norepinephrine 6 micrograms/mL|1mL of a solution of norepinephrine, containing 6 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
11306680|NCT02654847|Active Comparator|Norepinephrine 7 micrograms/mL|1mL of a solution of norepinephrine, containing 7 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
11306681|NCT02654847|Active Comparator|Norepinephrine 8 micrograms/mL|1mL of a solution of norepinephrine, containing 8 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
11306682|NCT02654834||Pediatric Operating Room (OR) Staff|OR Staff exposed to nitrous oxide, and other volatile anesthetics
11306683|NCT02654834||Pediatric Intensive Care Unit (ICU) Staff|ICU Staff unexposed to any volatile anesthetics
11306684|NCT02654821|Experimental|TCR treatment|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
11306685|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
11306686|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
11306687|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
11306688|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
11306689|NCT02654795|Placebo Comparator|Patients without stroke|This group will consists of patients scheduled for atrial fibrillation ablation without history of stroke.
11306690|NCT02654795|Experimental|Patients with history of stroke|This group will consists of patients after ischemic stroke and history of atrial fibrillation.
11306691|NCT02654782|Active Comparator|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
11306692|NCT02654782|Active Comparator|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
11306693|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
11306694|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
11306695|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
11306696|NCT02654743|Experimental|SF|"Sulforaphane (SF) will be administered in an approximate dosage of 1 µmol SF/lb (2.2 kg µmol/kg) body weight. This dosage roughly approximates the dosage that was used in the Singh et al, (2014; PNAS) clinical trial of sulforaphane in male adolescents and adults with autism. The sulforaphane will be supplied as glucoraphanin (GR)-enriched broccoli seed extract tablets (manufacturing details follow). Each active tablet will contain 125 mg broccoli seed extract (containing 37 µmol GR, which is equivalent to about 15 µmol SF), 50 mg dried broccoli sprouts (a source of myrosinase, the enzyme that converts GR to SF), 15 mg ascorbic acid, 55.90 mg microcrystalline cellulose, and other minor GRAS excipients used for tablet forming.
~The total dose per day will depend of study participants' body weight."
11306697|NCT02654730|Experimental|G6PD deficient 0.25 mg/kg PQ + DHAP|
11306698|NCT02654730|Experimental|G6PD deficient 0.4 mg/kg PQ + DHAP|
11306699|NCT02654730|Active Comparator|G6PD deficient DHAP only|
11306700|NCT02654730|Active Comparator|G6PD normal 0.25 mg/kg PQ + DHAP|
11306701|NCT02654730|Active Comparator|G6PD normal 0.4 mg/kg PQ + DHAP|
11306702|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
11306703|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
11306704|NCT02654704||Healthy Young Adults|Healthy young adults aged 18-25. Vaccination in all cohorts/groups.
11306705|NCT02654704||Asthma Young Adults|Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
11306706|NCT02654704||Immunocompromised Young Adults|"Young adults aged 18-25 that are immunocompromised (e.g. following treatment for leukemia).
~Vaccination in all cohorts/groups."
11306707|NCT02654704||Healthy Older Adults|Healthy older adults aged 55+ Vaccination in all cohorts/groups.
11306708|NCT02654704||Asthma Older Adults|Older adults 55+ with asthma. Vaccination in all cohorts/groups.
11307613|NCT02648334|Experimental|Lutonix drug coated balloon|Lutonix drug coated balloon
11306709|NCT02654704||Immunocompromised Older Adults|"Older adults aged 55+ that are immunocompromised (e.g. following treatment for leukemia).
~Vaccination in all cohorts/groups."
11306710|NCT02654678|Experimental|Enalapril Orodispersible Minitablets|Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure.
11306711|NCT02654665|Experimental|Liraglutide|Liraglutide will be administered once daily by subcutaneous injection at a starting dose of 0.6 mg, increasing at 0.6 mg/week increments to a maximum of 3.0 mg over the next 6 weeks, as tolerated.
11306712|NCT02654665|Active Comparator|Bariatric Surgery|Subjects will have outcomes measured within 28 days before surgery. Post-operative management and frequency of follow-up visits will be decided by the bariatric surgeon. Study visits for biochemical and endothelial function testing; MRI and liver biopsy and / or fibroscan will follow the same schedule as that of the lifestyle and liraglutide arms. Target weight loss for the first 26 weeks post-surgery is at least 30% of excess body weight.
11306713|NCT02654665|Active Comparator|Diet modification and exercise|Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
11306714|NCT02654652|Experimental|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
11306715|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
11306716|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
11306717|NCT02654626|Experimental|KBP-7072: Cohort 1|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
11306718|NCT02654626|Experimental|KBP-7072: Cohort 2|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
11306719|NCT02654626|Experimental|KBP-7072: Cohort 3|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
11306720|NCT02654626|Experimental|KBP-7072: Cohort 4|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
11306721|NCT02654613|Active Comparator|Quality Improvement Intervention|In intervention clinics, staff will follow QI methodology to undertake a detailed assessment of their HIV-TB care and to prioritize the steps to improve treatment outcomes. A senior nurse will be identified to be the QI champion and will be trained by the study team to fulfil this role. The QI champion in the clinic then provides peer-leadership, mentorship and support for the implementation of the prioritized changes until the checklist is complete and all integrated HIV-TB service components meet the required standard.
11306722|NCT02654613|No Intervention|Control Standard of Care|The control arm will continue with the usual support that is received for HIV-TB service integration
11306723|NCT02654587|Experimental|OSE2101|OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).
11306724|NCT02654587|Active Comparator|Docetaxel or Pemetrexed|"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.
~Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.
~Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal."
11306725|NCT02654574|Experimental|Face-to-face collection followed by collection by phone|Reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, followed by the collection of IADL by phone, one month later.
11306726|NCT02654574|Experimental|Collection by phone followed by face-to-face collection|Collection of IADL by phone, followed by the collection of the IADL questionnaire using the reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, one month later.
11306727|NCT02654561|Placebo Comparator|Saline|
11306728|NCT02654561|Experimental|Heparin|If severe sepsis with suspected DIC is diagnosed, the Heparin sodium(2ml:12500 units) will be administered intravenously continuously for 24 hours. The course of treatment will last 7 days or until the death or discharge.
11306729|NCT02654548|Experimental|PCOS women and babies|Sebum output using Sebutape on post-partum PCOS women and new born babies.
11306730|NCT02654548|Active Comparator|Non-PCOS women and babies|Sebum output using Sebutape on post-partum non-PCOS women and new born babies.
11306731|NCT02654522|Experimental|Filler|Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
11306770|NCT02654249|Other|THD and mucopexy|Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.
11306771|NCT02654249|Active Comparator|Ligasure hemorroidectomy|Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.
11306772|NCT02654236|Placebo Comparator|Placebo|Heavy Drinkers on placebo
11306773|NCT02654236|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
11306732|NCT02654522|No Intervention|Scale Validation|"One forearm of one of three subjects will be randomized to the scale control forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale control forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining randomized forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the control forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study."
11306733|NCT02654509|Experimental|EEE vaccine|Eastern Equine Encephalitis Vaccine will be administered as primary doses of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area and booster doses of 0.1 mL given intradermally in the volar aspect of the forearm. The primary series will be administered on Days 0 and 26-35 with a booster at 6 months. Titers will be collected 28-35 days after the second primary vaccine is < 1:40, the subject will receive a booster dose 28- 90 days of obtaining the titer result.
11306734|NCT02654496||Group 1 (Successful weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had successful weight loss
11306735|NCT02654496||Group 2 (Suboptimal weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had suboptimal weight loss
11306736|NCT02654496||Group 3 (Control group)|A control group who has not had Roux-en-Y gastric bypass surgery and are of similar age, gender, body mass index as the gastric bypass groups.
11306737|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
11306738|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
11306739|NCT02654457||Women with Breast Cancer #1|IVD Study
11306740|NCT02654457||Women with Breast Cancer #2|IVD Study
11306741|NCT02654457||Women with Breast Cancer #3|IVD Study
11306742|NCT02654444||GenASIs HiPath IHC #1|Expression of HER2 antibody. Semi-Quantitative value
11306743|NCT02654444||GenASIs HiPath IHC #2|Expression of HER2 antibody. Semi-Quantitative value
11306744|NCT02654444||GenASIs HiPath IHC #3|Expression of HER2 antibody. Semi-Quantitative value
11306745|NCT02654431||Breast Cancer patients|Breast cancer patients
11306746|NCT02654431||women with breast cancer|women with breast cancer
11306747|NCT02654431||Cancer patients|Cancer patients
11306748|NCT02654418|Experimental|SIC 8000, 10 mL ampoules|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with SIC 8000 injectate solution.
11306749|NCT02654418|Active Comparator|reference comparator|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with Reference Comparator Injectate solution (site standard of care injectate solution).
11306750|NCT02654405|Experimental|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
11306751|NCT02654405|Placebo Comparator|Placebo|Placebo capsule with 2 mg of sodium butyrate for making taste or odor, (9 mg/day)
11306752|NCT02654392|Placebo Comparator|placebo|This group will receive isoenergetic carbohydrate (corn syrup) supplement daily for 5 weeks
11306753|NCT02654392|Other|Polyunsaturated fatty acid group|This group will receive a plant essential fatty acid food supplement, Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils, containing a 2.5:1 omega-6 to omega-3 ratio (1.5 g per 70kg body mass plus an additional 0.5 g on exercise days)
11306754|NCT02654379||Cohort|Cohort consisting of participants who are in the center to receive an infusion for rituximab for a non-oncology indication.
11306755|NCT02654366|Experimental|Community Supported Risk Reduction Group|Six weekly sessions will be scheduled during daytime and evening hours to accommodate the daily schedules of BNEP registrants and their CSPs. Each session meets for 60 minutes. Groups will consist of 5-6 BNEP registrant-CSP dyads (10-12 individuals). While BNEP registrants and CSPs attending the group together will receive an attendance incentive, BNEP registrants attending without a CSP will not earn one. The group leader will follow a manual that includes a structured outline. The group manual content combines risk reduction / treatment readiness and community outreach approaches. Following the introduction, each group session is divided into two components: 1) Risk Reduction and Treatment Readiness (30 min) and 2) Community Outreach skills (20 min).
11306756|NCT02654353|Other|Group A: stepwise ablation|Stepwise ablation of persistent atrial fibrillation (conventional treatment arm) In this arm, patients will be treated with the conventional stepwiese ablation approach
11306757|NCT02654353|Active Comparator|Group B: sequential substrate ablation|Sequential substrate ablation of persistent atrial fibrillation (novel procedure) In this arm, patients will undergo an ablation procedure that consist of PVI, cardioversion, linear ablation and atrial fibrillation re-induction after blocked lines, followed by electrogram-guided ablation
11306758|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
11306759|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
11306760|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
11306761|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
11306762|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
11306763|NCT02654301|Placebo Comparator|Control group|sucrose drink (Control, sucrose 50g + deionized water 100g)
11306764|NCT02654301|Active Comparator|5 g xylose group|5 g xylose (Test 1, sucrose : xylose = 10:1),
11306765|NCT02654301|Active Comparator|3.33 g xylose group|3.33 g xylose (Test 2, sucrose : xylose = 15:1)
11306766|NCT02654301|Active Comparator|2.5 g xylose group|2.5 g xylose (Test 3, sucrose : xylose = 20:1)
11306767|NCT02654288||single arm|The pancreatic cancer patients without history of chemotherapy who will receive gemcitabine-based chemotherapy will be recruited and the sera IgG4 and IL-10 will be detected before and after chemotherapy.
11306775|NCT02654223|Experimental|MG56 Mannosylated 60 subcutaneous|60 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11306776|NCT02654223|Experimental|MG56 Mannosylated 100 subcutaneous|100 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11306777|NCT02654223|Experimental|MG56 Mannosylated 300 subcutaneous|300 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11306778|NCT02654223|Experimental|MG56 Mannosylated 500 subcutaneous|500 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
11306779|NCT02654223|Experimental|MG56 Mannosylated 60 sublingual|60 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11306780|NCT02654223|Experimental|MG56 Mannosylated 100 sublingual|100 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11306781|NCT02654223|Experimental|MG56 Mannosylated 300 sublingual|300 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11306782|NCT02654223|Experimental|MG56 Mannosylated 500 sublingual|500 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
11306783|NCT02654223|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
11306784|NCT02654197||H.pylori positive children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
11306785|NCT02654197||H.Pylori negative children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
11306786|NCT02654184|Active Comparator|Supine group|Anesthesia induction with sevoflurane for the patient while he is in supine position.
11306787|NCT02654184|Active Comparator|Right lateral group|Anesthesia induction with sevoflurane for the patient while he is in right lateral position position.
11306788|NCT02654171|Experimental|AK0529|Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.
11306789|NCT02654171|Placebo Comparator|Placebo|Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.
11306790|NCT02654158||Low-dose of Fuganlin Oral Liquid|"oral
~less than 1 years old: 5mL each time and three times a day
~1~3 years old: 10mL each time and three times a day
~4~6 years old: 10mL each time and four times a day
~7~12 years old: 10mL each time and five times a day"
11306791|NCT02654158||High-dose of Fuganlin Oral Liquid|"oral
~less than 1 years old: 10mL each time and three times a day
~1~3 years old: 20mL each time and three times a day
~4~6 years old: 20mL each time and four times a day
~7~12 years old: 20mL each time and five times a day"
11306792|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
11306793|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)
~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)
~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)
~Drug: Pomalidomide
~•Capsules,Oral,4 mg,once daily, on Days 1-21
~Other Name: Pomalyst
~Drug: Dexamethasone
~Subjects ≤ 75 years old:
~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)
~Subjects > 75 years old:
~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)
~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)
~Other Names:
~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
11306794|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide
~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst
~Drug: Dexamethasone
~Subjects ≤ 75 years old:
~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22
~Subjects > 75 years old:
~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,
~Other Names:
~Decadron
~Dexamethasone Intensol
~Dexpak
~Taperpak"
11306795|NCT02654119|Experimental|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
11306796|NCT02654106|Experimental|Refractory Brain Metastases|Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases
11306797|NCT02654093|Experimental|Group A|A → B → C / A: Cholecalciferol, B: Raloxifene, C: Cholecalciferol+Raloxifene
11306798|NCT02654093|Experimental|Group B|A → C → B
11306799|NCT02654093|Experimental|Group C|B → A → C
11306800|NCT02654093|Experimental|Group D|B → C → A
11306801|NCT02654093|Experimental|Group E|C → A → B
11306802|NCT02654093|Experimental|Group F|C → B → A
11307079|NCT02652273|Experimental|Abatacept|Abatacept 125mg administered via subcutaneous injection once a week for 24 weeks
11306803|NCT02654080|Experimental|Group 1: Vaccine|Participants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
11306804|NCT02654080|Placebo Comparator|Group 2: Placebo|Participants will receive placebo vaccine at Day 0 and Months 1, 3, 6, and 9.
11306805|NCT02654054|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
11306806|NCT02654054|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
11306807|NCT02654054|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
11306808|NCT02654041|Experimental|Hypothyroxinemia induced patients|Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.
11306809|NCT02654028|Experimental|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
11306810|NCT02654028|Active Comparator|Control group|These group of patients will not receive autotransfusion before or after liver resection.
11306811|NCT02654015|Experimental|Medical Management plus Apollo MIES|Subjects will receive best medical management for ICH plus they will receive the MIES surgery and use of the Apollo System for clot evacuation.
11306812|NCT02654002|Experimental|Cohort 1: Cilofexor 10 mg|Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
11306813|NCT02654002|Experimental|Cohort 2: Cilofexor 30 mg|Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
11306814|NCT02654002|Experimental|Cohort 3: Cilofexor 100 mg|Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
11306815|NCT02654002|Experimental|Cohort 4: Cilofexor 300 mg|Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
11306816|NCT02654002|Experimental|Cohort 5: Cilofexor 100 mg|Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
11306817|NCT02654002|Experimental|Cohort 6: Cilofexor 50 mg|Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
11306818|NCT02654002|Experimental|Cohort 7: Cilofexor 15 mg|Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
11306819|NCT02654002|Experimental|Cohort 8: Cilofexor 10 mg|Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
11306820|NCT02654002|Experimental|Cohort 9: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
11306821|NCT02654002|Experimental|Cohort 10: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
11306822|NCT02653989|Experimental|MDV9300|
11306823|NCT02653976|Experimental|SP-02L (darinaparsin for injection)|
11306824|NCT02653963|No Intervention|Conventional AGV|A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
11306825|NCT02653963|Experimental|Triamcinolone adjuctival AGV|Subtenon Periplate 10 mg triamcinolone acetonide around the AGV plate after fixation of AGV Plate to the sclera
11306826|NCT02653950|Active Comparator|Traditional|a control arm of patients undergoing traditional septoplasty for DNS
11306827|NCT02653950|Experimental|Endoscopic|patients undergoing endoscopic septoplasty.
11306828|NCT02653937|Experimental|Kampo medicine|7.5g per day of Tsumura's shigyakusan ( Tsumura & Co ) was administered to each of 110 cases.
11306829|NCT02653924|Active Comparator|silk suture|silk suture
11306830|NCT02653924|Active Comparator|vicryl suture|vicryl suture
11306831|NCT02653924|Active Comparator|nylon suture|nylon suture
11306832|NCT02653924|Active Comparator|polypropylene suture|polypropylene suture
11306833|NCT02653911|Experimental|acupuncture group|"Bilateral ST25, EX-CA1, CV4 and SP6 will be selected for treatment. After routine sterilization of the local skin, bilateral ST25, EX-CA1, CV4 and SP 6 will be inserted by the needles (0.30 mm in diameter, 40 mm in length) to a depth of 25-30 mm to the abdominal muscle layer with the manipulation of lifting, thrusting and rotating until de qi. Each session will last for 30 minutes, and the manipulation of lifting, thrusting and rotating evenly three times will be used for CV 4 and SP 6 every 10 minutes. If the date of treatment is during the menstrual circle, the treatment will be continued as usual. Participants will be treated three times a week for 12 weeks with 36 sessions."
11306834|NCT02653911|Sham Comparator|Sham-acupuncture group|The sham ST25, EX-CA1, CV4 and SP 6, which are 1 cun (25 mm) outward to ST25, EX-CA1, CV4 and SP 6, will be inserted to 2-3 mm with needles with a diameter of 0.30 mm and a length of 13 mm. The needles will be inserted without de qi or any manipulation. The treatment sessions will be the same as those in the acupuncture group.
11306835|NCT02653898|Active Comparator|Focused Screening and Treatment + ITU|Approved antimalarial based on the malaria species identified on the monthly follow ups, following national treatment guidelines in Cambodia AND Insecticide Treated Uniform with 40% Permethrin; DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
11306836|NCT02653898|Active Comparator|Focused Screening and Treatment + sITU|Approved antimalarial based on the malaria species identified at the monthly follow up and following national treatment guidelines in Cambodia AND sham treated uniform. DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
11306837|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + ITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive insecticide treated uniforms with 40% Permethrin
11306838|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + sITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive sham treated uniforms
11306839|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
11306840|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
11306841|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
11306842|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
11306843|NCT02653833|Experimental|Healthy Controls (HC)|Healthy men currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. This is repeated at baseline and shortly after taking beetroot juice extract.
11306844|NCT02653833|Experimental|Becker Muscular Dystrophy (BMD)|"currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. Using a lower body negative pressure (LBNP) chamber, the subjects are tested for impaired exercise induced vasodilation to the skeletal muscle or functional sympatholysis. This is repeated at baseline and shortly after taking beetroot juice extract."
11306845|NCT02653820|Experimental|Chemotherapy patients|Chemotherapy patients will receive reflexology treatment
11306846|NCT02653807|Experimental|mobilization with movement|MWM at the talocrural joint during active weight bearing ankle dorsiflexion with the belt
11306847|NCT02653807|Active Comparator|osteopathic mobilization|passive mobilization of the talo-crural joint
11306848|NCT02653781|Experimental|Realistic simulation; Performance|Student participation in the study will happen on demand by enrollment in activities of dialogue-exhibition (workshop) on realistic simulation in the context of patient safety. Check the performance of students in face of simulation workshop for test realistic simulation.
11306849|NCT02653781|Other|theoretical-practical classes|Will be to give a theoretical-practical classes for students of control group the provision of similar opportunities
11306850|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
11306851|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
11306852|NCT02653755|Active Comparator|Ineligible for omission of RT|Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.
11306853|NCT02653755|Active Comparator|Eligible for omission of RT|Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.
11306854|NCT02653742|Experimental|Ketorolac|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use.
11306855|NCT02653742|Experimental|Fentanyl|Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
11306856|NCT02653742|Experimental|Ketorolac and Fentanyl|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use and Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
11306857|NCT02653729|Experimental|Espidone, Olepra, Donu & C.B.T|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days
11306858|NCT02653729|Active Comparator|Espidone, Olepra & Donu|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night
11306859|NCT02653716|Active Comparator|Case Management|CM
11306860|NCT02653716|Experimental|New Orleans Intervention Model|NIM
11306861|NCT02653703|Placebo Comparator|Vehicle, topical ethanol 96%|Exposure: 10 % topical trans-cinnamaldehyde [CAS Number: 14371-10-9] Vehicle: 96% ethanol
11306862|NCT02653703|Experimental|Topical L-menthol 40%|Exposure: 10 % trans-cinnamaldehyde [CAS Number: 14371-10-9] Intervention: 40% l-menthol [CAS Number: 2216-51-5] Vehicle: 96% ethanol
11306863|NCT02653677|Active Comparator|commercial bread, wheat flour|Intake of the specific kind of bread
11306864|NCT02653677|Experimental|wheat, organic flour|Intake of the specific kind of bread
11306865|NCT02653677|Experimental|wheat, supermarket flour|Intake of the specific kind of bread
11306866|NCT02653677|Experimental|einkorn, organic flour|intake of the specific kind of bread
11306921|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
11306867|NCT02653664|Experimental|Condition #1: PsychoEducation|Condition #1 will include 8 90-minute group sessions that will educate the subject about chronic pain, discuss the impact of pain, and inform the subject of different ways to manage it in hopes of decreasing pain and its impact on the subject's life. Participants in this condition will be given pre-recorded audio recordings of the content of the sessions to listen to.
11306868|NCT02653664|Experimental|Condition #2:Self-Hypnosis Training|In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
11306869|NCT02653664|Experimental|Condition #3: Mindfulness Meditation|In condition #3, the facilitator will teach participants Vipassana meditation, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Time will also be devoted to problem solving around any difficulties with MM practice.
11306870|NCT02653651|Active Comparator|Ketamine|Ketamine infused at 0.1 mg/kg/hour
11306871|NCT02653651|Experimental|Lidocaine|Lidocaine infused at 1 mg/kg/hour
11306872|NCT02653651|Placebo Comparator|Placebo|An equal volume of saline
11306873|NCT02653638|Experimental|Drug|"Control-Hypercapnic Trials: Three stepwise CO2 elevations will be applied to the patient by adding fractional concentration of inspired CO2 (FICO2) at 2%, 4%, and 6% each time, balanced with room air. The end tidal CO2 (PetCO2) will be elevated and maintained constant for three minutes at each target level. Breath-by-breath changes in minute ventilation (VE) and PetCO2 will be measured.
~Drug-Indomethacin: Healthy volunteers, indomethacin suspension will be orally administered at 1.2 mg/kg. After drug administration, the patient will rest quietly for 90 minutes."
11306874|NCT02653625|Experimental|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
11306875|NCT02653612|Experimental|Experimental Arm|This cohort will receive the contrast agent
11306876|NCT02653599|Experimental|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
11306877|NCT02653599|Experimental|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
11306878|NCT02653599|Placebo Comparator|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
11306879|NCT02653586|Experimental|"program In Favor of Resilience Self"|"The program In Favor of Resilience Self was delivered to adolescence aged 15-17, over 2 months. The program contained nine weekly, 90-min lessons that focus on enhancing self- resilience, self-esteem, self-image, body image. All students completed a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
11306880|NCT02653586|No Intervention|control group|The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
11306881|NCT02653573|Experimental|Intervention|Telephone health coaching over 3 months with supporting education materials.
11306882|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
11306883|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
11306884|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
11306885|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
11306886|NCT02653547|Experimental|standard multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
11306887|NCT02653547|Experimental|high-frequency multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
11306888|NCT02653547|Experimental|standard multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
11306889|NCT02653547|Experimental|high-frequency multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
11306890|NCT02653534|Experimental|Intervention Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
11306891|NCT02653534|No Intervention|Control|Routine visits by government health workers
11306892|NCT02653521|Experimental|adaptive radiation therapy (ART)|40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.
11306893|NCT02653521|No Intervention|the control group|40 patients treated with original plan for full treatment course.
11306922|NCT02653313|Experimental|ParvOryx|ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).
11306923|NCT02653300|Experimental|Oral Insulin|treatment
11307240|NCT02651064|No Intervention|Non-HIP|Received SNAP benefits as usual.
11306894|NCT02653508|Experimental|Diet and Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, while the nutritional education comprised of a supplementary 15 minutes of group-based sessions that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
11306895|NCT02653508|Experimental|Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
11306896|NCT02653508|No Intervention|Control|61 overweight and obese adolescents aged 13-15 years old were the control group of the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
11306897|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
11306898|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
11306899|NCT02653482|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg daily
11306900|NCT02653482|Placebo Comparator|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
11306901|NCT02653469||Augmented ventilation with fluid loading|This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
11306902|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
11306903|NCT02653443|Experimental|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
11306904|NCT02653443|Experimental|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
11306905|NCT02653430|Experimental|Bariatric Surgery|Sleeve Gastrectomy
11306906|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg/day
11306907|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg/day
11306908|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg/day
11306909|NCT02653417|Placebo Comparator|Regimen 4|Placebo
11306910|NCT02653404||Cases|"A blood sample necessary to perform QFT-GIT will be taken, together with other routine blood samples, from children with following diagnosis:
~latent tuberculous infection: active TB contact, TST positive, lack of clinical and RX signs of active-TB
~active TB: clinical and radiologic evidences of active-TB, positivity to microbial tests to BK
~not infected: patients evaluated as TB contacts, with negative TST and negative clinical/radiological/microbial results for TB."
11306911|NCT02653391|Placebo Comparator|Elamipretide 1.0% Ophthalmic Solution and Vehicle Control|Each subject will receive one drop of elamipretide 1.0% ophthalmic solution in the randomly selected study eye BID and one drop of vehicle ophthalmic solution BID in the fellow control eye.
11306912|NCT02653391|Placebo Comparator|Elamipretide 3.0% Ophthalmic Solution and Vehicle Control|Each subject will receive one drop of elamipretide 3.0% ophthalmic solution or placebo in the randomly selected study eyes BID
11306913|NCT02653378|Active Comparator|DIET ARM|A 25% energy depletion (daily for 3 days) induced by reducing the amount of energy intake that would otherwise keep the individual in energy balance.
11306914|NCT02653378|Active Comparator|EX ARM|A 25% energy depletion (daily for 3 days) induced by performing aerobic exercise at 50% of V02max.
11306915|NCT02653365||Non-invasive ventilation|All patients eligible for inclusion in the study were treated with Non-invasive ventilation.
11306916|NCT02653352|No Intervention|Control|The control group received two one-hour general sessions on health issues and printed general advices regarding healthy diets.
11306917|NCT02653352|Experimental|Lifestyle modification|Intervention was focused on the reduction in consumption of sugar-sweetened carbonated beverages by students. During seven months of one school year, a healthy lifestyle education programme was implemented using simple messages encouraging water consumption instead of sugar-sweetened carbonated beverages. Education was delivered via classroom activities; banners were hung promoting water consumption, and water bottles with the logo of the campaign were given to children and schoolteachers.
11306918|NCT02653339|Experimental|Qufeng Shengshi Fang and Loratadine|Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
11306919|NCT02653339|Active Comparator|Loratadine|Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough[needs update] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
11306920|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
11306993|NCT02652897||Exposure to colon resection surgery|Patients undergoing elective colon cancer resection
11361829|NCT02288481|Placebo Comparator|Cohort 2 placebo|Placebo Suspension
11306924|NCT02653287|Experimental|Intervention|The experimental intervention is a unique combination of four individual counseling sessions based in motivational interviewing focusing on physical activity, dietary behavior and behavioral strategies. The individual sessions will provide a tailored personalized intervention including problem-solving and goal setting for increasing physical activity, and following a healthy diet. Healthy Lifestyle Coaches (RN or MPH) will be responsible for conducting the individual for a caseload of participants. There are no drugs involved in the intervention.
11306925|NCT02653287|Active Comparator|Control|The control group intervention will receive four individual phone calls checking in with participants regarding questions about the study or from the group sessions, and educational sessions focusing on SLE disease management, each lasting approximately 10-15 minutes.
11306926|NCT02653274|Active Comparator|OATS PORRIDGE|Oats breakfast porridge
11306927|NCT02653274|Active Comparator|RYE PORRIDGE|Rye breakfast porridge
11306928|NCT02653274|Active Comparator|FINGER (RAGI) MILLET PORRIDGE|Finger (ragi) millet breakfast porridge
11306929|NCT02653274|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge
11306930|NCT02653261|Experimental|Tranexamic Acid|Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
11306931|NCT02653261|Placebo Comparator|Placebo|An equal volume of saline
11306932|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
11306933|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
11306934|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
11306935|NCT02653235|Active Comparator|Typhoid vaccination|Salmonella typhi vaccination
11306936|NCT02653235|Placebo Comparator|Placebo|0.9% sodium chloride
11306937|NCT02653222|Experimental|Renal sympathicolysis|"The patient will have:
~Ambulatory Blood Pressure Monitoring
~Magnetic Resonance Angiography
~Blood test
~Renal sympathicolysis
~Ambulatory Blood Pressure Monitoring
~Magnetic Resonance Angiography"
11306938|NCT02653209|Experimental|Sitagliptin - DPP4i|
11306939|NCT02653209|Experimental|Canagliflozin - SGLT2i|
11306940|NCT02653209|Experimental|Pioglitazone - TZD|
11306941|NCT02653196|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|"Matched Unrelated Donor HSCT (minimum 9/10 human leukocyte antigen [HLA] match) OR Matched Related Donor HSCT (10/10 HLA match). Conditioning regimen begins 12 days prior to stem cell infusion and includes the following drugs:
~Keratinocyte Growth Factor Alemtuzumab Thiotepa Etoposide Melphalan Fludarabine Tacrolimus (Cyclosporine A may be substituted for Tacrolimus) Mycophenolate mofetil"
11306942|NCT02653183|Active Comparator|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.
~Duration of treatment:
~Total 5 days included the day of surgery and 4 post-operative days."
11306943|NCT02653183|Experimental|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.
~Duration of treatment:
~Total 5 days included the day of surgery and 4 post-operative days."
11306944|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
11306945|NCT02653170|Experimental|SCM|"One intervention is provided:
~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
11306946|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:
~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:
~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
11306947|NCT02653157||Burn patients with VAT or VAP with MDR-GNB|Adult patients with burn and/or inhalation injury requiring intubation
11306948|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
11306949|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
11306950|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
11306951|NCT02653131|Experimental|DPP-4|The administration of the DPP-4 inhibitor in the form of a pill once per day
11306952|NCT02653131|No Intervention|NO DPP|no therapy
11306953|NCT02653118||Cohort 1: V503 in the Base Study|Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
11306954|NCT02653118||Cohort 2: GARDASIL in the Base Study|Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
11306955|NCT02653105|Experimental|OLFM4|Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.
11306994|NCT02652884|Experimental|Group 1|will receive single dose intramuscular corticosteroid deltoid deposit (as phosphate and betamethasone acetate, 2 mL) for immediate postintubation.
11306995|NCT02652884|Placebo Comparator|Group 2|will receive 2 ml saline 0.9% NaCl in deltoid immediately postintubation.
11306956|NCT02653092|Active Comparator|Aim 1|"Reproduction of the reproductive phenotype of obesity in Normal Weight Women (NWW) by:
~infusing insulin and free fatty acids (FFAs) in short term experiments and measuring gonadotropin pulsatility and pituitary GnRH response; and
~inducing a chronic model of the reprometabolic syndrome by administering a eucaloric diet that is relatively high in pro-inflammatory omega-6 fatty acids and low in anti-inflammatory omega-3 fatty acids (high fat diet; HFD) for one month while monitoring gonadotropin pulsatility and daily urinary reproductive hormone excretion."
11306957|NCT02653092|Experimental|Aim 2|Assessment of the gluco-regulatory and anti-lipolytic actions of insulin with a 2-stage, Hyperinsulinemic, Euglycemic Clamp (HEC) to evaluate both suppression of lipolysis and hepatic glucose production.
11306958|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia, Arthrosis (finger- and Rhizarthrosis, Gonarthrosis, Anklearthrosis), and Arthritis with an planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
11306959|NCT02653066|No Intervention|Control|Participant is recruited via usual avenues including flyers and physician referral. This includes participants who received a HealtheRx with advertisement for phone survey but did not call in based on advertisement.
11306960|NCT02653066|Experimental|Intervention with consent form|After completing survey, participant in HealtheRx+ group receives $5 bill with their survey check and blank registry consent form.
11306961|NCT02653066|Experimental|Intervention with return of consent form|After returning signed consent form, participant in HealtheRx++ group is mailed $5 bill.
11306962|NCT02653040|Experimental|Dynamic lighting|Indoor lighting with low-lux no-blue wavelengths at night.
11306963|NCT02653040|No Intervention|Treatment as usual|Characterized by full white light with little variation through a day cyclus.
11306964|NCT02653027|Experimental|Lumacaftor Ivacaftor|Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
11306965|NCT02653014|Experimental|Cohort 1|Healthy Volunteers will receive multiple dose of KBP-5074
11306966|NCT02653014|Experimental|Cohort 2|Healthy Volunteers will receive multiple dose of KBP-5074
11306967|NCT02653014|Experimental|Cohort 3|Healthy Volunteers will receive multiple dose of KBP-5074
11306968|NCT02653014|Experimental|Cohort 4|Healthy Volunteers will receive multiple dose of KBP-5074
11306969|NCT02653014|Experimental|Cohort 5|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
11306970|NCT02653014|Experimental|Cohort 6|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
11306971|NCT02653001|Experimental|Experimental arm|Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components
11306972|NCT02652988|Active Comparator|Active-tDCs|17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
11306973|NCT02652988|Sham Comparator|Sham-tDCS|17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
11306974|NCT02652975|Experimental|Category 1|Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
11306975|NCT02652975|Experimental|Category 2|Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
11306976|NCT02652975|Experimental|Category 3|Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
11306977|NCT02652962|Experimental|Gelesis200 x 2, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
11306978|NCT02652962|Experimental|Gelesis200 x 2, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
11306979|NCT02652962|Placebo Comparator|Placebo x 2, 10 min|3 x Placebo capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
11306980|NCT02652962|Placebo Comparator|Placebo x 2, 30 min|3 x Placebo capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
11306981|NCT02652962|Experimental|Gelesis200 x 3, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
11306982|NCT02652962|Experimental|Gelesis200 x 3, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
11306983|NCT02652962|Placebo Comparator|Placebo x 3, 10 min|3 x Placebo capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
11306984|NCT02652962|Placebo Comparator|Placebo x 3, 30 min|3 x Placebo capsules administered 30 minutes before each of 3 meals (breakfast, lunch, dinner).
11306985|NCT02652949|Experimental|Endovascular Repair|Valiant Evo Thoracic Stent Graft System
11306986|NCT02652936|Experimental|AF-130 capsule|AF-130 oral capsules administered as a single dose or once daily for 7 days
11306987|NCT02652936|Placebo Comparator|AF-130 matching placebo capsule|Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
11306988|NCT02652923|Experimental|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
11306989|NCT02652923|Experimental|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
11306990|NCT02652910|Experimental|IL-2 programmed CD19.CAR-T cells|Administrated with IL-2 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
11306991|NCT02652910|Experimental|IL-7/IL-15 programmed CD19.CAR-T cells|Administrated with IL-7/IL-15 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
11306992|NCT02652897||Exposure to glioma resection surgery|Patients undergoing elective glioma resection
11306996|NCT02652871|Experimental|LY2510924 + Idarubicin + Cytarabine|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients. On Day 8, LY2510924 administered after bone marrow aspiration and/or biopsy is performed.
~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.
~Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.
~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.
~Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.
~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
11306997|NCT02652858|Experimental|Pulse wave's speed observational arm|Whole patients for who the pulse wave's speed are measured during a cardiopulmonary bypass during cardiac surgery
11306998|NCT02652845|Experimental|Intervention-Wellness Engagement Program|"The group assigned to the intervention arm will receive treatment as described below for a twelve week period:
~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events"
11306999|NCT02652845|No Intervention|Delayed treatment control group|The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.
11307000|NCT02652832|Active Comparator|Depression Electroconvulsive therapy|40 patients with major depression receiving a mean of 12 sessions of Electroconvulsive therapy
11307001|NCT02652832|Active Comparator|Depression active repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
11307002|NCT02652832|Sham Comparator|Depression sham repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of sham 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
11307003|NCT02652832|Active Comparator|Schizophrenia active transcranial magnetic stimulati|40 patients with schizophrenia and predominant negative symptoms receiving 20 sessions of intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
11307004|NCT02652832|Sham Comparator|Schizophrenia sham transcranial magnetic stimulation|patients with schizophrenia and predominant negative symptoms receiving 20 sessions of sham intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
11307005|NCT02652832|Active Comparator|Schizophrenia active transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
11307006|NCT02652832|Sham Comparator|Schizophrenia sham transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of sham transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
11307007|NCT02652832|No Intervention|Healthy volunteers|80 healthy volunteers receiving no stimulation
11307008|NCT02652819|Experimental|FG-4592|Intervention is investigational treatment FG-4592
11307009|NCT02652819|Placebo Comparator|Placebo|Double blinded placebo control
11307010|NCT02652806|Experimental|FG-4592|Intervention is investigational treatment FG-4592
11307011|NCT02652806|Active Comparator|EPO|Intervention is subject's current dose of Li Xue Bao (epoetin alfa)
11307012|NCT02652793|Experimental|Experimental|All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.
11307013|NCT02652780|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
11307014|NCT02652780|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
11307015|NCT02652767|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
11307016|NCT02652767|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
11307017|NCT02652754|Other|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
11307018|NCT02652741|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
11307019|NCT02652728|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
11307020|NCT02652715|Experimental|Basic science (Salvia hispanica seed)|Patients receive Salvia hispanica seed PO QD for 12 weeks.
11307021|NCT02652702|Experimental|Circular Stapler-assisted Colostomy|Using Circular Stapler-assisted Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
11307022|NCT02652702|Experimental|Hand-stitching Colostomy|Using Conventional Hand-stitching Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
11307023|NCT02652689|Experimental|Diagnostic ultrasound|Recording Doppler ultrasound signals noninvasively from the right chest wall
11307024|NCT02652676|Experimental|Reversible Pulmonary Artery Banding|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
11307025|NCT02652663||ECA-MRI group|ECA-MRI group (patients who underwent conventional MRI using extracellular contrast agent [ECA])
11307026|NCT02652663||Gd-EOB-MRI group|Gd-EOB-MRI group (patients who underwent gadoxetic acid-enhanced MRI)
11307027|NCT02652650|Experimental|Ethinylestradiol/Norethindrone|During the first oral contraceptive (OC) cycle participants will receive ethinylestradiol/norethindrone 35 microgram (mcg)/1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in). During the second OC cycle (from Day 29 to Day 56), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg alone qd for 21 days on Days 29 to 49 (Cycle II: OC alone, reference). During the third OC cycle (from Day 57 to Day 84), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg qd for 21 days on Days 57 to 77 and in addition JNJ-63623872, 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test).
11307028|NCT02652637|Experimental|Mechanical and oral antibiotic bowel preparation|Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.
11307029|NCT02652637|No Intervention|No bowel preparation|No mechanical bowel preparation or oral antibiotics.
11307030|NCT02652624|Experimental|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
11307031|NCT02652624|Active Comparator|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
11307032|NCT02652624|Experimental|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
11307033|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
11307034|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
11307035|NCT02652598|Experimental|Open-Label|Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
11307036|NCT02652585|Active Comparator|Naltrexone|"1 capsule naltrexone 25 mg per day, oral use, day 1 to day 3;
~1 capsule naltrexone 50 mg per day, oral use, day 4 to day 28"
11307037|NCT02652585|Placebo Comparator|Placebo|1 capsule placebo, oral use, day 1 to day 28
11307038|NCT02652572|Experimental|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
11307039|NCT02652559|Experimental|Home initiation|Home initiation of long-term NIV will be compared with standard in-hospital initiation. NIV at home will be titrated by a specialised nurse of our home mechanical ventilation centre (HMV) on transcutaneously measured gas exchange and respiratory electromyography and will be adjusted with the use of telemedicine.
11307040|NCT02652559|Active Comparator|Inhospital initiation|Inhospital initiation of NIV is standard care and in the study will be set as the control arm.
11307041|NCT02652546|Active Comparator|A|CC-11050 200mg (2 capsules) BID with food
11307042|NCT02652546|Placebo Comparator|B|Placebo (2 capsules) BID with food
11307043|NCT02652520|Experimental|Kidney transplantation|HEMO2Life® use in organ preservation solution. Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
11307044|NCT02652507|Other|Anesthesia for MRI|"All patients will receive the same drugs.
~A loading dose of dexmedetomidine of 2 mcg/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h. Bolus dose 2 mg/kg of ketamine will be given after the initial set of research images have been taken."
11307045|NCT02652494||Patients receiving Apremilast per daily clinical practice|Dutch patients receiving Apremilast according to daily clinical practice
11307076|NCT02652299||Longstanding Rheumatoid Arthritis group|Following informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
11307077|NCT02652299||Control group: Synovial tissue and peripheral blood|20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
11307078|NCT02652286|Other|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
11307046|NCT02652481|Other|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).
~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
11307047|NCT02652468|Experimental|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Participants receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Participants also undergo total nodal irradiation on day -1.
~TRANSPLANT: Participants undergo TCR alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg participant body weight (BW), patients may receive a second graft on day 1.
~GVHD PROPHYLAXIS: Participants receive mycophenolate mofetil orally twice a day (PO BID) on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the participant)."
11307048|NCT02652455|Experimental|PD-1, CD137 and Adoptive Cell Therapy|"Combination Therapy and Immunotherapy as described in intervention descriptions.
~Nivolumab Treatment: The first 6 participants will not have pre-treatment with nivolumab and instead will be scheduled for the removal of their tumor sample for tumor Infiltrating lymphocytes (TIL) growth in the lab. The second 6 participants will receive treatment with nivolumab prior to removal of tumor sample for TIL growth; about 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
~Surgery to remove tumor for growth of TIL followed by: TIL growth process; lymphodepleting chemotherapy with cyclophosphamide and fludarabine; TIL infusion; Interleukin-2 treatment."
11307049|NCT02652442|Active Comparator|vestibular rehabilitation|"Gaze stability exercises include adaptation and substitution exercises. Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. Participants will perform brief periods of gaze stability exercises 3 times daily.
~In addition, participants will perform balance and gait exercises to improve postural stability and mobility and will be provided a written home exercise program."
11307050|NCT02652442|Experimental|centrifugation|"Participants will be rotated in a darkened rotary chair booth with 1 ear positioned 7-8 cm off-axis and the other ear positioned on-axis. Following a 5-minute rest period, the procedure will be repeated with the opposite ear positioned off-axis. Participants will receive 10 sessions in a 4-week period.
~In addition, participants will perform balance and gait exercises to improve postural stability and mobility and will be provided a written home exercise program."
11307051|NCT02652429|Experimental|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
11307052|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
11307053|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
11307054|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
11307055|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
11307056|NCT02652416|Experimental|Placebo (SRD part)|placebo
11307057|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
11307058|NCT02652403|Active Comparator|Complete conventional dentures|Complete dentures fabricated by conventional technique.
11307059|NCT02652403|Active Comparator|Complete simplified dentures|Complete dentures fabricated by simplified technique
11307060|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
11307061|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
11307062|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
11307063|NCT02652377|Experimental|EDP-494 SAD Cohorts|EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration
11307064|NCT02652377|Experimental|EDP-494 MAD/POC Cohorts|EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days
11307065|NCT02652377|Placebo Comparator|EDP-494 SAD Placebo Cohort|
11307066|NCT02652377|Placebo Comparator|EDP-494 MAD/POC Placebo Cohort|
11307067|NCT02652351|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
11307068|NCT02652338|Active Comparator|MNC-01|potassium, magnesium, and vitamins (MNC-01)
11307069|NCT02652338|Placebo Comparator|Placebo|cellulose, microcrystalline [NF], HPMC E15,
11307070|NCT02652325|Active Comparator|povidone-iodine|
11307071|NCT02652325|Active Comparator|3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP swabs|
11307072|NCT02652325|Placebo Comparator|Saline|
11307073|NCT02652312|Active Comparator|Group 'D'|"Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.
~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.
~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
11307074|NCT02652312|Placebo Comparator|Group 'P'|"Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.
~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.
~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
11307075|NCT02652299||Early Rheumatoid Arthritis group|Following informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
11307080|NCT02652260|Experimental|Immediate Switch to MK-1439A|Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded MK-1439A orally, once daily for 12 weeks, followed by open-label MK-1439A orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label MK-1439A for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label MK-1439A, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label MK-1439A, with a maximum total duration of treatment of 312 weeks.
11307081|NCT02652260|Experimental|Deferred Switch to MK-1439A|Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label MK-1439A orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label MK-1439A for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label MK-1439A, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label MK-1439A, with a maximum total duration of treatment of 324 weeks.
11307082|NCT02652247|Experimental|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
11307083|NCT02652247|Experimental|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
11307084|NCT02652247|Experimental|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
11307085|NCT02652247|Experimental|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
11307086|NCT02652234|Experimental|Endostar-subcutaneous injection/Chemotherapy|
11307087|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
11307088|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
11307089|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
11307090|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
11307091|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
11307092|NCT02652182||1|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Huai'an first people's hospital
11307093|NCT02652182||2|patients with acute ST(S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Nanjing Drum Tower hospital
11307094|NCT02652169|Experimental|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
11307095|NCT02652169|Experimental|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
11307096|NCT02652169|Experimental|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
11307097|NCT02652169|Active Comparator|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
11307098|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
11307099|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
11307100|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
11307101|NCT02652143|Experimental|sibling oocytes in vivo|randomized oocytes assigned to in vivo culture
11307102|NCT02652143|Active Comparator|sibling oocyte in vitro|randomized oocytes assigned to in vitro culture
11307103|NCT02652130|Experimental|Safety population|All subjects who participated in Protocol MSB-GVHD001 and received at least one remestemcel-L infusion in that protocol.
11307104|NCT02652091||Interferon beta-1b|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are injecting Betaseron via the Betaconnect device.
11307105|NCT02652078|Sham Comparator|Control|Sham treatment in identical format to treatment arm but without shockwave production
11307106|NCT02652078|Experimental|Shockwave|Active shockwave treatment to calf muscle bulk
11307107|NCT02652065|Active Comparator|Healthy skin|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.
~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
11307108|NCT02652065|Experimental|Psoriasis plaque|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).
~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
11307109|NCT02652052|Other|Group 1: Observational|Observational only
11307110|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
11307111|NCT02652039||cancer patients|
11307112|NCT02652026|Experimental|Treatment Group|The Treatment Group (TG) received full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron, Acteon, Merignac, France) and Gracey curettes (Hu- Friedy, Chicago, USA).Also received Oral Hygienic Instructions
11307113|NCT02652026|Active Comparator|Control Group|The Control Group (CG) received periodontal prophylaxis at baseline, by removal of supragingival deposits (plaque and calculus) with ultrasonic scaler. Also received Oral Hygienic Instructions
11307114|NCT02652013|Experimental|40 patients with multiple sclerosis|The study sample will consist of 40 patients with multiple sclerosis. MS patients and control subjects will be recruited on the Rennes (Centre Hospitalier Universitaire and Pôle de Médecine Physique et de Réadaptation Saint-Hélier) and Angers sites (Centre Hospitalier Universitaire) participating in COGNISEP project
11361830|NCT02288481|Experimental|Cohort 3 60 mg TBA-354|
11307115|NCT02652013|Other|40 healthy subjects|All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
11307116|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
11307117|NCT02651974|Active Comparator|Control condition|A control invitation letter similar to the previous standard (non-incentive) invitation with slight wording and grammatical improvements will be mailed to patients randomly assigned to this group.
11307118|NCT02651974|Active Comparator|Cost condition|A control invitation letter with the addition of one line informing participants of the average value of the KIT procedure will be mailed to patients randomly assigned to this group.
11307119|NCT02651974|Active Comparator|Cost/Future condition|An invitation letter with the average value of the KIT procedure and a sentence assuring participants that should a follow-up test be requested, it will also be provided free of charge will be mailed to patients randomly assigned to this group.
11307120|NCT02651961|Active Comparator|One stage exchange|One stage exchange of the chronically infected implant
11307121|NCT02651961|Active Comparator|Two stage exchange|Two stage exchange of the chronically infected implant
11307122|NCT02651948|Experimental|Transperineal prostate biopsy (TPB)|Transperineal prostate biopsy MRI-guided
11307123|NCT02651948|Active Comparator|Transrectal prostate biopsy (TRB)|Transrectal prostate biopsy echo-guided
11307124|NCT02651935|Experimental|Intellivent ASV|Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
11307125|NCT02651935|No Intervention|PCV+PSV|PCV+PSV is a conventional ventilation strategy of pressure controlled ventilation PCV) and pressure support ventilation (PSV).In this arm, FiO2, pressure control levels, respiratory frequency and all the ventilator settings will be manually adjusted by the physicians in charge.
11307126|NCT02651909||Rivaroxaban Cohort|Evidence of Rivaroxaban use with-in the last 48hours Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
11307127|NCT02651909||Control cohort not taking Rivaroxaban|Not taking Rivaroxaban - matched to Rivaroxaban group by age gender, type of injury or illness requiring urgent surgery Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
11307128|NCT02651896||HypoIGRT|"Low Risk (T1-T2a, Gleason score 6, and PSA < 10 ng/mL)
~Intermediate Risk (T1-T2c, Gleason 7, and PSA 10-20 ng/mL)
~High Risk (T3 - 4 , Gleason 8-10, and/or PSA > 20 ng/mL) Neoadjuvant hormone therapy is allowed on groups 2 and 3"
11307129|NCT02651883|Active Comparator|Screening invitation (with education)|Participants will receive a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic.
11307130|NCT02651883|Experimental|Self-collection for HPV testing|Participants in the intervention arm will receive a kit to self-collect a sample and return it for HPV testing. Participants will then receive a phone call providing their HPV results plus (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic, if desired.
11307131|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
11307132|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
11307133|NCT02651870|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
11307134|NCT02651857|Experimental|Endoscopy exploratory single arm|
11307135|NCT02651844|Experimental|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
11307136|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.
~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
11307137|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
11307138|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
11307139|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
11307140|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.
~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
11307141|NCT02651805|Experimental|Mechanical Insufflation-Exsufflation Group|Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation
11307142|NCT02651805|Active Comparator|Usual Care Group|Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart
11307143|NCT02651792|Active Comparator|ketamine- propofol|IV Ketamine 1mg/kg + Propofol 1.2 mg/kg will be given for sedation.
11307144|NCT02651792|Active Comparator|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
11307145|NCT02651779|Active Comparator|Closed reduction and plasterimmobilisation|The control group will be treated with closed reduction and cast immobilization. This will take place under local anaesthesia by means of a haematoma block with 20 cc Lidocaine 1%. Closed reduction will be preferably performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilizing wrist and hand in the reduced position. Additional radiographs will be performed to verify the success of the reduction. After this has been confirmed, the wrist will be immobilized initially in a split plaster and later changed into a circular cast for five to six weeks immobilization in total.
11307146|NCT02651779|Other|Open reduction and internal plate fixation|The surgery will be performed by a certified trauma surgeon. According to the current standard treatment protocol, antibiotic prophylaxis will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis muscle and the radial artery. After the fracture site is exposed, the fracture will be reduced and provisionally fixed under fluoroscopy with K-Wires/reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Fracture reduction and screw placement will be confirmed by radiographic images. Additionally, fixation can be supported by a dorsal plate or radial column plate. This will be at discretion of the surgeon and depends on the fracture configuration and the position of the fragments. Wound closure will be performed at the discretion of the surgeon using standard techniques.
11307147|NCT02651766|No Intervention|Waiting List control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
11307148|NCT02651766|Experimental|Cupping massage treatment|Received the 5 cupping treatments, application twice a week on the upper back and neck
11307149|NCT02651753|Experimental|A|"Period 1: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
~Period 2: Test drug(CKD-337), 1 capsule administered under fed conditions."
11307150|NCT02651753|Experimental|B|Period 1: Test drug(CKD-337), 1 capsule administered under fed conditions. Period 2: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
11307151|NCT02651740|Experimental|Combining therapy|taking rifaximin for 3 days and then receiving fecal microbiota transplantation with donor stool through enteral nutrition tube
11307152|NCT02651727|Experimental|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
11307153|NCT02651727|Experimental|Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
11307154|NCT02651727|Experimental|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
11307155|NCT02651714|Placebo Comparator|Placebo|Oral
11307156|NCT02651714|Experimental|Tradipitant|Oral
11307157|NCT02651688|Experimental|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
11307158|NCT02651688|Experimental|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
11307159|NCT02651688|Placebo Comparator|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
11307160|NCT02651675|Experimental|AAV directed hLDLR gene therapy|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
11307161|NCT02651662|Experimental|Open label (cemiplimab)|Experimental cohorts will consist of multiple dose levels of cemiplimab administered intravenously (IV) every 2 weeks (Q2W)
11307162|NCT02651662|Experimental|Open label (cemiplimab and REGN1979)|Experimental cohorts will consist of a single dose level of cemiplimab administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)
11307163|NCT02651649|Experimental|Parturients with FGR/OSA who use CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for Continuous Positive Airway Pressure (CPAP). Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
11307164|NCT02651649|No Intervention|Parturients with FGR/OSA and no CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for CPAP. Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
11307165|NCT02651636|Experimental|Open label|Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
11307166|NCT02651623|Experimental|Sertraline|Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
11307167|NCT02651623|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
11307168|NCT02651623|Placebo Comparator|Drug - Placebo|placebo - placebo administered on Days 1 through 14
11307169|NCT02651610|Active Comparator|Taxane|Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
11307170|NCT02651610|Experimental|Bavituximab plus taxane|Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
11307171|NCT02651597|Experimental|Low Viscous|Low Viscous Beta Glucan Oatmeal
11307172|NCT02651597|Experimental|Medium Viscous|Medium Viscous Beta Glucan Oatmeal
11307173|NCT02651597|Experimental|High Viscous|High Viscous Beta Glucan Oatmeal
11361831|NCT02288481|Placebo Comparator|Cohort 3 placebo|Placebo Suspension
11307174|NCT02651584|Experimental|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.
~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
11307175|NCT02651584|Experimental|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).
~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).
~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
11307176|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the chest
11307177|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST & FINGER|Cohort of 10 patients undergoing general anesthesia, monitored by optical signals at the chest and at the fingertip
11307178|NCT02651558|Experimental|OBPM 2015-MD-0022 - FINGER|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the fingertip
11307179|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
11307180|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
11307181|NCT02651532||IBS + Confocal Laser Endomicroscopy|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
11307182|NCT02651532||Control + Confocal Laser Endomicroscopy|Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening
11307183|NCT02651519|Sham Comparator|Control|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
11307184|NCT02651519|Experimental|stellate-ganglion block|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.
11307185|NCT02651506|Experimental|Electromagnetic Navigation Bronchoscopy|
11307186|NCT02651506|Active Comparator|Transthoracic Needle Biopsy|
11307187|NCT02651493|Active Comparator|Down syndrome|photographs of individuals less than 18 yo with Down syndrome
11307188|NCT02651493|Active Comparator|Control group|photographs of individuals less than 18 yo with a genetic referral (not Down syndrome) or a healthy sibling to a child with Down syndrome
11307189|NCT02651480|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, plant-based diet for 14 weeks, and will attend nutrition classes in the form of a weekly support group.
11307190|NCT02651480|Active Comparator|Control Group|The control group will follow an unrestricted diet with no instruction.
11307191|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
11307192|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
11307193|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
11307194|NCT02651454|Experimental|Daesiho-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
11307195|NCT02651454|Experimental|Jowiseungcheung-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
11307196|NCT02651454|Placebo Comparator|Placebo|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
11307197|NCT02651441|Experimental|D-CIK|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.
11307198|NCT02651441|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
11307199|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
11307200|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
11307201|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
11307202|NCT02651402|Active Comparator|FRIENDS for Life Train-the-Trainer|Therapists implement FRIENDS (a CBT protocol for students with anxiety) in the school setting, while supported by their supervisor assigned to the Train-the-Trainer (TT) implementation strategy (supervisors participate in training workshops on conducting supervision with active therapists).
11307241|NCT02651051|Sham Comparator|High Fat Breakfast Meal|High fat breakfast meal served without addition of whey protein isolate
11307203|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer|Therapists implement an adapted version of FRIENDS (aFRIENDS) in the school setting while supported by their supervisor assigned to the TT strategy.
11307204|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer Plus|Therapists implement aFRIENDS in the school setting while supported by their supervisor assigned to the Train-the-Trainer Plus (TT+) implementation strategy (supervisors participate in training workshops and receive further/on-going consultation on conducting supervision with active therapists).
11307205|NCT02651376|Experimental|Conventional plus AAIT|Participants received conventional treatment (anti-opportunistic infections and ART) plus a dose (3 times of MNCs) of AAIT.
11307206|NCT02651363||Patients treated with Dolocordralan|
11307207|NCT02651350|Experimental|Methylprednisolone|Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
11307208|NCT02651350|Active Comparator|Standard Treatment|Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.
11307209|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
11307210|NCT02651324|Experimental|Treatment Group|A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
11307211|NCT02651324|Placebo Comparator|Placebo|A placebo (saline) will be given in place of ketamine
11307212|NCT02651311|Experimental|Block|"ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.
~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4."
11307213|NCT02651311|Placebo Comparator|No block|Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
11307214|NCT02651298|Experimental|Fractional CO2-laser|3 treatments with fractional co2-laser
11307215|NCT02651298|No Intervention|Untreated control|untreated control side of caesarean section scar
11307216|NCT02651285|Experimental|G-CSF|The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF
11307217|NCT02651285|Placebo Comparator|CONTROL|The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.
11307218|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
11307219|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
11307220|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
11307221|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
11307222|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
11307223|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
11307224|NCT02651207||local anaesthetic spray group|women will either chose the above, ethyl chloride spray prior to having their contraceptive implant fitted or the below injection. This comes in a canister and a maximum of 5 spray for 5 seconds will be applied topically to the skin at the site of the contraceptive implant insertion
11307225|NCT02651207||local anaesthetic injection group|women will either chose ethyl chloride spray prior to having their contraceptive implant fitted or the injection, subcutaneous 1% lidocaine, usually a dose of about 1-2 mls to the area skin where the contraceptive implant is to be inserted.
11307226|NCT02651194|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
11307227|NCT02651181|Experimental|Closed Loop System|
11307228|NCT02651168|Other|aflibercept|aflibercept treatment aflibercept, 40 mg/mL Solution for Intravitreal Injection
11307229|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
11307230|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
11307231|NCT02651142|Experimental|SLNB with para-SLN dissection|patients receive sentinel lymph node biopsy patients receive para-sentinel lymph node dissection
11307232|NCT02651142|Experimental|SLNB without para-SLN dissection|patients received sentinel lymph node biopsy
11307233|NCT02651116|Experimental|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
11307234|NCT02651116|Placebo Comparator|Placebo|10 mL of Placebo
11307235|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
11307236|NCT02651090|Experimental|sonazoid|treatment arm with sonazoid
11307237|NCT02651077||Case Group|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at Nantes University Hospital for surgical indication of endometriosis lesions ablation.
11307238|NCT02651077||Control Group|38 women aged 18 to 45 years old without suggestive signs of endometriosis
11307239|NCT02651064|Experimental|HIP|Received a 30% rebate on targeted fruits and vegetables (TFV) purchased using SNAP benefits in participating retailers. TFV earning the rebate included fresh, canned, frozen, and dried fruits and vegetables without added sugars, fats, oils, or salt, excluding white potatoes, mature legumes (dried beans and peas), and 100% juice.
11307242|NCT02651051|Experimental|High Fat Breakfast Meal + Whey Protein|High fat breakfast meal served with addition of whey protein isolate
11307243|NCT02651038|Experimental|Micafungin|Micafungin is administered per clinical need and the pharmacokinetic parameters are analyzed
11307244|NCT02651025|Experimental|Resistance Exercise Program|Patients included in intervention group will submit to resistance exercise training during hemodialysis, three times a week, for twelve weeks. This program includes exercises for the upper and lower limbs.
11307245|NCT02651025|No Intervention|Passive Stretching Program|Patients included in control group will submit to passive stretching program of lower limbs, during hemodialysis, three times a week, for twelve weeks.
11307246|NCT02650999|Experimental|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
11307247|NCT02650986|Experimental|Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
11307248|NCT02650986|Experimental|Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
11307249|NCT02650973|Experimental|Sequence A|3 doses of CHS-1701 or Neulasta, random order
11307250|NCT02650973|Experimental|Sequence B|3 doses of CHS-1701 or Neulasta, random order
11307251|NCT02650973|Experimental|Sequence C|3 doses of CHS-1701 or Neulasta, random order
11307252|NCT02650947|Experimental|Sucralose|Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
11307253|NCT02650947|Placebo Comparator|Placebo|Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
11307254|NCT02650934||Adverse remodelling|EF below 40% following MI and remain below 40% after reperfusion
11307255|NCT02650934||not adverse remodelling|EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
11307256|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
11307257|NCT02650921|No Intervention|No Intervention|
11307258|NCT02650895|Experimental|CD24Fc|Single dose of CD24Fc is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in CD24Fc and 2 subject in placebo.
11307259|NCT02650895|Placebo Comparator|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
11307260|NCT02650882|Placebo Comparator|placebo|Placebo group (PG) Nine athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a fixed load at 15% MIP, placebo protocol.
11307261|NCT02650882|Experimental|Experimental|Experimental group (EG) Ten athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a progressive load at 60%, 70% and 80 % of MIP.
11307262|NCT02650869|Experimental|Standard care + Breast milk+ Probiotics|The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.
11307263|NCT02650869|Active Comparator|Standard care|The control group will be given standard care without the addition of probiotics
11307264|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.
~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.
~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
11307265|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.
~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.
~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
11307266|NCT02650843||Patients with parkinsonism|Patients with parkinsonism that are referred for DAT SPECT imaging in Turku University Hospital, Finland or Helsinki University Hospital, Finland
11307267|NCT02650830||1) Normal control|metabolically healthy with no obesity
11307268|NCT02650830||2) prediabetes|defined in 'inclusion criteria'
11307269|NCT02650830||3) type 2 diabetes|defined in 'inclusion criteria'
11307270|NCT02650817|Experimental|Elacestrant (formerly RAD1901)|To receive daily oral elacestrant
11307271|NCT02650804|Experimental|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.
~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
11307272|NCT02650791|No Intervention|Prophylactic Platelet Transfusions|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 10^9/L.
11307359|NCT02650154||Pre-ketamine group|Blood samples are taken prior to the administration of ketamine.
11307360|NCT02650154||Post-ketamine group|Blood samples are taken several hours after the administration of ketamine.
11307273|NCT02650791|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 10^9/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions
11307274|NCT02650752|Experimental|Lapatinib in Tandem With Capecitabine|A minimum of one patient at each dose level will be enrolled. Patients will receive a 4 week treatment cycle consisting of lapatinib 3 day on/11 day off in tandem with capecitabine 7 day on/7 day off with lapatinib. Both drugs will be administered orally as outpatient. Safety, toxicity, and DLT will be assessed weekly during the cycle 1 (first 4 weeks). Each patient will be monitored during cycle 1 prior to enrolling the next patient to the next higher dose level. Dose escalation will take place if no DLT or less than two occurrences of grade 2 toxicity (except those listed below) is observed within a given patient. In the event that a second instance of separate grade 2 toxicity (except those listed below) is noted, the cohort will be expanded to 3 patients at the same dose level and the study will revert to the standard 3+3 design with 3 patients per cohort. There will be no intra-patient dose escalation.
11307275|NCT02650739||SS-OCTdetermined group|Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT
11307276|NCT02650739||Control group|Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon
11307277|NCT02650726|Placebo Comparator|control group|The participants in this group are instructed to consume placebo capsules every day during the trial period.
11307278|NCT02650726|Experimental|treatment group|The participants in this group are instructed to consume anthocyanin capsules every day during the trial period.
11307279|NCT02650713|Experimental|Dose-Escalation (Part IA): RO6958688 + Atezolizumab|Participants will receive RO6958688 weekly (QW) at escalating doses starting at 5 mg, in combination with a fixed dose (1200 mg) of atezolizumab every 3 weeks (Q3W). RO6958688 dosage will not exceed the MTD if defined in the BP29541 study.
11307280|NCT02650713|Experimental|Dose/Schedule Finding (Part IB): RO6958688 + Atezolizumab|"Part IB will explore different RO6958688 administration schedules in combination with atezolizumab, consisting of:
~Cohort A: will compare the QW vs Q3W dosing schedules at a flat dose of RO6958688.
~Step Up dosing schedules: RO6958688 dose will start at 40 mg and increase with each administration up to the MTD or 1200 mg, whichever occurs first."
11307281|NCT02650700|Experimental|Chemotherapy plus spleen radiotherapy|Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). The intervention is spleen radiotherapy.
11307282|NCT02650700|Other|Chemotherapy alone|Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy. The intervention is spleen radiotherapy.
11307283|NCT02650687||Elective Non Cardiac Surgical Patients|65 years of age and older
11307284|NCT02650674|Experimental|Product A: NP-0148|Cereal product belVita Milk & Cereals - High in SDS
11307285|NCT02650674|Experimental|Product B: NP-0149|Cereal product belVita Honey & Nuts - High in SDS
11307286|NCT02650674|Experimental|Product C: NP-0150|Cereal product belVita Mixed Berry - High in SDS
11307287|NCT02650674|Experimental|Product D: NP-0151|Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
11307288|NCT02650674|Experimental|Product E: NP-0152|Cereal product Kellogg's Trésor Duo Choco - Low in SDS
11307289|NCT02650674|Experimental|Glucose reference|Glucose solution performed on three occasions
11307290|NCT02650661|Experimental|Online program & Health coaching|"This group is provided with Online health management program, Health coaching and Workshop."
11307291|NCT02650661|Experimental|Online program|"This group is provided with Online health management program."
11307292|NCT02650661|Active Comparator|Enhanced Usual Care|"This group is provided with Standard health educational booklet."
11307293|NCT02650648|Experimental|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10^6/kg in level 1; 14.9x10^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
11307294|NCT02650635|Experimental|Treatment (CTX, pegfilgrastim, TLR8 agonist VTX-2337)|Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
11307295|NCT02650622||Cohort 1-Newborns aged 1-2 days|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
11307296|NCT02650622||Cohort 2-Children aged 0-18 years|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
11307297|NCT02650622||Cohort 3-Diseased childrens and families|Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
11307298|NCT02650609|Experimental|Methylprednisolone|"Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.
~Capsules will be administered orally in the morning, during breakfast with a glass of water.
~Dose is adapted according to the weight of the patient (1mg/kg):
~<60 kg: 3 pills of 16 mg/day
~60-80kg: 4 pills of 16 mg/day
~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
11307299|NCT02650609|Placebo Comparator|Placebo|"Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.
~Dose is adapted according to the weight of the patient (1mg/kg):
~<60 kg: 3 pills of 16 mg/day
~60-80kg: 4 pills of 16 mg/day
~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
11307361|NCT02650141|Experimental|ziyinxiehuo Granules|Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.
11307300|NCT02650596|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.
11307301|NCT02650596|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.
11307302|NCT02650583|Experimental|Supportive care (Enhancing Connections Program)|Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
11307303|NCT02650570||Head/Neck Cancer|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC)
11307304|NCT02650570||Healthy Control|Healthy controls age matched to the Head/Neck cancer group.
11307305|NCT02650557||CSF group|consecutive patients with angiographically documented CSF
11307306|NCT02650557||control group|age- and gender-matched control subjects
11307307|NCT02650544|Experimental|mirtazapine|Mirtazapine arm will be orally administered with mirtazapine 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
11307308|NCT02650544|Placebo Comparator|Placebo|Placebo arm will be orally administered with placebo 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
11307309|NCT02650518|No Intervention|Control|Subject receives the standard of care that is provided by the primary team taking up his/her case.
11307310|NCT02650518|Experimental|Catheter change+Short-course Antibiotics|
11307311|NCT02650505|Experimental|LEO 43204|LEO 43204 will be applied topically to the skin under open conditions 10 times
11307312|NCT02650505|Placebo Comparator|LEO 43204 vehicle|LEO 43204 vehicle will be applied topically to the skin under open conditions 10 times
11307313|NCT02650492|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
11307314|NCT02650479|Other|IV exenatide - pilot study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
11307315|NCT02650479|Experimental|Treatment Group A - core study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
11307316|NCT02650479|Experimental|Treatment Group B - core study|IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
11307317|NCT02650479|Experimental|Treatment Group C - core study|IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
11307318|NCT02650466|Experimental|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
11307319|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
11307320|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
11307321|NCT02650427|Experimental|DPPIV Inhibition|The study will include 3 weeks administration (± 7 days) of sitagliptin as monotherapy (taken orally). The study will use 3 doses: the first five patients will receive 100 mg/day, the next five 200 mg/day and the last five patients 600 mg/day. During this time, arrangements will be made for surgical resection, as per the standard of care treatment of patients. Blood samples will be obtained for immunology studies. The study will end one week after surgery. Patients will continue their treatment for HCC as prescribed by the clinician.
11307322|NCT02650414|Experimental|CART22 cells|"Subjects <50kg will receive 0.2-1 x 107 CART22 cells/kg as a split dose over three days as follows:
~Day 1, 10% fraction: 0.2-1x106 CART22 cells/kg
~Day 2, 30% fraction: 0.6-3x106 CART22 cells/kg
~Day 3, 60% fraction: 1.2-6x106 CART22 cells/kg
~Subjects ≥50kg will receive 1-5x108 CART22 cells as a split dose over three days as follows:
~Day 1, 10% fraction: 1-5x107
~Day 2, 30% fraction: 0.3-1.5x108
~Day 3, 60% fraction: 0.6-3x108"
11307323|NCT02650401|Active Comparator|Extracranial solid tumors harboring NTRK1/2/3,|"Arm closed for further enrollment
~ROS1, ALK non-gene fusion molecular alterations
~Oral entrectinib (RXDX-101)"
11307324|NCT02650401|Active Comparator|CNS tumors harboring- NTRK1/2/3, ROS1, ALK|"Arm closed for further enrollment
~molecular alterations, including gene fusions
~Oral entrectinib (RXDX-101)"
11307325|NCT02650401|Active Comparator|Neuroblastoma|"Arm closed for further enrollment
~Oral entrectinib (RXDX-101)"
11307326|NCT02650401|Active Comparator|Non-neuroblastoma, extracranial solid tumors|"Arm closed for further enrollment
~harboring - NTRK1/2/3, ROS1, ALK gene fusions
~Oral entrectinib (RXDX-101)"
11307327|NCT02650401|Active Comparator|Any participant unable to swallow capsules|"Arm closed for further enrollment
~Any participant who otherwise meet all other eligibility criteria
~Oral entrectinib (RXDX-101)"
11307328|NCT02650401|Active Comparator|Expansion: CNS tumors harboring NTRK1/2/3, ROS1|"gene fusions
~Oral entrectinib (RXDX-101)"
11307329|NCT02650401|Active Comparator|Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1|"NTRK 1,2,3 and ROS1 fusions
~Oral entrectinib (RXDX-101)"
11307614|NCT02648321|Experimental|Motivational Interviewing|Motivational Interviewing
11307330|NCT02650388|Other|Post TAVI neurocognitive outcome|"TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective Eyeball test, Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced."
11307331|NCT02650375|Experimental|Metatinib Tromethamine|
11307332|NCT02650362|Experimental|spinal cord stimulation|
11307333|NCT02650349|Experimental|spinal cord stimulation|The Vectris® SureScan® MRI lead will be connected to a RestoreSensor® SureScan® MRI neurostimulator.
11307334|NCT02650336||CIN proup|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
11307335|NCT02650336||control group|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
11307336|NCT02650310|No Intervention|Conventional transfer|This arm is the control group (conventional embryo transfer protocol) where there is no intervention.
11307337|NCT02650310|Experimental|Thermostable device transfer|This arm is the study group: embryo transfer protocol using a new thermostable device.
11307338|NCT02650297|Experimental|CDT and pneumatic compression pump|combined decongestive therapy consists of the pressure of bandage, manual lymphatic drainage, and exercises that increase the flow of lymph and skin care are used. Intermittent pneumatic pump is not as a part of CDT, but it can be used as an adjunct method. This device according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk.
11307339|NCT02650297|No Intervention|not CDT and pneumatic compression pump|Patients in the control group received no treatment for lymphedema but were placed on the waiting list for CDT as soon as possible after the 8 weeks follow-up period.
11307340|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
11307341|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using conventional instrumentation or navigation.
11307342|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
11307343|NCT02650271|Active Comparator|Lamivudine|Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.
11307344|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
11307345|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
11307346|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 66-69, 70-75, 76-80, 81-85).
11307347|NCT02650245|Experimental|Moderate protein and 10gm lactulose|40% of daily recommended intake of protein based on weight
11307348|NCT02650232|Other|Young Healthy Volunteers|We will evaluate in this group (18 - 40 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
11307349|NCT02650232|Other|Old Healthy Volunteers|We will evaluate in this group (50 - 80 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
11307350|NCT02650232|Other|Patients with heart failure|We will evaluate in this group (50 - 80 y + Heart failure) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
11307351|NCT02650219||gaucher disease type 1|"Inclusion criteria:
~Adult patients >= 18 years old
~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
11307352|NCT02650219||Control|healthy subjects intervention: genetic analyses
11307353|NCT02650206|Experimental|Liraglutide group|"Drug with diet control intervention: Subjects assigned to this group receive blinded pens containing liraglutide (commonly known as Victoza), manufactured by Novo Nordisk. Subjects will inject 0.6 mg daily into abdomen during the first week of the study, and if tolerated, will increase dose to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.
~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
11307354|NCT02650206|Placebo Comparator|Placebo group|"Diet control-only intervention: Subjects assigned to this group receive blinded pens containing placebo (normal saline) instead of liraglutide (commonly known as Victoza). Subjects will inject 0.6 mg of placebo daily during the first week of the study, will increase to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.
~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
11307355|NCT02650193|Experimental|HSP-130|"Cycle 0:
~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)
~Cycles 1-4:
~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.
~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.
~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
11307356|NCT02650180|Other|Soberlink Cellular Device|Soberlink Cellular Device: a Breath Alcohol Analyzer
11307357|NCT02650167|Experimental|Colostrum|
11307358|NCT02650167|Experimental|Witness|
11307362|NCT02650141|Active Comparator|zishenqinggan Granules|Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.
11307363|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
11307364|NCT02650102|Experimental|antipsychotics|This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
11307365|NCT02650102|No Intervention|health control|This group was treated with no invention
11307366|NCT02650089|Experimental|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
11307367|NCT02650089|Experimental|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 8 repetitions were performed for each exercise, with an interval of 90 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
11307368|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
11307369|NCT02650076|Experimental|Healthy|
11307370|NCT02650063|Experimental|DE-117 ophthalmic solution|
11307371|NCT02650050|Experimental|Micropulsed laser photocoagulation|
11307372|NCT02650050|Sham Comparator|Sham micropulsed laser photocoagulation|
11307373|NCT02650011||ACLF cohort|Patients who have chronic liver disease and admitted for acute deterioration of liver function
11307374|NCT02649998|Active Comparator|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
11307375|NCT02649998|Active Comparator|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
11307376|NCT02649998|Active Comparator|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
11307377|NCT02649985|Experimental|Relapsing Remitting Multiple Sclerosis|"Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, or at least one gadolinium enhancing lesion on a MRI within 3 months of enrollment.
~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
11307378|NCT02649985|Experimental|Secondary Progressive Multiple Sclerosis|"Subjects meeting the definition for SPMS by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year
~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
11307379|NCT02649985|Active Comparator|Alzheimer's Disease|"Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26
~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
11307380|NCT02649985|Other|Healthy Control|"This group will serve as non disease population.
~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
11307381|NCT02649972|Experimental|Cobimetinib|This is an open-label, multicenter, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors. Visits during the treatment period are to be completed on Day 1, Day 15 (this visit can be by telephone), Day 29, and every 28 days thereafter. For patients treated on the study for six months, at the discretion of the Principal Investigator, visits can be spaced out to every 56 days (every 2 cycles instead of every cycle).
11307382|NCT02649959|Experimental|Open Label|CM-AT
11307383|NCT02649946|Experimental|Covera Vascular Covered Stent following PTA|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
11307384|NCT02649946|Active Comparator|PTA only using uncoated PTA Balloon|Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
11307385|NCT02649933||Watch PAt 200|obese pregnant women, pregnancy between 12 and 15 weeks
11307386|NCT02649920|Experimental|Cervical ripening balloon|Prospective
11307387|NCT02649920|Active Comparator|Dinoprostone|Retrospective
11307388|NCT02649907|Experimental|Weight loss|3 months weight loss intervention by behavioral intervention
11307389|NCT02649894|Experimental|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
11307390|NCT02649894|Active Comparator|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
11307391|NCT02649881||isolated heart from heart transplantation|
11307392|NCT02649868|Experimental|1|Treatment of hepatic tumors using bead embolization.
11307393|NCT02649855|Experimental|A/Sequential docetaxel followed by PROSTVAC|Standard ADT followed by sequential docetaxel + prostvac
11307394|NCT02649855|Experimental|B/ Combined docetaxel with PROSTVAC|Standard ADT followed by combined docetaxel + prostvac
11307395|NCT02649855|Experimental|C/ PROSTVAC prior to docetaxel|Standard ADT followed by prostvac, then docetaxel
11307396|NCT02649842|Experimental|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
11307397|NCT02649829|Experimental|Single Arm|dendritic cell vaccination plus chemotherapy
11307398|NCT02649803|Other|community hospital|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the nearest community hospital or Shanghai Children's Medical Center, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to install asthma APP at their smart phone to follow up."
11307399|NCT02649790|Experimental|KPT-8602|"Relapsed/Refractory Multiple Myeloma (RRMM) - CLOSED TO ENROLLMENT
~Metastatic Colorectal Cancer (CRC) - CLOSED TO ENROLLMENT
~Relapsed/Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) - CLOSED TO ENROLLMENT
~Higher Risk Myelodysplastic Syndrome (MDS) - CLOSED TO ENROLLMENT
~Starting dose for CRC, mCRPC, MDS is 20 mg of KPT-8602"
11307400|NCT02649764|Experimental|Treatment (fludarabine phosphate, cytarabine, prexasertib)|Patients =/< 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients > 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
11307401|NCT02649751|Experimental|Group 1|"200 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
11307402|NCT02649751|Experimental|Group 2|"400 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
11307403|NCT02649751|Experimental|Group 3|"400 mg roscovitine (8) or (4) placebo twice daily for cycles of 7 days (4 days on and 3 days off)"
11307404|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
11307405|NCT02649712|Active Comparator|Unilateral stent|Patients undergo placement of unilateral biliary stent on day 1.
11307406|NCT02649712|Active Comparator|Bilateral stents|Patients undergo placement of bilateral biliary stents on day 1.
11307407|NCT02649699|Other|Additional 3D MRI scans|Participating patients will receive additional 3D MRI scans during pre and post RT planning for their primary brain tumors.
11307408|NCT02649686|Experimental|Durvalumab plus Trastuzumab|Durvalumab q3w until PD Trastuzumab q3w x 6
11307409|NCT02649673|Experimental|LCL161+topotecan+Pegylated GCSF (PEG-GCSF)|"Dose Escalation: Groups of 3-6 patients per dose level (DL) will initiate treatment in escalating doses until the maximum tolerated dose (MTD) is reached. MTD is defined as the highest combination of doses that results in dose-limiting toxicities for 2 of 6 patients per dosing group.
~LCL161: orally, on Days 1, 8, 15 of each 21-day cycle. Maximum dose not to exceed 1200 mg/week.
~topotecan: orally, for first 5 days of each 21-day cycle. Maximum dose not to exceed 2.3 mg/m2 per day.
~Pegylated GCSF (PEG-GCSF) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
~Dose Expansion: 24 additional patients will be treated at the MTD in 2 cohorts (SCLC-12 patients; ovarian cancer-12 patients)"
11307410|NCT02649647|Active Comparator|Conventional Resection|Patients receive conventional resection with standard proximal excision margin. The sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
11307411|NCT02649647|Experimental|Proximally Extended Resection|Patients receive proximally extended resection. The whole sigmoid colon and rectum proximal to the tumor is removed, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
11307412|NCT02649634|Experimental|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
11307413|NCT02649634|Active Comparator|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
11307414|NCT02649621|Experimental|Amniotic Membrane Extract Eye Drop recipient|patients with limbal stem cell Deficiency who receive amniotic membrane transplantation and amniotic membrane extract eye drop as eye drop.
11307415|NCT02649608|Experimental|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
11307416|NCT02649608|Experimental|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
11307417|NCT02649608|Experimental|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
11307418|NCT02649608|Experimental|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
11307419|NCT02649608|Experimental|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
11307420|NCT02649608|Experimental|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
11307421|NCT02649608|Experimental|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
11307422|NCT02649608|Experimental|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
11307423|NCT02649595|Other|Red Cross respite care|A 2 week free stay at a Red Cross respite center after hospitalization.
11307424|NCT02649595|No Intervention|Streets/communal programmes|Homeless being discharged from hospital to the streets and communal programmes.
11307425|NCT02649582|Experimental|Single Arm|Dendritic cell vaccine plus temozolomide chemotherapy
11307426|NCT02649569||Observational (continuous activity monitoring, questionnaires)|Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
11307427|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
11307428|NCT02649556|Active Comparator|CC|Ad libitum use of CC
11307429|NCT02649543|Active Comparator|Primary Closure|Primary Closure is made after surgery.
11307430|NCT02649543|Active Comparator|Delayed Primary Closure|Delayed Primary Closure is made after at least 7 days.
11307431|NCT02649543|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Device is used in the wound.
11307432|NCT02649530|Experimental|WNT974|Patients will receive 10 mg of WNT974 daily by mouth.
11307433|NCT02649517|Other|chronic inflammation|All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
11307434|NCT02649504|Active Comparator|R+3D, MMF|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
11307435|NCT02649504|Placebo Comparator|R+3D, Placebo|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Placebo will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
11307436|NCT02649478|Experimental|Fluticasone / Salmeterol|"fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (LOMI) inhaler device twice a day by inhalation throughout the study"
11307437|NCT02649478|Active Comparator|Advair Diskus 100/50|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
11307438|NCT02649478|Placebo Comparator|placebo inhaler|placebo inhaled powder twice a day by inhalation throughout the study
11307439|NCT02649465|Active Comparator|SGLT2 inhibitor|N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
11307440|NCT02649465|Active Comparator|Sulfonylurea|N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.
11307441|NCT02649452|Experimental|vibration|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
11307442|NCT02649452|Active Comparator|Exercises|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between
11307443|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
11307444|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 month followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
11307445|NCT02649426|Experimental|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
11307446|NCT02649426|Sham Comparator|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
11307447|NCT02649413|Experimental|Early response to prednisone treatment|intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.
11307448|NCT02649400||Diastolic Heart Failure|Women with diastolic heart failure and previous coronary artery disease
11307449|NCT02649387|Experimental|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks* for up to 36 courses in the absence of disease progression or unacceptable toxicity.
~Note: *The last course may last up to 56 days to accommodate the study drug discontinuation visit."
11307450|NCT02649374|No Intervention|Gestational diabetes mellitus|women diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
11307451|NCT02649374|Active Comparator|No GDM, Dietary Modifications|Women without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
11307452|NCT02649374|No Intervention|No GDM, free diet|Women without GDM, for whom diet. exercise are continued regulary without any modifications
11307453|NCT02649361|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11307454|NCT02649361|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11307455|NCT02649348|Other|pre-operative prehabilitation|Patients in the pre-operative prehabilitation group required the exercise intervention protocol, which included climbing six flights of stairs at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction following abdominal surgery by using a full elastic breathable abdominal bandage.
11307456|NCT02649348|No Intervention|Comparator|Patients in the control group did not need to undergo this pre-rehabilitation protocol and prepared conventionally.
11307520|NCT02648958|Experimental|Dexmedetomidine group|The dexmedetomidine group received the dexmedetomidine.
11307615|NCT02648321|Active Comparator|Health Education|Health Education
11307457|NCT02649335|Active Comparator|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study.
11307458|NCT02649335|Active Comparator|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
11307459|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
11307460|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
11307461|NCT02649309|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
11307462|NCT02649309|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
11307463|NCT02649309|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
11307464|NCT02649309|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
11307465|NCT02649296|Other|Treatment with Skanlab Bodywave|Treatment with Skanlab Bodywave twice a week for four weeks at the affected knee.
11307466|NCT02649296|No Intervention|No treatment|Treatment with Skanlab Bodywave without function twice a week for four weeks.
11307467|NCT02649283|Other|Breast symmetrisation with OrbiSymm|Standard surgical intervention of up to 30 patients including placement of the OrbiSymm device
11307468|NCT02649283|Other|Breast symmetrisation without device|Standard surgical intervention of up to 30 patients without the Orbix device; only routine reduction/symmetrisation intervention
11307469|NCT02649270|Experimental|Group1|10 Psoriasis patients,T1h 0.2mg/kg,only single dose administration at week 1.
11307470|NCT02649270|Experimental|Group2|10 Psoriasis patients,T1h 0.4mg/kg ,first administration at week 1 and continous administration from fifth week for 9 weeks.
11307471|NCT02649270|Experimental|Group3|10 Psoriasis patients,T1h 0.8mg/kg,first administration at week 1 and continous administration from fifth week for 9 weeks.
11307472|NCT02649270|Experimental|Group4|"10 Psoriasis patients,T1h 1.6mg/kg,first administration at week 1 and biweekly from fifth week for 9 weeks.
~."
11307473|NCT02649257|Experimental|MC 6125 AS IOL + CTR|All patients received the same procedure: cataract surgery with phakoemulsification, implantation of a capsular tension ring (CTR13/11) and implantation of an intraocular lens (MC 6125 AS).
11307474|NCT02649244|Experimental|The Family Caregiver Training Program|The experimental group received a 2 hour intervention training on activities of daily throughout the early, middle, and late stages of dementia including communication, eating/feeding, nutrition, bathing, grooming, dressing, toileting, and transferring.
11307475|NCT02649244|No Intervention|Standard Care|The control group received a 1 1/2 hour training, however the information was based on what has been deemed standard care by the Alzheimer's Association.
11307476|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
11307477|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
11307478|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
11307479|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
11307480|NCT02649218|Experimental|Ligelizumab|QGE031 240 mg s.c. q4w x 13 treatments
11307481|NCT02649205||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
11307482|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
11307483|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
11307484|NCT02649179|Experimental|local infiltration with ropivacaine|patients were to receive 0.75% ropivacaine
11307485|NCT02649179|Placebo Comparator|local infiltration with 0.9% saline|patients were to receive placebo
11307486|NCT02649166|Experimental|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Summit RC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
11307487|NCT02649153|Experimental|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus.
11307488|NCT02649153|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
11307489|NCT02649153|No Intervention|empty control|This group patients will not receive gum chewing or smoked plum.
11307490|NCT02649140|No Intervention|Group 1|Group1 is control group and participants do not need intervention.
11307491|NCT02649140|Experimental|Group 2|Group 2 is vinegar Group and participants in this group are asked to drink 15ml vinegar(Ninghuafu, Sanxi, China)after dinner at noon and evening respectively for a period of four weeks.
11307492|NCT02649127|Experimental|Imaginal Therapy Only|The imaginal exercise of exposure therapy will be manualized (Rothbaum, Foa & Hembree, 2007) and adapted with the permission of Dr. Foa for combat-related stress disorders (Peterson, Cigrang & Riggs, 2008). While traditional exposure therapy includes both imaginal exposure and in vivo exposure, this study will use only the imaginal exposure components. Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes.
11307552|NCT02648776||Control Group|Patients not taking any of the included or any other anxiety-hypnotic agents
11307616|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX, SBRT|
11307617|NCT02648269|Experimental|SEL-110|Single intravenous dose of SEL-110
11307493|NCT02649127|Experimental|Exercise Only|The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity [>60% of oxygen uptake reserve (VO2R)], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate >60% of their individually-determined heart rate reserve.
11307494|NCT02649127|Experimental|Imaginal Therapy & Exercise Combined|Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes. Participants will exercise listening to their tape at least 5-times/week outside of scheduled unit Physical Training. Participants will wear the heart rate monitor to record their exercise activity.
11307495|NCT02649127|Active Comparator|Nurse-led Self-Care|The Self-Care Group will use written materials that outline the benefits of thinking about problems the individual is facing as well as the benefits of exercise, however doing the two activities together will not be advocated as part of the material. A fact sheet prepared by the National Center for PTSD, Returning from the War Zone: A Guide for Military Personnel as well as a list of coping strategies and self-care behaviors adapted from the National Center for PTSD guide, Self-Care and Self-Help Following Disasters, will be used to guide the discussion. The research nurse will meet with the participant five times over 8-weeks at weeks 1, 2, 4, 6, and 8 to encourage use of the self-care fact sheet and assess the participant for safety.
11307496|NCT02649114|Active Comparator|Cognitive-Behavioural Therapy|This version of CBT is based on techniques employed in evidence-based approaches to a transdiagnostic sample. The programme includes; individualized formulation, taking into account different maintaining factors across cases (e.g., nutritional and/or emotional drivers for binging); agenda setting; homework; change in diet (particularly to improve carbohydrate intake); diary-keeping; exposure; behavioral experiments; cognitive restructuring; and surveys. The behavioral change is maintained as a focus, along with changes in mood and cognitions.
11307497|NCT02649114|Experimental|Compassion-Focused Therapy|There are four main treatment elements to the program. Two of these are linked to the experience of being a therapy group. This involves patients providing compassionate support to other group members.The third treatment element involves compassionate mind training which mainly focuses on activating the soothing system via imagery and related practical exercises.The final element of the program aims to help patients improve their ability to use their wider social network to access support.
11307498|NCT02649101|Experimental|thalidomide plus chemotherapy|thalidomide tablet 100mg qn po
11307499|NCT02649101|Active Comparator|chemotherapy|Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.
11307500|NCT02649075|Active Comparator|SBI 10 g BID|Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
11307501|NCT02649075|Placebo Comparator|Placebo BID|Placebo w/control protein
11307502|NCT02649062|Experimental|NGM282 Dose 1|NGM282
11307503|NCT02649062|Experimental|NGM282 Dose 2|NGM282
11307504|NCT02649062|Placebo Comparator|Placebo|Placebo
11307505|NCT02649049||Patients with NAFLD|Patients with NAFLD are the cases.
11307506|NCT02649049||control group|Healthy people without NAFLD are controls.
11307507|NCT02649036||Emergency call population|Citizens over 18 years old from the Capital Region of Denmark with a first time emergency call within a two-year study period (1/12-2011-30/11-2013)
11307508|NCT02649036||Background population|Citizens over 18 years old from the Capital Region of Denmark with no emergency call within a two-year study period (1/12-2011-30/11-2013)
11307509|NCT02649023||A: Patients with deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A"
11307510|NCT02649023||B: Patients without deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B"
11307511|NCT02649010|Active Comparator|Group A|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
11307512|NCT02649010|Active Comparator|Group B|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
11307513|NCT02648997|Experimental|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
11307514|NCT02648997|Experimental|Cohort 2: Nivolumab in Combination with Ipilimumab|"External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)
~Followed by 4 cycles of Nivolumab (1 mg/kg every 3 weeks) + Ipilimumab (3 mg/kg every 3 weeks)
~Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
11307515|NCT02648984|Other|Patient group|Patients with ventricular septal defect
11307516|NCT02648984|Other|Control group|Healthy control subjects
11307517|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
11307518|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
11307519|NCT02648958|Placebo Comparator|Control group|The control group received saline instead of dexmedetomidine.
11307521|NCT02648945|Active Comparator|high intensity exercise|"high intensity exercise on a treadmill according to Balke's Protocol.
~high intensity of exercises for each group of 15 participants were set at 80-85% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax
~After rearrangement, it will be:
~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
11307522|NCT02648945|Active Comparator|low intensity exercise|"low intensity exercise on a treadmill according to Balke's Protocol. low intensity of exercises for each group of 15 participants were set at 50-55% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax
~After rearrangement, it will be:
~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
11307523|NCT02648932|Other|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
11307524|NCT02648932|Other|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
11307525|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules, 3 times per day)
11307526|NCT02648906|Experimental|Choline alfoscerate|"Drug: Choline alfoscerate and Donepezil
~concomitant administration"
11307527|NCT02648906|Placebo Comparator|Placebo|Drug: Donepezil only
11307528|NCT02648893|Experimental|MBFC-Exp|The MBFC-Exp (Multiple biofortified food crops - Experimental) arm will consume meals based on biofortified food crops.
11307529|NCT02648893|Active Comparator|MBFC-C|The MBFC-C (Multiple biofortified food crops - Control) arm will consume the same meals based on non-biofortified (commercially available) food crops.
11307530|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
11307531|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
11307532|NCT02648867|Experimental|Patients receiving PushCoach feedback|Patients will receive continuous maternal feedback from the PushCoach device, which includes both audio and visual feedback of fetal head movement during the second stage of labor
11307533|NCT02648867|Active Comparator|Patients blinded to PushCoach feedback|Patients will not receive continuous maternal feedback from the PushCoach device (it will be in place and collect data), but will receive normal feedback from the clinician during the second stage of labor.
11307534|NCT02648854|Other|Group 1|<Group 1> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition)
11307535|NCT02648854|Other|Group 2|<Group 2> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition)
11307536|NCT02648841|Active Comparator|Adjuvant Chemotherapy|The interventions of adjuvant chemotherapy group is 8 cycles of SOX(S-1+Oxaliplatin) chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
11307537|NCT02648841|Experimental|Adjuvant Chemo-radiotherapy|The interventions of adjuvant chemo-radiotherapy group is concurrent chemo-radiotherapy to be give after 4-6 cycles of chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral. Six cycles of SOX chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
11307538|NCT02648828||Intern|Interns are in their first year of residency.
11307539|NCT02648828||Residents|Residents are in their 2nd or 3rd year of residency.
11307540|NCT02648828||Attendings|Attendings are physicians who have completed their residency.
11307541|NCT02648815|Active Comparator|Percutaneous catheter drainage group|Percutaneous catheter drainage (PCD) of necrotic tissue and pathological collections formed during acute pancreatitis
11307542|NCT02648815|Active Comparator|Abdominal paracentesis evacuation group|Abdominal paracentesis drainage (APD) of peritoneal fluid during acute pancreatitis
11307543|NCT02648802|Experimental|Cavity shaving and CM assessment|Standardized BCS with additional cavity shaving before CM assessment.
11307544|NCT02648802|Placebo Comparator|CM assessment|Standardized BCS with CM assessment.
11307545|NCT02648776||Estazolam|Exposure to sedative-hypnotic drugs; Patients who have taken estazolam for at least one week before the first date of enrollment
11307546|NCT02648776||Lorazepam|Exposure to sedative-hypnotic drugs; Patients who have taken lorazepam for at least one week before the first date of enrollment
11307547|NCT02648776||Diazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Diazepam for at least one week before the first date of enrollment
11307548|NCT02648776||Alprazolam|Exposure to sedative-hypnotic drugs; Patients who have taken Alprazolam for at least one week before the first date of enrollment
11307549|NCT02648776||Flunitrazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Flunitrazepam for at least one week before the first date of enrollment
11307550|NCT02648776||Zolpidem|Exposure to sedative-hypnotic drugs; Patients who have taken Zolpidem for at least one week before the first date of enrollment
11307551|NCT02648776||Zopiclone|Exposure to sedative-hypnotic drugs; Patients who have taken Zopiclone for at least one week before the first date of enrollment
11307553|NCT02648750|Experimental|Rehabilitation Assistant|Bridges stroke self-management programme. Delivered by rehabilitation assistants. Participants will receive a minimum of 4 sessions over a 4-6 week period.
11307554|NCT02648750|Active Comparator|Therapist|"Bridges stroke self-management programme. Delivered by registered stroke therapists (Occupational therapists or physiotherapists).
~Participants will receive a minimum of 4 sessions over a 4-6 week period."
11307555|NCT02648737|Experimental|Cognitive Behavioural Therapy (CBT)|Patients who will receive CBT plus clinical monitoring will receive 10 weekly individual sessions (60-75 minutes), tailored to the preferences and needs of each patient. In each session, a registered psychologist will address specified aspects of (coping with) anxiety and related concerns with a specific focus on behaviour and thoughts associated with anxiety.
11307556|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status. Patients who receive clinical monitoring only will be given the option to receive CBT once the trial is completed.
11307557|NCT02648724|Experimental|Part 1: Dose-Escalation|Sym015 will be tested in four dose titration cohorts. A substitute or an additional dose level could potentially be evaluated.
11307558|NCT02648724|Experimental|Part 2: Basket Cohort|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification will receive Sym015 at the RP2D. Included in this group will be a subset of patients who have received prior therapy with a MET-targeting TKI.
11307559|NCT02648724|Experimental|Part 2: NSCLC MET-Amplified Cohort|Patients with advanced NSCLC with MET-amplification will receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
11307560|NCT02648724|Experimental|Part 2: NSCLC METex14del Cohort|Patients with advanced NSCLC with METex14del will receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
11307561|NCT02648711|Experimental|CRLX101 alone|Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2 (or 10 mg/m^2 if 12 mg/m^2 is not well tolerated. No other dose levels will be explored.
11307562|NCT02648711|Experimental|CRLX101 in combination with bevacizumab|Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2. No other dose levels will be explored.
11307563|NCT02648711|Experimental|CRLX101 in combination with mFOLFOX6|Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 and 5FU 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous infusion). The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2.
11307564|NCT02648698|Experimental|Antibiotic group|This group received antibiotic therapy
11307565|NCT02648698|No Intervention|Control group|This group did not receive antibiotic therapy
11307566|NCT02648685||normal glycaemic metabolism|100 subjects
11307567|NCT02648685||Type 2 Diabetes|300 subjects
11307568|NCT02648672|Experimental|BPN14770|A single oral dose of BPN14770.
11307569|NCT02648672|Placebo Comparator|Placebo|A single oral dose of placebo matching BPN14770
11307570|NCT02648659|Experimental|triple with clarithromycin|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks
11307571|NCT02648659|Experimental|triple with metronidazole|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks
11307572|NCT02648659|Experimental|quadruple|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks
11307573|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
11307574|NCT02648633|Experimental|Nivolumab & Valproate Following G.K.|Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
11307575|NCT02648620|Experimental|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
11307576|NCT02648607|Experimental|Customised Orthosis|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
11307577|NCT02648594|Experimental|Intervention: Hook wire CT guided|"There is only one arm. When patient undergo surgery , the radiologist will place a CT-guided Hook wire in order to localize it in patient lung. The intervention consists to place a CT-guided hook wire in contact with the pulmonary nodule under local anesthesia.
~Then, the thoracoscopy will be realised. Then, the surgery piece will be examined to confirm if the node is in the surgery piece"
11307578|NCT02648581|Experimental|Subcutaneous Ustekinumab|
11307579|NCT02648568|Active Comparator|Hypnosis plus relaxation|Ericksonian hypnosis, based on sensations when awakening partially during N3 ; Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
11307580|NCT02648568|Active Comparator|Relaxation|Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
11307581|NCT02648555|No Intervention|Standard follow-up (controls)|Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine.
11307582|NCT02648555|Experimental|W+D protocol (lifestyle intervention)|Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine
11307583|NCT02648542|Active Comparator|CAS vs. tDCS|Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)
11307584|NCT02648542|Sham Comparator|Combined CAS+tDCS vs. Sham|Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation
11307585|NCT02648529|Experimental|Patients with BCECTS|Patients with BCECTS on which MRI, fMRI and neuropsychological assessment will be performed
11307586|NCT02648529|Other|Healthy volunteers|Healthy volunteers on which MRI, fMRI and neuropsychological assessment will be performed
11307612|NCT02648334|Active Comparator|IN.PACT drug coated balloon|IN.PACT drug coated balloon
11307587|NCT02648516|Experimental|Conventional plus AAIT|Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 2 study visit.
11307588|NCT02648503|Experimental|Deep neuromuscular block|PTC=1-2
11307589|NCT02648503|Active Comparator|Moderate neuromuscular block|TOF=1-2
11307590|NCT02648490|Experimental|HLX07, in patients with solid cancers.|"Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive weekly infusion of assigned dose of HLX07. No intra-patient dose escalation is allowed.The proposed dose escalation sequence is 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg.
~Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07, followed by dexamethasone 10 mg intravenous infusion for 10 minutes, and followed by diphenhydramine 30 mg intravenous infusion for 10 minutes. If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions."
11307591|NCT02648477|Experimental|Cohort 1 (pembrolizumab, doxorubicin hydrochloride)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV on day 1. Treatment repeats every 3 weeks for 6 courses, and then continues for up to 24 months with pembrolizumab alone in the absence of disease progression or unacceptable toxicity.
~Patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
11307592|NCT02648477|Experimental|Cohort 2 (pembrolizumab, anti-estrogen therapy)|"Patients receive pembrolizumab IV over 30 minutes on day 1 and an aromatase inhibitor (exemestane, anastrozole, or letrozole) PO QD on days 1-21. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
~In both arms, patients who stop pembrolizumab with stable disease or better may receive additional pembrolizumab therapy for up to 1 year if they progress after stopping study treatment."
11307593|NCT02648464|Experimental|Hydroxychloroquine|Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.
11307594|NCT02648464|Placebo Comparator|Placebo|Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.
11307595|NCT02648451|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES Rome for a period of 9 days
11307596|NCT02648438|Experimental|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
11307597|NCT02648438|Experimental|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
11307598|NCT02648425|Experimental|Regimen A / Amended Regimen A|"Regimen A: Cisplatin + 5-fluorouracil
~ASLAN001 daily in combination with:
~Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles.
~Or
~Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin
~ASLAN001 daily in combination with:
~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles."
11307599|NCT02648425|Experimental|Regimen B|"Regimen B: Cisplatin + capecitabine
~ASLAN001 daily in combination with:
~Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles."
11307600|NCT02648412|Experimental|Ketamine sedation|"Procedure scheduled under ketamine sedation. Baseline pupillary diameter measurement in alert subjects. Injection of a bolus of 1 mg/kg of ketamine. Every minute, tetanic stimulations of incremental intensities (10-20-30-40-60 milliamps), during 5 seconds.
~Pupillary diameter measurement before and after each stimulation. End of study period, beginning of procedure."
11307601|NCT02648399|Placebo Comparator|control group|only unilateral center lymph node dissection
11307602|NCT02648399|Experimental|experimental group|bilateral center lymph node dissection
11307603|NCT02648386|Sham Comparator|Laparoscopic surgery|Patients receive no interventions after rectal cancer treatment.
11307604|NCT02648386|Experimental|NeuroRegen scaffold transplantation|Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.
11307605|NCT02648386|Experimental|NeuroRegen scaffold/BMMCs transplantation|Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
11307606|NCT02648386|Experimental|NeuroRegen scaffold/HUC-MSCs transplantation|Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
11307607|NCT02648373|Experimental|Education|Patients receive an educational video about low back pain based on the Consumer Reports Choosing Wisely recommendation for patients with back pain to avoid early imaging and remain as active as possible. After the video the evaluator and patient discussed key themes from the video and the patient was able to ask any questions. Previously scheduled physical therapy then began with treatment at the therapist's discretion.
11307608|NCT02648373|Active Comparator|Control|Previously scheduled physical therapy was provided with treatment at the therapist's discretion. No educational intervention was provided before beginning physical therapy
11307609|NCT02648360|Experimental|Text Messaging Intervention Arm|Participants will be enrolled in either a dietary or physical activity text messaging program. The dietary program will include nutritional education, reading nutrition labels, portion control, making lifestyle changes, finding social support, and identifying triggers. The physical activity program will provide information on the benefits of physical activity, exercise tips, and encouragement to live more active lifestyles. The programs have limited interactive capability; patients will be asked to respond to specific questions, but questions asked by the participants will be answered with an automated message asking them to contact their health care provider.
11307610|NCT02648347|Experimental|vadadustat|
11307611|NCT02648347|Active Comparator|darbepoetin alfa|
11361832|NCT02288481|Experimental|Cohort 4 150 mg TBA-354|
11307618|NCT02648269|Experimental|SEL-212|Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
11307619|NCT02648269|Experimental|SEL-037|Single intravenous dose of SEL-037 (pegsiticase)
11307620|NCT02648256|Experimental|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:
~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.
~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
11307621|NCT02648243|No Intervention|Control|Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
11307622|NCT02648243|No Intervention|Pharmacist delivered usual care at discharge|Patients will receive the usual counseling at discharge by the clinical pharmacists.
11307623|NCT02648243|Experimental|structured intervention at discharge and tailored follow up|The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
11307624|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
11307625|NCT02648217|Experimental|IDegAsp U100 BID|
11307626|NCT02648217|Active Comparator|BIAsp U100 BID|
11307627|NCT02648204|Experimental|Semaglutide 0.5 mg/Week|
11307628|NCT02648204|Experimental|Semaglutide 1.0 mg/Week|
11307629|NCT02648204|Active Comparator|Dulaglutide 0.75 mg/Week|
11307630|NCT02648204|Active Comparator|Dulaglutide 1.5 mg/Week|
11307631|NCT02648191|Experimental|Active stimulation|
11307632|NCT02648191|Sham Comparator|Inactive stimulation|
11307633|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
11307634|NCT02648178|Active Comparator|HALO Triton|HALO tank model
11307635|NCT02648165|Experimental|ABM +|Attention Bias Modification
11307636|NCT02648165|Sham Comparator|ABM -|Sham Attention Bias Modification
11307637|NCT02648165|Experimental|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
11307638|NCT02648165|Sham Comparator|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
11307639|NCT02648139|Experimental|Experimental dentifrice|Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
11307640|NCT02648139|Active Comparator|Control Dentifrice|"Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%)
~Intervention protocol: three times per day (pea-like amount), for seven consecutive days."
11307641|NCT02648126|Other|Pure red cell aplasia participants|Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.
11307642|NCT02648113|Experimental|Restrictive transfusion strategy|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
11307643|NCT02648113|Experimental|Liberal transfusion strategy|Transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL.
11307644|NCT02648100||A|120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
11307645|NCT02648100||B|510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
11307646|NCT02648100||C|188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
11307647|NCT02648100||D|93 patients from the clinical trial GETUG 19 (UNICANCER)
11307648|NCT02648087|Other|With and without SDB|comparison of patients with and without sleep-disordered breathing
11307649|NCT02648074|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation.
11307650|NCT02648074|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).
~Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation."
11307651|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
11307652|NCT02648048|Experimental|Vismodegib and Pirfenidone|Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
11307653|NCT02648035||Subcutaneous Tocilizumab|Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
11307654|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
11307655|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
11307656|NCT02648009|Other|Healthy Volunteers|"Arm 1
~Group 1A: control male volunteers between 19 and 50 years of age.
~Group 1B: control female volunteers between 19 and 50 years of age.
~Group 1C: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice
~Group 1D: control male volunteers between 19 and 50 years of age.
~Group 1E: control female volunteers between 19 and 50 years of age.
~Group 1F: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice"
11307805|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
11361833|NCT02288481|Placebo Comparator|Cohort 4 placebo|Placebo Suspension
11307657|NCT02648009|Other|Hypertension Hypertrophy Volunteers|"Arm 2
~Group 2A: patients aged 30 to 75 with hypertension and hypertrophy
~Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM).
~Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.
~Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.
~Group 2E: patients aged 30 to 75 with hypertrophy
~Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM).
~Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.
~Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents."
11307658|NCT02647996||Conscious patients|"group: TBI patients awoken from comatose state with normal level of consciousness.
~intervention: fMRI (resting state) and structural (DTI)"
11307659|NCT02647996||DOC patients|"group: TBI patients awoken from comatose state with abnormal level of consciousness
~intervention: fMRI (resting state) and structural (DTI)"
11307660|NCT02647983|Experimental|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection to be used a MRI contrast agent.
11307661|NCT02647970|Experimental|Group A|Dietary intervention
11307662|NCT02647970|Active Comparator|Group B|Dietary intervention
11307663|NCT02647957|Experimental|Group A|Hospital using Code Stroke
11307664|NCT02647957|No Intervention|Group B|Hospital not using Code Stroke
11307665|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
11307666|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
11307667|NCT02647931|Experimental|Voice Therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia patients.
11307668|NCT02647918|Experimental|Group 1|Subjects with normal renal function
11307669|NCT02647918|Experimental|Group 2|Subjects with mild renal impairment
11307670|NCT02647918|Experimental|Group 3|Subjects with moderate renal impairment
11307671|NCT02647918|Experimental|Group 4|Subjects with severe renal impairment
11307672|NCT02647918|Experimental|Group 5|Subjects with ESRD requiring HD
11307673|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
11307674|NCT02647892|Active Comparator|Arm A|10 mg/mL lidocaine; Frequency: 1
11307675|NCT02647892|Active Comparator|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
11307676|NCT02647892|Active Comparator|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
11307677|NCT02647892|Active Comparator|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
11307678|NCT02647879||Hepatitis C infected|All patients diagnosed with hepatitis C in Iceland
11307679|NCT02647866|Experimental|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
11307680|NCT02647866|Experimental|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
11307681|NCT02647866|Experimental|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
11307682|NCT02647866|Experimental|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
11307683|NCT02647866|Placebo Comparator|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
11307684|NCT02647853|Experimental|TAT4 Gel concentration A|TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
11307685|NCT02647853|Experimental|TAT4 Gel concentration B|TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
11307686|NCT02647853|Placebo Comparator|Placebo|Placebo product once daily to 50 cm2 for 14 days.
11307687|NCT02647840|Other|Voice therapy|All participants will receive voice therapy based on the Estill model. This is very similar to our usual intervention.
11307688|NCT02647827|Active Comparator|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
11307689|NCT02647827|Active Comparator|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
11307690|NCT02647827|Active Comparator|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
11307691|NCT02647814|Experimental|Salud al Día|The participants in the intervention group will receive interactive text-messages with a link to support if needed for: clinic appointment reminders, follow-up on medicine and referral adherence, and illness care needs and use. Participants will additionally receive reminders for insurance renewal, food stamp applications, and health-promoting community events. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
11361834|NCT02288481|Experimental|Cohort 5 400 mg TBA-354|
11307692|NCT02647814|No Intervention|Usual Care|The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
11307693|NCT02647801|Experimental|Mindfulness intervention|The experimental group comes to weekly laboratory meetings and practices mindfulness. Participants also fill out self-report questionnaires which assess self-control and mindfulness.
11307694|NCT02647801|No Intervention|Control group|The control group comes to weekly laboratory meetings and fills out self-report questionnaires which assess self-control and mindfulness. No mindfulness training is carried out.
11307695|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
11307696|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
11307697|NCT02647775|Other|multi-port VATS|Multi-port VATS is an operative method
11307698|NCT02647775|Other|single-port VATS|Single-port VATS is an operative method
11307699|NCT02647762|Experimental|CF101 1mg|CF101 1mg, orally q12 hours
11307700|NCT02647762|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
11307701|NCT02647762|Active Comparator|MTX once weekly|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.
11307702|NCT02647762|Placebo Comparator|Placebo|Placebo control , orally q12 hours
11307703|NCT02647749|Experimental|Group 1 : Cardiac rythm radiofrequency ablation|Prospective recruitment
11307704|NCT02647749|Experimental|Group 1: Implantation or programming of a pacemaker|Prospective recruitment
11307705|NCT02647749|Experimental|Group 1: Risk of serious arrhythmias or sudden death|Prospective recruitment
11307706|NCT02647749|Active Comparator|Group 2: Cardiac rythm radiofrequency ablation|Retrospective recruitment
11307707|NCT02647749|Active Comparator|Group 2 : Implantation or programming of a pacemaker|Retrospective recruitment
11307708|NCT02647749|Active Comparator|Group 2 : Risk of serious arrhythmias or sudden death|Retrospective recruitment
11307709|NCT02647736|Experimental|Copeptin values in normo- to hyperosmolar states|
11307710|NCT02647723|Experimental|Oral supplement for pregnant women|450 mg/daily of DHA beginning at 10-16 weeks of gestation through the end of pregnancy
11307711|NCT02647723|Placebo Comparator|Sugar pill|450 mg/daily of sugar pill beginning at 10-16 weeks of gestation through the end of pregnancy
11307712|NCT02647710|Experimental|PHAT Life Intervention|PHAT Life: Preventing HIV/AIDS Among Teens, is a uniquely-tailored intervention designed for recently-arrested juvenile offenders on probation. The program will teach teens about HIV/AIDS, sexually transmitted infections, and safer decision-making. PHAT Life draws on social learning theory and a Social-Personal Framework to address individual and social mechanisms related to HIV-risk, including emotion regulation, peer norms, partner communication, relationship characteristics, and HIV/AIDS/STI and substance use knowledge, attitudes, and beliefs.
11307713|NCT02647710|Active Comparator|Health Promotion Control|A health promotion program focusing on nutrition, physical activity, substance use, and sexual health.
11307714|NCT02647697|Experimental|Radiprodil|Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.
11307715|NCT02647684|Experimental|Self- Direced Triple P|Self-directed Triple P workbook to be completed over 10 weeks. Over the course of the workbook parents will think about the changes they would like to make to their child's behaviour. They are taught strategies to enhance their relationship with their child, and promote desirable behaviours. They learn about options for managing problem behaviours and have the opportunity to decide if they would like to use any of these approaches with their child in a clear and consistent way. Parents have practice period to use the approaches they have learnt in weeks 1-3. By the end of week 6 they will have had practice in using their chosen positive parenting approaches, learnt to set goals and monitor their own behaviour when using these strategies. The final weeks aim to help parents identify times when the strategies may not be working and provide survival tips on what to do at these times.
11307716|NCT02647671|Experimental|Aquamin®|Experimental: Aquamin® (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
11307717|NCT02647671|Active Comparator|Calcium Carbonate|Active Comparator: Calcium Carbonate (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
11307718|NCT02647671|Placebo Comparator|Placebo|Placebo (Maltodextrin) - 4 capsules; 2 to be taken in the morning and 2 in the evening
11307719|NCT02647658|Experimental|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy (GBC+PIPT)
11307720|NCT02647658|Active Comparator|GBC|Guideline Based Care (GBC)
11307721|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
11307722|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
11307723|NCT02647632|Experimental|16 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 16 weeks
11307724|NCT02647632|Experimental|24 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 24 weeks
11307725|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
11307726|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
11307727|NCT02647606|Experimental|McGrath Group|MgGrath videolaryngoscope will be used for nasotracheal intubation with MILS
11307728|NCT02647606|Experimental|Pentax-AWS Group|Pentax-AWS videolaryngoscope will be used for nasotracheal intubation with MILS
11307729|NCT02647606|Experimental|Macintosh Laryngoscope Group|Macintosh Laryngoscope will be used for nasotracheal intubation with MILS
11307730|NCT02647593||gallstone hepatitis group,|gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),
11307731|NCT02647593||control group|control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)
11307732|NCT02647567|Experimental|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
11307733|NCT02647567|Placebo Comparator|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
11307734|NCT02647554|Experimental|Ulinastatin group|Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.
11307735|NCT02647554|Placebo Comparator|Placebo group|Placebo control group：Matching with medication
11307736|NCT02647541|Experimental|Nutritional intervention|Consultation with a dietitian, including nutritional recommendations and supplementation.
11307737|NCT02647541|No Intervention|Standard therapy|No specific nutritional recommendations.
11307738|NCT02647528|Experimental|Treatment|Patients in this arm receive treatment
11307739|NCT02647528|Placebo Comparator|Placebo|Patients in this arm do not receive treatment
11307740|NCT02647515|Experimental|ranibizumab|
11307741|NCT02647502|Active Comparator|Continuous calorie restriction|Participants will be provided with a diet that includes approximately 78% of calories each day that would be needed to maintain current BMI.
11307742|NCT02647502|Experimental|Intermittent calorie restriction|Participants will be provided a diet that with a daily calorie intake required to maintain current BMI, except only 25% of this calorie intake will be provided for 2 days a week.
11307743|NCT02647502|Placebo Comparator|Control calorie intake|Participants will be assigned to consume enough calories each day required to maintain current BMI
11307744|NCT02647489|Experimental|1A - 20 µg PAMVAC + Alhydrogel|The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
11307745|NCT02647489|Experimental|2A - 20 µg PAMVAC + GLA-SE|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
11307746|NCT02647489|Experimental|3A - 20 µg PAMVAC + GLA-LSQ|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
11307747|NCT02647489|Experimental|4A - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
11307748|NCT02647489|Experimental|5A - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
11307749|NCT02647489|Experimental|6A - 50 µg PAMVAC + GLA-LSQ|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
11307750|NCT02647489|Experimental|1B - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
11307751|NCT02647489|Experimental|2B - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
11307752|NCT02647489|Experimental|3B - 100 µg PAMVAC + Alhydrogel|The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
11307753|NCT02647489|Experimental|4B - 100 µg PAMVAC + GLA-SE|The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
11307754|NCT02647489|Placebo Comparator|5B - Placebo|The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)
11307755|NCT02647476|Experimental|Study group|Immunomodulating nutrition (Reconvan)
11307756|NCT02647476|Active Comparator|Control group|Standard nutrition (Peptisorb)
11307757|NCT02647463|Experimental|Attachment and Biobehavioral Catch-up|10-session intervention for parents and infants aimed at increasing parents' nurturance and following the lead, and reducing frightening behavior
11307758|NCT02647463|No Intervention|Waitlist Control|Waitlist Control
11307759|NCT02647450||GIANT Clinic Group|Patients are required to have been refereed to the GI and Nutrition team Clinic at the Royal Marsden Hospital. In the clinic they will be assessed for their symptoms using the Gastrointestinal Symptom Rating Scale (GSRS).
11307760|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
11307761|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
11307762|NCT02647424|Other|PCOS group|PCOS women with anovulation
11307763|NCT02647424|Other|Ovulatory group|Ovulatory group planned for intra-uterine insemination
11307764|NCT02647411||Projeto Boa Visão|Review of records between 1995 and 2000, in totality of 16.806 patients between 2 and 40 years old
11307765|NCT02647411||Projeto Olhar Brasil|Review of records between March and September 2014, in totality of 163 patients between 6 and 18 years old
11307766|NCT02647398|Experimental|A: Supervised combined training|INTERVENTION: Two supervised 75 min-vigorous aerobic training & strength training
11307767|NCT02647398|Active Comparator|B: Supervised strength training|ACTIVE COMPARATOR: Two supervised 45-minute sessions of strength training & Participants will be advised to comply with international recommendations of physical activity (150 min pf MVPA)
11307768|NCT02647385|Experimental|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
11307769|NCT02647385|Experimental|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
11307770|NCT02647372|Experimental|Endocrinological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be endocrinological evaluation including metabolic measures, calorimetric parameters.
11307771|NCT02647372|Experimental|Neurological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be neurological evaluation including UPDRS scale.
11307881|NCT02646722||moderate pain|patients move a arm on rocuronium injection
11307772|NCT02647359|Experimental|Ataluren|Participants will receive ataluren orally 3 times a day (TID) at a dose of 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 48 weeks in Stage 1 (double-masked period) and for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
11307773|NCT02647359|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren TID orally in the morning, at midday, and in the evening for 48 weeks in Stage 1 (double-masked period) and ataluren orally TID at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
11307774|NCT02647346|Experimental|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
11307775|NCT02647333|Experimental|Omega-3 fatty acid|Omega-3 fatty acids for 8 weeks, dosage are 3 and 4 g/day for women and men, respectively.
11307776|NCT02647333|Experimental|Omega-6 fatty acid|Omega-6 fatty acids for 8 weeks, dosage are 20 and 27 g/day for women and men, respectively.
11307777|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
11307778|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
11307779|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
11307780|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
11307781|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
11307782|NCT02647307|Experimental|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg).
11307783|NCT02647294|Experimental|Polyunsaturated omega-3 fatty acids|Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.
11307784|NCT02647294|Placebo Comparator|Placebo|Patients will receive placebo (soya oil)
11307785|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
11307786|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
11307787|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
11307788|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
11307789|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
11307790|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
11307791|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
11307792|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
11307793|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
11307794|NCT02647268|No Intervention|Control (no oxytocin) pretreatment|The myometrial samples are bathed in physiological saline solution (PSS).
11307795|NCT02647268|Active Comparator|Magnesium Sulphate|The myometrial samples are bathed in a 3.5mM magnesium sulphate solution.
11307796|NCT02647268|Active Comparator|Magnesium Sulphate + oxytocin|The myometrial samples are bathed in a 3.5mM magnesium sulphate plus 10-5M oxytocin solution.
11307797|NCT02647255|Experimental|PE and methylprednisolone pulse|Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange >7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
11307798|NCT02647255|Active Comparator|Methylprednisolone pulse|Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
11307799|NCT02647242|Experimental|Patients with parkinson's disease|Patients with parkinson's disease
11307800|NCT02647229|Active Comparator|Isosmotic bowel cleansing preparation|Isosmotic solution ingested prior to colonoscopy
11307801|NCT02647229|Active Comparator|Colonic Hyrdrotherapy|Colonic hydrotherapy is an FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician.2 There
11307802|NCT02647216|Active Comparator|Mindfulness Based Cognitive Therapy (MBCT)|MBCT is a structured 8-week group intervention which integrates aspects of cognitive behavioral therapy (CBT) with components of the Mindfulness Based Stress Reduction (MBSR) program.
11307803|NCT02647216|Active Comparator|Treatment as Usual (TAU)|Subjects randomized to TAU will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study (for the TAU group) and outside of the study (for the MBCT group) will be assessed at the 3-month follow up (Visit 3).
11307804|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
11307806|NCT02647190|Experimental|Erwinia Chrysanthemi asparaginase|This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.
11307807|NCT02647177||Pancreatic Cyst Group|Only the eligible participant in the study are considered for inclusion in this group.
11307808|NCT02647151|Active Comparator|METHYLAMINOLEVULINATE HYDROCHLORIDE|METHYLAMINOLEVULINATE HYDROCHLORIDE (MAL)cream 160mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
11307809|NCT02647151|Experimental|AMINOLEVULINIC ACID HYDROCHLORIDE|AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
11307810|NCT02647138|Experimental|White Noise|Subject will have white noise machine placed in room.
11307811|NCT02647125|Experimental|Huachansu Arm|Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.
11307812|NCT02647125|Active Comparator|Control Arm|Patients in this arm will receive thoracic radiotherapy alone.
11307813|NCT02647112|Experimental|Bladder EpiCheck|Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology
11307814|NCT02647112|No Intervention|Practice of medicine|Practice of medicine including cystoscopy and cytology
11307815|NCT02647099|Active Comparator|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
11307816|NCT02647099|Placebo Comparator|Placebo|One tablet placebo orally once daily for three years
11307817|NCT02647086|Experimental|Period 1|Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)
11307818|NCT02647086|Experimental|Period 2|Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).
11307819|NCT02647073|Experimental|Mobile monitoring device arm|Canary 01 Mobile Vital Signs Monitoring Device
11307820|NCT02647060||idiopathic pulmonary hypertension|"diagnose as idiopathic pulmonary arterial hypertension
~clinical stable over 3 months
~able to walk and can do bicycle cardiopulmonary exercise testing"
11307821|NCT02647060||secondary pulmonary hypertension|"diagnose as pulmonary hypertension
~clinical stable over 3 months
~able to walk and can do bicycle cardiopulmonary exercise testing"
11307822|NCT02647047|Experimental|Spinal|Patients will receive spinal analgesia (morphine 0.2 mg) before general anesthesia for minor laparotomic liver resection.
11307823|NCT02647047|Active Comparator|Epidural|Patients will receive epidural analgesia (bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL) before general anesthesia for minor laparotomic liver resection.
11307824|NCT02647034||pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
11307825|NCT02647034||non-pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
11307826|NCT02647021|Active Comparator|Therapeutic Exercise|"Therapeutic Exercise Program (standard care) will include:
~Neck range of motion and strengthening, and posture retraining.
~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function."
11307827|NCT02647021|Experimental|Therapeutic + Lower Body Exercise|"The Therapeutic Exercise Program (standard care) will include:
~Neck range of motion and strengthening, and posture retraining.
~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function.
~The Resistance Exercise component will target 6-8 muscle groups of the lower extremities and core including gluteal, quadriceps, hamstrings, abdominals, and gastrocnemius muscles. A progressive introduction of exercises will occur over the first 3 weeks.
~a personalized program of lower extremity resistance exercises
~core strengthening exercises"
11307828|NCT02647008|Experimental|ACTIVE TENS|ACTIVE TENS
11307829|NCT02647008|Placebo Comparator|PLACEBO|INACTIVE TENS
11307830|NCT02647008|No Intervention|CONTROL|NO TENS
11307831|NCT02646995|Experimental|Active|modified lipid formulation
11307832|NCT02646995|Active Comparator|Control|fish oil
11307833|NCT02646982|Experimental|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) >100 mm Hg, diastolic blood pressure (DBP) >40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
11307834|NCT02646982|Placebo Comparator|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
11307835|NCT02646969|Active Comparator|Formula regimen 1|"Product Control from enrollment to transition phase 1 (blinded administration), followed by open label administration for 2 months.
~Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old"
11307836|NCT02646969|Active Comparator|Formula regimen 2|Product Test 1 from enrollment to transition phase 1 (blinded administration) Product Control for 2 months(open label) Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old
11307837|NCT02646969|No Intervention|Reference group|Infants fed HM exclusively through at least 4 months of age. Once breastfeeding is over and if wished Infant will receive Product test 2 until 1 year old followed by the commercial follow-up formula
11307838|NCT02646956||Age Group-Children|Children between ages of 7 and 14
11307839|NCT02646956||Age Group-Adults|Healthy adults who are the parent of the children
11307876|NCT02646748|Experimental|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.
~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
11307877|NCT02646735|Experimental|Fulvestrant|Fulvestrant 500 mg
11307840|NCT02646943||Cohort of patients with chronic chagas cardiomyopathy|"We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice.
~The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG."
11307841|NCT02646930|Experimental|Incidence of CE|To determine rates of CE in women undergoing initial IVF and outcomes
11307842|NCT02646917|Experimental|SkinPenTreatment|3 SkinPen treatments to each patient, each one month apart.
11307843|NCT02646904|Experimental|Beclometasone Dipropionate (BDP)|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.
11307844|NCT02646904|Active Comparator|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
11307845|NCT02646891|Placebo Comparator|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
11307846|NCT02646891|Experimental|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
11307847|NCT02646891|Experimental|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
11307848|NCT02646891|Placebo Comparator|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
11307849|NCT02646891|Experimental|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
11307850|NCT02646891|Experimental|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
11307851|NCT02646891|Placebo Comparator|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
11307852|NCT02646891|Experimental|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
11307853|NCT02646891|Experimental|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
11307854|NCT02646891|Experimental|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
11307855|NCT02646878|Other|Harmony 1 Sensor Group A|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 90 minutes after sensor insertion.
11307856|NCT02646878|Other|Harmony 1 Sensor Group B|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 12 hours after sensor insertion.
11307857|NCT02646865|Experimental|Self-Compassion Enhanced Cognitive-Behavioral Therapy|Group Cognitive-Behavioral Therapy for social anxiety enhanced with exercises targeting self-compassion
11307858|NCT02646865|Active Comparator|Cognitive-Behavioral Therapy|Standard Group Cognitive-Behavioral Therapy for social anxiety
11307859|NCT02646852|Experimental|PLX038 Q3W|intravenous infusion once every 3 weeks
11307860|NCT02646852|Experimental|PLX038 QW ×2|intravenous infusion once weekly for 2 consecutive weeks of a 4-week cycle
11307861|NCT02646839|Experimental|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
11307862|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
11307863|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
11307864|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
11307865|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
11307866|NCT02646813|Active Comparator|Intraluminal Placement|These patients will have the Arndt endobronchial blocker placed within the endotracheal tube for lung isolation during their thoracic surgery. The observer will measure time required to place blocker correctly prior to surgery.
11307867|NCT02646813|Experimental|Extraluminal Placement|These patients will have the Arndt endobronchial blocker placed outside of the endotracheal tube for lung isolation during their thoracic surgery. The investigator will measure the time required for placement.
11307868|NCT02646800|Experimental|Micafungin group|Intravenous (IV)
11307869|NCT02646787|Experimental|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
11307870|NCT02646787|Experimental|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
11307871|NCT02646787|No Intervention|Control|No intervention during the subject's standard wound care session
11307872|NCT02646774|Experimental|Micafungin group|Injection
11307873|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
11307874|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
11307875|NCT02646748|Experimental|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
11307878|NCT02646735|Active Comparator|Exemestane|Exemestane 25mg
11307879|NCT02646722||No pain|patients show no pain on rocuronium injection
11307880|NCT02646722||mild pain|patients move a hand only on rocuronium injection
11307882|NCT02646722||severe pain|patients show generalized movement because of pain
11307883|NCT02646709|Experimental|Ketamine 1|Ketamine 1 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
11307884|NCT02646709|Experimental|Ketamine 1.5|Ketamine 1.5 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
11307885|NCT02646709|Experimental|Ketamine 2|Ketamine 2 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
11307886|NCT02646696||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
11307887|NCT02646696||Typically Developing Children|typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
11307888|NCT02646683|Other|Early Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)
~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
11307889|NCT02646683|Other|Late Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)
~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
11307890|NCT02646670|Active Comparator|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml . This group will be five about patients about any age, with diabetic macular edema randomly chosen
11307891|NCT02646670|Active Comparator|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml. This group will be about five patients about any age, with diabetic macular edema randomly chosen
11307892|NCT02646670|Active Comparator|Ranibizumab and Aflibercept|- In this group will be held two applications of 0.1 ml Aflibercept(the first and the third doses) interspersed with one application of Ranibizumab 0.1 ml(the second dose). This group will be about five patients about any age, with diabetic macular edema randomly chosen
11307893|NCT02646670|Active Comparator|Aflibercept and Ranibizumab|- This group will be held two applications of Ranibizumab 0.1 ml(the first and the third doses) interspersed with one application of Aflibercept 0.1 ml(the second dose). This group will be five about patients about any age, with diabetic macular edema randomly chosen
11307894|NCT02646657|Other|Early UC|Patients with 'early UC' defined as disease duration < 4 years and no other treatments than aminosalicylates and/or corticosteroids
11307895|NCT02646657|Other|Late UC|Patients with 'late UC' defined as active disease despite treatment with immunosuppressives (IS) and/or anti-TNF. Patients wih intolerance to IS AND anti-TNF will also be allowed in the latter group.
11307896|NCT02646644||Metastasized intestinal NET|We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
11307897|NCT02646631|Experimental|Usual Treatment|
11307898|NCT02646631|Experimental|MORE|
11307899|NCT02646631|Active Comparator|MORE + MI|
11307900|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
11307901|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
11307902|NCT02646605||patients initiating ART|HIV positive men and women initiating ART
11307903|NCT02646605||patients on established ART|HIV positive men and women on established ART
11307904|NCT02646592|Experimental|alfentanil|"Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.
~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery."
11307905|NCT02646579|Experimental|Spinal and Peripheral Dry Needling|Participants will receive dry needling to the low back and painful areas in the leg.
11307906|NCT02646579|Active Comparator|Peripheral Dry Needling|Participants will receive dry needling to painful areas in the leg.
11307907|NCT02646566|Experimental|APD421 standard|Single (standard) dose IV APD421
11307908|NCT02646566|Experimental|APD421 high|Single (high) dose IV APD421
11307909|NCT02646566|Placebo Comparator|Placebo|Single IV placebo
11307910|NCT02646553||Children refered to the obesity clinic.|All children refered to the obesity clinic for examination and optionally treatment are invited.
11307911|NCT02646540|Experimental|Tolvaptan 30 mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 30 mg of tolvaptan concomitantly with their standard dose of diuretics.
11307912|NCT02646540|Active Comparator|Metolazone 5mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 5mg metolazone concomitantly with their standard dose of diuretics.
11307913|NCT02646540|Active Comparator|IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive two and a half (2.5) times their standard dose of diuretics.
11307914|NCT02646527|Experimental|DT+|Dignity Therapy is conducted with patients and partners
11307915|NCT02646527|Experimental|DT|Dignity Therapy is conducted only with patients
11307916|NCT02646527|No Intervention|SPC|standard palliative care
11307917|NCT02646514|Experimental|RFA with RF catheter (ELRA®) with stenting|
11307918|NCT02646514|Active Comparator|stenting|
11307919|NCT02646501|Experimental|group A+PSGB|(Antiarrhythmic drug + percutaneous stellate ganglion block) group
11307920|NCT02646501|Active Comparator|group A|Antiarrhythmic drug group
11307921|NCT02646488|Active Comparator|Cluster 1|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
11307922|NCT02646488|Active Comparator|Cluster 2|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
11307923|NCT02646488|Active Comparator|Cluster 3|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
11307924|NCT02646488|Active Comparator|Cluster 4|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
11307925|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
11307926|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
11307927|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
11307928|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
11307929|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method - presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in EKG; and acute pulmonary edema - will be treated with HD.
11307930|NCT02646436|Other|PD treatment|Patients stage 5 (creatinine clearance < 15 ml/min) requiring dialysis treatment immediately without absolute contraindication to the PD method will receive unplanned PD treatment. High volume PD (HVPD) will be used during the first 7 days of PD in order to achieve metabolic and fluid control. The procedure for acute PD has been published recently by our team . At this point, patients will be discharged from hospital and they will be treated by intermitent PD at the dialysis unit of the University Hospital.until their family be trained and home be prepared for the implementation of technique.
11307931|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
11307932|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
11307933|NCT02646410|Other|FPD+NDOT|Fixed-point delivery (FPD) combined with non directly observed treatment (NDOT)
11307934|NCT02646410|Other|FPD+DOT|Fixed-point delivery (FPD) combined with directly observed treatment (DOT)
11307935|NCT02646410|Other|DDD+NDOT|door-to-door delivery (DDD) combined with non directly observed treatment (NDOT)
11307936|NCT02646410|Other|DDD+DOT|door-to-door delivery (DDD) combined with directly observed treatment (NDOT)
11307937|NCT02646397|Experimental|Fosinopril,benidipine combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.
11307938|NCT02646397|Experimental|Fosinopril,hydrochlorothiazide combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.
11307939|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
11307940|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
11307941|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
11307942|NCT02646358|Experimental|Cohort 1: Normal Renal Function|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
11307943|NCT02646358|Experimental|Cohort 2: Mild Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
11307944|NCT02646358|Experimental|Cohort 3: Moderate Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
11307945|NCT02646358|Experimental|Cohort 4: Severe Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
11307946|NCT02646358|Experimental|Cohort 5: End Stage Renal Disease|Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours
11307947|NCT02646345||Pre Checklist|All surgical encounters before surgical checklist implementation
11307948|NCT02646345||Post Checklist|All surgical encounters after surgical checklist implementation
11307949|NCT02646332|Experimental|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
11307950|NCT02646332|Active Comparator|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
11308150|NCT02644954|Placebo Comparator|Placebo|Topical coal tar and topical calcipotriol
11307951|NCT02646319|Experimental|Treatment (nanoparticle albumin-bound rapamycin)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
11307952|NCT02646306||Shoulder Impingement Syndrome|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
11307953|NCT02646306||Healthy Subjects|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
11307954|NCT02646280|Experimental|Massage therapy and contact experience|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading associated with a preparation to the contact phase of the massage using the typical elements of neurocognitive rehabilitation such as motor imagery, dynamic state during which a person mentally simulates an action, and language, necessary to understand the way of perceiving and organizing sensory, cognitive and phenomenological informations by the patients and so to interpretate pain in a more articulate way.
11307955|NCT02646280|Active Comparator|Massage therapy|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading.
11307956|NCT02646267|Experimental|standard intensity warfarin group|standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)
11307957|NCT02646267|Experimental|low intensity warfarin group|low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)
11307958|NCT02646267|Active Comparator|dabigatran etexilate group|110mg dabigatran etexilate was administrated twice a day
11307959|NCT02646254|Active Comparator|blood cardioplegia|these patients received blood cardioplegia
11307960|NCT02646254|Active Comparator|del nido cardioplegia|these patients received del nido cardioplegia
11307961|NCT02646241|Experimental|unroofing biopsy|
11307962|NCT02646241|Active Comparator|EUS-FNB|
11307963|NCT02646228||molecular profiling, patient derived cells|
11307964|NCT02646215|Active Comparator|Inspiratory muscle training group|Threshold inspiratory muscle training
11307965|NCT02646215|No Intervention|Control group|No training
11307966|NCT02646202|Active Comparator|Sclerotherapy group|thirty patients treated by sclerotherapy for OV using ethanolamine oleate 5%.
11307967|NCT02646202|Active Comparator|Endoscopic band ligation group|thirty patients treated by endoscopic banding using the Euro-Ligator system.
11307968|NCT02646202|Experimental|Sclero-ligation (SL) group|thirty patients treated by intra variceal endoscopic sclerotherapy combined with band ligation.
11307969|NCT02646189|Experimental|REP 2139-Ca + immunotherapy|"REP 2139-Ca is the calcium chelate complex formulation of REP 2139.
~Zadaxin is thymosin alpha 1
~Pegasys is pegylated interferon alpha 2a
~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is > 2000 copies / ml.
~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys."
11307970|NCT02646163|Experimental|REP 2055|Treatment with REP 2055
11307971|NCT02646150||critical limb ischemia|
11307972|NCT02646137|Active Comparator|Transarterial chemoembolization (TACE)|treated by transarterial chemoembolization
11307973|NCT02646137|Experimental|Radiofrequency ablation with TACE|Radiofrequency ablation combined with TACE
11307974|NCT02646137|Experimental|Microwave ablation combined with TACE|Microwave ablation combined with TACE.
11307975|NCT02646124|Experimental|Diazepam|Naproxen +Diazepam
11307976|NCT02646124|Active Comparator|Placebo|Naproxen + Placebo
11307977|NCT02646111|Experimental|Genotype 1b without cirrhosis|12 weeks without Ribavirin
11307978|NCT02646111|Experimental|Genotype 1b with cirrhosis|12 weeks with Ribavirin
11307979|NCT02646111|Experimental|Genotype 1a without cirrhosis|12 weeks with Ribavirin
11307980|NCT02646111|Experimental|Genotype 1a with cirrhosis|24 weeks with Ribavirin
11307981|NCT02646098|Active Comparator|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
11307982|NCT02646098|No Intervention|No CD34+ cell selection|No CD34+ cell selection
11307983|NCT02646085|Experimental|Intervention|C11 Methionine positron emission tomography (PET/CT) studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 10 millicuries of C11 Methionine will be injected intravenously. Approximately 60 minutes following tracer injection, the patient will be positioned on a Siemens Biograph PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first with while the patient is free breathing. PET will be acquired at 3 minutes per bed position using the 3D mode, approximately 6-7 bed positions. C11 Methionine PET/CT imaging will take less than 60 minutes.
11307984|NCT02646072|Active Comparator|Diabetes mellitus patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
11307985|NCT02646072|No Intervention|Diabetes mellitus control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
11307986|NCT02646072|Active Comparator|Non diabetic patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
11308284|NCT02643927|No Intervention|Control Group|control group: No intervention
11307987|NCT02646072|No Intervention|Non diabetic control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
11307988|NCT02646059|Experimental|Text group|Text messages containing reminds of blood donation information would be sent to donors in this group.
11307989|NCT02646059|Experimental|Telephone group|Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
11307990|NCT02646059|No Intervention|Control group|No intervention will be giving to this group.
11307991|NCT02646046|Experimental|Combi lone-CPR|"Intervention group
~: Newly developed method"
11307992|NCT02646046|Active Comparator|Conventional lone-CPR|Conventional CPR group
11307993|NCT02646033||robotic surgery|all those patients aged 40 - 60 years undergoing robotic surgeries, who does not have any ophthalmic complains.
11307994|NCT02646020|Experimental|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
11307995|NCT02646020|Active Comparator|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28
11307996|NCT02646007|Experimental|BM-MSC|Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienböck's disease.
11307997|NCT02645994|Experimental|Target Controlled Infusion|Propofol is administered through a target controlled infusion pump based on Marsh model to achieve a BIS of 50 and manually adjusted to maintain BIS between 40 and 60
11307998|NCT02645994|Active Comparator|Closed Loop Anesthesia Delivery System|Propofol is administered through Closed Loop Anesthesia Delivery System which is titrated automatically to achieve a target BIS of 50 and maintain it between 40 and 60.
11307999|NCT02645981|Experimental|Donafenib|Drug:Donafenib; Dose:200mg,bid,po.
11308000|NCT02645981|Active Comparator|Sorafenib(Nexavar)|Drug:Sorafenib; Dose:400mg,bid,po.
11308001|NCT02645955||Control group, disease history|people who didn't have disease history of Maintenance Hemodialysis
11308002|NCT02645955||The MHD patient group, diseases history|Maintenance Hemodialysis Patients
11308003|NCT02645942|Experimental|Intervention group|L-carnitine 1400 mg daily for 8 weeks
11308004|NCT02645942|Placebo Comparator|Placebo group|Placebo
11308005|NCT02645916|Experimental|DSGOST|admission to Danggui-Sayuk-Ga-Osuyu-Saenggang-tang granule
11308006|NCT02645916|Placebo Comparator|Placebo|admission to placebo
11308007|NCT02645903|Active Comparator|transversus abdominis plane block|"Patients who received a tranversus abdominis plane block with ultrasound after standard general anesthesia represented Group 1.
~The tranversus abdominis plane block was performed bilaterally by obtaining an image with real time ultrasound guidance with a 6-13 MHz linear probe.
~The block was placed with a 22 G 80 mm needle while obtaining real-time images via an in-plane technique.
~Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline. These were administered to the left and right abdominal walls.
~Postoperative analgesia was administered through a morphine the patient-controlled analgesia device."
11308008|NCT02645903|Placebo Comparator|nonblocked|Patients who received standard general anesthesia alone made up Group 2. Postoperative analgesia was administered through a morphine the patient-controlled analgesia device.
11308009|NCT02645890|Active Comparator|CKD-397|Tadalafil/ Tamsulosin Fixed dose combination
11308010|NCT02645890|Experimental|TD+TM|Tadalafil/ Tamsulosin Coadministration
11308011|NCT02645877||Prehospital care|All pre-hospital service data were collected from January 2005 to December 2014 from the Beijing Emergency Center and Beijing Red Cross Emergency Center, which oversee all pre-hospital care in Beijing. The major illnesses were classified into 34 disease spectrum categories according to the Medical Priority Dispatch System (MPDS) which total includes 34 diseases. Data on pre-hospital emergency demand and first aid-related time intervals were analyzed to determine trends over the period.
11308012|NCT02645864|Experimental|Apatinib and Irinotecan|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and irinotecan 150mg q2w. Cohort 2: apatinib 500 mg per day and irinotecan 150mg q2w. Cohort 3: apatinib 750 mg per day and irinotecan 150mg q2w.
~A dose limiting toxicity (DLT) event is defined as any of the following events:
~CTCAE Grade 4 event
~Grade 3 non-hematologic toxicity including fever, nausea, vomiting, and diarrhea that continues despite optimal medical management) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will stop and the dose of combination treatment in this cohort will be documented."
11308013|NCT02645851|Experimental|"PLR-induced SV changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
11308014|NCT02645851|Experimental|"PLR-induced PP changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
11308015|NCT02645851|Other|Usual Care|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
11308016|NCT02645838|Experimental|Motivational interviewing group|"Structural motivational interviewing for one section (about 20 mins)，provided by family physician
~Follow-up telephone call，provided by family physician"
11308017|NCT02645838|No Intervention|Brief advice group|Brief advice without motivational interviewing (about 5 mins), provided by family physician
11308018|NCT02645799|Active Comparator|LABR-312|"LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.
~Three (3) doses will be tested:
~Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.
~OCT follow-up will be performed at 9 months."
11308019|NCT02645799|Placebo Comparator|saline|"Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.
~Three (3) doses will be tested:
~Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.
~OCT follow-up will be performed at 9 months."
11308020|NCT02645786||Case|"Differentiated thyroid cancer group:
~who received total- or near-total thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD) of Chuncheon Sacred Heart Hospital.
~1) age less than 45 years old when receiving total or near-total thyroidectomy, 2) serum level of TSH<0.1 mU/L in the intermediate recurrence-risk or TSH<0.3 mU/L in the low recurrence-risk group13, 14 over 2 years before study entry, 3) receiving TSH suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and 4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea and chest discomfort) during therapy."
11308021|NCT02645786||Control|"Control group As each DTC patient was enrolled, control subjects were selected from patients who visited endocrinology department for thyroid nodule work-up. The control group had to meet the following criteria
~1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), 2) within the reference range of serum TSH (0.3-4.6 mU/L), 3) no history of structural heart disease, arrhythmia, or cardiac symptoms, 4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension."
11308022|NCT02645773|Experimental|Pre-laser|non-ablative laser Laser Pre-wounding low dose laser Pre-wounding medium dose laser Pre-wounding high dose
11308023|NCT02645773|Experimental|Immediate-laser|non-ablative laser Laser low dose - immediate after wounding Laser medium dose - immediate after wounding Laser high dose - immediate after wounding
11308024|NCT02645773|Experimental|Post-laser|non-ablative laser Laser low dose - post wounding Laser medium dose - post wounding Laser medium dose - post wounding
11308025|NCT02645773|No Intervention|Control|Untreated control wound
11308026|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
11308027|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
11308028|NCT02645747||Group 1|The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
11308029|NCT02645734|Active Comparator|Injection intravitreous bevacizumab|Injection intravitreous bevacizumab at a dose 1.25mg
11308030|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 1.25 mg|Injection ziv-aflibercept at dose of 1.25 mg
11308031|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 2.5 mg|Injection ziv-aflibercept at dose of 2.5 mg
11308032|NCT02645721|Experimental|Extended self-help program with guidance|The program is a comprehensive CBT program lasting 12 weeks, with as many modules. The modules are quite extensive. A guide with basic education in psychotherapy assists and counsels participants online.
11308033|NCT02645721|Active Comparator|Briefer Self-help program, no guidance|This self-help program also lasts 12 weeks but contains only 9 modules; a pause occurs during the final weeks of the program for self-testing of acquired skills. The modules are quite brief. Participants receive no guidance.
11308034|NCT02645721|Other|WL: Extended self-help program, choice of guidance intensity|Participants will be put on a waiting list. After 12 weeks on the waiting list, participants will receive access the the extended self-help program used in the experimental arm. However, participants will be offered a choice between three guidance options of varying intensity: proactive guidance, reactive guidance (only at participant request) or no guidance.
11308035|NCT02645708|Other|Retrograde Intrarenal Surgery (RIRS)|Patients in Group 1 undergo Retrograde Intrarenal Surgery
11308036|NCT02645708|Other|EPVL after RIRS|"Patients in Group 2 undergo external physical vibration lithecbole after Retrograde Intrarenal Surgery.
~with the help of changing the position and direction of the extracorporeally physical vibration machine, the urinary stone was discharged from the urinary collecting system"
11308037|NCT02645695|Active Comparator|routine pulmonary rehabilitation|routine pulmonary rehabilitation consisted of position giving technique
11308038|NCT02645695|Active Comparator|chest wall vibration technique|chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours.
11308039|NCT02645682|Experimental|anti-infection CVC (Certofix®protect)|intervention group
11308040|NCT02645682|Active Comparator|normal CVC (Certofix®)|control group
11308041|NCT02645669|Experimental|Study site|Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture
11308042|NCT02645669|Placebo Comparator|Control site|Only Scaling and Root planing (SRP) was performed
11308043|NCT02645656|Experimental|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals.
11308044|NCT02645643|Experimental|intervention group|Medical students rolled into this group would accept education of medical humanities.
11308045|NCT02645643|No Intervention|control group|Medical students rolled into this group would not gain education of medical humanities.
11308046|NCT02645630|Experimental|Right Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the right side.
11308285|NCT02643914|Experimental|Nicotine Cravings|
11308047|NCT02645630|Experimental|Left Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the left side.
11308048|NCT02645630|Active Comparator|Sham Cervical Manipulation|Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
11308049|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
11308050|NCT02645591|Experimental|Nerve Sparing RARP + AmnioFix®|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
11308051|NCT02645591|Active Comparator|Nerve Sparing RARP|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
11308052|NCT02645578|Experimental|RMNS group|Focus intervention: right median nerve stimulation plus standard management
11308053|NCT02645578|No Intervention|Control group|Standard management
11308054|NCT02645565|Active Comparator|Low dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
11308055|NCT02645565|Active Comparator|High Dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
11308056|NCT02645552|Experimental|Tranexamic acid|Focused intervention
11308057|NCT02645552|Placebo Comparator|Sodium chloride|Placebo control
11308058|NCT02645539|Experimental|Single Arm|All patients are treated with the intravascular ventricular assist system (iVAS).
11308059|NCT02645526|Experimental|KMC with woolen cap|In this group, the head of the patients will be covered with a woolen cap during KMC.
11308060|NCT02645526|No Intervention|KMC without woolen cap|In this group, the head of the patients will be uncovered during KMC.
11308061|NCT02645513|Experimental|Malaria-only text messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to malaria diagnosis and treatment.
11308062|NCT02645513|Experimental|Malaria, pneumonia, and diarrhea messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to diagnosis and treatment of malaria, pneumonia, and diarrhea
11308063|NCT02645513|Placebo Comparator|Control|No text message reminders to health workers, just the usual health system supports.
11308064|NCT02645500|Experimental|Physical activity message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to physical activity.
~The training workshop include one core session and one booster session at one month.
~Daily messages in relation to physical activity will be sent to the participants."
11308065|NCT02645500|Active Comparator|Healthy diet message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to healthy diet .
~The training workshop include one core session and one booster session at one month.
~Daily messages in relation to healthy diet will be sent to the participants."
11308066|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
11308067|NCT02645474|Active Comparator|Paravertebral block with ropivacaine|Patients are treated with an older technique (paravertebral block with ropivacaine), somehow established in treating pain after breast surgery. This technique has been shown to be effective but has an intrinsic risk of iatrogenic pneumothorax and is considered technically demanding.
11308068|NCT02645474|Experimental|PECS block with ropivacaine|Patients are treated with PECS block, which has been already adopted in common clinical practice as an alternative to paravertebral block for postoperative pain treatment after breast surgery. This technique is thought to be somehow simpler to perform and safer with regard to pneumothorax, however no studies have been done yet to statistically compare the two blocks with regard to safety and effectiveness.
11308069|NCT02645461|Active Comparator|Riluzole|Riluzole 50 mg twice daily in ALS patients
11308070|NCT02645461|Experimental|PEA plus Riluzole|Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
11308071|NCT02645448|Other|Resistance Exercise Low intensity|"Day 1 (Control Session)
~Day 2 (Resistance Exercise)
~Day 3 (Duration of effect)"
11308072|NCT02645448|Other|Resistance Exercise High intensity|"Day 1 (Control Session)
~Day 2 (Resistance Exercise)
~Day 3 (Duration of effect)"
11308073|NCT02645435|Active Comparator|Hip direct anterior approach|Patients with hip arthritis
11308074|NCT02645435|Active Comparator|Lateral hip approach|Patients with hip arthritis
11308075|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
11308076|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
11308077|NCT02645383|Active Comparator|PASCAL group|Patients undergone PASCAL laser photocoagulation
11308078|NCT02645383|Active Comparator|Conventional group|Patients undergone conventional laser photocoagulation
11308079|NCT02645370|Active Comparator|Active Comparator:Topiramate|The treatment with TPM is initiated at a 50 mg daily dose and sequentially increase every 7 days, as tolerated, in 25 mg increments up to a target dose of 150 mg total/day.
11308080|NCT02645370|Experimental|Experimental:Danzhen|The treatment with Danzhen is 3 tablets triple daily.
11308081|NCT02645357|Experimental|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
11308082|NCT02645357|Other|Control group|No on-screen, point-of-care computer reminders on clinical practice.
11361835|NCT02288481|Placebo Comparator|Cohort 5 placebo|Placebo Suspension
11308083|NCT02645344|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Low frequency rTMS at 1 Hz was applied over P5 of the contralesional hemisphere in addition to conventional rehabilitation
11308084|NCT02645344|Experimental|rTMS combined with sensory cueing (SC)|Vibration cueing was emitted using a wristwatch device on the hemiplegic arm combined with low frequency rTMS in addition to conventional rehabilitation
11308085|NCT02645344|Active Comparator|Conventional rehabilitation|Physical therapy and occupational therapy
11308086|NCT02645331|Experimental|Remind-to-move|RTM involved a wristwatch device worn on more-affected arm which emitted sensory cueing continuously to remind the children to use the more-affected hand to engage in daily activities or complete bimanual tasks intensively, 5 hour per day, 5 days every week, for 3 consecutive weeks.
11308087|NCT02645331|Active Comparator|Modified constraint induced movement therapy (mCIMT)|children were encouraged to wear a customer-made volar resting splint that extended from below the elbow to the fingertips on their noninvolved hands for 5 hour daily except for toileting, writing and specific physical sports, for 3 weeks. Each child was supervised by one therapist to complete structured unimanual practice with the affected hand during the supervised session, 5 days every week, for 3 consecutive weeks.
11308088|NCT02645331|Placebo Comparator|Conventional rehabilitation|Conventional splinting, muscle strengthening, stretching, and neurodevelopmental facilitation techniques for 1hr daily, 2 day per week for 3 weeks.
11308089|NCT02645305|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.
11308090|NCT02645292|Experimental|1 mile Walk using treadmill|Walking for 1 mile on treadmill (American Motion Fitness, 8800D) as fast as participant can, without any inclination
11308091|NCT02645292|Experimental|Stair Climbing|30 meters of vertical distance to be covered (14 flights of stairs with a total of 154 steps)
11308092|NCT02645279|Active Comparator|oral 30% glucose|oral 30% glucose total 200 mg/kg with 0.5-1 mL increments
11308093|NCT02645279|Active Comparator|IV midazolam|intravenous administration of midazolam 0.1 mg/kg
11308094|NCT02645266|Experimental|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
11308095|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
11308096|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
11308097|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
11308098|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
11308099|NCT02645240|Experimental|Heparin injection|Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
11308100|NCT02645227|Active Comparator|Group 1|Open flap debridement (OFD)
11308101|NCT02645227|Active Comparator|Group 2|OFD with Platelet rich fibrin (PRF)
11308102|NCT02645227|Active Comparator|Group 3|OFD with PRF and 1.2% Rosuvastatin
11308103|NCT02645214|Placebo Comparator|Control scrubs (non-antiseptic)|subject will wear control scrubs for the duration of a 12-hour ICU shift
11308104|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 1|subject will wear antiseptic impregnated scrubs-type 1 for the duration of a 12-hour ICU shift
11308105|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 2|subject will wear antiseptic impregnated scrubs-type 2 for the duration of a 12-hour ICU shift
11308106|NCT02645201|Active Comparator|Probiotic|Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days
11308107|NCT02645201|Placebo Comparator|Placebo|Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days
11308108|NCT02645188|Experimental|Experimental|Cueing
11308109|NCT02645188|No Intervention|Control|
11308110|NCT02645175|Experimental|TW1025|TW1025 oral solution, 20ml, 3 times per day (daily dose: 60 ml)
11308111|NCT02645175|Placebo Comparator|Placebo|TW1025 oral solution matched placebo, 20ml, 3 times per day
11308112|NCT02645162|Experimental|Preschool|"This arm will receive the community-based preschool intervention.
~The preschool sessions will include 2 groups per day (3 years 6months to 4 years 6 months in the morning session and 4 years 7 months to 5 year 6 months in the afternoon session at the time of enrolment)
~Each session will last 3 hours for 5 days per week.
~The expected CYL-to-child ratio will be 1:15; however, given the expected high level of local demand it may exceed to a maximum of 1:20 ratio."
11308113|NCT02645162|No Intervention|Control|The control group will receive standard services available in the community.
11308114|NCT02645149|Experimental|No actionable genetic aberration/available targeted therapy|Patients with BRAF and NRAS wild type tumour for whom there is no actionable genetic aberration in tumour tissue or no available matched targeted theray. These patients will receive trametinib based upon the known MAPK excess activity in the majority of melanomas that may be inhibited by a MEK inhibitor.
11308115|NCT02645149|Experimental|Matched targeted therapy|Patients with BRAF and NRAS wild type tumour for whom there is a targeted therapy available, will receive targeted drug matched to gene defect in tumour. If a patient cannot receive the matched targeted therapy because of the existence of one or more drug specific exclusion criteria, an alternative matched therapy may be assigned, or trametinin, or clinical trials if available.
11308116|NCT02645149|Experimental|Mucosal melanoma|Patients with mucosal melanoma and BRAF V600 and NRAS wild type tumour will receive trametinib with ribociclib. A large proportion of mucosal melanomas (47/67, 70%) harbour alterations (CDK4 and CCND1 amplifications, as well as CDKN2A deletions) potentially responsive to CDK4/6 and MEK inhibitors. In addition, although not identified as a significantly mutated driver, a number of samples also had CDK6 amplifications (9/67, 13%) that indicates potential sensitivity to CDK4/6 inhibitors.
11308117|NCT02645149|Other|BRAF / NRAS mutant melanoma|Patients with BRAF / NRAS mutations in tumour tissue will be treated with standard approved targeted therapies (dabrafenib and trametinib) or on clinical trials, and will be followed for clinical response and survival outcomes.
11308118|NCT02645136|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
11308119|NCT02645136|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation (AES) associated with Pelvic Floor Muscle Training (PFMT), supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
11308120|NCT02645136|Placebo Comparator|Control|Control Group
11308121|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
11308122|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
11308123|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
11308124|NCT02645110|Experimental|MC Hand soap|For bacterial removal trial: Hand washing with the tested soap following bacterial application
11308125|NCT02645110|Sham Comparator|Water|For bacterial removal trial: Hand washing with tap water alone following bacterial application
11308126|NCT02645097|Active Comparator|Proximal saphenous nerve block|The anesthesiologist will administer a saphenous proximal nerve block if specified in the randomization envelope.
11308127|NCT02645097|Active Comparator|Distal saphenous nerve block|The anesthesiologist will administer a saphenous distal nerve block if specified in the randomization envelope.
11308128|NCT02645084|Active Comparator|Intervention|Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
11308129|NCT02645084|No Intervention|Control|Control: Hospital-based standard practice for the detection of colorectal cancer patients with hereditary or familial colorectal cancer, informed by the referral criteria that are being used in the intervention group
11308130|NCT02645071|Experimental|Physical activity|The experimental arm is a 15-20 min interactive session, which aims to reduce participants' sedentary behavior and increase physical activity by increasing their motivation, self-efficacy, and knowledge of different types of easy exercises.
11308131|NCT02645058|Experimental|RIRS (retrograde intrarenal surgery)|In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones > 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
11308132|NCT02645058|Experimental|ESWL (extracorporeal shockwaves lithotripsy)|In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
11308133|NCT02645045||Dry eye|Patients with dry eye syndrome
11308134|NCT02645045||normal|Patients without dry eye
11308135|NCT02645032|Experimental|Test group|Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
11308136|NCT02645032|Active Comparator|Comparator group|"Biological/Vaccine:
~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).
~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28)."
11308137|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
11308138|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
11308139|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
11308140|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
11308141|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
11308142|NCT02645006|Experimental|Intervention arm- 3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
11308143|NCT02645006|Other|Control arm- 1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention
11308144|NCT02644993|Experimental|Proton beam therapy|
11308145|NCT02644980|Experimental|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
11308146|NCT02644980|Experimental|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
11308147|NCT02644967|Experimental|Arm 1|IMO-2125 intratumoral injection plus ipilimumab
11308148|NCT02644967|Experimental|Arm 2|IMO-2125 intratumoral injection plus pembrolizumab
11308149|NCT02644954|Active Comparator|Metformin|Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily
11308151|NCT02644941|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
11308152|NCT02644941|Active Comparator|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
11308153|NCT02644915|Experimental|study group|"Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.
~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
11308154|NCT02644915|Placebo Comparator|control group|"100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.
~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
11308155|NCT02644902|Experimental|Technology Arm|5 days training of health workers in THP through avatar assisted cascade training and supervision
11308156|NCT02644902|Active Comparator|Specialist Arm|5 days training and supervision of health workers in THP by specialists
11308157|NCT02644889||Patients advanced NSCLC EGFR mutated|This is an observational study, there is no intervention.
11308158|NCT02644876|Experimental|Penehyclidine group|Penehyclidine inhalation will be administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
11308159|NCT02644876|Placebo Comparator|Control group|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
11308160|NCT02644863|Experimental|DC-CIK|After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.
11308161|NCT02644863|Sham Comparator|Chemotherapy|After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.
11308162|NCT02644837|Active Comparator|i-Gel and AuraGain|"In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.
~Interventions with both devices will be
~Insertion of the laryngeal mask airway
~Assessment of ease of insertion
~Ability to perform positive pressure ventilation
~Measurement of OLP
~Fibreoptic assessment with Ambu A-scope
~Ability to insert nasogastric tube
~Record number of manipulations
~An assessment of device related trauma"
11308163|NCT02644837|Active Comparator|AuraGain and i-Gel|"In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.
~Interventions with both devices will be
~Insertion of the laryngeal mask airway
~Assessment of ease of insertion
~Ability to perform positive pressure ventilation
~Measurement of OLP
~Fibreoptic assessment with Ambu A-scope
~Ability to insert nasogastric tube
~Record number of manipulations
~An assessment of device related trauma"
11308164|NCT02644824|Experimental|Biventricular Pacing (BiVp)|Consented infants with wide QRS randomized to receive standard of care and BiVp.
11308165|NCT02644824|No Intervention|Control (wide QRS)|Consented infants with wide QRS randomized to receive standard of care alone.
11308166|NCT02644824|No Intervention|Control (narrow QRS)|This is an observation control group. Consented infants with narrow QRS will enter control group 2 without randomization.
11308167|NCT02644811|Experimental|Group A - Miniscrews|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.
~Fixed appliance in the maxilla or maxilla and mandible.
~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs."
11308168|NCT02644811|Active Comparator|Group B - Molarblock|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.
~Fixed appliance in the maxilla or maxilla and mandible.
~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs."
11308169|NCT02644798||ARDS patients|ARDS patients in Han nationality
11308170|NCT02644759|Experimental|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
11308171|NCT02644746|Experimental|Acupuncture group|Acupuncture has a long time used for chronic pain including low back pain, sciatica, and other pain related to spina via stimulating specific acupuncture points.
11308172|NCT02644746|Placebo Comparator|Placebo needle group|The placebo needle using in this trial will be unpenetrated needles. Based on our previous research, the placebo needle is a valid control for acupuncture research and may eliminate the placebo effect of acupuncture.
11308173|NCT02644720|Experimental|multifocal intraocular lens group|
11308174|NCT02644720|Active Comparator|monofocal intraocular lens group|
11308175|NCT02644707|Experimental|L-selenomethionine|A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
11308176|NCT02644707|Placebo Comparator|Placebo|A group randomized to receive placebo (control group) for 6 months
11308286|NCT02643901|Experimental|Ic-GW003 150ug/kg 4-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
11308177|NCT02644694|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
11308178|NCT02644668|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
11308179|NCT02644668|Experimental|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
11308180|NCT02644668|Experimental|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
11308181|NCT02644655|Experimental|CD19-specific chimeric antigen receptor|After pretreatment, cluster of differentiation antigen 19 (CD19)-specific chimeric antigen receptor will be transfused.
11308182|NCT02644642|Experimental|DLT(Double Lumen Tube) group|disconnection technique will be applied
11308183|NCT02644642|Experimental|BB(Bronchial Blocker) group|disconnection technique will be applied
11308184|NCT02644629|Active Comparator|Active IV|Will receive IV Ketamine, along with IN placebo.
11308185|NCT02644629|Active Comparator|Active IN|Will receive IN Ketamine, along with IV placebo.
11308186|NCT02644616|Active Comparator|trial group(tolvaptan group)|trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
11308187|NCT02644616|Placebo Comparator|control group|control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)
11308188|NCT02644603|Experimental|Enhanced Recovery After Surgery|Patients underwent ERAS protocol
11308189|NCT02644603|No Intervention|Conventional Treatment|Patients underwent conventional treatment
11308190|NCT02644590|Experimental|Melatonin treatment|Adolescents with Type 1 Diabetes will undergo baseline 24 hour ambulatory blood pressure monitoring, followed by treatment with Melatonin for 3 weeks, using a single tablet at bed time, and repeat of the 24-hour blood pressure test following treatment period.
11308191|NCT02644577|Experimental|metformin group|Metformin 1000mg/day
11308192|NCT02644577|Placebo Comparator|placebo group|starch
11308193|NCT02644564||Ultrasonography|Patients will undergo structured clinical examination and ultrasonography of both shoulders on the day of inclusion. They also fill out an injury registration form, Oxford Shoulder Score and QuickDASH. Follow-up at 3, 6 and 12 months will be identical, but without ultrasonography and injury registration form.
11308194|NCT02644551|Experimental|CELEXT07|suspension that is applied topically to the infected nail(s) daily.
11308195|NCT02644551|Placebo Comparator|placebo|placebo is a suspension that simulates the physical properties of the experimental agent CELEXT07. It is applied topically to the infected nail(s) daily.
11308196|NCT02644551|Active Comparator|Penlac|Is a standard of care for the condition and is applied topically to the infected nail(s) daily.
11308197|NCT02644538|No Intervention|nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks
11308198|NCT02644538|Active Comparator|PegIFN alfa-2a + nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks
11308199|NCT02644525|Placebo Comparator|2|Subjects given vitamin placebo
11308200|NCT02644525|Experimental|imatinib|Subjects given drug (200 mg, 400 mg, or 600 mg)
11308201|NCT02644499|Active Comparator|Combination therapy|Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
11308202|NCT02644499|Active Comparator|Monotherapy|Methotrexate (up to 25 mg once a week) for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
11308203|NCT02644486|Experimental|A Group|
11308204|NCT02644486|Experimental|B Group|
11308205|NCT02644486|Active Comparator|C Group|
11308206|NCT02644473|Experimental|Tranexamic acid|Investigators will administer topical (1.5g) TXA during total knee arthroplasty and total hip arthroplasty
11308207|NCT02644473|Placebo Comparator|Control|
11308208|NCT02644460|Experimental|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
11308209|NCT02644460|Experimental|Stratum B|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
11308210|NCT02644447|Experimental|HUC-MSCs Transplantation|
11308211|NCT02644447|Experimental|HUC-MSCs with Injectable Collagen Scaffold Transplantation|
11308212|NCT02644434|Active Comparator|Conventional Strategy|Patients randomized to the conventional strategy group would undergo either jailed wire technique (diameter of side branch<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of side branch≥2.5mm).
11308213|NCT02644434|Experimental|Intentional Strategy|Patients randomized to the intentional strategy group would undergo either jailed balloon technique (diameter of side branch<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of side branch≥2.5mm).
11308254|NCT02644187|Other|Right side first -BF-RhodoLED|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
11308214|NCT02644421|Experimental|VVZ-149|"The following doses will be administered intravenously:
~Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours
~Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours"
11308215|NCT02644421|Active Comparator|Lidocaine|"The following doses will be administered intravenously:
~Lidocaine 4mg/kg LBM over 0.5 hours
~Normal saline over 7.5 hours"
11308216|NCT02644421|Placebo Comparator|Placebo|Normal saline administered intravenously over 8 hours
11308217|NCT02644408|Experimental|Megestrol and chemoradiotherapy|"Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.
~chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w."
11308218|NCT02644408|Active Comparator|chemoradiotherapy|chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.
11308219|NCT02644395|Active Comparator|Amlodipine|Current treatment of choice
11308220|NCT02644395|Experimental|Chlorthalidone|Testing new indication for approved drug
11308221|NCT02644382||Key Informant interviews|20 in-person or phone qualitative interviews with patients.
11308222|NCT02644382||Focus Groups|four qualitative focus groups of 6-10 women each.
11308223|NCT02644382||Physician Interviews|physician qualitative interviews over the telephone.
11308224|NCT02644382||Usual care cohort (pilot)|50 women who will be surveyed before and after their surgical consult
11308225|NCT02644382||Decision aid cohort (pilot)|50 women who will be surveyed before and after their surgical consult and will also be sent a web-based decision aid
11308226|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
11308227|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
11308228|NCT02644343|Experimental|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.
~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
11308229|NCT02644330|Active Comparator|surgical group|The patients in Group A (surgical group) underwent surgical repair with cardiopulmonary bypass
11308230|NCT02644330|Experimental|closure group|The patients in Group B (closure group) underwent minimally invasive transthoracic device closure.
11308231|NCT02644317|Experimental|with modified shoe inserts|wear the modified shoe inserts and shoes for balance test.
11308232|NCT02644317|No Intervention|without modified shoe inserts|only wear the shoes for balance test.
11308233|NCT02644304|Active Comparator|Clomiphene citrate plus cabergoline|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)
11308234|NCT02644304|Active Comparator|Clomiphene citrate plus placebo|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)
11308235|NCT02644291|Experimental|mebendazole|oral mebendazole as dose escalation (three groups), or l oral mebendazole at maximum dose for extended cohort. Given in 3 divided doses with meals as chewable 500 mg tablets based on calculated patient surface area.
11308236|NCT02644278|Experimental|VX-984 120 mg + PLD 40 mg/m^2|
11308237|NCT02644278|Experimental|VX-984 240 mg + PLD 40 mg/m^2|
11308238|NCT02644278|Experimental|VX-984 480 mg + PLD 40 mg/m^2|
11308239|NCT02644278|Experimental|VX-984 720 mg + PLD 40 mg/m^2|
11308240|NCT02644252|Experimental|Performance status 0-1, Arm A|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
11308241|NCT02644252|Experimental|Performance status 0-1, Arm B|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
11308242|NCT02644252|Experimental|Performance status 2, Arm A|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
11308243|NCT02644252|Experimental|Performance status 2, Arm B|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression
11308244|NCT02644239|Active Comparator|Group control|classical ketogenic diet
11308245|NCT02644239|Active Comparator|Group case|Group case: modified ketogenic diet to reduce at least 20% saturated fat, up> 50% of the acid supply monounsaturated, increasing> 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group
11308246|NCT02644226||Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
11308247|NCT02644226||Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
11308248|NCT02644213|Experimental|research arm|"12 young, healthy civilian volunteers will participate in this study. The experiment will take place in a dome room.
~The experiment will be performed according to the protocol of using CAREN and MOTEK systems:
~CAREN high (Computer Assisted Rehabilitation Environment) which screens virtual scene in the dome.
~MOTEK (Motek Medical©, the Netherlands) which is a two track treadmill (for each leg) placed on a rotatable platform.
~each subject will undergo the same experiment protocol."
11308249|NCT02644200|No Intervention|ORS|Controls treated with oral rehydration solution (standard therapy)
11308250|NCT02644200|Active Comparator|ORS+GT|Group treated with oral rehydration solution plus gelatin tannate
11308251|NCT02644187|Other|Left side first -Aktilite CL128|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
11308252|NCT02644187|Other|Right side first -Aktilite CL128|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
11308253|NCT02644187|Other|Left side first -BF-RhodoLED|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
11308283|NCT02643927|Experimental|4-week shortened MBSR|Short 4 sessions intervention
11308255|NCT02644161|Active Comparator|Combination acupuncture treatment (CAI)|Post stroke depression patients will receive Dense Cranial Electroacupuncture Stimulation (DCEAS) and body acupuncture. Patients will continue their existing antidepressant and rehabilitation therapy as usual.
11308256|NCT02644161|Sham Comparator|Least acupuncture stimulation (LAS)|Post stroke depression patients will receive Least acupuncture stimulation (LAS). Patients will continue their existing antidepressant and rehabilitation therapy as usual.
11308257|NCT02644148|Other|Conventional Roux-en-Y anastomosis|Conventional Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
11308258|NCT02644148|Experimental|Uncut Roux-en-Y anastomosis|Uncut Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
11308259|NCT02644135|Experimental|Halo Oral Spray|Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
11308260|NCT02644135|Placebo Comparator|Halo Placebo|The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
11308261|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
11308262|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.
~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
11308263|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.
~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
11308264|NCT02644096|No Intervention|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
11308265|NCT02644096|Other|Intervention|counselling and support after discharge from hospital
11308266|NCT02644070|Experimental|alveolar bone preservation with mp3|Extraction sockets grafted with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy) with graft particle size between 600 and 1000 µm and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
11308267|NCT02644070|Experimental|alveolar bone preservation with apatos|Extraction sockets grafted with cortical porcine bone with particle size between 600 and 1000 µm (Apatos, Osteobiol, Coazze, Italy ) and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
11308268|NCT02644070|No Intervention|NO_graft|extraction sockets with spontaneous healing
11308269|NCT02644057|Active Comparator|M-group|Will be given milrinone as an intravenous infusion at 0.2-0.6 mcg/kg/min for a maximum period of 72 hours and adjusted based on creatinine clearance measured by cockcroft-gault equation. It would be titrated based on hemodynamic response , urine output and at the discretion of the treating physician
11308270|NCT02644057|Active Comparator|D-group|Will be given dobutamine as an intravenous infusion at a maximum rate of 20 mcg/kg/min depending on patient tolerance and would adjusted based on hemodynamic response, urine output and at the discretion of treating physician
11308271|NCT02644044|Experimental|Treatment|Treatment with IT methotrexate
11308272|NCT02644031|Experimental|Mtwo rotary system|( continuous rotation system)
11308273|NCT02644031|Experimental|safe-sider rotary system|(reciprocating system)
11308274|NCT02644031|Experimental|hand files|k-files
11308275|NCT02644018|Experimental|Ingavirin|Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
11308276|NCT02644018|Placebo Comparator|Placebo|Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
11308277|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
11308278|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
11308279|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
11308280|NCT02643953|No Intervention|Control Group|This arm includes women who are eligible and give birth (including cases of fetal or infant death) in the intervention period in comparative health wards, who will not receive the interventions and who will continue to receive their usual pattern of utilization of maternity care.
11308281|NCT02643953|Experimental|Other|The intervention will need to be multi-faceted, and will consist of provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; conditional cash transfers to promote uptake of services and targeted community health education and advocacy activities
11308282|NCT02643927|Experimental|standard 8-weeks MBSR|8-week program
11308287|NCT02643901|Experimental|Ic-GW003 300ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
11308288|NCT02643901|Experimental|Ic-GW003 500ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
11308289|NCT02643901|Experimental|Ic-GW003 650ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
11308290|NCT02643901|Experimental|Ic-GW003 850ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
11308291|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
11308292|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
11308293|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
11308294|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
11308295|NCT02643849|Experimental|Spanner|
11308296|NCT02643836|Experimental|Treatment PEMF|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
11308297|NCT02643836|Sham Comparator|Sham Treatment|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The sham group will contain 38 subjects. Each study subject will receive two hats, which contain a de-activated PEMF device, the device will still be blinking to show sham treatment activity. The sham subjects will receive the sham treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
11308298|NCT02643823|Experimental|hUC-MSC + DMARDs|Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.
11308299|NCT02643823|Active Comparator|DMARDs|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.
11308300|NCT02643810|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak heart rate) and low-intensity intervals (50-70% of peak heart rate).
11308301|NCT02643810|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 70-75% of peak heart rate.
11308302|NCT02643810|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
11308303|NCT02643797|Experimental|Intervention Group: MA Health Coaching|"Patients in the intervention group will receive the MA Health Coaching intervention during their primary care visits, as well a follow-up calls to encourage/monitor progress and offer support."
11308304|NCT02643797|No Intervention|Usual Care|"Patients in this group will receive treatment as usual during their primary care visits."
11308305|NCT02643784|Experimental|Rosuvastatin|Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
11308306|NCT02643784|No Intervention|Control|Control group(don't take rosuvastatin until 14th day), as directed by the study physician.
11308307|NCT02643771|Experimental|Diabetic group|Subjects with Chronic Periodontitis and Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
11308308|NCT02643771|Experimental|Nondiabetic group|Subjects with Chronic Periodontitis and without Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
11308309|NCT02643758|Experimental|Bifocal soft contact lenses|Device: Bifocal soft contact lenses Use of bifocal contact lenses with nasally decentered optical zone to control the progression of myopia
11308310|NCT02643758|No Intervention|Single vision spectacles|Control: Single vision spectacles
11308311|NCT02643745|Experimental|Nephrology Intervention|Nephrology intervention before surgery:
11308312|NCT02643745|No Intervention|Standard of Care|No nephrology intervention before surgery (standard of care)
11308313|NCT02643732|Experimental|Methylphenidate|"Methylphenidate 10mg (one tablet) twice daily, increasing to 20mg (two tablets) twice daily following assessment 2 weeks into trial.
~24 weeks duration"
11308314|NCT02643732|Placebo Comparator|Placebo|"Identical, over-encapsulated placebo tablets manufactured to be identical to the experimental tablets. One tablet twice daily, increased to two tablets twice daily following assessment 2 weeks into trial.
~24 weeks duration."
11308315|NCT02643719|Active Comparator|Topiramate|
11308316|NCT02643719|Active Comparator|Behavioral intervention|
11308317|NCT02643719|Active Comparator|topiramate and behavioral intervention|
11308318|NCT02643719|Active Comparator|Standard of Care|
11308319|NCT02643706||CIN|CIN was defined as an absolute increase in serum creatinine concentration of at least 0.5 mg/dL (44.2umol/l) or a relative rise of at least 25% from baseline on the follow-up blood sample drawn 24 to 72 hours after the operation.
11308320|NCT02643706||Control|The enrolled patients without CIN.
11308321|NCT02643693|Experimental|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
11308322|NCT02643693|Experimental|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
11308323|NCT02643693|Experimental|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
11308324|NCT02643680|Experimental|The novel biocellulose wound dressing|
11308325|NCT02643680|Active Comparator|Bactigras|
11308326|NCT02643667|Experimental|Phase I: Ibrutinib|"Ibrutinib: will be given by mouth daily
~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP
~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
11308327|NCT02643667|Experimental|Phase II: Ibrutinib|"Ibrutinib: will be given by mouth daily
~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP
~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
11308328|NCT02643654|Placebo Comparator|Placebo|The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
11308329|NCT02643654|Active Comparator|MABp1|MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α (IL-1α). The entire MABp1 heavy and light chain sequences are identical to those found in naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual. It is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
11308330|NCT02643641|Experimental|BM32-3|2 placebo injections will be given followed by 3 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
11308331|NCT02643641|Experimental|BM32-4|1 placebo injections will be given followed by 4 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
11308332|NCT02643641|Experimental|BM32-5|5 injections with 20 micrograms each of BM321, BM322, BM325 and BM326 will be given
11308333|NCT02643641|Placebo Comparator|Placebo|5 placebo injections (alhydrogel only) will be given
11308334|NCT02643628|Experimental|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
11308335|NCT02643628|Experimental|Microneedling followed by Bellafill treatment|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
11308336|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
11308337|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
11308338|NCT02643602|Experimental|Bicarbonate and theophylline|Hydration with bicarbonate in addition to theophylline
11308339|NCT02643602|Active Comparator|Sodium and theophylline|Hydration with sodium chloride in addition to theophylline
11308340|NCT02643589|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
11308341|NCT02643589|Active Comparator|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
11308342|NCT02643576|No Intervention|Control|Usual SNAP-like food benefits
11308343|NCT02643576|Experimental|Rewards|Usual SNAP-like food benefits, plus a modification to this food benefit program that entails a 30% bonus on eligible fruit and vegetable purchases (i.e. F&V bonus)
11308344|NCT02643576|Experimental|Restrictions|Usual SNAP-like food benefits, plus a modification that requires no sugar-sweetened beverages, candy, or sweet baked goods be purchased
11308345|NCT02643576|Experimental|Rewards plus restrictions|Usual SNAP-like food benefits, plus two modifications to this food benefit program: one modification includes a 30% bonus on eligible fruit and vegetable purchases and the other modification is that sugar-sweetened beverages, candy, or sweet baked goods are not allowed to be purchased (i.e. Bonus & Restriction)
11308346|NCT02643563|Experimental|Ropivacaine 0.5%|Low volume (5 ml) Interscalene Block with Ropivacaine 0.5%
11308347|NCT02643563|Active Comparator|Ropivacaine 1%|Low volume (5 ml) Interscalene Block with Ropivacaine 1%
11308348|NCT02643563|Active Comparator|Bupivacaine 0.5% + epinephrine 1:200,000|Low volume (5 ml) Interscalene Block with Bupivacaine 0.5% + epinephrine 1:200,000
11308349|NCT02643550|Experimental|Dose escalation|Dose escalation of monalizumab in combination with cetuximab
11308350|NCT02643550|Experimental|Expansion cohort 1|monalizumab + cetuximab expansion cohort
11308351|NCT02643550|Experimental|Expansion cohort 2|monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
11308352|NCT02643550|Experimental|Expansion cohort 3|monalizumab + cetuximab + anti-PD(L)1
11308353|NCT02643537||Luxation erecta|All patients with Inferior shoulder dislocation in fixed abduction, also known as luxatio erecta humeri (LEH)
11308354|NCT02643524|Active Comparator|Nutrition and Exercise Counseling|CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
11308355|NCT02643524|Active Comparator|Control|CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit
11308356|NCT02643511|Experimental|Prostate biopsy,Hemiablative focal Brachytherapy|This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
11308357|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
11308358|NCT02643485||Study group|Patients undergoing forefoot reconstruction of hallux valgus or hallux rigidus
11308359|NCT02643485||Control group|Healthy volunteers (Students)
11308360|NCT02643472|Other|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
11308361|NCT02643472|Experimental|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
11308362|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
11308363|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
11308364|NCT02643446||G1: IPV+OPV, 1 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV.
11308365|NCT02643446||G2: IPV+OPV, 1 m+7d followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV.
11308366|NCT02643446||G3: IPV+OPV, 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
11308367|NCT02643446||G4: IPV+OPV, 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 5 months of age, that is one month after the second dose of OPV.
11308368|NCT02643446||G5: OPV, 3 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 5 months of age, that is one month after the third dose of OPV.
11308369|NCT02643446||G6: OPV, 1 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
11308370|NCT02643446||G7: OPV, 1 m+7d followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of OPV.
11308371|NCT02643446||G8: IPV+IPV, 1 m+7d followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV.
11308372|NCT02643446||G9: IPV+IPV, 2 m followup|Using 2 doses of IPV and 1 doses of OPV at 2, 3,4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the second dose of IPV and just before the first dose of OPV.
11308373|NCT02643446||G10: IPV+OPV, 1 m and 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV;the third sample at 5 months of age, that is one month after the second dose of OPV.
11308374|NCT02643446||G11: IPV+OPV, 1 m+7d and 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV,the third sample at 4 months of age, that is one month after the first dose of OPV.
11308375|NCT02643446||G12: IPV+IPV,1 m+7d and 2 m followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV,the third sample at 4 months of age, that is one month after the second dose of IPV.
11308376|NCT02643433|Experimental|MR and JE coadministration group|Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
11308377|NCT02643433|Active Comparator|MR administration alone group|Infants aged 8 months are vaccinated measles-rubella combined vaccine alone
11308378|NCT02643420|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)
~Supplied in prefilled single-use syringes for subcutaneous injection
~Administered on Day 2 of each cycle"
11308379|NCT02643420|Active Comparator|Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta® [NDC 55513-190-01] manufactured by Amgen)
~Single-dose subcutaneous injection administered on Day 2 of each cycle"
11308380|NCT02643407|Experimental|Docetaxel plus Nedaplatin|docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
11308381|NCT02643407|Active Comparator|Docetaxel plus Cisplatin|docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
11308382|NCT02643394|Active Comparator|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
11308518|NCT02642484|Placebo Comparator|PLacebo|Calcium carbonate twice daily
11308383|NCT02643394|Active Comparator|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
11308384|NCT02643381|Experimental|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
11308385|NCT02643381|Experimental|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
11308386|NCT02643368|Active Comparator|mOPV2 at 6 and 7 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
11308387|NCT02643368|Active Comparator|mOPV2 at 6 and 8 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
11308388|NCT02643368|Active Comparator|mOPV2 at 6 and 10 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
11308389|NCT02643368|Active Comparator|mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age|Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age
11308390|NCT02643355|Experimental|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
11308391|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
11308392|NCT02643342|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39 of refractive index 1.56.
11308393|NCT02643342|Sham Comparator|Orthokeratology with normal compression factor|Subjects wearing orthokeratology lenses of normal compression factor about 0.50-0.75D.
11308394|NCT02643342|Active Comparator|Orthokeratology with increased compression factor|Subjects wearing orthokeratology lenses of increased compression factor about 1.50-1.75D.
11308395|NCT02643329|Experimental|BF-Gliclazide Tablet 80mg|During the study session, healthy male subjects will be administered a single oral dose of BF-Gliclazide Tablet 80 mg after an overnight fast of approximately 10 hours.
11308396|NCT02643329|Active Comparator|Diamicron 80mg Tablet|During the study session, healthy male subjects will be administered a single oral dose of Diamicron 80 mg Tablet after an overnight fast of approximately 10 hours.
11308397|NCT02643316|Active Comparator|Same day 4 L preparation of PEG|Receive 1 gallon (4 L) of Polyethylene Glycol (PEG) preparation on the morning of the colonoscopy.
11308398|NCT02643316|Active Comparator|Split dose 4 L preparation of of the PEG|Receive the split-dose regimen. Will take half (2 L) of the PEG preparation the evening before colonoscopy and half (2 L) of the PEG preparation on the morning of the procedure.
11308399|NCT02643303|Experimental|Phase 1, Cohort 1A|IV Durvalumab + IT/IM polyICLC
11308400|NCT02643303|Experimental|Phase 1, Cohort 1B|IV Durvalumab + IV Tremelimumab + IT/IM polyICLC
11308401|NCT02643303|Experimental|Phase 1, Cohort 1C|IV Durvalumab + IT Tremelimumab + IT/IM polyICLC
11308402|NCT02643303|Experimental|Phase 2 Cohort|Once the recommended combination doses of the triplet dosing regimen has been determined in Cohort 1C, subsequent subjects will be enrolled into Cohort 2 to receive the recommended combination doses of both checkpoint antibodies in combination with polyICLC.
11308403|NCT02643290|Other|Patients|Adult patients with low back pain secondary to an high degree scolisis are treated by fiting with a brace 2-4 hours a day and tracked for 6 months.
11308404|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
11308405|NCT02643277|Experimental|Mobile phone text messaging|The intervention will receive text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring. The messages provide tips and suggestions, and positive reinforcement or encouragement, for improving lifestyle behaviors and compliance with therapy.
11308406|NCT02643264|Experimental|rTMS 10 Hz|Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).
11308407|NCT02643264|Sham Comparator|rTMS Sham|Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).
11308408|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
11308409|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
11308410|NCT02643238|Experimental|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
11308411|NCT02643238|Active Comparator|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
11308412|NCT02643225||pregnant women with gestational diabetes|case group
11308413|NCT02643225||non diabetic pregnant women|control group
11308414|NCT02643212|Placebo Comparator|Placebo|
11308415|NCT02643212|Experimental|Rivaroxaban|Rivaroxaban 10mg, 1 once a day
11308416|NCT02643186|Active Comparator|misoprostol group|preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy
11308417|NCT02643186|Active Comparator|uterine artery ligation group|bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy
11308418|NCT02643173||Volatile|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents.
11308419|NCT02643173||Intravenous|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents.
11308621|NCT02641652|Placebo Comparator|Placebo|placebo
11308420|NCT02643160|Experimental|Functional Trunk Training Group|Functional Trunk Training which includes strengthening of trunk muscle and functional activities including trunk region.
11308421|NCT02643160|No Intervention|Control Group|No intervention, the continued their regular physical therapy
11308422|NCT02643147|Experimental|CA125 guided strategy|In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels
11308423|NCT02643147|Active Comparator|Conventional strategy|Standard treatment strategy Therapy is based on established european guidelines
11308424|NCT02643134|Other|Group 1|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
11308425|NCT02643134|Other|Group 2|Patients in Group 2 undergo external physical vibration lithecbole for the treatment after extracorporeal shockwave lithotripsy(ESWL).A multi-dimensional physical harmonic vibration inertial guidance technology
11308426|NCT02643121||children with sepsis, SIRS|Data will be collected and analyzed from childrens with SIRS or septic state who will be admitted to the Department of Anesthesia and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections, sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be defined according to commonly used criteria - by International pediatric sepsis consensus conference.
11308427|NCT02643121||control group, healthy children|The samples children undergoing elective surgery will be used as a controls, i.e. samples from patients without signs of infection.
11308428|NCT02643108|Experimental|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
11308429|NCT02643108|No Intervention|No episiotomy|No episiotomy is performed during operative vaginal delivery, unless vitally indicated (for example severe fetal distress). The woman may tear spontaneously. Regular manual perineal support is applied.
11308430|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
11308431|NCT02643082|Experimental|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
11308432|NCT02643082|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
11308433|NCT02643069|Experimental|Intervention Geriatric Program|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, according to the treating physicians (s) surgeon and the performance of a geriatrician . This management will consist of the therapeutic plan, access to geriatric levels of care, coordination with primary and social care, rehabilitation, and discharge plan.
11308434|NCT02643069|No Intervention|Usual clinical practice|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, agreed with the treating physicians (s) surgeon.
11308435|NCT02643056|Experimental|Panitumumab|6 mg/kg per administration
11308436|NCT02643043|Other|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
11308437|NCT02643030|Experimental|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
11308438|NCT02643030|Active Comparator|hypercapnia|Tidal volume (6ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
11308439|NCT02643017|Placebo Comparator|normal saline|
11308440|NCT02643017|Experimental|Dex|
11308441|NCT02643004|Active Comparator|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
11308442|NCT02643004|Active Comparator|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
11308443|NCT02642991|Experimental|Comfilcon A asphere lens (test)|Participants were randomized to wear comfilcon A asphere lens (test) for one week during the cross over study.
11308444|NCT02642991|Active Comparator|Comfilcon A sphere lens (control)|Participants were randomized to wear comfilcon A sphere lens (control) for one week during the cross over study.
11308445|NCT02642978|Experimental|RSRCLM|robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.
11308446|NCT02642978|Active Comparator|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.
11308447|NCT02642965|Experimental|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.
~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
11308448|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
11308449|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
11308450|NCT02642939|Experimental|mifepristone|mifepristone 300 mg capsule per day, orally in 28-day cycles
11308451|NCT02642926|Active Comparator|Monopolar endoscopic endometrial ablation|
11308452|NCT02642926|Experimental|Bipolar endoscopic endometrial ablation|
11308453|NCT02642913|Experimental|Enzalutamide without Sorafenib|Will get enzalutamide, at the dose approved by the FDA for prostate cancer. If this dose has serious side effects, a lower dose will be given to new patients as they take part in the study. At the end of this part of the study, the recommended dose of enzalutamide will be set for all patients on this study. More patients will then be treated with this dose.
11308454|NCT02642913|Experimental|Enzalutamide with Sorafenib|Will get enzalutamide and sorafenib. The first group of patients will get the recommended dose of enzalutamide with sorafenib by mouth either once or twice daily. The dose of sorafenib you receive will depend on when the patient starts the study. At the beginning of the study, patients will be treated with a lower dose of sorafenib. If this dose does not have serious side effects, a higher dose will be given to new patients as they take part in the study.
11308455|NCT02642900|Experimental|Nystatin 100.000 units|Patients were treated with a topical antifungal nystatin oral suspension(1000.000 units) 5mL every six hours/14 days. Patients were instructed to rinse the solution for 5 minutes and then to spit the solution out. Samples were collected on days 7, 14 and 30 after the end of treatment (follow-up).
11308456|NCT02642900|Active Comparator|Photodynamic Therapy|Patients used mouthwash with methylene blue 0.005% for 20 minutes (pre-irradiation time). The palatal mucosa was irradiated using a low level laser with the following settings: wavelength of 660 nm, energy density of 120 J/cm ², output power of 40 milliwatt, 2 minutes per point. PDT was performed in two sessions (one session per week). Samples were collected immediately after each clinical procedure and 30 days after the second procedure (follow-up).
11308457|NCT02642887|Experimental|The test group|This group included 30 recession defects treated with mTA + SCTG
11308458|NCT02642887|No Intervention|The control group|This group included 30 recession defects treated with cTT + SCTG
11308459|NCT02642874|Experimental|Methocarbamol|Methocarbamol twice daily
11308460|NCT02642874|Placebo Comparator|placebo|Calcium carbonate twice daily
11308461|NCT02642861|Active Comparator|Cyclobenzaprine|Cyclobenzaprine administration for 2 weeks
11308462|NCT02642861|Placebo Comparator|PLacebo|Calcium carbonate for 2 weeks
11308463|NCT02642848|Active Comparator|HTO with micro fracture|High tibial osteotomy(HTO) with micro fracture is an common treatment for the correction of malalignment of the knee treating osteoarthritis.
11308464|NCT02642848|Experimental|HTO with bone marrow stem cell|High tibial osteotomy(HTO) with transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone.
11308465|NCT02642848|Experimental|HTO with adipose derived stem cell|High tibial osteotomy(HTO) with autologous adipose-derived stromal vascular fraction transplantation using LipoSculptor collecting from abdominal fat tissue.
11308466|NCT02642809|Experimental|Arm 1: Pembrolizumab and Brachytherapy|"Brachytherapy dose=16 Gy delivered in 2 fractions of 8 Gy per fraction, separated by 7-10 days between fractions.
~Pembrolizumab started within 1 week after completion of brachytherapy administered as an intravenous infusion over 30 minutes. It will be given every 3 weeks.
~Standard of care endoscopic biopsy will take place at time of enrollment and 2-6 months (optional) after pembrolizumab initiation.
~Research endoscopic biopsy for 8 consented patients will take place 1-2 weeks after initiation of brachytherapy.
~Peripheral blood will be collected: Pre-brachytherapy, Post-brachytherapy but pre-pembrolizumab (on day 1), Day 22 after the start of pembrolizumab, 3, 6, and 12 months (+/- 2 weeks) after the start of pembrolizumab, and time of progression"
11308467|NCT02642796|No Intervention|Group I (control)|Patient controlled analgesia (epidural fentanyl): PCA only
11308468|NCT02642796|Experimental|group II|PCA plus lumbar plexus & sciatic nerve transcutaneous electric nerve stimulation (LS-TENS)
11308469|NCT02642796|Experimental|group III|PCA plus surgical wound transcutaneous electric nerve stimulation ( SW-TENS)
11308470|NCT02642783|Other|Descriptive analysis|panelists were asked to rate different sensory attributes for different laxative bowel cleansing solutions on a 15 cm line scale.
11308471|NCT02642783|Other|Acceptability test|panelists were asked to rate the acceptability of different laxative bowel cleansing solutions using the 9-point hedonic scale.
11308472|NCT02642757|Experimental|Brief intervention|AUDIT brief intervention
11308473|NCT02642757|Sham Comparator|Control group|Pamphlet on alcohol use
11308474|NCT02642744|Other|Attending nurse model|The attending nurse model of in-hospital care delivery aims to improve patient understanding, shared decision making, medication adherence, and reduce early readmissions after discharge to improve quality of life. On the inpatient stroke unit, the attending nurse will take ownership of essential aspects of an individual stroke patient's care, education, and transition out of the hospital. To further contribute to the patient's plan of care, the attending nurse will be present on daily teaching rounds.
11308475|NCT02642744|No Intervention|Conventional inpatient nursing care|Standard of care nursing care patients receive while inpatient
11308476|NCT02642731||Patients for elective TKA|patients with normal or near normal plasma creatinine who come for elective total knee arthroplasty
11308477|NCT02642718|Placebo Comparator|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
11308478|NCT02642718|Experimental|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision. (a single dose).
11308479|NCT02642705|Experimental|High intensity interval training N|High intensity interval training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing ambient air (normoxia)
11308480|NCT02642705|Experimental|High intensity interval training H|High intensity interval training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing hypoxic air (about 3 500 m of altitude)
11308481|NCT02642705|Active Comparator|Constant load exercise training N|Constant load exercise training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing ambient air (normoxia)
11308516|NCT02642497|Active Comparator|systemic ketamine group|Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
11308517|NCT02642484|Active Comparator|Gabapentin|Gabapentin twice daily
11308482|NCT02642705|Experimental|Constant load exercise training H|Constant load exercise training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing hypoxic air (about 3 500 m of altitude)
11308483|NCT02642705|Experimental|Hypoxic conditioning at rest|Hypoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, hypoxic breathing for one hour (about 4500 m of altitude) while seating quietly
11308484|NCT02642705|Sham Comparator|Normoxic conditioning at rest|Normoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, normoxic breathing for one hour (ambient air) while seating quietly
11308485|NCT02642692|Experimental|Patellar Tendon Graft|Kind of graft that will be used for acl reconstruction
11308486|NCT02642692|Experimental|Hamstring Graft|Kind of graft that will be used for acl reconstruction
11308487|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
11308488|NCT02642666|Experimental|Yoga intervention|While in the yoga intervention arm of the study participants will practice yoga at home and at school for six weeks with the goal of practicing yoga daily during that time period. Yoga classes will be held twice a week at school. On the days that the children do not practice yoga at school, they will practice yoga at home with the use of a children's yoga video that mirrors the yoga class that they attend at school.
11308489|NCT02642666|No Intervention|Normal school and home activities|While in the wait-list group the children will continue with their regular activities both at home and at school.
11308490|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
11308491|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
11308492|NCT02642640|Other|melatonin-placebo|subjects will receive melatonin first and placebo second
11308493|NCT02642640|Other|placebo-melatonin|subjects will receive placebo first and melatonin second
11308494|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
11308495|NCT02642614|Experimental|BI 1026706 low dose|
11308496|NCT02642614|Experimental|BI 1026706 medium|
11308497|NCT02642614|Experimental|BI 1026706 high dose|
11308498|NCT02642614|Placebo Comparator|Placebo|
11308499|NCT02642601|Experimental|indomethacin|one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer
11308500|NCT02642601|No Intervention|no medication|no indomethacine before embryo transfer
11308501|NCT02642588|Experimental|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
11308502|NCT02642588|No Intervention|control|women will be given only clear liquids during labor
11308503|NCT02642562|No Intervention|Standard care|Participants in this arm will receive their usual care
11308504|NCT02642562|Experimental|Standard care plus IV iron infusion|"Iron to be administered as iron (III) isomaltoside 1000.
~Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg Body weight <50 kg: 20 mg/kg Hb ≥10 g/dL and body weight 50 to <70 kg: 1000 mg Hb ≥10 g/dL and body weight ≥70 kg: 20 mg/kg up to a max of 1500 mg Hb < 10 g/dL and body weight 50 to <70 kg: 20 mg/kg Hb < 10 g/dL and body weight ≥70 kg: 20 mg/kg up to a max of 2000 mg"
11308505|NCT02642549|Experimental|Girls for Health Intervention (G4H)|G4H will integrate proven girls' education strategies with innovative vocational interventions to build 1350 girls' career aspirations and academic achievement
11308506|NCT02642549|No Intervention|Control Condition|standard of care to support school attendance among girls (i.e., school tracking of attendance and reaching out to truant girls).
11308507|NCT02642536|Active Comparator|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
11308508|NCT02642536|Active Comparator|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
11308509|NCT02642523|Placebo Comparator|Saline Infusion|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
11308510|NCT02642523|Experimental|Insulin Clamp|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
11308511|NCT02642523|Experimental|BNP Infusion (Nesiritide)|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
11308512|NCT02642510|Experimental|DVD Structured Education|Participants in this group will watch an educational DVD in addition to standard teaching by nursing staff.
11308513|NCT02642510|Active Comparator|Standard Educational Teaching|Participants in this group will receive educational teaching by their assigned nursing staff.
11308514|NCT02642497|Active Comparator|local ketamine group|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
11308515|NCT02642497|Placebo Comparator|control group|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
11308519|NCT02642471|Experimental|Arm 1|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
11308520|NCT02642471|No Intervention|Arm 2|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
11308521|NCT02642471|Experimental|Arm 3|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
11308522|NCT02642471|No Intervention|Arm 4|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
11308523|NCT02642458||trastuzumab plus chemotherapy|Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
11308524|NCT02642458||pertuzumab plus trastuzumab plus chemotherapy|Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
11308525|NCT02642445|Experimental|Renal Sympathetic Denervation|Renal sympathetic Denervation are conducted from the adventitia of renal artery
11308526|NCT02642445|No Intervention|Control Group|Renal Sympathetic Denervation are not conducted in control group.
11308527|NCT02642432|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
11308528|NCT02642419|Experimental|Rivaroxaban|
11308529|NCT02642419|Experimental|Rivaroxaban and single antiplatelet drug|
11308530|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
11308531|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
11308532|NCT02642380|Experimental|4 cycles|Oral administration of dexamethasone 40 mg for four consecutive days every 14 days for 4 courses
11308533|NCT02642380|Active Comparator|1 cycle|Oral administration of dexamethasone 40 mg for four consecutive days
11308534|NCT02642367|Experimental|no use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection without use of stylet with McGrath videolaryngoscope after endotracheal tube was rolled up circularly for 3 min
11308535|NCT02642367|Active Comparator|use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection using a styletted endotracheal tube with McGrath videolaryngoscope
11308536|NCT02642328|Experimental|HIIT Training|Circuit training with strength and power. The chosen exercises were (random order): Sit-Ups, Mountain Climbers, Plank, Side Skater, Push Ups, Ground Support with Vertical Jump, Overhead Squat, Box Jump.Time total = 4 minutes
11308537|NCT02642328|Active Comparator|Control|Running aerobic exercise at 65% of VO2Max
11308538|NCT02642315|Other|open-label|"open-label single arm study
~Horizant, 600 mg oral once daily at 5 pm for 360 days."
11308539|NCT02642302|Experimental|HIIT With 60 sec Rest|The experimental (1) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 60 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
11308540|NCT02642302|Experimental|HIIT With 120 sec Rest|The experimental (2) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 120 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
11308541|NCT02642302|Active Comparator|Control|Continuous exercise at 50-55% of VO2max with similar total work
11308542|NCT02642289|Experimental|Probiotic1: Lactobacillus acidophilus|Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)
11308543|NCT02642289|Placebo Comparator|Placebo|Inactivate substance
11308544|NCT02642289|Experimental|Probiotic2: Lactobacillus Rhamnosus GG ®|Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)
11308545|NCT02642276|Active Comparator|Maximal walking group|Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
11308546|NCT02642276|Active Comparator|Submaximal walking group|Patients to be randomized to the 'submaximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to 2/3 of pain-free walking distance.
11308547|NCT02642276|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
11308548|NCT02642263|No Intervention|Oxytocin|Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
11308549|NCT02642263|Experimental|Carbetocin|100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby. For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
11308550|NCT02642250|Experimental|Entoban Capsules|Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
11308551|NCT02642250|Experimental|Metronidazole DS|Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.
11308552|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
11308553|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
11308554|NCT02642224|Experimental|Social work intervention|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
11308555|NCT02642211|Active Comparator|phako|eyes receiving phakoemulsification for cataract surgery
11308556|NCT02642211|Active Comparator|MSICS|Eyes undergoing manual small incision cataract surgery
11308557|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
11308558|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
11308559|NCT02642172|Experimental|ITF (Inulin/OFS 75/25)|16 gram/day of ITF (Inulin/OFS 75/25)
11308560|NCT02642172|Placebo Comparator|placebo|16 gram/day of maltodextrin (placebo)
11308561|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
11308562|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
11308563|NCT02642133|Other|Intervention|All patients were in the same arm - this is a cohort study where the group serves as their own control. Patients who did not undergo the procedure were not included in this outcomes study.
11308564|NCT02642120|Experimental|Receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
11308565|NCT02642120|No Intervention|Do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
11308566|NCT02642107|Experimental|Elective neck irradiation|Whole neck irradiation is given in the positive neck. Elective neck irradiation of Level II,III,Va lymph node area is given in negative neck, and Level IV,Vb and Supraclavicular fossa lymph node area were not irradiated in negative neck.
11308567|NCT02642107|Active Comparator|Whole neck irradiation|Whole neck irradiation is given regardless of the positive or negative neck.
11308568|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
11308569|NCT02642068||ADHD group|Drug-naïve adult ADHD Probands
11308570|NCT02642068||Sibling group|Unaffected Siblings of Drug-naïve Adult ADHD
11308571|NCT02642068||Control group|Age-, sex-, handedness-, and IQ-matched controls without lifetime ADHD or a family history of ADHD
11308572|NCT02642055|Experimental|Neuro+ Intervention|30 sessions (900 minutes) of Neuro+ Attention Training administered over 10 weeks.
11308573|NCT02642055|Active Comparator|Treatment as Usual|Continuation of current treatment for ADHD
11308574|NCT02642042|Experimental|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11308575|NCT02642029|Other|Psychosis patients|Patients with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features will undergo a single session each of excitatory TMS, inhibitory TMS, and sham TMS (in randomized order).
11308576|NCT02642029|Other|Healthy control participants|Individuals without major psychiatric illness will undergo a single session each of excitatory TMS, inhibitory TMS, and sham TMS (in randomized order).
11308577|NCT02642016|Experimental|CDX-0158|
11308578|NCT02642003|Experimental|GCSF+SMT|5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
11308579|NCT02642003|No Intervention|SMT|
11308580|NCT02641990|Experimental|Group 1|ITCA 650 20/60 mcg/day, ITCA placebo
11308581|NCT02641990|Experimental|Group 2|ITCA placebo, ITCA 650 20/60 mcg/day
11308582|NCT02641964||ARDS group|patients with acute necrotizing pancreatitis complicated by ARDS
11308583|NCT02641964||non-ARDS group|acute necrotizing pancreatitis patients without ARDS
11308584|NCT02641951|Placebo Comparator|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
11308585|NCT02641951|Active Comparator|Pecs II block|Ultrasound guided Pecs II block
11308586|NCT02641938|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
11308587|NCT02641938|Placebo Comparator|Normal Saline|IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
11308837|NCT02640222||AC-experienced treated with VKA|AC-experienced treated with VKA
11308588|NCT02641925|Active Comparator|Omentum preserving|Omentum preserving: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed.
11308589|NCT02641925|Experimental|Total omentectomy|Total omentectomy: Whole omentum will be removed.
11308590|NCT02641912|Experimental|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
11308591|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.
~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
11308592|NCT02641899|Experimental|Experimental Treatment|ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg
11308593|NCT02641886|Experimental|Jian Pi Yi Shen Hua Tan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
11308594|NCT02641886|Placebo Comparator|the Placebo Group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
11308595|NCT02641873|Experimental|BBI608 + FOLFIRI +Bevacizumab|
11308596|NCT02641860|Other|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
11308597|NCT02641860|Other|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells mid-dose group
11308598|NCT02641860|Other|Mesenchymal progenitor cells Dosage 3|Mesenchymal progenitor cells high-dose group
11308599|NCT02641847|Experimental|High risk group A|TA(E)C x 4 cycles to GP x 4 cycles (docetaxel + doxorubicin (epirubicin) + cyclophosphamide to gemcitabine + cisplatin), docetaxel: 75 mg/m2 IV on day 1; doxorubicin: 50 mg/m2 IV on day 1 or epirubicin 75 mg/m2 IV on day 1; cyclophosphamide: 500 mg/m2 IV on day 1; gemcitabine: 1250 mg/m2 IV on day 1 and 8; cisplatin: 75 mg/m2 IV on day 1, dosing interval is 21 days.
11308600|NCT02641847|Active Comparator|High risk group B|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
11308601|NCT02641847|Other|Low risk group C|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
11308602|NCT02641834|Experimental|Veg Group|Group that starts with the Vegetarian diet
11308603|NCT02641834|Active Comparator|Med group|Group that starts with the Mediterranean diet
11308604|NCT02641821|Experimental|Nifedipine GITS|
11308605|NCT02641808|Experimental|follicular flushing group|Monofollicular IVF therapy with follicular flushing up to five times after aspiration of the follicule at the time to the oocyte pick-up
11308606|NCT02641808|Active Comparator|aspiration group|Monofollicular IVF therapy with aspiration only at the time of the oozyte pick-up
11308607|NCT02641795|Experimental|Experimental|Minimally invasive robotic cochlear implantation with custom device
11308608|NCT02641782|Active Comparator|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
11308609|NCT02641782|Experimental|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
11308610|NCT02641769|Other|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
11308611|NCT02641756|Experimental|Study Population|"This is a single arm study. The investigators will include 10 HIV positive patients under chronic CART (combined antiretroviral therapy).
~The intervention will consist on treatment interruption after in depth sampling under CART"
11308612|NCT02641743|Experimental|Inslow|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) Inslow at 7:00 AM.
11308613|NCT02641743|Placebo Comparator|standard balanced formula|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) standard balanced formula at 7:00 AM.
11308614|NCT02641730|Experimental|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
11308615|NCT02641730|Experimental|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
11308616|NCT02641730|Experimental|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
11308617|NCT02641717|Experimental|All subjects|All patients enrolled in this study will self-collect a vaginal swab (experimental) then have a physician collected vaginal swab (gold standard)
11308618|NCT02641704||Multidisciplinary program|Multidisciplinary program designed and administered by the Competence- and Integration Center in Sonderborg Municipality
11308619|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.
~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.
~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.
~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.
~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.
~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.
~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles
~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
11308620|NCT02641652|Active Comparator|Sertraline|sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
11308622|NCT02641639|Active Comparator|Fosbretabulin tromethamine|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P
11308623|NCT02641639|Placebo Comparator|Placebo|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo
11308624|NCT02641626|Experimental|Urgent Coronary Angiography|Urgent Coronary Angiography: as soon as possible, when the patient is randomized.
11308625|NCT02641626|Active Comparator|Deferred coronariography|Deferred coronary angiography: after extubation if the patient has a good neurologic prognosis.
11308626|NCT02641613|Active Comparator|supraclavicular|patients receive a supraclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
11308627|NCT02641613|Experimental|retroclavicular block|patients receive a retroclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
11308628|NCT02641600|Active Comparator|Elastic stockings|Class 1 elastic stockings (18-21 mmHg)
11308629|NCT02641600|Placebo Comparator|Placebo stockings|Placebo stockings (0 mmHg)
11308630|NCT02641587|Experimental|CHTP 1.2|Ad libitum use of the CHTP 1.2
11308631|NCT02641587|Active Comparator|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
11308632|NCT02641574||previous 1|women who have had in their past one cesarean section
11308633|NCT02641574||previous 2|women who have had in their past 2 cesarean sections
11308634|NCT02641574||previous 3|women who have had in their past 3 cesarean sections
11308635|NCT02641574||previous 4|women who have had in their past 4 cesarean sections
11308636|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
11308637|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
11308638|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
11308639|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
11308640|NCT02641548|Experimental|Silicone sock+heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet and a sock of silicone is used every night.
11308641|NCT02641548|Active Comparator|Heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet
11308642|NCT02641535|Experimental|research arm|"12 healthy volunteers from the border guard of the police forces will participate in this study. The subjects will undergo 4 experiment days:
~Recruitment , medical examination and VO2max test.
~Acclimatization day by performing moderate exercise protocol under hot and humid climate.
~3.2 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:
~Protective garment in current use + NBC mask.
~The new BC membrane protective garment + NBC mask"
11308643|NCT02641522|Experimental|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
11308644|NCT02641509|Experimental|NBI to perform the polipectomy|this arm will undergo polypectomy with the use of NBI to define the margins of the lesion
11308645|NCT02641509|Experimental|no NBI to perform the polypectomy|this arm will undergo polipectomy without the use of NBI to define the margins of the lesion
11308646|NCT02641496|Experimental|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
11308647|NCT02641496|Active Comparator|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
11308648|NCT02641483|Experimental|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
11308649|NCT02641470|Experimental|DA9301|Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
11308650|NCT02641470|Placebo Comparator|Placebo|Orally administration of placebo pills (1000 mg/day) for 4 weeks.
11308651|NCT02641457|Experimental|Aflibercept x Ranibizumab|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab
11308652|NCT02641444||Efavirenz|Receiving efavirenz as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
11308653|NCT02641444||Atazanavir|Receiving atazanavir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
11308654|NCT02641444||Raltegravir|Receiving raltegravir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
11308655|NCT02641444||Maraviroc|Receiving maraviroc as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
11308656|NCT02641431|Experimental|mapping/ablation|Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.
11308657|NCT02641418|Other|Exercise|only 1 arm to trial
11308658|NCT02641405|Experimental|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
11308659|NCT02641405|Placebo Comparator|Placebo|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
11361836|NCT02288481|Experimental|Cohort 6 1000 mg TBA-354|
11308660|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
11308661|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
11308662|NCT02641392|Experimental|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
11308663|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
11308664|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
11308665|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
11308666|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
11308667|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
11308668|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
11308669|NCT02641366||Tremor kinetics after DBS|This group have already undergone Deep Brain Stimulation (DBS) placement and will have measurements of tremor kinetics by using the electromagnetic tracking. The electromagnetic sensors will be placed on the arm and hand while the routine outpatient neurologic examinations are being performed. The testing will be performed with the DBS system in both the on and off settings.
11308670|NCT02641366||Tremor kinetics before and after DBS|This group will have measurements of tremor kinetics by using electromagnetic tracking prior to being scheduled to undergo Deep Brain Stimulation (DBS) placement. A total of two testing sessions will be performed: the first session will be performed during the routine preoperative visit, the second session will be performed during the routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
11308671|NCT02641353|Experimental|Treatment A - Apremilast 30 mg tablet fasted|A single oral dose of 30 mg apremilast tablet under fasted conditions.
11308672|NCT02641353|Experimental|Treatment B Apremilast 30 mg oral suspension fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 ml) under fasted conditions
11308673|NCT02641353|Experimental|Treatment C - Apremilast 30 mg oral suspension fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 ml) under fed conditions
11308674|NCT02641340|Experimental|Cycle 1, Cohort 1|Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
11308675|NCT02641340|Experimental|Cycle 1, Cohort 2|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
11308676|NCT02641340|Experimental|Cycle 1, Cohort 3|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
11308677|NCT02641340|Experimental|Cycle 1, Cohort 4|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
11308678|NCT02641340|Experimental|Cycle 2, Cohort 1|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
11308679|NCT02641340|Experimental|Cycle 2, Cohort 2|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
11308680|NCT02641340|Experimental|Cycle 2, Cohort 3|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
11308681|NCT02641340|Experimental|Cycle 2, Cohort 4|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
11308682|NCT02641340|Experimental|Cycle 3, Cohort 1|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
11308683|NCT02641340|Experimental|Cycle 3, Cohort 2|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
11308684|NCT02641340|Experimental|Cycle 3, Cohort 3|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
11308685|NCT02641340|Experimental|Cycle 3, Cohort 4|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
11308686|NCT02641327||Internal ward|Patients hospitalized in Internal Medicine unit with unstable blood pressure that need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical, hypotension or Hypertension patients, patients with kidney failure, heart disease, stroke)
11308687|NCT02641327||ICU|Patients hospitalized in intensive care with arterial line that allow continuous blood pressure measurement
11308688|NCT02641314|Experimental|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
11308689|NCT02641301|Experimental|Subjects Roux-en-Y-gastric bypass (RYGB)|Sustained release morphine sulfate, 30 mg
11308690|NCT02641301|Active Comparator|Control volunteers matched with RYGB|Sustained release morphine sulfate, 30 mg
11308691|NCT02641288|Experimental|Ropivacaine irrigation|Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
11308838|NCT02640222||AC-experienced treated with apixaban|AC-experienced treated with apixaban
11308692|NCT02641288|Placebo Comparator|Normal saline irrigation|Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
11308693|NCT02641275|Experimental|Intervention|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions.
11308694|NCT02641275|No Intervention|Control group|no intervention other than existing support (see exclusion criteria). However, intervention will be offered and studied secondary as well (after 1 1/2 year of no intervention).
11308695|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
11308696|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
11308697|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.
~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
11308698|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.
~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
11308699|NCT02641210|Experimental|Periodontal Treatment|The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration.
11308700|NCT02641210|No Intervention|No Periodontal Treatment|Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline.
11308701|NCT02641197|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after brachial artery occlusion by a standard upper arm pneumatic blood pressure cuff. The procedure is non-invasive and does not employ ultrasound.
11308702|NCT02641171||Entire Cohort|This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.
11308703|NCT02641158|Other|Control Group|
11308704|NCT02641158|Experimental|Care Facilitation Group|
11308705|NCT02641145|Experimental|Active AL cardiac amyloidosis|50 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of blood of the heart, as well as the heavy metal analysis of the blood at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
11308706|NCT02641145|Active Comparator|Remission AL cardiac amyloidosis|25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)<40 mg/dL for > 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart as well as a heavy metal analysis of the blood at baseline.
11308707|NCT02641145|Experimental|Active AL Pre-CMP|36 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up. Subjects with contraindications to Cardiac MRI or gadolinium contrast may still be eligible for study participation.
11308708|NCT02641145|No Intervention|Multiple Myeloma Controls|25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
11308709|NCT02641145|Experimental|Heart Failure|10 individuals with diagnosis of heart failure without amyloidosis by standard criteria will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline..
11308710|NCT02641132|Experimental|Pterygium surgery: Head and body.|Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.
11308711|NCT02641132|Active Comparator|Pterygium surgery: Body.|Application of Mitomycin C 0.02% after excision of the body only of the pterygium.
11308712|NCT02641119||Albumin|Patients receiving any amount of 5% albumin during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician.
11308713|NCT02641119||Saline-only|Patients receiving only saline during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician
11308714|NCT02641106|Experimental|Video Directly Observed Therapy|VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
11308839|NCT02640222||AC-experienced treated with dabigatran|AC-experienced treated with dabigatran
11308840|NCT02640222||AC-experienced treated with rivaroxaban|AC-experienced treated with rivaroxaban
11308841|NCT02640209|Experimental|Arm 1|
11308715|NCT02641106|Active Comparator|In-Person DOT|In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
11308716|NCT02641093|Experimental|Pembrolizumab|Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin
11308717|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
11308718|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
11308719|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
11308720|NCT02641067|Experimental|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
11308721|NCT02641054|Experimental|CVXL-0107 then cross-over to placebo|"Study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa.
~Cross-over to placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa"
11308722|NCT02641054|Placebo Comparator|Placebo then cross-over to CVXL-0107|"Placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa.
~Cross-over to study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa"
11308723|NCT02641041|Experimental|Cohort 1|A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1
11308724|NCT02641041|Experimental|Cohort 2|A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1
11308725|NCT02641041|Experimental|Cohort 3|One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15
11308726|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
11308727|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
11308728|NCT02641002|Experimental|Dose escalation of CC-90002|CC-90002 by intravenous (IV) infusion on a 28 day cycle
11308729|NCT02640989|Experimental|Group 1|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Seasonal trivalent influenza vaccine, Anflu®"
11308730|NCT02640989|Experimental|Group 2|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Seasonal trivalent influenza vaccine, VAXIGRIP"
11308731|NCT02640989|Active Comparator|Group 3|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Seasonal trivalent influenza vaccine, Fluarix"
11308732|NCT02640976|Active Comparator|Poor responders|"This group will include women who underwent IVF/ICSI cycle and produced 4 oocytes or less.
~intervention:
~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (300 IU).
~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.
~Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
11308733|NCT02640976|Active Comparator|Good responders|"This group will include women who produced (5 or more oocytes) after COH.
~Intervention:
~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml
~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.
~When at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
11308734|NCT02640963|Experimental|Intervention: the GrACE programme|The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
11308735|NCT02640963|Placebo Comparator|Control Group|All subjects assigned to the control group were given the option to engage in other activities that were offered by the facility during the 12-week intervention period. Activities were facility specific, and included Zumba aerobic exercise and walking, however no specific resistance exercises were offered.
11308736|NCT02640950|Experimental|Open-Label TMS|Active Transcranial Magnetic Stimulation
11308737|NCT02640937||Orthopaedic device related infections|"Inclusion Criteria:
~infections after fracture fixation or prosthetic joint surgery
~Affected bone or joint: Long bones of the lower extremity; hip joint, knee joint;
~Bacterial growth of S. epidermidis at the site of interest
~Written consent
~Age: 18 and older"
11308738|NCT02640924|Experimental|Proton radiotherapy|Proton radiotherapy will be totally 66 cobalt gray equivalent (CGE) in 10 fractions and delivered once daily, 5 fractions per week, over 2 weeks for HCC more than 1 cm away from the alimentary tract.
11308842|NCT02640196|Placebo Comparator|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
11308843|NCT02640196|Placebo Comparator|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope laryngoscope followed with intubating the difficult airway simulator
11361837|NCT02288481|Placebo Comparator|Cohort 6 placebo|Placebo Suspension
11308739|NCT02640924|Experimental|Radiofrequency Ablation|Multiple-electrode radiofrequency with switch-controller system (ME-SWC RFA) can create a large coagulation necrosis volume and successful treat HCC sized more than 3 cm, extending to 8.5 cm. ME-SWC RFA system uses up to 3 electrodes parallel insertion to inside of the tumors with an equilateral triangular confirmation before initiation of ablation. The distances between electrodes are about 1.5-2 cm, estimated by ultrasound measuring. The switching machine is set on the auto-mode, and all electrodes work alternately and switching each other automatically after impendence surge.
11308740|NCT02640898|Active Comparator|FU-based chemoradiotherapy|patients will be treated with the INT0116 regimen.
11308741|NCT02640898|Experimental|docetaxel-based chemoradiotherapy|patients will be treated with modified DCF chemotherapy in combination with docetaxel-based chemoradiotherapy.
11308742|NCT02640885|Experimental|Foley's cather tamponade|Balloon tamponade with 2-way Foley's Cather was successfully used during cesarean section due to sever postpartum haemorrhage after failure of medical treatment.
11308743|NCT02640872||HAPPY Cohort|A elderly cohort for chronic diseases
11308744|NCT02640859||Normal cohort|Normal cohort for biobank
11308745|NCT02640846|Active Comparator|Norepinephrine|Doser
11308746|NCT02640846|Active Comparator|Milrinone|Doser
11308747|NCT02640846|Active Comparator|Levosimendan|Doser
11308748|NCT02640833|Experimental|Duvelisib+Venetoclax|
11308749|NCT02640820|Experimental|Sensitization Phase|Up to two doses of Sensitizing DPCP Ointment will be applied and subjects who exhibit a sensitization response will enter the Treatment Phase. Pharmacokinetics (PK) of Sensitizing DPCP Ointment will be measured in a subset of subjects. For PK, blood will be collected prior to application of the Sensitizing DPCP Ointment and again at 1, 2, and 24 hours after application.
11308750|NCT02640820|Experimental|Treatment Phase|In the Treatment Phase, subjects will receive doses of Treatment DPCP Ointment weekly for 10 weeks. Subjects who at the end of the Treatment Phase have exhibited partial clearance of warts may be given the option to continue with an additional 10 weekly treatments.
11308751|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
11308752|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
11308753|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
11308754|NCT02640794|Active Comparator|Aspirin +clopidogrel|Patients would be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d)
11308755|NCT02640794|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d)
11308756|NCT02640781|Experimental|covered stent|newly designed covered stent group
11308757|NCT02640781|Active Comparator|uncovered stent|currently used uncovered stent group
11308758|NCT02640768|Experimental|educational training|educational training
11308759|NCT02640768|No Intervention|no educational training|no educational training wards
11308760|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
11308761|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
11308762|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
11308763|NCT02640729|Experimental|Nelotanserin|Nelotanserin 40mg then nelotanserin 80 mg
11308764|NCT02640729|Placebo Comparator|Placebo|Placebo
11308765|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
11308766|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
11308767|NCT02640703|Active Comparator|morning vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 am
11308768|NCT02640703|Active Comparator|evening vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 pm
11308769|NCT02640690|Experimental|Trauma-Sensitive Yoga (TSY) Intervention|10-weekly 1-hour TSY Sessions
11308770|NCT02640690|Active Comparator|Cognitive Processing Therapy-Cognitive Intervention (CPT-C)|12-weekly 1.5 hour CPT-C Sessions
11308771|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
11308772|NCT02640664|Experimental|Ranibizumab 0.1 mg|Ranibizumab 0.1 mg
11308773|NCT02640664|Experimental|Ranibizumab 0.2 mg|Ranibizumab 0.2 mg
11308774|NCT02640664|No Intervention|Laser therapy|Laser therapy
11308775|NCT02640651|Experimental|DC-Stimulator (PLUS version)|For tDCS stimulation, anodal stimulation of the right dorsolateral prefrontal cortex will be performed for twenty minutes at 2mA. The current will be applied by a battery-driven tDCS stimulator via a pair of saline-soaked sponge electrodes (25 cm2 surface). The anodal electrode will be placed on the scalp at the F4 position according to the international 10-20 EEG coordinate system. 20 minute tDCS sessions will be conducted ten times over a two week period
11308776|NCT02640638|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care
11308777|NCT02640638|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care
11308778|NCT02640625|Experimental|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
11308779|NCT02640612|Experimental|BI 695501|
11308780|NCT02640599|Experimental|Vestibular Rehabilitation + Areobic Exercise|
11308781|NCT02640599|Active Comparator|Vestibular Rehabilitation|
11308844|NCT02640196|Active Comparator|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq laryngoscope followed with intubating the difficult airway simulator
11308782|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).
~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
11308783|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
11308784|NCT02640560||Children with food allergy|"Children with food allergy to nuts, hazelnuts, walnuts, shellfish and mollusks (1-14 years old).
~The Parents of the cases children will compile a Food allergy questionnaire"
11308785|NCT02640560||Healthy Children|Healthy Children (1-14 years old) The Parents of the control children will compile a Control questionnaire
11308786|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
11308787|NCT02640534|Experimental|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
11308788|NCT02640534|Active Comparator|Enzalutamide|Enzalutamide 160 mg od until disease progression
11308789|NCT02640521|No Intervention|Control Parents|
11308790|NCT02640521|Active Comparator|Treatment Parents|Chart reminders (paper or electronic medical records, depending on clinic wishes) to prompt providers to ask about in home smoking at every medical visit; establishing a New York State Quit line referral system in the pediatric practice; and amending the training curriculum for providers and the patient education materials that are part of a provider toolkit, to focus on the negative impact of second hand smoke (SHS) on their children,and specifically, asthma outcomes.
11308791|NCT02640508|Experimental|Combination Eribulin and lenvatinib|Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.
11308792|NCT02640495||Study subjects|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
11308793|NCT02640482|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind [DB] treatment period)
11308794|NCT02640482|Experimental|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
11308795|NCT02640482|Experimental|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label [OL] treatment period)
11308796|NCT02640469|Active Comparator|Chlorhexidine with water rinse|This is a traditional method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
11308797|NCT02640469|Experimental|Chlorhexidine without water rinse|This is an experimental method of disinfection. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
11308798|NCT02640469|Active Comparator|Chlorhexidine + sterillium hand rub|This is a standard method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
11308799|NCT02640456||Para- or retropharyngeal abscess|Patients with para- or retropharyngeal abscess.
11308800|NCT02640456||Neck abscess|Patients with neck abscess without relation to the pharynx or salivary glands.
11308801|NCT02640443|Experimental|Treatment|Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.
11308802|NCT02640430|Active Comparator|standard treatment|"Control group will be made of 20 COPD patients with severe and very severe airflow obstruction, mucus hypersecretion and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.
~Control group will b treated with PEP-bottle over 10 daily sessions (20 minutes twice a day). Patients are asked to breath against a positive expiratory pressure determined by a column of water in a bottle (PEP Bolltle). PEP is one of the validated treatment used in the clearance of bronchial secretions in COPD patients.
~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
11308803|NCT02640430|Experimental|Free Aspire|"Experimental group will be made of 20 COPD patients with severe and very severe airflow obstruction , mucus hypersecretion , and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.
~Patients are asked to use FREE ASPIRE Free Aspire is an electro-medical device which removes bronchopulmonary secretions noninvasively, without using a suction catheter and without generating airway pressure, positive or negative.
~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
11308804|NCT02640417|Experimental|Nucleotides + B12|Nucleotides + Vitamin B12 Dose: two capsules, three times per day + placebo corresponding to Group B treatment
11308805|NCT02640417|Active Comparator|B vitamins|Vitamin B1 + Vitamin B6 + Vitamin B12 Dose: one tablet, three times daily + placebo corresponding to Group A treatment
11308806|NCT02640404|Experimental|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
11308807|NCT02640404|Experimental|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
11308808|NCT02640391||Quiescent UC|Patients with quiscent UC who will undergo colonoscopy for surveillance or mucosal healing check up
11308845|NCT02640196|Active Comparator|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
11308809|NCT02640365|Experimental|GROUP A / GROUP B (two differents cohorts)|"GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)
~Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)
~MM-398 : 60mg/m²
~Irinotecan (CPT-11) : 90mg/m²
~Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)
~MM-398 : 80mg/m²
~CPT-11: 90mg/m²
~Level 3A: DOUBLIRI dose 60/120 (12-18 patients)
~MM-398 : 60mg/m²
~CPT-11: 120mg/m²
~Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)
~MM-398 : 80mg/m²
~CPT-11 : 120 mg/m²
~GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)
~same level as group A + LV/5FU - bevacizumab regimen :
~Bevacizumab : 5mg/kg(day (d) 1)
~Leucovorin (LV) : 400mg/m² (d1)
~5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)"
11308810|NCT02640352|Active Comparator|Probi Defendum|Dietary supplement (tablet) with probiotics
11308811|NCT02640352|Placebo Comparator|Placebo|Dietary supplement (tablet) without probiotics
11308812|NCT02640339||Parkinson Disease|Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, with alpha-synuclein deposits in neurons which aggregate into Lewy bodies.
11308813|NCT02640339||Mutiple system atrophy|is a degenerative neurological disorder. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance, and autonomic functions of the body such as bladder control or blood-pressure regulation. Neuronal death probably occurs as a consequence of alpha-synuclein aggregation in oligodendroglia.
11308814|NCT02640339||REM sleep behavior disorder|a sleep disorder in which you physically act out vivid, often unpleasant dreams with vocal sounds and sudden, often violent arm and leg movements
11308815|NCT02640339||dementia with Lewy bodies|"causes a progressive decline in mental abilities.
~It may also cause visual hallucinations, which generally take the form of objects, people or animals that aren't there. This can lead to unusual behavior such as having conversations with deceased loved ones.
~Another indicator of Lewy body dementia may be significant fluctuations in alertness and attention, which may include daytime drowsiness or periods of staring into space. And, like Parkinson's disease, Lewy body dementia can result in rigid muscles, slowed movement and tremors."
11308816|NCT02640339||Pure autonomic failure|Pure autonomic failure is dysfunction of many of the processes controlled by the autonomic nervous system, such as control of blood pressure•Blood pressure may decrease when people stand, and they may sweat less and may have eye problems, retain urine, become constipated, or lose control of bowel movements
11308817|NCT02640339||Healthy controls|Healthy normals with no neurological involvement
11308818|NCT02640326|Active Comparator|Active Comparator|The catheterized arm will have Standard of care Foley urinary catheter insertion according to usual institutional care pathways in the operating room prior to surgery initiation. The urinary catheter will be assessed for removal on the morning of post-operative day 1, and patients will be monitored for urinary complications once catheter is removed until patient has successfully voided spontaneously within 8 +/- 2 hours.
11308819|NCT02640326|Experimental|Experimental Arm|The non-catheterized arm will have standard of care Foley urinary catheter insertion, with no Foley Urinary Catheter inserted prior to, during, or after surgery unless the patient is showing signs of urinary retention after surgery. Patient will be monitored for urinary complications starting in the recovery room until patient has successfully voided spontaneously within 8 +/- 2 hours
11308820|NCT02640313|Experimental|18F-choline PET-MR imaging|"Intervention: 18F-choline PET-MR imaging.
~Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.
~Procedure: dynamic and static 18F-choline PET-MR."
11308821|NCT02640300|Experimental|Immediate discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules at week 3. All capsules contained placebo (i.e., the antipsychotic drugs were abruptly discontinued). Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
11308822|NCT02640300|Experimental|Gradual discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
11308823|NCT02640287|Experimental|Waldenström macroglobulinemia|Patients with diagnosis of Waldenström macroglobulinemia
11308824|NCT02640287|Experimental|Others B-cell malignancies|Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma
11308825|NCT02640287|Other|Healthy subjects|Control healthy subjects without B-cell malignancy
11308826|NCT02640274|Experimental|Intervention group|The intervention is an individual nurse-led counselling programme in addition to usual care.
11308827|NCT02640274|Other|Control group|usual care
11308828|NCT02640261||Group 1|Single embryo transfer on day 5, according to standard embryo morphological criteria
11308829|NCT02640261||Group 2|Single embryo transfer on day 5, chosen on the basis of both embryo morphological criteria and levels of cytokines measured in the individual FF.
11308830|NCT02640248||Cuff ETT|
11308831|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
11308832|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
11308833|NCT02640222||AC-naive treated with VKA|AC-naive treated with VKA
11308834|NCT02640222||AC-naive treated with apixaban|AC-naive treated with apixaban
11308835|NCT02640222||AC-naive treated with dabigatran|AC-naive treated with dabigatran
11308836|NCT02640222||AC-naive treated with rivaroxaban|AC-naive treated with rivaroxaban
11308846|NCT02640183|Experimental|Group A (EMLA)|3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
11308847|NCT02640183|Placebo Comparator|Group B (Placebo)|3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
11308848|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
11308849|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
11308850|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
11308851|NCT02640144|Active Comparator|Treatment group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of Sodium Hyaluronate 1% - ARTHREASE TM
11308852|NCT02640144|Placebo Comparator|Control group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of BPS - Buffer Phosphate Solution - as a placebo
11308853|NCT02640131|Experimental|BSHR Intervention|"Couples will attend 30-minute clinic consultations with an Urologist and a Sexual Health Counsellor and receive session-specific chapters of the Kindness, Intimacy, Sexuality and Satisfaction manual over the course of the intervention.
~The BSHR Intervention involves two complementary components; the bio-medical, and the psychosocial. The bio-medical component for both arms intervention includes an urologist consultation at a pre-operative appointment and 5 f/u appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
~The psychosocial component aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive sexual health counseling and manualized support."
11308854|NCT02640131|Active Comparator|Attention Control|"Survivorship Counseling: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) and receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You Manual. The bio-medical component is the same in both arms.
~The core topics discussed during over 7 counseling sessions include: preparation for immediate post-surgery recovery, Kegel exercises, nutrition and prostate cancer, exercise and prostate cancer, and maintaining healthy lifestyle change."
11308855|NCT02640118|Active Comparator|Pancreatectomised + Lixisenatide|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a Lixisenatide-injection will be given subcutaneously"
11308856|NCT02640118|Placebo Comparator|Pancreatectomized + lixisenatide-placebo|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a placebo-injection will be given subcutaneously."
11308857|NCT02640118|Active Comparator|Healthy + Lixisenatide|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a Lixisenatide-injection will be given subcutaneously"
11308858|NCT02640118|Placebo Comparator|Healthy + lixisenatide-placebo|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
~Before the meal a placebo-injection will be given subcutaneously"
11308859|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
11308860|NCT02640092|Experimental|[18F]GTP1|Participants will complete [18F]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each [18F]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of [18F]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]GTP1.
11308861|NCT02640079|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy aimed at reducing pain catastrophizing.
11308862|NCT02640066|Experimental|acupuncture|acupuncture treatment with Supportive care
11308863|NCT02640066|No Intervention|standard treatment|Supportive care measures only
11308864|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
11308865|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
11308866|NCT02640040|Experimental|combined surgery|combined surgery for enrolled patients with CPT(Congenital Pseudarthrosis of Tibia): sleeve resection of the pathological soft tissues, intramedullary rod fixation, packaged lilac bone autograft,and llizarov external fixation device installation.
11308867|NCT02640027|No Intervention|Treatment in the Clinic Only|Patients in Group A will receive their follow-up care entirely at the investigators institution
11308868|NCT02640027|Experimental|Treatment in the Clinic and at Home|Cast removal at home using a telemedicine tool
11308869|NCT02640014|Experimental|Study 1: Milk OIT follow up|Follow up on patient with severe milk allergy how have participated to milk OIT.
11308870|NCT02640014|No Intervention|Study 1: Follow up|Follow up on patient with severe milk allergy how have not participated to milk OIT.
11308871|NCT02639988||rheumatoid arthritis and type 2 diabetes|
11308872|NCT02639988||osteoarthritis and type 2 diabetes|
11308873|NCT02639975|Experimental|100 mg PBF-677|
11308874|NCT02639975|Experimental|200 mg PBF-677|
11308875|NCT02639975|Experimental|400 mg PBF-677|
11308881|NCT02639962||NSTEMI|patients hospitalized with NSTEMI diagnosed according to the national Danish guidelines, and are scheduled to coronary angiography.
11308882|NCT02639962||patients with stable angina pectoris|Patients in this group have stable angina symptoms and had verified plaques by earlier CAG or Cardiac CT
11308883|NCT02639949|Experimental|Group CBT|
11308884|NCT02639949|Active Comparator|Standard Care|
11308885|NCT02639936||Immunocompetent controls|Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
11308886|NCT02639936||Solid organ transplant recipients|Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
11308887|NCT02639936||Stem cell transplant recipients|Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
11308888|NCT02639936||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
11308889|NCT02639936||Patients with chronic renal failure|Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
11308890|NCT02639936||Individuals with HIV infection|Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
11308891|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
11308892|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
11308893|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
11308894|NCT02639910|Experimental|Cohort A|tafasitamab (MOR208) in combination with idelalisib
11308895|NCT02639910|Experimental|Cohort B|tafasitamab (MOR208) in combination with venetoclax
11308896|NCT02639884|Experimental|Evaluation Group|All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring
11308897|NCT02639871||healthy volunteers|31P-MR Spectroscopy and CEST for Validation of MRI/MRS methods
11308898|NCT02639871||HD presymptomatic individuals|General medical exam Clinical assessment with illness rating scales: Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS) and Total Functional Capacity (TFC), 31P-MR Spectroscopy and CEST
11308899|NCT02639871||early affected HD patients|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
11308900|NCT02639871||Controls|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
11308901|NCT02639858|Experimental|Docetaxel-PM|Docetaxel-PM 75mg/m2 IV infusion
11308902|NCT02639845||Patients Prescribed Eye Drops|Patients who are scheduled to receive prescription eye drops due to complications such as cataract surgery, glaucoma, retina surgery, or eye-related condition.
11308903|NCT02639819|Experimental|Treatment|Study drug
11308904|NCT02639806||Prospective - General Anesthetic|The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
11308905|NCT02639806||Retrospective - Local Anesthetic with Sedation|The retrospective group will have received local anesthetic from the surgeon using lidocaine injected subcutaneously and received sedation using fentanyl and midazolam as needed to achieve the desired level of sedation.
11308906|NCT02639793|Active Comparator|manual radiofrequency ablation|Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
11308907|NCT02639793|Active Comparator|magnet navigation ablation|Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
11308908|NCT02639793|Active Comparator|cryoablation|Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
11308909|NCT02639780||healthy young female|
11308910|NCT02639780||healthy young male|
11308911|NCT02639780||healthy older female|
11308912|NCT02639780||healthy older male|
11308913|NCT02639780||obese older female|
11308914|NCT02639780||obese older male|
11308915|NCT02639767|Experimental|pemetrexed/cisplatin with pleural IMRT|This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.
11308916|NCT02639754|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
11308917|NCT02639754|Active Comparator|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
11308918|NCT02639741|Active Comparator|Oral Melatonin Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of melatonin (6 mg) or placebo tablet will be given one hour before the start of anesthesia.
11308919|NCT02639741|Active Comparator|Oral Vitamin C Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of vitamin C (2 gr) or placebo tablet will be given one hour before the start of anesthesia.
11308920|NCT02639741|Placebo Comparator|Oral Placebo Tablet|Preoperative single oral dose of placebo tablet will be given one hour before the start of anesthesia.
11308944|NCT02639572|Experimental|Siloss® bone graft|Based on the sequence, in the test site,Siloss® was placed.
11308945|NCT02639572|Placebo Comparator|Hydroxyapatitie Bone graf|Based on the sequence, the control site which was treated by Hydroxyapatite graft only.
11308921|NCT02639728|Experimental|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
11308922|NCT02639728|Experimental|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
11308923|NCT02639728|Experimental|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
11308924|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
11308925|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
11308926|NCT02639689|Experimental|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.
~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
11308927|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
11308928|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
11308929|NCT02639663|Experimental|women whom are interested in breastfeeding and have not begun.|"Post-partum primi and multiparous women Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
~Control group: participants will not receive any device for breastfeeding pain control"
11308930|NCT02639663|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
11308931|NCT02639650|Active Comparator|control group|etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle
11308932|NCT02639650|Experimental|study group|paclitaxel + cisplatin or carboplatin，two weeks a cycle
11308933|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
11308934|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
11308935|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
11308936|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
11308937|NCT02639624|Experimental|Low bicarbonate dialysate First|Dialysis with low bicarbonate dialysate (expected normal for an adult ~24 mEq) for the first half of dialysis then switched over to normal bicarbonate dialysate for the second half.
11308938|NCT02639624|Active Comparator|Normal bicarbonate dialysate First|Dialysis with normal (37 mEq) for the first half of dialysis then switched over to low bicarbonate dialysate
11308939|NCT02639611|Active Comparator|Immediate Post Operative Acupuncture Treatment|
11308940|NCT02639611|Active Comparator|Acupuncture Treatment After 6 Weeks of Recovery|
11308941|NCT02639598|Experimental|flunarizine|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).
~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 5 mg/day flunarizine once daily in the first week, followed by 10 mg/day flunarizine in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
11308942|NCT02639598|Active Comparator|topiramate|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).
~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 25 mg/day topiramate once daily in the first week, followed by 50 mg/day topiramate in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
11308943|NCT02639585|Experimental|Treatment arm|Daclinza and Sunvepra
11364034|NCT02273505|Active Comparator|Combination of Persantin and ASA|
11308946|NCT02639559|Experimental|Arm 1: Donors|-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10^6 CD34+ cells/kg and at least ≥ 2 x 10^6 CD34+ cells/kg from the combined collections.
11308947|NCT02639559|Experimental|Arm 2: Recipients|-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0
11308948|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308949|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308950|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308951|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308952|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308953|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308954|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1.33 mg/kg)|Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308955|NCT02639546|Experimental|Phase II (Suspension) Cobimetinib (1 mg/kg)|Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
11308956|NCT02639533|Experimental|Pregabalin|Pregabalin 150 mg PO single dose
11308957|NCT02639533|Placebo Comparator|Placebo|Placebo (a pill of same physical characteristics as the one used for the experimental arm, containing starch) PO single dose
11308958|NCT02639520|Active Comparator|Group Canephron® N|Canephron® N & fosfomycin trometamol-placebo
11308959|NCT02639520|Active Comparator|Group Fosfomycin Trometamol|Canephron® N-placebo & fosfomycin trometamol
11308960|NCT02639494|Experimental|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
11308961|NCT02639481|Active Comparator|Control group standard physiotherapy|Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
11308962|NCT02639481|Active Comparator|Erigo®Pro group without FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
11308963|NCT02639481|Active Comparator|Erigo®Pro group with FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
11308964|NCT02639468|Experimental|Tomographie par impédance électrique|Tomographie par impédance électrique
11308965|NCT02639455|No Intervention|Athlete group|Participants wo regularly exercise and are student athletes.
11308966|NCT02639455|No Intervention|Non-exercise group|Participants who are not student athletes.
11308967|NCT02639455|Experimental|Exercise group|Participants are not student athletes but commit to modest exercise for 5 weeks as part of this study.
11308968|NCT02639442|Experimental|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
11308969|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
11308970|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
11308971|NCT02639416|Active Comparator|Standard management|Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days
11308972|NCT02639416|Experimental|Polymeric formula|Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
11308973|NCT02639416|Experimental|Elemental formula|Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
11308974|NCT02639403|Experimental|RT for Obstructing Rectal Cancer|Conformal three-dimensional RT was planned (3D-RT) in patients with obstructing rectal cancer not amenable for curative resection
11308975|NCT02639390|Experimental|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
11365521|NCT02264002|Experimental|Cilobradine high dose 1|
11308976|NCT02639390|Active Comparator|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
11308977|NCT02639377|Experimental|Chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
11308978|NCT02639377|Placebo Comparator|Placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
11308979|NCT02639364|Active Comparator|conventional ventilation strategy|The conventional ventilation strategy use volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, combination with low tidal volume and adequate PEEP level.
11308980|NCT02639364|Experimental|BILEVEL-APRV protocol|According to our BILEVEL-APRV protocol, BILEVEL-APRV APRV mode with specific settings,combination with spontaneous breathing.
11308981|NCT02639351|Experimental|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
11308982|NCT02639351|Experimental|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
11308983|NCT02639351|Experimental|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
11308984|NCT02639351|Experimental|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
11308985|NCT02639351|Active Comparator|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
11308986|NCT02639338|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
11308987|NCT02639338|Experimental|SOF/VEL|SOF/VEL tablet for 12 weeks
11308988|NCT02639325||Patients|Patients who have solitary primary or recurrent brain tumor with associated seizures.
11308989|NCT02639312||1|hemifacial microsomia
11308990|NCT02639312||2|mandibular prognathism
11308991|NCT02639299||Healthy Volunteers|healthy, malaria-naive US adults
11308992|NCT02639286|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC)
11308993|NCT02639286|Experimental|ISIS 304801|300 mg of study drug administered via SC
11308994|NCT02639273|Experimental|Drug|single dose nalmefene
11308995|NCT02639273|Placebo Comparator|Placebo|single dose placebo
11308996|NCT02639260|Experimental|Cohort A|3,000 mg/day
11308997|NCT02639260|Experimental|Cohort B|10000 mg/day
11308998|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
11308999|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11309000|NCT02639234|Experimental|Vigil™ + Nivolumab|Patients meeting study eligibility criteria will receive doublet therapy comprising of (i) Vigil™ 1 x 10^7 cells by intradermal injection every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and (ii) nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks.
11309001|NCT02639221|Experimental|PXT002331|
11309002|NCT02639221|Placebo Comparator|Placebo|
11309003|NCT02639208|Experimental|PatientsLikeMe (PLM)|"After the screening procedures confirm eligibility.
~Baseline Survey Assessment and PatientsLikeMe Introduction
~Treatment Evaluation on PLM website at predetermined times per protocol
~Final Survey"
11309004|NCT02639195||Treatment, retrospective|Retrospective analysis on patients treated with manual physical therapy in quality of life outcomes as measured by pre and post treatment questionnaires. Chart review.
11309005|NCT02639195||Untreated control|Prospective data collection via questionnaire of subjects with a history of small bowel obstruction in an observational manner. No treatment is performed.
11309006|NCT02639182|Experimental|AGS-16C3F|Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
11309007|NCT02639182|Active Comparator|Axitinib|Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
11309008|NCT02639169|Experimental|music|Apply live music through techniques music therapy in group experimental and evaluation through the visual analog scale (VAS) and numeric.
11309009|NCT02639169|No Intervention|Comparative|Apply the visual analog scale (VAS) and numeric.
11309010|NCT02639156|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day will be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days.
11309011|NCT02639143|Experimental|ticagrelor|Ticagrelor, 180 mg, oral administration. followed by 90 mg bid
11309012|NCT02639143|Active Comparator|Clopidogrel|Clopidogrel 600 mg loading dose taken orally, followed by 75 mg qd.
11309013|NCT02639130|Active Comparator|Vildagliptin|"After a screening examination, patients were treated with vildagliptin and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.
~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.
~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
11309014|NCT02639130|Placebo Comparator|Placebo|"After a screening examination, patients were treated with placebo, and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.
~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.
~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
11309015|NCT02639117|Other|Vismodegib|Vismodegib 150 mgs po qd. Open label.
11309054|NCT02638831|Experimental|Ketorolac Tromethamine|Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
11309016|NCT02639104|Experimental|Cervical postural related neck pain|Patients recruit in this group who has a neck pain without radiculopathy. If the patient examination shows neurologic deficits, this patient will exclude in this study. All patients will undergo lateral cervical spine spot radiography and serratus anterior needle electromyography. Cervical segmental angle measurements will be done in all patients.
11309017|NCT02639104|Sham Comparator|Control group|The healthy volunteers recruit in this group. All inviduals will undergo lateral cervical spot radiography and serratus anterior needle electromypography
11309018|NCT02639091|Experimental|BAY 94-9343 + Pemetrexed + Cisplatin|Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
11309019|NCT02639078|Experimental|TD-0714|One time dosing in capsule formulation
11309020|NCT02639078|Placebo Comparator|Placebo|Placebo comparator one time dosing in capsule formulation
11309021|NCT02639065|Experimental|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
11309022|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
11309023|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
11309024|NCT02639039|Active Comparator|Cortisone Injection|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
11309025|NCT02639039|Active Comparator|Trigger Point Dry Needling|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
11309026|NCT02639026|Experimental|Cohort 1|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 1 tests 8 Gy x 3 fractions
11309027|NCT02639026|Experimental|Cohort 2|Subjects will receive 20 mg/kg MEDI4736 and 1 mg/kg tremelimumab in combination every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses. The total duration of therapy is 12 months. Cohort 2 tests 17 Gy x 1 fraction.
11309028|NCT02639013|Experimental|ttransducer technique|the nurses will measure intraabdominal pressure at each shift during the day by using transducer technique
11309029|NCT02639000|Experimental|Blastocyst|Embryo transfer of at maximum 2 embryos at blastocyst stage
11309030|NCT02639000|Active Comparator|Cleavage|Embryo transfer of at maximum 2 embryos at cleavage stage
11309031|NCT02638987|Experimental|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
11309032|NCT02638987|No Intervention|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
11309033|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
11309034|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
11309035|NCT02638961|Placebo Comparator|Standard treatment|Only standard medical treatment
11309036|NCT02638961|Active Comparator|IMT group|Standard medical treatment associated to Inspiratory muscle training
11309037|NCT02638961|Active Comparator|FES group|Standard medical treatment associated to functional electrostimulation of both legs for 45 minutes a day, 2 days per week for a total of 12 weeks.
11309038|NCT02638961|Active Comparator|IMT+FES group|Standard medical treatment associated to combination of inspiratory muscle training and functional electrostimulation of both legs
11309039|NCT02638948|Placebo Comparator|Placebo|Placebo + Methotrexate dose as specified
11309040|NCT02638948|Experimental|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
11309041|NCT02638948|Experimental|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
11309042|NCT02638935|Other|BI-RADS 3|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
11309043|NCT02638935|Other|BI-RADS 4a|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
11309044|NCT02638935|Other|BI-RADS 4b|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
11309045|NCT02638935|Other|BI-RADS 4c|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
11309046|NCT02638922||no treatment|girls who never received estradiol treatment
11309047|NCT02638922||Estradiol treatment|girls who received estradiol treatment
11309048|NCT02638909|Experimental|ceritinib|Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
11309049|NCT02638896|Experimental|Dose reduction arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
11309050|NCT02638896|Active Comparator|Dose maintenance arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
11309051|NCT02638896|Other|Etanercept discontinuation arm|AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.
11309052|NCT02638857|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.
11309053|NCT02638857|Experimental|DC-PMAT cells|After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.
11309126|NCT02638285|Experimental|LH group|LH group
11309127|NCT02638285|Experimental|clomiphene citrate|clomiphene citrate
11309055|NCT02638831|Active Comparator|Ketoprofen|Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
11309056|NCT02638818||minimally invasive whipple|Surgical technique (minimally invasive vs open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
11309057|NCT02638818||traditional whipple|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
11309058|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
11309059|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
11309060|NCT02638792|Experimental|Internet-based exposure therapy|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
11309061|NCT02638792|Active Comparator|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
11309062|NCT02638792|No Intervention|Waitlist|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, and 4, 12 months later using the same questionnaires as the treatment group. The participants will be able to choose which treatment they receive i.e. no randomization.
11309063|NCT02638779|Experimental|Blood sampling|Blood sampling will be performed in all patients and healthy volunteers
11309064|NCT02638766|Other|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
11309065|NCT02638753|Active Comparator|Education|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology.
11309066|NCT02638753|Experimental|Education combined with hypnosis|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology combined with hypnosis.
11309067|NCT02638740|Active Comparator|SCALING AND ROOT PLANING (SRP)|Scaling and root planning with ultrasonic scalar
11309068|NCT02638740|Experimental|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
11309069|NCT02638727|Active Comparator|Drug Arm|This group treat with L-Citrulline (3 grams per day)
11309070|NCT02638727|Placebo Comparator|Placebo Arm|this group treat with placebi every day
11309071|NCT02638714|Experimental|Stem Cells|Intervention: Transplantation of autologous purified stem cells
11309072|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
11309073|NCT02638688||2D ultrasound|2D-US measurements are the most accurate method for measuring fibroid volumes
11309074|NCT02638688||3D ultrasound|3D-US measurements are the most accurate method for measuring fibroid volumes
11309075|NCT02638688||postoperative|actual volume using change in water path measurements are the most accurate method for measuring fibroid volumes
11309076|NCT02638675|Experimental|Wellness program, accelerometer, incentives|During the intervention period (weeks 1 to 12), intervention participants will be eligible to earn daily reward points contingent on step count goal achievement. Intervention participants will earn 100 reward points (i.e. $1) for each day that specific step count goals are reached. During weeks 13 to 24, participants will no longer receive daily reward points for completing specific step count goals.
11309077|NCT02638675|Active Comparator|Wellness program and accelerometer|During the 24 week trial, control participants will receive no additional incentives when step count goals are reached.
11309078|NCT02638662||First time IVF patients. Observational|Those who are doing IVF for the first time.
11309079|NCT02638662||Donors Observational|Those who are doing IVF for the sole purpose of donating their eggs.
11309080|NCT02638662||2 or more IVF cycles Obervational|Those who have done IVF 2 or more times with no success.
11309081|NCT02638649||subjects who call 911 for dyspnea|All subjects who call 9-1-1 for difficulty breathing will have the potential to be enrolled in the study.
11309082|NCT02638636|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
11309083|NCT02638636|No Intervention|Waitlist|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment when the first group has finished (i.e. week 10).
11309084|NCT02638623|Active Comparator|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
11309085|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
11309086|NCT02638610|Experimental|Sensation measurement|patients with eyelid pathology going through eyelid surgery.
11309087|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
11309088|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
11309089|NCT02638584|Experimental|Ilaprazole|Ilaprazole tab 10mg, 2 tablets once daily for 8 weeks.
11309090|NCT02638584|Active Comparator|Rabeprazole|Rabeprazole tab 20mg, 1 tablet once daily for 8 weeks.
11309183|NCT02637921|Experimental|Hypoxic Bed rest|Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
11309091|NCT02638571|Sham Comparator|Usual education|Households in the control clusters (kebeles) will receive usual nutrition education from Health extension workers, about complementary foods, over 9 months.
11309092|NCT02638571|Experimental|Enhanced Education|Additional education sessions from Health extension workers (HEWs) trained on use of pulses for complementary foods (CF). HEWs provide nutrition education programs and counseling about pulse-cereal mix complementary foods, over 9 months.
11309093|NCT02638558|Experimental|written + oral explanation|patients will undergo both written and oral explanation for preparation with split dose
11309094|NCT02638558|Experimental|written explanation|patients will receive only a written explanation for preparation with split dose
11309095|NCT02638545|Experimental|dexmedetomidine|
11309096|NCT02638532|Other|Foot Fat Pad Grafting|All subject who enter into the study will undergo the fat pad grafting procedure to either the Heel or Forefoot based on the discretion of the PI, Co-investigator and the study subject.
11309097|NCT02638519|Other|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
11309098|NCT02638519|Other|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
11309099|NCT02638506|Experimental|Intranasal Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
11309100|NCT02638506|Placebo Comparator|Salinex|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
11309101|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
11309102|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
11309103|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
11309104|NCT02638480|No Intervention|Control|The control subjects will be treated with only the current SOC including NSAIDs and physical therapy.
11309105|NCT02638480|Experimental|Experimental|The experimental subjects will be treated with current SOC and will also use a kneeMD splint 3 times a day for 20 minutes per session
11309106|NCT02638467|Experimental|Bosutinib and Bone Marrow Transplant|Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI. Patients will be transplanted with the aim to transplant > 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow. Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
11309107|NCT02638454|Active Comparator|HL-YNG|"Healthy young sedentary males and females 20-30 yrs old
~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
11309108|NCT02638454|Experimental|FL-OLD|"Functionally-limited older sedentary males and females without sarcopenia (70-85 yrs old)
~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
11309109|NCT02638454|Experimental|SR-OLD|"Functionally-limited older sedentary males and females with clinically defined sarcopenia (70-85 yrs old)
~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
11309110|NCT02638428|Experimental|Refractory/relapsed solid tumor or AML|Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
11309111|NCT02638415|Experimental|HVPG group|HVPG-guided therapy
11309112|NCT02638415|Other|non-HVPG group|routine therapy
11309113|NCT02638402||Stage I, II, III, IV ovarian cancer|Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
11309114|NCT02638402||Stage I, II, III, IV endometrial cancer|Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital
11309115|NCT02638389|Experimental|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
11309116|NCT02638376|Active Comparator|KXL treatment only|
11309117|NCT02638376|Active Comparator|KXL and topography-guided PRK|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
11309118|NCT02638350|Experimental|Intervention lung ultrasound|All patients will have strategy with lung ultrasoundlung ultrasound
11309119|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
11309120|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
11309121|NCT02638324|Active Comparator|Renal nervous denervation.|Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
11309122|NCT02638324|Active Comparator|Renal nervous denervation (delayed)|Renal nervous denervation is performed after six months on the waiting list
11309123|NCT02638298|Experimental|NPWT dressing|
11309124|NCT02638298|Placebo Comparator|Standard dry gauze dressing|
11309125|NCT02638285|Experimental|HCG group|HCG group
11309128|NCT02638272|Other|spine surgery|The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.
11309129|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
11309130|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
11309131|NCT02638246|Experimental|Contingent|Participants in this group received incentives contingent on meeting pre-specified daily blood-glucose testing adherence goals.
11309132|NCT02638246|Active Comparator|Noncontingent|Participants in this group received incentives independent of meeting pre-specified daily blood glucose testing adherence goals.
11309133|NCT02638233|Other|Sofosbuvir 400mg/Ledipasvir 90 mg|Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC) for 8 weeks
11309134|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
11309135|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
11309136|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
11309137|NCT02638194|Active Comparator|Hookah Smoking Group|10 participants will smoke tobacco hookah for 2 hours
11309138|NCT02638194|Active Comparator|Hookah Secondhand Smoke Group|10 individuals will be exposed to secondhand hookah tobacco smoke for 2 hours
11309139|NCT02638181|Experimental|trabeculectomy|
11309140|NCT02638168|Active Comparator|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
11309141|NCT02638168|Placebo Comparator|Placebo|inert placebo ingredient
11309142|NCT02638155||Food Addiction Group|Those participants identified as having food addiction by the Yale Food Addiction Scale.
11309143|NCT02638155||No Food Addiction Group|Those participants with no identified food addiction
11309144|NCT02638142||Continuous Furosemide Infusion|continuous intravenous furosemide infusion
11309145|NCT02638142||Intermittent Furosemide Infusion|bolus intermittent intravenous furosemide infusion
11309146|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
11309147|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
11309148|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
11309149|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
11309150|NCT02638116|Experimental|Ibrutinib + Omeprazole|Participants will receive a dose of Ibrutinib 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7 and Omeprazole at a dose of 40 mg tablets orally once on Days 3 through 7.
11309151|NCT02638103|Experimental|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
11309184|NCT02637921|Active Comparator|Normoxic bed rest|Participants are on bed rest in normobaric normoxia with standardised nutritional intake
11309185|NCT02637908|Experimental|Mindfulness training|The mindfulness training (experimental condition) will receive 6-weeks of mindfulness training for parents provided in a group setting.
11309186|NCT02637908|No Intervention|Wait-list control|The wait-list control group will receive no intervention during the course of the study. The control group will be offered training following the completion of the study.
11309152|NCT02638103|Experimental|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
11309153|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
11309154|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
11309155|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.
~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
11309156|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.
~Level 1: Maximum Tolerated Dose (MTD)"
11309157|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.
~Level 1: Pembrolizumab 200 mg Q3 wks"
11309158|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.
~Level 1: MTD"
11309159|NCT02638077||Group 1|2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
11309160|NCT02638064|Experimental|Surgiflo injection|Injection of surgiflo in the pilonidal sinus cavity after curettage of its content
11309161|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
11309162|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
11309163|NCT02638038|Experimental|Oral INT 131 3 mg|Oral INT-131 Double blind study
11309164|NCT02638038|Experimental|Oral INT-131 1 mg|Oral INT-131 Double blind
11309165|NCT02638038|Placebo Comparator|Placebo|Oral placebo Double blind
11309166|NCT02638012|Experimental|HHT - Floseal|"Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.
~If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care)."
11309167|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
11309168|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
11309169|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
11309170|NCT02637986|Experimental|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
11309171|NCT02637986|Placebo Comparator|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
11309172|NCT02637986|Experimental|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
11309173|NCT02637986|Placebo Comparator|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
11309174|NCT02637973|Experimental|Empagliflozin|Empagliflozin, film-tablet, 25mg once daily
11309175|NCT02637973|Placebo Comparator|Placebo|Placebo, once daily
11309176|NCT02637960|Experimental|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
11309177|NCT02637960|Experimental|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
11309178|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
11309179|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
11309180|NCT02637934|Experimental|Biodistribution|The Biodistribution cohort will include up to 10 patients who will undergo a series of vertex to mid-thigh biodistribution [18F]FTT PET/CT scans over a period of approximately 4 hours.
11309181|NCT02637934|Experimental|Dynamic|The Dynamic cohort will include up to 20 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh scans imaging post injection of [18F]FTT.
11309182|NCT02637921|Active Comparator|Hypoxic ambulatory|Participants ambulatory in normobaric hypoxia with standardised nutritional intake
11309187|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
11309188|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
11309189|NCT02637882|Experimental|First intervention (ear plug)|"Other: ear plug
~Other Name: eastnova ear plug"
11309190|NCT02637882|Other|Second intervention (eye mask)|"Other: eye mask
~The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
~Other Name: Sleeping mask"
11309191|NCT02637882|Other|Ear plug and eye mask|The patients will receive the mixed intervention (eye mask) and (ear plug ) in the first night (N1) from 9 pm to 6 am.
11309192|NCT02637869||Control Group - non-intervention|Clinics that did not participate in the APM project
11309193|NCT02637869||Alternative Payment Model -intervention|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
11309194|NCT02637856|Experimental|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
11309195|NCT02637856|Experimental|Ocrelizumab (substudy)|Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
11309196|NCT02637843|Active Comparator|Slender arm|Uses the terumo slender sheath for radial angiography or angioplasty
11309197|NCT02637843|No Intervention|Standard arm|Uses the terumo standard sheath (Routine) for radial angiography or angioplasty
11309198|NCT02637830|Experimental|Fluoride varnish and fluoride toothpaste|Application of fluoride varnish (Duraphat) at the begining of the study. Application of fluoride toothpaste (Crest) twice a day for 3 days.
11309199|NCT02637830|Placebo Comparator|placebo toothpaste|Application of placebo toothpaste twice a day for 3 days
11309200|NCT02637830|Active Comparator|Fluoride toothpaste|Application of fluoride toothpaste (Crest) twice a day for 3 days
11309201|NCT02637817||Control Group|Neonates with no evidence of brain lesions on conventional MRI.
11309202|NCT02637817||Patients Group|Neonates with PWML diagnosed by conventional MRI.
11309203|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
11309204|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
11309205|NCT02637791|Experimental|Intervention|The virtual glove in their homes for a period of 8 weeks and advised to try to build up to using the system for a maximum of 20 minutes 3 times a day for 8 weeks.
11309206|NCT02637791|No Intervention|Control|Usual care
11309207|NCT02637778|Experimental|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
11309208|NCT02637778|Experimental|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
11309209|NCT02637765|No Intervention|Control Group|Usual Physical Activity
11309210|NCT02637765|Experimental|Intervention Group|8-week increased physical activity program
11309211|NCT02637752|Active Comparator|Lifestyle counseling|Intervention: Lifestyle counseling or nutrition/physical counselling
11309212|NCT02637752|No Intervention|No Intervention|To ensure that both groups benefited equally from the study, the control group received the counselling and the handouts at the end of the study.
11309213|NCT02637739|Experimental|Pregnancy of unknown location|pregnant women of at least 5 weeks by last menstrual period and transvaginal ultrasound did not revealed intra-uterine pregnancy or ectopic pregnancy Intervention: hysteroscope
11309214|NCT02637726|Experimental|TIVA0|Propofol : TIVA guided by clinical signs. Remifentanil
11309215|NCT02637726|Experimental|TIVA BIS|propofol : TIVA guided by EEG Monitoring. Remifentanil
11309216|NCT02637726|Experimental|TCI KBIS|Propofol : TCI Kataria guided by EEG Monitoring. Remifentanil.
11309217|NCT02637726|Experimental|TCI SBIS|Propofol : TCI Schnider guided by EEG Monitoring. Remifentanil.
11309218|NCT02637713|Experimental|Radiofrequency Energy to the Lower Esophageal Sphincter (LES)|All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.
11309219|NCT02637700|Experimental|Intravenous Immunoglobulin|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.
11309220|NCT02637700|Placebo Comparator|Placebo (Saline 0.9%)|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).
11309221|NCT02637687|Experimental|Pediatric patients_Dose 1|Pediatric cancer patients receiving BAY2757556 at an adult-equivalent dose of 50 mg twice daily (dose escalation cohort).
11309222|NCT02637687|Experimental|Pediatric patients_Dose 2|Pediatric cancer patients receiving BAY2757556 at an adult-equivalent dose of 75 mg twice daily (dose escalation cohort).
11309223|NCT02637687|Experimental|Pediatric patients_Dose 3|Pediatric cancer patients receiving BAY2757556 at an adult-equivalent dose of 100 mg twice daily (dose escalation cohort).
11309224|NCT02637687|Experimental|Pediatric patients_Dose 4|Pediatric cancer patients receiving BAY2757556 at an adult-equivalent dose of 150 mg twice daily (dose escalation cohort).
11309225|NCT02637687|Experimental|Pediatric patients_Dose 5|Pediatric cancer patients receiving BAY2757556 at dose of 100 mg/m2 twice daily (dose escalation cohort).
11309226|NCT02637687|Experimental|Pediatric patients_Dose 6|Pediatric cancer patients receiving BAY2757556 at dose of 150 mg/m2 twice daily (dose escalation cohort).
11309227|NCT02637687|Experimental|Pediatric patients_Dose 7|Pediatric cancer patients receiving BAY2757556 at dose of 200 mg/m2 twice daily (dose escalation cohort).
11309228|NCT02637687|Experimental|Pediatric patients_Recommended dose|Pediatric cancer patients receiving BAY2757556 at the recommended dose of 100 mg/m2 twice daily as determined in the dose escalation part (dose expansion cohort, Phase 1).
11309229|NCT02637687|Experimental|Pediatric patients_Fibrosarcoma|Pediatric patients with infantile fibrosarcoma (IFS) and documented ETV6 rearrangement or NTRK fusion receiving BAY2757556 at the recommended dose of 100 mg/m2 twice daily (efficacy cohort, Phase 2).
11309230|NCT02637687|Experimental|Pediatric patients_Extracranial|Pediatric patients with other extra-cranial solid tumors and documented ETV6 rearrangement or NTRK fusion receiving BAY2757556 at the recommended dose of 100 mg/m2 twice daily (efficacy cohort, Phase 2).
11309231|NCT02637687|Experimental|Pediatric patients_CNS tumors|Pediatric patients with primary central nervous system (CNS) tumors and documented ETV6 rearrangement or NTRK fusion receiving BAY2757556 at the recommended dose of 100 mg/m2 twice daily (efficacy cohort, Phase 2).
11309232|NCT02637674|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF
11309233|NCT02637661||Initial AMI|To study the sensitivity, specificity, positive predictive value, and negative predictive value of different earlobe crease as risk factors of AMI
11309234|NCT02637661||No coronary heart disease|To study the characteristics of earlobe crease
11309235|NCT02637648|Experimental|Sodium oxbate|oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
11309236|NCT02637648|Placebo Comparator|Placebo|oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
11309237|NCT02637635|Experimental|Breast reconstruction with implant|The patients will undergo breast reconstruction with an expander prosthesis.
11309238|NCT02637635|Experimental|Autologous fat transplantation|The patients will undergo lipofilling as a pre-treatment before they will undergo breast reconstruction with an expander prosthesis.
11309239|NCT02637622||Best-Worst Scaling (Case 2)|Preference elicitation survey using a best-worst scaling method.
11309240|NCT02637622||Discrete Choice Experiment|Preference elicitation survey using a discrete choice experiment method.
11309241|NCT02637609||Likert Scale|Priority elicitation survey using a Likert scale method.
11309242|NCT02637609||Best-Worst Scaling (Case 1)|Priority elicitation survey using a best-worst scaling method.
11309243|NCT02637596|Experimental|RFA group|Twenty-fourth consecutive patients with histologically proved pancreatic cancer [stage IIb (n=4), III (n=15), IV (n=5) ]underwent intraoperative RFA of primary tumor.
11309244|NCT02637583|Active Comparator|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
11309245|NCT02637583|Experimental|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
11309246|NCT02637583|Active Comparator|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
11309247|NCT02637570|Experimental|Hibiscus tea|420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day
11309248|NCT02637570|Experimental|green tea|450 mg green tea 2 hour after dinner with 1 glass of cool water every day
11309249|NCT02637570|Placebo Comparator|control group|450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day
11309250|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
11309251|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
11309252|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
11309253|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
11309254|NCT02637544|Active Comparator|Verum|"Acupuncture therapy.
~For this study arm following acupuncture points suitable for facial pain, according to traditional chinese medicine, were chosen:
~F2, F3, F34, IT3, IT19, S7, T21 and temporomandibular joint ear acupuncture points. Only intervention is the acupuncture therapy."
11309255|NCT02637544|Placebo Comparator|Placebo|Placebo acupuncture therapy. For this study arm points outside of the meridians according to traditional chinese medicine, were chosen. Only intervention is the acupuncture therapy.
11309256|NCT02637531|Experimental|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
11309257|NCT02637531|Experimental|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309258|NCT02637531|Experimental|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
11309259|NCT02637531|Experimental|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309260|NCT02637531|Experimental|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309261|NCT02637531|Experimental|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309262|NCT02637531|Experimental|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309263|NCT02637531|Experimental|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309264|NCT02637531|Experimental|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309328|NCT02637154|Active Comparator|Motivational Interviewing|With 30 patients Motivational Interviewing method will be used during each visit
11309265|NCT02637531|Experimental|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309266|NCT02637531|Experimental|Part H: High-circulating MDSCs: IPI-549 and nivolumab|Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
11309267|NCT02637518||Hospital Universitario de Getafe|"Assessment of frailty tools in elderly people
~The Geriatric Department attends patients:
~1800/year - acute unit. 800/year - Orthogeriatrics and Interconsultation Unit. 300/year - Day Hospital. 4000/year - Outpatient office. 1200/year - Domiciliary Care."
11309268|NCT02637518||Diabetes Frail Ltd.|Assessment of frailty tools in elderly people Has significant experience in managing research studies in older people.
11309269|NCT02637518||Università Cattólica del Sacro Cuore|"Assessment of frailty tools in elderly people
~The Geriatric Unit is compounded by:
~24 beds of Acute Care Ward 46 beds of Intensive Rehabilitation Unit 20 beds of Day Hospital Outpatient clinic"
11309270|NCT02637518||Gérontopole de Toulouse|"Assessment of frailty tools in elderly people
~The Geriatric Unit is compounded by:
~5 Acute Care Units - 100 beds. 3 Rehabilitation Unit - 75 beds. Long term care Unit - 140 beds. 2 Day Hospitals Outpatient Clinic"
11309271|NCT02637518||Jagiellonian University Medical College|Assessment of frailty tools in elderly people The Department of Internal Medicine and Gerontology is the largest centre in Poland limited to the Geriatric market.
11309272|NCT02637505|Active Comparator|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
11309273|NCT02637505|Sham Comparator|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
11309274|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
11309275|NCT02637479|Experimental|Pituitary radiosurgery group|Subjects will receive a pituitary radiosurgery by GammaKnife® during a brief hospitalization associated with standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
11309276|NCT02637479|Active Comparator|Control group|Subject will receive standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
11309277|NCT02637466|Experimental|Vortioxetine|In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
11309278|NCT02637466|Placebo Comparator|Placebo|"In cycle I of the study, 80 eligible depressed women with breast cancer will be randomized into an 8-week, double-blind, placebo-controlled, flexible-dose vortioxetine (10-20 mg) treatment arm versus placebo arm.
~Responders to placebo treatment will complete their study participation at the end of Cycle I, and will not proceed to Cycle II."
11309279|NCT02637453|Experimental|CPVI|Only circumferential pulmonary vein isolation(CPVI) was performed for these patients.
11309280|NCT02637453|Experimental|CPVI+ALA|Besides circumferential pulmonary vein isolation(CPVI), additional linear ablation(ALA) perpendicular to the pulmonary vein ostium was performed for these patients, ie. CPVI+ALA.
11309281|NCT02637440|No Intervention|Conservative|After the index primary PCI. The control group will receive best medical therapy and regular follow up and only PCI for recurrent angina with evidence of inducible ischaemia.
11309282|NCT02637440|Active Comparator|FFR guided|FFR group will undergo FFR at 4 weeks of the index primary PCI as OPD. If FFR is less than 0.8, then PCI will be performed
11309283|NCT02637440|Active Comparator|angiogram guided|The group will undergo PCI for all significant lesions more than 50
11309284|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
11309285|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
11309286|NCT02637414|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
11309287|NCT02637414|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
11309288|NCT02637401||Therapy group|Dialectical behaviour therapy: a psychological therpay involving 16 group sessions plus approximately 5 individual meetings over 4 months.
11309289|NCT02637388|Placebo Comparator|Placebo Comparator: Control Breakfast|Breakfast cereal and yoghurt only (placebo, negative control)
11309290|NCT02637388|Experimental|Experimental: beta-Glucan Breakfast|Breakfast cereal and yoghurt with the addition of 4g beta-glucan (14.7g Oatwell28 powder)
11309291|NCT02637375|Experimental|Therapy|Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.
11309292|NCT02637362|Active Comparator|Ankle + Sham metatarsal|Ankle block + sham metatarsal block
11309293|NCT02637362|Active Comparator|Ankle + Metatarsal|Ankle block + metatarsal block
11309294|NCT02637362|Active Comparator|Metatarsal + sham ankle|Metatarsal block + sham ankle block
11309295|NCT02637349|Experimental|POST SCP|Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
11309296|NCT02637349|Active Comparator|POST TAU|Patient receives treatment as usual (TAU) after active treatment ends.
11309297|NCT02637336|Experimental|Acupuncture|acupuncture session were inserted, and maintained for 20 minutes in paragraph 6 of the channel the pericardium (Neiguan).
11309298|NCT02637336|Experimental|Aerobic Exercise|The aerobic exercise session was conducted through 20 minutes.
11309299|NCT02637336|Experimental|Aromatherapy|Eucalyptus essential oil was inhaled by volunteers for 20 minutes
11309300|NCT02637336|No Intervention|Control|In the control session the volunteers remained seated at rest for 20 minutes without performing therapy.
11309301|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
11309302|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
11309303|NCT02637310|Experimental|N02RS1 1200mg|Combination of Broussonetia spp and Lonicera spp
11309304|NCT02637310|Placebo Comparator|Placebo|sugar pill
11309305|NCT02637297|Experimental|Group I (immediate intervention group)|Participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
11309306|NCT02637297|Active Comparator|Group II (wait-list control group)|At week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
11309307|NCT02637284|Experimental|Intervention 1a (cohort 1)|Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin (12 subjects)
11309308|NCT02637284|Experimental|Intervention 1a (cohort 2)|Single dose of 3 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
11309309|NCT02637284|Experimental|Intervention 1a (cohort 3)|Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
11309310|NCT02637284|Placebo Comparator|Control group 1a (cohort 1)|Single dose of 1 oral tablet of PCO-03 as placebo (2 subjects)
11309311|NCT02637284|Placebo Comparator|Control group 1a (cohort 2)|Single dose of 3 oral tablets of PCO-03 as placebo (2 subjects)
11309312|NCT02637284|Placebo Comparator|Control group 1 a (cohort 3)|Single dose of 6 oral tablets of PCO-03 as placebo by mouth (2 subjects)
11309313|NCT02637284|Experimental|Intervention 1b|Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks (36 subjects)
11309314|NCT02637284|Placebo Comparator|Control group 1b|Multiple dose regime of 3 oral tablets of PCO-03 as placebo every 8 hours during 2 weeks (6 subjects)
11309315|NCT02637271|Experimental|Total Meal Replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
11309316|NCT02637271|Active Comparator|Typical Diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
11309317|NCT02637245||Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema. There will be no intervention in this cohort, only observation of standard of care.
11309318|NCT02637232||Mirvaso® / Onreltea TM|
11309319|NCT02637206|Experimental|Part 1 (Single Application)|All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).
11309320|NCT02637206|Experimental|Part 2 (Repeat Application)|All subjects will have repeat applications of GSK2894512 0.5%, 1% cream and placebo twice a day for 7 days on both side (left and right, 3 in total) of their upper back (approximately 5 centimeter (cm) in diameter >10 cm away from another application area) under non-occlusive conditions and covered with gauze using adhesive. GSK2894512 0.5% and 1% cream and placebo will be randomized according to the randomization code in the same manner as Part 1.
11309321|NCT02637193|Experimental|Venlafaxine|Maximum dose of 450 mg/day (225 mg BID given at approximately 12 hours apart) Venlafaxine, dose titrated from a starting single dose (QD) of 75 mg venlafaxine in the morning of Days 1 and 2, followed by BID escalating doses administered on Days 3 through 10, followed by 450 mg/day (BID) on Days 11 through 13, and on Day 14 only the morning dose of 225 mg will be administered, then 3 days (Days 15, 16 and 17) of down titration
11309322|NCT02637193|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
11309323|NCT02637193|Placebo Comparator|Drug -- placebo|Placebo administered on Days 1 through 13 and on Days 15 to 17
11309324|NCT02637180||patients with low-energy fracture(s)|"The study will include patients from pre-defined groups of individuals (postmenopausal, perimenopausal, male, and steroid induced osteoporosis) who would be anyway eligible to receive treatment for their condition according to standard medical practice and Greek treatment guidelines.
~Drug: anti-osteoporotic medication (bisphosphonates, denosumab, strontium ranelate, teriparatide, SERMs)"
11309325|NCT02637167|Active Comparator|Rifaximin|Rifaximin: one tablet (550 mg) morning and evening for three months
11309326|NCT02637167|Active Comparator|Saccharomyces boulardii|S. boulardii: two capsules (500 mg) morning and evening for three months
11309327|NCT02637167|No Intervention|Control group|The third group receives no intervention
11309639|NCT02634970|Experimental|Ranibizumab at 0.5 mg|Single arm, intravitreal injection
11309329|NCT02637154|Active Comparator|Standard Education|With 30 patients Standard Education material will be used during each visit
11309330|NCT02637141|Experimental|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
11309331|NCT02637141|Experimental|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
11309332|NCT02637141|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
11309333|NCT02637128|Experimental|artemether-lumefantrine (AL)|"20mg artemether/120 mg lumefantrine per tablet, Coartem-D™; Novartis, Basel, Switzerland administered following manufacturer's prescribed weight-based dosing, twice daily for 3 days.
~5-14 kg: 1 tablet; 15-24: 2 tablets; 25-34 kg: 3 tablets; >34 kg: 4 tablets per dose"
11309334|NCT02637128|Experimental|artesunate-amodiaquine (ASAQ)|25mg artesunate/67.5 mg amodiaquine or 50 mg artesunate/135mg amodiaquine per tablet, Coarsucam™; Sanofi-Aventis, Paris, France administered following manufacturer's prescribed weight-based dosing, once daily for 3 days 4.5-8.9 kg: 1 25mg/67.5 mg tablet; 9-17.9 kg: 1 50mg/135 mg tablet; 18-35.9 kg 2 50mg/135 tablets; >36 kg: 4 50mg/135mg tablets per dose
11309335|NCT02637115|Placebo Comparator|Placebo|Placebo corresponds to a solution of Phosphate buffer saline (PBS) and glycerol, that is the carrier used in the 3 other groups receiving the bacteria (active arms)
11309336|NCT02637115|Experimental|Live Akk 9|Live Akkermansia muciniphila (Akk) at the dose of 10exp9 live bacteria (one billion of live bacteria) per day
11309337|NCT02637115|Experimental|Live Akk 10|Live Akkermansia muciniphila (Akk) at the dose of 10exp10 live bacteria (ten billion of live bacteria) per day
11309338|NCT02637115|Experimental|Killed Akk|This group corresponds to Akkermansia muciniphila that have been heat-killed. The initial quantity of bacteria before the heating procedure was of 10exp10 bacteria.
11309339|NCT02637102||Patients undergoing cardiac or vascular surgery|
11309340|NCT02637089||PD-non-MCI|Patients with Parkinson's disease, no mild cognitive impairment
11309341|NCT02637089||PD-MCI|Patients with Parkinson's disease with mild cognitive impairment
11309342|NCT02637089||MCI (non-PD-MCI)|Patients with mild cognitive impairment, no Parkinson's disease
11309343|NCT02637089||HC (non-PD-non-MCI)|Healthy Controls (age-matched to patients)
11309344|NCT02637076|Experimental|narcolepsy with cataplexy|patients given single dose of Xyrem
11309345|NCT02637076|Experimental|health controls|healthy controls given a single dose of Xyrem
11309346|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
11309347|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
11309348|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
11309349|NCT02637050||CTEPH Patients|Patients with confirmed diagnosis of CTEPH
11309350|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
11309351|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
11309352|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
11309353|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
11309354|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
11309355|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
11309356|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
11309357|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
11309358|NCT02637024|Experimental|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
11309359|NCT02637024|Experimental|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
11309360|NCT02636998||Normal weight|BMI <85th percentile
11309361|NCT02636998||Obese|BMI > 95th percentile
11309362|NCT02636972||Group 1|Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.
11309363|NCT02636972||Group 2A|History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
11309364|NCT02636972||Group 2B|History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
11309365|NCT02636972||Group 3|Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.
11309366|NCT02636972||Group 4|Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).
11309367|NCT02636972||Group 5|Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use
11309368|NCT02636972||Group 6|Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).
11309391|NCT02636803|Experimental|oxfendazole 6 mg/kg 3 times|patients receive 6 mg/kg oxfendazole three times
11309392|NCT02636803|Active Comparator|albendazole 400 mg|patients receive 400 mg albendazole once
11309369|NCT02636959|Active Comparator|high volume saline irrigation (HVSI)|High volume nasal spray, NeilMed® Sinus Rinse, is a high saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
11309370|NCT02636959|Active Comparator|low volume saline irrigation (LVSI)|Low volume nasal spray, Salinex Rinse, is a low saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
11309371|NCT02636946|Experimental|Bimatoprost Sustained-Release (SR)|"Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2).
~Contralateral Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2)."
11309372|NCT02636946|Active Comparator|Selective Laser Trabeculoplasty (SLT)|"Assigned Primary Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
~Contralateral Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2)."
11309373|NCT02636933||59 prematurely born children|Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
11309374|NCT02636933||93 full-term born children|Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
11309375|NCT02636920|Other|TEP-CASES|"25 Case Patients will follow the Therapeutic Education to the Patient (TEP).
~In addition the following procedures will be performed:
~Pediatric Asthma Quality of Life Questionnaire (PAQLQ);
~Children Asthma Control Test (C-ACT);
~Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);
~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
11309376|NCT02636920|No Intervention|TEP-CONTROLS|"25 Control Patients will follow the usual care program:
~The Pediatric Asthma Quality of Life Questionnaire (PAQLQ);
~The Children Asthma Control Test (C-ACT);
~the Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);
~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
11309377|NCT02636907|Experimental|BI 695501|
11309378|NCT02636894|Other|Restylane Silk|Restylane Silk
11309379|NCT02636881|Active Comparator|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
11309380|NCT02636881|Sham Comparator|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.
~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage [41-43].
~All the operating surgeons will receive proper training in the operative procedure before study start."
11309381|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
11309382|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
11309383|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
11309384|NCT02636842|Other|Location|Deltoid or Gluteal Muscle
11309385|NCT02636829|Experimental|Multiple Sclerosis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.
~Intervention: QALCIMUM questionnaire
~Intervention: Determination of calcium intake by a dietician interview"
11309386|NCT02636829|Experimental|Rheumatoid Arthritis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.
~Intervention: QALCIMUM questionnaire
~Intervention: Determination of calcium intake by a dietician interview"
11309387|NCT02636816|Experimental|Infusion|carbetocin is given slowly
11309388|NCT02636816|Active Comparator|Bolus|carbetocin is given quickly
11309389|NCT02636803|Experimental|oxfendazole 6 mg/kg|patients receive 6 mg/kg oxfendazole once
11309390|NCT02636803|Experimental|oxfendazole 30 mg/kg|patients receive 30 mg/kg oxfendazole once
11365522|NCT02264002|Experimental|Cilobradine high dose 2|
11309393|NCT02636790|Active Comparator|Surgery wait time (< 8 weeks)|Outcomes of patients with sinus surgery of less than 8 weeks.
11309394|NCT02636790|Active Comparator|Surgery wait time (> 1 year)|Outcomes of patients with sinus surgery of more than 1 year.
11309395|NCT02636764|Active Comparator|exercise group|An exercise protocol drawn up with the objective will be held to strengthen the musculature: flexor and extensor of the knee; extension, abduction, hip side rotator, using the weight and the elastic band.
11309396|NCT02636764|Placebo Comparator|exercise group + Ultrasound therapy|Apart from intervening in the exercise group, an ultrasound device is used .
11309397|NCT02636764|Experimental|exercise group + interferential current|Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
11309398|NCT02636764|Experimental|exercise group + short-wave diathermy|Besides the intervention of the exercise group after the exercises will be applied diathermies short wave in continuous mode. For that will be used apparatus, 27.12 megahertz, by means of vulcanized rubber electrodes (12x17 cm) with gentle warming for 30 minutes.
11309399|NCT02636764|Experimental|exercise group + Low level laser therapy|Apart from intervening in the exercise group, will be applied to Low level laser therapy, through the laser unit, Class 3b, gallium-aluminum-arsenide, continuous mode, wavelength: 830 nanometer, power: 30 watts.
11309400|NCT02636751|Experimental|In-person prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment. General information about pain control, such as ice application and medication usage will also be provided
11309401|NCT02636751|Experimental|Tele-prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
11309402|NCT02636751|Active Comparator|Usual care group|The participants in this group will be provided with the hospital's usual documentation before total joint arthroplasties, consisting of information regarding the pre- and post-surgery course and medication.
11309403|NCT02636738|Experimental|experiment|Vela XL thulium laser, laser fiber and accessories
11309404|NCT02636725|Experimental|Axitinib + Pembrolizumab|Concurrent Axitinib and Pembrolizumab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies.
11309405|NCT02636712||ImageReady™ MR Conditional Pacing System|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant
~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
11309406|NCT02636699|Experimental|Viaskin Peanut 250mcg|
11309407|NCT02636699|Placebo Comparator|Placebo|
11309408|NCT02636673||Robotic-assisted sigmoid resection|Patient that have undergone robotic-assisted sigmoid resection for benign or malignant disease between 2010 and 2015
11309409|NCT02636673||Laparoscopic sigmoid resection|Patient that have undergone laparoscopic sigmoid resection for benign or malignant disease between 2010 and 2015
11309410|NCT02636647|Active Comparator|FMT|Fecal transplant via enema once
11309411|NCT02636647|No Intervention|No treatment|No transplant performed
11309412|NCT02636634|Other|diagnostic imaging strategy|PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy
11309413|NCT02636621|Active Comparator|Brazilian Dental Appliance|The device increases the volume of the airway by mandibular traction.
11309414|NCT02636621|Placebo Comparator|Placebo|Oral device that does not change the volume of the airway
11309415|NCT02636608||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
11309416|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
11309417|NCT02636582|Experimental|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
11309418|NCT02636582|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
11309419|NCT02636569|Active Comparator|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
11309420|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
11309421|NCT02636556|Experimental|chemoradiation|concurrent chemoradiation.
11309422|NCT02636543||Group 2a-patient|75 patients who attended a genetic counselling consultation.
11309423|NCT02636543||Group 2a-public|75 persons belonging to general population.
11309424|NCT02636543||Group 2b-patient|75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).
11309425|NCT02636543||Group 2b-public|75 persons belonging to general population (those persons are different than patients from group 2a).
11309426|NCT02636543||Group 2b-professional|75 genetic professionals.
11309463|NCT02636296|Experimental|Pilates|Group received 12 week of inspired-Pilates intervention (2 days/week, 60 minutes duration).
11309427|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
11309428|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
11309429|NCT02636517|Other|C. Difficile without IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
11309430|NCT02636517|Other|C. Difficile with IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
11309431|NCT02636491|Experimental|investigational device|"MD-Logic-Automated Insulin Delivery System, Version 01.05.02
~The device is being used continuously over 60 hours for insulin therapy"
11309432|NCT02636491|Placebo Comparator|MiniMed Paradigm® Veo™ System|"sensor augmented insulin pump
~The device is being used continuously over 60 hours for insulin therapy"
11309433|NCT02636478||reference group|therapy naive patients with a sleep related breathing disorder
11309434|NCT02636478||therapy group|patients with devices treating their sleep related breathing disorder
11309435|NCT02636465||obese healthy adults|persons with BMI> 30 kg/m2
11309436|NCT02636465||obese COPD patients|COPD-patients (GOLD I-IV Group A-D) with BMI> 30 kg/m2
11309437|NCT02636465||OHS-patients|patients with defined OHS: BMI>30 kg/m2 and sleep related breathing disease, no COPD
11309438|NCT02636439|Active Comparator|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.
~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
11309439|NCT02636439|Active Comparator|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.
~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.
~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
11309440|NCT02636426|Experimental|sorafenib|In this phase I study patients are treated with high-dose, pulsatile sorafenib in escalating AUC0-12h cohorts.
11309441|NCT02636413|Experimental|LacTEST|0,45 g of gaxilose po, once, per diagnostic test performed.
11309442|NCT02636413|Active Comparator|Hydrogen Breath Test|25 to 50 g of lactose po, once, per diagnostic test performed.
11309443|NCT02636400|No Intervention|expectant|7 menstrual cycles of expectant management
11309444|NCT02636400|Experimental|postop IUI|4 IUI cycles within 7 menstrual cycles
11309445|NCT02636387||Desmopressin|0.2mg tablets, dose titrated to effect
11309446|NCT02636387||Placebo|Placebo Comparator
11309447|NCT02636374|Experimental|Guided Imagery|Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
11309448|NCT02636361|Experimental|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
11309449|NCT02636361|Experimental|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
11309450|NCT02636361|Experimental|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
11309451|NCT02636361|Experimental|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
11309452|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
11309453|NCT02636348|Experimental|Calcium/Vitamin D Bar|Dietary supplement consumed as 2 calcium and vitamin D fortified snack bars per day
11309454|NCT02636348|Experimental|Calcium/Vitamin D Pill|Dietary supplement consumed as several capsules per day
11309455|NCT02636348|Placebo Comparator|Placebo Bar|Placebo consumed as 2 isocaloric, unfortified snack bars per day
11309456|NCT02636348|Placebo Comparator|Placebo Pill|Placebo consumed as several capsules per day
11309457|NCT02636335|Experimental|Bright Light|"8 a.m. study participants will be exposed to Bright Light (4500 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.
~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
11309458|NCT02636335|Experimental|Control|"8 a.m. study participants will be exposed to a Control Light Condition (230 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.
~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
11309459|NCT02636322|Experimental|Arm I (RLI WITH EPOCH)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
11309460|NCT02636322|Experimental|Arm II (RLI WITH R-CHOP)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
11309461|NCT02636309|No Intervention|control group|control group only filled up the questionnaires. They didn't receive intervention
11309462|NCT02636309|Experimental|intervention group|physical therapy at work
11309464|NCT02636296|Other|Control|Control group was oriented to maintain the habitual activities during 12 weeks
11309465|NCT02636283|Active Comparator|Entresto|oral route
11309466|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
11309467|NCT02636270|Experimental|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
11309468|NCT02636257|Experimental|Recessive Spherical Headed Silicone Intubation|The silicone nasolacrimal intubation under nasal endoscopy can restore natural drainage pathway in tears and as an out-patient surgery, it is more simple,cheap and mini-invasive.Recessive Spherical Headed Silicone Intubation is safe,convenient and almost unpainful for no trauma.It has no facial scar and no damage for structure and function of lacrimal duct.Besides,silica gel is non-toxic and nonirritating.Nasal endoscopy handed by otorhinolaryngologist helps intraoperative visualization about anatomy of the nasal cavity,understanding and management of congenital nasolacrimal duct obstruction and is the only method that confirms the correct anatomic position of the catheterization and in real time,avoiding traditionally the blind raking-out wire by the ophthalmologist alone.Compare to the classic DCR,its short therapeutic effects are equal but more convenient and fewer time and money-cost.
11309469|NCT02636257|Other|Dacryocystorhinostomy|Nasolacrimal duct obstruction is common among patients with epiphora,which is seriously affect the quality of life. The treatment principle is to restore or rebuild the lacrimal duct drainage channel. The classic operation type is dacryocystorhinostomy(DCR), which is complex for face-section particularly.After surgery the lacrimal passage can't siphon the tear out physically any more so that it will effect the patients' life.Besides,the operating time,bleeding volume,hospitalization time and total cost for the surgery is higher.
11309470|NCT02636244|Experimental|SHAPE Gel|1% SHAPE Gel applied twice daily for 12 weeks.
11309471|NCT02636231|Active Comparator|IMRT and concurrent Endostar|"IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
~IMRT is to give GTV 60Gy in 27 fractions."
11309472|NCT02636231|Experimental|IMRT alone|IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.
11309473|NCT02636218|Active Comparator|0.9% NaCl control|Normal saline
11309474|NCT02636218|Experimental|Ketamine|Anesthetic
11309475|NCT02636205|Experimental|Armeo|Group receiving Armeo therapy
11309476|NCT02636192||Cohort 1|Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).
11309477|NCT02636192||Cohort 2|Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).
11309478|NCT02636179||448 children|Children aged 11-15 years from a historical cohort born after In Vitro Fertilization or Intracytoplasmic Sperm Injection at Hospital Saint Joseph of Marseille
11309479|NCT02636179||1344 children|Children aged 11-15 years born spontaneously schooling in the same geographic area as case
11309480|NCT02636166|Other|Pregnancy test|"Clearblue investigational Pregnancy test
~Clearblue Marketed pregnancy test
~Professional pregnancy test"
11309481|NCT02636153|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
11309482|NCT02636153|Experimental|Restricted Phosphorus Diet|Diet containing 500mg of phosphorus per day
11309483|NCT02636140|Experimental|Light|Randomized amount and color of light
11309484|NCT02636127|Experimental|Systemic Sclerosis (SSc) patient|15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
11309485|NCT02636127|Other|healthy patient|15 healthy patients will be recruited and blood samples will be obtained
11309486|NCT02636114|Active Comparator|scaling and root planing|this was an international study in which scaling and root planing was done in systemically healthy patients patients with chronic periodontitis
11309487|NCT02636114|No Intervention|control group|Scaling and planing was not done that no intervention is carried out in this group
11309488|NCT02636088|Experimental|Cetuximab|Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
11309489|NCT02636075||Upper 1/3 of thyroid tissue|
11309490|NCT02636075||Middle 1/3 of thyroid tissue|
11309491|NCT02636075||Lower 1/3 of thyroid tissue|
11309492|NCT02636075||Below thyroid tissue|
11309493|NCT02636062||Follow-up CAC > 0|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.
11309494|NCT02636062||Follow-up CAC zero|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.
11309495|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
11309496|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
11309497|NCT02636036|Experimental|enadenotucirev and nivolumab|
11309498|NCT02636023|Experimental|SPhENo-Cardiograph / ECG|SPhENo-Cardiograph and ECG
11309499|NCT02636010|Experimental|MK-3475 Pembrolizumab|MK-3475 at a dose of 200 mg every three weeks for 1 year with a potential expansion of 1 additional year of treatment in case of clinical benefit and patient agreement
11309500|NCT02635997||patients on antiresorptive therapy|Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day
11309564|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
11309565|NCT02635529|Active Comparator|OFD + DFDBA|Intrabony defects treatment was carried out with OFD + DFDBA
11309501|NCT02635984|Placebo Comparator|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
11309502|NCT02635984|Active Comparator|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
11309503|NCT02635971|Experimental|TAI chemotherapy|Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
11309504|NCT02635971|Active Comparator|Chemotherapy|Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
11309505|NCT02635958||Group 1|BMI 18.5 to 24.9
11309506|NCT02635958||Group 2|BMI 25 to 29.9
11309507|NCT02635958||Group 3|BMI 30 to 34.9
11309508|NCT02635958||Group 4|BMI ≥ 35
11309509|NCT02635945|Experimental|PBF-680 10 mg|2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
11309510|NCT02635945|Placebo Comparator|Placebo|2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
11309511|NCT02635932|Experimental|Functional Splint group|Patient will be using the functional splint during their activity daily life
11309512|NCT02635932|Active Comparator|Night Splint group|Patients will use the night splint during the sleep time
11309513|NCT02635919|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
11309514|NCT02635919|No Intervention|Control|Smokers in this group will not be given the mSMART application.
11309515|NCT02635906|Experimental|2 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for two hours
11309516|NCT02635906|Active Comparator|4 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for four hours
11309517|NCT02635893|Active Comparator|D-Cycloserine/Placebo + Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
11309518|NCT02635893|Active Comparator|Training+Med/Placebo+Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
11309519|NCT02635893|Active Comparator|Training+Med+Stimulation/Placebo Stim|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.
11309520|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
11309521|NCT02635867|Active Comparator|Indirect pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal Resin-based dentin bonding agent
11309522|NCT02635867|Active Comparator|Direct pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal
11309523|NCT02635854|Experimental|Test group|The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.
11309524|NCT02635854|Other|Control group|The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.
11309525|NCT02635828|Experimental|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
11309526|NCT02635815||Group I|twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up. All underwent upper gastrointestinal endoscopy.
11309527|NCT02635815||Group II|thirty four patients without bleeding. All underwent upper gastrointestinal endoscopy.
11309528|NCT02635802|Experimental|Remifentanil|injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished.
11309529|NCT02635802|Experimental|Lidocaine|injection form concentration 10mg/ml loading dose 100-400mg local anesthesia
11309530|NCT02635802|Experimental|Remifentanil+Lidocaine|"injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished
~+ injection form concentration 10mg/ml loading dose 100-400mg local anesthesia"
11309531|NCT02635789|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
11309532|NCT02635789|Placebo Comparator|Placebo gel|Placebo gel is matched ingredient with NPC-12G gel
11309533|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided in pull-apart peanut protein capsules or sachets
11309534|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
11309535|NCT02635763|Other|PNBs1|Femoral nerve and the lateral cutaneous nerve block combined with general anesthesia
11309536|NCT02635763|Other|PNBs2|Lumbar plexus and sacral plexus nerve block combined with general anesthesia
11309537|NCT02635750|Experimental|BI 409306|
11309538|NCT02635750|Experimental|Donepezil low dose|
11309539|NCT02635750|Experimental|Donepezil high dose|
11309540|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
11309541|NCT02635724|Experimental|Peramivir|Single dose 600 mg IV injection
11309566|NCT02635529|Active Comparator|OFD+DFDBA+AM|Intrabony defects treatment was carried out with OFD + DFDBA+ AM
11309567|NCT02635516|Experimental|Treatment|Only one arm was used and this arm received Near-Infrared Phototherapy.
11310692|NCT02628249|Experimental|Base + NEAA|Base protein intake + non essential amino acids
11309542|NCT02635711|Experimental|Adapted Taekwondo training|An adapted TKD training regime which was developed by our research team [16] will be used in this study. This training programme is designed to train balance control, eye-hand coordination and facilitate skeletal development for children with DCD. The high-impact striking techniques (e.g., punching and blocking) incorporated in the programme may stimulate bone growth [15]. Subjects who are assigned to the TKD training group will attend a weekly 1-h session of TKD training that will be held at the University of Hong Kong for 12 weeks. All TKD training sessions will be conducted by a qualified World Taekwondo Federation black belt coach.
11309543|NCT02635711|Active Comparator|Control|Subjects who are assigned to the DCD-control group will receive no TKD training during the study period. Instead, they will participate in jogging exercise daily (one hour per day) for 12 weeks. Participants will be encouraged to jog to school or other places every day, as appropriate. Pedometers will be used to monitor their exercise level and enhance habitual physical activity. The pedometer count (steps per day) will be documented in a log book by the parents. Signed log books will be returned to our research personnel after the intervention period. In addition, children with DCD in this group will receive an adapted TKD training menu and 12 training/demonstration sessions immediately after the follow-up testing is completed.
11309544|NCT02635698|Experimental|Intervention group, Optifast|OPTIFAST, medically supervised weight-management program
11309545|NCT02635698|Active Comparator|Control group, Low-energy, low-fat|Food-based program, current standard of care for weight management
11309546|NCT02635685|Experimental|Intervention group|Intervention with Clinical Decision Support tool installed on units.
11309547|NCT02635685|No Intervention|Control group|Control group without intervention with Clinical Decision Support tool installed on units.
11309548|NCT02635672|Experimental|Dose escalation of BAY 1251152 / Arm 1|Investigating BAY 1251152 in a dose escalation cohort in patients with solid tumors and aggressive NHL
11309549|NCT02635659|Experimental|Encapsulated nutrients|The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
11309550|NCT02635659|Placebo Comparator|Placebo|The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
11309551|NCT02635646|Experimental|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
11309552|NCT02635646|Active Comparator|individual approach|individual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
11309553|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
11309554|NCT02635620||e-cigarette group|Probands are smokers who intend to start vaping for the first time. The probands are recruited in e-cigarette shops. It is aimed to include 60 persons who start vaping. A baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking/vaping behaviour and health status at the beginning and after 1, 2 and 3 months.
11309555|NCT02635620||smoking cessation group|Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
11309556|NCT02635607|Other|Fixed Protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
11309557|NCT02635607|Other|Flexible protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
11309558|NCT02635594|Experimental|Carnipure® tartrate|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
11309559|NCT02635594|Placebo Comparator|Placebo|1000mg cellulose + 475mg L-tartaric acid
11309560|NCT02635581|Experimental|DELTA TT|
11309561|NCT02635555|Experimental|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.
~Episodes of hypotension will be treated with these vasopressors ."
11309562|NCT02635555|Active Comparator|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.
~Episodes of hypotension will be treated with these vasopressors ."
11309563|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
11309568|NCT02635503|Experimental|transrectal specimen extraction|Laparoscopic colorectal resection with natural orifice specimen extraction will be performed for patients in this group.
11309569|NCT02635503|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
11309570|NCT02635490||prophylactic antibiotics|
11309571|NCT02635477|Experimental|Intervention Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with an actigraphy device that displays an adaptive personalized daily step count goal and audible alerts to increase physical activity
11309572|NCT02635477|Experimental|Control Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with a matching actigraphy device that has a blacked-out screen and does not display step count goals or provide audible alerts (functions in silent monitoring mode only)
11309573|NCT02635464|Experimental|hUC-MSCs+Injectable collagen scaffold+CABG|
11309574|NCT02635464|Active Comparator|hUC-MSCs+CABG|
11309575|NCT02635464|Active Comparator|CABG|
11309576|NCT02635451||study group|Study group included 20 pregnant women with PPROM and fulfilled the inclusion and exclusion criteria.
11309577|NCT02635451||control group|Control group also included 20 pregnant women without PPROM following every recorded case of PPROM and matched for gestational age.
11309578|NCT02635438|Experimental|Arm A|Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days
11309579|NCT02635438|Active Comparator|Arm B|Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days
11309580|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
11309581|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
11309582|NCT02635412|Placebo Comparator|Scheduled delivery at 34 weeks|Scheduled delivery at 34 weeks (range 33 weeks 5 days to 34 weeks 3 days)
11309583|NCT02635412|Active Comparator|Scheduled delivery at 36 weeks|Scheduled delivery at 36 weeks (range 35 weeks 5 days to 36 weeks 3 days)
11309584|NCT02635399|Placebo Comparator|conventional group|Conventional PPPD
11309585|NCT02635399|Experimental|DJ-pexy group|PPPD with additional DJ-pexy to anchor DJ to transverse colon
11309586|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
11309587|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
11309588|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
11309589|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
11309590|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TRP) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
11309591|NCT02635360|Experimental|Following chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
11309592|NCT02635360|Experimental|Concurrent to chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.
11309593|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
11309594|NCT02635334|Experimental|Montelukast 10 mg daily for 8 weeks|Study subjects will take montelukast 10 mg orally daily for 8 weeks
11309595|NCT02635334|Placebo Comparator|Placebo daily for 8 weeks|Study subjects will take placebo orally daily for 8 weeks
11309596|NCT02635321||Patients with LGMD 2T|Four patients over 18 years old with genetically verified LGMD 2T.
11309597|NCT02635308|Experimental|Experimental|"High-Intensity, Unilaterally-Biased Resistance training 3x/wk x 12wk MOVE"
11309598|NCT02635295|Experimental|Mobile cooperation|Nursing student - nurse teacher mobile cooperation during the clinical practicum.
11309599|NCT02635295|No Intervention|Standard cooperation|Nursing student - nurse teacher standard cooperation during the clinical practicum.
11309600|NCT02635282|Active Comparator|IN fentanyl and midazolam|group of patients who are randomized to receive intranasal fentanyl and midazolam
11309601|NCT02635282|Experimental|IN ketamine|group of patients who are randomized to receive intranasal ketamine
11309602|NCT02635269|Experimental|Sugar|The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
11309603|NCT02635256|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
11309604|NCT02635243|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
11309605|NCT02635243|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
11309606|NCT02635243|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
11309607|NCT02635230||Patients with chronic oral anticoagulation and P2Y12 inhibitor|Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
11309608|NCT02635217|Experimental|Group A1|EGD performed before the Colonoscopy with Carbon Dioxide insufflation.
11309609|NCT02635217|Experimental|Group A2|EGD performed before the Colonoscopy with room air insufflation.
11309610|NCT02635217|Experimental|Group B1|Colonoscopy performed before the EGD with Carbon Dioxide insufflation.
11309611|NCT02635217|Experimental|Group B2|Colonoscopy performed before the EGD with room air insufflation.
11309612|NCT02635204|Experimental|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
11309613|NCT02635204|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
11309614|NCT02635191|Experimental|Tailored Group|In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
11309615|NCT02635191|Active Comparator|Standard group|In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.
11309616|NCT02635178|Experimental|Active|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to the psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
11309617|NCT02635178|Placebo Comparator|Control|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
11309618|NCT02635165|Active Comparator|Surgical treatment with Stracos|The patient was placed in the lateral decubitus position. The procedure involved a curvilinear thoracic incision overlying the center of the fractured segments. The intercostal muscles were dissected off the rib on its superior aspect away from the fracture site, and the fracture was then reduced. The investigators then chose the most suitable Stracos, which is to be found in two available sizes, 6 or 9 claws, according to the length of the fracture. The clip chosen was molded according to the shape of the corresponding rib and the claws were crimped using special pliers on and around the fractured rib.The investigators treated only one rib out of two with Stracos, and as for displaced or comminuted fractures, the adjacent rib was wrapped using vicryl suture on the osteosynthesis rib.
11309619|NCT02635165|No Intervention|Medical treatment|
11309620|NCT02635152|Experimental|Interpretation Bias Modification (IBM)|"Treatment consists of eight brief sessions. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response."
11309621|NCT02635152|Active Comparator|Progressive Muscle Relaxation (PMR)|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
11309622|NCT02635139|Experimental|Breakfast Skipping|Effect of breakfast skipping on metabolism
11309623|NCT02635139|Experimental|Dinner Skipping|Effect of dinner skipping on metabolism
11309624|NCT02635113|Experimental|PD Shoe|40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.
11309625|NCT02635100|Experimental|MNT Algorithm|All participants will be monitored using an existing (FDA approved) CPAP machine that has been modified to be externally controlled by a computer with the MNT algorithm, for titration.
11309626|NCT02635087||high risk group|"the miRNA tool predict this group of patients as high risk"
11309627|NCT02635074|Experimental|Treatment (ibrutinib, idarubicin, cytarabine)|"INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.
~CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11309628|NCT02635061|Experimental|ACY-241 in combination with nivolumab|
11309629|NCT02635048|Other|Group 1|Patients in Group 1 undergo mini percutaneous nephrolithotomy
11309630|NCT02635048|Other|Group 2|Patients in Group 2 undergo percutaneous nephrolithotomy
11309631|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
11309632|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
11309633|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
11309634|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
11309635|NCT02635009|Active Comparator|Arm I (PCI using 3DCRT)|Patients undergo PCI using 3DCRT daily for 2 weeks.
11309636|NCT02635009|Experimental|Arm II (PCI with HA using IMRT)|Patients undergo PCI with HA using IMRT daily for 2 weeks.
11309637|NCT02634983|Experimental|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
11309638|NCT02634983|Placebo Comparator|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
11310765|NCT02627755|Active Comparator|Glide group|Device: Glidescope® use
11309640|NCT02634957|Experimental|3 day absolute voice rest|participants would begin initiation of voice/speaking 3 days post phonomicrosurgery for benign vocal fold lesions
11309641|NCT02634957|Experimental|7 day absolute voice rest|participants would begin initiation of voice/speaking 7 days post phonomicrosurgery for benign vocal fold lesions
11309642|NCT02634944|Experimental|mTBI|mTBI (concussed) participants will be administered the VOMS after concussive event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
11309643|NCT02634944|Sham Comparator|Healthy Control|Healthy controls will be administered the VOMS tool. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
11309644|NCT02634944|Experimental|BLAST mTBI|Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
11309645|NCT02634944|Experimental|BLUNT mTBI|Blunt mTBI (concussed) participants will be administered the VOMS after concussive blunt event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
11309646|NCT02634931|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
11309647|NCT02634918||Ultrasound|3 groups of hemophilia patients - Those with > 20 bleeds into a joint, those with < 2 bleeds into a joint and those with no bleeds into a joint will be enrolled into the study
11309648|NCT02634918||those with < 2 bleeds into a joint and|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
11309649|NCT02634918||those with no bleeds into a joint will be enrolled into the st|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
11309650|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
11309651|NCT02634905|No Intervention|Control|
11309652|NCT02634892|No Intervention|Standard of Care (SOC)|Patients receive usual or standard of care regarding management of early stage pressure ulcers
11309653|NCT02634892|Experimental|SOC plus PRO-TECT|Patients receive usual or standard of care plus the addition of PRO-TECT.
11309654|NCT02634879|No Intervention|Control|Control Group
11309655|NCT02634879|Active Comparator|Loss Aversion|Each physician in this arm will have access to funds prior to earning them.
11309656|NCT02634879|Active Comparator|Group Incentive|Each physician will receive 50% of their potential incentive based on group performance. Physicians will also receive information on the performance of physicians on key CI measures in their group.
11309657|NCT02634866||Group N|The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
11309658|NCT02634866||Group D|The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
11309659|NCT02634866||Group D_HF|The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
11309660|NCT02634853|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
11309661|NCT02634853|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
11309662|NCT02634840|Experimental|Surgical intervention|"Patients receiving our modified bilateral sagittal split osteotomy procedure during orthognathic surgery, intervention arm in prospective cohort study"
11309663|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11309664|NCT02634814|Experimental|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-perceived strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
11309665|NCT02634814|Sham Comparator|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
11309689|NCT02634658|Experimental|Medical ICU Subjects|All Medical ICU subjects that meet eligibility criteria and are enrolled in the study will receive muscle Ultrasounds, Nerve Conduction Studies and Electromyography (EMG).
11309666|NCT02634814|Active Comparator|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
11309667|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.
~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
11309668|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.
~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
11309669|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.
~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
11309670|NCT02634788|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
11309671|NCT02634788|Experimental|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
11309672|NCT02634788|Experimental|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
11309673|NCT02634788|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
11309674|NCT02634775|Experimental|CKD - no dialysis|Change in treatment strategy: Start on dialysis, transplantation
11309675|NCT02634775|Experimental|Patients on PD|Change in treatment strategy: Change of PD prescription, start on HD, transplantation
11309676|NCT02634775|Experimental|Patients on HD|Change in treatment strategy: Change of HD prescription, transplantation
11309677|NCT02634749|Experimental|Nordic diet|The participant in the Nordic diet group will experience three interventions: a) a systematic introduction of taste portions, b) Protein reduced complementary foods (milk cereal drinks, porridge and baby milk with reduced protein content), and c) homemade and industry manufactured main meals with a predominance of Nordic ingredients.
11309678|NCT02634749|No Intervention|Regular diet|The participants will be given the current advice on infant feeding issued by the Swedish National Food Agency. They will also be given regular, commercially available milk cereal drinks, porridge, baby milk and industry manufactured main meals. No advice or recipes on meals will be given apart from the current recommendations.
11309679|NCT02634736|Experimental|Exergame plus usual treatment|Exergame programme plus usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
11309680|NCT02634736|No Intervention|Usual treatment|No exergame programme, just usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
11309681|NCT02634723||Previously Untreated Patients (PUPs)|PUPs in China with Moderate to Severe Hemophilia A
11309682|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
11309683|NCT02634697|Experimental|3RP Intervention Group|"AF Patients will undergo the 3RP intervention which will comprise of the following:
~i. One-one-one session: each subject will spend an hour with a clinician to set specific goals for the intervention. They will also answer questionnaires.
~ii. ECG monitoring: Enrolled subjects may be monitored with an ECG at some point after the time of consent up to the day of the one-on-one session, and again after completing the 8 weeks.
~iii. Weeks 1 - 8: subjects will meet with the clinician/staff member as a group once a week for 1.5 hours each where they will be taught a variety of techniques to elicit the relaxation response as well as other cognitive skills.
~At the end of the 4th (mid-point) and 8th (last) weekly session, subjects will answer questionnaires.
~iv. 6 month follow up: 3 months after the final 3RP session to answer questionnaires.
~v. Subjects will be asked to keep track of their AF episodes during the course of the study."
11309684|NCT02634697|Active Comparator|3RP Waitlist Control Group|The Control Group will wait for 6 months (from the time the Intervention group starts the 3RP intervention) and then will undergo the same study procedures as the intervention group - except for the 6 month follow up.
11309685|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
11309686|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine
~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
11309687|NCT02634671|Other|22Q11|24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
11309688|NCT02634671|Other|SCHIZOPHRENIA|24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
11309723|NCT02634437|Experimental|Severe Renal Impairment|Ulipristal acetate, 10 mg, oral administration
11309690|NCT02634658|Experimental|Neuro ICU Subjects|All Neuro ICU subjects that meet eligibility criteria and are enrolled in the study will receive Nerve Conduction Studies and Electromyography (EMG).
11309691|NCT02634645||Patients with Barrett's Esophagus|Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).
11309692|NCT02634645||Patients with invasive esophageal cancer|Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.
11309693|NCT02634632|Experimental|Subjects with cancer|choose to write advance directives
11309694|NCT02634619|Active Comparator|Ventral Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
11309695|NCT02634619|Active Comparator|Dorsal Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
11309696|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
11309697|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
11309698|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
11309699|NCT02634593|No Intervention|Control|Control
11309700|NCT02634593|Active Comparator|Low glycemin load snacks|Low glycemic load snacks, consumed during specific times
11309701|NCT02634580|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
11309702|NCT02634580|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
11309703|NCT02634580|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
11309704|NCT02634580|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
11309705|NCT02634567|No Intervention|Treatment as Usual|This group will not any training with the Cogmed training program.
11309706|NCT02634567|Experimental|Training Group|This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
11309707|NCT02634541|Active Comparator|DMARD-naive|Sulfasalazine will be given as the initial therapy.
11309708|NCT02634541|Experimental|Post-sulfasalazine|Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.
11309709|NCT02634528|Experimental|Julphar Insulin N|Julphar Insulin N, human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
11309710|NCT02634528|Active Comparator|Huminsulin® Basal|Huminsulin® Basal, neutral protamine hagedorn (NPH), human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
11309711|NCT02634515|Experimental|Julphar Insulin R|Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
11309712|NCT02634515|Active Comparator|Huminsulin® Normal|Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
11309713|NCT02634502|Experimental|Treatment|Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
11309714|NCT02634489|Active Comparator|Tamsulosin HCl and Solifenacin Succinate|Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.
11309715|NCT02634489|Active Comparator|EC905 (tamsulosin HCI and solifenacin succinate)|Participants will receive a fixed combination tablet (3 dose strengths).
11309716|NCT02634476|Experimental|cognitive bias modification training|Participants complete four sessions of the alcohol approach/avoidance task.
11309717|NCT02634476|Sham Comparator|sham training|Participants complete four sessions of the sham approach/avoidance task.
11309718|NCT02634463|Other|Antipsychotic Immunoassay Development Participants|No study agent will be administered as a part of this study. Participants must be on Aripiprazole or Olanzapine, or Paliperidone or Risperidone, orally, daily or long-acting injectable versions, as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for use in the development of antipsychotic immunoassays. Participants may also be on long acting injectable versions of the medication.
11309719|NCT02634450|No Intervention|Control|Current practice of Early Infant Diagnosis in Mozambique: using conventional system of collecting blood on Dried Blood Spot and sending it to central laboratory for PCR processing and receiving result by SMS printer.
11309720|NCT02634450|Active Comparator|Intervention|Point Of Care Device (Alere q) is used for Early Infant Diagnosis, with the sample collected and processed in the consultation room with the device
11309721|NCT02634437|Experimental|Normal Renal Function|Ulipristal acetate, 10 mg, oral administration
11309722|NCT02634437|Experimental|Moderate Renal Impairment|Ulipristal acetate, 10 mg, oral administration
11309724|NCT02634424|Experimental|MyPKFiT|Personalized prophylaxis : Treatment is adjustment according to PK modeling
11309725|NCT02634411|Experimental|8 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 8 days.
11309726|NCT02634411|Sham Comparator|15 days of effective antibiotic treatment|Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against PA of 15 days.
11309727|NCT02634398||Treated subjects|All subjects recruited and treated wiht the Axium neurostimulator
11309728|NCT02634385|No Intervention|Small Renal Mass|Patient's with a small renal mass will be undergoing embolization prior to laparoscopic partial nephrectomy.
11309729|NCT02634372|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
11309730|NCT02634372|Active Comparator|Supportive therapy|Supportive therapy: 20 individual sessions 60 minutes each for 6 months.
11309731|NCT02634359|Other|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
11309732|NCT02634359|Other|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).
~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
11309733|NCT02634359|Other|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
11309734|NCT02634346|Experimental|ALKS 3831|Administered as a coated bilayer tablet
11309735|NCT02634346|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
11309736|NCT02634346|Placebo Comparator|Placebo|Administered as a coated bilayer tablet
11309737|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
11309738|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
11309739|NCT02634320|Other|Aripiprazole Lauroxil|Intramuscular (IM) injection
11309740|NCT02634307|Experimental|ALKS 8700|Oral capsules taken twice daily.
11309741|NCT02634294|Experimental|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
11309742|NCT02634281|Experimental|group A|Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
11309743|NCT02634281|Active Comparator|group B|group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
11309744|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
11309745|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
11309746|NCT02634255|Active Comparator|Rocuronium elective surgery|patients undergoing inguinal herniorrhaphy
11309747|NCT02634255|Experimental|Rocuronium emergency surgery|patients undergoing appendectomy
11309748|NCT02634242|Experimental|Si-Wu-Tang (SWT)|Subjects are recommended to drink 125 mL of SWT (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
11309749|NCT02634242|Placebo Comparator|placebo|Subjects are recommended to drink 125 mL of Placebo (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
11309750|NCT02634229||Diabetic family members|(i) probands negative for GCK/MODY2 , HNF1A/MODY3 genes and HNF4A/MODY1; (ii) dominant inheritance of diabetes (three consecutive affected generations, or two generations with at least 2 diabetic patients in a generation); (iii) Diagnosis of diabetes before age 40 years in at least 3 diabetic family members; (iv) negative testing for anti-GAD and IA2-antibodies; and (v) body mass index < 30 kg/m2 (to avoid inclusion of patients with insulin-resistant type 2 diabetes).
11309751|NCT02634229||Healthy relatives|Healthy subjects whose relationship is relevant for genetic analysis and necessary for the validation step (family cosegregation study)
11309752|NCT02634216|Experimental|Type 1 Diabetics using CGM|Type 1 diabetics using Continuous Glucose MonitoringCGM to take 500 mg daily of Capros supplement (250 mg twice a day) at lunch and dinner.
11309753|NCT02634203|Experimental|Balloon Pulmonary Angioplasty (BPA)|Non-operable patients with CTEPH allocated to BPA arm
11309754|NCT02634203|Active Comparator|Riociguat|Non-operable patients with CTEPH allocated to Riociguat arm
11309755|NCT02634190||Triple negative women|Women 30 years of age or older coming for routine cervical screening who tested triple negative at baseline with the interventions: Thinprep® LBC, HR HC2® HPV DNA and APTIMA® HPV Assay
11309756|NCT02634190||Women tested positive|Women who tested positive in any of the tests Thinprep® LBC, HR HC2® HPV DNA or APTIMA® HPV Assay will undergo colposcopy and be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a 5 year period on a yearly basis
11309757|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
11309758|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
11309759|NCT02634164|No Intervention|control|"Control Treatment with Oral Glucose Tolerance Test:
~Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken."
11309760|NCT02634164|Experimental|Leucine Supplement|Control Treatment with Oral Glucose Tolerance Test:
11309761|NCT02634164|Experimental|Isoleucine Supplement|Isoleucine Combined with Oral Glucose Tolerance Test:
11309762|NCT02634164|Experimental|Leucine and Isoleucine Supplement|Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:
11309763|NCT02634151|Placebo Comparator|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
11309764|NCT02634151|Experimental|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
11309765|NCT02634138|Experimental|Intervention|Revitive IX Neuromuscular Electrical Stimulation Device
11309766|NCT02634099|Other|hemoglobine monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
11309767|NCT02634086||Percutaneous coronary intervention|Patients with triple-vessel coronary artery disease underwent percutaneous coronary intervention.
11309768|NCT02634086||Coronary artery bypass graft|Patients with triple-vessel coronary artery disease underwent coronary artery bypass graft.
11309769|NCT02634086||Optimal medication therapy|Patients with triple-vessel coronary artery disease underwent optimal medication therapy only.
11309770|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
11309771|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
11309772|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
11309773|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
11309774|NCT02634060|Experimental|Home Based Fecal Calprotectin|"IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients.
~IBDoc® results will be forwarded to the patient and the health care professional."
11309775|NCT02634047|Active Comparator|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
11309776|NCT02634047|Experimental|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
11309777|NCT02634034|Experimental|NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)|
11309778|NCT02634034|Experimental|Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)|
11309779|NCT02634034|Experimental|Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)|
11309780|NCT02634021|Active Comparator|dexmedetomidine group|dexmedetomidine 1 mcg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
11309781|NCT02634021|Experimental|midazolam group|midazolam 0.1 mg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
11309782|NCT02634008|Experimental|Cohort 1|Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.
11309783|NCT02634008|Experimental|Cohort 2|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks
11309784|NCT02634008|Experimental|Cohort 3|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks
11309785|NCT02633995||preeclampsia|spinal anaesthesia will be given for cesarean section
11309786|NCT02633995||normotensive|spinal anaesthesia will be given for cesarean section
11309787|NCT02633969|Experimental|Indomethacin Capsules low dose|Indomethacin Capsules low dose twice daily for up to three days
11309788|NCT02633969|Experimental|Indomethacin Capsules high dose|Indomethacin Capsules high dose twice daily for up to three days
11309789|NCT02633956|Experimental|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
11309790|NCT02633956|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
11309791|NCT02633956|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
11309792|NCT02633956|Placebo Comparator|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
11309793|NCT02633943||Subjects with hemoglobinopathies|Subjects treated with ex vivo gene therapy product in a bluebird bio-sponsored clinical trial who agree to participate in this study
11309794|NCT02633930|Experimental|berberine quadruple therapy|Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.
11309795|NCT02633930|Active Comparator|clarithromycin quadruple therapy|Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
11309796|NCT02633917|Experimental|Motor control exercises|One group should perform motor control exercises
11309797|NCT02633917|Active Comparator|Standard exercises|the other group should perform standard physiotherapy exercises
11309798|NCT02633904|Active Comparator|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
11309799|NCT02633904|Experimental|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
11309800|NCT02633891|Experimental|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
11309801|NCT02633891|Active Comparator|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
11309802|NCT02633878|Experimental|CHM+MP|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
11309803|NCT02633878|Placebo Comparator|CHM Placebo+MP Placebo|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
11309804|NCT02633878|Experimental|CHM+MP Placebo|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
11309805|NCT02633878|Experimental|CHM Placebo+MP|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
11309806|NCT02633852|Experimental|Aflibercept (EYLEA) 2mg /0.05 ml|Aflibercept (EYLEA) 2mg /0.05 ml
11309807|NCT02633839|Experimental|Adults who smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.
~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
11309808|NCT02633839|Experimental|Adults who don't smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.
~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
11309809|NCT02633826||kidney transplant recipients|kidney transplant recipients of an allograft from a living donor, no intervention
11309810|NCT02633813|Experimental|Naftifine hydrochloride 2%|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
11309811|NCT02633813|Active Comparator|Naftin® 2% (Naftifine hydrochloride 2%)|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
11309812|NCT02633813|Placebo Comparator|Placebo vehicle cream.|A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
11309813|NCT02633800|Experimental|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
11309814|NCT02633800|Placebo Comparator|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
11309815|NCT02633787|Experimental|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
11309816|NCT02633774|Active Comparator|Rhythm control group|1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation 2. check the echo, brain perfusion CT and K-MOCA on baseline 3. confirm a thrombus through the TEE 4. Cardioversion after 1 month 5. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines) 6. If AF recur, RFCA 7. check the brain perfusion CT, K-MOCA after 3M and 12M
11309817|NCT02633774|Active Comparator|Rate control group|1. No AAD, just anticoagulation 2. HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin) 3. check the echo, brain perfusion CT and K-MOCA on baseline 4. check the brain perfusion CT and K-MOCA after 3M and 12M 5. Without the treatment about antiarrythmia and rhythm control, diffication of rate control, the subject will be drop out for study.
11309818|NCT02633761|Active Comparator|Group 1|200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours
11309819|NCT02633761|Placebo Comparator|Group 2|placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.
11309820|NCT02633748|Other|Intervention|The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
11309821|NCT02633748|No Intervention|Control|The twenty participants in the control arm will undergo the same pre assessment as the intervention arm, receive a presentation on breathing exercises, and undergo the same post and three-month follow-up assessments. The control arm will also be offered the same Mindfulness-Based Cancer Survivorship program given to the intervention arm following the three month follow-up.
11309822|NCT02633735|Experimental|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
11309823|NCT02633735|No Intervention|Usual Care|
11309824|NCT02633722|Experimental|TRF-b|Participants are instructed to eat between 8am-5pm
11309825|NCT02633722|Experimental|TRF-d|Participants are instructed to eat only between 12-9pm
11309826|NCT02633722|No Intervention|Baseline|No lifestyle instruction given
11309827|NCT02633709|Placebo Comparator|Part 1: Single Ascending Dose: Placebo|Participants will receive a single dose of matching placebo orally on Day 1 of Part 1.
11309828|NCT02633709|Experimental|Part 1: Single Ascending Dose: Risdiplam|Participants will receive a single ascending dose (SAD) of Risdiplam orally on Day 1 of Part 1.
11309906|NCT02633202|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone: Patients receive intensity modulated-radiotherapy (IMRT) alone
11365524|NCT02264002|Placebo Comparator|Placebo|
11309829|NCT02633709|Experimental|Part 2: Food Effect: Fasted-Fed|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fasted state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fed state on Day 1.
11309830|NCT02633709|Experimental|Part 2: Food Effect: Fed-Fasted|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fed state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fasted state on Day 1.
11309831|NCT02633709|Experimental|Part 3: Itraconazole Interaction|In Period 1 a single oral dose of Risdiplam will be administered. After a wash-out period in Period 2 participants will be administered oral doses of itraconazole twice daily from Day 1 to Day 8. On Day 4 participants will receive a single oral dose of Risdiplam in the fed state in combination with itraconazole.
11309832|NCT02633696|Active Comparator|Legalón Sil i.v 350 mg|8 healthy volunteers received 1 vial of 350 mg iv of sylibin lyophilisate for solution for infusion (legalon sil) in two hours (single dose).
11309833|NCT02633696|Experimental|Silybin-phosphatidylcholine oral 360 mg|8 healthy volunteers received 9 capsules of 40 mg of sylibin each one (360 mg in total) orally.
11309834|NCT02633683|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
11309835|NCT02633670|Experimental|Hemopatch|The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion.
11309836|NCT02633670|Active Comparator|Standard technique|Standard hemostatic agents (floseal, tisseal).
11309837|NCT02633657|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
11309838|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
11309839|NCT02633631||Women seeking family planning services|Women seeking family planning and gynecological services will be enrolled in our study.
11309840|NCT02633618|Experimental|Analgecine|3ml, 2 times per day, continuous infusion for two weeks.
11309841|NCT02633618|Active Comparator|Neurotropin|3ml, 2 times per day, continuous infusion for two weeks.
11309842|NCT02633605||First Sense Breast Exam|
11309843|NCT02633592|Active Comparator|HRARM|Patients and healthy volunteers are subjected to position change ( LLP to SP) during pressure measurements with HR-ARM.
11309844|NCT02633592|Active Comparator|MRI Defecography|Patients and healthy volunteers are subjected to position change during MRI Defecography
11309845|NCT02633579|Active Comparator|Erythromycin lactobionate|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
11309846|NCT02633579|Active Comparator|Erythromycin lactobionate with atropine|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
11309847|NCT02633579|Placebo Comparator|Atropine|"Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.
~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %"
11309848|NCT02633579|Placebo Comparator|Placebo|Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
11309849|NCT02633566|Active Comparator|Functional plantar orthoses|Functional plantar orthoses in polypropylene with Medial Heel Skive technique
11309850|NCT02633566|Placebo Comparator|Placebo plantar orthoses|Plantar orthoses made in Ethil Vinyl Acetate (22º Shore) without correction of the pronation
11309851|NCT02633553|Experimental|radiotherapy group|complete resection and adjuvant radiotherapy
11309852|NCT02633553|No Intervention|observation group|complete resection
11309853|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
11309854|NCT02633527|Placebo Comparator|Placebo|Subjects in this arm will be administered Placebo
11309855|NCT02633527|Experimental|SPN-812 ER Low Dose|Subjects in this arm will be administered low dose of SPN-812 ER
11309856|NCT02633527|Experimental|SPN-812 ER Low-Medium Dose|Subjects in this arm will be administered low-medium dose of SPN-812 ER
11309857|NCT02633527|Experimental|SPN-812 ER High-Medium Dose|Subjects in this arm will be administered high-medium dose of SPN-812 ER
11309858|NCT02633527|Experimental|SPN-812 ER High Dose|Subjects in this arm will be administered high dose of SPN-812 ER
11309859|NCT02633514|Experimental|Radiochemotherapy|adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
11309860|NCT02633514|Sham Comparator|radiotherapy|adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
11309861|NCT02633501|Experimental|Subset 1 Arm 1|One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
11309862|NCT02633501|Experimental|Subset 1 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
11309863|NCT02633501|Experimental|Subset 2 Arm 1|One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
11309864|NCT02633501|Experimental|Subset 2 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
11309865|NCT02633488|Placebo Comparator|Placebo|12 weeks of Placebo tablet 3 x daily
11309866|NCT02633488|Experimental|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
11309867|NCT02633475||CONTROL: women no miscarriage|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
11309907|NCT02633202|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
11309908|NCT02633189|Experimental|erlotinib and bevacizumab|
11309868|NCT02633475||CASE: patients with IRM|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
11309869|NCT02633462|Active Comparator|Test Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis and treated with scaling and root planing(SRP) along with Myo-inositol supplementation
11309870|NCT02633462|Active Comparator|Control Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis treated with Myo-inositol along with oral hygiene instructions.
11309871|NCT02633449|Experimental|cognitive behavioral therapy + tDCS|Group cognitive behavioral therapy combined with tDCS
11309872|NCT02633449|Active Comparator|cognitive behavioral therapy + sham-tDCS|Group cognitive behavioral therapy combined with sham-tDCS
11309873|NCT02633449|Placebo Comparator|cognitive behavioral therapy|Group cognitive behavioral therapy only
11309874|NCT02633436||cancer tissues|SLC1A5 expression of esophageal cancer tissues from patients
11309875|NCT02633436||paired adjacent tissues|SLC1A5 expression of paired adjacent esophageal tissues from patients
11309876|NCT02633423|Experimental|PEEP and CPAP|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
11309877|NCT02633423|Experimental|ZEEP and CPAP|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
11309878|NCT02633423|Experimental|PEEP and NO VM|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
11309879|NCT02633423|Placebo Comparator|ZEEP and NO VM|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
11309880|NCT02633410|Active Comparator|Transtibial|Transtibial technique used to create femoral tunnel
11309881|NCT02633410|Active Comparator|Anteromedial|Anteromedial technique used to create femoral tunnel
11309882|NCT02633397|Experimental|Riociguat|Treatment Arm
11309883|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
11309884|NCT02633384|Experimental|SMOFlipid|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion
11309885|NCT02633384|Other|Lipofundin|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion
11309886|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
11309887|NCT02633358|Experimental|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
11309888|NCT02633358|No Intervention|Control group|No therapeutic hypothermia for controlled data.
11309889|NCT02633345|Experimental|Probiotic|The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 * 109 CFU/tablet. The participants will take two tablets a day for four weeks.
11309890|NCT02633345|Placebo Comparator|Control|Placebo tablets. The participants will take two tablets a day for four weeks.
11309891|NCT02633319|Experimental|Parenting Training|Skilful Parenting: 12-week group-based parent intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages.
11309892|NCT02633319|Experimental|Agricultural Training|Agrics: Initial 3-month agricultural training intervention with ongoing support afterwards.
11309893|NCT02633319|Experimental|Parenting and Agricultural Training|Village farmer groups receiving both Skilful Parenting and Agrics interventions.
11309894|NCT02633319|No Intervention|Control|6-month wait-list control group
11309895|NCT02633306|Experimental|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
11309896|NCT02633293|Experimental|Inhaled Treprostinil|Open-label access
11309897|NCT02633280||COPD-Untreated (Group 1)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that did not receive COPD treatment in the last 6 months (beta 2 agonists, corticosteroids, anticholinergics).
11309898|NCT02633280||COPD-uncontrolled (Group 2)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that receive a COPD treatment (e.g. beta 2 agonists, corticosteroids, anticholinergics) but with a post-bronchodilator FEV1< 80% and an FEV1/FVC < 0.7 or with 1-2 exacerbation/year
11309899|NCT02633280||Control subjects (Group 3)|In this Group will be enrolled patients of both sex and older than 40 years; (2) will be free from lung disease as determined by a physician; (3) will have a normal spirometry (FEV1> 85% and FEV1/FVC > 0.7)
11309900|NCT02633267|Experimental|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
11309901|NCT02633267|Active Comparator|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
11309902|NCT02633254|Experimental|Single arm|Treatment group Magentic Resonance guided High Intensity Focused Ultrasound will be employed on uterine fibroids
11309903|NCT02633241|Other|Dexmedetomidine-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg and Propofol100mcg/kg/minute to accomplish an MRI examination.
11309904|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
11309905|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
11309909|NCT02633189|Active Comparator|erlotinib|
11309910|NCT02633176|Active Comparator|cisplatin and docetaxel|"Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles.
~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m^2 intravenously every week.
~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
11309911|NCT02633176|Experimental|cetuximab, cisplatin, and docetaxel|"Induction chemotherapy: Patients receive cetuximab 400mg/m^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles.
~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m^2 intravenously followed by cisplatin 30mg/m^2 intravenously every week.
~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
11309912|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
11309913|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
11309914|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
11309915|NCT02633150|Experimental|Polyphenol|red grapes polyphenol supplementation on metabolic parameters in obese insulinoresistant subjects
11309916|NCT02633150|Placebo Comparator|Placebo|Placebo supplementation on metabolic parameters in obese insulinoresistant subjects
11309917|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months
11309918|NCT02633124|Experimental|Edelvaiss Multiline NEO|The Edelvaiss Multiline NEO design allows to position the access to the infusion line outside of the incubator, without increasing the residual volume and this device has been validated by the manufacturer as part of CE marking for a period of 21 days.
11309919|NCT02633124|Other|Standard Infusion Set|The infusion set used for the standard group is the infusion set usually used.
11309920|NCT02633111||Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
11309921|NCT02633098|Experimental|Artesunate|Artesunate 200mg oral tablets once daily for 14 days.
11309922|NCT02633098|Placebo Comparator|Matching placebo|Matching placebo oral tablets once daily for 14 days.
11309923|NCT02633085||Fixed Bearing or Mobile Bearing UKA|
11309924|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
11309925|NCT02633046|Other|Acthar Gel|All participants receive open-label treatment with Acthar Gel (1 mL 3x/week) for 50 weeks, followed by a 2-week follow-up during which they taper off treatment (1 mL 2x/week) and an End of Study/Early Termination Visit 4 weeks after their last dose (within 56 weeks)
11309926|NCT02633020|Experimental|AMG 714|Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
11309927|NCT02633020|Placebo Comparator|Placebo|Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
11309928|NCT02633007|Experimental|CVT-301 then Placebo (AB)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
11309929|NCT02633007|Experimental|Placebo then CVT-301 (BA)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
11309930|NCT02632981|Active Comparator|chronic periodontitis patients|gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
11309931|NCT02632981|Placebo Comparator|periodontally healthy controls|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
11309932|NCT02632968|Active Comparator|Pinhole surgery with orthodontic buttons|Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
11309933|NCT02632968|Active Comparator|Pinhole surgery without buttons|Pinhole surgery without orthodontic buttons The selected participants were assigned in test and control. In the control group, after administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions till the recession defects were covered. No sutures or orthodontic buttons were used in the control site.
11309934|NCT02632955|Experimental|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
11309975|NCT02632721|Other|Arm 2 (Phase II)|Monotherapy treatment with decitabine (standard of care treatment)
11309935|NCT02632955|Sham Comparator|Regular Angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
11309936|NCT02632942|Experimental|HAQ Criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:
~60% or greater diameter of the main AVF
~50% diameter of AVF with at least one more av>40% in diameter.
~50% in diameter and divides into branches of same size.
~av likely to interfere with cannulation on physical examination.
~>30% in diameter and associated with stenosis at site of origin."
11309937|NCT02632942|Active Comparator|Current Recommendation|Obliteration of accessory vein which satisfy the current recommendations only defined as accessory vein with a diameter greater than 25% of the AVF diameter.
11309938|NCT02632929||Diabetic Foot Ulcers at Amputation Risk|Patients at high risk for limb amputation from a diabetic foot ulcer will be treated with comprehensive, interdisciplinary approach (usual care) in combination with early application of advanced therapy; dehydrated human amniotic membrane allografts (AMNIOEXCEL®, Derma Science, Princeton, New Jersey).
11309939|NCT02632916|Active Comparator|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg
11309940|NCT02632916|Experimental|Denosumab|Subcutaneous denosumab 1.0mg/kg
11309941|NCT02632903|Experimental|Intravenous Zoledronic Acid|Intravenous Zoledronic Acid 0.025mg/kg at baseline and 6 months
11309942|NCT02632890||Patients survey|Adult patients treated with abatacept for rheumatoid arthritis
11309943|NCT02632890||HCP survey|HCP with at least 1 patient taking abatacept
11309944|NCT02632890||Retrospective chart review study|Adult patients treated with abatacept for rheumatoid arthritis
11309945|NCT02632877|Experimental|Pirfenidone with MODD|"Active ingredients: Pirfenidone 8% with modified oxide diallyl disulfide (MODD) 0.016%.
~Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency and duration: topically applied every eight hours for 6 months."
11309946|NCT02632877|Active Comparator|Ketanserin|"Active ingredients: Ketanserin 2%. Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).
~Frequency and duration: topically applied every 12 hours for 6 months."
11309947|NCT02632864|Experimental|Proton arm|Proton beam therapy
11309948|NCT02632851||Ectoin inhalation solution|treatment according to instructions for use
11309949|NCT02632851||Pari NaCl inhalation solution (0.9%)|treatment according to instructions for use
11309950|NCT02632838|Experimental|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
11309951|NCT02632838|No Intervention|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
11309952|NCT02632825|Experimental|Nasal High Flow|NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen
11309953|NCT02632825|No Intervention|Control|Control is no NHF intervention
11309954|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
11309955|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
11309956|NCT02632799|Experimental|NHF small cannula|NHF 8 L/min (Airvo2) , Smaller cannula (neonatal, yellow)
11309957|NCT02632799|Experimental|NHF big cannula|NHF 8 L/min (Airvo2) , Bigger cannula (neonatal, purple)
11309958|NCT02632799|Experimental|Mask CPAP|CPAP 5cm H2O
11309959|NCT02632799|No Intervention|no intervention|control
11309960|NCT02632786|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
11309961|NCT02632786|Placebo Comparator|Placebo|Placebo
11309962|NCT02632773|Experimental|Parent Learning Style 1|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
11309963|NCT02632773|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
11309964|NCT02632773|Other|Learning Style 1 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
11309965|NCT02632773|Other|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
11309966|NCT02632760|Active Comparator|ferric carboxymaltose|ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
11309967|NCT02632760|Placebo Comparator|Placebo|Placebo intravenous infusion
11309968|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
11309969|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
11309970|NCT02632734|Experimental|CoreBone Cone device|Experimental: CoreBone Cone device After extraction intervention will include the placement of CoreBone Cone device derived from coral that its dimensions is 4-5mm width and 8-10mm height. One cone for each extraction socket.Its advantage is that it fits well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month. We predict that CoreBone Cones are more effective than particulate device.
11309971|NCT02632734|Experimental|CoreBone 500 device|After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
11309972|NCT02632721|Experimental|Dose Escalation Cohorts (Phase I)|Combination treatment of decitabine with escalating doses of BI 836858
11309973|NCT02632721|Experimental|Extension Cohorts (Phase I)|Combination treatment of decitabine with BI 836858 at MDT (Maximum Tolerated Dose)
11309974|NCT02632721|Experimental|Arm 1 (Phase II)|Combination treatment of decitabine with BI 836858 at R2PD (Recommended Phase II dose)
11309976|NCT02632708|Experimental|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]) may continue on maintenance therapy and receive daily treatment with AG-120.
11309977|NCT02632708|Experimental|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
11309978|NCT02632708|Experimental|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
11309979|NCT02632708|Experimental|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
11309980|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
11309981|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
11309982|NCT02632695|Experimental|FOOTFIT Plus|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports and allows regular communication with the wound care provider on progress.
11309983|NCT02632695|Experimental|FOOTFIT|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports. There is not regular communication with the wound care provider on progress.
11309984|NCT02632669|Experimental|Hemigland focal LDR brachytherapy|Hemigland focal LDR brachytherapy using permanent iodine 125 seed implantation
11309985|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
11309986|NCT02632643|Experimental|lifestyle counseling|
11309987|NCT02632630|Active Comparator|Amino Acids w/Electrolytes in Dextrose|Peripheral parenteral nutrition (PPN)
11309988|NCT02632630|Active Comparator|Ensure product|Calorie and protein dense oral nutritional supplement for patients with elevated nutritional needs.
11309989|NCT02632630|Active Comparator|Crystalloid solutions|Standard care intravenous maintenance fluids.
11309990|NCT02632630|Active Comparator|Oral nutritional supplementation|Nutrient-enhanced drink products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake.
11309991|NCT02632617||CTA Group|Participants in CTA group will primarily receive computed tomographic angiography examination before surgery. Those with positive findings in CTA (≥50% diameter stenosis in main coronary artery) or uncertain diagnosis caused by motion artifact or calcium artifact are required to undergo ICA, and coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis according to the ICA result. Participants with negative findings in CTA do not need further coronary artery evaluation, and CABG won't be performed during the surgery.
11309992|NCT02632617||ICA Group|Participants in ICA group will undergo ICA as guideline recommend before surgery, coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis
11310030|NCT02632461|Experimental|Podcast (+Bite Counter)|Participants in this group will receive podcasts twice weekly in conjunction with using a wearable wrist device called a Bite Counter. The Bite Counter tracks the number of bites/calories per bite. (Podcasts plus Bite Counter)
11309993|NCT02632604|Active Comparator|Bottom-up to top-down cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes
11309994|NCT02632604|Active Comparator|Top-down to bottom-up cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes
11309995|NCT02632604|Placebo Comparator|Computer games|Participants are given 40 hours of computer games commonly found on the internet and which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc).
11309996|NCT02632578||HIV-positive|
11309997|NCT02632578||HIV-negative|
11309998|NCT02632565|Active Comparator|intra-articular 0.5% lidocaine|intra-articular 7 mL 0.5% lidocaine injection for 3 times with one week intervals
11309999|NCT02632565|Active Comparator|intra-articular saline|intra-articular 7 mL saline injection for 3 times with one week intervals
11310000|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
11310001|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
11310002|NCT02632539|Active Comparator|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
11310003|NCT02632539|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
11310004|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
11310005|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
11310006|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
11310007|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
11310008|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
11310009|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
11310010|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
11310011|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
11310012|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
11310013|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
11310014|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
11310015|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
11310016|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
11310017|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
11310018|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
11310019|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
11310020|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
11310021|NCT02632513|Experimental|continuous ultrasonic irrigation|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
11310022|NCT02632513|No Intervention|Syringe irrigation|In the syringe irrigation group, irrigation was done using 27 gauge syringe.
11310023|NCT02632500|Experimental|30 compressions and 2 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 30 compressions and 2 seconds of pause protocol (30 chest compressions followed by 2 seconds of pause) on a manikin connected to the Personal Computer."
11310024|NCT02632500|Experimental|50 compressions and 5 seconds of pauses|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 50 compressions and 5 seconds of pause protocol (50 chest compressions followed by 5 seconds of pause) on a manikin connected to the Personal Computer."
11310025|NCT02632500|Experimental|100 compressions and 10 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 100 compressions and 10 seconds of pause protocol (100 chest compressions followed by 10 seconds of pause) on a manikin connected to the Personal Computer."
11310026|NCT02632500|Experimental|hands-only|"After the randomization the participant will be asked to perform 8 minutes of CPR following the hands-only protocol (continuous chest compressions without any pauses) on a manikin connected to the Personal Computer."
11310027|NCT02632487|Active Comparator|Exercise|This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.
11310028|NCT02632487|Experimental|Exercise + Non-Exercise Physical Activity (NEPA)|This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).
11310029|NCT02632474|Experimental|Low-dose|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
11310766|NCT02627755|Experimental|Glide+aScope group|Device: combined use of two airway devices Glidescope® + aScope®
11310031|NCT02632461|Active Comparator|Podcast (+Mobile App)|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile application to track their diet. (Podcasts plus Mobile Diet Application)
11310032|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
11310033|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
11310034|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
11310035|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
11310036|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
11310037|NCT02632448|Experimental|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
11310038|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
11310039|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
11310040|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
11310041|NCT02632435|Other|Peripherally inserted central catheter|PICC line will be inserted for the delivery and duration of chemotherapy.
11310042|NCT02632435|Other|portacath|PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.
11310043|NCT02632422|Experimental|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
11310044|NCT02632422|Sham Comparator|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
11310045|NCT02632422|Experimental|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
11310046|NCT02632422|Sham Comparator|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
11310047|NCT02632422|Other|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
11310048|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
11310049|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
11310050|NCT02632396|Experimental|Treatment (ixazomib, rituximab)|Beginning between 70-180 days after stem cell transplant, patients receive ixazomib PO on days 1, 8, and 15, and rituximab IV (or SC after first dose if deemed appropriate) on day 1 of courses 1, 3, 5, 7, and 9. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11310051|NCT02632383|Experimental|Test Group|"Intervention: Young with Diabetes - app The test group receives standard care and the mHealth app Young with Diabetes - app to support young people to self-manage their diabetes.
~The young people's parents are also invited to download the app. The diabetes team (doctors, nurses and dieticians) also have the app and uses the app in their consultations with the young people."
11310052|NCT02632383|No Intervention|Control Group|The control group receives standard care
11310053|NCT02632370||Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
11310054|NCT02632357|Experimental|AS group|Subjects with ULNTT asymmetry > 10°
11310055|NCT02632357|No Intervention|S group|Subjects with ULNTT symmetry
11310056|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
11310057|NCT02632331|Experimental|Fasted dosing preceding group|
11310058|NCT02632331|Experimental|Fed dosing preceding group|
11310059|NCT02632318|Experimental|Light|Dawn simulation for 30 minutes prior to habitual wake time
11310060|NCT02632318|No Intervention|No light|Darkness for 30 minutes prior to habitual wake time
11310061|NCT02632305|Experimental|Treatment|"Eligible patients will receive nab-paclitaxel in combination with gemcitabine + cisplatin at the recommended phase II dose based on the phase I study completed in metastatic pancreas cancer patients.
~The doses of study drugs will be as follows:
~nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days
~Cisplatin 25 mg/m2 day 1 and 8 every 21 days
~Gemcitabine 800 mg/m2 day 1 and 8 every 21 days
~Nab-paclitaxel will be administered first followed by cisplatin and then gemcitabine on day 1 and 8 of each treatment cycle. Cycles will be 3 weeks in length (21 days)."
11310062|NCT02632292|Experimental|Absorb GT1|Bioresorbable everolimus-eluting scaffolds
11310063|NCT02632292|Active Comparator|Promus|Everolimus-eluting stents
11310064|NCT02632279|Experimental|TRP depleted|TRP depleted protein drink
11310065|NCT02632279|Placebo Comparator|Placebo|Balanced protein drink (+1.21g of TRP)
11310066|NCT02632266|Active Comparator|Powder HMF|Once patient has reached 80ml/kg/day of enteral feedings, 1 pack of powder HMF will be added to 50 ml of human or donor breast milk, then increased to a maximum of 2 packs for 50 ml following the unit feeding advancement protocol and this will be continued up until 48 hours prior to discharge.
11310067|NCT02632266|Active Comparator|Liquid HMF|Once patient has reached 80ml/kg/day of enteral feedings, researchers will add 1 packet (5 ml) of liquid HMF to 50 ml of human or donor breast milk, then increase to 2 packs to 50 ml following the unit feeding protocol and this will be continued up until 48 hours prior to discharge.
11310103|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
11310068|NCT02632253|Active Comparator|Moderate intensity continuous exercise|"Patients perform two weekly supervised MICE session on a cycling ergometer per week plus one self monitored 30-60 min MICE training of choice at home.
~MICE is performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down)."
11310069|NCT02632253|Experimental|High intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min.
~Additionally patients perform one self monitored 30-60 min MICE training of choice per week at home."
11310070|NCT02632240|Active Comparator|Control group|Surgery:The tunnel technique for covering gingival recession. Graft: connective tissue.
11310071|NCT02632240|Active Comparator|Study group|Surgery:The tunnel technique for covering gingival recession.Graft: xenogenic collagen matrix (Mucoderm).
11310072|NCT02632227||Hypovolemia|patients with hypovolemic signs including hypotension, decreased central venous pressure (less than 5mmHg), and decreased urine output
11310073|NCT02632214|Experimental|Deaf|Group of early profound deaf participants fMRI measure
11310074|NCT02632214|Experimental|Hearing signers|Group of hearing signer controls fMRI measure
11310075|NCT02632214|Sham Comparator|Hearing non signers|Group of hearing non signer controls fMRI measure
11310076|NCT02632201|Experimental|PIK-HER2 cells|PIK-HER2 cells treatment will be performed every 3 weeks with a total of three periods.
11310077|NCT02632201|Active Comparator|DC-PMAT|DC-PMAT treatment will be performed every 3 weeks with a total of three periods.
11310078|NCT02632188|Active Comparator|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
11310079|NCT02632188|Experimental|DC-PMAT treatment|On the basis of postoperative routine treatment, patients will receive 3 cycles of dendritic cell-precision multiple antigen T (DC-PMAT) cells treatment.
11310080|NCT02632175|Experimental|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
11310081|NCT02632162||cardiac surgery|active Group screening
11310082|NCT02632162||orthopedic surgery|control Group screening
11310083|NCT02632149|Experimental|Vagus nerve Stimulation is on|
11310084|NCT02632136|Active Comparator|TAP block group|"This group will receive 30 ml of 0.25% Bupivacine given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine.
~They will also receive normal saline injections at port sites, which will be injected before the ports are inserted. 15 ml of normal saline will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports."
11310085|NCT02632136|Placebo Comparator|Peri-Portal block Group|"They will receive 0.5% Bupivacaine injections at port sites, which will be injected before the ports are inserted. 15 ml of 0.5% Bupivacaine will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports.
~This group will also receive 30 ml of Normal Saline Injection given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine."
11310086|NCT02632123||Idiopathic pulmonary fibrosis|Patients newly diagnosed with idiopathic pulmonary fibrosis
11310087|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
11310088|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
11310089|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
11310090|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
11310091|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
11310092|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
11310093|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
11310094|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
11310095|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
11310096|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
11310097|NCT02632097|Experimental|Histoacryl|Intervention: Lichtenstein Hernioplasty with Histoacryl™(cyanoacrylate glue 0.5 ml) for mesh fixation (Optilene™ mesh 60 g/m2 (B. Braun))
11310098|NCT02632097|Experimental|Suture|Intervention: Lichtenstein Hernioplasty with Sutures (polypropylene 2/0) to fix the Optilene™ mesh 60 g/m2 (B. Braun)
11310099|NCT02632071|Active Comparator|80 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
11310100|NCT02632071|Active Comparator|120 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
11310101|NCT02632071|Active Comparator|180 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
11310102|NCT02632071|Active Comparator|240 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
11310104|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
11310105|NCT02632032|Other|Insulin therapy and diabetes education|Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.
11310106|NCT02632019|Active Comparator|gemcitabine|Gemcitabine treatments will be performed once a week with a total of six times
11310107|NCT02632019|Experimental|Dendritic cell-precision T cell for neo-antigen|Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.
11310108|NCT02632006|Experimental|PIK-PD-1 cells|PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.
11310109|NCT02632006|Active Comparator|DC-PMAT|DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.
11310110|NCT02631980|Experimental|IV iron|Postoperative iv iron administration (Ferinject) upon arrival in after surgery recovery room
11310111|NCT02631980|Placebo Comparator|IV placebo|Postoperative iv placebo administration upon arrival in after surgery recovery room
11310112|NCT02631967|Experimental|Kono anastomosis|Patients receiving Kono anastomosis
11310113|NCT02631967|Experimental|Stapled side-to-side anastomosis|Patients receiving stapled side-to-side anastomosis
11310114|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
11310115|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
11310116|NCT02631941|Experimental|Z7200|single dose (two inhalations)
11310117|NCT02631941|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
11310118|NCT02631941|Experimental|Z7200 with charcoal|single dose (two inhalations)
11310119|NCT02631941|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
11310120|NCT02631941|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
11310121|NCT02631928|Experimental|Julphar Insulin 30/70|human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
11310122|NCT02631928|Active Comparator|Huminsulin® Profil III|human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
11310123|NCT02631902|Experimental|Exercise|Community-based exercise program
11310124|NCT02631902|Experimental|Exercise plus dietary intervention|Community-based exercise and dietary intervention program
11310125|NCT02631902|No Intervention|Control|Habitual physical activity and habitual dietary pattern
11310126|NCT02631889|Experimental|Transcollation technology|the use of transcollation technology for hilium dissection during Lung surgery
11310127|NCT02631889|Active Comparator|Traditional Electrocautery|The use of electrocautery for hilium dissection during lung surgery
11310128|NCT02631876|Experimental|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee [BIRC]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
11310129|NCT02631876|Experimental|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
11310130|NCT02631863|Experimental|ALA|Patients will receive 3 topical treatments of aminolaevulinic acid 500mg
11310131|NCT02631863|Placebo Comparator|Placebo|Patients will receive 3 topical treatments of placebo 500mg
11310132|NCT02631850|Active Comparator|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
11310133|NCT02631850|Active Comparator|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
11310134|NCT02631850|Active Comparator|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 4 hours video conference consultation throughout the treatment period.
11310173|NCT02631577|Experimental|Atezolizumab-G-lena 20mg|Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
11310174|NCT02631551|Experimental|GSP 301 NS|
11310135|NCT02631850|Active Comparator|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on ADLs with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of stretching exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
11310136|NCT02631837|Experimental|vNOTES hysterectomy|vaginal Natural Orifice Transluminal Endoscopic Surgery
11310137|NCT02631837|Active Comparator|LSC hysterectomy|Laparoscopic hysterectomy
11310138|NCT02631824|Active Comparator|Standard treatment|open reduction and internal fixation TFNA
11310139|NCT02631824|Experimental|Augmentation|open reduction and internal fixation TFNA Augmentation (Cement)
11310140|NCT02631811|Experimental|Supportive /palliative care intervention|patients will be supported by a multidisciplinary palliative specialist team
11310141|NCT02631811|No Intervention|usual medical follow up|patients will be supported by the support care team if asked by the oncologist
11310142|NCT02631798|Experimental|Dye staining|Food grade dye mucosal staining
11310143|NCT02631785|Experimental|Anxious group|Youth diagnosed with anxiety disorder will receive Cognitive Behavioral Therapy for reducing anxiety symptoms.
11310144|NCT02631785|No Intervention|Control group|Healthy youth will be recruited for comparison but their participant in the study will not include intervention.
11310145|NCT02631772|Experimental|Late Cohort, Arm 1|Ledispasvir (LDV) and Sofosbuvir (SOF) monotherapy x 12 weeks
11310146|NCT02631772|Active Comparator|Late Cohort, Arm 2|Ledispasvir (LDV) and Sofosbuvir (SOF) +ribavirin x 12 weeks
11310147|NCT02631759|Experimental|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
11310148|NCT02631759|Placebo Comparator|Placebo|52 patients will be recruited over 2 years in the control group
11310149|NCT02631746|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
11310150|NCT02631733|Experimental|Treatment (liposomal irinotecan, veliparib)|Patients receive liposomal irinotecan IV over 90 minutes on days 1 and 15 and veliparib PO BID on days 5-12 and 19-25 or 3-12 and 17-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Within 2-6 days prior to beginning liposomal irinotecan treatment, patients may optionally receive FMX IV and undergo MRI at baseline and 24 hours after FMX infusion.
11310151|NCT02631720||Adult Lung Transplant Recipients|Adult lung transplant recipients undergoing lung transplant at each of the participating centers.
11310152|NCT02631707|No Intervention|Control Standard Protein Diet|Control Arm Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%).
11310153|NCT02631707|Experimental|Intervention High Protein Diet|Intervention Arm Percentage energy from carbohydrate (40%), protein (30%) and fat (30%).
11310154|NCT02631694|Experimental|Fear reactivation with propranolol|
11310155|NCT02631694|Placebo Comparator|Fear reactivation with placebo|
11310156|NCT02631694|Placebo Comparator|No fear reactivation with propranolol|
11310157|NCT02631681|Experimental|Men with prostate cancer on androgen deprivation therapy|Group based supervised combined aerobic and resistance training for 12 weeks.
11310158|NCT02631668|Experimental|ferrous succinate and vitamin C|In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
11310159|NCT02631668|Active Comparator|ferrous succinate with normal dosage|In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
11310160|NCT02631668|Active Comparator|ferrous succinate with double dosage|In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
11310161|NCT02631655|Other|device 18FDOPA|impact of device 18F-FDOPA PET on treatment decisions
11310162|NCT02631642|Experimental|HMPL-689|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
11310163|NCT02631642|Placebo Comparator|HMPL-689 placebo|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
11310164|NCT02631629|Placebo Comparator|Non-fortified foods SA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of South Asian (SA) origin
11310165|NCT02631629|Placebo Comparator|Non-fortified foods CA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of Caucasian (CA) origin
11310166|NCT02631629|Active Comparator|Vitamin D fortified foods SA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of South Asian (SA) origin
11310167|NCT02631629|Active Comparator|Vitamin D fortified foods CA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of Caucasian (CA) origin
11310168|NCT02631616|Experimental|Treatment arm|Monthly injections of Somatostatin (Sandoatatin LAR - 30mg)
11310169|NCT02631603|Experimental|Placebo|Capsules of placebo will be taken for 3 months.
11310170|NCT02631603|Active Comparator|Prednisolone|"Oral prednisolone, anticipated dose:
~first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.
~Individual capsules will be prepared using rounded dose."
11310171|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
11310172|NCT02631577|Experimental|Atezolizumab-G-lena 15mg|Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
11310175|NCT02631551|Active Comparator|Olopatadine HCl NS|
11310178|NCT02631538|Placebo Comparator|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
11310179|NCT02631538|Experimental|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
11310180|NCT02631538|Experimental|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
11310181|NCT02631538|Active Comparator|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
11310182|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
11310183|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
11310184|NCT02631512|Other|Woulgan Gel|Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)
11310185|NCT02631512|Other|Intrasite Hydrogel|Primary dressing with Intrasite Hydrogel
11310186|NCT02631499|Experimental|Adjuvant TACE|TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.
11310187|NCT02631499|No Intervention|Control|no interventions were assigned after hepatectomy
11310188|NCT02631486|Experimental|Early|"The first group will use sling for comfort only. Active assisted exercises in closed chain and in safe zone are allowed in the first 4 weeks.
~The rehabilitation stages will start from active assisted progressing to more active stages phases until full recovery. The whole program will last about 3 months."
11310189|NCT02631486|Active Comparator|Conservative|The second group will use a sling for 6 weeks. The rehabilitation stages will start with active assisted/closed chain movements with short levers, it will progress to more active stages phases until full recovery. The whole program will last about 3 months.
11310190|NCT02631473|Active Comparator|1st Stage-Group A|"Day 1: 50 mg NANO-efavirenz single dose
~Days 4-21: 50 mg NANO-efavirenz OD (once daily)"
11310191|NCT02631473|Active Comparator|1st Stage-Group B|"Days 1-7: 400mg NANO-lopinavir BID (twice daily)
~Days 8-21: Wash-out period
~Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID"
11310192|NCT02631473|Active Comparator|2nd Stage-Group A-Group 1-Dose level 1|"21 Days: 300mg NANO-efavirenz OD
~4 weeks: Wash-out period
~21 days: 600mg Sustiva OD"
11310193|NCT02631473|Active Comparator|2nd Stage-Group A-Group 2-Dose level 2|"21 Days: 200mg NANO-efavirenz OD
~4 weeks: Wash-out period
~21 days: 400mg Sustiva OD"
11310194|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 1|"7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD
~2 weeks: Wash-out period
~7 days: NANO-lopinavir (200mg +/- ritonavir®)"
11310195|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 2|"7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)
~2 weeks: Wash-out period
~7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD"
11310196|NCT02631460|Experimental|S1 and Carboplatin|S1 80-120 mg/d+Carboplatin AUC=5 Patients without progression received maintenance until disease progression with S1
11310197|NCT02631460|Active Comparator|pemetrexed and Carboplatin|pemetrexed 500 mg/m2+ Carboplatin AUC=5 Patients without progression received maintenance until disease progression with pemetrexed
11310198|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
11310199|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
11310200|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
11310201|NCT02631434|Experimental|sit-to-stand|To perform a sit-to-stand test
11310202|NCT02631434|Active Comparator|six minute walking test|To perform a six minutes walking test
11310203|NCT02631421||Pulmonary Arterial Hypertension|Clinical diagnosis of pulmonary arterial hypertension
11310204|NCT02631421||Healthy subjects and patients with other causes of PH|Patients referred for right heart catheterization who do not have PAH
11310205|NCT02631408|No Intervention|Control Group|No additional treatment. Routine iv. antibiotic prophylaxis only.
11310206|NCT02631408|Experimental|Vancomycin Group|Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
11310207|NCT02631395|Other|Training group|Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition season; the training Group (intervention Group) and the Control Group.The intervention group completed strength training exercises Three times a week the Whole competition season.
11310208|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
11310209|NCT02631382|Experimental|wet cupping : double cupping|wet cupping: (traditional cupping technique): cupping (suction) - Scarification - cupping (suction)
11310210|NCT02631382|Experimental|wet cupping: single cupping|wet cupping:(Asian cupping): Puncture by needles then cupping (suction):
11310211|NCT02631369|Experimental|inter- & intrarater reliability study|pre-study: inter- and intrarater reliability study in 30 healthy subjects, interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
11310212|NCT02631369|Experimental|cyclotorsion in forth nerve palsy|measurement of cyclotorsion on SLO-fundusphoto in 20 patients forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
11310305|NCT02630771||PDAP only|Persistent dentoalveolar pain disorder patients who do not fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
11310213|NCT02631369|Experimental|cyclotorsion in healthy subjects|measurement of cyclotorsion on SLO-fundusphoto in 30 healthy subjects to be compared to patients with forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
11310214|NCT02631356|Placebo Comparator|Ringer's lactate solution|Infusion of Ringer's lactate solution (10ml/kg) in the control group
11310215|NCT02631356|Active Comparator|Succinylated gelatin|Infusion of Succinylated gelatin (10ml/kg) in the test group
11310216|NCT02631343|Experimental|Intervention KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
11310217|NCT02631343|Other|Control|Routine visits by government health workers
11310218|NCT02631330|Experimental|Falls prevention group|"Intervention group that will receive a monthly talk (individual or collective) of 30 minutes on the advantages of having a free fall hazards environment and multiple physical exercise component: balance,muscle strength and aerobic capacity and risk polypharmacy and abuse of drugs, especially benzodiazepines). In the same monthly meeting, subjects will be train Multicomponent physical activity program during 60 minutes. 15 minutes of gait and balance training; 15 minutes of endurance training; 30 minutes of aerobic training according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459"
11310219|NCT02631330|No Intervention|Control group|Subjects will receive the same information provided at the beginning to Falls prevention group. They will not receive further information during the follow-up period.
11310220|NCT02631317||rt-PA|patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.
11310221|NCT02631304||Patients undergoing cardiac surgery|Elderly patients scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of cardiopulmonary bypass.
11310222|NCT02631291|Experimental|Lifestyle|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet.
11310223|NCT02631291|No Intervention|Usual Care|Participants randomized to this condition will receive the written education provided to all participants.
11310224|NCT02631291|Experimental|LIfestyle + coaching|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet; and behavioral self-monitoring + motivational interviewing lifestyle coaching.
11310225|NCT02631278|Other|single arm|Intraoperative radiofrequency ablation
11310226|NCT02631265|Active Comparator|Reduction of insulin basal rate at the time of exercise|
11310227|NCT02631265|Active Comparator|Reduction of insulin basal rate 20 minutes prior to exercise|
11310228|NCT02631265|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
11310229|NCT02631252|Experimental|Open-label, Single-arm|"Hydroxychloroquine + Mitoxantrone + Etoposide
~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days"
11310230|NCT02631239|Active Comparator|MESA|Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
11310231|NCT02631239|Experimental|ESA|Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
11310232|NCT02631226||Pregnant women colonized by resistant enterobacteria|
11310233|NCT02631200|Experimental|Advance care plan|Participants will be offered the opportunity to complete an advance care plan.
11310234|NCT02631200|No Intervention|Usual care|Participants will be offered usual care for 12 weeks (and only then be offered the opportunity to complete an advance care plan).
11310235|NCT02631187|Experimental|Balloon Eustachian Tuboplasty|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
11310236|NCT02631174|No Intervention|cohort 1|Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
11310237|NCT02631174|Active Comparator|cohort 2.1|"• Cohort 2.1 - 6 neonates undergoing ECMO.
~Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume
~Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume"
11310238|NCT02631174|Active Comparator|cohort 2.2|"• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB
~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.
~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
11310239|NCT02631174|Active Comparator|cohort 2.3|"• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB
~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.
~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
11310240|NCT02631174|Active Comparator|cohort 3|Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is < 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
11310241|NCT02631161|Experimental|EQUIA forte|Dental non-carious cervical restorations are being restored with a glass hybrid restorative system (Medical product: EQUIA forte).
11310686|NCT02628275|Active Comparator|Moderate to vigorous physical activity|MVPA (55-90% of maximum heart rate) for 150 min/week (current recommendations)
11310242|NCT02631161|Active Comparator|Filtek Supreme XT/Clearfil SE Bond|Dental non-carious cervical restorations are being restored with a composite resin based material/Adhesive combination (Medical product: Filtek Supreme XT/Clearfil SE Bond).
11310243|NCT02631148|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
11310244|NCT02631148|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
11310245|NCT02631135|Placebo Comparator|Group 1 (TIVA)|Only propofol (started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1)
11310246|NCT02631135|Active Comparator|Group 2 (TIVA+D)|Propofol started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1),and also dexmedetomidine infusion (started as 0.5 μg.kg-1 without making the loading dose and the dose change was not made during the operation)
11310247|NCT02631122|Active Comparator|Supraclavicular BPNB|Patients in this group will be randomized to receive an Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
11310248|NCT02631122|Active Comparator|Retroclavicular BNPB|Patients in this group will be randomized to receive an Ultrasound Guided Retroclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
11310249|NCT02631109|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
11310250|NCT02631096|Experimental|0.2 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
11310251|NCT02631096|Experimental|0.4 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
11310252|NCT02631096|Experimental|ARB-001467 or Placebo|HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
11310253|NCT02631096|Experimental|0.4 mg/kg ARB-001467|HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
11310254|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (high GI)|Subjects will consume meals which are high glycemic index for breakfast (Honey stars cereal), lunch (glutinous rice meal) and snack (white bread and jam) in the whole body calorimeter. A take-away high glycemic index dinner will be provided.
11310255|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (low GI)|Subjects will consume meals which are low glycemic index for breakfast (All bran cereal), lunch (basmati rice meal) and snack (multigrain bread and sugar-free jam) in the whole body calorimeter. A take-away low glycemic index dinner will be provided.
11310256|NCT02631070|Experimental|Experimental Arm - Luspatercept (ACE-536)|Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
11310257|NCT02631070|Placebo Comparator|Control Arm: Placebo|Subcutaneous injection every 3 weeks
11310258|NCT02631057||Non-Valvular Atrial Fibrillation|
11310259|NCT02631057||acute ischemic stroke|
11310260|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
11310261|NCT02631044|Experimental|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
11310262|NCT02631031|Other|morning administration|administration of single oral dose valsartan (160 mg) in the morning
11310263|NCT02631031|Other|evening administration|administration of single oral dose valsartan (160 mg) in the evening
11310264|NCT02631018|Experimental|Physical Activity Enhanced Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations. This arm, uniquely, will receive a culturally based physical activity component.
11310265|NCT02631018|Active Comparator|Standard Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
11310266|NCT02631005|Experimental|Walk With Ease Participants|"Participants will receive a copy of the Walk With Ease workbook. This workbook provides guidance on walking safety and on how to start and maintain a regular walking program. It is designed to help participants increase their physical activity over a six-week period. Participants will complete self-reported outcomes questionnaires before and after completion of the program."
11310267|NCT02630992|Experimental|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
11310268|NCT02630979||No treatment|Clinical and medical oncology physicians.
11310269|NCT02630966|Experimental|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
11310270|NCT02630966|Experimental|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
11310271|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
11310306|NCT02630771||PDAP + TMD|Persistent dentoalveolar pain disorder patients who also fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
11310307|NCT02630771||Painfree controls|Painfree subjects. Pressure pain threshold before/during conditioned pain modulation.
11310335|NCT02630602|Placebo Comparator|Control cheese|Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks
11310272|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
11310273|NCT02630940||Idiopathic pulmonary fibrosis sufferers|Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
11310274|NCT02630927|Placebo Comparator|Part 1 Single-Ascending (SAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
11310275|NCT02630927|Placebo Comparator|Part 2 Multiple-Ascending (MAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
11310276|NCT02630927|Experimental|Part 3 Bioavailability & Food Effect|The dose to be assessed in Part 3 will be selected based on emerging safety, tolerability and PK/PD data from preceding cohorts in Part 1 and Part 2, which will be reviewed during a dose decision meeting.
11310277|NCT02630927|Experimental|Experimental Part 4 (Subjects of Japanese Origin)|Two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3
11310278|NCT02630927|Experimental|Experimental Part 5 Open-label Multiple-Ascending (MAD)|Up to two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
11310279|NCT02630914|Experimental|Intervention|All patients will have the hybrid procedure of ablation of atrial fibrillation.
11310280|NCT02630901|Experimental|PRX003|
11310281|NCT02630901|Placebo Comparator|Placebo|
11310282|NCT02630888|Active Comparator|Memantine|Patients randomized to this group will receive a dose of 15 mg / day of memantine during the first week (V0); all have the dose of memantine increased on the second week (V1) at the dose of 30 mg / day (in two divided doses of 15 mg).
11310283|NCT02630888|Placebo Comparator|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine.
11310284|NCT02630875|Active Comparator|A4250 1|Dose I
11310285|NCT02630875|Active Comparator|A4250 2|Dose 2
11310286|NCT02630875|Active Comparator|A4250 3|Dose 3
11310287|NCT02630875|Active Comparator|A4250 4|Dose 4
11310288|NCT02630875|Active Comparator|A4250 5|Dose 5
11310289|NCT02630875|Active Comparator|A4250 6|Dose 6
11310290|NCT02630862|Active Comparator|aspirin|acetylsalcylic acid 100 mg per day give orally for six months, starting the day of carotid endoartherectomy
11310291|NCT02630862|Active Comparator|aspirin plus dipyridamole|acetylsalicylic acid 25 mg plus dipyridamole extended release 200 mg, combined in a capsule, per day starting the day of carotid endoartherectomy
11310292|NCT02630849|Experimental|IMF group|intercostal muscle flap and pericostal no-compression suture of the intercostal space
11310293|NCT02630849|Active Comparator|IINB group|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
11310294|NCT02630836|Experimental|XCEL-MT-OSTEO-BETA|Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing
11310295|NCT02630836|Other|Standard treatment|Standard surgical treatment with isolated endomedullary nailing
11310296|NCT02630823|Experimental|Arm 1: MK-3475|"Patients will undergo endometrial biopsy followed by 2 doses of MK-3475 3 weeks apart. 3-4 weeks after the second dose of MK-3475, the standard of care surgical resection will take place, followed by standard of care adjuvant therapy. Tissue and blood will be collected at the time of surgical resection for immune analysis. For patients whose pathology confirms high-risk features and advanced stage, MK-3475 will be given every 3 weeks starting 4 -6 weeks after completion of adjuvant therapy for a maximum of 4 doses post-surgery.
~MK-3475 will be given intravenously at a dose of 200 mg over the course of 30 minutes.
~The standard of care chemotherapy will consist of 6 cycles of paclitaxel and carboplatin AUC 5 every 3 weeks for 6 cycles.
~The decision to administer radiation therapy will be per the treating physician. If the patient does not receive radiation therapy, then the patient will start MK-3475 every 3 weeks x 4 doses after the completion of chemotherapy."
11310297|NCT02630810|Experimental|Early oral hydration|Early oral intake of 100 ml clear unsweetened water 1 hour following the Cesarean Section, then upon patient's desire, then starting semisolid, solid food when participant passed flatus.
11310298|NCT02630810|Active Comparator|Delayed oral hydration|Oral intake of 100 ml clear unsweetened water after 6 hours from the end of CS then upon patient's request,then starting semisolid, solid food when participant passed flatus.
11310299|NCT02630797|Placebo Comparator|Blueberry baseline|No blueberry products provided as part of the usual dietary intake
11310300|NCT02630797|Active Comparator|Blueberry Low|One blueberry product per day containing an equivalent of 0.75 cups of fresh blueberries provided as part of usual dietary intake for 42 days
11310301|NCT02630797|Active Comparator|Blueberry Medium|Two blueberry products per day containing an equivalent of 1.5 cups of fresh blueberries provided as part of usual dietary intake for 42 days
11310302|NCT02630797|Active Comparator|Blueberry High|Four blueberry products per day containing an equivalent of 3 cups of fresh blueberries provided as part of usual dietary intake for 42 days
11310303|NCT02630784|Experimental|Homecare ventilator|NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
11310304|NCT02630784|Active Comparator|ICU ventilator|NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.
11310308|NCT02630758|Experimental|Mindfulness-based Yoga|"Participants in the 12-week mindfulness-based yoga condition were guided by a gentle yoga DVD that included postures (asanas), pranayama (breathing exercises), and relaxation (meditation). Participants were asked to complete 60-75 minutes of the DVD twice per week and were encouraged to do more if they were interested.
~Following the initial baseline assessment and randomization telephone interview, participants in the yoga group completed weekly 15-minute telephone sessions for the first month and bi-weekly telephone sessions for the second and third for a total of eight sessions over the 12 weeks. The mindfulness telephone sessions were modified from the Mindfulness-Based Stress Reduction."
11310309|NCT02630758|Active Comparator|Walking Control Group|"The 12-week walking control condition included twice-weekly home practice with a 65-minute walking DVD (Sansone, 2008) and eight telephone sessions with the telephone counselor.
~Participants were asked to complete 60 minutes of the DVD (or other walking) twice weekly and encouraged to do more if they were interested.
~Participants received telephone sessions on the same schedule as the yoga condition. The education sessions covered a variety of health and wellness related topics."
11310310|NCT02630745|Active Comparator|Immediate periodontal surgery (Group 1)|periodontal surgical procedure in the form of open flap debridement will be performed immediately( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) after obturation of the root canal system( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
11310311|NCT02630745|Active Comparator|Delayed periodontal surgery (Group 2)|periodontal surgical procedure in the form of open flap debridement( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) will be performed 3 months after obturation of the root canal system ( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
11310312|NCT02630732|Active Comparator|Brain School|Pain Neuroscience Education Program
11310313|NCT02630732|Active Comparator|Back School|Classical Back School
11310314|NCT02630719|Active Comparator|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
11310315|NCT02630719|Placebo Comparator|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
11310316|NCT02630706|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
11310317|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
11310318|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
11310319|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
11310320|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
11310321|NCT02630680||Colorectal diseases patients|
11310322|NCT02630667|Experimental|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response.
11310323|NCT02630667|Experimental|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response.
11310324|NCT02630667|Experimental|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response.
11310325|NCT02630667|Placebo Comparator|Non-Caloric Placebo|Non-caloric placebo consisting of artificial sweeteners
11310326|NCT02630654||GEP NETs|Patients with a suspected diagnosis of metastatic GEP NETs
11310327|NCT02630654||Healthy controls|Healthy controls matched by age and gender.
11310328|NCT02630641||Prostate cancer patients|
11310329|NCT02630628|Experimental|Tacrolimus|route: oral duration: 96 weeks
11310330|NCT02630628|Active Comparator|Mycophenolate Mofetil|route: oral duration: 96 weeks
11310331|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.
~For Cohorts A & B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
11310332|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
11310333|NCT02630615||Cohort C (healthy volunteers)|Blood samples will be collected from eligible health volunteers only once. These samples will be used to test the CTC chip system. Two tubes of peripheral blood will be collected and taken to the PI's lab for processing.
11310334|NCT02630602|Active Comparator|Functional goat cheese|The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks
11310336|NCT02630589|Experimental|ABI implantation|All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
11310337|NCT02630576|Experimental|Men - Left Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
11310338|NCT02630576|Experimental|Men - Right Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
11310339|NCT02630576|Experimental|Women - Left Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
11310340|NCT02630576|Experimental|Women - Right Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
11310341|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
11310342|NCT02630550||Aortic Aneurysm Repair|The impact of large abdominal retractors and an abdominal aortic cross-clamp on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
11310343|NCT02630550||Femoral Endarterectomy|The impact of the clamping of a large peripheral arterial vessel on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
11310344|NCT02630524|Experimental|Low Carbohydrate Diet|
11310345|NCT02630524|Active Comparator|Standard Diet|
11310346|NCT02630511|Experimental|Mannitol - rest|Bronchial challenge following rest
11310347|NCT02630511|Experimental|Methacholine - rest|Bronchial challenge following rest
11310348|NCT02630511|Experimental|Placebo - rest|Bronchial challenge (placebo) following rest
11310349|NCT02630511|Experimental|Mannitol - exercise|Bronchial challenge following exercise
11310350|NCT02630511|Experimental|Placebo - exercise|Bronchial challenge (placebo) following exercise
11310351|NCT02630498|Experimental|study (first group)|The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
11310352|NCT02630498|No Intervention|Controlled (second group)|The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.
11310353|NCT02630485|Experimental|Graceful Lifestyle Changes & MYO|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.
~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
11310354|NCT02630485|Experimental|Graceful Lifestyle Changes|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.
~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
11310355|NCT02630485|Placebo Comparator|Letrozole & MYO|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
11310356|NCT02630485|Placebo Comparator|Letrozole|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
11310357|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.
~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
11310358|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.
~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.
~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
11310359|NCT02630459|Placebo Comparator|Double Blind Treatment Phase (DBTP): Placebo|Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
11310360|NCT02630459|Experimental|DBTP: Erenumab 28 mg QM|Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
11310361|NCT02630459|Experimental|DBTP: Erenumab 70 mg QM|Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
11310362|NCT02630459|Experimental|DBTP: Erenumab 140 mg QM|Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
11310363|NCT02630459|Experimental|Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM|Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.
11310364|NCT02630459|Experimental|CHU Sub-Study: Two 70 mg/mL AI/pens|A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study
11310365|NCT02630459|Experimental|CHU Sub-Study: One 140 mg/mL AI/pen|A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study
11310366|NCT02630446|Experimental|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
11310367|NCT02630446|No Intervention|standard dementia care|Control group receiving all types of standard dementia care except in-home respite care of the Baluchon type.
11310368|NCT02630433|Experimental|Index cholecystectomy|Cholecystectomy within 48 hours after inclusion.
11310369|NCT02630433|Active Comparator|Scheduled cholecystectomy|Cholecystectomy 6 weeks after inclusion.
11310370|NCT02630420|Experimental|cetuximab and savolitinib|Following assessment in Part 1 of dose-limiting toxicity and maximum tolerated dose, this drug combination will be administered in Part 2 of the study to assess safety, tolerability, response rate, and progression-free survival.
11310371|NCT02630407|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (product name: Hymovis, Fidia Spa, Padova, Italy) the day after ACL reconstruction (after drainage removal)
11310372|NCT02630407|Placebo Comparator|Placebo group|Single injection of 3 ml saline solution the day after ACL reconstruction (after drainage removal)
11310373|NCT02630394|Experimental|Azithromycin prophylaxis|Azithromycin will be supplied as a 250-mg tablet. Participants weighing less than 40 mg will be instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday), and participants who weigh more than 40 kg will be instructed to take 2 tablets on the same 3 days per week.
11310374|NCT02630381|Experimental|Shock wave arm|Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
11310375|NCT02630381|No Intervention|Contra-lateral arm|The distal radius and/or wrist that did not receive UESWT will not be treated
11310376|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.
~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
~Number of subjects : 14"
11310377|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.
~Experimental phase II soft-tissue sarcoma :
~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
~Number of subjects : 48"
11310378|NCT02630368|Experimental|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.
~Control-arm phase II soft-tissue sarcoma :
~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.
~Number of subjects : 24"
11310379|NCT02630368|Experimental|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.
~Experimental phase II Group breast cancer :
~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
~Number of subjects : 32"
11310380|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :
~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.
~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.
~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).
~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.
~Number of subjects : 47"
11310381|NCT02630368|Experimental|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :
~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.
~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.
~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).
~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.
~Number of subjects : 32"
11310382|NCT02630355|Sham Comparator|Control|Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation
11310383|NCT02630355|Active Comparator|Low Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.
11310384|NCT02630355|Active Comparator|Standard Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.
11310385|NCT02630355|Active Comparator|High Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.
11310386|NCT02630342|Experimental|Group 1: preparation materials only|This group will receive preparation materials for a clinical MRI scan. These include links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur only at home.
11310387|NCT02630342|Experimental|Group 2: Materials with review|This group will receive in preparation for a clinical MRI scan links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur at home and include a visit with research team to review preparation materials with the research team
11310476|NCT02629718|Active Comparator|B(RS)|Radical Surgery alone
11310388|NCT02630342|Experimental|Group 3: Mock MRI scanner|This group will receive the same materials as training group 1. In addition they will attend the mock scanner where the research team will utilise a mock MRI scanner to practice lying down in a scanner, staying still , wearing headphones and watching a movie/video on the mirror system.
11310389|NCT02630342|No Intervention|Neuro-oncology retrospective controls|A retrospective control group of neuro-oncology patients from the 3 years prior to the study initiation. This group will be used to determine the age at which patients were able to complete a diagnostic MRI without GA
11310390|NCT02630342|Experimental|Neuro-oncology prospective|Child life specialist preparation will be provided to these patients. This preparation for Diagnostic MRI scanning in which utilise the Mock MRI scanner as preparation for the scan.
11310391|NCT02630329|Experimental|vNOTES adnexectomy|Vaginal Natural Orifice Transluminal Endoscopic Surgery
11310392|NCT02630329|Active Comparator|LSC adnexectomy|Laparoscopic adnexectomy
11310393|NCT02630316|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
11310394|NCT02630316|Active Comparator|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
11310395|NCT02630303|Experimental|LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
11310396|NCT02630303|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).
~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
11310397|NCT02630290|Placebo Comparator|Ropivacaine|After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
11310398|NCT02630290|Experimental|Ropivacaine + Dexmedetomidine|After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
11310399|NCT02630277|Experimental|Arm 1|1:1 Intravitreal Aflibercept Injection once every 4 weeks
11310400|NCT02630277|Experimental|Arm 2|Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)
11310401|NCT02630264|Experimental|Combination therapy|"E10A+chemotherapy group (360 subjects):
~E10A (Endostatins) of 1.0×1012VP on day 1 and 6
~Paclitaxel Injection 160mg/m2 on day 3
~Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days."
11310402|NCT02630264|Experimental|Chemotherapy|"Chemotherapy-alone group (180 subjects):
~Paclitaxel Injection 160mg/m2 on day 1
~Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days"
11310403|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
11310404|NCT02630238|Experimental|Branched-Chain Amino Acid group|The branched-chain amino acid group will be on a hypocaloric diet, exercise and receive 0.342g/kg of BCAA per day, partially accounted for through their diet with the rest provided by a BCAA supplement
11310405|NCT02630238|Placebo Comparator|Placebo Group|The placebo will be on a hypocaloric diet, exercise and receive isoenergetic beverage with carbohydrate instead of branched-chain amino acids
11310406|NCT02630225|Experimental|Intervention|"Participants in this arm will receive three intervention services in addition to treatment as usual services:
~A brief intervention including a feedback session utilizing principles of Motivational Interviewing (MI).
~Extended outreach services (6 months) using the Critical Time Intervention (CTI) approach.
~Multi-agency attention."
11310407|NCT02630225|Other|Treatment as Usual|Participants in this arm will receive the usual care offered to victims of gun shot wounds.
11310408|NCT02630212||Control|Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
11310409|NCT02630212||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Qilu Hospital
11310410|NCT02630199|Experimental|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
11310411|NCT02630186|Experimental|Single Arm Rociletinib and MPDL3280A|Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.
11310412|NCT02630173|Experimental|Non vital teeth with apical radiolucency|Endodontic treatment was performed in non vital teeth with periapical radiolucency. Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 3 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 or #15K-files. Coronal flaring with # 2 and #3 Gates-Glidden drills was done.Calcium hydroxide was filled in the canals with the help of a lentulo spiral.At the second appointment,calcium hydroxide paste was removed and copious irrigation with 3% sodium hypochlorite was followed by 5.0 mL 17% ethylenediaminetetraacetic acid with a final rinse of 5.0 mL of 3% sodium hypochlorite. The canals were obturated with gutta-percha and ZOE sealer.
11310413|NCT02630173|Active Comparator|Vital teeth|Only scaling and root planing will be done in contralateral vital tooth with pocket depth >5mm .Non surgical periodontal treatment in the form of scaling and root planing was provided in minimum of two sessions using ultrasonic scaler (Satelec P5 Booster Suprasson) and hand instruments (Hu-friedy scalers and curettes).
11310414|NCT02630160|Active Comparator|Intraarticular Catheter with anesthesic|Intraarticular infusion with Bupivacaine Hydrochloride
11310415|NCT02630160|Placebo Comparator|Intraarticular Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by intraarticular catheter
11310416|NCT02630160|Active Comparator|Perifascial Catheter with anesthesic|Perifascial infusion with Bupivacaine Hydrochloride
11310417|NCT02630160|Placebo Comparator|Perifascial Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by Perifascial catheter
11310418|NCT02630147|Experimental|Night-vanilla|Intervention = exposition to vanilla scent A quantity of 2 ml of a saturated vanilla solution (2% vanillin) will be applied on premature pyjamas infant's, close to his face (on each shoulder and on the upper chest).
11310419|NCT02630147|No Intervention|Night-no vanilla|The only difference with the experimental arm is the absence of vanilla (usual, standard care)
11310420|NCT02630134|Experimental|Baeta|These patients receive the Baeta device and take it home.
11310421|NCT02630121|Placebo Comparator|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
11310422|NCT02630121|Active Comparator|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
11310423|NCT02630108|Experimental|Thermal Ablation & TACE|"Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.
~EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
11310424|NCT02630108|Active Comparator|TACE alone|Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
11310425|NCT02630095|Other|Control.|No anticoagulation，just routine follow up.
11310426|NCT02630095|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
11310427|NCT02630082|Other|Intervention|Circumcision and flexible sigmoidoscopy
11310428|NCT02630069|Experimental|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
11310429|NCT02630069|Placebo Comparator|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
11310430|NCT02630069|No Intervention|Healthy control|No intervention
11310431|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.
~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
11310432|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
11310433|NCT02630017|Experimental|Drug condition|40 mg methylphenidate on one study day
11310434|NCT02630017|Placebo Comparator|Placebo condition|matching placebo on other study day
11310435|NCT02630004|Experimental|Melatonin|Melatonin oral gel 3%
11310436|NCT02630004|Placebo Comparator|Placebo|Placebo oral gel
11310437|NCT02629991|Experimental|Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
11310438|NCT02629991|Placebo Comparator|Matched Placebo|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
11310439|NCT02629978|Experimental|radiofrequency ablation|In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
11310440|NCT02629965|Experimental|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
11310441|NCT02629965|Active Comparator|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
11310442|NCT02629952|Experimental|Blueberry Tea|3 cups of blueberry tea per day x 4 weeks
11310443|NCT02629952|No Intervention|No Treatment|No Treatment
11310444|NCT02629939|No Intervention|questionnaires|"Questionnaires will be distributed to families of heart patients to test the theoretical knowledge to perform CPR The questionnaires were distributed to internal, cardiology clinics and clinic T by a doctor, Paramedic or medical student. The family will be asked to fill out the questionnaire independently.
~The questionnaires will be distributed in Hebrew, Arabic, Russian and English The research questionnaire will include questions about able to perform basic CPR"
11310477|NCT02629705|Other|Group A|"Placebo intervention
~Assessment block (3 days)
~Washout-phase of 21-35 days
~Carrageenan intervention
~Assessment block (3 days)"
11310478|NCT02629705|Other|Group B|"Carrageenan intervention
~Assessment block (3 days)
~Washout-phase of 21-35 days
~Placebo intervention
~Assessment block (3 days)"
11310479|NCT02629692|Experimental|K0706 capsules|
11310480|NCT02629679||Males nonathletes|Boys non-involved in organized sport and exercising
11310481|NCT02629679||Females nonathletes|Girls non-involved in organized sport and exercising
11310482|NCT02629679||Males athletes|Athletic boys (involved in sports)
11310445|NCT02629939|Experimental|to participate in a short course for learning CPR|": The investigators will offer patients and their relatives to participate in a short course for learning CPR.
~Relatives will receive a prescription Containing a proposal for participation in the course
~Prescription will be awarded in four places:
~-.Family physicians as a suggestion during a routine visit / presentation of cardiac problem
~Heart Rehabilitation Institute - cardionegev
~Doctors internal medicine department as part of a patient's discharge letter with heart disease
~Doctors in cardiology clinic The prescription will be accompanied by several minutes of explanation about the program and its importance The investigators consider the level of responsiveness and participation, find out which arm yielded the highest number of participants (actual turnout of the total prescriptions distributed) And how to expand their activities"
11310446|NCT02629926||Patients to receive GH replacement|30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
11310447|NCT02629926||Patients who will not receive GH replacement|An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
11310448|NCT02629913|Experimental|Intervention|mementor somnium
11310449|NCT02629913|Other|Waitlist|
11310450|NCT02629900|Experimental|Intermittent fasting group|Participants will restrict their daily food intake (time restricted feeding) to an 8-hour time period between 1200 to 2000 hours. During the remaining 16-hour intermittent fasting period (2000 to 1200 hours) participants will be allowed to drink zero calorie beverages (diet soda pop, black coffee, tea, water, etc) in order to maintain normal hydration. There will be no attempt to restrict food intake. Rather simply to restrict the time period each day when food is consumed.
11310451|NCT02629887|Active Comparator|Face Mask|Standard Face Mask with T piece resuscitator for neonatal resuscitation. Face mask placement per Neonatal Resuscitation Program resuscitation guideline.
11310452|NCT02629887|Active Comparator|Non-inflatable supraglottic airway|Use of non-inflating supraglottic airway with T-piece resuscitator instead of Standard Face Mask with T piece resuscitator for neonatal resuscitation, replacing standard of care face mask in Neonatal Resuscitation Program guideline.
11310453|NCT02629874|Active Comparator|EA-230 (30mg/kg)|Subjects will receive EA-230, 30 mg/kg
11310454|NCT02629874|Active Comparator|EA-230 (90mg/kg)|Subjects will receive EA-230, 90 mg/kg
11310455|NCT02629874|Active Comparator|EA-230 (180mg/kg)|Subjects will receive EA-230, 180 mg/kg
11310456|NCT02629874|Placebo Comparator|Placebo|subjects receive placebo
11310457|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
11310458|NCT02629861|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
11310459|NCT02629861|Experimental|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
11310460|NCT02629848|Experimental|Motesanib + Paclitaxel + Carboplatin|Motesanib 125 mg, (5 x 25 mg) tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target Area Under the Curve (AUC) of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib 125 mg, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
11310461|NCT02629848|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
11310462|NCT02629835|Active Comparator|Intravenous dexamethasone 8 mg|patients receiving intravenous 8 mg of dexamethasone in parallel to ultrasound guided axillary nerve block with a standardized local anesthetic solution
11310463|NCT02629835|Active Comparator|Perineural dexamethasone 8 mg|patient receiving perineural 8 mg of dexamethasone in a mixture with a standardized local anesthetic solution for ultrasound guided axillary block
11310464|NCT02629822|Experimental|DOR/3TC/TDF|Treatment-naïve HIV-1 infected participants with non-nucleoside reverse transcriptase inhibitor (NNRTI) transmitted resistance were treated with open-label MK-1439A consisting of a single fixed-dose combination (FDC) tablet of 100 mg of MK-1439 (doravirine, DOR), 300 mg of lamivudine (3TC), and 300 mg of tenofovir disoproxil fumarate (TDF), administered orally once daily for 96 weeks. For some participants who continued into the study extension, study treatment may have continued for approximately an additional 96 weeks, through a total of approximately 192 weeks of treatment.
11310465|NCT02629809|Experimental|Treatment (iFCG)|See Detailed Description.
11310466|NCT02629796||CIDP treated (IVIG)|patients with a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to European criteria, treated with IVIG (intravenous immunoglobulin as a first line of treatment) as a usual treatment
11310467|NCT02629796||control|healthy subjects
11310468|NCT02629783|Experimental|Physiotherapy + Corticosteroid injection + Psychomotor therapy|Usual care + intervention
11310469|NCT02629783|Active Comparator|Physiotherapy + Corticosteroid injection|Usual care
11310470|NCT02629757|Experimental|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.
11310471|NCT02629744|Experimental|Etrolizumab|Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.
11310472|NCT02629731|Experimental|ankle OA|inclusion criteria: 1) diagnosis of ankle OA or PTTD [non-control subjects only], 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m) with the primary impediment to pain-free ambulation being ankle OA or PTTD
11310473|NCT02629731|Experimental|flat foot|inclusion criteria: 1) diagnosis of flat foot, 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m)
11310474|NCT02629731|No Intervention|control|inclusion criteria: 1) between 18 and 80 years of age, and 2) ambulatory (able to walk at least 15 m)
11310475|NCT02629718|Experimental|A(NACT)|Neoadjuvant Chemotherapy followed by Radical Surgery
11310484|NCT02629666|Active Comparator|Exercise Referral Scheme (ERS)|In the Exercise Referral Scheme (ERS) intervention participants will undergo a physical activity program of 16 weeks, with two sessions per week (60 minutes each session). Participants will be asked to perform the activity in a moderate to vigorous intensity (according to each individual's progression) during the central part of each session. Intensity will be estimated using the modified Borg Scale of Perceived Exertion (e.g. moderate intensity activity will be considered as a 4 to 6 and vigorous-intensity activity as a 7 to 9) or with training loads (i.e. ankle weights and dumbbells) corresponding to 70-80% of maximum, adjusted progressively during the training period. ERS programs will be based on a combination of aerobic, strength-based, balance and flexibility activities, with a specially trained PA specialist. These sessions will be always performed under the supervision of the same trainer. The PA intervention is adapted to the participants' functional status.
11310485|NCT02629666|Experimental|ERS + Self-management Strategies|"Participants will undergo the aforementioned Physical Activity program plus 11 sessions of Self-Management Strategies (SMS).
~SMS start with a face-to-face session in an indoor primary-care facility. The next 6 sessions are further implemented in a group format. SMS are aimed at increasing self-efficacy in reducing sedentary behaviour and at adopting/maintaining an active behaviour as complement to a standard physical activity program (ERS). SMS group sessions will be conducted during week 3 to 11 of the ERS, after the PA sessions (6 sessions: 3 once a week, 3 once every second week). There will be 4 telephone contacts during the adherence phase, at week 15, 20, 25 and 30."
11310486|NCT02629666|No Intervention|Control group|Researchers will give to all participants during the first informative meeting (prior assessment) a written general booklet standardized across sites with WHO recommendation regarding PA regular practice for health. During the intervention, a health advice meeting with standardized topics about healthy lifestyle and feedback on some outcomes regarding their results will be held twice in the Primary Health Centre (at week 5, and at week 11). Researchers will send a letter or phone call prior to each follow up reminding the next assessment.
11310487|NCT02629653|Other|Single arm|The endovascular cooling system will be Zoll IVTM. This system consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585)
11310488|NCT02629640||Research Participants|Medical history questionnaire; clinical assessment and review; participant follow-up; blood or buccal sample; post mortem examination.
11310489|NCT02629627|Experimental|cojugated ALC/Leucine+Metformin|Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
11310490|NCT02629627|Active Comparator|Metformin+placebo conjugatedALC/leucine|active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
11310491|NCT02629627|Placebo Comparator|Placebo of Metformin|Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
11310492|NCT02629627|Placebo Comparator|ACL/Leu placebo|Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
11310493|NCT02629614|Experimental|TAPS Stimulation|Temporal Afferent Patterned Stimulation (TAPS) is alternating bursts of TENS stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
11310494|NCT02629614|Sham Comparator|Sham Stimulation|0 amplitude stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
11310495|NCT02629601|Experimental|Active Rewards|Participant will receive the standard active rewards incentives.
11310496|NCT02629601|Active Comparator|Active Rewards Doubled|Participant will receive the standard active rewards doubled in magnitude.
11310497|NCT02629601|Active Comparator|Active Rewards & Lottery 1|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward.
11310498|NCT02629601|Active Comparator|Active Rewards & Lottery 1 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward. Includes broadcasting winners (number) each week.
11310499|NCT02629601|Active Comparator|Active Rewards & Lottery 2 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 2 with a 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward. Includes broadcasting winners (number) each week.
11310500|NCT02629588||Persons in coma or vegetative state|People who survived TBI have a period of complete unconsciousness or coma with no awareness of themselves or their surroundings received multimodal or unimodal sensory stimulation.People in a coma are unaware and unresponsive, but not asleep as there is no sleep-wake cycle. While in a coma, people are unable to speak, follow commands or open their eyes. The person in coma may have a simple reflex in response to touch or pain, but essentially there is no meaningful response to external stimuli. There is an absence of awareness of self and the environment, even under conditions of vigorous external stimulation. Coma can last from hours to days, depending on the severity of the brain damage, and sometimes a person can remain in a comatose state for months and even years.
11310501|NCT02629562|Experimental|Arm 1|first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously
11310502|NCT02629562|Experimental|Arm 2|first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously
11310503|NCT02629549|Experimental|OTL38|Dosage calculated by weight of individual
11310504|NCT02629536|Experimental|Active-verum-NAC tablet|Intervention: Twice-daily administration of N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablets
11310505|NCT02629536|Placebo Comparator|Sham-placebo tablet|Intervention: Twice daily administration of sham/placebo tablet
11310506|NCT02629523|Experimental|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
11310507|NCT02629510|Experimental|Tachosil|The group composed of patients whose surgical margin of cervix will be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
11310508|NCT02629510|No Intervention|No Tachosil|The group composed of patients whose surgical margin of cervix will NOT be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
11310509|NCT02629497|Experimental|Healthy subjects for Omega-6 protection|Platelets from healthy donors will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
11310510|NCT02629497|Experimental|T2DM patients for Omega-6 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
11310511|NCT02629497|Active Comparator|Healthy control for Omega-3 protection|Platelets from healthy donors will be assessed for regulation by Fish Oil (omega-3 fatty acid).
11310512|NCT02629497|Active Comparator|T2DM for Omega-3 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Fish Oil (omega-3 fatty acid).
11310513|NCT02629484|Active Comparator|Focused Cardiac Ultrasound|participants randomised to receive focused cardiac ultrasound prior to surgery for hip fracture
11310514|NCT02629484|No Intervention|Standard care (clinical assessment)|Participants randomised to standard care receive clinical assessment of the patient
11310515|NCT02629471|Experimental|response time due to light flashs pulses|light flashing effects on response time to random target appearance
11310516|NCT02629458|Experimental|Patients requiring surgery|
11310517|NCT02629432||Cosyconet COPD Cohort|MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort.
11310518|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
11310519|NCT02629406||Diabetes typ 1|Patients with typ 1diabetes with a duration of the disease between 10-20 years (HbA1C >65 mmol/l) and age 20-50 will be exposed to intermittent hypoxia.
11310520|NCT02629406||Healthy controls|Healthy controls, age 20-50 will be exposed to intermittent hypoxia.
11310521|NCT02629393|Experimental|ORGN001 (formerly ALXN1101)|
11310522|NCT02629380|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (Hymovis, Fidia Farmaceutici SpA, Padova, Italy) at the end of the arthroscopic meniscectomy
11310523|NCT02629380|Other|meniscectomy alone|Arthroscopic meniscectomy alone
11310524|NCT02629354|Experimental|Ibuprofen and Caffeine|
11310525|NCT02629354|Active Comparator|Ibuprofen|
11310526|NCT02629341|Active Comparator|Functional yogurt powder|This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic
11310527|NCT02629341|Placebo Comparator|Control yogurt powder|This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched
11310528|NCT02629328|Other|CardioCel|Treatment with CardioCel implant
11310529|NCT02629315|Active Comparator|10% neutral buffered formaldehyde|Specimens will be fixed for 24-48hours in 10% neutral buffered formaldehyde and then dissected for lymph nodes.
11310530|NCT02629315|Experimental|Carnoy's solution|Specimens will be fixed for 24-48hours in Carno'ys solution and then dissected for lymph nodes.
11310531|NCT02629302|Experimental|animal assisted therapy|"Standard therapy (speech therapy, occupational therapy and physiotherapy) that is done in the presence and with Integration of an animal."
11310532|NCT02629302|Active Comparator|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
11310533|NCT02629289|Other|Treatment A|HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region
11310534|NCT02629289|Other|Treatment B|US-approved Neulasta, 6 mg, single SC injection in the deltoid region
11310535|NCT02629289|Other|Treatment C|EU-approved Neulasta, 6 mg, single SC injection in the deltoid region
11310536|NCT02629250|Placebo Comparator|SV maximization|Goal-directed fluid therapy with stroke volume maximization. Device: The Volume-View system from Edwards Co.
11310537|NCT02629250|Experimental|supernormal DO2|"Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery.
~Device: The Volume-View system from Edwards Co."
11310538|NCT02629237|Experimental|Multifaceted education group|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
11310539|NCT02629237|No Intervention|control group|Subjects will not be asked to watch education film and not participate in counseling session before and after surgery.
11310540|NCT02629224|Experimental|Renal impairment|
11310541|NCT02629224|Experimental|Haemodialysis|
11310542|NCT02629211|Experimental|NaviAid™ AB|NaviAid™ AB device procedure
11310543|NCT02629198||normal weight|Healthy men and women ages 25-40 and 55-75. BMI 18.5 to 25.0
11310544|NCT02629198||overweight|Healthy men and women ages 25-40 and 55-75. BMI 25.0 to 30.0
11310545|NCT02629198||obese|Healthy men and women ages 25-40 and 55-75. BMI over 30
11310546|NCT02629185||normal weight|BMI 18.5 to 25.0 Healthy men and women ages 25-40 and 55-75
11310547|NCT02629185||overweight|BMI 25.0 to 30.0 Healthy men and women ages 25-40 and 55-75
11310548|NCT02629185||obese|BMI over 30.0 Healthy men and women ages 25-40 and 55-75
11310549|NCT02629172||Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)|Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label
11310550|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).
~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
11310551|NCT02629159|Active Comparator|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.
~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
11310687|NCT02628275|Active Comparator|Light physical activity|LPA (40-55% of maximum heart rate) for 150 min/week
11365525|NCT02263989|Experimental|Telmisartan film coated tablet|
11310552|NCT02629159|Experimental|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.
~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
11310553|NCT02629146|Experimental|Midazolam|Drug: Midazolam (experimental)
11310554|NCT02629146|Placebo Comparator|Isotonic saline|Drug: Isotonic saline (placebo)
11310555|NCT02629146|Active Comparator|Fentanyl|Drug: Fentanyl (active comparator)
11310556|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
11310557|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
11310558|NCT02629120|Active Comparator|1|There is only one treatment arm for this study
11310559|NCT02629107||Healthy Volunteers|Healthy volunteers, age 18-34.
11310560|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
11310561|NCT02629081||Controls & Cases|Controls (participants without heartburn or other GERD symptoms undergoing standard upper endoscopy for the following: anemia, weight loss, diarrhea, and screening for esophageal varices) and Cases (participants with heartburn or other GERD symptoms undergoing standard endoscopy for heartburn or other GERD symptoms.)
11310562|NCT02629068|Experimental|PURPOSE|"Parents in the PURPOSE group will join a secret Facebook group for 2 months. Groups will be lead by 2 peer leaders and include 20 parent participants."
11310563|NCT02629068|No Intervention|Treatment as Usual (TAU)|Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
11310564|NCT02629055|Experimental|Respiratory EMG|Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
11310565|NCT02629055|No Intervention|Care as usual|NIV will be initiated according to standard care protocol.
11310566|NCT02629042|Active Comparator|Control|
11310567|NCT02629042|Experimental|Experimental|
11310568|NCT02629029|Other|Surgical - therapeutic free flap|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will be imaged using two systems: (i) pre-operative CTA with IV contrast; (ii) intra-operative fluorescence endoscopy with ICG.
11310569|NCT02629016|Experimental|Mindfulness|Education and experiential exercises for mindfulness including movement, thoughts and meditation
11310570|NCT02629016|Active Comparator|Wellness|Education and experiential exercises for general wellness including sleep hygiene, goal setting and power poses.
11310571|NCT02629016|No Intervention|Waitlist|Students receive regular health class instruction without intervention.
11310572|NCT02629003|Active Comparator|[11C]Cimbi-36|"[11C]Cimbi-36
~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
11310573|NCT02629003|Active Comparator|[11C]Cimbi-36-5|"[11C]Cimbi-36-5
~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
11310574|NCT02628990|Experimental|1.6 g plant stanols|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols), consumed with a meal daily for 4 weeks
11310575|NCT02628990|Experimental|2 g plant stanols|A yoghurt drink containing plant stanol ester (2 grams plant stanols), consumed with a meal daily for 4 weeks
11310576|NCT02628990|Experimental|1.6 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
11310577|NCT02628990|Experimental|2 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (2 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
11310578|NCT02628990|Placebo Comparator|Placebo|A placebo yoghurt drink, consumed with a meal daily for 4 weeks
11310579|NCT02628977|Experimental|OSA Health Education & Support Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer educator.
11310580|NCT02628977|Active Comparator|Attention Control Group|Participants in the attention control group will receive standard sleep literature, providing information about Obstructive Sleep Apnea and access to available sleep services.
11310581|NCT02628964|Active Comparator|4.5% e-cig|e-cigarettes with nicotine cartridges
11310582|NCT02628964|Placebo Comparator|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
11310583|NCT02628951|Experimental|Ramucirumab + Paclitaxel|"Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
~Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason."
11310584|NCT02628938|Experimental|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
11310585|NCT02628938|Experimental|Miswak sticks|Sticks twice a day for 7 days
11310586|NCT02628938|Active Comparator|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
11310587|NCT02628925||Recovery room|10 medical staff working in the recovery room
11310588|NCT02628925||Orthopedic ward|10 medical staff working on the orthopedic ward
11310688|NCT02628249|Experimental|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.
11365526|NCT02263989|Active Comparator|Telmisartan conventional tablet|
11310589|NCT02628912||long-term survivors of HPV-related oropharyngeal cancer|This is a cross-sectional pilot study of long-term survivors of HPV-related oropharyngeal cancer treated with CTRT who are at least three years from treatment completion. This study consists of a onetime assessment of cardiopulmonary fitness, physical function status, measurement of lean body mass, endothelial function quality of life assessment, medical history and blood laboratory evaluation for traditional cardiac risk factors, endocrine derangement and inflammation.
11310590|NCT02628899|Other|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
11310591|NCT02628899|Other|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
11310592|NCT02628899|Other|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
11310593|NCT02628886|Experimental|maternal group|13-valent pneumococcal conjugate vaccine [Prevenar13®] (PCV13) vaccine, 0.5ml, once, stat, plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
11310594|NCT02628886|Placebo Comparator|control group|placebo sterile 0.9% sodium chloride, 0.5ml, once, stat plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
11310595|NCT02628886|Experimental|neonatal group|tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV 13 0.5ml at birth, 8 weeks and 16 weeks
11310596|NCT02628873|Experimental|Arm 1 (HyCoSy followed by HSG)|HyCoSy procedure followed by HSG procedure
11310597|NCT02628873|Experimental|Arm 2 (HSG followed by HyCoSy)|HSG procedure followed by HyCoSy procedure
11310598|NCT02628860|Experimental|Ferinject|"Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .
~Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.
~Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial."
11310599|NCT02628847|Experimental|Drug|Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
11310600|NCT02628847|Placebo Comparator|control|placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
11310601|NCT02628834|Experimental|Fascial mobilization|First day intervention: Patients will take fascial mobilization techniques to management of plantar flexor spasticity
11310602|NCT02628834|Experimental|Stretching exercise|Second day intervention:Patients will take fascial mobilization techniques to management of plantar flexor spasticity
11310603|NCT02628834|No Intervention|Healthy Volunteers|Healthy individuals will only be evaluated with no intervention
11310604|NCT02628821||Preterm Infants treated with non-invasive ventilation|"Preterm Infants of less than 32 weeks of Gestational age treated with synchronized non-invasive ventilation (SNIPPV) to prevent intubation or extubation failure based in a prospective protocol:
~nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria if they are in a stable situation.
~Electively For extubation:
~Preterm infants in which nCPAP extubation has previously failed or Prolonged mechanical ventilation (more than 15 days) with high respiratory parameters (PMAP > 10 cmH2O and FiO2>35%)."
11310605|NCT02628808||Autism Spectrum Disorder|For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
11310606|NCT02628808||controls|Age 6 to 40 Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
11310607|NCT02628795|Experimental|PRT + FM|Progressive resistance training + functional mobility training 3 d/wk x 16 wk
11310608|NCT02628795|Active Comparator|Usual Care|Post-surgical usual care including physical therapy
11310609|NCT02628782|Experimental|InSeal VCD|InSeal's Vascular Closure Device Use of the experimental VCD to close the access site of the artery
11310610|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
11310611|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
11310612|NCT02628756|Experimental|Endometrial injury|Hysteroscopic-guided endometrial injury (Karl Storz, Tuttlingen, Germany).
11310613|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.
~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
11310614|NCT02628730|Active Comparator|Ablation Index Group|PVI using radiofrequency ablation (RFA) guided by Ablation Index.
11310689|NCT02628249|Experimental|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.
11310690|NCT02628249|Experimental|Base + BCAA|Base protein intake + Branched chain amino acids
11365527|NCT02263976|Experimental|BEA 2180 BR|single rising doses
11310615|NCT02628730|Other|Reference Group (Contact Force Group)|That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
11310616|NCT02628717||SOF/SMV|SOF/SMV 400mg/150mg QD 12-24 weeks
11310617|NCT02628717||SOF/DCV|SOF/DCV 400mg/60mg QD 12-24 weeks
11310618|NCT02628717||SOF/LDV|SOF/LDV 400mg/90mg QD 12-24 weeks
11310619|NCT02628717||treatment duration|12 - 24 weeks
11310620|NCT02628704|Experimental|Selinexor, carfilzomib and dexamethasone|60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
11310621|NCT02628704|Placebo Comparator|Placebo, carfilzomib and dexamethasone|Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
11310622|NCT02628691||HCV coinfection with no-to-moderate fibrosis|
11310623|NCT02628678|Other|Fructooligosaccharide (FOS)|Subjects will be required to take 8 grams of FOS per day for a total of 10 days.
11310624|NCT02628665|Experimental|24 to 48 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power.
~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
11310625|NCT02628665|Active Comparator|48 to 72 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power.
~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
11310626|NCT02628652|Experimental|Gluco-Galacto-Oligosaccharide (GOS)|Subjects randomized to this treatment arm will ingest GOS once per day for a total of 14 days. One level of GOS will be taken during Phase I and 2 levels of GOS will be taken during Phase II.
11310627|NCT02628652|Experimental|Gluco-Oligosaccharide (GLOS)|Subjects randomized to this treatment arm will ingest GLOS once per day for a total of 14 days. One level of GLOS will be taken during Phase I and 2 levels of GLOS will be taken during Phase II.
11310628|NCT02628652|Active Comparator|FructoOligosaccharide (FOS)|Subjects randomized to this treatment arm will ingest FOS once per day for a total of 14 days. One level of FOS will be taken during Phase I and 2 levels of FOS will be taken during Phase II.
11310629|NCT02628639|Experimental|electroencephalography recording|Cerebral measurements from high-density electroencephalography after the presentation of personalized stimulations
11310630|NCT02628626|Placebo Comparator|Placebo|Patients in this arm will receive placebo for 4 weeks.
11310631|NCT02628626|Active Comparator|Colesevelam and Clonidine|Patients in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks.
11310632|NCT02628613|Active Comparator|Paclitaxel plus Epirubicin|Paclitaxel plus Epirubicin for 4 cycles, paclitaxel 80 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
11310633|NCT02628613|Experimental|Vinorelbine plus Epirubicin|Vinorelbine plus Epirubicin for 4 cycles, vinorelbine 25 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
11310634|NCT02628600|Experimental|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
11310635|NCT02628600|Experimental|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
11310636|NCT02628587|Experimental|Generic clopidogrel|Patients are assigned to take generic clopidogrel
11310637|NCT02628587|Active Comparator|Patent clopidogrel|Patients are assigned to take patent clopidogrel (Plavix)
11310638|NCT02628574|Experimental|TRX518 monotherapy (Parts A and B)|Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
11310639|NCT02628574|Experimental|TRX518 with gemcitabine (Part C)|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
11310640|NCT02628574|Experimental|TRX518 with pembrolizumab (Part D|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
11310641|NCT02628574|Experimental|TRX518 with nivolumab (Part E)|Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
11310642|NCT02628561|Active Comparator|Active tdcs/M1|Anodal tDCS on primary motor cortex and CIMT (constraint induced movement therapy)
11310643|NCT02628561|Experimental|Active tdcs/Premotor|Anodal tDCS on premotor cortex and CIMT (constraint induced movement therapy)
11310644|NCT02628561|Sham Comparator|Sham tdcs|Sham tDCS and CIMT (constraint induced movement therapy)
11310645|NCT02628548|Experimental|Cognitive training program 1|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
11310646|NCT02628548|Experimental|Cognitive training program 2|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
11310647|NCT02628535|Experimental|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
11310648|NCT02628522|Experimental|ADRCs therapy|"Infiltration with 20mL Lidocaine 2% and Epinephrine 1:100 000. Liposuction will be done from the abdomen using Tulip cannulas. Fat will be processed with Celution system.
~Isolated ADRCs will be administered in chronic anal fissures."
11310649|NCT02628509||cardiac devices|patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
11310691|NCT02628249|Experimental|Base + EAA|Base protein intake + essential amino acids.
11310650|NCT02628496|Experimental|Arm 1: CLM|"On the day of surgery, participants will have placement of laser-safe endotracheal tube and a rigid laryngoscope will be introduced into the oral cavity to gain access to the laryngeal introitus and then placed into suspension (standard of care)
~Fluorescein dye will be administered intravenously
~Confocal laser probe will be introduced through the rigid laryngoscope and touched first on the lesion of concern and put into scanning mode in order to obtain photos and video footage of the lesions. The probe will then be placed on normal appearing vocal fold tissue to obtain a control sample.
~The remainder of the procedure is standard excisional biopsy and KTP laser photoablation"
11310651|NCT02628483|Experimental|Ultimate Omega|5 capsules of Ultimate Omega fish oil daily in the morning with food
11310652|NCT02628483|Active Comparator|Meg-3|5 capsules of Meg-3 fish oil daily in the morning with food
11310653|NCT02628470|Experimental|group cervical manipulation|The patient is supine without a pillow and physiotherapist standing in the ipsilateral corner of the hand of the thrust.
11310654|NCT02628470|Placebo Comparator|Placebo group|Participants will receive a protocol of domiciliary cervical control exercises.
11310655|NCT02628470|Active Comparator|Group cervical mobilization|Oscillatory mobilization technique. With the patient in prone, the investigator applies an oscillatory motion in the most painful cervical segment for three minutes
11310656|NCT02628457||Mild Subgroup|patients with supraspinatus tendon retracted upto medial 1/3rd of humerus head and arthroscopic rotator cuff repair done by single row.
11310657|NCT02628457||Moderate Subgroup|patients with supraspinatus tendon retracted between medial 1/3rd of humerus head and glenoid,and arthroscopic rotator cuff repair done by single row.
11310658|NCT02628457||Severe subgroup|patients with supraspinatus tendon retracted beyond glenoid and arthroscopic rotator cuff repair done by single row
11310659|NCT02628444|Experimental|Group 1|3 injections of CYD dengue vaccine at Day 0, Day 0 + 6 months, and Day 0 + 12 months. Booster injection of CYD dengue vaccine 1 year or 2 years after third injection among previously dengue exposed participants only.
11310660|NCT02628444|Experimental|Group 2|1 injection of placebo (NaCl 0.9%) followed by 2 injections of CYD dengue vaccine at Day 0, Day 0 + 6 months, and Day 0 + 12 months. Booster injection of CYD dengue vaccine 1 year or 2 years after third injection among previously dengue exposed participants only.
11310661|NCT02628444|Experimental|Group 3|2 injections of placebo (NaCl 0.9%) followed by 1 injection of CYD dengue vaccine at Day 0, Day 0 + 6 months, and Day 0 + 12 months. Booster injection of CYD dengue vaccine 1 year or 2 years after third injection among previously dengue exposed participants only.
11310662|NCT02628431||General anesthesia|Patients that will recieve general anesthesia for elective surgery
11310663|NCT02628431||Regional or neuraxial anesthesia|Patients that will revieve regional or neuraxial anesthesia for elective surgery
11310664|NCT02628418|Experimental|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:
~General Rehabilitation
~Specific hand rehabilitation by Gloreha device"
11310665|NCT02628418|Other|Control Group|"The patients in the Control Group underwent to following interventions:
~General Rehabilitation
~Specific hand rehabilitation performed by physiotherapist"
11310666|NCT02628405|Experimental|Treatment (R2-ICE)|Patients receive lenalidomide PO daily on days 1-14, rituximab IV on day 1, ifosfamide IV over 24 hours on day 2, carboplatin IV over 1-2 hours on day 2, and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CMR, PMR, or NMR may receive 2 more cycles per physician discretion. After completion of 2 cycles of R2ICE treatment, patients achieving objective status of CMR, PMR or NMR may proceed to SCT during the event monitoring phase.
11310667|NCT02628392|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
11310668|NCT02628392|Experimental|DS-8500a 50 mg QD|DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
11310669|NCT02628392|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
11310670|NCT02628392|Placebo Comparator|placebo|placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
11310671|NCT02628392|Active Comparator|Sitagliptin|capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet
11310672|NCT02628379||Class 1, 2, or 3 alterations, with targeted therapy|Patients put on targeted therapies matched to specific genomic alterations.
11310673|NCT02628379||Site-specific therapy determined by tissue of origin testing|Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)
11310674|NCT02628379||Empiric CUP therapy|Patients put on empiric treatment at physician discretion
11310675|NCT02628366|Experimental|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
11310676|NCT02628366|No Intervention|Fixed Dialysate Temperature at 36.5°C|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
11310677|NCT02628353|Placebo Comparator|Placebo|control group
11310678|NCT02628353|Experimental|Phenolic compound|treated group
11310679|NCT02628327||Glaucoma subjects|Survey given to all glaucoma subjects agreening to study.
11310680|NCT02628314||Osteoarthritis|Study population to include adult men and women with osteoarthritis.
11310681|NCT02628301|Active Comparator|Hypercaloric diet|Hypercaloric diet (1.6x REE) for 30 days
11310682|NCT02628301|Placebo Comparator|Normal diet|Normocaloric diet (1.0xREE)
11310683|NCT02628288|Active Comparator|PCI with Axxess device + AbsorB BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with AXXESS device and additional Absorb BVS.
11310684|NCT02628288|Active Comparator|PCI with Modified T with Absorb BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with a modified T stenting technique using Absorb BVS.
11310693|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
11310694|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
11310695|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
11310696|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
11310697|NCT02628197|Active Comparator|CONTROL GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.Scaling and root planing was not done in this group.
11310698|NCT02628197|Active Comparator|TEST GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received scaling and root planing along with calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.
11310699|NCT02628171|Other|Control|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of cashew nuts (control).
11310700|NCT02628171|Active Comparator|Cashew|Participants will receive a controlled diet, typical of an American diet, with 42 g/day of cashew nuts (base diet with cashew nuts).
11310701|NCT02628145|Experimental|Resistance Training Intervention|The RT intervention will take place three times per week for approximately 12 weeks on non-consecutive days using 8-10 exercises for major muscle groups utilizing free weights and machines follow American College of Sports Medicine and National Strength and Conditioning Association guidelines for RT in older adults.
11310702|NCT02628145|Active Comparator|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
11310703|NCT02628132|Experimental|Durvalumab and Paclitaxel|After one cycle of paclitaxel, durvalumab will be given concurrently with paclitaxel. Once paclitaxel cycles are completed, durvalumab will be continued alone until disease progression or unacceptable toxicity.
11310704|NCT02628119|Experimental|Intra-procedural access flow|"Management of access dysfunction based on intra-procedure access flow monitoring.
~Criteria for target access flow:
~Within 90% of baseline access flow if known 180% increase from pre-intervention flow if access flow not known 600ml/min for thrombosed grafts and 500 ml/min for thrombosed arteriovenous fistula in case baseline access flow not known"
11310705|NCT02628119|Active Comparator|Standard Angioplasty|Intervention based on current standards of care i.e. 2 dimensional angiographic views.
11310706|NCT02628106|Experimental|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
11310707|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
11310708|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
11310709|NCT02628080|Experimental|Cohort 1|Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
11310710|NCT02628080|No Intervention|Cohort 2|Device: PET-CT, Device: DWI-MRI
11310711|NCT02628067|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).
11310712|NCT02628067|Experimental|Pembrolizumab 400 mg|Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H), excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).
11310713|NCT02628054|Active Comparator|Typhoid Vaccine|Typhoid vaccination in single 0.5mL injections into the non-dominant deltoid muscle in the arm
11310714|NCT02628054|Placebo Comparator|Placebo|A single 0.5mL injection of 0.9% sodium chloride saline solution into the non-dominant deltoid muscle in the arm
11310715|NCT02628041|Active Comparator|Permanent Iodine-125 seed implant|Prostate brachytherapy using Iodine-125 seed implant to a prescription dose of 144 Gy delivered to the Target volume defined as Clinical Target volume (CTV)+ 0-3 mm margin.
11310716|NCT02628041|Experimental|High-dose-Rate Prostate brachytherapy|"Prostate brachytherapy implant using Iridium-192 to a prescription dose of 19 Gy delivered to the CTV in one fraction. Greater than 95% coverage of the CTV with the prescription dose is considered per protocol, 90-95% coverage is considered a minor deviation and, < 90% coverage is considered a major deviation.
~Attempts should be made to achieve these other dosimetric values:
~D90: 105-115%
~V150 ≤ 35%
~V200 ≤ 12%"
11310717|NCT02628028|Experimental|Part A 5 mg LY3337641|Given once a day for 4 weeks.
11310718|NCT02628028|Experimental|Part A 10 mg LY3337641|Given once a day for 4 weeks.
11310719|NCT02628028|Experimental|Part A 30 mg LY3337641|Given once a day for 4 weeks.
11310720|NCT02628028|Placebo Comparator|Part A Placebo|Given once a day for 4 weeks.
11310721|NCT02628028|Experimental|Part B 5 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
11310722|NCT02628028|Experimental|Part B 10 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
11310723|NCT02628028|Experimental|Part B 30 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
11310724|NCT02628028|Placebo Comparator|Part B Placebo|Given once a day for 12 weeks.
11310725|NCT02628015||preschool children preterm|born 2010 or 2011 Birthweight <1500g
11310726|NCT02628015||preschool children full-term|born 2010 or 2011 born after 38 weeks
11310727|NCT02628015||school children preterm|same children from the preschool group will be tested 2 years later again
11310728|NCT02628015||school children full-term|same children from the preschool group will be tested 2 years later again
11310729|NCT02628015||youths preterm|born 2001 or 2002 Birthweight <1500g
11310730|NCT02628015||youths full-term|born 2001 or 2002 born after 38 weeks
11310731|NCT02628015||adults preterm|Birthweight <1500g
11310732|NCT02628015||adults full-term|born after 38 weeks
11310767|NCT02627742|Experimental|METANEB|Patients will receive standard care with the addition of therapy with The MetaNeb® System.
11311727|NCT02621424|Sham Comparator|sham|sham noise to block the sound of treatment
11310733|NCT02628002|Experimental|Test arm|The subjects randomized to the anti-gravity treadmill arm will be instructed on the safe use of the Alter-G treadmill by the study staff. After this instruction, subjects will be exercised on the Alter-G anti-gravity treadmill using the conventional Bruce protocol with unweighting to 75% of their body weight to reach target heart rate. If the subject is unable to reach the target heart rate, they will be further unweighted to 50% of their body weight to enable the subject to reach target heart rate on the Bruce protocol. If the subject is still unable to reach target heart rate with 50% unweighting, the patient's subsequent SPECT images will be excluded from use in the research comparison to control subject images.
11310734|NCT02628002|Active Comparator|Control arm|The control arm subjects will undergo the conventional treadmill/regadenoson pharmacological stress SPECT. Consistent with standard practice, these patients will perform adjunctive low-intensity walk on a conventional treadmill prior to regadenoson and Tc-99m injection if tolerated.
11310735|NCT02627989||Diflucortolone valerate (Nerisona/Texmeten)|Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
11310736|NCT02627976|Active Comparator|breast edema vest|
11310737|NCT02627963|Experimental|Tivozanib hydrochloride|Patients randomized to this arm will receive the study drug, tivozanib hydrochloride.
11310738|NCT02627963|Active Comparator|Sorafenib|Patients randomized to this arm will receive the comparator drug, sorafenib.
11310739|NCT02627950|Active Comparator|Isotonic sodium chloride + Ticagrelor|46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy
11310740|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor|46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
11310741|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor + Metoclopramide|46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
11310742|NCT02627937||pediatric sleep apnea|The children were confirmed to have OSAHS by comprehensive polysomnography (PSG).
11310743|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
11310744|NCT02627911|Other|Usual System (open-loop)|"In open loop, the patient will be provided with its usual pump and a CGM. To estimate rest and physical activity in patients being sedentary situation ( Centers : Caen, Nancy & Strasbourg) or in situations of physical activity ( Centers : CHSF Marseille and Besancon ) , the usual system will be complemented by an accelerometer  ActiGraph  and a  ActiHeart  heart rate monitor."
11310745|NCT02627911|Experimental|DIABELOOP System (closed-loop)|In the closed loop, the patient's pump will be replaced by the Diabeloop system consisting of insulin pump Cellnovo driven by remote control augmented by Diabeloop software and connected to the CGM.
11310746|NCT02627898|Experimental|Green tea extract|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
11310747|NCT02627898|Placebo Comparator|Placebo|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
11310748|NCT02627885|Active Comparator|ICBT|Internet-based CBT for Parkinsons Disease with therapist contact added to standard medical treatment
11310749|NCT02627885|Other|SMT|Standard Medical Treatment for Parkinsons Disease only
11310750|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
11310751|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
11310752|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
11310753|NCT02627859|Experimental|Durolane SJ|Durolane SJ intra-articular injection; device
11310754|NCT02627846|Active Comparator|EndoVenous Laser Ablation|EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
11310755|NCT02627846|Active Comparator|MechanoChemical Ablation (ClariVein®)|Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.
11310756|NCT02627833||Subject Group|Patients suffering from Bronchiolitis Obliterans
11310757|NCT02627833||Control Group|Age and sex matched control group
11310758|NCT02627820|Experimental|Experimental Drug|Isis 420915/GSK 299872, an antisense oligonucleotide. Administered subcutaneously three times per week for the first week, and then weekly for 18 months. Each dose shall contain 300 mg of active drug.
11310759|NCT02627807|Experimental|Individualized CTV|Patients receive IMRT using individualized CTV based on disease extension risk atlas and computer-aided delineation. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
11310760|NCT02627807|Active Comparator|Traditional CTV|Patients receive IMRT using traditional CTV. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
11310761|NCT02627794|Experimental|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.
~Restora™ Steroid eluting spacer (experimental).
~Each nostril will receive one each of above spacers."
11310762|NCT02627781||suspected appendicitis|This group includes all patients with suspected appendicitis, who are admitted to our University Hospital.
11310763|NCT02627768||Cohort 1: Ustekinumab Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
11310764|NCT02627768||Cohort 2: TNFi Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
11310768|NCT02627729|Active Comparator|Linear cutter-Circular stapler J pouch|J pouch anal anastomosis after laparoscopic low anterior resection
11310769|NCT02627729|Active Comparator|Circular stapler Side-to-end anastomosis|side to end coloanal anastomosis after laparoscopic low anterior resection
11310770|NCT02627716|Experimental|SOS Intervention Group|Subjects benefit from the SOS Plan in addition to the usual follow-ups
11310771|NCT02627716|No Intervention|Control Group|Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)
11310772|NCT02627690||Islet transplanted|patients who underwent islet transplantation
11310773|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
11310774|NCT02627677|Experimental|Cohort A: ponatinib 30 mg QD|ponatinib 30 mg, taken orally once daily
11310775|NCT02627677|Experimental|Cohort B: ponatinib 15 mg QD|ponatinib 15 mg, taken orally once daily
11310776|NCT02627677|Active Comparator|Cohort C: nilotinib 400 mg BID|nilotinib 400 mg, taken orally twice daily
11310777|NCT02627664||observational study|natural history of non dopaminergic signs
11310778|NCT02627651|Experimental|brain injury|children post brain injury
11310779|NCT02627651|Active Comparator|controls|children typically developed age matched
11310780|NCT02627638|Other|Osteopathic treatment|
11310781|NCT02627625|Experimental|test product A|tiotropium
11310782|NCT02627625|Experimental|test product B|tiotropium
11310783|NCT02627625|Experimental|test product C|tiotropium
11310784|NCT02627625|Active Comparator|Commercial product D|tiotropium
11310785|NCT02627625|Active Comparator|commercial product E|tiotropium
11310786|NCT02627612|Experimental|TM RWB PLUS Pro Vetus|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this group and request that they voluntarily join TM RWB and receive mentorship from their matched and assigned mentor. In addition to TM RWB membership, research participants will also receive approximately four months of mentorship from a ProVetus mentor to assist them in further transitioning within the five domains.
11310787|NCT02627612|Active Comparator|TM RWB ONLY|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this arm and request that they voluntarily join TM RWB. Weekly emails will provide lists of voluntary physical/social activities available to all Chapter members. No participation is required in these activities.
11310788|NCT02627612|No Intervention|Control Group (Waitlist)|Research participants (recent Veterans) will be placed on a waitlist for approximately sixteen months. Based on their desires, the research participants in this group will have opportunity to belong to TM RWB plus receive approximately four months of mentorship from trained, peer-mentors (who are TM RWB volunteers).
11310789|NCT02627599||Chronic Obstructive Pulmonary Disease|"More than 12 million adults are diagnosed with COPD
~COPD is the 3rd leading cause of death in the U.S.
~Breathing difficulty is the major reason patients seek medical attention
~COPD patients requiring hospitalization are associated with higher costs
~Oximetry is an important tool for assessing need for Long-Term Oxygen Therapy
~LTOT has been proven to improve survival and quality of life
~Patients provided with a breath responsive variable bolus oxygen conserving device:
~support increased activity
~improve quality of life
~increase functional capability
~reduce portable oxygen source utilization
~maintain and/or improve oxygen saturation"
11310790|NCT02627586|Active Comparator|Moderate intensity continuous exercise|Moderate intensity continuous exercise (MICE) is performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group will perform MICE training three times per week. Cycling resistance will be adjusted weekly according to heart rate and Borg scale.
11310791|NCT02627586|Experimental|High-intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. Moderate intensity continuous exercise (MICE) is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group performs two HIIT sessions and one MICE session per week.
~In both training forms cycling resistance will be adjusted weekly according to heart rate and Borg scale."
11310792|NCT02627573|Experimental|Thymoglobulin|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
11310793|NCT02627573|Experimental|PTCy|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
11310794|NCT02627560|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
11310795|NCT02627560|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
11310796|NCT02627547|Experimental|Experimental tests|2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training
11310797|NCT02627534|Active Comparator|Ultrasonic Debridement (UD)|Ultrasonic Debridement (UD) (n=20)
11310798|NCT02627534|Experimental|UD + Antimicrobial Photodynamic Therapy|Ultrasonic Debridement + aPDT (UD+aPDT) (n=20)
11310799|NCT02627521|Experimental|PRU Guided CABG|Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value >235 or a PRU value between >170 and <235 for two consecutive days as documented by VerifyNow assay.
11310800|NCT02627521|Active Comparator|CABG per standard of care|Timing of CABG per standard of care
11310887|NCT02626858|Other|extra treatment planning CT-scan|Extra pre-operative CT-scan for treatment planning in RT
11310888|NCT02626845|Active Comparator|Rituximab Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
11310801|NCT02627508|Experimental|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.
~Weeks 1 and 2: 30mg twice daily (total 60mg per day)
~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)
~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)
~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)
~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)
~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
11310802|NCT02627508|Placebo Comparator|Placebo|Placebo
11310803|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
11310804|NCT02627469|No Intervention|Control|Common oral hygiene help administered by nursing staff
11310805|NCT02627469|Experimental|Intervention|Extended professional oral hygiene care Electric toothbrush (Oral-B Professional Care 7000) 1100 ppm sodium fluoride dentifrice (Zendium Classic, Opus Health Care AB/Zendium)
11310806|NCT02627456|Experimental|1A|(n=5), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (4.5x105) via DVI. All 5 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination.
11310807|NCT02627456|Experimental|1B|(n=S), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (9.0x10S) via DVI. All S subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination
11310808|NCT02627456|Experimental|1C|(n=30), will be the targeted dose for the Pilot Safety Group. Subjects will receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. 15 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to each administration of PfSPZ Vaccine, while 15 will not, except prior to PfSPZ Vaccine #3 when all 30 subjects will receive antimalarial treatment with ASAQ.
11310809|NCT02627456|Experimental|1D|(n=15), will be the CHMI control group. Subjects will not receive any PfSPZ vaccinations but will serve as infectivity controls for CHMI. All 15 subjects will receive antimalarial treatment with ASAQ prior to PfSPZ Challenge.
11310810|NCT02627456|Experimental|2|(n=60), will be the targeted vaccine dose arm and receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the pilot study indicate otherwise.
11310811|NCT02627456|Placebo Comparator|3|(n=60), will be the placebo arm and receive vaccinations with normal saline via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the Pilot Study indicate otherwise.
11310812|NCT02627456|Active Comparator|4|(n=SS), will be group- matched (age, sex, village) controls for Arm 2 for the duration study. Subjects previously enrolled in Arm 3 may re-enroll in Arm 4. All subjects will receive antimalaria treatment at enrollment
11310813|NCT02627443|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11310814|NCT02627430|Experimental|Treatment (talazoparib and Hsp90 inhibitor AT13387)|Patients receive talazoparib PO QD on days 1-7 (course 0). Beginning in course 1, patients receive talazoparib PO QD on days 1-28 and HSP90 inhibitor AT13387 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11310815|NCT02627417|Experimental|Dapsone: (Disulone®)|Dapsone: Disulone® given orally at 100 mg per day
11310816|NCT02627417|Active Comparator|"Prednisone (Cortancyl®) alone and standard of care"|"Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and standard of care (control arm)"
11310817|NCT02627404|Other|Main module|Blood sample
11310818|NCT02627391|Experimental|Early surgery|Surgical aortic valve replacement
11310819|NCT02627391|Active Comparator|Delayed surgery according to guidelines|Surgical aortic valve replacement
11310820|NCT02627378|Active Comparator|Extracorporeal Membrane Oxygenation|Patients received Extracorporeal Membrane Oxygenation (ECMO) support
11310821|NCT02627378|Placebo Comparator|Non Extracorporeal Membrane Oxygenation|Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
11310822|NCT02627365|Experimental|Individualized, interactive SMS|Individualized, interactive SMS intervention plus Standard care. Messages sent automatically using the Text-IT system.
11310823|NCT02627365|No Intervention|Standard care|Standard care according to Kenyan guidelines, including clinic-based adherence education and counseling.
11310824|NCT02627352|Experimental|Transscleral Cyclophotocoagulation|Subjects undergo a Micropulse Transscleral Cyclophotocoagulation(TSCPC) laser surgery, where a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
11310825|NCT02627339||Healthy controls|Healthy controls age 10 to 90 years
11310826|NCT02627326|Active Comparator|Group 1|Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
11310827|NCT02627326|Active Comparator|Group 2 Chlorhexidine|Interventions done in 30 patients and included intracanal medicament . After biomechanical preparation of root canal, 2%Chlorhexidine gluconate gel as an intracanal medicament was placed in root canal from pulp chamber to apex for 3 months (replacing every month). After 3 months,periodontal surgery in the form of open flap debridement (OFD) was performed in the respective tooth and medicament was changed and placed further for 3 months (replacing every month). Obturation was done after 3 months of OFD.
11310828|NCT02627313|Experimental|GammaPod|GammaPod tumour bed boost
11310829|NCT02627287|Experimental|DV3316 pen-injector|
11310830|NCT02627287|Active Comparator|FlexPen®|
11310831|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
11310832|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
11310833|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.
~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
11310834|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
11310835|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide (TEC)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
11310836|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
11310837|NCT02627248|Experimental|Epirubicin and Docetaxel (ET)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
11310838|NCT02627248|Experimental|Epirubicin and Docetaxel+Huaier (ET+HE)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
11310839|NCT02627235|Experimental|DIAL Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
11310840|NCT02627235|Active Comparator|Wait List Control|Access to the intervention 12 weeks following baseline assessment.
11310841|NCT02627222|Active Comparator|Treatment|Daily consumption of two cassava-based meals prepared with pro-vitamin A rich biofortified cassava
11310842|NCT02627222|Placebo Comparator|Control|Daily consumption of two cassava-based meals prepared with common white cassava
11310843|NCT02627209|Active Comparator|serum angiotensin converting enzyme|spectrophotometric assay
11310844|NCT02627209|Active Comparator|serum lysozyme|radial immunodiffusion
11310845|NCT02627196|Experimental|Device and Medical Management|Subjects will be implanted with the BAROSTIM NEO System and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
11310846|NCT02627196|Active Comparator|Medical Management|Subjects will receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
11310847|NCT02627183||Paroxysmal AF + catheter ablation|Subjects with paroxysmal Atrial Fibrillation (AF) undergoing catheter ablation.
11310848|NCT02627183||Permanent/persistent AF + exercise|Subjects with permanent or persistent Atrial Fibrillation (AF) undergoing exercise training two times weekly for 12 weeks as part of their involvement in the OPPORTUNITY Study (NCT02602457).
11310849|NCT02627170||Healthy adults group|Age 20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
11310850|NCT02627157||myopia patients|20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
11310851|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
11310852|NCT02627131|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
11310853|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
11310854|NCT02627105|Experimental|Beef group|Subjects in this group are asked to consume 4 or more servings of beef per week and to exclude all other red meats from their diet for the 6 month study.
11310855|NCT02627105|Other|Non-beef group|Subjects in this group are asked to avoid all red meats from their diet for the 6 month study.
11365528|NCT02263976|Placebo Comparator|Placebo|
11310856|NCT02627092|Experimental|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.
~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
11310857|NCT02627092|No Intervention|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.
~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
11310858|NCT02627079|Active Comparator|Cohort 1|"Cohort 1 will include 15 sedentary participants who have completed all cancer therapy except adjuvant hormonal therapy.
~All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity level for 12 weeks.."
11310859|NCT02627079|Active Comparator|Cohort 2|Cohort 2 will include 15 sedentary participants in active treatment. All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity levels for 12 weeks.
11310860|NCT02627066|Active Comparator|Volume Control|This group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
11310861|NCT02627066|Active Comparator|Volume Control + Exercise|This group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
11310862|NCT02627053|Experimental|rivaroxaban|
11310863|NCT02627040|Active Comparator|InterTan Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
11310864|NCT02627040|Active Comparator|Gamma 3 Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
11310865|NCT02627027|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
11310866|NCT02627027|Experimental|TR group|T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
11310867|NCT02627014|Experimental|INTERVENTION|Manual Therapy in temporomandibular joint and cervical region. Home physical therapy in temporomandibular joint and cervical region.
11310868|NCT02627014|Active Comparator|CONTROL|Manual therapy in cervical region Home physical therapy in cervical region
11310869|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
11310870|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
11310871|NCT02626988|Experimental|Intervention|The intervention group will receive capacity building sessions on the 'Promotion of a biodiverse diet' and will include both Agriculture and Nutrition topics, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal. 5 Sessions will be held in each village over 12 months.
11310872|NCT02626988|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
11310873|NCT02626975||ACL reconstruction ballooning|"ACL reconstruction with short hamstring tendon autograft
~arm ballooning
~arm no ballooning"
11310874|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
11310875|NCT02626949|Experimental|MBSR Course|Mindfulness-Based Stress Reduction Course (MBSR) consisting of 8 weekly sessions, 2.5 hours each, and a 5 hour silent retreat during the 6th week of the program.
11310876|NCT02626949|Experimental|HEP Course|Health Enhancement Program (HEP) consisting of 8 weekly sessions, 2.5 hours each, and 1.5 hour monthly educational sessions after the 8 week intervention.
11310877|NCT02626936|Active Comparator|Dual-hormone CL with overestimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 95g of carbohydrates.
11310878|NCT02626936|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
11310879|NCT02626923||Patients on once daily Maraviroc|Maraviroc tablet 600 mg once daily 48 weeks
11310880|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
11310881|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
11310882|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
11310883|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
11310884|NCT02626897|Other|Sarcoidosis - GENEActiv device first|Six patients start with the GENEActiv wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the ActiGraph GT3X device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
11310885|NCT02626897|Other|Sarcoidosis - ActiGraph device first|Six patients start with the ActiGraph GT3X wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the GENEActiv device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
11310886|NCT02626884|Experimental|Ibrutinib|All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
11310889|NCT02626845|Placebo Comparator|Placebo Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
11310890|NCT02626832|Experimental|Healthy Control|This group is represented by healthy controls
11310891|NCT02626832|Experimental|Depression|This experimental group is represented by subjects with depression
11310892|NCT02626832|Experimental|Schizophrenia|This experimental group is represented by subjects with schizophrenia
11310893|NCT02626832|Experimental|Prodromal subjects|This experimental group is represented by subjects with prodromal symptoms for schizophrenia
11310894|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
11310895|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
11310896|NCT02626806||patients with hemodynamic significant CAD;|
11310897|NCT02626806||patients without hemodynamic significant CAD|
11310898|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
11310899|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for > 1 conventional, systemic pre-treatment
11310900|NCT02626780|Experimental|SVF Injection|Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
11310901|NCT02626767|Experimental|Intervention|Participants were required to complete a high-intensity interval exercise training intervention, which took place three time per week for 10 weeks. The exercise sessions comprised of 4 to 7 repetitions of 45 s maximal effort exercise, based on boxing, dance, soccer and basketball drills), interspersed with 90-s rest. During each repetitions participants were encouraged to reach >90% of their individual maximal heart rate. Participants were asked to maintain their dietary habits throughout the intervention period.
11310902|NCT02626767|No Intervention|Control|Participants were asked to maintain their usual diet, physical education and physical activity habits during the intervention period and were not aware that an exercise intervention was taking place at other study sites.
11310903|NCT02626754|Experimental|Sunitinib|Sunitinib malate, 12.5mg/capsule, 50mg/day
11310904|NCT02626741|Experimental|meal replacement group|the participants receive a meal replacement plus life style modification
11310905|NCT02626741|Experimental|control group|the participants receive life style modification only.
11310906|NCT02626715|Active Comparator|Reduced-Intensity Conditioning|"Campath (alemtuzumab), Droxia (hydroxyurea), Fludara (fludarabine), Alkeran (melphalan), Thiotepa (triethylenethiophosphoramide)
~Trade Name (generic name)"
11310907|NCT02626715|Active Comparator|Myeloablative Conditioning|"Campath (alemtuzumab), Thiotepa (triethylenethiophosphoramide) , Fludara (fludarabine), Busulfex (busulfan)
~Trade Name (generic name)"
11310908|NCT02626689||β-thalassemia transfusion dependent subjects|Participants will complete 3 quality of life instruments (i.e. FACT-AN, the SF-36v2, and the TranQol) once every 3 weeks, in addition to a TranQol instrument on the day of a RBC transfusion. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
11310909|NCT02626689||β-thalassemia Non Transfusion Dependent (NTD) subjects|Participants will complete 2 quality of life instruments (i.e. FACT-An and the the SF-36v2l) once every 3 weeks, in addition to completing the non-transfusion dependent Patient Recorded Outcome (PRO) tool on a daily basis. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
11310910|NCT02626676|Experimental|Educational Programme Group|Stage 5D Chronic Kidney Disease Patients on high-efficiency hemodialysis programme - 4-hour sessions, 3 times a week will be followed up
11310911|NCT02626663||aHUS|atypical Hemolytic Uremic Syndrome
11310912|NCT02626663||TTP|Thrombotic thrombocytopenic purpura
11310913|NCT02626663||MAHA|other microangiopathic hemolytic anemias
11310914|NCT02626650|Active Comparator|Check symptoms one has experienced|This is the baseline condition. When asked to indicate concussion symptoms (or most other kinds of symptoms for medical conditions), people usually place a check mark next to each symptom they have experienced.
11310915|NCT02626650|Experimental|Check symptoms one has not experienced|Participants place a check mark next to each symptom they have NOT experienced in the most recent sports season.
11310916|NCT02626650|Experimental|Uncheck symptoms one has experienced|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have experienced in the most recent sports season.
11310917|NCT02626650|Experimental|Uncheck symptoms one has not experienced.|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have NOT experienced in the most recent sports season.
11310918|NCT02626637|Experimental|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
11310919|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
11310920|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
11310921|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
11310922|NCT02626598||Treated patients|Patients treated with blended Belotero for etched-in fine lines of the cutaneous lip, and/or radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area will be evaluated with photographs, physician ratings, and patient improvement assessments.
11310923|NCT02626585|No Intervention|Control|Control group (n=20): Following removal of nasal cast on postoperative first week, no additional taping was applied to this group.
11310924|NCT02626585|Experimental|2-weeks of PRT|2-weeks of PRT (n=17): Following removal of nasal cast on postoperative first week, 2 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 3rd week).
11310925|NCT02626585|Experimental|4-weeks of PRT|4-weeks of PRT (n=20): Following removal of nasal cast on postoperative first week, 4 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 5th week).
11310926|NCT02626572|Experimental|S47445 5mg|
11310927|NCT02626572|Experimental|S47445 15mg|
11310928|NCT02626572|Experimental|S47445 50mg|
11310929|NCT02626572|Placebo Comparator|Placebo|
11310930|NCT02626546||Major surgical procedures|All patients selected to follow up
11310931|NCT02626533||Total knee arthroplasty patients|Patients undergoing total knee arthroplasty for osteoarthritis are enrolled in the study. Blood and joint fluid samples will be obtained from patients, and questionnaires will be administered to assess pain and stiffness.
11310932|NCT02626520|Experimental|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
11310933|NCT02626520|Experimental|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
11310934|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.
~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.
~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles
~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
11310935|NCT02626494|Experimental|Cocaine Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
11310936|NCT02626494|Active Comparator|Healthy Control Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
11310937|NCT02626481|Experimental|Daratumumab + Dexamethasone|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
11310938|NCT02626468||Normal|Participants with no diagnosis of respiratory disease between the ages of 0 and 80
11310939|NCT02626468||COPD|Patients from different diagnostic groups between the ages of 0 and 80
11310940|NCT02626455|Experimental|Copanlisib + R-B or R-CHOP / Arm 1|Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) [R-B] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP] (safety run-in and phase III)
11310941|NCT02626455|Placebo Comparator|Placebo + R-B or R-CHOP / Arm 2|Combination of placebo and R-B or R-CHOP (phase III only)
11310942|NCT02626442|Experimental|Group Exercise Class|6 month group balance/exercise class, three days a week - up to one hour. Exercise program includes walking around a track, bodyweight/balance exercises, and an obstacle course.
11310943|NCT02626442|No Intervention|Testing|Subjects enrolled in other MERCE exercise and robotics interventions will receive balance/walking tests, MRI with famous name recognition task, and cognitive testing pre and post their intervention.
11310944|NCT02626429|Experimental|Active, Young Adult Famale|Participants will complete a bout of exercise and then consume a randomly assigned amino acid intake prior to measuring whole body 13CO2 excretion and phenylalanine oxidation.
11310945|NCT02626416|Experimental|telemedicine group|Congenital cataract patients use telemedicine to pursue and adjust the time of follow-up under non-clinical settings
11310946|NCT02626416|No Intervention|non-telemedicine group|Congenital cataract patients pursue and adjust the time of follow-up through outpatient visit in the hospital
11310947|NCT02626403|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (bilateral fronto-parietal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
11310948|NCT02626403|Sham Comparator|sham tDCS|Patients will receive sham tDCS (15 second of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
11310949|NCT02626390|Experimental|Implicit Learning|Physiotherapy delivered based on implicit treatment guidance - achieved primarily by reducing the frequency of verbal coaching statements and promoting an external focus of attention.
11310989|NCT02626104|Placebo Comparator|B - Maltodextrin|Maltodextrin orally - 100 mg twice a day, for whole antibiotic treatment period.
11310950|NCT02626390|Active Comparator|Explicit Learning|Physiotherapy delivered based on explicit treatment guidance - achieved primarily by giving frequent verbal coaching statements and promoting an internal focus of attention.
11310951|NCT02626377|Experimental|Interventional arm|'Support provided by social worker'
11310952|NCT02626377|Other|Non-interventional arm|'Information booklet receipt'
11310953|NCT02626364|Experimental|Treatment|crenolanib 100mg PO TID
11310954|NCT02626351|Experimental|Receiving/ received QI intervention|A clinic which is presently receiving the Intensive Phase of the QI intervention, or is in the Maintenance Phase
11310955|NCT02626351|Active Comparator|Not yet received QI intervention|A clinic which has not yet received the QI intervention
11310956|NCT02626338|Experimental|Arm A|"Mitoxantrone
~Cytarabine
~Crenolanib"
11310957|NCT02626338|Experimental|Arm B|"Mitoxantrone
~Etoposide
~Cytarabine
~Crenolanib"
11310958|NCT02626338|Experimental|Arm C|"Fludarabine
~Cytarabine
~G-CSF
~Idarubicin
~Crenolanib"
11310959|NCT02626312|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy 5 days a week for a total of 15 or 25 fractions in the absence of disease progression or unacceptable toxicity.
11310960|NCT02626299|Placebo Comparator|200 mg/day DHA|Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
11310961|NCT02626299|Experimental|1000 mg/day DHA|The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
11310962|NCT02626286|Other|HIV quarterly global care|HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.
11310963|NCT02626273|Experimental|intervention group|an intervention group who will undergo the management program combining physical activity and restrictive diet at Tza Nou Medical House for 10 months
11310964|NCT02626273|Other|a control group|a control group who will not undergo any intervention
11310965|NCT02626260|Experimental|Cohort 1b|The subject test one adhesive strip on the peristomal area
11310966|NCT02626247|Active Comparator|Vitamin A + Long chain PUFA|The test product is a food supplement containing Vitamin A + Long chain Poly Unsaturated Fatty Acids (PUFA). It is presented as a hard shell capsule containing lipophylic nutrients.
11310967|NCT02626247|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
11310968|NCT02626234|Experimental|INC280|
11310969|NCT02626221||Single|Single Cohort Study
11310970|NCT02626208|Experimental|Nestorone®/ Estradiol 75|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 75 ug/day of estradiol
11310971|NCT02626208|Experimental|Nestorone®/Estradiol 100|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 100 ug/day of estradiol
11310972|NCT02626208|Experimental|Nestorone®/ Estradiol 200|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 200 ug/day of estradiol
11310973|NCT02626195|Experimental|nutritional support program apply|Preoperative nutritional support program is given for 5 or more days preoperatively by nutritional support program.
11310974|NCT02626195|No Intervention|historical control group|Historical control group is that did not receiving
11310975|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
11310976|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
11310977|NCT02626169|Active Comparator|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
11310978|NCT02626169|Active Comparator|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
11310979|NCT02626156|Experimental|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
11310980|NCT02626156|Active Comparator|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
11310981|NCT02626143|Experimental|Investigational nutrient-rich whey protein formula|
11310982|NCT02626143|Active Comparator|Cow's milk based formula|
11310983|NCT02626143|No Intervention|Breast milk|
11310984|NCT02626130|Experimental|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
11310985|NCT02626130|Experimental|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
11310986|NCT02626117|Active Comparator|CAF+ SCTG+ laser depithelialisation|CAF + SCTG and Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium.
11310987|NCT02626117|Sham Comparator|CAF+SCTG+ sham laser depithelialisation|CAF+ SCTG+ sham LASER deepithelialisation was applied to remove the sulcular epithelium.
11310988|NCT02626104|Experimental|A - Lactoferrin|Bovine lactoferrin orally - 100 mg twice a day, for whole antibiotic treatment period.
11310990|NCT02626091|Experimental|Perfusion evaluation of anastomosis|During left-sided colonic resections, anastomosis perfusion will be estimated by the visual appreciation of the surgeon and the ICG fluorescence-based enhanced reality. These two approaches will be compared.
11310991|NCT02626078||observation and interview of residents|residents will be observed over lunch and an interview will be held with each resident after lunch
11310992|NCT02626065|Experimental|Nivolumab, patients with BRAF mutation|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
~Blood sampling at different time"
11310993|NCT02626065|Experimental|Nivolumab, patients with BRAF wild type|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
~Blood sampling at different time"
11310994|NCT02626026|Experimental|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
11310995|NCT02626026|Placebo Comparator|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
11310996|NCT02626026|Experimental|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
11310997|NCT02626026|Placebo Comparator|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
11310998|NCT02626026|Experimental|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
11310999|NCT02626026|Placebo Comparator|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
11311000|NCT02626000|Experimental|Talimogene Laherparepvec + Pembrolizumab|Talimogene laherparepvec is administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 3 weeks after the initial dose and every 3 weeks (Q3W) thereafter. Pembrolizumab is administered by intravenous infusion at a dose of 200 mg Q3W after the initial dose. Participants are treated until complete response, no injectable lesions, confirmed disease progression, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first.
11311001|NCT02625987|Experimental|Continuous intradermic stitch|Closure was did with a continuous intradermic stitch.
11311002|NCT02625987|Sham Comparator|Separated stitches|Like comparator was used a closure with separated stitches.
11311003|NCT02625974|Experimental|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
11311004|NCT02625974|Other|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
11311005|NCT02625961|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
11311006|NCT02625948|Active Comparator|tranexamic acid|tranexamic acid
11311007|NCT02625948|Placebo Comparator|Placebo|0.9% NaCl
11311008|NCT02625948|No Intervention|observation(spot sign -)|regular clinical treatment
11311009|NCT02625922|Experimental|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
11311010|NCT02625922|Experimental|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
11311011|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
11311012|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
11311013|NCT02625896|Experimental|Intervention|A sequence of free fall manoeuvres performed using the human body: A free fall velocity reduction prior to main parachute deployment followed by a head high body attitude prior to main parachute extraction.
11311014|NCT02625896|No Intervention|Control|Normal main parachute extraction performed in a manner that is typical for the study participant.
11311015|NCT02625883||Survivors|Patients with out-of-Hospital resuscitation and return of spontaneous circulation. Structured interview for quality of life (questionnaire) one year after resuscitation.
11311016|NCT02625870|Experimental|Omega-3-Acid Ethyl Esters 90 Soft Capsules|
11311017|NCT02625870|Placebo Comparator|Corn Oil|
11311018|NCT02625857|Experimental|Dose Cohort 1A and 1B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
11311019|NCT02625857|Experimental|Dose Cohort 2A and 2B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
11311020|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
11311021|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
11311022|NCT02625831||SLE patients|"165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without.
~Biological analysis were performed."
11311023|NCT02625831||healthy patients|48 healthy patients. Biological analysis were performed.
11311024|NCT02625818||acute psychiatric condition|
11311025|NCT02625805|Experimental|Participants diagnosed with ADD/ADHD|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
11311204|NCT02624778|Placebo Comparator|Placebo x 72 weeks|Placebo administered IV for 72 wks
11311026|NCT02625805|Experimental|Healthy participants|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
11311027|NCT02625792|Experimental|Endo-Clot(TM)|The intervention group
11311028|NCT02625779|Active Comparator|Valproate and Placebo|Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks
11311029|NCT02625779|Experimental|Valproate and Cytidine-containing Drug|Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks
11311030|NCT02625779|Experimental|Valproate and Creatine-containing Drug|Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8
11311031|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
11311032|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
11311033|NCT02625753|Active Comparator|Codeine plus paracetamol|Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
11311034|NCT02625753|Placebo Comparator|placebo|Placebo every 6 hours for 72 hours after photorefractive keratectomy.
11311035|NCT02625740|Experimental|Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm
11311036|NCT02625740|Active Comparator|Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic)
11311037|NCT02625727|Experimental|hyaluronic acid group|hyaluronic acid injection
11311038|NCT02625727|Active Comparator|hyaluronic acid and corticosteroid group|hyaluronic acid combined corticosteroid injection
11311039|NCT02625714|Other|A group|Renexin® → SID142
11311040|NCT02625714|Other|B group|SID142 → Renexin®
11311041|NCT02625701|Experimental|Goal-Directed-Therapy (GDT)|"Besides the basal infusion of crystalloids at 3-6 ml/kg/h, colloids (200 ml) or crystalloids (200 ml) are given over 10 min in the presence of signs of absolute/relative hypovolemia as detected by a fall in cardiac output/stroke volume (CO/SV) or if Pressure Pulse Variation (PVV) or Stroke Volume Variation (SVV) exceeds 10-12%, particularly in the presence. Fluid filling is interrupted when SV fail to increase > 10% (or PVV/SVV =< 10%) Otherwise, vasopressors can be used to achieve appropriate mean arterial pressure (MAP>70 mmHg, within ±20% of baseline).
~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
11311042|NCT02625701|Active Comparator|Restrictive strategy|"Crystalloids are given at a fixed rate of 3-6 ml/kg/h. Otherwise, vasopressors can be used to achieve appropriate MAP (>70 mmHg, within ±20% of baseline).
~Blood losses are replaced with colloids (1:1) or crystalloids (2:1). Clinicians in charge of the patients are free to use hemodynamic parameters such as PVV or SVV, always attempting to limit the amount of fluid infusion and to maintain normovolemia"
11311043|NCT02625688|Placebo Comparator|Early cord clamping|Cord clamping will be applied after 30 seconds post delivery.
11311044|NCT02625688|Active Comparator|Delayed cord clamping|Cord clamping will be applied after 3 minutes post delivery.
11311045|NCT02625688|Active Comparator|Cord milking|The baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
11311046|NCT02625662||iFSHD group|First recruitment group
11311047|NCT02625649||RYGB|RYGB-operated type 2 diabetic patients
11311048|NCT02625649||non-RYGB|non-RYGB-operated type 2 diabetic controls
11311049|NCT02625636|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions
11311050|NCT02625636|Experimental|SAR438544 dose 2|Single dose of SAR438544 given SC under fasting conditions
11311051|NCT02625636|Experimental|SAR438544 dose 3|Single dose of SAR438544 given SC under fasting conditions
11311052|NCT02625636|Placebo Comparator|Placebo|Single dose of placebo given SC under fasting conditions
11311053|NCT02625636|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions
11311054|NCT02625636|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions
11311055|NCT02625623|Experimental|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
11311056|NCT02625623|Active Comparator|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
11311057|NCT02625610|Experimental|Avelumab|"Induction Phase: Subjects will be administered with oxaliplatin and either 5-Fluorouracil (5-FU) or capecitabine for 12 weeks.
~Maintenance Phase: Subjects will be administered with intravenous (IV) infusion of avelumab once every 2 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
11311237|NCT02624531|Other|fertility-sparing surgery|NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy
11311058|NCT02625610|Active Comparator|Oxaliplatin-fluoropyrimidine doublet|"Induction Phase: Subjects will be administered with oxaliplatin and either 5-FU or capecitabine for 12 weeks.
~Maintenance Phase: Subjects will continue the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5-FU/Leucovorin (LV) or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Subjects who are not deemed eligible to receive further chemotherapy will receive best supportive care (BSC) alone with no active therapy."
11311059|NCT02625597|Experimental|Dental Materials|
11311060|NCT02625584|Other|Shared Reading Control|Reading Together - Shared Reading Control. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will not be trained to read with their child. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
11311061|NCT02625584|Experimental|Dialogic Reading|Reading Together - Dialogic Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a dialogic reading style. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
11311062|NCT02625584|Experimental|Pausing for Reading|Reading Together - Pausing for Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a style which involves pausing, recasting and open questioning. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
11311063|NCT02625571|Experimental|Intervention|
11311064|NCT02625558|Active Comparator|Riociguat|Active drug
11311065|NCT02625558|Placebo Comparator|Placebo|placebo
11311066|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
11311067|NCT02625532|Active Comparator|Follicular phase|Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
11311068|NCT02625532|Experimental|Luteal phase|Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
11311069|NCT02625519|Experimental|Urinary follicle-stimulating hormone|Controled Ovarian stimulation with urinary follicle-stimulating hormone
11311070|NCT02625519|Experimental|Recombinant follicle-stimulating hormone|Ovarian stimulation with recombinant follicle-stimulating hormone
11311071|NCT02625506|Placebo Comparator|Levobupivacaine|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
11311072|NCT02625506|Active Comparator|Levobupivacaine and Tramadol|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
11311073|NCT02625493||study population|All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
11311074|NCT02625480|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
11311075|NCT02625467|Experimental|Penetrating keratoplasty|Conventional penetrating keratoplasty technique
11311076|NCT02625467|Experimental|PALK|Pachymetry and Excimer laser assisted lamellar keratoplasty
11311077|NCT02625454|Experimental|Intravenous Acetaminophen|Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen
11311078|NCT02625454|Active Comparator|Oral Acetaminophen|Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen
11311079|NCT02625441|Experimental|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
11311080|NCT02625441|Active Comparator|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
11311081|NCT02625428|Experimental|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
11311082|NCT02625428|Experimental|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
11311083|NCT02625415|Experimental|Vitamin B6|Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
11311084|NCT02625415|Placebo Comparator|Placebo|Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
11311085|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
11311086|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
11311087|NCT02625389|Experimental|Embolization with Lipiodol Ultra Fluid and glue|
11311088|NCT02625376|Experimental|Trans-Resveratrol|capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
11311089|NCT02625376|Active Comparator|Resvega|"capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.
~two capsules daily : one in the morning and evening for 24 months"
11311090|NCT02625376|Placebo Comparator|Placebo|capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
11311091|NCT02625363|Experimental|Glucose Ref - Std|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
11311092|NCT02625363|Experimental|Glucose Ref and 450 ml water|250 ml glucose solution with 50 gram available carbohydrate per serving. Sample was consumed with additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
11312064|NCT02619097|Experimental|0.2mg/kg|Pegol-sihematide injection, 0.2mg/kg, single-dose
11311093|NCT02625363|Experimental|White Bread with 250 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption
11311094|NCT02625363|Experimental|White Bread and 700 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption. Moreover, subjects given additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
11311095|NCT02625363|Experimental|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
11311096|NCT02625350|Experimental|Instant noodle without soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes and drained
11311097|NCT02625350|Experimental|Instant noodle with soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes, drained, and given additional 250 ml of water as soup
11311098|NCT02625350|Experimental|Glucose reference|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
11311099|NCT02625337|Active Comparator|Pembrolizumab mono|Pembrolizumab monotherapy
11311100|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib short|Pembrolizumab combined with a short scheme of dabrafenib+trametinib
11311101|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib intermediate|Pembrolizumab combined with an intermediate scheme of dabrafenib+trametinib
11311102|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib long|Pembrolizumab combined with a long scheme of dabrafenib+trametinib
11311103|NCT02625324|Experimental|Endovascular repair|Valiant Evo Thoracic Stent Graft System
11311104|NCT02625311|Experimental|MIS|Minimal invasive surgery for placement total knee prosthesis
11311105|NCT02625311|Active Comparator|conventional approach|"conventional open surgery for placement total knee prosthesis."
11311106|NCT02625298|Experimental|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
11311107|NCT02625298|Experimental|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
11311108|NCT02625285||G6PD Deficient Volunteers|"Subjects with age ≥ 18 years
~Male and female
~Previously tested G6PD deficient at SMRU clinic"
11311109|NCT02625285||G6PD Intermediate or Heterozygous Volunteers|"Subjects with age ≥ 18 years
~Female
~Previously tested G6PD intermediate or heterozygous for G6PD variants at SMRU clinic"
11311110|NCT02625285||G6PD-Normal Volunteers|"Subjects with age ≥ 18 years
~Male and female
~Previously tested G6PD normal at SMRU clinic"
11311111|NCT02625272|Experimental|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
11311112|NCT02625272|No Intervention|Group B|novel laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were divided at the beginning of the operation intracorporeally.
11311113|NCT02625272|No Intervention|Group C|the traditional laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer.
11311114|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
11311115|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
11311116|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
11311117|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
11311118|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
11311119|NCT02625246|Experimental|Group 1|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
11311120|NCT02625246|Experimental|Group 2|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
11311121|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
11311122|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
11311123|NCT02625220|Experimental|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
11311124|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
11311125|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
11311126|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
11311127|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
11311128|NCT02625194|Experimental|Oxygen|Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
11311129|NCT02625194|No Intervention|Control|Bronchoscope-guided intubation is performed without oxygen supply.
11311130|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
11311131|NCT02625168|Experimental|Afatinib|Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
11311205|NCT02624765|Active Comparator|RCT A (1st arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Digoxin as monotherapy.
11311132|NCT02625168|Experimental|Erlotinib|Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
11311133|NCT02625155|Other|Standard of Care (SOC Arm)|Standard of Care UDT
11311134|NCT02625155|Other|Selective PGx Testing (Test Arm)|Standard of Care UDT with selective PGx testing
11311135|NCT02625142|Experimental|Family-centered rounds checklist|"During the post-intervention period, health care team members on two pediatric inpatient services received the Family-centered Rounds Checklist tool, as well as training in how to use the checklist in the delivery of effective family-centered rounds"
11311136|NCT02625142|No Intervention|Usual care|Two pediatric inpatient services were not provided the Family-centered rounds checklist tool, and delivered morning rounds in their usual manner. These services served as a control.
11311137|NCT02625129||Pharmacist-provided travel care|
11311138|NCT02625103|Experimental|Clozapine|treatment as usual: administration of clozapine between 9 and 12 pm. Blood sampling 10 -14 hours post drug administration
11311139|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.
~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
11311140|NCT02625077|Experimental|Laparoscopic valvuloplasty|Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
11311141|NCT02625077|Active Comparator|Laparoscopic Toupet fundoplication|Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
11311142|NCT02625064||1: patient at High risk for ARDSp|Severe pneumonia and（PaO2/FIO2）>300mmHg
11311143|NCT02625064||2: patient at High risk for ARDSexp|Severe sepsis and without ARDS
11311144|NCT02625064||3: mild ARDS|PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
11311145|NCT02625064||4: moderate ARDS|PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O
11311146|NCT02625064||5: severe ARDS|PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O
11311147|NCT02625051|Active Comparator|Ureteroscopy|Kidney stone of participants in this arm will be treated with ureteroscopy (URS). A ureteral stent will be inserted at the end of the procedure.
11311148|NCT02625051|Active Comparator|Percutaneous nephrolithotomy|Kidney stone of participants in this arm will be treated with percutaneous nephrolithotomy (PNL). A percutaneous nephrostomy tube will be inserted at the end of the procedure.
11311149|NCT02625038|Experimental|Interventional|3D-planned osteotomies with patient-specific guides
11311150|NCT02625025|Experimental|Low pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Low Pression Pneumoperitoneum (8 mm Hg)
11311151|NCT02625025|Experimental|Standard pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Standard Pression Pneumoperitoneum (12 mm Hg)
11311152|NCT02625012||Vitiligo|A serial of vitiligo patients under treatment with UVB-NB
11311153|NCT02624999|Experimental|Immunotherapy|Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
11311154|NCT02624999|Active Comparator|Standard chemotherapy|Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
11311155|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
11311156|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
11311157|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
11311158|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).
11311159|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).
11311160|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
11311161|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
11311206|NCT02624765|Active Comparator|RCT A (2nd arm): AF without hydrops|Atrial Flutter (AF) without hydrops: Treatment with Sotalol as monotherapy.
11365529|NCT02263976|Experimental|Sub-Study|
11311162|NCT02624986|Experimental|FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
11311163|NCT02624973|Experimental|A|ER/PGR>50% TP53 wt
11311164|NCT02624973|Experimental|B|ER/PGR>50% TP53 mutated
11311165|NCT02624973|Experimental|C|ER/PGR<50% TP53 wt
11311166|NCT02624973|Experimental|D|ER/PGR<50% TP53 mutated
11311167|NCT02624973|Experimental|E|HER2+ TP53 wt
11311168|NCT02624973|Experimental|F|HER2+ TP53 mutated
11311169|NCT02624973|Experimental|G|Triple negative breast cancer TP53 wt
11311170|NCT02624973|Experimental|H|Triple negative breast cancer TP53 mutated
11311171|NCT02624960|Experimental|Accucinch Implant|Accucinch Implant procedure is completed
11311172|NCT02624947|Placebo Comparator|Treatment Group A|Formulation buffer (0.5mL injection)
11311173|NCT02624947|Active Comparator|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
11311174|NCT02624908|Active Comparator|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
11311175|NCT02624908|Placebo Comparator|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
11311176|NCT02624895||mCRC: Anti-EGFR MAbs + FOLFOX 1st line|• Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per clinical practice.
11311177|NCT02624895||mCRC: Anti EGFR MAbs + FOLFIRI 1st line|Adults (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFIRI plus panitumumab or FOLFIRI plus cetuximab as upfront treatment as per clinical practice
11311178|NCT02624882|Experimental|Positive rapid Group A Streptococcus (GAS) test|In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy
11311179|NCT02624882|Active Comparator|Negative rapid GAS test|If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
11311180|NCT02624869|Experimental|evolocumab (AMG 145)|Single arm all subjects receive evolocumab (AMG 145) every 4 weeks (QM)
11311181|NCT02624856|Experimental|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
11311182|NCT02624856|Active Comparator|Standard bupivacaine plus dexamethasone|Bupivacaine 0.5% 10 mL plus 2 mg dexamethasone for quadriceps sparing femoral nerve block and bupivacaine 0.25% 20 mL plus 2 mg of dexamethasone for posterior knee compartment periarticular injection.
11311183|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
11311184|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
11311185|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
11311186|NCT02624830|Experimental|Drug, Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to intravenous glucagon have been tested.
11311187|NCT02624817|Experimental|Drug: Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.
11311188|NCT02624804|Experimental|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated lymphocytes"
11311189|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;
~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
11311190|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;
~1-DAY ACUVUE® MOIST contact lenses"
11311191|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;
~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
11311192|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;
~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
11311193|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;
~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
11311194|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;
~1-DAY ACUVUE® MOIST contact lenses"
11311195|NCT02624778|Experimental|LY3002813 Single dose 1|LY3002813 administered intravenously (IV) once
11311196|NCT02624778|Experimental|LY3002813 Single dose 2|LY3002813 administered IV once
11311197|NCT02624778|Experimental|LY3002813 Single dose 3|LY3002813 administered IV once
11311198|NCT02624778|Experimental|LY3002813 Multiple dose 1 x 24 wks|LY3002813 administered IV for 24 wks
11311199|NCT02624778|Experimental|LY3002813 Multiple dose 2 x 24 wks|LY3002813 administered IV for 24 weeks
11311200|NCT02624778|Experimental|LY3002813 Multiple dose 3 x 72 wks|LY3002813 administered IV for 72 wks
11311201|NCT02624778|Experimental|LY3002813 Multiple dose 4 x 72 weeks|LY3002813 administered IV for 72 wks
11311202|NCT02624778|Placebo Comparator|Placebo given once|Placebo administered IV once
11311203|NCT02624778|Placebo Comparator|Placebo x 24 weeks|Placebo administered IV for 24 wks
11311207|NCT02624765|Active Comparator|RCT B (1st arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Digoxin as monotherapy.
11311208|NCT02624765|Active Comparator|RCT B (2nd arm): SVT without hydrops|Supraventricular Tachycardia (SVT) without hydrops: Treatment with Flecainide as monotherapy.
11311209|NCT02624765|Active Comparator|RCT C (1st arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Sotalol.
11311210|NCT02624765|Active Comparator|RCT C (2nd arm): SVT with hydrops|Supraventricular Tachycardia (SVT) with hydrops: Treatment with Digoxin and Flecainide.
11311211|NCT02624752|No Intervention|Standard of Care|"Standard of care could include liberalized diet consisting of 3 meals and snacks served daily or the standard oral nutrition supplementation (ONS) routinely used in the hospital, as prescribed by the medical team.These routine meals and snacks are the standard of care."
11311212|NCT02624752|Experimental|Ensure|Patients randomized to Enhanced Oral Nutritional Supplementation (ONS) will receive the standard of care hospital menu (3 meals and snacks per day) plus 2 cans of Ensure (or similar product) per day while in hospital and will continue 2 cans per day of Ensure when discharged home until they have been receiving the enhanced ONS for a total of 90 days.
11311213|NCT02624726|Experimental|FOLFIRI/Aflibercept|5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
11311214|NCT02624713|Other|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
11311215|NCT02624713|Other|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
11311216|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
11311217|NCT02624700|Experimental|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
11311218|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
11311219|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
11311220|NCT02624674|Experimental|Multi-spectral Imaging Group|All subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
11311221|NCT02624661|Experimental|Glycerol injection|The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
11311222|NCT02624648|Placebo Comparator|Placebo Group|"The effects of Placebo on sexual function, desire and depression in postmenopausal women.
~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).
~The Beck Depression Inventory II will be used to ward off depression"
11311223|NCT02624648|Experimental|Maca (Lepidium Meyenii Walp) Group|"The effects of Lepidium Meyenii Walp on sexual function, desire and depression in postmenopausal women.
~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).
~The Beck Depression Inventory II will be used to ward off depression"
11311224|NCT02624635|Active Comparator|Manual Therapy|The treatment for this group will be manual therapy.
11311225|NCT02624635|Experimental|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip.
11311226|NCT02624622|Active Comparator|CHW applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
11311227|NCT02624622|Experimental|Mother applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. Mother is given the chlorhexidine during the first prenatal care visit to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
11311228|NCT02624609|Placebo Comparator|Control without pomegranate juice|Control meal will be white bread and a glass of water containing the same amounts of sugars naturally present in the pomegranate juice.
11311229|NCT02624609|Experimental|Test with pomegranate juice|Test meal will be white bread with a glass of pomegranate juice
11311230|NCT02624596|Experimental|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
11311231|NCT02624596|Active Comparator|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
11311232|NCT02624557|Experimental|Moderate hepatic impairment group|Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9
11311233|NCT02624557|Experimental|Severe hepatic impairment group|Subjects with severe hepatic impairment with Child-Pugh score 10 - 15
11311234|NCT02624557|Experimental|Matching healthy control group|Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.
11311235|NCT02624544|Experimental|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
11311236|NCT02624544|Active Comparator|Group B|desonide
11311238|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
11311239|NCT02624505|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
11311240|NCT02624505|Active Comparator|90 mcg Reference Product|Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
11311241|NCT02624505|Active Comparator|180 mcg Reference Product|Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
11311242|NCT02624505|Experimental|90 mcg Test Product|Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
11311243|NCT02624492|Experimental|BI 836826-GemOx|
11311244|NCT02624492|Active Comparator|R-GemOx|
11311245|NCT02624479|Experimental|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
11311246|NCT02624479|Experimental|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
11311247|NCT02624479|Experimental|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
11311248|NCT02624466||CKD - no dialysis|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
11311249|NCT02624466||Patients on PD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and PD fluid, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
11311250|NCT02624466||Patients on HD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and spent dialysate, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
11311251|NCT02624453|Experimental|IMMY LFA positive patients|HIV positive patients who will be positive for cryptococcal antigen (by the IMMY LFA test) would be consented for lumbar puncture in search of cryptococcal meningitis (CM). If CM is not confirmed, they would be prescribed pre-emptive fluconazole based therapy at 800mg/day for two weeks (placed on antiretroviral therapy two weeks after screening for cryptococcal antigen), then 400mg/day for 8 weeks and thereafter 200mg/day until CD4 counts increases beyond 200cells/ml. (CM confirmed cases will be referred to the ACTA trial ISRCTN45035509)
11311252|NCT02624453|Active Comparator|IMMY LFA negative patients|HIV positive patient who will be negative for cryptococcal antigen (by the IMMY LFA test) would not be consented for lumbar puncture, will be placed immediately on antiretroviral therapy immediately after screening for cryptococcal antigen and would not be placed on fluconazole pre-emptive therapy.
11311253|NCT02624440|Experimental|Clarithromycin|p.o. clarithromycin 250 mg twice daily for 180 days
11311254|NCT02624440|Experimental|Sulfamethoxazole/trimethoprim|p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days
11311255|NCT02624440|Experimental|Observation|Observation without prophylactic antibiotic treatment
11311256|NCT02624427|Experimental|Glaucoma Eyes|Measurement of intraocular pressure (IOP)
11311257|NCT02624427|Active Comparator|Healthy Eyes|age-matched healthy eyes as controls will undergo Measurement of intraocular pressure (IOP)
11311258|NCT02624414|Other|Anti TNF induction therapy 6-12 months|All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.
11311259|NCT02624401|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion.
11311260|NCT02624401|Experimental|Propofol|Intravenous propofol using target controlled infusion.
11311261|NCT02624401|Experimental|S-ketamine|Intravenous S-ketamine using target controlled infusion.
11311262|NCT02624401|Experimental|Sevoflurane|Inhalational sevoflurane using target controlled inhalation.
11311263|NCT02624401|Placebo Comparator|Placebo|Intravenous saline.
11311264|NCT02624388|Experimental|Arm A: Genistein followed by Placebo|Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
11311265|NCT02624388|Experimental|Arm B: Placebo followed by Genistein|Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
11311266|NCT02624375|Experimental|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
11311267|NCT02624362|Experimental|Odor+ Positive belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor improves asthma symptoms (therapeutic suggestion)
11311268|NCT02624362|Experimental|Odor + Negative belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor worsens asthma symptoms (asthmogenic suggestion)
11311269|NCT02624349|Active Comparator|Transplant|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
11311270|NCT02624349|Active Comparator|Control|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
11311271|NCT02624336|Active Comparator|DTC1 mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
11365799|NCT02262234|Experimental|Education Program Type 2|
11311272|NCT02624336|Placebo Comparator|Oradex mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
11311273|NCT02624336|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
11311274|NCT02624323|Experimental|Axillary catheterization|Real-time ultrasound-guided axillary vein catheterization, in plain technique.
11311275|NCT02624323|Experimental|Jugular catheterization|Real-time ultrasound-guided jugular vein catheterization, out of plain technique.
11311276|NCT02624310|Experimental|Droxidopa First, Placebo Second|Participants in this arm will receive droxidopa first, then cross over and receive placebo
11311277|NCT02624310|Experimental|Placebo First, Droxidopa Second|Participants in this arm will receive placebo first, then cross over and receive droxidopa
11311278|NCT02624297|No Intervention|Control Group|Healthy control group for comparisons with coronary artery disease groups.
11311279|NCT02624297|No Intervention|CAD without OSA - Control|Clinical follow-up.
11311280|NCT02624297|Experimental|CAD without OSA - Intervention|Aerobic exercise training.
11311281|NCT02624297|No Intervention|CAD with OSA - Control|Clinical follow-up.
11311282|NCT02624297|Experimental|CAD with OSA - Intervention|Aerobic exercise training.
11311283|NCT02624284|Sham Comparator|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
11311284|NCT02624284|Experimental|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
11311285|NCT02624284|Experimental|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
11311286|NCT02624271|Experimental|GastroPanel|GastroPanel test on blood samples
11311287|NCT02624258|Experimental|RNA CART19 cells|CD19 RNA redirected autologous T-cells (RNA CART19 cells)
11311288|NCT02624245|Experimental|Experimental: Conventional Physical Therapy|Strength, this arm will receive hip and knee muscle strengthening with and without weight bearing.
11311289|NCT02624245|Active Comparator|Movement control training|Movement control training, this arm will receive movement control training associated to muscle strengthening.
11311290|NCT02624232||Patients with anorectal malformations|"Participants are identified through relevant diagnostic codes in ICD-10(Q 42) and ICD-9(75.120, 75.121) in patients which underwent surgery for ARM in the years 1985-2005 are included if informed consent is obtained.
~Relevant questionnaires regarding symptoms and QoL are completed before the following examinations:anorectal manometry, endoanal ultrasonography, pudendal nerve conduction velocity, colon transit time, Magnetic resonans(MR)-scan of the pelvis and uroflowmetry."
11311291|NCT02624219|Experimental|Group 1|N = 55 receive 7.5 mcg A/H5N8 + AS03 on Day 1, 22
11311292|NCT02624219|Experimental|Group 2|N = 55 receive 7.5 mcg A/H5N8 + MF59 on Day 1, 22
11311293|NCT02624219|Experimental|Group 3|N = 55 receive 15 mcg A/H5N8 unadjuvanted on Day 1, 22
11311294|NCT02624219|Experimental|Group 4|N = 55 receive 15 mcg A/H5N8 + AS03 on Day 1, 22
11311295|NCT02624219|Experimental|Group 5|N = 55 receive 15 mcg A/H5N8 + MF59 on Day 1, 22
11311296|NCT02624206|Active Comparator|Juice A|Half of the group to receive Juice A, a novel juice flavor.
11311297|NCT02624206|Active Comparator|Juice B|Half of the group to receive Juice B, a novel juice flavor different from Juice A.
11311298|NCT02624193|Experimental|MBSR Program|"MBSR Program:
~The MBSR intervention is a nine-week program designed to cultivate mindfulness, a focused non-judgmental awareness of the present moment. It consists of eight 2-hour weekly sessions and one 3-hour retreat and the content includes three main components: 1) material related to mindfulness, meditation, yoga, and the mind-body connection; 2) experiential practice of mindful meditation (sitting, lying down, walking), gentle mindful yoga, and body scan during group meetings and encouragement of home practice; and 3) group discussion focused on problem-solving related to barriers to effective practice. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
11311299|NCT02624193|Placebo Comparator|HT Program|"Healthy Topics Program:
~The health education program Healthy Topics (HT) will serve as an attention control group. The HT program is focused on providing age-appropriate health information and education. There is minimal content overlap in the MBSR and HT programs regarding self-care and healthy eating; however, the style, structure, and content of the MBSR and HT programs are distinct. HT participants will receive no training in MBSR or meditation. Topics covered include physical activity, nutrition, managing weight, building health, personal care, understanding adolescence, tobacco, alcohol, and other drugs. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
11311300|NCT02624180|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth
11311301|NCT02624180|Placebo Comparator|Placebo|Placebo for colchicine 1 tablet by mouth daily
11311302|NCT02624167|Active Comparator|NW-3509A|Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
11311303|NCT02624167|Placebo Comparator|Placebo|Patients will receive matching placebo BID
11311304|NCT02624141|Experimental|Epoetin Beta 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.
11311305|NCT02624128|Experimental|valproic acid plus cisplatin and cetuximab|
11311306|NCT02624102|Experimental|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
11311307|NCT02624102|Experimental|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
11311308|NCT02624102|Other|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
11311309|NCT02624089|Experimental|Ropivacaine Group|This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
11311310|NCT02624089|Placebo Comparator|Placebo group|This group will receive placebo (normal saline) based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered at the onset of pneuomoperitoneum during appendectomy.
11311311|NCT02624089|No Intervention|Non-enrolled group|This group will not receive either intervention (ropivicaine) or placebo (normal saline), but will have primary and secondary endpoints evaluated.
11311312|NCT02624076|Experimental|Acupuncture plus expectant management|
11311313|NCT02624076|Active Comparator|expectant management|
11311314|NCT02624063|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
11311315|NCT02624063|Experimental|Simeprevir + Sofosbuvir|Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
11311316|NCT02624050|Active Comparator|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
11311317|NCT02624050|Active Comparator|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
11311318|NCT02624037|Experimental|Individualized Dosage Precision IFX Dashboard|A clinician will select a dose and dosing frequency that is populated by a pharmacokinetic dashboard system that monitors and aims to dose patients to maintain a target trough infliximab concentration. Dosage and dosing frequency may vary from each patient.
11311319|NCT02624024||Acute chest pain or equivalent ischemic symptoms|acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI)
11311320|NCT02624011|Experimental|Physical inactivity|Study arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
11311321|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
11311322|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
11311323|NCT02623985|Experimental|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
11311324|NCT02623985|Experimental|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
11311325|NCT02623985|Experimental|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
11311326|NCT02623972|Experimental|Arm A: Eribulin > AC|"Eribulin-Administered via iv, at predetermined dosage and schedule per cycle
~Two research breast biopsies
~Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle
~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle
~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection
~Radiation Therapy
~Endocrine Therapy (if applicable)
~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
11311327|NCT02623972|Experimental|Arm B: AC > Eribulin|"Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle
~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle
~Two research breast biopsies
~Eribulin-Administered via iv, at predetermined dosage and schedule per cycle
~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection
~Radiation Therapy
~Endocrine Therapy (if applicable)
~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
11311328|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.
~After the IPC is removed, participant is called one time each month by study staff to check on their status."
11311329|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.
~After the IPC is removed, participant is called one time each month by study staff to check on their status"
11311330|NCT02623933|Experimental|MRI assisted HDR monotherapy|HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy
11311331|NCT02623920|Experimental|Brentuximab, Bendamustine, Rituximab|Brentuximab Vedotin in Combination with Bendamustine and Rituximab
11311332|NCT02623907||AS group|Severe AS patients, without severe AR
11311333|NCT02623907||AR|Severe AR patients, without severe AS
11311334|NCT02623881|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
11311335|NCT02623881|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
11311336|NCT02623868|Experimental|Group 1|A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
11311337|NCT02623868|Experimental|Group 2|B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
11311338|NCT02623868|Experimental|Group 3|C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
11311339|NCT02623868|Experimental|Group 4|A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
11311340|NCT02623868|Experimental|Group 5|B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
11311341|NCT02623868|Experimental|Group 6|C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
11311342|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
11311343|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
11311344|NCT02623842|Experimental|Radiofrequency|
11311345|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
11311346|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
11311347|NCT02623816|Experimental|Sub-optimal/optimal dosing|Patients will not change sub-optimal dosing regimen of omeprazole 20 mg for 6 weeks after which they will receive optimal dosing of omeprazole for 4 weeks. Rescue antacid use is permitted. Total duration of 10 weeks.
11311348|NCT02623816|No Intervention|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 10 weeks.
11311349|NCT02623816|Experimental|Optimal dosing|Patients will be administered optimal dosing of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
11311350|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
11311351|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
11311352|NCT02623790|Experimental|Test meal (butter)|Subjects will eat one test meal containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
11311353|NCT02623790|Experimental|Test meal (cheddar cheese)|Subjects will eat one test meal containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
11311354|NCT02623790|Experimental|Test meal (cream cheese)|Subjects will eat one test meal containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
11311355|NCT02623777|Experimental|AXOS as first intervention|AXOS as first intervention
11311356|NCT02623777|Experimental|SCFA as first intervention|SCFA as first intervention
11311357|NCT02623764||MCI due to Alzheimer´s disease|Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
11311358|NCT02623764||Mild dementia due to Alzheimer´s disease|Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
11311359|NCT02623764||Mild dementia due to Lewy body disease|Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
11311360|NCT02623751|Experimental|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
11311361|NCT02623738|Placebo Comparator|Placebo ophthalmic solution|Eyedrop
11311362|NCT02623738|Experimental|DE-117 ophthalmic solution low|Eyedrop
11311363|NCT02623738|Experimental|DE-117 ophthalmic solution high|Eyedrop
11311364|NCT02623738|Active Comparator|Latanoprost ophthalmic solution 0.005%|Eyedrop
11311365|NCT02623725|Experimental|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
11311366|NCT02623725|Experimental|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
11311367|NCT02623712|Active Comparator|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
11311368|NCT02623712|Active Comparator|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
11311369|NCT02623699|Experimental|Single Ascending Dose|Part A: Randomized single ascending dose
11311370|NCT02623699|Experimental|Multiple Ascending Dose|Part B: Randomized multiple ascending dose
11311371|NCT02623699|Experimental|Fixed Dose|Part C: Fixed Dose
11311372|NCT02623686|Experimental|Aroma group|"two massages delivered within a two day period
~the patient will choose the essential oils used from blend A and blend B (if no choice is made, therapist will choose blend A and B alternately). One drop of the essential oil blend will be added to 5 mls of grapeseed base oil.
~an Inhalation Patch with the same blend of oils as used in the massage will be left by the therapist for use on each of the two nights following the aromatherapy massage intervention. Its use will be explained to the patient and to the member of nursing staff. The Inhalation Patch will be applied to the patient's upper chest when it is time to sleep at approximately 11 pm and will be removed the following morning at approximately 6 am."
11311373|NCT02623686|No Intervention|Control Group|Normal Care
11311374|NCT02623673||bevacizumab plus dexamethasone 0.7mg|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
11311375|NCT02623660|Experimental|Experimental|This group will receive treatment from the ODIN1 device in conjunction with standard care and diagnostic device testing.
11311376|NCT02623660|Active Comparator|Control|This group will receive the standard care and the diagnostic device testing.
11311377|NCT02623647|Other|A single-arm, nonrandomized|stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions
11311378|NCT02623634||observation|this study measure the cuff leak volume and cuff leak ratio according to the cuff leak test with different positions and waveform,, at the same time observe the patient general condition, vital signs, oxygen saturation, cuff leak test results under different conditions and the breathing machine parameters, the diameter of the airway, the use of sedatives and hormones, after extubation stridor and intubation is happening again, the use of NPPV after extubation, patient outcomes
11311379|NCT02623608|Experimental|High fat meal|Subjects eat a high fat breakfast (reference breakfast) at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h.
11311380|NCT02623608|Experimental|High fat meal + Active Ingredient 1|"Subjects eat the same high fat breakfast with the active ingredient 1 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
11311381|NCT02623608|Experimental|High fat meal + Active Ingredient 2|"Subjects eat the same high fat breakfast with the active ingredient 2 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
11311382|NCT02623608|Experimental|High fat meal + Active Ingredient 3|"Subjects eat the same high fat breakfast with the active ingredient 3 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
11311383|NCT02623608|Experimental|High fat meal + Active Ingredient 4|"Subjects eat the same high fat breakfast with the active ingredient 4 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
11311384|NCT02623595|Experimental|SBRT+GM-CSF|Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
11311385|NCT02623582|Experimental|Cohort 1|The first 3 subjects to receive RNA CART123 cells will receive up to 3 doses of RNA CART123 cells, with no lymphodepleting chemotherapy prior to infusion.
11311386|NCT02623582|Experimental|Cohort 2|"The remaining 12 subjects of the study will receive up to six IV doses of RNA CART123 cells.
~Subjects in Cohort 2 may be given lymphodepleting chemotherapy 4 days (+/- 1 day) prior to the first CART123 cell infusion (if ALC> 500/uL).
~Lymphodepleting chemotherapy may be repeated before the fourth dose of RNA CART123 cells (if ALC> 500/uL).
~Lymphodepleting chemotherapy includes a single dose of cyclophosphamide (1g/m2) Weight used for dosing will be the weight obtained prior to the apheresis procedure Cell numbers are based on CAR+ cells with CAR expression determined by flow cytometry Based on the product release criteria, at least 20% of the total cells will be RNA CART123 cells.
~Dosing will not be changed for changes in subject weight The indicated doses are +/- 20% to account for manufacturing variability."
11311387|NCT02623569|Experimental|Ivabradine|Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR（heard rate）>80times/min of subjects.
11311388|NCT02623569|Active Comparator|Atenolol|Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR （heard rate）>80times/min of subjects.
11311389|NCT02623556|Experimental|TB subjects|"720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method.
~360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h."
11311390|NCT02623556|Experimental|non-TB subjects with lung disease and suspected TB subjects|360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
11311391|NCT02623543|Experimental|OrthoK|OrthoK lenses will be prescribed for subjects randomly and followed for 2yrs throughout wearing the lenses. There will be an enrollment appointment, dispense appointment, 1-day, 1-week, 1-month, 6-month, 12-month, and 24-month follow-ups.
11311392|NCT02623543|Placebo Comparator|Control|Subjects in the randomly assigned control will continue to wear their glasses throughout the 2yr follow-up period. There will be an enrollment appointment, 6-month, 12-month, and 24-month follow-ups.
11311393|NCT02623530|Active Comparator|Control group|Control group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), not based on the Active Learning Model for Critical Thinking (MEAPC).
11311394|NCT02623530|Experimental|Experimental group|Experimental group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), based on the Active Learning Model for Critical Thinking (MEAPC).
11311395|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
11311396|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
11311397|NCT02623504|Experimental|Equetro|200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.
11311398|NCT02623504|Placebo Comparator|Placebo|Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.
11311399|NCT02623491|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
11311400|NCT02623491|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10.
11311401|NCT02623478|Experimental|Insulin Lispro - Test Formulation|Novel formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
11311402|NCT02623478|Active Comparator|Insulin Lispro - Reference Formulation|Marketed formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
11311403|NCT02623465|Experimental|Part A:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin once in each of 3 periods
11311404|NCT02623465|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
11311405|NCT02623465|Experimental|Part B:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin with each meal for 14 days
11311406|NCT02623465|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
11311407|NCT02623452|Experimental|Part A:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin once in each of 3 periods
11311408|NCT02623452|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin once in each of 3 periods
11311409|NCT02623452|Experimental|Part B:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin with each meal for 14 days
11311410|NCT02623452|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin with each meal for 14 days
11311411|NCT02623439|Experimental|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
11311412|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Eligible eye(s) treated at study visit M01 (week 0).
~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.
~Retreatment permitted at later time points if retreatment criteria met.
~Re-treatment criteria:
~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.
~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)
~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
11311413|NCT02623426|Active Comparator|Intravitreal methotrexate 400µg in 0.1mL|"Eligible eye(s) treated at study visit M01 (week 0).
~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.
~Retreatment permitted at later time points if retreatment criteria met.
~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
11311414|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5mg in 0.05mL|"Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).
~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.
~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.
~Re-treatment permitted at later time points if re-treatment criteria met."
11311415|NCT02623413||Sites implementing contact precautions|"Centers isolating for VRE may only participate if complying with the following standards:
~Contact precautions triggered by the initial detection of VRE
~Patients discharged as a VRE-carrier must be placed in contact isolation upon readmission
~Termination of contact precautions after at least two consecutive VRE-negative consecutive fecal screening cultures
~Resumption of contact isolation on first subsequent VRE-positive culture
~Contact precautions must encompass the following measures:
~Patients: Placement in single rooms. Cohorting is only permitted, in case of unavailability of single rooms
~Staff and visitors: Wearing of gloves and gowns when entering the room.
~Patients: Wearing of gloves and gowns when leaving the room."
11311416|NCT02623413||Sites not implementing contact precautions|Only VRE colonized or infected patients with urinary or fecal incontinence or diarrhea (defined as > 3 loose bowel movements/day), must be isolated in single rooms at any time during the study.
11311417|NCT02623400||Preterm infants and their parents|Preterm infants born before 34 weeks gestational age and/or with a birth weight lower than 1500g and their parents.
11311418|NCT02623387|Active Comparator|Standard Paravertebral Block|Patients receiving a conventional paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered using anatomical landmarks
11311419|NCT02623387|Active Comparator|Ultrasound Guided Paravertebral Block|Patients receiving paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered under ultrasound guidance
11311420|NCT02623374|Experimental|SH-CBT|This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
11311521|NCT02622711|Experimental|PAI Physical Activity Intervention|Individualized physical activity counseling to reduce body weight
11312065|NCT02619097|Experimental|0.33mg/kg|Pegol-sihematide injection, 0.33mg/kg, single-dose
11311421|NCT02623374|No Intervention|No Treatment-Wait Control (NTWC)|Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e. baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation). They will be offered the SHCBT intervention off trial following the final assessment (i.e. A2).
11311422|NCT02623361|Placebo Comparator|Sham|
11311423|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
11311424|NCT02623348|Experimental|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
11311425|NCT02623348|No Intervention|usual care|No intervention
11311426|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
11311427|NCT02623335|No Intervention|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
11311428|NCT02623322|Experimental|MHAA4549A 3600 milligrams (mg)|Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
11311429|NCT02623322|Experimental|MHAA4549A 8400 mg|Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
11311430|NCT02623322|Placebo Comparator|Placebo|Participants will receive single-dose placebo by IV administration.
11311431|NCT02623309|Experimental|HAPLO graft|"Conditioning regimen
~Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.
~Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.
~Prophylaxis regimen for GVHD
~F CSA and MMF (starting day +5)
~Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4
~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d."
11311432|NCT02623309|Active Comparator|MUD graft|"Conditioning regimen
~Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.
~Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.
~Prophylaxis regimen for GVHD
~CSA and MMF will be used from day -1 after UD
~Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2
~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg"
11311433|NCT02623296|Experimental|GLPG1205 and single CYP450 substrate cocktail dose|Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
11311434|NCT02623296|Placebo Comparator|Placebo and single CYP450 substrate cocktail dose|Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail
11311435|NCT02623270|Experimental|Noninvasive Ventilation|After induction of anesthesia, checking of ability to bag mask ventilating the patient, the manual bag ventilation will be replaced by a Noninvasive Ventilator, V60 (Philips)
11311436|NCT02623244||ovarian endometrioma|Women with ovarian endometrioma noted by ultrasonography.
11311437|NCT02623244||The control group|Women with age and body mass index matched and without ovarian endometrioma in ultrasonography
11311438|NCT02623231|Experimental|escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
11311439|NCT02623231|Placebo Comparator|placebo|Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
11311440|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
11311441|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
11311442|NCT02623218|Active Comparator|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
11311443|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
11311444|NCT02623218|Active Comparator|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
11311445|NCT02623205|Active Comparator|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
11311446|NCT02623205|Placebo Comparator|Placebo|Lactose pill manufactured to mimic Escitalopram pill
11311447|NCT02623192||ARDS|
11311448|NCT02623179|Active Comparator|A-Culture and Sensitivity group|Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
11311449|NCT02623179|Active Comparator|B-Diagnosis by Molecular Testing|Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
11311450|NCT02623153|Active Comparator|capecitabine and oxaliplatin|capecitabine of 1000 mg/m2, orally administered twice a day on days 1-14 and oxaliplatin at 130 mg/m2on day 1, as intravenous 2 h infusion
11311451|NCT02623153|Experimental|S1, oxaliplatin and docetaxel|S1 of 40 mg/m2, orally administered twice a day on days 1-14,oxaliplatin 130 mg/m2 and docetaxel 40 mg/m2on day 1 as intravenous
11311452|NCT02623140|Experimental|Biofreedom|Biofreedom stent treatment at index procedure
11311453|NCT02623140|Active Comparator|Orsiro|Orsiro stent treatment at index procedure
11311454|NCT02623127|Experimental|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
11311455|NCT02623114|Experimental|Methylphenidate|ADHD patients with methylphenidate administration Generic names include concerta, metadata and penid. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
11311456|NCT02623114|Experimental|Atomoxetine|ADHD patients with atomoxetine administration Generic names include strattera. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
11311522|NCT02622711|Experimental|PADI Physical Activity+Diet Intervention|Individualized dietary and physical activity counseling to reduce body weight
11311457|NCT02623101|Active Comparator|Standard of care procedure|"Clinical suspected basal cell carcinomas, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most clinical suspicious part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. Hematoxylin/eosin stained sections of the punch biopsies will be evaluated by an experienced pathologist. Subjects will receive surgical excision according to subtype.
~When there is any doubt by reflectance confocal microscopic diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma."
11311458|NCT02623101|Experimental|Reflectance confocal microscopy (RCM)|The Vivascope 1500 and Vivascope 3000 (handheld divice) will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed on clinical suspected basal cell carcinomas, of all subtypes. When there are signs of a basal cell carcinoma imaged by RCM, subjects will receive surgical excision according to subtype. When there is any doubt by RCM diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma.
11311459|NCT02623088||PAP therapies|Patients with sleep apnea syndrome treated by CPAP after respiratory and vascular assessment and followed 5-7 years, as part of a clinical research.
11311460|NCT02623075|Experimental|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
11311461|NCT02623075|Experimental|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
11311462|NCT02623075|Active Comparator|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
11311463|NCT02623062|Active Comparator|Compound Sodium Alginate Oral Suspension sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
11311464|NCT02623062|Placebo Comparator|Matching placebo sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
11311465|NCT02623049||octogenarians patients - Apixaban|octogenarians patients who will be treated with Apixaban
11311466|NCT02623049||younger than 70 years patients - Apixaba|younger than 70 years patients who will be treated with Apixaba
11311467|NCT02623049||octogenarians patients - Rivaroxaban|octogenarians patients who will be treated with Rivaroxaban
11311468|NCT02623049||younger than 70 years patients - Rivaroxaban|younger than 70 years patients who will be treated with Rivaroxaban
11311469|NCT02623049||octogenarians patients - Dabigatran|octogenarians patients who will be treated with Dabigatran
11311470|NCT02623049||younger than 70 years patients - Dabigatran|younger than 70 years patients who will be treated with Dabigatran
11311471|NCT02623036|Active Comparator|Enalapril arm|Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.
11311472|NCT02623036|Active Comparator|Lisinopril arm|Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.
11311473|NCT02623023|Experimental|Combigan group|Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
11311474|NCT02623023|Placebo Comparator|Refresh tears|Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
11311475|NCT02623010|Experimental|Single arm|Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment
11311476|NCT02622997|Active Comparator|Refrigerated|Sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
11311477|NCT02622997|Experimental|Incubated at 25oC for 1 week|Sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
11311478|NCT02622997|Experimental|Incubated at 25oC for 2 weeks|Sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
11311479|NCT02622984|Experimental|RBIRT|Telehealth model or the remote administration of SBIRT, a short term, brief intervention and referral to treatment for alcohol abuse.
11311480|NCT02622984|Active Comparator|SBIRT|Face-to-face intervention and referral to treatment for alcohol abuse.
11311481|NCT02622971|Active Comparator|PBMT and Cryotherapy|Volunteers allocated in this group received phototherapy (PBMT - applied in six points of quadriceps) and cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
11311482|NCT02622971|Active Comparator|Cryotherapy and PBMT|Volunteers allocated in this group received cryotherapy (20 minutes in PRICE protocol) and phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
11311483|NCT02622971|Active Comparator|PBMT (active phototherapy)|Volunteers allocated in this group received active phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
11311484|NCT02622971|Placebo Comparator|PBMT (placebo phototherapy)|Volunteers allocated in this group received placebo phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. The placebo PBMT device was identical to the active devices and displayed the same settings and emitted the same sound regardless of the comparator.
11311523|NCT02622711|Experimental|LII Less Intensive Intervention|Materials and guidelines available to general public
11311694|NCT02621645|Experimental|Early intervention|Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
11311485|NCT02622971|Active Comparator|Cryotherapy|Volunteers allocated in this group cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. Two flexible ice packs filled with ice cubes and water (with a volume of 1.15 liters each) were used in order to cover the entire quadriceps. Rubber belts were used to apply compression and to affix the packs tightly to the volunteers' quadriceps.
11311486|NCT02622958|Experimental|PH94B Nasal Spray|Water based solution of 16 ppm PH94B. Each nasal spray delivers .8 micrograms PH94B in 50 microliters
11311487|NCT02622958|Placebo Comparator|Placebo Nasal Spray|Water based solution, each nasal spray delivers 50 microliters of droplets.
11311488|NCT02622945|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
11311489|NCT02622945|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
11311490|NCT02622932|Experimental|Anlotinib and 14C-labeled Anlotinib|each participant will be given a single dose of 14C-labeled gilteritinib.
11311491|NCT02622906|Placebo Comparator|Placebo|1 injection per month during 6 months of the placebo product
11311492|NCT02622906|Active Comparator|Pasireotide|1 injection per month during 6 months of the Pasireotide LP (60mg/injection)
11311493|NCT02622893|Active Comparator|Transperitoneal laparoscopic nephrectomy|Patients in this group underwent transperitoneal laparoscopic nephrectomy in 45-60º modified flank position after receiving epidural catheter in the sitting position before the surgery.
11311494|NCT02622893|Active Comparator|Retroperitoneal laparoscopic nephrectomy|Patients in this group underwent retroperitoneal laparoscopic nephrectomy in lateral decubitis position after receiving epidural catheter in the sitting position before the surgery.
11311495|NCT02622880|Active Comparator|: IMPACT|along 10 days before surgery
11311496|NCT02622880|Experimental|immunomodulatory supplement|along 10 days before surgery
11311497|NCT02622867|Experimental|Lactobacillus plantarum 3547|1 capsule/daily during 12 weeks with Lactobacillus plantarum 3547 (10x109 cfu/d). The capsule contains 77 mg probiotic Lp3547 and 390 mg maltodextrin
11311498|NCT02622867|Placebo Comparator|Maltodextrin|1 daily capsule of maltodextrin (425 mg) during 12 weeks
11311499|NCT02622854|Experimental|plasma exchange|plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides <=10 mmol/l
11311500|NCT02622854|Active Comparator|conservative treatment|infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
11311501|NCT02622841|Experimental|BLEND|Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.
11311502|NCT02622828|Other|Behavioural|Participant-identified community based activity
11311503|NCT02622815||Healthy blood donors|10,000 highly controlled blood donors in the age range 30-70 years
11311504|NCT02622815||Moli-sani subjects|A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).
11311505|NCT02622815||Cancer patients|4,000 Patients with breast, lung, and gastrointestinal tumors.
11311506|NCT02622802|Experimental|ex-vivo placenta perfusion|ex vivo placenta perfusion study with exposure to paracetamol, erythromycin and azithromycin
11311507|NCT02622789||Controls|Age-matched Healthy Controls
11311508|NCT02622789||General Exercises|Low Back Pain Participants Receiving General Exercises
11311509|NCT02622789||Pilates Exercises|Low Back Pain Participants Receiving Pilates Exercises
11311510|NCT02622776|Other|Vaginal DNA Collection|Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.
11311511|NCT02622763|Experimental|10 millions dose|a total of 10 millions tolerogenic dendritic cells
11311512|NCT02622763|Experimental|100 millions dose|a total of 100 millions tolerogenic dendritic cells
11311513|NCT02622750|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
11311514|NCT02622750|Active Comparator|four-branched Dacron graft|"A four-branched Dacron graft (Boston Scientific Inc, Boston, MA) and a stent graft (MicroPort Medical Co Ltd, Shanghai, China) were used in total arch replacement combined with stented elephant trunk (SET) implantation.The SET was inserted into the true lumen of the descending aorta.The proximal edge of the residual aorta was trimmed to match the proximal end of the stent graft.The anastomosis between the four-branched prosthetic graft and the distal aorta containing the intraluminal stented graft was carried out using open aortic technique."
11311515|NCT02622737|Experimental|Functional Training|Functional exercise training program
11311516|NCT02622737|Experimental|Stationary Bike|Stationary bike training program
11311517|NCT02622737|Experimental|Exergaming|Virtual Reality Exposure Therapy
11311518|NCT02622724|Experimental|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
11311519|NCT02622724|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.
~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
11311520|NCT02622711|Experimental|DI Dietary Intervention|Individualized dietary counselling to reduce body weight
11311524|NCT02622698|Placebo Comparator|Control|The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
11311525|NCT02622698|Experimental|Treatment|Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily. No other modifications were made to the patient's diet. Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
11311526|NCT02622685|Experimental|DWP10292|"Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration
~Arms: DWP10292"
11311527|NCT02622685|Placebo Comparator|DWP10292 Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations
~Arms: Placebo"
11311528|NCT02622685|Experimental|Ursodeoxycholic acid (UDCA)|"Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations
~Arms: Ursodeoxycholic acid (UDCA)"
11311529|NCT02622685|Placebo Comparator|Ursodeoxycholic acid (UDCA) Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations
~Arms: Placebo"
11311530|NCT02622672|Experimental|Placebo|glycerin.soy-lecithin, and water
11311531|NCT02622672|Experimental|Supplement|water-soluble Ubiquinol 100 mg/d
11311532|NCT02622659|Experimental|Fuganlin Oral Liquid|"Fuganlin Oral Liquid:oral
~less than 1 years old: 5mL each time and three times a day
~1~3 years old: 10mL each time and three times a day
~4~6 years old: 10mL each time and four times a day
~7~12 years old: 10mL each time and five times a day
~Xiaoer Jiebiao Oral Liquid placebo:oral
~1~2 years old: 5mL each time and twice a day
~3~5 years old: 5mL each time and three times a day
~6~14 years old: 10mL each time and twice a day"
11311533|NCT02622659|Active Comparator|Xiaoer Jiebiao Oral Liquid|"Xiaoer Jiebiao Oral Liquid:oral
~1~2 years old: 5mL each time and twice a day
~3~5 years old: 5mL each time and three times a day
~6~14 years old: 10mL each time and twice a day
~Fuganlin Oral Liquid placebo:oral
~less than 1 years old: 5mL each time and three times a day
~1~3 years old: 10mL each time and three times a day
~4~6 years old: 10mL each time and four times a day
~7~12 years old: 10mL each time and five times a day"
11311534|NCT02622646||Well controlled patients|Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
11311535|NCT02622646||Poor controlled patients|Patients with poor disease control, based on the international guidelines: AJBR>2, ABR>2 for severe BE or ABR >5 for non-severe BE
11311536|NCT02622633|Experimental|Stimulation|One week after implantation of the device, participants randomized in this arm will receive continuous magnetic stimulation of high frequency (50Hz) with epidural electrode for 12 weeks. And then, the epidural electrode will be turned off for more 12 weeks in a crossover fashion.
11311537|NCT02622633|Sham Comparator|Sham Stimulation|One week after implantation of the device, participants randomized in this arm will receive sham stimulation for 12 weeks and then continuous magnetic stimulation with epidural electrode of high frequency (50Hz) stimulation for more 12 weeks.
11311538|NCT02622620||Patients with glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
11311539|NCT02622607|Experimental|ZOL|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 months for 12 months.
11311540|NCT02622607|No Intervention|Control|No investigational treatment
11311541|NCT02622594|Active Comparator|1|Treatment 1 will include microneedling performed prior to ALA application to their right face and ALA application only to the left face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
11311542|NCT02622594|Active Comparator|2|Treatment 2 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
11311543|NCT02622594|Active Comparator|3|Treatment 3 will include microneedling performed prior to ALA application to their right face and ALA application only to the left side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
11311544|NCT02622594|Active Comparator|4|Treatment 4 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
11311545|NCT02622581||NSCLC, Non-squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.
~3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)"
11311546|NCT02622581||NSCLC, Squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.
~1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)"
11311547|NCT02622581||NSCLC, Non-squamous cell carcinoma (not tested)|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.
~Not tested for molecular alterations (CRISP satellite untested patients stage IIIB/IIIC/IV).)."
11311548|NCT02622581||NSCLC, Stage II/III|800 patients with NSCLC stage II, or stage IIIA, or with NSCLC stage IIIB/C if they are eligible for curative surgery and/or radiochemotherapy
11311549|NCT02622581||Small cell lung cancer (SCLC)|Up to 1200 patients with SCLC (limited stage (LD) or extensive stage (ED)) if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, or are receiving best supportive care
11311550|NCT02622568|Active Comparator|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
11311585|NCT02622321|Experimental|Arm C (Prophylactic Treatment): Emicizumab|Participants, who received prophylactic bypassing agents prior to study entry, will receive prophylactic emicizumab. Participants will continue to receive bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or aPCC.
11311663|NCT02621879|Experimental|Bilateral Gluteal Advancement Flap|Advancement of both gluteal muscles to the midline after release incisions in their fascia.
11311551|NCT02622568|Experimental|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
11311552|NCT02622555||Mirabegron treatment|Women with overactive bladder syndrome eligible for Mirabegron treatment
11311553|NCT02622542|Active Comparator|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
11311554|NCT02622542|Experimental|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
11311555|NCT02622529||Screening through Questionnaires|All of the patients within this single existent Arm will receive the questionnaires.
11311556|NCT02622516|Active Comparator|Intervention Group (IG)|Participants in the intervention group subjects (IG) will receive physiotherapy treatment in vestibular rehabilitation based on multisensory exercises consisting of the group of therapeutic proposals that stimulation of the vestibular, proprioceptive and visual associated with manual therapy treatment proposed by the techniques cervical global pompage and classic massage therapy on neck and shoulder girdle .
11311557|NCT02622516|Experimental|Control Group (CG)|Participants in the control group subjects (CG) will receive physiotherapy treatment in vestibular rehabilitation based on Cawthorne and Cooksey Exercises, consisting of eye movements in different directions, slowly and quickly; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
11311558|NCT02622503||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.
11311559|NCT02622490|Active Comparator|Low carb. one meal|Intervention: One meal of 750 kcal with 20 % of energy content from carbohydrates
11311560|NCT02622490|Active Comparator|Low Carb. 5 small meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 20 % of energy content from carbohydrates.
11311561|NCT02622490|Active Comparator|High carb. one meal|Intervention: One meal of 750 kcal with 50 % of energy content from carbohydrates
11311562|NCT02622490|Experimental|High carb. 5 meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 50 % of energy content from carbohydrates.
11311563|NCT02622477||Participants with idiopathic pulmonary fibrosis|Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.
11311564|NCT02622464|Experimental|micro injection of SVF in vocal cords|micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords
11311565|NCT02622451|Other|Youth Behavioral Intervention|Teen Intervene
11311566|NCT02622451|Other|Parent Education|Everyday Parenting
11311567|NCT02622438|Other|Course and follow up of patients affected by FSHD|
11311568|NCT02622425|Active Comparator|PD01|Carotenoid-producing Bacillus strain PD01
11311569|NCT02622425|Placebo Comparator|Placebo|Maltodextrin
11311570|NCT02622412|Experimental|Intervention Group|Patients randomised to the intervention group will get immediate access to the Multi-professional breathlessness service (MBS).
11311571|NCT02622412|Other|Control Group|Patients randomised to the control group will get delayed MBS intervention. They will receive standard care and get access to the service after a waiting time of eight weeks.
11311572|NCT02622399|Experimental|Project NOW|Participants in the intervention arm receive access to free mobile communications and a web-based informational platform supported by txtwire.
11311573|NCT02622399|No Intervention|Control|Participants in the control arm do not receive access to the txtwire platform.
11311574|NCT02622386|Experimental|Riboflavin|Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
11311575|NCT02622386|Placebo Comparator|Placebo|Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
11311576|NCT02622373||Birth Between 23-32 Weeks Gestation|Babies born between 23-32 weeks of gestational age will have their body composition determined using PEA POD Infant Body Composition System at 34 weeks, 36 weeks and 40 weeks of corrected age.
11311577|NCT02622373||Birth Between 34-36 Weeks Gestation|Babies born at 34 weeks and 36 weeks of gestational age will have their body composition measured using PEA POD Infant Body Composition System as soon as they are off parenteral nutrition and receiving full enteral nutrition.
11311578|NCT02622373||Birth at Term|Body composition will be measured using PEA POD Infant Body Composition System in this group will be obtained prior to discharge.
11311579|NCT02622360||Dyslexia|Individuals with confirmed dyslexia.
11311580|NCT02622360||Control|Healthy control subjects.
11311581|NCT02622334|Experimental|Part A|Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days.
11311582|NCT02622334|Experimental|Part B|Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days.
11311583|NCT02622321|Experimental|Arm A (Episodic Treatment): Emicizumab|Participants, who received episodic treatment with bypassing agents prior to study entry, will receive prophylactic emicizumab. Participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or activated prothrombin complex concentrate (aPCC).
11311584|NCT02622321|Active Comparator|Arm B (Episodic Treatment): No Emicizumab|Participants, who received episodic treatment with bypassing agents prior to study entry, will not receive emicizumab prophylaxis. These participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Participants will continue to receive bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or aPCC.
11311641|NCT02622009||NONSMOKERS|BRONCHOSCOPIC PROCEDURE IN NONSMOKERS
11311586|NCT02622321|Experimental|Arm D (Episodic or Prophylactic Treatment): Emicizumab|Participants who received episodic bypassing agents while participating in Study BH29768 but were unable to enroll in Arms A or B, or participants who received prophylactic bypassing agents but were unable to enroll in Arm C, will be enrolled in this arm to receive prophylactic emicizumab. Participants will continue to receive bypassing agent therapy to treat breakthrough bleeds, with rFVIIa and/or aPCC.
11311587|NCT02622308|Experimental|single-case design|"The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:
~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design)."
11311588|NCT02622295|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session high-frequency active-resisted stance or single-session low-frequency active-resisted stance
11311589|NCT02622295|Experimental|3 year Training Study|Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to 3 years of high-frequency active-resisted stance training or 3 years of low-frequency active-resisted stance training
11311590|NCT02622282|Experimental|Experimental Group|Participants will receive text messages and telephone calls during the length of their participation. Participants will receive a handout with information on PAD and physical activity.
11311591|NCT02622282|Active Comparator|Control Group|Participants will receive a handout with information on PAD and physical activity.
11311592|NCT02622269|Experimental|Patient-regulated compression|Patient-regulated compression device
11311593|NCT02622269|Active Comparator|Standard compression|Standard compression device
11311594|NCT02622256|Experimental|Health System: HTN Intervention|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys.
11311595|NCT02622256|No Intervention|Health System: HTN Control, survey only|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys. Participants in this arm will be exposed to daily messages about heart health and asked to tweet about health.
11311596|NCT02622243|Experimental|tiotropium|2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
11311597|NCT02622243|Experimental|glycopyrronium|1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge
11311598|NCT02622230|Experimental|Mianhuahua Flavonoids Tablets|Mianhuahua Flavonoids Tablets, oral administration
11311599|NCT02622230|Placebo Comparator|Placebo|Placebo, oral administration
11311600|NCT02622217|Experimental|Sleep deprived|Participants undergo a simulation session after an on call night
11311601|NCT02622217|No Intervention|Rested|Participants undergo a simulation session after a night of normal sleep at home
11311602|NCT02622204||Corrective osteotomy|patients with knee osteoarthritis undergoing corrective osteotomy
11311603|NCT02622191|Experimental|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
11311604|NCT02622191|Experimental|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
11311605|NCT02622178|Experimental|Healthy Subjects|42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
11311606|NCT02622178|Experimental|Glaucoma Suspects|45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
11311607|NCT02622178|Experimental|Glaucoma Patients|49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
11311608|NCT02622165|Experimental|The REWARD serious game intervention|A mobile 4-week serious game intervention will be administered.
11311609|NCT02622165|No Intervention|Control group|School curriculum as usual
11311610|NCT02622152|Active Comparator|Right lateral position group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for 30 minutes period on the supine position Repositioning the patients for 30 minutes period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
11311611|NCT02622152|Active Comparator|Routine hospital care group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for two-hours period on supine position Repositioning the patients for two-hours period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
11311612|NCT02622139|Experimental|Multispectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography (MSOT) for the evaluation of disease activity in inflammatory bowel diseases (IBD)
11311642|NCT02622009||CURRENT OR EXSMOKERS|BRONCHOSCOPIC PROCEDURE IN CURRENT OR EXSMOKERS
11311664|NCT02621866|Experimental|Active|UVA irradiation.
11311665|NCT02621866|Sham Comparator|Sham UVA irradiation|
11311725|NCT02621437|Other|control group|Patients will have 6 phone questionnaires.
11311726|NCT02621424|Experimental|RTMS|repetitive transcranial magnetic stimulation
11311613|NCT02622126|Active Comparator|Normotensive pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).
~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
11311614|NCT02622126|Active Comparator|Mild preeclampsia pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).
~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
11311615|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
11311616|NCT02622100||Bioresorbable Vascular Scaffold|
11311617|NCT02622087|Experimental|Hormonal contraceptive|Women who receive one-session-treatment while they are on the hormonal contraceptive pill
11311618|NCT02622087|Experimental|Naturally cycling- high estradiol|Naturally cycling women who receive one-session-treatment during a period of high estradiol
11311619|NCT02622087|Experimental|Naturally cycling-low estradiol|Naturally cycling women who receive one-session-treatment during a period of low estradiol
11311620|NCT02622074|Experimental|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via intravenous (IV) infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
11311621|NCT02622074|Experimental|Cohort B: KNpCb (Regimen 1) / KAC|Participants first receive KNpCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
11311622|NCT02622074|Experimental|Cohort C: KNpCb (Regimen 2) / KAC|Participants first receive KNpCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
11311623|NCT02622074|Experimental|Cohort D: KNpCb (Regimen 3) / KAC|Participants first receive KNpCb Regimen 3 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
11311624|NCT02622074|Experimental|Cohort E: KTCb (Regimen 1) / KAC|Participants first receive KTCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
11311625|NCT02622074|Experimental|Cohort F: KTCb (Regimen 2) / KAC|Participants first receive KTCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
11311626|NCT02622061||PCD Subjects|Participants 5 and older with PCD.
11311627|NCT02622061||Healthy Subjects|Participants 5 and older without any pulmonary disease.
11311628|NCT02622048|Experimental|Stage 2 Parents experiencing psychosis|Parents all receive the self-directed Triple P Positive Parenting Programme
11311629|NCT02622035|Experimental|1|Gain frame; Anger
11311630|NCT02622035|Experimental|1b|high visual perception load high interactive
11311631|NCT02622035|Experimental|2|Gain frame; Fear
11311632|NCT02622035|Experimental|2b|high visual perceptual load
11311633|NCT02622035|Experimental|3|Loss frame; Anger
11311634|NCT02622035|Experimental|3b|low visual preceptual load
11311635|NCT02622035|Experimental|4|Loss frame; Fear
11311636|NCT02622022|Active Comparator|Morphine|18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily
11311637|NCT02622022|Placebo Comparator|Placebo|18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily
11311638|NCT02622009||COPD I|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE I
11311639|NCT02622009||COPD II|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE II
11311640|NCT02622009||COPD III|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE III
11311643|NCT02621996|Experimental|Hammock group|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
11311644|NCT02621996|Active Comparator|control group|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
11311645|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
11311646|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
11311647|NCT02621970|Experimental|IC plus CC plus IMRT plus AC|Induction chemotherapy: TP -- Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 2 cycles; Concurrent chemotherapy: PX -- Cisplatin 25 mg/m2, D1-3 and Xeloda 2000mg/m2, D1-14, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy; Adjuvant chemotherapy: Xeloda 2500mg/m2, D1-14, every 3 weeks for 2 cycles
11311648|NCT02621970|Active Comparator|CC plus IMRT|Concurrent chemotherapy: Cisplatin 100 mg/m2, D1, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
11311649|NCT02621957|Experimental|Female Healthy Volunteers|Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4). During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8. Pravastatin will be co-administered on Day 7.
11311650|NCT02621944|Experimental|Participants 1-10|"This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.
~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.
~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
11311651|NCT02621944|Experimental|Participants 11-20|"This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.
~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.
~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
11311652|NCT02621944|Experimental|Participants 21-30|"This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.
~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.
~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
11311653|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
11311654|NCT02621931|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
11311655|NCT02621931|Experimental|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
11311656|NCT02621918|Experimental|Progressive Resistance Training (PRT)|For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
11311657|NCT02621918|Experimental|Aerobic Exercise (AER)|Aerobic exercise was conducted with a mini ergometer cycling (Mini Bike E5 Acte Sports) attached to the patient chair. Patients exercised 50-60 minutes of continuous workout with increased load. The workload was adjusted when necessary, according to the perceived effort made by the patient. The scale of perceived exertion, Borg scale (Borg and Noble , 1974), was used in accordance with the proposed By The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995), which defines the values of perceived exertion between 12 and 16.
11311658|NCT02621918|Placebo Comparator|NEPLA|The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
11311659|NCT02621905|Active Comparator|Sporanox|100 mg
11311660|NCT02621905|Experimental|Lozanoc|50 mg
11311661|NCT02621892|Experimental|50mg BID|Tenapanor
11311666|NCT02621853|Other|MRI+RAMAN|Patients will undergo an MRI for assessment of the fat content of the liver. Then during surgery, their livers will be illuminated (for a few seconds) by Raman spectroscope (the device in question) to see if MRI findings correlate well with Raman spectroscopy findings.
11311667|NCT02621840|Experimental|Intervention|Patients in the intervention group will be mandated to complete the PAT with Dr. Koka. After scheduling the surgery with the surgical coordinator, intervention patients will be required to go directly to Dr. Koka's office, to complete all necessary pre-operative steps.
11311668|NCT02621840|No Intervention|Usual Care|Patients in the usual care group will be treated with the standard protocol that is currently utilized in the Wills Eye Hospital Cataract and Primary Eye Care (CPEC) Service. After scheduling the surgery with the surgical coordinator, the patient will be given pre-admission testing (PAT) paperwork to be completed. The patient schedules the PAT on his or her own with the primary care physician.The patient will be given the information for Dr. Koka's cardiology office if he or she has any problem getting the PAT done.
11311669|NCT02621827|Experimental|Non-pregnant, non-lactating (NPNL)|"NPNL women are age and parity matched to pregnant women. Each NPNL women is studied twice, approximately 3 months apart.
~At each study period the participant receives (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3."
11311670|NCT02621827|Experimental|Pregnant/Lactating|Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
11311671|NCT02621814|Experimental|Experimental 1|Formula feeding
11311672|NCT02621814|Experimental|Experimental 2|Formula feeding
11311673|NCT02621801|Experimental|Intervention|Stress Management and Resiliency Training for Residents (SMART-R)
11311674|NCT02621801|Active Comparator|Waitlist Control|The control group will receive the same intervention (SMART-R) after the experimental group.
11311675|NCT02621788|Experimental|First Year Residents|Stress Management and Resiliency Training for Residents (SMART-R) delivered to first year residents in the departments of medicine and psychiatry at Massachusetts General Hospital
11311676|NCT02621775|Experimental|Computer-based stress management program|Immediate e-learning condition with minimal contact (n =40),
11311677|NCT02621775|Experimental|Stress management in face-to-face|Immediate treatment in face - to- face (n = 40)
11311678|NCT02621775|Other|Waiting list|Waiting list (n=40)
11311679|NCT02621762|Experimental|Mg first|Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
11311680|NCT02621762|Experimental|Bicarbonate first|Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
11311681|NCT02621749|Active Comparator|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
11311682|NCT02621749|Active Comparator|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
11311683|NCT02621710||Minimally invasive hysterectomy|Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition
11311684|NCT02621710||Abdominal hysterectomy|Patients undergoing scheduled abdominal hysterectomy for benign condition
11311685|NCT02621697|Experimental|Cognitive motor training|Evaluate the effectiveness of a 12-week training based on dual-task (motor and cognitive) in institutionalized elderly.
11311686|NCT02621697|Active Comparator|Control Group|kinesiotherapeutic conventional treatment
11311687|NCT02621684|Experimental|Arm 1: Aerobics|"Complete baseline questionnaires either online or on paper
~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline
~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.
~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.
~Require physical evaluation and orientation to the WellAware gym
~12 week walking program at the WellAware Center
~required to check in with gym staff to check attendance
~advised to walk at own pace for 3 days per week
~15 minutes per day for the first 2 weeks
~30 minutes per day for the next 2 weeks
~50 minutes or more for remaining weeks"
11311688|NCT02621684|Experimental|Arm 2: Resistance training|"Complete baseline questionnaires either online or on paper
~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline
~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.
~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.
~Require physical evaluation and orientation to the WellAware gym
~12 week weight lifting program at WellAware Center
~exercise physiologists will work with each patient to develop a custom routine
~exercise load will start at 60% of one-repetition maximum and progress from 8 to 12 repetitions
~2-4 sets of repetition exercises will be performed to target upper & lower muscle groups
~resistance load will be added by 5 pounds when patients can complete more than 12 repetitions"
11311689|NCT02621684|Active Comparator|Arm 3: Usual care|"Complete baseline questionnaires either online or on paper
~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline
~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.
~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations."
11311690|NCT02621671|Experimental|Arm 1: Cognitive Interviews|"Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions.
~Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease.
~The entire visit will take no more than 90 minutes with no follow-up.
~The first 10-20 participants will be randomized to this arm."
11311691|NCT02621671|Experimental|Arm 2: Experimental survey|"Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions.
~After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool.
~Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned.
~The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity."
11311692|NCT02621658|Active Comparator|Clear Liquid Diet|Clear Liquid Diet the day before colonoscopy.
11311693|NCT02621658|Experimental|Full Liquid Diet|Full Liquid Diet the day before colonoscopy.
11311695|NCT02621645|Active Comparator|Late intervention|Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
11311696|NCT02621632|Other|Healthy subjects and patients|To done a novel compression system. 20 healthy subjects and 20 patients done a novel compression system termed Socknleg and a compression class III stocking as a comparator.The Socknleg compression system was developed by the investigator and produced by Sigvaris AG, St. Gallen, Switzerland.
11311697|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
11311698|NCT02621619|Placebo Comparator|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
11311699|NCT02621606|Experimental|Part 1, Healthy Participants|Healthy participants receive a single intravenous (IV) dose of ~370 megabecquerel (MBq) [11C]MK-6884 in Part 1 of the study.
11311700|NCT02621606|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants receive two separate IV doses of ~370 MBq [11C]MK-6884 in Part 2 of the study. Administration of the two doses is separated by at least 3 hours.
11311701|NCT02621606|Experimental|Part 3, Participants with AD|Participants with AD receive a single IV dose of ~370 MBq [11C]MK-6884 in Part 3 of the study.
11311702|NCT02621593|Experimental|Treatment of dry eye secondary to MGD|Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
11311703|NCT02621580|No Intervention|Control|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and do not require laser or anti-VEGF treatment in at least one eye.
11311704|NCT02621580|Experimental|Treatment: Pan-Retinal Photocoagulation|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and require PRP laser in at least one eye.
11311705|NCT02621567|Experimental|Bright Light Therapy Group|Participants in this group will receive bright light therapy lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
11311706|NCT02621567|Placebo Comparator|Dim Light Group|Participants in this group will receive modified dim lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
11311707|NCT02621554|Experimental|resveratrol supplementation|Dietary Supplement: Resveratrol
11311708|NCT02621554|Placebo Comparator|placebo supplementation|Dietary Supplement: Placebo
11311709|NCT02621541|Experimental|Preoperative diagnosis|Preoperative diagnosis
11311710|NCT02621528|Other|CeraFlex occluder|The Lifetech CeraFlex™ study is a triple-arm study.
11311711|NCT02621515|Experimental|Nivolumab|All patients in this trial will receive treatment with nivolumab for 24 months. Treatment will be discontinued if confirmed disease progression has been demonstrated, if unacceptable toxicity or intercurrent illness prevents further treatment, and when informed consent is withdrawn. After discontinuation of treatment, follow-up will start. Duration of follow-up depends on survival of patients, with a maximum of 24 months. Therefore the end of this study is determined as 24 months after the last patient in this trial has started follow-up, has died, withdraws consent or is lost to follow-up for a different reason
11311712|NCT02621502|Experimental|Quinoa variety 1|1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
11311713|NCT02621502|Experimental|Quinoa variety 2|1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
11311714|NCT02621502|Experimental|Quinoa variety 3|1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
11311715|NCT02621502|Experimental|Quinoa variety 4|1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
11311716|NCT02621502|Active Comparator|Anhydrous Glucose|1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
11311717|NCT02621489|Experimental|Bydureon 2 mg Once Weekly|Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.
11311718|NCT02621489|Active Comparator|Humulin kwickpen|Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
11311719|NCT02621476|Experimental|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
11311720|NCT02621476|Experimental|Usual care|Usual care
11311721|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
11311722|NCT02621450|Placebo Comparator|standart dialysate|dialysate sodium 140 mEq/L
11311723|NCT02621450|Other|low sodium dialysate|dialysate sodium will be reduced from 140 mEq/L to 137 mEq/L
11311724|NCT02621437|Experimental|Intervention group (osteopathy)|Patients will have three sessions of osteopathy and 6 phone questionnaires.
11311728|NCT02621411||Substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are found current use of the certain substance(s).
11311729|NCT02621411||Non-substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are not found use of any substance.
11311730|NCT02621398|Experimental|Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients undergo 3D CRT or IMRT QD 5 days a week for 6 weeks. Beginning 2-6 weeks after, 2 weeks before the end, or at the start of chemotherapy and radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11311731|NCT02621385|Experimental|Tradipitant|One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16
11311732|NCT02621359|Experimental|Quadruple therapy|Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
11311733|NCT02621346|Experimental|Imagery Group|The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
11311734|NCT02621346|Active Comparator|Maintenance Group|The maintenance group will continue to perform the leg press three times per week at 1/3rd of final strength assessment. This is the percentage of intensity recommended to maintain muscle mass and strength gains by the American College of Sports Medicine.
11311735|NCT02621346|Active Comparator|Control Group|Control group will come in 3 times per week for 20 minutes and complete 3 sets of 8-12 of a bicep curl 1/3 of predicted 1 RM
11311736|NCT02621333|Experimental|CIK combined chemotherapy group|autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.
11311737|NCT02621333|Active Comparator|chemotherapy group|platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.
11311738|NCT02621320|Experimental|Vitamin D|alcohol-based (Ethanol 65%) Vitamin D3 (Vi-De 3®. WILD) solution 6000IU per day.
11311739|NCT02621320|Placebo Comparator|Placebo|Same alcohol-based solution (Ethanol 65%) as intervention product but without cholecalciferol
11311740|NCT02621307|Experimental|Salba|50g glucose 25g ground Salba (Salba Corporation Ltd, Buenos Aires, Argentina) 200ml water
11311741|NCT02621307|Experimental|Flax|50g glucose 31g ground Flax (Bob's Red Mill Natural Raw Whole Flaxseed) 200ml water
11311742|NCT02621307|Placebo Comparator|Control|50g glucose 200ml water
11311743|NCT02621294|Experimental|Measuring protein requirement|Measuring protein requirement of athletes by feeding different amount of protein in the form of amino acid mixture and measuring their oxidation through expired CO2
11311744|NCT02621281|Active Comparator|cold storage|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
11311745|NCT02621281|Active Comparator|Kidney Transporter machines|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
11311746|NCT02621268|Experimental|Indocyanine Green|Dosage calculated by weight of individual, 5mg/kg.
11311747|NCT02621255|Active Comparator|General anesthesia|General Anesthesia: Effect of general anesthesia will compare with regional anesthesia without use of nonsteroid antiinflammatory drug usage. Propofol 2mg/kg and rocuronium will be administered to patients for anesthesia induction. Anesthesia maintenance will ensure with sevoflurane %2 and N2O/O2 %50/50 mixture.
11311748|NCT02621255|Active Comparator|bupivacaine|Regional Anesthesia: Effect of regional anesthesia will compare with general anesthesia without use of nonsteroid antiinflammatory drug usage. Combined epidural-spinal anesthesia will be performed to patients. %5 bupivacain and 20µg fentanyl will apply for spinal anesthesia. Anesthesia maintenance will ensure with bupivacain.
11311749|NCT02621242|Other|Cohort|All subjects will undergo all procedures
11311750|NCT02621190|No Intervention|A|patients without CTCs or AR-V7 negative CTCs are treated according to their physician's discretion
11311751|NCT02621190|Experimental|B|patients with AR-V7 positive CTCs are treated with cabazitaxel 25mg/m2 q3w
11311752|NCT02621177|Experimental|NBP607|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
11311753|NCT02621177|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
11311754|NCT02621164|Experimental|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
11311755|NCT02621164|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
11311756|NCT02621151|Experimental|Pembrolizumab, Gemcitabine, and RT|"Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)
~Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)
~External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)
~Gemcitabine 27 mg/m^2 IV twice weekly for 4 weeks concurrent with EBRT
~Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
11311757|NCT02621138||cerebral palsy|Age 6-12 years Gross Motor Function Classification System I-II
11311758|NCT02621138||control|Age 6-12 years
11311759|NCT02621125|Experimental|Fertilix|Fertilix supplementation
11311760|NCT02621125|Placebo Comparator|Placebo|Placebo
11311761|NCT02621112|Experimental|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
11312066|NCT02619097|Experimental|0.5mg/kg|Pegol-sihematide injection, 0.5mg/kg, single-dose
11311762|NCT02621112|Active Comparator|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
11311763|NCT02621112|Active Comparator|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
11311764|NCT02621086|Experimental|Level 1|10g of Cellodextrin
11311765|NCT02621086|Experimental|Level 2|20g of Cellodextrin
11311766|NCT02621086|Experimental|Level 3|30g of Cellodextrin
11311767|NCT02621086|Experimental|Level 4|50g of Cellodextrin
11311768|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
11311769|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
11311770|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
11311771|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
11311772|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
11311773|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
11311774|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
11311775|NCT02621034|Experimental|Control|K-file hand instrumentation
11311776|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
11311777|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
11311778|NCT02621021|Experimental|1/ACT TIL|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)
11311779|NCT02621021|Experimental|2/ACT TIL+Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab
11311780|NCT02621021|Experimental|3/Retreatment|Standard dose pembrolizumab
11311781|NCT02621008|Experimental|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
11311782|NCT02620995|Experimental|hypertensive patients|Hypertensive patients will receive a single oral dose of sildenafil citrate (100 mg) - acute protocol - and a chronic 30-day treatment with sildenafil citrate (50 mg twice daily) - chronic protocol. Penile and systemic microvascular function will be evaluated before and one hour after acute sildenafil administration and in the end of each treatment period.
11311783|NCT02620995|Sham Comparator|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
11311784|NCT02620982|Experimental|ARIES Application|Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
11311785|NCT02620969||Patients on haemodialysis|During a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
11311786|NCT02620956|Active Comparator|obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
11311787|NCT02620956|Experimental|asthmatic obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
11311788|NCT02620943||Exposed Group|Pregnant mothers reporting inadequate (<4) dietary diversity during pregnancy
11311789|NCT02620943||Unexposed group|Pregnant mothers reporting adequate (>=4) dietary diversity during pregnancy
11311790|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
11311791|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
11311792|NCT02620891|Active Comparator|experimental group|Using helium oxygen mixture
11311793|NCT02620891|No Intervention|matched group|Using air oxygen mixture
11311794|NCT02620878|Experimental|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.
~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
11311845|NCT02620579|Experimental|Personalized Pharmaceutical and Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive the pain processing education modules as the combined intervention for this arm.
11311795|NCT02620878|Active Comparator|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).
~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
11311796|NCT02620865|Experimental|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
11311797|NCT02620852|Active Comparator|Annual Arm|Women in this arm will receive Athena standard of care mammography screening, including annual mammograms. They will complete a health questionnaire and receive screening advice based on a basic risk assessment.
11311798|NCT02620852|Experimental|Risk-Based Arm|Women in this arm will receive risk-based screening, where risk is calculated based on a model including personal history, family history, and genetic testing. All women in the risk-based arm complete a health questionnaire, provide a saliva sample for genetic testing, and receive screening advice based on a comprehensive risk assessment. Women in this arm will be tested for a panel of 9 genes related to breast cancer risk as well as a panel of SNPs, which can further modify risk. Women will be assigned a screening start date, screening stop date, and screening frequency.
11311799|NCT02620839|Experimental|Cohort 1A|Alpelisib: 200 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
11311800|NCT02620839|Experimental|Cohort 2A|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
11311801|NCT02620839|Experimental|Cohort 2B|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
11311802|NCT02620839|Experimental|Cohort 3A|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
11311803|NCT02620839|Experimental|Cohort 3B|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
11311804|NCT02620839|Experimental|Cohort 4A|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
11311805|NCT02620839|Experimental|Cohort 4B|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
11311806|NCT02620826|Experimental|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
11311807|NCT02620826|Active Comparator|Pulpotomy|Primary molars treated with MTA pulpotomy.
11311808|NCT02620813|No Intervention|No Acne|Healthy subjects without acne between the ages of 15-45
11311809|NCT02620813|Experimental|Acne Subjects on Topical Tretinoin Treatment|Subjects with acne before and after topical retinoid therapy
11311810|NCT02620813|Experimental|Acne Subjects on Systemic Isotretinoin Treatment|Subjects with acne before and after isotretinoin therapy
11311811|NCT02620800|Experimental|FABLOx|5 fluorouracil (5-FU ) (180 mg/m^2/day for 14 days), by continuous intravenous infusion (CIVI) via ambulatory pump, nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15, bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15, calcium leucovorin (20 mg/m^2) IV bolus on Days 1, 8, 15, and oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15. First bevacizumab infusion is given over 90 minutes.
11311812|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
11311813|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
11311814|NCT02620774|Experimental|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
11311815|NCT02620774|Active Comparator|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
11311816|NCT02620761|Placebo Comparator|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
11311817|NCT02620761|Experimental|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
11311818|NCT02620748|Experimental|Tranexamic Acid|This arm will receive an injection of Tranexamic Acid
11311819|NCT02620748|Placebo Comparator|Saline|This arm will receive an injection of Saline Solution
11311846|NCT02620579|Placebo Comparator|Placebo Pharmaceutical, General Education|This group will have the placebo pharmaceutical administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
11311913|NCT02620072|Placebo Comparator|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
11311820|NCT02620735|Active Comparator|Exercise Only|Participants receive 12-weeks PA training (1x/week - 60 min) group sessions with a CEP/RKin, and a progressively structured home-based exercise program based on the American College of Sports Medicine (ACSM) guidelines.It combines aerobic-resistance exercise with flexibility training, and progresses towards increased in intensity and improved fitness. The goal is at least 150 min/week of moderate-intensity aerobic activity. Participants are also asked to complete 3-5 additional home-based sessions of aerobic, and resistance activities each week. Initial intensity is based on the performance of the exercises during a group session and is self-monitored via the 10-point rating of perceived exertion, with a prescribed training zone of 4-7.
11311821|NCT02620735|Experimental|Exercise + iMOVE|Participants will receive the same exercise program at the Exercise Only group + 1) one-on-one telephone-based counselling (10 x 30-minute telephone: weeks 1, 2, 3, 4, 5, 6, 8, and 12 (during the exercise program) and at weeks 20,28 (post-exercise program booster sessions)); 2) supportive software on smart-phone devices (the HealthCoach program), 3) use of Fit-bit and corresponding software. The iMOVE intervention was designed to enhance sustained behavior change. The theoretical constructs employed are based on promoting motivation and establishing: a) exercise self-efficacy, b) social support for exercise and c) positive exercise-induced feelings during the acute intervention (12 weeks) and post-exercise program period (6 months).
11311822|NCT02620722|Experimental|LOP Measurement|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument and the gold-standard technique with the handheld Doppler ultrasound.
11311823|NCT02620709|Experimental|Hula intervention|"Participants randomized to the intervention arm will receive the 6-month KaHOLO Program within 1 week of baseline data collection. The first 3 months of the KaHOLO was designed and standardized as a culturally-based PA, which includes 12 weeks of hula lessons. These hula lessons consist of two 60 minute classes per week over 12 weeks. Each hula lesson will consist of 15 participants, providing with the opportunity to engage in social support network.
~The last three months of the program will be reduced to once a week sessions. One week will consist of hula lessons for 60 minutes. The remaining 3 weeks will consist of the intervention group meeting for 45 minutes with the community-peer educator."
11311824|NCT02620709|No Intervention|Wait-List Control|After baseline data collection and education, participants randomized to the wait-list control arm will not receive the KaHOLO Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not receive the intervention for 6 months until after the intervention arm is completed and their 6 month follow-up data collection is completed. They will not receive any other intervention from us during the 6 month period but they will be instructed to continue with their routine medical care as usual.
11311825|NCT02620696|Experimental|Treatment 1|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide placebo daily from Days 1-42"
11311826|NCT02620696|Experimental|Treatment 2|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 25 mg daily for 14 days (Days 15-28)
~netazepide placebo daily from Days 1-14, and from Days 29-42"
11311827|NCT02620696|Experimental|Treatment 3|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 25 mg daily for 14 days (Days 29-42)
~netazepide placebo daily from Days 1-28"
11311828|NCT02620696|Experimental|Treatment 4|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide placebo daily from Days 1-28"
11311829|NCT02620696|Experimental|Treatment 5|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 1 mg daily for 14 days (Days 15-28)
~netazepide placebo daily from Days 1-14"
11311830|NCT02620696|Experimental|Treatment 6|"esomeprazole 40 mg daily for 28 days (Days 1-28)
~netazepide 5 mg daily for 14 days (Days 15-28)
~netazepide placebo daily from Days 1-14"
11311831|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.
~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
11311832|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.
~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
11311833|NCT02620670|Active Comparator|Individuals with obesity|Body mass index (BMI) is 30.0 to 39.9 kg / m2 and a waist circumference greater than 80 cm in women and 90 cm for men Physical activity of moderate intensity for 3 days
11311834|NCT02620670|Active Comparator|Individuals with normal weight|Body mass index BMI is 18.5 to 24.9 kg / m2 with lower waist circumference of 80 cm for women and 90 cm for men Physical activity of moderate intensity for 3 days
11311835|NCT02620657||Non interventional study|The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
11311836|NCT02620644|Other|G1 Diabetics with no retinpathy|Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
11311837|NCT02620644|Other|G2 Non diabetics|Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
11311838|NCT02620631|Placebo Comparator|Placebo|Subjects receive intrathecal injection of saline at time of spinal anesthesia
11311839|NCT02620631|Experimental|Morphine|Subjects receive intrathecal injection of morphine sulfate 0.2mg at time of spinal anesthesia
11311840|NCT02620618|Experimental|Intravitreal Infliximab|Patients with refractory behcets uveitis.
11311841|NCT02620605|Active Comparator|Late administration of Cabirgoline 0.5 mg|Cabergoline 0.5mg (Dostinex®, Pfizer Australia Pty Ltd ) administrated once daily started on day of HCG triggering and continued for 8 days.
11311842|NCT02620605|Experimental|Early administration of Cabirgoline 0.5mg|Cabergoline 0.5mg(Dostinex®, Pfizer Australia Pty Ltd ) once daily stared once patients fulfilling the inclusion criteria at any day of cycle and continued for 8 days post HCG trigger.
11311843|NCT02620592|Active Comparator|ZYDPLA1 tablet|ZYDPLA1 tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
11311844|NCT02620592|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
11311847|NCT02620579|Active Comparator|Placebo Pharmaceutical, Personalized Education|This group will have the placebo pharmaceutical administered orally and receive the pain processing education modules as the combined intervention for this arm.
11311848|NCT02620579|Active Comparator|Personalized Pharmaceutical, General Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
11311849|NCT02620566|Active Comparator|Bupivacain -Caudal|Single shot Caudal Block will receive Group C with 1ml per kg Bupivacain 0,25%.
11311850|NCT02620566|Active Comparator|Bupivacain- Local|Single shot Local Infiltration will receive Group L with 0,2ml per kg Bupivacain 0,25%.
11311851|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
11311852|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
11311853|NCT02620514|No Intervention|Health-literacy Assessment|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with low adherence will continue to one or more intervention groups that address needs based on the results of the survey.
11311854|NCT02620514|Experimental|Health-literacy Assessment + Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
11311855|NCT02620514|Experimental|Health-literacy Assessment + Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education about IBD.
11311856|NCT02620514|Experimental|Health-literacy Assessment + Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education regarding their medications.
11311857|NCT02620514|Experimental|Health-literacy Assessment + Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive financial support for medications.
11311858|NCT02620501|Placebo Comparator|Placebo|Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
11311859|NCT02620501|Experimental|Experimental|Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
11311860|NCT02620488|Active Comparator|Healthy Control|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
11311861|NCT02620488|Experimental|Sickle Cell Disease|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
11311862|NCT02620475|Active Comparator|Gold standard of care|The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.
11311863|NCT02620475|Experimental|SutureSafe dressings|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
11311864|NCT02620462|Experimental|Wearable sensor-based exercise training|The intervention group in addition to standard of care, will receive 6 weeks of sensor-based balance training that provides real-time visual feedback of lower extremities during exercise. The visual feedback is provided on computer screen.
11311865|NCT02620462|No Intervention|Control Group|The control group only receives standard of care.
11311866|NCT02620449|Experimental|single arm study|
11311867|NCT02620436|Experimental|Core Mother Shelter Model|Existing mother shelters will be renovated, and mother shelters will be built at intervention sites, to meet the Core Mother Shelter Model. This model includes ensuring a safe infrastructure with four walls, a roof, doors and windows that lock, a toilet, running water, and beds.
11311868|NCT02620436|No Intervention|Standard of Care|Existing mother shelters with no changes made, except to ensure that they can provide standard of care.
11311869|NCT02620410|Other|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
11311870|NCT02620384|Placebo Comparator|Experimental: Placebo|This group will receive all standard heart failure therapy and placebo pill.
11311871|NCT02620384|Active Comparator|Experimental: Metolazone|This group will receive all standard heart failure therapy with addition of metolazone.
11311872|NCT02620371|Placebo Comparator|(bupivacaine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine)
11311873|NCT02620371|Active Comparator|(bupivacaine, ketamine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine plus ketamine 1 mg/kg) .
11311874|NCT02620358|Experimental|High Work of Breathing|"If patient has weaning criteria, a Spontaneous Breathing Trial (SBT) with T Tube for 2 hours will be done.
~The patient will be extubated after the SBT if he has no criteria of SBT failure."
11311875|NCT02620358|Experimental|Low Work of Breathing|"If patient has weaning criteria a Spontaneous Breathing Trial (SBT) with Pressure Support Ventilation of 8 cmH2O for 30 minutes will be done.
~The patient will be extubated after the SBT if he has no criteria of SBT failure."
11311876|NCT02620345|Experimental|Dydrogesterone M/ Women Pregnancy|"Reducing the size of fibroids with medication
~Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy
~Dosage:
~1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day
~The lost in size of fibroids throughout pregnancy after 48 weeks."
11311910|NCT02620098|No Intervention|Control|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The control group consisted of 12 kindergarteners comprising all students in a kindergarten support classroom at a third school. They received no additional interventions.
11311911|NCT02620085||Graves' disease|Patient had been diagnosed of Graves' disease and now under euthyroid status
11311877|NCT02620345|Experimental|Dydrogesterone M/ Reproductive Age|"Reducing the size of fibroids with medication
~Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age
~Dosage:
~1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day
~The lost in size of fibroids after 24 weeks."
11311878|NCT02620332|Placebo Comparator|Placebo injection|Water for injection
11311879|NCT02620332|Experimental|MultiPepT1De injection low dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
11311880|NCT02620332|Experimental|MultiPepT1De injection medium dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
11311881|NCT02620332|Experimental|MultiPepT1De injection high dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
11311882|NCT02620319|Experimental|biodegradable stent|endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
11311883|NCT02620306|Experimental|Fimasartan(A)|
11311884|NCT02620306|Experimental|Fimasartan(B)|
11311885|NCT02620306|Active Comparator|Losartan(A)|
11311886|NCT02620306|Active Comparator|Losartan(B)|
11311887|NCT02620293|Experimental|Eczema Emollient|Eczema Repair Emollient
11311888|NCT02620280|Active Comparator|Carbo-abrax, surgery, anthra|Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
11311889|NCT02620280|Experimental|Carbo-abrax-MPDL3280A, surgery, anthra|Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
11311890|NCT02620267|Experimental|tDCS Stimulation|Each subject will receive all three types of stimulation on separate days- anodal, cathodal, and sham stimulation
11311891|NCT02620241|Other|sitting position|infants are in a sitting position for 20 minutes
11311892|NCT02620228|Experimental|BIP Biopsy System|Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
11311893|NCT02620215|Experimental|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
11311894|NCT02620215|Active Comparator|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
11311895|NCT02620176|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
11311896|NCT02620176|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
11311897|NCT02620163|Experimental|YH22162|YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
11311898|NCT02620163|Active Comparator|telmisartan/amlodipine|Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
11311899|NCT02620150|Experimental|Experimental|CCBT plus Escitalopram, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
11311900|NCT02620150|Placebo Comparator|Placebo|CCBT plus Placebo, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
11311901|NCT02620137|Experimental|Multicentrum® 3 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 3 months
11311902|NCT02620137|Active Comparator|Multicentrum® 12 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 12 months
11311903|NCT02620124|No Intervention|Natural cycle, control|Treatment cycles with normal luteal support with progesteron
11311904|NCT02620124|Experimental|Natural cycle, intervention|Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
11311905|NCT02620124|No Intervention|Hormone replacement cycle, control|Standard hormone replacement cycle with estrogen and progesteron
11311906|NCT02620124|Experimental|Hormone replacement cycle, intervention|Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
11311907|NCT02620111|Experimental|Whey protein high leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
11311908|NCT02620111|Active Comparator|Whey protein normal leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein normal in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
11311909|NCT02620098|Experimental|Size Matters Handwriting Program|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The intervention group consisted of 23 kindergarten students comprising all students in two kindergarten support classrooms, one in each of two neighboring schools. All students in the group received the Size Matters Handwriting Program.
11311912|NCT02620072|Experimental|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
11311914|NCT02620059|Experimental|Lifestyle Intervention|"Behavioral: Lifestyle Intervention These women will receive the Healthy Lifestyle Intervention. This intervention will have been delivered during 12 weeks, which will be Distance learning program (multimedia or internet). During the intervention (12 weeks) and follow up period, women will receive not only motivational messages through the Short Message System (SMS) but also a pedometer to record their steps.The intervention will focus on women increasing physical activity (walking) to 10'000 steps per day and receiving healthy eating guidelines.
~This intervention curriculum will cover topics related to healthy eating, physical activity, and stress management during postpartum. General information about postpartum period will also be provided."
11311915|NCT02620059|No Intervention|Control|These women will receive general information via pamphlet about postpartum period and tips for stress management.
11311916|NCT02620046|Experimental|Group A: Vedolizumab SC 108 mg Q2W|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:
~Completed the Maintenance Period (Week 52), or
~Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6 ."
11311917|NCT02620046|Experimental|Group B: Vedolizumab SC 108 mg QW|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.
~Participants from current study who experience treatment failure while on study."
11311918|NCT02620033|No Intervention|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
11311919|NCT02620033|Active Comparator|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
11311920|NCT02620020|Experimental|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
11311921|NCT02620020|Experimental|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
11311922|NCT02620020|Experimental|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
11311923|NCT02620020|Experimental|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
11311924|NCT02620007|Experimental|Experimental arm|oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
11311925|NCT02620007|Placebo Comparator|Control arm|a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks
11311926|NCT02619994|Active Comparator|Control Arm|"Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.
~Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.
~Treatment duration: for at least 20 months"
11311927|NCT02619994|Experimental|Experimental Arm|"Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.
~Delamanid (100 mg bid for the entire treatment period)
~Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)
~Levofloxacin (750 ~1000 mg/day)
~Pyrazinamide (1000~ 2000 mg/day)"
11311928|NCT02619981|Active Comparator|Father present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Father present
11311929|NCT02619981|Active Comparator|Mother Present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Mother present
11311930|NCT02619981|Active Comparator|Both parents present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , both parents present
11311931|NCT02619968|Experimental|Experimental group|"Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application.
~Application of the tourniquet Will be held in conjunction with exercises for the experimental group.
~Tennis ball: will initially be 3 sets, where one series with 10 grips, increasing 5 grips every week, 60 seconds rest every series.
~Halter: are performed with load of 1 kg, 2 kg and 3 kg. Handgrip: they will be performed 3 sets of dynamic manual hold exercises in the intensity of 40% of MVC.
~Home program: at home will be performed isometric exercises with tennis ball on the same frequency as in performing ambulatory without applying the tensiometer."
11311932|NCT02619968|Sham Comparator|Group control|Will be held the same isometric and isotonic concentric ambulatory and home with the same duration, frequency and intensity, except is not to apply the tourniquet.
11311933|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
11311934|NCT02619942|Active Comparator|D2 radical operation group|In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.
11311935|NCT02619942|Experimental|CME group|In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.
11311936|NCT02619916|Experimental|MBCT|Mindfulness-Based Cognitive Therapy
11311939|NCT02619903|Placebo Comparator|COPD Placebo|Subjects with COPD get a dental cleaning comparable to tooth brushing. When exiting the trial after 12 months, they do however receive the intervention.
11311940|NCT02619903|Active Comparator|COPD Test|Subjects with COPD that do get the additional dental cleaning, as well as dental examination.
11311941|NCT02619890||Patients with glioma requiring treatment|Patients with glioma requiring treatment, who undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent
11311942|NCT02619877|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
11311943|NCT02619877|Active Comparator|Standard therapy|Standard therapy for patients with diabetic foot ulcer
11311944|NCT02619864|Experimental|AZD2014 plus temozolomide|Patients will receive single agent AZD2014 for 2 days immediately prior to surgery at a fixed dose of 125 mg bid po (i.e. on days -2, -1, and on morning of day 0 [day of surgery]). After recovery from surgery, patients will start the dose escalation (within 7-21 days after tumour resection).
11311945|NCT02619851|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
11311946|NCT02619851|Active Comparator|Conventional Therapy|Typical therapy conducted for burn injury patients
11311947|NCT02619838||Aptus CCS 5.0 or/and 7.0 screws|Procedure/Surgery: Subtalar, Double or Triple Arthrodesis of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint of the foot with the Aptus CCS 5.0 or/and 7.0 screws
11311948|NCT02619825|Other|"Group 1 healthy volunteers"|Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness [VD] and left ventricular [LV]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups [0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years]).
11311949|NCT02619825|Other|Group 2 Patients CMH primitive|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Hypertrophic Cardiomyopathy (HCM) non obstructive primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
11311950|NCT02619825|Other|Group 3 Patients primitive CMD:|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Dilated Cardiomyopathy primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
11311951|NCT02619812|Active Comparator|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
11311952|NCT02619812|Active Comparator|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
11311953|NCT02619812|Active Comparator|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
11311954|NCT02619812|Placebo Comparator|Group D: Double Placebo|Double placebo twice per day
11311955|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
11311956|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
11311957|NCT02619786|Experimental|inhaled colistin|Inhaled colistin 75 mg mixed with normal saline up to 4 ml every 12 hours at least 5 days
11311958|NCT02619773|Experimental|Mupirocin dressing|"Mupirocin + island dressing applied to surgical incision until postoperative day 5.
~Intervention: mupirocin ointment applied to extrication incision."
11311959|NCT02619773|No Intervention|Island dressing|Island dressing applied to surgical incision until postoperative day 2. This arm will not undergo any intervention.
11311960|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
11311961|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
11311962|NCT02619747|Active Comparator|Compound Sodium Alginate Oral Suspension sachet|Single dose of contents of two 10 ml sachets of Compound Sodium Alginate Oral Suspension
11311963|NCT02619747|Placebo Comparator|Matched placebo|Single dose of contents of two 10 ml sachets of matched placebo
11311964|NCT02619734|No Intervention|Control|Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers
11311965|NCT02619734|Experimental|Stem Cell Injection|Intramuscular implantation of Autologous bone marrow-derived mononuclear cells
11311966|NCT02619721|Experimental|Sacral Neuromodulation is on|Sacral Neuromodulation is on as soon as implantation
11311967|NCT02619721|Placebo Comparator|Sacral Neuromodulation is off|Sacral Neuromodulation is off after implantation
11311968|NCT02619708|No Intervention|Standard Preoperative Experience|The preoperative visit will be performed, as it would be normally. Patients will be given a description of the preoperative experience, they will be told what to expect, they will be given brochures detailing what will happen on the day of the surgery, and will be given the opportunity to ask questions. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
11311969|NCT02619708|Experimental|Immersive Preoperative Experience|The preoperative visit will be performed, as it would be normally, with the only addition of a 5-minute video for the patients randomized to the intervention group. Patients will be given a few minutes to watch the video, and will have the chance to ask questions. The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
11311970|NCT02619695|Experimental|Ketoprofen|Interventional arm: ketoprofen gel 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
11311971|NCT02619695|Placebo Comparator|Placebo|Placebo arm: placebo gel form of ketoprofen
11311972|NCT02619682|Experimental|Treatment (ixazomib citrate and lenalidomide)|Within 30-120 days after finishing autologous transplant, patients receive ixazomib citrate PO on days 1, 8 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-28. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients will continue to alternate between ixazomib citrate and lenalidomide every 2 courses for up to 24 months in the absence of disease progression or unacceptable toxicity.
11311973|NCT02619669|Experimental|TAK-228 followed by TAK-228 plus Letrozole|"Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.
~The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects."
11311974|NCT02619656|Experimental|Treatment|"Patients randomized to insufflation with CO2.
~Intervention: CO2 Insufflation with CO2Efficient Endoscopic Insufflator on managed flow setting at 3.4 L/min"
11311975|NCT02619656|Active Comparator|Control|"Patients randomized to insufflation with ambient air.
~Intervention: Ambient air insufflation with Evis Exera 111 CLV-190 on medium air flow setting 0.68 L/min"
11311976|NCT02619643|Experimental|Primed PAS 1A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
11311977|NCT02619643|Experimental|Unprimed PAS 1B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
11311978|NCT02619643|Sham Comparator|Sham PAS|A single session of sham paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied
11311979|NCT02619643|Experimental|Primed PAS 2A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
11311980|NCT02619643|Experimental|Unprimed PAS 2B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
11311981|NCT02619643|Experimental|Primed PAS 1C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
11311982|NCT02619643|Experimental|Primed PAS 2C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
11311983|NCT02619630|Experimental|High-Risk (HR) patients|Nelarabine during consolidation and maintenance
11311984|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
11311985|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
11311986|NCT02619604|Other|Clinician education|
11311987|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
11311988|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
11311989|NCT02619578|Other|TEAS Group|TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
11311990|NCT02619578|Other|Con Group|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
11311991|NCT02619565|Other|Blood samples if evolution of the disease|blood samples at Day 0 and also if there is an evolution of the disease
11311992|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
11311993|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
11311994|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
11311995|NCT02619539||Trauma patients|All patients having / suspected to have severe trauma injuries admitted to participating centers.
11311996|NCT02619526|Experimental|Nebivolol|Nebivolol 10mg, once a day
11311997|NCT02619526|Active Comparator|Carvedilol|Carvedilol 25mg, twice a day
11311998|NCT02619513|No Intervention|General anesthesia group(Group GA)|Group GA received general anesthesia only and intravenous analgesia pump.
11311999|NCT02619513|Experimental|TEB group(Group GE)|Group GE received continuous thoracic epidural block(TEB) combined with general anesthesia and postoperative continuous thoracic epidural analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
11312062|NCT02619110|Other|conventional physical therapy|The conventional physical therapy training focused on strengthening, postural control, functional mobility and forward gait training program but excluded backward walking training
11366159|NCT02260063|Experimental|Epinastine syrup|
11312000|NCT02619513|Experimental|PVB without DEX group (Group GT)|Group GT received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block(PVB) combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
11312001|NCT02619513|Experimental|PVB with DEX group(Group GTD)|Group GTD received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia,but with dexmedetomidine 0.5μg/kg added to ropivacaine in PVB as an adjuvant.
11312002|NCT02619500|Experimental|Thrust Manipulation|Subjects in this arm will receive spinal thrust manipulation to both the cervical and thoracic spines.
11312003|NCT02619500|Active Comparator|Non-thrust Mobilizations|Subjects in this arm will receive spinal non-thrust mobilizations to both the cervical and thoracic spines
11312004|NCT02619487|Experimental|8-12 years old, parent receiving text|text message to parent only
11312005|NCT02619487|Active Comparator|13-18 years old, parent receiving text|text message to parent only
11312006|NCT02619487|Active Comparator|13-18 years, both receiving text|Text message to parent and adolescent
11312007|NCT02619487|No Intervention|No text|No text will be sent
11312008|NCT02619474|Experimental|Experimental|Patients who have been admitted to the 3F or 3M wards under the care of the clinical teaching unit (CTU) after the introduction of the new, labelled whiteboard.
11312009|NCT02619474|No Intervention|Control|Patients who have been admitted to the 3R surgical ward under the care of any of the nursing groups without the introduction of the new labelled whiteboard.
11312010|NCT02619461|Experimental|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes.
11312011|NCT02619461|No Intervention|Control|Resting
11312012|NCT02619448|Experimental|Chemotherapy with hypofractionated RT|Carboplatin AUC 2 + Paclitaxel 50 mg/m2 given weekly x 4 concurrently with radiation therapy (70 Gy in 20 fractions) over 4 weeks
11312013|NCT02619435|Experimental|regorafenib|
11312014|NCT02619422|Other|Intensivo|intensive cardiac rehabilitation program in less time
11312015|NCT02619422|No Intervention|Convencional|standard cardiac rehabilitation program
11312016|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
11312017|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
11312018|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
11312019|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
11312020|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
11312021|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
11312022|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
11312023|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
11312024|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
11312025|NCT02619383|Experimental|HBOT|All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
11312026|NCT02619370|Experimental|Intervention|Play 'My Gift of Grace,' a conversation card game for 4-6 players (the game consists of 20 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues); all game sessions will be audio recorded and transcribed.
11312027|NCT02619370|Active Comparator|Control|"Review and discuss a brochure on ACP called Advance Care Planning: Tips from the National Institute of Aging. Discussion will be prompted by the researcher asking participants to discuss the information they've just read with the group. However, there will not be a formal structure to this discussion."
11312028|NCT02619357|Experimental|Cohort 1|10 subjects diagnosed with COPD (GOLD stages 2 and 3). Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
11312029|NCT02619357|Experimental|Cohort 2|10 subjects diagnosed with asthma. Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
11312030|NCT02619331|Experimental|Atopic volunteers|Allergy tests will be performed in allergic patients with rhinoconjunctivitis and allergy test reading measured following two different methodologies. 1) test reading based on conventional wheal and flare measurement (wheal diameter in mm, CWFM), 2) test reading based on high speed laser doppler imaging (HS-LDI). Both type of tests reading will be compared.
11312060|NCT02619123|Experimental|invitation to tailored screening|44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.
11312061|NCT02619110|Other|backward walking treadmill training|The intervention group not only received four weeks of conventional physical therapy but also accepted additional four weeks of backward walking treadmill training at the same time
11312063|NCT02619097|Experimental|0.08mg/kg|Pegol-sihematide injection, 0.08mg/kg, single-dose
11312031|NCT02619318|Experimental|The Balancing Everyday Life (BEL) intervention|The BEL was developed on the basis of previous research on lifestyle interventions made by our own group and other researchers [1, 2]. It is a group-based programme (5-8 participants) with 12 sessions, one session a week, and 2 booster sessions with two-week intervals. The themes for the group sessions are, e.g., activity balance, healthy living, work-related activities, and social activities. Each session contains a main group activity and a home assignment to be completed between sessions. The main group activity starts with analysing the present situation and proceeds with identifying desired goals and finding strategies for how to reach them. The home assignment is aimed at testing one of the proposed strategies. Self-analysis, setting goals, finding strategies and evaluating the outcome of tested strategies form a process for each session, but also for the BEL intervention as a whole.
11312032|NCT02619318|Active Comparator|Care as usual (standard occupational therapy)|Standard occupational therapy involves support to open-market employment and support in managing everyday life in general.
11312033|NCT02619305|Experimental|Immediate treatment|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
11312034|NCT02619305|No Intervention|Delayed treatment|Participants will be social network ties of women receiving no intervention but who will be placed on a waitlist to receive the intervention after a 12-month delay.
11312035|NCT02619292|Experimental|Mindful Movement Program|"Mindfulness is moment-to-moment, present-centered, purposive non-judgmental awareness; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals"
11312036|NCT02619279|Experimental|Immediate treatment|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
11312037|NCT02619279|No Intervention|Delayed treatment|Participants' mothers will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
11312038|NCT02619266|Experimental|Acupuncture+Placebo|Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
11312039|NCT02619266|Active Comparator|Megestrol Acetate+Sham acupuncture|Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
11312040|NCT02619266|Placebo Comparator|Placebo+Sham acupuncture|Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
11312041|NCT02619253|Experimental|Dose Finding Cohort|Estimate the Recommended Phase 2 Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2 patient cohorts according to the 3 + 3 standard design (100 and 200 mg).
11312042|NCT02619253|Experimental|Expansion Cohort|Once the Expansion Test Dose is identified, the Dose Expansion Phase will be opened and the combination will be tested in patients with advanced renal cell or urothelial cell carcinoma. Forty-five patients with prior treatments will be enrolled in three expansion cohorts: 15 anti-PD1 naive renal and urothelial patients, 15 anti-PD1 resistant renal and urothelial patients (defined as patients with transient clinical response or without clinical response to prior immune-checkpoint inhibition), and 15 patients with androgen-sensitive or castration-resistant prostate cancer.
11312043|NCT02619240||patients suspected of TB|patients suspected of TB requiring to undergo bronchoscopy as part of the investigation
11312044|NCT02619227|Experimental|Immediate treatment|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
11312045|NCT02619227|No Intervention|Delayed treatment|Participants will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
11312046|NCT02619214|Experimental|Oxygen 30%|Patient receives 1 hour of general anesthesia with a 30% oxygen concentration.
11312047|NCT02619214|Experimental|Oxygen 60%|Patient receives 1 hour of general anesthesia with a 60% oxygen concentration.
11312048|NCT02619201|Experimental|ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
11312049|NCT02619201|Active Comparator|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
11312050|NCT02619188||Hyperemesis gravidarum|Hyperemesis gravidarum patients admitted to hospital PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis), Intervention at discharge : PUQE-form, Nutritional form and Blood sampling
11312051|NCT02619188||Control: Healthy pregnant women|Outpatients NOT subjected to severe nausea and emesis (PUQE-score <13). PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis).
11312052|NCT02619175|Experimental|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).
~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
11312053|NCT02619175|Active Comparator|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.
~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
11312054|NCT02619162|Experimental|Letrozole+Nintedanib|Letrozole+Nintedanib
11312055|NCT02619149|Active Comparator|Intervention|Piperacillin-tazobactam combination product
11312056|NCT02619149|Placebo Comparator|Control|Saline solution
11312057|NCT02619136|Experimental|Restrictive Transfusion Strategy|We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
11312058|NCT02619136|Active Comparator|Liberal Transfusion Strategy|We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
11312059|NCT02619123|Active Comparator|invitation to mammography screening|44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.
11312067|NCT02619097|Experimental|0.7mg/kg|Pegol-sihematide injection, 0.7mg/kg, single-dose
11312068|NCT02619084|Experimental|STN DBS ON First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
11312069|NCT02619084|Experimental|STN DBS OFF First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
11312070|NCT02619071|Experimental|Refractory or relapsed acute myeloid leukemia|
11312071|NCT02619058|Experimental|Arm 1（NKT cells single low dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 1×10^9 on d1, 2×10^9 on d3, 4×10^9 on d29, 8×10^9 on d31.
11312072|NCT02619058|Experimental|Arm 2（NKT cells single high dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3, 5×10^9 on d29, 5×10^9 on d31.
11312073|NCT02619058|Experimental|Arm 3（NKT cells multiple dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3 of each 28 days-cycle, the dosing will be ended after 8 cycles.
11312074|NCT02619045|Other|Solid tumors|Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.
11312075|NCT02619032|Active Comparator|Remifentanil|Drug: Remifentanil (Ultiva). Intraoperative intravenous infusion of remifentanil 0.5-1 μg/kg/min for up to 1 h.
11312076|NCT02619032|Active Comparator|Fentanyl|Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.
11312077|NCT02619019|Active Comparator|Dexamethasone group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
11312078|NCT02619019|Active Comparator|Pethidine group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
11312079|NCT02619019|Placebo Comparator|Control group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
11312080|NCT02619006||Immediate Cord Clamping|Healthy term infants who were previously randomized or assigned at birth to the control group known as immediate cord clamping. The cord was clamped and cut within10 seconds after birth.
11312081|NCT02619006||Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
11312082|NCT02618993|Placebo Comparator|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
11312083|NCT02618993|Experimental|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
11312084|NCT02618980|Experimental|early endoscopy|endoscopic hemostasis
11312085|NCT02618980|No Intervention|without early endoscopy|Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.
11312086|NCT02618967|Placebo Comparator|Placebo Arm|7 dose levels of matching AMG 570 placebo administered as single dose subcutaneous in healthy volunteers.
11312087|NCT02618967|Active Comparator|AMG 570 Arm|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
11312088|NCT02618954|Other|Study patient|Articular ultrasound at each study follow-up
11312089|NCT02618941|Experimental|AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/adjuvanted
11312090|NCT02618941|No Intervention|Control|Untreated control group
11312091|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.
~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
11312092|NCT02618915|Experimental|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10^12 genome copies (GC)/kg DTX101
11312093|NCT02618915|Experimental|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10^12 GC/kg DTX101
11312094|NCT02618902|Experimental|tolerogenic dendritic cells (tolDC)|Each vaccine (5x106, 10x106 , or 15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the subclavicular region (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides.
11312095|NCT02618889|Active Comparator|CBT plus botox|Participants will be randomized to receive BoNT (onabotulinumtoxinA). Patients will undergo study assessments four weeks later. We will inject a total of 250 units of onabotulinumtoxinA, as the average optimal dose in cervical dystonia,11 using a 100:1 dilution with normal saline. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
11312134|NCT02618642|Placebo Comparator|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
11312135|NCT02618629|Experimental|14C-Z-215|
11312136|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally OD for 12 weeks.
11366160|NCT02260063|Active Comparator|Epinastine tablets|
11312096|NCT02618889|Placebo Comparator|CBT plus placebo|Participants will be randomized to receive normal saline (placebo). We will inject a total of 250 units of normal saline, as this is the average optimal dose of onabotulinumtoxinA in cervical dystonia. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
11312097|NCT02618876|Active Comparator|Nalbuphine group|30 children will be given Caudal Bupivacaine plus Nalbuphine.
11312098|NCT02618876|Other|Control group|30 children will be given Caudal Bupivacaine.
11312099|NCT02618863|Active Comparator|1 , cricoid pressure|30 male
11312100|NCT02618863|Active Comparator|2,cricoid pressure|30 female
11312101|NCT02618850|Other|Advanced CRC patients undergoing first-line chemotherapy|single cohort
11312102|NCT02618837|Active Comparator|Downstream strategy arm|downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
11312103|NCT02618837|Active Comparator|Upstream strategy arm|upstream administration strategy (ticagrelor only)
11312104|NCT02618824|Active Comparator|HTK Solution|Hearts will be arrested with HTK solution during cardiac operation
11312105|NCT02618824|Active Comparator|HTK Solution + TWBC|Hearts will be arrested with HTK solution during cardiac operation and received terminal warm blood cardioplegia before aortic cross clamp removal.
11312106|NCT02618811||Group 1|not sarcopenic
11312107|NCT02618811||Group 2|sarcopenic
11312108|NCT02618811||Group 3|not myosteatotic
11312109|NCT02618811||Group 4|myosteatotic
11312110|NCT02618785|Experimental|Hyoscine|The experiment group receive Hyoscine 10 mg 2 tablets by mouth before hysterosalpingography procedure
11312111|NCT02618785|Placebo Comparator|Placebo|The control group receive placebo by mouth before hysterosalpingography procedure
11312112|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
11312113|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
11312114|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
11312115|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
11312116|NCT02618746|Experimental|Group A, Telerehabilitation|The 12-month home care/rehabilitative program will include the following components: a) individualized action plan; b) educational session on self management; c) physical exercise sessions to remote monitoring; d) access to the call centre; e) professional weekly calls by physiotherapists, dietician and physician with remote connection as a response to possible incidents; f) remote monitoring selectively and temporarily.
11312117|NCT02618746|Active Comparator|Group B, Hospital based Rehabilitation|Patients assigned to the hospital based program will visit the hospital twice weekly for 12 months in order to participate in a multidisciplinary rehabilitation program including exercise, physiotherapy dietary and psychological advice by the staff of the rehabilitation centre based at the University clinic.
11312118|NCT02618746|No Intervention|Group C, Usual care Group|The control group will follow the usual care not involving the initial 8-week rehabilitation program neither maintenance hospital rehabilitation sessions or home telemonitoring of vital signs.
11312119|NCT02618733|Experimental|Ticagrelor|Ticagrelor 90mg, twice a day
11312120|NCT02618733|Active Comparator|Clopidogrel|Clopidogrel 75mg, once a day
11312121|NCT02618720|Experimental|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
11312122|NCT02618720|Placebo Comparator|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
11312123|NCT02618707||Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
11312124|NCT02618694|Experimental|Group 1|patient had posterior retroperitoneoscopic adrenalectomy
11312125|NCT02618694|Active Comparator|Group 2|patient had Transperitoneal laparoscopic adrenalectomy
11312126|NCT02618681||AMI with earlobe crease|To observe the prognosis for AMI with earlobe crease
11312127|NCT02618681||AMI without earlobe crease|To observe the prognosis for AMI without earlobe crease
11312128|NCT02618668|Experimental|Ketamine / Propofol Admixture|Ketamine / Propofol Admixture: I.V propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+ 4 ml saline in a 20-ml syringe which resulted in 0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol.
11312129|NCT02618668|Active Comparator|Propofol|I.V propofol 2 mg/kg
11312130|NCT02618655||Fever，none definite diagnosis|Those who have fever，but the doctor can not make definite diagnoses with the diagnostic methods available.
11312131|NCT02618642|Active Comparator|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
11312132|NCT02618642|Active Comparator|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
11312133|NCT02618642|Active Comparator|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
11312137|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
11312138|NCT02618603|Experimental|BoNT-A treatment group|Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);
11312139|NCT02618603|Active Comparator|Triamcinolone acetonide treatment group|Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;
11312140|NCT02618577|Experimental|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:
~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
11312141|NCT02618577|Active Comparator|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
11312142|NCT02618564|Active Comparator|2 TABS QHS|Sennosides 2 tabs, taken two nights before the colonoscopy
11312143|NCT02618564|Active Comparator|3 TABS QHS|Sennosides 3 tabs, taken two nights before the colonoscopy
11312144|NCT02618564|Active Comparator|2 TABS AM|Sennosides 2 tabs, taken the morning before the colonoscopy
11312145|NCT02618564|Active Comparator|3 TABS AM|Sennosides 3 tabs, taken the morning before the colonoscopy
11312146|NCT02618564|Active Comparator|2 TABS AM & QHS|Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.
11312147|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
11312148|NCT02618525|Active Comparator|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
11312149|NCT02618525|Active Comparator|Jaw thrust maneuver|Jaw thrust maneuver is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
11312150|NCT02618512|Experimental|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
11312151|NCT02618499|Active Comparator|oxytocin inmediately at birth|Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
11312152|NCT02618499|Experimental|oxytocin at 3 minutes|Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped
11312153|NCT02618486|Experimental|Obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
11312154|NCT02618486|Active Comparator|Non obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
11312155|NCT02618473|No Intervention|seloken|"In seloken arm, patients performs the cardiac CT procedure regarding the national scan guidelines, ande receive 5-10 intravenous seloken, until heart rate below 60 beats pr minit is achieved."
11312156|NCT02618473|Experimental|non-seloken|"Patients randomized to non-seloken, do not receive any medication."
11312157|NCT02618460|Experimental|Whole Group|
11312158|NCT02618447|Experimental|Arm 1: 4D phase contrast MR scan|"Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes):
~Scan 1: Baseline (pre-portal vein embolization (PRE))
~Scan 2: Early after PVE (within 48 hours)
~Scan 3: Late after PVE (at 3-8 weeks).
~Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan.
~Scan 2: 4D phase contrast sequences and imaging for localization."
11312159|NCT02618434|Experimental|Low dose SPN-810|Subjects will be treated with low dose of SPN-810
11312160|NCT02618434|Experimental|High dose SPN-810|Subjects will be treated with high dose of SPN-810
11312161|NCT02618434|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
11312162|NCT02618421||Participants Aged 40 Years or Over|Cross-section of general population of males and females in China, Taiwan, and South Korea
11312163|NCT02618408|Experimental|Low dose SPN-810|Subjects will be treated with low dose SPN-810
11312164|NCT02618408|Experimental|High dose SPN-810|Subjects will be treated with high dose SPN-810
11312165|NCT02618408|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
11312166|NCT02618395|Experimental|Treatment A|
11312167|NCT02618395|Experimental|Treatment B|
11312168|NCT02618395|Experimental|Treatment C|
11312169|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
11312170|NCT02618369|Other|MR-HIFU treatment|"The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.
~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan."
11312171|NCT02618356|Experimental|combined use Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.
~BSA(body surface area) S-1 dosage <1.25 m2 80 mg/d
~1.25m2 - <1.5 m2 100 mg/d
~1.5 m2 120 mg/d"
11312172|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
11312173|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
11312174|NCT02618330|Experimental|retainer: 0.75-mm-thick film|
11312175|NCT02618330|Experimental|retainer: 1.00-mm-thick film|
11312269|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
11312176|NCT02618317|Active Comparator|Heparin Lock Solution|Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .
11312177|NCT02618317|Experimental|Trissodium Citrate 30%|Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .
11312178|NCT02618317|Experimental|Minocycline-EDTA 30 mg/ml - 3 mg/ml|Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.
11312179|NCT02618304|Experimental|moderate to severe meibomian gland dysfunction|
11312180|NCT02618291|Experimental|Active Geriatric Evaluation (AGE tool)|The Active Geriatric Evaluation is a comprehensive assessment and management tool consisting of a 20-minute clinical screening instrument (Brief Assessment Tool, BAT) to identify 8 geriatric syndromes, and complementary diagnostic evaluations and propositions of management & treatment for each syndrome.
11312181|NCT02618291|Active Comparator|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
11312182|NCT02618278|Experimental|Intervention|Patients randomised to the intervention arm will receive a individual, goal -orientated physiotherapy management package within 2 weeks G.P referral for physiotherapy.
11312183|NCT02618278|Active Comparator|Usual care|Patients randomised to usual care will receive the same individual, goal-orientated physiotherapy management as the intervention arm but at 6 weeks post G.P referral, as is usual care.
11312184|NCT02618265|Experimental|Mobile terminal|Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
11312185|NCT02618265|Active Comparator|traditional management|Stroke received traditional management for secondary prevention administration
11312186|NCT02618265|Active Comparator|website platform management|Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
11312187|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
11312188|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
11312189|NCT02618239|Experimental|Healthy subjects|Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
11312190|NCT02618226|Other|Optic nerve ultrasound|Optic nerve sheath diameter (ONSD) measurement will be performed in subjects with concomitant measurement of Intracranial Pressure (ICP) from an invasive ICP monitor. The operator measuring ONSD will be blinded to concomitant ICP.
11312191|NCT02618213|Active Comparator|Continous Positive Airway Pressure|CPAP is administered through a binasal tube fitted with a Benveniste gas jet administered with humified airflow. Start flow is 12-14 l/min and can be changed to maximum 15 or minimum 12 l/min. Oxygen can be supplied as needed to keep SpO2 (peripheral capillary Oxygen saturation) within acceptable limits.
11312192|NCT02618213|Active Comparator|High Flow Oxygenation Therapy|HFOT is administered by optiflow Junior ( Fisher&Paykal Healthcare® Auckland, New Zealand) Start flow 12-14 l/min. Oxygen can be supplied as needed to keep Sp02 within acceptable limits
11312193|NCT02618200|Experimental|3D prostate ultrasound|3D prostate ultrasound will be performed in patients the day before radical prostatectomy
11312194|NCT02618187|Experimental|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
11312195|NCT02618187|Placebo Comparator|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
11312196|NCT02618187|Experimental|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
11312197|NCT02618187|Experimental|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
11312198|NCT02618174|Placebo Comparator|Neutral Control Condition|Message about age of University of Birmingham
11312199|NCT02618174|Placebo Comparator|Food-based Control Condition|Message about variety of vegetables in the world
11312200|NCT02618174|Active Comparator|Health Condition|Message about the health benefits of eating vegetables
11312201|NCT02618174|Active Comparator|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
11312202|NCT02618174|Experimental|Liking Social Norm|Message suggesting most people like eating vegetables
11312203|NCT02618161|Experimental|Arm A|HDR Brachytherapy single dose of 15 Gy followed by EBRT of 46 Gy in 23 fractions and Androgen deprivation therapy 6 months to 3 years, (sequencing of HDR followed by EBRT)
11312204|NCT02618161|Active Comparator|ARM B|External Beam Radiotherapy (EBRT) of 46 Gy in 23 fractions, followed by single dose of HDR brachytherapy of 15 Gy boost and Androgen deprivation therapy 6 months to 3 years (timing of HDR Brachytherapy Treatment is changed compared to ARM A)
11312205|NCT02618148|Experimental|ESTROGEN HERBALS 21|"Used for women who wish to monthly menstruation
~Applies to the following strengths:
~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
11312206|NCT02618148|Experimental|ESTROGEN HERBALS 28|"Used for women who do not wish to monthly menstruation
~Applies to the following strengths:
~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
11312270|NCT02617654|Active Comparator|Liraglutide treatment|Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
11312271|NCT02617654|Placebo Comparator|Placebo treatment|Treatment with placebo once daily for 52 weeks
11312338|NCT02617199|Active Comparator|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
11312207|NCT02618135|Experimental|Intervention Group|10 child participants in the intervention group will take part in a total of 24 sessions spread over an 8-week period, and a final follow-up review 1 month after the completion of the training session. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy.
11312208|NCT02618135|Other|Control Group|10 child participants in the control group will not receive BCI training during the first 8 weeks of their study participation; they will act as controls. At week 9, subjects in this group will go through the BCI training similar to the intervention group. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy. They will take part in a total of 24 sessions spread over an 8-week period, followed by a final follow-up review 1 month after the completion of the training sessions.
11312209|NCT02618109|Other|Relapse Group|"Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.
~Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis."
11312210|NCT02618109|Other|Control Group|"Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.
~Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.
~These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients."
11312211|NCT02618096|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
11312212|NCT02618096|Active Comparator|Oxytocin & Dinoprostone|"Women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
11312213|NCT02618083|Experimental|retinal detachment|color Doppler ultrasound of the eye
11312214|NCT02618070|Experimental|Functional dyspepsia patient|Yogurt ingestion
11312215|NCT02618070|Experimental|Healthy|Yogurt ingestion
11312216|NCT02618057|Experimental|Steroid|Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days
11312217|NCT02618057|Active Comparator|Control|Levofloxacin, 10mg/kg/day, IV, for 5days
11312218|NCT02618044||Obese patients without preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass without preoperative GER at 24h-impedance pH monitoring (Group G-)
11312219|NCT02618044||Obese patients with preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass with preoperative GER at 24h-impedance pH monitoring (Group G+)
11312220|NCT02618031|Other|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
11312221|NCT02618031|Experimental|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
11312222|NCT02618018|Experimental|intraocular lens|AT TORBI 709M toric intraocular lens
11312223|NCT02618005|Experimental|LcS group|Consuming probiotic capsule
11312224|NCT02618005|No Intervention|Control group|
11312225|NCT02617992||EMR Surveillance|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions undertaking a surveillance visit will be included in this cohort.
11312226|NCT02617979|Experimental|Arm 1: SAFECARE at Home|"Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.
~The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.
~All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients."
11312227|NCT02617979|No Intervention|Arm 2: Standard of Care|-All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
11312228|NCT02617966|Other|single study arm|all participants
11312229|NCT02617953|Experimental|Active rTMS(A)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
11312230|NCT02617953|Experimental|Active rTMS(B)|Temporal low frequency repetitive transcranial magnetic stimulation
11312231|NCT02617953|Sham Comparator|Sham condition(C)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
11312232|NCT02617940|Experimental|fissure sealant|single placement of resin-based sealant on occlusal surface and oral hygiene orientation
11312233|NCT02617940|Placebo Comparator|oral hygiene orientation|single application of water on occlusal surface and oral hygiene orientation
11312234|NCT02617927||Vedolizumab Cohort|"Group 1a Mothers exposed to Vedolizumab at any time during pregnancy (and up to 3 months prior to last menstrual period [LMP], if this information is available).
~Group 1b Infants born to Group 1a patients."
11312235|NCT02617927||Anti-TNF Agents Cohort|"Group 2a Patients with IBD who were exposed to anti-TNFs at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
~Group 2b Infants born to Group 2a patients."
11312236|NCT02617927||Conventional therapy only Cohort|"Patients with IBD who were exposed to conventional therapy only any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
~• Group 3b Infants born to Group 3a patients."
11312336|NCT02617212|Active Comparator|Conventional treatment|Implant surgery. Three abutment dis-/reconnections.
11312237|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).
~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.
~Radiographs and DXA will be read in random and varied order."
11312238|NCT02617888|Active Comparator|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
11312239|NCT02617888|No Intervention|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
11312240|NCT02617888|No Intervention|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
11312241|NCT02617875|Active Comparator|Conventional EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a conventional EMS physician, if this is the result of the randomization software.
11312242|NCT02617875|Other|Tele-EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a tele-EMS physician, if this is the result of the randomization software.
11312243|NCT02617862|Experimental|PCI imaging system|
11312244|NCT02617849|Experimental|Pembrolizumab, Carboplatin, Paclitaxel|Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
11312245|NCT02617823|No Intervention|semi-recumbent|rutine positioning at the hospital today
11312246|NCT02617823|Experimental|lateral position|experimental position to be evaluated against rutine
11312247|NCT02617810|Experimental|JNJ-42847922 Plus Midazolam Plus Warfarin|Participants will receive Treatment A (midazolam 4 milligram [mg] syrup once on Day 1 and warfarin 25 mg tablet once on Day 3) followed by Treatment B (JNJ-42847922 20 mg once daily from Day 1 to Day 9, midazolam 4 mg syrup once on Day 7 and warfarin 25 mg tablet once on Day 9). A washout period of 14 to 21 days will be maintained between each treatment period.
11312248|NCT02617797|Experimental|Radiofrequency|Experimental group: women with urinary incontinence are subjected to standard treatment cinesiotherapy perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic in beyond the RF application in the genital area once a week to total 5 sessions.
11312249|NCT02617797|Sham Comparator|Radiofrenquency Off|Control group: women with stress urinary incontinence will be submitted to the treatment of cinesioterapia standard perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic beyond the application of radiofrequency off in genital area once a week with the total of 5 sessions.
11312250|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
11312251|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
11312252|NCT02617771|Active Comparator|Vit D|Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
11312253|NCT02617771|No Intervention|Control|
11312254|NCT02617758|Experimental|Treatment AB|Participants will receive Treatment A (single application of DURAGESIC fentanyl transdermal system 100 microgram per hour (µg/h) dose) as Reference in Period 1; followed by Treatment B (single application of Fentanyl transdermal system [JNJ-35685-AAA-G021] 100 µg/h dose) as test in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
11312255|NCT02617758|Experimental|Treatment BA|Participants will receive Treatment B [single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose] as test in Period 1; followed by Treatment A (single application of DURAGESIC fentanyl transdermal system 100 µg/h dose) as Reference in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
11312256|NCT02617745|Experimental|Stupp protocol|Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
11312257|NCT02617732|Experimental|Tianqi capsule|a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
11312258|NCT02617732|Placebo Comparator|placebo|a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
11312259|NCT02617719||Primary care|Staff, patients aged 75 years and older and their carers associated with a single, participating United Kingdom primary care practice.
11312260|NCT02617706|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 - 4 weeks + standard wound care
11312261|NCT02617706|No Intervention|Standard of care|standard wound care for 4 weeks
11312262|NCT02617693|Other|Standard of care|
11312263|NCT02617693|Experimental|Life style intervention|
11312264|NCT02617680|Experimental|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Concentration of oxygen should be 50%.
11312265|NCT02617680|Experimental|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially.Concentration of oxygen should be 50%.
11312266|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
11312267|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
11312268|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
11312339|NCT02617186|Active Comparator|Thoracoscopic Lobectomy|
11312272|NCT02617641|Experimental|TAVIEenM@RCHE intervention|The experimental group will receive a web-based tailored nursing intervention. Between 3 and 4 sessions of 15 to 25 minutes each are completed within 4 weeks. A booster session is delivered at 8 weeks post randomization.
11312273|NCT02617641|Active Comparator|Publicly available websites|The control group will receive hyperlinks to four publicly available websites and one online booklet on the topic of walking.
11312274|NCT02617628|Active Comparator|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
11312275|NCT02617628|Active Comparator|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
11312276|NCT02617615|Experimental|MB-110|oral hard-gel capsule formulation. One dose strength, 25 mg of MB-110, will be filled into the #00 hard-gel capsule.
11312277|NCT02617615|Placebo Comparator|Placebo|in the same #00 hard-gel capsules.
11312278|NCT02617602|Experimental|Goal directed therapy|Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals
11312279|NCT02617602|Active Comparator|Control|Conventional therapy
11312280|NCT02617589|Experimental|Nivolumab + Radiotherapy Arm|Nivolumab IV infusion + Radiotherapy dose as specified
11312281|NCT02617589|Active Comparator|Temozolomide + Radiotherapy Arm|Temozolomide + Radiotherapy dose as specified
11312282|NCT02617576||Flavored contrast|This group of patients will have the choice to flavor their contrast.
11312283|NCT02617576||Unflavored contrast|This group of patients will drink the contrast without flavoring.
11312284|NCT02617563||Minimally invasive lumbar fusion|A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.
11312285|NCT02617550|Experimental|Vericiguat + Nitroglycerin|Co-administration of vericiguat and nitroglycerin
11312286|NCT02617550|Placebo Comparator|Placebo + Nitroglycerin|Aministration of matching placebo and nitroglycerin.
11312287|NCT02617537|Experimental|BAY86-5300|Patients suffering from dysmenorrhea, treated with Yaz
11312288|NCT02617537|Placebo Comparator|Placebo|Patients suffering from dysmenorrhea,treated with placebo
11312289|NCT02617524|Experimental|Valve Medical Dedicated Sheath|Valve Medical Dedicated Sheath version 00
11312290|NCT02617511|Experimental|Omega-3 Supplementation|This groups will supplement their regular diet with 2.97 grams of combined omega-3 fatty acid (EPA/DHA) supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
11312291|NCT02617511|Placebo Comparator|Placebo|This group will supplement their regular diet with 3.0 grams of a combined omega-3-6-9 supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
11312292|NCT02617498|Active Comparator|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
11312293|NCT02617498|Active Comparator|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
11312294|NCT02617485|Experimental|MabionCD20®|"A course of MabionCD20® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.
~Intervention: Drug: Rituximab"
11312295|NCT02617485|Active Comparator|MabThera®|"A course of MabThera® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.
~Intervention: Drug: Rituximab"
11312296|NCT02617472|Experimental|Pelvic floor exercise|Pelvic floor exerciser, daily use
11312297|NCT02617459|Experimental|Levobetaxolol eye drops|Levobetaxolol eye drops 5ml/25mg per bottle
11312298|NCT02617459|Active Comparator|Betaxolol eye drops|Betaxolol eye drops 5ml/12.5mg per bottle
11312299|NCT02617446|Placebo Comparator|Placebo|i.v. infusion for 24 hours
11312300|NCT02617446|Active Comparator|treatment|The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.
11312301|NCT02617433|Experimental|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.
11312302|NCT02617420||Intervention|All patients will be enrolled in one arm. These patients will have monitoring devices placed on their asthma controller and rescue medication, with data transmitted both to their smartphones and a dashboard accessed by their primary pediatric pulmonary provider.
11312303|NCT02617407|Experimental|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
11312304|NCT02617407|Active Comparator|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
11312305|NCT02617394|Active Comparator|Control group|
11312306|NCT02617394|Experimental|Study group|
11312307|NCT02617381|Experimental|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
11312308|NCT02617368||KC group|KC group included patients those were diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system
11312309|NCT02617368||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
11312310|NCT02617368||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
11312311|NCT02617355|Other|Prototype vs Covidien magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs Covidien magnetic drape
11312337|NCT02617199|Experimental|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
11312312|NCT02617355|Other|Prototype vs 4 commercial drapes|"New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs 4 commercially available magnetic drapes:
~Green Covidien Magnetic Drape Jac-Cell Medic Reusable Magnetic Pad DeRoyal Magnetic Pad size 10 x 16 DeRoyal Magnetic Pad size 20 x 16"
11312313|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
11312314|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
11312315|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
11312316|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group.
11312317|NCT02617316|Other|barefoot first|Ten runners carried on barefoot test first and then in-shoes.
11312318|NCT02617316|Other|in shoes first|Ten runners carried on in-shoes test first and then barefoot.
11312319|NCT02617303|Experimental|OTAGO'S program arm|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive OTAGO'S exercise program during three months, followed by adherence phase. Falls and fractures will be quarterly followed during 15 months.
11312320|NCT02617303|Active Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. Normal medical treatment will be provided by family physicians and nurses. Falls and fractures will be quarterly followed during 15 months.
11312321|NCT02617290|Experimental|Ticagrelor Arm|Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
11312322|NCT02617290|Active Comparator|Clopidogrel Arm|Clopidoprel is an oral antiplatelet agent which was approved for use in the European Union by the European Commission in 1997 and available as generic since 2007. The standard dose of clopidogrel is one 75 mg tablet once a day. The dosage for the loading dose is normally 300 mg but 600 mg is also used. Clopidogrel is the standard of care for PCI at the moment.
11312323|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
11312324|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
11312325|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
11312326|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
11312327|NCT02617264|Experimental|Axillary lymph node FNA Biopsy|A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
11312328|NCT02617251||neonatology patients|neonatology patients
11312329|NCT02617251||paediatric patients|paediatric patients
11312330|NCT02617238|Active Comparator|PWV group|"Cardiovascular risk management based on PWV will include altogether
~the implementation of international guidelines,
~the normalisation of blood pressure, and
~the normalisation of arterial stiffness"
11312331|NCT02617238|No Intervention|Conventional group|These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension
11312332|NCT02617225||DHaAL Intervention|The group receives standard Ailment-free Life (DHaAL) DHaAL intervention
11312333|NCT02617225||DHaAL +CFSS Intervention|This group received the standard DHaAL intervention and additional support under another UNICEF program named Child Friendly School System (CFSS).
11312334|NCT02617225||Control|This group receive the standard / business-as-usual support from the Education Department, but does not receive DHaAL or CFSS Interventions.
11312335|NCT02617212|Experimental|Definitive abutment|Implant surgery. No abutment dis-/reconnections.
11312341|NCT02617173|Experimental|Transcutaneous electrical nerve stimulation|Low current electrical stimulator
11312342|NCT02617160|Experimental|MD Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
11312343|NCT02617160|Active Comparator|Control Group-Medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
11312344|NCT02617134|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
11312345|NCT02617121|Active Comparator|Gabapentin|oral gabapentin 300 mg 1 hours before induction of anesthesia
11312346|NCT02617121|Active Comparator|ramosetron|ramosetron 0.3 mg iv at end of surgery
11312347|NCT02617121|Active Comparator|Gabapentin and ramosetron|oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery
11312348|NCT02617108|Experimental|Foley balloon|Foley balloon following TCRS: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
11312349|NCT02617108|No Intervention|control groups|control groups: women will not receive any therapy of the treatment (comparison group).
11312350|NCT02617108|Experimental|postoperative estrogen therapy groups|Subjects received postoperative hormone therapy as per the protocol in use in our center for Asherman Syndrome. Immediately after the operation, the subjects were started on a 3- month course of cyclical hormonal therapy, consisting of orally administrated oestradiol valerate 2-4mg/day for 21 days, orally administrated medroxyprogesterone acetate 8mg /day from day 12 to 21 of the oestradiol valerate therapy. The second treatment cycle started one week after the completion of the first cycle, and the third treatment cycle started one week after the second cycle.
11312351|NCT02617095|Experimental|T2762|One drop of T2762 in each eye 3 to 6 times daily
11312352|NCT02617095|Active Comparator|Optive|One drop of Optive in each eye 3 to 6 times daily
11312353|NCT02617082||partial breast irradiation|
11312354|NCT02617069|Experimental|Group 1 (Cardiac surgery+botulinum toxin)|All patients underwent conventional cardiac surgery. After the main stage of the surgery botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
11312355|NCT02617069|Active Comparator|Group 2 (Cardiac surgery+placebo)|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
11312356|NCT02617056||Observational group|Subjects with dementia
11312357|NCT02617043|Experimental|HF-WBI|Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.
11312358|NCT02617017|Experimental|Buspirone|
11312359|NCT02617017|Placebo Comparator|Placebo|
11312360|NCT02616991|Experimental|Cohort|computed tomography venography
11312361|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
11312362|NCT02616952|Experimental|Chinese herbal therapy group|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks.
11312363|NCT02616952|Other|Pelvic floor muscle training group|Pelvic floor muscle training includes intensive exercises and home exercises. Intensive exercises are conducted in hospital once a week while home exercises are performed three times daily for 12 weeks.
11312364|NCT02616939||Patients with suspected cardiac disease|"Patients eligible for cardiac CT will be included with a focus on symptomatic patients with low-intermediate risk for obstructive coronary artery disease.
~Patients will undergo Cardiac CT scanning (with the SpotLight CT)."
11312365|NCT02616926|Experimental|Hepatic resection|"Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
~Intervention: Hepatic resection"
11312366|NCT02616926|Active Comparator|TACE + RFA|"TACE is performed as a primary treatment for hepatocellular carcinoma. RFA will be performed two weeks later if necessary.
~Intervention: TACE; RFA"
11312367|NCT02616913|Experimental|R,R-monatin|150 mg single dose
11312368|NCT02616913|Active Comparator|Moxifloxacin|400 mg tablet single dose
11312369|NCT02616913|Placebo Comparator|Placebo|placebo single dose
11312370|NCT02616900|Experimental|eSight Eyewear|Main arm
11312371|NCT02616887||Vertebral metastases|Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .
11312372|NCT02616874|Experimental|MVA.HIVconsv plus romidepsin|MVA.HIVconsv plus romidepsin
11312373|NCT02616861|Experimental|IW-1973|1973 Escalating Doses
11312374|NCT02616861|Placebo Comparator|Placebo|Matching Placebo
11312375|NCT02616848|Experimental|Everolimus, Eribulin|
11312376|NCT02616835|Experimental|theta-burst TMS|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
11312467|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
11366161|NCT02260050|Experimental|WAL 801 CL new formulation|
11312377|NCT02616835|Sham Comparator|sham theta-burst TMS|Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
11312378|NCT02616822|Experimental|trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
11312379|NCT02616822|Placebo Comparator|Placebo|Used for placebo substance single dose
11312380|NCT02616809|Experimental|Sitting|Participants will sit continuously for 8 hours in a simulated office environment
11312381|NCT02616809|Experimental|slow cycling|Participants will cycle at regular hourly intervals during an 8-hr simulated office environment
11312382|NCT02616809|Experimental|standing|Participants will change posture (from sitting to standing) during hourly intervals for an 8-hr period in a simulated office environment
11312383|NCT02616809|Experimental|slow walking|Participants will transition from sitting to slow walking on a treadmill desk at regular hourly intervals during an 8-hr period in a simulated office environment
11312384|NCT02616796|Experimental|Social gaze training|Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
11312385|NCT02616796|No Intervention|No Training|Appropriate social gaze behavior will not be reinforced.
11312386|NCT02616783|Experimental|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
11312387|NCT02616783|Active Comparator|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
11312388|NCT02616770|Experimental|S1226 (4%)|S1226 (4%) dosed as single dose for 2 minutes
11312389|NCT02616770|Placebo Comparator|Saline (for 4%)|3 mL saline and medical air as single dose for 2 minutes
11312390|NCT02616770|Experimental|S1226 (8%)|S1226 (8%) dosed as single dose for 2 minutes
11312391|NCT02616770|Placebo Comparator|Saline (for 8 %)|3 mL saline and medical air as single dose for 2 minutes
11312392|NCT02616770|Experimental|S1226 (12%)|S1226 (12%) dosed as single dose for 2 minutes
11312393|NCT02616770|Placebo Comparator|Saline (for 12%)|3 mL saline and medical air as single dose
11312394|NCT02616757|Active Comparator|Simple Bone Cyst Patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.
~There will also be optional blood samples taken o measure bone alkaline phosphatase."
11312395|NCT02616757|Active Comparator|Fracture patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.
~There will also be optional blood samples taken to measure bone alkaline phosphatase."
11312396|NCT02616757|Placebo Comparator|Health volunteers|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.
~There will also be optional blood samples taken to measure bone alkaline phosphatase."
11312397|NCT02616744|Experimental|Arm A: Ibandronic acid|Ibandronic acid 150 mg per os per month for two years
11312398|NCT02616744|Placebo Comparator|Arm B: Placebo|Placebo per os per month for two years
11312399|NCT02616731|Active Comparator|Tranexamic acid|
11312400|NCT02616731|Active Comparator|Diosmin|
11312401|NCT02616718|Experimental|Ventral incisional hernia|Repeated computed tomography scan of abdomen
11312402|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
11312403|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
11312404|NCT02616692||HCC patients / Cohort 1|Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics
11312405|NCT02616679||Cognitively Normal|Participants will be deemed cognitively normal based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
11312406|NCT02616679||Amnestic Mild Cognitive Impairment (aMCI)|Participants will be deemed aMCI based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
11312407|NCT02616666|Experimental|Dapagliflozin 10 mg|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
11312408|NCT02616666|Active Comparator|Standard of Care (SOC)|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
11312409|NCT02616653|Active Comparator|Sitting followed by lateral position|First half of participants will be assigned to have their L3-L4 intervertebral space located first in the sitting position followed by the lateral position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
11312410|NCT02616653|Active Comparator|Lateral followed by sitting position|Second half of participants will be assigned to have their L3-L4 intervertebral space located first in the lateral position followed by the sitting position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
11312411|NCT02616640|Experimental|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
11312412|NCT02616640|Experimental|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
11312468|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
11312413|NCT02616640|Experimental|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
11312414|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
11312415|NCT02616614|Active Comparator|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
11312416|NCT02616614|Experimental|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
11312417|NCT02616614|Placebo Comparator|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
11312418|NCT02616601|Experimental|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
11312419|NCT02616601|Active Comparator|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
11312420|NCT02616601|Placebo Comparator|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
11312421|NCT02616588|Experimental|Intervention Arm|All participants are enrolled into the intervention arm and receive the Veteran Patient Navigator and Social Work Intervention.
11312422|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
11312423|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
11312424|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
11312425|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.
11312426|NCT02616562|Active Comparator|Open labelled daily Norditropin® (0.034 mg/kg/day)|Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.
11312427|NCT02616549|Experimental|Sudarshan Kriya Yoga|
11312428|NCT02616549|No Intervention|Waitlist Control|
11312429|NCT02616536|Active Comparator|Flipped classroom|The flipped classroom is new pedagogical method, which employs asynchronous video lectures and practice problems as homework and active, group-based problem solving activities in the classroom.
11312430|NCT02616536|Active Comparator|traditional classroom|The classroom lecture is a special form of communication in which voive, gesture. Movements, facial expression and eye contact can either complement or detract from the content. No matter what your topic, your delivery and manner of speaking immeasurably influence your student's' attentiveness and learning.
11312431|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
11312432|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
11312433|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
11312434|NCT02616510||PCOS|Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism
11312435|NCT02616510||POI|amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L
11312436|NCT02616497|Active Comparator|Aspirin|100mg/day
11312437|NCT02616497|Active Comparator|Triflusal|300mg twice or 600mg once daily
11312438|NCT02616484|Active Comparator|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.
~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
11312439|NCT02616484|Placebo Comparator|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.
~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
11312440|NCT02616471|Experimental|High-fat cheese (HFC) group|"The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).
~No further dairy and cheese consumption is allowed"
11312441|NCT02616471|Experimental|Low-fat cheese (LFC) group|The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
11312442|NCT02616471|Active Comparator|No-cheese/carbohydrate group (CTR)|For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
11312443|NCT02616458|Experimental|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours. The research assistant provided and reviewed proper dosing instructions for acetaminophen and ibuprofen, and provided a prescription for antipyrine/benzocaine analgesic ear drops to each family to use as pain relief if their child did develop ear pain in the subsequent 12 months.
11312444|NCT02616458|Active Comparator|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
11312445|NCT02616445|Placebo Comparator|MAD Study|
11312446|NCT02616445|Placebo Comparator|Fed-Fasted|
11312447|NCT02616445|Experimental|CSF|
11312448|NCT02616432|Experimental|Tomosynthesis + FFDM|Women enrolled to DBT Arm will undergo manufacturer-defined DBT
11312449|NCT02616432|No Intervention|FFDM - Standard of Care for Screening|Women enrolled to the FFDM Arm will undergo bilateral digital mammogram with standard CC and MLO views acquired
11312450|NCT02616419|Experimental|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
11312451|NCT02616419|Active Comparator|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
11312452|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
11312453|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
11312454|NCT02616393|Experimental|Cohort A - Brain Metastases|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with BM
11312455|NCT02616393|Experimental|Cohort B - Leptomeningeal Metastases|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with LM
11312456|NCT02616393|Experimental|Cohort C - Brain Metastases at initial presentation|Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC with BM at initial presentation
11312457|NCT02616380||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
11312458|NCT02616367|Experimental|liposomal bupivacaine Periarticular injection|Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).
11312459|NCT02616367|Active Comparator|Ropivacaine Periarticular Injection|Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine
11312460|NCT02616354|Active Comparator|Group I|"Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
11312461|NCT02616354|Placebo Comparator|Group II|"group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).
~Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
11312462|NCT02616341|Experimental|Team ERP (T-ERP) Intervention|The ERP team intervention (T-ERP) consists of 25 sessions over 20 weeks with four components: (a) 3-4 pretherapy individual session with therapist, (b) 12 weekly group sessions (90-mins) led by a therapist and, (c) 10 individual coaching sessions with a case manager during weeks 2-11 of the group, and (d) 2 booster group sessions to reinforce relapse prevention
11312463|NCT02616341|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes standard community treatment consisting of a personalized treatment plan and assistance with treatment referrals to available community resources
11312464|NCT02616328||Participants with confirmed rheumatoid arthritis|
11312465|NCT02616315|Placebo Comparator|Group A: Placebo|Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
11312466|NCT02616315|Experimental|Group B: Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
11312469|NCT02616302|Experimental|>30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
11312470|NCT02616302|Experimental|>30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
11312471|NCT02616289|Experimental|Emollient|Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.
11312472|NCT02616289|No Intervention|Control|Routine Standard of care only for severe acute malnutrition.
11312473|NCT02616276|Active Comparator|Control|Control breakfast
11312474|NCT02616276|Experimental|Intervention 1|High glycemic index breakfast
11312475|NCT02616276|Experimental|Intervention 2|Low glycemic index breakfast
11312476|NCT02616263|Experimental|Foot Intervention|The intervention is a progressive, home based exercise program aimed to increase ankle and foot plantarflexion muscle strength, increase ankle dorsiflexion and toe flexion range of motion, and to retrain individuals to dorsiflex the ankle while keeping the toes in a neutral position. A trained physical therapist with experience working with older adults with diabetes and foot specific complications will monitor and progress the exercise program assuring participant safety and maximizing exercise benefit.
11312477|NCT02616263|Active Comparator|Shoulder Intervention|Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation and a tailored dose of active shoulder motion.
11312478|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.
~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
11312479|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
11312480|NCT02616237|Experimental|Intervention Group|"Lifestyle Intervention: The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.
~Besides the Facebook contents, the participants will also receive government printed health information on healthy eating, physical activity, obesity and cancers."
11312481|NCT02616237|No Intervention|Control Group|The participants randomized into the Control Group will only receive government printed health information on healthy eating, physical activity, obesity and cancers.
11312482|NCT02616224||Participants with unresectable LA/mBC|
11312483|NCT02616198|Active Comparator|EquiaFil G-coat|EquiaFil G-coat combination was applied on one randomly selected cavity to be restored
11312484|NCT02616198|Active Comparator|EquiaFil Fuji Varnish|EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored
11312485|NCT02616198|Active Comparator|Riva SC G-coat|River SC G-coat combination was applied on one randomly selected cavity to be restored
11312486|NCT02616198|Active Comparator|Riva SC Fuji Varnish|River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored
11312487|NCT02616185|Experimental|Dose Escalation|PF-06753512
11312488|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
11312489|NCT02616159|Experimental|Oatmeal 1|40 g cereal
11312490|NCT02616159|Experimental|Oatmeal2|40 g cereal
11312491|NCT02616159|Experimental|Oatmeal 3|40 g cereal
11312492|NCT02616159|Placebo Comparator|Ready to eat cereal|32.2 g cereal
11312493|NCT02616159|Placebo Comparator|Hot cereal|28.8 g cereal
11312494|NCT02616146|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11312495|NCT02616146|Active Comparator|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
11312496|NCT02616120|Placebo Comparator|Placebo|placebo identified to SQJZ herbal mixtures, 29.375g, 2 times per day.for 12 weeks.
11312497|NCT02616120|Active Comparator|SQJZ herbal mixtures|SQJZ herbal mixtures 29.375g, 2 times per day.for 12 weeks.
11312498|NCT02616107|Experimental|Intervention|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the intervention group and will receive the booklet, Managing Cancer Care: A Caregiver's Guide (MCC-CG) (N=18)
11312499|NCT02616107|Active Comparator|Control|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the control group and will receive the Symptom Management Toolkit (N=17)
11312500|NCT02616094|Experimental|Treatment Seeking Alcohol Dependent Adults|Group consists of 100 treatment seeking alcohol dependent (AD) men and women (ages 18-60). AD subjects will complete either 8 weeks of outpatient treatment at the Yale Stress Center, or the first 4 weeks as inpatient treatment at the CNRU, followed by 4 weeks of outpatient treatment at the Yale Stress Center. While in outpatient treatment, AD subjects may be admitted to the CNRU or HRU for the 1-5 days prior to one or both of their scans, to ensure abstinence for their scans.
11312501|NCT02616094|Active Comparator|Social Drinking Controls|Group consists of demographically and handedness matched 50 socially drinking controls. Healthy controls will be moderate and binge/heavy social drinkers who will participate in a single MRI session after baseline assessments. Healthy controls may be admitted to the HRU overnight prior to their scan.
11312529|NCT02615938|Placebo Comparator|Start HCQ block Placebo|At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
11312626|NCT02615288|Active Comparator|High Dose Vitamin D3 (10,000 IU daily)|
11312627|NCT02615288|Placebo Comparator|Low Dose Vitamin D3 (1000 IU daily)|
11366162|NCT02260050|Active Comparator|WAL 801 CL conventional formulation|
11312502|NCT02616094|Active Comparator|Prazosin/Placebo Group|This is a separate group of 60 treatment seeking AD subjects in a NIAAA-funded RCT of Prazosin vs placebo for alcohol dependence ( PI: Sinha, Hic protocol 0705002691, NCT00585780) to assess target primary and secondary predictors of alcohol treatment outcomes in the context of a currently ongoing RCT. AD subjects enrolled in the PZ/PL RCT will NOT be given drugs as part of this study. That study and intervention is listed elsewhere (NCT00585780). Subjects will participate in a baseline scan and a second scan between weeks 10-12 of the 12-week RCT with follow-ups. PZ/PL is only given to subjects enrolled in 0705002691, not the current protocol.
11312503|NCT02616081||Clean Intermittent Catheterization|
11312504|NCT02616081||Indwelling Catheter|
11312505|NCT02616081||Bladder Surgery|
11312506|NCT02616068|Experimental|transdermal patch & placebo|transdermal patch 100 mg once a day for 7 days and placebo (for loxoprofen sodium 60 mg tablet) by mouth, every 8 hours for 7 days
11312507|NCT02616068|Active Comparator|loxoprofen sodium & placebo|loxoprofen sodium 60 mg by mouth, every 8 hours for 7 days and placebo (for transdermal patch 100 mg) once a day for 7 days
11312508|NCT02616055|Experimental|50mg Daily|One 50mg tesevatinib tablet per day
11312509|NCT02616055|Experimental|100mg Daily|Two 50mg tesevatinib tablets per day
11312510|NCT02616055|Experimental|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
11312511|NCT02616055|Experimental|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
11312512|NCT02616042|Experimental|Centella asiatica and bamboo salt|Participants received a dentifrice which contains Centella asiatica, bamboo salt, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime). All participants used the assigned dentifrices for 4 days in each trial cycle.
11312513|NCT02616042|Experimental|Centella asiatica|Participants received a dentifrice which contains Centella asiatica, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
11312514|NCT02616042|Placebo Comparator|Control dentifrice|Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
11312515|NCT02616029|Experimental|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.
~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
11312516|NCT02616029|Experimental|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.
~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
11312517|NCT02616016|Other|MRI guided High Intensity Focused Ultrasound Treatment|"Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images.
~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.
~An individual treatment sonication will last approximately 30 seconds."
11312518|NCT02616003|Other|Giant Obese Patients (BMI >65 kg/m2)|Patients with a BMI above 65 kg/m2 that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 800 kcal) for weight loss surgery to achieve technical operability.
11312519|NCT02615990|Experimental|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
11312520|NCT02615990|Active Comparator|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
11312521|NCT02615977|Experimental|Intervention|"In the verum treatment condition, i.e. Zooming Joystick Task, 90% of all alcohol-related pictures appear in the landscape format and hence are trained to be pushed away."
11312522|NCT02615977|Placebo Comparator|Placebo Intervention|In the placebo condition, i.e. Zooming Joystick Task (Placebo), alcohol picture are as often pushed away as pulled towards the subject.
11312523|NCT02615951|Other|Nutrient transporters study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression
11312524|NCT02615951|Other|Chemokine receptors study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression
11312525|NCT02615951|Other|Genes study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression
11312526|NCT02615951|Other|Protein surface study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression
11312527|NCT02615951|Other|Protein surface & genes data validation|"Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from protein surface study and genes study arms analysis."
11312528|NCT02615938|Experimental|Start HCQ block Verum|During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
11312589|NCT02615496||Educational materials: Physicians|
11312590|NCT02615496||Educational materials: Patients|
11366163|NCT02260037|Experimental|Epinastine nasal|single rising doses
11312530|NCT02615938|Experimental|Stop HCQ block Verum|Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
11312531|NCT02615938|Placebo Comparator|Stop HCQ block Placebo|Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
11312532|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation, it is proposed by one of the investigators, patients that clinical data from this psychiatric examination, conducted as part of their usual care, are recorded as part of the research that their is proposed and explained. An information note is then distributed and not collected their opposition
11312533|NCT02615912|Other|Surfactant Exposure|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5% Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5% Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% Silwet* DA-63 (Momentive) 1.5% Sodium lauryl sulfate (Sigma Aldrich) 1.0% Water
11312534|NCT02615899|Active Comparator|Matched|Administer Targeted (specific) balance exercise interventions
11312535|NCT02615899|Active Comparator|Mismatched|Administer Untargeted (non-specific) balance exercise interventions
11312536|NCT02615886|Experimental|Observational Control|Randomized participants will be observed for diarrhea incidences throughout the 6 month trial with no intervention.
11312537|NCT02615886|Experimental|Rice Bran|Randomized participants will consume a measured dose of rice bran daily throughout the 6 month trial.
11312538|NCT02615873|Experimental|AP CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
11312539|NCT02615860|Experimental|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
11312540|NCT02615860|Active Comparator|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
11312541|NCT02615847|Experimental|Memantin arm|Memantinhydrochlorid, administered once per day during 12 month. Dosage is from 0-20 mg.
11312542|NCT02615834|No Intervention|Control group|
11312543|NCT02615834|Active Comparator|Study group|
11312544|NCT02615821|Experimental|Affective Mental Contrasting|"Before the goal formation or mental contrasting activities, participants will receive information about the affective benefits of exercising (e.g. regular physical activity has been shown to reduce stress, physical activity is enjoyable), and related research support including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit affective judgements. Specifically, the affective condition will include the additional prompts Why might you find exercise to be enjoyable, pleasant, exciting, or fun? for eliciting outcomes, and Why might you find exercise to be unenjoyable, unpleasant, boring, or miserable? for eliciting obstacles."
11312545|NCT02615821|Active Comparator|Instrumental Mental Contrasting|"Before the goal formation or mental contrasting activities,participants will receive information about the instrumental benefits of exercising (e.g., regular physical activity reduces the risk of developing cancer) and related research support, again including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit either instrumental judgements. Specifically, the instrumental conditions will include the prompts Why might you find exercise to be useful, advantageous, beneficial, or important? for eliciting outcomes, and Why might you find exercise to be unimportant, useless, inconvenient, or detrimental? for eliciting obstacles."
11312546|NCT02615821|Active Comparator|Standard Mental Contrasting|In the standard condition, the space where the affective and instrumental benefits of physical activity were listed in the instrumental and affective conditions, will be left blank in the standard condition, and no additional prompting questions will be given, allowing for the idiosyncratic identification of obstacles and outcome.
11312547|NCT02615808|Experimental|Oxygen saturation data visualization|During intervention periods staff in both units will have access to the data visualization tool in the electronic health record.
11312548|NCT02615808|No Intervention|Control|During control periods, the staff will not have access to the data visualization and will continue to use standard of care electronic health record and monitor data to understand oxygen status and trends.
11312549|NCT02615795|No Intervention|Control|Best practice
11312550|NCT02615795|Experimental|Intervention|Best practice + Tele Monitoring of physiological parameters (heart frequence, oxygen saturation, weight, FEV1), and answers to disease specific questions, using Tunstall monitoring device.
11312551|NCT02615782|Experimental|A group|"Period 1: CKD-397 1T single oral administration under fasting condition
~Period 2: CKD-397 1T single oral administration under fed condition (high fat meals)"
11312552|NCT02615782|Experimental|B group|"Period 1: CKD-397 1T single oral administration under fed condition (high fat meals)
~Period 2: CKD-397 1T single oral administration under fasting condition"
11312553|NCT02615769|Experimental|Invitation with focused information of spirometry|
11312554|NCT02615769|Active Comparator|Standard invitition|
11312555|NCT02615756|Experimental|Physical exercise|
11312556|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
11312557|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
11312558|NCT02615730|Experimental|Paclitaxel & GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
11312591|NCT02615483|Experimental|Web-based platform|Access to a web-based platform
11312592|NCT02615483|No Intervention|Control|Conventional
11312559|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
11312560|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
11312561|NCT02615704||Active APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP with MEMS
11312562|NCT02615704||Active APP without MEMs|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP without MEMS
11312563|NCT02615704||Control APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP with MEMS
11312564|NCT02615704||Control APP without MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP without MEMS
11312565|NCT02615691|Experimental|Previously untreated patients (PUPs)|<6 years of age with severe hemophilia A (baseline Factor VIII (FVIII) level < 1%)
11312566|NCT02615678|Experimental|Acupuncture|Acupuncture including scalp needling will be applied to selected points based on literature
11312567|NCT02615639|Experimental|HPDC-T cells & entecavir|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.
11312568|NCT02615639|Active Comparator|entecavir|entecavir 0.5mg tablet by mouth, every night.
11312569|NCT02615639|Experimental|HPDC-T cells & IFN-a-2a|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
11312570|NCT02615639|Active Comparator|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
11312571|NCT02615639|Experimental|HPDC-T cells & Telbivudine|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.
11312572|NCT02615639|Active Comparator|Telbivudine|Telbivudine 600mg tablet by mouth, every night.
11312573|NCT02615626||Group 1|Periodontal healthy
11312574|NCT02615626||Group 2|Gingivitis, Non-surgical Periodontal Treatment
11312575|NCT02615626||Group 3|Chronic Periodontitis, Non-surgical Periodontal Treatment
11312576|NCT02615613|Experimental|High acceptability meal|A custard recipe was used as the high acceptability meal
11312577|NCT02615613|Experimental|Low acceptability meal|The regular custard recipe was reformulated to yield a low acceptability version
11312578|NCT02615600|Experimental|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
11312579|NCT02615587||AF patients in Denmark / Cohort 1|"The base population of AF patients for diagnosis and health care utilization / resource use will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code will be identified.
~Further Data sources used:
~Registry of Medicinal Product Statistics: for determining the individuals' use of prescription medicine DREAM database: for investigation of sickness benefit and productivity loss Statistics Denmark's databases: on social services from municipalities Cause of Death Registry: AF-patients or controls who died during the study period (2000-2013) Danish Civil Registry: used for identification of controls, holds information about age, gender"
11312580|NCT02615574|Experimental|αDC1 vaccine + CKM|all subjects enrolled in study
11312581|NCT02615561|Experimental|Phase 1 (Cure phase)|Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)
11312582|NCT02615561|Experimental|Phase 2 (Care phase) / Arm 1|Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD
11312583|NCT02615561|Active Comparator|Phase 2 (Care phase) / Arm 2|Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD
11312584|NCT02615548|Experimental|Community exercise class|Regular community exercise class is the intervention. It is an exercise class that incorporate PWR moves( UP,ROCK,STEP,TWIST) and cardiovascular training.
11312585|NCT02615548|Active Comparator|self-directed exercise activity|Self-directed exercise.
11312586|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
11312587|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
11312588|NCT02615509|Other|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.
~After collecting the cases together with ground truth a readers study will be performed."
11312593|NCT02615470|Experimental|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
11312594|NCT02615470|Active Comparator|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
11312595|NCT02615457|Experimental|Arm I|Patients taking Huaier Granule for adjuvant treatment after the triple negative breast cancer has been surgically removed. The Huaier Granule (Qidong Gaitianli Medicines Co., Ltd.) should be given orally from the 3rd day after surgery up to 5 years after surgery or until study termination.
11312596|NCT02615457|No Intervention|Arm II|Patients not taking Huaier Granule after the triple negative breast cancer has been surgically removed.
11312597|NCT02615444|Experimental|Beta-glucan enriched oatcake|Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
11312598|NCT02615444|Placebo Comparator|Isocaloric control|Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.
11312599|NCT02615431||MitraClip Intervention|the influence of MitraClip on Apnoea Asleep
11312600|NCT02615418|Active Comparator|Fully active treatement|
11312601|NCT02615418|Sham Comparator|partially active|first 2.5 weeks will receive sham treatment followed by active
11312602|NCT02615405|Experimental|EPA|3.5 g/day in Studies 1 & 2
11312603|NCT02615405|Active Comparator|DHA|1.75 g/day in Studies 1 & 2
11312604|NCT02615405|Placebo Comparator|Placebo capsules|oleic oil in Study 1
11312605|NCT02615392|Experimental|Park prescription|The participants in this group will receive a brief counseling on physical activity together with a park prescription that highlights the importance of engaging in at least 150 minutes of physical activity per week and the possibility of engaging in physical activity in the park. In addition, they are invited to join in a structured and supervised physical activity program in the park. The structured physical activity program will take place in public parks located in the participants' neighbourhood. Participants will receive text messages for reminder and registration purposes approximately once a week. Also, participants will receive a sheet to monitor their weekly physical activity, information about parks in their neighborhood, and a counseling phone call half-way through the study.
11312606|NCT02615392|No Intervention|Control|The participants in this group will not be given any park prescription or be invited to participate in the weekly program in the park. However, they will receive all the information materials provided to the experimental group after the study has ended.
11312607|NCT02615379|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care
11312608|NCT02615379|No Intervention|Standard of care|standard wound care for 2 weeks
11312609|NCT02615366|Active Comparator|Tranexamic Acid|Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution [1% TXA] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
11312610|NCT02615366|Placebo Comparator|Placebo Control|Placebo control will be either 100 ml of 0.9% NaCl solution or tablets of similar appearance containing no medicinal ingredients; placebo will be administered according to the same regimen as the intervention group.
11312611|NCT02615353|Experimental|Lifestyle Intervention|6 months of a bi-weekly Nutrition Education, Physical Activity, and Behavioral Modification program
11312612|NCT02615353|Placebo Comparator|Usual Care Control|Medical screening and dietary counseling with a Endocrinologist and Registered Dietitian
11312613|NCT02615340|Active Comparator|Enteral melatonin 0.5 mg|Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
11312614|NCT02615340|Active Comparator|Enteral melatonin 2 mg|Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
11312615|NCT02615340|Placebo Comparator|Enteral matched placebo|Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
11312616|NCT02615327|Experimental|Active Treatment 1|8g Polydextrose
11312617|NCT02615327|Experimental|Active Treatment 2|12 g Polydextrose
11312618|NCT02615327|Experimental|Active Treatment 3|16 g Polydextrose
11312619|NCT02615327|Placebo Comparator|Placebo|0 g Polydextrose
11312620|NCT02615314||BPPV without migraine|Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
11312621|NCT02615314||BPPV with migraine|Thirty-two patients (11.4%) with migraine were identified. Diagnosis and classification of migraine and its differentiation from other type of headaches was based on third edition of International classification of headache disorders (ICHD-III beta) by international headache society (IHS). All patients with migraine had migrainous headache with or without aura and they all were diagnosed in our institution and followed by our neurology staff.
11312622|NCT02615301|Experimental|Salmon (HD+HK)|Tailor-made salmon with high levels of vitamin D3 and K1
11312623|NCT02615301|Experimental|Salmon (LD+HK)|Tailor-made salmon with low levels of vitamin D3 and high K1
11312624|NCT02615301|Experimental|Salmon (HD+LK)|Tailor-made salmon with high levels of vitamin D3 and low K1
11312625|NCT02615301|Experimental|Supplement (vitamin D + Calcium)|Supplement with vitamin D and Calcium
11312628|NCT02615275|Experimental|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
11312629|NCT02615262|Experimental|Experimental|Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia
11312630|NCT02615262|Placebo Comparator|Control|0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia
11312631|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
11312632|NCT02615236|Experimental|PERINEAL ULTRASOUND|Perineal ultrasound with a bedside scanner by inserting a the probe into the perineum and reviewed in real-time
11312633|NCT02615236|Active Comparator|Clinical diagnosis|Diagnosis of OASIS will be clinically
11312634|NCT02615223|Experimental|Arm1|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
~Patients receive cryoablation therapy."
11312635|NCT02615223|Experimental|Arm2|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
11312636|NCT02615210|No Intervention|Standard|Standard of care biopsies with optional SOC-directed biopsy afterwards
11312637|NCT02615210|Experimental|Study|SOC-directed biopsies using the SpyGlass System plus standard of care biopsies
11312638|NCT02615197|Active Comparator|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014).
11312639|NCT02615197|Experimental|Dialectical Behavior Therapy + DBT Prolonged Exposure protocol|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014) plus an adapted version of Prolonged Exposure therapy for PTSD.
11312640|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of erosive esophagitis [EE] confirmed by endoscopy).
11312641|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of EE confirmed by endoscopy).
11312642|NCT02615184|Experimental|Maintenance: Dexlansoprazole 30 mg|Participants in the Healing Period: Dexlansoprazole 60 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
11312643|NCT02615184|Experimental|Maintenance: Dexlansoprazole 15 mg|Participants in the Healing Period: Dexlansoprazole 30 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
11312644|NCT02615184|Placebo Comparator|Maintenance: Placebo|Participants who are eligible to enter the Maintenance of Healing period as confirmed by endoscopy will be re-randomized to receive placebo-matching capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
11312645|NCT02615171|Active Comparator|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
11312646|NCT02615171|Active Comparator|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
11312647|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
11312648|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
11312649|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
11312650|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
11312651|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
11312652|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.
~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
11313012|NCT02612831|Other|Early bariatric surgery|patient receive their procedure early (within 3 months)
11312653|NCT02615132|Experimental|Treatment Group|The study SLP will instruct the patient to use the ipad apps as intervention for at least one-hour per day, until they are admitted to outpatient SLP services or for a maximum of 8 weeks, whichever comes first. Throughout the telemedicine treatment phase, patients' progress will be monitored remotely by a study SLP through Apps/Skype/Facetime/Telephone consultation on a weekly basis.
11312654|NCT02615132|No Intervention|Control|Patients will be sent home with standard of care.
11312655|NCT02615119|Experimental|Anorexia nervosa|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
11312656|NCT02615119|Experimental|Generalized anxiety disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
11312657|NCT02615119|Experimental|Panic disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
11312658|NCT02615119|Experimental|Major depressive disorder|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
11312659|NCT02615119|Experimental|Brain injury|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
11312660|NCT02615119|Active Comparator|Healthy comparison|Intravenous bolus infusions of isoproterenol (up to 4 micrograms per infusion) and normal saline.
11312661|NCT02615106|Experimental|Endostar Combined With Radiotherapy|Drug: Endostar Endostar 7.5 mg/m2/day, day 1-14 Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
11312662|NCT02615080|Active Comparator|CRD007|CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks
11312663|NCT02615080|Placebo Comparator|Placebo|Matching placebo tablets given given twice daily for 14 weeks
11312664|NCT02615067|Experimental|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
11312665|NCT02615054||treated with trastuzmab no cardiac effects|
11312666|NCT02615054||treated with trastuzmab with cardiac effects|
11312667|NCT02615054||healthy volunteers no cancer treatment|
11312668|NCT02615041|Experimental|1 g by bolus injection|1 g of meropenem with bolus injection every 8 h regimen
11312669|NCT02615041|Experimental|1 g by 3 h infusion|1 g of meropenem with 3 h infusion every 8 h regimen
11312670|NCT02615041|Experimental|2 g by 3 hinfusion|2 g of meropenem with 3 h infusion every 8 h regimen
11312671|NCT02615028|Other|Closed eyes double-leg stance|Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
11312672|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
11312673|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
11312674|NCT02615002|Experimental|piromelatine 5 mg|5 mg tablets once daily
11312675|NCT02615002|Experimental|piromelatine 20 mg|20 mg tablets once daily
11312676|NCT02615002|Experimental|piromelatine 50 mg|50 mg tablets once daily
11312677|NCT02615002|Placebo Comparator|Placebo|Placebo tablet once daily
11312678|NCT02614989|Experimental|MRI guided Focused Ultrasound treatment|"MRI guided focused ultrasound thalamotomy
~Patients will undergo unilateral thalmotomy using MRI guided Focused Ultrasound intervention for the treatment of the tremor"
11312679|NCT02614976|No Intervention|Control|No padding before application of blood pressure cuff
11312680|NCT02614976|Experimental|Padding|Padding before application of blood pressure cuff
11312681|NCT02614963|Experimental|Clostridium Butyricum group|Irritable bowel syndrome patients treated with Clostridium Butyricum
11312682|NCT02614963|Placebo Comparator|Placebo group|Irritable bowel syndrome patients treated with placebo
11312683|NCT02614950|Experimental|Treatment interuption|
11312684|NCT02614937|Experimental|Squalamine and ranibizumab to Week 10|"All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy.
~All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6.
~Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups"
11312685|NCT02614937|Experimental|Continue Squalamine, ranibizumab PRN|Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
11312686|NCT02614937|Experimental|Stop Squalamine, ranibizumab PRN|Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
11312687|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
11312688|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
11312689|NCT02614911||Sick patients|Biological sampling of blood for all patients. Biological sampling of saliva, biopsies (skin and endoscopic), feces, for some patients
11312690|NCT02614911||Healthy relatives|Biological sampling of blood for all healthy relatives
11312691|NCT02614898||Eculizumab|The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.
11312692|NCT02614885||Prophylactic Mastectomy|Females undergoing prophylactic mastectomy with RFA performed on the excised tissue.
11312693|NCT02614872|Experimental|GLASSIA®|Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
11312694|NCT02614872|No Intervention|Institution standard of care (SOC)|Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
11312695|NCT02614859|Active Comparator|A|
11312696|NCT02614859|Experimental|B|
11312697|NCT02614846|Experimental|Hetrombopag Olamine|All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
11312698|NCT02614833|Experimental|Paclitaxel + IMP321 at the RPTD|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
11366164|NCT02260037|Placebo Comparator|Placebo|
11312699|NCT02614833|Active Comparator|Comparator: Paclitaxel + Placebo|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
11312700|NCT02614820|Experimental|treatment group|inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals
11312701|NCT02614820|Other|control group|inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals
11312702|NCT02614807|Experimental|Intervention|All recruited patients will receive a standard endorsement of lower fluid intake (<1.5 Litres/day) by a hypertension nurse and physician and an additional treatment consisting of a bottle (237 ml) of Nepro (a low sodium, low potassium content protein supplement) a day (supply for 4 weeks will be provided).
11312703|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
11312704|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
11312705|NCT02614768|Experimental|Glucose Sensor|Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
11312706|NCT02614742|Active Comparator|SFX-01|300mg bid for up to 28 days.
11312707|NCT02614742|Placebo Comparator|Placebo|300mg placebo bid for up to 28 days
11312708|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.
~Interventions:
~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
11312709|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.
~Interventions:
~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
11312710|NCT02614716|Experimental|LY3090106|LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
11312711|NCT02614716|Placebo Comparator|Placebo|Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
11312712|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
11312713|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
11312714|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
11312715|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
11312716|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
11312717|NCT02614664||Single ventricle|Patients with single ventricle physiology presenting for laparoscopic procedures.
11312718|NCT02614651|Experimental|The study population|"The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute.
~Intervention: Find visual comfort threshold related to light intensity
~Intervention: Find the size of the visual field
~Intervention: Effectiveness of brightness control
~Intervention: Performance of color correction
~Intervention: Vuzix Wrap 1200DX virtural reality glasses"
11312719|NCT02614638|Active Comparator|1st observational period (before experimental intervention)|"Patients in this arm are included during a first month of observation before the intervention is implemented.
~Intervention: One month of department-wide observation"
11312720|NCT02614638|Experimental|2nd obs. period (during experimental intervention)|"Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented.
~Intervention: Pharm Tech participates in department"
11312721|NCT02614625||Normal subjects|Patient with healthy, normal eyes
11312722|NCT02614625||Eyes with corneal disease|"Subjects that have any of the following conditions
~Corneal dystrophy or degeneration
~Corneal scarring
~Corneal ulcer
~Corneal injury
~Keratoconus
~Patients who had undergone corneal surgery
~Patients with other corneal disease"
11312723|NCT02614625||Eyes with retinal disease|"Subjects that have any of the following conditions:
~Diabetic macular edema
~Cystoid macular edema
~Age related macular degeneration
~Retinal vascular disorders (e.g. retinal artery occlusion)
~Epiretinal membrane
~Choroidal nevus
~Macular hole
~Patients who had undergone retinal surgery
~Patients with other retinal disease"
11312724|NCT02614625||Eyes with glaucoma|Eyes diagnosed with glaucoma of any type and any stage
11312725|NCT02614612|Experimental|Itacitinib (200 mg)|Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
11312726|NCT02614612|Experimental|Itacitinib (300 mg)|Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
11312727|NCT02614599|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
11312728|NCT02614599|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
11312729|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
11312730|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
11312731|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
11312732|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
11312733|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
11312734|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
11312735|NCT02614573|Experimental|The study population|The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.
11312736|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
11312737|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
11312738|NCT02614547|Active Comparator|SAGE-547|Intravenous
11312739|NCT02614547|Placebo Comparator|Placebo|Intravenous
11312740|NCT02614534|Experimental|Proactive cytoreductive surgery + HIPEC|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).
11312741|NCT02614534|Active Comparator|Proactive cytoreductive surgery|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).
11312742|NCT02614508|Experimental|Cohort A (buparlisib, ofatumumab)|Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11312743|NCT02614508|Experimental|Cohort B (buparlisib, ibrutinib)|Patients receive buparlisib as in Cohort A and ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11312744|NCT02614495|Experimental|Surufatinib|300mg once-daily
11312745|NCT02614482|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 1 month and 4 months.
11312746|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
11312747|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
11312748|NCT02614456|Experimental|Interferon-gamma and nivolumab|"Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously Nivolumab: 3 mg/kg intravenously
~Induction phase: IFN-γ every other day alone for 1 week Combination phase: IFN-γ every other day & Nivolumab every 2 weeks for 3 months Single agent phase: Nivolumab every 3 weeks up to 1 year"
11312749|NCT02614443|Experimental|Depression Condition|Participants in this group will be offered the Space from Depression programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
11312750|NCT02614443|Experimental|Anxiety Condition|Participants in this group will be offered the Space from Anxiety programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
11366165|NCT02260024|Active Comparator|Pramipexole IR|
11312751|NCT02614443|Experimental|Stress Condition|Participants in this group will be offered the Space from Stress programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
11312752|NCT02614430|Active Comparator|Vocational training|Participants are randomized into the intervention group (training) where they are offered a training course of 4-9 weeks of physical training three times a week with a physiotherapist.
11312753|NCT02614430|No Intervention|Control|Participants are randomized into the control group where they are offered the standard treatment.
11312754|NCT02614417||Polysomnography|Patients undergo an one-night in-hospital polysomnography to diagnose sleep-disordered breathing
11312755|NCT02614404|Experimental|Imatinib|Dose escalation study of imatinib, 400mg/day, 600mg/day, 800mg/day, to determine the efficacy of each imatinib treatment in eliminating parasitemia along with the safety and tolerability of each treatment. Standard of care rescue drug is dihydroartemisinin-piperaquine.
11312756|NCT02614391|Experimental|Active distraction using a tablet|Children were admitted in a comfortable room with a parent and started to play with a videogame suitable for their age three minutes before procedure. They continued to play the videogame during venipuncture. The use of a computer tablet permitted to play with one hand only.
11312757|NCT02614391|Active Comparator|Passive distracion|Children were admitted in a comfortable room with a parent and received various kinds of passive distractions: nurses singing a song, reading a book, blowing bubbles and playing a puppet show. The technique that most engaged the child, was continued during procedure.
11312758|NCT02614378|Active Comparator|Subject receiving treatment|participant receiving air insufflation
11312759|NCT02614378|Placebo Comparator|Subject receiving placebo|participant not receiving air insufflation
11312760|NCT02614365|Experimental|Aerobic Exercise|6-month 3-time/week aerobic exercise, and a 12-month passive follow-up.
11312761|NCT02614365|Active Comparator|Stretch Exercise|6-month 3-time/week stretch exercise, and a 12-month passive follow-up.
11312762|NCT02614352|Experimental|AG1502|
11312763|NCT02614352|Active Comparator|Candesartan + Atorvastatin|
11312764|NCT02614339|Experimental|metformin|
11312765|NCT02614339|Active Comparator|control|
11312766|NCT02614326|Experimental|Memory Flexibility (MemFlex) Training|MemFlex training draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014). MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks used throughout the workbook, and guides the participant in completion of the tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive a phone call at the beginning of week three to check progress, and clarify any difficulties.
11312767|NCT02614326|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. The workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The participant will receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties.
11312768|NCT02614313|Active Comparator|Fructose double-blind|Fructose during breath test, double-blind 35g
11312769|NCT02614313|Active Comparator|Fructose open|Fructose during breath test, open 35g
11312770|NCT02614313|Placebo Comparator|Sweet placebo double-blind|Assugrin during breath test double-blind
11312771|NCT02614313|Placebo Comparator|Neutral placebo double-blind|Water during breath test double-blind
11312772|NCT02614300|Active Comparator|Pulmonary Rehabilitation|These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
11312773|NCT02614300|Active Comparator|Chest Physiotherapy|"The ELTGOL technique (total slow expiration with glottis open in lateral decubitus) for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary."
11312774|NCT02614300|Active Comparator|Pulmonary Rehabilitation and Chest Physiotherapy|"This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.
~Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs."
11312775|NCT02614300|No Intervention|Control Group|"For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.
~The physiotherapist will also do monthly telephone calls for patient's monitoring."
11312776|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
11312777|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
11312778|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
11313007|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
11312779|NCT02614261|Experimental|Galcanezumab 120 mg|"Galcanezumab 240 mg given as loading dose at first dosing visit followed by 120 mg once a month for 2 months by subcutaneous (SC) injection.
~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
11312780|NCT02614261|Experimental|Galcanezumab 240 mg|"Galcanezumab 240 mg given by SC injection once a month for 3 months.
~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
11312781|NCT02614261|Placebo Comparator|Placebo|"Placebo given by SC injection once a month for 3 months.
~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
11312782|NCT02614248|Experimental|Coconut Oil|Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
11312783|NCT02614248|Active Comparator|Standard of Care|Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
11312784|NCT02614235|Experimental|Pocket-ECG III System|After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
11312785|NCT02614235|Active Comparator|Conventional Holter|Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
11312786|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
11312787|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
11312788|NCT02614196|Experimental|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
11312789|NCT02614196|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
11312790|NCT02614196|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
11312791|NCT02614196|Experimental|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
11312792|NCT02614196|Experimental|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
11312793|NCT02614196|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
11312794|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
11312795|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
11312796|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
11312797|NCT02614157|Experimental|LLND+TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
11312798|NCT02614157|No Intervention|TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND
11312799|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
11312800|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
11312801|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
11312802|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
11312803|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
11312804|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
11312805|NCT02614118|Active Comparator|Ketorolac tromethanine|10 mg oral Ketorolac tromethanine 45 minutes before root canal treatment
11312806|NCT02614118|Active Comparator|Acetaminphen & Ketorolac tromethamine|1000 mg Acetaminophen and 10 mg Ketorolac tromethamine oral 45 minutes before root canal treatment
11312807|NCT02614118|Placebo Comparator|Placebo|placebo 45 minutes before root canal treatment
11312808|NCT02614105|Experimental|Pelvic floor muscle training|Participants in the pelvic floor muscle training group will receive group exercise sessions (1 hour) at the physiotherapy out-patient department of the hospital once a week for 16 weeks with guidance from an experienced pelvic floor physiotherapist. The group exercise sessions will focus on pelvic floor muscle training, relaxation and breathing techniques. Participants in the pelvic floor muscle training group will also receive an individually adapted pelvic floor muscle training program for daily home use.
11312835|NCT02613884|Experimental|Treatment|All patients with a 25OHD level <30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
11312836|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
11312809|NCT02614105|Experimental|Cough-suppression|Participants in the cough-suppression group will receive a group education session with general information about cough-suppression therapy and advice about how to distinguish between unproductive and productive cough to enable them to perform airway clearance techniques when required. In addition, participants will receive one to two individual sessions (30-60 minutes) of cough-suppression therapy tailored to the individual needs based on symptoms and underlying disease activity
11312810|NCT02614105|Experimental|Control group|Participants in the group will receive guidance and instruction in terms of correct contraction of the pelvic floor muscles at clinical assessment. Control group participants will receive brief written information about pelvic floor muscle training and cough-suppression therapy, but no other form of regular follow-up or intervention throughout the intervention period.
11312811|NCT02614092|Experimental|Water based Activity+ Cognitive Training|water-based physical activity + classroom based cognitive training
11312812|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
11312813|NCT02614066|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
11312814|NCT02614040|Active Comparator|0.9% Saline|Patients in a month randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
11312815|NCT02614040|Active Comparator|Physiologically-balanced|Patients in a month randomized to physiologically-balanced isotonic fluid will receive physiologically-balanced isotonic crystalloid (Plasma-Lyte© A or Lactated Ringer's) whenever isotonic intravenous fluid administration is ordered by the treating provider.
11312816|NCT02614014|Experimental|Psychological intervention|Cognitive-behavior interventional program
11312817|NCT02614014|No Intervention|Control|No intervention
11312818|NCT02614001|Experimental|inspiratory muscle training, stroke rehabilitation|Inspiratory muscle training with a pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) will be start at a resistance equal to 30% of their MIP or at a load which patient can tolerate, and then the loading will be gradually increased 2cm H2O per week or as symptom tolerated and according to the RPE scale. Each patient will receive regular post-stroke rehabilitation program.
11312819|NCT02614001|Other|control group|stroke rehabilitation.
11312820|NCT02613988|Other|MR imaging and standard treatment|Patients with glioblastoma undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) at pre-CCRT; 4 weeks after completion of the CCRT; and every 2 or 3 months during the adjuvant temozolomide therapy.
11312821|NCT02613975|Experimental|on positional device|patients who could not tolerate cpap will be provided with positional device for treatment of OSA which will vibrate when patients lie in prone position
11312822|NCT02613975|Experimental|patients on dental device|patients on dental devices but not optimally treated for OSA will be provided positional device for optimization of treatment for OSA, which will vibrate when patients lie in prone position
11312823|NCT02613962|Experimental|relapsed or refractory pediatric tumor|This is a prospective, international, multicentric clinical proof-of-concept study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory pediatric tumors. The molecular screening will be done on a newly biopsied or resected tumor sample obtained at the time of relapse/progression, using high-throughput technologies, primarily WES and RNA Sequencing, and bioinformatics analysis.
11312824|NCT02613949|Active Comparator|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
11312825|NCT02613949|Active Comparator|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
11312826|NCT02613949|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
11312827|NCT02613936|Experimental|Active anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
11312828|NCT02613936|Sham Comparator|Placebo anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
11312829|NCT02613923|Experimental|GO! To Sleep|Participants in the intervention group will be provided with a code and website address to participate in this program. This program includes reminder emails and is 6 weeks in duration. Participants will be given a blood draw to measure biomarkers.
11312830|NCT02613923|Active Comparator|informational control|Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
11312831|NCT02613910|Experimental|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to <= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if <LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
11312832|NCT02613897|Active Comparator|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
11312833|NCT02613897|Active Comparator|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
11312834|NCT02613897|Placebo Comparator|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
11366166|NCT02260024|Experimental|Pramipexole SR C2 in the fasted state|
11312837|NCT02613845||Cardiac surgery|Study subjects are all patients who underwent cardiac surgery with cardiopulmonary bypass at the University Hospital Basel during the year 2013.
11312838|NCT02613832|Experimental|EPAP Group|The EPAP devices increase the alveolar pressure. This effect is obtained through valves that generate a resistance to airflow during expiration.
11312839|NCT02613832|Experimental|Breath Stacking Group|The Breath Stacking consists on the implementation of subsequent inspiratory efforts through a one way valve, which allows stacked volume of gas during each inspiration, until it reaches a maximum lung volume.
11312840|NCT02613819|Experimental|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)
~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.
~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
11312841|NCT02613806|Experimental|D group (dexmedetomidine)|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion with microperfusion pump at the beginning of the surgery,and continued till end of surgery.
11312842|NCT02613806|Active Comparator|C group (saline)|The patients received equal volume normal saline by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
11312843|NCT02613793||Preterm pre-eclampsia (cases)|Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
11312844|NCT02613793||Pregnant patients (controls)|Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition
11312845|NCT02613780|Active Comparator|Sequential group|Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking
11312846|NCT02613780|Active Comparator|Simultaneous group|Photorefractive keratectomy and crosslinking will be performed on the same day
11312847|NCT02613767||Obese|"BMI >30 kg/m2, Protein meal,
~L-[ring 13C6]Phenylalanine infusion"
11312848|NCT02613767||Overweight|"BMI >25 and < 30 kg/m2, Protein meal,
~L-[ring 13C6]Phenylalanine infusion"
11312849|NCT02613767||Healthy-Weight|"BMI >18 and < 25 kg/m2, Protein meal,
~L-[ring 13C6]Phenylalanine infusion"
11312850|NCT02613754|Experimental|Contingency Management|Contingency Management (CM+): This procedure is designed to reinforce treatment attendance, non-gambling behaviour, and study completion. Participants will earn points that will be recorded on vouchers that could be subsequently redeemed for gift cards at a variety of local businesses. Submission of evidence of gambling behaviour or non-attendance re-sets the point value for future vouchers to the starting level. This intervention is in addition to Treatment as Usual.
11312851|NCT02613754|Active Comparator|Treatment as Usual|Treatment as Usual (TAU): This is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling.
11312852|NCT02613741|Experimental|Intervention|12 weeks of lifestyle-based physical activity intervention
11312853|NCT02613741|No Intervention|Control|12 weeks of no intervention
11312854|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
11312855|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
11312856|NCT02613715|Experimental|Blackberry juice with 12% ethanol|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml alcohol beverage (38%) and 17 g sugar.
11312857|NCT02613715|Experimental|Blackberry juice|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml water and 17 g sugar.
11312858|NCT02613702|Experimental|Modified Free Gingival Graft|Twenty patients will receive the modified free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap, similarly to what is done in a connective tissue graft surgery.
11312859|NCT02613702|Active Comparator|Original Free Gingival Graft technique|Twenty patients will receive the original technique of free gingival graft at the inferior incisors area.
11312860|NCT02613689|Experimental|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
11312861|NCT02613689|Active Comparator|Control Group|Subjects will receive SMS support text messages
11312862|NCT02613676|Experimental|TcB screening before discharge|Participants in this group will be screened for jaundice using the JM 105 transcutaneous device. The TcB value will be plotted on the Bhutani nomogram to assess the risk category. Infants who are categorised as high risk according to the nomogram will require blood sampling for TsB and assessment for need for phototherapy.
11312863|NCT02613676|Other|Standard care (visual inspection)|Participants in this group will be managed routinely according to the current standard of care where babies are assessed for jaundice by visual inspection. Babies in this group will require blood draw for TsB if there are visibly jaundiced
11312864|NCT02613663|Experimental|immediate implants with nanobone graft|Nano-hydroxyapatite bone graft fill the gap between immediate implant and labial bone wall.
11312865|NCT02613663|Active Comparator|immediate implants with autogenous bone graft|Autogenous graft fill the gap between immediate implant and labial bone wall.
11312866|NCT02613650|Experimental|MEK162 and mFOLFIRI, all patients|
11312867|NCT02613598|Experimental|Bortezomib and Ruxolitinib|Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.
11312868|NCT02613585|Experimental|Permethrin Impregnated Clothing|Uniforms and work clothing (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin by Insect Shield.
11312869|NCT02613585|No Intervention|Untreated Clothing|Uniforms and work clothing sent to Insect Shield, washed and refolded (no permethrin applied).
11312870|NCT02613572|Experimental|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
11312871|NCT02613572|Experimental|alpha lipoic acid 800mg|once daily with meal x 5 days
11312872|NCT02613572|Experimental|alpha lipoic acid 1200mg|once daily x 5 days
11366167|NCT02260024|Experimental|Pramipexole SR C2A in the fasted state|
11312873|NCT02613572|Placebo Comparator|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
11312874|NCT02613572|Experimental|ALA 600 mg|once daily with a meal for 2 weeks
11312875|NCT02613572|Placebo Comparator|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
11312876|NCT02613572|Experimental|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
11312877|NCT02613559|Experimental|TK001 0.1mg|Injection:single Intravitreal Injection
11312878|NCT02613559|Experimental|TK001 0.5mg|Injection:single Intravitreal Injection
11312879|NCT02613559|Experimental|TK001 1.0mg|Injection:single Intravitreal Injection
11312880|NCT02613559|Experimental|TK001 2.0mg|Biological: TK001 Injection:single Intravitreal Injection
11312881|NCT02613559|Experimental|TK001 2.5mg|Biological: TK001 Injection:single Intravitreal Injection
11312882|NCT02613559|Experimental|TK001 3.0mg|Injection:single Intravitreal Injection
11312883|NCT02613546|Experimental|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:
~evaluation session;
~sessions of psychoeducation about the CBT model
~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
11312884|NCT02613546|Other|Control|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
11312885|NCT02613533|Experimental|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
11312886|NCT02613520|Experimental|Group 1a (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
11312887|NCT02613520|Placebo Comparator|Group 1a (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
11312888|NCT02613520|Other|Group 1a (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
11312889|NCT02613520|Experimental|Group 1b (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
11312890|NCT02613520|Placebo Comparator|Group 1b (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
11312891|NCT02613520|Other|Group 1b (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
11312892|NCT02613520|Experimental|Group 2a (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
11312893|NCT02613520|Placebo Comparator|Group 2a (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
11312894|NCT02613520|Experimental|Group 2b (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
11312895|NCT02613520|Placebo Comparator|Group 2b (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
11312896|NCT02613520|Experimental|Group 3a (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
11312897|NCT02613520|Placebo Comparator|Group 3a (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
11312898|NCT02613520|Experimental|Group 3b (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
11312899|NCT02613520|Placebo Comparator|Group 3b (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
11312900|NCT02613520|Experimental|Group 4a (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
11312901|NCT02613520|Placebo Comparator|Group 4a (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
11312902|NCT02613520|Experimental|Group 4b (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
11312903|NCT02613520|Placebo Comparator|Group 4b (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
11312904|NCT02613520|Experimental|Group 5a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.
11312905|NCT02613520|Experimental|Group 5b (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
11312906|NCT02613520|Placebo Comparator|Group 5b (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
11312907|NCT02613520|Experimental|Group 5c (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
11312908|NCT02613520|Placebo Comparator|Group 5c (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
11312909|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
11312910|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
11312911|NCT02613494|Active Comparator|Hyoscine|Hyoscine hydrobromide
11312912|NCT02613494|Active Comparator|Glycopyrrolate|Glycopyrronium bromide
11312913|NCT02613494|Placebo Comparator|Placebo|Placebo
11312914|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
11312915|NCT02613468|Placebo Comparator|Periodontally healthy|"Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.
~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
~Intervation: Collection of periodontal records and pregnancy parameters."
11313008|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
11312916|NCT02613468|Placebo Comparator|Periodontally diseased, untreated|"This group is comprised of individuals who do not accept treatment Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.
~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.
~Birth weight was recorded at the end of pregnancy."
11312917|NCT02613468|Active Comparator|Periodontally diseased, treated|"This group is comprised of individuals who agree to treatment. Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.
~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.
~Initial Periodontal Therapy is completed (calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
~Birth weight was recorded at the end of pregnancy. Intervation: Collection of periodontal records and pregnancy parameters."
11312918|NCT02613455|Active Comparator|Kenalog (triamcinolone )|Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
11312919|NCT02613455|Active Comparator|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
11312920|NCT02613429|Active Comparator|Cranial horizontal|identification of the airway by from the cranial end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination from the cranial end at the level of the thyroid catilage , horizontally and thereafter moving caudally
11312921|NCT02613429|Active Comparator|caudal longitudinal|identification of the airway from the distal end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination caudally, and then moving cranially
11312922|NCT02613416|Experimental|Denosumab|6 monthly subcutaneous injections of denosumab
11312923|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
11312924|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
11312925|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
11312926|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
11312927|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
11312928|NCT02613390|Experimental|MRI-Based Image Guidance|"MRI images of the spine taken of anesthetized participant in the operative prone position. These images are exported into a computer navigation program, and used to help the doctor perform surgery.
~Pain and symptom questionnaires completed at baseline and at follow up."
11312929|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
11312930|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
11312931|NCT02613364|Experimental|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
11312932|NCT02613364|Experimental|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
11312933|NCT02613364|Active Comparator|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
11312934|NCT02613351|Experimental|scooting|incremental test to establish the relationship between leg and breathing heaviness with increasing demand (speed) during scooting
11312935|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
11312976|NCT02613026|Experimental|Combined therapy group|pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.
11313009|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
11313010|NCT02612844|Experimental|NNC0143-0406|
11312936|NCT02613325|Experimental|Arm 1: fPAM imaging & Single cell PAM imaging|"fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.
~When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.
~Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.
~To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged"
11312937|NCT02613286|Experimental|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
11312938|NCT02613286|Active Comparator|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
11312939|NCT02613273|Experimental|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
11312940|NCT02613273|Experimental|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
11312941|NCT02613273|No Intervention|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
11312942|NCT02613260|No Intervention|Usual Care|Patients in this study arm will receive usual care from their primary care clinic.
11312943|NCT02613260|Experimental|FIT Outreach + Usual Care|Patients in this study arm will receive usual care at their primary care clinic and the intervention.
11312944|NCT02613247|Experimental|Immediate-start group|Hylan G-F 20 6 mL intra-articular knee injection
11312945|NCT02613247|Other|Delayed-start group|Washout control group which then becomes an experimental group (Hylan G-F 20 6 mL intra-articular knee injection) at 6 weeks post-enrolment
11312946|NCT02613234|Experimental|Experimental Group|Active Intervention on brain waves by cathode tDCS
11312947|NCT02613234|Sham Comparator|Control Group|Sham Intervention on brain waves by cathode tDCS
11312948|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
11312949|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
11312950|NCT02613195|Experimental|Hydrogen-rich Celsior solution|Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.
11312951|NCT02613195|No Intervention|Celsior solution|Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.
11312952|NCT02613182|Experimental|Open Label|Open Label Study Drug NEOD001
11312953|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
11312954|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
11312955|NCT02613156||laparoscopic group|patients in the laparoscopic group underwent laparoscopic resection of recurrent HCC
11312956|NCT02613156||control group|patients in the control group underwent conventional open surgery
11312957|NCT02613143||Surgery|
11312958|NCT02613130|Experimental|Two-Step stannous fluoride toothpaste|Two-Step stannous fluoride toothpaste
11312959|NCT02613130|Active Comparator|Potassium nitrate toothpaste|Potassium nitrate toothpaste
11312960|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
11312961|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
11312962|NCT02613104|Experimental|Sad to Happy|emotion recognition modification - sad>happy
11312963|NCT02613104|Placebo Comparator|Sad control|emotion recognition modification - sad>happy control
11312964|NCT02613104|Experimental|Angry to Happy|emotion recognition modification - angry>happy
11312965|NCT02613104|Placebo Comparator|Angry control|emotion recognition modification - angry>happy control
11312966|NCT02613091|Experimental|Clemastine|This group will receive 8mg of clemastine daily.
11312967|NCT02613078|Experimental|Gut-Directed Hypnotherapy (GDH)|Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week)
11312968|NCT02613078|Experimental|Probiotic (NS)|Nutritional supplement SymbioLact B once a day diluted in water or tea
11312969|NCT02613078|Active Comparator|Active Controls (AC)|AC group keeps a symptom dairy (self-monitoring)
11312970|NCT02613065|Experimental|Eggwhite protein shake|Participants drink a NOW Foods protein shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
11312971|NCT02613065|Active Comparator|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
11312972|NCT02613052|Placebo Comparator|Agitated Normal Saline|Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.
11312973|NCT02613052|Active Comparator|Albumin only|10 mL of agitated 5% albumin will be used for the bubbly study.
11312974|NCT02613052|Experimental|Albumin and Propofol|7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.
11312975|NCT02613039|Other|female outpatient subjects|Patients requiring combined Oral Contraceptives therapy.
11313011|NCT02612844|Active Comparator|Insulin Aspart|
11312977|NCT02613026|Experimental|Sequential therapy group|cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.
11312978|NCT02613013|Active Comparator|single LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
11312979|NCT02613013|Experimental|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure
11312980|NCT02613000||All enrolled patients/Group A|500 consecutive adult patients will be enrolled in Part A (clinical data)
11312981|NCT02613000||Patients with blood and urine sampling/Group B|Patients with informed consent signed (anticipated 200 out of 500 patients) will participate in Part A (clinical data) and B (intestinal-specific biomarkers from blood and urine)
11312982|NCT02612987|Experimental|iCBT|
11312983|NCT02612974|Experimental|Group A|Hirudinaria granulosa and Qurse mafasil are given
11312984|NCT02612974|Active Comparator|Group B|Qurse mafasil only given
11312985|NCT02612961|Experimental|Saline Instillation|3mL normal saline from pink sodium chloride bullet instilled into tracheostomy immediately prior to suctioning.
11312986|NCT02612961|Sham Comparator|Placebo|Pretend to instill 3mL of normal saline using empty pink sodium chloride bullet immediately prior to suctioning.
11312987|NCT02612948|No Intervention|Standard Care|Standard care for delerium
11312988|NCT02612948|Active Comparator|Quetiapine|Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
11312989|NCT02612922|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
11312990|NCT02612922|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
11312991|NCT02612909|Placebo Comparator|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
11312992|NCT02612909|Active Comparator|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
11312993|NCT02612909|Active Comparator|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
11312994|NCT02612909|Placebo Comparator|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
11312995|NCT02612909|Experimental|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
11312996|NCT02612896|Experimental|Elimination arm|"Both human and porcine interventions at four-monthly intervals in the first two study years, for a total of six iterations (only human interventions will be detailed here):
~Human: Mass drug administration, praziquantel 10mg/kg, according to the list of WHO recommended anthelmintic drugs for use in preventive chemotherapy for taeniasis. And Health Education"
11312997|NCT02612896|Experimental|Control intervention arm|Human: yearly health education, for a total of five iterations. The intervention on the pig host will not be detailed here)
11312998|NCT02612883||Esophagus|Measuring of tissue perfusion of the esophagus
11312999|NCT02612883||Liver|Measuring of tissue perfusion of the liver
11313000|NCT02612883||Stomach|Measuring of tissue perfusion of the stomach
11313001|NCT02612883||Pancreas|Measuring of tissue perfusion of the pancreas
11313002|NCT02612883||Colon|Measuring of tissue perfusion of the colon
11313003|NCT02612870|Active Comparator|Sienna+ retro and Technetium 1|"Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
11313004|NCT02612870|Active Comparator|Sienna+ peri and Technetium 1|"Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
11313005|NCT02612870|Active Comparator|Sienna+ retro 4-6 and Technetium 1|"Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
11313006|NCT02612870|Active Comparator|Sienna+ peri 4-6 and Technetium 1|"Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.
~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.
~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
11313013|NCT02612831|Other|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
11313014|NCT02612805|Experimental|Aerobic training group|This group perform aerobic hydrogymnastics.
11313015|NCT02612805|Active Comparator|Combined training group|This group perform combined hydrogymnastics.
11313016|NCT02612805|Placebo Comparator|Training placebo|This group perform stretching and relaxation in aquatic environment.
11313017|NCT02612792|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
11313018|NCT02612792|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
11313019|NCT02612792|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin for treating furcation defect
11313020|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
11313021|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
11313022|NCT02612766|Other|Single Arm|This is a single-arm interventional study, in which each patient gets 50 grams/day of pure, uncontaminated oats
11313023|NCT02612753|Experimental|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
11313024|NCT02612753|Sham Comparator|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
11313025|NCT02612740|Experimental|Test Group|The bone defect was filled with granules of deproteinized bovine bone (Bio-Oss, Geistlich Pharm, AG Wolhausen, Switzerland)
11313026|NCT02612740|No Intervention|Control Group|No filling material was used in the bone healing
11313027|NCT02612727|Experimental|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
11313028|NCT02612727|Active Comparator|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
11313029|NCT02612714|Other|medication status|Rosuvastatin 5 mg qd for 6 months, Quitted rosuvastatin for 6 months, Re-administrated rosuvastatin for 6 months
11313030|NCT02612701|Experimental|Cigarettes|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
11313031|NCT02612701|Experimental|E-cigarettes (nicotine free e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
11313032|NCT02612701|Experimental|E-cigarettes (low nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
11313033|NCT02612701|Experimental|E-cigarettes (high nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
11313034|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
11313035|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
11313036|NCT02612675|Active Comparator|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
11313037|NCT02612675|Experimental|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
11313038|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
11313039|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
11313040|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
11313041|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
11313042|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
11313043|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
11313044|NCT02612649||Ramosetron group|Female patients with diarrhea-predominant irritable bowel syndrome
11313045|NCT02612636|Active Comparator|ear plug and eye mask|"The patients will not receive the intervention in the first night (N1) from 9 pm to 6 am
~The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
~The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
~The patients will receive the intervention (eye mask and ear plug) in the fourth night (N4) from 9 pm to 6 am."
11313046|NCT02612636|No Intervention|control|The researcher will assess and observe the patients who are receiving the routine hospital nursing care during the four nights.
11313047|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
11313048|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
11313049|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
11313050|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
11313051|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
11313052|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
11313593|NCT02609048|Experimental|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
11313053|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
11313054|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
11313055|NCT02612597|Experimental|Bedrest|4 days of bedrest
11313056|NCT02612597|Experimental|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
11313057|NCT02612584|Experimental|Pinhole soft contact lens|
11313058|NCT02612571||Wind instrument players|A wind instrument is defined as any instrument that contains a resonator, in which a column of air is set into resonation by the player blowing into a mouthpiece at one end of the resonator.
11313059|NCT02612571||Non-wind instrument players|A non-wind instrument is defined as any instrument that does not contain a resonator.
11313060|NCT02612558|Experimental|Fostamatinib 150 mg|Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks
11313061|NCT02612545|Active Comparator|ACT|Patients randomized to ACT will receive DHA-PPQ only
11313062|NCT02612545|Experimental|TACT|Patients randomized to TACT will receive DHA-PPQ plus MQ
11313063|NCT02612532|Experimental|LuCID|"Standardised exhaled volatile organic compound collection by ReCIVA breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)"
11313064|NCT02612519|Experimental|Alfapump - Substudy 1|Alfapump implantation
11313065|NCT02612519|Active Comparator|TIPS - Substudy 1|TIPS implantation
11313066|NCT02612519|Experimental|Alfapump - Substudy 2|Alfapump implantation
11313067|NCT02612519|No Intervention|Standard - Substudy 2|Standard treatment
11313068|NCT02612506|Experimental|Hepalatide|Hepalatide 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
11313069|NCT02612506|Placebo Comparator|Placebo|Placebo 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
11313070|NCT02612480|Experimental|Ticagrelor and acetylsalicylic acid|7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
11313071|NCT02612480|Active Comparator|Clopidogrel and acetylsalicylic acid|7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
11313072|NCT02612480|Placebo Comparator|Placebo and acetylsalicylic acid|7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
11313073|NCT02612480|Placebo Comparator|Placebo|7 day treatment with 2 placebos
11313074|NCT02612467|Experimental|Stratified care|Patients are stratified into low, medium, high risk of poor outcome. Stratified care are delivered by special trained physiotherapists according to risk group
11313075|NCT02612467|Active Comparator|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
11313076|NCT02612454|Experimental|Body weight ≥60 kg|Administered every two weeks (Q2W)
11313077|NCT02612454|Experimental|Body weight 30 kg to <60 kg|Administered Q2W
11313078|NCT02612454|Experimental|Body weight 15 kg to <30 kg|Administered every 4 weeks (Q4W)
11313079|NCT02612454|Experimental|Body weight 5 kg to <15 kg|Administered Q4W
11313080|NCT02612441|Experimental|1 real Acupuncture group-intervention|real Acupuncture Needles
11313081|NCT02612441|Sham Comparator|2 sham Acupuncture group|sham Acupuncture Needles
11313082|NCT02612428|Experimental|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
11313083|NCT02612428|Other|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
11313084|NCT02612415|Experimental|High flow nasal cannula (HFNC)|Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC
11313085|NCT02612415|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure delivered using any interface (hood, mask or prongs)
11313086|NCT02612402|Experimental|Learning algorithm|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT the Patients will receive daily messages, a learning algorithm will study the exercise response to each type of message and personalize the best message sequence for each patient.
11313087|NCT02612402|Active Comparator|control|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT THE Patients will receive a weekly reminder to exercise.
11313088|NCT02612389|Experimental|MM Intervention taught via DVD|Receive Meditative Movement training via DVD with pre and post interventional testing.
11313089|NCT02612389|No Intervention|MM Intervention Waitlist Control|Testing at same frequency as Meditative Movement interventional subjects.
11313090|NCT02612376||AD, DS, Mild Cognitive Impairment|Persons with age-related Mild Cognitive Impairment (MCI) or Alzheimer Disease (AD) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria. Individuals with Down Syndrome (DS) according to clinical diagnosis, with cognitive ability sufficient to follow directions.
11313091|NCT02612376||Healthy Controls|"Non-DS community-dwelling controls
~Non-pregnant mothers and fathers of DS individuals (controls)
~An Informant (study partner) available to complete functional interviews/survey measures annually."
11313092|NCT02612363|Experimental|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group
~Analgesia
~Dexmedetomidine start at 0.7ug/kg/hour
~Dose range: 0.2- 0.7 u/kg/hour
~Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
11313093|NCT02612363|Placebo Comparator|Standard sedation|"Control drug for sedation in early goal directed sedation group
~Analgesia
~Control drug
~Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
11313154|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
11313155|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
11313094|NCT02612350||Increased Risk for Cancer Development|The group is to include at least 1000 individuals who are at high risk for the development of cancer. Risk is assessed through the completion of a clinical history questionnaire. Examples of such subjects include those with known hereditary cancer syndrome pathogenic variants without a diagnosis of cancer, with significant family history of breast, ovarian, colon, or lung cancer or melanoma, or another strong history of cancer but no prior molecular diagnosis, heavy smokers or those exposed to carcinogens and mutagens. The individuals who meet criteria for inclusion will undergo cell-free DNA isolation and circulating-tumor DNA (ctDNA) analysis for the detection of genetic mutations associated with the possible development of a malignancy.
11313095|NCT02612337|Experimental|OTO-104|12 mg dexamethasone
11313096|NCT02612337|Placebo Comparator|Placebo|
11313097|NCT02612324|Experimental|Pono Choices|Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program for Middle School Youth in Hawaii. The program includes 9.5 hours of scripted lessons or modules.
11313098|NCT02612324|Active Comparator|Business as Usual|Middle school sexual health content or programs chosen by control group schools.
11313099|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
~TGR-1202: Fixed oral daily dose"
11313100|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6
~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
11313101|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
11313102|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
11313103|NCT02612298|Experimental|arotinolol|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks
11313104|NCT02612298|Active Comparator|Metoprolol|Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
11313105|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
11313106|NCT02612272|Active Comparator|Corticosteroid|"This arm will receive intra-articular betamethasone.
~4cc of 1% lidocaine, 1cc of 0.9% normal saline and 1cc (6 mg) of betamethasone.
~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site
~Please see detailed description of study for further information."
11313107|NCT02612272|Experimental|Ketorolac|"This arm will receive intra articular ketorolac.
~2cc (60 mg) of ketorolac and 4cc of 1% lidocaine
~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site
~Please see detailed description of study for further information."
11313108|NCT02612259|Experimental|TRYPTOPHAN|"tryptophan 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.
~Total treatment duration for each patient is 6 months."
11313109|NCT02612259|Placebo Comparator|PLACEBO|"lactose capsules 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.
~Total treatment duration for each patient is 6 months."
11313110|NCT02612246|Experimental|GLPG1972 single dose|Single oral dose of GLPG1972 solution - ascending doses
11313111|NCT02612246|Placebo Comparator|Placebo single dose|Single oral dose of placebo solution
11313112|NCT02612246|Experimental|GLPG1972 multiple doses|Multiple oral doses of GLPG1972 solution - ascending doses
11313113|NCT02612246|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo solution
11313114|NCT02612233|Active Comparator|Pregabalin|Pregabalin 150mg ON week 1 increased to Pregabalin 300mg ON weeks 2-11 then decrease to Pregabalin 150mg ON week 12 then STOP
11313115|NCT02612233|Active Comparator|Duloxetine|Duloxetine 30mg ON week 1 increase to Duloxetine 60mg weeks 2-11 then decrease to Duloxetine 30mg ON week 12 then STOP
11313116|NCT02612233|Placebo Comparator|Placebo|1 capsule ON week 1- increase to 2 capsules ON week 2-11 then decrease to 1 capsule ON week 12 then STOP.
11313117|NCT02612220|Experimental|Experimental Group|Complete hemostasis will be achieved using BioFoam® Surgical Matrix
11313118|NCT02612220|Active Comparator|Control Group|Complete hemostasis will be achieved without the use of topical agents, using conservative hemostasis
11313119|NCT02612194|Experimental|Cohort 1|c-MET high (> 50%), RON null (0-9%)
11313120|NCT02612194|Experimental|Cohort 2|c-MET + (10-100%), RON + (10-100%)
11313121|NCT02612194|Experimental|Cohort 3|c-MET null (0-9%), RON + (10-100%)
11313122|NCT02612181|Experimental|Dexmedetomidine group|Dexmedetomidine group: Dexmedetomidine infusion for dexmedetomidine group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Dexmedetomidine doses 0-0.7 mcg/kg/h
11313123|NCT02612181|Placebo Comparator|Control group|Control group: Placebo infusion for control group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Control drug doses 0-0.7 mcg/kg/h
11313124|NCT02612168|Experimental|All patients|Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
11313125|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
11313126|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
11313156|NCT02612025|Experimental|Exercise group|Exercise training during intensive medical treatment
11313157|NCT02612025|No Intervention|Control group|Usual Care
11313158|NCT02612012||Axillary radiotherapy|
11313789|NCT02607865|Experimental|Semaglutide 7 mg|
11313127|NCT02612142|Experimental|aerobic exercise (AE)|Intervention type: Behavioral. Intervention name: Aerobic exercise Intervention description: 10 days of daily aerobic exercise (brisk walking, jogging); duration: 30 minutes per session; intensity: 65%-75% of age-predicted maximal heart rate. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
11313128|NCT02612142|Sham Comparator|stretching exercise (ST)|Intervention type: Behavioral. Intervention name: Stretching exercise Intervention description: 10 days of daily stretching exercise; duration: 30 minutes per session. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
11313129|NCT02612142|No Intervention|no intervention (NI)|No behavioral intervention. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
11313130|NCT02612129|Experimental|arimoclomol|arimoclomol capsules for oral administration (3 times daily). Doses:150-600 mg/day (based on weight)
11313131|NCT02612129|Placebo Comparator|Placebo|Matching placebo capsules
11313132|NCT02612116|Active Comparator|pulverized ticagrelor sublingually|Pulverized ticagrelor 180 mg (Brilique) administered sublingually
11313133|NCT02612116|Active Comparator|pulverized ticagrelor orally|Pulverized ticagrelor 180 mg (Brilique) administered orally
11313134|NCT02612116|Active Comparator|Integral ticagrelor orally|Ticagrelor 180 mg (Brilique) administered orally in integral tablets
11313135|NCT02612103||Active Crohns disease|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index > 4.
11313136|NCT02612103||Crohns disease in remission|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4.
11313137|NCT02612103||Active ulcerative colitis|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index > 3.
11313138|NCT02612103||Ulcerative colitis in remission|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index ≤ 3.
11313139|NCT02612103||Irritable bowel syndrome|Verified irritable bowel syndrome according to standard criteria.
11313140|NCT02612103||Healthy controls|No known chronic diseases which needs continuously medication.
11313141|NCT02612090|Active Comparator|Active Treatment Beverage|Strawberry
11313142|NCT02612090|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
11313143|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
11313144|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
11313145|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
11313146|NCT02612051|Experimental|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
11313147|NCT02612051|Experimental|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
11313148|NCT02612051|Experimental|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
11313149|NCT02612051|Experimental|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11313150|NCT02612051|Experimental|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11313151|NCT02612051|Experimental|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11313152|NCT02612051|Experimental|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
11313153|NCT02612051|Experimental|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.
11313790|NCT02607865|Experimental|Semaglutide 14 mg|
11313159|NCT02611999|No Intervention|Control|Physicians in this Arm received only a paper memo with a list of common imaging tests and procedures.
11313160|NCT02611999|Experimental|Single Price|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
11313161|NCT02611999|Experimental|Paired Inside/Outside Prices|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
11313162|NCT02611986|Experimental|McGrath MAC|tracheal intubation using the McGrath MAC
11313163|NCT02611986|Experimental|Macintosh Laryngoscope|tracheal intubation using the Macintosh Laryngoscope
11313164|NCT02611973|Experimental|HU without aspirin|
11313165|NCT02611973|Active Comparator|HU + aspirin maintenance|
11313166|NCT02611973|Other|HU + AAG|Observational arm
11313167|NCT02611960|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle until progressive disease (PD) or unacceptable toxicity or a maximum of up to 35 cycles.
11313168|NCT02611960|Active Comparator|Standard of Care Chemotherapy|Participants receive capecitabine 1000 mg/m^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle OR gemcitabine 1250 mg/m^2 IV Days 1 and 8 of each 3-week cycle OR docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.
11313169|NCT02611947||Healthy Volunteers|"Inclusion criteria:
~Aged 18 or more.
~Never smoked.
~No respiratory infection in the 4 weeks before the begin of the study.
~No history of pulmonary resection.
~No active malignancy or malignancy of any organ system within the past 5 years."
11313170|NCT02611934|Experimental|Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
11313171|NCT02611934|No Intervention|no-Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
11313172|NCT02611921|Experimental|Crossover Group: Ketamine verses Placebo|"Phase 1: Two ascending doses of intranasal ketamine
~Two week washout
~Phase 2: Two doses of placebo"
11313173|NCT02611921|Experimental|Crossover Group: Placebo verses Ketamine|"Phase 1: Two doses of placebo
~Two week washout
~Phase 2: Two ascending doses of intranasal ketamine"
11313174|NCT02611908|Experimental|ibrutinib +obinutuzumab|
11313175|NCT02611895|Experimental|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
11313176|NCT02611882|Experimental|high-risk prostate cancer pre-prostatectomy (preRP) population|"Patients with high-risk prostate cancer pre-prostatectomy.
~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
11313177|NCT02611882|Experimental|Biochemical Recurrence (BCR) population|"Patients with prostate cancer with biochemical recurrence.
~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
11313178|NCT02611882|Experimental|Castrate Resistant Prostate cancer (CRCP) population|"Patients with castrate resistant prostate cancer.
~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
11313179|NCT02611869|Experimental|Cryoballoon|
11313180|NCT02611869|Active Comparator|RF ablation|
11313181|NCT02611856||monochorial-biamniotic pregnancies|
11313182|NCT02611843|Experimental|Peer-Supported Web CBT|Semi-structured brief sessions conducted weekly for the 12 weeks of study treatment by a certified peer support specialist. Sessions focus on helping participants use the skills they are learning in the Web CBT treatment in their daily lives. Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
11313183|NCT02611843|Experimental|Self-Managed Web CBT|Self-managed Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
11313184|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
11313185|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
11313186|NCT02611830|Experimental|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
11313187|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)
~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
11313188|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)
~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
11313189|NCT02611804|Experimental|Diclofenac Sodium Gel, 3%|Diclofenac Sodium Gel, 3%, applied twice daily for 60 days
11313190|NCT02611804|Active Comparator|Solaraze®|Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days
11313191|NCT02611804|Placebo Comparator|Vehicle of Test Product|Vehicle of Test Product, Gel, applied twice daily for 60 days
11313192|NCT02611791|Experimental|Radiofrequency|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genitalia.
11313791|NCT02607865|Active Comparator|Sitagliptin 100 mg|
11313193|NCT02611791|Sham Comparator|Radiofrenquency Off|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genital which was turned off, but a water-soluble gel was used
11313194|NCT02611778|Experimental|FYB201|FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
11313195|NCT02611778|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
11313196|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
11313197|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
11313198|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
11313199|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
11313200|NCT02611739|Experimental|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
11313201|NCT02611739|Active Comparator|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
11313202|NCT02611726|Active Comparator|Acupuncture treatment|Individualized acupuncture needle insertion according to traditional Chinese and Japanese medicine on top of standard medical care during In-Vitro-Fertilization. Acupuncture needles will be inserted to body surface points following traditional diagnosis (anamnesis, tongue, pulse and abdomen inspection) according to practitioner discretion.
11313203|NCT02611726|No Intervention|Control|Standard medical care during In-Vitro-Fertilization.
11313204|NCT02611713||Arm A: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
11313205|NCT02611713||Arm B: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device
11313206|NCT02611700|Experimental|experimental group|Nimotuzumab+TP(paclitaxel+cisplatin)
11313207|NCT02611700|Placebo Comparator|control group|Placebo + TP(paclitaxel+cisplatin)
11313208|NCT02611687|Experimental|pitolisant|tablet, oral, once a day.
11313209|NCT02611687|Placebo Comparator|placebo|tablet, oral, once a day.
11313210|NCT02611661|Other|Stratum 1: Observe|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~No further treatment just observation"
11313211|NCT02611661|Experimental|Stratum 2: Percutaneous ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
11313212|NCT02611661|Experimental|Stratum 3: SBRT|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
11313213|NCT02611661|Experimental|Stratum 4: SBRT + Percutaneous Ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation
~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
11313214|NCT02611661|No Intervention|Stratum 5: Referral for systemic therapy|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study
~Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
11313215|NCT02611648|No Intervention|standard HLD|Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)
11313216|NCT02611648|Experimental|double HLD|Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)
11313217|NCT02611648|Experimental|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
11313218|NCT02611635||VKA treatment of AF / Cohort 1|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
11313219|NCT02611635||NOAC treatment of AF / Cohort 2|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
11313291|NCT02611141|Other|Patient without a Retromolar Gap|20 patients without a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
11313293|NCT02611102|Experimental|MCT oil + Butter in Coffee|This group will be provided with MCT oil and butter to add to their daily coffee intake.
11313220|NCT02611622|Active Comparator|Arm 1: Control|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one
~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.
~Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey
~Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
11313221|NCT02611622|Experimental|Arm 2: LUMA ENT™|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one
~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.
~Participants in the intervention group will proceed to viewing the LUMA ENT™ videos pertinent to their thyroid condition using either of the two iPADS (the videos should not last longer than 10 minutes)
~Once video viewing is complete, participants will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist, especially as relates to questions that arise as a result of viewing the video
~Subsequently, the participants will proceed to filling out Demographic Survey and Patient Satisfaction Survey"
11313222|NCT02611609|Experimental|Cohort 1|Low dose MultiStem
11313223|NCT02611609|Experimental|Cohort 2|High dose MultiStem
11313224|NCT02611609|Experimental|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
11313225|NCT02611596|Experimental|Ranolazine|Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
11313226|NCT02611596|Placebo Comparator|Placebo|Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
11313227|NCT02611583|Active Comparator|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
11313228|NCT02611583|Placebo Comparator|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
11313229|NCT02611570||LDCT and follow-up|LDCT(1.5 mSV) at enrollment. If subjects with positive result of LDCT, then subjects will be under surgery, resection or followed by every 3-12 months for their possible occurrence of lung cancer.The frequency of follow-up depends on their pathological status and changes of nodules.
11313230|NCT02611557|Other|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
11313231|NCT02611544|Active Comparator|Acceptance and Commitment Therapy|6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
11313232|NCT02611544|Active Comparator|Survivorship Education|6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
11313233|NCT02611544|Active Comparator|Enhanced Usual Care|"Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled Facing Forward: Life After Cancer Treatment."
11313234|NCT02611531|Experimental|Video Module Education (VME)|The RE will provide participants with a tablet device and will demonstrate how to access VME and complete the pre/post e-learning assessments. The RE will provide technical support but will neither participate directly in the education nor help with the self-assessments. The participants will first complete the pre-assessment e-learning tool on the tablet. They will then watch the video instruction that will provide a complete demonstration with verbal instructions on correct inhaler technique. Next the participants will complete the post-assessment e-learning tool. Based on participants' performance, they will be directed to further tailored video-instruction. The cycle of self-assessment and video instruction will continue until sufficient mastery has been achieved.
11313235|NCT02611531|Active Comparator|Teach-To-Goal (TTG)|Participants assigned to the TTG condition will be provided with an intensive, iterative education and evaluation strategy that consists of the following steps.
11313236|NCT02611518|Experimental|Panel 1|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 17.
11313237|NCT02611518|Experimental|Panel 2|Participant will be administered a single oral dose of metformin 500-mg on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 16.
11313238|NCT02611505|Experimental|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram [mg] of esketamine base per 100 microliter [mcl]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
11313239|NCT02611505|Experimental|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
11313240|NCT02611505|Experimental|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
11313241|NCT02611492|Active Comparator|Intensive Arm (A)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
~+ Post-SCT Maintenance"
11313242|NCT02611492|Experimental|Light Arm (B)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)
~+ Post-SCT Maintenance"
11313243|NCT02611466|Experimental|ASP7962|Participants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
11313244|NCT02611466|Active Comparator|Naproxen|Participants receive 500 mg of naproxen orally twice daily for 4 weeks.
11313245|NCT02611466|Placebo Comparator|Placebo|Participants receive placebo orally twice daily for a period of 4 weeks.
11313246|NCT02611453|Experimental|Single arm|"All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. Air contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium."
11313247|NCT02611440|Experimental|Pharmacist Intervention|It will be a semi -structured interviews with patient and pharmacist over various time after the stroke (at Month0, M3, M6, M9) combined with patient's therapeutic follow-up from various healthcare professionals.
11313248|NCT02611440|No Intervention|Control|No pharmacist intervention planned.
11313249|NCT02611427|Active Comparator|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
11313250|NCT02611427|Active Comparator|Education|Booklet about physical activity
11313251|NCT02611414|Experimental|anodal tDCS|TDCS will be delivered with two saline-soaked sponge electrodes. The main electrode to anodal stimulation will be placed over the motor cortex, M1. The second electrode is neutral and will be placed on the skin overlying the supraorbital region The current will be delivered at the intensity of 2mA for 20 minutes. The procedure will be repeated at five consecutive days.
11313252|NCT02611414|Sham Comparator|Sham tDCS|Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
11313253|NCT02611401|Experimental|Mindulness Based Intervention|intervention with group-based Mindfulness Based Intervention
11313254|NCT02611401|Active Comparator|Active Control|intervention with group-based Psychoeducation and Relaxation
11313255|NCT02611388|Experimental|2/10HZ TEAS pretreatment|Patients were given 30min of 2/10HZ TEAS before anesthesia
11313256|NCT02611388|Experimental|10/50HZ TEAS pretreatment|Patients were given 30min of 10/50HZ TEAS before anesthesia
11313257|NCT02611388|Sham Comparator|fake stimulation|Patients were only attached electrodes without electric current
11313258|NCT02611375|Experimental|tDCS + FTP group|This group of individuals with tetraplegia will receive transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1). Stimulation at 2mA will be applied for 20 minutes while subjects complete a total of 1 hour of functional task practice (FTP) per session. (Only 20 minutes of functional task practice be be performed with stimulation on). 3 sessions will be completed per week for 4 weeks.
11313259|NCT02611375|Active Comparator|PNSS + FTP group|This group of individuals with tetraplegia will receive peripheral nerve somatosensory stimulation (PNSS) to the median nerve of the primary hand being trained. Stimulation will be set to elicit a sensory - not motor - response. Stimulation will be performed concurrently with the entire functional task practice (FTP) session. 3 sessions will be completed per week for 4 weeks.
11313260|NCT02611375|Active Comparator|sham tDCS + FTP group|This group of individuals with tetraplegia will receive sham transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1) alongside functional task practice. Stimulation will be briefly turned on at the beginning of FTP and again after 20 minutes of practice in order to create a sham effect and maintain blinding of the participants. 3 sessions will be completed per week for 4 weeks.
11313261|NCT02611362|Experimental|Intervention|"The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
11313262|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
11313263|NCT02611336|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
11313264|NCT02611323|Experimental|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
11313265|NCT02611323|Experimental|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
11313266|NCT02611323|Experimental|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
11313292|NCT02611128||Peripubertal girls|Peripubertal girls with varying androgen concentrations will have careful phenotype/genotype assessment, primarily to assess the relationship between urinary exosomal DENND1A.V2 and serum free testosterone concentrations.
11314456|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
11313267|NCT02611323|Experimental|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
11313268|NCT02611310||Participants with HER2-positive unresectable LA/mBC|
11313269|NCT02611297|Other|Transbronchial lung biopsy with cryoprobe|
11313270|NCT02611284|Experimental|Treatment Cohort (LISA)|All preterm infants born at < 32 WG between October 2013 and November 2014 who met inclusion criteria were managed by the new LISA technique.
11313271|NCT02611284|Other|Historical Cohort (INSURE)|The control group was collected from the period immediately before the study's initiation (from Jun 2012 to September 2013). This cohort was comprised of preterm infants of less than 32 WG who met the inclusion criteria.
11313272|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
11313273|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
11313274|NCT02611258|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
11313275|NCT02611245|Experimental|Indocyanine green|This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.
11313276|NCT02611232|Active Comparator|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
11313277|NCT02611232|Placebo Comparator|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
11313278|NCT02611219|Experimental|Arm 1: Pediatric patients|"Patients will wear a Fitbit Flex during hospitalization
~Completion of Demographic Data Form at baseline, discharge from hospital, and at the six week clinic visit
~Assist in recording time out of bed using the SCT Daily Activity Log
~Fill out (some with help of parents) applicable questionnaires: Child Health Ratings Inventories-General Health Module (5-12 years), General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years) at baseline, discharge from hospital, and at six week clinic visit
~Patients will be assessed using standard physical therapy assessment tools to determine functioning, muscle strength, endurance, and mobility: The Functional Independence Measure for Children and Manual Muscle Testing is done weekly, discharge from hospital, and at six week clinic visit. The 3-Minute Step Test is done at admission, discharge from hospital, and at six week clinic visit."
11313279|NCT02611219|Experimental|Arm 2: Parents of pediatric patients|"Parents will be considered participants as they will be completing study questionnaires.
~Completion of Demographic Data Form at baseline
~Assist in recording time out of bed using the SCT Daily Activity Log
~Fill out applicable questionnaires: General Health Module-Baseline Parent Report -Adolescent (13-18 Years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), and General Health Module Follow Up Parent Report-School Age (5-12 years), HSCT Module-Follow UP Parent Report School Age (5-12 years), HSCT Module-Follow Up Parent Report Adolescent (13-18 years), HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years) at baseline, discharge from hospital, and at six week clinic visit.
~Assist child with Child Health Ratings Inventories-General Health Module (5-12 years) at baseline, discharge at hospital, and at six week clinic visit"
11313280|NCT02611206|Experimental|Open Label rTMS|All participants who qualify will undergo 6 weeks of open-label rTMS.
11313281|NCT02611193|Experimental|Manipulative treatment|Manipulative Treatment
11313282|NCT02611193|Sham Comparator|Simulated manipulative treatment|Simulated manipulative treatment
11313283|NCT02611180||Arm 1: Acute skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).
~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.
~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
11313284|NCT02611180||Arm 2: Chronic skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).
~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.
~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
11313285|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
11313286|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
11313287|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
11313288|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
11313289|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
11313290|NCT02611141|Other|Patient with Retromolar Gap|20 patients with a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
11313294|NCT02611102|Placebo Comparator|Low calorie coffee|This group will continue to drink their normal daily coffee with < 50kcal of creamer and/or sweetener.
11313295|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
11313296|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
11313297|NCT02611076|Experimental|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
11313298|NCT02611076|Active Comparator|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
11313299|NCT02611063|Experimental|fostamatinib|Subjects will receive fostamatinib 100 mg qd, 150 mg qd, or 100 mg bid with dosage determined by the modified continual reassessment method. The treatment period begins at baseline 90 days after transplant and continues for up to 1 year after transplant. In patients with steroid-refractory cGVHD who are also included on this study, these subjects also receive fostamatinib 100mg qd, 150mg qd, or 100mg bid dosage determined by the modified continual reassessment method.
11313300|NCT02611050|Experimental|Option Grid|Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
11313301|NCT02611050|Other|Usual Care|Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.
11313302|NCT02611037|Experimental|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2), methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).
~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.
~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
11313303|NCT02611024|Experimental|PM01183 Escalation Group|"PM01183 1.0 mg/m^2 D1 60 min (-5/+20 min) i.v. infusion q3wk
~Irinotecan 75 mg/m^2 D1-8 90 min (-5/+30 min) i.v. infusion q3wk"
11313304|NCT02611024|Experimental|Irinotecan Escalation Group|"PM01183 3.0 mg/m^2 D1 60 min (-5/+20 min) i.v. infusion q3wk
~Irinotecan 15 mg/m^2 D1-8 90 min (-5/+30 min) i.v. infusion q3wk"
11313305|NCT02611011||Women|Women seeking health services will perform the Congo Red Dot test (GV-005) individually by following the the test instructions
11313306|NCT02610985|Active Comparator|2-Dimensional laparoscopic hysterectomy|traditional 2-D laparoscopy
11313307|NCT02610985|Experimental|3-Dimensional laparoscopic hysterectomy|experimental 3-D laparoscopy
11313308|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
11313309|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
11313310|NCT02610959|Experimental|Intervention group|Intervention with cod 200 grams two times the week for four months.
11313311|NCT02610959|Experimental|Control group|Control group which will continue to eat their habitual diet.
11313312|NCT02610946|Placebo Comparator|Paper-based|Use of paper-based calenders, reminders, medication list, and blood pressure, fluid intake tracking methods in adolescent renal transplant care
11313313|NCT02610946|Experimental|Electronic application|Use of electronic apps (iphone or i-Pad mini) to determine whether it can improve compliance with transplant care and readiness to transition to adult care.
11313314|NCT02610933|No Intervention|Vitamin K antagonist|Vitamin K antagonist treatment targeting an international normalized ratio of 2 to 3 for 18 months
11313315|NCT02610933|Active Comparator|rivaroxaban|Rivaroxaban 10 mg tablet by mouth once daily for 18 months
11313316|NCT02610933|Active Comparator|rivaroxaban and vitamin K2|Rivaroxaban 10 mg tablet by mouth once daily and MK-7 2000 microgram tablet by mouth thrice weekly for 18 months
11313317|NCT02610920|Experimental|Iron-tracer Injection and Biopsy|Single injection of 30mg of iron sucrose followed by axillary ultrasound-guided biopsy of lymph node within 2 hours.
11313318|NCT02610907|Experimental|Cohort 01a|"This is a sub-study testing three patches consisting of an adhesive patch and a sleeve. The sleeve can contain one of three solutions:
~Buffer Own output Simulated output (digestive enzymes)
~All subjects will test the three solutions at the same time, hence the three patches with different solutions will be placed on the peristomal skin simultanously."
11313319|NCT02610894|Experimental|mHealth application|Participants will be provided an iPad Mini tablet computer loaded with an mHealth application (PoCAH) to provide enhanced post-operative pain care management. The app will utilize algorithms tailored to the patient's needs and symptoms in an attempt to reduce poor outcomes related to post-operative pain management.
11313320|NCT02610894|Active Comparator|Control Group|Participants will be provided an iPad Mini tablet computer loaded with a PDF of the As usual standard discharge and care instructions for post-operative pain care management.
11313432|NCT02610062|Experimental|AGS67E 0.6 mg/kg Schedule 2|Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
11313321|NCT02610881|Experimental|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
11313322|NCT02610881|Experimental|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
11313323|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
11313324|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
11313325|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
11313326|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
11313327|NCT02610842|Experimental|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
11313328|NCT02610829|Experimental|Gamma Tocopherol|Subjects will ingest 1400 mg gamma tocopherol, orally administered in 3 doses separated by 12 hours.
11313329|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
11313330|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
11313331|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
11313332|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
11313333|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
11313334|NCT02610790||Connected bracelet|Patients with a colorectal surgery planned will be included. Fifteen days before surgery, patients will have a connected bracelet permitting to quantify the number of steps and distance achieved each day before surgery.
11313335|NCT02610777|Active Comparator|Azacitidine|Azacitidine 75 milligram per square meter (mg/m^2), intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles.
11313336|NCT02610777|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 mg/m^2, intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+ or - 10) infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles.
11313337|NCT02610764|Experimental|Experimental diagnostic test|"Evaluation and enumeration of circulating Tumor cells from the blood with two different CTC-detection platforms: one established test (CellSearch) and one experimental test (ScreenCell).
~Control diagnostic test: CT-Scan of the Chest and the Abdomen, Endoscopy and Endosonography, Clinical response and histo pathologic response. (% Of vital tumor Cells in the histologic specimen)."
11313338|NCT02610751||Smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
11313339|NCT02610751||Non-smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
11313340|NCT02610738|Experimental|Junior KICk-OFF education programme|Participants will attend an age appropriate self management programme (Junior KICk-OFF) designed to improve their knowledge and understanding of type 1 diabetes
11313341|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
11313342|NCT02610712|Experimental|TRD patients|Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
11313343|NCT02610699|Active Comparator|Smartphone otoscope/Conventional otoscope|Participating clinicians will use a smartphone otoscope for one month followed by a conventional otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
11313344|NCT02610699|Active Comparator|Conventional otoscope/Smartphone otoscope|Participating clinicians will use a conventional otoscope for one month followed by a smartphone otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
11313345|NCT02610686|Other|Chloroquine|Single treatment arm
11313346|NCT02610647|Other|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.
~Intervention: Tapping test"
11313347|NCT02610647|Experimental|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Tapping test"
11313348|NCT02610647|Experimental|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Blinding mask
~Intervention: Tapping test"
11313349|NCT02610647|Experimental|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Anti-noise helmet
~Intervention: Tapping test"
11313350|NCT02610647|Experimental|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.
~Intervention: Wrist anesthesia
~Intervention: Blinding mask
~Intervention: Anti-noise helmet
~Intervention: Tapping test"
11313351|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
11313352|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
11313353|NCT02610621|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and chemotherapy.
11313354|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
11313355|NCT02610595|Experimental|experimental group|Jianpixiaozhong particles and Wuse Dietotherapy
11313356|NCT02610582|Experimental|Single Arm|"dose escalation rAAVhCNGA3
~low dose: ≤ 1x10e10 vgp (n=3)
~intermediate dose: ≤ 5x10e10 vgp (n=3)
~high dose: ≤ 1x10e11 vgp (n=3)"
11313357|NCT02610569|Active Comparator|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
11313358|NCT02610569|Experimental|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
11313359|NCT02610556|Experimental|TP plus IMRT|Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
11313360|NCT02610556|Active Comparator|DDP plus IMRT|Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
11313361|NCT02610543|Experimental|UCB5857|UCB5857 once daily for 12 weeks
11313362|NCT02610543|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
11313363|NCT02610530||Non-Surgery|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
11313364|NCT02610530||Surgery-A|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
11313365|NCT02610530||Surgery-B|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
11313366|NCT02610517|Other|Provider Training|Training providers to offer alcohol pharmacotherapy to at-risk drinkers interested in quitting or reducing their drinking as part of overall HIV care could be an important strategy to reduce hazardous alcohol use in this medically-ill population.
11313367|NCT02610517|Other|Patient Intervention|Determine the effectiveness of a computer-delivered brief intervention (CBI) for reducing hazardous drinking in the HIV clinical care setting at two intervention clinics: University of Alabama at Birmingham (UAB) and the University of Washington (UW).
11313368|NCT02610504|Experimental|Durolane 3ml|Single intra-articular injection into shoulder
11313369|NCT02610491|Placebo Comparator|Placebo|Cellulose
11313370|NCT02610491|Active Comparator|Hesperidin|Citrus peel extract
11313371|NCT02610465||1|Computed Tomography (CT) images
11313372|NCT02610452|Experimental|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.
~Intervention: Clown therapy"
11313373|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
11313374|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
11313375|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
11313376|NCT02610400|Experimental|RACD without RAVC|In this arm, subjects will receive RACD without the addition of RAVC.
11313377|NCT02610400|Experimental|RACD+RAVC|"In this arm, subjects will receive both:
~(i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)"
11313378|NCT02610400|Experimental|rfMDA without RAVC|In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.
11313379|NCT02610400|Experimental|rfMDA+RAVC|"In this arm, subjects will receive both:
~(i) reactive focal mass drug administration (rfMDA) and (ii) RAVC."
11313380|NCT02610387|Active Comparator|Arm 1:tDCS|Transcranial direct current stimulation (tDCS) Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days
11313381|NCT02610387|Sham Comparator|Arm 2: Sham tDCS|Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days
11313382|NCT02610374|Other|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
11313383|NCT02610374|Other|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
11313384|NCT02610374|Other|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
11313385|NCT02610361|Experimental|BGB-283|
11313386|NCT02610348|Experimental|Group A|Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
11313387|NCT02610348|Experimental|Group B|Toddlers vaccinated with Infanrix hexa® in study A3L12
11313388|NCT02610335|Active Comparator|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
11313389|NCT02610335|Other|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
11313390|NCT02610322|Experimental|Whole soy group|Whole soy replacement diet: to incorporate 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods.
11313391|NCT02610322|Placebo Comparator|Control group|Usual diet: to receive a conventional lifestyle education on MetS.
11313392|NCT02610309|Experimental|Family-Based Crisis Intervention|The Family-Based Crisis Intervention (FBCI) is a single-session intervention that takes place in the Emergency Department. Adolescents randomized to the experimental condition received a standard psychiatric evaluation followed by the experimental intervention. FBCI was administered by licensed psychiatric social workers who were trained in the intervention. The research clinician provided FBCI to the suicidal adolescent and his/her parent(s)/guardian(s) in a 60-90 minute session in which she helped the adolescent and family develop a joint crisis narrative of the problem and taught them cognitive-behavioral skill-building, therapeutic readiness, psycho-education about depression, and safety planning.
11313393|NCT02610309|No Intervention|Treatment As Usual|Treatment as usual included an emergency psychiatry evaluation (standard care).
11313394|NCT02610296|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
11313395|NCT02610296|Placebo Comparator|Placebo|isotonic saline
11313396|NCT02610283|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
11313397|NCT02610283|Placebo Comparator|Placebo|isotonic saline
11313398|NCT02610270|Experimental|2 Gums|Athletes that continued their usual training and diet, who took 2 gums of omega 3 (DHA 760 mg) during the experimental period.
11313399|NCT02610270|Experimental|3 Gums|Athletes that continued their usual training and diet, who took 3 gums of omega 3 (DHA 1140 mg) during the experimental period.
11313400|NCT02610270|No Intervention|Control|Athletes and coaches that continued their usual training and diet, but did not take any supplements during the experimental period.
11313401|NCT02610257|Active Comparator|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
11313402|NCT02610257|Active Comparator|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
11313403|NCT02610257|Active Comparator|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
11313404|NCT02610257|Active Comparator|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
11313405|NCT02610257|No Intervention|No Vibration|
11313406|NCT02610244|No Intervention|Treatment As Usual|Standard treatment as usual as directed by the physician.
11313407|NCT02610244|Experimental|Modified Cogmed Training|10 weeks of computerized training (3x weekly for 35-minutes each session) that targets thinking skills that are often impaired in individuals diagnosed with ADHD.
11313408|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
11313409|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
11313410|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
11313411|NCT02610205||Caring touch interventions|The study was conducted as a mixed-methods design. A recruitment of potential study participants was made up from a list of incoming patients arriving at the emergency department following an MVA, and who upon medical examinations were given an injury severity score between 0-3 and subsequently discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating of 0 indicates no physical injury; 1-3 represents minor physical injuries. The patients were informed about the study by mail during the week after the MVA, and those interested in participating in the caring touch intervention were asked to contact the investigator and subsequently completed a written informed consent form during the first encounter with the therapist.
11313412|NCT02610179|Active Comparator|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
11313413|NCT02610179|Experimental|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
11313414|NCT02610166|Experimental|Game|Access to the game.
11313415|NCT02610166|Active Comparator|Usual Care|Control group.
11313416|NCT02610153||Cohort 1|Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units
11313417|NCT02610140|Experimental|BAY94-9343|Drug Anetumab ravtansine given Intravenously (IV)
11313418|NCT02610140|Active Comparator|Vinorelbine|Drug Vinorelbine given Intravenously
11313419|NCT02610127||OBIZUR - Prospective Participants|Participants enrolled and treated with Obizur after the prospective study start date
11313420|NCT02610127||OBIZUR - Retrospective Participants|Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
11313421|NCT02610114|Experimental|Z-Score and computer algorithm|
11313422|NCT02610114|Active Comparator|Z-Score|
11313423|NCT02610101|Active Comparator|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
11313424|NCT02610101|Active Comparator|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
11313425|NCT02610101|Active Comparator|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
11313426|NCT02610088|Active Comparator|Dapagliflozin|Dapagliflozin will be started in patient with type 2 diabetes mellitus
11313427|NCT02610088|Active Comparator|Gliclazide|Gliclazide will be started in patient with type 2 diabetes mellitus
11313428|NCT02610075|Experimental|AZD1775|This is a single-arm study in which all patients will receive AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
11313429|NCT02610062|Experimental|AGS67E 1.2 mg/kg Schedule 1|Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
11313430|NCT02610062|Experimental|AGS67E 1.8 mg/kg Schedule 1|Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
11313431|NCT02610062|Experimental|AGS67E 2.4 mg/kg Schedule 1|Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
11313433|NCT02610062|Experimental|AGS67E 0.9 mg/kg Schedule 2|Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
11313434|NCT02610049|Active Comparator|Control|Subjects will receive 8 sessions of Cognitive Processing Therapy.
11313435|NCT02610049|Experimental|Experimental|Subjects will receive 8 sessions of CPT + Art Therapy 8 sessions of individual therapy.
11313436|NCT02610049|Experimental|Experimental 2|Subject to receive 8 sessions of individual therapy for Art + CPT Cognitive Processing Therapy intervention pre-specified to be administered separately.
11313437|NCT02610036||neuropathic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
11313438|NCT02610036||neuroischemic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
11313439|NCT02610023||Observational (Willett FFQ, Fred Hutchinson FFQ, CCAT)|After consenting to participate in this study, participants will visit the Clinical Research Center (CRC) on 3 occasions. One of the three FFQ's will be completed at each visit and there will be 4 to 6 weeks between visits. Participants will also complete a blood draw and assessment of skin carotenoids at this CRC visit. Prior to each visit, participants will complete a 3-day diet record, a daily sun exposure diary, and a 3-day activity record.
11313440|NCT02610010|Experimental|IMRT alone|Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy
11313441|NCT02610010|Active Comparator|IMRT plus concurrent chemotherapy|Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy
11313442|NCT02609997|Experimental|Single-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
11313443|NCT02609997|Experimental|Three-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a three-piece IOL
11313444|NCT02609984|Experimental|CMB305 (sequentially administered LV305 and G305)+Atezolizumab|Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
11313445|NCT02609984|Active Comparator|Atezolizumab|Participants received 1200 mg/day atezolizumab by IV infusion Q3W for up to approximately 2 years.
11313446|NCT02609971|Experimental|Vibration group|The vibration group (Vibration at 50 Hz) will hold an exercise protocol on the vibration platform (model Power Plate® pro5 ™), which is to stay on on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
11313447|NCT02609971|No Intervention|Control group|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
11313448|NCT02609958|Experimental|Treatment Arm A|Varlitinib (ASLAN001) tablets
11313449|NCT02609945|Experimental|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.
~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
11313450|NCT02609932|Other|SD or SS|In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
11313451|NCT02609906|Other|PhilosTM with augmentation (Depuy-Synthes)|The intervention group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)
11313452|NCT02609906|Other|MultiLoc®-Nail (Depuy-Synthes)|The comparison group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
11313453|NCT02609893|Active Comparator|Modified Directly Observed Therapy|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks
11313454|NCT02609893|Active Comparator|Unobserved Dosing|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks
11313455|NCT02609880|Experimental|Cognitive Behavioral Therapy|This group will receive Cognitive Behavioral Therapy to optimize sleep, pain, and mood in women with gynecologic cancers. The therapy will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
11313456|NCT02609880|Placebo Comparator|Psychoeducation|This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
11313457|NCT02609867|Experimental|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
11313458|NCT02609854|Experimental|Sham Sustained Acoustic Medicine Device|Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
11313459|NCT02609854|Experimental|3 MHz Sustained Acoustic Medicine Device|3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
11313460|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
11313461|NCT02609828|Experimental|Arm 1|Tanezumab 20 mg subcutaneously
11313462|NCT02609828|Placebo Comparator|Arm 2|Placebo matched to active treatment subcutaneously
11313463|NCT02609815|Experimental|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
11313464|NCT02609815|Active Comparator|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
11313465|NCT02609802|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
11313466|NCT02609802|Experimental|Desflurane|Anesthesia was maintained with desflurane.
11313467|NCT02609789|Experimental|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
11313468|NCT02609789|Experimental|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
11313469|NCT02609789|Experimental|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
11313470|NCT02609789|Experimental|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
11313471|NCT02609789|Experimental|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
11313472|NCT02609789|Experimental|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
11313473|NCT02609789|Experimental|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
11313474|NCT02609776|Experimental|Part 1:JNJ-61186372 Monotherapy+Combination Dose Escalations|The first cohort of participants will receive intravenous (IV) infusions of JNJ-61186372 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of JNJ-61186372 at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of JNJ-61186372 once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and JNJ-61186372 on Cycle 1 Day 1 (C1D1) prior to initiation of JNJ-61186372 (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day JNJ-61186372 treatment cycle. In Chemotherapy Combination Cohort, participants will receive JNJ-61186372, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
11313475|NCT02609776|Experimental|Part 2:JNJ-61186372 Monotherapy+Combination Dose Expansion|Participants will receive IV infusion of JNJ-61186372 as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety, tolerability, pharmacokinetic, and to assess preliminary efficacy in monotherapy and combination therapy cohorts.
11313476|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
11313477|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
11313478|NCT02609737|Experimental|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging & therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
11313479|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
11313480|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
11313481|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
11313482|NCT02609698|Experimental|Coroflex ISAR 3 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 3 months
11313483|NCT02609698|Active Comparator|Coroflex ISAR 6 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 6 months
11313484|NCT02609685|Other|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
11313485|NCT02609685|No Intervention|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
11313527|NCT02609438|Active Comparator|Long breaks|Participants instructed to take two 15-minute activity breaks during each workday
11313528|NCT02609425|Other|STRATAFIX|Anastomosis of esophagus to stomach
11313529|NCT02609412|Experimental|Static compression of LMTRP|static compression of most sensitive LMTRP with the foam roll for 90 seconds
11313486|NCT02609672|Experimental|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
11313487|NCT02609672|Other|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
11313488|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
11313489|NCT02609646||linezolid|patients treated with linezolid
11313490|NCT02609646||meropenem|patients treated with meropenem
11313491|NCT02609646||piperacillin/tazobactam|patients treated with piperacillin/tazobactam
11313492|NCT02609646||vancomycin|patients treated with vancomycin
11313493|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
11313494|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
11313495|NCT02609620|Experimental|Treatment|In the treatment group: The LunGuard Peristaltic Feeding Tube (PFT) will be positioned in the ICU and positioning will be verified by X-ray. Nutritional formula will be fed into the stomach via the feeding lumen of the PFT
11313496|NCT02609620|Active Comparator|Control|Patients in the control group will have a Convatec Levin Duodenal Tube inserted according to standard procedure, which is considered the gold standard.
11313497|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
11313498|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
11313499|NCT02609594|Active Comparator|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
11313500|NCT02609594|Experimental|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
11313501|NCT02609594|Experimental|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
11313502|NCT02609568||Control Group 1|Children with non-trauma complaints
11313503|NCT02609568||Control Group 2|Children with non TBI and musculoskeletal trauma
11313504|NCT02609568||Cases|Children admitted to hospital with moderate/severe isolatedTBI
11313505|NCT02609555|Experimental|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
11313506|NCT02609542||STOL group|"STOL children will be recruited in the neuropediatric unit at the GHICL in Lille. Children will be followed and we will determine if capacities of verbal memory of the children presenting STOL diagnosed at an early stage of their development (before 6 years) are predictive of the evolution of the disorder according to their cognitive profile and more specifically, their language profile as well as their tests performances. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
~Patients with a persistent STOL will be identified at the end of the follow up."
11313507|NCT02609542||Control group|Children with no language development disorder willing to participate in the study will be recruited at school. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
11313508|NCT02609529|Experimental|SBI|Entergam 10 g/day PO
11313509|NCT02609529|Placebo Comparator|Placebo|Placebo 10 g/day PO
11313510|NCT02609516||Healthy|Patients without any of the pre-specified chronic diseases
11313511|NCT02609516||Multimorbid|Patients having any two or more of the pre-specified chronic diseases
11313512|NCT02609503|Experimental|Open label|Pembrolizumab
11313513|NCT02609503|Other|Radiation|Intensity Modulated Radiation Therapy (IMRT)
11313514|NCT02609490|Experimental|Treatment-Azilsartan|Azilsartan tabelts
11313515|NCT02609490|Active Comparator|Positive Control-olmesartan medoxomil|olmesartan medoxomil tablets
11313516|NCT02609477|Experimental|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
11313517|NCT02609477|Experimental|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
11313518|NCT02609477|Experimental|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
11313519|NCT02609477|Active Comparator|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
11313520|NCT02609477|Active Comparator|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
11313521|NCT02609477|Placebo Comparator|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
11313522|NCT02609464|Active Comparator|Inturrupted Knotte Sutures|
11313523|NCT02609464|Active Comparator|Barbed Sutures|
11313524|NCT02609451|Experimental|2 weeks|Ileostomy closure after 2 weeks
11313525|NCT02609451|Experimental|12 weeks|Ileostomy closure after 12 weeks
11313526|NCT02609438|Active Comparator|Short breaks|Participants instructed to stand/move for 1-2 minutes every half hour throughout the workday
11313530|NCT02609412|Experimental|Dynamic self-myofascial release of calf|dynamic self-myofascial release rolling back and forth on the entire calf for 90 seconds with the foam roll
11313531|NCT02609412|Placebo Comparator|Placebo laser acupuncture of LMTRP|placebo laser acupuncture applied on most sensitive LMTRP of the calf, light and acoustic sounds provided, but laser remains switched off, 90 seconds
11313532|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
11313533|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
11313534|NCT02609386|Experimental|Regimen 1|IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.
11313535|NCT02609386|Active Comparator|Regimen 2|Regimen 1 but without IRX-2
11313536|NCT02609373|Other|Sleep intervention|Sleep intervention
11313537|NCT02609360|Active Comparator|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
11313538|NCT02609360|Active Comparator|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
11313539|NCT02609360|Experimental|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
11313540|NCT02609347|Experimental|Manual Therapy Group|Participants in the manual therapy group will receive 3 treatment sessions of joint mobilization based on the physical therapist's clinical decision making.
11313541|NCT02609347|Sham Comparator|Control Group|Participants in the control group will receive a sham manual therapy treatment consisting of soft tissue mobilization and Grade I mobilizations at the proximal tib/fib joint.
11313542|NCT02609334|Placebo Comparator|Placebo|Matching placebo tables are given as a single dose
11313543|NCT02609334|Active Comparator|CRD007 Low dose|"Low dose of CRD007 (pemirolast sodium) given as a single dose"
11313544|NCT02609334|Active Comparator|CRD007 High dose|"High dose CRD007 (pemirolast sodium) given as a single dose"
11313545|NCT02609321|Experimental|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
11313546|NCT02609321|Active Comparator|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
11313547|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
11313548|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
11313549|NCT02609295|Placebo Comparator|Placebo|Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily
11313550|NCT02609295|Experimental|ALA group|Individuals who consumed 1.2 g (two capsules) of perilla oil daily
11313551|NCT02609282|Experimental|Prompt group|Following an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered by Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing.
11313552|NCT02609282|No Intervention|Control group|The control group will receive the same education session as the prompt group, but will receive no prompts on their PC.
11313553|NCT02609269||Decipher GRID Patients|Patients who have been tested with any of the Decipher suite of genomic solutions.
11313554|NCT02609256|Experimental|Stereotactic infarct tissue aspiration|Patients receive the stereotactic infarct tissue aspiration 24-48 hours after cerebral infarction beside medical therapy.
11313555|NCT02609256|Sham Comparator|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc;
11313556|NCT02609243|Active Comparator|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
11313557|NCT02609243|Active Comparator|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
11313558|NCT02609243|Active Comparator|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
11313559|NCT02609243|Active Comparator|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
11366168|NCT02260024|Experimental|Pramipexole SR C2B in the fasted state|
11313560|NCT02609230|Experimental|A|For the first arm (A), dose escalation will use the following single patient dose-escalation cohorts based on 'Design 4' proposed by Simon and colleagues: 125, 250, and 500 mg. every 3 weeks.
11313561|NCT02609230|Experimental|B|Following completion of Arm A dose escalation, subsequent cohorts will be tested in a minimum of 3 patients, the Arm B dose cohort will consist of dose levels administered every week (planned dosing of 250, 375, 500 and 625 mg).
11313562|NCT02609217||Multiparous|12 multiparous women and their partners, planned to undergo elective term cesarean section.
11313563|NCT02609217||Nulliparous|12 nulliparous women and their partners, planned to undergo elective term cesarean section.
11313564|NCT02609204|Experimental|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
11313565|NCT02609191|Experimental|The study population: first 30 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body exam using the Discovery A
~Intervention: First whole body exam using the Stratos DR
~Intervention: Second whole body exam using the Stratos DR"
11313566|NCT02609191|Experimental|The study population: last 20 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.
~Intervention: Whole body exam using the Discovery A
~Intervention: First whole body exam using the Stratos DR"
11313567|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
11313568|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
11313569|NCT02609165|Active Comparator|study group|rhNGF 180 µg/ml eye drops solution
11313570|NCT02609165|Placebo Comparator|control group|vehicle eye drops solution
11313571|NCT02609152|Experimental|Continuous perfusion of esmolol|Intervention: Drug: Continuous perfusion of esmolol
11313572|NCT02609152|Placebo Comparator|Continuous perfusion of saline|Intervention: Continuous perfusion of saline
11313573|NCT02609139|Experimental|<=400mg Modified Release Tablets, Fasted|Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
11313574|NCT02609139|Experimental|100mg Modified Release Tablets, Fasted|100 mg PF-06650833 modified release tablets administered under fasted conditions
11313575|NCT02609139|Experimental|20mg Modified Release Tablets, Fasted|20 mg PF-06650833 modified release tablets administered under fasted conditions
11313576|NCT02609139|Experimental|<= 400mg Modified Release Tablets, Fed|Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
11313577|NCT02609139|Experimental|100mg Modifed Release Tablets, Fed|100 mg PF-06650833 modified release tablets administered with high fat meal food intake
11313578|NCT02609139|Experimental|20mg Modified Release Tablets, Fed|20 mg PF-06650833 modified release tablets administered with high fat meal food intake
11313579|NCT02609126|Experimental|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
11313580|NCT02609126|Placebo Comparator|Vehicle|4 mL carrier fluid
11313581|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
11313582|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
11313583|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
11313584|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
11313585|NCT02609087|Experimental|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
11313586|NCT02609087|Experimental|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
11313587|NCT02609074|Experimental|CPC/rhBMP-2|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.
~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC/rhBMP-2 microffolds (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
11313588|NCT02609074|Active Comparator|CPC|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.
~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC paste (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
11313589|NCT02609061|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
11313590|NCT02609061|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
11313591|NCT02609061|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating furcation defect
11313592|NCT02609048|Placebo Comparator|Placebo Dose|Placebo Capsule Two Capsules Daily
11313594|NCT02609048|Experimental|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
11313595|NCT02609035|Experimental|Intervention|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.
11313596|NCT02609035|No Intervention|Control|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.
11313597|NCT02609022|Experimental|CV-MG01|The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
11313598|NCT02609022|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
11313599|NCT02609009|Experimental|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
11313600|NCT02609009|Other|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
11313601|NCT02608996|Active Comparator|Subcutaneous BNP|Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
11313602|NCT02608996|Placebo Comparator|Subcutaneous placebo|Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
11313603|NCT02608983|Experimental|Treatment 1|
11313604|NCT02608983|Experimental|Treatment 2|
11313605|NCT02608983|Placebo Comparator|Treatment 3|
11313606|NCT02608970|Experimental|BMS-986177|BMS-986177 specified dose on specified days
11313607|NCT02608970|Other|Placebo|Placebo specified dose on specified days
11313608|NCT02608957|Experimental|Latella Knee Implant System|
11313609|NCT02608944|Experimental|MRI perfusion vs. PET Imaging perfusion|Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging
11313610|NCT02608931|Experimental|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
11313611|NCT02608931|Placebo Comparator|Placebo Capsules|placebo
11313612|NCT02608918|Experimental|BMS-955176|BMS-955176 specified dose on specified days
11313613|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
11313614|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
11313615|NCT02608892|Experimental|Intervention|BSweet2Babies video
11313616|NCT02608892|No Intervention|Control|Usual care
11313617|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
11313618|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
11313619|NCT02608866|Experimental|SF-SSRS|Single-Fraction (SF) Stereotactic Spine Radiosurgery
11313620|NCT02608866|Experimental|MF-SSRS|Multiple-Fraction (MF) Stereotactic Spine Radiosurgery
11313621|NCT02608853||Liraglutide-like Cohort|
11313622|NCT02608853||LEADER™-like Cohort|
11313623|NCT02608840|Experimental|MCI auditory stimulation|MCI patients receiving auditory stimulation during sleep (crossover arm 1)
11313624|NCT02608840|Sham Comparator|MCI sham stimulation|Sham intervention: MCI patients sleeping with headphones but sounds not played (crossover arm 2)
11313625|NCT02608840|Experimental|Older adult auditory stimulation|healthy older adults receiving auditory stimulation during sleep (crossover arm 1)
11313626|NCT02608840|Sham Comparator|older adult sham stimulation|Sham intervention: healthy older adults sleeping with headphones but sounds not played (crossover arm 2)
11313627|NCT02608827|Active Comparator|Slow breathing group (GRL)|After randomization and have done aerobic exercise, patients allocated in this arm of the study, using the device-guided breathing - Slow breathing group (GRL), for 15 minutes during the experimental session.
11313628|NCT02608827|Placebo Comparator|Music group (GC)|After randomization and have done aerobic exercise, patients allocated in this study arm will hear slow music - Music group (GC), for 15 minutes during the experimental session.
11313629|NCT02608801||Patients from NoFRACT|Patients from NoFRACT who consent to participate in this sub-study, will be offered examination and treatment with anti-osteoporotic drugs cf. treatment algorithm in the main-study. I.e. if osteoporosis is present clinically or at DXA scan, treatment is started.
11313630|NCT02608788|Active Comparator|S.L.® & Difflam Forte ®|"1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg and 3.0 mg/ml Benzydamine ,Difflam Forte ® 5.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
11313631|NCT02608788|Placebo Comparator|placebo ( for Acular® )|placebo(distilled water)spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
11313632|NCT02608788|Active Comparator|Acular® & S.L.®|"5％ Ketorolac Tromethamine , Acular® 8.0 mg and 1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
11313633|NCT02608788|Experimental|Difflam Forte ® & Acular®|"3.0 mg/ml Benzydamine , Difflam Forte ® 5.0 mg and 5％ Ketorolac Tromethamine Acular® 8.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
11313634|NCT02608775|Experimental|Metrodoloris Medical System|Application of a skin electrode
11313635|NCT02608775|Active Comparator|Aisys® care station, Acertys|SPI calculated from photoplethysmography
11366169|NCT02260024|Experimental|Pramipexole SR C in the fasted state|
11313636|NCT02608762||pediatric/adolescent patients with brain tumors|A prospectively recruited of newly-diagnosed pediatric/adolescent patients with brain tumors or head/neck cancers
11313637|NCT02608749|Experimental|IC|Integrated care (IC)
11313638|NCT02608749|Experimental|LEE|Lower extremity exercise (LEE)
11313639|NCT02608749|Experimental|HC|Home care (HC)
11313640|NCT02608736|Experimental|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
11313641|NCT02608736|Placebo Comparator|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
11313642|NCT02608723|Active Comparator|Standard shock waves device|3 sessions were applied: one per week.
11313643|NCT02608723|Active Comparator|Austere shock waves device|3 sessions were applied: one per week.
11313644|NCT02608723|Active Comparator|Sophisticated shock waves device|3 sessions were applied: one per week.
11313645|NCT02608710|Experimental|Single Dose|Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9.
11313646|NCT02608710|Experimental|Multiple Dose|RDEA3170 12 mg once daily (qd)
11313647|NCT02608710|Experimental|Single Dose Food Effect|Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8.
11313648|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
11313649|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
11313650|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
11313651|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
11313652|NCT02608684|Experimental|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles followed by single-agent pembrolizumab maintenance therapy for up to 2 years of treatment (6 cycles combination treatment + 28 cycles maintenance).
~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion
~-Day 1 and Day 8 of each 3 week cycle Standard of care
~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion
~-Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care
~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion
~-Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
11313653|NCT02608671|No Intervention|Continuous skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
11313654|NCT02608671|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
11313655|NCT02608658|Experimental|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
11313656|NCT02608632|Experimental|Group 1 (RDN guided by HFS)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access. After that high-frequency stimulation (HFS) was used before the initial and after each radiofrequency (RF) delivery within the renal artery. RDN was considered to have been achieved when the sudden increase of blood pressure (> 15 mm Hg from invasive arterial monitoring) was eliminated in response to HFS.
~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery."
11313657|NCT02608632|Active Comparator|Group 2 (RDN as standard procedure)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access.
~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery. High-frequency stimulation (HFS) was performed before and after RDN to just to verify the response of BP"
11313658|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
11313659|NCT02608606|No Intervention|oral administration of tacrolimus|Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.
11313660|NCT02608606|Active Comparator|sublingual administration of tacrolimus|sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.
11313661|NCT02608593||Implant reconstruction with Strattice|Women having immediate breast reconstruction with partial or total Strattice cover
11313662|NCT02608593||Implant reconstruction without Strattice|Women having immediate implant based breast reconstruction where no Strattice has been used
11313663|NCT02608580|Other|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.
~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
11313664|NCT02608567||Preserved LV GLS|"Patients will be compared according to the level of LV global longitudinal strain (GLS) as derived from transthoracic echocardiography and speckle tracking analysis.
~Two groups will be compared regarding outcome: preserved LV GLS vs. reduced LV GLS. The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data."
11313665|NCT02608567||Reduced LV GLS|The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data.
11313666|NCT02608554|Experimental|Taichi|The 24 forms of simplified TCC recommended as the popular health sport by the General Administration of Sport of China were applied.
11313667|NCT02608554|Active Comparator|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise.
11313668|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
11313669|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
11313670|NCT02608502|Experimental|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
11313671|NCT02608502|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
11313672|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
11313673|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
11313674|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
11313675|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
11313676|NCT02608463|Experimental|Neuropathic Pain|Subjects will complete the painDETECT Questionnaire at study entry and be assigned to this group with a score ≥13. They will receive be invited to participate in repetitive transcranial magnetic stimulation (rTMS).
11313677|NCT02608463|No Intervention|Non-neuropathic Pain|Subjects will complete the painDETECT Questionnaire at study entry and be assigned to this group with a score on the 1≥score≤12 on the PDQ. They will receive no study intervention.
11313678|NCT02608463|No Intervention|Control|Subjects will complete the painDETECT Questionnaire at study entry and be assigned to this group with a score = 0 on the PDQ. They will receive no study intervention.
11313679|NCT02608450|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
11313680|NCT02608450|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
11313681|NCT02608437|Experimental|SGI-110 and Ipilimumab|SGI-110 in combination with Ipilimumab
11313682|NCT02608424|Experimental|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .
~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
11313683|NCT02608411|Experimental|ARQ-197|ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.
11313684|NCT02608398||overweight children at weight-loss camp|This is an observational study there is no intervention. The investigators will carry out metabolic profiling on a cohort of overweight or obese children who are attending a commercial weight loss camp for 2-5 weeks.
11313685|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
11313686|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
11313687|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
11313688|NCT02608372|Experimental|Sequence A|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-UP-CTR
11313689|NCT02608372|Experimental|Sequence B|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-CTR-UP
11313690|NCT02608372|Experimental|Sequence C|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-LD-CTR
11313691|NCT02608372|Experimental|Sequence D|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-CTR-LD
11313692|NCT02608372|Experimental|Sequence E|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-LD-UP
11313693|NCT02608372|Experimental|Sequence F|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-UP-LD
11313694|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
11313695|NCT02608346|Other|Blood sampling|
11313696|NCT02608333|Experimental|ESDM-12|ESDM -12 : 60 children will receive 12 hours a week of ESDM ( Early Start Denver Model)intervention delivered by trained therapists during 2 years.ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
11313697|NCT02608333|Active Comparator|Control group|control group: 120 children will receive heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period
11313698|NCT02608320|Experimental|Treatment Sequence (ACB) Position (RLR)|Participants will receive treatment A (Duragesic 12.5 microgram per hour [mcg/h]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
11313699|NCT02608320|Experimental|Treatment Sequence (BAC) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
11313700|NCT02608320|Experimental|Treatment Sequence (CBA) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
11313701|NCT02608320|Experimental|Treatment Sequence (BCA) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
11313702|NCT02608320|Experimental|Treatment Sequence (CAB) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
11313703|NCT02608320|Experimental|Treatment Sequence (ABC) Position (RLR)|Participants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
11313704|NCT02608320|Experimental|Treatment Sequence (ACB) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
11313705|NCT02608320|Experimental|Treatment Sequence (BAC) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
11313706|NCT02608320|Experimental|Treatment Sequence (CBA) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
11313707|NCT02608320|Experimental|Treatment Sequence (BCA) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
11313708|NCT02608320|Experimental|Treatment Sequence (CAB) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
11313709|NCT02608320|Experimental|Treatment Sequence (ABC) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
11313710|NCT02608320|Experimental|Treatment Sequence (DFE) Position (RLR)|Participants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
11313711|NCT02608320|Experimental|Treatment Sequence (EDF) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
11313712|NCT02608320|Experimental|Treatment Sequence (FED) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
11313713|NCT02608320|Experimental|Treatment Sequence (EFD) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
11313714|NCT02608320|Experimental|Treatment Sequence (FDE) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
11313715|NCT02608320|Experimental|Treatment Sequence (DEF) Position (RLR)|Participants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
11313716|NCT02608320|Experimental|Treatment Sequence (DFE) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
11313717|NCT02608320|Experimental|Treatment Sequence (EDF) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
11313718|NCT02608320|Experimental|Treatment Sequence (FED) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
11313719|NCT02608320|Experimental|Treatment Sequence (EFD) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
11313720|NCT02608320|Experimental|Treatment Sequence (FDE) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
11313721|NCT02608320|Experimental|Treatment Sequence (DEF) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
11314457|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
11313722|NCT02608307||AYA patients|Adolescence and young adults (AYA) who meet eligibility criteria and consent to participate in the study.
11313723|NCT02608307||Parents of AYA patients|Parents of AYA patients who meet eligibility criteria and consent to participate in the study.
11313724|NCT02608307||Health Care Providers (HCPs)|Health care providers who meet eligibility criteria and consent to participate in the study.
11313725|NCT02608294|Experimental|Experimental Group|Kinesio Taping Procedure application with 35% strain.
11313726|NCT02608294|Sham Comparator|Sham Group|Kinesio Taping Sham procedure application without strain.
11313727|NCT02608281|Other|CEDEM|diagnostic contrast enhanced Dual Energy mammograms after Iodine based contrast media administration compared to CE MRI
11313728|NCT02608268|Experimental|Dose escalation MBG453 alone|
11313729|NCT02608268|Experimental|Dose escalation MBG453 in combination with PDR001|
11313730|NCT02608268|Experimental|Dose Ranging group|
11313731|NCT02608268|Experimental|Dose Expansion of MBG453 alone|
11313732|NCT02608268|Experimental|Dose Expansion of MBG453 in combination with PDR001|
11313733|NCT02608268|Experimental|Safety run in for MBG453 in combination with decitabine|
11313734|NCT02608255|Experimental|acute coronary syndromes|
11313735|NCT02608242|Experimental|YH22189|YH22189 FDC tablet of Yuhan Corporation
11313736|NCT02608242|Active Comparator|Twynsta 80/10mg|Telmisartan/Amlodipine 80/10mg (FDC)
11313737|NCT02608242|Active Comparator|Crestor 20mg|Rosuvastatin 20mg
11313738|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.
~BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).
~BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.
~Nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.
~Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.
~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
11313739|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.
~First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes
~Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes
~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
11313740|NCT02608216|Experimental|FLT PET/CT|All subjects will receive an [18F]FLT PET/CT scan.
11313741|NCT02608203|Experimental|patients with gastroenteropancreatic neuroendocrine tumors|
11313742|NCT02608190|Experimental|Active training|Patients will undergo active working memory training (see description of protocol).
11313743|NCT02608190|Active Comparator|Passive training|Patients will undergo passive working memory training (see description of protocol).
11313744|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
11313745|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
11313746|NCT02608164|Active Comparator|Vitamin D oral spray solution|An oral spray solution containing 3000IU (75micrograms) vitamin D3 per spray
11313747|NCT02608164|Active Comparator|Vitamin D capsules|A capsule containing 3000IU (75micrograms) vitamin D3 per capsule
11313748|NCT02608151|Active Comparator|Touch massage without oil|massage without oil
11313749|NCT02608151|Experimental|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
11313750|NCT02608138||1|Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
11313751|NCT02608125|Experimental|PRN1371|Drug: PRN1371
11313752|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
11313753|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
11313754|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
11313755|NCT02608086|Other|Control|"Flyer What can I do facing a crisis?"
11313756|NCT02608086|Experimental|Psychological First Aid|"Psychological First Aid according to an adapted protocol based on the WHO PFA Operation Guide 2012 Brochure Network and Services Flyer What can I do facing a crisis?."
11313757|NCT02608073|Experimental|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
11313758|NCT02608060|Experimental|Epoetin Beta - 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
11313759|NCT02608047||dengue patients|Dengue patients confirmed by Non-structural protein and RNA
11313760|NCT02608047||Healthy controls|Healthy population without any diseases
11313792|NCT02607852|Other|Arm A|Patients between the ages of 5-18 years. They will complete the 5-18 version of the BOQ on iPads or through the HTTPS Tonic link.
11313846|NCT02607514|Experimental|immediate yoga arm|participants will immediately start the 8-week hyperthermic yoga intervention
11313761|NCT02608034|Experimental|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
11313762|NCT02608021||Amnestic mild cognitive impairment|
11313763|NCT02608021||Cognitively normal|
11313764|NCT02608008||Data analysis transfemoral aortic valve implantation|Periinterventional data analysis during structural heart procedures like transfemoral aortic valve implantation with and without the use of EchoNavigator System Release II.
11313765|NCT02608008||Data analysis MitraClip|Periinterventional data analysis during structural heart procedures like MitraClip Implantations with and without the use of EchoNavigator System Release II.
11313766|NCT02608008||Data analysis PFO|Periinterventional data analysis during structural heart procedures like PFO implantations with and without the use of EchoNavigator System Release II.
11313767|NCT02608008||Data analysis ASD|Periinterventional data analysis during structural heart procedures like ASD implantations with and without the use of EchoNavigator System Release II.
11313768|NCT02607995||low key intervention|for the whole group
11313769|NCT02607982|Experimental|Concurrent Chemoradiotherapy Arm|Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
11313770|NCT02607969|Experimental|seen once every six weeks|Parents will be educated about home program and they will be asked to control once every six weeks.
11313771|NCT02607969|Experimental|seen once a week.|Parents will be educated about home program and they will be asked to control once a week.
11313772|NCT02607956|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for at least 144 weeks
11313773|NCT02607956|Active Comparator|Blinded Phase: DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for at least 144 weeks
11313774|NCT02607956|Experimental|Open-Label (OL) Phase|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
11313775|NCT02607943|Experimental|Insulin Glargine|subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events
11313776|NCT02607943|Active Comparator|Regular Insulin|short acting regular insulin pre-meal with added NPH at bed time if start eating
11313777|NCT02607930|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 144 weeks
11313778|NCT02607930|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 144 weeks
11313779|NCT02607930|Experimental|Open-Label (OL) Phase|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
11313780|NCT02607917|Experimental|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
11313781|NCT02607917|Experimental|Media|These geographic areas will receive the media intervention over a two year period.
11313782|NCT02607917|No Intervention|No Intervention|Adjacent states will receive no intervention.
11313783|NCT02607904|Experimental|GWP42003-P|"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).
~Participants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.
~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
11313784|NCT02607891|Experimental|STP + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early.
~STP Arm: Last patient completion October 2018"
11313785|NCT02607891|Placebo Comparator|STP + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.
~STP Arm: Last patient completion February 2018"
11313786|NCT02607891|Experimental|VPA + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.
~VPA Arm: Last patient completion February 2018"
11313787|NCT02607891|Placebo Comparator|VPA + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.
~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.
~VPA Arm: Last patient completion January 2018"
11313788|NCT02607865|Experimental|Semaglutide 3 mg|
11313793|NCT02607852|Other|Arm B|Patients between the ages of 0-4 years. They will complete the 0-4 version of the BOQ and appropriate Pediatric Symptom Checklists (i.e. baby or preschool) on iPads or through the HTTPS Tonic link.
11313794|NCT02607839|Placebo Comparator|normal saline|normal saline intravenous infusion
11313795|NCT02607839|Active Comparator|glucose|glucose intravenous infusion
11313796|NCT02607826|Experimental|Intervention arm|
11313797|NCT02607826|No Intervention|Standard of Care|
11313798|NCT02607813|Experimental|Dose escalation LXH254|
11313799|NCT02607813|Experimental|Dose expansion LXH254: Group 1|
11313800|NCT02607813|Experimental|Dose expansion LXH254: Group 2|
11313801|NCT02607813|Experimental|Dose expansion LXH254: Group 3|
11313802|NCT02607813|Experimental|Dose expansion: LXH254 + PDR001|
11313803|NCT02607813|Experimental|Dose escalation LXH254 + PDR001|
11313804|NCT02607800|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
11313805|NCT02607800|Active Comparator|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
11313806|NCT02607787|Experimental|Exercise Group|As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme. The home-based walking and strengthening intervention is individually tailored for each participant. They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
11313807|NCT02607787|Other|Control Group|This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study. However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24. They are aware of their group allocation throughout the duration of the study.
11313808|NCT02607774|Experimental|Secukinumab|Secukinumab over 24 weeks
11313809|NCT02607761|Experimental|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
11313810|NCT02607761|No Intervention|Control|No intervention
11313811|NCT02607761|Active Comparator|Control 1|2 minutes video with same images but information on work-family balance.
11313812|NCT02607748|Experimental|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
11313813|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
11313814|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
11313815|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
11313816|NCT02607722||Nintedanib|Patients with IPF
11313817|NCT02607709|Placebo Comparator|Nephroureterektomy|scheduled to receive routine standard open or robot assisted nephroureterectomy without lymphadenectomy
11313818|NCT02607709|Experimental|Nephroureterektomy + Lymphadenectomy|scheduled to received mapped lymphadenectomy in conjugation with nephroureterectomy
11313819|NCT02607696|Experimental|Zolpidem 1.75 mg|Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily
11313820|NCT02607696|Experimental|Zolpidem 3.50 mg|Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily
11313821|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
11313822|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
11313823|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
11313824|NCT02607670|Experimental|TAT4 Gel|The participant will apply TAT4 Gel to the nasolabial fold area once daily.
11313825|NCT02607670|Placebo Comparator|Placebo|The participant will apply Placebo Gel to the nasolabial fold area once daily.
11313826|NCT02607657|Experimental|Eplerenone 25 mg|Eplerenone 25 mg Tablet Oral Once daily
11313827|NCT02607657|Experimental|Eplerenone 50 mg|Eplerenone 50 mg Tablet Oral Once daily
11313828|NCT02607657|Experimental|Eplerenone 100 mg|Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily
11313829|NCT02607657|Experimental|Eplerenone 50 mg x 2|Eplerenone 50 mg Tablet Oral Twice daily
11313830|NCT02607657|Experimental|Eplerenone 25 mg x 2|Eplerenone 25 mg Tablet Oral Twice daily
11313831|NCT02607644|Experimental|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
11313832|NCT02607644|Active Comparator|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
11313833|NCT02607631|Experimental|Single arm|Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity
11313834|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
11313835|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
11313836|NCT02607592|Experimental|Nadaplatin and Pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
11313837|NCT02607592|Active Comparator|Cisplatin/Pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
11313838|NCT02607579|Active Comparator|Ropivacaine|This group is given an adductor canal block with Ropivacaine which is the previous gold standard medication.
11313839|NCT02607579|Experimental|Exparel|This group is given an adductor canal block with Exparel which is believed to last longer and provide a better pain relief post-operatively.
11313840|NCT02607566|Experimental|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
11313841|NCT02607566|Active Comparator|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
11313842|NCT02607553|Experimental|Experimental: G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
11313843|NCT02607540|Experimental|Two cycles PF-radiotherapy|"2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
~radiotherapy： 50Gy，2 Gy/d，5d/w."
11313844|NCT02607540|Active Comparator|Four cycles PF-radiotherapy|"4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
~radiotherapy： 50Gy，2 Gy/d，5d/w."
11313847|NCT02607514|Other|delayed yoga arm|participants will wait 8-weeks to start the 8-week hyperthermic yoga intervention
11313848|NCT02607501|Other|eCLIPs BRS|Implant eCLIPs BRS at target aneurysm
11313849|NCT02607488|Placebo Comparator|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
11313850|NCT02607488|Active Comparator|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.
~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
11313851|NCT02607488|Active Comparator|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
11313852|NCT02607488|Active Comparator|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
11313853|NCT02607475|Experimental|Robotic telesonography compared to conventional sonography|All participants will receive two imaging studies: (1) Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix), and (2) conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare).
11313854|NCT02607462|Experimental|PRP|Platelet-rich plasma taken made from centrifuged venous blood.
11313855|NCT02607462|Placebo Comparator|Saline|Sodium chloride 0.9% used as placebo.
11313856|NCT02607449|Experimental|A|Standard TB treatment+ treatment regiment with FS-1 drug. Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.
11313857|NCT02607449|Placebo Comparator|B|Standard TB treatment + treatment regiment with a placebo. Instead of study drug the placebo was given to the patients orally once per day along with other prescribed TB drugs (in quntity equal to study drug).
11313858|NCT02607436|Experimental|Sarpogrelate + Aspirin|Sarpogrelate as an active drug
11313859|NCT02607436|Active Comparator|Aspirin alone|Aspirin as an active comparator
11313860|NCT02607423|Experimental|Diagnostic (18F-FDG PET/CT)|"Patients undergo fludeoxyglucose F-18 PET/CT at baseline and after course 1 of chemotherapy. Patients undergo 1 of 3 chemotherapy regimens at the discretion of the investigator.
~CHEMOTHERAPY REGIMEN 1: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, and 8. Patients also receive cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY REGIMEN 2: Patients receive docetaxel IV over 60 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~CHEMOTHERAPY REGIMEN 3: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
11313861|NCT02607410|Active Comparator|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
11313862|NCT02607410|Active Comparator|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
11313863|NCT02607384|Experimental|Vision problems|Children with refractive error will be prescribed eyeglass wearing, and children with convergence insufficiency will be given orthoptic exercises. Children with any other vision problem will be given a specialist referral to a pediatric eye specialist.
11313864|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
11313865|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
11313866|NCT02607358||Clopidogrel|Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing
11313867|NCT02607358||Acetacylicacid|Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing
11313868|NCT02607345|Active Comparator|Glucomedics®|25gr Glucomedics®
11313869|NCT02607345|Experimental|Zusto®|25gr Zusto®
11313870|NCT02607332|Experimental|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
11313871|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
11313872|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
11313873|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
11313874|NCT02607306|Active Comparator|Insulin degludec OD|
11313875|NCT02607306|Active Comparator|Liraglutide OD|
11313876|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
11313877|NCT02607280|Experimental|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
11313878|NCT02607267||laparoscopic Roux en Y Gastric Bypass|patients undergoing LRYGB, being the first surgical treatment for severe obesity
11313879|NCT02607267||laparoscopic Sleeve Gastrectomy|patients undergoing LSG, being the first surgical treatment for severe obesity
11313880|NCT02607254|Experimental|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
11313881|NCT02607254|Experimental|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
11313882|NCT02607241|Active Comparator|BRS|"OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.
~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval."
11313883|NCT02607241|Experimental|DCB-only|FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance
11313884|NCT02607228|Experimental|GS-5829 Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of GS-5829 to determine the MTD.
11313885|NCT02607228|Experimental|GS-5829 + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive GS-5829 in combination with enzalutamide once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of GS-5829 may be increased.
11313886|NCT02607228|Experimental|GS-5829 Dose Expansion (Group 1)|Participants will receive ≤ the MTD of GS-5829 (based on safety, pharmacodynamics (PD), and tolerability).
11313887|NCT02607228|Experimental|GS-5829 + Enzalutamide Dose Expansion (Group 2)|Participants will receive ≤ the MTD of GS-5829 plus enzalutamide (based on safety, PD, and tolerability).
11313888|NCT02607228|Experimental|GS-5829 + Enzalutamide Dose Expansion (Group 3)|Participants will receive GS-5829 plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
11313889|NCT02607215|Experimental|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days
~DDP:75 mg/m2, D1 every 21 days"
11313890|NCT02607215|Active Comparator|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
11313891|NCT02607202|Experimental|Arm A|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes. Treatment to be repeated Q21 days.
11313892|NCT02607202|Experimental|Arm B|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by carboplatin AUC 2 on Day 1 and 8 by IV administration over 60 minutes. Treatment to be repeated Q21 days.
11313893|NCT02607176|Experimental|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
11313894|NCT02607163|Experimental|dexmedetomidine|dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
11313895|NCT02607163|Placebo Comparator|control|saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
11313896|NCT02607137|Experimental|Health Education|Health information related to physical activity
11313897|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
11313898|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
11313899|NCT02607111|Experimental|open label|Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks
11313900|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
11313901|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
11313902|NCT02607072|Experimental|Aspirin 200 mg daily|Aspirin 200 mg daily
11313903|NCT02607072|Experimental|Aspirin 100 mg daily|Aspirin 100 mg daily
11313904|NCT02607072|Placebo Comparator|Placebo control|Placebo control
11313905|NCT02607046|No Intervention|Control|Standard Medical Care
11313906|NCT02607046|Experimental|Exercise|Exercise Training
11313907|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
11313908|NCT02607046|Experimental|Exercise + NMES|Combined Exercise Training and Neuromuscular Electrical Stimulation
11313909|NCT02607033|Experimental|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
11313910|NCT02607033|Active Comparator|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
11313911|NCT02607020|Experimental|Physical exercise|
11313912|NCT02607020|Active Comparator|Relaxation|
11313913|NCT02607007|Experimental|2% M.F. Milk|Breakfast meal: 250 mL 2% M.F. milk, 75 g white toast, 23.2 g strawberry jam, 100 mL water
11313914|NCT02607007|Experimental|2% M.F. Plain Greek Yogurt|Breakfast meal: 175 g 2% plain Greek yogurt, 75 g white toast, 23.2 g strawberry jam, 100 mL + 75 mL water
11313915|NCT02607007|Experimental|31% M.F. Cheddar Cheese|Breakfast meal: 30 g 31% M.F. cheddar cheese, 75 g white toast, 27.0 g strawberry jam, 100 mL + 220 mL water
11313916|NCT02607007|Experimental|Soy Beverage|Breakfast meal: 250 mL soy beverage, 75 g white toast, 19.3 g strawberry jam, 100 mL water
11313917|NCT02607007|Experimental|Water (control)|Breakfast meal: 250 mL + 100 mL water
11313918|NCT02606994|Experimental|Oral Defense Toothpaste|The experimental group will brush with Oral Defense Toothpaste three times per day during the study
11313919|NCT02606994|Placebo Comparator|Crest Toothpaste/Magic Mouth Rinse|The placebo group will brush with Crest Toothpaste three times per day during the study. Participants in the placebo comparator group who require additional management of their oral mucositis pain will be provided Magic Mouth Rinse.
11313920|NCT02606981|Experimental|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
11313921|NCT02606981|Placebo Comparator|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
11313922|NCT02606955|Experimental|BIA REST|BIA DW assessment
11313923|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
11313924|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
11313925|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
11313926|NCT02606916|Experimental|SMART & S-1/DDP|Patients in experimental group receive daily simultaneous modulated accelerated radiotherapy combined with DDP and S-1.
11313927|NCT02606903|Experimental|BI 695501 prefilled syringe|
11313928|NCT02606903|Experimental|BI 695501 autoinjector|
11313929|NCT02606877|Experimental|Treatment naïve|Treatment naïve to pirfenidone
11313930|NCT02606877|Experimental|Pirfenidone-treated|Treatment before with pirfenidone
11313931|NCT02606864|Experimental|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
11313932|NCT02606864|Experimental|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
11313933|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
11313934|NCT02606812|Experimental|Traditional-food|During the 3 months, a dish containing traditional food will be provided 5 days per week. The food will contain an average of 600 Kcal, ≤ 50 mg of cholesterol, ≥ 10 g of fiber, ≥ 130 g of vegetables, and ≤ de 200 mg of sodium. Each dish will be accompanied with 3 standard-sized corn tortillas.
11313935|NCT02606812|No Intervention|Control|Is the group who will intake the cafeteria fast food. The control group will receive habitually consumed fast food provided by the cafeteria of the campus at a similar caloric proportion.
11313936|NCT02606799|No Intervention|Standard Care|intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
11313937|NCT02606799|Experimental|CytoSorb|all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
11313938|NCT02606786|Experimental|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
11313939|NCT02606773|Experimental|600 mg Novo C plus|Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)
11313940|NCT02606773|Experimental|900 mg Novo C Plus|Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)
11313941|NCT02606773|Active Comparator|500 mg intravenous vitamin C|Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)
11313942|NCT02606773|Active Comparator|500 mg oral vitamin C|Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)
11313943|NCT02606760|Experimental|P-3073|P-3073
11313944|NCT02606760|Placebo Comparator|vehicle of P-3073|vehicle of P-3073
11313945|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
11313946|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
11313947|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
11313948|NCT02606721||Challenge Subjects|Male or female subjects aged 5 - 35 with suspected food allergy and an upcoming scheduled clinical food challenge
11313949|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
11313950|NCT02606695||NuvaMap and NuvaMap OR in Thoracolumbar Spinal Fusion|
11313951|NCT02606682|Experimental|NPT200-11 - Cohort 1, Dose 1|Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313952|NCT02606682|Experimental|NPT200-11 - Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313953|NCT02606682|Experimental|NPT200-11 - Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313954|NCT02606682|Experimental|NPT200-11 - Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313955|NCT02606682|Experimental|NPT200-11 - Cohort 5 ,Dose 5|Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313956|NCT02606682|Experimental|NPT200-11 -Cohort 6, Dose 6|Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313957|NCT02606682|Experimental|NPT200-11 - Cohort 7, Dose 7|Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
11313958|NCT02606669|Experimental|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
11313959|NCT02606669|No Intervention|Control|Diet and Physical Activity advice only. No treatment plan.
11313996|NCT02606344|Experimental|Intervention Group (IG)|Loans were provided to poor women who enrolled in the intervention group. A participatory learning and action curriculum was integrated into loan meetings, which took place every 2 weeks.
11313997|NCT02606344|No Intervention|Control Group (CG)|
11313998|NCT02606331|Experimental|Piezosurgery|In one half of the dental arch, piezosurgery will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
11366170|NCT02260024|Experimental|Pramipexole SR C2 in the fed state|
11313960|NCT02606643|Active Comparator|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.
~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
11313961|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
11313962|NCT02606630|Experimental|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
11313963|NCT02606617|Active Comparator|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
11313964|NCT02606617|Placebo Comparator|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
11313965|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
11313966|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
11313967|NCT02606591|Experimental|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
11313968|NCT02606565|Experimental|Intervention arm: 4% chlorhexidine|Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
11313969|NCT02606565|No Intervention|Control arm: Dry cord care|Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
11313970|NCT02606552|Active Comparator|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
11313971|NCT02606552|Experimental|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
11313972|NCT02606552|Other|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
11313973|NCT02606539|Active Comparator|surgery and methotrxate|The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG
11313974|NCT02606539|Active Comparator|methotrxate|The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG
11313975|NCT02606526|Experimental|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
11313976|NCT02606526|Active Comparator|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
11313977|NCT02606513|Experimental|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
11313978|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
11313979|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
11313980|NCT02606487||CF pulmonary exacerbation group|Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
11313981|NCT02606461|Experimental|Selinexor 60mg|"Phase 2: 57 patients were randomized to selinexor or placebo in a 1:1allocation.
~Phase 3: Approximately 277 patients will be randomized to selinexor (~185 patients) or placebo (~92 patients) in a 2:1 allocation."
11313982|NCT02606461|Placebo Comparator|Placebo|"Phase 2: Approximately 57 patients were randomized to selinexor or placebo in a 1:1 allocation.
~Phase 3: Approximately 277 patients will be randomized to selinexor (~185 patients) or placebo (~92 patients) in a 2:1 allocation."
11313983|NCT02606448|Active Comparator|Femoral Nerve Block|Patients in this group received preoperative ultrasound guided femoral nerve blocks by senior anesthesiologist using ropivicaine.
11313984|NCT02606448|Experimental|Liposomal Bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
11313985|NCT02606435|Experimental|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
11313986|NCT02606435|Active Comparator|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
11313987|NCT02606422|Experimental|Active HD-tDCS plus Speech-Language Therapy|Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
11313988|NCT02606422|Sham Comparator|Sham plus Speech-Language Therapy|Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.
11313989|NCT02606409|Active Comparator|Dexmedetomidine|Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for >24h.
11313990|NCT02606409|Active Comparator|Propofol|Propofol sedation at 10-70µg/kg/h for >24h.
11313991|NCT02606383|Experimental|Dapaconazole|Dapaconazole 2% Cream Topical
11313992|NCT02606383|Active Comparator|Ketoconazole|Ketoconazole 2% Cream Topical
11313993|NCT02606370|Experimental|Unstable shoes|Wearing unstable shoes during 1 month
11313994|NCT02606370|No Intervention|Control Group|Not Wearing unstable shoes
11313995|NCT02606357|Experimental|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
11366171|NCT02260011|Experimental|Ipratropium bromide HFA-134a low|
11313999|NCT02606331|Experimental|ER:YAG Laser|In one half of the dental arch, ER:YAG laser irradiation will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
11314000|NCT02606318|Experimental|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
11314001|NCT02606318|Other|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
11314002|NCT02606305|Experimental|Regimen A|Dose escalation and dose expansion with IMGN853 and bevacizumab
11314003|NCT02606305|Experimental|Regimen B|Dose Escalation with IMGN853 and carboplatin
11314004|NCT02606305|Experimental|Regimen C|Dose Escalation with IMGN853 and pegylated liposomal doxorubicin
11314005|NCT02606305|Experimental|Regimen D|Dose escalation and dose expansion with IMGN853 and pembrolizumab
11314006|NCT02606305|Experimental|Regimen E|Dose expansion with IMGN853 and bevacizumab+carboplatin
11314007|NCT02606292|Experimental|Arm 1: PAE assessment|-The PAE-EUS assessment will be performed in the operating room by the after induction of general anesthesia and following strict sterile technique while the patient is being positioned and prepped for esophageal surgery.
11314008|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
11314009|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
11314010|NCT02606266|Experimental|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
11314011|NCT02606266|No Intervention|Control group|Control group with standard care who do not receive the investigational medicinal product
11314012|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
11314013|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
11314014|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
11314015|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
11314016|NCT02606227|Experimental|Experimental group:financial incentives|Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
11314017|NCT02606227|Other|Control group:no financial intervention|Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
11314018|NCT02606214|Experimental|Dose Level 1: 50 mg TBA-354|50 mg TBA-354 for 14 days (two 25 mg once daily)
11314019|NCT02606214|Placebo Comparator|Dose Level 1: Placebo|Placebo cohort for Dose Level 1
11314020|NCT02606214|Experimental|Dose Level 2: 100 mg TBA-354|100 mg TBA-354 for 14 days (one 100 mg tablet once daily)
11314021|NCT02606214|Placebo Comparator|Dose Level 2: Placebo|Placebo cohort for Dose Level 2
11314022|NCT02606214|Experimental|Dose Level 3: 200 mg TBA-354|200 mg TBA-354 for 14 days (two 100 mg once daily)
11314023|NCT02606214|Placebo Comparator|Dose Level 3: Placebo|Placebo cohort for Dose Level 3
11314024|NCT02606214|Experimental|Dose Formulation Comparison Cohort|"All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.
~Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose."
11314025|NCT02606201|Experimental|IPSMA|Injection Peri Sphincter Myofibers Autologous
11314026|NCT02606188|Active Comparator|Modified High-flow nasal cannula therapy|Patients undergoing bronchoscopy are given Modified High-flow nasal cannula oxygen therapy all the time.
11314027|NCT02606188|Active Comparator|Nasal cnnnula therapy|Patients undergoing bronchoscopy are given nasal cannula oxygen therapy all the time.
11314028|NCT02606175|Other|Admitted for renal transplantation|"Patients who are hospitalised on the abdominal transplantation surgery ward at the University Hospitals of Leuven (UZLeuven) and undergo a kidney transplantation during this hospitalisation.
~Intervention: taking questionnaires and tests at predefined timepoints:
~at discharge: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire
~1 month after kidney transplantation: BAASIS, medication knowledge test
~3 months after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test
~1 year after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire
~2 years after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire"
11314029|NCT02606149|Active Comparator|Standard of information|Information on chemotherapy as done in routine practice following national and international guidelines
11314030|NCT02606149|Experimental|Truthful information on chemotherapy risks|Information on the potential role of anticancer chemotherapy in worsening life-threatening conditions
11314031|NCT02606136|Experimental|pamrevlumab (FG-3019)|Each subject will receive pamrevlumab (FG-3019) (35 mg/kg, every 2 weeks) for up to 156 weeks.
11314032|NCT02606123|Experimental|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
11314033|NCT02606097|Experimental|regorafenib|regorafenib 160 mg daily, 3 weeks on/1 week off
11314034|NCT02606084|Experimental|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance [CLCR,m] greater than or equal to >= 50 to 79 milliliter/minute [mL/min]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
11314035|NCT02606084|Experimental|Cohort 2|Participants with moderate renal impairment (CLCR,m >=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
11314036|NCT02606084|Experimental|Cohort 3|Participants with severe renal impairment (CLCR,m less than [<] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
11314037|NCT02606084|Experimental|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m >= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
11314038|NCT02606058|No Intervention|Early cord clamping (Control Arm)|Immediate cord clamping (< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.
11314039|NCT02606058|Experimental|Deferred cord clamping|Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.
11314040|NCT02606045|Active Comparator|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
11314041|NCT02606045|Active Comparator|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
11314042|NCT02606032|Active Comparator|Metronidazole+doxycylcine+terbinafine|Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days
11314043|NCT02606032|Placebo Comparator|Placebo|Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days
11314044|NCT02606006|Active Comparator|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
11314045|NCT02606006|Experimental|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
11314046|NCT02605993|Experimental|Cohort 1|"During the Treatment Period, participants were administered ravulizumab 1400 milligram (mg) on Day 1, ravulizumab 1000 mg on Day 15 and Day 29, and then ravulizumab 1000 mg every 4 weeks for 7 doses.
~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kilograms (kg), 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
11314047|NCT02605993|Experimental|Cohort 2|"During the Treatment Period, participants were administered ravulizumab 2000 mg on Day 1, ravulizumab 1600 mg on Day 22 and Day 43, and then ravulizumab 1600 mg every 6 weeks for 4 doses.
~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
11314048|NCT02605993|Experimental|Cohort 3|"During the Treatment Period, participants were administered ravulizumab 1600 mg on Day 1 and Day 15, ravulizumab 2400 mg on Day 29, and then ravulizumab 2400 mg every 8 weeks for 3 doses.
~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
11314049|NCT02605993|Experimental|Cohort 4|"During the Treatment Period, participants were administered ravulizumab 3000 mg on Day 1, ravulizumab 5400 mg on Day 29, and then ravulizumab 5400 mg every 12 weeks for 2 doses.
~During the Extension Period, participants were administered ravulizumab 5400 mg every 12 weeks for up to 5 years."
11314050|NCT02605980||Male|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
11314051|NCT02605980||Female|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
11314052|NCT02605967|Experimental|PDR001 - Investigational drug|anti-PD1 humanized monoclonal antibody
11314053|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
11314054|NCT02605954|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
11314055|NCT02605954|Active Comparator|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.
~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
11314056|NCT02605928|Experimental|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
11314057|NCT02605915|Experimental|Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.
11314058|NCT02605915|Experimental|Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg|Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
11314059|NCT02605915|Experimental|Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.
11314060|NCT02605915|Experimental|Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.
11314061|NCT02605915|Experimental|Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide|Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.
11314124|NCT02605525|Experimental|SM101 24 mg/kg|Human soluble recombinant Fcγ Receptor IIB
11314062|NCT02605915|Experimental|Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel|Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.
11314063|NCT02605915|Experimental|Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
11314064|NCT02605915|Experimental|Cohort 2B: Atezolizumab/Trastuzumab emtansine|Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
11314065|NCT02605915|Experimental|Cohort 2C: Safety Expansion|Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
11314066|NCT02605915|Experimental|Cohort 2D: Safety Expansion|Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
11314067|NCT02605902|Active Comparator|iCBIT|internet-delivered Comprehensive Behavioral Intervention for Tics (iCBIT) consisting of psychoeducation, habit reversal training (HRT), function-based assessment and intervention, and relaxation training
11314068|NCT02605902|Placebo Comparator|Control intervention/reference test|internet-delivered psychoeducation and relaxation training.
11314069|NCT02605902|Active Comparator|face-to-face CBIT-treatment|face-to-face CBIT-treatment
11314070|NCT02605889|Experimental|Group A|Laser acupuncture
11314071|NCT02605889|Sham Comparator|Group B|Simulation Laser acupuncture
11314072|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
11314073|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
11314074|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
11314075|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
11314076|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
11314077|NCT02605850|Placebo Comparator|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
11314078|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
11314079|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
11314080|NCT02605837|Experimental|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
11314081|NCT02605837|Placebo Comparator|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
11314082|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
11314083|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
11314084|NCT02605811|Experimental|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
11314085|NCT02605811|Active Comparator|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
11314086|NCT02605798|Experimental|T test|Test drug (Elbanovir)1 tablet contains 400 mg Sofosbuvir
11314087|NCT02605798|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11314088|NCT02605798|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11314089|NCT02605785|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will received a Tau PET scan.
11314090|NCT02605772|Experimental|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
11314091|NCT02605772|Experimental|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
11314092|NCT02605759|Experimental|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
11314210|NCT02604927|Experimental|Beta-alanine|800 mg of beta-alanine, four times per day, during 28 days.
11314093|NCT02605746|Experimental|2-4 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.
11314094|NCT02605746|Experimental|4-8 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.
11314095|NCT02605746|Experimental|22-26 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.
11314096|NCT02605720|Experimental|Dihydroartemisinin-piperaquine|
11314097|NCT02605707|Experimental|Intravenous stem cell transplantation|Intravenous transplantation of autologous endothelial progenitor cells plus conventional treatment include rehabilitation
11314098|NCT02605707|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
11314099|NCT02605694|Experimental|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
11314100|NCT02605694|Active Comparator|Arm 2|"R-CHOP will be administered as follows:
~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)
~Cyclophosphamide (750 mg/m2)
~Doxorubicin hydrochloride (50 mg/m2)
~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)
~Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)
~Prednisone (100 mg) will be administered."
11314101|NCT02605681||septic patients|We recruited the patients admitted to the Department of Critical Care Medicine, Zhongda Hospital, a tertiary hospital, from November 2017 to March 2018. The inclusive criteria were adult patients (age > 18 years-old and < 80 years-old) diagnosed with sepsis, according the definition of the Surviving Sepsis Campaign (2016). Exclusive criteria included: 1. age < 18 years-old or > 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dL), autoimmune diseases and Alzheimer syndrome; 5. patients deceased or discharge from ICU within 24 hours; or, 6. written consents could not be obtained.
11314102|NCT02605668|Experimental|Intensified Psychological Intervention|Intensified psychological intervention (Cognitive Behavioral Therapy), based on optimized extinction learning
11314103|NCT02605668|Active Comparator|Treatment As Usual|Standard intervention (Cognitive Behavioral Therapy) without optimized extinction learning
11314104|NCT02605655|Experimental|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
11314105|NCT02605655|Placebo Comparator|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
11314106|NCT02605642||CT-P13|biosimilar infliximab
11314107|NCT02605629|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
11314108|NCT02605629|Placebo Comparator|Placebo|Patients will self-administer the study placebo twice per day (morning, evening) for 6 months, for the efficacy assessment
11314109|NCT02605616|Experimental|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
11314110|NCT02605616|Placebo Comparator|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
11314111|NCT02605590|Experimental|1.25 mg|Part 1: single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.
11314112|NCT02605590|Experimental|2.5 mg|Part 1: single inhaled dose of 2.5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 2.5 mg AIR DNase for 5 consecutive days.
11314113|NCT02605590|Experimental|5 mg|Part 1: single inhaled dose of 5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 5 mg AIR DNase for 5 consecutive days.
11314114|NCT02605590|Placebo Comparator|Placebo|Placebo comparator for each of the dose levels, administered accordingly as single inhaled dose in Part 1 followed by once daily inhaled dose for 5 consecutive days in Part 2.
11314115|NCT02605577|Experimental|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
11314116|NCT02605577|No Intervention|control group|group of late preterm infants using current nutritional management protocol during hospital stay
11314117|NCT02605564|Active Comparator|study Group A|Gluten free diet
11314118|NCT02605564|Placebo Comparator|Study Group B|No intervention
11314119|NCT02605551|Active Comparator|OMT Group|During the initial visit, the subject will have his BP recorded manually by the osteopathic physician in a standardized fashion. The subject will then undergo the OMT protocol and have his BP recorded again immediately afterwards. This will represent the conclusion of the initial visit. There will be 2 subsequent visits about 2-3 weeks apart that will be identical to this visit. Following the third visit, the next follow-up will be 2 months afterwards. However, the patient will only have his BP checked, and will not undergo an OMT treatment. The final visit will be another 2 months afterwards and will also be a simple BP check with no OMT treatment. The principles of lifestyle modification (diet/exercise/weight loss) will also be discussed at each visit.
11314120|NCT02605551|Placebo Comparator|Control Group|Patients in this arm will only receive lifestyle modification recommendations at each visit, along with a BP check. No antihypertensive medication changes will be made unless indicated by the guidelines.
11314121|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
11314122|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
11314123|NCT02605525|Experimental|SM101 12 mg/kg|Human soluble recombinant Fcγ Receptor IIB
11314125|NCT02605525|Placebo Comparator|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
11314126|NCT02605512|Other|Breast cancer patients with 3DCRT|Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
11314127|NCT02605499|Experimental|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
11314128|NCT02605499|No Intervention|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
11314129|NCT02605486|Experimental|Palbociclib in Combination with Bicalutamide|This is a non-randomized, open-label, phase I/II trial for patients with AR(+) MBC . There will be a dose finding phase I portion of the study to establish the recommended phase II dose (R2PD). This will be followed by a phase II where efficacy is evaluated. Patients with AR(+)ER(-) breast cancer treated on the phase I at the recommended phase II dose will be counted towards the primary endpoint analysis for the phase II study.
11314130|NCT02605460|Other|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY) 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
11314131|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
11314132|NCT02605434|Experimental|AP-CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
11314133|NCT02605434|Active Comparator|SINEMET®|IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
11314134|NCT02605421|Experimental|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
11314135|NCT02605408||Cataract surgery|Phacoemulsification and artificial IOL implantation with and without LenSx® laser system
11314136|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
11314137|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
11314138|NCT02605382|Experimental|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
11314139|NCT02605382|Placebo Comparator|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
11314140|NCT02605369|Experimental|Intervention arm: An integrated package|Pregnant women in the intervention clusters will receive an integrated package consisting of peer support for facility based births by pregnancy buddies, mama kits and mobile phone messages. These components will all aim at mitigating the three delays and increasing the proportion of facility based births.
11314141|NCT02605369|No Intervention|Control arm: Standard of care|Pregnant women in the control clusters will continue to receive the standard of care for pregnant women according to Ugandan Ministry of Health guidelines
11314142|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 1]|Phase 1: Radium-223 dichloride; 30 kiloBecquerel (kBq)/kg body weight (33 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
11314143|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 2]|Phase 1: Radium-223 dichloride; 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
11314144|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 3]|Phase 1: Radium-223 dichloride; 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
11314145|NCT02605356|Placebo Comparator|Placebo +SoC [Phase 2]|Phase 2: Matching placebo (isotonic saline) every 4 weeks for a total of 6 doses plus SoC (Standard of care) bortezomib/dexamethasone.
11314146|NCT02605356|Experimental|Radium-223 dichloride + SoC [Phase 2]|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 4 weeks for 6 doses plus SOC bortezomib/dexamethasone
11314147|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
11314148|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
11314149|NCT02605330||Fibrinogen plasma level in CABG|In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
11314150|NCT02605330||Fibrinogen plasma level in AVR|In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
11314151|NCT02605330||Fibrinogen plasma level in AAR|In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
11314152|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
11314153|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
11314211|NCT02604914|Experimental|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
11314154|NCT02605291|Experimental|Experimental arm 1|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
11314155|NCT02605291|Experimental|Experimental arm 2|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
11314156|NCT02605291|Experimental|Experimental arm 3|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
11314157|NCT02605278|Experimental|Clinical program for pain and depression|Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.
11314158|NCT02605278|Active Comparator|Control|Care as usual
11314159|NCT02605265|Active Comparator|Capecitabine Alone|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT
~Adjuvant Chemotherapy:
~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
11314160|NCT02605265|Experimental|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:
~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
~Chemotherapy in Interval Between CRT and Surgery:
~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
~Surgery:
~Scheduled 6-8 weeks after the completion of CRT
~Adjuvant Chemotherapy:
~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
11314161|NCT02605252|Experimental|CHB patients|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.
11314162|NCT02605239|Experimental|bleaching teeth|Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception
11314163|NCT02605226|Experimental|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
~Patients receive cryoablation therapy."
11314164|NCT02605226|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
11314165|NCT02605213|Experimental|Vancomycin|Vancomyicn 250 mg every 6 hours for 12 weeks
11314166|NCT02605213|Placebo Comparator|Placebo|placebo every 6 hours for 12 weeks
11314167|NCT02605200|Other|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
11314168|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
11314169|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
11314170|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
11314171|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
11314172|NCT02605174|Experimental|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
11314173|NCT02605174|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
11314174|NCT02605174|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
11314175|NCT02605174|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
11314176|NCT02605161||Parkinson's disease group|"patients diagnosed with Parkinson's disease by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus
~to undergo pre-operative MRI with contrast"
11314177|NCT02605161||Control group|"patients diagnosed with either essential tremor or cervical dystonia by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus
~to undergo pre-operative MRI with contrast"
11314178|NCT02605148|Experimental|Gluten free diet|Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
11314179|NCT02605148|Active Comparator|Normal diet|Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.
11314180|NCT02605135||Continued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab and 10 mL of vaginal lavage at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months
11314181|NCT02605135||Discontinued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage (Aim 2) at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months. Should the participant discontinue pessary use, we will additionally culture the microbes that are present on the pessary and compare those to the vaginal microbiota.
11314212|NCT02604914|Experimental|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
11314182|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
11314183|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
11314184|NCT02605109||RiskMERS|Exposed to case-patients
11314185|NCT02605096|Experimental|MRI group|"This arm assess the use of MRI as the first line examination of suspected scaphoid fracture (replacing conventional plain x-ray).
~Patients with negative findings will receive a splint and contact card to a specialist wrist clinic if the pain persists for ten to fourteen days after initial presentation.
~Patients with positive findings will receive a plaster cast and undergo a CT scan (to evaluate displacement) and will be referred to the fracture clinic. Furthermore, if the CT scan confirms a displaced fracture, that might require surgery, the patient should be seen by a Hand Specialist at fracture clinic.
~All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
11314186|NCT02605096|Active Comparator|X-ray group|"This arm is the current standard of care pathway for the diagnosis of patients with suspected scaphoid fracture. This includes an initial clinical assessment on arrival to the Emergency Department of Urgent Care Centre followed by a plain x-ray (using a 4-view scaphoid protocol).
~Patients with negative/positive findings for scaphoid fracture in the initial X-ray will be immobilised with a splint/plaster cast.
~All patients will be referred to an initial fracture clinic and a proportion of patients are likely to require additional imaging scans (usually CT but also MRI) and follow-up appointments in the fracture clinic. All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
11314187|NCT02605083|Experimental|eFT508|Escalation cohort
11314188|NCT02605070|Experimental|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
11314189|NCT02605070|No Intervention|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.
~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.
~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
11314190|NCT02605057|Experimental|LEO 80185 gel|LEO 80185 gel will be allocated to 7 different test sites on each subject
11314191|NCT02605057|Experimental|Dovobet Ointment|Dovobet Ointment will be allocated to 7 different test sites on each subject
11314192|NCT02605044|Experimental|Masitinib + FOLFIRI|masitinib + FOLFIRI
11314193|NCT02605044|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
11314194|NCT02605005||GA|general anesthesia
11314195|NCT02605005||ISB|interscalene block
11314196|NCT02604992|Experimental|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
11314197|NCT02604992|Experimental|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
11314198|NCT02604992|Experimental|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
11314199|NCT02604992|Experimental|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
11314200|NCT02604992|Experimental|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
11314201|NCT02604992|Experimental|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
11314202|NCT02604966|Experimental|Artesunate (AS) group|P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
11314203|NCT02604966|Active Comparator|DHA - PPQ group|P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
11314204|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
11314205|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
11314206|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
11314207|NCT02604940|Experimental|dexmedetomidine|Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
11314208|NCT02604940|Active Comparator|Normal Saline|Control group will receive Normal saline over 15 minutes at the beginning of surgical closure
11314209|NCT02604927|Placebo Comparator|Placebo|800 mg of dextrose, four times per day, during 28 days.
11314213|NCT02604914|Active Comparator|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
11314214|NCT02604901|Experimental|Screening and Brief Intervention (BI)|Screening and Brief Intervention (BI) at initial prescription fill and at each additional refill.
11314215|NCT02604901|Experimental|Pill Box (PB)|Pill Box (PB) and information about their medications at the initial fill and at each additional refill.
11314216|NCT02604901|Experimental|Brief Intervention + Pill Box (BI+PB)|Screening and Brief Intervention (BI) and Pill Box (PB) at initial prescription fill and at each additional refill.
11314217|NCT02604901|No Intervention|Standard Care (SC)|The Standard Care (SC) arm administered traditional dispensing and counseling by Rite Aid® pharmacists.
11314218|NCT02604888|Other|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Alopecia Areata in several types apply on the scalp drops of the MEXIS/M6S PATENT - lotion against Alopecia
11314219|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
11314220|NCT02604862|Experimental|FIB ONE administration|All participants in this clinical study will be dosed on one occasion with FIB ONE. The final dosage will be less than 100 µg.
11314221|NCT02604862|Experimental|AZD1236 administration|To quantify the change in mean FIB ONE fluorescence amplification gradient in the presence of AZD1236 in the fibroproliferative lung
11314222|NCT02604849||Received therapy desconolizacion against Klebsiella pneumoniae|
11314223|NCT02604849||Patients who do not receive the therapy|
11314224|NCT02604836|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
11314225|NCT02604823|Experimental|Group A (Naïve Participants)|Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms [mcg]) subcutaneously once weekly for 48 weeks.
11314226|NCT02604823|Experimental|Group B (Conventional Interferon Pretreated Participants)|Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
11314227|NCT02604823|Experimental|Group C (Lamivudine Pretreated Participants)|Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
11314228|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
11314229|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
11314230|NCT02604797|Experimental|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
11314231|NCT02604797|Experimental|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
11314232|NCT02604784|Experimental|cohort A|Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.
11314233|NCT02604784|Experimental|cohort B|Cohort B: For patients that have not indication for systemic therapy with standard chemotherapy. This cohort has a phase I design; with a dose-escalation design the maximum tolerated doses and recommended doses of Cisplatin + Doxorubicin and Oxaliplatin (according to the pathology) administered through PIPAC in patients with peritoneal carcinomatosis will be evaluated.
11314234|NCT02604758|Experimental|Tidal Model|the psychiatric nursing approach based on the Tidal Model
11314235|NCT02604758|No Intervention|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
11314236|NCT02604745||Degenerative Mitral Regurgitation|This cohort includes patients that have had mitral valve surgery for Degenerative Mitral Regurgitation (Type II)
11314237|NCT02604732|Active Comparator|Patients who stop Aspirin|Patients need to stop Aspirin 1 week before the surgery
11314238|NCT02604732|Experimental|Patients who continue Aspirin|Patients will continue Aspirin
11314239|NCT02604719|Experimental|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
11314240|NCT02604719|Placebo Comparator|placebo|10 ml normal saline will be administered intravenously just after birth
11314241|NCT02604706|Experimental|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
11314242|NCT02604706|Experimental|LP Acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. BC-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
11314243|NCT02604706|Active Comparator|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
11314244|NCT02604693||Chronic Beryllium Disease|Those that have been diagnosed with the disease. No interventions will be administered.
11314458|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
11314245|NCT02604693||Beryllium Sensitization|Those that have been diagnosed with beryllium sensitization and do not have chronic beryllium disease. No interventions will be administered.
11314246|NCT02604693||normal controls|Those that do not have chronic beryllium disease or beryllium sensitization. No interventions will be administered
11314247|NCT02604680|Experimental|BLI1100-1|Topical gel
11314248|NCT02604680|Experimental|BLI1100-2|Topical gel
11314249|NCT02604680|Experimental|BLI1100-3|Topical gel
11314250|NCT02604680|Experimental|BLI1100-4|Topical gel
11314251|NCT02604680|Placebo Comparator|Placebo|Topical gel
11314252|NCT02604667||Group 1: Cancer and Stroke|Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
11314253|NCT02604667||Group 2: Stroke and No Cancer|Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
11314254|NCT02604667||Group 3: Cancer and No Stroke|Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
11314255|NCT02604654|Experimental|Yiqitongluo group|Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.
11314256|NCT02604641|Placebo Comparator|Placebo group|0 mg CoQ10 daily
11314257|NCT02604641|Active Comparator|Quvital LD group|50 mg CoQ10 daily
11314258|NCT02604641|Active Comparator|Quvital HD group|150 mg CoQ10 daily
11314259|NCT02604628|No Intervention|Control|Patients will be treated as standard of care.
11314260|NCT02604628|Experimental|Antibiotic Stewardship Intervention|Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.
11314261|NCT02604615|Experimental|Capecitabine-oxaliplatin 2 cycles|oxaliplatin：65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
11314262|NCT02604615|Active Comparator|Capecitabine-oxaliplatin 4 cycles|oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
11314263|NCT02604602||PPH|
11314264|NCT02604602||non-PPH|
11314265|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
11314266|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
11314267|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
11314268|NCT02604576|Experimental|Group 1|FDC Bromopride 10 mg and Simethicone 80 mg
11314269|NCT02604576|Active Comparator|Group 2|Bromopride 10 mg (Digesan ® - Sanofi Aventis)
11314270|NCT02604563||Arm A: Clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
~Peripheral blood draw will occur at baseline and no more than every 6 months until death.
~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
~May be approached about optional bone marrow biopsy"
11314271|NCT02604563||Arm B: No clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
~Peripheral blood draw will occur at baseline and no more than every 6 months until death.
~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
~May be approached about optional bone marrow biopsy"
11314272|NCT02604563||Arm C: No clonal hematopoiesis & no follow-up|"Complete several self-administered health assessments at baseline with no further follow-up
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up
~Peripheral blood draw will occur at baseline with no further follow-up
~Buccal swabs will occur at baseline with no further follow-up"
11314273|NCT02604563||Arm D: Hip replacement|"Complete several self-administered health assessments at baseline and every 6 months until death.
~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.
~Participants with or without clonal hematopoiesis who are undergoing hip replacement
~Peripheral blood draw will occur at baseline and no more than every 6 months until death.
~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death
~May be approached about optional bone marrow biopsy"
11314274|NCT02604550|Active Comparator|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
11314275|NCT02604550|Active Comparator|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
11314276|NCT02604537|Active Comparator|Betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone (Celestone)
11314277|NCT02604537|Experimental|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac (Toradol)
11314278|NCT02604524|Experimental|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
11314279|NCT02604524|Placebo Comparator|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
11314595|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
11314280|NCT02604511|Experimental|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
11314281|NCT02604498|Experimental|Liver function impaired|Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
11314282|NCT02604498|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
11314283|NCT02604485|Other|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
11314284|NCT02604472||CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
11314285|NCT02604472||IC+CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
11314286|NCT02604459|Active Comparator|Usual general anesthesia care|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.
~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
11314287|NCT02604459|Experimental|Optimized general anesthesia care|The subjects will have general anesthesia with propofol, fentanyl, sevoflurane. In addition the subjects will be monitored with a depth of anesthesia monitor (BIS) and a cerebral oximeter (Foresight). These additional monitors will be used to direct care. BP management: Systolic BP will be maintained within 20% of baseline systolic BP variables.
11314288|NCT02604446|Experimental|Tapentadol|depot Tapentadol in addition to usual pain treatment
11314289|NCT02604446|Active Comparator|Oxycodone|depot Oxycodone in addition to usual pain treatment
11314290|NCT02604446|Placebo Comparator|Placebo|depot glucose placebo in addition to usual pain treatment.
11314291|NCT02604433|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
11314292|NCT02604433|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
11314293|NCT02604420||Transplant, no TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
11314294|NCT02604420||Transplant, +TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
11314295|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
11314296|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
11314297|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
11314298|NCT02604394|Active Comparator|Rheolytic Thrombectomy with PCI|"Rheolytic Thrombectomy (RT) will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).
~The single-pass antrograde thrombectomy technique will be used."
11314299|NCT02604394|Sham Comparator|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
11314300|NCT02604381|Experimental|Glucosamine Sulfate Potassium Chloride/Ginkgo Biloba Extract|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
11314301|NCT02604381|Placebo Comparator|Placebo|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
11314302|NCT02604368|Experimental|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, administered once a day on a per weight basis.
11314303|NCT02604368|Placebo Comparator|Placebo|Soybean oil, soft gelatin capsule, administered once a day on a per weight basis.
11314304|NCT02604355|Experimental|Healthy Participants (Multiple-Ascending Dosing)|
11314305|NCT02604355|Experimental|Healthy Participants (Single-Ascending Dosing)|
11314306|NCT02604355|Experimental|Healthy Participants (Study of Food Effect)|
11314307|NCT02604355|Experimental|Participants with Chronic Hepatitis B (Proof of mechanism)|
11314308|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
11314309|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
11314310|NCT02604329|Experimental|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
11314311|NCT02604316|Experimental|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate
11314312|NCT02604316|No Intervention|Control- Non Arabinoxylan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
11314313|NCT02604316|Experimental|Beta-Glucan|10 days of weight loss diet calculated as 100% RMR AND 6g Beta-Glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
11314314|NCT02604316|No Intervention|Control Non Beta glucan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
11314353|NCT02604056|Active Comparator|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
11314354|NCT02604056|Experimental|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
11314315|NCT02604290|Experimental|Kinesio Taping method|"The tape is applied depending on the physical examination:
~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.
~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.
~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
11314316|NCT02604290|Sham Comparator|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
11314317|NCT02604277|Experimental|Group Intervention Program|Patients diagnosed with Bipolar Disorder will receive therapy in a group setting of 4 to 12 male and female participants.
11314318|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
11314319|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
11314320|NCT02604251|Experimental|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
11314321|NCT02604251|Active Comparator|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
11314322|NCT02604238|Experimental|Group A|"Administered a safe dose of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a safe dose of Alteplase."
11314323|NCT02604238|No Intervention|Group B|All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.
11314324|NCT02604225|Experimental|Penthrox|Methoxyflurane
11314325|NCT02604225|Placebo Comparator|Placebo|Saline 0.9%
11314326|NCT02604212|Placebo Comparator|Placebo Low Dose Comparator|Placebo (low dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
11314327|NCT02604212|Placebo Comparator|Placebo High Dose Comparator|Placebo (high dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
11314328|NCT02604212|Experimental|ARC-520 1.0 mg/kg|Low dose (1.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
11314329|NCT02604212|Experimental|ARC-520 2.0 mg/kg|High dose (2.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
11314330|NCT02604199|Placebo Comparator|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
11314331|NCT02604199|Placebo Comparator|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
11314332|NCT02604199|Experimental|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
11314333|NCT02604199|Experimental|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
11314334|NCT02604186|Experimental|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
11314335|NCT02604186|Placebo Comparator|Placebo Injections|Placebo injections at adductors and triceps surae
11314336|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
11314337|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
11314338|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
11314339|NCT02604160|Experimental|LY3113593|Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A.
11314340|NCT02604160|Placebo Comparator|Placebo|0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.
11314341|NCT02604147|Sham Comparator|Simulated inspiratory muscle training|Inspiratory muscle training with load of 15% of maximal inspiratory pressure.
11314342|NCT02604147|Experimental|Inspiratory muscle training group|Inspiratory muscle training with initial load of 50% of maximal inspiratory pressure.
11314343|NCT02604134|Other|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
11314344|NCT02604134|Other|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
11314345|NCT02604121|Experimental|transepithelial brushing|transepithelial brushing in liquid-based technology + biopsy
11314346|NCT02604108|Experimental|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
11314347|NCT02604108|Experimental|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
11314348|NCT02604095|Experimental|Melatonin|Take one table at bedtime.
11314349|NCT02604082|Active Comparator|Vibocompression (VB)|Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration
11314350|NCT02604082|Active Comparator|Hyperinflation (HMV)|Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
11314351|NCT02604082|Experimental|HMV+VB|Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
11314352|NCT02604069|Experimental|Continuous Glucose Monitor|Application of CGM for 6 days following free flap reconstruction in conjunction with clinical monitoring
11314355|NCT02604043|Experimental|supraglottic impendence/pH probe|
11314356|NCT02604030|Experimental|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
11314357|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
11314358|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
11314359|NCT02604004|Active Comparator|Period 1|Epivir ® tablet 150-mg single dose (drug reference)
11314360|NCT02604004|Experimental|Period 2|Lamivudine 150-mg tablet single dose (drug test)
11314361|NCT02603978|No Intervention|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
11314362|NCT02603978|Active Comparator|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
11314363|NCT02603978|Active Comparator|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
11314364|NCT02603978|Active Comparator|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
11314365|NCT02603965|Experimental|Diagnostic (Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
11314366|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
11314367|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
11314368|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
11314369|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
11314370|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
11314371|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
11314372|NCT02603926|Experimental|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
11314373|NCT02603913||Normal pregnancy|Normal uncomplicated pregnancy
11314374|NCT02603913||Pre-eclampsia|"Hypertension (>140 mmHg systolic or >90 mmHg diastolic) developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:
~Proteinuria (>300 mg/day)
~Other maternal organ dysfunction
~renal insufficiency (creatinine >90 μmol/L)
~liver involvement (elevated transaminases - and/or severe right upper quadrant or epigastric pain)
~neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)
~hematological complications (thrombocytopenia, disseminated intravascular coagulation, hemolysis)
~Uteroplacental dysfunction"
11314375|NCT02603913||Pregnancy induced hypertension|New onset of hypertension (>140 mmHg systolic or >90 mmHg diastolic) after 20 weeks gestation, without proteinuria, in a previously normotensive woman.
11314376|NCT02603913||Preterm birth|Babies born alive before 37 weeks of pregnancy are completed.
11314377|NCT02603913||Intra-uterine growth restriction|Moderate IUGR is an estimated fetal weight and / or abdominal circumference < 10th percentile for its gestational age Severe IUGR is an EFW (estimated fetal weight) and/ or AC (abdominal circumference) < 5th percentile for its gestational age
11314378|NCT02603900|Experimental|Adductor Canal Catheter|This group will receive ropivacaine 0.5% 15 ml for the adductor canal block under ultrasound guided nerve block. A multi-orifice catheter will be placed in the adductor canal and an infusion of ropivacaine 0.2% at 10 ml/hr will be continued for 72 hours.
11314379|NCT02603900|Experimental|Local Infiltration of Analgesia|Local infiltration using 20 ml of free bupivacaine solution (Marcaine 0.25% with epinephrine 1:200000, ) diluted with 40 ml of normal saline following implantation of the knee prosthesis, the solution will be injected into the vastus medialis (5 ml), medial retinaculum (5 ml), origin of MCL (5 ml) and LCL (5 ml), lateral portion of quadriceps tendon (5 ml), vastus lateralis (5 ml), and subcutaneous tissues especially along saphenous nerve distribution (30 ml). Postoperatively, a sham adductor canal catheter will be placed as in the ACC arm following stabilization in the PACU to infuse only normal saline with an initial bolus of 15 ml saline and infusion of saline at 10ml/hr for 72 hours.
11314380|NCT02603887|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11314381|NCT02603874|Experimental|Target Tape|Including target tape in the procedure
11314382|NCT02603874|No Intervention|Control|Without target tape in the procedure
11314383|NCT02603861|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
11314384|NCT02603861|Experimental|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
11314385|NCT02603861|Experimental|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
11314386|NCT02603861|Experimental|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
11314387|NCT02603861|Active Comparator|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
11314388|NCT02603848|Experimental|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
11314389|NCT02603848|Active Comparator|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
11314390|NCT02603835|Experimental|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
11314391|NCT02603822|Experimental|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
11314392|NCT02603809|Placebo Comparator|Placebo|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
11314393|NCT02603809|Experimental|Aprocitentan 5 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
11314394|NCT02603809|Experimental|Aprocitentan 10 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
11314395|NCT02603809|Experimental|Aprocitentan 25 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
11314396|NCT02603809|Experimental|Aprocitentan 50 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
11314397|NCT02603809|Active Comparator|Lisinopril 20 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
11314398|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
11314399|NCT02603783|Active Comparator|Capsaicin|1,5 mg capsaicin in 30 minutes
11314400|NCT02603783|Placebo Comparator|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
11314401|NCT02603770|Experimental|XueZhiKang (XZK)|XueZhiKang (XZK) 1200 mg
11314402|NCT02603770|Active Comparator|Lovastatin|Lovastatin 20 mg
11314403|NCT02603757|Active Comparator|Group A|Standard-dose of 2,000 IU Vitamin D3, daily
11314404|NCT02603757|Experimental|Group B|Higher-dose of 50,000 IU of Vitamin D3, weekly
11314405|NCT02603744|Experimental|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
11314406|NCT02603744|Experimental|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
11314407|NCT02603744|Experimental|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
11314408|NCT02603718|Experimental|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
11314409|NCT02603718|Experimental|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
11314410|NCT02603705|Experimental|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
11314411|NCT02603692||Pediatric group (ages 8-17)|PROMIS pediatric domains for emotional distress (anxiety and depression), physical function (fatigue, pain interference, mobility and upper extremity), and peer relations
11314412|NCT02603692||Adult group (ages 18-35)|PROMIS adult domains. To reduce respondent burden, the multi-form design will be used which includes the short form of physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity.
11314413|NCT02603692||Parent/guardian proxy|Parent/guardian will complete the parental proxy PROMIS instruments based on corresponding child age (ages 5 to 17 years)
11314414|NCT02603679|Active Comparator|A: Weekly Paclitaxel|Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period. Thereafter, treatment is switched to endocrine treatment in combination with palbociclib. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
11314415|NCT02603679|Experimental|B: Tamoxifen + Palbociclib|Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
11314416|NCT02603679|Experimental|B: Aromatase Inhibitor + Palbociclib|Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
11314417|NCT02603679|Experimental|B: Goserelin + Aromatase Inhibitor + Palbociclib|Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
11314418|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
11314422|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
11314423|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
11314424|NCT02603614|Experimental|Cenderitide-Placebo|"Infusion Period A: Cenderitide Infusion Period B: Placebo
~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
11314425|NCT02603614|Experimental|Placebo-Cenderitide|"Infusion Period A: Placebo Infusion Period B: Cenderitide
~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
11314426|NCT02603601|Active Comparator|Standard lifestyle intervention|The standard lifestyle intervention is a 1-hour individual nutritional counseling session with a registered dietician at BIDMC.
11314427|NCT02603601|Experimental|Mind-body lifestyle intervention|The mind-body lifestyle intervention is a 10-week mindfulness-based intervention that integrates mindfulness with traditional behavioral strategies to improve long-term weight maintenance.
11314428|NCT02603588|Experimental|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
11314429|NCT02603588|Sham Comparator|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
11314430|NCT02603575|Experimental|Caspofungin and corticosteroids|patients treat with caspofungin and corticosteroids on the base of sulfanilamide
11314431|NCT02603575|Active Comparator|Caspofungin and no corticosteroids|patients treat with caspofungin on the base of sulfanilamide
11314432|NCT02603575|Active Comparator|corticosteroids and no caspofungin|patients treat with corticosteroids on the base of sulfanilamide
11314433|NCT02603575|Active Comparator|no corticosteroids and no caspofungin|patients treat with sulfanilamide only
11314434|NCT02603562|Experimental|ATYR1940|Intrapatient dose escalation ATYR1940: ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg for up to 12 Weeks. The dose level in this study will not exceed 3.0 mg/kg.
11314435|NCT02603562|Placebo Comparator|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
11314436|NCT02603549||Surgery or Blood Patch|
11314437|NCT02603536|Experimental|Vulnerable or pilot participant|"In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period. Participants will be requested to respond to the outgoing message How are you? within 48 hours; they may respond that they are doing well or that they have a problem. A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
11314438|NCT02603523|Experimental|Senior Dance|The intervention group will attend a single educational class on fall risk factors and prevention, and will participate in a 12-week, twice-weekly group-based program of Senior Dance. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. Senior Dance-certified instructors will lead the classes. The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups.
11314439|NCT02603523|No Intervention|Control group|Participants in the control group will attend the same educational class on fall risk factors and prevention that intervention group participants will receive, and will be instructed not to take part in any regular exercise programs such as supervised group exercise, Tai Chi, Yoga, or any dance activity during the study period. At the end of the study, they will be offered Senior Dance classes, twice a week, during 12 weeks.
11314440|NCT02603510|Experimental|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
11314441|NCT02603510|Experimental|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
11314442|NCT02603497|Experimental|Control (Subjects with normal renal function)|Oral
11314443|NCT02603497|Experimental|Mild renal impairment|Oral
11314444|NCT02603497|Experimental|Moderate renal impairment|Oral
11314445|NCT02603497|Experimental|Severe renal impairment|Oral
11314446|NCT02603471|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
11314447|NCT02603471|Active Comparator|Informational group|A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
11314448|NCT02603458|Placebo Comparator|Placebo|Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
11314449|NCT02603458|Experimental|NRX-1074 Dose Group|Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
11314450|NCT02603445|Experimental|Follicular lymphoma (FL)|
11314451|NCT02603445|Experimental|Mantle cell lymphoma (MCL)|
11314452|NCT02603432|Experimental|Arm A|Avelumab plus Best Supportive Care (BSC)
11314453|NCT02603432|Other|Arm B|"Best Supportive Care (BSC) alone
~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone."
11314454|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
11314455|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
11314459|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
11314460|NCT02603406|Experimental|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
11314461|NCT02603406|No Intervention|Group B|mechanical barrier disruption procedure Drug: no-specific intervention
11314462|NCT02603393|Experimental|QVA149|
11314463|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
11314464|NCT02603380||Clinical staff|Clinicians in the Royal Infirmary of Edinburgh.
11314465|NCT02603380||Patients|Patients in intensive care units and general wards in the Royal Infirmary of Edinburgh.
11314466|NCT02603367|Experimental|Supportive care (COMFORT communication intervention)|"Participants receive the printed communication tool A Communication Guide for Caregivers, a guide developed from the COMFORT communication curriculum, a national training program for palliative care communication. After a 1 week period to review the material, participants undergo communication coaching with a research nurse by phone over approximately 1 hour."
11314467|NCT02603354|Active Comparator|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
11314468|NCT02603354|Experimental|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
11314469|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
11314470|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
11314471|NCT02603328|Active Comparator|Treatment|Atorvastatin 80mg OD (optimal dose). Treatment dose will be de-escalated to 40mg based on reported adverse events.
11314472|NCT02603328|Placebo Comparator|Placebo|Identically looking capsules containing no active ingredient
11314473|NCT02603302|Experimental|Locally advanced rectal cancer|"RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU
~Surgery 8 weeks after the neoadjvuant treatment."
11314474|NCT02603289||Teen|< 17 years of age
11314475|NCT02603289||Adult|17 years of age or older
11314476|NCT02603289||Adult with Primer Aligners|17 years of age or older This group will get Primer Aligners
11314477|NCT02603276|Active Comparator|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
11314478|NCT02603276|Active Comparator|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
11314479|NCT02603276|Experimental|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
11314480|NCT02603263||Workplace Restaurant Customers|"1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study)
~Study consists of three phases:
~Pre Intervention
~Intervention
~Post Intervention
~All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster."
11314481|NCT02603250||Wicking|50% of the 132 children enrolled in the study will have their Hb measured using the wicking method of HemoCue® 201+ blood collection.
11314482|NCT02603250||Gravity|50% of the 132 children enrolled in the study will have their Hb measured using the gravity method of HemoCue® 201+ blood collection.
11314483|NCT02603237|Other|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
11314484|NCT02603237|Other|Fat tolerance test|The same participants will receive an oral standardized fat load test
11314485|NCT02603224|Experimental|MRG-201|
11314486|NCT02603224|Placebo Comparator|Placebo|
11314487|NCT02603211||Women with Breast Tumors|Women with breast tumors.
11314488|NCT02603198|Active Comparator|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
11314489|NCT02603198|Active Comparator|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
11314490|NCT02603185|Experimental|Hemay007|"Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.
~Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.
~Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses"
11314491|NCT02603185|Placebo Comparator|Placebo|"Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.
~Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses"
11314492|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
11314493|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
11314494|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
11314495|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
11314596|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
11314496|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
11314497|NCT02603159|Experimental|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
11314498|NCT02603159|Active Comparator|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
11314499|NCT02603146|Experimental|Hydroxychloroquine Group|Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
11314500|NCT02603146|Placebo Comparator|Placebo Group|Subjects randomized to placebo HCQ. Subjects will receive 200 - 400 mg of HCQ placebo (1-2 pills), based upon IBW, taken daily for 12 months.
11314501|NCT02603133|Other|Cohort 1|The intervention will begin for all NICUs, with baseline surveys as necessary pre-work. For those unable to attend, a link to the baseline survey will be emailed with site champion instructions to complete in groups at staff meetings and during shift change. Two weeks later, three randomly (random number generator) assigned NICUs (block 1) included in the first block webinar will then receive Module 1 of the intervention with Modules 2-6 being rolled out monthly. The second block of three NICUs starts approximately six-month later.
11314502|NCT02603133|Other|Cohort 2|This second block of 3 NICUs will start approximately six-months after roll-out of group 1. At time point 0 this NICUs in this group will receive a lecture on safety culture, unrelated to the burnout intervention.
11314503|NCT02603133|Experimental|Cohort 3 (July cohort) WISER 2.0|"Individually randomized to one of two cohorts. Cohort 1 to start will serve as the waitlist control 1 before starting their version of the intervention. Each cohort will experience modified versions of WISER, which only differ by the spacing of intervention. Participants will receive 10-day sequential or 10-day non-sequential rollout of the resilience tools. Seq will receive the tools on ten consecutive days. NSeq will receive messages daily noThursdays, Fridays and Saturdays.
~Days 1 through 3 will be offered 3GT. Day 4 will continue with 3GT but add a single day activity for Gratitude. Day 5 adds a single activity for Awe. Day 6 adds a single day activity for RAK. Days 7 -10 the participant is offered the choice of Gratitude, Awe or RAK to accompany their daily 3GT. At 1 month follow-up time point, participants will receive 8 days of the 1 Good Chat tool, as a booster. At 6 month follow-up, participants will receive a gratitude exercise."
11314504|NCT02603120|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
11314505|NCT02603120|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
11314506|NCT02603120|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
11314507|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Participants will switch to B/F/TAF FDC and continue treatment for at least 48 weeks.
~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 96 additional weeks."
11314508|NCT02603107|Experimental|Current antiretroviral regimen|"Randomized Phase: Participants will remain on current antiretroviral regimen consisting of ritonavir boosted ATV (RTV+ATV), ritonavir boosted DRV (RTV+DRV), cobicistat boosted ATV (COBI+ATV or ATV/co), or cobicistat boosted DRV (COBI+DRV or DRV/co) plus either FTC/TDF or ABC/3TC for at least 48 weeks.
~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 96 additional weeks."
11314509|NCT02603094|Experimental|clear fluids until premedication|allowed to drink until premedication, aprox 30 minutes before anaesthesia induction. Fasting for solids and non-clear fluids is six hours.
11314510|NCT02603094|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction clear fluid Ingestion. Fasting for solids and non-clear fluids is six hours.
11314511|NCT02603081|Placebo Comparator|Placebo|0 mg SPI-1005 bid po x 21d
11314512|NCT02603081|Active Comparator|Low dose|200 mg SPI-1005 bid po x 21d
11314513|NCT02603081|Active Comparator|Mid dose|400 mg SPI-1005 bid po x 21d
11314514|NCT02603081|Active Comparator|High dose|600 mg SPI-1005 bid po x 21d
11314515|NCT02603068|Experimental|Individual Maximum Tolerated Dose (iMTD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.
11314516|NCT02603068|Experimental|Fixed Dose (FD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.
11314517|NCT02603055|Experimental|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
11314518|NCT02603055|Active Comparator|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co., Ltd. three doses, 30μg/0.5ml per dose
11314519|NCT02603042||Observation|Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease
11314520|NCT02603029|Placebo Comparator|Placebo cream|Cream with 0% Silver fir wood extract (Belinal)
11314521|NCT02603029|Active Comparator|Belinal cream|Cream with 2% Silver fir wood extract (Belinal)
11314522|NCT02603016|Experimental|GLSE compound group|GLSE compound 2g each time by mouth,twice a day for 42 days.
11314523|NCT02603016|Experimental|Maitake mushroom extract compound group|Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
11314524|NCT02603016|Experimental|Ginseng compound group|Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
11314525|NCT02603016|No Intervention|blank control group|Take nothing.
11314526|NCT02603003|Placebo Comparator|Cisplatin|Cisplatin
11314527|NCT02603003|Placebo Comparator|Pemetrexed|Pemetrexed
11314528|NCT02603003|Experimental|Jinfukang|Jinfukang
11314529|NCT02602990||Cerebral AVM treated with SQUID™|
11314530|NCT02602977|Experimental|multiple-dose RIPC|Multiple-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive 4 cycles of remote ischemic preconditioning of the upper limb per day in the 7 consecutive days before the endotoxemia experiment. The last dose will be applied 40 minutes before LPS administration.
11366172|NCT02260011|Experimental|Ipratropium bromide HFA-134a high|
11314531|NCT02602977|Experimental|single-dose RIPC|Single-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive a single RIPC dose, starting 40 minutes before LPS administration.
11314532|NCT02602977|Active Comparator|control group|Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
11314533|NCT02602964|Experimental|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
11314534|NCT02602964|No Intervention|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
11314535|NCT02602951|Experimental|Control|Pilot subjects
11314536|NCT02602951|Experimental|Patients|Patients with an intracranial disorder or needing a supraaortic trunk MRA
11314537|NCT02602938|Experimental|aspirin|"The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles.
~The CTC was evaluated at baseline, and every 28 days for 2 months."
11314538|NCT02602925|Experimental|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
11314539|NCT02602925|Other|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
11314540|NCT02602912|Experimental|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability.
11314541|NCT02602899|Experimental|PINS Deep Brain Stimulator|Deep Brain Stimulator is on,continuous stimulation to the brain,
11314542|NCT02602886|Experimental|Exposure and Response Prevention Therapy|
11314543|NCT02602873||good efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can reach effective outcome.
11314544|NCT02602873||poor efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can not reach effective outcome.
11314545|NCT02602860|Experimental|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.
~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
11314546|NCT02602860|Experimental|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.
~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.
~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg."
11314547|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
11314548|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
11314549|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
11314550|NCT02602834|Experimental|HTx|Heart transplant recipients n=15
11314551|NCT02602834|Active Comparator|Control|Healthy controls n=5
11314552|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
11314553|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
11314554|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
11314555|NCT02602808||post-ERCP pancreatitis|Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.
11314556|NCT02602795|Experimental|Distress Tolerance (DT)|Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
11314557|NCT02602795|Active Comparator|HIV/STI Intervention|Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
11314558|NCT02602795|No Intervention|Treatment As Usual (TAU)|Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.
11314559|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.
~The investigators will perform transcriptome profiling in this group."
11314560|NCT02602769||Control cohort|Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
11314561|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
11314562|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
11314563|NCT02602743|Experimental|remifentanyl, ketamine|Experimental:Remifentanyl and ketamine Remifentanyl vial 2 mg, Ketamine vial 500mg/10 mlt by intravenous. 2 mg/kg ketamine and 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
11366173|NCT02260011|Active Comparator|Atrovent® CFC low|
11314564|NCT02602743|Active Comparator|propofol, ketamine|"Active comparator:Propofol and ketamine Propofol injectable emulsion vial 200 mg/20 mlt, Ketamine vial 500mg/10 mlt by intravenous.
~2 mg/kg ketamine and 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started."
11314565|NCT02602730|Experimental|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
11314566|NCT02602730|Active Comparator|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
11314567|NCT02602717|Experimental|thyroid cancer|
11314568|NCT02602704|Active Comparator|Bazedoxifene & Calcium/Vit D|"Enrollment: 57
~Drug: Bazedoxifene 20 mg/day (Viviant)
~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
11314569|NCT02602704|Active Comparator|Calcium/Vit D|"Enrollment: 57
~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
11314570|NCT02602691|Active Comparator|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
11314571|NCT02602691|Experimental|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
11314572|NCT02602678|Experimental|PRONE-Supine|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
11314573|NCT02602678|Experimental|SUPINE - Prone|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
11314574|NCT02602665|Experimental|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
11314575|NCT02602665|Experimental|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
11314576|NCT02602652|Experimental|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
11314577|NCT02602639|Experimental|Functional electrical stimulation rowing|Using an Odstock 4 channel neuromuscular stimulator with Concept 2 Rower
11314578|NCT02602613|Experimental|AMEND|
11314579|NCT02602600|Experimental|Liraglutide|Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.
11314580|NCT02602587|Experimental|blood samples and bone marrow samples|The patients included in this study will be processed according to the standard treatment in force for their disease. This study does not in any way interfere with this treatment regimen, and is only based on additional samples of blood and bone marrow in acts planned in the prognostic or follow-up protocols. Treatment shall start within the 15 days following inclusion and first sampling.
11314581|NCT02602574||ERCP- induced acute pancreatitis|"All patients with indication for ERCP will be prepared for ERCP. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.
~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample.
~Upon clinical and laboratory confirmation of acute pancreatitis according to ESGE guidelines for post-ERCP pancreatitis, will be further monitored during hospitalization for evaluation of the severity of the disease."
11314582|NCT02602574||non -ERCP acute pancreatitis|"All patients with acute pancreatitis according to Atlanta criteria admitted through Emergency Department will be taken 30 ml of heparinized peripheral venous blood and urine sample upon 24 hours after the clinical symptoms have started. 10 mL of collected blood samples will be examined in the Department of Laboratory Medicine. Other 20 mL of blood samples will be sent to Department of Physiology and Immunology, School of Medicine where immunologic analysis will be performed.
~This group of patients will be further monitored during hospitalization for evaluation of the severity of the disease. Severity of the disease will be assessed according to the Atlanta criteria."
11314583|NCT02602574||Control group|"Control group will consist of patients who underwent ERCP but didn't develop acute pancreatitis. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.
~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample."
11314584|NCT02602561|Active Comparator|HMB|3 g HMB/day
11314585|NCT02602561|Placebo Comparator|Placebo|Placebo administered similar to the active comparator
11314586|NCT02602548||Open Shoulder Surgery|Culture
11314587|NCT02602548||Arthroscopic Shoulder Surgery|Culture
11314588|NCT02602535|Experimental|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
11314589|NCT02602535|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
11314590|NCT02602522|Experimental|Experimental|The patients in this arm will be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
11314591|NCT02602522|Active Comparator|controlled|The patients in this arm will be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule prepared, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
11314592|NCT02602509|Experimental|Celecoxib plus rifampicin group|Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg
11314593|NCT02602509|Experimental|Celecoxib plus pyrazinamide group|Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg
11314594|NCT02602496|Experimental|Control|3 servings of refined grains per day.
11366174|NCT02260011|Active Comparator|Atrovent® CFC high|
11314597|NCT02602483|Experimental|Triple combination|Powder for oral administration
11314598|NCT02602483|Active Comparator|Ibuprofen|Powder for oral administration
11314599|NCT02602483|Active Comparator|Magnesium + ascorbic acid|Powder for oral administration
11314600|NCT02602483|Placebo Comparator|Placebo|Powder for oral administration
11314601|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
11314602|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
11314603|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
11314604|NCT02602444||STEMI|ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
11314605|NCT02602444||NSTEMI|non-ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
11314606|NCT02602431|Active Comparator|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
11314607|NCT02602431|Placebo Comparator|Extra-oral placebo|Laser point will be placed in region without irradiation on.
11314608|NCT02602431|Active Comparator|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
11314609|NCT02602431|Placebo Comparator|intra-oral placebo|Laser point will be placed in region without irradiation on.
11314610|NCT02602418|Experimental|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
11314611|NCT02602418|Other|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
11314612|NCT02602392|Experimental|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
11314613|NCT02602392|Active Comparator|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
11314614|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
11314615|NCT02602366|Other|Month 1|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
11314616|NCT02602366|Other|Month 2|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
11314617|NCT02602366|Other|Month 3|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
11314618|NCT02602366|Other|Month 4|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
11314619|NCT02602353|Experimental|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
11314620|NCT02602353|Placebo Comparator|Placebo Patch|One Placebo Patch applied once daily for 3 days
11314621|NCT02602353|Other|No Treatment|No Treatment for 3 days
11314622|NCT02602340|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
11314623|NCT02602327|Experimental|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
11314624|NCT02602314|Experimental|Imatinib + Nilotinib|
11314625|NCT02602314|Experimental|Nilotinib|
11314626|NCT02602301|Active Comparator|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
11314627|NCT02602301|Active Comparator|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
11314628|NCT02602301|Placebo Comparator|3|Group C in which 109 women continued their labour course without any further augmentation.
11314629|NCT02602288|Experimental|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
11314630|NCT02602288|Active Comparator|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
11314631|NCT02602275|Experimental|Neurexan®|0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
11314632|NCT02602275|Placebo Comparator|Placebo|3 tablets, 40-60 minutes before the second MRI
11314633|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
11314634|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
11314635|NCT02602249|No Intervention|Experimental Group A(control group)|saline infusion and follow up
11314636|NCT02602249|Experimental|Experimental Group B|MUC1-gene-DC-CTL will be used against tumor cells.
11314637|NCT02602249|Experimental|Experimental Group C|MUC1-peptide-DC-CTL will be used against tumor cells.
11314638|NCT02602236|Experimental|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
11314639|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
11314640|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
11314641|NCT02602210|Active Comparator|group A|Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
11314642|NCT02602210|Placebo Comparator|group B|Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)
11314643|NCT02602197|Active Comparator|Paracetamol|1 gr paracetamol received intravenously bolus 15 minutes after anesthetic induction and at the postoperative 6 th,12 th, 18 th and 24 th hours
11314644|NCT02602197|Active Comparator|Dexketoprofen|50 mg dexketoprofen received intravenous bolus 15 minutes after anesthetic induction and at the postoperative 8 th,16 th and 24 th hours.
11314645|NCT02602184|Experimental|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
11314646|NCT02602184|Placebo Comparator|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
11314647|NCT02602171|Experimental|dereverberation condition|Oldenburger Sentence test, localization test
11314648|NCT02602171|Experimental|reverberation condition|Oldenburger Sentence test, localization test
11314649|NCT02602158|Active Comparator|Octanoic acid (1-13C, 99%)|100 µL 13C Octanoic acid (Cambridge isotope laboratories)
11314650|NCT02602158|Active Comparator|TRIOCTANOIN (1,1,1-13C3, 99%)|100 µL 13C Trioctanoin (Cambridge isotope laboratories)
11314651|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease that were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have an SFA stent) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for six months. At six months a standard post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
11314652|NCT02602132|Experimental|Clamping group|Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
11314653|NCT02602132|No Intervention|Free drainage group|The urinary catheter will be removed without prior clamping.
11314654|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
11314655|NCT02602106|Experimental|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.
~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
11314656|NCT02602106|No Intervention|Control group|Sedentary healthy pregnant women
11314657|NCT02602093|Active Comparator|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
11314658|NCT02602093|Active Comparator|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
11314659|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
11314660|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
11314661|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
11314662|NCT02602067|Experimental|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).
~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
11314663|NCT02602054|Experimental|Surgical treatment|Implement surgical treatment for closure of patent ductus arteriosus
11314664|NCT02602054|Active Comparator|Control group|"- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg
~- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg
~- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg"
11314665|NCT02602041||Patients with breast cancer and partners|We will invite 10 women with early stage breast cancer (BC) and their partners for a semi-structured interview.
11314666|NCT02602041||Patients with testicular cancer and partners|We will invite 10 men with disseminated testicular cancer (TC) and their partners for a semi-structured interview.
11314667|NCT02602028|Experimental|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
11314668|NCT02602028|Experimental|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
11314669|NCT02602002|Experimental|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
11314670|NCT02602002|Placebo Comparator|Placebo|Saline (0.9%)
11314671|NCT02601989|Experimental|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
11314672|NCT02601989|Placebo Comparator|Placebo|Per oral intake of placebo
11314673|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
11314728|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
11366175|NCT02260011|Placebo Comparator|Placebo|
11314674|NCT02601963|Experimental|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
11314675|NCT02601963|Experimental|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
11314676|NCT02601963|Placebo Comparator|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
11314677|NCT02601950|Experimental|Open-label Tazemetostat|All Cohorts [Cohort 1 - MRT, RTK, ATRT, or tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] Cohort 2 - Relapsed/refractory synovial sarcoma (SS18-SSX rea), Cohort 3 - Other INI1-negative tumors or any solid tumor with an EZH2 GOF mutation, Cohort 4 - Renal medullary carcinoma, Cohort 5 - Epithelioid sarcoma, Cohort 6 - Epithelioid sarcoma undergoing mandatory tumor biopsy and Cohort 7 - Poorly differentiated chordoma (or other chordoma with Sponsor approval)] will receive 800 mg oral Tazemetostat BID x 28 days
11314678|NCT02601937|Experimental|Open-label Tazemetostat|"Dose Escalation: Level 1 (Starting Dose) Oral Tazemetostat 240 mg/m^2 BID; Level 2 Oral Tazemetostat 300 mg/m^2 BID; Level 3 Oral Tazemetostat 400 mg/m^2 BID; Level 4 Oral Tazemetostat 520 mg/m^2 BID; Level 5 Oral Tazemetostat 700 mg/m^2 BID; Level 6 Oral Tazemetostat 900 mg/m^2 BID; Level 7 Oral Tazemetostat 1200 mg/m^2 BID
~Dose Expansion:
~Cohort 1: Oral tazemetostat 1200mg/m2 BID Cohort 2: Oral tazemetostat 520mg/m2 BID Cohort 3: Oral tazemetostat 520mg/m2 BID Cohort 4: Oral tazemetostat 800mg/m2 TID (2400mg/m2/day)"
11314679|NCT02601924|Active Comparator|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
11314680|NCT02601924|Active Comparator|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
11314681|NCT02601924|Active Comparator|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
11314682|NCT02601924|Active Comparator|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
11314683|NCT02601911|Active Comparator|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
11314684|NCT02601911|Active Comparator|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
11314685|NCT02601911|Placebo Comparator|Placebo|This group receive a caplet including placebo, before applying the injection.
11314686|NCT02601898|Experimental|Lipoic acid|vaginal capsules of lipoic acid (10 mg, one capsule per day)
11314687|NCT02601898|Active Comparator|Progesterone|Vaginal soft gel of progesterone (200 mg, two capsules per day)
11314688|NCT02601885|Experimental|Group 2|Participants will receive multiple doses of ABT-555 or placebo
11314689|NCT02601885|Experimental|Group 3|Participants will receive multiple doses of ABT-555 or placebo
11314690|NCT02601885|Experimental|Group 1|Participants will receive multiple doses of ABT-555 or placebo
11314691|NCT02601859|Experimental|Phase 3|Administration of Lithium to 20 individuals with MCI (non-randomised) for 9 weeks. Lithium dose escalates from 100mg to 200mg to 400mg, then a 3 week wash out period, total study duration 12 weeks. Blood samples taken at regular intervals throughout trial and analysed for GSK-3 enzyme activity in blood.
11314692|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
11314693|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
11314694|NCT02601807|Active Comparator|Active|Subjects given active ActiPatch device before or after crossover (randomised)
11314695|NCT02601807|Placebo Comparator|Placebo|Subjects given placebo ActiPatch device before or after crossover (randomised)
11314696|NCT02601794|Experimental|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
11314697|NCT02601794|No Intervention|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
11314698|NCT02601781|Experimental|Primary PCI (PPCI) with BVS|Primary percutaneous coronary intervention (PPCI) with bioresorbable vascular scaffold (BVS) implantation in STEMI patients. Following the arterial route, PPCI (performed according to the international guidelines) aims to recanalize an occluded coronary artery that is then maintained patent inserting an endovascular permanent prosthesis (stent). In this study we aim to assess the results following the use of a fully bioresorbable prosthesis (BVS) during PPCI using a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation). BVS has the theoretical advantage, as compared with a permanent stent, to disappear within 24-36 months from implantation restoring the native pristine vessel state.
11314699|NCT02601768||ASD II|Transcatheter closure of ASD II
11314700|NCT02601755|Experimental|iCanCope app and website|Intervention: Behavioral: iCanCope app and website
11314701|NCT02601755|Active Comparator|Attention control group|Intervention: Behavioral: Attention control group
11314702|NCT02601742|Active Comparator|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
11314703|NCT02601742|Placebo Comparator|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
11314704|NCT02601729||RT-CGM population|Prospective data collection during standardized clinical follow-up and from filled out questionnaires.
11314705|NCT02601729||Pump only population|Retrospective data collection on demographic and clinical characteristics.
11314729|NCT02601612|Experimental|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
11366176|NCT02259998|Experimental|Persantin® new formulation|
11314706|NCT02601716|Experimental|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.
~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
11314707|NCT02601716|Experimental|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.
~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
11314708|NCT02601716|Experimental|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.
~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
11314709|NCT02601716|Experimental|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10^5. PfSPZ Vaccine administered by DVI.
~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10^5 PfSPZ) 21 days prior to the second CHMI.
~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
11314710|NCT02601716|Other|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
11314711|NCT02601716|Other|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
11314712|NCT02601703|Experimental|Tacrolimus Ointment 0.1%|
11314713|NCT02601703|Active Comparator|Protopic® ointment, 0.1%|
11314714|NCT02601703|Placebo Comparator|Placebo of Tacrolimus Ointment|
11314715|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
11314716|NCT02601677|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
11314717|NCT02601677|Active Comparator|Standard Control|Fluoxetine
11314718|NCT02601664|Active Comparator|Combined Intervention|Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
11314719|NCT02601664|Active Comparator|Conventional PCI|Conventional PCI
11314720|NCT02601651|Experimental|Lidocaine|Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
11314721|NCT02601651|Placebo Comparator|Normal saline|Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
11314722|NCT02601638|Experimental|Arm 1|"Demographics and Health History Questionnaire (5-10 minutes to complete)
~Pre-Class Laryngectomy Survey (5-10 minutes to complete)
~Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes
~Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.
~Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)
~Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.
~Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
11314723|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
11314724|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
11314725|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
11314726|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
11314727|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
11314730|NCT02601612|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
11314731|NCT02601612|Experimental|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
11314732|NCT02601612|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
11314733|NCT02601599|Experimental|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
11314734|NCT02601599|No Intervention|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
11314735|NCT02601586|Experimental|PR oxycodone|"A titration phase of two weeks, in three steps:
~Level 1 (from D1 to D5):
~Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)
~Levodopa placebo 100 mg/day bid (50 mg/50 mg)
~Level 2 (from D6 to D10):
~Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)
~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)
~Level 3 (from D11to D15):
~Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)
~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)
~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
~A withdrawal period:"
11314736|NCT02601586|Active Comparator|levodopa|"A titration phase of two weeks, in three steps:
~Level 1 (from D1 to D5):
~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)
~Levodopa 100 mg/day bid (50 mg/50 mg)
~Level 2 (from D6 to D10):
~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)
~Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)
~Level 3 (from D11to D15):
~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)
~Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)
~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
~A withdrawal period:"
11314737|NCT02601586|Placebo Comparator|Placebo|"A titration phase of two weeks, in three steps:
~Level 1 (from D1 to D5):
~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)
~Levodopa placebo 100 mg/day bid (50 mg/50 mg)
~Level 2 (from D6 to D10):
~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)
~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)
~Level 3 (from D11to D15):
~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)
~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)
~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).
~A withdrawal period:"
11314738|NCT02601573|Experimental|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
11314739|NCT02601573|Experimental|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
11314740|NCT02601573|Experimental|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
11314741|NCT02601573|Experimental|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
11314742|NCT02601573|Experimental|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
11314743|NCT02601560|Experimental|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
11314744|NCT02601560|Experimental|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
11314745|NCT02601560|Experimental|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
11314746|NCT02601560|Experimental|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
11314747|NCT02601560|Experimental|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
11314748|NCT02601560|Placebo Comparator|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
11314749|NCT02601560|Experimental|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
11314750|NCT02601560|Placebo Comparator|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
11314751|NCT02601547|Experimental|intervention|"PET-FDG brain imaging and NPT should be performed at T0 (within the 15 days before chemotherapy), at Tf (within 1 month after chemotherapy termination), T+12 (Tf+12 months: within the first month after one year of achievement of chemotherapy). Several PET parameters should be calculated: minimal Standard Uptake Value (SUV), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
~NPT scores (3 values) should be correlated with the five better values on PET-FDG.
~Each patient will be monitored along a time period of 18 months.
~Duration of the study: one year to include the 15 patients with all the exams; 18 months follow-up for each; total of 30 months."
11314752|NCT02601534|Experimental|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.
~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
11314778|NCT02601326|Active Comparator|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
11314813|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
11315169|NCT02598791|Placebo Comparator|IIGI+NaCl (placebo)|4 hour i.v. NaCl (placebo) during isoglycemic conditions
11314753|NCT02601534|Placebo Comparator|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.
~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
11314754|NCT02601521|Experimental|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response [automated phone calls] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
11314755|NCT02601521|Active Comparator|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
11314756|NCT02601508|Active Comparator|Modarate Blockade Group|Neuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine & glycopyrrolate will be given for the recovery.
11314757|NCT02601508|Experimental|Deep Blockade Group|Neuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
11314758|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score > 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
11314759|NCT02601482|Experimental|Control (CON)|No exercise intervention.
11314760|NCT02601482|Experimental|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
11314761|NCT02601482|Experimental|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
11314762|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
11314763|NCT02601443|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
11314764|NCT02601443|No Intervention|Routine care (watch and wait)|
11314765|NCT02601430|Experimental|BOLD-MRI|Blood Oxygen Level Dependent (BOLD)-MRI assessment of limb perfusion before and after standard of care endovascular therapy.
11314766|NCT02601417|No Intervention|Control|Group which considers both blood culture and bile culture for antibiotics choice
11314767|NCT02601417|Experimental|Trial|Group which considers only blood culture and ignore bile culture for antibiotics choice. Patients in this arm would undergo bile culture but ignore the result when choosing antibiotics
11314768|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
11314769|NCT02601391|Other|STEPPS within forensic services.|"Forensic inpatients attend the STEPPS-HI group. Consent will be obtained. Pre and post group psychometric questionnaires will be completed as well as each service user attending a short semi-structured interview following the conclusion of the group .
~Primary nurse will fill in pre and post group questionnaires. Facilitators will complete short feedback forms each session and attend a focus group upon completion.
~Psychology Assistants/Interns will collect records of self harm and violence/aggressive incidents for each service user as well as records of nursing observation level and leave status taken."
11314770|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
11314771|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
11314772|NCT02601365|Experimental|Aerosolized Sargramostim|A self-controlled, open-label study to evaluate safety of Sargramostim administered by nebulization
11314773|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
11314774|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.
~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
11314775|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
11314776|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.
~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
11314777|NCT02601326|Active Comparator|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
11314779|NCT02601313|Experimental|Axicabtagene ciloleucel/brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma (MCL) will receive conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0 or brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 CAR T cells/kg, with a maximum dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 1 or brexucabtagene autoleucel at a targeted dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 2.
11314780|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
11314781|NCT02601287|Experimental|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
11314782|NCT02601287|Experimental|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
11314783|NCT02601274|Experimental|Single Group Assignment|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .
11314784|NCT02601261||Patients with some access to internet during stay|
11314785|NCT02601261||Patients without access to internet during stay|
11314786|NCT02601248|Experimental|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
11314787|NCT02601235|Experimental|Naridrin|Naridrin: 2 drops in each nostril once daily as prescription
11314788|NCT02601235|Active Comparator|0.05 % Oxymetazoline Hydrochloride|2 pumps in each nostril every 12 hours
11314789|NCT02601222|Experimental|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
11314790|NCT02601222|Placebo Comparator|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
11314791|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11314792|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
11314793|NCT02601196|Other|Ulipristal acetate treatment|Women who receive UPA treatment before another IVF cycle.
11314794|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
11314795|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
11314796|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
11314797|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
11314798|NCT02601157|Experimental|Orsiro SES/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
11314799|NCT02601157|Active Comparator|Orsiro SES/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
11314800|NCT02601157|Experimental|CX-ISAR/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
11314801|NCT02601157|Active Comparator|CX-ISAR/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
11314802|NCT02601144|Experimental|VFS|variable frequency deep brain stimulation (VFS)
11314803|NCT02601144|Active Comparator|HFS|high frequency deep brain stimulation (HFS)
11314804|NCT02601144|Active Comparator|LFS|low frequency deep brain stimulation (LFS)
11314805|NCT02601144|No Intervention|DBS off|deep brain stimulation off
11314806|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
11314807|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
11314808|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
11314809|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
11314810|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
11314811|NCT02601118|Experimental|training group|41 training students were pre-tested before education with Micro Expression Training Tool (METT) and Subtle Expression Training Tool (SETT) at baseline and then, took second METT and SETT tests after a 1-hour class about interpreting micro and subtle expressions.
11314812|NCT02601118|No Intervention|control group|41 control students were pre-tested before education with METT and SETT at baseline and then, took the second tests without attend the training class.
11314814|NCT02601105|Active Comparator|Centella Asiatica|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
11314815|NCT02601092|Experimental|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.
~No drugs or devices will be used."
11314816|NCT02601092|Active Comparator|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.
~No drugs or devices will be used."
11314817|NCT02601079|Active Comparator|Conventional biopsy|"4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
11314818|NCT02601079|Active Comparator|Endodrill biopsy|"4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
11314819|NCT02601066|Experimental|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
11314820|NCT02601053|Active Comparator|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
11314821|NCT02601053|Experimental|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
11314822|NCT02601040|Experimental|Attenuated Hepatitis A Vaccine, H2 Strain|Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.
11314823|NCT02601040|Experimental|Inactivated Hepatitis A Vaccine, Lu8 Strain|Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.
11314824|NCT02601040|Placebo Comparator|Group A Meningococcal Polysaccharide vaccine|Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.
11314825|NCT02601027|Placebo Comparator|Placebo|sham TAP catheter with saline infusion
11314826|NCT02601027|Experimental|TAP catheter|infusion of 0.125% bupivacaine through TAP catheter
11314827|NCT02601014|Experimental|Treatment (nivolumab and ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
11314828|NCT02601001|Placebo Comparator|Treatment group C|Placebo
11314829|NCT02601001|Active Comparator|Treatment group A|25 mg and 37.5 mg
11314830|NCT02601001|Active Comparator|Treatment group B|25 mg and 50 mg
11314831|NCT02600988|No Intervention|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
11314832|NCT02600988|Experimental|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
11314833|NCT02600988|Experimental|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
11314834|NCT02600975|Active Comparator|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
11314835|NCT02600975|Active Comparator|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
11314836|NCT02600962||STEMI|Patients discharged with STEMI
11314837|NCT02600962||NSTEMI|Patients discharged with NSTEMI
11314838|NCT02600949|Experimental|Treatment (synthetic tumor-associated peptide vaccine therapy)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4 and 6, then every 3 weeks until week 30, then at weeks 39 and 51. Beginning 30 minutes after each vaccine is administered, patients then receive imiquimod cream topically after 30 minutes. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 3 weeks until week 51 in the absence of disease progression or unacceptable toxicity.
11314839|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
11314840|NCT02600923|Experimental|Palbociclib + Letrozole|palbociclib and letrozole combination
11314841|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.
~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.
~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.
~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
11314842|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.
~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.
~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.
~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
11314843|NCT02600897|Experimental|Dose-escalation Cohort: FL|Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
11314844|NCT02600897|Experimental|Dose-escalation Cohort: DLBCL|Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
11314845|NCT02600897|Experimental|Expansion Cohort: FL|Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
11314846|NCT02600897|Experimental|Expansion Cohort: DLBCL|Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
11314847|NCT02600884|Experimental|Families Talking Together Plus (FTT+HPV)|Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
11314848|NCT02600884|Active Comparator|Brief motivational interviewing (BMI)|Parents in the brief motivational interviewing (BMI) group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
11314849|NCT02600871|Experimental|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.
~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.
~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
11314850|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.
~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.
~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
11314851|NCT02600858|Experimental|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
11314852|NCT02600858|Other|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
11314853|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
11314854|NCT02600832|Experimental|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
11314855|NCT02600832|Sham Comparator|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
11314856|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
11314857|NCT02600819|Experimental|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
11314858|NCT02600806|Other|Azithromycin/levofloxacin|Azithromycin or levofloxacin are given according to serum procalcitonin levels
11314859|NCT02600793|Experimental|Arm 1|Single dose IV ceftaroline will be administered
11314860|NCT02600780|Active Comparator|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
11314861|NCT02600780|Experimental|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
11314862|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
11314863|NCT02600754|Experimental|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
11314864|NCT02600754|Experimental|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
11366177|NCT02259998|Active Comparator|Persantin® commercial formulation|
11314865|NCT02600754|No Intervention|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
11314866|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
11314867|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
11314868|NCT02600728|Experimental|experimental group (EG)|The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS).
11314869|NCT02600728|Active Comparator|control group (CG)|The control training (CT) consisted of a similar gait training without DMCS.
11314870|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
11314871|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
11314872|NCT02600702|No Intervention|usual care|quadricep exercise
11314873|NCT02600702|Experimental|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
11314874|NCT02600702|Active Comparator|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
11314875|NCT02600689|Experimental|Physical exercise training|Combined aerobic and resistance exercise for 30 or more minutes at least 3 times per week for 12 weeks using the Wii Fit Plus
11314876|NCT02600689|Active Comparator|Cognitive exercise training|Cognitive, brain-training, video gaming ~30 minutes per session, 3 times per week for 12 weeks
11314877|NCT02600676|Active Comparator|TENS, 10 weeks (active) 2 hours a day.|26 children.
11314878|NCT02600676|Placebo Comparator|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
11314879|NCT02600663||acute back pain|
11314880|NCT02600650|Experimental|Experimental|Receive daily authentic Testosterone boosting supplement
11314881|NCT02600650|Placebo Comparator|Placebo|Receive daily placebo supplementation
11314882|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
11314883|NCT02600637|Active Comparator|Education|Educational group program
11314884|NCT02600624||Participants|Women who are in active labor and their newborn infants.
11314885|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
11314886|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
11314887|NCT02600598|Experimental|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
11314888|NCT02600598|Experimental|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
11314889|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
11314890|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
11314891|NCT02600572|Experimental|Isometric exercise|Subjects performing the isometric exercises intervention
11314892|NCT02600572|Experimental|Eccentric exercise|Subjects performing the eccentric exercises intervention
11314893|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
11314894|NCT02600533|No Intervention|Standard care/control group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the standard of care group will be provided standard educational resources (booklet and DVD), with no additional instructions. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
11314895|NCT02600533|Experimental|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
11314896|NCT02600520|Active Comparator|Rosuvastatin Group|SRP followed by RSV gel LDD
11314897|NCT02600520|Active Comparator|Atorvastatin Group|SRP followed by ATV gel LDD
11314898|NCT02600520|Placebo Comparator|Placebo group|SRP followed by placebo gel LDD
11314899|NCT02600507|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as capsules once daily for 6 weeks
11314900|NCT02600507|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as capsules once daily for 6 weeks
11314901|NCT02600507|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
11314902|NCT02600494|Experimental|40 mg ITI-007 (Lumateperone)|40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
11314903|NCT02600494|Experimental|60 mg ITI-007 (Lumateperone)|60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
11314904|NCT02600494|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
11314905|NCT02600481|Experimental|low-pressure pneumoperitoneum group|Subjects assigned to the low-pressure pneumoperitoneum group will receive 7-10 mm Hg carbon dioxide pneumoperitoneum, and the expected duration is longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
11315029|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
11314906|NCT02600481|Active Comparator|standard-pressure pneumoperitoneum group|Subjects assigned to the standard-pressure pneumoperitoneum group will receive 12-16 mm Hg carbon dioxide pneumoperitoneum, which is expected lasted longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
11314907|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
11314908|NCT02600455||Patients who are treated with ORENCIA|Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
11314909|NCT02600442||main and unique cohort|
11314910|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
11314911|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
11314912|NCT02600416|Other|AV port reversal|Patients undergoing citrate CVVH.
11314913|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
11314914|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
11314915|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
11314916|NCT02600390|Experimental|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
11314917|NCT02600390|Experimental|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
11314918|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
11314919|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
11314920|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
11314921|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
11314922|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
11314923|NCT02600312|Active Comparator|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
11314924|NCT02600312|No Intervention|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
11314925|NCT02600299|Experimental|Intervention Arm|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship. This program is designed to take place on three individual days on a weekend. For each session, three major topics will be covered, with lectures and interactive workshop integrated. Sessions will be conducted by healthcare professionals who are experts/well-versed in their respective domains.
11314926|NCT02600299|Placebo Comparator|Usual Care|No active intervention provided.
11314927|NCT02600286|Experimental|1|"Arm (1) will be randomised to receive either :
~5 mg/per os of EllaOne every day through 12 months.
~10 mg/per os of EllaOne every day through 12 months.
~EllaOne placebo/per os every day through 12 months."
11314928|NCT02600286|Experimental|2|"Arm (2) will be randomised to receive either :
~5 mg/per os of EllaOne every day through 12 months.
~10 mg/per os of EllaOne every day through 12 months.
~EllaOne placebo/per os every day through 12 months."
11314929|NCT02600286|Experimental|3|"Arm (3) will be randomised to receive either :
~5 mg/per os of EllaOne every day through 12 months.
~10 mg/per os of EllaOne every day through 12 months.
~EllaOne placebo/per os every day through 12 months."
11314930|NCT02600273|Active Comparator|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
11314931|NCT02600273|Experimental|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
11314932|NCT02600273|Experimental|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
11314933|NCT02600273|Experimental|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
11314934|NCT02600260|Other|enoxaparin|A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
11314935|NCT02600260|Other|no intervention|Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
11314936|NCT02600247|Experimental|Duloxetine group|"Experimental: Duloxetine group
~Phase I (preemptive): 1day before operation (30mg for 1 day)
~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon"
11314937|NCT02600247|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
11314938|NCT02600234|Experimental|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
11314939|NCT02600234|Placebo Comparator|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
11314940|NCT02600208|Experimental|Single Experimental Arm|Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device
11314941|NCT02600195|Experimental|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
11314942|NCT02600195|No Intervention|Control sites|Continue current practices
11314943|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
11314944|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
11314945|NCT02600169||Patients treated with pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.
11314946|NCT02600156|Experimental|Single arm study|MR guided focal laser ablation of prostate cancer using the Visualase Thermal Therapy System.
11314947|NCT02600130|Experimental|Cohort 1|Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.
11314948|NCT02600130|Experimental|Cohort 2|Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.
11314949|NCT02600130|Placebo Comparator|Cohort 3|Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion.
11314950|NCT02600117|Other|Tenofovir disoproxil fumarate|300 mg, orally, once a day for 3 years or when sAg+ve seroconverts to sAb+ve whichever comes earlier
11314951|NCT02600104|Experimental|all subjects|will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
11314952|NCT02600091|Experimental|MBCT Intervention|Participants in the Mindfulness-based Cognitive Therapy Intervention arm will receive an 8-week programme in mindfulness-based cognitive therapy
11314953|NCT02600091|No Intervention|Waiting List Control|The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
11314954|NCT02600078|Active Comparator|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
11314955|NCT02600078|Sham Comparator|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
11314956|NCT02600078|Active Comparator|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
11314957|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.
~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
11314958|NCT02600052|Experimental|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
11314959|NCT02600052|Active Comparator|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
11314960|NCT02600039|Experimental|ELTGOL|
11314961|NCT02600039|Active Comparator|Acapella|
11314962|NCT02600026|Experimental|Video Camera: Intervention|DriveCam video event recorder with feedback
11314963|NCT02600026|Placebo Comparator|Video Camera: Monitoring|DriveCam video event recorder with no feedback
11314964|NCT02600000|Experimental|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
11314965|NCT02600000|Experimental|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
11314966|NCT02600000|Experimental|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
11314967|NCT02600000|Experimental|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
11315030|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
11314968|NCT02599987|Experimental|Inspiratory Muscle Training Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The training group will carry with IMT load of 50% of MIP. Weekly, patients attend the Cardiopulmonary Physical Therapy Laboratory for evaluation of MIP and load adjustment, performing a training session in the presence of the therapist, while other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
11314969|NCT02599987|Sham Comparator|Sham Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The sham group will carry without load, but will be subjected to the same procedures in the experimental group (simulation of load adjustment in the Cardiopulmonary Physical Therapy Laboratory) to ensure blinding of the study, other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
11314970|NCT02599961|Experimental|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
11314971|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
11314972|NCT02599935|Experimental|educational intervention and supplements|structured educational intervention and dietary supplements
11314973|NCT02599935|Active Comparator|usual interventions|Usual treatment without nutritional supplements or structured assessment
11314974|NCT02599922|Experimental|Group 1: 2.0 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314975|NCT02599922|Experimental|Group 2: 4.0 x 10^10 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314976|NCT02599922|Experimental|Group 3: 1.2 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314977|NCT02599922|Experimental|Group 4: 3.6 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314978|NCT02599922|Experimental|Group 4a: 3.6 x 10^11 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314979|NCT02599922|Experimental|Group 5: 1.1 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314980|NCT02599922|Experimental|Group 5a: 1.1 x 10^12 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314981|NCT02599922|Experimental|Group 6: 3.2 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
11314982|NCT02599922|Experimental|Group 7: MTD of AGTC-401|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
11314983|NCT02599909||1/ Cohort 1|Subjects with hepatocellular carcinoma
11314984|NCT02599896|Experimental|Group 1|5 mg/kg/IV on Day 0
11314985|NCT02599896|Experimental|Group 2|5 mg/kg SC on Day 0
11314986|NCT02599896|Experimental|Group 3|20 mg/kg IV on Day 0
11314987|NCT02599896|Experimental|Group 4|40 mg/kg IV on Day 0
11314988|NCT02599896|Experimental|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
11314989|NCT02599896|Experimental|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
11314990|NCT02599896|Experimental|Group 7|5 mg/kg SC on Day 0, Week 4
11314991|NCT02599896|Experimental|Group 8|20 mg/kg IV on Day 0, Week 4
11314992|NCT02599883|Experimental|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
11314993|NCT02599870|Experimental|NeuroIDgenetix Test Panel Intervention|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
11314994|NCT02599870|No Intervention|Control|The medical provider for the control group will not receive the NeuroIDgenetix Test Panel results and will make post-operative pain management recommendations based as usual. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
11314995|NCT02599857|Experimental|CONCOR smartphone application|Use of CONCOR smartphone application
11314996|NCT02599857|No Intervention|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
11314997|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
11314998|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
11314999|NCT02599831|Experimental|Electrical pudendal nerve stimulation|"Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum).
~Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 times per week for 8 weeks."
11315062|NCT02599389|Experimental|Drug-coated balloons|Angioplasty with use of drug-coated balloons
11315000|NCT02599831|Active Comparator|PFM training with Transanal ES|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of < 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
11315001|NCT02599818|Experimental|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
11315002|NCT02599818|No Intervention|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
11315003|NCT02599805|Experimental|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
11315004|NCT02599805|No Intervention|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:
~Full medical assessment in all cases.
~Surgical operation/Intervention where indicated.
~Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
11315005|NCT02599792|Experimental|CTP-656, 150 mg|Single Oral Dose
11315006|NCT02599792|Active Comparator|Kalydeco, 150 mg|Single oral dose
11315007|NCT02599792|Experimental|CTP-656, 75 mg or matching placebo|Subjects will be administered 75 mg CTP-656 for 7 days.
11315008|NCT02599792|Experimental|CTP-656, 150 mg or matching placebo|Subjects will be administered 150 mg CTP-656 for 7 days.
11315009|NCT02599792|Experimental|CTP-656, high dose or matching placebo|Subjects will be administered up to 300 mg CTP-656 for 7 days.
11315010|NCT02599779|Experimental|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.
~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
11315011|NCT02599779|Experimental|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.
~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
11315012|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
11315013|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
11315014|NCT02599753|Experimental|18F-DTBZ for Parkinson's Disease|The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
11315015|NCT02599740|Placebo Comparator|Placebo|Rice only
11315016|NCT02599740|Active Comparator|Assumed active|Assumed key active consumed with rice
11315017|NCT02599740|Active Comparator|Natural fruit extract|Natural fruit extract consumed with rice
11315018|NCT02599727|Experimental|Active Isometric exercise|Subjects performing the isometric exercises intervention
11315019|NCT02599727|Active Comparator|No exercise|Subjects not performing the isometric exercises intervention
11315020|NCT02599714|Experimental|Triplet Combination (Dose Finding)|Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
11315021|NCT02599714|Experimental|Triplet Combination (Dose Expansion)|Additional patients will be enrolled at the dose determined in Part A.
11315022|NCT02599701|Placebo Comparator|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
11315023|NCT02599701|Experimental|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
11315024|NCT02599675|Experimental|Vitamin D3|Vitamin D3 capsules for 12 weeks (2000 IU daily, equivalent to 50 ug)
11315025|NCT02599675|Placebo Comparator|Placebo|Placebo capsules for 12 weeks (the number of daily capsules will match that of the vitamin D-group)
11315026|NCT02599662|Other|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
11315027|NCT02599662|Other|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
11315028|NCT02599662|Other|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
11315031|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
11315032|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
11315033|NCT02599623|Experimental|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
11315034|NCT02599623|Active Comparator|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
11315035|NCT02599610|Active Comparator|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
11315036|NCT02599610|Experimental|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
11315037|NCT02599597|Experimental|Therapist-assisted iCBT|Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse. Monthly depression screening with therapist feedback.
11315038|NCT02599597|Active Comparator|Monthly screening with feedback|Monthly depression screening with therapist feedback.
11315039|NCT02599597|No Intervention|Control|No intervention, follow-up along with all participants at 6 and 12-months.
11315040|NCT02599584|Experimental|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
11315041|NCT02599584|No Intervention|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
11315042|NCT02599571|Other|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
11315043|NCT02599571|Other|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
11315044|NCT02599558|Experimental|Cytosponge,Diet,EEsAI Pro,Phone call|Patients going through the six food elimination diet (clinically)for EoE, will be asked to participate. We will introduce 1 of the 6 foods previously eliminated for two weeks, than another for two weeks, at the end of 4 weeks the participant will return to swallow the cytosponge to monitor them through the diet, rather than multiple repeat Upper Endoscopies. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the diet, which foods to add or take out of the diet.
11315045|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
11315046|NCT02599532|Other|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
11315047|NCT02599532|Other|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
11315048|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
11315049|NCT02599493|Experimental|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
11315050|NCT02599493|Active Comparator|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
11315051|NCT02599480|Active Comparator|mirabegron|Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
11315052|NCT02599480|Placebo Comparator|Placebo|Patients will be orally administererd with a placebo once a day during 12 months.
11315053|NCT02599467|Experimental|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.
~Procedure: ULNT 1 and EMG recording."
11315054|NCT02599467|Experimental|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.
~Procedure: ULNT 1 and EMG recording"
11315055|NCT02599467|Active Comparator|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.
~Procedure: ULNT 1 and EMG recording."
11315056|NCT02599454|Experimental|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.
~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
11315057|NCT02599441||Ankle fracture cases|
11315058|NCT02599415|Other|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
11315059|NCT02599402|Experimental|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
11315060|NCT02599402|Experimental|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
11315061|NCT02599389|No Intervention|Standard balloon|Angioplasty with use of standard balloons
11366178|NCT02259985|Experimental|Itasetron tablet fed|
11315063|NCT02599389|Experimental|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
11315064|NCT02599376|Active Comparator|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
11315065|NCT02599376|Experimental|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
11315066|NCT02599350||1|Patients receiving mechanical ventilation
11315067|NCT02599337|Experimental|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
11315068|NCT02599337|Active Comparator|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
11315069|NCT02599324|Experimental|Renal Cell Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.
~Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus."
11315070|NCT02599324|Experimental|Urothelial Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.
~Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel."
11315071|NCT02599324|Experimental|Gastric Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.
~Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
11315072|NCT02599324|Experimental|Colorectal Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.
~Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
11315073|NCT02599324|Experimental|Urothelial Carcinoma Ibrutinib- Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b.
11315074|NCT02599324|Experimental|Urothelial Carcinoma with Pembrolizumab - Recruiting|Phase 1b: Patients will receive ibrutinib at various dose levels in combination with pembrolizumab to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.
11315075|NCT02599311|Other|the efficacy|transvaginal synthetic mesh
11315076|NCT02599311|No Intervention|the recurrence rate|transvaginal synthetic mesh
11315077|NCT02599311|No Intervention|the quality of life|transvaginal synthetic mesh
11315078|NCT02599311|Other|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
11315079|NCT02599298|Active Comparator|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
11315080|NCT02599298|No Intervention|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
11315081|NCT02599285||Fixation|Patients with a trimalleolar AO Weber C fracture with open reduction and fixation of the posterior malleolar fragment.
11315082|NCT02599285||No Fixation|Patients with a trimalleolar AO Weber C fracture without open reduction and fixation of the posterior malleolar fragment.
11315083|NCT02599272|Other|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
11315084|NCT02599272|Active Comparator|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
11315085|NCT02599272|Active Comparator|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
11315086|NCT02599259|Experimental|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
11315087|NCT02599259|No Intervention|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
11315088|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.
~Interventions:
~In hospital pain evaluation
~In hospital questionnaires
~Telephone conctact at 3 months"
11315089|NCT02599207|Experimental|Matched related umbilical cord blood|Six subjects will receive an infusion of HLA matched sibling umbilical cord blood cells.
11315090|NCT02599207|Experimental|Mismatched related umbilical cord blood|Nine subjects will receive an infusion of HLA-mismatched (≥3/6 match) or matched sibling umbilical cord blood cells.
11315091|NCT02599194|Experimental|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
11315092|NCT02599181|Experimental|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland prior to perineural catheter removal.
11315093|NCT02599181|No Intervention|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
11315168|NCT02598791|Active Comparator|IIGI+GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
11366179|NCT02259985|Active Comparator|Itasetron tablet fasted|
11315094|NCT02599168|Active Comparator|Dexmedetomidine group|Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
11315095|NCT02599168|Placebo Comparator|Non-Dexmedetomidine group|Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
11315096|NCT02599155|Placebo Comparator|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
11315097|NCT02599155|Active Comparator|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
11315098|NCT02599142|Active Comparator|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
11315099|NCT02599142|Experimental|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
11315100|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
11315101|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
11315102|NCT02599116|Other|Microbiome cohort|"Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.
~Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires
~Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
11315103|NCT02599103|Placebo Comparator|fat-free milkshake|
11315104|NCT02599103|Active Comparator|Olive oil|
11315105|NCT02599103|Experimental|soybean oil|
11315106|NCT02599103|Experimental|fried soybean oil|
11315107|NCT02599103|Experimental|palm oil|
11315108|NCT02599103|Experimental|fried palm oil|
11315109|NCT02599103|Experimental|camellia oil|
11315110|NCT02599103|Experimental|fried camellia oil|
11315111|NCT02599103|Experimental|tallow|
11315112|NCT02599103|Experimental|fried tallow|
11315113|NCT02599090|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle
~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
11315114|NCT02599090|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
11315115|NCT02599090|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
11315116|NCT02599090|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
11315117|NCT02599077|Experimental|Dienogest|the patient handling with 2 mg dienogest / day.
11315118|NCT02599077|Active Comparator|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
11315119|NCT02599064|Experimental|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
11315120|NCT02599051|Active Comparator|Monarc|Placement of a transobturator monarc sling for stress urinary incontinence
11315121|NCT02599051|Experimental|Mini-arc|Placement of a single incision mini-arc sling for stress urinary incontinence
11315122|NCT02599038|Experimental|Serine supplementation|Serine oral administration 20mg/kg/day
11315123|NCT02599025|No Intervention|Supine position|Children tested while lying down
11315124|NCT02599025|No Intervention|Standing position|Children tested while standing
11315125|NCT02599025|Experimental|Cycling supine postion|Children lying down with APT cycling system
11315126|NCT02599025|Experimental|Cycling standing postion|Children standing with Innowalk cycling system
11315127|NCT02599012|Experimental|Subjects|
11315128|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
11315129|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
11315130|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
11315131|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
11315132|NCT02598986|Placebo Comparator|white pita bread|Pita bread made of white wheat flour
11315133|NCT02598986|No Intervention|Whole grain pita bread|no macronutrient supplementation
11315134|NCT02598986|Experimental|Restored white pita bread|macronutrient supplementation
11315135|NCT02598986|Experimental|Fortified white pita bread|macronutrient supplementation 2
11315136|NCT02598973|Active Comparator|Exercise|aerobic walking
11315137|NCT02598973|No Intervention|No exercise|normal activity
11315138|NCT02598960|Experimental|BMS-986156: Dose Escalation|
11315139|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Escalation|
11315140|NCT02598960|Experimental|BMS-986156: Dose Expansion|
11315141|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Expansion|
11315142|NCT02598960|Experimental|BMS986156 + Nivo: Cohort Expansion|
11315143|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
11315144|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
11315145|NCT02598934|Experimental|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
11315146|NCT02598934|Experimental|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
11315147|NCT02598921|Other|Three dimensional ultrasound|Three dimensional ultrasound evaluated the uterine cavity for cavitary lesions
11315148|NCT02598921|Other|Office hysteroscopy|Office hystrescopy evaluated the uterine cavity for cavitary lesions
11315149|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
11315150|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
11315151|NCT02598895|Experimental|Treatment (docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
11315152|NCT02598882|Active Comparator|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
11315153|NCT02598882|Active Comparator|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
11315154|NCT02598869|Active Comparator|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
11315155|NCT02598869|Active Comparator|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
11315156|NCT02598856|Experimental|Intranasal naloxone 1x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
11315157|NCT02598856|Active Comparator|Intranasal naloxone 2x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
11315158|NCT02598856|Active Comparator|Intravenous naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
11315159|NCT02598856|Active Comparator|Intramuscular naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
11315160|NCT02598843|Active Comparator|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is removed and patients mobilise fully weightbearing for a further 2 weeks out of cast, with internal shoe insert heel raise. Commence physiotherapy at 10 weeks, when cast removed.
11315161|NCT02598843|Experimental|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossur rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 8 weeks.
11315162|NCT02598830|Experimental|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:
~weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+
~weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+
~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:
~weeks 15-17, familiarization period
~week 18, test period
~weeks 19-28, intervention period
~weeks 29-30, test period"
11315163|NCT02598830|Placebo Comparator|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)
~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:
~weeks 15-17, familiarization period
~week 18, test period
~weeks 19-28, intervention period
~weeks 29-30, test period"
11315164|NCT02598817||Standard Infant Formula|Standard Infant Formula containing High Sn-2
11315165|NCT02598804|Experimental|Intervention group|"No single group but 2 groups :
~Intervention group (5 educational workshop in addition to spa therapy)
~Control group (Written information booklet in addition to spa therapy)"
11315166|NCT02598804|Other|control group|"No single group but 2 groups :
~Intervention group (5 educational workshop in addition to spa therapy)
~Control group (Written information booklet in addition to spa therapy)"
11315167|NCT02598791|Active Comparator|IIGI+GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
11315170|NCT02598791|Active Comparator|IIGI+GIP+GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
11315171|NCT02598791|Other|50 g OGTT|50 g oral glucose tolerance test (OGTT)
11315172|NCT02598778|Active Comparator|Chlorhexidine gluconate (.12%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
11315173|NCT02598778|Active Comparator|Sodium fluoride oral rinse (.05%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
11315174|NCT02598778|Active Comparator|Coconut oil|A food product. In previous studies it has shown positive effects on the reduction of oral plaque and gingivitis as an oral rinse.
11315175|NCT02598778|Placebo Comparator|Deionized water|Water that has had the majority of its ions removed.
11315176|NCT02598765|Active Comparator|Standard Trabeculectomy|Patients in the Standard Trabeculectomy arm will undergo regular trabeculectomy
11315177|NCT02598765|Experimental|Microtrabeculectomy|Patients in the Microtrabeculectomy arm will undergo microtrabeculectomy
11315178|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
11315179|NCT02598739|Experimental|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.
~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).
~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
11315180|NCT02598739|Other|Control group|Waiting list for the exercises.
11315181|NCT02598726|Experimental|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
11315182|NCT02598713|Experimental|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
11315183|NCT02598687|Other|treatment|treatment arm: TH-302 pre-treatment day 4 and weekly during treatment. 5 x carboplatin and paclitaxel, radiotherapy: 23 x 1.8Gy HX4 scans day 1 and day 8,surgery 6-10 weeks after chemo-radiotherapy
11315184|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
11315185|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
11315186|NCT02598661|Experimental|Part 1: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
11315187|NCT02598661|Experimental|Part 2: Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
11315188|NCT02598661|Placebo Comparator|Part 2: Placebo|Matching Placebo to Imetelstat will be administered.
11315189|NCT02598648|Other|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
11315190|NCT02598648|Other|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.
~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
11315191|NCT02598648|Other|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2< 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
11315192|NCT02598635|Experimental|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
11315193|NCT02598635|Placebo Comparator|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
11315424|NCT02597049|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
11315194|NCT02598622|Experimental|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
11315195|NCT02598622|Experimental|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
11315196|NCT02598609|Other|Cluster A|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
11315197|NCT02598609|Other|Cluster B|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.
11315198|NCT02598609|Other|Cluster C|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.
11315199|NCT02598596|Experimental|Pegloticase regimen <120 kg - Main Study|Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
11315200|NCT02598596|Experimental|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
11315201|NCT02598596|Experimental|Pegloticase PK Sub-Study|Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
11315202|NCT02598596|Experimental|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
11315203|NCT02598596|Experimental|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
11315204|NCT02598596|Experimental|Pegloticase and Azathioprine|Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
11315205|NCT02598583|Experimental|Cohort 1|"Intravenous infusion of ALXN1210 as follows:
~Induction phase: a) 400 milligrams (mg) on Day 1 and Day 8, 600 mg on Day 15; or b) 600 mg on Day 1, 600 mg on Day 15
~Maintenance phase: the first 5 doses of 900 mg on Day 29 and every 4 weeks thereafter
~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:
~≥40 to <60 kilograms (kg): 3000 mg every 8 weeks
~≥60 to <100 kg: 3300 mg every 8 weeks
~≥100 kg: 3600 mg every 8 weeks"
11315206|NCT02598583|Experimental|Cohort 2|"Intravenous infusion of ALXN1210 as follows:
~Induction phase: 600 mg on Day 1, 900 mg on Day 15
~Maintenance phase: the first of 5 doses of 1800 mg on Day 29 and every 4 weeks thereafter
~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:
~≥40 to <60 kg: 3000 mg every 8 weeks
~≥60 to <100 kg: 3300 mg every 8 weeks
~≥100 kg: 3600 mg every 8 weeks"
11315207|NCT02598570|Experimental|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
11315208|NCT02598557|Experimental|Arm I (exemestane)|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
11315209|NCT02598557|Experimental|Arm II (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
11315210|NCT02598557|Experimental|Arm III (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
11315211|NCT02598544|Other|lean men|
11315212|NCT02598544|Other|Obese men without type 2 diabetes|
11315213|NCT02598544|Other|Obese men with type 2 diabetes|
11315214|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
11315215|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
11315216|NCT02598518|Experimental|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
11315271|NCT02598063|Experimental|Peginterferon alfa-2a + Lamivudine|Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
11315217|NCT02598518|Active Comparator|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
11315218|NCT02598505|Experimental|Indacaterol|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
11315219|NCT02598505|Placebo Comparator|Placebo|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
11315220|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
11315221|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
11315222|NCT02598466||Abatacept|
11315223|NCT02598453|Experimental|Ibandronate IV|Participants will receive ibandronate 3 mg IV once every 3 months
11315224|NCT02598453|Experimental|Ibandronate Oral|Participants will receive ibandronate 150 milligrams (mg) tablet once monthly
11315225|NCT02598440|Experimental|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
11315226|NCT02598440|Experimental|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
11315227|NCT02598427|Experimental|Intrathecal Pertuzumab and Trastuzumab|"Four cohorts will enroll in a dose escalation of pertuzumab and a consistent dose of trastuzumab. The cohorts will be assigned as follows:
~Cohort: Intrathecal Dose:
~10mg pertuzumab, 80mg trastuzumab
~20mg pertuzumab, 80mg trastuzumab
~40mg pertuzumab, 80mg trastuzumab
~80mg pertuzumab, 80mg trastuzumab"
11315228|NCT02598414|Experimental|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
11315229|NCT02598414|Active Comparator|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
11315230|NCT02598388|Experimental|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
11315231|NCT02598388|Experimental|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
11315232|NCT02598388|Experimental|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
11315233|NCT02598375||Children with feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have the feeding intolerance at least for12 hours or more.
11315234|NCT02598375||Children without feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have not the feeding intolerance signs at least for 12 hours or less
11315235|NCT02598362|Other|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
11315236|NCT02598362|Other|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
11315237|NCT02598349|Experimental|Proton Radiation with capecitabine|"The following will be performed in this group: Proton Radiation Therapy with concomitant oral chemotherapy, capecitabine taken on radiation treatment days for 6 weeks. A surgical resection will be performed between 8 and 16 weeks if radiographic studies suggest operability.
~Additionally, a Functional Assessment of Cancer Therapy (FACT-Hep) questionnaire is to be filled out by participants at baseline, at week 4 and week 6, then 1 month after completion of treatment, then every 3 months for 1 year, and then every 6 months for 3 years. The FACT-Hep questionnaire is specific to those with gastrointestinal cancers focusing on hepatobiliary and pancreatic cancer."
11315238|NCT02598336|Other|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
11315239|NCT02598336|Other|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
11315240|NCT02598323|Experimental|patients with active singleton pregnancy between 16 and 26 SA|
11315241|NCT02598310|Experimental|nab-paclitaxel plus trastuzumab|Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
11315242|NCT02598297|Active Comparator|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
11315243|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
11315244|NCT02598284|Experimental|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
11315245|NCT02598284|Experimental|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
11315246|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
11315247|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
11315272|NCT02598050||older surgical patients|Mini Cog
11315273|NCT02598037|Other|FTO gene polymorphism|test meal after fasting for 12 hours
11366180|NCT02259985|Active Comparator|Itasetron infusion fasted|
11315248|NCT02598258|Experimental|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
11315249|NCT02598245|Active Comparator|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
11315250|NCT02598245|Experimental|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
11315251|NCT02598232|Experimental|1,414nm Nd:YAG laser|It has high absorption coefficient in water and a short pulse width.
11315252|NCT02598219|Experimental|Pre-operative SN mapping with radionucleide|"1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA
~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye
~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.
~If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).
~If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology"
11315253|NCT02598219|Other|B : Current initial staging protocols|Current initial staging protocols
11315254|NCT02598206|Experimental|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:
~A - B B - A"
11315255|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
11315256|NCT02598180|Experimental|VergenixTM Flowable Gel|VergenixTM Flowable Gel
11315257|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
11315258|NCT02598154||Study population|The study population consists of patients whose age is between 20 and 75 years and who experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients or patients consultating in the neurological rehabilitation service (NHS) at the Grau du Roi Medical Center, Nîmes University Hospital.
11315259|NCT02598141|Other|Per-op biopsy around material|"Patients included in this study require biopsies for suspicion of infected osteo-articular materials (implants, protheses, nails, screw, plates).
~Interventions:
~Biological sampling grinding
~Biological sampling with standard procedures"
11315260|NCT02598128|Experimental|RELiZORB|Treatment (RELiZORB)
11315261|NCT02598128|Placebo Comparator|Control|Placebo control
11315262|NCT02598115|No Intervention|Before collarborative pharmaceutical care|"All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.
~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
11315263|NCT02598115|Experimental|After collarborative pharmaceutical care|"All clusters start in the No Intervention arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.
~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
11315264|NCT02598102|Experimental|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
11315265|NCT02598102|Placebo Comparator|Placebo|Placebo one hour prior to stent removal
11315266|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:
~NYMC BX-51B reassortant of B/Massachusetts/2/2012
~NYMC X-179A reassortant of A/California/7/2009 (H1N1)
~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
11315267|NCT02598089|Placebo Comparator|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
11315268|NCT02598076|Active Comparator|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
11315269|NCT02598076|Experimental|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
11315270|NCT02598063|Active Comparator|ADV + Lamivudine|Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
11366182|NCT02259972|Experimental|BI 113823 tablet|dose group 5 only
11315274|NCT02598024|Experimental|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
11315275|NCT02598024|Experimental|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
11315276|NCT02598024|No Intervention|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
11315277|NCT02598011|Experimental|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.
~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
11315278|NCT02598011|Experimental|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.
~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
11315279|NCT02597998|Experimental|14C-BI 409306|14C-BI 409306 oral solution
11315280|NCT02597985|Active Comparator|Prehabilitation|Will receive 4 weeks of supervised exercised prescription before they undergo TAVR and will monitor and record, improvement if any, in the short-term physical performance battery score
11315281|NCT02597985|Placebo Comparator|Usual care|Will receive usual care
11315282|NCT02597972|Active Comparator|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
11315283|NCT02597972|Active Comparator|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
11315284|NCT02597959||risk factors of musculoskeletal injuries|trainees for surgical assistants - determining the level of risk
11315285|NCT02597959||design wearable devices|Creating feedback mechanism to reduce surgical assistant musculoskeletal risk
11315286|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
11315287|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
11315288|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
11315289|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
11315290|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
11315291|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
11315292|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
11315293|NCT02597894|Other|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
11315294|NCT02597868|Active Comparator|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
11315295|NCT02597868|Experimental|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
11315296|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
11315297|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
11315298|NCT02597842|Experimental|shuangxuezu|Patients were given 30min of TEAS before induction until the end of the operation at two acupoints.
11315299|NCT02597842|Experimental|neiguanxuezu|Patients were given TEAS at neiguan acupoint.
11315300|NCT02597842|Experimental|zusanlixuezu|Patients were given TEAS at Zusanli acupoint.
11315301|NCT02597842|Sham Comparator|duizhaozu|Patients were not given TEAS at two acupoints.
11315302|NCT02597829|Other|Open Label Certolizumab Pegol|Active Treatment
11315303|NCT02597816|Other|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
11315304|NCT02597803|Experimental|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
11315305|NCT02597803|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
11315306|NCT02597803|Experimental|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
11315307|NCT02597790||Group A (HIV/HCV coinfected)|
11315308|NCT02597790||Group B (HIV monoinfected)|
11315309|NCT02597777|Placebo Comparator|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
11315310|NCT02597777|Experimental|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
11315311|NCT02597764|Active Comparator|Standard Urotherapy (SU)|Standard Urotherapy (SU): A non-invasive therapy combining cognitive, behavioral and physical therapy. The study team will explain the problem to the children and their parents and educate them on the following: proper voiding mechanics, sitting, standing positions, how and when to void, techniques on relaxing pelvic floor muscles, and avoiding straining. An assessment of bowel habits will be done and their diet and drinking/voiding habits will be modified to maintain proper hydration with timed voiding. Voiding diaries will be provided for the assessment of the bladder and bowel habits.
11315312|NCT02597764|Experimental|Standard Urotherapy (SU) + Diaphragmatic Beathing (DB)|"Standard Urotherapy (SU) with the addition of Diaphragmatic Breathing (DB):
~A non-invasive breathing technique that is performed by a marked expansion of the abdomen (contracting diaphragm) rather than chest cavity during inspiration and tightening of the stomach muscles during expiration. Participants will lie on their back on a flat surface. Head is supported with a pillow and knees are bent forward supported by another pillow. Participants will place one hand on chest and the other on the abdomen, then start inhalation by moving their abdomen out against their hand, breathing in through their nose while keeping their chest and the other hand as still as possible. During expiration, the participants will tighten their abdominal muscles by forcing them inward and breathe out through pursed lips while keeping the hand on the chest as still as possible. Participants will be asked to perform this exercise for 10 minutes 3 times daily for 3 months."
11315313|NCT02597751|Experimental|Treatment Arm|Participants are randomized to treatment group. After the first MRI scan, participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a second MRI scan. Twelve weeks later, participants have a third, follow-up scan.
11315314|NCT02597751|No Intervention|Waitlist control|"Participants are randomized to the waitlist control group. After the first MRI scan, participants wait for 12 weeks and then have a 2nd MRI scan. Participants then have 10 treatment sessions with an occupational therapist and are assessed by an independent occupational therapist before and after treatment. Participants then have a third MRI scan to examine brain changes associated with intervention."
11315315|NCT02597738|Experimental|Lung/ Head and Neck Cancer Group|Blood/Urine Sample Collection Fresh tissue biopsy A one time fresh tissue biopsy of the patient's lung cancer (outside of their normal standard of care biopsy) will be collected for the research. Patients will also complete research blood and urine sample collections every two to four weeks for one year, then up to 120 days for years two through five.
11315316|NCT02597738|Experimental|Chronic inflammatory disease|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
11315317|NCT02597738|Experimental|At risk for lung cancer|Blood/Urine Sample Collection A one time blood and urine sample collection will be completed.
11315318|NCT02597738|Experimental|Healthy people who exercise|Blood/Urine Sample Collection Blood and urine collection one time prior to exercise and one time after exercise.
11315319|NCT02597738|Experimental|Lung cancer with planned resection|"Blood/Urine Sample Collection Blood and/or urine sample collection one time before surgery and one time after surgery. Blood and/or urine sample collection at subsequent visits.
~Fresh tissue biopsy Tissue sample collection from surgery is there is any tissue considered to be pathological waste that would normally be discarded."
11315320|NCT02597738|Experimental|Solid tumor cancer w/ radiation therapy|Blood/Urine Sample Collection Blood and/or urine sample collection prior to radiation treatment. Blood and/or urine collection after completion of radiation therapy. Blood and/or urine collection at subsequent visits for next 5 years.
11315321|NCT02597725||Urodynamics|There is no intervention in this study.
11315322|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
11315323|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
11315324|NCT02597699|Active Comparator|Arm 1: Sufentanil + Lidocaïne|"For patients randomized to arm 1, as in the current practice, we will inject Sufentanil intra-cordially at the dose of 1.5 μg / kg of the estimated fetal weight, then the Lidocaïne 1% bolus of 10 ml (10 mg / ml).
~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of fetal asystole, we will inject 100mg of Lidocaïne 1% in bolus of 10 ml. In the event of failure of the procedure, we will inject 10ml of KCL 10% intra-cordial if the cord is always accessible, if not intra-cardiac."
11315325|NCT02597699|Experimental|Arm 2: Remifentanil + Lidocaïne|"For patients randomized to arm 2, we will inject 30 μg of intravenous Remifentanil (Ultiva®) followed by Xylocaine 1% in a 10 ml bolus (10 mg / ml).
~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of asystole, we will inject 100 mg of Lidocaïne 1% in bolus of 10 ml. In case of failure of the procedure, we will inject 10 ml of KCL 10% intra-cordial if the cord is still accessible, if not intra-cardiac."
11315326|NCT02597686|Experimental|SD-PB training|
11315327|NCT02597673|Active Comparator|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
11315351|NCT02597569||Historical Control|Patient participants will be recruited from an inpatient rehabilitation stroke unit prior to introducing CO-OP KT training to the stroke team. Patient participants will receive Usual Care from their stroke team.
11315425|NCT02597049|Placebo Comparator|Placebo|Placebo given SC once a week for 24 weeks.
11315426|NCT02597036|Experimental|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
11315328|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
11315329|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
11315330|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
11315331|NCT02597660|Active Comparator|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
11315332|NCT02597660|Placebo Comparator|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
11315333|NCT02597647|Experimental|Live attenuated influenza vaccine|Healthy adult volunteers given intranasal FluMist (Live Attenuated Influenza vaccine). Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after LAIV.
11315334|NCT02597647|Placebo Comparator|Saline nasal spray|Healthy adult volunteers given intranasal saline nasal spray. Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after saline administration.
11315335|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
11315336|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
11315337|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
11315338|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
11315339|NCT02597621||Healthy Controls|Healthy controls.
11315340|NCT02597608|Experimental|UPPR: Control|No interventions are provided.
11315341|NCT02597608|Experimental|UPPR: Livelihoods only|Livelihoods programmes offered by UPPR.
11315342|NCT02597608|Experimental|UPPR: Livelihoods plus nutrition|Livelihoods programmes offered by UPPR, plus nutrition programmes offered by UPPR.
11315343|NCT02597608|Experimental|CLP: Livelihoods only|Livelihoods programmes offered by CLP.
11315344|NCT02597608|Experimental|CLP: Livelihoods plus nutrition|Livelihoods programmes offered by CLP, plus nutrition programmes offered by CLP.
11315345|NCT02597608|Experimental|Shiree: Livelihoods only|Livelihoods programmes offered by Shiree.
11315346|NCT02597608|Experimental|Shiree: Livelihoods plus nutrition|Livelihoods programmes offered by Shiree, plus nutrition programmes offered by Shiree.
11315347|NCT02597595|Experimental|patients|thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
11315348|NCT02597595|No Intervention|controls|thirty healthy children of matched age and sex
11315349|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.
~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
11315350|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.
~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
11315352|NCT02597569||CO-OP KT Exposure group|Patient participants will be recruited from an inpatient rehabilitation stroke unit after the stroke team has been exposed to CO-OP KT training. Patient participants will receive Usual Care, augmented by CO-OP KT, from their stroke team.
11315353|NCT02597556|Active Comparator|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
11315354|NCT02597556|Placebo Comparator|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
11315355|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
11315356|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
11315357|NCT02597530|Experimental|Long-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.Patients in Long-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and continued until the end of the surgery with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
11315358|NCT02597530|Other|Short-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.The patients in Short-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
11315359|NCT02597530|Placebo Comparator|Sham group|Patients in sham group will be pasted electrodes 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
11315360|NCT02597517||Intervention group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and positive stool antigen test for H pylori in whom gastric body mucosal will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
11315361|NCT02597517||Control group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and negative stool antigen test for H pylori in whom gastric mucosal body will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
11315362|NCT02597504|Active Comparator|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
11315363|NCT02597504|Experimental|Validity and Reliability|"Reliability:
~Test-Retest
~Validity:
~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
11315364|NCT02597491|Active Comparator|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
11315365|NCT02597491|Active Comparator|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
11315366|NCT02597491|Active Comparator|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
11315367|NCT02597491|Active Comparator|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
11315368|NCT02597491|Active Comparator|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
11315369|NCT02597491|Active Comparator|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
11315370|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
11315371|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
11315372|NCT02597465|Experimental|SPARC1507|SPARC1507
11315373|NCT02597465|Experimental|Chemotherapy|Chemotherapy
11315374|NCT02597452|Other|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
11315375|NCT02597439|Active Comparator|Omega-3 fatty acids|Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
11315376|NCT02597439|Placebo Comparator|Placebo|Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
11315377|NCT02597426||Patient|Nasopharyngeal carcinoma (NPC) patients who are disease free more than four years after definitive management with radiotherapy +/- chemotherapy who were treated with Intensity-Modulated Radiotherapy (IMRT), study will involve Collection of demographic data, endocrine assessment (Pituitary and Thyroid), Patient reported outcomes (Quality of Life Questionnaire), neurocognitive assessment (Behavioral rating scale) and audiology assessment (Assessment of hearing)
11315378|NCT02597426||Caregiver/Family member|Caregivers for patients who consent to participate. Study will involve Frontal Systems Behavior Scale- FrSBe (behavioral rating scale)
11315379|NCT02597413||Before group|Women in this group are included before the implementation of a strategy of systematic catheterization (they will not be catheterized).
11315380|NCT02597413||After group|"Women in this group are included after the implementation of a department-wide strategy of systematic catheterization.
~Intervention: catheterization"
11315423|NCT02597049|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
11366183|NCT02259972|Placebo Comparator|Placebo|
11315381|NCT02597400|Experimental|HMS5552 and Metformin|"All subjects will receive the following:
~Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;
~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;
~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
11315382|NCT02597387|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
11315383|NCT02597374|Experimental|Experimental|A 45 mn EEG for all the participants.
11315384|NCT02597361|Active Comparator|Irbesartan|Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.
11315385|NCT02597361|Placebo Comparator|Placebo|Placebo once or twice per day for 2 years.
11315386|NCT02597348|Experimental|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
11315387|NCT02597348|No Intervention|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
11315388|NCT02597335|Experimental|IDH1/IDH2|
11315389|NCT02597322|Experimental|AXITINIB|
11315390|NCT02597309|Active Comparator|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
11315391|NCT02597309|Placebo Comparator|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
11315392|NCT02597283|Experimental|Biguard stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
11315393|NCT02597283|Active Comparator|Sirolimus-eluting stent system|PCI with regular sirolimus-eluting stent system
11315394|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
11315395|NCT02597257|Placebo Comparator|Normal Saline|"normal saline
~total 250 ml
~once a week
~4 times"
11315396|NCT02597257|Active Comparator|Lidocaine HCl|"lidocaine 3 mg/kg mixed in normal saline
~total 250 ml
~once a week
~4 times"
11315397|NCT02597244|Experimental|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
11315398|NCT02597231|Experimental|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
11315399|NCT02597231|Placebo Comparator|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
11315400|NCT02597218||Patients following hepatectomy|"Patients following hepatectomy of any type, any gender. Roughly, we will describe: type of resection, presence of cancer,use of mechanical/pharmacological prophylaxis, major/minor bleedings ocurring during observation period.
~Outcomes: Venous thromboembolism (VTE)[deep vein thrombosis (DVT) and pulmonary embolism (PE)] and portal thrombosis (PT)."
11315401|NCT02597205|Experimental|Mobile app|Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages
11315402|NCT02597192|Active Comparator|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
11315403|NCT02597192|Placebo Comparator|Placebo group|oral hygiene products without Bacillus
11315404|NCT02597179||Metastatic Breast Cancer, Young Breast Cancer|Patients with feasible biopsy site.
11315405|NCT02597166|Other|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
11315406|NCT02597153|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
11315407|NCT02597140|Experimental|Lidocaine group|Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
11315408|NCT02597140|Placebo Comparator|Control group|Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.
11315409|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
11315410|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
11315411|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
11315412|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
11315413|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
11315414|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
11315415|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
11315416|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
11315417|NCT02597114|Experimental|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
11315418|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
11315419|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
11315420|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
11315421|NCT02597075|Active Comparator|Arm B:|Standard therapy
11315422|NCT02597062|Experimental|Carfilzomib plus cyclophosphamide plus dexamethasone|20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg
11315427|NCT02597036|Experimental|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
11315428|NCT02597036|Experimental|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
11315429|NCT02597036|Experimental|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
11315430|NCT02597036|Experimental|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
11315431|NCT02597023|Experimental|MitoQ|MitoQ, 20 mg per day for six weeks
11315432|NCT02597023|Placebo Comparator|Placebo|Placebo, inert excipient, one time per day for six weeks
11315433|NCT02597010|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
11315434|NCT02597010|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
11315435|NCT02596984|Experimental|caspofungin|Caspofungin will be administered according to the international recommendation.
11315436|NCT02596971|Experimental|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
11315437|NCT02596971|Experimental|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
11315438|NCT02596971|Experimental|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
11315439|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
11315440|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
11315441|NCT02596932|Other|Tight control|"Intervention Standard Care:
~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60 mg/dL"
11315442|NCT02596932|Experimental|Less tight control|"Intervention:
~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60mg/dL"
11315443|NCT02596919|Other|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
11315444|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
11315445|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
11315446|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
11315447|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
11315448|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
11315449|NCT02596893|Placebo Comparator|Placebo|Placebo once daily (QD) until the Week 52 Visit
11315450|NCT02596880|Experimental|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
11315451|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
11315452|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
11315453|NCT02596828|Experimental|RIST|
11315454|NCT02596815|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 3 times a week during 6 continuous weeks.The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
11315455|NCT02596815|Active Comparator|Waiting list control group|Patients assigned to a 6 week waiting list to receive treatment
11315456|NCT02596802|Experimental|FETO therapy|Intervention name: FETO therapy
11315457|NCT02596789|Other|state dependency TMS|TMS performed at rest and during a cognitive/emotional task
11315458|NCT02596776|Active Comparator|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
11315459|NCT02596776|Experimental|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
11315486|NCT02596581|No Intervention|diabetics with periodontally healthy group|Control group
11315487|NCT02596581|No Intervention|systemically and periodontally healthy group|Control group
11315460|NCT02596776|Active Comparator|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
11315461|NCT02596763|Other|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
11315462|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
11315463|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
11315464|NCT02596737|Other|workers|"Workers will fulfil a visual analog scale of Well-being regarding 3 main categories: Physically, Mentally, At Work."
11315465|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
11315466|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
11315467|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
11315468|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
11315469|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
11315470|NCT02596685|Experimental|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.
~Patients undergo a second bronchoscopy during week 5."
11315471|NCT02596685|Experimental|Arm B (control)|"Patients receive no intervention.
~Patients undergo a second bronchoscopy during week 5."
11315472|NCT02596685|Experimental|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
11315473|NCT02596685|Experimental|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
11315474|NCT02596672|Experimental|Intervention|They will complete a 12-week peer-led walking programme. Participants will be paired together as walking partners and will be given a pedometer and step count logs for self-monitoring. The walking co-ordinators will facilitate walking groups two times a week in the local areas, lasting for 30 minutes. The nature of the walks will be tailored to the participants stated preferences of types of activity. Participants will also receive local walking route maps. After 12 weeks, the formal peer-led component will finish and participants will be encouraged to continue walking with their walking partners other activity programmes organised in the fold in order to maintain activity levels.
11315475|NCT02596672|No Intervention|Control|"Folds assigned to the control group will not receive any additional support to change their physical activity behaviour over the course of the intervention period.
~At the six-month data collection point they will be offered a referral to a local walking group in their area or advice on beginning a self-directed walking programme (similar to Public Health Agency www.choosetolivebetter.com/content/getting-active). They will be asked to complete outcome measures at baseline and follow up time-points. Post-study a sample of control participants will be asked to attend a focus group, exploring their views on social activity as form of physical activity for older adults in folds."
11315476|NCT02596659|Experimental|The experimental group|Participants in the experimental group received radial extracorporeal shock wave therapy (rESWT) plus physical therapy for 3 weeks.
11315477|NCT02596659|Sham Comparator|The control group|Participants in the control group received sham shockwave therapy plus physical therapy for 3 weeks.
11315478|NCT02596646|Active Comparator|Group A|Early Precut
11315479|NCT02596646|Active Comparator|Group B|Prolonged cannulation attempts
11315480|NCT02596633|No Intervention|Treatment as Usual|Participants carry on with their usual care
11315481|NCT02596633|Active Comparator|Intervention|ACT self help book with telephone support calls; Telephone-support Acceptance and Commitment therapy (ACT)
11315482|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
11315483|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
11315484|NCT02596594|Experimental|Port intervention|"The subcutaneous intraumbilical port-system will be implanted in IUGR patients with the cerebroplacental ratio less than 1 (cerebroplacental ratio= PI in the middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.
~The fetuses will receive AAs and glucose supplementation via a subcutaneously implanted intraumbilical perinatal port system till the delivery. Control by doppler and cardiotocogram"
11315485|NCT02596594|No Intervention|control|"IUGR patients with the cerebroplacental ratio less than 1 (CPR= PI middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.
~Control by doppler and cardiotocogram"
11315488|NCT02596581|Active Comparator|diabetics with chronic periodontitis group|non-surgical periodontal treatment was performed
11315489|NCT02596581|Active Comparator|chronic periodontitis group|non-surgical periodontal treatment was performed
11315490|NCT02596568|Experimental|Active tDCS stimulation|Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
11315491|NCT02596568|Sham Comparator|Sham tDCS stimulation|tDCS electrodes will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor, however stimulation will never be turned on.
11315492|NCT02596555|Experimental|Dabigatran treatment|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
11315493|NCT02596542|Experimental|Water temperature|
11315494|NCT02596529|Experimental|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
11315495|NCT02596529|Active Comparator|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
11315496|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.
~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
11315497|NCT02596490|Experimental|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:
~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
11315498|NCT02596490|Experimental|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:
~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.
~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.
~Participants continue daily meditation practice and some other short exercises at home."
11315499|NCT02596490|Experimental|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
11315500|NCT02596490|Experimental|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
11315501|NCT02596490|Other|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
11315502|NCT02596477|Experimental|Vepoloxamer - Low dose|Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
11315503|NCT02596477|Experimental|Vepoloxamer - High dose|Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
11315504|NCT02596477|Placebo Comparator|5% dextrose in water (D5W)|D5W administered intravenously over 3 hours
11315505|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
11315506|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
11315507|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
11315508|NCT02596438||Asian Americans|Foreign born or children of foreign born Asian American from Hepatitis B endemic areas residing in Sacramento, CA.
11315509|NCT02596425|Experimental|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
11315510|NCT02596425|Experimental|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
11315511|NCT02596425|Experimental|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
11315512|NCT02596412|Experimental|augmented reality (Mini-Docs) on tablet|• Cerebral-palsied children using the module with augmented reality (Mini-Docs) on tablet during TB injections in addition to regular drug techniques (experimental group)
11315513|NCT02596412|No Intervention|Control|Cerebral-palsied children with the usual pain care during TB injections, which combines drug techniques to distractibility techniques (control group)
11315514|NCT02596399|Experimental|DSTA4637S|
11315515|NCT02596399|Placebo Comparator|Placebo|
11315516|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
11366184|NCT02259959|Experimental|BI 1744 CL in combination with Tiotropium|
11315517|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
11315518|NCT02596373|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
11315519|NCT02596373|Active Comparator|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
11315520|NCT02596360|Experimental|Dextromethorphan|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
11315521|NCT02596360|Placebo Comparator|Placebo|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
11315522|NCT02596347||Beryllium Sensitization (BeS)|Blood draw
11315523|NCT02596347||Chronic Beryllium Disease(CBD)|blood draw BAL
11315524|NCT02596334|Active Comparator|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
11315525|NCT02596334|Experimental|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
11315526|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
11315527|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
11315528|NCT02596308|Experimental|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
11315529|NCT02596308|Experimental|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
11315530|NCT02596295||Mothers for term infants|Lactating mothers
11315531|NCT02596295||Mothers for preterm infants|Lactating mothers
11315532|NCT02596282|Active Comparator|Clinical Officer (CO),|COs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
11315533|NCT02596282|Experimental|Nurse Midwife (NMW)|NMWs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
11315534|NCT02596269|Experimental|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
11315535|NCT02596269|Placebo Comparator|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
11315536|NCT02596256|Experimental|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
11315537|NCT02596256|Active Comparator|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
11315538|NCT02596243|Experimental|GX-188E|GX-188E + EP
11315539|NCT02596243|Placebo Comparator|placebo|Placebo + EP
11315540|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
11315541|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
11315542|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
11315543|NCT02596217|Experimental|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
11315544|NCT02596217|Experimental|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
11315545|NCT02596217|Experimental|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
11315546|NCT02596217|Experimental|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
11315547|NCT02596217|Experimental|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
11315548|NCT02596217|Experimental|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
11315549|NCT02596217|Placebo Comparator|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
11315550|NCT02596217|Placebo Comparator|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
11315551|NCT02596204|Active Comparator|Data Upload|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. Subjects will continue to receive usual diabetes care. Phone calls and emails to the diabetes clinic will be initiated by the family.
11315552|NCT02596204|Experimental|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (diabetes educator, nurse practitioner and/or physician) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
11315553|NCT02596191|Experimental|patients with mild CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 1 and 10
11315554|NCT02596191|Experimental|patients with moderate CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score between 11 and 20
11315555|NCT02596191|Experimental|patients with severe CMT 1A disease|Charcot-Marie-Tooth Neuropathy Score ≥21
11315556|NCT02596191|Other|control group|Healthy volunteers
11315557|NCT02596178|Experimental|EIT Guided PEEP Therapy|
11315558|NCT02596165|Experimental|Pulse wave analysis measurement|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
11315559|NCT02596152|Experimental|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
11315560|NCT02596152|Active Comparator|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
11315561|NCT02596139||Healthy people|
11315562|NCT02596126|Active Comparator|Treatment Prevention for Secondary CV|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
11315563|NCT02596126|Experimental|Cardiovascular Polypill|Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
11315564|NCT02596113||No pathological findings|blood and biopsy samples from normal colon mucosa
11315565|NCT02596113||>1 cm adenomatous polys|blood and biopsy samples from the polyp
11315566|NCT02596113||Colorectal cancer|blood (plasma) and biopsy samples from colorectal cancer
11315567|NCT02596100|Experimental|Tablet|80mg immediate release tablet
11315568|NCT02596100|Experimental|Capsule|80mg immediate release capsule
11315569|NCT02596087|No Intervention|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
11315570|NCT02596087|Experimental|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
11315571|NCT02596074|Experimental|Omiganan (CLS001)|CLS001 topical gel, 2.5%
11315572|NCT02596074|Placebo Comparator|Vehicle|Vehicle topical gel
11315573|NCT02596061|No Intervention|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
11315574|NCT02596061|Experimental|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
11315575|NCT02596061|Experimental|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
11315576|NCT02596061|Experimental|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
11315577|NCT02596048|Other|Iomeron|Patients will undergo a injection of Iomeron if they are scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral MDCTA examination
11315578|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
11315579|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
11315580|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
11315581|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
11315582|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
11315583|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
11315584|NCT02595996|Experimental|Treatment|Patients will be given propranolol in escalating doses
11315585|NCT02595983|Experimental|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
11315586|NCT02595970|Experimental|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
11315587|NCT02595957||Cascade Testing|Family members of individuals who have received secondary genomic findings after exome/genome sequencing
11315588|NCT02595957||Secondary findings recipients|Individuals who have received secondary genomic findings after exome/genome sequencing
11315589|NCT02595944|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
11315590|NCT02595944|No Intervention|Arm II (observation)|Patients are followed serially with imaging for 1 year.
11315591|NCT02595931|Experimental|Treatment (irinotecan, M6620)|Patients receive irinotecan hydrochloride IV over 90 minutes and M6620 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
11315592|NCT02595918|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
11315680|NCT02595307|Experimental|Pamphlet|Participant group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
11315593|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11315594|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11315595|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
11315596|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11315597|NCT02595879|Experimental|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 2 hours on days 1 and 11 and PO on days 2-5, 8-10, 12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 90-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy.
11315598|NCT02595866|Experimental|Treatment (pembrolizumab and cART)|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients continue receiving their recommended combination antiretroviral therapy orally daily. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11315599|NCT02595840|Experimental|Arm A: Afatinib|Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
11315600|NCT02595840|Experimental|Arm B: Pemetrexed|Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle
11315601|NCT02595827|No Intervention|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
11315602|NCT02595827|Active Comparator|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
11315603|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
11315604|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
11315605|NCT02595788||Supine position|Examination in the supine position
11315606|NCT02595788||Prone position|Change from supine to prone position
11315607|NCT02595775|Experimental|Round 1: Intervention arm|"Half of the endoscopists in Ontario will receive an individualized audit & feedback report.
~Individualized A/F report."
11315608|NCT02595775|No Intervention|Round 1: Control|Half of the endoscopists in Ontario will NOT receive an individualized audit & feedback report.
11315609|NCT02595775|Other|Round 2: Month 12|"All endoscopists in Ontario will receive an individualized audit & feedback report at month 12.
~Individualized A/F report"
11315610|NCT02595775|Other|Round 2: Poor performers|"In Round 2, selected 60 poorer performers will be randomly assigned to receive one of the following interventions at month 12:
~A/F report plus a high intensity intervention
~A/F report plus a low intensity intervention
~A/F report alone"
11315611|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
11315612|NCT02595749|Experimental|Intranasal Oxytocin (40 IU)|Two 20 IU doses of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be administered to each participant. Doses will be separated by 2 hours. Each 20 IU dose transferred into two, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 10 minutes.
11315613|NCT02595749|Placebo Comparator|Saline Nasal Spray|Two doses of placebo (consisting of 2ml sterile saline [Ocean Nasal Spray Solution]) will be administered to each participant. Doses will be separated by 2 hours. Each placebo dose transferred into two, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 10 minutes.
11315614|NCT02595736|Placebo Comparator|Placebo (SC)|Single subcutaneous (SC) dose of placebo
11315615|NCT02595736|Experimental|LY3200327 (SC)|Single escalating subcutaneous (SC) dose of LY3200327
11315616|NCT02595736|Experimental|LY3200327 (IV)|Single intravenous (IV) dose of LY3200327
11315617|NCT02595736|Placebo Comparator|Placebo (IV)|Single intravenous (IV) dose of placebo
11315618|NCT02595723|Experimental|Phenytoin, Then Megestrol|Participants first received pretreatment with Phenytoin 200 mg capsule twice/day for one day. Participants then received both Phenytoin (200 mg capsule twice/day) and liquid Megestrol (800 mg/day) for three consecutive days.
11315619|NCT02595723|Experimental|Placebo, Then Megestrol|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Megestrol (800 mg/day) for three consecutive days.
11315620|NCT02595723|Experimental|Placebo, Then Placebo|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Placebo (matching liquid Megestrol 800 mg/day) for three consecutive days.
11315621|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
11315681|NCT02595307|No Intervention|No Pamphlet|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
11315717|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
11315718|NCT02595060|Experimental|150 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
11315622|NCT02595697|Experimental|J-EMT for Toddlers with Autism|The J-EMT intervention:(a) teach foundational social communicative behaviors, (b) teach related skills that predict long term language outcomes, (c) teach a range of communicative functions, (d) target specific spoken language skills as well as foundational skills, (e) incorporate instructional methods, contexts, and partners that increase social use of language in natural contexts, and (f) promote generalization and maintenance of newly learned skills to everyday activities and routines. In addition, because parents are essential partners for young children with ASD who are learning to communicate, studies are needed that (g) include parents and (h) specify the method and fidelity of parent instruction and fidelity and dosage with which parents use the trained strategies
11315623|NCT02595697|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
11315624|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
11315625|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
11315626|NCT02595671|Active Comparator|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
11315627|NCT02595671|Active Comparator|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
11315628|NCT02595671|Active Comparator|Digital Super Coach|Only receive coaching via digital super coach.
11315629|NCT02595671|Active Comparator|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
11315630|NCT02595658|Experimental|1|Carbohydrate only meal: Participants will consume a standardised carbohydrate meal (80 g of carbohydrates, 25 g protein, 0 g fat: meal composition, white rice, chicken, curry sauce; 420 kcal) and will self-administer (into the subcutaneous tissue of the abdomen, as per their regular routine) a rapid-acting insulin dose calculated as per the carbohydrate-counting ratio (e.g. 1 IU of insulin per 10 g of carbohydrates).
11315631|NCT02595658|Experimental|2|Participants will replicate Trial 1, but on this occasion the meal consumed will have an additional 50 g of fat (via addition of Ghee). This fat will be added to the sauce within the meal (80 g of carbohydrates, 25 g of protein, 50 g of fat; 735 Kcal). Participants will administer their rapid-acting insulin as per the carbohydrate counting method (i.e. the same IU of insulin as per Trial 1).
11315632|NCT02595658|Experimental|3|Trial 3) Participants will replicate Trial 2, but will administer a rapid-acting insulin dose that has been increased by 30%.
11315633|NCT02595658|Experimental|4|Participants will replicate Trial 2, but will administer an additional rapid-acting insulin dose of 30% 3 hrs post-meal.
11315634|NCT02595645|Experimental|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
11315635|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
11315636|NCT02595619|Experimental|RRT plus ECCO2R|
11315637|NCT02595606|Experimental|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
11315638|NCT02595606|No Intervention|control group|without treatment
11315639|NCT02595593|Active Comparator|Rib Fixation System|This group of subjects will receive a surgical rib plating procedure after trauma
11315640|NCT02595593|No Intervention|Critical Care and Pain Control|This group will receive critical care and pain control after trauma
11315641|NCT02595580|Experimental|GlucoPred|
11315642|NCT02595567|Other|ITPC|
11315643|NCT02595554|Active Comparator|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
11315644|NCT02595554|Experimental|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
11315645|NCT02595541|Active Comparator|milrinone group|milrinone
11315646|NCT02595541|Active Comparator|sildenafil and milrinone group|milrinone and sildenafil
11315647|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
11315648|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
11315649|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
11315650|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
11315651|NCT02595515|Experimental|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
11315652|NCT02595515|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
11315653|NCT02595502|Active Comparator|Sequence 1: Test Control Test|Test/control/test using the Johnson & Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
11315654|NCT02595502|Active Comparator|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
11315655|NCT02595489|Experimental|Vitamin D3|Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
11315656|NCT02595476|Experimental|BIS 55|"Induction:
~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)
~Orotracheal Intubation
~Remifentanil target decreased to 1 ng/ml
~Propofol target adjustment to reach BIS 55
~10 minutes steady state
~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds
~Pupillary dilation recording (videopupillometer Algiscan)"
11315657|NCT02595476|Active Comparator|BIS 25|"Induction:
~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)
~Orotracheal Intubation
~Remifentanil target decreased to 1 ng/ml
~Propofol target adjustment to reach BIS 25
~10 minutes steady state
~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds
~Pupillary dilation recording (videopupillometer Algiscan)"
11315658|NCT02595463|Experimental|Lidocaine|Following intraoperative IV placement, a 1.5 mg/kg bolus does of lidocaine hydrochloride is given and is followed by a continuous infusion of 2 mg/kg/hr until discharge from the Phase 1 recovery period.
11315659|NCT02595463|Placebo Comparator|Placebo|Following intraoperative IV placement, a bolus of saline is given and is followed by a continuous infusion until discharge from the Phase 1 recovery period. The volume of the bolus and rate of infusion are equivalent to that which would have been given in the experimental arm.
11315660|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
11315661|NCT02595437|Experimental|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
11315662|NCT02595424|Experimental|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11315663|NCT02595424|Active Comparator|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11315664|NCT02595398|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
11315665|NCT02595398|Sham Comparator|Sham Procedure|Matching suprachoroidal syringe with sham procedure
11315666|NCT02595385|Active Comparator|RAP|Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
11315667|NCT02595385|Active Comparator|CS|Reinfusion of shed blood during the operation
11315668|NCT02595385|Active Comparator|RAP and CS|RAP and CS used in combination
11315669|NCT02595385|No Intervention|Control|No intervention
11315670|NCT02595372|Experimental|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
11315671|NCT02595359|Experimental|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
11315672|NCT02595346|Experimental|hydroxychlorquine|hydroxychloroquine 200 mg twice a day for 6 months
11315673|NCT02595346|Placebo Comparator|control|placebo 2 pills a day for 6 months
11315674|NCT02595333|Experimental|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
11315675|NCT02595333|Experimental|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
11315676|NCT02595333|Experimental|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
11315677|NCT02595333|Experimental|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
11315678|NCT02595320|Experimental|Group A|capecitabine, 1500 mg, twice a day for 7 days on then 7 days off
11315679|NCT02595320|Active Comparator|Group B|capecitabine, 1250 mg/m2 OR 1000 mg/m2, twice a day for 14 days on then 7 days off
11315682|NCT02595294|Experimental|Cervical Lateral Glide|"15 minutes Cervical Lateral Glide neural mobilization
~5 times a week
~During 6 weeks
~Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
11315683|NCT02595294|No Intervention|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
11315684|NCT02595281|Experimental|Study arm|
11315685|NCT02595268|Experimental|Pitavastatin Then JNJ-63623872|Participants will sequentially receive single oral dose of pitavastatin 1 milligram (mg) on Day 1, followed by JNJ-63623872 600 mg twice daily on Days 4 through 12 with a single oral dose of pitavastatin 1 mg administered in the morning of Day 9. All study drug intakes will be taken orally, under fed conditions (within approximately 10 minutes after completion of a meal).
11315686|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
11315687|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.
~This is the study group we will compare with high risk and no risk patients. No intervention"
11315688|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.
~No intervention"
11315689|NCT02595242|Experimental|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
11315690|NCT02595242|Experimental|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
11315691|NCT02595242|Experimental|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
11315692|NCT02595229|Active Comparator|PQ (Pronator quadraus) repair|Following volar plate osteosynthesis the pronator quadratus muscle is sutured with 3 to 5 U-shaped stitches using a polyfilament absorbable synthetic suture.
11315693|NCT02595229|No Intervention|No PQ repair|Following volar plate osteosynthesis the pronator quadratus muscle is placed in its anatomical position without suture repair.
11315694|NCT02595216|Experimental|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.
~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
11315695|NCT02595203|Experimental|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of [14C-pos 1]-Debio 1450 BES solution.
11315696|NCT02595203|Experimental|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of [14C-pos 1]-Debio 1450 BES solution.
11315697|NCT02595203|Experimental|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of [14C-pos 25]-Debio 1450 BES solution.
11315698|NCT02595190|Experimental|surgery group|sacral canal cyst microscopic tamponade treatment; resting state functional magnetic resonance imaging (rfMRI)
11315699|NCT02595190|Experimental|drug group|gabapentin + tramadol tablets; resting state functional magnetic resonance imaging (rfMRI)
11315700|NCT02595190|Placebo Comparator|control group|resting state functional magnetic resonance imaging (rfMRI)
11315701|NCT02595177|Experimental|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
11315702|NCT02595177|Experimental|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
11315703|NCT02595177|Experimental|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
11315704|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
11315705|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
11315706|NCT02595151||gastric intestinal metaplasia|Those fulfilling the criteria of GIM by CLE according to the study by Yuting Guo et al were included.
11315707|NCT02595151||normal gastric|diagnosed during routine colonoscopy procedures.
11315708|NCT02595138|Experimental|A|zoledronic acid received
11315709|NCT02595138|No Intervention|B|observation
11315710|NCT02595125|Sham Comparator|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
11315711|NCT02595125|Experimental|Direct technique|Intrauterine device (IUD) insertion by the direct technique
11315712|NCT02595112|Experimental|Patient undergoing otorhinolaryngologic surgery|Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure.
11315713|NCT02595099|Experimental|Mindfulness training|8 week programme of Mindfulness training
11315714|NCT02595086|Experimental|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
11315715|NCT02595086|Active Comparator|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
11315719|NCT02595060|Experimental|450 mcg inhaled molgramostim|once daily inhaled molgramostim (rhGM-CSF) for 3 days
11315720|NCT02595060|Placebo Comparator|inhaled placebo|once daily inhaled placebo for 3 days
11315721|NCT02595047|Experimental|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
11315722|NCT02595034|Experimental|Clindamycin/BP Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
11315723|NCT02595034|Active Comparator|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
11315724|NCT02595034|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
11315725|NCT02595021|Experimental|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
11315726|NCT02595021|Active Comparator|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
11315727|NCT02595008|Experimental|DSXS topical product|treatment with DSXS twice daily for 28 days
11315728|NCT02594995|Experimental|NBP in thrombolysis group|NBP 25mg bid for 2 weeks administered after 24 hours after receiving recombinant plasminogenactivator(rt-PA) thrombolysis
11315729|NCT02594995|Experimental|NBP group|NBP 25mg bid for 2 weeks administered for the patients who do not receive rt-PA
11315730|NCT02594995|No Intervention|Control group|Control group not receiving rt-PA thrombolysis, receiving basic therapy for acute stroke, e.g. aspirin/clopidogrel and lipid-lowering therapy
11315731|NCT02594995|No Intervention|Control in thrombolysis group|Control group receiving rt-PA thrombolysis
11315732|NCT02594982|Other|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
11315733|NCT02594969|Active Comparator|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
11315734|NCT02594969|Experimental|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
11315735|NCT02594956|Active Comparator|With Nasogastric Decompression|This group will receive conventional care according to the protocol of the service in place with removal of the nasogastric tube the 3rd postoperative day if the flow is < 500ml / 24h, if not removal will take place on the 5th postoperative day.
11315736|NCT02594956|Experimental|Without Nasogastric decompression|The nasogastric tube will be take off at the end of the surgery, just after the extubation.
11315737|NCT02594943|Active Comparator|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
11315738|NCT02594943|Active Comparator|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
11315739|NCT02594930|Experimental|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
11315740|NCT02594917||Test Group|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart failure, or exercise intolerance.
11315741|NCT02594917||Control Group|It will also include ten additional patients (ages 18-60 yrs) who are unaffected first-degree family members of the above subjects.
11315742|NCT02594904|Experimental|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
11315743|NCT02594904|Experimental|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
11315744|NCT02594904|Experimental|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
11315745|NCT02594904|Experimental|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
11315746|NCT02594891|Experimental|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
11315747|NCT02594891|Placebo Comparator|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
11315748|NCT02594878|Experimental|Pamidronatdinatrium 3mg/ml|Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
11315749|NCT02594878|Placebo Comparator|Natrium chloride 9 mg/ml|Natrium chloride 9 mg/ml volume equals experimental drug
11315750|NCT02594865|Active Comparator|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
11315751|NCT02594865|Active Comparator|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
11315752|NCT02594852|Experimental|Intervention (+ laser)|+ laser therapy
11315753|NCT02594852|Placebo Comparator|Non-intervention (- laser)|- laser
11315754|NCT02594839|Experimental|MSCs|2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
11315755|NCT02594839|Placebo Comparator|placebo|2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
11315756|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
11315757|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
11315758|NCT02594800|Active Comparator|standard dose|Drug: Rosuvastatin rosuvastatin 10 mg daily for 52 weeks.
11315759|NCT02594800|Experimental|intensive dose|Drug: Rosuvastatin rosuvastatin 20 mg daily for 52 weeks.
11315760|NCT02594787|Active Comparator|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
11315761|NCT02594787|Placebo Comparator|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
11315762|NCT02594774|Experimental|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
11315763|NCT02594774|No Intervention|Standard medical treatment|Standard medical treatment
11315764|NCT02594761|Experimental|Treatment A|Hercules: 8 mg/kg i.v. infusion over 90 minutes
11315765|NCT02594761|Active Comparator|Treatment B|Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
11315766|NCT02594761|Active Comparator|Treatment C|Herceptin US: 8 mg/kg i.v. infusion over 90 minutes
11315767|NCT02594748|Experimental|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
11315768|NCT02594748|Active Comparator|Comparison group|The comparison group will receive routine care
11315769|NCT02594735|Other|open label|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
11315770|NCT02594722|Experimental|One single arm group|"COPD included in a pulmonary rehabilitation program
~Intervention:
~Investigators used a bedside cycloergometer with electrical stimulation. COPD perform 2 measure of oxygen uptake during exercise for compare aerobic capacities:
~Functional Electrical Stimulation Cycling (FES-cycling)
~Classic Cycloergometer endurance training with a sham electrical stimulation"
11315771|NCT02594709|Experimental|ONSM Multisession Radiosurgery|Multisession Radiosurgery
11315772|NCT02594696|Experimental|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.
~Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)
~Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
11315773|NCT02594683||Key Group of Interest|Exclusively formula fed subjects since 1 month of age
11315774|NCT02594683||Other-Fed Group|Mixed feeding of formula and breast milk
11315775|NCT02594683||Breastfeeding Group|Exclusively breastfeeding at least until 4 months of age
11315776|NCT02594670|Experimental|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
11315777|NCT02594670|Other|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
11315778|NCT02594670|Sham Comparator|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
11315779|NCT02594657|Experimental|pedal rate ON 50 RPM|
11315780|NCT02594657|Experimental|pedal rate on 80 RPM|
11315781|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
11315782|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
11315783|NCT02594631|Active Comparator|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
11315784|NCT02594631|Active Comparator|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
11315785|NCT02594605|Experimental|Platelet Rich Fibrin|Platelet Rich Fibrin was applied with conventional flap surgery for treatment of periodontal bone loss in test group.
11315786|NCT02594605|Active Comparator|Conventional Flap Surgery|Platelet Rich Fibrin was not applied to control groups. Only conventional flap surgery was applied to control groups.
11315787|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
11315788|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
11315789|NCT02594592||Older Men|Older Men (age > 55 years). complete questionaire
11315790|NCT02594592||Older Women|Older Women (age > 55 years),complete questionaire
11315791|NCT02594579|Active Comparator|Vitamin D|Dietary Supplement: Vitamin D3
11315792|NCT02594579|Placebo Comparator|Placebo|Dietary Supplement: Placebo
11315793|NCT02594566|Experimental|Research Subjects|A total of 3 injections of the vaccine (CyMVectin) will be given at Days 0, 28 (+4 days), and 56 (+4 days).
11315794|NCT02594553|Experimental|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
11315795|NCT02594553|No Intervention|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
11315796|NCT02594540|Experimental|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
11315797|NCT02594540|Sham Comparator|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
11315798|NCT02594527|Experimental|Volunteer-led physical activity sessions|Patient will receive volunteer-led physical activity sessions twice a day during admission.
11315799|NCT02594501|Experimental|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
11315800|NCT02594501|Active Comparator|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
11315801|NCT02594488|Active Comparator|Remote monitoring|Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
11315802|NCT02594488|No Intervention|Control arm|Follow-up at the same frequency, but with no implantable cardiac monitor
11315803|NCT02594475|Experimental|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
11315804|NCT02594475|Active Comparator|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
11315805|NCT02594462|Other|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.
~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
11315806|NCT02594449|Active Comparator|low concentration Benzalkonium Chloride|To use low concentration Benzalkonium Chloride Solution to gargle
11315807|NCT02594449|Active Comparator|high concentration Benzalkonium Chloride|To use high concentration Benzalkonium Chloride Solution to gargle
11315808|NCT02594449|Placebo Comparator|Normal Saline|To use Normal Saline to gargle
11315809|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
11315810|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
11315811|NCT02594423|Active Comparator|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
11315812|NCT02594423|Active Comparator|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
11315813|NCT02594410|Experimental|Treatment|patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
11315814|NCT02594397|Experimental|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
11315815|NCT02594397|Active Comparator|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
11315816|NCT02594397|Sham Comparator|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
11315817|NCT02594384|Experimental|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
11315818|NCT02594384|Experimental|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
11315819|NCT02594384|Experimental|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
11315820|NCT02594384|Experimental|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
11315821|NCT02594371|Experimental|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules
~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
11315822|NCT02594371|Active Comparator|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
11315823|NCT02594358|Active Comparator|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
11315824|NCT02594358|Active Comparator|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
11315825|NCT02594345|Experimental|Intervention group|
11315826|NCT02594332|Experimental|Mepolizumab|100 mg SC every 4 weeks for 13 injections
11315827|NCT02594332|Experimental|Placebo|Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
11315828|NCT02594319|Active Comparator|Control|Daily reporting of fruit and vegetable consumption
11315829|NCT02594319|Experimental|Daily reward|Incentives for fruit and vegetable consumption delivered daily
11315830|NCT02594319|Experimental|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
11315888|NCT02594020|Other|sono abrasion versus dental bur|1 tooth prepared with sono abrasion ans 1 tooth prepared with dental bur
11315831|NCT02594306|Experimental|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
11315832|NCT02594306|Experimental|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
11315833|NCT02594306|Active Comparator|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
11315834|NCT02594293|No Intervention|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
11315835|NCT02594293|Experimental|Pegasys 24 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks
11315836|NCT02594293|Experimental|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
11315837|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
11315838|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
11315839|NCT02594267|Experimental|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.
~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.
~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.
~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.
~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.
~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
11315840|NCT02594254|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
11315841|NCT02594254|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
11315842|NCT02594254|Experimental|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
11315843|NCT02594254|Experimental|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
11315844|NCT02594254|Experimental|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
11315845|NCT02594254|Experimental|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
11315846|NCT02594254|Experimental|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
11315847|NCT02594241|Active Comparator|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
11315848|NCT02594241|Placebo Comparator|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
11315849|NCT02594228|Experimental|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
11315850|NCT02594228|Experimental|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
11315851|NCT02594215|Experimental|Experimental|Experimental
11315852|NCT02594202||1|Adults (greater than or equal to 18 years of age) with biopsy-proven or suspected prostate cancer
11315853|NCT02594189|Other|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
11315854|NCT02594176|Experimental|Test Product|2.2 g FLEXISEQ® twice daily
11315855|NCT02594176|Placebo Comparator|Placebo|2.2 g placebo twice daily
11315856|NCT02594163|Experimental|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
11315857|NCT02594163|Active Comparator|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
11315889|NCT02594020|Other|air abrasion versus sono abrasion|1 tooth prepared with air abrasion versus 1 tooth prepared with sono abrasion
11315858|NCT02594150|No Intervention|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
11315859|NCT02594150|Experimental|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
11315860|NCT02594150|Experimental|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
11315861|NCT02594150|Experimental|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
11315862|NCT02594137|Experimental|Without Watertight Duraplasty|"After standard craniectomy (12x15cm) and dural opening, the intervention, which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed."
11315863|NCT02594137|No Intervention|With Watertight Duraplasty|After standard craniectomy (12x15cm) and dural opening, watertight duraplasty with pericranium or an artificial graft is performed. Usual closure is then performed. This kind of duraplasty is performed by most neurosurgeons and this group will be used as a control.
11315864|NCT02594124|Experimental|Group 1|Participants transitioned from ISIS 396443-CS3B (NCT02193074)
11315865|NCT02594124|Experimental|Group 2|Participants transitioned from ISIS 396443-CS4 (NCT02292537)
11315866|NCT02594124|Experimental|Group 3|Participants transitioned from ISIS 396443-CS12 (NCT02052791)
11315867|NCT02594124|Experimental|Group 4|Participants transitioned from ISIS 396443-CS3A (NCT01839656)
11315868|NCT02594124|Experimental|Group 5|Participants transitioned from 232SM202 (NCT02462759)
11315869|NCT02594111|Active Comparator|Colchicine|Colchicine 1.8 mg PO over 1 hour
11315870|NCT02594111|Placebo Comparator|Placebo|Matching placebo
11315871|NCT02594098|Experimental|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
11315872|NCT02594098|Placebo Comparator|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
11315873|NCT02594085|Experimental|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
11315874|NCT02594085|Experimental|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
11315875|NCT02594085|Experimental|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
11315876|NCT02594085|Experimental|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
11315877|NCT02594085|Experimental|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
11315878|NCT02594085|Experimental|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.
~In this arm the the subjects test:
~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
11315879|NCT02594072|Experimental|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
11315880|NCT02594072|Active Comparator|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
11315881|NCT02594059|Experimental|Pulmonary idiopathic fibrosis|Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
11315882|NCT02594046|Experimental|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
11315883|NCT02594046|Placebo Comparator|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
11315884|NCT02594033|Experimental|3 mm needle|
11315885|NCT02594033|Experimental|3.5 mm needle|
11315886|NCT02594033|Active Comparator|4 mm needle|
11315887|NCT02594020|Other|dental bur versus air abrasion|1 tooth prepared with air abrasion versus one prepared tooth with dental bur
11315890|NCT02594007|Experimental|discharge home|SEEQ for 28 days. Cardiocom for 30 days
11315891|NCT02594007|Experimental|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
11315892|NCT02593994||Onyx Drug Eluting Stent|
11315893|NCT02593981|Active Comparator|Fruit/Honey Drink|Fruit/Honey Drink (2 canisters) will be taken orally twice a day. Subjects will consume the drink on days 1 through 28.
11315894|NCT02593981|Placebo Comparator|Placebo|Placebo (2 canisters) will be taken orally twice a day. Subjects will consume the placebo drink on days 1 through 28.
11315895|NCT02593968|Experimental|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
11315896|NCT02593968|Placebo Comparator|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
11315897|NCT02593955|Active Comparator|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
11315898|NCT02593955|Active Comparator|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
11315899|NCT02593955|No Intervention|Healthy control|MRI sub-study only
11315900|NCT02593942|Experimental|group I|remifentanil
11315901|NCT02593942|Experimental|group II|remifentanil, propofol
11315902|NCT02593929|Experimental|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
11315903|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
11315904|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
11315905|NCT02593890|Active Comparator|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
11315906|NCT02593890|No Intervention|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
11315907|NCT02593877|Experimental|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
11315908|NCT02593877|No Intervention|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
11315909|NCT02593864|Experimental|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
11315910|NCT02593851|Experimental|Part 1: Cohort 1a|Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
11315911|NCT02593851|Experimental|Part 1: Cohort 1b|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.
11315912|NCT02593851|Experimental|Part 1: Cohort 1c|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
11315913|NCT02593851|Experimental|Part 1: Cohort 1d|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
11315914|NCT02593851|Experimental|Part 1: Cohort 1e|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
11315915|NCT02593851|Experimental|Part 1: Cohort 2a|Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
11315916|NCT02593851|Experimental|Part 1: Cohort 2b|Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
11315917|NCT02593851|Experimental|Part 1: Cohort 2c|Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7
11315918|NCT02593851|Experimental|Part 1: Cohort 2d|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
11315919|NCT02593851|Experimental|Part 1: Cohort 2e|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
11315920|NCT02593851|Experimental|Part 1: Cohort 3a|Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
11315921|NCT02593851|Experimental|Part 1: Cohort 3b|Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
11315922|NCT02593851|Experimental|Part 1: Cohort 3c|Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
11315923|NCT02593851|Experimental|Part 1: Cohort 3d|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
11315957|NCT02593643|Active Comparator|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
11315958|NCT02593643|Experimental|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
11315924|NCT02593851|Experimental|Part 1: Cohort 3e|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
11315925|NCT02593851|Experimental|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
11315926|NCT02593838|Other|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
11315927|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
11315928|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
11315929|NCT02593812|Experimental|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
11315930|NCT02593812|Other|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
11315931|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
11315932|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
11315933|NCT02593786|Experimental|Nivolumab monotherapy|Nivolumab specified dose on specified days
11315934|NCT02593786|Experimental|Cohort Expansion|Nivolumab specified dose on specified days
11315935|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
11315936|NCT02593760|Active Comparator|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
11315937|NCT02593760|Experimental|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
11315938|NCT02593747|Experimental|Loratadine oral solution/syrup then Claritin peach syrup|Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
11315939|NCT02593747|Experimental|Claritin peach syrup then Loratadine oral solution/syrup|Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
11315940|NCT02593734|No Intervention|Control|No intervention
11315941|NCT02593734|Experimental|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
11315942|NCT02593721|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
11315943|NCT02593721|Active Comparator|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
11315944|NCT02593708|Experimental|Cohort 0|"Neratinib: 80 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
11315945|NCT02593708|Experimental|Cohort 1|"Neratinib: 120 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
11315946|NCT02593708|Experimental|Cohort 2|"Neratinib: 160 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
11315947|NCT02593708|Experimental|Cohort 3|"Neratinib: 200 mg, daily, oral
~Paclitaxel: 80 mg/m2, weekly, intravenously
~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously
~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
11315948|NCT02593695|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
11315949|NCT02593695|Active Comparator|Standard Control|Fluoxetine
11315950|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
11315951|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
11315952|NCT02593669|Experimental|Neutral IOL|Phacoemulsification cataract surgery is performed with neutral IOL implantation.
11315953|NCT02593669|Experimental|Blue-blocking IOL|Phacoemulsification cataract surgery is performed with blue-blocking IOL implantation.
11315954|NCT02593656|Experimental|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
11315955|NCT02593656|Active Comparator|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
11315956|NCT02593643|Experimental|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
11315959|NCT02593643|Active Comparator|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
11315960|NCT02593630|Experimental|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
11315961|NCT02593617|Other|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
11315962|NCT02593617|Other|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
11315963|NCT02593617|Other|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
11315964|NCT02593617|Other|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
11315965|NCT02593617|Other|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
11315966|NCT02593617|Other|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
11315967|NCT02593591||Biomarker group|Advanced cancer undergoing genomic profiling
11315968|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
11315969|NCT02593565||Intervention|Woman, 18 years of age or older, currently pregnant, and have a diagnosis of vasculitis.
11315970|NCT02593552|Experimental|Video camera|DriveCam video event recorder with counseling feedback
11315971|NCT02593539|Experimental|GSK2269557 DPI 1000 mcg|Subjects will receive GSK2269557 1000 mcg once daily via dry powder inhaler (DPI) for 84 days
11315972|NCT02593526|No Intervention|No Diuretic and 37°C dialysate|Standard of care, no diuretic
11315973|NCT02593526|Experimental|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
11315974|NCT02593526|Experimental|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
11315975|NCT02593526|Experimental|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
11315976|NCT02593513|Experimental|Daifert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
11315977|NCT02593513|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
11315978|NCT02593500|Experimental|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:
~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.
~Treatment period 2:
~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
11315979|NCT02593500|Experimental|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:
~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.
~Treatment period 2:
~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
11315980|NCT02593487|Experimental|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
11315981|NCT02593487|Active Comparator|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
11315982|NCT02593474|Other|Detoxification / induction|The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
11315983|NCT02593461|Experimental|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
11315984|NCT02593461|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
11315985|NCT02593448|Active Comparator|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.
~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.
~Intervention: NIRS during VOT on several timepoints."
11315986|NCT02593448|Experimental|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.
~Intervention: NIRS during VOT on several timepoints."
11315987|NCT02593435||No treatment|There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.
11315988|NCT02593422|Experimental|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
11315989|NCT02593422|Active Comparator|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
11315990|NCT02593409|Other|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
11315991|NCT02593396|Placebo Comparator|placebo|Placebo BD
11315992|NCT02593396|Experimental|Active|Bupropion hydrochloride sustained-release 150mg BD
11315993|NCT02593383|Experimental|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
11315994|NCT02593383|Experimental|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
11315995|NCT02593383|Experimental|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
11315996|NCT02593383|Experimental|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
11315997|NCT02593383|Placebo Comparator|Placebo group|Placebo Group: Blank Gel
11315998|NCT02593370|Experimental|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
11315999|NCT02593370|Active Comparator|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
11316000|NCT02593357|Experimental|COPD patients|measure of endothelial function with EndoPAT® in COPD patients
11316001|NCT02593344|Experimental|endopat|measure of endothelial function with endopat
11316002|NCT02593331|Placebo Comparator|Placebo|Participants will receive placebo matching to BFKB8488A.
11316003|NCT02593331|Experimental|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
11316004|NCT02593331|Experimental|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
11316005|NCT02593318|Experimental|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
11316006|NCT02593318|Experimental|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
11316007|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
11316008|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
11316009|NCT02593305|No Intervention|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
11316010|NCT02593292|Active Comparator|PROSPERO group (intervention group)|
11316011|NCT02593292|Placebo Comparator|control group|
11316012|NCT02593279|Active Comparator|asthma with proximal or diffuse lung damage|
11316013|NCT02593279|Experimental|asthma with small airway prevailing damage|
11316014|NCT02593266|Experimental|Intervention Group|weekly sessions of PIP for depression.
11316015|NCT02593266|No Intervention|Waiting list control group|This is treatment as usual.
11316016|NCT02593253|Experimental|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
11316017|NCT02593253|Active Comparator|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
11316018|NCT02593240|Experimental|Human Performance Institute©|These participants will be part of the intervention sites and will receive the Human Performance Institute© intervention for the duration of the study (18 months).
11316019|NCT02593240|Experimental|The iDiet® with Voucher|These participants will be part of the intervention sites and will receive the iDiet® with Voucher for the duration of the study (18 months).
11316020|NCT02593240|Experimental|The iDiet® with Food|These participants will be part of the intervention sites and will receive the iDiet® with Food for the duration of the study (18 months).
11316021|NCT02593240|No Intervention|Wait-listed control|These participants will be part of the control sites and will participate in outcome assessments for a 6-month period only.
11316022|NCT02593227|Experimental|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
11316023|NCT02593227|Experimental|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
11316024|NCT02593227|Experimental|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
11316025|NCT02593227|Experimental|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
11316026|NCT02593214|Experimental|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
11316027|NCT02593201|Experimental|Treatment|One extra week of antibiotic therapy
11316028|NCT02593201|Sham Comparator|Control|No extra antibiotics
11316029|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
11316030|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
11316031|NCT02593175|Experimental|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
11316032|NCT02593162|Experimental|Group 1|12 weeks of Faldaprevir plus low dose TD-6450 plus Ribavirin
11316033|NCT02593162|Experimental|Group 2|12 weeks of Faldaprevir plus high dose TD-6450 plus Ribavirin
11316034|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
11316035|NCT02593149|No Intervention|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
11316036|NCT02593136|Experimental|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
11316037|NCT02593136|Experimental|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
11316038|NCT02593123|Experimental|Arm I (MMF-15, sargramostim)|Patients receive mycophenolate mofetil PO or IV BID on days 1-15 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
11316039|NCT02593123|Experimental|Arm II (MMF-30, filgrastim)|Patients receive mycophenolate mofetil PO or IV BID on days 1-30 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
11316040|NCT02593110|Active Comparator|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
11316041|NCT02593110|Active Comparator|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
11316042|NCT02593110|Active Comparator|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
11316043|NCT02593110|Placebo Comparator|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
11316044|NCT02593097|Experimental|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
11316045|NCT02593097|Experimental|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
11316046|NCT02593084|Experimental|Higher Intensity Resistance Training|Participants will take part in a 12-week higher-intensity resistance training protocol.
11316047|NCT02593084|Active Comparator|Lower Intensity Resistance Training|Participants will take part in a 12-week lower-intensity resistance training protocol that will serve as the active comparator.
11316048|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
11316049|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
11316050|NCT02593058|Experimental|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
11316051|NCT02593058|Active Comparator|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
11316052|NCT02593045|Experimental|IPH4102|
11316053|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
11316054|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
11316055|NCT02593019|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
11316056|NCT02592993|Experimental|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
11316057|NCT02592980|Experimental|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
11316058|NCT02592980|Experimental|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
11316059|NCT02592967|Experimental|Cohort 1A and 1B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
11316060|NCT02592967|Experimental|Cohort 2A and 2B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
11316061|NCT02592954|Experimental|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
11316062|NCT02592954|Placebo Comparator|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
11316063|NCT02592928||Lleida Health Sector|"Lleida (168k inhabitants and 21 Primary Care centers). Primary Care centers from this health sector
~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
11316064|NCT02592928||Vic Health Sector|"Vic (49k inhabitants and 11 Primary Care Centers). Primary Care centers from this health sector
~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
11316065|NCT02592928||AISBE Health Sector|"Atenció Integral en Salut Barcelona Esquerra (AISBE) (540k inhabitants and 19 Primary Care centers). Primary Care centers from this health sector
~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
11316066|NCT02592915|Experimental|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
11316067|NCT02592915|Placebo Comparator|Control Group|Patients randomized in the Control Group will receive the Placebo
11316068|NCT02592902|Active Comparator|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
11316069|NCT02592902|Active Comparator|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
11316070|NCT02592889|No Intervention|CONTROL|OPTIMIZED MEDICAL TREATMENT
11316071|NCT02592889|Active Comparator|DEVICE|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM + OPTIMIZED MEDICAL TREATMENT
11316072|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
11316073|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
11316074|NCT02592863|Experimental|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
11316075|NCT02592863|Placebo Comparator|Placebo|Patients will take placebo 3 times per day for 12 weeks
11316076|NCT02592850|Experimental|Osteopathic Manipulative Treatment|Active manipulative treatment.
11316077|NCT02592850|Sham Comparator|Sham Osteopathic Manipulative Treatment|Sham manipulative treatment.
11316078|NCT02592837|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
11316079|NCT02592837|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
11316080|NCT02592824|Active Comparator|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
11316081|NCT02592824|Placebo Comparator|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
11316082|NCT02592811|Active Comparator|ESLBD|"Endoscopic Sphincterotomy plus Large Balloon Dilatation +/- lithotripsy
~ERCP with deep cancellation of BDS
~Endoscopic large sphincterotomy
~Large Balloon Dilatation of Oddi Sphincter: with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
~Stone extraction with dormia basket or extraction balloon
~Mechanical Lithotripsy if needed"
11316083|NCT02592811|Active Comparator|CONV|"Conventional treatment associating Endoscopic Sphincterotomy +/- Mechanical Lithotripsy (ES+/-LM)
~ERCP with deep cancellation of BDS
~Endoscopic large sphincterotomy
~Stone extraction with dormia basket or extraction balloon
~Mechanical Lithotripsy if needed"
11316084|NCT02592798|Experimental|Abatacept|"Abatacept intravenous injection every 28 days
~Adults will use the weight-tiered dose: < 60 kg: 500 mg, 60 to 100 kg: 750 mg, > 100 kg: 1000 mg
~Pediatric patients 6 to 17 years who weigh < 75 kg will receive:10 mg/kg"
11316085|NCT02592798|Other|Placebo|Normal saline or D5W (5% Dextrose in Water)
11316086|NCT02592785|Experimental|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
11316087|NCT02592772|Experimental|Reduced Nicotine Non-Menthol (RNC)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine non menthol cigarettes (RNC: NRC 200; 0.07 mg nicotine yield cigarettes without menthol) during the 6 week experimental phase.
11316088|NCT02592772|Experimental|Reduced Nicotine Menthol (RNC-Men)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine menthol cigarettes (RNC-Men: NRC 201; 0.07 mg reduced nicotine content menthol cigarettes) during the 6 week experimental phase.
11316089|NCT02592772|Experimental|Conventional Nicotine Non-Menthol (CN)|Study participants will be randomized from their own brand of menthol cigarettes to the regular/conventional nicotine non menthol cigarettes (CN: NRC 600; 0.8 mg nicotine content) during the 6 week experimental phase.
11316090|NCT02592759|Experimental|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
11316091|NCT02592759|No Intervention|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
11316092|NCT02592746|Experimental|Palbociclib + Exemestane + GnRH agonist|
11316093|NCT02592746|Active Comparator|Capecitabine|
11316094|NCT02592733||Historical Cohort|Patients who have undergone infrarenal endovascular repair at each centre in the past.
11316095|NCT02592733||Prospective Cohort|Patients undergoing infrarenal endovascular repair in the study using CYDAR in addition to the local angiography equipment.
11316096|NCT02592720|Experimental|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
11316097|NCT02592720|Placebo Comparator|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
11316098|NCT02592707|Experimental|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
11316099|NCT02592694|Experimental|Cocktail with thrombus aspiration|Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration
11316100|NCT02592694|Active Comparator|Thrombus aspiration|Thrombus aspiration alone
11316101|NCT02592681|Experimental|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
11316102|NCT02592681|Active Comparator|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
11316103|NCT02592681|Sham Comparator|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
11316104|NCT02592668|Experimental|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
11316105|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
11316147|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
11366185|NCT02259959|Placebo Comparator|Placebo|
11316106|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
11316107|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
11316108|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
11316109|NCT02592642|Experimental|Group 1|Self-management Program, Workbook, Video, Pedometer
11316110|NCT02592642|Active Comparator|Group 2|Instructional Workbook, Video, and Pedometer
11316111|NCT02592642|Experimental|Group a|Para-spinal TENS
11316112|NCT02592642|Placebo Comparator|Group b|Para-spinal Placebo TENS
11316113|NCT02592642|Experimental|Group c|Prototype Spinal Stenosis Belt
11316114|NCT02592642|Sham Comparator|Group d|Sham spinal stenosis belt
11316115|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
11316116|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
11316117|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
11316118|NCT02592616|Experimental|CON|Control (CON).
11316119|NCT02592616|Experimental|CW|Continuous Walking (CW).
11316120|NCT02592616|Experimental|IW|Interval Walking (IW).
11316121|NCT02592603|Active Comparator|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
11316122|NCT02592603|No Intervention|Standard Colonoscopy|Standard Colonoscopy without any additional device
11316123|NCT02592590|Experimental|Group A|
11316124|NCT02592590|Experimental|Group B|
11316125|NCT02592590|Experimental|Group C|
11316126|NCT02592590|Active Comparator|Group D|
11316127|NCT02592577|Experimental|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
11316128|NCT02592564|Experimental|Psychological treatment|Psychological treatment during 9 weeks.
11316129|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
11316130|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
11316131|NCT02592551|Placebo Comparator|Untreated arm (control)|Untreated arm (control)
11316132|NCT02592538|Experimental|RFA+stent+S-1|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
11316133|NCT02592538|Placebo Comparator|RFA+stent|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
11316134|NCT02592525|Experimental|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
11316135|NCT02592525|Experimental|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
11316136|NCT02592525|Experimental|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
11316137|NCT02592525|Experimental|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
11316138|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
11316139|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
11316140|NCT02592499|Experimental|HM III|Patients randomized to mechanical circulatory support will be treated with the HeartMate III (HM III) left ventricular assist device system.
11316141|NCT02592499|Active Comparator|OMM, Optimal Medical Management|"Patients randomized to OMM will be treated according to international guidelines.
~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012 Jul;33(14):1787-84"
11316142|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
11316143|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
11316144|NCT02592473|Experimental|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
11316145|NCT02592460|Experimental|poor-polyamines diet|
11316146|NCT02592460|Active Comparator|high-polyamines diet|
11316185|NCT02592161|Placebo Comparator|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
11316148|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
11316149|NCT02592434|Experimental|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
11316150|NCT02592434|Placebo Comparator|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
11316151|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
11316152|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
11316153|NCT02592408|Active Comparator|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
11316154|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
11316155|NCT02592408|Active Comparator|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
11316156|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
11316157|NCT02592395|Experimental|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
11316158|NCT02592382|Placebo Comparator|Isotonic saline spray|Isotonic saline (0.9% of NACL) given as nasal spray 3 times a day ( one puff for each nostril) for a two months period
11316159|NCT02592382|Experimental|Xylitol spray|Solid Xylitol diluted in normal saline(0.9% NACL) to a concentration of 5%. given as a nasal spray 3 times a day(one puff for each nostril) for two months period
11316160|NCT02592356|Experimental|Cabozantinib or Lenvatinib|Patients treated with cabozantinib s-malate or lenvatinib mesylate are observed for body weight, skeletal muscle and adipose tissue changes. Patients complete 3 to 4 questionnaires every 2 weeks for 6 months and then monthly up to 12 months. Patients also undergo physical assessments and body composition measurements by DXA and CT scans at baseline, months 3, 6, and 12.
11316161|NCT02592343|Experimental|Experimental: Lyophilized Fecal Microbiota Transplantation|All eligible patients with a history of recurrent or refractory CDI will receive 2 lyophilized FMTs
11316162|NCT02592330|Experimental|Cultivated Autologous Limbal Epithelial Cell (CALEC) graft|Participants will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
11316163|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
11316164|NCT02592304|Other|dual energy ct|
11316165|NCT02592291|Experimental|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
11316166|NCT02592291|No Intervention|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
11316167|NCT02592278|Experimental|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
11316168|NCT02592278|Experimental|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
11316169|NCT02592278|Active Comparator|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
11316170|NCT02592252|Experimental|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
11316171|NCT02592252|Experimental|Microfinance only|Receive microfinance only
11316172|NCT02592252|Experimental|Gender training only|10 sessions of participatory gender training for women and their male partners
11316173|NCT02592252|No Intervention|No intervention|No microfinance or participatory gender training
11316174|NCT02592239|Experimental|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
11316175|NCT02592239|Experimental|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
11316176|NCT02592226|Active Comparator|Control group|
11316177|NCT02592226|Experimental|Protocol Group|
11316178|NCT02592213|Experimental|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
11316179|NCT02592200|Experimental|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
11316180|NCT02592200|Placebo Comparator|Placebo|Placebo capsules (two doses)
11316181|NCT02592187|Experimental|Experimental intervention|ReMemory-MCI training
11316182|NCT02592187|Active Comparator|Control intervention|Control intervention
11316183|NCT02592174|Other|HIV subjects|"Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.
~Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.
~Two substudies will be proposed:
~cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)
~sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
11316184|NCT02592161|Experimental|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
11316187|NCT02592122|Active Comparator|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
11316188|NCT02592122|Active Comparator|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
11316189|NCT02592109|Experimental|Enhanced Counseling using CFR based on LP|"The counseling will be done by individual face-to-face communications. The intervention's arm will get a counseling with an additional of 7-day cycle with adequate n-3 and optimal n-3/6 ratio for complementary feeding menu obtained from linear programming formulation.
~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet; definition, function, and source of omega-3; example of menu that contains adequate omega-3. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
11316190|NCT02592109|Active Comparator|General CFR Counseling|"The control's arm will get general counseling combining balance diet and IYCF principal, which already been used by Ministry of Health, with additional of 7-day cycle menu guidance modified from existing or available menu which can be downloaded for public on Ministry of Health official website.
~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet based on Ministry of Health's Recommendation, and example of balanced diet menu. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
11316191|NCT02592096|Experimental|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
11316192|NCT02592096|Experimental|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
11316193|NCT02592096|Experimental|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
11316194|NCT02592096|Active Comparator|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
11316195|NCT02592083|Active Comparator|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
11316196|NCT02592083|Experimental|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
11316197|NCT02592083|Experimental|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
11316198|NCT02592070|Experimental|30 minute treadmill walking|All participants will walk on the treadmill for 30 minutes and perform a battery of cognitive tasks immediately prior, immediately after, and one hour after completion of the 30 minute walking period.
11316199|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
11316200|NCT02592044|Experimental|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
11316201|NCT02592044|Placebo Comparator|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
11316202|NCT02592031|Experimental|XM17|XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.
11316203|NCT02592031|Experimental|Gonal-f®|Gonal-f® will be provided in pens with integrated vials of 0.5 mL
11316204|NCT02592031|Active Comparator|Zoladex®|Zoladex® 3.6 mg will be administered by subcutaneous injection
11316205|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
11316206|NCT02591992|Active Comparator|Cardiac CT|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo computed tomography angiography (cardiac CT) as the first-choice imaging diagnostics
11316207|NCT02591992|Active Comparator|Invasive coronary angiography|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo invasive coronary angiography
11316208|NCT02591966||Biomarker group|"The patients who receive neoadjuvant systemic treatments:
~The patients who have distant metastatic sites at first and recur from surgery:
~The patients who are going to receive first-line chemotherapy:"
11316209|NCT02591953|Experimental|Ultrasound-guided Injection|Injection performed with ultrasound-guidance
11316210|NCT02591953|Active Comparator|Landmark-guided Injection|Injection performed at point of maximal tenderness along biceps tendon
11316211|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
11316212|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
11316213|NCT02591927|Active Comparator|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
11316214|NCT02591927|Placebo Comparator|Glucose 5%|Glucose 5%
11316306|NCT02591355|Experimental|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
11316307|NCT02591355|Placebo Comparator|Saline|Saline solution injection
11366373|NCT02258737|Active Comparator|standard care|
11316215|NCT02591914|Experimental|Altering regimens of Fovista™and Anti-VEGF Therapy|"All subjects will be treated with Fovista™ 1.5 mg/eye in combination with anti-VEGF therapy.
~The following doses of Anti-VEGF therapy will be delivered based on the Investigator's discretion:
~Lucentis® 0.5 mg/eye
~Avastin® 1.25 mg/eye
~Eylea® 2 mg/eye
~Subjects will be treated with Fovista™ and Anti-VEGF therapy every month for the first three months.
~The regimen for administration of each intravitreal agent will be as follows:
~Injection Day #1-Administration of Fovista™ 1.5mg/eye
~Injection Day #2-Administration of Fovista™ 1.5mg/eye followed by anti-VEGF therapy after Fovista™ injection
~The same regimen will be delivered monthly until the subject reaches maximum visual acuity benefit. Maximum visual acuity is defined as no increase in ETDRS visual acuity at two consecutive visits.
~Subsequent re-treatment with the Anti-VEGF therapy will use a PRN (as-needed) regimen based on protocol specified retreatment criteria."
11316216|NCT02591901|Experimental|Uro Vaxom|Uro Vaxom, Once daily for 3 months
11316217|NCT02591901|Placebo Comparator|Placebo|Placebo identical to main drug in shape and form
11316218|NCT02591888|Active Comparator|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
11316219|NCT02591888|Placebo Comparator|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
11316220|NCT02591862|Other|Coversin|"This is an open label, non-comparator study.
~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given."
11316221|NCT02591849|Active Comparator|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
11316222|NCT02591849|Placebo Comparator|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
11316223|NCT02591836|Experimental|Gemcabene 300 mg|Gemcabene 300 mg QD
11316224|NCT02591836|Experimental|Gemcabene 600 mg|Gemcabene 600 mg QD
11316225|NCT02591836|Experimental|Gemcabene 900 mg|Gemcabene 900 mg QD
11316226|NCT02591836|Placebo Comparator|Placebo|
11316227|NCT02591836|Active Comparator|Atorvastatin 10 mg|
11316228|NCT02591836|Active Comparator|Atorvastatin 40 mg|
11316229|NCT02591836|Active Comparator|Atorvastatin 80 mg|
11316230|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 10 mg|
11316231|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 40 mg|
11316232|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 80 mg|
11316233|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 10 mg|
11316234|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 40 mg|
11316235|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 80 mg|
11316236|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 10 mg|
11316237|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 40 mg|
11316238|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 80 mg|
11316239|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
11316240|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
11316241|NCT02591810|Active Comparator|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
11316242|NCT02591810|Active Comparator|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
11316243|NCT02591810|Active Comparator|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
11316244|NCT02591797|Experimental|"hand-eye-mouth technique"|"hand-eye-mouth (MOB) seeks to focus the patient in performing a sequence of movements in a fun way so that your attention is diverted from the puncture dental needle, also it seeks to the patient does not see the needle. The operator prior to infiltrate local anesthetic teaches the child a game to put the sleepy little water.After explain a first time, the sequence once or twice is repeated until the patient has mastered. We call this test. When we apply the anesthetic, the entire sequence must be repeated as in trials with the same tranquility and in the same tone of the game. The operator will use this technique during the inferior alveolar and lingual nerve block procedure"
11316245|NCT02591797|Active Comparator|Conventional technique|the operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child´s field of view by hand during the inferior alveolar and lingual nerve block
11316246|NCT02591784|Experimental|Nimotuzumab group|Nimotuzumab+radiotherapy
11316247|NCT02591771|Experimental|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
11316308|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
11316309|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
11316248|NCT02591758||Stable Angina with coronary angiogram|This study aims to correlate the biometric data collected and derived from the Hexoskin with the standard physiological assessment, in patients referred for coronary angiography for limiting angina. Afterwards, the clinician will decide of the best treatment strategy for the patient: coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) or no revascularization.
11316249|NCT02591732||Patient treated with Apixaban|
11316250|NCT02591732||Patient treated with Rivaroxaban|
11316251|NCT02591732||Patient treated with Dabigatran|
11316252|NCT02591732||Patient treated with vitamin K antagonists|
11316253|NCT02591719|Experimental|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
11316254|NCT02591719|Sham Comparator|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
11316255|NCT02591719|Active Comparator|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
11316256|NCT02591706|Active Comparator|Dental implant (C1)|"Internal Conical Connection: The C1 has a six-position cone index, except for the C1 narrow platform that has a four-position cone index. The conical connection is 2.00mm in depth, with a 12° cone. As a result of our meticulous manufacturing process a perfect fit between the implant and the abutment is achieved, eliminating micro-movements and minimizing bone resorption.
~Patient will be randomly assigned to one of the two groups after flap opening."
11316257|NCT02591706|Experimental|Dental implant (V3)|"The unique triangular shape of the coronal portion of the V3 implant results in less titanium and more bone and soft tissue visible in the esthetic zone, for a restorative-driven approach and easier soft tissue management. The V3 provides doctors with a more advantageous starting point; where greater volume of bone and soft tissue is achieved at the onset of implant placement.
~Patient will be randomly assigned to one of the two groups after flap opening."
11316258|NCT02591693|Experimental|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.
~On-going usual care from multi-professional team at hospice."
11316259|NCT02591693|No Intervention|Usual Care|On-going usual care from multi-professional team at hospice.
11316260|NCT02591680|Experimental|Neuromuscular training|Neuromuscular, this arm will receive neuromuscular training and muscle strengthening.
11316261|NCT02591680|Active Comparator|Strength|Strength, this arm will receive only muscle strengthening.
11316262|NCT02591667|Experimental|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.
~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.
~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
11316263|NCT02591654|Experimental|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
11316264|NCT02591641|Experimental|Standard of Care First, then Liquicell|Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
11316265|NCT02591641|Experimental|Liquicell First, then Standard of Care|Subjects were secured on a standard ambulance stretcher with an anti-shear mattress overlay placed on top of the stretcher, with a shear and pressure sensor attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken throughout the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated without the LiquiCell ASMO.
11316266|NCT02591628|Active Comparator|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
11316267|NCT02591628|No Intervention|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
11316268|NCT02591615|Active Comparator|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles
~OR
~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
11316269|NCT02591615|Active Comparator|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles
~Patients with CR, PR, or SD by irRC will then be treated with:
~For Squamous Carcinoma:
~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles
~OR
~For Non-squamous Carcinoma
~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
11316270|NCT02591602|Experimental|CASI|Teleradiology service for patients residing at home or in nursing homes
11316271|NCT02591602|No Intervention|CONTROLLI|X-ray hospital department
11316339|NCT02591134|Experimental|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
11316272|NCT02591589|Experimental|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
11316273|NCT02591589|Active Comparator|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
11316274|NCT02591576||ST-elevation myocardial infarction (STEMI)|
11316275|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
11316276|NCT02591563||Healthy children|6-36 months of age who will have the following study procedures: Venipuncture, Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis
11316277|NCT02591550||patients with normal cough sensitivity|
11316278|NCT02591550||patients with high cough sensitivity|
11316279|NCT02591550||healty controls|
11316280|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
11316281|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
11316282|NCT02591524|Experimental|Cystic fibrosis airway colonization|Flexible bronchoscopy via the nasal route on the date of baseline visit, nasal lavage at baseline and after 6 month
11316283|NCT02591511|Experimental|health-education app|Smart phone and pad is a stroke-related health education app intervention group
11316284|NCT02591511|Active Comparator|health education manuals|stroke-related health education manual control group
11316285|NCT02591498|Active Comparator|Auditory|Administration of 40 hours of auditory training exercises
11316286|NCT02591498|Active Comparator|Visual|Administration of 40 hours of visual training exercises
11316287|NCT02591498|Placebo Comparator|Video Games|Administration of 40 hours of commercial video games
11316288|NCT02591485|Experimental|Attention Control Training|Computerized attention modification training, comprised of six sessions that delivered by internet, in purpose of modulate biases in attention for threat stimuli.
11316289|NCT02591485|No Intervention|Follow-up only|In this condition, a follow-up interviews will be conducted 3 months since the traumatic event had occurred.
11316290|NCT02591472|Active Comparator|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
11316291|NCT02591472|Experimental|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
11316292|NCT02591459|Other|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
11316293|NCT02591433|Experimental|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
11316294|NCT02591420|Experimental|Group 1: immediate ART and placebo infusion|Participants will start ART and will receive a single infusion of placebo at Day 0.
11316295|NCT02591420|Experimental|Group 2: immediate ART and VRC01 infusion|Participants will start ART and receive a single infusion of VRC01 at Day 0.
11316296|NCT02591420|Experimental|Group 3: immediate VRC01 infusion and subsequent ART|Participants will receive a single infusion of VRC01 on Day 0 followed by ART initiation on Day 7.
11316297|NCT02591407|Active Comparator|TAP Block- Exparel|Transversus abdominis plane block utilizing the medication Exparel®
11316298|NCT02591407|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia
11316299|NCT02591394|Experimental|STEP Clinic|
11316300|NCT02591394|Active Comparator|Usual Care|
11316301|NCT02591381|Experimental|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
11316302|NCT02591381|Experimental|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
11316303|NCT02591368|Active Comparator|Ligament reconstr. tendon interposition|Ligament reconstruction, tendon interposition.
11316304|NCT02591368|Active Comparator|Mini Tight rope with one-suture|Mini Tight rope with one suture
11316305|NCT02591368|Active Comparator|Mini Tight rope with two-suture|Mini Tight rope with two sutures
11316310|NCT02591329|Experimental|Experimental|The experimental condition (EXP) will receive the targeted intervention material developed and designed by the researchers using focus group discussions with parents. This information will include salient benefits of the consumption of calcium-rich products. In addition, self-regulatory strategies will be provided to encourage purchasing and consumption of calcium-rich products and address any potential barriers to purchase and consumption. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a grocery pad and a recipe book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
11316311|NCT02591329|Active Comparator|Standard Care|Individuals in the Control condition (CON) will receive general healthy eating materials including Canada's Food Guide, Healthier Grocery Shopping Guide and Cooking with Kids. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a note pad and an activity book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
11316312|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
11316313|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
11316314|NCT02591303|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency <85%) with 10 days actigraphy
11316315|NCT02591303|Experimental|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency >85%)
11316316|NCT02591290|Experimental|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
11316317|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
11316318|NCT02591251|Active Comparator|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
11316319|NCT02591251|Active Comparator|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
11316320|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
11316321|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
11316322|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
11316323|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
11316324|NCT02591225|Experimental|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
11316325|NCT02591225|Active Comparator|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
11316326|NCT02591212|Active Comparator|#ConnectDots|"Green Dot Intensive Bystander Training (INT Condition) (Randomized):
~Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
~Administered by: UK VIP Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training."
11316327|NCT02591212|Placebo Comparator|#ConnectWell|"Wellness Initiatives for Student Empowerment delivered by UK's Student Wellness Office Programming: Addresses elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
~Administered by: UK VIP/Student Wellness Ambassadors Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training"
11316328|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
11316329|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
11316330|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
11316331|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
11316332|NCT02591186|Experimental|Acupuncture arm|Participants receiving acupuncture during IVF process
11316333|NCT02591186|No Intervention|Control|Control arm not receiving acupuncture during IVF process
11316334|NCT02591173|Experimental|Angiotensin-(1-7)|Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
11316335|NCT02591173|Placebo Comparator|Saline|Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
11316336|NCT02591160|Other|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
11316337|NCT02591147|Active Comparator|Silver Diamine Fluoride 38%|Group 1 (SDF 38%) will receive the application of silver diammine fluoride (38% SDF solution) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
11316338|NCT02591147|Placebo Comparator|Placebo (Sterile water)|Group 2 Placebo (control) will receive the application of sterile water (placebo) in addition to 5% sodium fluoride varnish to each approximal carious lesion (scores RA1,RA2,RA3) in a posterior tooth (premolar or molar) that is in contact with an adjacent tooth, using super floss, for a duration of 3 minutes under rubber dam isolation.
11316412|NCT02590627|Active Comparator|A|Artemether-lumefantrine
11316413|NCT02590627|Experimental|B|Dihydroartemisinin-piperaquine
11316340|NCT02591134|Placebo Comparator|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
11316341|NCT02591108|Experimental|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
11316342|NCT02591108|Active Comparator|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
11316343|NCT02591095|Experimental|ABT-263|oral Navitoclax (ABT-263) daily
11316344|NCT02591069|Experimental|All patients will undergo the same procedure|
11316345|NCT02591056|Experimental|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
11316346|NCT02591043|Other|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
11316347|NCT02591030|Placebo Comparator|GEMCIS|
11316348|NCT02591030|Experimental|mFOLFIRINOX|
11316349|NCT02591017|Other|morphine drops solo and placebo spray|"morphine 2% drops
~daily fixed dose of morphine equivalents < 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards
~daily fixed dose of morphine equivalents =/> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards"
11316350|NCT02591017|Other|ketamine/chitosan spray nasal and placebo drops|5 mg ketamine all 5 minutes, maximal 4 times an hour
11316351|NCT02591017|Other|morphine drops and ketamine/chitosan spray nasal|see above
11316352|NCT02591004|Experimental|Magesium sulphate|"Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).
~Doppler on fetal middle cerebral artery"
11316353|NCT02591004|Active Comparator|Nifedipine|"Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.
~Doppler on fetal middle cerebral artery"
11316354|NCT02590991||Prebiotics group|No intervention since is a follow-up study
11316355|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
11316356|NCT02590991||Control group|No intervention since is a follow-up study
11316357|NCT02590978|Experimental|Early cholecystectomy|Cholecystectomy within the first 72 hours of admission.
11316358|NCT02590978|Other|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
11316359|NCT02590965|Placebo Comparator|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
11316360|NCT02590965|Experimental|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
11316361|NCT02590952|Experimental|Epitinib|Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily)
11316362|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
11316363|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
11316364|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:
~An angiographic stenosis of more than 50% and less than 90% of the left main
~Any proximal descending anterior with a stenosis of more than 50% and less than 90%
~Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%
~Single remaining patent coronary artery with stenosis >50% and less than 90%"
11316365|NCT02590913|Experimental|group fructose|Volunteer was randomized into either group fructose or glucose
11316366|NCT02590913|Experimental|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
11316367|NCT02590900||at delivery|women who underwent cesarean at delivery, and needed iv paracetamol as part of multimodal analgesia. In these cases, paracetamol was administered q6h (2g loading dose, 1g q6h for 24 h), and blood and urine samples were collected to describe paracetamol disposition at delivery.
11316368|NCT02590900||postpartum|a subgroup of 8 women initially included in at delivery, underwent a second PK study 2-3 months postpartum and another PK study about 1 year after delivery. This PK study was based on a single iv paracetamol administration (2 g), and blood and urine samples were collected to describe paracetamol disposition in postpartum
11316369|NCT02590900||healthy female volunteers|"a group of 8 young healthy women not on oral contraceptives underwent a single PK study (2 g intravenous paracetamol) and blood and urine samples were collected to described paracetamol disposition in healthy female volunteers, not on oral contraceptives.
~Raw data as published by Gregoire et al (Clin Pharm Ther 2007) were available in 14 young women, all on contraceptives."
11316414|NCT02590614|Experimental|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
11316415|NCT02590614|Placebo Comparator|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
11316416|NCT02590601|Active Comparator|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.
~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
11316370|NCT02590887|Experimental|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010).
~The final beverage shall consist of:
~Oily phase: refined sunflower oil 5% w/w of the emulsion
~Aqueous phase (water) 95% w/w of the emulsion, containing equal volumes of solution A and B:
~Solution A:
~Hydrolyzed Lupine (1.17% w/w)
~Sucrose (14.03% w/w)
~Vanilla flavor (0.42% w/w)
~Drinking water (84.38% w/v)
~Solution B:
~Xanthan gum (0.28% w/w)
~Drinking water (99.72% w/v)
~The samples will guard and kept by the investigator until the day of delivery to the volunteers.
~The duration of treatment 4 weeks, during which the volunteers daily consume the contents of a tetra brik."
11316371|NCT02590874|Experimental|Duloxetine group|Active drug group
11316372|NCT02590874|Placebo Comparator|Placebo group|Inactive drug group
11316373|NCT02590861|Experimental|Dental implant|All participants will receive the same intervention, this is a single group study.
11316374|NCT02590848|No Intervention|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
11316375|NCT02590848|Experimental|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
11316376|NCT02590835|Active Comparator|Control group|Treated with conventional orthodontics
11316377|NCT02590835|Experimental|Test group|subjected to piezo-assisted orthodontics
11316378|NCT02590822|No Intervention|Standard Care|The Standard Care group will be contacted weekly (where possible) to reinforce cognitive behavioural adaptations and encourage compliance to diet and exercise. They will be provided with standard lifestyle advice according to NICE guidance.
11316379|NCT02590822|Experimental|Total Dietary Replacement|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
~The TDR will be undertaken alongside health behaviour coaching and relapse prevention contact & current medications will need to be adjusted initially and throughout the study."
11316380|NCT02590822|Experimental|Supervised Exercise|"The exercise group will attend thrice weekly 60minute supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. An initial assessment of cardiorespiratory fitness will be performed (VO2 max) to allow design of a tailored exercise programme.
~Current medication will need to be adjusted initially and throughout the study."
11316381|NCT02590809|Experimental|Treatment group|20 patients
11316382|NCT02590809|Placebo Comparator|Placebo group|20 patients
11316383|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
11316384|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
11316385|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
11316386|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
11316387|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
11316388|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
11316389|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
11316390|NCT02590783|Experimental|experimental intervention surgery|screw osteosynthesis of the sacrum and in certain cases additional plate osteosynthesis of dislocated pubic rami fractures, postoperative analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
11316391|NCT02590783|Active Comparator|control intervention conservative|analgesia, physiotherapy, work-up for osteoporosis, geriatric rehabilitation if necessary
11316392|NCT02590770|Active Comparator|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
11316393|NCT02590770|Placebo Comparator|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
11316394|NCT02590757|Active Comparator|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
11316395|NCT02590757|Active Comparator|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
11316396|NCT02590744|Experimental|eye patch|cover the sick eye with eye patch for 3 hours preoperatively.
11316397|NCT02590744|Placebo Comparator|non-eye patch|do not cover the sick eye before surgery.
11316398|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
11316399|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
11316400|NCT02590718|Experimental|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
11316401|NCT02590718|No Intervention|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
11316402|NCT02590705|Experimental|Group 1|surface anesthesia with lidocaine
11316403|NCT02590705|No Intervention|Group 2|no anesthesia
11316404|NCT02590692|Experimental|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
11316405|NCT02590679|Experimental|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
11316406|NCT02590666|Experimental|Bipolar electrode|Polyps resection with bipolar electrode
11316407|NCT02590666|Active Comparator|Microscissors or graspers|Polyps resection with microscissors or graspers
11316408|NCT02590653|Experimental|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
11316409|NCT02590653|Active Comparator|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
11316410|NCT02590640|Active Comparator|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
11316411|NCT02590640|Sham Comparator|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
11316417|NCT02590601|Other|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
11316418|NCT02590588|Experimental|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
11316419|NCT02590575|Other|CO2 removal|
11316420|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
11316421|NCT02590549|Experimental|MyoRing Implantation combined with corneal cross linking|Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)
11316422|NCT02590536|Experimental|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
11316423|NCT02590536|Placebo Comparator|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
11316424|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
11316425|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
11316426|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
11316427|NCT02590510|Experimental|The small dose of group|The dose of methotrexate is 10 mg
11316428|NCT02590510|Active Comparator|The high dose of group|The dose of methotrexate is 15 mg
11316429|NCT02590497|Experimental|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
11316430|NCT02590471|Active Comparator|Stenting of the femoral artery.|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted.
11316431|NCT02590471|Experimental|Stenting of the femoral artery and fasciotomy.|Under local anesthesia standard endovascular exposure is made and lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
11316432|NCT02590458|Experimental|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
11316433|NCT02590445|Active Comparator|Active stimulation|Stimulator on followed by off
11316434|NCT02590445|Sham Comparator|Sham stimulation|Stimulator off followed by on
11316435|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Open Label)|LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
11316436|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Open Label)|LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
11316437|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 290 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
11316438|NCT02590432|Experimental|LINZESS® 145 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
11316439|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
11316440|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was reduced to 72 μg, if applicable.
11316441|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
11316442|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with CIC.
11316507|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1
~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
11316443|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with IBS-C.
11316444|NCT02590419|No Intervention|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
11316445|NCT02590419|Experimental|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
11316446|NCT02590406|Active Comparator|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
11316447|NCT02590406|Experimental|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.
~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
11316448|NCT02590393|Active Comparator|Nicotine + NNTAs|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain tobacco extract with nicotine + NNTAs in a vehicle of propylene glycol. The yields of nicotine and NNTAs will be in the range of typical commercial cigarettes (e.g., 0.6 mg nicotine delivered in 10 puffs of 35 mL), with a ratio of NNTA:nicotine yield that is also typical of commercial cigarettes.
11316449|NCT02590393|Active Comparator|Nicotine control|"Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain the same concentration of nicotine, but very low amounts (1/10th) of NNTAs as in Group 1. This specialized product will be developed from low nicotine, low NNTA content tobacco extract currently used in the Spectrum cigarettes offered as part of the National Institute on Drug Abuse (NIDA) drug supply program. This extract will then be fortified with additional nicotine to match nicotine levels in Group 1. A propylene glycol vehicle will remain the same as in Group 1."
11316450|NCT02590393|Active Comparator|Vehicle control|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain only propylene glycol vehicle and extract from low nicotine/NNTA content tobacco. The nicotine yield will be less than 0.05 mg per 10 puffs of 35 mL, i.e., less than 1/10 of the yield in the other two groups, and NNTA yield will be correspondingly low.
11316451|NCT02590380|Active Comparator|treatment group (MESA)|Patients randomized to the treatment group will receive surgery with the MESA Rail Deformity System.
11316452|NCT02590380|Active Comparator|control group (USS II)|Patients randomized to the control group will receive surgery with the DePuy Synthes USS II System.
11316453|NCT02590367|Experimental|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
11316454|NCT02590367|Placebo Comparator|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
11316455|NCT02590354|Experimental|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
11316456|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
11316457|NCT02590315|Experimental|Digital Breast Tomosynthesis - DBT|Invitation for breast screening and random allocation. Participants randomised to DBT will be screened with bilateral, two-view combo mode (DBT images are obtained with DM images). DBT participants will have an additional radiation exposure for the combined DM and DBT examinations.
11316458|NCT02590315|Active Comparator|Conventional digital mammography - DM|Invitation for breast screening and random allocation. Participants randomised to DM will be screened with bilateral, two-view DM.
11316459|NCT02590302|Other|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
11316460|NCT02590289|Experimental|BBI-5000 Dose 1|Low dose of BBI-5000
11316461|NCT02590289|Experimental|BBI-5000 Dose 2|Middle dose of BBI-5000
11316462|NCT02590289|Experimental|BBI-5000 Dose 3|High dose of BBI-5000
11316463|NCT02590289|Experimental|BBI-5000 Dose 4|High dose of BBI-5000
11316464|NCT02590276|Experimental|Evaluation|Characterization
11316465|NCT02590263|Experimental|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
11316466|NCT02590263|Experimental|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
11316467|NCT02590263|Experimental|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
11316468|NCT02590263|Experimental|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
11317823|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
11316469|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
11316470|NCT02590237|Active Comparator|Direct Laryngoscopy|The trachea will be intubated via direct laryngoscopy using a traditional straight blade (Miller) laryngoscope.
11316471|NCT02590237|Experimental|KingVision Video Laryngoscope|The trachea will be intubated using the Ambu KingVision Video Laryngoscope size 1 pediatric blade.
11316472|NCT02590224|Active Comparator|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
11316473|NCT02590224|Active Comparator|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
11316474|NCT02590211|Other|non-poker players|(control group)
11316475|NCT02590211|Other|expert unproblematic poker players|(comparator)
11316476|NCT02590211|Other|pathological poker players|(comparator)
11316477|NCT02590198||ANAES algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
11316478|NCT02590198||PCT algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
11316479|NCT02590185|Experimental|cocktail probe drugs|"A capsule of omeprazole ABBOTT® 10mg
~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)
~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)
~A tablet of fexofenadine Zentiva® 120mg"
11316480|NCT02590146|Experimental|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
11316481|NCT02590146|No Intervention|Control group|Patients in this group will receive standard of care pain management offered in the office.
11316482|NCT02590133|Experimental|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
11316483|NCT02590133|Active Comparator|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
11316484|NCT02590120|Active Comparator|Enteral nutrition product : product A|Administration during 16 hours.
11316485|NCT02590120|Active Comparator|Enteral nutrition product : product B|Administration during 16 hours.
11316486|NCT02590107|Experimental|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
11316487|NCT02590094|Active Comparator|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
11316488|NCT02590094|Active Comparator|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
11316489|NCT02590094|Active Comparator|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
11316490|NCT02590094|Active Comparator|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
11316491|NCT02590094|Active Comparator|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
11316492|NCT02590094|Active Comparator|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
11316493|NCT02590094|Active Comparator|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
11316494|NCT02590094|Active Comparator|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
11316495|NCT02590094|Active Comparator|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
11316496|NCT02590081|Active Comparator|Normal saline|Normal saline will be used for wash back procedure at the end of hemodiaysis.
11316497|NCT02590081|Experimental|dextrose 5%|Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.
11316498|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
11316499|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
11316500|NCT02590055|Experimental|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
11316501|NCT02590042|Experimental|ADSC-SVF-002|Cells will be administered at 1x10^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10^6 cells/mL of defect.
11316502|NCT02590029|Experimental|Mindfulness|15 minute mindfulness session
11316503|NCT02590029|Experimental|Suggestion|15 minute therapeutic suggestion session
11316504|NCT02590029|Active Comparator|Psychoeducation|15 minute psychoeducation session
11316505|NCT02590016|Experimental|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
11316506|NCT02590016|Active Comparator|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
11367148|NCT02253953|Placebo Comparator|Placebo|for D3 - D10
11316508|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
11316509|NCT02589990|Experimental|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
11316510|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.
~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
11316511|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.
~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
11316512|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.
~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
11316513|NCT02589964|Active Comparator|Probiotic|"Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:
~Lactobacillus acidophilus-over 7.5 billion Bifidobacterium lactis-over 6.0 billion Bifidobacterium longum-over 1.5 billion"
11316514|NCT02589964|Placebo Comparator|Placebo|"Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:
~Rice maltodextrin"
11316515|NCT02589938|Active Comparator|Standard Oral Hygiene|All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
11316516|NCT02589938|Experimental|Standard Oral Hygiene + True Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
~The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes."
11316517|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
~The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points."
11316518|NCT02589925|Sham Comparator|sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
11316519|NCT02589925|Active Comparator|NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
11316520|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
11316521|NCT02589886|Active Comparator|intervention|This arm will receive the education and self-help internet intervention added to usual care
11316522|NCT02589886|No Intervention|control|This arm will receive usual care only
11316523|NCT02589873|Active Comparator|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
11316524|NCT02589873|Active Comparator|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
11316525|NCT02589847|Experimental|RBX2660 Open-label|RBX2660 (microbiota suspension)
11316526|NCT02589847|Other|Historical control antibiotics|Retrospective Historical Control with standard of care
11316527|NCT02589834|Active Comparator|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
11316528|NCT02589834|No Intervention|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
11316529|NCT02589821|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
11316530|NCT02589821|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
11316531|NCT02589808|Experimental|Full TTE|Full echocardiogram.
11316532|NCT02589808|Experimental|VScan|Handheld echocardiogram.
11316533|NCT02589795|Experimental|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.
~50 µg CN54gp140, intradermally without electroporation, at Week 20."
11316534|NCT02589795|Experimental|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.
~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
11316535|NCT02589795|Experimental|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
11316794|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
11316536|NCT02589782|Experimental|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
11316537|NCT02589782|Experimental|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
11316538|NCT02589782|Experimental|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
11316539|NCT02589782|Active Comparator|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
11316540|NCT02589769|Experimental|unsaturated fat|an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods
11316541|NCT02589769|Active Comparator|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced.
11316542|NCT02589756|Experimental|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
11316543|NCT02589756|Experimental|The nut group|Participants who will avoid fatty fish
11316544|NCT02589756|Placebo Comparator|The control group|Participants who will avoid both fatty fish and nuts
11316545|NCT02589743|Active Comparator|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
11316546|NCT02589743|Experimental|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
11316547|NCT02589743|Active Comparator|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
11316548|NCT02589743|Experimental|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
11316549|NCT02589730|Experimental|online mutual management|The patients received the online coaching of a doctor and diabetes educator via smart phone based welltang app.
11316550|NCT02589730|Experimental|online self-management|The patients received the online coaching of a doctor alone via smart phone based welltang app.
11316551|NCT02589730|No Intervention|hospital regular management|The patients received usual care and did not use smart phone.
11316552|NCT02589691|Experimental|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
11316553|NCT02589691|Placebo Comparator|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
11316554|NCT02589678|Other|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
11316555|NCT02589678|Other|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
11316556|NCT02589665|Experimental|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
11316557|NCT02589665|Experimental|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
11316558|NCT02589665|Experimental|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
11316559|NCT02589665|Placebo Comparator|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
11316560|NCT02589665|Experimental|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
11316561|NCT02589665|Experimental|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
11316562|NCT02589665|Placebo Comparator|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
11316563|NCT02589665|Experimental|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
11316564|NCT02589665|Experimental|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
11316565|NCT02589665|Experimental|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
11316566|NCT02589652||Switch group|Patients who have been assigned to pegylated interferon alfa-2a.
11316567|NCT02589652||Sequential combination group (S-C group)|Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.
11316568|NCT02589652||ETV group|Patients who have been assigned to entecavir monotherapy.
11316569|NCT02589639|Experimental|empagliflozin 10 mg|
11316570|NCT02589639|Experimental|empagliflozin 25 mg|
11316571|NCT02589639|Placebo Comparator|placebo|
11316572|NCT02589626|Experimental|empagliflozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
11316573|NCT02589626|Experimental|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
11316574|NCT02589613|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
11316575|NCT02589613|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
11316576|NCT02589613|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
11316577|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
11316578|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
11316579|NCT02589587|Active Comparator|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
11316580|NCT02589587|Other|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
11316581|NCT02589574|No Intervention|Control|Subjects of the control group will receive the usual announcement on the dates and times of offering free influenza vaccination, and reminder from hospital, and access to informational flyers posted at the hospital
11316582|NCT02589574|Experimental|Intervention|Subjects of the intervention group besides the usual information same as those stated in the control group, will receive four reminders on dates and details for free influenza vaccine. Together with the reminder, electronic text messages of educational information will be received
11316583|NCT02589561|Active Comparator|face to face fitting|face to face fitting of hearing aids
11316584|NCT02589561|Experimental|remote fitting|remote fitting of hearing aids
11316585|NCT02589535||septic|Group Gb: postoperative septic patients in intensive care unit (ICU)] Gb1: the group of septic patients treated with extracorporeal hemoperfusion therapy and conventional therapy according to the Surviving Sepsis Campaign guidelines Gb2 group treated with conventional therapy according to the Surviving Sepsis Campaign guidelines
11316586|NCT02589535||no septic|Ga: postoperative patients in emergency surgical ward (ES)
11316587|NCT02589535||healthy|Healthy people
11316588|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
11316589|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
11316590|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
11316591|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
11316592|NCT02589496|Experimental|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
11316593|NCT02589483|Experimental|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
11316594|NCT02589470|Experimental|COMETE|patients will attend a specific rehabilitation programme of memory
11316595|NCT02589470|No Intervention|CONTROL|the control group where patients will benefit from a standard treatment
11316596|NCT02589457|Active Comparator|Viread® tablet|Tenofovir Disoproxil Fumarate
11316597|NCT02589457|Experimental|CKD-390|Tenofovir Disoproxil Fumarate
11316598|NCT02589444|Experimental|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
11316599|NCT02589444|Sham Comparator|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
11316600|NCT02589444|Other|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations > 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
11316601|NCT02589431||Patients with severe sepsis|
11316602|NCT02589431||Controls|Healthy subjects
11316603|NCT02589418|Experimental|Healthy subjects|All subjects participate at 3 experimental conditions (Acupuncture, Sham-Acupuncture and No Acupuncture) at 3 different days in a randomized order.
11316604|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
11316605|NCT02589392|Experimental|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
11316606|NCT02589392|Active Comparator|Body wash|Cetaphil® Restoraderm® body wash (1/day)
11316607|NCT02589379||Pancreatic Resection|All consecutive patients undergoing pancreatic resection for benign or malignant disease and meet inclusion criteria.
11316608|NCT02589366|Experimental|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
11316609|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
11316610|NCT02589340|Experimental|Buspirone|Two week titration up to 10 mg tablet/3 times a day for 7 days
11316611|NCT02589340|Placebo Comparator|Placebo|Two week titration up to 3 tablets/3 times a day for 7 days
11316612|NCT02589327|Experimental|Exercise Intervention|Hight intensity resistance training group
11316613|NCT02589327|No Intervention|Control|No-exercise control group
11316614|NCT02589314||root planning|
11316615|NCT02589301|Experimental|Pegfilgrastim|Pegfilgrastim (Hematopoietic Growth Factor) injectable solution 6 mg / 0,6mL in a single subcutaneous application.
11316616|NCT02589301|Active Comparator|Neulastim (pegfilgrastim)|Neulastim injectable solution 6 mg / 0,6mL in a single subcutaneous application.
11316617|NCT02589288|Active Comparator|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
11316795|NCT02587936|Experimental|Collaborative model|Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator
11316618|NCT02589288|Experimental|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
11316619|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
11316620|NCT02589249|Placebo Comparator|Placebo|placebo
11316621|NCT02589249|Active Comparator|AyuFlex1|AyuFlex1 (500 mg/d)
11316622|NCT02589249|Active Comparator|AyuFlex2|AyuFlex2 (1000 mg/d)
11316623|NCT02589236|Placebo Comparator|Placebo|Placebo Capsule
11316624|NCT02589236|Experimental|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
11316625|NCT02589236|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
11316626|NCT02589223|Active Comparator|Multisensory Stimulation Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
11316627|NCT02589223|Placebo Comparator|Control Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
11316628|NCT02589210|Experimental|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
11316629|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
11316630|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
11316631|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
11316632|NCT02589184|Experimental|hypergravity WITH isometric load|Patient performing rehabilitation exercises under hypergravity as well as loaded isometric squats
11316633|NCT02589184|Experimental|hypergravity WITHOUT isometric load|Patient performing rehabilitation exercises under hypergravity
11316634|NCT02589184|Experimental|normal gravity WITH isometric load|Patient performing rehabilitation exercises under normal gravity as well as loaded isometric squats
11316635|NCT02589184|Active Comparator|normal gravity WITHOUT isometric load|Patient performing rehabilitation exercises under normal gravity
11316636|NCT02589171|Experimental|Neo Close Abdominal Closure|
11316637|NCT02589171|Active Comparator|Carter Thomason Device|
11316638|NCT02589158|Experimental|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
11316639|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.
~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.
~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
~Melphalan administered at 60 mg/m2 on days -3 and -2.
~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.
~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.
~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
11316640|NCT02589132|No Intervention|Standard of Care|Families receiving Standard of Care
11316641|NCT02589132|Experimental|Mobile-Thrive application|Standard care plus Mobile-Thrive app
11316642|NCT02589119|Other|MSC-AFP|Single Treatment Group
11316643|NCT02589106|Experimental|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
11316644|NCT02589093|Experimental|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
11316645|NCT02589080|Experimental|Non-invasive sensory feedback|
11316646|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
11316647|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
11316648|NCT02589054||Patients|
11316649|NCT02589041|Experimental|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
11316650|NCT02589028|Experimental|premeal protein bar first|"intervention: premeal protein-enriched bar intake
~protein enriched bar(total serving: 30g, 43.28% carbohydrate; 1.29% fat; 40.39% protein; 42.63% fiber) will be given 30 minutes before breakfast
~protein enriched bar is provided with 150 ml of water
~amount of protein bar : 30g
~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
11316796|NCT02587936|No Intervention|Standard Care|Group to receive regular care
11317012|NCT02586571||Partial Breastfeeding|Mother/infant pairs with partial breastfeeding along with complementary foods at 6 months of age.
11316651|NCT02589028|Other|breakfast first|"intervention: breakfast follows by protein bar
~protein enriched bar is provided with 150 ml of water shortly after breakfast
~amount of protein bar : 30g
~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
11316652|NCT02589002|Experimental|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
11316653|NCT02589002|No Intervention|Control|Absence of sucralose ingestion
11316654|NCT02588989||transposition of the great arteries|Patients with a TGA
11316655|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
11316656|NCT02588963|Experimental|Experimental Group 1|Children whose caregivers were subjected to a health education session
11316657|NCT02588963|Experimental|Experimental Group 2|Children who were subjected to nasal clearance protocol
11316658|NCT02588963|Experimental|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
11316659|NCT02588963|Placebo Comparator|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
11316660|NCT02588950|Experimental|Part A: U-500R Single Injection|Bolus of U-500R administered via single subcutaneous (SC) injection in one of the two periods
11316661|NCT02588950|Experimental|Part A: U-500R CSII|Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII) in one of the two periods
11316662|NCT02588950|Experimental|Part B: U-500R TID|U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
11316663|NCT02588950|Experimental|Part B: U-500R BID|U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
11316664|NCT02588937|Experimental|EntecaBell ODT.|
11316665|NCT02588937|Active Comparator|Baraclude Tab.|
11316666|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
11316667|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
11316668|NCT02588911|Active Comparator|Conventional Surgery|Limb with GSV insufficiency in the same patient, randomised to conventional surgery
11316669|NCT02588911|Active Comparator|Radiofrequency Ablation|Limb with GSV insufficiency in the same patient, randomised to radiofrequency ablation
11316670|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
11316671|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
11316672|NCT02588885|Experimental|Trauma-sensitive Care|Participants will attend 7, one-hour psychotherapy sessions, which will be concurrent with trauma-sensitive care at physical therapy appointments.
11316673|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
11316674|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
11316675|NCT02588846|Experimental|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
11316676|NCT02588846|Experimental|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
11316677|NCT02588833|Experimental|Cohort 1|180 mg APL-2/day
11316678|NCT02588833|Experimental|Cohort 2|270 mg APL-2/day
11316679|NCT02588820|Experimental|Antiretroviral treatment|
11316680|NCT02588807|Experimental|Spirit1|Patients will take a daily nutritional supplement for 8 months
11316681|NCT02588794|Active Comparator|intervention|Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
11316682|NCT02588794|No Intervention|control|Standart CVVHD
11316683|NCT02588781|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
11316684|NCT02588768|Active Comparator|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
11316685|NCT02588768|Placebo Comparator|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
11316686|NCT02588755|Active Comparator|TACE+ Tegafur|Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
11316687|NCT02588755|Experimental|TACE|Patients will be treated with TACE alone in 4 or 8 weeks after resection.
11316688|NCT02588742|Experimental|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
11316689|NCT02588742|Placebo Comparator|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
11367218|NCT02253472|Experimental|Deep Brain Stimulation|Stimulation is on.
11316690|NCT02588729|Experimental|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women's smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
11316691|NCT02588729|No Intervention|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
11316692|NCT02588716|Active Comparator|Terlipressin|Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
11316693|NCT02588716|Placebo Comparator|Control|same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
11316694|NCT02588703|Experimental|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
11316695|NCT02588703|Active Comparator|Usual Care|9-session 2-hour group counseling
11316696|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
11316697|NCT02588677|Experimental|Masitinib (3.0) & Riluzole|masitinib 3 mg/kg/day + riluzole
11316698|NCT02588677|Experimental|Masitinib (4.5) & Riluzole|masitinib 4.5 mg/kg/day (2) + riluzole
11316699|NCT02588677|Placebo Comparator|Placebo & Riluzole|Matched placebo
11316700|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
11316701|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
11316702|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
11316703|NCT02588638||Adult patients|Unclear movement disorder, unclear cognitive decline
11316704|NCT02588638||Patients < 18 years|Patients with (penetrating) suspected cerebral neurogenetic diseases
11316705|NCT02588625|Experimental|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
11316706|NCT02588625|Experimental|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
11316707|NCT02588612|Experimental|Autologous Genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|After Screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will be administered a single dose of NY-ESO-1ᶜ²⁵⁹T cell infusion. Subjects who have a confirmed response (or have stable disease for >4 months) but subsequent disease progression following the initial infusion and whose tumor continues to express the appropriate antigen target may be eligible for a second infusion.
11316708|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
11316709|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
11316710|NCT02588573|Active Comparator|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
11316711|NCT02588573|Active Comparator|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
11316712|NCT02588560||HCV lymphoma patients with chemotherapy|Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
11316713|NCT02588547|Active Comparator|Granisetron 1|Intravenous granisetron 1 mg
11316714|NCT02588547|Active Comparator|Granisetron 0.7|Intravenous granisetron 0.7 mg
11316715|NCT02588547|Placebo Comparator|Placebo|intravenous 0.9% Sodium chloride (2 ml)
11316716|NCT02588534|Active Comparator|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
11316717|NCT02588534|Other|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
11316718|NCT02588521|Experimental|AL-794|AL-794 administered orally in a suspension
11316719|NCT02588521|Placebo Comparator|Vehicle|Suspension vehicle alone
11316720|NCT02588508|Experimental|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
11316721|NCT02588508|Experimental|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
11316722|NCT02588508|No Intervention|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
11316723|NCT02588495|No Intervention|Fasting|Participant will remain fasted following initial gastric ultrasound
11316724|NCT02588495|Experimental|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
11316725|NCT02588482|Experimental|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
11316726|NCT02588469|Experimental|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
11316727|NCT02588469|Active Comparator|control group|Physical activity program without compression socks during 3 months.
11316728|NCT02588456|Experimental|Single Arm|
11316832|NCT02587663|Experimental|Group 2 (bilateral whole-breast ultrasound)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
11317013|NCT02586558|Active Comparator|Experimental Infant Formula|Milk-based infant formula with prebiotics
11316729|NCT02588443|Experimental|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
11316730|NCT02588443|Experimental|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
11316731|NCT02588417|Active Comparator|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
11316732|NCT02588417|Active Comparator|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
11316733|NCT02588391|Experimental|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
11316734|NCT02588391|Experimental|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
11316735|NCT02588391|Other|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
11316736|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
11316737|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
11316738|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
11316739|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
11316740|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
11316741|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
11316742|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
11316743|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
11316744|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
11316745|NCT02588365|Experimental|Brain Training (Active)|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
11316746|NCT02588365|Experimental|Brain Training (Passive)|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent level."
11316747|NCT02588365|Experimental|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
11316748|NCT02588352|Experimental|Healthy volunteers|Open label administration of salt tablets for one week
11316749|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
11316750|NCT02588326|Active Comparator|MFF 1, then MFF 2|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
11316751|NCT02588326|Active Comparator|MFF 2, then MFF 1|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray. After a wash out period then Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray. All formulations will be a 200 mcg single dose.
11316752|NCT02588313|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
11316753|NCT02588313|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
11316754|NCT02588313|Placebo Comparator|Placebo formulation|Placebo formulation
11316755|NCT02588300|Experimental|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
11316756|NCT02588287|Experimental|Tenofovir PK before and after SOF/LDV|
11316757|NCT02588274|Experimental|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm*40mm/0.3mm*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
11316758|NCT02588274|Placebo Comparator|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
11316759|NCT02588261|Experimental|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
11316830|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH & Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
11316760|NCT02588261|Active Comparator|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
11316761|NCT02588248|Experimental|Peppermint Oil|"Solution A) Peppermint oil solution (1.6% peppermint oil, which is 0.8% L-menthol)
~Ingredients:
~16mL of peppermint oil (provided by the NowFoods® company)
~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution
~1L prepackage sterile water
~2.6mL of undyed simethicone"
11316762|NCT02588248|Placebo Comparator|Placebo|"Solution B) Placebo solution
~Ingredients:
~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution
~1L prepackage sterile water
~2.6mL of undyed simethicone
~Instructions to prepare:
~Add tween and simethicone to sterile water. Then, shake vigorously.
~Once solution has settled, and patient has been randomized, draw 20mL of solution into a plastic syringe"
11316763|NCT02588235|Experimental|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
11316764|NCT02588235|Active Comparator|Atorvastatin Therapy|Atorvastatin (20 mg/day）
11316765|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
11316766|NCT02588209|Experimental|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
11316767|NCT02588209|Active Comparator|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
11316768|NCT02588196|Experimental|treatment of dexamethasone group|
11316769|NCT02588183|Experimental|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
11316770|NCT02588170|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
11316771|NCT02588170|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
11316772|NCT02588157|Active Comparator|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
11316773|NCT02588157|Active Comparator|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
11316774|NCT02588144|Active Comparator|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
11316775|NCT02588144|Experimental|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
11316776|NCT02588131|Experimental|tremelimumab plus MEDI4736|Tremelimumab in combination with MEDI4736
11316777|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
11316778|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
11316779|NCT02588105|Experimental|Safety and Tolerability|All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability
11316780|NCT02588092|Experimental|Part 1: ADCT-301 (dose escalation)|"Weekly administration - Participants will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.
~3-week administration - Participants will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.
~The dose escalation will be conducted according to a 3+3 design."
11316781|NCT02588092|Experimental|Part 2: ADCT-301 (dose expansion)|Participants will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee.
11316782|NCT02588079|Experimental|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
11316783|NCT02588079|No Intervention|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
11316784|NCT02588066|Experimental|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
11316785|NCT02588066|No Intervention|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
11316786|NCT02588027|Active Comparator|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
11316787|NCT02588027|Placebo Comparator|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
11316788|NCT02588014||Schizophrenia|Individuals with schizophrenia
11316789|NCT02588014||Control|Neurotypical individuals
11316790|NCT02588001|Experimental|Enzalutamide Group|
11316791|NCT02587988|Experimental|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
11316792|NCT02587988|Active Comparator|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
11316793|NCT02587975|Experimental|Evogliptin 10 mg|Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL
11316797|NCT02587910|Placebo Comparator|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
11316798|NCT02587910|Placebo Comparator|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
11316799|NCT02587897||Dental Hygiene Students|Students enrolled in the 2-year dental hygiene academic coursework programs at the University of Southern California and Loma Linda University who are exposed to high-intensity work-related hand activities as part of their training program.
11316800|NCT02587897||Occupational Therapy Students|Students enrolled in the 2-year occupational therapy academic coursework program at the University of Southern California.
11316801|NCT02587884|Active Comparator|Group TACE|Patients will treated with TACE after resection.
11316802|NCT02587884|No Intervention|Group Control|Patients will treated without TACE after resection.
11316803|NCT02587871|Experimental|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
11316804|NCT02587858||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI, other clinical findings, and PANK2 gene sequencing.
11316805|NCT02587858||PLAN|This group consists of individuals diagnosed with PLAN using a combination of MRI, other clinical findings and PLA2G6 gene sequencing.
11316806|NCT02587858||BPAN|This group consists of individuals diagnosed with BPAN using a combinatino of MRI, other clinical findings, and WDR45 gene sequencing.
11316807|NCT02587845|Active Comparator|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
11316808|NCT02587845|Experimental|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
11316809|NCT02587832|Active Comparator|HHHFNC|Randomized to HHHFNC
11316810|NCT02587832|Active Comparator|NCPAP|Randomized to NCPAP
11316811|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
11316812|NCT02587806|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
11316813|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
11316814|NCT02587780||Inactive|people who perform < 30mins.day physical activity at a 'moderate' level of intensity.
11316815|NCT02587780||Active|people who perform 30mins-60 mins.day of physical activity at a 'moderate' level of intensity.
11316816|NCT02587780||Very active|People who perform > 60 mins.day of physical activity at a >moderate level of intensity.
11316817|NCT02587767|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
11316818|NCT02587767|Active Comparator|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
11316819|NCT02587754|Active Comparator|Verum acupuncture|10 sessions of verum acupuncture
11316820|NCT02587754|Placebo Comparator|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
11316821|NCT02587741|Experimental|oral drugs|oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid
11316822|NCT02587741|Experimental|lantus|basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.
11316823|NCT02587741|Experimental|Novomix30|premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .
11316824|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
11316825|NCT02587715|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
11316826|NCT02587702|Experimental|Improved Infant Formula Group|Containing β-Palmitate Content
11316827|NCT02587702|Placebo Comparator|General Infant Formula Group|Excluding β-Palmitate Content
11316828|NCT02587702|Active Comparator|Human Milk Group|Containing β-Palmitate Content Naturely in Human Milk
11316829|NCT02587689|Experimental|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
11316831|NCT02587663|Active Comparator|Group 1 (standard of care)|Patients undergo standard of care diagnostic imaging comprising bilateral mammography and targeted breast ultrasound.
11317014|NCT02586558|Placebo Comparator|Reference group|Milk-based infant formula without prebiotics
11316833|NCT02587663|Experimental|Group 3 (bilateral breast contrast-enhanced MRI)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral breast contrast-enhanced MRI.
11316834|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11316835|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11316836|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11316837|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
11316838|NCT02587624||RMN AF ablation|Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.
11316839|NCT02587611|Experimental|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.
~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
11316840|NCT02587611|Active Comparator|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.
~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
11316841|NCT02587598|Experimental|INCB053914|Monotherapy
11316842|NCT02587598|Experimental|INCB053914 + Azacitidine|
11316843|NCT02587598|Experimental|INCB053914 + I-DAC|
11316844|NCT02587598|Experimental|INCB053914 + Ruxolitinib|
11316845|NCT02587585|Experimental|Feedback against tailored target|For each two hour epoch, the watch calculate the level of activity for the same epoch the day before, and adds 5% as the new target to be achieved.
11316846|NCT02587585|Sham Comparator|No Feedback|For participants assigned to the control group, the smart watch will not provide any activity feedback against a target; it simply shows which two hour epoch a person is in.
11316847|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
11316848|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
11316849|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
11316850|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
11316851|NCT02587559|No Intervention|Control|usual medical advice regarding symptomatic control and activity modification
11316852|NCT02587559|Experimental|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
11316853|NCT02587546|Experimental|laryngeal carcinoma|patients with T1-T2 (some T3) laryngeal carcinoma will undergo treatment using thulium contact laser surgery - tumour resection
11316854|NCT02587546|Experimental|bilateral vocal cord paralysis|patients with bilateral vocal cord paralysis treated with partial arytenoidectomy will be treated using thulium laser surgery and laterofixation
11316855|NCT02587546|Experimental|subglottic stenosis|patients with subglottic stenosis treated endoscopically (incisions and dilatation) will be treated with thulium laser surgery
11316856|NCT02587533|Active Comparator|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
11316857|NCT02587533|Active Comparator|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
11316858|NCT02587533|Active Comparator|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
11316859|NCT02587533|Active Comparator|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
11316860|NCT02587520|Experimental|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
11316861|NCT02587520|Experimental|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
11316862|NCT02587520|Experimental|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
11316863|NCT02587520|Experimental|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
11316864|NCT02587520|Active Comparator|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
11316865|NCT02587520|Active Comparator|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
11316866|NCT02587520|Experimental|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
11316867|NCT02587520|Experimental|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
11316868|NCT02587520|Experimental|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
11316869|NCT02587520|Experimental|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
11316870|NCT02587520|Active Comparator|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
11316871|NCT02587520|Active Comparator|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
11317078|NCT02586129|Active Comparator|Rosuvastatin|PO, Once Daily, 16 weeks
11316872|NCT02587520|Experimental|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (>=65) years received a single dose of the SP0173 Tdap vaccine.
11316873|NCT02587520|Experimental|Older Adults: SP0173 Formulation 2|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
11316874|NCT02587520|Experimental|Older Adults: SP0173 Formulation 3|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
11316875|NCT02587520|Experimental|Older Adults: SP0173 Formulation 4|Healthy participants aged >= 65 years received a single dose of the SP0173 Tdap vaccine.
11316876|NCT02587520|Active Comparator|Older Adults: Adacel®|Healthy participants aged >=65 years received Adacel®.
11316877|NCT02587520|Active Comparator|Older Adults: Boostrix®|Healthy participants aged >=65 years received Boostrix®.
11316878|NCT02587507|Placebo Comparator|Water|The subjects will ingest the HFHC meal with 500mL of water.
11316879|NCT02587507|Experimental|Orange juice|The subjects will ingest the HFHC meal with 500mL of orange juice.
11316880|NCT02587507|Active Comparator|Water with glucose|The subjects will ingest the HFHC meal with 500mL of water with glucose (isocaloric control of the orange juice).
11316881|NCT02587494|Active Comparator|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
11316882|NCT02587494|No Intervention|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for >24h post ROSC.
11316883|NCT02587468|Experimental|Juice Plus+(R)|Check of phenolic absorption between baseline and after 8wks of intake before-after comparison
11316884|NCT02587455|Experimental|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
11316885|NCT02587455|Experimental|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
11316886|NCT02587442|Experimental|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
11316887|NCT02587429|Experimental|Patienteducation|(Patients with PCS>22). An education in pain coping delivered by physiotherapists. The education consist of seven sessions over a four months period. Each session is individual and will last 30 minutes. Focus will be on pain behaviour and pain coping based on Cognitive Behavioral Therapy.
11316888|NCT02587429|No Intervention|Control group 1|(Patients with PCS>22). Patients randomly assigned to this arm will undergo usual treatment for total knee arthroplasty.
11316889|NCT02587429|No Intervention|Control group 2|(Patients with PCS<12). Patients in this arm will undergo usual treatment for total knee arthroplasty. Patients in this arm are not randomized but matched by age, gender and BMI with patients in control group 1.
11316890|NCT02587416|Experimental|Gemcabene 300 mg|Gemcabene 300 mg
11316891|NCT02587416|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
11316892|NCT02587416|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg
11316893|NCT02587403|Active Comparator|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
11316894|NCT02587403|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
11316895|NCT02587390|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
11316896|NCT02587390|Active Comparator|Simvastatin 80 mg|Simvastatin 80 mg
11316897|NCT02587377|Other|Cohort 1|single cohort of patient
11316898|NCT02587364|Experimental|Gemcabene 50 mg|Gemcabene 50 mg
11316899|NCT02587364|Experimental|Gemcabene 150 mg|Gemcabene 150 mg
11316900|NCT02587364|Experimental|Gemcabene 450 mg|Gemcabene 450 mg
11316901|NCT02587364|Experimental|Gemcabene 750/600 mg|Gemcabene 750/600 mg
11316902|NCT02587364|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
11316903|NCT02587364|Placebo Comparator|Placebo|Placebo
11316904|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
11316905|NCT02587351|Placebo Comparator|Placebo|Matched placebo
11316906|NCT02587338|Experimental|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
11316907|NCT02587338|Experimental|Sham tDCS|sham stimulation, same electrode positions
11316908|NCT02587325|Experimental|ABI-009|
11316909|NCT02587312|Active Comparator|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
11316910|NCT02587312|Experimental|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
11316911|NCT02587286|Experimental|Gather app|Use of the Gather mHealth diabetes management system
11316912|NCT02587286|No Intervention|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
11316913|NCT02587273|Other|Fentanyl|This is a pharmacokinetics study with a single arm. All participants will will undergo the intervention described under the intervention section
11316914|NCT02587260|Active Comparator|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
11316915|NCT02587260|Active Comparator|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
11316916|NCT02587260|Active Comparator|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
11316917|NCT02587260|Active Comparator|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
11316918|NCT02587260|Active Comparator|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
11316919|NCT02587260|Active Comparator|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
11317079|NCT02586116|Active Comparator|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
11316920|NCT02587234|Experimental|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
11316921|NCT02587234|Sham Comparator|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
11316922|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
11316923|NCT02587221|Placebo Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
11316924|NCT02587208|Active Comparator|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
11316925|NCT02587208|Active Comparator|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
11316926|NCT02587195|Experimental|Teriflunomide|Teriflunomide 14 mg Once Daily
11316927|NCT02587182|Experimental|Dry needling|Dry needling in the masseter and temporalis muscles
11316928|NCT02587169|Experimental|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
11316929|NCT02587156|Experimental|Meal serving at high dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount above 1.5 g protein/kg/day
11316930|NCT02587156|Active Comparator|Meal serving at low dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount below 0.8 g protein/kg/day
11316931|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
11316932|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
11316933|NCT02587130|Experimental|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
11316934|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
11316935|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
11316936|NCT02587104|Experimental|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
11316937|NCT02587091|No Intervention|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
11316938|NCT02587091|Experimental|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
11316939|NCT02587078|Active Comparator|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
11316940|NCT02587078|Active Comparator|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
11316941|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
11316942|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
11316943|NCT02587052||Prograf|100 patients treated with Prograf
11316944|NCT02587039|Placebo Comparator|Control: Usual care|This group will receive usual care and delirium assessments.
11316945|NCT02587039|Experimental|Treatment: Ischemic Pre-conditioning|Remote Ischemic pre-conditioning before cardiac surgery and delirium assessments.
11316946|NCT02587013|Experimental|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
11316947|NCT02587013|Active Comparator|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
11316948|NCT02587000|Active Comparator|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
11316949|NCT02587000|Placebo Comparator|Placebo|2 tablets of 5mg per day during 3 months, per os
11316950|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).
~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
11316951|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
11316952|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.
~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
11316953|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
11367219|NCT02253472|Sham Comparator|Placebo|Stimulation is off.
11316954|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
11316955|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
11316956|NCT02586961|Placebo Comparator|0.9% saline solution - oral betamethasone placebo|Control arm: 0.9% saline solution - oral betamethasone placebo
11316957|NCT02586961|Experimental|adrenaline - oral betamethasone|Experimental arm : adrenaline and betamethasone
11316958|NCT02586948|Experimental|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
11316959|NCT02586935|Active Comparator|Tideglusib|
11316960|NCT02586935|Placebo Comparator|Placebo|
11316961|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
11316962|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
11316963|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
11316964|NCT02586883|Experimental|Patients with multiple bronchi dilations|
11316965|NCT02586883|Active Comparator|Control patients without transport abnormality|
11316966|NCT02586883|Active Comparator|Patients with typical cystic fibrosis|
11316967|NCT02586857|Experimental|Cohort 1|ACP-196 200mg administered PO BID
11316968|NCT02586857|Experimental|Cohort 2|ACP-196 400mg administered PO QD
11316969|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
11316970|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
11316971|NCT02586831|Active Comparator|Arm A|"The treatment arm A includes commercially available drugs approved for other indications:
~Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg (day 0 and 1).
~Pegylated GCSF (Neulasta®) will be administered at a dose of 6mg SC every two weeks for a total of 6 doses (Day 2, 14, 28, 42, 56, and 70).
~Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®), 1 million IU/dose will be given SC for 5 consecutive days (days 10-14), and then every two weeks.
~Etanercept (Enbrel®) will be administered at a dose of 25 mg SC weekly up to 52 weeks.
~Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks; Adjust according to symptoms."
11316972|NCT02586831|Placebo Comparator|Arm B|The subjects randomized in Arm B (control group) will receive respective placebos in a blinded fashion.
11316973|NCT02586818||Normal|SOC fingerstick and venous blood draw for subject not on anticoagulation medications.
11316974|NCT02586818||Therapeutic|SOC fingerstick and venous blood draw for subjects who are indicated for and have been on anticoagulation medications for greater than or equal to 3 months. Results from this study will be used solely for research purposes and will not be used for anticoagulation management of study subjects. No patient follow up is required.
11316975|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
11316976|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
11316977|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
11316978|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
11316979|NCT02586792|Experimental|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
11316980|NCT02586792|Experimental|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
11316981|NCT02586779|Experimental|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
11316982|NCT02586779|Other|control group|consultations in the control group will be generated without whatsApp.
11316983|NCT02586766|Experimental|Behavioral: Project Sync|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care
11316984|NCT02586766|No Intervention|Comparison Group|This group did not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
11316985|NCT02586753|Experimental|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
11316986|NCT02586753|Experimental|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
11316987|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
11316988|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
11317010|NCT02586571||Exclusive Breastfeeding A|Mother/infant pairs with exclusive breastfeeding up to 6 months of age. Secondary outcome measure 2 (Metabolisable energy content of breast milk) measured in this group only.
11367279|NCT02253082|Active Comparator|OctaplasLG®|replacement to bleeding
11316989|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
11316990|NCT02586714||Normal weight|
11316991|NCT02586714||Overweight|
11316992|NCT02586714||Obese|
11316993|NCT02586701|Active Comparator|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
11316994|NCT02586701|No Intervention|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
11316995|NCT02586688|Active Comparator|Phase I TMS Active|Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
11316996|NCT02586688|Sham Comparator|Phase I TMS Sham|Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
11316997|NCT02586688|Other|Phase II Open Label Active TMS|Open label active TMS coil. Open label active NeuroStar® TMS.
11316998|NCT02586688|Other|Phase III Long-Term Follow up TMS Active|Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
11316999|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
11317000|NCT02586649|Experimental|Tiotropium Bromide group|The study participants will be randomly assigned to receive Tiotropium bromide,single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Tiotropium bromide capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
11317001|NCT02586649|Placebo Comparator|Placebo|The study participants will be randomly assigned to receive placebo , single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Placebo capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
11317002|NCT02586636|Other|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
11317003|NCT02586636|Other|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
11317004|NCT02586623|Experimental|Open Label Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally. During the Open Label Titration Period, patients will first receive 100 mg TID and their dose will be raised (in 100 mg increments) at subsequent visits until optimal dose is determined. During the Open Label Treatment Period, patients will receive active droxidopa100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to the patient's individual dose at the end of the Open-Label Titration Period).
11317005|NCT02586623|Placebo Comparator|Randomized Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period) or matching placebo.
11317006|NCT02586610|Experimental|Neoadjuvant Treatment|"All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:
~Pembrolizumab 200 mg IV Days 1, 22 and 43
~Capecitabine 825 mg/m2 PO in twice daily doses (total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
~Radiation therapy 50.4 GY. Daily fractions of 1.8 Gy over a 6 week interval, excludes weekends"
11317007|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
11317008|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
11317009|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
11317011|NCT02586571||Exclusive Breastfeeding B|Mother/infant pairs with exclusive breastfeeding up to 6 months of age.
11317015|NCT02586545|Experimental|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
11317016|NCT02586545|No Intervention|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
11317017|NCT02586532||1|Residents of towns participating in China Demonstration Project.
11317018|NCT02586519|Experimental|Active SurroSense Rx System + RCW|Patients randomized to the experimental group will be fitted with an active (alerting) version of the SurroSense R® smart insole System. This device will be placed in the RCW, underneath the liner. The device tab will be fed up the instep, through a hole in the liner, and affixed to the dorsum of the RCW by way of a tie.
11317019|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + RCW|Patients randomized to this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion.
11317020|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + iTCC|Patients in this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion. The RCW will be further secured using a device specific tie such that it acts as an iTCC.
11317021|NCT02586506|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
11317022|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
11317023|NCT02586467|Experimental|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
11317024|NCT02586467|Experimental|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
11317025|NCT02586467|Experimental|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
11317026|NCT02586467|Experimental|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
11317027|NCT02586467|Experimental|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
11317028|NCT02586454|Experimental|Transmuscular quadratus lumborum (QL) block|Bilateral QL block using 20 ml 0.375% ropivacaine in each side (to a maximum dose 3 mg/kg) plus patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
11317029|NCT02586454|Active Comparator|Control|Patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
11317030|NCT02586441|Experimental|Electroencephalography|"Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.
~Raw EEG in a steady state was collected for 5 minutes.
~Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)
~Mechanical ventilation was initiated
~Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).
~On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.
~After extubation, BIS-VISTA TM monitoring was stopped."
11317031|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.
~Devices approved for use in DEFUSE 3:
~Trevo Retriever
~Solitaire™ FR Revascularization Device
~Penumbra thrombectomy system
~Covidien MindFrame Capture Revascularization Device"
11317032|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
11317033|NCT02586402|Experimental|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
11317034|NCT02586402|Active Comparator|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
11317035|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
11317036|NCT02586376|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
11317037|NCT02586376|Experimental|4J LLLT|The Laser radiation will be made with 4J by spot.
11317038|NCT02586376|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
11317039|NCT02586376|Experimental|8J LLLT|The Laser radiation will be made with 8J by spot.
11317040|NCT02586363|Active Comparator|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
11317041|NCT02586363|Experimental|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
11317042|NCT02586363|Experimental|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
11317080|NCT02586116|Active Comparator|C-Plus|C-Plus PEEK IBF Device with autograft
11317081|NCT02586103||MRI|Patients who undergo simulated practice MRI on the day of or prior to their scheduled MRI.
11317111|NCT02585921|Experimental|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
11317194|NCT02585440|Experimental|Group D|CMX157, tablet, 50 mg, QD, 14 days versus CMX157, placebo tablet, 50 mg, QD, 14 days
11317043|NCT02586350|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
11317044|NCT02586350|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
11317045|NCT02586337|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
11317046|NCT02586337|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
11317047|NCT02586324|Other|global medium|
11317048|NCT02586324|Experimental|SSM|
11317049|NCT02586311|Experimental|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
11317050|NCT02586311|Active Comparator|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
11317051|NCT02586298|Experimental|ICSI with mitochondria|Half of the Metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and autologous mitochondria from the patient's ovarian cortex will be introduced into the oocyte during the intracytoplasmic sperm injection in the vitro fertilization treatment.
11317052|NCT02586298|Active Comparator|Control ICSI without mitochondria|The other half of the metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and will not receive autologous mitochondria during the intracytoplasmic sperm injection (ICSI) in the vitro fertilization treatment. Control Group
11317053|NCT02586285|Active Comparator|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
11317054|NCT02586285|No Intervention|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
11317055|NCT02586272|Experimental|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
11317056|NCT02586272|Other|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
11317057|NCT02586259||Cortiment®|Treatment according to routine clinical practice.
11317058|NCT02586246|Experimental|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
11317059|NCT02586246|Experimental|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
11317060|NCT02586233|Experimental|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
11317061|NCT02586233|Placebo Comparator|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
11317062|NCT02586220||normal pregnant women|150 normal pregnant women (28-32 weeks' gestation)
11317063|NCT02586220||pregnant women with gestational|100 pregnant women with gestational diabetes (28-32 weeks' gestation)
11317064|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
11317065|NCT02586194|Experimental|Control (Subjects with normal hepatic function)|Oral
11317066|NCT02586194|Experimental|Mild hepatic impairment|Oral
11317067|NCT02586194|Experimental|Moderate hepatic impairment|Oral
11317068|NCT02586181|Placebo Comparator|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate"
11317069|NCT02586181|Experimental|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
11317070|NCT02586168|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
11317071|NCT02586168|Placebo Comparator|Placebo|Placebo
11317072|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
11317073|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
11317074|NCT02586142|Experimental|Botulinum toxin type A(BTX-A) injection|To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.
11317075|NCT02586142|Active Comparator|BTX-A injection plus stretching exercise|Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.
11317076|NCT02586129|Experimental|YH14755|PO, Once Daily, 16 weeks
11317077|NCT02586129|Active Comparator|Metformin|PO, Once Daily, 16 weeks
11317082|NCT02586090|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
11317083|NCT02586090|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
11317084|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
11317085|NCT02586064|Experimental|IPT-PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
11317086|NCT02586064|Active Comparator|PE|Exposure based intervention including exposure to memories and avoided places and activities
11317087|NCT02586051|Experimental|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.
~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
11317088|NCT02586051|Experimental|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.
~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
11317089|NCT02586038|Experimental|MLN-DEX-CYCLO arm|"Patients will receive nine 28-days induction cycles.
~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Cyclophosphamide: 300 mg/sqm orally on days 1, 8, 15"
11317090|NCT02586038|Experimental|MLN-DEX-THAL arm|"Patients will receive nine 28-days induction cycles.
~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Thalidomide: 100 mg/day orally"
11317091|NCT02586025|Experimental|Trastuzumab, Pertuzumab, Docetaxel|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
11317092|NCT02586025|Experimental|Trastuzumab, Placebo, Docetaxel|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
11317093|NCT02586012|Experimental|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
11317094|NCT02586012|Experimental|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
11317095|NCT02586012|Experimental|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
11317096|NCT02586012|Experimental|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
11317097|NCT02586012|Experimental|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
11317098|NCT02586012|Experimental|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
11317099|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
11317100|NCT02585986|Active Comparator|Probiotic|daily intake of 1 capsule containing probiotic.
11317101|NCT02585986|Placebo Comparator|Placebo|daily intake of 1 capsule containing placebo
11317102|NCT02585973|Other|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
11317103|NCT02585960|Experimental|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
11317104|NCT02585960|Experimental|FVIII trough target 1-3%|Standard treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 1-3%
11317105|NCT02585960|Experimental|FVIII trough target 8-12%|Intensified treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 8-12%
11317106|NCT02585947|Experimental|tenofovir for 24 weeks|"prophylactic (preemptive) treatment
~300mg for 24 weeks
~once daily"
11317107|NCT02585947|Experimental|tenofovir for 48 weeks|"prophylactic (preemptive) treatment
~300mg for 48 weeks
~once daily"
11317108|NCT02585934|Experimental|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
11317109|NCT02585934|Placebo Comparator|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
11317110|NCT02585921|No Intervention|Health & Wellness|Following enrollment, participants will learn about health and wellness.
11368953|NCT02241915|Sham Comparator|Control|No microbial sealant
11317112|NCT02585921|Experimental|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
11317113|NCT02585921|Experimental|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
11317114|NCT02585908|No Intervention|Experimental Group A(control group)|regular treatment and follow up
11317115|NCT02585908|Experimental|Experimental Group B|CIK will be used against tumor cells.
11317116|NCT02585908|Experimental|Experimental Group C|γδ T will be used against tumor cells.
11317117|NCT02585908|Experimental|Experimental Group D|CIK and γδ T will be used against tumor cells.
11317118|NCT02585895|Experimental|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
11317119|NCT02585895|Active Comparator|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
11317120|NCT02585882|Experimental|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
11317121|NCT02585882|No Intervention|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
11317122|NCT02585869|Experimental|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
11317123|NCT02585869|Experimental|Gemcabene 300 mg|Gemcabene 300 mg once daily (QD)
11317124|NCT02585869|Experimental|Gemcabene 600 mg|Gemcabene 600 mg once daily (QD)
11317125|NCT02585869|Experimental|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
11317126|NCT02585869|Placebo Comparator|Placebo|Placebo once daily (QD)
11317127|NCT02585856|Experimental|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
11317128|NCT02585856|Placebo Comparator|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
11317129|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
11317130|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
11317131|NCT02585817|Experimental|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
11317132|NCT02585804|Experimental|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
11317133|NCT02585791|Experimental|vape NFEC containing 100% PG|Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
11317134|NCT02585791|Experimental|vape 100% vegetable glycerin -VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
11317135|NCT02585791|Experimental|vape PG+VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
11317136|NCT02585778|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
11317137|NCT02585778|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
11317138|NCT02585765|Experimental|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
11317139|NCT02585765|Placebo Comparator|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
11317140|NCT02585752|Experimental|Single centre, single arm|Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.
11317141|NCT02585739|Experimental|patient|patient with Cluster headache
11317142|NCT02585739|Other|healthy subject|patient without Cluster headache
11317143|NCT02585726|Active Comparator|Historical Control with Propensity Analysis|
11317144|NCT02585726|Experimental|VenaSeal Treatment Arm|
11317145|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
11317146|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
11317147|NCT02585700|Experimental|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:
~NYMC BX-51B reassortant of B/Massachusetts/2/2012
~X-181 reassortant of H1/A/California/7/2009
~X-223A reassortant of H3/A/Texas/50/2012."
11317148|NCT02585700|Placebo Comparator|Placebo|0.5 mL of phosphate buffered saline
11317149|NCT02585687|Experimental|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
11317193|NCT02585440|Experimental|Group C|CMX157, tablet, 25 mg, QD, 14 days versus placebo CMX157, placebo tablet, 25 mg, QD, 14 days
11317150|NCT02585674|Experimental|MyStar DoseCoach|MyStar DoseCoach - Device-supported treat-to-target regimen. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
11317151|NCT02585674|Active Comparator|Routine Titration|Routine Titration - Routine titration defined by the Investigator. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
11317152|NCT02585661|Active Comparator|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
11317153|NCT02585661|Experimental|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
11317154|NCT02585648|Experimental|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
11317155|NCT02585648|Experimental|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
11317156|NCT02585635||Families|Families of children with haemophilia
11317157|NCT02585635||Clinicians|Haemophilia physicians
11317158|NCT02585622|Experimental|Bone marrow-derived Mesenchymal Stromal Cells|
11317159|NCT02585622|Placebo Comparator|Cryostor CS10|
11317160|NCT02585596|Experimental|YH23537 1000mg/day|YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks
11317161|NCT02585596|Experimental|YH23537 2000mg/day|YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks
11317162|NCT02585596|Experimental|YH23537 3000mg/day|YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks
11317163|NCT02585596|Experimental|YH23537 3000mg/day loading 1000mg/day|YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks
11317164|NCT02585596|Placebo Comparator|Placebo|YH23537 500mg placebo 3tab twice a day
11317165|NCT02585583|Other|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
11317166|NCT02585570|Experimental|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
11317167|NCT02585570|Experimental|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
11317168|NCT02585570|No Intervention|Normal saline|normal saline for 5minutes
11317169|NCT02585557|Experimental|Cluster A|50 practices randomly assigned to start intervention at month 9. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
11317170|NCT02585557|Experimental|Cluster B|50 practices randomly assigned to start intervention at month 11. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
11317171|NCT02585557|Experimental|Cluster C|50 practices randomly assigned to start intervention at month 12. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
11317172|NCT02585557|Experimental|Cluster D|50 practices randomly assigned to start intervention at month 14. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
11317173|NCT02585557|Experimental|Cluster E|50 practices randomly assigned to start intervention at month 16. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
11317174|NCT02585544|Other|Genital prolapse|Single arm: i.e., all patients
11317175|NCT02585531|Experimental|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
11317176|NCT02585531|Active Comparator|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
11317177|NCT02585518||Obese|Children and adolescents with a BMI at or above the 85th percentile for age and sex
11317178|NCT02585518||Healthy control|Children and adolescents with a BMI below the 85th percentile for age and sex
11317179|NCT02585505|Active Comparator|Intravenous|stem cells will be injected through intravenously in the subjects
11317180|NCT02585505|Active Comparator|superior pancreaticoduodenal|stem cells
11317181|NCT02585505|Active Comparator|splenic artery|stem cells will be injected through splenic in the subjects
11317182|NCT02585492|Active Comparator|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
11317183|NCT02585492|Experimental|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
11317184|NCT02585479|Experimental|systemic chemotherapy|Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.
11317185|NCT02585479|Active Comparator|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.
11317186|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
11317187|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
11317188|NCT02585453|Experimental|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
11317189|NCT02585453|Active Comparator|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
11317190|NCT02585453|Active Comparator|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
11317191|NCT02585440|Experimental|Group A|CMX157, tablet, 5 mg, QD, 14 days versus CMX157 placebo, 5 mg, tablet, QD, 14 days
11317192|NCT02585440|Experimental|Group B|CMX157, tablet, 10 mg, QD, 14 days versus CMX157, placebo tablet, 10 mg, QD, 14 days
11317195|NCT02585440|Experimental|Group E|CMX157, tablet, 100 mg, QD, 14 days versus CMX157, placebo tablet, 100 mg, QD, 14 days
11317196|NCT02585427|Experimental|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
11317197|NCT02585427|Experimental|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
11317198|NCT02585427|Experimental|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
11317199|NCT02585427|Experimental|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
11317200|NCT02585427|Experimental|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
11317201|NCT02585427|Experimental|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
11317202|NCT02585414||85 healthy subjects with no history of DES|
11317203|NCT02585414||255 subjects with DES|
11317204|NCT02585401||Eylea product and application information / Cohort 1|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.
11317205|NCT02585388|Active Comparator|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
11317206|NCT02585388|Experimental|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
~And:
~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
11317207|NCT02585375|Experimental|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
11317208|NCT02585375|Active Comparator|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
11317209|NCT02585362|Active Comparator|Intervention group|Participants will receive physical exercise, nutrition counseling and a whey protein Supplement over 12 weeks
11317210|NCT02585362|No Intervention|Control group|Participants will receive standard care
11317211|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
11317212|NCT02585336|No Intervention|Observation|
11317213|NCT02585336|Experimental|Brief intervention|
11317214|NCT02585323|Active Comparator|Immediate Intervention Group|Education session, Fitbit/FitViz, PT counselling: Participants receive this intervention in Months 1-3. The session will include a presentation on physical activity, an individual goal-setting session with a registered physiotherapist, and an orientation to the Fitbit Flex and the FitViz app. In Months 1 and 2, participants will use the Fitbit/FitViz. The PT will review the progress with participants via 20-minute bi-weekly phone calls, and progressively modify their activities. In Month 3, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls. In Months 4-9, participants may continue using the Fitbit/FitViz without access to a PT.
11317215|NCT02585323|Placebo Comparator|Delayed Intervention Group|Same intervention with a 3 month delay: The full intervention will be initiated in Month 4 and with a brief education session, use of a Fitbit Flex paired with the FitViz app, and counseling by a physiotherapist. In Months 6-9, participants will continue using Fitbit/FitViz without the PT phone calls.
11317216|NCT02585297||Control- semen|Semen of fertile men
11317217|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
11317218|NCT02585297||Case-semen|Semen of infertile men
11317219|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
11317220|NCT02585284||vicenarian|20 to 29 years. Five males and five females
11317221|NCT02585284||tricenarian|30 to 39 years. Five males and five females
11317222|NCT02585284||quadragenarian|40 to 49 years. Five males and five females
11317223|NCT02585284||quinquagenarian|50 to 59 years. Five males and five females
11317224|NCT02585284||sexagenarian|60 to 69 years. Five males and five females
11317225|NCT02585284||septuagenarian|70 to 79 years. Five males and five females
11317226|NCT02585284||octogenarian|80 to 89 years. Five males and five females
11317227|NCT02585284||nonagenarian|90-99 years. Five males and five females
11317228|NCT02585271|Other|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
11317229|NCT02585271|Other|Stent|Patients undergo placement of the stent as a bridge to surgery
11317230|NCT02585258|Experimental|arm A|prednisolone 5 mg per day
11317231|NCT02585258|Placebo Comparator|arm B|placebo capsules once per day
11317232|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
11317233|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
11317234|NCT02585232|Active Comparator|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
11317297|NCT02584907|Experimental|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
11368954|NCT02241902||No pyuria|
11317235|NCT02585232|Experimental|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
11317236|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).
~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.
~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
11317237|NCT02585206|No Intervention|Arm 1|"All 4 factors off - standard text message program
~Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity OFF"
11317238|NCT02585206|Active Comparator|Arm 2|Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity ON
11317239|NCT02585206|Active Comparator|Arm 3|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity OFF
11317240|NCT02585206|Active Comparator|Arm 4|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity ON
11317241|NCT02585206|Active Comparator|Arm 5|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity OFF
11317242|NCT02585206|Active Comparator|Arm 6|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity ON
11317243|NCT02585206|Active Comparator|Arm 7|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity OFF
11317244|NCT02585206|Active Comparator|Arm 8|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity ON
11317245|NCT02585206|Active Comparator|Arm 9|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity OFF
11317246|NCT02585206|Active Comparator|Arm 10|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity ON
11317247|NCT02585206|Active Comparator|Arm 11|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity OFF
11317248|NCT02585206|Active Comparator|Arm 12|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity ON
11317249|NCT02585206|Active Comparator|Arm 13|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity OFF
11317250|NCT02585206|Active Comparator|Arm 14|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity ON
11317251|NCT02585206|Active Comparator|Arm 15|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity OFF
11317252|NCT02585206|Active Comparator|Arm 16|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity ON
11317253|NCT02585206|No Intervention|WEB|"Phase II arm.
~Full access to standard BecomeAnEX.org web-based smoking cessation program."
11317254|NCT02585206|Active Comparator|WEB+OA_TXT|"Phase II arm.
~Full access to standard BecomeAnEX.org web-based smoking cessation program PLUS optimal-adherence text message program from Phase I."
11317255|NCT02585193|Other|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
11317256|NCT02585180|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
11317257|NCT02585180|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
11317258|NCT02585167|Active Comparator|Operation|"the fistula will be excised after dividing the sphincter and primary reconstruction
~."
11317259|NCT02585167|Experimental|VAAFT|the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.
11317260|NCT02585141|Experimental|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
11317261|NCT02585141|Active Comparator|incision|Surgical incision of perianal abscess under general anesthesia.
11317262|NCT02585128|Other|Patients following TAVI|
11317263|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
11317264|NCT02585102|Other|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
11317265|NCT02585102|Other|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
11317266|NCT02585089|Active Comparator|Spanish cured-pork ham|"One group will receive dry-cured pork ham of >10 months proteolysis (intervention product).
~Intervention: Dietary intake Dry-cured pork ham contains high doses of bioactive peptides produced during more than 10 months of proteolysis."
11317267|NCT02585089|Placebo Comparator|Cooked pork ham|The other group will receive cooked, uncured ham (placebo product). Intervention: Dietary intake. Cooked ham does not display bioactive peptides as they are produced during proteolysis of pork ham.
11317268|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
11317269|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
11317270|NCT02585050||patients alive discharged from hospital|patients alive discharged from hospital following CPR
11317298|NCT02584907|No Intervention|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
11317271|NCT02585037|Experimental|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
11317272|NCT02585037|Experimental|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
11317273|NCT02585037|Placebo Comparator|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
11317274|NCT02585024|Experimental|1.5 mg cytisine|1.5 mg cytisine given as a single dose
11317275|NCT02585024|Experimental|3 mg cytisine|3 mg cytisine given as a single dose
11317276|NCT02585024|Experimental|4.5 mg cytisine|4.5 mg cytisine given as a single dose
11317277|NCT02585024|Experimental|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
11317278|NCT02585024|Experimental|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
11317279|NCT02585024|Experimental|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
11317280|NCT02585011|Experimental|Ropivacaine|Local infiltration anesthesia, single shot during surgery. 150 ml Ropivacaine (2mg/ml), added 0.5 ml Epinephrine (1mg/ml)
11317281|NCT02585011|Placebo Comparator|Placebo|Single shot during surgery.150 ml saline
11317282|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
11317283|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
11317284|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
11317285|NCT02584985|Other|ETAP : Endoscopic Transanal Proctectomy|"Primary transanal approach :
~Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).
~Secondary transabdominal approach :
~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
11317286|NCT02584985|Other|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
11317287|NCT02584972||children with Autism Spectrum Disorder|no intervention required
11317288|NCT02584972||heathy children|no intervention required
11317289|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
11317290|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
11317291|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
11317292|NCT02584946|Placebo Comparator|Low-AVA oat flour cookies|
11317293|NCT02584946|Experimental|High-AVA oat flour cookies|
11317294|NCT02584933|Experimental|ceritinib|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent ceritinib study at the time of the rollover.
11317295|NCT02584920|Experimental|HLX01|375mg/m2 iv single dose
11317296|NCT02584920|Active Comparator|Rituximab|375mg/m2 iv single dose
11368955|NCT02241902||Persistent pyuria|
11317299|NCT02584894|Placebo Comparator|rTMS 1Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 1Hz on dorsolateral prefrontal cortex (1Hz rTMS is describe in the literature to have no effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter . Heart rate measure With electrocardiogram
11317300|NCT02584894|Experimental|rTMS 10Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 10Hz on dorsolateral prefrontal cortex (10Hz rTMS is describe in the literature to have effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter. Heart rate measure with electrocardiogram
11317301|NCT02584881|Experimental|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
11317302|NCT02584881|No Intervention|Control|Standard care at discharge will be implemented with these trauma patients
11317303|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
11317304|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
11317305|NCT02584855|Experimental|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
11317306|NCT02584855|Experimental|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.
~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
11317307|NCT02584855|Placebo Comparator|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.
~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
11317308|NCT02584855|Experimental|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.
~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
11317309|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
11317310|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
11317311|NCT02584816|Experimental|Group 1 - BRV-PV Lot A|BRV-PV Lot A + DPT- HepB-Hib + OPV
11317312|NCT02584816|Experimental|Group 2 - BRV-PV Lot B|BRV-PV Lot B+ DPT- HepB-Hib + OPV
11317313|NCT02584816|Experimental|Group 3 - BRV-PV Lot C|BRV-PV Lot C + DPT- HepB-Hib + OPV
11317314|NCT02584816|Active Comparator|Group 4 - ROTARIX|ROTARIX + DPT-HepB-Hib + OPV
11317315|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
11317316|NCT02584777|Experimental|Pacritinib|Oral administration
11317317|NCT02584764|Experimental|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
11317318|NCT02584751|Active Comparator|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
11317319|NCT02584751|Active Comparator|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
11317320|NCT02584751|Experimental|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
11317321|NCT02584751|Active Comparator|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
11317322|NCT02584738|Experimental|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.
~Intravenous methylprednisolone or oral prednisolone"
11317323|NCT02584738|Placebo Comparator|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone
11317324|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
11317325|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
11317326|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
11317327|NCT02584712|No Intervention|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
11317328|NCT02584712|Active Comparator|Exercise Training|This group undergone exercise training intervention during 4 weeks.
11317329|NCT02584699|Experimental|SABR|SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)
11317330|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
11317824|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
11317331|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
11317332|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
11317333|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
11317334|NCT02584660|Experimental|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
11317335|NCT02584660|Experimental|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
11317336|NCT02584647|Experimental|Phase 1: PLX3397 and Sirolimus|Cohort 1 (Phase 1): Subjects with unresectable or metastatic sarcoma will take orally PLX3397 (600 - 1000mg) in combination with Sirolimus (2-6mg) daily .
11317337|NCT02584647|Experimental|Phase 2: PLX3397 and Sirolimus|Cohort 2 (Phase 2): Subjects with unresectable or metastatic Malignant Peripheral Nerve Sheath Tumors (MPNSTs) will take PLX3397 and Sirolimus at the recommended Phase 2 dose (RP2D).
11317338|NCT02584634|Experimental|Group A|ALK negative Non-Small Cell Lung Cancer
11317339|NCT02584634|Experimental|Group B|ALK positive Non-Small Cell Lung Cancer
11317340|NCT02584621|Experimental|Check Yourself App With Feedback|Participants complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their visit with their health provider. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Health providers receive a summary report of health risk behaviors from Check Yourself prior to the visit.
11317341|NCT02584621|No Intervention|Usual Care|Participants are asked to complete health risk screening questions on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
11317342|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
11317343|NCT02584582|Experimental|Liraglutide + Liquid meal test|Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
11317344|NCT02584582|Experimental|Exenatide + Liquid meal test|Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
11317345|NCT02584582|Other|Baseline + Liquid meal test|Baseline day with no additional medication
11317346|NCT02584569|Experimental|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
11317347|NCT02584556|Experimental|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
11317348|NCT02584556|Active Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
11317349|NCT02584543|Experimental|HEV vaccine and HBV vaccine Co-administration group|
11317350|NCT02584543|Active Comparator|HEV vaccine control group|
11317351|NCT02584543|Active Comparator|HBV vaccine control group|
11317352|NCT02584530|No Intervention|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
11317353|NCT02584530|Experimental|Interventional group|Ultrasound guidance for PICC line placement and X-ray
11317354|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
11317355|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
11317356|NCT02584504|Experimental|Alirocumab 150 mg Q4W|Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
11317357|NCT02584504|Experimental|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
11317358|NCT02584504|Placebo Comparator|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
11318362|NCT02577692|Experimental|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
11317359|NCT02584491|Experimental|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
11317360|NCT02584478|Experimental|AL3818 plus carboplatin and paclitaxel|"Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
~Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b."
11317361|NCT02584465|Active Comparator|A-Tamoxifen|Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression
11317362|NCT02584465|Experimental|B-Regorafenib|Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression
11317363|NCT02584452|Active Comparator|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
11317364|NCT02584452|Active Comparator|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
11317365|NCT02584439|Other|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
11317366|NCT02584439|Other|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
11317367|NCT02584426|Experimental|Cefazolin Treatment|Subjects will receive antibiotic treatment with phonophoresis (i.e., hypodermoclysis) during test 1, and will be given standard of care for 8 weeks.
11317368|NCT02584426|No Intervention|Standard of Care Control|Subjects will not receive intervention and will receive standard of care for 8 weeks.
11317369|NCT02584413|Experimental|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
11317370|NCT02584400|Experimental|[18F]HX4 PET imaging|Injection with the hypoxia tracer [18F]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
11317371|NCT02584387|Experimental|3D VVRET|"Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)
~1 30 minute 3D VRET treatment session for arachnophobia."
11317372|NCT02584387|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
11317373|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
11317374|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age
~Venography with balloon occlusion test will be performed."
11317375|NCT02584361|Active Comparator|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
11317376|NCT02584361|Active Comparator|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
11317377|NCT02584348|Experimental|Gastric Ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed
11317378|NCT02584335|Active Comparator|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
11317426|NCT02584010|Experimental|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
11317427|NCT02584010|No Intervention|Control|This group will not receive any intervention as a control group.
11317456|NCT02583802|Experimental|Ear pills and Shengmai capsule|On regular hemodialysis based on given auricular Ear pills and Shengmai capsule
11317379|NCT02584335|Placebo Comparator|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
11317380|NCT02584322|Experimental|ERAS patients|Enhanced recovery pathway
11317381|NCT02584309|Experimental|Arm 1: dexrazoxane & standard of care doxorubicin|"Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.
~Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.
~Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.
~In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
11317382|NCT02584309|Active Comparator|Arm 2: control (standard of care doxorubicin)|"Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.
~The last 10 patients enrolled after completion of enrollment to Arm 1 (dexrazoxane & standard of care doxorubicin) will be enrolled to Arm 2 (control arm - standard of care doxorubicin only)"
11317383|NCT02584296|No Intervention|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
11317384|NCT02584296|Experimental|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
11317385|NCT02584283|Experimental|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
11317386|NCT02584283|No Intervention|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
11317387|NCT02584270|Experimental|Prosthesis + Articulation Therapy|This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
11317388|NCT02584270|Other|No Prosthesis; Articulation Therapy Only|This arm will not receive a palatal augmentation prosthesis, but will receive standard articulation therapy, and is the control arm.
11317389|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
11317390|NCT02584257|Active Comparator|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
11317391|NCT02584257|Active Comparator|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
11317392|NCT02584257|Experimental|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
11317393|NCT02584257|Experimental|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
11317394|NCT02584244|Experimental|Patients with colorectal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
11317395|NCT02584244|Experimental|Patients with esophageal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
11317396|NCT02584244|Experimental|Pancreatic cancer patients receiving neoadjuvant chemotherapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
11317428|NCT02583997|Active Comparator|Routine third molar extraction|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care (i.e. with suturing of the lower alveoli).
~Intervention: Suturing of lower alveoli"
11318363|NCT02577692|Experimental|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
11317397|NCT02584244|Experimental|Pancreatic cancer patients not receiving neoadjuvant chemo|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
11317398|NCT02584231|Experimental|Patients needing an urinary concentration test|Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)
11317399|NCT02584231|Experimental|Patients suffering from treatment resistant nocturnal enuresis|Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)
11317400|NCT02584218|Experimental|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
11317401|NCT02584218|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
11317402|NCT02584205|Experimental|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
11317403|NCT02584205|Placebo Comparator|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
11317404|NCT02584192|Experimental|the rehabilitation group|entailing an early home-based CR program
11317405|NCT02584192|Other|the control group|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
11317406|NCT02584179|Experimental|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.
~All men will have standard transrectal ultrasound guided biopsies"
11317407|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
11317408|NCT02584166||Control group|No intervention in 57 maternity units
11317409|NCT02584153|Experimental|Myoseal|The fibrin sealant and silver microparticles are sprayed onto the surface of the sutured myofascial incision following abdominal surgery.
11317410|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
11317411|NCT02584127|Experimental|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
11317412|NCT02584127|Experimental|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
11317413|NCT02584114|Experimental|Memory training group|The intervention is self-administration of 4 hours of memory training over 4 days per week, for 3 weeks (12 hours total). Memory training will be done with the Peak app for memory training http://www.peak.net.
11317414|NCT02584114|Active Comparator|Non-memory training group|The intervention is self-administration of 4 hours of training of games that do not involve memory such as language and card games over 4 days per week, for 3 weeks (12 hours total).
11317415|NCT02584101|Experimental|ACT|ACT therapy
11317416|NCT02584101|Active Comparator|Enhanced Treatment as Usual|Group support
11317417|NCT02584075|Experimental|Lifestyle intervention|
11317418|NCT02584062|Experimental|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
11317419|NCT02584062|Experimental|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
11317420|NCT02584049|Active Comparator|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
11317421|NCT02584049|Sham Comparator|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
11317422|NCT02584036||Receiving Influenza Vaccine|Patients who receive an influenza vaccine at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
11317423|NCT02584023|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
11317424|NCT02584023|Active Comparator|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
11317425|NCT02584010|Experimental|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
11369423|NCT02238756|Active Comparator|Rabipur|
11317429|NCT02583997|Experimental|Third molar extraction without suturing|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care, except that the resulting alveoli will not be sutured.
~Intervention: Non suturing of lower alveoli"
11317430|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
11317431|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
11317432|NCT02583971||Patients with AF|"Split into 3:
~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.
~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.
~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
11317433|NCT02583958|Experimental|Device Urgo 3103166|Soft-adherent hydro-desloughing dressing
11317434|NCT02583958|Active Comparator|Device Aquacel Extra|Hydrofibre dressing
11317435|NCT02583945|Experimental|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
11317436|NCT02583932|Experimental|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
11317437|NCT02583932|Placebo Comparator|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
11317438|NCT02583932|No Intervention|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
11317439|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
11317440|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
11317441|NCT02583919|Placebo Comparator|Placebo|Placebo
11317442|NCT02583906|Other|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
11317443|NCT02583906|No Intervention|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
11317444|NCT02583893|Experimental|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
11317445|NCT02583867|Experimental|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
11317446|NCT02583854|Active Comparator|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
11317447|NCT02583854|Experimental|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
11317448|NCT02583841|Active Comparator|Scaling and Root Planing( SRP)|This was an interventional study in which scaling and root planing was done in systemically healthy patients with chronic periodontitis
11317449|NCT02583841|No Intervention|Control Group|Scaling and root planing was not done , that is no intervention is carried out in the patients of this group.
11317450|NCT02583828|Active Comparator|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
11317451|NCT02583828|Experimental|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
11317452|NCT02583828|Experimental|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
11317453|NCT02583828|Active Comparator|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
11317454|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
11317455|NCT02583802|No Intervention|Control group|Control group received regular hemodialysis treatment, no given Ear pills and Shengmai capsule completed in the treatment of the first stage. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
11369424|NCT02238756|Experimental|CV8102 + Rabipur|
11317457|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
11317458|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
11317459|NCT02583776|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
11317460|NCT02583776|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
11317461|NCT02583763||Fetuses/Children with IUGR|"The moving sequences of the heart movement are collected at the regular ultrasound examinations during pregnancy. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.
~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
11317462|NCT02583763||Healthy Controls|"The moving sequences of the heart movement are collected at two occasions approximately 4 weeks apart. This takes place during gestational weeks 28-36. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.
~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyze the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
11317463|NCT02583750|Experimental|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
11317464|NCT02583750|Experimental|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
11317465|NCT02583737|Active Comparator|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
11317466|NCT02583737|Active Comparator|group freeze bone allograft|sinus lifting with freeze bone bank filling
11317467|NCT02583698|Experimental|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP > 90 mmHg and HR >55/min
11317468|NCT02583698|Placebo Comparator|placebo|
11317469|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
11317470|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
11317471|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
11317472|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
11317473|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
11317474|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
11317475|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
11317476|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
11317477|NCT02583672|Experimental|N-acetylcysteine|The first 10 GD1 subjects will take 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. An interim analysis will be performed to determine if this dose produces changes in systemic redox status and brain glutathione (GSH) levels. If no signal of a significant change is observed, the remaining 20 subjects will receive up to 3600 mg NAC orally twice a day (7200 mg/day).
11317478|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
11317479|NCT02583646||normal weight|Girls age 8-14 below 85% in respect to weight for their age group
11317480|NCT02583646||overweight|Girls age 8-14 at or above 85% in respect to weight for their age group
11317481|NCT02583633|Active Comparator|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
11317482|NCT02583633|Active Comparator|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;
~One softgel every 20 min (4 doses)
~Two softgel every 6 hr (4 doses)
~One softgel every 6 hr (4 doses)
~One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
11317483|NCT02583620|Other|Emmetropic volunteers|Blood sample
11317484|NCT02583620|Other|High myopic volunteers|Blood sample
11317485|NCT02583607|Experimental|Brava and fat transfer|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.
~Woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
11318393|NCT02577458|Experimental|CM082 plus everolimus|CM082 plus everolimus
11370109|NCT02233881||Chronic obstructive pulmonary disease patients|
11317486|NCT02583594|Experimental|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
11317487|NCT02583594|Experimental|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
11317488|NCT02583581|Experimental|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
11317489|NCT02583568|Experimental|Part 1|In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
11317490|NCT02583568|Experimental|Part 2|In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
11317491|NCT02583555|Active Comparator|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
11317492|NCT02583555|No Intervention|Controls|Questionnaire every 3 months
11317493|NCT02583542|Experimental|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
11317494|NCT02583542|Experimental|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:
~Triple-negative breast cancer (TNBC)
~Squamous cell lung cancers
~Non-squamous cell lung cancers with KRAS mutations
~Non-squamous cell lung cancers with wild-type KRAS"
11317495|NCT02583529|Experimental|Back Tibial Nerve Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
11317496|NCT02583529|Placebo Comparator|Placebo Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
11317497|NCT02583516|Experimental|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
11317498|NCT02583516|Experimental|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
11317499|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
11317500|NCT02583490|Experimental|Low Pulse Amplitude ECT (LAP)|Right Unilateral LAP ECT
11317501|NCT02583490|Active Comparator|standard Right Unilateral ECT|standard Right Unilateral ECT
11317502|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
11317503|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
11317504|NCT02583464|Experimental|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
11317505|NCT02583464|Experimental|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
11317506|NCT02583451|Experimental|Treatment A|Treatment A is a placebo tablet matching lemborexant and placebo tablet matching zopiclone on nights in the clinic; placebo tablet matching lemborexant on nights at home.
11317507|NCT02583451|Experimental|Treatment B|Treatment B is zopiclone 7.5 mg tablet and placebo tablet matching lemborexant on nights in the clinic; placebo tablet matching lemborexant on nights at home.
11317508|NCT02583451|Experimental|Treatment C|Treatment C is lemborexant 2.5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 2.5 mg tablet on nights at home.
11317509|NCT02583451|Experimental|Treatment D|Treatment D is lemborexant 5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 5 mg tablet on nights at home.
11317510|NCT02583451|Experimental|Treatment E|Treatment E is lemborexant 10 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 10 mg tablet on nights at home.
11317511|NCT02583438|Experimental|Lifestyle intervention|
11317512|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
11317513|NCT02583412|Active Comparator|Group 1: Accelerated Schedule|
11317514|NCT02583412|Active Comparator|Group 2: Standard Schedule|
11317515|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
11317544|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
11317516|NCT02583386|Active Comparator|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
11317517|NCT02583386|No Intervention|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
11317518|NCT02583386|Active Comparator|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
11317519|NCT02583386|Other|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
11317520|NCT02583373|Active Comparator|CAL02 Low-dose|Liposomal formulation
11317521|NCT02583373|Active Comparator|CAL02 High-dose|Liposomal formulation
11317522|NCT02583373|Placebo Comparator|Placebo|Saline
11317523|NCT02583360|Active Comparator|Modified Flow Rate|This group of subjects will be prescribed the use of a bottle nipple that has a slower flow rate than what the subject was initially using. This will be administered per parent choice, as compliance to a specific feeding method can be challenging in babies.
11317524|NCT02583360|Active Comparator|Modified Thickening|This group of subjects will receive modified thickening. The subjects will be prescribed thickened formula using a standard thickening agent. This will be administered per parent choice, as compliance to a specific feeding method can be challenging in babies.
11317525|NCT02583334|Experimental|Verum Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
11317526|NCT02583334|Sham Comparator|Sham Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).
11317527|NCT02583321|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
11317528|NCT02583321|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
11317529|NCT02583308|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
11317530|NCT02583308|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
11317531|NCT02583295|Active Comparator|Music group|Music sound
11317532|NCT02583295|Active Comparator|Maternal sound group|Maternal sound
11317533|NCT02583282|Experimental|Doxycycline|Intrapleural doxycycline
11317534|NCT02583282|Active Comparator|Iodopovidine|Intrapleural iodopovidine
11317535|NCT02583269|Experimental|Arm 1 (muscadine grape skin extract) 1 pill 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
11317536|NCT02583269|Experimental|Arm 2 (muscadine grape skin extract) 2 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
11317537|NCT02583269|Experimental|Arm 3 (muscadine grape skin extract) 3 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
11317538|NCT02583269|Experimental|Arm 4 (muscadine grape skin extract) 4 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
11317539|NCT02583269|Experimental|Arm 5 muscadine grape skin extract) 5 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
11317540|NCT02583256|Experimental|aQIV/aQIV|Subjects previously vaccinated with aQIV followed one year later by aQIV
11317541|NCT02583256|Experimental|aQIV/QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
11317542|NCT02583256|Experimental|QIV/aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
11317543|NCT02583256|Experimental|QIV/QIV|Subjects previously vaccinated with QIV followed one year later by QIV
11317545|NCT02583217||Ketamine|Ketamine+propofol
11317546|NCT02583217||Remifentanyl|Remifentanyl+propofol
11317547|NCT02583204|No Intervention|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
11317548|NCT02583204|Experimental|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
11317549|NCT02583204|Experimental|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
11317550|NCT02583191|Experimental|Rivaroxaban|Arm A: Rivaroxaban
11317551|NCT02583191|Active Comparator|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
11317552|NCT02583178|Experimental|Aegis Sierra Ligation System|The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
11317553|NCT02583165|Experimental|Monotherapy arm|MEDI1873
11317554|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
11317555|NCT02583139|Experimental|Music Narrative Group|Prescribed medical/chemotherapy treatment plus standard care + Designed Music Narratives
11317556|NCT02583139|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
11317557|NCT02583126|Experimental|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
11317558|NCT02583126|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
11317559|NCT02583113||Total and Unicompartment Knee Replacement|
11317560|NCT02583100|Experimental|Intensive Feedback|Participants in this arm will receive intensive feedback on their complication rates, surgical technique, and peri-operative surgical management from peer surgeons participating in the study.
11317561|NCT02583100|Active Comparator|Routine Feedback|Participants in this arm will receive routine feedback on their complication rates.
11317562|NCT02583074|Experimental|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
11317563|NCT02583074|Sham Comparator|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
11317564|NCT02583048|Experimental|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.
~Participants also received Multidrug Background Treatment (MBT) for TB.
~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
11317565|NCT02583048|Experimental|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.
~Participants also received Multidrug Background Treatment (MBT) for TB.
~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
11317566|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.
~Participants also received Multidrug Background Treatment (MBT) for TB.
~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
11317567|NCT02583035|Other|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
11317568|NCT02583022|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
11317569|NCT02583022|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
11317570|NCT02583022|Active Comparator|Elidel cream 1%|Elidel cream 1%, Twice daily for 4 weeks
11317571|NCT02583009|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
11317572|NCT02583009|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
11317573|NCT02583009|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
11317574|NCT02583009|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
11317575|NCT02582996|Experimental|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
11317576|NCT02582996|Active Comparator|Tylenol®|Acetaminophen
11317577|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
11317578|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
11317579|NCT02582957|Experimental|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
11317580|NCT02582957|No Intervention|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
11317581|NCT02582944|Experimental|Arm 1: Electromagnetic navigation|"The bronchoscope will be inserted transorally into the tracheobronchial tree and a standard airway inspection will be performed.
~Following airway inspection, the bronchoscope will be removed and the tip tracked steerable catheter with optical system will be advanced transorally through the vocal cords and into the tracheobronchial tree.
~Once the tip tracked catheter has been advanced to the peripheral pulmonary target lesion, the optical SpinView system will be removed from the tip tracked catheter and the 1.4mm radial endobronchial ultrasound mini-probe will be inserted through the tip-tracked catheter into the lung periphery to confirm the presence of a peripheral pulmonary lesion and accurate navigation.
~Once target confirmation has been performed using radial probe endobronchial ultrasound, biopsy of the peripheral lesion will be performed using biopsy forceps, brushes and aspiration needles."
11317582|NCT02582931|Experimental|Arm 1: MRI-guided SBRT|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
~Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.
~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
11317583|NCT02582918|No Intervention|Group 1: Usual Care|Usual care with opportunistic visit-based HCC surveillance.
11317584|NCT02582918|Experimental|Group 2: Patient Education and Patient Navigation Services|Mailed HCC surveillance outreach with patient education and patient navigation services.
11317585|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
11317586|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
11317587|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
11317588|NCT02582892|Other|Vit D|Vit D 20 mg/day
11317589|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
11317590|NCT02582866|Experimental|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.
~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
11317591|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.
~Lumbar puncture Blood sample"
11317592|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
11317593|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
11317594|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
11317595|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
11317596|NCT02582827|Experimental|ABI-011|IDN 5404 protein-bound particles for injectable suspension
11317597|NCT02582814|Experimental|dapagliflozin 5mg + insulin|dapagliflozin tablet 5mg + adjustable insulin
11317598|NCT02582814|Experimental|dapagliflozin 10mg + insulin|dapagliflozin tablet 10mg + adjustable insulin
11317599|NCT02582801|Experimental|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
11317600|NCT02582801|Active Comparator|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
11317601|NCT02582788|Active Comparator|Bleach|Patients will use bleach added to their baths twice a week.
11317602|NCT02582788|Active Comparator|Vinegar|Patients will use vinegar (dilute acetic acid) added to their baths twice a week.
11317603|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
11317604|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
11317605|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGy of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
11317606|NCT02582775|Experimental|Arm D: HCT with 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
11317607|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
11317608|NCT02582775|Experimental|Arm F: HCT Alone, 200 cGy BID of TBI|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
11317609|NCT02582775|Experimental|Arm G: HCT plus MSC, 200 cGy|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
11317610|NCT02582762|Experimental|Nail gel|apply nail gel twice daily
11317611|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
11317612|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
11317613|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
11317614|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
11319092|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
11317615|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
11317616|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
11317617|NCT02582723|Active Comparator|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
11317618|NCT02582723|Active Comparator|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
11317619|NCT02582723|Experimental|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
11317620|NCT02582710|Experimental|VASCAZEN|Patients treated with Vascazen
11317621|NCT02582710|Placebo Comparator|Placebo|Patients treated with a placebo
11317622|NCT02582697|Active Comparator|Standard Arm - Standard BEP|"Participants 16 years or older will receive 4 cycles of Standard BEP as follows:
~Bleomycin 30,000 IU IV weekly for 3 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients < 16 years old and weighs ≥ 45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients <16 years old and weighs < 45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count ≥1 x10^9/ L
~The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.
~Each cycle is 3 weeks (21 days).
~The planned total duration of treatment is 12 weeks."
11317623|NCT02582697|Experimental|Experimental Arm - Accelerated BEP|"Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:
~Bleomycin 30,000 IU IV wkly for 2 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1- 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients <16years and weighs ≥45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Pegylated G-CSF 6 mg SCI on day 6
~Patients <16years and weighs <45 kg will receive:
~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses
~Etoposide 100 mg/m2 IV on day 1 - 5
~Cisplatin 20 mg/m2 IV on day 1 - 5
~Filgrastim 10mcg/kg/day on day 6, until ANC ≥1 x10^9/ L
~Each cycle is 2 weeks (14days)
~Following 4xBEP cycles, patients will receive additional bleomycin as follows:
~- Bleomycin *15,000 - 30,000 IU IV wkly for 4 doses
~* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.
~The planned total duration is 12 weeks."
11317624|NCT02582684|Experimental|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
11317625|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
11317626|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) ± Ribavirin (RBV) according to standard of care and in line with the current local label
11317627|NCT02582645|Experimental|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
11317628|NCT02582645|Active Comparator|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
11317629|NCT02582632|Experimental|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
11317630|NCT02582619||Rehabilitation Professionals|Focus group consisting of rehabilitation professionals that will inform the study on vocational rehabilitation interventions rendered during acute to in-patient rehabilitation in KwaZulu-Natal.
11317631|NCT02582619||People living with Spinal Cord Injuries (PLWSCI)|"Focus group consisting of PLWSCI that will inform the study on the perspective of the patient on vocational rehabilitation needs or desires during acute care and in-patient rehabilitation.
~This group will inform the study on the employment rate amongst people living with spinal cord injuries as well as factors that influence employment.
~This group will also inform the study on the perceived barriers and facilitators of employment"
11317632|NCT02582619||Stakeholders|"Representatives from the following departments or organisations will be invited to participate in the interviews and focus groups:
~Government Departments:
~Education Social Development Health Labour Transport
~Private Companies:
~Insurance Companies and Health Risk Management companies Non-profit Organisations QASA DPSA"
11317633|NCT02582619||Experts|A delphi technique will be used to get an expert opinion and consensus on the aspects of the model to be developed.
11317634|NCT02582606|Experimental|Regular|Regular meal pattern
11317635|NCT02582606|Experimental|Irregular|Irregular meal pattern
11317636|NCT02582593|Active Comparator|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
11317637|NCT02582593|Sham Comparator|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
11317686|NCT02582255|Experimental|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
11317687|NCT02582242|Experimental|BIAsp 30 TID|
11317638|NCT02582593|Active Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
11317639|NCT02582593|Sham Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
11317640|NCT02582593|Active Comparator|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
11317641|NCT02582593|Sham Comparator|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
11317642|NCT02582580|Active Comparator|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
11317643|NCT02582580|Active Comparator|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
11317644|NCT02582580|Active Comparator|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
11317645|NCT02582567|Experimental|Exercise intervention|3 times per week from the 17th week of gestation until delivery
11317646|NCT02582567|No Intervention|Control group|Usual care (control) group
11317647|NCT02582554|Experimental|Intervention|Intervention: NutriSTEP The intervention will be the administration of NutriSTEP, a nutrition risk screening questionnaire for preschoolers along with a nutrition education brochure called How to Build a Healthy Preschooler
11317648|NCT02582554|No Intervention|Control|Control: Wait-list control The wait-list control group will complete the NutriSTEP and receive the nutrition education information at the end of the 3 month study period
11317649|NCT02582541|Active Comparator|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
11317650|NCT02582541|Experimental|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
11317651|NCT02582528|Experimental|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
11317652|NCT02582528|Active Comparator|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
11317653|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
11317654|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
11317655|NCT02582502|Experimental|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
11317656|NCT02582502|Other|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
11317688|NCT02582242|Active Comparator|BIAsp 30 BID|
11317689|NCT02582229|Experimental|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
11317657|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
11317658|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
11317659|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
11317660|NCT02582437|Experimental|Chronic Opioid User|"The patients (ASA class I-III) who receive elective surgery s aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.
~The Patients who use opioid medication daily and regularly immediately before the day of surgery for more than four weeks. The minimum criteria for opioid dose in the intervention goup is oral morphine 20mg per day: Morphine Equivalent Daily Dose(MEDD)"
11317661|NCT02582437|No Intervention|Opioid Naive patient|"The patients (ASA class I-III) who receive elective surgery aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.
~The patients who do not use opioid medications immediately before the day of surgery for four weeks."
11317662|NCT02582424|Experimental|PDL-0101|EPA +astaxanthin
11317663|NCT02582424|Placebo Comparator|placebo|olive oil
11317664|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
11317665|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
11317666|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
11317667|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
11317668|NCT02582398|Experimental|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
11317669|NCT02582398|Placebo Comparator|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
11317670|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
11317671|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
11317672|NCT02582372|Experimental|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
11317673|NCT02582372|Active Comparator|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
11317674|NCT02582359|Experimental|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy
~MLN9708 -oral on predetermined days per cycle
~Cytarabine, continuous infusion for predetermined duration and dosage
~Daunorubicin short IV infusion or rapid injection for predetermined
~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
11317675|NCT02582346|Experimental|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
11317676|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
11317677|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
11317678|NCT02582320||Study patients|Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.
11317679|NCT02582307|Experimental|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
11317680|NCT02582307|Active Comparator|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
11317681|NCT02582281|Experimental|Non touch technique|"the intrauterine device TCu 380A will be inserted in the conventional method as follows: First, insert the speculum and view the cervix. The position of the cervix will very often confirm if the uterus is anteverted or retroverted. Second, using the Allis forceps hold the back of a cotton-ball swab and dip it into a povidine-iodine disinfectant solution, or equivalent. Swab the cervix. Then cut the threads to the appropriate length and remove the speculum.
~This technique omits the sounding of the uterus which is considered a quintessential procedure before IUD insertion for which there is no one established piece of evidence.The IUD is checked afterwards by transvaginal ultrasound."
11317682|NCT02582281|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
11317683|NCT02582268|Experimental|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
11317684|NCT02582268|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
11317685|NCT02582255|Experimental|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
11317691|NCT02582203|Active Comparator|Ceftaroline|600 mg IV (over 1 hour) every 12 hours for renal function > 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
11317692|NCT02582203|Active Comparator|Vancomycin|Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.
11317693|NCT02582190|Other|Colchicine group|Colchicine add on therapy in atrial fibrillation
11317694|NCT02582177|Experimental|Candicort®/ Nizoral®|Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
11317695|NCT02582177|Experimental|Baycuten N®/ Canesten®|Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
11317696|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
11317697|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
11317698|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
11317699|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
11317700|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
11317701|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
11317702|NCT02582138|Experimental|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
11317703|NCT02582138|Active Comparator|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
11317704|NCT02582125|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
11317705|NCT02582112|Active Comparator|Warming group|Active Comparator: Warming group
11317706|NCT02582112|Placebo Comparator|Control group|Control group
11317707|NCT02582099|Active Comparator|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
11317708|NCT02582099|Placebo Comparator|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
11317709|NCT02582086|Experimental|BOR15001L7 Cream|BOR15001L7 Cream with 5% 15019L0
11317710|NCT02582086|Placebo Comparator|Placebo Cream|Placebo Cream
11317711|NCT02582073|Placebo Comparator|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
11317712|NCT02582073|Placebo Comparator|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
11317713|NCT02582073|Experimental|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
11317714|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
11317715|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
11317716|NCT02582073|Active Comparator|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
11317717|NCT02582060|Other|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
11317718|NCT02582047|Active Comparator|Influenza vaccination with PPV23|concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine
11317719|NCT02582047|Active Comparator|Influenza vaccination with PCV13|concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine
11317720|NCT02582034|Active Comparator|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
11317721|NCT02582034|Experimental|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is > 205 GY, if possible 250 or 300 Gy.
11317722|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
11317723|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
11317724|NCT02582008|Experimental|Arm A (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
11317794|NCT02581553|Experimental|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
11318498|NCT02576782|Active Comparator|perineural dexamethasone group|21 patients received perineural dexamethasone plus bupivacaine 0.5%
11317725|NCT02582008|Active Comparator|Arm B (varenicline, NRT)|Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.
11317726|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
11317727|NCT02581982|Experimental|Treatment (pembrolizumab, paclitaxel)|Patients receive pembrolizumab IV over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11317728|NCT02581969||Prophylaxis|Prophylaxis group: treatment is based on regularly repeated infusions of clotting factor, 20-30 IU/kg -3 times a week
11317729|NCT02581969||On-demand|On-demand group: treatment administered when bleeding episode occur
11317730|NCT02581956|Experimental|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
11317731|NCT02581956|Placebo Comparator|No Intervention|No exercise required
11317732|NCT02581943|Experimental|Arm I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11317733|NCT02581943|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11317734|NCT02581930|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11317735|NCT02581917||Ancillary-Correlative (metabolic changes)|Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
11317736|NCT02581904|Experimental|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
11317737|NCT02581904|Active Comparator|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
11317738|NCT02581904|Active Comparator|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
11317739|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
11317740|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
11317741|NCT02581878|Experimental|Cohort 1a|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).
11317742|NCT02581878|Experimental|Cohort 1b|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
11317743|NCT02581878|Experimental|Cohort 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
11317744|NCT02581878|Experimental|Cohort 3|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
11317745|NCT02581878|Experimental|Cohort 4|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
11317746|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
11317747|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
11317748|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
11317749|NCT02581852|Other|Single arm assessment|Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
11317750|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
11317751|NCT02581826|Active Comparator|Silodosin|"Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.
~This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).
~The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
11317752|NCT02581826|Placebo Comparator|Placebo|"Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.
~This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).
~The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
11317753|NCT02581813|Experimental|RDa (Recommended dairy group)|4 servings of dairy per day + exercise (3 times per week with combination of aerobic and resistance exercise).
11317754|NCT02581813|Experimental|LDa (Low dairy group)|0-1 serving of dairy per day + exercise (the same as the RDa group)
11317755|NCT02581813|No Intervention|GCon (growth controls)|This no-intervention group will serve as the control to account for growth during the study.
11317756|NCT02581800|No Intervention|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
11317757|NCT02581800|Experimental|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
11317758|NCT02581787|Experimental|Treatment (fresolimumab, SABR)|In Phase 1: Patients receive fresolimumab IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12 in total of 5 subjects. In Phase 2: . Fresolimumab will be administered IV at the dose selected in the preceding Phase 1 on Days 1, 15 and 36 and SABR will be administered in 4 fractions between Days 8 and 12.
11317759|NCT02581774||term isolated oligohydramnios|Labor Monitoring and normal delivery tracking
11317760|NCT02581774||prolonged pregnancies|Labor Monitoring and normal delivery tracking
11317761|NCT02581761|Experimental|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
11317762|NCT02581761|Placebo Comparator|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
11317763|NCT02581748|Experimental|safety|Assessment of safety of HLX02 at different doses
11317764|NCT02581748|Active Comparator|PK comparative|Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin®(U.S. and German)
11317765|NCT02581735||Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.
~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
11317766|NCT02581722|Experimental|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
11317767|NCT02581709|Experimental|Countering cognitive impairment|Each participant will complete neuropsychological assessments at baseline (prior to chemotherapy) and after chemotherapy. Patients identified as experiencing cognitive decline measured using Reliable Change Index on at least one cognitive function measure from before until after chemotherapy will be offered the intervention. Participants in the interventions will complete a neuropsychological assessment after completion of the intervention. Questionnaires to assess other non-cognitive factors e.g. quality-of-life will be administered at the end of chemotherapy to all participants and after the intervention to participants in the intervention.
11317768|NCT02581696|Other|Single arm|This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers. Subjects judged to be appropriate to this study by screening.
11317769|NCT02581683|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
11317770|NCT02581683|Active Comparator|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
11317771|NCT02581683|Sham Comparator|Sham|Participants in this arm will receive a sham adductor canal block
11317772|NCT02581670|Experimental|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
11317773|NCT02581657|Experimental|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
11317774|NCT02581657|Placebo Comparator|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
11317775|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
11317776|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
11317777|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
11317778|NCT02581631|Experimental|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
11317779|NCT02581618|Experimental|Study group|"Remote ischemic preconditioning arm
~Blood pressure cuff will be inflated up to 200 mmHg in the non-dominant arm for 5 minutes before guiding catheter engagement."
11317780|NCT02581618|No Intervention|Control group|No intervention will be performed. Percutaneous coronary intervention will be performed without ischemic preconditioning.
11317781|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
11317782|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
11317783|NCT02581592|Experimental|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
11317784|NCT02581592|Experimental|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
11317785|NCT02581579|Active Comparator|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
11317786|NCT02581579|Placebo Comparator|Placebo|MANITOL CAPSULES
11317787|NCT02581566|Active Comparator|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
11317788|NCT02581566|Active Comparator|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
11317789|NCT02581566|Other|control Group|30 patients will be given Intrathecal Bupivacaine
11317790|NCT02581553|Experimental|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
11317791|NCT02581553|Experimental|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
11317792|NCT02581553|Experimental|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).
11317793|NCT02581553|Experimental|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).
11317795|NCT02581553|Experimental|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
11317796|NCT02581540||Suspected Cardiac Chest Pain|This cohort is observed for the incidence of MACE (death, non-fatal myocardial infarction and emergency revascularisation)
11317797|NCT02581527|Active Comparator|Rifampicin 150mg (Control)|2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)
11317798|NCT02581527|Experimental|Rifampicin 1200mg (Regimen 1)|2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)
11317799|NCT02581527|Experimental|Rifampicin 1800mg (Regimen 2)|2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)
11317800|NCT02581514|Experimental|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
11317801|NCT02581501|Experimental|Gemcitabine, ABRAXANE®, and Xeloda|"Level-1
~ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12.
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day
~Level 1
~ABRAXANE® 100 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day
~Level 2
~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 600 mg/m2 over 75 min Days 5 and 12
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day
~Level 3
~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12
~GEMCITABINE 750 mg/m2 over 75 min Days 5 and 12
~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day"
11317802|NCT02581488|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
11317803|NCT02581488|Active Comparator|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
11317804|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.
~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
11317805|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
11317806|NCT02581462|Experimental|FLOT alone|Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
11317807|NCT02581462|Experimental|FLOT + Herceptin/Pertuzumab|Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
11317808|NCT02581449|Experimental|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
11317809|NCT02581449|Placebo Comparator|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
11317810|NCT02581436|Experimental|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
11317811|NCT02581436|Active Comparator|Standard follow-up|Post Transplant surveillance based on standard of care.
11317812|NCT02581423|Experimental|Capecitabine|Participants will receive capecitabine for up to approximately 6 months.
11317813|NCT02581410|Experimental|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
11317814|NCT02581410|Active Comparator|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
11317815|NCT02581397|Experimental|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.
~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.
~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).
~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
11317816|NCT02581397|Experimental|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.
~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.
~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).
~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
11317817|NCT02581397|Active Comparator|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.
~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.
~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
11317818|NCT02581384|Experimental|Stereotactic Body Radiotherapy|"Stereotactic Body Radiotherapy (SBRT)
~Different dose levels will be used in the two cohorts.
~Ewing sarcoma, rhabdomyosarcoma, and others with non-renal tumor patients begin at a pre-determined dose per protocol.
~Wilms tumors or other primary renal tumors renal tumor patients begin at pre-determined dose per protocol.
~The two cohorts will be enrolling patients independently and simultaneously."
11317819|NCT02581371|Experimental|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
11317820|NCT02581371|Placebo Comparator|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
11317821|NCT02581358|Experimental|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
11317822|NCT02581345|Experimental|M923|Participants assigned to receive M923
11317825|NCT02581332|Other|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
11317826|NCT02581319|Other|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
11317827|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
11317828|NCT02581293|Experimental|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
11317829|NCT02581293|Experimental|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
11317830|NCT02581293|Experimental|Both of them will be closed|Group 3: Both of them will be closed
11317831|NCT02581293|Experimental|None of them will be closed|Group 4: None of them will be closed
11317832|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel during ECMO
11317833|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel after removing ECMO
11317834|NCT02581254|Experimental|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp <10mm
11317835|NCT02581254|Experimental|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp <10mm
11317836|NCT02581241|Experimental|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.
~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.
~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
11317837|NCT02581241|Active Comparator|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.
~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.
~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
11317838|NCT02581228||Training Set|The objective of the Training stage is to assess the predictive potential of ML-PrediCare for melanoma patients' response to Ipilimumab, Pembrolizumab and Nivolumab.
11317839|NCT02581228||Validation Set|The objective of the Validation stage is to test the predictive power of ML -PrediCare in an independent set of patients diagnosed with melanoma.
11317840|NCT02581215|Experimental|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:
~Oxaliplatin 85 mg/m2 over 2-4 hours
~Irinotecan 165 mg/m2 over 90 minutes
~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
~Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
11317841|NCT02581215|Placebo Comparator|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:
~Oxaliplatin 85 mg/m2 over 2-4 hours
~Irinotecan 165 mg/m2 over 90 minutes
~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
~Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
11317842|NCT02581202||HIV-1 infected participants|HIV-1-infected participants on any triple highly active antiretroviral therapy (HAART) with plasma HIV-1 ribonucleic acid (RNA) level < 50 copies/mL for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically appropriate to lopinavir with ritonavir plus lamivudine (LPV/r+3TC) as decided by the physician in the routine clinical settings. Or HIV-1 infected participants who were switched on the dual therapy (LPV/r+3TC) no more than 60 days prior to enrollment.
11317843|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
11317844|NCT02581176|Experimental|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
11317845|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
11317846|NCT02581150|Other|Outpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during an ambulatory hospitalisation, with the use of an arterial closure device (ACD).
~The patients treated for PAD (Peripheral Arterial Disease) are informed and prepared in the morning of D0. The surgical endovascular procedure is performed at D0 before 1:00 p.m. The patients leave the hospital in the evening at D0 after a systematic visit."
11317847|NCT02581150|Other|Conventional inpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during a conventional hospitalisation, with or without ACD (ACD will be used at the discretion of the interventionalist).
~The patients treated for PAD arrive at the hospital the day before surgery (D-1). The surgical endovascular procedure takes place the next day (D0). The day after (D1), the patients leave the hospital after a systematic visit."
11317848|NCT02581137|Experimental|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11317849|NCT02581124|Experimental|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
11317850|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
11317851|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
11317852|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
11317853|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
11317854|NCT02581072|Experimental|SB204 4%|SB204 4% once
11317855|NCT02581072|Experimental|SB204 8% or 12 %|SB204 8 or 12 % (supratherapeutic) once
11317856|NCT02581072|No Intervention|Moxifloxacillin|Moxifloxacillin 400 mg orally
11317857|NCT02581072|Placebo Comparator|Vehicle Gel|Placebo
11317858|NCT02581059|Experimental|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
11317859|NCT02581059|Active Comparator|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
11317860|NCT02581046|Experimental|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
11317861|NCT02581046|Experimental|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
11317862|NCT02581033|Experimental|Nucleoside analogue therapy cessation|To determine if a sustained virological response can be achieved after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
11317863|NCT02581020||1|Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.
11317864|NCT02581007|Experimental|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan & Post-transplant cyclophosphamide
11317865|NCT02580994|Experimental|Pembrolizumab + chemotherapy|Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease
11317866|NCT02580994|Active Comparator|Chemotherapy|4 cycles of cis/carboplatin and etoposide
11317867|NCT02580981|Experimental|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).
~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
11317868|NCT02580968|Experimental|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
11317869|NCT02580968|Active Comparator|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
11317870|NCT02580955|Experimental|LEGFLOW DCB|patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
11317871|NCT02580942|Experimental|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
11317872|NCT02580942|Sham Comparator|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
11317873|NCT02580929|Experimental|radiation|
11317874|NCT02580929|No Intervention|no radiation|
11317875|NCT02580916|Experimental|Group 1 (Postal)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team and deemed 'low risk'; SCQOLIT questionnaires will be administered by post.
11317876|NCT02580916|Experimental|Group 2 (Clinic-based)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team, for whom all aspects of the study will be conducted in the Dermatology clinic. SCQOLIT questionnaires will be administered according to the protocol.
11317877|NCT02580916|No Intervention|Group 3 (Interviews)|A Qualitative Researcher (Co-Investigator) will undertake structured interviews with approximately 20 patients from both Group 1 and 2. Potential participants will be invited to volunteer their contact details at the time of consent to the Questionnaire study. This is optional; they may refuse to do so and still take part in the main questionnaire study. The patient will then be contacted by the Qualitative Researcher (Co-Investigator) at a later date and subsequently consented for the interview.
11317878|NCT02580916|No Intervention|Group 4 (Clinician focus group)|We aim to discuss the project at the end of the study period in the same setting, to establish staff perspectives on the study, to establish usefulness of the SCQOLIT tool and to identify any barriers to implementation.
11317879|NCT02580890|Experimental|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
11317880|NCT02580890|Sham Comparator|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
11317881|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
11317882|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
11317883|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
11317884|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
11317885|NCT02580851|Other|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
11317886|NCT02580851|Other|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol [21-23]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
11317887|NCT02580838|Experimental|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
11317888|NCT02580838|Active Comparator|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
11317889|NCT02580838|No Intervention|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
11317890|NCT02580825|Active Comparator|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
11317891|NCT02580825|Active Comparator|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
11317892|NCT02580812|Experimental|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
11317893|NCT02580812|Active Comparator|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
11317894|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
11317895|NCT02580786|Experimental|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
11317896|NCT02580786|No Intervention|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
11317897|NCT02580773|Other|Prophylactic anticoagulation|
11317898|NCT02580773|Experimental|Curative anticoagulation|
11317899|NCT02580760||Cosmetic silicone injection|People responding to inclusion criteria with a history of cosmetic silicone injection
11317900|NCT02580747|Experimental|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
11317901|NCT02580734|Placebo Comparator|placebo|tablet without melatonin
11317902|NCT02580734|Experimental|melatonin|tablet with melatonin
11317903|NCT02580721|Active Comparator|Thick mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
11317904|NCT02580721|Experimental|Thin mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
11317905|NCT02580721|Experimental|Thickened mucosa with connective tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Soft tissue augmentation will be performed with sub epithelial connective tissue graft.
11317906|NCT02580721|Experimental|Thickened mucosa with ADM|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Acellular dermal matrix, thick 1 x 4 cm will be used for vertical soft tissue augmentation.
11317907|NCT02580708|Experimental|Rociletinib and Trametinib|
11317908|NCT02580695|Experimental|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)
~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB
~Arm 2a: single infusion group. UC-MSCs at 0 month
~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
11317909|NCT02580695|Active Comparator|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
11317910|NCT02580682|Experimental|Sanfu herbal patch|one kind of acupoint application which used in hot dog days of summer,The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba asarum), Bai Jie Zi (Semen Sinapis Albae), and Rou Gui (Cortex Cinnamomi) at a ratio of 2:2:1:1:2:1.The bilateral Feishu (BL13), Pishu (BL20), Shenshu (BL23), Neiguan (PC6), and Guanyuan (CV4) acupoints were selected for treatment
11317911|NCT02580682|Experimental|Sanfu moxibustion|use moxibustion in hot dog days of summer,and adopting the indirect moxibustion box method at the bilateral BL13, BL20, and BL23 acupoints
11317912|NCT02580682|Experimental|Sanfu herbal patch and Sanfu moxibustion|use herbal patch and moxibustion together in hot dog days
11317913|NCT02580682|No Intervention|controlled|patients in this group will not accept herbal patch or moxibustion therapy in these 3 years. After the 3-year experimental period they will be offered corresponding treatments for free as well, so they are in our wait list.
11372929|NCT02215031|Placebo Comparator|Placebo|
11317914|NCT02580669|Experimental|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
11317915|NCT02580669|Experimental|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
11317916|NCT02580669|Experimental|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
11317917|NCT02580656|Experimental|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
11317918|NCT02580643||APS Injection|Autologous Protein Solution
11317919|NCT02580630|Active Comparator|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.
~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.
~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
11317920|NCT02580630|Active Comparator|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.
~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.
~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
11317921|NCT02580617|Experimental|ALLO-ASC|Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells
11317922|NCT02580604|Experimental|Calcium Infusion|Continuous calcium infusion during exercise
11317923|NCT02580604|Placebo Comparator|Saline Infusion|Continuous saline infusion during exercise
11317924|NCT02580591|Experimental|Empagliflozin low dose|
11317925|NCT02580591|Experimental|Empagliflozin high dose|
11317926|NCT02580591|Experimental|Empagliflozin medium dose|
11317927|NCT02580591|Placebo Comparator|Placebo|
11317928|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
11317929|NCT02580552|Experimental|Part A, MF|Intratumoral Injection of cobomarsen
11317930|NCT02580552|Experimental|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
11317931|NCT02580552|Experimental|Part C, MF|Subcutaneous or intravenous administration of cobomarsen as monotherapy
11317932|NCT02580552|Experimental|Part D, CLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
11317933|NCT02580552|Experimental|Part E, DLBCL, activated B-cell (ABC) subtype|Subcutaneous or intravenous administration of cobomarsen as monotherapy
11317934|NCT02580552|Experimental|Part F, ATLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
11317935|NCT02580539|Experimental|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
11317936|NCT02580539|Experimental|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
11317937|NCT02580526|Active Comparator|V-E mask ventilation technique crossover C-E mask ventilation|
11317938|NCT02580526|Active Comparator|C-E mask ventilation technique crossover V-E mask ventilation|
11317939|NCT02580513|No Intervention|Control|3 days with normal circadian alignment.
11317940|NCT02580513|Experimental|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
11317941|NCT02580500|Active Comparator|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
11317942|NCT02580500|Active Comparator|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
11317943|NCT02580487||retrospective group|Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files
11317944|NCT02580487||Prospective group|Patients who were interviewed before and after surgery when they were at the hospital
11317945|NCT02580474|Experimental|Daclatasvir plus Asunaprevir|
11317946|NCT02580461|Experimental|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
11317947|NCT02580461|No Intervention|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
11317948|NCT02580448|Experimental|Female Triple Negative Breast Cancer Patients|TNBC Patients - Enrollment is complete in this cohort
11317949|NCT02580448|Experimental|Female Estrogen Receptor (+) Breast Cancer Patients|Female ER(+) BC Patients - Enrollment is complete in this cohort
11317950|NCT02580448|Experimental|Male Breast Cancer Patients|Locally advanced or metastatic males with BC
11317951|NCT02580409|Other|Single-arm studies|Behavioral Intervention
11317952|NCT02580396|Other|Patients eligible for CanADVICE+® (smart phone app)|
11318389|NCT02577484||Participants|Subjects who satisfy both general and angiographic inclusion/exclusion criteria, and who have the pressure measurement taken with the Navvus catheter.
11317953|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.
~When both needles were positioned inadequately for a facet joint."
11317954|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.
~when one of the needles for a facet joint medial branch was placed inadequately."
11317955|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.
~When all needles were placed adequately.'"
11317956|NCT02580370|Experimental|Dose A|Botulinum toxin type A
11317957|NCT02580370|Placebo Comparator|Dose B|Placebo comparator
11317958|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
11317959|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
11317960|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
11317961|NCT02580344|Other|Ibuprofen|
11317962|NCT02580331|Placebo Comparator|SRP and placebo|Oral prophylaxis followed by placement of placebo gel
11317963|NCT02580331|Active Comparator|SRP and 1% metformin|Oral prophylaxis followed by placement of 1% metformin gel
11317964|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
11317965|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
11317966|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
11317967|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
11317968|NCT02580279|Experimental|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
11317969|NCT02580279|Placebo Comparator|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
11317970|NCT02580253|Experimental|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
11317971|NCT02580253|Active Comparator|mFOLFOX6|Oxaliplatin (85 mg/m2 )+Fluorouracil (2800 mg/m2 ) q2w
11317972|NCT02580240|Placebo Comparator|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
11317973|NCT02580240|Experimental|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
11317974|NCT02580227|Active Comparator|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
11317975|NCT02580227|Placebo Comparator|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
11317976|NCT02580214|Experimental|Acerto|Preoperative immune nutrition for 5 days (Impact, Nestle) Preoperative fasting of 2h with a drink containing 12% maltodextrine No intravenous fluids postoperatively
11317977|NCT02580214|No Intervention|Control|No immune nutrition Preoperative fasting of 6-8 h Crystalloid intravenous fluids until PO day 1
11318009|NCT02580006|Experimental|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.
~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
11318010|NCT02579993|Experimental|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
11318390|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
11318391|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
11317978|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.
~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
11317979|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
11317980|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
11317981|NCT02580175|Active Comparator|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation
11317982|NCT02580175|Active Comparator|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
11317983|NCT02580162|Active Comparator|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
11317984|NCT02580162|Experimental|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
11317985|NCT02580162|Experimental|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
11317986|NCT02580162|Experimental|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
11317987|NCT02580149|Active Comparator|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
11317988|NCT02580149|Active Comparator|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
11317989|NCT02580123|Experimental|Experimental group|Received the intervention program.
11317990|NCT02580123|No Intervention|Control group|received the standard care
11317991|NCT02580110|Experimental|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
11317992|NCT02580110|Experimental|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
11317993|NCT02580110|Experimental|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
11317994|NCT02580097||Stroke|Ischemic stroke patients with sympton onset in 48 hours and no contradiction to MRI scan
11317995|NCT02580084|Active Comparator|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
11317996|NCT02580084|Experimental|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
11317997|NCT02580071|Experimental|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:
~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
11317998|NCT02580071|No Intervention|Control|Control group will receive standard of care
11317999|NCT02580058|Experimental|avelumab|Arm A: avelumab alone
11318000|NCT02580058|Experimental|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
11318001|NCT02580058|Active Comparator|PLD|Arm C: PLD alone
11318002|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
11318003|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
11318004|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
11318005|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
11318006|NCT02580019|No Intervention|conventional stroke treatment|Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation
11318007|NCT02580019|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation
11318008|NCT02580006|Experimental|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.
~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
11318260|NCT02578407|Experimental|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
11318011|NCT02579980|Experimental|DCE and DWI MRI group|Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.
11318012|NCT02579967|Experimental|1/IOC Arm-Closed with amendment L|Immunosuppression Only Conditioning Arm
11318013|NCT02579967|Experimental|2/RIC Arm|Reduced Intensity Conditioning Arm
11318014|NCT02579967|Experimental|3/MAC Arm-Closed with amendment L|Myeloablative Conditioning Arm
11318015|NCT02579967|Experimental|4/RIC-MMF Arm|Reduced Intensity Conditioning with MMF duration de-escalation design
11318016|NCT02579954|No Intervention|control group|
11318017|NCT02579954|Experimental|intervention|Rehabilitation
11318018|NCT02579941|Experimental|Pregnant women at term, vaginal childbirth|
11318019|NCT02579941|Experimental|Pregnant women at term, cesarean delivery|
11318020|NCT02579941|Experimental|Female volunteers, age 18 to 40|
11318021|NCT02579928|Experimental|Ketamine|Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
11318022|NCT02579928|Experimental|Midazolam|Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),
11318023|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
11318024|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
11318025|NCT02579902|Active Comparator|Vitamin D3|50000 IU vitamin D3 capsule, one capsule every 2 weeks for 6 months.
11318026|NCT02579902|Placebo Comparator|placebo|Placebo capsule, one capsule every 2 weeks for 6 months.
11318027|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
11318028|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
11318029|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
11318030|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
11318031|NCT02579863|Experimental|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
11318032|NCT02579863|Active Comparator|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
11318033|NCT02579850|Experimental|CHF 5993 + Ultibro matched placebo|"Fixed triple therapy with BDP/FF/GB 100/6/12.5 mcg (CHF 5993) administered 2 puffs twice daily via pMDI + Fixed combination of indacaterol and of glycopyrronium (Ultibro® Breezhaler®) matched placebo administered once daily via DPI for 52-week treatment.
~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.
~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments Saint George's Respiratory Questionnaire EXACT-pro questionnaire"
11318034|NCT02579850|Active Comparator|Ultibro + CHF 5993 matched placebo|"Fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg (Ultibro® Breezhaler®) administered once daily via DPI + Fixed triple therapy with BDP/FF/GB (CHF 5993) matched placebo administered 2 puffs twice daily via pMDI for 52-week treatment.
~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.
~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments, Saint George's Respiratory Questionnaire, EXACT-pro questionnaire"
11318035|NCT02579837|No Intervention|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
11318036|NCT02579837|Experimental|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.
~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
11318037|NCT02579824|Experimental|DS-3032b|"Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.
~Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase."
11318038|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
11318039|NCT02579798|Experimental|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
11318040|NCT02579798|Active Comparator|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
11318041|NCT02579785|Experimental|mhealth intervention|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number. Also receives Mobile phone based intervention for post-abortion contraceptive uptake.
11318042|NCT02579785|No Intervention|Standard Care|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number.
11318043|NCT02579772|Active Comparator|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
11318044|NCT02579772|Placebo Comparator|Placebo|Treatment with placebo pills
11318045|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
11318046|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
11318047|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
11318048|NCT02579746|Experimental|intervention|The intervention group received usual care plus the DASHNa-CC intervention.
11318049|NCT02579746|Active Comparator|control|The control group received usual care.
11318050|NCT02579733|Active Comparator|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
11318051|NCT02579733|Placebo Comparator|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
11318052|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
11318053|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
11318054|NCT02579707|Active Comparator|Treatment A: Unfed|Treatment A: Single oral dose of AG-120 at Hour 0 on Day 1, following a 10-hour overnight fast.
11318055|NCT02579707|Active Comparator|Treatment B: Fed|Treatment B: Single oral dose of AG-120 at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
11318056|NCT02579707|Experimental|Part 2 Single Dose|PART 2 is an open-label study to determine the safety and PK parameters of a single 1000-mg oral dose of AG-120.
11318057|NCT02579681|Experimental|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
11318058|NCT02579668|Experimental|Language therapy in BSL|Working with Deaf practitioners to provide language activities in British Sign Language aimed at developing children's language skills.
11318059|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
11318060|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
11318061|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
11318062|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
11318063|NCT02579642|Placebo Comparator|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
11318064|NCT02579642|Experimental|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
11318065|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
11318066|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
11318067|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
11318068|NCT02579616|Experimental|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
11318069|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
11318070|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
11318071|NCT02579590||DEMPA group|This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
11318072|NCT02579590||Implanon group|"This group are using Implanon  (etonogestrel implant) 68 mg implant for 6-12 month"
11318073|NCT02579590||Cerazette group|This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
11318074|NCT02579590||Normal healthy group|Those women not using any method of contraception
11318075|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
11318261|NCT02578394|Active Comparator|Group A|Anakinra 100mg and Placebo Depo-Medrone
11318262|NCT02578394|Active Comparator|Group B|Depo-Medrone 120mg and Placebo (Anakinra)
11318076|NCT02579564|Experimental|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
11318077|NCT02579564|Active Comparator|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
11318078|NCT02579551|Experimental|Treatment (surgical excision)|Patients undergo surgical excision of the skin lesion consisting of 1 and 2 mm circumferential margins during visit 1.
11318079|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
11318080|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
11318081|NCT02579525|Experimental|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
11318082|NCT02579525|Active Comparator|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
11318083|NCT02579512||Extra-corporeal ECG Signal Analysis|
11318084|NCT02579499|Active Comparator|Fixed high-potent statin group|According to 2013 ACC/AHA guideline, patients will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels.
11318085|NCT02579499|Experimental|Targeted LDL-C goal statin group|Patients will be tiltrated statin intensity guided by follow-up LDL-C level
11318086|NCT02579473|Experimental|Cohort 0|"Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
11318087|NCT02579473|Experimental|Cohort 1|"Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
11318088|NCT02579473|Experimental|Cohort 2|"Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
11318089|NCT02579473|Experimental|Cohort 3|"Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal wash-out PK of rotigotine and pro-drug SER-214."
11318090|NCT02579460|Experimental|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
11318091|NCT02579434|Experimental|Male young adults|Arm 1: Male healthy volunteers aged from 20 to 45 years Midazolam (IV) on day 1
11318092|NCT02579434|Experimental|Male elderly adults|Arm 2: Male healthy volunteers aged over 45 years Midazolam (IV) on day 1
11318093|NCT02579434|Experimental|Female elderly adults|Arm 3: Female healthy volunteers aged over 45 years Midazolam (IV) on day 1
11318094|NCT02579434|Experimental|Female young adults|Arm 4: Female healthy volunteers aged 20 to 45 years Midazolam (IV) on day 1, Day 15
11318095|NCT02579421|Active Comparator|Males - Progesterone|200 mg progesterone BID
11318096|NCT02579421|Placebo Comparator|Males - Placebo|placebo BID
11318097|NCT02579421|Active Comparator|Females - Progesterone|200 mg progesterone BID
11318098|NCT02579421|Placebo Comparator|Females - Placebo|placebo BID
11318099|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
11318100|NCT02579395|Experimental|With spouse/romantic partner|
11318101|NCT02579395|Experimental|Without spouse/romantic partner|
11318102|NCT02579395|Other|Control|No Intervention
11318103|NCT02579382|Placebo Comparator|TDF + placebo|"Main Study Phase: Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily for up to 48 weeks + placebo administered orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
11318104|NCT02579382|Experimental|TDF + Vesatolimod 1 mg|"Main Study Phase:TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 1 mg tablet orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
11318105|NCT02579382|Experimental|TDF + Vesatolimod 2 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 2 mg tablet orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
11318106|NCT02579382|Experimental|TDF + Vesatolimod 4 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 4 mg tablet orally once a week (every 7 days) for 12 doses.
~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
11318107|NCT02579369|Experimental|ALLO-ASC-DFU|
11318108|NCT02579369|Active Comparator|Conventional Therapy|
11318109|NCT02579356|Experimental|Part1-A|The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
11318110|NCT02579356|Experimental|Part1-B|The Part1-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan once a day for 6 days in period 2.
11318111|NCT02579356|Experimental|Part2-A|The Part2-A of groups take Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
11318112|NCT02579356|Experimental|Part2-B|The Part2-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Atorvastatin once a day for 6 days in period 2.
11318263|NCT02578381|Experimental|Boston Scientific PW versus St Jude PW|Performance of Boston Scientific PW vs St Jude PW
11318113|NCT02579343|Experimental|Auricular Acupuncture + Lexipro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
11318114|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
11318115|NCT02579330|Experimental|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
11318116|NCT02579330|Sham Comparator|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
11318117|NCT02579317|Experimental|Resonance Breathing|Breathing is paced to the cardiovascular resonance frequency where heart, respiratory, and brain signals become aligned. This can potentially positively impact cognitive-emotional functioning.
11318118|NCT02579317|Placebo Comparator|Non-Resonance Breathing|Breathing is paced at a non-resonance frequency. It does not align heart, respiratory, and brain signals, and thus does not impact cognitive-emotional functioning.
11318119|NCT02579291|Experimental|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
11318120|NCT02579291|Active Comparator|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
11318121|NCT02579278||mrEMVI positive rectal tumours|20 patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).
11318122|NCT02579278||mrEMVI negative rectal tumours|20 patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.
11318123|NCT02579265|Experimental|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
11318124|NCT02579265|Active Comparator|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
11318125|NCT02579252|Experimental|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.
~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
11318126|NCT02579252|Placebo Comparator|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
11318127|NCT02579239|Experimental|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
11318128|NCT02579239|Placebo Comparator|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
11318129|NCT02579226|Experimental|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
11318130|NCT02579226|Experimental|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
11318131|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
11318132|NCT02579200|Active Comparator|Inspiratory Muscle Training (IMT)|POWERbreathe®KHA (IMT group)
11318133|NCT02579200|Sham Comparator|Sham Training|POWERbreathe®KH2 (sham group)
11318134|NCT02579187|Placebo Comparator|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
11318135|NCT02579187|Active Comparator|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
11318136|NCT02579187|Active Comparator|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
11318137|NCT02579187|Active Comparator|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
11318138|NCT02579174|Other|Manual (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for both the tibia component and the femur component
11318139|NCT02579174|Other|Manual (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for the tibia component and custom instrumentation for the femur component
11318140|NCT02579174|Other|Custom (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for both the tibia component and the femur component
11318141|NCT02579174|Other|Custom (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for the tibia component and manual instrumentation for the femur component
11318142|NCT02579161|Active Comparator|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period
~Intervention drug to be determined based on patient history etc."
11318143|NCT02579161|Active Comparator|Continued antibiotics|"Continued antibiotics until the removal of any external catheters
~Intervention drug to be determined based on patient history etc."
11318144|NCT02579148|Experimental|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
11318145|NCT02579148|Experimental|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
11318146|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
11318147|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
11318148|NCT02579109|Other|autistic patient|patient with autistic trouble
11318149|NCT02579109|Other|healthy volunteers|healthy volunteers
11318150|NCT02579096|Active Comparator|Allopurinol|Patients will be titrated up to the dose that will lower to target uric acid levels.
11318151|NCT02579096|Sham Comparator|Placebo (Febuxostat)|Placebo in the shape of Febuxostat will be given with allopurinol
11318152|NCT02579096|Active Comparator|Febuxostat|Febuxostat will be titrated up to the dose that will lower to target uric acid levels.
11318153|NCT02579096|Sham Comparator|Placebo (Allopurinol)|Placebo in the shape of Allopurinol will be given with Febuxostat
11318154|NCT02579083|Experimental|Segment A: Single MB66 Administration|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
11318155|NCT02579083|Placebo Comparator|Segment B: Repeated Administrations Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
11318156|NCT02579083|Experimental|Segment B: Repeated Administrations MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
11318157|NCT02579070|Experimental|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
11318158|NCT02579070|Placebo Comparator|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
11318159|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
11318160|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
11318161|NCT02579044|Other|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
11318162|NCT02579031|Active Comparator|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
11318163|NCT02579031|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
11318164|NCT02579018|Experimental|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
11318165|NCT02579018|Experimental|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
11318166|NCT02579018|Experimental|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
11318167|NCT02579005|Experimental|Patients with a living donor|Radiation + PBMC
11318168|NCT02579005|Experimental|Patients with a UCB donor|Radiation + UCB
11318169|NCT02578992|Experimental|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
11318170|NCT02578992|No Intervention|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
11318171|NCT02578979|Experimental|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
11318172|NCT02578979|Active Comparator|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
11318264|NCT02578381|Experimental|Boston Sci PW vs Boston Sci PW|Boston Sci PW vs Boston Sci PW
11318265|NCT02578381|Active Comparator|St Jude PW versus St Jude PW|Performance of St Jude PW vs St Jude PW
11318173|NCT02578966|Experimental|Motivational Interview|INTERVENTION GROUP: in this group, composed of 6 UBS, the children and their respective mothers/fathers/responsible adults will be attended by the dentists at least once a year with an approach based on the Motivational Interview.
11318174|NCT02578966|Active Comparator|Traditional health education|CONTROL GROUP: in this group, composed of 6 UBS, the children and their respective mother/fathers/responsible adults will be attended by the dentists at least once a year based on the recommendations by the Brazilian Ministry of Health (BRASIL,2008-a) and on SSC-GHC's protocol (BRASIL, 2008-b). Additionally, the professional guidance script and the parents' booklet of SSC-GHC's oral health Program may be used.
11318175|NCT02578953|Experimental|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
11318176|NCT02578953|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
11318177|NCT02578940|Experimental|Single arm|Single intravenous administration of 18F-Fluciclovine for PET Scan
11318178|NCT02578927|Experimental|GT+Ex|Ingestion of one dose of 2 g of green tea (GT) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
11318179|NCT02578927|Placebo Comparator|PL+Ex|Ingestion of one dose 2 g of placebo (PL) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
11318180|NCT02578927|Active Comparator|Green Tea|Ingestion of one dose 2g of green tea (GT) at 10 minutes after the period of rest. In this section the volunteers does not practice aerobic exercise.
11318181|NCT02578914|Experimental|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
11318182|NCT02578914|Sham Comparator|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
11318183|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
11318184|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
11318185|NCT02578888|Active Comparator|Palliative Therapy|EORTCQLQ-30 and FAMCARE questionnaire every 6 weeks for 3 visits.
11318186|NCT02578888|Experimental|Palliative Therapy+ idiographic|EORTC QLQ-30, and FAMCARE questionnaire every 6 weeks for 3 visits plus patients undergo idiographic assessment.
11318187|NCT02578875||Sample|Discarded patient samples and autopsy material
11318188|NCT02578862|Experimental|Total Intravenous|Intravenous propofol for maintenance of anesthesia
11318189|NCT02578862|Active Comparator|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
11318190|NCT02578849||PD_no_LID|Patients with Parkinson´s disease without dyskinesia
11318191|NCT02578849||PD_LID|Patients with Parkinson´s disease with L-DOPA induced dyskinesia
11318192|NCT02578849||HC|Health controls, age-mathced.
11318193|NCT02578836|Experimental|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
11318194|NCT02578823|Experimental|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.
~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).
~A total of 40 participants will be enrolled."
11318195|NCT02578823|Active Comparator|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).
~A total of 20 participants will be enrolled."
11318196|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
11318197|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
11318198|NCT02578797|Experimental|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
11318199|NCT02578784|Placebo Comparator|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
11318200|NCT02578784|Active Comparator|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
11318201|NCT02578771|Experimental|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
11318202|NCT02578771|Experimental|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
11318203|NCT02578771|Active Comparator|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep [Chlorhexidine gluconate(CHG)/IPA] Teal Tint
11318204|NCT02578771|Placebo Comparator|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
11318205|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
11318206|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
11318207|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
11318208|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
11318209|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
11318210|NCT02578732|Experimental|FOLFOXA|"Schema:
~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**
~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment
~Antiemetics will be administered as per standard institutional policy."
11318211|NCT02578719|Placebo Comparator|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
11318212|NCT02578719|Placebo Comparator|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
11318213|NCT02578706|Active Comparator|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
11318214|NCT02578706|Active Comparator|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
11318215|NCT02578706|Placebo Comparator|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
11318216|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
11318217|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.
11318218|NCT02578667|No Intervention|Gorbly Compression not needed|
11318219|NCT02578667|Experimental|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
11318220|NCT02578654|Experimental|Interventions|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
11318221|NCT02578641|Experimental|Arm A|"4 cycles* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.
~*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion.
~As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days"
11318222|NCT02578641|Active Comparator|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
11318223|NCT02578628|Active Comparator|Active|These subjects will continue to receive Patient Engagement services.
11318224|NCT02578628|No Intervention|Control|These patients will have all Patient Engagement services discontinued.
11318225|NCT02578602|Experimental|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
11318226|NCT02578589|Active Comparator|surgery|
11318227|NCT02578589|Active Comparator|Conservative treatment|
11318228|NCT02578576||patients with flare-up|Disease flare-up is demonstrated by coloscopy at one month after resection.
11318229|NCT02578576||patients without flare-up|No flare-up is found by coloscopy at one month after resection.
11318230|NCT02578550|Experimental|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
11318231|NCT02578550|Experimental|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
11318232|NCT02578537|Experimental|Ticagrelor group|ticagrelor 180mg loading, followed by 90mg bid for 30 days
11318233|NCT02578537|Active Comparator|Clopidogrel group|clopidogrel 600mg loading, followed by 75mg/d for 30 days
11318234|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
11318235|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
11318236|NCT02578511|Experimental|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.
~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
11318237|NCT02578498|Placebo Comparator|High carbohydrate diet|high carbohydrate intake
11318238|NCT02578498|Active Comparator|Low carbohydrate diet|low carbohydrate intake
11318239|NCT02578485|Experimental|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
11318240|NCT02578485|Active Comparator|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
11318241|NCT02578485|Placebo Comparator|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
11318242|NCT02578485|Placebo Comparator|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
11318243|NCT02578485|Sham Comparator|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
11318244|NCT02578472|Experimental|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
11318245|NCT02578472|Experimental|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
11318246|NCT02578472|Experimental|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
11318247|NCT02578472|Experimental|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
11318248|NCT02578472|Experimental|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
11318249|NCT02578472|Experimental|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
11318250|NCT02578459|Experimental|Intrathecal Drug Delivery (ITDD)|These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain.
11318251|NCT02578459|Active Comparator|Conventional Medical Management (CMM)|These subjects will be treated with conventional medical management to treat their pain.
11318252|NCT02578446|Experimental|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
11318253|NCT02578446|Active Comparator|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
11318254|NCT02578433|Experimental|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
11318255|NCT02578433|Other|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
11318256|NCT02578420|Placebo Comparator|open-label placebo|"Participants (N=40) will have the information that they are receiving an inert cream (i.e. placebo). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes. The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary."
11318257|NCT02578420|Sham Comparator|deceptive placebo|"Participants (N=40) will have the information that they are receiving an analgesic cream (Antidolor, containing Lidocain), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream."
11318258|NCT02578420|Placebo Comparator|control group|Participants (N=40) will have the information that they are receiving an inert control cream.
11318259|NCT02578420|No Intervention|no treatment group|"Participants (N=40) will be told that they are in the no treatment group and that they will not receive an analgesic cream."
11372930|NCT02215018|Experimental|BI 44370 TA solution|
11318266|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP
~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).
~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.
~For HER-2 positive disease, trastuzumab should be added:
~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
11318267|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)
~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).
~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.
~For HER-2 positive disease, trastuzumab should be added:
~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
11318268|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
11318269|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
11318270|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
11318271|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
11318272|NCT02578329|Experimental|Med Diet|Intensively advised Mediterranean diet
11318273|NCT02578329|Active Comparator|Low Fat diet|usual low-fat dietary advice
11318274|NCT02578316|Experimental|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
11318275|NCT02578303|Experimental|Dementia group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).
~ROC method will be used to find a threshold value of IAH that separates the two groups.
~Interventions:
~Vascular flow measurement by PC-MRI
~Neuropsychological assessment
~Registration of sleep apnea
~Registration of blood pressure
~ECG holters
~Blood test
~Geriatric standard evaluation"
11318276|NCT02578303|Other|control group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).
~ROC method will be used to find a threshold value of IAH that separates the two groups.
~Interventions:
~Vascular flow measurement by PC-MRI
~Neuropsychological assessment
~Registration of sleep apnea
~Registration of blood pressure
~ECG holters
~Blood test
~Geriatric standard evaluation"
11318277|NCT02578290|Experimental|Treatment|Clinical Decision Support (CDS)
11318278|NCT02578290|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
11318279|NCT02578277|Experimental|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
11318280|NCT02578264||All participants|All subjects enrolled in the study will provide tumor and normal tissue and blood samples.
11318281|NCT02578251|Experimental|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
11318282|NCT02578251|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
11318283|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
11318284|NCT02578212|Placebo Comparator|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
11318285|NCT02578212|Sham Comparator|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
11318286|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
11318287|NCT02578186|Experimental|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
11318288|NCT02578186|Placebo Comparator|Placebo|Placebo elixir taken when subjects had trouble falling asleep
11318289|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
11318290|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
11318291|NCT02578160|Experimental|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
11318292|NCT02578160|Active Comparator|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
11318361|NCT02577705|No Intervention|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
11318293|NCT02578147|Experimental|Mighty Girls|Girls in this group complete 3 different activities after school: 6 classroom sessions, 4 DRAMA-RAMA game play sessions, and 4 short game experience surveys. Classroom sessions are 1 hour long, 3 days a week for 2 weeks. Topics include: goal setting, choices and their effects; defining what makes a behavior risky; learning how to not get talked into doing risky things by friends (e.g., going to a party at a house where parents are not home); and learning to be critical of TV shows and other media that make it seem like lots of teens are having sex. These sessions teach girls skills and strategies that help them score game points in DRAMA-RAMA. These are important skills and strategies that they can use in everyday life to make wise choices. Classroom sessions are designed to be fun.
11318294|NCT02578147|Active Comparator|Game Girls|Girls in this group take part in activities that can be done from home or anywhere they have Wi-Fi access: 4 Science Valley game play sessions and 4 short game experience surveys. Science Valley is a web based game in which girls explore a virtual world and experiment with objects in this world using a computer, tablet or cell phone. Girls will play this game for about 20-30 minutes. There are no classroom sessions required to be able to play Science Valley. Science Valley is designed to be fun and to give girls a chance to build skills important to doing well in school: her problem solving and critical thinking skills. Girls will be given a link to use to access Science Valley on the internet. At the end of the game, they do a short game experience survey that asks questions about how easy, how hard, how fun etc. it was to play Science Valley. This survey will appear on the screen at the end of the Science Valley game play session.
11318295|NCT02578134|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
11318296|NCT02578134|Sham Comparator|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
11318297|NCT02578121|Experimental|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
11318298|NCT02578108|Active Comparator|no diagnostic genicular nerve blocks|no diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
11318299|NCT02578108|Active Comparator|diagnostic genicular nerve blocks|Set of diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
11318300|NCT02578095|Placebo Comparator|Placebo|Placebo QD
11318301|NCT02578095|Experimental|VK5211- 0.5mg|0.5mgQD
11318302|NCT02578095|Experimental|VK5211- 1.0mg|1.0mg QD
11318303|NCT02578095|Experimental|VK5211- 2.0mg|2.0mg QD
11318304|NCT02578082|Experimental|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR <30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
11318305|NCT02578082|Experimental|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.
~Intervention is TD-4208, 175mcg, inhaled, single dose."
11318306|NCT02578069|Experimental|Experimental|NOVA Intracranial sirolimus eluting stent system
11318307|NCT02578069|Active Comparator|Control|Apollo Intracranial stent system
11318308|NCT02578056|Experimental|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
11318309|NCT02578056|Sham Comparator|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
11318310|NCT02578043|Experimental|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
11318311|NCT02578043|Active Comparator|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
11318312|NCT02578043|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
11318313|NCT02578030|Experimental|SHP465 12.5 mg|A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
11318314|NCT02578030|Experimental|SHP465 25 mg|A single dose of SHP465 25 mg for Subjects aged 13-17 years
11318315|NCT02578017|Experimental|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
11318316|NCT02578017|No Intervention|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
11318317|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
11318318|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
11318319|NCT02577991|No Intervention|Control group|No steroid
11318320|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
11318321|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
11318322|NCT02577978|Other|Medacta Sphere|Ball-and-socket
11318323|NCT02577978|Other|Medacta PS|Cam-and-post
11318324|NCT02577965|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
11318325|NCT02577965|Active Comparator|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
11318326|NCT02577952||People with Lipodystrophy & family|People currently living with lipodystrophy and their family members.
11318327|NCT02577939|Experimental|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
11318328|NCT02577926|Experimental|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
11318329|NCT02577926|Active Comparator|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
11318330|NCT02577913||FC patch low|Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
11318331|NCT02577913||LNG-COC|Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol
11318332|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
11318333|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
11318334|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
11318335|NCT02577874||Chinese Subjects|7 blood glucose tests taken over a two hour period
11318336|NCT02577874||European Subjects|7 blood glucose tests taken over a two hour period
11318337|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
11318338|NCT02577848|Experimental|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
11318339|NCT02577848|Placebo Comparator|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
11318340|NCT02577835||Hypertensive patients|No intervention. Patients will be sumbitted to standard tests required for hypertension management, including ambulatory blood pressure monitoring, and pharmacologically treated according to recommendations of international guidelines. The registry will include data from subjects fulfilling the inclusion criteria and whose data are contained in existing databases collected by the participating centers and who are regularly followed-up at the center. New subjects can be enrolled for this project, but they must be submitted to ambualtory blood pressure monitoring because it is required for evaluating their hypertension status, according to current recommendations.
11318341|NCT02577822|Other|Short Stem Group|Short femoral stem
11318342|NCT02577822|Other|Long Stem Group|standard-length stem
11318343|NCT02577809|Active Comparator|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
11318344|NCT02577809|Active Comparator|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
11318345|NCT02577809|Active Comparator|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
11318346|NCT02577783|Experimental|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
11318347|NCT02577783|Active Comparator|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
11318348|NCT02577770|Experimental|200mg caffeine plus acupuncture|In healthy subjects
11318349|NCT02577770|Experimental|400mg caffeine plus acupuncture|In healthy subjects
11318350|NCT02577770|Placebo Comparator|Decaffeinated plus acupuncture|In healthy subjects
11318351|NCT02577757|Other|healthy volunteers|achieving functional MRI
11318352|NCT02577757|Experimental|Eligible patients with awakened surgery|achieving functional MRI
11318353|NCT02577744|Active Comparator|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
11318354|NCT02577744|Active Comparator|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
11318355|NCT02577731|Other|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
11318356|NCT02577731|Other|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
11318357|NCT02577731|Other|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
11318358|NCT02577718|Experimental|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
11318359|NCT02577705|Experimental|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
11318360|NCT02577705|Experimental|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
11318364|NCT02577666|Experimental|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
11318365|NCT02577666|Experimental|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
11318366|NCT02577666|Other|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
11318367|NCT02577653|Other|subjects|participant undergoing posturographic evaluation
11318368|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
11318369|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
11318370|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
11318371|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
11318372|NCT02577614|Experimental|FEIBA|Single dose of commercially available FEIBA
11318373|NCT02577614|Placebo Comparator|Normal Saline|Single dose of NaCl 0.9%
11318374|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
11318375|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
11318376|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
11318377|NCT02577588|Experimental|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
11318378|NCT02577575|Experimental|Oxytocin|40 IU Oxytocin
11318379|NCT02577575|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
11318380|NCT02577549|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
11318381|NCT02577549|Active Comparator|Attention Control|The attention control intervention will cover an 18-month period. There will be four total face to face group meetings over the 18 months, with one meeting each at months 1, 6, 12, and 18; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
11318382|NCT02577536||1 All Subjects|No interventions
11318383|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours
11318384|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours
11318385|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
11318386|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
11318387|NCT02577497|Experimental|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
11318388|NCT02577497|Experimental|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
11318392|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
11318394|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
11318395|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.
~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.
~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.
~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
11318396|NCT02577432|Active Comparator|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
11318397|NCT02577432|Active Comparator|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
11318398|NCT02577419|Experimental|Target Fortification|
11318399|NCT02577419|Experimental|Higher Initial Concentration|
11318400|NCT02577419|Active Comparator|Portagen Growth Reference|
11318401|NCT02577406|Experimental|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
11318402|NCT02577406|Active Comparator|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
11318403|NCT02577393|Experimental|prophylactic EGCG group|
11318404|NCT02577393|Experimental|therapeutic EGCG group|
11318405|NCT02577393|Placebo Comparator|conventional therapy group|
11318406|NCT02577380|Experimental|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
11318407|NCT02577380|No Intervention|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
11318408|NCT02577367|Experimental|Levothyroxine on empty stomach|Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
11318409|NCT02577367|Active Comparator|Levothyroxine during feeding|Levothyroxine will be given while the enteral feeding is running
11318410|NCT02577354|Experimental|Treatment|
11318411|NCT02577354|Experimental|Control|
11318412|NCT02577341|Experimental|Nimotuzumab|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.
11318413|NCT02577341|Active Comparator|Control|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.
11318414|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
11318415|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
11318416|NCT02577302|Experimental|CAN-Stim Group - CAN-Stim System|"Intervention: tibial medical device
~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
11318417|NCT02577302|Active Comparator|SNS Group - Interstim® System|"Intervention: SNS Medical device
~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
11318418|NCT02577289|Active Comparator|Control group ( Hydroxyappetite)|Patients will undergo open sinus lift using nano crystalline hydroxyapatite as augmentation material and placing implants simultaneously then evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
11318419|NCT02577289|Experimental|Test group (PRF)|Patients will undergo open sinus lift using PRF as sole augmentation material and placing implants simultaneously then Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
11318420|NCT02577276|Experimental|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
11318421|NCT02577250|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
11318422|NCT02577237|Experimental|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
11318423|NCT02577237|Active Comparator|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
11318456|NCT02577029|Experimental|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
11318499|NCT02576782|Active Comparator|systemic dexamethasone group|21 patients received systemic (intravenous) dexamethasone plus perineural bupivacaine 0.5%
11319093|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
11318424|NCT02577224|Experimental|Intervention|Participants randomized to the intervention group (patient-initiated treatment) will be asked to initiate their own treatment during the nine months they are taking part in the trial. Intervention group participants will receive information about when and how to initiate an appointment. Contact details for the service will be provided along with information on how quickly an appointment will be made, with whom and the procedure in the case of an emergency. All patients requesting an appointment will be booked in to the next available slot within the twice weekly ring-fenced nurse-led clinics. Any subsequent scheduled appointments will be cancelled and all future treatment will be initiated by the patient.
11318425|NCT02577224|No Intervention|Control|Participants in the control group will receive treatment as usual. This consists of scheduled appointments in the hospital-based nurse-led botulinum toxin clinic. The frequency with which these appointments takes place are based on clinical judgement, but tend to range between every 6 weeks to every 4 months.
11318426|NCT02577211|Experimental|Hipocaloric enteral nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
11318427|NCT02577211|Active Comparator|Normocaloric enteral nutrition|25 kcal per kg of body weight and 1.7 grams of protein per kg.
11318428|NCT02577198|Experimental|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
11318429|NCT02577198|Other|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
11318430|NCT02577185|Experimental|botulinum toxin type A|Experimental drug
11318431|NCT02577185|Placebo Comparator|sodium chloride 9 mg/ml|Vehicle drug
11318432|NCT02577172|Experimental|Exercise group|Aerobic- and Strength Training program
11318433|NCT02577172|Active Comparator|Control group|One lifestyle counseling session
11318434|NCT02577159|Experimental|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
11318435|NCT02577146|Experimental|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
11318436|NCT02577133|Active Comparator|Lactobacillus reuteri group|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
11318437|NCT02577133|Placebo Comparator|Placebo group|Placebo (5 drops) for 28 days
11318438|NCT02577120||Low TEWL|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.
11318439|NCT02577120||High TEWL - No treatment|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
11318440|NCT02577120||High TEWL - Epiceram skin barrier function|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
11318441|NCT02577120||High TEWL - Ceramiseal|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site
11318442|NCT02577120||High TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
11318443|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
11318444|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
11318445|NCT02577081|Experimental|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
11318446|NCT02577068|Active Comparator|nefopam group|
11318447|NCT02577068|Active Comparator|propacetamol group|
11318448|NCT02577068|Experimental|nefopam and propacetamol group|
11318449|NCT02577055|Active Comparator|myomectomy|Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
11318450|NCT02577055|Experimental|embolisation|Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)
11318451|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
11318452|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
11318453|NCT02577029|Experimental|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous [IV]) every 4 weeks for 48 weeks (13 doses)."
11318454|NCT02577029|Experimental|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
11318455|NCT02577029|Experimental|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
11318495|NCT02576808|Experimental|Ginger extract|Drug
11318496|NCT02576808|Active Comparator|Loratadine|Drug
11318497|NCT02576795|Experimental|BMN 270|BMN 270 is administered as a single IV Infusion.
11372931|NCT02215018|Experimental|BI 44370 TA tablet|
11318457|NCT02577029|Experimental|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
11318458|NCT02577029|Experimental|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
11318459|NCT02577029|Experimental|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
11318460|NCT02577029|Experimental|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
11318461|NCT02577016|Experimental|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
11318462|NCT02577016|Active Comparator|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
11318463|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
11318464|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
11318465|NCT02576990|Experimental|Pembrolizumab: rrPMBCL|Participants with rrPMBCL receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to a maximum of 35 administrations (approximately 2 years).
11318466|NCT02576990|Experimental|Pembrolizumab: rrRS|Participants with rrRS receive pembrolizumab 200 mg IV Q3W for up to a maximum of 35 administrations (approximately 2 years). Effective with Protocol Amendment 04, enrollment into this cohort was closed.
11318467|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
11318468|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
11318469|NCT02576964|Experimental|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared [mg/m^2] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous [SC] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
11318470|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
11318471|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
11318472|NCT02576951|Experimental|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
11318473|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
11318474|NCT02576938|Experimental|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks
~(Triamcinolone 0.1% topical also permitted)"
11318475|NCT02576938|Placebo Comparator|Placebo|"Administered orally once daily, for 16 weeks
~(Triamcinolone 0.1% topical also permitted)"
11318476|NCT02576925||Eligible patients|Adults having had a transient diplopia during the last 8 days.
11318477|NCT02576912|Experimental|Active Delta-9-THC and Placebo Pregnenolone|
11318478|NCT02576912|Experimental|Active Delta-9-THC and Active Pregnenolone|
11318479|NCT02576912|Experimental|Placebo Delta-9-THC and Active Pregnenolone|
11318480|NCT02576912|Placebo Comparator|Placebo Delta-9-THC and Placebo Pregnenolone|
11318481|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
11318482|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
11318483|NCT02576886|Experimental|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
11318484|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
11318485|NCT02576860|Experimental|Treatment|CLS001 (Omignan) gel applied once daily
11318486|NCT02576860|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
11318487|NCT02576847|Experimental|Treatment|Omiganan gel applied once daily
11318488|NCT02576834|Experimental|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
11318489|NCT02576834|Other|Services as Usual (SAU)|client receives services they would normally receive within the community
11318490|NCT02576821|Other|Patients with Hippocampal sclerosis non AD|Patients with Hippocampal sclerosis non AD (n=40)
11318491|NCT02576821|Other|Patients with Alhzeimer's Disase|Patients with Alhzeimer's Disase (n=40)
11318492|NCT02576821|Other|Patients with DLFT|Patients with DLFT (n=20)
11318493|NCT02576821|Other|Patients with CBD/PSP|Patients with CBD/PSP (n=20)
11318494|NCT02576821|Other|Normal controls|Normal controls (n=20)
11318500|NCT02576782|Sham Comparator|control group|21 patients received only perineural bupivacaine 0.5% plus intravenous saline
11318501|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
11318502|NCT02576756||with difficult intubation|Control population
11318503|NCT02576756||without difficult intubation|Control population
11318504|NCT02576743||Healthy subjects|Subjects with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning. 7 Tesla MRI
11318505|NCT02576743||Patients|Patients with an unruptured brain aneurysm or an unruptured arteriovenous malformation (AVM) with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning 7 Tesla MRI
11318506|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
11318507|NCT02576730||healthy subjects|patients without foot and ankle fracture s
11318508|NCT02576717|Experimental|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
11318509|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
11318510|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
11318511|NCT02576678|Experimental|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).
~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.
~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
11318512|NCT02576665|Experimental|Toca 511/Toca FC|"Toca 511: 14 mL intravenously daily for 3 days followed by up to 4 mL intratumorally or into resection cavity walls following biopsy or resection. Cutaneous melanoma patients may receive intralesional injections (up to 4 mL) daily for 5 days.
~Toca FC: 220 mg/kg/day orally starting at Week 5-6. Cycles are 5- to 7- day courses of treatment every 4 to 6 weeks."
11318513|NCT02576652|Other|Osteoarthritis Participants|Participants previously treated with denosumab and planning to undergo total hip replacement (THR) received one cycle of tetracycline administered at either 250 mg four times a day or 500 mg twice a day for 3 days and one cycle of demeclocycline administered at either 150 mg four times a day or 300 mg twice a day for 3 days, ten days after last dose of tetracycline in cycle 1. THR surgery was performed 5 to 42 days after the last dose of demeclocycline.
11318514|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
11318515|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
11318516|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
11318517|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
11318518|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
11318519|NCT02576626|Other|A|Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation
11318520|NCT02576626|Other|B|"Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.
~Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation"
11318521|NCT02576613|Experimental|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
11318522|NCT02576613|Experimental|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
11318523|NCT02576600|Experimental|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
11318524|NCT02576600|Sham Comparator|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
11318525|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.
~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
11318526|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
11318527|NCT02576574|Experimental|Arm A: Avelumab|
11318528|NCT02576574|Active Comparator|Arm B: Platinum-containing chemotherapy regimen|"Platinum-containing chemotherapy regimen: Investigator's choice platinum containing chemotherapy regimen to be administered consisting of one of the following:
~Non-squamous tumor histology
~Pemetrexed (500 milligram per meter square [mg/m^2]) +cisplatin (75 mg/m^2) or Pemetrexed (500 mg/m^2) + carboplatin (AUC 6 mg/mL*min)
~Squamous tumor histology
~Paclitaxel (200 mg/m^2) +carboplatin (AUC 6 mg/mL*min)
~Gemcitabine (1250 mg/m^2)+ cisplatin (75 mg/m^2)
~Gemcitabine (1000 mg/m^2 )+carboplatin (AUC 5 mg/mL*min)"
11318529|NCT02576574|Experimental|Arm C: Avelumab|
11318530|NCT02576561|Experimental|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml* GPI- 0100 (1:1 ratio)
11318531|NCT02576561|Active Comparator|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml* GPI- 0100 (1:1 ratio)
11318532|NCT02576561|Placebo Comparator|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
11318565|NCT02576457|Experimental|BMS-936559|BMS-936559 Intravenous infusion on specified days
11318533|NCT02576561|Experimental|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml* GPI- 0100 (1:1 ratio)
11318534|NCT02576561|Active Comparator|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml* GPI- 0100 (1:1 ratio)
11318535|NCT02576561|Placebo Comparator|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
11318536|NCT02576561|Experimental|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml* GPI- 0100 (1:1 ratio)
11318537|NCT02576561|Active Comparator|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml* GPI- 0100 (1:1 ratio)
11318538|NCT02576561|Placebo Comparator|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
11318539|NCT02576548|Experimental|MEDI4276 0.05 mg/kg|Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318540|NCT02576548|Experimental|MEDI4276 0.1 mg/kg|Participants received IV dose of 0.1 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318541|NCT02576548|Experimental|MEDI4276 0.2 mg/kg|Participants received IV dose of 0.2 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318542|NCT02576548|Experimental|MEDI4276 0.3 mg/kg|Participants received IV dose of 0.3 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318543|NCT02576548|Experimental|MEDI4276 0.4 mg/kg|Participants received IV dose of 0.4 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318544|NCT02576548|Experimental|MEDI4276 0.5 mg/kg|Participants received IV dose of 0.5 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318545|NCT02576548|Experimental|MEDI4276 0.6 mg/kg|Participants received IV dose of 0.6 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318546|NCT02576548|Experimental|MEDI4276 0.75 mg/kg|Participants received IV dose of 0.75 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318547|NCT02576548|Experimental|MEDI4276 0.9 mg/kg|Participants received IV dose of 0.9 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
11318548|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
11318549|NCT02576522|Experimental|brain metastatic patients|Patients with single, large brain metastases from solid tumors
11318550|NCT02576509|Experimental|Nivolumab|Nivolumab specified dose on specified days
11318551|NCT02576509|Active Comparator|Sorafenib|Sorafenib specified dose on specified days
11318552|NCT02576496|Experimental|Tinostamustine (EDO-S101)|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
11318553|NCT02576470|Experimental|Videofluoroscopy (VF) and Barium|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium to provide biofeedback for targeted dysphagia swallowing maneuver.
11318554|NCT02576470|Active Comparator|Surface Electromyography (sEMG)|This group will receive the following types of procedures during visits. sEMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
11318555|NCT02576470|Active Comparator|Mixed VF and sEMG|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium, and EMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
11318556|NCT02576470|Experimental|VF with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
11318557|NCT02576470|Experimental|sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with anodal transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
11318558|NCT02576470|Experimental|Mixed VF, sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
11318559|NCT02576470|Sham Comparator|VF with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images without the transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
11318560|NCT02576470|Sham Comparator|sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images without the transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
11318561|NCT02576470|Sham Comparator|Mixed VF, sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images without transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
11318562|NCT02576470|Experimental|VF with reward|This group will receive the following the procedure outlined below for biofeedback. The biofeedback is based on the videofluoroscopy (VF) and Barium with financial reward.
11318563|NCT02576470|Experimental|sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3-days.
11318564|NCT02576470|Experimental|Mixed VF, sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3 days.
11318567|NCT02576444|Experimental|Group 1|Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
11318568|NCT02576444|Experimental|Group 2|Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
11318569|NCT02576444|Experimental|Group 3|Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
11318570|NCT02576444|Experimental|Group 4|Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
11318571|NCT02576431|Experimental|Arm 1_NSCLC|Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)
11318572|NCT02576431|Experimental|Arm 2_Thyroid|Patients with solid thyroid tumors harboring NTRK fusions (arm closed)
11318573|NCT02576431|Experimental|Arm 3_Sarcoma|Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)
11318574|NCT02576431|Experimental|Arm 4_Colorectal|Patients with solid colorectal tumors harboring NTRK fusions
11318575|NCT02576431|Experimental|Arm 5_Salivary|Patients with solid salivary tumors harboring NTRK fusions (arm closed)
11318576|NCT02576431|Experimental|Arm 6_Biliary|Patients with solid biliary tumors harboring NTRK fusions (arm closed)
11318577|NCT02576431|Experimental|Arm 7_Primary CNS|Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)
11318578|NCT02576431|Experimental|Arm 8_Other tumors|Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions
11318579|NCT02576431|Experimental|Arm 9_Solid tumors without confirmed NTRK fusion|Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)
11318580|NCT02576431|Experimental|Arm 10_Lung cancer|Patients with lung cancer harboring NTRK fusions
11318581|NCT02576431|Experimental|Arm 11_Melanoma|Patients with melanoma harboring NTRK fusions
11318582|NCT02576431|Experimental|Arm 12_Breast cancer|Patient with non-secretory breast cancer harboring NTRK fusions
11318583|NCT02576418|Experimental|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
11318584|NCT02576392|Experimental|Intervention|Informational letter mailed approximately 2 weeks prior to surgery, informational letter mailed approximately 2 weeks post surgery, pharmacist call if refill opioid medicine more than 28 days after surgery
11318585|NCT02576392|No Intervention|Control|Usual Care
11318586|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
11318587|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
11318588|NCT02576366|Experimental|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
11318589|NCT02576366|Experimental|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
11318590|NCT02576353|Experimental|Cohort 1|After a 10-hour fast, the 10 participants in this cohort are randomized to receive Fentanyl Sublingual (under the tongue) Spray (FSS) 100 mcg (n=8), or Fentanyl Citrate Intravenously (FCIV) 50 mcg (n=2).
11318591|NCT02576353|Experimental|Cohort 2|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 200 mcg (n=8), or FCIV 50 mcg (n=2).
11318592|NCT02576353|Experimental|Cohort 3|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 400 mcg (n=8), or FCIV 50 mcg (n=2).
11318593|NCT02576353|Experimental|Cohort 4|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 600 mcg (n=8), or FCIV 50 mcg (n=2).
11318594|NCT02576353|Experimental|Cohort 5|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 800 mcg (n=8), or FCIV 50 mcg (n=2).
11318595|NCT02576340|Active Comparator|study|drug was administered
11318596|NCT02576340|No Intervention|control|no drug administered
11318597|NCT02576327|Experimental|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
11318598|NCT02576327|Active Comparator|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
11318599|NCT02576314|Active Comparator|Sofosbuvir and Daclatasvir|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
11318600|NCT02576314|Active Comparator|Ledipasvir/sofosbuvir|Participants will receive Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet daily for 12 weeks.
11318601|NCT02576301|Experimental|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
11318602|NCT02576301|Experimental|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
11318603|NCT02576301|Experimental|OXi4503 dose escalation|MTD for OXi4503 will be determined
11318604|NCT02576301|Experimental|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
11318605|NCT02576288|Experimental|Sitagliptin|100mg will be administered by mouth daily for 28days
11318606|NCT02576288|Placebo Comparator|Matching Placebo|One placebo will be administered by mouth daily for 28days
11318607|NCT02576275|Experimental|Duvelisib + Rituximab + Bendamustine|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
~Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.
~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
11372932|NCT02215018|Placebo Comparator|Placebo solution|
11318608|NCT02576275|Placebo Comparator|Placebo + Rituximab + Bendamustine|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib.
~Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.
~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
11318609|NCT02576262||HPV-positive women，30-65 years of age|
11318610|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
11318611|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
11318612|NCT02576236|Experimental|Triple therapy guided by result of the molecular resistance|"If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.
~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
11318613|NCT02576236|Active Comparator|Quadruple concomitant therapy|high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
11318614|NCT02576223|Active Comparator|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
11318615|NCT02576223|Placebo Comparator|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
11318616|NCT02576197|Active Comparator|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
11318617|NCT02576197|Placebo Comparator|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
11318618|NCT02576184|Experimental|Biologic Mesh|Biologic mesh placed in retromuscular position
11318619|NCT02576184|Experimental|Synthetic Mesh|Synthetic mesh placed in retromuscular position
11318620|NCT02576184|No Intervention|No Mesh|No mesh
11318621|NCT02576171|Experimental|Group-therapy + ICBT|This is an open trial with only one study arm
11318622|NCT02576158||Subjects will be women, 30-65 years of age|Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment.
11318623|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
11318624|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
11318625|NCT02576119|Experimental|Part 1: Sentinal Cohorts|Study is in 2 sequential cohorts (BMS-955176 or placebo) each to evaluate the safety, tolerability, and PK following multiple-dose administration of BMS-955176.
11318626|NCT02576119|Experimental|Part 2: Main QTc Study|3 period nested crossover study.
11318627|NCT02576106|Experimental|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
11318628|NCT02576093|Experimental|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
11318629|NCT02576093|Experimental|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
11318630|NCT02576093|Experimental|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
11318631|NCT02576093|Placebo Comparator|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
11318632|NCT02576080|Active Comparator|Standard Group|The Standard Group will receive adjuvant imatinib at a dose of 400 mg per day for a period of 3 years. Patients will be assessed for metastases every three months for three years with thoraco-abdominal and pelvic CT scan.
11318633|NCT02576080|Other|Experimental Group|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan. Surveillance
11318634|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
11318635|NCT02576067|Placebo Comparator|Placebo|matching placebo
11318636|NCT02576054|Experimental|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
11318637|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
11318638|NCT02576028|Other|standard treathment|two sessions of 45 minutes of active exercises for 10 days
11318639|NCT02576028|Experimental|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
11318640|NCT02576015|Experimental|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
11318641|NCT02576015|Sham Comparator|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
11318642|NCT02576002||Pediatric PAH patients|US pediatric population with PAH in MarketScan database during the period 2010-2013
11372933|NCT02215018|Placebo Comparator|Placebo tablet|
11318643|NCT02575989|Active Comparator|1: control group|Classic - current management of trauma patients by French medical teams
11318644|NCT02575989|Experimental|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia
~Continuous monitoring of body temperature
~Ambulance warming (target : 30°C)
~Patient warming with dedicated blanket
~Infusion fluid warming (and temperature control)"
11318645|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
11318646|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
11318647|NCT02575976|Other|wait list control|no cardiac rehabilitation
11318648|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.
~Experimental: Phase 2
~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
11318649|NCT02575950|Experimental|LEO43204 0,018%|Experimental drug
11318650|NCT02575950|Placebo Comparator|Vehicle|Placebo
11318651|NCT02575937|Experimental|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
11318652|NCT02575937|Experimental|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
11318653|NCT02575937|Experimental|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
11318654|NCT02575924|Active Comparator|sequential medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3
~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5
~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
11318655|NCT02575924|Active Comparator|sequential medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3
~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5
~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
11318656|NCT02575924|Active Comparator|sequential medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3
~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5
~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
11318657|NCT02575924|Active Comparator|one step medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
11318658|NCT02575924|Active Comparator|one step medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
11318659|NCT02575924|Active Comparator|one step medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)
~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
11318660|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
11318661|NCT02575898|Other|One|"Creative writing and questionnaires interventions:
~First Session, Second Session, Third through Sixth Sessions"
11318662|NCT02575885|Experimental|Arm I (different type of ENDS product at each visit)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
11318663|NCT02575885|Experimental|Arm II (BLU e-cigarette ENDS product with different flavors)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
11318664|NCT02575872|Experimental|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
11318665|NCT02575872|No Intervention|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
11318666|NCT02575859|Experimental|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
11318667|NCT02575859|No Intervention|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.
~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor [pT] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
11318668|NCT02575846|Active Comparator|Human Milk|Neonates fed human milk
11318669|NCT02575846|Placebo Comparator|Formula|Neonates fed formula
11318670|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
11318671|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
11318672|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
11318673|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
11318674|NCT02575807|Experimental|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.
~* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
11318675|NCT02575807|Experimental|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).
~IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
11318676|NCT02575807|Experimental|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).
~IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
11318677|NCT02575807|Experimental|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).
~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.
~IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
11318678|NCT02575807|Experimental|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.
~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).
~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
11318679|NCT02575794|Experimental|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pharmacological Study"
11318680|NCT02575781|Experimental|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
11318681|NCT02575781|Experimental|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
11318682|NCT02575781|Experimental|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
11318683|NCT02575768||Severe AS: asymptomatic|Asymptomatic
11318684|NCT02575768||Severe AS: pure angina|Presence of exertional chest pain
11318685|NCT02575768||Normal controls|Healthy controls
11318686|NCT02575755|Experimental|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
11318687|NCT02575755|Active Comparator|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
11318688|NCT02575755|Experimental|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
11318689|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
11318690|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
11318691|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
11318692|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
11318693|NCT02575729|Experimental|Inject betamethasone by sonography|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
11318694|NCT02575729|Active Comparator|Inject betamethasone directly|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease directly. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
11319094|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
11318695|NCT02575716|Experimental|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
11318696|NCT02575716|Placebo Comparator|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
11318697|NCT02575703|Experimental|[¹⁴C]-LY3023414|Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
11318698|NCT02575690|Placebo Comparator|Placebo group|Obese patients with well-treated hypertension that receive placebo (pure microcrystalline cellulose)
11318699|NCT02575690|Experimental|Spirulina group|Obese patients with well-treated hypertension that receive Hawaiian spirulina (Cyanotech Corporation, Hawaii, US)
11318700|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
11318701|NCT02575664|Experimental|Buprenorphine|Buprenorphine 5 microg/h/7days patch
11318702|NCT02575664|Placebo Comparator|Placebo|Placebo patch
11318703|NCT02575651|Experimental|Fluzoparib|Each subject will receive a single dose of fluzoparib on day 1, and then subject will receive fluzoparib twice daily for 28 days during cycle 1.
11318704|NCT02575638|Experimental|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
11318705|NCT02575625|Experimental|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).
~Experimental procedures consist in:
~Fibroscan measure, preceded by tracking sonography.
~liver MRI (for substudy about MRI comparison, in step 2)
~a blood test for biological assessment of liver functions"
11318706|NCT02575612|Experimental|vacuum-assisted biopy|All patients enrolled in this study received a vacuum-assisted biopsy before surgery.
11318707|NCT02575599|Active Comparator|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
11318708|NCT02575599|No Intervention|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
11318709|NCT02575586|Experimental|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
11318710|NCT02575586|Active Comparator|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
11318711|NCT02575573||Admitted patients at the ED|
11318712|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
11318713|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
11318714|NCT02575534|Experimental|observational|"All patients will undergo 12-lead ECG and transthoracic echocardiography on the day of the study. These studies will be performed on patients as their previously implanted device is reprogrammed to pace in different modes. Patients will then receive an infusion of procainamide (12 mg/kg up to a maximum of 1 g) at a rate of 20 mg/min. Repeat ECG and echocardiograms will then be performed.
~The patient's device will be programmed to a specific setting before and after the procainamide infusion."
11318715|NCT02575521|Placebo Comparator|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
11318716|NCT02575521|Active Comparator|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
11318717|NCT02575508|Experimental|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11318718|NCT02575495|Experimental|7 days course of antibiotic treatment|To assign the 7 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
11318719|NCT02575495|Active Comparator|14 days course of antibiotic treatment|To assign the 14 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
11318720|NCT02575482|Experimental|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
11318721|NCT02575482|Placebo Comparator|Placebo|Placebo in healthy male subjects
11318722|NCT02575456|Experimental|Group A|(4×10^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10^10 vp/vial), one shot in each arm, total dose of 1.6×10^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
11318723|NCT02575456|Experimental|Group B|(4×10^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10^10vp/vial), total dose of 8×10^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
11318724|NCT02575456|Placebo Comparator|Group C|(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
11318725|NCT02575443|Experimental|Moderate block (MB) group|
11318726|NCT02575443|Experimental|Deep block (DB) group|
11318727|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
11318728|NCT02575417|Experimental|Patient Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.
~Eligibility Criteria for Patient Only Groups:
~are 18 years or older
~speak and read English
~have at least one chronic illness (cancer, chronic pulmonary disease, coronary artery disease, congestive heart failure, peripheral vascular disease, severe chronic liver disease, diabetes with end organ damage, renal failure)
~have not completed an advance directive within the past 18 months
~are able to sit for about 2.5-3 hours
~are able to focus on the game for about 1.5-2 hours
~can complete required surveys"
11318729|NCT02575417|Experimental|Caregiver Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.
~Eligibility Criteria for Caregiver Only Groups:
~are 18 years or older
~speak and read English
~have been an unpaid caregiver for an adult over the age of 18 in the last 12 months. Being an unpaid caregiver may include helping with personal needs or household chores, managing a person's finances, arranging for outside services, or visiting regularly to see how they are doing. This person need not live with participants in order for them to identify as caregivers;
~are able to sit for about 2.5-3 hours
~are able to focus on the game for about 1.5-2 hours
~can complete required survey
~care recipient is capable of discussing medical issues
~care recipient has not completed an AD in past 18 months"
11318730|NCT02575417|Experimental|Surrogate Decision Maker with Patient|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.
~Eligibility Criteria for Surrogate Decision Maker and Patient Group:
~considers themselves a surrogate decision maker for an adult with a chronic illness (defined in Patient Only Group)
~are 18 years or older
~speak and read English
~are able to sit for about 2.5-3 hours
~are able to focus on the game for about 1.5-2 hours
~can complete required surveys
~both patient and surrogate decision maker are able to attend study session together
~patient must meet eligibility criteria defined in Patient Only group"
11318731|NCT02575404|Experimental|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
11318732|NCT02575404|Experimental|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
11318733|NCT02575404|Experimental|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
11318734|NCT02575391|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
11318735|NCT02575378|Other|Metronomic chemotherapy|Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
11318736|NCT02575378|Experimental|Metronimic chemotherapy plus Chinese Traditional Medicine|"Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
~Chinese Traditional Medicine"
11318737|NCT02575365|Experimental|Fingolimod arm|0.5 mg p.o fingolimod daily
11318738|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.
~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
11318739|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
11318740|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
11318741|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
11318742|NCT02575326|Other|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
11318743|NCT02575313|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
11318744|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
11318745|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
11318746|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
11318747|NCT02575274|Experimental|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
11318748|NCT02575274|Other|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
11318749|NCT02575261|Experimental|Experimental:CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.
11318750|NCT02575261|No Intervention|No Intervention|
11318751|NCT02575248|Experimental|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
11318752|NCT02575248|Active Comparator|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
11318753|NCT02575235|Experimental|1.5mg Cetylpyridinium Chloride|1.5mg CPC will be taken daily for four weeks.
11318754|NCT02575235|Experimental|4.5mg Cetylpyridinium Chloride|4.5mg CPC will be taken daily for four weeks.
11318755|NCT02575235|Placebo Comparator|Control|Placebo will be taken daily for four weeks
11318756|NCT02575222|Experimental|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
11318757|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
11318758|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
11318759|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
11318760|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
11318761|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
11318814|NCT02574884|No Intervention|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
11318762|NCT02575183|Experimental|Varenicline (Chantix)|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: 0.5 mg orally once a day Days 4 to 7: 0.5 mg orally twice a day Days 8 to end of treatment: 1 mg orally twice a day. Intervention 'Varinecline (Chantix)' and Intervention 'Behavioral Therapy'"
11318763|NCT02575183|Placebo Comparator|Placebo|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive a Placebo for Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: a placebo (matched to 0.5 mg of Varenicline) orally once a day Days 4 to 7: a placebo (matched to 0.5 mg of Varenicline) orally twice a day Days 8 to end of treatment: a placebo (matched to 1 mg of Varenicline) orally twice a day.
~Intervention 'Placebo (for Varenicline)' and Intervention 'Behavioral Therapy'"
11318764|NCT02575170|Experimental|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
11318765|NCT02575170|Placebo Comparator|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
11318766|NCT02575157|No Intervention|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
11318767|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:
~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.
~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
11318768|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:
~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.
~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
11318769|NCT02575131|Experimental|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
11318770|NCT02575131|Active Comparator|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
11318771|NCT02575131|Experimental|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
11318772|NCT02575131|Active Comparator|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
11318773|NCT02575131|Experimental|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).
~The breakfast is consumed at TNO"
11318774|NCT02575131|Experimental|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
11318775|NCT02575131|Active Comparator|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
11318776|NCT02575131|Experimental|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams* of water and consumed with 307 grams of skimmed milk at home
11318777|NCT02575131|Active Comparator|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
11318778|NCT02575131|Experimental|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).
~The breakfast is consumed at home"
11318779|NCT02575105||Pediatric Hydrocephalus|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
11318780|NCT02575105||Pediatric Control|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
11318781|NCT02575105||Adult Hydrocephalus|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
11318782|NCT02575105||Adult Control|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
11318783|NCT02575092|Active Comparator|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
11318784|NCT02575092|Experimental|Group B, hypertension|The hypertensive patients with their plasma Hcy levels <10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
11318785|NCT02575092|Experimental|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
11318786|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
11318787|NCT02575079|No Intervention|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
11318788|NCT02575066|Other|radiotherapy combined with pazopanib|patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
11318789|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
11318790|NCT02575040|Other|Fecal microbiota transplantation|Fecal microbiota transplantation only
11318791|NCT02575027|Experimental|Treatment (4pi radiotherapy)|Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation.
11318792|NCT02575014|Experimental|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
11318793|NCT02575014|No Intervention|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
11318794|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.
~The following interventions/exposures will be administered:
~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
11318795|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.
~The following interventions/exposures will be administered:
~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
11318796|NCT02574988||SCAR Patients|Patients diagnosed with severe cutaneous adverse reactions with be recruited
11318797|NCT02574975|Active Comparator|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
11318798|NCT02574975|Experimental|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
11318799|NCT02574975|Experimental|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
11318800|NCT02574975|Experimental|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
11318801|NCT02574975|Experimental|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
11318802|NCT02574962|Experimental|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
11318803|NCT02574949|Active Comparator|Conventional rate fluoroscopy|Radiation: 15 FPS Cine 15 PPS
11318804|NCT02574949|Experimental|Intermediate frame rate 7.5 fps|Radiation: 7.5 low Frame rate
11318805|NCT02574949|Experimental|Low frame rate|Low Cine 10 PPS
11318806|NCT02574936|Other|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
11318807|NCT02574923|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
11318808|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
11318809|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
11318810|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
11318811|NCT02574897|Experimental|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
11318812|NCT02574897|Active Comparator|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
11318813|NCT02574884|Other|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
11318815|NCT02574884|Other|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
11318816|NCT02574871||Single Group|Psychological and biological data collection
11318817|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
11318818|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
11318819|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
11318820|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
11318821|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
11318822|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
11318823|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
11318824|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.
~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
11318825|NCT02574819|Experimental|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
11318826|NCT02574819|Placebo Comparator|Placebo|Placebo administered every other day for 2 weeks.
11318827|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
11318828|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
11318829|NCT02574780|Experimental|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
11318830|NCT02574780|Experimental|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
11318831|NCT02574767|Experimental|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
11318832|NCT02574767|Experimental|Routine diet & PA + PUFA Supplementation|Routine Diet & Physical Activity counseling care plus n3LC-PUFAs supplementation.
11318833|NCT02574767|Experimental|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
11318834|NCT02574767|Placebo Comparator|Routine diet & PA + PUFA placebo|Routine Diet & Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
11318835|NCT02574754|Experimental|warfarin|Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
11318836|NCT02574741|Active Comparator|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
11318837|NCT02574741|Active Comparator|Placebo|50% will be randomized to placebo.
11318838|NCT02574741|Active Comparator|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
11318839|NCT02574728|Experimental|Oral sirolimus, celecoxib, etoposide, and cyclophosphamide|Participants in this group will receive oral sirolimus and celecoxib in addition to cycles of oral etoposide and cyclophosphamide for up to two years.
11318840|NCT02574715||Levonorgestrel (Jaydess, BAY86-5028)|women aged 18 to 29 years following 6 (±1) months of Jaydess® use as their contraceptive method.
11318841|NCT02574702|No Intervention|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
11318842|NCT02574702|Experimental|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.
~Intervention: application of a contralateral drainage in surgical wound closure."
11318843|NCT02574689|Experimental|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
11318844|NCT02574689|Active Comparator|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
11318845|NCT02574663|Experimental|TGR-1202|TGR-1202 daily dose
11318846|NCT02574663|Experimental|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
11318847|NCT02574663|Experimental|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
11318848|NCT02574663|Experimental|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
11318933|NCT02574104||Institution 11|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
11318849|NCT02574650|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
11318850|NCT02574637|Placebo Comparator|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
11318851|NCT02574637|Experimental|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
11318852|NCT02574637|Experimental|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
11318853|NCT02574637|Experimental|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
11318854|NCT02574637|Experimental|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
11318855|NCT02574624|Experimental|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
11318856|NCT02574611|Active Comparator|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical (eating, sleeping, mobility, etc.)"
11318857|NCT02574611|Active Comparator|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical (eating, sleeping, mobility, etc.)"
11318858|NCT02574611|Experimental|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate
11318859|NCT02574611|Placebo Comparator|SCI placebo group|Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo)
11318860|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease
~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
11318861|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
11318862|NCT02574585|Experimental|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
11318863|NCT02574585|No Intervention|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
11318864|NCT02574572|Experimental|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
11318865|NCT02574559|Experimental|Caregiver of Child With Autism Spectrum Disorder|Caregivers attending eight weekly sessions of Cognitive Based Compassion Training Sessions and Meditation.
11318866|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
11318867|NCT02574533|Experimental|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.
~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
11318868|NCT02574520|Experimental|SABER®-Bupivacaine|Extended Release Solution for instillation; SABER®-Bupivacaine /Once
11318869|NCT02574520|Active Comparator|Bupivacaine HCl|Solution for infiltration; Bupivacaine HCl/Once
11318870|NCT02574507|Experimental|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
11318871|NCT02574481|Experimental|ELUVIA Stent Implantation|Percutaneous stent placement in the SFA/PPA
11318872|NCT02574481|Active Comparator|Zilver PTX Stent Implantation|Percutaneous stent placement in the SFA/PPA
11318873|NCT02574468|Active Comparator|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
11318934|NCT02574104||Institution 12|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
11318935|NCT02574104||Institution 13|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
11318936|NCT02574104||Institution 14|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
11318874|NCT02574468|Active Comparator|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
11318875|NCT02574455|Experimental|IMMU-132|Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)
11318876|NCT02574455|Active Comparator|Control Arm|"Treatment of Physician's Choice determined before randomization from only one of the following treatments (see Appendix 2 for more details on administration and dosing management):
~Eribulin (1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle). See section 6.5.1 Capecitabine (1000-1250 mg/m2 orally twice daily on Days1-14 of a 21-day cycle). See section 6.5.2 Gemcitabine (800-1200 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle). See section 6.5.3 Vinorelbine (25 mg/m2 weekly IV on Day 1 weekly) See section 6.5.4 (Note: eligible patients with Grade 2 neuropathy should not be prescribed vinorelbine as TPC)"
11318877|NCT02574442||Initial Colposcopy Visit|Women with a scheduled colposcopy and biopsy appointment at the Women's Clinic at Vancouver General Hospital
11318878|NCT02574429|Experimental|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
11318879|NCT02574403|Experimental|without eculizumab|
11318880|NCT02574377|Experimental|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
11318881|NCT02574377|Experimental|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
11318882|NCT02574377|Experimental|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
11318883|NCT02574364|Active Comparator|traditional incision|traditional incision : McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
11318884|NCT02574364|Experimental|modified incision|modified incision :The application of abdomen CT before surgery provides a new approach to the incision and new perception.
11318885|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
11318886|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
11318887|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
11318888|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
11318889|NCT02574338|Active Comparator|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
11318890|NCT02574338|Active Comparator|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
11318891|NCT02574325|Placebo Comparator|Placebo|Placebo
11318892|NCT02574325|Experimental|ARI-3037MO|ARI-3037MO
11318893|NCT02574312|Active Comparator|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
11318894|NCT02574312|Experimental|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
11318895|NCT02574299|No Intervention|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
11318896|NCT02574299|No Intervention|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
11318897|NCT02574299|Other|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
11318898|NCT02574299|No Intervention|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
11318899|NCT02574299|No Intervention|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
11318900|NCT02574299|Other|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
11318901|NCT02574286|Experimental|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
11318902|NCT02574273|Active Comparator|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
11318937|NCT02574104||Institution 15|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
11318938|NCT02574091|Experimental|Cohort 1-Experimental|"4 healthy adult participants will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
11319095|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
11318903|NCT02574273|Other|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
11318904|NCT02574260|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
11318905|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
11318906|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
11318907|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
11318908|NCT02574234|Experimental|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).
~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).
~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
11318909|NCT02574221|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
11318910|NCT02574221|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
11318911|NCT02574208|Active Comparator|"HIV testing by ELISA"|Patients enrolled in this arm will be tested by usual HIV Elisa
11318912|NCT02574208|Experimental|"HIV testing by rapid test"|Patients enrolled in this arm will be tested by the new rapid HIV test
11318913|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
11318914|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
11318915|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
11318916|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 1|alveolar recruitment maneuvers by CPAP then alveolar recruitment maneuvers by eSigh
11318917|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 2|alveolar recruitment maneuvers by eSigh then alveolar recruitment maneuvers by CPAP
11318918|NCT02574156|Experimental|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
11318919|NCT02574156|Experimental|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
11318920|NCT02574130|Experimental|Nebulized amikacin|Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
11318921|NCT02574130|Placebo Comparator|placebo|nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.
11318922|NCT02574117|Experimental|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
11318923|NCT02574104||Institution 1|"McGill University Health Center NICU staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Complete"
11318924|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Complete"
11318925|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Complete"
11318926|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Active"
11318927|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Active"
11318928|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Active"
11318929|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Preparing"
11318930|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Preparing"
11318931|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff
~Simulate a functional NICU prior to moving patients to preserve safety at transition
~STATUS: Pending"
11318932|NCT02574104||Institution 10|"recruiting
~Simulate a functional NICU prior to moving patients to preserve safety at transition"
11319167|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
11318939|NCT02574091|Placebo Comparator|Cohort 1-Placebo|"2 healthy adult participants will be randomized to receive placebo (blank cream), applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
11318940|NCT02574091|Experimental|Cohort 2-Experimental|"4 healthy adult participants will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
11318941|NCT02574091|Placebo Comparator|Cohort 2-Placebo|"2 healthy adult participants will be randomized to receive matching placebo, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).
~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
11318942|NCT02574091|Experimental|Cohort 3-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
11318943|NCT02574091|Placebo Comparator|Cohort 3-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
11318944|NCT02574091|Experimental|Cohort 4-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
11318945|NCT02574091|Placebo Comparator|Cohort 4-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).
~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
11318946|NCT02574078|Experimental|Group A Nivolumab|Opdivo specified dose on specified days
11318947|NCT02574078|Experimental|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days
~Opdivo/Pemetrexed specified dose on specified days"
11318948|NCT02574078|Active Comparator|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days
~Pemetrexed specified dose on specified days"
11318949|NCT02574078|Experimental|Group B Nivolumab|Opdivo specified dose on specified days
11318950|NCT02574078|Other|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
11318951|NCT02574078|Active Comparator|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days
~Carboplatin/paclitaxel specified dose on specified days
~Carboplatin/pemetrexed specified dose on specified days
~Carboplatin/docetaxel specified dose on specified days
~Carboplatin/gemcitabine specified dose on specified days
~Paclitaxel specified dose on specified days
~Docetaxel specified dose on specified days
~Gemcitabine specified dose on specified days
~Pemetrexed specified dose on specified days"
11318952|NCT02574078|Experimental|Group C Nivolumb|Opdivo specified dose on specified days
11318953|NCT02574078|Active Comparator|Group D Erlotinib|Erlotinib specified dose on specified days
11318954|NCT02574078|Experimental|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
11318955|NCT02574078|Experimental|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
11318956|NCT02574065|Experimental|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
11318957|NCT02574065|Placebo Comparator|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
11318958|NCT02574052|Other|Behavioral|"The whole experiment was divided into three phases with each phase lasting two weeks.
~First Stage-Behavioral: just record participants' food choices Second Stage-Behavioral: menu labelling without nutrition education Third Stage- Behavioral; menu labelling with nutrition education"
11318959|NCT02574039|Experimental|Oat bran|66g oat bran made up in 350ml skimmed milk
11318960|NCT02574039|Placebo Comparator|Control|Refined grain product and 350ml skimmed milk
11318961|NCT02574026|Experimental|Psychomotor tasks|20 healthy subjects and 10 tetraplegic patients will participate to acquisition of MEG, EEG, MRI data during a motor tasks
11318962|NCT02574013|Experimental|sponge-assisted surgery group|Patients offered surgery with use of the retractor sponge
11318963|NCT02574013|No Intervention|Control group|Patients receiving standard care, i.e. surgery in Trendelenburg position
11318964|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:
~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
11318965|NCT02573987|Active Comparator|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
11318966|NCT02573987|Active Comparator|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
11318967|NCT02573974|Other|Case group|the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer
11318968|NCT02573974|Other|Control group|the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer
11318969|NCT02573961|Active Comparator|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
11319168|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
11318970|NCT02573961|Active Comparator|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
11318971|NCT02573961|Sham Comparator|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
11318972|NCT02573935|Experimental|Clarithromycin|Clarithromycin combined with VCD induction therapy
11318973|NCT02573935|Placebo Comparator|Placebo|Placebo combined with VCD induction therapy
11318974|NCT02573922|Experimental|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
11318975|NCT02573922|Active Comparator|Oxycodone|Oxycodone prolonged release tablet twice a day
11318976|NCT02573909|Experimental|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
11318977|NCT02573909|Experimental|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
11318978|NCT02573896|Experimental|NK cells with Ch14.18 & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of Ch14.18 on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
11318979|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
11318980|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
11318981|NCT02573870|Experimental|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
11318982|NCT02573870|Placebo Comparator|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
11318983|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
11318984|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
11318985|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
11318986|NCT02573844|Active Comparator|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.
~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
11318987|NCT02573844|Placebo Comparator|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.
~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
11318988|NCT02573831|Placebo Comparator|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
11318989|NCT02573831|Experimental|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
11318990|NCT02573818||SEDASYS System|
11318991|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
11318992|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire<22 Rigiscan test are performed for two nights
11318993|NCT02573779||Infants fed mother's own milk|Infants fed >50% mother's own milk with enteral feeding.
11318994|NCT02573779||Donor milk fed infants|Infants fed <50% mother's own milk (and thus >50% donor human milk) with enteral feeding.
11318995|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
11318996|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
11318997|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
11318998|NCT02573753|Experimental|sleep restriction|Sleep restriction
11318999|NCT02573753|No Intervention|normal sleep|Normal sleep
11319000|NCT02573753|Experimental|weight gain|Weight gain
11319001|NCT02573740|Experimental|ABT-957|ABT-957 given twice a day for 84 days
11319002|NCT02573740|Placebo Comparator|Placebo|Placebo given twice a day for 84 days
11319003|NCT02573727|Experimental|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.
~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.
~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
11319004|NCT02573727|Active Comparator|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.
~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
11319005|NCT02573714|Experimental|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
11319006|NCT02573714|Placebo Comparator|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
11319007|NCT02573701|Experimental|1 Guideline treatment|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
11319008|NCT02573701|Active Comparator|2 Treatment as Usual|Participants will receive the Treatment as Usual (atypical antipsychotic) plus psychosocial treatment decided by clinician
11319009|NCT02573688|Experimental|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
11319010|NCT02573662||Case subjects|Physical active non-diabetic individuals of age 18 to 50 years, who are undergoing knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are recruited as cases for this case-control study. OGTT, blood- and urine sampling and DXA scans will be performed 3 times throughout the study period.
11319011|NCT02573662||Control group|Non-diabetic individuals matched for age, gender and physical activity are recruited as control subjects to establish a reference level likely to image the cases before they experienced their knee injury. Blood- and urine sampling, OGTT and DXA scans will be carried out 1-3 times for each control subject. No lifestyle intervention is implemented.
11319012|NCT02573649|Active Comparator|CLS-ON first|Closed-loop Stimulation on first
11319013|NCT02573649|Active Comparator|CLS-OFF first|Closed-loop Stimulation off first
11319014|NCT02573623||HIV-infected children with confirmed TB|Hospitalized children with TB confirmed by culture or GeneXpert
11319015|NCT02573623||HIV-uninfected children aged<5 years with confirmed TB|Hospitalized children aged<5 years with TB confirmed by culture or GeneXpert
11319016|NCT02573623||HIV-uninfected children aged>4 years with confirmed TB|Hospitalized children aged>4 years with TB confirmed by culture or GeneXpert
11319017|NCT02573623||HIV-infected control children|Children hospitalized in the surgery ward without any evidence of tuberculosis infection
11319018|NCT02573623||HIV-uninfected controls aged <5 years|Children <5 years hospitalized in the surgery ward without any evidence of tuberculosis infection
11319019|NCT02573623||HIV-uninfected controls aged >4 years|Children >4 years hospitalized in the surgery ward without any evidence of tuberculosis infection
11319020|NCT02573610|Experimental|DE-108|High concentration / Antibacterial Ophthalmic Solution
11319021|NCT02573610|Active Comparator|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
11319022|NCT02573597|Active Comparator|Part A Group 1|CEI bupivacaine and CEI sufentanil
11319023|NCT02573597|Active Comparator|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
11319024|NCT02573597|Active Comparator|Part B Group 3|CEI bupivacaine and PIEB sufentanil
11319025|NCT02573597|Active Comparator|Part B Group 4|PIEB bupivacaine and CEI sufentanil
11319026|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
11319027|NCT02573558||DEX|patients who received dexmedetomidine during the operation
11319028|NCT02573558||PPF|patients who received propofol during the operation
11319029|NCT02573545|Experimental|Test group: with IFE|Patients treated with IFE software
11319030|NCT02573545|Active Comparator|Test group: without IFE|Patients treated with Numaris 4 software
11319031|NCT02573519|Active Comparator|Diabetic patient|"The study consists of four different parts:
~11C Donepezil PET/CT scan
~3D-Transit
~3D-Transit during treatment with pyridostigmine
~3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
11319032|NCT02573519|Active Comparator|Healthy subjects|"The study consists of two different parts:
~11C Donepezil PET/CT scan
~3D-Transit"
11319033|NCT02573506|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
11319034|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment
~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)
~If <PR, move directly to CRT if not surgical candidates.
~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.
~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
11319060|NCT02573324|Experimental|ABT-414, Radiation and Radiation/Temozolomide (TMZ)|ABT-414 is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. ABT-414 is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
11372934|NCT02215005|Experimental|Telmisartan + Ramipril|5 days qd
11319035|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment
~If CR/PR, three more weeks of nab-paclitaxel followed by CRT
~If <PR, move directly to CRT if not surgical candidates.
~CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.
~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
11319036|NCT02573493|Experimental|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"6 weeks of nab-paclitaxel and cisplatin (days 1 & 22) followed by primary tumor site assessment
~If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab
~If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab
~CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy
~Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
11319037|NCT02573480|Experimental|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
11319038|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
11319039|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
11319040|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
11319041|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
11319042|NCT02573454|Experimental|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
11319043|NCT02573454|Active Comparator|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
11319044|NCT02573441|Experimental|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
11319045|NCT02573441|Experimental|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
11319046|NCT02573441|Other|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
11319047|NCT02573428||Autism Spectrum Disorder|Individuals who receive a clinical diagnosis of Autism Spectrum Disorder
11319048|NCT02573428||Developmental/Psychiatric Controls|Individuals who receive a clinical diagnosis of another developmental or psychiatric disorder
11319049|NCT02573428||Healthy Controls|Individuals who have no specific developmental or psychiatric diagnosis
11319050|NCT02573415|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
11319051|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
11319052|NCT02573402|Sham Comparator|Control|Sham stimulation.
11319053|NCT02573389|No Intervention|"Retrospective and prospective non-stented"|Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
11319054|NCT02573389|Experimental|"Prospective stented"|Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
11319055|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
11319056|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
11319057|NCT02573363|Experimental|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.
~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
11319058|NCT02573350|Experimental|Delamanid|All patients received an initial dose of 100 mg BID (200 mg total daily dose), with an option to titrate to 200 mg BID (400 mg total daily dose) after an initial 2-week hospitalization at the investigator's discretion.
11319059|NCT02573337|Experimental|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
11319091|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
11319061|NCT02573324|Placebo Comparator|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
11319062|NCT02573311|Experimental|men|
11319063|NCT02573298|Active Comparator|Ice|patients randomized to receive local ice on inflamed joint
11319064|NCT02573298|Active Comparator|Cold gas|patients randomized to receive cold gas on inflamed joint
11319065|NCT02573285|Active Comparator|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
11319066|NCT02573285|Active Comparator|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
11319067|NCT02573272||Epileptic patients with AEDs and eslicarbacepine|
11319068|NCT02573259|Experimental|Arm 1 PF-06801591|0.5 mg/kg IV every 21 days (Part 1)
11319069|NCT02573259|Experimental|Arm 2 PF-06801591|1.0 mg/kg IV every 21 days (Part 1)
11319070|NCT02573259|Experimental|Arm 3 PF-06801591|3.0 mg/kg IV every 21 days (Part 1)
11319071|NCT02573259|Experimental|Arm 4 PF-06801591|10 mg/kg IV every 21 days (Part 1)
11319072|NCT02573259|Experimental|Arm 5 PF-06801591|300 mg SC every 28 days (Part 1 and 2)
11319073|NCT02573246|Experimental|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
11319074|NCT02573246|Sham Comparator|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
11319075|NCT02573246|Experimental|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
11319076|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11319077|NCT02573233|Experimental|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11319078|NCT02573220|Experimental|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11319079|NCT02573194|Experimental|Animal source of proteins|Breakfast based on animal proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
11319080|NCT02573194|Experimental|Plant source of proteins|Breakfast based on plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
11319081|NCT02573194|Experimental|Animal and plant source of proteins|Breakfast based on both animal and plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
11319082|NCT02573194|Experimental|Low protein|Breakfast very low in protein: 1700 kJ, 5 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
11319083|NCT02573181|Experimental|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
11319084|NCT02573181|Active Comparator|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
11319085|NCT02573168|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
11319086|NCT02573168|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
11319087|NCT02573168|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.
~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
11319088|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
11319089|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
11319090|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
11319096|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
11319097|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
11319098|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
11319099|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
11319100|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
11319101|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
11319102|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
11319103|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
11319104|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
11319105|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
11319106|NCT02573142|Active Comparator|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
11319107|NCT02573142|Experimental|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
11319108|NCT02573129|Experimental|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
11319109|NCT02573129|Experimental|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
11319110|NCT02573116|Experimental|Obstructive sleep apnea with chronic parodontis|patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
11319111|NCT02573116|No Intervention|Obstructive sleep apnea without chronic parodontis|patients with severe OSA treated by CPAP
11319112|NCT02573090|Experimental|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
11319113|NCT02573090|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
11319114|NCT02573051|Active Comparator|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
11319115|NCT02573051|Active Comparator|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
11319116|NCT02573038|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
11319117|NCT02573025|Experimental|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
11319118|NCT02573025|Experimental|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
11319119|NCT02573012|Experimental|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
11319120|NCT02573012|Experimental|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
11319121|NCT02572999||Valvular heart disease|All patients aged 70 years or older, consecutively admitted for elective heart valve surgery or if admitted for elective transcatheter aortic valve implantation, or if a patient presents with symptomatic moderate to severe valvular heart disease on hospital admission as evidenced by moderate to severe valve regurgitation or stenosis will be included in this cohort. Participants will be observed up to 30 days post-hospital discharge
11319122|NCT02572986|Experimental|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
11319123|NCT02572986|Active Comparator|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
11319124|NCT02572973|Active Comparator|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
11319169|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
11319345|NCT02571400||Patients scheduled to undergo surgery|Patients scheduled to undergo surgery at St Vincent's Private Hospital Sydney
11319125|NCT02572973|Placebo Comparator|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
11319126|NCT02572960|Placebo Comparator|Cholecalciferol|Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks
11319127|NCT02572960|Active Comparator|Valsartan|Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks
11319128|NCT02572960|Placebo Comparator|Placebo|Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks
11319129|NCT02572960|Active Comparator|Cholecalciferol and Valsartan|Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks
11319130|NCT02572947|Experimental|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
11319131|NCT02572934||Chemotherapy group (CT-group)|Patients treated with chemotherapy >20 years ago
11319132|NCT02572934||Radiotherapy group (RT-group)|Patients treated with radiotherapy >20 years ago
11319133|NCT02572934||Surgery-only group (SU-group)|Patients treated with only orchidectomy >20 years ago
11319134|NCT02572934||Control-group|Healthy controls
11319135|NCT02572921|Experimental|Positive Psychotherapy|Experimental Group (Positive Psychotherapy)
11319136|NCT02572921|Active Comparator|Cognitive Behavioral Therapy|Active Control Group (Cognitive Behavioral Therapy)
11319137|NCT02572908|Active Comparator|Fermented wheat bread for 7 days|Long sourdough fermentation
11319138|NCT02572908|Placebo Comparator|Yeast baked wheat bread for 7 days|Regular toast bread
11319139|NCT02572908|Other|Run-in|Gluten-free diet for 7 days before entering either bread period
11319140|NCT02572895|Active Comparator|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
11319141|NCT02572895|Placebo Comparator|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
11319142|NCT02572882|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
11319143|NCT02572882|Experimental|p-inulin|This arm is the 12 week p-inulin treatment phase (8 grams twice daily, oral).
11319144|NCT02572882|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
11319145|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
11319146|NCT02572856|Experimental|CGM patients|Apply continuous glucose monitor, calibrate and make glucose measurements. Measurements are blinded to the care provider
11319147|NCT02572843|Experimental|MEDI4736|Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.
11319148|NCT02572830|Experimental|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
11319149|NCT02572830|Active Comparator|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
11319150|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
11319151|NCT02572817|Active Comparator|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
11319152|NCT02572804|Active Comparator|Rectus Sheath Catheter Group|Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
11319153|NCT02572804|Active Comparator|Epidural Group|Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
11319154|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
11319155|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
11319156|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
11319157|NCT02572765||Normotensive|Normotensive subjects
11319158|NCT02572765||Hypertensive|Hypertensive subjects
11319159|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
11319160|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
11319161|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
11319162|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
11319163|NCT02572726|Active Comparator|active rTMS|active repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
11319164|NCT02572726|Sham Comparator|'sham' rTMS|'sham' repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
11319165|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
11319166|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
11319170|NCT02572687|Experimental|Ramucirumab + MEDI4736 (NSCLC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given intravenously (IV) every 3 weeks (q3w) of a 21 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.
~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q3w. Participants may continue to receive study treatment until discontinuation criteria are met."
11319171|NCT02572687|Experimental|Ramucirumab + MEDI4736 (Gastric/GEJ)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV every 2 weeks (q2w) of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.
~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
11319172|NCT02572687|Experimental|Ramucirumab + MEDI4736 (HCC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV q2w of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.
~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
11319173|NCT02572674|Other|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
11319174|NCT02572661|Other|Squamous Head and Neck Cancer|radiation
11319175|NCT02572648||Participants with Heart Failure|Participants with heart failure will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
11319176|NCT02572648||Healthy Controls|Healthy controls will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
11319177|NCT02572635|Experimental|Cohort 1|50 µg of PnuBioVax
11319178|NCT02572635|Experimental|Cohort 2|200 µg of PnuBioVax
11319179|NCT02572635|Experimental|Cohort 3|500 µg of PnuBioVax
11319180|NCT02572635|Placebo Comparator|Placebo|Placebo
11319181|NCT02572622|Experimental|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
11319182|NCT02572622|Experimental|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
11319183|NCT02572622|Experimental|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
11319184|NCT02572609|Experimental|Mucosolvan ® adult syrup|
11319185|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
11319186|NCT02572596|Experimental|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
11319187|NCT02572596|Active Comparator|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
11319188|NCT02572583|Experimental|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
11319189|NCT02572583|Active Comparator|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
11319190|NCT02572583|Active Comparator|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
11319191|NCT02572570|Experimental|Filtek Bulk Fill Posterior|Commercially available tooth-colored filling that will be used for direct restoration as per manufacturer's instructions.
11319192|NCT02572570|Active Comparator|Filtek Supreme Ultra|Commercially available tooth-colored filling that will be used for direct restoration as per manufacturer's instructions.
11319193|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
11319194|NCT02572544|Experimental|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
11319195|NCT02572531|Active Comparator|L. reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 2 weeks
11319196|NCT02572531|Placebo Comparator|Placebo|Placebo lozenges three times daily for 2 weeks
11319197|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
11319198|NCT02572505|Experimental|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
11319199|NCT02572492|Experimental|Carfilzomib/dexamethasone maintenance|Carfilzomib/dexamethasone maintenance after salvage HDT
11319200|NCT02572492|Sham Comparator|Observation without maintenance|Observation without maintenance after salvage HDT
11319201|NCT02572466||ESRD group|"Aged 18 years or older.
~was diagnosed as End-stage renal disease for more than one year.
~Attend hemodialysis 3 times a week consistently for more than 6 months.
~Hemodialysis with Kt/V > 1.2
~No urine output or is less than 500 ml per day.
~No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
11319202|NCT02572466||Control group|"Aged 18 years or older.
~without kidney disease (eGFR > 60 ml/min/1.73m2)"
11319203|NCT02572453|Experimental|Treatment (onalespib)|Patients receive onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11319204|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
11319247|NCT02572128|Experimental|Study 2|Iron and zinc fortified rice hot extruded or coated.
11372935|NCT02215005|Active Comparator|Telmisartan|5 days qd
11319205|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
11319206|NCT02572414|Experimental|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention consisted of three, 3-hour weekly small-group intervention sessions led by a trained facilitator using a detailed, scripted manual designed to increase adherence to guidelines for physical activity, 5-a-Day diet, and colon cancer screening.
11319207|NCT02572414|Active Comparator|Health Awareness Control|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
11319208|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
11319209|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
11319210|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
11319211|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
11319212|NCT02572388|Active Comparator|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
11319213|NCT02572388|Active Comparator|Group 2|50µg of R21 on days 0, 28, and 56.
11319214|NCT02572388|Active Comparator|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
11319215|NCT02572388|Active Comparator|Group 4|2µg of R21 mixed with 50µg of Matrix-M
11319216|NCT02572375|Experimental|Codeine Phosphate/Guaifenesin ER Tablet|Patients receiving an extended release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin twice a day for 6 and a half days total. Total dosage [2 tablets] is 60 mg Codeine Phosphate and 1200 mg Guaifenesin twice a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
11319217|NCT02572375|Active Comparator|Codeine Phosphate/Guaifenesin IR Tablet|Patients receiving an immediate release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin six times a day for 6 and a half days total. Dosage is 20 mg Codeine Phosphate and 400 mg Guaifenesin six times a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
11319218|NCT02572349|Experimental|IW-1701|Single Dose
11319219|NCT02572349|Placebo Comparator|Matching Placebo for IW-1701|Single Dose
11319220|NCT02572336|Active Comparator|THR-18|Single administration of intravenous THR-18 solution
11319221|NCT02572336|Placebo Comparator|Placebo|Single administration of intravenous THR-18 lookalike solution
11319222|NCT02572323|Active Comparator|Immediate group|1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
11319223|NCT02572323|Placebo Comparator|Deferred group|No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months
11319224|NCT02572310|Experimental|HV Cement|Simplex High Viscosity Bone Cement
11319225|NCT02572297||video-EEG|Patients suffering from drug-resistant partial epilepsy for whom a video-EEG monitoring of their seizures was scheduled as part of pre-surgical assessment
11319226|NCT02572284|Experimental|Dose Escalation of SBRT|Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
11319227|NCT02572271|Active Comparator|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
11319228|NCT02572271|Active Comparator|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
11319229|NCT02572258|Experimental|Nutritional oats cookie and educational session|Nutritional cookie with oats and nuts
11319230|NCT02572258|No Intervention|Educational session only|
11319231|NCT02572245|Active Comparator|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
11319232|NCT02572245|Active Comparator|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
11319233|NCT02572232|Experimental|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
11319234|NCT02572219|Active Comparator|Nutraceutical|Treated with nutraceutical compound
11319235|NCT02572219|Placebo Comparator|Placebo|Treated with placebo
11319236|NCT02572206|Other|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.
~30 minute structural MRI will be obtained to permit co-registration of PET images."
11319237|NCT02572193|Experimental|Active case|POEM procedure
11319238|NCT02572180|Active Comparator|NIRS-based NF in 3D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 3D virtual reality classroom environment.
11319239|NCT02572180|Active Comparator|NIRS-based NF in 2D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 2D (normal computer screen) classroom environment.
11319240|NCT02572180|Active Comparator|EMG-based BF in 3D|An electromyogram (EMG)-based biofeedback training in which participants learn to self-regulate activity of the musculi supraspinatus will take place in a 3D virtual reality classroom environment.
11319241|NCT02572167|Experimental|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
11319242|NCT02572154|Other|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
11319243|NCT02572154|Other|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
11319244|NCT02572141|Experimental|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
11319245|NCT02572141|Active Comparator|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
11319246|NCT02572128|Experimental|Study 1|Iron fortified rice hot or cold extruded.
11319248|NCT02572115|Active Comparator|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
11319249|NCT02572115|Active Comparator|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
11319250|NCT02572115|No Intervention|Control|This arm does not get the intervention.
11319251|NCT02572102|Experimental|Energy Drink|Two 16 ounce containers of an Energy Drink
11319252|NCT02572102|Active Comparator|Panax Ginseng|800 mg of Panax Ginseng in 70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
11319253|NCT02572102|Placebo Comparator|Placebo|70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
11319254|NCT02572089|Experimental|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
11319255|NCT02572089|Experimental|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
11319256|NCT02572089|Experimental|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
11319257|NCT02572089|Experimental|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
11319258|NCT02572089|Experimental|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
11319259|NCT02572076|Experimental|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
11319260|NCT02572050|Experimental|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
11319261|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
11319262|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
11319263|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
11319264|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
11319265|NCT02572024|Active Comparator|Baroreflex activation therapy|BAT ON
11319266|NCT02572024|Placebo Comparator|Placebo|BAT OFF
11319267|NCT02572011|No Intervention|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
11319268|NCT02572011|Experimental|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
11319269|NCT02571998|Experimental|Treatment|Omiganan (CLS001) Topical Gel applied once daily
11319270|NCT02571998|Placebo Comparator|Vehicle Gel|Vehicle Topical Gel applied once daily
11319271|NCT02571972|Experimental|Dorzolamide-timolol|"On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.
~Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.
~Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits
~At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
11319272|NCT02571959|Experimental|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
11319273|NCT02571946|Experimental|Proton beam therapy|
11319274|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
11319275|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
11319276|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
11319277|NCT02571907|Experimental|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
11319278|NCT02571894|No Intervention|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
11319279|NCT02571894|Experimental|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
11319280|NCT02571881|Active Comparator|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
11319281|NCT02571881|Experimental|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
11319524|NCT02570334|Experimental|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
11319282|NCT02571855|Experimental|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
11319283|NCT02571855|Placebo Comparator|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
11319284|NCT02571855|Experimental|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
11319285|NCT02571855|Placebo Comparator|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
11319286|NCT02571855|Experimental|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
11319287|NCT02571855|Placebo Comparator|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
11319288|NCT02571842|Experimental|Rituximab|"Drug: Rituximab
~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4
~Other Name: Mabthera"
11319289|NCT02571842|Active Comparator|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB
~An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of <130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB
~Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily
~Other Name: Enalapril, Lorsartan, Prednisolone"
11319290|NCT02571829|Experimental|ribociclib|single arm ribociclib Oral 600 mg x 1 a day duration according to response.
11319291|NCT02571816|Experimental|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
11319292|NCT02571816|Experimental|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
11319293|NCT02571816|Experimental|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
11319294|NCT02571803|Experimental|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
11319295|NCT02571803|Active Comparator|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
11319296|NCT02571790|Experimental|Relaxation optimized virtual reality|six relaxation sessions with virtual reality
11319297|NCT02571790|Experimental|Classical relaxation (without Virtual Reality).|six relaxation sessions without virtual reality
11319298|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
11319299|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
11319300|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
11319301|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
11319302|NCT02571777|Active Comparator|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
11319303|NCT02571764|Experimental|Nutritional Oats Cookie|
11319304|NCT02571751|Experimental|Breast Augmentation|
11319305|NCT02571738|Active Comparator|CHAM|Cryopreserved Human Amniotic Membrane
11319306|NCT02571738|Placebo Comparator|Control|Standard of Care
11319307|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:
~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.
~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested
~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab
~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes
~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
11319308|NCT02571712|Other|GANFORT®|One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.
11319309|NCT02571699|Active Comparator|Subgluteal sciatic block|Subgluteal block with similar volume
11319310|NCT02571699|Experimental|Subgluteal block|Subgluteal block with decreasing volume
11319311|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
11319312|NCT02571660|Active Comparator|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
11319313|NCT02571660|Experimental|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
11319314|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
11319315|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
11319316|NCT02571608|Active Comparator|Metformin|Metformin, dosage same as the patient's regular dosage
11319317|NCT02571608|Placebo Comparator|Placebo|Placebo
11319344|NCT02571413|Other|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
11319669|NCT02569372|Experimental|GC1102 180,000 IU(Single does)|GC1102 180,000 IU(Single does) I.V.
11319318|NCT02571595|Experimental|Immediate dCBT-I group|Digital cognitive behavioural therapy for insomnia (dCBT-I) is a 6 session training program (spanning 6 to 12 weeks) designed to improve sleep. Participants in the immediate dCBT-I group will receive the Sleepio intervention shortly after enrollment.
11319319|NCT02571595|Experimental|Waitlist control group|Participants in the waitlist control group will receive sleep hygiene recommendations from validated online resources for HIV patients (http://www.catie.ca/en/positiveside/winter-2013/sleep-tight) around the time of enrollment. They will start the digital cognitive behavioural therapy for insomnia (dCBT-I) intervention 12-14 weeks after the initial enrollment.
11319320|NCT02571582||Patients died|"All patients underwent extensive evaluation:
~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
11319321|NCT02571582||living patients|"All patients underwent extensive evaluation:
~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
11319322|NCT02571569|Experimental|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
11319323|NCT02571569|Experimental|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
11319324|NCT02571569|Experimental|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
11319325|NCT02571556|Experimental|Dexamethasone Phosphate Ophthalmic Solution|
11319326|NCT02571543|Experimental|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.
~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
11319327|NCT02571543|No Intervention|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
11319328|NCT02571530|Experimental|Intra-arterial Cerebral Infusion of Trastuzumab|Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption
11319329|NCT02571517|Experimental|Glucocorticoids|"methylprednisolone intravenous administration of 2mg/kg/day (divided in two doses) and/or oral prednisolone 2,5 mg/kg/day (in two divided doses) during 7 days.
~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis"
11319330|NCT02571517|Placebo Comparator|Placebo|"will receive iv/oral glucose 5% solution as placebo of 2mg/kg/day and/or 2,5 mg/kg/day (divided in two doses) during 7 days.
~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis."
11319331|NCT02571504|Experimental|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
11319332|NCT02571504|Experimental|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
11319333|NCT02571491|Experimental|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:
~KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation
~during surgery remifentanil 0,3 mcg / kg / min.
~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
11319334|NCT02571491|Placebo Comparator|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:
~0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation
~during surgery remifentanil 0.3 mcg / kg / min.
~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
11319335|NCT02571478|Experimental|7-Month Wait List Group|Couples will be randomly assigned to a wait list group. This group will wait seven months before starting The Marriage Checkup.
11319336|NCT02571478|Experimental|MC Right Away|Couples will be randomly assigned to receive The Marriage Checkup right away.
11319337|NCT02571452|Experimental|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
11319338|NCT02571452|Active Comparator|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
11319339|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
11319340|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
11319341|NCT02571426|Active Comparator|Propofol|Continuous infusion during surgery. Individual dosage.
11319342|NCT02571426|Active Comparator|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
11319343|NCT02571413|Other|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
11319346|NCT02571387|Experimental|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
11319347|NCT02571387|Sham Comparator|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
11319348|NCT02571387|No Intervention|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
11319349|NCT02571374|Experimental|symbiotic group|Symbiotic group
11319350|NCT02571374|Placebo Comparator|placebo group|placebo group
11319351|NCT02571361|Active Comparator|Treatment A:|Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
11319352|NCT02571361|Active Comparator|Treatment B:|Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
11319353|NCT02571361|Active Comparator|Treatment C:|Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
11319354|NCT02571361|Active Comparator|Treatment D:|Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
11319355|NCT02571348|Active Comparator|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
11319356|NCT02571348|Active Comparator|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
11319357|NCT02571348|Active Comparator|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
11319358|NCT02571335|Experimental|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
11319359|NCT02571335|Active Comparator|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
11319360|NCT02571322|Experimental|Whole Body Vibration training|Use of the HyperVibe Whole Body Vibration training device for 12 weeks 3 times per week crossover to aerobic exercise
11319361|NCT02571322|Placebo Comparator|Aerobic Exercise|Aerobic exercise training for 12 weeks 3 times per week crossover to use of the HyperVibe Whole Body Vibration training device
11319362|NCT02571309|Other|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;
~Lung function testing with Bluetooth connection of external spirometry
~Symptom evaluation
~Actual treatment plan, based om lung function and symptoms
~Trend views of lung function, symptoms and asthma control"
11319363|NCT02571309|Other|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
11319364|NCT02571296|Active Comparator|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.
~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
11319365|NCT02571296|Placebo Comparator|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.
~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
11319366|NCT02571283|Experimental|Randomized Group A [Cocktail Injection]|"COCKTAIL INJECTION:
~Cocktail Injection Consists of:
~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose"
11319367|NCT02571283|Experimental|Randomized Group B [Cocktail Injection Plus Exparel]|"COCKTAIL INJECTION PLUS EXPAREL:
~Cocktail Injection Consists of:
~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose
~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
11319368|NCT02571283|Experimental|Randomized Group C [Marcaine Plus Exparel]|"MARCAINE PLUS EXPAREL:
~Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose
~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
11319369|NCT02571270|Active Comparator|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
11319370|NCT02571270|Active Comparator|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
11319371|NCT02571270|Active Comparator|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
11319372|NCT02571270|Active Comparator|survival|The survival of patients with heart failure may increase with exercise training.
11319373|NCT02571257|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
11319374|NCT02571257|Experimental|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
11319375|NCT02571257|Experimental|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
11319376|NCT02571244|Experimental|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
11319377|NCT02571244|No Intervention|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
11319378|NCT02571231|Experimental|HFV+vg|volume guarantee given
11319379|NCT02571231|Experimental|HFV-VG|Volume guarantee not given
11319380|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
11319381|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
11319382|NCT02571192|Experimental|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
11319383|NCT02571179|Experimental|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
11319384|NCT02571166|Experimental|HSV529|
11319385|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
11319386|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
11319387|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
11319388|NCT02571140|Active Comparator|Active Comparator|Subcutaneous injection of Teriparatide
11319389|NCT02571140|Experimental|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
11319390|NCT02571127|Experimental|Only treatment|two weekly applications (monday and thursday or tuesday and friday) for 12 weeks
11319391|NCT02571114|Active Comparator|Control 1|white bread - 25 g available carbohydrate
11319392|NCT02571114|Active Comparator|Control 2|white bread - 25 g available carbohydrate
11319393|NCT02571114|Sham Comparator|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
11319394|NCT02571114|Experimental|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
11319395|NCT02571101|Experimental|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
11319396|NCT02571101|Experimental|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
11319397|NCT02571101|Placebo Comparator|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
11319398|NCT02571088|Experimental|Training Program|The treatment will consist in an endurance training program. Only patients of the trained group will be subjected to this training program which will typically consist in 3 training sessions per week during 8 weeks i.e., 24 training sessions. Each training session will last 45 min. All training sessions will take place at the hospital and will be under medical supervision.
11319399|NCT02571088|No Intervention|No Training Program|It will be asked to the control patients to not change their habitual physical activity during the entire period of observation
11319400|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
11319401|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
11319402|NCT02571062|Experimental|experimental formulation|crossover design
11319403|NCT02571062|Experimental|final formulation|crossover design
11319404|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
11319405|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
11319406|NCT02571036|Experimental|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]
11319407|NCT02571036|Experimental|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]
11319408|NCT02571036|Experimental|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]
11319409|NCT02571036|Experimental|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]
11319410|NCT02571036|Experimental|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]
11319411|NCT02571036|Experimental|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]
11319670|NCT02569372|Experimental|GC1102 240,000 IU(Single does)|GC1102 240,000 IU(Single does) I.V.
11319412|NCT02571036|Experimental|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]
11319413|NCT02571036|Experimental|Expansion Cohort 7|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas.
11319414|NCT02571036|Experimental|Expansion Cohort 8|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]
11319415|NCT02571036|Experimental|Expansion Cohort 9|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]
11319416|NCT02571036|Experimental|Expansion Cohort 10|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]
11319417|NCT02571010|Experimental|Vibrotactile stimulation|"Patients in this arm will have
~treatment by medications and rehabilitation
~treatment by vibrotactile at medical center
~stimulation at home by soft tissue
~non stimulation on allodynia area"
11319418|NCT02571010|Sham Comparator|Sham Stimulation with Vibradol device switched off|"Patients in this arm will have
~treatment by medications and rehabilitation
~Sham vibrotactile treatment at medical center but with Vibradol device switched off
~abdominal breath exercises at home
~non stimulation on allodynia area"
11319419|NCT02571010|Other|Standard Medical treatment|Observational group, treated as usually by medications and rehabilitation.
11319420|NCT02570997|Active Comparator|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
11319421|NCT02570997|Placebo Comparator|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
11319422|NCT02570984|Active Comparator|Active|omalizumab 0.016 mg/kg/IU total IgE
11319423|NCT02570984|Placebo Comparator|Placebo|looks like active drug
11319424|NCT02570971|No Intervention|Control|Patients will receive supportive care measures.
11319425|NCT02570971|Experimental|Investigational|Patients will receive 500mL of 20% mannitol
11319426|NCT02570958|Experimental|Indocyanine green|
11319427|NCT02570945|Experimental|Intervention|Pharmacist-physician medication review
11319428|NCT02570945|No Intervention|Control|
11319429|NCT02570932|Experimental|Autologous Mesenchymal Bone Marrow Cell|"All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)
~Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
11319430|NCT02570919|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
11319431|NCT02570919|Experimental|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
11319432|NCT02570893|Experimental|adjuvant chemoradiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
11319433|NCT02570893|Experimental|adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
11319434|NCT02570880|Experimental|Bread sample vs. glucose solution|glycemic index
11319435|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
11319436|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
11319437|NCT02570854|Experimental|CSJ137|In Part 1 up to 48 subjects will receive a single dose of CSJ137. In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
11319438|NCT02570854|Placebo Comparator|Placebo|In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
11319439|NCT02570841|Active Comparator|Capsaicin|Treatment with Topical High dose Capsaicin
11319440|NCT02570841|Placebo Comparator|Placebo|Treatment with Topical Placebo
11319441|NCT02570828|Experimental|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
11319442|NCT02570815|Experimental|indocyanine green|Non-toxic, fluorescent dye
11319443|NCT02570802|Other|ultrasound of peripheral nerves|Ultrasonographic examination
11319444|NCT02570789|Experimental|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
11319445|NCT02570776||observation|Cohort of patients for Endoscopy & they are assessed for Helicobacter pylori through the histopathology & also throgh C14 C UBT.
11319446|NCT02570763|Experimental|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
11319447|NCT02570763|Sham Comparator|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
11319448|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
11319449|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
11319450|NCT02570737||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
11319451|NCT02570737||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
11319452|NCT02570724|Active Comparator|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
11319453|NCT02570724|Active Comparator|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
11319454|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
11319455|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
11319456|NCT02570685|Experimental|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
11319457|NCT02570685|Experimental|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
11319458|NCT02570685|Active Comparator|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
11319459|NCT02570672|Experimental|Metformin|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated)
11319460|NCT02570672|Placebo Comparator|Placebo|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated) vs. placebo.
11319461|NCT02570659|No Intervention|Information Folder|A folder with advise and exercises used by physiotherapeutic clinic of Södersjukhuset Hospital (Treatment as usual)
11319462|NCT02570659|Experimental|Information Video|A multiprofessional information video
11319463|NCT02570646|Experimental|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
11319464|NCT02570633|Experimental|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
11319465|NCT02570633|Placebo Comparator|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
11319466|NCT02570620|Experimental|Observational cohort of patients|Patients will benefit from an ultrasonography of the cervix through endovaginal before induction of prostaglandins
11319467|NCT02570594|Other|healthy volunteers|
11319468|NCT02570581|Placebo Comparator|Plain jelly control|Plain jelly control
11319469|NCT02570581|Active Comparator|Jelly with: Paracetamol|"Jelly with:
~Paracetamol"
11319470|NCT02570581|Active Comparator|Jelly with Furosemide|Jelly with Furosemide
11319471|NCT02570581|Active Comparator|Jelly with Levothyroxine sodium salt|Jelly with Levothyroxine sodium salt
11319472|NCT02570581|Active Comparator|Jelly with memantine|Jelly with memantine
11319473|NCT02570581|Active Comparator|jelly with zopiclone|Jelly with zopiclone
11319474|NCT02570581|Active Comparator|jelly with alprazolam|elly with alprazolam
11319475|NCT02570581|Active Comparator|jelly with Oxazepam|Jelly with Oxazepam
11319476|NCT02570581|Active Comparator|jelly with donepezil|jelly with donepezil
11319477|NCT02570581|Active Comparator|Jelly with clopidogrel|jelly with clopidogrel
11319478|NCT02570581|Active Comparator|jelly with ramipril|jelly with ramipril
11319479|NCT02570581|Active Comparator|jelly with Paracetamol + Furosemide + Levothyroxine sodium sa|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
11319480|NCT02570581|Placebo Comparator|Plain apple compote control|Plain apple compote control
11319481|NCT02570581|Active Comparator|Apple compote Paracetamol|Apple compote Paracetamol
11319482|NCT02570581|Active Comparator|Apple compote Furosemide|Apple compote Furosemide
11319483|NCT02570581|Active Comparator|Apple compote Levothyroxine sodium salt|Apple compote Levothyroxine sodium salt
11319484|NCT02570581|Active Comparator|Apple compote Memantine|Apple compote Memantine
11319485|NCT02570581|Active Comparator|Apple compote Zopiclone|Apple compote Zopiclone
11319486|NCT02570581|Active Comparator|Apple compote Alprazolam|Apple compote Alprazolam
11319487|NCT02570581|Active Comparator|Apple compote Oxazepam|Apple compote Oxazepam
11319488|NCT02570581|Active Comparator|Apple compote Donepezil|Apple compote Donepezil
11319489|NCT02570581|Active Comparator|Apple compote Clopidogrel|Apple compote Clopidogrel
11319490|NCT02570581|Active Comparator|Apple compote Ramipril|Apple compote Ramipril
11319491|NCT02570581|Active Comparator|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopi|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopiclone Alprazolam
11319492|NCT02570568|Active Comparator|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
11319493|NCT02570568|Experimental|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
11319525|NCT02570321|Experimental|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
11319526|NCT02570321|Active Comparator|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
11319494|NCT02570568|Experimental|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
11319495|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
11319496|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
11319497|NCT02570529|Experimental|Albis®|The intervention group
11319498|NCT02570529|Placebo Comparator|Placebo|The placebo comparator group
11319499|NCT02570516|Active Comparator|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
11319500|NCT02570516|Experimental|NBI colonoscopy|Colonoscopy using NBI is performed in first place
11319501|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
11319502|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
11319503|NCT02570490|Experimental|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
11319504|NCT02570490|Active Comparator|Linezolid|600 mg by mouth every 12 hours for 10 days
11319505|NCT02570477|Active Comparator|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
11319506|NCT02570477|Active Comparator|Standard Therapy|125mg Vancomycin four times per day
11319507|NCT02570464|Experimental|Patients undergoing aortic aneurysm surgery with RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery with Remote ischemic preconditioning (RIPC)
11319508|NCT02570464|Sham Comparator|Patients undergoing aortic aneurysm surgery without RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery without Remote ischemic preconditioning (RIPC)
11319509|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
11319510|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
11319511|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
11319512|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
11319513|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
11319514|NCT02570399|Experimental|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
11319515|NCT02570386|Active Comparator|Control arm|Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
11319516|NCT02570386|Active Comparator|Intervention arm|Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
11319517|NCT02570373|Experimental|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
11319518|NCT02570360|Active Comparator|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
11319519|NCT02570360|Placebo Comparator|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
11319520|NCT02570347|Active Comparator|Routine use arm|"All participants allocated to this arm will be given
~Injection Tetanus toxoid 0.5 ml intramuscularly Stat
~Antibiotic (Co-amoxiclav) will be given to all patients for a minimum duration of 5 days.
~Daily clinical assessment would be done. Change of antibiotics is allowed if clinical failure occurs.
~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
11319521|NCT02570347|Experimental|Clinically-directed use arm|"Participants allocated to this arm will be given
~Injection Tetanus toxoid 0.5 ml intramuscularly Stat
~Daily clinical assessment would be done. Antibiotic (Co-amoxiclav) will be started only if clinical failure occurs.
~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
11319522|NCT02570334|Experimental|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
11319523|NCT02570334|Experimental|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
11319744|NCT02568813|Experimental|Scales passation|
11319527|NCT02570321|Experimental|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
11319528|NCT02570321|Active Comparator|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
11319529|NCT02570321|Experimental|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
11319530|NCT02570321|Active Comparator|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
11319531|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen. This arm is closed
11319532|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen
11319533|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
11319534|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
11319535|NCT02570282|Experimental|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
11319536|NCT02570282|Placebo Comparator|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
11319537|NCT02570269|Active Comparator|AuraGain|The patient will get a fiberoptic Intubation via the AuraGain larynxmask
11319538|NCT02570269|Placebo Comparator|Slotted Guedeltubus|The patient will get a fiberoptic intubation via the slotted Guedeltubus
11319539|NCT02570256|Experimental|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
11319540|NCT02570256|Experimental|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
11319541|NCT02570256|Experimental|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
11319542|NCT02570243|Active Comparator|Standard dose of Heparin|50IU/Kg heparin intravenously
11319543|NCT02570243|Experimental|High dose of Heparin|100IU/Kg heparin intravenously
11319544|NCT02570230|Placebo Comparator|Control|NSS infusion
11319545|NCT02570230|Experimental|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
11319546|NCT02570217|Experimental|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
11319547|NCT02570217|Active Comparator|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
11319548|NCT02570204|Experimental|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
11319549|NCT02570191|Experimental|Peginterferon alfa-2a|Participants received 180 micrograms (uG) of Pegasys (0.5 milliliter [mL] solution) once a week subcutaneously for 48 weeks.
11319550|NCT02570178|No Intervention|standard practice advice|standard practice advice
11319551|NCT02570178|Other|balance training|balance training using the Nintendo™ Wii console and its balance board.
11319552|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319553|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319554|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319555|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319556|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319557|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319558|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
11319559|NCT02570152|Experimental|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
11319560|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
11319561|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
11319562|NCT02570126|Experimental|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
11319563|NCT02570126|Active Comparator|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
11319599|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
11319600|NCT02569840|Other|Amino Acid Feed|An amino acid based multi-nutrient powdered feed
11319564|NCT02570113|Experimental|Renal Denervation by Neurolysis|Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
11319565|NCT02570100|Experimental|Biological collection|Before, during and after their treatment by chemotherapy, patients will undergo laboratory examinations.
11319566|NCT02570087|Active Comparator|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
11319567|NCT02570087|No Intervention|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
11319568|NCT02570074|Experimental|Fosfomycin - 3 doses QoD/7 doses QD|Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
11319569|NCT02570074|Experimental|Fosfomycin - 7 doses QD/3 doses QoD|Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
11319570|NCT02570061|Experimental|telephone|Information about the Calmette study was given by telephone
11319571|NCT02570061|Active Comparator|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
11319572|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
11319573|NCT02570035||Mirabegron group|Subjects with overactive bladder and cardiovascular disease prescribed mirabegron
11319574|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
11319575|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
11319576|NCT02570009|Active Comparator|TEAMS|
11319577|NCT02570009|Active Comparator|TEAMS+|
11319578|NCT02569996|Experimental|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
11319579|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
11319580|NCT02569970|Active Comparator|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
11319581|NCT02569970|Placebo Comparator|PLACEBO|1 month of treatment before EEG video.
11319582|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11319583|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11319584|NCT02569944|Active Comparator|perineal bag|Perineal bag was placed in infants to collect an urine sample.
11319585|NCT02569944|Experimental|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
11319586|NCT02569931|Experimental|study group|"36 participants recruited aged between 18 to 50 years of age
~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:
~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.
~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.
~During surgery the study group will undergo intra-operative tracking and pressure measurements."
11319587|NCT02569931|Other|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.
~The control group will undergo gait analysis and electromyography."
11319588|NCT02569918|Experimental|Surface electrical stimulation|Operation of hand prosthesis with surface electrical sensory feedback
11319589|NCT02569905|Active Comparator|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
11319590|NCT02569905|Active Comparator|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
11319591|NCT02569905|Placebo Comparator|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
11319592|NCT02569892|Experimental|Laser Arm|Sub-threshold laser utilizing Pascal laser with endpoint-management software
11319593|NCT02569892|Sham Comparator|Sham Laser Arm|Sham laser treatment
11319594|NCT02569879||Infants Group|"All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.
~All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.
~All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.
~All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014."
11319595|NCT02569879||Pregnant women Group|• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014
11319596|NCT02569866|Active Comparator|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
11319597|NCT02569866|Placebo Comparator|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
11319598|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
11319601|NCT02569827|Placebo Comparator|Cohort 1|"Placebo Q6H for 5 days
~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
11319602|NCT02569827|Active Comparator|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
11319603|NCT02569827|Active Comparator|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
11319604|NCT02569827|Active Comparator|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
11319605|NCT02569814|Other|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
11319606|NCT02569814|Other|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
11319607|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
11319608|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
11319609|NCT02569788|Experimental|CIRT Arm|Patients included in this arm were treated with carbon ion radiotherapy (CIRT).
11319610|NCT02569775|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
11319611|NCT02569762|Experimental|Sucralose-Aspartame|Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
11319612|NCT02569762|Experimental|Aspartame-Sucralose|Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
11319613|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
11319614|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
11319615|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
11319616|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (<40%)
11319617|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
11319618|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
11319619|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus…). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis…
11319620|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
11319621|NCT02569710|Experimental|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
11319622|NCT02569710|Experimental|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
11319623|NCT02569710|Experimental|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
11319624|NCT02569710|Experimental|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
11319625|NCT02569710|Experimental|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
11319626|NCT02569710|Experimental|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
11319627|NCT02569710|Experimental|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
11319628|NCT02569710|Experimental|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram [mg], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
11319629|NCT02569697|Other|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
11319630|NCT02569697|Other|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
11319631|NCT02569697|Other|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
11319632|NCT02569697|Other|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
11319633|NCT02569684|Active Comparator|Arm A|Prebiotic fibers: Oligofructose and inulin
11319634|NCT02569684|Placebo Comparator|Arm B|Maltodextrin
11319635|NCT02569671|Other|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
11319636|NCT02569671|Other|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
11319637|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
11319638|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
11319639|NCT02569645|Experimental|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
11319640|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
11319641|NCT02569619|Experimental|Activity Intervention|The activity intervention is MoVo-LISA (Göhner & Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
11319642|NCT02569619|Active Comparator|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
11319643|NCT02569606||Timeframe 2005 - 2007|Data of timeframe 2005 up to 2007 will be included
11319644|NCT02569606||Timeframe 2012 - 2014|Data of timeframe 2012 up to 2014 will be included
11319645|NCT02569593|Other|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
11319646|NCT02569567||US elastography|"Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic.
~Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis."
11319647|NCT02569554|Experimental|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
11319648|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:
~6 months of treatment; or
~24 months of treatment (if continued on chronic suppressive therapy)"
11319649|NCT02569528||Patients|Patients of consenting providers will complete a short survey and interview.
11319650|NCT02569528||Providers|Physicians treating patients with atrial fibrillation will complete a short survey and interview.
11319651|NCT02569515|Experimental|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
11319652|NCT02569502|Experimental|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
11319653|NCT02569489|Experimental|HBI-8000, Paclitaxel, Trastuzumab|HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
11319654|NCT02569476|Experimental|BGB-3111 and obinutuzumab|In the dose-escalation part, the dose levels and regimens will be evaluated. In the indication-specific expansion cohorts, patients will be assigned to different cohorts based on histology type.
11319655|NCT02569463|Experimental|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
11319656|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
11319657|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
11319658|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
11319659|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
11319660|NCT02569424|Experimental|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
11319661|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
11319662|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
11319663|NCT02569398|Experimental|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
11319664|NCT02569398|Experimental|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
11319665|NCT02569398|Experimental|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
11319666|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
11319667|NCT02569372|Experimental|GC1102 80,000 IU(Single does)|GC1102 80,000 IU(Single does) I.V.
11319668|NCT02569372|Experimental|GC1102 120,000 IU(Single does)|GC1102 120,000 IU(Single does) I.V.
11372936|NCT02215005|Active Comparator|Ramipril|5 days qd
11319671|NCT02569372|Experimental|GC1102 80,000 IU(Multiple does)|GC1102 80,000 IU(Multiple does) I.V.
11319672|NCT02569372|Experimental|GC1102 120,000 IU(Multiple does)|GC1102 120,000 IU(Multiple does) I.V.
11319673|NCT02569372|Experimental|GC1102 180,000 IU(Multiple does)|GC1102 180,000 IU(Multiple does) I.V.
11319674|NCT02569372|Experimental|GC1102 240,000 IU(Multiple does)|GC1102 240,000 IU(Multiple does) I.V.
11319675|NCT02569359|Experimental|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
11319676|NCT02569359|Placebo Comparator|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
11319677|NCT02569346|Active Comparator|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
11319678|NCT02569346|Experimental|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
11319679|NCT02569346|Experimental|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
11319680|NCT02569333|Experimental|Educational Video|Subjects to have access to educational video during hospital stay
11319681|NCT02569333|No Intervention|Usual Care|Patients to receive usual care and will not have access to educational video.
11319682|NCT02569320|Experimental|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11319683|NCT02569307|Active Comparator|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
11319684|NCT02569307|Active Comparator|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
11319685|NCT02569307|Active Comparator|Placebo|Placebo added to TAU
11319686|NCT02569307|Active Comparator|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
11319687|NCT02569294|Experimental|Choice 1: Yoga intervention|See intervention description
11319688|NCT02569294|Experimental|Choice 2: Hypnosis intervention|See intervention description
11319689|NCT02569294|Experimental|Choice 3: CBT intervention|See intervention description
11319690|NCT02569294|No Intervention|Control group|Participants who agreed not to participate in any of the interventions proposed.
11319691|NCT02569281|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
11319692|NCT02569281|Active Comparator|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
11319693|NCT02569268||exposure population|No special intervention(s) .
11319694|NCT02569242|Experimental|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11319695|NCT02569242|Active Comparator|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
~OR
~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
11319696|NCT02569229||Patients with Cystic Fibrosis|Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children's hospital Basel and university children's hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
11319697|NCT02569216|Experimental|Electrical Inhibition (EI) intervention|Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
11319698|NCT02569203|Placebo Comparator|control group|standard enteral nutrition
11319699|NCT02569203|Experimental|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
11319700|NCT02569203|Experimental|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
11319701|NCT02569190|Experimental|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
11319702|NCT02569138|Experimental|Insole (Experimental)|specially designed insole, featuring hard and thin design, modified insole
11319703|NCT02569138|Experimental|Insole (Control)|usual insole found in footwear, non-modified insole
11319704|NCT02569125|Experimental|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
11319705|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
11319706|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
11319707|NCT02569099|Experimental|Intervention using standardised care|"Caregiver training /standardised care: where the participants (caregivers)s are trained on caring for relative who has survived a stroke once only for one hour using a developed curriculum.
~Plus Conventional care: where the participants continue to receive the usual care as offered in protocols for treatment of stroke in Zimbabwe."
11319708|NCT02569099|No Intervention|Control|No training offered to caregivers but conventional care only where the people who have survived a stroke receive the usual care as offered in protocols for treatment of stroke in Zimbabwe.
11319709|NCT02569073|Experimental|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
11319710|NCT02569073|Placebo Comparator|Placebo|Patients who receive Placebo every other night, orally
11319711|NCT02569060|Experimental|Immediate Intervention|"Participants randomized to the Intervention Arm will immediately begin a four-component intervention.
~Testing and monitoring of blood glucose levels
~Referral to and/or coordination with primary care provider
~Diabetes-appropriate food packages
~Diabetes self-management education and support"
11319712|NCT02569060|Active Comparator|Waitlist Control|"Participants randomized to the Waitlist Control arm will receive no intervention for six months, after which time they will begin a modified, four-component intervention.
~Testing and monitoring of blood glucose levels
~Referral to and/or coordination with primary care provider
~Diabetes-appropriate food packages
~Limited diabetes self-management education and support"
11319713|NCT02569047|Active Comparator|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
11319714|NCT02569047|Experimental|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
11319715|NCT02569034|Active Comparator|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
11319716|NCT02569034|Experimental|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
11319717|NCT02569021||Biphasic DBS stimulations|Subjects in this group will have Biphasic DBS stimulation setting performed, Unified Parkinson's Disease Rating Scale (UPDRS), Tremor Rating Scale (TRS), kinesia accelerometer assessment, Trigno wireless system (EMG) assessment and GaitRite walking assessment performed.
11319718|NCT02569008|Experimental|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
11319719|NCT02569008|Experimental|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
11319720|NCT02569008|Experimental|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
11319721|NCT02569008|Experimental|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
11319722|NCT02568995|Experimental|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
11319723|NCT02568995|Active Comparator|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
11319724|NCT02568982||patient with Cushing's disease|
11319725|NCT02568969|Experimental|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
11319726|NCT02568930||Heart Transplantation (HT)|The cohort includes advanced heart failure patients (60-80 years of age) listed for HT and their caregivers.
11319727|NCT02568930||Mechanical Circulatory Support (MCS)|The cohort includes advanced heart failure patients (60-80 years of age) scheduled for DT MCS and their caregivers.
11319728|NCT02568917|Active Comparator|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
11319729|NCT02568917|Experimental|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
11319730|NCT02568904||Alcohol binge|Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge
11319731|NCT02568904||Fructose|75 g Fructose orally
11319732|NCT02568904||Glucose|75 g Glucose orally
11319733|NCT02568904||Vehicle|2ml tap water per kg body weight
11319734|NCT02568891|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
11319735|NCT02568891|Placebo Comparator|Placebo|similar looking and tasting placebo without bacteria
11319736|NCT02568878|Experimental|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
11319737|NCT02568865||Major Depressive Disorder|
11319738|NCT02568865||Healthy Volunteers|
11319739|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
11319740|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
11319741|NCT02568839|Active Comparator|A standard treatment|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.
~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
11319742|NCT02568839|Experimental|B experimental treatment|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.
~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
11319743|NCT02568826|Experimental|IDN 5243|IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities for intramuscular administration in 4 mg/mL vials. It will be administered twice daily for 5 consecutive days with the first administration in the morning (8.00-10.00 AM) and the second in the evening (6.00-8.00 PM).
11319745|NCT02568800|Experimental|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
11319746|NCT02568800|Active Comparator|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
11319747|NCT02568787|Experimental|Rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
11319748|NCT02568787|Placebo Comparator|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
11319749|NCT02568774|Experimental|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
11319750|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
11319751|NCT02568761|Active Comparator|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
11319752|NCT02568761|Active Comparator|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
11319753|NCT02568748|Experimental|CIK with TACE for HCC stage B|HCC patients stage B treated with TACE and CIK as adjuvant therapy.
11319754|NCT02568748|Experimental|TACE only for HCC stage B|HCC patients stage B treated with TACE without receiving CIK cells infusion
11319755|NCT02568748|Experimental|CIK in HCC stage C or D|HCC stage C or D will receive supportive treatment in addition to CIK cells infusion
11319756|NCT02568748|No Intervention|Supportive treatment in HCC stage C or D|HCC stage C or D will receive supportive treatment only .
11319757|NCT02568735|Experimental|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight> 90kg by mouth
11319758|NCT02568735|Active Comparator|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
11319759|NCT02568722|Active Comparator|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
11319760|NCT02568722|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
11319761|NCT02568709|Active Comparator|Interventional|40 IU Oxytocin
11319762|NCT02568709|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
11319763|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
11319764|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
11319765|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
11319766|NCT02568670|Experimental|according to clinical signs|removal the peripheral catheter according to clinical signs
11319767|NCT02568670|No Intervention|sistematically every 96 hours|removal the peripheral catheter every 96 hours
11319768|NCT02568657|Active Comparator|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
11319769|NCT02568657|Active Comparator|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
11319770|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
11319771|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
11319772|NCT02568631|Experimental|serious game JeStiMulE|"Evaluation of the social cognition for adults with autism.
~The objective of the players of JeStiMulE (Educational Game for Multisensory Stimulation of Children with developmental disorders) will be to end the game after a period of learning and two periods of game (with emotional words and with idiomatic expressions understanding each three modules). The session ends when the module is carried out, what corresponds approximately at 1 am by module, that is 6 sessions of game.
~Evaluation of the social cognition for adults with autism."
11319773|NCT02568631|Placebo Comparator|control video game|"Evaluation of the social cognition for adults with autism.
~The objective of the players of the control video game will be to play 6 sessions of one hour.
~Evaluation of the social cognition for adults with autism."
11319774|NCT02568618|Other|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
11319817|NCT02568267|Experimental|ROS1-rearranged NSCLC|Oral entrectinib (RXDX-101)
11319775|NCT02568618|Other|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
11319776|NCT02568605|Experimental|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
11319777|NCT02568605|Placebo Comparator|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
11319778|NCT02568605|Other|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
11319779|NCT02568592|Experimental|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
11319780|NCT02568592|Experimental|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
11319781|NCT02568592|Experimental|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
11319782|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
11319783|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
11319784|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
11319785|NCT02568553|Experimental|Treatment (blinatumomab, lenalidomide)|"INDUCTION: Patients receive blinatumomab IV continuously on days 1-56 and lenalidomide PO on days 29-49 in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients achieving response including stable disease receive blinatumomab IV continuously on days 1-7 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receiving response including stable disease after completion of Consolidation receive lenalidomide PO on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
11319786|NCT02568527|Experimental|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
11319787|NCT02568514|No Intervention|Usual care|Patients admitted to hospital floors without any other intervention.
11319788|NCT02568514|Experimental|Secure text messaging|Patients admitted to hospital floors on which physicians and other staff are able to communicate with each other (not to the patient) using mobile secure text messaging.
11319789|NCT02568501|Experimental|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
11319790|NCT02568501|Experimental|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
11319791|NCT02568488|Experimental|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
11319792|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
11319793|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
11319794|NCT02568462|Experimental|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
11319795|NCT02568449|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11319796|NCT02568436|No Intervention|Conventional Decrowding|Crowded upper incisors will be treated in the conventional manner with a fake irradiation without using low level laser therapy.
11319797|NCT02568436|Experimental|Low Level Laser Therapy|Each maxillary incisor will be subjected to low level laser therapy at specific times in order to accelerate tooth movement
11319798|NCT02568423|Experimental|Mirikizumab IV|Mirikizumab given by intravenous (IV) infusion once.
11319799|NCT02568423|Experimental|Mirikizumab SC|Mirikizumab given by subcutaneous (SC) injection once.
11319800|NCT02568423|Placebo Comparator|Placebo IV|Placebo given by IV infusion once.
11319801|NCT02568423|Placebo Comparator|Placebo SC|Placebo given by SC injection once.
11319802|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
11319803|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
11319804|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
11319805|NCT02568384|Experimental|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:
~40 to 70% of subjects will have type 1 diabetes
~Not more than 30% of subjects will use an insulin pump"
11319806|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
11319807|NCT02568332|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.
~Subjects: 20 HIV seropositive individuals"
11319808|NCT02568319|Experimental|LIPO-202|Experimental arm
11319809|NCT02568319|Placebo Comparator|Placebo|Placebo comparator
11319810|NCT02568306|Experimental|NNC0165-1562|
11319811|NCT02568306|Placebo Comparator|Placebo|
11319812|NCT02568293|Experimental|SBCV|SBCV is administered to the site immediately post balloon dilation.
11319813|NCT02568293|Placebo Comparator|Control|Saline is used as a control and is delivered immediately post balloon dilation.
11319814|NCT02568280|Experimental|Faster aspart|
11319815|NCT02568280|Active Comparator|Insulin aspart|
11319816|NCT02568267|Experimental|NTRK1/2/3-rearranged NSCLC|Oral entrectinib (RXDX-101)
11319818|NCT02568267|Experimental|ALK- or ROS1-rearranged NSCLC|"with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)
~Oral entrectinib (RXDX-101)"
11319819|NCT02568267|Experimental|NTRK/1/2/3-rearranged mCRC|Oral entrectinib (RXDX-101)
11319820|NCT02568267|Experimental|ROS1-rearranged mCRC|Oral entrectinib (RXDX-101)
11319821|NCT02568267|Experimental|ALK-rearranged mCRC|Oral entrectinib (RXDX-101)
11319822|NCT02568267|Experimental|NTRK1/2/3-rearranged other solid tumor|Oral entrectinib (RXDX-101)
11319823|NCT02568267|Experimental|ROS1-rearranged other solid tumor|Oral entrectinib (RXDX-101)
11319824|NCT02568267|Experimental|ALK-rearranged other solid tumor|Oral entrectinib (RXDX-101)
11319825|NCT02568254|Active Comparator|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
11319826|NCT02568254|Active Comparator|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
11319827|NCT02568254|Active Comparator|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
11319828|NCT02568254|Active Comparator|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
11319829|NCT02568254|Active Comparator|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
11319830|NCT02568254|Active Comparator|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
11319831|NCT02568241|Experimental|interferon Alfa-2b|High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI
11319832|NCT02568228|Experimental|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to ~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
11319833|NCT02568228|Experimental|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to ~900 mg/day EPA + DHA + DPA.
11319834|NCT02568228|Placebo Comparator|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
11319835|NCT02568215|Experimental|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
11319836|NCT02568215|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
11319837|NCT02568215|Placebo Comparator|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
11319838|NCT02568202||Survey|
11319839|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
11319840|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
11319841|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
11319842|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
11319843|NCT02568176|Experimental|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
11319844|NCT02568176|Experimental|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
11319845|NCT02568163|Other|questionary|
11319846|NCT02568150|Other|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
11319847|NCT02568137|Experimental|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
11319848|NCT02568137|No Intervention|Usual background care|Standard care
11319849|NCT02568124|Experimental|Tranexamic acid|Tranexamic acid 750 mg daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
11319850|NCT02568124|Placebo Comparator|Placebo|Placebo tablet daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
11319851|NCT02568111|Experimental|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
11319852|NCT02568111|Placebo Comparator|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
11319853|NCT02568098|Experimental|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
11319854|NCT02568098|Experimental|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
11319855|NCT02568098|Experimental|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
11319856|NCT02568085|Experimental|1|thyroidectomy + Arista
11319860|NCT02568059|Experimental|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
11319861|NCT02568059|Experimental|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
11319862|NCT02568046|Experimental|Sym004 12 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level 1
11319863|NCT02568046|Experimental|Sym004 9 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level -1
11319864|NCT02568046|Experimental|Sym004 (RP2D) + FOLFIRI|Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI
11319865|NCT02568033|Experimental|A|"Chemotherapy:
~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle
~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle
~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions
~Schedule is:
~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
11319866|NCT02568020|No Intervention|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
11319867|NCT02568020|Experimental|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
11319868|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
11319869|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
11319870|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
11319871|NCT02567994|Experimental|Teneligliptin|20mg qd
11319872|NCT02567994|Active Comparator|Sitagliptin|100mg qd
11319873|NCT02567981|Experimental|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
11319874|NCT02567981|Active Comparator|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
11319875|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
11319876|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
11319877|NCT02567955|Active Comparator|Immunogenicity two doses of Gardasil-9|Subjects will receive two doses of Gardasil-9
11319878|NCT02567955|Experimental|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a dose Cervarix and a dose Gardasil-9
11319879|NCT02567942|Other|propofol group|The patient who anesthetized by using propofol.
11319880|NCT02567942|Other|sevoflurane group|The patient who anesthetized by using propofol.
11319881|NCT02567929|Active Comparator|propofol group|The patient who anesthetized by using propofol.
11319882|NCT02567929|Active Comparator|sevoflurane group|The patient who anesthetized by using propofol
11319883|NCT02567916|Experimental|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
11319884|NCT02567916|Active Comparator|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
11319885|NCT02567903|Active Comparator|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
11319886|NCT02567903|Experimental|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
11319887|NCT02567890|Experimental|Internet-based DBI|Internet-based DBI, which consists of four interactive occasions, some homework assignments, and monitoring
11319888|NCT02567890|Placebo Comparator|Expressive writing|Expressive Writing (placebo/attention control) where participants write texts. This is the active control condition.
11319889|NCT02567890|No Intervention|Waiting list|A wait-list control condition.Those in the wait-list condition will not receive any treatment until they have done the 6-month follow-up assessment.
11319890|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
11319891|NCT02567864|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
11319892|NCT02567864|Active Comparator|control|The control group maintains daily activities.
11319893|NCT02567851|Experimental|Brentuximab Vedotin|brentuximab vedotin will be administered at an initial dose of 1.8 mg/kg every 3 weeks as a 30-minute outpatient i.v. infusion. A maximum of 16 cycles
11319894|NCT02567838|Experimental|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
11319895|NCT02567838|Placebo Comparator|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
11319896|NCT02567825|Active Comparator|Treatment A- surgical management|Tympanostomy tube placement
11319897|NCT02567825|Other|Treatment B - nonsurgical management|Nonsurgical management
11319898|NCT02567812||In-patient with PID|In-patient with PID who diagnosed at Kangbuk Samsung Hospital
11319899|NCT02567799|Experimental|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
11319960|NCT02567318|Experimental|MRI-scan|All study participants will complete a MRI-scan of the brain
11319900|NCT02567786|Active Comparator|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
11319901|NCT02567786|Active Comparator|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
11319902|NCT02567773|Experimental|Part A: GSK2881078|The first cohort subjects will receive GSK2881078 1.5 mg (for males) or 0.75 mg (for females) twice daily for 3 days followed by once daily for 25 days. The subsequent cohort subjects will receive GSK2881078 doses selected after reviewing the unblinded data from at least 2 weeks of dosing of at least 6 subjects in the first cohort. Each cohort subjects will receive GSK2881078 dose twice daily for the first 3 days followed by 25 days of once daily.
11319903|NCT02567773|Placebo Comparator|Part A: Placebo|Subjects will receive placebo twice daily for 3 days followed by once daily for 25 days.
11319904|NCT02567773|Experimental|Part B: GSK2881078-Itraconazole|Subjects will receive GSK2881078 (dose level will be determined based on the results from Part A) on Day 1 of Period-1 and Day 6 of Period-2. Subjects will also receive itraconazole 200 mg twice daily on Day1 of Period-2 and 200 mg once daily on Days 2-34 of Period-2.
11319905|NCT02567760|Active Comparator|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
11319906|NCT02567760|Placebo Comparator|Placebo group|Subject receive the Placebo product for 8 weeks.
11319907|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
11319908|NCT02567734|Experimental|Irreversible electroporation|In this group，eligible patients were selected to receive the CT-guided percutaneous irreversible electroporation ablation.
11319909|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
11319910|NCT02567708|Experimental|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
11319911|NCT02567695|Experimental|Treatment Sequence 1|Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.
11319912|NCT02567695|Experimental|Treatment Sequence 2|Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.
11319913|NCT02567682|Experimental|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
11319914|NCT02567656|Experimental|Single arm|RP6530 administered orally twice a day.
11319915|NCT02567643|Experimental|Stereotactic Radiosurgery|
11319916|NCT02567617|Active Comparator|Intervention group|Group receiving capsules with polyphenols.
11319917|NCT02567617|Placebo Comparator|Placebo controlled group|Group receiving capsules with starch.
11319918|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
11319919|NCT02567591|Experimental|A: physical activity program|at home physical activity program (during 12 weeks)
11319920|NCT02567591|No Intervention|B: conventional management|conventional management
11319921|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
11319922|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
11319923|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
11319924|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
11319925|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
11319926|NCT02567552|Experimental|Prolutex|Subcutaneous progesterone
11319927|NCT02567552|Active Comparator|Prontogest|Intramuscular progesterone
11319928|NCT02567539|Experimental|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
11319929|NCT02567526|No Intervention|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
11319930|NCT02567526|Experimental|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
11319931|NCT02567513|No Intervention|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
11319932|NCT02567513|Experimental|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
11319933|NCT02567513|Experimental|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
11319934|NCT02567500|Experimental|Patients with auditory hallucination|"Patients with auditory hallucination:
~Evaluation at time 0 and 6 month after of:
~The social cognitive marker (NeuroPsychologic assessment (NEPSY) II) : theory of mind and affect recognition
~The emotional marker:
~Differential Emotion Scale IV (DES IV): emotional individual stability
~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:
~Mini International Neuropsychiatric Interview (MINI) -Kids
~Psychosis section of Kiddie-SADS"
11321060|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
11319935|NCT02567500|Placebo Comparator|Patients without auditory hallucination|"Patients without auditory hallucination:
~Evaluation at time 0 and 6 month after of:
~The social cognitive marker (NEPSY II) : theory of mind and affect recognition
~The emotional marker:
~Differential emotion scale IV (DES IV): emotional individual stability
~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:
~Mini International Neuropsychiatric Interview (MINI) -Kids
~Psychosis section of Kiddie-SADS (Schedule for Affective Disorders and Schizophrenia )"
11319936|NCT02567487|Active Comparator|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
11319937|NCT02567487|Active Comparator|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
11319938|NCT02567474|No Intervention|control|no intervention
11319939|NCT02567474|Experimental|intervention|self management intervention based on 5A model
11319940|NCT02567461|Experimental|DAPT plus high-dose edoxaban|High-dose edoxaban will be represented by edoxaban 60mg od, which will be reduced to 30mg od in patients with ClCr ≤50mL/min.
11319941|NCT02567461|Experimental|DAPT plus low-dose edoxaban|Low-dose edoxaban will be defined as edoxaban 30mg od, which will be reduced to 15mg od in patients with ClCr ≤50mL/min.
11319942|NCT02567461|Active Comparator|DAPT|Aspirin 81 mg od plus clopidogrel 75 mg od
11319943|NCT02567448|Active Comparator|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
11319944|NCT02567448|Active Comparator|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
11319945|NCT02567435|Experimental|Regimen A (VAC/VI)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
11319946|NCT02567435|Experimental|Regimen B (VAC/VI/temsirolimus)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
11319947|NCT02567435|Experimental|Regimen C (FOXO1 fusion negative, VAC/VA)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11319948|NCT02567422|Experimental|Treatment (M6620, cisplatin, radiation therapy)|Patients receive ATR kinase inhibitor M6620 IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity.
11319949|NCT02567409|Experimental|Arm A (berzosertib, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
11319950|NCT02567409|Experimental|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
11319951|NCT02567396|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11319952|NCT02567383|Experimental|Hyperthermia|Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
11319953|NCT02567370|Placebo Comparator|Placebo|
11319954|NCT02567370|Active Comparator|AMG 581|
11319955|NCT02567357|Active Comparator|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
11319956|NCT02567357|Experimental|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
11319957|NCT02567344|Experimental|Active rTMS|Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
11319958|NCT02567344|Sham Comparator|Sham rTMS|Sham rTMS will be delivered to the Left DLPFC at 10 Hz using an electronic sham system used in multiple other investigations. A total of 4000 pulses of sham rTMS will be delivered.
11319959|NCT02567331|Experimental|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
11319961|NCT02567305||Actual Sepsis|"For infants below 44 weeks inclusive of corrected age clinical sepsis is defined, according to the Expert Meeting on Neonatal and Pediatric Sepsis (Report on the Expert Meeting on Neonatal and Pediatric Sepsis - 8 June 2010, EMA London). Confirmed sepsis is defined as positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)
~For children above 44 weeks corrected age clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005). Confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)"
11319962|NCT02567305||Suspected Sepsis|None of the above.
11319963|NCT02567292|No Intervention|Retrospective Control Group|Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
11319964|NCT02567292|Experimental|Exclusive Human Milk Diet Group|A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or <2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants >37 weeks and/or >2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
11319965|NCT02567279|Active Comparator|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
11319966|NCT02567279|Placebo Comparator|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
11319967|NCT02567266|Experimental|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
11319968|NCT02567266|Experimental|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
11319969|NCT02567266|Active Comparator|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
11319970|NCT02567253|Experimental|low dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
11319971|NCT02567253|Experimental|high dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
11319972|NCT02567253|Experimental|low dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
11319973|NCT02567253|Experimental|high dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
11319974|NCT02567240|Experimental|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
11319975|NCT02567240|No Intervention|Normal mediums|Islets will be harvested with regular mediums
11319976|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
11319977|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
11319978|NCT02567214|Experimental|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled
~1 time per day 21 days"
11319979|NCT02567214|Experimental|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled
~1 time per day 21 days"
11319980|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
11319981|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
11319982|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
11319983|NCT02567149|Experimental|Cidofovir|Cidofovir clinical resolution of treated warts as evaluated by the investigators
11319984|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
11319985|NCT02567136||Healthy Controls|Healthy control volunteers
11319986|NCT02567123|Experimental|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
11319987|NCT02567123|No Intervention|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
11319988|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
11319989|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
11319990|NCT02567097|Active Comparator|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
11319991|NCT02567097|Active Comparator|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
11319992|NCT02567097|Experimental|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
11375250|NCT02199899|Placebo Comparator|Placebo|
11319993|NCT02567097|Experimental|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
11319994|NCT02567084|Other|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc"
11319995|NCT02567071|Experimental|Intervention Group|75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
11319996|NCT02567071|Placebo Comparator|Placebo Group|75 children born by planned C-section will be exposed to clean swab.
11319997|NCT02567071|No Intervention|Control Group|75 children born vaginally.
11319998|NCT02567058|Experimental|3 groups of subjects|"3 groups:
~group I : healthy volunters
~group II : patient with an immobilisation (between 1 and 2 months)
~group III : patient with an antecedent of Achilles tendon breakage during the 10 past years
~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
11319999|NCT02567045|Experimental|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.
~Colonoscopy will be performed in case of a positive FIT."
11320000|NCT02567045|Active Comparator|one-time Colonoscopy|One-time Colonoscopy with sedation
11320001|NCT02567032|Experimental|Oxytocin|40 IU Oxytocin
11320002|NCT02567032|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
11320003|NCT02567019|Experimental|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
11320004|NCT02567019|Active Comparator|healthy volunteers|blood samples will be done for healthy volunteers
11320005|NCT02567006|Active Comparator|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
11320006|NCT02567006|Placebo Comparator|Usual care|Not receiving SMS messages
11320007|NCT02566993|Experimental|Experimental Arm|Lurbinectedin (PM01183) / Doxorubicin
11320008|NCT02566993|Active Comparator|Control Arm 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
11320009|NCT02566993|Active Comparator|Control Arm 2|Topotecan
11320010|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
11320011|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
11320012|NCT02566967|Other|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
11320013|NCT02566954|Experimental|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.
~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
11320014|NCT02566941|Experimental|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
11320015|NCT02566941|No Intervention|Control|
11320016|NCT02566928|Experimental|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
11320017|NCT02566928|No Intervention|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
11320018|NCT02566915|No Intervention|CPET submaximal without EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.
11320019|NCT02566915|Experimental|CPET submaximal with EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.
11320069|NCT02566616|Experimental|Intervention|"Cubital Tunnel Release with stimulator for nerve location
~1 hour of Ulnar nerve stimulation"
11375254|NCT02199860|Experimental|SD I - single rising doses|
11320020|NCT02566902|Active Comparator|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
11320021|NCT02566902|Experimental|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
11320022|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
11320023|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
11320024|NCT02566876|Active Comparator|Mixture of three Bifidobacteria|Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
11320025|NCT02566876|Placebo Comparator|Placebo|Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
11320026|NCT02566863|Experimental|Dexmedetomidine|Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure
11320027|NCT02566850|Experimental|Ekso Users|SCI subjects using Ekso
11320028|NCT02566837|Active Comparator|ELEC|electrical stimulation guidance
11320029|NCT02566837|Experimental|ECHO|ultrasound guidance
11320030|NCT02566824|Experimental|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
11320031|NCT02566824|Active Comparator|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
11320032|NCT02566824|Active Comparator|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
11320033|NCT02566811|Experimental|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)* with lymph node dissection to determine whether lymph nodes are positive or negative:
~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only
~Patients will then be followed up, to include assessment of adverse events and quality of life.
~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
11320034|NCT02566811|Active Comparator|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)*. Patients will receive systemic adjuvant treatment to include chemotherapy.
~Patients will then be followed up, to include assessment of adverse events and quality of life.
~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
11320035|NCT02566798|Experimental|Oleogrape|Patients are taking capsules of OleograpeSEED (Extract of grape and olive) 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days
11320036|NCT02566798|Placebo Comparator|Placebo|Patients are taking capsules of placebo (lactose) 3 times a day in the morning, at noon and in the evening during 7 days
11320037|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
11320038|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
11320070|NCT02566616|Active Comparator|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
11320470|NCT02563847|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11375255|NCT02199860|Experimental|SD II - single rising doses|
11320039|NCT02566772|Experimental|TAS3681|All patients will receive TAS3681 in 28 day cycles,. The study will enroll patients who have progressed after abiraterone or enzalutamide (expansion phase) and those who have progressed after abiraterone, enzalutamide and chemotherapy (dose escalation phase). - Number of cycles: approximately 6 or until discontinuation criteria is met. Eleven dose escalation cohorts are planned, one of which will include preliminary assessment of food effect. The MTD/recommended dose for further development will be used for patients in the expansion phase.
11320040|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
11320041|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
11320042|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
11320043|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
11320044|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
11320045|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
11320046|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
11320047|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
11320048|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
11320049|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
11320050|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
11320051|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
11320052|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
11320053|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
11320054|NCT02566746|Experimental|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
11320055|NCT02566746|Active Comparator|Continuation of optimal medical therapy|"Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde during 12 months.
~At 12 months : patients will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter during 12 months."
11320056|NCT02566733|Experimental|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
11320057|NCT02566733|Active Comparator|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
11320058|NCT02566720|Other|Treatment and MRI scanning|After informed consent has been obtained, the subjects will be examined by a physician and assigned a Disability Ratings Scale (DRS) score. Subjects will undergo MRI tractography study, which does not require the administration of contrast. All participants will receive oral amantadine at escalating doses to ensure tolerance (50mg twice daily for 7 days, then 100mg twice daily for 1 week, then 150mg twice daily, then 200mg twice daily). The usual length of stay on the inpatient brain injury program is ninety days. The MRI tractography study and DRS score will be repeated near the time of discharge or ninety days from enrollment.
11320059|NCT02566707|Experimental|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
11320060|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
11320061|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
11320062|NCT02566681|Experimental|MSC construct for Osteonecrosis|Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
11320063|NCT02566668||Asthmatic|1 year observational follow-up
11320064|NCT02566668||Non-Asthmatic|1 year observational follow-up
11320065|NCT02566655|Experimental|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
11320066|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
11320067|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
11320068|NCT02566629||healthy controls|collect faeces from healthy controls
11320071|NCT02566603|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
11320072|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
11320073|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
11320074|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
11320075|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
11320076|NCT02566564|Experimental|open label, single arm|Open label, single arm, dose escalating
11320077|NCT02566551|Experimental|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
11320078|NCT02566551|Active Comparator|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
11320079|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
11320080|NCT02566525|No Intervention|Control|Standard of care
11320081|NCT02566512|Other|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
11320082|NCT02566512|Other|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
11320083|NCT02566499|Experimental|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
11320084|NCT02566486|Other|Reciprocating system|Waveone root canal instrumentation file
11320085|NCT02566486|Other|Rotational system|ProTaper Next root canal instrumentation file
11320086|NCT02566460|Experimental|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
11320087|NCT02566460|Sham Comparator|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
11320088|NCT02566447||Symptomatic|Subjects will be categorized by the clinician as symptomatic for Trichomonas vaginalis infection.
11320089|NCT02566434|Experimental|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
11320090|NCT02566421|Experimental|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
11320091|NCT02566408|Experimental|Supportive Care (interview about KAPs towards PA)|"Participants undergo a 2-hour one-on-one interview and answer survey questions about their beliefs, attitudes, and preferences (KAPs) towards physical activity (PA). Ten topics will be used to explore older women's attitudes toward PA. Six topics will also be used to explore ethnic-specific and culture-specific contexts that surround older women's participation in PA.
~REFINEMENT OF THE PA INTERVENTION: Approximately 1-2 months after the conclusion of interviews, participants are invited to a joint session and presented with results of analyzed data. Participants are asked to review results and themes identified from interviews, and to concur whether conclusions capture their KAPs. Through this process a set of preferences that is agreed upon by all as most critical for enhancing PA participation, adherence, and retention will be identified."
11320092|NCT02566395|Experimental|Haploidentical Stem Cell Transplantation|Subjects will receive pretransplantation conditioning of total-body irradiation (1,200 cGy delivered in 8 fractions over 4 days [Days -9 through -6] and cyclophosphamide (60 mg/kg IV daily x 2 on Days -3 and -2). Donor lymphocyte infusion will occur on day -6; donor CD34+ cells will be infused on Day 0.
11320093|NCT02566382|Experimental|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
11320094|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
11320095|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
11320096|NCT02566356|Experimental|Oxytocin|40 IU Oxytocin
11320097|NCT02566356|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
11320098|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
11320099|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
11320100|NCT02566330||EndoBarrier|Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
11320101|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
11320102|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
11320103|NCT02566304|Experimental|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -7.
~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
11320104|NCT02566291||Supreme Group|Measuring Success rate and Insertion Time
11320105|NCT02566291||Gain Group|Measuring Success rate and Insertion Time
11320106|NCT02566278|Experimental|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) > 3 months to verify the Pcrit measurement obtained by the clinical equipment.
11320107|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
11320108|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
11320109|NCT02566252|Experimental|PUL-042|PUL-042 Inhalation Solution
11320110|NCT02566252|Experimental|Cromolyn sodium|Pre-Treatment with cromolyn sodium followed by PUL-042 Inhalation Solution Administration
11320111|NCT02566252|Experimental|Albuterol sulfate|Pre-Treatment with albuterol sulfate followed by PUL-042 Inhalation Solution Administration
11320112|NCT02566239|Experimental|Shared Data|"Share activity data with care team.
~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.
~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
11320113|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.
~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
11320114|NCT02566226|Placebo Comparator|Bupivacaine with normal saline|
11320115|NCT02566226|Active Comparator|Bupivacaine with intrathecal morphine|
11320116|NCT02566213|Other|Motor skills measurements|
11320117|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
11320118|NCT02566187|Other|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
11320119|NCT02566187|Other|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
11320120|NCT02566161||Trio Cohort|families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).
11320121|NCT02566148||HIV group|group living with HIV
11320122|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
11320123|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
11320124|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
11320125|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
11320126|NCT02566122||muscle strength ,muscle mass|
11320127|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
11320128|NCT02566096|Placebo Comparator|TAP with bupivicaine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
11320129|NCT02566096|Active Comparator|TAP with bupivicaine with morphine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
11320130|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
11320131|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
11320132|NCT02566070|Active Comparator|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
11320133|NCT02566070|Experimental|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
11320134|NCT02566057|Experimental|PGx testing guided treatment (PGT)|Results of the GeneceptTM Assay will be provided to their prescribers who may use the knowledge to guide medication management.
11320135|NCT02566057|No Intervention|Treatment as usual condition (TAU)|Patients will also utilize the GeneceptTM Assay but the results will not be provided back to their prescribers, who will treat the patients without the knowledge of pharmacogenetic testing results.
11320136|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).
~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.
~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
11320162|NCT02565875|Placebo Comparator|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator
~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
11320137|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).
~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.
~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
11320138|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
11320139|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
11320140|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
11320141|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.
~In general all proximal humerus fractures were operated except minimally or undisplaced."
11320142|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
11320143|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
11320144|NCT02565992|Experimental|CAVATAK and pembrolizumab|Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
11320145|NCT02565979|Active Comparator|Resveratrol|resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
11320146|NCT02565979|Placebo Comparator|Placebo|placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
11320147|NCT02565966|Experimental|Modified Atkins Diet (MAD)|
11320148|NCT02565966|No Intervention|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
11320149|NCT02565953|Experimental|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
11320150|NCT02565953|Active Comparator|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
11320151|NCT02565940||diabetic patient with foot infection|
11320152|NCT02565927|Experimental|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
11320153|NCT02565927|Active Comparator|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
11320154|NCT02565914|Experimental|Part A: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
11320155|NCT02565914|Experimental|Part B: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
11320156|NCT02565914|Experimental|Part C: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
11320157|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
11320158|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
11320159|NCT02565888|Active Comparator|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
11320160|NCT02565888|Experimental|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
11320161|NCT02565875|Experimental|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator
~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
11320163|NCT02565862|Active Comparator|Treatment A|"Day 1-2: 500mg twice daily (BID) metformin film-coated tablets
~Day 3-8: 1000mg BID metformin film-coated tablets"
11321933|NCT02554240|Active Comparator|Na Hyaluronate 20mg|Na Hyaluronate 20mg
11320164|NCT02565862|Experimental|Treatment B|"Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets
~Day 17-22: 1000mg BID metformin film-coated tablets
~+ 60mg QD daclatasvir film-coated tablets"
11320165|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
11320166|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
11320167|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
11320168|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
11320169|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
11320170|NCT02565823|Experimental|Exercise intervention|Subjects will undergo an acute bout of exercise for 45 mins at 75% of peak aerobic capacity
11320171|NCT02565810|Experimental|SB5 40mg|
11320172|NCT02565797|Experimental|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
11320173|NCT02565797|Experimental|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
11320174|NCT02565797|No Intervention|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
11320175|NCT02565784|Experimental|Intradermal injection|Restylane and/or Perlane
11320176|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
11320177|NCT02565758|Experimental|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
11320178|NCT02565758|Experimental|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
11320179|NCT02565745|Experimental|Skin Dressing|Hydrocolloid dressings applied during hospitalization
11320180|NCT02565745|Active Comparator|Moisturizing cream|Use of moisturizing cream, as part of conventional skin care
11320181|NCT02565732|Experimental|Dose A|Botulinum toxin type A
11320182|NCT02565732|Experimental|Dose B|Botulinum toxin type A
11320183|NCT02565732|Placebo Comparator|Dose C|Placebo comparator
11320184|NCT02565719|Experimental|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
11320185|NCT02565719|Experimental|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
11320186|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
11320187|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
11320188|NCT02565706|Active Comparator|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
11320189|NCT02565706|Active Comparator|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
11320190|NCT02565706|Experimental|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
11320191|NCT02565706|Active Comparator|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
11320192|NCT02565693|Experimental|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:
~Age ≥ 80 years
~Body weight ≤ 60 kg
~Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
11320193|NCT02565693|Other|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:
~- No antithrombotic treatment
~or:
~Acetylsalicylic acid 80 mg once daily
~Carbasalate calcium 100 mg once daily
~Clopidogrel 75 mg once daily
~Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily
~Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
11320194|NCT02565680|Placebo Comparator|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
11320195|NCT02565680|Experimental|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
11320196|NCT02565667|Experimental|KOL group|KOL stapler was used for rectal anastomosis
11320197|NCT02565667|Active Comparator|traditional stapler group|traditional stapler was used for rectal anastomosis
11320198|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
11320199|NCT02565641|Experimental|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
11320200|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
11320201|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
11320202|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
11320203|NCT02565602|Other|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
11320204|NCT02565589||ICU patient|Critically ill patients who were enrolled less than 24 hours after ICU admission.
11320205|NCT02565589||Control|Age-, sex-, and BMI-matched healthy subjects.
11320206|NCT02565576|Active Comparator|CFZ533|CFZ533
11320207|NCT02565576|Placebo Comparator|Placebo|Placebo
11320208|NCT02565563|Active Comparator|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
11320209|NCT02565563|Active Comparator|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
11320210|NCT02565550|Experimental|IBS patients|eat the low FODMAPs diet for one week
11320211|NCT02565550|Active Comparator|healthy controls|eat the low FODMAPs diet for one week
11320212|NCT02565537|Active Comparator|iDesign WFG LASIK|Wavefront-guided LASIK
11320213|NCT02565537|Active Comparator|Wavelight WFO LASIK|Wavefront-optimized LASIK
11320214|NCT02565524|Experimental|genetic and phenotypic profile|blood sample, clinical and neurocognitive assessment
11320215|NCT02565511|Experimental|Arm#1|CAD106 (450 µg) + Alum (450 µg) given i.m. at week 1, 7, 13 and quarterly thereafter
11320216|NCT02565511|Placebo Comparator|Arm#2|Placebo to CAD106 + Alum (450 µg) given i.m. at week 1, 7, 13 and quarterly thereafter
11320217|NCT02565511|Experimental|Arm#3|CNP520 (50 mg) capsules oral intake (p.o.)
11320218|NCT02565511|Placebo Comparator|Arm#4|Placebo to CNP520 capsules oral intake (p.o.)
11320219|NCT02565498|Other|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
11320220|NCT02565498|Experimental|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
11320221|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
11320222|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
11320223|NCT02565472|Experimental|Apple Juice|12 oz apple juice
11320224|NCT02565472|Experimental|Grape Juice|12 oz grape juice
11320225|NCT02565459|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
11320226|NCT02565459|No Intervention|No intervention|
11320227|NCT02565446|Other|MRE|Clinical Cohort: NAFLD COHORT RECRUITED FROM THE LIVER CLINIC: 120 adult subjects evaluated at Mayo Clinic with a diagnosis of NAFLD who are at risk to have NASH will be recruited from our outpatient Liver Disease Clinic. Metabolic syndrome is a strong predictor of NASH and will be used to best identify subjects with a clinical indication for liver biopsy according to AASLD guidelines. The proposed sample size for this experiment will be calculated based on sensitivity and specificity of MRE for differentiating various stages of fibrosis.
11320228|NCT02565433|Experimental|questionnaire administration|Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)
11320229|NCT02565420|Active Comparator|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
11320230|NCT02565420|Placebo Comparator|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
11320231|NCT02565407|Experimental|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
11320232|NCT02565407|Active Comparator|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
11320233|NCT02565394|Experimental|Micro-Break with Dynamic Activity|Micro Break with web based application of a video to lead surgeons through dynamic exercise activities
11320234|NCT02565394|No Intervention|Comparator|A baseline survey will be completed following a surgical day with no dynamic activities
11320235|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch
~In-person smoking cessation counseling"
11320236|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch
~In-person smoking cessation counseling
~Contingent financial rewards for smoking abstinence"
11320237|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch
~In-person smoking cessation counseling
~Text messages to support smoking abstinence"
11320238|NCT02565368|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
11320239|NCT02565368|Experimental|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
11320240|NCT02565355|Other|Lifestyle Modification/Dietary Exclusion|In the lifestyle modification group, where specific IgG antibodies to foods are identified, the intervention is appropriate dietary elimination. The IgG antibody results will be disclosed and specific dietary elimination advice will be provided by an experienced dietician; provide diet alternatives to prevent nutritional deficiencies and improve adherence to diet. To improve compliance, a maximum of 2 high IgG positive foods will be eliminated at any one time in each 4 week period. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
11320316|NCT02564874|Experimental|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
11320591|NCT02563119|Active Comparator|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
11320241|NCT02565355|Other|The Standard Treatment Group|The standard therapy group will not receive results of IgG antibody testing. The patients will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relief as appropriate. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
11320242|NCT02565342|Experimental|Interscalene brachial plexus block|
11320243|NCT02565316|Active Comparator|Nepeta menthoides Boiss & Bohse freeze dried extract capsule|
11320244|NCT02565316|Active Comparator|Sertraline capsule|
11320245|NCT02565303|Experimental|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
11320246|NCT02565303|Experimental|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
11320247|NCT02565290|Active Comparator|Omega-3|2 capsules of omega 3 - 2 times a day
11320248|NCT02565290|Placebo Comparator|Soy oil|2 capsules of soy oil - 2 times a day
11320249|NCT02565277|Active Comparator|Influenza Vaccine|Fluzone injection once IM
11320250|NCT02565277|Placebo Comparator|Placebo|Saline Injection once IM
11320251|NCT02565264|Experimental|plasma-derived exosomes|plasma-derived exosomes
11320252|NCT02565251|Experimental|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
11320253|NCT02565251|Experimental|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
11320254|NCT02565251|Experimental|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
11320255|NCT02565251|Experimental|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
11320256|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
11320257|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
11320258|NCT02565212|Experimental|GROUP 1|montelukast sodium and mometasone
11320259|NCT02565212|Active Comparator|Group 2|montelukast
11320260|NCT02565212|Active Comparator|Group 3|mometasone furoate
11320261|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
11320262|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
11320263|NCT02565186|Experimental|Lasmiditan 100mg|Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
11320264|NCT02565186|Experimental|Lasmiditan 200mg|Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
11320265|NCT02565173|Experimental|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
11320266|NCT02565173|Experimental|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
11320267|NCT02565173|Experimental|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
11320268|NCT02565173|Active Comparator|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
11320269|NCT02565173|Placebo Comparator|placebo BID|placebo Ophthalmic Formulation
11320270|NCT02565160||Septic Arthritis|Patients suspected of having septic arthritis
11320271|NCT02565160||Osteoarthritis|Patients suffering with osteoarthritis undergoing an intervention
11320272|NCT02565160||Joint Revision|Patients who has a prosthetic joint in situ
11320273|NCT02565147|Experimental|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
11320274|NCT02565147|Active Comparator|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
11320275|NCT02565134|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
11320276|NCT02565134|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
11320277|NCT02565134|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
11320278|NCT02565134|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
11320279|NCT02565121|Experimental|Olfactory disorder after brain trauma|Recruited from 250 patients with moderate to severe traumatic brain injury in the Hodeskadeprosjektet (TBI) cohort. Treatment with (first) corticosteroids and (second) olfactory stimulation.
11320280|NCT02565108|Experimental|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.
~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
11320592|NCT02563119|Active Comparator|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
11320281|NCT02565108|Placebo Comparator|Placebo|"Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.
~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
11320282|NCT02565095|Other|Carotid Baroreflex measurements|
11320283|NCT02565082|Experimental|Sickle cell disease|This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
11320284|NCT02565082|Other|Control|This arm will include an approximate number of 30 healthy volunteers.
11320285|NCT02565069|Experimental|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
11320286|NCT02565056|Active Comparator|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
11320287|NCT02565056|No Intervention|Treatment as usual|Treatment as usual.
11320288|NCT02565043|Experimental|RENASYS TOUCH Negative Pressure Wound Therapy Device|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the intermittent/variable therapy mode, for up to 28 days of therapy."
11320289|NCT02565043|Active Comparator|RENASYS TOUCH Negative Pressure Wound Therapy System|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the continuous therapy mode for up to 28 days of therapy."
11320290|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
11320291|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease& have not undergone PEA surgery due to the following reasons:
~Multiple co-morbidities
~Patients choice
~Mild disease /symptoms
~Awaiting Surgery"
11320292|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
11320293|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
11320294|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
11320295|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
11320296|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
11320297|NCT02565004||1|Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079
11320298|NCT02565004||2|Individuals found to harbor a germline APC promoter 1B variant not previously enrolled in Cohort l.
11320299|NCT02564991||1|125 inpatient alcoholics (AD)
11320300|NCT02564991||2|125 non-substance abusing controls (NSAC)
11320301|NCT02564978|Experimental|Minocycline|Oral administration of minocycline.
11320302|NCT02564965|Other|Greater than 50% Necrosis|Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
11320303|NCT02564965|Other|Less than 50% Necrosis|Subjects who have less than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
11320304|NCT02564952|Experimental|GWP42003-P|"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.
~Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant."
11320305|NCT02564939|Active Comparator|ramelteon|receive ramelteon
11320306|NCT02564939|Placebo Comparator|placebo|receive placebo
11320307|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
11320308|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
11320309|NCT02564913||control group|
11320310|NCT02564913||pre-DM group|
11320311|NCT02564913||DM group|
11320312|NCT02564900|Experimental|Part 1 Dose escalation|Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.
11320313|NCT02564900|Experimental|Part 2 Dose expansion|Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), and HER2 expressing other solid malignant tumor (Part 2d)
11320314|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
11320315|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
11320471|NCT02563847|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11320317|NCT02564874|Experimental|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
11320318|NCT02564861|Experimental|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
11320319|NCT02564861|Experimental|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
11320320|NCT02564861|Experimental|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
11320321|NCT02564861|Experimental|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
11320322|NCT02564848|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
11320323|NCT02564835|Experimental|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
11320324|NCT02564835|Active Comparator|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
11320325|NCT02564835|No Intervention|Usual Care|Participants randomized to this arm will receive standard care only.
11320326|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
11320327|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
11320328|NCT02564809|Experimental|Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a cognitive training program (Fit Brains training) 6 hours a week for 8 weeks.
11320329|NCT02564809|Experimental|Exercise + Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a combination of aerobic exercise and a cognitive training program (Fit Brains training) for 6 hours a week over 8 weeks.
11320330|NCT02564809|Sham Comparator|Balanced And Tone|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will complete 3 weekly training sessions of 1 hour for 8 weeks.
11320331|NCT02564796|Placebo Comparator|Control|Group II (non-treatment group): Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
11320332|NCT02564796|Experimental|Epoetin alfa and iron supplements|Group I (treatment group): Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
11320333|NCT02564770||Rheumatoid arthritis (RA) participants|Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
11320334|NCT02564744|Experimental|Debio 1562|Participants with a diagnosis of relapsed and/or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma (FL), Marginal Zone/Mucosa-associated Lymphoid Tissue (MZ/MALT), Mantle Cell Lymphoma (MCL) or other Non-Hodgkin's Lymphoma (NHL) with the Sponsor's approval, will receive Debio 1562 and Rituximab in 3 different parts of study i.e., Safety run in, Part 2 and Expansion (Part 3). Participants in Part 2 will be enrolled in two parallel cohorts (Cohort A and Cohort B).
11320335|NCT02564718|Experimental|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
11320336|NCT02564705||anterior cohort|Anterior Lumbar Interbody Fusion (ALIF)
11320337|NCT02564705||posterior cohort|"Posterolateral Fusion (PLF)
~Posterior Lumbar Interbody Fusion (PLIF)
~Transforaminal Lumbar Interbody Fusion (TLIF)"
11320338|NCT02564679|Experimental|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
11320339|NCT02564679|Experimental|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
11320340|NCT02564666|Active Comparator|Telephone counseling|regular telephone counseling per week
11320341|NCT02564666|No Intervention|No telephone counseling|no regular telephone counseling
11320342|NCT02564653|Other|Technical Assistance, training,clinical reminders|provider adherence to tobacco use treatment guidelines
11320343|NCT02564653|Other|TTC + help of community health workers|We will assess this secondary aim by comparing smoking cessation outcomes among smokers who receive brief provider counseling alone only vs. smokers who receive provider counseling + community health worker counseling. The purpose of this assessment is to specifically analyze the impact of the community health worker counseling component of the intervention using a quasiexperimental design that leverages the larger RCT.
11320344|NCT02564640|Active Comparator|videolaryngoscope|patients intubated by using the videolaryngoscopy
11320345|NCT02564640|Active Comparator|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
11320346|NCT02564627|Experimental|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
11320347|NCT02564627|Active Comparator|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
11320348|NCT02564627|Other|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
11320430|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
11320349|NCT02564614|Experimental|RO7070179|Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
11320350|NCT02564601|Experimental|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
11320351|NCT02564601|Experimental|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
11320352|NCT02564601|No Intervention|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
11320353|NCT02564588|Experimental|Dasotraline|Dasotraline 4, 6, 8 mg
11320354|NCT02564588|Placebo Comparator|Placebo|Placebo Comparator
11320355|NCT02564575|Experimental|Cohort 1|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^6 PFU/mL of the HPIV3-EbovZ GP vaccine.
11320356|NCT02564575|Experimental|Cohort 2|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^7 PFU/mL of the HPIV3-EbovZ GP vaccine.
11320357|NCT02564562|Experimental|Treatment|Radiolabeled PF-06463922 in healthy volunteers
11320358|NCT02564549|Active Comparator|Group 1 (TRUS-guided biopsy)|"Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.
~mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.
~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).
~Patients will be followed, as per standard of care, for any potential infections from biopsies.
~Annual PSA tests performed as per routine standard of care."
11320359|NCT02564549|Experimental|Group 2 (mpMRI with targeted biopsy)|"Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.
~Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.
~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).
~Patients will be followed, as per standard of care, for any potential infections from biopsies.
~Annual PSA tests performed as per routine standard of care."
11320360|NCT02564536|Experimental|Arm 1: Pacritinib and Decitabine|"Patients will receive one cycle of single agent pacritinib.
~Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.
~Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.
~Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.
~Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.
~Patients may continue treatment for up to 12 cycles."
11320361|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
11320362|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
11320363|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
11320364|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
11320365|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
11320366|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
11320367|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
11320368|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
11320369|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.
~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
11320370|NCT02564471|Experimental|Doxyclycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.
~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
11320371|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
11320372|NCT02564458|Experimental|Interval Exercise Training/Motivational Accelerometry (IET/MA)|All patients on the experimental arm receive the intervention of 5-12 weeks of pre-transplant IET, motivational accelerometry via the FitBit Surge, pre- and post-fitness assessments, and periodic quality of life and symptom surveys.
11320373|NCT02564458|No Intervention|Normal Standard of Care (control)|All patients on the control arm participate in the pre- and post-fitness assessment, are given the FitBit Surge without the motivational component, and are also given periodic quality of life and symptom surveys.
11320469|NCT02563847|Active Comparator|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11320374|NCT02564445|Experimental|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.
~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
11320375|NCT02564445|Experimental|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.
~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
11320376|NCT02564445|Experimental|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.
~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).
~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
11320377|NCT02564432||POP 10 patient cohort|This is an observational study
11320378|NCT02564419|Experimental|Medtronic Activa PC+S|"Objective of this pilot phase early feasibility study is to assess the safety and feasibility of Medtronic Activa PC+S implant (device) by;
~Evaluating the ability of the Activa PC+S system to sense ECoG signals in subjects living with quadriplegia (C5 or C6 level).
~Assessing the feasibility of activating fundamental upper extremity muscles to reproduce hand grasp.
~These are important first steps towards creating and designing a device that can enhance or assist in performing activities of daily living (ADL) in the life of these subjects. Attachment 15.3"
11320379|NCT02564406|Experimental|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
11320380|NCT02564393||T|Control
11320381|NCT02564393||A|Adult with cystic fibrosis
11320382|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
11320383|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
11320384|NCT02564367|Experimental|Treatment|"First Cohort 1:
~(n = 30 patients) 18 cycles S-1"
11320385|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
11320386|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
11320387|NCT02564341|Experimental|TEACH Collaborative Care Intervention|Physicians randomized to the intervention will receive: 1) collaboration with an IT enabled nurse care manager; 2) physician education and academic detailing; and 3) facilitated access to a specialist in addictions to help manage the most challenging HIV-infected patients on COT.
11320388|NCT02564341|No Intervention|Standard of Care Control|Physicians in the control group will receive information summarizing guidelines for COT but will not have access to the support of the TEACH intervention.
11320389|NCT02564328|Active Comparator|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
11320390|NCT02564328|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
11320391|NCT02564315|Active Comparator|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320392|NCT02564315|Active Comparator|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320393|NCT02564315|Active Comparator|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320394|NCT02564315|Active Comparator|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:
~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;
~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320395|NCT02564315|Active Comparator|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320396|NCT02564315|Active Comparator|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320593|NCT02563119|No Intervention|Healthy controls|Thirty healthy, lean controls
11320397|NCT02564315|Active Comparator|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320398|NCT02564315|Active Comparator|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:
~Phase 2: Preparation Phase Recycling Counseling;
~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
11320399|NCT02564315|Placebo Comparator|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:
~Phase 2: Preparation Phase Control Treatment
~Phase 3: No Treatment"
11320400|NCT02564302|No Intervention|Control|These patients will not receive a device, but have to fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
11320401|NCT02564302|Experimental|Treatment Group|These patients will receive the device. they are expected to use it for at least 5 minutes per day. Patients in this arm will fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
11320402|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
11320403|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
11320404|NCT02564276|Experimental|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
11320405|NCT02564276|Experimental|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
11320406|NCT02564263|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).
11320407|NCT02564263|Active Comparator|Chemotherapy|Participants received Investigator's choice of paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).
11320408|NCT02564237|Experimental|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
11320409|NCT02564237|Active Comparator|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
11320410|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
11320411|NCT02564198|Experimental|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of ramucirumab given intravenously (IV) every other week over a 6-week cycle. Participants may continue treatment until discontinuation criteria are met.
~(Part B-CNS Tumors) Maximum tolerated dose and/or recommended Phase 2 Dose (RP2D) determined from Part A of ramucirumab given IV every other week over a 6-week cycle. Participants may continue treatment until discontinuation criteria are met."
11320412|NCT02564185|Active Comparator|Control|"The control group will follow usual practice."
11320413|NCT02564185|Experimental|Education program|"The Education program group benefit in addition of a therapeutic education program including nursing follow-up at 1, 3 and 6 months."
11320414|NCT02564172|Experimental|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
11320415|NCT02564172|Active Comparator|OMM group|Optimal medical management alone.
11320416|NCT02564159|Experimental|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
11320417|NCT02564159|Other|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)
~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay < 48 hours"
11320418|NCT02564146|Active Comparator|nab-paclitaxel and gemcitabine (A)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine
~Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles"
11320419|NCT02564146|Experimental|gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine
~Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles"
11320420|NCT02564133|Experimental|detection of a patent foramen ovale|
11320421|NCT02564107|Experimental|Ibandronate|Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
11320422|NCT02564094|Experimental|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
11320423|NCT02564081|Experimental|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
11320424|NCT02564081|Active Comparator|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
11320425|NCT02564081|No Intervention|Ctrl|No intervention
11320426|NCT02564068|Experimental|Oxytocin Only|Subjects will come in for one visit, and will receive only oxytocin
11320427|NCT02564068|Experimental|Oxytocin & Placebo Crossover|Subjects will come in for two visit: They will receive either placebo or oxytocin on visit 1 and the other intervention of visit 2. Subjects will be blinded as to which drug they are receiving on which visit.
11320428|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
11320429|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
11320594|NCT02563106|Experimental|SYN-004|SYN-004 150 mg
11320431|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
11320432|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
11320433|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
11320434|NCT02564042|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
11320435|NCT02564042|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
11320436|NCT02564042|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
11320437|NCT02564042|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
11320438|NCT02564042|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
11320439|NCT02564042|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
11320440|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
11320441|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
11320442|NCT02564029|Placebo Comparator|Placebo|Single dose
11320443|NCT02564029|Active Comparator|Lorazepam|2mg single dose
11320444|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
11320445|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
11320446|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
11320447|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
11320448|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
11320449|NCT02563977||DIEP flap breast reconstruction|14 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
11320450|NCT02563951|Experimental|GNS Spray 0.5mg|One spray of GNS 0.5mg/spray into right nostril.
11320451|NCT02563951|Experimental|GNS Spray 1.0mg|One spray of GNS 0.5mg/spray into both left and right nostril.
11320452|NCT02563951|Experimental|GNS Spray 2.0mg|One spray of GNS 1.0mg/spray into both left and right nostril.
11320453|NCT02563951|Active Comparator|Kytril 1mg (IV injection)|A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)
11320454|NCT02563951|Active Comparator|Kytril 1mg (Tablet)|a single dose (kytril 1mg, one tablet) orally administered with 240mL of water
11320455|NCT02563938|Experimental|AK001|Up to six single ascending doses of AK001.
11320456|NCT02563938|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion.
11320457|NCT02563925|Experimental|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab & durvalumab (75 mg & 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior & 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number & size of their brain metastases. Following the 1st dose, tremelimumab & duvralumab will be administered q28 days from the date of 1st tremelimumab & durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
11320458|NCT02563912|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
11320459|NCT02563912|Active Comparator|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
11320460|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
11320461|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
11320462|NCT02563886|Experimental|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
11320463|NCT02563886|Active Comparator|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
11320464|NCT02563873|No Intervention|Standard pacemaker settings|Standard pacemaker settings will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange
11320465|NCT02563873|Experimental|Tailored pacemaker settings|The pacemaker settings will be altered to match optimal heart rate range with respect to cardiac contractility, as determined by echocardiography. This will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange.
11320466|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:
~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
11320467|NCT02563847|Active Comparator|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11320468|NCT02563847|Active Comparator|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11320472|NCT02563847|Placebo Comparator|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11320473|NCT02563847|Placebo Comparator|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
11320474|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
11320475|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
11320476|NCT02563821|Active Comparator|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.
~Injection of the rest of the loading dose (8mL).
~In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.
~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10."
11320477|NCT02563821|Active Comparator|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.
~Injection of the rest of the loadind dose (8 mL)
~In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.
~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10 (0 = no pain and 10 = insufferable pain)."
11320478|NCT02563808|Active Comparator|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
11320479|NCT02563808|Experimental|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
11320480|NCT02563795||Group I|Pregnant with BMI<30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
11320481|NCT02563795||Group II|Pregnant with BMI<30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
11320482|NCT02563795||Group III|Pregnant with BMI>30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
11320483|NCT02563795||Group IV|Pregnant with BMI>30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
11320484|NCT02563782|Sham Comparator|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
11320485|NCT02563782|Active Comparator|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
11320486|NCT02563769|Experimental|Treatment Arm 1|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
11320487|NCT02563769|Experimental|Treatment Arm 2|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
11320488|NCT02563769|Experimental|Treatment Arm 3|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
11320489|NCT02563756|Experimental|UKA, unicompartmental knee replacement|Procedure: Participants are operated with a mobile bearing medial unicompartmental knee arthroplasty (Oxford). They are followed with CT, functional tests and PROM, compared with those operated with TKA.
11320490|NCT02563756|Experimental|TKA, total knee replacement|Procedure: Participants are operated with a cruciate retaining conventional tricompartmental prosthesis (PFC). They are followed with CT, functional tests and PROM, compared with those operated with UKA.
11320491|NCT02563743|Experimental|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
11320492|NCT02563743|Active Comparator|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
11320493|NCT02563730|Experimental|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
11320494|NCT02563717|Active Comparator|Reference Device: T-piece System|
11320495|NCT02563717|Active Comparator|Investigational Device: The New System|
11320496|NCT02563704|Active Comparator|ARTES|"Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.
~Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.
~Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
11320559|NCT02563353|Experimental|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.
~24 months of Whole-body vibration on vibration platforms"
11320595|NCT02563106|Placebo Comparator|Placebo|Matching placebo
11320497|NCT02563704|Active Comparator|QLD|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.
~Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.
~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
11320498|NCT02563704|Active Comparator|QNLD3|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.
~Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.
~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
11320499|NCT02563704|Active Comparator|QNLD2|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.
~Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.
~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
11320500|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
11320501|NCT02563678|Active Comparator|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
11320502|NCT02563678|Active Comparator|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
11320503|NCT02563678|Active Comparator|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
11320504|NCT02563678|Active Comparator|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
11320505|NCT02563678|Active Comparator|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
11320506|NCT02563678|Experimental|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
11320507|NCT02563678|Experimental|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
11320508|NCT02563678|Active Comparator|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
11320509|NCT02563678|Experimental|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
11320510|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) > 30
11320511|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) < 15
11320512|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
11320513|NCT02563613|Experimental|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
11320514|NCT02563613|Experimental|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
11320515|NCT02563613|Placebo Comparator|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
11320516|NCT02563600|Experimental|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
11320517|NCT02563600|Experimental|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
11320518|NCT02563600|No Intervention|No telephone call|No telephone call made to patient.
11320519|NCT02563587|Experimental|Group LT-CT|Laughter therapy with conventional treatment
11320520|NCT02563587|Placebo Comparator|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
11320521|NCT02563587|Sham Comparator|Group CT|Conventional treatment only
11320522|NCT02563574|Experimental|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
11320523|NCT02563574|Active Comparator|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
11320524|NCT02563561|Experimental|Apaziquone and Placebo|One Dose of Apaziquone and One Dose of Placebo
11320525|NCT02563561|Experimental|Apaziquone and Apaziquone|Two Doses of Apaziquone
11320526|NCT02563561|Placebo Comparator|Placebo and Placebo|Two Doses of Placebo
11320527|NCT02563548|Experimental|GAC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks).
11320528|NCT02563548|Experimental|NSCLC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
11320529|NCT02563535|Experimental|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
11320530|NCT02563535|Active Comparator|conventional PTA|angioplasty with conventional balloon
11320531|NCT02563522|Active Comparator|Active|VM202 + standard of care
11320532|NCT02563522|Placebo Comparator|Control|Placebo (VM202 Vehicle) + standard of care
11320533|NCT02563509|Experimental|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
11320534|NCT02563509|No Intervention|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
11320535|NCT02563496|Experimental|Tafenoquine 50 mg|Subjects with weight band of >=5 to <=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
11320536|NCT02563496|Experimental|Tafenoquine 100 mg|Subjects with weight band of >10 to <=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
11320537|NCT02563496|Experimental|Tafenoquine 150 mg|Subjects with weight band of >10 to <=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
11320538|NCT02563496|Experimental|Tafenoquine 200 mg|Subjects with weight band of >20 to <=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
11320539|NCT02563496|Experimental|Tafenoquine 300 mg|Subjects with weight band of >35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
11320540|NCT02563483|Experimental|Yoga and compassion meditation program|"The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of asana (poses), pranayama (breathing exercise) and meditation."
11320541|NCT02563483|No Intervention|control|this group was a non treatment group.
11320542|NCT02563457|Experimental|case|diabetic patients who will receive periodontal treatment blood sampling
11320543|NCT02563457|Experimental|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
11320544|NCT02563444|Experimental|Ultrasound fusion guiding system|
11320545|NCT02563431|Active Comparator|SP-ED|Classic use
11320546|NCT02563431|Experimental|4P-ED|Literature update
11320547|NCT02563418|Experimental|Patient with Huntington's disease|
11320548|NCT02563405|Active Comparator|doxazosin|To observe the effects of doxazosin (4 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
11320549|NCT02563405|Active Comparator|nifedipine|To observe the effects of nifedipine (30 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
11320550|NCT02563392|Experimental|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
11320551|NCT02563392|Active Comparator|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
11320552|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.
~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.
~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
11320553|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.
~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
11320554|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.
~Patients in this group will have morning hypertension that is classified into two types:
~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.
~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
11320555|NCT02563366|Experimental|MSCs group|Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.
11320556|NCT02563366|Placebo Comparator|Control group|Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.
11320557|NCT02563353|Active Comparator|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
11320558|NCT02563353|Experimental|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.
~12 months of Whole-body vibration on vibration platforms."
11375256|NCT02199860|Experimental|SD II - single rising doses + Placebo|
11320560|NCT02563340|Experimental|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
11320561|NCT02563340|Active Comparator|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
11320562|NCT02563327|Active Comparator|Standard Therapy|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~Study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
11320563|NCT02563327|Experimental|Rifapentine-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
11320564|NCT02563327|Experimental|Rifapentine- and Moxifloxacin-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg."
11320565|NCT02563314|Experimental|intervention|
11320566|NCT02563314|Other|control|
11320567|NCT02563301|Active Comparator|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
11320568|NCT02563301|Active Comparator|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
11320569|NCT02563288|Active Comparator|Esmolol|Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
11320570|NCT02563288|Active Comparator|Dexmedetomidine|Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
11320571|NCT02563275|Other|Human fine motor skills measurements during weightlessness|
11320572|NCT02563262|Other|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
11320573|NCT02563249|Other|Dexterity, Coordination,Perception measurements|Dexterity, Hand-eye Coordination and Perception of Orientation and Distances
11320574|NCT02563236|Experimental|Parabolic flight and Augmented Reality interface alignments|
11320575|NCT02563223|Other|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
11320576|NCT02563210|Experimental|airway resistance measurement|interruption and plethysmography techniques airway resistance measurement at each routine visit
11320577|NCT02563197|Experimental|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
11320578|NCT02563184|Active Comparator|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
11320579|NCT02563184|Active Comparator|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
11320580|NCT02563171|Placebo Comparator|Healthy periodontium without obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
11320581|NCT02563171|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
11320582|NCT02563171|Placebo Comparator|Healthy periodontium with obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
11320583|NCT02563171|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
11320584|NCT02563158|No Intervention|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
11320585|NCT02563158|Experimental|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
11320586|NCT02563145|Experimental|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.
~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
11320587|NCT02563145|Active Comparator|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.
~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
11320588|NCT02563145|No Intervention|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
11320589|NCT02563132|Experimental|Carbon dioxide insufflation colonoscopy (CO2)|Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
11320590|NCT02563132|No Intervention|Air insufflation colonoscopy (AI)|Air insufflation during both insertion and withdrawal phase of the colonoscopy.
11375257|NCT02199860|Placebo Comparator|Placebo|
11320596|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
11320597|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
11320598|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
11320599|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
11320600|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
11320601|NCT02563067|Experimental|QAW039 Dose 1|QAW039 Dose 1 once daily
11320602|NCT02563067|Experimental|QAW039 Dose 2|QAW039 Dose 2 once daily
11320603|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
11320604|NCT02563054|Active Comparator|5-Fluorouracil + Cisplatin|Participants will receive 5-FU in combination with cisplatin upto disease progression.
11320605|NCT02563054|Experimental|Capecitabine + Cisplatin|Participants will receive capecitabine in combination with cisplatin upto disease progression.
11320606|NCT02563041|Experimental|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
11320607|NCT02563041|Active Comparator|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
11320608|NCT02563028|Experimental|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
11320609|NCT02563015|Experimental|Cholecalciferol 400|400 IU orally per day
11320610|NCT02563015|Experimental|Cholecalciferol 1000|1000 IU orally per day
11320611|NCT02563015|Active Comparator|Reference 400|400 IU orally per day
11320612|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
11320613|NCT02563002|Active Comparator|Standard of Care|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
11320614|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
11320615|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
11320616|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
11320617|NCT02562976||early gastric cancer group|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia in patients with early gastric cancer or high-grade neoplasia(HGN)
11320618|NCT02562976||non-early gastric cancer group|patients diagnosed as non- gastritis, gastritis or low-grade neoplasia (LGN) by pathology were defined as non-EGC group
11320619|NCT02562963|Experimental|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
11320620|NCT02562950|Experimental|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
11320621|NCT02562950|Experimental|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
11320622|NCT02562937|Experimental|Intervention|text messages related to sedentary behaviour
11320623|NCT02562937|No Intervention|Control|text messages unrelated to sedentary behaviour.
11320624|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
~Reevaluate at day 119:
~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
11320625|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;
~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.
~After day 91:
~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:
~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
11375258|NCT02199847|Experimental|Pharmaton® Caplets|
11320626|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;
~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.
~After day 91:
~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
~Reevaluate at day 119:
~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
11320627|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
11320628|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
11320629|NCT02562885|Experimental|Acoustic pulses|"During NREM sleep:
~15 minutes without acoustic pulses
~15 minutes with acoustic pulses
~15 minutes without acoustic pulses
~Two different protocols are applied:
~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.
~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.
~Participants with ESES/CSWS: only Protocol A."
11320630|NCT02562872|Experimental|Cohort 1 Active DSM265|
11320631|NCT02562872|Placebo Comparator|Cohort 1 Placebo|
11320632|NCT02562872|Experimental|Cohort 2a Active DSM265|
11320633|NCT02562872|Placebo Comparator|Cohort 2a Placebo|
11320634|NCT02562872|Experimental|Cohort 2b Active DSM265|
11320635|NCT02562872|Placebo Comparator|Cohort 2b Placebo|
11320636|NCT02562859|Experimental|GLPG1837 as oral suspension fasted|Single dose of 500 mg GLPG1837 as oral suspension after an overnight fast
11320637|NCT02562859|Experimental|GLPG1837 as oral tablet fasted|Single dose of 500 mg GLPG1837 as oral tablet after an overnight fast
11320638|NCT02562859|Experimental|GLPG1837 as oral tablet fed|Single dose of 500 mg GLPG1837 as oral tablet after a high-fat high-calorie breakfast
11320639|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
11320640|NCT02562833|Experimental|Self-Management and exercise|
11320641|NCT02562833|Active Comparator|Educational|
11320642|NCT02562820|Experimental|Ketamine|Subjects will receive intravenous infusion of a 0.1, 0.5, 1.0, 2.0 or 4.5 mg/kg dose over the course of 40 minutes
11320643|NCT02562820|Placebo Comparator|Placebo|Subjects will receive an intravenous infusion of normal saline over the course of 40 minutes
11320644|NCT02562807|Active Comparator|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
11320645|NCT02562807|Placebo Comparator|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
11320646|NCT02562807|Active Comparator|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
11320647|NCT02562807|Placebo Comparator|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
11320648|NCT02562794|Experimental|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
11320649|NCT02562794|No Intervention|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
11320650|NCT02562781|Active Comparator|Supplemental Oxygen|Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
11320651|NCT02562781|Experimental|Air or supplemental oxygen|Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
11320652|NCT02562768|Experimental|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
11320653|NCT02562768|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
11320654|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
11320655|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
11320656|NCT02562742||SOF+REB|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating clinical site.
11320657|NCT02562729|Experimental|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
11320658|NCT02562716|Experimental|Arm I (mFOLFIRINOX, surgery)|Patients receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive 5-fluorouracil IV over 46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin, irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or unacceptable toxicity.
11320659|NCT02562716|Experimental|Arm II (gemcitabine, nab-paclitaxel, and surgery)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy, patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride treatment in the absence of disease progression or unacceptable toxicity.
11320757|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
11375259|NCT02199847|Placebo Comparator|Placebo|
11320660|NCT02562703|Active Comparator|ACTIVE tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
11320661|NCT02562703|Sham Comparator|SHAM tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.
11320662|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).
~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.
~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
11320663|NCT02562677|Experimental|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
11320664|NCT02562664|Active Comparator|CC with placebo|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with placebo tablets taken twice daily continuously for three cycles.
11320665|NCT02562664|Active Comparator|CC plus Metformin|received t100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with plus Metformin 500 mg twice daily continuously for three cycles.
11320666|NCT02562651|Experimental|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
11320667|NCT02562651|Active Comparator|Active comparator|Standard care for STEMI
11320668|NCT02562638|No Intervention|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
11320669|NCT02562638|Experimental|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
11320670|NCT02562625|Experimental|Pembrolizumab Alone|If the patient is randomised to the Pembrolizumab Arm Only then they will receive 200mg of pembrolizumab every 3 weeks.
11320671|NCT02562625|Experimental|Pembrolizumab plus Radiotherapy|If The patient is randomised to this arm they will receive 200mg of pembrolizumab every 3 weeks in combination with a radiotherapy dosage of 24Gy in 3 fractions to be given over 3 consecutive days (only).
11320672|NCT02562612|Experimental|SM-88|SM-88 multiple ascending doses
11320673|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin
~Interventions:
~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).
~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .
~Radiation: Intensity-modulated radiotherapy (IMRT)"
11320674|NCT02562586|Active Comparator|Closed Suction Drainage System|Group 1: patients undergoing total hip replacement received a Closed Suction Drainage System for 24 hours after the surgical procedure
11320675|NCT02562586|No Intervention|No Closed Suction Drainage System|Group 2: patients undergoing total hip replacement have not received a Closed Suction Drainage System after the surgical procedure
11320676|NCT02562573|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
11320677|NCT02562560|Experimental|TGA|
11320678|NCT02562560|Experimental|Controls|
11320679|NCT02562547||All Vaginal Births|The application of the Hem-Avert Perianal Stabilizer
11320680|NCT02562534|Other|Patients with conductives troubles|Patients with conductives troubles
11320681|NCT02562534|Other|Patients with rythm troubles|Patients with rythm troubles
11320682|NCT02562534|Other|Volonteers|Volonteers with normal ECG
11320683|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
11320684|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
11320685|NCT02562508|Experimental|9-17y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
11320686|NCT02562508|Experimental|9-14y (0,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
11320687|NCT02562508|Experimental|18-26y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
11320688|NCT02562495|Experimental|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
11320689|NCT02562482|Experimental|Group 1: VRC-CHKVLP059-00-VP 20 mcg|Group 1 subjects were randomized to receive two intramuscular (IM) injections of CHIKV VLP vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days) at a dose of 20 micrograms (mcg).
11320690|NCT02562482|Placebo Comparator|Group 2: Placebo (VRC-PBSPLA043-00-VP)|Group 2 subjects were randomized to receive two intramuscular (IM) injections of Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) placebo at Day 0 and Day 28 (+14 days).
11320919|NCT02561091|Placebo Comparator|Placebo|Placebo gel for intratympanic use
11320920|NCT02561091|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
11320691|NCT02562469|Experimental|ACTIVATE|ACTIVATE is a computerized neurocognitive training program (ACTIVATE; see: www.c8sciences.com) that simultaneously targets eight core neurocognitive factors (i.e., sustained attention, working memory (WM), response inhibition, speed of information processing, cognitive flexibility and control, multiple simultaneous attention, category formation, and pattern recognition and inductive thinking). ACTIVATE Is completed at home via computer with parent support. ACTIVATE intervention is conducted 3-5 times per week for between 20-30 minutes over the course or 3-4 months.
11320692|NCT02562456|Active Comparator|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars (rubber dam isolation + Adhesive system + composite resin Filtek z350)
11320693|NCT02562456|Experimental|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars with GIC Fuji IX
11320694|NCT02562443|Experimental|rigosertib + best supportive care (BSC)|
11320695|NCT02562443|Active Comparator|Physician's Choice (PC) + best supportive care (BSC)|
11320696|NCT02562430|Experimental|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
11320697|NCT02562430|Active Comparator|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
11320698|NCT02562417|Placebo Comparator|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
11320699|NCT02562417|Experimental|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
11320700|NCT02562391|Active Comparator|PVI+Box lesions|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.
11320701|NCT02562391|Experimental|PVI+Box lesions+LAA cutting|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.The left atrial appendage was removed by stapling and then cutting.
11320702|NCT02562378|Experimental|Trastuzumab + doxorubicin|Trastuzumab and non-pegylated liposomal doxorubicin: Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
11320703|NCT02562365|Experimental|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
11320704|NCT02562365|No Intervention|B: Follow-up|No interevention
11320705|NCT02562352|Experimental|TAPER program|"The intervention arm is comprised of:
~Identification of medications that are appropriate for discontinuation/dose reduction.
~Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction."
11320706|NCT02562352|No Intervention|Control|Standard of Care as wait list control
11320707|NCT02562339|Experimental|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
11320708|NCT02562339|Experimental|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
11320709|NCT02562326|Experimental|BioChaperone insulin lispro|
11320710|NCT02562326|Active Comparator|Humalog®|
11320711|NCT02562313|Experimental|BioChaperone insulin lispro|
11320712|NCT02562313|Active Comparator|Humalog®|Insulin lispro
11320713|NCT02562300|Active Comparator|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
11320714|NCT02562300|Active Comparator|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
11320715|NCT02562287|Experimental|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
11320716|NCT02562287|Active Comparator|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
11320717|NCT02562274|Placebo Comparator|Placebo group|Subjects are received the placebo product which has same color and smell look like the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) treatments once daily for 8 weeks
11320718|NCT02562274|Active Comparator|MP 50 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 50 mg/day treatments once daily for 8 weeks
11320719|NCT02562274|Active Comparator|MP 1500 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 1500 mg/day treatments once daily for 8 weeks
11320720|NCT02562261||Healthy|
11320721|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
11320722|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following
~Temperature of <36 °C (96.8 °F) or >38 °C (100.4 °F)
~Heart rate >90bpm
~Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)
~WBC <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³), or 10% bands in response to an infectious process.."
11320723|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output < 0.5 ml/kg/hr)] Septic shock is defined as severe sepsis plus persistently low blood pressure (< 5th percentile for age or systolic blood pressure < 2 standard deviations below normal for age) following the administration of intravenous fluids.
11320724|NCT02562248|Active Comparator|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
11320725|NCT02562248|Active Comparator|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
11320726|NCT02562235|Experimental|Riociguat|Participants with age >=6 to <18 years received riociguat up to 2.5 mg three times a day (titration between 0.5 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration of the dose for safety reasons was allowed at any time.
11320727|NCT02562222|Experimental|anodal tDCS on M1|anodal tDCS on left primary motor cortex
11320728|NCT02562222|Experimental|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
11320729|NCT02562222|Experimental|anodal tDCS on V1|anodal tDCS on visual cortex
11320730|NCT02562222|Experimental|cathodal tDCS on V1|cathodal tDCS on visual cortex
11320731|NCT02562222|Experimental|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
11320732|NCT02562222|Experimental|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
11320733|NCT02562222|Sham Comparator|sham tDCS|sham tDCS
11320734|NCT02562209|Experimental|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
11320735|NCT02562209|Active Comparator|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
11320736|NCT02562196|Experimental|optimized protocol chosen|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
11320737|NCT02562196|Sham Comparator|sham tDCS|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
11320738|NCT02562183|Experimental|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
11320739|NCT02562170|Active Comparator|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
11320740|NCT02562170|Active Comparator|Protexa|immediate breast reconstruction with an implant and Protexa
11320741|NCT02562157|Experimental|Patients with antro duodenal obstructions|NOTES gastroenteric anastomosis
11320742|NCT02562144|Experimental|Xylocaine spray|
11320743|NCT02562144|Placebo Comparator|Placebo|
11320744|NCT02562118|Experimental|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by Letrozole 2.5mg daily + lenvatinib x 12 weeks (for Part A) or continuous till progression or intolerability (Part B)
11320745|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
11320746|NCT02562092|No Intervention|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
11320747|NCT02562092|Other|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
11320748|NCT02562092|Other|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
11320749|NCT02562079|Experimental|subjects SSc diagnosed|
11320750|NCT02562079|Experimental|subjects Localised sclerosis diagnosed|
11320751|NCT02562079|Experimental|subjects Sc|
11320752|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
11320753|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
11320754|NCT02562053|Active Comparator|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
11320755|NCT02562053|Active Comparator|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
11320756|NCT02562053|Placebo Comparator|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
11320758|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
11320759|NCT02562027|Experimental|High-risk NSCLC participants|"Baseline assessment of demographics and comorbidities
~Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.
~Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living
~HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.
~All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
11320760|NCT02562014|Other|Lean|Participants with body mass index <=25
11320761|NCT02562014|Other|Overweight|Participants with body mass index >25
11320762|NCT02562001|Experimental|Outpatient active group|This group will receive active tDCS, combined with Lokomat gait training
11320763|NCT02562001|Experimental|Inpatient active group|This group will receive active tDCS, combined with Lokomat gait training
11320764|NCT02562001|Experimental|Outpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
11320765|NCT02562001|Experimental|Inpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
11320766|NCT02561988|Experimental|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
11320767|NCT02561975|Experimental|Patient suffering from complex congenital heart disease|
11320768|NCT02561962|Experimental|Dose Exploration|
11320769|NCT02561949|Experimental|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
11320770|NCT02561949|Experimental|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
11320771|NCT02561936|Experimental|Panel 1: Group 1|Participants will receive Treatment A (25 milligram [mg] rilpivirine [RPV] formulated as the oral tablet under fed condition [standardized breakfast]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 [10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 [10*2.5 mg tablets, dispersed in water] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 [10*2.5 mg tablets, dispersed in water] under fed condition).
11320772|NCT02561936|Experimental|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
11320773|NCT02561936|Experimental|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
11320774|NCT02561936|Experimental|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
11320775|NCT02561936|Experimental|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [yoghurt] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition).
11320776|NCT02561936|Experimental|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
11320777|NCT02561936|Experimental|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
11320778|NCT02561936|Experimental|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
11320779|NCT02561923|Experimental|Rivaroxaban|Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
11320780|NCT02561923|Experimental|Rivaroxaban plus tranexamic acid (TXA)|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
11320781|NCT02561923|Experimental|Rivaroxaban plus Kcentra|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 [international units per minute] IU/min) on Day 4 in Part 2.
11320782|NCT02561923|Experimental|Rivaroxaban plus Saline|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline [Kcentra saline control or TXA saline control] on Day 4 in Part 2.
11320783|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
11320784|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
11320785|NCT02561884|Experimental|AB|Olostar Tab. followed by Olmetec and Crestor
11320786|NCT02561884|Experimental|BA|Olmetec and Crestor followed by Olostar Tab.
11320787|NCT02561871|Experimental|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 169.
11320921|NCT02561091|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
11320788|NCT02561871|Experimental|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
11320789|NCT02561871|Experimental|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
11320790|NCT02561858|Experimental|acid load test|
11320791|NCT02561845||rosuvastatin group|patients who received rosuvastatin
11320792|NCT02561832|Experimental|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
11320793|NCT02561806|Active Comparator|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants >100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
11320794|NCT02561806|Experimental|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
11320795|NCT02561793|Active Comparator|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
11320796|NCT02561793|Placebo Comparator|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
11320797|NCT02561780|Active Comparator|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.
~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
11320798|NCT02561780|Active Comparator|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.
~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
11320799|NCT02561780|No Intervention|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
11320800|NCT02561767|Experimental|MSCs group|"Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
~The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx."
11320801|NCT02561767|Placebo Comparator|Control group|Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
11320802|NCT02561754|Active Comparator|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
11320803|NCT02561754|Experimental|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
11320804|NCT02561754|Experimental|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
11320805|NCT02561741|Experimental|COV155|
11320806|NCT02561728|Experimental|Plagiocephaly|Children with a misshaped head due to positioning. This is also known as flat head. Children with plagiocephaly will be treated with either the Hangar Helmet or the P-Pod helmet.
11320807|NCT02561728|Experimental|Craniosynostosis|Craniosynostosis occurs when one or multiple sutures fuse too early. Several sutures may be fused alone or in combination. An open or endoscopic surgical procedure to open the suture(s) is necessary to allow for normal brain growth and development. After surgery a cranial remolding helmet is used to direct skull growth. Children with craniosynostosis will be treated with either the Hangar Helmet or the P-Pod helmet
11320808|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
11320809|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
11320810|NCT02561689|Experimental|Fissure sealant material 1|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
11320811|NCT02561689|Experimental|Fissure sealant material 2|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
11320812|NCT02561676|Experimental|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
11320813|NCT02561676|Experimental|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
11321934|NCT02554227||Spondylodiscitis|vertebral osteomyelitis, erosive osteochondrose
11320814|NCT02561663|Experimental|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
11320815|NCT02561663|Experimental|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
11320816|NCT02561650|Experimental|COV155|
11320817|NCT02561637|Experimental|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
11320818|NCT02561637|Other|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
11320819|NCT02561624|Experimental|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
11320820|NCT02561624|No Intervention|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
11320821|NCT02561611|No Intervention|Control Group|"Usual Working Condition Group (UWC)
~The no-intervention control condition will be asked to maintain their usual work and lifestyle throughout the study. Participants may be contacted by Pennington Biomedical staff during the intervention."
11320822|NCT02561611|Experimental|Intervention Group|"Combined Intervention (Walk More and Pedal Desk; WMPD)
~Participants in the WMPD condition will engage in both step-counting (Walk More, WM) and pedal desk (PD) intervention components."
11320823|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
11320824|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
11320825|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
11320826|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
11320827|NCT02561572|Experimental|Intervention|Acupuncture at the Yintang point for 30 minutes.
11320828|NCT02561572|No Intervention|Control|No intervention for 30 minutes.
11320829|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
11320830|NCT02561546|Experimental|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
11320831|NCT02561546|Active Comparator|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
11320832|NCT02561533|Experimental|BRAF immunohistochemistry (IHC)|
11320833|NCT02561520|Experimental|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
11320834|NCT02561507||American College of Surgeons members|Survey participants
11320835|NCT02561494|Placebo Comparator|Control|Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
11320836|NCT02561494|Experimental|Nefopam|Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
11320837|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:
~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)
~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
11320838|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.
~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
11320839|NCT02561468|Experimental|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
11320840|NCT02561468|Placebo Comparator|Control|100 ml normal saline is infused before starting operation.
11320841|NCT02561455|Experimental|ASP2215|Subject will continue dosing at the dose received in original study.
11320842|NCT02561442|Active Comparator|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
11320843|NCT02561442|Experimental|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
11320844|NCT02561442|Experimental|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
11320845|NCT02561429|Experimental|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
11321061|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
11320846|NCT02561416|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
11320847|NCT02561416|Active Comparator|Psycho-educational Program|Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
11320848|NCT02561416|Other|Treatment As Usual|Treatment As Usual.
11320849|NCT02561403|Experimental|EVO multitask video game|
11320850|NCT02561403|Experimental|EVO words video game|
11320851|NCT02561403|No Intervention|Assessment Only|
11320852|NCT02561390|Experimental|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
11320853|NCT02561390|Experimental|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
11320854|NCT02561377|Experimental|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
11320855|NCT02561377|Experimental|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
11320856|NCT02561377|No Intervention|standard care|standard care complied with the daily lifestyle.
11320857|NCT02561338|Experimental|HMS5552 dose 1|75mgQD oral administration
11320858|NCT02561338|Experimental|HMS5552 dose 2|100mgQD oral administration
11320859|NCT02561338|Experimental|HMS5552 dose 3|50mgBID oral administration
11320860|NCT02561338|Experimental|HMS5552 dose 4|75mgBID oral administration
11320861|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
11320862|NCT02561325|Experimental|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
11320863|NCT02561325|Placebo Comparator|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
11320864|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
11320865|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
11320866|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
11320867|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
11320868|NCT02561286|Experimental|HIV risk reduction|BRO HIV Risk Reduction Intervention
11320869|NCT02561286|Active Comparator|Health promotion control|Health Promotion Intervention
11320870|NCT02561273|Experimental|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:
~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.
~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11320871|NCT02561260||autoimmune encephalitis|
11320872|NCT02561260||unknowm encephalitis|
11320873|NCT02561260||other encephalopathy|
11320874|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
11320875|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 1|3 patients dosed at 0.01 mg/kg until MTD determined
11320876|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 2|4 patients dosed at 0.02 mg/kg until MTD determined
11320877|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 3|4 patients dosed at 0.04 mg/kg until MTD determined
11320878|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 4|4 patients dosed at 0.08 mg/kg until MTD determined
11320879|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 5|3 patients dosed at 0.12 mg/kg until MTD determined
11320880|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 6|4 patients dosed at 0.18 mg/kg until MTD determined
11320881|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 7|5 patients dosed at 0.27 mg/kg until MTD determined
11320882|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 8|7 patients dosed at 0.40 mg/kg until MTD determined
11320883|NCT02561234|Experimental|AEB1102 Dose Escalation Cohort 9|7 patients dosed at 0.33 mg/kg until MTD determined MTD determined at 0.33 mg/kg
11320884|NCT02561234|Experimental|AEB1102 Expansion|Uveal: 11 patients dosed at 0.33 mg/kg Cutaneous Melanoma: 11 dosed at 0.33 mg/kg SCLC: 13 patients dosed at 0.33 mg/kg
11320922|NCT02561078|Experimental|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
11321157|NCT02559466|Experimental|Patients stimulated with a H-TMS (deep)|20 sessions navigated with Deep Transcranial Magnetic Stimulation
11320885|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patienst with obesity.
11320886|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
11320887|NCT02561208|Active Comparator|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
11320888|NCT02561208|No Intervention|Usual Care Group|Women with HPV self-collected tests receive usual care.
11320889|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
11320890|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
11320891|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
11320892|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
11320893|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
11320894|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
11320895|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
11320896|NCT02561169|Experimental|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
11320897|NCT02561169|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
11320898|NCT02561156|Experimental|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
11320899|NCT02561156|Experimental|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
11320900|NCT02561156|Experimental|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
11320901|NCT02561156|Experimental|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
11320902|NCT02561156|Experimental|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
11320903|NCT02561156|Experimental|Part 1 Cohort 6: TAK- 653 18 mg|TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
11320904|NCT02561156|Experimental|Part 1 Additional Cohorts: TAK- 653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
11320905|NCT02561156|Experimental|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
11320906|NCT02561156|Experimental|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
11320907|NCT02561156|Experimental|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
11320908|NCT02561156|Experimental|Part 2 Cohort 4: TAK-653 6 mg|TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
11320909|NCT02561156|Experimental|Part 2 Cohort 5: TAK-653 9 mg|TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
11320910|NCT02561156|Experimental|Part 2 Additional Cohorts: TAK-653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
11320911|NCT02561143|Experimental|Intervention group|Patients in the intervention group will be given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
11320912|NCT02561143|Placebo Comparator|Control group|Patients in the control group will be given whole wheat flour (100 g) daily along with nutritional counseling and physical activity counseling for six months.
11320913|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
11320914|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
11320915|NCT02561117|Active Comparator|q8h|Metronidazole given every 8 hours
11320916|NCT02561117|Experimental|q24h|Metronidazole given once daily
11320917|NCT02561104|Experimental|LenSx|Laser-assisted cataract surgery performed using the LenSx femtosecond laser.
11320918|NCT02561104|Experimental|Phaco|Traditional manual phacoemulsification cataract surgery
11320923|NCT02561078|Active Comparator|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
11320924|NCT02561065|Experimental|Lifestyle intervention high risk group.|Participants in the intervention group will receive the intervention on top of standard care.
11320925|NCT02561065|No Intervention|Standard care high risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
11320926|NCT02561065|Experimental|Lifestyle intervention low risk group.|Participants in the intervention group will receive the intervention on top of standard care.
11320927|NCT02561065|No Intervention|Standard care low risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
11320928|NCT02561039|Experimental|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
11320929|NCT02561039|Experimental|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
11320930|NCT02561026|Experimental|FP Transfusion|patients randomized to receive frozen plasma transfusions
11320931|NCT02561026|No Intervention|no FP Transfusion|patients not receiving frozen plasma transfusions
11320932|NCT02561013|Experimental|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
11320933|NCT02561013|Active Comparator|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
11320934|NCT02561000|Experimental|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
11320935|NCT02561000|Experimental|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
11320936|NCT02561000|Placebo Comparator|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
11320937|NCT02560974|Experimental|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
11320938|NCT02560974|No Intervention|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
11320939|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
11320940|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
11320941|NCT02560948|Placebo Comparator|Placebo|
11320942|NCT02560948|Experimental|gpASIT+TM|
11320943|NCT02560935|Active Comparator|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
11320944|NCT02560935|Active Comparator|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
11320945|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
11320946|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
11320947|NCT02560909|Experimental|Experimental|The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.
11320948|NCT02560909|Active Comparator|Control|The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.
11320949|NCT02560870|Active Comparator|Aloe Vera mouthwash|mouthwash (Aleo Vera)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
11320950|NCT02560870|Active Comparator|Chlorhexidine mouthwash|mouthwash (Chlorhexidine )10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
11320951|NCT02560831|Experimental|Therapeutic exercise and Pompage|strengthening exercises, balance training and knee's pompage
11320952|NCT02560831|Active Comparator|Control|Educational lectures.
11320953|NCT02560818|Active Comparator|Control population : Healthy Volunteers|"20 Healthy Volunteers will be recruited:
~10 women to recover breast tissue (from surgical waste) : populations A and C
~10 women to recover ovarian tissue (from surgical waste) : population B"
11320954|NCT02560818|Experimental|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
11320955|NCT02560805|Experimental|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
11320956|NCT02560805|Experimental|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
11320997|NCT02560545|Placebo Comparator|Placebo|Oil
11320957|NCT02560792|Experimental|Positive Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to positive affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to positive feelings.
11320958|NCT02560792|Experimental|Negative Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to negative affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to negative feelings.
11320959|NCT02560792|Experimental|Control Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise - affect was not mentioned.
11320960|NCT02560779|Experimental|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
11320961|NCT02560766|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
11320962|NCT02560766|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
11320963|NCT02560766|Placebo Comparator|Placebo|Placebo once daily
11320964|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
11320965|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
11320966|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
11320967|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
11320968|NCT02560740|Experimental|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
11320969|NCT02560740|Placebo Comparator|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
11320970|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
11320971|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
11320972|NCT02560688|Experimental|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
11320973|NCT02560688|Other|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
11320974|NCT02560688|Experimental|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
11320975|NCT02560675||120 healthy subjects|"One hundred and twenty healthy subjects (range 20-79; 20 subjects per age decade, 10 M and 10 F) will participate in the first phase of the study aimed to collect normative data from healthy population.
~Study design Phase I - Normative data collection for the inhibitory and excitatory pain modulation responses, a study on healthy subjects (no blood tests)"
11320976|NCT02560675||750 subjects wuith acute whiplash-injury|"Seven hundred and fifty acute whiplash-injury based mild TBI will participate in this study.
~Phase II - Multi-modal assessment of acute mild TBI whiplash patients and follow-up"
11320977|NCT02560662|Experimental|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
11320978|NCT02560662|No Intervention|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
11320979|NCT02560649|Experimental|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):
~HBsAg<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
11320980|NCT02560649|Active Comparator|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):
~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
11320981|NCT02560649|Active Comparator|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):
~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
11320982|NCT02560636|Experimental|Dose level 1a|Radiotherapy: 24Gy in 6f Pembrolizumab: 100mg
11320983|NCT02560636|Experimental|Dose level 1b|Radiotherapy: 24Gy in 6f Pembrolizumab: 200mg
11320984|NCT02560636|Experimental|Dose level 2a|Radiotherapy: 24Gy in 4f Pembrolizumab: 100mg
11320985|NCT02560636|Experimental|Dose level 2b|Radiotherapy: 24Gy in 4f Pembrolizumab: 200mg
11320986|NCT02560636|Experimental|Dose level 3a|Radiotherapy: 30Gy in 5f Pembrolizumab: 200mg
11320987|NCT02560623|Active Comparator|Cases - Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic brushings of the esophagus.
11320988|NCT02560623|Active Comparator|Controls - No Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic biopsies of the esophagus.
11320989|NCT02560610|Active Comparator|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
11320990|NCT02560610|Placebo Comparator|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
11320991|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
11320992|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)
~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.
~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
11320993|NCT02560571|Experimental|all patients|all study patients will undergo ultrasound and blood test
11320994|NCT02560558|Experimental|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
11320995|NCT02560558|Active Comparator|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
11320996|NCT02560545|Active Comparator|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
11320998|NCT02560532|Experimental|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
11320999|NCT02560519|Active Comparator|Ringers acetate solution|Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
11321000|NCT02560519|Experimental|Albumin solution|Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
11321001|NCT02560506|Experimental|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
11321002|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
11321003|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
11321004|NCT02560480||groin injury (group A)|magnetic resonance imaging performed in all athletes with acute or subacute groin injury
11321005|NCT02560480||control (group B)|magnetic resonance imaging performed in selected asymptomatic control athletes
11321006|NCT02560467|Experimental|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
11321007|NCT02560454|Experimental|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.
~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
11321008|NCT02560454|Experimental|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.
~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
11321009|NCT02560454|No Intervention|Control|Control ( waiting list)
11321010|NCT02560441|Other|chemotherapy followed by radiotherapy|Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.
11321011|NCT02560441|Other|radiotherapy followed by chemotherapy|Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.
11321012|NCT02560441|Other|IPGDP regimen chemotherapy|Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.
11321013|NCT02560415|Experimental|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
11321014|NCT02560415|Active Comparator|2: Comparator|Treatment as usual
11321015|NCT02560402||Patients with sepsis or trauma|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma
11321016|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
11321017|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
11321018|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
11321019|NCT02560376|Experimental|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
11321020|NCT02560363|Experimental|Treatment sequence 1|Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
11321021|NCT02560363|Experimental|Treatment sequence 2|Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
11321022|NCT02560363|Experimental|Treatment sequence 3|Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
11321023|NCT02560363|Experimental|Treatment sequence 4|Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
11321024|NCT02560337|Experimental|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.
~Treatment continues until progression or unacceptable toxicity."
11321059|NCT02560077|Active Comparator|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
11321025|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.
~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
11321026|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.
~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.
~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
11321027|NCT02560311||HER2+ metastatic breast cancer|
11321028|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
11321029|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11321030|NCT02560285||Development / 2000 participants|"Age >18 years;
~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
11321031|NCT02560285||Validation / 1000 participants|"Age >18 years;
~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
11321032|NCT02560272|Experimental|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
11321033|NCT02560272|Active Comparator|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
11321034|NCT02560259|Active Comparator|Physiotherapy Group|Physiotherapy
11321035|NCT02560259|Placebo Comparator|Conservative group|Conservative treatment
11321036|NCT02560246||Preterm Labor|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
11321037|NCT02560246||Term Labor|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
11321038|NCT02560233|Experimental|Contingent|Contingent RT-fMRI-NF
11321039|NCT02560233|Sham Comparator|Non-contingent|Sham RT-fMRI-NF
11321040|NCT02560220|Experimental|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
11321041|NCT02560207|Active Comparator|Intermittent cefotaxime|Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
11321042|NCT02560207|Experimental|Continuous cefotaxime|After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .
11321043|NCT02560194|Active Comparator|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
11321044|NCT02560194|Placebo Comparator|FOBT only|People in this are offered fecal occult blood testing only.
11321045|NCT02560181|Other|HDR whole gland salvage treatment|Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart
11321046|NCT02560168|Experimental|Coronary artery disease|Patients scheduled for computed tomographic coronary angiography (CTA)
11321047|NCT02560155|No Intervention|Nose-SA-carriers control|Control Group, no intervention
11321048|NCT02560155|Active Comparator|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement
~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
11321049|NCT02560155|No Intervention|Non-nose-SA-carriers control|Control Group, no intervention
11321050|NCT02560155|Active Comparator|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
11321051|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
11321052|NCT02560129||ICU Survivors|ICU survivors will be seen in a MICU Recovery Clinic where Questionnaires, Physical and Cognitive Function assessments will be measured
11321053|NCT02560103||Single group|No treatment
11321054|NCT02560090|Placebo Comparator|Control Group|Survey assessments as well as collection of medical records and billing information.
11321055|NCT02560090|Active Comparator|Telephonic Nurse Intervention|Survey assessments as well as collection of medical records and billing information. A nurse will communicate with participants via telephone to support diabetes self-management practices.
11321056|NCT02560090|Active Comparator|In-person Community Health Worker Intervention|Survey assessments as well as collection of medical records and billing information. A community health worker will work with participants in person to support diabetes self-management practices.
11321057|NCT02560077|Placebo Comparator|placebo|The placebo and cashew apple fruit juice had the same color and smell
11321058|NCT02560077|Active Comparator|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
11321062|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
11321063|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
11321064|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
11321065|NCT02560025|Experimental|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
11321066|NCT02560012|Other|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.
~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
11321067|NCT02559999|Other|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
11321068|NCT02559973|Experimental|RBP-6000 - Light MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a light molecular weight (MW) polymer.
11321069|NCT02559973|Experimental|RBP-6000 - Heavy MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a heavy molecular weight (MW) polymer.
11321070|NCT02559973|Active Comparator|RBP-6000 - Intermediate MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with an intermediate molecular weight (MW) polymer (reference).
11321071|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
11321072|NCT02559934|Experimental|SR-T100 gel|A single dose of 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 25 cm2 skin area covered by an occlusive dressing at least 20 hours a day and will be given once daily for sixteen consecutive weeks.
11321073|NCT02559921|Experimental|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
11321074|NCT02559921|Experimental|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
11321075|NCT02559921|Active Comparator|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
11321076|NCT02559921|Experimental|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
11321077|NCT02559921|Experimental|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
11321078|NCT02559921|Experimental|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
11321079|NCT02559921|Placebo Comparator|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
11321080|NCT02559908|Experimental|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
11321081|NCT02559908|Other|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
11321082|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
11321083|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
11321084|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
11321085|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
11321086|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
11321087|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
11321088|NCT02559856|Active Comparator|Apixaban|10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.
11321089|NCT02559856|Active Comparator|Rivaroxaban|15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.
11321090|NCT02559843|Experimental|pomegranate juice|200 ml pomegranate juice + lifestyle modification
11321091|NCT02559843|Active Comparator|control|lifestyle modification including dietary recommendations
11321092|NCT02559830|Experimental|transduced CD34+ hematopoietic stem cell|Transplantation of autologous CD34+ hematopoietic stem cells transduced with ARSA/ABCD1 encoding lentiviral vector. Dosage: 2x10^6/Kg （Minimum）to 20x10^6/Kg （Maximum） transduced CD34+ cells at bedside for infusion
11321093|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg
~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg
~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
11321125|NCT02559609|Experimental|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
11321126|NCT02559609|Experimental|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
11321094|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg
~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg
~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
11321095|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg
~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg
~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
11321096|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.
~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
11321097|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast
~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age
~Placebo solid oral capsule in children 12-17 years of age"
11321098|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
11321099|NCT02559791|Experimental|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
11321100|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
11321101|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
11321102|NCT02559752||Arm 1: NIH Toolbox Cognitive Battery testing|"This study will use the NIH Toolbox Cognitive Battery computer testing software to investigate the cognitive outcomes in children with CNS tumors receiving PBRT.
~Participants recruited for the study will complete one 45-minute testing session prior to the completion of the first week of radiation therapy.
~They will then complete serial tests 6-12 months after the completion of PBRT and then yearly thereafter."
11321103|NCT02559739||Sleep deficiency/fragmentation|Patients with sleep deficiency/fragmentation
11321104|NCT02559739||No sleep deficiency/fragmentation|Patients without sleep deficiency/fragmentation
11321105|NCT02559726|Experimental|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
11321106|NCT02559726|Experimental|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
11321107|NCT02559726|Other|healthy volunteers|20 healthy volunteers
11321108|NCT02559713|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
11321109|NCT02559700|Experimental|Brain training programme|Participants will complete a package of online brain training games focusing on reasoning and problem solving. The intervention will be accessed via a computer. There is no minimum or maximum dosage but participants will be recommended to complete the intervention five times a week. The package takes approximately 10 minutes to complete, depending on individual performance.
11321110|NCT02559687|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years)
11321111|NCT02559674|Experimental|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
11321112|NCT02559661||Medical students|Students with limited knowledge of the anatomy and pathology of the eye.
11321113|NCT02559661||Ophthalmological trainees|The trainees have never done eye surgery but have a better understanding of the eyes pathology and anatomy than the medical students.
11321114|NCT02559661||Vitreoretinal surgeons|The vitreoretinal surgeons knows the eyes anatomy and pathology well and have training and skills in vitreoretinal surgery.
11321115|NCT02559648|Active Comparator|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
11321116|NCT02559648|Placebo Comparator|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
11321117|NCT02559635|No Intervention|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
11321118|NCT02559635|Experimental|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
11321119|NCT02559622|Experimental|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
11321120|NCT02559622|Experimental|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
11321121|NCT02559622|Other|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
11321122|NCT02559622|Other|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
11321123|NCT02559609|Active Comparator|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
11321124|NCT02559609|Experimental|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
11321127|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
11321128|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
11321129|NCT02559583||Participants with Chronic Lymphocytic Leukemia (CLL)|This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.
11321130|NCT02559583||Participants with Multiple Myeloma (MM)|This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.
11321131|NCT02559583||Participants with Non-Hodgkin's lymphoma (NHL)|This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.
11321132|NCT02559570|Placebo Comparator|Placebo|Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
11321133|NCT02559570|Experimental|LIN Dose A (9 ug or 18 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
11321134|NCT02559570|Experimental|LIN Dose B (18 ug or 36 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
11321135|NCT02559570|Experimental|LIN Dose C (36 ug or 72 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
11321136|NCT02559570|Experimental|LIN 145 µg|Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
11321137|NCT02559557|Experimental|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.
~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
11321138|NCT02559531|Experimental|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
11321139|NCT02559518|Experimental|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
11321140|NCT02559518|Experimental|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
11321141|NCT02559518|Sham Comparator|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
11321142|NCT02559518|Experimental|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
11321143|NCT02559518|Experimental|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
11321144|NCT02559518|Sham Comparator|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
11321145|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
11321146|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
11321147|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
11321148|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
11321149|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
11321150|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
11321151|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
11321152|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
11321153|NCT02559492|Experimental|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
11321154|NCT02559492|Experimental|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
11321155|NCT02559479|Active Comparator|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
11321156|NCT02559479|Active Comparator|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
11321158|NCT02559466|Other|Patients stimulated with a conventional TMS|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
11321159|NCT02559453|Active Comparator|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
11321160|NCT02559453|Active Comparator|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
11321161|NCT02559440|Active Comparator|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
11321162|NCT02559440|Placebo Comparator|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
11321163|NCT02559440|Active Comparator|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
11321164|NCT02559440|Placebo Comparator|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
11321165|NCT02559440|Active Comparator|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
11321166|NCT02559440|Active Comparator|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
11321167|NCT02559427|Active Comparator|Immediate SPA treatment|3-week immediate SPA treatment (soon after randomization)
11321168|NCT02559427|Sham Comparator|Late SPA treatment|3-week late SPA treatment (soon after primary endpoint at 4 1/2 months visit)
11321169|NCT02559414|No Intervention|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
11321170|NCT02559414|Active Comparator|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
11321171|NCT02559414|Active Comparator|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
11321172|NCT02559388|Active Comparator|montelukast|montelukast 10 milligram, daily for 30 days
11321173|NCT02559388|Placebo Comparator|placebo|Placebo one tablet for 30 days
11321174|NCT02559336|No Intervention|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
11321175|NCT02559336|Experimental|Intervention|Integrated oncology care and palliative care
11321176|NCT02559310|Experimental|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
11321177|NCT02559310|Active Comparator|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
11321178|NCT02559297|Active Comparator|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
11321179|NCT02559297|Experimental|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
11321180|NCT02559284|Experimental|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
11321181|NCT02559284|Active Comparator|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
11321182|NCT02559258|Experimental|Cohort 1|
11321183|NCT02559258|Experimental|Cohort 2|
11321184|NCT02559258|Experimental|Cohort 3|
11321185|NCT02559258|Experimental|Cohort 4|
11321186|NCT02559258|Experimental|Cohort 5|
11321187|NCT02559245|Experimental|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
11321188|NCT02559245|Experimental|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
11321189|NCT02559245|No Intervention|controled|participants will follow their usual diet
11321190|NCT02559232||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fibrillation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
11321191|NCT02559206|Experimental|30 μg linaclotide DR1 and placebo|
11321192|NCT02559206|Experimental|100 μg linaclotide DR1 and placebo|
11321193|NCT02559206|Experimental|300 μg linaclotide DR1 and placebo|
11321194|NCT02559206|Experimental|30 μg linaclotide DR2 and placebo|
11321195|NCT02559206|Experimental|100 μg linaclotide DR2 and placebo|
11321196|NCT02559206|Experimental|300 μg linaclotide DR2 and placebo|
11321197|NCT02559206|Experimental|290 μg linaclotide IR and placebo|
11321198|NCT02559206|Placebo Comparator|Placebo|
11321199|NCT02559193||No treatment.|Data collection only trial design.
11321200|NCT02559180|Experimental|Single Arm|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
11321201|NCT02559167|Active Comparator|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
11321202|NCT02559167|Placebo Comparator|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
11321234|NCT02558894|Experimental|MEDI4736 monotherapy|MEDI4736 via IV infusion.
11321235|NCT02558894|Experimental|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
11321203|NCT02559154|Experimental|modified BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
11321204|NCT02559154|Active Comparator|conventional BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
11321205|NCT02559141|Other|Study group (SG)|"Before induction of anaesthesia:
~Arterial line
~Nexfin Monitoring System
~Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)
~Baseline blood samples. Induction of anaesthesia
~Study Group:
~PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²
~Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
11321206|NCT02559141|No Intervention|Control group (CG)|"MAP ≥65 mmHg
~CVP ≤12 mmHg
~Haemoglobin level ≥8 g/dl.
~Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
11321207|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
11321208|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
11321209|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
11321210|NCT02559128||HF-T2D-|20 healthy control volunteers
11321211|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
11321212|NCT02559102|Experimental|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
11321213|NCT02559102|Active Comparator|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
11321214|NCT02559089||anti-NMDA receptor encephalitis|
11321215|NCT02559089||other autoimmune encephlitis|
11321216|NCT02559089||other encephalopathy|
11321217|NCT02559076|Experimental|Ten Steps Leaflet|Ten steps leaflet advice for healthy lifestyle
11321218|NCT02559076|No Intervention|Usual care|Usual care given
11321219|NCT02559063|Experimental|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
11321220|NCT02559063|Active Comparator|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience [and amount of time]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
11321221|NCT02559037|Experimental|Acupuncture-moxibustion group|Receiving acupuncture and moxibustion treatment.
11321222|NCT02559037|Sham Comparator|Sham acupuncture-moxibustion group|Receiving sham acupuncture and sham moxibustion.
11321223|NCT02559024|Experimental|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
11321224|NCT02559024|Experimental|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
11321225|NCT02559024|Experimental|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
11321226|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
11321227|NCT02558972|Placebo Comparator|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
11321228|NCT02558972|Placebo Comparator|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
11321229|NCT02558959|Experimental|Irinotecan and Capecitabine|irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w
11321230|NCT02558959|Active Comparator|Irinotecan|irinotecan 180mg/m2 d1, q2w
11321231|NCT02558946|Active Comparator|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
11321232|NCT02558946|Active Comparator|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
11321233|NCT02558933|Experimental|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
11321236|NCT02558881||Virtual colonoscopy|"With virtual colonoscopy, the patient does not need to be hospitalized for examination, which is usually done without hospitalization. A bowel preparation is necessary. It may vary from site to site, but it generally comprises polyethylene glycol or sodium phosphate. The residual stools are marked by ingestion of a radiopaque product to differentiate colic lesions. But no contrast agent is injected intravenously. The patient should be supine and a rectal probe is set up to inject either air or CO2. The vesting period does not exceed thirty seconds apnea, and overall completion time of the examination (patient table) is about 10 minutes."
11321237|NCT02558881||Colon capsule|The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
11321238|NCT02558868|Experimental|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
11321239|NCT02558868|Active Comparator|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
11321240|NCT02558855|Active Comparator|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
11321241|NCT02558855|Sham Comparator|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
11321242|NCT02558842|Experimental|Education Strategy|Educational Strategy and Oversight Distance
11321243|NCT02558842|No Intervention|Routine|Routine hospital assistance
11321244|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
11321245|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
11321246|NCT02558816|Experimental|Ibrutinib - GA101 - GDC_0199|STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibrutinib 560mg day 1-28 ; GA101 1000mg D 1 ; GDC-0199 20mg/d at W1, 50mg/d at W2, 100mg at W3, 200 mg/d at W4 / C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC-0199:400mg/d W1 and 400, 600 or 800mg/d W2-3-4 + 400, 600 or 800 mg/d C3-C6 (patients 1-12).Patients 13-24:GDC-199 400mg/d / C7(Maintenance phase)-C23:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2 cycles (from C8);GDC:400, 600 or 800 mg D1-28 (patient 1-12).Patients 13-24 : 400mg/d STEP C:C1-C1bis=Step B; C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC:400mg/d C7 (Maintenance phase)-C23 : Ibrutinib 560mg D1-28 (-->progression);GA101 1000mg D1/2 cycles (from C8);GDC-0199 400mg/d
11321247|NCT02558803|No Intervention|Usual Care|The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms
11321248|NCT02558803|Experimental|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
11321249|NCT02558790|Experimental|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
11321250|NCT02558777|Experimental|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
11321251|NCT02558777|No Intervention|Control Group|Usual care
11321252|NCT02558764|No Intervention|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
11321253|NCT02558764|Other|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
11321254|NCT02558751|Active Comparator|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
11321255|NCT02558751|Active Comparator|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
11321256|NCT02558751|Active Comparator|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
11321257|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
11321258|NCT02558738||Normison ear spray|treatment according to instruction for use
11321259|NCT02558725|No Intervention|one capsule of iron supplement|instructed to take one capsule at least 2 hours after consumption of dairy products
11321260|NCT02558725|Active Comparator|two capsules of iron supplement|instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
11321261|NCT02558712|Other|Face to face exam|Standard of clinical care, 8 point eye exam
11321262|NCT02558699|Active Comparator|conventional group|Group operating the atrial fibrillation by physician's personal experience, not by virtual simulation.
11321263|NCT02558699|Experimental|3D atrial computer model|Group choosing choose the best effective rotor mapping by simulating 3D atrial computer model which consider patinet's heart size and shape.
11321264|NCT02558686|Experimental|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
11321265|NCT02558686|Sham Comparator|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
11321266|NCT02558686|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
11321267|NCT02558673|Experimental|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
11321384|NCT02557880|Experimental|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
11321268|NCT02558673|Experimental|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef [Philly-Gourmet Beef Patties]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
11321269|NCT02558673|Experimental|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish [cod fillet]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
11321270|NCT02558673|Active Comparator|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
11321271|NCT02558660|Experimental|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
11321272|NCT02558647|Experimental|CBT for insomnia (CBT-I)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) comprises a fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention
11321273|NCT02558647|Active Comparator|Psychoeducation about Sleep (PE)|The PE intervention gives participants access to a website with information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
11321274|NCT02558634|Experimental|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on
~DBS system includes:
~Implantable Pulse Generator (IPG)
~DBS Lead
~DBS Lead Extension Kit"
11321275|NCT02558634|Sham Comparator|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off
~DBS system includes:
~Implantable Pulse Generator (IPG)
~DBS Lead
~DBS Lead Extension Kit"
11321276|NCT02558621|Experimental|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
11321277|NCT02558608|Experimental|WR AND DIPL|patients undergo wedge resection and dissection the inferior pulmonary ligament by thoracoscopic surgery or video assisted thoracoscopic surgery
11321278|NCT02558608|Active Comparator|WR|patients undergo wedge resection by thoracoscopic surgery or video assisted thoracoscopic surgery without dissection the inferior pulmonary ligament
11321279|NCT02558595|Experimental|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
11321280|NCT02558595|Placebo Comparator|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
11321281|NCT02558582|Experimental|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
11321282|NCT02558582|Experimental|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
11321283|NCT02558582|Experimental|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
11321284|NCT02558582|Experimental|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
11321285|NCT02558569|Experimental|Levobupivacaine|Scalp nerve block with 0.5% Levobupivacaine adds up to intravenous fentanyl for intraoperative pain control during supratentorial craniotomy with brain tumor removal. The scalp block includes 4-6 nerves which give sensory supply to related location with the use of total 10-15 ml of 0.5% Levobupivacaine. Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given. is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
11321286|NCT02558569|Sham Comparator|NSS|Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
11321287|NCT02558556|Experimental|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.
~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.
~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.
~The complete procedure will be recorded on video."
11321288|NCT02558556|No Intervention|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.
~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.
~The complete procedure will be recorded on video.
~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
11321935|NCT02554214|Experimental|Glafkos device|
11321289|NCT02558543|Active Comparator|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
11321290|NCT02558543|Placebo Comparator|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
11321291|NCT02558530|Other|Low carbohydrate diet|Isocaloric diet, <20 g carbohydrates per day
11321292|NCT02558517|No Intervention|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
11321293|NCT02558517|Experimental|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
11321294|NCT02558504|Active Comparator|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
11321295|NCT02558504|Experimental|Radiofrequency ablation|"The equipment processing is:
~The radiofrequency generator,
~The radiofrequency balloon 360,
~the radiofrequency probe 90.
~The radiofrequency treatment should be carried out according to the following protocol:
~The radiofrequency treatment is done within 2 months following the last endoscopic assessment.
~The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.
~Endoscopy is performed under general anesthesia.
~The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.
~The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.
~During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
11321296|NCT02558491|Experimental|Decision Support System|Blinded CGM data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters that will be used during the Experimental Admission.
11321297|NCT02558491|No Intervention|Usual Care|Subjects will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
11321298|NCT02558465||Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxavban administration group
11321299|NCT02558439|Placebo Comparator|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
11321300|NCT02558439|Experimental|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
11321301|NCT02558439|Experimental|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
11321302|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
11321303|NCT02558413|Active Comparator|BTA-C585 oral capsules|25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg
11321304|NCT02558413|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
11321305|NCT02558400|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
11321306|NCT02558400|Active Comparator|AR-13324 Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
11321307|NCT02558400|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
11321308|NCT02558387|Experimental|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
11321309|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
11321310|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
11321311|NCT02558361|Other|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis [target joint] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR & ex vivo cytokine production assays. UA/pregnancy test.
~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.
~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
11321312|NCT02558348|Experimental|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.
~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
11321385|NCT02557880|Active Comparator|Treatment as Usual|Sleep hygiene counseling
11321313|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
11321314|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
11321315|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
11321316|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.
~The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.
~A slit lamp examination and indirect ophthalmoscopy will be performed.
~Experimental:
~The subject's eye will be held open with an eye speculum during the exam.
~Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.
~Intraocular Pressure will be measured.
~An Optic Coherence Tomography (OCT) will be performed.
~At each step along the process of ICP reduction, the eye exam, IOP & OCT will be performed.
~Optional:
~The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.
~OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
11321317|NCT02558296|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
11321318|NCT02558296|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
11321319|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
11321320|NCT02558283|Active Comparator|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
11321321|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
11321322|NCT02558283|Active Comparator|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
11321323|NCT02558270|Active Comparator|patients dapa|Patients will be administered Dapagliflozin 10mg
11321324|NCT02558270|Placebo Comparator|patients placebo|Patients will be administered a placebo
11321325|NCT02558270|Active Comparator|controls dapa|controls will be administered Dapagliflozin 10mg
11321326|NCT02558270|Placebo Comparator|controls placebo|controls will be administered a placebo
11321327|NCT02558257||Palliative Care Survey|Initial consultation visit followed by phone survey within 1 week +/- 4 days of initial consultation.
11321328|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
11321329|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
11321330|NCT02558218|Active Comparator|Systane ultra group|Participants in this group were administered systane ultra quid (Alcon, Fort Worth) for two months postoperatively), additionally to tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.
11321331|NCT02558218|Active Comparator|Control group|Participants in this group were administered the standard postoperative medication [tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.]
11321332|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
11321333|NCT02558192|Experimental|Probiotics|Vials containing 3 x 10^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
11321334|NCT02558192|Placebo Comparator|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
11321335|NCT02558179||Nugent Score >/= 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Diagnosis of bacterial vaginosis (study group) according to Nugent score and/or diagnosis of vulvovaginal candidiasis; and/or diagnosis of Trichomonas vaginalis.
11321336|NCT02558179||Nugent Score< 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (<7).
11321337|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)
~with shock due sepsis/SIRS, cardiac failure or hemorrhage
~age > 18 years,
~noradrenalin support
~< 24 hours of ICU admission
~Signed informed consent"
11321338|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)
~without shock, without vasopressor support and without fluid dependent circulation
~age > 18 years
~< 24 hours of ICU admission
~Signed informed consent"
11321339|NCT02558153|Experimental|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
11321340|NCT02558153|Active Comparator|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
11321341|NCT02558140|Experimental|Part 1: Dose Escalation|All participants will be given RO6874813 as a single low dose of 0.5 milligrams per kilogram (mg/kg) via intravenous (IV) infusion in a 7-day pharmacokinetic (PK) run-in period (Cycle 0). This is followed by dose escalation (Cycle 1) for which participants will receive escalating doses of RO6874813 (starting dose = 1 mg/kg) via IV infusion every week (qw) or every 2 weeks (Q2W) for 28 to 42 days to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
11321342|NCT02558140|Experimental|Part 2: Tumor Biopsy and Imaging|The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.
11321343|NCT02558140|Experimental|Part 3: Preliminary Efficacy Assessment|Participants with locally advanced or metastatic non-resectable FAP+ sarcoma will be treated with RO6874813 at the RP2D and as per schedule determined upon completion of Part 1. Participants continuing treatment with RO6874813 beyond 36 weeks will enter the extension phase of Part 3 and will be monitored for disease status and clinical safety per routine standard of care.
11321344|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
11321345|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
11321346|NCT02558114|Other|Group A|Patients will receive ribavirin during 12 weeks
11321347|NCT02558114|Other|Group B|"Patients will receive:
~ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)
~- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
11321348|NCT02558101|Active Comparator|Control invitation materials|Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
11321349|NCT02558101|Experimental|Intervention invitation materials|A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
11321350|NCT02558088|Experimental|salmeterol|
11321351|NCT02558075|Experimental|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
11321352|NCT02558062|Experimental|BAC ONE administration|All participants in this clinical study will be dosed on one occasion with BAC ONE. The final dosage will be 80 µg (± 25%).
11321353|NCT02558049|Experimental|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
11321354|NCT02558036|Active Comparator|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
11321355|NCT02558036|Active Comparator|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
11321356|NCT02558036|Active Comparator|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
11321357|NCT02558036|Active Comparator|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
11321358|NCT02558023|Experimental|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.
~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.
~Maximum dose of 30 mg.h-1."
11321359|NCT02558023|Active Comparator|Nicardipine|"Nicardipine : IV
~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.
~Maximum dose of 6 mg.h-1"
11321360|NCT02558010|Experimental|Methadone Group|Patients will receive a total of 0.2mg/kg IV methadone intraoperative (0.1mg / kg preincision and 0.1mg/kg prior to emergence) with a maximum dosing of 20 mg.
11321361|NCT02558010|Active Comparator|Control Group|Patient will receive normal saline placebo initially, then morphine prior to emergence.
11321362|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
11321363|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
11321364|NCT02557997||ART-controlled|ART-controlled HIV infected adults
11321365|NCT02557997||ART-failing|ART-failing HIV infected adults
11321366|NCT02557984|Placebo Comparator|Placebo|Placebo Pill
11321367|NCT02557984|Experimental|Amisulpride|400 mg Amisulpride (Solian®)
11321368|NCT02557984|Experimental|Naltrexone|50 mg Naltrexone (Naltrexin®)
11321369|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
11321370|NCT02557958|Experimental|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
11321371|NCT02557958|Placebo Comparator|Placebo|Placebo daily for 8 weeks
11321372|NCT02557945|Experimental|Gabapentin|Gabapentin 3600mg PO daily
11321373|NCT02557945|Placebo Comparator|Placebo|Matching placebo PO daily
11321374|NCT02557932|Active Comparator|Standard triple therapy|7 day-PPI based standard triple therapy
11321375|NCT02557932|Active Comparator|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
11321376|NCT02557919|Experimental|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
11321377|NCT02557919|Other|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
11321378|NCT02557906|Experimental|Implant and Surgimend|Breast reconstruction surgery with an implant and an ADM (Surgimend)
11321379|NCT02557906|Active Comparator|Autologous tissue|Breast reconstruction surgery with autologous tissue
11321380|NCT02557906|Active Comparator|Implant + dermal sling/LD flap|Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
11321381|NCT02557893|Experimental|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
11321382|NCT02557893|Sham Comparator|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
11321383|NCT02557893|Placebo Comparator|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
11321420|NCT02557620|Experimental|semaglutide OW + placebo semaglutide OD|
11321386|NCT02557867|Experimental|Obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
11321387|NCT02557867|Experimental|Non-obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
11321388|NCT02557854|Experimental|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
11321389|NCT02557841|Experimental|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
11321390|NCT02557841|Experimental|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
11321391|NCT02557841|Sham Comparator|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
11321392|NCT02557828|Active Comparator|palpation|participants who are randomized to have radial arterial cannulation via palpation technique
11321393|NCT02557828|Active Comparator|ultrasound|participants who are randomized to have radial arterial cannulation via a new ultrasound technique
11321394|NCT02557815|Experimental|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
11321395|NCT02557815|Sham Comparator|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
11321396|NCT02557802|Experimental|Group A|Nasal spray at day 0, intramuscular injection at day 28
11321397|NCT02557802|Experimental|Group B|Intramuscular injection at day 0, nasal spray at day 28
11321398|NCT02557789|Experimental|Treatment A|Lefamulin as a 600 mg IR tablet in the fasted state
11321399|NCT02557789|Experimental|Treatment B|Lefamulin as 600 mg API in capsule (three 200 mg capsules) in the fasted state
11321400|NCT02557789|Experimental|Treatment C|Lefamulin as 150 mg i.v. in 250 mL citrate buffered saline infused over 1 h
11321401|NCT02557789|Experimental|Treatment D|Lefamulin as a 600 mg IR tablet one hour after breakfast
11321402|NCT02557776|Experimental|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
11321403|NCT02557763|Experimental|Oxford UKA|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
11321404|NCT02557737|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
11321405|NCT02557737|Experimental|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
11321406|NCT02557737|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
11321407|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
11321408|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
11321409|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
11321410|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
11321411|NCT02557685|No Intervention|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
11321412|NCT02557672|Active Comparator|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
11321413|NCT02557672|Experimental|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
11321414|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
11321415|NCT02557633|Placebo Comparator|Placebo|2% w/v L-Tyrosine
11321416|NCT02557633|Experimental|Grass MATA MPL 10200 SU|Grass MATA MPL cumulative dose 10200 SU given as six injections of placebo, placebo, 600SU, 1600SU, 4000SU and 4000SU.
11321417|NCT02557633|Experimental|Grass MATA MPL 18200 SU|Grass MATA MPL cumulative dose 18200 SU given as six injections of 600SU, 1600SU, 4000SU, 4000SU, 4000SU and 4000SU.
11321418|NCT02557620|Experimental|semaglutide OD + placebo semaglutide OW|
11321419|NCT02557620|Placebo Comparator|placebo semaglutide OW + placebo semaglutide OD|
11321421|NCT02557607|Other|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
11321422|NCT02557594|Experimental|Viread → DA-2802|"Viread 300mg(Tenofovir disoproxil fumarate)
~DA-2802 319mg(Tenofovir disoproxil orotate)"
11321423|NCT02557594|Experimental|DA-2802 → Viread|"Viread 300mg(Tenofovir disoproxil fumarate)
~DA-2802 319mg(Tenofovir disoproxil orotate)"
11321424|NCT02557581|Experimental|Terbutaline|Beta2-adrenergic stimulation with terbutaline
11321425|NCT02557581|Placebo Comparator|Placebo|Placebo
11321426|NCT02557581|Experimental|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
11321427|NCT02557568|Experimental|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
11321428|NCT02557568|Experimental|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
11321429|NCT02557542|Experimental|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
11321430|NCT02557542|Active Comparator|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
11321431|NCT02557529|Experimental|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
11321432|NCT02557529|Active Comparator|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
11321433|NCT02557516|Experimental|Phase 1 Level 1 - 1 mg/kg|In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
11321434|NCT02557516|Experimental|Phase 1 Level 2 - 2 mg/kg|In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
11321435|NCT02557516|Experimental|Phase 1 Level 3 - 4 mg/kg|In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
11321436|NCT02557516|Experimental|Phase 2 RP2D - 2 mg/kg|In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
11321437|NCT02557503|Experimental|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
11321438|NCT02557503|No Intervention|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
11321439|NCT02557490|Experimental|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
11321440|NCT02557490|No Intervention|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
11321441|NCT02557477|Active Comparator|Active|Participants received 3 capsules of Omega 3/6 fatty acids twice daily
11321442|NCT02557477|Placebo Comparator|Placebo|Participants received 3 capsules of identical placebo (palm oil) twice daily
11321443|NCT02557464|Experimental|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
11321444|NCT02557464|Active Comparator|control group|24 age matched controls participants
11321445|NCT02557451|Experimental|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
11321446|NCT02557451|Experimental|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
11321447|NCT02557438||Roux-en-Y Gastric Bypass|Males and females aged 13-21 undergoing Roux-en-Y gastric bypass (RYGB) surgery
11321448|NCT02557438||Vertical Sleeve Gastrectomy|Males and females aged 13-21 undergoing vertical sleeve gastrectomy (VSG) surgery
11321449|NCT02557438||Non-surgical Obese Controls|Males and females aged 13-21 who are obese and not undergoing weight loss surgery
11321450|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
11321451|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
11321452|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
11321453|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
11321454|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
11321455|NCT02557412|Placebo Comparator|Conventional treatment|Hygiene and diet recommendations on sleep.
11321456|NCT02557412|Active Comparator|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
11321457|NCT02557412|Active Comparator|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
11321498|NCT02557139|Experimental|Regimen A|200 mg KD025 tablet in the fasted state
11321499|NCT02557139|Experimental|Regimen B|200 mg KD025 tablet in the fed state
11321500|NCT02557139|Experimental|Regimen C|200 mg KD025 as drug in capsule in the fed state
11321458|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
11321459|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
11321460|NCT02557386|Experimental|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
11321461|NCT02557386|Experimental|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
11321462|NCT02557386|Experimental|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
11321463|NCT02557386|Experimental|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
11321464|NCT02557386|Experimental|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
11321465|NCT02557386|Experimental|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
11321466|NCT02557373|Placebo Comparator|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
11321467|NCT02557373|Experimental|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
11321468|NCT02557360|Experimental|S-adenosyl-L-methionine|Patients with primary biliary cirrhosis will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
11321469|NCT02557347|Experimental|Intervention|Aggressive fluid management
11321470|NCT02557334|Experimental|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
11321471|NCT02557334|Experimental|High Dose Strawberry Powder|40 g freeze dried strawberry powder
11321472|NCT02557334|Placebo Comparator|Placebo Powder|40 g color and taste matched placebo powder
11321473|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
11321474|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
11321475|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
11321476|NCT02557308||Remsima™|Patients who are taking Remsima™ for the treatment
11321477|NCT02557308||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
11321478|NCT02557295||Remsima™|Patients who are taking Remsima™ for the treatment
11321479|NCT02557295||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
11321480|NCT02557295||Biologic naive patients|Biologic naive patients (in Korea only)
11321481|NCT02557282||Predicate software|Olea Sphere PACS with CT Perfusion Module
11321482|NCT02557282||Investigational software|Vue PACS 12.1.5 Computed Tomography (CT) Perfusion
11321483|NCT02557269|Active Comparator|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
11321484|NCT02557269|Placebo Comparator|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
11321485|NCT02557269|Other|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
11321486|NCT02557217|Experimental|NP202|1000mg oral NP202 daily for 90 days
11321487|NCT02557217|Placebo Comparator|Placebo|Oral placebo daily for 90 days
11321488|NCT02557204|Active Comparator|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
11321489|NCT02557204|Experimental|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
11321490|NCT02557204|Experimental|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
11321491|NCT02557204|Experimental|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
11321492|NCT02557191||Group 1|Preterm infants <32 weeks gestational age
11321493|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
11321494|NCT02557178|No Intervention|Control|
11321495|NCT02557165||COPD patients|Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
11321496|NCT02557165||Patients with normal lung function|Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
11321497|NCT02557152||Patients that were treated with the GentleWave System|
11321503|NCT02557113|Active Comparator|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
11321504|NCT02557113|Experimental|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
11321505|NCT02557100|Experimental|Treatment A|Abatacept Single Blind Treatment Period
11321506|NCT02557100|Active Comparator|Treatment B|Adalimumab Single Blind Treatment Period
11321507|NCT02557100|Active Comparator|Treatment C|Abatacept Cumulative Treatment Period
11321508|NCT02557087|Experimental|Hyoscine|Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
11321509|NCT02557087|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
11321510|NCT02557074|Experimental|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -
~IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment
~IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
11321511|NCT02557074|Placebo Comparator|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
11321512|NCT02557061|Experimental|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
11321513|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
11321514|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
11321515|NCT02556996|Experimental|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
11321516|NCT02556996|Placebo Comparator|Placebo|Three doses administered orally at 2-week intervals
11321517|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
11321518|NCT02556970|Experimental|Single-port surgery|"After induction of anaesthesia and lung isolation, a single intercostal incision will be placed laterally. This will usually be anterior to the border of the latissimus dorsi muscle, and in the 4th-7th space as appropriate to the planned surgery.
~A soft tissue wound protector can be used to protect the wound edges, but rigid intercostal retraction is not permitted. All instruments will be placed via this incision."
11321519|NCT02556970|Active Comparator|Multiple port surgery|Patients in this arm will have 3 separate incisions placed to site the camera and other instruments. This will involve three separate incisions.
11321520|NCT02556957|Experimental|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
11321521|NCT02556957|Active Comparator|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
11321522|NCT02556944|Experimental|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
11321523|NCT02556931|Experimental|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
11321524|NCT02556931|Experimental|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
11321525|NCT02556918|Experimental|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
~Interventions:
~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
11321526|NCT02556918|Placebo Comparator|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
~Interventions:
~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
11321527|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
11321528|NCT02556892|Experimental|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
11321529|NCT02556879|Other|Liver retransplantation|"Donor specific antibodies :Additional samples for Donor specific at each visit
~Serum bank : Additional samples for serum bank at each visit if possible
~DNA banq : Additional sample for DNA banq at inclusion visit if possible
~Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)
~Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
11321530|NCT02556866|Experimental|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
11321531|NCT02556866|Placebo Comparator|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
11321532|NCT02556853|Experimental|Ultrasound|Determination of correct placement of the double lumen tube by lung ultrasound.
11321533|NCT02556853|Active Comparator|Clinical|Determination of correct placement of the double lumen tube by clinical examination.
11321534|NCT02556840|Active Comparator|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose > 0.95g/l or post-prandial blood glucose > 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.
~Insulin administered to patients either by subcutaneous injections or by pump."
11321535|NCT02556840|Experimental|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.
~Insulin administered to patients either by subcutaneous injections or by pump."
11321536|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.
~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
11321537|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.
~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
11321538|NCT02556814|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
11321539|NCT02556814|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
11321540|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
11321541|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
11321542|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
11321543|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
11321544|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
11321545|NCT02556788|Placebo Comparator|Placebo Cream|Placebo Cream
11321546|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
11321547|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
11321548|NCT02556762|Experimental|SMART boost|Radiotherapy with simultaneous modulated accelerated boost
11321549|NCT02556762|Active Comparator|Standard dose RT|Standard dose radiotherapy
11321550|NCT02556749|Experimental|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
11321551|NCT02556749|Placebo Comparator|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
11321552|NCT02556736|Experimental|Group 1|Single intravitreal injection of RST-001
11321553|NCT02556723|Experimental|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
11321554|NCT02556710|Experimental|4 mL AMPION™|AMPION™, 4 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
11321555|NCT02556710|Placebo Comparator|4 mL Saline Placebo|Saline placebo, 4 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride.
11321556|NCT02556697|Experimental|patients with a suspicion of emphysema|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
11321557|NCT02556697|Experimental|patients with a suspicion of scleroderma|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
11321558|NCT02556671||Moderate CKD Patients Undergoing PCI|
11321560|NCT02556658|Experimental|Smartpilot View group|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
11321561|NCT02556658|Active Comparator|Control group|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
11321562|NCT02556645|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
11321563|NCT02556645|Active Comparator|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
11321564|NCT02556632|Experimental|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
11321565|NCT02556632|Experimental|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
11321566|NCT02556632|Placebo Comparator|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
11321567|NCT02556619|No Intervention|Standard Therapy|Patients will undergo standard medical care for Hepatocellular Carcinoma diagnosis.Patients however will not be denied early palliative care if requested.
11321568|NCT02556619|Experimental|Early Palliative Care/Symptom Control|"Patients will undergo palliative care services at time of Hepatocellular Carcinoma diagnosis.
~Palliative care and symptom control services are adapted from the National Consensus Project for Quality Palliative Care.
~Early referral, patients meeting inclusion criteria will be enrolled and referred to palliative care within 3 weeks of the index consultation with Medical-Oncology, Surgical-Oncology or Gastroenterology.
~Intervention will be:
~Establish palliative care goals
~Symptom Assessment and Control
~End-of-Life Care"
11321569|NCT02556606|Experimental|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
11321570|NCT02556606|Experimental|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
11321571|NCT02556606|Experimental|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
11321572|NCT02556606|Active Comparator|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
11321573|NCT02556593|Experimental|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
11321574|NCT02556593|Active Comparator|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
11321575|NCT02556580|Active Comparator|Conscious healthy volunteers|Intervention: intravenious infusion Drug: albumin 20%
11321576|NCT02556580|Experimental|Surgery under general anesthesia|Intervention: intravenious infusion Drug: albumin 20%
11321577|NCT02556580|Experimental|Post-surgical inflammation|Intervention: intravenious infusion Drug: albumin 20%
11321578|NCT02556567|Other|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
11321579|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
11321580|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
11321581|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
11321582|NCT02556528|Experimental|Health Coaching|
11321583|NCT02556515|Active Comparator|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
11321584|NCT02556515|Experimental|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
11321585|NCT02556502|Experimental|FDG PET positive or negative|
11321586|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
11321587|NCT02556463|Experimental|Escalation MEDI9197|MEDI9197
11321588|NCT02556463|Experimental|Escalation MEDI9197 with durvalumab|MEDI9197 in combination with durvalumab
11321589|NCT02556463|Experimental|Escalation MEDI9197 durvalumab radiation|MEDI9197 in combination with durvalumab and palliative radiation
11321590|NCT02556463|Experimental|MEDI9197 with palliative radiation|MEDI9197 in combination with palliative radiation
11321591|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
11321592|NCT02556450|No Intervention|Control group|Only background treatment
11321593|NCT02556437|Experimental|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
11321594|NCT02556437|Experimental|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
11321595|NCT02556424|Active Comparator|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
11321596|NCT02556424|Experimental|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
11321597|NCT02556411|Active Comparator|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
11321598|NCT02556411|Experimental|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
11321599|NCT02556398|Experimental|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
11321600|NCT02556385|Experimental|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
11321601|NCT02556385|Active Comparator|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
11321602|NCT02556372|Experimental|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
11321603|NCT02556346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11321604|NCT02556346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11321605|NCT02556346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11321606|NCT02556346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11321607|NCT02556346|Experimental|MT-3724 Phase 1b|MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
11321608|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
11321609|NCT02556320|Experimental|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
11321610|NCT02556307||Peginterferon alfa-2a + Ribavirin|
11321611|NCT02556294|Experimental|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
11321612|NCT02556294|Other|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
11321613|NCT02556281|Experimental|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
11321614|NCT02556268|Experimental|Riociguat and ATRIPLA|
11321615|NCT02556268|Experimental|Riociguat and COMPLERA|
11321616|NCT02556268|Experimental|Riociguat and STRIBILD|
11321617|NCT02556268|Experimental|Riociguat and TRIUMEQ|
11321618|NCT02556268|Experimental|Riociguat and antiretroviral protease inhibitor with TRIUMEQ|
11321619|NCT02556255|Experimental|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
11321620|NCT02556242|Experimental|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
11321621|NCT02556242|Active Comparator|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
11321622|NCT02556229|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
11321623|NCT02556203|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
11321624|NCT02556203|Active Comparator|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
11321625|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
11321626|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
11321627|NCT02556164|Experimental|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
11321628|NCT02556164|Sham Comparator|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
11321629|NCT02556151|Active Comparator|1 Hz|Six sessions of weekly therapy with 1 Hz magnetic stimulations of the lumbar and sacral regions.
11321630|NCT02556151|Active Comparator|5 Hz|Six sessions of weekly therapy with 5 Hz magnetic stimulations of the lumbar and sacral regions.
11321631|NCT02556151|Active Comparator|15 Hz|Six sessions of weekly therapy with 15 Hz magnetic stimulations of the lumbar and sacral regions.
11321632|NCT02556138|Experimental|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
11321748|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
11376141|NCT02193906|Placebo Comparator|Placebo group|Placebo task.
11321633|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
11321634|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
11321635|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
11321636|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
11321637|NCT02556099|Experimental|Hydroxyurea Treatment|Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic clinical evaluations, laboratory tests, and transcranial doppler examinations every 6 months.
11321638|NCT02556086|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
11321639|NCT02556073|Active Comparator|Usual care|"Usual care means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics."
11321640|NCT02556073|Experimental|Usual care+Smartphone action|Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
11321641|NCT02556060|Experimental|lamotrigine|lamotrigine extended release up to 200 mg/day,
11321642|NCT02556060|Placebo Comparator|Placebo|Identical Placebo
11321643|NCT02556047|Other|Injections|"Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length
~Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length
~Two injections of 0.1 ml saline per subject using Mantoux technique by N&S"
11321644|NCT02556034||Disease evaluation|Rheumatoid arthritis evaluations.
11321645|NCT02556021|Experimental|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
11321646|NCT02556021|Experimental|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
11321647|NCT02556021|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
11321648|NCT02555995|Experimental|All study participants|Patient's eyes are OCT-scanned with standard device and investigational device.
11321649|NCT02555982|Experimental|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:
~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
11321650|NCT02555982|Other|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:
~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
11321651|NCT02555943|Active Comparator|Prophylactic/Early anti-HBV treatment|"HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
~."
11321652|NCT02555943|Experimental|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
11321653|NCT02555917|Experimental|Remnant preserving|"Anterior cruciate ligament reconstruction:
~anterior cruciate ligament remnant will be preserved in the operation"
11321654|NCT02555917|Active Comparator|Remnant resecting|"Anterior cruciate ligament reconstruction:
~anterior cruciate ligament remnant will be removed in the operation"
11321655|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
11321656|NCT02555878|Experimental|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
11321657|NCT02555878|Experimental|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
11321658|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
11321659|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
11321660|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
11321661|NCT02555839||Pomalidomide and Dexamethasone|Pomalidomide 4mg capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
11321719|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321662|NCT02555839||Pomalidomide, Bortezomib and Dexamethasone|Cycle 1-8: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle until progression or unacceptable toxicity; from cycle 9 onwards: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 8, 9 of a 21 day cycle until progression or unacceptable toxicity
11321663|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
11321664|NCT02555800|Experimental|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
11321665|NCT02555800|Experimental|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
11321666|NCT02555800|Placebo Comparator|Saline|Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.
11321667|NCT02555787||Patients converted from tacrolimus BD to Advagraf|Oral
11321668|NCT02555774|Experimental|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
11321669|NCT02555774|Active Comparator|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
11321670|NCT02555774|No Intervention|No intervention|This group receives no intervention.
11321671|NCT02555761||Lastacaft®|One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.
11321672|NCT02555748|Active Comparator|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).
~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
11321673|NCT02555748|Active Comparator|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).
~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
11321674|NCT02555735||Metastatic Pancreatic Cancer|Participants with metastatic pancreatic cancer treated with physician-choice standard of care chemotherapy.
11321675|NCT02555722|Experimental|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
11321676|NCT02555722|Active Comparator|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
11321677|NCT02555709|Placebo Comparator|Placebo 1|healthy volunteers
11321678|NCT02555709|Experimental|VTP-43742 Dose 1|healthy volunteers
11321679|NCT02555709|Experimental|VTP-43742 Dose 2|healthy volunteers
11321680|NCT02555709|Experimental|VTP-43742 Dose 3|healthy volunteers
11321681|NCT02555709|Experimental|VTP-43742 Dose 4|healthy volunteers
11321682|NCT02555709|Experimental|VTP-43742 Dose 5|healthy volunteers
11321683|NCT02555709|Experimental|VTP-43742 Dose 6|healthy volunteers
11321684|NCT02555709|Experimental|VTP-43742 Dose 7|healthy volunteers
11321685|NCT02555709|Placebo Comparator|Placebo 2|psoriatic patients
11321686|NCT02555709|Experimental|VTP-43742 Dose 8|psoriatic patients
11321687|NCT02555709|Experimental|VTP-43742 Dose 9|psoriatic patients
11321688|NCT02555709|Experimental|VTP-43742 Dose 10|psoriatic patients
11321689|NCT02555709|Experimental|VTP-43742 Dose 11|psoriatic patients
11321690|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
11321691|NCT02555683|Experimental|QAW039 150 mg|QAW039 150 mg once daily
11321692|NCT02555683|Experimental|QAW039 450 mg|QAW039 450 mg once daily
11321693|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
11321694|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
11321695|NCT02555657|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations.
11321696|NCT02555657|Active Comparator|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
11321697|NCT02555644|Experimental|Prexasertib + Cisplatin + Radiation Therapy (Part A)|"Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.
~Cisplatin administered IV every 7 days over an approximately 49-day treatment period.
~Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.
~Participants may remain on treatment until completion of the treatment period."
11321747|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
11321814|NCT02554877|Experimental|PF-06291874, 60 mg|
11321698|NCT02555644|Experimental|Prexasertib + Cetuximab + Radiation Therapy (Part B)|"Prexasertib administered IV every 14 days over an approximately 56-day treatment period.
~Cetuximab administered IV every 7 days over an approximately 56-day treatment period.
~Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).
~Participants may remain on treatment until completion of the treatment period."
11321699|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
11321700|NCT02555618|Experimental|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.
11321701|NCT02555618|Active Comparator|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
11321702|NCT02555566|Experimental|Kidney transplant recipients|"blood sampling is done for determination of EPHX Lys55Arg and other polymorphisms status in Kidney transplant recipients.
~flow-mediated distal stimulation of the forearm radial artery by cutaneous heating is assessed for evaluation of EEts level in Kidney transplant recipients."
11321703|NCT02555553|No Intervention|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
11321704|NCT02555553|Experimental|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
11321705|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321706|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321707|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321708|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321709|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321710|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321711|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321712|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321713|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321714|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321715|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321716|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321717|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321718|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321815|NCT02554877|Experimental|PF-06291874, 100 mg|
11321720|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
11321721|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment >4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
11321722|NCT02555501|Experimental|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser
~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
11321723|NCT02555501|Active Comparator|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
11321724|NCT02555488|Experimental|2|in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals.
11321725|NCT02555488|Experimental|1|In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done
11321726|NCT02555475|No Intervention|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
11321727|NCT02555475|Experimental|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
11321728|NCT02555462|Experimental|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
11321729|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
11321730|NCT02555410||Brain Sentinel Seizure Detection and Warning System|To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
11321731|NCT02555397|Experimental|Single|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
11321732|NCT02555384|Active Comparator|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
11321733|NCT02555384|Placebo Comparator|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
11321734|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
11321735|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
11321736|NCT02555358|Experimental|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
11321737|NCT02555358|Active Comparator|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
11321738|NCT02555358|Active Comparator|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
11321739|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
11321740|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
11321741|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
11321742|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
11321743|NCT02555332||Women underwent screening for thyroid function|All these women underwent screening for thyroid function (TSH,FT4,TPOAb) at the first antenatal visit and the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The correlation between the combination of TSH level and TPOAb status and the risk of Gestational Diabetes Mellitus was analyzed.
11321744|NCT02555319|Experimental|Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
11321745|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
11321746|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
11322776|NCT02548962|Experimental|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
11321749|NCT02555293|Experimental|film-coated Rifaximin (550 mg)|(550 mg) tablet twice daily for at least 14 days but up to 28 days dependent on the need for a PVE and the period between PVE (portal vein embolization) or randomization and surgery. Preoperative Rifaximin treatment in case of a PVE will start the day after PVE and will last for 14-21 days. In case patients are not pre-treated with a PVE they will receive Rifaximin for 7-10 days prior to surgery. Regardless of PVE, patients will receive additional Rifaximin treatment the first 7 days postoperatively.
11321750|NCT02555293|No Intervention|standard therapy|Patients directed to the control group will not receive Rifaximin.
11321751|NCT02555280|Experimental|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
11321752|NCT02555280|Active Comparator|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
11321753|NCT02555267||Elderly patients with DLBCL|Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy
11321754|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
11321755|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
11321756|NCT02555241|Experimental|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
11321757|NCT02555241|Experimental|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
11321758|NCT02555241|Experimental|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
11321759|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
11321760|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
11321761|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
11321762|NCT02555189|Experimental|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11321763|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11321764|NCT02555176|Experimental|Low Carbohydrate Diet|Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
11321765|NCT02555163|Experimental|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
11321766|NCT02555163|Active Comparator|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
11321767|NCT02555150|Active Comparator|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
11321768|NCT02555150|Active Comparator|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
11321769|NCT02555150|Placebo Comparator|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
11321770|NCT02555137||outcome cohort study|'prediction score' and 'rule-out criteria'
11321771|NCT02555124|Experimental|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
11321772|NCT02555124|Experimental|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
11321773|NCT02555124|Experimental|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
11321774|NCT02555111|Experimental|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
11321775|NCT02555111|No Intervention|untreated|the patient won't receive any treatment during his study participation.
11321776|NCT02555098|Experimental|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
11321777|NCT02555098|Active Comparator|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
11321778|NCT02555085|Experimental|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321779|NCT02555085|Experimental|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321780|NCT02555085|Experimental|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321781|NCT02555085|Experimental|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321782|NCT02555085|Experimental|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321783|NCT02555085|Experimental|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321784|NCT02555085|Experimental|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
11321785|NCT02555085|Experimental|SC Dose|Single SC dose or matching placebo
11321786|NCT02555072|Other|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
11321787|NCT02555059||BAYQ3939|Pediatrics patients treated with Ciproxan injection in daily clinical practice.
11321788|NCT02555046|No Intervention|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
11321789|NCT02555046|Experimental|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
11321790|NCT02555033|Experimental|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
11321791|NCT02555033|Experimental|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
11321792|NCT02555033|Experimental|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
11321793|NCT02555020|Experimental|Allocated to MN NPO group,|"Patients was administered in hospital
~Randomization
~Patient was allocated to MN group
~Patients were NPO from mid night (MN) to Surgery"
11321794|NCT02555020|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Placebo group
~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
11321795|NCT02555020|Active Comparator|Allocated to Carbohydrated group|"Patients was administered in hospital
~Randomization
~Patient was allocated to Carbohydrated group
~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
11321796|NCT02555007|Experimental|Oral Vinorelbine|
11321797|NCT02554994|Active Comparator|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.
~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
11321798|NCT02554994|Active Comparator|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
11321799|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
11321800|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
11321801|NCT02554955|Experimental|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram [mg/kg] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily [BID] within first week and 1 grams per day [g/day] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
11321802|NCT02554942|Experimental|Epoetin beta|Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram [IU/kg]) for 16 weeks.
11321803|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
11321804|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
11321805|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
11321806|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
11321807|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
11321808|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
11321809|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
11321810|NCT02554890|Experimental|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
11321811|NCT02554890|Active Comparator|Enalapril|"Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.
~Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
11321812|NCT02554877|Placebo Comparator|Placebo|
11321813|NCT02554877|Experimental|PF-06291874, 30 mg|
11321816|NCT02554864|Active Comparator|Adductor Canal Block- Injection -Site A|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site A - after the sartorius muscle crosses over the femoral artery
11321817|NCT02554864|Active Comparator|Adductor Canal Block - Injection -Site B|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site B - before the sartorius muscle crosses over the femoral artery
11321818|NCT02554864|Active Comparator|Adductor Canal Block -Injection -Site C|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site C - as the sartorius muscle crosses over the femoral artery
11321819|NCT02554851|Placebo Comparator|placebo|This group will receive the standard medication and the placebo drug
11321820|NCT02554851|Experimental|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
11321821|NCT02554838|Active Comparator|Rehabilitation|"Rehabilitation :
~Physical activity
~Home assessment and modification"
11321822|NCT02554838|Experimental|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :
~Physical activity
~Home assessment and modification
~Cognitive behavioral therapy"
11321823|NCT02554825|Experimental|Healthy Futures|
11321824|NCT02554825|Other|Control|
11321825|NCT02554812|Experimental|Cohort A1|NSCLC patients treated with avelumab + utomilumab (Dose level 1)
11321826|NCT02554812|Experimental|Cohort A2|NSCLC patients treated with avelumab + utomilumab (Dose level 2)
11321827|NCT02554812|Experimental|Cohort A3|NSCLC patients treated with avelumab + utomilumab (Dose level 3)
11321828|NCT02554812|Experimental|Cohort A4|Melanoma patients treated with avelumab +utomilumab
11321829|NCT02554812|Experimental|Cohort A5|SCCHN patients treated with avelumab + utomilumab
11321830|NCT02554812|Experimental|Cohort A6|TNBC patients treated with avelumab + utomilumab
11321831|NCT02554812|Experimental|Cohort A7|SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
11321832|NCT02554812|Experimental|Cohort A8|NSCLC first-line Stage IV treated with avelumab +PF-05082566
11321833|NCT02554812|Experimental|Combination B Dose Escalation|PF-04518600 + avelumab in selected tumor types
11321834|NCT02554812|Experimental|Combination B Expansion Cohorts|PF-04518600 + avelumab in selected tumor types
11321835|NCT02554812|Experimental|Combination C Dose escalation cohorts|PD 0360324 + avelumab in selected tumor types
11321836|NCT02554812|Experimental|Combination C Dose expansion cohorts|PD 0360324 + aveluamb in selected tumor types
11321837|NCT02554812|Experimental|Combination D Dose escalation cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
11321838|NCT02554812|Experimental|Combination D Dose expansion cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
11321839|NCT02554812|Experimental|Cohort A9|NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
11321840|NCT02554812|Experimental|Cohort A10|NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
11321841|NCT02554812|Experimental|Cohort F1|CMP-001 +avelumab in SCCHN
11321842|NCT02554812|Experimental|Cohort F2|CMP-001+avelumab+utomilumab in SCCHN
11321843|NCT02554812|Experimental|Cohort F3|CMP-001 +avelumab+PF-04518600 in SCCHN
11321844|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
11321845|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
11321846|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
11321847|NCT02554786|Experimental|QMF149 150/160 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.
11321848|NCT02554786|Experimental|QMF149 150/320 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.
11321849|NCT02554786|Active Comparator|MF 400 µg|Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening
11321850|NCT02554786|Active Comparator|Salmeterol /fluticasone 50/500 μg|Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.
11321851|NCT02554786|Active Comparator|MF 800 μg|MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.
11321852|NCT02554773|Experimental|Fitusiran|Patients will be administered subcutaneous (SC) fitusiran once every month for the duration of the study
11321853|NCT02554760|Experimental|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
11321854|NCT02554747|Experimental|Navigated laser|Aflibercept, Navilas®
11321855|NCT02554747|Active Comparator|Conventional laser|Aflibercept, Pascal
11321856|NCT02554734|Experimental|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
11321857|NCT02554734|Experimental|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
11321858|NCT02554734|Active Comparator|Stalevo|Levodopa, carbidopa, entacapone
11321859|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
11321891|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
11321860|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
11321861|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
11321862|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
11321863|NCT02554695|Placebo Comparator|placebo|single subcutaneous injection of placebo (normal saline)
11321864|NCT02554695|Active Comparator|Denosumab|single subcutaneous injection of denosumab 60 mg
11321865|NCT02554695|No Intervention|young normal premenopausal women|no intervention
11321866|NCT02554682|Other|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
11321867|NCT02554682|Other|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
11321868|NCT02554682|No Intervention|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
11321869|NCT02554682|Other|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
11321870|NCT02554682|No Intervention|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
11321871|NCT02554669|No Intervention|Control|No physical activity
11321872|NCT02554669|Experimental|Postabsorptive physical activity|Physical activity performed before breakfast
11321873|NCT02554669|Experimental|Postprandial physical activity|Physical activity performed in the postprandial period after breakfast
11321874|NCT02554643|Experimental|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks
~+ Soccer training, 3 times a week, during 12 weeks"
11321875|NCT02554643|Experimental|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks
~+ Running training, 3 times a week, during 12 weeks"
11321876|NCT02554643|Active Comparator|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
11321877|NCT02554630||Preterm Neonate|Neonates of gestational age 24-37 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
11321878|NCT02554630||Term Neonates|Neonates of gestational age 37-42 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
11321879|NCT02554630||Healthy Adult Control|Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
11321880|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
11321881|NCT02554578|Experimental|Pharmaceutical care programme supported by mHealth|
11321882|NCT02554578|No Intervention|Routine healthcare by the transplant team|
11321883|NCT02554565|Other|Tumor biopsies and blood sampling|
11321884|NCT02554552|Experimental|YY1201 2ml|YY1201 2ml
11321885|NCT02554552|Experimental|YY1201 3ml|YY1201 3ml
11321886|NCT02554552|Placebo Comparator|Placebo 2ml|Phosphate buffered saline 2ml
11321887|NCT02554552|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
11321888|NCT02554539|Experimental|Obese|Women, aged 21-45 with BMI >30
11321889|NCT02554539|Experimental|Normal weight|Women, aged 21-45 with BMI < 25
11321890|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
11321892|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
11321893|NCT02554500|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11321894|NCT02554500|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11321895|NCT02554500|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11321896|NCT02554500|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11321897|NCT02554500|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11321898|NCT02554487|Experimental|sSDB ASV+|sSDB ASV+: Patients with an AHI > 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
11321899|NCT02554487|No Intervention|sSDB ASV-|sSDB ASV-: Patients with an AHI > 20 no ASV treatment.
11321900|NCT02554487|No Intervention|no SDB|no SDB: Stroke patients without SDB (AHI < 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
11321901|NCT02554474|Active Comparator|Immediate Intervention Group|Education, Fitbit/FitViz, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered PT, and an orientation to the Fitbit and FitViz app. Participants will use the Fitbit/FitViz. The PT will review the progress with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls.
11321902|NCT02554474|Placebo Comparator|Delayed Intervention Group|Same intervention with a 2 month delay: The full intervention will be initiated in Month 3 and 4 with a brief education session, use of a Fitbit paired with the FitViz app, and counseling by a PT. In Month 5-6, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
11321903|NCT02554461||female players|national team players
11321904|NCT02554461||male players|national team players
11321905|NCT02554448|Experimental|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
11321906|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
11321907|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
11321908|NCT02554422|Experimental|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
11321909|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
11321910|NCT02554396|Experimental|PRX-100|PRX-100 ophthalmic solution
11321911|NCT02554396|Placebo Comparator|Placebo|saline solution
11321912|NCT02554383|Active Comparator|Treatment A|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
11321913|NCT02554383|Placebo Comparator|Treatment B|Placebo made to match the study antibiotic will be taken bid orally for 10 days
11321914|NCT02554370|Experimental|Psychoeducational programme|Psychoeducational programme
11321915|NCT02554370|No Intervention|Usual care|No psychoeducational programme
11321916|NCT02554357|Experimental|Exparel block in arthroscopic surgery|Evaluation of Exparel block in arthroscopic shoulder surgery.
11321917|NCT02554357|Experimental|Bupivacaine block in shoulder surgery|Evaluation of Bupivacaine block in shoulder surgery.
11321918|NCT02554344|Experimental|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
11321919|NCT02554331|Experimental|Patients RBD|Patients RBD subject to FP-CIT single-photon emission computed tomography and Neuropsychological evaluation and Gait recording with sensors
11321920|NCT02554331|Other|controls healthy volunteers|controls healthy volunteers subject to Neuropsychological evaluation and Gait recording with sensors
11321921|NCT02554318|Experimental|Intervention|"TB standard therapy with fixed dose combination :
~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,
~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets
~and 166.5 grams cooked fermented soybean (tempeh) daily for two months"
11321922|NCT02554318|Active Comparator|Control|"TB standard therapy with fixed dose combination :
~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,
~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets"
11321923|NCT02554305|Active Comparator|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
11321924|NCT02554305|Active Comparator|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
11321925|NCT02554305|No Intervention|Peripheral vascular procedure|No oxygenation machine will be used in this group
11321926|NCT02554305|No Intervention|percutaneous coronary intervention|No oxygenation machine will be used in this group
11321927|NCT02554279|Experimental|menotropin|menotropins for injection
11321928|NCT02554279|Active Comparator|recombinant FSH|
11321929|NCT02554253|Active Comparator|ketamine|Ketamine induction
11321930|NCT02554253|Active Comparator|Propofol|Propofol induction
11321936|NCT02554201|Experimental|Electrical pudendal nerve stimulation|Electrical pudendal nerve stimulation At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of four weeks
11321937|NCT02554201|Active Comparator|Transvaginal electrical stimulation|At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 30 min three times a week for a total of four weeks.
11321938|NCT02554188|Placebo Comparator|Control|Participants will receive Seasonal influenza (flu) vaccine.
11321939|NCT02554188|Experimental|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
11321940|NCT02554175|Experimental|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
11321941|NCT02554162|Active Comparator|Extruded wholegrain rye flakes|Rye products with varying structures
11321942|NCT02554162|Active Comparator|Extruded wholegrain rye puffs|Rye products with varying structures
11321943|NCT02554162|Active Comparator|Fresh wholegrain rye bread|Rye products with varying structures
11321944|NCT02554162|Active Comparator|Wholegrain rye beverage|Rye products with varying structures
11321945|NCT02554162|Active Comparator|Fresh wheat bread|Rye products with varying structures
11321946|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
11321947|NCT02554136|Experimental|Sequence 1|HGP0918 -> HGP0816 -> HGP0918 + HGP0816
11321948|NCT02554136|Experimental|Sequence 2|HGP0816 -> HGP0918 + HGP0816 -> HGP0918
11321949|NCT02554136|Experimental|Sequence 3|HGP0918 + HGP0816 -> HGP0918 -> HGP0816
11321950|NCT02554136|Experimental|Sequence 4|HGP0918 -> HGP0918 + HGP0816 -> HGP0816
11321951|NCT02554136|Experimental|Sequence 5|HGP0816 -> HGP0918 -> HGP0918 + HGP0816
11321952|NCT02554136|Experimental|Sequence 6|HGP0918 + HGP0816 -> HGP0816 -> HGP0918
11321953|NCT02554123|Experimental|Vitamin E ointment|Vitamin E ointment application. Every 12 hours during 7 days.
11321954|NCT02554123|Placebo Comparator|Vaseline ointment|Vaseline ointment application. Every 12 hours during 7 days.
11321955|NCT02554110|Experimental|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
11321956|NCT02554110|Sham Comparator|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
11321957|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
11321958|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
11321959|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
11321960|NCT02554084|Experimental|Dry Eye Disease|Optical Coherence Tomography
11321961|NCT02554084|Active Comparator|Normals|Optical Coherence Tomography
11321962|NCT02554071|Experimental|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
11321963|NCT02554058|Experimental|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
11321964|NCT02554045|Active Comparator|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
11321965|NCT02554045|Placebo Comparator|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
11321966|NCT02554032|Active Comparator|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
11321967|NCT02554032|Active Comparator|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
11321968|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
11321969|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
11321970|NCT02554006|Other|good clinical practice|all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
11321971|NCT02554006|Experimental|bundle group|patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
11321972|NCT02553993|Experimental|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
11321973|NCT02553993|Experimental|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.
~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
11321974|NCT02553993|Placebo Comparator|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
11321975|NCT02553980|Experimental|Physical activity promotion I|"Participants in this group attended the VT3 program (with Automatic HR detection)"
11321976|NCT02553980|Experimental|Physical activity promotion II|"Participants in this group attended the VT2 program (self PA report)"
11321977|NCT02553980|Placebo Comparator|Control|Participants in this group did not receive any VT treatment, and live as usual.
11321978|NCT02553967|Experimental|Immediate breast reconstruction|"Total mastectomy + immediate reconstructive surgery
~6 months after surgery : Functional MRI and questionnaires"
11321979|NCT02553967|Experimental|Secondary breast reconstruction|"Within 2 months before surgery : Functional MRI
~Reconstructive surgery
~6 months after surgery : Functional MRI and questionnaires"
11321980|NCT02553954|Experimental|Collection of healthy skin tissue|Collection of healthy skin tissue
11321981|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11321982|NCT02553928|Experimental|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
11321983|NCT02553928|Experimental|Memantine (twice daily)|Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
11321984|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
11321985|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
11321986|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
11321987|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
11321988|NCT02553902|Active Comparator|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.
~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
11321989|NCT02553902|Active Comparator|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
11321990|NCT02553889|Experimental|PK Cohort|A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC).
11321991|NCT02553889|Placebo Comparator|Cohort A|"Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used.
~For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.
~Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
11321992|NCT02553889|Placebo Comparator|Cohort B|"Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used.
~For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.
~Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
11321993|NCT02553876||Observational|All patients referred with pain in the hand and/or upper limb will be evaluated. Patients will first be assessed for suitability for neurostimulation implantation and then included in the study. Patients wiil fill in questionnaires (pain scores, Quality of Life and satisfaction) at baseline and post-operatively at regular intervals (as per standard of care in the Netherlands.)
11321994|NCT02553863|Experimental|Intervention group|Acupuncture for 30min [twice weekly for 8 weeks]
11321995|NCT02553863|Other|Control group|Standard care
11321996|NCT02553850||Ibandronate|Patients receiving ibandronate will be evaluated for bone turnover markers for 12 months. Ibandronate is not an investigational medicinal product (IMP) in this study.
11321997|NCT02553837|Experimental|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
11321998|NCT02553824|Experimental|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
11321999|NCT02553824|Placebo Comparator|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
11322000|NCT02553811|Experimental|intervention|accuracy diagnostic in carpal tunnel syndrome = evaluation and comparison ultrasonography X electromyography
11322001|NCT02553798|Experimental|Glycopyrronium|Glycopyrronium Topical Wipes
11322002|NCT02553785|Experimental|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
11322003|NCT02553772|Experimental|OM3 Tear|Carboxymethylcellulose based eye drop [Omega-3 (OM3) Tear] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
11322004|NCT02553772|Active Comparator|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
11322005|NCT02553759|Experimental|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
11322038|NCT02553551|Placebo Comparator|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.
~After discharge, no additional capsule was given."
11322006|NCT02553759|Active Comparator|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
11322007|NCT02553746|Experimental|Ultrasound|
11322008|NCT02553746|Active Comparator|Landmarks|
11322009|NCT02553733|Active Comparator|Beetroot juice (Beet-It Organic Shot)|Subjects will consume 70 ml of beetroot juice (Beet-It Organic Shot) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
11322010|NCT02553733|Placebo Comparator|Beetroot juice placebo (Beet-It Organic Placebo)|Subjects will consume 70 ml of beetroot juice placebo (Beet-It Organic Placebo) twice per day (morning, afternoon) for 5 to 7 days to assess the short term effects of this nitrate supplement on graded treadmill walking responses (day 4) and vasodilator/vasoconstrictor responses in the coronary and lower leg circulations (day 5 or 6 or 7). On both study visits, subjects will consume their morning dose 1 hour 45 min before experiments begin.
11322011|NCT02553720|Experimental|Aquatic Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
11322012|NCT02553720|Other|Control Group|Conventional management without aquatic exercise
11322013|NCT02553707|Experimental|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
11322014|NCT02553694|Experimental|Enhanced education and Enhanced follow up|Subjects will watch a short video and will be contacted by an MD by phone
11322015|NCT02553694|Active Comparator|Usual education and Usual follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and will be contacted by a sleep center staff member by phone
11322016|NCT02553694|Experimental|Enhanced education and Usual follow up|Subjects will watch a short video immediately prior to the initiation of the in-laboratory polysomnogram and will be contacted by sleep center non-MD staff member by phone
11322017|NCT02553694|Experimental|Usual education with Enhanced follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and contacted by an MD by phone
11322018|NCT02553681|Experimental|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
11322019|NCT02553681|Active Comparator|untreated|untreated RGP contact lenses made from roflufocon D
11322020|NCT02553668|Experimental|Hyperoxia|Participants receive 100% oxygen
11322021|NCT02553655|Active Comparator|4x 5min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 5 minutes following by 5 minutes of rest. This will be repeated for 4 times.
11322022|NCT02553655|Active Comparator|3x 10min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
11322023|NCT02553655|Sham Comparator|3x 10min Sham Preconditioning|Either the right or left leg of the participant(s) will be squeezed without causing ischemia for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
11322024|NCT02553642|Experimental|melanoma and bladder cancer patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks OR nivolumab at dose of 480mg every 4 weeks for up to 2 years All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
11322025|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
11322026|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
11322027|NCT02553616|Experimental|Behavioral intervention|Intervention to promote healthy behaviors.
11322028|NCT02553603|Placebo Comparator|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
11322029|NCT02553603|Placebo Comparator|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
11322030|NCT02553603|Experimental|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
11322031|NCT02553603|Experimental|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
11322032|NCT02553577||Conventional cigarettes -only|Women who are pregnant and use conventional tobacco products -only
11322033|NCT02553577||Electronic Cigarette (ecig) (ENDS) -ONLY|Women who are pregnant and use electronic cigarettes (ecigs) -only
11322034|NCT02553577||Conventional + ecig use (DUAL)|Women who are pregnant and use conventional + ecigs (dual)
11322035|NCT02553564|Experimental|Intervention group|"Checklist driven clinical encounter after hospital discharge
~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.
~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
11322036|NCT02553564|No Intervention|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.
~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
11322037|NCT02553551|Experimental|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.
~After discharge, no additional vitamin C pill was given."
11322039|NCT02553538|Experimental|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
11322040|NCT02553538|No Intervention|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
11322041|NCT02553525|Experimental|Therapeutic Stimulation Patterns|This group will receive temporal patterns of stimulation that are designed to suppress oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to alleviate motor symptoms.
11322042|NCT02553525|Experimental|Symptogenic Stimulation Patterns|This group will receive symptogenic patterns of stimulation that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to exacerbate motor symptoms.
11322043|NCT02553499|Experimental|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to ~3 months).
11322044|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to ~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
11322045|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
11322046|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
11322047|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
11322048|NCT02553460|Experimental|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.
~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
11322049|NCT02553447|Experimental|Arm I (high-dose cholecalciferol)|Patients receive high-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
11322050|NCT02553447|Experimental|Arm II (low-dose cholecalciferol)|Patients receive low-dose cholecalciferol PO daily for 3 years in the absence of disease progression or unacceptable toxicity.
11322051|NCT02553447|No Intervention|Arm III (control)|Patients receive no intervention.
11322052|NCT02553434|Experimental|Pigtail catheter (case)|Inserting 14 French pigtail catheter
11322053|NCT02553434|No Intervention|Chest tube|inserting 32-36 French chest tube
11322054|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
11322055|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
11322056|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
11322057|NCT02553408|Other|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
11322058|NCT02553382|Experimental|Dietary, Herbal|
11322059|NCT02553382|Placebo Comparator|Positive Control|
11322060|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
11322061|NCT02553356|Experimental|Fasted|PT2385 taken after fasting.
11322062|NCT02553356|Experimental|Non-Fasting|PT2385 taken after eating a high calorie meal.
11322063|NCT02553343|Experimental|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
11322064|NCT02553343|Experimental|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
11322065|NCT02553343|Active Comparator|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
11322066|NCT02553343|Active Comparator|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
11322067|NCT02553330|Experimental|Ruxolitinib Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;
~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
11322068|NCT02553330|Placebo Comparator|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
11322069|NCT02553317|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
11322070|NCT02553317|Placebo Comparator|Placebo|Placebo once daily
11322071|NCT02553291|Experimental|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
11322072|NCT02553291|Active Comparator|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
11322115|NCT02553148||South Africa|One of the 23 countries studied
11322116|NCT02553148||Tajikistan|One of the 23 countries studied
11322073|NCT02553278|Experimental|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:
~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
11322074|NCT02553278|Experimental|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:
~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
11322075|NCT02553265|Active Comparator|Placebo, Low Dose Carbidopa, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
11322076|NCT02553265|Active Comparator|High Dose Carbidopa, Placebo, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
11322077|NCT02553265|Active Comparator|Low Dose Carbidopa, High Dose Carbidopa, Placebo|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
11322078|NCT02553252|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
11322079|NCT02553252|No Intervention|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
11322080|NCT02553239|Experimental|Cryoablation|Cryoablation with the CoolLoop® catheter
11322081|NCT02553226|Active Comparator|Continued group|Recieve routine treatment with oxytocin according to the danish national guidelines.
11322082|NCT02553226|Placebo Comparator|discontinued group (placebo)|The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
11322083|NCT02553213|Experimental|LSG group|Laparoscopic sleeve gastrectomy
11322084|NCT02553213|Experimental|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
11322085|NCT02553213|Other|Control group|Caloric restriction
11322086|NCT02553200|Active Comparator|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
11322087|NCT02553200|Experimental|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
11322088|NCT02553200|Sham Comparator|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
11322089|NCT02553187|Experimental|Treatment group|Kanglaite Injection plus standard therapy.
11322090|NCT02553187|No Intervention|Control group|Blank control and standard therapy.
11322091|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
11322092|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
11322093|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
11322094|NCT02553161|Experimental|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food & Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
11322095|NCT02553161|Placebo Comparator|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
11322096|NCT02553161|No Intervention|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
11322097|NCT02553148||Argentina|One of the 23 countries studied
11322098|NCT02553148||Armenia|One of the 23 countries studied
11322099|NCT02553148||Australia|One of the 23 countries studied
11322100|NCT02553148||Brazil|One of the 23 countries studied
11322101|NCT02553148||China|One of the 23 countries studied
11322102|NCT02553148||Egypt|One of the 23 countries studied
11322103|NCT02553148||Ethiopia|One of the 23 countries studied
11322104|NCT02553148||Germany|One of the 23 countries studied
11322105|NCT02553148||India|One of the 23 countries studied
11322106|NCT02553148||Indonesia|One of the 23 countries studied
11322107|NCT02553148||Jordan|One of the 23 countries studied
11322108|NCT02553148||Kenya|One of the 23 countries studied
11322109|NCT02553148||Kyrgyzstan|One of the 23 countries studied
11322110|NCT02553148||Malaysia|One of the 23 countries studied
11322111|NCT02553148||Malawi|One of the 23 countries studied
11322112|NCT02553148||Mexico|One of the 23 countries studied
11322113|NCT02553148||Russia|One of the 23 countries studied
11322114|NCT02553148||Serbia|One of the 23 countries studied
11322120|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
11322121|NCT02553122|Other|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
11322122|NCT02553122|Active Comparator|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
11322123|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
11322124|NCT02553096|Experimental|ACCESS|ACCESS is used when participants experience more COPD symptoms.
11322125|NCT02553096|No Intervention|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
11322126|NCT02553083|Active Comparator|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
11322127|NCT02553083|Active Comparator|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
11322128|NCT02553083|Active Comparator|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
11322129|NCT02553070||Pharmacy Students|Participants will be asked to indicate their perception of poisoning severity by answering a short survey.
11322130|NCT02553057|Active Comparator|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
11322131|NCT02553057|Active Comparator|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
11322132|NCT02553057|Active Comparator|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
11322133|NCT02553044|Experimental|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
11322134|NCT02553044|Experimental|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
11322135|NCT02553044|Experimental|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
11322136|NCT02553044|No Intervention|Concurrent Control|Control group to receive no intervention.
11322137|NCT02553018|Experimental|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.
~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.
~Frequency: one injection per week Duration: until the end of the study"
11322138|NCT02553018|Active Comparator|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.
~Frequency: one injection per week Duration: until the end of the study"
11322139|NCT02553005|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
11322140|NCT02553005|Experimental|verum acupuncture|Real acupuncture treatment
11322141|NCT02553005|No Intervention|Control|
11322142|NCT02552992|Experimental|Yoga Classes|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
11322143|NCT02552992|Active Comparator|Self-Directed Mind-Body Program|Study Participants will receive: The Back Pain Helpbook, a mind-body self-care program for better living.
11322144|NCT02552966|Experimental|UESAD|Upper Esophageal Sphincter Assist Device
11322145|NCT02552953|Experimental|CYC065 - 4 hour infusion (Part 1 completed)|CYC065 will be administered by 4 -hour infusion every 3 weeks.
11322146|NCT02552953|Experimental|CYC065 - 1 hour infusion (Part 2 - ongoing)|CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks
11322147|NCT02552953|Experimental|CYC065 - Oral (Part 3 - ongoing)|CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks
11322148|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
11322149|NCT02552927|Experimental|CALF|Chest shield with aluminum foil
11322150|NCT02552927|Sham Comparator|SHIELD|Chest shield without aluminum foil
11322151|NCT02552901|Experimental|LFT Dye Detection Monitor|
11322152|NCT02552901|Active Comparator|Serial Blood Draws|
11322153|NCT02552888|Experimental|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
11322154|NCT02552888|Placebo Comparator|Placebos|identical placebos.
11322155|NCT02552875|Active Comparator|Tetanic Stimulation|50 Hz tetanic stimulation for 5 seconds before TOF-twitch stabilization at the one arm
11322156|NCT02552875|Active Comparator|Staircase Stimulation|TOF-twitch stabilisation without 50 Hz tetanic stimulation at the contralateral arm
11322157|NCT02552862|Active Comparator|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).
~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
11322158|NCT02552862|Placebo Comparator|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
11322159|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
11322196|NCT02552641|Experimental|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
11322197|NCT02552628|Experimental|"Stimulation on"|"The deep brain stimulation is on"
11322160|NCT02552836|Experimental|Interpersonal Psychotherapy (IPT)|Patients assigned to IPT will receive 12 sessions of individual therapy of approximately 50 minutes duration. Therapy will be manualized and slightly adapted to meet the needs of patients with Parkinson's Disease. Therapy focuses on one of four interpersonal events that are linked with onset or maintenance of depression (role transition, role disputes, unresolved grief, and interpersonal deficits).
11322161|NCT02552836|Active Comparator|Supportive Psychotherapy (SP)|Patients assigned to SP will receive 12 sessions of individual therapy of approximately 50 minutes duration. SP strives to create a supportive therapeutic relationship by emphasizing non-specific therapeutic interactions and techniques. Therapy will be manualized,
11322162|NCT02552823|Placebo Comparator|White bread 1|Groups 1 and 2, Visit 1 White bread (equal to 50g available carbohydrate) given to fasting participant
11322163|NCT02552823|Experimental|Pea variety 1 with rice|Group 1,Visit 2-5 Pea variety 1 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
11322164|NCT02552823|Experimental|Pea variety 2 with rice|Group 1, Visit 2-5 Pea variety 2 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
11322165|NCT02552823|Experimental|Pea variety 3 with rice|Group 1, Visit 2-5 Pea variety 3 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
11322166|NCT02552823|Experimental|Rice|Group 1, Visit 2-5 Rice (equal to 50g available carbohydrate) given as breakfast to fasting participants
11322167|NCT02552823|Placebo Comparator|White bread 2|Groups 1 and 2, Visit 6 White bread (equal to 50g available carbohydrate) given to fasting participant
11322168|NCT02552823|Experimental|Pea variety 1 with potato|Group 2, Visit 2-5 Pea variety 1 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
11322169|NCT02552823|Experimental|Pea variety 2 with potato|Group 2, Visit 2-5 Pea variety 2 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
11322170|NCT02552823|Experimental|Pea variety 3 with potato|Group 2, Visit 2-5 Pea variety 3 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
11322171|NCT02552823|Experimental|Potato|Group2, Visit 2-5 Potato (equal to 50g available carbohydrate) given as breakfast to fasting participants
11322172|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
11322173|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
11322174|NCT02552797|Experimental|Using Power Up|Participants will use 'Power Up' to help them make shared decisions about their treatment or care
11322175|NCT02552797|No Intervention|Not using Power Up|Participants will continue treatment as usual
11322176|NCT02552784|Experimental|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
11322177|NCT02552771|Active Comparator|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
11322178|NCT02552771|Active Comparator|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
11322179|NCT02552758|Experimental|Omega-3 fatty acid|omega-3 fatty acid
11322180|NCT02552758|Placebo Comparator|placebo|placebo
11322181|NCT02552745||study group|parecoxib sodium was administered postoperatively
11322182|NCT02552745||control group|parecoxib sodium was not administered postoperatively
11322183|NCT02552732|Experimental|NHF with or without Oxygen|NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge
11322184|NCT02552706|Experimental|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
11322185|NCT02552706|Placebo Comparator|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
11322186|NCT02552693|Experimental|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.
~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
11322187|NCT02552693|No Intervention|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
11322188|NCT02552680|Experimental|Exercise + guideline|Participants will participate in eight meetings consisting of exercise and guidelines on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
11322189|NCT02552680|Active Comparator|brochure|Participants will receive a manual-brochure - containing information about general health.
11322190|NCT02552667|Experimental|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
11322191|NCT02552667|Active Comparator|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
11322192|NCT02552654|Experimental|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
11322193|NCT02552654|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
11322194|NCT02552641|Experimental|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
11322195|NCT02552641|Experimental|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
11322198|NCT02552628|Sham Comparator|"Stimulation off"|"The deep brain stimulation is off"
11322199|NCT02552615|Experimental|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
11322200|NCT02552615|Active Comparator|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
11322201|NCT02552615|Experimental|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
11322202|NCT02552602|Active Comparator|Group A|Study participants in this arm will be given Multivitamin A
11322203|NCT02552602|Active Comparator|Group B|Study participants in this arm will be given Multivitamin B
11322204|NCT02552602|Active Comparator|Group C|Study participants in this arm will be given Multivitamin C
11322205|NCT02552589|Experimental|Test group|Amine fluoride toothpaste
11322206|NCT02552589|Placebo Comparator|Control group|Placebo Sodium monofluorophosphate toothpaste
11322207|NCT02552576|Experimental|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
11322208|NCT02552563|No Intervention|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
11322209|NCT02552563|Active Comparator|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
11322210|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
11322211|NCT02552537|Active Comparator|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
11322212|NCT02552537|Sham Comparator|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
11322213|NCT02552524|Experimental|rTMS active then rTMS placebo|"A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo (rTMS active then rTMS placebo).
~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit."
11322214|NCT02552524|Experimental|rTMS placebo then rTMS active|"A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS active at the frequency of 10 Hz (rTMS placebo then rTMS active).
~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit"
11322215|NCT02552511||Exposure|Perinatal factors exposure
11322216|NCT02552498|Experimental|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
11322217|NCT02552498|Experimental|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
11322218|NCT02552498|Experimental|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
11322219|NCT02552459|Active Comparator|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
11322220|NCT02552459|Experimental|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
11322221|NCT02552459|Experimental|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
11322222|NCT02552459|Experimental|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
11322223|NCT02552446||All patients|All ICU patients mechanically ventilated staying more than 72 hours were included and indirect calorimetry was performed and compared to predictive energy expenditure formulas using different body weights.
11322224|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
11322225|NCT02552407||Manual Aspiration Thrombectomy with PCI|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to Manual Aspiration Thrombectomy followed by percutaneous coronary intervention (PCI).
11322226|NCT02552407||PCI Alone|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to percutaneous coronary intervention (PCI) alone without manual aspiration thrombectomy.
11322227|NCT02552394|Experimental|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
11322315|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
11322316|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
11323027|NCT02547311|No Intervention|Standard Clinical Care - Control|Standard Clinical Care - Control
11322228|NCT02552381||Group I|"Patients without LMWH treatment.
~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.
~The following assays will be performed for these patients :
~Fibrin Structure measured at baseline and every month using prototype assays
~Other markers activity : sFVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
11322229|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.
~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.
~The following assays will be performed for these patients :
~Fibrin Structure measured at baseline and every month using prototype assays,
~Anti-FXa activity measured at baseline and every month,
~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
11322230|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.
~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.
~The following assays will be performed for these patients :
~Fibrin Structure measured at baseline and every month using prototype assays,
~Anti-FXa activity measured at baseline and every month,
~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
11322231|NCT02552368|Experimental|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
11322232|NCT02552355|Experimental|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
11322233|NCT02552355|Placebo Comparator|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
11322234|NCT02552355|Active Comparator|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
11322235|NCT02552355|Active Comparator|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
11322236|NCT02552342|Active Comparator|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
11322237|NCT02552342|Placebo Comparator|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
11322238|NCT02552329|No Intervention|Control group|Since no medication or other treatments are currently approved by Food and Drug Administration (FDA) for treatment of MCI, participants in the usual care group will not receive any form of treatment. They will receive an educational material about cognitive impairment. They will also be asked to maintain their daily routine.
11322239|NCT02552329|Experimental|Tai Chi exercise group|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down.
11322240|NCT02552316|Other|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
11322241|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
11322242|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
11322243|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
11322244|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
11322245|NCT02552290|Active Comparator|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
11322317|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <42 nmol/L.
11322318|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <55 nmol/L.
11322319|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values <75 nmol/L.
11322246|NCT02552290|Active Comparator|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.
~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
11322247|NCT02552290|Other|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
11322248|NCT02552277|Experimental|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
11322249|NCT02552277|Experimental|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
11322250|NCT02552277|Placebo Comparator|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
11322251|NCT02552264|Active Comparator|Immediate intervention|Acceptance and Commitment Therapy
11322252|NCT02552264|Placebo Comparator|Waitlist control|Acceptance and Commitment Therapy
11322253|NCT02552251|Experimental|A: hydrocortisone|hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
11322254|NCT02552251|Experimental|B :dexamethasone (DECTANCYL)|dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
11322255|NCT02552251|Experimental|C : prednisone (CORTANCYL)|prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
11322256|NCT02552238|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
11322257|NCT02552225|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
11322258|NCT02552225|Placebo Comparator|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
11322259|NCT02552212|Experimental|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
11322260|NCT02552212|Placebo Comparator|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
11322261|NCT02552199||with hyperhidrosis|Patients with primary hyperhidrosis
11322262|NCT02552199||healthy|Healthy adult patients
11322263|NCT02552186|Active Comparator|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
11322264|NCT02552186|No Intervention|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
11322265|NCT02552173||stem anteversion|intraoperative surgeon's estimation and postopertive CT sacn were taken to measure stem anteversion
11322266|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
11322267|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
11322268|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
11322269|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
11322270|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
11322271|NCT02552134|Experimental|frequent participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence.
11322272|NCT02552134|Experimental|medium participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
11322273|NCT02552134|Experimental|low participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
11322274|NCT02552134|Active Comparator|recommendation to be active|"During the stay in the health care resort participants are introduced to be active in the future. They will receive a brochure Physical Activity: Health for all."
11322275|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
11322276|NCT02552108|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
11322277|NCT02552108|No Intervention|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
11322278|NCT02552095|Other|Triathlon PKR|Patient who receives the Triathlon.
11322279|NCT02552082||Scorpio NRG|
11322280|NCT02552069||Tritanium® cup|
11322281|NCT02552056|Experimental|CAMH training|"Intervention clinics will receive a CAMH integration package comprising of:
~Training PHC workers (midwives, nurses and/or clinical officers) on how to screen and refer for CAMH, based on WHO mhGAP implementation guide.
~Support supervision in the clinics to reinforce training and provide on-job support to PHC staff.
~Provision of job aids and training materials"
11322282|NCT02552056|No Intervention|No CAMH training|Clinics will continue to provide the standard of care.
11322320|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values <50 nmol/L.
11322434|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
11322283|NCT02552043|Experimental|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (>12 years and <13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
11322284|NCT02552043|No Intervention|Control group|The CG carried out their routine patient management
11322285|NCT02552030|Experimental|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
11322286|NCT02552017|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
11322287|NCT02552017|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
11322288|NCT02552004|Experimental|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
11322289|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
11322290|NCT02551978|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
11322291|NCT02551978|No Intervention|Control|Children in the same primary school, aged between 9 and 12 years do receive basic information during the study phase.
11322292|NCT02551965|Experimental|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
11322293|NCT02551952|Experimental|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
11322294|NCT02551952|Experimental|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
11322295|NCT02551952|Active Comparator|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
11322296|NCT02551952|Sham Comparator|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
11322297|NCT02551939|Experimental|fat graft|Autologous Fat Grafting
11322298|NCT02551926|Experimental|mobile text messaging|Patients will receive some SMS in a regular interval.
11322299|NCT02551926|Experimental|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
11322300|NCT02551926|Experimental|brochures|Patients will receive some messages by as a printed media
11322301|NCT02551926|Active Comparator|Control|control group will be included without any intervention
11322302|NCT02551913|Active Comparator|control|The adolescents will not receive any specific information
11322303|NCT02551913|Experimental|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
11322304|NCT02551900|Experimental|Warm water exercise & Cold water exercise|
11322305|NCT02551900|Active Comparator|Warm water exercise & Land cycling exercise|
11322306|NCT02551887|No Intervention|Usual Care|Usual Care Only
11322307|NCT02551887|Active Comparator|Automated Reminder|Reminder
11322308|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
11322309|NCT02551874|Experimental|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
11322310|NCT02551874|Active Comparator|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
11322311|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir|Daclatasvir 60mg tablet and Sofosbuvir 400mg tablet oral dosing once daily for 8 weeks
11322312|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir + Ribavirin|Daclatasvir 60mg tablet + Sofosbuvir 400mg tablet+ Ribavirin 1000-1200mg tablet(weight based dosing) oral dosing split into am and pm once daily for 8 weeks
11322313|NCT02551848|Experimental|Essential tremor treatment|"A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.
~Participants will be treated by BoNT-A injections every 12 weeks over 72 weeks. BoNT-A parameters will be determined solely by biomechanical analysis of tremulous movements in both upper extremity BoNT-A dose will range from 50-300 U per arm"
11322314|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
11322321|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values <50 nmol/L.
11322322|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents >70 years of age.
11322323|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values <25 nmol/L.
11322324|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons > 63 years of age.
11322325|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
11322326|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
11322327|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
11322328|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
11322329|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
11322330|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
11322331|NCT02551796|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
11322332|NCT02551796|Experimental|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
11322333|NCT02551796|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
11322334|NCT02551783|Experimental|Urethroplasty with buccal mucosa graft|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
11322335|NCT02551783|Active Comparator|Ventral Buccal|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
11322336|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
11322337|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
11322338|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
11322339|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
11322340|NCT02551744|Active Comparator|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
11322341|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
11322342|NCT02551731|Experimental|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
11322343|NCT02551718|Experimental|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
11322344|NCT02551705|Experimental|functional Imaging mutation carrier|Premanifest mutation carrier, behavioral and neural emotional memory processing
11322345|NCT02551705|Active Comparator|functional Imaging non-carrier|non-carrier family member, behavioral and neural emotional memory processing
11322346|NCT02551692|Placebo Comparator|NRT|
11322347|NCT02551692|Placebo Comparator|VAR|
11322348|NCT02551692|Placebo Comparator|PLAC|
11322349|NCT02551679|Active Comparator|ACP-01|Injection into lower extremity
11322350|NCT02551679|Placebo Comparator|Placebo|Injection into lower extremity
11322351|NCT02551666|Active Comparator|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
11322352|NCT02551666|Experimental|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
11322353|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
11322354|NCT02551640|Experimental|Group A|"Receive a Samsung smartphone
~Receive the FeatForward app
~Receive a Samsung smartwatch
~Continue to receive medical care as usual"
11322355|NCT02551640|No Intervention|Group B|"Receive a Samsung smartphone
~Receive a Samsung smartwatch
~Continue to receive medical care as usual"
11322356|NCT02551627|Experimental|Test Product|MMN fortified beverage powder [27 gram (g)] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
11322357|NCT02551627|Active Comparator|Control|Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
11322358|NCT02551614|Experimental|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
11322359|NCT02551614|Experimental|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
11322360|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
11322361|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.
~They were followed when possible one year after surgery."
11322362|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
11322363|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
11322364|NCT02551575|Active Comparator|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
11322365|NCT02551575|Experimental|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
11322366|NCT02551575|Experimental|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
11322367|NCT02551562|Placebo Comparator|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
11322368|NCT02551562|Experimental|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
11322369|NCT02551549|Experimental|CD101 IV|multiple ascending dose intravenous infusion
11322370|NCT02551549|Placebo Comparator|Placebo|normal saline
11322371|NCT02551536|Active Comparator|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
11322372|NCT02551536|Experimental|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
11322373|NCT02551523|Experimental|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
11322374|NCT02551523|Active Comparator|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
11322375|NCT02551510|Active Comparator|Suture|Skin incision closure with standard subcuticular technique
11322376|NCT02551510|Active Comparator|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl®
11322377|NCT02551497|Experimental|Other drug|Other drug BID
11322378|NCT02551497|Experimental|placebo|Placebo to match BID
11322379|NCT02551484|Experimental|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
11322380|NCT02551484|Experimental|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
11322381|NCT02551471||French patients|
11322382|NCT02551471||Australians patients|
11322383|NCT02551458|Experimental|Arm A: Systematic surgery|
11322384|NCT02551458|Experimental|Arm B: Surveillance and rescue surgery in cases of resectable|
11322385|NCT02551445|Experimental|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
11322386|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,
~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,
~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
11322387|NCT02551419|Experimental|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
11322388|NCT02551419|Placebo Comparator|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
11322389|NCT02551393|Experimental|Intervention Group|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home Blood pressure monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
11322390|NCT02551393|No Intervention|Control Group|Usual Care of hypertension in primary care clinic
11322391|NCT02551380|Experimental|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
11322392|NCT02551380|Placebo Comparator|control|treatment with one capsule of placebo twice a day during 12 weeks
11322393|NCT02551367|Experimental|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
11322432|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
11322433|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
11322394|NCT02551367|Active Comparator|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
11322395|NCT02551354|Experimental|Patients|"Pain assess by :
~Visual Analogic Scale (VAS).
~Portable video pupillometer"
11322396|NCT02551341|No Intervention|control|normal ventilation
11322397|NCT02551341|Experimental|intervention|higher PEEP ventilation
11322398|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
11322399|NCT02551328||Propofol|Patients with no preconditioning
11322400|NCT02551315||Type 2 diabetics, no fractures|Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
11322401|NCT02551315||Type 2 diabetics, prevalent fractures|Postmenopausal women and men with T2DM, with prevalent fragility fractures
11322402|NCT02551315||Controls, no fractures|Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
11322403|NCT02551315||Controls, prevalent fractures|Age and sex-matched non-diabetic controls
11322404|NCT02551302|Other|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
11322405|NCT02551302|Other|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
11322406|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
11322407|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
11322408|NCT02551276|Experimental|Experimental|Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
11322409|NCT02551276|Placebo Comparator|Control|Placebo and resistance training for 10 weeks
11322410|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
11322411|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
11322412|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with
~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with
~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
11322413|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.
~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
11322414|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
11322415|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
11322416|NCT02551211|Experimental|Patients with resectable non-small cell lung cancer|
11322417|NCT02551198|Active Comparator|HAPREP® (PEG-Asc)|"subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation
~: PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
11322418|NCT02551198|Experimental|SUCLEAR® (OSS)|"subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation
~: OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]"
11322419|NCT02551185|Experimental|ACY-241 in combination with Paclitaxel|
11322420|NCT02551172|Experimental|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
11322421|NCT02551172|Placebo Comparator|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
11322422|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
11322423|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
11322424|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
11322425|NCT02551146|Experimental|A Locator with retention elements|"GC Pilier Locator abutment with retention elements:
~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements."
11322426|NCT02551146|Active Comparator|B Locator without retention elements|"GC Pilier Locator abutment without retention elements:
~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants."
11322427|NCT02551133|Active Comparator|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
11322428|NCT02551133|Active Comparator|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
11322429|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
11322430|NCT02551107|Experimental|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.
~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
11322431|NCT02551107|Active Comparator|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
11322435|NCT02551068|Experimental|60% Oxgyen|While participants are exercising, they will be breathing 60% oxygen through a mask.
11322436|NCT02551068|Placebo Comparator|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
11322437|NCT02551055|Experimental|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
11322438|NCT02551055|Experimental|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
11322439|NCT02551055|Experimental|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
11322440|NCT02551055|Experimental|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
11322441|NCT02551055|Experimental|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
11322442|NCT02551055|Experimental|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
11322443|NCT02551055|Experimental|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
11322444|NCT02551042|Experimental|Active treatment arm|Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion
11322445|NCT02551042|Placebo Comparator|Placebo arm|Placebo will be 0.9 % Sodium chloride solution IV infusion
11322446|NCT02551029|Experimental|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum.
11322447|NCT02551029|Placebo Comparator|Placebo (saline)|Through a naso-duodenal tube, a saline solution will be infused into the duodenum.
11322448|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
11322449|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
11322450|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
11322451|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
11322452|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
11322453|NCT02550990|Active Comparator|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
11322454|NCT02550990|Active Comparator|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
11322455|NCT02550990|Experimental|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.
~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
11322456|NCT02550977|Experimental|Gestodene/EE Patch|
11322457|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
11322458|NCT02550951|Experimental|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
11322932|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
11322459|NCT02550951|Experimental|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
11322460|NCT02550938|Experimental|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
11322461|NCT02550938|Experimental|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
11322462|NCT02550938|Experimental|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
11322463|NCT02550938|Experimental|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
11322464|NCT02550925|Experimental|Acceptance and Commitment Therapy Group|
11322465|NCT02550925|Active Comparator|Usual Care|
11322466|NCT02550912|Active Comparator|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
11322467|NCT02550912|Placebo Comparator|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
11322468|NCT02550899|Active Comparator|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
11322469|NCT02550899|Active Comparator|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
11322470|NCT02550899|Active Comparator|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
11322471|NCT02550886||Patient/Caregiver Dyad|
11322472|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
11322473|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
11322474|NCT02550860|Active Comparator|soybean oil (SO)-based IVFE (Medialipide)|
11322475|NCT02550860|Active Comparator|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
11322476|NCT02550834|Experimental|Experimental : Curling group|
11322477|NCT02550834|No Intervention|Control : Usual care group|
11322478|NCT02550808||Heart failure|
11322479|NCT02550808||Chronic obstructive pulmonary disease|
11322480|NCT02550808||Chronic kidney disease|
11322481|NCT02550808||Malignancy|
11322482|NCT02550808||Controls|
11322483|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
11322484|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
11322485|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
11322486|NCT02550782|Active Comparator|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine
~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
11322487|NCT02550782|Experimental|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine
~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
11322488|NCT02550769|Experimental|TRANSANAL TOTAL MESORECTAL EXCISION|Transanal approach of total mesorectal excision.
11322489|NCT02550769|Active Comparator|Laparoscopic-LAR|Type of surgical intervention as control group: Laparoscopic low anterior resection with total mesorectal excision for rectal cancer
11322490|NCT02550756|Experimental|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
11322491|NCT02550756|Experimental|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
11322492|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose: 200mg/day
11322493|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose: 250mg/day
11322494|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose: 300mg/day
11322495|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose: 150mg/day
11322496|NCT02550730|Experimental|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
11322497|NCT02550730|Active Comparator|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
11322498|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
11322499|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
11322500|NCT02550704|Experimental|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
11322501|NCT02550691|Experimental|Subject carrying 3 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
11322502|NCT02550691|Other|Subject carrying 2 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
11322503|NCT02550691|Other|Subject carrying 3 copies of the SMN2 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
11322504|NCT02550678|Experimental|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
11322505|NCT02550678|Experimental|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
11322506|NCT02550678|Experimental|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
11322507|NCT02550678|Experimental|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
11322508|NCT02550678|Experimental|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
11322509|NCT02550665|Experimental|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
11322510|NCT02550665|Experimental|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
11322511|NCT02550665|Active Comparator|no titration of donepezil|no titration and direct escalation to 23mg donepezil
11322512|NCT02550652|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
11322513|NCT02550652|Placebo Comparator|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
11322514|NCT02550639|Active Comparator|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
11322515|NCT02550639|Experimental|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
11322516|NCT02550639|Active Comparator|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
11322517|NCT02550639|Experimental|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
11322518|NCT02550626||Delirium|occurrence of post-operative delirium
11322519|NCT02550626||No delirium|no presence of post-operative delirium
11322520|NCT02550600|Experimental|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
11322521|NCT02550600|Active Comparator|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.
~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
11322522|NCT02550574|Experimental|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
11322523|NCT02550574|Active Comparator|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
11322524|NCT02550561|Experimental|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
11322525|NCT02550548|Experimental|GIP infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
11322526|NCT02550548|Experimental|GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GLP-1 infused at 4 incremental dosages, (initial dose will be 1.0 ng/kg/min, followed by 2.0, 3.0, and 4.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
11322527|NCT02550548|Experimental|GIP + GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP + GLP-1 infused simultaneously at 4 incremental dosages (doses will be half the amounts described above). These doses will be infused continuously for 30 minutes, followed immediately by the next higher doses. The total time of this procedure is 240 minutes.
11322528|NCT02550548|Experimental|GIP + Ex-9 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages (as described above) with Ex-9 infused at a steady dose of 2.5 mcg/kg/min starting 90 minutes before the GIP infusion and maintained throughout the clamp experiment. The total time of this procedure is 240 minutes.
11322933|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
11322529|NCT02550535|Experimental|Gene-modified WT1 TCR-transduced T cells|A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen. Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
11322530|NCT02550522|Experimental|BCI|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton
11322531|NCT02550509|Experimental|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
11322532|NCT02550496|Experimental|tinea capitis|
11322533|NCT02550483|Active Comparator|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
11322534|NCT02550483|Active Comparator|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
11322535|NCT02550483|Placebo Comparator|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
11322536|NCT02550470|Active Comparator|Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
11322537|NCT02550470|Active Comparator|Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
11322538|NCT02550470|Active Comparator|Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
11322539|NCT02550457|No Intervention|Control group|It will not apply any tape.
11322540|NCT02550457|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
11322541|NCT02550457|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
11322542|NCT02550457|Placebo Comparator|Placebo group|Apply Micropore tape in the erector spine muscles.
11322543|NCT02550444|Placebo Comparator|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
11322544|NCT02550444|Experimental|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
11322545|NCT02550444|Experimental|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
11322546|NCT02550418|Experimental|Budesonide|
11322547|NCT02550405|Experimental|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
11322548|NCT02550405|No Intervention|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
11322549|NCT02550392|Experimental|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) and usual care.
11322550|NCT02550392|No Intervention|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
11322551|NCT02550379|Placebo Comparator|Placebo|The placebo protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point at baseline. A test phase is then administered which is identical to the baseline phase to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
11322552|NCT02550379|Experimental|Intervention|The ER training protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point however this balance point is adjusted by 2 points on the 15 face continuum to train the participant to rate more faces as 'happy'. A test phase, identical to the baseline phase, is then administered to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
11322553|NCT02550366||CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
11322554|NCT02550353|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
11322555|NCT02550353|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
11322556|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
11322557|NCT02550327|Experimental|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.
~The patient will complete a total of 6 cycles of chemotherapy."
11322558|NCT02550314|Experimental|NPC-18,FBG-18|"Intervention drug:
~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue
~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
11322559|NCT02550301||Mean Platelet Volume|4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
11322560|NCT02550288|Active Comparator|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
11322561|NCT02550288|Active Comparator|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
11322562|NCT02550288|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
11322563|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
11322564|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
11322565|NCT02550275|Other|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
11322566|NCT02550275|Other|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
11322567|NCT02550275|Other|controls|unaffected patient with Huntington's disease
11322568|NCT02550262|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11322569|NCT02550262|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11322570|NCT02550262|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11322571|NCT02550262|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
11322572|NCT02550249|Experimental|Nivolumab|Nivolumab 3 mg every 2 weeks
11322573|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of 5.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair, stool and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of nine years also by the child itself.
11322574|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 500 obese children and adolescents that will be assessed and compared to a lean control group (N=500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, liver elastography, spirometry and actigraphy.
11322575|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of 1,000 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
11322576|NCT02550223|Experimental|Oblique|Ultrasound guided radial artery catheterization using oblique view obtained by tilting the US probe 30-45 degrees over the course of the artery
11322577|NCT02550223|Active Comparator|Transverse group|Ultrasound guided radial artery catheterization using transverse view
11322578|NCT02550223|Active Comparator|Longitudinal group|Ultrasound guided radial artery catheterization using longitudinal view
11322579|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
11322580|NCT02550197|Experimental|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
11322581|NCT02550197|Active Comparator|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
11322582|NCT02550184|Experimental|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.
~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
11322583|NCT02550184|Active Comparator|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.
~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
11322584|NCT02550158|Experimental|Educated Group|"Training of patients by the educational program EDU-MICI"
11322585|NCT02550158|Other|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
11322586|NCT02550145|Experimental|Exendin(9-39)|IV infusion of Exendin (9-39).
11322587|NCT02550145|Placebo Comparator|Placebo|IV infusion of normal saline
11322588|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
11322589|NCT02550119|Experimental|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
11322590|NCT02550119|Placebo Comparator|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
11322591|NCT02550106|Experimental|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
11322592|NCT02550093|Active Comparator|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing.
11322593|NCT02550093|Placebo Comparator|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing.
11322594|NCT02550080|Experimental|The prospective genetic screening arm|Prospective HLA-B*1301 screen before administrated treatment included dapsone
11322595|NCT02550080|Active Comparator|The control arm|No HLA-B*1301 screen before administrated treatment included dapsone
11322596|NCT02550067|Active Comparator|Depot medroxyprogesterone acetate (DMPA)|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
11322597|NCT02550067|Active Comparator|Levonorgestrel implant (LNG)|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
11322598|NCT02550067|Active Comparator|Copper T380a IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
11322599|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
11322600|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
11322601|NCT02550041|Other|Cystic fibrosis|
11322602|NCT02550028|Experimental|Oral levetiracetam|Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
11322603|NCT02550028|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance
11322604|NCT02550015|Experimental|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
11322605|NCT02550015|Other|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
11322606|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
11322607|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
11322608|NCT02549989|Experimental|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
11322609|NCT02549976|Experimental|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.
~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :
~Upper tract location : upper endoscopy
~Colorectal location : colonoscopy
~Perianal location : pelvic MRI
~All patients : abdominal MRI"
11322610|NCT02549963|Experimental|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
11322611|NCT02549963|Active Comparator|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
11322612|NCT02549950|Active Comparator|Conventional OrthodonticTreatment|Conventional orthodontic mechanics: canine and incisor retraction
11322613|NCT02549950|Experimental|Accelerated Tooth Movement|Accelerated orthodontics: Peizo-Corticision Accelerated canine and Incisor retraction
11322614|NCT02549937|Experimental|Escalation 50 mg|Escalation cohort at 50 mg/day
11322615|NCT02549937|Experimental|Escalation 100mg|Escalation cohort at 100 mg/day
11322616|NCT02549937|Experimental|Escalation 200 mg|Escalation cohort at 200 mg/day
11322617|NCT02549937|Experimental|Escalation 300 mg|Escalation cohort at 300 mg/day
11322618|NCT02549937|Experimental|Escalation 400 mg|Escalation cohort at 400 mg/day
11322619|NCT02549937|Experimental|Expansion|Subjects will receive RP2D surufatinib daily treatment continuously with every 28-day treatment cycle. Four expansion cohorts will enroll BTC, pNET, EP-NET, and STS patients, respectively.
11322620|NCT02549924|Experimental|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
11322621|NCT02549924|Placebo Comparator|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
11322677|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
11322622|NCT02549911|Experimental|HIPEC,Chemotherapy AND surgery|"surgical exploration,if PCI<20,then we perform this study
~HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
~chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )
~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
11322623|NCT02549898|Experimental|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
11322624|NCT02549898|Experimental|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
11322625|NCT02549898|Experimental|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
11322626|NCT02549898|Experimental|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
11322627|NCT02549885|Experimental|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
11322628|NCT02549885|Experimental|Static stretching|Static stretching of neck muscles.
11322629|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
11322630|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
11322631|NCT02549859|Experimental|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
11322632|NCT02549846|Active Comparator|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
11322633|NCT02549846|Other|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
11322634|NCT02549833|Experimental|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
11322635|NCT02549833|Active Comparator|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
11322636|NCT02549820|Experimental|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
11322637|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
11322638|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
11322639|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
11322640|NCT02549794|Active Comparator|High concentration (370)|CT angiography with hign concentration iodine contrast agent of 370 mg iodine/ml
11322641|NCT02549794|Experimental|Low concentration (320)|CT angiography with low concentration iodine contrast agent of 320 mg iodine/ml
11322642|NCT02549794|Experimental|Low concentration (270)|CT angiography with low concentration iodine contrast agent of 270 mg iodine/ml
11322643|NCT02549781|Experimental|Gambler performing Go-Nogo|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
11322644|NCT02549781|Active Comparator|Social layer performing Go-Nogo|"In this study, social player performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
11322745|NCT02549105|Active Comparator|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
11322746|NCT02549105|Active Comparator|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
11322645|NCT02549781|Placebo Comparator|non-gamer witnesses performing Go-Nogo|"In this study, non-gamer witnesses performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
11322646|NCT02549768|Active Comparator|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
11322647|NCT02549768|Placebo Comparator|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
11322648|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
11322649|NCT02549742|Experimental|Electrochemotherapy|25 patients treated with electrochemotherapy
11322650|NCT02549729|No Intervention|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
11322651|NCT02549729|Experimental|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
11322652|NCT02549729|No Intervention|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
11322653|NCT02549729|Experimental|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
11322654|NCT02549716|Experimental|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
11322655|NCT02549716|Experimental|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
11322656|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
11322657|NCT02549703||Secondary Progressive Multiple Sclerosis|
11322658|NCT02549703||Primary Progressive Multiple Sclerosis|
11322659|NCT02549690|Active Comparator|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
11322660|NCT02549690|Active Comparator|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
11322661|NCT02549677|Experimental|EC regimen|Epirubicin, cyclophosphamide
11322662|NCT02549677|Active Comparator|TC regimen|docetaxel, cyclophosphamide
11322663|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
11322664|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
11322665|NCT02549651|Experimental|MEDI4736|
11322666|NCT02549651|Experimental|MEDI4736 and tremelimumab|
11322667|NCT02549651|Experimental|MEDI4736 and AZD9150|
11322668|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
11322669|NCT02549625|Experimental|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
11322670|NCT02549612|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
11322671|NCT02549612|No Intervention|Control|No intervention is used in this group.
11322672|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
11322673|NCT02549599|Experimental|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
11322674|NCT02549599|Other|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
11322675|NCT02549586|Experimental|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
11322676|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
11322747|NCT02549092|Active Comparator|Optimized Medical Treatment|26 Week Period
11322748|NCT02549092|Experimental|ABT-SLV187|26 Week Period
11322749|NCT02549053|Experimental|Barrett esophagus patients|esophagus biopsies (pathologic and healthy zones)
11322750|NCT02549053|Sham Comparator|control patients|esophagus biopsies (healthy zones)
11322678|NCT02549560|Active Comparator|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
11322679|NCT02549560|Sham Comparator|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
11322680|NCT02549547|Experimental|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
11322681|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:
~Are 18 to 85 years old at the time of enrollment;
~Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);
~Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;
~Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR
~Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);
~Are willing to participate in up to four study sessions."
11322682|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:
~Are 18 to 85 years old at the time of study enrollment;
~Can read, write, and understand English,
~Are willing to participate in three planned study sessions."
11322683|NCT02549521|Active Comparator|Oral magnesium substitution|Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
11322684|NCT02549521|Placebo Comparator|Magnesium + or Magnesium -|Placebo tablets without magnesium.
11322685|NCT02549508|Experimental|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
11322686|NCT02549508|Experimental|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
11322687|NCT02549495||Patients with Diabetes or Hypertension|All patients in the seven study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
11322688|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
11322689|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
11322690|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
11322691|NCT02549469|Active Comparator|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
11322692|NCT02549456|Experimental|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
11322693|NCT02549456|Experimental|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
11322694|NCT02549443|Active Comparator|Insulin|hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
11322695|NCT02549443|Active Comparator|Insulin and amino acids|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
~Amino Acids (AA) in amounts to preserve normal AA"
11322696|NCT02549443|Active Comparator|Insulin and hyperaminoacidemia|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
~AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)"
11322697|NCT02549430|Experimental|Arm A|Palbociclib monoterapy
11322698|NCT02549430|Experimental|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
11322699|NCT02549417|Experimental|KHK7580|
11322700|NCT02549404|Experimental|KHK7580|
11322701|NCT02549391|Experimental|KHK7580|
11322702|NCT02549391|Active Comparator|KRN1493|
11322703|NCT02549378|Experimental|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
11322704|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
11322705|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
11322706|NCT02549352|Experimental|LEO 43204 gel|Treatment once daily for 3 days
11322707|NCT02549352|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
11322708|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
11322709|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
11322710|NCT02549326|Placebo Comparator|Obese, placebo|Placebo daily for 12 weeks
11322711|NCT02549326|Active Comparator|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
11322712|NCT02549326|Placebo Comparator|Control, placebo|Placebo daily for 12 weeks
11322713|NCT02549326|Active Comparator|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
11322714|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
11322715|NCT02549300|No Intervention|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
11322716|NCT02549300|Experimental|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
11322717|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
11322718|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
11322719|NCT02549274|Experimental|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
11322720|NCT02549274|Active Comparator|physiotherapy|Patients will have only conventional physiotherapy
11322721|NCT02549261|Experimental|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
11322722|NCT02549261|Experimental|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
11322723|NCT02549261|Placebo Comparator|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
11322724|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.
~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
11322725|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.
~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
11322726|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
11322727|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
11322728|NCT02549209|Experimental|Investigational Treatment|"Subjects with no prior therapy:
~Pembrolizumab administered at 200 mg
~Paclitaxel administered at 175mg/m2
~Carboplatin administered at an AUC of 6
~Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:
~Pembrolizumab administered at 200 mg
~Paclitaxel administered at 135mg/m2
~Carboplatin administered at an AUC of 5"
11322729|NCT02549196|Experimental|Cohort 1|Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
11322730|NCT02549196|Experimental|Cohort 2|Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
11322731|NCT02549196|Experimental|Cohort 1b|Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
11322732|NCT02549196|Experimental|Cohort 3c|Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
11322733|NCT02549183|Active Comparator|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
11322734|NCT02549183|Active Comparator|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
11322735|NCT02549183|Active Comparator|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
11322736|NCT02549183|Active Comparator|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
11322737|NCT02549170|Experimental|Epoch 1: HYQVIA/HyQvia|Participants will receive SC HYQVIA/HyQvia at a dose of 80 Unit per gram (U/g) immunoglobulin (IgG) which will be same as the participants pre-randomization monthly equivalent IgG dose (or at matching infusion volume for participants in the placebo group) when administered at a dosing frequency of every 2, 3, or 4 weeks for 6 months or until relapse.
11322738|NCT02549170|Placebo Comparator|Epoch 1: Placebo with rHuPH20|Participants will receive sequential 0.25% albumin placebo with rHuPH20 at a dose of 80U/g IgG subcutaneously for 6 months or until relapse. Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
11322739|NCT02549170|Experimental|Epoch 2: IGIV|Participants will recieve an induction dose of 2 Gram per kilogram (g/kg) Intravenous immunoglobulin G (IGIV), followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks for 6 months or until relapse.
11322740|NCT02549144|Experimental|Low versus high fat/cholesterol diet|The first day of the study protocol a low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days was prescribed to the participants followed by a high-fat/high-cholesterol (HFHC) normocaloric diet for further 14 days.
11322741|NCT02549131|Active Comparator|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
11322742|NCT02549131|Active Comparator|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.
~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
11322743|NCT02549118|Experimental|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
11322744|NCT02549118|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
11322751|NCT02549040|Experimental|MK-1439 fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: MK-1439 100 mg film coated tablet. During Period 3, participants received Treatment C: MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
11322752|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
11322753|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
11322754|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
11322755|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
11322756|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322757|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322758|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322759|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322760|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322761|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322762|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322763|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322764|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
11322765|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
11322766|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
11322767|NCT02549001|Experimental|P-3058 10%|P-3058 10%
11322768|NCT02549001|Placebo Comparator|vehicle of P-3058 10%|vehicle of P-3058 10%
11322769|NCT02549001|Active Comparator|amorolfine 5%|Loceryl®
11322770|NCT02548988|Experimental|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
11322771|NCT02548988|Experimental|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
11322772|NCT02548975||Delirium|Patients diagnosed with delirium at any time postoperatively with the CAM-ICU.
11322773|NCT02548975||No delirium|Patients not diagnosed with delirium postoperatively.
11322774|NCT02548962|Experimental|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
11322775|NCT02548962|Experimental|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
11322777|NCT02548936|Experimental|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
11322778|NCT02548936|No Intervention|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
11322779|NCT02548923|Active Comparator|dexmedetomidine group|Patients who received dexmedetomidine for sedation
11322780|NCT02548923|No Intervention|propofol group|Patients who received propofol for sedation
11322781|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
11322782|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
11322783|NCT02548897|Experimental|Freezing of gait in PD|All participants will undergo an deep brain stimulation (DBS) for the FOG, and an electroencephalography (EEG) to better understand the neurophysiological underpinnings of the symptom. In addition, review changes in scalp recorded EEG and gait parameters during natural FoG episodes while participants are ambulatory in an advanced gait laboratory setting using a wireless EEG amplifier with active electrodes.
11322784|NCT02548884|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
11322785|NCT02548884|Active Comparator|Double guide wire|Double guide wire technique used in difficult biliary cannulation
11322786|NCT02548871|Experimental|Teen Outreach Program|Teen Outreach Program
11322787|NCT02548871|No Intervention|Comparison|Business as usual
11322788|NCT02548858|Active Comparator|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
11322789|NCT02548858|Active Comparator|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
11322790|NCT02548832|Active Comparator|Berberine more Placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
11322791|NCT02548832|Active Comparator|Bezafibrate more placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
11322792|NCT02548832|Experimental|Berberine more Bezafibrate|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
11322793|NCT02548806|Experimental|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
11322794|NCT02548806|Experimental|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
11322795|NCT02548806|Active Comparator|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
11322796|NCT02548793|Active Comparator|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
11322797|NCT02548793|Experimental|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
11322798|NCT02548780|Experimental|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.
~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
11322799|NCT02548767|Experimental|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
11322800|NCT02548767|Placebo Comparator|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
11322801|NCT02548767|Experimental|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
11322802|NCT02548767|Placebo Comparator|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
11322803|NCT02548754|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
11322804|NCT02548754|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
11322805|NCT02548741|Active Comparator|Treatment (Metformin)|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the active comparator (metformin).
11322934|NCT02547922|Experimental|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
11322806|NCT02548741|Placebo Comparator|Placebo|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the placebo comparator.
11322807|NCT02548741|Other|Non-diabetic|Forty matched non-diabetic patients with HbA1C ≤ 5.6%. They will not receive either treatment (metformin) or placebo.
11322808|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
11322809|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
11322810|NCT02548715|Placebo Comparator|Control|Daily placebo
11322811|NCT02548715|Experimental|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
11322812|NCT02548702|Experimental|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
11322813|NCT02548702|No Intervention|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
11322814|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
11322815|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
11322816|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
11322817|NCT02548676||Healthy controls|age- and sex matched controls
11322818|NCT02548663|Experimental|active; sport therapy|active exercise carefully calibrated on residual capacities.
11322819|NCT02548663|Experimental|passive; osteopathic treatment|manipulative treatment according to osteopathic principles.
11322820|NCT02548650|Experimental|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
11322821|NCT02548650|Active Comparator|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
11322822|NCT02548637|Experimental|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
11322823|NCT02548611|Experimental|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
11322824|NCT02548611|Active Comparator|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
11322825|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
11322826|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
11322827|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
11322828|NCT02548585|Placebo Comparator|Placebo|Participants will receive placebo (matched to either 100 micrograms [mcg], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
11322829|NCT02548585|Experimental|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
11322830|NCT02548585|Experimental|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
11322831|NCT02548585|Experimental|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
11322832|NCT02548585|Experimental|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
11322833|NCT02548585|Experimental|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
11322834|NCT02548585|Experimental|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
11322835|NCT02548572|Experimental|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
11322935|NCT02547922|Experimental|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
11322836|NCT02548572|Placebo Comparator|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
11322837|NCT02548559|Experimental|Cannabidiol|1 ml of sublingual cannabidiol tincture (10 mg/ml CBD) administered three times per day (TID) for four weeks.
11322838|NCT02548546|Active Comparator|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
11322839|NCT02548546|Active Comparator|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
11322840|NCT02548546|Active Comparator|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
11322841|NCT02548533|Active Comparator|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
11322842|NCT02548533|Experimental|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
11322843|NCT02548494|Placebo Comparator|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
11322844|NCT02548494|Experimental|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
11322845|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
11322846|NCT02548468|Experimental|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
11322847|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
11322848|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
11322849|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
11322850|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
11322851|NCT02548416|Active Comparator|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
11322852|NCT02548416|Active Comparator|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
11322853|NCT02548403|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
11322854|NCT02548403|Active Comparator|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
11322855|NCT02548390|Experimental|RXDX-107|
11322856|NCT02548377|Experimental|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
11322857|NCT02548377|Sham Comparator|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
11322858|NCT02548364|Experimental|Calcifediol|One capsule with 15,690 IU p.o. every two weeks
11322859|NCT02548364|Placebo Comparator|Placebo|One capsule with placebo p.o. every two weeks
11322860|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
11322861|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
11322862|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
11322863|NCT02548338|Other|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
11322864|NCT02548338|Other|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
11322865|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
11322866|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
11322867|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
11322868|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
11322869|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
11322870|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
11322871|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
11322872|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
11322873|NCT02548299|Experimental|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
11322936|NCT02547922|Placebo Comparator|Placebo|Placebo IV Q4W plus SOC
11323026|NCT02547311|Experimental|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
11322874|NCT02548299|Experimental|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
11322875|NCT02548299|Experimental|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
11322876|NCT02548286|Active Comparator|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
11322877|NCT02548286|Experimental|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
11322878|NCT02548273||Diabetics|diabetics with cataract who opted for phacoemulsification surgery
11322879|NCT02548273||controls|non-diabetics with cataract who opted for phacoemulsification surgery (subjects without corneal opacity, PXF ,high myopia, uveitis)
11322880|NCT02548260|Experimental|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
11322881|NCT02548260|Experimental|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
11322882|NCT02548260|Experimental|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
11322883|NCT02548260|Experimental|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
11322884|NCT02548247|Experimental|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
11322885|NCT02548247|Placebo Comparator|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
11322886|NCT02548234|Experimental|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
11322887|NCT02548234|Experimental|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
11322888|NCT02548208|Active Comparator|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
11322889|NCT02548208|Sham Comparator|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
11322890|NCT02548208|No Intervention|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
11322891|NCT02548195|Experimental|GEMOX|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.
11322892|NCT02548195|Active Comparator|Capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
11322893|NCT02548182|No Intervention|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
11322894|NCT02548182|Active Comparator|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults [REF]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
11322895|NCT02548182|Active Comparator|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
11322896|NCT02548169|Active Comparator|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
11322897|NCT02548169|Active Comparator|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
11322898|NCT02548156|Other|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
11322899|NCT02548156|Other|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
11322900|NCT02548156|Other|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
11322929|NCT02547948|Experimental|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
11322930|NCT02547948|No Intervention|No Intervention|
11322931|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
11323023|NCT02547337||Healthy subjects|
11322901|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
11322902|NCT02548130||Patients before MELD score|Recipients before the MELD score
11322903|NCT02548130||Patients after the MELD score|Recipients after the MELD score
11322904|NCT02548117|Active Comparator|Finasteride|ARM 1 subjects will receive finasteride 5 mg orally daily.
11322905|NCT02548117|No Intervention|No Treatment|The ARM 2 (control group) will not receive any study treatment.
11322906|NCT02548104|Active Comparator|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
11322907|NCT02548104|Experimental|Adductor canal ACB + genicular (IPACK)|Group II Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
11322908|NCT02548091|Active Comparator|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
11322909|NCT02548091|Other|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
11322910|NCT02548078|Experimental|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
11322911|NCT02548078|Experimental|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
11322912|NCT02548065|Active Comparator|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
11322913|NCT02548065|Placebo Comparator|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
11322914|NCT02548052|Experimental|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
11322915|NCT02548039||Asian Normogonadotrophic Anovulatory Women|Asian women with normal gonadotropin levels but do not ovulate.
11322916|NCT02548026|Experimental|High Eating Frequency (High EF)|8 Eating Occasions
11322917|NCT02548026|Experimental|Low Eating Frequency (High EF)|3 Eating Occasions
11322918|NCT02548013|Experimental|Home management|outpatient management patients if stable will be discharged to continue treatment at home
11322919|NCT02548013|Active Comparator|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
11322920|NCT02548000|Experimental|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
11322921|NCT02548000|Active Comparator|Stretching control|The control group will perform one stretching session a week.
11322922|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
11322923|NCT02547974|Experimental|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
11322924|NCT02547974|Experimental|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
11322925|NCT02547974|Experimental|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
11322926|NCT02547974|Placebo Comparator|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
11322927|NCT02547961|Experimental|HER2-CAR-T|In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
11322928|NCT02547961|No Intervention|No Intervention|
11322937|NCT02547909|Experimental|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
11322938|NCT02547896|Experimental|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
11322939|NCT02547896|Experimental|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
11322940|NCT02547883|Experimental|Patients stopping statin|
11322941|NCT02547883|No Intervention|Patients continuing statin|
11322942|NCT02547870|Experimental|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
11322943|NCT02547870|Experimental|Aged RPV-LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
11322944|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
11322945|NCT02547844|Active Comparator|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
11322946|NCT02547844|Experimental|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
11322947|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
11322948|NCT02547818|Active Comparator|Group I|ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
11322949|NCT02547818|Active Comparator|Group II|ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
11322950|NCT02547818|Active Comparator|Group III|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
11322951|NCT02547818|Placebo Comparator|Group IV|ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
11322952|NCT02547805|Placebo Comparator|Placebo|Five (5) capsules of placebo by mouth (PO) three times per day (TID) with meals
11322953|NCT02547805|Experimental|ALLN-177|Five (5) capsules of ALLN-177 (1,500 units per capsule) PO TID with meals
11322954|NCT02547792|Experimental|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
11322955|NCT02547792|Experimental|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
11322956|NCT02547792|Placebo Comparator|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
11322957|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
11322958|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
11322959|NCT02547766|Experimental|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
11322960|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
11322961|NCT02547753||Control group|healthy patients who need tooth extraction
11322962|NCT02547740||Early Glaucomatous Damage|Patients with early functional glaucomatous damage.
11322963|NCT02547740||Ophthalmologically Healthy|Healthy subjects that are ophthalmologically normal
11322964|NCT02547727|Experimental|Four-site intradermal vaccination|0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
11322965|NCT02547727|Active Comparator|Intramuscular vaccination|0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
11322966|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
11322967|NCT02547701|Experimental|P-3058|
11322968|NCT02547688|Other|Nasal High Flow|All subjects are in this group
11322969|NCT02547662|Experimental|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11322970|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
11322971|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
11322972|NCT02547649|Active Comparator|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
11322973|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
11322974|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
11322975|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
11322976|NCT02547597|Experimental|Carvedilol|Carvedilol 25 mg twice a day
11322977|NCT02547597|Active Comparator|Atenolol|Atenolol 50 mg twice a day
11323024|NCT02547324|Experimental|Slump sitting|Slump sitting flexion of lumbar spine
11323025|NCT02547324|Active Comparator|Forward bending|Forward erect bending of lumbar spine
11322978|NCT02547584|Active Comparator|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
11322979|NCT02547584|Active Comparator|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40
11322980|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
11322981|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue|
11322982|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
11322983|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue|
11322984|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid|
11322985|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Low residue|
11322986|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
11322987|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue|
11322988|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
11322989|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue|
11322990|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid|
11322991|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Low residue|
11322992|NCT02547558|Experimental|Indacaterol|"Drug:
~-Indacaterol, inhaled, single dose, 300 mcg
~Diagnostic Interventions:
~Arterial blood gases
~Cardiac output
~Vital signs
~Exhaled breath
~Spirometry"
11322993|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
11322994|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
11322995|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
11322996|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
11322997|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
11322998|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
11322999|NCT02547519|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
11323000|NCT02547519|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
11323001|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
11323002|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
11323003|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
11323004|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
11323005|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
~Abatacept started on frst day."
11323006|NCT02547480|Experimental|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
11323007|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
11323008|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
11323009|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
11323010|NCT02547428|Experimental|CTN SR first, then Placebo|Participants will receive CTN SR at a TDD of 400 mg followed by placebo (after washout period). CTN SR will be titrated up from 100 to 400 mg daily, at specified increments, for 3 weeks. Placebo will be titrated in the same manner to protect the blind.
11323011|NCT02547428|Experimental|Placebo first, then CTN SR|Participants will receive placebo followed by CTN SR at a TDD of 400 mg (after washout period). CTN SR will be titrated up from 100 to 400 mg daily, at specified increments, for 3 weeks. Placebo will be titrated in the same manner to protect the blind.
11323012|NCT02547415||patients with questionnaires and psychological testing|children and adolescents with chronic pain without proven medical cause, type painful somatic complaints
11323013|NCT02547402|Experimental|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
11323014|NCT02547389|Active Comparator|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
11323015|NCT02547389|Other|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
11323016|NCT02547376||Eligible patients with Soft Tissue Sarcoma|Primary Soft Tissue Sarcoma group
11323017|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
11323018|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
11323019|NCT02547350|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy
11323020|NCT02547350|Experimental|single intravesical instillation|intravesical instillation within 24 hours postoperatively
11323021|NCT02547350|Experimental|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
11323022|NCT02547337||Type 1 diabetes|
11323028|NCT02547298|Experimental|All patients|All patients in this study receive hydrodistension
11323029|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
11323030|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
11323031|NCT02547259|Experimental|schizophrenic pain words test|schizophrenic will have memory test with pain words on computer
11323032|NCT02547259|Experimental|schizophrenic negative words test|schizophrenic will have memory test with negative words on computer
11323033|NCT02547259|Other|Healthy volunteer pain words test|Healthy volunteer will have memory test with pain words on computer
11323034|NCT02547259|Other|Healthy volunteer negative words test|Healthy volunteer will have memory test with negative words on computer
11323035|NCT02547246|Experimental|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
11323036|NCT02547246|Placebo Comparator|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
11323037|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
11323038|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
11323039|NCT02547220|Experimental|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
11323040|NCT02547220|Placebo Comparator|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
11323041|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
11323042|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
11323043|NCT02547181|Experimental|Splint|Patients will be provided instructed to use a tensor bandage as well as specific behaviours to prevent movement of the injured part of the hand.
11323044|NCT02547181|Experimental|Behavioral Modification|Patients are given a removable plaster/fiberglass splint with a tensor bandage underneath
11323045|NCT02547168|Experimental|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
11323046|NCT02547155|Experimental|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
11323047|NCT02547155|Active Comparator|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
11323048|NCT02547142|Experimental|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
11323049|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
11323050|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
11323051|NCT02547116|No Intervention|Standard anti-staphylococcal antibiotic|
11323052|NCT02547116|Experimental|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
11323053|NCT02547103|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate-soaked cloths, clean topical area around catheter exit site with CHG 2% soaked cloths
11323054|NCT02547103|Active Comparator|Normal saline (usual care)|Normal saline, clean topical area around catheter exit site
11323055|NCT02547103|Active Comparator|Mupirocin ointment|Mupirocin ointment 2%, clean topical area around catheter exit site with Mupirocin ointment
11323056|NCT02547090||CP who underwent PSF by two attendings in 2012|
11323057|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
11323058|NCT02547077|Experimental|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
11323059|NCT02547077|Active Comparator|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
11323060|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
11323061|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
11323062|NCT02547051|Experimental|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
11323063|NCT02547038|Experimental|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
11323064|NCT02547038|Active Comparator|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
11323108|NCT02546739|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
11323065|NCT02547025|Experimental|rabeprazole+3 antibiotics|patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
11323066|NCT02547025|Experimental|rabeprazole+bismuth+2 antibiotics|patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
11323067|NCT02547025|Active Comparator|rabeprazole+amox+tetr+levo|patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days
11323068|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
11323069|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
11323070|NCT02546999|Experimental|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
11323071|NCT02546999|Placebo Comparator|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
11323072|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
11323073|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
11323074|NCT02546973||Patients with anal cancer|All patients with anal cancer during 2011-2013 will be asked to participate
11323075|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
11323076|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
11323077|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
11323078|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
11323106|NCT02546752|Experimental|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
11323107|NCT02546752|No Intervention|Usual Care Arm|This arm will receive usual care.
11323079|NCT02546960|Experimental|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
11323080|NCT02546960|Placebo Comparator|Placebo|Participants will be stratified according to their age in 2 groups >= 18 to <50 years and >=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the IDMC.
11323081|NCT02546947|No Intervention|Appropriate clinical group|group of patients with clinical dose adjustment
11323082|NCT02546947|Active Comparator|TOF adapted group|group with an objective of less than 2 responses to TOF stimulation monitored
11323083|NCT02546934|Experimental|ABX, cisplatin|AP (ABX and cisplatin combination)
11323084|NCT02546934|Active Comparator|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
11323085|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
11323086|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of >0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
11323087|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
11323088|NCT02546882|Experimental|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
11323089|NCT02546882|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
11323090|NCT02546869|Experimental|Lebrikizumab|Participants will receive lebrikizumab SC using prefilled syringes (PFS), q4w up to Week 12.
11323091|NCT02546856|Active Comparator|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
11323092|NCT02546856|Experimental|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
11323093|NCT02546843|Experimental|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).
~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.
~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
11323094|NCT02546843|Active Comparator|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.
~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.
~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
11323095|NCT02546830|Experimental|FreeO2 v2.2 active|Automatic Oxygen Administration
11323096|NCT02546830|Active Comparator|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
11323097|NCT02546804|Experimental|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
11323098|NCT02546804|Experimental|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
11323099|NCT02546804|Active Comparator|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
11323100|NCT02546791||Chronic myeloid leukemia patients treated with Dasatinib|patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days
11323101|NCT02546778|Experimental|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
11323102|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU
~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
11323103|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.
~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
11323104|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
11323105|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
11323109|NCT02546739|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
11323110|NCT02546739|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
11323111|NCT02546726|Experimental|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
11323112|NCT02546726|Active Comparator|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
11323113|NCT02546713|Other|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
11323114|NCT02546713|Other|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
11323115|NCT02546700|Experimental|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
11323116|NCT02546700|Experimental|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
11323117|NCT02546700|Placebo Comparator|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
11323118|NCT02546700|Placebo Comparator|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
11323119|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
11323120|NCT02546674|Experimental|Nilotinib|Patients with newly diagnosed CML in chronic phase will be enrolled.
11323121|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.
~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:
~The investigator believes it is in the patient's interest to receive durvalumab;
~The patient consents to the continued treatment;
~It is clinically appropriate for the patient to continue on durvalumab treatment;
~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
11323122|NCT02546661|Experimental|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
11323123|NCT02546661|Experimental|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
11323124|NCT02546661|Experimental|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
11323125|NCT02546661|Experimental|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
11323126|NCT02546661|Experimental|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
11323127|NCT02546661|Experimental|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
11323128|NCT02546661|Experimental|Module G: MEDI4736 + Selumetinib|
11323129|NCT02546648|Experimental|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
11323130|NCT02546648|Experimental|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
11323131|NCT02546635|Experimental|Potential food effect|
11323132|NCT02546635|Experimental|Multi-dosing|
11323133|NCT02546622||Arm A Prospective|"Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.
~These patients will be followed prospectively for up to 1 year."
11323134|NCT02546622||Arm B Retrospective|"Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.
~Patients must have switched products within the past 50 weeks at the time of enrollment.
~These patients will be assessed retrospectively and/or followed prospectively for up to 1 year."
11323135|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
11323136|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
11323137|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
11323138|NCT02546596|Experimental|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
11323139|NCT02546583|Experimental|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
11323140|NCT02546583|Experimental|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
11323233|NCT02545959|Experimental|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
11323141|NCT02546583|No Intervention|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
11323142|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
11323143|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
11323144|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
11323145|NCT02546557||OPTICABG|Patients undergoing a coronary artery bypass graft surgery for the repair of a multi-vessel disease or left main-coronary disease.
11323146|NCT02546544|Other|Linsitinib|Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
11323147|NCT02546531|Experimental|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.
~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.
~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.
~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
11323148|NCT02546531|Experimental|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.
~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.
~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.
~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
11323149|NCT02546518|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
11323150|NCT02546518|Active Comparator|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
11323151|NCT02546505|No Intervention|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
11323152|NCT02546505|Experimental|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
11323153|NCT02546505|Experimental|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
11323154|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
11323155|NCT02546479||Patientis|patients diagnosed with scoliosis and other spinal deformities
11323156|NCT02546466|Experimental|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
11323157|NCT02546466|Sham Comparator|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
11323158|NCT02546466|Active Comparator|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
11323231|NCT02545972|Experimental|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
11323232|NCT02545959|Active Comparator|Control group|receive a single pulse of methylprednisolone IV (120mg)
11323159|NCT02546453|Other|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
11323160|NCT02546440|Experimental|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
11323161|NCT02546427|Experimental|Treatment|"Step 1: Pelvic Lymph Node Irradiation
~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each
~Step 2: Treat boost volume to prostate and seminal vesicles
~Acceptable treatment modalities:
~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT
~Permanent prostate implant (PPI):
~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
11323162|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
11323163|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
11323164|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
11323165|NCT02546401|Experimental|Group 1|"Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF).
~Intervention: drug (insulin Aspart)"
11323166|NCT02546401|Experimental|Group 2|"Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE).
~Intervention: drug (insulin Aspart)"
11323167|NCT02546388|Experimental|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
11323168|NCT02546388|Experimental|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
11323169|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
11323170|NCT02546362|Experimental|Cefaly active device|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
11323171|NCT02546349|Experimental|high eNO: ICS/LABA|patients with eNO >=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
11323172|NCT02546349|Active Comparator|high eNO: LAMA|patients with eNO >=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
11323173|NCT02546349|Experimental|Low eNO: ICS/LABA|patients with eNO < 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
11323174|NCT02546349|Active Comparator|Low eNO: LAMA|patients with eNO < 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
11323175|NCT02546336|Experimental|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
11323176|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
11323177|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
11323178|NCT02546310|Experimental|HTL0009936 high dose|high dose infusion
11323179|NCT02546310|Experimental|HTL0009936 low dose|low dose infusion
11323180|NCT02546310|Placebo Comparator|HTL0009936 matching placebo|matching infusion
11323181|NCT02546297|Active Comparator|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，12 months.
11323182|NCT02546297|Active Comparator|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，12 months.
11323183|NCT02546297|Active Comparator|LAMA+LABA Group|Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.
11323184|NCT02546284|Experimental|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
11323185|NCT02546271|Experimental|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
11323186|NCT02546258|Other|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
11323187|NCT02546245|Experimental|Heroes of Knowledge Game|
11323188|NCT02546245|Active Comparator|Attention/Time Control Games|
11323189|NCT02546232|Active Comparator|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
11323190|NCT02546232|Experimental|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.
~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
11323191|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
11323192|NCT02546206|Experimental|Probiotic Yoghurt|Probiotic yoghurt consumption
11323193|NCT02546206|Placebo Comparator|Natural Yoghurt|Natural yoghurt consumption
11323262|NCT02545738|Experimental|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
11323194|NCT02546193|Experimental|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).
~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
11323195|NCT02546193|Active Comparator|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.
~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
11323196|NCT02546180|Experimental|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
11323197|NCT02546180|Active Comparator|Standard Education|Subjects in this arm were randomized to standard preoperative education.
11323198|NCT02546167|Experimental|Cohort 1|will receive 1-5x10^7 CART-BCMA cells given as a split dose infusion over 3 days.
11323199|NCT02546167|Experimental|Cohort 2|Cyclophosphamide infusion prior to 1-5x10^7 CART BCMA cells given as a split dose infusion over 3 days.
11323200|NCT02546167|Experimental|Cohort 3|Cyclophosphamide infusion prior to 1-5x10^8 CART BCMA cells given as a split dose infusion over 3 days.
11323201|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
11323202|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
11323203|NCT02546141|Active Comparator|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
11323204|NCT02546141|Active Comparator|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
11323205|NCT02546141|Active Comparator|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
11323206|NCT02546141|Active Comparator|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
11323207|NCT02546141|Active Comparator|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
11323208|NCT02546141|Active Comparator|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
11323209|NCT02546141|Active Comparator|whey protein|portion size that contains 25 g of protein, oral, single administration
11323210|NCT02546141|Active Comparator|micellar casein|portion size that contains 25 g of protein, oral, single administration
11323211|NCT02546128|Experimental|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
11323212|NCT02546128|Placebo Comparator|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
11323213|NCT02546115|Active Comparator|Intervention|standard practice (structured rehabilitation programme) + TNS
11323214|NCT02546115|Active Comparator|control|standard practice (structured rehabilitation programme)
11323215|NCT02546102|Experimental|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
11323216|NCT02546102|Placebo Comparator|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
11323217|NCT02546089|Active Comparator|intervention group|"local anaesthetic - lidocaine 1%, dry needling, autologous blood injection,
~+ structured rehab programme"
11323218|NCT02546089|Placebo Comparator|control group|"local anaesthetic - lidocaine 1%, dry needling,
~+ structured rehab programme"
11323219|NCT02546076|Active Comparator|Laser coagulation|Er:YAG laser treatment with coagulation modality
11323220|NCT02546076|Active Comparator|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
11323221|NCT02546063|Other|GoCARB app|Smartphone app
11323222|NCT02546063|No Intervention|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
11323223|NCT02546050|Experimental|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
11323224|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
11323225|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
11323226|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
11323227|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
11323228|NCT02545998|No Intervention|Standard care|Patients will receive a face-to-face asthma review
11323229|NCT02545998|Active Comparator|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
11323230|NCT02545985|Experimental|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
11323263|NCT02545738|Placebo Comparator|Placebo|Placebo s.c. for 12 weeks.
11323234|NCT02545959|Experimental|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
11323235|NCT02545946|Active Comparator|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
11323236|NCT02545946|Active Comparator|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
11323237|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
11323238|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
11323239|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
11323240|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:
~Level -1 - 27mg/m2
~Level 0 - 36mg/m2
~Level 1 - 45mg/m2
~Level 2 - 56mg/m2
~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
11323241|NCT02545894|No Intervention|BASELINE TESTING|Language and cognitive assessments conducted
11323242|NCT02545894|Experimental|Treatment|"Intervention given:
~visual tracking pressing a button every time a picture is seen on the screen
~playing dominoes and snap
~pressing a button every time a specific picture is seen on the screen
~Pressing a button every time a specific sound is heard
~Matching objects to a picture
~Matching gestures to objects
~Matching two connected objects
~Sorting objects by categories
~Matching sounds to objects
~Complete the category and odd on out with objects
~Choosing target objects by pointing
~Choosing objects to complete the category by pointing"
11323243|NCT02545894|No Intervention|Post intervention|Repeated testing
11323244|NCT02545868|Experimental|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
11323245|NCT02545868|Other|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period. Participants who complete the 12-week immunization study period will have the option to receive two single infusions of OCR 300 mg, on Day 84 and Day 98, and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
11323246|NCT02545855|Experimental|Arm A (myAIRVO2® + HOT, HOT)|Subjects will receive the myAIRVO2® therapy plus HOT for week 1-6 and HOT only for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
11323247|NCT02545855|Experimental|Arm B (HOT, myAIRVO2® + HOT)|Subjects will receive HOT only for week 1-6 and the myAIRVO2® therapy plus HOT for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
11323248|NCT02545842|Experimental|Group 1|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
11323249|NCT02545842|Experimental|Group 2|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
11323250|NCT02545842|Experimental|Group 3|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
11323251|NCT02545829|Experimental|Sequence 1|HGP1406 → HIP1302
11323252|NCT02545829|Experimental|Sequence 2|HIP1302 → HGP1406
11323253|NCT02545816|Other|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
11323254|NCT02545803|Other|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
11323255|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
11323256|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
11323257|NCT02545777|Active Comparator|treatment group|Take oral medicine of tonifying spleen and descending turbid, one bag each time, two times a day, continuous treatment for 10 days.The onset of the joints afford steeping washing and wet wrapping medicine of descending turbid and clearing heat, once per day, continuous treatment for 10 days.
11323258|NCT02545777|Active Comparator|Control group|Take diclofenac sodium enteric-coated, 50 mg, three times a day, continuous treatment for 10 days.
11323259|NCT02545764|Experimental|Intervention|Strength and neuromuscular exercise programme
11323260|NCT02545764|No Intervention|Control|Control group will receive opportunity for the training programme after data capturing is finished
11323261|NCT02545751|Experimental|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
11323264|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
11323265|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
11323266|NCT02545699|Experimental|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
11323267|NCT02545699|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
11323268|NCT02545686|Experimental|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:
~Chest wall movement assessment without CPAP
~Breath hold assessment without CPAP
~Chest wall movement assessment with CPAP
~Breath hold assessment with CPAP"
11323269|NCT02545673|Experimental|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
11323270|NCT02545673|Active Comparator|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
11323271|NCT02545660|Experimental|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
11323272|NCT02545660|Experimental|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
11323273|NCT02545647|No Intervention|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
11323274|NCT02545647|Active Comparator|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
11323275|NCT02545634|Placebo Comparator|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
11323276|NCT02545634|Experimental|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
11323277|NCT02545621||ARDS Group (acute respiratory distress syndrome)|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
11323278|NCT02545621||control group|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
11323279|NCT02545608|Experimental|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
11323280|NCT02545608|Other|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
11323281|NCT02545595|Experimental|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
11323282|NCT02545595|Experimental|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
11323283|NCT02545595|Experimental|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
11323284|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
11323285|NCT02545569|Active Comparator|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
11323286|NCT02545569|Experimental|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
11323287|NCT02545556|Experimental|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
11323288|NCT02545556|Placebo Comparator|control|liver cancer patients received traditional therapy
11323289|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
11323290|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
11323291|NCT02545530|Active Comparator|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
11323292|NCT02545530|No Intervention|transdermal clonidine-|regular antihypertensive treatment
11323293|NCT02545517|Experimental|Conv-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 and JE primary series regimen on days 1 and 29 in the parent study V49_23 were enrolled in the Conv-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
11323506|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
11323294|NCT02545517|Experimental|Acc-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study V49_23 were enrolled in the Acc-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
11323295|NCT02545517|Experimental|Conv-R Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 in the parent study V49_23 were enrolled into the Conv-R Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
11323296|NCT02545504|Experimental|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
11323297|NCT02545504|Placebo Comparator|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
11323298|NCT02545491|Experimental|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
11323299|NCT02545491|Active Comparator|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
11323300|NCT02545478||Infected Group|subjects with suspected infection
11323301|NCT02545478||Non-infected group|subjects without any infection
11323302|NCT02545465||BAY63-2521|Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
11323303|NCT02545452|Experimental|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
11323304|NCT02545452|Experimental|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
11323305|NCT02545452|Experimental|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
11323306|NCT02545452|Experimental|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
11323307|NCT02545439|Experimental|ALKS 5461|Sublingual tablet
11323308|NCT02545426|Active Comparator|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
11323309|NCT02545426|Active Comparator|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
11323310|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
11323311|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
11323312|NCT02545374|Experimental|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.
~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
11323313|NCT02545374|Active Comparator|Control|"In the control arm, patient care depend on his home, as is currently the case:
~If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.
~If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
11323314|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
11323315|NCT02545322|Experimental|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment
~Image-guided adaptive Radiotherapy arm:
~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
11323316|NCT02545309||SSC-CIP|Patients with secondary sclerosing cholangitis in critically ill patients
11323317|NCT02545309||control|Patients with similar degree of critical illness who do not develop secondary sclerosing cholangitis in critically ill patients
11323318|NCT02545296|Other|In-vitro Diagnostics|All infants are recruited into the same arm.
11323319|NCT02545283|Experimental|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
11323320|NCT02545283|Placebo Comparator|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
11324062|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
11323321|NCT02545270|Experimental|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
11323322|NCT02545270|Experimental|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
11323323|NCT02545270|Experimental|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
11323324|NCT02545257|Active Comparator|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
11323325|NCT02545257|No Intervention|Control group (standard care)|Normal, standard care (control group)
11323326|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
11323327|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
11323328|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
11323329|NCT02545231|Active Comparator|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
11323330|NCT02545231|Active Comparator|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
11323331|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
11323332|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
11323333|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
11323334|NCT02545205|Active Comparator|Conventional gait training|
11323335|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
11323336|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
11323337|NCT02545179|Experimental|intervention|web-based daily care training 12 week interactive web based caring training education
11323338|NCT02545179|No Intervention|control|Previous therapy
11323339|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
11323340|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
11323341|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
11323342|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
11323343|NCT02545153|Active Comparator|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
11323344|NCT02545153|Placebo Comparator|Control|Suturing the incision without fibrin glue
11323345|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:
~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
11323346|NCT02545127|Experimental|Merotocin (a selective oxytocin-receptor agonist)|
11323347|NCT02545127|Placebo Comparator|Placebo|
11323348|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
11323349|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
11323350|NCT02545088|Active Comparator|1st control group|
11323351|NCT02545088|Active Comparator|2nd control group|
11323352|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
11323353|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
11323354|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.
~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
11323355|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
11323356|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
11323357|NCT02545049|Placebo Comparator|Placebo|Matching placebo
11323392|NCT02544841|Experimental|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
11323393|NCT02544841|Active Comparator|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
11323394|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
11323358|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
11323359|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
11323360|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
11323361|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
11323362|NCT02544997|Experimental|Poziotinib|12mg P.O. for 2wks q21days
11323363|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
11323364|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
11323365|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
11323366|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
11323367|NCT02544971|Active Comparator|Control group|Treatment as usual
11323368|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
11323369|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
11323370|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
11323371|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
11323372|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
11323373|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
11323374|NCT02544919|No Intervention|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
11323375|NCT02544919|Active Comparator|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
11323376|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
11323377|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
11323378|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
11323379|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
11323380|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
11323381|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
11323382|NCT02544880|Experimental|Phase 1 - Tadalafil + Vaccine|Tadalafil, Anti-MUC1 Vaccine, and Anti-Influenza Vaccine -
11323383|NCT02544880|Experimental|Phase 2 - Arm TV|Tadalafil, Anti-MUC1 Vaccine, and Anti-Influenza Vaccine
11323384|NCT02544880|Placebo Comparator|Phase 2 - Arm TVp|Tadalafil and Vaccine Placebo
11323385|NCT02544880|Placebo Comparator|Phase 2 - Arm TpV|Tadalafil Placebo; Anti-MUC1 Vaccine and Anti-Influenza Vaccine.
11323386|NCT02544880|Other|Non-Randomized Control Group|For eligible participants who opt out of receiving study intervention.
11323387|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
11323388|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
11323389|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
11323390|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
11323391|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
11323396|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for three consecutive days.
11323397|NCT02544815|Placebo Comparator|Placebo|Oral placebo for three days.
11323398|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
11323399|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
11323400|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
11323401|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
11323402|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
11323403|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
11323404|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
11323405|NCT02544750|Experimental|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
11323406|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
11323407|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
11323408|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
11323409|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
11323410|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
11323411|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
11323412|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
11323413|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
11323414|NCT02544685|Active Comparator|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1
~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy
~Prophylaxis duration: 3 months"
11323415|NCT02544685|Placebo Comparator|Placebo group|"Interventions: administration of placebo
~Start: 5 days before or 2 days after starting chemotherapy
~Duration: 3 months"
11323416|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
11323417|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
11323418|NCT02544646|Other|trabeculectomy|
11323419|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
11323420|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
11323421|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
11323422|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
11323423|NCT02544620||Total Hip arthroplasty|"Unselected primary THA
~American Society of Anesthesiologists (ASA) score I/II
~Can be operated as #1 or #2
~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
11323424|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA
~American Society of Anesthesiologists (ASA) score I/II
~Can be operated as #1 or #2
~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
11323425|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA
~American Society of Anesthesiologists (ASA) score I/II
~Can be operated as #1 or #2
~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
11323426|NCT02544607|Experimental|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
11323427|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
11323428|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
11323429|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
11323430|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
11323431|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
11323432|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
11323433|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
11323434|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
11323507|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
11323508|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
11323435|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
11323436|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
11323437|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
11323438|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
11323439|NCT02544529|Experimental|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
11323440|NCT02544529|Placebo Comparator|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
11323441|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
11323442|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
11323443|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
11323444|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
11323445|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
11323446|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
11323447|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
11323448|NCT02544464|Placebo Comparator|Control group|placebo
11323449|NCT02544451|Experimental|LUM/IVA to LUM/IVA|
11323450|NCT02544451|Experimental|Placebo (PBO) to LUM/IVA|
11323451|NCT02544451|No Intervention|Observational Cohort|
11323452|NCT02544438|Experimental|Astarabine|Astarabine
11323453|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase
~Peripheral blood stem cell mobilization:Etoposide
~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
11323454|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
11323455|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
11323456|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
11323457|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
11323458|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
11323459|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
11323460|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
11323461|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
11323462|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
11323463|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
11323464|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
11323465|NCT02544347|Other|Control group|gingival crevicular fluid was collected
11323466|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
11323467|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
11323468|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
11323469|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
11323470|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
11323471|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
11323472|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
11323473|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
11323474|NCT02544308|Active Comparator|No further treatment|No further treatment
11323475|NCT02544308|Experimental|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 & 22 Up to 9 cycles
11323476|NCT02544295|Experimental|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
11323477|NCT02544295|Experimental|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
11323478|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
11323479|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
11323480|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
11323481|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
11323482|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
11323483|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
11323484|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
11323485|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
11323486|NCT02544217|Experimental|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
11323487|NCT02544217|Experimental|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
11323488|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
11323489|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
11323490|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
11323491|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
11323492|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
11323493|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
11323494|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
11323495|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
11323496|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
11323497|NCT02544165|No Intervention|Control group|no intervention group
11323498|NCT02544152|Experimental|Lubiprostone|Participants receive 8 mcg lubiprostone capsules twice daily (BID)
11323499|NCT02544152|Placebo Comparator|Placebo|Participants receive 0 mcg capsules BID
11323500|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
11323501|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
11323502|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
11323503|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
11323504|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
11323505|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
11323509|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
11323510|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
11323511|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
11323512|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
11323513|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
11323514|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
11323515|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
11323516|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
11323517|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
11323518|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
11323519|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
11323520|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
11323521|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
11323522|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
11323523|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
11323524|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
11323525|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
11323526|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
11323527|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
11323528|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
11323529|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
11323530|NCT02544061|Experimental|NM-IL-12 plus Standard of Care (SOC)|"Single 12 µg unit subcutaneous dose of NM-IL-12 plus SOC.
~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
11323531|NCT02544061|Placebo Comparator|Placebo plus SOC|"Single subcutaneous dose of placebo plus SOC
~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
11323532|NCT02544035|Experimental|1|6-11 month-olds
11323533|NCT02544035|Experimental|10|36-71 month-olds (1.5-2 year olds)
11323534|NCT02544035|Experimental|11|72-107 month-olds (6-8 year-olds)
11323535|NCT02544035|Experimental|12|108-144 month-olds (9-12 year-olds)
11323536|NCT02544035|Experimental|2|12-18 month-olds (1-1.5 year olds)
11323537|NCT02544035|Experimental|3|19-35 month-olds (1.5-2 year-olds)
11323538|NCT02544035|Experimental|4|36-71 month-olds (3-5 year-olds)
11323539|NCT02544035|Experimental|5|72-107 month-olds (6-8 year-olds)
11323540|NCT02544035|Experimental|6|108-144 month-olds (9-12 year-olds)
11323541|NCT02544035|Experimental|7|6-11 month-olds
11323542|NCT02544035|Experimental|8|12-18 month-olds (1-1.5 year olds)
11323543|NCT02544035|Experimental|9|19-35 month-olds (1.5-2 year olds)
11323544|NCT02544022||1/Phase 1 Focus Group|Patients with NF1 who have PNs and report experiencing PN related pain and parents ofthese patients. (completed)
11323545|NCT02544022||2/Phase 1 Patients|Patients with NF1 who have PNs
11323546|NCT02544022||3/Phase 1 Parent|Parents of patients in cohort 2
11323547|NCT02544022||4/Phase 2 Patients|Patients with NF1 who have PNs
11323548|NCT02544022||5/Phase 2 Parents|Parents of patients enrolled in cohort 4
11323549|NCT02544009||1|16 subjects who previously participated in the Biggest Loser study
11323550|NCT02543996||Affected or unaffected cohorts (including genetic carriers or|Affected or unaffected cohorts (including genetic carriers or non-carriers as reference biospecimens)
11323551|NCT02543983|Experimental|1|Participants will be administered open-label intravenous ketamine.
11323552|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.
~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.
~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
11323553|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.
~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.
~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
11323554|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
11323555|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
11323556|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
11323557|NCT02543918|Experimental|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.
~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
11323558|NCT02543918|Other|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
11324362|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
11323559|NCT02543905||Family History Cohort|"Men with a family history of prostate cancer defined as:
~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years
~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years
~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
11323560|NCT02543905||Black African / Black Caribbean Cohort|Both parents and all 4 grandparents from that origin
11323561|NCT02543892|Experimental|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
11323562|NCT02543892|Placebo Comparator|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
11323563|NCT02543892|Experimental|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
11323564|NCT02543892|Placebo Comparator|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
11323565|NCT02543892|Experimental|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
11323566|NCT02543892|Placebo Comparator|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
11323567|NCT02543892|Experimental|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
11323568|NCT02543892|Placebo Comparator|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
11323569|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
11323570|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
11323571|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
11323572|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
11323573|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
11323574|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
11323575|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
11323576|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
11323577|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
11323578|NCT02543827|Experimental|MV140 I|The subjects will receive daily dose of MV140 during 6 months
11323579|NCT02543827|Experimental|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
11323580|NCT02543827|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 6 month
11323581|NCT02543801|Active Comparator|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
11323582|NCT02543801|Active Comparator|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
11323583|NCT02543801|Active Comparator|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
11323584|NCT02543801|Active Comparator|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
11323585|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
11323586|NCT02543788|Other|Controls|healthy volunteers
11323587|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
11323588|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.
~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.
~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.
~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
11323589|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.
~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
11323590|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
11323722|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
11323591|NCT02543723|Active Comparator|MEMS Intervention|Participants randomized to the lite group will receive a Medication Event Monitoring System (MEMS) device with feedback. Participants will be advised to only open their pill bottles when they take their medications. Participants will also be given a MEMS diary to record unscheduled cap openings, such as those to refill the bottle, so that those unscheduled events unrelated to adherence can be removed from analysis. The nurse coach will explain to the participant how to interpret the feedback report.
11323592|NCT02543723|Active Comparator|Nurse Coach Intervention|Before beginning their OCA regimen, participants in Arm 2 will be administered a barriers/facilitators screening tool that will help the nurse coach identify specific adherence strategies (i.e. cognitive education, knowledge skills, and affective support) tailored to the participant's needs. Once a tailored intervention plan is developed, participants will receive a 60-minute session conducted by the nurse coach. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first).
11323593|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
11323594|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
11323595|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
11323596|NCT02543684|Experimental|ready to eat mixed meal 1|
11323597|NCT02543684|Experimental|ready to eat mixed meal 2|
11323598|NCT02543684|Experimental|ready to eat mixed meal 3|
11323599|NCT02543684|Experimental|oral glucose load|
11323600|NCT02543671|Active Comparator|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
11323601|NCT02543671|Placebo Comparator|plain cheese|plain (non-fortified) reduced-fat yellow cheese
11323602|NCT02543658|Experimental|Neostigmine|Intramuscular injection of neostigmine on the basis of conventional conservative treatment
11323603|NCT02543658|Other|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
11323604|NCT02543645|Experimental|Varlilumab and Atezolizumab|
11323605|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
11323606|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
11323607|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
11323608|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
11323609|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
11323610|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
11323611|NCT02543593|Experimental|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
11323612|NCT02543593|Sham Comparator|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
11323613|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
11323614|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
11323615|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
11323616|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
11323617|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57
11323618|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57
11323619|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
11323620|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
11323621|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
11323622|NCT02543541|Active Comparator|Standard Supportive Care|
11323623|NCT02543541|Experimental|Structured Supportive Care|
11323624|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
11323625|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
11323754|NCT02542644|Other|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
11323755|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
11323626|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
11323627|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
11323628|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
11323629|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
11323630|NCT02543489|Other|Flex IM Rod|
11323631|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
11323632|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
11323633|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
11323634|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
11323635|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
11323636|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
11323637|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
11323638|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
11323639|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
11323640|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
11323641|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
11323642|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
11323643|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
11323644|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
11323645|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
11323646|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
11323647|NCT02543359|Experimental|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
11323648|NCT02543359|Experimental|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
11323649|NCT02543359|Experimental|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
11323650|NCT02543346|Other|cetirizine hydrochloride|
11323651|NCT02543346|Placebo Comparator|placebo|
11323652|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
11323653|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
11323654|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
11323655|NCT02543320|Experimental|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
11323656|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
11323657|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
11323658|NCT02543294|Experimental|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
11323659|NCT02543294|Experimental|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
11323660|NCT02543294|Experimental|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
11323661|NCT02543281|Active Comparator|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
11323662|NCT02543281|Experimental|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
11323663|NCT02543268|Experimental|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
11323664|NCT02543268|Experimental|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
11323665|NCT02543268|Experimental|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
11323666|NCT02543268|Experimental|Group 4|Placebo (0.9% saline)- single dose IM injection on Day 1 and Day 57
11323667|NCT02543255|Experimental|Abiraterone acetate + prednisone + leuprolide + cabazitaxel|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (20 mg/m2, with 6 mg pegfilgrastim administered 24 h following cabazitaxel) prior to radical prostatectomy.
11323668|NCT02543255|Active Comparator|Abiraterone acetate + prednisone + leuprolide|Participants randomized to this arm will receive abiraterone acetate (1000 mg/day) , prednisone (5 mg twice daily), and leuprolide (22.5 mg every 3 months) prior to radical prostatectomy.
11323669|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
11323670|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
11323671|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
11323672|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
11323673|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
11323674|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
11323675|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
11323676|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
11323677|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
11323678|NCT02543203|Active Comparator|Essential Oil Mixture A|"Topical: Apply 1 drop to the back of the neck and 1 drop to the feet. Rub in the oil for 30 seconds to 1 minute. Each bottle has an orifice that allows the oil to be expelled drop by drop. Dilution is not required, except for the most sensitive skin. Apply in the morning.
~Aromatic Method: Diffuse one diffuser-full (8-12 drops of oil in water) at night."
11323679|NCT02543203|Active Comparator|Essential Oil Mixture B|"Topical: Apply 1 drop to the back of the neck and 1 drop to the feet. Rub in the oil for 30 seconds to 1 minute. Each bottle has an orifice that allows the oil to be expelled drop by drop. Dilution is not required, except for the most sensitive skin. Apply in the morning.
~Aromatic Method: Diffuse one diffuser-full (8-12 drops of oil in water) at night."
11323680|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel
~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
11323681|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
11323682|NCT02543177|Experimental|group A|direct coronary angiography
11323683|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
11323684|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
11323685|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
11323686|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
11323687|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
11323688|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
11323689|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
11323690|NCT02543125|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O,R:30 per minute .
11377461|NCT02185625|Experimental|Safe Delivery smartphone application|
11323691|NCT02543125|Active Comparator|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O.
11323692|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
11323693|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
11323694|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.
~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).
~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
11323695|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
11323696|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
11323697|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
11323698|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
11323699|NCT02543047|Active Comparator|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
11323700|NCT02543047|Active Comparator|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
11323701|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
11323702|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
11323703|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
11323704|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
11323705|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
11323706|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
11323707|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
11323708|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
11323709|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
11323710|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:
~Workflow redesign:
~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms
~Communication improvement:
~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders
~Chronic disease QI projects:
~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
11323711|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
11323712|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
11323713|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
11323714|NCT02542956|Active Comparator|Exparel|Injection of Exparel
11323715|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
11323716|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
11323717|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
11323718|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
11323719|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
11323720|NCT02542917||All patients|IBDoc home test for faecal calprotectin
11323721|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
11324363|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
11323723|NCT02542891|Experimental|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.
~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
11323724|NCT02542891|Active Comparator|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.
~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
11323725|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.
~A brief explanation of this self-application will be showed prior the intervention."
11323726|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
11323727|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
11323728|NCT02542865|No Intervention|Control Group|No treatment was administered
11323729|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
11323730|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
11323731|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
11323732|NCT02542826|Experimental|Pulmonary Rehabilitation|
11323733|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
11323734|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
11323735|NCT02542800|Experimental|Healthy participants|
11323736|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
11323737|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
11323738|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
11323739|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
11323740|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
11323741|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
11323742|NCT02542735||Spanish di@bet.es cohort|Representative of Spanish population
11323743|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
11323744|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
11323745|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
11323746|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
11323747|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
11323748|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
11323749|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
11323750|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
11323751|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
11323752|NCT02542670||control group|Genetic: Whole genome Sequencing
11323753|NCT02542657|Experimental|Treatment (PiC-D therapy)|"Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY:
~Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11377462|NCT02185625|No Intervention|Control|
11323756|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
11323757|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
11323758|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
11323759|NCT02542605|Other|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
11323760|NCT02542605|Placebo Comparator|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
11323761|NCT02542605|Experimental|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
11323762|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
11323763|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
11323764|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
11323765|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
11323766|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
11323767|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
11323768|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
11323769|NCT02542540|No Intervention|Children with OI without training|No training
11323770|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
11323771|NCT02542514|Experimental|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
11323772|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
11323773|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
11323774|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
11323775|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
11323776|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
11323777|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
11323778|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
11323779|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
11323780|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
11323781|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
11323782|NCT02542423|Other|patients undergoing cardiac surgery|
11323783|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
11323784|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
11323785|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
11323786|NCT02542384|Active Comparator|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
11323787|NCT02542384|Active Comparator|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
11323788|NCT02542384|Placebo Comparator|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
11323789|NCT02542371||HIV infected with known subclinical atherosclerosis|
11323790|NCT02542371||HIV infected without known subclinical atherosclerosis|
11323791|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
11323792|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
11323793|NCT02542345|Experimental|magnetic resonance imaging|
11323794|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
11323795|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
11323796|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
11323797|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
11323798|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
11323799|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
11323800|NCT02542293|Experimental|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
11323801|NCT02542293|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
11323802|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
11323803|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
11323804|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
11323805|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
11323806|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
11323807|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
11323808|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
11323809|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
11323810|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
11323811|NCT02542241|Experimental|Sodium Chloride [3%]|
11323812|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
11323813|NCT02542215|Experimental|Cobiprostone 30 mcg four times daily|Cobiprostone oral spray, four times daily, in addition to standard care radiation and chemotherapy
11323814|NCT02542215|Placebo Comparator|Placebo 0 mcg four times daily|Matching placebo oral spray, four times daily, in addition to standard care radiation and chemotherapy
11323815|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
11323816|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
11323817|NCT02542176|Placebo Comparator|Grape Powder Placebo|
11323818|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
11323819|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
11323820|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
11323821|NCT02542124|Experimental|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
11323822|NCT02542111|Experimental|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
11323823|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
11323824|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
11323825|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
11323826|NCT02542072|Active Comparator|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
11323827|NCT02542072|Active Comparator|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
11323828|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
11323829|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
11323830|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
11323831|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
11323832|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
11323833|NCT02542033|Active Comparator|verum|500mL treated apple juice with low sugar content given on one experimental day
11323834|NCT02542033|Placebo Comparator|control|500mL un-treated apple juice with normal sugar content given on one experimental day
11323835|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
11323836|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
11323837|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
11323838|NCT02541968|Active Comparator|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
11323839|NCT02541968|Experimental|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
11323840|NCT02541968|Experimental|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
11323841|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
11323842|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
11323843|NCT02541942|Other|Collection of specimen|
11323844|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
11323845|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
11377785|NCT02183376|Experimental|BI 1356 - moderate liver impairment|
11323846|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
11323847|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
11323848|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
11323849|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
11323850|NCT02541877|Experimental|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
11323851|NCT02541877|Active Comparator|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
11323852|NCT02541877|Active Comparator|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
11323853|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
11323854|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
11323855|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
11323856|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
11323857|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
11323858|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
11323859|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
11323860|NCT02541799|Experimental|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
11323861|NCT02541799|Active Comparator|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
11323862|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
11323863|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
11323864|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
11323865|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
11323866|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
11323867|NCT02541760|No Intervention|Control|No intervention
11323868|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
11323869|NCT02541747|No Intervention|control|Rest as control
11323870|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
11323871|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
11323872|NCT02541721|Experimental|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
11323873|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
11323874|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
11323875|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.
~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
11323904|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
11323905|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
11323876|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.
~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
11323877|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
11323878|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
11323879|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
11323880|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
11323881|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
11323882|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
11323883|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
11323884|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
11323885|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
11323886|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
11323887|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
11323888|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
11323889|NCT02541604|Experimental|Atezolizumab|Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams [mg]) on Day 1 of each 21-day cycle.
11323890|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
11323891|NCT02541591|Active Comparator|Control|MAP>65mmHg
11323892|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11323893|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III
~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
11323894|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
11323895|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
11323896|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
11323897|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
11323898|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
11323899|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
11323900|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
11323901|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
11323902|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
11323903|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
11323906|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
11323907|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
11377786|NCT02183376|Experimental|BI 1356 - severe liver impairment|
11323908|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
11323909|NCT02541435||conventional radiotherapy|450 breast cancer patients treated with conventional radiotherapy with or without anthracyclines and/or trastuzumab during 2007-2012
11323910|NCT02541435||breath controlled radiotherapy|350 breast cancer patients treated with laser assisted breath controlled radiotherapy with or without anthracyclines and/or trastuzumab during 2015-2017
11323911|NCT02541435||controls|per participating patient 2 age-matched female controls from the HUNT-3 population (total 800)
11323912|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
11323913|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
11323914|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
11323915|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
11323916|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
11323917|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
11323918|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
11323919|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
11323920|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
11323921|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
11323922|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
11323923|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
11323924|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
11323925|NCT02541383|No Intervention|Arm A Part 2|Observation
11323926|NCT02541383|Experimental|Arm B Part 2|daratumumab
11323927|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
11323928|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
11323929|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
11323930|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
11323931|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
11323932|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
11323933|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
11323934|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
11323935|NCT02541331|Experimental|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
11323936|NCT02541331|Placebo Comparator|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
11323937|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
11323938|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
11323939|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
11323940|NCT02541305|Experimental|Experimental|Propioceptive program
11323941|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
11323942|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
11323943|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
11323944|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
11323945|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
11323946|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
11323947|NCT02541253|Experimental|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
11323948|NCT02541253|Active Comparator|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
11324028|NCT02540707|Experimental|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
11323949|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
11323950|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
11323951|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
11323952|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
11323953|NCT02541214|Experimental|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
11323954|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
11323955|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
11323956|NCT02541188||breast cancer in young women is in the Maghreb|breast cancer in young women (< 40years old) is in the Maghreb
11323957|NCT02541188||Breast cancer in young women in the western countries|Breast cancer in young women (< 40years old) in the western countries
11323958|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
11323959|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
11323960|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
11323961|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
11323962|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
11323963|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
11323964|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
11323965|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
11323966|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
11323967|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
11323968|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
11323969|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
11323970|NCT02541123||Cohort E|Uninjured control group
11323971|NCT02541097|Active Comparator|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
11323972|NCT02541097|Active Comparator|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
11323973|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
11323974|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
11323975|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
11323976|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
11323977|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
11323978|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
11323979|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
11323980|NCT02541058||Suspected 22q.11.2 deletion/duplication|
11323981|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
11323982|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
11323983|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
11324029|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
11377787|NCT02183363|Experimental|BI 1356 - Tablet TFII|
11323984|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
11323985|NCT02541019|Experimental|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
11323986|NCT02541019|Experimental|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
11323987|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
11323988|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
11323989|NCT02540993|Experimental|BAY94-8862|Finerenone tablet
11323990|NCT02540993|Placebo Comparator|Placebo|Matching placebo
11323991|NCT02540967||BAY86-4875|Gadovist administration goup
11323992|NCT02540954|Experimental|Flexible dosing intervals|Flexible dosing intervals: 2 mg aflibercept (Eylea) injected intravitreally with flexible injection intervals (more than 8 weeks)
11323993|NCT02540954|Experimental|Fixed injection intervals|2 mg aflibercept (Eylea) injected intravitreally with fixed injection intervals (8 weeks ±7 days)
11323994|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
11323995|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
11323996|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
11323997|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
11323998|NCT02540889|Experimental|trial arm|100 hours of therapy.
11323999|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
11324000|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11324001|NCT02540863|Experimental|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:
~Suboccipital release.
~Compression - decompression of temporomandibular joint.
~Horizontal release of temporomandibular joint.
~Deep fascia release in temporal region.
~Masseter deep fascia release.
~Pterygoiddeep fascia release.
~Intraoral pterygoid deep fascia release."
11324002|NCT02540863|Active Comparator|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
11324003|NCT02540850||CRC group|stage 0-IV CRC subjects
11324004|NCT02540850||precancerous disease group|subjects with adenoma or polyps
11324005|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
11324006|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
11324007|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
11324008|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
11324009|NCT02540811|Experimental|dCELL® ACL Scaffold|
11324010|NCT02540785|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
11324011|NCT02540785|Experimental|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
11324012|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
11324013|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
11324014|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
11324015|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
11324016|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
11324017|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
11324018|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
11324019|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
11324020|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
11324021|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
11324022|NCT02540733||Diabetic stroke|
11324023|NCT02540733||Non-diabetic storke|
11324024|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
11324025|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
11324026|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
11324027|NCT02540707|Placebo Comparator|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
11324061|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
11324030|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
11324031|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
11324032|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
11324033|NCT02540668|Experimental|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
11324034|NCT02540668|Experimental|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
11324035|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
11324036|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
11324037|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
11324038|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
11324039|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
11324040|NCT02540629|Experimental|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
11324041|NCT02540616|Experimental|Transcranial Electrical Stimulation-Real|The participant will perform real TES. The forms of TES used in this study will include transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS). Each stimulation session will last for 20-minutes.
11324042|NCT02540616|Sham Comparator|Transcranial Electrical Stimulation-Sham|The participant will perform sham TES for 20-minutes. The form of sham TES will depend on the active arm, e.g. if tACS is on the active arm, then the sham tACS will be a different frequency of stimulation. If tDCS is the active arm, then a short ramp up of tDCS followed by a ramp down (about 60-seconds) will be used as the sham arm.
11324043|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
11324044|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
11324045|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
11324046|NCT02540551|Experimental|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
11324047|NCT02540538|Active Comparator|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
11324048|NCT02540538|Experimental|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
11324049|NCT02540538|Experimental|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.
~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
11324050|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
11324051|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
11324052|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
11324053|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
11324054|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
11324055|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.
~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
11324056|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
11324057|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
11324058|NCT02540473|Experimental|Group therapy|12 week manualized group therapy (one hour per week)
11324059|NCT02540473|Other|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
11324060|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
11324063|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
11324064|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
11324065|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
11324066|NCT02540434|Active Comparator|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
11324067|NCT02540434|Active Comparator|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
11324068|NCT02540421||Case|Recurrent lesions
11324069|NCT02540421||Control|Absence of lesions
11324070|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
11324071|NCT02540395|Active Comparator|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).
~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
11324072|NCT02540395|Experimental|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).
~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
11324073|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).
~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
11324074|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).
~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
11324075|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
11324076|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
11324077|NCT02540356|Experimental|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
11324078|NCT02540356|Experimental|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
11324079|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
11324080|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
11324081|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
11324082|NCT02540330|Active Comparator|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
11324083|NCT02540330|Experimental|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
11324084|NCT02540317|Experimental|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
11324085|NCT02540317|No Intervention|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
11324086|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
11324087|NCT02540304|No Intervention|Business as Usual|Business as usual
11324088|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
11324089|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
11324090|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
11324091|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
11324092|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
11324093|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
11324094|NCT02540239|Placebo Comparator|2L PEG|only used 2L PEG
11324095|NCT02540239|Experimental|Simethione+2L PEG|used 2L PEG+Simethione
11324096|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
11377788|NCT02183363|Experimental|BI 1356 - Tablet iFF|
11324097|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
11324098|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
11324099|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
11324100|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
11324101|NCT02540187||haemophilia A|"Blood specimen for measuring :
~Free TFPI and TFPI activity levels
~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)
~Thrombin generation assay (TGA) in fresh PRP and frozen PPP
~Hemorrhage score for each patient"
11324102|NCT02540187||Haemophilia B|"Blood specimen for measuring :
~Free TFPI and TFPI activity levels
~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)
~Thrombin generation assay (TGA) in fresh PRP and frozen PPP
~Hemorrhage score for each patient"
11324103|NCT02540174|Experimental|Arm A|integrated addiction treatment program
11324104|NCT02540174|Other|Arm B|standard of care
11324105|NCT02540161|Experimental|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
11324106|NCT02540161|Experimental|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
11324107|NCT02540161|Experimental|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
11324108|NCT02540161|Experimental|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
11324109|NCT02540148|Experimental|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
11324110|NCT02540148|Sham Comparator|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
11324111|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
11324112|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
11324113|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
11324114|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
11324115|NCT02540109|Experimental|High-Definition tDCS (Active)|
11324116|NCT02540109|Experimental|High-Definition tDCS (Sham)|
11324117|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
11324118|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
11324119|NCT02540083|Experimental|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
11324120|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
11324121|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
11324122|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
11324123|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
11324124|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
11324125|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
11324126|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
11324127|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.
~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
11324128|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.
~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
11324129|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
11324130|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
11324131|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
11324132|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
11324133|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
11324134|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
11324135|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
11324136|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
11324137|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
11324138|NCT02539966|Experimental|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
11324139|NCT02539966|Experimental|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
11324140|NCT02539966|Experimental|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
11324141|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
11324142|NCT02539927||Controlled|
11324143|NCT02539927||Not controlled|
11324144|NCT02539927||Control status yet to be clarified|
11324145|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
11324146|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
11324147|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
11324148|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
11324149|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
11324150|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
11324151|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
11324152|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
11324153|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
11324154|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
11324155|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
11324156|NCT02539849|Other|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
11324157|NCT02539836|Experimental|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
11324158|NCT02539836|Active Comparator|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
11324159|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
11324160|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
11324161|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
11324162|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.
~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
11324163|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
11324164|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
11324165|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
11324166|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
11324167|NCT02539784|Experimental|Spinal Cord Stimulation|
11324168|NCT02539771|Other|Nocturnal VOC|
11324169|NCT02539771|Other|Diurnal VOC|
11324170|NCT02539771|Other|Slightly symptomatic|
11324171|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
11324172|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
11324173|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
11324174|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
11324175|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
11324176|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
11324177|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
11324178|NCT02539693|Experimental|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
11324179|NCT02539693|Experimental|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
11324180|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
11324181|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
11324182|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
11377789|NCT02183363|Active Comparator|BI 1356 - Tablet TFIIb|
11324183|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
11324184|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
11324185|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
11324186|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
11324187|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
11324188|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
11324189|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
11324190|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
11324191|NCT02539615|Experimental|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
11324192|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
11324193|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
11324194|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
11324195|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
11324196|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
11324197|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
11324198|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
11324199|NCT02539550|Placebo Comparator|Placebo|Placebo
11324200|NCT02539550|Experimental|PF-06266047|PF-06266047
11324201|NCT02539537|Active Comparator|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8 and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
11324202|NCT02539537|Experimental|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 min. The irinotecan will begin 30 min. after the start of the folinic acid infusion.
~5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.
~Treatment will be continued for 24 weeks (12 cycles)."
11324203|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
11324204|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
11324205|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
11324206|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
11324207|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
11324208|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
11324209|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
11324210|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
11324211|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
11324212|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
11324213|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
11324214|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
11324215|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
11324216|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
11377790|NCT02183350|Experimental|BI 1356 BS - single rising dose|
11324217|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
11324218|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral
~Pharmacokinetics"
11324219|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
11324220|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
11324221|NCT02539381|Other|Gold Standard Assessments|"Formal perimetry (Goldman or Octopus visual field)
~Albert's visual inattention test
~Star cancellation visual inattention test
~line bisection test
~These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.
~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.
~Researcher will record a score (0-10) to quantify the participant's compliance"
11324222|NCT02539381|Other|Usual Clinical Screening Practice|"Visual field assessment to confrontation
~Visual inattention assessment to bilateral stimuli
~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.
~Researcher will record a score (0-10) to quantify the participant's compliance"
11324223|NCT02539381|Other|Stroke Vision App|"Digital tumbling E visual accuity assessment
~Digital visual field assessment
~Digital line crossing assessment
~Digital shape cancellation assessment
~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.
~Researcher will record a score (0-10) to quantify the participant's compliance"
11324224|NCT02539368||CT-P13|biosimilar infliximab
11324225|NCT02539368||Remicade|infliximab
11324226|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
11324227|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
11324228|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
11324229|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
11324230|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
11324231|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
11324232|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
11324233|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
11324234|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
11324235|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
11324236|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
11324237|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
11324238|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
11324239|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
11324240|NCT02539238|Active Comparator|control|Annual BLS training
11324241|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
11324242|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.
~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
11324243|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.
~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
11324244|NCT02539212|Active Comparator|microwave ablation|microwave ablation
11324245|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
11324246|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
11324247|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
11324248|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
11324249|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
11324358|NCT02538523|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
11324250|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
11324251|NCT02539160|Active Comparator|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
11324252|NCT02539160|Experimental|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
11324253|NCT02539160|Active Comparator|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
11324254|NCT02539160|Experimental|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
11324255|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
11324256|NCT02539134|Experimental|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
11324257|NCT02539134|Experimental|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
11324258|NCT02539134|Experimental|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
11324259|NCT02539134|Experimental|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
11324260|NCT02539134|Experimental|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
11324261|NCT02539134|Experimental|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
11324262|NCT02539134|Experimental|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
11324263|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
11324264|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
11324265|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
11324266|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
11324267|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
11324268|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
11324269|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
11324270|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
11324271|NCT02539069|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
11324272|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
11324273|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
11324274|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
11324275|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
11324276|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
11324277|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
11324278|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
11324279|NCT02538991|Experimental|Bulkamid|
11324280|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
11324281|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
11324282|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
11324283|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
11324364|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
11377791|NCT02183350|Placebo Comparator|Placebo|
11324284|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
11324285|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
11324286|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
11324287|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
11324288|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11324289|NCT02538913|Experimental|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
11324290|NCT02538913|Active Comparator|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
11324291|NCT02538900|Experimental|Group 1|Low-intensity, self-paced walking exercise. Home based exercise.
11324292|NCT02538900|Experimental|Group 2|Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.
11324293|NCT02538900|Active Comparator|Group 3|Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.
11324294|NCT02538887||Radio Frequency Surgical Detection|
11324295|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
11324296|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
11324297|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
11324298|NCT02538861|Active Comparator|ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
11324299|NCT02538861|Active Comparator|ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
11324300|NCT02538861|Active Comparator|ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
11324301|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
11324302|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
11324303|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
11324304|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
11324305|NCT02538835|Experimental|Metacognitive Therapy|
11324306|NCT02538835|Active Comparator|Mindfulness based cognitive therapy|
11324307|NCT02538835|Placebo Comparator|Support groups|
11324308|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
11324309|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
11324310|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
11324311|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
11324312|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
11324313|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
11324314|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
11324315|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
11324316|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
11324359|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11324360|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
11324317|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
11324318|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
11324319|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
11324320|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
11324321|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
11324322|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
11324323|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
11324324|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
11324325|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
11324326|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
11324327|NCT02538705|Experimental|Neovasculgen|
11324328|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
11324329|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
11324330|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
11324331|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
11324332|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
11324333|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
11324334|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
11324335|NCT02538666|Placebo Comparator|Placebo|Placebo
11324336|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
11324337|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
11324338|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
11324339|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
11324340|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
11324341|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
11324342|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
11324343|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
11324344|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
11324345|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
11324346|NCT02538614|Experimental|Phase 1b: Idelalisib + BI 836826|Participants will receive escalating dose of idelalisib at dose levels, 50 mg, 100 mg, and 150 mg + BI 836826 10 mg on Day 8, 50 mg on Day 9 and Day 15, and 100 mg on Day 22, every 2 weeks through Week 18, and every 4 weeks through Week 46. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
11324347|NCT02538614|Experimental|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
11324348|NCT02538601|Experimental|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
11324349|NCT02538601|Active Comparator|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
11324350|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
11324351|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
11324352|NCT02538575|Experimental|6-minute walk test|
11324353|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
11324354|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
11324355|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
11324356|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
11324357|NCT02538523|Active Comparator|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
11324365|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.
~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.
~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
11324366|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
11324367|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.
~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
11324368|NCT02538445|Experimental|Patients group 1|Memorization of the verbs by miming the action
11324369|NCT02538445|Experimental|Patients group 2|Memorization of the verbs by imagining the action
11324370|NCT02538445|Experimental|Patients group 3|Memorization of the action verbs by means of another word
11324371|NCT02538445|Experimental|Patients group 4|Simple memorization of the verbs
11324372|NCT02538445|Active Comparator|Healthy volonteers group 1|Memorization of the verbs by miming the action
11324373|NCT02538445|Active Comparator|Healthy volonteers group 2|Memorization of the verbs by imagining the action
11324374|NCT02538445|Active Comparator|Healthy volonteers group 3|Memorization of the action verbs by means of another word
11324375|NCT02538445|Active Comparator|Healthy volonteers group 4|Simple memorization of the verbs
11324376|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
11324377|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
11324378|NCT02538419|Active Comparator|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.
~All participants will receive CPAP in addition to this intervention."
11324379|NCT02538419|Active Comparator|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.
~All participants will receive CPAP in addition to this intervention."
11324380|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
11324381|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
11324382|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
11324383|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
11324384|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
11324385|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
11324386|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
11324387|NCT02538367|Experimental|YH12852 IR 0.05mg|Once daily
11324388|NCT02538367|Experimental|YH12852 IR 0.1mg|Once daily
11324389|NCT02538367|Experimental|YH12852 IR 0.3mg|Once daily
11324390|NCT02538367|Experimental|YH12852 IR 0.5mg|Once daily
11324391|NCT02538367|Experimental|YH12852 IR 1mg|Once daily
11324392|NCT02538367|Experimental|YH12852 IR 2mg|Once daily
11324393|NCT02538367|Experimental|YH12852 IR 3mg|Once daily
11324394|NCT02538367|Experimental|YH12852 DR1 0.5mg|Once daily
11324395|NCT02538367|Experimental|YH12852 DR1 1mg|Once daily
11324396|NCT02538367|Experimental|YH12852 DR1 2mg|Once daily
11324401|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
11324402|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
11324403|NCT02538341|Active Comparator|Zoster Vaccine Live (Zostavax)|Zostavax (zoster vaccine live) is used to prevent herpes zoster virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active Herpes Zoster Vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
11324404|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
11324405|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
11324406|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
11324407|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and [18F]FDOPA PET/CT
11324408|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
11324409|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
11324410|NCT02538289|Other|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
11324411|NCT02538289|Other|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
11324412|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
11324413|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
11324414|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
11324415|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
11324416|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
11324417|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
11324418|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
11324419|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
11324420|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
11324421|NCT02538211|Placebo Comparator|Control|"Control group - subjects will receive no antibiotics
~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
11324422|NCT02538211|Active Comparator|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:
~Ciprofloxacin 500mg 2dd1
~Vancomycin 250mg 3dd2
~Metronidazole 500mg 3dd1
~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
11324423|NCT02538211|Active Comparator|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:
~• Vancomycine 250mg 3dd2
~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
11324424|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
11324425|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);
~Left forearm, ID with classical syringe filled with vaccine (0.1mL);
~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
11324426|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);
~Left forearm, ID with classical syringe filled with placebo (0.1mL);
~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
11324427|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);
~Left forearm, ID with classical syringe filled with placebo (0.1mL);
~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
11324428|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
11324429|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
11324430|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
11324431|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
11324432|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
11324433|NCT02538133|Experimental|99mTc-Exametazime (HMPAO)-labeled leucocytes|
11324434|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
11324435|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
11324436|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
11377926|NCT02182518|Experimental|Epinastine|
11324437|NCT02538094|Sham Comparator|Sham Stimulation First|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS first and then Anodal Stimulation second.
11324438|NCT02538094|Experimental|Anodal Stimulation First|Transcranial direct current stimulation using Anodal stimulation first over the area of interest and then Sham Stimulation second.
11324439|NCT02538081|Active Comparator|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
11324440|NCT02538081|Active Comparator|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
11324441|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
11324442|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
11324443|NCT02538055|Placebo Comparator|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
11324444|NCT02538055|Experimental|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
11324445|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
11324446|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
11324447|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
11324448|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
11324449|NCT02538016|Other|Tolvaptan|
11324450|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)
~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
11324451|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)
~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
11324452|NCT02537977|Experimental|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
11324453|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
11324454|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
11324455|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
11324456|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
11324457|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
11324458|NCT02537938|Experimental|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
11324459|NCT02537938|No Intervention|Placebo|Placebo comparator given once a day for 14 days as a capsule.
11324460|NCT02537925|Active Comparator|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
11324461|NCT02537925|Experimental|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
11324462|NCT02537912|Active Comparator|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
11324463|NCT02537912|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
11324464|NCT02537899|Other|Treatment|NeuroAiD
11324465|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
11324466|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.
~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
11324467|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
11324468|NCT02537860|Experimental|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
11324469|NCT02537860|Experimental|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
11324535|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
11324975|NCT02534480|Active Comparator|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
11324470|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
11324471|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
11324472|NCT02537834|Experimental|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
11324473|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
11324474|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
11324475|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
11324476|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
11324477|NCT02537782|Other|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
11324478|NCT02537769|Experimental|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
11324479|NCT02537769|Active Comparator|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
11324480|NCT02537756|Experimental|1- Verbalize, Choice|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
11324481|NCT02537756|Experimental|2- Listen, Choice|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics they choose
11324482|NCT02537756|Experimental|3- Verbalize, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
11324483|NCT02537756|Experimental|4- Listen, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics assigned to them
11324484|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
11324485|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
11324486|NCT02537717|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
11324487|NCT02537717|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
11324488|NCT02537704|Experimental|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.
~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).
~The lifestyle objectives for participants will be as follows:
~To lose 5-10% of initial weight through healthy eating.
~To do 150 minutes of physical activity each week."
11324489|NCT02537691|Other|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of >/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
11324490|NCT02537678|Experimental|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
11324491|NCT02537678|Active Comparator|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
11324492|NCT02537665|Other|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
11324493|NCT02537665|Placebo Comparator|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
11324494|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
11324495|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
11324496|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
11324497|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
11324498|NCT02537626|Active Comparator|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
11324499|NCT02537626|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
11324536|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
11324500|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
11324501|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
11324502|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
11324503|NCT02537600|Experimental|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :
~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
11324504|NCT02537587|Active Comparator|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
11324505|NCT02537587|Active Comparator|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
11324506|NCT02537587|Experimental|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
11324507|NCT02537587|Experimental|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
11324508|NCT02537587|Experimental|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
11324509|NCT02537587|Experimental|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
11324510|NCT02537587|Experimental|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
11324511|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
11324512|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
11324513|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
11324514|NCT02537561|Experimental|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"Dose levels of the drugs will be dependent on which dose level the participants is enrolled.
~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.
~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.
~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.
~Cisplatin and gemcitabine will be given for a total of 6 cycles.
~Talazoparib may be continued as a single agent maintenance therapy."
11324515|NCT02537561|Experimental|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study
~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.
~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.
~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.
~Cisplatin and gemcitabine will be given for a total of 6 cycles.
~Talazoparib may be continued as a single agent maintenance therapy."
11324516|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
11324517|NCT02537522|Experimental|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
11324518|NCT02537522|Experimental|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
11324519|NCT02537522|Experimental|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
11324520|NCT02537522|Experimental|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
11324521|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
11324522|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
11324523|NCT02537496|Experimental|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
11324524|NCT02537496|Sham Comparator|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
11324525|NCT02537496|No Intervention|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
11324526|NCT02537483|Experimental|IDP-120 Gel|IDP-120 Gel, applied topically to the face once daily for 12 weeks.
11324527|NCT02537483|Active Comparator|IDP-120 Component A|IDP-120 Component A, applied topically to the face once daily for 12 weeks
11324528|NCT02537483|Active Comparator|IDP-120 Component B|IDP-120 Component B, applied topically to the face once daily for 12 weeks
11324529|NCT02537483|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks
11324530|NCT02537470|Other|Arm 1|Placebo
11324531|NCT02537470|Experimental|Arm 2|Biphasic remogliflozin etabonate
11324532|NCT02537457|Experimental|BAY59-7939 Rivaroxaban granule|
11324537|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks
~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
11324538|NCT02537405|Experimental|BAY59-7939 granule|
11324539|NCT02537405|Active Comparator|BAY59-7939 tablet|
11324540|NCT02537392|Experimental|Vitamin B Complex and Folic Acid|Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
11324541|NCT02537392|Experimental|Iron and Folic Acid|Daily supplements of iron (60 mg) and folic acid (0.4 mg).
11324542|NCT02537392|Active Comparator|Folic Acid|Daily supplement of 0.4 mg folic acid.
11324543|NCT02537379||SOF+COPE|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
11324544|NCT02537366|Placebo Comparator|Placebo|Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
11324545|NCT02537366|Experimental|DEX|Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
11324546|NCT02537353|Placebo Comparator|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
11324547|NCT02537353|Active Comparator|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
11324548|NCT02537340||EMVI-MR positive|Patients with primary rectal cancer and extramural vascular invasion detected by staging MR
11324549|NCT02537340||EMVI-MR negative|Patients with primary rectal cancer and without extramural vascular invasion detected by staging MR
11324550|NCT02537314|Active Comparator|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
11324551|NCT02537314|Placebo Comparator|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
11324552|NCT02537301||ERCP-chat group|All the doctors who finished their ERCP training in Xijing Hospital of Digestive Diseases and were invited to join in a chatting group in a mobile social app (Wechat).
11324553|NCT02537288|Experimental|Placebo matched to fedovapagon|One dose of placebo (matched to fedovapagon)
11324554|NCT02537288|Experimental|Fedovapagon 2 mg|One dose of 2 mg fedovapagon
11324555|NCT02537288|Experimental|Fedovapagon 20 mg|One dose of 20 mg fedovapagon
11324556|NCT02537288|Experimental|Moxifloxacin 400 mg (open label)|One dose of moxifloxacin 400 mg (open label)
11324557|NCT02537275|Experimental|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
11324558|NCT02537262|Experimental|carbohydrate group|
11324559|NCT02537262|Placebo Comparator|NPO(None Per Oral) group|
11324560|NCT02537249|Experimental|Dexmedetomidine|
11324561|NCT02537249|Sham Comparator|Saline 0.9%|
11324562|NCT02537236|Experimental|Group one|20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids
11324563|NCT02537236|Active Comparator|Group two|20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids
11324564|NCT02537236|Experimental|Group three|20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.
11324565|NCT02537236|Active Comparator|Group four|20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids
11324566|NCT02537236|Placebo Comparator|Group five|20 subjects, control group received conventional diet.
11324567|NCT02537223|Experimental|BYL719, Cisplatin, and Radiation Therapy|BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.
11324568|NCT02537210|Active Comparator|Mesalazine|mesalazine 2g od po for 12 months
11324569|NCT02537210|Placebo Comparator|Placebo oral capsule|placebo 5 capsules od po for 12 months
11324570|NCT02537197|Experimental|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
11324571|NCT02537184|Other|Group 1 - Recall Interval of 4 months|"Oral clinical conditions:
~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
11324764|NCT02535845|Active Comparator|Information only group|HPV information only in a tablet-based application (HPV Informational Video)
11324572|NCT02537184|Other|Group 2 - Recall Interval of 8 months|"Oral clinical conditions:
~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
11324573|NCT02537171|Active Comparator|Apatinib 750mg group|Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).
11324574|NCT02537171|Active Comparator|Apatinib 500mg group|Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
11324575|NCT02537158|Experimental|sorafenib group|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
11324576|NCT02537158|Experimental|TACE group|TACE group patients will accept TACE therapy once at a month after resection.
11324577|NCT02537158|No Intervention|control group|Control group patients will not accept any intervention,except necessary supportive treatment.
11324578|NCT02537145||Obese pregnant women|20 obese pregnant women (BMI ≥ 30)
11324579|NCT02537145||Lean pregnant women|20 lean pregnant women (BMI 18,5 - 25)
11324580|NCT02537132|Experimental|Home Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home
11324581|NCT02537132|Active Comparator|Outpatient Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic
11324582|NCT02537119|Experimental|Dynamic massage therapy|Rubbing on hamstrings combined with articular movement
11324583|NCT02537119|Active Comparator|Massage therapy|Rubbing on hamstrings
11324584|NCT02537106|Experimental|1.5% NaCl|After standardized induction to general anesthesia group A patients will be given the infusion of hyperosmotic 1.5% NaCl 5 ml/kg/BW during 15 min.
11324585|NCT02537106|Experimental|3% NaCl|After standardized induction to general anesthesia group B patients will be given the infusion of hyperosmotic 3% NaCl 5 ml/kg/BW during 15 min.
11324586|NCT02537093|Active Comparator|Synchronous telepsychiatry (STP)|Control Arm/Synchronous telepsychiatry (STP): After baseline assessment, subjects will be assessed by a psychiatrist using live interactive videoconferencing every 6 months for a 1 year follow up (3 STP assessments: baseline plus 2 assessments). A report with treatment recommendations following American Psychiatric Association guidelines will be sent to the PCP who will be able to have adlib telephone or email consultations with the telepsychiatrist. The telepsychiatrist will have access to all previous clinical information about the patients.
11324587|NCT02537093|Experimental|Asynchronous telepsychiatry (ATP)|Intervention Arm (ATP): All ATP assessments at 6 monthly intervals post baseline will be conducted by an ATP trained clinician. This interview will be video recorded.The ATP clinicians will then fill out a standardized medical template that will be reviewed by a psychiatrist who will provide a written assessment and psychiatric treatment plan. He will have access to any previous assessments and the PCP will also have continuing access to this psychiatrist by phone or email between the 3 consultations.
11324588|NCT02537080|Experimental|Nimodipine group|1 tbl of 30 mg nimodipine will be administered orally with premedication
11324589|NCT02537080|Experimental|Control group|1 tbl of placebo will be administered orally with premedication
11324590|NCT02537067|Experimental|Autologous cultured Chondrocyte|Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant.
11324591|NCT02537054|Experimental|Aflibercept|2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use
11324592|NCT02537041|Other|healthy volunteers|to obtain normal values diastolic myocardial stiffness references. The objective will be to confirm the increase with age in myocardial stiffness assessed by elastography in healthy subjects.
11324593|NCT02537041|Other|diastolic Heart Failure|older patients with isolated diastolic HF (EF> 45%, 60-80 years, n = 20) and infiltrative cardiomyopathy restrictive-type amyloidosis (n = 20) . The objective will be to study the results of elastography on two separate clinical types of IC diastolic well identified.
11324594|NCT02537041|Other|systolic Heart Failure|"elderly patients with heart failure with impaired ejection (<45%) fraction, but no segmental dysfunction.
~The evaluation of myocardial stiffness by elastography in all these patients will be compared to conventionally ultrasound and biological parameters currently used for diagnosis of elderly's diastolic HF"
11324595|NCT02537028|Experimental|MSC2364447C 25 mg|
11324596|NCT02537028|Experimental|MSC2364447C 75 mg|
11324597|NCT02537028|Placebo Comparator|Placebo|
11324598|NCT02537015|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
11324599|NCT02537002|Experimental|Cohort 1- PF-05230907 or Placebo|
11324600|NCT02537002|Experimental|Cohort 2- PF-05230907 or Placebo|
11324601|NCT02536989|Experimental|1|receive high dose PPI treament with intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
11324602|NCT02536989|Active Comparator|2|receive usual dose PPI treatment with ntravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
11324603|NCT02536976|Experimental|Active treatment|mirabegron
11324604|NCT02536976|Placebo Comparator|Placebo|Matching placebo
11324605|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
11324606|NCT02536950|No Intervention|Blinded Sensor|Subjects will wear a blinded Dexcom G4P (Generation 4 Platinum) AP (Artificial Pancreas) glucose sensor for a week
11324822|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
11324607|NCT02536950|Experimental|Fixed set point|Subjects will be in a hotel and use a fixed set point for glucose control for two days initialized at 130 mg/dl. The setpoint will be adjusted, if necessary, over the two days in the hotel before they are sent home for 5 days
11324608|NCT02536950|Experimental|Variable Set Point|"Subjects will begin using a variable setpoint which will make adjustments based on their past glucose control over the previous day"
11324609|NCT02536937|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
11324610|NCT02536937|Experimental|GZ385660 (subjects with mild renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
11324611|NCT02536937|Experimental|GZ385660 (subjects with moderate renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
11324612|NCT02536937|Experimental|GZ385660 (subjects with severe renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
11324613|NCT02536924|Experimental|Waiting room intervention plus TAU|The treatment group will receive waiting room intervention plus treatment as usual.
11324614|NCT02536924|Experimental|Only TAU.|The control group will receive only treatment as usual.
11324615|NCT02536911|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
11324616|NCT02536911|Experimental|GZ385660 (subjects with mild hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
11324617|NCT02536911|Experimental|GZ385660 (subjects with moderate hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
11324618|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice
~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.
~Blood samples
~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)
~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug
~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5
~Fracture patients with reduced kidney function will be treated with anti-RANKL
~Anti-osteoporosis drug prescribed by hospital physician
~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year
~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
11324619|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
11324620|NCT02536885|Experimental|Liberal group|During the surgery, blood pressure of the patients will be maintained within ± 25% of the patient's normal blood pressure.
11324621|NCT02536885|Experimental|Restrictive group|During the surgery, blood pressure of the patients will be maintained within ± 10% of the patient's normal blood pressure.
11324622|NCT02536859|Experimental|IDeg|
11324623|NCT02536859|Active Comparator|IGlar U300|
11324624|NCT02536846|Experimental|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
11324625|NCT02536833|Experimental|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
11324626|NCT02536833|Experimental|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
11324627|NCT02536833|Experimental|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
11324628|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
11324629|NCT02536820|Other|Conventional treatment + PNIT|PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved
11324630|NCT02536820|Active Comparator|Conventional treatment|Conventional treatment: Usual treatment that each diabetic patient recieved
11324631|NCT02536807|Experimental|Hyaluronan|Hyaluronan gel injection
11324632|NCT02536807|Placebo Comparator|Control|Control placebo gel injection
11324633|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
11324634|NCT02536781|Placebo Comparator|Placebol|Placebo
11324635|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
11324636|NCT02536768|Experimental|Intervention|Minimum package of interventions to improve ART adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
11324637|NCT02536768|No Intervention|Comparison|Standard of care HIV treatment
11324638|NCT02536755|Experimental|eliglustat|Cytochrome P450 (CYP) 2D6 Intermediate (IM), Extensive (EM) and Ultra-Rapid (URM) Metaboliser patients will be treated at 84 mg twice daily. CYP2D6 Poor Metabolisers (PM) will be treated at 84 mg once daily.
11324639|NCT02536742|Experimental|Experimental|Palbociclib plus Fulvestrant
11324640|NCT02536729||Oral Sodium Phosphate - Normal preparation|Oral sodium phospate exposure with special diet (Liquid)
11324641|NCT02536729||Oral Sodium Phosphate - Modified preparation|Oral sodium phospate exposure with special diet (Liquid), but the participant can normally lunch the day before the test
11324642|NCT02536729||polyethylene glycol + Electrolytes|polyethylene glycol + Electrolytes exosure with special diet (Liquid)
11324643|NCT02536716|Active Comparator|Platform-matched dental implant|Platform-matched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
11324644|NCT02536716|Experimental|Platform-switched dental implant|Platform-switched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
11324645|NCT02536703|Experimental|Lotus Valve System|Transcatheter Aortic Valve Implantation (TAVI) with Lotus Valve System
11324646|NCT02536690|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 1 mg/kg and will be adjusted as described in summary.
11377927|NCT02182505|Experimental|Berodual® Respimat®, low dose|
11324647|NCT02536690|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary.
11324648|NCT02536690|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by midazolam 0.03 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.
~Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary."
11324649|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
11324650|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
11324651|NCT02536638||Pyelonephritis Group|patients with pyelonephritis
11324652|NCT02536638||Without pyelonephritis Group|patients without pyelonephritis
11324653|NCT02536625||Everolimus|Immunomonitoring
11324654|NCT02536612|Experimental|Lottery|"Conditional economic incentive (CEI) lotto arm participants will get a chance to win a type of lottery or lotto ticket with a 50% chance of winning each time: (a) if they come back to the clinic and are still using a modern contraception method after 3 months (including IUD, injectable contraceptive, or implant); (b) if they come back to the clinic and are still using modern contraception after 6 months; and (c) if they come back to the clinic at 6 months and they don't have a new curable STD (such as syphilis).
~They will also will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months."
11324655|NCT02536612|Active Comparator|No Lottery|Participants in the Control (No CEI Lotto) group will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months; they will NOT have a chance to win a lottery even if they are still using a modern contraception and are free of new curable STDs.
11324656|NCT02536586|Experimental|LY3023414|LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
11324657|NCT02536573|No Intervention|Control|Intraoperative fluoroscopy of the hip is used to visually estimate the acetabular cup angle and make any necessary adjustments.
11324658|NCT02536573|Experimental|Radlink Surgical Positioning System|Fluoroscopic image of the hip joint is imported into the Radlink Surgical Positioning software. The software calculates a target cup position using bony landmarks, and the surgeon matches the cup to the target.
11324659|NCT02536560||Antibiotics|150 infants, (because of hospital protocol) treated with antibiotics because of a perinatal infection during the first week of life
11324660|NCT02536560||Controls|The control group comprises 300 healthy newborns, born in the hospital and needing clinical observation for 24-48 hours for several reasons like maternal comorbidity, low probability of neonatal infection, blood sugar monitoring, meconium containing amniotic fluid, or delivery by caesarean section
11324661|NCT02536547||patients with suspected VAP|"All patients with suspected VAP will be included in the study (new or extension of a radiological image in a patient in mechanical ventilation for at least 48 hours associated with at least two of the following:criteria :
~fever ≥38.5 ° C or <36, 5 ° C leukocytosis> 10 * 103 / ml or leukopenia <4 * 103 / ml secretions purulent tracheal reduction in PaO2 / FiO2 <300 or PaO 2 <60 mmHg"
11324662|NCT02536534||Patients with PAH and CTEPH|Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
11324663|NCT02536521||Hemodynamically stable|
11324664|NCT02536521||Hemodynamically unstable|Hemodynamically unstable patients are defined as those with a 20% decrease in systolic blood pressure according to the change of intraabdominal pressure.
11324665|NCT02536508|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
11324666|NCT02536508|Experimental|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
11324667|NCT02536508|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
11324668|NCT02536495|Experimental|Treatment (docetaxel, selinexor)|Patients receive docetaxel IV on day 1 and selinexor PO BID on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11324669|NCT02536482|Experimental|Amix|Dietary supplement. The formula is based in free amino-acid to treat children with cow's milk allergy. The children should have a minimum consumption of 400 mL, daily.
11324670|NCT02536469|Experimental|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
11324671|NCT02536430|Active Comparator|Buccal infiltration of Ketorolac|A buccal infiltration of 30 mg/mL of Ketorolac Tromethamine was applied for the patients in case group.
11324672|NCT02536430|Placebo Comparator|buccal infiltration of Normal Saline|A buccal infiltration of Normal Saline was applied for the patients in control group.
11324673|NCT02536417|Active Comparator|Treatment arm: melatonin|melatonin 0.5 mg as treatment, to be given daily at bedtime
11324674|NCT02536417|Placebo Comparator|Placebo arm|Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm
11324675|NCT02536404|Experimental|Etrasimod (APD334) High Dose|
11324676|NCT02536404|Active Comparator|Placebo|
11324677|NCT02536391|Experimental|Sequence 1: Tablet/Capsule/Tablet with food|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
11324678|NCT02536391|Experimental|Sequence 2: Tablet/Tablet with food/Capsule|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.
11324679|NCT02536391|Experimental|Sequence 3: Capsule/Tablet/Tablet with food|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
11324823|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
11324680|NCT02536391|Experimental|Sequence 4: Capsule/Tablet with food/Tablet|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.
11324681|NCT02536391|Experimental|Sequence 5: Tablet with food/Tablet/Capsule|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.
11324682|NCT02536391|Experimental|Sequence 6: Tablet with food/Capsule/Tablet|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.
11324683|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
11324684|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
11324685|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
11324686|NCT02536352|Experimental|Fluoride prenatal vitamin|Prenatal vitamin-mineral containing 3 mg fluoride
11324687|NCT02536352|Active Comparator|Standard prenatal vitamin|Prenatal vitamin-mineral containing 0 mg fluoride
11324688|NCT02536339|Experimental|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
11324689|NCT02536326|Experimental|renal denervation|
11324690|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
11324691|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
11324692|NCT02536300|Experimental|Idelalisib 150 mg Continuously|"Participants will receive idelalisib 150 mg twice daily continuously.
~For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily."
11324693|NCT02536300|Experimental|Idelalisib 100 mg|"Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily.
~As of protocol amendment 5, enrollment to this arm has been closed."
11324694|NCT02536300|Experimental|Idelalisib 150 mg 28-Day Cycles|Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.
11324695|NCT02536287|Experimental|total PTX without autotransplantation|all parathyroid glands were found and removed
11324696|NCT02536287|Active Comparator|total PTX with autotransplantation|all parathyroid glands were found and removed,and then a portion of it is sliced into 1*1*1 mm pieces for autotransplantation
11324697|NCT02536274|Experimental|Schwertbad Aachen|20 Patients with specific back pain will get Lumbo Sensa® bandage. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
11324698|NCT02536274|Experimental|Schön Klinik Fürth|20 Patients with specific back pain will get Dynaflex® flexion orthosis. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
11324699|NCT02536274|No Intervention|Schön Klinik Fürth & Schwertbad Aachen|20 Patients with specific back pain will get no intervention. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
11324700|NCT02536274|No Intervention|RPE|20 healthy Subjects of the same age without back pain participate in the course for one time to prove the significance of the procedures. (control group) Study related procedures include a course with 6 exercises: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
11324701|NCT02536261||Withdrawal group|Withdrawal observation after reaching the withdrawal standard
11324702|NCT02536261||Continue treatment group|Continue treatment obsevation after reaching the withdrawal standard
11324703|NCT02536248|Experimental|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks
~Wash-out 14 days
~Placebo for 6 weeks"
11324704|NCT02536248|Placebo Comparator|Placebo first, then Sitagliptin|"Placebo for 6 weeks
~Wash-out 14 days
~Sitagliptin 100 mg/d for 6 weeks"
11324705|NCT02536235|Experimental|Intervention: intraoperative topical heat|
11324706|NCT02536235|No Intervention|Control: no intraoperative heat|
11324824|NCT02535468||Prospective Arm|
11324707|NCT02536222|Experimental|Reactive case investigation : FT/FDA with DHA-PQ|All consenting household members eligible to receive DHA-PQ and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHA-PQ. If no one in the household tests RDT positive then no one in the household will receive DHA-PQ.
11324708|NCT02536222|No Intervention|No Intervention: Standard of Care (Control)|The standard of care arm will have the standard of care offered by the Ministry of Health which applies to all arms. This includes available mosquito net coverage and passive case detection of individuals seeking treatment from a health provider at a health post or community.
11324709|NCT02536209|Experimental|Regimen 1|Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
11324710|NCT02536209|Experimental|Regimen 2|Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
11324711|NCT02536209|Experimental|Regimen 3|Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
11324712|NCT02536209|Experimental|Regimen 4|Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
11324713|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
11324714|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
11324715|NCT02536183|Experimental|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
11324716|NCT02536183|Experimental|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
11324717|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
11324718|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
11324719|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
11324720|NCT02536157|Active Comparator|Dorsal block splint|Thermoplastic splint in 20 degrees flexion applied to the dorsum of the PIPJ.
11324721|NCT02536157|Experimental|Volar gutter splint|Thermoplastic splint in 0 degrees flexion applied to the volar surface of the finger.
11324722|NCT02536144|Experimental|MCCES|Magnetic -controlled capsule endoscopy system (MCCES) is a robot system that the capsule would be swallowed to observe the mucosa of the human alimentary canal especially the colon under the control of the magnetic-manipulator.
11324723|NCT02536144|Active Comparator|Colonoscopy|Colonoscopy has now been in use for many years to visualize and diagnose abnormalities of the colon and it is the gold standard for detecting colorectal lesions.In this study,the additional utility of the colonoscopy is to monitor the movement of the Magnetic -controlled capsule endoscopy.
11324724|NCT02536131|Other|Study group|7-10 sessions gut-directed hypnotherapy within 12 weeks
11324725|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
11324726|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
11324727|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
11324728|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
11324729|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
11324730|NCT02536092|Experimental|755nm and 1064nm Nd:YAG laser|755nm and 1064nm Nd:YAG laser
11324731|NCT02536066|No Intervention|Control|maintain usual physical activity patterns
11324732|NCT02536066|Experimental|Intervention|Addition of daily postprandial physical activity in addition to usual activity patterns
11324733|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
11324734|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
11324735|NCT02536027|Experimental|septic AKI patients|septic AKI patients requiring CVVH
11324736|NCT02536014|Experimental|Dexmedetomidine|
11324737|NCT02536014|Active Comparator|Saline|
11324738|NCT02536001|Other|One mesh Endofast reliant system|Patients with anterior compartment stage III and uterus prolapse grade II will be treated with one mesh - Anterior Endofast reliant system (fixation of posterior arms to the sacrospinous ligament)
11324739|NCT02536001|Other|two meshes Endofast reliant system|intervention: Patients with anterior compartment stage III and uterus prolapse grade II will be treated with 2 meshes: anterior Endofast reliant system mesh to correct the anterior compartment and posterior Endofast reliant system mesh to correct the apical prolapse (fixation to the sacrospinous ligament)
11324740|NCT02535988|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of colorectal cancer receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy; Systemic agents are either capecitabine (Xeloda), paclitaxel or S-1;
11324741|NCT02535975|Experimental|Metformin|Metformin 500mg PO three times a day for 24 weeks
11324742|NCT02535975|Placebo Comparator|Placebo|Placebo tab. PO three times a day for 24 weeks
11324743|NCT02535962|Experimental|Corticosteriod + Probiotic Treatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.
~Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year."
11324744|NCT02535962|Placebo Comparator|Corticosteriod + PlaceboTreatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.
~Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product."
11324745|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
11324746|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
11324747|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
11324748|NCT02535936|Other|3Tesla MRI with DTI-MRI and rsfcMRI|Patients will receive 2 post-operative MRI's with DTI and rsfcMRI at 2 months and 12 months.
11324749|NCT02535923|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
11324750|NCT02535923|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
11324751|NCT02535910|Experimental|breakfast rich in vitamin D3|subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
11324752|NCT02535910|Experimental|breakfast rich in 25(OH) D3|subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
11324753|NCT02535910|Placebo Comparator|Control|subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast
11324754|NCT02535897|Placebo Comparator|CON|500 ml of flavoured water
11324755|NCT02535897|Active Comparator|CHO|500 ml of flavoured water containing 80 g carbohydrate
11324756|NCT02535897|Active Comparator|CHO-PRO|500 ml of flavoured water containing 40 g carbohydrate and 40 g whey protein
11324757|NCT02535884|Experimental|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
11324758|NCT02535884|Sham Comparator|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
11324759|NCT02535871|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
11324760|NCT02535871|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
11324761|NCT02535858|Experimental|Heart and respiratory rate and video|To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication.
11324762|NCT02535858|Experimental|Heart and respiratory rate and VE|A second group has fifty adult volunteers (DG) ongoing outpatient chemical dependency clinic [treatment average's population: 5 months and 14 days]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
11324763|NCT02535845|Experimental|Self-persuasion group|HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
11324825|NCT02535468||Contrived Arm|
11324765|NCT02535832|Placebo Comparator|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
11324766|NCT02535832|Active Comparator|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
11324767|NCT02535819|Experimental|Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
11324768|NCT02535819|Other|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
11324769|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.
~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.
~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
11324770|NCT02535793|Other|laboratory workers with symptoms in presence of drosophila|
11324771|NCT02535780|Experimental|TMS Treatment Group|15 sessions active Transcranial magnetic stimulation (TMS) treatment
11324772|NCT02535780|Sham Comparator|TMS Sham Group|15 sessions sham Transcranial magnetic stimulation (TMS) treatment
11324773|NCT02535780|Experimental|tDCS Treatment Group|15 sessions active Transcranial direct current stimulation (tDCS) treatment
11324774|NCT02535780|Sham Comparator|tDCS Sham Group|15 sessions sham Transcranial direct current stimulation (tDCS) treatment
11324775|NCT02535767|Experimental|A: 0.40 mg/kg PQ G6PDd|0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
11324776|NCT02535767|Experimental|B: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
11324777|NCT02535767|Experimental|C: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
11324778|NCT02535767|Experimental|D: PQ G6PDn|A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.
11324779|NCT02535754|Experimental|ALIVE|Email program N=170
11324780|NCT02535754|Experimental|CCS BCY|Comprehensive program N=285
11324781|NCT02535754|Experimental|ALIVE + CCS BCY|Email + comprehensive program N=225
11324782|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
11324783|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
11324784|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
11324785|NCT02535715|Experimental|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
11324786|NCT02535702|Experimental|Attentional Bias Task|Subjects will briefly see two images side by side on a screen. Immediately after, a dot appears on the left or on the right. The subjects task is to press the left or right button, following the position of the image (left or right). Images can contain food-related items. We will also show short 1-minute food-related movies. Subjects will be asked to fast for three hours before this task begins.
11324787|NCT02535702|Experimental|Cue Reactivity Task|In this task subjects will view pictures of various items on the screen in front of them. Subjects will rate the items by how much they would like to have them. Subjects will choose how much they want the item by pressing a button.
11324788|NCT02535702|Experimental|Delay Discounting Task|Subjects will be asked to imagine whether they would receive money now or money later (in the future). The future money option may be several days from now or as far out as 6 weeks from now. For example, a s ubject may see a $100 option in 6 weeks or a $10 option now. Subjects will not receive actual money for participation in this task
11324789|NCT02535702|Experimental|Motivational Reward Task|Subjects will make a choice among some items presented on the screen in front of them. One of the items will be the winner item. The other items will be loser items. Each time a subject is presented with various items, they will choose the item they think is the winner item. Subjects will start with bonus points at the beginning of the task, so they can add more points to this amount as they continue to choose winner items.
11324790|NCT02535702|Experimental|NSPRD Task|During the MRI scan, subjects will get small electric shocks through electrodes placed on one of their toes. The shocks feel like an elastic band snapping against the skin. Right after a shock, subjects will see a dot on the computer screen. Subejcts will press a button to rate the intensity of the shock.
11324791|NCT02535702|Experimental|Reasoning Task|Subjects will identify changes in various shapes when they are displayed on the screen in front of them. Some changes of the shapes may be that they were rotated, enlarged, or multiplied. Subjects will choose the changes in the shapes by pressing a button.
11324826|NCT02535455|Experimental|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
11324827|NCT02535429|Experimental|massage|massage
11324828|NCT02535429|No Intervention|Control|
11325492|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
11324792|NCT02535702|Experimental|Self-control Task|During the MRI scan, subjects will do a task that requires close concentration. Subjects will be asked to respond quickly to images on the computer screen, during which they will hear distracting noises. The subject will be able to remove the distraction in order to complete the task. During some sub-study sessions, subjects will start with no money ($0) and may be able to earn up to $40 if they do not remove the distraction. At other sub-study sessions, subjects will start with $40 and may lose between 25 to $1 each time they remove the distraction. Subjects cannot lose more than $40 in these sessions. Compensation for this sub-study is up to $40 per session, depending on their performance.
11324793|NCT02535702|Experimental|Spinner Task and MID Task (monetary incentive delay task)|The Spinner task requires the subject to participate in a game of chance while lying in the MRI scanner. Subjects will be asked to respond by pressing a button. The MID task is a reaction time task. The MID Task tests how quickly a subject can press a button to hit a target on the screen in front of them. If the subject presses the button as soon as the target appears, the subject will score points. Subjects should try to score as many points as you can.
11324794|NCT02535689|Active Comparator|1|ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
11324795|NCT02535689|Active Comparator|2|ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
11324796|NCT02535689|Placebo Comparator|3|ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.
11324797|NCT02535676|Active Comparator|Active tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 20 minutes.
11324798|NCT02535676|Sham Comparator|Sham tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 19 minutes.
11324799|NCT02535663|Experimental|test group|Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks
11324800|NCT02535663|Placebo Comparator|placebo|Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks
11324801|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
11324802|NCT02535637||Mothers-Infant|Mothers who were planning to exclusively breastfeed for six months were enrolled into the study along with their infant.
11324803|NCT02535624|Active Comparator|ANGIO|Patients with persistent hemodynamic instability (systolic blood pressure (SBP) <90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
11324804|NCT02535624|Active Comparator|PACKING|Indication for pelvic packing was persistent SBP<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units. These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
11324805|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
11324806|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
11324807|NCT02535598|Active Comparator|Normal presentation|Standard internet based CBT presentation.
11324808|NCT02535598|Experimental|Enhanced presentation|Enhanced internet CBT presentation.
11324809|NCT02535598|Active Comparator|Normal support|Standard internet based CBT support.
11324810|NCT02535598|Experimental|Enhanced support|Enhanced internet CBT support.
11324811|NCT02535585|Active Comparator|knotted anchors|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
11324812|NCT02535585|Active Comparator|knotless anchors|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
11324813|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
11324814|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
11324815|NCT02535559|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
11324816|NCT02535559|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
11324817|NCT02535533|Experimental|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.
~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.
~During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients."
11324818|NCT02535507|Experimental|Pyrotinib treatment arm|pyrotinib treatment arm
11324819|NCT02535494|No Intervention|Standard Training|Participants receive our standard overdose training.
11324820|NCT02535494|Experimental|Extensive Training|Participant receives an more in-depth, extensive training concerning opioid overdose.
11324821|NCT02535494|Experimental|Extensive Training w/ Significant Other|Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.
11324974|NCT02534480|Active Comparator|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
11324829|NCT02535416|Experimental|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
11324830|NCT02535416|Experimental|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
11324831|NCT02535416|Experimental|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
11324832|NCT02535416|Experimental|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
11324833|NCT02535416|Experimental|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
11324834|NCT02535416|Experimental|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
11324835|NCT02535416|Experimental|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
11324836|NCT02535416|Experimental|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
11324837|NCT02535416|Experimental|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
11324838|NCT02535403|Experimental|ICBT|14 weeks of internet-based cognitive behavioral therapy with therapist support
11324839|NCT02535403|No Intervention|Wait-list|14 weeks wait-list control
11324840|NCT02535390|Experimental|Action based cognitive remediation|Participants in this condition will engage in simulated real world tasks in addition to standard cognitive remediation and group therapy sessions.
11324841|NCT02535390|Active Comparator|Standard cognitive remediation|Participants in this condition will engage in computerized cognitive training exercises in addition to standard cognitive remediation and group therapy sessions.
11324842|NCT02535377||High cryoresistance|High resistance to sperm cryopreservation (decreased sperm motility <20%)
11324843|NCT02535377||Low cryoresistance|Low resistance to sperm cryopreservation (decreased sperm motility >20%)
11324844|NCT02535364|Experimental|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
11324845|NCT02535351|Active Comparator|A: TKIs|sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
11324846|NCT02535351|Experimental|B: TKIs + Cytoreductive Nephrectomy|Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
11324847|NCT02535338|Experimental|Treatment (erlotinib hydrochloride, onalespib lactate)|Patients receive erlotinib hydrochloride PO daily and onalespib lactate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
11324848|NCT02535325|Experimental|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.
~CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.
~Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
11324849|NCT02535312|Experimental|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
11324850|NCT02535312|Experimental|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
11324851|NCT02535299|Experimental|insulin|basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
11324852|NCT02535286|Experimental|TG-1501 + Ublituximab + Umbralisib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals
11324853|NCT02535273|Experimental|Low-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery"
11324854|NCT02535273|Experimental|Moderate-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery"
11324855|NCT02535273|Experimental|High-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery"
11324856|NCT02535273|Placebo Comparator|normal saline Control group|Intravenous injection normal saline equal quantity，completed within 10 minutes. Local anesthesia: lidocaine Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
11324857|NCT02535260||Fertility Monitor|Clearblue Fertility Monitor
11324858|NCT02535247|Experimental|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
11324859|NCT02535247|Active Comparator|Combination|MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study
11324860|NCT02535221|Experimental|Endocrine therapy;|Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
11324861|NCT02535221|Active Comparator|Chemotherapy|Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
11324862|NCT02535208|Experimental|Restrictive transfusion group|
11324863|NCT02535208|Active Comparator|Liberal transfusion group|
11324864|NCT02535195|Active Comparator|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
11324865|NCT02535195|Placebo Comparator|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
11324866|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
11324867|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
11324868|NCT02535169|Experimental|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
11324869|NCT02535169|Placebo Comparator|Usual Care|1. Dietary consult only
11324870|NCT02535156|Experimental|Schizotypal Personality Disorder|Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).
11324871|NCT02535156|Experimental|Healthy controls|Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).
11324872|NCT02535143|Experimental|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
11324873|NCT02535143|Placebo Comparator|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
11324874|NCT02535130|Experimental|Nebulization combined to positive expiratory pressure|Experimental arm
11324875|NCT02535130|Active Comparator|Nebulization|Control arm
11324876|NCT02535117|Experimental|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
11324877|NCT02535117|Active Comparator|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
11324878|NCT02535104|Experimental|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
11324879|NCT02535104|Placebo Comparator|Control|Vehicle - innert gel
11324880|NCT02535091|Experimental|YKP3089|Multiple dose
11324881|NCT02535078|Experimental|Arm 1|IMCgp100 with durvalumab (MEDI4736)
11324882|NCT02535078|Experimental|Arm 2|IMCgp100 with tremelimumab
11324883|NCT02535078|Experimental|Arm 3|IMCgp100 with durvalumab (MEDI4736) and tremelimumab
11324884|NCT02535078|Experimental|Arm 4|IMCgp100 (single agent)
11324885|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
11324886|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
11324887|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
11324888|NCT02535039|Placebo Comparator|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
11324889|NCT02535039|Experimental|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg * d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
11324890|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
11377928|NCT02182505|Experimental|Berodual® Respimat®, high dose|
11324891|NCT02535013|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
11324892|NCT02535013|Active Comparator|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
11324893|NCT02535000|Experimental|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
11324894|NCT02535000|Active Comparator|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
11324895|NCT02534987|Experimental|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
11324896|NCT02534987|No Intervention|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
11324897|NCT02534961|Active Comparator|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
11324898|NCT02534961|No Intervention|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
11324899|NCT02534948|Experimental|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
11324900|NCT02534948|No Intervention|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
11324901|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:
~≥12 to <18 months and ≥18 to <24 months"
11324902|NCT02534935|Active Comparator|Control|"Arm stratified by age:
~≥12 to <18 months and ≥18 to <24 months"
11324903|NCT02534922|Experimental|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
11324904|NCT02534909|Experimental|LFG316|During the treatment period, all patients will receive LFG316
11324905|NCT02534896|Experimental|Treatment 1: Sunpharma1505 (Low dose) and Placebo|
11324906|NCT02534896|Experimental|Treatment II: Sunpharma1505 (High Dose) and Placebo|
11324907|NCT02534896|Active Comparator|Treatment III: Reference1505 and Placebo|
11324908|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
11324909|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
11324910|NCT02534870|Experimental|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
11324911|NCT02534857|Experimental|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
11324912|NCT02534857|Placebo Comparator|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
11324913|NCT02534844|Experimental|Part A- 900 mg VTS-270|Participants receive 900 milligram (mg) of VTS-270 administered by the lumbar intrathecal (IT) route every 2 weeks.
11324914|NCT02534844|Experimental|Part A- 1200 mg VTS-270|Participants receive 1200 mg of VTS-270 administered by the lumbar IT route every 2 weeks.
11324915|NCT02534844|Experimental|Part A- 1800 mg VTS-270|Participants receive 1800 mg of VTS-270 administered by the lumbar IT route every 2 weeks.
11324916|NCT02534844|Other|Part A- Sham|Participants receive 1 to 2 skin pricks with a needle.
11324917|NCT02534844|Experimental|Part B- 900 mg VTS-270|Participants receive 900 mg of VTS-270 administered by the lumbar IT route every 2 weeks.
11324918|NCT02534844|Other|Part B- Sham|Participants receive 1 to 2 skin pricks with a needle.
11324919|NCT02534844|Experimental|Part C- 900 mg VTS-270|Participants receive 900 mg of VTS-270 administered by the lumbar IT route every 2 weeks.
11324920|NCT02534831|Experimental|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
11324921|NCT02534818|Experimental|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
11324922|NCT02534818|Active Comparator|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
11324923|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
11324924|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
11324925|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
11324926|NCT02534779|Experimental|Placebo Vaginal Insert|Placebo insert
11324927|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
11324928|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
11324929|NCT02534753|Experimental|Single Group|
11324930|NCT02534740|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
11324931|NCT02534740|Experimental|48.8 mg tafamidis soft gel capsule formulation 1|
11324932|NCT02534740|Experimental|48.8 mg tafamidis soft get capsule formulation 2|
11324933|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 1|
11324934|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 2|
11324935|NCT02534727||Sputum and blood participants|These participants will contribute both blood and sputum to the study
11324936|NCT02534727||Sputum only participants|These participants will only contribute sputum to the study
11324937|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
11324938|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.
~(Screening period July 1, 2015-June 30, 2016)
~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
11324939|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
11324940|NCT02534688|Experimental|LNG-IUS group|Single intervention LNG IUS
11324941|NCT02534688|Experimental|DMPA group|Three intervention DmPA 12 wk apart
11324942|NCT02534662|Experimental|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
11324943|NCT02534649|Other|Experimental|Newly obtained biopsy and Blood samples collection
11324944|NCT02534636|Experimental|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
11324945|NCT02534636|Experimental|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
11324946|NCT02534636|Experimental|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
11324947|NCT02534636|Experimental|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
11324948|NCT02534623|Active Comparator|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
11324949|NCT02534623|Active Comparator|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
11324950|NCT02534610|Experimental|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
11324951|NCT02534610|Experimental|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
11324952|NCT02534610|Placebo Comparator|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
11324953|NCT02534597|Experimental|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
11324954|NCT02534597|Experimental|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
11324955|NCT02534597|Experimental|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
11324956|NCT02534597|Experimental|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
11324957|NCT02534597|Experimental|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
11324958|NCT02534597|Experimental|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
11324959|NCT02534597|Experimental|_pt|Receives the delayed Promotores training, followed by technical assistance.
11324960|NCT02534597|Experimental|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
11324961|NCT02534597|Experimental|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
11324962|NCT02534597|Experimental|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
11324963|NCT02534571|Experimental|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, <=150gm , once
11324964|NCT02534571|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clip or4 pulse , once only
11324965|NCT02534558|Experimental|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
11324966|NCT02534558|Experimental|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
11324967|NCT02534545|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
11324968|NCT02534545|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
11324969|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
11324970|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
11324971|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
11324972|NCT02534506|Experimental|Urelumab (+ Nivolumab) intravenous (IV) infusion|
11324973|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
11324976|NCT02534480|Active Comparator|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
11324977|NCT02534480|Active Comparator|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
11324978|NCT02534480|Active Comparator|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
11324979|NCT02534467|Experimental|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
11324980|NCT02534467|Active Comparator|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
11324981|NCT02534454|Experimental|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
11324982|NCT02534454|Experimental|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
11324983|NCT02534454|Experimental|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
11324984|NCT02534454|Experimental|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
11324985|NCT02534441|Experimental|Skin patch testing to 6 known and 3 novel surfactants|
11324986|NCT02534428|Experimental|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
11324987|NCT02534428|Active Comparator|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
11324988|NCT02534415|Active Comparator|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
11324989|NCT02534415|Experimental|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
11324990|NCT02534415|Experimental|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
11324991|NCT02534402|Experimental|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
11324992|NCT02534402|No Intervention|Control Group|no treatment
11324993|NCT02534389|Experimental|fish oil group|4 soft gel with omega-3 fish oil
11324994|NCT02534389|No Intervention|control group|without intervention
11324995|NCT02534376|Experimental|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
11324996|NCT02534363|Active Comparator|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
11324997|NCT02534363|Active Comparator|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
11324998|NCT02534363|Active Comparator|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
11324999|NCT02534350|Experimental|Presatovir|Presatovir 200 mg (4 x 50 mg) on Day 1, followed by 100 mg (2 x 50 mg) from Day 2 to Day 14
11325000|NCT02534350|Placebo Comparator|Placebo|Placebo tablets for a total of 14 days
11325001|NCT02534337|Experimental|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
11325002|NCT02534337|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
11325003|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
11325004|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
11325005|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks.
11325006|NCT02534298|Experimental|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
11325007|NCT02534298|Other|control group|Normal hearing subject functional magnetic resonance imaging
11325008|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
11325009|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
11325010|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
11325011|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
11325012|NCT02534246|Experimental|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
11325013|NCT02534246|Experimental|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
11325014|NCT02534233|Experimental|CryoBalloon ablation|Patients having ablation of dysplastic tissue in esophagus.
11325015|NCT02534220|Active Comparator|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
11325016|NCT02534220|Experimental|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
11325017|NCT02534207|Experimental|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
11325018|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
11325019|NCT02534181|Active Comparator|Intervention group|"Patients will undergo a caloric management protocol:
~Days 1 and 2:
~Reduction of caloric intake to 5kcal/kg/day;
~Replacement of serum phosforus, potassium and magnesium;
~Administration of 100mg intravenous thiamine, vitamins and microelements.
~From day 3:
~If serum phosphorus < 2.5mg/dL, protocol will be followed according to day 2;
~If serum phosphorus > 2.5mg/dL, a gradual increase to target caloric intake will ensue."
11325020|NCT02534181|No Intervention|Control group|"Nutritional management will be followed according to institutional protocol.
~Electrolyte replacement will be provided at the clinician's discretion."
11325021|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
11325022|NCT02534155|Active Comparator|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
11325023|NCT02534155|Active Comparator|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
11325024|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
11325025|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
11325026|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
11325027|NCT02534116|Experimental|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
11325028|NCT02534116|Active Comparator|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
11325029|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
11325030|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
11325031|NCT02534077|Experimental|1|Drug: Omegaven
11325032|NCT02534064|Experimental|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
11325033|NCT02534064|Experimental|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
11325034|NCT02534064|No Intervention|Group C: No yogurt|no changes in dietary habits during 24 weeks.
11325035|NCT02534051|Active Comparator|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
11325036|NCT02534051|No Intervention|Usual Care|The control group will receive the usual prenatal care.
11325037|NCT02534038|Placebo Comparator|Placebo|Placebo drug to be taken twice a day for 6 weeks
11325038|NCT02534038|Active Comparator|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
11325039|NCT02534025|Experimental|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
11325040|NCT02534025|No Intervention|C group|no intervention will be added to routine anesthetic mangement
11325041|NCT02534012|Experimental|PVB group|Patients will receive nerve stimulator guided paravertebral block
11325042|NCT02534012|Experimental|GA group|Patients will receive general anesthesia
11325043|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
11325044|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
11325045|NCT02533986|Placebo Comparator|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
11325046|NCT02533986|Experimental|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
11325047|NCT02533973|Active Comparator|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
11325048|NCT02533973|Active Comparator|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
11325049|NCT02533960||NOAC|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).
~Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs)."
11325050|NCT02533960||VKA|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).
~Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)"
11325051|NCT02533960||Without OAC|"Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.
~Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation."
11325052|NCT02533947|Experimental|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
11325053|NCT02533947|Other|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
11325054|NCT02533934|Experimental|Study Drug|Treatment with Harvoni
11325055|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
11325056|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
11325057|NCT02533908|Active Comparator|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
11325058|NCT02533908|Placebo Comparator|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
11325059|NCT02533895|Experimental|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.
~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
11325060|NCT02533895|Other|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
11325061|NCT02533882|Experimental|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
11325062|NCT02533882|Active Comparator|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
11325063|NCT02533882|No Intervention|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
11325064|NCT02533869|Experimental|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
11325065|NCT02533856|No Intervention|Usual Care|Discharge from emergency department by usual care
11325066|NCT02533856|Experimental|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
11325067|NCT02533843|Active Comparator|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
11325068|NCT02533843|Active Comparator|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
11325069|NCT02533843|Active Comparator|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
11325070|NCT02533830|Active Comparator|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
11325071|NCT02533830|Placebo Comparator|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
11325072|NCT02533817|Experimental|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
11325073|NCT02533817|Active Comparator|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
11325074|NCT02533791|Experimental|low dose group|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
11325075|NCT02533791|Experimental|high dose group|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
11325076|NCT02533791|Placebo Comparator|placebo group|placebo
11325077|NCT02533778|Experimental|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
11325078|NCT02533765|Experimental|Olaparib|Olaparib 300mg twice daily continuously
11325079|NCT02533752||Main Group|This an observational registry - there is only one group
11325080|NCT02533739|Experimental|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
11325081|NCT02533739|Sham Comparator|Control group|This group will consist of participants without vestibular/vertigo impairments.
11325082|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
11325083|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
11325084|NCT02533713|Experimental|Immediate gait training|Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
11325085|NCT02533713|Other|Delayed gait training|Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
11325086|NCT02533700|Experimental|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, epirubucin and prednisone),2 cycles of IVE(ifosfamide, epirubucin, etoposide)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
11325087|NCT02533700|Active Comparator|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,epirubucin and prednisone)
11325088|NCT02533687|Active Comparator|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
11325089|NCT02533687|Active Comparator|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
11325090|NCT02533687|Active Comparator|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
11325091|NCT02533674|Experimental|gemcitabine plus PM060184|
11325123|NCT02533414|Active Comparator|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
11377929|NCT02182505|Active Comparator|Berodual® MDI Aerochamber®|
11325092|NCT02533661|Experimental|Family-centered intervention program|"The FCIP group received:
~In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.
~After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
11325093|NCT02533661|No Intervention|Usual care program|"The UCP group received:
~In-hospital intervention: environmental modulation and teaching of child development skills.
~After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
11325094|NCT02533648|Experimental|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
11325095|NCT02533648|Placebo Comparator|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
11325096|NCT02533635|Experimental|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
11325097|NCT02533635|Experimental|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
11325098|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
11325099|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
11325100|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
11325101|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
11325102|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
11325103|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
11325104|NCT02533570|Experimental|Brentuximab vedotin|4 dose groups
11325105|NCT02533570|Placebo Comparator|Placebo|Matching placebo
11325106|NCT02533557|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
11325107|NCT02533557|Active Comparator|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
11325108|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
11325109|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
11325110|NCT02533518|Experimental|patients with lung cancer|
11325111|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
11325112|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
11325113|NCT02533492|Active Comparator|Vicryl|Vicryl suture for wound closure after total knee replacement
11325114|NCT02533492|Experimental|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
11325115|NCT02533479|Experimental|Caloric restriction|three alternate days weekly along 4 weeks.
11325116|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
11325117|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
11325118|NCT02533453|Experimental|Bydureon|exenatide once weekly
11325119|NCT02533440|Experimental|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
11325120|NCT02533440|Active Comparator|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
11325121|NCT02533427|Experimental|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.
~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
11325122|NCT02533414|Experimental|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
11325251|NCT02532686|Experimental|DAAOI-2|DAAOI-2: 500-2000mg/d
11325124|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
11325125|NCT02533388|Experimental|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
11325126|NCT02533388|Sham Comparator|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
11325127|NCT02533375|Experimental|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
11325128|NCT02533362|Experimental|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
11325129|NCT02533349|Active Comparator|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
11325130|NCT02533349|Placebo Comparator|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
11325131|NCT02533336|Experimental|DL+LLINs|DL treated with abamectin and fenpyroximate
11325132|NCT02533336|No Intervention|LLINs|LLINs only
11325133|NCT02533323|Experimental|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
11325134|NCT02533310|Experimental|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
11325135|NCT02533310|Experimental|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
11325136|NCT02533297|Experimental|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
11325137|NCT02533284|Experimental|Magnesium sulfate group|US guided TAP with magnesium sulfate
11325138|NCT02533284|Experimental|B group|TAP bupevecaine
11325139|NCT02533284|Placebo Comparator|C group|control TAP saline
11325140|NCT02533271|Experimental|Experimental group|The intervention of Experimental group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
11325141|NCT02533271|Other|Control group|The intervention of Control group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
11325142|NCT02533245|Experimental|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.
~Intervention:
~Home-based individualized exercise training program
~Supervised group training sessions
~Climb of the Mont Ventoux"
11325143|NCT02533245|No Intervention|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
11325144|NCT02533245|Experimental|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.
~Intervention:
~Supervised group training sessions
~Climb of the mont ventoux"
11325145|NCT02533232|Placebo Comparator|placebo|Matching placebo for Minocycline
11325146|NCT02533232|Experimental|Minocycline|Minocycline 200mg once a day orally
11325147|NCT02533206|Experimental|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
11325148|NCT02533206|Active Comparator|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
11325149|NCT02533193|Active Comparator|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
11325150|NCT02533193|Active Comparator|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
11325151|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
11325152|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
11325153|NCT02533154|Experimental|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
11325154|NCT02533154|Active Comparator|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
11325155|NCT02533141|Experimental|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
11325156|NCT02533141|Placebo Comparator|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
11325157|NCT02533128|Placebo Comparator|Liberal blood pressure management|
11325158|NCT02533128|Active Comparator|Tight blood pressure management|
11325159|NCT02533102|Experimental|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
11325160|NCT02533102|Experimental|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
11325161|NCT02533102|Experimental|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
11325162|NCT02533102|Experimental|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
11325163|NCT02533102|Experimental|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
11325164|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
11325165|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
11325166|NCT02533076|Other|Cystinosis Patients|Cystinosis patients
11325167|NCT02533076|Other|Healthy volunteers|Healthy volunteers
11325168|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
11325169|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
11325170|NCT02533050|Experimental|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10. After randomization, they will be treated with CPAP treatment.
11325171|NCT02533050|No Intervention|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10. After randomization, they will be not treated.
11325172|NCT02533050|No Intervention|Control group|Patients with CAD but without SAS (AHI<15).
11325173|NCT02533037|Active Comparator|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
11325174|NCT02533037|Experimental|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
11325175|NCT02533024|Experimental|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
11325176|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
11325177|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
11325178|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
11325179|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325180|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325181|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325182|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325183|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325184|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325252|NCT02532686|Placebo Comparator|placebo|
11325185|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325186|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
11325187|NCT02532985|Placebo Comparator|Negative control|No added fiber
11325188|NCT02532985|Active Comparator|Positive fiber control|90g positive control fiber
11325189|NCT02532985|Experimental|Novel fiber 30g|30g novel fiber
11325190|NCT02532985|Experimental|Novel fiber 60g|60g novel fiber
11325191|NCT02532985|Experimental|Novel fiber 90g|90g novel fiber
11325192|NCT02532972|Experimental|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
11325193|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
11325194|NCT02532946|Experimental|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
11325195|NCT02532946|No Intervention|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
11325196|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
11325197|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
11325198|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
11325199|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
11325200|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
11325201|NCT02532894|Experimental|Esmoke|Inhaling e-cigarette vapor
11325202|NCT02532894|No Intervention|Control|
11325203|NCT02532881|Experimental|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
11325204|NCT02532881|Placebo Comparator|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
11325205|NCT02532868|Experimental|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
11325206|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
11325207|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
11325208|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
11325209|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c<5.7%, BMI<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325210|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325211|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325212|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c<5.7%, No signs and history of T2D, and BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325213|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325360|NCT02531997|Other|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
11325214|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325215|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325216|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
11325217|NCT02532816|Experimental|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
11325218|NCT02532816|Active Comparator|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
11325219|NCT02532816|Placebo Comparator|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
11325220|NCT02532803|Experimental|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
11325221|NCT02532790|Experimental|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
11325222|NCT02532790|Experimental|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
11325223|NCT02532777|Experimental|Prednisone & Cyclophosphamide|"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).
~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
11325224|NCT02532777|Experimental|Prednisone & Mycophenolate mofetil|"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).
~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
11325225|NCT02532777|Experimental|Prednisone & Leflunomide|"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.
~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.
~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
11325226|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
11325227|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
11325228|NCT02532738|Experimental|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
11325229|NCT02532738|Experimental|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
11325230|NCT02532738|Placebo Comparator|Ctrl|Patients in this arms receive routine treatment with NS injection
11325231|NCT02532725||Lean|Men aged 35-55 years, having <20% body fat
11325232|NCT02532725||Obese|Men aged 35-55 years, having >29% body fat
11325233|NCT02532712|Experimental|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
11325234|NCT02532712|Placebo Comparator|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
11325235|NCT02532712|Experimental|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
11325236|NCT02532712|Placebo Comparator|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
11325237|NCT02532712|Experimental|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
11325238|NCT02532712|Placebo Comparator|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
11325239|NCT02532712|Experimental|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
11325240|NCT02532712|Placebo Comparator|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
11325241|NCT02532712|Experimental|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
11325242|NCT02532712|Placebo Comparator|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
11325243|NCT02532712|Experimental|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
11325244|NCT02532712|Placebo Comparator|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
11325245|NCT02532712|Experimental|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
11325246|NCT02532712|Placebo Comparator|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
11325247|NCT02532712|Experimental|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
11325248|NCT02532712|Placebo Comparator|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
11325249|NCT02532699|Active Comparator|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
11325250|NCT02532699|Placebo Comparator|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
11325253|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or > 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
11325254|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
11325255|NCT02532660|Experimental|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
11325256|NCT02532660|Placebo Comparator|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
11325257|NCT02532660|Experimental|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
11325258|NCT02532647|Experimental|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
11325259|NCT02532647|Active Comparator|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
11325260|NCT02532647|Placebo Comparator|Placebo|"Placebo administered in double-blind manner.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
11325261|NCT02532634|Experimental|ramosetron, aprepitant, dexamethasone|"Ramosetron 0.3mg IV day1
~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3
~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
11325262|NCT02532634|Active Comparator|palonosetron, aprepitant, dexamethasone|"Palonosetron 0.25mg IV day1
~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3
~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
11325263|NCT02532621|Experimental|Venous InterGraft Connector|Venous InterGraft Connector will be implanted and used with a sutured arterial anastomosis to create a AV shunt for dialysis access.
11325264|NCT02532608|Experimental|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
11325265|NCT02532595|Active Comparator|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
11325266|NCT02532595|Experimental|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
11325267|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
11325268|NCT02532569|Other|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
11325269|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
11325270|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
11325271|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
11325272|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
11325273|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
11325274|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
11325275|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
11325276|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
11325277|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
11325278|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
11325279|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
11325280|NCT02532530|Other|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
11325281|NCT02532517|Experimental|Enterprise|
11325282|NCT02532504|Experimental|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
11325283|NCT02532504|No Intervention|Treatment As Usual|Treatment As Usual
11325284|NCT02532491|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
11325285|NCT02532491|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
11325286|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
11325287|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
11325361|NCT02531984|Experimental|Withdrawal of Azithromycin treatment|
11325362|NCT02531984|Other|ongoing Azithromycin treatment|
11325288|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
11325289|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
11325290|NCT02532452|Experimental|Viral Specific VST Infusion|3rd party VST infusion
11325291|NCT02532439|Experimental|Patient group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
11325292|NCT02532439|Experimental|control group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
11325293|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2<55mmHg).
11325294|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
11325295|NCT02532413|Experimental|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.
~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
11325296|NCT02532413|Active Comparator|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
11325297|NCT02532413|Experimental|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.
~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
11325298|NCT02532413|Active Comparator|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
11325299|NCT02532400|Experimental|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
11325300|NCT02532400|Active Comparator|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
11325301|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.
~Intervention: Telephone follow-up at 7 and 30 days."
11325302|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.
~Intervention: Telephone follow-up at 7 and 30 days."
11325303|NCT02532387||Control subjects|"Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment
~Historical controls:
~Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.
~Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
11325304|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
11325305|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
11325306|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
11325307|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
11325308|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
11325309|NCT02532335|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
11325310|NCT02532335|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
11325311|NCT02532335|Active Comparator|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
11325312|NCT02532335|Placebo Comparator|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
11325313|NCT02532322|Experimental|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
11325314|NCT02532322|Placebo Comparator|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
11325315|NCT02532309|Experimental|Rosuvastatin dose adjustment|
11325316|NCT02532309|Experimental|Rosuvastatin fixed dose|
11325317|NCT02532296|Active Comparator|Control|Receive usual hospital discharge, care transition and post-discharge care.
11325318|NCT02532296|Experimental|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
11325319|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
11325320|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
11325321|NCT02532270|Experimental|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
11325399|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 10 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325493|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
11325322|NCT02532270|Experimental|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
11325323|NCT02532257|Experimental|Treatment (lenalidomide, rituximab, ibrutinib)|Patients receive lenalidomide PO on days 1-21, rituximab IV over 4-6 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of all subsequent cycles, and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11325324|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line. The investigator will also collect saliva and buccal swabs for genetic analysis
11325325|NCT02532231|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
11325326|NCT02532218|Active Comparator|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
11325327|NCT02532218|Placebo Comparator|Placebo|Matching Placebo 3g bid for 24 wks
11325328|NCT02532192|Experimental|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
11325329|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
11325330|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
11325331|NCT02532153|Other|Open-Label Ketamine|
11325332|NCT02532140|Experimental|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
11325333|NCT02532140|Experimental|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
11325334|NCT02532140|Experimental|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
11325335|NCT02532127|Experimental|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
11325336|NCT02532114|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
11325337|NCT02532101|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
11325338|NCT02532088|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
11325339|NCT02532088|Placebo Comparator|Placebo|Placebo
11325340|NCT02532075|Experimental|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
11325341|NCT02532075|Experimental|Expiratory Warm Up|(EWU). Two sets of 15 breaths
11325342|NCT02532075|Experimental|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
11325343|NCT02532075|Other|Control Trial|No warm up
11325344|NCT02532062|Experimental|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
11325345|NCT02532062|Active Comparator|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
11325346|NCT02532049|Active Comparator|Group 1|ChAd63 Pfs25-IMX313 (5x10^9 vp)
11325347|NCT02532049|Active Comparator|Group 2A|ChAd63 Pfs25-IMX313 (5x10^10 vp)
11325348|NCT02532049|Active Comparator|Group 2B|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
11325349|NCT02532049|Active Comparator|Group 2C|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
11325350|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
11325351|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
11325352|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
11325353|NCT02532023|Active Comparator|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
11325354|NCT02532023|Active Comparator|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
11325355|NCT02532023|Placebo Comparator|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
11325356|NCT02532023|Placebo Comparator|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
11325357|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
11325358|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
11325359|NCT02531997|Active Comparator|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
11325363|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
11325364|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
11325365|NCT02531958|Experimental|1 Egg|Consumption of 1 egg per day for 4 weeks
11325366|NCT02531958|Experimental|2 Eggs|Consumption of 2 eggs per day for 4 weeks
11325367|NCT02531958|Experimental|3 Eggs|Consumption of 3 eggs per day for 4 weeks
11325368|NCT02531945|Experimental|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.
~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
11325369|NCT02531932|Active Comparator|Carboplatin alone|AUC 4 every 3 weeks as an IV infusion
11325370|NCT02531932|Experimental|Carboplatin + Everolimus|Carboplatin AUC 4 every 3 weeks IV infusion plus daily oral everolimus 5mg pill
11325371|NCT02531919|Experimental|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
11325372|NCT02531906|Experimental|Arm I (gabapentin)|"Patients receive gabapentin PO TID for up to 7 weeks during radiotherapy.
~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
11325373|NCT02531906|Experimental|Arm II (gabapentin, methadone, oxycodone)|"Patients receive gabapentin PO TID, methadone hydrochloride PO BID, and oxycodone hydrochloride PO Q8H PRN for up to 7 weeks during radiotherapy.
~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
11325374|NCT02531893||Irritable youth|Participants meet full DMDD criteria for IBT and either full DMDD or one of two core DMDD criteria for CBT.
11325375|NCT02531880|Experimental|1|Patients will be given the study drug
11325376|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
11325377|NCT02531854|Experimental|ADXS11-001 + Pemetrexed|
11325378|NCT02531854|Active Comparator|Pemetrexed Only|
11325379|NCT02531841|Active Comparator|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
~Rituximab 375 mg/m²/d i.v. (d0,5)
~Methotrexate 3.5 g/m² i.v. (d1)
~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
~Thiotepa 30 mg/m² i.v. (d4)
~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):
~Rituximab 375 mg/m²/d i.v. (d0)
~Dexamethasone 40 mg/d i.v. (d1-3)
~Etoposide 100 mg/m²/d i.v. (d1-3)
~Ifosfamide 1500 mg/m²/d i.v. (d1-3)
~Carboplatin 300 mg/m² i.v. (d1)"
11325380|NCT02531841|Active Comparator|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
~Rituximab 375 mg/m²/d i.v. (d0,5)
~Methotrexate 3.5 g/m² i.v. (d1)
~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
~Thiotepa 30 mg/m² i.v. (d4)
~Consolidation Treatment High-dose chemotherapy
~Carmustine* 400 mg/m² i.v. (d-6)
~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
~Autologous Stem Cell Transplantation (d0)
~*if not available at study site, Busulfan can be administered instead:
~Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))
~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
~Autologous Stem Cell Transplantation (d0)"
11325381|NCT02531828|Experimental|Biopolymer Film|Application of dressings for surgical correction.
11325382|NCT02531828|Active Comparator|Polyurethane Film, or the like|Application of dressings for surgical correction
11325383|NCT02531815|Experimental|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
11325384|NCT02531815|Experimental|Cohort 2 (SC) PF-06741086, Placebo|
11325385|NCT02531815|Experimental|Cohort 3 (SC) PF-06741086, Placebo|
11325386|NCT02531815|Experimental|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
11325387|NCT02531815|Experimental|Cohort 5 (IV) PF-06741086, Placebo|
11325388|NCT02531815|Experimental|Cohort 6 (IV) PF-06741086, Placebo|
11325389|NCT02531815|Experimental|Cohort 7 (IV) PF-06741086, Placebo|
11325390|NCT02531815|Experimental|Cohort 8 (subcutaneous [SC]) PF-06741086|
11325391|NCT02531802|Experimental|Adult: ETVAX (Full)|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14
11325392|NCT02531802|Experimental|Adult: ETVAX (Full) + 10 ug dmLT|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
11325393|NCT02531802|Placebo Comparator|Adult: Placebo|Adult arm (18-45 year olds) receiving a placebo on days 0 and 14
11325394|NCT02531802|Experimental|24-59 months: ETVAX (1/4)|24-59 month old children receiving a quarter adult dose (2.5 x 10^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
11325395|NCT02531802|Experimental|24-59 months: ETVAX (1/2)|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
11325396|NCT02531802|Experimental|24-59 months: ETVAX (full)|24-59 month old children receiving a full adult dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
11325397|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 2.5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325398|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325400|NCT02531802|Placebo Comparator|24-59 months: Placebo|24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
11325401|NCT02531802|Experimental|12-23 months: ETVAX (1/4)|12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
11325402|NCT02531802|Experimental|12-23 months: ETVAX (1/2)|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
11325403|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325404|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325405|NCT02531802|Placebo Comparator|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
11325406|NCT02531802|Experimental|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
11325407|NCT02531802|Experimental|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
11325408|NCT02531802|Experimental|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
11325409|NCT02531802|Experimental|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325410|NCT02531802|Experimental|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
11325411|NCT02531802|Placebo Comparator|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
11325412|NCT02531789||Observation|45 patients receiving elective colorectal surgery
11325413|NCT02531776|Experimental|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
11325414|NCT02531763|No Intervention|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
11325415|NCT02531763|Active Comparator|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
11325416|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
11325417|NCT02531737|Experimental|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
11325418|NCT02531724|Active Comparator|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
11325419|NCT02531724|Placebo Comparator|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
11325420|NCT02531711|Experimental|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
11325421|NCT02531711|Active Comparator|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
11325422|NCT02531698|Experimental|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
11325423|NCT02531698|Other|Licensed pediatric hepatitis A vaccine|
11325424|NCT02531685|Experimental|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
11325425|NCT02531685|Experimental|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
11325426|NCT02531685|Experimental|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
11325427|NCT02531685|Experimental|Cohort 4|"A sentinel group of 5 subjects receive 2.0 mcg dmLT intradermally on days 1, 22, and 43. 1 subject receives placebo.
~Safety data from days 1-14 in sentinel will be reviewed and upon approval to proceed, 8 additional subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 2 subjects receive placebo."
11325428|NCT02531685|Experimental|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
11325429|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
11325430|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
11325431|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
11325489|NCT02531282|Active Comparator|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
11325432|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
11325433|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
11325434|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
11325435|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
11325436|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
11325437|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
11325438|NCT02531620|Experimental|Physiatry|Pre-operative Physiatry assessment and intervention
11325439|NCT02531620|Other|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
11325440|NCT02531594|Experimental|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.
~nicotine"
11325441|NCT02531594|Placebo Comparator|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
11325442|NCT02531581|Experimental|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output <500 cc / 24 at the 4th hour.
~Establishment of an infusion G5 500cc% in vein custody."
11325443|NCT02531581|Active Comparator|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
11325444|NCT02531568|Experimental|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
11325445|NCT02531555|Active Comparator|Group M|Mechanical periodontal treatment (Group M): Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
11325446|NCT02531555|Experimental|Group L|Pocket disinfection with diode laser (Group L): Subgingival irradiation with a GaAlAs diode laser (CHEESE®, Gigaa Laser, China) was applied to residual pockets each for 20 sec in continious mode. The diode laser had a wavelenght of 810 nm and power output of 1 W for subgingival irradiation (Maximum output power of device was 7 W). Diode laser application was performed parallel to root surface by a 200 µm fiber tip inserted at the bottom of periodontal pocket and slowly moved from apical to coronal direction in a sweeping motion without local anesthesia.
11325447|NCT02531555|Experimental|Group M+L|Combined treatment (Group M+L): Following mechanical periodontal treatment, pocket irradiation with diode laser was performed as mentioned above.
11325448|NCT02531542|Other|READ echography|
11325449|NCT02531529|Experimental|D group|intraoperative dexmedetomedine infusion
11325450|NCT02531529|Sham Comparator|F group|Intraoperative fentanyl infusion
11325451|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
11325452|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
11325453|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
11325454|NCT02531490|Active Comparator|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
11325455|NCT02531490|No Intervention|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
11325456|NCT02531490|No Intervention|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
11325457|NCT02531477|Experimental|experimental group|Intracarotid injection of propofol to detect efficacy and safety as a novel route for drug delivery
11325488|NCT02531282|Experimental|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
11325490|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
11325458|NCT02531464|Experimental|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
11325459|NCT02531464|No Intervention|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
11325460|NCT02531451|Experimental|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
11325461|NCT02531451|Active Comparator|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
11325462|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
11325463|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
11325464|NCT02531425|Experimental|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
11325465|NCT02531412|Experimental|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
11325466|NCT02531412|Placebo Comparator|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
11325467|NCT02531399|Experimental|Healthy Subjects|20 healthy female and male volunteers, age 18-45 years, non-smokers. Measurements with FDOCT, DVA, LDV and LSFG will be done in all healthy subjects.
11325468|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
11325469|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
11325470|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
11325471|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
11325472|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
11325473|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
11325474|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
11325475|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
11325476|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
11325477|NCT02531360|Experimental|[18F]MNI-815 (MNI-815)|At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815
11325478|NCT02531347|Experimental|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
11325479|NCT02531347|Active Comparator|Conventional blood pressure monitoring|Conventional blood pressure monitoring
11325480|NCT02531334|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
11325481|NCT02531334|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
11325482|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
11325483|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
11325484|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.
~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
11325485|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
11325486|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
11325487|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
11325491|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
11325494|NCT02531256|Experimental|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
11325495|NCT02531243|Experimental|CALMS|12 session family therapy using multi-user biofeedback games
11325496|NCT02531217|Experimental|ATYR1940|ATYR1940 will be given intravenously at a dose of 3.0 mg/kg, weekly
11325497|NCT02531204|Experimental|ASP1585 granules preceding group|
11325498|NCT02531204|Active Comparator|ASP1585 capsules preceding group|
11325499|NCT02531191|Experimental|New Tablet Preceding Group|Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
11325500|NCT02531191|Experimental|Current Tablet Preceding Group|Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
11325501|NCT02531178|Experimental|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
11325502|NCT02531178|Experimental|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
11325503|NCT02531178|Experimental|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
11325504|NCT02531165|Experimental|Morphine|"Pre-hospital Ticagrelor 180 mg loading dose orally.
~Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.
~Aspirin 500 mg loading dose orally (or intravenously).
~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
~Primary PCI."
11325505|NCT02531165|Experimental|Fentanyl|"Pre-hospital Ticagrelor 180 mg loading dose orally.
~Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.
~Aspirin 500 mg loading dose orally (or intravenously).
~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
~Primary PCI."
11325506|NCT02531152|Experimental|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
11325507|NCT02531152|Experimental|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
11325508|NCT02531152|Experimental|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
11325509|NCT02531152|Experimental|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
11325510|NCT02531152|Experimental|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
11325511|NCT02531152|Active Comparator|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
11325512|NCT02531139|Experimental|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
11325513|NCT02531139|Active Comparator|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
11325514|NCT02531126|Experimental|RPC0163 (Ozanimod)|
11325515|NCT02531113|Experimental|RPC1063 (Ozanimod)|
11325516|NCT02531100|Experimental|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
11325517|NCT02531100|Other|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
11325518|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
11325519|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
11325520|NCT02531074|Experimental|Mobile Application plus Usual Care|
11325521|NCT02531074|Active Comparator|Food Journal plus Usual Care|
11325522|NCT02531061|Experimental|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
11325523|NCT02531061|Experimental|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
11325524|NCT02531048|Experimental|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :
~laser stimulations on lower limbs
~laser stimulations cervical
~20 laser stimulations for each site on the upper limbs
~laser stimulations on face and neck"
11325525|NCT02531035|Placebo Comparator|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
11325526|NCT02531035|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
11325527|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
11325528|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
11325529|NCT02531009||Healthy|Approximately 10 healthy adults will be enrolled into this study
11325530|NCT02531009||SSc|Participants with dcSSc and lcSSc
11325531|NCT02530996||200|Telehealth outreach for Veterans and routine clinic visits
11325532|NCT02530996||32|SSc receive BH4 intervention (blinded)
11325533|NCT02530983||Esophagectomy/Esophageal Reconstruction|Patients who have undergone esophagectomy or esophageal reconstruction
11325534|NCT02530957|Experimental|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
11377935|NCT02182479|Placebo Comparator|Placebo via Respimat®|
11325535|NCT02530957|Other|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
11325536|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
11325537|NCT02530931|Experimental|patients with Meniere's disease|
11325538|NCT02530918|Experimental|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
11325539|NCT02530918|Experimental|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
11325540|NCT02530918|Active Comparator|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
11325541|NCT02530918|Experimental|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
11325542|NCT02530918|Experimental|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
11325543|NCT02530918|Experimental|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
11325544|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Approximately 8 genotypically confirmed DMD patients amenable to exon 45 skipping
11325545|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Approximately 4 genotypically confirmed DMD patients amenable to exon 45 skipping.
11325546|NCT02530905|Experimental|SRP-4045 (open label)|Approximately 12 DMD patients who completed the double-blind dose titration part of the study.
11325547|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
11325548|NCT02530879|Experimental|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
11325549|NCT02530879|Active Comparator|Antireflux medication|"Intervention includes treatment with one of the following:
~Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day
~Lansoprazole-Dose range 15mg per day- 30mg twice a day
~Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day
~Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.
~Rantidine may be used in combination with any of the above"
11325550|NCT02530879|Experimental|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
11325551|NCT02530866|Active Comparator|Standard care|Women in this arm will target fasting blood glucose values <95 mg/dL and 1 hour post-prandial values <140 mg/dL
11325552|NCT02530866|Experimental|Intensive therapy|Women in the arm will target fasting blood glucose values <90 mg/dL and 1 hour post-prandial values <120 mg/dL.
11325553|NCT02530853|Experimental|Group A|Laser acupuncture
11325554|NCT02530853|Sham Comparator|Group B|Simulation Laser acupuncture
11325555|NCT02530840|Experimental|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
11325556|NCT02530840|Experimental|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
11325557|NCT02530840|Experimental|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
11325558|NCT02530840|No Intervention|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
11325559|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
11325560|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
11325561|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
11325562|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
11325563|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
11325564|NCT02530801|Other|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
11325565|NCT02530788|Active Comparator|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
11325566|NCT02530788|Placebo Comparator|Placebo|Placebo arm receiving Sodium Chloride solution
11325567|NCT02530775|Active Comparator|instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion with use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
11325568|NCT02530775|Active Comparator|non-instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion without the use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
11325569|NCT02530762|Placebo Comparator|Negative control|No added fiber
11325570|NCT02530762|Active Comparator|Positive Fiber control|50g positive control fiber
11325571|NCT02530762|Experimental|Novel Fiber 10g|10g novel fiber
11325572|NCT02530762|Experimental|Novel Fiber 30g|30g novel fiber
11325573|NCT02530762|Experimental|Novel Fiber 50g|50g novel fiber
11325574|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
11325633|NCT02530359|Active Comparator|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
11325679|NCT02530099|Experimental|Procedure-group|Receive training on a laparoscopic procedure.
11325575|NCT02530723|Experimental|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
11325576|NCT02530723|Experimental|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
11325577|NCT02530723|Experimental|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
11325578|NCT02530723|No Intervention|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
11325579|NCT02530710|Experimental|Q203|Q203 drug products (10mg and 100mg tablets)
11325580|NCT02530710|Placebo Comparator|Placebo|Placebo tablets (same excipients used in Q203 drug products)
11325581|NCT02530697|Active Comparator|Group 1 - Mucosal Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 400mg 3x/daily for 28 days.
11325582|NCT02530697|Experimental|Group 2 - Mucosal Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Oral Pentoxifylline 400mg 3x/daily for 28 days.
11325583|NCT02530697|Experimental|Group 3 - Cutaneous Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 20 days Oral Pentoxifylline 400mg 3x/daily for 20 days.
11325584|NCT02530697|Experimental|Group 4 - Cutaneous Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily Oral Pentoxifylline 400mg 3x/daily for 20 days.
11325585|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
11325586|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
11325587|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
11325588|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
11325589|NCT02530658||Participants|"St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative.
~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
11325590|NCT02530645|Experimental|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
11325591|NCT02530645|Active Comparator|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
11325592|NCT02530632|Active Comparator|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
11325593|NCT02530632|Experimental|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
11325594|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11325595|NCT02530606|Experimental|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
11325596|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
11325597|NCT02530580|Experimental|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
11325598|NCT02530580|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
11325599|NCT02530567|Experimental|Intervention|"The measurement of portosystemic pressure gradient will be performed before liver biopsy.
~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.
~The MRI machine used is the Siemens 3T."
11325600|NCT02530554|Experimental|CHG Cloth|3 min application time
11325601|NCT02530554|Active Comparator|Comparator CHG|Marketed 2% CHG
11325602|NCT02530541|Experimental|CHG 1 min|1 min application time
11325603|NCT02530541|Experimental|CHG 2 min|2 min application time
11325604|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
11325605|NCT02530528|Experimental|CHG 1 min|1 min application time
11325606|NCT02530528|Experimental|CHG 2 min|2 min application time
11325607|NCT02530528|Experimental|CHG 3 min|3 min application time
11325608|NCT02530528|Active Comparator|Comparator CHG|Marketed CHG
11325609|NCT02530515|Experimental|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
11325610|NCT02530502|Experimental|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.
~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
11377936|NCT02182479|Placebo Comparator|Placebo via MDI|
11325611|NCT02530489|Experimental|Treatment (atezolizumab, nab-paclitaxel)|"NEOADJUVANT: Patients receive atezolizumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo definitive breast surgery within 6 weeks of the completion of treatment.
~ADJUVANT: Within 4 weeks after surgery, patients receive atezolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
11325612|NCT02530476|Experimental|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.
~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.
~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
11325613|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.
~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
11325614|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.
~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.
~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
11325615|NCT02530476|Experimental|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.
~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.
~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
11325616|NCT02530463|Experimental|Cohort I (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.
11325617|NCT02530463|Experimental|Cohort II (ipilimumab)|Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.
11325618|NCT02530463|Experimental|Cohort III (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.
11325619|NCT02530463|Experimental|Cohort IV (azacitidine, nivolumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11325620|NCT02530463|Experimental|Cohort V (azacitidine, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11325621|NCT02530463|Experimental|Cohort VI (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11325622|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
11325623|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
11325624|NCT02530437|Experimental|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
11325625|NCT02530437|Experimental|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
11325626|NCT02530424|Experimental|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
11325627|NCT02530411|Experimental|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
11325628|NCT02530411|Placebo Comparator|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
11325629|NCT02530398|Experimental|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
11325630|NCT02530385|Experimental|FMT|Active FMT capsules
11325631|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
11325632|NCT02530372|Experimental|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.
~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.
~The UriCap is held in position by means of a single-use medically approved adhesive tape."
11377937|NCT02182466||Colonic endoscopy indicated|
11325634|NCT02530359|Active Comparator|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
11325635|NCT02530359|Placebo Comparator|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
11325636|NCT02530346|Active Comparator|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.
~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
11325637|NCT02530346|Experimental|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
11325638|NCT02530333|No Intervention|Basketball Control|Control group of basketball players
11325639|NCT02530333|Experimental|Basketball intervention|Intervention group of basketball players
11325640|NCT02530333|No Intervention|Soccer Control|Control group of soccer players
11325641|NCT02530333|Experimental|Soccer Intervention|intervention group of soccer players
11325642|NCT02530320|Experimental|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
11325643|NCT02530307|Experimental|HT-3951 (15mg)|HT-3951 capsules administered once daily
11325644|NCT02530307|Placebo Comparator|Placebo|Placebo capsules administered once daily
11325645|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
11325646|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
11325647|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
11325648|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
11325649|NCT02530268||Ankylosing Spondylitis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
11325650|NCT02530268||Psoriatic Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
11325651|NCT02530255|Placebo Comparator|Placebo|Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
11325652|NCT02530255|Active Comparator|cycloastragenol|Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
11325653|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
11325654|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
11325655|NCT02530229||Periprosthetic joint infection|Patients with suspected periprosthetic joint infection of the hip, knee and shoulder
11325656|NCT02530229||Septic arthritis|Patients with suspected septic arthritis of a native joint of the hip, knee and shoulder
11325657|NCT02530216|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
11325658|NCT02530216|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
11325659|NCT02530203|Other|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
11325660|NCT02530203|Experimental|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
11325661|NCT02530190|No Intervention|Control|20 minutes of supine rest
11325662|NCT02530190|Active Comparator|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
11325663|NCT02530190|Active Comparator|Massage|20 minutes of massage therapy
11325664|NCT02530177||Patients having CYTOTOXIC CHEMOTHERAPY|Participants will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.
11325665|NCT02530177||Patients having ENDOCRINE THERAPY|Participants will undergo study related assessments and Medical and Personal History Questionnaire data collection forms and the appropriate HRQoL questionnaires, will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for standard-of-care visits. Initially, these visits will be coinciding with the appropriate therapy and subsequently they will be performed during the standard-of-care follow-up visits.
11325666|NCT02530177||COMPARATOR (menopausal women)|Menopausal women will include unrelated visitors accompanying breast cancer patients (e.g. friends) attending the breast medicine or dermatology clinics, or female employees of MSKCC. There will be no follow-up visits (after baseline) for participants in the comparator cohort.
11325667|NCT02530164|Active Comparator|real tDCS|
11325668|NCT02530164|Placebo Comparator|sham tDCS|
11325669|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
11325670|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
11325671|NCT02530138|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
11325672|NCT02530138|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
11325673|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11325674|NCT02530112||Phase 1|First round of survey respondents.
11325675|NCT02530112||Phase 2|Second round of survey respondents.
11325676|NCT02530112||Phase 3|Third round of survey respondents.
11325677|NCT02530099|No Intervention|Control group|Receive no training.
11325678|NCT02530099|Experimental|CN-group|Receive basic camera navigation training.
11377938|NCT02182453|Experimental|BI 10773 - single rising dose|
11325680|NCT02530086|Active Comparator|Placement of a Nasogastric tube|Placement of a Nasogastric tube
11325681|NCT02530086|Experimental|No placement of a Nasogastric tube|No placement of a Nasogastric tube
11325682|NCT02530073|Experimental|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)
11325683|NCT02530060|Experimental|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
11325684|NCT02530047|Experimental|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
11325685|NCT02530034|Experimental|Treatment (Hu8F4)|Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11325686|NCT02530021||Heart rate monitor|"Hospitalized patients with chest pain and suspected ischemic heart disease who are candidates for non invasive exercise stress test by their treating physician.
~The patients will perform a one hour heart rate variability monitoring prior to the stress test."
11325687|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
11325688|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
11325689|NCT02529982|Active Comparator|intervention|500 mg curcumin capsule
11325690|NCT02529982|Placebo Comparator|control|placebo
11325691|NCT02529969|Active Comparator|intervention|500 mg curcumin capsule
11325692|NCT02529969|Placebo Comparator|placebo|500 mg placebo
11325693|NCT02529956|Experimental|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
11325694|NCT02529956|Experimental|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
11325695|NCT02529956|Experimental|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
11325696|NCT02529956|Experimental|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
11325697|NCT02529956|Experimental|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
11325698|NCT02529956|Placebo Comparator|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
11325699|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
11325700|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
11325701|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
11325702|NCT02529917|Experimental|Hemp powder|Hemp powder supplement
11325703|NCT02529917|Active Comparator|Soy powder|Soy powder supplement
11325704|NCT02529904|Experimental|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.
~Adult participants will receive one dose of MF59-ATIV."
11325705|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
11325706|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
11325707|NCT02529878|Experimental|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
11325708|NCT02529865|Experimental|ADRCs and Adipose tissue|Periurethral injection of autologous adipose derived regenerative cells and adipose tissue
11325709|NCT02529852|Experimental|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.
~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.
~Each study cycle is 21 days."
11325710|NCT02529839|Experimental|Experimental|"Fludarabine 30mg/m2 for 4 days, Cyclophosphamide 50mg/kg for 2 days, Alemtuzumab administered subcutaneously 24mg total dose.
~Autologous bone marrow transplantation"
11325711|NCT02529826|Experimental|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
11325712|NCT02529813|Experimental|Arm I (CD19 positive chimeric antigen receptor T-cells)|"LYMPHODEPLETING CHEMOTHERAPY: Patients may receive standard chemotherapy comprised of fludarabine phosphate IV over 1 hour and cyclophosphamide IV over 3 hours on days -5 to -3 or cyclophosphamide IV every 12 hours on days -5 to -3 at the discretion of the treating physician.
~Within 30 days post completion of lymphodepletion, patients receive CD19 positive chimeric antigen receptor T-cells IV over 15-30 minutes on day 0, or split into two portions on days 0 and 1."
11325713|NCT02529800|Experimental|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
11325714|NCT02529800|Experimental|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
11325715|NCT02529800|Experimental|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
11325716|NCT02529787|Experimental|A Test|Test drug (Doxirazole) 1 capsule contains 60 mg of Dexlansoprazole
11325717|NCT02529787|Active Comparator|B Reference|Reference drug (Dexilant) 1 capsule contains 60 mg of Dexlansoprazole
11325718|NCT02529774|Experimental|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
11325719|NCT02529774|Active Comparator|Systemic Chemotherapy|
11325720|NCT02529761|Experimental|Sorafenib combined with TACE|220 subjects in this study group will receive the treatment of sorafenib combined with conventional TACE.
11325721|NCT02529761|Active Comparator|TACE monotherapy|110 subjects in this study group will receive the treatment of conventional TACE monotherapy.
11325722|NCT02529748|Experimental|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
11325723|NCT02529709|Experimental|High-protein meal condition|
11325724|NCT02529709|Active Comparator|High-monounsaturated fat meal condition|
11325725|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
11325726|NCT02529683|Experimental|Nuvaring (only arm)|Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
11325727|NCT02529670|Experimental|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
11325728|NCT02529670|Active Comparator|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
11325729|NCT02529670|Active Comparator|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
11325730|NCT02529657|Placebo Comparator|Placebo|23 patients were induced to think they will be getting the same treatment, although the LLLT is not operating.
11325731|NCT02529657|Experimental|Low level Laser Therapy|25 patients were submitted to spine surgery and have received low level laser therapy during surgery, 24 hours after surgery and 48 hours after surgery.
11325732|NCT02529644|Active Comparator|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
11325733|NCT02529644|Experimental|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
11325734|NCT02529631|Active Comparator|Drug: orlistat 60mg capsules|"A tailored blister-strip for one day contains
~three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with
~six placebo tablets Administration: 3 times daily 2 tablets with each main meal"
11325735|NCT02529631|Active Comparator|Medical device: polyglucosamine|"A tailored blister-strip for one day contains
~three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with
~six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine"
11325736|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.
~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
11325737|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.
~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
11325738|NCT02529605|Active Comparator|Product B® IsaGenesis®, Then IsaGenesis®|Participants will come into the clinic in a fasting state to receive the Product B® IsaGenesis®, which will be a one time dose of the liquid-gel formulation contained in 2 capsules, 1280 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the IsaGenesis®. This will be given for a comparison in a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule.
11325739|NCT02529605|Active Comparator|IsaGenesis®, Then Product B® IsaGenesis®|Participants will come into the clinic in a fasting state to receive the IsaGenesis®, which will be a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the Product B® IsaGenesis®. This will be given for a comparison in a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
11325740|NCT02529592|Experimental|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
11325741|NCT02529592|Placebo Comparator|Placebo|Placebo administered intravenously
11325742|NCT02529579|Active Comparator|Gemcitabine|Standard Gemcitabine Therapy
11325743|NCT02529579|Experimental|cellular immunotherapy & Gemcitabine|iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
11325744|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.
~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
11325745|NCT02529540|Other|Group 1|Self-refraction with adjustable glasses
11325746|NCT02529540|Other|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
11325747|NCT02529540|Other|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
11325748|NCT02529527|Experimental|MyFamilyPlan|Web-based health education tool (interactive self-assessment) provided for participant completion 7-10 days prior to a scheduled primary care visit.
11325749|NCT02529527|No Intervention|Control|Standard preconception health education document provided for participant review 7-10 days prior to a scheduled primary care visit.
11325750|NCT02529514|Active Comparator|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
11325751|NCT02529514|Placebo Comparator|Placebo|Placebo per os for 7 days at 10 pm every day
11325752|NCT02529501||SA|Patients undergoing spinal anesthesia
11325753|NCT02529501||GA|Patients undergoing short general anesthesia
11325754|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
11325755|NCT02529475|Experimental|Gadoteric acid|Gadoteric acid 0.2 mmol/kg
11325756|NCT02529462|Experimental|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
11325757|NCT02529462|Active Comparator|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
11325758|NCT02529449|Placebo Comparator|Placebo|once daily
11325759|NCT02529449|Experimental|ASP1941 Low dose group|once daily
11325760|NCT02529449|Experimental|ASP1941 Middle dose group|once daily
11325761|NCT02529449|Experimental|ASP1941 High dose group|once daily
11325762|NCT02529423|Placebo Comparator|Placebo|Placebo
11325763|NCT02529423|Experimental|Multi-nutrient supplement|Multi-nutrient supplement
11325764|NCT02529423|Experimental|Placebo + Behavioral Activation|Placebo + Behavioral Activation
11325765|NCT02529423|Experimental|Multi-nutrient + Behavioral Activation|Multi-nutrient + Behavioral Activation
11325766|NCT02529410|Experimental|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
11325767|NCT02529410|Active Comparator|Biventricular leads|1 left ventricular lead and one right ventricular lead
11325768|NCT02529397|Experimental|Adaptive Working Memory Training|The experimental group will receive working memory training through a commercial computerized program: five weeks of adaptive working memory training concurrently with a behavioral weight loss program. Adaptive working memory training becomes progressively more challenging depending on an individual's performance on a given task. They will attend weekly classes of a behavioral weight loss program.
11325769|NCT02529397|Placebo Comparator|Non-adaptive Working Memory Training|The control group will receive five weeks of non-adaptive (placebo) cognitive training concurrent with the identical behavioral weight loss program as in the experimental group. Non-adaptive cognitive training remains at a constant level.
11325770|NCT02529384||malignant group|The lesion which is malignant tumors in breast
11325771|NCT02529384||begin group|The lesion which is begin lesion in breast
11325772|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
11325773|NCT02529371|Experimental|UriCap-RM|The device is comprised of a reusable part and a single use adhesive tape. The device is removed once daily and the reusable part is rinsed, dried and reapplied with a new adhesive tape.
11325774|NCT02529358|Experimental|EG stand|Standardized text messages
11325775|NCT02529358|Experimental|EG ind|Personalized text messages
11325776|NCT02529358|Other|Control|Standardized text messages after 10 weeks
11325777|NCT02529345|Experimental|RoadSaver stent|patient treated with the RoadSaver stent of Terumo
11325778|NCT02529332|Experimental|Omega-3 Supplementation Group|Omega-3 supplementation
11325779|NCT02529332|No Intervention|Control Group|
11325780|NCT02529319|Experimental|MRI-Guided Ablation|"Surgery
~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
11325781|NCT02529319|Active Comparator|Conventional Ablation|"Surgery
~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
11325782|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
11325783|NCT02529293|Active Comparator|BioChaperone Lispro U-100|injection of 2 doses of 0.2 U/kg on separate visits
11325784|NCT02529293|Experimental|BioChaperone Lispro U-200|injection of 2 doses of 0.2 U/kg on separate visits
11325785|NCT02529280|Experimental|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
11325786|NCT02529280|No Intervention|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
11325787|NCT02529267||Experienced abuse|Experienced IPV in the past 12 months
11325788|NCT02529267||Did not experience abuse|Did not experience IPV in the past 12 months.
11325789|NCT02529254|Experimental|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
11325790|NCT02529254|No Intervention|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
11325791|NCT02529241|Experimental|Group 1: LCB01-0371|Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
11325792|NCT02529241|Experimental|Group 2: LCB01-0371|Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
11325793|NCT02529228|Experimental|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
11325794|NCT02529228|Experimental|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
11325795|NCT02529228|Experimental|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
11325796|NCT02529228|Experimental|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
11325797|NCT02529215|Experimental|Just-in-time training (JITT) group|Receive a 20min just-in-time simulation-based teaching session targeting: (1) CPR quality and (2) medication administration within 3 hours of the scheduled in situ simulation.
11325798|NCT02529215|No Intervention|No additional training (control) group|Control group who receives no additional training.
11325799|NCT02529202|Experimental|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
11325800|NCT02529189|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
11325801|NCT02529189|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
11325802|NCT02529176|Experimental|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
11325803|NCT02529176|No Intervention|No alert|Physicians will receive no best-practice alert from the electronic medical record.
11325804|NCT02529163|Active Comparator|Late-life Schizophrenia ICP|"The Late-Life Schizophrenia ICP arm will follow a medication algorithm composed of 3 trials and titration schedule with prompts.
~First trial is Risperidone (2- 4mg daily).
~Second trial: Quetiapine (100 - 400mg daily) OR Aripiprazole (100 - 200mg daily) OR OR Ziprasidone (80mg daily) OR Loxapine (100mg daily)
~Third trial: Clozapine (450mg daily) or Olanzapine (20mg daily)
~If non compliant depot preparation of: Paliperidone (50 - 150mg monthly), Risperidone (12.5 - 50mg q 2 weeks), Flupentixol (10 - 20mg q 2-3 weeks) or Aripiprazole ( up to 400mg monthly)
~Prompts will be given to for non-pharmacological interventions such as:
~metabolic monitoring
~skin hygiene
~pain management
~nutritional counseling
~counseling"
11325805|NCT02529163|Active Comparator|Treatment as Usual (TAU)|The TAU will not receive any prompts to follow a specific treatment. The TAU group will be treated according to the current standard of care by the treating physician. They will have an opportunity to be offered the same non-pharmacological interventions seen with the ICP group but at the discretion of the treating physician. Pharmacological interventions will include an anti-psychotic medication that is selected at the discretion of treating physician with no set titration schedule or timeline to meet a maximum dosage. Max dosage will be decided by the treating physician.
11325806|NCT02529150|Experimental|exercise|
11325807|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
11325808|NCT02529124|Placebo Comparator|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
11325809|NCT02529124|Active Comparator|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
11325810|NCT02529124|Active Comparator|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
11325811|NCT02529111|Experimental|intervention|"The Echonavigator software will be used on all patients. It will be used after the introduction of the percutaneous closure of ASD prosthesis. The image fusion on fluoroscopy will then be applied."
11325812|NCT02529098|Sham Comparator|asymptomatic patients|fMRI Asymptomatic patients
11325813|NCT02529098|Experimental|symptomatic patients|fMRI patients with visual difficulties
11325814|NCT02529085|Experimental|Infants with PWS|Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
11325815|NCT02529085|Other|control group|Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
11325816|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
11325817|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
11325818|NCT02529059|Experimental|Switch from Atripla to Eviplera|
11325819|NCT02529046|Active Comparator|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
11325820|NCT02529046|Placebo Comparator|Aerobic exercise|Placebo group received 4 g/day of olive oil.
11325821|NCT02529020|Experimental|Mouthguard|All subjects perform all tests wearing mouthguard.
11325822|NCT02529020|Experimental|No mouthguard|All subjects perform all tests without mouthguard
11325823|NCT02529007|Active Comparator|Standard|These patients have standard colonoscopy performed
11325824|NCT02529007|Experimental|Endocuff|These patients have colonoscopy performed with the endo-cuff attached to the end of the colonoscope
11325825|NCT02528994|Experimental|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
11325826|NCT02528994|Experimental|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
11325827|NCT02528994|Experimental|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
11325828|NCT02528994|Experimental|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
11325829|NCT02528981|Experimental|Probiotic|L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to 100 randomized pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU). These organisms have been previously shown to colonize the vagina after being taken orally (11) and displace the pathogens causing bacterial vaginosis (12) and vaginal yeast infections (13), and have been shown to be an effective treatment, or accessory to treatment of these conditions. (7- 9, 13)
11325830|NCT02528981|Placebo Comparator|Placebo|Placebo capsules will be supplied to 100 randomized pregnant people in gelatin capsules that are identical to the probiotics that the experimental group will receive.
11325831|NCT02528968|Other|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
11325832|NCT02528955|Active Comparator|A:De-Intensification Radiotherapy (RT) primary tumor region|"A:De-Intensification Radiotherapy (RT) primary tumor region
~≤ pT2, R ≥ 5 mm, L0, Pn0
~> 3 lymph node metastasis or patients with < 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection"
11325833|NCT02528955|Active Comparator|B:De-Intensification Radiotherapy contralateral lymph nodes|"> pT2 and/or R < 5mm and/or L1 and/or Pn1
~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
11325834|NCT02528955|Active Comparator|C:De-Intensification RT primary tumor region /contralateral LN|"≤ pT2, R ≥ 5 mm, L0, Pn0
~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
11325835|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
11325836|NCT02528929|Active Comparator|At-risk serology|Gluten-free diet
11325837|NCT02528929|Active Comparator|Not at-risk serology|Gluten-free diet
11325838|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
11325839|NCT02528903|Experimental|Cohort A|
11325840|NCT02528903|Experimental|Cohort B|
11325841|NCT02528903|Experimental|Cohort C|
11325842|NCT02528903|Experimental|Cohort D|
11325843|NCT02528903|Experimental|Cohort E|
11325844|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
11325845|NCT02528877|Experimental|Supportive care (ruxolitinib phosphate, tacrolimus, sirolimus)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV over 20 minutes on day -4. Beginning greater than 48 hours after completion of melphalan, patients undergo peripheral blood stem cell or bone marrow transplant according to standard guidelines on day 0.
~GVHD PROPHYLAXIS: Patients receive ruxolitinib phosphate PO BID on days -3 to 30 tapered to day 60, tacrolimus IV continuously or PO BID on days -3 to 100 , and sirolimus PO QD on day -3 to 100. Treatment continues in the absence of disease progression or unacceptable toxicity."
11325846|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
11325847|NCT02528864||Endometrial/uterine cancer|"1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.
~2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.
~3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
11325848|NCT02528851|Experimental|Higher CPAP|Infants extubated to CPAP level 2cm H2O higher than extubation EAP
11325849|NCT02528851|Active Comparator|Equivalent CPAP|Infants extubated to CPAP equivalent to extubation EAP
11325850|NCT02528838||Patients receiving Revlimid according to clinical practice|
11325851|NCT02528825|Experimental|smooth emergence|ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
11325852|NCT02528812|Experimental|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
11325853|NCT02528812|Experimental|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
11325854|NCT02528812|Sham Comparator|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
11325855|NCT02528812|Experimental|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
11325856|NCT02528812|No Intervention|control group|received no intervention
11377939|NCT02182453|Placebo Comparator|Placebo|
11325857|NCT02528799|Experimental|Nexvax2 DQ2.5 Homozygotes (Cohort 1)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
11325858|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
11325859|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
11325860|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
11325861|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
11325862|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
11325863|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
11325864|NCT02528773||HIV positive|Persons newly diagnosed with HIV.
11325865|NCT02528760|Experimental|Metaclopromide group|
11325866|NCT02528760|Experimental|Erythromycin group|
11325867|NCT02528760|Placebo Comparator|Placebo group|
11325868|NCT02528747||Study population|Breast cancer patients with metastatic bone disease
11325869|NCT02528721|Experimental|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
11325870|NCT02528721|Experimental|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
11325871|NCT02528708|Placebo Comparator|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
11325872|NCT02528708|Experimental|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
11325873|NCT02528695|Active Comparator|Healthy euglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
11325874|NCT02528695|Active Comparator|healthy hypoglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
11325875|NCT02528695|Experimental|Type 2 diabetes hypoglycemic clamp|In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
11325876|NCT02528682|Experimental|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
11325877|NCT02528669|Experimental|RX Navigait|Individuals in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals. In addition, they will be given additional education about the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
11325878|NCT02528669|No Intervention|Control Group|Participants in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals but will not receive additional education regarding the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
11325879|NCT02528656|Experimental|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
11325880|NCT02528656|Experimental|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
11325881|NCT02528643|Experimental|Enzalutamide|Participants received enzalutamide 160 mg once daily until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.
11325882|NCT02528643|Placebo Comparator|Placebo|Participants received placebo once daily until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.
11325883|NCT02528630|Experimental|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
11325884|NCT02528630|Active Comparator|Control group|Performed a session regarding joint protection and energy conservation
11325885|NCT02528617|Other|Gaucher Type 1 or 3|Velaglucerase alfa IV 60 units/kg every other week for duration of the study.
11325886|NCT02528604|Active Comparator|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
11325887|NCT02528604|Active Comparator|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
11325888|NCT02528604|Active Comparator|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
11325889|NCT02528591|Experimental|renal transplant patient|
11325890|NCT02528578|Experimental|healthy volunteers|
11325891|NCT02528565||Patients with failed RYGB (EWL <50%)|
11325892|NCT02528552|Active Comparator|LH80 PRO|Low level laser therapy
11325893|NCT02528552|Sham Comparator|Sham device|No low level laser therapy
11325894|NCT02528539|Experimental|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.
~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.
~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
11325895|NCT02528526|Experimental|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
11326033|NCT02527629||Decellularized human valves|Aortic heart valve replacement
11325896|NCT02528513|Experimental|midazolam|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
~After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation."
11325897|NCT02528513|Experimental|midazolam/propofol|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
~After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation."
11325898|NCT02528513|Experimental|midazolam/dexmedetomidine|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
~After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation."
11325899|NCT02528500|Experimental|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
11325900|NCT02528474|Experimental|Pantera Lux|
11325901|NCT02528474|Active Comparator|SeQuent Please|
11325902|NCT02528461||Sofosbuvir|"All patients receiving Sofosbuvir based treatment regimes during the study period will be included in the study.
~All patients will receive all interventions (galactose elimination capacity test, gastroscopy, fibroscan), except liver biopsy which the patients may decline to participate in without affecting the participation in the rest of the study. If varices are found during the gastroscopy a liver vein catheterization will be performed."
11325903|NCT02528448|Active Comparator|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
11325904|NCT02528448|Active Comparator|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
11325905|NCT02528435||JIA patients|observationational study including children diagnosed with JIA. Patients aged 9 years and above, whom are treated with low-dose MTX may be included.
11325906|NCT02528435||ALL patients|observationational study including children diagnosed with ALL. Patients aged 9 years and above, whom are in maintenance treatment with low-dose MTX may be included.
11325907|NCT02528422|Active Comparator|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
11325908|NCT02528422|Active Comparator|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
11325909|NCT02528422|Placebo Comparator|Isotonic Sodium Chloride|Intravenous injection on examination day.
11325910|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
11325911|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
11325912|NCT02528396|Experimental|BioChaperone insulin lispro|
11325913|NCT02528396|Active Comparator|Humalog®|
11325914|NCT02528383|Experimental|Vagifem|Postmenopausal women diagnosed with breast cancer, are currently on an anti-estrogen called an aromatase inhibitor and you have agreed to undergo treatment with Vagifem based on your physician's recommendation.
11325915|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
11325916|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.
~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
11325917|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Subjects will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
11325918|NCT02528357|Experimental|Part 1B: GSK3174998 Monotherapy- Cohort expansion|Subjects will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation part 1A) Q3W for up to 2 years or 35 cycles, whichever comes first.
11325919|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Subjects will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
11325920|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Subjects will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
11325921|NCT02528344|Experimental|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
11325922|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
11325923|NCT02528318|Experimental|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP
~1 repeat dose allowed if repeat dosing criteria are met."
11325924|NCT02528318|Experimental|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP
~1 repeat dose allowed if repeat dosing criteria are met."
11325925|NCT02528318|Experimental|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP
~1 repeat dose allowed if repeat dosing criteria are met."
11325926|NCT02528318|Experimental|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP
~1 repeat dose will be allowed if repeat dosing criteria are met."
11325927|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
11325928|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
11325929|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
11325930|NCT02528279|Other|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:
~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
11325931|NCT02528266|Experimental|Nerve Capping Device|Implant with the experimental device
11325932|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
11325933|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
11325934|NCT02528253|Experimental|Tanezumab 5 mg SC|
11325935|NCT02528253|Experimental|Tanezumab 10 mg SC|
11325936|NCT02528253|Active Comparator|Tramadol PR oral|
11325937|NCT02528240|Experimental|+ L-PRF|With leukocyte and platelet rich fibrin
11325938|NCT02528240|Active Comparator|- L-PRF|Without leukocyte and platelet rich fibrin
11325939|NCT02528227|Experimental|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
11325940|NCT02528227|Placebo Comparator|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
11325941|NCT02528214|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
11325942|NCT02528214|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
11325943|NCT02528201|Active Comparator|Celecoxib 200 milligrams mg QD|celecoxib 200 milligrams (mg) once a day (QD)
11325944|NCT02528201|Active Comparator|Celexocib 400 mg QD|celecoxib 400 milligrams (mg) once a day (QD)
11325945|NCT02528201|Active Comparator|Diclofenac 50 mg TID|diclofenac 50 milligrams (mg) three times a day (TID)
11325946|NCT02528188|Active Comparator|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
11325947|NCT02528188|Experimental|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
11325948|NCT02528188|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
11325949|NCT02528175|Experimental|MRg-FU|Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
11325950|NCT02528149||patients with renal aneurysm|Patient with one or more renal artery aneurysm (RAA) operated and with tissue; adjacent part and aneurysm; cryopreserved. Blood sample performed at day 1.
11325951|NCT02528136|Experimental|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
11325952|NCT02528136|Active Comparator|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
11325953|NCT02528123|Experimental|Small incision lenticule extraction|Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.
11325954|NCT02528110|Sham Comparator|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
11325955|NCT02528110|Experimental|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
11325956|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
11325957|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
11325958|NCT02528084|Experimental|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
11325959|NCT02528084|Experimental|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
11325960|NCT02528084|No Intervention|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
11325961|NCT02528071||Patients|ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
11325962|NCT02528071||Control|Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT
11325963|NCT02528058||Myopic traction maculopathy|
11325964|NCT02528032|Other|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
11325965|NCT02528019|Active Comparator|DPP-4 inhibitors|sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)
11325966|NCT02528019|Active Comparator|SGLT2 inhibitors|ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)
11325967|NCT02528019|Active Comparator|Glimepiride|glimepiride (0.5-8mg daily)
11325968|NCT02528006|Other|Titanium Bridges|Surgery
11325969|NCT02527993|Experimental|Glucobay|Tablet Glucobay (acarbose) 50 mg x 6 daily for 7 days.
11325970|NCT02527993|Experimental|Januvia|Tablet Januvia (sitagliptin) 100 mg orally O.D for 7 days.
11325971|NCT02527993|Experimental|Verapamil|Tablet Verapamil 120 mg orally O.D for 7 days.
11325972|NCT02527993|Experimental|Victoza|Subcutaneous injection of Victoza (liraglutide) 0,6-1,2 mg O.D for three weeks.
11325973|NCT02527993|Experimental|Signifor|Subcutaneous injection of Signifor (pasireotide) 300 µg as a single dose prior to a meal tolerance test.
11325974|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
11325975|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
11325976|NCT02527967||Group 1 (≤4 days)|Group 1 consisted of patients whose hospital stay was shorter or equal to the target LOS (≤ 4 days).
11325977|NCT02527967||Group 1 (>4 days)|In group 2 were patients whose hospital stay was longer than 4 days.
11325978|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.
~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
11325979|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.
~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
11325980|NCT02527941|Experimental|metronidazole|50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).
11325981|NCT02527928||desoxycholate|Amphotericin B desoxicholate
11325982|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
11325983|NCT02527928||ABLiposomal|Amphotericin B liposomal
11325984|NCT02527915|Experimental|Mental Health eConsults|Primary care clinics that will receive the eConsults intervention at the start of the study.
11325985|NCT02527915|Active Comparator|Usual care|"Primary care clinics that will deliver care as usual for nine months, and will receive the eConsults intervention nine months subsequent to the eConsults intervention clinics."
11325986|NCT02527902|Experimental|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
11325987|NCT02527902|Experimental|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
11325988|NCT02527902|Experimental|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
11325989|NCT02527902|Experimental|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
11325990|NCT02527902|Experimental|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2.
11325991|NCT02527889|Experimental|Exercise Group|The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
11325992|NCT02527889|No Intervention|Control Group|The control group will receive no exercise training and continue to receive standard medical care.
11325993|NCT02527876|Experimental|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
11325994|NCT02527876|Experimental|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
11325995|NCT02527876|Placebo Comparator|Delayed Control/FtBit Flex|No exercise offered
11325996|NCT02527863|Active Comparator|60 mg Tolvaptan|Oral administration of 60 mg tolvaptan on each examination day.
11325997|NCT02527863|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet.
11325998|NCT02527850|Experimental|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
11325999|NCT02527850|Sham Comparator|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
11326000|NCT02527837|Active Comparator|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
11326001|NCT02527837|Placebo Comparator|Placebo|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
11326002|NCT02527824|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.
~Oxaliplatin 65 mg/m2 iv on day 1
~Irinotecan 135 mg/m2 iv on day 1
~S-1 80 mg/m2/day on day 1-7"
11326068|NCT02527343|Active Comparator|Open Label Extension (OLE)|Volanesorsen administered subcutaneously once weekly for 104 weeks
11326003|NCT02527811|Experimental|ulinastatin group|the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
11326004|NCT02527811|No Intervention|control group|patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
11326005|NCT02527798|Experimental|Furosemide Cohort 1|Within cohort 1, infants will be randomized using a 3:1 scheme to receive furosemide or placebo. Those randomized to receive furosemide will receive (1mg/kg daily intravenously or 2 mg/kg daily enterally for 28 days.
11326006|NCT02527798|Placebo Comparator|Placebo Cohort 1|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
11326007|NCT02527798|Experimental|Furosemide Cohort 2|Cohort 2 Infants will receive furosemide (1mg/kg every 6 hours intravenously or 2 mg/kg every 6 hours daily enterally) for 28 days.
11326008|NCT02527798|Experimental|Furosemide Cohort 3|Cohort 3 Infants will receive furosemide (2mg/kg every 6 hours intravenously or 4 mg/kg every 6 hours daily enterally) for 28 days.
11326009|NCT02527798|Placebo Comparator|Placebo Cohort 2|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
11326010|NCT02527798|Placebo Comparator|Placebo Cohort 3|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
11326011|NCT02527785|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"triple combination with oxaliplatin, irinotecan, and S-1.
~Treatment will be delivered as a 2-week cycle.
~Oxaliplatin 65 mg/m2 iv on day 1
~Irinotecan 135 mg/m2 iv on day 1
~S-1 80 mg/m2/day on day 1-7"
11326012|NCT02527772|Experimental|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
11326013|NCT02527772|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
11326014|NCT02527746|Experimental|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
11326015|NCT02527746|Experimental|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
11326016|NCT02527746|Experimental|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
11326017|NCT02527733|Active Comparator|Ranibizumab|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
11326018|NCT02527733|Active Comparator|Ranibizumab and laser|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
11326019|NCT02527720|Experimental|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
11326020|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg bid in combination with ritonavir 100 mg bid and escalating to lonafarnib 75 mg bid and then 100 mg bid as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
11326021|NCT02527694|Experimental|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
11326022|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
11326023|NCT02527681|Experimental|Ceftobiprole|single dose of ceftobiprole at 7.5 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril
11326024|NCT02527668|Experimental|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
11326025|NCT02527668|Active Comparator|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
11326026|NCT02527668|Placebo Comparator|Placebo|1 Placebo capsule per day for 6 months
11326027|NCT02527655|Experimental|Choice-Based Physical Activity and Active Transportation|Participants will meet one-on-one with an activity coach to develop a choice-based physical activity and active transportation plan based on their interest, abilities, and resources; attend group-based motivational meetings; and receive ongoing support and encouragement for physical activity and active transportation (e.g., telephone-assisted support, community centre and transit passes).
11326028|NCT02527655|No Intervention|Wait-List Control|Participants will be offered the Choice-Based Physical Activity and Active Transportation intervention after the experimental arm has completed the study.
11326029|NCT02527642|Active Comparator|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
11326030|NCT02527642|Active Comparator|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
11326031|NCT02527642|Experimental|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
11326032|NCT02527642|Experimental|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
11326034|NCT02527616|Experimental|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
11326035|NCT02527616|Experimental|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
11326036|NCT02527603|Experimental|Spaso Method|Randomized for Sp method + 1 initial dose of 50mg dexketoprofen IM or 25mg Oral
11326037|NCT02527603|Experimental|Boss-Holzach-Matter Method|Randomized for BHM method +1 initial dose of 50mg dexketoprofen IM or 25mg Oral
11326038|NCT02527590|Experimental|patient with neuropathic pain with allodynia|
11326039|NCT02527590|Experimental|healthy volunteers|
11326040|NCT02527577|Experimental|ropivacaïne chlorhydrate monohydrate|
11326041|NCT02527577|Placebo Comparator|placebo|
11326042|NCT02527564|Experimental|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
11326043|NCT02527564|Placebo Comparator|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
11326044|NCT02527551|Other|Haptic massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
11326045|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
11326046|NCT02527525|Experimental|Stepped Care|150 subjects will be randomized to the stepped care intervention. All 150 participants will be assigned a parent coach after randomization to stepped care condition. At the child's next follow up clinic visit participants who have elevated depression scores OR who's child has not met A1c target will move on to Step 2 of the intervention- 5 sessions with a study interventionist. At the following child's clinic visit, participants can either remain in Step 1, move to Step 2, or if needed, move on to Step 3- using a continuous glucose monitor for 1 week followed by a meeting with a certified diabetes educator and a diabetes team clinical psychologist.
11326047|NCT02527525|No Intervention|Usual Care|Participants randomized to usual care will participate in regular diabetes clinic visits and diabetes education, as they would have done without participation in this study.
11326048|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
11326049|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
11326050|NCT02527499|Experimental|ROCBT group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Ride-On Cars with Bimanual Training Program (ROCBT) group.
11326051|NCT02527499|Active Comparator|Early Mobility Training group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Early Mobility Training Program group.
11326052|NCT02527499|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Regular Therapy Program group.
11326053|NCT02527486||No predefined subgroups|
11326054|NCT02527473|No Intervention|Standard Education Group|Control group will receive standard basic life support training for one hour.
11326055|NCT02527473|Experimental|HEROS Group|HEROS group will receive the dispatcher-assisted basic life support training that includes standardized video-based CPR education, interactive role-playing with the dispatcher as well as group discussion for one hour.
11326056|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
11326057|NCT02527421|Experimental|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
11326058|NCT02527421|Experimental|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
11326059|NCT02527395|Other|Clinical pain models|Brief thermal sensitization. Heat pain detection threshold. Pain during 1 min. thermal stimulation
11326060|NCT02527382|Experimental|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
11326061|NCT02527382|No Intervention|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
11326062|NCT02527369|Experimental|XP1100RF group|Subjects in the XP1100RF group will be treated with the XP1100RF device.
11326063|NCT02527356|Experimental|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
11326064|NCT02527356|Active Comparator|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
11326065|NCT02527356|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
11326066|NCT02527343|Active Comparator|volanesorsen 300mg|volanesorsen administered subcutaneously once weekly for 52 weeks
11326067|NCT02527343|Placebo Comparator|Placebo|Placebo administered subcutaneously once weekly for 52 weeks.
11378001|NCT02182063|Experimental|BIBF 1120 low dose|
11326069|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
11326070|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=55%
11326071|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<55%.
11326072|NCT02527304|Experimental|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
11326073|NCT02527291||Study Group|"The Study group will comprise of seropositive CMV patients undergoing cardiothorathic surgery and having a complicated postoperative course.
~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done three times: at enrollment, follow up 1 (7 days post operation) and follow up 2 (14 days post operation).
~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
11326074|NCT02527291||Control Group 1|"The first control group will be comprised of patients who are seropositive CMV undergoing cardiothorathic surgery and having a normal postoperative course.
~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done two times: at enrollment and follow up 1 (7 days after discharge).
~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
11326075|NCT02527291||Control Group 2|"The second control group will include seronegative patients for CMV undergoing cardiothorathic surgery with complicated and uncomplicated post-operative course.
~Blood work for CMV PCR and IL28 will be done at enrollment. All other visits include data collection from computerized medical records only."
11326076|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
11326077|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
11326078|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
11326079|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
11326080|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.
~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
11326081|NCT02527252|Experimental|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:
~Pelvic Diaphragm Release.
~Respiratory Diaphragm Release.
~Thoracic Inlet Release.
~Hyoid release.
~Sacral technique for stabilize L5/sacrum.
~CV-4 Still Point Induction."
11326082|NCT02527252|Active Comparator|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
11326083|NCT02527226|No Intervention|No facial exercises|This group will not receive any training in facial exercises.
11326084|NCT02527226|Experimental|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
11326085|NCT02527213|Experimental|Sodium Thiosulfate|Sodium Thiosulfate at 25g in 100 ml normal sterile saline (NSS)
11326086|NCT02527213|Placebo Comparator|Placebo|similarly-formulated placebo in 100 ml NSS
11326087|NCT02527200|Experimental|Liraglutide|
11326088|NCT02527200|Placebo Comparator|Placebo|
11326089|NCT02527187|Experimental|Betula verrucosa allergen extract|"The investigational product contained the allergen extract of the pollen of Betula verrucosa and will be tested by administration onto skin. The test will be carried out on the forearm following prick test technique.
~The allergen extract of the pollen of Betula verrucosa will be tested in four concentrations (100, 50, 25 and 10 HEP/mL)."
11326090|NCT02527174|Experimental|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.
~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
11326091|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.
~They are intended for single use only."
11326092|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
11326093|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
11326094|NCT02527135|Experimental|Behavioural|Intervention arm receiving weekly HIV sensitization text messages
11326095|NCT02527135|No Intervention|Control|No weekly messages were sent to this group
11326133|NCT02526862|Active Comparator|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
11326165|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
11326096|NCT02527122|Experimental|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.
~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
11326097|NCT02527109|Placebo Comparator|Placebo|Intra-anal placebo administered BID.
11326098|NCT02527109|Experimental|Nifedipine 12 mg/day|Intra-anal Nifedipine 12 mg administered OD.
11326099|NCT02527109|Experimental|Nifedipine 24 mg/day|Intra-anal Nifedipine 12 mg administered BID.
11326100|NCT02527096|Experimental|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
11326101|NCT02527083|Active Comparator|BIA|Balanced Inhalational Anesthesia (consisting of a sevoflurane inhaled anesthestic only)
11326102|NCT02527083|Active Comparator|TIVA-K|Total intravenous anesthetic with ketamine
11326103|NCT02527083|Active Comparator|TIVA-R|Total intravenous anesthetic with remifentanil
11326104|NCT02527070|Experimental|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
11326105|NCT02527070|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
11326106|NCT02527044|Experimental|Treatment: FFR prior to CABG|Patients will undergo a fractional flow reserve prior to their coronary bypass surgery. The results will be blinded from both physician and patients. 6 months after surgery, the investigators will evaluate the impact of preoperative FFR on arterial bypass graft functionality
11326107|NCT02527031|Active Comparator|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
11326108|NCT02527031|Active Comparator|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
11326109|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
11326110|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
11326111|NCT02527005|Active Comparator|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
11326112|NCT02527005|Active Comparator|Sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses
11326113|NCT02526992|Other|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
11326114|NCT02526979|Experimental|mirabegron|single dose
11326115|NCT02526966|Other|patient with primitive form of IgA nephropathy|
11326116|NCT02526953|Experimental|Paclitaxel|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.
11326117|NCT02526953|Active Comparator|Standard|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.
11326118|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART< 200/mm3.
~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
11326119|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
11326120|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART> 350/mm3.
~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
11326121|NCT02526927|Experimental|Patients 20 - 30 years-old|HR-pQCT and DEXA for measure bone quality and quantity
11326122|NCT02526927|Experimental|Patients 10 - 20 years-old|Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
11326123|NCT02526914|Experimental|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
11326124|NCT02526914|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
11326125|NCT02526914|Placebo Comparator|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
11326126|NCT02526901||No treatment|
11326127|NCT02526888|Experimental|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
11326128|NCT02526888|Experimental|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
11326129|NCT02526875|Experimental|night|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
11326130|NCT02526875|Active Comparator|morning|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
11326131|NCT02526862|No Intervention|A-Mask or direct interface|Mask or direct interface
11326132|NCT02526862|Active Comparator|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
11326163|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
11326134|NCT02526862|Active Comparator|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
11326135|NCT02526849|Experimental|Fecal microbiota transplantation (FMT)|On day 1-6, patients received 100ml fresh FMT by nasointestinal tube, once per day. The nasointestinal tube was placed in the patient's proximal jejunum through endoscopy. Then, donor fecal microbiota was infused within 5 minutes through nasointestinal tube.
11326136|NCT02526849|Experimental|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
11326137|NCT02526836|Other|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.
~Conventional surgery"
11326138|NCT02526836|Active Comparator|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.
~Complete mesocolic excision with central vascular ligation"
11326139|NCT02526823|Active Comparator|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses
11326140|NCT02526823|Experimental|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses
11326141|NCT02526810|Active Comparator|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
11326142|NCT02526810|Experimental|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
11326143|NCT02526784|Active Comparator|Injection A|Degarelix s.c. standard injections
11326144|NCT02526784|Experimental|Injection B|Degarelix s.c. optimised injections
11326145|NCT02526784|Experimental|Injection C|Degarelix i.m. injections
11326146|NCT02526771|Experimental|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
11326147|NCT02526771|Active Comparator|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
11326148|NCT02526758|Experimental|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
11326149|NCT02526758|Active Comparator|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
11326150|NCT02526745|Experimental|high doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
11326151|NCT02526745|Experimental|low doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
11326152|NCT02526745|Experimental|high doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
11326153|NCT02526745|Experimental|middle doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with middle doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
11326154|NCT02526745|Experimental|low doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
11326155|NCT02526745|Placebo Comparator|placebo|placebo in 100 adults aged 50-80 years old on day 0
11326156|NCT02526732|Experimental|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
11326157|NCT02526719|No Intervention|Standard Nipple-Sparing Mastectomy|Patients in the control group will receive usual care. The surgical oncologist will perform the NSM and sentinel lymph node biopsy if indicated (active breast cancer or DCIS). We will submit a nipple core biopsy and a 1cm thick biopsy of immediately retro-areolar ductal tissue for permanent section pathology for control patients, and all patients will have the mastectomy specimen submitted for permanent section pathology. Under the same general anaesthesia, the plastic surgeon will perform the IBR (2-stage tissue expander to implant or 1-stage direct to implant). Patients who later have a positive nipple core and retro-areolar biopsy will have a discussion with the surgical oncologist regarding the need for revision breast surgery to excise the NAC, as is current practice.
11326158|NCT02526719|Experimental|Nipple Delay Intervention|Patients in the experimental group will have a nipple-delay intervention in addition to usual care. The nipple delay procedure will be performed by the plastic surgeon in the minor clinic procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
11326159|NCT02526706|Experimental|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
11326160|NCT02526693|Other|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
11326161|NCT02526693|Other|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
11326162|NCT02526680|Experimental|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
11326166|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
11326167|NCT02526654|Experimental|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
11326168|NCT02526641||AbbVie|
11326169|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
11326170|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
11326171|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
11326172|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
11326173|NCT02526615|Placebo Comparator|Placebo|placebo, 2 tablets per day
11326174|NCT02526615|Active Comparator|Metformin|500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
11326175|NCT02526615|Active Comparator|Rosiglitazone|2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day
11326176|NCT02526602|Experimental|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
11326177|NCT02526602|Active Comparator|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
11326178|NCT02526576|Experimental|Stromal Vascular Fraction|Subjects will receive stromal vascular fraction assisted fat transfer.
11326179|NCT02526576|Active Comparator|Biopsy for Control -regular fat transfer|Subjects will receive regular fat transfer. A biopsy procedure will analyzes the different between experimental and control groups.
11326180|NCT02526563||Iliac crest wound catheter group|These patients will receive an iliac crest wound catheter after an iliac crest bone harvest to repair a palatal defect. This catheter is part of standard of care. This study will collect blood to measure unbound ropivicaine levels.
11326181|NCT02526550|Experimental|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
11326182|NCT02526537||Gefitinib|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
11326183|NCT02526537||Non-specific treatment|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
11326184|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
11326185|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
11326186|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
11326187|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
11326188|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
11326189|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
11326190|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
11326191|NCT02526511|Experimental|Diagnostic (pMRI)|Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.
11326192|NCT02526498|Experimental|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
11326193|NCT02526485||Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
11326194|NCT02526472|Experimental|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
11326195|NCT02526472|Experimental|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
11326196|NCT02526459|Experimental|birth plan|Use of birth plan
11326197|NCT02526459|No Intervention|no birth plan|No use of birth plan
11326198|NCT02526446|Experimental|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
11326199|NCT02526446|Other|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
11326200|NCT02526433||Pregnancy women and new mothers|The study tracks what interventions women are already registered in and compares these with their mental wellbeing.
11326201|NCT02526420|Experimental|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects >= 35 years of age
11326202|NCT02526420|Experimental|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects < 35 years of age
11326203|NCT02526420|Experimental|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
11326204|NCT02526407|No Intervention|Control|Participants continue with usual care. No planned intervention.
11326205|NCT02526407|Active Comparator|Group play|Participants take part in 10 weeks of group play activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
11326206|NCT02526407|Experimental|Singing|Participants take part in 10 weeks of group singing activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
11326207|NCT02526394|Active Comparator|1|Repevax + Meningitec
11326208|NCT02526394|Active Comparator|2|Repevax + Neis-VacC
11326209|NCT02526394|Active Comparator|3|Repevax + Menitorix
11326210|NCT02526394|Active Comparator|4|Boostrix + Meningitec
11326211|NCT02526394|Active Comparator|5|Boostrix + NeisVacC
11326212|NCT02526394|Active Comparator|6|Boostrix + Menitorix
11326213|NCT02526394|Active Comparator|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
11326214|NCT02526394|Active Comparator|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
11326215|NCT02526381|Experimental|Danlou Tablets|Danlou prescription is a tablet, each piece weighs 0.3 g, taken orally, three times a day, five at a time, from jilin Cornell's pharmaceutical corporation, Limited Liability Company .
11326216|NCT02526381|Experimental|Tongmai Yangxin Pills|Tongmai Yangxin prescription is a pill,each pill weighs 0.1 g,taken orally, 2 times a day,40 pills at a time,produced by tianjin new pharmaceutical group corporation, Limited Liability Company . LeRenTang pharmaceutical.
11326217|NCT02526381|No Intervention|no drugs|
11326218|NCT02526368|Experimental|Pre-surgical Prostate Cancer patients|"A minimum of 20 patients will be required to have high-risk localized disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy.
~Magnetic Resonance (MR) scan using pyruvate (13C) injection prior to prostate surgery.Participants will remain monitored on the study until the time of your radical prostatectomy or 30 days after the pyruvate (13C) injection, whichever is longer."
11326219|NCT02526355|Experimental|Mobile based Intervention|Mobile based Intervention (Learning Through Play Plus) comprised of both LTP and CBT
11326220|NCT02526355|No Intervention|Waiting List Control|Waiting List Control group will receive no intervention, but intervention will be offered to interested participants at the end of the study
11326221|NCT02526342|Active Comparator|Negative Pressure Wound Therapy|Patients receive a Negative Pressure Wound Therapy-Dressing (V.A.C. Ultra (KCI®,San Antonio, Texas, USA) with a subatmospheric pressure of 125mmHg to cover the muscle flap for five days following surgery.
11326222|NCT02526342|No Intervention|Conventional Dressing|Patients receive a conventional dressing for the muscle flap including fatty gauze and cotton gauze.
11326223|NCT02526329|Experimental|Treatment (donor regulatory T lymphocytes)|Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
11326224|NCT02526316|Other|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
11326225|NCT02526303|Experimental|Anticoagulation|Drug: Nadroparin Calcium and Warfarin Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,along with Nadroparin Calcium 85IU／kg，subcutaneous, q12h,for the first 5 days at least.
11326226|NCT02526303|No Intervention|Non-anticoaglated|No anticoagulatoin or other treatment for PVT will be used in this group of patients.
11326227|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
11326228|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
11326229|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
11326230|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
11326231|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
11326232|NCT02526264|Experimental|Krankenhaus Nordwest Concept|specific preoperative education program realised by a specialized stoma-therapist containing individualized information on material maintenance, hygiene, nutrition, complications, activities of daily life and occupation
11326233|NCT02526264|Experimental|Standard concept|standard preoperative education program administered by a surgeon containing information on surgery, outcome, risks and alternatives
11326234|NCT02526238|Experimental|TMS and trunk rotation|TMS and trunk rotation
11326235|NCT02526238|Sham Comparator|Sham TMS and trunk rotation|Sham TMS and trunk rotation
11326236|NCT02526225|Active Comparator|ginkgo diterpene lactone meglumine injection|ginkgo diterpene lactone meglumine injection
11326237|NCT02526225|Placebo Comparator|Ginkgo diterpene lactone meglumine injection simulation|Ginkgo diterpene lactone meglumine injection simulation
11326238|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
11326239|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
11326619|NCT02523729|Experimental|intervention one|subjects drunk one can Anke Malz product.
11326240|NCT02526199|Active Comparator|Group BA|Bupivacaine + Adrenaline Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml
11326241|NCT02526199|Experimental|Group BAD|Bupivacine + Adrenaline + Dexamethasone Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml PLUS Dexamethsone 8 mg
11326242|NCT02526186|No Intervention|Standard of Care|Standard of Care only
11326243|NCT02526186|Experimental|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
11326244|NCT02526173|Experimental|dHACM|This group will receive RALP using full nerve sparing technique plus dHACM application.
11326245|NCT02526173|Other|Control|This group will receive RALP using full nerve sparing technique only.
11326246|NCT02526160|Experimental|Burosumab 1 mg/kg|Burosumab 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
11326247|NCT02526160|Placebo Comparator|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by burosumab 1 mg/kg, for the duration of the study.
11326248|NCT02526147|No Intervention|Control|Receives no intervention
11326249|NCT02526147|Experimental|Cash|Household receives cash transfer monthly for 6 months
11326250|NCT02526147|Experimental|Voucher|Household receives food voucher to use at local supermarket monthly for 6 months
11326251|NCT02526147|Experimental|Food|Household receives food transfer composed of rice, lentils, canned sardines, and vegetable oil, monthly for 6 months
11326252|NCT02526134|Experimental|Laying of medical devices|radio opaque markers
11326253|NCT02526121|Experimental|Phlebotomy associated with dietary and lifestyle counseling|
11326254|NCT02526121|Active Comparator|Dietary and lifestyle counseling.|
11326255|NCT02526108|Experimental|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
11326256|NCT02526082||Total, observational|Various cardiovascular risk groups described below
11326257|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
11326258|NCT02526082||High-risk control|Healthy but at high risk in 1974
11326259|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
11326260|NCT02526082||Sick control|Medications or clinical disease in 1974
11326261|NCT02526082||Refused|Refused or no response in 1974
11326262|NCT02526069|Other|SweetSpot users|Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview.
11326263|NCT02526056|Experimental|Physiotherapists|The physiotherapist have to play the exergame once.
11326264|NCT02526056|Experimental|elderly people|The elderly people have play the exergame twice.
11326265|NCT02526043|Experimental|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
11326266|NCT02526043|Experimental|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
11326267|NCT02526030|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
11326268|NCT02526030|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
11326269|NCT02526030|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
11326270|NCT02526017|Experimental|Phase 1 a monotherapy dose escalation|FPA008: specified dose on specified days
11326271|NCT02526017|Experimental|Phase 1a combination therapy dose escalation|FPA008 + BMS-936558: specified dose on specified days
11326272|NCT02526017|Experimental|Phase 1b combination therapy dose expansion|FPA008 + BMS-936558: specified dose on specified days
11326273|NCT02526004|Active Comparator|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
11326274|NCT02526004|Experimental|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
11326275|NCT02525991|Experimental|Staccato® Delivery System Loxapine|Staccato® Delivery System Loxapine, 9.1 mg one dose
11326276|NCT02525978|Experimental|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
11326277|NCT02525978|Experimental|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
11326278|NCT02525965|Experimental|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
11326279|NCT02525965|Active Comparator|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of narrow resection margin <1cm
11326280|NCT02525952|Experimental|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
11326281|NCT02525952|Active Comparator|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
11326282|NCT02525952|Experimental|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
11326283|NCT02525952|Active Comparator|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
11326284|NCT02525939|Active Comparator|dalcetrapib|dalcetrapib 600 mg po QD
11326285|NCT02525939|Placebo Comparator|placebo|matching placebo tablet po QD
11326286|NCT02525926|Experimental|denervation|
11326287|NCT02525926|Sham Comparator|control group|
11326288|NCT02525913|Other|Bi-lateral mastectomy|
11326289|NCT02525900|Placebo Comparator|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
11326290|NCT02525900|Experimental|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
11326497|NCT02524626|Active Comparator|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
11326498|NCT02524600|Experimental|"New Technology IQ-SPECT applied to myocardial imaging"|
11326291|NCT02525900|Experimental|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
11326292|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
11326293|NCT02525861|Experimental|Cohort I|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
11326294|NCT02525861|Experimental|Cohort II|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
11326295|NCT02525848|Active Comparator|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
11326296|NCT02525848|Active Comparator|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
11326297|NCT02525848|Active Comparator|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
11326298|NCT02525835|Experimental|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
11326299|NCT02525835|Experimental|High Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
11326300|NCT02525822|Experimental|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
11326301|NCT02525822|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
11326302|NCT02525822|Placebo Comparator|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
11326303|NCT02525822|Placebo Comparator|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
11326304|NCT02525809|Other|mobility insert with tripod attachment (Novae E®)|mobility insert with tripod attachment (Novae E®)
11326305|NCT02525809|Other|mobility insert with press fit pure (Sunfit®)|mobility insert with press fit pure (Sunfit®)
11326306|NCT02525809|Other|fixed insert (Quartz®).|fixed insert (Quartz®).
11326307|NCT02525796|Placebo Comparator|Placebo + Cinacalcet|Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks
11326308|NCT02525796|Active Comparator|Amiloride + Cinacalcet|Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks
11326309|NCT02525796|Experimental|Eplerenone + Cinacalcet|Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks
11326310|NCT02525770|Active Comparator|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
11326311|NCT02525770|Active Comparator|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
11326312|NCT02525757|Experimental|Group 1: Chemotherapy + Radiation|"Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.
~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.
~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
11326313|NCT02525757|Experimental|Group 2: MPDL3280A + Chemotherapy + Radiation|"Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation.
~Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.
~Maintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year."
11326314|NCT02525744|Experimental|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
11326315|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
11326316|NCT02525744|Experimental|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
11326317|NCT02525744|Experimental|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
11326318|NCT02525731||Patient Cohort|The TEACH patient cohort component will establish an observational cohort of HIV-infected patients on chronic opioid therapy.
11326319|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
11326320|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.
~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
11326321|NCT02525705|Experimental|Every EA patients|This is a one group interventional study. Every patient is included in the same arm.
11326322|NCT02525692|Experimental|A: GBM ONC201 Q3W|
11326323|NCT02525692|Experimental|B: GBM ONC201 Q1W|
11326324|NCT02525692|Experimental|C: GBM Surgical Cohort ONC201 Q1W|
11326325|NCT02525692|Experimental|D: H3 K27M Glioma ONC201 Q1W|
11326326|NCT02525692|Experimental|E: Diffuse Midline Glioma Surgical Cohort ONC201 Q1W|
11326327|NCT02525692|Experimental|F: Non-H3 K27M Diffuse Midline Glioma ONC201 Q1W|
11326328|NCT02525679|Experimental|BI 655130|
11326329|NCT02525679|Placebo Comparator|Placebo|
11326330|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
11326331|NCT02525640|Experimental|Hearing Aid|CROS hearing aid
11326332|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
11326333|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
11326334|NCT02525614|Active Comparator|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
11326335|NCT02525614|Active Comparator|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
11326336|NCT02525601|Active Comparator|Triathlon CR cemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented Peri-Apatite (PA) knee fixation and migration properties versus the cemented version.
11326337|NCT02525601|Active Comparator|Triathlon CR uncemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented PA knee fixation and migration properties versus the cemented version.
11326338|NCT02525588|Active Comparator|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
11326339|NCT02525588|Active Comparator|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
11326340|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
11326341|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
11326342|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
11326343|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
11326344|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
11326345|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
11326346|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
11326347|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
11326348|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
11326349|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
11326350|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
11326351|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
11326352|NCT02525510|Active Comparator|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.
11326353|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Right Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
11326354|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
11326355|NCT02525510|Active Comparator|Not Pump Eligible - Normothermia|Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
11326356|NCT02525510|Active Comparator|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
11326357|NCT02525497|Experimental|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h;
11326358|NCT02525497|Active Comparator|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h;
11326499|NCT02524587|Active Comparator|acetabular polyethylene vitamys®|acetabular polyethylene vitamys®
11326359|NCT02525484|Experimental|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
11326360|NCT02525484|Experimental|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
11326361|NCT02525484|Experimental|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
11326362|NCT02525484|Experimental|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
11326363|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 24 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.
~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
11326364|NCT02525458|Experimental|QAMS-containing PMMA|PMMA containing 5% QAMS
11326365|NCT02525458|Placebo Comparator|QAMS-free PMMA|PMMA containing 0% QAMS
11326366|NCT02525445|Active Comparator|acupuncture positive communication|Genuine acupuncture needles combined with positive communication regarding the expected treatment effects
11326367|NCT02525445|Sham Comparator|sham acupuncture positive communication|Sham acupuncture needles combined with positive communication regarding the expected treatment effects
11326368|NCT02525445|Active Comparator|acupuncture neutral communication|Genuine acupuncture needles combined with neutral communication regarding the expected treatment effects
11326369|NCT02525445|Sham Comparator|sham acupuncture neutral communication|Sham acupuncture needles combined with neutral communication regarding the expected treatment effects
11326370|NCT02525432|Experimental|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
11326371|NCT02525432|Placebo Comparator|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
11326372|NCT02525419|Experimental|Weight Loss Phase|12 week weight loss phase consisting of High Protein - Intermittent Fast-Low Calorie diet in 43 Obese Men and Women
11326373|NCT02525419|Experimental|Weight Loss Maintenance Phase|52 week weight loss maintenance phase consisting of either High Protein - Intermittent Fast (HP-IF) or Heart Healthy (HH) diet
11326374|NCT02525393|Experimental|tDCS+rTMS|Stroke patients were treated with an initial two weeks of transcranial direct current stimulation and after six months with two weeks of repetitive transcranial magnetic stimulation.
11326375|NCT02525393|Experimental|rTMS+tDCS|Stroke patients were treated with an initial two weeks of repetitive transcranial magnetic stimulation and after six months with two weeks of transcranial direct current stimulation.
11326376|NCT02525393|Sham Comparator|Sham stimulation|Stroke patients were treated with two weeks of sham transcranial direct current stimulation.
11326377|NCT02525380|Experimental|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.
~DC Bead is produced from polyvinyl alcohol."
11326378|NCT02525367|Experimental|PD-Experimental|PD patients using the online cognitive training for 8 weeks, 3 times a week
11326379|NCT02525367|Active Comparator|PD-Control|PD patients using the active control condition for 8 weeks, 3 times a week
11326380|NCT02525367|Experimental|MS-Experimental|MS patients using the online cognitive training for 8 weeks, 3 times a week
11326381|NCT02525367|Active Comparator|MS-Control|MS patients using the active control condition for 8 weeks, 3 times a week
11326382|NCT02525367|Experimental|postECT-Experimental|Depressed elderly treated with ECT patients using the online cognitive training for 8 weeks, 3 times a week
11326383|NCT02525367|Active Comparator|postECT-Control|Depressed elderly treated with ECT patients using the active control condition for 8 weeks, 3 times a week
11326384|NCT02525341|Experimental|Yoga Group|Participants in the yoga group received a total of eight weekly 45 minute yoga classes. A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
11326385|NCT02525341|Active Comparator|Aerobic and Strengthening Exercise Group|Participants in the exercise group received a total of eight weekly 45 minute exercise classes. A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants. Handouts were provided for participants to practice the program at home for 30 minutes a day, 3 days a week (on non-consecutive days).
11326500|NCT02524587|Active Comparator|standard polyethylene acetabular irradiated at 3 Mrad|standard polyethylene acetabular irradiated at 3 Mrad
11326386|NCT02525341|Active Comparator|General education|Participants in this group received a one-time OA educational brochures from the Arthritis Foundation including topics focusing on the disease process, diet and exercise and OA management education. Participants were instructed not to begin any new exercise programs during the study period.
11326387|NCT02525328||CT subjects|blood or saliva specimen
11326388|NCT02525328||subjects without CT|blood or saliva specimen
11326389|NCT02525315|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
11326390|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
11326391|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
11326392|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
11326393|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
11326394|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
11326395|NCT02525289|No Intervention|Control Group|six hours after extubation receiving breathing exercises. After 48 hour postoperative time, sitting on armchair and keeping the erect position and walking in the same place.
11326396|NCT02525289|Active Comparator|Bed Rotation Group|six hours after extubation receiving breathing exercises and submitted the continuous rotational bed therapy in the first postoperative day until 48 hours.
11326397|NCT02525289|Active Comparator|Orthostatic Group|six hours after extubation receiving breathing exercises and changing the body position following the sequence: sitting on the bed, sitting on the bed with the feet on the floor , standing and walking in the same place, in the first postoperative day until 48 hours.
11326398|NCT02525276|Experimental|training + HT|training + HT
11326399|NCT02525276|Experimental|training - HT|training - HT
11326400|NCT02525276|Placebo Comparator|-training + HT|-training + HT
11326401|NCT02525276|No Intervention|- training - HT|- training - HT
11326402|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
11326403|NCT02525250|Experimental|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
11326404|NCT02525237|Experimental|Apatinib plus S-1|Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
11326405|NCT02525224|Other|Nutritional Supplement|Proprietary nutritional supplement
11326406|NCT02525211|Experimental|Ropivacaine|Ropivacaine
11326407|NCT02525211|Placebo Comparator|placebo|physiological saline
11326408|NCT02525198|Placebo Comparator|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
11326409|NCT02525198|Experimental|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
11326410|NCT02525172|Experimental|ITT|immune modulation therapy
11326411|NCT02525159|Active Comparator|DIM pills|75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days
11326412|NCT02525159|Placebo Comparator|Placebo pills|2 pills once a day for 30 days
11326413|NCT02525146|Experimental|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
11326414|NCT02525146|No Intervention|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
11326415|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
11326416|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
11326417|NCT02525120|Experimental|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
11326418|NCT02525120|Active Comparator|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
11326419|NCT02525107|Experimental|SCD patients on Hydroxyurea|Omega-3 capsules [750 mg], 4 capsules a day for 52 weeks. [Each capsule will contain 417.9mg Docosahexaenoic acid [DHA], 50.8 mg Eicosapentaenoic acid [EPA] and 11.9mg Arachidonic acid [AA] and 1000 IU Vitamin E]
11326420|NCT02525107|Experimental|SCD patients not on Hydroxyurea|Dietary Supplement: Placebo [730 mg], 4 capsules a day for 52 weeks.[Each capsule will contain 538.2mg Oleic Acid [OA] and 1000 IU Vitamin E]
11326421|NCT02525094|Experimental|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
11326422|NCT02525094|Placebo Comparator|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
11326501|NCT02524574|Experimental|cardiac Rehabilitation|
11326502|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
11326423|NCT02525081|Experimental|ACE-inhibitor|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.
~Patients taking a dose of
~2,5 mg will take a half tablet a day
~5 mg will take one whole tablet a day
~10 mg will take two tablets a day"
11326424|NCT02525081|Placebo Comparator|Placebo|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.
~Patients taking a dose of
~2,5 mg will take a half tablet a day
~5 mg will take one whole tablet a day
~10 mg will take two tablets a day"
11326425|NCT02525068|Experimental|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose-levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
11326426|NCT02525068|Placebo Comparator|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
11326427|NCT02525068|Experimental|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
11326428|NCT02525055|Experimental|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus
11326429|NCT02525055|Experimental|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus
11326430|NCT02525055|Experimental|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus
11326431|NCT02525055|Experimental|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus
11326432|NCT02525055|Experimental|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
11326433|NCT02525055|Experimental|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
11326434|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
11326435|NCT02525042||Comparator 1|family controls
11326436|NCT02525042||Comparator 2|population controls
11326437|NCT02525029|Experimental|1: High-Risk aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.
~Individual patient dose reductions: If a patient has toxicity that meets the definition of dose limiting, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.
~Continue protocol treatment through day 7. Assess response at day 7:
~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.
~If no response, the patient will be taken off study treatment."
11326438|NCT02525029|Experimental|2a: Steroid-Dependent aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.
~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.
~Continue protocol treatment through day 14. Assess response at day 14:
~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.
~If no response, the patient will be taken off study treatment"
11326439|NCT02525029|Experimental|2b: Steroid-Refractory aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses.
~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.
~Continue protocol treatment through day 14. Assess response at day 14:
~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.
~If no response, the patient will be taken off study treatment"
11326440|NCT02525016|Experimental|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
11326441|NCT02525003|Placebo Comparator|Group 1: placebo|Group 1: daily dose of regular bread (87 g/d) and placebo pill (0 µg of vitamin D/d) for 8 weeks
11326442|NCT02525003|Experimental|Group 2: Vitamin D2 supplement|Group 2: daily dose of regular bread (87 g/d) and D2 supplement (25 µg of vitamin D2/d.) for 8 weeks
11326443|NCT02525003|Experimental|Group 3: Vitamin D3 supplement|Group 3: daily dose of regular bread (87 g/d) and D3 supplement (25 µg of vitamin D3/d.) for 8 weeks
11326444|NCT02525003|Experimental|Group 4: Vitamin D2-fortified bread|Group 4: D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
11326445|NCT02524990|Experimental|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
11326492|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
11326446|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.
~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
11326447|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
11326448|NCT02524964|Experimental|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
11326449|NCT02524964|Sham Comparator|control|same volume/day of normal saline.
11326450|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 20 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 20 mg/m2. Drug infusions will last approximately 2 hours.
11326451|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 26 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 26 mg/m2. Drug infusions will last approximately 2 hours.
11326452|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 34 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 34 mg/m2 . Drug infusions will last approximately 2 hours.
11326453|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 44 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 44 mg/m2 . Drug infusions will last approximately 2 hours.
11326454|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 57 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 57 mg/m2. Drug infusions will last approximately 2 hours.
11326455|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 74 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 74 mg/m2 . Drug infusions will last approximately 2 hours.
11326456|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 96 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 96 mg/m2 . Drug infusions will last approximately 2 hours.
11326457|NCT02524938|Experimental|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
11326458|NCT02524938|Sham Comparator|Control group|Conventional coffee (habitual diet)
11326459|NCT02524925|Active Comparator|fast track protocol|Oral fluids intake (0.5 lt) 6 hours after operation Mobilization 4 hours after operation Check discharge criteria the 4th-6th postoperative day
11326460|NCT02524925|No Intervention|conventional protocol|Oral intake after bowel mobilization Mobilization after the 1st postoperative day Check discharge criteria the 7th-15th postoperative day
11326461|NCT02524899|Active Comparator|Cognitive Remediation Therapy and placebo|7.5 weeks of twice weekly cognitive remediation sessions
11326462|NCT02524899|Experimental|Guanfacine and CRT|7.5 weeks of twice weekly cognitive remediation sessions with 8 weeks of guanfacine
11326463|NCT02524886|Active Comparator|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
11326464|NCT02524886|Sham Comparator|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
11326465|NCT02524860|Experimental|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
11326466|NCT02524847|Experimental|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
11326467|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
11326468|NCT02524821|Active Comparator|drugs only, fasted|1 x 850 mg metformin tablet, under fasting conditions.
11326469|NCT02524821|Experimental|Gelesis100 plus drugs, fasted|3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.
11326470|NCT02524821|Active Comparator|drugs only, fed|1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.
11326471|NCT02524821|Active Comparator|Gelesis100 plus drugs, fed|3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).
11326493|NCT02524652|Experimental|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
11326494|NCT02524652|Active Comparator|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
11326495|NCT02524639|Experimental|Sirolimus|All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.
11326496|NCT02524626|Sham Comparator|Sham stimulation|no stimulation of vagus nerve
11378002|NCT02182063|Experimental|BIBF 1120 high dose|
11326472|NCT02524795|Experimental|Hiomega-3 supplement|"Patients in the study group received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company). Participants were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.
~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
11326473|NCT02524795|No Intervention|Control group|"Patients in the control group did not receive the nutrient nor any kind of placebo. They were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.
~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
11326474|NCT02524782|Experimental|MEDI-4166|MEDI-4166 administered subcutaneously
11326475|NCT02524782|Placebo Comparator|Placebo|Placebo administered subcutaneously
11326476|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
11326477|NCT02524756|Active Comparator|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
11326478|NCT02524756|Active Comparator|Group (B)|laparoscopic radical hysterectomy type III/C2
11326479|NCT02524743|Placebo Comparator|Placebo (Group I)|"For pretreatment the patients were administered IV 5ml normal saline.
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
11326480|NCT02524743|Active Comparator|Group II|"For pretreatment the patients were administered IV acetaminophen 50 mg
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
11326481|NCT02524743|Active Comparator|Group III|"For pretreatment the patients were administered IV acetaminophen 25 mg.
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
11326482|NCT02524743|Active Comparator|Group IV|"For pretreatment the patients were administered IV lidocaine 20 mg
~The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
11326483|NCT02524743|Active Comparator|Group V|"For pretreatment the patients were administered IV lidocaine 40 mg.
~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
11326484|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
11326485|NCT02524717|Experimental|JNJ-56021927|Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
11326486|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
11326487|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
11326488|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.
~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
11326489|NCT02524678|Placebo Comparator|Placebo|Placebo
11326490|NCT02524678|Active Comparator|URC102|URC102
11326491|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
11326503|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
11326504|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
11326505|NCT02524548|Experimental|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
11326506|NCT02524548|No Intervention|Standard care|Routine care
11326507|NCT02524535|Other|Therapetic alliance|
11326508|NCT02524522|Active Comparator|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
11326509|NCT02524522|Active Comparator|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 > 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI > 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
11326510|NCT02524509||CHONDRON|Patients who already received autologous chondrocyte implantation using CHONDRON (Autologous Cultured Chondrocyte) for knee cartilage defects
11326511|NCT02524509||Microfracture|patients already underwent microfracture
11326512|NCT02524483|Experimental|Therapeutic Challenge Group|The Therapeutic Challenge Group will complete the Therapeutic Challenge Program twice a day, five days each week for 6 weeks.
11326513|NCT02524483|Active Comparator|Therapeutic Exercise Group|The Therapeutic Exercise Group will complete the Therapeutic Exercise Program twice a day, five days each week for 6 weeks.
11326514|NCT02524470|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
11326515|NCT02524457||Premenopausal|Premenopausal women going through gynecological surgery
11326516|NCT02524457||Postmenopausal|Postemnopausal women going through gynecological surgery
11326517|NCT02524457||Postmenopausal + HT|Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum)
11326518|NCT02524444|Active Comparator|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
11326519|NCT02524444|Active Comparator|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
11326520|NCT02524431|Active Comparator|Glaucoma subjects|During glaucoma surgery, collection of trabecular meshwork tissue during surgery that is not needed is cut away from the surgical site. The physician will keep this tissue for analysis by the researchers at Wills Eye Hospital and Thomas Jefferson University Center for Translational Medicine.
11326521|NCT02524431|Active Comparator|Control cadaver eyes|control cadaver eye are ordered and the collection of trabecular meshwork tissue during surgery and is processed at Thomas Jefferson University
11326522|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
11326523|NCT02524405||Normal Controls|Upto 85 normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
11326524|NCT02524405||Alzheimer's Disease (AD)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
11326525|NCT02524405||Mild Cognitive Impairment (VCI)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association criteria for amnestic or multi-domain MCI with MoCA score ≥18 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
11326526|NCT02524405||Subcortical Vascular Impairment (VCI)|Sixty-five subjects meeting the American Heart Association-American Stroke Association (AHA-ASA) criteria for probable vascular dementia (VaD) or probable vascular mild cognitive impairment (VaMCI) due to subcortical ischemic vascular disease , and probable or possible Cerebral Amyloid Angiopathy using the Modified Boston Criteria116 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
11326527|NCT02524405||LBD Spectrum|Sixty- five subjects with: Dementia with Lewy Bodies (DLB) meeting the criteria for probable Dementia with Lewy Bodies with MMSE score ≥20; or PD-MCI meeting the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's Disease with MoCA score 18-24; or; PDD meeting the criteria for probable Parkinson's Disease - Dementia and MMSE score ≥20 will be enrolled. All patients involved will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
11326528|NCT02524392|Experimental|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
11326529|NCT02524392|No Intervention|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
11326530|NCT02524379|Experimental|Glyburide Treatment Arm|Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
11326531|NCT02524366|Experimental|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
11326532|NCT02524366|Active Comparator|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
11326533|NCT02524353|Experimental|cardiac surgery|cardiac surgery
11326534|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
11326535|NCT02524327|Experimental|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.
~Objective of depth anesthesia: 40-60"
11326536|NCT02524327|Active Comparator|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.
~Objective of depth anesthesia: 40-60"
11326537|NCT02524301|Experimental|anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
11326538|NCT02524301|Experimental|Recovered anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
11326539|NCT02524301|Experimental|Healthy Volonteers|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
11326540|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11326541|NCT02524275|Experimental|Treatment (docetaxel, capecitabine)|Patients receive docetaxel IV over 1 hour on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11326542|NCT02524262|Experimental|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
11326543|NCT02524262|Placebo Comparator|Placebo|Oral intake of identically-looking placebo capsules
11326544|NCT02524249|Active Comparator|Early caffeine group|90 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates >75% of fluid goals by feeds.
11326545|NCT02524249|Placebo Comparator|Late caffeine group|90 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates >75% of fluid goals by feeds.
11326546|NCT02524236|Active Comparator|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.
~Botox injection in the prostate"
11326547|NCT02524236|Active Comparator|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.
~Botox injection in the prostate"
11326548|NCT02524223|Other|Population of couples candidate for MAP program|MAP = medically assisted procreation
11326549|NCT02524210|Experimental|Arm A|"Period  Dabigatran
~Washout period (at least 6 days)
~Period  Rabeprazole + Dabigatran
~Washout period (at least 6 days)
~Period  Omeprazole + Dabigatran"
11326550|NCT02524210|Experimental|Arm B|"Period Rabeprazole + Dabigatran 
~Washout period (at least 6 days)
~Period  Dabigatran
~Washout period (at least 6 days)
~Period  Omeprazole + Dabigatran"
11326551|NCT02524210|Experimental|Arm C|"Period  Rabeprazole + Dabigatran
~Period  Omeprazole + Dabigatran
~Period  Dabigatran"
11326552|NCT02524197|Active Comparator|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
11326553|NCT02524197|Active Comparator|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
11326554|NCT02524197|Active Comparator|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
11326555|NCT02524197|Active Comparator|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.
~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.
~Patients will record their daily intake of study medication on the diary provided."
11326556|NCT02524184|Experimental|Sildenafil|Eleven patients receive sildenafil 100mg/day (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM)for 7 days.
11326557|NCT02524184|Placebo Comparator|Placebo group|An identical placebo for 7 days in placebo group.
11326558|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
11326559|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
11326590|NCT02523950|Active Comparator|Combined group|Procedure/Surgery: Phacoemulsification + IOL implantation and DMEK are performed simultaneously.
11326620|NCT02523729|Experimental|intervention two|subjects drunk two cans Anke Malz product.
11326560|NCT02524158|Experimental|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
11326561|NCT02524158|No Intervention|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
11326562|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.
~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
11326563|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.
~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
11326564|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.
~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
11326565|NCT02524132|Experimental|Physical Activity|5 minute movement breaks
11326566|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
11326567|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
11326568|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
11326569|NCT02524093|Experimental|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
11326570|NCT02524093|Placebo Comparator|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
11326571|NCT02524080|Other|Emergency Department|Triage to optimal healthcare level
11326572|NCT02524080|Other|Healthcare Center|Triage to optimal healthcare level
11326573|NCT02524067|Experimental|Intervention|Intervention: Circadian lighting, systematic information, music, foreclosure of the individual patient
11326574|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
11326575|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
11326576|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
11326577|NCT02524041|Experimental|secondary hyperparathyroidism|Blood specimen and HR-pQCT for measure bone quality and quantity
11326578|NCT02524028||Case Participant Cohort|Participants with atrial fibrillation
11326579|NCT02524028||Control Participant Cohort|Participants without atrial fibrillation or any other heart disease
11326580|NCT02524015|Other|Control|Standard Physical Therapy
11326581|NCT02524015|Experimental|Intervention|Novel Physical Therapy
11326582|NCT02524002|Placebo Comparator|Usual Clear Diet|This intervention consists of soup broth, variety of juices (apple, cranberry, grape), ginger ale, water, and ice.
11326583|NCT02524002|Experimental|Accel Gel|"This intervention is an enhanced clear liquid gel is Accel Gel, produced by PacificHealth Labs of Matawan, NJ. This gel has 4:1 carb to protein ratio formula, and ingredients that are not contraindicated in pregnancy (only the flavors with minimal caffeine are used).
~http://www.pacifichealthlabs.com/accel-gel-all-natural-rapid-energy-gel-product.html"
11326584|NCT02523989||study group|children confirmed to have developmental delays
11326585|NCT02523989||control group|children with typical development
11326586|NCT02523976|Experimental|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
11326587|NCT02523963|Experimental|study group|"children with developmental delays participated 6 sessions of family work shop
~The family work shop has 5 courses, with 6 families in one course.
~Intervention of one course: 2-3 hours per session, one time per week, for a total of 6 weeks."
11326588|NCT02523963|No Intervention|control|children with normal development not participate the work shop followed up at before, and 6 weeks later
11326589|NCT02523950|Active Comparator|Staged group|Procedure/Surgery: Phacoemulsification + IOL implantation is performed in the first stage and DMEK is performed secondarily.
11326591|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.
~The criteria for exclusion of PE or DVT are:
~low or intermediate clinical probability and D-dimer <0,50 µg/mL
~low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)
~high clinical probability and negative CT and US.
~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
11326592|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.
~The criteria for confirmation of PE or DVT are:
~PE on spiral computed tomography (CT)
~proximal deep vein thrombosis on ultrasonography (US).
~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
11326593|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
11326594|NCT02523911|Active Comparator|Simethicone Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
11326595|NCT02523911|Placebo Comparator|Placebo Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
11326596|NCT02523898|Experimental|metformine and clomiphene citrate|. metformin will be given at a dose of 500 mg three times a day for 8weeks. .In case of failure of ovulation after the end of this period, metformin was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene. When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose.
11326597|NCT02523898|Active Comparator|placebo and clomiphene citrate|"The patients in group two will be receiving placebo. In case of failure of ovulation after the end of this period, placebo was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration .In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene.When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose. .
~10 days). ."
11326598|NCT02523872||Acute respiratory failure|Patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration
11326599|NCT02523859|Active Comparator|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
11326600|NCT02523859|Experimental|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
11326601|NCT02523846|Active Comparator|Background morphine infusion to IV-PCA Morphine|Calculate based on patient's age, in mg/hour
11326602|NCT02523846|Experimental|Patient re-education to IV-PCA Morphine|Using patient information leaflet
11326603|NCT02523833|Other|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
11326604|NCT02523820|Experimental|fluticasone propionate|Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation
11326605|NCT02523820|Placebo Comparator|placebo|Normal saline (NSS) 4 ml nebulized after extubation
11326606|NCT02523807||Patients with Parkinson's Disease|Patients with tremor due to Parkinson Disease
11326607|NCT02523807||Patients with Essential tremor|Patients with tremor due to Essential tremor
11326608|NCT02523794|Experimental|Electro-kinetically Modified Water|Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
11326609|NCT02523794|Placebo Comparator|Placebo|Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
11326610|NCT02523781|No Intervention|Control group|The control group does not receive the information pamphlet
11326611|NCT02523781|Experimental|Intervention group|The intervention group receives the information pamphlet
11326612|NCT02523768|Experimental|ATG-F|The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
11326613|NCT02523768|Active Comparator|Simulect|The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).
11326614|NCT02523755|Active Comparator|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
11326615|NCT02523755|Sham Comparator|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
11326616|NCT02523742|Other|Neuropsychiatric Disorders|Neuropsychiatric Disorders patients
11326617|NCT02523742|Other|Healthy volunteers|control subjects matched to patients by age, sex, socio-cultural level and laterality
11326618|NCT02523729|No Intervention|control|subjects drunk no Anke Malz product.
11326621|NCT02523716|Experimental|Hypoxia|Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
11326622|NCT02523716|Sham Comparator|Normoxia|Exposure to normal, sea-level air
11326623|NCT02523703|Other|Healthy Volunteers|Healthy Volunteers
11326624|NCT02523703|Other|Multiple Sclerosis patient|Multiple Sclerosis patient
11326625|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
11326626|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
11326627|NCT02523664|Active Comparator|Hydrocortisone|10 mg hydrocortisone orally
11326628|NCT02523664|Placebo Comparator|Placebo|placebo orally
11326629|NCT02523651|Experimental|DPSC injection|20 patients will receive DPSC injection（1000000 cells/ 0.5ml） at the local periodontal defects immediately after periodontal scaling and root planing.
11326630|NCT02523651|Placebo Comparator|Placebo control|20 patients will receive saline injection at the local periodontal defects immediately after periodontal scaling and root planing.
11326631|NCT02523638|Other|Pegylated- Proline-Interferon alpha-2b|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
11326632|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
11326633|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
11326634|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
11326635|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
11326636|NCT02523612|Experimental|Patients with atypical lesions|
11326637|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
11326638|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
11326639|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
11326640|NCT02523573||Study population|Adult ARF ICU patients needing BAL with HFNC
11326641|NCT02523560|Experimental|telerehabilitation group|1 week hospital rehabilitation and 8 weeks home-based telerehabilitation and telemanagement (including HomeMonitoring)
11326642|NCT02523560|No Intervention|control group|Patients qualified to the control group will undergo a 9-week procedure appropriate to their clinical condition/status standardized for a particular center (usual care).
11326643|NCT02523547|Experimental|Cavir|entecavir/0.5mg/day
11326644|NCT02523547|Active Comparator|Baraclude|entecavir/0.5mg/day
11326645|NCT02523534|Experimental|Recurrence Mapping|Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.
11326646|NCT02523521|No Intervention|Bronchopylmonary Dysplasia Control|Nothing
11326647|NCT02523521|Experimental|Bronchopylmonary Dysplasia Intervention|physical activity program.
11326648|NCT02523521|No Intervention|Healthy children|Nothing.
11326649|NCT02523508|Experimental|Experimental group|Passive manual lumbar mobilization on L2-3 level
11326650|NCT02523508|Placebo Comparator|Control group|Passive limb mobilization which did not involve the spine
11326651|NCT02523469|Experimental|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.
~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
11326652|NCT02523469|Experimental|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.
~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
11326653|NCT02523469|Experimental|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atzolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.
~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
11326654|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.
~For exploratory Arm 1:
~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
11326655|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.
~For exploratory Arm 1:
~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.
~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
11326656|NCT02523456|Experimental|Introduce EWS and Training on EWS|The group of patients who admitted to a ward where the staff has trained on EWS and EWS has been introduced.
11326657|NCT02523456|No Intervention|EWS not introduced|The group of patients who admitted to a ward where the staff has no special training on EWS and EWS has not been introduced.
11326658|NCT02523443|Active Comparator|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
11326659|NCT02523443|Experimental|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
11326660|NCT02523430|Experimental|HepaSphere|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
11326661|NCT02523430|Placebo Comparator|control|nasopharyngeal carcinoma patients received traditional therapy
11326662|NCT02523417|Experimental|HepaSphere|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
11326663|NCT02523417|Placebo Comparator|control|breast cancer patients received traditional therapy
11326664|NCT02523404|Experimental|HepaSphere|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
11326665|NCT02523404|Placebo Comparator|control|lung cancer patients received traditional therapy
11326666|NCT02523391|Experimental|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
11326667|NCT02523391|Experimental|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
11326668|NCT02523378|Experimental|ESAS Self-Administration - Group A|Participants complete the symptom questionnaire alone. It is then counterchecked by health care professional (HCP).
11326669|NCT02523378|Experimental|ESAS Assisted-Completion - Group B|Participants complete the symptom questionnaire with the help of the research nurse or assistant.
11326670|NCT02523365|Experimental|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
11326671|NCT02523365|Placebo Comparator|control|cervical carcinoma patients received traditional therapy
11326672|NCT02523352|Experimental|Treatment|Volunteers with a BMI > 35 Kg/m2 and central fat distribution, without any past medical history
11326673|NCT02523326||Group A|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
11326674|NCT02523326||Group B|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
11326675|NCT02523326||Group C|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
11326676|NCT02523313|Active Comparator|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
11326677|NCT02523313|Experimental|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
11326678|NCT02523313|Placebo Comparator|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
11326679|NCT02523300|Experimental|TEVAR+GC|The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR
11326680|NCT02523300|Placebo Comparator|TEVAR+Vehicle|The patients underwent TEVAR. Then saline will be given after TEVAR
11326681|NCT02523287|Active Comparator|Fluad - 5 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
11326682|NCT02523287|Active Comparator|Fluad - 3 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.
~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
11326683|NCT02523287|Placebo Comparator|Saline - 5 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.
~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
11326684|NCT02523287|Placebo Comparator|Saline - 3 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.
~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
11326685|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
11326686|NCT02523274|Experimental|Resveratrol 250 mg/day + exercise|250 mg/day resveratrol taken orally in combination with exercise
11326687|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
11326688|NCT02523261|Experimental|ADAPT|
11326689|NCT02523261|Active Comparator|Stent Retriever|
11326690|NCT02523248|Active Comparator|Tonsillectomy|Tonsillectomy with cold steel
11326691|NCT02523248|Active Comparator|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
11326692|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.
~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
11326693|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009
~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
11326694|NCT02523222|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
11326695|NCT02523222|Active Comparator|Dextrose Gel|Infants given 40% Dextrose gel (0.5ml/kg) in the buccal mucosa after their first feed, within the first hour of life.
11326696|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
11326697|NCT02523196|Active Comparator|Hepatic Venous Pressure Gradient (HVPG)|Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.
11326698|NCT02523196|Experimental|HepQuant-SHUNT (HQ-Shunt)|Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices.
11326699|NCT02523183||Subjects with medically refractory epilepsy|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.
11326700|NCT02523170|Experimental|EUS guided nCLE|For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
11326701|NCT02523157|Experimental|Intervention|Wellbeing Plan
11326702|NCT02523157|Active Comparator|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
11326703|NCT02523144|Active Comparator|Chloral Hydrate + placebo|Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
11326704|NCT02523144|Active Comparator|Dexmedetomidine 2mcg/kg + placebo|Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
11326705|NCT02523144|Active Comparator|Dexmedetomidine 3mcg/kg + placebo|Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
11326706|NCT02523131|Experimental|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
11326707|NCT02523131|Active Comparator|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
11326708|NCT02523105|Other|Participants diagnosed with depression.|EEG monitoring and evaluation
11326709|NCT02523105|Other|Healthy participants.|EEG monitoring and evaluation
11326710|NCT02523092|Experimental|Acthar gel|After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
11326711|NCT02523079|Experimental|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
11326712|NCT02523079|Experimental|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
11326713|NCT02523079|Experimental|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
11326714|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
11326715|NCT02523053|Active Comparator|Hepatectomy|Surgical removal of all lesions
11326716|NCT02523053|Experimental|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
11326717|NCT02523040|Experimental|Lenalidomide|"After the screening procedures confirm participation in the research study.
~- Lenalidomide Oral, Daily for 21 days of each cycle"
11326718|NCT02523027|Experimental|Experimental Group 1:|Oral nutritional supplement (List No S691/Z0) and dietary counseling
11326719|NCT02523027|Experimental|Experimental Group 2|Oral nutritional supplement (List No- P968/Z0) and dietary counseling.
11326720|NCT02523027|No Intervention|Control Group|Dietary Counselling only.
11326721|NCT02523014|Experimental|Arm A - vismodegib|Patients receive vismodegib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11326722|NCT02523014|Experimental|Arm B - GSK2256098|Patients receive FAK inhibitor GSK2256098 PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11326723|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
11326724|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
11326725|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
11378003|NCT02182050|Experimental|BIBF 1120 ES low dose|
11326726|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
11326727|NCT02522988|Experimental|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
11326728|NCT02522988|No Intervention|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
11326729|NCT02522988|No Intervention|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
11326730|NCT02522988|Experimental|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
11326731|NCT02522975|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
11326732|NCT02522975|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.
~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
11326733|NCT02522962|Experimental|GroupCoreSIT|Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training. Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
11326734|NCT02522962|Active Comparator|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
11326735|NCT02522949|Active Comparator|ColdZyme|ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
11326736|NCT02522949|Placebo Comparator|Placebo|Sugar based mouth spray manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
11326737|NCT02522936|Experimental|Biotene|Participants will be given Biotene oral spray to use as needed when taking oxybutynin.
11326738|NCT02522936|No Intervention|Routine care|Participants will be given routine care.
11326739|NCT02522923|Experimental|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
11326740|NCT02522923|Active Comparator|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
11326741|NCT02522910|Experimental|Roniciclib with Docetaxel|
11326742|NCT02522897|Active Comparator|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
11326743|NCT02522897|Experimental|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
11326744|NCT02522884|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
11326745|NCT02522871|Experimental|OCS Liver System|OCS Liver System
11326746|NCT02522871|Other|Control|Standard of care (ice)
11326747|NCT02522858|Placebo Comparator|Placebo|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, normal saline 0.5mL would be injected intravenously.
11326748|NCT02522858|Experimental|Atropine|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, ,atropine 0.03mg/kg would be injected intravenously.
11326749|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
11326750|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
11326751|NCT02522832|Experimental|Titre 1|Low infectious titre of innoculum
11326752|NCT02522832|Experimental|Titre 2|Medium infectious titre of innoculum
11326753|NCT02522832|Experimental|Titre 3|High infectious titre of innoculum
11326754|NCT02522819|Experimental|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
11326755|NCT02522806|Experimental|Group A|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle.
11326756|NCT02522806|No Intervention|Group B|none endometrial biopsy
11326757|NCT02522780|Experimental|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
11326758|NCT02522780|Placebo Comparator|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
11326759|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
11326760|NCT02522767|Placebo Comparator|Placebo|Matching placebo
11326761|NCT02522754|Placebo Comparator|Placebo|Placebo
11326762|NCT02522754|Experimental|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
11326763|NCT02522754|Experimental|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
11326764|NCT02522754|Experimental|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
11326765|NCT02522741|Experimental|Parenting STAIR|
11326766|NCT02522728|Active Comparator|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
11326807|NCT02522442|Experimental|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
11378004|NCT02182050|Experimental|BIBF 1120 ES high dose|
11326767|NCT02522728|Active Comparator|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
11326768|NCT02522715|Experimental|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of cycle 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
11326769|NCT02522702||Routine colonoscopy Cohort|
11326770|NCT02522689|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
11326771|NCT02522689|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
11326772|NCT02522676|Active Comparator|Conventional PCNL|Endoscopic kidney stone surgery: Patients will undergo conventional percutaneous nephrolithotripsy.
11326773|NCT02522676|Active Comparator|Mini PCNL|Endoscopic kidney stone surgery: Patients will undergo mini percutaneous nephrolithotripsy.
11326774|NCT02522676|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
11326775|NCT02522676|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
11326776|NCT02522676|Active Comparator|Retrograde intrarenal surgery|Endoscopic kidney stone surgery: Patients will undergo retrograde intrarenal surgery.
11326777|NCT02522676|Active Comparator|Extracorporeal shock wave lithotripsy|Non-invasive kidney stone treatment: Patients will undergo extracorporeal shock wave lithotripsy.
11326778|NCT02522663|No Intervention|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
11326779|NCT02522663|Experimental|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
11326780|NCT02522650|Experimental|Amiloride Phase|Subject receives 5mg of Amiloride twice daily for 8 weeks.
11326781|NCT02522650|Active Comparator|Triamterene Phase|Subject receives 50mg of Triamterene twice daily for 8 weeks.
11326782|NCT02522650|No Intervention|Washout Phase|Subject does not take any study medication for 4 weeks
11326783|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
11326784|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
11326785|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
11326786|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
11326787|NCT02522611|Experimental|Resiniferatoxin|Schedule a maximum of 3 periganglionic DRG injection(s) at contiguous level(s) to treat targetedDRG responsible for chronic CIBP
11326788|NCT02522598|Experimental|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
11326789|NCT02522598|Placebo Comparator|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
11326790|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
11326791|NCT02522572|Experimental|Group A|4 doses of plerixafor and plasmapheresis
11326792|NCT02522572|Experimental|Group B|4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
11326793|NCT02522572|Experimental|Group C|6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
11326794|NCT02522559|Experimental|Spice Intervention|Spice intervention: Student-approved vegetable recipes will be served in the school cafeteria.
11326795|NCT02522546||nasopharyngeal swab|Children ages 1-5 years and their household contacts
11326796|NCT02522533|Experimental|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
11326797|NCT02522520|Active Comparator|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.
~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
11326798|NCT02522520|Active Comparator|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity
~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
11326799|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
11326800|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
11326801|NCT02522494|Active Comparator|Intervention|Patients randomized to the intervention will view the video
11326802|NCT02522494|Other|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
11326803|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
11326804|NCT02522468|Experimental|Radioactive Seed Localization|Radioactive Seeds
11326805|NCT02522468|Active Comparator|Wire Localization|Wire
11326806|NCT02522455|Other|Preterm infants with RDS|
11378005|NCT02182050|Placebo Comparator|Placebo|
11326808|NCT02522442|Active Comparator|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
11326809|NCT02522429|Experimental|Low Intensity Focused Ultrasound Device|15 acute DOC patients, 15 chronic DOC patients
11326810|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
11326811|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
11326812|NCT02522390||Nutrition Researcher Cohort|This cohort study is an observational, one-group study. The intervention consists of research activities that participants are asked to perform throughout the cohort, including the use of do-it-yourself devices, filling out online-questionnaires and sample collection with supplied kits for the analysis of various health parameters. The frequency with which participants are asked to measure these health parameters varies, ranging from once to weekly.
11326813|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
11326814|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
11326815|NCT02522364|Active Comparator|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
11326816|NCT02522364|Active Comparator|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
11326817|NCT02522351|Active Comparator|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
11326818|NCT02522351|Active Comparator|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
11326819|NCT02522351|Active Comparator|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
11326820|NCT02522351|Experimental|Cereal extract concentration 1|Cereal extract at concentration 1
11326821|NCT02522351|Experimental|Cereal extract concentration 2|Cereal extract at concentration 2
11326822|NCT02522351|Experimental|Cereal extract concentration 3|Cereal extract at concentration 3
11326823|NCT02522338|Other|iohexol plasma clearance|patients had received iohexol for measuring GFR
11326824|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11326825|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11326826|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
11326827|NCT02522299|Placebo Comparator|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
11326828|NCT02522299|Experimental|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
11326829|NCT02522299|Placebo Comparator|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
11326830|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
11326831|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
11326832|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
11326833|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
11326834|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
11326835|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
11326836|NCT02522260|Active Comparator|Group 3|Standard supportive care
11326837|NCT02522247|Active Comparator|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
11326838|NCT02522247|No Intervention|Controls|Only waiting 6 months
11326839|NCT02522234|Experimental|F-627 240 µg/kg|"F-627 at the dose of 240 mcg/kg administered by s.c. injection on Day 2 of each cycle for up to 6 cycles.
~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
11326840|NCT02522234|Experimental|F-627 320 µg/kg|"F-627 at the dose of 320 mcg/kg administered by s.c. injection on Day 2 of each cycle for 6 cycles.
~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
11326841|NCT02522221|Experimental|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
11326842|NCT02522221|Active Comparator|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
11327159|NCT02520232|Experimental|Physical activity program (A)|Physical exercises
11326843|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
11326844|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
11326845|NCT02522182|Experimental|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
11326846|NCT02522182|Active Comparator|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
11326847|NCT02522169|Active Comparator|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:
~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
11326848|NCT02522169|Experimental|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
11326849|NCT02522156|Experimental|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:
~Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.
~Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.
~Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.
~Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
11326850|NCT02522156|Placebo Comparator|Control|"Four audiotape-guided imagery exercises, as follows:
~Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.
~Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.
~Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.
~Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
11326851|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
11326852|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
11326853|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
11326854|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
11326855|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
11326856|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
11326857|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
11326858|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
11326859|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
11326860|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
11326861|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
11326862|NCT02522091|Other|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
11326863|NCT02522091|Other|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
11326864|NCT02522091|Other|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
11326865|NCT02522091|Other|Alzheimer's Disease patient|Alzheimer's Disease patient
11326866|NCT02522091|Other|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
11326867|NCT02522078|Active Comparator|Dry Misoprostol|400 µg of dry misoprostol
11326868|NCT02522078|Experimental|Wet misoprostol|400 µg of wet misoprostol
11326869|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
11326941|NCT02521688||Group III (PTD + HP)|include tenmothersexhibiting spontaneous preterm delivery with healthy periodontium +incisional biopsy from placenta and GCF sample
11326870|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
11326871|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
11326872|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
11326873|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
11326874|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
11326875|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
11326876|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
11326877|NCT02522026||Healthy volunteers|
11326878|NCT02522026||Healthy smokers|
11326879|NCT02522026||COPD GOLD1|
11326880|NCT02522026||COPD GOLD2|
11326881|NCT02522026||COPD GOLD3/4|
11326882|NCT02522013|Experimental|Aminophylline group|IV injection of aminophylline
11326883|NCT02522013|Placebo Comparator|isotonic saline group|IV injection of isotonic saline group
11326884|NCT02522000||Patients with functional dyspepsia|
11326885|NCT02522000||Healthy controls|
11326886|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
11326887|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
11326888|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
11326889|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
11326890|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
11326891|NCT02521948|Experimental|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
11326892|NCT02521935|Active Comparator|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
11326893|NCT02521935|Active Comparator|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
11326894|NCT02521922|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
11326895|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
11326896|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
11326897|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
11326898|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
11326899|NCT02521870|Experimental|Dose Escalation Phase 1b|Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
11326900|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
11326901|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
11326902|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
11326903|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
11326904|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 5)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
11327160|NCT02520232|Experimental|Physical activity program (B)|Physical exercises
11326905|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 6)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
11326906|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 7)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
11326907|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 8)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
11326908|NCT02521857|Experimental|ALKS 5461|Sublingual tablet
11326909|NCT02521844|Experimental|Dose Escalation|ETC-1922159 + pembrolizumab
11326910|NCT02521844|Experimental|Dose Expansion|ETC-1922159 as single agent until disease progression, then in combination with pembrolizumab at the recommended dose (RD) identified in the dose escalation segment
11326911|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.
~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
11326912|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.
~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.
~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
11326913|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
11326914|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
11326915|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
11326916|NCT02521805|Experimental|PAF|Animal protein added fiber
11326917|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
11326918|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
11326919|NCT02521792|Experimental|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
11326920|NCT02521779|Experimental|Test Meal Saturated Fat|Saturated-fat Treatment Meal
11326921|NCT02521779|Experimental|Test Meal N-6 Fat|N-6 fat Treatment Meal.
11326922|NCT02521779|Experimental|Test Meal N-3 Fat|N-3 fat Treatment Meal.
11326923|NCT02521779|Experimental|Test Meal Low-fat|Low-fat Treatment Meal.
11326924|NCT02521766|Experimental|All HMIOL Cohort|HMIOL implantation with or without optic exchange
11326925|NCT02521766|Experimental|Cohort 1|HMIOL implantation with no optic exchange
11326926|NCT02521766|Experimental|Cohort 2|HMIOL implantation with optic exchange
11326927|NCT02521766|Other|Fellow Eye|IOL implantation per standard of care
11326928|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
11326929|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
11326930|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
11326931|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
11326932|NCT02521740||controls|someone who lives with an healthy elderly
11326933|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.
~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
11326934|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.
~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.
~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
11326935|NCT02521714|Experimental|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
11326936|NCT02521714|Experimental|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
11326937|NCT02521714|Experimental|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
11326938|NCT02521701|Experimental|NFL101|"Level 1: 100 µg
~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29
~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.
~Level 2: 200 µg
~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29
~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
11326939|NCT02521688||Group I (PTD + CP)|include ten mothers exhibiting spontaneous preterm delivery with moderate to severe chronic periodontitis +incisional biopsy from placenta and GCF sample
11326940|NCT02521688||Group II (TD + CP)|include ten mothers exhibiting spontaneous term delivery with moderate to severe chronic periodontitis+incisional biopsy from placenta and GCF sample
11326942|NCT02521688||Group IV (TD + HP)|ten mothersexhibiting spontaneous term delivery with healthy periodontium(Armitage GC. 1999)+ incisional biopsy from placenta and GCF sample
11326943|NCT02521675|Other|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
11326944|NCT02521675|Other|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
11326945|NCT02521662|Active Comparator|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
11326946|NCT02521662|Active Comparator|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
11326947|NCT02521662|Active Comparator|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
11326948|NCT02521649|Experimental|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
11326949|NCT02521649|Experimental|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
11326950|NCT02521649|Experimental|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
11326951|NCT02521649|Experimental|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
11326952|NCT02521649|Experimental|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
11326953|NCT02521636|Placebo Comparator|Anibiotic therapy guided with actual french recommandations|Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.
11326954|NCT02521636|Experimental|Anibiotic therapy guided with serum PCT value|"Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:
~PCT <0.1 ng / mL: no antibiotics
~0.1 <PCT <0.25 ng / mL: antibiotic advised
~PCT> 0.25 ng / mL: highly recommended antibiotics"
11326955|NCT02521623|Experimental|Surgimend|Patients randomized to this arm will receive SurgiMend® Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
11326956|NCT02521623|Active Comparator|Strattice|Patients randomized to this arm will receive Strattice™ Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
11326957|NCT02521610|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RG7625 as oral capsules once or twice daily for 8 days. Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin purified protein derivative [PPD], Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
11326958|NCT02521610|Experimental|RG7625|Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
11326959|NCT02521597|Experimental|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
11326960|NCT02521597|Active Comparator|Traditional otoscope|The control group will be using a classic otoscope
11326961|NCT02521571|Experimental|Intervention Group|
11326962|NCT02521571|Placebo Comparator|Control Group|
11326963|NCT02521558|Experimental|Intervention Group|In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
11326964|NCT02521558|Active Comparator|Control Group|The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.
11326965|NCT02521545|Experimental|BIIB061|Single oral dose of 30 mg BIIB061 of the new formulation
11326966|NCT02521532|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
11326967|NCT02521532|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
11326968|NCT02521519|Other|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
11327000|NCT02521311|Placebo Comparator|Placebo|Participants will receive placebo until 3 months and then will be off treatment until 9 month time point.
11327161|NCT02520232|No Intervention|Control|No physical exercices assigned by the protocol
11326969|NCT02521519|Other|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
11326970|NCT02521506|Experimental|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
11326971|NCT02521506|Active Comparator|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
11326972|NCT02521493|Experimental|Arm A (standard risk)|"INDUCTION II: Patients receive cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV over 1-15 minutes, and thioguanine PO BID on days 1-4. Induction II continues for a minimum of 28 days.
~INDUCTION III: Patients receive cytarabine, daunorubicin hydrochloride, and thioguanine as in Induction II. Induction III continues for a minimum of 28 days.
~INTENSIFICATION I: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 60-120 minutes on days 1-3. Intensification I continues for a minimum of 28 days.
~INTENSIFICATION II: Patients receive cytarabine and etoposide as in Intensification I. Intensification II continues for a minimum of 28 days.
~(This arm is closed to accrual and treatment with amendment #4A 01/07/2019)"
11326973|NCT02521493|Experimental|Arm B (high risk)|"INDUCTION II: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours on days 1-4 and mitoxantrone hydrochloride IV over 15-30 minutes on days 3-6. Induction II continues for a minimum of 28 days.
~INTENSIFICATION I: Patients receive high dose cytarabine IV over 1-3 hours Q12 hours and etoposide IV over 90-120 minutes on days 1-5. Intensification I continues for a minimum of 28 days.
~INTENSIFICATION II: Patients receive high dose cytarabine IV over 3 hours Q12 hours on days 1, 2, 8, and 9. Patients also receive asparaginase or asparaginase Erwinia chrysanthemi IM or IV over 30 minutes on days 2 and 9. Intensification II continues for a minimum of 28 days."
11326974|NCT02521480|Active Comparator|Active Transcranial Magnetic Stimulation|During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression.
11326975|NCT02521480|Sham Comparator|Sham Transcranial Magnetic Stimulation|During sham TMS, a coil will be placed on the left prefrontal area of the head. Sham TMS will simulate active treatment as described in active arm.
11326976|NCT02521467|Active Comparator|PRF|Platelets Rich Fibrin
11326977|NCT02521467|Placebo Comparator|palatal stent|Palatal stent
11326978|NCT02521454|Experimental|MBRT|Mindfulness-Based Resilience Training
11326979|NCT02521454|No Intervention|WL Control|waitlist control group
11326980|NCT02521441|Experimental|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
11326981|NCT02521441|Experimental|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
11326982|NCT02521441|Experimental|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
11326983|NCT02521415|Experimental|ketamine|ketamine (1mg/kg)
11326984|NCT02521415|Active Comparator|fentanyl|fentanyl (1.5 micrograms/kg)
11326985|NCT02521402|Other|Keloid Revision Surgery with Biovance|All enrolled patients will have Biovance applied during Keloid Revision Surgery
11326986|NCT02521389|Experimental|Part 1|3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required.
11326987|NCT02521389|Experimental|Part 2|Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects.
11326988|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
11326989|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
11326990|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
11326991|NCT02521363|Experimental|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
11326992|NCT02521363|Experimental|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
11326993|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
11326994|NCT02521337||pregnant women not in active labor|
11326995|NCT02521337||pregnant women in preterm labor|
11326996|NCT02521337||pregnant women in term labor|
11326997|NCT02521324|Experimental|Immediate treatment (IT)|Subjects from this group will perform 2 weeks of DGB with the DGB2 system immediately after 1 week of baseline monitoring. All subjects will answer questionnaires pertaining to their sleep quality.
11326998|NCT02521324|Active Comparator|Wait list control (WLC)|The subjects from the WLC group will do the same (answer questionnaires and perform 2 weeks of DGB with the DGB2 system) at a 1 week delay.
11326999|NCT02521311|Experimental|Clemastine|Participants will receive clemastine until 3 months and then will be off treatment until 9 month time point.
11327564|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
11327001|NCT02521298|Active Comparator|Strength Training + Placebo|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.
~Placebo: Ultrasound-guided subcutaneous injection of 2 ml isotonic saline over the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
11327002|NCT02521298|Experimental|Strength Training + Cortico-Steroid Inj.|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.
~Cortico-Steroid Injection: Ultrasound-guided injection of 1 ml depomedrol 40 mg/ml + 1 ml lidocaine 10 mg/ml deep to the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
11327003|NCT02521298|Experimental|Strength Training + Dry Needling|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.
~Dry Needling: Ultrasound-guided penetration of the proximal part of the common extensor tendon origin is repeated 10 times using a 0,8 mm needle, followed by subcutaneous injection of 2 ml isotonic saline superficial to the tendon. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
11327004|NCT02521285|Experimental|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
11327005|NCT02521285|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
11327006|NCT02521272|Experimental|air pocket|Breathing in the simulated avalanche snow.
11327007|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
11327008|NCT02521259||normal BIS group|BIS range from 40 to 60
11327009|NCT02521246|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 12,5 mg) a day, in the morning.
11327010|NCT02521246|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 25 mg) a day, in the morning.
11327011|NCT02521246|Active Comparator|Comparator: Losartan+hydrochlorothiazide (Hyzaar®)|The patients will take 1 tablet (Losartan 100 mg + Hydrochlorothiazide 25 mg) a day, in the morning.
11327012|NCT02521233|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
11327013|NCT02521233|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
11327014|NCT02521233|Active Comparator|Comparator: losartan+hydrochlorothiazide (Hyzaar®)|he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
11327015|NCT02521220|Experimental|L-citrulline|Oral food-supplemental amino-acid L-citrulline. 2 times 3g per day.
11327016|NCT02521220|Placebo Comparator|Maltodextrin|Maltodextrin as placebo. 2 times 3g per day
11327017|NCT02521207|Experimental|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
11327018|NCT02521207|Active Comparator|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
11327019|NCT02521207|Experimental|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
11327020|NCT02521207|Experimental|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
11327021|NCT02521194|Experimental|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
11327022|NCT02521194|Experimental|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
11327023|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
11327024|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
11327025|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
11327026|NCT02521168|Experimental|Oral triiodothyronine|Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
11327027|NCT02521168|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
11327028|NCT02521155|Experimental|Intervention group|Safeguard Your Smile an oral health literacy intervention.
11327029|NCT02521155|No Intervention|Control group|No intervention, only a conventional pamphlet will be given.
11327030|NCT02521142||AMD: treatment-naive|
11327031|NCT02521142||AMD: active neovascular AMD|
11327032|NCT02521129|Experimental|Ablation|Intervention: ablation of biopsy needle track with a new device
11327033|NCT02521116|Other|Healthy subjects|healthy study subjects, age 18-80 years
11327034|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
11328302|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
11327035|NCT02521090|Experimental|Treatment (EGFRBi-armed autologous T cells)|"PHASE I: Patients receive EGFRBi-armed autologous T cells IT twice weekly for 4 weeks.
~PHASE II: Patients receive EGFRBi-armed autologous T cells* IT twice weekly for 4 weeks and then IV over 15-30 minutes twice weekly for 2 weeks.
~*NOTE: Six selected patients receive EGFRBi-armed autologous T cells IV on day -3, -2, or -1 prior to first IT infusion."
11327036|NCT02521077|Experimental|Odd Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
11327037|NCT02521077|Experimental|Even Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
11327038|NCT02521064||Exclusive Enteral Nutrition (EEN)|The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
11327039|NCT02521064||Prednisone|Patients who receive the prednisone intervention will follow the Division of Pediatric Gastroenterology and Nutrition protocol for corticosteroid induction therapy, with 2 weeks of high dose IV/PO prednisone (maximum 40mg/day) followed by a 6 week wean (approximately decreasing 5mg/day per week). The patient will receive a phone call from the nurse practitioner at two weeks and will be seen in clinic at 4 weeks to assess progress and symptom improvement.
11327040|NCT02521051|Experimental|Alectinib and Bevacizumab.|"Phase 1
~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Alectinib, orally, twice a day, per cycle
~Bevacizumab, iv, once per cycle
~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
11327041|NCT02521025|Experimental|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
11327042|NCT02521025|Experimental|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
11327043|NCT02521012|Active Comparator|Vitamin D 10 micrograms|"Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as reference"
11327044|NCT02521012|Experimental|Vitamin D 100 micrograms|Vitamin D supplementation 100 micrograms/day given to depressed individuals
11327045|NCT02520999|Active Comparator|5days|5 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
11327046|NCT02520999|Active Comparator|35days|35 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
11327047|NCT02520986|Experimental|Carbon dioxide Laser ablation|Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
11327048|NCT02520986|Active Comparator|Electrocoagulation|Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
11327049|NCT02520973|Experimental|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
11327050|NCT02520973|Active Comparator|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
11327051|NCT02520947|Experimental|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
11327052|NCT02520947|Other|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
11327053|NCT02520934|Experimental|Case_Miglustat|Besides regular ERT, patients in this group also need to take Miglustat for 24 months.
11327054|NCT02520934|No Intervention|Control|Patients will be tested for their pupil cycle time.
11327055|NCT02520921|Active Comparator|Arm 1 : Novel strategy|enteric coated aspirin 100 mg in the morning and 100 mg in the evening
11327056|NCT02520921|Active Comparator|Arm 2 : Conventional strategy|enteric coated aspirin 100 mg in the morning
11327057|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
11327058|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
11327059|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
11327060|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
11327061|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
11327062|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
11328535|NCT02510781|Active Comparator|B group|Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab
11327063|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
11327064|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
11327065|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
11327066|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
11327067|NCT02520882|Experimental|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
11327068|NCT02520869|Active Comparator|swim-up|swim-up technique for semen processing
11327069|NCT02520869|Active Comparator|zeta test|zeta test technique for semen processing
11327070|NCT02520856||Hypertrophic cardiomyopathy|"All patients with newly diagnosed unexplained HCM will be prospectively included.
~All patients will undergo both classical genetic analysis and WES technology."
11327071|NCT02520843|Experimental|Crohn's disease treated by SVF|Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
11327072|NCT02520830|Active Comparator|Blueberry Group|Dietary Supplement: 22 gram freeze-dried blueberry powder per day
11327073|NCT02520830|Placebo Comparator|Placebo Group|blueberry polyphenol deprived powder 22 gram per day
11327074|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
11327075|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
11327076|NCT02520804|Active Comparator|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
11327077|NCT02520804|Experimental|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
11327078|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11327079|NCT02520778|Experimental|Treatment (navitoclax, osimertinib)|Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
11327080|NCT02520752|Experimental|INC280|
11327081|NCT02520739|Placebo Comparator|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
11327082|NCT02520739|Experimental|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
11327083|NCT02520739|Experimental|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
11327084|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
11327085|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
11327086|NCT02520713|Other|Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
11327087|NCT02520700|Experimental|Study participants|This was split scalp design - so each patient had one half of scalp treated with daylight PDT and one side treated with the artificial white light PDT - a surgical light (Maquet Power 500 LED surgery light)
11327088|NCT02520687|Experimental|Dietary nitrate, beetroot juice|Once daily 70mL dose of beetroot juice, containing 400mg inorganic nitrate, for 7 consecutive days.
11327089|NCT02520687|Placebo Comparator|Nitrate-depleted beetroot juice|Once daily 70mL dose of beetroot juice, depleted of nitrate, for 7 consecutive days.
11327090|NCT02520674|Other|Glaucoma and Ocular Hypertension|Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy.
11327091|NCT02520661|No Intervention|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
11327092|NCT02520661|Active Comparator|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
11327093|NCT02520648|Active Comparator|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
11327094|NCT02520648|Experimental|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
11327119|NCT02520505|Other|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
11328690|NCT02509715|Active Comparator|IONM group|Intraoperative nerve monitoring used thyroid surgery
11327095|NCT02520648|Experimental|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
11327096|NCT02520635||TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
11327097|NCT02520635||post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
11327098|NCT02520622|Experimental|Control|Patients use digital photographs loaded onto a mobile device
11327099|NCT02520622|Experimental|Reminders|Patients use digital photographs loaded onto a mobile device and receive skin exam reminders
11327100|NCT02520622|Experimental|Social Support|Patients use digital photographs loaded onto a mobile device and a social support network
11327101|NCT02520622|Experimental|Combined|Patients use digital photographs loaded onto a mobile device and a social support network and receive skin exam reminders
11327102|NCT02520609||Healthy volunteers|Healthy volunteers
11327103|NCT02520609||Patients with metabolic syndrome without NAFLD|Patients with metabolic syndrome without NAFLD
11327104|NCT02520609||Patients with NAFLD|Patients with NAFLD
11327105|NCT02520583|Experimental|MICROBAC|Bacterial cultures
11327106|NCT02520583|Placebo Comparator|Placebo|Maltodextrin
11327107|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
11327108|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
11327109|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
11327110|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
11327111|NCT02520544|Active Comparator|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
11327112|NCT02520544|Active Comparator|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
11327113|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
11327114|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
11327115|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
11327116|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
11327117|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
11327118|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
11327120|NCT02520505|Active Comparator|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
11327121|NCT02520492|Experimental|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.
~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
11327122|NCT02520479|Experimental|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1] before radiotherapy(RT) and then two consolidation cycles after RT."
11327123|NCT02520466|Active Comparator|flavanol-containing drink|flavanol-containing drink
11327124|NCT02520466|Placebo Comparator|flavanol-free drink|flavanol-free drink matched for taste and calories
11327125|NCT02520453|Experimental|Durvalumab|Durvalumab 20 mg/Kg IV Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
11327126|NCT02520453|Placebo Comparator|Placebo|Placebo Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
11327127|NCT02520440||GIF and/or MOF patients|Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
11327128|NCT02520440||Controls|patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
11327129|NCT02520427|Experimental|Group 1: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)|
11327130|NCT02520427|Experimental|Group 2: Minimal Residual Disease Positive (MRD+) AML|
11327131|NCT02520427|Experimental|Group 3: Myelodysplastic syndrome (MDS)|
11327132|NCT02520427|Experimental|Group 4: R/R AML with alternative pretreatment|
11327133|NCT02520427|Experimental|Group 5: R/R AML with alternative dose schedule|
11327134|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
11327135|NCT02520401|Experimental|Test|Probiotic tablet
11327136|NCT02520401|Placebo Comparator|Control|Control tablet
11327137|NCT02520388|Experimental|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)
~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
11327138|NCT02520388|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
11327139|NCT02520375|Experimental|Prebiotic|This group will be administered a prebiotic mouthrinse and toothpaste
11327140|NCT02520375|Placebo Comparator|Control|This group will be administered a control mouthrinse and toothpaste
11327141|NCT02520362||Postmenopausal Women|Postmenopausal Women
11327142|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
11327143|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
11327144|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
11327145|NCT02520336|Experimental|active management|Laboratoy test request given postpartum with phone reminder prior to test
11327146|NCT02520336|No Intervention|Routine care|
11327147|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
11327148|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
11327149|NCT02520310|Experimental|AVJ-514|The AVJ-514 system
11327150|NCT02520297|Experimental|TRV130|Drug: TRV130
11327151|NCT02520284|Experimental|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
11327152|NCT02520284|Experimental|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
11327153|NCT02520284|Placebo Comparator|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
11327154|NCT02520271|Active Comparator|Depression|Behavioral activation only
11327155|NCT02520271|Active Comparator|Depression and SUD|Motivational interview and Behavioral activation
11327156|NCT02520258|Experimental|Aspartame Consumers - Cohort 1|"Experimental Group/Arm
~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).
~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
11327157|NCT02520258|Active Comparator|Aspartame Naive Participants - Cohort 2|"Control Group/Arm
~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).
~Phase II - Not applicable for this cohort."
11327162|NCT02520219|Experimental|GDP+Endostar|"Patients in this group will be given conventional chemotherapy medicine:
~GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma and Endostar."
11327163|NCT02520219|Active Comparator|GDP|"Patients in this group will be given conventional chemotherapy medicine:
~GDP (gemcitabine+dexamethasone+cis-platinum) chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma."
11327164|NCT02520206||Arthritis|subjects with arthritis
11327165|NCT02520206||Health control subjects|Health control
11327166|NCT02520193|No Intervention|Standard mobilization strategy|
11327167|NCT02520193|Experimental|protocolized early mobilization strategy|
11327168|NCT02520180|Experimental|Firehawk™ stent system|MicroPort Firehawk™ stent system
11327169|NCT02520180|Active Comparator|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
11327170|NCT02520167|Experimental|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
11327171|NCT02520167|No Intervention|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index > 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
11327172|NCT02520154|Experimental|Treatment (carboplatin, paclitaxel, and pembrolizumab)|"NACT: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
~ADJUVANT THERAPY: Beginning 3-6 weeks after surgery, paclitaxel IV over 1 hour on days 1, 8, and 15, patients receive carboplatin IV over 1 hour on day 1, and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity."
11327173|NCT02520141|Experimental|Treatment (ramucirumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11327174|NCT02520128|Other|Cohort 1 (closed to recruitment)|"Cohort 1: Patients with Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)
~Dose schedules for Cohort 1:
~Pre-operative RT - 50 Gy in 25 daily fractions over 5 weeks
~Post-operative RT - 60 Gy in 30 daily fractions to the high dose planning target volume (PTV) and 52.2 Gy in 30 daily fractions to the low dose PTV treated concurrently over 6 weeks
~Post-operative RT (positive resection margins) - 66 Gy in 33 daily fractions to the high dose PTV, and 53.46Gy in 33 fractions to the low dose PTV treated concurrently over 6 ½ weeks."
11327175|NCT02520128|Other|Cohort 2|"Cohort 2: Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)
~Dose schedules for Cohort 2:
~Pre-operative RT - 50.4 Gy in 28 daily fractions over 5½ weeks
~Post-operative RT - 54 Gy in 30 daily fractions over 6 weeks
~Primary RT - 54 Gy in 30 daily fractions over 6 weeks."
11327176|NCT02520128|Other|Cohort 3|"Cohort 3: Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant Radiotherapy (Intensity Modulated Radiotherapy)
~Dose schedule for Cohort 3:
~Primary RT - 70 Gy in 35 daily fractions over 7 week
~Post-operative RT (non-chordoma) - primary bone sarcoma 60 Gy in 30 daily fractions over 6 weeks
~Post-operative RT (chordoma) - 70 Gy in 35 daily fractions over 7 weeks."
11327177|NCT02520115|Experimental|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
11327178|NCT02520115|Experimental|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
11327179|NCT02520102|Experimental|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
11327180|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
11327181|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
11327182|NCT02520076|Experimental|AAT treated group|Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
11327183|NCT02520063|Experimental|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
11327184|NCT02520063|Experimental|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
11327185|NCT02520063|Experimental|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
11327186|NCT02520063|Experimental|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
11329443|NCT02504580|Experimental|Part C Cohort A|200 mg HTX-002 by infiltration
11327187|NCT02520050|Active Comparator|Traditional MNT|Will be instructed to follow a MNT plan as recommended by the ADA through consultation with a RD.
11327188|NCT02520050|Active Comparator|Structured MNT|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day.
11327189|NCT02520050|Active Comparator|Structured MNT plus Weekly Support|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal-replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day plus weekly coaching.
11327190|NCT02520024|Experimental|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
11327191|NCT02520024|No Intervention|Treatment as usual|Participants in the control condition will receive services as usual.
11327192|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
11327193|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
11327194|NCT02519998||Concussed patients|The clinical focus of this study will be on concussed athletes, both children and adults, and we will also include non-sports patients who have mild traumatic brain injury due to other situations including slip and fall, occupational, motor vehicle accidents, assault, and blast exposure.
11327195|NCT02519998||Non-concussed patients|Cohort control. Primarily athletes who undergo routine pre-season baseline assessment
11327196|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):
~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.
~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.
~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):
~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.
~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
11327197|NCT02519972|Experimental|Low dose computed tomography|All the Low dose computed tomography of lung was performed with 64 slices multidetectors CT in single hold breath covering entire lung. The protocol of scanning parameters (120KVp, 40-80 mA, 1.25 mm or less in thickness) was standardized. The raw data would be reconstructed to axial images (3 mm thickness and interval) and coronal images (3 mm thickness and interval). The scan should be finished in a single breath (15-20 second) from the thoracic inlet to adrenal glands.
11327198|NCT02519946|Experimental|On-Line Diet and Exercise Intervention|
11327199|NCT02519933|Active Comparator|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
11327200|NCT02519933|Active Comparator|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
11327201|NCT02519920|Experimental|group 1|This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.
11327202|NCT02519920|Experimental|group 2|This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.
11327203|NCT02519920|Experimental|group 3|This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.
11327204|NCT02519920|Active Comparator|group 4|This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.
11327205|NCT02519894|Experimental|Intervention group|Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
11327206|NCT02519894|Placebo Comparator|Controlled group|Standard education
11327207|NCT02519881|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
11327208|NCT02519881|Active Comparator|microfracture|simple microfracture for cartilage defect of ankle
11327209|NCT02519868|Experimental|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
11327210|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
11327211|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
11327212|NCT02519842|Experimental|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
11327213|NCT02519842|Placebo Comparator|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
11327214|NCT02519842|Experimental|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
11327251|NCT02519543|Placebo Comparator|Placebo|Placebo comparator to be given twice daily, once with breakfast and once with supper
11327215|NCT02519829|Active Comparator|Monocryl closure|"The skin incision is closed with monocryl dissolvable sutures and a topical adhesive (glue) called Dermabond and covered with a Tegaderm dressing.
~Intervention: Monocryl closure, Tegaderm dressing"
11327216|NCT02519829|Active Comparator|Vicryl and staple closure|"The skin incision is closed with vicryl and staples and covered with a gauze dressing.
~Intervention: Vicryl and Staple closure, Gauze dressing"
11327217|NCT02519816|Experimental|Intervention|Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
11327218|NCT02519777|Placebo Comparator|Arm A: Placebo MVC and placebo DTG|In addition to their existing ART regimens, participants in Arm A will receive placebo for MVC and placebo for DTG.
11327219|NCT02519777|Experimental|Arm B: DTG and placebo MVC|In addition to their existing ART regimens, participants in Arm B will receive DTG and placebo for MVC.
11327220|NCT02519777|Experimental|Arm C: MVC and DTG|In addition to their existing ART regimens, participants in Arm C will receive MVC and DTG
11327221|NCT02519764|Experimental|Hydration when thirsty|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
11327222|NCT02519764|Experimental|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
11327223|NCT02519751|Experimental|D3 Creatine followed by creatine supplementation|Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
11327224|NCT02519738|Active Comparator|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
11327225|NCT02519738|Active Comparator|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
11327226|NCT02519738|Active Comparator|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
11327227|NCT02519725|Active Comparator|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
11327228|NCT02519725|No Intervention|Without diary|No diary is open during the ICU stay
11327229|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
11327230|NCT02519699|Experimental|Norepinephrine|Noradrenaline continuous infusion IV
11327231|NCT02519686||Trendelenburg position maneuver|Trendelenburg (TD) positioning (supine with head tilt-down) is used in abdominal and gynecological surgery as well as during colonoscopy to allow better access to the pelvic organs, as gravity pulls the bowel out of the pelvic cavity and the rectosigmoid angle straightens.
11327232|NCT02519686||Left lateral position maneuver|Left Lateral (LL) position (patient laying on their side, traditionally used for colonoscopies)
11327233|NCT02519660|Experimental|Lidocaine/Tetracaine patch (Ralydan)|Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
11327234|NCT02519660|Active Comparator|Lidocaine/Prilocaine cream (EMLA)|EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
11327235|NCT02519647|Active Comparator|tracheal intubation with Gliderite|Gliderite will be used for intubation
11327236|NCT02519647|Experimental|Tracheal intubation with S-Guide|S-Guide will be used for intubation
11327237|NCT02519634|Other|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
11327238|NCT02519634|Other|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
11327239|NCT02519621|Active Comparator|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
11327240|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
11327241|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
11327242|NCT02519608|Active Comparator|Aspirin 100 mg + Clopidogrel 75 mg|dual antiplatelet therapy as suggested by guidelines with aspirin 100 mg and clopidogrel 75 mg daily
11327243|NCT02519608|Experimental|Aspirin 100 mg + Ticagrelor 90 mg x2|dual antiplatelet therapy with aspirin 100 mg and ticagrelor 90 mg x 2 daily
11327244|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
11327245|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
11327246|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
11327247|NCT02519582|Experimental|Niclosamid|Patients receive 2 g niclosamide orally per day until progression or toxicity
11327248|NCT02519569|Experimental|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
11327249|NCT02519556|Experimental|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
11327250|NCT02519556|Placebo Comparator|Placebo|Placebo of Maltodextrin in sachet
11329444|NCT02504580|Experimental|Part B Cohort F|400 mg HTX-002 by infiltration
11327252|NCT02519543|Experimental|Metformin|Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper
11327253|NCT02519530|Experimental|Intervention|Behavioral: Teen Outreach Program
11327254|NCT02519530|No Intervention|Comparison|This group did not receive TOP, they received business as usual health curriculum offered through the public school system
11327255|NCT02519517|Experimental|permissive hypercapnia|during one lung ventilation, right ventricular function was assessed by TEE and the effect of rising PCO2 appreciated
11327256|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
11327257|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
11327258|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
11327259|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
11327260|NCT02519478|Experimental|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
11327261|NCT02519478|No Intervention|Control|Control group subjects participate in normal football activities as they would normally have during a football season
11327262|NCT02519465|Active Comparator|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
11327263|NCT02519465|Active Comparator|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
11327264|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
11327265|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
11327266|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
11327267|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
11327268|NCT02519452|Experimental|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
11327269|NCT02519439|Experimental|ganaxolone|Up to a maximum of 1800 mg/day
11327270|NCT02519426||Cumulative complexity score <9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score lower than 9.
11327271|NCT02519426||Cumulative complexity score y≥9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score higher than 9.
11327272|NCT02519426||Pell Gregory index <Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 1A, Class 1B, Class 1C, or Class 2A
11327273|NCT02519426||Pell Gregory index ≥Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 2B, Class 2C, Class 3A, Class 3B, or Class 3C
11327274|NCT02519426||Winter index <Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Mesio-Angular, Disto-Angular or Vertical impaction
11327275|NCT02519426||Winter index ≥Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Horizontal, Buccal / Lingual Obliquity, Transverse, Inverse impaction
11327276|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
11327277|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
11327278|NCT02519374|Placebo Comparator|Placebo|Placebo
11327279|NCT02519374|Active Comparator|PROMITOR® dose 1|Investigational product dose 1
11327280|NCT02519374|Active Comparator|PROMITOR® dose 2|Investigational product dose 2
11327281|NCT02519374|Active Comparator|PROMITOR® dose 3|Investigational product dose 3
11327282|NCT02519348|Experimental|Durvalumab & Tremelimumab (Regimen 1)|Durvalumab in combination with Tremelimumab (Regimen 1)
11327283|NCT02519348|Experimental|Durvalumab|Durvalumab given as monotherapy
11327284|NCT02519348|Experimental|Tremelimumab|Tremelimumab given as monotherapy
11327285|NCT02519348|Experimental|Durvalumab & Tremelimumab (Regimen 2)|Durvalumab in combination with Tremelimumab (Regimen 2)
11327286|NCT02519348|Experimental|Durvalumab & Bevacizumab|Durvalumab in combination with Bevacizumab
11327287|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.
~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
11327288|NCT02519322|Experimental|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
11327289|NCT02519322|Experimental|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
11327290|NCT02519322|Experimental|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
11327291|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
11327292|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
11327293|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
11327294|NCT02519296|Active Comparator|Prolonged Exposure Therapy|"In total 30 Danish veterans will be recruited, who meet the ICD-10 diagnostic criteria for PTSD, and treated with PE.
~Intervention with eight sessions of PE, psychometrics, blood analyses and fMRI."
11327295|NCT02519296|Active Comparator|30 Danish veterans without PTSD|"A group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group.
~Observation with psychometrics, blood analyses and fMRI."
11327296|NCT02519283|Active Comparator|Standard of Care|In keeping with the strategy-based pragmatic nature of the trial, the discharge procedures will largely be kept as they are in common practice. Investigators will standardize usual care for ED discharge to include HF medication reconciliation as well as encourage 7-day follow-up.
11327297|NCT02519283|Active Comparator|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
11327298|NCT02519270|Experimental|Dose Escalation Stage/ Expansion Stage|"The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.
~In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles."
11327299|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
11327300|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
11327301|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
11327302|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
11327303|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
11327304|NCT02519205||ED Nurses|ED triage nurses from Duke University Hospital (DUH) and Duke Regional Hospitals (DRH).
11327305|NCT02519192|Experimental|VAC Arm, Vac sponge irrigations|For patients who fall under the VAC arm, a physician will do the initial placement of the wound VAC (V.A.C.Ulta™ Negative Pressure Wound Therapy System) at the patient's bedside. An information sheet will be provided to the patient, and the patient will be taught how to irrigate the sponge system independently. While inpatient, nursing will perform VAC sponge irrigation.
11327306|NCT02519192|Active Comparator|NonVac, ostomy bag, wet to dry dressings|For patients who fall under the non-VAC arm, a physician or wound care nurse will perform the initial application of the ostomy bag or wet to dry dressing change. An information sheet will be provided to the patient. While inpatient, members from the nursing or physician team will perform ostomy bag application and ostomy dressing changes.
11327307|NCT02519179|Experimental|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
11327308|NCT02519166|Other|Patients with chronic wounds|
11327309|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
11327310|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
11327311|NCT02519140|Experimental|Cook medical EMR Gel|"Prospective study involving excised human stomachs and colon harvested from sleeve gastrectomies and colectomies performed for benign or malignant disease.
~Different Cook submucosal injections of varying viscosities will be injected into different areas of the excised stomachs or colons.
~Data collected will involve lifting characteristics and dissection adequacy of the varying viscosities of gel."
11327312|NCT02519127|Experimental|Low glycaemic load diet|Subjects will be following a low glycaemic load diet, typically high in polyphenols, proteins, vegetables, pulses, fibres and nuts, and low in glycemic carbohydrates, for six continuous weeks.
11327313|NCT02519127|Experimental|Western diet|Subjects will be following a western diet, typically high in saturated fat, refined sugars and salt, and low in fruit and vegetables and fibers, for six continuous weeks.
11327314|NCT02519114|Experimental|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
11327315|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
11327316|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
11327317|NCT02519036|Experimental|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
11327318|NCT02519036|Experimental|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
11327319|NCT02519036|Experimental|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
11327320|NCT02519036|Experimental|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
11327321|NCT02519036|Experimental|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
11327322|NCT02519036|Placebo Comparator|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
11327323|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
11327324|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
11327325|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
11327326|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
11327327|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
11327328|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
11327329|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
11327330|NCT02518958|Experimental|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
11327331|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
11327332|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
11327333|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
11327334|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
11327335|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
11327336|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
11327337|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
11327338|NCT02518906|Experimental|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
11327339|NCT02518906|Experimental|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
11327340|NCT02518880|Other|Plasma volume measurements|
11327341|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
11327342|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
11327343|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
11327344|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
11327345|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
11327346|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
11327347|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
11327348|NCT02518828|Active Comparator|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
11327349|NCT02518828|Active Comparator|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
11327391|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
11327350|NCT02518815|Experimental|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
11327351|NCT02518815|No Intervention|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
11327352|NCT02518802|Experimental|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
11327353|NCT02518802|Active Comparator|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
11327354|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
11327355|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
11327356|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
11327357|NCT02518776|Other|Neuropsychological tests|
11327358|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
11327359|NCT02518750|Experimental|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:
~Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.
~Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.
~Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
11327360|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
11327361|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
11327362|NCT02518724|Active Comparator|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:
~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).
~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
11327363|NCT02518724|Placebo Comparator|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:
~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).
~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
11327364|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
11327365|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
11327366|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
11327367|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
11327368|NCT02518685|Sham Comparator|Control|Sham procedure plus Lifestyle Counseling
11327369|NCT02518672|Active Comparator|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
11327370|NCT02518672|Placebo Comparator|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
11327371|NCT02518659|Other|Inulin|Intervention by inulin, max 20gr per day
11327372|NCT02518659|No Intervention|No Inulin|Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
11327373|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
11327374|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
11327375|NCT02518620|Experimental|ALX-0061 150 mg q2w (+ MTX)|
11327376|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:
~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
11327377|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:
~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
11327378|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
11327379|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
11327380|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
11327381|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
11327382|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
11327383|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
11327384|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
11327385|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:
~Placebo, 1 liquid filled enterically coated capsule, single dose"
11327386|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
11327387|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
11327388|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
11327389|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
11327390|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
11327392|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
11327393|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
11327394|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
11327395|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
11327396|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
11327397|NCT02518581|Other|Doubly labelled water|
11327398|NCT02518568|Experimental|Drug|
11327399|NCT02518555|Experimental|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11327400|NCT02518555|Experimental|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
11327401|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
11327402|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
11327403|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
11327404|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
11327405|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
11327406|NCT02518516||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (rosuvastatin, high doses of atorvastatin, and high doses of simvastatin between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
11327407|NCT02518516||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
11327408|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
11327409|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
11327410|NCT02518490|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
11327411|NCT02518490|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
11327412|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.
~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
11327413|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
11327414|NCT02518464|Experimental|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
11327415|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
11327416|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
11327417|NCT02518438|Active Comparator|the tramadol group|A preprepared 20 ml solution (tramadol 2 mgkg-1 within a 0.9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
11327418|NCT02518438|Placebo Comparator|the placebo group|A preprepared 20 ml solution (0,9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
11327419|NCT02518412|Experimental|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
11327420|NCT02518412|Placebo Comparator|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
11327421|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
11327422|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
11327423|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period
~An Omeprazole Treatment Period 1 (Day -15 to Day -1)
~A G17DT treatment period (Day 0 to Day 85)
~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
11327463|NCT02518126||IUGR|Women with AGA embryos so that their fetal weight estimate puts them in a percentile between 20th and 80th percentiles
11378006|NCT02182037|Experimental|BIBT 1011 BS|
11327424|NCT02518360|Experimental|OSTEOPATHIC PROTOCOL|"Physiotherapist applies an osteopathic treatment in non-specific low back pain patients.
~The experimental group is treated with osteopathy, three sessions (20 minutes/session) and a frequency one session/week. Osteopathic treatment osteopathic is a body adjustment protocol. This protocol adjusts the musculoskeletal disorders since neck to lower limbs in the experimental group. Before treatment, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry."
11327425|NCT02518360|Active Comparator|Auto Stretching|The patients realizes stretching protocol: two stretching global postures once a week (10 minutes for each posture) for three weeks: the first is for the anterior muscular chain and the second posture to stretch the posterior muscle chain. Before three stretching, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry.
11327426|NCT02518347|Experimental|FDS-Strawberry|Freeze-dried strawberry powder (50g/d)
11327427|NCT02518347|Placebo Comparator|Placebo|Powder matched for carbohydrates and fiber in the strawberries
11327428|NCT02518334|Experimental|Alcohol consumption|Alcohol consumption and wine consumption
11327429|NCT02518321|Experimental|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
11327430|NCT02518321|Experimental|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
11327431|NCT02518308|Experimental|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
11327432|NCT02518308|No Intervention|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
11327433|NCT02518295|Active Comparator|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
11327434|NCT02518295|Active Comparator|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
11327435|NCT02518295|Active Comparator|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
11327436|NCT02518295|Placebo Comparator|Negative control|Lactose free milk
11327437|NCT02518269|Active Comparator|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
11327438|NCT02518269|Active Comparator|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
11327439|NCT02518269|Active Comparator|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
11327440|NCT02518256|Other|(Suspected) Ovarian Epithelial Cancer|Lavage of the Cavum uteri and proximal fallopian tubes
11327441|NCT02518243|Experimental|Alzheimer's Disease|
11327442|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
11327443|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
11327444|NCT02518217|Active Comparator|Apps Only|
11327445|NCT02518217|Experimental|ShapeUp Empower|
11327446|NCT02518217|Experimental|ShapeUp Empower + Incentives|
11327447|NCT02518204|Experimental|BPT, NP|Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
11327448|NCT02518204|Experimental|NP, BPT|Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
11327449|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
11327450|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
11327451|NCT02518178|Active Comparator|NFC Sticker|Participants will receive an NFC (Near Field Communication) sticker, placed on their existing immunization (MAMTA) card. This will serve as a comparator to the NFC necklace while still allowing for patient data to be digitized and utilized by the health service provider, Seva Mandir.
11327452|NCT02518178|Experimental|NFC Necklace|Participants will receive a necklace with an NFC pendant, which interfaces with the Khushi Baby mobile application to digitize the data. This arm will allow for the assessment of peer influence effects of the necklace as a social symbol.
11327453|NCT02518178|Experimental|NFC Necklace + Voice Reminder|In addition to the NFC necklace, mothers of the participants in this arm will receive dialect-specific voice call reminders, informing them about the next camp and the importance of vaccinations.
11327454|NCT02518165|Active Comparator|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
11327455|NCT02518165|Placebo Comparator|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
11327456|NCT02518152|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
11327457|NCT02518152|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
11327458|NCT02518152|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
11327459|NCT02518139|Experimental|TD-4208-1|88 mcg
11327460|NCT02518139|Experimental|TD-4208-2|175 mcg
11327461|NCT02518139|Active Comparator|Tiotropium|18 mcg
11327462|NCT02518126||control|Women with IUGR embryos so that their fetal weight estimate puts them in a percentile bellow 10th percentile
11327464|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
11327465|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~There were no participants enrolled to Part B of the study."
11327466|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~There were no participants enrolled to Phase 2 of the study."
11327467|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.
~There were no participants enrolled to Phase 2 of the study."
11327468|NCT02518100|Experimental|VSP 3-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 3-lead (NEHB) configuration:
~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
11327469|NCT02518100|Experimental|VSP 1-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration. The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 1-lead (PAL) configuration:
~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
11327470|NCT02518087|Experimental|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time > 60 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
11327471|NCT02518087|No Intervention|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time > 60 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
11327472|NCT02518074|Other|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
11327473|NCT02518048|Active Comparator|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
11327474|NCT02518048|Active Comparator|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
11327475|NCT02518035|Placebo Comparator|Control|No silicone gel treatment after remove of stitches
11327476|NCT02518035|Experimental|Experimental|Silicone gel applied for twice per day
11327477|NCT02518022|Experimental|Intervention|For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours
11327478|NCT02518022|No Intervention|Standard|No Insulin Treatment of carbohydrates in beer.
11327479|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
11327480|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
11327481|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
11327482|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
11327483|NCT02517983||Chronic respiratory disease|
11327484|NCT02517970|Experimental|Classical Music versus Television show|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
11327485|NCT02517957|Experimental|Qinzhuliangxue Keli|Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
11327486|NCT02517957|Active Comparator|loratadine tablets|Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
11327487|NCT02517957|Active Comparator|Qinzhuliangxue and loratadine|Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
11327488|NCT02517944||Familial hypercholesterolemia patients|"clinical data
~biological data
~cardiac and aortic RMI with gadolinium"
11327489|NCT02517944||Control group|"clinical data
~biological data
~cardiac and aortic RMI with gadolinium"
11327490|NCT02517931|Active Comparator|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
11327526|NCT02517723|Experimental|SIC + NET|Waiting List + Standard Inpatient Care + Narrative Exposure Therapy
11327527|NCT02517723|Active Comparator|SIC + DBT|Waiting List + Standard Inpatient Care + Dialectical Behavior Therapy
11329445|NCT02504580|Experimental|Part C Cohort B|200 mg HTX-011B by instillation
11327491|NCT02517931|Placebo Comparator|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
11327492|NCT02517918|Experimental|Sirolimus combined with CP, MT and ZA|Drug : Metronomic Cyclophosphamide, Methotrexate, Sirolimus, Zoledronic acid Assessment of the maximum tolerated dose of sirolimus Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
11327493|NCT02517905|Experimental|Bupivacaine liposome|Subjects will receive a single dose of 133 mg (10 mL)
11327494|NCT02517905|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo (normal saline, 10 mL)
11327495|NCT02517892|Experimental|Patients with metastatic oncogen-driven cancer|
11327496|NCT02517879|Experimental|Group 1 - 1-3 days|Community health worker hang-up visit 1-3 days after the community point distribution
11327497|NCT02517879|Experimental|Group 2 - 5-7 days|Community health worker hang-up visit 5-7 days after the community point distribution
11327498|NCT02517879|Experimental|Group 3 - 10-12 days|Community health worker hang-up visit 10-12 days after the community point distribution
11327499|NCT02517879|Experimental|Group 4 - 15-17 days|Community health worker hang-up visit 15-17 days after the community point distribution
11327500|NCT02517879|Placebo Comparator|Group 5 - No hang-up visit|Did not receive any hang-up visit after the community point distribution
11327501|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
11327502|NCT02517853|Experimental|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
11327503|NCT02517853|Sham Comparator|Sham comparator|Sham tibial nerve stimulation during 16 sessions
11327504|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
11327505|NCT02517827|Active Comparator|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
11327506|NCT02517827|Active Comparator|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
11327507|NCT02517814|Experimental|Patients with cardiomyopathy|Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months.
11327508|NCT02517801|Experimental|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily)
11327509|NCT02517801|Placebo Comparator|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily)
11327510|NCT02517788|Experimental|Part A: Interferon beta-1a in HSA-free solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a without albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
11327511|NCT02517788|Experimental|Part A: Interferon beta-1a combined with HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
11327512|NCT02517788|Active Comparator|Part A: Interferon beta-1a in marketed HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU original interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
11327513|NCT02517788|Experimental|Part B: Interferon beta-1a in HSA-free solution|Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
11327514|NCT02517788|Active Comparator|Part B: Interferon beta-1a in marketed HSA+ solution|Part B: Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU original interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
11327515|NCT02517775|Active Comparator|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
11327516|NCT02517775|Active Comparator|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
11327517|NCT02517775|Active Comparator|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
11327518|NCT02517775|Active Comparator|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
11327519|NCT02517775|Active Comparator|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
11327520|NCT02517775|Placebo Comparator|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
11327521|NCT02517762|Experimental|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
11327522|NCT02517762|Experimental|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
11327523|NCT02517749|Active Comparator|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
11327524|NCT02517749|Active Comparator|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
11327525|NCT02517736|Experimental|sorafenib at a dose of 800 mg / day|
11327528|NCT02517710|Placebo Comparator|Control|Group of patients receiving standard hysterotomy closure with synthetic braided suture
11327529|NCT02517710|Experimental|Stratfix|group of patients having the hysterotomy incision closed with barbed synthetic suture. Time to closure, blood loss, and postoperative pain
11327530|NCT02517697|Experimental|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
11327531|NCT02517697|Placebo Comparator|Placebo|placebo capsules three time daily (TID)
11327532|NCT02517684|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
11327533|NCT02517684|Active Comparator|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
11327534|NCT02517671|Other|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
11327535|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
11327536|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
11327537|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
11327538|NCT02517632|Experimental|Exercise group|This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
11327539|NCT02517632|Other|Control group|This arm will have only the counseling from pharmaceutical and nutritional professionals.
11327540|NCT02517619|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
11327541|NCT02517619|Active Comparator|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
11327542|NCT02517606|Experimental|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
11327543|NCT02517606|Active Comparator|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
11327544|NCT02517593|Other|PRS|Providing polygenic risk score (PRS)
11327545|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
11327546|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
11327547|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
11327548|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
11327549|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
11327550|NCT02517554||Remote cancer genetic services by videoconference|
11327551|NCT02517554||Remote cancer genetic services by telephone|
11327552|NCT02517554||Usual Care|
11327553|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
11327554|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
11327555|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
11327556|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
11327557|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
11327558|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
11327559|NCT02517489|Experimental|Hydrocortisone|Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
11327560|NCT02517489|Placebo Comparator|Placebo|Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
11327561|NCT02517476|Experimental|Nutritional support|For the purpose of this study, we have developed nutritional guidelines by consensus and adapted to current guidelines (e.g., ESPEN, ASPEN). These guidelines specify a reinforced nutritional therapy strategy to cover nutritional requirements, focusing on nutritional targets based on the specific nutritional diagnoses defined by the IDNT. The nutritional guidelines may vary according to important medical diagnoses (i.e. renal failure). They specify not only nutritional targets, but also escalation of the route (i.e. food fortification, oral, enteral, parenteral) if targets cannot be achieved (≤75%) every 5 hours. Nutritional goals are being assessed daily in patients in the intervention group.
11327562|NCT02517476|No Intervention|"Usual care (appetite-guided) controls"|"In control patients, we will use conventional nutrition according to the ability and desire of the patient to eat, using standard care food provided by the hospital kitchen (appetite-guided)."
11327563|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
11327565|NCT02517450|Experimental|experimental group|The subjects had to participate an adventure-based training programme.
11327566|NCT02517450|Placebo Comparator|placebo control group|The subjects had to participate a placebo control programme
11327567|NCT02517437|Active Comparator|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
11327568|NCT02517437|Active Comparator|Interscalene block|Interscalene block.
11327569|NCT02517424|Experimental|High THC/Low CBD Cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
11327570|NCT02517424|Experimental|High THC/High CBD cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
11327571|NCT02517424|Placebo Comparator|Low THC/Low CBD cannabis|Product will be administered via vaporization up to 2 grams per day as needed.
11327572|NCT02517411|Experimental|Experimental group|COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
11327573|NCT02517411|Other|Control group|COPD patients with stable disease will be recruited and they will receive standard care.
11327574|NCT02517398|Experimental|MSB0011359C (M7824)|
11327575|NCT02517385|Experimental|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
11327576|NCT02517372|Active Comparator|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
11327577|NCT02517372|Active Comparator|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
11327578|NCT02517372|Active Comparator|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
11327579|NCT02517359|Experimental|Single dose, healthy volunteers|
11327580|NCT02517359|Experimental|14 day repeat dose, healthy volunteers|
11327581|NCT02517359|Experimental|28 day repeat dose, healthy volunteers|
11327582|NCT02517359|Experimental|14 day repeat dose, asthma patients|
11327583|NCT02517359|Experimental|14 day repeat dose, smokers|
11327584|NCT02517346|Active Comparator|Standard follow up-Sleep Unit|Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit
11327585|NCT02517346|Experimental|Telemonitoring|Patients diagnosed as OSA and treated with CPAP in sleep unit, followed up by telemonitoring system
11327586|NCT02517333|Other|Proof-of-principle (PoP)|"Proof-of-principle phase of the study. All participants undergo the exercise intervention as part of the feasibility.
~Screen within Year 9 Class
~Targeted recruitment for those scoring in bottom 5th percentile
~Invite students to take part in 6-week intervention
~Enroll students participating
~Pre-intervention assessment
~Start 6-week Epic Club gym intervention (1-2 times weekly for 45-60 mins) consisting of 30 min cardiovascular exercise and 25-30 min strength/resistance and weight training
~Post-intervention assessment
~Exit to longer-term sport/physical activity"
11327587|NCT02517320|Experimental|MT-3995 Low|
11327588|NCT02517320|Experimental|MT-3995 Middle|
11327589|NCT02517320|Experimental|MT-3995 High|
11327590|NCT02517320|Placebo Comparator|Placebo|
11327591|NCT02517307|Experimental|glycerol/saline|Glycerol/Saline infusion
11327592|NCT02517307|Experimental|intralipid|Intralipid/Heparin infusion
11327593|NCT02517294|Active Comparator|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
11327594|NCT02517294|Active Comparator|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
11327595|NCT02517281|Experimental|Patients having received targeted therapies|Patients treated using targeted therapies
11327596|NCT02517268|Active Comparator|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
11327597|NCT02517268|Experimental|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
11327598|NCT02517255|Experimental|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed within 7 days of rescue percutaneous coronary intervention (PCI) and after 3 and 6 months.
11327599|NCT02517242|Experimental|Pens Device|All patients will receive pens device, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
11327600|NCT02517242|Active Comparator|Syringe|All patients will receive syringe to insulin, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
11327601|NCT02517229|Other|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
11327602|NCT02517216|Other|parabolic flight and MRI scans|
11327603|NCT02517190|Other|Stress response measurements|
11327604|NCT02517177|Other|Cardiovascular parameters measurements|
11327605|NCT02517164||Fallers|patients aged 50 years and over who already fell
11327606|NCT02517164||At risk of falls|patients aged 50 years and over at risk of falls
11327607|NCT02517151|Experimental|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
11327608|NCT02517151|Placebo Comparator|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
11327609|NCT02517138|Other|Measurements of eye movements and perception|
11327610|NCT02517125|Experimental|Patients with head and neck cancer|
11327611|NCT02517112|Other|Cardiovascular parameters measurements|
11327612|NCT02517099|Active Comparator|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
11327634|NCT02516956|Placebo Comparator|Breakfast meal 4|"Breakfast meal 4 is a non-caloric meal representing fasting condition (control arm).
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
11327613|NCT02517099|Active Comparator|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
11327614|NCT02517086|Active Comparator|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
11327615|NCT02517086|Active Comparator|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
11327616|NCT02517086|Active Comparator|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
11327617|NCT02517060||Healthy participants|Male or female healthy participants
11327618|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
11327619|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
11327620|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
11327621|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
11327622|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
11327623|NCT02517008|Experimental|Mama kits intervention|"Health facilities randomized to this arm provided mama kits - packages of childcare materials including a cloth (chitenge), baby blanket, and diaper - to all mothers who delivered at these facilities between June 1, 2013 - Aug 31, 2013."
11327624|NCT02517008|No Intervention|No intervention|Health facilities randomized to this arm provided obstetric services as normal.
11327625|NCT02516995|Experimental|Patients with prostate cancer|
11327626|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:
~Section 1: Demographic information survey
~Section 2: Whooley questions
~Section 3: Edinburgh Postnatal Depression Scale
~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
11327627|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:
~Section 1: Demographic information survey
~Section 2: Whooley questions
~Section 3: Edinburgh Postnatal Depression Scale
~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
11327628|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
11327629|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
11327630|NCT02516969|Experimental|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes <25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
11327631|NCT02516956|Experimental|Breakfast meal 1|"Breakfast meal 1 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 2 and health-related cognitive perception as Breakfast meal 3.
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
11327632|NCT02516956|Experimental|Breakfast meal 2|"Breakfast meal 2 is isocaloric (330 kcal) and balanced for protein and fiber contents with regard to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 1 but a higher health-related cognitive perception than the other two experimental breakfasts.
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
11327633|NCT02516956|Experimental|Breakfast meal 3|"Breakfast meal 3 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same health-related cognitive perception as Breakfast meal 1 but lower lipid and higher sugar amounts than the other two experimental breakfasts.
~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
11378007|NCT02182037|Placebo Comparator|BIBT 1011 BS placebo|
11327635|NCT02516943|Active Comparator|Control|The patient were retrospectively included according to the last digit of their admission number (odd number). The had arterial blood gas analysis every 4 hour during the ICU stay.
11327636|NCT02516943|Active Comparator|Guideline|The patient were prospectively included and they had arterial blood gas analysis following the pathological- based guidelines for arterial blood gas analysis in patients aftercardiac surgery
11327637|NCT02516930|Other|Crowdsourced video|One-minute crowd-sourced video promoting condom use among men who have sex with men and transgender individuals.
11327638|NCT02516930|Other|Social marketing video|One-minute social marketing video promoting condom use among men who have sex with men and transgender individuals
11327639|NCT02516917|Experimental|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
11327640|NCT02516904|Experimental|CD101 IV|single intravenous infusion ascending dose
11327641|NCT02516904|Placebo Comparator|Placebo|normal saline
11327642|NCT02516891|Experimental|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
11327643|NCT02516891|No Intervention|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
11327644|NCT02516878|Experimental|Acupuncture group|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.
~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
11327645|NCT02516878|Sham Comparator|Control group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion.
~The Semen Vaccariae embedded tape used in treatment group will be applied on 4 non-acupoints at the helix unilaterally, retained until the next visit and then the alternate ear will be used."
11327646|NCT02516865|Experimental|Group 1|
11327647|NCT02516865|Experimental|Group 2|
11327648|NCT02516865|No Intervention|Group 3|
11327649|NCT02516852|Experimental|Intervention|
11327650|NCT02516852|No Intervention|Control|
11327651|NCT02516839|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
11327652|NCT02516839|Experimental|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
11327653|NCT02516839|Experimental|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
11327654|NCT02516839|Active Comparator|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
11327655|NCT02516826|Experimental|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
11327656|NCT02516826|Experimental|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
11327657|NCT02516826|Experimental|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
11327658|NCT02516813|Experimental|Phase Ia Arm A: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 10 times, for two consecutive weeks in concomitance with fractionated radiotherapy (RT) (5 fractions /week).
11327659|NCT02516813|Experimental|Phase Ia Arm B: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A capsule once daily up to 35 times, for 7 consecutive weeks in concomitance with fractionated RT and Cisplatin (5 fractions/week).
11327660|NCT02516813|Experimental|Phase Ib Arm A Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week).
11327661|NCT02516813|Experimental|Phase Ib Arm B Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week) and cisplatin.
11327662|NCT02516813|Experimental|Ancillary cPoP: MSC2490484A+Fractionated RT|Ancillary Clinical proof-of-principle (cPOP) study, subjects will receive first dose of RT on Day 1, and will receive MSC2490484A capsule or Tablet formulation within 1.5 hour before the second dose of RT on Day 2.
11327663|NCT02516800||Aortic valve calcification|Patients with calcific aortic valve disease, age = 65 years or below
11327664|NCT02516800||Control group|Matched control group
11327665|NCT02516787|Other|EEG and NIRS measurements|
11327666|NCT02516774|Experimental|Dose escalation|Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
11327667|NCT02516761|Experimental|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
11327709|NCT02516475|Placebo Comparator|starch|1 corn starch capsule for 15 weeks
11378699|NCT02177461|Active Comparator|Enalapril|
11327668|NCT02516761|Experimental|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
11327669|NCT02516761|Active Comparator|Control group|With this group no intervention is done, but they are assessed like the other groups.
11327670|NCT02516735|Experimental|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
11327671|NCT02516735|Active Comparator|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
11327672|NCT02516722|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
11327673|NCT02516696|Experimental|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
11327674|NCT02516696|Active Comparator|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
11327675|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
11327676|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
11327677|NCT02516670|Experimental|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11327678|NCT02516670|Placebo Comparator|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11327679|NCT02516657|Experimental|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
11327680|NCT02516644|Experimental|Virtual reality|Xbox Kinect + treadmill training
11327681|NCT02516644|Active Comparator|Conventional Therapy|Specific conventional training for Parkinson's Disease
11327682|NCT02516631|Active Comparator|Oral (A)|One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
11327683|NCT02516631|Active Comparator|Oral (B)|Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
11327684|NCT02516631|Active Comparator|Sublingual (C)|Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
11327685|NCT02516618|Experimental|Cohort 1|Participants in this cohort will receive dose 1 of Fasinumab or placebo
11327686|NCT02516618|Experimental|Cohort 2|Participants in this cohort will receive dose 2 of Fasinumab or placebo
11327687|NCT02516618|Experimental|Cohort 3|Participants in this cohort will receive dose 3 of Fasinumab or placebo
11327688|NCT02516618|Experimental|Cohort 4|Participants in this cohort will receive dose 4 of Fasinumab or placebo
11327689|NCT02516618|Experimental|Cohort 5|Participants in this cohort will receive dose 5 of Fasinumab or placebo
11327690|NCT02516605|Experimental|LJN452|
11327691|NCT02516605|Placebo Comparator|Placebo|
11327692|NCT02516592|Experimental|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
11327693|NCT02516592|Active Comparator|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
11327694|NCT02516566|Experimental|PEEP group|Mechanical ventilation with PEEP 8 cmH2O
11327695|NCT02516566|No Intervention|No PEEP group|Mechanical ventilation with no PEEP
11327696|NCT02516553|Experimental|arm A|once daily continuous oral intake in 3-week cycles
11327697|NCT02516553|Experimental|arm B|once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles
11327698|NCT02516553|Experimental|arm C|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
11327699|NCT02516540|No Intervention|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
11327700|NCT02516540|Experimental|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
11327701|NCT02516527|Experimental|Induction Phase:Ipilimumab|Ipilimumab dose as specified
11327702|NCT02516527|Experimental|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
11327703|NCT02516514|Experimental|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
11327704|NCT02516514|Active Comparator|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
11327705|NCT02516501|Active Comparator|Control|Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.
11327706|NCT02516501|Experimental|Intervention group 1|Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).
11327707|NCT02516501|Experimental|Intervention group 2|Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.
11327708|NCT02516475|Active Comparator|zinc sulfate|1 zinc sulfate capsule for 15 weeks
11327710|NCT02516462|Experimental|IVM|Immature oocytes recovered from each subject will be placed into IVM media for maturation.
11327711|NCT02516449|Experimental|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
11327712|NCT02516449|No Intervention|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
11327713|NCT02516436|Experimental|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
11327714|NCT02516436|Active Comparator|Buprenorphine|Buprenorphine in a buccal film
11327715|NCT02516423|Experimental|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
11327716|NCT02516423|Active Comparator|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
11327717|NCT02516410|Experimental|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
11327718|NCT02516410|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
11327719|NCT02516397|Experimental|Omnia group|After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks.
11327720|NCT02516397|Placebo Comparator|Placebo group|After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks.
11327721|NCT02516384|Experimental|Fecal Microbiota Transplantation|Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.
11327722|NCT02516371|Other|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
11327723|NCT02516345|Active Comparator|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.
~Step Targets for Children in CBI arm:
~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week
~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week
~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
11327724|NCT02516345|Experimental|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.
~Step targets for children and parents in FBI arm:
~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week
~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week
~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
11327725|NCT02516332|Experimental|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
11327726|NCT02516332|Experimental|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
11327727|NCT02516332|Placebo Comparator|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
11327728|NCT02516319|Active Comparator|Serial Blood Draws|Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.
11327729|NCT02516319|Experimental|Liver Funtion Test Dye Detection Monitor|All cohorts receive continuous LFT monitoring post ICG injection.
11327730|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
11327731|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
11327732|NCT02516293|Experimental|Intervention group|"Physical exercise intervention
~Nutritional counseling
~Pharmaceutical counseling"
11327733|NCT02516280|Experimental|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
11327734|NCT02516280|Active Comparator|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
11327735|NCT02516267|No Intervention|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
11328153|NCT02513368|Active Comparator|connective tissue graft|augmentation procedure with connective tissue graft
11327736|NCT02516267|Active Comparator|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
11327737|NCT02516254|Experimental|fortified bread|daily intake of fortified bread (1000IU vitamin D per 50 g) plus placebo
11327738|NCT02516254|Experimental|supplement|daily intake of plain bread (50 g) plus supplement (1000 IU per tablet)
11327739|NCT02516254|Placebo Comparator|placebo|daily intake of plain bread plus placebo
11327740|NCT02516241|Experimental|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
11327741|NCT02516241|Experimental|Monotherapy|MEDI4736 (Durvalumab)
11327742|NCT02516241|Active Comparator|Standard of Care|Standard of Care Chemotherapy Treatment
11327743|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
11327744|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
11327745|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
11327746|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
11327747|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
11327748|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
11327749|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
11327750|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
11327751|NCT02516215||8_Anemia|Patients with diagnosed anemia
11327752|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.
~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
11327753|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.
~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).
~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
11327754|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.
~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.
~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
11327755|NCT02516189|Experimental|Group A|group of elderly participants of strength training program
11327756|NCT02516189|No Intervention|Group B|group of seniors who did not practice strength training program
11327757|NCT02516176|Experimental|Treadmill Training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
11327758|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.
~They are intended for single use only."
11327759|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
11327760|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
11327761|NCT02516137|Experimental|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
11327762|NCT02516137|Sham Comparator|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
11327763|NCT02516137|Placebo Comparator|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
11327764|NCT02516124||NISSC|Autologous HSCT
11327765|NCT02516111|Active Comparator|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
11327766|NCT02516111|Active Comparator|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
11327767|NCT02516111|Active Comparator|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
11327768|NCT02516111|Active Comparator|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
11327769|NCT02516098|Active Comparator|Hyoscine butylbromide SCT|
11327770|NCT02516098|Experimental|Hyoscine butylbromide|
11327771|NCT02516085|Experimental|L-arginine and metformin|7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks
11327772|NCT02516072|No Intervention|Control|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR.
11378700|NCT02177461|Experimental|Telmisartan + clonidine TTS1|
11327773|NCT02516072|Experimental|Remote Ischaemic preconditioning (RIPC)|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR. Additionally, patients will receive RIPC; a blood pressure cuff will be placed around one arm of the patient, it will then be inflated to a pressure of 250mmHg for 5 minutes. The cuff will then be deflated and the arm allowed to reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles immediately prior to the procedure.
11327774|NCT02516059|Active Comparator|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
11327775|NCT02516059|Active Comparator|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
11327776|NCT02516059|Placebo Comparator|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
11327777|NCT02516046|Experimental|Flortaucipir PET Scan|
11327778|NCT02516020|Active Comparator|Global|EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)
11327779|NCT02516020|Active Comparator|Origio|Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)
11327780|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
11327781|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
11327782|NCT02515981|Experimental|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
11327783|NCT02515981|Experimental|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
11327784|NCT02515968|Active Comparator|Desflurane|Anesthesia is maintained with desflurane during surgery.
11327785|NCT02515968|Experimental|Propofol|Anesthesia is maintained with propofol during surgery.
11327786|NCT02515955|Experimental|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327787|NCT02515955|Experimental|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327788|NCT02515955|Experimental|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327789|NCT02515955|Experimental|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327790|NCT02515955|Experimental|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327791|NCT02515955|Experimental|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327792|NCT02515955|Experimental|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327793|NCT02515955|Experimental|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
11327794|NCT02515942|Experimental|CLG561|CLG561 10 mg, one IVT injection every 28 days for a total of 12 injections
11327795|NCT02515942|Experimental|CLG561+LFG316|CLG561 5mg + LFG316 5 mg, one IVT injection every 28 days for a total of 12 injections
11327796|NCT02515942|Sham Comparator|Sham Injection|One sham injection every 28 days for total of 12 sham injections
11327797|NCT02515929|Experimental|Oligomeric Proanthocyanidins|90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
11327798|NCT02515929|Placebo Comparator|Placebo|Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
11327799|NCT02515903|Experimental|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
11327800|NCT02515903|Placebo Comparator|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
11327801|NCT02515890|Experimental|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
11327802|NCT02515890|Experimental|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
11327803|NCT02515890|Experimental|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
11327804|NCT02515890|Experimental|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
11327805|NCT02515890|Experimental|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
11327806|NCT02515877|Experimental|Radiotherapy + Vistide + Chemoterapy|
11327807|NCT02515864|Experimental|FYU-981 anticipated therapeutic dose|Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)
11327808|NCT02515864|Experimental|FYU-981 supratherapeutic dose|Drug: FYU-981, Moxifloxacin Placebo (Oral)
11327809|NCT02515864|Placebo Comparator|Placebo|Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)
11327810|NCT02515864|Active Comparator|Moxifloxacin|Drug: Moxifloxacin, FYU-981 Placebo (Oral)
11327811|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
11327812|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
11327813|NCT02515838|Placebo Comparator|Placebo|Placebo infusion
11327814|NCT02515838|Experimental|Sevuparin|Sevuparin infusion
11327815|NCT02515812|Experimental|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
11327816|NCT02515812|Active Comparator|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
11327817|NCT02515799|Active Comparator|Tacholiquine|Inhalation
11327818|NCT02515799|Placebo Comparator|Saline Solution 0,9%|Inhalation
11327819|NCT02515786|Experimental|oxygen humidification|Oxygen by nasal catheter delivery will be humidified by bubles.
11327820|NCT02515786|No Intervention|Dry oxygen|oxygen by nasal catheter delivery will be dry
11327821|NCT02515773|Experimental|MET and LIFE|Participants randomized to this group will receive both Metformin and lifestyle intervention.Participants randomized to treatment with MET will start at a dose of 500 mg orally at night and slowly titrated in 2-week intervals to ensure that each patient achieves maximum insulin-sensitizing effects of the drug while minimizing the chance of side effects. Investigators will also recommend that MET be taken with food to minimize side effects. If a participant's BMI percentile <5% (=underweight) his/her treatment with MET will be discontinued. Although the risk of low vitamin B12 while taking MET is associated with age > 50 years and having type II diabetes, Investigator will monitor B12 levels and a CBC throughout study participation.
11327822|NCT02515773|Experimental|Healthy lifestyle intervention (LIFE)|Participants randomized to this group will receive just lifestyle intervention alone.This healthy lifestyle intervention (LIFE) consists of counseling participants and families regarding a healthy eating plan, physical activity and sedentary activities. Prior to study initiation, clinical site staff will participate in a live (or taped) training session from a dietician to lean to administer LIFE. A trained site staff member (e.g. medical assistant or case manager) will meet with participants and their families for a 15-20 minute session at baseline that will focus on nutritional issues using the Traffic Light Plan (TLP).
11327823|NCT02515760|Experimental|Lung cancer group|Bone marrow puncture in patients with non-small cell lung cancer
11327824|NCT02515760|Experimental|Control group (healthy donors)|Bone marrow puncture in healthy donors
11327825|NCT02515747|No Intervention|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
11327826|NCT02515747|Active Comparator|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
11327827|NCT02515747|Active Comparator|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
11327828|NCT02515734|Active Comparator|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
11327829|NCT02515734|Experimental|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
11327830|NCT02515721|Experimental|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
11327831|NCT02515721|Experimental|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
11327832|NCT02515708|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device.
11327833|NCT02515708|Other|Normothermic Machine Perfusion (single pump)|This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.
11327834|NCT02515695|Experimental|0.5 MIU i.v. and 1.5 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
11328023|NCT02514330|Experimental|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
11327835|NCT02515695|Experimental|1 MIU i.v. and 3 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
11327836|NCT02515695|Experimental|2 MIU i.v. and 6 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
11327837|NCT02515695|Experimental|4 MIU i.v. and 12 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.
~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
11327838|NCT02515682|Active Comparator|High equol|High equol group will be given natural S-equol supplementation 20mg per day for 24 week.
11327839|NCT02515682|Active Comparator|Low equol|Low equol group will be given natural S-equol supplementation 10mg/d (+10mg starch) for 24 weeks
11327840|NCT02515682|Placebo Comparator|Placebo|Placebo group will be given placebo control (made from starch) 20 mg per day for 24 weeks.
11327841|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
11327842|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
11327843|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
11327844|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
11327845|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
11327846|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
11327847|NCT02515630|Experimental|Momelotinib|MMB for 24 weeks (± 7 days)
11327848|NCT02515617|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
11327849|NCT02515617|Experimental|Period with endotracheal tubes allowing SSD|During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
11327850|NCT02515604|Active Comparator|Single dose group|
11327851|NCT02515604|Active Comparator|Repeated dose group|
11327852|NCT02515578|Active Comparator|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
11327853|NCT02515578|Experimental|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
11327854|NCT02515565|Experimental|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
11327855|NCT02515565|Other|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
11327856|NCT02515552|Other|All applicants|Study applicants who consented and completed the application to participate in the Fibromyalgia Wellness Project. From that point forward all subjects used the intervention program to at whatever frequency they chose voluntarily. It was recommended subjects complete a SMARTLog at least three times per week for at least three months.
11327857|NCT02515539|Experimental|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
11327858|NCT02515526|Active Comparator|Reference|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam
11327859|NCT02515526|Experimental|Test|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.
11327860|NCT02515513|Active Comparator|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
11327861|NCT02515513|Active Comparator|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
11327862|NCT02515500|Active Comparator|Gradual Cessation|
11327863|NCT02515500|Experimental|Gradual Cessation w/ Quitbit|
11327864|NCT02515487|Experimental|Breast cancer patients receiving chemotherapy treatment|
11327865|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
11327933|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
11327866|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
11327867|NCT02515461|Experimental|Intervention: Low energy shockwave therapy|Low energy shockwave therapy performed on both kidneys applying 3000 shocks on each kidney.
11327868|NCT02515448|Experimental|Gentamicine injectable(day 1+2)and then gentamicine inhalation|
11327869|NCT02515435|Experimental|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
11327870|NCT02515422|Active Comparator|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
11327871|NCT02515422|Active Comparator|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
11327872|NCT02515422|Active Comparator|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
11327873|NCT02515422|Placebo Comparator|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
11327874|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
11327875|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
11327876|NCT02515396|Experimental|Treatment Group A|MMI-0100 Inhaled, once daily x 5, followed by 3 week washout period, followed by Placebo Inhaled, once daily x 5
11327877|NCT02515396|Experimental|Treatment Group B|Placebo Inhaled, once daily x 5, followed by 3 week washout period, followed by MMI-0100 Inhaled, once daily x 5
11327878|NCT02515383||Part 1 (MDASI questionnaire, interview)|Patients complete the MDASI questionnaire and then complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
11327879|NCT02515383||Part 2 (MDASI questionnaires, interview)|Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1 week after beginning standard of care treatment, patients complete the MDASI questionnaire at 4 additional time points, each 1 week apart. Patients may also complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
11327880|NCT02515370|Other|Friends for Life Circles|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
11327881|NCT02515370|No Intervention|Standard|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
11327882|NCT02515357|Placebo Comparator|Control group|This arm will receive standard care, i.e. CPAP prescription and brief written healthy lifestyle advice.
11327883|NCT02515357|Experimental|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle on top of standard care.
11327884|NCT02515357|Experimental|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern on top of standard care.
11327885|NCT02515344|Experimental|A: nominative list|"Providing a list of patients not compliant with CRC sreening
~General Practitioners allocated to the intervention group (A) will receive:
~a nominative list of their patients who were not compliant to colorectal cancer screening.
~a document providing general information about colorectal cancer screening"
11327886|NCT02515344|Active Comparator|B: general information|"Providing general information about CRC screening
~General Practitioners allocated to group (B) will receive:
~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
11327887|NCT02515344|No Intervention|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
11327888|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
11327889|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
11327890|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
11327891|NCT02515318|Experimental|Physiotherapy program|Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment
11327892|NCT02515318|Active Comparator|Control group|Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
11327893|NCT02515305|Experimental|Test product|
11327894|NCT02515305|Active Comparator|Reference product|
11327895|NCT02515305|Placebo Comparator|Placebo product|
11327896|NCT02515292||IUGR: newborn with intrauterine growth restriction|"Inclusion criteria:
~newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction
~agreement of the parents that their child to be included in the study"
11327897|NCT02515292||control: newborn without intrauterine growth restriction|"Inclusion criteria:
~- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group"
11327898|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
11327934|NCT02515032|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
11327935|NCT02515032|Placebo Comparator|Placebo|An isocaloric placebo comparator
11327899|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
11327900|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
11327901|NCT02515240|Active Comparator|healthy controls|healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
11327902|NCT02515240|Active Comparator|newly diagnosed HIV >200|Newly diagnosed HIV positive patients with CD4 count >200, immunized with one shot of PPV23 vaccine.
11327903|NCT02515240|Active Comparator|newly diagnosed HIV <200|Newly diagnosed HIVpositive patients with CD4 count <200, immediately immunized with one shot of PPV23 vaccine.
11327904|NCT02515240|Active Comparator|newly diagnosed HIV <200 delayed|Newly diagnosed HIV positive patients with CD4 count <200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
11327905|NCT02515240|Active Comparator|HAART experienced HIV>200|HIV positive, on HAART treatment for 5 years, nadir CD4 count <200, but at present CD4 count is >200, immunized with one shot of PPV23 vaccine.
11327906|NCT02515240|Active Comparator|HAART experienced HIV<200|HIVpositive, on HAART treatment for 5 years, nadir CD4 count <200, and at present CD4 count is <200, immunized with one shot of PPV23 vaccine.
11327907|NCT02515227|Experimental|6MHP + Pembrolizumab|6 MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
11327908|NCT02515201|Active Comparator|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
11327909|NCT02515201|Active Comparator|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
11327910|NCT02515188|Experimental|propacetamol group|
11327911|NCT02515188|Placebo Comparator|placebo group|
11327912|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
11327913|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
11327914|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
11327915|NCT02515162|Experimental|Fischer Cone Biopsy Excisor|Conization Methode using a triangular electrode , i.e. Fischer Cone Biopsy Excisor
11327916|NCT02515162|Active Comparator|Loop Excision Procedure|Conization Methode using a circular electrode , i.e. Loop excision Procedure
11327917|NCT02515149|No Intervention|Standard of care|Referral laboratory based CD4 measurement after home-based HIV testing
11327918|NCT02515149|Experimental|Point of care|POC CD4 testing after home-based HIV testing
11327919|NCT02515136|Experimental|Parkinson's disease|Parkinson's disease patients
11327920|NCT02515136|Other|Controls|Healthy volunteers paired with Parkinson's disease patients on sex and age group, whose data will be extracted from a CNRS existing database
11327921|NCT02515123|Experimental|E-Motion System|E-motion tube + E-motion EPG 1000
11327922|NCT02515123|Sham Comparator|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
11327923|NCT02515110|Experimental|Treatment (EBRT)|"External Beam Radiation Therapy (EBRT). Within 10 weeks after the last breast cancer surgery or the last dose of adjuvant chemotherapy, patients undergo hypofractionated RNI five days a week over 3-4 weeks.
~The two subgroups are Cohort (A) sentinel lymph node (SLN) and Cohort (B) axillary lymph node (ALN) dissection. They are categorized depending on type of axillary surgery and treatment group. The type of axillary surgery is Sentinel lymph node (SLN) biopsy only vs axillary dissection with or without previous SLN biopsy. The treatment groups are lumpectomy vs mastectomy vs mastectomy/reconstruction."
11327924|NCT02515097|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
11327925|NCT02515097|Placebo Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
11327926|NCT02515084|Experimental|18F-FDG-PET and dw-MRI|At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
11327927|NCT02515071|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
11327928|NCT02515071|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
11327929|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
11327930|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
11327931|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
11327932|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
11328024|NCT02514330|No Intervention|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
11327936|NCT02515019|No Intervention|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
11327937|NCT02515019|Experimental|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
11327938|NCT02515006|Experimental|Homeopathy|Individualized homeopathy treatment as a supportive care
11327939|NCT02515006|No Intervention|Control|Usual Care
11327940|NCT02514993||Study group|Inclusion criteria for the study were (a) sternal fracture and concomitant thoracic spine fracture, (b) Injury Severity scale (ISS) ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
11327941|NCT02514993||Control group|The inclusion criteria for the control group included: (a) Thoracic spine fracture without concomitant sternal fracture, (b) ISS ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
11327942|NCT02514980|Active Comparator|Bupivacaine group|Infraorbital nerve block using bupivacaine 0.25% on each side.
11327943|NCT02514980|Active Comparator|Bupivacaine-Ketamine group.|Infraorbital nerve block using bupivacaine 0.25% combined with 0.5mg/kg ketamine on each side.
11327944|NCT02514967|Experimental|Blisibimod|
11327945|NCT02514967|Placebo Comparator|Placebo|
11327946|NCT02514954|Experimental|BioChaperone® Combo|1 single dose 400 U/mL
11327947|NCT02514954|Active Comparator|Humalog® Mix25|1 single dose 100 U/mL
11327948|NCT02514941|Experimental|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
11327949|NCT02514941|Experimental|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
11327950|NCT02514941|Experimental|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
11327951|NCT02514928|Experimental|pancreatoduodenectomy & nerve resection|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
11327952|NCT02514928|Active Comparator|pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
11327953|NCT02514915|Other|Stereotactic Radiosurgery|Subjects will receive stereotactic radiosurgery prior to resection
11327954|NCT02514902|Experimental|Lateral Flow Device|Determine the feasibility of testing whole blood samples from patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. No diagnostic or treatment decisions will be based on the results for any patient and the patient will not be told of the results.
11327955|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
11327956|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
11327957|NCT02514876|Experimental|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
11327958|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:
~CMR
~EV with an inter-electrode gap (lower pair) of 5 cm
~EV with an inter-electrode gap (lower pair) of 15 cm"
11327959|NCT02514850|Experimental|Biochaperone Combo|single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
11327960|NCT02514850|Active Comparator|Humalog Mix25|single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
11327961|NCT02514850|Active Comparator|Humalog and Lantus|simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
11327962|NCT02514837|Experimental|Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
11327963|NCT02514824|Experimental|MLN0128|"Dose escalation will occur using a standard 3+3 dose escalation approach. Each cohort should be evaluated for tolerability after completing 2 cycles of treatment before proceeding to escalation or de-escalation. The phase II part of the study will use the phase II dose or RP2D determined during the phase I part of the study.
~MLN0128, orally, on predetermined days per treatment cycle"
11327990|NCT02514616|Active Comparator|Active Electric Stimulation Therapy|The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
11328025|NCT02514317|Experimental|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
11329446|NCT02504580|Experimental|Part B Cohort G|400 mg HTX-011B by instillation
11327964|NCT02514811|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
11327965|NCT02514811|No Intervention|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
11327966|NCT02514798|Experimental|High-flow humidified nasal oxygen delivery system|We will describe effects of varying settings of high-flow nasal oxygen (10-30-45-60 L/min) on respiratory rate, tidal volume, and diaphragmatic work of breathing in patients with severe COPD. We will also describe changes in gas exchange and effects on the subjects' comfort and dyspnea. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system.
11327967|NCT02514798|Active Comparator|CPAP (Positive Control)|"We want to describe the breathing responses to varying setting of CPAP in the subject population. We plan to use the CPAP response as a positive control, to determine if our population responds as described by CPAP studies in the literature. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system."
11327968|NCT02514772|Experimental|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
11327969|NCT02514772|Active Comparator|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
11327970|NCT02514759|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions (one per week at 40-50 minutes each) and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
11327971|NCT02514759|No Intervention|Control group|The control group received business as usual.
11327972|NCT02514746|Experimental|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
11327973|NCT02514733||Young donor|Kidney transplant recipient > 60 years of age who received organ from donor <=40 years of age
11327974|NCT02514733||Old donor|Kidney transplant recipient >= 60 years of age who received organ from donor >=50 years of age
11327975|NCT02514720|Other|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
11327976|NCT02514720|Other|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
11327977|NCT02514694|Active Comparator|LEO 32731|Active
11327978|NCT02514694|Placebo Comparator|Placebo|Placebo
11327979|NCT02514681|Active Comparator|Trastuzumab + chemotherapy|Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
11327980|NCT02514681|Experimental|Trastuzumab+ pertuzumab + chemotherapy|Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
11327981|NCT02514668|Experimental|Isatuximab|Isatuximab (escalating dose) on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression
11327982|NCT02514655|Experimental|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
11327983|NCT02514655|Active Comparator|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
11327984|NCT02514642|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
11327985|NCT02514642|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
11327986|NCT02514629|Placebo Comparator|Placebo|Placebo for 52 weeks
11327987|NCT02514629|Experimental|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
11327988|NCT02514629|Experimental|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
11327989|NCT02514629|Experimental|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
11328022|NCT02514330|Experimental|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
11329447|NCT02504580|Placebo Comparator|Part C Cohort C|Saline Solution by instillation
11327991|NCT02514616|Sham Comparator|Delayed Electric Stimulation Therapy|The subject receives no active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject will receive Active Electric Stimulation Therapy at week 14 visit, and an extended open-label follow-up phase includes annual visits through 5 years.
11327992|NCT02514603|Experimental|Prexasertib|Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
11327993|NCT02514590|Experimental|Freedom SCS System - 1500 HZ|Epidural Space covering vertebrae level T8-T11 determined by paresthesia mapping for painful area.
11327994|NCT02514577|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
11327995|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
11327996|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
11327997|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
11327998|NCT02514564||Control|This group will not perform exercise.
11327999|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
11328000|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
11328001|NCT02514538|Experimental|Non-effervescent tablets|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
11328002|NCT02514538|Active Comparator|Effervescent Paracetamol|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
11328003|NCT02514525|Other|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
11328004|NCT02514512|No Intervention|Standard SABR|Patients receive standard treatment
11328005|NCT02514512|Experimental|MLC Tracking SABR|Patients are treated with MLC tracking
11328006|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
11328007|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
11328008|NCT02514460|Active Comparator|Intervention: Stents|Stents group
11328009|NCT02514460|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
11328010|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan|All patients in Part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy, topotecan. Patients will have PK assessment completed on days 1 and 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
11328011|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan -PART 2|All patients in Part 2 will be randomized 2:1 to receive trilaciclib (G1T28) to be administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
11328012|NCT02514447|Experimental|Placebo + Topotecan -PART 2|All patients in Part 2 will be randomized 1:2 to receive placebo administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
11328013|NCT02514434|Experimental|Ultrasonography|Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
11328014|NCT02514434|Experimental|Non-contrast MRI|Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
11328015|NCT02514421|Experimental|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
11328016|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
11328017|NCT02514382|Experimental|Treatment (dexamethasone, bortezomib, wild-type reovirus)|Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11328018|NCT02514356|Active Comparator|Own adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own Adherence'.
11328019|NCT02514356|Active Comparator|Own and group level adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own and Group Adherence'.
11328020|NCT02514343|Experimental|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
11328021|NCT02514343|Experimental|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
11328026|NCT02514291|Experimental|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
11328027|NCT02514291|No Intervention|Standard care|Standard pediatric neurology care
11328028|NCT02514278|Experimental|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:
~oxaliplatin: 85 mg/m2
~irinotecan: 180 mg/m²
~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)
~5FU: 2400 mg/m2
~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
11328029|NCT02514278|Active Comparator|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
11328030|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
11328031|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
11328032|NCT02514239|Experimental|BI 836909|given as continuous intravenous infusion
11328033|NCT02514226|Placebo Comparator|G1-control group|"Arm description: G1 - control group - (n = 30) dental hygiene orientation (DHO) + supragingival treatment + simulation of using photodynamic therapy (PDT).
~In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes and ultrasound. Supragingival treatment will be performed above the gingival margin. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed."
11328034|NCT02514226|Active Comparator|G2- positive control group|"Arm description: G2 - positive control group (gold standard) - (n = 30) - DHO + periodontal treatment + simulation of using PDT.
~All participants will receive periodontal treatment - scaling and root planning (SRP) by an experienced specialist with universal curetes and ultrasound in a full mouth manner. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed"
11328035|NCT02514226|Active Comparator|G3 -experimental active comparator group|"Arm description: G3 - experimental group - (n = 30) DHO +SRP + PDT with methylene blue
~In G3, periodontal treatment and photodynamic therapy (PDT) will be performed. The scaling and root planing will be performed identical as G2. The PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the photosensitizer"
11328036|NCT02514213|Experimental|Arm A|2mg INO-5150 and electroporation device CELLECTRA®-5P
11328037|NCT02514213|Experimental|Arm B|8.5mg INO-5150 and electroporation device CELLECTRA®-5P
11328038|NCT02514213|Experimental|Arm C|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
11328039|NCT02514213|Experimental|Arm D|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
11328040|NCT02514200|Experimental|Topography-based CXL (KXL2)|Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
11328041|NCT02514200|Active Comparator|Conventional pulsed CXL (pCXL)|Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
11328042|NCT02514187|Other|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
11328043|NCT02514187|Other|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
11328044|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
11328045|NCT02514161|Active Comparator|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.
~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:
~First week: 30% Maximum Inspiratory Pressure (MIP)
~Second week: 40% MIP
~Third week: 50% MIP
~Fourth week: 60% MIP
~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
11328097|NCT02513836|Experimental|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
11328203|NCT02512978|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
11328046|NCT02514161|Experimental|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:
~- MT:
~Upper cervical region mobilization in flexion
~Lower cervical postero-anterior mobilization + maintained traction
~Costovertebral joint postero-anterior mobilization
~Thoracic vertebral posteroanterior mobilization
~Thrust dorsal
~- MCE:
~Isometric contraction of the deep neck flexors.
~Isometric contraction of the neck extensors.
~Neural self-mobilization.
~Cervical retraction with theraband.
~Sphinx.
~Scapular adduction exercises in prone.
~Scapular adduction exercises in sitting position with theraband."
11328047|NCT02514148|Other|NO Intervention Control group|No therapeutic intervention are being giving to the group of patients, they only will have their Neurologist previously prescribed pharmacological treatment.
11328048|NCT02514148|Experimental|Therapeutic exercise( TE)|The intervention giving to the patients consist on a therapeutic exercise protocol based on neck and low intensity general exercises.
11328049|NCT02514148|Experimental|Therapeutic patient education ( TPE)|The intervention giving to the patients consist on a therapeutic patient education based on pain neurophysiology protocol.
11328050|NCT02514148|Experimental|TE + TPE|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol.
11328051|NCT02514148|Experimental|TE + TPE + Manual therapy|The intervention giving to the patients consist on the combination of the therapeutic exercise protocol and the therapeutic patient education protocol plus a manual therapy techniques protocol.
11328052|NCT02514135||Elevated Intra-abdominal Pressure|Patients with intra-abdominal pressure > 12 mmHg at any time throughout admission
11328053|NCT02514135||Normal Intra-abdominal Pressure|Patients with intra-abdominal pressure < 12 mmHg throughout admission
11328054|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
11328055|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
11328056|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
11328057|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
11328058|NCT02514083|Experimental|Ibrutinib and short-course fludarabine|"Ibrutinib 420 mg PO daily for the duration of the study
~Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4"
11328059|NCT02514070|Experimental|Group 1|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
11328060|NCT02514070|Experimental|Group 2|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
11328061|NCT02514057||Healthy|Volunteers over 18 years
11328062|NCT02514057||Gastrointestinal disorders|Over 18 and with any gastrointestinal or liver disorder
11328063|NCT02514057||Non-gastrointestinal disorders|Over 18 and with any medical condition requiring hospital attention in which there is no primary gastrointestinal or liver disease
11328064|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
11328065|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
11328066|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
11328067|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
11328068|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
11328069|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
11328070|NCT02514031|Experimental|ARQ-761|"A 2 week lead-in monotherapy of ARQ-761 (The amount of ARQ-761 that will be given to the participant will depend on the time at which the participant was enrolled in the study
~Afterwards the 28-day cycle of combination treatment of ARQ-761 along with gemcitabine (1000 mg/m2) + nab-paclitaxel (125 mg/m2) will begin."
11328071|NCT02514018|Other|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
11328072|NCT02514018|Other|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
11328073|NCT02514005|Active Comparator|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
11328074|NCT02514005|Experimental|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
11328075|NCT02513992|Experimental|intra-arterial injection of tracer|The perfusion tracer 99m-Technetium Ethyl Cysteinate Dimer will be injected via an intra-arterial catheter by a pressure injector to obtain a subtracted ictal SPECT co-registered with MRI (SISCOM)
11328076|NCT02513979|Active Comparator|angiotensin type II receptor antagonists|Hypertensive patients treated with angiotensin type II receptor antagonists
11328077|NCT02513979|No Intervention|No treatment|Normotensive patients
11328078|NCT02513953|Experimental|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
11328122|NCT02513602||CONTROL group (healthy patients)|Healthy patients, with an inserted mandibular implant, retrospectively enrolled with a preoperative cbct scan.
11328123|NCT02513589|Experimental|Experimental arm|
11328079|NCT02513940|Experimental|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
11328080|NCT02513940|Experimental|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
11328081|NCT02513940|Experimental|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
11328082|NCT02513940|Experimental|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
11328083|NCT02513940|Experimental|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
11328084|NCT02513940|Experimental|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
11328085|NCT02513927|Active Comparator|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
11328086|NCT02513927|Active Comparator|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
11328087|NCT02513914|Experimental|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
11328088|NCT02513914|Active Comparator|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
11328089|NCT02513901|Experimental|Chidamide|"Step 1 - Six participants will receive Chidamide 10 mg twice a week(BIW) for 4 consecutive weeks.
~Step 2 - Another six participants will receive Chidamide 30 mg twice a week(BIW) for 4 consecutive weeks.
~Participants will be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety concerns are noted, Step 2 will be enrolled."
11328090|NCT02513888|Experimental|Vitamin D + diet and lifestyle|subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification
11328091|NCT02513888|Placebo Comparator|placebo + diet and lifestyle|Subjects will be given placebo with diet and lifestyle
11328092|NCT02513875|Experimental|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
11328093|NCT02513875|Placebo Comparator|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
11328094|NCT02513862|Experimental|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
11328095|NCT02513862|No Intervention|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
11328096|NCT02513849|Experimental|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
11328152|NCT02513368|Experimental|Bio-Oss®, Bio-Gide®|augmentation procedure with Bio-Oss® and Bio-Gide®
11328098|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. They will repeat the questionnaire (POEM) after this education on opioid knowledge on the same day.
11328099|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
11328100|NCT02513810|Experimental|Short-term DAPT after Biofreedom|
11328101|NCT02513810|Active Comparator|Long-term DAPT after BioMatrix or Ultimaster|
11328102|NCT02513797|Experimental|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
11328103|NCT02513797|Active Comparator|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
11328104|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
11328105|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
11328106|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
11328107|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
11328108|NCT02513758||HIV patients|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
11328109|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
11328110|NCT02513745|Active Comparator|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
11328111|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
11328112|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
11328113|NCT02513693|Experimental|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine
~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
11328114|NCT02513693|Experimental|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex
~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).
~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.
~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
11328115|NCT02513680|Active Comparator|LASER and LED therapy application|The first group will use the two techniques under study combined: Infrared Laser + Amber LED (830 nm - 150mW + 590 nm - 1.500 mW)
11328116|NCT02513680|Active Comparator|LED Therapy application|The second group will use only Amber LED (590 nm - 1.500 mW)
11328117|NCT02513667|Experimental|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
11328118|NCT02513667|Experimental|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
11328119|NCT02513654|Experimental|Lamotrigine dispersible tablets 25mg, 50mg, 100mg|Each subjects will start dosing with lamotrigine 25mg dispersible tablet once daily at Day 1 and remain at this dose level for 2 weeks (Days1-14), then will be titrated to 50 mg once daily at Day 15 and last for weeks 3-4 (Days 15-28), and then titrated to 100 mg once daily at Day 29 during weeks 5-6 (Days 29-42).
11328120|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
11328121|NCT02513602||TEST group (kidney transplanted)|"Kidney transplanted patients, passed through dialysis phase presenting a mandibular edentulism. It will be scheduled one or two dental implants to be inserted in mandible.
~This group will be subjected to a dental implant insertion procedure."
11328124|NCT02513576|Experimental|Physiotherapy exercises|Two strategies of abdominal exercises with and without movement of the upper limbs applied in patients with sternal instability as randomization.
11328125|NCT02513563|Experimental|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
11328126|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
11328127|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
11328128|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
11328129|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
11328130|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
11328131|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
11328132|NCT02513524||Direct Observed Therapy test|Patients with resistant hypertension (as defined in the eligibility criteria) will be enrolled. They will all have undergone 24 hour ambulatory blood pressure monitoring (ABPM) before enrollment. As part of the study, the subjects will undergo direct observed therapy testing, followed by another 24 hour ABPM, which will be repeated at 1 month.
11328133|NCT02513511|Experimental|Hypnosis|the investigators will put the patient into a hypnotic state and analyze laryngoscopy under hypnosis, followed by intubation.
11328134|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
11328135|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
11328136|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
11328137|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
11328138|NCT02513459|Experimental|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
11328139|NCT02513446|Experimental|BI 1026706|Single dose
11328140|NCT02513446|Experimental|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
11328141|NCT02513433|Active Comparator|Bupivacaine & Levobupivacaine|Bupivacaine 15 ml 0.5% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
11328142|NCT02513433|Active Comparator|Bupivacaine & Ropivacaine|Bupivacaine 15 ml 0.5% and Ropivacaine 15 ml 0.75% in epidural route before surgery
11328143|NCT02513433|Active Comparator|Ropivacaine & Levobupivacaine|Ropivacaine 15 ml 0.75% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
11328144|NCT02513420|Experimental|Perineal muscle training|This group will recibe a training of a combination of perineal massage and pelvic floor muscle excersice that will start after 33 weeks of gestation. Every week until the childbith, They will be evaluated with a diary.
11328145|NCT02513420|No Intervention|Usual prental care|Usually pregnant women have not a training focused in pelvic floor muscle, so this group won't receive any indication of pelvic floor training except if They complains of urinary incontinence.
11328146|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
11328147|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
11328148|NCT02513394|Experimental|Arm A|Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.
11328149|NCT02513394|Other|Arm B|Standard adjuvant endocrine therapy for a duration of at least 5 years.
11328150|NCT02513381|Active Comparator|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
11328151|NCT02513381|Placebo Comparator|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
11328154|NCT02513355|Experimental|NP(Changchun marina+cisplatin)+Endostar|Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
11328155|NCT02513355|Experimental|TP(Taxol+cisplatin or parapl) +Endostar|"Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.
~Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4."
11328156|NCT02513342|Experimental|Endostar+Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.
11328157|NCT02513342|Active Comparator|Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.
11328158|NCT02513329|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivacaine
11328159|NCT02513329|Sham Comparator|Saline|Saline injection
11328160|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
11328161|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
11328162|NCT02513303|Experimental|Treatment Group|AV fistula surgery with investigational product (Sirolimus-eluting Collagen Implant)
11328163|NCT02513303|No Intervention|Control Group|AV fistula surgery without investigational product
11328164|NCT02513290|Experimental|Bilastine group|Bilastine 20 mg administered once a day for ten days.
11328165|NCT02513290|Experimental|Loratadine group|Loratadine 10 mg administered once a day for ten days.
11328166|NCT02513251||Case group|Chronic pain patient
11328167|NCT02513238|Active Comparator|Stemcells injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.
11328168|NCT02513238|Placebo Comparator|Saltwater injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%.
11328169|NCT02513225|Experimental|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
11328170|NCT02513225|Other|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
11328171|NCT02513212|Other|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
11328172|NCT02513212|Other|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
11328173|NCT02513199|Experimental|TACE/SBRT combination|
11328174|NCT02513199|Active Comparator|TACE alone|
11328175|NCT02513186|Experimental|Isatuximab|"VCDI cohort: Isatuximab (escalating dose) + bortezomib + cyclophosphamide + dexamethasone (VCDI): Induction phase will be 50 weeks (12 cycles). The duration of a cycle will be 42 days (6 weeks) for Cycle 1 (C1) and 28 days (4 weeks) for subsequent cycles. The duration of a cycle of the maintenance phase will be 28 days (4 weeks). After C12, isatuximab will be administered at its initial assigned dose and dexamethasone once every 28 days.
~VRDI cohort parts A and B: Isatuximab + bortezomib + dexamethasone + lenalidomide (VRDI): Induction phase will be 24 weeks (4 cycles at 6 weeks/cycle). The duration of a cycle of the maintenance phase will be 28 days (4 weeks). Maintenance therapy may continue until disease progression, unacceptable AE or patient willingness to discontinue.
~VRDI Part A: Enrollment to begin after the VCDI cohort is completed.
~VRDI Part B: Enrollment to begin after the VRDI part A is completed."
11328176|NCT02513173||Low back pain group|No intervention
11328177|NCT02513173||Control|No intervention
11328178|NCT02513160|Experimental|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
11328201|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
11328179|NCT02513160|Experimental|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
11328180|NCT02513160|Active Comparator|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
11328181|NCT02513160|Placebo Comparator|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
11328182|NCT02513147|Experimental|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
11328183|NCT02513147|Active Comparator|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
11328184|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
11328185|NCT02513121|No Intervention|Observational Arm|Standard of care
11328186|NCT02513108|Active Comparator|same day discharge|patients discharged same day after uncomplicated PCI
11328187|NCT02513108|No Intervention|standard care|standard care where patients are discharged the day after procedure after adequate observation
11328188|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
11328189|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
11328190|NCT02513082|Experimental|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
11328191|NCT02513082|Active Comparator|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
11328192|NCT02513069|Experimental|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
11328193|NCT02513069|Active Comparator|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
11328194|NCT02513030||Replacement of defibrillator|
11328195|NCT02513017|Experimental|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.
~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
11328196|NCT02513017|Experimental|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
11328197|NCT02513017|No Intervention|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
11328198|NCT02513004|Experimental|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
11328199|NCT02513004|Active Comparator|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
11328200|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
11328202|NCT02512978|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
11328204|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
11328205|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
11328206|NCT02512952|Active Comparator|Group 1|SRP with Open flap debridement (OFD) alone for treating periodontal pocket
11328207|NCT02512952|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into bone defect
11328208|NCT02512952|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into bone defect
11328209|NCT02512939|Experimental|Contacts of TB cases|Blood test, not yet marketed, development phase
11328210|NCT02512926|Experimental|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
11328211|NCT02512913|Experimental|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
11328212|NCT02512913|No Intervention|Usual Care|Couples in the control condition will receive usual care
11328213|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
11328214|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
11328215|NCT02512887|Experimental|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
11328216|NCT02512887|Active Comparator|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
11328217|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
11328218|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
11328219|NCT02512861|Placebo Comparator|Placebo|Normal Saline
11328220|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
11328221|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
11328222|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
11328223|NCT02512822|Experimental|Participants|Noninvasive Radiofrequency
11328224|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
11328225|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
11328226|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
11328227|NCT02512796||Transplant patients, MRI with Gadolinium contrast dye|Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.
11328228|NCT02512796||Non-transplant patients, MRI with Gadolinium contrast dye|Non-transplant patients exposed to gadolinium contrast.
11328229|NCT02512796||Healthy controls, no transplant no Gadolinium contrast dye|Age- and sex-matched healthy controls not exposed to gadolinium contrast.
11328230|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
11328231|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
11328232|NCT02512770|Experimental|dilatation|esaphageal dilatation group
11328233|NCT02512770|No Intervention|control|control group ( only endoscopy for control)
11328234|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
11328235|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample.
11328236|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
11328237|NCT02512744|No Intervention|Capping trial protocol|"Decannulation protocol based on tolerance to 24 hours capping trial to decide when to decannulate.
~Decapping during the capping trial for aspiration of respiratory secretions is considered a failure criteria of the trial.
~High flow conditioned oxygen therapy through tracheal cannula will be applied during periods out of capping trials."
11328238|NCT02512744|Experimental|Suctioning frequency protocol|"Decannulation protocol based on suctioning frequency to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
~Intervention: suctioning frequency of respiratory secretions will be recorded untill fulfill decannulation criteria. Capping trials will not be allowed in this group.
~High flow conditioned oxygen therapy will be applied through tracheal cannula during all the study period."
11328239|NCT02512731|Active Comparator|Goal directed fluid therapy using esophageal doppler monitor|The esophageal doppler monitor directs the fluid therapy.
11328240|NCT02512731|No Intervention|Fluid therapy using standard management|The esophageal doppler monitor is in place however blinded to the healthcare providers, fluid management is as per standard clinical practice.
11328241|NCT02512718|Experimental|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
11328242|NCT02512718|Active Comparator|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
11328243|NCT02512705|Other|Seclusion Room|The current practice is followed as a control group A.
11328244|NCT02512705|Experimental|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
11328245|NCT02512692|Experimental|90Y TARE with Gemcitabine and Cisplatin|"90Y TARE will be given on day 3 or 4 of cycle 1 and start at 75% of the dose calculated by the body surface area formula and escalated by 25% per cohort in combination with cisplatin 25 mg/m2 and gemcitabine 300 mg/m2 in cycles 1 and 2.
~Once the 90Y TARE has reached the 100% dose level, the gemcitabine dose will increase to 600mg/m2 in dose level 3 and 1000mg/m2 in dose level 4. The cisplatin dose will remain at 25/mg/m2.
~For all dose levels, from cycle 3 to cycle 8, the cisplatin dose will be 25mg/m2 and the gemcitabine dose will be 1000mg/m2."
11328246|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.
~Drug to be given in combination of Busulfan, Campath and Fludarabine"
11328247|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
11328248|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
11328249|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
11328250|NCT02512666|Experimental|Non-Invasive Imaging|"Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients.
~For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery"
11328251|NCT02512653|Experimental|1|Cupressus arizonica allergen extract at 4 different concentrations. Positive control. Negative control
11328252|NCT02512640|Active Comparator|Volume-controlled ventilation|Volume-controlled ventilation throughout the surgery
11328253|NCT02512640|Active Comparator|Pressure-controlled ventilation|Pressure-controlled ventilation throughout the surgery
11328254|NCT02512627|Active Comparator|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
11328255|NCT02512627|Active Comparator|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
11328256|NCT02512627|Experimental|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
11328257|NCT02512627|Experimental|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
11328258|NCT02512614|No Intervention|Comparison|Hand hygiene education.
11328259|NCT02512614|Experimental|Intervention|Hand hygiene education and 4 antimicrobial hand towels
11328260|NCT02512601|Experimental|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
11328261|NCT02512588|Experimental|BTD-001|
11328262|NCT02512588|Experimental|Placebo|
11328263|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).
~In Part B: one cohort with a single dose"
11328264|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
11328265|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.
~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
11328266|NCT02512562|Active Comparator|Group 1: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
11328267|NCT02512562|Active Comparator|Group 2: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
11328268|NCT02512549|Active Comparator|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
11328269|NCT02512549|No Intervention|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
11328270|NCT02512536|Experimental|Experimental|"Intervention:
~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.
~Drug: Dysport 300 units im. One single injection over course of study."
11328271|NCT02512523|Experimental|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
11328272|NCT02512523|Active Comparator|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
11328273|NCT02512510|Active Comparator|TD-4208-1|88 mcg
11328274|NCT02512510|Active Comparator|TD-4208-2|175 mcg
11328275|NCT02512510|Placebo Comparator|Placebo|Placebo
11328276|NCT02512497|Experimental|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:
~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.
~Romidepsin Maintenance Therapy - Part 2:
~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
11328277|NCT02512484||high risk TB individuals attending A&E Departments|Assessment against inclusion/exclusion criteria in terms of risk of TB. If eligible, assessment and testing as appropriate for active or latent TB
11328278|NCT02512471|Experimental|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
11328279|NCT02512471|Active Comparator|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
11328280|NCT02512458|Experimental|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
11328281|NCT02512445|Experimental|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
11328282|NCT02512445|Active Comparator|Supportive Care Therapy|6-session psychotherapy intervention
11328283|NCT02512432|Other|Keratoconus|
11328284|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
11328285|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
11328286|NCT02512406||Patients with Tourette Syndrome|Questionnaires including the Sensory Profile or the Adult/Adolescent Sensory profile and Children's Yale-Brown Obsessive Compulsive Scale or Yale Global Tic Severity Scale will be administered. When time permits, the Children's Yale-Brown Obsessive Compulsive Scale or Yale-Brown Obsessive Compulsive Scale will also be administered. Demographic data will also be collected for each study patient.
11328287|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
11328288|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
11328289|NCT02512380|Experimental|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
11328290|NCT02512380|Active Comparator|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
11328291|NCT02512367|Experimental|Intervention|
11328292|NCT02512367|Placebo Comparator|Surveillance|
11328293|NCT02512354||Fetus|
11328294|NCT02512328|No Intervention|Regular colonoscopy preparation|Comparison group. Regular colonoscopy preparation
11328295|NCT02512328|Experimental|APP supported colonoscopy preparation|APP as additional device for colonoscopy preparation
11328296|NCT02512315|Active Comparator|CRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CRT).
11328297|NCT02512315|Experimental|NACT-CRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CRT.
11328298|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
11328299|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
11328300|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
11328301|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
11378701|NCT02177461|Active Comparator|Enalapril + clonidine TTS1|
11328303|NCT02512289|Active Comparator|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
11328304|NCT02512289|Sham Comparator|Sham stimulation|Sham tDCS associated with RAT
11328305|NCT02512276|Experimental|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications [defined as combined (average of averages) proportion of days covered (PDC) < 80%] who also have poor or worsening disease control.
11328306|NCT02512276|No Intervention|Usual care|Patients randomized to this arm will receive usual care.
11328307|NCT02512263|Experimental|Intervention group|They will have to do all the tests and to follow the home-based training program during 9 weeks.
11328308|NCT02512263|No Intervention|control group|They will have to do all the tests but not to follow the home-based training program.
11328309|NCT02512237|Experimental|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
11328310|NCT02512237|Experimental|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
11328311|NCT02512237|Experimental|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
11328312|NCT02512237|Experimental|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
11328313|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
11328314|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
11328315|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
11328316|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
11328317|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
11328318|NCT02512198|Experimental|Bronchodilators|"Prescription Data Feedback to GP Practices - practices will be fed back data for people with presumed asthma who have either been dispensed more than 12 short-acting beta-agonist bronchodilators in the last 12 months who are not concurrently prescribed inhaled corticosteroids (poor asthma control with inadequate prevention) or been dispensed a long-acting beta-agonist bronchodilator as a single agent in the last 12 months who are not or are only infrequently concurrently prescribed inhaled corticosteroids (potentially harmful prescribing). To minimise inclusion of people with COPD, patient aged 35 years and older prescribed long-acting antimuscarinic bronchodilators will be excluded.
~Practices in the bronchodilator arm are controls for the antibiotic experimental arm (below)."
11328319|NCT02512198|Experimental|Antibiotics|"Prescription Data Feedback to GP Practices - number of women in the GP practice aged 12 years and older dispensed more than 6 courses of urinary tract infection (UTI) antibiotics in the last year. UTI antibiotics are defined as trimethoprim, nitrofurantoin, co-trimoxazole, quinolones and cefalexin.
~Practices in the antibiotic arm are controls for the bronchodilator experimental arm (above)."
11328320|NCT02512185||Chemotherapy|Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
11328321|NCT02512185||Abiraterone|Men with mCRPC starting Abiraterone
11328322|NCT02512185||Enzalutamide|Men with mCRPC starting Enzalutamide
11328323|NCT02512172|Experimental|Oral CC - 486 & MK-3475|Oral CC - 486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
11328324|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
11328325|NCT02512172|Experimental|Oral CC - 486 & Romidepsin & MK-3475|Oral CC - 486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
11328326|NCT02512159|Experimental|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
11328327|NCT02512159|Active Comparator|Healing|"Patients who were managed with traditional conservative treatment."
11328328|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
11328329|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.
~Intervention: colonoscopy."
11328330|NCT02512133|Experimental|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
11328331|NCT02512133|Experimental|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
11328332|NCT02512120|Experimental|volume controlled ventilation|Randomized 23 patients will be applied VCV during RALP.
11328333|NCT02512120|Active Comparator|autoflow-volume controlled ventilation|Randomized 23 patients will be applied autoflow-VCV during RALP.
11328334|NCT02512107|Active Comparator|Juice Plus+|Subject will be taking supplement.
11328335|NCT02512107|Placebo Comparator|Placebo|Subjects will be taking the placebo.
11328336|NCT02512068|Experimental|Trelagliptin 25 mg|Trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period I + II)
11328337|NCT02512068|Experimental|Placebo and Trelagliptin 25 mg|Placebo tablet, orally, once weekly before breakfast for up to Week 12 (Period I), followed by trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period II)
11328338|NCT02512055|Experimental|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
11328339|NCT02512042|Experimental|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
11328340|NCT02512042|Active Comparator|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
11328341|NCT02512029|Experimental|TBI Subjects|Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.
11328342|NCT02512029|Experimental|Control|Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451.
11328343|NCT02512016|Other|Nulliparous Women in Third Trimester|Study Procedures
11328344|NCT02512003|Experimental|Fantom Treatment group|
11328345|NCT02511990|Experimental|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml
~3 mg/kg, single dose IV administration of 10-1074"
11328346|NCT02511990|Experimental|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml
~10 mg/kg, single dose IV administration of 10-1074"
11328347|NCT02511990|Experimental|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml
~30 mg/kg, single dose IV administration of 10-1074"
11328348|NCT02511990|Experimental|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml
~30 mg/kg, single dose IV administration of 10-1074"
11328349|NCT02511990|Experimental|Group 2A|"HIV-uninfected individuals
~3 mg/kg, single dose IV administration of 10-1074"
11328350|NCT02511990|Experimental|Group 2B|"HIV-uninfected individuals
~10 mg/kg, single dose IV administration of 10-1074"
11328351|NCT02511990|Experimental|Group 2C|"HIV-uninfected individuals
~30 mg/kg, single dose IV administration of 10-1074"
11328352|NCT02511990|Experimental|Group 2D|"HIV-uninfected individuals
~30 mg/kg, single dose IV administration of 10-1074"
11328353|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
11328354|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
11328355|NCT02511964|Experimental|Interval Training at 1% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 1% incline; Group metabolically balanced.
11328356|NCT02511964|Experimental|Interval Training at 10% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 10% incline; Group metabolically balanced.
11328357|NCT02511964|No Intervention|Control|Only Dependent Variables Measures
11328358|NCT02511951|Experimental|one-layer duct-to-mucosa anastomosis|one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
11328359|NCT02511951|Active Comparator|two-layer duct-to-mucosa anastomosis|two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
11328360|NCT02511938|Experimental|Menu Only intervention|Restaurants will receive a new healthy kids' menu
11328361|NCT02511938|Experimental|Menu Plus Intervention|Restaurants will receive a new healthy kids' menu, supporting marketing materials, and brief trainings for customer service staff and kitchen staff to support and promote the new menu items.
11328362|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
11328363|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
11328364|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
11328365|NCT02511912|Experimental|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.
~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
11328366|NCT02511899|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
11328367|NCT02511899|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
11328368|NCT02511886|Experimental|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
11328369|NCT02511886|Placebo Comparator|Placebo|Subjects remain on placebo for entire study
11328370|NCT02511873|Experimental|Fycompa|Fycompa dose is chosen based on tolerability and efficacy. 2mg to 8mg daily for 6 weeks then washed out.
11328371|NCT02511873|Placebo Comparator|Placebo|Inactive ingredient equal to 2mg tablets
11328372|NCT02511860|Placebo Comparator|Placebo|Patients will consume a placebo pill containing methylcellulose.
11328373|NCT02511860|Active Comparator|Active|Patients will consume 850 mg of burdock twice per day.
11328374|NCT02511847|Other|single-arm|"Drug: Afatinib (single group assignment)
~First phase: Afatinib montherapy
~The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
11328375|NCT02511834|Experimental|VEST supported|Vein graft supported by VEST
11328376|NCT02511834|Active Comparator|Control|Vein grafts unsupported by VEST
11328377|NCT02511821|Experimental|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
11328378|NCT02511808|Active Comparator|Step-up Treatment: MI|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive two sessions of MI.
11328395|NCT02511704|Experimental|Electronic cigarette|"Multiple dose
~Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) + Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) separated by 60 minutes"
11328379|NCT02511808|Other|Control: BA|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive one additional session of BA.
11328380|NCT02511808|Active Comparator|Step-up Treatment: Specialist Care|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive four sessions of BSCT if they received MI at the previous randomization or five sessions of combined MI and BSCT if they received BA at the previous randomization.
11328381|NCT02511808|Other|Control: MI|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive one session of MI if they received MI at the previous randomization or two sessions of MI if they received BA at the previous randomization.
11328382|NCT02511795|Experimental|AZD1775 (6 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 3 days (6 doses) on Days 1-3 of Week 1 and Days 8-10 of Week 2. Olaparib will be given orally BID on Days 1-14.
~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
11328383|NCT02511795|Experimental|AZD1775 (10 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 5 days (10 doses) on Days 1-5 of Week 1 and Days 8-12 of Week 2. Olaparib will be given orally BID on Days 1-14.
~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
11328384|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
11328385|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
11328386|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
11328387|NCT02511769|Experimental|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
11328388|NCT02511769|Active Comparator|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
11328389|NCT02511756|Other|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
11328390|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
11328391|NCT02511730|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
11328392|NCT02511730|Active Comparator|FFDM Alone|Breast Images with FFDM alone
11328393|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
11328394|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
11328433|NCT02511444|Other|single arm|All patients will have GBS culture and real time PCR performed.
11328396|NCT02511704|Active Comparator|Cigarette|"Multiple dose
~Nicotine 0.8 mg, administrated by cigarette (10 puffs) + Nicotine 0.8 mg, administrated by cigarette (10 puffs) separated by 60 minutes"
11328397|NCT02511691|Other|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
11328398|NCT02511678|Experimental|Cryoablation|All participants will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles within 14 days of screening. In the case of participants with multiple metastatic lesions involving bone, the most painful lesion is to be selected for cryoablation. If treatment could not be completed within 14 days of screening, the participant will be re-screened using the inclusion and exclusion criteria. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators.
11328399|NCT02511665|Experimental|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
11328400|NCT02511665|Placebo Comparator|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
11328401|NCT02511665|Experimental|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
11328402|NCT02511652|Active Comparator|Ambu AuraGain|Insertion of the supraglottic device and evaluation of its clinical performance
11328403|NCT02511652|Active Comparator|LMA Supreme|Insertion of the supraglottic device and evaluation of its clinical performance
11328404|NCT02511639|Experimental|Arm A: Everolimus & Aromatase inhibitors|Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
11328405|NCT02511639|Active Comparator|Arm B: Aromatase inhibitors|Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
11328406|NCT02511626||Case group|Women with a surgically confirmed diagnosis of endometriosis
11328407|NCT02511626||Control group 1|Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)
11328408|NCT02511626||Control group 2|Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)
11328409|NCT02511613|Placebo Comparator|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
11328410|NCT02511613|Active Comparator|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
11328411|NCT02511600|Experimental|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
11328412|NCT02511600|Active Comparator|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
11328413|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
11328414|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
11328415|NCT02511574|Experimental|cervical pessary|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
11328416|NCT02511574|Active Comparator|natural progesterone|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
11328417|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
11328418|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
11328419|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
11328420|NCT02511548|Experimental|Intervention|Financial incentive
11328421|NCT02511548|No Intervention|Control|No financial incentive
11328422|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
11328423|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
11328424|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
11328425|NCT02511522|Active Comparator|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
11328426|NCT02511522|Experimental|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
11328427|NCT02511509|Experimental|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
11328428|NCT02511509|Active Comparator|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
11328429|NCT02511483|Placebo Comparator|IV-PCA morphine + Placebo PO|"Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.
~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
11328430|NCT02511483|Experimental|IV-PCA morphine + Propranolol PO|"The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .
~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
11328431|NCT02511470|Other|CPR with metronome on|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome on. Data for compression rate and depth will be collected during this time interval.
11328432|NCT02511470|Other|CPR with metronome off|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome off. Data for compression rate and depth will be collected during this time interval.
11328434|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
11328435|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
11328436|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
11328437|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
11328438|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
11328439|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
11328440|NCT02511405|Experimental|Arm 1|VB-111 + Bevacizumab
11328441|NCT02511405|Active Comparator|Arm 2|Bevacizumab
11328442|NCT02511392|Active Comparator|Group 1: Real rTMS-1 Hz|Included 15 patients, they received 1 Hz rTMS with intensity of 100% of the RMT continuous with total 2000 applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval
11328443|NCT02511392|Active Comparator|Group 2: Real rTMS-10 Hz|Included 15 patients, they received 10 Hz rTMS with intensity of 100% of the RMT applied in 10 trains, each of them 200 pulses, with 20 seconds intertrain interval
11328444|NCT02511392|Sham Comparator|Group 3: Sham rTMS|Included 15 patients; they received the same number of pulses 2000 pulse applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval, but coil was placed over the same area but perpendicular to the scalp.
11328445|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
11328446|NCT02511366|Experimental|ileal infusion of casein|Ileal infusion of casein
11328447|NCT02511366|Placebo Comparator|ileal infusion of tap water|ileal infusion of tap water
11328448|NCT02511353|Placebo Comparator|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
11328449|NCT02511353|Experimental|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
11328450|NCT02511353|Experimental|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
11328451|NCT02511340|Experimental|Flumatinib mesylate tablet 600 mg qd|Flumatinib, 600mg, qd
11328452|NCT02511327||Preterm born infants of vaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
11328453|NCT02511327||Term born infants vaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
11328454|NCT02511327||Term born infants unvaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy. Infant vaccination against pertussis is performed according to the national recommended schedule.
11328455|NCT02511327||Preterm born infants unvaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy.Infant vaccination against pertussis is performed according to the national recommended schedule.
11328456|NCT02511314|Experimental|Intervention|"Tena Identifi is an integrated electronic monitoring system based upon a wearable continence pad which allows registration of resident's micturition patterns over a 72 hour period, allowing caregivers to construct an individualised continence care plan, including use of appropriate products.
~To create a voiding report, a resident wears the Identifi Sensor Wear with an attached Identifi Logger for three consecutive days (72 hours). The logger continuously logs the moisture status of the brief. The resulting data is sent to a server via 3 G signal where it is mapped onto a graph indicating voiding times and volumes."
11328457|NCT02511314|No Intervention|Control Intervention|"The control portion of the study is usual care, defined as the routine practices and procedures, including continence assessment approach, prescribed in the nursing home unit or facility."
11328458|NCT02511301|Experimental|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.There are no interventions after the CBR™ is removed from the Study Subject
11328459|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
11328460|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
11328461|NCT02511288||Cohort 3|Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
11328462|NCT02511275|Other|renal microdialysis|patient with renal microdialysis
11328463|NCT02511262||Specimen Collection|Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
11328464|NCT02511249||cohort|"1 evaluation day : The evaluation team included a neuropsychologist, a speech therapist and either a pediatric neurologist or a pediatric physical and rehabilitation medicine practitioner.
~tests carried out : Global intellectual functioning (WISC-IV), Oral language (N-EEL), Gross and fine motor abilities (clinical examination, Box & Block test, 9 Hole Peg test)"
11328465|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
11328466|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
11328467|NCT02511223|Experimental|Single Arm|Only one Arm,All patients will receive Olaparib 300 mg (MILIGRAM)bid p.o till disease progression
11328468|NCT02511210|Active Comparator|regional anesthesia|spinal anesthesia or peripheral nerve block
11328470|NCT02511197|Experimental|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
11328471|NCT02511184|Experimental|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
11328472|NCT02511171|No Intervention|No intervention|Subjects do not receive osteopathic care
11328473|NCT02511171|Experimental|Cranial osteopathic manipulative treatment|Subjects receive individualised osteopathic treatment
11328474|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
11328475|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
11328476|NCT02511145|Active Comparator|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
11328477|NCT02511145|Active Comparator|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
11328478|NCT02511145|Active Comparator|Metvixia|minizone with Metvixia cream application, without pretreatment
11328479|NCT02511145|Active Comparator|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
11328480|NCT02511145|Experimental|Microneedles pretreatment only|minizone with Microneedles pretreatment only
11328481|NCT02511145|Experimental|Laser pretreatment only|minizone with Laser pretreatment only
11328482|NCT02511145|No Intervention|Normal skin|Normal skin control mini-zone
11328483|NCT02511132|Experimental|Vigil + temozolomide + irinotecan|(i) oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle), (ii) irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle), intravenously (iii) peg-filgrastim 100μg/kg (Day 6) subcutaneously (optional and may be administered at home), and (iv) Vigil 1.0 x 10e7 cells/injection, intradermally on Day 15 and every 43 weeks thereafter. One cycle = 21 days.
11328484|NCT02511106|Experimental|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
11328485|NCT02511106|Placebo Comparator|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
11328486|NCT02511093|Experimental|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:
~BP measurements;
~an educational and counselling intervention on patient adherence;
~an educational and counselling intervention on lifestyle (physical activity and diet).
~Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
11328487|NCT02511093|No Intervention|Usual care|
11328488|NCT02511080|Active Comparator|Spot-on group|Use active measures against intraoperative hypothermia
11328489|NCT02511080|No Intervention|control|standard measures against intraoperative hipothermia
11328490|NCT02511067|Active Comparator|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
11328491|NCT02511067|Experimental|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
11328492|NCT02511067|Experimental|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
11328493|NCT02511054|Experimental|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples > 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
11328494|NCT02511054|Experimental|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
11328495|NCT02511054|Experimental|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
11328496|NCT02511054|Experimental|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
11328497|NCT02511041|Experimental|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
11328498|NCT02511028|Experimental|ferumoxytol|A 510 mg dose (17 mL) of ferumoxytol diluted in 50 mL of 0.9% normal saline will be intravenously infused over 17 minutes
11378702|NCT02177448|Experimental|BIBR277 and placebo matching enalapril|
11328499|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
11328500|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
11328501|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
11328502|NCT02511002||1|Post influenza infection
11328503|NCT02510976|Active Comparator|Prucalopride|Prucalopride tablet 2 mg
11328504|NCT02510976|Placebo Comparator|Placebo|matching placebo tablet
11328505|NCT02510963|Experimental|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
11328506|NCT02510963|Experimental|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
11328507|NCT02510963|Active Comparator|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
11328508|NCT02510950|Experimental|Arm 1: Peptide/poly-ICLC|"For all patients, concurrent chemoradiation with temozolomide will be given per standard of care and is outside the scope of this study as per standard of care.
~The long peptide + poly-ICLC will be given on Cycle 1 Day 1 of maintenance temozolomide.
~If the vaccine is not ready by this time, the first vaccination will begin on Day 1 of the next cycle of maintenance temozolomide.
~The peptide + poly-ICLC vaccine will be given again on Days 8, 15, and 22 of the first cycle, as a priming strategy.
~On all subsequent cycles, the peptide vaccine + poly-ICLC will be given on Day 22 (+/-3 days)."
11328509|NCT02510937|Experimental|Low dose CC-90001|Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks
11328510|NCT02510937|Experimental|High dose CC-90001|High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks
11328511|NCT02510924|Active Comparator|Tracheal intubation with Airtraq sp|Tracheal intubation with Airtraq sp.
11328512|NCT02510924|Experimental|Tracheal intubation with Airtraq Mobile|Tracheal intubation with Airtraq Mobile
11328513|NCT02510911|Experimental|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
11328514|NCT02510911|Experimental|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
11328515|NCT02510911|Placebo Comparator|corn starch (250 mg approx.)|approx. 250 mg corn starch as placebo
11328516|NCT02510898|Experimental|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
11328517|NCT02510885|Experimental|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
11328518|NCT02510872|Experimental|18F-FDG PET combined with CT with iodinated contrast injection|18F-FDG PET combined with CT with iodinated contrast injection
11328519|NCT02510872|Sham Comparator|18F-FDG PET combined with CT without injection|18F-FDG PET combined with CT without injection
11328520|NCT02510859|Experimental|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
11328521|NCT02510859|No Intervention|Traditional nutritional follow up|Traditional nutritional follow up that is to say with a nutritional consultation before starting treatment and then when necessary on medical advice
11328522|NCT02510846|Experimental|Intensive educative program|5 hours a week
11328523|NCT02510846|Active Comparator|Usual practice of educative program|1 hour a week
11328524|NCT02510833|Experimental|Continuing Intervention Group|
11328525|NCT02510833|Active Comparator|Control Group|
11328526|NCT02510820|Active Comparator|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
11328527|NCT02510820|Active Comparator|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
11328528|NCT02510807|Experimental|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
11328529|NCT02510807|No Intervention|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
11328530|NCT02510794|Experimental|Ranibizumab Dose 1|Participants will receive ranibizumab delivered through the implant with Dose 1 formulation in the study eye on Day 1 and if required, implant refill will be done starting from Month 1 according to protocol-defined refill criteria.
11328531|NCT02510794|Experimental|Ranibizumab Dose 2|Participants will receive ranibizumab delivered through the implant with Dose 2 formulation in the study eye on Day 1 and if required, implant refill will be done starting from Month 1 according to protocol-defined refill criteria.
11328532|NCT02510794|Experimental|Ranibizumab Dose 3|Participants will receive ranibizumab delivered through the implant with Dose 3 formulation in the study eye on Day 1 and if required, implant refill will be done starting from Month 1 according to protocol-defined refill criteria.
11328533|NCT02510794|Active Comparator|Ranibizumab 0.5 mg ITV injection|Participants will receive ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
11328536|NCT02510768|Experimental|ELAPR002f|ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
11328537|NCT02510768|Experimental|ELAPR002g|ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
11328538|NCT02510768|Placebo Comparator|Saline|Saline
11328539|NCT02510755|Other|PTSD group|PTSD group
11328540|NCT02510755|Other|Healthy Volunteers|Healthy Volunteers, age-matched controls.
11328541|NCT02510742|Active Comparator|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
11328542|NCT02510742|Sham Comparator|Control|Sham neurostimulation of amplitude=0
11328543|NCT02510729|Active Comparator|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
11328544|NCT02510729|Placebo Comparator|Sham Stimulation|Sham stimulation with amplitude=0
11328545|NCT02510716|Experimental|Scheduled Gradual Reduction (SGR)|Four week SGR program plus support text messages.
11328546|NCT02510716|Active Comparator|Support Message Only|Support text messages only.
11328547|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
11328548|NCT02510703|Other|no diabetes|no diabetes
11328549|NCT02510677|Other|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
11328550|NCT02510664|Experimental|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
11328551|NCT02510651|Experimental|ORSHFS|Melanocyte-keratinocyte suspension.
11328552|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
11328553|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
11328554|NCT02510612|Experimental|Dexmedetomidine|Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h
11328555|NCT02510612|Placebo Comparator|placebo|Patients in group P will be given normal saline during anesthesia induction and maintenance phase
11328556|NCT02510599|Experimental|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
11328557|NCT02510586|Experimental|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
11328558|NCT02510586|No Intervention|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
11328559|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
11328560|NCT02510560|Experimental|NTRA-2112 A|NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.
11328561|NCT02510560|Experimental|NTRA-2112 B|NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.
11328562|NCT02510560|Placebo Comparator|Placebo|Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.
11328563|NCT02510547|Active Comparator|CrossBoss Catheter|Crossing the CTO with upfront use of the CrossBoss catheter
11328564|NCT02510547|Active Comparator|Antegrade Wire Escalation Strategy|Crossing the CTO with upfront antegrade wire escalation strategy
11328565|NCT02510534|Active Comparator|Control|This arm receives Menopur 150 international units x 1 dose
11328566|NCT02510534|Active Comparator|Treatment|This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
11328567|NCT02510521|Placebo Comparator|in rest situation|No intervention during one week. Daily usual activities are allowed.
11328568|NCT02510521|Experimental|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:
~warming-up sequence
~work sequence (starting at 50% of the intensity achieved during warm-up)
~relaxation sequence
~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
11328569|NCT02510521|Experimental|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :
~warming-up sequence
~work sequence (starting at 50% of the intensity achieved during warm-up)
~relaxation sequence
~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
11328570|NCT02510508|Experimental|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
11328571|NCT02510508|Active Comparator|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
11328572|NCT02510508|No Intervention|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
11328573|NCT02510495|No Intervention|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
11328574|NCT02510495|Experimental|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
11328575|NCT02510495|Experimental|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
11328576|NCT02510495|Experimental|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
11328577|NCT02510495|Experimental|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
11328578|NCT02510482||Aortic valve stenosis|Individuals with clinically stable moderate aortic valve stenosis
11328579|NCT02510469|Experimental|Apatinib Maintenance Therapy After Adjuvant Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
11328580|NCT02510469|No Intervention|Only Adjuvant Chemotherapy|No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
11328581|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging (DOSI)
11328582|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
11328583|NCT02510430|Experimental|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
11328584|NCT02510430|Experimental|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
11328585|NCT02510430|Placebo Comparator|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
11328586|NCT02510417|Experimental|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
11328587|NCT02510404|Experimental|mCTLs against three viruss|The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
11328588|NCT02510391|Experimental|PIPA|Modularized treatment for anxiety in children ages 3-7 years old
11328589|NCT02510378|Experimental|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
11328590|NCT02510365|Experimental|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
11328591|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
11328592|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
11328593|NCT02510313|No Intervention|Classic VUP (Control)|Families receive benefits (cash) in exchange for state-sanctioned labour intensive work.
11328594|NCT02510313|No Intervention|Expanded VUP|Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
11328595|NCT02510313|Experimental|Sugira Muryango & Classic VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned labour intensive work.
11328596|NCT02510313|Experimental|Sugira Muryango & Expanded VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
11328597|NCT02510287|Active Comparator|Continuous Epidural Infusion|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.
~A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.
~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
11328749|NCT02509273|Experimental|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
11328598|NCT02510287|Experimental|Programmed Intermittent Epidural Bolus|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.
~A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.
~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
11328599|NCT02510274|Experimental|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
11328600|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
11328601|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
11328602|NCT02510261|Experimental|Patisiran (ALN-TTR02)|
11328603|NCT02510248|Experimental|Study Drug|Study drug will be AL-704 once or twice daily for up to 7 days in dosages ranging from 100 mg to 1500 mg.
11328604|NCT02510248|Placebo Comparator|Placebo|Placebo to match study drug dosing.
11328605|NCT02510235|Experimental|Lubricin|Lubricin 150 µg/ml eye drops solution
11328606|NCT02510235|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
11328607|NCT02510222|Experimental|Oral Magnesium sulfate|Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
11328608|NCT02510222|Placebo Comparator|Control|Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
11328609|NCT02510209|Experimental|Teen Outreach Program|
11328610|NCT02510209|No Intervention|Control|Business as usual.
11328611|NCT02510196|Active Comparator|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
11328612|NCT02510196|No Intervention|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
11328613|NCT02510183|Active Comparator|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
11328614|NCT02510183|Placebo Comparator|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
11328615|NCT02510183|No Intervention|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
11328616|NCT02510157|Active Comparator|dexamethasone|Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
11328617|NCT02510157|Placebo Comparator|normal saline|Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
11328618|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
11328619|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
11328620|NCT02510131|Active Comparator|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.
~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.
~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.
~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
11328621|NCT02510131|Experimental|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.
~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.
~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.
~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
11328622|NCT02510118|Experimental|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
11328623|NCT02510118|Experimental|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
11328624|NCT02510105|Experimental|ARDS patients|
11328625|NCT02510092|Active Comparator|Coronary artery diseae with revascularization indicated|Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.
11328626|NCT02510092|No Intervention|Coronary artery disease not requiring revascularization|Subjects with coronary artery disease that do not require revascularization.
11328627|NCT02510066|Experimental|Acupuncture|Acupuncture participants would receive electroacupuncture on Jiaji (Ex-B2) points for 3 times in a week.
11328628|NCT02510066|Placebo Comparator|Placebo acupuncture|Placebo acupuncture participants would receive placebo acupuncture on non-point points for the same period.
11328629|NCT02510053|Other|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
11328750|NCT02509273|Active Comparator|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
11328630|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
11328631|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
11328632|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
11328633|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
11328634|NCT02510014|Experimental|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
11328635|NCT02510014|Experimental|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
11328636|NCT02510001|Experimental|Dose Escalation Phase Dose 1.|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
11328637|NCT02510001|Experimental|Dose Escalation Phase 2.|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
11328638|NCT02510001|Experimental|Dose Escalation Phase 3.|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
11328639|NCT02510001|Experimental|Diose Escalation Phase 4.|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
11328640|NCT02510001|Experimental|Dose Escalation Phase 5.|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
11328641|NCT02510001|Experimental|Dose Escalation Phase 6.|Crizotinib 200mg OD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
11328642|NCT02510001|Experimental|Dose Escalation Phase 7|Binimetinib 30mg BD continuous administration or days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
11328643|NCT02510001|Experimental|Dose Escalation Phase 8|Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
11328644|NCT02510001|Experimental|Dose Escalation Phase 9|Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg BD continuous administration
11328645|NCT02510001|Experimental|Dose Escalation Phase 10|Binimetinib 30mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
11328646|NCT02510001|Experimental|Dose Escalation Phase 11|Binimetinib 45mg BD continuous administration or days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
11328647|NCT02510001|Experimental|Dose Expansion Phase|PF-02341066 (Crizotinib) 200mg OD/ 200mg BD Days 1-28 continuously Binimetinib 30mg/45mg Dosage to be determined once the recommended Phase II dose has been identified in the dose escalation phase.
11328648|NCT02509988|Experimental|Intervention (study nutritional drink)|"Study nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).
~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
11328649|NCT02509988|Active Comparator|Control (standard nutritional drink)|"Standard nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).
~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
11328650|NCT02509975|Experimental|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
11328651|NCT02509962|Experimental|Slow sodium tablets|Increased dietary salt intake
11328652|NCT02509949|Experimental|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
11328653|NCT02509949|Placebo Comparator|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
11328654|NCT02509936|Active Comparator|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
11328655|NCT02509936|Experimental|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
11328656|NCT02509923|Experimental|1|3-way cross-over, Z-215 10 mg/day / Z-215 20 mg/day / Rabeprazole Sodium 10 mg/day
11328657|NCT02509923|Experimental|2|3-way cross-over, Z-215 20 mg/day / Z-215 40 mg/day / Rabeprazole Sodium 20 mg/day
11328658|NCT02509923|Experimental|3|3-way cross-over, Z-215 20 mg/day (before breakfast) / Z-215 20 mg/day (after breakfast) / Rabeprazole Sodium 10 mg/day (after breakfast)
11328659|NCT02509910||Standard therapy|intraoperative standard fluid therapy for major abdominal surgery
11328660|NCT02509910||Goal directed therapy|intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients
11328661|NCT02509897|Active Comparator|Hypoxic training|Endurance training
11328662|NCT02509897|Placebo Comparator|Normoxic training|Endurance training
11328663|NCT02509871|Other|Body composition measurement|DXA, impedance
11328664|NCT02509858|Active Comparator|thyroxine in eythyroid diabetics|50 μg of thyroxine once daily, for 2 months.
11328665|NCT02509858|Active Comparator|thyroxine in euthyroid healthy humans|50 μg of thyroxine once daily, for 2 months.
11328666|NCT02509858|Placebo Comparator|placebo in euthyroid diabetics|50 μg of placebo once daily, for 2 months.
11328751|NCT02509260|Experimental|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
11328667|NCT02509845|Experimental|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
11328668|NCT02509845|Experimental|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
11328669|NCT02509845|Experimental|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
11328670|NCT02509832|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
11328671|NCT02509832|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
11328672|NCT02509819|Experimental|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
11328673|NCT02509806|Experimental|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
11328674|NCT02509806|No Intervention|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
11328675|NCT02509793|Experimental|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
11328676|NCT02509780|Experimental|Vichy|
11328677|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
11328678|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
11328679|NCT02509754|Experimental|Atrial fibrillation catheter ablation|Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
11328680|NCT02509754|Experimental|Rate control arm|Patients randomized to rate control only arm will undergo ICD implantation and optimization of the rate control therapy. In case of uncontrolled ventricular rate at 24-h ECG Holter, defined as a mean resting heart rate higher than 90 bpm, patients will receive atrioventricular (AV) node ablation and resyncronization therapy (CRT-D) implantation, performed following common practice at each Center. In case of failure or technical difficulties of the transvenous approach, epicardial screw-in or steroid-eluting passive lead is implanted via a limited thoracotomy. Transcatheter AV node ablation is performed as follows: a non-irrigated tip ablation catheter is introduced on the right side of the interatrial septum and ablation performed on the fast pathway region or the smallest His bundle signal. The goal of the procedure is AV modulation below 30 bpm or complete AV block.
11328681|NCT02509741|Experimental|Educational intervention|High-protein and low-GI diet education
11328682|NCT02509741|Experimental|Dietary intervention|High-protein and low-GI diet plus education
11328683|NCT02509741|Experimental|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
11328684|NCT02509741|No Intervention|control|Routine diet recommendation
11328685|NCT02509728|Active Comparator|standard nutrition|standard nutrition
11328686|NCT02509728|Experimental|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
11328687|NCT02509728|Experimental|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
11328688|NCT02509728|Experimental|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
11328689|NCT02509715|No Intervention|Standard Conventional group|Standard conventional thyroid surgery
11328691|NCT02509702|Experimental|Connected to Care|The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
11328692|NCT02509702|No Intervention|Control|The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
11328693|NCT02509689|Experimental|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.
~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
11328694|NCT02509676|Experimental|dynamic stretching exercise|This group will perform dynamic stretching exercise to their left side gastrocnemius muscles for 5 weeks (5 days a week, 3 sets of exercise a day, each set including 5 repetitions of dynamic stretching lasting 45 seconds)
11328695|NCT02509676|No Intervention|control|this group will not perform any stretching exercises for 5 weeks
11328696|NCT02509663|Active Comparator|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
11328697|NCT02509663|Active Comparator|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
11328698|NCT02509637|Active Comparator|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
11328699|NCT02509637|Active Comparator|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
11328700|NCT02509637|Active Comparator|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
11328701|NCT02509624|Experimental|Mild hepatic impairment (Class A)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of GS-4997 on Day 1.
11328702|NCT02509624|Experimental|Moderate hepatic impairment (Class B)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of GS-4997 on Day 1.
11328703|NCT02509624|Experimental|Severe hepatic impairment (Class C)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of GS-4997 on Day 1.
11328704|NCT02509611|Experimental|Immediate treatment|Participants who are randomly assigned to the immediate treatment group will receive 60-minute biweekly Hatha yoga for 12 weeks.
11328705|NCT02509611|Active Comparator|Waitlist control|Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
11328706|NCT02509598|Experimental|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
11328707|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
11328708|NCT02509572|Experimental|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
11328709|NCT02509572|No Intervention|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
11328710|NCT02509559|Active Comparator|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
11328711|NCT02509559|Placebo Comparator|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
11328712|NCT02509546|Experimental|Treatment (8-chloro-adenosine)|Patients receive 8-chloro-adenosine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11328713|NCT02509533|Experimental|V.A.C.® Therapy|In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.
11328714|NCT02509533|Active Comparator|usual dressing method (compresses)|In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.
11328715|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
11328716|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
11328717|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec|Talimogene Laherparepvec
11328718|NCT02509507|Experimental|Phase Ib/II Talimogene Laherparepvec + Pembrolizumab|Combination treatment of Talimogene Laherparepvec and Pembrolizumab
11328719|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
11328720|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
11328721|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
11328722|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
11328723|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
11328724|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
11328725|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
11328726|NCT02509468|No Intervention|Observational|"Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).
~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)"
11328727|NCT02509468|Experimental|Experimental|At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)
11328728|NCT02509455||Normal 1|SwayStar device used 1st, Sensoro used 2nd
11328729|NCT02509455||Normal 2|Sensoro device used 1st, SwayStar used 2nd
11328730|NCT02509442|Other|Diffusion of direct electric stimulation|Neurosurgery awakened
11328731|NCT02509429|Experimental|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:
~the first with Control-to-Range algorithm (CTR),
~the second with Threshold Low Glucose Suspend (TLGS)."
11328732|NCT02509429|Experimental|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:
~the first with Threshold Low Glucose Suspend (TLGS),
~the second with Control-to-Range algorithm (CTR)."
11328733|NCT02509403|Experimental|Intervention|Essential oils infused Perineal Hygiene wipe
11328734|NCT02509390|Experimental|Severe trauma patients|All severe trauma patients (ISS>15) admitted in our trauma center Blood samples (additional blood tubing)
11328735|NCT02509377|Experimental|BMI 35.0 to 40.0|"Mothers who meet all inclusion exclusion criteria for open fetal repair of myelomeningocele except BMI.
~These mothers have a BMI between 35.0 and 40.0"
11328736|NCT02509364||AE-IPF|"Diagnosis criteria for AE-IPF:
~Diagnosed IPF patient experiences unexplained dyspnea within 1 month
~With objective evidence of hypoxia and new onset of pulmonary infiltration based on imaging examination
~With other diagnosis like pulmonary embolism, pneumothorax or heart failure excluded."
11328737|NCT02509364||Stable-IPF|"Diagnosis criteria for Stable-IPF:
~Exclusion of other known causes of ILDs
~Presence of a usual interstitial pneumonitis (UIP) pattern on high-resolution computed tomography (HRCT)
~Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy."
11328738|NCT02509364||Health control|Healthy volunteer
11328739|NCT02509351|Experimental|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
11328740|NCT02509351|Active Comparator|placeboo|women receiving placebo
11328741|NCT02509338|Experimental|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
11328742|NCT02509312|Experimental|Experimental|Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours
11328743|NCT02509312|Placebo Comparator|Control|Patients in this arm will be given a placebo medication at cord clamp, and then 3 additional doses of placebo every 6 hours.
11328744|NCT02509299|Experimental|Experimental group 1|patients will be involved in the Physiotherapy program 1. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises added to standard treatment.
11328745|NCT02509299|Experimental|Experimental group 2|patients will be involved in the physiotherapy program 2. The program was a combined intervention including the Control Group treatment plus neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises.
11328746|NCT02509299|Other|Control group|patients will receive standard medical treatment without physiotherapy intervention.
11328747|NCT02509286|Experimental|Perioperative Chemotherapy (FLOT):|"The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.
~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
11328748|NCT02509286|Active Comparator|Neoadjuvant Chemoradiation (CROSS):|"The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.
~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
11328752|NCT02509260|Active Comparator|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
11328753|NCT02509247|Experimental|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
11328754|NCT02509247|No Intervention|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
11328755|NCT02509221||Less than 30 minutes|
11328756|NCT02509221||30-60 minutes|
11328757|NCT02509221||More than 60 minutes|
11328758|NCT02509208|Experimental|SurgiClot|All qualified subjects will be treated with the SurgiClot haemostatic dressing
11328759|NCT02509195|Experimental|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
11328760|NCT02509182|Active Comparator|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
11328761|NCT02509182|Experimental|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
11328762|NCT02509169|Experimental|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
11328763|NCT02509169|Active Comparator|TAE|Trans-catheter embolization (TAE) will be given once per month
11328764|NCT02509156|Experimental|Allo-MSCs|Target dose of 100 million allo-MSCs
11328765|NCT02509156|Placebo Comparator|Placebo|Buminate solution
11328766|NCT02509143|Experimental|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture on the points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4), Pericardium 6 (PC6), Heart 8 (HT8), and Gall Bladder 41 (GB41) within 48 hours after surgery
11328767|NCT02509143|Active Comparator|P6 stimulation with intravenous infusion of ramosetron|P6 stimulation by wearing a study wristband within 48 hours after surgery
11328768|NCT02509143|Active Comparator|Intravenous infusion of ramosetron|A mixture of standard antiemetic medication (5-Hydroxytryptophan receptor antagonist; ramosetron hydrochloride 0.3 mg) and analgesics, including anon-steroidal anti-inflammatory drug (NSAID) (ketorolac tromethamine 120 mg), and a semi-synthesized opioid (oxycodone 20 mg), will be infused by intravenous patient-controlled analgesia (1ml bolus/20 min lockout, 1ml/hr continuous infusion).
11328769|NCT02509130||Patients who attended RAAC/SAAC.|Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study. Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
11328770|NCT02509130||Patients eligible for RAAC, but DNA'd|Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
11328771|NCT02509130||Asthma Outpatients|Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
11328772|NCT02509130||Healthcare Professionals|Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
11328773|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
11328774|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
11328775|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
11328776|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
11328777|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
11328778|NCT02509104|Experimental|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
11328779|NCT02509104|Experimental|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
11328780|NCT02509091|Experimental|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
11328781|NCT02509091|No Intervention|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
11328782|NCT02509078|Active Comparator|Early Neuromuscular Blockade (NMB)|Patients will receive cisatracurium besylate for the first 48 hours of the trial.
11328783|NCT02509078|No Intervention|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
11328784|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
11328785|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
11328786|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
11328787|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
11328788|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
11328789|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
11328790|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
11328791|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
11328792|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
11328793|NCT02509052|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11328794|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
11328795|NCT02509026|Experimental|Etanercept|etanercept 50 mg QW
11328796|NCT02509000|Active Comparator|Active-mode|Air purifier in active-mode
11328797|NCT02509000|Sham Comparator|Sham-mode|Air purifier in sham-mode
11328798|NCT02508987||Group 1|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as periodontally healthy.Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 18.50-24.99 kg/m2: Normal-weight"
11328799|NCT02508987||Group 2|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as gingivitis. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index.
~18.50-24.99 kg/m2: Normal-weight"
11328800|NCT02508987||Group 3|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index.18.50-24.99 kg/m2: Normal-weight"
11328801|NCT02508987||Group 4|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as either 'periodontally healthy'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
11328802|NCT02508987||Group 5|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'gingivitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
11328803|NCT02508987||Group 6|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.
~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
11328804|NCT02508961|Experimental|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
11328805|NCT02508961|Active Comparator|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
11328806|NCT02508935|Experimental|XARTEMIS XR|All participants received XARTEMIS XR
11328807|NCT02508922|Experimental|Vitamin D3|2000iu vitamin D will be taken daily for 20 weeks.
11328808|NCT02508922|Placebo Comparator|Placebo|Matching placebo drops will be taken daily for 20 weeks
11328809|NCT02508909|Experimental|Videoscopic ilioinguinal lymphadenectomy for melanoma|Melanoma groin lymph node metastasis.
11328810|NCT02508896|Experimental|AFFITOPE® AT04A+adjuvant|3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
11328811|NCT02508896|Experimental|AFFITOPE® AT06A+adjuvant|3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
11328812|NCT02508896|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization
11328813|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
11328814|NCT02508870|Experimental|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
11328815|NCT02508870|Experimental|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
11328816|NCT02508870|Experimental|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
11328817|NCT02508870|Experimental|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
11328818|NCT02508870|Experimental|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
11328819|NCT02508870|Experimental|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
11328820|NCT02508857|Active Comparator|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
11328821|NCT02508857|Experimental|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
11328822|NCT02508857|Placebo Comparator|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
11328823|NCT02508844|Experimental|Vivomixx®|Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus
11328824|NCT02508844|Placebo Comparator|Placebo|microcrytalline cellulose, magnesium stearate and silicon dioxide.
11328825|NCT02508831|Experimental|Bilateral amputation of upper limb|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
11328826|NCT02508818|Other|Cardiovascular measurements|
11328827|NCT02508805|Experimental|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.
~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
11328828|NCT02508805|Active Comparator|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
11328829|NCT02508792|Active Comparator|LASER|"Subject will receive application of LASER before muscle fatigue protocol.
~Note: this is a crossover study."
11328830|NCT02508792|Placebo Comparator|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.
~Note: this is a crossover study."
11328831|NCT02508779|Experimental|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
11328832|NCT02508779|Active Comparator|Routine Care|Routine care provided by subject's medical team
11328833|NCT02508766|Experimental|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
11328834|NCT02508766|No Intervention|Control group|Volunteers received no intervention. They just sat there for 20 minutes before being evaluated.
11328835|NCT02508753|Experimental|CXA-101/tazobactam therapeutic dose|
11328836|NCT02508753|Experimental|CXA-101/tazobactam supra-therapeutic dose|
11328837|NCT02508753|Active Comparator|Moxifloxacin|
11328838|NCT02508753|Placebo Comparator|Placebo|
11328839|NCT02508740|Experimental|normal renal function|Healthy subjects with normal renal function (Stage 1, >90 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
11328840|NCT02508740|Experimental|mild renal impairment|Patients with mild renal impairment (Stage 2, 60-89 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
11328841|NCT02508740|Experimental|moderate renal impairment|Patients with moderate renal impairment (Stage 3, 30-59 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
11328842|NCT02508740|Experimental|severe renal impairment|Patients with severe renal impairment (Stage 4, <30 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
11328843|NCT02508740|Experimental|End Stage Renal Disease (ESRD)|Patients with End Stage Renal Disease (ESRD) receiving dialysis for at least 3 months preceding the initial dose in this study (Stage 5) will participate in 2 treatment periods and will receive a single oral dose of 0.25 mg bevenopran at 3 hours after completion of the last hemodialysis session of the week in Period 1 and a single oral dose of 0.25 mg bevenopran at 3 hours before initiation of the last hemodialysis session of the week in Period 2
11328844|NCT02508727|Other|Healthy volunteers|Healthy volunteers
11328845|NCT02508727|Other|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
11328846|NCT02508727|Other|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
11328847|NCT02508714|Active Comparator|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
11328848|NCT02508714|Active Comparator|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
11328849|NCT02508701|Other|Altruistic inside-dorm|"Altruistic & personal message with direct recommendation and access to the vaccine on-site
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
11328850|NCT02508701|Other|Generic inside-dorm|"Generic message and access to the vaccine on-site
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
11328851|NCT02508701|Other|Generic outside-dorm|"Generic message and off-site access to the vaccine
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
11328852|NCT02508701|Other|Altruistic outside-dorm|"Altruistic & personal message with direct recommendation and off-site access to the vaccine
~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
11328853|NCT02508688|Experimental|thoracoscopic mesh repair group|63 patients with refractory HH (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair were included in this study.
11328854|NCT02508662||Advanced Cancer (Refractory) with Genomic Mutation|Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
11328855|NCT02508649|Placebo Comparator|Placebo|
11328856|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
11328857|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
11328858|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
11328859|NCT02508649|Experimental|Selepressin 4|"Starting dose 5.0 ng/kg/min
~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
11328860|NCT02508636|Experimental|Single Arm|"Enzalutamide: 160 mg (for 40 mg capsules) per day; Oral - swallow capsules hole, with or without food; Enzalutamide therapy to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months.
~Leuprolide: any duration formulation: single 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months; Intramuscular injection"
11328861|NCT02508623|Experimental|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
11328862|NCT02508623|Placebo Comparator|Placebo|Placebo 1 tablet BID for +60 days
11328863|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
11328864|NCT02508584|Experimental|Intervention|This is a single patient treatment IND
11328865|NCT02508571|Placebo Comparator|Preterm infant control|Preterm infant without intervention
11328866|NCT02508571|Experimental|Preterm infant single intervention|Direct swallowing training (DST) for preterm infant
11328867|NCT02508571|Experimental|Preterm infant combined interventions|Combined DST and oral sensorimotor stimulation (OSMS) for preterm infant
11328868|NCT02508558|Other|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
11328869|NCT02508545|Other|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
11328870|NCT02508532|Experimental|Avapritinib (formerly BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
11328871|NCT02508519|Experimental|Zonal|The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
11328872|NCT02508519|Experimental|Balance|The balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
11378706|NCT02177422|Experimental|Telmisartan|
11328873|NCT02508519|No Intervention|Control|The control group will provide only the estimation of the the pain level according to a visual analog pain scale (VAS) but receive no acupuncture treatment. Then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded.
11328874|NCT02508506|Experimental|ALKS 5461|Sublingual tablet
11328875|NCT02508493||Major Depressive Disorder Population|100 Individuals with DSM-5-defined MDD, aged 18-65
11328876|NCT02508493||Healthy Control Population|100 healthy controls matched on age, sex and years of education
11328877|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
11328878|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
11328879|NCT02508467|Experimental|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
11328880|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
11328881|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
11328882|NCT02508441|Experimental|Andes-1537 for Injection|Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
11328883|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|
11328884|NCT02508428|Active Comparator|Standard Enduron polyethylene|
11328885|NCT02508415|Experimental|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
11328886|NCT02508415|No Intervention|No Non Surgical Periodontal Therapy|No treatment received
11328887|NCT02508402|Active Comparator|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
11328888|NCT02508402|Placebo Comparator|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
11328889|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
11328890|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
11328891|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
11328892|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (10 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
11328893|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
11328894|NCT02508376|Experimental|ID93 (10 mcg) + GLA-SE (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
11328895|NCT02508376|Experimental|ID93 (10 mcg) alone|N=10 subjects will receive intervention on Days 1, 29, 57
11328896|NCT02508363|Active Comparator|Health Fair Alone (Control)|"No Follow Up Participant does not require referrals or assistance and was not advised to see a provider in the next three months.
~Regular follow-up call within two weeks of health fair by IHCD intern or staff. Participant has abnormal values, requires referrals or assistance or was advised to see a provider in the next three months.
~Up to 3 call attempts to get participant into needed care. Further contact only by participant request.
~Urgent follow-up call or in-person assistance within 1 day of health fair by IHCD intern or staff Participant advised to seek urgent care within one week.
~Three total call or in-person attempts to get participant into needed care. Further contact only by participant request The follow up call attempts may extend up to 3 months past the date of health fair to complete any needs the driver may have."
11328897|NCT02508363|Experimental|Health Fair + Navigator Case Management|"• Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.
~Navigator Case Management by trained staff
~Tailored assistance for any health needs a minimum of once a month 12 months. Assistance includes pre-appointment reminder calls, post-appointment follow up calls, and health promotion reminders.
~NCM case management will continue follow-up at a minimum of once per month or as requested by the participant for the study duration and will consistently offer appointment reminders and follow-ups."
11328898|NCT02508363|Experimental|Health Fair + Taxi Health Improvement Promoters|"Health Fair standard services Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.
~Taxi health Improvement Promoters (TIPs)
~Weekly check-ins with each participant, in person or by phone, about scheduling of, and attendance at, primary care appointments along with other health or study questions Mosio Text Messaging Program
~Send primary care provider recommendations to participant up to three times
~Two pre-appointment reminders & one post-appointment check-in
~Twice weekly health promotion reminders after primary care appointment"
11328899|NCT02508350|Experimental|daptomycin|Daptomycin for injection 10-12mg/kg/day,determination of plasma concentration
11328900|NCT02508337|Experimental|XG-102|sterile ophthalmic solution for sub-conjunctival injection
11328901|NCT02508337|Placebo Comparator|placebo|sterile ophthalmic solution for sub-conjunctival injection
11328902|NCT02508324|Other|Intervention|"All potential recipients will have complete (HLA) typing and determination of HLA antibodies. An appropriate umbilical cord blood unit (CBU) will be identified or in the absence of an appropriate CBU, a haplo-identical cells (donor) will be identified.
~Within 72 hours after completion of the chemotherapy regimen, and no sooner than 24 hours after administration of the last dose of chemotherapy, umbilical cord graft or haplo-graft will be administered."
11328903|NCT02508311|Active Comparator|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
11328904|NCT02508311|Placebo Comparator|Placebo|Subjects will receive 16 weeks of placebo medication.
11328936|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.
~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
11328905|NCT02508298|Active Comparator|Indocyanine green retention test|A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
11328906|NCT02508298|Active Comparator|Liver stiffness measurement|ARFI measurements of the liver will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
11328907|NCT02508298|Active Comparator|Spleen stiffness measurement|ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
11328908|NCT02508272||Trauma patients|age ≥18 y ISS ≥ 17 points admission < 6 h.
11328909|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
11328910|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
11328911|NCT02508246|Experimental|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
11328912|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
11328913|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
11328914|NCT02508220|Other|Oxy-Placebo|Syntocinon first, Placebo second 2 puffs in each nostril
11328915|NCT02508220|Other|Placebo-Oxy|Placebo first, Syntocinon second 2 puffs in each nostril
11328916|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
11328917|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
11328918|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
11328919|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
11328920|NCT02508181|Active Comparator|I-gel intra ocular pressure|supraglottic airway device
11328921|NCT02508181|Active Comparator|LMA Supreme intra ocular pressure|supraglottic airway device
11328922|NCT02508168|Experimental|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
11328923|NCT02508168|Experimental|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
11328924|NCT02508155|Experimental|MEDI7352 IV|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
11328925|NCT02508155|Placebo Comparator|IV Placebo|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
11328926|NCT02508155|Experimental|MEDI7352 Subcutaneous Injection|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
11328927|NCT02508155|Placebo Comparator|Subcutaneous Placebo|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
11328928|NCT02508142|Active Comparator|Hyoscine-N-Butylbromide|20 mg Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL)
11328929|NCT02508142|Placebo Comparator|Placebo|100 mL normal saline
11328930|NCT02508129|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
11328931|NCT02508129|Experimental|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
11328932|NCT02508129|Placebo Comparator|Enhanced Usual Care (EUC)|EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
11328933|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
11328934|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
11328935|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.
~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
11328937|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
11328938|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11328939|NCT02508064|Experimental|Part 1|BMS-663068 1 × 600 mg extended-release (ER) tablet formulation
11328940|NCT02508064|Experimental|Part 1: Prototype 1|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)
11328941|NCT02508064|Experimental|Part 1: Prototype 2|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)
11328942|NCT02508064|Experimental|Part 1: Prototype 3|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)
11328943|NCT02508064|Experimental|Part 1: Prototype 4|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)
11328944|NCT02508064|Experimental|Part 1: Prototype 5|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)
11328945|NCT02508064|Experimental|Part 2|BMS-663068 1 × 600 mg ER tablet formulation
11328946|NCT02508064|Experimental|Part 2: Prototype 1|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)
11328947|NCT02508064|Experimental|Part 2: Prototype 2|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)
11328948|NCT02508064|Experimental|Part 2: Prototype 3|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)
11328949|NCT02508064|Experimental|Part 2: Prototype 4|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)
11328950|NCT02508051|No Intervention|No daily emails|The usual care group will receive no intervention except for a reminder every six months to take a test of journal-based CME questions from 2 anesthesiology journals
11328951|NCT02508051|Placebo Comparator|Article email links|The email link group will get e-mailed web links to different specific articles, including articles on which the CME questions are based, published in 2 anesthesiology journals Monday through Friday with a reminder to take the same test every six months
11328952|NCT02508051|Experimental|Blog email links|The experimental group will get e-mailed web links to blogs Monday through Friday based on the same specific articles as in group 2; each daily blog will focus on a specific article, including articles on which CME questions are based, the blogs will have web links to the articles on which they are based and every six months group 3 will get a reminder to take the same test.
11328953|NCT02508038|Experimental|TCRαβ+/CD19+ depleted Haploidentical HSCT+ Zoledronate|Patients with high-risk leukemia (who are at least one year of age and who have not received TBI as conditioning for a previous HSCT) will receive myeloablative conditioning with ATG, Fludarabine, Thiotepa, and TBI. All other subjects will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotepa, and Melphalan prior to transplant with a KIR/KIR ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCR-αβ+ and CD19+ cells. Patients will receive 5 doses of zoledronate (at 28 day intervals) starting 28 days after stem cell transplant.
11328954|NCT02508012|Experimental|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
11328955|NCT02508012|No Intervention|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
11328956|NCT02507999|Experimental|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
11328957|NCT02507999|No Intervention|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
11328958|NCT02507986|Active Comparator|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
11328959|NCT02507986|Experimental|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
11328960|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
11328961|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
11328962|NCT02507960|Other|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
11328963|NCT02507934|Experimental|Lubricin|Lubricin 150 μg/ml eye drops solution
11328964|NCT02507934|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
11328965|NCT02507895|Experimental|MI-BCI training|subjects will undergo 12 sessions over 4 weeks of MI-BCI training
11328966|NCT02507882|Experimental|HCC|This group will include patients with chronic hepatitis C (no. =135)
11328967|NCT02507882|Experimental|HCC with Cirrhosis|This group will include patients with chronic hepatitis C (no. =135) with cirrhosis (F4).
11328968|NCT02507882|Experimental|HCV related HCC patients|This group will include patients with HCV related HCC (no. =135) This is confirmed by presence of focal lesion detected by Imaging (computed tomography (CT) and ultrasound), and elevated serum AFP.
11328969|NCT02507869|Experimental|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
11328970|NCT02507869|Active Comparator|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
11328971|NCT02507856||investigational group|early/late dabigatran
11328973|NCT02507843|Active Comparator|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
11328974|NCT02507843|Placebo Comparator|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
11328975|NCT02507830||Glubran 2 fixation|Mesh fixation with Glubran 2 glue in primary inguinal hernia repair
11328976|NCT02507817||31-32 with Mg for neuroprotection|"Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection.
~blood sample and tissue sample (placenta)."
11328977|NCT02507817||33-34 without Mg for neuroprotection|"Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection.
~blood sample and tissue sample (placenta)."
11328978|NCT02507817||PET with Mg after 34 weeks|"Women that had severe preeclamsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivere after 34 weeks of gestation.
~blood sample and tissue sample (placenta)."
11328979|NCT02507817||control|"Low risk pregnanacies in similar weeks to group 3 that did not require any special teatment and delivered after 34 weeks of gestation.
~blood sample and tissue sample (placenta)."
11328980|NCT02507804|Experimental|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
11328981|NCT02507804|Active Comparator|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
11328982|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
11328983|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
11328984|NCT02507778|Other|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
11328985|NCT02507765|Experimental|Treatment (SBRT, TACE)|Patients undergo SBRT on day 1 and TACE on day 2.
11328986|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
11328987|NCT02507739|Other|possibility to walk during labor|possibility to walk during labor
11328988|NCT02507739|Other|no possibility to walk during labor|no possibility to walk during labor
11328989|NCT02507726|Experimental|Flexima Active Soft convexe|Flexima Active soft convexe (1 to 3 appliances per day)
11328990|NCT02507700|Active Comparator|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
11328991|NCT02507700|Sham Comparator|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
11328992|NCT02507687|Experimental|Bimatoprost Sustained-Release (SR)|"Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose B administrations at Day 4 and Week 16 (Stage 2).
~Contralateral Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2)."
11328993|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|"Assigned Primary Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
~Contralateral Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose B administrations at Day 4 and Week 16 (Stage 2)."
11328994|NCT02507661|Experimental|alveolar ridge preservation - 2 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
11328995|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 2 months|no-preservation of alveolar ridge - 2 months
11328996|NCT02507661|Experimental|preservation of alveolar ridge - 4 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
11328997|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 4 months|no-preservation of alveolar ridge - 4 months
11328998|NCT02507661|Experimental|preservation of alveolar ridge - 9 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
11328999|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 9 months|no-preservation of alveolar ridge - 9 months
11329000|NCT02507648|Experimental|A Test|Test drug (Oseltamivir) 1 tablet contains 75 mg Oseltamivir
11329001|NCT02507648|Active Comparator|B Reference|Reference drug (Tamiflu®) 1 tablet contains 75 mg Oseltamivir
11329002|NCT02507635|No Intervention|healthy volunteers|healthy volunteers
11329003|NCT02507635|Active Comparator|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
11329004|NCT02507635|Active Comparator|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
11329005|NCT02507622|Other|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
11329006|NCT02507609|Active Comparator|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
11329007|NCT02507609|Active Comparator|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
11329008|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
11329009|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
11329010|NCT02507583|Experimental|Cohort 1|After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.
11329011|NCT02507570|Experimental|Open label|Single arm study to evaluate safety and tolerability of Enzalutamide with concurrent administration of Radium ra 223 dichloride in subjects with symptomatic metastatic prostate cancer.
11329012|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
11329013|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
11329014|NCT02507544|Experimental|TRX-818|
11329015|NCT02507531|Experimental|Treatment|Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.
11329016|NCT02507518|Experimental|Experimental|Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
11329017|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
11329018|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
11329019|NCT02507492|Experimental|RM-493 Once Daily|Dose once daily in the morning
11329020|NCT02507479|Experimental|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
11329021|NCT02507466|Experimental|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
11329022|NCT02507466|Active Comparator|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
11329023|NCT02507466|Active Comparator|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
11329024|NCT02507453|Other|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
11329025|NCT02507440|Active Comparator|Viscous Lidocaine|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of 2% lidocaine viscous solution and swallow.
11329026|NCT02507440|Placebo Comparator|Placebo|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of placebo and then swallow. Placebo will be 3% methylcellulose which will be flavored and colored to match the characteristics of 2 % lidocaine.
11329027|NCT02507427|Experimental|Nerve monitoring arm|They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
11329028|NCT02507414|Experimental|Group 1|"Patients under going Whipple's procedure, gastric resection and liver resection (n=75).
~Interventions:
~Blood samples obtained pre-, intra-, and one day postoperatively (n=15).
~Measurements of microcirculation using LSCI from procedure start and up to 60 min during surgery.
~Head down tilt of 20 degrees at three time points."
11329029|NCT02507401||Total laryngectomy patients|Users of voice prostheses
11329030|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
11329031|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
11329032|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
11329033|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
11329034|NCT02507362|Experimental|experimental|Radiation: adjusted corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 7 minutes after 30 mitunes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
11329035|NCT02507362|Active Comparator|control|radiation: accelerated corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 10 minutes after 30 minutes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
11329036|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
11329037|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
11329173|NCT02506426|Experimental|Septoplasty alone|A surgery that is performed to straighten a bent nasal septum. It is shorter (take approximately 25 - 30 minutes) and less invasive (do not open the facial sinuses) that might provide the same benefits compared to the larger and longer endoscopic sinus surgery.
11329038|NCT02507336|Experimental|Group A - CR+Thalidomide|Patients who achieved complete response (CR) in 20030165 and continue to receive maintenance Thalidomide. Patients in Group A will receive daily oral thalidomide (THALOMID®) as per standard of care and THALOMID® REMS™ guidelines. Patients will continue with thalidomide (THALOMID®) as per standard of care guidelines, until progression of disease, discontinuation due to toxicity, death or study withdrawal. Patients will receive annual clinical/laboratory evaluations.
11329039|NCT02507336|No Intervention|Group B - CR+No Thalidomide|Patients who achieved complete response (CR) in 20030165, but are not receiving maintenance Thalidomide. Patients will receive annual clinical/laboratory evaluations.
11329040|NCT02507336|No Intervention|Group C - PD or Expired|All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
11329041|NCT02507323|Active Comparator|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
11329042|NCT02507323|Active Comparator|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
11329043|NCT02507310|Active Comparator|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
11329044|NCT02507310|Experimental|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
11329045|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
11329046|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
11329047|NCT02507284|Experimental|SRX246 120mg BID|SRX246 capsules, administered orally, in divided doses twice daily
11329048|NCT02507284|Experimental|SRX246 160mg BID|SRX246 capsules, administered orally, in divided doses twice daily
11329049|NCT02507284|Placebo Comparator|Placebo|Placebo capsules, administered orally, in divided doses twice daily
11329050|NCT02507271|Experimental|Experimental Group|
11329051|NCT02507271|Placebo Comparator|Control Group|
11329052|NCT02507258||PROFEMUR® Am Femoral Stem|Single study group previously implanted with a primary PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component
11329053|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
11329054|NCT02507232|Active Comparator|Arm A|NovoTTF-200A
11329055|NCT02507232|Active Comparator|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
11329056|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
11329057|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
11329058|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
11329059|NCT02507206|Experimental|DAR 0-100A then Placebo|15 mg is dissolved in 150 cc NS administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
11329060|NCT02507206|Placebo Comparator|Placebo then DAR 0-100A|15 mg dissolved in 150 cc NS saline is administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
11329061|NCT02507206|No Intervention|Healthy Control|patients without diagnosis of SPD
11329062|NCT02507193|Active Comparator|Open reduction internal fixation(ORIF)|This surgical intervention is performed using a plate and screws.Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
11329063|NCT02507193|Active Comparator|Intermedullary (IM) Nail|This surgical intervention is performed using an intermedullary nail. Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
11329064|NCT02507180||Pregnant women with suspected DVT|Pregnant women presenting with suspected DVT will have the LEFt clinical decision rule applied by the attending physician and will have a clinical D-dimer test done.
11329065|NCT02507167|Placebo Comparator|mixed meal|
11329066|NCT02507167|Active Comparator|mixed meal 2 h after single dose rifampin (600 mg)|
11329067|NCT02507154|Experimental|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
11329068|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
11329069|NCT02507128|Experimental|GLP-1 group|The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
11329070|NCT02507128|Placebo Comparator|Control group|the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).
11329071|NCT02507115|Experimental|TMAP|Alcohol-related Text messages 4 days/week for 6 weeks
11329072|NCT02507115|Sham Comparator|Control|Motivational Text messages 4 days/week for 6 weeks
11329073|NCT02507102|Experimental|Investigational Voyager Therapy|Investigational treatment with Voyager Therapy
11329074|NCT02507089|Experimental|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
11329075|NCT02507089|Active Comparator|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
11329076|NCT02507076|Experimental|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
11329077|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
11329078|NCT02507050|Experimental|Intervention|Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.
11329079|NCT02507050|No Intervention|Standard therapy|Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).
11329080|NCT02507037|Experimental|gum+PEG|used 2L PEG+sugarless gum
11329081|NCT02507037|Placebo Comparator|PEG|only used 2L PEG
11329082|NCT02507024||Intervention|The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
11329083|NCT02507011|Experimental|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
11329084|NCT02507011|Placebo Comparator|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
11329085|NCT02506998|Experimental|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.
~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
11329086|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
11329087|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
11329088|NCT02506972|Other|30g oats|Classic Quick Quaker Oats
11329089|NCT02506972|Other|30g oats plus 9g sugar|Classic Quick Quaker Oats
11329090|NCT02506972|Other|40g oats|Classic Quick Quaker Oats
11329091|NCT02506972|Other|60g oats|Classic Quick Quaker Oats
11329092|NCT02506972|Other|22g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
11329093|NCT02506972|Other|29g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
11329094|NCT02506972|Other|33g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
11329095|NCT02506972|Other|44g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
11329096|NCT02506959|Experimental|Treatment (panobinostat, Gem/Bu/Mel, ASCT)|Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.
11329097|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
11329098|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
11329099|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
11329100|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
11329101|NCT02506920|Active Comparator|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
11329102|NCT02506920|Active Comparator|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
11329103|NCT02506920|Active Comparator|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
11329104|NCT02506920|Active Comparator|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
11329105|NCT02506920|Active Comparator|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
11329106|NCT02506920|Active Comparator|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
11329107|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
11329108|NCT02506894|Active Comparator|magnesium sulfate|this group will receive magnesium sulfate loading dose 6 g in 500 cc of ringer solution over 20 minutes then maintenance dose of 1 g/ hour for 24 hours.
11329109|NCT02506894|Placebo Comparator|placebo group|this group will receive sodium chloride 0.9% solution for 24 hours.
11329110|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
11329199|NCT02506192|Experimental|Delayed-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
11329111|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
11329112|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
11329113|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
11329114|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
11329115|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
11329116|NCT02506855|Experimental|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:
~Weight <70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)
~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
11329117|NCT02506855|Placebo Comparator|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:
~Weight <70kg: 20mL each side
~Weight greater than or equal to 70kg: 20mL each side"
11329118|NCT02506842|Experimental|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
11329119|NCT02506842|Experimental|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m^2 on days 8 and 22, folinic acid at 200mg/m^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m^2 on days 1,8,15 and 22.
11329120|NCT02506829|Active Comparator|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
11329121|NCT02506829|Experimental|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
11329122|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
11329123|NCT02506803|Experimental|NAC-GEMABR|Neoadjuvant chemotherapy 2 courses of NAC-GEMABR for subsequent 10 patients.
11329124|NCT02506790|Experimental|Toremifene and metformin|Toremifene 60 mg daily with metformin 850 mg BID
11329125|NCT02506790|Experimental|Toremifene and melatonin|Toremifene 60 mg daily with melatonin 3 mg before sleep daily
11329126|NCT02506790|Active Comparator|Toremifene|Toremifene 60 mg daily
11329127|NCT02506777|Experimental|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID
11329128|NCT02506777|Experimental|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily
11329129|NCT02506777|Active Comparator|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days
11329130|NCT02506751|Experimental|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:
~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)
~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)
~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)
~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
11329131|NCT02506738|Active Comparator|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
11329132|NCT02506738|No Intervention|Control|Patients in the control group received the usual care.
11329133|NCT02506725|Experimental|Prenatal Care in groups|We will do prenatal care using centering care pregnancy methodology in 10 sessions
11329134|NCT02506725|No Intervention|Control Group|We will do in this arm conventional Prenatal care available in the family clinics
11329135|NCT02506712|Experimental|spinal cord injury|use a wheelchair with and without a assisting device to power manuel wheelchair
11329136|NCT02506712|Other|volunteer|push a wheelchair with and without a assisting device to power manuel wheelchair
11329137|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
11329138|NCT02506686|Experimental|Meropenem|Meropenem i.v.
11329139|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
11329448|NCT02504580|Active Comparator|Part C Cohort D|0.25% bupivacaine hydrochloride injection
11329140|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
11329141|NCT02506660|Active Comparator|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
11329142|NCT02506660|Experimental|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
11329143|NCT02506647|Experimental|Sequence 1|Gan & Lee insulin glargine followed by Lantus
11329144|NCT02506647|Active Comparator|Sequence 2|Lantus followed by Gan & Lee insulin glargine
11329145|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
11329146|NCT02506621|Experimental|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be
~R test
~Nuubo
~TECHNOMED pocket ECG
~ZIO xt patch
~MoMe"
11329147|NCT02506608|Experimental|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:
~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)
~TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)
~Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)
~Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)
~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
11329148|NCT02506595|Experimental|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
11329149|NCT02506595|No Intervention|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
11329150|NCT02506582|Experimental|Test group|jerusalem artichoke and fermented soybeans powder mixture supplementation
11329151|NCT02506582|Placebo Comparator|Placebo group|placebo supplementation
11329152|NCT02506556|Experimental|experimental|BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
11329153|NCT02506543|Experimental|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
11329154|NCT02506543|Active Comparator|Wait-list control|No intervention
11329155|NCT02506530|Active Comparator|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
11329156|NCT02506530|Experimental|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
11329157|NCT02506530|Active Comparator|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
11329158|NCT02506517|Experimental|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
11329159|NCT02506504|Experimental|Inspiratory help then sham ventilation|The initial evaluation is performed using an Inspiratory Pressure Support. After the training, the final evaluation is performed using an Inspiratory help (sham ventilation).
11329160|NCT02506504|Experimental|Sham ventilation then Inspiratory help|"The initial evaluation is performed using an inspiratory help (sham ventilation).
~After the training, the final evaluation is performed using an Inspiratory Pressure Support."
11329161|NCT02506491|Experimental|Pilates exercise program|Incorporate Pilates principles to stimulate core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
11329162|NCT02506491|Experimental|Muscular exercise program|To train core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
11329163|NCT02506491|Active Comparator|Control group|Healthy active but nonexercising old women
11329164|NCT02506478||ED patients|All ED patients who are able to drink water/juice, and be able to communicate juice preference.
11329165|NCT02506465|Experimental|iTind arm|iTind implant is implant during the study for 5-7 days.
11329166|NCT02506465|Sham Comparator|Sham arm|Foley catheter is used during the study
11329167|NCT02506452|Active Comparator|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
11329168|NCT02506452|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
11329169|NCT02506439|Experimental|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg [400 IU] daily
11329170|NCT02506439|Experimental|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg [800 IU] daily
11329171|NCT02506439|Placebo Comparator|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
11329172|NCT02506426|Active Comparator|Endoscopic Sinus Surgery + Septoplasty|A surgery that uses special telescopes through the nostrils to make the nasal septum straight and open the facial sinuses without any incisions. The sinuses are opened using special microscopic instruments and the procedure takes approximately 90 - 120 minutes.
11329200|NCT02506192|Placebo Comparator|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
11329174|NCT02506413|Other|MNCH Intervention Package|"The division assigned to this arm received a comprehensive Maternal and Newborn Health (MNH) intervention package using the 'MamaToto Process'. Key intervention activities included:
~engaging district leaders in district health system strengthening;
~strengthening health facility-based MNH services; and
~establishing a Maternal, Newborn, and Child Health focused lay Community Health Worker program."
11329175|NCT02506387||Mitraclip patients|Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.
11329176|NCT02506348|Experimental|Diclofenac+Nepafenac|one drop Diclofenac in one eye one drop Nepafenac in other eye
11329177|NCT02506335|Other|Hep quant cholate testing|diagnostic measure of liver function
11329178|NCT02506322|Experimental|SEKT Cognitive-Behavioral-Emotional|Specific psychotherapy (SEKT - 4 modules) for typical problems of Bipolar patients to maintain remission and to prevent relapse. Including classical elements of self observation, psychoeducation, cognitive and behavioral interventions, social rhythm but also emotion regulation and meta-cognitive techniques. Delivered in a group setting in 4 one day treatment workshops, each one month apart. Homework assignment and electronical monitoring during time between sessions.
11329179|NCT02506322|Active Comparator|FEST Clinical Supportive Educational|This supportive, active control psychotherapy (FEST) is using general principals and non-specific interventions such as positive attitude, optimism, support, empathy, focus on emotion, self-help, strengthening and eliciting own resources, time and room for discussion of personal experiences. Psychoeducation about illness and drug treatment (mood stabilizer) to facilitate compliance.
11329180|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
11329181|NCT02506309|Active Comparator|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
11329182|NCT02506296|Other|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:
~Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol
~Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol
~Groups will be compared for:
~glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)
~glycaemic response to standard DPPIV inhibitor therapy"
11329183|NCT02506283|Experimental|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
11329184|NCT02506283|Sham Comparator|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
11329185|NCT02506270|Active Comparator|AirSeal Trocar valveless|patients are treated with the AirSeal-CO2-insufflator and trocar-system
11329186|NCT02506270|Sham Comparator|Conventional trocar|patients are treated with a conventional insufflation and trocar system
11329187|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
11329188|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
11329189|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
11329190|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
11329191|NCT02506244|Experimental|Immediate Monitoring|"Individuals randomized to immediate monitoring will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of the 4 month monitoring period of time 0 to 4 months.
~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) continuously over the 4 month monitoring period."
11329192|NCT02506244|Active Comparator|Delayed Monitoring|"Individuals randomized to delayed monitoring will receive usual care for 4 months after which they will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of study months 4 through 8.
~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) daily for months 4 through 8."
11329193|NCT02506231|Experimental|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
11329194|NCT02506231|Placebo Comparator|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
11329195|NCT02506218|Experimental|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
11329196|NCT02506218|Active Comparator|30 g protein breakfast|
11329197|NCT02506218|Active Comparator|10 g protein breakfast|
11329198|NCT02506205|Experimental|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, & Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
11329201|NCT02506179||Open-label cohort|Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
11329202|NCT02506166|No Intervention|No or Mild Sleep Apnea Group (Group 1)|"ICM patients with no or mild sleep apnea enrolled in this arm will continue with standard therapy (ICD/CRT-D implant + maximal medical therapy), but will receive no active Positive Airway Pressure (PAP) therapy for sleep apnea treatment. See Part: Study Population for more details.
~In all ICM patients enrolled into ESCAPE-SCD Study, the ICD/CRT-D devices will be implanted based on current ESC Guidelines for primary prevention of sudden cardiac death (see Section: References)"
11329203|NCT02506166|No Intervention|Obstructive Sleep Apnea - Control Group (Group 2)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), but no PAP therapy for sleep apnea treatment. See Part: Study Population for more details."
11329204|NCT02506166|Active Comparator|Obstructive Sleep Apnea - Active Group (Group 3)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), plus as intervention, all patinets in this group will receive sleep apnea treatment by using PAP device. See Part: Study Population for more details."
11329205|NCT02506166|No Intervention|Central Sleep Apnea Group (Group 4)|"ICM patients with predominant central sleep apnea enrolled in this group will receive standard therapy (ICD/CRT-D implant + maximal medical therapy). Because the SERVE-HF Trial demonstrated a negative effect of predominantly central sleep apnea treatment on cardiovascular mortality in patients with HFrEF by using adaptive servo-ventilation therapy, patients in Group 4 will not receive any PAP therapy for treatment of sleep disordered breathing. See Part: Study Population for more details."
11329206|NCT02506153|Active Comparator|Arm I (high-dose recombinant interferon alfa-2B, ipilimumab)|"INDUCTION THERAPY: Patients receive high-dose recombinant interferon alfa-2B intravenously (IV) over 20 minutes on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for a total of 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive high-dose recombinant interferon alfa-2B subcutaneously (SC) on days 1, 3, and 5. Treatment repeats every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity. Or patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for 3 years in the absence of disease progression or unacceptable toxicity."
11329207|NCT02506153|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
11329208|NCT02506140|Experimental|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
11329209|NCT02506140|Active Comparator|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
11329210|NCT02506127|Experimental|Open-label|"Theta burst stimulation (TBS) is a form of repetitive transcranial magnetic stimulation (TMS). Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.
~Each treatment session thus involves < 10 minutes of stimulation. The subject and researchers know what treatment is being administered."
11329211|NCT02506127|Active Comparator|Blinded Active|"Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.
~Each treatment session thus involves < 10 minutes of stimulation. The subject and researcher will not know what type of treatment will be administered."
11329212|NCT02506127|Sham Comparator|Blinded Sham|"This is a sham treatment which will mimic the open-label and blinded active to enable the effects of the supposedly active treatment to be assessed objectively. The subject and researcher will not know what type of treatment will be administered.
~Each treatment session will be < 10 minutes in duration."
11329213|NCT02506114|Experimental|Arm A|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.
11329214|NCT02506114|Experimental|Arm B|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
11329215|NCT02506114|Experimental|Arm C|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
11329216|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
11329217|NCT02506101|No Intervention|no intervention|untreated
11329218|NCT02506088|Experimental|Your Voice Your View|Participants in schools assigned to the treatment group will engage in a four session intervention aimed at prevention of sexual violence. Your Voice Your View is grounded in social norms theory and bystander intervention training. The intervention also includes a social norms marketing campaign.
11329219|NCT02506088|No Intervention|Wait List Control Group|Participants in schools assigned to the wait list control group will complete survey assessments at the same schedule as schools assigned to the treatment group. Schools will have the option to implement Your Voice Your View following completion of the 6-month survey.
11329220|NCT02506075|Experimental|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.
~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
11329221|NCT02506075|Experimental|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
11329222|NCT02506075|No Intervention|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
11329260|NCT02505802|No Intervention|Control group|No special treatment was performed in the control group. Both groups received comprehensive rehabilitation for 8 weeks.
11329261|NCT02505776||GLASH VISTA™|Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.
11329262|NCT02505763|Experimental|Strategy with thoracic ultrasound|"Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.
~Use of other examinations like chest CT if necessary"
11329223|NCT02506062|Experimental|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
11329224|NCT02506062|Placebo Comparator|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
11329225|NCT02506049|Other|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
11329226|NCT02506036|Active Comparator|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
11329227|NCT02506036|Experimental|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
11329228|NCT02506023|Active Comparator|Hemophilia A carriers with mild mutation|Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
11329229|NCT02506023|Active Comparator|Hemophilia A Carriers with severe mutation|Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
11329230|NCT02506023|Active Comparator|Control|Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
11329231|NCT02505997|Experimental|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
11329232|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
11329233|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
11329234|NCT02505971|Active Comparator|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
11329235|NCT02505971|Active Comparator|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
11329236|NCT02505958|Other|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories. Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
11329237|NCT02505958|Other|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
11329238|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
11329239|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
11329240|NCT02505932||Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
11329241|NCT02505932||Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
11329242|NCT02505919|Experimental|Treatment|AQUABEAM System
11329243|NCT02505919|Active Comparator|Control|Transurethral Resection of the Prostate (TURP)
11329244|NCT02505893|Experimental|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
11329245|NCT02505880|Active Comparator|1: General anesthesia|General anesthesia
11329246|NCT02505880|Experimental|2: Hypnosis|Hypnosis with local anesthesia
11329247|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
11329248|NCT02505867|No Intervention|Control|No device provided
11329249|NCT02505854|Active Comparator|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin
11329250|NCT02505854|Active Comparator|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide
11329251|NCT02505854|Placebo Comparator|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin
11329252|NCT02505841|Active Comparator|Group 1|Curare: Atracurium injection at 0.5 mg/kg
11329253|NCT02505841|Experimental|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
11329254|NCT02505841|Experimental|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
11329255|NCT02505828|Other|Septic arthritis|with bacteriological identification
11329256|NCT02505828|Other|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
11329257|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
11329258|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
11329259|NCT02505802|Experimental|BoNT-A treatment group|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu). Both groups received comprehensive rehabilitation for 8 weeks.
11329886|NCT02501811|Experimental|c-kit+ cells|Target dose of 5 million c-kit+ cells
11329263|NCT02505763|No Intervention|Strategy without thoracic ultrasound|"Usual care : without thoracic ultrasound
~Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.
~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
11329264|NCT02505750|Active Comparator|EBRT 45 Gy/capecitabine + EBRT boost|"3D conformal EBRT 45 Gy (1.8Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).
~A cone down EBRT targeting the GTV will deliver a boost dose of 9 Gy in 5 fractions. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy: surgery (radical TME or local excision) or watch-and-wait (W-W)."
11329265|NCT02505750|Experimental|EBRT 45 Gy/capecitabine + CXB boost|"Arm B divided in 2 subgroups depending on the tumour diameter:
~B1: If the tumour is < 3 cm, a CXB boost dose (90Gy/3 fractions/4 weeks) will be initially delivered to the tumour. After 2 weeks rest, patients will receive 3D conformal EBRT 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days). Clinical evaluation will be performed 3 weeks after the end of irradiation (week 14) and will guide the final strategy (surgery or W-W) as in arm A.
~B2: If the tumour is ≥ 3 cm, patients will receive EBRT first 45 Gy (1.8 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (825 mg/m2 bid, on radiation days).
~A CXB boost dose (90 Gy/3 fractions/4 weeks) will be delivered to residual tumour, after a rest of 2 weeks. On week 14 after the start of treatment, the tumour response evaluation will guide the final strategy (surgery or W-W) as in arm A. Adjuvant chemotherapy will be left to institution choice."
11329266|NCT02505737|Experimental|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
11329267|NCT02505737|Other|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
11329268|NCT02505724|Active Comparator|Conventional training|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice
11329269|NCT02505724|Experimental|Intervention|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice. In addition, they received two 1/2 hour peer-coaching sessions
11329270|NCT02505711|Experimental|Homestead Food Production|Enrolled in Homestead Food Production program from 2015 to 2019, 48 clusters, approx. 1350 women and 750 children
11329271|NCT02505711|No Intervention|Control|(Health system strengthening in the study area), 48 clusters, approx. 1350 women and 750 children
11329272|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
11329273|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
11329274|NCT02505659|Experimental|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
11329275|NCT02505659|No Intervention|CONTRL GROUP|a control group (without preoperative reeducation)
11329276|NCT02505633|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
11329277|NCT02505633|Active Comparator|1P1I group|After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
11329278|NCT02505620||Surgical|Surgical correction of OSAS disease
11329279|NCT02505620||Conservative|Conservative treatment of OSAS disease
11329280|NCT02505607|No Intervention|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
11329281|NCT02505607|Experimental|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
11329282|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
11329283|NCT02505594||Control Group|Apnea-hypopnea index (AHI) < 5 events/h
11329284|NCT02505581|Experimental|Oral + Parenteral prophylaxis|
11329285|NCT02505581|Active Comparator|Only Parenteral prophylaxis|
11329286|NCT02505568|Experimental|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
11329449|NCT02504580|Experimental|Part D Cohort A|400 mg HTX-011B via a combination of injection and instillation
11329450|NCT02504580|Experimental|Part E Cohort A|HTX-009 by injection
11329287|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
11329288|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
11329289|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.
~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
11329290|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
11329291|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
11329292|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
11329293|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
11329294|NCT02505529|Experimental|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
11329295|NCT02505529|Experimental|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
11329296|NCT02505529|No Intervention|Control Group|6-weeks of no change in lifestyle.
11329297|NCT02505516|Placebo Comparator|metformin|metformin 500mg
11329298|NCT02505516|No Intervention|not on metformin|
11329299|NCT02505503|Active Comparator|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
11329300|NCT02505503|Placebo Comparator|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
11329301|NCT02505490|Experimental|No Television|The purpose is to determine whether a change in liking of food will occur with a lack of television.
11329302|NCT02505490|Experimental|Television|The purpose is to determine whether a change in liking of food will occur while watching television.
11329303|NCT02505477|Experimental|N-acetylcysteine|Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
11329304|NCT02505477|Placebo Comparator|Placebo|Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
11329305|NCT02505464||Pregnant Women & their fetuses/infants|Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
11329306|NCT02505451|Experimental|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
11329307|NCT02505451|Experimental|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
11329308|NCT02505451|Experimental|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
11329309|NCT02505438|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
11329310|NCT02505438|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
11329311|NCT02505438|Experimental|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
11329312|NCT02505438|Experimental|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
11329313|NCT02505425|Experimental|Active Intervention|"Behavioral: behavioral support
~Usual HF Care + ENABLE CHF-PC"
11329314|NCT02505425|Active Comparator|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
11329315|NCT02505399|Experimental|ticagrelor|"In the intervention group, Ticagrelor will be administered orally, according to the following scheme:
~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
~90 mg the following morning (D Day before rotational atherectomy and angioplasty),
~90 mg the following evening (D Day after rotational atherectomy and angioplasty),
~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
11329451|NCT02504580|Experimental|Part E Cohort B|HTX-009 by instillation
11329452|NCT02504580|Experimental|Part F Cohort A|300 mg of HTX-011B
11329316|NCT02505399|Active Comparator|clopidogrel|"In the control group, Clopidogrel will be administered orally, according to the following scheme:
~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
~75 mg the following morning (D Day before rotational atherectomy and angioplasty),
~0 mg the following evening (D Day after rotational atherectomy and angioplasty),
~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
11329317|NCT02505386|Active Comparator|Ertapenem IV|IV administration of ertapenem
11329318|NCT02505386|Experimental|Ertapenem SC|SC administration of ertapenem
11329319|NCT02505373|Experimental|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
11329320|NCT02505373|Active Comparator|Control Group CG|Control Group CG (structured interview)
11329321|NCT02505360|Other|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
11329322|NCT02505347|Experimental|No splint|will be able to move the arm as tolerated following surgery.
11329323|NCT02505347|Active Comparator|Splint|will receive a splint following surgery for 6 weeks.
11329324|NCT02505334|Experimental|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
11329325|NCT02505334|Active Comparator|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
11329326|NCT02505321|Experimental|fATDIVA - OTTT (Cases)|"Individuals identified with the polygenic lipodystrophy genetic variants of interest will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
11329327|NCT02505321|Experimental|fATDIVA - OTTT (Controls)|"Control individuals carrying the average number of risk alleles and matched to individuals identified with the polygenic lipodystrophy genetic variants of interest for gender, age and BMI, will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
11329328|NCT02505308|Experimental|DIVA-1 CCND2|Individuals carrying a genetic change in the CCND2 gene and controls matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
11329329|NCT02505308|Experimental|DIVA-2 Low Risk of Diabetes|Individuals carrying the fewest genetic risk alleles for diabetes and controls carrying the average number of genetic risk alleles, matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
11329330|NCT02505295|Active Comparator|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
11329331|NCT02505295|Placebo Comparator|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
11329332|NCT02505282||Orthostatic Hypotension|>20mmHg systolic BP drop or >10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
11329333|NCT02505282||Control|No fall in BP or <20mmHg systolic BP drop and <10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
11329334|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:
~- Participants will receive combination therapy:
~Brentuximab Vedotin intravenously on predetermined days per cycle
~Adriamycin intravenously on predetermined days per cycle
~Dacarbazine intravenously on predetermined days per cycle"
11329335|NCT02505256||case group|cases who presented as breast pain or breast lumps, and no intervention will be administered.
11329336|NCT02505243||HCV patients|HCV patients treated with direct acting antivirals and ribavirin
11329337|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
11329338|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
11329339|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
11329375|NCT02504983|Active Comparator|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
11329453|NCT02504580|Experimental|Part F Cohort B|75 mg of 0.25% Marcaine
11329454|NCT02504580|Placebo Comparator|Part F Cohort C|10.26 mL of normal saline
11329340|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]
~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).
~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.
~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).
~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
11329341|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
11329342|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
11329343|NCT02505191|Experimental|Test|St. John's wort prolonged-release tablet 500 mg
11329344|NCT02505191|Active Comparator|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
11329345|NCT02505178|Experimental|Problem Solving Therapy|Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).
11329346|NCT02505165|Experimental|Parent Uncertainty Intervention|A pediatric cancer-specific, clinic based, six-module interdisciplinary uncertainty intervention. Modules one through three target uncertainty prevention. Modules four through six target uncertainty responses for situations in which uncertainty cannot be prevented or avoided.
11329347|NCT02505165|Other|Education/Support Only|"Sessions in this condition aim to provide education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Information presented will be based upon, Young People with Cancer: A Handbook for Parents, a parent resource developed by the National Cancer Institute. Parents will also be provided with relevant educational brochures from COG. Each session will also include a structured set of questions that will facilitate discussion. All ESO interventionists will be trained in non-directive approaches including reflective listening. Content provided in the ESO sessions will offer valuable information to parents without providing the specific skills of the IMPACT."
11329348|NCT02505152|Experimental|Shunt|Perform percutaneous transhepatic intrahepatic portosystemic shunt
11329349|NCT02505139||Study Group|
11329350|NCT02505126|Experimental|Active tDCS group|Active tDCS
11329351|NCT02505126|Placebo Comparator|Placebo tDCS group|Placebo tDCS : Inactive tDCS
11329352|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
11329353|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
11329354|NCT02505100|Experimental|Touching relaxant|session of massage
11329355|NCT02505100|Experimental|Hypnoses|session of hypnoses
11329356|NCT02505100|No Intervention|Standared care|standard care
11329357|NCT02505087|Active Comparator|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
11329358|NCT02505087|Experimental|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
11329359|NCT02505087|No Intervention|Healthy volunteers|The purpose of this group is to collect reference values for biochemical markers.
11329360|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
11329361|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
11329362|NCT02505061|Experimental|Program|"The participants performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively"
11329363|NCT02505048|Experimental|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.
~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
11329364|NCT02505035|Active Comparator|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
11329365|NCT02505035|No Intervention|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
11329366|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
11329367|NCT02505009|Experimental|entecavir pretreated vaccine arm|Arm A,case group: 75 cases will be enrolled to receive Engerix-B injection and compared with histological non-vaccine treated controls
11329368|NCT02505009|Experimental|tenofovir pretreated vaccine arm|Arm B case group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
11329369|NCT02505009|Active Comparator|Entecavir pretreated control arm|Arm A control group: Age, gender and pretreatment DNA matched histological controls
11329370|NCT02505009|Active Comparator|tenofovir pretreated control arm|Arm B control group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
11329371|NCT02504996|Active Comparator|Paracetamol|1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.
11329372|NCT02504996|Active Comparator|morphine|0.1 mg/kg morphine in 100 ml saline with a rapid infusion.
11329373|NCT02504996|Placebo Comparator|placebo|100 ml saline
11329374|NCT02504983|Active Comparator|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
11329376|NCT02504983|Experimental|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
11329377|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
11329378|NCT02504957|Other|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
11329379|NCT02504944|Experimental|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.
11329380|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.
~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
11329381|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.
~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
11329382|NCT02504905|Experimental|PAR-CD|CD and age/sex matched HV control
11329383|NCT02504905|Experimental|PAR-WC|WC and age/sex matched HV control
11329384|NCT02504892|Experimental|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
11329385|NCT02504892|Experimental|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
11329386|NCT02504879||Melorheostosis patients|Patients aged > 18 years with possible and confirmed melorheostosis.
11329387|NCT02504879||Relatives of patients with melorheostosis|Relatives of patients with melorheostosis may be included for genetic testing only
11329388|NCT02504866|Experimental|AET|Aerobic exercise will be performed on an elliptical trainer at a vigorous intensity
11329389|NCT02504866|No Intervention|Control|Wait-list control that performs no exercise for first 12 weeks; randomized to an exercise intervention(either AET or RET) after 12 weeks
11329390|NCT02504866|No Intervention|Healthy Volunteer|Healthy volunteers will perform specific measures for asingle study visit
11329391|NCT02504866|Experimental|RET|Rapid reciprocal exercise will be performed on an elliptical trainer at light to moderate intensity
11329392|NCT02504853||Affected Genetic|Affected Genetic
11329393|NCT02504853||Affected Non-Syndromic Food|Affected Non-Syndromic Food
11329394|NCT02504853||Unaffected Relative / Healthy Volunteer|Unaffected Relative / Healthy Volunteer
11329395|NCT02504840||healthy volunteers|healthy volunteers
11329396|NCT02504840||patient controls|Participants with diseases that share features with MS.
11329397|NCT02504840||patients with suspected or confirmed multiple sclerosis|Participants with definite, probable, or possible MS.
11329398|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
11329399|NCT02504814|Experimental|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
11329400|NCT02504801|Active Comparator|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
11329401|NCT02504801|Placebo Comparator|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
11329402|NCT02504788|Experimental|Hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) if the role of RT was considered either adjuvant following craniotomy with tumor removal or therapeutic for treating oligometastatic brain disease.
11329403|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
11329404|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
11329405|NCT02504762|Experimental|Treatment: HCR|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
11329441|NCT02504580|Experimental|Part B Cohort D|400 mg HTX-011B by injection
11329442|NCT02504580|Placebo Comparator|Part B Cohort E|Saline solution by injection
11329406|NCT02504762|Active Comparator|Control: Conventional CABG|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
11329407|NCT02504749|Active Comparator|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
11329408|NCT02504749|Active Comparator|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.
~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
11329409|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
11329410|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
11329411|NCT02504710|Active Comparator|Traditional Learning System|Traditional systems of manual therapy teaching
11329412|NCT02504710|Experimental|Kinematic Real-Time Feedback|Kinematic real time feedback to learn Manual therapy
11329413|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer > 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
11329414|NCT02504684|Active Comparator|1470-nm|Endovenous 1470-nm diode laser
11329415|NCT02504684|Experimental|1920-nm Group|Endovenous 1920-nm diode laser
11329416|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
11329417|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
11329418|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
11329419|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
11329420|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
11329421|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
11329422|NCT02504658|Experimental|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
11329423|NCT02504658|Active Comparator|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
11329424|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
11329425|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
11329426|NCT02504632|Experimental|test group|Patient with severe, symptomatic AS (Aortic valve area < 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.
11329427|NCT02504632|Other|control group|Patient with stable coronary artery disease, unscathed of AS Patient under aspirin treatment (75-160 mg/d for at least one week)
11329428|NCT02504619|Experimental|CordIn|Transplantation of CordIn
11329429|NCT02504606|Experimental|Besylsartan|amlodipine besylate 6.944mg+losartan K 100mg
11329430|NCT02504606|Active Comparator|Amosartan|amlodipine besylate 7.841mg+losartan K 100mg
11329431|NCT02504593|Other|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
11329432|NCT02504580|Experimental|Part A Cohort A|200 mg of HTX-011 by injection
11329433|NCT02504580|Experimental|Part A Cohort B|400 mg of HTX-011 by injection
11329434|NCT02504580|Experimental|Part A Cohort C|200 mg of HTX-011 by instillation
11329435|NCT02504580|Experimental|Part A Cohort D|400 mg of HTX-011 by instillation
11329436|NCT02504580|Experimental|Part A Cohort E|200 mg HTX-011 injection and 200 mg instillation
11329437|NCT02504580|Placebo Comparator|Part A Cohort F|Saline solution by injection
11329438|NCT02504580|Experimental|Part B Cohort A|200 mg HTX-011A by injection
11329439|NCT02504580|Experimental|Part B Cohort B|400 mg HTX-011A by injection
11329440|NCT02504580|Experimental|Part B Cohort C|200 mg HTX-011B by injection
11329457|NCT02504554|Experimental|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
11329458|NCT02504554|Experimental|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
11329459|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
11329460|NCT02504528|Experimental|allergic asthma|asthma patients that sensitive to house dust mites.
11329461|NCT02504528|Experimental|normal controls|normal controls with or without sensitive to house dust mites.
11329462|NCT02504515|Active Comparator|Homeopathy|
11329463|NCT02504515|Active Comparator|Allopathy homeopathy control|
11329464|NCT02504515|Active Comparator|Acupuncture|
11329465|NCT02504515|Active Comparator|Allopathy acupuncture control|
11329466|NCT02504515|Active Comparator|Anthroposophic medicine|
11329467|NCT02504515|Active Comparator|Allopathy anthroposophy control|
11329468|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
11329469|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
11329470|NCT02504489|Active Comparator|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
11329471|NCT02504489|Experimental|Docetaxel + Plinabulin (DP)|The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade >1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
11329472|NCT02504476|Active Comparator|AMG 581 - Dose 1|
11329473|NCT02504476|Active Comparator|AMG 581 - Dose 2|
11329474|NCT02504476|Active Comparator|AMG 581 - Dose 3|
11329475|NCT02504476|Active Comparator|AMG 581 - Dose 4|
11329476|NCT02504476|Placebo Comparator|Placebo - Dose 1|
11329477|NCT02504476|Placebo Comparator|Placebo - Dose 2|
11329478|NCT02504476|Placebo Comparator|Placebo - Dose 3|
11329479|NCT02504476|Placebo Comparator|Placebo - Dose 4|
11329480|NCT02504476|Other|AMG 581/Midazolam - Drug Interaction|
11329481|NCT02504463|Experimental|Samidorphan IV|Samidorphan solution for IV administration
11329482|NCT02504463|Experimental|Samidorphan sublingual|[14c]-Samidorphan for sublingual administration
11329483|NCT02504463|Experimental|Samidorphan oral|[14c]-Samidorphan for oral administration
11329484|NCT02504437|Experimental|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
11329485|NCT02504437|Active Comparator|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
11329486|NCT02504437|Sham Comparator|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
11329487|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
11329488|NCT02504411|Experimental|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
11329489|NCT02504411|Active Comparator|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
11329490|NCT02504398|Experimental|Fast injection|Vaccine injections will be given at a rate of approximately 2-4 ml/sec by the immunizer
11329491|NCT02504398|Active Comparator|Slow injection|Vaccine injections will be given at a rate of approximately 10 ml/sec by the immunizer
11329492|NCT02504385|Experimental|Virtual Reality Timocco|The study group will integrate the use of Timocco in occupational therapy sessions. The session will begin with 15 minutes of spatial activity involving sensory-motor practice, 15 minutes of activity in a virtual environment, and 15 minutes of structured activity at a desk.
11329493|NCT02504385|Active Comparator|Conventional OT intervention|The control group will be given conventional occupational therapy without using Timocco. In order to ensure that the therapy sessions in this group have a structure similar to that one used in the study group, each session will include 25 to 30 minutes of spatial sensory-motor activity, followed by 15 to 20 minutes of structured practice at a desk.
11329494|NCT02504372|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).
11329495|NCT02504372|Placebo Comparator|Placebo|Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).
11329524|NCT02504177|Experimental|The group of keep medication NOAC|The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
11329887|NCT02501811|Experimental|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
11329496|NCT02504359|Experimental|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.
~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.
~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
11329497|NCT02504346|Experimental|Treatment|Non-randomized trial, all patients receive therapy - singel-arm
11329498|NCT02504333|Active Comparator|AG|nab-Paclitaxel followed by Gemcitabine
11329499|NCT02504333|Experimental|AG-mFOLFOX|nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial
11329500|NCT02504320|Experimental|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
11329501|NCT02504320|Experimental|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
11329502|NCT02504320|Experimental|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
11329503|NCT02504320|Experimental|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
11329504|NCT02504307|Experimental|Inspiron|Sirolimus Eluting Stent Inspiron
11329505|NCT02504307|Active Comparator|Cronus|Bare Metal Stent
11329506|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
11329507|NCT02504294|Other|Standard of Care|Standard of care arm
11329508|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 2 times) in our IVF institute.
11329509|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
11329510|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
11329511|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
11329512|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
11329513|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
11329514|NCT02504255||Patients with Crohn's Disease|patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
11329515|NCT02504242|Experimental|Inject BMP|ExcelOS Inject / rhBMP-2
11329516|NCT02504242|Active Comparator|Locally Harvested Bone|Locally Harvested Bone
11329517|NCT02504229|Experimental|Chemotherapy+DC-CIK|Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
11329518|NCT02504229|Active Comparator|Chemotherapy alone|Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.
11329519|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
11329520|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
11329521|NCT02504203|Active Comparator|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
11329522|NCT02504203|No Intervention|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
11329523|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
11329888|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
11379304|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
11329525|NCT02504177|Active Comparator|The group of stop medication NOAC 1 day|The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
11329526|NCT02504164|Experimental|No premedication|No premedication before sedation
11329527|NCT02504164|Active Comparator|Midazolam|Premedication with midazolam before sedation
11329528|NCT02504151|Experimental|Order 1|The subject will receive treatment with CBD for four weeks, followed by a two week washout period, followed by four weeks of placebo.
11329529|NCT02504151|Experimental|Order 2|The subject will receive placebo for four weeks, followed by a 2 week washout period, followed by four weeks of treatment with CBD.
11329530|NCT02504138|Experimental|Desflurane balanced anesthesia group|
11329531|NCT02504138|Active Comparator|Propofol total intravenous anesthesia group|
11329532|NCT02504125|Experimental|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
11329533|NCT02504125|Placebo Comparator|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
11329534|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
11329535|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
11329536|NCT02504086|Experimental|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
11329537|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.
~There is no intervention."
11329538|NCT02504060|Placebo Comparator|Starch capsule|During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.
11329539|NCT02504060|Experimental|N-acetyl-D-glucosamine|During the 12- weeks treatment phase of the study, the daily dose of 100mg*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.
11329540|NCT02504047|Experimental|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
11329541|NCT02504034|Experimental|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
11329542|NCT02504021|Experimental|Family Consultation Condition|The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
11329543|NCT02504021|No Intervention|Treatment as Usual Control Condition|Standard of care for the nephrology unit.
11329544|NCT02504008|Experimental|AXS-02 (oral zoledronate)|Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36
11329545|NCT02504008|Placebo Comparator|Placebo|Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36
11329546|NCT02503995|Active Comparator|No intervention|Participants not undertaking any additional exercise
11329547|NCT02503995|Experimental|Water-based exercise group|Participants assigned to a water-based exercise group
11329548|NCT02503995|Experimental|Land-based exercise group|Participants assigned to a land-based exercise group
11329549|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
11329550|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
11329551|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
11329552|NCT02503956|Experimental|Treated group|Patients treated with perforated punctal plugs
11329553|NCT02503956|Active Comparator|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
11329554|NCT02503943|Experimental|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide(50mg, 3/d)"
11329555|NCT02503943|Active Comparator|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
11329556|NCT02503943|Active Comparator|"Mitiglinide"|"Mitiglinide(50mg, 3/d)"
11329557|NCT02503930|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
11329558|NCT02503930|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
11329559|NCT02503917||Healthy volunteers|Healthy female adult volunteers
11329560|NCT02503917||Cervical cancer patients|Patients receiving radiotherapy for cervical cancer at the Royal Marsden who will receive a planning CT scan and daily CBCT scanning as part of their treatment.
11329561|NCT02503904|Active Comparator|TAD+IVAD|
11329562|NCT02503904|Active Comparator|IVAD|
11329563|NCT02503891|Experimental|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
11329564|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
11329565|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
11329566|NCT02503865|No Intervention|Healthy people|64 healthy people
11329889|NCT02501798|Experimental|Drug: Methylphenidate|Drug: Methylphenidate 7 days dosage as (prior to study) clinically titrated long acting Equasym (brand)
11329567|NCT02503852|Experimental|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
11329568|NCT02503852|Experimental|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
11329569|NCT02503852|Active Comparator|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
11329570|NCT02503852|Placebo Comparator|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
11329571|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.
~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
11329572|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
11329573|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
11329574|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
11329575|NCT02503826|Experimental|1.5 SF|Sufentanil,1.5mcg/kg
11329576|NCT02503826|Experimental|2.0 SF|Sufentanil, 2.0mcg/kg
11329577|NCT02503826|Experimental|2.5 SF|Sufentanil, 2.5mcg/kg
11329578|NCT02503813|Experimental|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
11329579|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
11329580|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
11329581|NCT02503774|Experimental|Monotherapy|MEDI9447 (oleclumab) only
11329582|NCT02503774|Experimental|Combination|MEDI9447 (oleclumab) and MEDI4736 (durvalumab)
11329583|NCT02503761|Active Comparator|Infusion arm|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
11329584|NCT02503761|Active Comparator|Bolus group|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.
11329585|NCT02503748|Experimental|Intervention|Online Tutorial
11329586|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
11329587|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11329588|NCT02503709|Experimental|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
11329589|NCT02503696||IBD|Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
11329590|NCT02503683|Active Comparator|ALN-AAT|
11329591|NCT02503683|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11329592|NCT02503670|Other|HealthyDads.ca web-based program|An on-line self-help psychoeducational website tailored to new dads. Psychoeducational learning modules and tools, including a 6 week physical activity challenge..
11329593|NCT02503670|Other|Control group|No access to the intervention. Will complete the same questionnaires as the Healthydads.ca group over the study period.
11329594|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.
~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
11329595|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
11329596|NCT02503644|Active Comparator|IVA337 800mg|Patients receive twice daily 400mg IVA337.
11329597|NCT02503644|Active Comparator|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
11329598|NCT02503644|Placebo Comparator|Placebo|Patients receive twice daily placebo.
11329599|NCT02503631||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.
11329600|NCT02503618||HIV-negative YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-negative
11329601|NCT02503618||HIV-positive YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-positive
11329602|NCT02503605|Active Comparator|Biosimilar recombinant FSH|Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
11329603|NCT02503605|Active Comparator|Urinary FSH|Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
11329604|NCT02503592|Active Comparator|Cochlear Implant group - Vestibular testing|Adult patients who have been implanted with a Med-El Cochlear implant device within the last 3 months who completed pre-op vestibular testing as standard of care. These subjects will undergo a series of post-op vestibular testing, at the 3 month and 12 month follow up visits
11329605|NCT02503592|No Intervention|Control Group - existing historical vestibular data|This group will consist of existing historical vestibular testing data only. No subjects will be enrolled on this arm.
11329606|NCT02503579|Experimental|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
11329607|NCT02503579|No Intervention|control|"1 training at the beginning of the study
~1 training at the end of the study"
11329608|NCT02503566|Experimental|All patients|Optical coherence tomography will be performed in all patients
11329609|NCT02503553|Experimental|Decision aid|"Option grid for cerebral aneurysm treatment
~Patients will receive an option grid during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded."
11329610|NCT02503553|Placebo Comparator|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
11329611|NCT02503540|Other|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
11329612|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
11329613|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
11329614|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
11329615|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
11329616|NCT02503488|Experimental|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
11329617|NCT02503488|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
11329618|NCT02503475|Other|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:
~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
11329619|NCT02503475|Experimental|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:
~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
11329620|NCT02503475|Other|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:
~Verum- Experimental Sham- Sham comparator"
11329621|NCT02503462|Experimental|darunavir/ritonavir vs cobicistat|All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.
11329622|NCT02503423|Experimental|Phase 1 - Part 1|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
11329623|NCT02503423|Experimental|Phase 1 - Part 2|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
11329624|NCT02503423|Experimental|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
11329625|NCT02503423|Experimental|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
11329626|NCT02503423|Experimental|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
11329627|NCT02503423|Experimental|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
11329628|NCT02503423|Experimental|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
11329818|NCT02502227|Active Comparator|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
11379305|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
11329629|NCT02503423|Experimental|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
11329630|NCT02503423|Experimental|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
11329631|NCT02503410|Active Comparator|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
11329632|NCT02503410|Experimental|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
11329633|NCT02503397||Latent iron deficiency|Infants with cord serum ferritin levels ≤ 75 ng/mL
11329634|NCT02503397||Normal iron status|Infants with cord serum ferritin levels > 75 ng/mL.
11329635|NCT02503371||Women under IVF stimulation at the begining and end|Coagulation parameters will be measured for all parturients at the beginning and conclusion of an IVF simulation cycle with the use of thromboelastogram
11329636|NCT02503358|Experimental|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over a fixed rate on days 1 and 8.
11329637|NCT02503358|Experimental|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
11329638|NCT02503358|Experimental|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
11329639|NCT02503345|Placebo Comparator|Placebo|Placebo capsules (1, 2 or 5) PO TID
11329640|NCT02503345|Experimental|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
11329641|NCT02503345|Experimental|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
11329642|NCT02503345|Experimental|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
11329643|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
11329644|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
11329645|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
11329646|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
11329647|NCT02503319|Experimental|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
11329648|NCT02503319|Experimental|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
11329649|NCT02503319|Active Comparator|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
11329650|NCT02503306|Experimental|Avanafil dose 1|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
11329651|NCT02503306|Experimental|Avanafil dose 2|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
11329652|NCT02503306|Placebo Comparator|Placebo|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
11329653|NCT02503293|Other|Chrono Super PID then Generic Syringe - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
~• Chrono Super PID then Generic Syringe-Gammanorm"
11329654|NCT02503293|Other|Generic Syringe then Chrono Super PID - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
~• Generic Syringe then Chrono Super PID-Gammanorm"
11329655|NCT02503280|Experimental|Group A - Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
11329656|NCT02503280|Experimental|Group B - Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
11329657|NCT02503280|Placebo Comparator|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
11329658|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
11329659|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
11329660|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
11329661|NCT02503241|Experimental|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.
~Intervention : PEEP INCREMENTAL"
11329662|NCT02503241|Experimental|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.
~Intervention :PEEP DECREMENTAL"
11329724|NCT02502812|Experimental|Treatment Sequence A (Innovator) - B (Clop F1) - C (Clop F2)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
11329663|NCT02503228|Other|Receiving MOPS-Preserved Cartilage|"The group will be receiving a cartilage transplant as standard of care. The only difference between the patients participating in this study and non-study participants will be that the cartilage transplant that study participants receive will be preserved in the MOPS instead of the standard media.
~The preservation process will be performed by the Musculoskeletal Transplant Foundation. Once the cartilage is received by the Missouri Orthopaedic Institute, it and the study participant will be treated as though they are preserved in the standard media and a non-study participant, respectively."
11329664|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
11329665|NCT02503202|Experimental|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
11329666|NCT02503202|Experimental|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
11329667|NCT02503202|Experimental|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
11329668|NCT02503202|Experimental|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
11329669|NCT02503202|Placebo Comparator|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
11329670|NCT02503189|Experimental|KCT-0809|
11329671|NCT02503189|Placebo Comparator|Placebo|
11329672|NCT02503176|Experimental|KCT-0809|
11329673|NCT02503163|Experimental|KCT-0809|
11329674|NCT02503150|Experimental|APDC + Chemotherapy|Patients in Arm APDC + Chemotherapy will receive APDC combined with chemotherapy.
11329675|NCT02503150|Active Comparator|Chemotherapy|Patients in Arm Chemotherapy will receive chemotherapy only.
11329676|NCT02503137|Experimental|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
11329677|NCT02503137|Experimental|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
11329678|NCT02503137|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for approximately 90 days
11329679|NCT02503124|Experimental|Chronobiological intervention|Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
11329680|NCT02503124|Active Comparator|Control|Treatment as usual including a private educational meeting in sleep hygiene.
11329681|NCT02503111|Experimental|Ablative therapy|Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
11329682|NCT02503111|Active Comparator|Active Surveillance|The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.
11329683|NCT02503098|Experimental|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
11329684|NCT02503098|Active Comparator|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
11329685|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
11329686|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
11329687|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
11329688|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
11329689|NCT02503072|Active Comparator|Prizes conditional on adherence|Participants in this group are eligible for a prize drawing if they come on their scheduled clinic day. They receive the intervention 'Behavioral: Small lottery prizes based on adherence'.
11329690|NCT02503072|Active Comparator|Prizes conditional on clinic visits|Participants in this group are eligible for a prize drawing if they show 95% adherence or higher based on their MEMS-cap measured adherence. They receive the intervention 'Behavioral: Small lottery prizes based on timely clinic visits'.
11329691|NCT02503046||Arthritis with Periodontitis|"Patients aged between 30-65 years with 6 positive diagnostic criteria for Rhematoid Arthritis. Patients should have Clinical attachment loss >6mm, and Probing pocket depth>5mm in more than 6 teeth to satisfy criteria for periodontitis.
~5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA) Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels."
11329692|NCT02503046||Periodontitis group|"Patients aged between 30-65 years with Periodontal findings being presence of atleast 20 teeth in the mouth .More than 6 teeth with Clinical attachment loss >6mm and Probing pocket depth>5mm to satisfy criteria for periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).
~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
11329693|NCT02503046||Healthy Subjects|"Subjects aged between 30-65 years with no systemic diseases and periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).
~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
11329694|NCT02503033|Experimental|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.
~At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily."
11329695|NCT02503020|Active Comparator|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
11329696|NCT02503020|Active Comparator|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
11329697|NCT02503007|Placebo Comparator|Placebo|A placebo similar in composition and appearance to the experimental treatment.
11329698|NCT02503007|Experimental|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
11329699|NCT02502994|Other|Intervention|Single arm of the castration resistant prostate cancer
11329815|NCT02502253|Experimental|Low dose|
11329816|NCT02502253|Experimental|moderate dose|
11329700|NCT02502981|Experimental|CKD stage 2 & 3|"Patients with CKD stage 2 & 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.
~Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20."
11329701|NCT02502968|Experimental|Cytarabine & BL8040|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle
~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle"
11329702|NCT02502968|Active Comparator|Cytarabine & Placebo|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle
~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle"
11329703|NCT02502942|Experimental|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) > 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
11329704|NCT02502942|Experimental|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study > 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
11329705|NCT02502942|Experimental|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI > 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
11329706|NCT02502942|Active Comparator|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
11329707|NCT02502929|Active Comparator|Enhanced standard care|Participants in this arm will receive referrals for medical and social services as indicated.
11329708|NCT02502929|Experimental|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
11329709|NCT02502929|Experimental|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
11329710|NCT02502916||Preterm infant|Preterm infants born from October 2009 to June 2010 at a gestational age of less than 32 weeks or with birth weight of less than 1,200 g
11329711|NCT02502903|Placebo Comparator|Part A|Single ascending dose (SAD) in NHVs, 7 cohorts, BIVV009 by IV infusion (0.3,1, 3, 10, 30, 60, or 100 mg/kg) or placebo.
11329712|NCT02502903|Placebo Comparator|Part B|Multiple ascending dose (MAD) in NHVs, 2 cohorts, 4 weekly IV doses of BIVV009 (30 or 60mg/kg) or placebo.
11329713|NCT02502903|Experimental|Part C|Multiple dose (MD) in a single cohort of patients with various complement-mediated disorders. All patients in Part C will receive a single IV test dose of BIVV009 of 10 mg/kg followed by 4 weekly doses of 60 mg/kg.
11329714|NCT02502903|Experimental|Part E|Multiple dose (MD) in a single cohort of patients with cold agglutinin disease previously treated with BIVV009. All patients in Part E will receive a single IV test dose at week 0, week 1, and every 2 weeks thereafter until EOT. Patients who weigh less than 75 kg will receive fixed doses of 6.5 grams of BIVV009; patients who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009. Dose will be increased from 6.5g to 7.5g dose level if patients current weight is >= 75 kg and there is evidence of hematologic breakthrough OR patients current weight is >= 75 kg and there has been at least a 10 percent increase from the patients last recorded weight. Dose will be decreased from 7.5g to 6.5g for patients whose last weight was >= 75 kg and current weight decreased to < 75 kg. Dose decrease will require Sponsor approval.
11329715|NCT02502877|Other|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
11329716|NCT02502877|Active Comparator|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
11329717|NCT02502864|Experimental|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
11329718|NCT02502851|Active Comparator|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
11329719|NCT02502851|Active Comparator|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
11329720|NCT02502838||Prolapse surgery without TVT|Patients who plan to undergo prolapse repair alone
11329721|NCT02502838||Prolapse surgery with TVT|Patients who plan to undergo prolapse repair with an additional TVT procedure
11329722|NCT02502825|Experimental|asthma|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
11329723|NCT02502825|Experimental|normal controls|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
11329817|NCT02502253|Experimental|High dose|
11329890|NCT02501798|Active Comparator|Drug: Placebo|Drug: Placebo 7 days Empty green-yellow capsule
11329725|NCT02502812|Experimental|Treatment Sequence A(Innovator) -C(Clop F2)-B (Clop F1)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
11329726|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - A (Innovator) - C (Clop F2)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
11329727|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - C (Clop F2) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
11329728|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - A (Innovator) - B (Clop F1)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
11329729|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - B (Clop F1) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
11329730|NCT02502799|Active Comparator|Continued Monitoring and Assessment|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. Participants randomized to the continued monitoring and assessment arm will receive no additional intervention. Primary and secondary outcomes will be monitored.
11329731|NCT02502799|Active Comparator|PT with ACBT|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
11329732|NCT02502799|Active Comparator|PT with ACBT and Methylphenidate|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT and Methylphenidate arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (ACBT). Adolescents will also receive methylphenidate.
11329733|NCT02502786|Experimental|humanized anti-GD2 antibody, hu3F8, when combined with GM-CSF|One cycle consists of treatment with hu3F8 at a dose of 2.4mg/kg/dose for 3 days (day 1, 3, and 5) in the presence of subcutaneous (sc) GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. Cycles are repeated at ~2-4 week intervals between first days of hu3F8, through 5 cycles. A maximum of 5 cycles will be administered on protocol.
11329734|NCT02502773|Experimental|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
11329735|NCT02502773|Experimental|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
11329736|NCT02502760|Experimental|Prehabilitation|"Immediately after randomization and until surgery, patients in this arm will:
~- Receive a personalized physical exercise program
~- Receive nutritional counselling with Whey protein isolate powder
~- Receive relaxation techniques"
11329737|NCT02502760|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patients in the other arm but to be started after surgery.
11329738|NCT02502747|Experimental|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
11329739|NCT02502747|Active Comparator|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
11329740|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
11329741|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
11329742|NCT02502721|Experimental|Part A|To study effect of DWC20151 on DWC20152 PK
11329743|NCT02502721|Experimental|Part B|To study effect of DWC20152 on DWC20151 PK
11329744|NCT02502708|Experimental|Group 1 (CLOSED)|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.
~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
11329745|NCT02502708|Experimental|Group 2 (CLOSED)|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.
~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
11329927|NCT02501577|Experimental|SAD 2|FOI für placement
11329746|NCT02502708|Experimental|Group 3 (CLOSED)|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.
~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
11329747|NCT02502708|Experimental|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).
~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.
~Temozolomide to be given at 200 mg/m^2 x 5 days"
11329748|NCT02502708|Experimental|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.
~Indoximod will be administered at 32 mg/kg/dose divided twice daily.
~Cyclophosphamide to be given at 2.5 mg/kg/dose daily
~Etoposide to be given at 50 mg/m2/dose daily"
11329749|NCT02502695||Cohort 1-VATS-associated best practices|"Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.
~After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
11329750|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
11329751|NCT02502682|No Intervention|Control|Receive the bathing standard of care.
11329752|NCT02502682|Experimental|Interventional|Receive daily bathing with 2% Chlorhexidine gluconate bathing wipes.
11329753|NCT02502669|Active Comparator|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
11329754|NCT02502669|Active Comparator|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
11329755|NCT02502669|Placebo Comparator|Placebo group|Large and small placebo tablets once per week
11329756|NCT02502643|Experimental|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
11329757|NCT02502643|Active Comparator|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
11329758|NCT02502630|Experimental|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
11329759|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
11329760|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
11329761|NCT02502604|Experimental|Goal Management Training|Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
11329762|NCT02502604|No Intervention|Wait List Control|Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.
11329763|NCT02502591|Experimental|intervention|Additional pain relief (a Pudendal Nerve Block (PNB)) will be administered during surgery in addition to routine care.
11329764|NCT02502591|No Intervention|control|routine care only
11329765|NCT02502578|Experimental|CNT-01|Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
11329766|NCT02502565||Uric Acid Level|
11329767|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
11329768|NCT02502539|Experimental|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
11329769|NCT02502526|Experimental|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
11329770|NCT02502526|Active Comparator|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
11329771|NCT02502526|Active Comparator|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
11329772|NCT02502513|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department and completion of intrusive memory diary"
11329773|NCT02502513|No Intervention|Control|Usual care in the maternity department plus completion of intrusive memory diary
11329774|NCT02502500|Active Comparator|Celecoxib|Celecoxib
11329775|NCT02502500|Experimental|AKB-6548 and Celecoxib|AKB-6548; celecoxib
11329776|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
11329777|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
11329778|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
11329779|NCT02502474|Experimental|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
11329780|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
11379306|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
11329781|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
11329782|NCT02502448|No Intervention|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
11329783|NCT02502448|Active Comparator|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
11329784|NCT02502435||Patients with Night-Eating Syndrome|Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
11329785|NCT02502435||Matched Healthy Controls|Healthy volunteers; 18-65 years of age; eating <25% of their caloric intake after dinner; no nocturnal ingestions
11329786|NCT02502422|Other|Classic laryngeal mask airway|single arm
11329787|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
11329788|NCT02502383|Experimental|ACTION PAC|
11329789|NCT02502383|Active Comparator|Comparison|
11329790|NCT02502370|Active Comparator|Group1 Arm A Observation|
11329791|NCT02502370|Experimental|Group 1 Arm B LV5FU2|
11329792|NCT02502370|Active Comparator|Group 2 Arm C LV5FU2|
11329793|NCT02502370|Experimental|Group 2 ARM D FOLFOX|
11329794|NCT02502357|Experimental|Healing Statements|Patients in the healing statements group will be read healing statements during anesthesia induction, prior to undergoing surgery.
11329795|NCT02502357|No Intervention|No Healing Statements|Patients in the no healing statements group will not be read healing statements during anesthesia induction prior to undergoing surgery. They will receive standard of care.
11329796|NCT02502344|Experimental|medical intervention group|subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.
11329797|NCT02502344|No Intervention|clinical observeral group|subjects in this group will not accept medical interventions
11329798|NCT02502331|Experimental|study group|Test Oral Cholera Vaccine
11329799|NCT02502331|Active Comparator|comparator group|Euvichol®
11329800|NCT02502318|Experimental|Lobectomy using video-thoracoscopy|
11329801|NCT02502318|Active Comparator|Lobectomy using thoracotomy|
11329802|NCT02502305|Experimental|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
11329803|NCT02502305|No Intervention|Control group|control group receives 3 questionnaires at an interval of 6 weeks
11329804|NCT02502292|Experimental|Intervention: Fotonovela|The Photo Novel Intervention is presented to users of four different facilities (sports clubs, senior homes) who are older than 50 years. The researchers welcome scheduled eligible participants, introduce the study and ask them for their consent. Afterwards, the participants are asked to fill in the questionnaire. Then, participants are randomized to one of the four groups and are presented with the photo novel or traditional brochure either as a hard copy brochure or as pdf on a tablet computer (2x2 group design). They are instructed to read the material in their own pace and answer the accompanying questions after each story / tip.and the accompanying questionnaire.
11329805|NCT02502279|No Intervention|Control|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters with 0 PEEP/CPAP.
11329806|NCT02502279|Active Comparator|Lung Recruitment- PEEP group|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
11329807|NCT02502279|Active Comparator|Lung Recruitment- PEEP and CPAP group|"Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus
~lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
~Postoperative CPAP mask immediately after extubation"
11329808|NCT02502266|Active Comparator|Phase II Arm I (reference regimen)|Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. (12/05/2016)
11329809|NCT02502266|Experimental|Phase II Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11329810|NCT02502266|Experimental|Phase II Arm III (cediranib maleate)|Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11329811|NCT02502266|Experimental|Phase II Arm IV (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
11329812|NCT02502266|Active Comparator|Phase III Arm I (reference regimen)|Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. (12/05/2016)
11329813|NCT02502266|Experimental|Phase III Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II.
11329814|NCT02502266|Experimental|Phase III Arm III (single-agent cediranib maleate)|Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11329819|NCT02502227|Active Comparator|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
11329820|NCT02502227|No Intervention|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
11329821|NCT02502201|Active Comparator|six-minute walk study indoors first|Participants randomized to indoor six-minute walk test first
11329822|NCT02502201|Experimental|six-minute walk study outdoors first|Participants randomized to outdoor six-minute walk test first
11329823|NCT02502201|Active Comparator|six-minute walk study indoors second|Participants randomized to indoor six-minute walk test second
11329824|NCT02502201|Experimental|six-minute walk study outdoors second|Participants randomized to outdoor six-minute walk test second
11329825|NCT02502188|Experimental|Part 1 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
11329826|NCT02502188|Experimental|Part 2 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
11329827|NCT02502175|Experimental|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
11329828|NCT02502175|Active Comparator|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
11329829|NCT02502162|Experimental|LDN|Naltrexone HCL, 4.5 mg, Once a day.
11329830|NCT02502162|Placebo Comparator|Placebo|Sugar pill
11329831|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
11329832|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
11329833|NCT02502136|Experimental|CO2 in sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with sedation
11329834|NCT02502136|Placebo Comparator|Air in sedated colonoscopy|Room air insufflation during colonoscopy with sedation
11329835|NCT02502136|Experimental|CO2 in mild sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with mild sedation
11329836|NCT02502136|Placebo Comparator|Air in deep sedated colonoscopy|Room air insufflation during colonoscopy with deep sedation
11329837|NCT02502136|Experimental|CO2 in sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with sedation
11329838|NCT02502136|Placebo Comparator|Air in sedated panendoscopy|Room air insufflation during panendoscopy with sedation
11329839|NCT02502136|Experimental|CO2 in mild sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with mild sedation
11329840|NCT02502136|Placebo Comparator|Air in deep sedated panendoscopy|Room air insufflation during panendoscopy with deep sedation
11329841|NCT02502123||OnabotulinumtoxinA (BOTOX®)|Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
11329842|NCT02502110|Experimental|rosuvastatin 20mg/day|To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.
11329843|NCT02502110|No Intervention|blank control|Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.
11329844|NCT02502097|Experimental|Gefapixant followed by Placebo|Participants were randomized to receive gefapixant 50 mg twice daily (BID) for 14 days during Period 1, followed by placebo BID for 14 days during Period 2 (after a 14 to 21-day washout period)
11329845|NCT02502097|Experimental|Placebo followed by Gefapixant|Participants were randomized to receive placebo BID for 14 days during Period 1, followed by gefapixant 50 mg BID for 14 days during Period 2 (after a 14 to 21-day washout period)
11329846|NCT02502097|Experimental|Enrolled prior to Amendment 3|Participants were randomized to receive either placebo BID for 14 days during Period 1 followed by gefapixant 50 mg BID for 10 days then gefapixant 150 mg BID for 4 days BID during Period 2 (after a 14 to 21-day washout period); or gefapixant 50 mg BID for 10 day then gefapixant 150 mg BID for 4 days during Period 1, followed by placebo BID for 14 days during Period 2 (after a 14 to 21-day washout period)
11329847|NCT02502084|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
11329848|NCT02502071|Experimental|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
11329849|NCT02502045|Experimental|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days. A flexible window of has been allowed to accommodate participants and care routines.
11329850|NCT02502045|Placebo Comparator|Non-Therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
11329851|NCT02502032|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
11329852|NCT02502032|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg.
11329853|NCT02502032|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg.
11329854|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
11329855|NCT02502006|Experimental|High Dose|During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
11329884|NCT02501824|Experimental|speech therapy second|10 weeks of waiting, then 11 sessions of speech therapy (anthroposophic therapeutic speech)
11329885|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
11329856|NCT02502006|Experimental|Low dose|During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
11329857|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
11329858|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
11329859|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
11329860|NCT02501967|Experimental|COMET|The intervention consists of completion of the tool (COMET) by means of a 30 minute telephone interview prior to the primary care visit and provision of the tool's output to the patient and primary care physician. The COMET tool takes information about the patient's medications and chronic conditions from the electronic health record, and then supplements this with information obtained by a telephone interview assessing the patient's cognition, social supports, medication adherence, home medication regimen, medication side effects, and health status. In addition, there is a chart review screen to record renal function, blood pressure, and hemoglobin A1C. All of this information is run through a set of algorithms to identify medication reconciliation errors and potentially inappropriate medications.
11329861|NCT02501967|No Intervention|Usual Care|
11329862|NCT02501954|Experimental|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
11329863|NCT02501954|Active Comparator|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
11329864|NCT02501941|Experimental|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
11329865|NCT02501941|Experimental|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
11329866|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
11329867|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
11329868|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
11329869|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
11329870|NCT02501915|Experimental|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
11329871|NCT02501915|Experimental|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
11329872|NCT02501902|Experimental|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
11329873|NCT02501889|Experimental|Walnut-rich weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. All participants will have contact with the project coordinator a minimum of every 1-2 weeks. Walnuts will be provided to participants in the walnut-rich study arm.
11329874|NCT02501889|Active Comparator|Standard weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Participants assigned to this arm will be instructed to abstain from the consumption of nuts during the study. All participants will have contact with the project coordinator a minimum of every 1-2 weeks.
11329875|NCT02501876||T2D-MCI|110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.
11329876|NCT02501876||nonT2D-MCI|110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.
11329877|NCT02501863|Experimental|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl
~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
11329878|NCT02501863|Experimental|Ropivacaine|"Femoral nerve block with ropivacaine
~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
11329879|NCT02501850|Experimental|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
11329880|NCT02501850|Active Comparator|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
11329881|NCT02501837|Experimental|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
11329882|NCT02501837|Placebo Comparator|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
11329883|NCT02501824|Experimental|speech therapy first|11 sessions of speech therapy (anthroposophic therapeutic speech), then waiting phase
11379954|NCT02169544||Patients who are prescribed other RA treatments|
11329891|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
11329892|NCT02501772|Experimental|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
11329893|NCT02501772|Sham Comparator|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
11329894|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
11329895|NCT02501746|Active Comparator|Usual Clinical Care (UC)|This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension.
11329896|NCT02501746|Experimental|Usual clinical care plus microfinance groups only (MF)|Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program.
11329897|NCT02501746|Experimental|Group medical visits only (GMV)|Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
11329898|NCT02501746|Experimental|GMV integrated into GMV-MF|Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit.
11329899|NCT02501733|Other|Medacta GMK Sphere® Knee Prosthesis|All subjects enrolled will receive the Medacta GMK Sphere® Medial Knee Prosthesis
11329900|NCT02501720|Active Comparator|Tourniquet Group|Post burn flexion contractures will be released under tourniquet control
11329901|NCT02501720|Experimental|Tumescent technique group|Post burn flexion contractures will be released using Tumescent solution
11329902|NCT02501681|Active Comparator|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
11329903|NCT02501681|Active Comparator|colloid|Group B (n=20); colloids as priming solution used in patients
11329904|NCT02501668||Lung cancer in population|Lung cancer cases in sample population (670,258 cases)
11329905|NCT02501668||COPD in population|COPD cases (670,258 cases)
11329906|NCT02501668||COPD with lung cancer|Lung cancer in COPD
11329907|NCT02501668||ILD without IPF|Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
11329908|NCT02501668||ILD with lung cancer|Lung cancer cases in ILD
11329909|NCT02501668||Idiopathic pulmonary fibrosis|Idiopathic pulmonary fibrosis cases
11329910|NCT02501668||IPF with lung cancer|Lung cancer cases in IPF patients
11329911|NCT02501668||Connective tissue disorder with ILD|CTD with ILD cases
11329912|NCT02501668||CTD ILD with lung cancer|Lung cancer cases in CTD with ILD
11329913|NCT02501668||CTD without ILD|CTD with ILD cases in sample population
11329914|NCT02501668||CTD without ILD with lung cancer|Lung cancer in CTD without ILD
11329915|NCT02501655|Active Comparator|Phase 1|Jet Nebulizer - control group
11329916|NCT02501655|Experimental|Phase 2|Mesh nebulizers
11329917|NCT02501642|Experimental|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
11329918|NCT02501642|Other|Treatment as usual|Treatment as usual
11329919|NCT02501629|Experimental|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
11329920|NCT02501629|Placebo Comparator|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
11329921|NCT02501616|Active Comparator|Metformin first|"Metformin first 8 wks --> Dapagliflozin 8wks.
~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
11329922|NCT02501616|Active Comparator|Dapagliflozin first|"Dapagliflozin first 8 wks --> Metformin 8wks.
~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
11329923|NCT02501603|Experimental|afatinib plus paclitaxel|afatinib plus paclitaxel
11329924|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.
~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
11329925|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.
~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
11329926|NCT02501577|Experimental|SAD 1|FOI for placement
11329928|NCT02501564|Experimental|Naproxen Sodium Codeine|One tablet twice a day
11329929|NCT02501564|Placebo Comparator|Placebo|One tablet twice a day
11329930|NCT02501551|Experimental|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
11329931|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
11329932|NCT02501525|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
11329933|NCT02501525|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
11329934|NCT02501499||Breastfeeding Buddies participants|Mothers that participated in Me Breastfeed workshops. Half will have been in the education-only group and half will have a buddy/peer support person in addition to the workshop.
11329935|NCT02501499||Volunteer Focus Group|Breastfeeding buddies volunteers that deliver education and support programs.
11329936|NCT02501486|Other|ACTH stimulation test|this is a single arm study. An ACTH-stimulation test will be done
11329937|NCT02501473|Experimental|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
11329938|NCT02501473|Experimental|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
11329939|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
11329940|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
11329941|NCT02501473|Experimental|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors [injectable lymphoma mass(es) ≥ 4 cm in total size] for up to 8 weeks.
11329942|NCT02501473|Experimental|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
11329943|NCT02501473|Experimental|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
11329944|NCT02501473|Experimental|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m^2 on Day 0 and then QW for up to 3 weeks.
11329945|NCT02501460|Active Comparator|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
11329946|NCT02501460|Placebo Comparator|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
11329947|NCT02501447|Experimental|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
11329948|NCT02501447|No Intervention|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
11329949|NCT02501434|No Intervention|Control|Standard of Care
11329950|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
11329951|NCT02501421|Active Comparator|TB/FLU-04L|Live recombinant influenza vectored tuberculosis vaccine
11329952|NCT02501421|Placebo Comparator|Placebo|Buffer
11329953|NCT02501408|Experimental|Propriofoot prosthesis|New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month
11329954|NCT02501408|No Intervention|Control|Usual prosthesis is worn for 1 month
11329955|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
11329956|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
11329957|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
11329958|NCT02501369|Experimental|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.
~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
11329959|NCT02501356|Active Comparator|ISOThrive supplement 1|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
11329960|NCT02501356|Active Comparator|ISOThrive supplement 2|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
11329994|NCT02501122||Adenotonsillectomy|Measuring quality of care in patients undergoing adenotonsillectomy.
11381245|NCT02160743|Experimental|group 2|fed, fasting
11329961|NCT02501356|Placebo Comparator|Placebo supplement|Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
11329962|NCT02501343|Experimental|Sodium bicarbonate|High acid load meal (Western style meal) with Sodium bicarbonate (Sodibic 840mg*2)
11329963|NCT02501343|Placebo Comparator|Placebo|High acid load meal (Western style meal) with sodibic-matching placebo
11329964|NCT02501330||Bosutinib|
11329965|NCT02501317|Experimental|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
11329966|NCT02501317|Active Comparator|Kari Bo protocol|control group will be treated with the protocol already widely used
11329967|NCT02501304|Experimental|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
11329968|NCT02501291|Experimental|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
11329969|NCT02501278|Experimental|Arm A: Immunotherapy during and after CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.
11329970|NCT02501278|Experimental|Arm B: Immunotherapy during CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.
11329971|NCT02501278|Active Comparator|CRT without immunotherapy|Standard chemoradiotherapy without immunotherapy
11329972|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
11329973|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
11329974|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
11329975|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
11329976|NCT02501252|Experimental|CORN Based at health post|Trained CORN based at health post will provide SBA and other RH services on demand at health post or household levels on an outreach bases.
11329977|NCT02501252|Active Comparator|CORN Based at health center|Trained CORN based at health center, but working in the community in an outreach basis will provide SBA and other RH services
11329978|NCT02501252|No Intervention|Control|will be composed of a randomly selected comparable controls clusters. Control clusters (arm) will be similar with the other two arms (groups) except for the intervention.
11329979|NCT02501239|Experimental|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
11329980|NCT02501239|Active Comparator|Behavioral Weight Loss|Weight Watchers groups
11329981|NCT02501226|Other|Control group|Treatment as usual
11329982|NCT02501226|Experimental|Interventional group|ENVIE psychoeducational program
11329983|NCT02501213|No Intervention|A : observation|Clinical monitoring and best supportive care.
11329984|NCT02501213|Active Comparator|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
11329985|NCT02501200|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
11329986|NCT02501200|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
11329987|NCT02501187|Experimental|Patients operated for ptosis by levator advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- levator advancement.
11329988|NCT02501187|Experimental|Patients operated for ptosis by white line advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- white line advancement
11329989|NCT02501187|Experimental|Patients operated for ptosis by Müller resection|patients undergoing surgical repair for aponeurotic ptosis by the procedure- Müller's muscle-conjunctival resection.
11329990|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
11329991|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
11329992|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
11329993|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
11329995|NCT02501109|Experimental|Group A|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
11329996|NCT02501109|Experimental|Group B|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
11329997|NCT02501109|Experimental|Gruop C|Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
11329998|NCT02501096|Experimental|Lenvatinib + Pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma.
11329999|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
11330000|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
11330001|NCT02501057|Active Comparator|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
11330002|NCT02501057|Active Comparator|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
11330003|NCT02501057|Experimental|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
11330004|NCT02501044||Hemodialysis Patients|
11330005|NCT02501031|Experimental|Flaxseed (ground)|
11330006|NCT02501031|No Intervention|Usual diet|
11330007|NCT02501018|Experimental|CLI Due to ASO with CLBS12 + SOC|This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
11330008|NCT02501018|Active Comparator|CLI Due to ASO with SOC|This group of subjects with CLI due to ASO will be administered with SOC only.
11330009|NCT02501018|Experimental|CLI Due to BD with CLBS12|CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.
11330010|NCT02501005|Experimental|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
11330011|NCT02501005|Other|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
11330012|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
11330013|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
11330014|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
11330015|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
11330016|NCT02500966|Experimental|DUDA device|"The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).
~Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)"
11330017|NCT02500966|Active Comparator|Control group|"The number of patients to be recruited in this arm will be 120.
~Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device"
11330018|NCT02500953|Experimental|Japanese male single fasted ASP dose-1|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330019|NCT02500953|Experimental|Japanese male single fasted ASP dose-2|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330020|NCT02500953|Experimental|Japanese male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330021|NCT02500953|Experimental|Japanese male single fasted ASP dose-4|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330022|NCT02500953|Experimental|Japanese male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330023|NCT02500953|Experimental|Japanese male single fasted ASP dose-6|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330024|NCT02500953|Experimental|Japanese male single fasted ASP dose-7|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330080|NCT02500680|Experimental|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 3µg (Standard Dose) Single Dose
11330025|NCT02500953|Experimental|Japanese female single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330026|NCT02500953|Experimental|Japanese female single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330027|NCT02500953|Experimental|Caucasian male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330028|NCT02500953|Experimental|Caucasian male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330029|NCT02500953|Experimental|Japanese male single fed ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects after a meal.
11330030|NCT02500953|Experimental|Japanese male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330031|NCT02500953|Experimental|Japanese female single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330032|NCT02500953|Experimental|Caucasian male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
11330033|NCT02500953|Experimental|Japanese male single fed placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects after a meal.
11330034|NCT02500953|Experimental|Japanese male multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
11330035|NCT02500953|Experimental|Japanese male multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
11330036|NCT02500953|Experimental|Japanese male multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
11330037|NCT02500953|Experimental|Japanese female multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
11330038|NCT02500953|Experimental|Japanese female multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
11330039|NCT02500953|Experimental|Japanese female multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
11330040|NCT02500953|Experimental|Japanese male multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
11330041|NCT02500953|Experimental|Japanese female multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
11330042|NCT02500953|Experimental|Japanese male ASP dose-5 before a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
11330043|NCT02500953|Experimental|Japanese male ASP dose-5 during a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
11330044|NCT02500953|Experimental|Japanese male ASP dose-5 after a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
11330045|NCT02500940|Experimental|Control group|Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
11330046|NCT02500940|Active Comparator|Test group|Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
11330047|NCT02500927|Experimental|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
11330048|NCT02500914|Experimental|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.
~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
11330049|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
11330050|NCT02500888|Experimental|Treatment|Radiosurgery by linear accelerator.
11330051|NCT02500875|Experimental|PTNiA|"Topical negative pressure therapy with instillation of saline solution (6 times daily).
~During the instillation of saline solution, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.
~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
11330052|NCT02500875|Experimental|PTNiB|"Topical negative pressure therapy with instillation of Amukine Med 0,05% (6 times daily).
~During the instillation of Amukine Med 0,05%, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.
~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
11330081|NCT02500680|Experimental|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 5µg (Standard Dose) Single Dose
11330053|NCT02500875|Active Comparator|PTN|"Topical negative pressure therapy (without instillation). The device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.
~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
11330054|NCT02500849|Experimental|Cohort 1:|target busulfan AUC levels: 8,000 µM*min (+/- 1,000)
11330055|NCT02500849|Experimental|Cohort 2:|busulfan AUC levels: 12,000 µM*min (+/- 1,000)
11330056|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
11330057|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
11330058|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
11330059|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
11330060|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
11330061|NCT02500810|Experimental|monosialoganglioside|patients receive monosialoganglioside.
11330062|NCT02500810|No Intervention|control|blank control
11330063|NCT02500797|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
11330064|NCT02500797|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
11330065|NCT02500784|Active Comparator|Formoterol A|12 months, formoterol, 20microgram/2ml, inhaler, BID
11330066|NCT02500784|Placebo Comparator|Formoterol B|12 months, normal saline, 2ml, inhaler, BID
11330067|NCT02500771|Experimental|children and tutors using V-Motive|"The following intervention will be administered:
~ABA therapy enhanced with V-Motive software
~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
11330068|NCT02500758|Experimental|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
11330069|NCT02500758|Active Comparator|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
11330070|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
11330071|NCT02500732|Placebo Comparator|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
11330072|NCT02500732|Active Comparator|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
11330073|NCT02500719||Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement of the application of our Fitted Q Learning algorithm prior to implementing with our PTSD participant group.
11330074|NCT02500719||PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
11330075|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
11330076|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
11330077|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
11330078|NCT02500693|Experimental|Screening|
11330079|NCT02500680|Experimental|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 1µg (Standard Dose) Single Dose
11330179|NCT02500056|Active Comparator|UM group|Ultrapro mesh
11330082|NCT02500680|Experimental|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg (Standard Dose) Single Dose
11330083|NCT02500680|Active Comparator|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
11330084|NCT02500680|Active Comparator|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
11330085|NCT02500680|Experimental|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
11330086|NCT02500680|Experimental|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
11330087|NCT02500680|Active Comparator|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
11330088|NCT02500680|Experimental|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose (as 2 x 0.25 mL in each arm)
11330089|NCT02500680|Active Comparator|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose (0.5 mL) in one arm and 0.5 mL of PBS in the other arm
11330090|NCT02500667|Experimental|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
11330091|NCT02500654|Experimental|Surgery and Emdogain®|access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline
11330092|NCT02500654|Placebo Comparator|Surgery alone|access peri-implant surgery and cleaning of implant surface with saline
11330093|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.
~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
11330094|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.
~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
11330095|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
11330096|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
11330097|NCT02500615|Experimental|0 PG: 100 VG|
11330098|NCT02500615|Experimental|30 PG: 70 VG|
11330099|NCT02500615|Experimental|50 PG: 50 VG|
11330100|NCT02500615|Experimental|70 PG: 30 VG|
11330101|NCT02500615|Experimental|100 PG: 0 VG|
11330102|NCT02500602|Experimental|Doxazosin|Participants will be randomly assigned to receive doxazosin (target dose of 16 mg/day) or placebo. Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff will administer the study medication or placebo at the weekly visits, and participants will be given take-home doses of the medication or placebo to self-administer on the days in between study visits.
11330103|NCT02500602|Placebo Comparator|Placebo|Placebo pill
11330104|NCT02500589|Experimental|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
11330105|NCT02500589|Other|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
11330106|NCT02500576|Experimental|Arm I (pembrolizumab, high-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide IV over 2 hours on days -7 and -6 followed by fludarabine phosphate IVPB over 15-30 minutes on days -5 to -1. Patients also receive therapeutic tumor infiltrating lymphocytes IV over 15-60 minutes on day 0 followed by high-dose aldesleukin IV over 15 minutes every 8-16 hours for up to 15 doses on days 1-5. Beginning between 21-28 days after TIL infusion, patients receive maintenance therapy comprising pembrolizumab IV over 30 minutes every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11330107|NCT02500576|Experimental|Arm II (pembrolizumab, low-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide and fludarabine phosphate and therapeutic tumor infiltrating lymphocytes as in Arm I, followed approximately 6 hours later by low-dose aldesleukin SC for 14 days. Patients also receive pembrolizumab as in Arm I.
11330108|NCT02500563|Active Comparator|Amino acid based infant formula|
11330109|NCT02500563|Experimental|Extensively hydrolyzed casein infant formula|
11330110|NCT02500563|Other|Mother's own breast milk|
11330111|NCT02500550|Experimental|ATIR101|
11330112|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.
~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
11330113|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.
~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
11330114|NCT02500524|Experimental|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
11330115|NCT02500524|Active Comparator|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
11330116|NCT02500485|Experimental|SHR3824 20mg/SP2086 100mg|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
11330117|NCT02500472|Experimental|Kava Supplement|See intervention description.
11330118|NCT02500459|Experimental|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
11330119|NCT02500446|Active Comparator|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
11330120|NCT02500446|Placebo Comparator|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
11330121|NCT02500433|Experimental|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
11330122|NCT02500433|Other|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.
~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
11330123|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).
~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
11330124|NCT02500407|Experimental|Dose Escalation|Participants will receive BTCT4465A (Mosunetuzumab) via intravenous (IV) infusion or subcutaneous (SC) injection as a single-agent or in combination with atezolizumab. Dose escalation will be guided by the observed incidence of DLTs at each dose level.
11330125|NCT02500407|Experimental|Dose Expansion|Participants will receive BTCT4465A (Mosunetuzumab) at the RP2D as a single-agent or in combination with atezolizumab.
11330126|NCT02500394|Placebo Comparator|standard care|Patients in the standard care population receive - if biomarkers are elevated -treatment of AKI in accordance with KDIGO 2012 guidelines
11330127|NCT02500394|Active Comparator|interventional care|Patients in the interventional population receive - if biomarkers are elevated - individualized treatment/volume substitution (balanced electrolyte solution = Ionosteril; 1,25-5 ml/kg/bw/6 hours) ) on the basis of predefined criteria
11330128|NCT02500381|Experimental|SRP-4045|Patients amenable to exon 45 skipping will receive SRP-4045 intravenous (IV) infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks in OL period (up to Week 144 in study).
11330129|NCT02500381|Experimental|SRP-4053|Patients amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks in OL period (up to Week 144 in study).
11330130|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Patients amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in double-blinded period. This will be followed by an open label extension period in which all patients will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV for 48 weeks in OL period (up to Week 144 in study).
11330131|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
11330132|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
11330133|NCT02500355|Active Comparator|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
11330134|NCT02500355|Active Comparator|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
11330135|NCT02500355|Placebo Comparator|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
11330136|NCT02500342|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
11330180|NCT02500043|Experimental|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11330347|NCT02499042|Active Comparator|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
11330137|NCT02500342|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
11330138|NCT02500329|Experimental|gemigliptin|gemigliptin for 4 weeks
11330139|NCT02500329|Active Comparator|acarbose|acarbose for 4 weeks
11330140|NCT02500316|Experimental|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
11330141|NCT02500290||Acute coronary syndrome|
11330142|NCT02500277|Active Comparator|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
11330143|NCT02500277|Active Comparator|Forceps biopsy|Pleural biopsy with a flexible forceps
11330144|NCT02500264|Active Comparator|Protocol #1|interventions: 1.6Hz, Rampdown 0.4S, electrodes position - both L.Rectus Abdominis, 5cmX5cm Size, on inspirium
11330145|NCT02500264|Active Comparator|Protocol #2|1Hz, Rampdown 0.6S, electrodes position - both Rectus Abdominis, 5cmX5cm Size, on inspirium
11330146|NCT02500264|Active Comparator|Protocol #3|1.6Hz, Rampdown 0.4S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium Oblique
11330147|NCT02500264|Active Comparator|Protocol #4|1Hz, Rampdown 0.6S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium
11330148|NCT02500251|Experimental|Group A (5 subjects)|Subjects will receive bortezomib and plasmapheresis.
11330149|NCT02500251|Experimental|Group B (5 subjects)|Subjects will receive belimumab, bortezomib, and plasmapheresis.
11330150|NCT02500251|Experimental|Group C (5 subjects)|Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.
11330151|NCT02500238||Control|This group will provide 2 breath carbon monoxide (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings will be taken from this group.
11330152|NCT02500238||Smoking|This group will provide 1 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
11330153|NCT02500238||Vaping|This group will provide 2 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
11330154|NCT02500225|Active Comparator|Etomidate|0.2 mg/kg etomidate during anesthesia induction
11330155|NCT02500225|Active Comparator|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
11330156|NCT02500212|Experimental|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.
~Envarsus® tablets will be administered orally once daily in the morning"
11330157|NCT02500212|Active Comparator|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.
~Advagraf® capsules will be administered orally once daily in the morning"
11330158|NCT02500199|Experimental|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
11330159|NCT02500186|Experimental|High GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.
11330160|NCT02500186|Experimental|Low GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet
11330161|NCT02500186|Experimental|High GI meal containing 40% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.
11330162|NCT02500160|Experimental|patient specific instrumentation (MRI)|MRI based patient-specific instrumentation
11330163|NCT02500160|Active Comparator|patient specific instrumentation (CT)|CT based patient-specific instrumentation
11330164|NCT02500147|Experimental|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
11330165|NCT02500147|Placebo Comparator|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
11330166|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
11330167|NCT02500121|Placebo Comparator|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
11330168|NCT02500121|Experimental|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
11330169|NCT02500108||Treated with domperidone|Patients who received a new prescription for domperidone (ATC A03FA03) in the year prior to the index date.
11330170|NCT02500108||Unexposed (reference) group|Patients with no prescription for domperidone in the year prior to the index date.
11330171|NCT02500095|No Intervention|Control|12 hours of fasting
11330172|NCT02500095|Experimental|Fasting and saline|72 hours of fasting and concomitant saline
11330173|NCT02500095|Experimental|Fasting and GHR blockade|72 hours of fasting and concomitant Growth hormone receptor (GHR) blockade with Pegvisomant (Somavert) for inhibition of the fasting-induced GH secretion
11330174|NCT02500069|Placebo Comparator|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
11330175|NCT02500069|Experimental|Duodenum|Infusion of casein in duodenum
11330176|NCT02500069|Experimental|Jejunum|Infusion of casein in jejunum
11330177|NCT02500069|Experimental|Ileum|Infusion of casein in ileum
11330178|NCT02500056|Active Comparator|OM group|Optilene LP mesh
11330181|NCT02500043|Experimental|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11330182|NCT02500030|Experimental|Air Stacking|Air Stacking was performed with the subject seated in his wheelchair using a manual resuscitation bag (LIFESAVER® model 5345, Hudson, Temecula, USA) connected to a corrugated tube with an internal diameter of 22 mm, a one-way valve and a pipette. The maximum capacity of the bag was 1600 mL. A chest physiotherapist insufflated the patient during the inspiratory phase, requesting that inspire as much air as possible
11330183|NCT02500030|Experimental|Glossopharyngeal Breathing|"Glossopharyngeal Breathing was also performed with the subject seated in his wheelchair and performing successive maneuvers of swallowing air until the maximum volume achieve was maintained. Then, the patient was instructed to breathe through ventilometer to register the MIC. Three measurements for each of the techniques were performed, and the highest reading was recorded. A difference of <10% between the measurements was used as the repeatability criterion"
11330184|NCT02500017|Experimental|Melatonin|A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
11330185|NCT02500017|Placebo Comparator|Placebo|Matching placebo capsules to be administered once a day for a total of 8 weeks
11330186|NCT02500004|Active Comparator|Cachectic pancreatic cancer|"Cachectic patients with pancreatic cancer
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
11330187|NCT02500004|Active Comparator|Cachectic NSCLC|"Cachectic patients with non-small cell lung cancer
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
11330188|NCT02500004|Active Comparator|Cachectic COPD|"Cachectic COPD patients.
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
11330189|NCT02500004|Active Comparator|Non-cachectic COPD|"Non-cachectic COPD patients.
~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
11330190|NCT02500004|Other|Healthy individuals|"BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
11330191|NCT02499991|Experimental|Treatment|"Treatment group will keep diary of social events according to training instructions.
~Memory intervention will be used."
11330192|NCT02499991|No Intervention|Control|Control group will use own memory of social events without training instructions.
11330193|NCT02499978|Experimental|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
11330194|NCT02499978|Active Comparator|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
11330195|NCT02499965|Active Comparator|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
11330196|NCT02499965|Placebo Comparator|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
11330197|NCT02499952|Experimental|Experimental Arm|Pembrolizumab
11330198|NCT02499939|Active Comparator|Standard Care|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home.
11330199|NCT02499939|Experimental|Experimental: Ultrasound Therapy|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
11330200|NCT02499926|Experimental|Dietary supplement: Arginine|Graded arginine excess intake
11330201|NCT02499913|Active Comparator|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
11330202|NCT02499913|Experimental|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
11330203|NCT02499900|Experimental|Copaxone® 40 mg/mL|Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
11330204|NCT02499900|Active Comparator|Copaxone® 20 mg/mL|Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
11330205|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)
~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
11330206|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days
~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
11330341|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
11330207|NCT02499874|Experimental|Single treatment arm|All subjects will be administered oral Efavirenz 400mg together with the rest of the oral antiretroviral combination (tenofovir 245 mg/emtricitabine 200mg or tenofovir 245mg/lamivudine 300mg or lamivudine 300mg/zidovudine 600mg) throughout the study period
11330208|NCT02499861|Experimental|Decitabine and Genistein|continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
11330209|NCT02499848|Experimental|Intraprostatic administration|PRX302
11330210|NCT02499835|Experimental|Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
11330211|NCT02499835|Experimental|Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
11330212|NCT02499835|Experimental|Extended Treatment Arm III|pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
11330213|NCT02499835|Experimental|Extended Treatment Arm IV|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
11330214|NCT02499822|Experimental|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
11330215|NCT02499822|Experimental|Ramipril 10 mg|Ramipril 10 mg in tablets.
11330216|NCT02499809|Experimental|Passive|Passive recovery
11330217|NCT02499809|Experimental|Vibration|Vibration recovery
11330218|NCT02499796|Experimental|Single Arm|"Every patient receives 20 minutes of invasive mechanical ventilation with each of the three humidification systems in random sequence:
~Heated and moisture exchanger (HME)
~Heated humidifier (HH)
~Hygrovent Gold"
11330219|NCT02499783|Experimental|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.
~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
11330220|NCT02499783|Experimental|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.
~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
11330221|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
11330222|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
11330223|NCT02499757|Experimental|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
11330224|NCT02499757|Experimental|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
11330225|NCT02499757|Experimental|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
11330226|NCT02499757|Experimental|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
11330227|NCT02499744|Active Comparator|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
11330228|NCT02499744|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
11330229|NCT02499731|Experimental|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
11330230|NCT02499731|Experimental|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
11330231|NCT02499718|Experimental|Noninvasive ventilator|noninvasive positive pressure ventilation combined with long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
11330232|NCT02499718|No Intervention|LTOT|long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
11330233|NCT02499705|Experimental|Sucralose|Flavored beverage with sucralose.
11330234|NCT02499705|Experimental|Sucrose|Flavored beverage with sucrose.
11330235|NCT02499705|Experimental|Sucralose + maltodextrin|Flavored beverage with Splenda + maltodextrin .
11330236|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
11330237|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
11330342|NCT02499068|Experimental|COPD, Telehealth|Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
11330238|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
11330239|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
11330240|NCT02499653|Experimental|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
11330241|NCT02499653|Active Comparator|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
11330242|NCT02499640|No Intervention|GC|Control group - CG (n = 20), which suffered no recuperative technique
11330243|NCT02499640|Experimental|G1|G1 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
11330244|NCT02499640|Experimental|G2|G2 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
11330245|NCT02499640|Experimental|G3|G3 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
11330246|NCT02499640|Experimental|G4|G4 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
11330247|NCT02499627|Experimental|Bendamustine + Brentuximab for 6 cycles|Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
11330248|NCT02499614|Experimental|Patients with MET amplification or MET exon 14 mutation|Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
11330249|NCT02499614|Experimental|Patients with ROS1 translocation|Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
11330250|NCT02499601|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
11330251|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
11330252|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
11330253|NCT02499562|Experimental|Hydronidone(180mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.
~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
11330254|NCT02499562|Experimental|Hydronidone(270mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.
~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
11330255|NCT02499562|Experimental|Hydronidone(360mg) & Entecavir|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.
~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
11330256|NCT02499562|Experimental|Entecavir & Placebo(360mg)|placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
11330257|NCT02499549|Experimental|10% Cocamide diethanolamine 8 hours|Cocamide DEA topical lotion applied 8 hours/overnight with drying
11330258|NCT02499549|Experimental|10% Cocamide diethanolamine 2 hours|Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days
11330259|NCT02499536|Experimental|Study participants|After general anesthesia development of the atelectasis will be investigated by the lung ultrasound
11330260|NCT02499523|Active Comparator|THR with conventional technique|Use of conventional technique in THR
11330261|NCT02499523|Experimental|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
11330262|NCT02499510|Experimental|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
11330263|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose I or LY SARM Dose 2 daily, oral per cycle.
11330264|NCT02499497|Active Comparator|LY2452473 Dose I|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY2452473 Dose I or LY2452473 Dose 2 daily, oral per cycle.
11330265|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY2452473 Dose I or LY SARM Dose 2 daily, oral per cycle.
11330266|NCT02499484|Active Comparator|GTN and eccentric exercises|Participants will complete a 12 week eccentric exercise program and use 0.5cm of glyceryl trinitrate ointment daily for 24 weeks
11330267|NCT02499484|Placebo Comparator|Placebo and eccentric exercises|Participants will use a placebo ointment with no active ingredient for 24 weeks and complete an eccentric exercise program for 12 weeks
11330268|NCT02499471|Other|Before levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure 6.8 ± 2.8 weeks after thyroidectomy, when plasma free T4-levels were at the minimum, before daily levothyroxine therapy 137.75 ± 25.75 μg.
11330269|NCT02499471|Other|After levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure four to six months after the initial measurements, after daily levothyroxine therapy 137.75 μg (fT4 levels 23.1 ± 3.9 pmol/L, TSH 0.5 ± 0.6 mU/L)
11330270|NCT02499445|Active Comparator|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
11330271|NCT02499445|Active Comparator|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
11330272|NCT02499445|Active Comparator|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
11330273|NCT02499432|Experimental|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
11330274|NCT02499432|No Intervention|Standard training|Training as usual
11330275|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
11330276|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter > 40 mm Atrial fibrillation Age ≥ 50
11330277|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
11330278|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF < 50% MR ≥ moderate
11330279|NCT02499406|Other|Skills group|Dialectical behavior therapy skills group
11330280|NCT02499393|Experimental|TH+MgSO4|Therapeutic hypothermia plus magnesium sulphate intravenous infusion Neonates who were randomized to the study group (TH+MgSO4) received three 250 mg/kg doses of magnesium sulfate given as one - hour continuous infusion spaced 24 hours apart on three consecutive days. 20% Magnesium Sulfuricum (Polpharma), 2 g /10 ml were used.
11330281|NCT02499393|No Intervention|TH- therapeutic hypothermia|therapeutic hypothermia without magnesium sulphate
11330282|NCT02499380||Treatment|Patients treated with PneumRx Coil System
11330283|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
11330284|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
11330285|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
11330286|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
11330287|NCT02499367|Active Comparator|No induction treatment|
11330288|NCT02499354|Active Comparator|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
11330289|NCT02499354|Active Comparator|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
11330290|NCT02499341|Active Comparator|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
11330291|NCT02499341|Active Comparator|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
11330292|NCT02499328|Experimental|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
11330293|NCT02499328|Experimental|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
11330294|NCT02499328|Experimental|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
11330295|NCT02499328|Experimental|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
11330296|NCT02499328|Experimental|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
11330297|NCT02499328|Experimental|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
11330298|NCT02499328|Experimental|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
11330299|NCT02499328|Experimental|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
11330300|NCT02499328|Experimental|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
11330301|NCT02499328|Experimental|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
11330302|NCT02499328|Experimental|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
11330303|NCT02499328|Experimental|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
11330304|NCT02499328|Experimental|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
11330305|NCT02499328|Experimental|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
11330306|NCT02499328|Experimental|Part B8: AZD9150 (every other week)+MEDI4736: naive 1L|Patients in Arm B8 will be evaluated for efficacy until disease progression and then followed up for safety and survival
11330307|NCT02499315|Experimental|AMG 357|
11330308|NCT02499315|Placebo Comparator|Placebo|
11330343|NCT02499068|No Intervention|COPD, Normal clinical practice|Patients would do the usual clinical practice.
11330344|NCT02499055|Experimental|FearFighter|The experimental group will use the program FearFighter™.
11330345|NCT02499055|No Intervention|Control group|The control group receive no intervention for nine weeks.
11330346|NCT02499042|Experimental|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
11382066|NCT02154971||Control|non-HIV (matched for age and gender)
11330309|NCT02499302|Experimental|Mental training|"The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:
~Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale
~Relaxation: Bodily stress reduction, mindfulness
~Visualization: Contact with positive emotions, techniques of worrying reduction
~Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'
~Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis"
11330310|NCT02499302|No Intervention|Routine follow-up|Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.
11330311|NCT02499276|Experimental|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
11330312|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
11330313|NCT02499250|Experimental|RIPC arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
11330314|NCT02499250|Active Comparator|Control arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
11330315|NCT02499237|Active Comparator|Denosumab|Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
11330316|NCT02499237|Experimental|Denosumab plus zoledronic acid|Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
11330317|NCT02499224|Experimental|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
11330318|NCT02499211|Experimental|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
11330319|NCT02499211|No Intervention|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
11330320|NCT02499185|Experimental|Nephro Check Test|We take urine samples and analyse the level of [TIMP-2]●[IGFBP-7] using the NephroCheck Test to diagnose AKI
11330321|NCT02499185|Active Comparator|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
11330322|NCT02499172|Experimental|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
11330323|NCT02499172|No Intervention|Cohort 2|Cohort 2: Women who received at least one dose and who became pregnant after the mass vaccination campaign; hence their fetuses were not exposed to the vaccine.
11330324|NCT02499172|No Intervention|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
11330325|NCT02499172|No Intervention|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
11330326|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
11330327|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
11330328|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
11330329|NCT02499133|Other|adult who suffered traumatic brain injury|
11330330|NCT02499133|Other|control group|
11330331|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
11330332|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
11330333|NCT02499107|Experimental|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
11330334|NCT02499107|Experimental|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
11330335|NCT02499107|Experimental|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
11330336|NCT02499107|Experimental|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
11330337|NCT02499107|Experimental|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
11330338|NCT02499094|Experimental|Intervention A- Heuristic based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as simple heuristic-based behavioral measures
11330339|NCT02499094|Experimental|Intervention B- Machine Learning Based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as machine learning model-based behavioral measures
11330340|NCT02499094|No Intervention|Control|No intervention
11382067|NCT02154958||Unexplained infertility|
11330348|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
11330349|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
11330350|NCT02499016|Experimental|suprapubic single-incision laparoscopic appendectomy|single incision laparoscopic surgery will be performed for patients in this group.
11330351|NCT02499016|Active Comparator|conventional multiport appendectomy|Conventional laparoscopic surgery will be performed for patients in this group.
11330352|NCT02499003|Experimental|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
11330353|NCT02498990|Experimental|Weight reduction|
11330354|NCT02498977|Active Comparator|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
11330355|NCT02498977|Active Comparator|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
11330356|NCT02498977|Active Comparator|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
11330357|NCT02498951|Experimental|Arm I (obinutuzumab)|Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity
11330358|NCT02498951|Active Comparator|Arm II (observation)|Patients undergo observation for a total of 3 years.
11330359|NCT02498938||SERPINA1 gene in COPD and periodontitis|patients aged between 30-70 yrs with COPD (satisfying Gold's criteria) and chronic periodontitis (>4mm pocket probing depth)
11330360|NCT02498925|Experimental|Behavioral Activation|"12 weeks (1 50-min session per week) of Behavioral Activation for the anhedonic adolescents.
~Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral strategies to improve mood and places little emphasis on cognitive restructuring techniques."
11330361|NCT02498912|Experimental|Cyclophosphamide followed by Autologous T Cells|Cohorts of 3-6 pts will be infused with escalating doses of modified T cells to establish the MTD of modified T cells. There are 5 planned dose levels: 3 x 10^5, 1 x 10^6, 3 x 10^6, & 1 x 10^7 & 3 x 10^7 4H11-28z/fIL-12/EGFRt+ T cells/kg. Cohort I-IV & VI will be treated escalating dose levels. Once the MTD of T cells is established, the next cohort will receive lymphodepleting cyclophosphamide dose of 750 mg/m^2 or a regimen of cyclophosphamide dose 300 mg/m2 x 3 days concurrent with fludarabine dose 25-30 mg/m2 x 3 days 2-7 days prior to starting the T cell infusion at one dose level below the MTD. If MTD isn't established after Cohort IV, Cohort V will receive conditioning chemotherapy 2-7 days prior to starting the T cell infusion at the same dose as Cohort III. Pts in Cohort V received cyclophosphamide chemotherapy on Day 1 or cyclophosphamide concurrent with fludarabine on Day 1-3, followed 2 to 4 days later by T cell infusion. This cohort is closed to further accrual.
11330362|NCT02498899|Experimental|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
11330363|NCT02498899|Experimental|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
11330364|NCT02498886|Experimental|Iron deficient anaemic: IDA|"Iron deficient anaemic women.
~Interventions: two iron supplements will be used:
~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.
~Each compound will be labelled with a stable isotope of iron:
~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.
~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
11330365|NCT02498886|Experimental|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.
~Interventions: two iron supplements will be used:
~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.
~Each compound will be labelled with a stable isotope of iron:
~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.
~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
11330366|NCT02498886|Experimental|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.
~Interventions: two iron supplements will be used:
~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.
~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.
~Each compound will be labelled with a stable isotope of iron:
~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.
~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
11330367|NCT02498873|Active Comparator|Linear Periodization|Linear Periodization Running (Crossover Design)
11330368|NCT02498873|Active Comparator|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
11330369|NCT02498860|Experimental|Pemebit plus Cisplatin|Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles
11330370|NCT02498847|Experimental|ENGAGE intervention|8 in-person weekly treatment sessions with an occupational therapist of 30 minutes - 1 hour duration intervention content provided on website, homework assigned each week after intervention period, monthly calls conducted to check on health status
11330371|NCT02498847|No Intervention|Usual Care|participated in usual care and received monthly calls to check on health status
11330372|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
11330373|NCT02498834|No Intervention|Control group|Standard of care will be used
11330374|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
11330375|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
11330376|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
11330377|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
11330378|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
11330379|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
11330380|NCT02498795|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.
~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
11330381|NCT02498795|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.
~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
11330382|NCT02498795|Placebo Comparator|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
11330383|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 2 weeks|1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)
11330384|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 4 weeks|1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)
11330385|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 8 weeks|1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)
11330386|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 2 weeks|1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)
11330387|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 4 weeks|1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)
11330388|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 8 weeks|1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)
11330389|NCT02498782|Placebo Comparator|Placebo|Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.
11330390|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
11330391|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
11330392|NCT02498756|Experimental|IP plus CIK|Patients receive ipilimumab and CIK.
11330393|NCT02498756|Active Comparator|IP alone|Patients receive ipilimumab alone.
11330394|NCT02498743|Experimental|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
11330395|NCT02498743|No Intervention|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
11330396|NCT02498730|Active Comparator|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
11330397|NCT02498730|Active Comparator|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
11330398|NCT02498730|Sham Comparator|Control|Only Dependent Variables Measures
11330399|NCT02498717|Active Comparator|RICE (control)|Standard of Care procedures including ice and elevation.
11330400|NCT02498717|Experimental|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
11330401|NCT02498704|Sham Comparator|Sham Needling intervention, Control|Sham dry needling, group does not receive true dry needling intervention.
11330402|NCT02498704|Experimental|Dry Needling Intervention, experimental|Group receives true dry needling intervention.
11330403|NCT02498691|Experimental|Type exposed|endometriosis
11330404|NCT02498691|Experimental|Type unexposed|Without endometriosis
11330405|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
11330406|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
11330407|NCT02498665|Experimental|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
11330408|NCT02498665|Experimental|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
11330409|NCT02498665|Experimental|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
11330410|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
11330411|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
11330412|NCT02498639|Active Comparator|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
11330413|NCT02498639|Active Comparator|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
11330414|NCT02498626||venous saturations|venous saturations from the central venous line, venous side of the heart lung machine and from the pulmonary artery
11330415|NCT02498613|Experimental|Treatment (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
11330416|NCT02498600|Active Comparator|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
11330417|NCT02498600|Experimental|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
11330418|NCT02498574|Experimental|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
11330419|NCT02498574|Placebo Comparator|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
11330420|NCT02498561|Active Comparator|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
11330421|NCT02498561|Placebo Comparator|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
11330422|NCT02498561|Active Comparator|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
11330423|NCT02498561|Placebo Comparator|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
11330424|NCT02498548|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
11330425|NCT02498548|No Intervention|Unexercised SCI Knee|"Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. This group will serve as unexercised control for the Trained SCI Knee group"
11330426|NCT02498548|Experimental|Trained SCI Knee|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will specifically focus on rehabilitation of the knee joint.
11330427|NCT02498535|Experimental|Nitric oxide gas at 160 ppm|Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
11330428|NCT02498535|Placebo Comparator|Breathing 20.3% oxygen|Breathing 20.3% oxygen inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days.. 100% nitrogen will be injected into the breathing circuit (instead of 99.5% nitrogen and 0.5% NO).
11330429|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
11330430|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
11330431|NCT02498509|Experimental|Treatment|CKD-342
11330432|NCT02498509|Active Comparator|Control 1|Mometasone furoate
11330433|NCT02498509|Active Comparator|Control 2|Levocabastine HCL
11330434|NCT02498496|Experimental|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
11330435|NCT02498496|Placebo Comparator|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
11383969|NCT02142725|Experimental|LT-02|LT-02 0.8g four times daily
11330436|NCT02498483|Experimental|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
11330437|NCT02498483|No Intervention|Non-treatment Arm|Routine circumcision without acetaminophen.
11330438|NCT02498457|Active Comparator|low calcium dialysis|patients in this group will be dialyzed using a dialysate with a calcium concentration 1.25mmol/L.
11330439|NCT02498457|Other|Routine dialysis|Patients in this groups will be dialyzed using routine dialysate with a calcium concentration 1.5mmol/L.
11330440|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
11330441|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
11330442|NCT02498431|Experimental|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
11330443|NCT02498431|Active Comparator|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
11330444|NCT02498431|Active Comparator|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
11330445|NCT02498418|Experimental|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
11330446|NCT02498418|Active Comparator|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
11330447|NCT02498418|Placebo Comparator|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
11330448|NCT02498392|Placebo Comparator|Responders-Placebo|Participants who responded in the placebo lead-in period will be administered with Matching Placebo orally.
11330449|NCT02498392|Experimental|Responders-JNJ-42165279|Participants who responded in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 milligrams (mg) tablets once daily for 6 weeks.
11330450|NCT02498392|Placebo Comparator|Non Responders-Placebo|Participants who did not respond in the placebo lead-in period will be administered with Matching Placebo orally.
11330451|NCT02498392|Experimental|Non Responders-JNJ-42165279|Participants who did not respond in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 mg tablets once daily for 6 weeks.
11330452|NCT02498379|Experimental|Cu[64]-25%CANF-Comb|Single IV injection of 4-8 mCi Cu[64]-25%CANF-Comb followed by PET-CT scan at 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours post injection.
11330453|NCT02498366|Experimental|experimental protocol|50 healthy, male, trained and aged 18-30 will be recruited and asked to undergo a series of physical tests.
11330454|NCT02498353|Experimental|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.
~TME surgery after radiotherapy."
11330455|NCT02498353|Active Comparator|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.
~TME surgery after radiotherapy."
11330456|NCT02498340|Experimental|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
11330457|NCT02498327|Placebo Comparator|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
11330458|NCT02498327|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
11330459|NCT02498314|Experimental|Grade I-II SZ mobilization|Grade I-IISZ hip traction in resting position
11330460|NCT02498314|Experimental|Grade II TZ mobilization|Grade IITZ hip traction in resting position
11330461|NCT02498314|Experimental|Grade III mobilization|Grade III hip traction in resting position
11330462|NCT02498301|Experimental|Rifaximin 550 mg once/day|rifaximin, 550 mg, once daily, by mouth
11330463|NCT02498301|Experimental|Rifaximin 550 mg twice/day|rifaximin, 550 mg, twice daily, by mouth
11330464|NCT02498301|Placebo Comparator|Placebo|Placebo pills, twice daily, by mouth
11330465|NCT02498288|Experimental|Isotretinoin Arm|All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
11330466|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
11330467|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
11330468|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
11330469|NCT02498262|Experimental|Virtual Reality Training System|
11330470|NCT02498249|Experimental|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.
~Individuals will be subject to application of low level laser with a total dose of 18 J"
11331231|NCT02493049|No Intervention|No add on treatment|No add on treatment. Control group
11330471|NCT02498249|Placebo Comparator|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.
~Individuals will be subject to application of low level laser with a total dose of 0 J"
11330472|NCT02498236|Experimental|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
11330473|NCT02498236|Placebo Comparator|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
11330474|NCT02498223|Experimental|research arm|50 subjects (healthy soldiers, male and female) from combat units will undergo the experiment protocol.
11330475|NCT02498210|Experimental|IVF after IVM|"If the patients will not concive during the IVM cycle . results of this following IVF cycle will be compared to the initial IVF preformance
~Intervention : In Vitro Maturation Procedure"
11330476|NCT02498197|Experimental|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
11330477|NCT02498197|Active Comparator|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
11330478|NCT02498184|Experimental|real acupuncture|traditional chinese acupuncture
11330479|NCT02498184|Sham Comparator|sham acupuncture|non effective acupuncture
11330480|NCT02498171|Experimental|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
11330481|NCT02498171|Active Comparator|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
11330482|NCT02498158||experimental protocol|Functional neural connectivity at rest of 3 groups (heat tolerant, heat intolerant and healthy subjects) will be assessed using the anatomical and functional MRI scans and compared.
11330483|NCT02498145|Experimental|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
11330484|NCT02498145|Active Comparator|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
11330485|NCT02498132|Experimental|Behavioral Activation|Behavioral Activation will be administered via Moodivate will mirror the core BA components outlined above. Moodivate will also be modified for a mobile environment in key ways, with the most salient being: 1) Elimination of the need for a therapist: By eliminating the need for a therapist, we will be able to reach a broad patient/consumer base that may not utilize traditional therapy resources and will combat the primary barrier to PCPs recommending psychotherapy to their patients with elevated depressive symptoms and 2) Elimination of paper forms: By eliminating paper forms, we will increase the sensitivity of BA to motivational and organizational deficits frequently observed in patients with elevated depressive symptoms while also increasing treatment fidelity by prompting the patient to complete activities at scheduled times and giving the patient reinforcement for completing activities.
11330486|NCT02498132|Active Comparator|Cognitive Based Therapy|Moodkit will be used to administer cognitive based therapy which is commonly compared to behavioral activation.
11330487|NCT02498132|Active Comparator|Treatment as Usual|TAU will be provided to individuals. These subject will be provided with therapy but will not utilize a mobile application.
11330488|NCT02498119||Normal|Patient sample within the normal range of blood results.
11330489|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
11330490|NCT02498106|Active Comparator|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
11330491|NCT02498106|Placebo Comparator|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
11330492|NCT02498093|Experimental|Maximal strength training|Maximal strength training supervised by a physiotherapist
11330493|NCT02498093|Active Comparator|Control|Conventional rehabilitation supervised by a physiotherapist
11330494|NCT02498080|Experimental|DEB PTA|Devices: paclitaxel drug eluting balloon PTA
11330495|NCT02498080|Active Comparator|standard PTA|devices: standard balloon PTA
11330496|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
11330497|NCT02498054|Experimental|Education with new meter feature.|Subjects experience a computer stimulation of a new meter feature ( colour range indicator) to help subjects interpret whether blood glucose results are low, in-range or high based on accepted guidance.
11330498|NCT02498041|Experimental|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
11330499|NCT02498041|Active Comparator|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
11330500|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
11330501|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
11330502|NCT02498015|Experimental|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
11330503|NCT02498015|Experimental|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
11330504|NCT02498002|Active Comparator|Daily Calorie Restriction (DCR)|During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis.
11330505|NCT02498002|Experimental|Fasting with Weight Loss (IMF-WL)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake).
11330506|NCT02498002|Experimental|Fasting without Weight Loss (IMF-WS)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake).
11330507|NCT02497989|Experimental|Inter-personal Communication (IPC)|Interpersonal communication will entail delivery of intervention massages that are custom-made to address individual participants' specific barriers and facilitators of VMMC. RAs will discuss with uncircumcised men why they have not gone for VMMC using the 'VMMC Demand Creation Toolkit'. The aim will be to fully address their barriers and re-enforce their facilitators. RAS will be trained behavioral counselors, circumcised men, female partners, CHWs, or any other cadre of individuals identified during the formative phase.
11330508|NCT02497989|Experimental|Dedicated Service Outlets (DSO)|RAs shall visit all households with eligible men to inform them about the availability of, and give information on location of DSO sites in the Location. DSOs are sites: where services are offered exclusively to men aged ≥25 years by male service providers in the same age bracket; providing services in the evenings/weekends/designated days of the week, and through special mobile services for older men. DSO sites we will strive to shorten the waiting time to ≤ three hours. They will be informed that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do.
11330509|NCT02497989|Experimental|Combined IPC & DSO|Both Inter-personal Communication (IPC) and Dedicated Service Outlets (DSO) interventions (as described above) will be implemented concurrently. This will be done to determine the effect of both interventions delivered jointly compared to each delivered singly, and compared to no intervention.
11330510|NCT02497989|No Intervention|Control|In these Locations, participants will only be given the 'All You Need to Know About VMMC' booklet at the time of enrollment, which is the standard of care.
11330511|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
11330512|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
11330513|NCT02497963|Experimental|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
11330514|NCT02497963|Active Comparator|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
11330515|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
11330516|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
11330517|NCT02497924|Experimental|GBT440|GBT440 / [C14] GBT440
11330518|NCT02497911|Experimental|Adductor Canal Catheter|Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
11330519|NCT02497911|Experimental|Intraarticular Catheter|Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
11330520|NCT02497898|No Intervention|regular chemotherapy|Patients after chemotherapy are just followed up.
11330521|NCT02497898|Experimental|CIK regimen|Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.
11330522|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
11330523|NCT02497872|Experimental|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
11330524|NCT02497872|Active Comparator|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
11330525|NCT02497859|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:
~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
11330526|NCT02497859|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:
~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
11330588|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
11330589|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
11330590|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
11330527|NCT02497846|Experimental|TEOSYAL® PureSense Redensity [I]/MicronJet®|"injection of the acid hyaluronic gel with lidocaine as an anesthetic and a dermo-restructuring complex (including 8 amino acids , 3 antioxidants Acid, vitamin B6 and 2 minerals).
~Product will be injected in a unique device group:
~in crow's feet in order to cover the zone to be treated. Quantity of product injected will be determined by the injector and noted (up to 1 ml by side). A subject can be injected in the left or/and right side.
~using a MicronJet microneedle for the superficial wrinkles."
11330528|NCT02497833|Placebo Comparator|control|the participants in this arm are instruted to consume placebo capsules
11330529|NCT02497833|Experimental|treatment|the participants in this arm are instruted to consume retinoic acid capsules
11330530|NCT02497820|Active Comparator|100 mg daily aspirin|They will receive one small tablets each day for two years in a blinded fashion
11330531|NCT02497820|Active Comparator|300 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
11330532|NCT02497820|Active Comparator|600 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
11330533|NCT02497794|Active Comparator|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
11330534|NCT02497794|Placebo Comparator|without postoperative chew gum|The control group will be followed without chew gum.
11330535|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
11330536|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
11330537|NCT02497768|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (pistachios or Brazils) on two separate visit days.
11330538|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
11330539|NCT02497742|Active Comparator|Once daily BMP|Patient in this arm will receive once daily basic metabolic panel to monitor electrolytes
11330540|NCT02497742|Active Comparator|Twice daily BMP|Patient in this arm will receive twice daily basic metabolic panel to monitor electrolytes
11330541|NCT02497729|No Intervention|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
11330542|NCT02497729|Active Comparator|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
11330543|NCT02497729|Active Comparator|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
11330544|NCT02497729|Active Comparator|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
11330545|NCT02497716|Experimental|Rivaroxaban|Single arm, open label study
11330546|NCT02497703|Experimental|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
11330547|NCT02497690|Active Comparator|In-person ART|In-person approach to provide ART.
11330548|NCT02497690|Experimental|Telehealth ART|Telemedicine technology approach (e.g. interactive video) to provide ART.
11330549|NCT02497677|Experimental|Circle of Security-Parenting|Circle of Security-Parenting (COS-P) is a brief educative group program for parents
11330550|NCT02497677|Active Comparator|Care as Usual (CAU)|Care as usual (CAU) i.e. the active control condition will be standard practices for infants and families at risk in Copenhagen.
11330551|NCT02497664|Other|Active Breathing Control|Planning-CT will be made of patients using the Active Breathing Control Technique (in expiration and inspiration phase)
11330552|NCT02497651|Experimental|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
11330553|NCT02497651|Experimental|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
11330554|NCT02497638|Experimental|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
11330555|NCT02497638|Placebo Comparator|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
11330556|NCT02497625|Experimental|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
11330557|NCT02497625|Active Comparator|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
11330558|NCT02497625|Other|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
11330559|NCT02497612|Experimental|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams [mg]) oral suspension as follows: BW greater than or equal to (>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW >=24 kg to less than (<) 35 kg: FQ 300 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 200 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 150 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 100 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 75 mg + OZ439 150 mg.
11330616|NCT02497222|Placebo Comparator|Normal Saline|Normal Saline 4 ml, inhaled twice daily by nebulization for 21 days.
11331232|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
11330560|NCT02497612|Experimental|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 600 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 450 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 300 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 225 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 150 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 115 mg + OZ439 150 mg.
11330561|NCT02497612|Experimental|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 900 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 675 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 450 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 335 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 225 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 170 mg + OZ439 150 mg.
11330562|NCT02497612|Experimental|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 1200 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 900 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 600 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 450 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 300 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 225 mg + OZ439 150 mg.
11330563|NCT02497599|Experimental|Intraoperative dual-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW. At day 4 or 5 after antibody injection a whole body planar scan and SPECT/CT scan will be acquired. At day 7 standard of care (partial) nephrectomy will be performed. This will be extended with the use of dual-modality imaging.
11330564|NCT02497586|Experimental|MRS|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.
11330565|NCT02497560|Active Comparator|Treatment|all natural dietary supplement
11330566|NCT02497560|Other|Treatment + Omega-3s|all natural dietary supplement + omega-3s
11330567|NCT02497560|Placebo Comparator|Placebo|vegetable oil
11330568|NCT02497547|Experimental|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
11330569|NCT02497547|Experimental|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
11330570|NCT02497547|Placebo Comparator|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
11330571|NCT02497534||Affected with Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
11330572|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
11330573|NCT02497534||Carriers of Friedreich's ataxia|An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
11330574|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
11330575|NCT02497508|Experimental|Nivolumab|Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg
11330576|NCT02497495|No Intervention|GC|Control group - CG (n = 21), which suffered no recuperative technique
11330577|NCT02497495|Experimental|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
11330578|NCT02497495|Experimental|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
11330579|NCT02497495|Experimental|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
11330580|NCT02497495|Experimental|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
11330581|NCT02497469|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
11330582|NCT02497469|Active Comparator|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
11330583|NCT02497456|Experimental|Follow-up counselling|Participants in the experimental arm will receive home-based HIV counselling and testing and referral for HIV care if found to have HIV infection. Additionally, participants will receive home-based follow-up counselling at 1 and 2 months after HIV diagnosis.
11330584|NCT02497456|No Intervention|Standard of care|Participants in this arm will receive only home-based HIV counselling and testing and referral for HIV care if found to have HIV infection.
11330585|NCT02497443|Experimental|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells
11330586|NCT02497443|No Intervention|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
11330587|NCT02497404|Experimental|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
11330591|NCT02497378|Experimental|JNJ-54767414 (Daratumumab) +Bortezomib+Dexamethasone|Participants will be administered JNJ-54767414 (daratumumab) intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, then on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks), First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles. Bortezomib at a dose of 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle for 8 treatment cycles and Dexamethasone orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles.
11330592|NCT02497365|Experimental|Group A: Besifloxacin|Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
11330593|NCT02497365|Active Comparator|Group B: Fortified Antibiotics|Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.
11330594|NCT02497352|Experimental|Flaxseed|30 g milled brown flaxseed + lifestyle modification
11330595|NCT02497352|Active Comparator|control|lifestyle modification including dietary and physical activity recommendation
11330596|NCT02497339|Experimental|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
11330597|NCT02497339|Experimental|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
11330598|NCT02497326|Active Comparator|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
11330599|NCT02497326|Experimental|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
11330600|NCT02497313|Placebo Comparator|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
11330601|NCT02497313|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
11330602|NCT02497313|Active Comparator|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
11330603|NCT02497313|Active Comparator|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
11330604|NCT02497300|Experimental|Spironolactone|Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.
11330605|NCT02497300|Active Comparator|Amiloride|Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.
11330606|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
11330607|NCT02497274|Experimental|Roux Y gastric bypass|candidates for bariatric surgery by Roux Y gastric bypass with taste assessment and epithelium gustatory smear and biopsy
11330608|NCT02497274|Experimental|Sleeve gastrectomy|candidates for bariatric surgery by sleeve gastrectomy with taste assessment and epithelium gustatory smear and biopsy
11330609|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
11330610|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
11330611|NCT02497248||- Patients with paroxysmal AF.|Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.
11330612|NCT02497248||- Patients with persistent AF.|Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..
11330613|NCT02497248||- Patients with mitral stenosis.|- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..
11330614|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
11330615|NCT02497222|Experimental|RNS60|RNS60 4 ml, inhaled twice daily by nebulization for 21 days.
11331233|NCT02493023|Experimental|navigated bronchoscopy|
11330617|NCT02497196|Experimental|Part 1:Active tPCS, Active tDCS|12 out of the 48 total health subjects will receive active tPCS and active tDCS. This will be done for 20 minutes simultaneously.
11330618|NCT02497196|Experimental|Part 1: Active tPCS, Sham tDCS|12 out of the 48 total health subjects will receive active tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
11330619|NCT02497196|Experimental|Part 1:Sham tPCS, Active tDCS|12 out of the 48 total health subjects will receive sham tPCS and active tDCS. This will be done for 20 minutes simultaneously.
11330620|NCT02497196|Sham Comparator|Part 1: Sham tDCS, Sham tDCS|12 out of the 48 total health subjects will receive sham tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
11330621|NCT02497196|Experimental|Part 2: Active tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and active tDCS (1/4 combinations all subjects will receive).
11330622|NCT02497196|Experimental|Part 2: Active tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and sham tDCS (1/4 combinations all subjects will receive).
11330623|NCT02497196|Experimental|Part 2: Sham tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and active tDCS (1/4 combinations all subjects will receive).
11330624|NCT02497196|Sham Comparator|2: Sham tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and sham tDCS (1/4 combinations all subjects will receive).
11330625|NCT02497183|Experimental|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
11330626|NCT02497170|Other|Life style changes|Pre and post after education intervention Education program
11330627|NCT02497157|Experimental|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
11330628|NCT02497144|Active Comparator|NMES Group|"Intervention: NMES group will receive neuromuscular electrical stimulation using high frequency galvanic stimulation and breathing exercises.
~Neuromuscular electrical stimulation will be applied bilaterally to quadriceps femoris muscle for 3days/6 weeks by a physiotherapist.
~NMES group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
11330629|NCT02497144|Sham Comparator|Control Group|"Sham: Control group will receive breathing exercises. Control group will perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.
~Control group will be followed-up by telephone once a week."
11330630|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
11330631|NCT02497118|Experimental|Endostatin plus NP|drug:Endostatins Intravenous drip， 7.5mg/m^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
11330632|NCT02497118|Active Comparator|NP neoadjuvant chemotherapy|drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
11330633|NCT02497105|Experimental|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
11330634|NCT02497105|No Intervention|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
11330635|NCT02497092|Active Comparator|Slow angled injection|Slow and angled insertion of the needle through the sclera
11330636|NCT02497092|Active Comparator|Slow straight injection|Slow and straight insertion of the needle through the sclera
11330637|NCT02497092|Active Comparator|Fast angled injection|fast and angled insertion of the needle through the sclera
11330638|NCT02497092|Active Comparator|Fast straight injection|fast and straight insertion of the needle through the sclera
11330639|NCT02497079|Experimental|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
11330640|NCT02497079|Experimental|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
11330641|NCT02497079|Experimental|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
11330642|NCT02497066|Placebo Comparator|Neuropathic Pain|Subjects with neuropathic pain will receive a neuropathic pain cream combined of Ketamine 10%/Gabapentin 6%/Clonidine 0.2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
11330643|NCT02497066|Placebo Comparator|Nociceptive pain|Subjects with nociceptive pain will receive a nociceptive pain cream combined of Ketoprofen 10%/Baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
11330644|NCT02497066|Placebo Comparator|Mixed pain|Subjects who have a mixed (nociceptive and neuropathic) pain conditions will receive a mixed pain cream combined of Ketamine 10%/Gabapentin 6%/Diclofenac 3%/baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
11330645|NCT02497053|Experimental|Arm A|Four cycles of pemetrexed/platinum
11330646|NCT02497053|Active Comparator|Arm B|Six cycles of pemetrexed/platinum
11330647|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
11330648|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
11330649|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
11330650|NCT02497027|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
11330651|NCT02497027|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
11330652|NCT02497014|Experimental|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
11330653|NCT02497014|Experimental|2 Stents|Patients who are going to receive 2 stents in both vessels
11330654|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
11330655|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
11330656|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
11330657|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
11330658|NCT02496988|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
11330659|NCT02496988|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
11330660|NCT02496975|Experimental|Cyclosporine A|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
11330661|NCT02496975|Active Comparator|Placebo|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
11330662|NCT02496962|Experimental|Statin group|drug: atorvastatin (Pfizer, U.S.); the frequency: 20mg atorvastatin was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
11330663|NCT02496962|Placebo Comparator|Control group|drug: placebo (Pfizer, U.S.); the frequency: Placebo was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
11330664|NCT02496949|Experimental|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
11330665|NCT02496936|Experimental|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
11330666|NCT02496936|Experimental|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
11330667|NCT02496936|Experimental|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
11330668|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
11330669|NCT02496936|Experimental|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
11330670|NCT02496923|Experimental|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
11330671|NCT02496923|Active Comparator|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
11330672|NCT02496910|Active Comparator|Group 1 - Period 1|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
11330673|NCT02496910|Experimental|Group 2 - Period 1|YH22162 FDC tablet of Yuhan Corporation
11330674|NCT02496910|Experimental|Group 1 - Period 2|YH22162 FDC tablet of Yuhan Corporation
11330675|NCT02496910|Active Comparator|Group 2 - Period 2|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
11330676|NCT02496897|Experimental|FP-02.2 Low Dose|A low dose of the FP-02.2 vaccine.
11330677|NCT02496897|Experimental|FP-02.2 High Dose|A high dose of the FP-02.2 vaccine.
11330678|NCT02496897|Experimental|FP-02.2 Low Dose with IC31® Adjuvant|A low dose of the FP-02.2 vaccine with IC31® Adjuvant.
11330679|NCT02496897|Experimental|FP-02.2 High Dose with IC31® Adjuvant|A high dose of the FP-02.2 vaccine with IC31® Adjuvant.
11330680|NCT02496897|Placebo Comparator|Placebo|Placebo component.
11330681|NCT02496897|Experimental|IC31® Adjuvant|IC31® Adjuvant alone.
11330682|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
11330683|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
11330684|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
11330685|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
11330686|NCT02496871|Active Comparator|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
11330687|NCT02496871|Experimental|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
11330688|NCT02496858||Early-onset CAD|The anticipated 2000 young CAD patients who aged ≤45years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
11330689|NCT02496858||Late-onset CAD|The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
11330690|NCT02496858||Age-matched controls|The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
11330691|NCT02496845|Experimental|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
11330692|NCT02496845|Experimental|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
11330693|NCT02496832|Experimental|FAZA PET-CT scan|"FAZA PET-CT imaging within 14 days of treatment from the EMR200592-001 study.
~FAZA PET-CT imaging about 5 weeks after start of treatment from the EMR200592-001 study."
11330694|NCT02496819|Experimental|Metacognitive self-regulated learning intervention|It involves training of daily tasks using a self-correct strategy. Participants' performance will be video-taped and they will then watch the video playback for reflection and self-correction under the guidance of the occupational therapist.
11330695|NCT02496819|Experimental|Sensory Integration intervention|It involves active, fun physical activity completing 8 stations of activities involving tactile, proprioceptive and vestibular tasks. Frequent breaks will be given to avoid exhaustion and fatigue throughout the activities.
11330696|NCT02496819|Active Comparator|Activity-Based Intervention|It provides constructional, drawing and crafts activity. Participants are guided to complete these tasks
11330697|NCT02496806|Experimental|Treatment|400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)
11330698|NCT02496793|Experimental|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
11330699|NCT02496793|No Intervention|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
11330700|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
11330701|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
11330702|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
11330703|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
11330704|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
11330705|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
11330706|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
11330707|NCT02496754|Experimental|New protocol group|Use long term GnRH-a 3.75mg at day 2 of menstrual cycle. Around 30 days later, controlled ovarian hyperstimulation using gonadotropins is initiated.
11330708|NCT02496754|Active Comparator|Standard GnRH-a long protocol|Use short GnRH-a 0.1mg at luteal phase of last menstrual cycle for 10 days and 0.05mg for another 4 days. Once pituitary down regulation is achieved,controlled ovarian hyperstimulation using gonadotropins is initiated. During ovarian stimulation, short GnRH-a is used daily at the dose of 0.05mg until human chorionic gonadotrophin (HCG) trigger.
11330709|NCT02496741|Experimental|Metformin and chloroquine combination|"Metformin will be administered in a 3+3 dose-escalation schedule.
~Chloroquine will be administered in a fixed dose."
11330710|NCT02496728|Experimental|Cardiovascular Health|Participants will be given the results of their health assessment and feedback regarding their health behaviors and overall health. Recommendations for change will be given if warranted. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor health behaviors that are not already at ideal levels using the study application (environmental cues). Participants will be asked to join a secret Facebook group where informational materials will be posted, participants can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
11331433|NCT02491580||KTx Europe|Patients who have received a kidney transplant in Uppsala.
11330711|NCT02496728|Active Comparator|Whole Health|Participants will be given the results of their health assessment. They will then receive educational materials about sunscreen use, safe sex, hydration and vehicular safety. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor how much water they drink using the study application. Participants will be asked to join a secret Facebook group where informational materials will be posted, they can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
11330712|NCT02496715|Experimental|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
11330713|NCT02496715|Experimental|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
11330714|NCT02496715|Placebo Comparator|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
11330715|NCT02496702|Experimental|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.
~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
11330716|NCT02496702|No Intervention|Control|No training.
11330717|NCT02496676|Active Comparator|magnesium threonate|Participants will receive 12 weeks of magnesium threonate and 12 weeks of placebo. Will be dose escalated based on weight.
11330718|NCT02496676|Placebo Comparator|Placebo|Participants will receive 12 weeks of placebo and 12 weeks of magnesium threonate
11330719|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11330720|NCT02496650|Experimental|Group D|Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
11330721|NCT02496650|No Intervention|Group C|Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
11330722|NCT02496637|Experimental|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
11330723|NCT02496637|Active Comparator|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
11330724|NCT02496637|No Intervention|No Treatment Control|No intervention, assessment only
11330725|NCT02496624|Other|Lung cancer|
11330726|NCT02496611|Experimental|Meal Replacement Therapy|A short-term (1-3 month) meal replacement induction period design to achieve ≥5% BMI reduction. If participants achieve ≥5% BMI they will be randomized to drug or placebo in phase 2 of the trail.
11330727|NCT02496611|Placebo Comparator|Weight Loss Maintenance with Pharmacotherapy|We hypothesize that adolescents with severe obesity receiving GLP-1RA treatment following a short-term meal replacement induction period will demonstrate superior maintenance of initial BMI reduction 52 weeks following randomization compared to those assigned to placebo (primary endpoint) and that a higher proportion of those assigned to GLP-1RA treatment vs. placebo will maintain ≥5% BMI reduction from baseline to the 52-week time point (secondary endpoint)
11330728|NCT02496598|Experimental|In Vitro Follicle Activation (IVA)|Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.
11330729|NCT02496585|Experimental|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
11330730|NCT02496585|Experimental|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
11330731|NCT02496572||Short-course MDR-TB regimen patients|"Short course MDR-TB treatment regimen. New presumptively diagnosed MDR TB patients (adults and children) with Xpert® MTB/RIF or Hain MTBDR, or confirmed with Hain MTBDR plus on positive cultures if initial molecular tests negative or confirmed from MGIT culture/DST if initial molecular tests negative;
~Children (<14 years old) suspected of MDR TB without bacteriological confirmation but documented as a close contact of a confirmed MDR TB patient"
11330732|NCT02496559|Active Comparator|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
11330733|NCT02496559|No Intervention|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
11330734|NCT02496546|Experimental|LEO 32731 cream|Topical application
11330735|NCT02496546|Placebo Comparator|LEO 32731 cream vehicle|Topical application
11330736|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
11330814|NCT02495935|Sham Comparator|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
11330737|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
11330738|NCT02496520|Experimental|Vaccines with autologous dendritic cells|Vaccines with autologous dendritic cells
11330739|NCT02496507|Experimental|Intervention|Provision of a sit-stand workstation for use at work.
11330740|NCT02496507|No Intervention|Control|Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
11330741|NCT02496494|Experimental|Tacrolimus conversion group|Cyclosprine was converted to tacrolimus in kidney transplant recipients.
11330742|NCT02496481|Experimental|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
11330743|NCT02496481|Experimental|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
11330744|NCT02496481|Experimental|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
11330745|NCT02496481|No Intervention|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.
~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
11330746|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
11330747|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
11330748|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
11330749|NCT02496442|Active Comparator|using Aqueduct|Patients passing procedures with Aqueduct
11330750|NCT02496442|No Intervention|Not using Aqueduct|Patients passing the standard procedures
11330751|NCT02496429|Other|BrownieForSymphony use|Each participant will use the BrownieForSymphony pumpset
11330752|NCT02496416|Experimental|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Randolph, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
11330753|NCT02496416|Active Comparator|Control|The control group will participate in an eight week stretching program during weeks 2-9 of the study. The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
11330754|NCT02496403|Experimental|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
11330755|NCT02496403|No Intervention|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
11330756|NCT02496390|Placebo Comparator|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).
~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
11330757|NCT02496390|Active Comparator|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).
~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
11330758|NCT02496377|Active Comparator|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
11330759|NCT02496377|Experimental|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
11330760|NCT02496364|Active Comparator|Group A|"Patients undergoing PLIF will be randomized for Intravenous and topical application of tranexamic acid.
~Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 5mg/ml for Intravenous infusion;
~Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 30mg/ml topical application."
11330761|NCT02496364|Placebo Comparator|Group B|"Patients undergoing PLIF will be randomized for Intravenous infusion of tranexamic acid and topical application of placebo (i.e. saline solution 0,9%)
~Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 5mg/ml for Intravenous infusion;
~Placebo for topical application, up to 100ml"
11330762|NCT02496364|Placebo Comparator|Group C|"Patients undergoing PLIF will be randomized for topical application of tranexamic acid and intravenous infusion of placebo (i.e. saline solution 0,9%)
~Tranexamic acid diluted in saline solution 0,9 to reach a concentration of 30mg/ml for topical application;
~Placebo for intravenous infusion, up to 500ml"
11330763|NCT02496364|Placebo Comparator|Group D|"Patients undergoing PLIF will be randomized for Intravenous and topical application of placebo (i.e. saline solution 0,9%).
~Placebo for intravenous infusion, up to 500ml;
~Placebo for topical application, up to 100ml."
11330764|NCT02496351|Active Comparator|TENS INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours. The intensity of the impulse will be determined in a test carried out 3 days before surgery. The other parameters will be continuous, biphasic, compensated and symmetric impulse, frequency of 80 Hz, time impulse between 250 and 290 microseconds, modulation time 5´´
11330765|NCT02496351|Placebo Comparator|TENS NO INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours, but in this case TENS just will be on. No intensity impulse should be programmed.
11330766|NCT02496338|Experimental|Intervention group|Training program about menopausal health isues
11330767|NCT02496338|No Intervention|Control group|No training program about menopausal health isues
11330768|NCT02496325|Other|perineal technic|
11330769|NCT02496312|Experimental|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
11330770|NCT02496299|Active Comparator|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
11330771|NCT02496299|Active Comparator|Bupivacaine,B|B ,1ml/kg bupivacaine:
11330772|NCT02496286|Experimental|Eligible patients requiring paracentesis for symptom control|
11330773|NCT02496273|Experimental|CEA Specific CTL|Patients receiving CEA-specific CTLs as therapy for Gastric Cancer
11330774|NCT02496247|Experimental|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
11330775|NCT02496247|No Intervention|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
11330776|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
11330777|NCT02496208|Experimental|Part I (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 22 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity.
11330778|NCT02496208|Experimental|Part II (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of 4 cycles with ipilimumab, patients continue receiving cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 21 cycles in the absence of disease progression or unacceptable toxicity. After 26 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity.
11330779|NCT02496182|Placebo Comparator|Placebo|Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.
11330780|NCT02496182|Experimental|Pirfenidone 1800 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day
11330781|NCT02496182|Experimental|Pirfenidone 1200 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day
11330782|NCT02496169|Experimental|eucaLimus|Percutaneous Coronary Intervention (PCI)
11330815|NCT02495922|Active Comparator|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
11330954|NCT02495038|Experimental|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
11330783|NCT02496156|Active Comparator|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
11330784|NCT02496156|Experimental|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
11330785|NCT02496143|Experimental|Cohort 1|500 mg EC-18 dose or placebo
11330786|NCT02496143|Experimental|Cohort 2|1000 mg EC-18 dose orplacebo
11330787|NCT02496143|Experimental|Cohort 3|2000 mg EC-18 dose or placebo
11330788|NCT02496143|Experimental|Cohort 4|4000 mg EC-18 dose or placebo
11330789|NCT02496130||minilaparotomy|Subjects in this group will have tissue (uterus) extracted via mini-laparotomy incision with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
11330790|NCT02496130||vaginal extraction|Subjects in this group will have tissue (uterus) extracted via vaginal extraction with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
11330791|NCT02496117|Active Comparator|RNS-checked RDN|20 patients with hypertension will be enrolled undergoing RNS-checked RDN
11330792|NCT02496117|Experimental|RNS-guided RDN|20 patients with hypertension will be enrolled undergoing RNS-guided RDN
11330793|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
11330794|NCT02496104||Term newborns|Infant born at term
11330795|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
11330796|NCT02496078|Active Comparator|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week
~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
11330797|NCT02496078|Placebo Comparator|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week
~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
11330798|NCT02496065|Experimental|BLZ-100|
11330799|NCT02496052|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
11330800|NCT02496052|Sham Comparator|Foley catheter balloon only|patients, who are with IUA, treated by uterine application of Foley balloon only+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
11330801|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
11330802|NCT02496026|Experimental|tDCS plus wrist robot therapy|In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
11330803|NCT02496026|Sham Comparator|Sham tDCS plus wrist robot therapy|Group B is treated as Group A, but tDCS, even if the cap is applied on the patient head, is not activated and no current is delivered.
11330804|NCT02496013|Experimental|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:
~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30~45min after the injection.
~Patients for lymph node imaging:
~The patients were locally injected 10~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
11330805|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
11330806|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
11330807|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
11330808|NCT02495974||Patients with mCRPC prescribed enzalutamide|Oral
11330809|NCT02495961||Low risk population|Colombian children, between 6 and 12 years old, regular students of a Primary school.
11330810|NCT02495961||High risk population|Mexican children, between 6 and 12 years old, regular students of a Primary school.
11330811|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
11330812|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
11330813|NCT02495935|Experimental|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
11330951|NCT02495051||single group-study|
11330816|NCT02495922|Experimental|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
11330817|NCT02495922|Experimental|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
11330818|NCT02495922|Experimental|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
11330819|NCT02495896|Experimental|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11330820|NCT02495896|Experimental|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11330821|NCT02495896|Experimental|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11330822|NCT02495883|Other|Essential Tremor Group|"50ml of 40% ethanol will be administered to participants diagnosed with Essential Tremor.
~Propranolol SR 60-120mg will be administered daily to participants over an estimated period of two weeks."
11330823|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers
11330824|NCT02495870|Experimental|Pork, 58°C, 72 minutes|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 72 minutes
11330825|NCT02495870|Experimental|Pork, 58°C, 17 hours|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 17 hours
11330826|NCT02495870|Experimental|Meat balls, 58°C, 17 hours|Meat balls made from pork Semitendinosus. Sous-vide cooked at 58°C for 17 hours
11330827|NCT02495870|Active Comparator|Pork, 160°C (until 58°C in core)|Pork muscle (semitendinosus) oven cooked at 160°C until 58° in core.
11330828|NCT02495857|Experimental|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
11330829|NCT02495857|Active Comparator|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
11330830|NCT02495857|Placebo Comparator|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
11330831|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
11330832|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
11330833|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
11330834|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
11330835|NCT02495818|Experimental|Lidocaine|Suprascapular nerve block with infusion of 5ml lidocaine at 2%, guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
11330836|NCT02495818|Sham Comparator|Saline solution|Intervention with suprascapular nerve block with 5ml saline solution guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
11330837|NCT02495805|Active Comparator|adductor canal block (ACB)|Subjects randomized to this groups receive a continuous proximal adductor canal block (ACB) during surgery.
11330838|NCT02495805|Active Comparator|femoral nerve block (FNB)|Subjects randomized to this groups receive a continuous femoral nerve block (FNB) during surgery.
11330839|NCT02495792|No Intervention|Control group|Group does not receive the biofeedback sensor
11330840|NCT02495792|Experimental|Biofeedback group|Group does receive the biofeedback sensor
11330841|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
11330842|NCT02495766|Experimental|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
11330843|NCT02495766|Experimental|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
11330844|NCT02495753|Experimental|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
11330845|NCT02495753|Active Comparator|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
11330846|NCT02495740|Experimental|E-bike intervention|Intervention is active commuting to work by an electric assisted bike to work for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
11330847|NCT02495740|Active Comparator|Bike intervention|Intervention is active commuting to work by classic bike for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
11330848|NCT02495727|Experimental|Control Group|This group will undertake two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
11330849|NCT02495727|Experimental|Pre-Training Group|This group will undertake four weeks of strength training exercise (10 sessions) before two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
11330952|NCT02495038|No Intervention|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium
~ED95, dose causing on average 95% suppression of neuromuscular response."
11330850|NCT02495727|Experimental|Exercise Snacking Group|This group will undertake home-based 'exercise snacks' of simple lower limb movement (5 minutes, 3 times a day) whilst undertaking two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
11330851|NCT02495714|Experimental|Intervention schools|Active Learning; One hour each schoolday of physical Activity as part of academic learning Dietary councelling; teaching children and parents about a healty diet
11330852|NCT02495714|No Intervention|Control schools|No intervention
11330853|NCT02495701||Patients|Patients having Hip arthroscopic surgery
11330854|NCT02495688|Experimental|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
11330855|NCT02495688|Active Comparator|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
11330856|NCT02495675|No Intervention|No flow|Subjects will be spontaneously breathing in room air with no flow.
11330857|NCT02495675|Experimental|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
11330858|NCT02495675|Experimental|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
11330859|NCT02495675|Experimental|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
11330860|NCT02495675|Experimental|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
11330861|NCT02495662|Experimental|Liposomal prednisolone|Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
11330862|NCT02495662|Placebo Comparator|Placebo|Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
11330863|NCT02495649|Other|[18F]-DOPA|evaluate the added value of PET-CT with [18F]-DOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.
11330864|NCT02495636|Experimental|Safety Run Up Group|The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
11330865|NCT02495636|Experimental|Expanded Trial Group|If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
11330866|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
11330867|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
11330868|NCT02495623|Placebo Comparator|Placebo|Placebo
11330869|NCT02495610|Other|Gait analysis and MRI|"Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.
~MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
11330870|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
11330871|NCT02495597||Control Group|age- and sex matched to subject-group
11330872|NCT02495584|Experimental|Treatment 1|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
11330873|NCT02495584|Experimental|Treatment 2|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (placebo) daily for 24 weeks
11330874|NCT02495584|Experimental|Treatment 3|500ml unfortified milk (placebo) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
11330875|NCT02495584|Placebo Comparator|Treatment 4|500ml unfortified milk (placebo) +1 supplement capsule (placebo) daily for 24 weeks
11330876|NCT02495571|Experimental|ALS Patients|Study Group: Evaluation of the cough reflex and the voluntary cough by spirometer and nebulizer
11330877|NCT02495571|Other|Healthy Subjects|Control group matched by aged and sex with the study group
11330878|NCT02495558|Experimental|Patients with Tracheostomy|Assessment of reflex cough Assessment of the deccanultation outcome (follow-up)
11330879|NCT02495545|Experimental|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
11330880|NCT02495545|Active Comparator|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
11330953|NCT02495038|Experimental|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
11330881|NCT02495532|Active Comparator|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.
~Intervention A: Carnoy solution Intervention B: GEWF solution"
11330882|NCT02495532|Active Comparator|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.
~Intervention A: Carnoy solution Intervention B: GEWF solution"
11330883|NCT02495519|Experimental|imatinib|Imatinib 400 mg/day until disease progression
11330884|NCT02495506|Experimental|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
11330885|NCT02495506|Active Comparator|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
11330886|NCT02495493|Experimental|Induction DCS chemotherapy|"Induction chemotherapy -- S-1 35mg/m2 bid day 1-14
~Docetaxel 30 mg/m2 day1, 8
~Cisplatin 30 mg/m2 day1, 8
~Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy"
11330887|NCT02495480|Experimental|sheathed group|The sterilized disposable sheath covered the outer surface of the colonoscope, then colonoscope will be performed in conventional way;a new sheath will be placed on the endoscope in sheathed group as a intervention
11330888|NCT02495480|No Intervention|conventional group|Colonoscopy will be performed with air insufflation during insertion
11330889|NCT02495467|Experimental|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
11330890|NCT02495467|Experimental|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
11330891|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).
~GA101-miniCHOP regimen:
~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os
~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
11330892|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
11330893|NCT02495428|Experimental|Kinesio Tape Group|muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method
11330894|NCT02495428|No Intervention|Control group|They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention
11330895|NCT02495415|Experimental|Fenretinide emulsion|Patients enrolled will receive 600 mg fenretinide/m2/day on Day 1, followed by 1200 mg fenretinide/m2/day on Days 2 - 5 as a continuous intravenous infusion via central line over 5 days. Cycles are repeated every 3 weeks.
11330896|NCT02495402|No Intervention|No Intervention: Control|No Intervention
11330897|NCT02495402|Experimental|Motivational Interviewing|A brief interview intervention for substance abuse
11330898|NCT02495389|Experimental|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
11330899|NCT02495376|Active Comparator|Group A|Group A participates in the first available MBSR course.
11330900|NCT02495376|Active Comparator|Group B|Group B waits 16 weeks before participating in the MBSR course.
11330901|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.
~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
11330902|NCT02495350||Initially didn't want an epidural and didn't receive one.|
11330903|NCT02495350||Initially didn't want an epidural and did receive one.|
11330904|NCT02495350||Initially wanted an epidural and didn't received one|
11330905|NCT02495350||Initially wanted an epidural and did receive one.|
11330906|NCT02495337||TIssue Collection|Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
11330907|NCT02495324|Experimental|Fimasartan|Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
11330908|NCT02495324|Active Comparator|Valsartan|Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
11330909|NCT02495324|Other|Olmesartan medoxomil|Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks
11330910|NCT02495311||Women with uterine myoma|Women with uterine myoma
11330911|NCT02495311||Women with adenomyosis|Women with adenomyosis
11330912|NCT02495311||Women without uterine myoma or adenomyosis|Control group
11330913|NCT02495298|Experimental|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
11330914|NCT02495298|Sham Comparator|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
11330915|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
11330916|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
11330917|NCT02495272|Active Comparator|Control Group|Oxytocin 10IU im was administered after placental delivery
11330918|NCT02495272|Experimental|Study Group|Oxytocin 10IU im was administered after the anterior shoulder could be seen.
11330919|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
11330920|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
11330921|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
11330922|NCT02495246|Active Comparator|Group 1|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 28 days later.
11330923|NCT02495246|Active Comparator|Group 2|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 28 days later.
11330924|NCT02495246|Active Comparator|Group 3|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 56 days later.
11330925|NCT02495246|Active Comparator|Group 4|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 56 days later.
11330926|NCT02495233|Experimental|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
11330927|NCT02495233|Experimental|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
11330928|NCT02495220|Experimental|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
11330929|NCT02495220|Experimental|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
11330930|NCT02495207|No Intervention|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
11330931|NCT02495207|Experimental|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
11330932|NCT02495194|Experimental|Active Horticultural Therapy|15 sessions of Horticultural Therapy program teaching the elderly about gardening techniques and for them to benefit from the therapeutic effects of the parks
11330933|NCT02495194|Other|Waitlist Control Group|Participants will receive the same horticultural therapy program at the end of the assessments
11330934|NCT02495181|Sham Comparator|Aflibercept Monotherapy|IVT Aflibercept 2 mg + Sham PDT
11330935|NCT02495181|Active Comparator|Aflibercept + verteporfin PDT|IVT Aflibercept 2 mg + Verteporfin PDT
11330936|NCT02495168|Experimental|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
11330937|NCT02495168|Active Comparator|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
11330938|NCT02495168|Placebo Comparator|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
11330939|NCT02495155|Active Comparator|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
11330940|NCT02495155|Active Comparator|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
11330941|NCT02495155|Active Comparator|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
11330942|NCT02495129|Experimental|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
11330943|NCT02495129|Experimental|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
11330944|NCT02495103|Experimental|1|Phase I Component
11330945|NCT02495103|Experimental|2|Phase II Component
11330946|NCT02495090|Other|Hypospadias|Familial hypospadias trios (patients + parents)
11330947|NCT02495077|Experimental|Experimental Arm|rATG is co-administered with anti-TNFa (infliximab/Remicade®) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
11330948|NCT02495077|Active Comparator|Control group|Rabbit anti-thymocyte globulin (rATG/Thymoglobulin®) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
11330949|NCT02495064|Experimental|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.
~MF Brief introduction:
~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.
~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.
~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
11330950|NCT02495064|No Intervention|Chemoradiotherapy|conventional Chemoradiotherapy only
11330955|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
11330956|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
11330957|NCT02495012|Placebo Comparator|control|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
11330958|NCT02495012|Active Comparator|treatment|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
11330959|NCT02494999|Experimental|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
11330960|NCT02494999|Active Comparator|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
11330961|NCT02494986|Experimental|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other antiretrovirals (ARVs).
11330962|NCT02494973|Active Comparator|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:
~Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
~Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
11330963|NCT02494973|Experimental|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:
~Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,
~Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
11330964|NCT02494960|Placebo Comparator|Control Group|The doctor will offer a placebo intervention.
11330965|NCT02494960|Experimental|Intervention Group A|"The doctor will offer the brief smoking cessation AWARD model .
~At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model ."
11330966|NCT02494960|Experimental|Intervention Group B|The doctor will offer the brief smoking cessation AWARD model.
11330967|NCT02494947|Experimental|interval training|high intensity interval-based aerobic exercise
11330968|NCT02494947|Other|controls|usual care
11330969|NCT02494934|Experimental|Cognitive-behavioural therapy|Eight sessions of psychotherapy incorporating cognitive-behavioural and sex therapy interventions.
11330970|NCT02494934|Experimental|physical therapy|Eight sessions of physical therapy targeting the pelvic floor muscles.
11330971|NCT02494921|Experimental|Treatment|Docetaxel: 75 mg/m^2; Day 1 of 21-Day Cycle Ribociclib: 200 mg/day; Days 2-14 of 21-Day Cycle Prednisone: 5 mg, oral, twice a day Filgrastim: as clinically indicated
11330972|NCT02494921|Experimental|Alternate Treatment|Docetaxel: 35 mg/m^2; Days 1, 8 , 15 of 21-Day Cycle Ribociclib: 200 mg/day; Days 2-14 of 21-Day Cycle Prednisone: 5 mg, oral, twice a day Filgrastim: as clinically indicated
11330973|NCT02494908|Active Comparator|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
11330974|NCT02494908|Active Comparator|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
11330975|NCT02494895|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
11330976|NCT02494895|Active Comparator|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
11330977|NCT02494882|Experimental|Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone|"Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).
~Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.
~Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.
~Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.
~Or, post-remission induction (consolidation) therapy to be determined per the treating physician"
11330978|NCT02494869|Experimental|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
11330979|NCT02494869|Experimental|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
11331008|NCT02494674|Experimental|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
11331009|NCT02494661|Experimental|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
11330980|NCT02494869|Experimental|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
11330981|NCT02494869|Active Comparator|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
11330982|NCT02494856|Experimental|Surgery with Naproxen|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg.
11330983|NCT02494856|Experimental|Surgery with Naproxen and Esomeprazole|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg and esomeprazole 20mg.
11330984|NCT02494843|Active Comparator|Online haemodiafiltration|
11330985|NCT02494843|Active Comparator|Haemodialysis|
11330986|NCT02494830|Experimental|ketamine 5 mg intravenous|
11330987|NCT02494830|Experimental|ketamine 10 mg oral|
11330988|NCT02494830|Experimental|ketamine 20 mg oral|
11330989|NCT02494830|Experimental|ketamine 40 mg oral|
11330990|NCT02494830|Experimental|ketamine 80 mg oral|
11330991|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
11330992|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
11330993|NCT02494804|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
11330994|NCT02494804|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
11330995|NCT02494791|Other|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
11330996|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
11330997|NCT02494765|Active Comparator|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
11330998|NCT02494765|Active Comparator|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
11330999|NCT02494752|Experimental|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
11331000|NCT02494752|Active Comparator|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
11331001|NCT02494739|Experimental|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
11331002|NCT02494739|Placebo Comparator|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
11331003|NCT02494726||Ischemic Stroke|Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
11331004|NCT02494726||Healthy Controls|Healthy controls who have had their blood analyzed using thromboelastography (TEG)
11331005|NCT02494726||Hemorrhagic Stroke|Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
11331006|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
11331007|NCT02494700|Experimental|Treatment (low dose orbital EBRT)|Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
11331120|NCT02493894|Sham Comparator|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
11331010|NCT02494661|Active Comparator|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
11331011|NCT02494648|Experimental|Inspiratory muscles strengthening|"The device used is : POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK).
~Class I, CE labelled. POWERbreathe fitness Plus uses the technique of training against resistance to increase the strength, the power and the endurance of the respiratory muscles (diaphragm and rib cage)."
11331012|NCT02494648|Placebo Comparator|Control|No intervention
11331013|NCT02494635||Diagnostic (ultrasound, biomarker studies)|Previously collected tumor tissue samples, bladder washings, and urine cells are stained with calcium dye, washed and immersed in external buffer solution, and then transferred to the ultrasound imaging system. Tissue, bladder wash cells and urine cells samples are also analyzed for biomarkers of invasiveness derived from or related to REST gene via qRT-PCR, Western blot, and FISH.
11331014|NCT02494609|Experimental|Treatment A|once daily dosing for 7 days, followed by 7-day washout
11331015|NCT02494609|Experimental|Treatment B|once daily dosing for 28 days
11331016|NCT02494609|Experimental|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
11331017|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
11331018|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
11331019|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
11331020|NCT02494583|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
11331021|NCT02494583|Experimental|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
11331022|NCT02494583|Placebo Comparator|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
11331023|NCT02494570|Experimental|ABI-009|
11331024|NCT02494544|Active Comparator|ConforMIS iTotal Knee replacement|iTotal patient-specific knee replacement system
11331025|NCT02494544|Active Comparator|DePuy total knee replacement|Off the shelf knee replacement system
11331026|NCT02494544|Active Comparator|Zimmer total knee replacement|Off the shelf knee replacement system
11331027|NCT02494544|Active Comparator|Biomet total knee replacement|Off the shelf knee replacement system
11331028|NCT02494544|Active Comparator|Smith & Nephew total knee replacement|Off the shelf knee replacement system
11331029|NCT02494544|Active Comparator|Stryker total knee replacement|Off the shelf knee replacement system
11331030|NCT02494531|Other|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
11331031|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:
~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
~45 minutes of upper extremity repetitive arm exercises"
11331032|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:
~45 minutes of cycling on a recumbent stationary bike at your self-selected speed
~45 minutes of upper extremity repetitive arm exercises"
11331033|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:
~45 minutes of stroke education
~45 minutes of upper extremity repetitive arm exercises"
11331034|NCT02494505|Experimental|mycophenolate mofetil|
11331035|NCT02494505|Placebo Comparator|placebo|placebo pills
11331036|NCT02494492|Experimental|IVT of regulator T-cells|intravitreous administration of regulator T-cells
11331037|NCT02494479|Active Comparator|50mg of Purisol daily|One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
11331038|NCT02494479|Active Comparator|100mg of Purisol daily|One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
11331039|NCT02494479|Active Comparator|200mg of Purisol daily|Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
11331040|NCT02494479|Placebo Comparator|Placebo daily|Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
11331041|NCT02494466|Active Comparator|Group E (n=10)|Patients with high Ig E levels
11331042|NCT02494466|Active Comparator|Group C (n=10)|Patients with normal Ig E levels
11331043|NCT02494466|Active Comparator|Group M (n=10)|Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE
11331044|NCT02494453||Cardiac MRI|
11331045|NCT02494427|Experimental|1|CAD/CAM manufactured fixed unitary dental prostheses
11331046|NCT02494427|Active Comparator|2|Conventionally manufactured unitary dental prostheses
11331047|NCT02494414||French prospective cohort of cardiac arrest survivors|Outcome of cardiac arrest survivors: prospective cohort of Ile-de-France
11331048|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
11331049|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
11331050|NCT02494388||Serous cystadenoma|Serous cystadenoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
11331051|NCT02494388||Mucinous cystic neoplasms|Mucinous cystic neoplasms patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
11331052|NCT02494388||Intraductal papillary mucinous neoplasms (IPMN)|IPMN patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
11331053|NCT02494388||Mucinous cystdenocarcinoma|Mucinous cystadenocarcinoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
11331054|NCT02494388||Other cystic lesions|Other cystic lesions patients (cystic neuroendocrine tumors, solid pseudopapillary neoplasms, cystic lymphangioma, etc.) Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients..
11331055|NCT02494375|Experimental|Sleep and glucose assessement.|
11331056|NCT02494362|Experimental|Experimental Group|Computer gaming hand exercise regimen.
11331057|NCT02494349|Experimental|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
11331058|NCT02494349|Experimental|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
11331059|NCT02494336|Active Comparator|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
11331060|NCT02494336|Active Comparator|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
11331061|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
11331062|NCT02494310|Experimental|HRME - Prevention Mobile Unit|Procedures to be done in the mobile unit (van): Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
11331063|NCT02494310|Experimental|HRME - Barretos Cancer Hospital|Procedures to be done at Barretos Cancer Hospital: Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
11331064|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
11331065|NCT02494284|Experimental|Short term dual therapy|
11331066|NCT02494284|Active Comparator|Long term dual therapy|
11331067|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
11331068|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
11331069|NCT02494258|Experimental|Oral Azacitidine (CC-486)|This study is an open-label, single-arm study and is divided into the screening period, treatment period and follow-up period. It is intended to evaluate the long-term safety of CC-486 and is to be taken at the same dose, schedule and frequency used from the last dose of CC-486 given in the parent study.
11331070|NCT02494245|Active Comparator|Intervention|128 participants will take part in the STARFISH intervention
11331071|NCT02494245|No Intervention|Control|Participants allocated to the control group will be given a booklet with general advice on physical activity.
11331072|NCT02494232||minor blunt thoracic trauma patient|demographic data, physical examination findings
11331073|NCT02494219|Experimental|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
11331074|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
11331075|NCT02494193|Active Comparator|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
11331076|NCT02494193|Experimental|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
11331077|NCT02494180|Placebo Comparator|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
11331078|NCT02494180|Placebo Comparator|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
11331079|NCT02494167|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
11331080|NCT02494167|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
11331081|NCT02494154|Active Comparator|Conventional flow via nasal prongs|Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.
11331514|NCT02490995|No Intervention|Group A|Information given by the anaesthetist during the consultation
11331082|NCT02494154|Experimental|High flow nasal cannulas 20L/min|Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
11331083|NCT02494154|Experimental|High flow nasal cannulas 40L/min|Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
11331084|NCT02494154|Experimental|High flow nasal cannulas 60L/min|Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
11331085|NCT02494141|Experimental|Curcumin|25/mg/kg per day for 1 year.
11331086|NCT02494141|Placebo Comparator|Placebo|Equivalent placebo for 1 year.
11331087|NCT02494128|Active Comparator|Intervention group|Education in group leadership
11331088|NCT02494128|No Intervention|Control group|This group fills in the questionnaire. No intervention given.
11331089|NCT02494115|Experimental|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
11331090|NCT02494102|Placebo Comparator|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
11331091|NCT02494102|Active Comparator|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
11331092|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
11331093|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
11331094|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
11331095|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
11331096|NCT02494050|Experimental|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
11331097|NCT02494050|Experimental|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
11331098|NCT02494050|Active Comparator|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
11331099|NCT02494024|Experimental|Single dose C2N-8E12 level 1|Single IV infusion of C2N-8E12
11331100|NCT02494024|Experimental|Single dose C2N-8E12 level 2|Single IV infusion of C2N-8E12
11331101|NCT02494024|Experimental|Single dose C2N-8E12 level 3|Single IV infusion of C2N-8E12
11331102|NCT02494024|Experimental|Single dose C2N-8E12 level 4|Single IV infusion of C2N-8E12
11331103|NCT02494024|Placebo Comparator|Single dose placebo|Single IV infusion of placebo
11331104|NCT02494011|Experimental|traditional exercise (group I)|"Mobilization:2 strokes per one second and repeated 6 times during session
~stretching exercise: 15 to 20 minutes
~passive range of motion: 5 minutes at beginning and at end
~active range of motion: 20 repetition
~oedema control: 15s active contraction of fingers of 15s relax for 3 times"
11331105|NCT02494011|Experimental|russian current stimulation (group II)|The frequency was 2.5 kHz for 15 minutes
11331106|NCT02494011|Experimental|CKC (group III)|"wall press exercise - plyometric exercise-Quadruped rhythmic stabilization- press up exercise
~closed kinetic chain exercises performed 10 times and each week 2 more repetitions added as a progression"
11331107|NCT02493985|Active Comparator|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
11331108|NCT02493985|Experimental|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
11331109|NCT02493972|Experimental|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
11331110|NCT02493959|Experimental|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
11331111|NCT02493946|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
11331112|NCT02493946|Placebo Comparator|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
11331113|NCT02493933|Active Comparator|Phytoestrogen|Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
11331114|NCT02493933|Active Comparator|Isosorbid mononitrate|Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
11331115|NCT02493933|Active Comparator|N-Acetyl cysteine|Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
11331116|NCT02493920|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
11331117|NCT02493920|No Intervention|Control|Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
11331118|NCT02493907||heart failure|heart failure patients with CRT
11331119|NCT02493894|Experimental|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
11331121|NCT02493881|Active Comparator|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
11331122|NCT02493881|Active Comparator|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
11331123|NCT02493868|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
11331124|NCT02493868|Experimental|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
11331125|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
11331126|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
11331127|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
11331128|NCT02493842|Experimental|Invasive nerve stimulation|"Invasive nerve stimulation using the following experimental devices
~Transverse Intrafascicular Multichannel Electrode for human (TIME-4H)
~The STIMEP stimulator
~The EPIONE Psychophysical Testing Platform software for stimulator control
~Nerve stimulation therapy is provided while providing visual guidance to the subject and without the use of hand prosthetic devices"
11331129|NCT02493829|Experimental|AML Cell Vaccine|
11331130|NCT02493816|Experimental|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
11331131|NCT02493803|Experimental|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
11331132|NCT02493803|No Intervention|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
11331133|NCT02493790||Volunteers|Cognitive and motor performances were measured in a single and dual task situations.
11331134|NCT02493790||COPD patients|Cognitive and motor performances were measured in a single and dual task situations, before rehabilitation, and compared to those of healthy subjects. Then, Chronic Obstructive Pulmonary Disease patients were re-evaluated after rehabilitation.
11331135|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
11331136|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
11331137|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
11331138|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
11331139|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
11331140|NCT02493738|Experimental|Lozanoc 50mg|Lozanoc 50mg, oral administration
11331141|NCT02493738|Active Comparator|Sporanox 100mg|Sporanox 100mg, oral administration
11331142|NCT02493725|Active Comparator|Eculizumab|Eculizumab, 900 mg intravenously once a week
11331143|NCT02493725|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
11331144|NCT02493712|Experimental|High dose|High dose, twice a day for 6 weeks.
11331145|NCT02493712|Placebo Comparator|Placebo: C|Placebo, twice a day
11331146|NCT02493712|Experimental|Low dose|Low dose, twice a day for 6 weeks
11331147|NCT02493699|Experimental|Exercise|physical exercise- based intervention (Karate techniques training)
11331148|NCT02493699|No Intervention|Control|Not participating in physical exercise- based intervention (Karate techniques training)
11331149|NCT02493673|Active Comparator|CPAP therapy|Continuous positive airway pressure therapy
11331150|NCT02493673|Sham Comparator|Sham CPAP|Sham- Continuous positive airway pressure
11331151|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
11331152|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
11331229|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
11331153|NCT02493647|Experimental|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
11331154|NCT02493647|No Intervention|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
11331155|NCT02493634|Other|pressure gradient measurement|Diagnostic procedure to measure pressure gradient in series of patients. Focus is on safety and absence of adverse events
11331156|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
11331157|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
11331158|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
11331159|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
11331160|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
11331161|NCT02493582|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
11331162|NCT02493582|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
11331163|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
11331164|NCT02493556|Experimental|LLLT before muscle damage|Low Level Laser Therapy (LLLT) will be applied before the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
11331165|NCT02493556|Placebo Comparator|Placebo LLLT before muscle damage|Placebo LLLT will be applied before the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
11331166|NCT02493556|Active Comparator|LLLT after muscle damage|Low Level Laser Therapy (LLLT) will be applied after the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
11331167|NCT02493556|Placebo Comparator|Placebo LLLT after muscle damage|Placebo LLLT will be applied after the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
11331168|NCT02493543||Spinal cord injury|Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
11331169|NCT02493543||Controls|Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.
11331170|NCT02493530|Experimental|Escalation and expansion|TGR1202 and Ruxolitinib combination
11331171|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
11331172|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
11331173|NCT02493504|Experimental|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
11331174|NCT02493504|No Intervention|Control|75 received no intraoperative heparin injection.
11331175|NCT02493465|Experimental|LVH everolimus|Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.
11331176|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
11331177|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
11331178|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
11331179|NCT02493439|Experimental|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
11331180|NCT02493439|Placebo Comparator|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
11331181|NCT02493426|Placebo Comparator|Placebo|Saline Nasal spray designed to look and feel like the drug intervention
11331182|NCT02493426|Experimental|Intranasal Oxytocin|Oxytocin nasal spray designed to look as seem exactly like Placebo
11331183|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
11331184|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
11331185|NCT02493400||Exercise group|A follow up from 3 months detraining from the exercise group. Patients follows their earlier randomisation.
11331186|NCT02493400||Active Comparator: PAP group|A follow up from 3 months detraining from the active comparator group. Patients follows their earlier randomisation.
11331230|NCT02493049|Experimental|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
11331187|NCT02493387|Experimental|Exercise group|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the RPE 6-20 scale
11331188|NCT02493387|Active Comparator|PAP group|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
11331189|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
11331190|NCT02493348|Experimental|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
11331191|NCT02493348|Active Comparator|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
11331192|NCT02493335|Experimental|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
11331193|NCT02493335|Experimental|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
11331194|NCT02493335|Placebo Comparator|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
11331195|NCT02493322|Experimental|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
11331196|NCT02493322|Experimental|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
11331197|NCT02493322|Experimental|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
11331198|NCT02493309|Experimental|Prolonged sitting|
11331199|NCT02493309|Active Comparator|Light activity breaks|
11331200|NCT02493296||Observational|The cohort will have their central aortic pressure, and carotid-femoral and brachio-femoral pulse-wave velocities measured. These measurements will take place pre-operatively, within a week of surgery, 6-weeks and 1-year post-operatively also. The surgery will be abdominal aortic aneurysm repair.
11331201|NCT02493283|Active Comparator|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
11331202|NCT02493283|Active Comparator|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
11331203|NCT02493270|Experimental|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
11331204|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
11331205|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
11331206|NCT02493244|Experimental|Treatment|Participants clean their eyelids with Cliradex wipes before going to bed at night.
11331207|NCT02493244|No Intervention|Control|No treatment
11331208|NCT02493231|Active Comparator|Nefopam|The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr
11331209|NCT02493231|Active Comparator|Ketamine|It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr
11331210|NCT02493231|Placebo Comparator|Saline|It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr
11331211|NCT02493218|Experimental|Mindfulness Instruction|Instruction on mindfulness concepts and practices. Classes are 45-90 minutes each and held weekly for 12 weeks.
11331212|NCT02493218|Active Comparator|Health Education Instruction|Instruction on general health and wellness. Classes are 45-90 minutes each and held weekly for 12 weeks.
11331213|NCT02493192|Active Comparator|Meperidine|Use pethidine and haloperidol injection as a pain relief.
11331214|NCT02493192|Experimental|birth ball|Use birth ball as a pain relief.
11331215|NCT02493179|Active Comparator|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
11331216|NCT02493179|Placebo Comparator|Placebo|Placebo
11331217|NCT02493166|Active Comparator|patients with Multiple sclerosis Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
11331218|NCT02493166|Active Comparator|Healthy volontiers Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
11331219|NCT02493140|Active Comparator|Cashew apple extract (Cashewin)|
11331220|NCT02493140|Placebo Comparator|Placebo|
11331221|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
11331222|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
11331223|NCT02493114||Patients with lung cancer|No study intervention
11331224|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
11331225|NCT02493101||Control|Healthy controls
11331226|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
11331227|NCT02493075|Experimental|CF guided group|Ablation will be performed with smart-touch catheter.The operator will kown the real-time contact force (CF), ablation time, FTI, etc during the procedure.
11331228|NCT02493075|Active Comparator|Usual ablation group|Although we use the same catheter,operator will be blinded to CF data during the procedure.
11383970|NCT02142725|Experimental|B: LT-02|LT-02 1.6g twice daily
11331234|NCT02493010|Experimental|Intervention|Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.
11331235|NCT02493010|No Intervention|Waitlist Control|Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
11331236|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
11331237|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
11331238|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
11331239|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
11331240|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
11331241|NCT02492945|Experimental|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
11331242|NCT02492945|Active Comparator|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
11331243|NCT02492932|Experimental|IJV_2nd|Ultrasonography examination of the patients who are assumed to take second attempt of internal jugular venous catheterization
11331244|NCT02492919|Experimental|Medixair®|Cardiac reanimation unit bed with Medixair®
11331245|NCT02492919|No Intervention|NO Medixair®|Cardiac reanimation unit bed with NO Medixair®
11331246|NCT02492906||Osteoarthrosis group|Patients with primary severe knee osteoarthrosis or with chronic knee pain.
11331247|NCT02492906||Healthy patients|Healthy patients
11331248|NCT02492893|Experimental|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
11331249|NCT02492893|No Intervention|Treatment as Usual|
11331250|NCT02492867|Experimental|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
11331251|NCT02492854|Active Comparator|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
11331252|NCT02492854|Experimental|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
11331253|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
11331254|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
11331255|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
11331256|NCT02492828||Patients for filled prescriptions for apixaban|
11331257|NCT02492828||Patients for filled prescriptions for warfarin|
11331258|NCT02492815||Population with condition and without condition|Participating in EAP
11331259|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
11331260|NCT02492789|Experimental|INCSHR01210|"3 dose levels are designed in this study.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle)."
11331261|NCT02492776|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
11331262|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
11331263|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
11331264|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
11331265|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
11331266|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
11331267|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11331268|NCT02492737|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
11331302|NCT02492464|Active Comparator|Red yeast rice|Red yeast rice extract 200 mg, containing 10 mg monacolin K per daily dose, 1 capsule per day, per 6 months
11331269|NCT02492711|Experimental|Margetuximab plus chemotherapy|Margetuximab 15 mg/kg every 21 days plus Capecitabine 1000 mg/m2 BID for 14 days in a 21-day cycle or Eribulin 1.4 mg/m2 Day 1 and 8 of a 21-day cycle or Gemcitabine 1000 mg/m2 Day 1 and 8 of a 21-day cycle or Vinorelbine 25-30 mg/m2 Day 1 and 8 of a 21-day cycle
11331270|NCT02492711|Active Comparator|Trastuzumab plus chemotherapy|Trastuzumab 8 mg/kg loading dose then 6 mg/kg every 21 days plus Capecitabine 1000 mg/m2 BID for 14 days in a 21-day cycle or Eribulin 1.4 mg/m2 Day 1 and 8 of a 21-day cycle or Gemcitabine 1000 mg/m2 Day 1 and 8 of a 21-day cycle or Vinorelbine 25-30 mg/m2 Day 1 and 8 of a 21-day cycle
11331271|NCT02492698|Experimental|Probiotic group|consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.
11331272|NCT02492698|Placebo Comparator|Placebo group|consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.
11331273|NCT02492685|Experimental|Contrast enhanced EUS group|Contrast enhanced EUS with quantitative analysis
11331274|NCT02492659|Experimental|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
11331275|NCT02492659|Other|control group|the control group underwent conventional phacoemulsification
11331276|NCT02492646|Experimental|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
11331277|NCT02492646|Experimental|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
11331278|NCT02492633|Active Comparator|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
11331279|NCT02492633|Experimental|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
11331280|NCT02492620|Active Comparator|Ferric Citrate|Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
11331281|NCT02492620|No Intervention|Standard of Care (SOC)|Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.
11331282|NCT02492607|Active Comparator|Standard treatment|Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.
11331283|NCT02492607|Experimental|Active surveillance|Active surveillance : monitoring by annual digital mammography for a period of 10 years
11331284|NCT02492594||Pediatric patients with febrile neutropenia|Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed
11331285|NCT02492594||Adult patients with febrile neutropenia|Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed
11331286|NCT02492568|Experimental|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
11331287|NCT02492568|Active Comparator|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
11331288|NCT02492555|Experimental|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
11331289|NCT02492555|Active Comparator|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
11331290|NCT02492542|Experimental|Electric Stimulation Treatment|Patients in the intervention group were treated with electric stimulation based on the routine clinical nursing.
11331291|NCT02492542|No Intervention|control group|patients in this group only received routine clinical nursing without electric stimulation
11331292|NCT02492529|Other|Healthy volunteers|"60 old healthy volunteers (aged 25-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Neuropsychological tests
~Experimental procedure"
11331293|NCT02492529|Experimental|Patients with early Alzheimer disease|"20 patients (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Neuropsychological tests
~Experimental procedure
~A cranial MRI"
11331294|NCT02492529|Experimental|Old healthy volunteers|"20 healthy volunteers (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Neuropsychological tests
~Experimental procedure
~A cranial MRI"
11331295|NCT02492516|Experimental|Stem cell|The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.
11331296|NCT02492503|Active Comparator|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
11331297|NCT02492503|Active Comparator|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
11331298|NCT02492490|Experimental|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.
~Subjects with uremia in the intervention group will undergo puncture to collect SVF
~SVF will be cultured to abstain MSC
~The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
11331299|NCT02492490|Active Comparator|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
11331300|NCT02492477|Experimental|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
11331301|NCT02492477|Experimental|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
11331303|NCT02492464|Placebo Comparator|Placebo|Placebo 200 mg (neutral fibre), 1 capsule per day, per 6 months
11331304|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
11331305|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
11331306|NCT02492451|No Intervention|Control group|Only IUI
11331307|NCT02492438|Active Comparator|PPV23 naive, PPV23 vaccination|vaccination with PPV-23 in 40 PPV-23 naive patients
11331308|NCT02492438|Experimental|PPV23 naive, PCV13 vaccination|vaccination with PCV-13 in 40 PPV-23 naive patients
11331309|NCT02492438|Experimental|PPV23 > 4 years ago, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago
11331310|NCT02492438|Experimental|PPV23 < 4 years, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago
11331311|NCT02492412|Experimental|HE10|Drug: HE10 1~2 drops b.i.d at 12 hour interval for 12 weeks
11331312|NCT02492412|Active Comparator|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1~2 drops b.i.d at 12 hour interval for 12 weeks
11331313|NCT02492399|Other|myectomy by Morrow|"Procedure: myectomy by Morrow.
~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.
~Evaluation results will be made myoectomy as TEE and direct tensiometer."
11331314|NCT02492399|Other|extended myectomy|"Procedure: extended myectomy.
~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.
~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
11331315|NCT02492386|Experimental|Treatment|Bioabsorbable everolimus-eluting stent deployment
11331316|NCT02492373|Active Comparator|laser+steroid 2 days before and after laser|Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.
11331317|NCT02492373|Other|laser+steroid 2 days after laser|Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment
11331318|NCT02492360||Severe Toxicity Group|Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
11331319|NCT02492360||Control Group|Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
11331320|NCT02492347|Active Comparator|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
11331321|NCT02492347|Other|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
11331322|NCT02492334|Experimental|Doxazosin|Participants will be randomized to receive 12 weeks of doxazosin treatment.
11331323|NCT02492334|Placebo Comparator|Placebo|Participants will be randomized to receive 12 weeks of placebo
11331324|NCT02492321|Active Comparator|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
11331325|NCT02492321|Placebo Comparator|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
11331326|NCT02492308|Experimental|SVF-MSC induction|"collection of autologous SVF
~culture of SVF to abstain MSC
~infusion of MSC during and after living-relative kidney transplantation"
11331327|NCT02492308|Active Comparator|Basiliximab induction|The control group will be inducted with Basiliximab
11331328|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
11331329|NCT02492282|Experimental|Closed-Loop|This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
11331330|NCT02492282|Active Comparator|Open-Loop|This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.
11331331|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
11331432|NCT02491580||KTx Uppsala|Patients who have received a kidney transplant in Uppsala.
11331332|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
11331333|NCT02492256|Active Comparator|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
11331334|NCT02492256|Experimental|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
11331335|NCT02492243|Experimental|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction >=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
11331336|NCT02492230|Active Comparator|Control Group|After successful PCI the control group will take Triple therapy (warfarin + clopidogrel+aspirin) during 45 days and after combination of warfarin+clopidogrel to 6 months after procedure and then only warfarin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up.
11331337|NCT02492230|Experimental|Study Group|Left Atrial Appendage Closure Device will be implanted immediately after successful PCI procedure. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The study group will take Triple therapy (warfarin+clopidogrel+aspirin) during 45 days following PCI and after control TEE, warfarin will be discontinued. Then patients from the study group will take DAPT combination (clopidogrel+aspirin) to 6 months after procedure and then only aspirin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up
11331338|NCT02492217|Experimental|Adalimumab|Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.
11331339|NCT02492204||Survivors|
11331340|NCT02492204||Non survivors|
11331341|NCT02492191|Active Comparator|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
11331342|NCT02492191|No Intervention|Control|The control group will receive standard care; i.e., no follow-up
11331343|NCT02492178|Experimental|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
11331344|NCT02492178|Experimental|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
11331345|NCT02492165|Experimental|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
11331346|NCT02492165|Experimental|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
11331347|NCT02492165|Experimental|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
11331348|NCT02492165|Experimental|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
11331349|NCT02492152|No Intervention|Control group|Women who will not be using this medicine that is checked.
11331350|NCT02492152|Experimental|Study group|Women who will use DIANATAL according to manufacturer's protocol from the stage of active labor.
11331351|NCT02492139|Other|Pumping|Each particpant will pump with the current pumpset one week and then two weeks with the pumpset
11331352|NCT02492126||Chronic Cough|Subjects with chronic cough will undergo cough reflex sensitivity testing to citric acid. The dose, starting at 0.03 mol/L citric acid will be administered as single breath inhalations using flow-limited calibrated pots and a dosimeter with 3 placebo inhalations of normal saline randomly interspersed. Following each inhalation, the number of coughs in the subsequent 15 seconds will be counted and recorded. The challenge will be terminated once the citric acid has induced 5 or more coughs.
11331353|NCT02492113|Experimental|Patients with BMI > 35|"ICU patients with a BMI > 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation
~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
11331354|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant
~Patient Enrollment and Baseline Data Collection
~First Intervention Visit:
~Comprehensive assessment of sexual dysfunction
~Normalization & Education
~Therapeutic interventions
~Referral to Sexual Health Clinic if applicable
~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
11331355|NCT02492087|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
11331356|NCT02492087|Sham Comparator|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
11331357|NCT02492074|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
11331358|NCT02492074|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
11331359|NCT02492074|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)
11331360|NCT02492074|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
11331361|NCT02492061|Active Comparator|Demand creation|In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
11331362|NCT02492061|No Intervention|Standard of care|In the standard of care arm, participants receive general adult health talks to educate them about the importance of HIV testing (including couples' HCT) but no invitations are issued to invite couples to test for HIV together with their partners at a designated health facility. However, couples can seek HCT out of their own volition. The sessions are not stratified by marital status, and attendants include all those who are willing and are able to attend.
11331363|NCT02492048|Active Comparator|Split Thickness Skin Graft Harvest|Retrospective review
11331364|NCT02492048|Experimental|Cellutome Epidermal Harvesting System|Prospective patients will receive a skin graft utilizing the Cellutome Epidermal Harvesting System
11331365|NCT02492035|Experimental|Physical activity|Tailoring intervention with kinesiologist
11331366|NCT02492035|Experimental|Diet|Tailoring intervention with nutritionist
11331367|NCT02492035|Experimental|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
11331368|NCT02492035|No Intervention|Standard medical care|Follow with family doctor as usual care.
11331369|NCT02492022|Experimental|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
11331370|NCT02492022|Experimental|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
11331371|NCT02492022|Placebo Comparator|Placebo|Encapsuled non active ingredients
11331372|NCT02492009|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
11331373|NCT02492009|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
11331374|NCT02491996|Experimental|DTIG|Outpatients who treated by DTIG at Outpatient Unit for Gambling Disorder of Kurihama Medical and Addiction Center
11331375|NCT02491983|Active Comparator|Arm A|Combination of Palbociclib and Letrozole
11331376|NCT02491983|Experimental|Arm B|Combination of Palbociclib and Fulvestrant
11331377|NCT02491970|Experimental|Fluticasone/Formoterol|Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
11331378|NCT02491970|Active Comparator|Fluticasone/Salmeterol|Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
11331379|NCT02491957|Experimental|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
11331380|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
11331381|NCT02491931|Active Comparator|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
11331382|NCT02491931|Placebo Comparator|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
11331383|NCT02491918|Active Comparator|In the bag IOL|Cataract surgery with IOL implantation in the capsular bag
11331384|NCT02491918|Active Comparator|Optic Capture of IOL|intraocular lens implantation in the capsular bag with posterior optic capture
11331385|NCT02491905|Experimental|low dose HL tablet|HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal
11331386|NCT02491905|Experimental|high dose HL tablet|HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal
11331387|NCT02491905|Placebo Comparator|placebo group|Placebo by oral administration, twice daily in an hour after meal
11331388|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
11331389|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
11331390|NCT02491879|Experimental|Ketoprofen|Ketoprofen gel
11331391|NCT02491879|Placebo Comparator|Placebo|Placebo form of ketoprofen gel
11331392|NCT02491866|Other|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
11331393|NCT02491840|Experimental|Gastric and cardia adenocarcinomas|Biopsy of Gastric and cardia adenocarcinomas
11331394|NCT02491827||Cellvizio mini laser probe|Cellvizio mini laser probe will be administered via the endoscopic device used for the neurosurgical procedure to provide confocal laser endomicroscopy in patients requiring neurosurgery due to glioma multiforme or subcranial tumors
11331395|NCT02491814|Experimental|1% M.F. Milk and Breakfast Cereal|Breakfast meal: 250 ml 1% M.F. Milk, 54 g Cheerios breakfast cereal, 100 mL water
11331396|NCT02491814|Experimental|Yogurt Beverage and Breakfast Cereal|Breakfast meal: 250 ml Yogurt Beverage, 54 g Cheerios breakfast cereal, 100 mL water
11331397|NCT02491814|Experimental|Soy Beverage and Breakfast Cereal|Breakfast meal: 250 ml Soy Beverage, 54 g Cheerios breakfast cereal, 100 mL water
11331398|NCT02491814|Experimental|Almond Beverage and Breakfast Cereal|Breakfast meal: 250 ml Almond Beverage, 54 g Cheerios breakfast cereal, 100 mL water
11331399|NCT02491814|Experimental|Water (control) and Breakfast Cereal|Breakfast meal: 250 ml Water, 54 g Cheerios breakfast cereal, 100 mL water
11331400|NCT02491801|Experimental|3.25% M.F. Milk|3.25% M.F. Milk
11331401|NCT02491801|Experimental|Greek Yogurt|Greek Yogurt (2% M.F.)
11331402|NCT02491801|Experimental|Cheddar Cheese|Regular Fat Cheddar Cheese
11331403|NCT02491801|Experimental|Control 1|Skim milk
11331404|NCT02491801|Experimental|Control 2|Filtered water, calorie-free control
11331405|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
11331406|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
11331407|NCT02491762||bilateral|bilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
11331408|NCT02491762||unilateral|unilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
11331409|NCT02491749|Experimental|Ultra Fast-Track Anesthesia|Patients who fulfilled the extubation criteria were extubated at the end of surgery and transferred to the ICU for follow up.
11331410|NCT02491749|Experimental|Conventional|patients who did not fulfill extubation criteria were left intubated and sedated and transferred to the ICU for later management
11331411|NCT02491736|Experimental|ketoprofen|2.5% ketoprofen gel
11331412|NCT02491736|Placebo Comparator|Placebo|Placebo gel
11331413|NCT02491723|Experimental|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
11331414|NCT02491710|Experimental|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
11331415|NCT02491710|Active Comparator|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
11331416|NCT02491697|Active Comparator|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.
~Drug: Capecitabine"
11331417|NCT02491697|Experimental|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.
~Drug: Capecitabine"
11331418|NCT02491684|Placebo Comparator|Placebo (matching)|Placebo, once daily inhalation for 14 days
11331419|NCT02491684|Experimental|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
11331420|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
11331421|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
11331422|NCT02491658|Experimental|Treat Psoriasis Vulgaris with UC-MSCs|Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1×10^6/kg) within 8 weeks.
11331423|NCT02491645|Experimental|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,
~Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .
~Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
11331424|NCT02491645|No Intervention|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
11331425|NCT02491632|Experimental|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
11331426|NCT02491632|Experimental|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
11331427|NCT02491619|Experimental|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
11331428|NCT02491606|Experimental|Load only|Loading with tafenoquine 400 mg base for three days followed by placebo weekly.
11331429|NCT02491606|Experimental|Low weekly dose|Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.
11331430|NCT02491606|Experimental|High weekly dose|Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.
11331431|NCT02491606|Experimental|Placebo|Loading with placebo for 3 days followed by placebo once weekly.
11331434|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
11331435|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
11331436|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
11331437|NCT02491554|Active Comparator|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
11331438|NCT02491554|Experimental|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
11331439|NCT02491541|Experimental|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
11331440|NCT02491541|Active Comparator|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
11331441|NCT02491528|Experimental|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
11331442|NCT02491528|Active Comparator|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
11331443|NCT02491502|Experimental|Echopulse|Echopulse HIFU
11331444|NCT02491489|Experimental|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
11331445|NCT02491489|Active Comparator|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
11331446|NCT02491476|Experimental|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
11331447|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
11331448|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
11331449|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
11331450|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
11331451|NCT02491450|Experimental|A Test|Test drug (Heterosofir)1 tablet contains 400 mg Sofosbuvir
11331452|NCT02491450|Active Comparator|B Reference|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
11331453|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
11331454|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
11331455|NCT02491424|Experimental|Fixation of ITAP to lower limb amputees.|"Direct skeletal fixation of ITAP to lower limb amputees. 20 patients in the study will be fitted with Intraosseous Transcutaneous Amputation Prosthesis.
~The device has been designed to be surgically implanted in a one stage procedure."
11331456|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
11331457|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
11331458|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
11331459|NCT02491385|Experimental|TEA|thoracic epidural analgesia group
11331460|NCT02491385|Active Comparator|iv-PCA|intravenous patient controlled analgesia group
11331461|NCT02491372|Experimental|Intervention|Acceptance and commitment therapy group
11331462|NCT02491372|No Intervention|Comparison|Treatment as usual
11331463|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11331464|NCT02491346|Active Comparator|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
11331465|NCT02491346|Experimental|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
11331466|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.
~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
11331467|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.
~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.
~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
11331515|NCT02490995|Experimental|Group B|Movie + Information given by the anaesthetist during the consultation
11331516|NCT02490982||Teriflunomide|Patient-reported outcomes and clinical assessment
11383971|NCT02142725|Placebo Comparator|Placebo|LT-02 Placebo
11331468|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.
~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.
~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
11331469|NCT02491320|Experimental|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
11331470|NCT02491320|Active Comparator|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
11331471|NCT02491307|Experimental|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
11331472|NCT02491307|No Intervention|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
11331473|NCT02491294|Experimental|School Only|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components
11331474|NCT02491294|Experimental|School + Family|Students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs)
11331475|NCT02491294|Experimental|School + About Eating|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components and their parents are invited to participate in the online 6 lesson About Eating program.
11331476|NCT02491294|Experimental|School + Family + About Eating|students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs) and their parents are invited to participate in the online 6 lesson About Eating program.
11331477|NCT02491294|No Intervention|Control|students and their parents in all schools during cohort 1 and 4 (and Ponderosa students in cohort 3) are tested but provided no intervention
11331478|NCT02491281|Experimental|LNA043|LNA043 given intra-articularly
11331479|NCT02491281|Placebo Comparator|Placebo|Placebo given intra-articularly
11331480|NCT02491268|Experimental|Cilostazol 50mg B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.
~Protocol treatment defines as follows;
~Investigational Treatment:
~Cilostazol 50mg B.I.D. p.o. 96 Weeks"
11331481|NCT02491268|Placebo Comparator|Placebo B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.
~Protocol treatment defines as follows;
~Comparative Treatment:
~Placebo B.I.D. p.o. 96 Weeks"
11331482|NCT02491255|Experimental|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
11331483|NCT02491229|Other|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
11331484|NCT02491229|Other|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
11331485|NCT02491216|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
11331486|NCT02491216|No Intervention|Control Group|No acupressure therapy will be provided during the study.
11331487|NCT02491203|No Intervention|Usual care|All study participants in the control group will receive a 4-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
11331488|NCT02491203|Experimental|Telerehabilitation system|Participants in the experimental group will receive four weeks written home exercise program provided by a clinician, i.e. usual care discharge home program plus virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and the program adapted to ensure it remains at an appropriate level for the patient.
11331489|NCT02491190|Experimental|Treatment|Empower educational module: After the patient activation measure/s are collected, for parents or patients assigned to the intervention arm, they will be given an opportunity to launch the EMPOWER video and interactive powerpoint. They will be able to pause on reviewing the educational material and come back to it, as with other assigned education, and they will be able to review it again if they would like. Discharge surveys will be assigned 24 hours prior to the estimated discharge time in Apex. Oneview will display notifications that the surveys have been assigned.
11331517|NCT02490956|Experimental|Rabies vaccination|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
11333208|NCT02479490|Experimental|Prednisone + Everolimus|Prednisone + Everolimus
11331490|NCT02491190|No Intervention|Control|Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
11331491|NCT02491177|Other|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
11331492|NCT02491177|Other|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
11331493|NCT02491177|Other|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
11331494|NCT02491177|No Intervention|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
11331495|NCT02491164|Experimental|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
11331496|NCT02491138|Placebo Comparator|Standard information|In this arm, participants will receive standard information pamphlets about the benefits of good sleeping habits.
11331497|NCT02491138|Experimental|Appearance-based information|In this arm, participants will receive information about how sleep modifies their physical appearance. This will involve a computer transformation that morphs their face according to hours of sleep obtained.
11331498|NCT02491125|Placebo Comparator|Placebo|12 weeks placebo maltodextrin 15g/day ( 5 g in beverage, to be consumed three times a day)
11331499|NCT02491125|Experimental|soluble wheat bran fibre|12 weeks soluble wheat bran fibre 15g/day (5 g in beverage, to be consumed three times a day)
11331500|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
11331501|NCT02491086|Experimental|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling [25-27]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
11331502|NCT02491086|Active Comparator|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
11331503|NCT02491073||Eslicarbazepine acetate treated|
11331504|NCT02491073||Non-Eslicarbazepine acetate treated|
11331505|NCT02491060|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
11331506|NCT02491060|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
11331507|NCT02491047|Experimental|BonyPid-1000|Implantation of BonyPid-1000 medical device, constructed of bone filler coated with controlled release antibiotic formulation, concomitantly with standard of care treatment (SOC)
11331508|NCT02491047|Other|Study control arm|Standard of care treatment (SOC) only
11331509|NCT02491034|Other|Intervention|Depression Education Intervention
11331510|NCT02491021|Active Comparator|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
11331511|NCT02491021|No Intervention|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
11331512|NCT02491008|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
11331513|NCT02491008|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
11331518|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
11331519|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
11331520|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
11331521|NCT02490930|Experimental|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
11331522|NCT02490917|Experimental|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
11331523|NCT02490917|Other|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
11331524|NCT02490904|Experimental|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
11331525|NCT02490904|Placebo Comparator|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
11331526|NCT02490891|Experimental|PET scan with RGD K5 imaging|PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
11331527|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.
~Patients who meet the criteria for clinical progression will be treated as per treating MD."
11331528|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.
~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
11331529|NCT02490865|Experimental|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
11331530|NCT02490865|Placebo Comparator|Normal Saline|Administration of normal saline used as control
11331531|NCT02490852|Experimental|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
11331532|NCT02490852|Active Comparator|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
11331533|NCT02490852|Active Comparator|Human milk|Healthy term infants fed exclusively human milk
11331534|NCT02490839|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
11331535|NCT02490839|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
11331536|NCT02490826|Active Comparator|Table-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a table top material version.
~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
11331537|NCT02490826|Active Comparator|Tablet-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a tablet (digital) material version.
~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
11331538|NCT02490813|Placebo Comparator|Control|This arm will receive the placebo.
11331539|NCT02490813|Experimental|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
11331540|NCT02490800|Experimental|Drug: BAL101553|Oral daily administration of BAL101553
11331541|NCT02490787|Experimental|Concizumab|
11331542|NCT02490787|Placebo Comparator|Placebo|
11331543|NCT02490774|Experimental|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
11331544|NCT02490774|Experimental|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
11331545|NCT02490774|Experimental|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
11331546|NCT02490774|Experimental|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
11331547|NCT02490774|Active Comparator|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
11331548|NCT02490774|Active Comparator|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
11331549|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
11331550|NCT02490748|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
11331551|NCT02490748|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
11331552|NCT02490735|No Intervention|No-CIK|After accepting chemotherapy, patients will regularly follow up.
11331553|NCT02490735|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year
11331554|NCT02490722|Active Comparator|Intervention|Four times two hours interdisciplinary patient education and usual care
11331555|NCT02490722|No Intervention|Control|Usual care
11331556|NCT02490709|Experimental|Local excision|Local excision for rectal cancer with good response
11331557|NCT02490696|Experimental|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
11331558|NCT02490696|Experimental|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
11331559|NCT02490683|Experimental|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
11331560|NCT02490683|Experimental|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
11331561|NCT02490683|Placebo Comparator|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
11331562|NCT02490670|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
11331563|NCT02490670|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
11331564|NCT02490657|Experimental|Iloprost group|
11331565|NCT02490657|Placebo Comparator|normal saline|
11331566|NCT02490644||MGB1 in valvular heart surgery|Evaluation of the high mobility group box 1 as a prognostic biomarker in patients undergoing valvular heart surgery
11331567|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
11331568|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
11331569|NCT02490618|Experimental|Test|Probiotic tablet
11331570|NCT02490618|Placebo Comparator|Control|Control tablet
11331571|NCT02490605|Experimental|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
11331572|NCT02490605|Active Comparator|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
11331573|NCT02490592|Experimental|G1|Thirty children aged seven to twelve years who had seventy one active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride foam, Flúor Care (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
11331574|NCT02490592|Experimental|G2|Twenty-eight children aged seven to twelve years who had seventy five active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride gel, Flugel FFA (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
11331575|NCT02490579||Facebook Survey Group|"During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and ad copy followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics."
11331576|NCT02490579||Clinical Survey Group|During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
11331577|NCT02490579||Social Network Group|Once a pregnant participant completes the survey, she will be asked to provide her email address. If she is willing to do so, Qualtrics will automatically send her an email containing a weblink to the survey for her social network. She can then provide this link to 1 or 2 social network members that she feels influence her health behaviors during pregnancy. These members are asked similar questions about their response to the video, as well as some additional questions about how they advise their pregnant person about different health topics. It is necessary to provide a unique weblink to her, so that the survey responses from the pregnant woman and her unique social network members can be linked.
11331578|NCT02490566|Experimental|Technology Arm|Tablet computer with chronic disease apps will be given to patients. This tablet will also be used for follow-up visits done via video conferencing. Intervention: Telehealth.
11331613|NCT02490358||3|COPD ex-smoker subjects
11333276|NCT02479100|No Intervention|Follow Standard care|Patient will follow standard care pathway.
11331579|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of ~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
11331580|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of ~1 million inhabitants, the fourth urban area in France)
11331581|NCT02490540|Experimental|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
11331582|NCT02490540|Experimental|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
11331583|NCT02490540|Experimental|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
11331584|NCT02490527|Placebo Comparator|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
11331585|NCT02490527|Experimental|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
11331586|NCT02490514||Mircera|Patients with stage III-IV CKD received open-label Mircera for 12 months at a dose to be determined by the investigator.
11331587|NCT02490501|Active Comparator|SC0806|Intervention with SC0806 (implantation of device with FGF1 and peripheral nerves) in addition to rehabilitation
11331588|NCT02490501|Other|Controls|Rehabilitation only
11331589|NCT02490488|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
11331590|NCT02490488|Placebo Comparator|Placebo & gemcitabine|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
11331591|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
11331592|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
11331593|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
11331594|NCT02490462|Experimental|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
11331595|NCT02490462|Active Comparator|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
11331596|NCT02490449|Experimental|Exprerimental group|medication after diet
11331597|NCT02490449|Active Comparator|control group|medication before diet
11331598|NCT02490436|Experimental|A: active drug first|Cetuximab in treatment period 1, placebo in treatment period 2, and open-label cetuximab in treatment period 3.
11331599|NCT02490436|Experimental|B: placebo first|Placebo in treatment period 1, cetuximab in treatment period 2, and open-label cetuximab in treatment period 3.
11331600|NCT02490423|Active Comparator|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
11331601|NCT02490423|No Intervention|Standard of Care|The standard of care arm will utilize Intermountain cardiovascular clinical program care processes as they are in place today for treatment of the study subjects.
11331602|NCT02490410|Experimental|whey protein|2 x 10g whey protein per day orally for 6 months
11331603|NCT02490410|Other|whey protein+soy protein|10g whey protein + 10g soy protein per day orally for 6 months
11331604|NCT02490410|Other|soy protein|2 x 10g soy protein per day orally for 6 months
11331605|NCT02490397|Experimental|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
11331606|NCT02490397|Sham Comparator|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
11331607|NCT02490384|Active Comparator|Physical exam indicated cerclage|Cerclage
11331608|NCT02490384|No Intervention|Expectant management|No cerclage
11331609|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.
~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
11331610|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.
~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
11331611|NCT02490358||1|Healthy smoking subjects
11331612|NCT02490358||2|COPD smoking subjects
11331614|NCT02490345|Active Comparator|Gabapentin Administration|gabapentin 600mg orally every 8 hours x 48 hours
11331615|NCT02490345|Placebo Comparator|Placebo|Placebo , 1 tablet, orally every 8 hours x 48 hours
11331616|NCT02490332|Experimental|Ventilation tube treatment|Ventilation tube insertion in the tympanic membrane
11331617|NCT02490332|No Intervention|Conservative treatment|Conventional treatment
11331618|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
11331619|NCT02490306|Experimental|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
~Interventions: Strokefinder MD100 measurement"
11331620|NCT02490306|Experimental|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.
~Interventions: Strokefinder MD100 measurement"
11331621|NCT02490306|Experimental|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
~Interventions: Strokefinder MD100 measurement"
11331622|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.
~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
11331623|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.
~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
11331624|NCT02490280|Experimental|Trier Social Stress Test|Participants will be administered the Trier Social Stress Test (TSST). The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
11331625|NCT02490267||1|children with primary or secondary glaucoma
11331626|NCT02490267||2|children w/ cataract or previously treated for cataract
11331627|NCT02490267||3|children w/ microphthalmia, anophthalmia or coloboma
11331628|NCT02490267||control group|age matched children without eye and vision problems.
11331629|NCT02490254||1|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.
11331630|NCT02490228|Other|surgical group|transurethral resection of urethral caruncle
11331631|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
11331632|NCT02490202|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
11331633|NCT02490202|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
11331634|NCT02490189|Experimental|Mindfulness-Based Intervention|Participants in the mindfulness-based intervention arm will receive 12 weekly sessions of 2 to 2.5 hours duration. The intervention will be delivered in a group format. Participants will be assigned weekly homework.
11331635|NCT02490189|Active Comparator|Cognitive Behavior Group Therapy|Participants in the cognitive behavior group therapy arm will receive 12 weekly sessions of 2 to 2.5 hours in duration. Participants will be assigned weekly homework.
11331636|NCT02490176|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
11331637|NCT02490176|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
11331638|NCT02490163|Experimental|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
11331639|NCT02490163|Active Comparator|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
11331640|NCT02490150|Experimental|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
11331641|NCT02490150|Active Comparator|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
11331642|NCT02490137|Experimental|Game Players|Participants that will play video game
11331643|NCT02490137|No Intervention|Control|No video game experience
11331644|NCT02490124||Type 1 Diabetic|Type 1 Diabetic
11331645|NCT02490124||Control|normal healthy control
11331646|NCT02490111|Experimental|DWJ1319 300 mg BID|DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
11331647|NCT02490111|Experimental|DWJ1319 300 mg QD|DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
11331648|NCT02490111|Placebo Comparator|Placebo|Placebo, orally, twice daily (BID) for up to 12 months
11331649|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
11331650|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
11331710|NCT02489786|Active Comparator|Regimen 4|digoxin dose is calculated using Jusko-Koup method and given daily
11384168|NCT02141516|Experimental|Group A|Complement deficiency
11331651|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
11331652|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
11331653|NCT02490098|Active Comparator|Sensor-augmented pump therapy|Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
11331654|NCT02490085|Active Comparator|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
11331655|NCT02490085|Active Comparator|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
11331656|NCT02490072|Experimental|Dexmedetomidine group|
11331657|NCT02490072|Placebo Comparator|normal saline|
11331658|NCT02490059|Active Comparator|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
11331659|NCT02490059|Experimental|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
11331660|NCT02490046|Experimental|MS and rec UTIs not using a catheter|people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose
11331661|NCT02490046|Experimental|MS and rec UTIs using a catheter|people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose
11331662|NCT02490033|Other|Contact force unblinded|
11331663|NCT02490033|Other|Contact force blinded|
11331664|NCT02490033|Other|ECI unblinded|
11331665|NCT02490033|Other|ECI blinded|
11331666|NCT02490020|Experimental|iv of BMSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)
11331667|NCT02490020|No Intervention|routine treatment protocol to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
11331668|NCT02490020|Experimental|ia and iv of MSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)
11331669|NCT02490020|No Intervention|routine treatment to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
11331670|NCT02490020|Experimental|Routine CMR treatment plus MSC to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)
11331671|NCT02490020|No Intervention|Routine CMR treatment to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)
11331672|NCT02490020|Experimental|Routine AMR treatment plus MSC to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)
11331673|NCT02490020|No Intervention|Routine AMR treatment to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)
11331711|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
11331712|NCT02489773||Group 2|HbA1c values <7.5%
11331713|NCT02489760|Experimental|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
11331674|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
11331675|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
11331676|NCT02489994|Experimental|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
11331677|NCT02489981||Spiriva|Patients with severe persistent asthma
11331678|NCT02489968|Experimental|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
11331679|NCT02489968|Experimental|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
11331680|NCT02489968|Experimental|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
11331681|NCT02489968|Experimental|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
11331682|NCT02489955|Experimental|AUC group|
11331683|NCT02489955|Active Comparator|Trough dose monitoring|
11331684|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
11331685|NCT02489929|Experimental|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
11331686|NCT02489916|Experimental|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
11331687|NCT02489903|Experimental|Small Cell Lung Cancer (Arm 1)|RRx-001 weekly for 3 weeks followed by up to 4 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 and carboplatin or cisplatin (for patients with stable disease (SD) or better at discontinuation of platinum).
11331688|NCT02489903|Active Comparator|Small Cell Lung Cancer (Arm 2)|Carboplatin or cisplatin plus etoposide or irinotecan or vinorelbine until progression or intolerable toxicity
11331689|NCT02489903|Experimental|Non Small Cell Lung Cancer|RRx-001 weekly for 3 weeks followed by up to 6 cycles of cisplatin or carboplatin plus paclitaxel or nab-paclitaxel or pemetrexed and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
11331690|NCT02489903|Experimental|Neuroendocrine tumors|RRx-001 weekly until progression followed by up to 6 cycles of carboplatin or cisplatin plus etoposide and then RRx-001 maintenance (for patients with stable disease or better at discontinuation of platinum).
11331691|NCT02489903|Experimental|Ovarian epithelial cancer (Arm 1)|RRx-001 weekly for 2 weeks followed by 2 cycles of Carboplatin chemotherapy and then RRx-001/Carboplatin maintenance (for patients with stable disease or better at discontinuation of platinum).
11331692|NCT02489903|Active Comparator|Ovarian epithelial cancer (Arm 2)|Carboplatin, Etoposide, Doxil, Gemcitabine or Vinorelbine or Taxane until progression or intolerable toxicity
11331693|NCT02489890|No Intervention|Non-CIK|After accepting chemotherapy, patients will regularly follow up.
11331694|NCT02489890|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year.
11331695|NCT02489877||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis
11331696|NCT02489877||without Multiple Sclerosis|Healthy individuals without neurological disease associated
11331697|NCT02489877||with other neurological diseases|Patients diagnosed with the following diseases: Lateral Amniotrofic Sclerosis, Headache , Parkinson's disease, Dementia and Epilepsy.
11331698|NCT02489864|Active Comparator|Terlipressin and albumin|"Patients in this group received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
~albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day."
11331699|NCT02489864|Placebo Comparator|Albumin|Only albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day.
11331700|NCT02489851|Active Comparator|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)
~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
11331701|NCT02489851|Active Comparator|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)
~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
11331702|NCT02489825|Other|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
11331703|NCT02489825|Other|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
11331704|NCT02489812|Experimental|music|The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
11331705|NCT02489799|Active Comparator|Intervention|Advance care planning video
11331706|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
11331707|NCT02489786|Active Comparator|Regimen 1|patient takes 0.25mg of digoxin daily except friday
11331708|NCT02489786|Active Comparator|Regimen 2|patient takes 0.25mg of digoxin daily except Thursday and Friday
11331709|NCT02489786|Active Comparator|Regimen 3|patient takes 0.125mg of digoxin daily
11331714|NCT02489760|Experimental|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
11331715|NCT02489747|Experimental|WBE group|wheat bran extract
11331716|NCT02489747|Placebo Comparator|Placebo group|placebo
11331717|NCT02489734|Experimental|low concentration (LC)|low concentration group
11331718|NCT02489734|Experimental|high concentration (HC)|high concentration group
11331719|NCT02489708|Experimental|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
11331720|NCT02489695|Experimental|axitinib|axitinib 10mg twice a day
11331721|NCT02489682|Experimental|Informed Consent Format - short written|"Intervention to be administered:
~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
11331722|NCT02489682|Experimental|Informed Consent Format - long written|"Intervention to be administered:
~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
11331723|NCT02489682|Experimental|Informed Consent Format - video|"Intervention to be administered:
~- Video informed consent information, followed immediately by outcomes questionnaire"
11331724|NCT02489669|No Intervention|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for >18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
11331725|NCT02489669|Experimental|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP >18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
11331726|NCT02489656|Experimental|Coloplast Hydrocoated silicone JJ stent|Double loop ureteral stent endoscopic placement
11331727|NCT02489656|Active Comparator|Boston Percuflex Plus JJ stent|Double loop ureteral stent endoscopic placement
11331728|NCT02489643|Experimental|Receiving training|Patients will be visited and receive information about the prescribed topical treatment according to the normal course and procedure of an outpatient visit at our institution. At the end of the visit, they will also receive practical instructions on dosages and application modalities of the topical therapy.
11331729|NCT02489643|No Intervention|No-receiving training|
11331730|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
11331731|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
11331732|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).
~-- Pathologic evaluation of excised tissue"
11331733|NCT02489604|Experimental|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
11331734|NCT02489604|Experimental|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
11331735|NCT02489591|No Intervention|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
11331736|NCT02489591|Experimental|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
11331737|NCT02489565|No Intervention|Tertiary care|Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
11331738|NCT02489565|Experimental|Primary care|Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
11331739|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
11331740|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
11331741|NCT02489526|Experimental|VVZ-149 Injections|
11331742|NCT02489526|Placebo Comparator|Placebo|
11331743|NCT02489513|Other|Single group assignment|[14C]-AG-120
11331744|NCT02489500|Active Comparator|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
11331745|NCT02489500|Experimental|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
11331746|NCT02489487|Experimental|VM-1500 + Raltegravir|VM-1500 40 mg in combination with 400 mg Raltegravir
11331747|NCT02489487|Experimental|VM-1500 +Darunavir|VM-1500 40 mg in combination with 600 mg Darunavir boosted with 100 mg Ritonavir
11331748|NCT02489487|Experimental|VM-1500|VM-1500 40 mg alone
11331749|NCT02489474||Recipients undergoing liver transplantation|Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury.
11331750|NCT02489461|Experimental|VM-1500 20 mg + ART|VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
11331751|NCT02489461|Experimental|VM-1500 40 mg + ART|VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
11331752|NCT02489461|Active Comparator|Efavirenz 600 mg + ART|Efavirenz 600 mg (Stage I and Stage II), ART
11331753|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.
~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
11331754|NCT02489435|Experimental|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
11331755|NCT02489435|Experimental|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
11331756|NCT02489435|Experimental|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
11331757|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
11331758|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
11331759|NCT02489409|Experimental|Experimental group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).
11331760|NCT02489409|Active Comparator|Control group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.
11331761|NCT02489396||Grocery Customers|All customers who shop on the Rosie site during the intervention period.
11331762|NCT02489383|Active Comparator|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
11331763|NCT02489383|Active Comparator|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
11331764|NCT02489370|Experimental|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.
~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
11331765|NCT02489370|No Intervention|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
11331766|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
11331767|NCT02489344|Experimental|GZ/SAR402671|Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
11331768|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
11331769|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
11331770|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
11331771|NCT02489292|Experimental|HepaStem|Target total dose 50x10E6 cells/kg
11331772|NCT02489279|Experimental|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
11331773|NCT02489279|Active Comparator|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
11331774|NCT02489266|Experimental|Arm 1|Patients will receive cyclophosphamide and fludarabine followed by infusion of the AKTi-treated TIL, followed by high dose aldesleukin.
11331775|NCT02489253||polygenic hypercholesterolemia|patients with high cholesterol level where no mutation was found in their FH-causing genes and had to gene score in their six LDL-C raising gene score undergo a carotid ultrasound, a CT coronary angiogram and a blood test
11331776|NCT02489253||monogenic FH|patients with a mutation in FH-causing gene undergo a carotid ultrasound, a CT coronary angiogram and a blood test
11331777|NCT02489240|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
11331778|NCT02489240|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
11331779|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
11331780|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
11331781|NCT02489214|Experimental|donafenib tosilate tablets|200mg bid
11331782|NCT02489201|Experimental|donafenib tosilate tablets|200mg bid
11331783|NCT02489188||ankle osteoarthritis|patients with ankle osteoarthritis scheduled for arthroplasty
11331784|NCT02489188||knee osteoarthritis|patients with knee osteoarthritis scheduled for arthroplasty
11331785|NCT02489188||hip osteoarthritis|patients with hip osteoarthritis scheduled for arthroplasty
11331786|NCT02489188||lumbar spinal stenosis|patients with lumbar spinal stenosis scheduled for lumbar spinal stenosis decompression
11384169|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
11331787|NCT02489188||muscle contracture|patients with functionally limited range of motion at the knee because of muscle contracture scheduled for manual therapy
11331788|NCT02489188||healthy subjects|healthy subjects
11331789|NCT02489175|Experimental|Stomaplasty KoringTM group|The KoringTM is a stomaplasty ring made of propylene, flexible and non-absorbable. It is fixed to the anterior sheath of the abdominal wall in order to prevent PSH.
11331790|NCT02489175|No Intervention|No preventive measure|In these patients, the stoma creation will be traditional, with no mesh implanted
11331791|NCT02489162|Experimental|MyotonPRO|Experimental: Measurement of biomechanical properties of mimic muscles on the ipsilateral palsy side with the healthy contralateral side ( case - control design)
11331792|NCT02489162|Active Comparator|Non-invasive electromyography (EMG)|Comparing experimental intervention with gold standard
11331793|NCT02489149|Experimental|Multi-sector interventions|"Multi-sector interventions
~Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.
~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.
~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.
~Helping families to have more knowledge about your citizen rights."
11331794|NCT02489149|Placebo Comparator|Control|Conventional approach of current public food and nutrition policies.
11331795|NCT02489136|Other|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
11331796|NCT02489136|Placebo Comparator|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
11331797|NCT02489136|No Intervention|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
11331798|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
11331799|NCT02489110|Experimental|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
11331800|NCT02489110|Active Comparator|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
11331801|NCT02489097|Active Comparator|Nitrous Oxide|Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
11331802|NCT02489097|Placebo Comparator|Air/Oxygen (placebo)|Receives a mixture of 70% Air in 30% Oxygen
11331803|NCT02489071|Experimental|Brain Training|8-session cognitive training program
11331804|NCT02489071|Experimental|Brain Health|8-session cognitive education program
11331805|NCT02489071|No Intervention|Control|Wait-list control group
11331806|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
11331807|NCT02489032|Experimental|SBIRT Training & Support Tool|The SBIRT Training & Support Tool has two components, both of which will be evaluated: (1) online SBIRT Training for EAP and behavioral health practitioners conducting alcohol SBIRT with their adult clients and (2) mobile/web interactive alcohol screening tools and brief intervention protocols to facilitate use of SBIRT by practitioners.
11331808|NCT02489032|Other|Waitlist control|Subjects randomized to the control condition will be placed on a wait-list and given access to the SBIRT Training & Support Tool after 3 months and completion of the 3-month follow-up assessment.
11331809|NCT02489019|Placebo Comparator|Control|Individuals assigned to this condition will receive 0.9 mcg/kg sodium chloride (NaCL)
11331810|NCT02489019|Experimental|Low Dose|Individuals assigned to this condition will receive 1 mcg/kg fentanyl
11331811|NCT02489019|Experimental|High Dose|Individuals assigned to this condition will receive 2 mcg/kg fentanyl
11331812|NCT02489006|Experimental|Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery|"Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery.
~Platinum-based chemotherapy chosen by the study doctor and per standard of care after surgery.
~Olaparib, orally, at 300 mg twice per day, continuously, after chemotherapy."
11331813|NCT02489006|Experimental|Olaparib Prior to Surgery and Post Surgery|Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery and after surgery.
11331814|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
11331815|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
11331816|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
11331817|NCT02488980|Experimental|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
11331818|NCT02488980|Active Comparator|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
11331819|NCT02488980|Placebo Comparator|Placebo|Placebo
11331820|NCT02488967|Active Comparator|Arm I (AC-->WP)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
11331916|NCT02488252|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin at stable dose
11331821|NCT02488967|Experimental|Arm II (AC-->WP + carboplatin)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11331822|NCT02488954|Experimental|Probiotics|Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks
11331823|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
11331824|NCT02488902|Placebo Comparator|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
11331825|NCT02488902|Experimental|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
11331826|NCT02488902|Experimental|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
11331827|NCT02488902|Experimental|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
11331828|NCT02488902|Experimental|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
11331829|NCT02488902|Experimental|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
11331830|NCT02488889|Active Comparator|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
11331831|NCT02488889|Active Comparator|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
11331832|NCT02488863||Older Adults with Musculoskeletal Pain|Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
11331833|NCT02488863||Older Adults without Musculoskeletal Pain|Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
11331834|NCT02488863||Young Controls|Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
11331835|NCT02488850|Active Comparator|Surgery|An anatomical surgical resection of primary tumor
11331836|NCT02488850|Active Comparator|Radiotherapy|Stereotactic Ablative Radiotherapy (SABR), outpatient treatment that is typically delivered in between 3-8 fractions
11331837|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
11331838|NCT02488824|Experimental|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
11331839|NCT02488824|Active Comparator|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
11331840|NCT02488798||postmenopausal bleeding group|"100 women with postmenopausal bleeding undergoing 2D greyscale vaginal ultrasound and 3D Endometrial power Doppler and the features were classified using six different vascular patterns described by IETA group including the following patterns; single dominant vessel without branching, with branching, multiple vessels with focal origin, with multifocal origin at the myometrium-endometrium junction, scattered vessels or circular flow (Kucur et al., 2013 ).
~All patients then had Office hysteroscopy carried out in the outpatient clinic using vaginoscopic approach (Cooper et al., 2010). With endometrial samples from lesions or from the cavity for histopathological analysis."
11331841|NCT02488785|No Intervention|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
11331842|NCT02488785|Experimental|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
11331843|NCT02488772|Experimental|Treatment Group|Patients allocated to treatment group will be supplied with sleep interventions (sleep mask and ear plugs), and standardized instructions of use.
11331844|NCT02488772|Active Comparator|Control Group|Patients allocated to control group will be assessed for sleep quality, but not offered sleep mask and ear plugs. They will receive standard of care as decided by treating emergency physician.
11331845|NCT02488759|Experimental|Neoadjuvant Cohort|"Nivolumab intravenous infusion as specified
~**Not participating: Japan, Korea, and Taiwan"
11331846|NCT02488759|Experimental|Metastatic Monotherapy Cohort|Nivolumab intravenous infusion as specified
11331847|NCT02488759|Experimental|Nivolumab plus Ipilimumab Cohort|"Nivolumab intravenous infusion as specified with Ipilimumab intravenous infusion as specified
~**Not participating: Belgium, France and Germany
~Cohort expansion participating countries: Spain, US, UK, Netherlands, Japan and Mexico
~**Not participating in cohort expansion: France, Germany, Korea and Taiwan"
11332112|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
11331848|NCT02488759|Experimental|Nivolumab plus Relatlimab Cohort|"Nivolumab intravenous infusion as specified with Relatlimab intravenous infusion as specified
~** Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands
~Enrollment is closed for this cohort"
11331849|NCT02488759|Experimental|Nivolumab plus Daratumumab Cohort|"Nivolumab intravenous infusion as specified with Daratumumab intravenous infusion as specified
~**Not Participating: Belgium, Germany, France, Japan, Korea, Taiwan, UK, and Netherlands
~Enrollment is closed for this cohort"
11331850|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
11331851|NCT02488733|Experimental|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
11331852|NCT02488733|Other|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
11331853|NCT02488720||Clinically normal older inviduals|500 clinically normal older individuals with florbetapir positron emission tomography (PET) scan that does not show evidence of brain amyloid pathology at screening.
11331854|NCT02488707|Active Comparator|LISR group|Cases which undergo rectal resection with laparoscopic intersphincteric resection.
11331855|NCT02488707|Active Comparator|TAMIS Group|Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.
11331856|NCT02488694|Experimental|Arm A: Afatinib|105 patients to be treated with afatinib
11331857|NCT02488694|Active Comparator|Arm B: Pemetrexed|105 patients to be treated with pemetrexed
11331858|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
11331859|NCT02488668|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
11331860|NCT02488655|Experimental|Echopulse|Echopulse HIFU
11331861|NCT02488642|Experimental|isosorbide dinitrate-oxytocin|"Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
~If the cervical conditions (<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening."
11331862|NCT02488642|Placebo Comparator|misoprostol-oxytocin|"Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
~If the cervical conditions (<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening."
11331863|NCT02488629|Experimental|SCB01A|This study is a single arm, open-label, Phase II trial
11331864|NCT02488616|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
11331865|NCT02488616|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
11331866|NCT02488603|Experimental|Decision aids|
11331867|NCT02488603|No Intervention|usual care|
11331868|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease
~Clinical intervention:
~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
11331869|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry
~Clinical intervention: Inhaled corticosteroids (ICS)"
11331870|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma
~Clinical Intervention: LABA + LAMA + ICS"
11331871|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma
~Clinical Intervention: LABA + ICS inhaled therapy"
11331872|NCT02488590||OTHER|"patients with another diagnosis or healthy persons
~clinical Intervention: undefined - according to diagnosis"
11331873|NCT02488577|Active Comparator|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
11331874|NCT02488577|Active Comparator|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
11331875|NCT02488564|Experimental|Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin|"Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.
~Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment."
11331876|NCT02488551|Experimental|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
11331877|NCT02488551|Active Comparator|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
11331878|NCT02488538|Active Comparator|Combined oral contraceptives and Fuoxetine|Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. .
11331879|NCT02488538|Active Comparator|Combined oral contraceptives|Group 2 will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
11332143|NCT02486822|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
11331880|NCT02488538|Placebo Comparator|Placebo|Group 3 will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine.
11331881|NCT02488525|Experimental|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
11331882|NCT02488525|No Intervention|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
11331883|NCT02488512|Experimental|90Y-DOTATOC|90Y-DOTATOC
11331884|NCT02488499|Active Comparator|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
11331885|NCT02488499|Experimental|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
11331886|NCT02488486|Experimental|Automated postoperative sedation|Postoperative sedation is provided automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 40 and 60.
11331887|NCT02488473|Experimental|Ropivacaine + Dexmedetomidine|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Dexmedetomidine 100ug/ml
11331888|NCT02488473|Placebo Comparator|Ropivacaine + Placebo|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Saline
11331889|NCT02488460|No Intervention|Normal math|This arm serves as the control group receiving regular math lessons
11331890|NCT02488460|Experimental|Active math|This arm serves as the intervention group receiving physically active math lessons
11331891|NCT02488434|Active Comparator|fertile chip|sperm selection by using fertile chip and conventional methods
11331892|NCT02488434|No Intervention|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
11331893|NCT02488421||Patient treated with Apixaban|
11331894|NCT02488421||Patient treated with Rivaroxaban|
11331895|NCT02488421||Patient treated with Dabigatran|
11331896|NCT02488421||Patient treated with vitamin K antagonists|
11331897|NCT02488408|Experimental|Part A|To identify the maximum tolerated dose (MTD) of BGB324 in patients with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent, or in patients with high risk MDS (Norway only).
11331898|NCT02488408|Experimental|Part B|"To identify the safety and tolerability of BGB324:
~as a single agent in patients with AML who are unsuitable for intensive chemotherapy
~in a combination with cytarabine in patients with AML who are unsuitable for intensive chemotherapy
~in a combination with decitabine in patients with AML who are unsuitable for intensive chemotherapy (US only)
~as a single agent in patients with previously treated MDS (US Only) or in patients with high/intermediate (int-2) risk MDS (Norway Only)"
11331899|NCT02488395||de novo Parkinson's patients|"This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.
~This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
11331900|NCT02488395||matching controls|"This group includes age-matching control participants to the first Parkinson group.
~This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
11331901|NCT02488382|Experimental|Lonquek|treatment with Lonquek for autologous stem cell collection
11331902|NCT02488369|Experimental|Patients with non-Hodgkin's lymphoma|
11331903|NCT02488356|Experimental|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
11331904|NCT02488356|Placebo Comparator|Placebo|Inert fillers that is manufactured to look and taste the same as verum
11331905|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
11331906|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
11331907|NCT02488330|Experimental|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
11331908|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
11331909|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
11331910|NCT02488304|Experimental|HRCT scans|High Resolution Computed Tomography scans will be taken
11331911|NCT02488291|Experimental|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
11331912|NCT02488291|Experimental|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
11331913|NCT02488278|No Intervention|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
11331914|NCT02488265|Experimental|Motor training|Balance training, Screening to prevent falls
11331915|NCT02488265|Experimental|Balance RhytmicalTraining|Balance training, Screening to prevent falls
11331917|NCT02488252|Experimental|Chinese Medicine on top of standard medical care|"Semi-individualised Chinese Medicine treatment on top of standard medical care The treatment plan consists of 5 different formulas and will be prescribed to patients categorised to 5 subgroups according to clinical manifestation. Patients having multiple manifestations that fit more than 1 subgroup will not be included.
~Minor adjustment of the medication will be allowed and determined by the Chinese Medicine practitioner to reflect actual clinical practice. Dosage will follow strictly the China Pharmacopeia.
~A: spleen and kidney Qi deficiency, B: spleen and kidney Yang deficiency, C: spleen and kidney Qi and Ying deficiency, D: liver and kidney Ying deficiency, E: Ying and Yang deficiency
~Rehmannia-6 decoction: Wolfiporia cocos, Rehmannia glutinosa, Common macrocarpium Fruit, Dioscorea opposita , Paeonia suffruticosa Andr., Oriental waterplantain rhizome
~Rehmannia-8 decoction: Radix Aconiti Lateralis preparata, Cinnamomum cassia Presl, Rehmannia-6 decoction"
11331918|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
11331919|NCT02488226|Experimental|Gaze Contingent|Participants will view social videos using Gaze-contingent eye-tracking technology . If the participants looking patterns deviate from a normative pattern, they will be redirected to the normative point of regard using gaze-contingent cues.
11331920|NCT02488226|No Intervention|Control Condition|Participants will view unaltered social videos which do not change based on where the participant is looking.
11331921|NCT02488213|Active Comparator|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
11331922|NCT02488213|Experimental|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
11331923|NCT02488187|Other|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
11331924|NCT02488187|Other|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
11331925|NCT02488174|Active Comparator|Standard Care|The pre-intervention control condition will be usual care: that is, clinicians practice as usual without clinician notification of risk and without prompting on care practices as recommended by PROOFcheck.
11331926|NCT02488174|Experimental|PROOFcheck|The intervention for this study will consist of 3 parts: 1) Education of clinicians on prevention of severe ARF and MOF in and out of the ICU, and best practice with regards to patients with severe ARF; 2) Clinicians will be notified that a patient they are taking care of has been identified as being at high risk for developing severe ARF requiring prolong MV; 3) Notified clinicians will be directed to PROOFcheck with a bundle of recommendations for best care for patients with ARF.
11331927|NCT02488161||Patients with colorectal cancer|One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.
11331928|NCT02488148|Experimental|Hot yoga|3 hot yoga classes per week to be completed at local studios in Austin, TX.
11331929|NCT02488148|Experimental|Non-heated yoga|3 yoga classes to be completed at local studios in Austin, TX.
11331930|NCT02488148|No Intervention|Control|Maintain usual activities for the 12-week duration of the study.
11331931|NCT02488135|Experimental|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
11331932|NCT02488135|Active Comparator|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
11331933|NCT02488122|Experimental|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
11331934|NCT02488122|Sham Comparator|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
11331935|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
11331936|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
11331937|NCT02488096|Active Comparator|TRUS-Guided Biopsy|Transrectal Ultrasound (TRUS)-guided biopsy systematic 12-core biopsy (standard care)
11331938|NCT02488096|Experimental|MRI + TRUS-Guided biopsy|Prostate MRI later followed by systematic 12-score TRUS-guided biopsy + targeted biopsy of additional MRI-detected scores.
11331939|NCT02488083|Experimental|all subjects treated by UltraShape|all the patients undergo fat reduction treatment by UltraShape
11331940|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
11331941|NCT02488057|Active Comparator|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
11331942|NCT02488057|Active Comparator|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
11331943|NCT02488044|Experimental|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.
~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
11331944|NCT02488031|Experimental|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
11331945|NCT02488031|Experimental|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
11331946|NCT02488018|Experimental|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
11331947|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
11331948|NCT02487992|Experimental|CIK plus S-1 and Bevacizumab|"Cytokine-Induced Killer Cells are used to treat advanced colorectal cancer patients with S-1 and Bevacizumab.
~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress.
~Cytokine-induced killer cells 3 cycles,every 1 year. Continue until the disease progress."
11331949|NCT02487992|No Intervention|S-1 and Bevacizumab|"S-1 is an oral anticancer agent, is a derivative of fluorouracil. Bevacizumab (Avastin) is a recombinant human monoclonal IgG1 antibody, which plays a role in the biological activity of human vascular endothelial growth factor. Bevacizumab is mainly used in the treatment of advanced colorectal cancer.
~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress."
11331950|NCT02487979|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11331951|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
11331952|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
11331953|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
11331954|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
11331955|NCT02487953|Experimental|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
11331956|NCT02487953|Active Comparator|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
11331957|NCT02487953|Active Comparator|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
11331958|NCT02487940|Active Comparator|Intralipid|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
11331959|NCT02487940|Placebo Comparator|Placebo|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
11331960|NCT02487927||Weaning success|patients pass SBT and weaning without any ventilation in 48 hours
11331961|NCT02487927||weaning failure|patients do not pass SBT or ventilation with any ventilation in 48 hours
11331962|NCT02487914|Active Comparator|lidocaine iontophoresis using interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the iontophoresis of Lidocaine using interferential current.
11332144|NCT02486822|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
11331963|NCT02487914|Active Comparator|interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of interferential current.
11331964|NCT02487914|Active Comparator|lidocaine|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of topical Lidocaine.
11331965|NCT02487901|Active Comparator|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
11331966|NCT02487901|Sham Comparator|Drill|making gutter on the hinge side of lamina with conventional drill
11331967|NCT02487888|Experimental|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
11331968|NCT02487888|Experimental|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
11331969|NCT02487888|Experimental|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
11331970|NCT02487888|Experimental|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
11331971|NCT02487888|Experimental|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
11331972|NCT02487875|Experimental|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
11331973|NCT02487875|Active Comparator|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
11331974|NCT02487862|No Intervention|Screening|Participants were screened for the inclusion and exclusion criteria to select the study group. No intervention has been done.
11331975|NCT02487862|Placebo Comparator|catagerizing the study population|The selected participants where assigned into respective groups
11331976|NCT02487862|No Intervention|Stress Reduction Protocol|Participants were evaluated for the outcome of the intervention.
11331977|NCT02487849|Experimental|HIPEC|If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.
11331978|NCT02487836|Other|First attempt stenting (T0 = date of the first act)|Efficacy of laying of a biliary stent for chemotherapy realization
11331979|NCT02487823|Experimental|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
11331980|NCT02487823|Experimental|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
11331981|NCT02487823|Experimental|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
11331982|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
11331983|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
11331984|NCT02487797|Experimental|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
11331985|NCT02487797|Active Comparator|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
11331986|NCT02487784|Experimental|Particulate allograft + autogenous bone.|In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
11331987|NCT02487784|Active Comparator|Block allograft|The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
11331988|NCT02487771|Placebo Comparator|Placebo Capsule|
11331989|NCT02487771|Experimental|DHA Capsule|
11331990|NCT02487758|Experimental|Ridge preservation Flap|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
11331991|NCT02487758|Experimental|Ridge preservation Flapless|The test will be a flapless technique with tunneling and an intramucosal vertical incision on the buccal.
11331992|NCT02487745|Active Comparator|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
11331993|NCT02487745|Experimental|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
11331994|NCT02487732|Active Comparator|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
11331995|NCT02487732|Active Comparator|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
11331996|NCT02487719|Active Comparator|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.
~intervention: oral iron sulfate 1 tbl daily until birth"
11331997|NCT02487719|Active Comparator|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.
~intervention: oral iron polymaltose 1 tbl daily until birth"
11331998|NCT02487719|No Intervention|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level > 50 mcg/L at inclusion. No additional iron supplementation.
~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
11331999|NCT02487706|Experimental|Dolutegravir 50mg/day per 5 days|Dolutegravir 50mg/day per 5 days
11332000|NCT02487693|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
11332001|NCT02487693|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
11332002|NCT02487680|Experimental|Breakfast meal|A breakfast like meal will be provided together with a drink to overnight fasted subjects
11332003|NCT02487680|Experimental|Lunch meal|A lunch like meal will be provided together with a drink to overnight fasted subjects
11332004|NCT02487667|Active Comparator|Intervention Group|Therapeutic exercise
11332005|NCT02487667|No Intervention|Control Group|No treatment
11332006|NCT02487654|Active Comparator|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
11332007|NCT02487654|Experimental|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
11332008|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
11332009|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
11332010|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
11332011|NCT02487628|Experimental|HQ® Matrix Soft Tissue Mesh|HQ® Matrix Soft Tissue Mesh is a warp-knitted, multifilament, bioengineered scaffold which is comprised of the silk fibroin protein of the Bombyx mori (B. mori) silkworm. The porous network structure makes it soft and pliable and convenient to implant. The mesh is mechanically strong, biocompatible, and long-term bioresorbable. The pore size is suitable for macrophage migration and recruitment, which hinders bacteria growth. The mesh is provided in single sheets of varying widths and lengths and may be cut to the shape or size desired for a specific application. It is sterile and for single-patient use only.
11332012|NCT02487628|Active Comparator|ULTRAPRO® Partially Absorbable Lightweight Mesh|ULTRAPRO® Partially Absorbable Lightweight Mesh (Ethicon, Inc.) is manufactured from approximately equal parts of absorbable poliglecaprone-25 monofilament fiber and non-absorbable polypropylene monofilament fiber. Designed for open and laparoscopic hernia repairs, it allows surgeons the versatility to perform various hernia repairs with a single technology. It offers excellent strength with minimal foreign body mass, to allow patients to heal more naturally with increased comfort and mobility.
11332013|NCT02487602|Active Comparator|A|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
11332014|NCT02487602|Active Comparator|B|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
11332015|NCT02487602|Placebo Comparator|C|Placebo capsules 30 minutes before a standard radiolabeled lunch.
11332016|NCT02487602|Experimental|D|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a radiolabeled water.
11332017|NCT02487602|Experimental|E|Up to 5 Gelesis100 and/or placebo capsules 10 minutes before a radiolabeled meal.
11332018|NCT02487589|No Intervention|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).
~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
11332019|NCT02487589|Experimental|Treated group|Telephone support, telemonitoring and tele-exercise
11332020|NCT02487576|Other|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
11332021|NCT02487576|Other|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
11332022|NCT02487563|Experimental|Experimental Group 1|Decitabine in combination with rhTPO.
11332023|NCT02487563|Experimental|Experimental Group 2|Decitabine
11332024|NCT02487563|Active Comparator|Control Group|Conventional treatment except decitabine.
11332025|NCT02487550|Experimental|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
11332026|NCT02487550|Other|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
11332027|NCT02487537|Placebo Comparator|Non-sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day; soft drink does not contain glucose or any kind of sweet tasting substance
11332028|NCT02487537|Active Comparator|Sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day, soft drinks contains an amount of sweetener, which is isosweet compared to 100 g of sucrose in one liter of beverage
11332029|NCT02487524|Other|Nerve resection with pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
11332030|NCT02487524|Other|Nerve resection without pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
11332031|NCT02487524|Other|No nerve resection but pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
11332032|NCT02487511|Active Comparator|14 days|14 days treatment regimen
11332033|NCT02487511|No Intervention|7 days|7 days treatment regimen
11332034|NCT02487498|Experimental|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
11332035|NCT02487498|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
11332036|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
11332037|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
11333448|NCT02477826|Experimental|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
11332038|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
11332039|NCT02487459|Experimental|BPX-501 and AP1903|"Three cohorts, 3 patients each, will receive two infusions (at the same dose) of BPX-501.
~If needed to treat aGVHD, a single dose of AP1903 will be administered IV."
11332040|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
11332041|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
11332042|NCT02487433|Experimental|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
11332043|NCT02487433|Experimental|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
11332044|NCT02487420|Other|Arm 18m|arm 18m: 6 months between step 1 and step 2; 6 months between step 2 and step 3, 3 months between all other steps step by step gradual introduction of egg containing food products during 18 months, unless next step can not be taken
11332045|NCT02487420|Other|arm 30 m|arm 30m: 9 months between step 1 and step 2; 9 months between step 2 and step 3, 6 months between all other steps step by step gradual introduction of egg containing food products during 30 months, unless next step can not be taken
11332046|NCT02487407|Experimental|ODM-109|ODM-109 capsules for oral administration
11332047|NCT02487407|Placebo Comparator|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
11332048|NCT02487394|Active Comparator|Asthma, Smokers and Non-Smokers|In Phase I, One arm will contain subjects who are active smokers and the other arm will contain subjects with no active smoking. Active smoking will be defined as daily use of cigarettes, pipes, cigarillos or cigars at time of entry into the study and through duration of study. No active smoking defined as never smoking or having stopped smoking for 5 years or greater.
11332049|NCT02487394|Active Comparator|COPD, Smokers and Non-Smokers|For Phase II, Phase II will again be divided into two arms based on active smoking status as discussed previously.
11332050|NCT02487381|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
11332051|NCT02487381|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
11332052|NCT02487381|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) a
11332053|NCT02487381|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
11332054|NCT02487368|Experimental|Needle stimulation pad|a self-administered treatment with a mechanical needle stimulation pad, a mechanical device to be used for 30 minutes daily for 14 days.
11332055|NCT02487355|Active Comparator|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
11332056|NCT02487355|Active Comparator|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
11332057|NCT02487355|Active Comparator|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
11332058|NCT02487355|Active Comparator|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
11332059|NCT02487342|Experimental|milk|semi-skimmed milk (< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
11332060|NCT02487342|Active Comparator|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
11332061|NCT02487329|Active Comparator|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
11332062|NCT02487329|Experimental|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
11332063|NCT02487329|Experimental|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
11332064|NCT02487329|Experimental|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
11332065|NCT02487316|Experimental|crizotinib combined with chemotherapy|crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
11332066|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
11332067|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
11332068|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
11332069|NCT02487290|Experimental|Treatment|Aneufix ACP-T5
11332070|NCT02487277|Experimental|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4
~1 cycle = 28 days
~PEGPH20: 3ug/kg on Days 1, 8, 15
~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
11332071|NCT02487277|Experimental|Combination therapy alone|"1 cycle = 28 days
~PEGPH20: 3ug/kg on Days 1, 8, 15
~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15
~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
11332072|NCT02487251|Experimental|Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
11332073|NCT02487251|Experimental|Supports for Family Mealtimes|"In Phase 1 of the study, participants receive one or more interventions intended to promote the frequency of family meals as an obesity prevention strategy. Supports range from the least to the most comprehensive. The interventions include: Meal Delivery, Ingredient Delivery, Community Kitchen, Healthy Eating Classes, Cooking Demonstrations and Provision of Cookware. The goal of this phase was to identify intervention components most robustly related to primary outcomes.
~The goal of Phase 2 is to test the finalized intervention in a randomized controlled trial. In Phase 2 of the study, participants are randomly assigned to a meal delivery/cookware provision intervention or to a usual exposure group. Participants in the intervention group receive two meals per week for 12 weeks and a set of cookware/dinnerware."
11332074|NCT02487238|Experimental|Fecal Microbiota Enema|Live, healthy, human donor stool prepared as fecal enemas. Fecal enemas are prepared and collected by Rebiotix(®) (RBX2660), using extensively screened donor stool. Enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
11332075|NCT02487238|Placebo Comparator|Normal Saline Enema|Normal saline enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
11332076|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
11332077|NCT02487225|Placebo Comparator|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
11332078|NCT02487212|Active Comparator|Laser+Topical corticosteroid|Hypertrophic scars were treated with fractional Erbium: Yttrium aluminium garnet (YAG) (2,940-nm) laser, then 0.05% Clobetasol propionate ointment was immediately applied on the perforated scar on one side
11332079|NCT02487212|Placebo Comparator|Laser+Petrolatum gel|Hypertrophic scars were treated with fractional Erbium: YAG (2,940-nm) laser, then topical petrolatum gel was immediately applied on the perforated scar on the other side
11332080|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
11332081|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
11332082|NCT02487186|Active Comparator|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
11332083|NCT02487186|Active Comparator|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)
~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
11332084|NCT02487173|Experimental|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:
~Respirio Flu Test
~Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
~Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
11332085|NCT02487160|Experimental|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
11332086|NCT02487160|Active Comparator|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
11332087|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
11332088|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
11332089|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
11332090|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
11332091|NCT02487121|Experimental|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
11332092|NCT02487121|Active Comparator|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
11332093|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 5.0 mg/325 mg|every 4 to 6 hours
11332094|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 7.5 mg/325 mg|every 4 to 6 hours
11332095|NCT02487108|Experimental|Hydrocodone bitartrate/acetaminophen 10 mg/325 mg|every 4 to 6 hours
11332096|NCT02487108|Placebo Comparator|Matching placebo|every 4 to 6 hours
11332097|NCT02487095|Experimental|1/Phase I|VX-970 + (M6620) topotecan at escalating doses
11332098|NCT02487095|Experimental|2/Phase II|VX-970 (M6620) + topotecan at MTD/RP2D
11332099|NCT02487082|Other|Group A|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
11332100|NCT02487082|Other|Group B|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
11332101|NCT02487069|Experimental|MSD group|The patients will received HSCT from MSD.
11332102|NCT02487069|Experimental|MUD group|The patients will received HSCT from MUD.
11332103|NCT02487069|Experimental|HRD group|The patients will received HSCT from HRD.
11332104|NCT02487043|Experimental|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
11332105|NCT02487043|No Intervention|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
11332106|NCT02487030|Experimental|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
11332107|NCT02487030|Experimental|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
11332108|NCT02487030|Experimental|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
11332109|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
11332110|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
11332111|NCT02487030|Experimental|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
11384170|NCT02141516|Active Comparator|Group C|age-matched healthy controls
11332113|NCT02487017|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
11332114|NCT02487017|Experimental|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
11332115|NCT02487004||chronic hemodialysis patients|
11332116|NCT02486991|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
11332117|NCT02486991|Experimental|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
11332118|NCT02486978|Placebo Comparator|Control (no supplement)|Reference will be white bread to give 50 g available carbohydrates with placebo capsule
11332119|NCT02486978|Experimental|Dose 1|Test will comprise white bread to give 50 g available carbohydrates and one capsule of pomegranate/olive and one capsule placebo
11332120|NCT02486978|Experimental|Dose 2|Test will comprise white bread to give 50 g available carbohydrates and 2 capsules of pomegranate/olive.
11332121|NCT02486965|Experimental|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.
~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.
~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
11332122|NCT02486965|Placebo Comparator|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
11332123|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
11332124|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
11332125|NCT02486926|Placebo Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
11332126|NCT02486926|Active Comparator|Remifentanil|Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
11332127|NCT02486926|Active Comparator|Alfentanil|"Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.
~The incidence and severity of emergence agitation was compared with sevoflurane group."
11332128|NCT02486926|Other|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
11332129|NCT02486926|Other|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
11332130|NCT02486913|No Intervention|Conventional Health Check|Patients undergoing conventional National Health Service Health Check
11332131|NCT02486913|Experimental|Enhanced Health Check|Patients undergoing National Health Service Health Check enhanced by risk report
11332132|NCT02486900|Experimental|Neurofeedback training group|The neurofeedback group will perform 6 training sessions over a period of 4 months: 4 fortnightly sessions in the first two months will be followed by 2 monthly 'booster' sessions. Each session will include several behavioural assessments and fMRI-based neurofeedback training in an MRI scanner (1 h). The neurofeedback training phase will be be followed-up by two behavioural assessments 8 and 12 months after the first training.
11332133|NCT02486900|No Intervention|Treatment-as-usual control group|The control group will receive treatment as usual (e.g. medication, counselling) but no neurofeedback training during the study period. Patients in the control group will be invited for four behavioural assessment sessions (baseline assessment, follow-up assessments 4/8/12 months after baseline).
11332134|NCT02486887|Experimental|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
11332135|NCT02486887|No Intervention|conventional follow-up|conventional follow-up
11332136|NCT02486874|Experimental|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
11332137|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
11332138|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
11332139|NCT02486848|Placebo Comparator|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
11332140|NCT02486848|Active Comparator|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
11332141|NCT02486835|Experimental|"Cough Syrup for adults and children"|Marked (authorized) medical device acting by protecting the oropharynx, in a non pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris.Dosage form: syrup Dosage: 5 ml three times a day. Frequency: the duration of the study for each patient is 4 nights, 3 days.
11332142|NCT02486835|Placebo Comparator|Placebo|The placebo intervention is a syrup of same taste and colour without the protective components. Dosage form: syrup. Dosage: 5 ml three times a day Frequency: the duration of the study for each patient is 4 nights, 3 days.
11385222|NCT02134834|Experimental|Ascending single dose of OP0595|
11332145|NCT02486809|Experimental|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
11332146|NCT02486809|Experimental|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
11332147|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
11332148|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
11332149|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
11332150|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
11332151|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
11332152|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
11332153|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
11332154|NCT02486770|Experimental|Group 1|Aerucin 2.0mg/kg
11332155|NCT02486770|Experimental|Group 2|Aerucin 8.0mg/kg
11332156|NCT02486770|Experimental|Group 3|Aerucin 20.0mg/kg
11332157|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
11332158|NCT02486744|Active Comparator|80 Units of Acthar|Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
11332159|NCT02486744|Active Comparator|40 Units of Acthar|Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months
11332160|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
11332161|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
11332162|NCT02486731||Controls|Healthy subjects
11332163|NCT02486718|Experimental|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
11332164|NCT02486718|Active Comparator|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
11332165|NCT02486705|Active Comparator|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
11332166|NCT02486705|Experimental|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
11332167|NCT02486692|Experimental|Phase II- Experimental Group|Participants were provided with instructions and a web link for accessing the AboutFace website after the baseline assessment.
11332168|NCT02486692|No Intervention|Phase II- Usual Care Group|Participants were provided with instructions and a web link for accessing some online PTSD education materials after the baseline assessment.
11332169|NCT02486679|Active Comparator|PGE2|Patients allocated to vaginal PGE2 (Prostin) for cervical ripening
11332170|NCT02486679|Active Comparator|Foley catheter|Patients allocated to foley catheter placement for cervical ripening
11332171|NCT02486666|Experimental|Experimental Arm|"Experimental Arm:patients will not have any dose titration regardless of anti-Xa level.
~Premature neonates will receive enoxaparin 2.0 mg/kg/dose rounded to nearest whole mg twice daily, while term neonates will receive enoxaparin 1.7 mg/kg/dose rounded to nearest whole mg twice daily. Children≥1 month corrected age will receive 1.5 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing) while children≥2 month corrected age will receive 1.0 mg/kg/dose twice daily (maybe rounded +/- 10% for convenience of dosing)."
11332172|NCT02486666|Other|Control Arm|Control Arm: patients who will have dose titration based on anti-Xa levels to maintain a therapeutic range of 0.5-1.0 u/mL (standard of care).
11332173|NCT02486653|Experimental|Tamsulosin|
11332174|NCT02486653|Placebo Comparator|Placebo|
11332175|NCT02486640||Betaferon|
11332176|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
11332177|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
11332178|NCT02486601|Experimental|nab-paclitaxel + FOLFOX|nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)
11332179|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
11332180|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
11332181|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
11332182|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
11332183|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
11332184|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
11332185|NCT02486575|Other|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
11332186|NCT02486575|Other|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.
~Intervention Type: Behavioral (tutored learning)"
11332187|NCT02486562||People diagnosed with Multiple Sclerosis|
11332188|NCT02486549|Experimental|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
11332189|NCT02486549|Active Comparator|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
11332190|NCT02486536|Active Comparator|Group A|Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
11332191|NCT02486536|Active Comparator|Group B|the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
11332192|NCT02486536|Active Comparator|Group C|the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
11332193|NCT02486536|Active Comparator|Group D|Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
11332194|NCT02486536|Active Comparator|Group E|Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
11332195|NCT02486523|Active Comparator|Control group|"Outpatient management of children diagnosed with severe acute malnutrition.
~Interventions allocated:
~Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
11332196|NCT02486523|Experimental|Intervention group|"Outpatient management of children diagnosed with severe acute malnutrition + household WASH package
~Interventions allocated:
~Behavioral: Hygiene promotion sessions Device: Household WASH package The content of the kit: soap and aquatab for 3 months, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
~Behavioral: Household visits during the OTP phase Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
11332197|NCT02486510|No Intervention|Group 1 (Control)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.
~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)"
11332198|NCT02486510|Experimental|Group 2 (Treatment)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.
~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc."
11332199|NCT02486497|Active Comparator|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
11332200|NCT02486497|Active Comparator|Gemcitabine group|Grade of hENT1 immunostaining is 2.
11332201|NCT02486484|Experimental|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
11332202|NCT02486471|Other|Observational approach|Wait and see
11332203|NCT02486471|Active Comparator|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
11332204|NCT02486458|No Intervention|Negative control|No treatment will be applied
11332205|NCT02486458|Experimental|Varnish 4 h|Fluoride varnish will be applied on teeth and removed after 4 hours
11332206|NCT02486458|Experimental|Varnish 24 h|Fluoride varnish will be applied on teeth and removed after 24 hours
11332207|NCT02486458|Experimental|Fluoride Gel|Fluoride gell will be applied on teeth and removed after 4 minutes
11332208|NCT02486445|Experimental|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours.
11332209|NCT02486432|Experimental|Single arm Levodopa/Carbidopa|The intervention is dosing with Sinemet® which is an oral tablet containing Levodopa/Carbidopa. Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
11332210|NCT02486419||Summer|
11332211|NCT02486419||Winter|
11332212|NCT02486406|Experimental|Genotype 4, with or without compensated cirrhosis|12 weeks of treatment
11332213|NCT02486406|Experimental|Genotype 1a, without cirrhosis|12 weeks of treatment
11332214|NCT02486406|Experimental|Genotype 1a, with compensated cirrhosis|24 weeks of treatment
11332215|NCT02486406|Experimental|Genotype 1b, with or without compensated cirrhosis|12 weeks of treatment
11332216|NCT02486393||type of surgery|patients undergoing parotid surgery
11332217|NCT02486380|Experimental|Full face/Nasal masks|Simplus/Eson
11332218|NCT02486367|Active Comparator|Standard care/clopidogrel|300mg load followed by 75mg daily.
11332219|NCT02486367|Experimental|Ticagrelor|180mg load followed by 90mg twice daily for 30 days.
11332220|NCT02486354|Experimental|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
11332221|NCT02486341|Experimental|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
11332222|NCT02486341|Experimental|Long-acting basal insulin analogues|
11332223|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
11332224|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
11332291|NCT02485808||Medical|"Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.
~There will be no interventions, as this is an observational cohort."
11333449|NCT02477826|Experimental|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
11332225|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) <70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
11332226|NCT02486302||Observation Group|
11332227|NCT02486289|Experimental|NBMI (Emeramide) 100mg|NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
11332228|NCT02486289|Experimental|NBMI (Emeramide) 300mg|NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.
11332229|NCT02486289|Placebo Comparator|Placebo|Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.
11332230|NCT02486276|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
11332231|NCT02486276|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo
11332232|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
11332233|NCT02486263|Other|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
11332234|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
11332235|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
11332236|NCT02486250||ReVeRe 1|A subset of 200 participants from the Main Study Recruits and all MRI & PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
11332237|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI & PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
11332238|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
11332239|NCT02486224|Experimental|Kona Deep|Subjects will receive Kona Deep post-exercise
11332240|NCT02486224|Placebo Comparator|Spring Water|Subjects will receive commercially available Spring Water post-exercise
11332241|NCT02486224|Active Comparator|Sports Drink|Subjects will receive commercially available Sports Drink post-exercise
11332242|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
11332243|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
11332244|NCT02486198|Placebo Comparator|placebo+oxaliplatin-based chemotherapy|equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
11332245|NCT02486198|Experimental|GM+oxaliplatin-based chemotherapy|monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
11332246|NCT02486185|Other|SARC-F|screening test for sarcopenia being studied, the SARC-F
11332247|NCT02486172|Other|Peer supporter|Peer support program
11332248|NCT02486159|Experimental|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.
~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
11332249|NCT02486133|Experimental|A|Prezista & Norvir & Tivicay
11332250|NCT02486133|Active Comparator|B|Prezista & Norvir & Truvada or Prezista & Norvir & Kivexa
11332251|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
11332252|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
11332253|NCT02486107||ACDF|anterior cervical discectomy and fusion
11332254|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
11332255|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
11332256|NCT02486068|Experimental|ABSORB scaffold|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with ABSORB scaffold.
11332257|NCT02486068|Active Comparator|Xience|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with Xience Prime.
11332258|NCT02486055|Active Comparator|Cohort 1|In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
11332292|NCT02485808||Controls|"Men and women who are not experiencing lower urinary tract symptoms.
~This group will undergo MRI, pain and auditory sensitivity testing."
11332259|NCT02486055|Active Comparator|Cohort 2|In Cohort 2 doses BPM31510 Oral Nanosuspension 4% will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
11332260|NCT02486042|Other|Standard Nutrition|Infants in this group will receive the standard intravenous nutrition with predominantly Omega-6 fatty acids.
11332261|NCT02486042|Experimental|Omega-3 Group/Added Nutrition|Infants in this group will receive the experimental intravenous nutrition with Omega-3 fatty acids known as Omegaven in addition to standard nutrition.
11332262|NCT02486016|Experimental|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
11332263|NCT02486016|Active Comparator|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
11332264|NCT02486016|Active Comparator|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
11332265|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
11332266|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
11332267|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
11332268|NCT02485990|Experimental|Arm A: Tremelimumab Alone|25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
11332269|NCT02485990|Experimental|Arm B1: DESE Tremelimumab and Olaparib|18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
11332270|NCT02485990|Experimental|Arm B2: Tremelimumab and Olaparib|25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
11332271|NCT02485977||Pulmonary Hypertension|Adult patients with pulmonary hypertension referred for cardiac catheterization in the PI institution
11332272|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
11332273|NCT02485951|Active Comparator|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
11332274|NCT02485951|Active Comparator|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
11332275|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
11332276|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
11332277|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
11332278|NCT02485912|Active Comparator|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
11332279|NCT02485912|Active Comparator|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
11332280|NCT02485899|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
11332281|NCT02485886|Experimental|68Ga-BMV101 injection and PET/CT scan|The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
11332282|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
11332283|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
11332284|NCT02485860|No Intervention|standard dressings|
11332285|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
11332286|NCT02485834|Active Comparator|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
11332287|NCT02485834|Experimental|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
11332288|NCT02485821|Experimental|Estradiol + Misoprostol|100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.
11332289|NCT02485821|Placebo Comparator|Placebo + Misoprostol|100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.
11332290|NCT02485808||Surgical|"Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.
~There will be no interventions, as this is an observational cohort."
11385223|NCT02134834|Placebo Comparator|Normal Saline|
11332293|NCT02485808||Neuroimaging & Sensory Testing|"Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.
~This group will undergo MRI, pain and auditory sensitivity testing."
11332294|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
11332295|NCT02485782||Hemodialysis patients|"midweek dialysis session
~patients on maintenance hemodialysis at least 3 months
~stable dry weight
~single-pool Kt/V >1.4
~no clinical cardiovascular disease during the 6 months preceding entry"
11332296|NCT02485769|Experimental|PF-06650833|Active arm , PF-06650833 kinase.
11332297|NCT02485769|Placebo Comparator|Placebo|Placebo arm
11332298|NCT02485756|Experimental|Educational handout|Participants in the intervention group will read an educational handout on hormonal contraceptives/antiepileptic interactions.
11332299|NCT02485756|No Intervention|Control (no educational handout)|Those in the standard care group will not receive the educational handout.
11332300|NCT02485743|Active Comparator|Active Diet Products|A range of products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
11332301|NCT02485743|Placebo Comparator|Placebo Diet Products|A range of products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
11332302|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
11332303|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
11332304|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
11332305|NCT02485704|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
11332306|NCT02485704|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
11332307|NCT02485691|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m^2 intravenously in 1 hour every 3 weeks + prednisone 10 mg orally given daily + Primary prophylactic G-CSF (the choice of the G-CSF product is left to the Investigator's decision). Treatment will continue until confirmed disease progression or unacceptable toxicity.
11332308|NCT02485691|Experimental|Abiraterone acetate or enzalutamide|Abiraterone acetate oral 1000 mg once daily continuously + prednisone 5 mg orally given twice daily OR enzalutamide oral 160 mg once daily continuously. Treatment will continue until confirmed disease progression or unacceptable toxicity.
11332309|NCT02485678|Experimental|Proactive Telephone Toxicity Management|Proactive Telephone Toxicity Management
11332310|NCT02485678|Active Comparator|Control Arm|Control
11332311|NCT02485665|No Intervention|Kegel exercise education|Prostate cancer patients of control group will received Kegel exercise education for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
11332312|NCT02485665|Experimental|Extracorporeal biofeedback device|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
11332313|NCT02485652|Experimental|HM61713|HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
11332314|NCT02485639|Experimental|Arm 1|All study participants will receive licensed inactivated influenza vaccine intramuscularly on Day 1.
11332315|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
11332316|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
11332317|NCT02485613||bortezominb and dexamethasone group|
11332318|NCT02485600||DUODOPA patients.|Patients starting DUODOPA treatment at time of enrollment.
11332319|NCT02485587|Experimental|Individualized Arousal-Biofeedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 20 sessions of arousal (electrodermal activity) feedback, 1 session/week. Each session will last about 1 hour. After the first 10 sessions (10 weeks after the beginning of the training phase), parents/caregivers will be asked to evaluate behavioral measures of aggression.
~After training completion (approximately 20 weeks after the beginning of the training phase), subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the training phase)."
11332320|NCT02485587|Active Comparator|Treatment as usual|After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
11332321|NCT02485587|No Intervention|Typically developing (TD) control group|Healthy, typically developing children will only undergo baseline assessment (observational) for comparison
11332322|NCT02485574|Experimental|Bone bridging|To compare bone bridging between anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in left side of disc space and anterior bridging cages augmented with auto bone in rt side of disc space in transforaminal lumbar interbody arthrodesis
11332323|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
11332324|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
11332325|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
11332326|NCT02485548|Experimental|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
11332327|NCT02485548|Active Comparator|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
11332328|NCT02485535|Experimental|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11332329|NCT02485522||Fecal incontinence|Women age >18 years old with a diagnosis of fecal incontinence
11332330|NCT02485522||Controls|Women age >18 without a diangosis of fecal incontinence
11332331|NCT02485509|Experimental|20 mg VM-1500/Placebo Healthy group|VM-1500 20 mg or placebo single dose.
11332332|NCT02485509|Experimental|40 mg VM-1500/Placebo Healthy group|VM-1500 40 mg or placebo single dose.
11332333|NCT02485509|Experimental|20 mg VM-1500/Placebo Patient group|VM-1500 20 mg or placebo once daily for 7 days.
11332334|NCT02485509|Experimental|40 mg VM-1500/Placebo Patient group|VM-1500 40 mg or placebo once daily for 7 days.
11332335|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
11332336|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
11332337|NCT02485470|Experimental|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
11332338|NCT02485470|No Intervention|Usual Care|
11332339|NCT02485457|Experimental|Low volume|"The protocol will follow the following steps :
~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
11332340|NCT02485457|Experimental|High volume|"The protocol will follow the following steps :
~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)
~followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
11332341|NCT02485444|Active Comparator|Oxytocin|
11332342|NCT02485444|No Intervention|Observation|
11332343|NCT02485431|Experimental|Deflazacort, fasted|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water in Fasted state.
11332344|NCT02485431|Experimental|Deflazacort, high-fat meal|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water with high fat meal served 30 minutes prior to dosing.
11332345|NCT02485431|Experimental|Deflazacort, crushed, fasted|36mg of Deflazacort crushed and mixed with apple sauce.
11332346|NCT02485431|Experimental|Deflazacort alternate strength,fasted|Investigational Formulation Deflazacort tablet (6 X 6mg).
11332347|NCT02485431|Experimental|Deflazacort suspension with apple juice|Deflazacort oral suspension (36mg) mixed with 100ml apple juice in fasted state.
11332348|NCT02485418|Experimental|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:
~20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes"
11332349|NCT02485405||stressed|stressed volunteers perform Trier social stress test
11332350|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
11332351|NCT02485392|Active Comparator|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
11332352|NCT02485392|Active Comparator|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
11332353|NCT02485379|Other|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
11332354|NCT02485366|Experimental|Rejuvenated PRBCs|The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).
11332355|NCT02485353|Other|Vosaroxin and Cytarabine|
11332356|NCT02485340|Active Comparator|Sumatriptan|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
11332357|NCT02485340|Placebo Comparator|Placebo|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)
11332460|NCT02484677|Experimental|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
11332358|NCT02485327|Experimental|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.
~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
11332359|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
11332360|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
11332361|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
11332362|NCT02485249|Experimental|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
11332363|NCT02485236|Active Comparator|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
11332364|NCT02485236|Active Comparator|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
11332365|NCT02485210|Active Comparator|Covencional treatment|"Convencional endodontic treatment for deciduous teeth, with Surgical chemical preparation with series of Kerr files appropriate for each case, using initial file and an additional two files of larger size, with irrigation and aspiration with 1% sodium hypochlorite (Milton's solution) and endo PTC (Fórmula & Ação) with each change of file.
~Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session."
11332366|NCT02485210|Experimental|Photodynamic therapy|Endodontic Treatment with photodynamic terapy Irrigation of the root canal system Insertion of sterile paper cone immersed in Chimiolux® methylene blue for three minutes; administration of wireless Therapy XT EC laser device (DMC - São Carlos, Brazil) after removal of cone; energy density: 4 J/cm², power: 100 mw; wavelength: 660 nm; exposure time: 40 seconds Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session
11332367|NCT02485197|Other|Low 25(OH)D|We will recruit individuals with low 25(OH)D (<30ng/mL).
11332368|NCT02485197|Other|High 25(OH)D|"We will recruit individuals with higher 25(OH)D (at least 20ng/mL units higher then that of the low 25(OH)D group)."
11332369|NCT02485184|Active Comparator|TIPS group|Transjugular intrahepatic portosystemic shunt
11332370|NCT02485184|Active Comparator|ET & drugs groups|"Endoscopic therapy.
~Non-selective beta blockers.
~Anticoagulation therapy."
11332371|NCT02485171|Experimental|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
11332372|NCT02485171|No Intervention|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
11332373|NCT02485158|Experimental|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
11332374|NCT02485158|Experimental|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
11332375|NCT02485145|Experimental|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
11332376|NCT02485145|Experimental|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
11332377|NCT02485132||T2DM at SU initiation|T2DM newly prescribed a SU
11332378|NCT02485119|Experimental|BAY94-9343|"Cohort 1: Safety, tolerability and PK of 4.5 mg/kg dose given Q3W. Proceeding to Cohort 2 or not will be decided based on both safety variables during Cycle 1 (21 days) of 3 to 6 subjects in Cohort 1 and PK obtained from Cycle 1 (at least Day 1 to Day 5).
~Cohort 2: Safety, tolerability and PK of 6.5 mg/kg dose given Q3W. Whether recruitment will be continued up to 9 subjects for Cohort 2 or not will be decided based on safety variables during Cycle 1 (21 days) of the first 3 subjects in Cohort 2. The safety and tolerability of 6.5 mg/kg will be assessed based on the data of 9 subjects during Cycle 1 in Cohort 2, and considering long term toxicity, the safety and tolerability of BAY94-9343 will be assessed all safety data by the end of 3 cycles in Cohort 2."
11332379|NCT02485106|Active Comparator|Rifaximin group|Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days
11332380|NCT02485106|Active Comparator|Control group|Corticosteroid or Pentoxifylline for 28 days
11332381|NCT02485093|Active Comparator|No pacing|Ventricular intrinsic conduction enhanced
11332382|NCT02485093|Experimental|Pacing|Septal ventricular pacing with optimized AV delay
11332383|NCT02485080|Experimental|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
11332461|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
11332660|NCT02483416||group 1|Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
11332384|NCT02485067|Experimental|THVD-201|"1. Treatment period(12 weeks)
~Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)
~One capsule and One tablet bid on an empty stomach
~2. Open-label extension period(An additional 12 weeks)
~Regardless of the previous type of arm, all patients only take THVD-201 during this period.
~One capsule bid on an empty stomach"
11332385|NCT02485067|Active Comparator|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)
~Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet
~One capsule and One tablet bid on an empty stomach
~2. Open-label extension period(An additional 12 weeks)
~Regardless of the previous type of arm , all patients only take THVD-201 during this period.
~One capsule bid on an empty stomach"
11332386|NCT02485054||Eligible patients|Adults having had a transient visual disturbance during the last 8 days, except a diplopia
11332387|NCT02485041|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
11332388|NCT02485041|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
11332389|NCT02485041|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
11332390|NCT02485041|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
11332391|NCT02485041|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
11332392|NCT02485041|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
11332393|NCT02485028|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
11332394|NCT02485028|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
11332395|NCT02485028|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
11332396|NCT02485028|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
11332397|NCT02485028|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
11332398|NCT02485028|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
11332399|NCT02485015|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
11332400|NCT02485015|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
11332401|NCT02485002|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
11332402|NCT02485002|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
11332403|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
11332404|NCT02484976|Experimental|Family Based Behavioral Treatment|Central satiety brain and hormonal responses will be compared pre-and post-Family Based Behavioral Treatment, as well, as to a non-obese sample.
11332405|NCT02484963|Experimental|zolpidem|Tablet zolpidem 5mg once daily will be given for 4 weeks
11332406|NCT02484963|Placebo Comparator|Placebo|One tablet of placebo will be given for 4 weeks
11332407|NCT02484950|Experimental|Rotator cuff repair with stem cells|Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
11332408|NCT02484950|Placebo Comparator|Rotator cuff repair without stem cells|Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.
11332409|NCT02484937|Active Comparator|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
11332410|NCT02484937|Experimental|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
11332411|NCT02484924||Clopidogrel Group|Those patients treated with clopidogrel for ACS (before new guideline implementation)
11332412|NCT02484924||Ticagrelor Group|Those patients treated with ticagrelor for ACS (after new guideline implementation)
11332413|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
11332414|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
11332415|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
11332416|NCT02484885|Other|Healthy Volunteers|Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
11332417|NCT02484872||Lung neoplasms|Lung neoplasms irrespective of stage and histology
11332418|NCT02484859|Active Comparator|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
11332766|NCT02482649|Experimental|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
11332419|NCT02484859|Active Comparator|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
11332420|NCT02484846|Experimental|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
11332421|NCT02484846|Experimental|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
11332422|NCT02484846|Experimental|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
11332423|NCT02484846|Experimental|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
11332424|NCT02484846|Active Comparator|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
11332425|NCT02484846|Experimental|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
11332426|NCT02484846|Experimental|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
11332427|NCT02484833|Active Comparator|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
11332428|NCT02484833|Experimental|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
11332429|NCT02484820|Experimental|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
11332430|NCT02484820|No Intervention|Control|Standard care only, No silicone pessary will be placed in the vagina.
11332431|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
11332432|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
11332433|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
11332434|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
11332435|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
11332436|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
11332437|NCT02484794|Active Comparator|Treatment as Usual|Patients will receive standard outpatient treatment that consists of group psychotherapy, skills training, self-monitoring, nutritional counselling, and meal support.
11332438|NCT02484794|Experimental|Treatment with Smartphone App|Patients will receive the same standard outpatient treatment but will use the smartphone application instead of the paper food record. Patients in this group will receive daily feedback through the app, as opposed to weekly, but will still attend the weekly nutritional counselling group.
11332439|NCT02484781|Active Comparator|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
11332440|NCT02484781|Active Comparator|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
11332441|NCT02484768|Experimental|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
11332442|NCT02484768|Placebo Comparator|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
11332443|NCT02484755|Experimental|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
11332444|NCT02484742|No Intervention|Sleep control condition|8 hours of sleep throughout the 18-day stay in the Clinical Research Center
11332445|NCT02484742|Experimental|Insomnia symptom induction condition|4 4-day cycles, each consisting of 3 nights with sleep disruption followed by one night of recovery sleep.
11332446|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
11332447|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
11332448|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
11332449|NCT02484716|Experimental|Timolol|Timolol 0.5% eye-drops solution packaged in a nasal spray device.
11332450|NCT02484716|Placebo Comparator|Placebo|NaCl solution packaged in a nasal spray device.
11332451|NCT02484703|Placebo Comparator|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
11332452|NCT02484703|Experimental|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
11332453|NCT02484703|Experimental|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
11332454|NCT02484703|Experimental|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
11332455|NCT02484690|Active Comparator|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
11332456|NCT02484690|Experimental|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
11332457|NCT02484690|Experimental|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
11332458|NCT02484690|Experimental|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
11332459|NCT02484690|Experimental|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
11332767|NCT02482649|Active Comparator|Drugs|Methylphenidate or Atomoxetine
11332462|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
11332463|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
11332464|NCT02484638|Experimental|CSL689 low-dose|"Part 1: single injection of low-dose CSL689 for PK evaluation
~Part 2: up to 2 injections of low-dose CSL689 per bleeding event (bleeding events 1 to 3*)
~Part 3: up to 3 injections of low-dose CSL689 per bleeding event * Note: All subjects in the low-dose arm will be treated with high-dose CSL689 for bleeding events 4-6 in Part 2"
11332465|NCT02484638|Experimental|CSL689 high-dose|"Part 1: single injection of high-dose CSL689 for PK evaluation
~Part 2: up to 2 injections of high-dose CSL689 per bleeding event (bleeding events 4 to 6*)
~Part 3: up to 3 injections of high-dose CSL689 per bleeding event
~Note: All subjects in the high-dose arm will be treated with low-dose CSL689 for bleeding events 1-3 in Part 2"
11332466|NCT02484638|Active Comparator|Eptacog alfa low-dose|Single injection of low-dose Eptacog alfa in Part 1 for PK evaluation
11332467|NCT02484638|Active Comparator|Eptacog alfa high-dose|Single injection of high-dose Eptacog alfa in Part 1 for PK evaluation
11332468|NCT02484625|Experimental|Potato chips|Commercial potato chips, 180 kcal
11332469|NCT02484625|Experimental|Greek yogurt|Greek yogurt, 180 kcal
11332470|NCT02484625|Experimental|Cookies|Sandwich-type cookies, 180 kcal
11332471|NCT02484625|Experimental|Cheese|Mozzarella cheese, 180 kcal
11332472|NCT02484625|Experimental|Milk (fluid)|Milk, 2% m.f., 180 kcal
11332473|NCT02484612|Experimental|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
11332474|NCT02484612|Experimental|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
11332475|NCT02484599|Experimental|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, & Jansen, 2014).
11332476|NCT02484599|Placebo Comparator|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
11332477|NCT02484586|Other|Presbyope group|"40 years and over with a reading add.
~Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA
~Test lens: Etafilcon A
~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
11332478|NCT02484586|Other|Non-Presbyope group|"18-39 years with no reading add.
~Control lens: Etafilcon A, Nelfilcon A, Omafilcon A
~Test lens: Etafilcon A
~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
11332479|NCT02484573|Experimental|Propanolol|Patients will take the non-selective beta blocker propranolol for approximately 4 weeks starting immediately after endoscopy for esophageal variceal ligation. Patients will be initiated on a dose of 20mg by mouth every 12 hrs before titration to maximum tolerated dose. Patients will undergo testing before and after treatment for the variables listed in the outcomes section below.
11332480|NCT02484560|Experimental|Ambulatory Patients|Ambulatory patients receiving stem cell therapy
11332481|NCT02484560|Experimental|Non-Ambulatory Patients|non-ambulatory patients receiving stem cell therapy
11332482|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
11332483|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
11332484|NCT02484521|Active Comparator|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
11332485|NCT02484521|Other|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
11332486|NCT02484508|Experimental|Guli capsule|Guli capsule, the tested drug of this study
11332487|NCT02484508|Active Comparator|Kangguzengsheng capsule|Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study
11332488|NCT02484495|Experimental|Program evaluation in intervention areas|"A quasi-experimental matched-control cluster design will be used in which outcomes are compared in intervention and non-intervention areas. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Sixty intervention clusters have been purposively selected whereas the data will be collected from randomly selected subjects. The following interventions will be provided:
~Processed complementary food rations will be distributed to all children 6-23 months of age, from a grain bank based on bartering of raw materials.
~Monthly 15 sachets of MNP will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification."
11332561|NCT02484066|Active Comparator|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
11332801|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
11332489|NCT02484495|No Intervention|Non intervention areas|A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
11332490|NCT02484482|Experimental|Group 1|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Fasting→Standard Meal→High Fat Meal"
11332491|NCT02484482|Experimental|Group 2|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Standard Meal→High Fat Meal→Fasting"
11332492|NCT02484482|Experimental|Group 3|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~High Fat Meal→Fasting→Standard Meal"
11332493|NCT02484482|Experimental|Group 4|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Fasting→High Fat Meal→Standard Meal"
11332494|NCT02484482|Experimental|Group 5|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~Standard Meal→Fasting→High Fat Meal"
11332495|NCT02484482|Experimental|Group 6|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.
~High Fat Meal→Standard Meal→Fasting"
11332496|NCT02484469|Experimental|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
11332497|NCT02484469|Placebo Comparator|Unexposed|Standard Team-Based learning session about leprosy
11332498|NCT02484456|Experimental|Test Session 1|2 weeks of 1,080 or 1,440 mg/day (single daily dose) of study drug
11332499|NCT02484456|Placebo Comparator|Test Session 2|2 weeks of single daily dose of placebo pill
11332500|NCT02484443|Experimental|Treatment (sargramostim and dinutuximab)|Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
11332501|NCT02484430|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11332502|NCT02484417|Experimental|Cohort 1: RSV A2 10^5 PFU/dose|Challenge 4 subjects with low dose and proceed to larger cohort after safety review.
11332503|NCT02484417|Experimental|Cohort 2: RSV A2 10^5 PFU/dose|Challenge 12 subjects with the low dose and proceed to high dose after safety review.
11332504|NCT02484417|Experimental|Cohort 3: RSV A2 10^6.3 PFU/dose|Challenge 12 subjects with the high dose
11332505|NCT02484404|Experimental|P1 MEDI+C|Ph I MEDI4736 + cediranib dose escalation
11332506|NCT02484404|Experimental|P1 MEDI+O|Ph I MEDI4736 + olaparib dose escalation
11332507|NCT02484404|Experimental|P1 MEDI+O+C|Ph I MEDI4736 + olaparib + cediranib dose escalation
11332508|NCT02484404|Experimental|P2 MEDI+C|Ph II MEDI4736 + cediranib at RP2D
11332509|NCT02484404|Experimental|P2 MEDI+O|Ph II MEDI4736 + olaparib at RP2D
11332510|NCT02484404|Experimental|P2 MEDI+O+C|Ph II MEDI4736 + olaparib + cediranib at RP2D
11332511|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
11332512|NCT02484378|Experimental|CER-001|CER-001 infusion
11332513|NCT02484378|Placebo Comparator|Placebo|Placebo infusion
11332514|NCT02484365||single arm study|No treatment or intervention will given to the patients
11332515|NCT02484352|Other|0 mg/kg of oxycodone|Intervention: patients receive 10 ml of normal saline without oxycodone through intravenous route before intubation.
11332516|NCT02484352|Other|0.05 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.05 mg/kg of oxycodone in normal saline through intravenous route before intubation.
11332517|NCT02484352|Other|0.1 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.1 mg/kg of oxycodone in normal saline through intravenous route before intubation.
11332518|NCT02484352|Other|0.15 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.15 mg/kg of oxycodone in normal saline through intravenous route before intubation.
11332519|NCT02484352|Other|0.2 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.2 mg/kg of oxycodone in normal saline through intravenous route before intubation.
11332520|NCT02484339|Experimental|Treatment Group A|"Radium-223 dichloride (Xofigo®) 55 kilobecquerel (kBq)/kgbw (6 i.v. injections every 4 weeks)
~External beam radiotherapy (EBRT)->conventional or high dose radiotherapy"
11332521|NCT02484339|Other|Treatment Group B|External beam radiotherapy (EBRT) ->conventional or high dose radiotherapy
11332522|NCT02484313|Experimental|Greek yogurt|25 g available carbohydrates
11332523|NCT02484313|Experimental|Cookies|25 g available carbohydrates
11332524|NCT02484300|Experimental|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
11332525|NCT02484300|Experimental|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
11332526|NCT02484300|Experimental|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
11332527|NCT02484300|Placebo Comparator|Placebo|Placebo outcomes versus melatonin
11332528|NCT02484287|Active Comparator|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
11332529|NCT02484287|Active Comparator|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
11332530|NCT02484287|Active Comparator|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
11332531|NCT02484274|Other|infants followed by pediatrician|
11334794|NCT02468557|Experimental|Idelalisib|Participants will receive a single dose of idelalisib.
11332532|NCT02484261|No Intervention|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
11332533|NCT02484261|Experimental|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
11332534|NCT02484248|Active Comparator|cross-over of Ketotifen|Patients will begin the active ketotifen treatment first and cross over to placebo.
11332535|NCT02484248|Placebo Comparator|cross-over of Placebo|Patients will begin the placebo treatment first and cross over to the active ketotifen.
11332536|NCT02484235|Experimental|Group HIIT|Only Aerobic Training with HIIT
11332537|NCT02484235|Experimental|Group Strength|Only Strength Training
11332538|NCT02484235|Experimental|HIIT and Strength|Both intervention HIIT and Strength training
11332539|NCT02484209|Experimental|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
11332540|NCT02484209|Active Comparator|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
11332541|NCT02484196||Couples|Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
11332542|NCT02484196||Women|Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
11332543|NCT02484183|No Intervention|Low-flow oxygen|Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is <90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (>70 breaths/minute if 1-11 months; >60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
11332544|NCT02484183|Experimental|bubble CPAP|Bubble continuous positive airway pressure (bCPAP) patients are eligible if respiratory danger signs are present or if oxygen saturation is <90%. bCPAP will be initiated at 7 centimeters (cm) water (H20) if 1-2 months of age or 8cm H20 if 2-59 months of age using the minimum oxygen flow necessary to achieve these pressures. Gradual weaning can be attempted after 24-48 hours of treatment. All changes will be followed by 60 minutes of monitoring.
11332545|NCT02484170|Active Comparator|mannitol in vehicle cream /vehicle cream|one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
11332546|NCT02484170|Active Comparator|vehicle cream /mannitol in vehicle cream|one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
11332547|NCT02484157|Experimental|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
11332548|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
11332549|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
11332550|NCT02484131|Experimental|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
11332551|NCT02484131|Experimental|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
11332552|NCT02484131|No Intervention|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
11332553|NCT02484118|Experimental|Targeted blood flow rate 320 ml/min|Hemodialysis blood flow will be targeted at 320 ml/min during hemodialysis for two weeks
11332554|NCT02484118|Experimental|Targeted blood flow rate 380 ml/min|Hemodialysis blood flow will be targeted at 380 ml/min during hemodialysis for two weeks
11332555|NCT02484105|Experimental|Comforting Conversation|Conversation according to the initital qualitative study.
11332556|NCT02484105|Active Comparator|Standard Communication|Standard information prior to and during endoscopy.
11332557|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
11332558|NCT02484079|Active Comparator|Cold polypectomy|"Patients in this arm will have their polyps removed by cold polypectomy, i.e. a metal sling that is closed around the basis of the polyp, and the polyp is cut off.
~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
11332559|NCT02484079|Active Comparator|Hot polypectomy|"Patients in this arm will have their polyps removed by hot polypectomy, i.e. a metal sling taht is closed around the basis of the polyp, electrical currents is applied, and the polyp is cut off.
~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
11332560|NCT02484066|Experimental|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
11332562|NCT02484053|Experimental|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
11332563|NCT02484053|Experimental|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
11332564|NCT02484040|Experimental|Two-week course arm|"Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.
~Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid"
11332565|NCT02484040|No Intervention|Conventional arm|conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid
11332566|NCT02484027|Experimental|statin-therapy|Rosuvastatin orally at a dose of 20mg daily is assigned to patients immediately for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
11332567|NCT02484027|Sham Comparator|non-statin-therapy|No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
11332568|NCT02484014|Experimental|TSM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by teachers as SEHER Mitra)
11332569|NCT02484014|Experimental|SM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by SEHER Mitra)
11332570|NCT02484014|Other|Comparison Arm|Tarang Adolescence Education Programme
11332571|NCT02484001|Experimental|ESL 800 mg|ESL will be administered orally once daily (QD)
11332572|NCT02484001|Experimental|ESL 1200 mg|ESL will be administered orally once daily (QD)
11332573|NCT02484001|Experimental|ESL 1600 mg|ESL will be administered orally once daily (QD)
11332574|NCT02484001|Experimental|ESL 400 mg|ESL will be administered orally once daily (QD)
11332575|NCT02483988|Experimental|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
11332576|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
11332577|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
11332578|NCT02483962|Placebo Comparator|Gelatine capsule|Gelatine capsules containing no active ingredients, will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
11332579|NCT02483962|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butcher's broom extract and 3,2 mg of vitamin B6, will be taken once per day, in the morning after breakfast, for 30 days.
11332580|NCT02483949|No Intervention|Control|
11332581|NCT02483949|Experimental|Intervention|Lifestyle intervention with peer-counseling follow-up
11332582|NCT02483936|Experimental|Test 1: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
11332583|NCT02483936|Experimental|Test 2: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
11332584|NCT02483936|Active Comparator|Comparator 1: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
11332585|NCT02483936|Active Comparator|Comparator 2: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
11332586|NCT02483923|Experimental|Group S|
11332587|NCT02483923|Placebo Comparator|Group C|
11332588|NCT02483910|Experimental|DI-LL via telehealth|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
11332589|NCT02483910|Active Comparator|Standard of care delivered via telehealth|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.
~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
11332590|NCT02483897|Experimental|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
11332591|NCT02483897|Placebo Comparator|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
11332592|NCT02483884|Experimental|Low risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with low risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
11332593|NCT02483884|Experimental|Intermediate risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with intermediate risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
11332594|NCT02483884|Experimental|High risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with high risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
11332595|NCT02483871|Experimental|Rosuvastatin|Two Cohorts, one at 20 mg and one at 40 mg will enroll in a dose escalation of rosuvastatin
11332596|NCT02483858|Experimental|PQR309|Different dose Evaluation (continous and intermittent) 20-160mg daily
11332597|NCT02483845|Experimental|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
11332598|NCT02483832|Active Comparator|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
11332599|NCT02483832|Active Comparator|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
11332600|NCT02483806|Experimental|PEEP 0 cmH2O|PEEP 0 cmH2O (zero end expiratory pressure, ZEEP)
11332601|NCT02483806|Experimental|PEEP 5 cmH2O|
11332602|NCT02483806|Experimental|EEP 10 cmH2O|
11332658|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
11332603|NCT02483793|Active Comparator|Oxybutynin group|This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.
11332604|NCT02483793|Active Comparator|Tamsulosin group|This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age ≥ 4.
11332605|NCT02483780|Experimental|Storytelling intervention|"Two communes will be assigned to intervention group. Within each commune, 25 adults with HTN will be enrolled.
~Patients will receive 2 DVDs with stories of patients who have successfully controlled their hypertension and Learn More section, which will be coordinated with specific patient stories and will fill in gaps not covered by the storytellers."
11332606|NCT02483780|No Intervention|Usual care|"Two communes will be assigned to usual care group. Within each commune, 25 adults with HTN will be enrolled.
~Patients will receive 2 DVDs with only didactic material about common non-communicable diseases but without hypertension related stories."
11332607|NCT02483767|Experimental|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
11332608|NCT02483767|Active Comparator|standard chemotherapy without goserelin|standard chemotherapy without goserelin
11332609|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
11332610|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
11332611|NCT02483741|Experimental|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
11332612|NCT02483741|No Intervention|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
11332613|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test +|These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
11332614|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test -|These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
11332615|NCT02483715|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
11332616|NCT02483715|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
11332617|NCT02483702|Experimental|Patients under 4 months Receive Irradiated Blood|Patients under 4 months of age will receive irradiated blood products, as per hospital protocol. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
11332618|NCT02483702|Experimental|Patients Over 4 Months Recieve Non-Irradiated Blood|Patients over 4 months of age will receive non-irradiated blood products. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
11332619|NCT02483689|Placebo Comparator|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
11332620|NCT02483689|Experimental|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
11332621|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
11332622|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
11332623|NCT02483663||27 Monozygotic Pairs|
11332624|NCT02483663||27 Dizygotic Pairs|
11332625|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
11332626|NCT02483624|Experimental|Low Dose|10 patients 225 mg of BR-DIM. 2 capsules AM and 1 PM. 52 weeks duration.
11332627|NCT02483624|Experimental|High Dose|10 patients 375 mg of BR-DIM. 3 capsules AM and 2 PM. 52 weeks duration.
11332628|NCT02483624|Placebo Comparator|Placebo|10 patients receiving weight matched placebo. 5 for high dose and 5 for low dose. 52 weeks of weight matched pills.
11332629|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.
~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
11332630|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.
~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
11332631|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.
~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
11332632|NCT02483598|Experimental|Buspirone|Buspirone alone
11332633|NCT02483598|Active Comparator|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
11332659|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
11332634|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
11332635|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
11332636|NCT02483572|Experimental|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
11332637|NCT02483572|No Intervention|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
11332638|NCT02483559|Other|Amber Lenses|Participants will be randomized to participate in the amber lens condition first or second. Outcome measures to assess the effects of wearing amber lenses to block the blue light spectrum of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
11332639|NCT02483559|Other|Placebo Lenses|Participants will be randomized to participate in the placebo lens condition first or second. Outcome measures to assess the effects of wearing placebo lenses to allow all spectrums of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
11332640|NCT02483546|Experimental|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
11332641|NCT02483546|Active Comparator|traditionally teaching|students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
11332642|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
11332643|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
11332644|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
11332645|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
11332646|NCT02483507|Active Comparator|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
11332647|NCT02483507|Active Comparator|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
11332648|NCT02483507|Active Comparator|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
11332649|NCT02483494|Experimental|APN-led Telemedicine|Participants will receive APN-led Telemedicine in addition to usual care.
11332650|NCT02483494|No Intervention|Usual care|Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.
11332651|NCT02483468|Experimental|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
11332652|NCT02483468|Sham Comparator|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
11332653|NCT02483455|Experimental|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
11332654|NCT02483455|Placebo Comparator|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
11332655|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer < 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer < 500ug/L
11332656|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer > or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer > or = 500 ug/L and High Clinical Pretest Probability
11332657|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
11332661|NCT02483416||group 2|Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
11332662|NCT02483403|Other|Healthy Volunteers|Healthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
11332663|NCT02483390|Experimental|Intervention group: All dyads are in the intervention arm.|
11332664|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
11332665|NCT02483364|Experimental|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
11332666|NCT02483351|Experimental|Liberal RBC Transfusion Strategy|
11332667|NCT02483351|Active Comparator|Restrictive RBC Transfusion Strategy|
11332668|NCT02483338|Other|Children surgery|
11332669|NCT02483325|Other|Busulfan with adapted doses|Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)
11332670|NCT02483312|Experimental|IL-12|A single dose of IL-12, given intravenously.
11332671|NCT02483299|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
11332672|NCT02483299|Active Comparator|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
11332673|NCT02483286|Experimental|ICG|Integrated Care Group
11332674|NCT02483286|Experimental|MTG|Muscle Training Group
11332675|NCT02483286|Experimental|XBG|X-box Group
11332676|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
11332677|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
11332678|NCT02483260|Other|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
11332679|NCT02483247|Experimental|Combo with Capecitabine|
11332680|NCT02483247|Experimental|Combo with Doxorubicin|
11332681|NCT02483247|Experimental|Combo with Nivolumab (US only)|
11332682|NCT02483247|Experimental|Combo with Pembrolizumab|
11332683|NCT02483247|Experimental|Combo with Paclitaxel|
11332684|NCT02483247|Experimental|Combo with Sunitinib|
11332685|NCT02483234|Experimental|Psoriasis/Psoriatic arthritis|Patients with Psoriasis and inflammatory and/or structural lesions and/or erosions in the MRI/HR-qCT scan will be treated with Secukinumab. Patients with psoriatic arthritis will be treated with Secukinumab. Bone changes will be evaluated influenced by IL-17 blockade
11332686|NCT02483221|Active Comparator|TCI-PCA|
11332687|NCT02483221|Active Comparator|PCA|
11332688|NCT02483208|Experimental|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
11332689|NCT02483208|Other|Advate|Advate infusion to analyze pharmacokinetics.
11332690|NCT02483195|Active Comparator|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
11332691|NCT02483195|Active Comparator|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
11332692|NCT02483182|Experimental|ZEP-3 ointment 1.0%|Topical administration
11332693|NCT02483182|Active Comparator|Acyclovir cream 5%|Topical administration
11332694|NCT02483169|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
11332695|NCT02483169|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
11332696|NCT02483169|Experimental|Cilostazol|cilostazol plus placebo of aspirin
11332697|NCT02483169|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
11332698|NCT02483156|Active Comparator|SOF + RBV|Sofosbuvir 400 mg once daily +RBV (1000 mg/day) for 12-24 weeks
11332699|NCT02483156|Experimental|sof + RBV + AH|Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg for 12-24 weeks
11332700|NCT02483143|Active Comparator|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
11332701|NCT02483143|Active Comparator|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
11332702|NCT02483143|Placebo Comparator|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
11332703|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
11332704|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
11332705|NCT02483104|Experimental|veliparib (ABT-888)|
11332706|NCT02483091|Experimental|Multifaceted KT intervention|Webinars, online vignettes and e-module, copy of guideline recommendations
11332707|NCT02483091|No Intervention|Control|Printed copy of guideline recommendations
11332708|NCT02483078|Active Comparator|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
11332802|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
11387189|NCT02121639|Experimental|AZD5363|AZD5363
11332709|NCT02483078|Placebo Comparator|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
11332710|NCT02483065||inpatients with dementia|
11332711|NCT02483065||inpatients without dementia|
11332712|NCT02483052|Experimental|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
11332713|NCT02483039|Experimental|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
11332714|NCT02483039|No Intervention|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
11332715|NCT02483026|Experimental|Intensive supplements care pre-surgery|Multi vitamins pills vitamin D
11332716|NCT02483026|Other|Standard supplements care pre-surgery|vitamin D (Vitamin D will be given in a reduced doses compared to the intervention group)
11332717|NCT02483013|Active Comparator|Whitening dentifrices|Two groups used whitening dentifrices, three times per day during four weeks
11332718|NCT02483013|Placebo Comparator|Placebo|One group used conventional dentifrice, three times per day during four weeks
11332719|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.
~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.
~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.
~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.
~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
11332720|NCT02482987|Experimental|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
11332721|NCT02482987|Experimental|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
11332722|NCT02482948|Active Comparator|Collagenase|This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
11332723|NCT02482948|Active Comparator|Active leptospermum honey|This is an active medicinal grade honey used to promote autolytic debridement and applied daily
11332724|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
11332725|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
11332726|NCT02482922|Experimental|IET and Nutrition|3 times per week of interval exercise training Once daily meal replacement
11332727|NCT02482909|Experimental|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
11332728|NCT02482909|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
11332729|NCT02482883|Active Comparator|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
11332730|NCT02482883|Sham Comparator|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
11332731|NCT02482870|Active Comparator|Macintosh|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a Macintosh laryngoscope.
11332732|NCT02482870|Active Comparator|KingVision|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a King Vision video laryngoscope.
11332733|NCT02482857|Experimental|Acetylsalicylic acid 75 mg twice daily|Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.
11332734|NCT02482857|Active Comparator|Acetylsalicylic acid 160 mg once daily|Aspirin 160 mg OD is an accepted and used dosage after CABG.
11332735|NCT02482857|Active Comparator|Acetylsalicylic acid 75 mg once daily|Aspirin 75 mg OD is an accepted and used dosage after CABG.
11332736|NCT02482844|Other|Pacemaker|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
11332737|NCT02482844|Other|holter implantable|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
11332738|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
11332739|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
11332740|NCT02482818|Placebo Comparator|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.
~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).
~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.
~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
11332741|NCT02482818|Experimental|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.
~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).
~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.
~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.
~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
11332742|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
11332743|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
11332744|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
11332745|NCT02482792|Experimental|Norwegian Psychomotor Physiotherapy|NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
11332746|NCT02482792|Active Comparator|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.They will receive one session weekly with COPE, given by a physiotherapist, maximum 4 times, followed by active individual Physiotherapy (PT).
11332747|NCT02482766|Experimental|INRECSURE|Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
11332748|NCT02482766|Active Comparator|INSURE|Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.
11332749|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11332750|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11332751|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11332752|NCT02482740|Experimental|tamoxifen|tamoxifen 20 mg given everyday for 12 months
11332753|NCT02482740|Active Comparator|letrozole|letrozole 2.5 mg given everyday for 12 months
11332754|NCT02482727|No Intervention|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
11332755|NCT02482727|Experimental|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
11332756|NCT02482714|Experimental|Rehab Institute|This group will do some physical activity in a specialized institute
11332757|NCT02482714|Active Comparator|Club structure|This group will do some physical activity in a club.
11332758|NCT02482688|Experimental|Multisensory Acute|Multisensory intervention delivered within 2 months post-stroke.
11332759|NCT02482688|Experimental|Multisensory Chronic|Multisensory intervention delivered 6 months post-stroke.
11332760|NCT02482688|Active Comparator|Unisensory Acute|Unisensory intervention delivered within 2 months post-stroke.
11332761|NCT02482688|Active Comparator|Unisensory Chronic|Unisensory intervention delivered 6 months post-stroke.
11332762|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332763|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332764|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332765|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332768|NCT02482636|Other|Group 1|"Group 1 will receive the following interventions:
~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months
~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months
~Rotavirus vaccine oral 1.5ml at 2 and 3 months
~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months
~Meningococcal C/Hib vaccine IM 0.5ml at 12 months
~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
11332769|NCT02482636|Other|Group 2|"Group 2 will receive the following interventions:
~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months
~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)
~Rotavirus vaccine oral 1.5ml at 2 and 3 months
~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months
~Meningococcal C/Hib vaccine IM 0.5ml at 12 months
~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
11332770|NCT02482623|Experimental|Intervention|Dyads in this arm will receive care provided by an interprofessional team trained through the DSM-H to provide patient/caregiver-centered dementia care through home healthcare.
11332771|NCT02482623|No Intervention|Control|Dyads in this arm will receive usual care provided in the home healthcare setting.
11332772|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332773|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332774|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
11332775|NCT02482597|Experimental|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
11332776|NCT02482597|Active Comparator|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
11332777|NCT02482584|Active Comparator|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
11332778|NCT02482584|Other|Control group|Control group
11332779|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
11332780|NCT02482558|Experimental|High GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day high glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
11332781|NCT02482558|Experimental|Low GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day low glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
11332782|NCT02482545|Experimental|Breakfast Meal Replacement|Once daily of a powdered meal replacement (high fat, high protein) will be consumed, mixed with water, at breakfast.
11332783|NCT02482545|No Intervention|Control|No placebo or intervention
11332784|NCT02482532|Experimental|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
11332785|NCT02482519|Other|10 day overfeeding/fasting|10 day high calorie diet followed by a 10 day fast
11332786|NCT02482506|Other|SG-WLP|Self-guided weight loss program
11332787|NCT02482506|Active Comparator|MF-WLP|Moving Forward Weight Loss Program
11332788|NCT02482493|Active Comparator|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
11332789|NCT02482493|Active Comparator|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
11332790|NCT02482480|Experimental|Interventional group|"Participants followed a 8-week intervention program with a total of 24 sessions (12 of those were supervised). The aim of the supervision was to increase the adherence to the treatment and to control the compliance of patients. General physical activity consisted in walking along previously standardized urban parks designed for the urban EPOC training project (Arbillaga-Etxarri et al, 2016). The duration of walking were 30 minutes. The physiotherapist supervised the accomplishment of other activities such as oropharyngeal exercises and diet control.
~Oropharyngeal exercises:
~Expiratory muscle strength training (EMST):
~Masako Manoeuvre
~Shaker Head Lift:
~Facial exercise"
11332791|NCT02482480|Sham Comparator|Control Group|Control group participants only received general recommendations regarding general physical activity, diet and sleep hygiene. After 8-weeks of control, they were re-evaluated with the same evaluation test used in the beginning of the study period. Recommendations for general physical activity were walking during 30 minutes at least 3 times a week maintaining the greatest possible pace. Also, control group patients received the same diet control document as intervention group and verbal advice for sleep hygiene. Approximately 1 month after enrolment, a follow-up phone call was completed were we also informed about the new re-evaluation data.
11332792|NCT02482467|Other|Cases|Prenatal diagnosis of ovarian cyst
11332793|NCT02482467|Other|controls|No prenatal diagnosis of cyst
11332794|NCT02482454|Other|RFA alone|Patients undergo radiofrequency ablation alone.
11332795|NCT02482454|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA
11332796|NCT02482441|Experimental|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
11332797|NCT02482441|Experimental|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
11332798|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
11332799|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
11332800|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
11387190|NCT02121639|Placebo Comparator|Placebo|Placebo
11332803|NCT02482415|Experimental|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
11332804|NCT02482415|No Intervention|Control|
11332805|NCT02482402|Experimental|Inhaled Iloprost|2 inhalations per day of 2.5 µg Iloprost [Ventavis®] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg) will be performed according to each patient's health condition.
11332806|NCT02482402|Placebo Comparator|Placebo inhaled|2 to a maximum of 6 inhalations per day of placebo solution (PLA) will be performed. Study medication will be inhaled using the portable, hand-held I-Neb AAD vibrating mesh technology nebulizer system.
11332807|NCT02482389|Experimental|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
11332808|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
11332809|NCT02482363|Active Comparator|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
11332810|NCT02482363|Sham Comparator|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
11332811|NCT02482350|Experimental|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
11332812|NCT02482337|Experimental|POEM procedure|Patients who underwent POEM
11332813|NCT02482324|Other|Treatment A-B|12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
11332814|NCT02482324|Other|Treatment B-A|12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
11332815|NCT02482311|Experimental|AZD1775|"Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.
~This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types."
11332816|NCT02482298|Experimental|Dose A|
11332817|NCT02482298|Experimental|Dose B|
11332818|NCT02482298|Placebo Comparator|Placebo|
11332819|NCT02482272|Active Comparator|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
11332820|NCT02482272|Experimental|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
11332821|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)
~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)
~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week
~Both groups will receive:
~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
11332822|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.
~Both groups will receive:
~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
11332823|NCT02482220|Experimental|High intensity|in this group, the participants will follow a high intensity physical activity program (High Intensity Interval exercise from 75 to 95% VO2max)
11332824|NCT02482220|Experimental|Moderate intensity|in this group, the participants will follow a moderate intensity physical activity program (Intensity from 50 to 65% VO2max)
11332825|NCT02482207|Experimental|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
11332826|NCT02482207|Placebo Comparator|Placebo|Life style modification alone
11332827|NCT02482194|Experimental|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
11332828|NCT02482168|Experimental|APX005M every 3 week|Subjects receive APX005M intravenously every 3 week until disease progression, unacceptable toxicity or death.
11332829|NCT02482168|Experimental|APX005M every 2 week|Subjects receive APX005M intravenously every 2 week until disease progression, unacceptable toxicity or death.
11332830|NCT02482168|Experimental|APX005M every 1 week|Subjects receive APX005M intravenously every 1 week until disease progression, unacceptable toxicity or death.
11332831|NCT02482155|Experimental|ibuprofen|ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
11332832|NCT02482142|Placebo Comparator|phosphorus alone|Effect of phosphorus (500mg) ingestion alone. No meal. Needed to determine the impact of phosphorus alone on DIT
11332833|NCT02482142|Placebo Comparator|high CHO meal alone|Ingestion of placebo tablets with the high carbohydrate meal
11332834|NCT02482142|Active Comparator|High CHO meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high carbohydrate meal
11332835|NCT02482142|Active Comparator|High protein meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high protein meal
11332836|NCT02482142|Placebo Comparator|High protein meal alone|Ingestion of placebo tablets with the high protein meal
11332837|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
11332838|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
11332839|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
11332840|NCT02482090|Experimental|Patient group|"All patients receive the same treatment. Alle patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.
~Stem Cells are harvested a minimum of 3 weeks before treatment for potential later use if the patients are having difficulties recovering from the lymphodepleting chemotherapy.
~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1.
~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5.
~Interleukin-2 is administered in an i.v. continous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days.
~Stem Cells can be administered after treatment if needed."
11332841|NCT02482077|Experimental|SOF+RBV 8 wk|Participants will receive SOF+RBV for 8 weeks.
11332842|NCT02482077|Experimental|SOF+RBV 12 wk|Participants will receive SOF+RBV for 12 weeks.
11332843|NCT02482077|Experimental|SOF+DCV 8 wk|Participants will receive SOF+DCV for 8 weeks.
11332844|NCT02482077|Experimental|SOF+DCV 12 wk|Participants will receive SOF+DCV for 12 weeks.
11332845|NCT02482077|Experimental|LDV/SOF 8 wk|Participants will receive LDV/SOF for 8 weeks.
11332846|NCT02482077|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF for 12 weeks.
11332847|NCT02482064|No Intervention|Traditional Obturators|Patients will use traditional obturators which are going to be made from ordinary heat-activated acrylic resin.
11332848|NCT02482064|Experimental|Flexible Obturators|Patients will use the new obturators made from flexible resin.
11332849|NCT02482038|Experimental|geko device|
11332850|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
11332851|NCT02482025|Active Comparator|SMMRT|Receives Usual Care PLUS SMMRT Intervention
11332852|NCT02482012||Staff|Staff nurses and physicians in the NICU
11332853|NCT02482012||Parents|Parents of infants in the NICU and a smaller group of parents of infants in the well baby nursery.
11332854|NCT02481999||Study group: Patients|"470 children for elective surgery 0,5 to 8 years
~Analysis of EEG data will divided in four age-related groups because of the different baseline EEG activity:
~0.5 - 12 month: 5-7 Hz activity / blocked by eye opening
~12 - 36 month: 7-8 Hz activity / Variability 5 - 10 Hz
~3 - 6 years: 8 Hz activity / amplitude 100µV
~6 - 8 years 10Hz activity / amplitude 100 µV"
11332855|NCT02481999||Control group: Healthy children for POCD assessment|80 healthy children (siblings of study group children and children from Kindergarten) 0,5 to 8 years with no operation
11332856|NCT02481986|Experimental|Community health worker|Participants in this arm will be offered 10 home visits in a 12-month period from community health workers (CHWs). Visits will cover a core asthma curriculum and provide social support.
11332857|NCT02481986|Active Comparator|Certified asthma educator|Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
11332858|NCT02481973|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
11332859|NCT02481960|Experimental|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
11332860|NCT02481947|Experimental|BLI400 Laxative|21 gm BLI400 powder
11332861|NCT02481947|Active Comparator|Lubiprostone|24 mcg capsule bid
11332862|NCT02481934|Experimental|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
11332863|NCT02481921|Experimental|MEDIC-HF|Multidisciplinary Education & Intervention Class in Heart Failure
11332864|NCT02481921|No Intervention|Usual Care|Usual heart failure care
11332865|NCT02481895|Experimental|Experimental|E-neurocognitive module training.
11332866|NCT02481895|No Intervention|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
11332867|NCT02481882|Other|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
11332868|NCT02481882|Other|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
11332869|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.
~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.
~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
11336391|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
11332870|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.
~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.
~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
11332871|NCT02481856|Experimental|12 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
11332872|NCT02481856|Experimental|7 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
11332873|NCT02481856|Experimental|2 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
11332874|NCT02481856|Placebo Comparator|Placebo|No active ingredient, Oral lyophilisate
11332875|NCT02481843||Hyperoxia|2-hours of hyperoxia (FiO2 = 1.0)
11332876|NCT02481843||Control|2-hours control without hyperoxia
11332877|NCT02481830|Experimental|Arm A Nivolumab|Nivolumab intravenous infusion as specified
11332878|NCT02481830|Active Comparator|Arm B Chemotherapy Topotecan|Topotecan as specified
11332879|NCT02481830|Active Comparator|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
11332880|NCT02481817||iSGS patients|Participants will receive standard of care treatment at the respective center and will be followed longitudinally for symptom changes, need for further treatment, complications, and will have Patient-reported outcomes (PROs) administered at a priori determined intervals.
11332881|NCT02481804|Experimental|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
11332882|NCT02481791|Experimental|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
11332883|NCT02481765|Experimental|Direct current Stimulation|High definition transcranial direct current stimulation (HD-tDCS)
11332884|NCT02481752|Experimental|AAT Training Group|Individuals in this condition will receive four sessions of AAT training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
11332885|NCT02481752|Sham Comparator|SHAM Training Group|Individuals in this condition will receive four sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
11332886|NCT02481726|Experimental|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
11332887|NCT02481713|Experimental|MI condition|motivational interview condition
11332888|NCT02481713|Sham Comparator|CI condition|learning style interview condition
11332889|NCT02481687||Ulcerative colitis|"Consecutively admitted patients with active ulcerative colitis, confirmed by histopathology.
~I-SCAN and pCLE will be applied in all patients."
11332890|NCT02481687||Crohn's disease|"Consecutively admitted patients with active Crohn's disease, confirmed by histopathology.
~I-SCAN and pCLE will be applied in all patients."
11332891|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
11332892|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
11332893|NCT02481661|Experimental|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
11332894|NCT02481661|Active Comparator|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
11332895|NCT02481648|Experimental|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.
~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
11332896|NCT02481648|No Intervention|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
11332897|NCT02481635|Experimental|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.
~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.
~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)
~Surgery: Tumor resection and arterial resection/reconstruction"
11332898|NCT02481609|Experimental|NAC arm|Topical intranasal N-acetyl cysteine (NAC 200 mg/2 ml vials) BID for one month
11332899|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.
~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
11332900|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).
~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
11332901|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).
~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
11332902|NCT02481583|Experimental|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
11332903|NCT02481583|Experimental|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
11332904|NCT02481570|Experimental|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
11332905|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
11332906|NCT02481557|No Intervention|No Treatment|No Treatment
11332907|NCT02481544|Experimental|Gratitude Journaling Plus Standard of Care|"The most often used gratitude intervention consists of journaling, writing lists of things for which the individual is grateful. This technique was first employed and found to be effectual for enhancing wellbeing by Emmons and McCullough and has been suggested to be as effective as methods frequently used in clinical therapy. We are proposing an 8-week intervention in which the participant records 3-5 things for which they are grateful most days of the week. A longer intervention was chosen because Emmons and McCullough (2003) suggest that healthy behavior changes only occurred in a prolonged multi-week intervention. To ensure some conformity in the intervention, instructions that will be used will be similar to Emmons and McCullough (2003): There are many things in our lives, both large and small, that we might be grateful about. Think back over your day (week) and write down on the lines below up to five things in your life that you are grateful or thankful for."
11332908|NCT02481544|Sham Comparator|Memorable Events Journaling Plus Standard of Care|"In the sham control condition, individuals will record memorable events with methods identical to the gratitude journaling condition: Patients will be asked to record 3-5 memorable events in a given day, on most days of the week. Patients will be contacted once per week to remind them to continue with the memorable events journal. Patients will be given 2 journals during their first testing session (one journal is for the first four weeks and the second is for the second four weeks of journaling). Patients will be contacted once per week to remind them to continue with gratitude journal writing. Patients will be instructed to record the date of each journal entry next to each new day of journaling Patients will be provided with materials to return their first journal by mail and will and return their second journal at the T2 laboratory testing session."
11332909|NCT02481544|No Intervention|Standard of Care|SOC consists of medical care that is included in post-MI treatment, such as physician visits and medication adjustments and cardiac rehabilitation. These patients will not have any active intervention, but will undergo the same testing routine as the gratitude intervention group. These patients will be given the opportunity to participate in the gratitude journaling intervention after they have completed the study. Patient records will be evaluated at each timepoint for changes in medications and medical treatment.
11332910|NCT02481531|Active Comparator|Previously marketed infant formula|Cow's milk-based infant formula
11332911|NCT02481531|Experimental|Previously marketed formula using a similar protein|Cow's milk-based infant formula
11332912|NCT02481518|Experimental|Magnesium|Magnesium preloading group : Magnesium preloading for Cisplatin treatment
11332913|NCT02481518|Active Comparator|Control|Control group : Normal saline preloading for cisplatin treatment
11332914|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
11332915|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
11332916|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
11332917|NCT02481492|Experimental|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
11332918|NCT02481492|Experimental|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
11332919|NCT02481479|Other|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
11332920|NCT02481466|Experimental|Portfolio diet and structured exercise|Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
11336481|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
11332921|NCT02481466|Active Comparator|DASH-like diet and structured exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program-a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
11332922|NCT02481466|Experimental|Portfolio diet and routine exercise|Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
11332923|NCT02481466|Active Comparator|DASH-like diet and routine exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
11332924|NCT02481453|Experimental|Rapamycin|rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year
11332925|NCT02481453|Placebo Comparator|Placebo|Placebo oral solution, 2 ml/day, once a day, during one year
11332926|NCT02481440|Experimental|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
11332927|NCT02481427|Experimental|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
11332928|NCT02481427|Experimental|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
11332929|NCT02481414|Experimental|PepCan|PepCan 50 mcg per peptide/injection plus 0.3 mL Candin
11332930|NCT02481414|Active Comparator|Candin|0.3 mL Candin plus sterile saline
11332931|NCT02481401|No Intervention|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for 4 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
11332932|NCT02481401|Experimental|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
11332933|NCT02481401|Active Comparator|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors, for a total of 12 months.
11332934|NCT02481388||Weakness Group (WG)|Patients with heart failure and a maximum inspiratory pressure (MIP) <70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
11332935|NCT02481388||Control group (CG)|Patients with heart failure and do not have a maximum inspiratory pressure (MIP) > 70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
11332936|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.
~Women will receive the multiple micronutrient with iron for 12 weeks."
11332937|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.
~Women will receive the multiple micronutrient without iron for 12 weeks."
11332938|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.
~Women will receive iron for 12 weeks."
11332939|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.
~Women will receive a placebo for 12 weeks."
11332940|NCT02481362|Active Comparator|Order 1|Order for sessions: Cake, apricots
11332941|NCT02481362|Active Comparator|Order 2|Order for sessions: apricots, Cake
11332942|NCT02481349|Experimental|Arm I (couple-based Hatha yoga program)|Patients and their partners attend up to 15, 45-60 minute sessions of Hatha yoga over the course of radiation therapy 5 times a week for 5-6 weeks. The program comprises four main components: joint loosening with breath synchronization; postures with deep relaxation techniques; breath energization with sound resonance; and meditation. At the fifth session, patients and their partners receive a DVD and are encouraged to practice on their own (individually and/or together) on the days when they do not meet with the instructor.
11332943|NCT02481349|Active Comparator|Arm II (waitlist control)|Patients receive standard of care provided by the health care team and complete questionnaires before and after radiation therapy.
11332977|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
11332978|NCT02481089||training group|
11332944|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin
~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin
~Stage III & high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX
~Questionnaires
~Peripheral nervous system examination
~Whole Genome Sequence"
11332945|NCT02481323|Active Comparator|Group 1|Isosorbide mononitrate 25mg bd
11332946|NCT02481323|Active Comparator|Group 2|Cilostazol 100mg bd
11332947|NCT02481323|Active Comparator|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
11332948|NCT02481323|Other|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
11332949|NCT02481310|Experimental|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:
~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.
~CNS PROPHYLAXIS:
~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.
~MAINTENANCE:
~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
11332950|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
11332951|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
11332952|NCT02481284||Laser Doppler Perfusion Imaging|20 consequetive cases undergoing breast reconstruction with Deep inferior epigastric artery perforator flap who had evaluation of the microcirculation of the abdominal skin with laser Doppler perfusion imaging
11332953|NCT02481271|No Intervention|Usual care|Does not receive a specific study intervention
11332954|NCT02481271|Experimental|preoperative relaxation program|preoperative relaxation program
11332955|NCT02481271|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
11332956|NCT02481271|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
11332957|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
11332958|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
11332959|NCT02481245|Experimental|Bipolar I and Bipolar II Disorder|30 currently depressed patients with DSM-IV bipolar I or bipolar II disorder who are currently taking an adequate dose of an FDA-approved anti-manic medication will receive Bezafibrate treatment.
11332960|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 4μg|4μg group: vaccines serial number is A0001-A0100（18-55 years-old group A0001-A0020，7-17 years-old group A0021-A0040，1-6 years-old group A0041-A0060，7-10 months-old group A0061-A0080，2 months-old group A0081-A0100）
11332961|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 8μg|8μg group: vaccines serial number is B0001-B0100（18-55 years-old group B0001-B0020，7-17 years-old group B0021-B0040，1-6 years-old group B0041-B0060，7-10 months-old group B0061-B0080，2 months-old group B0081-B0100）
11332962|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:
~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
11332963|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:
~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
11332964|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
11332965|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
11332966|NCT02481193|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
11332967|NCT02481193|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
11332968|NCT02481193|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
11332969|NCT02481180|Experimental|T0001|
11332970|NCT02481180|Active Comparator|Enbrel|
11332971|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
11332972|NCT02481154|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
11332973|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:
~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
11332974|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:
~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
11332975|NCT02481128|No Intervention|A (access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy with preoperative access to lymphoscintigraphy findings
11332976|NCT02481128|Experimental|B (no access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
11332979|NCT02481076|Experimental|compression therapy|"Intervention arm: administration of
~Flowtron Hydroven boot in the Emergency Department
~Coban2 Lite after surgery
~Flowtron Hydroven boot after surger, before discharge"
11332980|NCT02481076|Other|controle|"The leg is elevated on a Braun frame. This is the old fashioned conservative treatment to prevent swelling."
11332981|NCT02481063|Active Comparator|Eccentric|6 Weeks Training with eccentric Overload (Squat with Yoyo Technology) 3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
11332982|NCT02481063|Active Comparator|Control|3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
11332983|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
11332984|NCT02481037|Experimental|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
11332985|NCT02481037|No Intervention|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
11332986|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
11332987|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
11332988|NCT02480998|Experimental|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
11332989|NCT02480998|Active Comparator|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
11332990|NCT02480985|Other|Pituitary function evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to determine the risk factors and the outcome associated with pituitary disorders.
11332991|NCT02480972|Other|Magnetic resonance imaging|multiparametric MRI including perfusion, diffusion, MR fat quantification and MR elastography
11332992|NCT02480959|Other|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
11332993|NCT02480959|Other|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
11332994|NCT02480946|Experimental|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
11332995|NCT02480946|Experimental|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
11332996|NCT02480946|Experimental|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
11332997|NCT02480946|Experimental|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
11332998|NCT02480933|Experimental|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
11332999|NCT02480933|Experimental|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
11333000|NCT02480907|Active Comparator|Workshop Group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
11333001|NCT02480907|Active Comparator|Internet-based support group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the Internet-based support group for parents, including material from the manual and the DVD and additional information available online within a structured program. Over the course of three months, parents will get access to the 8 support sessions online with the instruction to work out the program at home. Additionally email support is offered after completing each session.
11333002|NCT02480907|No Intervention|Control group - TAU|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will get treatment as usual and take part in conventional parental intervention groups.
11333003|NCT02480894|Experimental|Sequential Dosing|Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
11333004|NCT02480881|Experimental|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
11333005|NCT02480868|Experimental|ARTEBONE|Bone Void Filler
11333006|NCT02480855|Other|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
11333007|NCT02480855|No Intervention|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
11333008|NCT02480842|Experimental|Alloplastic group A|"After randomization (15 days after surgery):
~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
11333009|NCT02480842|Experimental|Alloplastic group B|"After randomization (15 days after surgery):
~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
11333010|NCT02480842|Experimental|Oncoplastic group A|"After randomization (15 days after surgery):
~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
11333011|NCT02480842|Experimental|Oncoplastic group B|"After randomization (15 days after surgery):
~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
11333012|NCT02480816|Experimental|Bicarbonated mineral water (BW)|Bicarbonated mineral water
11333013|NCT02480816|Active Comparator|Control mineral water (CW)|Mineral water low in mineral content (control)
11333014|NCT02480803|Active Comparator|continuous levodopa infusion|continuous intrajejunal infusion of levodopa-carbidopa
11333015|NCT02480803|Active Comparator|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
11333016|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
11333017|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
11333018|NCT02480764|Experimental|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
11333019|NCT02480764|Experimental|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
11333020|NCT02480764|Active Comparator|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
11333021|NCT02480751|Experimental|1: Exprimental (TRK-100STP)|high dose
11333022|NCT02480751|Experimental|2: Exprimental (TRK-100STP)|low dose
11333023|NCT02480751|Placebo Comparator|3: Placebo Comparator|Placebo
11333024|NCT02480738|Experimental|Mild cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
11333025|NCT02480738|Experimental|Subjective cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
11333026|NCT02480738|Active Comparator|Normal controls|Intervention: Computerized Cognitive Training Apparatus
11333027|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).
~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.
~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.
~We plan to collect CSF samples for thrombin activity assay."
11333028|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).
~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.
~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.
~We plan to collect CSF samples for thrombin activity assay."
11333029|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
11333030|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
11333031|NCT02480699|Experimental|Hemodialysed patients|
11333032|NCT02480686|Experimental|SOF+PEG+RBV|Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.
11333033|NCT02480673|Experimental|Free diet plus Chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days without changing their diet
11333034|NCT02480673|Experimental|Normocaloric diet plus chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days along with a normocaloric diet
11333035|NCT02480673|Active Comparator|Normocaloric diet plus oatmeal|This subjects will consume 1 cookie oatmeal before breakfast and dinner for 90 days along with a normocaloric diet
11333036|NCT02480673|Active Comparator|Normocaloric diet|This subjects will only go under a normocaloric diet for 90 days
11333037|NCT02480660|Experimental|Video Intervention Group|Subjects will be randomized to intervention group where participants will be asked to watch a 7 minute educational video.
11333038|NCT02480660|No Intervention|Control Group|Subjects will be randomized to control group ( no intervention) and receive standard of educational care on adolescent to adult oriented health care transitions.
11333039|NCT02480647|Experimental|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system
~Other names:
~Mirena."
11333040|NCT02480647|Active Comparator|etonogestrel|"Etonogestrel implant:
~Other name: Implanon Releasing 20μg/day."
11333041|NCT02480634|Active Comparator|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
11333042|NCT02480634|Experimental|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
11333043|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
11333044|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
11333045|NCT02480608|Experimental|combination Imatinib + Hydroxyurea|Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.
11333046|NCT02480608|Active Comparator|monotherapy Imatinib|Imatinib monotherapy
11333047|NCT02480595||EVAR|Patients undergoing endovascular repair with the latest generation Aorfix™ AAA Flexible Stent Graft System for treatment of abdominal aortic and aorto-iliac aneurysms where the aorta in the aneurysm neck is bent through an angle between 0° and 90°
11333048|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
11333049|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
11333050|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
11333051|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
11333052|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
11333053|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
11333054|NCT02480569|Experimental|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
11333055|NCT02480569|Experimental|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
11333056|NCT02480556|Experimental|Group A|manual seperation of the placenta
11333057|NCT02480556|Active Comparator|Group B|Conservative separation of placenta
11333058|NCT02480543|Active Comparator|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
11333059|NCT02480543|Active Comparator|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
11333060|NCT02480543|Active Comparator|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
11333061|NCT02480530|No Intervention|Control|Patients will be given educational material on the importance of adherence to statin medications. The GlowCaps device will be set to only record adherence.
11333062|NCT02480530|Experimental|Individual Feedback|In addition to educational material on adherence to statin medications, the research coordinator will review set-up of personal reminders for the GlowCaps device which will be set to glow and buzz when the medication is missed. In addition, patients will receive information on the weekly adherence feedback report.
11333063|NCT02480530|Experimental|Feedback Friend|The patient will be given educational material on the importance of adhering to statin medications. The research coordinator will review set-up of alarm features of GlowCaps device. Similar to Arm 2, patients will be given information on interpretation of weekly adherence feedback report. If the patient chooses a family/friend, they will be called and provided information on the interpretation of weekly adherence feedback report. If the patient chooses a reciprocal partner, they will be assigned to another patient who has made a similar choice
11333064|NCT02480517|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
11333065|NCT02480517|Sham Comparator|Sham Control|Blinded Sham Control Arm
11333066|NCT02480504|Experimental|intermittent energy restriction|dietary intervention, intermittent energy restriction. Participants in the experimental group will follow av 5:2 diet and consume a very low calorie diet providing 400 (females) to 600 (males) calories of energy to days a week and for an average male participant, this will reduce energy intake approximately 22%.
11333067|NCT02480504|Active Comparator|continuous energy restriction|dietary intervention, continuous energy restrictions.Participants in the active comparator group will be asked to reduce daily energy intake by 22-23%
11333068|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
11333069|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
11333070|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
11333071|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
11333072|NCT02480465|Experimental|Lobelitazone 0.5mg|Lobelitazone 0.5mg
11333073|NCT02480465|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg
11333074|NCT02480452||CVI|All children consulting at the CVI clinic (with suspicion of CVI) receiving a diagnosis of CVI
11333075|NCT02480452||no CVI|All children consulting at the CVI clinic (with suspicion of CVI) not receiving a diagnosis of CVI
11333076|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
11333177|NCT02479685|Active Comparator|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
11333077|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
11333078|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
11333079|NCT02480426|Experimental|CT-image guidance|Previously acquired portal venous phase of CT datasets and intra-operative CT datasets were registered on a dedicated workstation. The selected volume of interest of the CT-image showing portal vein vasculature was overlaid onto the fluoroscopic display as real-time 3D CT-image guidance during the procedure.
11333080|NCT02480426|Active Comparator|CO2 portography|two two-dimensional (2D) CO2 portograms
11333081|NCT02480400|Experimental|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
11333082|NCT02480400|Active Comparator|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
11333083|NCT02480387|Experimental|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
11333084|NCT02480374|Experimental|Single Arm|
11333085|NCT02480361|Experimental|Acupuncture|The patients who were received acupuncture after gastric cancer surgery
11333086|NCT02480361|No Intervention|Non-acupuncture|The patients who were not received acupuncture after gastric cancer surgery
11333087|NCT02480348|Experimental|Polymer-free DES (Drug Eluting Stent)|
11333088|NCT02480335|Experimental|Usual care and bosentan|Usual care and also treatment with bosentan.
11333089|NCT02480335|No Intervention|Usual care|Usual care only.
11333090|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
11333091|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
11333092|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
11333093|NCT02480322||BMI-matched control group|
11333094|NCT02480322||Normal-weight control group|
11333095|NCT02480296|Experimental|MYK-461|Oral Tablet x 28 days
11333096|NCT02480296|Placebo Comparator|Placebo|Oral Tablet x 28 days
11333097|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
11333098|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
11333099|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
11333100|NCT02480244|Experimental|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
11333101|NCT02480244|Active Comparator|Control|Control arm receives no health-related behavioral intervention
11333102|NCT02480231|Active Comparator|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
11333103|NCT02480231|Active Comparator|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
11333104|NCT02480218||Tamoxifen|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed tamoxifen.
11333105|NCT02480218||Aromatase Inhibitors|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed aromatase inhibitors.
11333106|NCT02480205|Experimental|NeuroBox to deliver the NeuroPAP|
11333107|NCT02480192|Experimental|Experimental Group (CBT-Meno)|After an initial assessment, the experimental group received 12 weekly sessions (2 hours each) of group-based cognitive-behavioural therapy for menopausal symptoms (CBT-Meno) (up to n=8 per group). Symptoms that were targeted included vasomotor symptoms (hot flashes/night sweats), depressive symptoms, anxiety, poor sleep, and sexual concerns. Participants were re-assessed at 12-weeks post-baseline and at 3 months post-treatment.
11333108|NCT02480192|No Intervention|Waitlist|After an initial assessment, the waitlist comparison group did not receive any treatment for 12 weeks. They were then re-assessed at 12-weeks post-baseline and this data was used to compare this group to the experimental group to determine the effectiveness of the CBT-Meno treatment. After this re-assessment participants in the waitlist condition were offered the same CBT-Meno treatment as the experimental group: 12 weekly sessions (2 hours long) of cognitive-behavioural therapy for menopausal symptoms.
11333109|NCT02480179|Experimental|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
11333110|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
11333111|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
11333112|NCT02480153|Experimental|PF-06410293|
11333113|NCT02480153|Active Comparator|Adalimumab|
11333175|NCT02479698|Experimental|Treatment (BK-specific cytotoxic T lymphocytes)|Patients receive allogeneic BK-specific cytotoxic T-lymphocytes IV over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 19 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.
11333178|NCT02479672|Active Comparator|VividTrac video laryngoscope|VividTrac® Videolaryngoscope, A device for endotracheal intubation
11333114|NCT02480140|Experimental|Self-regulated constraint-induced movement therapy|Self-regulated constraint-induced movement therapy (SR-CIMT) - participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days) (CIMT) (the same CIMT protocol as in the CIMT group described under 'comparator/control treatment'); participants were taught using the self-regulation (SR) strategy to relearn the tasks; SR strategy involved participants self reflecting on their abilities and deficits in performing the tasks, identifying problems and solutions in achieving the most independence in the tasks, and then actually carrying out the tasks.
11333115|NCT02480140|Active Comparator|Constraint-induced movement therapy|In the constraint-induced movement therapy group (CIMT), participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days); therapist provided demonstration on the adapted task performance with one arm (the side of participants' hemiplegic arm), and participants to practice the tasks with the unrestrained hemiplegic arm under supervision.
11333116|NCT02480140|Active Comparator|Conventional occupational therapy|It involved therapist to demonstrate the adapted task performance followed by patient's practice under supervision.
11333117|NCT02480127|Experimental|Endometrial injury|In the intervention group, endometrial sampling is obtained twice by Pipelle [one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
11333118|NCT02480127|No Intervention|Control|In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
11333119|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
11333120|NCT02480114|Experimental|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
11333121|NCT02480101|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine
11333122|NCT02480101|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
11333123|NCT02480088|Experimental|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
11333124|NCT02480088|Active Comparator|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
11333125|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
11333126|NCT02480062|Experimental|mWELLCARE software arm|The doctor and nurse care coordinators (NCCs) in the mWELLCARE intervention arm will be trained on the use of mWELLCARE software loaded on a tablet computer. Patients diagnosed with hypertension and/or diabetes will be registered by the nurse using mWellcare application. The nurse will record patient parameters, medical history, medication etc and generate a management plan (including drug recommendation, lifestyle advise) using the mWellcare application based on standard treatment guidelines. The doctor will review the recommendation and agree or disagree giving reasons. Patient will be followed up using SMS.
11333127|NCT02480062|Active Comparator|Usual care arm|"In the control arm or the usual care arm CHCs, the doctor and Nurse will get refresher training in the detection, management and follow up of hypertension and diabetes patients based on standard guidelines. They will be provided with charts for quick reference to standard treatment guidelines. Patients diagnosed with hypertension and/or diabetes will be managed by the doctor at the CHC. The nurse will assist in recording blood pressure, height, weight etc, providing lifestyle advise and follow up advice to patients."
11333128|NCT02480049|Experimental|A Test|test drug (Asmakast)1 tablet contains 10 mg Montelukast
11333129|NCT02480049|Active Comparator|B Reference|reference drug (Singulair) 1 tablet contains 10 mg Montelukast
11333130|NCT02480036|Experimental|Combined IORT and Kyphoplasty|IORT with Kyphoplasty IORT Device: Intrabeam®
11333131|NCT02480023|Experimental|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
11333132|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
11333133|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
11333134|NCT02479997|Active Comparator|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.
~Interventions - patient assigend RI groups are injected only RI
~fill the Primay Case Report Form during surgery
~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
11333135|NCT02479997|Active Comparator|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.
~Interventions - patient assigend RI groups are injected RI +ICG
~prepare fluorescence camera when the surgery begin
~surgeon uses the camera to decect fluorescence flow on SLN
~fill the Primay Case Report Form during surgery
~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
11333176|NCT02479685|Experimental|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
11333136|NCT02479984|Experimental|Staging laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.
~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
11333137|NCT02479971|Active Comparator|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
11333138|NCT02479971|Experimental|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin and clyndamycin solution will be performed.
11333139|NCT02479958|Experimental|Control|
11333140|NCT02479958|Experimental|APDT 1|
11333141|NCT02479958|Experimental|APDT 2|
11333142|NCT02479945|Other|Selective internal iliac vein sampling|
11333143|NCT02479932|Active Comparator|Extraperitoneal cesarean|
11333144|NCT02479932|Active Comparator|Transperitoneal cesarean|
11333145|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
11333146|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
11333147|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
11333148|NCT02479906|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
11333149|NCT02479906|Experimental|Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.
11333150|NCT02479893||cold snare polypectomy|CSP: In this group polyps will be removed with the cold snare polypectomy technique, as a single piece. Additionally, a 1-2mm of normal tissue around the small polyp will also be ensnared in the CSP.
11333151|NCT02479893||hot snare polypectomy|HSP: In this group polyps will be removed with the hot snare polypectomy technique as a single piece with a electrosurgical snare and monopolar current with a setting of 30-35 W in the endocut function.
11333152|NCT02479893||APC polyp destruction-polypectomy|APC: In APC group polyps will be cauterized by application of high power argon plasma coagulation on small waves at 50-60W and flow at 2lt/min,as result the polyp destruction.
11333153|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
11333154|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
11333155|NCT02479867|Experimental|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
11333156|NCT02479867|Experimental|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
11333157|NCT02479854|Experimental|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
11333158|NCT02479854|Active Comparator|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
11333159|NCT02479841|Experimental|self management program|Participation in an 11 week self-management program
11333160|NCT02479841|No Intervention|Control group|
11333161|NCT02479828|Active Comparator|Fascia iliaca compartment block (FICB)|Under ultrasound guidance performing fascia iliaca compartment block, in which 40 ml ropivacaine 0,5% are injected under the fascia iliaca.
11333162|NCT02479828|Placebo Comparator|Placebo (not FICB)|Half of the patients will not receive FICB
11333163|NCT02479815|Other|1gm MNP, 15 sachets per month|Quasi experimental matched control cluster design where for every child 1gm Micronutrient Powder (MNP) for two days, is given which totlas to 15 sachets per month
11333164|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
11333165|NCT02479789|Experimental|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
11333166|NCT02479789|Placebo Comparator|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
11333167|NCT02479776|Active Comparator|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
11333168|NCT02479776|Placebo Comparator|saline injection|saline is injected and patients crossed over to active arm at 6 months
11333169|NCT02479763|No Intervention|Conventional loss-of-resistance|
11333170|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
11333171|NCT02479750|Experimental|ColdZyme|ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
11333172|NCT02479750|Placebo Comparator|Placebo|Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
11333173|NCT02479711|Experimental|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
11333174|NCT02479711|Active Comparator|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
11333179|NCT02479672|Active Comparator|Direct laryngoscopy|Direct laryngoscopy, A device for endotracheal intubation
11333180|NCT02479659|No Intervention|Control|Facilities in this arm maintained status quo HIV testing and routine childhood immunization services
11333181|NCT02479659|Experimental|Simple Intervention|This included: 1) HIV testing commodity reinforcement and 2) a policy reinforcement meeting
11333182|NCT02479659|Experimental|Comprehensive Intervention|This arm included: 1) HIV testing commodity reinforcement, 2) a policy reinforcement meeting, 3) community sensitization, 4) Opt-out HIV testing for mothers and newborns, and 5) Operational support for service integration
11333183|NCT02479646|Experimental|Treatment A|MYL-1401H: single subcutaneous injection (2mg)
11333184|NCT02479646|Active Comparator|Treatment B|EU-Neulasta: single subcutaneous injection (2mg)
11333185|NCT02479646|Active Comparator|Treatment C|US-Neulasta: single subcutaneous injection (2mg)
11333186|NCT02479633|Other|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
11333187|NCT02479633|Other|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
11333188|NCT02479620|Active Comparator|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.
~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
11333189|NCT02479620|No Intervention|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.
~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
11333190|NCT02479607|Experimental|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
11333191|NCT02479607|No Intervention|Control group|Standard care according to the clinic's routines.
11333192|NCT02479594|Experimental|competence-feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
11333193|NCT02479594|Placebo Comparator|control|Therapists assigned to this group will receive no competence-feedback.
11333194|NCT02479581|Experimental|ERAS group|Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program
11333195|NCT02479581|Experimental|Conventional control group|Perioperative management follows the conventional program
11333196|NCT02479568|Active Comparator|Control|Control drink (placebo)
11333197|NCT02479568|Experimental|Natural Florida orange juice|100% Florida orange juice (OJ) (natural content of hesperidin)
11333198|NCT02479568|Experimental|Enriched Florida orange juice|100% Florida orange juice (OJ) (enriched hesperidin content)
11333199|NCT02479555|Active Comparator|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.
~Patients will be randomized 1:1 to receive either the active treatment or control therapy.
~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
11333200|NCT02479555|No Intervention|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.
~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
11333201|NCT02479542|Active Comparator|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
11333202|NCT02479542|Experimental|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
11333203|NCT02479529|Experimental|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
11333204|NCT02479529|Other|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
11333205|NCT02479516|Experimental|CHAPP intervention communities|"CHAPP intervention: The proposed CHAPP intervention will include:
~Diabetes risk assessment (modified FINRISK and assessment of lifestyle risk behaviours) sessions be at least every 2 weeks in accessible community locations, manned by trained volunteers of LLO
~Volunteers educate CHAPP participants regarding their diabetes risk factors and ways to practice healthy lifestyle (including referral to local resources/activities) using diabetes education materials adapted for local context
~Use of an accepted process have participant data transmitted to a central web database system through a combination of cell-phone and computer-based technology
~Have participant assessment result forwarded to the Municipal Health Officer (doctor) for follow-up and screening"
11333206|NCT02479516|No Intervention|Delayed Intervention communities|
11333207|NCT02479503||French Adult Heart Transplantation Center|All center performing adult heart transplantation in France in 2015.
11333209|NCT02479477|Experimental|kinesio therapy|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.
~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase."
11333210|NCT02479477|No Intervention|control|the control group will continue their daily tasks uring eitgh weeks. To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase.
11333211|NCT02479464|No Intervention|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
11333212|NCT02479464|Other|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
11333213|NCT02479451|Experimental|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
11333214|NCT02479438||Diagnosed with GERD|Collect data on GERD patients
11333215|NCT02479425|Active Comparator|3 point turning|patients nursed by the traditional re-positioning (two hours on back, two hours on right and two hours on left).
11333216|NCT02479425|Experimental|2 points turning|patients nursed on the right and left side sonly in 30ْ avoiding the back
11333217|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
11333218|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
11333219|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
11333220|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
11333221|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
11333222|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
11333223|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
11333224|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
11333225|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
11333226|NCT02479399||Suglat group|Tablets
11333227|NCT02479386||Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
11333228|NCT02479373|Experimental|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
11333229|NCT02479373|Other|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
11333230|NCT02479360||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
11333231|NCT02479347|Experimental|Chloraprep|Preoperative skin preparation with chlorhexidine 2% in alcohol 70% solution
11333232|NCT02479347|Active Comparator|Povidone-iodine|Preoperative skin preparation with povidone-iodine 10% solution
11333233|NCT02479334|Placebo Comparator|Fat challenge breakfast|200 ml control drink (non-energy flavored water) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
11333234|NCT02479334|Experimental|Fat challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
11333235|NCT02479334|Placebo Comparator|Carbohydrate challenge breakfast|200 ml control drink (non-energy flavored water) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
11333236|NCT02479334|Experimental|Carbohydrate challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
11333237|NCT02479321|No Intervention|Control group|Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative and immediate postoperative period hemodynamic monitoring will be done by controlling blood pressure, heart rate, oxygen saturation and diuresis.
11333238|NCT02479321|Experimental|PGDT noninvasive monitoring group|PGDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®
11333239|NCT02479308|Active Comparator|Moxifloxacin|Oral tablet
11333240|NCT02479308|Experimental|ALKS 5461|Sublingual tablet
11333241|NCT02479308|Placebo Comparator|Placebo|
11388201|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
11333242|NCT02479295|Active Comparator|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
11333243|NCT02479295|Active Comparator|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
11333244|NCT02479282|Other|group A|natural cesarean section
11333245|NCT02479282|Other|group B|traditional cesarean section
11333246|NCT02479269|Experimental|intervention|Aerobic exercise+ blood sampling
11333247|NCT02479269|No Intervention|control|Blood sampling
11333248|NCT02479256|Experimental|Clomiphene citrate + placebo|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily), and one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
11333249|NCT02479256|Experimental|Tamoxifen + placebo|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily), and one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
11333250|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
11333251|NCT02479230|Experimental|vaccine: gemcitabine hydrochloride|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
11333252|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
11333253|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
11333254|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
11333255|NCT02479204|Experimental|Part A ACT-334441 + atenolol|4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
11333256|NCT02479204|Experimental|Part A ACT-334441 + diltiazem|4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
11333257|NCT02479204|Experimental|Part B ACT-334441 + atenolol|12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
11333258|NCT02479204|Experimental|Part B ACT-334441 + diltiazem|12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
11333259|NCT02479191||Female (Treatment Group)|Device: Ovation Abdominal Stent Graft Platform
11333260|NCT02479191||Male (Control Group)|Device: Ovation Abdominal Stent Graft Platform
11333261|NCT02479165|Active Comparator|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.
~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
11333262|NCT02479165|Active Comparator|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.
~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
11333263|NCT02479152|Active Comparator|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
11333264|NCT02479152|Other|LUCAS2|LUCAS2 will be used for CPR
11333265|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
11333266|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
11333267|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
11333268|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
11333269|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
11333270|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
11333271|NCT02479126||Interstitial Lung Disease|Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
11333272|NCT02479113||Lean with normal glucose tolerance|"Pregnant women who are lean with normal glucose tolerance
~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
11333273|NCT02479113||Obese with Normal glucose tolerance|"Pregnant women who are obese with normal glucose tolerance
~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
11333274|NCT02479113||Gestational diabetes mellitus|"Pregnant women who have Gestational Diabetes Mellitus
~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
11333275|NCT02479100|Other|Undergo a CESM|Patients will undergo an experimental Contrast Enhanced Spectral Mammogram (CESM) in addition to standard diagnostic procedures
11333277|NCT02479087|Experimental|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.
~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.
~The initial dosage can be then adjusted on the base of response."
11333278|NCT02479074|Active Comparator|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
11333279|NCT02479074|Active Comparator|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
11333280|NCT02479074|Active Comparator|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
11333281|NCT02479048|Active Comparator|Test meal 1 (TM1)|High fat meal (HF) with ½ avocado (~68g)
11333282|NCT02479048|Active Comparator|Test meal 2 (TM2)|High fat meal (HF) with 1 avocado (~136g)
11333283|NCT02479048|Placebo Comparator|Control meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
11333284|NCT02479035|Active Comparator|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
11333285|NCT02479035|Active Comparator|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
11333286|NCT02479035|Placebo Comparator|Control meal|0 g red raspberry
11333287|NCT02479022|Experimental|Level 1-7 escalating doses|
11333288|NCT02478996|Experimental|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
11333289|NCT02478996|No Intervention|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
11333290|NCT02478983|Experimental|LMA Supreme|1 arm will receive LMA supreme for airway management
11333291|NCT02478983|Active Comparator|LMA Proseal|1 arm will receive LMA Proseal for airway management
11333292|NCT02478970|Experimental|Corneal endotheliopathy|Patients with primary corneal endotheliopathies, such as posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome will be evaluated with the NIDEK CEM-350 and Konan SP4000
11333293|NCT02478970|Placebo Comparator|Normal|Patients without corneal endotheliopathies will be evaluated with the NIDEK CEM-350 and Konan SP4000
11333294|NCT02478957|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 6 weeks
11333295|NCT02478957|Placebo Comparator|Placebo|Placebo, administered via inhalation three times daily for 6 weeks
11333296|NCT02478944|Experimental|Inflammatory bowel disease|Patients with Crohn's disease and ulcerative colitis undergoing manometry
11333297|NCT02478918|Experimental|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
11333298|NCT02478918|No Intervention|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
11333299|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
11333300|NCT02478879|Experimental|ZP-PTH Patch|Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment
11333301|NCT02478879|Active Comparator|FORTEO(R) Pen|Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.
11333302|NCT02478866|Experimental|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg, 600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
11333303|NCT02478840|Experimental|Lamazym|1 mg Lamazym/kg Body weight
11333304|NCT02478827|Experimental|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
11333305|NCT02478827|Experimental|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
11333306|NCT02478827|No Intervention|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
11333307|NCT02478814|Experimental|Active, Young Adult Males|Subjects will receive different levels of amino acid intakes varying from 0.2 to 2.6 g/kg/day.
11333308|NCT02478801|Experimental|Endurance trained|subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day.
11333309|NCT02478788|Experimental|LR-MAS - Low-risk ADHD adolescents|ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
11336482|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
11333310|NCT02478788|Experimental|HR-MAS - High-risk ADHD adolescents|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD."
11333311|NCT02478788|Placebo Comparator|HR-P - High-risk ADHD on Placebo|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed."
11333312|NCT02478788|No Intervention|HC (Healthy Controls)|Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo MR scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging evaluations will be performed at baseline and Week 12 (or termination).
11333313|NCT02478775|Experimental|Frequent Blood Sampling|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period.
11333314|NCT02478762|Active Comparator|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
11333315|NCT02478762|Experimental|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
11333316|NCT02478749|Experimental|Infant|patients aged younger than 1year
11333317|NCT02478749|Experimental|Child|patients aged 1year to 5years
11333318|NCT02478749|Experimental|Adult|adult patients
11333319|NCT02478736||delirium group|the patients with delirum after on-pump cardiac surgery
11333320|NCT02478736||no delirium group|the patients without delirum after on-pump cardiac surgery
11333321|NCT02478710|Placebo Comparator|Aerosolized Placebo|Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.
11333322|NCT02478710|Experimental|Aerosolized Tobramycin or Vancomycin|Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
11333323|NCT02478697|Experimental|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
11333324|NCT02478697|No Intervention|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
11333325|NCT02478684|Active Comparator|30 seconds of DCC|30 Seconds of placental blood transfusion
11333326|NCT02478684|Active Comparator|60 seconds DCC|60 Seconds of placental blood transfusion
11333327|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
11333328|NCT02478658|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:
~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
11333329|NCT02478658|No Intervention|Control|No intervention
11333330|NCT02478645|Experimental|ramosetron 0.3|
11333331|NCT02478645|Active Comparator|ramosetron 0.45|
11333332|NCT02478645|Active Comparator|ramosetron 0.6|
11333333|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
11333334|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
11333335|NCT02478619|Active Comparator|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
11333336|NCT02478619|Placebo Comparator|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
11333337|NCT02478606|No Intervention|Control Group|Without intervention
11333338|NCT02478606|Experimental|Static Group|Will receive passive static stretching in hamstring muscle
11333339|NCT02478606|Experimental|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
11333340|NCT02478593|Experimental|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
11333341|NCT02478593|No Intervention|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
11333342|NCT02478580|Experimental|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
11333343|NCT02478580|Placebo Comparator|Placebo|A single oral placebo will be given in preoperative area
11333344|NCT02478567|Experimental|Scapular Training|Initiated scapular training exercise for the first 4 weeks followed by addition of rotator cuff exercises the next four weeks
11333451|NCT02477826|Experimental|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy
11333345|NCT02478567|Experimental|Rotator Cuff Training|initiated rotator cuff training exercise for the first 4 weeks followed by addition of scapular training exercises the next four weeks.
11333346|NCT02478554|No Intervention|Population-based|Participants will be randomly assigned to population-based fetal growth curves
11333347|NCT02478554|Active Comparator|Customized-based|Participants will be randomly assigned to customized-based fetal growth curves (intervention)
11333348|NCT02478541|Active Comparator|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
11333349|NCT02478541|Active Comparator|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
11333350|NCT02478528|Experimental|Experimental|
11333351|NCT02478515|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
11333352|NCT02478502|Experimental|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
11333353|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
11333354|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
11333355|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
11333356|NCT02478450|Experimental|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
11333357|NCT02478450|Experimental|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
11333358|NCT02478450|Experimental|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
11333359|NCT02478450|Experimental|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
11333360|NCT02478450|Experimental|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
11333361|NCT02478450|Experimental|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
11333362|NCT02478437|Active Comparator|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
11333363|NCT02478437|Active Comparator|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
11333364|NCT02478424|Experimental|Cannabidiol arm|Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
11333365|NCT02478411|Experimental|Cycle ergometer physiotherapy|15 minutes of cycle ergometer physiotherapy plus 15 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
11333366|NCT02478411|Active Comparator|Conventional physiotherapy|30 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
11333367|NCT02478398|Experimental|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
11333368|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
11333369|NCT02478385|Active Comparator|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
11333370|NCT02478385|Placebo Comparator|Labour in a standard labour room|The woman gives labour in a standard labour room
11333371|NCT02478372|Active Comparator|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
11333372|NCT02478372|Experimental|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
11333373|NCT02478359|No Intervention|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
11333450|NCT02477826|Experimental|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
11333374|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
11333375|NCT02478346|Experimental|All Patients|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used).
11333376|NCT02478333|Experimental|ALS-008176 (250 mg) or Placebo|Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
11333377|NCT02478333|Experimental|ALS-008176 (500 mg) or Placebo|Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
11333378|NCT02478333|Experimental|ALS-008176 (750 mg) or Placebo|Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
11333379|NCT02478320|Experimental|Ilorasertib (ABT-348)|"Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
~Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle."
11333380|NCT02478307|Active Comparator|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
11333381|NCT02478307|Active Comparator|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
11333382|NCT02478307|Active Comparator|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
11333383|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
11333384|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
11333385|NCT02478281|Experimental|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
11333386|NCT02478268|Active Comparator|Patients with idiopathic pulmonary fibrosis|
11333387|NCT02478268|Active Comparator|Healthy volunteers|
11333388|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
11333389|NCT02478255|Active Comparator|Healthy volunteers|
11333390|NCT02478242|Active Comparator|Nafamostat mesilate group|Nafamostat mesilate was used for maintenance anticoagulation during continuous renal replacement therapy.
11333391|NCT02478242|Placebo Comparator|No anticoagulation group|Normal saline was used for maintenance anticoagulation during continuous renal replacement therapy.
11333392|NCT02478229|Experimental|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
11333393|NCT02478216|No Intervention|C group|Remote ischemic preconditioning will not be applied
11333394|NCT02478216|Experimental|R group|Remote ischemic preconditioning will be applied.
11333395|NCT02478203|Placebo Comparator|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
11333396|NCT02478203|Active Comparator|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
11333397|NCT02478203|Active Comparator|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
11333398|NCT02478190|Experimental|Tight control|Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
11333399|NCT02478190|Experimental|Loose control|Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
11333400|NCT02478177||Stroke|Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants
11333401|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
11333402|NCT02478151|Experimental|OrganOx Metra|OrganOx Metra Device
11333403|NCT02478138|Other|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
11333404|NCT02478125|Active Comparator|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
11333405|NCT02478125|Active Comparator|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
11333406|NCT02478125|Experimental|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.
~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
11333407|NCT02478112|Experimental|Biodegradable Balloon Implant|Biodegradable balloon implanted before radiotherapy
11333408|NCT02478099|Experimental|1 Treatment with MPDL3280A|Treatment with MPDL3280A
11333445|NCT02477852|Experimental|anti-tuberculosis treatment four weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
11333446|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
11333409|NCT02478086|Experimental|use amine acids parenteral 3.5g|"Amino acids parenteral (Levamin Nomo 10% ®) Group A with an initial doses of amino acids until reaching 3.5 g/kg/day during 28 days.For the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
11333410|NCT02478086|Experimental|use amine acids parenteral 4g|"Group B with an initial doses of 2.5 g/kg/day with daily increments of 0.5 g/kg/day until reaching 4 g/kg/day during 34 days.Weight, urea, creatinine and blood urea nitrogen (BUN) were measured weeklyFor the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
11333411|NCT02478060|Experimental|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
11333412|NCT02478060|Experimental|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
11333413|NCT02478060|Experimental|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
11333414|NCT02478060|Experimental|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
11333415|NCT02478060|Experimental|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
11333416|NCT02478047|Active Comparator|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
11333417|NCT02478047|Experimental|Matching points ST36+CV12|
11333418|NCT02478047|Experimental|Matching points PC6+CV12|
11333419|NCT02478047|Experimental|Matching points CV3+CV12|
11333420|NCT02478034|Experimental|fludrocortisone|effects of fludrocortisone on cognition compared to placebo
11333421|NCT02478034|Placebo Comparator|Placebo|effects of fludrocortisone on cognition compared to placebo
11333422|NCT02478021|Experimental|Hydrocortisone|10 mg hydrocortisone
11333423|NCT02478021|Placebo Comparator|Placebo|1 pill Placebo
11333424|NCT02478008|Experimental|CardiAQ TMVI System (Transapical DS)|
11333425|NCT02477995|Experimental|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
11333426|NCT02477995|Active Comparator|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
11333427|NCT02477982||control group|BMI ≤ 25 kgm-2
11333428|NCT02477982||obese group|BMI ≥ 30 kgm-2
11333429|NCT02477969|Experimental|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
11333430|NCT02477969|Experimental|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
11333431|NCT02477969|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
11333432|NCT02477956|Experimental|vitamin D3|subjects taking the standard vitamin D protocol with added monthly high dose cholecalciferol of 100,000 IU cholecalciferol
11333433|NCT02477956|Active Comparator|Control|group of subjects taking the standard vitamin D
11333434|NCT02477943||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
11333435|NCT02477943||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
11333436|NCT02477917|Experimental|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
11333437|NCT02477904|Experimental|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
11333438|NCT02477904|Active Comparator|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
11333439|NCT02477904|Active Comparator|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
11333440|NCT02477878|Experimental|BPX-501 and Rimiducid|"All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).
~Two doses of Rimiducid ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
11333441|NCT02477865|Experimental|PEX168(100µg)|PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.
11333442|NCT02477865|Experimental|PEX168(200µg)|PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.
11333443|NCT02477865|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.
11333444|NCT02477852|Experimental|anti-tuberculosis treatment two weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
11333452|NCT02477813|Experimental|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
11333453|NCT02477800|Experimental|Low Dose|Monthly intravenous (IV) infusion
11333454|NCT02477800|Experimental|High Dose|Monthly intravenous (IV) infusion
11333455|NCT02477787|Experimental|treatment|patients will receive donor-derived NK cell infusion after haploidentical HCT
11333456|NCT02477787|No Intervention|control|patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT
11333457|NCT02477774|Experimental|Arista|Arista to ALT donor site
11333458|NCT02477774|No Intervention|Control|No Arista to ALT donor site
11333459|NCT02477761|No Intervention|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
11333460|NCT02477761|Experimental|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
11333461|NCT02477748|Active Comparator|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
11333462|NCT02477748|Placebo Comparator|Placebo|Inert tablets
11333463|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
11333464|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
11333465|NCT02477722|Experimental|EFP-NF|Subjects are asked to change their brain activity in response to feedback they receive from the brain itself, mediated via various visual or auditory stimuli.
11333466|NCT02477722|Sham Comparator|Sham-NF|Placebo
11333467|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
11333468|NCT02477696|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity.
11333469|NCT02477696|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
11333470|NCT02477670|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
11333471|NCT02477670|Experimental|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
11333472|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
11333473|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
11333474|NCT02477631|Experimental|Deferiprone|patient treated with study drug
11333475|NCT02477618|Active Comparator|SAGE-547|Intravenous
11333476|NCT02477618|Placebo Comparator|Placebo|Intravenous
11333477|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
11333478|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
11333479|NCT02477592|Experimental|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
11333480|NCT02477592|Active Comparator|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
11333481|NCT02477579|Experimental|NovaCross|NovaCross microcatheter will be used.
11333482|NCT02477566|Experimental|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
11333483|NCT02477566|Active Comparator|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
11333484|NCT02477553|Experimental|Quantitative|"Subjects view:
~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.
~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
11333485|NCT02477553|Active Comparator|Verbal|"Subjects view:
~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.
~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
11333486|NCT02477540|Experimental|2-time injection group : Cellgram-CLI|Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
11333487|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
11333488|NCT02477514|Experimental|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
11333489|NCT02477501|Active Comparator|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
11333490|NCT02477501|Active Comparator|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
11333491|NCT02477488|Experimental|Allopurinol HS|Allopurinol at bedtime compared to AM administration
11333492|NCT02477475||NEXIUM|Oral dose 20mg/day
11333493|NCT02477462||Primary Biliary Cirrhosis|Subjects meeting internationally accepted criteria for the diagnosis of primary biliary cirrhosis
11333494|NCT02477462||Control|Subjects without evidence of primary biliary cirrhosis, liver disease, or inflammatory condition who are of similar age and sex distribution to the Primary Biliary Cirrhosis group
11333495|NCT02477449|Experimental|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
11333496|NCT02477449|Experimental|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
11333497|NCT02477449|Experimental|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
11333498|NCT02477436|Experimental|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
11333499|NCT02477436|Experimental|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
11333500|NCT02477436|Experimental|Avanafil 200mg group|Avanafil 100mg 2 tablets
11333501|NCT02477436|Placebo Comparator|Placebo group|Placebo 100mg 2tablets
11333502|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
11333503|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
11333504|NCT02477410|Experimental|Hydrolysed porcine protein from blood|Dietary intervention with hydrolysed porcine protein from blood
11333505|NCT02477410|Experimental|Hydrolysed porcine protein from muscle|Dietary intervention with hydrolysed porcine protein from muscle
11333506|NCT02477410|Experimental|Hydrolysed whey protein|Dietary intervention with hydrolysed whey protein
11333507|NCT02477397|Experimental|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
11333508|NCT02477397|Active Comparator|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
11333509|NCT02477384|Active Comparator|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
11333510|NCT02477384|Active Comparator|EVL plus propranolol|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
11333511|NCT02477371|Experimental|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR > 0,8 are deferred.
11333512|NCT02477371|Active Comparator|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
11333513|NCT02477358|No Intervention|Control|Teeth are extracted, 2 mm of root removed and teeth are replaced and splinted to adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
11333514|NCT02477358|Experimental|Test|"Teeth are extracted, 2 mm of root removed, Platelet Rich Fibrin placed in socket, tooth replaced and splinted to adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
~Intervention- the PRF is added"
11333515|NCT02477332|Experimental|QGE031 24 mg s.c. q4w|ligelizumab 24 mg injection subcutaneous every 4 weeks
11333516|NCT02477332|Experimental|QGE031 72 mg s.c. q4w|ligelizumab 72 mg injection subcutaneous every 4 weeks
11333517|NCT02477332|Experimental|QGE031 240 mg s.c. q4w|ligelizumab 240 mg injection subcutaneous every 4 weeks
11333518|NCT02477332|Active Comparator|Omalizumab 300 mg s.c. q4w|omalizumab 300 mg injection subcutaneous every 4 weeks
11333519|NCT02477332|Placebo Comparator|Placebo s.c. q4w|placebo injection subcutaneous every 4 weeks
11333520|NCT02477332|Experimental|QGE031 120 mg s.c. s.d.|ligelizumab 120 mg injection subcutaneous single dose
11333521|NCT02477319||Part A|"Cohort 1: Healthy Controls
~Cohort 2: Partial CFTR function CF (class IV/V)
~Cohort 3: Absent CFTR function CF (Class I/II)"
11333522|NCT02477319||Part B|CF patients who are homozygous for the F508del
11333523|NCT02477306|Experimental|Study group|60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods
11333524|NCT02477293|Experimental|Hyeonggaeyeongyo-tang|
11333525|NCT02477280|Experimental|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
11333526|NCT02477280|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
11333527|NCT02477267|Experimental|Test-Reference Sequence|SL spray, followed by SL film
11333528|NCT02477267|Experimental|Reference-Test Sequence|SL film followed by SL spray
11333529|NCT02477254||SLE patients|SLE patients who received HPV vaccination
11333530|NCT02477254||Control subjects|Healthy subjects who received HPV vaccination
11334070|NCT02473458|Placebo Comparator|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
11333531|NCT02477241|Other|Healthy female subjects|Healthy female subjects with or without overactive bladder undergoing functional MRI brain and urodynamic study.
11333532|NCT02477228|Active Comparator|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
11333533|NCT02477228|Active Comparator|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
11333534|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.
~Dexamethasone 40 mg oral weekly.
~Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2"
11333535|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.
~Dexamethasone 40 mg oral weekly.
~Bendamustine dose levels: MTD given on days 1 and 2"
11333536|NCT02477202|Experimental|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (<30/30+ kg/m^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
11333537|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
11333538|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
11333539|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
11333540|NCT02477150|Active Comparator|SLE (vaccine)|Zostavax SC injection (0.65ml)
11333541|NCT02477150|Placebo Comparator|SLE (placebo)|Placebo SC injection (normal saline 0.65ml)
11333542|NCT02477137|Experimental|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
11333543|NCT02477137|No Intervention|Control group|Usual care according to the routines at the clinic.
11333544|NCT02477124|Active Comparator|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
11333545|NCT02477124|Active Comparator|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
11333546|NCT02477098|Experimental|Pre RSB|patients who receive preoperative rectus sheath block of ropivacaine hydrochloride and receive postoperative rectus sheath block of saline
11333547|NCT02477098|Experimental|Post RSB|patients who receive preoperative rectus sheath block of saline and receive postoperative rectus sheath block of Ropivacaine hydrochloride
11333548|NCT02477085||all women with an induced labor|prospective population-based cohort of all women who have an induced labor during one month in seven perinatal networks
11333549|NCT02477072|Active Comparator|Fixed heparin dose (general anesthesia)|Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
11333550|NCT02477072|Experimental|Weight-adjusted doses of heparin|Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
11333551|NCT02477072|Active Comparator|Fixed heparin dose (regional anesthesia)|For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
11333552|NCT02477059|Experimental|tocilizumab|2 infusions four weeks apart
11333553|NCT02477059|Placebo Comparator|saline solution|2 infusions four weeks apart
11333554|NCT02477046|Experimental|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
11333555|NCT02477046|Experimental|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
11333556|NCT02477046|Experimental|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
11333557|NCT02477033|Active Comparator|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
11333558|NCT02477033|Placebo Comparator|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
11333559|NCT02477020|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
11333560|NCT02477020|Placebo Comparator|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
11336483|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
11333561|NCT02477007|Experimental|Ibuprofen+placebo of paracetamol|Patients will receive in addition to morphine (usual care) ibuprofen and placebo of paracetamol
11333562|NCT02477007|Experimental|Paracetamol + placebo of ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and placebo of ibuprofen
11333563|NCT02477007|Experimental|Paracetamol + ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and ibuprofen
11333564|NCT02477007|Placebo Comparator|Placebo of paracetamol + placebo of ibuprofen|Patients will receive morphine alone(usual care).
11333565|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
11333566|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
11333567|NCT02476981|Experimental|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
11333568|NCT02476981|Experimental|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
11333569|NCT02476981|Other|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
11333570|NCT02476981|Other|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
11333571|NCT02476981|Other|ephedrine|Adrenergic agonist to treat hypotension
11333572|NCT02476968|Other|Olaparib|Open Label Drug
11333573|NCT02476955|Experimental|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 milligrams (mg) every day (QD), 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
11333574|NCT02476942||Cohort A: Adults and Adolescents with FVIII Inhibitors|Adults and adolescents with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
11333575|NCT02476942||Cohort B: Children with FVIII Inhibitors|Children with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
11333576|NCT02476942||Cohort C: Adults and Adolescents without FVIII Inhibitors|Adults and adolescents with severe hemophilia A without the presence of FVIII inhibitors will be observed.
11333577|NCT02476929|Active Comparator|Nasal nitrous oxide|Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
11333578|NCT02476929|Active Comparator|Electronic nose|Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
11333579|NCT02476916|Experimental|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
11333580|NCT02476916|Experimental|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
11333581|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
11333582|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
11333583|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
11333584|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
11333585|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
11333586|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
11333587|NCT02476864|Experimental|Sequence AB|Subjects receive treatment A in Period 1 followed by treatment B in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
11333588|NCT02476864|Experimental|Sequence BA|Subjects receive treatment B in Period 1 followed by treatment A in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
11333589|NCT02476851|Experimental|Supernatant Hemoglobin|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of < 100mg/dL. In instances where resulting supernatant hemoglobin levels are > 100 mg/dL for the INA, if supernatant hemoglobin levels are > 100 mg/dL for the Kawasumi needle assembly (the control needle assembly or CNA), then there would be justification for removing these data from analyses."
11333590|NCT02476838|Other|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
11333591|NCT02476825|Active Comparator|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler [Accuhaler]), 500 micrograms b.i.d. for 4 weeks
11333592|NCT02476825|No Intervention|Observational|Observation
11333609|NCT02476747|Experimental|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
11333610|NCT02476747|Active Comparator|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
11333646|NCT02476474|Active Comparator|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
11333593|NCT02476812|Experimental|Positive Piggy Bank|"Patients randomized to this group will meet with a research assistant who provides an overview of the intervention, explains the rationale for this treatment, and then gives the patients the instructions, piggy bank, and currency slips. Participants in this group will receive instructions. At the end of the monitoring period, 30 days, they are to close their account by opening the piggy bank and reviewing all of the slips of paper.
~Study personnel will contact patients within 72 hours to answer questions. Participants will also be contacted at 30 days to let patients know that they should read all of their currency slips in one sitting. They are also told that the intervention part of the study is over and are asked they complete the follow up questionnaires. Then, study personnel will call again to let the participant know that the second set of questionnaires will be arriving by mail."
11333594|NCT02476812|No Intervention|Waitlist Control|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. Those in the control group who meet study criteria will also receive regular care after their epidural steroid injection (e.g., physician visits, medication maintenance, standard patient education). These patients will follow the same questionnaire follow up procedures as listed above including phone calls. The phone call at 72 hours will be to simply thank them for their participation in the study. At the end of the study period, approximately three months, Wait List control patients will also be offered the Positive Piggy Bank intervention along with the supportive phone calls. Should they choose to try the Positive Piggy Bank intervention, they will be required to return to the center to pick up supplies and receive instruction. They will also complete study questionnaires by mail at 30 days to assess intra-individual change.
11333595|NCT02476799|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
11333596|NCT02476799|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
11333597|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen
~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment
~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy
~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire
~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
11333598|NCT02476773|Experimental|Group 1|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
11333599|NCT02476773|Experimental|Group 2|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
11333600|NCT02476773|Experimental|Group 3|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
11333601|NCT02476773|Experimental|Group 4|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
11333602|NCT02476773|Experimental|Group 5|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
11333603|NCT02476773|Experimental|Group 6|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.
~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
11333604|NCT02476760||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
11333605|NCT02476760||Treated with insulin|Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
11333606|NCT02476760||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
11333607|NCT02476760||Treated with a single oral agent|Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
11333608|NCT02476760||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.
11333645|NCT02476487|Experimental|FDG PET CT|FDG PET CT
11333611|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
11333612|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
11333613|NCT02476708|Experimental|Curcumin 1800mg|curcumin capsule 600mg taken 3 times per day for 8 weeks
11333614|NCT02476708|Placebo Comparator|Placebo|placebo capsule taken 3 times per day for 8 weeks
11333615|NCT02476695||S0/1|S0 = no fibrosis and S1 = portal fibrosis without septa
11333616|NCT02476695||S2|S2 = portal fibrosis with few septa
11333617|NCT02476695||S3|S3 = numerous septa without cirrhosis
11333618|NCT02476695||S4|S4 = liver cirrhosis (compensatory stage)
11333619|NCT02476682||Normal subjects|blood or stool samples will be collected from people referred for screening colonoscopy
11333620|NCT02476682||Colorectal cancer|blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
11333621|NCT02476682||Polyps <10mm and no high risk features|blood or stool samples will be collected from people with no polyps or low risk polyps (<10mm, no villous component or dysplasia) detected at colonoscopy
11333622|NCT02476682||Advanced Mucosal Neoplasia|blood or stool samples will be collected from people with AMN detected at resection
11333623|NCT02476682||Sessile Serrated Adenoma|blood or stool samples will be collected from people with SSP detected at resection
11333624|NCT02476682||non-colorectal neoplastic disease|Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
11333625|NCT02476656||GPNC|CenteringPregnancy group prenatal care
11333626|NCT02476656||IPNC|Individual prenatal care
11333627|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
~Patients are admitted to the hospital ward for 14 days."
11333628|NCT02476630||Study subjects|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
11333629|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
11333630|NCT02476604|Experimental|Electronic Messaging|Subjects randomized to the intervention arm will receive health coaching and electronic messages at the rate of up to six times per week over an 8 week period.
11333631|NCT02476604|No Intervention|Control|Subjects randomized to the control arm will undergo all of the same measurements for baseline and follow up data but will not receive the intervention of health coaching and electronic messaging.
11333632|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
11333633|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
11333634|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
11333635|NCT02476578|No Intervention|Control|No email is sent.
11333636|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
11333637|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
11333638|NCT02476552|Experimental|Niraparib Oral and IV|Single Oral dose of Niraparib capsules (unlabeled active pharmaceutical ingredient) orally and a 15-minute IV infusion of Niraparib (labeled active pharmaceutical ingredient)
11333639|NCT02476552|Experimental|Niraparib Oral|Single Oral dose of Niraparib capsules (labeled active pharmaceutical ingredient)
11333640|NCT02476539|Experimental|Hemay022|"Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days.
~Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days."
11333641|NCT02476526|Experimental|Low Volume Contrast|Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
11333642|NCT02476526|Sham Comparator|Control|Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
11333643|NCT02476500|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
11333644|NCT02476500|Experimental|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
11333647|NCT02476474|Active Comparator|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
11333648|NCT02476461|Active Comparator|xiapex|1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
11333649|NCT02476461|Experimental|PNF|percutaneous needle fasciotomi is performed at affected cords
11333650|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
11333651|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
11333652|NCT02476448|Experimental|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
11333653|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
11333654|NCT02476435|Active Comparator|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
11333655|NCT02476435|Placebo Comparator|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
11333656|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
11333657|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
11333658|NCT02476409|Experimental|Tolvaptan|Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily
11333659|NCT02476409|Placebo Comparator|Placebo|Augmentation of current dose of loop diuretic
11333660|NCT02476396||patient-subject|Patients will be recruited from the population of patients scheduled to undergo carotid endarterectomy for established clinical indications. These indications include patients scheduled to have a carotid endarterectomy due to the presence of a high-grade atherosclerotic cervical internal carotid artery stenosis with or without clinical symptoms, following the ACAS or NASCET criteria (carotid artery stenosis of 60% or greater without clinical symptoms; stenosis 70% or greater with clinical symptoms).
11333661|NCT02476396||patient-control|The controls will be recruited by the patient-subjects. The investigators will ask their patient-subjects to speak to a spouse or family member to see if they are interested in participating. If they do have an interest they will contact the research team/study coordinator(s). In case, a spouse or a family member is accompanying the patient-subject, they will be recruited at the same time as the patient-subject.
11333662|NCT02476383|Active Comparator|augmented spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner interacting in a warm and friendly way who is free to respond to participant conversation. Participants in this group will receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
11333663|NCT02476383|Active Comparator|neutral spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner engaging in minimal interaction. Participants in this group will not receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
11333664|NCT02476370|No Intervention|Usual care|Does not receive a specific study intervention
11333665|NCT02476370|Experimental|preoperative relaxation program|preoperative relaxation program
11333666|NCT02476370|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
11333667|NCT02476370|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
11333668|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
11333669|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
11333670|NCT02476344|Experimental|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
11333671|NCT02476331|Experimental|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
11333672|NCT02476331|No Intervention|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
11333673|NCT02476318|Experimental|ArterX Vascular Sealant|
11333674|NCT02476305|Experimental|cryoablation|patients undergo cryoablation procedure for desmoid tumor
11333675|NCT02476279|Experimental|Indomethacin alone|Indomethacin 100 mg rectally immediately after ERCP
11333676|NCT02476279|Active Comparator|Indomethacin+pancreatic stent|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
11333677|NCT02476266|No Intervention|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
11333757|NCT02475707|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
11333678|NCT02476266|Active Comparator|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
11333679|NCT02476266|Experimental|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
11333680|NCT02476253|Experimental|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
11333681|NCT02476253|No Intervention|Control|No intervention
11333682|NCT02476240|Active Comparator|Internally Focused PD-SAFEx|While performing the exercises in PD-SAFEx™, participants will be instructed to focus their attention on sensory feedback. This will include focusing participants' attention on the stretch in their limbs while walking, on the straightness of their backs while sitting, on limb and body orientation in space while coordinating their movements, and on chest movements during breathing exercises. Throughout each exercise session, the instructor and volunteers will constantly provide attention-directing instructions.
11333683|NCT02476240|Experimental|Externally Focused PD-SAFEx|While performing the exercises from the PD-SAFEx™ program, participants will be instructed to focus their attention externally on the movement of coloured labels attached to their feet, knees, elbows and hands. Participants will be reminded and encouraged by the exercise instructor and volunteers to perform all exercises while focusing attention on the labels.
11333684|NCT02476240|No Intervention|Control Group|This group will be asked to refrain from changing activities of their daily lives throughout the 20-week duration of the experiment (from pre-assessment to washout).
11333685|NCT02476227|Experimental|Visitag group|Ablation using CARTO system. Visitag module: automated algorithm to collect RF ablation points using Visitag module. Criteria of ablation point: catheter stability range of motion ≤2.5mm, catheter stability time >15sec, contact force >5g over >50% of time. Optimal contact force suggested: 10-40g.
11333686|NCT02476227|Active Comparator|Control group|Ablation using CARTO system. Manual collection of RF ablation points by operator or by assistant. Optimal contact force suggested: 10-40g.
11333687|NCT02476214|Experimental|Intervention group|Group prenatal care- receiving prenatal care through a group
11333688|NCT02476214|No Intervention|Control group|Individual prenatal care - receiving regular individual prenatal care
11333689|NCT02476201|Experimental|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
11333690|NCT02476188|Experimental|Patients|Samples of blood at H0, H+6, H+24 and H+72
11333691|NCT02476188|Experimental|Patients control|Samples of blood at H0
11333692|NCT02476188|Active Comparator|Control (healthy person)|Samples of blood at H0
11333693|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
11333694|NCT02476162||Group 1: Daily for 3 Months|Participants randomly assigned to this group will be instructed to measure their blood pressure (BP) every day during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
11333695|NCT02476162||Group 2: Daily for 1 Week/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
11333696|NCT02476162||Group 3: 3 Consecutive Days Once/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
11333697|NCT02476136||Placebo group|Patients participating in one of the included randomized controlled trials, assigned to the placebo group
11333698|NCT02476136||Intervention group|Patients participating in one of the included randomized controlled trials, assigned to the investigational antidepressant (paroxetine, duloxetine or fluoxetine) or active comparator (venlafaxine) group.
11333699|NCT02476123|Experimental|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.
~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.
~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
11333700|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
11333701|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
11333702|NCT02476084||Conventional synthetic DMARD naïve|"Naive RA patients commencing Methotrexate and Hydroxychloroquine.
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
11333703|NCT02476084||DMARD-IR: anti-TNF|"Conventional synthetic DMARD inadequate responders commencing Anti-TNF
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
11333704|NCT02476084||DMARD-IR: anti-IL6|"Conventional synthetic DMARD inadequate responders commencing anti-IL6
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
11333705|NCT02476084||DMARD-IR: anti-CTLA-4|"Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
11388958|NCT02109887||PCP with innocent bystander CMV|
11333706|NCT02476084||DMARD-IR: anti-CD20|"Conventional synthetic DMARD inadequate responders commencing anti-CD20
~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
11333707|NCT02476071|Experimental|Mass Media and Stylish Events|Mass Media (radio messages/posters promoting HIV prevention) plus one annual Stylish Man Event (SMEvent), a multimedia/community mobilization event promoting VMC.
11333708|NCT02476071|Active Comparator|Control arm: mass media only|Mass media (radio messages and posters which promote VMC for HIV prevention). .
11333709|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
11333710|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
11333711|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
11333712|NCT02476045|Active Comparator|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.
~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
11333713|NCT02476045|Experimental|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.
~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
11333714|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
11333715|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
11333716|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
11333717|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
11333718|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
11333719|NCT02476006|Experimental|Alirocumab|Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.
11333720|NCT02475993|Experimental|SMART app|SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
11333721|NCT02475993|No Intervention|Standard of care control group|The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit
11333722|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
11333723|NCT02475967|Experimental|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
11333724|NCT02475967|Active Comparator|Control group|The control group patients receive conventional cardiac care alone.
11333725|NCT02475954|Active Comparator|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
11333726|NCT02475954|Other|Standard Care|VA standard care depression in Parkinson's Disease (PD)
11333727|NCT02475941|Experimental|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
11333728|NCT02475941|Active Comparator|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
11333729|NCT02475928|Placebo Comparator|100 mg placebo|100 mg Placebo plus nutritional education
11333730|NCT02475928|Experimental|100 mg zinc supplement|Nutritional education plus 100 mg of zinc gluconate
11333731|NCT02475915|Experimental|ART + VHM|"Group 1: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
~Plus: 3 X 14-day cycles of vorinostat administered at weeks 0, 4 and 8; hydroxychloroquine and maraviroc prescribed at week 0 for a period of 10 weeks."
11333732|NCT02475915|Active Comparator|ART alone|Group 2: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and either an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
11333733|NCT02475902|Experimental|Computer guided home exercise program|"A laptop computer & MS Kinect camera will be connected to a 40 TV to deliver guided fall prevention exercises. Research staff will train the participants in the use of the computerized program and be supervised performing the exercises during the instruction period. Then participants will be instructed to exercise 3 times per week for 4 weeks. Half of the participants will begin the study with the computerized version of the home exercise program while the other half begins with the paper booklet version of the home exercise program. After one month the arms will cross over."
11333734|NCT02475902|Active Comparator|Paper guided home exercise program|A paper booklet with pictures and written instructions, and an exercise log for the home exercise program will be given to half of the participants. Participants will be carefully instructed in performing the exercises correctly and then asked to perform the exercises 3 times per week for one month. Participants who began the study with the paper exercise program will switch to the computerized version of the exercise program for the second month.
11333735|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
11333736|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
11333737|NCT02475876|Other|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
11333738|NCT02475876|Other|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
11333739|NCT02475863|Experimental|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
11333740|NCT02475863|Active Comparator|Standard practice|Dosing adjustments according to the normal unit protocol
11333741|NCT02475850|Other|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
11333742|NCT02475850|Other|Control|Usual fall prevention care
11333743|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.
~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
11333744|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.
~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
11333745|NCT02475824|Experimental|MMD arm|Both midazolam® (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea) are given intravenously at the initiation of sedation. In addition, a continuous IV infusion of dexmedetomidine (1ug/kg/h, Precedex; Hospira, Seoul, Republic of Korea) is administered 15 min before the ERCP till complete procedure
11333746|NCT02475824|Active Comparator|BPS arm|IV bolus dose of midazolam® (0.06mg/kg, 50% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea). Repeated doses of 10-20 mg propofol® are titrated to achieve the target level of sedation. 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
11333747|NCT02475785|Experimental|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.
~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
11333748|NCT02475785|Active Comparator|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.
~Insertion of FFRD with application over the lower archwire"
11333749|NCT02475785|No Intervention|untreated control group|Patients will be observed for an average duration of 6-8 months
11333750|NCT02475772|Experimental|Cisplatin and doxorubicin|Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
11333751|NCT02475759|Active Comparator|two weeks prehabilitation group|optimal caloric intake for two weeks in malnourished congenital heart disease children
11333752|NCT02475759|Active Comparator|one week prehabilitation group|optimal caloric intake for one week in malnourished congenital heart disease children
11333753|NCT02475746|Experimental|PF-06372865 treatment arm|treatment arm includes two treatment periods, a single dose of PF-06372865 (period 1) followed by 8-days itraconazole with a single dose of PF-06372865 co-administered on Day 4
11333754|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
11333755|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
11333756|NCT02475707|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
11333758|NCT02475681|Active Comparator|Obinutuzumab in Combination with Chlorambucil|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
11333759|NCT02475681|Experimental|Acalabrutinib in Combination with Obinutuzumab|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. ACP-196 will be orally administered starting on Cycle 1 Day 1. Daily administration of ACP-196 will continue until disease progression or unacceptable toxicity.
11333760|NCT02475681|Experimental|Acalabrutinib Monotherapy|Acalabrutinib will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
11333761|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
11333762|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
11333763|NCT02475642|Active Comparator|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
11333764|NCT02475642|Active Comparator|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
11333765|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
11333766|NCT02475616|Experimental|PCO371|Single oral dose of PCO371
11333767|NCT02475616|Placebo Comparator|Placebo Comparator|Single oral dose of placebo
11333768|NCT02475603|Experimental|tourniquet|Total knee arthroplasty will be performed with tourniquet
11333769|NCT02475603|Experimental|non-tourniquet|Total knee arthroplasty will be performed without tourniquet
11333770|NCT02475590|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
11333771|NCT02475590|Experimental|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
11333772|NCT02475577|Experimental|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
11333773|NCT02475577|Experimental|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
11333774|NCT02475577|Experimental|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
11333775|NCT02475564|Placebo Comparator|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
11333776|NCT02475564|Experimental|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
11333777|NCT02475551|Experimental|Treatment|IdeS as a single infusion
11333778|NCT02475538|Experimental|Electroacupuncture|"Subjects in this group will be treated with electroacupuncture along with a gradual tapering schedule.
~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.
~Subjects will receive electroacupuncture 2 times per week for 4 consecutive weeks. Electroacupuncture involves acupuncture needling at traditionally used acupoints according to Chinese medicine theory."
11333779|NCT02475538|Placebo Comparator|Placebo acupuncture|"Subjects in this group will be treated with placebo acupuncture along with a gradual tapering schedule.
~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.
~The subjects will be receive placebo acupuncture 2 times per week for 4 consecutive weeks. Placebo acupuncture is a treatment that simulates the procedure of acupuncture treatment but may not have the effects of acupuncture."
11333780|NCT02475525|Experimental|Arginine enriched oral nutritional supplement group|Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
11333781|NCT02475525|No Intervention|Control|This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
11333782|NCT02475512|Experimental|Wash wipes|Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
11333783|NCT02475512|Placebo Comparator|Standard care|Washing will be done using water and pH neutral soap. No other preventive barrier or hydration products will be allowed in the genital-anal region.
11336484|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
11333784|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) between (and including) base cohort entry and the index day - 365 days.
11333785|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
11333786|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
11333787|NCT02475486|Other|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is > 5
11333788|NCT02475486|Other|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is < or equal to 5
11333789|NCT02475473|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:
~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
11333790|NCT02475473|No Intervention|Control|Control
11333791|NCT02475460|Experimental|HM 3 LIS|All patients implanted with the HM 3 LVAD via less invasive surgical technique
11333792|NCT02475447|Placebo Comparator|Placebo|Placebo-matched tablets twice daily for 4 weeks.
11333793|NCT02475447|Experimental|Asimadoline|Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.
11333794|NCT02475434|Experimental|Cream Supplement group|Infants randomized to the cream supplement group will receive an exclusive HM-based diet with the addition of a HM-derived cream caloric supplement.
11333795|NCT02475434|No Intervention|Control Group|Infants randomized to the Control group will receive the standard regimen of an exclusive HM-based diet (no cream supplement).
11333796|NCT02475421|Experimental|Healthy, lean subjects|Healthy subjects with BMI < 27 kg/m^2
11333797|NCT02475421|Experimental|Healthy, obese subjects|Healthy subjects with BMI > 33 kg/m^2
11333798|NCT02475421|Experimental|Diabetic, lean subjects|Diabetic subjects with BMI < 27 kg/m^2
11333799|NCT02475421|Experimental|Diabetic, obese subjects|Diabetic subjects with BMI > 33 kg/m^2
11333800|NCT02475408|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
11333801|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
11333802|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
11333803|NCT02475369|Other|Group 1|"pancrelipase: 3 (three) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with meals and 2 (two) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with snacks.
~And Placebo"
11333804|NCT02475369|Other|Group 2|"pancrelipase: 3 (three) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with meals and 2 (two) 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase tablets with snacks.
~And placebo"
11333805|NCT02475356||Mirena|Mirena treatment group
11333806|NCT02475343|Experimental|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
11333807|NCT02475343|Experimental|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
11333808|NCT02475343|Experimental|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
11333809|NCT02475317|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.
11333810|NCT02475317|Experimental|Maralixibat 10mg|Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.
11333811|NCT02475317|Experimental|Volixibat 10mg|Participants will receive volixibat 10 mg capsule orally QD for 7 days.
11333812|NCT02475317|Experimental|Maralixibat 20mg|Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.
11333813|NCT02475317|Experimental|Volixibat 20mg|Participants will receive volixibat 20 mg capsule orally QD for 7 days.
11333814|NCT02475317|Experimental|Maralixibat 50mg|Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.
11333815|NCT02475317|Experimental|Maralixibat 50mg BID|Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.
11333816|NCT02475317|Experimental|Maralixibat 100mg|Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.
11333817|NCT02475304|Experimental|Experimental FP187|Treatment with a daily dose of 500mg FP187 (twice daily). Other names: Dimethyl fumarate
11333818|NCT02475304|Placebo Comparator|Placebo Comparator|Patients will receive the same number of tablets as patients randomized to FP187 arm in order to maintain the blind. The colour and shape of the FP187 and placebo tablets will be the same so that no visible difference is detectable
11333819|NCT02475291||Significant coronary lesions|Significant lesions with more than 70% diameter stenosis at proximal major coronary arteri(es).
11333820|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
11333821|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
11333822|NCT02475252|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
11333823|NCT02475252|Experimental|Novices|Medical students will perform a hysteroscopy on a training model.
11333824|NCT02475239|Experimental|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
11333825|NCT02475239|Active Comparator|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
11333826|NCT02475226||Patients with body and head trauma|type of the brain injury in patients with brain damage associated both general body and head trauma
11333827|NCT02475226||Patients with pure head trauma|type of the brain injury in patients with brain damage associated pure head trauma
11333828|NCT02475226||Patients with spontaneous hemorrhage|type of the brain injury in Patients with brain damage associated spontaneous hemorrhage
11333829|NCT02475213|Experimental|enoblituzumab plus pembrolizumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Pembrolizumab: Keytruda; human programmed death receptor-1 (PD-1)-blocking antibody approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor, or with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
11333830|NCT02475213|Experimental|enoblituzumb plus MGA012|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. MGA012: anti-PD-1 monoclonal antibody.
11333831|NCT02475174|Experimental|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
11333832|NCT02475174|Experimental|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
11333833|NCT02475161|Experimental|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
11333834|NCT02475148|Experimental|Part 1: Cohort 1|Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.
11333835|NCT02475148|Experimental|Part 1: Cohort 2|Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.
11333836|NCT02475148|Experimental|Part 1: Cohort 3|Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.
11333837|NCT02475148|Experimental|Part 1: Cohort 4|Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.
11333838|NCT02475148|Experimental|Part 1: Cohort 5|Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.
11333839|NCT02475148|Experimental|Part 1: Cohort 6|Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.
11333840|NCT02475148|Experimental|Part 2: Cohort 7|Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
11333841|NCT02475148|Experimental|Part 3: Cohort 8|Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
11333842|NCT02475135|Experimental|Panel 1: Group 1|Subject will receive a single oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) (D/C/F/TAF) under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 1 and by FDC of elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/ tenofovir alafenamide (TAF) (E/C/F/TAF) under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 2.
11333843|NCT02475135|Experimental|Panel 1: Group 2|Subject will receive a single oral tablet of FDC containing E/C/F/TAF under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 1 and a single oral tablet of FDC containing D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 2.
11333844|NCT02475135|Experimental|Panel 2: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 1 and a single oral tablet of DRV, a tablet of emtricitabine/ tenofovir alafenamide (FTC/TAF) and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2.
11333845|NCT02475135|Experimental|Panel 2: Group 2|Subject will receive a single oral tablet of DRV, a tablet of FTC/TAF and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2 and a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 2.
11333846|NCT02475135|Experimental|Panel 3: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 1 and a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 2.
11333847|NCT02475135|Experimental|Panel 3: Group 2|Subject will receive a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 1 followed by a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 2.
11333848|NCT02475122|Other|open-label study|open-label study
11333849|NCT02475109|Experimental|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
11333884|NCT02474875|Experimental|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
11333947|NCT02474433|Active Comparator|PO Misoprostol|Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
11333850|NCT02475096|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
11333851|NCT02475083|Experimental|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
11333852|NCT02475083|Active Comparator|Conventional Group|Conventional physiotherapy with exercises for balance training.
11333853|NCT02475070|Active Comparator|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
11333854|NCT02475070|Active Comparator|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
11333855|NCT02475057|Experimental|Degarelix (LHRH antagonist)|Degarelix (LHRH antagonist) EndoPAT2000
11333856|NCT02475057|Active Comparator|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000
11333857|NCT02475044|No Intervention|Treatment as usual (TAU)|Participants recive Psycho-education and neuro-psycological diagnosis.
11333858|NCT02475044|Experimental|Cognitive-Behavioral Therapy (CBT)|Participants recive 16 sessions of CBT in addition to arm TAU treatment.
11333859|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
11333860|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
11333861|NCT02475018|Experimental|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
11333862|NCT02475018|Placebo Comparator|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
11333863|NCT02475018|No Intervention|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
11333864|NCT02475005|Experimental|Mobile self management app on smartphone|Mobile self management app on smartphone
11333865|NCT02475005|No Intervention|Treatment as usual|Treatment as usual (control group)
11333866|NCT02474992|Experimental|Intervention|This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
11333867|NCT02474992|No Intervention|Comparison|This arm is not eligible for participation in the intervention during the first twelve months of the study. Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group. Participants in this arm will still have access to standard HIV care at the facility of their choice. At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
11333868|NCT02474979|Experimental|CBPM-system|CBPM-system (Continuous Bedside Pressure Mapping System): the bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure. The CBPM-system will be used in addition to standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
11333869|NCT02474979|Experimental|Control|Standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
11333870|NCT02474966|Experimental|Real-Sham dTMS|This arm will be treated before with real deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with sham dTMS (the second day)
11333871|NCT02474966|Experimental|Sham-Real dTMS|This arm will be treated before with sham deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with real dTMS (the second day)
11333872|NCT02474953|Experimental|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
11333873|NCT02474953|Experimental|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
11333874|NCT02474940|Experimental|Intervention #1|NF-HYP
11333875|NCT02474940|Experimental|Intervention #2|MM-HYP
11333876|NCT02474940|Experimental|Intervention #3|HYP-ONLY
11333877|NCT02474927|Experimental|Carfilzomib Treatment Arm|Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.
11333878|NCT02474914|Active Comparator|Octreotide|Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
11333879|NCT02474914|Placebo Comparator|Placebo|pancreaticoduodenectomy without octreotide postoperative
11333880|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
11333881|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
11333882|NCT02474888||Rituximab|a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
11333883|NCT02474875|Active Comparator|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
11333921|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
11388959|NCT02109887||PCP without any evidence of CMV|
11333885|NCT02474875|Experimental|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
11333886|NCT02474875|Experimental|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
11333887|NCT02474862|Experimental|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
11333888|NCT02474862|Active Comparator|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
11333889|NCT02474849|Active Comparator|Conventional cigarette|
11333890|NCT02474849|Experimental|First-generation e-cigarette|
11333891|NCT02474849|Experimental|Rechargeable cig-like e-cigarette|
11333892|NCT02474849|Experimental|Closed modular system e-cigarette A|
11333893|NCT02474849|Experimental|Closed modular system e-cigarette B|
11333894|NCT02474836|Active Comparator|Atopic subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
11333895|NCT02474836|Active Comparator|Non atopic subjects|Healthy volunteers
11333896|NCT02474836|Other|Allergic Subjects|
11333897|NCT02474823|Other|Sleep Apnea assessment|all participants are in the same arm & undergo the same assessments: PSG, HST, ESAP
11333898|NCT02474810|Experimental|Intensive|In the Intensive Protocol, alteplase intervention is administered to all catheters based on blood flow and/or line reversal
11333899|NCT02474810|Experimental|Standard|In the Standard Protocol, alteplase intervention is administered to all catheters based only on blood flow.
11333900|NCT02474797|Experimental|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
11333901|NCT02474745|Experimental|INTERVENTION GROUP|"Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:
~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
11333902|NCT02474745|Other|CONTROL GROUP|"Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:
~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
11333903|NCT02474732|Other|Usability|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
11333904|NCT02474719|Experimental|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).
~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
11333905|NCT02474719|Experimental|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.
~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
11333906|NCT02474706|Experimental|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
11333907|NCT02474706|Active Comparator|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
11333908|NCT02474680||Care Coordination Group|Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'
11333909|NCT02474667|Active Comparator|BB3|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
11333910|NCT02474667|Placebo Comparator|Normal Saline|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
11333911|NCT02474654|Experimental|Arm 1: PI+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
11333912|NCT02474654|Experimental|Arm 2:NS+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml
11333913|NCT02474654|Experimental|Arm 3: PI+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
11333914|NCT02474654|Experimental|Arm 4: PI+FNB+NS|Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
11333915|NCT02474654|Active Comparator|Arm 5:NS+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml
11333916|NCT02474641|Active Comparator|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or
~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or
~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
11333917|NCT02474641|Experimental|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
11333918|NCT02474628|Placebo Comparator|Placebo|0.3 g∙kg-1body mass of calcium carbonate
11333919|NCT02474628|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
11333920|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
11333922|NCT02474602|Experimental|Group A - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
11333923|NCT02474602|Experimental|Group B - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
11333924|NCT02474602|Experimental|Group C - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
11333925|NCT02474602|Experimental|Group D - Active or Placebo Phototherapy'|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.
~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
11333926|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
11333927|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
11333928|NCT02474576|Experimental|Percutaneous aponeurotomy|Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy
11333929|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
11333930|NCT02474550||CISL 14-03|"Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).
~Aged 19 or more
~Treated with R-CHOP therapy"
11333931|NCT02474537|Experimental|Normal hepatic function|Subjects with normal hepatic function
11333932|NCT02474537|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
11333933|NCT02474537|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
11333934|NCT02474537|Experimental|Severe hepatic impairment|Subjects with severe hepatic impairment
11333935|NCT02474524|Experimental|Health intervention|+ treatment as usual
11333936|NCT02474524|Active Comparator|Social intervention|+ treatment as usual
11333937|NCT02474511||general anesthesia|In this group，the patient is received radiofrequency ablation under general anesthesia.
11333938|NCT02474511||local anesthesia|In this group，the patient is received radiofrequency ablation under local anesthesia.
11333939|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
11333940|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
11333941|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
11333942|NCT02474485|Active Comparator|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:
~BVS Absorb implantation. For in stent restenosis treatment during index procedure.
~OCT visualization.During index procedure and at 9 month follow-up.
~Control coronary angiography. Control angiography will be performed at 9 month follow-up.
~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
11333943|NCT02474485|Active Comparator|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:
~DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.
~OCT visualization.During index procedure and at 9 month follow-up.
~Control coronary angiography. Control angiography will be performed at 9 month follow-up.
~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
11333944|NCT02474459|Active Comparator|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
11333945|NCT02474459|Active Comparator|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
11333946|NCT02474446|Experimental|1|"Anthropometry measurement, Skin colour grading using Fitzpatrick scale, Dietary intake of calcium and vitamin D using food frequency questionnaire (FFQ), Baseline fasting blood samples for vitamin D, VDBP, VDBP genotype, Calcium, Phosphorus, Albumin, Parathyroid Hormone(PTH), Alkaline Phosphatase, Bone turnover markers(P1NP, CTX).
~Fasting urine for Calcium Creatinine ratio. Saliva for bio-available Free Vitamin D measurement.
~Vitamin D administration under direct supervision. Spot Urine sample for calcium : creatinine ratio after a week. Repeat all measurements done at baseline except VDBP genotype 4 weeks from baseline."
11336667|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
11333948|NCT02474433|Active Comparator|PV Misoprostol|Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
11333949|NCT02474433|Active Comparator|Buccal Misoprostol|Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
11333950|NCT02474420|Active Comparator|Deferasirox|deferasirox iron chelation therapy and standard of care by the treating physician
11333951|NCT02474420|Experimental|Deferasirox plus amlodipine|deferasirox iron chelation therapy with amlodipine
11333952|NCT02474407|Experimental|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
11333953|NCT02474407|Active Comparator|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
11333954|NCT02474394|Active Comparator|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
11333955|NCT02474394|Active Comparator|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
11333956|NCT02474381|Experimental|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
11333957|NCT02474381|Active Comparator|Single PTA|Angioplasty of arteries below tibial plateau level only
11333958|NCT02474368|Experimental|Cohort 1|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)
~Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks
~Cisplatin will be administered intravenously on predetermined days
~Stereotactic Body Radiotherapy (SBRT)"
11333959|NCT02474368|Experimental|Cohort 2|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
11333960|NCT02474355|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
11333961|NCT02474342|Experimental|Autologous Adipose Tissue derived MSCs|
11333962|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
11333963|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
11333964|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
11333965|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
11333966|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.
~Interventions/Exposures to be administered:
~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.
~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
11333967|NCT02474316|Experimental|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
11333968|NCT02474316|Active Comparator|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
11333969|NCT02474303|Other|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
11333970|NCT02474290|Experimental|Sorafenib group|Sorafenib will be used from day 30 to 180 post-transplantation.
11333971|NCT02474290|No Intervention|non-Sorafenib group|
11333972|NCT02474277|Other|30 sec chair stand test|all patients in this Group receives a diagnostic test for functional impairment
11333973|NCT02474264|Other|male BRCA mutations carriers|Endothelial function assessment and Cardiovascular biomarkers
11333974|NCT02474264|Other|healthy males - control group|Endothelial function assessment and Cardiovascular biomarkers
11390256|NCT02101203|Experimental|Placebo|40 subjects administered placebo
11333975|NCT02474251|Active Comparator|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
11333976|NCT02474251|Active Comparator|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index [AHI]-all >30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
11333977|NCT02474238|Experimental|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
11333978|NCT02474238|Active Comparator|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
11333979|NCT02474212|Active Comparator|Enoxaparin 40 mg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
11333980|NCT02474212|Active Comparator|Enoxaparin 40 mg i.v.|Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
11333981|NCT02474212|Active Comparator|Enoxaparin 0.5 mg/kg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
11333982|NCT02474212|Active Comparator|Enoxaparin 1 mg/kg i.v.|Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
11333983|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
11333984|NCT02474186|Experimental|Radiation therapy|"Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol"
11333985|NCT02474173|Experimental|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.
~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of cycle 1 and on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11333986|NCT02474160||Ancillary-correlative (tissue and blood procurement)|Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
11333987|NCT02474147|Experimental|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
11333988|NCT02474147|Active Comparator|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
11333989|NCT02474147|Active Comparator|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
11333990|NCT02474134|Other|PF530/Betaferon|Single subcutaneous injection of two interferon beta-1b products (PF530 and Betaferon) 0.25 mg
11333991|NCT02474134|Other|Betaferon/PF530|Single subcutaneous injection of two interferon beta-1b products (Betaferon and PF530) 0.25 mg
11333992|NCT02474108|Placebo Comparator|without prevention|isolated mitral valve replacement or reconstruction, implantation of cardiac monitor
11333993|NCT02474108|Active Comparator|group of prevention|"mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.
~Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe."
11333994|NCT02474095|Experimental|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
11333995|NCT02474095|Active Comparator|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
11333996|NCT02474082|Experimental|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
11333997|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
11333998|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
11333999|NCT02474069|Active Comparator|Secukinumab 4-weekly|
11334000|NCT02474056||trauma patients|patients with decreased blood volume
11334001|NCT02474056||surgical patients|patients with decreased blood volume
11334002|NCT02474056||non surgical patients|patients with decreased blood voloume
11334003|NCT02474043|Active Comparator|Usual care|Standard health education and prevention counseling by trained staff
11334004|NCT02474043|Experimental|Hep-Net Intervention|Computerized tailored behavioral intervention
11334005|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
11334006|NCT02474004|Experimental|medial meniscus repair|patients receiving medial meniscus repair
11334007|NCT02474004|Active Comparator|medial partial meniscectomy|patients having medial partial meniscectomy
11334008|NCT02473978||Participants undergoing cesarean sections|The participants preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
11334009|NCT02473978||Participants throughout cesarean sections|The participants intraoperative data will be compared to preoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
11334010|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
11334011|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
11334272|NCT02472184|Active Comparator|Office Hysteroscopy|Group of patients in which office hysteroscopy will be performed prior to endometrial biopsy
11334012|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.
~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
11334013|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
11334014|NCT02473939|Experimental|VR942 Dose 1|VR942 Dose 1
11334015|NCT02473939|Experimental|VR942 Dose 2|VR942 Dose 2
11334016|NCT02473939|Experimental|VR942 Dose 3|VR942 Dose 3
11334017|NCT02473939|Experimental|VR942 Dose 4|VR942 Dose 4
11334018|NCT02473939|Experimental|VR942 Dose 5|VR942 Dose 5
11334019|NCT02473926|Experimental|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.
~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
11334020|NCT02473926|Other|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
11334021|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
11334022|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
11334023|NCT02473900|Experimental|Sequence 1|HIP1403→HGP0919
11334024|NCT02473900|Experimental|Sequence 2|HGP0919→HIP1403
11334025|NCT02473887|Experimental|gastroenteritis with persistent vomiting.|patients with gastroenteritis with persistent vomiting received single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
11334026|NCT02473874||Skin Spect dermoscope|Skin mole
11334027|NCT02473874||Spatially modulated quantitative|Skin mole
11334028|NCT02473861|Experimental|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
11334029|NCT02473861|Experimental|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require >1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
11334030|NCT02473848|Experimental|Ingenol mebutate 500 ucg|active arm
11334031|NCT02473835|Experimental|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
11334032|NCT02473809|Experimental|Liraglutide|"Liraglutide (Victoza), subcutaneous 1,8 mg once daily for 180 days"
11334033|NCT02473809|Placebo Comparator|Placebo|Saline, subcutaneous once daily for 180 days
11334034|NCT02473796|Experimental|Home based child care|The home based child care included treatment of various various childhood illnessed by locally avialable trained village health workers, improving hygiene and nutrition among children and women throgh health education. This care was in adiition to the local health care provided by the Government's primary health care services.
11334035|NCT02473796|No Intervention|control|The control arm included population where the home based neonatal care was not implimented. The health services were provided by the Government run primary health care services. Vital statistics data was collected by VHWs.
11334036|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
11334037|NCT02473770||Disaster responders|Conducting emergency disaster relief.
11334038|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
11334039|NCT02473744|Experimental|Oedematous lower limb subcutaneous drainage|In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
11334040|NCT02473731|Experimental|A|Treatment with KTN3379 in HPV positive head and neck cancer patients
11334041|NCT02473731|Experimental|B|Treatment with KTN3379 in HPV negative head and neck cancer patients
11334068|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
11334389|NCT02471339|Experimental|1/ACT|2 ACT Training Sessions followed by weekly emails and video chats
11334042|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
11334043|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
11334044|NCT02473705|Active Comparator|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
11334045|NCT02473705|Active Comparator|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
11334046|NCT02473705|Experimental|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
11334047|NCT02473705|Placebo Comparator|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
11334048|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
11334049|NCT02473666||All Health Conditions.|All Health Conditions. Area of Focus: Transfusions of blood products.
11334050|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
11334051|NCT02473627|Experimental|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
11334052|NCT02473627|Experimental|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .
~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:
~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
11334053|NCT02473614|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
11334054|NCT02473614|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
11334055|NCT02473601|Experimental|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
11334056|NCT02473601|Other|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
11334057|NCT02473588|Other|LTIA Group|Patients in the LTIA Group (all patients) will have blood pressure recorded continuously. LTIA will be used to measure stroke volume and cardiac output after the completion of data collection
11334058|NCT02473575|Experimental|Caffeine gum|caffeine (300 mg) in gum form x 1 ingestion
11334059|NCT02473575|Placebo Comparator|Placebo gum|placebo gum consumed x 1 ingestion
11334060|NCT02473575|No Intervention|Non-intervention group|A third group of runners will be used to adjust for changes in environmental conditions. They will complete 2 runs without consuming either placebo or experimental treatment
11334061|NCT02473562|Experimental|Varenicline|Varenicline capsule 1 mg BID
11334062|NCT02473562|Placebo Comparator|Placebo|Placebo capsule
11334063|NCT02473549|Experimental|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
11334064|NCT02473536|Experimental|Stereotactic ablative radiation therapy|SABR
11334065|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.
~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
11334066|NCT02473510|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
11334067|NCT02473510|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
11334069|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
11336924|NCT02454907|Active Comparator|Control|One kind of communication with the clinic will be used.
11334071|NCT02473458|Experimental|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
11334072|NCT02473458|Experimental|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
11334073|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
11334074|NCT02473432|Experimental|RMT + usual care|Device: Orygen-Dual® valve trainer Intensity: 30% of maximal respiratory pressures (increasing intervals: 10 cmH2O per week) Training schedule: 5 sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, two sessions per day, 5 days per week, for 3 weeks.
11334075|NCT02473432|Experimental|NMES + usual care|Device: Vital Stim (Chattanooga Group, Hixson, TN, USA) Administration of 80 Hz transcutaneous electrical biphasic stimulus Schedule: 40 minutes per day, 5 sessions per week during hospitalization in the Neurorehabilitation ward (3 weeks approx).
11334076|NCT02473432|Active Comparator|Usual care|Usual care (standard multidisciplinary inpatient rehabilitation program) consisting of physical, occupational and speech therapy sessions to improve activities of daily life, mobility and communication skills (minimum 3 hours per day, 5 days a week, during 3 weeks), Standard swallow therapy (usual care of dysphagia in stroke patients) consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
11334077|NCT02473419||Vayarin|Vayarin x 16 weeks
11334078|NCT02473419||Placebo|Placebo x 16 weeks
11334079|NCT02473419||Vayarin and Placebo|Placebo x 8 weeks and then Vayarin x 8 weeks
11334080|NCT02473406|Experimental|Thymosin|Thymosin alpha 1 has been shown to have immunomodulatory properties
11334081|NCT02473406|Placebo Comparator|Placebo|normal saline;
11334082|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
11334083|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
11334084|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
11334085|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
11334086|NCT02473380|Experimental|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
11334087|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
11334088|NCT02473354|Other|Resp Depression Sequence 1 - 3|"Sequence #1: breathe 21% through the facemask and increase ventilation to achieve a target hypocapnic ET CO2 of 25 - 30 mmHg. Subject will then breathe a gas mixture containing 6% CO2 / 30% O2 to achieve a target hypercapnic ET CO2 up to 60 mmHg or HCVR is terminated at the discretion of the PI.
~Sequence #2: breathe 21% O2 (normoxia) before remifentanil administration Sequence #3: breathe 50% O2 (hyperoxia) before remifentanil administration"
11334089|NCT02473341|Experimental|Bovine colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.
~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
11334090|NCT02473341|Placebo Comparator|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks
~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
11334091|NCT02473328|Experimental|non comparative open study|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4), switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.
~The administration will be done once a day orally for 48 weeks."
11334092|NCT02473315|Experimental|cryotherapy|
11334093|NCT02473315|Placebo Comparator|light cryotherapy|
11334094|NCT02473302|Placebo Comparator|ham|160g per day during 4 days
11334095|NCT02473302|Experimental|ham + pomegranate extract|160g per day during 4 days
11334096|NCT02473302|Experimental|ham + tocopherol|160g per day during 4 days
11334097|NCT02473302|Placebo Comparator|rare sirloin steak|110g per day during 4 days
11334098|NCT02473302|Experimental|marinated rare sirloin steak|110g per day during 4 days
11334099|NCT02473302|Experimental|marinated cooked sirloin steak|110g per day during 4 days
11334100|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
11334101|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
11334102|NCT02473276|Active Comparator|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
11334103|NCT02473276|Sham Comparator|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
11334134|NCT02473068|Active Comparator|Group 1|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 31°C.
11337839|NCT02449070|No Intervention|Control|Receive primary PCI and the standard therapy.
11334104|NCT02473276|Active Comparator|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
11334105|NCT02473276|Sham Comparator|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
11334106|NCT02473263|No Intervention|Conventional|No antibiotic administration and no hemodynamic target are required
11334107|NCT02473263|Active Comparator|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
11334108|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
11334109|NCT02473237|Experimental|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
11334110|NCT02473237|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
11334111|NCT02473224|Experimental|Cohort 1|9 secretor-positive subjects will receive 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
11334112|NCT02473224|Experimental|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10^2GEC, or 1.2 x10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
11334113|NCT02473224|Experimental|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, 1.2 x 10^6 GEC, or 1.2 x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
11334114|NCT02473224|Experimental|Cohort 4|8 secretor-negative and 3 secretor-positive subjects will receive 1.2 x 10^7 GEC oral dose on Day 1, n=11
11334115|NCT02473211|Experimental|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
11334116|NCT02473198|Active Comparator|Femoral Nerve Block (Group 1)|"In group1 (standard group) all patients receive the standard current perioperative pain management protocol for TKR.
~The patient will then undergo an ultrasound guided femoral nerve block with bupivacaine 0.25% 20 cc. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint. Postoperatively patients will receive narcotic pain medication on a PRN basis."
11334117|NCT02473198|Experimental|Exparel (Group 2)|Group 2 will receive standard perioperative pain management for TKR; will undergo placebo femoral nerve block under ultrasound guidance with normal saline (NS) 20 cc. Following femoral bone cuts they will receive local anesthetic injection mixture of 30cc 0.25% bupivicaine with epinephrine 20 cc of preservative free normal saline, 30mg of toradol and 10 mg of morphine sulfate into the periarticular tissues including periosteum, joint capsule and posterior capsule of the knee joint and collateral ligaments and subcutaneous tissues. Prior to cementing prosthesis, a second injection with mixture of 20mL 1.3% Exparel and 40mL normal saline solution will be injected into the same tissues, joint capsules and collateral ligaments.
11334118|NCT02473185|Experimental|Methylphenidate|Methylfenidate 20 mg Tablet single-dose per os
11334119|NCT02473185|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
11334120|NCT02473172|Experimental|Pressure Support Ventilation|Assisted mechanical ventilation
11334121|NCT02473172|Experimental|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
11334122|NCT02473159|Experimental|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
11334123|NCT02473146|Experimental|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:
~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
11334124|NCT02473146|No Intervention|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
11334125|NCT02473133|Experimental|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
11334126|NCT02473133|Sham Comparator|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
11334127|NCT02473120|Experimental|Determination of ESR1 mutations|Blood sample will be collected every 3 months during two years to determine ESR1 mutations
11334128|NCT02473107|Other|Control Caries Detection Strategy|Detection and treatment based on more advanced lesions, despite activity status - Advanced caries lesions detection (no activity assessment)
11334129|NCT02473107|Other|Test Caries Detection Strategy|Detection and treatment based on all detected caries lesions, considering their activity status as a differential in clinical decision-making - All caries lesions detection (+activity assessment)
11334130|NCT02473094|Experimental|Neoadjuvant capecitabine and metformin|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;
~Metformin 2500mg/d for five weeks;
~3D radiotherapy 50,4Gy divided in 25 fractions"
11334131|NCT02473094|Placebo Comparator|Neoadjuvant capecitabine and placebo|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;
~Placebo 2500mg/d for five weeks;
~3D radiotherapy 50,4Gy divided in 25 fractions"
11334132|NCT02473081|Experimental|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
11334133|NCT02473081|Other|Usual care|Participants in this group received usual care only.
11334135|NCT02473068|Experimental|Group 2|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 27°C.
11334136|NCT02473055|Experimental|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
11334137|NCT02473055|No Intervention|control|control infants remained prone in an incubator wearing only diaper
11334138|NCT02473042|Experimental|Electrical Stimulation + Standard of Care Antiemetics|"Participants receive light electrical stimulation to the wrist area during surgery. Participants also receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).
~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
11334139|NCT02473042|Active Comparator|Standard of Care Antiemetics|"Participants receive standard of care drugs to reduce post-operative nausea and vomiting (PONV).
~Questionnaire completed about participant's pre-treatment expectations and their nausea about 15 minutes after they wake up after surgery, then every 30 minutes until they leave the clinic."
11334140|NCT02473029||Cases|Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease
11334141|NCT02473016|Experimental|Treatment|All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
11334142|NCT02473003|Experimental|High intensity|high intensity exercise 80-90%
11334143|NCT02473003|Experimental|Low/Medium intensity|low/medium intensity exercise 40-50%
11334144|NCT02473003|Experimental|High Intensity with BM|high intensity exercise with Behavioral medicine strategies¨ 80-90%
11334145|NCT02473003|Experimental|Low/Medium intensity with BM|low/medium intensity exercise with Behavioral medicine strategies 40-50%
11334146|NCT02472990|Other|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)
~Measurement of leg strength using a dynamometer
~Measurement of Motor Function
~Walk test 6 minutes
~Walk test 10 meters
~Walk analysis: 3D recording of walking
~Muscle MRI"
11334147|NCT02472990|Other|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)
~Measurement of leg strength using a dynamometer
~Measurement of Motor Function
~Walk test 6 minutes
~Walk test 10 meters
~Walk analysis: 3D recording of walking
~Muscle MRI"
11334148|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
11334149|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
11334150|NCT02472964|Active Comparator|Herceptin© + Taxane|"Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.
~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal ."
11334151|NCT02472964|Experimental|MYL- 1401O + Taxane|"Part 1:MYL-1401O Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.
~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to MYL-1401O alone once every 3 weeks until DP or subject withdrawal."
11334152|NCT02472951|Active Comparator|Type 2 diabetic subjects|
11334153|NCT02472951|Active Comparator|Prediabetic subjects|
11334154|NCT02472951|Active Comparator|Healthy subjects|
11334155|NCT02472938|Experimental|BG00012|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
11334156|NCT02472938|Placebo Comparator|Placebo|Placebo capsules orally twice a day.
11334157|NCT02472925|Other|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
11334158|NCT02472925|Experimental|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is >30 hours (greater than 6 hours overdue).
11334159|NCT02472925|Experimental|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect >85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
11334160|NCT02472912|Experimental|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
11334161|NCT02472912|Active Comparator|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
11334162|NCT02472912|Active Comparator|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
11334163|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
11334164|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
11334165|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
11334166|NCT02472886|Experimental|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
11334167|NCT02472886|Experimental|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
11334168|NCT02472886|Experimental|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
11334169|NCT02472873|Experimental|study group - sclerotherapy|Aspiration and Sclerotherapy of endometriomas.
11334170|NCT02472873|Other|control group - cystectomy|cystectomy of endometriomas.
11334171|NCT02472860|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
11334172|NCT02472860|Placebo Comparator|Control Condition|Youth appropriate online games
11334173|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
11334174|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
11334175|NCT02472834|Experimental|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
11334176|NCT02472834|No Intervention|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
11334177|NCT02472821|Active Comparator|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
11334178|NCT02472821|Active Comparator|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
11334179|NCT02472821|No Intervention|No-intervention control|No interventions; pre- and post- measures only.
11334180|NCT02472808|Other|cTBNA without ROSE|Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
11334181|NCT02472808|Other|cTBNA with ROSE|Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
11334182|NCT02472808|Other|EBUS-TBNA without ROSE|Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
11334183|NCT02472808|Other|EBUS-TBNA with ROSE|Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
11334184|NCT02472795|Experimental|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
11334185|NCT02472795|Experimental|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
11334186|NCT02472795|Experimental|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
11334187|NCT02472795|Experimental|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
11334188|NCT02472795|Placebo Comparator|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
11334189|NCT02472769|Active Comparator|IBP-9414|IBP-9414 Oral Daily
11334190|NCT02472769|Placebo Comparator|Placebo|Sterile water
11334191|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
11334192|NCT02472743|Experimental|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:
~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).
~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.
~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes)."
11334193|NCT02472730|Experimental|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
11334194|NCT02472730|No Intervention|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
11334195|NCT02472717|Experimental|Interventional arm|liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
11334196|NCT02472717|Placebo Comparator|Placebo arm|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
11334197|NCT02472704|Active Comparator|Gluten challenge|Gluten powder (10 g every 12 hours), 24 weeks
11334198|NCT02472704|Placebo Comparator|Placebo challenge|Placebo (maltodextrin; 10 g every 12 hours), 24 weeks
11334199|NCT02472691|Experimental|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
11334200|NCT02472678|Other|Standard care|The control group will receive standard care.
11334201|NCT02472678|Experimental|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
11334202|NCT02472665|Experimental|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
11334203|NCT02472652|Other|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
11334204|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
11334205|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
11334206|NCT02472626|Experimental|Treatment (CPI-613, cytarabine, daunorubicin hydrochloride)|"INDUCTION: Patients receive cytarabine IV continuously on days 1-7, daunorubicin hydrochloride IV on days 1-3, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 3-7. Patients then undergo biopsy on day 14. Patients experiencing significant residual disease receive cytarabine IV continuously on days 1-5, daunorubicin hydrochloride IV on days 1-2, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5.
~CONSOLIDATION: Beginning 42 days later, patients receive cytarabine IV continuously on days 1-16 and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 2-6. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients not undergoing transplant after consolidation receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
11334207|NCT02472613|Experimental|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
11334208|NCT02472613|Active Comparator|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
11334209|NCT02472600|Active Comparator|colistin + neomycin followed by FMT|"CAPSULE APPROACH:
~Treatment days 1-5
~Colistin sulphate 2 million IU per os 4x/day (for 5 days)
~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment
~Treatment days 7 and 8:
~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day
~NASOGASTRIC TUBE APPROACH:
~Treatment days 1-5
~Colistin sulphate 2 million IU per os 4x/day (for 5 days)
~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)
~Treatment day 6 and 7:
~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7
~Treatment day 7:
~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
11334210|NCT02472600|No Intervention|No intervention|Control arm without any intervention
11334211|NCT02472587||Pap test|Women attending our institute in order to do Pap test
11334212|NCT02472574|Experimental|0.3 mg|Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
11334213|NCT02472574|Experimental|0.5 mg|Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
11334214|NCT02472574|Experimental|1.0 mg|Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
11334215|NCT02472561|Experimental|Mobile Health Application Group 1|"Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease; patients will be asked to read approximately one chapter per week for educational purposes."
11334216|NCT02472561|No Intervention|Usual Care Group 2|"Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments."
11334217|NCT02472548|Experimental|Group A, DPX-RSV(A) low dose (Step 1)|
11334218|NCT02472548|Experimental|Group B, RSV(A)-Alum low dose (Step 1)|
11334219|NCT02472548|Experimental|Group D, DPX-RSV(A) high dose (Step 2)|
11334220|NCT02472548|Experimental|Group E, RSV(A)-Alum high dose (Step 2)|
11334221|NCT02472548|Placebo Comparator|Group C & F, Placebo control (Step 1 and 2)|
11334222|NCT02472535|Experimental|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
11334223|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
11334224|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
11334225|NCT02472509|Experimental|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
11334226|NCT02472483|Experimental|bipolar disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT
~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
11334227|NCT02472483|Experimental|anxious disorders|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT
~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
11334228|NCT02472483|Experimental|alcohol disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT
~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
11334229|NCT02472470|Experimental|Treatment|intermitten TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 2 weeks.
11334230|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
11334231|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
11334232|NCT02472431|Experimental|ADRC injection|
11334233|NCT02472418|Experimental|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
11334234|NCT02472418|Experimental|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
11334235|NCT02472418|Placebo Comparator|Placebo (treatment C)|Placebo (treatment C)
11334236|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
11334237|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
11334238|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
11334239|NCT02472392|Active Comparator|Treatment Plan A|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.
11334240|NCT02472392|Active Comparator|Treatment Plan B|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
11334241|NCT02472379|Experimental|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
11334242|NCT02472379|Placebo Comparator|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
11334243|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
11334244|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
11334245|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
11334246|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
11334247|NCT02472340||Sedentary, Pre-frail|10 sedentary, pre-frail elderly, >61 year of age
11334248|NCT02472340||Active, Healthy|10 Active, healthy elderly, >61 years of age
11334249|NCT02472327|No Intervention|Typical Care|These patients will receive normal peripartum care and support.
11334250|NCT02472327|Experimental|Pre-operative support|These patients will receive additional emotional support prior to undergoing an unplanned cesarean section during labor.
11334251|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
11334252|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
11334253|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
11334254|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
11334255|NCT02472301|Experimental|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
11334256|NCT02472301|Experimental|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
11334257|NCT02472301|Active Comparator|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
11334258|NCT02472288|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)
~BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)
~20 minutes duration, middle frequency (30 Hz) of electrical stimulation
~conventional treatments permitted"
11334259|NCT02472288|Sham Comparator|Sham group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)
~BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)
~20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)
~conventional treatments permitted"
11334260|NCT02472275|Experimental|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
11334261|NCT02472262|Experimental|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
11334262|NCT02472262|Experimental|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
11334263|NCT02472262|Active Comparator|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
11334264|NCT02472249|Experimental|Norepinephrine intra-arteriel/hepatic|This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
11334265|NCT02472236|Experimental|Digoxin and PEX168(200µg)|Digoxin: 0.5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
11334266|NCT02472223|Active Comparator|Betadine 5%|One time in-office use (4-5 drops)
11334267|NCT02472223|Placebo Comparator|Artificial Tears|Standard of Care
11334268|NCT02472210|Placebo Comparator|Placebo|Saline IM Injection
11334269|NCT02472210|Active Comparator|Onabotulinum Toxin A|IM Injection
11334270|NCT02472197|Experimental|morcellation|
11334271|NCT02472197|Active Comparator|standard resection|
11334273|NCT02472184|Active Comparator|Endometrial biopsy|Group of patients in which endometrial biopsy will be performed prior to office hysteroscopy
11334274|NCT02472171|Experimental|Group 1|"Order of treatments:
~A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
11334275|NCT02472171|Experimental|Group 2|"Order of treatments:
~A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil"
11334276|NCT02472171|Experimental|Group 3|"Order of treatments:
~B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
11334277|NCT02472171|Experimental|Group 4|"Order of treatments:
~B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil"
11334278|NCT02472171|Experimental|Group 5|"Order of treatments:
~C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil"
11334279|NCT02472171|Experimental|Group 6|"Order of treatments:
~C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil"
11334280|NCT02472158|Experimental|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
11334281|NCT02472158|Active Comparator|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
11334282|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.
~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
11334283|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
11334284|NCT02472132|Experimental|Intervention|Prospective implantation of POC US for CVC tip placement.
11334285|NCT02472132|No Intervention|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
11334286|NCT02472119|Experimental|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
11334287|NCT02472119|Active Comparator|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
11334288|NCT02472093|Active Comparator|Physical exercises treatment|The types of exercises included: low-impact to moderate aerobic training (gradually starting from 50% of the Fc max to 70%-80% of Fc max); walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing.
11334289|NCT02472093|Experimental|Perceptive Rehabilitation Treatment|Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
11334290|NCT02472093|Active Comparator|Control group|The control group did brief educational sessions.
11334291|NCT02472080|Experimental|gemcitabine -oxaliplatine combination|
11334292|NCT02472067|No Intervention|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
11334293|NCT02472067|Experimental|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
11334294|NCT02472054|Experimental|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)
~Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)
~The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).
~Maintenance treatment (D4 to D14)
~MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14
~CSA IVC or PO at a target rate of 150-200 ng / ml"
11334295|NCT02472041|Experimental|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
11334296|NCT02472041|Experimental|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
11334297|NCT02472028|Experimental|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to <135 mmHg
11334298|NCT02472028|Active Comparator|usual strategy|usual strategy based on the usual care of routine care
11334299|NCT02472015|No Intervention|normal care|patients who will have normal care
11334300|NCT02472015|Experimental|telemedicine|patients who will have telemedicine
11334301|NCT02472002|Experimental|Mesenchymal cell therapy|
11334302|NCT02471989|Experimental|Low-FODMAP diet|FOS in diet
11334303|NCT02471989|Active Comparator|Classical GERD diet|avoid fatty meals, head of bed elevation...
11334304|NCT02471976|No Intervention|Group A|the centres applies their usual practices
11334305|NCT02471976|Other|Group B|strategy promoting early consideration and collegiate vulnerability of patients
11334306|NCT02471963|Active Comparator|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
11334307|NCT02471963|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
11334308|NCT02471950||Elective Cardiac surgery|Those patients scheduled for elective heart surgery requiring cardiopulmonary bypass who will be given 2.5% isoflurane while on bypass.
11334309|NCT02471937|Experimental|Pregnant women negative for GBS colonization|Only women negative for GBS during all the study will be included.
11334310|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Trans thoraciq cardiac ultrasonography wil be perforfomed for pregnant women having a spinal or spinal-epidural anesthesia for elective caesarean section. All patients are more 18 years old and more 37 weeks pregnancy
11334311|NCT02471911|Experimental|All subjects|"All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.
~RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone."
11334312|NCT02471898|Experimental|HTX-011|Evaluate the analgesic efficacy of HTX-011
11334313|NCT02471898|Placebo Comparator|Placebo|Saline
11334314|NCT02471885|Experimental|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
11334315|NCT02471885|Placebo Comparator|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
11334316|NCT02471872|Experimental|Air Pollution Education|Students are presented with a one-hour interactive information session about air pollution and the environment.
11334317|NCT02471872|Placebo Comparator|Non-Air Pollution Education|Students are presented with a one-hour interactive information session about vaccines.
11334318|NCT02471859|Experimental|Part A: GDC-3280|Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.
11334319|NCT02471859|Placebo Comparator|Part A: Placebo|Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.
11334320|NCT02471859|Experimental|Part B: GCD-3280|Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\n
11334321|NCT02471859|Placebo Comparator|Part B: Placebo|Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\n
11334322|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort I|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade and achieved best response of confirmed complete or partial response, or stable disease will receive GDC-0919, at the MTD or maximum administered dose (MAD) determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
11334323|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort II|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
11334324|NCT02471846|Experimental|Biopsy Cohort A|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive GDC-0919 during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
11334325|NCT02471846|Experimental|Biopsy Cohort B|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive atezolizumab during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
11334326|NCT02471846|Experimental|Dose-Escalation Cohort(s)|Approximately 6 to 65 participants will be enrolled and treated at escalating doses of GDC-0919 in combination with fixed-dose atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio. Successive groups of at least 3 participants will be evaluated during a 21-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage. The MTD or MAD, whichever is reached first, will be considered for the expansion stage.
11334327|NCT02471846|Experimental|Expansion Cohorts|Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
11334328|NCT02471833|Experimental|Telmisartan 20mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 20mg once a day orally.
11334390|NCT02471339|Active Comparator|2/WL|Waitlist group - no intervention for first 8 weeks (then will receive ACT intervention as Arm 1)
11334329|NCT02471833|Experimental|Telmisartan 40mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 40mg once a day orally.
11334330|NCT02471833|Placebo Comparator|Placebo|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive placebo once a day orally.
11334331|NCT02471820|Experimental|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 & 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 & 22 of every cycle for 4 cycles
11334332|NCT02471807|Experimental|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
11334333|NCT02471794|No Intervention|Standard Shared Medical Appointment|The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
11334334|NCT02471794|Experimental|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
11334335|NCT02471794|No Intervention|Retrospective|A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention. The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
11334336|NCT02471755|Active Comparator|Electro-acupuncture Group|
11334337|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
11334338|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
11334339|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
11334340|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
11334341|NCT02471729|Experimental|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
11334342|NCT02471716|Experimental|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
11334343|NCT02471716|Experimental|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
11334344|NCT02471703||SMF mini-stem hip replacement recipient|Received the device via total hip arthroplasty
11334345|NCT02471690|Active Comparator|Oritavancin|IV -Single Dose - 1200 mg Oritavancin
11334346|NCT02471690|Placebo Comparator|Placebo|250 mL Dextrose 5% in Water
11334347|NCT02471677|Active Comparator|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
11334348|NCT02471677|Experimental|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
11334349|NCT02471664|Experimental|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
11334350|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
11334351|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
11334352|NCT02471638|Experimental|Single arm study|PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
11334353|NCT02471625||Traumatic Brain Injury|Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
11334354|NCT02471625||Control|Men and women ages 18-65 with no history of head trauma and a score of 15 on the GCS scale.
11334355|NCT02471599|Experimental|tonsillectomy group|The case group will receive tonsillectomy.
11334356|NCT02471599|Active Comparator|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
11334357|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.
~At the end of the procedure, a final IVUS imaging run must be performed.
~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
11334358|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.
~At the end of the procedure, a final OCT imaging run must be performed."
11390366|NCT02100527|Experimental|PF-05175157|
11334359|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).
~Stenting will be performed with angiography guidance according to local standard practice.
~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
11334360|NCT02471573|Active Comparator|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
11334361|NCT02471573|Active Comparator|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
11334362|NCT02471560|Experimental|dimethyl fumarate|As prescribed by the Investigator according to the local Summary of Product Characteristics.
11334363|NCT02471560|Active Comparator|injectable MS DMT|As prescribed by the Investigator according to the local Summary of Product Characteristics.
11334364|NCT02471547|No Intervention|TURBT ONLY|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.
~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
11334365|NCT02471547|Experimental|BWT with Mitomycin-C prior TURBT|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.
~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
11334366|NCT02471534|Experimental|Pediatric patients with hypovolemia|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
11334367|NCT02471521|Experimental|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
11334368|NCT02471521|Active Comparator|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
11334369|NCT02471508|Experimental|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
11334370|NCT02471495|Experimental|Synergo® RITE + MMC|"Induction
~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).
~Maintenance
~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
11334371|NCT02471482|Experimental|Music First group|"Mozart music lullaby for 30 minutes with recording of cerebral oxygenation (by using Near infrared spectroscopy) and vital signs (respiratory rate, heart rate, oxygen saturations and frequency of apneic episodes continuously) followed by 10 minutes of washout period and then period of no music for next 30 minutes (with same variables recorded as outlined for music session).
~This cycle is repeated every 6 hours for 24 hours. In addition, the behavioral response of baby is observed during the study period by video recording which will be in 'Mute' video mode and then reviewed by our developmental staff"
11334372|NCT02471482|Experimental|No Music First group|"No music in first 30 minutes of study followed by 10 minutes of washout period and then 30 minutes of Mozart music lullaby while recording same variables. This cycle was repeated every 6 hours for 24 hours."
11334373|NCT02471456||EVH|Patients that have undergone Endoscopic Vein Harvesting (EVH)
11334374|NCT02471456||OVH|Patients that have undergone open vein harvest (OVH)
11334375|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
11334376|NCT02471430|Experimental|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.
11334377|NCT02471430|Experimental|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
11334378|NCT02471430|Experimental|Arm C|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.
11334379|NCT02471417|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
11334380|NCT02471417|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
11334381|NCT02471404|Active Comparator|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
11334382|NCT02471404|Active Comparator|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
11334383|NCT02471404|Active Comparator|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
11334384|NCT02471391|Experimental|Ibrutinib + ABT-199|
11334385|NCT02471378||Pregnant Women 15-25 years old|Malaria-infected pregnant Women
11334386|NCT02471365||Healthy Volunteers|Non-pregnant and non-nursing females between 35 and 74 who usesa high number (e.g., 15 or more products a day) of consumer products.
11334387|NCT02471352||1-Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
11334388|NCT02471352||2-Healthy Volunteers|Healthy Volunteers
11334391|NCT02471326|Experimental|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
11334392|NCT02471313|Experimental|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent [18F] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
11334393|NCT02471300||1|stable mild-moderate asthmatic subjects
11334394|NCT02471287||Affected Patients|Participants with eye disease
11334395|NCT02471287||Unaffected first degree relatives|Unaffected first degree relatives of participants with a known or suspected inherited eyedisease.
11334396|NCT02471274|Experimental|Group 1|healthy control subjects with normal hepatic function
11334397|NCT02471274|Experimental|Group 2|subjects with mild hepatic impairment
11334398|NCT02471274|Experimental|Group 3|subjects with moderate hepatic impairment
11334399|NCT02471274|Experimental|Group 4|subjects with severe hepatic impairment
11334400|NCT02471248|Experimental|Ankle Robot with Power Assistance|In this experimental group, the Ankle Robot assists the ankle dorsiflexion when the stroke patients voluntarily perform the swing phase gait movement.
11334401|NCT02471248|Placebo Comparator|Sham group|In this sham group, the Ankle Robot provides very low assistance to generate tactile feedback to the stroke patients indicating they are performing the swing phase gait movement, but no assistance will be given to support their ankle dorsiflexion.
11334402|NCT02471235|Experimental|Intervention group|The physiotherapist will provide every patient an individualized physical training programme that fits their cardiopulmonary status. Patients will have the training as out-patient in the physiotherapy department for 4-8 sessions, 2 hours each time, 1-2 times weekly. Home exercise will be taught. Our case manager will give phone calls to the subject every 2 weeks to provide support and reinforcement for having continuous exercise at home for one year. Patients will be invited to attend reinforcement out-patient physiotherapy training once very month or every 2 months if they are willing to attend.
11334403|NCT02471235|No Intervention|Control group|The control group will receive no physiotherapy training by physiotherapist and no phone calls from case manager for reinforcement of home exercise. .
11334404|NCT02471222|Experimental|ADS-5102 (amantadine HCl extended release)|
11334405|NCT02471222|Placebo Comparator|Placebo|
11334406|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
11334407|NCT02471196|Experimental|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
11334408|NCT02471196|Experimental|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
11334409|NCT02471196|Placebo Comparator|Placebo|Placebo twice a day for 12 weeks.
11334410|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.
~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
11334411|NCT02471157||Eugonadal|Eugonadal men
11334412|NCT02471157||Hypogonadal|Hypogonadal men
11334413|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
11334414|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
11334415|NCT02471144|Placebo Comparator|Placebo|Placebo
11334416|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
11334417|NCT02471131|Experimental|WATCHMAN Implantation|
11334418|NCT02471118|Experimental|1st 50 subjects to Enter the Study|"At Baseline, subjects will be randomized (1:1) to receive study drug (Adalimumab or placebo). The study drug will be provided as a subcutaneous injection (pre-filled syringe) either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo for Adalimumab every other week for 16 weeks. Efficacy will be assessed at Week 16 while the safety of the study drug will be monitored throughout the study.
~At Week 16 all subjects will begin to receive open label ADA 40 mg EOW and will continue to receive open label ADA up to Week 50. An End of Study visit will be done at Week 52. A Telephone Follow-up will be done at Week 62 to review Adverse Events and Concomitant Medications."
11334419|NCT02471118|Experimental|2nd group of 50 subjects|At Baseline, subjects will be randomized (1:1) to receive either adalimumab 40 mg every other week or placebo for 16 weeks. All subjects will begin to receive open label adalimumab 40 mg every other week from week 16-week 30, with An End of Study visit at Week 32. A Telephone Follow-up will be done at Week 42 to review Adverse Events and Concomitant Medications.
11334420|NCT02471105|Experimental|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
11334421|NCT02471105|Experimental|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
11334422|NCT02471092|Placebo Comparator|Water Control|Skim milk products. Water and permeate control; 250mL serving.
11334423|NCT02471092|Active Comparator|Skim Milk|Skim milk products. Skim milk (regular 80:20 protein ratio); 250mL serving.
11334424|NCT02471092|Experimental|High Protein Milk|Skim milk products. High protein milk (regular 80:20 protein ratio); 250mL serving.
11334425|NCT02471092|Experimental|High Protein Milk (Modified Ratio)|Skim milk products. High protein milk with modified protein ratio (40:60 ratio); 250 mL serving.
11334426|NCT02471092|Experimental|Skim Milk (Modified Ratio)|Skim milk products. Skim milk with modified protein ratio (40:60 ratio); 250 mL serving.
11334427|NCT02471066|Experimental|active rTMS|12 patients will be enrolled in this arm.
11334428|NCT02471066|Sham Comparator|sham rTMS|12 patients will be enrolled in this arm.
11334633|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 4|ASP4070 low dose x 1 time, Placebo x 3 times
11390367|NCT02100527|Placebo Comparator|Placebo|
11334429|NCT02471053|Experimental|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
11334430|NCT02471040|Experimental|Type 1 diabetic subjects|Subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
11334431|NCT02471040|Active Comparator|Healthy Subjects|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
11334432|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
11334433|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
11334434|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
11334435|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
11334436|NCT02471001||Heart Surgery Using Heart-lung Machine|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being two additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
11334437|NCT02470988|Active Comparator|CBASP|Cognitive Behavioural Analysis System of Psychotherapy (CBASP) is a form of therapy specifically designed to treat individuals with chronic depression. CBASP combines a number of elements, with a focus on teaching the client to become aware of their interpersonal behaviour and its consequences.
11334438|NCT02470988|Experimental|CBASP Without DPI|In this arm CBASP will be delivered without Disciplined Personal Involvement (DPI) by the therapist.
11334439|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
11334440|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
11334441|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
11334442|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
11334443|NCT02470936|Experimental|Group 1- Lifestyle Intervention|Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to the website composed of four topic areas (get active, eat well, stop smoking, and find support), receive a Fitbit and access to a Fitbit account and community group, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
11334444|NCT02470936|No Intervention|Group 2 - Control|Men randomized to the control group will receive standard of care. They will receive access to the website and personalized lifestyle recommendations on the 8 healthy habits targeted in the study after the 3 month trial.
11334445|NCT02470923|Other|Group 1|Usual care including medical advice to quit and confrontation with abnormal spirometry results if relevant.
11334446|NCT02470923|Other|Group 2|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, and follow up for at least 5 weeks after discharge (will be done weekly by phone for five consecutive weeks).
11334447|NCT02470923|Other|Group 3|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, offering and providing nicotine replacement therapy (NRT) and follow up (will be done weekly by phone for five consecutive weeks).
11334448|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
11334449|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.
~SBRT: 8.0Gy escalated dose"
11334450|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.
~SBRT: 7.5Gy conventional dose"
11334451|NCT02470884|Experimental|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
11334452|NCT02470871|Experimental|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose
11334453|NCT02470871|Experimental|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.
11334454|NCT02470858|Experimental|LDV/SOF+ASV|Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
11334455|NCT02470858|Experimental|SOF+DCV+SMV|Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
11334456|NCT02470858|Experimental|SOF+DCV+ASV|Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks
11334634|NCT02469688|Placebo Comparator|Part2 Placebo intradermal vaccination group|Placebo x 4 times
11390939|NCT02096731||neither tiotropium nor LABA|
11334457|NCT02470845|Experimental|Tian Jiu group|The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
11334458|NCT02470845|Sham Comparator|Placebo-control group|The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
11334459|NCT02470845|No Intervention|Waitlist-control group|The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
11334460|NCT02470832|Experimental|Combination therapy RG1662 + itraconazole|Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food
11334461|NCT02470832|Experimental|RG1662 Monotherapy|Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)
11334462|NCT02470832|Experimental|itraconazole Monotherapy|Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)
11334463|NCT02470819|Experimental|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
11334464|NCT02470806|Experimental|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
11334465|NCT02470806|Active Comparator|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
11334466|NCT02470793|Active Comparator|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
11334467|NCT02470793|Experimental|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
11334468|NCT02470780|Experimental|Three-month follow-up|
11334469|NCT02470780|Experimental|Six-month follow-up|
11334470|NCT02470767||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fribilation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
11334471|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
11334472|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
11334473|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
11334474|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
11334475|NCT02470728|No Intervention|Control Group|Those randomized into the control group will receive the current standard of care for pain management. This standard care pathway involves a pain management specialist consultation only at the request of the primary admitting team. The pain management consultation can occur at any time during the patient's inpatient stay and care by these specialists ends at discharge.
11334476|NCT02470728|Experimental|Treatment Group|Subjects randomized into the treatment (early intervention) group will receive the New Clinical Pathway: pain management care coordinated by pain-management specialists from inpatient admission through 60 days after discharge.
11334477|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
11334478|NCT02470702|Experimental|Oritavancin|Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
11334479|NCT02470702|Placebo Comparator|Placebo|Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
11334480|NCT02470689|Active Comparator|Diacerin cream 1%|
11334481|NCT02470689|Placebo Comparator|ultraphil cream|
11334482|NCT02470676|Active Comparator|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
11334483|NCT02470676|Experimental|Progesterone plus Experimental device|Experimental device + 200 mg daily progesterone vaginal suppositories (Utrogestan)
11334484|NCT02470663|Experimental|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
11334485|NCT02470663|Active Comparator|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
11334486|NCT02470650|Experimental|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
11334487|NCT02470650|Active Comparator|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
11334488|NCT02470650|Active Comparator|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
11334489|NCT02470637|Experimental|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
11334490|NCT02470624||treatment following current guideline|
11334491|NCT02470611|Experimental|Sodium Alendronate|Adjunctive use of 1% sodium alendronate gel as part of periodontitis treatment
11334492|NCT02470611|Placebo Comparator|Placebo|Adjunctive use of placebo gel as part of periodontitis treatment
11334493|NCT02470585|Active Comparator|Placebo + Carboplatin + Paclitaxel -> Placebo|Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
11334790|NCT02468609|Other|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
11334494|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Placebo|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
11334495|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Veliparib|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.
11334496|NCT02470572|Active Comparator|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
11334497|NCT02470572|Placebo Comparator|Conventional light microscope|conventional light microscope
11334498|NCT02470559|Experimental|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
11334499|NCT02470546|Active Comparator|Metformin|Patients receiving metformin
11334500|NCT02470546|Placebo Comparator|Placebo|Patients receiving placebo
11334501|NCT02470533|Active Comparator|Transarterial chemoembolization|Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
11334502|NCT02470533|Experimental|Stereotactic body radiation therapy|Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) < of 5%
11334503|NCT02470520||AKI without CRRT|Patients with AKI who are not treated with continuous renal replacement therapy
11334504|NCT02470520||AKI with CRRT|Patients with AKI who are treated with continuous renal replacement therapy
11334505|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
11334506|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
11334507|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
11334508|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
11334509|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
11334510|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
11334511|NCT02470468|Experimental|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
11334512|NCT02470468|Experimental|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
11334513|NCT02470468|Other|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
11334514|NCT02470455||Normoglycemic group|25 patients were recruited who were on Atorvastatin and with normal blood glucose and Hb1Ac level.
11334515|NCT02470455||Prediabetic with normal GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with normal GTT.
11334516|NCT02470455||Prediabetic with impaired GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with impaired GTT.
11334517|NCT02470442|Experimental|Sevoflurane/Desflurane|After induction of general anesthesia with sevoflurane, anesthesia was maintained with desflurane.
11334518|NCT02470442|Experimental|Sevoflurane|the anesthetic induction and maintenance with sevoflurane.
11334519|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
11334520|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
11334521|NCT02470416|Active Comparator|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
11334522|NCT02470416|Active Comparator|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
11334523|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
11334524|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
11334525|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
11334526|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
11334527|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
11334528|NCT02470390|Active Comparator|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.
~Will be administered on either study day 1 or 3 per protocol and randomization."
11334529|NCT02470390|Active Comparator|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.
~Will be administered on either study day 1 or 3 per protocol and randomization."
11334530|NCT02470390|Active Comparator|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.
~Will be administered on study day 5 per protocol."
11334531|NCT02470377|Experimental|Transcranial Magnetic Stimulation|After determination of the motor threshold, the TMS coil will be positioned at predetermined locations over the brain using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses (repetitive TMS) at 1Hz up to 10Hz or in theta burst mode will be delivered at one or more locations over the head, depending on the brain location under study (brain locations determined by MRI data). Real or active sham conditions will be used in the study but all participants will receive real treatment at some point during their enrollment. Real rTMS over one area may also be compared to real rTMS over another area.
11334596|NCT02469909|Other|Gradual tracheostomy tube decrease|In the gradual decannulation group The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
11334532|NCT02470338|Active Comparator|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
11334533|NCT02470338|Sham Comparator|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
11334534|NCT02470325|Active Comparator|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
11334535|NCT02470325|Active Comparator|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
11334536|NCT02470325|Active Comparator|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
11334537|NCT02470325|Active Comparator|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
11334538|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
11334539|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
11334540|NCT02470299|Experimental|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
11334541|NCT02470299|Placebo Comparator|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
11334542|NCT02470286|Experimental|SA001|Dose escalation
11334543|NCT02470286|Placebo Comparator|Placebo|Dose escalation
11334544|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
11334545|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
11334546|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
11334547|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (< 5.7%)
11334548|NCT02470247|Experimental|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.
~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
11334549|NCT02470247|Sham Comparator|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
11334550|NCT02470234|Experimental|Methylphenidate HCl ER Capsules|Active drug, administered once
11334551|NCT02470221||Goal-directed fluid therapy|The fluid in group Goal-directed fluid therapy will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the Flo-Trac monitoring system.
11334552|NCT02470221||Conventional fluid therapy|The fluid in group Conventional fluid therapy will be administered based on the principle crystalloid solution: colloid solution =2-3:1. The total volume of fluid will be adjusted in accordance with blood pressure, heart rate and urine output of each patient.
11334553|NCT02470195|Experimental|workshop|workshop of procedural simulation
11334554|NCT02470195|No Intervention|control|no specific workshop of procedural simulation
11334555|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
11334556|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
11334557|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
11334558|NCT02470169|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
11334559|NCT02470169|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
11334560|NCT02470169|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
11334597|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
11334598|NCT02469896|Active Comparator|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
11334599|NCT02469883|Experimental|Sinotecean|
11334561|NCT02470156|Experimental|High Intensity Arm (Intervention)|"Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a full dose of the intervention."
11334562|NCT02470156|Active Comparator|Low Intensity Arm (Comparison)|Women in the Low Intensity (comparison) arm are interviewed and coached four times during the study (at baseline, 4 months, 8 months, and 12 months).
11334563|NCT02470143||Bike application arm|The bike application arm contains cardiac patients that will be instructed to use the cycling application during a one month period.
11334564|NCT02470130|Active Comparator|relax actor|actor during simulation and relaxation before debriefing
11334565|NCT02470130|No Intervention|no relax actor|actor during simulation and no relaxation before debriefing
11334566|NCT02470130|Active Comparator|relax observer|observer during simulation and relaxation before debriefing
11334567|NCT02470130|No Intervention|no relax observer|observer during simulation and no relaxation before debriefing
11334568|NCT02470117|Active Comparator|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
11334569|NCT02470117|Sham Comparator|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
11334570|NCT02470104|Experimental|Enteral Donor Breastmilk|"Donor milk will be pasteurized prior to use.
~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.
~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.
~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
11334571|NCT02470104|No Intervention|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
11334572|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
11334573|NCT02470078|Experimental|Pharyngeal electrical stimulation|Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.
11334574|NCT02470078|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days.
11334575|NCT02470065|Experimental|Neo adjuvant afatinib|once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
11334576|NCT02470065|Active Comparator|Immediate surgery|immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
11334577|NCT02470052|Experimental|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
11334578|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
11334579|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
11334580|NCT02470026|Experimental|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
11334581|NCT02470026|Experimental|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
11334582|NCT02470013|Experimental|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
11334583|NCT02470013|No Intervention|Control Group|Nutrition counselling upon hospital discharge (usual care)
11334584|NCT02470000|Experimental|Experimental Group|Intravascular laser irradiation of blood (ILIB, output power 0.3mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
11334585|NCT02470000|Sham Comparator|Control Group|Intravascular laser irradiation of blood (ILIB, output power 0mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
11334586|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
11334587|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
11334588|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
11334589|NCT02469974|Experimental|Ruxolitinib / INC 424|Ruxolitinib, Jakafi ®, will be given orally at standard dose daily for 16 weeks pre ASCT and up to 3 months post-ASCT for 10 patients (allowing for 2 additional screen failures). Patients will restart ruxolitinib at 100 days after the ASCT as long as their platelet count is at least 50 x103. For patients whose platelet count is below 50 x103 at day 100, ruxolitinib should be restarted once platelet count reaches 50 x103. The dose of ruxolitinib can be titrated up as per clinical guidelines. PBSC mobilization will include G-CSF 10 mcg/kg/day. HDC for ASCT will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2.
11334590|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
11334591|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
11334592|NCT02469948|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
11334593|NCT02469948|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
11334594|NCT02469922|Experimental|Positron emission tomography|Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed
11334595|NCT02469909|Other|immediate decannulation|In the immediate decannulation group - the tracheostomy tube is removed and the patient would be monitored overnight in an intermediate monitored unit. On the next day a clinical evaluation would be held, and the patient would be discharge or transferred to his department according to the clinical course of the patient
11334631|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 2|ASP4070 low dose x 4 times
11334632|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 3|ASP4070 high dose x 1 time, Placebo x 3 times
11334600|NCT02469870|Experimental|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
11334601|NCT02469870|Active Comparator|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
11334602|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
11334603|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
11334604|NCT02469844||Patients with epilepsy having seizures in sleep|
11334605|NCT02469831|Active Comparator|group D|deep neuromuscular block by rocuronium defined :post tetanic (PTC) >1 but no response to a train of four (TOF) stimulation.
11334606|NCT02469831|Active Comparator|group I|intermediate neuromuscular block by rocuronium defined as TOF count of 1-3.
11334607|NCT02469805|Active Comparator|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
11334608|NCT02469805|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
11334609|NCT02469805|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
11334610|NCT02469792|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
11334611|NCT02469779|Experimental|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
11334612|NCT02469779|Active Comparator|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
11334613|NCT02469766|Active Comparator|Extracorporeal Shockwaves|Patients in this arm will undergo SWL
11334614|NCT02469766|Active Comparator|Semirigid URS|Patients in this arm will undergo Semirigid Ureteroscopy
11334615|NCT02469766|Active Comparator|Flexible URS|Patients in this arm will undergo Flexible Ureteroscopy
11334616|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
11334617|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
11334618|NCT02469740|Experimental|Ticagrelor|Patients in this group will be prescribed ticagrelor 90 mg BD for 4 weeks.
11334619|NCT02469740|Active Comparator|Clopidogrel|Patients in this group will be prescribed clopidogrel 75 mg OD for 4 weeks
11334620|NCT02469727|Experimental|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
11334621|NCT02469727|No Intervention|Usual care control|No intervention provided.
11334622|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
11334623|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
11334624|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.
~Either cryoablation or thermal ablation may be performed as per standard institutional policies.
~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
11334625|NCT02469688|Experimental|Part1 ASP4070 intramuscular vaccination group|ASP4070 high dose x 4 times
11334626|NCT02469688|Experimental|Part1 ASP4070 intradermal vaccination group|ASP4070 high dose x 4 times
11334627|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 1|ASP4070 high dose x 4 times
11334628|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 2|ASP4070 high dose x 1 time, Placebo x 3 times
11334629|NCT02469688|Placebo Comparator|Part2 Placebo intramuscular vaccination group|Placebo x 4 times
11334630|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 1|ASP4070 high dose x 4 times
11390940|NCT02096731||tiotropium + LABA|
11334635|NCT02469675|Experimental|All subjects|"All subjects undergo same full protocol, including different combinations of stimulation on different days:
~Transcranial Magnetic Stimulation Cervical Transcutaneous Stimulation Median Nerve Stimulation"
11334636|NCT02469662|Experimental|Retrospective|Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available
11334637|NCT02469662|Experimental|Prospective|Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow
11334638|NCT02469623|Experimental|Dipole Density Mapping|
11334639|NCT02469610|Experimental|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
11334640|NCT02469610|Other|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
11334641|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
11334642|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
11334643|NCT02469584|Experimental|1|symptomatic cystocele described as Points Aa or Ba >= 0 according to the International Continence Society pelvic organ prolapse quantification system (POP-Q). The changes in POPQ score preoperatively and three months after the anterior colporrhaphy with the new small stitch technic will be analyzed.
11334644|NCT02469571|Active Comparator|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
11334645|NCT02469571|Placebo Comparator|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
11334646|NCT02469558|Active Comparator|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
11334647|NCT02469558|Placebo Comparator|placebo|a similar looking and tasting placebo without bacteria
11334648|NCT02469545|Active Comparator|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
11334649|NCT02469545|Placebo Comparator|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
11334650|NCT02469532||Atherectomy|"Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures."
11334651|NCT02469532||Angioplasty|"Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures."
11334652|NCT02469519|Experimental|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone [12 mg intramuscular injection, 24 hours apart X 2 doses] or if unavailable may give Dexamethasone [6 mg intramuscularly 12 hours apart x 4 doses]
11334653|NCT02469519|Placebo Comparator|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
11334654|NCT02469506|Experimental|NMES group|Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
11334655|NCT02469506|No Intervention|Control group|Patients will receive daily visits by the investigator to check progress.
11334656|NCT02469493|Experimental|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
11334657|NCT02469493|Experimental|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
11334658|NCT02469493|Sham Comparator|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
11334659|NCT02469493|No Intervention|Waitinglist control|In this group, patients received no electroacupuncture
11334660|NCT02469480|Experimental|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
11334661|NCT02469480|Active Comparator|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
11334662|NCT02469467|Experimental|VS-505|750 mg capsule
11334663|NCT02469454|Experimental|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
11334664|NCT02469454|Active Comparator|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted after 6 week of the delivery. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
11334665|NCT02469441||Arm A|Arm A (treatment arm: coffee): patients after colorectal surgery receive coffee in addition to the regular infusion therapy and/or alimentation
11334666|NCT02469441||Arm B|Arm B (control arm: water / tea): patients after colorectal surgery receive water or tea (excluding black tea) and no coffee until the first bowel movement in addition to the regular infusion therapy and/or alimentation
11334667|NCT02469428|Sham Comparator|Clean air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11334668|NCT02469428|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11334669|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.
~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
11334670|NCT02469402|Active Comparator|Standard infant formula|Standard infant formula
11334671|NCT02469402|Experimental|Protein reduced formula|Protein reduced alpha-lactalbumin formula
11334672|NCT02469402|No Intervention|Breast-feeding|Exclusive breast-feeding
11334673|NCT02469389|Experimental|ENCoRE|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
11334674|NCT02469389|Active Comparator|H&W|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
11334675|NCT02469376|Experimental|Diagnosis with GP1|Injection and scanning of [18F]-GP1
11334676|NCT02469363|Active Comparator|Macintosh laryngoscope|Endotracheal intubation with classic (Macintosh) laryngoscope
11334677|NCT02469363|Active Comparator|Mc-Coy laryngoscope|Endotracheal intubation with Mc-Coy laryngoscope
11334678|NCT02469363|Active Comparator|C-Mac videolaryngoscope|Endotracheal intubation with C-Mac videolaryngoscope
11334679|NCT02469363|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation with McGrath videolaryngoscope
11334680|NCT02469350|Experimental|Rehabilitation with serious game|18 rehabilitation sessions with serious game during a 6-8 weeks period
11334681|NCT02469337|Active Comparator|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
11334682|NCT02469337|Active Comparator|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
11334683|NCT02469337|Active Comparator|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)*0.7 under close supervision and monitoring of their vital parameters.
11334684|NCT02469337|No Intervention|Control|Patients in this group will have surgery as standard practice with none of the above interventions
11334685|NCT02469324|Active Comparator|Cognitive-Behavioral Therapy|see intervention explanation
11334686|NCT02469324|Experimental|Compassionate Mind Training|
11334687|NCT02469311|Sham Comparator|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
11334688|NCT02469311|Active Comparator|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
11334689|NCT02469311|Active Comparator|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
11334690|NCT02469311|Sham Comparator|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
11334691|NCT02469311|Sham Comparator|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
11334692|NCT02469311|Active Comparator|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
11334693|NCT02469311|Sham Comparator|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
11334694|NCT02469311|Active Comparator|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
11334695|NCT02469298|Experimental|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
11334696|NCT02469298|Placebo Comparator|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
11334697|NCT02469298|Experimental|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
11334791|NCT02468596|Experimental|Patients|Patients suffering from anti-MAG neuropathy
11334698|NCT02469298|Active Comparator|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
11334699|NCT02469285|Experimental|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
11334700|NCT02469285|Active Comparator|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
11334701|NCT02469285|Experimental|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
11334702|NCT02469272|Experimental|Fecal Microbiota Transplantation|Intervention: standardized preparation of frozen fecal material from lean healthy donors Route: infused into the duodenum through the working channel of the instrument at upper endoscopy Dosing: 1 dose
11334703|NCT02469259|Experimental|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
11334704|NCT02469259|Placebo Comparator|Placebo|Subjects will receive intranasal saline spray
11334705|NCT02469246|Experimental|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks
~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
11334706|NCT02469246|Active Comparator|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks
~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
11334707|NCT02469246|Experimental|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
11334708|NCT02469233|Experimental|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
11334709|NCT02469233|Active Comparator|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
11334710|NCT02469220|Experimental|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
11334711|NCT02469220|Active Comparator|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
11334712|NCT02469220|No Intervention|Control|Watchful waiting. No diets or food supplements are administered
11334713|NCT02469207||Deceased organ donors|Patients with consent for organ donation towards transplantation and research. Organs not used for transplantation will be used for this study if determined appropriate and necessary.
11334714|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
11334715|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
11334716|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
11334717|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
11334718|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
11334719|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
11334720|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
11334721|NCT02469142|Experimental|ADM tension-free hernia reparation|Use ADM to repair incarcerated inguinal hernia by tension-free
11334722|NCT02469142|Placebo Comparator|traditional tension hernia reparation|Just repair incarcerated inguinal hernia by nothing in tension condition
11334723|NCT02469129|Experimental|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace.
11334724|NCT02469129|Experimental|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism
11334725|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles
~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
11334726|NCT02469103|Experimental|C2 & colonoscopy|C2 and colonoscopy
11334727|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
11334728|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
11334792|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
11334729|NCT02469077|Experimental|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
11334730|NCT02469077|Active Comparator|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
11334731|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
11334732|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
11334733|NCT02469051|Other|Breathhold SPECT-MPI vs. standard freebreathing SPECT-MPI|
11334734|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
11334735|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
11334736|NCT02469025|Experimental|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.
~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
11334737|NCT02469025|Experimental|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.
~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
11334738|NCT02469012|Experimental|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
11334739|NCT02468999|Active Comparator|insulin nasal spray|160 Units of human insulin as nasal spray
11334740|NCT02468999|Placebo Comparator|placebo nasal spray|Nasal spray containing placebo solution
11334741|NCT02468986||Uncontrolled Rheumatoid Arthritis|"18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is >3.2 and C-reactive protein (mg/dL) elevated above normal range.
~Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing."
11334742|NCT02468986||Controlled Rheumatoid Arthritis|18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) <3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
11334743|NCT02468986||Healthy Controls|18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
11334744|NCT02468973|Other|Life style counseling|Students will meet chronic patients and will counsel for life style
11334745|NCT02468960|Other|OPN strategy (study group)|"Interventions planned in this arm are as follows:
~Predilatation with OPN NC balloon catheter.
~Absorb BVS implantation.
~Treated segment visualization by OCT.
~Clinical FU at 12 months."
11334746|NCT02468960|Other|Standard strategy (control group)|"Interventions planned in this arm are as follows:
~Predilatation with standard compliant balloon.
~Absorb BVS implantation.
~Treated segment visualization by OCT.
~Clinical FU at 12 months."
11334747|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
11334748|NCT02468908|Experimental|Molgramostim nebuliser solution, inhaled|Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
11334749|NCT02468908|Placebo Comparator|Nebuliser solution, inhaled|Inhaled nebuliser solution
11334750|NCT02468895||Idiopathic Inflammatory Myopathy|PM, DM, sIBM, necrotizing myopathy, anti-synthetase syndrome, suspected myopathy
11334751|NCT02468882|Experimental|Intervention group|"Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily therapeutic dose."
11334752|NCT02468882|No Intervention|Control group|The control group will receive the standard of care, thus will maintain their ad libitum diet.
11334753|NCT02468869|Experimental|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
11334754|NCT02468869|Active Comparator|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
11334755|NCT02468856|Active Comparator|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
11334756|NCT02468856|Placebo Comparator|Placebo|one time administration per study session in the morning of day 2
11334793|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
11334757|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
11334758|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
11334759|NCT02468817|Active Comparator|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
11334760|NCT02468817|Experimental|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
11334761|NCT02468804|Experimental|Parkinson's Disease Subjects|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
11334762|NCT02468804|Experimental|Control Subjects|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
11334763|NCT02468791|Experimental|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
11334764|NCT02468791|Active Comparator|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
11334765|NCT02468778|Experimental|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
11334766|NCT02468778|Active Comparator|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® Device approved for use in high-risk PCI.
11334767|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
11334768|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
11334769|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
11334770|NCT02468752|Sham Comparator|Air|Normobaric air breathing
11334771|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
11334772|NCT02468739|Experimental|Ganglioside-monosialic acid arm|"Patients will receive treatment of adjuvant chemotherapy. Ganglioside-monosialic acid(GM1, 80mg per day) will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).
~Chemotherapy regimens:
~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.
~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
11334773|NCT02468739|Placebo Comparator|placebo arm|"Patients will receive treatment of adjuvant chemotherapy. Placebo will be given at 1 day before the start of chemotherapy for three days (Day -1, 1 and 2).
~Chemotherapy regimens:
~Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by paclitaxel (175 mg/m2 *4 cycles) after four courses of chemotherapy; Epirubicin (90 mg/m2) combined with cyclophosphamide (600 mg/m2) followed by docetaxel (75 mg/m2 *4 cycles) after four course of chemotherapy; Docetaxel (75 mg/m2 q21d) combined with cyclophosphamide (600 mg/m2) for four courses.
~The first day (D1) of each cycle is treated with taxane-based chemotherapy. 14-21 days are usually as one cycle. The methods of pretreatment and hydration shall be decided by the physicians."
11334774|NCT02468726|Experimental|NER1008|Use of NER1008 enema for bowel cleansing
11334775|NCT02468726|Active Comparator|Fleet|Use of Fleet enema for bowel cleansing
11334776|NCT02468713|Experimental|Group 1|Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)
11334777|NCT02468713|Experimental|Group 2|Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)
11334778|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
11334779|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
11334780|NCT02468687|Other|N-methyl-pyrrolidone|NMP dose escalation in accelerated phase and standard phase
11334781|NCT02468674|Other|Follow-up (arm 1)|Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
11334782|NCT02468674|No Intervention|Follow-up (arm 2)|Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
11334783|NCT02468661|Experimental|INC280 200mg BID + ERL 150mg QD|Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
11334784|NCT02468661|Experimental|INC280 400mg BID + ERL 150mg QD|Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
11334785|NCT02468648|Experimental|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
11334786|NCT02468635|Other|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
11334787|NCT02468635|Other|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
11334788|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
11334789|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
11334795|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib + nab-paclitaxel.
11334796|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib + mFOLFOX6.
11334797|NCT02468544|Experimental|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
11334798|NCT02468531|Other|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
11334799|NCT02468531|Experimental|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
11334800|NCT02468518|Experimental|Patients|Vitamin E capsule 200 IU bd x 12 weeks
11334801|NCT02468518|Active Comparator|Arsenic exposed controls|Vitamin E capsule 200 IU bd x 12 weeks
11334802|NCT02468518|Active Comparator|Healthy volunteers|Vitamin E capsule 200 IU bd x 12 weeks
11334803|NCT02468505|Experimental|STEPS|structured psychosocial transition support that includes individual counseling, and education/training for parent and school personnel
11334804|NCT02468505|No Intervention|TAU|typical transition services and supports
11334805|NCT02468492|Experimental|Platelet Rich Plasma|Approximately 5mL of intraarticular PRP once at baseline
11334806|NCT02468492|Other|Normal Saline|Approximately 5mL of intraarticular normal saline once at baseline
11334807|NCT02468466|Experimental|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
11334808|NCT02468466|Active Comparator|Community intervention as usual|Suicide prevention program as usual
11334809|NCT02468453|Experimental|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
11334810|NCT02468453|Experimental|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
11334811|NCT02468453|Experimental|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
11334812|NCT02468453|Experimental|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
11334813|NCT02468440|Experimental|ESPAIR|Patients with an educational therapy's program since registration in transplant list.
11334814|NCT02468440|No Intervention|normal care|Patients without educational therapy
11334815|NCT02468427|Experimental|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
11334816|NCT02468427|Active Comparator|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
11334817|NCT02468414|Experimental|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
11334818|NCT02468401|Experimental|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
11334819|NCT02468388|Experimental|maltitol|
11334820|NCT02468388|Active Comparator|xylitol|
11334821|NCT02468388|Placebo Comparator|gum base|
11334822|NCT02468388|No Intervention|no gum|
11334823|NCT02468375|Experimental|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
11334824|NCT02468362|Active Comparator|Laparoscopic group|
11334825|NCT02468362|Active Comparator|Open group|
11334826|NCT02468349|Experimental|Telemedicine|The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.
11334827|NCT02468349|No Intervention|Standard care|The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.
11334828|NCT02468336|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after BA occlusion by a standard upper arm sphygmomanometric blood pressure (BP) cuff. The procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis.
11334829|NCT02468336|Active Comparator|Brachial Artery Ultrasound Imaging|A non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery (BA) using high resolution continuous ECG-gated B-mode (2D) ultrasound imaging during reactive hyperemia, a state of transient increase in tissue blood flow that occurs following a brief period of ischemia, e.g., BA occlusion. BA diameter is measured at end-diastole, coincident with the R wave of a simultaneously recorded ECG.
11334830|NCT02468323|Placebo Comparator|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
11334831|NCT02468323|Experimental|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
11390941|NCT02096731||tiotropium mono|
11334832|NCT02468323|Experimental|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
11334833|NCT02468310|Experimental|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
11334834|NCT02468310|No Intervention|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
11334835|NCT02468297|Experimental|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
11334836|NCT02468297|Placebo Comparator|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
11334837|NCT02468284|Experimental|Degarelix|
11334838|NCT02468258|Active Comparator|endometrial flushing (A)|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected in a sterile container and was centrifuged at 600 rpm for 10 min at room temperature and a 5-ml sample of the supernatant was obtained for laboratory workup, while the remaining amount of supernatant was used to flush the endometrium through an applied uterine catheter in FF group and was discarded in the other group.
11334839|NCT02468258|No Intervention|B|no intervention Control group included 40 women would not have FF endometrial flushing.
11334840|NCT02468245|Active Comparator|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
11334841|NCT02468245|Experimental|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
11334842|NCT02468232|Experimental|LCZ696|Before randomization, all patients receive 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm will start with 100 mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 200 mg b.i.d. at week 4 if they are tolerant to 100 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
11334843|NCT02468232|Active Comparator|Enalapril|In double blind period, all randomized patients in this arm will receive enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 10 mg b.i.d. at week 4 if they are tolerant to 5 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
11334844|NCT02468219|Active Comparator|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
11334845|NCT02468219|Experimental|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
11334846|NCT02468206|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
11334847|NCT02468206|Active Comparator|NBCA|Endoscopic Cyanoacrylate injection in the gastric varix
11334848|NCT02468193|Experimental|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
11334849|NCT02468180|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
11334850|NCT02468180|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
11334851|NCT02468167|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
11334852|NCT02468167|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
11334853|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
11334854|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
11334855|NCT02468141|Experimental|SJDBT group|Herbal medicine
11334856|NCT02468141|Placebo Comparator|Placebo|Placebo control
11334857|NCT02468128|Experimental|SDE 150mg|Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)
11334858|NCT02468128|Placebo Comparator|placebo|Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)
11334859|NCT02468115|Experimental|VIS410|Single intravenous fixed dose of VIS410
11334860|NCT02468115|Placebo Comparator|Placebo|Single intravenous infusion of placebo
11334861|NCT02468102||Rivaroxaban / Cohort 1|Patients who have filled a prescription for rivaroxaban in any pharmacy in Sweden during the study period.
11334862|NCT02468102||Standard of care drugs / Cohort 2|Patients who have filled a prescription for standard of care drugs (warfarin, aspirin, clopidogrel, ticlopidine, prasugrel or ticagrelor) in any pharmacy in Sweden during the study period.
11334863|NCT02468089|Experimental|Carbepenem+albumin+GMCSF.|
11334864|NCT02468089|Active Comparator|Carbepenem+albumin|
11334865|NCT02468076|Experimental|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
11334866|NCT02468063|Experimental|Noradrenaline + low dose terlipressin|
11334867|NCT02468063|Active Comparator|Noradrenaline|
11334868|NCT02468050|Experimental|Self Management|In addition to the weekly supervised exercise session, participants in this arm will view an instructional video. The video will deliver theory driven training of cognitive behavioural strategies for self management of exercise. It is expected that this will improve adherence to the exercise program.
11334869|NCT02468050|Experimental|Exercise|Personalized 6 week moderate intensity (50 - 75% of heart rate reserve) facility and home based exercise program including cardiovascular and muscular conditioning.
11334870|NCT02468050|No Intervention|Prospective Cohort Control|Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
11334899|NCT02467842|Experimental|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
11391756|NCT02091024|Placebo Comparator|Placebo|Placebo 200mg, twice a day
11334871|NCT02468037|Experimental|Phlebotomy|All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (<50 ng/mL for females and <70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described
11334872|NCT02468037|No Intervention|Control|Subjects receive counseling to follow a healthy diet and regular exercise.
11334873|NCT02468024|Active Comparator|Arm 1 lung surgery|Sublobar Resection (SR)
11334874|NCT02468024|Experimental|Arm 2 radiation therapy|Stereotactic Ablative Radiotherapy (SAbR)
11334875|NCT02468011|Experimental|Vibration|Whole body vibration with 35 Hz
11334876|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
11334877|NCT02467985|No Intervention|Control|
11334878|NCT02467985|Experimental|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
11334879|NCT02467972|Experimental|UBF group|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
11334880|NCT02467972|Placebo Comparator|Control|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
11334881|NCT02467972|Experimental|Inulin group|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
11334882|NCT02467972|Experimental|Nisin group|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
11334883|NCT02467959||Ultrasound|Ultrasound evaluation
11334884|NCT02467946|Experimental|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
11334885|NCT02467933|Placebo Comparator|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
11334886|NCT02467933|Experimental|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
11334887|NCT02467920|Experimental|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
11334888|NCT02467920|Active Comparator|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
11334889|NCT02467907|Experimental|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
11334890|NCT02467894|Experimental|Group-based Care|Participants who are randomized to group-based care will attend monthly outpatient clinic visits as part of a group of 8-10 patients with CKD and hypertension.
11334891|NCT02467894|No Intervention|Usual Care|Participants who are randomized to usual care will see their provider on clinic days when there is no group meeting.
11334892|NCT02467881|Active Comparator|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
11334893|NCT02467881|Active Comparator|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
11334894|NCT02467881|Other|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
11334895|NCT02467868|Experimental|MYL-1401H|MYL-1401H
11334896|NCT02467868|Active Comparator|Neulasta|Neulasta
11334897|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
11334898|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
11335076|NCT02466568|Active Comparator|Phase II Control Arm|Nivolumab treatment without GM.CD40L. Nivolumab will be given every 2 weeks at a dose of 3mg/kg.
11334900|NCT02467842|Active Comparator|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
11334901|NCT02467842|Active Comparator|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
11334902|NCT02467829|No Intervention|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
11334903|NCT02467829|Experimental|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
11334904|NCT02467829|Experimental|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
11334905|NCT02467816|Experimental|School lunch intervention|Intervention schools (6 middle and 6 high) will receive the complete school lunch intervention for two school years.
11334906|NCT02467816|No Intervention|School lunch control|Control schools (6 middle and 6 high) will not receive the school lunch intervention for two school years. Lunch delivery will proceed as normal.
11334907|NCT02467803|Active Comparator|Intervention|We applied scapula mobilization with shoulder ROM exercises
11334908|NCT02467803|Other|Control|We applied only shoulder ROM exercises
11334909|NCT02467790|Experimental|Mild renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
11334910|NCT02467790|Experimental|Moderate renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
11334911|NCT02467790|Experimental|Normal renal function|PEX 168: 200µg,Subcutaneous,one time.
11334912|NCT02467777|Active Comparator|Forced Air|Bair Hugger
11334913|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
11334914|NCT02467738|Experimental|Cesium-131 Brachytherapy|Patients undergo brachytherapy using Cesium-131 during surgical resection
11334915|NCT02467725|Experimental|Dynamic Culture Platform|Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
11334916|NCT02467725|No Intervention|Static Culture|The embryos randomized to the static or control arm of the study will be placed directly into the incubator and will not have any additional vibration, per routine care. The embryos will be placed in the incubator at the two pronucleur stage of development and remain in the incubator until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
11334917|NCT02467686|Active Comparator|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.
~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.
~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.
~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
11334918|NCT02467686|Placebo Comparator|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.
~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.
~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
11334919|NCT02467673|Active Comparator|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.
~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
11334920|NCT02467673|Active Comparator|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.
~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
11334921|NCT02467660|Experimental|Online Mindfulness Meditation Training|Weekly 1-hr online training and daily meditation for 30-45 min for 6 wks
11334922|NCT02467660|Experimental|Online Health & Wellness Education|6-week training entails completing weekly 1-hour online training and listening to educational podcasts for 30-45 minutes per day
11334923|NCT02467660|No Intervention|Wait List Control|No training
11334924|NCT02467647|Experimental|A|Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
11334925|NCT02467647|Active Comparator|B|Arm B: Thalidomide 100mg oral once per day for 6 months
11334926|NCT02467634|Experimental|HuCNS-SC|HuCNS-SC sub-retinal transplantation
11334927|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
11334928|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
11335102|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:
~Day -1 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mCC)
~Day 2 = Wash-out
~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
11334929|NCT02467608|Experimental|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.
~Dosage is as below:
~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
11334930|NCT02467608|Other|HRZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.
~Dosage is as below:
~Isoniazid (H):300mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
11334931|NCT02467595|Experimental|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group
~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1
~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.
~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .
~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
11334932|NCT02467595|Active Comparator|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group
~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1
~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.
~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .
~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
11334933|NCT02467595|Placebo Comparator|S group|"saline
~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.
~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.
~When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
11334934|NCT02467582|Experimental|Aspirin 100 mg|Asprin 100 mg daily for 3 years standard chemo if indicated
11334935|NCT02467582|Active Comparator|Placebo|Placebo daily for 3 years standard chemo if indicated
11334936|NCT02467569|Experimental|Hemay020|"Part one: Dose Escalation Group Hemay020 capsules will be taken orally in doses of 25mg, 50mg, 100mg, 200mg or 300mg once daily for 28 days.
~Part two: Extension Group Hemay020 capsules will be taken in two dose groups that assessed by Part one for 28 days."
11334937|NCT02467556|Other|intervention|Open label study with psychological intervention and physiotherapy intervention with medication of morphine, memantine for ten weeks (morphine 30mg tbl per day and memantine up to 40mg tbl per day if tolerated).
11334938|NCT02467543|Placebo Comparator|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
11334939|NCT02467543|Experimental|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
11334940|NCT02467530|Experimental|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
11334941|NCT02467530|No Intervention|Original diet|Patients will continue their original diet.
11334942|NCT02467517|Experimental|INTRAVENOUS KETAMINE|
11334943|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
11334944|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
11334945|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
11334946|NCT02467478|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
11334947|NCT02467478|Active Comparator|Linagliptin|Linagliptin 5mg once daily for 12 weeks
11334948|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
11334949|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
11334950|NCT02467452|Experimental|BDP/FF/GB|Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg
11334951|NCT02467452|Active Comparator|FlF/VI + Tiotropium|FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule
11334952|NCT02467439|Active Comparator|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
11335103|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
11335104|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
11334953|NCT02467439|No Intervention|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
11334954|NCT02467426||Chemotherapy|intraarterial chemotherapy with cisplatin and mitoxantrone
11334955|NCT02467413|Active Comparator|BAC treatment group|BAC, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
11334956|NCT02467413|Placebo Comparator|BAC Matched vehicle|BAC Matched vehicle, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
11334957|NCT02467400|Placebo Comparator|placebo|Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
11334958|NCT02467400|Active Comparator|Atenolol|Atenolol 50 mg 1/day for 20 weeks
11334959|NCT02467400|Active Comparator|Nebivolol|Nebivolol 5 mg/day for 20 weeks
11334960|NCT02467400|Active Comparator|Propranolol 40 mg|Propranolol 20 mg bid for 20 weeks
11334961|NCT02467400|Active Comparator|Propranolol 80 mg|Propranolol 40 mg bid for 20 weeks
11334962|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
11334963|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
11334964|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
11334965|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
11334966|NCT02467361|Experimental|Combo with Ipilimumab|
11334967|NCT02467361|Experimental|Combo with Nivolumab|
11334968|NCT02467361|Experimental|Combo with Pembrolizumab|
11334969|NCT02467348|Experimental|Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
11334970|NCT02467348|Active Comparator|No Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.
11334971|NCT02467335|Active Comparator|Healthy Subjects|Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.
11334972|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Mild Rating|Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
11334973|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Moderate Rating|Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
11334974|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Severe Rating|Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
11334975|NCT02467322|Experimental|Albumin|MVP (Moderate Volume Paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid.
11334976|NCT02467322|Active Comparator|No Albumin|MVP(Moderate Volume Paracentesis) of less than 5 liters without albumin.
11334977|NCT02467296|Active Comparator|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
11334978|NCT02467296|Active Comparator|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
11334979|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.
~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
11334980|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
11334981|NCT02467270|Experimental|Cohort A|Ponatinib 45 mg once daily starting dose.
11334982|NCT02467270|Experimental|Cohort B|Ponatinib 30 mg once daily starting dose.
11334983|NCT02467270|Experimental|Cohort C|Ponatinib 15 mg once daily starting dose.
11334984|NCT02467257|Experimental|Intrevention arm|Patients received Gum Arabic as intervention
11334985|NCT02467244||Euthyroid group|Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
11334986|NCT02467244||Hypothyroid group|Fifty (50) hypothyroid patients attending the outpatient department of General Medicine, AIIMS, Bhubaneswar, will be recruited for the present study following inclusion and exclusion criteria.
11334987|NCT02467231||Exposed|Females ages 11-35 to be exposed to alkylating agent chemotherapy
11334988|NCT02467218|Experimental|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
11335164|NCT02465970|Experimental|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
11335165|NCT02465970|Placebo Comparator|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
11334989|NCT02467218|Experimental|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
11334990|NCT02467205|Other|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
11334991|NCT02467205|No Intervention|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
11334992|NCT02467192|Experimental|Low dose CT|All patients will have Thoracic CT scan
11334993|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
11334994|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
11334995|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
11334996|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
11334997|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
11334998|NCT02467140|Active Comparator|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
11334999|NCT02467140|Active Comparator|Tack fixation|During surgery, the mesh will be fixated with tacks.
11335000|NCT02467127|No Intervention|control group|Patients without headache. No drugs will be administered
11335001|NCT02467127|Experimental|Chronic Headache|Patients with headache > 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
11335002|NCT02467127|Experimental|Chronic headache with drug overuse|Patients with headache > 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
11335003|NCT02467127|Experimental|Acute Headache|Patients without chronic headache but with an history of headache < 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
11335004|NCT02467114|Experimental|All study participants|Stimulation with TMS, a sham coil & no intervention
11335005|NCT02467101|Experimental|Corticosteroid/Saline|"Corticosteroid/Saline
~Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.
~In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).
~The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).
~This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6)."
11335006|NCT02467088|Experimental|Individualised Homoeopathic Remedy|Each participant will receive an individualised homoeopathic remedy, in a vehicle of sucrose pillules, according to the symptoms of their PMS. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing as outlined by De Schepper.
11335007|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
11335008|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
11335009|NCT02467062|Active Comparator|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
11335010|NCT02467062|Other|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
11335011|NCT02467049|Active Comparator|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
11335012|NCT02467049|Experimental|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
11335013|NCT02467036|Experimental|Family Based Behavioral Treatment Egg|The FBT+Egg group will participate in group-based FBT and will be assigned to eat eggs a minimum of 5 days a week for breakfast. Families are provided eggs each week to facilitate compliance, along with recipes
11335014|NCT02467036|Active Comparator|Family Based Behavioral Treatment Cereal|The FBT+Cereal group will participate in group-based FBT and will be assigned to eat cereal a minimum of 5 days a week for breakfast. Families are provided cereal each week to facilitate compliance.
11335015|NCT02467023|Experimental|effective muscle stimulation group|Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.
11335166|NCT02465957|Experimental|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
11335167|NCT02465944|Experimental|FFP104 - 2.5 mg/kg|FFP104
11335168|NCT02465944|Experimental|FFP104 - 5.0 mg/kg|FFP104
11335016|NCT02467023|Active Comparator|ineffective muscle stimulation group|Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.
11335017|NCT02467010|Experimental|Bortezomib, cyclophosphamide, dexamethason|"To assess the efficacy of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy.
~To assess the safety of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy in patients with refractory or relapsed multiple myeloma."
11335018|NCT02466997|Experimental|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
11335019|NCT02466997|Placebo Comparator|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.
~Counselling on natural light exposure during the duration of the trial will be given."
11335020|NCT02466984|Experimental|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
11335021|NCT02466984|Active Comparator|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
11335022|NCT02466971|Active Comparator|Arm I (cisplatin, IMRT or RT, brachytherapy)|Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, 30, (and day 36 or 37 at the treating physician's discretion). Patients then undergo EBRT (either conventional RT or IMRT) QD 5 days a week for 25 fractions followed by LDR or HDR brachytherapy according to institution's standards. Treatment continues in the absence of disease progression or unacceptable toxicity.
11335023|NCT02466971|Experimental|Arm II (cisplatin, IMRT or RT, brachytherapy, triapine)|Patients receive cisplatin and undergo EBRT followed by brachytherapy as in Arm I. Patients also receive triapine IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Treatment continues in the absence of disease progression or unacceptable toxicity.
11335024|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
11335025|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
11335026|NCT02466945|Other|V063B-DP3003|all patients will received the study product (V063B-DP3003)
11335027|NCT02466932||Birth Weight|
11335028|NCT02466919|Experimental|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10
11335029|NCT02466919|Active Comparator|Sequential|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10
11335030|NCT02466906|Experimental|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
11335031|NCT02466906|Placebo Comparator|placebo group|Placebo was injected subcutaneously perioperation.
11335032|NCT02466893|Other|ADAPT Technique/Standard SR Group|
11335033|NCT02466880|Experimental|Telemedicine|Diabetes education and support via telemedicine
11335034|NCT02466880|Active Comparator|Usual care|Diabetes education and support in person
11335035|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
11335036|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
11335037|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
11335038|NCT02466828|Experimental|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
11335039|NCT02466815|Experimental|Treatment A, then Treatment B and then Treatment C|Participants will receive treatment A (JNJ-42756493 10 milligram [mg] tablet, current clinical formulation [G-018] which uses milled active pharmaceutical ingredient [API]) in period 1, treatment B (JNJ-42756493 10 mg tablet, Prototype Formulation I [G-025] which uses coarser API) in period 2 and then treatment C (JNJ-42756493 10 mg tablet, Prototype Formulation II [G-025] which uses coarser API) in period 3.
11335040|NCT02466815|Experimental|Treatment B, then Treatment C and then Treatment A|Participants will receive treatment B in period 1, treatment C in period 2 and then treatment A in period 3.
11335041|NCT02466815|Experimental|Treatment C, then Treatment A and then Treatment B|Participants will receive treatment C in period 1, treatment A in period 2 and then treatment B in period 3.
11335042|NCT02466815|Experimental|Treatment A, then Treatment C and then Treatment B|Participants will receive treatment A in period 1, treatment C in period 2 and then treatment B in period 3.
11335043|NCT02466815|Experimental|Treatment B, then Treatment A and then Treatment C|Participants will receive treatment B in period 1, treatment A in period 2 and then treatment C in period 3.
11335044|NCT02466815|Experimental|Treatment C, then Treatment B and then Treatment A|Participants will receive treatment C in period 1, treatment B in period 2 and then treatment A in period 3.
11335045|NCT02466802|Experimental|A: regorafenib and sildenafil citrate|Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335046|NCT02466776|Active Comparator|Stainless steel staples|Patients in this arm will receive stainless steel staples for skin closure at time of cesarean section.
11335047|NCT02466776|Active Comparator|Absorbable subcuticular Suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
11335169|NCT02465944|Placebo Comparator|Placebo|Placebo
11335170|NCT02465931|Other|Comparison Condition|Paper and pencil informed consent
11391913|NCT02089880|Experimental|C-brace then stance control orthosis|
11335048|NCT02466763|Active Comparator|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
11335049|NCT02466763|Active Comparator|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
11335050|NCT02466750|Experimental|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
11335051|NCT02466750|Experimental|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
11335052|NCT02466737|Experimental|no axillary surgery|
11335053|NCT02466737|Active Comparator|sentinel lymph node biopsy|standard arm in first randomization
11335054|NCT02466737|Experimental|sentinel lymph node biopsy alone|
11335055|NCT02466737|Active Comparator|completion axillary lymph node dissection|standard arm in second randomization
11335056|NCT02466724|Experimental|Web Group|Patients given web site (aiddly) instructions for colonoscopy
11335057|NCT02466724|No Intervention|Paper Group|Patients given paper instructions for colonoscopy
11335058|NCT02466711|Active Comparator|Relamorelin|
11335059|NCT02466711|Placebo Comparator|Placebo|
11335060|NCT02466698|Experimental|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
11335061|NCT02466698|Active Comparator|Usual Care|Patients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
11335062|NCT02466685|Experimental|JNJ-18038683|Subjects will be randomized to receive JNJ-18038683 or placebo after the completion of the baseline assessments. Subjects randomized to JNJ-18038683 will receive 10 mg for one week, then titrate to 20 mg for the duration of the trial, with the provision for a single, downward dose adjustment for intolerance, based upon investigator judgment.
11335063|NCT02466685|Placebo Comparator|Placebo|Placebo treatment for 8 weeks.
11335064|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
11335065|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
11335066|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
11335067|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
11335068|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
11335069|NCT02466633|Experimental|Change in in-hospital cardiac monitoring method|Pre- and post-intervention, where the intervention is a change in in-hospital cardiac monitoring method
11335070|NCT02466607|Other|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
11335071|NCT02466607|Other|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
11335072|NCT02466594|Other|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
11335073|NCT02466581|Active Comparator|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:
~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids
~Cimzia plus Methotrexate and steroids
~Orencia plus Methotrexate and steroids
~RoActemra plus Methotrexate and steroids
~This intervention is de-escalated starting at randomization."
11335074|NCT02466581|Active Comparator|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:
~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids
~Cimzia plus Methotrexate and steroids
~Orencia plus Methotrexate and steroids
~RoActemra plus Methotrexate and steroids
~This intervention is de-escalated starting 24 weeks after randomization."
11335075|NCT02466568|Experimental|Phase I and Phase II Treatment Arm|Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.
11335077|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
11335078|NCT02466542|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
11335079|NCT02466542|Active Comparator|Esmolol group|Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
11335080|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
11335081|NCT02466516|Experimental|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
11335082|NCT02466516|Experimental|SEL 18 mg|SEL 18 mg for 24 weeks.
11335083|NCT02466516|Experimental|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
11335084|NCT02466516|Experimental|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
11335085|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks.
11335086|NCT02466503|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
11335087|NCT02466503|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
11335088|NCT02466490|Experimental|Fimasartan 60 mg Tablets|FMS 60 mg tablets once a day during the initial 8 treatment weeks of the study
11335089|NCT02466490|Active Comparator|Fimasartan 120 mg Tablets|FMS 120 mg tablets once a day during 4 weeks (treatment weeks 8 to 12)
11335090|NCT02466490|Active Comparator|Fimasartan; Hydrochlorothiazide 60/12.5|FMS 60 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 4 weeks (treatment weeks 8 to 12)
11335091|NCT02466490|Experimental|Fimasartan; Hydrochlorothiazide 120/12.5|FMS 120 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 12 weeks (treatment weeks 12 to 24)
11335092|NCT02466477|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
11335093|NCT02466477|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
11335094|NCT02466477|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.
~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
11335095|NCT02466464|Active Comparator|Microporous Polysaccharide Hemospheres (MPH)|Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
11335096|NCT02466464|Active Comparator|Merocel (Control)|Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
11335097|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, >4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
11335098|NCT02466438|Experimental|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).
~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.
~Patients with Normal Renal function:
~Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)
~Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)
~Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)
~Patients with Acute Kidney injury:
~Pediatric and surgery units: 2 months-6 years (10)
~PICU: 2 months-6 years (10)
~Haematology-oncology unit: 2 months-6 years (10)"
11335099|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
11335100|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
11335101|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:
~Day -1 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of CHTP 1.1 M)
~Day 2 = Wash-out
~Day 3 = 2nd intervention (single product use of mCC)."
11335171|NCT02465931|Experimental|Intervention condition|Digital informed consent tool
11337975|NCT02448264|Placebo Comparator|Placebo|Placebo to Match BCX7353 capsules, administered orally
11335105|NCT02466386|Experimental|Roll-over Participants|Participants who has completed the antecedent study (SPD489-211 or SPD489-347) will be included in this arm. Participants will begin with once daily oral dosing of 5 mg of SPD489 and should be titrated in a step wise fashion until an optimal dose is reached with 10, 15, 20, and 30 mg capsules.
11335106|NCT02466386|Experimental|Directly Enrolled Participants|Participant will be directly enrolled in this study and did not participate in antecedent study SPD489-211 or SPD489-347. Participants will begin with once daily oral dosing of 5 mg of SPD489 and should be titrated in a step wise fashion until an optimal dose is reached with 10, 15, 20, and 30 mg capsules.
11335107|NCT02466373|No Intervention|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
11335108|NCT02466373|Experimental|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
11335109|NCT02466373|Experimental|Clonidine 1200mcg|"4 patients receive 1200 µg/day of clonidine without loading schedule.
~4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
11335110|NCT02466373|Experimental|Clonidine 1800mcg|"4 patients receive 1800 µg/day of clonidine without loading schedule.
~4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
11335111|NCT02466360||chronic lower back pain|
11335112|NCT02466347|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
11335113|NCT02466347|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
11335114|NCT02466334|Active Comparator|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
11335115|NCT02466334|Placebo Comparator|Placebo|IV placebo for 20 minutes
11335116|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
11335117|NCT02466308|Experimental|SAM Ultrasound Diathermy Device|SAM (sam Professional System) 3 MHz ultrasound diathermy device: 4 hours/day, at least 5 days per week, for 6 weeks
11335118|NCT02466295|Experimental|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
11335119|NCT02466295|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
11335120|NCT02466282|Active Comparator|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
11335121|NCT02466282|Experimental|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
11335122|NCT02466269||the preauricular approach|A classic preauricular incision was used to treat diacapitular condylar fractures
11335123|NCT02466256|Placebo Comparator|Autosert Group|Procedure / Surgery : Intraocular lens implantation with Autosert injector
11335124|NCT02466256|Placebo Comparator|Royale Group|Procedure / Surgery : Intraocular lens implantation with Royale Injector
11335125|NCT02466256|Placebo Comparator|Monarch III Injector|Procedure / Surgery : Intraocular lens implantation with Monarch III group
11335126|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.
~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
11335127|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.
~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
11335128|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
11335129|NCT02466217||1: AID groups|Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes
11335130|NCT02466217||2: Control groups|knee arthritis, hip arthritis, muscular dystrophy, healthy subject
11335131|NCT02466204|Active Comparator|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
11335132|NCT02466204|Active Comparator|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
11335133|NCT02466191|Experimental|memantine first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
11335134|NCT02466191|Experimental|gabapentin first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
11335135|NCT02466178||Serene RF System|Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.
11335136|NCT02466165|Experimental|MS patients intervention group|the feasibilty and influence of high intense interval exercise on the cardiometabolic risk state in MS patients will be investigated in a pilot trial.
11335137|NCT02466165|No Intervention|healthy controls|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
11335138|NCT02466165|No Intervention|larger group of MS patients|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
11335139|NCT02466152|Experimental|GSK2894512 2.0% Cohort|Subjects will apply a thin layer of GSK2894512 2.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
11335140|NCT02466152|Experimental|GSK2894512 1.0% Cohort|Subjects will apply a thin layer of GSK2894512 1.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
11335141|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
11335142|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
11335143|NCT02466113|Experimental|An experimental group|A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
11335144|NCT02466113|Other|A control group|A classic stratified tool is applied in this group. Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
11335145|NCT02466100|Experimental|Goc Intervention|Patient education materials, study nurse phone call, tip sheet, provider tip sheet
11335146|NCT02466100|No Intervention|usual care|care as usual in the community
11335147|NCT02466087|Experimental|Mg Cl|500mg Mg Cl per day for 6 weeks
11335148|NCT02466087|No Intervention|Control|No intervention
11335149|NCT02466074|Experimental|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
11335150|NCT02466074|Placebo Comparator|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
11335151|NCT02466061|Experimental|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.
~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).
~Month 12 followup weight data also will be collected through medical record abstraction."
11335152|NCT02466061|Experimental|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.
~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).
~Month 12 follow up weight data also will be collected through medical record abstraction."
11335153|NCT02466061|Active Comparator|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.
~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).
~Month 12 follow up weight data also will be collected through medical record abstraction."
11335154|NCT02466048|Experimental|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
11335155|NCT02466048|Active Comparator|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
11335156|NCT02466035|Experimental|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
11335157|NCT02466035|No Intervention|Other formula|Children assuming other hypoallergenic formulas
11335158|NCT02466022|Experimental|Dexmedetomidine|Patients will receive one 0.5ug/kg bolus of Dexmedetomidine over 10 minutes for sedation prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
11335159|NCT02466022|Placebo Comparator|Normal Saline|Patients will receive 0.1cc/kg Normal Saline bolus delivered over 10 minutes for control arm prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
11335160|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)
~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
11335161|NCT02465996|Other|postprandial distress syndrome (PDS)|"FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).
~pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination."
11335162|NCT02465996|Other|epigastric pain syndrome (EPS)|pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.
11335163|NCT02465983|Experimental|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
11335172|NCT02465918|Active Comparator|Original Setting- MCS 30 min off/0 min off|Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.
11335173|NCT02465918|Experimental|MCS 25 min on/5 min off|Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.
11335174|NCT02465918|Experimental|MCS 20 min on/10 min off|Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.
11335175|NCT02465918|Experimental|MCS 15 min on/15 min off|Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.
11335176|NCT02465905|Active Comparator|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
11335177|NCT02465905|Active Comparator|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
11335178|NCT02465892|No Intervention|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
11335179|NCT02465892|Experimental|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
11335180|NCT02465879|Experimental|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
11335181|NCT02465866|Experimental|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
11335182|NCT02465866|Experimental|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
11335183|NCT02465866|Active Comparator|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
11335184|NCT02465866|Active Comparator|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
11335185|NCT02465853|Placebo Comparator|Placebo group|Injection 0.9% Physiological saline solution<2.5 ml and physical therapy and occupational therapy
11335186|NCT02465853|Experimental|Hyaluronic Acid|injection Hyaluronic Acid 2.5ml and physical therapy and occupational therapy
11335187|NCT02465840|Placebo Comparator|Immobilization programs|custom-made protective hand splint physical therapy and occupational therapy
11335188|NCT02465840|Experimental|Kleinert programs|custom-made dynamic hand splint physical therapy and occupational therapy
11335189|NCT02465827|Active Comparator|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.
~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
11335190|NCT02465827|Active Comparator|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
11335191|NCT02465827|Placebo Comparator|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
~Saline for nerve blockades for both nerves mentioned."
11335192|NCT02465814|Experimental|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
11335193|NCT02465814|Experimental|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
11335194|NCT02465814|Experimental|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
11335195|NCT02465814|Experimental|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
11335196|NCT02465814|Active Comparator|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
11335197|NCT02465814|Active Comparator|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
11335198|NCT02465814|Active Comparator|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
11335199|NCT02465801|Experimental|Group 1|"Intervention: HSA-GCSF 1.2 mg
~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
11335200|NCT02465801|Experimental|Group 2|"Intervention:HSA-GCSF 1.5 mg
~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.
~Intervention: Drug: TE or TEC"
11335201|NCT02465801|Active Comparator|Group 3|"Intervention: GCSF
~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.
~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o'clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.
~Intervention: Drug: TE or TEC"
11335235|NCT02465580|Placebo Comparator|hrIL-2 placebo|1 million U doses of placebo s.c. injection
11335202|NCT02465788|Experimental|755nm alexandrite laser with bipolar RF|GentleTouch (Helos) combines 755nm alexandrite laser energy with bipolar RF energy.
11335203|NCT02465775|Experimental|UltraShape treatment in all subjects|UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
11335204|NCT02465762|Experimental|ultrashape fat reduction treatment|all patient undergo non-invasive fat and circumference reduction at the flanks area
11335205|NCT02465749|Experimental|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
11335206|NCT02465749|Experimental|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
11335207|NCT02465749|Experimental|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
11335208|NCT02465749|Other|control|Routine drug treatment
11335209|NCT02465736|Experimental|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.
~Interventions:
~Radiation: (44 Gy/20 fractions)
~Drug: Docetaxel
~Drug: Cisplatin"
11335210|NCT02465736|Experimental|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.
~Interventions:
~Radiation: (44 Gy/20 fractions)
~Drug: Vinorelbine
~Drug: Cisplatin"
11335211|NCT02465723|Experimental|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
11335212|NCT02465710||pelvic organ prolapse|All women who underwent surgical treatment of pelvic organ prolapse in this study.
11335213|NCT02465697|Experimental|BPD Emotion Regulation Training|Guided practice in reappraisal
11335214|NCT02465697|No Intervention|BPD Control|no training in reappraisal
11335215|NCT02465697|Experimental|APD Emotion Regulation Training|Guided practice in reappraisal
11335216|NCT02465697|No Intervention|APD Controls|no training in reappraisal
11335217|NCT02465697|Experimental|Healthy Controls Emotion Regulation Training|Guided practice in reappraisal
11335218|NCT02465697|No Intervention|Healthy Controls|no training in reappraisal
11335219|NCT02465684|Experimental|tourniquet|UKA surgery with tourniquet
11335220|NCT02465684|Experimental|no tourniquet|UKA without tourniquet
11335221|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
11335222|NCT02465645|Experimental|Carvedilol + Simvastatin|"Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
~Simvastatin will be administered orally at a start dose of 20 mg for 15 days followed by 40 mg OD for the next 3 months. Along with Simvastatin, Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min."
11335223|NCT02465645|Active Comparator|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
11335224|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
11335225|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
11335226|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
11335227|NCT02465619||Severe acute hepatitis|Severe acute hepatitis without ascites.
11335228|NCT02465619||Non-cirrhotic|
11335229|NCT02465619||Cirrhotic patients with ascites|
11335230|NCT02465619||decompensated cirrhosis|
11335231|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
11335232|NCT02465606|Active Comparator|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
11335233|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
11335234|NCT02465580|Active Comparator|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
11335236|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
11335237|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
11335238|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
11335239|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
11335240|NCT02465554||No atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of 0. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into No atherosclerosis/endothelial function normal and No atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
11335241|NCT02465554||Atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into atherosclerosis/endothelial function normal and atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
11335242|NCT02465541|Experimental|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
11335243|NCT02465541|Active Comparator|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
11335244|NCT02465528|Experimental|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
11335245|NCT02465528|Experimental|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
11335246|NCT02465528|Experimental|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
11335247|NCT02465528|Experimental|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
11335248|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
11335249|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
11335250|NCT02465502|Experimental|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
11335251|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
11335252|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
11335253|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
11335254|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
11335255|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
11335256|NCT02465476|No Intervention|normal care|patient who will have normal treatment pathway
11335257|NCT02465476|Experimental|telemedicine|patient who will have telemedicine
11335258|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
11335259|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
11335260|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
11335261|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
11335262|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
11335263|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
11335264|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
11335265|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
11335266|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
11335267|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
11335268|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
11335269|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
11335270|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
11335271|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
11335272|NCT02465411|Experimental|Long-term CGM|Continuous glucose monitoring with DexCom G4 platina or later generations during 12 months following participation in the CGMMDI trial
11335273|NCT02465398|Other|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
11335274|NCT02465385|Experimental|Intervention|Linaclotide 290mcg
11335275|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
11335276|NCT02465372|No Intervention|Control|Standard practice.
11340068|NCT02433925|Placebo Comparator|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
11335277|NCT02465359|Experimental|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
11335278|NCT02465346|Experimental|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-> primary hospital with regional stroke unit.
11335279|NCT02465346|Active Comparator|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
11335280|NCT02465333|Other|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:
~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
11335281|NCT02465333|Other|Pathway B|"Screening visit followed by:
~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A
~Heel fat grafting procedure and local anesthetic and visits at:
~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
11335282|NCT02465320|Active Comparator|COL-1077|lidocaine bioadhesive gel, 10%
11335283|NCT02465320|Placebo Comparator|Placebo|placebo bioadhesive gel
11335284|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
11335285|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
11335286|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
11335287|NCT02465294|Placebo Comparator|Potato starch and magnesium stearate|This arm will be used as a control to asses the efficacy of the other probiotic arms. The placebo will contain encapsulated potato starch and magnesium stearate which is used the matrix in the probiotic supplements. The placebo refers only to the intervention supplement, not the behavioral lifestyle intervention. All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
11335288|NCT02465294|Experimental|Lactobacillus|Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
11335289|NCT02465294|Experimental|Mix of Bifidobacterium and Lactobacillus|A blend of Bifidobacterium and Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
11335290|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
11335291|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
11335292|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
11335293|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
11335294|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
11335295|NCT02465255|Experimental|Ketorolac|Ketorolac 0.5 mg/kg administrated by sublingual route
11335296|NCT02465255|Active Comparator|Tramadol|Tramadol 2.0 mg/kg administrated by sublingual route
11335297|NCT02465255|Active Comparator|Acetaminophen (paracetamol)|Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route
11335298|NCT02465242||NPi greather than 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi greater than 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
11335299|NCT02465242||NPi less than or equal to 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi less than or equal to 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
11335300|NCT02465229|Experimental|Diagnostic methods of indeterminate biliary stricture|
11335301|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
11335302|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
11335303|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
11335304|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
11335305|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
11335306|NCT02465203|Other|Follow up from feeder studies|Follow up arm
11335307|NCT02465164|Other|Cook catheter|Control
11335308|NCT02465164|Active Comparator|Cook catheter plus low dose oxytocin|Test group
11335309|NCT02465151|Experimental|No Protein|
11335310|NCT02465151|Experimental|Low Protein|
11335311|NCT02465151|Experimental|Medium Protein|
11335312|NCT02465151|Experimental|High Protein|
11335313|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
11335314|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
11335315|NCT02465125|Active Comparator|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
11335316|NCT02465125|Active Comparator|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
11335317|NCT02465112|Experimental|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
11335318|NCT02465112|Active Comparator|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
11335319|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
11335320|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
11335321|NCT02465086|Experimental|Training|This arm, which is a half of the sample size, will be receiving training of linguistic recursion
11335322|NCT02465086|No Intervention|No training|The no intervention group, which is a half of the sample size, will not be recieving training in linguistic recursion.
11335323|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
11335324|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
11335325|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
11335326|NCT02465060|Experimental|Subprotocol A (EGFR activating mutation)|Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335327|NCT02465060|Experimental|Subprotocol B (HER2 activating mutation)|Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335328|NCT02465060|Experimental|Subprotocol C1 (MET amplification)|Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335329|NCT02465060|Experimental|Subprotocol C2 (MET exon 14 deletion/mutation)|Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335330|NCT02465060|Experimental|Subprotocol E (EGFR T790M or rare activating mutation)|Patients with EGFR T790M or rare activating mutation receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335331|NCT02465060|Experimental|Subprotocol F (ALK translocation)|Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335332|NCT02465060|Experimental|Subprotocol G (ROS1 translocation or inversion)|Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335333|NCT02465060|Experimental|Subprotocol H (BRAF V600E/R/K/D mutation)|Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335334|NCT02465060|Experimental|Subprotocol I (PIK3CA mutation)|Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335335|NCT02465060|Experimental|Subprotocol J (HER2 amplification >= 7 copy numbers)|Patients with HER2 amplification >= 7 copy numbers receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11335336|NCT02465060|Experimental|Subprotocol K1 (FGFR amplification)|Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11336073|NCT02460341|Experimental|ondansetron-8|Single dose of 8 mg ondansetron (crossover with single dose of placebo)
11335337|NCT02465060|Experimental|Subprotocol K2 (FGFR mutation or fusion)|Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335338|NCT02465060|Experimental|Subprotocol L (mTOR mutation)|Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11335339|NCT02465060|Experimental|Subprotocol M (TSC1 or TSC2 mutation)|Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11335340|NCT02465060|Experimental|Subprotocol N (PTEN mutation or deletion and PTEN expression)|Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335341|NCT02465060|Experimental|Subprotocol P (PTEN loss)|Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335342|NCT02465060|Experimental|Subprotocol Q (HER2 amplification)|Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11335343|NCT02465060|Experimental|Subprotocol R (BRAF fusion or BRAF non-V600 mutation)|Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335344|NCT02465060|Experimental|Subprotocol S1 (NF1 mutation)|Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335345|NCT02465060|Experimental|Subprotocol S2 (GNAQ or GNA11 mutation)|Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335346|NCT02465060|Experimental|Subprotocol T (SMO or PTCH1 mutation)|Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335347|NCT02465060|Experimental|Subprotocol U (NF2 inactivating mutation)|Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335348|NCT02465060|Experimental|Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)|Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11335349|NCT02465060|Experimental|Subprotocol W (FGFR pathway aberrations)|Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335350|NCT02465060|Experimental|Subprotocol X (DDR2 S768R, I638F, or L239R mutation)|Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335351|NCT02465060|Experimental|Subprotocol Y (Akt mutation)|Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335352|NCT02465060|Experimental|Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)|Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335353|NCT02465060|Experimental|Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)|Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335354|NCT02465060|Experimental|Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)|Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335355|NCT02465060|Experimental|Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)|Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335356|NCT02465060|Experimental|Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)|Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335357|NCT02465060|Experimental|Subprotocol Z1F (PIK3CA mutation)|Patients with PIK3CA mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335358|NCT02465060|Experimental|Subprotocol Z1G (PTEN loss)|Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335359|NCT02465060|Experimental|Subprotocol Z1H (PTEN mutation)|Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335360|NCT02465060|Experimental|Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)|Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11335361|NCT02465060|Experimental|Subprotocol Z1K (AKT mutation)|Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335362|NCT02465060|Experimental|Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)|Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11335363|NCT02465047|Experimental|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
11335364|NCT02465047|No Intervention|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
11335823|NCT02461901||Metronidazole or vancomycin treatment|Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)
11335365|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
11335366|NCT02465034|Active Comparator|Healthy Control|Healthy individuals matched for age, gender and handedness with the subcortical stroke group will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
11335367|NCT02465021|Experimental|Snack bar 1|Dietary intervention: 190 Kcal, 12g fat, 14g carbohydrate, 5g fibre, 6g sugar, 10g protein
11335368|NCT02465021|Experimental|Snack bar 2|Dietary intervention: 200 Kcal, 15g fat, 12g carbohydrate, 5g fibre, 4g sugar, 8g protein
11335369|NCT02465021|Experimental|Snack bar 3|Dietary intervention: 210 Kcal, 16g fat, 12g carbohydrate, 2g fibre, 6g sugar, 6g protein
11335370|NCT02465021|Experimental|Control 1|Dietary intervention: Water (500 g)
11335371|NCT02465021|Experimental|Control 2|Dietary intervention: White bread (190 Kcal, 2g fat, 37g carbohydrate, 2g fibre, 3g sugar, 6g protein)
11335372|NCT02465021|Experimental|Control 3|Dietary intervention: Soft baked pretzel (190 Kcal, 2g fat, 38g carbohydrate, 2g fibre, 6g sugar, 4g protein)
11335373|NCT02465008|Experimental|levobupivaciane group|Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
11335374|NCT02465008|Placebo Comparator|Placebo Comparator (saline solution)|Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
11335375|NCT02464995|Experimental|Thermoplasty group|Procedure: Bronchial thermoplasty with the Alair System and conventional therapy
11335376|NCT02464995|No Intervention|Control group|Conventional therapy
11335377|NCT02464982||Women with 1 year non-invasive technology areola tattoo|Women with 1 year non-invasive technology areola tattoo realized in standard care as part of 1 breast mammary reconstruction following an operated breast cancer
11335378|NCT02464969|Experimental|Apixaban|Subjects between birth to <18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
11335379|NCT02464969|Active Comparator|Standard of Care|Subjects will receive a dose and dosing regimen of anticoagulation treatment based on usual and customary care per local practices.
11335380|NCT02464930||No-GERD Controls|"NERD controls will be enrolled from subjects presenting to the endoscopy unit who are being evaluated for reasons other than GERD or BE surveillance. These are patients who are referred to the endoscopy unit for: evaluation of anemia, dysphagia, occult blood positivity, gastrointestinal blood loss etc.
~No history of GERD
~Response no to presence of symptoms on a standardized GERD questionnaire
~No prescriptions for acid suppressive medication over the past 2 years as documented in electronic pharmacy records.
~Normal endoscopy that does not find Barrett's esophagus, hiatus hernia or erosive esophagitis."
11335381|NCT02464930||GERD Controls|"Respond yes to the presence of symptoms on a standardized GERD questionnaire
~Prescriptions for acid suppressive medication as documented in electronic pharmacy records."
11335382|NCT02464930||BE Cases|• Patients who present for evaluation of reflux symptoms and are found to have at least 1 cm of columnar lined esophagus on endoscopy with intestinal metaplasia on biopsies. This will include patients with esophageal adenocarcinoma
11335383|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
11335384|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
11335385|NCT02464904|Experimental|Cryotherapy|Cryospray and biopsies
11335386|NCT02464904|Other|Control|Biopsies
11335387|NCT02464891|Experimental|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
11335388|NCT02464865|Experimental|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
11335389|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
11335390|NCT02464865|Experimental|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
11335391|NCT02464852|Other|Snood|All recruited participants will try out the snood
11335392|NCT02464839||Hallux valgus patients|All of participants will perform a potassium hydroxide (KOH) examination and fungal culture to prove a fungal nail and feet fungal infection
11335393|NCT02464826|Experimental|Edit arms|Nailprotex apply to the abnormal nail twice daily
11335394|NCT02464813|Active Comparator|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
11335395|NCT02464813|Placebo Comparator|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
11335396|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
11336074|NCT02460341|Experimental|ondansetron-16|Single dose of 16 mg ondansetron (crossover with single dose of placebo)
11335397|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
11335398|NCT02464787|Experimental|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
11335399|NCT02464774|Experimental|Breast-Conserving Therapy|"Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:
~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.
~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.
~Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:
~N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes."
11335400|NCT02464774|Active Comparator|Mastectomy|"Patients undergo mastectomy (MT) with surgical axillary staging.
~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:
~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.
~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles."
11335401|NCT02464761|Experimental|Dose escalating PDT|
11335402|NCT02464748|Experimental|Intervention|Patients and their primary carer will use a weekly telehealth system. This involves a series of questions on a tablet computer that is transmitted to their regional MND care centre for review and action.
11335403|NCT02464748|No Intervention|Control|Usual care
11335404|NCT02464722|Experimental|Dexmedetomidine|"Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.
~Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1
~After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done
~Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.
~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
~At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
11335405|NCT02464722|Active Comparator|Remifentanil|"Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1
~Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.
~After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.
~Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.
~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
~At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
11335406|NCT02464709|Experimental|Actinic keratosis patients|Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
11335407|NCT02464696|Experimental|Non-Invasive Positive Pressure Ventilation (NIPPV)|"Participants placed on intermittent NIPPV oxygen therapy delivered through a mask. Supplemental oxygen administered during periods off of NIPPV. Settings and FIO2 titrated to maintain an SpO2 > 92%.
~If at any time participant develops a contraindication to NIPPV, NIPPV therapy discontinued and participant will remain on supplemental oxygen therapy."
11335408|NCT02464696|Active Comparator|High Flow Oxygen Therapy|"Participants maintained on high flow nasal cannula oxygen therapy.
~Participants can receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician(s) at any time (assuming no contraindications to NIPPV exist)."
11335409|NCT02464683|Placebo Comparator|Placebo|The patient will take a single tablet of placebo daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
11335410|NCT02464683|Experimental|VitaminD|The patient will take a single tablet of Vitamin D (200 International Units) daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
11335411|NCT02464670|Experimental|Group 1|INO-4201 IM + EP, 2 mg, 3 doses
11335412|NCT02464670|Experimental|Group 2|INO-4202 IM + EP, 2 mg, 3 doses
11335413|NCT02464670|Experimental|Group 3|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
11335414|NCT02464670|Experimental|Group 4|INO-4212 IM + EP, 4 mg, 3 doses
11335415|NCT02464670|Experimental|Group 5|INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
11335416|NCT02464670|Experimental|Group 6|INO-4201 ID + EP 0.2A, 1 mg, 3 doses
11335417|NCT02464670|Experimental|Group 7|INO-4201 ID + EP 0.2A, 2 mg, 2 doses
11335418|NCT02464670|Experimental|Group 8|INO-4201 ID + EP 0.2A, 1 mg, 2 doses
11335419|NCT02464670|Experimental|Group 9|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
11335420|NCT02464670|Experimental|Group 10|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
11335421|NCT02464670|Experimental|Group 11|INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
11335422|NCT02464670|Experimental|Part II: Group 3A|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
11335423|NCT02464670|Experimental|Part II: Group 3B|INO-4201 ID + EP 0.1A, 2 mg, 3 doses
11335454|NCT02464423|No Intervention|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
11391914|NCT02089880|Experimental|Stance control orthosis then C-brace|
11335424|NCT02464657|Experimental|Nivolumab + Idarubicin + Cytarabine|"Phase I starting dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Dose of Nivolumab escalated in successive cohorts of patients. After 2 cycles, if the disease appears to get better, participants receive Nivolumab by vein about every 2 weeks for up to 1 year.
~Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
11335425|NCT02464644|Experimental|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.
~They will be directed to appropriate questions, according to answers to the previous questions."
11335426|NCT02464644|Other|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.
~They will be directed to appropriate questions, according to answers to the previous questions."
11335427|NCT02464631|Active Comparator|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
11335428|NCT02464631|Experimental|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
11335429|NCT02464631|Experimental|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
11335430|NCT02464618|No Intervention|Usual care|The social contact of patients in this arm will not be contacted
11335431|NCT02464618|Active Comparator|Social contact intervention|The social contact of patients in this arm will be contacted and asked to facilitate the endoscopy care plan of the patient
11335432|NCT02464605|Experimental|SEL-037 (pegsiticase)|Pegylated uricase
11335433|NCT02464592|Active Comparator|Biopsy with Cryoprobes|Transbronchial lung biopsy with a cryoprobe.
11335434|NCT02464592|Active Comparator|Biopsy with Conventional Forceps|Transbronchial lung biopsy with conventional forceps.
11335435|NCT02464566|Experimental|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).
~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:
~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
11335436|NCT02464566|Active Comparator|C Group|One session regarding diet restriction and physical activity with printed health education papers.
11335437|NCT02464553|Experimental|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
11335438|NCT02464553|Experimental|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
11335439|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
11335440|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
11335441|NCT02464527|Experimental|Stimulus-stimulus pairing (SSP)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
11335442|NCT02464527|Active Comparator|Waitlist Control (Delayed Treatment)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations will be randomly assigned to the Waitlist Control group. During the waitlist control subject's assigned session block of six weeks, s/he will not receive any treatment. The subjects will receive the stimulus-stimulus pairing procedure (delayed procedure) after the completion of the assigned 6-week block as a waitlist control participant. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
11335443|NCT02464514|Other|Healthy obese children|High carbohydrate meal High fat meal
11335444|NCT02464514|Other|Children with Prader Willi Syndrome|High carbohydrate meal High fat meal
11335445|NCT02464501|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
11335446|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
11335447|NCT02464475|Experimental|OMT|
11335448|NCT02464475|Sham Comparator|Sham|
11335449|NCT02464462|Experimental|CaD Group|This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium
11335450|NCT02464462|Placebo Comparator|Placebo Group|This arm received rice powder pills
11335451|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
11335452|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
11335453|NCT02464436|Experimental|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
11335487|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
11335912|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
11335455|NCT02464423|Active Comparator|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
11335456|NCT02464410|Experimental|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
11335457|NCT02464410|Active Comparator|Enhanced Usual Care|In addition to covering the VHA's long-term OA informed consent process, the enhanced usual care (EUC) condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic. This EUC condition will include some information related to risks of opioid use as part of the informed consent and will consequently have sufficient face validity as an intervention on opioid safety to effectively blind participant to randomization. However, the EUC therapist will not use the motivational enhancement approach of discussing strategies for avoiding these risks. It is designed to be equal in length to the motivational intervention.
11335458|NCT02464397|Experimental|OPTIMAX-BAS 1|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 1 month after the index procedure.
11335459|NCT02464397|Active Comparator|SYNERGY-EES 1|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
11335460|NCT02464397|Experimental|OPTIMAX-OCT 6|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 6 months after the index procedure.
11335461|NCT02464397|Active Comparator|SYNERGY-EES 6|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 6 months after the index procedure.
11335462|NCT02464384|Other|cohort study|Collection of blood samples and ultrasound / MRI and x-ray examination.
11335463|NCT02464371||ICU acquired muscle weakness (IAMW) group +|"The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).
~Kinetic of microRNAs is measured"
11335464|NCT02464371||ICU acquired muscle weakness (IAMW) group -|The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured
11335465|NCT02464358|Experimental|IMB Intervention Group|"The IMB group received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, they received the following:
~Additional educational content related to HPV, Cervical Cancer, and HPV vaccination,
~Motivational content to help identify and problem-solve benefits and barriers to vaccination,
~Skills-building content, including brief communication skills training and ways to access the vaccine."
11335466|NCT02464358|Active Comparator|Attention Control Group|The attention control group also received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, to maintain consistency with the treatment's presentation format, participants watched a set of short video clips encompassing aspects of women's general and sexual health.
11335467|NCT02464345|Experimental|HAPIFED|HAPIFED therapy
11335468|NCT02464345|Active Comparator|CBT-E|CBT-E therapy
11335469|NCT02464332|Experimental|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.
~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.
~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
11335470|NCT02464319|Active Comparator|Experimental: hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
11335471|NCT02464319|Placebo Comparator|Placebo Comparator: hrIL-2 placebo|1 million U doses of placebo s.c. injection
11335472|NCT02464306|Experimental|SOT Recipients|SOT recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with a first-episode of CDI. Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days. The rate of sustained clinical response (SCR; cure without recurrence at 30 days) will be assessed.
11335473|NCT02464306|No Intervention|Historical Cohort|Historical cohort of SOT recipients who received standard of care therapy for CDI at our institution.
11335474|NCT02464293|Experimental|mindfulness-based cognitive therapy|
11335475|NCT02464280||Patients scheduled for lung imaging|"Patients with lung changes and scheduled for lung imaging will undergo:
~the scheduled conventional X-ray examination
~the scheduled CT scan
~the tomosynthesis scan"
11335476|NCT02464280||Patients scheduled for wrist imaging|"Patients with wrist fracture or with osteoprotetic material in the wrist and scheduled for wrist imaging will undergo:
~the scheduled conventional X-ray examination
~the scheduled CT scan
~the tomosynthesis scan"
11335477|NCT02464254|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
11335478|NCT02464254|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
11335479|NCT02464241||normal control|normal control
11335480|NCT02464241||patients|patients with optic or macular pathology or amblyopia
11335481|NCT02464228|Experimental|Tipifarnib|tipifarnib, oral
11335482|NCT02464215|Active Comparator|open surgery|Conventional procedure,Open surgery
11335483|NCT02464215|Experimental|laparoscopic surgery|Minimum invasive procedure，Laparoscopic surgery
11335484|NCT02464202|Experimental|stereolithography tooth replica|stereolithographic tooth replica used as a guide for tooth autotransplantation decreases extra-alveolar time and reduces trauma to periodontal ligament tissue therefore increasing the success rate after transplantation
11335485|NCT02464189||Children with asthma|
11335486|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
11335913|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
11335488|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
11335489|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11335490|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11335491|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11335492|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11335493|NCT02464150|Experimental|Participants|Participants are subjected to gluten intervention in an unblinded fashion.
11335494|NCT02464137|Experimental|Radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
11335495|NCT02464124|Experimental|lactulose plus nitazoxanide|"Nitazoxanide dosing: 500 mg tablets twice daily
~Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day"
11335496|NCT02464124|Active Comparator|Lactulose alone|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
11335497|NCT02464111|Experimental|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
11335498|NCT02464111|Experimental|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
11335499|NCT02464111|Experimental|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
11335500|NCT02464111|Experimental|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
11335501|NCT02464111|Experimental|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
11335502|NCT02464111|Experimental|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
11335503|NCT02464098||Group 1|Participants with diagnosis of hematological malignancy or solid tumor.
11335504|NCT02464098||Group 2|Participants undergoing hematopoietic stem cell transplantation (HSCT).
11335505|NCT02464085||Longitudinal evaluation of recovery|Stroke survivors with subacute and severe upper limb disability
11335506|NCT02464072|Experimental|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
11335507|NCT02464072|Active Comparator|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
11335508|NCT02464072|Experimental|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
11335509|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
11335510|NCT02464046|Experimental|JNJ-42847922 then Placebo|Participants receive 2*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
11335511|NCT02464046|Experimental|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
11335512|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
11335513|NCT02464020|Experimental|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
11335514|NCT02464020|No Intervention|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
11335515|NCT02464007|Experimental|sSIFN-co|Dose escalation of rSIFN-co
11335516|NCT02463994|Experimental|MPDL3280A + HIGRT|
11335517|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
11335518|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
11335519|NCT02463968||CHRONIC CHIKUNGUNYA|Twenty participants with chronic chikungunya defined as continued knee joint effusion at least three months after diagnosis of chikungunya will be enrolled in the study.
11335520|NCT02463968||ACUTE CHIKUNGUNYA|Ten participants with acute chikungunya defined as clinical symptoms of chikungunya with acute fever and joint pain within 10 days the onset of symptoms.
11335521|NCT02463968||HEALTHY CONTROLS|Five healthy controls will have only blood drawn once.
11335522|NCT02463955|Experimental|Thoracoscopy|"experimental intervention (flexible video endoscope)
~reference procedure (video-rigid thoracoscope)"
11335523|NCT02463942|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
11335524|NCT02463942|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
11335525|NCT02463942|Other|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
11335526|NCT02463929|Experimental|diphenhydramine|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5mg/kg diphenhydramine intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
11335527|NCT02463929|Placebo Comparator|control|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5cc/kg normal saline intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
11335528|NCT02463916|Active Comparator|Immediate exercise|This group will immediately commence an 8 week exercise programme.
11335529|NCT02463916|Active Comparator|Delayed exercise|This group will continue regular activities for 8 weeks and then commence 8 week exercise programme.
11335530|NCT02463903|Experimental|Coping effectiveness Training (CET)|The intervention consists of Coping Effectiveness Training (CET), a manual-based group intervention based on a cognitive transactional theory of stress and coping. The purpose of CET is to improve skills to appraise stress, teach a number of techniques to cope with stress, and to give an opportunity to interact with other people with similar experiences of living with CHF. The CET program will, in this study, be modified for patients with CHF. The intervention consists of seven, 90-minute weekly sessions led by a nurse with a Masters degree in nursing science and extensive experience in heart failure care in collaboration with a professional psychologist. Each group consisted of 8 to 12 patients.
11335531|NCT02463903|No Intervention|Control|The control group will receive standard health care and will not take part of the intervention.
11335532|NCT02463890|Experimental|Training|"In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
11335533|NCT02463890|Other|Control|In this group, patients will receive only diets and physical activity counselling
11335534|NCT02463877|Other|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
11335535|NCT02463864|Experimental|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
11335536|NCT02463864|Sham Comparator|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
11335537|NCT02463851|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
11335538|NCT02463851|Active Comparator|AF-Ablation with Contact Force single-tip electrode|Regular AF-ablation with a regular Contact Force single-tip ablation catheter
11335539|NCT02463838|Experimental|Care Support Intervention|Eligible members are assigned a CareSupport Coordinator who carries a caseload of 25-35 members. A team of 5 Coordinators is supervised by a master's level Social Worker. Community Coordinators work with members to conduct standardized assessments to develop a Care Plan shared with other providers within and outside of SFHP. Coordinators provide members advocacy and navigation across systems of care, to improve coordination focus on treatment goals. Coordinator focus on prevention and early intervention around disease management, advocacy, appointment reminders and accompaniment, home visits, and regular communication with primary care and other providers. Coordinators are encouraged to be accountable for coordinating and following through on all aspects of a member's needs.
11335540|NCT02463838|No Intervention|Usual Care|All eligible SFHP members randomized to usual care will receive medical and health plan by virtue of enrollment in the SFHP and Medi-Cal. Services include assignment to a primary care physician and access to all services available through Medi-Cal in the county of San Francisco.
11335541|NCT02463825|Experimental|Group 1 Pimozide (2mg per day)|Pimozide will be initiated at 1 mg twice daily and maintained on 2mg/day for 50 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will then be stopped.
11335542|NCT02463825|Experimental|Group 2 Pimozide (4mg per day)|Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
11335543|NCT02463825|Placebo Comparator|Group 3 Placebo (Lactose tablet)|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 3
11335544|NCT02463812|Experimental|Intralipid|Patients will receive Intralipid infusion in the recovery room.
11335545|NCT02463812|Placebo Comparator|Control|Patients will receive infusion of normal saline in the recovery room.
11335546|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20
~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
11335547|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
11335548|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
11335549|NCT02463747|Experimental|Prolonged Infusion of antibiotics|"Prolonged (4 hours) Infusion of antibiotics.
~Intervention:
~Primary care would be one of three options:
~Piperacillin/tazobactam : 4.5gr, TID, I.V.
~Or
~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.
~Or
~Meropenem: 1.0gr, TID, I.V.
~Supplementation of Vancomycin will be at the discretion of the treating physician."
11335583|NCT02463461|Experimental|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects placed in this group will given an Actigraph by Ambulatory Monitoring Activity Monitor for the one night of the study.
11336075|NCT02460341|Experimental|ondansetron-24|Single dose of 24 mg ondansetron (crossover with single dose of placebo)
11335550|NCT02463747|Active Comparator|Fixed time infusion of antibiotics|"Fixed time (half and hour) infusion of antibiotics.
~Intervention:
~Primary care would be one of three options:
~Piperacillin/tazobactam : 4.5gr, TID, I.V.
~Or
~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.
~Or
~Meropenem: 1.0gr, TID, I.V.
~Supplementation of Vancomycin will be at the discretion of the treating physician/"
11335551|NCT02463721|Other|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
11335552|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
11335553|NCT02463695|Experimental|vestibular deficit|"Initial clinical assessment including otoneurological examination, pure tone audiometry, tympanometry vestibular screening tests and Magnetic Resonance Imaging as clinically indicated.
~The cortical vestibular evoked potentials will add approximately add an extra 30 minutes to the test sequence but is minimally invasive and will not cause any pain or discomfort. It will be conducted on both the affected and non-affected ears."
11335554|NCT02463695|Active Comparator|otologically normal controll|Normative data will be collected from 36 normal ears from subjects that have no history of audiovestibular symptoms and are not being investigated for any balance disorders. The cortical vestibular evoked potentials will be recorded from both ears
11335555|NCT02463682|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 1)|The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
11335556|NCT02463682|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
11335557|NCT02463643|Experimental|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
11335558|NCT02463643|Experimental|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
11335559|NCT02463643|Experimental|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
11335560|NCT02463643|Active Comparator|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
11335561|NCT02463630|Experimental|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
11335562|NCT02463617|Other|PD patients|
11335563|NCT02463604|Experimental|Remote Ischemic Preconditioning|"A blood pressure cuff is placed on upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.
~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
11335564|NCT02463604|Sham Comparator|Control|"A blood pressure cuff is placed on upper arm and inflated to 10 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.
~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
11335565|NCT02463591|Experimental|Beriplex 50 IU/Kg|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Placebo).
11335566|NCT02463591|Placebo Comparator|Placebo|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Placebo identically in appearance to Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Beriplex).
11335567|NCT02463565||hospitalized patients|
11335568|NCT02463552|Placebo Comparator|Placebo|
11335569|NCT02463552|Experimental|Naproxen|
11335570|NCT02463526|Experimental|Group 1 - MWM condition/Sham condition|Subjects will receive treatment for 4 times with Mulligan's Mobilization with Movement (MWM) condition, and after 72 hrs, will be treated 4 times with the sham condition.
11335571|NCT02463526|Experimental|Group 2 - Sham condition/MWM condition|Subjects will receive treatment for 4 times with sham condition, and after 72 hrs, will be treated 4 times with the Mulligan's Mobilization with Movement (MWM) condition.
11335572|NCT02463513|Placebo Comparator|Treatment 1|
11335573|NCT02463513|Active Comparator|Treatment 2|
11335574|NCT02463513|Active Comparator|Treatment 3|
11335575|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
11335576|NCT02463487|Active Comparator|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
11335577|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
11335578|NCT02463474|Experimental|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
11335579|NCT02463461|Experimental|ActiSleep Activity Monitor|Subjects placed in this group will given an ActiSleep Activity Monitor for the one night of the study.
11335580|NCT02463461|Experimental|Jawbone Activity Monitor|Subjects placed in this group will given a Jawbone Activity Monitor for the one night of the study.
11335581|NCT02463461|Experimental|Actiwatch 2 Activity Monitor|Subjects placed in this group will given an Actiwatch 2 Activity Monitor for the one night of the study.
11335582|NCT02463461|Experimental|FitBit Activity Monitor|Subjects placed in this group will given a FitBit Activity Monitor for the one night of the study.
11336114|NCT02460068|Active Comparator|fotemustine|fotemustine alone
11335584|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
11335585|NCT02463435|Active Comparator|Nutritional intervention|Patients under only nutritional intervention for weight loss
11335586|NCT02463435|Experimental|Nutritional intervention plus olive oil|Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
11335587|NCT02463435|Experimental|Olive oil|Patient under habitual food consumption plus extra virgin olive oil supplementation
11335588|NCT02463422||San Diego, CA|Toddlers detected with ASD and other disorders based on the Get SET Early Model in San Diego.
11335589|NCT02463422||Phoenix, AZ|Toddlers detected with ASD and other disorders based on the Get SET Early Model in Phoenix.
11335590|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
11335591|NCT02463396|Experimental|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
11335592|NCT02463396|No Intervention|Treatment as usual (TAU)|Usually medication & psycho-education
11335593|NCT02463383|Experimental|Sequence 1|"Ibuprofen Tab 400MG
~Placebo Tab"
11335594|NCT02463383|Experimental|Sequence 2|"Placebo tab
~Ibuprofen Tab 400MG"
11335595|NCT02463370|Experimental|Group II|Group II patients will receive local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas and the remaining injections are placebo (saline).
11335596|NCT02463370|Experimental|Group V|Group V patients will receive local anesthesia in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum. The remaining maxillary injection is placebo.
11335597|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
11335598|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
11335599|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
11335600|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
11335601|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
11335602|NCT02463344||MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE
~Cohort 1 50,000 cells
~Cohort 2 100,000 cells
~Cohort 2a Better Vision 100,000 cells
~Cohort 3 150,000 cells
~Cohort 4 200,000 cells"
11335603|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
11335604|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
11335605|NCT02463318|Experimental|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
11335606|NCT02463318|Experimental|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
11335607|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
11335608|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
11335609|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
11335610|NCT02463292||patient group|The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
11335611|NCT02463292||peer control group|The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.
11335612|NCT02463279|Experimental|SinuSys Dilation System|Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
11335613|NCT02463266||SUSTAIN Monitoring and Care Management|SUSTAIN program participants who complete an initial clinical assessment and, if indicated, agree to follow-up services including Monitoring and/or Care Management.
11335614|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.
~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
11335615|NCT02463227|Experimental|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
11335616|NCT02463214|No Intervention|Standard Room|Standard bone marrow transplant recovery, single occupancy, room
11335617|NCT02463214|Experimental|Engineered Room|Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.
11335618|NCT02463201||Obese children and adolescents|Attending a weightloss programme, that consist of lifestyle counseling, dietary restriction and exercise. The prevalence of obstructive sleep apnea (OSA) will be investigated in group. Children diagnosed with OSA will be followed to investigate if weight loss changes the condition.
11335914|NCT02461342||Dr.Tang's research group|Dr.Tang's research group for genetic, environment and its interaction analysis of human complex disease
11335619|NCT02463188|Experimental|Sleep Fitness Intervention|The intervention consists of 5-7 sessions on sleep science, the connection between sleep and substance use, behavior change strategies, and motivation to change behavior.
11335620|NCT02463188|No Intervention|Psychoeducation (PE)|The control classes will receive an 1-session psycho-educational (PE) intervention that provides information on sleep but does not provide guidance for implementing behavior change and does not explicitly teach about sleep's relationship to substance use.
11335621|NCT02463175|Experimental|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
11335622|NCT02463175|Experimental|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
11335623|NCT02463162|No Intervention|Control|"This group will receive usual care which is to receive no intervention."
11335624|NCT02463162|Experimental|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
11335625|NCT02463149|Experimental|Youth Chef Academy|Receives intervention
11335626|NCT02463149|No Intervention|Control|Usual classroom curriculum
11335627|NCT02463136|Experimental|Behaviour and brain training|fMRI-based neurofeedback
11335628|NCT02463110|Experimental|1: Sertraline|ACS, depression
11335629|NCT02463110|Placebo Comparator|2: Placebo|ACS, depression
11335630|NCT02463110|Other|3: Control|ACS, no depression, no treatment
11335631|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
11335632|NCT02463084|Experimental|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
11335633|NCT02463084|Experimental|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
11335634|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
11335635|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
11335636|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
11335637|NCT02463058|Experimental|Research arm|"10 young and healthy civilian volunteers will participate in this study. The subjects will undergo 5 experiment days:
~Recruitment , medical examination and VO2max test.
~Acclimatization day by performing moderate exercise protocol under hot and humid climate.
~3 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:
~Protective garment in current use + NBC mask.
~The new BC protective undergarment + standard combat uniforms
~The new BC protective undergarment + standard combat uniforms + NBC mask"
11335638|NCT02463045|Experimental|TOP1288 1mg (or placebo)|TOP1288 1mg single dose or placebo
11335639|NCT02463045|Experimental|TOP1288 10mg (or placebo)|TOP1288 10mg single dose or placebo
11335640|NCT02463045|Experimental|TOP1288 100mg (or placebo)|TOP1288 100mg single dose or placebo
11335641|NCT02463045|Experimental|TOP1288 200mg single dose or placebo|TOP1288 200mg single dose or placebo
11335642|NCT02463045|Experimental|TOP1288 400mg dose or placebo|TOP1288 400mg (200mg bid) dose or placebo
11335643|NCT02463045|Experimental|TOP1288 A mg or placebo|TOP1288 A mg daily for 4 days
11335644|NCT02463045|Experimental|TOP1288 B mg or placebo|TOP1288 B mg daily for 4 days
11335645|NCT02463045|Experimental|TOP1288 C mg or placebo|TOP1288 C mg daily for 4 days
11335646|NCT02463045|Experimental|TOP1288 D mg or placebo|TOP1288 D mg bid for 4 days
11335647|NCT02463045|Experimental|TOP1288 Xmg or placebo|TOP1288 X mg od or bid for 4 days
11335648|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
11335649|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
11335650|NCT02463019|Other|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
11335651|NCT02463006|Experimental|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
11335652|NCT02463006|Active Comparator|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
11335653|NCT02462993|Experimental|Aloe vera group|Group recieving scaling and root planing and aloe vera gel local drug delivery
11335654|NCT02462993|No Intervention|SRP group|Group recieving only scaling and root planing
11335655|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
11335656|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
11335657|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
11335658|NCT02462954|Experimental|ContraGel|ContraGel, a personal lubricant has a Conformite Europeenne (CE) mark and has been used with barrier devices in Europe and other countries outside the US, but it is not currently approved by the US FDA.
11335659|NCT02462954|Placebo Comparator|HEC Placebo|The placebo gel is supplied by CONRAD in pre-filled individual applicators, each applicator containing 4.0 mL of HEC gel. Placebo gel contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
11335660|NCT02462941|Experimental|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
11335700|NCT02462668|Placebo Comparator|Control|"Preoxygenation with Bag-mask ventilation before fibreoptic bronchoscopy assisted intubation.
~Intervention: Bag-mask ventilation."
11392316|NCT02087410||study|patients with polycystic ovary syndrome
11335661|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
11335662|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
11335663|NCT02462928|Active Comparator|Ranibizumab 0.5 mg (rQ4)|Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
11335664|NCT02462915|Experimental|i-gel, an brand of supraglottic airway device|a supraglottic airway devices with a gastric suction channel
11335665|NCT02462915|Experimental|endotracheal tube|traditional use for protect airway during the surgery
11335666|NCT02462902|Experimental|5% albumin Infusion|(250 ml over 15 to 30 minutes)
11335667|NCT02462902|Active Comparator|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)
11335668|NCT02462889|Experimental|Intravitreal aflibercept injection|Subjects will be randomized to receive intravitreal aflibercept injection every three months for 24 months.
11335669|NCT02462889|Placebo Comparator|Placebo|Subjects will be randomized to receive sham injection every three months for 24 months.
11335670|NCT02462863|Experimental|Immunonutrient treatment|Administration of arginine and fish oil.
11335671|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
11335672|NCT02462837|Experimental|Treatment Arm|after stent placement, patient will be given Mirabegron 50 mg, PO, once daily, for 2 weeks
11335673|NCT02462837|Placebo Comparator|Placebo Arm|after stent placement, patient will be given placebo PO, once daily, for 2 weeks
11335674|NCT02462824|Experimental|Home-based exercise intervention|PAD Participants randomized to the home-based exercise intervention will be asked to take part in walking exercise to determine whether a patient-centered home-based exercise program improves walking ability, mobility, pain, and social functioning.
11335675|NCT02462824|No Intervention|Usual care group|PAD participants randomized to usual care will not receive any study interventions. Rather, they will receive usual care from their own physicians.
11335676|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
11335677|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
11335678|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
11335679|NCT02462798|Placebo Comparator|Whole grain rye bread|Whole grain rye bread, 200 g/d. Control intervention.
11335680|NCT02462798|Experimental|Whole grain sourdough rye bread|Whole grain rye bread, 200 g/d. Experimental intervention.
11335681|NCT02462785|Active Comparator|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
11335682|NCT02462785|Experimental|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
11335683|NCT02462772|Experimental|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
11335684|NCT02462772|Placebo Comparator|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
11335685|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
11335686|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
11335687|NCT02462746|No Intervention|No supplement|This group subjects will not receive the supplement
11335688|NCT02462746|Active Comparator|1.5 gram of l-cysteine|Intervention: single dose of 1.5 g L-Cysteine.
11335689|NCT02462746|Active Comparator|3 grams of l-cysteine|Intervention: single dose of 3.0 g L-Cysteine.
11335690|NCT02462733|Active Comparator|Tools of the Mind (TOM)|These 10 classrooms will be exposed to the TOM program.
11335691|NCT02462733|Active Comparator|Playing to Learn (PTL)|These 10 classrooms will be exposed to the PTL program.
11335692|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
11335693|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
11335694|NCT02462707|Experimental|PF-03084014|
11335695|NCT02462694|Active Comparator|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
11335696|NCT02462694|Experimental|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
11335697|NCT02462681|Active Comparator|bupivacaine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
11335698|NCT02462681|Active Comparator|bupivacaine + 0.5 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
11335699|NCT02462681|Active Comparator|bupivacaine + 1 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 1mg/kg ketamine paravertebrally divide into 3-4 ml in each level
11335761|NCT02462278|Experimental|TempuRing|Women will wear the continuous temperature sensor, TempuRing, for 3 menstrual cycles.
11335701|NCT02462668|Experimental|NIPPV|"The NIPPV group preoxygenation with noninvasive positive pressure ventilation(NIPPV), And then receives fibreoptic bronchoscopy intubation through a face mask (there is a small hole allow to insert the tracheal tube through the mask into trachea) during NIPPV.
~Intervention: noninvasive positive pressure ventilation(NIPPV)"
11335702|NCT02462655|Experimental|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
11335703|NCT02462655|Experimental|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
11335704|NCT02462642|Experimental|Brahmi - 36 subjects|36 subjects both male and female will consume 2 capsules of Brahmi for 84 days.
11335705|NCT02462642|Placebo Comparator|Placebo- 36 subjects|36 subjects male and female who will take 2 capsules of placebo every day
11335706|NCT02462642|Experimental|Brahmi - 8 Subjects|For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
11335707|NCT02462642|Placebo Comparator|Placebo- 4 subjects|4 male subjects in PK part will be in the placebo arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
11335708|NCT02462629|Experimental|BLZ-100|
11335709|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
11335710|NCT02462603|Experimental|EPI-589 500 milligrams (mg) twice daily (bid)|All enrolled participants will receive treatment with EPI-589
11335711|NCT02462590|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
11335712|NCT02462590|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population [Morrow 2010]. This has also been used successfully in the PROSPECT Pilot Trial.
11335713|NCT02462577|Active Comparator|local instillation of morphine 5 mg|5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
11335714|NCT02462577|Active Comparator|local instillation of morphine 10 mg|5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
11335715|NCT02462577|Active Comparator|local instillation of morphine 15 mg|5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
11335716|NCT02462577|Placebo Comparator|local instillation of local anesthetics|5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
11335717|NCT02462564||postoperative cognitive dysfunction|Z score>1.96
11335718|NCT02462564||non-postoperative cognitive dysfunction|Z score<1.96
11335719|NCT02462551|Experimental|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
11335720|NCT02462538|Experimental|Brentuximab vedotin and Imatinib|Brentuximab vedotin (every 3 weeks i.v., 1.8 mg/kg) and imatinib (200mg daily orally, escalated from 100mg daily) for up to 48 weeks
11335721|NCT02462525|Experimental|ABBV-838 dose escalation|Varying doses of ABBV-838
11335722|NCT02462525|Experimental|ABBV-838 plus pomalidomide/dexamethasone|ABBV-838 to be evaluated with pomalidomide/dexamethasone.
11335723|NCT02462512||FNAB of Thyroid nodule|The Patients with thyroid nodule who are scheduled for FNAB
11335724|NCT02462499|Experimental|Treatment|Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
11335725|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
11335726|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
11335727|NCT02462486|Active Comparator|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
11335728|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
11335729|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
11335822|NCT02461901||Fidaxomicin treatment|Patients being treat with fidaxomicin (on the decision of their treating physician)
11392317|NCT02087410||control|healthy patients serves as control group
11335730|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
11335731|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
11335732|NCT02462447||Prostate Cancer|Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.
11335733|NCT02462447||Healthy Volunteer|Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.
11335734|NCT02462434|Experimental|Early palliative care team consultation|Early pediatric palliative care team consultation for single ventricle patients will occur in this group following birth but prior to the first stage palliative surgery.
11335735|NCT02462434|No Intervention|Usual care|Usual care for single ventricle patients will be provided with palliative care team consultation occurring at any point (if it is determined the child and family would benefit from palliative care consultation) during the child's neonatal hospital stay.
11335736|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
11335737|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
11335738|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
11335739|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
11335740|NCT02462408|Experimental|Posterior approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
11335741|NCT02462408|Active Comparator|Conventional approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
11335742|NCT02462395|Experimental|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
11335743|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
11335744|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
11335745|NCT02462382|Other|Rotator cuff repair|During arthroscopic rotator cuff repair procedure, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament. It is after this procedure that pain control will be assessed.
11335746|NCT02462369|Experimental|Saxagliptin|Saxagliptin 5mg/d, 52 weeks
11335747|NCT02462369|Active Comparator|glimepiride|glimepiride 1~4mg/d,52 weeks
11335748|NCT02462356|Active Comparator|Conventional VATS|Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
11335749|NCT02462356|Experimental|Uniportal VATS|Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
11335750|NCT02462343|Other|2 minute walk test|
11335751|NCT02462343|Other|6 minute walk test|
11335752|NCT02462330|Placebo Comparator|Placebo comparator|injection of human albumin 4%
11335753|NCT02462330|Experimental|Autologous MSC from bone marrow|intramyocardial injection of 6.10e7 stem cells
11335754|NCT02462317|Active Comparator|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
11335755|NCT02462317|Active Comparator|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
11335756|NCT02462317|Placebo Comparator|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
11335757|NCT02462304|Experimental|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
11335758|NCT02462304|Active Comparator|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
11335759|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
11335760|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
11335762|NCT02462265|Experimental|'Oshadi D & Oshadi R; salvage therapy'|Oshadi D (180mg/tid) & Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
11335763|NCT02462252|Experimental|BL-8040 plus hATG, methylprednisolone, cyclosporine|"BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.
~Standard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.
~Standard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.
~Standard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)"
11335764|NCT02462239|Experimental|Whole-body FDG PET-CT|Whole-body FDG PET-CT (Experimental arm)
11335765|NCT02462239|No Intervention|No PET-CT|No PET-CT (Control arm)
11335766|NCT02462226|Active Comparator|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.
~Patients will be given access to the website to learn about the arm precaution program."
11335767|NCT02462226|Experimental|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.
~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
11335768|NCT02462213||Amyloidosis|Patients being managed for amyloidosis without prior history of cardiac involvement
11335769|NCT02462213||Cardiac amyloidosis|Patients being managed for cardiac amyloidosis
11335770|NCT02462200|Active Comparator|BCS Arm (breast-conserving surgery - standard of care)|"Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization
~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).
~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken."
11335771|NCT02462200|Experimental|CSM Arm (breast-conserving surgery with cavity shave margins)|"Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained
~A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation
~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).
~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken."
11335772|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
11335773|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
11335774|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
11335775|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
11335776|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
11335777|NCT02462174|Active Comparator|Topical ketamine and topical bupivacaine|0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.
11335778|NCT02462174|Active Comparator|Caudal ketamine and caudal bupivacaine|0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.
11335779|NCT02462161|Experimental|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
11335780|NCT02462161|Placebo Comparator|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
11335781|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
11335782|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
11335783|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
11335784|NCT02462135|Experimental|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
11335785|NCT02462135|Active Comparator|Passive information activities|The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
11335786|NCT02462122|Experimental|IDP-118 Lotion|Lotion
11335787|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
11335788|NCT02462109|Experimental|Lorazepam|"Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative."
11335789|NCT02462096|Experimental|Treatment|Subject to undergo the ReLeaf study procedure.
11335790|NCT02462083|Experimental|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
11335791|NCT02462070|Experimental|IDP-118 Lotion|Lotion
11335792|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
11335793|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
11335794|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
11335795|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
11335796|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
11335797|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:
~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths
~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
11335798|NCT02462044|Experimental|240|Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s
11335799|NCT02462044|Experimental|300|Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s
11335800|NCT02462044|Experimental|370|Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s
11335801|NCT02462031|Experimental|KD101|
11335802|NCT02462031|Placebo Comparator|KD101 placebo|
11335803|NCT02462018|Experimental|WalkAide|
11335804|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
11335805|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
11335806|NCT02461979|Other|Hepatocellular carcinoma (HCC)|The VDR genotype in 20 HCV cirrhotic patient with HCC
11335807|NCT02461979|Other|Liver cirrhosis|The VDR genotype in 20 HCV cirrhotic patient without HCC
11335808|NCT02461979|Other|Control group|The The VDR genotype in 10 healthy individuals as control
11335809|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
11335810|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
11335811|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
11335812|NCT02461953|Experimental|low flux hemodialysis|low flux hemodialysis alone, 3 times a week, 4 hours per session
11335813|NCT02461953|Experimental|high flux hemodialysis|high flux hemodialysis alone, 3 times a week, 4 hours per session
11335814|NCT02461953|Experimental|low flux hemodialysis + hemoperfusion|low flux hemodialysis 2times a week and the HD+HP once a week
11335815|NCT02461953|Experimental|high flux hemodialysis + hemoperfusion|high flux hemodialysis 2times a week and the HD+HP once a week
11335816|NCT02461940|No Intervention|Standard care|The control group will receive the standard care provided by the STI clinic.
11335817|NCT02461940|Active Comparator|Adolescent Behavioral intervention|Participants allocated to the intervention arm receive 4 on-site personalised counselling and 2 phone/online sessions over a 12-month period, targeting individual, relational, sociocultural and environmental factors pertaining to the acquisition of STI/HIV.
11335818|NCT02461927|Experimental|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
11335819|NCT02461927|Experimental|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
11335820|NCT02461927|Placebo Comparator|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
11335821|NCT02461914|Experimental|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
11392318|NCT02087397|Experimental|AD-SVF Cell Injection|
11335824|NCT02461888|Experimental|Ixazomib, CD|"Ixazomib, cyclophosphamide and dexamethasone (ICD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Ixazomib 4mg orally on days 1, 8 and 15
~Cyclophosphamide 500mg orally on days 1, 8 and 15
~Dexamethasone 40mg orally on days 1-4 and 12-15"
11335825|NCT02461888|Active Comparator|CD|"Cyclophosphamide and dexamethasone (CD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Cyclophosphamide 500mg orally on days 1, 8 and 15
~Dexamethasone 40mg orally on days 1-4 and 12-15"
11335826|NCT02461875|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
11335827|NCT02461875|Experimental|GnRH antagonist rescue & cabergoline group|Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.
11335828|NCT02461862||Intra Uternine Device|Women who came to the medical service, to insert an intra uterine Device (IUD) of Cu or a Levonorgestrel Intra Uterine System( Lng- IUS) after have been attended in the Family Planning Service of Federal University of São Paulo . All patient have had the pain evaluated by Application of the Visual Analog Scale of Pain (VAS), and also their vital signs ( Evaluation of blood pressure,Evaluation of radial pulse) evaluated pre and five minutes after the IUD/ IUS insertion.
11335829|NCT02461849|Experimental|Imatinib|Imatinib 400mg qd daily Until disease progression, patient's refusal
11335830|NCT02461836|Experimental|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
11335831|NCT02461836|Experimental|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
11335832|NCT02461823|Experimental|Z Crown|A Zirconia crown will be provided to patients.
11335833|NCT02461823|Active Comparator|PFM Crown|A Porcelain metal crown will provided to patients.
11335834|NCT02461810|Experimental|SpineJack® system|VCF treatment system Vertebral fracture surgery
11335835|NCT02461810|Active Comparator|Balloon Kyphoplasty|VCF treatment system Vertebral fracture surgery
11335836|NCT02461797|Other|healthy controls|biopsy of nasal mucosa healthy controls
11335837|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray
11335838|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control
11335839|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
11335840|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
11335841|NCT02461771|Experimental|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
11335842|NCT02461771|Experimental|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
11335843|NCT02461771|Experimental|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
11335844|NCT02461758|Other|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
11335845|NCT02461758|Other|Vedolizumab Group + standard dose influenza vaccine (SDIV)|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
11335846|NCT02461758|Other|High dose influenza vaccine (HDIV)|"This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
11335847|NCT02461758|Other|Standard dose influenza vaccine (SDIV)|"This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
11335848|NCT02461745|Active Comparator|Genotype 1a|ombitasvir, paritaprevir/r, dasabuvir + ribavirin
11335849|NCT02461745|Active Comparator|Genotype 1b|ombitasvir, paritaprevir/r, dasabuvir
11335850|NCT02461732|Active Comparator|CBT for Substance Dependence|Standard CBT for substance use disorders
11335851|NCT02461732|Experimental|Integrated CBT for PTSD and Substance Dependence|Integrated CBT for PTSD and substance use disorders, combining elements of cognitive processing therapy for PTSD with coping skills and relapse prevention for substance use disorders
11335852|NCT02461719|Experimental|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes
11335853|NCT02461719|Active Comparator|Restasis eye drop|Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes
11335854|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
11335855|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
11335856|NCT02461680|Experimental|Tangential resection|the tendon's injury is treated with a tangential resection
11335857|NCT02461680|Active Comparator|Suture|The tendon's injury is sutured
11335858|NCT02461667|Placebo Comparator|placebo|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
11335859|NCT02461667|Active Comparator|Metformin|SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally
11335860|NCT02461667|Active Comparator|Alendronate|SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
11335861|NCT02461641|Other|Standard of Care|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe.
11335862|NCT02461641|Experimental|NuShield|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.
11336115|NCT02460068|Experimental|fotemustine and ipilimumab|fotemustine in combination with ipilimumab
11335863|NCT02461641|Experimental|Affinity|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a fresh hypothermically stored amniotic membrane, Affinity, for up to 4 weeks.
11335864|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
11335865|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
11335866|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
11335867|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
11335868|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
11335869|NCT02461589|Placebo Comparator|Placebo 50 µL|
11335870|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
11335871|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
11335872|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
11335873|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
11335874|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
11335875|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
11335876|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
11335877|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
11335878|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
11335879|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
11335880|NCT02461576||HIV-1 infected|this is a study comparing Xpert HIV-1 VL assay quantitation to an already FDA approved HIV-1 quantitative HIV-1 RNA assay in known HIV-1 infected individuals
11335881|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
11335882|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
11335883|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
11335884|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
11335885|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
11335886|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
11335887|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
11335888|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
11335889|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
11335890|NCT02461524|Other|Endovasculair repair|Endurant Evo AAA Stent graft system
11335891|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
11335892|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
11335893|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
11335894|NCT02461485|Experimental|1=BOW_01|1= Fermented Milk Product containing Probiotics
11335895|NCT02461485|Experimental|2=BOW_01 + fiber C|2= Fermented Milk Product containing Probiotics + Fibers C
11335896|NCT02461485|Experimental|3 =BOW_01 + fiber W|3= Fermented Milk Product containing Probiotics + Fibers W
11335897|NCT02461485|Placebo Comparator|4 = Control|4= Non fermented Milk Product with same color, texture and organoleptic properties as investigational products 1 to 3.
11335898|NCT02461472||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
11335899|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
11335900|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
11335901|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
11335902|NCT02461446||PTEN Macrocephaly|PTEN participants with Macrocephaly group
11335903|NCT02461446||Controls|Healthy control group
11335904|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
11335905|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
11335906|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
11335907|NCT02461407|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11335908|NCT02461407|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11335909|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
11335910|NCT02461368|Experimental|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
11335911|NCT02461368|Active Comparator|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
11392319|NCT02087384|Experimental|Gardasil|Gardasil
11335915|NCT02461329|Experimental|Gelatine solution|"Gelofusine will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).
~The blood pressure and heart rate before and after fluid challenge will be recorded."
11335916|NCT02461329|Experimental|Balanced Crystaloid solution|"Ringerfundin will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).
~The blood pressure and heart rate before and after fluid challenge will be recorded."
11335917|NCT02461316||Combination Treatment in Chronic Lymphocytic Leukemia (CLL)|All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
11335918|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
11335919|NCT02461277|Active Comparator|Fast-track protocol|Before surgery, patients are informed about the surgical procedure, anesthesia and rehabilitation protocol. The surgery occurs in accordance with the principles of the Fast-track: minimal invasive surgery, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization.
11335920|NCT02461277|No Intervention|Conventional care|Usual care routine postoperative
11335921|NCT02461264|Active Comparator|ARM A|Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, two new packed red blood cells are transfused and so on.
11335922|NCT02461264|Experimental|ARM B|Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, a single unit is transfused and so on.
11335923|NCT02461251|Experimental|Rotational thromboelastometry (ROTEM)|"Rotational thromboelastometry results are used to guide the treatment of major obstetric hemorrhage, eg. administration of prothrombin complex concentrate, fresh-frozen plasma, fibrinogen concentrate or platelets. In case of massive hemorrhage, shock packs of blood products in 1:1:1 ratio are administered."
11335924|NCT02461251|No Intervention|Standard care|"Patients are treated according to clinical decision making and conventional coagulation tests, and in case of massive hemorrhage, shock packs are administered."
11335925|NCT02461238|Active Comparator|Vouchers|Families included in the Voucher arm will receive vouchers for fruits and vegetables by mail every month for a period of 1 year coupled to nutritional education from a dietician
11335926|NCT02461238|Other|Control|Families included in the control arm will only receive nutritional education
11335927|NCT02461225|Active Comparator|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
11335928|NCT02461225|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.
11335929|NCT02461225|Active Comparator|Erchonia® FX-635™ Placebo Cross-over|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
11335930|NCT02461212|Experimental|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
11335931|NCT02461212|Experimental|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
11335932|NCT02461199||Fecal microbiota transplantation|Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.
11335933|NCT02461186|Experimental|Arterolane maleate-piperaquine phosphate (Synriam)|
11335934|NCT02461186|Experimental|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
11335935|NCT02461173|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
11335936|NCT02461173|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
11335937|NCT02461173|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
11335938|NCT02461160|Placebo Comparator|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
11335939|NCT02461160|Experimental|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
11335940|NCT02461160|Experimental|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
11335941|NCT02461160|Experimental|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
11335942|NCT02461160|Placebo Comparator|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
11335943|NCT02461160|Experimental|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
11335944|NCT02461160|Experimental|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
11335945|NCT02461160|Experimental|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
11335946|NCT02461160|Experimental|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
11335947|NCT02461160|Experimental|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
11335948|NCT02461160|Experimental|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
11335949|NCT02461160|Experimental|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
11335950|NCT02461160|Experimental|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
11335951|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
11335952|NCT02461134|Experimental|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
11335953|NCT02461121|Experimental|MST（microtransplantation）|The microtransplantation conditioning regimen included high-dose Ara-C chemotherapy (2.0 to 2.5 g/m2 per 12 hours intravenously on days -4 to -2) followed by an infusion of HLA mismatched stem cell 24 hours (day 0) after the completion of cytarabine.
11335954|NCT02461121|Active Comparator|NST（nonmyeloablative transplantation）|The NST（nonmyeloablative transplantation）conditioning regimen consisted of 30 mg/m2/d fludarabine for days -6 to -2, 1.5-2 mg/kg/d anti-lymphocyte globulin for days -5 to -2, 40 mg/kg/d cyclophosphamide for days -4 and -2 and 2.0-3.0 g/m2/d cytarabine for days -6 to -4，followed by an infusion of HLA matched stem cell after the completion of regimen. The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
11335955|NCT02461108|Experimental|Price difference|Introduce a 10% price difference between foods labeled as nutritious and foods labeled as less nutritious and frame the price difference as either a Subsidy, Tax, or combination of a Tax and Subsidy.
11335956|NCT02461108|No Intervention|No price difference|No price difference between nutritious and less nutritious foods.
11335957|NCT02461095|Active Comparator|Impairment based approach|The intervention will address the patients impairments found during evaluation. Treatment will based on the Physical therapist evaluation and will be individualized to each patient.
11335958|NCT02461095|Experimental|PFPS algorithm|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
11335959|NCT02461082|Other|EMST and sham-TMS|Active expiratory muscle strength training in combination with sham transcranial magnetic stimulation
11335960|NCT02461082|Other|sham-EMST and TMS|Sham expiratory muscle strength training in combination with active transcranial magnetic stimulation
11335961|NCT02461082|Other|EMST and TMS|Active expiratory muscle strength training in combination with active transcranial magnetic stimulation
11335962|NCT02461082|Other|sham-EMST and sham-TMS|Sham expiratory muscle strength training in combination with sham transcranial magnetic stimulation
11335963|NCT02461069|Active Comparator|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
11335964|NCT02461069|No Intervention|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
11335965|NCT02461056|Active Comparator|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
11335966|NCT02461056|Active Comparator|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
11335967|NCT02461056|Active Comparator|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
11335968|NCT02461043|Experimental|Arm A|chemotherapy and radiotherapy
11335969|NCT02461043|Active Comparator|Arm B|radiotherapy
11335970|NCT02461030|Experimental|CSPR + NS treatment|"In-office and at home Colgate sensitive pro-relief - CSPR
~Intervention: Non-surgical periodontal treatment (full-mouth debridement, scaling and root planing with ultrasonic/hand instruments) associated with In-office application of Colgate Sensitive Pro-Relief (CSPR) + tooth brushing with at home CSPR toothpaste during 8 weeks."
11336069|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
11394878|NCT02070354||Group 3|6 months after bariatric surgery
11335971|NCT02461030|Placebo Comparator|Villevie® + NS treatment|"In-office Villevie® prophy paste + Colgate Toothpaste
~Treatment: In-office application of a Villevie® (fluoride-free) prophy paste + tooth brushing with a Colgate Cavity Protection Toothpaste during 8 weeks, after non-surgical periodontal treatment. (Full-mouth debridment/ Scaling and root planing with ultrasonic/hand instruments)"
11335972|NCT02461017||Endotracheal Leak|Assess for Audible Endotracheal Leak; Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
11335973|NCT02461004|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
11335974|NCT02461004|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
11335975|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
11335976|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
11335977|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
11335978|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
11335979|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
11335980|NCT02460965||Patients with schizophrenia|
11335981|NCT02460965||Patients with borderline personality disorder|
11335982|NCT02460965||Patients with hearing impairment|
11335983|NCT02460965||Patients with visual loss|
11335984|NCT02460965||Patients with Parkinson's Disease|
11335985|NCT02460965||Patients with Alzheimer's Disease|
11335986|NCT02460965||Patients with dementia with Lewy Bodies|
11335987|NCT02460965||Healthy participants|
11335988|NCT02460926|Experimental|Scaling & Root Planing - Quadrant|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. Q-SRP patients received four quadrants sessions of PT with an interval of 1 week between sessions
11335989|NCT02460926|Experimental|Scaling & Root Planing - Full Mouth|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. FM-SRP patients received treatment within 24 hrs in two separate sessions, one side of the mouth for each session: two quadrants were instrumented in an afternoon session, whereas the other two were instrumented the following morning
11335990|NCT02460913|Experimental|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
11335991|NCT02460913|Active Comparator|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
11335992|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
11335993|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will receive placebo and standard of care
11335994|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
11335995|NCT02460900|Active Comparator|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
11335996|NCT02460887|Experimental|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
11335997|NCT02460887|Active Comparator|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
11335998|NCT02460874|Experimental|Pilot Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS. Treatment planning MRI may be done within 21 days prior to SRS treatment.
~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day).
~Step 3: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring.
~Step 4: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI.
~Step 5: 3 months after SRS, undergo MRI."
11335999|NCT02460874|Placebo Comparator|Randomized Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS.Treatment planning MRI may be done within 21 days prior to SRS treatment.
~Step 2: Randomization (1:1)
~Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.
~Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.
~Step 3: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring.
~Step 4: 1 month after SRS, discontinue investigation medication, undergo MRI.
~Step 5: 3 months after SRS, undergo MRI."
11336000|NCT02460861|Active Comparator|PCA Magdeburg|Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg
11336001|NCT02460861|Active Comparator|Non-prostate cancer Magdeburg/Gronau|Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau
11336002|NCT02460861|Active Comparator|PCA Gronau|Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa
11336003|NCT02460848|Experimental|Outpatient therapeutic program, counseling and cash transfer|Ten outpatient therapeutic program sites (OTP) will be randomly allocated to unconditional cash transfer for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
11336070|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
11336004|NCT02460848|Active Comparator|Outpatient therapeutic program and counseling|Ten outpatient therapeutic program sites (OTP) will be randomly allocated for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
11336005|NCT02460835|Experimental|Adaptive Radiation Therapy|
11336006|NCT02460822|Experimental|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
11336007|NCT02460809|Active Comparator|In-lab tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in a controlled laboratory environment with an investigator.
11336008|NCT02460809|Experimental|In-home tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in their own home. Patients will be taught how to use a blue-tooth enabled telerehabilitation module that is being controlled by an investigator in the lab on the University campus. For safety, an investigator will be in the home with each patient during tDCS use and finger tracking training but will only be supervising procedures.
11336009|NCT02460796||hippotherapy group or study group|8 weeks of hippotherapy therapy: Familiarization sessions were initially 15 minutes and gradually evolved to 30 minutes in order to allow all participants to adapt to the horse's rhythmic movements and to the act of mounting the horse. Each session had warm up before the training and exercises for relaxation in the end of each session.
11336010|NCT02460796||control group|8 weeks of Parkinson's disease lectures: this group did not hippotherapy classes in the same period.
11336011|NCT02460783|Experimental|5-2 CR|Healthy living diet for 5 days/week; Calorie Restriction(530 Kcal in the form of a shake) for 2 days/week
11336012|NCT02460783|Active Comparator|Healthy Living|Healthy living diet for 7 days/week
11336013|NCT02460770|Experimental|autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery
11336014|NCT02460757||Patients with COPD|
11336015|NCT02460757||Patients with interstitial lung disease|
11336016|NCT02460757||Healthy subjects|
11336017|NCT02460744|Experimental|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
11336018|NCT02460731|Experimental|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors]
11336019|NCT02460718|No Intervention|control group|Participants received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight.
11336020|NCT02460718|Experimental|Encourage study|"Participants in the intervention arm were paired with a peer coach, interacting by telephone weekly for the first 8 weeks and then monthly for a total of 10 months.
~Participants also received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight."
11336021|NCT02460705|Experimental|IBD patients receiving FMT|IBD patients receiving biologically active human fecal material sourced from OpenBiome. The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL, through the endoscope. The material will be delivered to the most proximal point of insertion.
11336022|NCT02460692|Placebo Comparator|Placebos|The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
11336023|NCT02460692|Active Comparator|Dronabinol|A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
11336024|NCT02460692|Experimental|Vaporized Cannabis 3.7% THC/5.6% CBD|The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
11336025|NCT02460679|Experimental|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
11336026|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
11336027|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
11336028|NCT02460653|No Intervention|Current|Current level of HFNC support
11336029|NCT02460653|Experimental|Low|Low flow range per kg.
11336030|NCT02460653|Experimental|Medium|Medium flow range per kg.
11336031|NCT02460653|Experimental|High|High flow range per kg
11336032|NCT02460640|Active Comparator|Tap Block|the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
11336033|NCT02460640|Active Comparator|No Tap Block|the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia
11336034|NCT02460627|Experimental|Lidocaine adhesive tape|
11336035|NCT02460627|Placebo Comparator|Adhesive tape|
11336071|NCT02460367|Experimental|Phase 1: Dose Escalation|Up to 18 participants will be enrolled and treated at escalating doses of Indoximod with a fixed dose of tergenpumatucel-L and docetaxel. Treatment may continue until definitive disease progression or significant toxicology.
11336072|NCT02460354|Experimental|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
11336036|NCT02460614|Experimental|Rhinopharyngeal clearance + 0.9% saline|The retrograde rhinopharyngeal clearance (RRC) is based on the inspiratory reflex that follows a slow and prolonged expiration (passive exhalation technique performed using a slow thoracic-abdominal compression that begins at the end of a spontaneous exhalation and continues until the expiratory reserve volume). At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver. The instillation of saline (0.9%) preceded this step, resulting in the inhalation of the substance during the forced inspiration, contributing to the nasopharyngeal clearance.
11336037|NCT02460614|Active Comparator|Aspiration + 0.9% saline|Nasopharyngeal aspiration consisted in the introduction of a catheter that, by using negative pressure (vacuum), promotes the suction of secretion from the airways. In order to do that, a sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient. The saline instillation of 0.9% was used for humidification before the procedure.
11336038|NCT02460601|Experimental|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
11336039|NCT02460601|Placebo Comparator|Placebo|2.5g/time,tid,oral administration,6 weeks
11336040|NCT02460588|Placebo Comparator|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
~All patients will receive non experimental medication with high dose of corticosteroid."
11336041|NCT02460588|Experimental|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
~All patients will receive non experimental medication with high dose of corticosteroid.
~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
11336042|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
11336043|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
11336044|NCT02460562|Active Comparator|PMMA resin|A denture base will be made with PMMA resin as a standard material.
11336045|NCT02460562|Experimental|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin & S-PRG filler for subject to wear.
11336046|NCT02460549|Experimental|therapeutic education program|patients attend three sessions of therapeutic education
11336047|NCT02460536|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
11336048|NCT02460536|Active Comparator|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
11336049|NCT02460536|Active Comparator|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
11336050|NCT02460536|Placebo Comparator|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
11336051|NCT02460523|Active Comparator|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
~Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.
~No improvement: the patient will undergo ERCP and then LC."
11336052|NCT02460523|Active Comparator|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.
~b- No improvement: the patient will undergo ERCP and then LC."
11336053|NCT02460510|Experimental|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity >320mm
11336054|NCT02460510|Active Comparator|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of <160 mmol/L.
11336055|NCT02460497|Experimental|Treatment|
11336056|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
11336057|NCT02460471|Experimental|palliative radiation therapy|25 Gy in 5 daily fractions
11336058|NCT02460458||Type 3 VWD|Diagnosis of Type 3 von Willebrand Disease
11336059|NCT02460445|Experimental|Intervention|Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.
11336060|NCT02460445|Active Comparator|Control|Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.
11336061|NCT02460432|Experimental|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
11336062|NCT02460432|Active Comparator|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
11336063|NCT02460419|Experimental|maintenance capecitabine|maintenance capecitabine plus best supportive care(BSC)
11336064|NCT02460419|Other|best supportive care|Best supportive care and following-up every 6-8 weeks
11336065|NCT02460406|Other|control group|traditional physiotherapy (stretching, normal range of movement, walking)
11336066|NCT02460406|Active Comparator|intervention group|progressive functional strength training protocol on lower extremities consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises.
11336067|NCT02460393|Placebo Comparator|Placebo group|The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
11336068|NCT02460393|Experimental|experimental group|The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
11336116|NCT02460068|Experimental|ipilimumab and nivolumab|ipilimumab in combination with nivolumab
11336076|NCT02460315|Active Comparator|early cholecystectomy|group (A) will be managed by early laparoscopic cholecystectomy after clearness ERCP
11336077|NCT02460315|Active Comparator|late cholecystectomy|group (B) will be managed by late LC one month after ERCP.
11336078|NCT02460302|Experimental|Vaginal Progesterone|"In the experimental arm, the participants will be randomized (1:1 allocation) to receive a vaginal progesterone suppository (100mg) as the intervention.
~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the drug three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
11336079|NCT02460302|Placebo Comparator|Placebo Comparator|"In the placebo arm, the participants will be randomized (1:1 allocation) to receive a vaginal suppository (100mg) containing hard fat without any active hormonal ingredient as the intervention.
~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the placebo three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
11336080|NCT02460289|Experimental|Treatment|
11336081|NCT02460276|Experimental|Lenalidomide, ibrutinib and rituximab.|
11336082|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
11336083|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
11336084|NCT02460250|Experimental|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
11336085|NCT02460237|Experimental|Arm I (intervention)|Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
11336086|NCT02460237|Active Comparator|Arm II (control)|Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
11336087|NCT02460224|Experimental|Arm A|Single agent treatment arm with LAG525
11336088|NCT02460224|Experimental|Arm B: combination of LAG525 and PDR001|Combination treatment arm with LAG525 and PDR001
11336089|NCT02460224|Experimental|Arm C|Single agent treatment arm with LAG525 in Japanese pts
11336090|NCT02460211|Active Comparator|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
11336091|NCT02460211|Placebo Comparator|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
11336092|NCT02460198|Experimental|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 4 years).
11336093|NCT02460198|Experimental|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 4 years).
11336094|NCT02460185|No Intervention|Control|Without maternal physical exercise practice
11336095|NCT02460185|Active Comparator|Study Group|Behavioral: 30 minutes of walking, 3 times a week at 4 Km/h. Induction of labor was performed at 41 weeks.
11336096|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
11336097|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
11336098|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
11336099|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
11336100|NCT02460146|Active Comparator|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
11336101|NCT02460146|Placebo Comparator|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
11336102|NCT02460133|Other|HCV Genotype 1, with and without cirrhosis|
11336103|NCT02460120|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
11336104|NCT02460107|Placebo Comparator|Normal saline|Normal saline
11336105|NCT02460107|Active Comparator|Botulinum toxin type A 50U|Botulinum toxin 50U
11336106|NCT02460107|Active Comparator|Botulinum toxin type A 100U|Botulinum toxin 100U
11336107|NCT02460094|Experimental|Panel 1: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
11336108|NCT02460094|Experimental|Panel 2: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
11336109|NCT02460094|Experimental|Panel 3: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
11336110|NCT02460094|Experimental|Panel 4: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
11336111|NCT02460081|Experimental|PDA-002 -3x10^6 cells|Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.
11336112|NCT02460081|Experimental|PDA-002 - 30X10^6 cells|Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.
11336113|NCT02460081|Placebo Comparator|Placebo|Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.
11336117|NCT02460055|Active Comparator|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
11336118|NCT02460055|Active Comparator|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
11336119|NCT02460016|Experimental|AK0529|AK0529 pellets
11336120|NCT02460003|Experimental|Physiotherapy program|Physiotherapy program and usual drugs
11336121|NCT02460003|Active Comparator|Home exercise program|Home exercise program and usual drugs
11336122|NCT02459977|Experimental|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
11336123|NCT02459977|Active Comparator|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
11336124|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).
~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
11336125|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
11336126|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
11336127|NCT02459938|Experimental|ZP-Glucagon 0.5 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
11336128|NCT02459938|Experimental|ZP-Glucagon 1.0 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
11336129|NCT02459938|Active Comparator|Glucagon by injection, 0.5 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
11336130|NCT02459938|Active Comparator|Glucagon by injection, 1.0 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
11336131|NCT02459925|Active Comparator|CBT- Mental Health Program|Cognitive Behavioral Therapy. Manualized Stress Management class; brief individual behavioral counseling.
11336132|NCT02459925|Active Comparator|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
11336133|NCT02459912|Other|Unilateral Nerve-Sparing Cryoablation|Unilateral Nerve-Sparing Cryoablation of the Prostate using Galil Medical Precise Cryoablation System with IceRod Needles.
11336134|NCT02459899|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
11336135|NCT02459899|Experimental|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
11336136|NCT02459899|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
11336137|NCT02459899|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
11336138|NCT02459886|Experimental|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
11336139|NCT02459886|Experimental|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
11336140|NCT02459886|Experimental|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
11336141|NCT02459886|Experimental|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
11336142|NCT02459886|Experimental|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
11336143|NCT02459886|Experimental|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
11336144|NCT02459886|Experimental|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
11336145|NCT02459873|Experimental|Computer games to assess change in executive function skills|Children in Intervention group get to train using executive function games at more difficult levels.
11336146|NCT02459873|Active Comparator|Easy games as active comparators for executive function skills|Children in Non-intervention group get to play executive function games at an easy level.
11336147|NCT02459860|Experimental|Problem Solving Treatment|Problem Solving Treatment Individual, face-to-face PST sessions over a span of 8 weeks and 3 monthly booster sessions. The PST protocol is highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies.
11336148|NCT02459860|Active Comparator|Enhanced Usual Care|Enhanced Usual Care EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
11336149|NCT02459847|Experimental|Mindfulness|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant listening to a 19-minute audio-recorded body scan (i.e., mindfulness training), followed by standard care.
11336150|NCT02459847|Experimental|Biofeedback|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant receiving 20 minutes of visual biofeedback training using sonographic imaging (i.e., sonographic biofeedback), followed by standard care.
11336151|NCT02459834|Experimental|Allulose + 75g OGTT|Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
11336152|NCT02459834|Experimental|Fructose + 75g OGTT|Fructose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
11336153|NCT02459834|Active Comparator|75g OGTT (Control)|A 75 g OGTT (alone) of 500 mL will be given to each participant. The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
11336154|NCT02459821|Experimental|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
11336155|NCT02459821|Active Comparator|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
11336156|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
11336157|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
11336158|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
11336159|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
11336160|NCT02459782|Other|US Guided Dual Quadrant Peribulbar block|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
11336161|NCT02459769|Active Comparator|Dyadic Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks). Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
11336162|NCT02459769|Other|Individual Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks). The caregiver is told not to change his/her exercise behavior in any way.
11336163|NCT02459756|Active Comparator|Intervention|Spray dried blackcurrant powder dissolved in water
11336164|NCT02459756|Placebo Comparator|Placebo|(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
11336165|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
11336166|NCT02459730|Experimental|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
11336167|NCT02459730|Active Comparator|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
11336168|NCT02459717|Experimental|Probiotics and prebiotic|fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
11336169|NCT02459717|Placebo Comparator|Placebo|pasteurized fermented milk (125 grams) without prebiotics
11336170|NCT02459704|Experimental|SCPF + EMD (TEST)|Semilunar coronally positioned flap with Enamel matrix derivative (Emdogain)
11336171|NCT02459704|Active Comparator|SCPF (CONTROL)|Semilunar coronally positioned flap alone
11336172|NCT02459691|Active Comparator|Usual Care Only|Patients assigned to this group will continue medical care as usual.
11336173|NCT02459691|Experimental|Vida Sana|Patients assigned to this group will continue medical care as usual and in addition will receive the culturally adapted intervention.
11336174|NCT02459678|Other|Standard of Care|The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.
11336175|NCT02459678|Experimental|Enhanced adherence package|The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.
11336176|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
11336177|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
11336178|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
11336179|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
11336180|NCT02459652|Experimental|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
11336181|NCT02459639||Anthroposophic integrative care|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.
~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
11336182|NCT02459639||Multimodal pain rehabilitation|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.
~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
11336183|NCT02459626||HFpEF and servere diastolic dysfuntion|Left ventricular ejection fraction (LV-EF) > 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=>2, Diagnostic P-V-loops and MRI
11336184|NCT02459626||HFpEF no servere diastolic dysfuntion|LV-EF > 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=>2, Diagnostic P-V-loops and MRI
11336185|NCT02459626||No HF or diastolic dysfunction|LV-EF > 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI
11336186|NCT02459613|Experimental|Imaging|99mTc Annexin V-128 SPECT
11336187|NCT02459600|Experimental|All participants|"The measurement will be done at all the participants. the results will the divides in the following way:
~Refraction measurements under general anesthesia without cycloplegic eye drops.
~Refraction measurements under general anesthesia with cycloplegic eye drops."
11336188|NCT02459587|Experimental|CLF|Crisis Line Facilitation
11336189|NCT02459587|No Intervention|EUC|Enhanced Usual Care
11336190|NCT02459574|Active Comparator|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
11336191|NCT02459574|Active Comparator|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
11336192|NCT02459574|Experimental|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
11336193|NCT02459561|Experimental|EndoBarrier Arm|The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
11336194|NCT02459561|Other|Medical Therapy Arm|"The standard medical therapy arm will be carried out in accordance with the guidelines of the American Diabetes Association. These guidelines have been chosen as they are applicable to an International audience and thus would adhere to the current best worldwide practice that would still be likely to be relevant when the results are published following study completion.
~Diabetes reviews appointments with a Diabetologist/Endocrinologist will be performed with the control arm patients at visits 2, 4, 6, 7, 9, 11, 12, 13 and 15.
~At study visit 4, 80 subjects will arrive at Mary's Hospital or Southampton Hospital and receive the best Medical Care and dietary advice as part of the Medical Therapy Arm Interventions."
11336195|NCT02459548|Experimental|Primary Care Group|This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
11336196|NCT02459548|Other|Sleep Unit Group|This group will be follow up in Sleep unit at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
11336197|NCT02459535|Active Comparator|Glucose only|oral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336198|NCT02459535|Active Comparator|Glucose + Saccharin|oral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336199|NCT02459535|Active Comparator|Saccharin only|oral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336200|NCT02459535|Active Comparator|Glucose + Aspartame|oral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336201|NCT02459535|Active Comparator|Aspartame only|oral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336202|NCT02459535|Active Comparator|Glucose + Sucralose|oral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336203|NCT02459535|Active Comparator|Sucralose only|oral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
11336204|NCT02459522||Dr.Tang's research group|This group included participants with completed both the short-term HRV test and Ewing's test.
11336205|NCT02459509|Active Comparator|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
11336206|NCT02459509|Active Comparator|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
11336207|NCT02459496|Active Comparator|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
11336208|NCT02459496|Active Comparator|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
11336209|NCT02459483|Experimental|Nurse phone call|a nurse will interview patients by phone every 14 +/- 2 days for 6 months
11336210|NCT02459483|No Intervention|Control Group|Common practice
11336211|NCT02459470|Experimental|SVV and PPV|"SVV(stroke volume variation): recorded using the Flotrac/Vigileo system (Edwards Lifesciences)
~PPV(pulse pressure variation): recorded using philips Intelivue MP70 monitors (Philips Medical System)
~Intervention: Other: Fluid loading using HES 130/0.4; voluven; Fresenius Kabi; Stans, Switzerland"
11336212|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
11336213|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
11336214|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
11336215|NCT02459444|Experimental|IMT group and physiotherapy|Inspiratory muscle training with POWERBREATHE an approximate load of 50 % of MIP , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
11336216|NCT02459444|Placebo Comparator|Sham IMT group|Inspiratory muscle training with the same device in the experimental group , however without charge , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
11336217|NCT02459431|Active Comparator|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
11336218|NCT02459431|Active Comparator|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
11336219|NCT02459418|Experimental|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
11336220|NCT02459418|Active Comparator|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
11336221|NCT02459405|Experimental|NIR anastomotic perfusion assessment|"Patient will have their anastomosis assessed after they receive 7.5 to 9 mg of Indocyanine green intravenously (at a concentration of 2.5mg/ml).
~The microvascularisation assessment will be performed using a near infrared device(Pinpoint device), allowing to increase reality.
~This procedure will be repeated twice during the surgery, the first time before and the second time after the anastomosis has been done."
11336222|NCT02459392|Other|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
11336223|NCT02459392|Experimental|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
11336224|NCT02459392|Other|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
11336225|NCT02459392|Experimental|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
11336226|NCT02459366||control|establish the reliability of measurement of lumbopelvic asymmetry, mechanical and physical properties of thoracolumbar fascia, and the norm of different age
11336227|NCT02459366||low back pain|compare the differences among asymptomatic subjects and patients with and without lumbopelvic asymmetry, and investigate whether lumbopelvic symmetry, core muscle contractility, proprioception and standing balance change after manipulating thoracolumbar fascia tissue by physical therapy
11336228|NCT02459353|Experimental|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
11336229|NCT02459353|Placebo Comparator|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
11336230|NCT02459340|Experimental|patient group|Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)
11336231|NCT02459340|No Intervention|healthy control group|passive control group
11336232|NCT02459327|Experimental|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
11336233|NCT02459327|No Intervention|Control|
11336234|NCT02459314|Placebo Comparator|soymilk|Soymilk (SM) contained 5 gm soy protein and 6.5 gm sugar per 180 mL package.
11336235|NCT02459314|Active Comparator|sterol/fiber-enriched soymilk|PLant sterol and soluble fiber-enriched soymilk (SFSM) contained 1 gm free plant sterol, 5 gm inulin (soluble fiber), 5 gm soy protein and 6.5 gm sugar per 180 mL package
11336327|NCT02458677|Placebo Comparator|Placebo|
11394879|NCT02070354||Group 4|12 months after bariatric surgery
11336236|NCT02459301|Experimental|IPH2201|"Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.
~Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1"
11336237|NCT02459288|Experimental|Clopidogrel first|Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks
11336238|NCT02459288|Experimental|Ticagrelor first|Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks
11336239|NCT02459275|Experimental|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
11336240|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
11336241|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
11336242|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
11336243|NCT02459249|Experimental|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
11336244|NCT02459249|Placebo Comparator|Treatment of Mexican Health Minister|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
11336245|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
11336246|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
11336247|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
11336248|NCT02459223|Active Comparator|Test Group|Treated with nutritional biscuits and khichadi. Nutritional biscuits providing 2.5 to 3 gm Protein and 90-100kcal/kg body Weight/day, as well as local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
11336249|NCT02459223|Active Comparator|Control Group|Treated with only local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
11336250|NCT02459210|Experimental|CLUES|active treatment
11336251|NCT02459210|Active Comparator|therapy and computer games|supportive therapy + computer games
11336252|NCT02459197|Active Comparator|T4P1001|
11336253|NCT02459197|Sham Comparator|Placebo|
11336254|NCT02459184|Experimental|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
11336255|NCT02459184|Active Comparator|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
11336256|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.
~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
11336257|NCT02459158|Experimental|Low dose of ME1100|
11336258|NCT02459158|Experimental|High dose of ME1100|
11336259|NCT02459145|Active Comparator|Graduated Exercise Protocol|Intervention involves exercise starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation. The exercise protocol includes treadmill speed and track minutes per lap conversion, rate of perceived exertion and talk test for each stage of exercise plus total time to execute for 5 days each week.
11336260|NCT02459145|Other|Rest followed by Protocol|No activity in weeks 1 - 8. In week 9 we will begin their intervention phase as described in graduated exercise protocol
11336261|NCT02459132|Experimental|Exercise Group|Subjects in the exercise group will attend supervised exercise sessions three times a week, for 12 weeks. The exercise intervention will consist of uphill walking or jogging on a treadmill between 50% and 95% of VO2peak for 35 minutes (including a 5-minute warm up and cool down). The participants will complete four, 4-minute, high-intensity intervals at 85-95% of VO2peak. The work period intervals will be interspersed with three, 3-minute periods of active recovery at an intensity below that of their ventilatory threshold.
11336262|NCT02459132|No Intervention|Usual Care|The usual care group will not receive an intervention, and they will be asked to maintain baseline physical activity levels throughout the observation period.
11336263|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
11336264|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
11336265|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
11336266|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
11336267|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
11336268|NCT02459080|Active Comparator|TD-4208-1|88 mcg
11336269|NCT02459080|Active Comparator|TD-4208-2|175 mcg
11336270|NCT02459080|Placebo Comparator|Placebo|Placebo
11336271|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
11336272|NCT02459054|Experimental|Primary Pediatric Arm|Cardiac transplant-eligible pediatric patients at imminent risk of death from biventricular failure who are 10 - 18 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
11336273|NCT02459054|Experimental|Primary Adult Arm|Cardiac transplant-eligible adult patients at imminent risk of death from biventricular failure who are 19 - 75 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
11336274|NCT02459054|Experimental|Secondary Arm|Cardiac transplant-eligible pediatric and adult patients at imminent risk of death from biventricular failure who do not meet enrollment criteria for a Primary Arm, but meet less restrictive enrollment criteria for the Secondary Arm. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
11336275|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.
~EG-EUS and CE-EUS will be applied in all patients."
11336276|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.
~EG-EUS and CE-EUS will be applied in all patients."
11336277|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.
~EG-EUS will be applied in all patients."
11336278|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.
~EG-EUS will be applied in all patients."
11336279|NCT02459028|Experimental|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
11336280|NCT02459028|Active Comparator|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
11336281|NCT02459015|Experimental|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
11336282|NCT02459015|Active Comparator|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
11336283|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
11336284|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
11336285|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
11336286|NCT02458989|Active Comparator|Scalpel|Use of a scalpel as a first incision during thyroid operation.
11336287|NCT02458989|Experimental|Electrocautery|Use of an electrocautery as a first incision during thyroid operation.
11336288|NCT02458976|Experimental|PDL|Pre-treatment of surgical area with PDL
11336289|NCT02458963|Active Comparator|IVF group|Women will undergo one full IVF cycle
11336290|NCT02458963|Active Comparator|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
11336291|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.
~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
11336292|NCT02458924|Active Comparator|Schizophrenia|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
11336293|NCT02458924|Active Comparator|Bipolar disorder|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
11336294|NCT02458924|Active Comparator|First degree relatives|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
11336295|NCT02458924|Active Comparator|Health controls|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
11336296|NCT02458898|Experimental|Text Message Intervention|A series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
11336297|NCT02458898|No Intervention|Control (No Text Messages)|Routine care by primary gastroenterologist with no text messages.
11336298|NCT02458872|Experimental|Intervention Arm|Safety huddle alarm intervention.
11336299|NCT02458872|No Intervention|Control Arm|Usual care.
11336300|NCT02458859|Active Comparator|PICO|PICO Negative Pressure Wound Therapy (NPWT) system
11336301|NCT02458859|No Intervention|Standard care|Standard care
11336302|NCT02458846|Experimental|Screened Schools|25 schools. Screening involved: crowded HOTV acuity test, Preschool Randot Stereoacuity Test, and Plusoptix autorefractor. Referral criteria followed AAPOS guidelines for screening for amblyopia and amblyopia risk factors. Children who fail any one of the three tests (including uncooperative/unable children) will be given a referral letter, which includes an assigned appointment time for a comprehensive eye exam at school with a licensed optometrist. Any needed glasses will be dispensed at no cost to the parents. 6 months after the eye exam, we will follow up with a phone call to parents to offer any additional support (such as replacing broken/lost glasses)
11336303|NCT02458846|No Intervention|Care As Usual Schools|"25 schools were randomly allocated to the care as usual schools. No intervention was provided by the research team, however, children may have received optometry/ophthalmology care via regular referral channels (e.g., family physicians, teachers)"
11336304|NCT02458833|Experimental|Intervention|Behavioral: Home Plate intervention
11336305|NCT02458833|Experimental|Delayed Entry Control|This Arm will receive the Home Plate intervention 3 months after the Intervention Arm completes the intervention.
11336306|NCT02458820|No Intervention|Usual Care|Patients will be recorded and interpreted as per standard of care. If a seizure is noted by the neurology service, the standard seizure treatment protocol will be used by the clinical team.
11336307|NCT02458820|Experimental|DSA EEG + Usual Care|Patients will undergo at least hourly interpretation of DSA by the ICU bedside care provider. If the bedside care provider is concerned that there is a seizure on DSA they will contact the EEG tech on call for confirmation. If a seizure is confirmed by neurology, the standard seizure treatment protocol will be used by the clinical team.
11336308|NCT02458794|Active Comparator|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
11336309|NCT02458794|Active Comparator|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
11336310|NCT02458781|Placebo Comparator|Placebo|"Placebo capsule:
~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
11336311|NCT02458781|Active Comparator|Ciprofloxacin|"Ciprofloxacin 250mg capsule:
~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
11336312|NCT02458781|Active Comparator|Metronidazole|"Metronidazole 250mg capsule:
~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
11336313|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.
~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
11336314|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.
~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
11336315|NCT02458755|Experimental|High-dose statin treatment|Atorvastatin (40mg) or Rosuvastatin (20mg)
11336316|NCT02458742|Experimental|Morphine|0.5%Bupivacaine 2 ml with morphine 50 mcg for spinal anesthesia
11336317|NCT02458742|Placebo Comparator|Placebo|0.5%Bupivacaine 2 ml for spinal anesthesia
11336318|NCT02458729|Placebo Comparator|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
11336319|NCT02458729|Active Comparator|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
11336320|NCT02458729|Active Comparator|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
11336321|NCT02458716|Experimental|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
11336322|NCT02458703|Experimental|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
11336323|NCT02458703|Experimental|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
11336324|NCT02458690|Experimental|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
11336325|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
11336326|NCT02458677|Experimental|PRX003|
11336328|NCT02458664||Colo-rectal cancer|All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
11336329|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
11336330|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
11336331|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
11336332|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
11336333|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
11336334|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
11336335|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
11336336|NCT02458625|Active Comparator|Iron sucrose 500 mg|One treatment arm will receive a single dose of I.V iron sucrose 500 mg.
11336337|NCT02458625|Active Comparator|Iron sucrose 500 mg+60 mg Iron bisglycinate|Second treatment arm will receive a single dose of I.V iron sucrose 500 mg and oral treatment with 60 mg Iron bisglycinate for 6 weeks after giving birth.
11336338|NCT02458612|Other|control group|We will apply only upper limbs exercises with traditional therapy.
11336339|NCT02458612|Active Comparator|intervention group|We will apply mirror therapy and progressive strength training for upper extremities.
11336340|NCT02458599|Experimental|Test product|One ready-to-drink beverage of 500 milliliter (mL) volume, containing 20 gram (g) protein will be administered orally, twice daily for four days.
11336341|NCT02458599|Active Comparator|Reference product 1|One ready-to-drink beverage of 500 mL volume, containing 20 g carbohydrate will be administered orally, twice daily for four days.
11336342|NCT02458599|Placebo Comparator|Reference product 2|One ready-to-drink beverage of 500 mL volume, containing 0 g carbohydrate will be administered orally, twice daily for four days.
11336343|NCT02458586|Placebo Comparator|MUFA|daily intake of 50 g of olive oil over a period of 8 weeks
11336344|NCT02458586|Active Comparator|PUFA|daily intake of 50 g of canola oil (rapeseed oil) over a period of 8 weeks
11336345|NCT02458573|Experimental|continuous epidural analgesia group|
11336346|NCT02458573|Active Comparator|continuous intravenous analgesia group|
11336347|NCT02458560|Experimental|single-arm|
11336348|NCT02458547|Experimental|Group D|General anesthesia with desflurane
11336349|NCT02458547|Active Comparator|Group P|General anesthesia with propofol total intravenous anesthesia
11336350|NCT02458547|Active Comparator|Group S|Spinal anesthesia with 0.5% bupivacaine
11336351|NCT02458534|Experimental|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
11336352|NCT02458534|Experimental|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
11336353|NCT02458534|Active Comparator|Macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
11336354|NCT02458521|Experimental|Transcranial Magnetic Stimulation|TMS sessions will consist of both 10Hz left pre-frontal stimulation for 3,500 pulses followed by 1Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session.
11336355|NCT02458521|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7.
11336356|NCT02458508||GBM patients|patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation
11336357|NCT02458495|No Intervention|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.
~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
11336358|NCT02458495|Experimental|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
11336359|NCT02458482|Active Comparator|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
11336360|NCT02458482|Experimental|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
11336361|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
11336362|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
11336363|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
11336389|NCT02458300|Active Comparator|Intervention Arm.|Nebulization of hypertonic saline. Application of Prolonged slow expiration technique (PSE) expiratory volume. Patient coughing Provocation (TP) Inspiratory maneuver to rhinopharyngeal cleaning DRR Aspiration of secretions
11336364|NCT02458456|Sham Comparator|IHG 5% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
11336365|NCT02458456|Experimental|IHG 30% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
11336366|NCT02458456|Experimental|IHG 30% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
11336367|NCT02458456|Sham Comparator|IHG 5% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
11336368|NCT02458456|Experimental|IHG 10% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
11336369|NCT02458456|Experimental|IHG 10% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
11336370|NCT02458443|Sham Comparator|IHG 5% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip (IHG) exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
11336371|NCT02458443|Sham Comparator|IHG 5% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
11336372|NCT02458443|Experimental|IHG 30% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
11336373|NCT02458443|Experimental|IHG 30% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
11336374|NCT02458417|Active Comparator|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
11336375|NCT02458417|Experimental|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
11336376|NCT02458417|Experimental|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
11336377|NCT02458417|No Intervention|Control|No intervention
11336378|NCT02458391|Experimental|Treatment 2x/wk|Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
11336379|NCT02458391|Experimental|Treatment 4x/wk|Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
11336380|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
11336381|NCT02458365|Other|Comparison|Health In Motion
11336382|NCT02458352|Other|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
11336383|NCT02458339|Experimental|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
11336384|NCT02458326|Experimental|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
11336385|NCT02458326|Other|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
11336386|NCT02458313|Experimental|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
11336387|NCT02458313|Placebo Comparator|Placebo|Placebo capsules b.i.d. for 12 weeks.
11336388|NCT02458300|Placebo Comparator|Control Arm|Nebulized hypertonic saline. Aspiration of secretions
11336390|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
11336392|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
11336393|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
11336394|NCT02458274||Patient without bronchiolitis obliterans syndrome|Lung transplanted patient without bronchiolitis obliterans syndrome
11336395|NCT02458274||Patient with bronchiolitis obliterans syndrome|Patient with bronchiolitis obliterans syndrome three years after lung transplantation.
11336396|NCT02458248|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
11336397|NCT02458248|No Intervention|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
11336398|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
11336399|NCT02458222|Experimental|game therapy then standard therapy|participants will take part in language game therapy followed by standard aphasia therapy
11336400|NCT02458222|Experimental|standard therapy then game therapy|participants will have standard aphasia therapy first then will take part in language game therapy
11336401|NCT02458209|Active Comparator|Treatment A|150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Pfizer Andover
11336402|NCT02458209|Experimental|Treatment B|• Treatment B: 150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma
11336403|NCT02458209|Experimental|Treatment C|150 mg SC dose administered in a prefilled pen using drug substance manufactured at Pfizer Andover.
11336404|NCT02458196|Experimental|Prednisone|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
11336405|NCT02458196|Experimental|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
11336406|NCT02458183|Experimental|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
11336407|NCT02458183|Active Comparator|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.
~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
11336408|NCT02458157|Experimental|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP < 50 or mottling beyond the edge of kneecaps).
~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.
~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
11336409|NCT02458157|Active Comparator|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
11336410|NCT02458144|Other|"MIS anterior group"|"Total Hip Arthroplasty anterior surgical approach"
11336411|NCT02458144|Other|"MIS anterolateral group"|"Total Hip Arthroplasty anterolateral surgical approach"
11336412|NCT02458131|Experimental|TEEN HEED|Adolescent pre-diabetics will receive 8-12 weekly peer-led diabetes prevention educational workshops in community sites. The in-person group workshops will be supplemented by support through mobile health technologies such as text messaging and social media.
11336413|NCT02458131|No Intervention|Wait List Control|Adolescent pre-diabetics in this group will not receive any intervention until collection of all follow up data and will then be offered the same intervention as the participants in the experimental arm.
11336414|NCT02458118|Experimental|Secretin|Secretin 1 IU/kg over 3 min
11336415|NCT02458105|Experimental|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
11336416|NCT02458105|Active Comparator|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
11336417|NCT02458092|Experimental|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
11336418|NCT02458092|Experimental|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
11336419|NCT02458079|Experimental|Pentoxiphylline|
11336420|NCT02458079|Active Comparator|Stool Microbiota Transplantation|
11336421|NCT02458066|Active Comparator|Bendiocarb|IRS: bendiocarb
11336422|NCT02458066|Active Comparator|Deltamethrin|IRS: deltamethrin
11336423|NCT02458053|Experimental|TEAM Enhanced|The enhanced intervention will include group sessions where the participant attends with partner ( including a couples skill training session), weekly tailored feedback, and weekly lessons.
11336663|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study
~anticipated n = 500"
11336424|NCT02458053|Active Comparator|TEAM Traditional|The intervention will include group sessions where the male attends alone, weekly tailored feedback, and weekly lessons.
11336425|NCT02458040||Biomarker-positive patients|
11336426|NCT02458040||Biomarker-negative patients|
11336427|NCT02458040||All patients|
11336428|NCT02458027|Experimental|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
11336429|NCT02458027|Experimental|40 g Hemp Protein Shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
11336430|NCT02458027|Active Comparator|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
11336431|NCT02458027|Experimental|40 g Soybean Protein Shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
11336432|NCT02458027|Placebo Comparator|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
11336433|NCT02458014|Experimental|Treatment (blinatumomab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
11336434|NCT02458001|Experimental|SAFFRON stepped care|3 level intervention: level 1:Self help booklet level 2: CNS delivered intervention level 3: psychologist delivered intervention
11336435|NCT02458001|No Intervention|enhanced treatment as usual (ETU)|level 1 intervention: self help booklet Non study trained CNS will offer assessment, advice, vaginal dilator training where appropriate, arrange topical oestrogens or other creams
11336436|NCT02457988|Experimental|Vivify Kit|Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.
11336437|NCT02457988|No Intervention|Standard of Care|Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.
11336438|NCT02457975|Active Comparator|Intravitreous VEGF-inhibitors|Three intravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
11336439|NCT02457975|Experimental|670nm PBM plus VEGF-inhibitors|Subjects in the 670 nm Photobiomodulation (PBM) intervention arm will be treated (in addition to Anti-VEGF treatment) with 670nm light (WARP10, Quantum, Devices, Inc, Barneveld, WI). The portable, battery-operated 670 nm LED array specifically designed not to generate heat will be held 1 inch from the closed treatment eye. A 90-sec light treatment will be delivered. After 90 sec a timer turns off the light. The dose of light delivered at the surface of the cornea is calculated to be 4.5 J/cm2 (90 sec x 0.05 W/cm2 = 4.5 J/cm2). PBM treatment will be applied for 90 sec once per day, three consecutive days per week for 8 weeks. Previous clinical studies, have shown this treatment regimen and dose to be safe and effective in the treatment of dry AMD and non-center involving DME
11336440|NCT02457949|No Intervention|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
11336441|NCT02457949|Experimental|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
11336442|NCT02457949|Experimental|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
11336443|NCT02457936|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
11336444|NCT02457936|Active Comparator|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
11336445|NCT02457923|Experimental|Mobile phone counselling|"The intervention will include:
~An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.
~Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.
~Server generated reminders and alerts, delivered to the mother, ASHA and ANM.
~An App for field supervisor to monitor ASHAs
~Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
11336446|NCT02457923|No Intervention|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
11336447|NCT02457910|Experimental|Taselisib 2 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
11336448|NCT02457910|Active Comparator|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib
11336449|NCT02457910|Experimental|Taselisib 4 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
11336480|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
11336450|NCT02457910|Experimental|Taselisib 6 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
11336451|NCT02457910|Experimental|Taselisib 8 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
11336452|NCT02457910|Experimental|Enzalutamide + Taselisib|Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11336453|NCT02457910|Experimental|Cross-Over|Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD
11336454|NCT02457897|Experimental|Patients with insulin receptor mutation|
11336455|NCT02457884|Active Comparator|Temporal Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
11336456|NCT02457884|Active Comparator|Spatial Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
11336457|NCT02457884|Active Comparator|Combined Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
11336458|NCT02457884|Placebo Comparator|Control Group|Receive 6 weekly 1-hour training sessions of leisure reading activities
11336459|NCT02457871|Experimental|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
11336460|NCT02457871|No Intervention|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
11336461|NCT02457858|Experimental|BMX-010 treated islets|Islet isolation using BMX-010
11336462|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
~Intervention: Biological: G207"
11336463|NCT02457832|Experimental|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
11336464|NCT02457832|Experimental|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
11336465|NCT02457832|Active Comparator|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
11336466|NCT02457832|No Intervention|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
11336467|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
11336468|NCT02457806|Experimental|Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart
11336469|NCT02457806|Active Comparator|Kovacaine Mist and Placebo|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart
11336470|NCT02457806|Active Comparator|Placebo and Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart
11336471|NCT02457806|Placebo Comparator|Placebo spray|3 sprays of placebo in each nostril administered 4 minutes apart
11336472|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
11336473|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
11336474|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
11336475|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
11336476|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
11336477|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
11336478|NCT02457780|Experimental|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
11336479|NCT02457780|Active Comparator|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
11394880|NCT02070354||Group 5|24 months after bariatric surgery
11336485|NCT02457702|Experimental|Orally administered Labeled Glycerol|Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
11336486|NCT02457689|Placebo Comparator|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
11336487|NCT02457689|Active Comparator|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
11336488|NCT02457689|Placebo Comparator|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
11336489|NCT02457689|Active Comparator|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
11336490|NCT02457676|Experimental|Alert Program for Self-Regulation|Participants with FASD who received the Alert Program for Self-Regulation therapy between the two testing periods.
11336491|NCT02457676|No Intervention|FASD Alert Waitlist|Participants with FASD who did not receive therapy between the two testing periods but were provided intervention on study completion.
11336492|NCT02457676|No Intervention|Typically Developing Control|Normally developing controls not exposed to alcohol in utero who were not treated between the two testing periods.
11336493|NCT02457650|Experimental|Anti-NY ESO-1 TCR-transduced T cells|Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
11336494|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.
~ALI(acute liver injury): including [ALT>3NL(normal level),AST>3NL or TB>2NL within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB>5NL)within 1 month before enrollment)].
~Standary therapy"
11336495|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
11336496|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
11336497|NCT02457598|Experimental|Tirabrutinib + Idelalisib (Combination I)|"Dose Escalation:
~Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib 20 mg + idelalisib 50 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 20 mg + idelalisib 50 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + idelalisib up to 100 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + idelalisib for an additional 6 years from the date of Protocol Amendment 8."
11336498|NCT02457598|Experimental|Tirabrutinib + Entospletinib (Combination II)|"Dose Escalation:
~Participants will receive a single dose of tirabrutinib 40 mg on Day 1 of Cycle 1 and tirabrutinib 40 mg + entospletinib 200 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 40 mg + entospletinib 200 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + entospletinib up to 400 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + entospletinib for an additional 6 years from the date of Protocol Amendment 8."
11336499|NCT02457598|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)|"Dose escalation:
~Participants will receive tirabrutinib + idelalisib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and idelalisib doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
11336532|NCT02457325|Experimental|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
11336533|NCT02457312|Active Comparator|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
11336500|NCT02457598|Experimental|Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)|"Dose escalation:
~Participants will receive tirabrutinib + entospletinib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and entospletinib doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.
~Dose Expansion:
~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
11336501|NCT02457598|Experimental|Single Agent Tirabrutinib (Combination V)|Participants with relapsed or refractory chronic lymphocytic leukemia (CLL) may be enrolled to receive tirabrutinib 80 mg once daily.
11336502|NCT02457585|Experimental|experimental group|"anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).
~evaluation of response at 30weeks by PET CT, acute phase reactants, symptom
~No placebo group"
11336503|NCT02457572||Valsalva maneuver|This is an observational study and as a diagnostic intervention, subjects in the study would receive valsalva maneuver. Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration. The investigators perform this procedure to every patients and do not assign this intervention to the subjects of the study.
11336504|NCT02457559|Experimental|Tirabrutinib|Participant will receive tirabrutinib once or twice daily for up to 5 years.
11336505|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
11336506|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
11336507|NCT02457533|No Intervention|Control|Only SF-36 and CAT
11336508|NCT02457533|Active Comparator|Active|Lifestyle behavioral. Health plan, telephone support
11336509|NCT02457520|Experimental|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
11336510|NCT02457507|Experimental|Vitamin B12|Vitamin B12, 1mg, daily, 27 months
11336511|NCT02457507|Placebo Comparator|Placebo|Placebo comparator
11336512|NCT02457481|Experimental|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
11336513|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
11336514|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
11336515|NCT02457442|Active Comparator|PR1|Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)
11336516|NCT02457442|Active Comparator|PR2|Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)
11336517|NCT02457442|Active Comparator|SR1|Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)
11336518|NCT02457442|Active Comparator|SR2|Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)
11336519|NCT02457442|Active Comparator|SPR1|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.
11336520|NCT02457442|Active Comparator|SPR2|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.
11336521|NCT02457429|Other|Routine oesophageal pH monitoring|Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
11336522|NCT02457416|Active Comparator|Peanut oral immunotherapy|Oral immunotherapy with peanut
11336523|NCT02457416|No Intervention|Controls|Avoid peanut exposure
11336524|NCT02457403|Experimental|ROTEM|
11336525|NCT02457403|Active Comparator|Conventional|
11336526|NCT02457390|Experimental|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.
~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.
~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
11336527|NCT02457377|Experimental|Laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
11336528|NCT02457351|Experimental|Roniciclib + Itraconazole|Pharmacokinetics and safety in patients with advanced solid tumor
11336529|NCT02457338|Experimental|Supplement Group|This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.
11336530|NCT02457338|No Intervention|Control Group|This group will receive standard care plus lactation consultation only.
11336531|NCT02457325|Experimental|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
11336534|NCT02457312|Placebo Comparator|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
11336535|NCT02457299|Active Comparator|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
11336536|NCT02457299|Active Comparator|One Stage Esophagectomy|Esophagectomy alone
11336537|NCT02457286|Experimental|Metformin|Metformin is being compared to exercise and diet modifications. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
11336538|NCT02457286|Experimental|Lifestyle modification|The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating participants condition or disorder. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
11336539|NCT02457273|Experimental|Assigned Interventions|TLC 388
11336540|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
11336541|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
11336542|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
11336543|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
11336544|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
11336545|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
11336546|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
11336547|NCT02457234|Experimental|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
11336548|NCT02457234|Active Comparator|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
11336549|NCT02457234|No Intervention|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
11336550|NCT02457221|Experimental|Tacrolimus group|Tacrolimus capsules + steroid
11336551|NCT02457221|Active Comparator|Cyclophosphamide group|Cyclophosphamide injections + steroid
11336552|NCT02457208|Experimental|2HRZE/4HR|"2HRZE/4HR
~Intensive phase: 2 months HRZE - once daily
~Continuation phase: 4 months HR - once daily
~Adults will be treated with fixed dose combination (FDC) tablets containing:
~Intensive phase (content per tablet)
~Isoniazid -75 mg,
~Rifampicin - 150 mg,
~Pyrazinamide - 400 mg,
~Ethambutol - 275 mg
~Continuation phase (content per tablet)
~Isoniazid 150 mg
~Rifampicin 300 mg
~*Drug dosing will be adjusted by patient body weight."
11336553|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
11336554|NCT02457182|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
11336555|NCT02457182|Placebo Comparator|Usual Care|Usual medical therapy
11336556|NCT02457169|Experimental|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
11336557|NCT02457169|Other|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
11336558|NCT02457156|Experimental|Blumgart Anastomosis|"Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a Blumgart method of pancreatico-jejunostomy.
~Octreotide will be administered."
11336559|NCT02457156|Active Comparator|Cattell-Warren Anastomosis|"Re-construction of the pancreatic remnant following pancreato-duodenectomy using a Cattell-Warren method of pancreatico-jejunostomy.
~Octreotide will be administered."
11336560|NCT02457143|Experimental|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
11336561|NCT02457143|Experimental|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
11336562|NCT02457130|Experimental|Group A|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.
~Ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week; washout period of 2-4 weeks; crossover to clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week."
11336563|NCT02457130|Experimental|Group B|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.
~Clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week; washout period of 2-4 weeks; crossover to ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week."
11336564|NCT02457104||normal weight individuals not taking PPI|
11336565|NCT02457104||normal weight individuals taking PPI|
11336568|NCT02457091|Active Comparator|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
11336569|NCT02457091|Experimental|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
11336570|NCT02457078|Experimental|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
11336571|NCT02457078|Placebo Comparator|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
11336572|NCT02457065|Experimental|Receive Plaque|"Treatment
~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
11336573|NCT02457065|No Intervention|Do Not Receive Plaque|"Control
~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
11336574|NCT02457052|Experimental|DATP +|Introduction of a device allowing a custom sitting to help patients with swallowing disorders .
11336575|NCT02457052|No Intervention|DATP -|No introduction of a device allowing a custom sitting to help patients with swallowing disorders .
11336576|NCT02457039|Active Comparator|Comprehensive acupuncture (CAI)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Dense cranial electroacupuncture stimulation (DCEAS) and Body acupuncture (BA).
11336577|NCT02457039|Sham Comparator|Least acupuncture stimulation (LAS)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Least acupuncture stimulation (LAS)
11336578|NCT02457026|Experimental|Adjunctive PDT + Aflibercept|Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
11336579|NCT02457026|Active Comparator|Aflibercept Alone|"Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3. At Study Visit 4, participants will have repeat assessment of disease activity. From Study Visit 4 onwards, aflibercept will be administered according to a treat-and-extend strategy. If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially extended from every 28 days to every 42 days. If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments. For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time."
11336580|NCT02457013|Experimental|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
11336581|NCT02457013|Active Comparator|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
11336582|NCT02457000||Normal, healthy volunteers|Normal, healthy volunteers without any skin pathology will be asked to undergo various procedures to evaluate their sleep and skin health.
11336583|NCT02457000||Volunteers with skin pathology|Volunteers with skin pathology including but not limited to eczema, psoriasis, acne, and other inflammatory dermatoses will be asked to undergo various procedures to evaluate their sleep and skin health.
11336584|NCT02456987|Experimental|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
11336585|NCT02456987|No Intervention|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
11336586|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
11336587|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
11336588|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
11336589|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
11336590|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
11336591|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
11336592|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
11336593|NCT02456961|Active Comparator|Standard epithelium-off CXL|Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)
11336629|NCT02456740|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
11336664|NCT02456532|Placebo Comparator|Placebo|Intervention: Six months of nightly placebo
11336665|NCT02456532|Active Comparator|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
11394881|NCT02070354||Group 6|≥ 36 months after bariatric surgery
11336594|NCT02456961|Experimental|Transepithelial CXL via iontophoresis of riboflavin|"impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.
~Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes"
11336595|NCT02456948|Experimental|Minocycline|Minocycline and standard antidepressant treatment
11336596|NCT02456948|Placebo Comparator|Placebo|Placebo and standard antidepressant treatment
11336597|NCT02456935|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
11336598|NCT02456935|Active Comparator|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
11336599|NCT02456922|Other|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
11336600|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
11336601|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
11336602|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
11336603|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
11336604|NCT02456883|Experimental|gilteritinib and 14C-labeled gilteritinib|Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
11336605|NCT02456870|Other|MA|Middle-aged overweight and obese men (age 25-40yr)
11336606|NCT02456870|Other|OA|Older overweight and obese men (age 55-75yr)
11336607|NCT02456857|Experimental|Treatment (DAE)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during course 4 of therapy. Patients then undergo surgery.
11336608|NCT02456844|Experimental|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
11336609|NCT02456844|Experimental|Group 2|Methotrexate,Leucovorin and BMS-986142
11336610|NCT02456831|Active Comparator|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
11336611|NCT02456831|Experimental|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
11336612|NCT02456831|Experimental|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
11336613|NCT02456831|Experimental|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
11336614|NCT02456818||Centers using contact isolation|"Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures
~Contact isolation terminated, after at least two negative consecutive fecal screening cultures
~Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions
~Contact isolation must include:
~Patient placement in single rooms
~Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical
~Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room"
11336615|NCT02456818||Centers using no contact isolation|"not regularly isolating for ESBL-EC
~ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (>3 loose bowel movements/day) isolated in single rooms with above described contact precautions"
11336616|NCT02456805|Active Comparator|Infant Formula 1|A standard commercial milk-based infant formula
11336617|NCT02456805|Experimental|Infant Formula 2|A standard commercial soy-based infant formula.
11336618|NCT02456792|Active Comparator|IVF group|Women will undergo one full IVF cycle
11336619|NCT02456792|Active Comparator|LOD group|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
11336620|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.
~RDQ greater or equal to 12
~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
11336621|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.
~RDQ greater or equal to 12
~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
11336622|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9
~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
11336623|NCT02456766||F0|Liver Steatosis Grade: <5%
11336624|NCT02456766||F1|Liver Steatosis Grade: 5-33%
11336625|NCT02456766||F2|Liver Steatosis Grade: 34-66%
11336626|NCT02456766||F3|Liver Steatosis Grade: > 66%
11336627|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.
~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
11336628|NCT02456740|Placebo Comparator|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
11336662|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)
~anticipated n = 150"
11336666|NCT02456532|Active Comparator|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
11336630|NCT02456740|Experimental|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
11336631|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
11336632|NCT02456727|Active Comparator|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
11336633|NCT02456714|Experimental|Progressive cholangiocarcinoma, second line treatment|FOLFIRINOX
11336634|NCT02456701|Experimental|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
11336635|NCT02456688|Experimental|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
11336636|NCT02456688|Experimental|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
11336637|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
11336638|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
11336639|NCT02456662|Placebo Comparator|Placebo|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
11336640|NCT02456662|Active Comparator|Ondansetron|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
11336641|NCT02456649|Experimental|MarginProbe|Single arm study - MarginProbe in addition to standard procedure
11336642|NCT02456636|Active Comparator|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
11336643|NCT02456636|Active Comparator|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
11336644|NCT02456636|Active Comparator|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
11336645|NCT02456623|Experimental|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
11336646|NCT02456623|Active Comparator|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
11336647|NCT02456610|Experimental|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
11336648|NCT02456597|Active Comparator|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
11336649|NCT02456597|Placebo Comparator|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
11336650|NCT02456584|Experimental|DMPA 150|single subcutaneous injection of 150mg/mL of DMPA in the abdomen
11336651|NCT02456584|Experimental|DMPA 300|single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
11336652|NCT02456584|Active Comparator|DMPA 104|two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen
11336653|NCT02456571||Group A|men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.
11336654|NCT02456571||Group B|men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
11336655|NCT02456571||Group C|men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
11336656|NCT02456571||Group D|men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)
11336657|NCT02456558|Experimental|Intravenous deferiprone, 1.5 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 1.5 g, twice-daily
11336658|NCT02456558|Experimental|Intravenous deferiprone, 2 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 2 g, twice-daily
11336659|NCT02456558|Placebo Comparator|Placebo|Subjects in this arm will receive an infusion of placebo twice-daily for 10 days, at a volume equivalent to that of the active product in the respective cohort
11336660|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)
~anticipated n = 500"
11336661|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)
~anticipated n = 500"
11397508|NCT02052921|Experimental|Observation|Conservative approach
11336668|NCT02456506|Experimental|Hyperfractionated IMRT Group|IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)
11336669|NCT02456506|Active Comparator|Conventional Fraction IMRT Group|IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)
11336670|NCT02456493||increased carotid IMT group|Patients who have increased carotid IMT (intima media thickness)
11336671|NCT02456493||normal carotid IMT group|Patients who have normal carotid IMT
11336672|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
11336673|NCT02456480|Experimental|CLS001 topical gel 1%|
11336674|NCT02456480|Placebo Comparator|Vehicle gel|
11336675|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
11336676|NCT02456454|Experimental|Risperidone|Risperidone, PO 0.25-2 mg/day
11336677|NCT02456454|Experimental|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
11336678|NCT02456454|Placebo Comparator|Placebo|Liquid placebo PO matched for color and taste.
11336679|NCT02456441|Experimental|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
11336680|NCT02456441|Placebo Comparator|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
11336681|NCT02456428||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
11336682|NCT02456428||Treated with insulin|Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
11336683|NCT02456428||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
11336684|NCT02456428||Treated with single oral agent|Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
11336685|NCT02456428||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.
11336686|NCT02456415|Experimental|K-MET™ Bioresorbable Bone screw|The K-MET™ Bioresorbable Bone Screw, intended to be used for trauma therapy, consists of Cortex screws, Cannulated headless screws. For Headless screw and Cannulated headless screws, the design is similar to normal headless compression screws but the compression function was achieved by using different lengths for the front and rear pitches. These screws are dynamic and allow therewith the fracture at the Carpal, metacarpal, and small hand bone.
11336687|NCT02456402|Experimental|Drug Coated Balloon|PCB (SeQuent Please®, paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany)
11336688|NCT02456402|Active Comparator|Bare Metal Stent|BMS (Vision®)
11336689|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
11336690|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
11336691|NCT02456376|Experimental|Children with Cerebral palsy|"Sensory integration testing
~SR stimulation and Sensory integration testing"
11336692|NCT02456376|Active Comparator|Children with Typical Development|"Sensory integration testing
~SR stimulation and Sensory integration testing"
11336693|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
11336694|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
11336695|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
11336696|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
11336697|NCT02456350|Experimental|Anti-CD19-CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
11336698|NCT02456337|Experimental|CAF+MC+EMD|Coronally Advanced Flap with Mucograft and Emdogain
11336699|NCT02456337|Active Comparator|CAF+MC|Coronally Advanced Flap with Mucograft
11336700|NCT02456337|Active Comparator|CAF+EMD|Coronally Advanced Flap with Emdogain
11336701|NCT02456337|Active Comparator|CAF|Coronally Advanced Flap alone
11336702|NCT02456324|Experimental|Treatment Group|Patients Treated with PICS-AF device
11336703|NCT02456324|Other|Historical Controls|Patients Treated with Commercially Available Fistula Plug Devices at Same Sites
11336704|NCT02456311|Other|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
11336705|NCT02456298|Active Comparator|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
11336706|NCT02456298|Experimental|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
11336707|NCT02456272|Experimental|External hearing aid & Otosclerosis surgery|Trying an hearing aid for at least two months and then undergo otosclerosis surgery
11340106|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
11336708|NCT02456259||Neck cannula group|Patients in this group are indicated for neck cannula insertion due to tzpu of cardiac surgery (MICS)
11336709|NCT02456259||Central venous catheter only group|Patients in this group are indicated for central venous catheter insertion only.
11336710|NCT02456246|Experimental|FLT-PET|"Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy.
~Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT
~Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence."
11336711|NCT02456233|Active Comparator|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
11336712|NCT02456233|Experimental|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
11336713|NCT02456220|Experimental|Herbst Group|Patients treated with Herbst appliance.
11336714|NCT02456220|No Intervention|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
11336715|NCT02456207|Experimental|Experimental|SCT400:375 mg/m2, iv, one infusion
11336716|NCT02456207|Active Comparator|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
11336717|NCT02456194|Experimental|Calcium Sulfate + Antibiotics + Internal Fixation|
11336718|NCT02456181|Experimental|JumpMath|"The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude 3)."
11336719|NCT02456168||SLE|
11336720|NCT02456168||Healthy control|
11336721|NCT02456155|Experimental|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
11336722|NCT02456155|Placebo Comparator|endoscope group|Conventional methods for placing Nasal Jejunal Tube
11336723|NCT02456142|Experimental|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
11336724|NCT02456142|Active Comparator|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
11336725|NCT02456129|Experimental|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
11336726|NCT02456116|Experimental|acupuncture/PCA/NSAID|"standard program with defined points:
~Ear acupuncture needles bitten once (day 0-5)
~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
11336727|NCT02456116|Sham Comparator|sham acupuncture/PCA/NSAID|"standard program with defined points:
~Ear sham-acupuncture needles bitten once (day 0-5)
~Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
11336728|NCT02456116|Other|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
11336729|NCT02456103|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
11336730|NCT02456077|Experimental|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
11336731|NCT02456077|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
11336732|NCT02456064|Experimental|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
11336733|NCT02456064|No Intervention|Normal group|In this group will be controlled as usual in the consultations.
11336734|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
11336735|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
11336736|NCT02456038|Experimental|Asfotase Alfa (ALXN1215)|Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.
11336737|NCT02456025|Active Comparator|Topical tacrolimus|20 eyes with active Vernal Keratoconjunctivitis
11336738|NCT02456025|Placebo Comparator|Placebo|20 eyes with active Vernal Keratoconjunctivitis
11336739|NCT02456012|Experimental|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
11336740|NCT02456012|Experimental|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
11336741|NCT02456012|No Intervention|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
11336742|NCT02455999|Experimental|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
11336743|NCT02455999|Experimental|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
11336744|NCT02455999|Placebo Comparator|Placebo|Placebo eye drops administration via the ophthalmic route
11336745|NCT02455986|Experimental|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.
~School and team based competition. 27/05/15 - 22/06/15 (8 weeks)
~Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)
~Prizes of low monetary value will be given to participants based on competition performance"
11336781|NCT02455791|Experimental|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
11336782|NCT02455778|Experimental|Cinnamon|3 grams of oral cinnamon per day in form of capsules (6) along with standard diet and exercise protocol
11336746|NCT02455986|No Intervention|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
11336747|NCT02455973|Experimental|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
11336748|NCT02455973|Placebo Comparator|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
11336749|NCT02455960|Experimental|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
11336750|NCT02455960|Placebo Comparator|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
11336751|NCT02455947|Experimental|Inquiry Based Stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie.It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
11336752|NCT02455947|No Intervention|Control group|A non interventional group/ The participants completed questionnaires before and after the intervention.
11336753|NCT02455934|Placebo Comparator|Sucrose|Sucrose 50 g
11336754|NCT02455934|Active Comparator|SAlloulose2.5|Sucrose 50 g + D-allulose (psicose) 2.5 g
11336755|NCT02455934|Active Comparator|SAllulose5|Sucrose 50 g + D-allulose (psicose) 5 g
11336756|NCT02455934|Active Comparator|SAllulose7.5|Sucrose 50 g + D-allulose (psicose) 7.5 g
11336757|NCT02455934|Active Comparator|SAllulose10|Sucrose 50 g + D-allulose (psicose) 10 g
11336758|NCT02455921|Active Comparator|sugammadex|iv sugammadex 2 mg/Kg
11336759|NCT02455921|Active Comparator|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg
~Efficacy, safety and effect on cognitive and behavioural function"
11336760|NCT02455908|Experimental|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:
~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.
~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.
~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
11336761|NCT02455895|Active Comparator|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
11336762|NCT02455895|Placebo Comparator|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
11336763|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
11336764|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
11336765|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
11336766|NCT02455869|Placebo Comparator|Placebo group|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
11336767|NCT02455869|Active Comparator|Atorvastatin group|SRP plus Atorvastatin SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
11336768|NCT02455869|Active Comparator|Alendronate Group|Alendronate SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
11336769|NCT02455856|Experimental|JNJ-42847922 plus Itraconazole|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
11336770|NCT02455843|Experimental|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
11336771|NCT02455843|Placebo Comparator|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
11336772|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
11336773|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
11336774|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
11336775|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
11336776|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
11336777|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
11336778|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
11336779|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
11336780|NCT02455804|Other|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
11336783|NCT02455778|Placebo Comparator|Placebo|2.5 grams of wheat flour per day in form of capsules ( 6) along with standard diet and exercise protocol
11336784|NCT02455765|Experimental|White rice control|Subjects will consume white rice as control (50g carbohydrate)
11336785|NCT02455765|Experimental|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
11336786|NCT02455765|Experimental|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
11336787|NCT02455765|Experimental|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
11336788|NCT02455765|Experimental|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
11336789|NCT02455765|Experimental|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
11336790|NCT02455765|Experimental|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
11336791|NCT02455752|Active Comparator|Reroperitoneal Group|LE-TME
11336792|NCT02455739|Experimental|chewing gum positive|chewing gum group will chew gum
11336793|NCT02455739|No Intervention|chewing gum negative|chewing gum group will not chew gum
11336794|NCT02455726|Experimental|Mg-group|"Standard therapy plus magnesium oxide.
~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
11336795|NCT02455726|Placebo Comparator|C-group|"Standard therapy plus fructose.
~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.
~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
11336796|NCT02455713||Intervention|Alter PEEP and PIP and measure hemodynamic outcomes.
11336797|NCT02455700|Active Comparator|Hand driven enamel reduction|This group will have enamel reduction in the lower incisor region carried out using hand held devices
11336798|NCT02455700|Active Comparator|Rotary ( motor driven) device|This group will ahve enamel reduction in the lower incisor region carried out using a rotary (motor driven) device
11336799|NCT02455687|Active Comparator|Hi-Mg + Bud|Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.
11336800|NCT02455687|Placebo Comparator|Hi-Mg + P|Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.
11336801|NCT02455687|Active Comparator|Std-Mg + Bud|Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.
11336802|NCT02455687|Placebo Comparator|St-Mg + P|Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline
11336803|NCT02455674||Age under 6 years|"All children 1 to 6 years
~Used formula for weight calculation:
~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
11336804|NCT02455674||Age over 6 years|"All children 6 to 12 years
~Used formula for weight calculation:
~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
11336805|NCT02455661|Experimental|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
11336806|NCT02455661|Active Comparator|Femoral PCI with AngioSeal device|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
11336807|NCT02455661|Active Comparator|Femoral PCI with StarClose device|
11336808|NCT02455648|Experimental|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
11336809|NCT02455648|Sham Comparator|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
11336810|NCT02455635|Active Comparator|women with pain|women who felt pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
11336811|NCT02455635|Active Comparator|women without pain|women who didn't feel pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
11336812|NCT02455622|Experimental|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
11336813|NCT02455609|Active Comparator|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
11336814|NCT02455609|Active Comparator|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
11336815|NCT02455609|Active Comparator|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
11336816|NCT02455596|Experimental|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
11336817|NCT02455583|No Intervention|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
11336818|NCT02455583|Experimental|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
11336853|NCT02455362|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
11336854|NCT02455362|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
11336855|NCT02455362|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
11336856|NCT02455362|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
11336819|NCT02455557|Experimental|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
11336820|NCT02455544||Pregnant Women|Any pregnant women that is referred to or presents to our tertiary care facility with concern for preeclampsia, will have a Congo Red Dot test preformed by research nurses. The research nurses are not involved in patient management and the results are blinded to the clinical providers and have no impact on clinical diagnosis or patient management.
11336821|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
11336822|NCT02455518|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
11336823|NCT02455518|Active Comparator|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
11336824|NCT02455518|Active Comparator|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
11336825|NCT02455518|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
11336826|NCT02455505||Risk Screening tool & Cognitive Interview|
11336827|NCT02455479|Other|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
11336828|NCT02455479|Other|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
11336829|NCT02455479|Other|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
11336830|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans
~First one prior to estradiol challenge test
~Second one immediately following one day of estradiol challenge test
~(1) FDG-PET/CT scan at screening
~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
11336831|NCT02455440|Active Comparator|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
11336832|NCT02455440|Placebo Comparator|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
11336833|NCT02455427|Active Comparator|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
11336834|NCT02455427|Sham Comparator|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.
~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
11336835|NCT02455414||Wolfram Syndrome Group|"Participant has confirmation of a WFS1 mutation OR
~Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old"
11336836|NCT02455414||WFS Pre-symptomatic Sibling Group|"Has had genotyping
~Willingness to share result of genotyping
~Participant has confirmation of WFS1 (+/+) mutation but is asymptomatic."
11336837|NCT02455414||WFS Control Sibling Group|"Has had genotyping
~Willingness to share result of genotyping
~Patient has confirmation of NO WFS1 mutation (-/-) or confirmation as a carrier (+/- or -/+)."
11336838|NCT02455414||T1DM Group|"Age within the 0-28 yrs age range of WS participant
~Dx of T1 diabetes mellitus"
11336839|NCT02455414||Healthy Control (HC) Group|• Age within the 0-28 yrs age range of WFS participants
11336840|NCT02455414||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
11336841|NCT02455401|Experimental|high dose remifentanil group|Intervention: high dose remifentanil will be administrated.
11336842|NCT02455401|Experimental|low dose remifentanil group|Intervention: low dose remifentanil will be administrated
11336843|NCT02455401|Placebo Comparator|No remifentanil group|Intervention: no remifenatnil will be administrated
11336844|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
11336845|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
11336846|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
11336847|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:
~detection of PUUV RNA in plasma collected at admission.
~or/and detection of IgM and IgG against PUUV in serum collected at admission,
~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
11336848|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
11336849|NCT02455362|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
11336850|NCT02455362|Experimental|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
11336851|NCT02455362|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
11336852|NCT02455362|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
11398033|NCT02049242|Active Comparator|Single tourniquet|
11336857|NCT02455362|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
11336858|NCT02455362|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
11336859|NCT02455362|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
11336860|NCT02455362|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
11336861|NCT02455336|Experimental|Fenofibrate|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
11336862|NCT02455336|Other|No Intervention|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive no therapy for 4 months
11336863|NCT02455323|Experimental|Suboccipital inhibitory|Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
11336864|NCT02455323|Experimental|Spinal Manipulative|Suboccipital inhibitory pressure technique. This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility.
11336865|NCT02455323|Experimental|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
11336866|NCT02455323|Placebo Comparator|Control group|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
11336867|NCT02455310||Outpatients with dementia|Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
11336868|NCT02455310||Nursing home residents|Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
11336869|NCT02455297|Experimental|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
11336870|NCT02455284|Experimental|Healthy subjects|MRI and neuropsychological evaluation
11336871|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
11336872|NCT02455258|Experimental|Dance/Movement Therapy (DMT)|
11336873|NCT02455258|Active Comparator|Aerobics Exercise (AE)|
11336874|NCT02455258|No Intervention|Waiting List|This group is placed on a waiting list and asked to refrain from making any changes to their current lifestyle.
11336875|NCT02455245|Active Comparator|Carboplatine and Vincristine|"Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
~Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC >1,000/µL and platelet count >100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
~Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children <12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle."
11336876|NCT02455245|Experimental|Carboplatin alone|"Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks).
~Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks"
11336877|NCT02455232|Experimental|hemiplegic patient|muscle participation in upper limb spasticity
11336878|NCT02455206|Active Comparator|Usual Care|outpatient pulmonary Rehabilitation program
11336879|NCT02455206|Experimental|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
11336880|NCT02455193|Experimental|Exercise intervention|10 weeks of a moderate exercise intervention
11336881|NCT02455193|Active Comparator|Diet intervention|10 weeks of a diet intervention
11336882|NCT02455180|Experimental|4x 1 gram bolus (q12H) dosage regimen|1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).
11336883|NCT02455180|Experimental|4x 5 grams bolus (q12H) dosage regimen|5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).
11336884|NCT02455180|Experimental|4 gram continuous dosage regimen|1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
11336885|NCT02455180|Experimental|20 gram continuous dosage regimen|5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
11336886|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
11336887|NCT02455154|Placebo Comparator|Letrozole|"Early Breast Cancer patients receiving adjuvant endocrine therapy
~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po."
11336888|NCT02455154|Active Comparator|Letrozole + Xinglinggubao|"Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao
~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.
~Xinglinggubao: 0.5g bid po"
11336889|NCT02455154|Active Comparator|Letrozole + Zhongyaofufang|"Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)
~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.
~Zhongyaofufang: qow po"
11336890|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
11336891|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
11336892|NCT02455128|Experimental|Experimental Group|This group will receive the therapeutic listening.
11336893|NCT02455128|No Intervention|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
11336894|NCT02455115|Experimental|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
11336895|NCT02455115|Experimental|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
11336896|NCT02455115|Experimental|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
11336897|NCT02455102|Active Comparator|Electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
11336898|NCT02455102|No Intervention|No electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.
11336899|NCT02455089|Experimental|Test group|"250 SLE patients : All SLE patients included in the study. Intervention : Blood analysis including GADD34 RNA level measurement every 3 months up to 1 year.
~They will provided a blood sample every 3 months during a year. The result of GADD34 RNA level in mononuclear blood cells will be correlated to the clinical assessment of a SLE flare during the next 3 months.
~A flare occurence will the group"
11336900|NCT02455076|Active Comparator|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
11336901|NCT02455076|Active Comparator|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
11336902|NCT02455076|Active Comparator|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
11336903|NCT02455076|Active Comparator|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
11336904|NCT02455076|Active Comparator|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
11336905|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
11336906|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
11336907|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
11336908|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
11336909|NCT02455037|No Intervention|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
11336910|NCT02455037|Experimental|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
11336911|NCT02455011|Experimental|REMD-477 Treatment A|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
11336912|NCT02455011|Placebo Comparator|Matching placebo|Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
11336913|NCT02455011|Experimental|REMD-477 Treatment B|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
11336914|NCT02455011|Experimental|REMD-477 Treatment C|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
11336915|NCT02455011|Experimental|REMD-477 Treatment D|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
11336916|NCT02455011|Experimental|REMD-477 Treatment E|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
11336917|NCT02454998|Experimental|Orthodontic treatment arm|Previous to the surgical alveolar bone grafting, orthodontic treatment is performed several months before surgery
11336918|NCT02454998|No Intervention|No orthodontic treatment arm|No orthodontic treatment previous to surgical alveolar bone grafting
11336919|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
11336920|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
11336921|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
11336922|NCT02454933|Experimental|MEDI4736 & AZD9291 Combination|10mg/kg q2w (IV) infusion & once daily tablet 80 mg
11336923|NCT02454933|Experimental|AZD9291 Monotherapy|Once daily tablet 80 mg
11336925|NCT02454907|Experimental|Experimental|A different kind of communication with the clinic will be used.
11336926|NCT02454894|Experimental|Group 1|no anesthesia; postoperative management
11336927|NCT02454894|No Intervention|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
11336928|NCT02454894|Experimental|Group 3|surface anesthesia with lidocaine; postoperative management
11336929|NCT02454894|Experimental|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
11336930|NCT02454881|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
11336931|NCT02454881|Active Comparator|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
11336932|NCT02454881|Active Comparator|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
11336933|NCT02454881|Active Comparator|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
11336934|NCT02454868|Experimental|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
11336935|NCT02454855|Experimental|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
11336936|NCT02454855|Placebo Comparator|"Group Placebo"|standard anticancer treatment + placebo (3 months)
11336937|NCT02454842|Experimental|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
11336938|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
11336939|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
11336940|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
11336941|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
11336942|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
11336943|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
11336944|NCT02454816|Experimental|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
11336945|NCT02454816|Active Comparator|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
11336946|NCT02454777|Experimental|ARM I (HIT group)|Participants undergo HIT exercises over 30 minutes, thrice weekly for 8 weeks.
11336947|NCT02454777|Active Comparator|Arm II (Delayed group)|Participants maintain their current sedentary activity level (< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT program as in Arm I.
11336948|NCT02454764|Experimental|Tenofovir + Interferon alpha 2 b|
11336949|NCT02454764|Active Comparator|Tenofovir|
11336950|NCT02454751|Experimental|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
11336951|NCT02454738|Experimental|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
11336952|NCT02454725|Experimental|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
11336953|NCT02454725|Active Comparator|Comparison|HIV counseling and testing
11336954|NCT02454712|Experimental|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
11336955|NCT02454712|Active Comparator|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
11336956|NCT02454699|Experimental|1000mg MBX400|6 subjects receive 1000 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
11336957|NCT02454699|Experimental|100mg MBX400|6 subjects receive 100 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
11336958|NCT02454699|Experimental|350mg MBX400|6 subjects receive 350 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
11336959|NCT02454699|Experimental|750mg MBX400|6 subjects receive 750 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
11336960|NCT02454673||Group A|"3-4 cycles of preoperative chemotherapy
~Surgery"
11336961|NCT02454673||Group B|"3-4 cycles of induction chemotherapy
~Radiotherapy with concurrent chemotherapy for 5 weeks
~Surgery"
11336962|NCT02454660|Experimental|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
11336963|NCT02454660|No Intervention|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
11336964|NCT02454634|Experimental|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
11336965|NCT02454621|Active Comparator|Control|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation and are asked to tick critical situations/appropriate responses that might be useful to them."
11336966|NCT02454621|Experimental|Volitional help sheet|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation. Implementation intentions are formed by linking critical situations with appropriate responses by drawing lines between critical situations and appropriate responses."
11336967|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
11336968|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
11336969|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
11336970|NCT02454582|Other|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
11336971|NCT02454582|Other|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
11336972|NCT02454556|Experimental|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
11336973|NCT02454556|Active Comparator|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
11336974|NCT02454543|Other|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
11336975|NCT02454543|Other|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
11336976|NCT02454530||Cancer patients treated with Nivestim®|
11336977|NCT02454517|Experimental|Arm I (diet and exercise lifestyle intervention)|The goals of the diet and exercise lifestyle intervention is for patients to lose 7% total body weight. Patients meet with a nutritionist 11 times during the first 6 months to receive the structured diet and exercise instruction. Participants complete exercise sessions supervised by an exercise specialist, and will wear a heart rate monitor periodically during the study.
11336978|NCT02454517|Active Comparator|Arm II (control)|Patients receive an informational intervention along with a 20-30 minute individual session with a dietitian and a goal of 30 minutes of physical activity 5 days a week.
11336979|NCT02454504|Active Comparator|sugammadex|this arm will receive sugammadex at the end of the surgery
11336980|NCT02454504|Active Comparator|neostigmine|this arm will receive neostigmine at the end of the surgery
11336981|NCT02454491|Active Comparator|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
11336982|NCT02454491|Experimental|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
11336983|NCT02454478|Experimental|Lenvatinib plus Everolimus|
11336984|NCT02454465|Experimental|Intervention group|The first group at the top of the waiting list will receive the Acceptance and Commitment Therapy group intervention, which is 1 hour per week for six weeks.
11336985|NCT02454465|No Intervention|Waiting list group|The outcomes of those on the waiting list will be compared with those in the intervention group. Once the intervention group completes, those on the waiting list will be invited to attend the Acceptance and Commitment Therapy group intervention.
11336986|NCT02454452|Active Comparator|Saphenous vein stripping|Saphenous venous stripping surgical technique
11336987|NCT02454452|Active Comparator|CHIVA|conservative hemodynamic treatment venous insufficiency (CHIVA)
11336988|NCT02454452|Experimental|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
11336989|NCT02454439|Experimental|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
11336990|NCT02454439|Other|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
11336991|NCT02454426|Experimental|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
11336992|NCT02454413|Sham Comparator|brush + water|denture brushing with water and soap + overnight storage in water
11336993|NCT02454413|Active Comparator|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
11336994|NCT02454413|Sham Comparator|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
11336995|NCT02454413|Active Comparator|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
11336996|NCT02454400|Other|Pre-surgery physiotherapy|Twice a week, in 9 weeks
11336997|NCT02454400|Other|Waiting-list|Standard information by the orthopedic surgeon
11336998|NCT02454387|Experimental|Experimental: ONO-4474 Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
11336999|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
11399085|NCT02041975|Experimental|Prebiotic|Nutriose FB06 14g/day
11337000|NCT02454387|Experimental|Experimental: ONO-4474 Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
11337001|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
11337002|NCT02454387|Experimental|Experimental: ONO-4474 Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
11337003|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
11337004|NCT02454387|Experimental|Experimental: ONO-4474 Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
11337005|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
11337006|NCT02454387|Experimental|Experimental: ONO-4474 Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
11337007|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
11337008|NCT02454374|Experimental|Knee Loading|Progressive joint loading intervention will be taught by a program of exercises by the treating physiotherapist. The intervention consists of knee flexion (bending) and knee extension (straightening). Participants will be assessed for their immediate response to treatment during each assessment or treatment session and advised on the appropriate level of self-directed exercises to be performed twice daily. The clinician will review the patient at follow up appointments during the treatment period, progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate. The physiotherapist will encourage compliance during the treatment period and beyond
11337009|NCT02454374|Active Comparator|Routine physiotherapy care|Normal care delivered to the control group will be based on current NICE guidelines (2014) for non-pharmacological management of OA which includes verbal and written advice/education; education regarding weight loss; exercise to include local muscle strengthening and general aerobic fitness; with or without manual therapy. Clinicians will be asked to refrain from using the progression of techniques specifically documented in the progressive loading protocol (not currently considered to constitute 'normal care'). Treating clinicians will be asked to record specific exercises and manual therapy techniques employed in the patient's records. Participants will be asked to complete a home treatment record sheet.
11337010|NCT02454361|Experimental|KBP-7072 cohort 1|KBP-7072 by mouth once
11337011|NCT02454361|Experimental|KBP-7072 cohort 2|KBP-7072 by mouth once
11337012|NCT02454361|Experimental|KBP-7072 cohort 3|KBP-7072 by mouth once
11337013|NCT02454361|Experimental|KBP-7072 cohort 4|KBP-7072 by mouth once
11337014|NCT02454361|Experimental|KBP-7072 cohort 5|KBP-7072 by mouth once
11337015|NCT02454361|Experimental|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
11337016|NCT02454348|Active Comparator|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
11337017|NCT02454348|Active Comparator|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
11337018|NCT02454335|Active Comparator|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
11337019|NCT02454335|Active Comparator|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
11337020|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
11337021|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
11337022|NCT02454309|Experimental|Cranberry concentrate|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
11337023|NCT02454309|Placebo Comparator|Placebo|A capsule containing control formulation
11337024|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
11337025|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
11337026|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
11337027|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
11337028|NCT02454270|Experimental|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
11337029|NCT02454270|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
11337030|NCT02454270|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
11337031|NCT02454270|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
11337032|NCT02454270|Experimental|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
11337033|NCT02454270|Experimental|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
11337034|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
11337035|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
11337036|NCT02454244|Experimental|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
11337037|NCT02454244|Experimental|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
11337038|NCT02454244|Active Comparator|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
11337039|NCT02454231|Experimental|peripheral blood EPC injection|
11337040|NCT02454231|Active Comparator|bone marrow MNC injection|
11337041|NCT02454218|Active Comparator|Transcranial Direct Current Stimulation|The intensity of the asset is little perceived and painless.
11337042|NCT02454218|Placebo Comparator|Simulation Transcranial Current|Will receive only simulation.
11337043|NCT02454205|Active Comparator|Conventional treatment 21-24 months|"Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.
~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.
~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol."
11337044|NCT02454205|Experimental|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:
~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.
~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
11337045|NCT02454192|Other|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
11337046|NCT02454192|No Intervention|Usual Care|Usual asthma care and management
11337047|NCT02454179|Experimental|Arm 1|pembrolizumab
11337048|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
11337049|NCT02454153|Active Comparator|REMStar Postive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
11337050|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
11337051|NCT02454140|Experimental|Cohort 1|SBRT 40 Gy in 5 fractions
11337052|NCT02454140|Experimental|Cohort 2|SBRT 45 Gy in 5 fractions (starting dose level)
11337053|NCT02454140|Experimental|Cohort 3|SBRT 50 Gy in 5 fractions
11337054|NCT02454140|Experimental|Cohort 4|SBRT 55 Gy in 5 fractions
11337055|NCT02454140|Experimental|Cohort 5|SBRT 60 Gy in 5 fractions
11337056|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
11337057|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
11337058|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
11337059|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
11337060|NCT02454114|Active Comparator|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
11337061|NCT02454114|Active Comparator|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.
~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
11337062|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
11337063|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
11337064|NCT02454088|Active Comparator|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
11337065|NCT02454088|Placebo Comparator|Placebo|Injection of Calcium hydroxylapatite with a placebo
11337066|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
11399086|NCT02041975|Placebo Comparator|Placebo|Maltodextrin
11337067|NCT02454062|Experimental|Dose Escalation TAS-114 (PART 1)|Each cycle will be 21 days: 14 days of treatment and 7 days recovery. TAS-114 and S-1 will be escalated according to a defined dosing table and specific DLT criteria.
11337068|NCT02454062|Experimental|Expansion phase TAS-114 (PART 2)|"The TAS-114 and S-1 MTD established in the Dose Escalation Phase will be administered BID for 14 days followed by a 7 day recovery period.
~This regimen is repeated every 21 days thereafter. Approximately 40 to 60 evaluable patients will be enrolled in the Expansion Phase. PGx, PD and PK analysis will be performed based on specific criteria."
11337069|NCT02454049|Active Comparator|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
11337070|NCT02454049|Active Comparator|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
11337071|NCT02454049|Placebo Comparator|water|85ml of plain water, ingested 3 hours before the exercise test
11337072|NCT02454036|Experimental|BBI Intervention|Biobehavioral Intervention
11337073|NCT02454023|Active Comparator|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
11337074|NCT02454023|Experimental|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
11337075|NCT02454010|Experimental|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
11337076|NCT02454010|Experimental|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
11337077|NCT02454010|Experimental|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
11337078|NCT02454010|Experimental|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
11337079|NCT02454010|Experimental|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
11337080|NCT02454010|Experimental|Expansion Phase (Cohort 6), Ovarian|In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)
11337081|NCT02454010|Experimental|Expansion Phase (Cohort 7), Adv Tumors|In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)
11337082|NCT02453984|Experimental|1|89Zr-MPDL3280A-PET scan
11337083|NCT02453971|Experimental|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
11337084|NCT02453971|No Intervention|control|It is an assessment only condition.
11337085|NCT02453958|Experimental|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
11337086|NCT02453958|Experimental|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
11337087|NCT02453945|Experimental|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
11337088|NCT02453945|No Intervention|Control|Usual Care
11337089|NCT02453932|Experimental|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
11337090|NCT02453932|Active Comparator|Donepezil|Donepezil and placebo identified to Tianzhi granule
11337091|NCT02453932|Placebo Comparator|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
11337092|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.
~Collection of clinical information and biochemical laboratory results."
11337093|NCT02453906|Experimental|healthy subjects|they receive XNKQ acupuncture, as well as control 1, control 2, and control 3 in a randomized order.
11337094|NCT02453893|Experimental|oral iloperidone|2~12mg/day for 2 weeks,12~24mg/day for 6 weeks.
11337095|NCT02453893|Active Comparator|oral risperidone|1~3mg/day for 2 weeks,3~6mg/day for 6 weeks.
11337096|NCT02453880|Experimental|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
11337097|NCT02453867|Active Comparator|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels >5 ng/ml), mycophenolate mofetil >1g/d in MMF or >720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
11337098|NCT02453867|Experimental|Reduced immunosuppression|"The Intervention is stopping medication:
~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels >5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
11337099|NCT02453854|Active Comparator|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
11337100|NCT02453854|Experimental|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
11337101|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
11337102|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
11337103|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
11337104|NCT02453828|Experimental|Checklist|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care with an additional, electronically pre-populated checklist displayed on the anesthesia record keeping system
11337105|NCT02453828|Active Comparator|Standard of Care|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care
11337106|NCT02453815|Experimental|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
11337107|NCT02453815|Placebo Comparator|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
11337108|NCT02453802|Active Comparator|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
11337109|NCT02453802|Active Comparator|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.
~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
11337110|NCT02453802|Placebo Comparator|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.
~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
11337111|NCT02453789|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
11337112|NCT02453789|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
11337113|NCT02453776|Experimental|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
11337114|NCT02453776|No Intervention|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
11337115|NCT02453763||Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation and an magnetic resonance imaging (MRI).
11337116|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
11337117|NCT02453737|Other|Catheter-based brachytherapy APBI|7 Gy x 3 fractions
11337118|NCT02453737|Other|3D-CRT APBI|7.3 Gy x 3 fractions
11337119|NCT02453737|Other|Proton APBI|7.3 Gy x 3 fractions
11337120|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
11337121|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
11337122|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
11337123|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
11337124|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
11337125|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
11337126|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
11337127|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
11337128|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
11337129|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
11337130|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
11337131|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
11337132|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
11337133|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
11337134|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
11337135|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
11337136|NCT02453698|Experimental|Methylphenidate|
11337137|NCT02453698|Placebo Comparator|Control Group|
11337138|NCT02453685|Experimental|BIAsp|
11337139|NCT02453685|Active Comparator|IGlar + IAsp|
11337140|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
11337141|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
11337142|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
11337143|NCT02453659|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
11337144|NCT02453659|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
11337145|NCT02453646|Experimental|NexSite HD Patients|NexSite HD patient catheter device placement
11337146|NCT02453633|Experimental|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
11337147|NCT02453633|Active Comparator|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
11337148|NCT02453620|Experimental|Treatment (entinostat, nivolumab, ipilimumab)|Patients receive entinostat PO on days -14 and -7 and then weekly, nivolumab IV over 60 minutes on day 1 and then every 2 weeks, and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11337149|NCT02453607||CD Monotherapy|Crohn's disease treated with infliximab (monotherapy)
11337150|NCT02453607||CD Combo therapy|Crohn's disease treated with infliximab in combination with thiopurine (a 6MP metabolite) (combo therapy)
11337151|NCT02453594|Experimental|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
11337152|NCT02453594|Experimental|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
11337153|NCT02453594|Experimental|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
11337154|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
11337155|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
11337156|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
11337157|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
11337158|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
11337159|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
11337160|NCT02453555|Placebo Comparator|Linagliptin placebo|
11337161|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin high dose placebo|
11337162|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin low dose placebo|
11337163|NCT02453529|Experimental|WCK 4873|Oral tablets
11337164|NCT02453516|Experimental|Serratus Block Group|Patients will receive a preoperative ultrasound-guided serratus block with 0.4ml/kg (max.30ml) of ropivacaine 0.5% with 1:4000,000 epinephrine injected between the serratus anterior (superficial) and external intercostal (deep) muscles followed by subsequent general anesthesia
11337165|NCT02453516|Placebo Comparator|Placebo Block - Control Group|Patients will receive a preoperative placebo injection with a subcutaneous injection of 1ml normal sterile saline solution in the midaxillary line and the ultrasound probe will be used to simulate the pressure and block duration associated with the serratus block. These patients will then receive general anesthesia.
11337166|NCT02453503|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
11337167|NCT02453503|Experimental|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
11337168|NCT02453490|Experimental|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
11337169|NCT02453490|Active Comparator|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
11337170|NCT02453477|Experimental|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.
~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.
~The product will be injected intraosseously."
11337171|NCT02453477|Experimental|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.
~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.
~The product will be injected intraosseously."
11337172|NCT02453477|Experimental|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.
~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.
~The product will be injected intraosseously."
11337173|NCT02453464|Experimental|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
11337174|NCT02453451|Experimental|2D-/3D-TTE; 3D-TEE, Walking Test|6 months after the MitraClip procedure
11337175|NCT02453425|Active Comparator|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
11337176|NCT02453425|Active Comparator|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
11337177|NCT02453425|Active Comparator|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
11337178|NCT02453412|No Intervention|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
11337179|NCT02453412|Experimental|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
11337180|NCT02453386|Experimental|Tozadenant 60 mg BID|"During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.
~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
11337181|NCT02453386|Experimental|Tozadenant 120 mg BID|"During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.
~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
11337182|NCT02453386|Placebo Comparator|Placebo BID|"During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.
~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
11337183|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
11337184|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
11337185|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
11337186|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
11337187|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
11337188|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
11337189|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
11337190|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
11337191|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
11337192|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
11337193|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
11337194|NCT02453308|Active Comparator|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.
~1.2 Dihydroartemisinin-piperaquine for 3 days
~1.3 Artesunate-Mefloquine for 3 days"
11337195|NCT02453308|Active Comparator|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.
~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.
~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
11337196|NCT02453295|Experimental|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
11337197|NCT02453295|No Intervention|Comparison Group|The CG will receive LE treatment as usual, without the hope intervention. They will be administered the same questionnaires (by phone) as the IG at the same timepoints. Potential participants (n=46) will be screened based MIQ. The individuals scoring in the top ~30% (n=16) will be excluded from the study. The remaining 30 individuals scoring the lowest level of hope will be admitted into the study.
11337198|NCT02453282|Experimental|Monotherapy|PD-L1 monoclonal Antibody monotherapy.
11337199|NCT02453282|Experimental|Combination Therapy|PD-L1+Tremelimumab combination therapy
11337200|NCT02453282|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
11337201|NCT02453269|Experimental|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
11337202|NCT02453269|No Intervention|Control group|The children in the control group (G2) were not exposed to interventions.
11337203|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
11337204|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
11337205|NCT02453243|No Intervention|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
11337206|NCT02453243|Other|Intervention|"Safety Plan Intervention: Clinician training in safety planning, and
~A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean
~Combine, this is expected to increase safety planning by clinicians."
11337207|NCT02453243|No Intervention|Maintenance|Test sustainability of safety planning during the Maintenance phase.
11337208|NCT02453230|Active Comparator|light on|BPP done with lights on
11337209|NCT02453230|No Intervention|light off|Biophysical profile examinations done with the light off
11337210|NCT02453217|Experimental|Chinese CHIP|Chinese Health Improvement Profile (CHIP) screening and intervention
11337211|NCT02453217|No Intervention|Treatment as usual|Routine community mental health care and medical outpatient appointments
11337212|NCT02453204|Experimental|Sitting|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
11337237|NCT02453009|Experimental|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
11337213|NCT02453204|Experimental|Standing|Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
11337214|NCT02453204|Experimental|Walking|The walking condition will be identical to standing, but the breaks in sitting time will be punctuated with five minute bouts of self-paced walking rather than standing.
11337215|NCT02453191|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy
~Talimogene Laherparepvec Dose Levels:
~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
11337216|NCT02453178|Experimental|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
11337217|NCT02453178|Active Comparator|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
11337218|NCT02453165|Experimental|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
11337219|NCT02453165|Active Comparator|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
11337220|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
11337221|NCT02453139|Experimental|Exercise group|6 month supervised and home based moderate intensity aerobic exercise programme
11337222|NCT02453139|No Intervention|Control|Non-exercising control group receiving usual care
11337223|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
11337224|NCT02453100|Experimental|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.
~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
11337225|NCT02453100|Placebo Comparator|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
11337226|NCT02453087|Experimental|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
11337227|NCT02453087|Experimental|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
11337228|NCT02453087|Experimental|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
11337229|NCT02453061|Placebo Comparator|Placebo group|Subjects will receive safflower oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
11337230|NCT02453061|Active Comparator|Triheptanoin group|Subjects will receive triheptanoin oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
11337231|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
11337232|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
11337233|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
11337234|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
11337235|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
11337236|NCT02453022|Experimental|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
11399244|NCT02040792|Experimental|175 mcg|TD-4208
11337238|NCT02453009|Active Comparator|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
11337239|NCT02452996|Active Comparator|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
11337240|NCT02452996|Active Comparator|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
11337241|NCT02452996|Active Comparator|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
11337242|NCT02452983|Experimental|Sertraline|Sertraline tablets 100mg daily for 4 (28-day) cycles
11337243|NCT02452970|Experimental|RRx-001 the cisplatin and gemcitabine|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
11337244|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.
~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.
~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
11337245|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)
~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.
~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
11337246|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
11337247|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
11337248|NCT02452918|Experimental|oritavancin|oritavancin, a single 1200mg IV dose, over 3 hours
11337249|NCT02452905|Active Comparator|Nitazoxanide|Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
11337250|NCT02452905|Placebo Comparator|Placebo|The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide. It is reconstitutes, administered and dosed as per the active study drug.
11337251|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
11337252|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
11337253|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
11337254|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
11337255|NCT02452879|Experimental|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
11337256|NCT02452879|Placebo Comparator|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
11337257|NCT02452879|Active Comparator|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
11337258|NCT02452866|Experimental|SYM-1219|
11337259|NCT02452853|Experimental|HR combined with FOLFOX4|"HR ;
~FOLFOX4 4 weeks after HR"
11337260|NCT02452840||NVAMD Patients with PDA|NVAMD Patients with PDA
11337261|NCT02452827||Primary Chronic Neck Pain|Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.
11337870|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
11337262|NCT02452827||Control|Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated.
11337263|NCT02452814||Cohort|
11337264|NCT02452801|Experimental|ALKS 5461|Sublingual tablet
11337265|NCT02452788|Other|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
11337266|NCT02452788|No Intervention|Usual Care|Usual Care
11337267|NCT02452775|Experimental|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
11337268|NCT02452775|Experimental|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
11337269|NCT02452775|Experimental|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
11337270|NCT02452775|Experimental|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
11337271|NCT02452762|Experimental|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
11337272|NCT02452762|Placebo Comparator|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
11337273|NCT02452749|Experimental|Cardiovascular Health Dietary Supplement|The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months
11337274|NCT02452736|Experimental|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|This is a Single arm, Non-randomized Study. All patients meet the eligibility criteria and sign the informed consent form will participate in this study.
11337275|NCT02452723|Experimental|ISC-hpNSC|
11337276|NCT02452710|Experimental|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
11337277|NCT02452710|No Intervention|NT-Control|- No Placebo Tablets
11337278|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
11337279|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
11337280|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
11337281|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
11337282|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
11337283|NCT02452658|Experimental|Changed menu|All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions.
11337284|NCT02452645|Experimental|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
11337285|NCT02452645|Active Comparator|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
11337286|NCT02452632|Experimental|ASP1941 group|once daily over a 24 week treatment
11337287|NCT02452632|Placebo Comparator|Placebo group|once daily over a 24 week treatment
11337288|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
11337289|NCT02452606|Experimental|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
11337290|NCT02452593|Active Comparator|"Tibial Nerve Stimulation"|"This group will do transcutaneous electrical stimulation of the tibial nerve at home.
~Development of an innovative portable equipment, with domestic technology for home application of the posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Frequency: 20 Hz, Pulse width: 200 us; duration: 15min daily"
11337291|NCT02452593|Active Comparator|"Pelvic Floor Exercises"|This group will make pelvic muscle training 3 times a day . In decubit dorsal posture, legs flexed and abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions keeping 4 seconds and relaxing 8 seconds for 10 times.
11337292|NCT02452580||Family Centered Care Unit|Cohort of premature infants and their families receiving Family Centered Care hospitalized at VVHF
11337293|NCT02452580||Open-bay Care Unit|Cohort of premature infants and their families receiving and traditional open-bay care hospitalized at HUH
11337294|NCT02452567|Experimental|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
11337295|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11337296|NCT02452541|Other|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
11337297|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.
~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
11337298|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.
~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
11337299|NCT02452515|Experimental|BAY1142524 (5 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
11399245|NCT02040792|Experimental|350 mcg|TD-4208
11337300|NCT02452515|Experimental|BAY1142524 (10 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
11337301|NCT02452515|Experimental|BAY1142524 (25 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
11337302|NCT02452515|Experimental|BAY1142524 (50 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
11337303|NCT02452502|Active Comparator|moderate dose|Drug: Atorvastatin Atorvastatin 20 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
11337304|NCT02452502|Experimental|high dose|Drug: Atorvastatin Atorvastatin 80 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
11337305|NCT02452489|Other|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
11337306|NCT02452489|Other|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
11337307|NCT02452489|Other|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
11337308|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
11337309|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
11337310|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11337311|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11337312|NCT02452463|Experimental|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
11337313|NCT02452450|Experimental|Ibuprofen lysine|
11337314|NCT02452450|Experimental|Ibuprofen sodium|
11337315|NCT02452450|Experimental|Ibuprofen liquid capsules|
11337316|NCT02452450|Active Comparator|Ibuprofen acid|
11337317|NCT02452450|Active Comparator|Paracetamol|
11337318|NCT02452437|Experimental|control|Oxycodone will be administered and subjects will undergo hemodialysis
11337319|NCT02452437|Experimental|hemodialysis|Oxycodone will be administered and subjects will undergo hemodialysis
11337320|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.
~(Enrollment complete- 33 enrolled)"
11337321|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors
~(Enrollment Complete- 45 enrolled)"
11337322|NCT02452411|Experimental|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
11337323|NCT02452411|Experimental|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
11337324|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
11337325|NCT02452398|Placebo Comparator|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
11337326|NCT02452385|Experimental|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
11337327|NCT02452372|Active Comparator|givosiran (ALN-AS1)|
11337328|NCT02452372|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11337329|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
11337330|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
11337331|NCT02452333|Experimental|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
11337332|NCT02452333|Experimental|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
11337333|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
11337334|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
11337335|NCT02452307|Experimental|Peptide vaccine|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51
11337336|NCT02452307|Experimental|Peptide vaccine + GM-CSF|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)
11337337|NCT02452307|Experimental|Peptide vaccine + local hyperthermia|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia
11337338|NCT02452307|Experimental|Peptide vaccine + Imiquimod|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod
11337339|NCT02452307|Experimental|Peptide vaccine + mRNA/Protamin|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin
11337340|NCT02452294|Experimental|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
11337341|NCT02452281|Experimental|ipilimumab + HSPPC-96|"Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
~HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.
~Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.
~Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine."
11337342|NCT02452268|Experimental|NIZ985|"Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.
~Cycle length 28 days.
~Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.
~MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.
~Following identification of the MTD / RDE, dose expansion will follow."
11337343|NCT02452268|Experimental|NIZ985 + PDR001|"The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.
~On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.
~Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual."
11337344|NCT02452255|Active Comparator|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
11337345|NCT02452255|Active Comparator|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
11337346|NCT02452255|Placebo Comparator|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
11337347|NCT02452255|Active Comparator|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
11337348|NCT02452242|Experimental|ABX464|
11337349|NCT02452242|Placebo Comparator|Placebo|
11337350|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
11337351|NCT02452216|Experimental|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
11337352|NCT02452203|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for 90 minutes.
11337353|NCT02452203|Placebo Comparator|Chair|The participant will lay in the supine position while reclined in a zero-gravity chair for 90 minutes.
11337354|NCT02452190|Experimental|Reslizumab|Reslizumab
11337355|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
11337356|NCT02452177|Experimental|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
11337357|NCT02452177|Placebo Comparator|Placebo|
11337358|NCT02452164|Active Comparator|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
11337359|NCT02452164|Other|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
11337360|NCT02452151|Experimental|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
11337361|NCT02452151|Active Comparator|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
11337362|NCT02452138||Low EAA|Endotoxin Activity Assay [EAA] level < 0.40 EAA units
11337363|NCT02452138||Intermediate EAA|Endotoxin Activity Assay [EAA] level between 0.40-0.59 EAA units
11337364|NCT02452138||High EAA|Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
11337365|NCT02452125|Experimental|Nicotine Gum|Nicotine chewing gum administered for 30 minutes
11337366|NCT02452112|Active Comparator|Lidocaine|Active arm with administration of active 5% Lidocaine patch
11337367|NCT02452112|Placebo Comparator|Placebo|Placebo arm with administration of placebo patch
11337368|NCT02452099|Other|5% DMSO|
11337369|NCT02452099|Other|7.5% DMSO|
11337370|NCT02452099|Other|10% DMSO|
11337371|NCT02452086|Active Comparator|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt
~, 3 days/week, for 4 weeks (12 sessions)"
11337372|NCT02452086|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
11337373|NCT02452073||CRE group|patients with chronic radiation enteritis
11337374|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
11337375|NCT02452073||control group|age-matched healthy volunteers
11337376|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
11337377|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
11337378|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
11337379|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
11337380|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
11337381|NCT02452034|Experimental|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
11337382|NCT02452034|Experimental|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
11337383|NCT02452034|Experimental|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
11337384|NCT02452034|Experimental|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
11337385|NCT02452034|Experimental|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
11337386|NCT02452034|Experimental|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
11337387|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
11337388|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
11337389|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
11337390|NCT02451995|Active Comparator|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
11337391|NCT02451982|Experimental|Arm A: CY/GVAX alone|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
11337392|NCT02451982|Experimental|Arm B: CY/GVAX with nivolumab|Patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide, nivolumab, and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive nivolumab every 4 weeks for another 6 treatments as well as cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
11337393|NCT02451982|Experimental|Arm C: CY/GVAX with nivolumab and urelumab|Patients receive low-dose cyclophosphamide, nivolumab, and urelumab IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and the vaccine on day 1. Beginning approximately 28 days after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and GVAX on day 1. Treatment with cyclophosphamide, nivolumab, urelumab, and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive nivolumab and urelumab every 4 weeks for another 6 treatments as well as cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
11337394|NCT02451969|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0
~Intervention: investigational 23-valent PPV"
11337395|NCT02451969|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0
~Intervention: control 23-valent PPV"
11337396|NCT02451956|Experimental|AZD5363 in combination with paclitaxel|AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.If paclitaxel therapy is stopped then AZD5363 can be given on a 4on/3off continuous schedule.
11337424|NCT02451800|Active Comparator|stretching by DVD|"For the intervention participants are asked to do stretching exercises at home following Bob Anderson's DVD-Stretching: the DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
11337397|NCT02451943|Experimental|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
11337398|NCT02451943|Placebo Comparator|Doxorubicin + Placebo|75 mg/m^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
11337399|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:
~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).
~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:
~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.
~Part C were Japan participants. Part C were Japan participants."
11337400|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
11337401|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.
~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
11337402|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
11337403|NCT02451904||Uncomplicated Malaria|Intensive monitoring
11337404|NCT02451904||Sepsis|Intensive monitoring
11337405|NCT02451904||Acidosis|Intensive monitoring
11337406|NCT02451904||Encephalitis|Intensive monitoring
11337407|NCT02451904||Healthy Individuals|Monitoring
11337408|NCT02451891|Active Comparator|Group 1a|MVA-EBO Z (1 x 10^8 pfu)
11337409|NCT02451891|Active Comparator|Group 1b|MVA-EBO Z (1.5 x 10^8 pfu)
11337410|NCT02451891|Active Comparator|Group 2|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 14 days
11337411|NCT02451891|Active Comparator|Group 3|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 28 days
11337412|NCT02451891|Active Comparator|Group 4|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1.5 x 10^8 pfu) after 28 days
11337413|NCT02451878|Experimental|Intervention|The E-Couch self-help social anxiety module which is based on cognitive behavioural therapy principles. This module contains a literacy section and 5 toolkits comprising exposure practice, cognitive restructuring (modifying your thinking), attention practice, social skills training and relaxation. E-Couch is designed to be completed at the participant's own pace. It is free to use, browser-based and widely accessible on a range of connected devices.
11337414|NCT02451878|No Intervention|Control|Wait list control (WLC)
11337415|NCT02451865|Experimental|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
11337416|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
11337417|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
11337418|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
11337419|NCT02451826|Active Comparator|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
11337420|NCT02451826|Active Comparator|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
11337421|NCT02451813|Experimental|Intervention|"A 22 GA 5 cm nerve block needle will be advanced to the following conditions:
~Needle tip slightly indenting the fascia iliaca
~Needle tip advanced through fascia iliaca
~Needle tip slightly indenting the anterior surface of the femoral nerve
~Needle tip withdrawn 1 mm from nerve.
~At each of these conditions, 1 ml of dextrose solution will be injected and spread of injectate observed sonographically. A blinded observer will measure injection pressure. If opening pressure reaches 15 psi, this investigator will halt the injection. In addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4."
11337422|NCT02451800|Experimental|in-class yoga|"The intervention is a in-class yoga course taught by yoga instructors for 3 times per week for 3 months. This class is based on Peggy Cappy's Program: More Yoga for Every Body. Class is taught at Sanford Wellness Centers in Sioux Falls, South Dakota and Fargo, North Dakota. Each class in 1 hour in length."
11337423|NCT02451800|Active Comparator|yoga by DVD|"For the intervention participants are asked to do yoga at home following the Peggy Cappy's Program: More Yoga for Every Body DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
11337425|NCT02451787|Experimental|Active|vitamin D supplementation group (2500 IU day for 3 months)
11337426|NCT02451787|Placebo Comparator|Control|no vitamin D supplementation
11337427|NCT02451774|Experimental|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.
~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
11337428|NCT02451774|Placebo Comparator|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
11337429|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
11337430|NCT02451748|Other|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28<2.6). The subjects that achieve remission (DAS28<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
11337431|NCT02451748|Other|DMARD's plus Cimzia (Certolizumab pegol)|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
11337432|NCT02451735|No Intervention|Intervention Development|Psychoeducational Intervention (PEI) development. PEIs include printed and DVD materials, and represent a commonly used and effective approach to implement theoretically based individual-level interventions. These materials serve as important sources of information for the general public, cancer patients, and survivors from a variety of backgrounds, including populations with limited health literacy. An interview and feedback collection process will take place to provide data to improve current PEI materials.
11337433|NCT02451735|Experimental|Intervention Pilot - Intervention Group|The intervention group will receive the PEI materials: video and booklet. Self-reported feedback will be collected and reviewed to compare response with the control group.
11337434|NCT02451735|Active Comparator|Intervention Pilot - Control Group|The control group will receive a patient factsheet about Genetic Counseling (GC). Self-reported feedback will be collected and reviewed to compare response with the intervention group.
11337435|NCT02451722|Active Comparator|Healthy subjects|"Kyboot shoes will be administered to the healthy subjects.
~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
11337436|NCT02451722|Active Comparator|Diabetic patients|"Kyboot shoes will be administered to the diabetic patients.
~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
11337437|NCT02451709|Experimental|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.
~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.
~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
11337438|NCT02451709|Active Comparator|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.
~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.
~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.
~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
11337439|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
11337440|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
11337441|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
11337442|NCT02451683|Experimental|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
11337443|NCT02451683|Active Comparator|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
11337444|NCT02451670|Experimental|Prioritized Clinical Decision Support|Patients receiving care in clinics randomized to the intervention arm of the study and their primary care providers were presented with patient-specific written advice as to prioritized treatment and lifestyle changes that could reduce their cardiovascular risk, prompted by an electronic health record-based alert during their primary care visit.
11337445|NCT02451670|No Intervention|Usual Care|Patients receiving care in clinics randomized to the usual care arm of the study and their providers were not presented with the prioritized clinical decision support.
11337446|NCT02451657||Cohort|
11337447|NCT02451644|Experimental|high risk for PTD with pedometer|Patient with high risk for preterm delivery including short cervix or rapture of membranes
11337448|NCT02451631|Active Comparator|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
11337449|NCT02451631|Experimental|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
11337450|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
11337451|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
11337452|NCT02451605|Active Comparator|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
11337554|NCT02450903|Experimental|LDK378|Oral LDK378 750mg once daily
11337453|NCT02451605|Active Comparator|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
11337454|NCT02451605|Active Comparator|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
11337455|NCT02451579|Active Comparator|Cetirizine Hydrochloride|Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
11337456|NCT02451579|Placebo Comparator|Placebo|Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
11337457|NCT02451566||Fast-Track Group|Includes subject who complete the Fast-Track EVAR protocol.
11337458|NCT02451566||Standard P-EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access.
11337459|NCT02451566||Standard EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair).
11337460|NCT02451553|Experimental|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11337461|NCT02451540|Active Comparator|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
11337462|NCT02451540|Placebo Comparator|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
11337463|NCT02451527|Experimental|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
11337464|NCT02451514|Experimental|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
11337465|NCT02451514|Experimental|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
11337466|NCT02451514|Experimental|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
11337467|NCT02451501|Experimental|Lying|Nebulization in lying position
11337468|NCT02451501|Active Comparator|Sitting|Nebulization in sitting position
11337469|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
11337470|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
11337471|NCT02451475|Other|Amitriptyline|Amitriptyline 25 mg/day
11337472|NCT02451475|Active Comparator|Venlafaxine|Venlafaxine 75 mg/day
11337473|NCT02451475|Active Comparator|Paroxetine|Paroxetine 25 mg/day
11337474|NCT02451462|Experimental|Zoledronic acid arm|Zoledronic acid
11337475|NCT02451462|No Intervention|placebo arm|placebo
11337476|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
11337477|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
11337478|NCT02451423|Experimental|MPDL3280A|MPDL3280A: Intravenously; Day 1 of each 21-day Cycle
11337479|NCT02451410|Experimental|Nutrition and physical activity|This arm includes all preschool classes receiving the educational and behavioral intervention to improve nutrition and physical activity
11337480|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
11337481|NCT02451384|Experimental|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
11337482|NCT02451384|Experimental|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
11337483|NCT02451384|Experimental|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
11337484|NCT02451371|Experimental|tDCS|Patients with schizophrenia to receive tDCS treatment
11337485|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
11337486|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
11337487|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
11337488|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged >=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
11337489|NCT02451345|Experimental|Intervention|Personalized risk model+website+phone coaching
11337490|NCT02451332|Experimental|vaccinated|These women will have received the seasonal influenza vaccine.
11337491|NCT02451319|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
11337492|NCT02451319|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
11337493|NCT02451319|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
11337494|NCT02451306|Experimental|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.
~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
11337495|NCT02451306|Placebo Comparator|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.
~The placebo does not contain any psychoactive substance."
11337496|NCT02451306|No Intervention|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
11337497|NCT02451293|Active Comparator|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
11337498|NCT02451293|Placebo Comparator|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
11337499|NCT02451280|Experimental|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
11337500|NCT02451280|Experimental|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
11337501|NCT02451280|Experimental|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
11337502|NCT02451267|Experimental|positive CPR: research group|physical therapy treatment with aerobic exercise
11337503|NCT02451267|Experimental|negative CPR: research group|physical therapy treatment with aerobic exercise
11337504|NCT02451267|Active Comparator|positive CPR: control group|physical therapy treatment
11337505|NCT02451267|Active Comparator|negative CPR: control group|physical therapy treatment
11337506|NCT02451254|Experimental|Atrial Fibrillation|Atrial Fibrillation patients electively admitted for circumferential ablation of the pulmonary veins.
11337507|NCT02451254|Active Comparator|control|patients electively admitted for SVT ablation
11337508|NCT02451241|Sham Comparator|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
11337509|NCT02451241|Experimental|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
11337510|NCT02451228||Single-group|Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.
11337511|NCT02451215|Experimental|Laser interstitial thermotherapy (LITT) treated patients|All patients enrolled on the trial will undergo LITT therapy per protocol. Side-effects and outcomes will be monitored and compared with disease matched historical controls.
11337512|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.
~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
11337513|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.
~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
11337514|NCT02451189|Experimental|Inulin acetate ester|Inulin acetate ester, 10g/day for 30 days
11337515|NCT02451189|Experimental|Inulin propionate ester|Inulin propionate ester, 10g/day for 30 days
11337516|NCT02451189|Experimental|Inulin butyrate ester|Inulin butyrate ester, 10g/day for 30 days
11337517|NCT02451176|Active Comparator|Active Comparator: Davol Bard ®Soft Mesh|Device: Davol Bard ®Soft Mesh Synthetic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: synthetic mesh SoftMesh™ (CR Bard)
11337518|NCT02451176|Active Comparator|Active Comparator: LifeCell Strattice®|Device: LifeCell Strattice® Reconstructive Tissue Matrix Biologic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: Biologic mesh Strattice
11337519|NCT02451163|Active Comparator|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
11337520|NCT02451163|Placebo Comparator|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
11337521|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
11337522|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
11337523|NCT02451137|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre [U/mL]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
11337782|NCT02449447|Experimental|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
11337524|NCT02451137|Active Comparator|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
11337525|NCT02451124|Experimental|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
11337526|NCT02451111|Active Comparator|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
11337527|NCT02451111|Placebo Comparator|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
11337528|NCT02451098|Experimental|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)
11337529|NCT02451098|Active Comparator|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, placebo will be administered (Duration 8 weeks)
11337530|NCT02451098|Experimental|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)
11337531|NCT02451098|Active Comparator|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, placebo will be administered (Duration 8 weeks)
11337532|NCT02451098|Experimental|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)
11337533|NCT02451098|Active Comparator|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, placebo will be administered (Duration 8 weeks)
11337534|NCT02451085|Experimental|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
11337535|NCT02451085|Other|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
11337536|NCT02451072|Experimental|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
11337537|NCT02451059|Experimental|Intervention-WE CARE|"The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.
~Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.
~A peer patient navigator will offer personalized guidance to families with accessing community resources. The patient navigator will be available for at least a 1/2 day per week at each intervention health center to meet with families and offer guidance. Providers can communicate the patient navigator to refer families via the electronic medical record and families will also have the opportunity to contact the peer navigator at any time via the hotline number listed on the referral information sheets."
11337538|NCT02451059|No Intervention|Control-Standard of Care|Participants in the delayed-intervention control group will receive standard pediatric care. However, since the health centers share a common EMR, and for ethical reasons, investigators will also embed the health IT referral mechanism into the EMR at the control sites. Control providers will be made aware of this prior to the start of the study. Although this may potentially reduce the effect size, the investigator's prior study found that the impact on referral rates of provider access to resource information was minimal. Families at control health centers will not receive the WE CARE surveys at health supervision visits and will not have access to the peer patient navigators
11337539|NCT02451033|Active Comparator|standard medical therapy|Standard medical therapy
11337540|NCT02451033|Active Comparator|G-CSF|Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
11337541|NCT02451033|Active Comparator|G-CSF plus growth hormone|Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.
11337542|NCT02451020|Experimental|Altitude exposure|Stay at 3200 m for 3 weeks
11337543|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
11337544|NCT02450994|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
11337545|NCT02450994|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
11337546|NCT02450981|Experimental|BCD-021 group|BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.
11337547|NCT02450968|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
11337548|NCT02450968|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
11337549|NCT02450955|Active Comparator|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading.
11337550|NCT02450955|Experimental|Occiput-Atlas-Axis Technique|The technique is applied in two stages: in the first stage, a light core decompression is performed and then small circumductions are made with the aim of increasing viscoelasticity of tissues. Subsequently the appropriate joint barrier is sought by selective tension and high-velocity rotation manipulation is performed in a cranial helical motion without raising the subjects head.
11337551|NCT02450942|Experimental|18F-FDS injection and PET/CT scan|The patients were intravenously injected with 18F-FDS and underwent PET/CT scan 1 h after the injection.
11337552|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
11337553|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
11337555|NCT02450890|Placebo Comparator|Placebo First, then ORADUR®|Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
11337556|NCT02450890|Experimental|ORADUR® First, then Placebo|ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)
11337557|NCT02450877|Experimental|Azacitidine Treatment|: Subjects randomized to the experimental arm will receive up to 3 cycles of IV azacitidine on Days 1 through 7 at the dose selected from the safety run-in part.
11337558|NCT02450877|Other|Control Arm: 'Watch and Wait'|Subjects randomized to the control arm will undergo 'watch and wait' until clinical relapse (defined as at least 5% blasts in PB (peripheral blood) and/or BM (bone marrow) and/or proven histological extramedullary relapse).
11337559|NCT02450864|Experimental|patient with ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
11337560|NCT02450864|Sham Comparator|patient without ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
11337561|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders
11337562|NCT02450838|Experimental|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
11337563|NCT02450838|Experimental|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
11337564|NCT02450838|Placebo Comparator|Placebo|Participants will receive one IM injection of placebo at study entry.
11337565|NCT02450825|Other|Mechanically ventilated patients|Mechanically ventilated patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 and Day 2 to 4. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
11337566|NCT02450825|Other|Spontaneously breathing patients|Spontaneously breathing patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 only. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
11337567|NCT02450812||Radium-223-dichloride (Xofigo, BAY88-8223)|patients with mCRPC with symptomatic bone metastases
11337568|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
11337569|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
11337570|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
11337571|NCT02450786|Experimental|Donepezil group|Donepezil is started in 5mg for 8 weeks followed by dose escalation to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
11337572|NCT02450786|No Intervention|control group|No administration of any therapeutic medications for dementia including cholinesterase inhibitor or NMDA receptor blocking agents. Standard treatment protocol of Parkinson's disease with mild cognitive impairment would be fulfilled including dopaminergic or nondopaminergic medications as well as nootropic drugs.
11337573|NCT02450773|Experimental|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
11337574|NCT02450773|Placebo Comparator|Placebo|Placebo #1, Placebo #2
11337575|NCT02450760|Other|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
11337576|NCT02450760|Other|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
11337577|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
11337578|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
11337579|NCT02450721||Acute stroke|"Patients in the acute phase of atherothrombotic stroke or TIAs with 50-99% ACAS within the first 3 days af vascular event.
~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE, National Institutes of Health Stroke Scale (NIHSS)"
11337580|NCT02450721||Stable carotid artery stenosis|"Patients with 50-99% ACAS without history of vascular events during one month before enrollment.
~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE"
11337581|NCT02450721||Control group|Healthy volunteers without ACAS Interventions to be administered:Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE
11337973|NCT02448277|Experimental|Glidescope|experimental Glidescope group:Glidescope is used to assist nasotracheal tube into trachea
11337582|NCT02450708||For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
11337583|NCT02450708||For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
11337584|NCT02450695|Experimental|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
11337585|NCT02450695|Sham Comparator|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
11337586|NCT02450682|Active Comparator|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
11337587|NCT02450682|Other|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
11337588|NCT02450656|Experimental|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
11337589|NCT02450656|Active Comparator|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
11337590|NCT02450643|Active Comparator|Test then Control|Subjects will perform a DBPCFC with the Test formula followed by the Control formula
11337591|NCT02450643|Active Comparator|Control then Test|Subjects will perform a DBPCFC with the Control formula followed by the Test formula
11337592|NCT02450630|Experimental|training on diagnosis, treatment and referral of children|Intervention Arm : training in diagnosis, treatment and referral of sick children
11337593|NCT02450630|No Intervention|Presumptive treament of sick children|Control Arm - Training of private providers in completing study tools i.e. filling in register and referral forms. No training in diagnosis, treatment and referral and no community awareness on referral
11337594|NCT02450617|Experimental|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
11337595|NCT02450617|Active Comparator|Conventional Individual treatment - PTSD|Conventional individual treatment.
11337596|NCT02450617|Experimental|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
11337597|NCT02450617|Active Comparator|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
11337598|NCT02450604|Other|Patients with chronic pains of unknown aetiology|
11337599|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
11337600|NCT02450578|Experimental|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
11337601|NCT02450578|Active Comparator|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
11337602|NCT02450578|Experimental|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
11337603|NCT02450578|Experimental|Cohort 3: DSM265 / placebo, sporozoite inoculum|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
11337604|NCT02450565||Neuropathic pain subjects|The diagnosis of neuropathic pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
11337605|NCT02450565||Nociceptive pain subjects|The diagnosis of nociceptive pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
11337606|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
11337607|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
11337608|NCT02450552|Placebo Comparator|Placebo|
11337609|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11337610|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11337611|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
11337612|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
11337613|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
11337614|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
11337615|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
11337616|NCT02450500|Experimental|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
11337617|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
11337618|NCT02450474|Other|A: baseline - IPC|"A: baseline - IPC - washout - NMES - washout - follow up
~The baseline phase, washout phase and follow up phase will consist of treatment as normal. IPC phase will consist of normal care plus IPC of the lower limbs for the duration of each dialysis session."
11337619|NCT02450474|Other|B: baseline - NMES|"B: baseline - NMES - washout - IPC - washout follow up
~The baseline phase, washout phase and follow up phase will consist of treatment as normal. NMES phase will consist of normal care plus stimulation of the foot and calf muscles for a period of one hour during dialysis."
11337620|NCT02450461||Asthma|20 patients with asthma
11337621|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
11337622|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11337623|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11337624|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11337625|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11337626|NCT02450435||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11337627|NCT02450435||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11337628|NCT02450435||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11337629|NCT02450435||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11337630|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11337631|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11337632|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11337633|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11337634|NCT02450409|Active Comparator|gap technique (GT)|"The patients receive a total knee arthroplasty using the established gap technique (gold standard serving as control). The intervention is the implantation of a total knee arthroplasty with this specific technique.
~Implantation of TKA using the gap technique is the intervention. Intervention is not a drug but a specific operative technique."
11337635|NCT02450409|Experimental|anatomical alignment (AA)|"The patients receive a total knee arthroplasty using the new anatomical alignment technique (experimental). The intervention is the implantation of a total knee arthroplasty with this specific technique.
~Implantation of TKA using anatomical alignment Intervention is not a drug but a specific operative technique."
11337636|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
11337637|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
11337638|NCT02450370|Active Comparator|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
11337639|NCT02450370|Experimental|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
11337640|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11337641|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11337642|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11337643|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11337644|NCT02450344|Experimental|Internet intervention|Interactive health promotion
11337645|NCT02450344|Active Comparator|Conventional intervention|Passive health promotion
11337646|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
11337647|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
11337648|NCT02450318|Experimental|Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
11337649|NCT02450305||Treated with HBO|QOL questionnaires at 5 time points for those having HBO therapy at least one year post radiation therapy for head and neck cancer, daily x6 weeks
11337650|NCT02450305||Not treated with HBO|QOL questionnaires for those at least one year post radiation therapy for head and neck cancer at 5 times points.
11337651|NCT02450279|Active Comparator|Nebulization with a vibrating-mesh nebulizer|Nebulization performed with a vibrating-mesh nebulizer
11337652|NCT02450279|Active Comparator|Nebulization with a jet nebulizer|Nebulization performed with a jet nebulizer
11337653|NCT02450266|Active Comparator|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
11400097|NCT02035488|Experimental|Tobramycin|Patients with bronchiectasis
11337654|NCT02450266|Experimental|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
11337655|NCT02450253|Active Comparator|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
11337656|NCT02450253|Placebo Comparator|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
11337657|NCT02450240||Depression and Anxiety Disorders|"350 subjects who screen positive for anxiety or depressive symptoms on the Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
11337658|NCT02450240||Eating Disorders|"350 subjects who screen positive for problems related to eating behavior on the Eating Disorder Screen (SCOFF), score ≥ 2.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
11337659|NCT02450240||Substance Use Disorders|"350 subjects who screen positive for problems related to substance use on the Drug Abuse Screening Test (DAST-10), score > 2.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
11337660|NCT02450240||Healthy Controls|"150 subjects who do not screen positive for anxiety and depression symptoms or problems related to eating behavior and/or substance use.
~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
11337661|NCT02450227|Active Comparator|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.
~Followed by:
~Minced spinach (10 mg lutein) given every second day for a 15 days period."
11337662|NCT02450227|Experimental|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.
~Followed by:
~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
11337663|NCT02450214|Sham Comparator|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
11337664|NCT02450214|Experimental|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
11337665|NCT02450214|Experimental|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
11337666|NCT02450201|Experimental|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
11337667|NCT02450201|Experimental|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
11337668|NCT02450188|Active Comparator|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
11337669|NCT02450188|Active Comparator|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).
~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
11337670|NCT02450175|No Intervention|Cases|Patients with cancer whose platelets are examined
11337671|NCT02450175|Placebo Comparator|Control|Patients without cancer whose platelets are examined for comparison
11337672|NCT02450162||conventional lateral rectus recession|This is the standard technique for recession with two single-armed sutures.Exposure of the rectus muscle insertion includes freeing the insertion and proximal muscle borders sufficiently to place the sutures. And the needle is passed through the tendon avoiding the anterior ciliary arteries. If the sutures are passed as shown a true knot is formed, and the muscle is detached. Then a caliper measures from the limbus or the original insertion. A passage of the needle through sclera. The recessed muscle is ideally parallel to the old insertion (or nearly so). Conjunctival incision was finally sutured.
11337673|NCT02450162||hang-back lateral rectus recession|"The hang-back recession has been described as a simple, safe alternative to conventional recession. The procedure is said to be less likely to result in scleral perforation because needles are placed through relatively thicker sclera near the insertion site. It is the modified techique for recession with one double-armed sutures."
11337674|NCT02450149|Experimental|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
11337675|NCT02450136|Experimental|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
11337676|NCT02450123|Experimental|sunitinib|sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.
11337677|NCT02450110|Experimental|Intervention|Spinal cord stimulation on top of standard treatment
11337678|NCT02450110|No Intervention|Control|Standard treatment
11337679|NCT02450097|Other|Lifestyle counseling|"Intermittent Caloric restriction in 3 Groups:
~I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat"
11337680|NCT02450084|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
11337681|NCT02450084|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
11337682|NCT02450058|Active Comparator|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
11337683|NCT02450058|Active Comparator|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
11337684|NCT02450045|Active Comparator|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
11337685|NCT02450045|No Intervention|Control|Patients will receive standard care without a continuous femoral nerve block.
11337686|NCT02450032|Experimental|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
11337687|NCT02450019|Other|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP. Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to protective.
11337688|NCT02450019|Other|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2). Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to traditional.
11337689|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
11337690|NCT02449980|Active Comparator|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
11337691|NCT02449980|Active Comparator|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
11337692|NCT02449967|Experimental|HepaSphere|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
11337693|NCT02449967|No Intervention|control|pancreatic cancer patients did not receive any interventional therapy
11337694|NCT02449954|Active Comparator|morphine group|intravenous 0.1mg/kg morphine
11337695|NCT02449954|Active Comparator|tramadol group|intravenous 2 mg/kg tramadol
11337696|NCT02449954|Active Comparator|ketorolac group|intravenous30 mg ketorolac
11337697|NCT02449941||Helicobacter pylori(HP) positive|Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
11337698|NCT02449928|Active Comparator|lactate group,|
11337699|NCT02449928|Active Comparator|control group|
11337700|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
11337701|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
11337702|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
11337703|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
11337704|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
11337705|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
11337706|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
11337707|NCT02449876|Experimental|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
11337708|NCT02449863||Low risk ultrasound|Patients with a low risk ultrasound
11337709|NCT02449863||High risk ultrasound|Patients with a high risk ultrasound
11337710|NCT02449850|No Intervention|Observation only|Observation only
11337711|NCT02449850|Experimental|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
11337712|NCT02449850|Experimental|Skin care|Intervention: regular baths with bath-oil 0.5-9 months of age
11337713|NCT02449850|Experimental|Food intervention and skin care|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age Intervention: regular baths with bath-oil 0.5-9 months of age
11337714|NCT02449837||Head and Neck Cancer|Patient with locally advanced head and neck cancer but no distant metastasis scheduled to receive radiotherapy to the head and neck region with or without chemotherapy/targeted therapy (palliative or curative intent).
11400359|NCT02033720||Asystole|Initial arrest rhythm is asystole.
11337715|NCT02449837||Cervical Cancer|Patients with locally advanced cervical cancer without distant metastasis scheduled for radiotherapy to the pelvic region with or without chemotherapy/targeted therapy (palliative or curative intent).
11337716|NCT02449837||Non-Small Cell Lung Cancer|Patients with stage I to III non-small cell lung cancer, without distant metastasis, scheduled to receive stereotactic body radiotherapy for early stage lung disease and/or external beam radiotherapy for locally advanced lung disease, with or without concurrent/sequential chemotherapy and/or targeted therapy (curative intent).
11337717|NCT02449837||Rectal Cancer|Patients with locally advanced rectal cancer (no distant metastasis) scheduled to receive neoadjuvant chemoradiotherapy (curative intent).
11337718|NCT02449837||Metastatic Prostate Cancer|Patients with metastatic prostate cancer scheduled for palliative radiotherapy, or biochemically recurrent prostate cancer following radical prostatectomy scheduled for salvage prostatic fossa radiotherapy, with or without androgen deprivation, or with high risk prostate cancer.
11337719|NCT02449837||Oligometastatic Disease|Patients with oligometastatic cancer, defined as any solid malignancy with< 5 measurable sites of metastatic disease, limited to a maximum of 3 anatomic organ systems, excluding the primary tumor and regional lymph nodes. At least 1 site of metastatic disease, but as many as all 5 sites, in addition to the primary tumor and regional lymph nodes, is amenable to local ablative therapy with external beam radiation, stereotactic cranial radiosurgery or stereotactic body radiotherapy. Treatment will be guided by multi-disciplinary evaluation and may also include surgery, chemotherapy or target agents at the discretion of the primary oncologists. Patients may present with oligometastatic disease or have oligometastatic disease recurrence after definitive therapy for localized disease.
11337720|NCT02449837||Immunotherapy|Melanoma or metastatic NSCLC scheduled to receive ipilimumab, nivolumab, and/or pembrolizumab.
11337721|NCT02449837||Head and Neck Induction chemotherapy|Locally advanced head and neck cancer (HNSCC) scheduled to receive induction chemotherapy followed by radiotherapy.
11337722|NCT02449837||Ovarian Cancer|Patients with Ovarian cancer that receive any type of treatment or no treatment.
11337723|NCT02449837||Healthy Cohort|Healthy individuals over 50 with no known malignancy.
11337724|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
11337725|NCT02449811||Perindopril|Treatment period 1: Perindopril 5mg, oral, once daily, for 4 weeks Treatment period 2: Perindopril 10mg, oral, once daily, for 4 weeks
11337726|NCT02449811||Olmesartan|Treatment period 1: Olmesartan 20mg, oral, once daily, for 4 weeks Treatment period 2: Olmesartan 40mg, oral, once daily, for 4 weeks
11337727|NCT02449811||Amlodipine|Treatment period 1: Amlodipine 5mg, oral, once daily, for 4 weeks Treatment period 2: Amlodipine 10mg, oral, once daily, for 4 weeks
11337728|NCT02449811||Hydrochlorothiazide|Treatment period 1: Hydrochlorothiazide 25mg, oral, once daily, for 4 weeks Treatment period 2: Hydrochlorothiazide 50mg, oral, once daily, for 4 weeks
11337729|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
11337730|NCT02449785|Experimental|Cystic fibrosis adults|
11337731|NCT02449759|Experimental|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
11337732|NCT02449759|No Intervention|Control Group|This group will receive no intervention
11337733|NCT02449746|Active Comparator|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.
~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
11337734|NCT02449746|Active Comparator|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
11337735|NCT02449733|Experimental|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
11337736|NCT02449733|Experimental|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).
~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
11337737|NCT02449720|Active Comparator|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
11337783|NCT02449447|Active Comparator|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
11337784|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study
~There was no intervention - just a questionnaire for each group"
11337738|NCT02449720|Placebo Comparator|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
11337739|NCT02449720|Active Comparator|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
11337740|NCT02449720|Placebo Comparator|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
11337741|NCT02449707|Active Comparator|Control|Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
11337742|NCT02449707|Experimental|Ultrasonic Pins|Lateral Window Technique Augmentation for Maxillary Sinus with the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of the Purus® Cancellous Allograft, and Resorb X Membrane.Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
11337743|NCT02449694|Experimental|OCS Liver|OCS Liver will be used to preserve the donor liver
11337744|NCT02449681|Experimental|TH-4000 (Tarloxotinib)|
11337745|NCT02449668|Sham Comparator|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
11337746|NCT02449668|Experimental|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
11337747|NCT02449655|Experimental|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
11337748|NCT02449655|Active Comparator|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
11337749|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
11337750|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
11337751|NCT02449629||TGMY in HIV Care|TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit (AMTU) site or elsewhere.
11337752|NCT02449629||TGMY Not in HIV Care|TGMY (16-24 years of age) not currently in care who are living with HIV, not living with HIV, or those who are unaware of their HIV status.
11337753|NCT02449629||Health Care and Social Service Providers|Health care and social service providers who work with TGMY at AMTU sites or elsewhere that serve TGMY within the AMTU cities.
11337754|NCT02449616|Experimental|Study Drug|MST-188
11337755|NCT02449603|Experimental|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
11337756|NCT02449603|Active Comparator|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper <7 mmol/L.
11337757|NCT02449590|Active Comparator|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
11337758|NCT02449590|Placebo Comparator|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
11337759|NCT02449577|Experimental|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337760|NCT02449577|Experimental|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337974|NCT02448264|Experimental|BCX7353|BCX7353 capsules administered orally
11337761|NCT02449577|Experimental|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337762|NCT02449577|Experimental|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337763|NCT02449577|Experimental|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337764|NCT02449577|Experimental|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337765|NCT02449577|Experimental|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337766|NCT02449577|Experimental|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337767|NCT02449577|Experimental|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337768|NCT02449577|Experimental|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337769|NCT02449577|Experimental|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
11337770|NCT02449564|Experimental|sirolimus|sirolimus 1mg daily
11337771|NCT02449551|Experimental|Volitinib|Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
11337772|NCT02449538|Experimental|everolimus|everolimus 10 mg qd daily
11337773|NCT02449525|Experimental|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
11337774|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
11337775|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
11337776|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
11337777|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
11337778|NCT02449486|Active Comparator|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
11337779|NCT02449486|Placebo Comparator|Placebo|Saline infusion 4 ml/h for 48 hours
11337780|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
11337781|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
11337836|NCT02449083||Arm 2|Patients with atrioseptal or ventriculoseptal Shunt with indication to coronary angiography
11337785|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study
~There was no intervention - just a questionnaire for each group"
11337786|NCT02449421|Experimental|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
11337787|NCT02449421|Experimental|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
11337788|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
11337789|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
11337790|NCT02449382|Active Comparator|continuous venovenous hemofiltration|CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.
11337791|NCT02449382|Active Comparator|Control group|Treatment of hypernatremia is correction of water deficit.
11337792|NCT02449369|Active Comparator|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
11337793|NCT02449369|Active Comparator|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
11337794|NCT02449369|Experimental|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
11337795|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
11337796|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
11337797|NCT02449343|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11337798|NCT02449343|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11337799|NCT02449330|Experimental|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
11337800|NCT02449330|No Intervention|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
11337801|NCT02449330|Experimental|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
11337802|NCT02449330|No Intervention|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
11337803|NCT02449317|Other|Control|standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
11337804|NCT02449317|Experimental|Bioimpedance guided|"Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water
~extracellular water/total body water < 0.36 : 4 ml/kg/hr
~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr
~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
11337805|NCT02449304|Experimental|Endometrial Ablation (4th gen)|A single-centre uncontrolled observational study is proposed. All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents, who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo RFA G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
11337806|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
11337807|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
11337808|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
11337809|NCT02449278|Experimental|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .
~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
11337810|NCT02449278|Active Comparator|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
11337811|NCT02449265|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
11337837|NCT02449083||Arm 3|Patients with chronic obstructive pulmonary disease with indication to coronary angiography
11337838|NCT02449070|Experimental|Nicorandil|Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.
11337812|NCT02449265|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).
~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
11337813|NCT02449252|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
11337814|NCT02449252|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).
~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
11337815|NCT02449239|Experimental|Vicinium|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.
~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
11337816|NCT02449200|Experimental|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
11337817|NCT02449200|No Intervention|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
11337818|NCT02449187|Experimental|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing
~Interventions:
~Drug: JLP-1310"
11337819|NCT02449187|Experimental|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing
~Interventions:
~Drug: JLP-1310"
11337820|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
11337821|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
11337822|NCT02449161|Experimental|MPA|medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation
11337823|NCT02449161|Placebo Comparator|placebo|1 placebo/day, for 90 days, following endometrial ablation
11337824|NCT02449148|Experimental|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
11337825|NCT02449148|Experimental|Continuous Calorie Restriction|daily energy intake of 80 %
11337826|NCT02449148|No Intervention|Healthy Nutrition|general advice on healthy nutrition
11337827|NCT02449122|Experimental|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
11337828|NCT02449122|Active Comparator|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
11337829|NCT02449122|No Intervention|Control|Liver cancer patients never received any interventional therapy.
11337830|NCT02449109|No Intervention|Control|Liver cancer patients never received any interventional therapy.
11337831|NCT02449109|Experimental|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
11337832|NCT02449109|Active Comparator|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
11337833|NCT02449096|Other|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation
~All Patients will be operated following a standardized protocol of our foot and ankle department:
~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.
~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.
~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.
~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
11337834|NCT02449096|Active Comparator|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
11337835|NCT02449083||Arm 1|Patients with indication for MRI and coronary angiography
11337840|NCT02449057|Experimental|JUST|Juveniles Under Supervision and Treatment. This entails swift, certain, and modest sanctions for violations of terms of community supervision.
11337841|NCT02449057|No Intervention|Probation-as-Usual|Juvenile probation-as-usual.
11337842|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
11337843|NCT02449031||TOBI Podhaler cohort|
11337844|NCT02449031||non-TOBI Podhaler cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
11337845|NCT02449018|Experimental|QBW251|QBW251 will be provided to participants during 70 days
11337846|NCT02449018|Placebo Comparator|Placebo|Placebo will be provided to participants during 70 days
11337847|NCT02449005|Experimental|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
11337848|NCT02449005|Experimental|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
11337849|NCT02449005|Active Comparator|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
11337850|NCT02448992|Experimental|PCI via hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian-iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole-brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
11337851|NCT02448992|No Intervention|observation without PCI|
11337852|NCT02448979|Active Comparator|Left thoracotomy|Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
11337853|NCT02448979|Active Comparator|Right thoracotomy|Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)
11337854|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
11337855|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
11337856|NCT02448953|Active Comparator|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
11337857|NCT02448953|Active Comparator|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
11337858|NCT02448940|Experimental|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
11337859|NCT02448940|Placebo Comparator|lactose|2 capsule/day Containing lactose
11337860|NCT02448927|Other|TAVI patients without balloon aortic valvuloplasty|Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
11337861|NCT02448927|Active Comparator|TAVI patients with balloon aortic valvuloplasty|Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
11337862|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).
~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).
~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).
~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.
~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
11337863|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).
~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).
~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).
~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.
~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
11337864|NCT02448888|Experimental|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
11337865|NCT02448888|Experimental|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
11337866|NCT02448875|Active Comparator|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
11337867|NCT02448875|Experimental|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
11337868|NCT02448875|Experimental|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
11337869|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
11337871|NCT02448849|Experimental|MSC recipients|The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.
11337872|NCT02448849|Placebo Comparator|Placebo|The patients with nonunion fracture who underwent percutaneous injection of placebo.
11337873|NCT02448836|Experimental|Active dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of dTMS active treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
11337874|NCT02448836|Sham Comparator|Sham dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
11337875|NCT02448823|Experimental|Stylish Events and Mass Media|Mass Media (radio, posters) and annual Stylish Man/Stylish Living Event (SMLEvent), a multimedia event promoting CHP.
11337876|NCT02448823|Active Comparator|Control arm: mass media only|Mass media
11337877|NCT02448810|Experimental|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
11337878|NCT02448810|Experimental|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
11337879|NCT02448810|Experimental|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
11337880|NCT02448810|Experimental|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
11337881|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
11337882|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
11337883|NCT02448797|Experimental|icotinib|125 mg three times daily (375 mg per day) orally for two years.
11337884|NCT02448797|Active Comparator|standard chemotherapy|"Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.
~cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.
~For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles."
11337885|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
11337886|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"After the screening procedures confirm eligibility participate in the research study.
~Palbociclib Oral, predetermined time per cycle, predetermined dosage per protocol.
~Bazedoxifene Oral, daily per cycle, predetermined dosage per protocol."
11337887|NCT02448745|No Intervention|Control|21 clusters composed of one or more villages with a total number of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is the only malaria control intervention.
11337888|NCT02448745|Experimental|Intervention|21 clusters composed of one or more villages with a total of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is available and in addition insecticide treated wall lining is installed in all sleeping areas with homeowner consent. All 4 walls and the ceiling are covered with lining.
11337889|NCT02448732|Experimental|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
11337890|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
11337891|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
11337892|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
11337893|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
11337894|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
11337895|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
11337896|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
11337897|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
11337898|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
11337899|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
11337900|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
11337901|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
11337902|NCT02448706|Active Comparator|Hearing Aid Fitting Order A|High level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
11337903|NCT02448706|Active Comparator|Hearing Aid Fitting Order B|Low level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
11337904|NCT02448693|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging. All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
11337905|NCT02448693|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly Narrow Band Imaging and secondly High Definition White Light Endoscopy (WLE). All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
11337906|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
11337907|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
11337972|NCT02448277|Experimental|Pentax Airway scope|experimental Pentax Airway scope group:Pentax Airway scope is used to assist for nasotracheal intubation.
11337908|NCT02448667|Experimental|FAXE Kondi - a sugary soft-drink|100 ml FAXE Kondi (10 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
11337909|NCT02448667|Placebo Comparator|FAXE Kondi Free - a sugarfree soft-drink|100 ml FAXE Kondi Free (0 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
11337910|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
11337911|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
11337912|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
11337913|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
11337914|NCT02448641|Sham Comparator|Sham Control|Sham surgery
11337915|NCT02448628|Experimental|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
11337916|NCT02448615||Birth Cohort|The cohort will comprise approximately 1500 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02208960).
11337917|NCT02448602|Other|Single point group (Shenmen)|Patients will be acupuncture with Shenmen(HT7).
11337918|NCT02448602|Other|Sancai coordinated points group|Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).
11337919|NCT02448602|Other|Control group|Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.
11337920|NCT02448589|Experimental|TAS-119 Monotherapy|"Dose Escalation:
~A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:
~Dose Expansion:
~A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)"
11337921|NCT02448576|Experimental|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
11337922|NCT02448576|No Intervention|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
11337923|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
11337924|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
11337925|NCT02448550|Experimental|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
11337926|NCT02448550|Active Comparator|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
11337927|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.
~PM01183 predetermined dose daily via IV per cycle
~Doxorubicin predetermined dose daily via IV per cycle"
11337928|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure
~PM01183 predetermined dose given twice via IV per cycle
~Gemcitabine predetermined dose given twice via IV per cycle"
11337929|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine
~-PM01183 predetermined dose once via IV per cycle"
11337930|NCT02448524|Experimental|MiStentTM|MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).
11337931|NCT02448524|Active Comparator|TIVOLI|TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.
11337932|NCT02448511|Experimental|Ozone|this group received local application of ozone gas in addition to conventional treatment.
11337933|NCT02448511|Sham Comparator|Placebo|This group received sham treatment in addition to conventional treatment
11337934|NCT02448498|Experimental|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
11337935|NCT02448498|Experimental|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
11337936|NCT02448498|Experimental|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
11337937|NCT02448485||Aortic Valve Intervention|Consecutive symptomatic patients who underwent aortic valve intervention (SAVR or TAVI) for the treatment of severe AS since 2010
11337938|NCT02448485||Conservative Treatment|Asymptomatic patients with aortic stenosis followed conservatively at our department
11337939|NCT02448459|Experimental|COOL-COS|All women will receive Letrozole, Clomiphene, and Corifollitropin Alfa for controlled ovarian stimulation
11337940|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
11337941|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
11337942|NCT02448433|Other|Phototherapy|
11337943|NCT02448420|Experimental|Arm A: HER2-positive/Hormone receptor-negative|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.
~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
11337944|NCT02448420|Experimental|Arm B1: HER2+/Hormone receptor-positive|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.
~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
11337945|NCT02448420|Experimental|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
~Letrozole: daily oral dose of 2.5 mg."
11337946|NCT02448420|Experimental|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy
~Trastuzumab or biosimilar: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.
~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
11337947|NCT02448420|Active Comparator|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab.
11337948|NCT02448407|Experimental|Platelet rich plasma|Three intraarticular injection, one each fifteen days
11337949|NCT02448407|Active Comparator|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
11337950|NCT02448394|Experimental|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
11337951|NCT02448394|No Intervention|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
11337952|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.
~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.
~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.
~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
11337953|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
11337954|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
11337955|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
11337956|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
11337957|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
11337958|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
11337959|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
11337960|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
11337961|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
11337962|NCT02448355|Experimental|Patient undergoing carotid endarterectomy|"All patients undergoing carotid endarterectomy in Shaare Zedek Medical Center Visual acuity measurement (Snellen) SS-OCT (DRI-Atlantis, Topcon) 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
~On pre-op visit (Monday)
~Day 1 post-surgery
~Discharge day
~Week 1 post-surgery
~Month 1 post-surgery"
11337963|NCT02448342|Experimental|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
11337964|NCT02448342|Active Comparator|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
11337965|NCT02448329|Experimental|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
11337966|NCT02448316|Active Comparator|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
11337967|NCT02448316|Active Comparator|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
11337968|NCT02448303|Experimental|Arm 1|pembrolizumab
11337969|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
11337970|NCT02448290|Experimental|docetaxel+selumetinib|Selumetinib 75 mg will be administered orally twice a day with continuous dosing schedule Docetaxel 60 mg/m2 will be administered via intravenous access every 3 weeks.
11337971|NCT02448277|Experimental|Macintosh Laryngoscope|experimental Macintosh Laryngoscope group: laryngoscope is used to assist for nasotracheal intubation.
11401695|NCT02024516|Experimental|50 gr concentrated pomegranate juice|
11337976|NCT02448251|Experimental|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
11337977|NCT02448251|Experimental|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
11337978|NCT02448238|Experimental|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
11337979|NCT02448225|Experimental|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
11337980|NCT02448212|Experimental|PART 1 (Test/Retest)|Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121
11337981|NCT02448212|Experimental|PART 2 (PET Receptor Occupancy Study)|Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121
11337982|NCT02448199|Experimental|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
11337983|NCT02448199|Active Comparator|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
11337984|NCT02448199|Active Comparator|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
11337985|NCT02448186|Experimental|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
11337986|NCT02448186|No Intervention|Waitlist|3-month waitlist control
11337987|NCT02448173|Experimental|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
11337988|NCT02448173|Active Comparator|Surgery|Surgical resection of Stage II colon cancer
11337989|NCT02448160|Experimental|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
11337990|NCT02448147|Active Comparator|Interval training|
11337991|NCT02448147|Active Comparator|Continuous training|
11337992|NCT02448147|No Intervention|Control|
11337993|NCT02448134|Experimental|Youth Access|"Youth Engagement in Prosocial Alcohol-Free Activities Participate in the Reward and Reminder program in their community"
11337994|NCT02448134|No Intervention|Control|Student will receive regular information and programs.
11337995|NCT02448121|Experimental|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
11337996|NCT02448108|Experimental|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
11337997|NCT02448108|Experimental|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
11337998|NCT02448108|Other|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
11337999|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
11338000|NCT02448082|Placebo Comparator|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
11338001|NCT02448082|Experimental|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
11338002|NCT02448069|Experimental|Argatroban treatment|Intravenous Argatroban delivered at 100mcg/kg bolus, then 12-hour infusion initiated at 3mcg/kg/min.
11338003|NCT02448056||Pre-treatment|All enrolled HCC patients.
11338004|NCT02448056||Post-treatment one week|All enrolled HCC patients.
11338005|NCT02448056||Post-treatment one month|All enrolled HCC patients.
11338006|NCT02448043|Other|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.
~Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
11338007|NCT02448043|Other|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.
~Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
11338008|NCT02448030|Experimental|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
11338009|NCT02448030|Placebo Comparator|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
11338010|NCT02448017|Active Comparator|The Herbst appliance|Orthodontic functional appliance
11338011|NCT02448017|Active Comparator|Twin block appliance|Orthodontic functional appliance
11338012|NCT02448004|Experimental|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
11338013|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
11338014|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
11338165|NCT02447003|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months.
11338015|NCT02447978||PCR-positive pertussis cases|Cases will be all individuals who tested PCR-positive for pertussis and negative for parapertussis during the study period and who received 5 doses of DTaP vaccines (either manufactured by GSK or any brand, depending on study objective) through 84 months of age before testing PCR-positive.
11338016|NCT02447978||PCR-negative pertussis controls|Controls will consist of persons who tested PCR-negative for both pertussis and parapertussis and who received 5 DTaP doses (either manufactured by GSK or any brand, depending on study objective) before testing PCR negative.
11338017|NCT02447978||KPNC-matched controls|Controls will consist of all KPNC members of the same sex, age (year and quarter of birth), race or ethnic group (7 groups; 6 for reported, 1 for imputed), and medical centre as each pertussis case and who were members on the date the case tested PCR-positive (anchor date).
11338018|NCT02447965|Active Comparator|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
11338019|NCT02447965|Placebo Comparator|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
11338020|NCT02447952|Experimental|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
11338021|NCT02447939|Experimental|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
11338022|NCT02447926|Other|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
11338023|NCT02447913|Experimental|Voucher|
11338024|NCT02447913|No Intervention|Control|
11338025|NCT02447900|Other|Treatment|
11338026|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
11338027|NCT02447874|Experimental|Standard dose|Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
11338028|NCT02447874|Experimental|Loading dose + standard dose|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
11338029|NCT02447874|Experimental|Loading dose + continuous infusion|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
11338030|NCT02447861||3q29 deletion|Individuals with 3q29 deletion
11338031|NCT02447861||3q29 duplication|Individuals with 3q29 duplication
11338032|NCT02447861||Unaffected siblings|Unaffected siblings of 3q29 deletion or duplication individuals
11338033|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
11338034|NCT02447848|Experimental|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
11338035|NCT02447835|Active Comparator|Olanzapine|Olanzapine administration
11338036|NCT02447835|Placebo Comparator|Placebo|Placebo administration
11338037|NCT02447822|Active Comparator|6.0ATG|Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
11338038|NCT02447822|Active Comparator|4.5ATG|Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
11338039|NCT02447809|Experimental|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
11338040|NCT02447809|Active Comparator|Regular DAPT(IPA>60%)|ASA and Clopidogrel
11338041|NCT02447796|Active Comparator|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
11338042|NCT02447796|Active Comparator|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
11338043|NCT02447783|Placebo Comparator|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
11338044|NCT02447783|Active Comparator|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
11338045|NCT02447770|Experimental|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
11338046|NCT02447757||Parturients with remifentanil analgesia|Parturients after induction of remifentanyl analgesia during the delivery
11338047|NCT02447744|Experimental|MBSR group|Mindfulness based stress reduction intervention will be provided to this group.
11338048|NCT02447744|Other|Waitlist control|This arm waits while the MBSR group receives their intervention, and then gets the Mindfulness based stress reduction intervention after their waiting period.
11338166|NCT02446990|Experimental|Ivabradine|
11338049|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
11338050|NCT02447718|Active Comparator|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
11338051|NCT02447718|No Intervention|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
11338052|NCT02447705|No Intervention|Lamivudine group|continue Lamivudine
11338053|NCT02447705|Experimental|Telbivudine group|Telbivudine replaces Lamivudine
11338054|NCT02447692|Active Comparator|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
11338055|NCT02447692|Active Comparator|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
11338056|NCT02447679|Experimental|thalidomine|"Thalidomide 400mg/day for 1 year
~tegafur-uracil 2 tables for 1 year."
11338057|NCT02447666|Experimental|Azacitidine Myelodysplastic Syndrome (MDS)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
11338058|NCT02447666|Experimental|Azacitidine Juvenile Myelomonocytic Leukemia (JMML)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
11338059|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
11338060|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
11338061|NCT02447640|Experimental|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
11338062|NCT02447640|Experimental|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
11338063|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
11338064|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
11338065|NCT02447614|Experimental|Surgery|Adenotonsillectomy
11338066|NCT02447614|Experimental|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
11338067|NCT02447614|Experimental|no treatment|just regular follow-up
11338068|NCT02447601|Experimental|Simvastatin and PEX168(200µg)|Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
11338069|NCT02447588|Other|Group 1|Intrauterine insemination with sperm donor (IAD) at 36 hours post-hCG. Cases where the IAD is scheduled at 36 hours post-administration of hCG.
11338070|NCT02447588|Experimental|Group 2|Intrauterine insemination with sperm donor (IAD) at 24 hours post-hCG. Cases where the IAD is scheduled at 24 hours post-administration of hCG.
11338071|NCT02447575|Other|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.
~The inhaler technique is also evaluated by study staff prior to an education demonstration."
11338072|NCT02447562|Active Comparator|G_AH|Usual care group
11338073|NCT02447562|Other|G_SP|Phone-based care
11338074|NCT02447562|Experimental|G_NOMHAD|Intervention group with a health platform NOMHADchronic
11338075|NCT02447549|Active Comparator|WBRT|Standard dose whole bladder radiotherapy
11338076|NCT02447549|Experimental|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
11338077|NCT02447549|Experimental|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
11338078|NCT02447536|Active Comparator|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
11338079|NCT02447536|Active Comparator|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
11338080|NCT02447523||Patients with metabolic syndrome|Patients fulfilling criteria to establish the diagnosis of metabolic syndrome
11338081|NCT02447523||Patients without metabolic syndrome|Patients not fulfilling criteria of the metabolic syndrome
11338082|NCT02447510|Other|group 1|bone substitute grafting material applied to the defect site control (n=10)
11338083|NCT02447510|Other|group 2|experimental platelet rich growth factor PRGF applied to the defect site (n=10) G2
11338084|NCT02447510|Other|group 3|platelet rich fibrin PRF applied to the defect site (n=10) G3.
11338085|NCT02447497|Experimental|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes
11338086|NCT02447497|Placebo Comparator|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes
11338087|NCT02447497|Experimental|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 2 minutes and allow to dry for 3 minutes
11338088|NCT02447497|Placebo Comparator|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 2 minutes and allow to dry for 3 minutes
11338167|NCT02446990|Placebo Comparator|Placebo|
11338089|NCT02447484|Experimental|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
11338090|NCT02447484|Active Comparator|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
11338091|NCT02447471||study group|all participants
11338092|NCT02447458|Experimental|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
11338093|NCT02447458|Experimental|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
11338094|NCT02447458|Experimental|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
11338095|NCT02447458|Experimental|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
11338096|NCT02447458|Experimental|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
11338097|NCT02447458|Experimental|Cohort 6|Did not take place due to termination of the study.
11338098|NCT02447458|Placebo Comparator|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
11338099|NCT02447445||Older inpatient at MOP|The group includes older patients who are admitted to one of the Medicine for Older Patients (MOP) wards. Grip strength will be part of the routine assessment of older patient when admitted to MOP.
11338100|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
11338101|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
11338102|NCT02447419|Experimental|Gefitinib|Gefitinib 250 mg will be administered orally daily
11338103|NCT02447406|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Phase Ib:Volitinib should be administered at least 200mg orally once a day in 21 days for achieving appropriate antitumor activity.
~Phase II: Subjects will receive Volitinib once daily ( at the MTD determined from Phase Ib) for 21 days as one cycle.
~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
11338104|NCT02447393|Other|levocetirizine|Study Drug
11338105|NCT02447393|Other|cetirizine|Study Drug
11338106|NCT02447393|Other|placebo|Study Drug
11338107|NCT02447380|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.
~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
11338108|NCT02447367|Experimental|JLP-1207, Fasted followed by fed|JLP-1207 dosing in the fasted state followed by fed dosing
11338109|NCT02447367|Experimental|JLP-1207, Fed followed by fasted|JLP-1207 dosing in the fed state followed by fasted dosing
11338110|NCT02447341||In patients|
11338111|NCT02447341||Out patients|
11338112|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
11338113|NCT02447315|Experimental|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
11338114|NCT02447315|Experimental|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
11338115|NCT02447315|Experimental|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
11338116|NCT02447315|Experimental|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
11338117|NCT02447302|Experimental|Etrasimod Low Dose|Oral, low dose, daily for 12 Weeks
11338118|NCT02447302|Experimental|Etrasimod High Dose|Oral, high dose, daily for 12 weeks
11338119|NCT02447302|Placebo Comparator|Placebo|Oral, placebo, daily for 12 weeks.
11338120|NCT02447289|Experimental|Experimental|Intranasal administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.2 mg/kg, max. 5 mg)
11338121|NCT02447289|Active Comparator|Comparator|Oral administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.5 mg/kg, max. 20 mg)
11338122|NCT02447289|Active Comparator|Control|Oral administration of midazolam (1.0 mg/kg, max. 20 mg)
11338123|NCT02447276|Experimental|Group A|Group A will receive REGN475 dosing regimen 1
11338124|NCT02447276|Experimental|Group B|Group B will receive REGN475 dosing regimen 2
11338125|NCT02447276|Experimental|Group C|Group C will receive REGN475 dosing regimen 3
11338126|NCT02447276|Experimental|Group D|Group D will receive REGN475 dosing regimen 4
11338127|NCT02447276|Experimental|Group E|Group E will receive matching placebo
11338128|NCT02447263|Experimental|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
11338129|NCT02447263|No Intervention|control|liver cancer patients did not receive any interventional therapy
11338168|NCT02446977|Experimental|Vitamin B2 Streuli®|20mg IV
11338169|NCT02446977|Placebo Comparator|Solution for injection|4ml IV
11338203|NCT02446730|Active Comparator|BES with Clopidogrel 75mg|Biolimus-eluting stent with Clopidogrel 75mg once daily MD
11338303|NCT02446132|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
11338130|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
11338131|NCT02447237|Experimental|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
11338132|NCT02447237|Other|solid food|dietary counselling in fulfilling need of protein and energy through solid food
11338133|NCT02447224|Experimental|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
11338134|NCT02447224|Active Comparator|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
11338135|NCT02447211|Active Comparator|doxepin cream|Patients use doxepin cream 5% twice daily for two weeks
11338136|NCT02447211|Placebo Comparator|Placebo|Patients use cream without doxepin ingredient twice daily for two weeks
11338137|NCT02447185|Experimental|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.
~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.
~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
11338138|NCT02447185|Active Comparator|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.
~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.
~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
11338139|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
11338140|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
11338141|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
11338142|NCT02447159|Experimental|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
11338143|NCT02447159|No Intervention|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
11338144|NCT02447146|Experimental|Training group|9-week resistance training program
11338145|NCT02447146|Other|Control group|'Lectures on the disease'
11338146|NCT02447133|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Maestro device
11338147|NCT02447120|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the Maestro device
11338148|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
11338149|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
11338150|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
11338151|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
11338152|NCT02447068|No Intervention|Non-treatment Control|Control arm will not have any intervention
11338153|NCT02447068|Active Comparator|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
11338154|NCT02447068|Active Comparator|Luma Light|A NBUVB light will be used as an active comparator.
11338155|NCT02447068|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
11338156|NCT02447055|Experimental|Arm 1 (Flu/Mel/PT-Cy & Tac/MMF for certain cases)|"Fludarabine 30 mg/m^2 intravenously (IV) on Days -5, -4, -3, and -2
~Melphalan 140 mg/m^2 IV on Day -2
~Tocilizumab 8 mg/m^2 (capped at 800 mg) IV on Day -1
~Stem cell infusion on Day 0
~Cyclophosphamide 50 mg/kg IV on Days +3 and +4
~Tacrolimus 1 mg/day IV on Day +5 (for unrelated & haploidentical cases)
~Mycophenolate mofetil 15 mg/kg orally three times per day on Day +5 (for unrelated & haploidentical cases)
~Filgrastim 10 ug/kg/day subcutaneously until neutrophil recovery starting on Day +5"
11338157|NCT02447042|Experimental|2 ml/Kg|Fluid challenge with crystalloids (2 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
11338158|NCT02447042|Experimental|3 ml/Kg|Fluid challenge with crystalloids (3 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
11338159|NCT02447042|Experimental|4 ml/kg|Fluid challenge with crystalloids (4 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
11338160|NCT02447042|Experimental|5 ml/Kg|Fluid challenge with crystalloids (5 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
11338161|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
11338162|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
11338163|NCT02447016|Experimental|eviplera (complera)|Tab eviplera QD
11338164|NCT02447016|Active Comparator|atripla|Tab Atripla QD
11338170|NCT02446964|Experimental|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.
~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.
~GHVD PROPHYLAXIS: Patients receive tacrolimus* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.
~*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
11338171|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
11338172|NCT02446925|Experimental|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
11338173|NCT02446925|Active Comparator|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
11338174|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
11338175|NCT02446912|Placebo Comparator|Placebo|Placebo
11338176|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
11338177|NCT02446899|Experimental|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
11338178|NCT02446899|Placebo Comparator|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
11338179|NCT02446886|Active Comparator|Group A|"MS patients enrolled in this study will be randomized into:
~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
11338180|NCT02446886|Experimental|Group B|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
11338181|NCT02446873|No Intervention|Control|Control group
11338182|NCT02446873|Experimental|Treatment|Egg supplementation
11338183|NCT02446860|Experimental|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
11338184|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
11338185|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
11338186|NCT02446834|Experimental|intensive lifestyle intervention|3 months intensive lifestyle intervention, including low GI diet and exercise.
11338187|NCT02446834|Experimental|GLP-1 Receptor Agonists|3 months GLP-1 Receptor Agonists treatment
11338188|NCT02446834|Experimental|metformin|3 months metformin treatment
11338189|NCT02446834|Experimental|acarbose|3 months acarbose treatment
11338190|NCT02446821|Experimental|VeraCept IUD System|All women will receive VeraCept.
11338191|NCT02446808|Experimental|Intraoperative nerve monitoring|Patients for which intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
11338192|NCT02446795|Experimental|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
11338193|NCT02446795|Placebo Comparator|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
11338194|NCT02446782|Experimental|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
11338195|NCT02446782|Placebo Comparator|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
11338196|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
11338197|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
11338198|NCT02446756|Experimental|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
11338199|NCT02446756|Active Comparator|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
11338200|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
11338201|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
11338202|NCT02446730|Active Comparator|BES with Prasugel 5mg|Biolimus-eluting stent with Prasugrel 5mg once daily MD
11401970|NCT02022553|Experimental|rectal cancer, surgery|
11338204|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
11338205|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
11338206|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
11338207|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
11338208|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
11338209|NCT02446704|Experimental|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.
~Olaparib- Oral, on determined days per cycle
~Temozolomide- Oral, on determined days per cycle"
11338210|NCT02446691|Experimental|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
11338211|NCT02446678|Active Comparator|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
11338212|NCT02446678|No Intervention|Standard group|Perform standard esophagogastroduodenoscopy
11338213|NCT02446665|Experimental|PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
11338214|NCT02446665|Active Comparator|Non-PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
11338215|NCT02446652|Experimental|Hydralazine/Magnesium valproate + QT|This group will receive TRANSKRIP® (Hydralazine/Magnesium valproate) + Carboplatin plus Paclitaxel
11338216|NCT02446652|Placebo Comparator|placebo + QT|This group will receive placebo + Carboplatin plus Paclitaxel
11338217|NCT02446626|Active Comparator|1|Patients with Lyme disease, post treatment
11338218|NCT02446626|Active Comparator|2|Patients with post-Lyme disease complaints at least 12 months from initial treatment
11338219|NCT02446626|Active Comparator|3|Acute erythema migrans patients (possible positive control)
11338220|NCT02446626|Active Comparator|4|Lyme Arthritis patients (possible positive control)
11338221|NCT02446626|Active Comparator|5|Healthy Volunteers (negative control)
11338222|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
11338223|NCT02446600|Active Comparator|Arm I (platinum-based chemotherapy)|"REGIMEN I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
~REGIMEN II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
~REGIMEN III: Patients receive pegylated liposomal doxorubicin hydrochloride IV and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity."
11338224|NCT02446600|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11338225|NCT02446600|Experimental|Arm III (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11338226|NCT02446587||Stroke with Mechanical Thrombectomy|Eligible patients will be adults ≥18 with the final diagnosis of an acute ischemic infarction and large artery occlusion in anterior circulation strokes who undergo endovascular therapy with mechanical thrombectomy utilizing stent retrievers
11338227|NCT02446587||Stroke without Mechanical Thrombectomy|Patients who would have large artery occlusion treated with best medical management (IV-tPA if eligible) and not receiving endovascular therapy will be collected for a secondary analysis as a comparison group and to evaluate the selection methods in them as well
11338228|NCT02446574|Experimental|Arm A|"During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy
~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy"
11338229|NCT02446561|Active Comparator|MRXXX|Active comparator
11338230|NCT02446561|Experimental|MR1XXX|MR1XXX
11338231|NCT02446561|Experimental|MR2XXX|MR2XXX
11338232|NCT02446561|Experimental|MR3XXX|MR3XXX
11338233|NCT02446548|Experimental|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
11338234|NCT02446548|Experimental|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
11338235|NCT02446535|Experimental|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
11338236|NCT02446522|Active Comparator|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
11338237|NCT02446522|Active Comparator|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
11338238|NCT02446509|Experimental|Experimental Group|The experimental group will receive a 7-week group psychoeducation intervention. Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
11338302|NCT02446132|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
11338239|NCT02446509|Active Comparator|Wait List Control Group|Subjects in the wait list control group will receive the same 7 psychoeducation sessions after the experimental group receives these sessions.
11338240|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
11338241|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
11338242|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
11338243|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
11338244|NCT02446470|Experimental|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
11338245|NCT02446470|Active Comparator|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
11338246|NCT02446457|Experimental|Cohort I (rituximab, pembrolizumab)|Patients receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 16 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
11338247|NCT02446457|Experimental|Cohort II (rituximab, pembrolizumab, lenalidomide)|Patients receive rituximab IV over 4-8 hours on days 1, 8 and 15 of cycle 1, and day 1 of cycle 2. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 2 years, and lenalidomide PO on days 1-14 every 3 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11338248|NCT02446444|Experimental|Enzalutamide|Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
11338249|NCT02446444|Active Comparator|Conventional Non-steroidal Anti-androgen (NSAA)|"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.
~All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)"
11338250|NCT02446431|Experimental|Metronomic Therapy|"There is only one arm in this study. All subjects receive the same therapy for a period of 420 days (42 day cycles x 10 cycles).
~Bevacizumab: IV, 10 mg/kg, Days 1, 8
~Cyclophosphamide: PO, 25 mg/m2 Days 1-14 (max dose = 50mg/dose)
~Valproic Acid: PO, 5 mg/kg, three times per day (TID), Days 22-35
~Temsirolimus: IV, 25 mg/m2, Days 22, 29"
11338251|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
11338252|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
11338253|NCT02446405|Experimental|Enzalutamide|"Enzalutamide is 160 mg daily, by mouth, until clinical disease progression or prohibitive toxicity.
~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
11338254|NCT02446405|Active Comparator|Conventional NSAA|"Conventional NSAA, by mouth until clinical disease progression or prohibitive toxicity.
~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
11338255|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.
~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
11338256|NCT02446366|Experimental|Treatment (hypofractionated SBRT)|Patients undergo 5, 10, or 15 fractions of hypofractionated SBRT daily over 1-3 weeks.
11338257|NCT02446353|Experimental|Megace : fed|Megace / Apetrol ES : comparator / test, fed
11338258|NCT02446353|Experimental|Apetrol ES : fed|Apetrol ES / Megace : test / comparator, fed, cross-over
11338259|NCT02446353|Experimental|Megace : fasting|Megace / Apetrol ES : comparator / test, fasting
11338260|NCT02446353|Experimental|Apetrol ES : fasting|Apetrol ES / Megace : test / comparator, fasting, cross-over
11338261|NCT02446340|Experimental|dalazatide 5ug|8 subjects, 6 given active agent and 2 given placebo
11338262|NCT02446340|Experimental|dalazatide 15ug|8 subjects, 6 given active agent and 2 given placebo
11338263|NCT02446340|Experimental|dalazatide 30ug|8 subjects, 6 given active agent and 2 given placebo
11338264|NCT02446340|Experimental|dalazatide 60ug|8 subjects, 6 given active agent and 2 given placebo
11338265|NCT02446327|Other|Diastolic heart failure cohort|This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
11338266|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
11338267|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
11338268|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
11338269|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
11338270|NCT02446301|Experimental|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
11338271|NCT02446301|Experimental|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
11338272|NCT02446288|Active Comparator|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
11338273|NCT02446288|Active Comparator|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
11338274|NCT02446275|Experimental|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression.
11338275|NCT02446275|Experimental|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid.
11338276|NCT02446262|Other|Substudy 1: Instructed subjects|Participants are instructed about outcomes
11338277|NCT02446262|Other|Substudy 1: Uninstructed subjects|Participants learn through experience
11338278|NCT02446262|Other|Substudy 2: heat group|Participants learn about heat outcomes through conditioning
11338279|NCT02446262|Other|Substudy 2: salt group|Participants learn about salt outcomes through conditioning
11338280|NCT02446262|Other|Substudy 2: sugar group|Participants learn about sugar outcomes through conditioning
11338281|NCT02446262|No Intervention|Substudy 3: healthy volunteers|All participants experience all outcomes, within subjects designs
11338282|NCT02446262|Other|Substudy 4: healthy volunteers|Participants are instructed to attend toward or away from the stimulus
11338283|NCT02446262|Other|Substudy 5: healthy volunteers|Participants experience both placebo and cue-based expectations within subjects
11338284|NCT02446249|Experimental|single arm dose escalation|single arm dose escalation
11338285|NCT02446236|Experimental|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
11338286|NCT02446223|Experimental|Active|
11338287|NCT02446210|Active Comparator|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
11338288|NCT02446210|Active Comparator|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
11338289|NCT02446197|Experimental|Patient Directed Exercise Group|Participants will complete a combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
11338290|NCT02446197|No Intervention|Standard of care|Standard of care comprehensive inpatient rehabilitation program.
11338291|NCT02446184|Experimental|Fetal cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
11338292|NCT02446184|Active Comparator|Vesicoamniotic shunt|The fetal vesicoamniotic shunt is considered the standard prenatal therapy for severe LUTO. Amnioinfusion and vesicoamniotic shunt placement will be performed under ultrasound guidance.
11338293|NCT02446184|No Intervention|No fetal intervention group|Those patients that refuse fetal intervention and do not elect to terminate the pregnancy will be followed as part of the no fetal intervention group.
11338294|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
11338295|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
11338296|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
11338297|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
11338298|NCT02446158|Experimental|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
11338299|NCT02446158|No Intervention|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
11338300|NCT02446145|Experimental|Experimental intervention arm|"Eltrombopag daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)
~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes
~one cycle lasts 28 days"
11338301|NCT02446145|Placebo Comparator|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)
~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes
~one cycle lasts 28 days"
11338304|NCT02446132|Experimental|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
11338305|NCT02446119||Gastroparesis|"Inclusion criteria:
~1. Subjects will be of either sex, 18 to 70 years of age.
~patients with an established diagnosis of gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects will have delayed gastric emptying on gastric scintigraphy defined as greater than 60% retention at 2 hours and/or greater than 10% retention at 4 hours. This gastric emptying test would have been done prior to the endoscopy and is not part of the research study. Patients will undergo EndoFlip during upper endoscopy."
11338306|NCT02446119||Normals|"Inclusion criteria:
~1. Subjects will be of either sex, 18 to 70 years of age.
~control subjects will be nondiabetic patients without gastroparesis or gastroesophageal reflux symptoms undergoing upper endoscopy. Patients will undergo EndoFlip during upper endoscopy."
11338307|NCT02446106|Active Comparator|Soup with MSG|0.5% MSG incorporated into a soup preload
11338308|NCT02446106|Placebo Comparator|Control Soup|Negative control match for sodium (no MSG + 0.635% salt)
11338309|NCT02446093|Experimental|Test Arm|GMCI + chemoadiation + surgery
11338310|NCT02446093|Active Comparator|Control Arm|Chemoradiation + surgery
11338311|NCT02446080|Experimental|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
11338312|NCT02446080|Active Comparator|Control Group|Milk drink (150 mL/daily) for 60 days.
11338313|NCT02446067|No Intervention|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
11338314|NCT02446067|Active Comparator|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
11338315|NCT02446067|Sham Comparator|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
11338316|NCT02446054|Experimental|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
11338317|NCT02446041||ICS/LABA Patients|ICS/LABA Patients following standard of care
11338318|NCT02446028|Experimental|BIOD-531|BIOD-531 injected twice daily
11338319|NCT02446028|Active Comparator|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
11338320|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
11338321|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
11338322|NCT02446002|Experimental|Lofexidine + Naltrexone|
11338323|NCT02445989|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
11338324|NCT02445989|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
11338325|NCT02445976|Experimental|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
11338326|NCT02445976|Experimental|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
11338327|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
11338328|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
11338329|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
11338330|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
11338331|NCT02445950|Experimental|Technology-aided counseling|Customers receive intervention via technology-aided phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. The customers are able to view their change change needs and choose tasks/goals for the coaching. The independent phase lasts 13 weeks and coaching is done via a digital tool.
11338332|NCT02445950|Active Comparator|Traditional counseling|Customers receive intervention via traditional phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. Change needs and goals are set during the phone calls. The independent phase lasts 13 weeks and includes 3 phone calls.
11338333|NCT02445937|No Intervention|Control|The control group will receive usual care, in which the frequency and content of physician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
11338334|NCT02445937|Experimental|Behavioral: The PARTNER II Intervention|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
11338335|NCT02445924||Control group 1|ten non smoker volunteers
11338336|NCT02445924||Control group 2|ten smoker volunteers
11338337|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
11338338|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
11338339|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
11338340|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
11338341|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
11338342|NCT02445898|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
11338343|NCT02445898|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
11338344|NCT02445885|Experimental|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
11338345|NCT02445885|Active Comparator|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
11338346|NCT02445872|Experimental|Arm A|Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
11338347|NCT02445872|Active Comparator|Arm B|Palonosetron: 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 7.5mg PO on days 4-5.
11338348|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
11338349|NCT02445859|Experimental|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
11338350|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
11338351|NCT02445833|Experimental|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
11338352|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
11338353|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
11338354|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
11338355|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
11338356|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
11338357|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
11338358|NCT02445781|Experimental|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
11338359|NCT02445781|Experimental|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
11338360|NCT02445781|Experimental|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
11338361|NCT02445781|Experimental|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
11338362|NCT02445768|Active Comparator|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
11338363|NCT02445768|Active Comparator|3T scanner with MRI-compatible robot|Device: 3T scanner with MRI-compatible robot
11338364|NCT02445742|Experimental|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
11338365|NCT02445729|Active Comparator|Dressing Removal at 24 Hours|These patients are randomly assigned to have their dressing removed 24 hours after cesarean section.
11338366|NCT02445729|Active Comparator|Dressing Removal at 48 Hours|These patients are randomly assigned to have their dressing removed 48 hours after cesarean section.
11338367|NCT02445716|Active Comparator|Testosterone 500 mcg / Biolipid B2|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.
~The arm have 35 women. It consists of a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment."
11338368|NCT02445716|Placebo Comparator|Placebo|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.
~The arm have 35 women. It consists of a 4-week screening period plus a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment.
~Participants will be attended at the Federal University of São Paulo / Post Graduation Program in São Paulo, Brazil for their study visits."
11338369|NCT02445703|Experimental|Group 1 (HAV + HAV)|"Intervention: Inactivated Hepatitis A vaccine (HAV);
~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);
~Route of administration: intramuscular injection in deltoid region;"
11338370|NCT02445703|Experimental|Group 2 (HAV + HABV)|"Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);
~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.
~Route of administration: intramuscular injection in deltoid region;"
11338371|NCT02445703|Experimental|Group 3 (HABV + HABV)|"Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);
~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);
~Route of administration: intramuscular injection in deltoid region;"
11338372|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
11338373|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
11338374|NCT02445677|Experimental|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
11338375|NCT02445677|Placebo Comparator|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
11338376|NCT02445664|Experimental|Video intervention|A tablet-administered educational video (10 minutes duration).
11338377|NCT02445664|No Intervention|Control|No intervention (no video)
11338378|NCT02445651|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
11338379|NCT02445651|No Intervention|Control Cohort|Standard of Care Treatment
11338380|NCT02445638|Active Comparator|Whole egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 whole eggs for 4 weeks.
11338381|NCT02445638|Placebo Comparator|Yolk-free egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 yolk-free eggs for 4 weeks.
11338382|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
11338383|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
11338384|NCT02445599|Experimental|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.
~Every patient recieved additional thoracic epidural analgesia during and after the surgery.
~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
11340536|NCT02431039|Active Comparator|NEOSORB|Subjects who are treated by NEOSORB
11338385|NCT02445599|Experimental|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.
~Every patient recieved additional thoracic epidural analgesia during and after the surgery.
~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
11338386|NCT02445586|Experimental|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
11338387|NCT02445573|Active Comparator|EA group|
11338388|NCT02445573|Placebo Comparator|Sham EA group|
11338389|NCT02445560|Experimental|Probiotic capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
11338390|NCT02445560|Experimental|Probiotic capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
11338391|NCT02445560|Experimental|Placebo capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
11338392|NCT02445560|Placebo Comparator|Placebo capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
11338393|NCT02445547|Experimental|UC-MSCs|UC-MSCs by peripheral intravenous infusion
11338394|NCT02445547|Active Comparator|control|received hormone maintenance therapy
11338395|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
11338396|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
11338397|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
11338398|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
11338399|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
11338400|NCT02445508|Placebo Comparator|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
11338401|NCT02445508|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
11338402|NCT02445508|Active Comparator|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
11338403|NCT02445508|Active Comparator|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
11338404|NCT02445469|Other|Parkinson's disease|MRI exam of the brain
11338405|NCT02445469|Other|Multiple System Atrophy|MRI exam of the brain
11338406|NCT02445469|Other|Progressive Supranuclear Palsy|MRI exam of the brain
11338407|NCT02445469|Other|Vascular parkinsonism|MRI exam of the brain
11338408|NCT02445469|Other|Healthy volunteers|MRI exam of the brain
11338409|NCT02445456|Experimental|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
11338410|NCT02445456|Experimental|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
11338411|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
11338412|NCT02445417||EES|Epidermal Electronic System
11338413|NCT02445417||Hydrogel Electrode|Hydrogel based EEG electrode
11338414|NCT02445404|Active Comparator|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
11338415|NCT02445404|Experimental|Fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
11338416|NCT02445391|Active Comparator|Arm A (observation) (closed to accrual 05/16/2016)|Patients undergo observation.
11338417|NCT02445391|Experimental|Arm B (cisplatin or carboplatin)|Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11338485|NCT02444884|Experimental|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
11338418|NCT02445391|Experimental|Arm C (capecitabine)|Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11338419|NCT02445378|Experimental|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
11338420|NCT02445378|Experimental|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
11338421|NCT02445365|Experimental|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
11338422|NCT02445365|Sham Comparator|Sham|As above with a cuff pressure of 20 mmHg
11338423|NCT02445352|Active Comparator|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
11338424|NCT02445352|Experimental|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
11338425|NCT02445352|Active Comparator|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
11338426|NCT02445352|Experimental|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
11338427|NCT02445352|Active Comparator|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
11338428|NCT02445352|Experimental|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
11338429|NCT02445339|Active Comparator|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
11338430|NCT02445339|No Intervention|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
11338431|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
11338432|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
11338433|NCT02445313||Control|Normal, healthy participants
11338434|NCT02445313||AMD|Age-related Macular Degeneration participants
11338435|NCT02445300|Active Comparator|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
11338436|NCT02445300|Active Comparator|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
11338437|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
11338438|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
11338439|NCT02445274|Experimental|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
11338440|NCT02445274|No Intervention|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
11338441|NCT02445261|Active Comparator|normal growth|120 woman with normal fetal growth will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations were assessed
11338442|NCT02445261|Active Comparator|growth restricted group|70 woman with l growth restricted fetus will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations
11338443|NCT02445248|Experimental|CTL019|Single arm
11338444|NCT02445222|Other|Previously treated CAR-T patients|Patients who previously were exposed to lentiviral-based CART cell therapy
11338445|NCT02445209|Active Comparator|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).
~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
11338446|NCT02445209|Active Comparator|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).
~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
11338447|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
11341950|NCT02421666|No Intervention|control|eligible chronic HBV patients received standard care
11338448|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.
~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
11338449|NCT02445183||Lung Cancer|Confirmed diagnosis of lung cancer
11338450|NCT02445183||No Lung Cancer Controls|Unconfirmed lung cancer diagnosis, false positive
11338451|NCT02445170||Below-knee amputees|The present group consists of diabetic below-knee prosthetic user
11338452|NCT02445170||Transmetatarsal amputees|The present group consists of diabetic transmetatarsal amputees
11338453|NCT02445157||IPF_Reliability|Patients diagnosed with IPF according to NICE guidelines.
11338454|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
11338455|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
11338456|NCT02445131|Experimental|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
11338457|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
11338458|NCT02445105|Active Comparator|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
11338459|NCT02445105|Experimental|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
11338460|NCT02445092|Experimental|Catheter prewashing|"Intervention: prewashing the catheter before IUI.
~450 patients randomly included in this group will have their insemination catheter prewashed with the same media used to wash the sperm, prior to performing the insemination using the washed catheter."
11338461|NCT02445092|No Intervention|Control group|450 patients randomly assigned in this group will have their insemination performed routinely, without washing the insemination catheter..
11338462|NCT02445079||HIV infected|HIV infected sub-group
11338463|NCT02445079||HIV uninfected|HIV uninfected sub-group, age and gender matched to the HIV-infected group
11338464|NCT02445066|Other|Open label|Vitamin D3 - 4,000 IU/day for 4 months
11338465|NCT02445040|Experimental|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
11338466|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
11338467|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
11338468|NCT02445001|Experimental|ICG loaded erythrocytes|Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.
11338469|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
11338470|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
11338471|NCT02444975|Experimental|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
11338472|NCT02444975|Other|No intervention|No intervention
11338473|NCT02444962|Experimental|HAVD implant|
11338474|NCT02444949|Experimental|endostar+DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)+endostar (150mg/5d; civ; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
11338475|NCT02444949|Other|DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
11338476|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
11338477|NCT02444936|No Intervention|Control|There is no drug given in this arm.
11338478|NCT02444923|Experimental|Scleral rigid gas permeable contact lenses|The experimental intervention is the Scleral Rigid Gas Permeable contact lens (SRGPcl), Zenlens™. These lenses are designed to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with corneal contact.
11338479|NCT02444923|Placebo Comparator|Corneal rigid gas permeable contact lenses|The control intervention is the RoseK2™ Corneal Rigid Gas Permeable contact lens (CRGPcl). Corneal lenses are considered the gold standard in the management of the visual disability due to keratoconus and other related irregular cornea disorders.
11338480|NCT02444910|Experimental|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
11338481|NCT02444897|Experimental|Epidural PCA group|Epidural patient-controlled analgesia group
11338482|NCT02444897|Active Comparator|IV PCA group|Intravenous patient-controlled analgesia
11338483|NCT02444884|Experimental|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
11338484|NCT02444884|Experimental|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
11401971|NCT02022553|Active Comparator|rectal cancer, RACHEL, surgery|
11338486|NCT02444858|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous injection
11338487|NCT02444858|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
11338488|NCT02444845||Study Population|Hypertensive and diabetic patients who meet eligibility criteria will be enrolled and evaluated for the presence of anemia secondary to CKD. The first visit will capture medical history including risk factors for CKD; laboratory assessments will be performed at the second and third visits to evaluate glomerular filtration rate (eGFR) and anemia profile, respectively. Participants who are not diagnosted with CKD based upon the second visit will not return for the third visit.
11338489|NCT02444819|Experimental|HM61713|Subjects who entered the study will be administered HM61713 800 mg per day.
11338490|NCT02444806|Active Comparator|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
11338491|NCT02444806|Active Comparator|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
11338492|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
11338493|NCT02444780||elective cardiac surgery patients|consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period
11338494|NCT02444767|Experimental|13mg Bimatoprost Insert|Subjects in this arm have 13mg Bimatoprost Ocular Inserts placed in both eyes for 7 days.
11338495|NCT02444754||Health services research (surveys, questionnaires)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
11338496|NCT02444741|Experimental|Group I, Phase I (pembrolizumab + SBRT)|Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
11338497|NCT02444741|Experimental|Group I, Phase II (pembrolizumab + SBRT)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
11338498|NCT02444741|Experimental|Group II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT)|Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.
11338499|NCT02444741|Experimental|Group II, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will be salvaged with IMRT, PBRT, or 3D-CRT and analyzed as part of the fourth treatment group.
11338500|NCT02444741|Experimental|Group III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61.
11338501|NCT02444741|Experimental|Group IV, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.
11338502|NCT02444741|Experimental|Group V, Phase II (low dose radiation therapy)|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.
11338503|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
11338504|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.
~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
11338505|NCT02444715|Active Comparator|Standard care (SC)|
11338506|NCT02444715|Experimental|Interventional care (IC)|
11338507|NCT02444702||CLBP and degenerative lumbar spine|Participants with CLBP (>12 weeks) and degenerative changes of the lumbar spine confirmed by CT imaging who were recommended surgery and chose to undergo surgery will be recruited from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel. Included participants will be men or women, aged 40-80 years, of any race or ethnic background. Participants' diagnosis may include unstable degenerative spondylolisthesis, radicular pain, or documented stenosis with referred pain.
11338508|NCT02444689|Experimental|Electronic Media Application|Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
11338749|NCT02443012|Placebo Comparator|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
11338509|NCT02444689|Active Comparator|Control|Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
11338510|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
11338511|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
11338512|NCT02444663|Experimental|Device Valgus|Device performed fluoroscopic valgus stress X-rays
11338513|NCT02444663|Experimental|Device Varus|Device performed fluoroscopic varus stress X-rays
11338514|NCT02444637|Experimental|Rivastigmine (Exelon) Patch|For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
11338515|NCT02444624||not necrotizing enterocolitis group|not necrotizing enterocolitis preterm neonates matched with necrotizing enterocolitis preterm neonates
11338516|NCT02444624||necrotizing enterocolitis group|necrotizing enterocolitis preterm neonates of gestational age less than or equal to 31+6 weeks of amenorrhoea with confirmed NEC diagnosis (Bell stage II or III)
11338517|NCT02444611|Active Comparator|Group 1|BCG vaccine, 0,05ml intradermally at birth
11338518|NCT02444611|Active Comparator|Group 2|BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
11338519|NCT02444611|Active Comparator|Group 3|Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
11338520|NCT02444611|No Intervention|Group 4|No birth vaccines
11338521|NCT02444598|Experimental|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
11338522|NCT02444598|Active Comparator|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
11338523|NCT02444585|Experimental|Denosumab|Drug for prevention of bone loss
11338524|NCT02444585|Placebo Comparator|Control|Hip Replacement Patient without Drug
11338525|NCT02444572|Experimental|ENOXA® group|"Patients under ENOXA® 4000 IU according to randomization:
~Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion
~Start injections 12 hours after the surgical procedure
~Administer ENOXA® subcutaneously
~The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
11338526|NCT02444572|Active Comparator|LOVENOX® group|"Patients under LOVENOX® 4000 IU according to randomization:
~Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion
~Start injections 12 hours after the surgical procedure
~Administer LOVENOX® subcutaneously
~The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
11338527|NCT02444559|Experimental|Ropivacaine+Clonidine|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
11338528|NCT02444559|Placebo Comparator|Ropivacaine+Placebo|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ saline
11338529|NCT02444546|Experimental|Treatment (sargramostim, wild-type reovirus)|Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11338530|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
11338531|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
11338532|NCT02444520|Experimental|Integrated GP Care|"GP training in utilising cognitive behavioural skills during 10-minute consultations;
~GP Supervision;
~Audio-visual and written materials/guidelines for GP's;
~Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;
~Booklets for patients once consent gained."
11338533|NCT02444520|No Intervention|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
11338534|NCT02444507|Active Comparator|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
11338535|NCT02444507|Active Comparator|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
11338536|NCT02444481|Experimental|Polygynax, antibiotic, vaginal treatment|Polygynax combinaison of nystatine, polymyxin, neomycin, Local treatment of vaginal infection during 12 days. One vaginal capsule every evening.
11338537|NCT02444468|Experimental|IPC and bandage|Pneumatic device and bandage
11338538|NCT02444468|Active Comparator|Bandage only|Bandage only
11338539|NCT02444455|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous infusion
11338540|NCT02444442|Active Comparator|Renal Denervation|participants randomised to undergo renal denervation
11338541|NCT02444442|Sham Comparator|Sham control|participants randomised to undergo sham procedure
11338542|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
11338543|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
11338544|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
11338545|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
11338750|NCT02442999|No Intervention|Usual care|
11342215|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
11338546|NCT02444403|Other|Police Education Program (PEP)|The entire police force mandated for periodic refresher training will be assigned to classes which receive one PEP course over 2 years.
11338547|NCT02444390|Other|Exemestane+everolimus|Exemestane+everolimus are administered as per their approved indication
11338548|NCT02444377|Experimental|High-intensity interval -2min|5 bouts of 2 min cycling at varying intensities of VO2peak (80-100%) with 1 min recovery.
11338549|NCT02444377|Experimental|High-intensity interval -1min|10 bouts of 1 min cycling at 90% of VO2peak with 1 min rest periods
11338550|NCT02444377|No Intervention|Control|No exercise
11338551|NCT02444364|Experimental|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
11338552|NCT02444351|Active Comparator|control group|
11338553|NCT02444351|Experimental|botox group|
11338554|NCT02444338|Active Comparator|Control Group|optimal standard of care therapy
11338555|NCT02444338|Experimental|Device Group|MitraClip device plus optimal standard of care therapy
11338556|NCT02444325|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
11338557|NCT02444325|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a four session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 4-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by 2 CenteringPregnancy trained providers at each site and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
11338558|NCT02444312|Experimental|Benefit-finding Writing Activity|For two weeks, on six days of their choice, caregivers will be instructed to write about their thoughts and feelings in a diary/ notebook about the benefits of caring.
11338559|NCT02444312|Active Comparator|Neutral Writing activity|For two weeks, on six days of their choice, caregivers will be instructed to write about a neutral topic.
11338560|NCT02444286||standard care group|optimal standard of care therapy
11338561|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
11338562|NCT02444273|No Intervention|Control Group|Subjects will receive standard care both pre and post transplant.
11338563|NCT02444273|Experimental|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
11338564|NCT02444260|Sham Comparator|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
11338565|NCT02444260|Active Comparator|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
11338566|NCT02444247|Other|High Dose Exercise vs Sedentary Option|Relative Reinforcing Value of high dose exercise (300 kcal expenditure per session) versus sedentary activity will be determined.
11338567|NCT02444247|Other|Low Dose Exercise vs Sedentary Option|Relative Reinforcing Value of low dose exercise (150 kcal expenditure per session) versus sedentary activity will be determined.
11338568|NCT02444247|Other|No Exercise vs Sedentary Option|Relative Reinforcing Value of no exercise (0 kcal expenditure per session) versus sedentary activity will be determined.
11338569|NCT02444234|Experimental|Tedizolid PO|Tedizolid phophate 200mg tablet
11338570|NCT02444234|Experimental|Tedizolid IV|Tedizolid phophate 200mg IV
11338571|NCT02444208|Experimental|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
11338572|NCT02444208|Placebo Comparator|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
11338573|NCT02444195|Experimental|Guided Imagery|Guided Imagery With Audio Media
11338574|NCT02444195|No Intervention|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
11338575|NCT02444182|Experimental|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
11338576|NCT02444182|Placebo Comparator|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
11338577|NCT02444156|Experimental|Exercise training|All participants will receive usual care, including standard advice about diet and physical activity. In addition to usual care, participants will be asked to take part in a 12-week exercise programme. Participants will use an indoor rower (Concept 2, Model E) three times per week at Leicester Diabetes Centre. Each session will be supervised and the investigators will liaise with the participants to arrange convenient times to exercise, including mornings and evenings. The supervisors will teach the participants how to row correctly.
11338578|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
11338579|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
11338580|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
11338581|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
11338751|NCT02442999|Experimental|Screen for Sleep Apnea|Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea
11338582|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
11338583|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
11338584|NCT02444091|Experimental|Cyclophosphamide|Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2
11338585|NCT02444078|Experimental|Exercise|Exercise sessions will be done in groups of three-to-eight persons; whilst being a group-based exercise program, participants will be guided and the exercises will be adapted in an individual basis, which may increase adherence and compliance rates.
11338586|NCT02444078|Active Comparator|Social activity|Participants in this group will participate in group-based activities such as music (percussion instruments), arts and board games; no intervention on physical activity will be provided to these participants.
11338587|NCT02444065|Experimental|Cognitive Behavior Therapy (CBT)|In this arm, participants receive the Cognitive behavior therapy (CBT) intervention as an augmentative treatment to standard day hospital treatment as usual.
11338588|NCT02444065|Active Comparator|Motivational Interviewing (MI)|In this arm, participants receive the Motivational Interviewing intervention as an augmentative treatment to standard day hospital treatment as usual.
11338589|NCT02444052|Experimental|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
11338590|NCT02444052|Experimental|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
11338591|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
11338592|NCT02444026|Experimental|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
11338593|NCT02444026|No Intervention|Control|The control group will be offered the intervention AFTER the study
11338594|NCT02444013|Active Comparator|Folic acid|Oral folic acid (5 mg, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
11338595|NCT02444013|Placebo Comparator|Placebo|Oral placebo (1 tablet, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
11338596|NCT02444000|Experimental|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
11338597|NCT02444000|Active Comparator|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
11338598|NCT02443987|Experimental|Received intravenous fluids|The patient will receive 500ml of 0.9% NaCl fluid intravenously during the operation.
11338599|NCT02443987|No Intervention|Control Arm|The patient will receive no intravenous fluid as per current routine protocol
11338600|NCT02443974|Experimental|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
11338601|NCT02443974|Experimental|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
11338602|NCT02443974|No Intervention|Control group|Keep medication usual
11338603|NCT02443961|Experimental|Mesenchymal Stem Cell (MSC) therapy|There will only be one treatment arm to evaluate the security of the treatment with MSC.
11338604|NCT02443948||adjuvant/follow up setting|
11338605|NCT02443948||neo-adjuvant setting|
11338606|NCT02443948||advanced disease|
11338607|NCT02443935|Experimental|MGN1703|TLR-9 agonist MGN1703 administered to HIV-1 positive patients on cART
11338608|NCT02443922|Experimental|Glimepiride|Glimepiride 2mg qam
11338609|NCT02443922|Experimental|Sitagliptin|Sitagliptin 100mg qam
11338610|NCT02443922|Active Comparator|Metformin|Metformin as prescribed
11338611|NCT02443909|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w Holmium laser device who have 2-3 cm kidney stones
11338612|NCT02443909|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power) who have 2-3 cm kidney stones
11338613|NCT02443909|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power) who have 2-3 cm kidney ston
11338614|NCT02443896|Experimental|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.
~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
11338615|NCT02443896|Sham Comparator|No sealant applied to molars.|No molars will be sealed.
11338616|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
11338617|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
11338618|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
11338619|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
11338620|NCT02443857|Experimental|ChARMin|Single-arm only
11338621|NCT02443844|Active Comparator|First group|Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer
11338622|NCT02443844|Active Comparator|Second Group|Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer
11338623|NCT02443831|Experimental|CD19 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19CAR T-cells.
11338624|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
11338625|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
11338626|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
11338627|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
11338628|NCT02443779||Early Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
11338629|NCT02443779||Advanced Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
11338630|NCT02443766||Healthy Subjects|Healthy subjects will attend the weeklong meditation retreat.
11338631|NCT02443753|Experimental|Device|Subjects who receive the device
11338632|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of PF-05251749 administered to healthy volunteers in a cross over study design
11338633|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of PF-05251749 administered to healthy volunteers in a cross over study design
11338634|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of PF-05251749 administered to healthy volunteers to assess the PK of PF-05251749 in CSF
11338635|NCT02443727|Experimental|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
11338636|NCT02443727|Placebo Comparator|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.
~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
11338637|NCT02443714|Experimental|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
11338638|NCT02443714|Experimental|Conventional pen|Conventional insulin administration with insulin pens.
11338639|NCT02443701|Experimental|Exercise|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).
11338640|NCT02443701|Experimental|NEMES|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).The healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation, medium frequency current (1kHz), modulated at 70Hz, cycle Work 10%, intensity used will vary according to the capacity and tolerable for each individua. The stimulated muscle group will be the quadriceps femoris
11338641|NCT02443701|Experimental|Phototherapy|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump). The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. Phototherapy will be conducted through a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J. The application sites will be six points on the belly of the quadriceps femoris muscles bilaterally.
11338642|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
11338643|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
11338644|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
11338645|NCT02443649|Experimental|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
11338646|NCT02443649|Active Comparator|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
11338647|NCT02443623|Experimental|Single Arm Vaccinated with ACAM2000|"To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
~To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
11338648|NCT02443597||obese pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:
~Fetal nuchal translucency thickness.
~Nasal bone.
~Fetal facio-maxillary angle.
~The flow across the tricuspid valve as normal or regurgitated.
~A-wave in the ductus venosus as normal or reversed."
11338649|NCT02443597||lean pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:
~Fetal nuchal translucency thickness.
~Nasal bone.
~Fetal facio-maxillary angle.
~The flow across the tricuspid valve as normal or regurgitated.
~A-wave in the ductus venosus as normal or reversed."
11338650|NCT02443584|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
11338651|NCT02443584|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
11338652|NCT02443558|Experimental|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
11338653|NCT02443558|Experimental|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
11338654|NCT02443558|Active Comparator|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
11338655|NCT02443558|Active Comparator|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.
~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
11338656|NCT02443545|Experimental|Group 1: Deferiprone 3 years|Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study)..
11338657|NCT02443545|Experimental|Group 2: Deferiprone 2 years|Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).
11338658|NCT02443532|Experimental|Structured Group education|Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
11338659|NCT02443532|Other|Individual education|Usual care (individual consultations as routinely performed)
11338660|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
11338661|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
11338662|NCT02443506|Experimental|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
11338663|NCT02443506|Placebo Comparator|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
11338664|NCT02443493|Experimental|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
11338665|NCT02443493|Sham Comparator|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
11338666|NCT02443467||HER2-positive early breast cancer|Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer treated with loading dose of Herceptin (trastuzumab) administered as 6 mg/kg followed by once in 3 weeks administration at 4 mg/kg up to 12 months of treatment
11338667|NCT02443454||Patients after kidney transplantation|Short and Long-term results containing first 10 years after KTx.
11338668|NCT02443454||Healthy subjects|Medical staff: medical doctors, nurses
11338669|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
11338670|NCT02443415||Healthy Controls|Non-diabetic subjects
11338671|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
11338672|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
11338673|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
11338674|NCT02443402|Experimental|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
11338675|NCT02443402|Placebo Comparator|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
11338676|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
11338677|NCT02443376||Hemodialysis patients|Stable end-stage renal disease patients on maintenance conventional hemodialysis received 4-5 hours of treatment thrice weekly. Pulse wave velocity and central aortic pressure was measured before and after the midweek dialysis session.Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM) was measured before the midweek dialysis session just after Complior device
11338678|NCT02443376||Healthy subjects|Medical staff: medical doctors, nurses
11338679|NCT02443363||Patients After Kidney Transplantation|A total of 300 consecutive patients admitted to routine visit in Transplant Centre with functioning graft longer than 3 months to 10 years
11338680|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
11338681|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 1)|Gastric-GEJ, BTC: Ramucirumab given intravenously (IV) on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338682|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1a Schedule 2)|Gastric, NSCLC, Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338683|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A)|Gastric-GEJ: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338684|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A1)|BTC: Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338685|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort A2)|Gastric-GEJ (first line only): Ramucirumab given IV on day 1 and 8 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338686|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort B)|Gastric-GEJ: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338687|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort C)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338688|NCT02443324|Experimental|Experimental: Ramucirumab + Pembrolizumab (Phase 1b Cohort D)|Urothelial: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338689|NCT02443324|Experimental|Ramucirumab + Pembrolizumab (Phase 1b Cohort E)|NSCLC: Ramucirumab given IV on day 1 in combination with pembrolizumab given IV on day 1 of a 21 day cycle.
11338690|NCT02443311|Experimental|Group I|Pimecrolimus 1% cream (Elidel, Novartis Pharmaceuticals, East Hanover, NJ)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
11338691|NCT02443311|Active Comparator|Group II|Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
11338692|NCT02443298|Experimental|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
11338693|NCT02443298|Placebo Comparator|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
11338694|NCT02443285|Active Comparator|Cefotaxime|cefotaxime 2gm every 12 hours daily for 5 days
11338695|NCT02443285|Active Comparator|Ceftriaxone|ceftriaxone 2 gm every 24 hours for 5 days.
11338696|NCT02443272|Active Comparator|Control Arm|Receive standard incision and drainage
11338697|NCT02443272|Experimental|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
11338698|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
11338699|NCT02443259||late preterms|late preterm neonates
11338700|NCT02443246|Experimental|Vitamin D deficiency|Group 1
11338701|NCT02443246|Experimental|Vitamin D deficiency (Low)|Group 2
11338702|NCT02443233||Maternal hepatitis B carrier|
11338703|NCT02443233||Paternal hepatitis B carrier|
11338704|NCT02443220|Experimental|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
11338705|NCT02443220|Active Comparator|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
11338706|NCT02443220|Sham Comparator|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
11338707|NCT02443194|Active Comparator|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:
~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
11338708|NCT02443194|Placebo Comparator|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
11338709|NCT02443181|Experimental|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
11338710|NCT02443168|Experimental|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
11338711|NCT02443168|Experimental|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms [14C] AG-221
11338712|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
11338713|NCT02443155|Experimental|NNC0114-0006 + Placebo|
11338714|NCT02443155|Active Comparator|Liraglutide + Placebo|
11338715|NCT02443155|Placebo Comparator|Placebo|
11338748|NCT02443012|Experimental|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
11338716|NCT02443142|Experimental|Ibuprofen|Ibuprofen is a nonselective NSAID that inhibits both COX-1 and COX-2 isoenzymes. COX-2 inhibition prevents arachidonic acid from converting to vasoactive prostaglandins and reactive oxygen species in brain cell. The analgesic, antipyretic, and antiinflammatory activity of ibuprofen operates mainly through inhibition of COX-2. The experimental treatment oral doses of either ibuprofen (800 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
11338717|NCT02443142|Active Comparator|Acetaminophen|Acetaminophen is a poor inhibitor of both COX isoenzymes in the CNS and has significantly weaker antiinflammatory effects than NSAIDs. Acetaminophen does not inhibit COX in peripheral tissues and is less effective in the presence of peroxides. The active comparator treatment is oral doses of acetaminophen (1000 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
11338718|NCT02443129|Experimental|control group|"18-99 year old male + female
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
11338719|NCT02443129|Experimental|mydramide only|"Patients in the clinics undergoing pupil dilation
~Intervention:
~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
11338720|NCT02443129|Experimental|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation
~Intervention:
~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
11338721|NCT02443129|Experimental|All patients presenting with RD|"Patients with retinal detachment
~Intervention:
~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
11338722|NCT02443129|Experimental|Impact of previous grid treatment|"Patients after grid laser
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
11338723|NCT02443129|Experimental|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment
~Intervention:
~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
11338724|NCT02443129|Experimental|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).
~Longitudinal arm with newly diagnosed patients for 2 years follow-up
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
11338725|NCT02443129|Experimental|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
11338726|NCT02443129|Experimental|Retrospective analysis|"All patients pictured with DRI-OCT
~Intervention:
~DRI-1 Swept source OCT, Atlantis, Topcon"
11338727|NCT02443116|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 - Placebo
11338728|NCT02443116|Experimental|Cohort 1 - NGM282 3mg|Cohort 1 - NGM282 3mg
11338729|NCT02443116|Experimental|Cohort 1 - NGM282 6mg|Cohort 1 - NGM282 6mg
11338730|NCT02443116|Experimental|Cohort 2 - NGM282 0.3mg|Cohort 2 - NGM282 0.3mg
11338731|NCT02443116|Placebo Comparator|Cohort 2 - NGM282 1mg|Cohort 2 - NGM282 1mg
11338732|NCT02443116|Experimental|Cohort 2 - NGM282 3mg|Cohort 2 - NGM282 3mg
11338733|NCT02443116|Experimental|Cohort 3 - NGM282 1mg|Cohort 3 - NGM282 1mg
11338734|NCT02443116|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 - Placebo
11338735|NCT02443116|Experimental|Cohort 4 - NGM282 1mg|Cohort 4 - NGM282 1mg
11338736|NCT02443103|Experimental|Guanabenz|
11338737|NCT02443090|Experimental|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
11338738|NCT02443090|Placebo Comparator|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
11338739|NCT02443077|Experimental|Arm I (ibrutinib, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen.
~BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1.
~CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2.
~TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.
~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
11338740|NCT02443077|Placebo Comparator|Arm II (placebo, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.
~TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.
~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I."
11338741|NCT02443064|Experimental|MRSA blood stream infection patient|"Intervention:Vancomycin
~Dosing:
~15-20mg/kg, IV,q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1~2 h/ dosing, IV
~Drug combination:
~Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.
~Duration:
~Septicemia: 2~4 weeks Endocarditis: 6~8 weeks"
11338742|NCT02443051|Experimental|Attention Bias Modification|Training in bias modification for 80% of experimental trials
11338743|NCT02443051|Active Comparator|Control|Bias modification for 50% of trials
11338744|NCT02443038|Active Comparator|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
11338745|NCT02443038|Placebo Comparator|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
11338746|NCT02443025|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
11338747|NCT02443025|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
11338752|NCT02442986||Septic Shock or severe sepsis|Septic patients on ICU with severe sepsis or septic shock.
11338753|NCT02442986||Non-Septic, Surgical Patients|Non-septic patients after surgical treatment and anesthesia on ICU.
11338754|NCT02442986||Non-Septic, Non-Surgical Patients|Patients without sepsis criteria treated on ICU, non-surgical patients.
11338755|NCT02442973||Control group (CG):|Standard practice group
11338756|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
11338757|NCT02442960|Active Comparator|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
11338758|NCT02442960|Active Comparator|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
11338759|NCT02442947|Experimental|Research arm|"1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.
~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.
~4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:
~NBC protective garment (charcoal base).
~combat garment.
~2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
11338760|NCT02442934|Experimental|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
11338761|NCT02442934|Active Comparator|Standard Care|Standard care
11338762|NCT02442921|Experimental|Colchicine|20 patients will receive up to 2 mg of colchicine for 18 months
11338763|NCT02442921|Placebo Comparator|Placebo|20 patients will receive placebo for 18 months
11338764|NCT02442908|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
11338765|NCT02442908|Placebo Comparator|Placebo|An isocaloric placebo comparator
11338766|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
11338767|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
11338768|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.
~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
11338769|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
11338770|NCT02442869|Experimental|Phase I TAU plus Phase II CAMS|"Treatment as usual [TAU] -- treatment typically provided by counselor for 4-8 weeks
~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to
~Collaborative Assessment and Management of Suicidality (CAMS) long for 4-16 weeks"
11338771|NCT02442869|Experimental|Phase I TAU plus Phase II DBT|"Treatment as usual [TAU] -- treatment typically provided by counselor for 4-8 weeks
~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to
~Dialectical Behavioral Therapy (DBT) long for 4-16 weeks"
11338772|NCT02442869|Experimental|Phase I CAMS plus Phase II repeat CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) short for 4-8 weeks
~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to
~Collaborative Assessment and Management of Suicidality (CAMS) long for 4-16 weeks"
11338773|NCT02442869|Experimental|Phase I CAMS plus Phase II DBT|"Collaborative Assessment and Management of Suicidality (CAMS) short for 4-8 weeks
~If participant is responding, treatment ends. If participant is not responding, he is then re-randomized to
~Dialectical Behavioral Therapy (DBT) long for 4-16 weeks"
11338774|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
11338775|NCT02442843|Experimental|active tDCS|Investigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
11338776|NCT02442843|Sham Comparator|sham tDCS|Participants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
11338777|NCT02442843|No Intervention|Combat Controls|Participants without PTSD will undergo neuropsychological testing and a single fMRI scan.
11338778|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
11403635|NCT02011919|Other|Echopulse|Echopulse HIFU
11338779|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
11338780|NCT02442817|Active Comparator|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
11338781|NCT02442817|Active Comparator|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
11338782|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
11338783|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
11338784|NCT02442791|Experimental|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:
~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).
~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
11338785|NCT02442791|Placebo Comparator|Placebo|"Half of the participants will receive placebo, that will be given as follows:
~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
11338786|NCT02442778|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
11338787|NCT02442778|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
11338788|NCT02442778|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
11338789|NCT02442765|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
11338790|NCT02442765|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
11338791|NCT02442765|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
11338792|NCT02442752|Experimental|Regimen A: Dexlansoprazole 10 mg|Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.
11338793|NCT02442752|Experimental|Regimen B: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.
11338794|NCT02442752|Experimental|Regimen C: Dexlansoprazole 20 mg|Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.
11338795|NCT02442752|Experimental|Regimen D: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.
11338796|NCT02442739|Experimental|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
11338797|NCT02442739|Placebo Comparator|Placebo|oral placebo (syrup)
11338798|NCT02442726|Active Comparator|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
11338799|NCT02442726|Sham Comparator|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
11338800|NCT02442713|Experimental|fluvoxamine|fluvoxamine: 50-300mg/day
11338801|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
11338802|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
11338803|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
11338804|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
11338805|NCT02442687|Placebo Comparator|C|Identical appearing placebo
11338806|NCT02442674|Active Comparator|Tolvaptan|Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)
11338807|NCT02442674|Placebo Comparator|Placebo|Placebo tablet matching active drug
11338808|NCT02442648|Experimental|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
11338809|NCT02442648|Experimental|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
11338810|NCT02442648|Experimental|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
11338811|NCT02442648|Experimental|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
11338812|NCT02442635|Experimental|Condition 1|Yoga Breathing
11338813|NCT02442635|Experimental|Condition 2|Static Yoga
11338814|NCT02442635|Experimental|Condition 3|Flowing Yoga
11338815|NCT02442622|Active Comparator|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
11338816|NCT02442622|Experimental|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
11338817|NCT02442609||patient|patient schedulled for elective surgery, adult (> 18yrs), non emergency procedure, able to read questionaire
11338818|NCT02442596||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
11338819|NCT02442583|No Intervention|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
11338820|NCT02442583|No Intervention|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
11338821|NCT02442583|Experimental|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
11338822|NCT02442570|Active Comparator|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
11338823|NCT02442570|Active Comparator|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
11338824|NCT02442570|Active Comparator|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
11338825|NCT02442570|Placebo Comparator|placebo|three intravenous injections of placebo, 2 months apart
11338826|NCT02442557|Active Comparator|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
11338827|NCT02442557|Active Comparator|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
11338828|NCT02442557|Active Comparator|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
11338829|NCT02442557|Active Comparator|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
11338830|NCT02442557|Placebo Comparator|single dose placebo|a single intravenous injection of placebo
11338831|NCT02442557|Active Comparator|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
11338832|NCT02442557|Active Comparator|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
11338833|NCT02442557|Active Comparator|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
11338834|NCT02442557|Placebo Comparator|multiple dose placebo|three consecutive daily intravenous injections of placebo
11338835|NCT02442544|Placebo Comparator|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
11338836|NCT02442544|Experimental|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
11338837|NCT02442531|Experimental|CriPec® docetaxel|Docetaxel containing nanoparticle
11338838|NCT02442518||women with placenta praevia|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of pregnancy (lower placental edge within 20 mm from the internal os above 26 week's gestation)
11338839|NCT02442492|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
11338840|NCT02442492|Placebo Comparator|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
11338841|NCT02442479|Active Comparator|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
11338842|NCT02442479|Experimental|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
11338843|NCT02442479|Experimental|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
11338844|NCT02442479|Experimental|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
11338845|NCT02442466|Experimental|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
11338846|NCT02442466|Experimental|PBS|Intra-lesion administration of vehicle
11338847|NCT02442453|Active Comparator|curcuma longa|"curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.
~Test group:Topical application twice daily for ten minutes after brushing for four weeks."
11338848|NCT02442453|Placebo Comparator|Placebo gel|Placebo gel consists of corbopol 934 polymer and triethonalamine. Control group:Topical application twice daily for ten minutes after brushing for four weeks.
11338849|NCT02442440|Experimental|anisodamine group|administration of the drug
11338850|NCT02442440|No Intervention|control group|these arm do not use anisodamine, other resuscitation protocol is as usual.
11338851|NCT02442427|Active Comparator|Palivizumab|A single dose of IV palivizumab
11338852|NCT02442427|Placebo Comparator|Placebo|An equivalent volume of 0.9% normal saline.
11338853|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
11338854|NCT02442401|Experimental|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
11338855|NCT02442401|No Intervention|Control group|Conventional method was used to the donor site
11338856|NCT02442388|Experimental|Hand file|Instrumentation technique
11338857|NCT02442388|Experimental|ProTaper file|Instrumentation technique
11338858|NCT02442388|Experimental|Wave-One file|Instrumentation technique
11338859|NCT02442375|Active Comparator|standard dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning
~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
11338860|NCT02442375|Experimental|FDG-PET guided gradient dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning
~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
11338861|NCT02442362|Active Comparator|TOF Group|"Patients in the TOF group received chemotherapy with paclitaxel+oxaliplatin+fluorouracil"
11338862|NCT02442362|Experimental|SOX Group|The patients in the SOX group received chemotherapy with 'oxaliplatin+S1'
11338863|NCT02442349|Experimental|AZD9291|Once daily tablet 80 mg
11338864|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
11342374|NCT02418910||bipolar outpatients|Patients with Bipolar Disorder in any clinical state
11338865|NCT02442323|Experimental|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
11338866|NCT02442323|No Intervention|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
11338867|NCT02442310|Experimental|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
11338868|NCT02442310|Experimental|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
11338869|NCT02442310|Experimental|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
11338870|NCT02442310|Active Comparator|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
11338871|NCT02442297|Experimental|HER2-specific T cells - High Risk|Subjects with HER2 staining of Grade 3 (51-100% of cells staining for HER2) and intensity scores of 3+ will be assigned to the High Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
11338872|NCT02442297|Experimental|HER2-specific T cells - Standard Risk|All other patients not meeting the high risk description will be assigned to the Standard Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
11338873|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
11338874|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
11338875|NCT02442258|Experimental|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
11338876|NCT02442258|Experimental|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
11338877|NCT02442258|Experimental|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
11338878|NCT02442258|Experimental|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range < 15 mL/min/1.73 m2 as determined at Screening.
11338879|NCT02442258|Experimental|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
11338880|NCT02442258|Experimental|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) < 15 mL/min/1.73 m2 as determined at Screening.
11338881|NCT02442245|Placebo Comparator|Placebo|Placebo group will receive microcrystalline cellulose
11338882|NCT02442245|Active Comparator|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
11338883|NCT02442245|Sham Comparator|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
11338884|NCT02442232||Normotensive|
11338885|NCT02442232||Hypertensive taking ACEi|
11338886|NCT02442232||Hypertensive not taking ACEi|
11338887|NCT02442219||Coeliac|Persons with coeliac disease on a gluten free diet where diagnosis is confirmed by duodenal biopsy.
11338888|NCT02442219||Non coeliac gluten sensitive|Persons on a gluten free diet where coeliac disease is excluded by duodenal biopsy.
11338889|NCT02442219||Healthy control group|Persons on a gluten containing diet without known coeliac disease.
11338890|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
11338891|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
11338892|NCT02442193|Experimental|Individual Placement and Support|Individual Placement and Support
11338893|NCT02442193|No Intervention|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
11338894|NCT02442180|Experimental|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
11338895|NCT02442180|Placebo Comparator|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
11338896|NCT02442180|Experimental|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
11338897|NCT02442180|Placebo Comparator|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
11338898|NCT02442154|Experimental|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
11338899|NCT02442154|No Intervention|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
11338900|NCT02442128|Active Comparator|Group1|comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
11338901|NCT02442128|Active Comparator|Group 2|comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
11342668|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
11338902|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
11338903|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
11338904|NCT02442102|Experimental|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
11338905|NCT02442089|No Intervention|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
11338906|NCT02442089|Experimental|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
11338907|NCT02442063|Experimental|Radium Ra 223 dichloride|Radium Ra 223 dichloride (Xofigo, BAY88-8223)
11338908|NCT02442050|Experimental|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
11338909|NCT02442050|Active Comparator|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
11338910|NCT02442037|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
11338911|NCT02442037|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
11338912|NCT02442024|Experimental|Modified diet|This group will follow a modified diet over a period of two months.
11338913|NCT02442024|Active Comparator|Standard diet|This group will follow a standardized diet over a period of two months.
11338914|NCT02441985|Experimental|Real rTMS Stimulation|rTMS will be delivered over each cerebellar hemisphere, using a 70mm figure-of-eight coil connected to a Magstim RapidStim2 machine while positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. The inion will be taken as the boundary between the posterior cerebellum and the occipital cortex. Therefore the area stimulated will be caudal to the inion to stimulate the posterior cerebellum.
11338915|NCT02441985|Sham Comparator|Sham rTMS Stimulation|Patients randomized to receive sham treatment will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham Magstim RapidStim2 Placebo which produces discharge noise and vibration similar to the real coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. The investigator will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp. The investigator will use an electromyography to administer electrical shocks to the scalp simultaneous to each simulated rTMS train.
11338916|NCT02441972|Experimental|18F-Al-NOTA-PRGD2 PET/CT|Imaging with 18F-Al-NOTA-PRGD2 PET/CT.
11338917|NCT02441959|Active Comparator|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
11338918|NCT02441959|Active Comparator|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
11338919|NCT02441959|Other|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
11338920|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams [mg]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.
~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
11338921|NCT02441946|Experimental|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.
~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
11338922|NCT02441946|Active Comparator|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.
~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
11338923|NCT02441933|Active Comparator|control group|
11338924|NCT02441933|Experimental|carboplatin group|
11338925|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
11338926|NCT02441907|Other|aflibercept treatment|aflibercept, 40 mg/mL Solution for Intravitreal Injection
11338927|NCT02441894|Experimental|Cabazitaxel|"25 mg/m^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks.
~Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles."
11338928|NCT02441881|Active Comparator|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
11338929|NCT02441881|Active Comparator|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
11338930|NCT02441881|Active Comparator|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
11338931|NCT02441868|Experimental|Intervention|all participants will receive the training
11338932|NCT02441855||pneumonia|patients with community-acquired pneumonia
11338933|NCT02441855||control|patients admitted to emergency department with shortness of breath
11338934|NCT02441842|Active Comparator|Group A : Atenolol|oral atenolol (50mg)
11338935|NCT02441842|Placebo Comparator|Group C: Placebo|glucose tablet (10mg)
11338936|NCT02441842|Active Comparator|Group L: Lisinopril|oral lisinopril (5mg)
11338937|NCT02441829|Experimental|Mild Renal Impairment (CLcr 60-89 mL/min)|Participants with mild renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
11338938|NCT02441829|Experimental|Moderate Renal Impairment (CLcr 30-59 mL/min)|Participants with moderate impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
11338939|NCT02441829|Experimental|Severe Renal Impairment (CLcr 15-29 mL/min)|Participants with severe renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
11338940|NCT02441816|Other|Eylea Treatment|The intravitreal dose of Eylea will be 2mg (in 0.05ml) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks in the first year of treatment before applying a treat and extend paradigm to patient visits in year 2. This is an open-label study.
11338941|NCT02441803|Experimental|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.
~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
11338942|NCT02441803|Experimental|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.
~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
11338943|NCT02441803|Experimental|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.
~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
11338944|NCT02441790|Experimental|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
11338945|NCT02441790|Active Comparator|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
11338946|NCT02441777|Experimental|Control: Healthy|Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.
11338947|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
11338948|NCT02441751||bleeding|intraoperative blood loss > 500 ml
11338949|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
11338950|NCT02441738|Active Comparator|Hybrid Ablation|Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).
11338951|NCT02441738|Active Comparator|Catheter Ablation|Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).
11338952|NCT02441725|Other|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:
~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
11338953|NCT02441725|Other|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:
~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
11338954|NCT02441712|Experimental|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
11338955|NCT02441712|Sham Comparator|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
11338956|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
11338957|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
11338994|NCT02441426||Brazil|"Birth cohort study community in Brazil is urban, and located within the Papoco area of Fortaleza.
~Case control study is being conducted in the same area as the cohort study. Cases are children 6 - 24 months of age, with <-2 WAZ (weight for age) score, controls are age and community matched children with >-1 WAZ."
11338958|NCT02441686|Experimental|Bortezomib, Lenalidomide, Dexamethasone|"After the screening procedures confirm eligibility to participate in the research study: Each participant will be given a study drug-dosing diary for each treatment cycle. The diary will also include special instructions for taking the study drugs.
~- Study Drugs:
~Bortezomib- subcutaneous injection on predetermined days of each cycle
~Lenalidomide oral daily on predetermined days of each cycle.
~Dexamethasone oral on predetermined days of each cycle"
11338959|NCT02441673|Active Comparator|Nefopam|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.
~0.15mg/kg of Acupan(Nefopam) would be administered IV after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.
~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Acupan is not satisfactory."
11338960|NCT02441673|Active Comparator|Tramadol|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.
~1mg/kg of tramadol would be administered after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.
~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Tramadol is not satisfactory."
11338961|NCT02441660|Experimental|experimental group|Qutenza, Capsaicin 8% Patch will be used
11338962|NCT02441660|Active Comparator|control group|Active control with low dose capsaicin
11338963|NCT02441647|Experimental|Experimental group|
11338964|NCT02441621|Other|Passive leg raising|
11338965|NCT02441621|Other|premedication|
11338966|NCT02441621|Other|intubation and mechanical ventilation|
11338967|NCT02441621|Other|central venous catheter|
11338968|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
11338969|NCT02441621|Other|transesophageal echocardiography|
11338970|NCT02441621|Other|transpulmonary thermodilution catheter|
11338971|NCT02441608|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
11338972|NCT02441595|Experimental|MBCP intervention|The intervention involves eight 2.5 h weekly group sessions in which exercises in mindfulness are practiced and associated theory is taught to increase metacognition, emotional regulation and body awareness.
11338973|NCT02441595|Active Comparator|Control condition|Participants in the control condition are being offered a standardized course in psychoprophylaxis.
11338974|NCT02441582|Experimental|Telemetry|In this group, participants will have a prehospital 12 lead ECG taken and sent through to the receiving facility.
11338975|NCT02441582|Other|Non-Telemetry|In this group, participants will have a prehospital 12 lead ECG taken which will not be sent through to the receiving facility.
11338976|NCT02441569|Experimental|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
11338977|NCT02441569|Active Comparator|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
11338978|NCT02441556|Active Comparator|standard medical therapy|Patients receive standard medical therapy alone.
11338979|NCT02441556|Experimental|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
11338980|NCT02441530|Experimental|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
11338981|NCT02441530|Experimental|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
11338982|NCT02441530|Experimental|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
11338983|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
11338984|NCT02441504|Active Comparator|Low intensity exercise|physical inactivity
11338985|NCT02441491|Experimental|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.
~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
11338986|NCT02441478|Experimental|Patients|
11338987|NCT02441478|Active Comparator|Controls|
11338988|NCT02441465|Experimental|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
11338989|NCT02441452|Active Comparator|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
11338990|NCT02441452|No Intervention|Conventional care|Usual care routine postoperative.
11338991|NCT02441439|Other|Iron sucrose 200 mg|first arm will be treated with iron sucrose 200 mg 2-3 times a week
11338992|NCT02441439|Active Comparator|Iron sucrose 500 mg|Second arm will be treated with iron sucrose 500 mg once a week
11338993|NCT02441426||Bangladesh|"Birth cohort study community in Bangladesh is urban, and located in the Mirpur neighborhood of Dhaka.
~Case control study is being conducted in the same catchment area. Cases defined as children 6-24 months of age with <-2WAZ (weight for age) score, controls are age and community matched with >-1WAZ."
11338995|NCT02441426||India|Birth cohort study community in India is urban, and located in the southern state of Tamil Nadu, specifically in Vellore.
11338996|NCT02441426||Nepal|Birth cohort study community in Nepal is semi-urban, and located in Bhaktapur, approximately 25km from Kathmandu.
11338997|NCT02441426||Pakistan|Birth cohort study community in Pakistan is rural, and located in Naushero Feroze, Sindh.
11338998|NCT02441426||Peru|Birth cohort study community in Peru is rural, and located approximately 15km from Iquitos in Loreto.
11338999|NCT02441426||South Africa|Birth cohort study community in South Africa is rural/peri-urban, and comprised of nine settlements within Limpopo Province.
11339000|NCT02441426||Tanzania|Birth cohort study community in Tanzania is rural, and located within Haydom.
11339001|NCT02441413|Experimental|HRCT scans|HRCT scan will be taken
11339002|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
11339003|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:
~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
11339004|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
11339005|NCT02441374|Experimental|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
11339006|NCT02441374|Active Comparator|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
11339007|NCT02441361|No Intervention|control|Subjects will undergo bariatric surgery and no exercise training will be prescribed.
11339008|NCT02441361|Experimental|exercise training|Subjects will undergo bariatric surgery and exercise training will be prescribed.
11339009|NCT02441348||CTT group|CTT will be initiated in a prospective fashion to study population
11339010|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
11339011|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
11339012|NCT02441335||Group 3 (PTB-medically indicated)|Singleton pregnancy between 20 0/7 34 5/6 weeks gestational age who is admitted with a medically indicated preterm birth (IOL for abruption, non reassuring fetal heart tones, intrauterine growth restriction, preeclampsia, trauma, etc.)
11339013|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
11339014|NCT02441309|Experimental|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):
~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.
~Treatment Weeks 7-12 (post 2nd biopsy/resection):
~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.
~Treatment Weeks 13-36:
~Mifamurtide 2mg/m2, IV infusion, once/week."
11339015|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).
~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.
~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
11339016|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:
~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).
~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.
~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.
~Treatment Weeks 7-12 (post 2nd biopsy/resection):
~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).
~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.
~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
11339017|NCT02441296|Experimental|Formula with lactose|Carbohydrate-free formula with added lactose
11339018|NCT02441296|Experimental|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
11339019|NCT02441296|No Intervention|Breastfeeding|Breastfed reference group
11339020|NCT02441283|No Intervention|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
11339021|NCT02441270|Experimental|Cyclophosphamide|
11339022|NCT02441257|Experimental|control ventilation|patients are scheduled to receive control or spontaneous ventilation
11339023|NCT02441244|Experimental|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
11339024|NCT02441244|Placebo Comparator|Placebo Group|Placebo comparator group
11339025|NCT02441231|Experimental|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
11339026|NCT02441231|Placebo Comparator|Placebo Group|Placebo comparator group
11339027|NCT02441218|Experimental|Ivabradine|
11339028|NCT02441218|Placebo Comparator|Placebo|
11339029|NCT02441205|Experimental|HIIT Aging|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
11339315|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
11339030|NCT02441192|Experimental|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
11339031|NCT02441192|Experimental|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
11339032|NCT02441192|Experimental|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
11339033|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
11339034|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
11339035|NCT02441166|Other|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
11339036|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
11339037|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
11339038|NCT02441140|Experimental|Culdocentesis|"Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.
~During Surgery:
~Blood Collection
~Vaginal Swab
~Chromopertubation
~Culdocentesis
~Tissue Collection"
11339039|NCT02441127|Experimental|Diode laser group|In the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1W) was applied in continuous mode.
11339040|NCT02441127|Active Comparator|Scalpel control group|The surgical technique used in the control group was a FGG harvested by two horizontal and two vertical incisions by scalpel defining the area to be harvested .
11339041|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.
~The periods were separated with a washout period of 14 days."
11339042|NCT02441101|Experimental|RV DDD(R)-60 with AV optimization|RBBB pacing
11339043|NCT02441101|Placebo Comparator|RV DDD(R)-60|Standard demand pacing
11339044|NCT02441088|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|A radiopharmaceutical, 90Y--DOTA-tyr3-Octreotide, and a renal protectant, Aminosyn II, in a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Radiopharmaceutical will be administered IV in 3 doses, 6 weeks apart, with Aminosyn II administered concomittantly with each dose. Two followup visits are required at three and 6 months following third dose of 90Y-DOTA-tyr3-Octreotide.
11339045|NCT02441075|Experimental|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
11339046|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
11339047|NCT02441049|Experimental|Home-based promotora intervention|Study participants and their families received the home-based promotora family intervention
11339048|NCT02441049|No Intervention|Delayed treatment control|Study participants received intervention materials after the final study evaluation measures were taken, 10 months post-baseline.
11339049|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
11339050|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
11339051|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
11339052|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
11339053|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
11339054|NCT02441023|Experimental|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
11339055|NCT02441023|No Intervention|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
11339056|NCT02441010|No Intervention|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
11339057|NCT02441010|Sham Comparator|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
11339316|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
11339317|NCT02439216|Placebo Comparator|Placebo|Matching placebo
11339058|NCT02441010|Sham Comparator|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
11339059|NCT02441010|Active Comparator|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
11339060|NCT02441010|Active Comparator|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
11339061|NCT02441010|Experimental|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
11339062|NCT02441010|Experimental|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
11339063|NCT02440997|Placebo Comparator|foot bath only|10 minute foot bath with addition of jojoba only
11339064|NCT02440997|Experimental|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
11339065|NCT02440984|Other|Enteric nervous system dysfunction|colonic biopsies and usual care
11339066|NCT02440958|Experimental|modified FOLFIRINOX|
11339067|NCT02440945|Experimental|collection of blood|160 old people for the collection of blood
11339068|NCT02440932|Experimental|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich [low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).
~Dinner: ad libitum buffet meal"
11339069|NCT02440932|Other|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
11339070|NCT02440919|Other|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
11339071|NCT02440919|Other|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
11339072|NCT02440919|Other|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
11339073|NCT02440919|Other|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
11339074|NCT02440906|Experimental|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
11339075|NCT02440906|No Intervention|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
11339076|NCT02440906|No Intervention|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
11339077|NCT02440893||Corus CAD (ASGES) Post-metformin|Corus CAD (ASGES) second sample draw results to compare to Corus CAD (ASGES) first draw results (per patient).
11339078|NCT02440880|Placebo Comparator|CONTROL|TAP block without Dexamethasone neither intravenous nor in combination with the block
11339079|NCT02440880|Experimental|Group 2 (TD8IS)|Dexamethasone in combination with TAP block in dose of 8 mg
11339080|NCT02440880|Experimental|Group 3(TD4IS)|Dexamethasone in addition to TAP block in dose of 4 mg
11339081|NCT02440880|Experimental|Group 4 (TSID8):|Dexamethasone intravenous in addition to TAP block in dose of 8 mg
11339082|NCT02440880|Experimental|Group5(TSID4)|Dexamethasone intravenous 4mg+ TAP block
11339083|NCT02440867|No Intervention|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
11339084|NCT02440867|Experimental|TBS-MPC|"Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia
~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Continuous actimetry acquisition"
11339085|NCT02440867|Active Comparator|TBS-CPDLF|"Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia
~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Continuous actimetry acquisition"
11339086|NCT02440867|Sham Comparator|TBS-Sham|"Intervention with Sham TBS in 8 patients with schizophrenia
~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition
~Continuous actimetry acquisition"
11339087|NCT02440854||Afatinib|
11339088|NCT02440841|Experimental|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
11339089|NCT02440841|Experimental|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
11339090|NCT02440828|Experimental|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
11339091|NCT02440828|Placebo Comparator|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
11339318|NCT02439203|Experimental|JM-010|JM-010
11339319|NCT02439203|Placebo Comparator|Placebo|Placebo
11339092|NCT02440815|Other|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
11339093|NCT02440802||Gonadoliberin antagonist treatment|Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.
11339094|NCT02440789|Experimental|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.
~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
11339095|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
11339096|NCT02440750|Experimental|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
11339097|NCT02440750|Experimental|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
11339098|NCT02440737|Experimental|NEST Intervention|Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.
11339099|NCT02440724|Experimental|winged stent group|participants who are assigned to winged-stent group will be treated with deployment of a winged stent(partially covered or uncovered SEMS).
11339100|NCT02440711|Experimental|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
11339101|NCT02440711|Experimental|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
11339102|NCT02440685|Experimental|ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
11339103|NCT02440685|Experimental|ASN002 Recommended dose (RD) - DLBCL|ASN002 administered at the recommended dose in subjects with DLBCL. Arm Closed
11339104|NCT02440685|Experimental|ASN002 RD - Mantle Cell Lymphoma|ASN002 administered at the recommended dose in subjects with MCL. Arm Closed
11339105|NCT02440685|Experimental|ASN002 RD - Follicular Lymphoma|ASN002 administered at the recommended dose in subjects with FL.
11339106|NCT02440685|Experimental|ASN002 RD - Peripheral T-cell Lymphoma|ASN002 administered at the recommended dose in subjects with PTCL.
11339107|NCT02440685|Experimental|ASN002 RD - Myelofibrosis|ASN002 administered at the recommended dose in subjects with MF.
11339108|NCT02440685|Experimental|ASN002 RD - Chronic Lymphocytic Leukemia|ASN002 administered at the recommended dose in subjects with CLL.
11339109|NCT02440672|Other|Device:JOURNEY™ II CR Total Knee System (J II CR TKS)|Subjects having TKA with JOURNEY™ II CR Total Knee System
11339110|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
11339111|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
11339112|NCT02440646||CTA group|All-comers admitted to the chest-pain outpatient center with or without acute coronary syndrome underwent functional tests and coronary computed tomography angiography (CTA) (with intravenous contrast) with or without further quantitative coronary angiography (QCA) and percutaneous intervention (PCI).
11339113|NCT02440646||3D QCA group|All-comers admitted to the chest-pain outpatient center with or without acute coronary syndrome underwent functional tests and 3D quantitative coronary angiography (QCA) with or without implantation of stent.
11339114|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
11339115|NCT02440607|Experimental|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
11339116|NCT02440607|Active Comparator|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
11339117|NCT02440594|Experimental|Enhanced Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
11339186|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
11339320|NCT02439190|Active Comparator|Treatment A: BMS-986120|BMS-986120 on specified days
11404573|NCT02005523|Placebo Comparator|Saline|
11339118|NCT02440594|Active Comparator|Standard Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
11339119|NCT02440594|Experimental|Enhanced Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Enhanced BHL Program Services, which for this group include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Monitoring via a one-time BHP follow-up call with the enrollee after 6 weeks to discuss continuing versus discontinuing the medication.
11339120|NCT02440594|Active Comparator|Standard Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
11339121|NCT02440594|Experimental|Enhanced Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
11339122|NCT02440594|Active Comparator|Standard Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
11339123|NCT02440594|Experimental|Caregiver TEP Intervention|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Enhanced BHL Program Services which include: 1) a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services, and 2) the Telehealth Education Program (TEP) - BHPs provide manual and workbook-guided psychoeducation, support, and skills training.
11339124|NCT02440594|Active Comparator|Caregiver Control|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Standard BHL Program Services, which include a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services
11339125|NCT02440581|No Intervention|Control, low turnover|No intervention in low turnover osteoporosis control group.
11339126|NCT02440581|Experimental|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
11339127|NCT02440581|No Intervention|Control, high turnover|No intervention in high turnover osteoporosis control group.
11339128|NCT02440581|Experimental|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
11339129|NCT02440568|Experimental|Patients with newly diagnosed AML|Patients will receive Omacetaxine, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
11339130|NCT02440555||patients included|fulfill the self-administered questionnaire.
11339131|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
11339132|NCT02440529|Active Comparator|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
11339133|NCT02440529|Active Comparator|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
11339134|NCT02440516|Active Comparator|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
11339135|NCT02440516|Placebo Comparator|Waiting list|Waiting list
11339311|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
11339321|NCT02439190|Active Comparator|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
11339322|NCT02439177|Experimental|Omnitest 3|Blood glucose monitoring system
11339136|NCT02440490|Experimental|Computerised cognitive training|The cognitive training protocol will be run using pre-validated software, HappyNeuronPro, that delivers cognitive training games. The games are designed to be visually interesting and engaging, and are varied so that each session will comprise multiple different games, to avoid boredom. They begin with easy-to-follow instructions and demonstrations, then as the participant progresses, the difficulty is automatically increased in correspondence with their performance, to avoid ceiling or plateau effects. Participants will be assigned a program targeting multiple facets of cognition found to be compromised in chronic pain states, including divided attention, working memory, mentally planning a sequence of items to form a pattern or complete a puzzle, and response inhibition.
11339137|NCT02440490|Active Comparator|Video watching|This group will be provided with a variety of videos to watch, the content of which will be in the style of documentaries on general interest topics such as nature, travel, culture, and history. Each video is followed by multiple-choice questions that participants will answer, to ensure attention was engaged. The videos are visually stimulating and engaging, but involve no increment in difficulty or requirement to improve skills. They may provide some distraction from pain and may be relaxing, interesting and informative.
11339138|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
11339139|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
11339140|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
11339141|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
11339142|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
11339143|NCT02440438|Experimental|Clostridium difficile infection|
11339144|NCT02440425|Experimental|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
11339145|NCT02440412|Experimental|Massage Therapy|A 45 minutes massage therapy (manual) standardized session, based in Swedish techniques.
11339146|NCT02440412|Placebo Comparator|Rest condition|45 minutes of rest in supine position, listening music with headphones, and warm condition.
11339147|NCT02440412|No Intervention|Control|Normal working condition, as a office workers (secretaries and managements employees)
11339148|NCT02440399|Experimental|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):
~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams
~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).
~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.
~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.
~The total amount of paracetamol is limited to 4 gr per day."
11339149|NCT02440399|Experimental|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
11339150|NCT02440386|No Intervention|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
11339151|NCT02440386|Experimental|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
11339152|NCT02440360|Active Comparator|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
11339153|NCT02440360|Placebo Comparator|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health & Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
11339154|NCT02440347|Experimental|Computer controlled anesthetic delivery by Anaeject|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by computer controlled anesthetic delivery system (C-CLADS) for AMSA nerve block
11339155|NCT02440347|Active Comparator|Conventional anesthetic delivery by carpule syringe|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by conventional anesthetic delivery for AMSA nerve block
11339156|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
11339323|NCT02439177|Experimental|Omnitest 5|Blood glucose monitoring system
11339387|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
11339157|NCT02440321|Experimental|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
11339158|NCT02440321|Active Comparator|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
11339159|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
11339160|NCT02440295||Lower Extremity Amputations|"All patients >= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.
~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
11339161|NCT02440282||Group A|patients undergo general anesthesia
11339162|NCT02440282||Group B|spinal anesthesia
11339163|NCT02440282||Group C|ultrasound-guided sciatic nerve block
11339164|NCT02440269||A：day|the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm
11339165|NCT02440269||B：night|the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day
11339166|NCT02440256|Other|Cluster 1|Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
11339167|NCT02440256|Other|Cluster 2|Cluster 2 is the second OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the twelfth month of the trial. Cluster 2 will be a 'no intervention' arm in the first 12 months of the study, and will cross-over to a experimental arm for month 12-24.
11339168|NCT02440256|Other|Cluster 3|Cluster 3 is the final OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the 18th month of the trial. As such, Cluster 3 will be a 'no intervention' arm in the first 18 months of the study, and will cross-over to an experimental arm for months 18-24.
11339169|NCT02440243|Active Comparator|Patients active|Purethal Grass
11339170|NCT02440243|Placebo Comparator|Patients placebo|Placebo
11339171|NCT02440230|Experimental|OFS + Anastrozole|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
11339172|NCT02440230|Active Comparator|OFS + Exemestane|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
11339173|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
11339174|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
11339175|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
11339176|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
11339177|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
11339178|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
11339179|NCT02440191|Active Comparator|3DCRT|conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.
11339180|NCT02440191|Experimental|IMRT (Intensity modulated radiotherapy)|"Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.
~Unlike 3DCRT, concomittant boost technique is used in the IMRT arm."
11339181|NCT02440178|Experimental|micafungin prophylaxis|
11339182|NCT02440165|Experimental|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:
~Information and advice;
~Examples of energy and protein rich meals;
~patients will be asked to register their nutritional intake for two days at home;
~after a week, the nurse will call the patients to answer questions and to give advice.
~This nutrition care plan will be tailored to the individual patient requirements.
~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
11339183|NCT02440165|No Intervention|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
11339184|NCT02440152|Experimental|Deep brain stimulation|
11339185|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
11342800|NCT02416388|Experimental|R4-DEX-HDAC|High dose cytarabine and dexamethasone
11339187|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
11339188|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
11339189|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
11339190|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
11339191|NCT02440113||Nellix|Patients with endovascular Nellix repair
11339192|NCT02440100|Experimental|Multiple Doses PF-06648671 (Cohort1)|Healthy subjects receive 14-day repeated dose once a day at 4 mg of PF-06648671 or matching placebo
11339193|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 2)|Healthy subject receive 14-day repeated dose once a day at 12 mg of PF-06648671 or matching placebo
11339194|NCT02440100|Experimental|Multiple doses PF-06648671 (cohort 3)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo and CSF LP is collected at baseline and steady state predose on day 1 and 14
11339195|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 4)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo
11339196|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 5)|Healthy subject receive 14-day repeated dose once a day at 100 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours after last dosing on day 14
11339197|NCT02440100|Experimental|Multiple Doses in Healthy Elderly (cohort 7)|Healthy Elderly subjects receive 14-day repeated dose once a day at MTD PF-06648671 defined in healthy adult subjects (part 1)
11339198|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 8)|Healthy subjects receive 14-day repeated dose once a day at 360 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours post last dose
11339199|NCT02440100|Experimental|Midazolam DDI (optional cohort 9)|Healthy Subjects receive single dose of 2 mg midazolam in period 1 followed by 14 days PF-06648671 once a day and coadministration of PF-06648671 and midazolam 2 mg in period 2 (Optional cohort)
11339200|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 6)|Healthy subject receive 14-day repeated dose once a day at 200 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 25, 24 hours after last dosing on day 14
11339201|NCT02440074|Experimental|MSV autologous transplantation|
11339202|NCT02440061|Active Comparator|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
11339203|NCT02440061|Active Comparator|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
11339204|NCT02440048|Experimental|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
11339205|NCT02440048|Active Comparator|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
11339206|NCT02440048|No Intervention|extraction|10 extraction sockets with no use of bone substitute as negative control.
11339207|NCT02440035|Experimental|Group 1|Two subsequent Intramuscular injections of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
11339208|NCT02440035|Experimental|Group 2|Intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1, an intramuscular injection of placebo control on Day 85 and an injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 169.
11339209|NCT02440035|Experimental|Group 3|One intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1 and an intramuscular injection of placebo control on Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
11339210|NCT02440035|Experimental|Group 4|Two subsequent intramuscular injections of placebo control on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169.
11339211|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
11339212|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
11339213|NCT02440009|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
11339312|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
11404919|NCT02003157|Active Comparator|usual|embryo transfer usual procedure
11339214|NCT02440009|Experimental|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
11339215|NCT02439996|Experimental|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
11339216|NCT02439996|Experimental|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
11339217|NCT02439996|Active Comparator|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
11339218|NCT02439983|Placebo Comparator|Placebo|
11339219|NCT02439983|Experimental|Proprietary Nutritional Supplement|
11339220|NCT02439970|Active Comparator|Treatment 1|BCV plus vGCV placebo
11339221|NCT02439970|Active Comparator|Treatment 2|vGCV plus BCV placebo
11339222|NCT02439957|Active Comparator|Treatment 1|BCV plus vGCV placebo
11339223|NCT02439957|Active Comparator|Treatment 2|vGCV plus BCV placebo
11339224|NCT02439944|Experimental|Experimental Arm|Escalating nicotine patch dose to satiety over 6 weeks with dosage depending on the number of cigarettes smoked per day and the occurrence of adverse effects
11339225|NCT02439944|Active Comparator|Positive Control Arm|Nicotine patch dose of 21mg coupled with nicotine mouthspray which is to be used as needed.
11339226|NCT02439931|Experimental|Remote psychosocial intervention|10 sessions of remotely delivered psychoeducation and support
11339227|NCT02439905|Experimental|Dexmedetomidine group|
11339228|NCT02439905|Placebo Comparator|Normal saline group|
11339229|NCT02439892|Experimental|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
11339230|NCT02439892|Active Comparator|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
11339231|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
11339232|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
11339233|NCT02439866|Placebo Comparator|prescription placebo|control Group consisted of 30 patients who received gelatinous capsules filled with sugar as placebo
11339234|NCT02439866|Active Comparator|prescription Intravenous methylprednisolone|Group 2 or steroid consisted of 30 patients received methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day
11339235|NCT02439866|Active Comparator|prescription normobaric oxygen with face mask|Thirty patients in group 3 or oxygen received 100% normobaric oxygen with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
11339236|NCT02439853|Experimental|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
11339237|NCT02439853|No Intervention|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
11339238|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
11339239|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
11339240|NCT02439827|Experimental|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
11339241|NCT02439827|No Intervention|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
11339242|NCT02439814|Experimental|Pregnenolone|
11339243|NCT02439814|Placebo Comparator|Placebo|
11339244|NCT02439801||Compliance|"Pulmonary compliance (or lung compliance) is a measure of the lung's ability to stretch and expand. In clinical practice it is separated into two different measurements, static compliance and dynamic compliance. Static lung compliance is the change in volume for any given applied pressure. Dynamic lung compliance is the compliance of the lung at any given time during actual movement of air.
~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on static and dynamic compliance levels will be investigate."
11339245|NCT02439801||Pulmonary Function tests|"Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease.
~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on pulmonary function test values will be investigate."
11339246|NCT02439801||volatil agent elimination time|"Volatile anaesthetics are eliminated in the terminal phase via the lungs. A low blood:gas partition coefficient is therefore necessary for quick removal of the anaesthetic.
~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on volatil agent elimination time will be investigate."
11339247|NCT02439788|Experimental|GINAKIT Cells plus chemotherapy|Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)
11339248|NCT02439775|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
11339249|NCT02439775|Sham Comparator|Sham Procedure|Renal angiography
11339250|NCT02439762|Experimental|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
11339251|NCT02439762|Active Comparator|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
11339252|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
11339253|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
11339254|NCT02439736||CT positive for acute intracranial lesion|
11339255|NCT02439723|Experimental|Regorafenib|All patients will be treated with 160 mg regorafenib taken orally once daily for the first 21 days of each 28-day cycle. Doses are to be taken immediately following a light breakfast. During the seven-day break period of cycle 1, patients will start pantoprazole 40 mg twice daily for 8 days
11339256|NCT02439697|Experimental|Darbepoetin alfa (NESP®) same dose|Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)
11339257|NCT02439697|Experimental|Extended dosing Darbepoetin alfa (NESP®)|Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.
11339258|NCT02439697|Experimental|Darbepoetin alfa (NESP®) 120mcg|Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion
11339259|NCT02439671|Experimental|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
11339260|NCT02439671|No Intervention|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
11339261|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
11339262|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
11339263|NCT02439632|Experimental|prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.
~Placebo of levofloxacin hydrochloride tablet without active components."
11339264|NCT02439632|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
~Placebo of prulifloxacin film-coated tablet, without active components."
11339265|NCT02439619|Experimental|Feasibility Trial|
11339266|NCT02439606|Active Comparator|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
11339267|NCT02439606|Experimental|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
11339268|NCT02439593|Active Comparator|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:
~Drug and Radiation
~Intervention name:
~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)
~Intervention description:
~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
11339269|NCT02439593|Experimental|Thermochemoradiotherapy (CTRTHT)|"Intervention type:
~Drug, Radiation and Hyperthermia
~Intervention name:
~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),
~Intervention description:
~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
11339270|NCT02439580|Experimental|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
11339271|NCT02439580|Placebo Comparator|Placebo|Maltose capsule, 300 mg/day, for eight weeks
11339272|NCT02439567|Experimental|Patients|Treatment with new oral antiviral drugs for HCV infection, Fibroscan: Liver and Spleen elastography
11339273|NCT02439541|Experimental|UCMSC group|Patients in this arm received umbilical cord MSCs by intracoronary injection
11339274|NCT02439541|No Intervention|Control group|Patients in this arm did not receive any intervention.
11339275|NCT02439528|Other|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
11339276|NCT02439528|Other|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
11339277|NCT02439528|Other|Emphysema|Genetic analysis on patients with emphysema.
11339278|NCT02439528|Other|Healthy subject|Genetic analysis on healthy subject.
11339279|NCT02439515|Experimental|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.
~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
11339280|NCT02439515|Active Comparator|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
11339313|NCT02439255|Experimental|Arm I (BRB nectar)|Participants receive BRB nectar PO QD for 12 weeks.
11339314|NCT02439255|Placebo Comparator|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
11339281|NCT02439502|Experimental|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
11339282|NCT02439489|Experimental|BKM120-CIS|BKM120 (60, 80 100 mg po continuously) and Cisplatin (iv 75 mg/m2)
11339283|NCT02439489|Experimental|BKM120-CARBO|BKM120 and (60, 80 100 mg po continuously) and Carboplatin (iv AUC 5)
11339284|NCT02439476||Relapsed multiple myeloma patients who are considered eligible|Patients mobilized using G-CSF+Plerixafor according to Plerixafor label in France will be included. Apheresis will be performed according to standard practice and local guidelines. Once the autologous stem cell product becomes available, patients will undergo ASCT conditioned by high dose Melphalan according to standard practice in each centre
11339285|NCT02439450|Experimental|Arm 5: Viagenpumatucel-L + Nivolumab|Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
11339286|NCT02439450|Experimental|Arm 6: Viagenpumatucel-L + pembrolizumab +/- pemetrexed|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab ± pemetrexed every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab ± pemetrexed until confirmed disease progression or unacceptable toxicity, whichever occurs first.
11339287|NCT02439437|Active Comparator|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
11339288|NCT02439437|No Intervention|Treatment as usual|Treatment as usual
11339289|NCT02439424|Experimental|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
11339290|NCT02439411||Dabrafenib|
11339291|NCT02439411||Dabrafenib plus Trametinib|Patients treated with Dabrafenib plus Trametinib
11339292|NCT02439398|Experimental|Allogeneic human cardiac stem cells|After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
11339293|NCT02439398|Placebo Comparator|Placebo: Human Serum Albumin-HSA 5%|After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
11339294|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
11339295|NCT02439359|Placebo Comparator|Placebo|Placebo
11339296|NCT02439359|Experimental|CF-301|CF-301
11339297|NCT02439346|Experimental|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
11339298|NCT02439346|Experimental|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
11339299|NCT02439346|Experimental|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
11339300|NCT02439346|Experimental|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
11339301|NCT02439333|Active Comparator|Nasal high flow therapy|AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.
11339302|NCT02439333|Active Comparator|Conventional oxygen therapy|AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.
11339303|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
11339304|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
11339305|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
11339306|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
11339307|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
11339308|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
11339309|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
11339310|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
11339324|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
11339325|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
11339326|NCT02439151|Experimental|New Strategy|New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients
11339327|NCT02439151|Other|Conventional Strategy|Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients
11339328|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.
~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
11339329|NCT02439125|Experimental|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
11339330|NCT02439125|Experimental|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
11339331|NCT02439125|Experimental|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
11339332|NCT02439125|Placebo Comparator|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
11339333|NCT02439112|Active Comparator|Exercise|Supervised exercise combined with home based exercise and physical activity
11339334|NCT02439112|No Intervention|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
11339335|NCT02439099||MDD|Currently unmedicated patients with a depressive episode in the context of unipolar major depression
11339336|NCT02439099||Control|Healthy Controls
11339337|NCT02439099||Alzheimer's Disease|Patients with Alzheimer's disease
11339338|NCT02439099||Alcoholism|Subjects with alcoholism
11339339|NCT02439099||Schizophrenia|Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
11339340|NCT02439086|Experimental|Long Course Radiotherapy|all patients diagnosed with rectal cancer, amenable for neoadjuvant chemoradiotherapy, who agree to participate in this study will undergo 2 PET-CT scans: at baseline and 9 weeks after commencing therapy.
11339341|NCT02439073|Experimental|early initiated rehabilitation|A supervised 12-week rehabilitation program, initiated two weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
11339342|NCT02439073|Active Comparator|late initiated rehabilitation|A supervised 12-week rehabilitation program, initiated 14 weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
11339343|NCT02439060|Experimental|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
11339344|NCT02439060|No Intervention|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
11339345|NCT02439047|Experimental|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery
~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum
~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
11339346|NCT02439034|Active Comparator|Arm A|Paracetamol
11339347|NCT02439034|Experimental|Arm B|Paracetamol + Ketoprofen
11339348|NCT02439021|Experimental|CobraPLA|Patients will randomly assign to either LMA or Cobra PLATM
11339349|NCT02439021|Experimental|LMA|Patients will randomly assign to either LMA or Cobra PLATM
11339350|NCT02439008|Experimental|Blood samples collection|"Nine blood samples will be collected in each patient before, during and after radiotherapy treatment.
~Interventions :
~Blood samples collection before radiotherapy (T0)
~Blood samples collection during radiotherapy (T1-T3)
~Blood samples collection after radiotherapy (T4-T8)"
11339351|NCT02438995|Experimental|Cetuximab with Radiation Therapy|For subjects receiving radiation therapy, the treatment schedule will consist of a re-irradiation dose of approximately 70 Gy over 6-7 weeks. This experimental treatment arm will add IA Cetuximab administration every three weeks up to 2 doses to this radiation schedule.
11339352|NCT02438995|Experimental|Cetuximab Alone|For subjects who are not candidates for re-irradiation, this experimental treatment arm will include only IA Cetuximab administration every three weeks up to 2 doses.
11339353|NCT02438982|Active Comparator|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
11339354|NCT02438982|Experimental|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 , it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
11339355|NCT02438969||Cohort 1|Treatment-seeking or non-treatment-seeking individuals with AUD and ELS exposure
11339356|NCT02438969||Cohort 2|Treatment-seeking or non-treatment-seeking individuals with AUD without ELS exposure
11339357|NCT02438969||Cohort 3|Healthy volunteers with ELS exposure
11339358|NCT02438969||Cohort 4|Healthy volunteers without ELS exposure
11339359|NCT02438956|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
11339360|NCT02438956|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
11339361|NCT02438943|Active Comparator|Audit and Physician intervention|The intervention will comprise the feedback of the results of the baseline audit, training in motivational interviewing for clinic staff, use of a physician reminder stamp in the patients' charts and distribution of patient education cards
11339362|NCT02438943|Sham Comparator|Audit only|The intervention will comprise the feedback of the results of the baseline audit only
11342801|NCT02416388|Active Comparator|R4-HDAC (without DEX)|High dose cytarabine alone
11339363|NCT02438930|Experimental|Motivational interviewing counseling|"The brief intervention is adapted from the OPTIONS project, which is a brief client-centered risk reduction intervention for HIV-positive patients in clinical care. The OPTIONS intervention content is based upon the IMB model of health behavior change, and uses motivational interviewing techniques to create client-centered discussions in which HIV counselors and patients collaborate to identify patients' HIV transmission risk behaviors and to mutually identify strategies and goals for reducing the patient's risky behavior.
~The brief intervention will be facilitated by health care providers (nurses, lab technicians) specifically trained in the intervention protocol and will consist of 2 brief counseling sessions occurring during the same-day rapid HIV-testing procedure"
11339364|NCT02438930|Active Comparator|Standard of care counseling|Participants in this study condition will receive standard-of-care counseling that is usually implemented during HIV testing.
11339365|NCT02438917||Hepatitis C|Patients who are about to begin HCV treatment
11339366|NCT02438904|Experimental|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
11339367|NCT02438891|Experimental|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
11339368|NCT02438878|Experimental|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.
~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
11339369|NCT02438878|No Intervention|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
11339370|NCT02438865|Active Comparator|Single instillation group|will receive single intravesical dose of epirubicin intravesical therapy (50 mg) within 48 hours of radical nephroureterectomy with open bladder cuff excision.
11339371|NCT02438865|Active Comparator|Maintainance therapy group|will receive a single intravesical dose of epirubicin and an additional 6 weekly doses of intravesical therapy (50 mg) after surgery then monthly maintenance therapy for 1 year.
11339372|NCT02438852|Experimental|Arm I (ropivacaine hydrochloride)|Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.
11339373|NCT02438852|Placebo Comparator|Arm II (placebo)|Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.
11339374|NCT02438826|Experimental|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.
~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
11339375|NCT02438826|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.
~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
11339376|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
11339377|NCT02438800|No Intervention|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
11339378|NCT02438800|Experimental|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
11339379|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
11339380|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
11339381|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
11339382|NCT02438774|Active Comparator|Routine agriculture extension services|Routine agriculture extension services alone
11339383|NCT02438774|Experimental|Post-harvest intervention package|Post-harvest intervention package and routine agriculture extension services
11339384|NCT02438761|Experimental|PF-05212384|150 mg Intra-venous every week
11339385|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
11339386|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
11339388|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.
~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
11339389|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
11339390|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11339391|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11339392|NCT02438709|Experimental|COX-2 Inhibitor|Patients who take COX-2 inhibitor
11339393|NCT02438696|Experimental|3 BI 1060469 low dose|TF2 followed by iFF followed by TF1
11339394|NCT02438696|Experimental|1 BI 1060469 high dose|TF1 followed by TF2 followed by iFF
11339395|NCT02438696|Experimental|2 BI 1060469 high dose|iFF followed by TF1 followed by TF2
11339396|NCT02438696|Experimental|3 BI 1060469 high dose|TF2 followed by iFF followed by TF1
11339397|NCT02438696|Experimental|1 BI 1060469 low dose|TF1 followed by TF2 followed by iFF
11339398|NCT02438696|Experimental|2 BI 1060469 low dose|iFF followed by TF1 followed by TF2
11339399|NCT02438683|Placebo Comparator|1 Placebo|2 x single doses (1x resting conditions, 1 x exercise conditions)
11339400|NCT02438683|Experimental|2 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
11339401|NCT02438683|Experimental|3 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
11339402|NCT02438670|No Intervention|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
11339403|NCT02438670|Experimental|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.
~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
11339404|NCT02438670|Experimental|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.
~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
11339405|NCT02438657|Experimental|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:
~increase of the volume (0.5 mL) in case of failure,
~no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
11339406|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
11339407|NCT02438618|Experimental|Minimally invasive punch technique|New surgical technique for Ponto bone anchored hearing implants
11339408|NCT02438618|Other|Hultcrantz technique|Standard surgical technique for bone anchored hearing implants
11339409|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
11339410|NCT02438579|Experimental|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
11339411|NCT02438579|No Intervention|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
11339412|NCT02438566|Active Comparator|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
11339413|NCT02438566|Active Comparator|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
11339414|NCT02438553|Experimental|OSTNS Neurostimulator|Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
11339415|NCT02438553|Placebo Comparator|Placebo OSTNS Neurostimulator|Placebo Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
11339416|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
11339584|NCT02437292|Experimental|Ischemic compression with stretching|The participants will receive the ischemic compression with stretching onto the trapezius muscle
11339417|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
11339418|NCT02438527|Experimental|Chest Compressions Only|"After recruitment and consenting, volunteers in the chest compressions only arm will receive a chart with a description of Basic Life Support without mouth to mouth ventilations. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
11339419|NCT02438527|Experimental|Standard CPR|"After recruitment and consenting, volunteers in the standard CPR arm will receive a chart with a description of Basic Life Support. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart (including the initial check, chest compressions and mouth to mouth ventilations) for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
11339420|NCT02438501|Experimental|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
11339421|NCT02438501|Active Comparator|IFRT group|Chemotherapy / Involved-field radiotherapy
11339422|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
11339423|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
11339424|NCT02438462||Group with PE|"The criteria for confirmation of PE are:
~PE on spiral computed tomography (CT)
~proximal deep vein thrombosis on ultrasound (US)
~thromboembolic events objectively confirmed during the follow up"
11339425|NCT02438462||Group without PE|"The criteria for exclusion of PE are:
~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up
~low and moderate clinical probability and negative CT and negative follow up
~high clinical probability and negative CT, US and follow up."
11339426|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
11339427|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
11339428|NCT02438436|Experimental|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
11339429|NCT02438436|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
11339430|NCT02438436|No Intervention|empty control|
11339431|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
11339432|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
11339433|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
11339434|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
11339435|NCT02438397|Active Comparator|metformin+premix insulin|metformin:500mg tid
11339436|NCT02438397|Experimental|acarbose+premix insulin|acarbose:100mg tid
11339437|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
11339438|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
11339439|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
11339440|NCT02438371|Active Comparator|Single|They will receive nifedipine for the treatment of preterm labor
11339441|NCT02438371|Active Comparator|Combination|They will receive nifedipine plus indomethacin
11339442|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
11339443|NCT02438345|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
11339444|NCT02438345|Placebo Comparator|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
11339445|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
11339446|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
11339447|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
11339448|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
11339449|NCT02438319||patients with open angle glaucoma|patients with open angle glaucoma who had their optic discs routinely documented by fundus photography. Optic disc photographs will be analyzied by manual planimetry or automated planimetry.
11339450|NCT02438306|Experimental|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
11339451|NCT02438306|Sham Comparator|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
11339452|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
11339453|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
11339454|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
11339455|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
11339456|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
11339457|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
11339458|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
11339459|NCT02438241|Active Comparator|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
11339460|NCT02438241|Placebo Comparator|Placebo TENS Group|Will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
11339461|NCT02438241|Experimental|TENS group|Patients randomized to this group will receive conventional physical therapy for the control group, and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
11339462|NCT02438228|Other|Cardiac output measurement|
11339463|NCT02438215|Experimental|IRX4204|IRX4204 20 mg QD for Days 1-30
11339464|NCT02438202|Experimental|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
11339465|NCT02438189|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
11339466|NCT02438189|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
11339467|NCT02438176|Experimental|single puncture group|single trans-septal puncture
11339468|NCT02438176|Active Comparator|conventional group|conventional bilateral groin puncture
11339469|NCT02438163|Experimental|Patients with MDD|the group of depressed patients undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
11339470|NCT02438163|Experimental|healthy Controls|the group of healthy controls undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
11339471|NCT02438150|Experimental|Intervention|Will receive hospital fire video training
11339472|NCT02438150|Placebo Comparator|Control|Will receive non-fire video training
11339473|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
11339474|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
11339475|NCT02438124|Experimental|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
11339476|NCT02438124|Experimental|Contrôle|normal control with walking test and neuropsychological evaluation
11339477|NCT02438111||age related macular degeneration|metagenome AMD
11339478|NCT02438111||controls|metagenome controls
11339479|NCT02438098|Other|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
11339480|NCT02438085||ACS patients|prospective collection of data and follow-up
11339481|NCT02438072|Other|Overall population|
11339482|NCT02438059|Experimental|Intervention|Access to the SoSu-liv website and app for 38 weeks.
11339483|NCT02438059|No Intervention|Control|No treatment for 38 weeks.
11339484|NCT02438046|Experimental|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
11339485|NCT02438046|Placebo Comparator|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
11339486|NCT02438033|Experimental|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
11339487|NCT02438020|Experimental|Metformin|500 mg metformin oral intake before main meal
11339488|NCT02438020|Placebo Comparator|Placebo|Placebo tablet before main meal.
11339489|NCT02438007|Experimental|Galeterone|
11339490|NCT02438007|Active Comparator|Enzalutamide|
11339585|NCT02437292|No Intervention|Control|Rest on the bed
11342802|NCT02416388|Experimental|R4-VEN-IDAC|Intermediate dose cytarabine and venetoclax
11339491|NCT02437994|Experimental|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include supervised exercise training (interval exercise and resistance exercises), breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability.
11339492|NCT02437994|No Intervention|Control|In addition, a control group (Group C) which will not participate in the rehabilitation program (usual care) will be include at the same time as patients in Group A and B so as to be able and independently address study objectives 2 and 3 and 4. Group C will also randomized to those into paper-pencil version and electronic version.
11339493|NCT02437968|Experimental|Wave 1|South New Jersey school service providers.
11339494|NCT02437968|Experimental|Wave 2|Philadelphia suburbs and surrounding community service providers
11339495|NCT02437968|Experimental|Wave 3|Mississauga, ON (Canada) school district service providers.
11339496|NCT02437955|Experimental|FESO4+T|Ferrous sulfate fortified bread with tea
11339497|NCT02437955|Experimental|FESO4+W|Ferrous sulfate fortified bread with water
11339498|NCT02437955|Experimental|FeFu+T|Ferrous fumarate fortified bread with tea
11339499|NCT02437955|Experimental|FeFu+W|Ferrous fumarate fortified bread with water
11339500|NCT02437942|Experimental|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
11339501|NCT02437929||Patients receiving standard procedures|
11339502|NCT02437916|Experimental|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
11339503|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
11339504|NCT02437890|Placebo Comparator|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).
~***
~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:
~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
11339505|NCT02437890|Experimental|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).
~***
~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:
~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
11339506|NCT02437890|Experimental|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).
~***
~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:
~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.
~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
11339507|NCT02437890|Experimental|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).
~***
~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:
~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
11339508|NCT02437890|Experimental|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).
~***
~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:
~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.
~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
11339509|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
11339510|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
11339511|NCT02437864|No Intervention|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
11339512|NCT02437864|Experimental|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
11339513|NCT02437851|Experimental|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
11339514|NCT02437825|Experimental|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
11339515|NCT02437825|Placebo Comparator|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
11339516|NCT02437812|Experimental|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)
~The regimen will be administered as a dose dense schedule."
11339517|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
11339518|NCT02437786|Experimental|GRAZAX|GRAZAX
11339519|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adolescents|12 Cognitive-Behavioral Therapy sessions scheduled weekly over a 12-week period.
11339520|NCT02437773|Other|Stress Management Therapy - Adolescents|"12 SMT sessions scheduled weekly over a 12-week period.
~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
11339521|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adults|12 CBT sessions scheduled weekly over a 12-week period.
11339583|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
11339522|NCT02437773|Other|Stress Management Therapy - Adults|"12 SMT sessions scheduled weekly over a 12-week period.
~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
11339523|NCT02437773|Other|Healthy Control - Adolescents|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with adolescent patients with OCD will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
11339524|NCT02437773|Other|Healthy Control - Adults|Healthy control adults matched to gender, race and socioeconomic status (SES) with adult patients with OCD will be enrolled. These healthy adults will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
11339525|NCT02437773|Other|Optional CBT - Adolescents|OCD adolescent participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
11339526|NCT02437773|Other|Optional CBT - Adults|OCD adult participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
11339527|NCT02437747|Experimental|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
11339528|NCT02437747|Sham Comparator|SRP Group|Only scaling and root planing was done on the opposite side.
11339529|NCT02437734|Other|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
11339530|NCT02437721|Active Comparator|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
11339531|NCT02437721|Experimental|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
11339532|NCT02437721|No Intervention|Breast milk|non randomized reference group
11339533|NCT02437708|Experimental|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
11339534|NCT02437708|Active Comparator|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
11339535|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
11339536|NCT02437656|Experimental|Metformin treatment|"J1 : dosimetric scan
~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)
~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy
~J44 : end of the radiochemotherapy
~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
11339537|NCT02437643|Placebo Comparator|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein ~0.8g/kg). Participants will be provided one serving of dairy protein daily.
11339538|NCT02437643|Active Comparator|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein ~1.2 g/kg with > 30g per meal and >60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
11339539|NCT02437630||Patients with COPD|Patients with COPD aged >40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
11339540|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
11339541|NCT02437617||Control Group #1|Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
11339542|NCT02437617||Control Group #2|Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
11339543|NCT02437617||Matched Targeted Therapy Group|Participants with tumor aberrations who received matched targeted therapy.
11339544|NCT02437604|Experimental|Treatment A|Fp MDPI 200 mcg, 1 inhalation
11339545|NCT02437604|Experimental|Treatment B|FS MDPI 200/12.5 mcg, 1 inhalation
11339546|NCT02437604|Active Comparator|Treatment C|fluticasone propionate (FLOVENT DISKUS) 250 mcg, 2 inhalations
11339547|NCT02437604|Active Comparator|Treatment D|fluticasone propionate/salmeterol (ADVAIR DISKUS) 500/50 mcg, 1 inhalation
11339548|NCT02437591|Experimental|fidaxomicin|tablet twice daily
11339549|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
11339550|NCT02437565|Active Comparator|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
11339551|NCT02437565|Experimental|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
11339552|NCT02437552|Placebo Comparator|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
11339553|NCT02437552|Active Comparator|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
11339554|NCT02437539|Experimental|68Ga-NOTA-AE105 PET|One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
11339555|NCT02437526|Experimental|Treatment interruption|Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.
11339556|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.
~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
11339557|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
11339558|NCT02437487|Placebo Comparator|Placebo|Placebo
11339559|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
11339560|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
11339561|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
11339562|NCT02437461|Active Comparator|single dose 20 mg|Intraarticular injection of triamcinolone hexacetonide
11339563|NCT02437461|Experimental|single dose 40 mg|Intraarticular injection of triamcinolone hexacetonide
11339564|NCT02437448||Idiopathic lung fibrosis|20 IPF patients
11339565|NCT02437448||Controls|20 subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
11339566|NCT02437435|Experimental|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.
~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.
~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
11339567|NCT02437435|Placebo Comparator|Placebo technique|The researcher puts his right hand on the right shoulder of the patient for 20 times Metronome.
11339568|NCT02437422|Experimental|SANGUINATE|Single infusion of SANGUINATE
11339569|NCT02437396||Treatment naive GD1|Type 1 Gaucher disease subjects who are naive to any treatment
11339570|NCT02437396||Treated GD1|Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)
11339571|NCT02437396||Healthy Volunteers|Age matched healthy controls
11339572|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
11339573|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
11339574|NCT02437370|Experimental|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
11339575|NCT02437370|Experimental|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
11339576|NCT02437357|Experimental|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
11339577|NCT02437357|Active Comparator|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
11339578|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
11339579|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF<40%.
11339580|NCT02437318|Experimental|fulvestrant + alpelisib|Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
11339581|NCT02437318|Placebo Comparator|fulvestrant + placebo|Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
11339582|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
11339586|NCT02437279|Active Comparator|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
11339587|NCT02437279|Active Comparator|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
11339588|NCT02437266|Experimental|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
11339589|NCT02437266|No Intervention|Control|Rest on the bed for twenty minutes
11339590|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
11339591|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
11339592|NCT02437240|Experimental|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
11339593|NCT02437240|Active Comparator|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
11339594|NCT02437227|Experimental|Experimental: CCT3833|The starting dose of CCT3833 is 20 mg, taken as two 10 mg capsules. The starting schedule is a once daily continuous dosing schedule, but other dosing regimens may be considered depending on tolerability and exposures.The first dose of continuous dosing defines Cycle 1 Day 1. All treatment cycles have a duration of 28 days.
11339595|NCT02437214|Experimental|Use of music for anxiety in children|Children in the Exp group received the usual medical care in combination with the intervention. The intervention was started by the patients nurse without the knowledge of the research associate. In the intervention group, music was played until the CT scan was completed.
11339596|NCT02437214|No Intervention|Control|Children in the Con group received the usual medical care without listening to the music intervention.
11339597|NCT02437201|Experimental|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
11339598|NCT02437201|No Intervention|Control group|
11339599|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
11339600|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
11339601|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
11339602|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
11339603|NCT02437162|Placebo Comparator|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
11339604|NCT02437162|Experimental|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
11339605|NCT02437162|Experimental|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
11339606|NCT02437149|Experimental|Video and Brochure|Real stories video presentation and a brochure with information about distracted driving will be given to the participant.
11339607|NCT02437149|Experimental|Power Point and Brochure|Brief power point presentation and a brochure with information about distracted driving will be given to the participant.
11339608|NCT02437149|Experimental|Brochure Only|Only a brochure with information about distracting driving will be given to the participant.
11339609|NCT02437136|Experimental|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
11339610|NCT02437136|Experimental|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
11405138|NCT02001532||Healthy controls|Sex and age-matched healthy controls
11339611|NCT02437136|Experimental|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
11339612|NCT02437136|Experimental|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
11339613|NCT02437123|Experimental|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
11339614|NCT02437123|No Intervention|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
11339615|NCT02437110|Experimental|ALS|20 participants with ALS and a level of HERV-K >1000 copies/ml
11339616|NCT02437097|Experimental|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
11339617|NCT02437097|Experimental|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
11339618|NCT02437097|Experimental|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
11339619|NCT02437097|Placebo Comparator|Control|Participants will sit quietly for 30 minutes
11339620|NCT02437084|Other|Individuals without diabetes eligible to receive statin therapy|Eligible participants will receive 40 mg of atorvastatin
11339621|NCT02437071|Experimental|Pembrolizumab Plus Radiotherapy|pembrolizumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy
11339622|NCT02437071|Experimental|Pembrolizumab Plus Ablation|pembrolizumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy
11339623|NCT02437045|Active Comparator|Meropenem|Meropenem 1g every 8 hrs IV to day 4
11339624|NCT02437045|Experimental|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
11339625|NCT02437032|Active Comparator|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
11339626|NCT02437032|Active Comparator|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
11339627|NCT02437032|Active Comparator|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
11339628|NCT02437006|No Intervention|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
11339629|NCT02437006|Experimental|Low-intensity exercise|Low-intensity exercise plus rehabilitation
11339630|NCT02437006|Experimental|High-intensity exercise|High-intensity exercise plus rehabilitation
11339631|NCT02436993|Experimental|Carboplatin+Paclitaxel+Bevacizumab (HER2-)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
11339632|NCT02436993|Experimental|Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
11339633|NCT02436980|Active Comparator|tramadol|1mg/kg of tramadol drop (Contramal® drop, Abdi Ibrahim Ilaç San.,istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, Group T who were separated randomly to two premedication groups.
11339634|NCT02436980|Active Comparator|midazolam|0.15 mg/kg of midazolam (Dormicum®, ampoule, Roche Products A.Ş., istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, to Group M who were separated randomly to two premedication groups.
11339635|NCT02436954|Placebo Comparator|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
11339636|NCT02436954|Active Comparator|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
11339637|NCT02436928|Experimental|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
11339638|NCT02436928|Experimental|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
11339639|NCT02436928|Experimental|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
11339640|NCT02436928|Experimental|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
11339641|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
11339642|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
11339643|NCT02436902|Experimental|TACE|Transarterial chemoembolization (TACE) is performed two to four weeks after hepatic resection.
11339644|NCT02436902|Active Comparator|sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection.
11339645|NCT02436902|Other|TACE plus sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
11339646|NCT02436902|No Intervention|empty control|This group patients will receive best supportive care.
11339647|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
11339648|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
11339649|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
11339650|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
11339651|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
11339652|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
11339653|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
11339654|NCT02436850|Experimental|Intervention group|The intervention group will receive large volume thoracentesis.
11339655|NCT02436850|No Intervention|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
11339656|NCT02436837|Active Comparator|young|20 to 30 years old individuals used as a comparator for elderly group
11339657|NCT02436837|Experimental|elderly|target of treatment to improve the balance.
11339658|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
11339659|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
11339660|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
11339661|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
11339662|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
11339663|NCT02436798||Pediatric patients|"Children <6 months to 18 years of age receiving ondansetron for management of:
~Post-operative nausea and vomiting
~Chemotherapy-induced nausea and vomiting"
11339664|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:
~Hyperemesis gravidarum
~Post-operative nausea and vomiting"
11339665|NCT02436785|Active Comparator|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
11339666|NCT02436785|Active Comparator|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
11339667|NCT02436759|Experimental|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
11339668|NCT02436759|Placebo Comparator|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
11339669|NCT02436746||Neurofibromatosis type I (NF1)|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I
11339670|NCT02436746||Tuberous Sclerosis Complex (TSC)|Monozygotic twin pairs with genetically confirmed Tuberous Sclerosis Complex
11339671|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
11339672|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
11339673|NCT02436707|Active Comparator|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);
~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;
~Dexamethasone - 40 mg daily PO D1 - D4;
~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
11340104|NCT02433691|Placebo Comparator|Stretching and Toning|Anerobic stretching and toning followed by memory training
11339674|NCT02436707|Experimental|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21
~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)
~Gemcitabine 1000 mg/m2 IV 30 min D1, D8
~Dexamethasone 40 mg daily PO -- D1 - D4
~Cisplatin 75 mg/m2 IV 1 hour D1"
11339675|NCT02436707|Experimental|R-DICEP|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin
~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4
~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4
~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4
~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4
~G-CSF 300 mcg (<60kg); 480 mcg (60-90kg); 600 mcg (>90kg); SC, Daily, starting Day 15 until apheresis completed."
11339676|NCT02436694|Active Comparator|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
11339677|NCT02436694|Experimental|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
11339678|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
11339679|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:
~Nab-paclitaxel and gemcitabine"
11339680|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:
~Nab-paclitaxel and gemcitabine"
11339681|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
11339682|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
11339683|NCT02436629|Active Comparator|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
11339684|NCT02436629|Placebo Comparator|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
11339685|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
11339686|NCT02436603|Other|Nutrition/Mind-Body Coaching|The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.
11339687|NCT02436603|No Intervention|Waitlist Control Group|Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.
11339688|NCT02436590|Active Comparator|Active PEMF|Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization
11339689|NCT02436590|Placebo Comparator|Control/no PEMF|Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization
11339690|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
11339691|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
11339692|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
11339693|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
11339694|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
11339695|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
11339696|NCT02436551||Pregnant women in Tajikistan|
11339697|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
11339698|NCT02436525|Active Comparator|Group I:|"will be treated using conventional stainless steel orthodontic brackets ligated with stainless steel ligature. Oromco - USA.
~."
11339699|NCT02436525|Experimental|Group II|: will be treated using passive self-ligating stainless steel orthodontic brackets Oromco - USA.
11339700|NCT02436525|Experimental|Group III:|will be treated by active self-ligating stainless steel orthodontic brackets Oromco - USA .
11339701|NCT02436512|Experimental|Inhaled Nitric Oxide|Active Comparator: Nitric Oxide
11339702|NCT02436499|Experimental|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
11339703|NCT02436486|Placebo Comparator|Placebo|
11339704|NCT02436486|Experimental|Idalopirdine 120 mg|Therapeutic dosages
11339705|NCT02436486|Experimental|Idalopirdine 360 mg|Supra-therapeutic dosages
11339706|NCT02436486|Active Comparator|Moxifloxacin 400 mg|Positive Control
11339707|NCT02436473|Experimental|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
11339708|NCT02436473|Placebo Comparator|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
11339709|NCT02436473|Active Comparator|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
11340105|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
11339710|NCT02436473|Active Comparator|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
11339711|NCT02436460|Experimental|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
11339712|NCT02436447|Experimental|Normal renal function|
11339713|NCT02436447|Experimental|Mild renal impairment|
11339714|NCT02436447|Experimental|Moderate renal impairment|
11339715|NCT02436447|Experimental|Severe renal impairment|
11339716|NCT02436434|Active Comparator|pulsed radiofrequency|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
11339717|NCT02436434|Sham Comparator|Sham pulsed radiofrequency|Sham intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in controlled joint
11339718|NCT02436421|Other|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
11339719|NCT02436421|Other|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
11339720|NCT02436421|Other|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
11339721|NCT02436408|Experimental|Vismodegib|150mg taken orally once daily
11339722|NCT02436395|Experimental|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.
~We declare that we have no conflicts of interest."
11339723|NCT02436395|Experimental|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.
~We declare that we have no conflicts of interest."
11339724|NCT02436382|No Intervention|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
11339725|NCT02436382|Active Comparator|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
11339726|NCT02436369|Experimental|low fat yogurt enriched with flaxseed|200 gr low fat yogurt enriched with 30 gr flaxseed
11339727|NCT02436369|Placebo Comparator|low fat yogurt|200 gr low fat yogurt
11339728|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
11339729|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
11339730|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
11339731|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.
~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
11339732|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.
~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
11339733|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
11339734|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
11339735|NCT02436317|Experimental|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe [Saote/ Mylab 5/ Italy] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.
~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
11339736|NCT02436317|No Intervention|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
11339737|NCT02436304|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
11339738|NCT02436304|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
11339739|NCT02436304|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
11339740|NCT02436291|Experimental|CURE-EX device|twice daily treatment with CURE-EX device for 24-30 weeks
11339741|NCT02436278||IPF_MORT|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
11339742|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine (N=47) Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
11339743|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
11339744|NCT02436252|Experimental|DSP-7888|
11339745|NCT02436239|Experimental|Vilazodone|
11339746|NCT02436226|Active Comparator|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
11339747|NCT02436226|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
11339748|NCT02436213|Experimental|Healthy control|A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
11339749|NCT02436213|Experimental|Pulmonary AVM|A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
11339980|NCT02434601|Other|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
11339981|NCT02434601|Experimental|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
11339750|NCT02436213|Experimental|HHT but no pulmonary AVM|Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
11339751|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
11339752|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
11339753|NCT02436161|Experimental|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
11339754|NCT02436161|No Intervention|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
11339755|NCT02436135|Experimental|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
11339756|NCT02436135|Experimental|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
11339757|NCT02436135|Experimental|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
11339758|NCT02436135|Experimental|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
11339759|NCT02436109||study group|elective cesarean delivery patients
11339760|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
11339761|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
11339762|NCT02436083|No Intervention|control|no antibiotics
11339763|NCT02436083|Active Comparator|experimental group|drug administration (antibiotic)
11339764|NCT02436070|Active Comparator|Control|Subjects receive general, health-related text messages applicable for children with asthma.
11339765|NCT02436070|Experimental|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
11339766|NCT02436057|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
11339767|NCT02436057|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
11339768|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
11339769|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
11339770|NCT02436018|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
11339771|NCT02436018|Experimental|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
11339772|NCT02436018|Experimental|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
11339773|NCT02436005|Experimental|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
11339774|NCT02436005|Active Comparator|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
11339775|NCT02435992|Experimental|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
11339776|NCT02435992|Placebo Comparator|Placebo|Daily oral administration during Induction and Maintenance periods.
11339777|NCT02435979|Experimental|Proximal strengthening + hand therapy|Patients in this group will perform traditional hand therapy for 30 minutes and proximal strengthening of the core, cervical spine, and shoulder complex for up to 30 minutes
11339778|NCT02435979|Active Comparator|Traditional hand therapy|This group will receive traditional hand therapy for 45-60 minutes each session.
11339779|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
11339780|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
11339781|NCT02435966|No Intervention|Untreated control|Natural history of the condition
11339782|NCT02435953|Experimental|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
11339783|NCT02435953|Active Comparator|TACE alone|TACE treatment several times till tumor progress to advance stage
11339784|NCT02435927|Experimental|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
11339785|NCT02435927|Experimental|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
11339786|NCT02435914|Experimental|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
11339787|NCT02435914|Experimental|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
11339788|NCT02435914|Experimental|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
11339789|NCT02435914|Placebo Comparator|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
11339790|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
11339791|NCT02435888||Polycystic ovary syndrome|
11339792|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
11339793|NCT02435875||nonhypertensive|systolic blood pressure <140 mmHg and diastolic blood pressure<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
11339794|NCT02435862|Experimental|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
11339795|NCT02435862|Experimental|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
11339796|NCT02435862|Experimental|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
11339797|NCT02435862|Placebo Comparator|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
11339798|NCT02435849|Experimental|Single dose of CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
11339799|NCT02435836|Experimental|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
11339800|NCT02435823|Experimental|PulseRider|Endovascular treatment of intracranial aneurysms
11339801|NCT02435810||Family Member|A family member of a patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
11339802|NCT02435810||Patient|Patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
11339803|NCT02435797|Active Comparator|Nicorandil|Nicorandil for injection
11339804|NCT02435797|Placebo Comparator|normal saline|normal saline
11339805|NCT02435784|Active Comparator|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
11339806|NCT02435784|Placebo Comparator|TAU group|Treatment as usual (TAU) group.
11339807|NCT02435771|Experimental|BMI <25|Normal BMI
11339808|NCT02435771|Experimental|BMI 25-35|Overweight and obese by BMI
11339809|NCT02435771|Experimental|BMI >35|Obese by BMI
11339810|NCT02435758|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
11339811|NCT02435758|No Intervention|Excision of Denonvilliers Fascia|Standard TME surgery (U-shaped excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
11339812|NCT02435745||Ehlers-Danlos Syndrome|Patients with the diagnosis of Ehlers-Danlos syndrome
11339813|NCT02435745||Controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
11339814|NCT02435732|Placebo Comparator|Control group|Standard donor management + vehicle treatment (n=9)- placebo saline solution
11339815|NCT02435732|Experimental|CINRYZE 200 U/Kg IV|Intervention is CINRYZE 200 U/Kg IV single dose
11339816|NCT02435732|Experimental|200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV|CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery
11339817|NCT02435706|Experimental|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
11339818|NCT02435706|Active Comparator|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
11339819|NCT02435693|Experimental|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
11339820|NCT02435693|Other|control|without pharmaceutical care programe (control)
11339821|NCT02435680|Experimental|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
11339822|NCT02435680|Active Comparator|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
11339823|NCT02435667|Experimental|Resistance Exercise Training|Entails 36 supervised resistance exercise training sessions (3 sessions per week for 12 weeks). Each exercise session will be supervised by a trained, certified Exercise Physiologist specializing in Cardiac Rehabilitation. The specific resistance exercise training will include Aerobic Exercise, Resistance Exercise, and Core Strengthening Exercises. Other baseline and follow-up tests include: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
11339824|NCT02435667|Placebo Comparator|Standard Care|No resistance exercise training. Patients will stay on their current healthcare regimen as previously assigned by their physician. Patients will still undergo baseline and follow-up tests similar to the Resistance Exercise Training group, including: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
11339825|NCT02435654|Experimental|Treatment group|All EOS patients will receive olanzapine treatment with flexible dose(2.5 to 20 mg/day)according to standard body weight,olanzapine will be initiated at 2.5 or 5 mg/day and the dose could be increased by 2.5 or 5 mg/day dose increments at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,the investigator could decrease the dose at any time and in any number of dose decrements if patients experienced an adverse event.
11340026|NCT02434315|Experimental|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
11339826|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.
~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
11339827|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.
~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
11339828|NCT02435615|Experimental|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
11339829|NCT02435602|Active Comparator|NBI endoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy
~Biopsy at the visually abnormal lesions
~Pathologic examination of all biopsy tissue specimens
~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
11339830|NCT02435602|Active Comparator|lugol chromoendoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy
~Biopsy at the unstained lesions >= 5 mm diameter
~Pathologic examination of all biopsy tissue specimens
~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
11339831|NCT02435589|Experimental|Intervention group|"Intervention:
~systematic pain assessment
~Notification of results of assessments to nurses and physicians. Pain Assessments will be done with the use of 2 different behavioral pain tools by independent assessors and the results of the assessments will be notified to the nurses and physicians and their respond will be observed and documented"
11339832|NCT02435589|Active Comparator|Control Group|Intervention. Systematic pain assessments. Assessments of pain will be done by independent assessors but results will not be notified to nurses or physicians
11339833|NCT02435563|Experimental|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
11339834|NCT02435563|Experimental|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
11339835|NCT02435550|Experimental|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
11339836|NCT02435550|Experimental|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
11339837|NCT02435550|Experimental|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
11339838|NCT02435550|Experimental|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
11339839|NCT02435550|Experimental|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
11339840|NCT02435537|Active Comparator|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
11339841|NCT02435537|Active Comparator|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
11339842|NCT02435537|Active Comparator|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
11339843|NCT02435524|Experimental|A&T Intervention Communes|
11339844|NCT02435524|No Intervention|Control Communes|
11339845|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
11339846|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
11339847|NCT02435498|Experimental|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
11339848|NCT02435498|Active Comparator|Video|The online video will contain the same information within the website.
11339849|NCT02435498|Active Comparator|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
11339850|NCT02435485|Experimental|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
11339851|NCT02435485|Active Comparator|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
11339852|NCT02435485|Active Comparator|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
11339910|NCT02435069|No Intervention|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
11340027|NCT02434315|Experimental|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
11339853|NCT02435472|Experimental|Arm A (Exercise)|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. We will also request archival biopsy tissue samples from before and after the intervention.
11339854|NCT02435472|No Intervention|Arm B (Usual Care)|"Arm B will receive usual care (physical activity information) This group will receive general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
11339855|NCT02435472|No Intervention|Non-Randomized Group|There is also a non-randomized observational component to the study where we will collect biospecimens, survey, data, and administer one CPET. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research. This group provides us with a larger more heterogeneous population to follow long term to examine associations between exercise, biomarkers, fitness metrics, and clinical and psychosocial outcomes.
11339856|NCT02435459|Placebo Comparator|No lining|No lining material placed under amalgam dental restoration
11339857|NCT02435459|Active Comparator|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
11339858|NCT02435459|Active Comparator|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
11339859|NCT02435459|Active Comparator|RMGI cement|Placement of rmgi lining under amalgam dental restorations
11339860|NCT02435446|Experimental|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
11339861|NCT02435433|Experimental|Ramucirumab|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
11339862|NCT02435433|Placebo Comparator|Placebo|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
11339863|NCT02435433|Experimental|Open Label Ramucirumab|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
11339864|NCT02435433|Experimental|Ramucirumab ME2 Cohort|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
11339865|NCT02435433|Placebo Comparator|Placebo ME2 Cohort|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
11339866|NCT02435420||EMPERION Modular Primary Stem subjects|All subjects have previously been implanted with the EMPERION Modular Primary Stem for primary total hip arthroplasty.
11339867|NCT02435407|Experimental|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
11339868|NCT02435407|Active Comparator|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
11339869|NCT02435394|Experimental|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
11339870|NCT02435394|Experimental|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
11339871|NCT02435394|Active Comparator|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
11339872|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
11339873|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
11339874|NCT02435355|No Intervention|standard support|All patients in this study underwent this procedure, which is the regular procedure in France.
11339875|NCT02435355|Experimental|coached group|In the coached group (CG), patients received standard support completed by 5 sessions (day 3, 10, 30, 60, 90 with equipment at home) of telephone-based counselling session by competent staff. Sessions were performed by a qualified person in education, qualifies by a university degree (Paul Sabatier University, Toulouse, France). The dates of phone calls were planned with the patient availabilities.
11339876|NCT02435342|Experimental|30ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
11339877|NCT02435342|Experimental|60ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
11339878|NCT02435329||Healthy volunteers|"10 healthy volunteers
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
11339940|NCT02434822|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
11339941|NCT02434822|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
11340067|NCT02433925|Active Comparator|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
11406714|NCT01991119|Active Comparator|Dronedarone|Dronedarone group
11339879|NCT02435329||Type 2 diabetes without neuropathy|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
11339880|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
11339881|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
11339882|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients
~Anthropometric measures: Height, weight, BMI, waist circumference
~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature
~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.
~Assessment of skin microcirculation with Laser Doppler Iontophoresis
~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)
~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
11339883|NCT02435316|Active Comparator|Group 1|Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later
11339884|NCT02435316|Active Comparator|Group 2|Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later
11339885|NCT02435303|Experimental|Sildenafil|Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
11339886|NCT02435303|Placebo Comparator|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
11339887|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
11339888|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
11339889|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
11339890|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
11339891|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
11339892|NCT02435264|Experimental|Healthier Dining Program Intervention|Food centers that receive the Healthier Dining Program (HDP)
11339893|NCT02435264|No Intervention|Control centers|Food centers that do not receive the Healthier Dining Program (HDP)
11339894|NCT02435225|Experimental|Mindfulness group|Participation in a 12 week mindfulness therapy group.
11339895|NCT02435212|Active Comparator|Arm 1|
11339896|NCT02435212|Experimental|Arm 2|
11339897|NCT02435199|Experimental|EMA401 600mg|2 X 150mg BID
11339898|NCT02435199|Placebo Comparator|Placebo|Placebo to match, 2 capsules BID
11339899|NCT02435186|Experimental|p53 gene plus chemotherapy|Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv
11339900|NCT02435186|Active Comparator|chemotherapy|Intraperitoneal cisplatin, and paclitaxel iv
11339901|NCT02435173|Other|CDZ173|Part I was with-in patient dose escalation with CDZ173 10, 30 and 70 mg bid. Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo
11339902|NCT02435173|Placebo Comparator|Placebo|Part II is placebo controlled
11339903|NCT02435160|Experimental|Ulcerative Colitis|
11339904|NCT02435134||Healthy participants|
11339905|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
11339906|NCT02435108|Experimental|crizotinib arm|crizotinib medication
11339907|NCT02435095|Active Comparator|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
11339908|NCT02435095|Experimental|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.
~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
11339909|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
11339979|NCT02434614|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
11339911|NCT02435069|Experimental|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
11339912|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
11339913|NCT02435056|No Intervention|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
11339914|NCT02435056|Experimental|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
11339915|NCT02435043|Experimental|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management
11339916|NCT02435043|Active Comparator|Treatment as usual|standard management after stroke
11339917|NCT02435030||NP-C Patients|NPC type 1 or 2 patients aged 2-18 years
11339918|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
11339919|NCT02435004|Other|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
11339920|NCT02434991|Experimental|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
11339921|NCT02434978|Active Comparator|Supplementary doppler-guided endoscopic therapy|
11339922|NCT02434978|Placebo Comparator|control group|
11339923|NCT02434965|Experimental|Autologous Cord Blood and HPDSC|Autologous cord blood and placental blood will be collected after birth of child and administered in divided aliquots during the first week of life.
11339924|NCT02434952|Experimental|DHA PP plus primaquine, G6PD deficiency|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
11339925|NCT02434952|Active Comparator|DHA PP plus primaquine, G6PD normal|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
11339926|NCT02434952|Active Comparator|DHA PP alone, G6PD deficiency|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
11339927|NCT02434952|Active Comparator|DHA PP alone, G6PD normal|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
11339928|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
11339929|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
11339930|NCT02434887|Experimental|Experimental group|
11339931|NCT02434874|Experimental|Immediate Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated immediately.
11339932|NCT02434874|Other|Delayed Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated after 90 days.
11339933|NCT02434861|Experimental|Part A|Rolapitant IV and Digoxin
11339934|NCT02434861|Experimental|Part B|Rolapitant IV and Sulfasalazine
11339935|NCT02434861|Experimental|Part C|Rolapitant IV and Cooperstown Cocktail
11339936|NCT02434848|Active Comparator|Engerix B|15 subjects per group (n = 30 in total)
11339937|NCT02434848|Active Comparator|Fendrix|15 subjects per group (n = 30 in total)
11339938|NCT02434835|Experimental|[14C]KWA-0711|
11339939|NCT02434822|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
11339942|NCT02434809|Experimental|Patients with lung cancer|Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.
11339943|NCT02434796|Experimental|Arm 1 Male Peer Groups (MPG)|Women participate in savings groups and male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. This intervention aims to improve knowledge and attitudes about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals (e.g. caring for one's family) and to challenge gender stereotypes (e.g. women are not equal to men); and the ability to formulate positive outcome expectations regarding IPV (intolerance of violence perpetrated by themselves or others) and healthy relationships with their spouses and communities.
11339944|NCT02434796|Experimental|Arm 2 MPG & Community Dialogues|This arm will include women participants in savings groups, male peer groups and community dialogues. Village community leaders will engage in community dialogues on gender norms, IPV and HIV prevention.
11339945|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
11339946|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
11339947|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
11339948|NCT02434783||No arterial insufficiency|Healthy individuals (control)
11339949|NCT02434770|Experimental|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
11339950|NCT02434770|Experimental|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
11339951|NCT02434770|Active Comparator|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
11339952|NCT02434757|Experimental|Acthar 40 U|Acthar 40 U (0.5mL)
11339953|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
11339954|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
11339955|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
11339956|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
11339957|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
11339958|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
11339959|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
11339960|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
11339961|NCT02434731|Experimental|Buzzy® device|The Buzzy® device will be applied just above the selected site of the venipuncture; a ice pack will be attached under the device; the device will be turned on and after 15 second the procedure will be carried out.
11339962|NCT02434731|No Intervention|No intervention|No intervention for pain relief
11339963|NCT02434718|Experimental|Cohort 1|IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
11339964|NCT02434718|Experimental|Cohort 2|IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
11339965|NCT02434718|Experimental|Cohort 3|IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
11339966|NCT02434718|Experimental|Cohort 4|IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
11339967|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.
~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.
~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
11339968|NCT02434692|Experimental|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
11339969|NCT02434666|Experimental|CPC-201|
11339970|NCT02434653|Experimental|Postpartum anemia diagnosis following symptoms|Post partum anemia will be assessed by taking hemoglobin level following symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL in the first 5 days following delivery
11339971|NCT02434653|Experimental|Postpartum anemia diagnosis following patients screening|Post partum anemia will be assessed by taking hemoglobin level in patients at increased risk to develop post-partum anemia in the first 5 days following delivery, defined as patients with initial (before or immediately after delivery) hemoglobin level of 10.5 g/dl or less regardless of symptoms, or in cases of severe post partum hemorrhage.
11339972|NCT02434640|Experimental|BAY1128688 [Dose1]|BAY1128688 dose level 1
11339973|NCT02434640|Experimental|BAY1128688 [Dose2]|BAY1128688 dose level 2
11339974|NCT02434640|Experimental|BAY1128688 [Dose3]|BAY1128688 dose level 3
11339975|NCT02434640|Experimental|BAY1128688 [Dose4]|BAY1128688 dose level 4
11339976|NCT02434640|Placebo Comparator|Placebo|Placebo to match arm 1,2, 3 and 4
11339977|NCT02434627|Experimental|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
11339978|NCT02434614|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
11339982|NCT02434601|Experimental|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
11339983|NCT02434588|Experimental|Bhattacharjee ring|
11339984|NCT02434575||PAE|Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.
11339985|NCT02434575||TURP|Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.
11339986|NCT02434575||Other|Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.
11339987|NCT02434562||Medical castration|Patients treated with androgen deprivation therapy (e.g. for hypersexuality, transgender subjects, ...)
11339988|NCT02434562||Male hypogonadism|Patients treated with testosterone replacement therapy (e.g. for late-onset hypogonadism, secondary hypogonadism)
11339989|NCT02434562||Thyroid disorders|Patients treated for hyperthyroidism or hypothyroidism (incl. during treatment for thyroid cancer)
11339990|NCT02434562||Obesity and weight loss|Patients treated for obesity with weight loss interventions (mainly bariatric surgery)
11339991|NCT02434562||Miscellaneous|Various disorders associated with alterations in SHBG, androgens and/or estrogens
11339992|NCT02434549|Active Comparator|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
11339993|NCT02434549|Placebo Comparator|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
11339994|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
11339995|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
11339996|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
11339997|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
11339998|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
11339999|NCT02434484||Symbenda|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.
11340000|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
11340001|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
11340002|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
11340003|NCT02434458||Control|Healthy control subjects
11340004|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
11340005|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
11340006|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
11340007|NCT02434432|Experimental|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
11340008|NCT02434432|Active Comparator|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
11340009|NCT02434432|No Intervention|Condition 3|Infants in this arm will have the headphones applied but no music played.
11340010|NCT02434419|Experimental|PENS with training|Patients undergoing percutaneous electrostimulation (PENS) of the pectoral muscle combined with specific training during 12 weeks postoperatively
11340011|NCT02434419|Active Comparator|Specific training|Patients undergoing specific training during 12 weeks postoperatively
11340012|NCT02434419|No Intervention|No intervention|No specific treatment was assigned to these patients postoperatively
11340013|NCT02434406|Experimental|Web-based intervention|Participants get access to the web-based intervention and are asked to work through the 8 modules of the intervention within eight weeks. The intervention program sends automated weekly email reminders about the current session. In addition, users are offered weekly optional 30-minute telephone support with a trained intervention coach.
11340014|NCT02434406|No Intervention|Wait-list control|Participants get standard care and will be offered access to the web-based intervention at 8-weeks post-randomization.
11340015|NCT02434393||Late Life Depression|120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)
11340016|NCT02434380|Active Comparator|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
11340017|NCT02434380|Active Comparator|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
11340018|NCT02434367|Experimental|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
11340019|NCT02434367|No Intervention|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
11340020|NCT02434354|Experimental|Arm 1|
11340021|NCT02434341||septic patients|wake septic patients on mechanical ventilation
11340022|NCT02434341||COPD patients|wake COPD patients on mechanical ventilation
11340023|NCT02434328|Experimental|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
11340024|NCT02434328|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
11340025|NCT02434315|Active Comparator|Group A - Control|FreeStyle Libre Pro 3 sensor wears
11340028|NCT02434289|Experimental|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
11340029|NCT02434276|Experimental|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
11340030|NCT02434276|Experimental|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
11340031|NCT02434276|Active Comparator|Control|Fluzone Quadrivalent vaccine
11340032|NCT02434263|Experimental|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
11340033|NCT02434250|Experimental|SLT arm|Patient receiving 'Selective Laser Trabeculoplasty' (SLT) due to failed Phacoemulsification Cataract Extraction with Intraocular Lens Implantation combined with Eximer Laser Trabeculectomy (phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension to control intraocular pressure and/or glaucoma progression.
11340034|NCT02434237||patients|
11340035|NCT02434237||healthy subjects|
11340036|NCT02434224|Experimental|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants' chest (or back) in order to continuously assess the infants' breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants' behavioral state, facial and gestural expression, the therapist transforms the infants' rhythms and subtle expressions into infant-directed improvised humming.
11340037|NCT02434224|No Intervention|control|standard care
11340038|NCT02434211|Experimental|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
11340039|NCT02434172||Screening|There are no arms to the study. All participants will undergo screening. Preemptive treatment will only be provided to those who are CrAg positive.
11340040|NCT02434159|Active Comparator|Scan|Heart scan prior to device insertion
11340041|NCT02434159|No Intervention|No scan|No heart scan prior to device insertion
11340042|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
11340043|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
11340044|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).
~(Blood Draw)"
11340045|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
11340046|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.
~(Blood Draw)"
11340047|NCT02434107|Experimental|Completion Lymphadenectomy|Completion Lymphadenectomy and monitoring afterwards
11340048|NCT02434107|Experimental|Clinical Monitoring (Palpation and node ultrasound)|Monitoring only
11340049|NCT02434094||T1DM Clinicians|Clinicals currently teaching T1DM patients how to use insulin pumps and continuous glucose monitors will be asked to complete the eDAPT on-line training program.
11340050|NCT02434094||T1DM Subjects with DiAs experience|T1DM subjects will prior DiAs experience will be asked to complete the eDAPT on-line training program.
11340051|NCT02434094||T1DM Subjects with no prior DiAs experience|T1DM subjects will no prior DiAs experience will be asked to complete the eDAPT on-line training program.
11340052|NCT02434081|Experimental|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
11340053|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
11340054|NCT02434042|Active Comparator|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
11340055|NCT02434042|Placebo Comparator|Placebo|100% dextrin
11340056|NCT02434029|Experimental|Budesonide|Budesonide 1mg orodispersible tablet twice daily
11340057|NCT02434029|Placebo Comparator|Placebo|Placebo orodispersible tablet twice daily
11340058|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
11340059|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study
~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day
~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)
~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
11340060|NCT02433964|Experimental|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
11340061|NCT02433964|Placebo Comparator|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
11340062|NCT02433951||healthy individuals|Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
11340063|NCT02433951||CABG patients|Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
11340064|NCT02433951||endo-ACAB patients|Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
11340065|NCT02433938|Experimental|Underwent tibial nerve stimulation|Patients that underwent standard postoperative protocol + tibial nerve stimulation for 3 days
11340066|NCT02433938|Sham Comparator|Did not undergo tibial nerve stimulation|Patients that underwent standard postoperative protocol + sham tibial nerve stimulation (standard postoperative protocol+sham tns)
11340069|NCT02433912|Experimental|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
11340070|NCT02433912|Active Comparator|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
11340071|NCT02433899|Experimental|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.
~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
11340072|NCT02433899|Active Comparator|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
11340073|NCT02433886|Experimental|Gamma Ventral Capsulotomy|
11340074|NCT02433873|Placebo Comparator|Placebo|Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
11340075|NCT02433873|Experimental|Supplement A|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
11340076|NCT02433873|Experimental|Supplement B|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
11340077|NCT02433860|Experimental|pregnant nicotine users|watch video and tobacco cessation counselling using SCRIPT protocol
11340078|NCT02433847|Experimental|mosapride|
11340079|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
11340080|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
11340081|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
11340082|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
11340083|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
11340084|NCT02433834|Placebo Comparator|Placebo|Placebo
11340085|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
11340086|NCT02433821|Experimental|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
11340087|NCT02433821|No Intervention|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
11340088|NCT02433808|Experimental|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
11340089|NCT02433808|Placebo Comparator|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
11340090|NCT02433795|Experimental|Bendamustine plus rituximab(BR)|Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).
11340091|NCT02433782|Experimental|Experimental group|Treatment through myofascial therapy for the treatment of pain and restricted mobility in patients with hemophilic arthropathy of the knee and ankle
11340092|NCT02433782|No Intervention|Control group|No myofascial intervention. Patients continue their treatment with FVIII or FIX concentrates, normally
11340093|NCT02433769|Active Comparator|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
11340094|NCT02433769|Experimental|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
11340095|NCT02433743|No Intervention|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
11340096|NCT02433743|Experimental|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
11340097|NCT02433730|Active Comparator|placebo|intramuscular injection
11340098|NCT02433730|Active Comparator|testosterone|intramuscular injection
11340099|NCT02433717|Experimental|Paliperidone ER|Six-week paliperidone ER
11340100|NCT02433704|Active Comparator|Intraosseous Administration|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
11340101|NCT02433704|No Intervention|Systemic Intravenous Administration|Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.
11340102|NCT02433691|Active Comparator|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
11340103|NCT02433691|Experimental|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
11406936|NCT01989533|Experimental|D|Intranasal Open Label
11340107|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
11340108|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
11340109|NCT02433652|Experimental|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
11340110|NCT02433652|Experimental|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
11340111|NCT02433639|Experimental|treatment|single arm study: TH-302 monotherapy is given
11340112|NCT02433626|Experimental|COTI2|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
11340113|NCT02433626|Experimental|COTI2 + cisplatin|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 3 weeks of treatment as described (5 days on, 2 days off per week). Cisplatin 60 mg/m2 IV will be administered on Day 1 of each 3 week cycle. Participants will remain on treatment until they experience a lack of benefit.
11340114|NCT02433600|Active Comparator|Cow's milk-based infant formula|
11340115|NCT02433600|Experimental|Cow milk-based infant formula with enriched protein fractions|
11340116|NCT02433587|Experimental|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
11340117|NCT02433587|Experimental|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
11340118|NCT02433574|Experimental|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
11340119|NCT02433561|Active Comparator|Intraplexic catheter|Intraplexic approach (Patients will have the catheter placed within the plexus, classical approach)
11340120|NCT02433561|Experimental|Extraplexic catheter|Extraplexic approach (Patients will have the catheter placed out of the plexus.)
11340121|NCT02433548|Experimental|Fascia iliaca block|Fascia iliaca block (Injection of 30 mLs of bupivacaine 0.5% with epinephrine 5 mcg/mL below the fascia iliaca, Carbostesin®)
11340122|NCT02433548|Sham Comparator|Sham injection|No fascia iliaca block (Sham injection = Subcutaneous injection of 5 cc of normal saline, no intervention)
11340123|NCT02433535|Experimental|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
11340124|NCT02433535|Placebo Comparator|Placebo|A placebo capsule will be given daily for 12 weeks.
11340125|NCT02433522|Experimental|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
11340126|NCT02433522|Placebo Comparator|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
11340127|NCT02433509|Experimental|HUCB monocyte cells w/ Mannitol in acute ischemic stroke|"The cord blood need to be infusion within less than 10 days after the onset of stroke, with the cord blood mononuclear cells 200 million ~ 500 million will used.
~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
11340128|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
11340129|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
11340130|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.
~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
~Interventions:
~Cycle 1: cytarabine, HPC-A donor infusion
~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
11340131|NCT02433470|Active Comparator|Active tDCS|Active transcranial direct current stimulation
11340132|NCT02433470|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
11340133|NCT02433457|Experimental|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
11340134|NCT02433457|Experimental|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
11340135|NCT02433457|Experimental|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
11340136|NCT02433457|Experimental|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
11340137|NCT02433457|Experimental|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
11340138|NCT02433457|Experimental|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
11340139|NCT02433457|Experimental|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
11340140|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
11340141|NCT02433431|Active Comparator|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
11340296|NCT02432391|No Intervention|Routine Care|Participants continue their routine medical care for type 2 diabetes
11340142|NCT02433431|Active Comparator|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
11340143|NCT02433431|Active Comparator|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
11340144|NCT02433418|Active Comparator|Tubal flushing with Urografin®|Women will have HSG using water soluble media
11340145|NCT02433418|No Intervention|Control group|Women will not receive any intervention
11340146|NCT02433405||Group 1|Chronic Periodontitis-serum amyloid A, Fetuin-A
11340147|NCT02433405||Group 2|Plaque induced Gingivitis-serum amyloid A, Fetuin-A
11340148|NCT02433405||Group 3|Control Group-serum amyloid A, Fetuin-A
11340149|NCT02433392|Experimental|CM-BC2|Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
11340150|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
11340151|NCT02433366||Patients|
11340152|NCT02433366||Physicians|
11340153|NCT02433353|Experimental|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
11340154|NCT02433353|Placebo Comparator|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
11340155|NCT02433340|Experimental|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
11340156|NCT02433327|Active Comparator|PEWS - trigger tool|"Paediatric Early Warning Score:
~Children randomized to PEWS - trigger tool"
11340157|NCT02433327|Active Comparator|RM - trigger tool|"Paediatric Early Warning Score:
~Children randomized to Central Denmark Region (RM)- trigger tool"
11340158|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
11340159|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
11340160|NCT02433262|Placebo Comparator|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:
~Fasting glucose >6 2 hour glucose >7.7"
11340161|NCT02433262|Active Comparator|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes & Pregnancy Study Group) Fasting glucose >5 2 hour glucose >8.4
11340162|NCT02433249|Active Comparator|1 Physical Activity|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. All participant receive Fitbit Ones and are asked to use them on a daily basis.
11340163|NCT02433249|Experimental|2 Interpersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
11340164|NCT02433249|Experimental|3.Intrapersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
11340165|NCT02433249|Experimental|4.Full Intervention|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal and interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
11340166|NCT02433236|Experimental|Fostamatinib Disodium tablet 100 mg|Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months
11340167|NCT02433236|Experimental|Fostamatinib Disodium tablet 150 mg|Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months
11340168|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
11340169|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
11340170|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
11340171|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
11340172|NCT02433210|Active Comparator|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
11340173|NCT02433210|Active Comparator|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
11340174|NCT02433210|Active Comparator|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
11340175|NCT02433197|Experimental|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
11340176|NCT02433197|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
11340177|NCT02433184|Experimental|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
11340178|NCT02433184|Active Comparator|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
11340179|NCT02433171||Melanoma Brain Metastases|Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
11340180|NCT02433171||Lung Cancer Brain Metastases|Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
11340181|NCT02433158|Experimental|Cohort 1|includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old)
11340182|NCT02433158|Experimental|Cohort 2|includes one pediatric stratum (6-11 years old).
11340183|NCT02433132|Other|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
11340184|NCT02433119|Experimental|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
11340185|NCT02433119|Active Comparator|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
11340186|NCT02433106|Experimental|Intervention|GAA 15 Specific neuromuscular exercise training
11340187|NCT02433106|Active Comparator|Control|Control Usual training
11340188|NCT02433093|Experimental|Basimglurant: Healthy Cohort (1)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
11340189|NCT02433093|Experimental|Basimglurant: Healthy Cohort (2)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
11340190|NCT02433093|Experimental|Basimglurant: Healthy Cohort (3)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
11340191|NCT02433093|Experimental|Basimglurant: Healthy Cohort (4)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
11340192|NCT02433093|Experimental|Basimglurant: MDD Cohort (5)|Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
11340193|NCT02433093|Placebo Comparator|Placebo: Healthy Cohorts (1 to 4)|Healthy participants will receive a 22-day regimen of matching placebo capsules.
11340194|NCT02433093|Placebo Comparator|Placebo: MDD Cohort (5)|Participants with MDD will receive a 22-day regimen of matching placebo capsules.
11340195|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
11340196|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.
~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
11340197|NCT02433067|Experimental|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
11340198|NCT02433067|Active Comparator|Control group|"- Arm B (control group) standard oncologic care"
11340199|NCT02433054||CE-certified dedicated venous stents|Patients receiving self-expanding venous nitinol stents.
11340200|NCT02433041|Active Comparator|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
11340201|NCT02433041|Active Comparator|Ketamine|Ketamine 1mg/kg at induction of anesthesia
11340202|NCT02433041|Active Comparator|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
11340203|NCT02433041|Placebo Comparator|Saline solution (NaCl 0.9%)|Placebo
11340204|NCT02433015|Active Comparator|Tobacco Cigarette Group|This group will not receive an electronic cigarette and will continue to smoke combustible tobacco cigarettes as previously.
11340205|NCT02433015|Experimental|Electronic Cigarette Group|This group will receive an electronic cigarette to use for the duration of the study.
11340206|NCT02433002||Main study|1300 participants will undergo baseline (month 0) and final (month 36) reference GFR, estimated GFR (eGFR) and urinary albumin-to-creatinine ratio (ACR) tests. Additionally they will provide ACR and eGFR tests at 6-monthly intervals.
11340207|NCT02433002||Sub-study of patterns of progression|A subset of the cohort (n=375) will receive annual reference GFR tests.
11340208|NCT02433002||Biological variability study|In a further sub-study 20 participants will undergo the reference test four times over four weeks.
11340209|NCT02432989|No Intervention|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
11340210|NCT02432989|Experimental|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
11340211|NCT02432976|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.
~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .
~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
11340212|NCT02432976|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.
~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.
~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
11340213|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
11340214|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
11340215|NCT02432937|Placebo Comparator|Corever middle dose|
11340216|NCT02432937|Placebo Comparator|Corever high dose|
11340217|NCT02432937|Placebo Comparator|Placebo|
11340218|NCT02432924|Experimental|Feedback Group|Participants randomised into the intervention group will be invited to return to the university for a one-off 60 minute set-up session once their physical activity monitor has been returned and processed. Within this session the participant will be given detailed instructions on how to use and wear the activity monitor and real time display and upload their data to and navigate the multidimensional feedback web platform (See materials section for details). They will also be introduced to the concept of goal setting and talked through the different aspects of the instantaneous feedback display and how that might benefit them. Following this visit the participant will be given licence to wear and use the physical activity monitoring devices for a 6-week period and encouraged to self-monitor their behaviour using the combined instantaneous and multidimensional feedback.
11340219|NCT02432924|No Intervention|Waiting List Control Group|Participants who have been randomised into the control arm will be put on a 3 month waiting list to receive the intervention described above. They will still attend assessment visits at week 6 and week 12 while they are not receiving any advice or feedback. Following their 12 week assessment, participants in the control arm will be invited to attend the same 60 minute set-up session as received by the intervention group and then provided with the armband monitor and display to then receive the intervention in full. No further post-intervention or follow-up assessments will be taken from these participants.
11340220|NCT02432911|Experimental|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
11340221|NCT02432911|Active Comparator|Low dose cytarabine|cytarabine 20mg bid for 10 days.
11340222|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
11340223|NCT02432885|Experimental|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
11340224|NCT02432885|No Intervention|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
11340225|NCT02432872|Experimental|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
11340226|NCT02432872|Active Comparator|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
11340227|NCT02432872|Experimental|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
11340228|NCT02432872|Active Comparator|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
11340229|NCT02432859|Active Comparator|Electrical stimulation|In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
11340230|NCT02432859|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero
11340263|NCT02432664|Active Comparator|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
11340537|NCT02431026|Experimental|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
11340231|NCT02432846|Experimental|Intuvax+ Nephrectomy+Sunitinib|Two Intuvax (ilixadencel) vaccinations (10 milj cells/vaccination) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
11340232|NCT02432846|Active Comparator|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
11340233|NCT02432833|Experimental|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
11340234|NCT02432833|Active Comparator|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
11340235|NCT02432807|Experimental|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
11340236|NCT02432807|Placebo Comparator|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
11340237|NCT02432794|Experimental|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.
~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
11340238|NCT02432794|No Intervention|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
11340239|NCT02432781|Experimental|Carbohydrate group|Carbohydrate-rich drink 400 mL 3 h before surgery
11340240|NCT02432781|Active Comparator|Control group|10% dextrose solution mixed with insulin 16 unit 100 mL/h
11340241|NCT02432768|Active Comparator|Triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
11340242|NCT02432768|Placebo Comparator|Placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day.
11340243|NCT02432755|Experimental|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
11340244|NCT02432755|Active Comparator|hospital-based therapy|hospital-based individualized occupational therapy
11340245|NCT02432755|Experimental|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
11340246|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
11340247|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
11340248|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.
~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
11340249|NCT02432716|Experimental|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
11340250|NCT02432716|Experimental|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
11340251|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
11340252|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
11340253|NCT02432690|Experimental|Arm A|
11340254|NCT02432677|Experimental|Remifentanil + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.
~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
11340255|NCT02432677|Other|Placebo + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.
~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
11340256|NCT02432677|Other|Remifentanil + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
11340257|NCT02432677|Other|Placebo + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
11340258|NCT02432664|Experimental|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
11340259|NCT02432664|Placebo Comparator|Placebo Part I|Oral capsules given once daily for one day
11340260|NCT02432664|Experimental|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
11340261|NCT02432664|Placebo Comparator|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
11340262|NCT02432664|Experimental|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
11340295|NCT02432404|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
11340264|NCT02432651|Other|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
11340265|NCT02432651|Other|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
11340266|NCT02432651|Other|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
11340267|NCT02432612|Experimental|Sativex|Sativex will be administered by trained, clinical trial personnel, via a pump action oromucosal spray. Sativex will be administered as 2 actuations (sprays) under the tongue or inside the cheeks every 4 minutes until 6 sprays have been administered. Following the administration of the first and second set of 2 actuations, patients will be offered 50 mL water to drink; and following the final set of 2 actuations, 100 mL of water will be offered (i.e., a total of 200 mL water will be offered during the Sativex dosing). There must be a period of at least 2 minutes and no more than 3 minutes between Sativex administration and consumption of water. Patients will not be permitted their regular medication until 2 hours post dose of investigational medicinal product (IMP) to minimize any possible drug interactions.
11340268|NCT02432599|Experimental|F18-choline PET|F18-choline PET examination will be performed before surgery
11340269|NCT02432586|Other|Intensive Education|Attendance of 2 intensive education sessions
11340270|NCT02432573|No Intervention|Standard care|Postpartum patients that receive physician rounding at current time
11340271|NCT02432573|Experimental|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
11340272|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
11340273|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
11340274|NCT02432547|Active Comparator|Aflibercept Monotherapy|Intravitreal aflibercept injections according to a treat and extend regimen.
11340275|NCT02432547|Experimental|Targeted laser therapy with Aflibercept|Targeted laser photocoagulation therapy to areas of peripheral retinal ischaemia and intravitreal aflibercept injections using a treat and extend regimen.
11340276|NCT02432534|Experimental|UVB + treatement|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
11340277|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
11340278|NCT02432508|Active Comparator|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
11340279|NCT02432508|Sham Comparator|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
11340280|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
11340281|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
11340282|NCT02432482|Active Comparator|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
11340283|NCT02432482|Experimental|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers
~offer of nicotine patches"
11340284|NCT02432469|Experimental|Intervention group|APP specific for this study, with reminder, education materials and feedback mechanism for improving secondary medications
11340285|NCT02432469|No Intervention|Control group|Usual Care
11340286|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.
~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
11340287|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.
~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
11340288|NCT02432443|Experimental|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
11340289|NCT02432443|Active Comparator|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
11340290|NCT02432430|Experimental|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
11340291|NCT02432430|Active Comparator|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
11340292|NCT02432417|No Intervention|Standard|Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
11340293|NCT02432417|Experimental|Experimental arm|"Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
~In addition this treatment will be combined with a daily intake of the recommended phase two dose (RPTD) of chloroquine (CQ)."
11340294|NCT02432404|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
11340297|NCT02432391|Experimental|GEM|Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.
11340298|NCT02432378|Experimental|Cisplatin + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
11340299|NCT02432378|Experimental|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
11340300|NCT02432365|Experimental|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
11340301|NCT02432352|Experimental|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
11340302|NCT02432352|No Intervention|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
11340303|NCT02432339|Experimental|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
11340304|NCT02432339|Placebo Comparator|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
11340305|NCT02432326|Experimental|Arm A|
11340306|NCT02432313|Experimental|Modified Release Formulation x (MRx)|Various formulations of Modified Release anatabine citrate tablets
11340307|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
11340308|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
11340309|NCT02432287|Experimental|Placebo|Placebo
11340310|NCT02432274|Experimental|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
11340311|NCT02432274|Experimental|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
11340312|NCT02432274|Experimental|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
11340313|NCT02432274|Experimental|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
11340314|NCT02432274|Experimental|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
11340315|NCT02432261|Experimental|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
11340316|NCT02432261|Experimental|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
11340317|NCT02432248|Experimental|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
11340318|NCT02432248|Placebo Comparator|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
11340319|NCT02432235|Experimental|ADCT-301|"In Part 1 (dose-escalation), patients will receive a 1-hour intravenous infusion of ADCT-301 on Day 1 every 3 weeks (21-day cycle). Dose escalation will be conducted according to a continual reassessment method.
~In Part 2 (expansion), patients will be assigned to receive the recommended dose(s) of ADCT-301 as determined by the Dose Escalation Steering Committee (DESC)."
11340320|NCT02432222|Experimental|Music Training|Music training
11340321|NCT02432222|Experimental|Visual Arts Training|Visual arts training
11340322|NCT02432222|No Intervention|Control|Waitlist control
11340323|NCT02432209|Active Comparator|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
11340324|NCT02432209|Placebo Comparator|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
11340325|NCT02432196|Experimental|Harpoon Medical TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
11340326|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
11340327|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
11340328|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
11340329|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
11340330|NCT02432170|Experimental|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle
~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
11340331|NCT02432157|Experimental|Hypertonic saline (HTS)|A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
11340394|NCT02431767|Placebo Comparator|Group 2: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
11406937|NCT01989520|Experimental|Treatment A|Phase IIb formulation
11340332|NCT02432157|Active Comparator|Standard fluid|Routine fluid management strategy as pre-specified by our SAH management protocol at Jefferson University Hospital according to the American Heart Association and Neurocritical Care Guidelines for the management of SAH (this includes conventional intravenous fluids or normal saline solutions to maintain a normal hydration status and guided by the treating doctor and daily assessments of fluid balance).
11340333|NCT02432144|Experimental|UX003|4 mg/kg UX003 every other week (QOW)
11340334|NCT02432131||Divers with PFO|
11340335|NCT02432131||Divers without PFO|
11340336|NCT02432118|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
11340337|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
11340338|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
11340339|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
11340340|NCT02432092||Affected|participants with cardiomyopathy
11340341|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
11340342|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
11340343|NCT02432066|Active Comparator|GTS-21|Participants in the GTS-21 arm will receive 150 mg/BID GTS-21 over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
11340344|NCT02432066|Placebo Comparator|Placebo|Participants in the Placebo arm will receive placebo compound twice daily over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
11340345|NCT02432053|Experimental|Transplantation|Advagraf
11340346|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
11340347|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
11340348|NCT02432027|Experimental|IMP 1|C-82 Topical Gel, 1%
11340349|NCT02432027|Placebo Comparator|IMP 2|C-82 Topical Gel, placebo
11340350|NCT02432027|Active Comparator|IMP 3|Daivonex cream
11340351|NCT02432027|Active Comparator|IMP 4|Diprosis gel
11340352|NCT02432014|Other|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
11340353|NCT02432014|Other|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
11340354|NCT02432014|Other|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
11340355|NCT02432014|Other|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
11340356|NCT02432001||Image-Guided Biopsies|Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.
11340357|NCT02431988|Experimental|CAR19 T-cells|"Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.
~The CAR19 T-cells are to be administered on day 0."
11340358|NCT02431975|Experimental|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
11340359|NCT02431962|Experimental|Screening arm|Annual low dose screening chest CT scan x 3.
11340360|NCT02431962|Experimental|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
11340361|NCT02431962|Active Comparator|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
11340362|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
11340363|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
11340364|NCT02431936|Experimental|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
11340365|NCT02431936|Placebo Comparator|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
11340366|NCT02431923||EVD Close Contacts|At least one of the following:-Household contact of survivor at time of or since EVD event-Sexual contact with survivor since EVD event-Other selected contacts
11340367|NCT02431923||EVD Survivors|Subject listed on the Ministry of Health registry for Ebola survivors
11340368|NCT02431923||Non Contact Controls|Selected Controls
11340369|NCT02431910|No Intervention|Control group|The control group remains at rest for 10 minutes, which is not applied KT in the RF, VL and VM muscles. The volunteers of this group perform all evaluation without the application of KT
11340395|NCT02431767|Experimental|Group 3: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
11340538|NCT02431026|No Intervention|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
11340370|NCT02431910|Placebo Comparator|Placebo group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 0%.
11340371|NCT02431910|Experimental|Kinesio Taping group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 50%. This application will be held with subjects standing on one foot, with the hip of the non-dominant limb at 0º and knee flexed at 90º.
11340372|NCT02431897|Experimental|Estrogen Cream|
11340373|NCT02431897|Placebo Comparator|Placebo Cream|
11340374|NCT02431884||body fluids/tissues & history|collect body fluids/tissues & med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
11340375|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
11340376|NCT02431871||Control|Age an sex matched controls of DDH patients
11340377|NCT02431858|Experimental|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
11340378|NCT02431858|Active Comparator|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
11340379|NCT02431845|Experimental|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
11340380|NCT02431832|Experimental|Augmentin tab|
11340381|NCT02431819|Experimental|contention socks|Patients wear evolutive contention socks during 15 days.
11340382|NCT02431806|Placebo Comparator|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
11340383|NCT02431806|Experimental|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
11340384|NCT02431806|Experimental|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
11340385|NCT02431806|Active Comparator|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
11340386|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
11340387|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.
~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.
~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.
~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
11340388|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
11340389|NCT02431780|No Intervention|non ANSeR Software System|Routine clinical EEG monitoring
11340390|NCT02431780|Experimental|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
11340391|NCT02431767|Experimental|Group 1: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.6 mg admixed with IL-12 DNA 0.2 mg to be administered as 0.1 mL by intradermal (ID) injection over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
11340392|NCT02431767|Placebo Comparator|Group 1: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
11340393|NCT02431767|Experimental|Group 2: Treatment|Participants will receive the PENNVAX®-GP vaccine 0.8 mg to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
11340833|NCT02429076|Experimental|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
11340396|NCT02431767|Placebo Comparator|Group 3: Placebo|Participants will receive placebo to be administered as 0.1 mL ID over their left and right deltoids (unless medically contraindicated) at Months 0, 1, 3, and 6 using the CELLECTRA® 3P EP system.
11340397|NCT02431767|Experimental|Group 4: Treatment|Participants will receive the PENNVAX®-GP vaccine 8 mg admixed with IL-12 DNA 1 mg to be administered as 1 mL intramuscular (IM) injection in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
11340398|NCT02431767|Placebo Comparator|Group 4: Placebo|Participants will receive placebo to be administered as 1 mL IM in either deltoid at Months 0, 1, 3, and 6 using the CELLECTRA® 5P EP system.
11340399|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.
~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.
~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
11340400|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.
~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.
~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
11340401|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
11340402|NCT02431728|Active Comparator|Melatonin|capsule containing 5mg melatonin plus cellulose
11340403|NCT02431728|Placebo Comparator|Matched Placebo|capsule containing cellulose
11340404|NCT02431702|Active Comparator|Part-1: Oral Antipsychotics (OAP)|All Participants will receive Paliperidone Extended Release (ER) 1.5 to 12 milligram (mg) or risperidone 1 to 6 mg once daily orally for 2 months. Subjects who tolerate paliperidone ER/risperidone but find it inadequately efficacious after treatment for an adequate duration at an adequate dosage (per clinical judgment), may be switched to another protocol-specified OAP at the discretion of the investigator.
11340405|NCT02431702|Experimental|Part-2: Paliperidone Palmitate (PP)|Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
11340406|NCT02431702|Active Comparator|Part-2: OAP|Participants who will complete Part-1 will be randomized to receive Oral Antipsychotics for 9 months.
11340407|NCT02431702|Experimental|Part-3: PP - PP|Participants who will complete Part-2 (with PP treatment) will continue to receive Paliperidone Palmitate for 9 months.
11340408|NCT02431702|Experimental|Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive PP treatment for 9 months. PP treatment includes PP1M and PP3M. Participants will be subsequently switched to PP3M following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
11340409|NCT02431702|Active Comparator|Part-3: OAP - OAP|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive OAP treatment for additional 9 months.
11340410|NCT02431689|Active Comparator|Antagonist|"Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.
~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
11340411|NCT02431689|Active Comparator|Short|"Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.
~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
11340412|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
11340413|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
11340414|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
11340415|NCT02431663|Experimental|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
11340416|NCT02431663|Active Comparator|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.
~Maximum duration of infusion for each drug will be 48 hours."
11340439|NCT02431520|Experimental|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for Hybrid Capture II (HCII).
11340440|NCT02431520|Active Comparator|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
11340539|NCT02431013|Experimental|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
11342803|NCT02416388|Active Comparator|R4-IDAC (without VEN)|Intermediate dose cytarabine alone
11340417|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).
~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
11340418|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).
~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
11340419|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
11340420|NCT02431624|Experimental|Test treatment|BTDS 40 milligram
11340421|NCT02431624|Active Comparator|Reference treatment|BTDS 20 milligram
11340422|NCT02431611|Active Comparator|Control condition|Control behavioral phone-based smoking cessation intervention
11340423|NCT02431611|Experimental|Biomarker Feedback Intervention|Biomarker feedback plus behavioral phone-based smoking cessation intervention
11340424|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
11340425|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
11340426|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
11340427|NCT02431585|Other|rechallenge|Double blind placebo controlled cross over
11340428|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)
~Immunotherapy
~Assess Inflammation (PBR PET)"
11340429|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)
~Immunotherapy
~Assess Inflammation (PBR PET)"
11340430|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation
~Assess inflammation (PBR PET)
~Follow Patients"
11340431|NCT02431559|Experimental|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
11340432|NCT02431559|Experimental|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
11340433|NCT02431559|Experimental|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
11340434|NCT02431559|Experimental|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
11340435|NCT02431546|Experimental|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.
~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
11340436|NCT02431546|No Intervention|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
11340437|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
11340438|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
11342804|NCT02416375||Observation|Adult Cystic Fibrosis patients
11340441|NCT02431507|Experimental|Treatment Arm with Magnetic Apnea Device|The treatment arm with magnetic apnea device includes: surgical implantation of the magnetic apnea device(MAGNAP) to treat obstructive sleep apnea in each eligible enrolled subject . A custom fitted external brace will be created for wear throughout the 13 months of treatment and evaluated for improvement of symptoms..
11340442|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
11340443|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
11340444|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
11340445|NCT02431481|Experimental|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
11340446|NCT02431481|Experimental|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
11340447|NCT02431481|Experimental|End Stage Renal Disease|End stage renal disease not on dialysis; GFR <15 ml/min
11340448|NCT02431481|Experimental|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
11340449|NCT02431481|Experimental|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
11340450|NCT02431468|Experimental|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
11340451|NCT02431468|Experimental|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
11340452|NCT02431468|Placebo Comparator|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
11340453|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
11340454|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
11340455|NCT02431442|Active Comparator|Cohort 1: RM-493 SC Infusion 14 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)
11340456|NCT02431442|Active Comparator|Cohort 2: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
11340457|NCT02431442|Active Comparator|Cohort 3: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
11340458|NCT02431442|Active Comparator|Cohort 4: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
11340459|NCT02431442|Active Comparator|Cohort 5: RM-493 SC Injection 14 days|Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)
11340460|NCT02431442|Active Comparator|Cohort 6: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
11340461|NCT02431442|Placebo Comparator|Cohort 1: Placebo SC Infusion 14 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)
11340462|NCT02431442|Placebo Comparator|Cohort 2: Placebo SC Infusion 28 Days|Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)
11340463|NCT02431442|Placebo Comparator|Cohort 3: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
11340464|NCT02431442|Placebo Comparator|Cohort 4: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
11340465|NCT02431442|Placebo Comparator|Cohort 5: Placebo SC Injection 14 days|Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)
11340466|NCT02431442|Placebo Comparator|Cohort 6: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
11340467|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
11340468|NCT02431416|Active Comparator|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
11340469|NCT02431416|Placebo Comparator|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
11340470|NCT02431403|Experimental|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
11340471|NCT02431403|Experimental|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
11340472|NCT02431403|Experimental|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
11340473|NCT02431403|Experimental|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP
~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
11343446|NCT02412358|Active Comparator|Butler|Patients use Butler toothbrush for plaque removal
11340474|NCT02431390|Experimental|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
11340475|NCT02431390|Active Comparator|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
11340476|NCT02431377|Experimental|S-26 Gold|Standard Infant Formula containing enriched with alpha-lactalbumin
11340477|NCT02431364|Experimental|Cohort 1|5 mg verdinexor on Days 1 and 3 or Placebo
11340478|NCT02431364|Experimental|Cohort 2|10 mg verdinexor on Days 1 and 3
11340479|NCT02431364|Experimental|Cohort 3|20 mg verdinexor on Days 1 and 3
11340480|NCT02431364|Experimental|Cohort 4|40 mg verdinexor on Days 1 and 3
11340481|NCT02431364|Experimental|Cohort 5|60 mg verdinexor on Days 1 and 3
11340482|NCT02431364|Experimental|Cohort 6|80 mg verdinexor on Days 1 and 3
11340483|NCT02431364|Experimental|Cohort 7|100 mg verdinexor on Days 1 and 3
11340484|NCT02431351|Experimental|Selinexor|60 mg once weekly
11340485|NCT02431338|Experimental|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
11340486|NCT02431338|No Intervention|Control group|Standard treatment with primary percutaneous coronary intervention alone.
11340487|NCT02431325|Experimental|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
11340488|NCT02431325|Placebo Comparator|Placebo|Placebo, subcutaneous injection, 6 months duration
11340489|NCT02431312|Experimental|Group A: low dose, standard regimen|Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
11340490|NCT02431312|Experimental|Group A: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
11340491|NCT02431312|Experimental|Group A: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
11340492|NCT02431312|Experimental|Group B: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
11340493|NCT02431312|Experimental|Group B: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
11340494|NCT02431312|Active Comparator|Active Control: nucleos(t)ide analogue treatment|Participants continued treatment with nucleos(t)ide analogue treatment.
11340495|NCT02431286|Experimental|Aprepitant|patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
11340496|NCT02431286|Placebo Comparator|placebo|patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
11340497|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
11340498|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
11340499|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
11340500|NCT02431260|Experimental|INCB054329 Monotherapy|
11340501|NCT02431247|Experimental|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
11340502|NCT02431247|Active Comparator|DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC|Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
11340503|NCT02431221|Experimental|Intervention|Perhexiline maleate will be supplied in 100 mg and 25 mg tablets. It will be initially administered at a dose of 200 mg once a day in tablet form for at least six months. After initiation of dosing, perhexiline dosing will be determined using plasma level guided dose adjustment. Dosing decisions will be made by an unblinded dose control center.
11340504|NCT02431221|Placebo Comparator|Placebo|Placebo will be administered once a day in tablet form for at least six months. Tablets will be identical in size and shape to perhexiline tablets. Adjustments in placebo dosing will be made by an unblinded dose control center to mimic decisions made for subjects in the experimental arm.
11340505|NCT02431208|Experimental|Cohort A: ATZ (Run-In)|Cohort A will involve a safety run-in to evaluate atezolizumab administered as a single agent in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
11340534|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
11340506|NCT02431208|Experimental|Cohort B1: ATZ + LEN (Dose Escalation)|Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
11340507|NCT02431208|Experimental|Cohort C: ATZ + LEN (Post-ASCT):|Cohort C will evaluate atezolizumab administered in combination with lenalidomide in participants with MM who have measureable disease after ASCT. NOTE: This cohort is closed to enrollment.
11340508|NCT02431208|Experimental|Cohort D1: ATZ + DAR (Run-in)|Cohort D1 will involve a safety run-in to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment.
11340509|NCT02431208|Experimental|Cohort D2: ATZ + DAR (Expansion)|Cohort D2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received 2 but no more than 3 lines of prior treatment that must have included a PI and IMiD and are refractory to the last line of treatment.
11340510|NCT02431208|Experimental|Cohort D3: ATZ + DAR (Progressed)|Cohort D3 will involve an expansion to evaluate atezolizumab in combination with daratumumab in participants with relapsed or refractory MM who have received 2 or more lines of prior treatment and have progressed with an anti-cluster of differentiation (CD) 38 monoclonal antibody, either alone or in combination, and are refractory to both a proteasome inhibitor (PI) and immunomodulatory drug (IMiD).
11340511|NCT02431208|Experimental|Cohort E1: ATZ + DAR + LEN (Dose Escalation)|Cohort E1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
11340512|NCT02431208|Experimental|Cohort E2: ATZ + DAR + LEN (Expansion)|Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
11340513|NCT02431208|Experimental|Cohort F1: ATZ + DAR + POM (Dose Escalation)|Cohort F1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose pomalidomide in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort has been completed.
11340514|NCT02431208|Active Comparator|Cohort F2: ATZ + DAR + POM (Expansion)|Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
11340515|NCT02431208|Active Comparator|Cohort F3: DAR + POM + Dexamethasone|Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
11340516|NCT02431182|Experimental|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.
~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
11340517|NCT02431182|No Intervention|Control group|No intervention will be administred until the delayed post-test is finished
11340518|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
11340519|NCT02431143|Experimental|Miltefosine|allometric dosing
11340520|NCT02431130|Experimental|Low-fidelty instructor driven simulation training|participants receive simulation training
11340521|NCT02431130|No Intervention|No simulation training|
11340522|NCT02431104|Experimental|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
11340523|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.
~Optical Coherence Tomography is performed in all definite cases"
11340524|NCT02431091|Active Comparator|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.
~Optical Coherence Tomography is performed in matched control A patients"
11340525|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values>the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
11340526|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values<the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
11340527|NCT02431065|Experimental|Group 3, Direct injection group|Test group 2, Rectus sheath block will be performed under direct visualization. Ropivacaine (0.75%, 10ml) will be directly injected into the right and left rectus sheath at the end of the operation.
11340528|NCT02431065|Active Comparator|Group 2, ultrasonography group|Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
11340529|NCT02431065|Placebo Comparator|Group 1|Control group, Rectus sheath block will be performed under sonographic guidance. Normal saline 10 ml will be injected into the right, left rectus sheath under ultrasonography guidance at the end of the operation.
11340530|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
11340531|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
11340532|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
11340533|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
11340535|NCT02431039|Experimental|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
11340540|NCT02431013|Active Comparator|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
11340541|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.
~This is a prospective observational cohort study."
11340542|NCT02430987|Active Comparator|Metabolic syndrome|"The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol < 50mg/dL; (3) triglycerides > 150mg/dL; (4) arterial blood pressure (SAH) > 130/85mmHg; and (5) fasting glucose > 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
~Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese"
11340543|NCT02430987|Placebo Comparator|Obesity|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese
11340544|NCT02430974|No Intervention|Chemotherapy|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).
11340545|NCT02430974|Experimental|Chemotherapy & Icotinib|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).Two weeks after chemotherapy completed, patients assigned to the consolidation therapy group began oral icotinib treatment (125 mg, thrice daily). Icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity.
11340546|NCT02430948|Active Comparator|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
11340547|NCT02430948|Experimental|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
11340548|NCT02430948|Experimental|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
11340549|NCT02430948|Experimental|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
11340550|NCT02430935|Experimental|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
11340551|NCT02430935|Active Comparator|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
11340552|NCT02430922|Experimental|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
11340553|NCT02430909|Placebo Comparator|CZP / CZP + PBO / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30
~+Placebo from Week 8 to Week 18"
11340554|NCT02430909|Experimental|CZP / CZP + UCB4940 / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30
~+ UCB4940 from Week 8 until Week 18"
11340555|NCT02430909|Other|CZP / CZP/ CZP|Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30
11340556|NCT02430896||ADHD group|Children and adolescents who met the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD and needed pharmacotherapy. Subjects will be taking Methylphenidate or Atomoxetine for 52 weeks.
11340557|NCT02430896||Normal control group|Children and adolescents will be recruited by advertisement, and will be assigned to normal group if they do not meet the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD .
11340558|NCT02430883|Active Comparator|first group|patients who have upper pole kidney stones treated with flexible renoscopy
11340559|NCT02430883|Active Comparator|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
11340560|NCT02430883|Active Comparator|third group|patients who have lower pole kidney stones treated with flexible renoscopy
11340561|NCT02430883|Active Comparator|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
11340562|NCT02430883|Active Comparator|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
11340563|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
11340564|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
11340565|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
11340566|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
11340614|NCT02430506|Experimental|AERAS-402|1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non-animal source) and water. Administered intramuscular (IM) injection to deltoid area on days 0 and 56.
11340567|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
11340568|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
11340569|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
11340570|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
11340571|NCT02430857|Experimental|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
11340572|NCT02430857|No Intervention|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
11340573|NCT02430831|Active Comparator|Reuteri group|Milk formula added with probiotic L reuterii DSM 17938
11340574|NCT02430831|Placebo Comparator|Placebo|Milk formula without probiotic L reuterii DSM 17938
11340575|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
11340576|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
11340577|NCT02430805|Other|NOE|multicentric family-based cohort. prospective and transversal study
11340578|NCT02430792|Active Comparator|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
11340579|NCT02430792|No Intervention|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
11340580|NCT02430779|Experimental|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
11340581|NCT02430779|No Intervention|Control|The patients without treatment
11340582|NCT02430766|Experimental|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
11340583|NCT02430766|No Intervention|Control|The patients without treatment
11340584|NCT02430753|Experimental|IRE Group|irreversible electroporation for Lung Neoplasms accompanied by Respiratory Function Insufficiency
11340585|NCT02430753|No Intervention|Control|The patients without treatment
11340586|NCT02430740|Other|control group|standard care recFSH
11340587|NCT02430740|Experimental|study group|modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC
11340588|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
11340589|NCT02430701|Experimental|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
11340590|NCT02430701|No Intervention|Control|The patients without treatment
11340591|NCT02430688|Experimental|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
11340592|NCT02430688|No Intervention|Control|The patients without treatment
11340593|NCT02430675|Experimental|Group A|irreversible electroporation for Unresectable Laryngeal Neoplasms
11340594|NCT02430675|No Intervention|Control|The patients without treatment
11340595|NCT02430662|Experimental|IRE Group|irreversible electroporation for Unresectable Gallbladder Neoplasms
11340596|NCT02430662|No Intervention|Control|The patients without treatment
11340597|NCT02430649|Experimental|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
11340598|NCT02430649|No Intervention|Control|The patients without treatment
11340599|NCT02430636|Experimental|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
11340600|NCT02430636|No Intervention|Control|The patients without treatment
11340601|NCT02430623|Experimental|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
11340602|NCT02430623|No Intervention|Control|The patients without treatment
11340603|NCT02430610|Experimental|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
11340604|NCT02430610|No Intervention|Control|The patients without treatment
11340605|NCT02430597|Experimental|IRE Group|irreversible electroporation for Unresectable Hilus Pulmonis Neoplasms
11340606|NCT02430597|No Intervention|Control|The patients without treatment
11340607|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
11340608|NCT02430545|Experimental|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
11340609|NCT02430532|Experimental|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
11340610|NCT02430532|Experimental|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
11340611|NCT02430519|Experimental|11 Patients with Grade II Manibular Molar Furcation|Group A- Furcation Treatment with PRF
11340612|NCT02430519|Experimental|11 Patients with Grade II Mandibular Molar Furcation D|Group B- Furcation Treatment with Allograft and GTR
11340613|NCT02430506|Placebo Comparator|Placebo|1.0 mL sterile buffer administered by intramuscular (IM) injection to deltoid area on days 0 and 56.
11340615|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
11344189|NCT02407262|Placebo Comparator|Placebo|"Placebo (olive oil) capsules
~1g/day for 4 weeks"
11340616|NCT02430480|Experimental|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
11340617|NCT02430467|Active Comparator|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
11340618|NCT02430467|Active Comparator|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
11340619|NCT02430454|Experimental|Experimental|Subjected to increased cognitive load
11340620|NCT02430454|No Intervention|Control|Not subjected to increased cognitive load
11340621|NCT02430428|Experimental|VisuMax lenticule removal|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
11340622|NCT02430415|Experimental|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
11340623|NCT02430415|Experimental|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
11340624|NCT02430402|Experimental|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
11340625|NCT02430402|No Intervention|Usual care|Usual care provided as needed / agreed between patient and health care providers
11340626|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
11340627|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
11340628|NCT02430363|Active Comparator|MK-3475|"Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.
~Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.
~MK-3475 will be given intravenously over the course of 30 minutes"
11340629|NCT02430363|Experimental|Suppressor of the PI3K/Akt pathways|"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks.
~BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1.
~Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks.
~Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 .
~Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks.
~The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home"
11340630|NCT02430350|Experimental|Compound Edaravone|Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
11340631|NCT02430350|Active Comparator|Edaravone|Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days
11340632|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
11340633|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
11340634|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
11340635|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
11340636|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
11340637|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
11340638|NCT02430298|Placebo Comparator|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
11340639|NCT02430298|Active Comparator|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
11340640|NCT02430285|Other|Endoscopic Ultrasound|All consecutive patients entering the emergency department due to acute abdominal pain and showing biochemical and/or radiological findings consistent with possible acute biliary pancreatitis, undergo Endoscopic Ultrasound with linear array Olympus 180 series echoendoscopes (Olympus Europa Holding, Hamburg, Germany).
11340641|NCT02430272|Experimental|Anticholinergic premedication|Premedication with 0.005mg/Kg of glycopyrrolate
11340642|NCT02430272|No Intervention|Control group|Same volume of normal saline
11340643|NCT02430259|Experimental|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
11340644|NCT02430259|No Intervention|No preventive treatment|Follow up without intervention
11340645|NCT02430246|Experimental|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
11340646|NCT02430246|Placebo Comparator|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
11340647|NCT02430246|Experimental|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
11340750|NCT02429648|Active Comparator|PVI performed in Atrial Fibrillation|PVI then DCC after if patient remains in Atrial Fibrillation
11340648|NCT02430246|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
11340649|NCT02430246|Experimental|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
11340650|NCT02430246|Placebo Comparator|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
11340651|NCT02430246|Other|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
11340652|NCT02430246|Other|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
11340653|NCT02430233|Experimental|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
11340654|NCT02430233|No Intervention|No treatment|No treatment
11340655|NCT02430207|Experimental|Femoral Vein|patients receiving temporary pacing via femoral vein
11340656|NCT02430207|Experimental|Subclavian Vein|patients receiving temporary pacing via subclavian vein
11340657|NCT02430194|Experimental|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD;
11340658|NCT02430194|Experimental|lonafarnib/ritonavir - II|lonafarnib 150 mg QD + ritonavir 100 mg QD;
11340659|NCT02430194|Experimental|lonafarnib/ritonavir - III|lonafarnib 75 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
11340660|NCT02430194|Experimental|lonafarnib/ritonavir - IV|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
11340661|NCT02430194|Experimental|lonafarnib/ritonavir - V|lonafarnib 100 mg BID + ritonavir 50 mg BID;
11340662|NCT02430194|Experimental|lonafarnib/ritonavir - VI|lonafarnib 100 mg QD + ritonavir 100 mg QD;
11340663|NCT02430194|Experimental|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW;
11340664|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW;
11340665|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 50 mg BID + ritonavir 100 mg BID
11340666|NCT02430194|Experimental|lonafarnib/ritonavir - X|lonafarnib 25 mg BID + ritonavir 100 mg BID
11340667|NCT02430181|Experimental|lonafarnib 200 mg BID|lonafarnib 200 mg BID; n=3
11340668|NCT02430181|Experimental|lonafarnib 300 mg BID|lonafarnib 300 mg BID; n=3
11340669|NCT02430181|Experimental|lonafarnib 100 mg TID|lonafarnib 100 mg TID; n=3
11340670|NCT02430181|Experimental|100 mg BID lonafarnib/PEG IFN-a|lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
11340671|NCT02430181|Experimental|200 mg BID lonafarnib/PEG IFN-a|lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
11340672|NCT02430181|Experimental|300 mg BID lonafarnib/PEG IFN-a|lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=3
11340673|NCT02430181|Experimental|lonafarnib/ritonavir|lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
11340674|NCT02430168|Active Comparator|RIRS|Retrograde intrarenal surgery
11340675|NCT02430168|Active Comparator|PCNL|Percutaneous nephrolithotomy
11340676|NCT02430155|Active Comparator|Bakri balloon group|The women in this group will be managed by Bakri balloon
11340677|NCT02430155|Active Comparator|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
11340678|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
11340679|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
11340680|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
11340681|NCT02430129|Active Comparator|Total knee arthroplasty/Persona|Total knee arthroplasty with Zimmer Persona posterior cruciate retaining prosthesis (Zimmer, Warsaw, IN)
11340682|NCT02430129|Experimental|Unicompartment knee arthroplasty/Oxford|Unicompartmental knee arthroplasty with Biomet Oxford mobile-bearing unicompartmental knee prosthesis (Biomet, Warsaw, IN)
11340683|NCT02430116|No Intervention|negative control group|The myocardial tissues of the right atrial appendage were obtained at 3 min before CPB was established in the NEG group.
11340684|NCT02430116|Active Comparator|I/R group|The myocardial tissues of the right atrial appendage were obtained at 45 min after opening the aorta in the I/R group.
11340685|NCT02430116|Experimental|I-postC group|The procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
11340686|NCT02430103||Chemotherapy plus GnRHa|Patients of the group will receive (neo)chemotherapy plus GnRHa ( Goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration).
11340687|NCT02430103||Chemotherapy|Patients of the group will receive (neo)chemotherapy merely.
11340688|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
~Injection Surgical anaesthesia
~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block
~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
11340767|NCT02429557|Active Comparator|Sham abdominal compression and midodrine|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
11344608|NCT02404480|Experimental|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
11340689|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.
~Indications:
~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.
~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
11340690|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.
~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.
~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
11340691|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
11340692|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
11340693|NCT02430064|Experimental|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
11340694|NCT02430051|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
11340695|NCT02430051|Experimental|Sensory Adapted Dental Environment|In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
11340696|NCT02430038||Acceptability and feasibilty|Where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls
11340697|NCT02430038||Predictive Model|Nulliparous term labouring women with cephalic presentation
11340698|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
11340699|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one <50% stenotic lesion on coronary angiography.
11340700|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
11340701|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
11340702|NCT02430012|Active Comparator|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
11340703|NCT02430012|No Intervention|Control group|The control goup will maintain the routine practice pattern.
11340704|NCT02429999|Active Comparator|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
11340705|NCT02429999|Active Comparator|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
11340706|NCT02429986|Other|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
11340707|NCT02429973|Experimental|Experimental|6 cycles of gemcitabine plus rapamycin
11340708|NCT02429960|Other|Analgesia monitoring|Remifentanil is increased step-by-step according to the study protocol. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli consisting of the intracutaneous pain model and tetanic stimulation for the time period of 30 s with 80 milliampere, 50 Hz are applied. All stimulations are accompanied by the measurement of the analgesic monitoring-devices (PhysioDoloris®, SPI® and AlgiScan®). Moreover the investigators measure and inspect changes in heart rate and blood pressure as well as occurrence of defensive movements of the patients.
11340709|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
11340710|NCT02429934|Active Comparator|Abatacept|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
11340711|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks.
11340712|NCT02429921|Experimental|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
11340713|NCT02429921|Experimental|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
11340714|NCT02429908|Other|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
11340715|NCT02429895|Experimental|All subjects (open-label extension)|All subjects will start treatment with ABT-122
11340716|NCT02429882|Experimental|Brodalumab|
11340717|NCT02429882|Placebo Comparator|Placebo|
11340718|NCT02429869|Experimental|Everolimus|
11340719|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
11340720|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
11340831|NCT02429089|Experimental|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
11340721|NCT02429843|Experimental|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
11340722|NCT02429830|Other|Single arm study|Previous LSG patient will be treated with the LINX device and serve as their own control
11340723|NCT02429817|Active Comparator|Aeroneb Solo|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo connected to the high flow nasal cannula.
11340724|NCT02429817|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via the jet nebulizer connected to the high flow nasal cannula.
11340725|NCT02429804|Experimental|Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI)|Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.
11340726|NCT02429791|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
11340727|NCT02429791|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
11340728|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
11340729|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
11340730|NCT02429765|Active Comparator|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
11340731|NCT02429765|Placebo Comparator|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
11340732|NCT02429752|Experimental|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
11340733|NCT02429739|Experimental|Working Memory Training|Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
11340734|NCT02429739|No Intervention|Passive control group|"The control group will receive treatment as usual (Ordinary school days, special education if normally received)."
11340735|NCT02429726|Experimental|rAdp53|2 x 10^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21
11340736|NCT02429726|Active Comparator|cisplatin|cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
11340737|NCT02429726|Experimental|rAdp53 plus cisplatin|2 x 10^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
11340738|NCT02429713|Experimental|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
11340739|NCT02429713|Active Comparator|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
11340740|NCT02429700|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
11340741|NCT02429700|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
11340742|NCT02429687|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
11340743|NCT02429687|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
11340744|NCT02429674|Other|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
11340745|NCT02429661|Experimental|RC (Girls First Resilience Curriculum)|The Girls First Resilience Curriculum is delivered in peer support groups of 12-15 students per group over 23 weekly 1-hour sessions. The curriculum draws from fields such as positive psychology, emotional competence/intelligence, and restorative practices, and aims to improve students' psychosocial assets and wellbeing.
11340746|NCT02429661|Experimental|HC (Girls First Health Curriculum)|The Girls First Health Curriculum is delivered in peer support groups of 12-15 students per group over 21 weekly 1-hour sessions. The curriculum covers topics such as nutrition, sexual and reproductive health, clean water, hygiene, and common diseases, and aims to improve students' physical health and wellbeing.
11340747|NCT02429661|Experimental|RC+HC (Girls First)|Girls First is a combination of the Girls First Resilience Curriculum (RC) and the Girls First Health Curriculum (HC).
11340748|NCT02429661|No Intervention|SC (School-as-usual control)|Participants receive no intervention and attend school as they usually would.
11340749|NCT02429648|Active Comparator|PVI performed in Normal Sinus Rhythm|DCC first then PVI
11406938|NCT01989520|Experimental|Treatment B|Putative phase III formulation
11340751|NCT02429635|Experimental|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.
~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.
~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
11340752|NCT02429635|Experimental|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.
~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
11340753|NCT02429622|Experimental|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
11340754|NCT02429622|Experimental|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
11340755|NCT02429622|Experimental|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
11340756|NCT02429622|Experimental|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.
~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
11340757|NCT02429609|Experimental|Keratoconic subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)
~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)
~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)
~Anterior eye examination (approx. 4 minutes)
~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)
~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)
~Two measurements of visual acuity will be made:
~Standard ETDRS logMAR acuity measurement (5 minutes)
~Vanishing Optotype logMAR acuity measurement (5 minutes)"
11340758|NCT02429609|Experimental|Healthy subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)
~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)
~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)
~Anterior eye examination (approx. 4 minutes)
~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)
~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)
~Two measurements of visual acuity will be made:
~Standard ETDRS logMAR acuity measurement (5 minutes)
~Vanishing Optotype logMAR acuity measurement (5 minutes)"
11340759|NCT02429596|Experimental|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
11340760|NCT02429596|No Intervention|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
11340761|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
11340762|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
11340763|NCT02429570|Experimental|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
11340764|NCT02429557|Experimental|Abdominal compression and placebo pill|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
11340765|NCT02429557|Sham Comparator|Sham abdominal compression and placebo|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
11340766|NCT02429557|Experimental|Abdominal compression and midodrine|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
11340832|NCT02429076|Experimental|Propofol|Subjects in this arm will receive propofol general anesthesia
11340768|NCT02429544|Experimental|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
11340769|NCT02429544|Experimental|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
11340770|NCT02429544|Other|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
11340771|NCT02429531|Experimental|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
11340772|NCT02429531|Experimental|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
11340773|NCT02429518||Miltefosine|Miltefosine: target of 2.5 mg/kg/day for 28 days
11340774|NCT02429505||Miltefosine|Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed >75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
11340775|NCT02429492|Experimental|ALS patients|Patients with amyotrophy lateral sclerosis (ALS)
11340776|NCT02429492|Experimental|Control subjetcs|Neurologically intact subjects sex and age-matched to ALS patients
11340777|NCT02429479|Active Comparator|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
11340778|NCT02429479|Experimental|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
11340779|NCT02429479|Active Comparator|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
11340780|NCT02429479|Experimental|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
11340781|NCT02429466|Experimental|Guadecitabine (SGI-110)|
11340782|NCT02429453|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
11340783|NCT02429453|Experimental|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
11340784|NCT02429440|Experimental|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
11340785|NCT02429440|Active Comparator|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
11340786|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
11340787|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
11340788|NCT02429414|Experimental|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
11340789|NCT02429414|Experimental|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
11340790|NCT02429401|Experimental|Culturally adapted brief intervention|
11340791|NCT02429401|Active Comparator|Non-adapted brief intervention|
11340792|NCT02429388|Experimental|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
11340793|NCT02429388|No Intervention|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
11340794|NCT02429375|Experimental|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
11406939|NCT01989520|Experimental|Treatment C|Slow dissolution variant 1
11340795|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
11340796|NCT02429349|Experimental|Diagnostic Procedure|Surgery - Unilateral surgical removal of ovary, freezing of tissue, post cancer cure autotransplant
11340797|NCT02429323|Active Comparator|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
11340798|NCT02429323|Active Comparator|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
11340799|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
11340800|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
11340801|NCT02429297|Experimental|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
11340802|NCT02429297|Experimental|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
11340803|NCT02429297|Experimental|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
11340804|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
11340805|NCT02429271|Active Comparator|Ticagrelor|1st day 270 mg & from then onwards 180 mg per day
11340806|NCT02429271|Active Comparator|Clopidogrel|1st day 300 mg & from then onwards 75 mg per day
11340807|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
11340808|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
11340809|NCT02429232|Experimental|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
11340810|NCT02429232|Active Comparator|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
11340811|NCT02429219|Active Comparator|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
11340812|NCT02429219|Experimental|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
11340813|NCT02429206|Active Comparator|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
11340814|NCT02429206|Experimental|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
11340815|NCT02429193|Experimental|Abiraterone / enzalutamide|Abiraterone + prednisone; Enzalutamide
11340816|NCT02429180|Experimental|Rehabilitation training|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.
~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals
~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.
~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme
~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
11340817|NCT02429180|No Intervention|Control|Control: treatment as usual plus receipt of a UK Stroke Association booklet on exercise after stroke.
11340818|NCT02429167|Experimental|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
11340819|NCT02429167|Sham Comparator|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
11340820|NCT02429154|Active Comparator|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
11340821|NCT02429154|Other|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
11340822|NCT02429141|Experimental|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
11340823|NCT02429141|Experimental|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
11340824|NCT02429128|Active Comparator|Lean PCOS training|14 weeks exercise training
11340825|NCT02429128|Other|Lean healthy controls|14 weeks exercise training
11340826|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
11340827|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
11340828|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
11340829|NCT02429102|Experimental|Single ascending dose, MT-8554 or Placebo|
11340830|NCT02429102|Experimental|Multiple ascending dose, MT-8554 or Placebo|
11340834|NCT02429063|Experimental|Bright White Light|Participants use the bright white light intervention for 30 minutes upon waking each morning for 60 days.
11340835|NCT02429063|Experimental|Dim Red Light|Participants use the dim red light intervention for 30 minutes upon waking each morning for 60 days.
11340836|NCT02429050|Active Comparator|intervention|sustained release morphine
11340837|NCT02429050|Placebo Comparator|control|placebo
11340838|NCT02429037|Experimental|rAd-p53 plus radiation and chemotherapy|rAd-p53 tumor injection combined with radio- and chemo-therapy.
11340839|NCT02429037|Active Comparator|radiation and chemotherapy|radiation combined with chemotherapy
11340840|NCT02429024|No Intervention|Control|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.
11340841|NCT02429024|Experimental|Intervention|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.
11340842|NCT02429011||MDD|patients with current MDD
11340843|NCT02429011||Healthy Control (HC)|healthy control volunteers
11340844|NCT02428998|Experimental|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
11340845|NCT02428998|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
11340846|NCT02428985||Riociguat|Riociguat treatment group
11340847|NCT02428972|Experimental|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
11340848|NCT02428972|Active Comparator|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
11340849|NCT02428959|Experimental|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
11340850|NCT02428946|Active Comparator|Morning bromocriptine|Bromocriptine is taken in the morning
11340851|NCT02428946|Active Comparator|Evening bromocriptine|Bromocriptine is taken in te evening
11340852|NCT02428933|Other|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
11340853|NCT02428920|Experimental|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
11340854|NCT02428920|No Intervention|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
11340855|NCT02428894||LVAD recipients|
11340856|NCT02428881|Experimental|Complete retention- onabotulinumtoxinA|Women in complete urinary retention receiving onabotulinumtoxinA
11340857|NCT02428881|Experimental|Obstructed voiding- onabotulinumtoxinA|Women with obstructed voiding receiving onabotulinumtoxinA
11340858|NCT02428868|Experimental|Tranexamic acid - intravenous iron|"IV iron (Ferroven®) : 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
~IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later."
11340859|NCT02428868|Active Comparator|Tranexamic acid|IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.
11340860|NCT02428868|Placebo Comparator|Placebo|20 mL saline, in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
11340861|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen
~Dasatinib, oral, daily, predetermined dosage per cycle
~Radiologic Response Assessment every 2 cycles"
11340862|NCT02428842|Other|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.
~Blood and tumor sampling will also be performed at disease progression/relapse."
11340863|NCT02428829|Experimental|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
11340864|NCT02428829|Active Comparator|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
11340865|NCT02428816|Experimental|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
11340866|NCT02428816|Experimental|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
11340867|NCT02428790||ABI Patients|Patients with acquired brain injury.
11340868|NCT02428777|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
11340869|NCT02428777|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
11340870|NCT02428777|Placebo Comparator|Placebo|Women will receive an oral placebo 1 hour before the procedure
11340871|NCT02428764|Experimental|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
11340872|NCT02428751|Active Comparator|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
11344609|NCT02404480|Experimental|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
11340873|NCT02428751|Experimental|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
11340874|NCT02428725|Experimental|Acute coronary syndrome patient|Acute coronary syndrome patient undergoing PCI and eligible for ticagrelor therapy according to the guidelines accepting blood samples measuring platelets reactivity
11340875|NCT02428712|Experimental|PLX8394|"Group A: Phase 1-Dose Escalation: Adult patients.
~Phase 2a-RP2D Confirmation/Redefinition (Formulation 2): Adult and adolescent patients.
~Phase 2a-Dose Extension: Adult and adolescent patients with advanced unresectable solid tumors will be enrolled among two cohorts.
~Cohort 1: Activating BRAF V600 mutations (glioma patients only)
~Cohort 2: Activating BRAF non-V600 mutations
~Group B: Phase 1-Dose Escalation: Pediatric patients. Enrollment to Group B is closed.
~Phase 2a-Dose Extension: Pediatric patients with advanced unresectable BRAF-mutated tumors, including LCH. As of Protocol Amendment 10, enrollment to Group B is closed."
11340876|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
11340877|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
11340878|NCT02428686|Experimental|epoetin beta|
11340879|NCT02428673|Other|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
11340880|NCT02428660|Other|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
11340881|NCT02428660|Experimental|Group 1|MTM + software-based drug & gene interaction risk analysis + pharmacogenetic testing
11340882|NCT02428660|Active Comparator|Group 2|MTM + software-based drug & gene interaction risk analysis only
11340883|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
11340884|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
11340885|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
11340886|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
11340887|NCT02428634|Experimental|Program SI! for Elementary 6 levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. The intervention is implemented during all the elementary levels (PSIE13+PSIE46).
11340888|NCT02428634|No Intervention|Normal curriculum|The schools on the control group keep their normal curriculum and don't join any school program about health until the end of the study.
11340889|NCT02428634|Experimental|Program SI! for Elementary first levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the first three levels (PSIE13).
11340890|NCT02428634|Experimental|Program SI! for Elementary last levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the last three levels (PSIE46).
11340891|NCT02428621|Experimental|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
11340892|NCT02428621|Active Comparator|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
11340893|NCT02428621|No Intervention|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
11340894|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
11340895|NCT02428595|Experimental|Treatment|Eclipse™ System
11340896|NCT02428582|Active Comparator|bare stent inserted|Standard bare stent will be placed
11340897|NCT02428582|Experimental|Covered stent inserted|Covered stent will be placed
11340898|NCT02428569|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
11340899|NCT02428569|Experimental|PREPARED Decision Support|Participants randomized to this arm of the study will receive the PREPARED educational book and video.
11340900|NCT02428556|Active Comparator|Facts only|"Scenario describes study results without breakthrough language, promising language, no cautions about conditional approval"
11344610|NCT02404480|Experimental|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
11340901|NCT02428556|Active Comparator|promising language|"study description describes drug as promising; no warning about conditional approval"
11340902|NCT02428556|Active Comparator|"breakthrough with may warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
11340903|NCT02428556|Active Comparator|"breakthrough with is warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
11340904|NCT02428556|Experimental|breakthrough only|"Scenario describes study results with breakthrough language, no cautions about conditional approval"
11340905|NCT02428543|Experimental|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
11340906|NCT02428517||Young/MSD|Patients who are <55 years old, and will receive alloHCT for Young/MSD
11340907|NCT02428517||Young/MUD&FMD|Patients who are <55 years old, and will receive alloHCT for Young/MUD&FMD
11340908|NCT02428517||Old/MSD|Patients who are >=55 years old, and will receive alloHCT for Old/MSD
11340909|NCT02428517||Old/MUD&FMD|Patients who are >=55 years old, and will receive alloHCT for Old/MUD&FMD
11340910|NCT02428504||End of life decision|
11340911|NCT02428491|Experimental|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
11340912|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
11340913|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
11340914|NCT02428465|Experimental|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
11340915|NCT02428465|No Intervention|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
11340916|NCT02428452|Experimental|Treatment|Six-month Social ABCs parent-training program received immediately
11340917|NCT02428452|No Intervention|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
11340918|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
11340919|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
11340920|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
11340921|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
11340922|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
11340923|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
11340924|NCT02428400|Experimental|TG1050|"TG1050 SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~TG1050 Part B cohort, dose(s) and schedule to be determined"
11340925|NCT02428400|Placebo Comparator|Placebo|"Placebo SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles
~Placebo Part B cohort, dose(s) and schedule to be determined"
11340926|NCT02428387|Experimental|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
11340927|NCT02428387|No Intervention|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
11340928|NCT02428374|Active Comparator|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
11340929|NCT02428374|Active Comparator|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
11340930|NCT02428374|Active Comparator|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
11340931|NCT02428374|Active Comparator|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
11340932|NCT02428361|Experimental|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
11340933|NCT02428348|Experimental|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
11340934|NCT02428322|Experimental|Intervention|2,000iu vitamin D3 per day for 15 weeks
11340935|NCT02428322|Placebo Comparator|Placebo|An identical placebo capsule daily for 15 weeks.
11340936|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
11340937|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
11340938|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
11341332|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
11340939|NCT02428296|Experimental|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
11340940|NCT02428283|Experimental|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
11340941|NCT02428283|Active Comparator|Control|Remifentanil was administered intravenously.
11340942|NCT02428270|Experimental|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.
~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
11340943|NCT02428257|Experimental|hypobaric|continuous spinal anesthesia with 2,5 mg boluses of hypobaric bupivacaine, prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
11340944|NCT02428257|Active Comparator|isobaric|continuous spinal anesthesia with 2,5 mg boluses of 0.5% isboaric bupivacaine
11340945|NCT02428244|No Intervention|Arm 1, Control|Standard of care intervention: All patients at the University as a standard of care receive informational materials about smoking cessation. They are referred to the patient resource center at our institution. Patients will be provided this, also they will be provided with a smoking cessation Quitline Brochure
11340946|NCT02428244|Experimental|Standard of care + brief counseling|Patients who are randomized into this arm will receive the standard of care (outlined above). Additionally, patients will also receive a smoking education/counseling session. Patients will receive 10-30 minutes of guided discussion regarding the risks and benefits with regards to smoking and the healing of their traumatic injuries. The smoking educators, who will be trained in accordance with the guidelines provided by MdQuit.org will utilize motivational interviewing techniques to enhance interest in quitting. Patients will receive a description of the quitline, and the quitlined will be the recommended resource. If patients elect to enroll in the quitline, they will be consented using the standardized quitline protocols.
11340947|NCT02428244|Experimental|Standard of care + counseling/follow-up|"Patients who are randomized into this arm will receive the same intervention as patients in Arm 2, except when patients arrive for their follow-up, the smoking educator will check-in with their progress for approximately 5 minutes. The techniques utilized during this check-in visit will include repetition of previously described motivational interviewing, at this point patients who elect to be referred to the quitline will be given this opportunity."
11340948|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
11340949|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
11340950|NCT02428218|Experimental|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
11340951|NCT02428218|Experimental|Placebo|Participants will receive matching placebo capsule(s) taken orally.
11340952|NCT02428205|Experimental|Propranolol arm|Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing > 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing < 15 kg will be excluded for safety reasons.
11340953|NCT02428205|Placebo Comparator|Placebo arm|Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
11340954|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
11340955|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11340956|NCT02428179||Control group without Study intervention|Control group without Study intervention
11340957|NCT02428179||Group with Study intervention|Group with Study intervention
11340958|NCT02428153|Experimental|cases|static and dynamic stretching exercises
11340959|NCT02428140|Experimental|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
11340960|NCT02428140|Experimental|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
11340961|NCT02428127|Experimental|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
11340962|NCT02428127|Active Comparator|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
11340963|NCT02428127|Placebo Comparator|Control|200mL lukewarm water given twice a day
11340964|NCT02428114||5 days of filgrastim|Standard of care
11340965|NCT02428114||7 days of filgrastim|Standard of care
11340966|NCT02428114||10 days of filgrastim|Standard of care
11340967|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
11340968|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
11340969|NCT02428088|Placebo Comparator|Placebo|Placebo
11340970|NCT02428075|Experimental|FCHV visit-normotensive|
11340971|NCT02428075|No Intervention|FCHV no visit-normotensive|
11340972|NCT02428075|Experimental|FCHV visit-prehypertensive|
11340973|NCT02428075|No Intervention|FCHV no visit-prehypertensive|
11340974|NCT02428075|Experimental|FCHV visit-hypertensive|
11340975|NCT02428075|No Intervention|FCHV no visit-hypertensive|
11340976|NCT02428062|No Intervention|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
11406940|NCT01989520|Experimental|Treatment D|Slow dissolution variant 2
11340977|NCT02428062|Experimental|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
11340978|NCT02428062|No Intervention|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
11340979|NCT02428049||Lung cancer patients|Lung cancer patients in stages IA-IIIA destined to have stereotactic or conventional radiotherapy and chemotherapy in curative intent
11340980|NCT02428049||Control group|COPD patients
11340981|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
11340982|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
11340983|NCT02428023||GrThalasaemia|estimation of IMT of the carotides arteries and calcium scoring
11340984|NCT02428023||GrNormal|estimation of IMT of the carotides arteries and calcium scoring
11340985|NCT02428010|Experimental|Treatment|TMVR Implant
11340986|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
11340987|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
11340988|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
11340989|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
11340990|NCT02427984||Controls|Patients free from hip devices
11340991|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
11340992|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
11340993|NCT02427958|Experimental|Leuprorelin|Participants with body weight greater than or equal to (>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
11340994|NCT02427945|Experimental|Control|Provision of information on safe water
11340995|NCT02427945|Experimental|Treatment traditional|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.
11340996|NCT02427945|Experimental|Treatment couple|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old, and her husband.
11340997|NCT02427932||Pregnant/Ampicillin|pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus
11340998|NCT02427932||Non-pregnant/Ampicillin|non-pregnant participants who will receive Ampicillin for a qualifying hospital admission
11340999|NCT02427932||Pregnant and Non-pregnant/Ampicillin and Gentamicin|pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission
11341000|NCT02427932||Non-Pregnant/Gentamicin|non-pregnant participants who will receive Gentamicin for a qualifying hospital admission
11341001|NCT02427919|Experimental|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7~D+10 when blasts disappear from peripheral blood smear.
~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.
~Intervention type : Drug Intervention name : G-CSF (Filgrastim)
~-> Comparison of the effect of G-CSF (Filgrastim) use"
11341002|NCT02427919|Active Comparator|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.
~Intervention type : Drug Intervention name : G-CSF (Filgrastim)
~-> Comparison of the effect of G-CSF (Filgrastim) use"
11341003|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
11341004|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
11341005|NCT02427893|Active Comparator|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
11341006|NCT02427893|Active Comparator|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
11341007|NCT02427880|Experimental|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
11341008|NCT02427880|Active Comparator|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
11341009|NCT02427867|Experimental|remote ischemic preconditioning|Three cycles of 5 minutes ischemia will be applied to the upper left arm (or right arm or legs if the left arm will not be deemed suitable by the attending physician), achieved by inflation of a blood-pressure cuff to 200 mm Hg, followed by 5 minutes reperfusion while the cuff will be deflated.
11341010|NCT02427867|Placebo Comparator|no ischemic preconditioning|The cuff will be placed around the arm but not inflated.
11341551|NCT02424305|Experimental|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
11341011|NCT02427854|No Intervention|No training|Incidence of obstetric perineal injuries in the participating hospitals before implementation of the manual perineal protection method.
11341012|NCT02427854|Active Comparator|Education by animated training video|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video only.
11341013|NCT02427854|Active Comparator|Interactive hands on bedside training|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video and additionally by an interactive hands-on bedside training.
11341014|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.
~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.
~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
11341015|NCT02427828|Active Comparator|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
11341016|NCT02427828|No Intervention|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
11341017|NCT02427802|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
11341018|NCT02427802|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
11341019|NCT02427802|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
11341020|NCT02427789|No Intervention|Control|In this group patients will not have physical exercises
11341021|NCT02427789|Active Comparator|Physical Exercise|In this group patients will make physical exercise
11341022|NCT02427776|Experimental|IMP|
11341023|NCT02427763|Active Comparator|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours
~Interventions:
~hours of use
~collect biofilm
~collect saliva
~collect epithelium"
11341024|NCT02427763|Active Comparator|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours
~Interventions:
~hours of use
~collect biofilm
~collect saliva
~collect epithelium"
11341025|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
11341026|NCT02427737|Experimental|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
11341027|NCT02427737|No Intervention|Control|MRI sites not trained in Comfort Talk®.
11341028|NCT02427724|Active Comparator|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
11341029|NCT02427724|Active Comparator|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
11341030|NCT02427724|Placebo Comparator|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
11341031|NCT02427711|Active Comparator|Bipolar sealer|Prospective use of bipolar sealer for skin and knee capsule incision revisions of non-septic knee arthroplasty.
11341032|NCT02427711|Placebo Comparator|Scalpel|Conventional surgical incision with scalpel - data extracted from a retrospective group.
11341033|NCT02427698|Active Comparator|cyrolipolysis|
11341034|NCT02427698|Active Comparator|cryolipolysis plus subcision|
11341035|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
11341036|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
11341037|NCT02427659|Other|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
11341038|NCT02427659|Other|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
11341039|NCT02427659|Other|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
11341040|NCT02427646|Experimental|ET BoNT-A treatment|ET participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
11344611|NCT02404480|Experimental|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
11341041|NCT02427646|Experimental|PD tremor BoNT-A treatment|PD participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
11341042|NCT02427633|No Intervention|Control|Randomized to standard care (control group) - observations only
11341043|NCT02427633|Experimental|UKRC 1997|Randomized to modified UKRC 1997 - Intervention and Observations
11341044|NCT02427633|Experimental|UKRC 2010|Randomized to modified UKRC 2010 - Intervention and Observations
11341045|NCT02427620|Experimental|Treatment (ibrutinib, rituximab, consolidation chemotherapy)|"PART I (IBRUTINIB PLUS RITUXIMAB): Patients receive ibrutinib PO QD on days 1-28 and rituximab IV over 6-8 hours on days 1, 8, 15, and 22 of cycle 1 and then over 4 hours on day 1 of cycles 3-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve complete response.
~PART II (CONSOLIDATION THERAPY): Patients receive rituximab IV over 6 hours on day 1; dexamethasone PO or IV on days 1-4; cyclophosphamide IV over 3 hours BID on days 2-4; doxorubicin hydrochloride IV over 15-30 minutes on day 5; and vincristine sulfate IV over 15-30 minutes on day 5 of cycles 1, 3, 5, and 7. Patients also receive rituximab IV over 6 hours on day 1; methotrexate IV over 24 hours on day 2; and cytarabine IV over 2 hours BID on days 3 and 4 of cycles 2, 4, 6, and 8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
11341046|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
11341047|NCT02427594|Experimental|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
11341048|NCT02427594|Experimental|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
11341049|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.
~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.
~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
11341050|NCT02427568|Placebo Comparator|Placebo|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by supplement half the size of the initial dose.
11341051|NCT02427568|Active Comparator|MDMA|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.25 to 2.5 hours later by a supplemental dose of 62.5 mg MDMA.
11341052|NCT02427555|Experimental|Barley kernel bread|
11341053|NCT02427555|Sham Comparator|Whit wheat flour bread|
11341054|NCT02427542|Active Comparator|CBT for DP|Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
11341055|NCT02427542|Placebo Comparator|Treatment as usual|Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
11341056|NCT02427529|Experimental|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
11341057|NCT02427529|Placebo Comparator|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
11341058|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
11341059|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
11341060|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
11341061|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
11341062|NCT02427490|Active Comparator|Unenhanced Monitoring|Family caregivers of cancer patients receiving outpatient palliative care will complete standardized questionnaires at the time of study enrollment and two, four, and eight weeks after study enrollment.
11341063|NCT02427490|Experimental|Problem-Solving Intervention|Family caregivers of cancer patients receiving outpatient palliative care will use videoconferencing tools to participate in three problem-solving sessions with a member of the research team.
11341064|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
11341065|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
11341154|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
11341066|NCT02427464|Experimental|VM202|"Subjects randomized to the VM202 treatment arm will receive the following intramuscular injections in each calf:
~Day 0 - 16 injections of 0.5mL of VM202 / calf
~Day 14 - 16 injections of 0.5mL of VM202 / calf
~Day 90 - 16 injections of 0.5mL of VM202 / calf
~Day 104 - 16 injections of 0.5mL of VM202 / calf"
11341067|NCT02427464|Placebo Comparator|Placebo|"Subjects in the placebo control group will receive the following intramuscular injections in each calf:
~Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf
~Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf
~Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf
~Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
11341068|NCT02427451|Experimental|Treatment (obinutuzumab, ibrutinib, Bcl-2 inhibitor GDC-0199)|Patients receive obinutuzumab IV on day 1 (days 1, 2, 8, and 15 for course 1 only) every 28 days for up to 8 courses. Beginning in course 2, patients receive ibrutinib PO QD on days 1-28. Beginning in course 3, patients receive Bcl-2 inhibitor GDC-0199 PO QD on days 1-28. Treatment repeats every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
11341069|NCT02427438|Active Comparator|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
11341070|NCT02427438|Active Comparator|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
11341071|NCT02427425|Experimental|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
11341072|NCT02427425|Placebo Comparator|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
11341073|NCT02427412|Active Comparator|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
11341074|NCT02427412|Placebo Comparator|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
11341075|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
11341076|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
11341077|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
11341078|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
11341079|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
11341080|NCT02427386|Active Comparator|dynamized estrogen in alcohol solution|Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
11341081|NCT02427386|Placebo Comparator|placebo (alcohol solution)|This arm received alcohol solution during the 24-week study duration.
11341082|NCT02427373|Active Comparator|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
11341083|NCT02427373|Active Comparator|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
11341084|NCT02427373|Active Comparator|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
11341085|NCT02427347|Experimental|Intervention group|Intervention including acupuncture treatment and healthy education.
11341086|NCT02427347|Other|Control group|Healthy education is given as a baseline treatment.
11341087|NCT02427334|Active Comparator|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
11341088|NCT02427334|Active Comparator|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
11341089|NCT02427334|Placebo Comparator|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
11341155|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
11341090|NCT02427321||Cystoscopy cohort|"Video recording of flexible cystoscopic examination. All participants enrolled on the study will have video from their flexible cystoscopic examination recorded.
~Diagnosis and pathology information will be collected from the participants medical notes for a period of eight weeks following the recorded cystoscopy."
11341091|NCT02427308||miltefosine patients that become pregnant|
11341092|NCT02427295|Experimental|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 >600 ng/ml
~medical treatment : Sandostatin (Octreotide Acetate)"
11341093|NCT02427295|No Intervention|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
11341094|NCT02427295|No Intervention|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation
~and IGF-1 <600ng/ml"
11341095|NCT02427282|Active Comparator|MS. Frog|miniscrew-supported frog molar distalizing appliance
11341096|NCT02427282|Experimental|Stand. Frog|Standard Frog appliance
11341097|NCT02427269||Barrett's Esophagus (BE) Surveillance|Patients who have never received ablative therapy for Barrett's Esophagus and are receiving routine care surveillance upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
11341098|NCT02427269||Barrett's Esophagus (BE) Pre-Ablation|Patients who are receiving routine care upper endoscopy with ablative therapy for their Barrett's Esophagus for the first time. Subjects will have esophageal biopsies, blood, and data collected for this study.
11341099|NCT02427269||Barrett's Esophagus (BE) Post-Ablation|Patients with a history of Barrett's Esophagus who are status post ablation and are receiving routine care follow-up EGD for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
11341100|NCT02427269||Esophageal Cancer(ECA/IMC)|Patients with esophageal cancer who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
11341101|NCT02427269||Squamous Cell Carcinoma (SCC)|Patients with squamous cell cancer of the esophagus who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
11341102|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
11341103|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
11341104|NCT02427256||Pathologic Adults age 29-80 yrs|
11341105|NCT02427243|Experimental|Crenezumab Formulation 2|A single dose given as two subcutaneous injections on Day 1
11341106|NCT02427243|Experimental|Crenezumab Formulation 3|A single dose given as two subcutaneous injections on Day 1
11341107|NCT02427230|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training daily during 12 weeks.
11341108|NCT02427230|Active Comparator|PFMT and electrical stimulation|Pelvic floor muscle training and intravaginal neuromuscular electrical stimulation daily during 12 weeks.
11341109|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
11341110|NCT02427191|Experimental|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
11341111|NCT02427191|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
11341112|NCT02427178|Experimental|Open label|"Hematopoietic allogeneic stem cells will be transplanted:
~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
11341113|NCT02427165|Placebo Comparator|Placebo|Single dose of nebulised placebo solution
11341114|NCT02427165|Experimental|RPL554 Dose 1|0.4 mg single dose nebulised RPL554
11341115|NCT02427165|Experimental|RPL554 Dose 2|1.5 mg single dose nebulised RPL554
11341116|NCT02427165|Experimental|RPL554 Dose 3|6 mg single dose nebulised RPL554
11341117|NCT02427165|Experimental|RPL554 Dose 4|24 mg single dose nebulised RPL554
11341118|NCT02427165|Active Comparator|Salbutamol Dose 1|2.5 mg single dose nebulised salbutamol
11341119|NCT02427165|Active Comparator|Salbutamol Dose 2|7.5 mg single dose nebulised salbutamol
11341120|NCT02427152||Lean|body mass index: 18-25 kg/m²
11341121|NCT02427152||Overweight/Obese|body mass index: >25 kg/m²
11341122|NCT02427139|Experimental|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.
~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
11341123|NCT02427126|Experimental|Apixaban|Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake
11341124|NCT02427126|Active Comparator|Aspirin|Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake
11341125|NCT02427113|Active Comparator|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
11341126|NCT02427113|Active Comparator|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
11341127|NCT02427100|No Intervention|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
11341128|NCT02427100|Active Comparator|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
11341156|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
11341129|NCT02427087|Active Comparator|Continuous Aerobic training|Aerobic training continuous (n=19 patients) carry a protocol continuous aerobic training twice a week for 24 weeks and the session will last 60 minutes/2 days/week with recommendation for healthy diet.
11341130|NCT02427087|Active Comparator|Healthy diet|Diet group (n=21 patients) only recommendation for healthy diet.
11341131|NCT02427074|Active Comparator|Balloon Compression Rhizotomy|Patients that are submitted to Balloon Compression Rhizotomy
11341132|NCT02427074|Active Comparator|Radiofrequency Thermal Coagulation Rhizotomy|Patients that are submitted to Radiofrequency Thermal Coagulation Rhizotomy
11341133|NCT02427061|Experimental|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.
~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
11341134|NCT02427061|Active Comparator|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.
~The control intervention focuses on job skills development."
11341135|NCT02427048|No Intervention|Pre-Intervention|Delayed feedback and peer comparison
11341136|NCT02427048|Experimental|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
11341137|NCT02427035|Experimental|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
11341138|NCT02427035|Experimental|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
11341139|NCT02427022|Experimental|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
11341140|NCT02427022|Active Comparator|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
11341141|NCT02427009|Experimental|The study population|"The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.
~Intervention: Prone position for 1 hour after blood patch"
11341142|NCT02426996|Experimental|Study population|"The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.
~Intervention: Scan of shoulder"
11341143|NCT02426983|Active Comparator|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
11341144|NCT02426983|Sham Comparator|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
11341145|NCT02426983|Active Comparator|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
11341146|NCT02426983|Placebo Comparator|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
11341147|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
11341148|NCT02426957|Experimental|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
11341149|NCT02426957|No Intervention|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
11341150|NCT02426944|Experimental|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
11341151|NCT02426944|Experimental|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
11341152|NCT02426931|Experimental|tf-URS|Participants in tf-URS group undergo ureteroscopy using the tip-flexible ureterorenoscope.
11341153|NCT02426931|Active Comparator|f-URS|Participants in f-URS group undergo ureteroscopy using the classic flexible ureteroscope.
11341159|NCT02426892|Experimental|ISA101 + Nivolumab|"HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
~Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose.
~There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond."
11341160|NCT02426879|Other|surgery|esophagectomy with three-field lymphnode dissection
11341161|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
11341162|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
11341163|NCT02426853|Experimental|Group 1 - UV Photography Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds. At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
11341164|NCT02426853|Active Comparator|Group 2 - Comparison Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
11341165|NCT02426840|Experimental|High dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily plus vitamin D2 (20,000 IU/cap) administered once weekly (a total of 1,200 mg of elemental calcium and 3,200 IU of vitamin D daily)
11341166|NCT02426840|Active Comparator|Normal dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily (a total of 1,200 mg of elemental calcium and 400 IU of vitamin D daily)
11341167|NCT02426827|Experimental|SCS in CV|
11341168|NCT02426814|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.
~Intervention: inhaler sensor"
11341169|NCT02426814|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.
~Interventions: inhaler sensor and mobile application for asthma adherence"
11341170|NCT02426801|No Intervention|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
11341171|NCT02426801|Sham Comparator|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.
~Intervention: inhaler sensor"
11341172|NCT02426801|Experimental|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).
~Interventions: inhaler sensor and mobile application for asthma adherence"
11341173|NCT02426788|Experimental|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):
~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
11341174|NCT02426788|No Intervention|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
11341175|NCT02426775|No Intervention|Methylmalonic Acidemia Control Arm|patients with Methylmalonic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
11341176|NCT02426775|Experimental|Methylmalonic Acidemia Active arm|patients with Methylmalonic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
11341177|NCT02426775|No Intervention|Propionic Acidemia Control Arm|patients with Propionic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and biotin)
11341178|NCT02426775|Experimental|Propionic Acidemia Active arm|patients with Propionic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and biotin)
11341179|NCT02426762|Experimental|Sealant skin closure|A quick skin sealant would be applied after laparoscopic surgery. All abdominal wounds are sealed by smearing the quick sealant (skin adhesive) twice. No additional gauges should be appended on wound areas. No further wound care should be applied unless any effusion or bleeding emerged around it.
11341180|NCT02426749|Active Comparator|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
11341181|NCT02426749|Sham Comparator|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
11341182|NCT02426736|Active Comparator|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11341183|NCT02426736|Active Comparator|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11341184|NCT02426736|Active Comparator|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11341185|NCT02426736|Active Comparator|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
11341186|NCT02426723|Experimental|CWP232291|"Phase 1a: single administration of CWP232291 ,
~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
11341187|NCT02426710|Experimental|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
11341188|NCT02426710|Active Comparator|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
11341189|NCT02426697|Experimental|Pecfent|Patients will receive 100 µg of transmucosal Pecfent before radiotherapy session (or 200 µg in patients with a stable opioid background pain treatment)
11341190|NCT02426697|Placebo Comparator|Placebo|Patients will receive 100 µg of transmucosal placebo before radiotherapy session or 200 µg in patients with a stable opioid background pain treatment)
11341191|NCT02426684|Experimental|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
11341192|NCT02426671|Experimental|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
11341193|NCT02426658|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
11341194|NCT02426632|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
11341195|NCT02426632|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
11341196|NCT02426632|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
11341197|NCT02426632|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
11341198|NCT02426632|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
11341199|NCT02426632|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
11341200|NCT02426632|Experimental|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
11341201|NCT02426632|Experimental|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
11341202|NCT02426632|Experimental|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
11341203|NCT02426632|Experimental|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
11341204|NCT02426632|Experimental|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
11341205|NCT02426632|Experimental|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
11341206|NCT02426619|Experimental|SDF regular|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush regularly once a year
11341207|NCT02426619|Experimental|SDF intensive|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
11341208|NCT02426619|Active Comparator|NaF varnish|3 applications of a 5% NaF varnish will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
11341209|NCT02426606|Experimental|White bread|
11341210|NCT02426606|Experimental|Lentil 1 + white rice|
11341211|NCT02426606|Experimental|Lentil 2 + white rice|
11341212|NCT02426606|Experimental|Lentil 3 + white rice|
11341213|NCT02426606|Experimental|White rice|
11341214|NCT02426606|Experimental|Lentil 1 + potato|
11341215|NCT02426606|Experimental|Lentil 2 + potato|
11341216|NCT02426606|Experimental|Lentil 3 + potato|
11341217|NCT02426606|Experimental|Potato|
11341218|NCT02426593||Subjects without heart failure|
11341219|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
11341220|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
11341221|NCT02426567|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
11341222|NCT02426567|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
11341223|NCT02426554|Active Comparator|Group 1|
11341224|NCT02426554|Placebo Comparator|Group 2|
11341225|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
11341226|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
11341227|NCT02426528|Experimental|Cultural and Social exposure A|Cultural and Social exposure
11341228|NCT02426528|No Intervention|Cultural and Social exposure B|Non Intervention (Control Group)
11341229|NCT02426515|Experimental|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
11341230|NCT02426515|No Intervention|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
11341231|NCT02426502|Experimental|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
11344649|NCT02404259|Other|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
11341232|NCT02426489|No Intervention|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
11341233|NCT02426489|Experimental|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
11341234|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
11341235|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
11341236|NCT02426463|Active Comparator|Propofol|Plasma samples and patient data are collected prospectively from 40 neonates who receive propofol as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
11341237|NCT02426463|Active Comparator|Oxycodone|Plasma samples and patient data are collected prospectively from 40 neonates who receive oxycodone as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
11341238|NCT02426450|Experimental|RFA+FOLFOX4|"RFA:
~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
~Oxaliplatin + 5-Fluorouracil/Leucovorin:
~4 weeks after RFA; Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.
~Repeated every 2 weeks"
11341239|NCT02426437|Other|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
11341240|NCT02426437|Other|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
11341241|NCT02426437|Other|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
11341242|NCT02426424|Experimental|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
11341243|NCT02426424|Experimental|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
11341244|NCT02426411|Experimental|EMA401 200 mg|2 X 50 mg capsules BID
11341245|NCT02426411|Experimental|EMA401 600 mg|2 X 150 mg capsules BID
11341246|NCT02426411|Placebo Comparator|Placebo|Placebo to match 2 capsules BID
11341247|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
11341248|NCT02426398||Healthy volunteers|Healthy volunteers
11341249|NCT02426385||1POD26PFT|Patients implanted with the POD 26% FineVision Toric
11341250|NCT02426385||2POD26PT|Patients implanted with the POD 26% Toric
11341251|NCT02426372|Experimental|QBECO SSI 0.02 mL|0.02 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
11341252|NCT02426372|Experimental|QBECO SSI 0.05 mL|0.05 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
11341253|NCT02426372|Experimental|QBECO SSI 0.1 mL|0.1 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
11341254|NCT02426359|Experimental|Q301 Cream|Q301 Cream
11341255|NCT02426359|Placebo Comparator|Vehicle|Vehicle
11341256|NCT02426346|Active Comparator|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
11341257|NCT02426346|Experimental|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
11341258|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
11341259|NCT02426320|Active Comparator|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
11341260|NCT02426320|Active Comparator|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
11341261|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
11341262|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
11341263|NCT02426294|Experimental|Pioglitazone|Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet. It is administered once-daily with 15mg, with or without meals. The once-daily administration begins with 15mg, and if need increase, researchers can increase up to 30mg at week 12.
11341264|NCT02426294|Active Comparator|Glimepiride|The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
11341265|NCT02426281|Experimental|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
11341266|NCT02426255||ICU patients|Patients with severe trauma (with or without brain injury) or Patients with hemorrhagic shock Data concerning the ICU stay will be collected for these patients
11341267|NCT02426242||ICU PATIENTS|Patients with brain-injury
11341268|NCT02426229|Experimental|dabigatran 75mg|dabigatran etexilate 75mg orally twice daily for 6 months
11341269|NCT02426216||Group A|Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.
11341270|NCT02426216||Group B|Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.
11341271|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
11341272|NCT02426190|Active Comparator|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols. The warm-up phase in the study refers to therapeutic exercise. The therapeutic exercise aims to condition and prepare patients for subsequent functional or therapeutic activities. The active comparator (Arm 1) is to ask participants to use modalities, such as a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
11341273|NCT02426190|Experimental|Arm 2|Patients in Arm 2 will use an anti-gravity treadmill (AlterG) during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
11341274|NCT02426190|Experimental|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
11341275|NCT02426190|Experimental|Arm 4|Patients in Arm 4 will use both an anti-gravity treadmill (AlterG) and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
11341276|NCT02426177|Active Comparator|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
11341277|NCT02426177|Active Comparator|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
11341278|NCT02426164|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
11341279|NCT02426164|Active Comparator|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
11341280|NCT02426151|Experimental|BEPO-A|Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process)
11341281|NCT02426151|Active Comparator|REPO-A|Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process)
11341282|NCT02426138|Experimental|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
11341283|NCT02426138|Active Comparator|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
11341284|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
11341285|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
11341286|NCT02426112|Active Comparator|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.
~10-20 kg: 250 mg
~20-29 kg: 500 mg
~30-39 kg: 750 mg
~40-49 kg: 1250 mg"
11341287|NCT02426112|Placebo Comparator|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.
~10-20 kg: 250 mg
~20-29 kg: 500 mg
~30-39 kg: 750 mg
~40-49 kg: 1250 mg"
11341288|NCT02426099|Experimental|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
11341289|NCT02426099|Active Comparator|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
11341290|NCT02426086|Experimental|Imetelstat 9.4 milligram/kilogram (mg/kg)|Participants will receive imetelstat intravenously as 9.4 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end. Once the end of the main study has been reached, participants who are receiving benefit from study treatment may continue to receive imetelstat during the Extension Phase until there is loss of benefit or unacceptable toxicity, as determined by the investigator according to local standard of care.
11341291|NCT02426086|Experimental|Imetelstat 4.7 mg/kg|Participants will receive imetelstat intravenously as 4.7 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end. Participants will have an option to continue the treatment at the current dose or at an escalated dose of 9.4 mg/kg based on investigator's discretion. Once the end of the main study has been reached, participants who are receiving benefit from study treatment may continue to receive imetelstat during the Extension Phase until there is loss of benefit or unacceptable toxicity, as determined by the investigator according to local standard of care.
11341292|NCT02426073||HE|Healthy elderlies
11341293|NCT02426073||DM|Elderlies with type 2 diabetes
11341294|NCT02426073||SA|Elderlies with sarcopenia
11341295|NCT02426073||DS|Elderlies with both type 2 diabetes and sarcopenia
11341296|NCT02426060|Experimental|Imrecoxib&Warfarin|
11341297|NCT02426047|Experimental|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
11341299|NCT02426021|Experimental|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
11341300|NCT02426021|Experimental|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
11341301|NCT02426021|Experimental|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
11341302|NCT02426021|Experimental|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
11341303|NCT02426021|Experimental|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
11341304|NCT02426021|Experimental|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
11341305|NCT02426021|Experimental|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
11341306|NCT02426021|Experimental|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
11341307|NCT02426021|Experimental|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
11341308|NCT02426021|Experimental|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
11341309|NCT02426008|Experimental|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
11341310|NCT02426008|Placebo Comparator|In Vitro culture media|culture media to monitor the embryological outcome as control group
11341311|NCT02425995|Experimental|Arthroscopic intercondylar and posteromedial portal|
11341312|NCT02425982||Conservative treatment|Patients who will opt conservative treatment or patients treated conservatively by surgeon decision.
11341313|NCT02425982||Operative treatment|Patients who opt for surgery when offered.
11341314|NCT02425969|Experimental|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
11341315|NCT02425969|Active Comparator|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
11341316|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
11341317|NCT02425943|Experimental|Sculptra Aesthetic|
11341318|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
11341319|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
11341320|NCT02425917|Experimental|geko|
11341321|NCT02425917|Active Comparator|ipc-calf|intermittent pneumatic compression of the calf
11341322|NCT02425904|Experimental|1-Recurrent or Refractory LCH|"Participants with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.
~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.
~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
11341323|NCT02425904|Experimental|2-LCH-related disorders|"Participants with LCH-related disorders who require systemic chemotherapy including:
~Participants with RDD who have not responded to or recurred after treatment with corticosteroids. ECD subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.
~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.
~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
11341324|NCT02425891|Experimental|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
11341325|NCT02425891|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
11341326|NCT02425878|Experimental|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
11341327|NCT02425878|Placebo Comparator|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
11341328|NCT02425865|Other|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if > 80 kg
11341329|NCT02425852|Active Comparator|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
11341330|NCT02425852|Active Comparator|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.
~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
11341331|NCT02425839|Experimental|Experimental group|"ultrasound exam by Supersonic Shear Imaging® technique
~EMG examination by electromyograph Keypoint system."
11341333|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
11341334|NCT02425813|Experimental|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.
~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.
~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
11341335|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
11341336|NCT02425787||Parents of deceased children (no BMT)|"Participants will be parents who have lost a child at St. Jude Children's Research Hospital (SJCRH). They will participate in a 60-90 minute interview.
~(Not recruiting)"
11341337|NCT02425787||Parents of deceased children (haploidentical BMT)|Participants will be parents whose child died after receiving a haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
11341338|NCT02425787||Parents of deceased children (non-haploidentical BMT)|Participants will be parents whose child died after receiving a non-haploidentical bone marrow transplant at St. Jude Children's Research Hospital (SJCRH), and who have not previously participated in an interview through this study. They will participate in a 30-90 minute interview.
11341339|NCT02425787||Parents of deceased children (not interviewed)|Participants will be parents who have lost a child at SJCRH, who have not previously participated in an interview through this study.They will participate in a 30-90 minute focus group.
11341340|NCT02425787||Hematology/Oncology Fellows|Participants will be Hematology/Oncology Fellows at SJCRH. They will participate in a 30-90 minute focus group.
11341341|NCT02425787||Legacy-Building|Participants will be parents who have lost a child at SJCRH and received legacy items. They will participate in a 30-90 minute interview.
11341342|NCT02425774|Placebo Comparator|Sham stimulation + Placebo|"no stimulation
~1 placebo tablet at two different timepoints before surgery"
11341343|NCT02425774|Active Comparator|Vagus stimulation + placebo|"Stimulation at the beginning and the end of the surgery
~1 placebo tablet at two different timepoints before surgery"
11341344|NCT02425774|Active Comparator|Prucalopride + sham stimulation|"1 prucalopride tablet at two different timepoints before surgery
~no stimulation"
11341345|NCT02425761|Active Comparator|Anterior Entry SIte|"Anterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the coronal suture, on the top of the head and near the front. Specifically, anterior entry is defined as ventricular catheter entry less than 1 centimeter anterior to the coronal suture near the mid-pupillary line.
~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using an anterior entry site."
11341346|NCT02425761|Active Comparator|Posterior Entry Site|"Posterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the lambdoid suture, on the back of the head. Specifically, posterior entry is defined as ventricular catheter entry 4 to 7 centimeters above the external occipital protuberance (inion), near the mid-pupillary line.
~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using a posterior entry site."
11341347|NCT02425748|Experimental|Group A|DC-CIK cells will be used against tumor cells.
11341348|NCT02425748|Experimental|Group B|γδ T cells will be used against tumor cells.
11341349|NCT02425748|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
11341350|NCT02425735|Experimental|Group A|DC-CIK cells will be used against tumor cells.
11341351|NCT02425735|Experimental|Group B|γδ T cells will be used against tumor cells.
11341352|NCT02425735|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
11341353|NCT02425722|Experimental|ASP0456 0.0625mg|oral
11341354|NCT02425722|Experimental|ASP0456 0.125mg|oral
11341355|NCT02425722|Experimental|ASP0456 0.25mg|oral
11341356|NCT02425722|Experimental|ASP0456 0.5mg|oral
11341357|NCT02425722|Placebo Comparator|Placebo group|oral
11341358|NCT02425709|Active Comparator|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
11341359|NCT02425709|Active Comparator|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
11341360|NCT02425709|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
11341361|NCT02425696||group 1|Normal individuals without migraine
11341362|NCT02425696||group 2|Migraineurs
11341363|NCT02425683|Experimental|Regorafenib|Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
11341364|NCT02425683|No Intervention|Standard of Care (No Treatment)|No study drug (which is the standard care for Stage IIIC colorectal cancer patients after they've received FOLFOX chemotherapy).
11341365|NCT02425670|Experimental|Bone marrow derived stem cells (BMSCs)|BMSCs 30-500 million plus conventional management
11341366|NCT02425670|No Intervention|Control|Control: conventional management
11341367|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
11341368|NCT02425644|Experimental|Ponesimod|Subjects to receive 20 mg ponesimod
11341369|NCT02425644|Active Comparator|Teriflunomide|Subjects to receive 14 mg teriflunomide
11341370|NCT02425605|Experimental|CCRT-sorafenib group|
11341407|NCT02425358|Experimental|BMC therapy within 3-7 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 3-7days after successful primary PCI.
11341371|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) <20, clinical stage <cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
11341372|NCT02425579|Experimental|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
11341373|NCT02425579|Placebo Comparator|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
11341374|NCT02425579|Experimental|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
11341375|NCT02425579|Placebo Comparator|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
11341376|NCT02425566|Experimental|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
11341377|NCT02425566|Experimental|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
11341378|NCT02425553||Faculty and Delegates of Ascona II Meeting|
11341379|NCT02425540||patients with unclassified ovarian mass|
11341380|NCT02425527|Experimental|The rehabilitation gaming|The rehabilitation gaming group (n=30) will use an internet browser-based digital brain training program CogniFit (https://www.cognifit.com), with a selection of about 33 games.The participants will use the rehabilitation gaming for at least 30 min per day over a period of 8 weeks.
11341381|NCT02425527|Active Comparator|The entertaining gaming|The entertaining gaming group (n = 30) will use commercial digital games with Sony Playstation 3 (PS3) consoles, played with wireless Sony DualShock gamepad controllers. The participants will be guided to play the console for at least 30 min per day over a period of 8 weeks
11341382|NCT02425527|No Intervention|"Do-nothing"|"The passive control group Do-nothing group (n = 30) will not have gaming activities organized by the project."
11341383|NCT02425514|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
11341384|NCT02425514|Experimental|NovoMax™|The ACDF surgery will be carried out with NovoMax™, which is the bioactive glass ceramic intervertebral spacer
11341385|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
11341386|NCT02425488|Experimental|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
11341387|NCT02425488|No Intervention|Non NET|People who receive basic information without follow the educational program but clinically controlled
11341388|NCT02425475||Mole|Patients with suspicious moles
11341389|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
11341390|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
11341391|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
11341392|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
11341393|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
11341394|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
11341395|NCT02425436|Active Comparator|Ginkgo Biloba Extract group|This group received Ginko Biloba, two tablets per day
11341396|NCT02425436|Placebo Comparator|Placebo group|This group received placebo two tablets per day .
11341397|NCT02425423|Experimental|New thickened infant formula|
11341398|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
11341399|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
11341400|NCT02425397||patients controls with no signs of ototoxicity|
11341401|NCT02425384|Experimental|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
11341402|NCT02425384|Active Comparator|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
11341403|NCT02425384|Placebo Comparator|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
11341404|NCT02425371|Experimental|Intervention|screening and treatment of comorbidities
11341405|NCT02425371|Placebo Comparator|Control|No screening of comorbidity
11341406|NCT02425358|Experimental|BMC therapy within 24 hours|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 24 hours after successful primary PCI.
11341408|NCT02425358|Experimental|BMC therapy within 7-30 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 7-30days after successful primary PCI.
11341409|NCT02425358|Active Comparator|PCI only|Patients with acute myocardial infarction who were performed successful primary PCI.
11341410|NCT02425345|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
11341411|NCT02425345|No Intervention|Usual Activity Control|Usual activity
11341412|NCT02425332|Experimental|Lokomat assessment|
11341413|NCT02425319||patients with CapFlex-PIP© implant|
11341414|NCT02425319||patients with silicone implant|
11341415|NCT02425319||patients with healthy PIP joints|
11341416|NCT02425306|Experimental|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
11341417|NCT02425306|Experimental|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:
~Day -6 (Cycle 1)
~Day 8 (Cycle 2)
~Day 22 (Cycle 3)
~Day 36 (Cycle 4)
~Day 50 (Cycle 5)"
11341418|NCT02425306|Experimental|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
11341419|NCT02425306|Experimental|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:
~Day -6 (Cycle 1)
~Day 8 (Cycle 2)
~Day 22 (Cycle 3)
~Day 36 (Cycle 4)
~Day 50 (Cycle 5)"
11341420|NCT02425293|Experimental|Intervention|Patients participating in a patient education seminar
11341421|NCT02425293|No Intervention|Control|Patients not participating in a patient education seminar
11341422|NCT02425280|Experimental|Narrative Exposure Therapy|For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
11341423|NCT02425280|Active Comparator|Treatment as Usual|For the TAU control group, participants will receive the usual care for posttraumatic stress symptoms currently offered by each unit.
11341424|NCT02425267|Experimental|Telerehabilitation|Telerehabilitation at home from a clinic
11341425|NCT02425267|Active Comparator|Face-to-face intervention in a clinic|Conventional physiotherapy
11341426|NCT02425254|Experimental|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
11341427|NCT02425254|Active Comparator|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
11341428|NCT02425241|Experimental|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.
~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
11341429|NCT02425241|Placebo Comparator|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.
~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
11341430|NCT02425202|Active Comparator|Ketamine infusion|Ketamine infusion at 0.1 mg/kg/hr up to maximum of 10 mg/hr
11341431|NCT02425202|Placebo Comparator|Saline infusion|Saline infusion
11341432|NCT02425189||LQT Positive (Group 1)|"Gene-positive LQTS patients
~Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
11341433|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
11341434|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:
~Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.
~Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.
~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
11341435|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:
~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.
~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
11341436|NCT02425176|Active Comparator|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:
~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.
~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
11341437|NCT02425163|Active Comparator|suspicious for Prostate Cancer|"PSA >4ng/ml or PSA-Velocity >0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.
~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
11341438|NCT02425150|Experimental|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
11341439|NCT02425150|Active Comparator|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
11341440|NCT02425150|No Intervention|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
11341441|NCT02425150|No Intervention|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
11341442|NCT02425137|Experimental|S-1/Gemcitabine|single-arm
11341443|NCT02425124|Active Comparator|Control|PC101 Enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.
11341444|NCT02425124|Experimental|Intervention|PC101 + Mental Health Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
11341445|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
11341446|NCT02425098|Experimental|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine [HD-TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
11341447|NCT02425098|Experimental|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine [TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^3 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
11341448|NCT02425085|Experimental|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
11341449|NCT02425085|Active Comparator|relaxing retinectomy|Patients receive relaxing retinectomy
11341450|NCT02425072|Experimental|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
11341451|NCT02425059|Experimental|IRE Group|irreversible electroporation for Unresectable Rectal Neoplasms
11341452|NCT02425059|No Intervention|Control|The patients without treatment
11341453|NCT02425046|Experimental|health coaching and community screening|Family Health Coaching and community benefits screening
11341454|NCT02425046|Other|community screening|community benefits screening only
11341455|NCT02425033|Experimental|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
11341456|NCT02425020|Experimental|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
11341457|NCT02425020|Experimental|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
11341458|NCT02425020|Active Comparator|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
11341459|NCT02425007|Experimental|Spiro|Incentive spirometry
11341460|NCT02425007|No Intervention|Control|Control group
11341461|NCT02424981|Experimental|inspiratory muscle training|Muscle training
11341462|NCT02424981|No Intervention|control|Control group
11341463|NCT02424968|Experimental|Treatment (TLI, ATG, transplant, CD8+ memory T-cells)|Patients undergo TLI on days -11 to -7 and -4 to -1 and receive ATG per standard institutional practice on days -11 to -7. Patients also receive cyclosporine PO daily starting on day -3 and will continue for at least 6 months post-transplant. Patients undergo non-myeloablative allogeneic HSCT on day 0. Patients also receive mycophenolate mofetil PO daily beginning on day 0 and continue until day 28. Based on the patient's status after the initial transplant, patients receive CD8+ memory T-cells IV over 10-20 minutes sometime between day 30 and day 60.
11341464|NCT02424955|Experimental|3D Perfusion Ultrasound|undergo 3D ultrasound perfusion imaging with perflutren
11341465|NCT02424942|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
11341466|NCT02424942|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
11341467|NCT02424929|Other|Awake|"Original surgery intervention.
~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
11341468|NCT02424929|Other|Asleep|"Sedation intervention.
~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
11341469|NCT02424916|Experimental|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
11341470|NCT02424903||with prosthetic joint infection|Patients admitted for a septic revision surgery
11341471|NCT02424903||without prosthetic joint infection|Patients admitted for an aseptic revision surgery
11341472|NCT02424890|Active Comparator|Repetitive Sim Group|9 simulation sessions
11341473|NCT02424890|Active Comparator|Control Group|3 simulation sessions
11341474|NCT02424877|Experimental|SandRA|cell phone monitoring
11341475|NCT02424877|No Intervention|Control|conventional monitoring
11341476|NCT02424864|Other|4D PET-CT|Other intervention: 4D PET-CT
11341477|NCT02424851|Active Comparator|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
11341478|NCT02424851|Active Comparator|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
11341479|NCT02424838|Active Comparator|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
11341480|NCT02424838|Active Comparator|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
11341481|NCT02424838|Active Comparator|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
11341482|NCT02424838|Active Comparator|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
11341483|NCT02424825|Experimental|Rouxbe|Subjects will attend a one-month online cooking course, and be followed before, during, and after their participation for quality-of-life, fatigue, and blood biomarker changes.
11341484|NCT02424812|Experimental|Intervention|school based handwashing education programme
11341485|NCT02424812|No Intervention|Control|no intervention
11341486|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
11341487|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
11341488|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
11341489|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
11341490|NCT02424786|Other|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.
~Feedback of this screening will be given to the team responsible for patient treatment."
11341491|NCT02424786|No Intervention|Control|Patients in this arm will receive standard pharmacological treatment
11341492|NCT02424773|Active Comparator|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
11341493|NCT02424773|Experimental|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
11341494|NCT02424747||De Novo Acute Kidney Injury|Patients who developed Acute Kidney Injury during intensive care admission and not previously diagnosed with chronic kidney disease or end stage renal disease.
11341495|NCT02424747||No Acute Kidney Injury.|Intensive care patients not diagnosed with acute kidney Injury during admission and not previously diagnosed with Chronic Kidney Disease or End Stage Renal Disease.
11341496|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
11341497|NCT02424708|Placebo Comparator|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
11341498|NCT02424708|Active Comparator|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
11341499|NCT02424708|Active Comparator|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
11341500|NCT02424695|Experimental|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks
~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
11341501|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
11341502|NCT02424669|Experimental|recently diagnosed ALS patients|
11341503|NCT02424669|Experimental|not recently diagnosed ALS patients|
11341504|NCT02424669|Active Comparator|patients with peripheral neuropathy, recently diagnosed|
11341505|NCT02424656||1|"Patients with TBI and DOC.
~Experimental measures (MRI, TMS-EEG, and clinical scales) will be performed at 4 time points: within 2 weeks of admission, 6-10 weeks after admission, at discharge, 1-year follow-up after TBI episode. FDG-PET will be performed in a subset of 25 patients at 3 time points: at admission, at discharge, and at 1-year follow-up."
11341506|NCT02424656||2|"Healthy patient-matched controls.
~Experimental measures (MRI, TMS-EEG, and FDG-PET) will be performed at 2 time points: within patient admission, and within patient discharge."
11341507|NCT02424643|No Intervention|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
11341508|NCT02424643|Experimental|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
11341509|NCT02424643|Experimental|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
11341510|NCT02424643|Experimental|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
11341511|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
11341512|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
11341513|NCT02424617|Active Comparator|Arm A|designed to determine the maximum dose of BGB324 that can be safely administered in combination with erlotinib administered at the approved oral dose level of 150 mg daily. It is anticipated that a maximum of three BGB324 dose levels will be evaluated, with up to approximately 18 patients enrolled. In the absence of unacceptable toxicity, patients will be allowed to continue receiving BGB324 in combination with erlotinib until disease progression.- (Arm completed)
11341514|NCT02424617|Active Comparator|Arm B|will incorporate a Simon-like two-stage design with relaxed stopping for futility to evaluate the safety, pharmacokinetics and clinical activity of BGB324 in combination with erlotinib in patients with an activating EGFR mutation who have progressed after receiving prior erlotinib.( Open to enrolment)
11341515|NCT02424617|Active Comparator|Arm C|will evaluate the safety, pharmacodynamics and clinical activity of BGB324 when administered in combination with erlotinib in patients with an activating EGFR mutation who have received at least twelve weeks of erlotinib without disease progression.(Open to enrolment)
11341516|NCT02424617|Other|Run in Arm|The primary goal of the Run-in Cohort is to establish the safety and tolerability of BGB324 administered as a single agent. Eligible patients will have either exhausted existing licensed therapies or be unsuitable for treatment with existing licensed therapies for NSCLC. BGB324 will be administered at a loading dose of 600 mg on Day 1 and Day 2 of Cycle 1, followed by 200 mg daily thereafter (Arm completed)
11341517|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
11341518|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
11341519|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
11341520|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
11341521|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
11341522|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
11341523|NCT02424552|Experimental|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
11341524|NCT02424552|Placebo Comparator|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
11341525|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
11341526|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
11341527|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
11341528|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
11341529|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
11341530|NCT02424513|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
11341531|NCT02424500|Experimental|d-Nav Device|"d-Nav Device: daily use to provide insulin dosage updates weekly - or sooner when needed based on analyzes and evaluates the historical blood glucose patterns.
~Insulin dosage is adjusted as required"
11341532|NCT02424500|Active Comparator|Blood Glucose Monitoring System|"Patient's personal Over the Counter Blood Glucose Monitoring System (OTC BGMS) for daily glucose testing to determine insulin dosage needed.
~Insulin dosage is adjusted as required"
11341533|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
11341534|NCT02424474|Experimental|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
11341535|NCT02424461|Active Comparator|7 day-antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days
~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days
~Placebo of ofloxacine for 7 days"
11341536|NCT02424461|Active Comparator|14-day antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days
~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
11341537|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
11341538|NCT02424435|Experimental|Methylprednisolone|This is an open-label study of methylprednisolone in patients with FRDA. Subjects will begin oral administration of 48 mg methylprednisolone at day 1 and will decrease their administered dose by 8 mg per day. After 6 days, subjects will spend 22 days off medication before repeating the same treatment cycle. Last dosing cycle of methylprednisolone will be administered at 24 weeks after baseline. Visits will occur at weeks 2, 6, 14, 26, and 30 following baseline.
11341539|NCT02424409|Active Comparator|1: Control|
11341540|NCT02424409|Experimental|2: Intervention|
11341541|NCT02424396|Experimental|1 : IL2|Interleukin-2 (ILT-101)
11341542|NCT02424396|Placebo Comparator|2 : Placebo|Placebo
11341543|NCT02424383|Experimental|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
11341544|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
11341545|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
11341546|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
11341547|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
11341548|NCT02424331|Experimental|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
11341549|NCT02424318|Experimental|Topiramate|topiramate 25mg twice for 1 week -> topiramate 50mg twice for 7 weeks
11341550|NCT02424305|Experimental|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
11341552|NCT02424305|Experimental|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
11341553|NCT02424292||Physical activity|Physical activity in a personalised program
11341554|NCT02424279|Active Comparator|Surgical treatment|Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
11341555|NCT02424279|No Intervention|Conservative Treatment|Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
11341556|NCT02424266||Healthy subjects|None invasive imaging of the tear film for subjects with no eye disease
11341557|NCT02424266||keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)|None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
11341558|NCT02424253|Experimental|ZPL-3893787|30mg once daily
11341559|NCT02424253|Placebo Comparator|Placebo|Once daily
11341560|NCT02424240||IGF-I/ IGFBP-3 ratio group|
11341561|NCT02424240||IGF-1 and IGFBP-3|
11341562|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
11341563|NCT02424214|Experimental|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
11341564|NCT02424214|Experimental|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
11341565|NCT02424214|No Intervention|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
11341566|NCT02424201|Experimental|study|Intramuscular oxytocin 10 units, 400 micrograms of misoprostol
11341567|NCT02424201|Other|control|Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c
11341568|NCT02424188|Experimental|TRIUMPH intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
11341569|NCT02424188|No Intervention|Treatment as Usual|referral to quit line
11341570|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
11341571|NCT02424162|Experimental|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
11341572|NCT02424162|Active Comparator|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
11341573|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
11341574|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
11341575|NCT02424136|Other|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
11341576|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
11341577|NCT02424110|Experimental|Argon beam coagulator ablation group|In the bipolar left atrial radiofrequency ablation, when the linear ablation was performed through along the lower edge of interatrial groove incision up to the mitral annulus, there is a gap between the ends of the ablation line and the mitral annulus And in the bipolar right atrial radiofrequency ablation, when the linear ablation was performed along the lower edge of the coronary sinus ostium up to the inferoseptal commissure and through the vertical incision on anterior wall of the right atrium up to the tricuspid annulus. There also have gaps between ends of the ablation line and the tricuspid annulus. In the experimental group the investigators plan to use conventional bipolar radiofrequency ablation and use argon beam coagulator to ablate these gaps.
11341578|NCT02424110|Experimental|Bipolar radiofrequency ablation group|Only use conventional bipolar radiofrequency ablation and do not deal with these gaps.
11341579|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
11341580|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
11341581|NCT02424084|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11341582|NCT02424084|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11341583|NCT02424084|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11341584|NCT02424084|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11341585|NCT02424084|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11344650|NCT02404259|Other|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
11341586|NCT02424071|Active Comparator|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
11341587|NCT02424071|Placebo Comparator|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
11341588|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
11341589|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
11341590|NCT02424045|Other|BCD chemotherapy|"All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).
~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV"
11341591|NCT02424032|Experimental|Exercise and connective tissue massage|Stabilization exercise and connective tissue massage have been applied
11341592|NCT02424032|Active Comparator|Exercise|Only stabilization exercise has been applied
11341593|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
11341594|NCT02424006|Experimental|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
11341595|NCT02424006|Active Comparator|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
11341596|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
11341597|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
11341598|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
11341599|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
11341600|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
11341601|NCT02423967|Active Comparator|Transplant uses fresh familial stool|Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
11341602|NCT02423967|Experimental|Transplant uses frozen anonymous stool|Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
11341603|NCT02423954|Experimental|Arm 1|Temsirolimus 25 mg every 14 days + nivolumab
11341604|NCT02423954|Experimental|Arm 2|Irinotecan 150 mg/m2 every 14 days + nivolumab
11341605|NCT02423954|Experimental|Arm 3|Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
11341606|NCT02423941|Experimental|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
11341607|NCT02423941|Active Comparator|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
11341608|NCT02423928|Experimental|Cryoimmunotherapy|"Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.
~Update January 2019: The protocol was changed as approved by the Norwegian Medicines Agency and the Regional Ethical Committee in Western Norway for the 3 last patients of altogether 18 patients. Consequently, the 3 last patients received 200 mg i.v. of pembrolizumab (and no ipilimumab) post-CryoIT."
11341609|NCT02423915|Experimental|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Mesna administered on Day -8 immediately following completion of the Fludarabine.
~Total body radiation 2 Gy delivered on Day -4.
~3rd party CB Treg infusion on Day -1.
~Three (3) participants treated at cell dose level 1: 1 x 10^6/kg fucosylated T-reg cells. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD transplant on Day 0.
~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
11341628|NCT02423746|Placebo Comparator|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.
~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
11347526|NCT02384551|Active Comparator|HTHS|High total carbohydrate with high total simple carbohydrate diet
11341610|NCT02423915|Experimental|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Total body radiation 2 Gy delivered on Day -4.
~3rd party CB Treg infusion on Day -1.
~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10^7/kg T-reg cells. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD infused on Day 0.
~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
11341611|NCT02423915|Experimental|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Total body radiation 2 Gy delivered on Day -4.
~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD infused on Day 0.
~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
11341612|NCT02423915|Experimental|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
~Fludarabine 40 mg/m2 by vein on Days -8 to -5.
~Cyclophosphamide 50 mg/kg by vein on Day -8.
~Total body radiation 2 Gy delivered on Day -4.
~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.
~Cord blood transplant, MRD, or MUD infused on Day 0.
~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
11341613|NCT02423902|Experimental|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
11341614|NCT02423889|Experimental|1|Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty
11341615|NCT02423876|Experimental|Arm I (epidural placement, ERP)|Patients undergo epidural placement in the First Day Surgery pre-operative area or similar areas suitable for insertion of epidural catheters. In the post-operative anesthesia care unit, patients may receive medication via the epidural on an as needed basis, as determined by the anesthesia team. Dosing and rate of standardized medication will be managed by the anesthesia team until the epidural is removed. Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
11341616|NCT02423876|Active Comparator|Arm II (ERP)|Patients complete the ERP comprising increased activity, dietary restrictions, fluid balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times. Patients will have access to additional pain medications as needed to control their pain.
11341617|NCT02423863|Experimental|Hiltonol Poly-ICLC|"Open labeled, non randomized adaptive 2-stage design protocol. 21 study subjects were enrolled in stage I of the protocol. Up to an additional 60 patients. . Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.
~For purposes of analysis patients enrolled in Stage II of this study will be prospectively identified at initial screening as belonging to statistical Cohorts A, B, or C, which are based on patient status with regard to aPD1/aPDL1 therapy at study entry, (PD, SD, or treatment naïve). For purposes of this study, patient status is considered to be the primary eligibility variable, although sub analyses will also consider histology and particular checkpoint blocker used when possible."
11341618|NCT02423850||Diabetic foot ulcers|Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
11341619|NCT02423824|Active Comparator|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
11341620|NCT02423824|Active Comparator|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
11341621|NCT02423811|Experimental|CCRT plus Fursultiamine|"Fursultiamine 100mg tid, po Radiotherapy 36Gy/18Fx Chemotherapy will include Cisplatin and 5-FU. Cisplatin 60-75 mg/m2 on days 1 and 29 with standard prehydration and antiemetic therapy.
~5-FU 600-1000 mg/m2day administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1 through 4 and 29 through 32"
11341622|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).
~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
11341623|NCT02423772|Experimental|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
11341624|NCT02423772|No Intervention|Treatment as Usual|
11341625|NCT02423759|Active Comparator|ciprofloxacin|standard chemoprophylaxis [500mg ciprofloxacin twice daily for 3 days]
11341626|NCT02423759|Experimental|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis [standard chemoprophylaxis plus 160mg]
11341627|NCT02423759|Experimental|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
11341718|NCT02423083|Experimental|Treatment arm|
11341719|NCT02423070||1|Heart and Lung Transplant patients
11341629|NCT02423746|Experimental|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.
~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
11341630|NCT02423733|No Intervention|Control|In addition to their usual clinical care will also be given written information about web sites that provide information on depression but will not be specifically directed to The Journal.
11341631|NCT02423733|Experimental|Computerized Therapy|In addition to their usual clinical care they will receive an invitation to use The Journal supported by an e-therapy coach who will provide patients with weekly email or telephone contact. The e-therapy coach will have a guideline script for each lesson of The Journal to reinforce the topic of each lesson, help identify and support patients in their goals and to coach them in goal setting and the techniques of problem solving.
11341632|NCT02423720|Other|Study Intervention|Audio-based mindfulness intervention A 8-week single arm pilot study will be conducted among Helen Diller Famiily Comprehensive Cancer Center (HDFCCC) patients with metastatic colorectal cancer receiving chemotherapy and their caregivers (44 participants, total). Participants will receive an informational booklet containing a practice log and an MP3 player containing an introductory lecture and guided meditations. Practice reminders will be sent via text messages. Weekly emails will contain practice instructions and links to validated questionnaires.
11341633|NCT02423707|Active Comparator|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
11341634|NCT02423707|Placebo Comparator|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
11341635|NCT02423694|Experimental|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).
~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
11341636|NCT02423694|Active Comparator|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
11341637|NCT02423681|Active Comparator|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
11341638|NCT02423681|Placebo Comparator|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
11341639|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
11341640|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
11341641|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
11341642|NCT02423655|Experimental|Deffered Dialysis Initiation|"Algorithm for deferred dialysis intervention:
~initiating dialysis in the absence of symptoms in patients with an eGFR of 5 ml/min /1.73 m2 or less"
11341643|NCT02423655|Active Comparator|Routine dialysis Initiation|"Algorithm for routine dialysis intervention:
~initiating dialysis in the absence of symptoms in patients with an eGFR of 7 ml/min /1.73 m2 (which is the average GFR for patients in Beijing to start dialysis )"
11341644|NCT02423642|Experimental|AKI requring CRRT and use regional citrate anticoagulation|CRRT use regional citrate anticoagulation
11341645|NCT02423642|Experimental|AKI requring CRRT and not use regional citrate anticoagulation|CRRT not use regional citrate anticoagulation
11341646|NCT02423629|Other|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
11341647|NCT02423616|Experimental|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
11341648|NCT02423603|Active Comparator|Paclitaxel + AZD5363|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
11407703|NCT01984606|Active Comparator|Sitagliptin|Sitagliptin once daily
11341649|NCT02423603|Placebo Comparator|Paclitaxel + Placebo|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
11341650|NCT02423590|Active Comparator|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.
~Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.
~On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
11341651|NCT02423590|Experimental|Gemcitabine/carboplatin + Apatorsen|"Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.
~Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.
~Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
11341652|NCT02423577|Experimental|FF-3 dry powder|FF-3
11341653|NCT02423577|Placebo Comparator|Placebo|
11341654|NCT02423564|Active Comparator|Healthy Population with Digesta Lac|Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
11341655|NCT02423564|Placebo Comparator|Healthy Population with Placebo|Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
11341656|NCT02423551|No Intervention|Control|Usual diet
11341657|NCT02423551|Experimental|MRE|MRE consumption
11341658|NCT02423538|Experimental|single ascending doses|single ascending doses, oral tablets
11341659|NCT02423538|Placebo Comparator|Placebo|Placebo Comparator, oral tablets
11341660|NCT02423525|Experimental|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
11341661|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
11341662|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
11341663|NCT02423499||Autism Spectrum Disorder|Autism Spectrum Disorder adults without intellectual disability
11341664|NCT02423499||Bipolar Disorder|Bipolar Disorder adults during normothymic phase of illness
11341665|NCT02423499||Healthy Volonteers|Healthy adults
11341666|NCT02423486|Experimental|Electromagnetic stimulation therapy|Electromagnetic stimulation therapy group
11341667|NCT02423486|Experimental|Electromagnetic stimulation therapy with biofeedback|Electromagnetic stimulation therapy with biofeedback group
11341668|NCT02423473|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
11341669|NCT02423473|Experimental|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
11341670|NCT02423460|Experimental|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
11341671|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
11341672|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
11341673|NCT02423434||Corneal Confocal Microscopy subjects|
11341674|NCT02423421|Active Comparator|Treatment group|The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor
11341675|NCT02423421|Placebo Comparator|Placebo group|The placebo group will have autologous faecal microbiota transplantation performed.
11341676|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
11341677|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
11341678|NCT02423395|Experimental|Orphenadrine(Norflex)|50 patients will be treated with orphenadrine 100 mg twice daily for 1 month
11341679|NCT02423395|Placebo Comparator|Placebo|50 patients will be given placebo
11341680|NCT02423382|Other|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
11341681|NCT02423382|Other|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
11341682|NCT02423382|Other|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
11341683|NCT02423369|Experimental|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
11341684|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
11409464|NCT01972568|Placebo Comparator|Placebo|
11341685|NCT02423343|Experimental|Galunisertib + Nivolumab (Phase 1b)|Galunisertib in escalating dose cohorts given orally daily or twice a day (BID) for the first 14 days of each 4 week cycle in combination with nivolumab given intravenously (IV) every 2 weeks for 2 cycles.
11341686|NCT02423343|Experimental|Galunisertib + Nivolumab (NSCLC) (Phase 2)|Galunisertib given orally BID for the first 14 days of each 4 week cycle in combination with nivolumab given IV every 2 weeks of each 4 week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11341687|NCT02423343|Experimental|Galunisertib + Nivolumab (HCC) (Phase 2)|Galunisertib given orally BID for the first 14 days of each 4 week cycle in combination with nivolumab given IV every 2 weeks of each 4 week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11341688|NCT02423330|Experimental|Strattice-LIFT|
11341689|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
11341690|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
11341691|NCT02423304||test|"50 periodontitis patients
~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
11341692|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
11341693|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
11341694|NCT02423278|Experimental|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.
~Under this arm, main therapeutic measures are listed as follows:
~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy
~radical gastrectomy plus D4 lymphadenectomy
~five-cycle SOX chemo as adjuvant chemotherapy
~five-year follow-up program to evaluate the prognosis."
11341695|NCT02423278|Experimental|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.
~Under this arm, main therapeutic measures are included as follows:
~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy
~radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)
~five-cycle SOX chemo as adjuvant chemotherapy
~five-year follow-up program to evaluate the prognosis."
11341696|NCT02423265|Active Comparator|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
11341697|NCT02423265|Placebo Comparator|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
11341698|NCT02423252|Experimental|Intervention group|Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
11341699|NCT02423252|No Intervention|Control|Patients in control group will receive standard care only. Same records and outcome measures with intervention group will apply for control group as well.
11341700|NCT02423239|Experimental|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
11341701|NCT02423239|Experimental|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
11341702|NCT02423239|Experimental|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
11341703|NCT02423226|Active Comparator|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
11341704|NCT02423226|Experimental|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
11341705|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
11341706|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
11341707|NCT02423187||Arm 1|Participants with combination therapy (rabeprazole and low-dose aspirin)
11341708|NCT02423174||Total Mesorectal Excision|Patients with an indication for surgical intervention for a total mesorectal excision
11341709|NCT02423148|Experimental|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-
~Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system
~Treatment will be administered on an inpatient basis"
11341710|NCT02423135|Experimental|Blood bags without DEHP|Intervention : Autologous blood transfusion
11341711|NCT02423135|Experimental|Blood bags with DEHP|Intervention : Autologous blood transfusion
11341712|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
11341713|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
11341714|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
11341715|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
11341716|NCT02423096||Schizophrenia|Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).
11341717|NCT02423096||Healthy controls|No special intervention will be provided for healthy controls.
11341720|NCT02423057|Experimental|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
11341721|NCT02423031||Caregivers|caregivers of pediatric patients with cancer and other serious illnesses
11341722|NCT02423031||pediatric patients|pediatric patients with cancer and other serious illnesses
11341723|NCT02423018|Active Comparator|Pregabalin|Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
11341724|NCT02423018|Placebo Comparator|Placebo|Placebo for 10 days
11341725|NCT02423005|Experimental|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
11341726|NCT02423005|Active Comparator|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
11341727|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
11341728|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
11341729|NCT02422979|Experimental|PART 1 - Cohort 1|3-6 patients
11341730|NCT02422979|Experimental|PART 1 - Cohort 2|3-6 patients
11341731|NCT02422979|Experimental|PART 1 - Cohort 3|3-6 patients
11341732|NCT02422979|Experimental|PART 2 - Cohort 1|Number of patients depend on Part 1
11341733|NCT02422979|Experimental|PART 2 - Cohort 2|Number of patients depend on Part 1
11341734|NCT02422979|Experimental|PART 3|Up to 30 patients
11341735|NCT02422966|Experimental|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
11341736|NCT02422966|Active Comparator|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
11341737|NCT02422953|Experimental|Intervention|Wheat Soya Blend, Wawa Mum, Micronutrient Powders, Behavior change and preventive health massages
11341738|NCT02422953|No Intervention|Control|Control group will receive routine public and private health services available in the area.
11341739|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.
~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
11341740|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.
~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
11341741|NCT02422927|Placebo Comparator|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
11341742|NCT02422927|Active Comparator|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
11341743|NCT02422914|Experimental|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
11341744|NCT02422914|Placebo Comparator|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
11341745|NCT02422914|Active Comparator|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
11341746|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
11341747|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
11341748|NCT02422888|Experimental|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
11341749|NCT02422888|Active Comparator|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
11341750|NCT02422875||Healthy Controls|Subjects are healthy persons without any autoimmune conditions or infectious diseases
11341751|NCT02422875||Autoimmune Disease|Subjects diagnosed with autoimmune disease including but not limited to: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome (SS), Scleroderma, Myositis, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), inflammatory arthritis, undifferentiated connective tissue disease, idiopathic thrombocytopenic purpura (ITP), Graft vs Host Disease (GVHD), Autoimmune Lymphoproliferative Syndrome (ALPS) and IgG4-related disease
11341752|NCT02422875||Infectious Disease|Subjects diagnosed with an infectious disease including but not limited to: Hepatitis C, Epstein Barr Virus (infectious mononucleosis - EBV), Sepsis, Guillain-Barre syndrome (GBS), Mycoplasma pneumoniae or Human Immunodeficiency Virus (HIV)
11341753|NCT02422875||Autoimmune - Family|Subjects have a brother, sister, mother, father, or child with an autoimmune disease
11341754|NCT02422875||Vaccination|Subjects have received or will receive a vaccination as part of regular standard of care from their healthcare provider or other outside source
11341755|NCT02422862|Experimental|UC-TSM|Upper cervical translatoric spinal mobilization (UC-TSM). UC-TSM is a physical therapy technique used to improve range of movement, consisting on a manual stretching of the cervical spine of the patient during 30 minutes.
11341756|NCT02422862|No Intervention|Control|The control group receive no treatment intervention during 30 minutes (a similar time as the UC-TSM group).
11341757|NCT02422849|Other|own GP|The patient is cared for by own General Practitioner in the acute stage
11341758|NCT02422849|Other|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
11341759|NCT02422836|Experimental|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:
~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
11341760|NCT02422823|Experimental|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
11341761|NCT02422823|Experimental|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
11341762|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
11341763|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
11341764|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
11341765|NCT02422797|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
11341766|NCT02422797|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
11341767|NCT02422784|Placebo Comparator|Control|Participants will be instructed to consume 240 mL of iced-tea daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
11341768|NCT02422784|Active Comparator|Rooibos Tea - Vitamin D3|Participants will be instructed to consume 240 mL of iced-tea fortified with 1000 IU water-soluable vitamin D3 daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
11341769|NCT02422784|Active Comparator|Rooibos Tea- Vitamin D3 & Calcium|Participants will be instructed to consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water-soluable vitamin D3 and 360 mg of calcium daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
11341770|NCT02422771|No Intervention|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
11341771|NCT02422771|Experimental|Intervention group|FIFA 11+ warm-up
11341772|NCT02422758|Experimental|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
11341773|NCT02422758|Placebo Comparator|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
11341774|NCT02422745|Active Comparator|Cocoa extract + multivitamin|
11341775|NCT02422745|Active Comparator|Cocoa extract + multivitamin placebo|
11341776|NCT02422745|Active Comparator|Cocoa extract placebo + multivitamin|
11341777|NCT02422745|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
11341778|NCT02422732|Other|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
11341779|NCT02422732|Other|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
11341780|NCT02422719|Experimental|Radotinib|Radotinib treatement single arm
11341781|NCT02422706|Active Comparator|group I|"Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)& Clarithromycin 500 mg twice daily .for 14 days .
~40 patients"
11341782|NCT02422706|Experimental|Group II|"Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily & Clarithromycin 500 mg twice daily for 14 days.
~40 patients."
11341783|NCT02422706|Experimental|Group III|"Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily & Doxicycline 100 mg once daily (LOND).
~40 patients"
11341784|NCT02422693|Experimental|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
11341785|NCT02422693|Active Comparator|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
11341786|NCT02422680||Patients referred to a colonoscopy|A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.
11341787|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
11341788|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
11341789|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
11341790|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
11341791|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
11341792|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341793|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341888|NCT02422056|Placebo Comparator|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
11341794|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341795|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341796|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341797|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341798|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341799|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341800|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341801|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
11341802|NCT02422641|Experimental|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
11341803|NCT02422628||EGFR mutation postive|Blood samples every 3 months till disease progression or intolerable due to side effect.
11341804|NCT02422628||EGFR mutation wild type|Blood samples before treatment once.
11341805|NCT02422628||Healthy Volunteers|Blood samples once.
11341806|NCT02422615|Experimental|Ribociclib + fulvestrant|Ribociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
11341807|NCT02422615|Placebo Comparator|Ribociclib placebo + fulvestrant|Ribociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
11341808|NCT02422602|Active Comparator|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
11341809|NCT02422602|Experimental|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
11341810|NCT02422589|Experimental|Ceritinib|
11341811|NCT02422576|Active Comparator|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
11341812|NCT02422576|Active Comparator|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
11341813|NCT02422576|Active Comparator|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
11341814|NCT02422563|Experimental|Arm A: NACT+radical hysterectomy|Arm A includes patients for dose dense chemotherapy using TP (paclitaxel, carboplatin) or TIP (cisplatin, paclitaxel, ifosfamide) weekly for six cycles. Radical hysterectomy is performed after the 6th week + lymphadenectomy
11341815|NCT02422563|Other|Arm B: Chemoradiation|Arm B includes patients undergoing primary cisplatin based chemo-radiation
11341816|NCT02422550||participants undergoing radiation therapy & normal volunteers|
11341817|NCT02422537|Active Comparator|Unmodified wheat bran|One single dose om 20 g
11341818|NCT02422537|Active Comparator|Wheat bran with reduced particle size|One single dose of 20 g
11341819|NCT02422537|Active Comparator|Destarched pericarp-enriched wheat bran|One single dose of 20 g
11341820|NCT02422537|Other|No bran-based dietary platform|No wheat bran fractions is administered
11341821|NCT02422524|Experimental|Child-Pugh A (Mild hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
11341822|NCT02422524|Experimental|Child-Pugh B (Moderate hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
11341823|NCT02422524|Experimental|Child-Pugh C (Severe hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
11341824|NCT02422524|Experimental|Non-hepatically impaired controls|18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
11341825|NCT02422511|Other|Well Infant Cohort, No Sequencing|Healthy infants and their parents enrolled through the Brigham and Women's Hospital (BWH) Well Newborn Nursery who are randomized not to receive sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, and any potentially medically relevant findings from the baby's medical history/physical exam.
11341826|NCT02422511|Other|Well Infant Cohort, Sequencing|Healthy infants and their parents enrolled through Brigham and Women's Hospital (BWH) Well Newborn Nursery who are randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
11341827|NCT02422511|Other|Sick Infant Cohort, No Sequencing|Infants and their parents enrolled through Boston Children's Hospital (BCH) and the BWH Neonatal Intensive Care Unit who are randomized not to receive sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, and any potentially medically relevant findings from the baby's medical history/physical exam.
11341828|NCT02422511|Other|Sick Infant Cohort, Sequencing|Infants and their parents enrolled through Boston Children's Hospital and the BWH Neonatal Intensive Care Unit who are randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
11341829|NCT02422498|Experimental|Concurrent Cisplatin & Radiation Therapy|
11341830|NCT02422485|Experimental|Salsalate|All participants will be administered 2,250 mg daily [1,500 mg every day before noon (every AM) and 750 mg every night at bedtime (every HS)] for 6 months.
11341831|NCT02422472|No Intervention|Standard|Standard of care ultrasound guided peripheral IV placement
11341832|NCT02422472|Experimental|Experimental|Ultrasound guided peripheral IV placement with the use of a guidewire
11341833|NCT02422459|Experimental|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
11341834|NCT02422459|No Intervention|Wait-list control|No treatment assigned
11341835|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
11341836|NCT02422446|No Intervention|Control|Control group will not receive EPA
11341837|NCT02422433|Experimental|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
11341838|NCT02422420|Experimental|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
11341839|NCT02422420|Experimental|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
11341840|NCT02422420|Other|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
11341841|NCT02422407||Subgroup 1|Healthy Volunteers - subset of which 10 will receive salivary gland biopsy.
11341842|NCT02422407||Subgroup 2|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with positive biopsy result.
11341843|NCT02422407||Subgroup 3|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with negative biopsy result.
11341844|NCT02422407||Subgroup 4|Presenting with sicca but not satisfying the criteria of the AECCSS for diagnosis of pSS.
11341845|NCT02422394|Experimental|Eltrombopag|"Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.
~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day."
11341846|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
11341847|NCT02422368|Experimental|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months
~Methylprednisolone includes :
~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
11341848|NCT02422368|Placebo Comparator|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
11341849|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
11341850|NCT02422329|Experimental|Educational Video|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
11341851|NCT02422329|Experimental|Fact Sheet|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants read educational material describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
11341852|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
11341853|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
11341854|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
11341889|NCT02422056|Experimental|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
11341855|NCT02422277|Active Comparator|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
11341856|NCT02422277|Active Comparator|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :
~- Oral intake of 50 mg once daily for 6 months."
11341857|NCT02422277|No Intervention|Control group|Patients will be only followed up without any therapy for assisting erection.
11341858|NCT02422264|Experimental|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
11341859|NCT02422264|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
11341860|NCT02422251|Experimental|Mobile high congruency bearing|Device B Braun Columbus total knee system using a rotating platform tibia and high congruency mobile bearing.
11341861|NCT02422251|Experimental|Fixed high congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and high congruency bearing.
11341862|NCT02422251|Experimental|Fixed low congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and low congruency bearing.
11341863|NCT02422251|No Intervention|Control|Healthy control group
11341864|NCT02422225|Experimental|Eldith DC-STIMULATOR group|"Intervention:
~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
11341865|NCT02422225|Sham Comparator|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
11341866|NCT02422212|Active Comparator|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
11341867|NCT02422212|Other|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
11341868|NCT02422212|Active Comparator|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
11341869|NCT02422199|Experimental|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
11341870|NCT02422199|Active Comparator|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
11341871|NCT02422186|Experimental|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11341872|NCT02422186|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11341873|NCT02422173|Experimental|Anodal tDCS|Participants in the acute post-stroke stage will receive anodal transcranial direct current stimulation
11341874|NCT02422173|Experimental|Cathodal tDCS|Participants in the acute post-stroke stage will receive cathodal transcranial direct current stimulation
11341875|NCT02422173|Experimental|Bilateral tDCS|Participants in the acute post-stroke stage will receive bilateral transcranial direct current stimulation
11341876|NCT02422173|Sham Comparator|Sham tDCS|Participants in the acute post-stroke stage will receive sham transcranial direct current stimulation
11341877|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
11341878|NCT02422134|Active Comparator|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
11341879|NCT02422134|No Intervention|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
11341880|NCT02422121|Experimental|RNS60|RNS60, 4 ml twice daily
11341881|NCT02422121|Placebo Comparator|Placebo|Normal Saline, 4 ml twice daily
11341882|NCT02422108|Experimental|intervention|Denosumab (Prolia) 60 mg s.c.
11341883|NCT02422095||Pancreatic fluid collections|Patients with pancreatic fluid collections undergoing endoscopy-based (EUS-guided) interventions
11341884|NCT02422095||Pancreatic cysts|Patients with pancreatic cysts undergoing EUS examination and possible EUS-guided sampling of cystic fluid.
11341885|NCT02422082|Active Comparator|L. reuteri|Lactobacillus reuteri (L. reuteri) ATCC PTA 6475 at a dose of 5 000 000 000 CFU as a powder in a stick-pack, orally twice daily (morning and evening) yielding a total daily dose of 10 000 000 000 CFU per day, for 12 months.
11341886|NCT02422082|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 12 months.
11341887|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
11341890|NCT02422043|Experimental|type 1 diabetes adolescents cohort|The participants of the prospective cohort of adolescents will be 12 to 17 years of age, type 1 diabetics with insulin, included in TPE program
11341891|NCT02422030|Experimental|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
11341892|NCT02422030|Experimental|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
11341893|NCT02422030|Experimental|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
11341894|NCT02422030|Experimental|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
11341895|NCT02422030|Experimental|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
11341896|NCT02422030|Experimental|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
11341897|NCT02422017|Experimental|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks in combination with dressings and compression.
11341898|NCT02422017|Other|Control|Local care treatment only (dressing and compression applied every other day)
11341899|NCT02422004|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have partial weight-bearing from day 0 and full weight-bearing from week 4. Furthermore, they were instructed in tendon strain exercise identical with the range of motion group.
11341900|NCT02422004|Experimental|Range of motion|Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
11341901|NCT02422004|Experimental|Immobilization|Delayed weight-bearing or range of motion (IMMOB). The immobilization group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks.
11341902|NCT02421991|Experimental|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
11341903|NCT02421991|Active Comparator|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
11341904|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
11341905|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
11341906|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
11341907|NCT02421965|Experimental|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
11341908|NCT02421965|Active Comparator|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
11341909|NCT02421952||Single Cohort|All subjects will be asked to assess their pain and nausea using the visual analogue scales (VAS), the modified faces scale and the BARF scale as described below in the preoperative and postoperative areas.
11341910|NCT02421939|Experimental|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
11341911|NCT02421939|Active Comparator|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
11341912|NCT02421926||IDEAL-E observational group|Subjects who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to 'IDEAL' study, finished the total study period of 'IDEAL' study or were dropped during the study period.
11409914|NCT01969682|Experimental|Arm A (ABT-199 and rifampin)|
11341913|NCT02421913|Active Comparator|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
11341914|NCT02421913|Placebo Comparator|placebo group (PG)|PG received the same dose of saline.
11341915|NCT02421900||group 1|Atrial fibrillation patients
11341916|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
11341917|NCT02421887|Placebo Comparator|Placebo|
11341918|NCT02421874|Experimental|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
11341919|NCT02421874|Active Comparator|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
11341920|NCT02421861|Experimental|Anxiety Management (AM)|
11341921|NCT02421861|Placebo Comparator|Usual Care (UC)|
11341922|NCT02421848||Cirrhotic Patients With Ascites|Cirrhotic Patients With Ascites
11341923|NCT02421835|Placebo Comparator|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
11341924|NCT02421835|Active Comparator|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
11341925|NCT02421835|Placebo Comparator|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
11341926|NCT02421835|Active Comparator|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
11341927|NCT02421822|Experimental|Fitwits Intervention|Fitwits office tool and games
11341928|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
11341929|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
11341930|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
11341931|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
11341932|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
11341933|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
11341934|NCT02421783||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
11341935|NCT02421783||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group
11341936|NCT02421783||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group
11341937|NCT02421770|Experimental|Experimental Chamaemelum Nobile|"Experimental Chamaemelum Nobile 2% gel During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel twice daily with occlusion on the affected are"
11341938|NCT02421770|Placebo Comparator|Placebo|During the 6-week double-blind phase, all patients will be randomly assigned to receive vehicle ( placebo)twice daily with occlusion on the affected are
11341939|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
11341940|NCT02421757|Placebo Comparator|Sham Device|Sham Device
11341941|NCT02421744|Experimental|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
11341942|NCT02421744|Active Comparator|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
11341943|NCT02421731|Experimental|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
11341944|NCT02421731|Active Comparator|Conventional therapy|This group will receive conventional rehabilitation therapy.
11341945|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
11341946|NCT02421692|No Intervention|Usual Care|SNF rehabilitation therapists provide all patients with usual standard of care.
11341947|NCT02421692|Experimental|Progressive Rehabilitation|SNF rehabilitation therapists have been trained on principles of progressive rehabilitation strategies and will implement to all eligible patients as new standard of care.
11341948|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
11341949|NCT02421666|Experimental|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
11409915|NCT01969669|Experimental|Arm A (ABT-199 and ketoconazole)|
11341951|NCT02421653|Experimental|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
11341952|NCT02421653|Experimental|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
11341953|NCT02421653|Experimental|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
11341954|NCT02421653|Active Comparator|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
11341955|NCT02421640|Experimental|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
11341956|NCT02421640|Active Comparator|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
11341957|NCT02421627|Experimental|Moxibustion group|Receiving moxibustion treatment
11341958|NCT02421627|Sham Comparator|Sham moxibustion group|Receiving sham moxibustion.
11341959|NCT02421614|Experimental|high olive oli|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The percentage of olive oil will be half of total fat.
11341960|NCT02421614|Experimental|high sunflower oil|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The total fat will be sunflower oil.
11341961|NCT02421614|No Intervention|kitchen formula|A high protein kitchen diet for tube feeding will be administered to acute respiratory failure patients.
11341962|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
11341963|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
11341964|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin
~OR
~topotecan"
11341965|NCT02421575|Experimental|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
11341966|NCT02421575|Experimental|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
11341967|NCT02421575|Experimental|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
11341968|NCT02421562|Experimental|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
11341969|NCT02421549|Active Comparator|Interrogation with unpaired remote monitoring transmitter|Interrogation with unpaired remote monitoring transmitter Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
11341970|NCT02421549|No Intervention|Interrogation with Programmer|Interrogation with programmer Interrogation with programmer according to usual standard of care
11341971|NCT02421536|Experimental|Vibrent Smartphone Application|"We propose to pilot the application of the mobile application VibrentTM (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline out of clinic assessment with the Vibrent smartphone application (research procedure)."
11341972|NCT02421523|Experimental|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of ~three times/week for 12 weeks.
11341973|NCT02421523|Active Comparator|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
11341974|NCT02421523|Experimental|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
11341975|NCT02421510|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
11341976|NCT02421510|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
11341977|NCT02421510|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
11341978|NCT02421497||Normal Healthy Volunteer|
11341979|NCT02421497||Non-CKD Control|
11341980|NCT02421497||Chronic Kidney Disease (CKD)|
11341981|NCT02421497||Dialysis Patients|
11341982|NCT02421497||Renal Transplant Recipients|
11341983|NCT02421484|Experimental|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
11341984|NCT02421471||Ingenol mebutate treatment cohort|Patients who are prescribed ingenol mebutate gel for the first time by investigator's medical judgment.
11341985|NCT02421458|Active Comparator|arm 1: 6 fractions of radiation|radiation in a 6 fractions scheme and a daily dose of 6 Gy
11341986|NCT02421458|Active Comparator|arm 2: 16 fractrions of radiation|radiation in a 16 fractions scheme and a daily dose of 3.125 Gy
11341987|NCT02421432|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
11341988|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
11341989|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
11341990|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
11341991|NCT02421406|Experimental|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
11341992|NCT02421406|Active Comparator|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
11341993|NCT02421393|Experimental|Exercise|Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
11341994|NCT02421393|No Intervention|Control|Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
11341995|NCT02421380|Experimental|Hyperpolarized Pyruvate MRI Reproducibility|This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
11341996|NCT02421367|Experimental|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.
~The placebo is sodium chloride.
~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.
~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
11341997|NCT02421367|Experimental|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.
~The placebo is sodium chloride.
~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.
~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
11341998|NCT02421367|Experimental|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.
~The placebo is sodium chloride.
~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.
~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
11341999|NCT02421354|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
11342000|NCT02421341|Experimental|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
11342001|NCT02421341|Placebo Comparator|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
11342002|NCT02421328|Active Comparator|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
11342003|NCT02421328|Active Comparator|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
11342004|NCT02421315|Experimental|OCD|Participants will have a current diagnosis of OCD.
11342005|NCT02421302|No Intervention|Well-nourished HIV+ ART naive|These children aged between 6months-12years will be followed up for 12weeks to look at their nutrition, immune and pharmacological responses. They will receive routine nutritional and ART adherence counseling
11342006|NCT02421302|Active Comparator|Moderately-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
11342007|NCT02421302|Active Comparator|Severely acute-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
11342008|NCT02421289|Experimental|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
11342009|NCT02421289|No Intervention|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
11342010|NCT02421276|Other|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
11342011|NCT02421276|Other|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
11342012|NCT02421263|Experimental|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
11342013|NCT02421263|Active Comparator|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
11342014|NCT02421250|Experimental|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
11342015|NCT02421250|No Intervention|Control|We will use standard-of-care for control group and not use the SpHb monitor.
11342016|NCT02421237|Experimental|Experimental condition|Narrative enhancement and cognitive therapy (NECT) groups. Structured psychoeducational and skills-training groups focused on self-stigma and its impact on people with schizophrenia
11342017|NCT02421237|Active Comparator|Control condition|Supportive group therapy groups. Unstructured supportive groups not focused on self-stigma.
11342018|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
11342019|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
11342020|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
11342021|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
11342022|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
11342023|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
11342024|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
11342025|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
11342026|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
11342027|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
11342028|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
11342029|NCT02421198|Experimental|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
11342030|NCT02421198|Experimental|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
11342031|NCT02421185|Experimental|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.
~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
11342032|NCT02421172|Experimental|Period 1: CJM112 High Dose|Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
11342033|NCT02421172|Placebo Comparator|Period 1: Placebo|Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
11342034|NCT02421172|Placebo Comparator|Period 2: CJM112 High Dose (Period 1) / Placebo (Period 2)|Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on CJM112 High Dose in Period 1
11342035|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 Low Dose (Period 2)|Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
11342036|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 High Dose (Period 2)|Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
11342037|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
11342254|NCT02419677|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA.
11409916|NCT01969656|Placebo Comparator|Placebo|
11342038|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
11342039|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
11342040|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
11342041|NCT02421133|Experimental|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
11342042|NCT02421133|Other|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
11342043|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
11342044|NCT02421107|Other|all patients|all patients
11342045|NCT02421094|Active Comparator|GR-MD-02|Active
11342046|NCT02421094|Placebo Comparator|Placebo|Placebo
11342047|NCT02421081|Active Comparator|having arteriel cut|30 patients who refer to Erciyes University emergency department because of wrist laceration with radial and/or ulnar artery incision,will be presenting to the study.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery,under a microscope using microsurgical techniques and polyamide suture will be held vascular repair.Patients will be assessed by Doppler ultrasonography again 4 weeks after surgery;flow velocity and vessel diameter will be measured at the anastomoses line and patient will be divided to 4 groups. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; The relationship between the anastomosis opening will be evaluated statistically.
11342048|NCT02421081|Active Comparator|having tendon cut|10 patients having similar age and sex with first group, who refer to Erciyes University emergency department because of wrist laceration without radial or ulnar artery cutting,will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery to repair tendons and/or nerves. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; and will compare with first group.
11342049|NCT02421081|No Intervention|healthy control|10 healty having similar age and sex with first group,controls who accept to give blood to determine normal range of serum CD34,CD133 and CD 309 will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.
11342050|NCT02421068||Preterm neonates|All neonates that receive at least one of the 9 drugs (phenobarbital, paracetamol, levetiracetam, midazolam, sildenafil, fentanyl, doxapram, ibuprofen, fluconazole) are included in the studied cohort
11342051|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
11342052|NCT02421055||Group 2|Sleeve Gastrectomy
11342053|NCT02421042|Experimental|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
11342054|NCT02421029|Experimental|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
11342055|NCT02421016|Experimental|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
11342056|NCT02421016|Active Comparator|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
11342057|NCT02421003|Experimental|Patients|Patients undergoing heart surgery
11342058|NCT02420990|Active Comparator|Behavioral Only- Treatment|All participants will receive behavioral interventions (CASH-AA): family psycho-education in ADHD symptoms, executive functioning, and developmental impacts; family-based motivation and ADHD accommodation interventions; and academic training focused on home environment support and organizational skills.
11342059|NCT02420990|Experimental|Integrated Treatment|Half of the participants will also receive medication decision-making interventions (MIP): ADHD medication psychoeducation, family decision-making interventions, and (for those who elect to start medication) coordinated medication management.
11342060|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT
~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
11342061|NCT02420964|Other|Nurse instruction|Traditional injection teaching method. No video instruction
11342062|NCT02420964|Other|Video instruction|Video instruction that can be paused/repeated by subject
11342063|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
11342064|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
11342065|NCT02420938|Experimental|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
11342066|NCT02420925|Experimental|Celiac Plexus Block|There is one treatment arm who undergoes celiac plexus block.
11347527|NCT02384551|Experimental|HTLS|High total carbohydrate with low total simple carbohydrate diet
11342067|NCT02420912|Experimental|Cohort I (nivolumab, ibrutinib)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11342068|NCT02420912|Experimental|Cohort II (nivolumab, previous ibrutinib)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
11342069|NCT02420912|Experimental|Cohort III (nivolumab, ibrutinib)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11342070|NCT02420899|Experimental|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
11342071|NCT02420886|Active Comparator|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
11342072|NCT02420886|No Intervention|Traditional Single step culture media|
11342073|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
11342074|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
11342075|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
11342076|NCT02420860|Experimental|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11342077|NCT02420847|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|Patients receive ixazomib citrate PO, gemcitabine hydrochloride IV over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11342078|NCT02420834|Experimental|Tear Supplement Hypromellose 0.15%|Preservative free Hypromellose Eye Drops BP 0.15% applied as required for 1 month
11342079|NCT02420834|Experimental|Tear Supplement Hypromellose 0.4%|Preservative free Hypromellose Eye Drops BP 0.4% applied as required for 1 month
11342080|NCT02420834|Experimental|Tear Supplement Carboxymethylcellulose|Tear Supplement 3: Preservative free 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears) applied as required for 1 month
11342081|NCT02420834|Experimental|Tear Supplement Liposomal spray|Preservative free Phospholipid liposomal spray (Tears Again) applied as required for 1 month
11342082|NCT02420821|Experimental|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
11342083|NCT02420821|Active Comparator|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
11342084|NCT02420795|Experimental|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11342085|NCT02420782|Experimental|ASP6282 single ascending dose (fasted)|Part 1
11342086|NCT02420782|Placebo Comparator|Placebo single ascending dose (fasted)|Part 1
11342087|NCT02420782|Experimental|ASP6282 single dose (fed)|Part 1
11342088|NCT02420782|Placebo Comparator|Placebo single dose (fed)|Part 1
11342089|NCT02420782|Experimental|ASP6282 single dose (fasted)|Part 1 Period 1
11342090|NCT02420782|Experimental|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
11342091|NCT02420782|Experimental|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
11342092|NCT02420782|Placebo Comparator|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
11342093|NCT02420782|Experimental|ASP6282 and pilocarpine|Part 3
11342094|NCT02420782|Other|Placebo and pilocarpine|Part 3
11342095|NCT02420769||Threatened abortion|Pregnant patients > 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.
11342096|NCT02420730|Experimental|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
11342097|NCT02420730|Experimental|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
11342098|NCT02420730|Experimental|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
11342099|NCT02420730|Placebo Comparator|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
11342100|NCT02420730|Experimental|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
11342101|NCT02420730|Experimental|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
11342317|NCT02419235|Placebo Comparator|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
11342102|NCT02420730|Experimental|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
11342103|NCT02420730|Placebo Comparator|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
11342104|NCT02420717|Experimental|Cohort A (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11342105|NCT02420717|Experimental|Cohort B (dasatinib)|Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11342106|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
11342107|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
11342108|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
11342109|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
11342110|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
11342111|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
11342112|NCT02420691|Experimental|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11342113|NCT02420665|Experimental|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
11342114|NCT02420652|Experimental|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
11342115|NCT02420652|Placebo Comparator|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
11342116|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
11342117|NCT02420613|Experimental|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.
~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
11342118|NCT02420613|Experimental|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
11342119|NCT02420587|Experimental|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
11342120|NCT02420574|Active Comparator|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
11342121|NCT02420574|Active Comparator|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
11342122|NCT02420561|Experimental|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
11342123|NCT02420561|Active Comparator|Control|Participants received a brochure on alcohol and drug use risks.
11342124|NCT02420548|Active Comparator|Services as Usual|Participants continue with any services they may be receiving outside of the study.
11342125|NCT02420548|Experimental|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
11342126|NCT02420535|Experimental|Immediately Receive Tool|Caregiver/Care Recipient Dyad will be randomly assigned to immediately receive the WeCareAdvisor Tool for 4 weeks.
11342127|NCT02420535|Active Comparator|One Month Delay|Caregiver/Care Recipient Dyad will be randomly assigned to a 4 week delay (usual care activities only) before receiving the WeCareAdvisor Tool for 4 weeks.
11342128|NCT02420522|Experimental|Active-first|Participants randomly assigned to this arm will receive one week of active Repetitive Transcranial Magnetic Stimulation prior to one week of Sham Transcranial Magnetic Stimulation, separated by at least one week.
11347528|NCT02384551|Experimental|LTHS|Low total carbohydrate with low total simple carbohydrate diet
11342129|NCT02420522|Experimental|Sham-first|Participants randomly assigned to this arm will receive one week of Sham Transcranial Magnetic Stimulation prior to one week of active Repetitive Transcranial Magnetic Stimulation, separated by at least one week.
11342130|NCT02420522|Active Comparator|Full-course Active|Participants in this arm will receive three weeks (30 session, twice-daily) of active Repetitive Transcranial Magnetic Stimulation. This arm will not involve random assignment.
11342131|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
11342132|NCT02420496|Experimental|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
11342133|NCT02420496|Active Comparator|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
11342134|NCT02420496|Placebo Comparator|Placebo|Infant will receive placebo in two daily doses given enterally
11342135|NCT02420483|Experimental|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
11342136|NCT02420470||healthy control group|fasting plasma glucose(FPG)<6.11mmol/L，and 2-h plasma glucose(2hPG)<7.77mmol/L；
11342137|NCT02420470||prodromal diabetes group|IFG：fasting plasma glucose(FPG) ≥5.6mmol/L (100mg/dl)，and<7.0mmol/L (126mg/dl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) <7.8 mmol/L ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol/L (140mg/dl)，and<11.1mmol/L (200mg/dl)，fasting plasma glucose(FPG)< 5.6mmol/L
11342138|NCT02420470||diabetes group|fasting plasma glucose(FPG)>7.0mmol/L, or 2-h plasma glucose(2hPG)>11.1mmol/L
11342139|NCT02420457||Back pain receiving epidural injection|Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
11342140|NCT02420444|Placebo Comparator|BCG SSI prime with Placebo|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.
~Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231."
11342141|NCT02420444|Experimental|BCG SSI prime with Placebo and AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.
~Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231.
~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:
~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.
~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
11342142|NCT02420444|Experimental|BCG SSI prime with AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.
~AERAS-404 50/500 on Study Days 0, 56, and 231.
~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:
~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.
~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
11342143|NCT02420431|Experimental|metacognitive therapy plus CR|Group psychological treatment focused on reducing worry and rumination and modifying beliefs about thinking in addition to treatment as usual (standard cardiac rehabilitation)
11342144|NCT02420431|Active Comparator|CR alone (control)|Usual group-based cardiac rehabilitation (treatment as usual) involving stress management, exercise, education
11342145|NCT02420418|Active Comparator|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .
~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
11342146|NCT02420418|Placebo Comparator|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.
~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .
~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
11342147|NCT02420405|Placebo Comparator|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
11342148|NCT02420405|Experimental|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
11342149|NCT02420392|Experimental|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
11342150|NCT02420392|No Intervention|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
11342151|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
11342152|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
11342153|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
11342154|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
11342155|NCT02420340|Other|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
11342156|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
11342157|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
11342158|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
11342159|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
11342160|NCT02420314|Experimental|Ascorbate, paclitaxel, carboplatin|Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks
11342161|NCT02420301|Experimental|Exercises on real points|Self administered exercises were done in real treatment points
11342162|NCT02420301|Placebo Comparator|Exercises on false points|Self administered exercises were done in false treatment points
11342163|NCT02420288|No Intervention|Control Group|Pregnant women not participating in supervised physical exercise program. The subjects in this group will be monitored during pregnancy to know if they make any kind of exercise on your own, to know which are really sedentary pregnant women.
11342164|NCT02420288|Experimental|Exercise Group|Pregnant women participating in supervised physical exercise program.
11342165|NCT02420275|Placebo Comparator|Severe brain injury patient|Severe brain injury patients with placebo
11342166|NCT02420275|Experimental|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
11342167|NCT02420262|Experimental|IDegLira|
11342168|NCT02420262|Active Comparator|IGlar plus IAsp|
11342169|NCT02420249|Experimental|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
11342170|NCT02420249|No Intervention|Control group|Participants in the control group will receive no Qigong training.
11342171|NCT02420236|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
11342172|NCT02420236|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
11342173|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
11342174|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
11342175|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11342176|NCT02420197|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
11342177|NCT02420197|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
11342178|NCT02420184|Experimental|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
11342179|NCT02420184|Placebo Comparator|No CPAP|Participants will receive standard medical care for CKD.
11342180|NCT02420171|Active Comparator|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
11342181|NCT02420171|No Intervention|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
11342182|NCT02420158|Experimental|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
11342183|NCT02420145|Experimental|Yoga|This group will participate in 12 weeks of yoga
11342184|NCT02420145|No Intervention|Waitlist|No intervention
11342185|NCT02420132||Main Study|Decentralized participant recruitment, participant and local ophthalmologist compliance, and use of the mVT mobile medical application in a more geographically diverse, decentralized cohort of participants with DME or nAMD receiving intravitreal ranibizumab therapy as part of standard-of-care treatment.
11342186|NCT02420132||Traditional Substudy|"Subset of participants enrolled through a single investigator who will determine visual acuity and anatomical markers of disease status using clinical gold standard assessments (certified ETDRS protocol visual acuity and macula OCT)."
11342187|NCT02420106|Active Comparator|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
11342188|NCT02420106|Active Comparator|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
11342345|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 >=350
11409917|NCT01969656|Active Comparator|Calcitriol|
11342189|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
11342190|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
11342191|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:
~Clinical progression to probable or definitive disseminated AdV disease Death"
11342192|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
11342193|NCT02420054|Active Comparator|Intermittent fasting|Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
11342194|NCT02420054|Active Comparator|Time control|A time control period.
11342195|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
11342196|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
11342197|NCT02420028|Experimental|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
11342198|NCT02420028|Active Comparator|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
11342199|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
11342200|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
11342201|NCT02420002|Active Comparator|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.
~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
11342202|NCT02420002|Experimental|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).
~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
11342203|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
11342204|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
11342205|NCT02419963|Other|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
11342206|NCT02419963|Other|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
11342207|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
11342208|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
11342209|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
11342210|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
11342211|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
11342212|NCT02419911|Other|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
11342213|NCT02419911|Other|Clearify|Clearify Visualization System used during laparoscopic surgery
11342214|NCT02419898||Feasibility Study|Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
11342216|NCT02419859|Experimental|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
11342217|NCT02419846|Experimental|Men over 40: Screening with intervention|Participants over the age of 40 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences. Participants may undergo a screening exam comprising a prostate specific antigen level and digital rectal exam.
11342218|NCT02419846|Experimental|Men 18-39: Educational intervention|Participants between 18 and 39 complete an educational intervention comprising a 10-20 minute PowerPoint presentation given by an experienced healthcare professional that discusses prostate cancer facts, screening guidelines, risks, benefits, and consequences.
11342219|NCT02419833|Experimental|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
11342220|NCT02419833|Active Comparator|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and within 2-72 hours of admission
11342221|NCT02419820|Experimental|APD791 10mg single dose|APD791 10mg single dose
11342222|NCT02419820|Experimental|APD791 20mg single dose|APD791 20mg single dose
11342223|NCT02419820|Experimental|APD791 40mg single dose|APD791 40mg single dose
11342224|NCT02419820|Experimental|APD791 10mg|APD791 10mg single dose + Aspirin + Clopidogrel
11342225|NCT02419820|Experimental|APD791 20mg|APD791 20mg single dose + Aspirin + Clopidogrel
11342226|NCT02419820|Experimental|APD791 40mg|APD791 40mg single dose + Aspirin + Clopidogrel
11342227|NCT02419820|Experimental|APD791 80mg|APD791 80mg single dose + Aspirin + Clopidogrel
11342228|NCT02419820|Experimental|APD791 160mg|APD791 160mg single dose + Aspirin + Clopidogrel
11342229|NCT02419820|Experimental|APD791 240mg|APD791 240mg single dose + Aspirin + Clopidogrel
11342230|NCT02419820|Experimental|APD791 320mg|APD791 320mg single dose + Aspirin + Clopidogrel
11342231|NCT02419820|Placebo Comparator|APD791 Placebo|APD791 placebo for single dose + Aspirin + Clopidogrel
11342232|NCT02419820|Experimental|APD791 2mg MD|APD791 2mg multiple dose + Aspirin + Clopidogrel
11342233|NCT02419820|Experimental|APD791 5mg MD|APD791 5mg multiple dose + Aspirin + Clopidogrel
11342234|NCT02419820|Experimental|APD791 10mg MD|APD791 10mg multiple dose + Aspirin + Clopidogrel
11342235|NCT02419820|Experimental|APD791 20mg MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
11342236|NCT02419820|Placebo Comparator|APD791 placebo MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
11342237|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
11342238|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
11342239|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
11342240|NCT02419781|Active Comparator|Group with endovascular treatment|Group with additional endovascular treatment
11342241|NCT02419781|Active Comparator|Group without endovascular treatment|Group without additional endovascular treatment
11342242|NCT02419768|Experimental|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
11342243|NCT02419768|No Intervention|Control|All patients will not change their physical activities
11342244|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
11342245|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
11342246|NCT02419742|Experimental|Trastuzumab|Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
11342247|NCT02419729|Experimental|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
11342248|NCT02419729|Active Comparator|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
11342249|NCT02419729|Sham Comparator|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
11342250|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
11342251|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
11342252|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
11342253|NCT02419677|Other|RFA alone|Patients undergo radiofrequency ablation alone.
11409918|NCT01969656|Experimental|50 ng 2MD|
11342255|NCT02419664|Experimental|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT
~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
11342256|NCT02419651|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
11342257|NCT02419651|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
11342258|NCT02419651|Placebo Comparator|Placebo|Women will receive oral placebo 1 hour before the procedure.
11342259|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
11342260|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
11342261|NCT02419625|Other|subgroup-specific HEV in Israel|The study will involve patient interviews using questionnaires
11342262|NCT02419612|Experimental|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
11342263|NCT02419612|Experimental|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
11342264|NCT02419599|Experimental|Group A|The group who will receive high energy density, low volume oral nutritional supplement, to be taken for 4 weeks (28 days)
11342265|NCT02419599|Active Comparator|Group B|The group who will receive the standard energy density oral nutritional supplement, to be taken for 4 weeks (28 days)
11342266|NCT02419586|Experimental|bubble gum chewing and routine care|Start chewing gum on postoperative day at three times daily with no more than 30 minutes till discharged
11342267|NCT02419586|No Intervention|routine care|Non interventional group will receive existing routine care as usual
11342268|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
11342269|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
11342270|NCT02419560|Experimental|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
11342271|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
11342272|NCT02419534|Active Comparator|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
11342273|NCT02419534|Active Comparator|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
11342274|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
11342275|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
11342276|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
11342277|NCT02419495|Experimental|Arm A (selinexor, carboplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
11342278|NCT02419495|Experimental|Arm B (selinexor, paclitaxel)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) on days 1-14. Patients then receive selinexor PO on days 1, 3, 8 and 10 and paclitaxel IV over 3 hours on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After 8 cycles of combination treatment, patients can continue single agent selinexor until disease progression.
11342279|NCT02419495|Experimental|Arm C (selinexor, eribulin mesylate)|Patients receive selinexor PO on days 1, 8, and 15 and eribulin mesylate IV over 1 hour on days 1 and 8. Combination treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
11342280|NCT02419495|Experimental|Arm D (selinexor, doxorubicin, cyclophosphamide) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15, doxorubicin hydrochloride IV over 90 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
11342281|NCT02419495|Experimental|Arm E (selinexor, carboplatin, paclitaxel) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment repeats every 21 days for up to 8 cycles depending con cancer type (6 cycles for non-small cell lung cancer, up to 8 cycles for ovarian cancer and other histological malignancies) in the absence of disease progression or unacceptable toxicity. After 6 to 8 cycles, patients can continue single agent selinexor until disease progression.
11342282|NCT02419495|Experimental|Arm F (selinexor, carboplatin, pemetrexed) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
11342283|NCT02419495|Experimental|Arm G (selinexor, topotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, and 15 and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
11342346|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 <200
11342284|NCT02419495|Experimental|Arm H (selinexor, FOLFIRI) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15 and 22, irinotecan hydrochloride IV over 90 minutes, fluorouracil IV continuously over 48 hours and leucovorin calcium IV over 2 hours on days 1 and 15. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients can continue single agent selinexor until disease progression.
11342285|NCT02419495|Experimental|Arm I (selinexor, irinotecan hydrochloride) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
11342286|NCT02419495|Experimental|Arm J (selinexor, capecitabine, oxaliplatin) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8 and 15, capecitabine PO twice daily (BID) on days 1-14 and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. After 8 cycles, patients can continue single agent selinexor until disease progression.
11342287|NCT02419495|Experimental|Arm K (selinexor, olaparib) (ARM CLOSED)|Patients receive selinexor PO on days 1, 8, 15, and 22 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11342288|NCT02419495|Experimental|Arm L (selinexor, pembrolizumab)|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11342289|NCT02419495|Experimental|Arm M (selinexor, nivolumab|Patients receive selinexor PO twice weekly (e.g. Monday/Wednesday or Tuesday/Thursday or Wednesday/Friday or Thursday/Saturday or Friday/Sunday) and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11342290|NCT02419482|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
11342291|NCT02419482|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
11342292|NCT02419482|No Intervention|control|Physical activity recommended
11342293|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
11342294|NCT02419456|Experimental|MK-2048A Intravaginal Ring (IVR) (Low Dose)|The MK-2048A IVR (Low Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
11342295|NCT02419456|Experimental|MK-2048A IVR (Original Dose)|The MK-2048A IVR (Original Dose) will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
11342296|NCT02419443|Placebo Comparator|Placebo|Patients randomized to the placebo-group were administered placebo-pills orally one hour prior to surgery, then three times a day for a maximum of 6 total doses.
11342297|NCT02419443|Active Comparator|Gabapentin|Patients randomized to the gabapentin-group were administered 300 mg orally one hour prior to surgery, then three times a day for a maximum of 6 total dose.
11342298|NCT02419430|Active Comparator|MBRT ClassRoom and Phone Application|MBRT ClassRoom and Phone Application
11342299|NCT02419430|Active Comparator|Phone application only|Phone application only
11342300|NCT02419430|Active Comparator|Questionnaires|Questionnaires
11342301|NCT02419417|Experimental|Monotherapy Treatment|Patients treated at various doses and schedules
11342302|NCT02419417|Experimental|Combination Therapy|Patients treated at selected doses and schdules
11342303|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
11342304|NCT02419391|Experimental|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
11342305|NCT02419391|Experimental|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
11342306|NCT02419391|Experimental|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
11342307|NCT02419378|Experimental|alemtuzumab|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.
~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
11342308|NCT02419365||PCD|Individuals with Primary Ciliary Dyskinesia will be assessed in a pure observational design without intervention
11342309|NCT02419352|Active Comparator|Sugammadex|Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
11342310|NCT02419352|Active Comparator|Neostigmine/atropine|Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
11342311|NCT02419326|Experimental|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
11342312|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
11342313|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
11342314|NCT02419287|Experimental|crizotinib|250mg BID
11342315|NCT02419261|Active Comparator|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
11342316|NCT02419261|Active Comparator|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
11342372|NCT02418936||WS|WS diagositic kit
11342373|NCT02418936||LVAS|LVAS diagositic kit
11409919|NCT01969656|Experimental|110 ng 2MD|
11342318|NCT02419235|Experimental|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
11342319|NCT02419222|Experimental|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
11342320|NCT02419209|Experimental|Individualised Homeopathic Remedy|A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.
11342321|NCT02419196||abdominal surgery|27 patients undergoing abdominal surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
11342322|NCT02419196||limb surgery|27 patients undergoing upper and lower limb surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
11342323|NCT02419196||flail chest|10 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
11342324|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
11342325|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
11342326|NCT02419170|Experimental|Surgery/Apheresis/Cyclophosphamide/Vaccine|"Standard of care surgery
~Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery
~Cyclophosphamide 300 mg/m^2 intravenously (Day -4)
~Personalized vaccine (Day 1)
~Booster dose of personalized vaccine (Day 43)
~Booster dose of personalized vaccine (Day 85)"
11342327|NCT02419157|Active Comparator|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~Selective enamel etching with 36% phosphoric acid"
11342328|NCT02419157|Active Comparator|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~Selective enamel etching with 36% phosphoric acid"
11342329|NCT02419157|Active Comparator|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~No selective enamel etching with 36% phosphoric acid"
11342330|NCT02419157|Active Comparator|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.
~No selective enamel etching with 36% phosphoric acid"
11342331|NCT02419144|Active Comparator|AMI followed by campaigns|Behavioral interventions
11342332|NCT02419144|Active Comparator|Campaigns followed by AMI|Behavioral interventions
11342333|NCT02419131|Experimental|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
11342334|NCT02419131|Experimental|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
11342335|NCT02419131|Active Comparator|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
11342336|NCT02419118|Experimental|Dara len dex|Daratumumab in combination with lenalidomide and dexamethasone
11342337|NCT02419118|Active Comparator|Len dex|Lenalidomide in combination with dexamethasone
11342338|NCT02419105|Active Comparator|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
11342339|NCT02419105|Active Comparator|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
11342340|NCT02419105|Active Comparator|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
11342341|NCT02419105|Placebo Comparator|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
11342342|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
11342343|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
11342344|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 >=350
11409920|NCT01969656|Experimental|170 ng 2MD|
11342347|NCT02419053||Pre-checklist|Surgical interventions performed for children before the introduction of the surgical safety checklist in Ontario, from October 2008 to September 2009.
11342348|NCT02419053||Post-checklist|Surgical interventions performed for children after the introduction of the surgical safety checklist in Ontario, from October 2010 to September 2011.
11342349|NCT02419040|Experimental|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
11342350|NCT02419040|Active Comparator|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
11342351|NCT02419040|Sham Comparator|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
11342352|NCT02419027|Experimental|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
11342353|NCT02419027|Placebo Comparator|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
11342354|NCT02419014|No Intervention|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
11342355|NCT02419014|Active Comparator|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
11342356|NCT02419014|Placebo Comparator|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
11342357|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:
~Period 1: Ceftriaxone 1 g infused IV over 30 minutes
~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
11342358|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes
~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
11342359|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:
~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]
~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
11342360|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]
~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
11342361|NCT02418988|Experimental|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
11342362|NCT02418988|Active Comparator|TACE|TACE will be applied alone
11342363|NCT02418975|Experimental|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
11342364|NCT02418975|Active Comparator|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
11342365|NCT02418962|Experimental|Group 1 (pilot group)|Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10^5 and 2.7x10^5 PfSPZ.
11342366|NCT02418962|Experimental|Group 2|The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks
11342367|NCT02418962|Placebo Comparator|Group 3|The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.
11342368|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
11342369|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.
~Dose will be titrated down to zero in the 2 weeks following treatment."
11342370|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.
~Dose will be titrated down to zero in the 2 weeks following treatment."
11342371|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.
~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
11342375|NCT02418884|Other|CAD+DM|Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.
11342376|NCT02418871|Experimental|FluidVision AIOL with an improved injector system|FluidVision AIOL implanted in the capsular bag following removal of the cataractous lens
11342377|NCT02418858|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
11342378|NCT02418858|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
11342379|NCT02418845|Experimental|SYM-1219|Administered orally
11342380|NCT02418845|Placebo Comparator|Placebo|Administered orally
11342381|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
11342382|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
11342383|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
11342384|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
11342385|NCT02418819|Placebo Comparator|Placebo|Placebo BID
11342386|NCT02418806|Experimental|Therapy group with follow up sessions|Weekly psychotherapy groups during 4 months with a monthly follow up period (12 months)
11342387|NCT02418806|Experimental|Therapy group without follow up sessions|Weekly psychotherapy groups during 4 months
11342388|NCT02418806|Active Comparator|Active comparator group|Weekly self-help groups during 4 months with a monthly follow up period (12 months)
11342389|NCT02418793|Experimental|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
11342390|NCT02418793|Experimental|Dose Cohort 2|MOD-5014 Dose cohort 2
11342391|NCT02418793|Experimental|Dose Cohort 3|MOD-5014 Dose cohort 3
11342392|NCT02418793|Experimental|Dose Cohort 4|MOD-5014 Dose cohort 4
11342393|NCT02418793|Experimental|Dose Cohort 5|MOD-5014 Dose cohort 5
11342394|NCT02418793|Experimental|Dose Cohort 6|Highest MOD-5014 dose tested in the study
11342395|NCT02418780|Experimental|Tai Chi|6-month Tai Chi training program combined with usual medical care
11342396|NCT02418780|No Intervention|Usual Care|Waitlist control group receiving usual medical care alone
11342397|NCT02418767|Experimental|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
11342398|NCT02418767|Experimental|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
11342399|NCT02418767|Experimental|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
11342400|NCT02418754|Experimental|REGN2176-3 (1 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
11342401|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
11342402|NCT02418754|Experimental|Intravitreal Aflibercept Injection (IAI) 2 mg|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
11342403|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg) to IAI 2 mg|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
11342404|NCT02418754|Experimental|IAI 2 mg to REGN2176-3 (3 mg:2 mg)|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
11342405|NCT02418741|Experimental|Degree of neck flextion|Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow
11342406|NCT02418728||persons with obesity|
11342407|NCT02418728||lean persons|
11342408|NCT02418715|Experimental|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
11342409|NCT02418715|No Intervention|Control|No training, no intervention.
11342410|NCT02418702|Experimental|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
11342411|NCT02418702|Placebo Comparator|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
11342412|NCT02418689|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
11342413|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
11342414|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
11342415|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
11409921|NCT01969656|Experimental|220 ng 2MD|
11342416|NCT02418663|Other|Postoperative elective surgical patients|Patients undergoing major elective thoracic and abdominal, the latter group including upper gastrointestinal, esophageal, and colorectal procedures. In this group FR will predicted by administering a fluid challenge of 250 ml of Lactated Ringer's solution and measuring SV with the ccNexfin
11342417|NCT02418650|Experimental|Part 1|A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
11342418|NCT02418650|Experimental|Part 2|A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
11342419|NCT02418637|Experimental|Farm workers|This is a one arm intervention including farm workers and owners
11342420|NCT02418624|Experimental|Dose escalation|carboplatin, olaparib
11342421|NCT02418598|Experimental|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
11342422|NCT02418598|Experimental|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
11342423|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11342424|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11342425|NCT02418572|Experimental|Transdermal testosterone gel|"Patients will receive once daily application of 0.55 gr TTG (Testosterone gel 1%; Laboratories Besins International,Paris,France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.
~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.
~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.
~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
11342426|NCT02418572|Placebo Comparator|Placebo transdermal gel|"Patients will receive once daily application of 0.55 gr identical placebo gel starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.
~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.
~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.
~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
11342427|NCT02418559|Experimental|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
11342428|NCT02418559|Experimental|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
11342429|NCT02418559|Experimental|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
11342430|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
11342431|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
11342432|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
11342433|NCT02418533|Experimental|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
11342510|NCT02418013|Placebo Comparator|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
11342511|NCT02418000|Experimental|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
11342434|NCT02418533|Experimental|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
11342435|NCT02418520|Experimental|Miswak chewing|Chewing Sticks
11342436|NCT02418520|No Intervention|H.Pylori|Oral H.Pylori
11342437|NCT02418507|Active Comparator|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
11342438|NCT02418507|Placebo Comparator|Placebo|The placebo is administered to randomized healthy participants
11342439|NCT02418494||Observational (ANCHOR HRQoL interview, cognitive interview)|Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
11342440|NCT02418481|Experimental|Group A|DC-CIK cells will be used against tumor cells.
11342441|NCT02418481|Experimental|Group B|γδ T cells will be used against tumor cells.
11342442|NCT02418481|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
11342443|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
11342444|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
11342445|NCT02418455|Experimental|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
11342446|NCT02418429|Active Comparator|waxy maize starch|pancake test meal - waxy maize starch
11342447|NCT02418429|Active Comparator|waxy maize starch and whey protein|pancake test meal - waxy maize starch and whey protein
11342448|NCT02418429|Active Comparator|resistant starch|pancake test meal - resistant starch
11342449|NCT02418429|Active Comparator|resistant starch and whey protein|pancake test meal - resistant starch and whey protein
11342450|NCT02418416|Experimental|Double activation|The Oocytes in this arm will undergo double activation with Ca ionophore 5 micro mol for 20 min them Strontium chloride 10 micro mol for 60 min.
11342451|NCT02418416|No Intervention|Control arm|The Oocytes will undergo Intracytoplasmic sperm injection only
11342452|NCT02418403|Active Comparator|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
11342453|NCT02418403|Experimental|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
11342454|NCT02418390|No Intervention|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
11342455|NCT02418390|Active Comparator|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
11342456|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:
~Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile
~Overweight before 10 years of age
~Informed consent from both obese children subject and legal representative e.g. parents"
11342457|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:
~Must be parent or direct sibling of obese subject
~Informed consent from both subject and parent is subject is below 21 years of age"
11342458|NCT02418364|Placebo Comparator|placebo reflexology|Placebo reflexology treatment
11342459|NCT02418364|No Intervention|control group|Data will be taken from questionnaires
11342460|NCT02418364|Experimental|reflexology treatment|Reflexology treatment
11342461|NCT02418338|Experimental|dmd children|echocardiography
11342462|NCT02418338|Other|healthy children|echocardiography
11342463|NCT02418325|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
11342464|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
11342465|NCT02418312|Placebo Comparator|placebo group|placebo for 6 months.
11342466|NCT02418299|Experimental|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
11342467|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
11342468|NCT02418273|Experimental|Denosumab|These subjects will receive two sequential doses of denosumab
11342469|NCT02418273|No Intervention|No drug intervention|These subjects do not receive denosumab
11342470|NCT02418260|Active Comparator|Open reduction and plate osteosynthesis|Open reduction and internal fixation with DCP 4.5mm plate.
11342471|NCT02418260|Experimental|Bridge Plate|Patients will be submitted to closed reduction and anterior bridge plate osteosynthesis (narrow 4.5mm DCP plate will be used)
11342472|NCT02418260|Experimental|Intramedullary nail|Patients will be submitted to closed reduction and locked intramedullary nail osteosynthesis.
11342473|NCT02418247|Active Comparator|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
11342474|NCT02418247|Sham Comparator|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
11342512|NCT02418000|Experimental|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
11342513|NCT02418000|Experimental|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
11347529|NCT02384551|Experimental|LTLS|Low total carbohydrate with low total simple carbohydrate diet
11342475|NCT02418221|Experimental|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure & pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
11342476|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
11342477|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
11342478|NCT02418195|Active Comparator|MDD with recent Suicide Attempt|All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
11342479|NCT02418195|Active Comparator|MDD with Suicidal Ideation no attempt|All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
11342480|NCT02418195|Active Comparator|MDD without Suicidal Ideation no attempt|All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
11342481|NCT02418195|No Intervention|Healthy Controls|Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.
11342482|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
11342483|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
11342484|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
11342485|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
11342486|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
11342487|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
11342488|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
11342489|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
11342490|NCT02418130|Experimental|UDCA004|UDCA004
11342491|NCT02418130|Placebo Comparator|Placebo of UDCA004|Placebo of UDCA004
11342492|NCT02418117|Experimental|Stereolitographic template's accuracy|Evaluating the accuracy of stereolitographic template comparing the final implant insertion to the planned implant position at coronal and apical level
11342493|NCT02418104|Experimental|CHS-1701|CHS-1701 followed by CHS-1701
11342494|NCT02418104|Active Comparator|Neulasta|Neulasta followed by Neulasta
11342495|NCT02418091|Experimental|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
11342496|NCT02418091|No Intervention|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
11342497|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
11342498|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
11342499|NCT02418065|Experimental|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
11342500|NCT02418065|Other|control group|oral nutritional supplementation
11342501|NCT02418052|Experimental|neck flexion group|Patients who fixed in neck flexion position after MIE
11342502|NCT02418052|No Intervention|control group|Patients without posture intervention after MIE
11342503|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
11342504|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
11342505|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
11342506|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
11342507|NCT02418013|Experimental|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
11342508|NCT02418013|Experimental|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
11342509|NCT02418013|Experimental|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
11342667|NCT02417142|Placebo Comparator|Placebo|"(existing treatment) + (Placebo)
~Intervention:
~Drug: Placebo"
11342514|NCT02418000|Experimental|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
11342515|NCT02418000|Experimental|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
11342516|NCT02417987|Active Comparator|High Volume injection|"A total volume of 50 ml:
~10 mls 0.5% bupivacaine hydrochloride and
~20 mg of Depomedrol (hydrocortisone)
~40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
11342517|NCT02417987|Active Comparator|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).
~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
11342518|NCT02417987|Sham Comparator|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
11342519|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
11342520|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
11342521|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
11342522|NCT02417948|Experimental|Arm I (educational brochure, online educational tutorial)|Participants receive a skin cancer educational and preventive brochure distributed by the National Cancer Institute and watch a 30-minute online tutorial video called X-Plain about skin cancer, preventative behaviors, and skin self-examinations.
11342523|NCT02417948|Active Comparator|Arm II (educational brochure)|Participants receive an educational brochure as in Arm I.
11342524|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
11342525|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
11342526|NCT02417922|Experimental|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).
~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
11342527|NCT02417922|Placebo Comparator|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
11342528|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
11342529|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
11342530|NCT02417896|Experimental|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
11342531|NCT02417896|No Intervention|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
11342532|NCT02417883|Experimental|Furosemide Stress Test|Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.
11342533|NCT02417870|Experimental|aldesleukin|
11342534|NCT02417857|Experimental|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
11342535|NCT02417857|Experimental|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
11342536|NCT02417844|Active Comparator|Tamsulosin HCl|
11342537|NCT02417844|Active Comparator|Tamsulosin|
11342538|NCT02417831|Active Comparator|tamsulosin capsules|
11342539|NCT02417831|Active Comparator|tamsulosin HCl capsules|
11342540|NCT02417818|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Plasma Therapy (PlasmaDerm)"
11342541|NCT02417818|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
~Intervention: Plasma Therapy (PlasmaDerm)"
11342542|NCT02417818|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Plasma Therapy (PlasmaDerm)"
11342543|NCT02417818|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Plasma Therapy (PlasmaDerm)"
11342544|NCT02417818|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342545|NCT02417818|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11409922|NCT01969656|Experimental|440 ng 2MD|
11342546|NCT02417818|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342547|NCT02417818|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342548|NCT02417818|Experimental|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342549|NCT02417818|Experimental|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342550|NCT02417818|Experimental|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342551|NCT02417818|Experimental|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
11342552|NCT02417805|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11342553|NCT02417805|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11342554|NCT02417805|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11342555|NCT02417805|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
11342556|NCT02417792||control|group of healthy participants
11342557|NCT02417792||Topical psoriasis treatment|Group of patients who are treated with topical medications for psoriasis
11342558|NCT02417792||Systemic psoriasis treatment|Group of patients who are treated with systematic medications for psoriasis
11342559|NCT02417779|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342560|NCT02417779|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342561|NCT02417779|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342562|NCT02417779|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342563|NCT02417779|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342564|NCT02417779|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342565|NCT02417779|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342566|NCT02417779|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342567|NCT02417779|Experimental|Hypertrophic burn scar|"Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342568|NCT02417779|Experimental|Hypertrophic burn scar (repetitive)|"Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342569|NCT02417779|Experimental|Flap|"Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342570|NCT02417779|Experimental|Flap (repetitive)|"Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.
~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
11342571|NCT02417766||Family members|Family members to the patients
11342572|NCT02417766||Patient|Patients at NIH
11342573|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
11342574|NCT02417740||Adult with absence of Portal Hypertension|Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.
11342604|NCT02417519|Experimental|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
11342575|NCT02417740||Adult with presence of Portal Hypertension|Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg).
11342576|NCT02417740||Minors likely to have the absence of Portal Hypertension|Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.
11342577|NCT02417740||Minors likely to have the presence of Portal Hypertension|Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5).
11342578|NCT02417701|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11342579|NCT02417688|Experimental|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
11342580|NCT02417675|Active Comparator|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.
~Infants receive the same care in each arm, according to the Standard of Care for Infants."
11342581|NCT02417675|Experimental|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.
~Infants receive the same care in each arm, according to the Standard of Care for Infants."
11342582|NCT02417662|Active Comparator|Systemic Anti-Cancer Therapy (SACT) alone|The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
11342583|NCT02417662|Experimental|SACT + Radical Radiotherapy (Conventional RT and SABR)|"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.
~The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines."
11342584|NCT02417649|Experimental|Ismigen|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
11342585|NCT02417649|Placebo Comparator|Placebo|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
11342586|NCT02417636|Experimental|Nurse-initiated and monitored ART|This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
11342587|NCT02417636|Active Comparator|Clinician - initiated and monitored ART|This is Standard of Care for the Uganda Ministry of Health to compared with the experimental task shifting. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Clinicians (Clinical Officer or Medical Officer) and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually.
11342588|NCT02417623|Experimental|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
11342589|NCT02417623|No Intervention|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
11342590|NCT02417610|Experimental|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
11342591|NCT02417610|Active Comparator|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
11342592|NCT02417597|Experimental|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
11342593|NCT02417597|Active Comparator|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
11342594|NCT02417597|No Intervention|Safety Control Group|Participants in this arm are aged over 65 years.
11342595|NCT02417584|Experimental|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
11342596|NCT02417571|Experimental|ABPM group|"Ambulatory blood pressure monitoring (ABPM) performed at 3, 6 months after randomization; adjusting drugs/doses based on ABPM results.
~Target BP: daytime ABP < 135/85 mm Hg according to British NICE clinical guideline 127."
11342597|NCT02417571|No Intervention|Office BP group|"Conventional BP management using office BP according to KDIGO guideline on BP management.
~Target BP: <140/90 mm Hg."
11342598|NCT02417558|Experimental|Alterniity Augmented Reality (AAR)|AAR training Participants use the patent pending AAR exercise and gaming (exergaming) platform that combines a physical training component (PTC) and a cognitive training component (CTC) in closed-feedback loop with Personalized Brain Network Activity (PBNA) test from a portable EEG.
11342599|NCT02417558|No Intervention|Passive Control Participants|Passive Control Participants do not receive an intervention serving as passive controls
11342600|NCT02417558|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the Aristotle University of Thessaloniki. The software is called VideoGrade and uses videos from Youtube (YouTube) documentaries (VideoGrade).
11342601|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
11342602|NCT02417519|Experimental|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
11342603|NCT02417519|Experimental|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
11409923|NCT01969643|Experimental|SGN-LIV1A Dose Escalation|
11342605|NCT02417519|Experimental|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
11342606|NCT02417519|Experimental|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
11342607|NCT02417519|Experimental|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
11342608|NCT02417506|Experimental|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
11342609|NCT02417506|Active Comparator|Ibuprofen|200 mg two capsule to be taken stat at the site
11342610|NCT02417493|Experimental|Simulation of Epinephrine Self-Injection|The patient will self-inject an empty syringe into his/her thigh simulating a self-injection of epinephrine during a routine outpatient visit to the allergist.
11342611|NCT02417493|No Intervention|Control Group|The patient will be encouraged to speak to their physician about self-injection, but will not undergo the self-injection protocol during a routine outpatient visit to the allergist.
11342612|NCT02417480|Active Comparator|Vegan arm|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. Researchers will ask participants on a vegan diet to follow their usual diet and exercise habits consistent for the two week study period.
11342613|NCT02417480|Experimental|Omnivorous arm|A diet containing all food groups. Researchers will ask participants on an omnivorous diet to follow habitual, usual diet and exercise habits for the first week. During the second week, participants will be asked to switch to a vegan diet for one week and to maintain their usual exercise habits.
11342614|NCT02417467|Experimental|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.
~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
11342615|NCT02417467|Other|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.
~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
11342616|NCT02417467|Other|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
11342617|NCT02417454|Experimental|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
11342618|NCT02417454|Placebo Comparator|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
11342619|NCT02417441|Experimental|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
11342620|NCT02417441|No Intervention|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
11342621|NCT02417428|Experimental|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
11342622|NCT02417428|Placebo Comparator|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
11342623|NCT02417428|Experimental|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
11342624|NCT02417428|Other|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
11342625|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
11342626|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
11342627|NCT02417402|Active Comparator|Untrained Physical Therapists|The patients allocated to the Control group will be treated by physical therapists who did not receive any training about clinical practice guidelines and pain management. These patients will receive the usual care from their physical therapists.
11342628|NCT02417402|Experimental|Trained Physical Therapists|The patients allocated to the Experimental group will be treated by physical therapists who received training about clinical practice guidelines and pain management.
11342629|NCT02417389|Experimental|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
11342630|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:
~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and
~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
11342631|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
11342632|NCT02417363||Group A|the control group,healthy individuals
11342666|NCT02417142|Experimental|Experimental|"(existing treatment) + (Drug)
~Intervention:
~Drug: Exenatide"
11342633|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
11342634|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
11342635|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
11342636|NCT02417350|Experimental|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
11342637|NCT02417350|Experimental|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
11342638|NCT02417337|Active Comparator|Group I|paracetamol 1000mg
11342639|NCT02417337|Experimental|Group II|ibuprofen 600mg + paracetamol 1000mg,
11342640|NCT02417337|Experimental|Group III|Mefenamic acid 500mg + Paracetamol 1000mg
11342641|NCT02417337|Experimental|Group IV|Diclofenac K 50mg + paracetamol 1000 mg
11342642|NCT02417337|Placebo Comparator|Group V|No medication
11342643|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
11342644|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
11342645|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
11342646|NCT02417298|Active Comparator|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
11342647|NCT02417298|Placebo Comparator|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
11342648|NCT02417285|Experimental|CC-122 in combination with Obinutuzumab|CC-122 will be administered orally QD starting on Day 1 for 5 consecutive days followed by 2 days off study drug every 7 days (5/7-day schedule) in each 28-day cycle in combination with Obinutuzumab administered as an intravenous (IV) infusion at a dose of 1000 mg on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8.
11342649|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
11342650|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
11342651|NCT02417246|Active Comparator|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
11342652|NCT02417246|Active Comparator|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
11342653|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
11342654|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
11342655|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
11342656|NCT02417220|Active Comparator|Weight Watchers Online 2015|
11342657|NCT02417220|Experimental|Weight Watchers Online 2015 Enhanced|
11342658|NCT02417207|Sham Comparator|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
11342659|NCT02417207|Active Comparator|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
11342660|NCT02417181|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the out-of-hours primary care service
11342661|NCT02417181|Experimental|Physician Assistants Care|Medical care provided by the Physician Assistant at the out-of-hours primary care service
11342662|NCT02417155|Experimental|HTR|The 'Hoftraining' group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
11342663|NCT02417155|Active Comparator|EIN|The 'extensive instruction' group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
11342664|NCT02417155|Active Comparator|STR|The 'short training' group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
11342665|NCT02417155|Active Comparator|SIN|The 'short instruction' group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
11342669|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
11342670|NCT02417116|Placebo Comparator|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
11342671|NCT02417116|Active Comparator|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
11342672|NCT02417116|Active Comparator|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
11342673|NCT02417103|Active Comparator|GLP-1 (Liraglutide)|Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
11342674|NCT02417103|Placebo Comparator|Placebo Comparator|Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
11342675|NCT02417090||Metformin therapy|9-year-old children whose mothers used metformin for gestational diabetes
11342676|NCT02417090||Insulin therapy|9-year-old children whose mothers used insulin for gestational diabetes
11342677|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
11342678|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11342679|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11342680|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
11342681|NCT02417051|Experimental|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
11342682|NCT02417051|No Intervention|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
11342683|NCT02417025|Experimental|PE-HBT|Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
11342684|NCT02417025|Active Comparator|PE-SD|Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
11342685|NCT02417012|Experimental|U-TURN intervention|"The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.
~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
11342686|NCT02417012|Active Comparator|Standard care|"The reference group will receive diabetes education and support by trained nurses.
~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
11342687|NCT02416999|Experimental|patient group|
11342688|NCT02416973|Other|Sham of Provant|Sham of Provant
11342689|NCT02416973|Other|Active Treatment|Active Provant Treatment
11342690|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
11342691|NCT02416960|Experimental|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
11342692|NCT02416960|Active Comparator|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
11342693|NCT02416960|No Intervention|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
11342694|NCT02416947|Placebo Comparator|0g SCF|Subjects will consume 0 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
11342695|NCT02416947|Active Comparator|10 g SCF|Subjects will consume 10 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
11342696|NCT02416947|Active Comparator|20g SCF|Subjects will consume 20 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
11342697|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
11342726|NCT02416765|Active Comparator|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
11409924|NCT01969643|Experimental|SGN-LIV1A + Trastuzumab|
11342698|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.
~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
11342699|NCT02416921|Experimental|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
11342700|NCT02416921|Active Comparator|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
11342701|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.
~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).
~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.
~G-CSF will be given 300 mcg SC once daily on Days 3-8.
~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.
~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
11342702|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.
~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).
~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.
~G-CSF will be given 300 mcg SC once daily on Days 3-8.
~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.
~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
11342703|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.
~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).
~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.
~G-CSF will be given 300 mcg SC once daily on Days 3-8.
~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.
~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
11342704|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
11342705|NCT02416882|Other|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
11342706|NCT02416882|Other|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
11342707|NCT02416869|Active Comparator|Intramuscular application|Intramuscular application of 4mg Dexamethasone
11342708|NCT02416869|Experimental|Submucosal application|Submucosal application of 4mg Dexamethasone
11342709|NCT02416869|Active Comparator|4mg Dexamethasone submucosal|4mg Dexamethasone submucosal application
11342710|NCT02416869|Experimental|8mg Dexamethasone submucosal|8mg Dexamethasone submucosal application
11342711|NCT02416869|Active Comparator|4mg Dexamethasone postoperative|4mg Dexamethasone postoperative application
11342712|NCT02416869|Experimental|4mg Dexamethasone preoperative|4mg Dexamethasone postoperative application
11342713|NCT02416843|Experimental|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
11342714|NCT02416843|Experimental|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
11342715|NCT02416843|Experimental|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
11342716|NCT02416817|Experimental|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
11342717|NCT02416817|Experimental|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
11342718|NCT02416804|Experimental|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
11342719|NCT02416804|Active Comparator|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
11342720|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.
~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
11342721|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.
~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
11342722|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
11342723|NCT02416778|Experimental|Treatment Arm|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
11342724|NCT02416765|Active Comparator|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
11342725|NCT02416765|Active Comparator|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
11342758|NCT02416596|Experimental|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
11342727|NCT02416765|Active Comparator|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
11342728|NCT02416765|Active Comparator|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
11342729|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
11342730|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
11342731|NCT02416739|Experimental|Nicotinamide|"Nicotinamide with EGFR-TKI:
~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day
~nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
11342732|NCT02416739|Placebo Comparator|Placebo|"Placebo tablet with EGFR-TKI:
~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day
~placebo tablet - per oral, twice a day, until the event or censoring occurs"
11342733|NCT02416726|Experimental|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
11342734|NCT02416726|Experimental|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
11342735|NCT02416726|Experimental|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
11342736|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
11342737|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
11342738|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
11342739|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
11342740|NCT02416700|Experimental|immediate implant surgery|Immediate implant surgery in one site.
11342741|NCT02416700|Active Comparator|conventional implant surgery|Conventional implant surgery in another site
11342742|NCT02416687|Active Comparator|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
11342743|NCT02416687|No Intervention|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
11342744|NCT02416674|Experimental|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
11342745|NCT02416661||Participants diagnosed with Gaucher disease|Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old
11342746|NCT02416648|Experimental|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
11342747|NCT02416648|Experimental|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
11342748|NCT02416648|No Intervention|Routine care|The control group received routine clinic care.
11342749|NCT02416635||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11342750|NCT02416635||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11342751|NCT02416635||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11342752|NCT02416635||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11342753|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
11342754|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
11342755|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
11342756|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
11342757|NCT02416609|Experimental|Gem Ox with LDR & sequential SBRT|Four GemOx cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered. Further two cycles of additional GemOx without LDR can be administered after SBRT.
11342798|NCT02416388|Experimental|R4-VOS-IDAC|Intermediate dose cytarabine and vosaroxin
11342799|NCT02416388|Active Comparator|R4-IDAC (without VOS)|Intermediate dose cytarabine alone
11342759|NCT02416596|No Intervention|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
11342760|NCT02416583|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
11342761|NCT02416583|Active Comparator|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
11342762|NCT02416570|Active Comparator|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
11342763|NCT02416570|Placebo Comparator|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
11342764|NCT02416557|Experimental|Group P|Patients using positive end-expiratory pressure (PEEP) of 10 cmH2O (centimeter of water) intraoperatively
11342765|NCT02416557|No Intervention|Group C|Patients using no positive end-expiratory pressure (zero PEEP) intraoperatively
11342766|NCT02416544|Experimental|Full participation|Participants in this group receive lunch which is calorie-restricted and low-salt during 12 weeks, the total duration of this study.
11342767|NCT02416544|Experimental|Two thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 4 weeks from the beginning of the study and maintain the diet during 8 weeks.
11342768|NCT02416544|Experimental|One thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 8 weeks from the beginning of the study and maintain the diet during 4 weeks.
11342769|NCT02416531|Active Comparator|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
11342770|NCT02416531|Experimental|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
11342771|NCT02416531|Experimental|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
11342772|NCT02416505|No Intervention|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.
~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
11342773|NCT02416505|Active Comparator|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.
~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
11342774|NCT02416505|Active Comparator|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.
~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
11342775|NCT02416492|Experimental|SB623 Cells|SB623 Cells: 2.5, 5 or 10 million cells surgically implanted adjacent to the injured cerebral region.
11342776|NCT02416492|Sham Comparator|Sham Surgery|Control Sham Surgery (partial burr hole only)
11342777|NCT02416479|Experimental|SystemCHANGE|SystemCHANGE supports patient-designed, interventionist-guided, small experiments to: 1) assess individual systems (including important others who shape medication taking) and the system's impact on medication taking and propose individual system solutions to improve MA, 2) implement the proposed individual systems' solutions to improve MA, 3) track MA data, and 4) evaluate MA data.
11342778|NCT02416479|Active Comparator|Patient-education attention-control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
11342779|NCT02416466|Experimental|anti-CEA CAR-T cells + Sir-Spheres|Three infusions of gene-modified anti-CEA T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2. A single dose of Sir-Spheres will be given 2 weeks following the final T cell dose.
11342780|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
11342781|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
11342782|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
11342783|NCT02416440||screening for diabetes prevalence|blood samples
11342784|NCT02416427|Experimental|Arm A|Atorvastatin 80 mg/day for 3 weeks
11342785|NCT02416427|No Intervention|Arm B|Observation
11342786|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
11342787|NCT02416414||Healthy Controls|Healthy individuals.
11342788|NCT02416401|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
11342789|NCT02416401|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
11342790|NCT02416388|Experimental|R1-IDA|Idarubicin
11342791|NCT02416388|Active Comparator|R1-DAUNO|Daunorubicin
11342792|NCT02416388|Active Comparator|R2-HDAC|High dose cytarabine
11342793|NCT02416388|Experimental|R2-IDAC|Intermediate dose cytarabine
11342794|NCT02416388|Active Comparator|R3-MAC-MTX|Methotrexate and mycophenolic acid
11342795|NCT02416388|Experimental|R3-MAC-MPA|Cyclosporine and mycophenolic acid
11342796|NCT02416388|Active Comparator|R3-RIC-CICLO|Cyclosporine
11342797|NCT02416388|Experimental|R3-RIC-MPA|Cyclosporine and mycophenolic acid
11342805|NCT02416362|No Intervention|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
11342806|NCT02416362|Experimental|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
11342807|NCT02416362|Experimental|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
11342808|NCT02416349|Active Comparator|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
11342809|NCT02416349|Placebo Comparator|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
11342810|NCT02416336|Experimental|Sentinella intraoperative use|"Standard of care intraoperative protocol
~Localize SLN with the Gamma Probe for In vivo count
~Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)
~Surgically remove/excise localized SLN
~Ex vivo count - excised SLN with Gamma Probe
~In vivo background/roaming count with Gamma Probe
~Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)
~Sentinella intraoperative imaging protocol
~Survey surgical field/Post-excision control with Sentinella for remaining SLNs
~If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs
~Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
11342811|NCT02416323|No Intervention|Usual Care|Community therapist delivers routine care to participant child with no training in AIM HI.
11342812|NCT02416323|Other|AIM HI Training|Therapist enrolls in AIM HI training
11342813|NCT02416310|Experimental|TEAS group|TEAS are performed by a specific investigator on the specially acupoint.
11342814|NCT02416310|Sham Comparator|Sham group|TEAS are performed by a specific investigator on the non-acupoint.
11342815|NCT02416310|Placebo Comparator|Control group|Only place cutted electrodes but do not give any electrical stimulation.
11342816|NCT02416297|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
11342817|NCT02416297|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
11342818|NCT02416284|Experimental|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
11342819|NCT02416271|Experimental|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
11342820|NCT02416271|Active Comparator|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
11342821|NCT02416258|Active Comparator|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
11342822|NCT02416258|Placebo Comparator|Aerosol spray vehicle|No active ingredient, topical
11342823|NCT02416258|Active Comparator|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
11342824|NCT02416258|Active Comparator|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
11342825|NCT02416258|Active Comparator|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
11342826|NCT02416258|Active Comparator|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
11342827|NCT02416245|Experimental|Test beverage powder|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
11342828|NCT02416245|Placebo Comparator|Control beverage powder|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
11342829|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
11342830|NCT02416206|Experimental|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
11342831|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
11342832|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
11342833|NCT02416180|Experimental|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
11342834|NCT02416167|Active Comparator|FYU-981 High dose|Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
11342864|NCT02416024||No Refractory hypotension group|Patient who did not require more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia.
11342835|NCT02416167|Active Comparator|FYU-981 High middle dose|Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
11342836|NCT02416167|Active Comparator|FYU-981 Middle dose|FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
11342837|NCT02416167|Active Comparator|FYU-981 Low dose|Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
11342838|NCT02416167|Placebo Comparator|Placebo|Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
11342839|NCT02416154||Follicular phase|Normally cycling women in the follicular phase of menses
11342840|NCT02416154||Luteal phase|Normally cycling women in the luteal phase of menses
11342841|NCT02416141|Active Comparator|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.
~Intervention: use of fast release oro dispersible tramadol 50 mg"
11342842|NCT02416141|Placebo Comparator|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.
~Intervention: use of placebo"
11342843|NCT02416128|Active Comparator|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
11342844|NCT02416128|Experimental|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
11342845|NCT02416115|Active Comparator|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
11342846|NCT02416115|Active Comparator|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
11342847|NCT02416115|Experimental|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
11342848|NCT02416102|Active Comparator|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
11342849|NCT02416102|Experimental|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
11342850|NCT02416102|Experimental|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
11342851|NCT02416089|Experimental|Tampostat|Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)
11342852|NCT02416089|Active Comparator|Condom catheter tamponade|Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
11342853|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level [EL2].
11342854|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level [EL2] .
11342855|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
11342856|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level [EL4] .
11342857|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
11342858|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level [EL4].
11342859|NCT02416063|Active Comparator|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .
~Drug:caudal Dexmedetomidine 1μg /kg.
~Intravenous :10 ml normal saline
~Anesthesia was induced and maintained with sevoflurane"
11342860|NCT02416063|Active Comparator|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg
~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline
~Anesthesia was induced and maintained with sevoflurane"
11342861|NCT02416063|Placebo Comparator|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .
~Intravenous: 10 ml Normal saline
~Anesthesia was induced and maintained with sevoflurane"
11342862|NCT02416037|Experimental|Prone Proseva|
11342863|NCT02416037|Active Comparator|Prone Talmor|
11342999|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
11342865|NCT02416024||Control|Patient who required more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia
11342866|NCT02416011|No Intervention|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
11342867|NCT02416011|Active Comparator|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
11342868|NCT02416011|Experimental|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
11342869|NCT02415998||TEE|
11342870|NCT02415985|Other|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
11342871|NCT02415985|Other|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
11342872|NCT02415972||All study participants|Patients with Stroke
11342873|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
11342874|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
11342875|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
11342876|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
11342877|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
11342878|NCT02415946|Active Comparator|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
11342879|NCT02415946|Experimental|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
11342880|NCT02415933|Experimental|Trickle Up|Economic empowerment
11342881|NCT02415933|Experimental|Trickle Up Plus|Economic empowerment + child rights sensitization
11342882|NCT02415933|No Intervention|Wait-list|Women in villages assigned to the control arm do not receive any intervention during the study period, but are placed on a wait-list to receive the intervention upon completion of the evaluation phase.
11342883|NCT02415920|Experimental|Experimental|These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
11342884|NCT02415920|Placebo Comparator|Control - Placebo|These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
11342885|NCT02415907|Experimental|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.
~Period II: Administration of Lu AF67708 single dose (week 4)"
11342886|NCT02415881|Experimental|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
11342887|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
11342888|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
11342889|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
11342890|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
11342891|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
11342892|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
11342893|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
11342894|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
11342895|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
11342896|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
11342897|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
11342898|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
11342899|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
11342900|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
11342901|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
11342902|NCT02415829|Experimental|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
11342903|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
11342904|NCT02415803|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
11342905|NCT02415803|Active Comparator|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
11342906|NCT02415803|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
11342907|NCT02415790|Experimental|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
11342908|NCT02415790|Experimental|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
11342909|NCT02415790|Experimental|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
11342910|NCT02415790|Experimental|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
11342911|NCT02415777|Experimental|udca003|udca003
11342912|NCT02415777|Placebo Comparator|placebo|placebo of udca003
11342913|NCT02415764|Other|Pilot test Intervention OnTrack>The Game|"Consumers who have been referred to OnTrackNY sites at Washington Heights Community Service or Mental Health Association Westchester in the past six months will be recruited to participate in a product evaluation of OnTrack>The Game.
~Intervention: This is a behavioral/attitudinal intervention, using OnTrack>The Game, which will include each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes)."
11342914|NCT02415751||self-care education|All patients in the study will receive self-care education
11342915|NCT02415725|Experimental|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
11342916|NCT02415712||Fomepizole Intravenous Infusion|Fomepizole Intravenous Infusion
11342917|NCT02415699|Experimental|DC-CIK Immunotherapy Plus Chemotherapy|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
11342918|NCT02415699|Active Comparator|Chemotherapy Alone|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
11342919|NCT02415673|Experimental|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
11342920|NCT02415673|Experimental|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
11342921|NCT02415660|Experimental|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
11342922|NCT02415660|Sham Comparator|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
11342923|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
11342924|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
11343000|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
11342925|NCT02415634|Experimental|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
11342926|NCT02415634|Active Comparator|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
11342927|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
11342928|NCT02415608|Experimental|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
11342929|NCT02415608|Experimental|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
11342930|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
11342931|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
11342932|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
11342933|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
11342934|NCT02415582|Experimental|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
11342935|NCT02415582|Experimental|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
11342936|NCT02415582|Sham Comparator|Control|Participants do not exercise and remain sitting for 45 minutes
11342937|NCT02415569|Experimental|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
11342938|NCT02415569|Experimental|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
11342939|NCT02415569|Active Comparator|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
11342940|NCT02415556|Experimental|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
11342941|NCT02415556|Placebo Comparator|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
11342942|NCT02415556|Experimental|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
11342943|NCT02415556|Placebo Comparator|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
11342944|NCT02415543|Active Comparator|GROUP A|Group A will undergo SIL-TEP inguinal hernia repair with a single port LESS (12 to 15 mm paraumbilical)
11342945|NCT02415543|Active Comparator|GROUP B|Group B will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
11342946|NCT02415530|Placebo Comparator|Term infant control|term infant without intervention
11342947|NCT02415530|Placebo Comparator|VLBW infant control|very low birth weight infant without intervention
11342948|NCT02415530|Experimental|VLBW infant intervention|Combined home visiting and group intervention for very low birth weight infant
11342949|NCT02415517|Experimental|Experimental group|Intervention: Cognitive Training
11342950|NCT02415517|Active Comparator|Active control group|Intervention: Test of general knowledge
11342951|NCT02415517|No Intervention|Passive control group|No intervention
11342952|NCT02415504|Experimental|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
11342953|NCT02415504|Other|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
11342954|NCT02415491|Experimental|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
11342955|NCT02415465|Active Comparator|Combined Spinal Epidural|Spinal Intraoperative Anesthesia with standard Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus) with standard post-operative analgesics.
11342956|NCT02415465|Active Comparator|General+Continuous Adductor Canal Block|General Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
11342957|NCT02415465|Active Comparator|Spinal+Continuous Adductor Canal Block|Spinal Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
11342958|NCT02415452||Acute Coronary Syndrome (ACS) patients|Acute coronary syndrome (ACS) patients who underwent coronary angiography ,drug-eluting stent (DES) implantation, and eye fundus examination.
11342959|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
11342960|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
11342961|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
11343001|NCT02415231|Experimental|humor|humor group will watch humor video for 20 minutes
11342962|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
11342963|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
11342964|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
11342965|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
11342966|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
11342967|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
11342968|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
11342969|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
11342970|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
11342971|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
11342972|NCT02415413|Experimental|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.
~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).
~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).
~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
11342973|NCT02415400|Active Comparator|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
11342974|NCT02415400|Active Comparator|Vitamin K Antagonist|VKA tablets orally once daily
11342975|NCT02415400|Placebo Comparator|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
11342976|NCT02415400|Placebo Comparator|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
11342977|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
11342978|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
11342979|NCT02415374|Placebo Comparator|Low-AVA oat flour cookies|Three low-AVA oat flour cookies
11342980|NCT02415374|Experimental|High-AVA oat flour cookies|Three high-AVA cookies
11342981|NCT02415361|No Intervention|Arm A|"Standard care consists of:
~a phone call from a CLP-nurse after the referral from the local birth hospital has been received
~telephone service at parents request and at the staffs availability
~invitation to a one-day-information course before surgery"
11342982|NCT02415361|Active Comparator|Arm B|"Systematic follow up by a special trained nurse consists of:
~telephone contact with the parents shortly after birth
~visit at the maternity ward within 36 hours after the referral has been received
~telephone follow ups at specific times and at parents request
~guidance and support in feeding and treatment
~written information
~cooperation with the staff at the maternity unit and the health centre
~follow up in accordance with a check-list and log
~invitation to a one-day-information course before surgery"
11342983|NCT02415348|Experimental|Fibroscan|Fibroscan under simultaneous cardiac monitoring
11342984|NCT02415335|Placebo Comparator|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
11342985|NCT02415335|Experimental|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
11342986|NCT02415309|Active Comparator|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
11342987|NCT02415309|Active Comparator|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
11342988|NCT02415309|Placebo Comparator|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
11342989|NCT02415296||stage 1|French online gamblers.
11342990|NCT02415296||stage 2|Validation of problematic gamblers score on possible problematic gamblers.
11342991|NCT02415296||stage 3|240 problematic gamblers.
11342992|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
11342993|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
11342994|NCT02415270|Experimental|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
11342995|NCT02415270|Experimental|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
11342996|NCT02415270|Placebo Comparator|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
11342997|NCT02415257|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.
~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
11342998|NCT02415257|No Intervention|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
11343002|NCT02415231|No Intervention|control non humor|control group did not watch humor, they sat quietly for 20 minutes.
11343003|NCT02415218|Experimental|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
11343004|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.
~The number of this group will be double than the control group to get more information about safety and efficacy."
11343005|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
11343006|NCT02415179|Experimental|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
11343007|NCT02415179|Active Comparator|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
11343008|NCT02415166|Experimental|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
11343009|NCT02415166|Placebo Comparator|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
11343010|NCT02415166|Experimental|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
11343011|NCT02415166|Placebo Comparator|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
11343012|NCT02415153|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11343013|NCT02415140||COPD|Spirometry confirmed COPD patients
11343014|NCT02415140||Control|normal geriatric patients without lung disease
11343015|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
11343016|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
11343017|NCT02415114|Active Comparator|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
11343018|NCT02415114|Active Comparator|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
11343019|NCT02415101|Active Comparator|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
11343020|NCT02415101|Active Comparator|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
11343021|NCT02415088|Active Comparator|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
11343022|NCT02415088|Active Comparator|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
11343023|NCT02415062|Experimental|high dose donepezil (23mg)|Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
11343024|NCT02415062|Active Comparator|standard dose denepezil (10mg)|Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
11343025|NCT02415049|Active Comparator|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
11343026|NCT02415049|Experimental|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
11343027|NCT02415036|Experimental|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).
~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
11343028|NCT02415036|Experimental|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).
~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
11343029|NCT02415023|Experimental|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
11343030|NCT02414997|Experimental|RIPC group|Surround left upper limb with cuff, inflate cuff to 200 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
11343031|NCT02414997|Sham Comparator|Sham RIPC group|Surround left upper limb with cuff, inflate cuff to 20 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
11343032|NCT02414984||Golimumab|Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
11343033|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
11343034|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
11343035|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
11343036|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
11343037|NCT02414945|Experimental|Tumor Infiltrating lymphocytes (TILs)|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days
~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10^10 - 1.6x10^11 cells
~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
11343138|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
11343139|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
11343140|NCT02414191|No Intervention|Control|Participants in this study arm will receive no form of feedback.
11343038|NCT02414932|Experimental|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate >110/minute or systolic/diastolic blood pressure (BP) >180/100 or >20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
11343039|NCT02414932|Active Comparator|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
11343040|NCT02414919||HERC|Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
11343041|NCT02414906|Experimental|Intervention group|Goal-directed therapy
11343042|NCT02414906|No Intervention|Control group|Control group
11343043|NCT02414893||Non obese|
11343044|NCT02414893||Morbidly obese|
11343045|NCT02414893||Sleeve gastrectomy|
11343046|NCT02414880|Active Comparator|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
11343047|NCT02414880|Active Comparator|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
11343048|NCT02414880|Active Comparator|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
11343049|NCT02414880|Active Comparator|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.
~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
11343050|NCT02414867||1|Normal weight mothers
11343051|NCT02414867||2|Overweight/Obese mothers
11343052|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
11343053|NCT02414854|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
11343054|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
11343055|NCT02414854|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
11343056|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
11343057|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation
11343058|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
11343059|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
11343060|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
11343061|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
11343062|NCT02414815|Experimental|AF group|Atrial fibrillation
11343063|NCT02414802|Experimental|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
11343064|NCT02414802|Other|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4-6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
11343065|NCT02414789|Experimental|SRM / MS-MS|
11343066|NCT02414776|Experimental|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
11343067|NCT02414763|No Intervention|Care as Usual|Participants will receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
11347530|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
11343068|NCT02414763|Experimental|Teachable Moment Brief Intervention|The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, functional analysis of the suicidal ideation and behaviors, and crisis response planning. Participants will also receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
11343069|NCT02414750|Experimental|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.
~During the study biopsies and blood will be taken from the patients."
11343070|NCT02414737|Experimental|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
11343071|NCT02414724|Experimental|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11343072|NCT02414711|Other|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.
~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
11343073|NCT02414711|Other|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.
~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
11343074|NCT02414698|Active Comparator|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
11343075|NCT02414698|Active Comparator|TESI|Transforaminal Epidural Steroid Injections
11343076|NCT02414685|Experimental|intravenous chemotherapy|"TIP regimen:
~Paclitaxel 250 mg/ m2 iv on day 1
~Ifosfamide 1,2 g/ m2/ day iv x 5 days
~Cisplatin 20 mg/ m2/ day iv x 5 days"
11343077|NCT02414672|Experimental|CareSTEPS|CareSTEPS provides skills training in six domains that are central to the caregiving role: self-care, stress management, symptom management, effective communication, problem-solving, and social support.
11343078|NCT02414672|No Intervention|Usual Medical Care (UMC)|Patients receive standard oncologic and generalist palliative care from their healthcare team.
11343079|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
11343080|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
11343081|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
11343082|NCT02414620|Experimental|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
11343083|NCT02414607|Experimental|Elderberry Juice|Participants will drink 5ml of elderberry juice, diluted in 8oz of water, 3 times per day for three months.
11343084|NCT02414607|Placebo Comparator|Placebo|Participants will drink 5ml of colored water, diluted in 8oz of water, 3 times per day for three months.
11343085|NCT02414594|Experimental|IONIS-APO(a)-LRx|Drug: IONIS-APO(a)-LRx
11343086|NCT02414594|Placebo Comparator|Placebo (Normal Saline)|Drug: Sterile Normal Saline (0.9% NaCl)
11343087|NCT02414581|Experimental|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
11343088|NCT02414581|Active Comparator|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
11343089|NCT02414581|Experimental|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
11343090|NCT02414568|Experimental|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
11343091|NCT02414555|Active Comparator|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
11343092|NCT02414555|Active Comparator|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
11343093|NCT02414529|Placebo Comparator|Placebo group|"Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.
~Subjects are blinded then they will crossover groups"
11343094|NCT02414529|Active Comparator|Treatment group|"Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.
~Subjects are blinded then they will crossover groups."
11343095|NCT02414516|Experimental|OBP-801|
11343096|NCT02414503|Active Comparator|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
11343097|NCT02414503|Active Comparator|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
11343098|NCT02414503|Placebo Comparator|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
11343099|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
11343100|NCT02414464|Experimental|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
11343101|NCT02414464|Experimental|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
11343102|NCT02414464|Experimental|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
11343103|NCT02414451|Experimental|Propranolol arm|"Propranolol will be administered via oral capsule(s) daily for a period of 10 weeks, involving gradual titration up from 40mg to 100mg and subsequent tapering off of the drug. The titration/tapering schedule will be as follows:
~Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules"
11343141|NCT02414191|Other|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
11343104|NCT02414451|Placebo Comparator|Placebo arm|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:
~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
11343105|NCT02414438|No Intervention|Current Practice Arm|Physicians follow current care procedures
11343106|NCT02414438|Experimental|FirstStep and NextStep Information|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are able to order test results in Round 2
11343107|NCT02414438|Experimental|FirstStep and NextStep Results|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are specifically prompted to order test results in Round 2
11343108|NCT02414425|Experimental|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.
~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
11343109|NCT02414425|Placebo Comparator|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.
~Anorectal manometry will be performed for evaluation of efficacy of placebo"
11343110|NCT02414412|Active Comparator|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
11343111|NCT02414412|Placebo Comparator|Placebo|placebo 250mg orally 2 times a day for 4 weeks
11343112|NCT02414399|Experimental|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
11343113|NCT02414399|Placebo Comparator|Placebo|5 days of taste/appearance/bottle-matched placebo
11343114|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
11343115|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
11343116|NCT02414373|Experimental|Ropivacaine|Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)
11343117|NCT02414373|Active Comparator|Bupivacaine|Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)
11343118|NCT02414360|Experimental|Shortened Format|Shortened format of a systematic review
11343119|NCT02414360|Active Comparator|Control|Full length systematic review
11343120|NCT02414347||Experimental F 18 T807|
11343121|NCT02414334|Active Comparator|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
11343122|NCT02414334|Experimental|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
11343123|NCT02414321||Fontan group|"Right heart catheterization:
~pulmonary artery OCT analysis
~dobutamine stress test
~pulmonary vascular response test (nitric oxide)
~trans-thoracic echocardiography"
11343124|NCT02414321||Control group|"Right heart catheterization:
~- pulmonary artery OCT analysis"
11343125|NCT02414321||PAH group|"Right heart catheterization:
~- pulmonary artery OCT analysis"
11343126|NCT02414308|Experimental|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
11343127|NCT02414295|Experimental|Mesenchymal stem cell injection|Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery
11343128|NCT02414282||Experimental F 18 T807|
11343129|NCT02414269|Experimental|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
11343130|NCT02414269|Experimental|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
11343131|NCT02414269|Experimental|CAR T cell and pembrolizumab|Pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration. Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by reassessment. Those responding or deriving clinical benefit, without unacceptable toxicity, will continue pembrolizumab. Patients will be followed weekly for the first four weeks. Patients in cohorts 9 and in Phase II will receive pembrolizumab 4 weeks(+3/- 1 week window) following CAR T cell administration.
11343132|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
11343133|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
11343134|NCT02414230||Experimental F 18 T807|
11343135|NCT02414217|Experimental|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
11343136|NCT02414217|Experimental|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
11343137|NCT02414217|No Intervention|Control|Participants were given written educational materials about diabetes.
11343142|NCT02414191|Other|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
11343143|NCT02414178|Experimental|Experimental F 18 T807|
11343144|NCT02414165|Experimental|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)
~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
11343145|NCT02414165|Active Comparator|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:
~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.
~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.
~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:
~at a dose of 50 mg/m2 PO once daily continuously, or
~at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
11343146|NCT02414152|Experimental|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
11343147|NCT02414139|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID as second or third line
11343148|NCT02414139|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mg BID as second or third line
11343149|NCT02414139|Experimental|cMET GCN < 4|Pre-treated patients with cMET GCN < 4 treated with INC280 at 400mg BID as second or third line
11343150|NCT02414139|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line
11343151|NCT02414139|Experimental|cMET dysregulation - treatment-naïve|Treatment-naïve patients with cMET dysregulation treated with INC280 at 400mg BID
11343152|NCT02414139|Experimental|cMET dysregulation - second line|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line
11343153|NCT02414139|Experimental|cMET mutations treatment-naïve|Treatment-naïve patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
11343154|NCT02414126|Active Comparator|Children with dilated cardiomyopathy with an ejection fraction|
11343155|NCT02414126|Active Comparator|Children with univentricular congenital heart disease|
11343156|NCT02414126|Active Comparator|Children with left valvulopathy|
11343157|NCT02414113||Low GNOS donors|
11343158|NCT02414113||High GNOS donors|
11343159|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
11343160|NCT02414087|Active Comparator|study group|ICB Medical Insoles
11343161|NCT02414087|Placebo Comparator|control group|without ICB Medical insoles
11343162|NCT02414074|Other|Youth Behavioral Intervention|Teen Intervene Program
11343163|NCT02414074|Other|Parent Education|Everyday Parenting Program
11343164|NCT02414061|Experimental|Breakfast - Carbohydrate + Whey Protein|Addition of whey protein isolate (20 g dissolved in flavoured water) to breakfast meal composition
11343165|NCT02414061|Placebo Comparator|Breakfast - Carbohydrate|Only flavoured water consumed with breakfast meal
11343166|NCT02414061|No Intervention|No Breakfast|Only water consumed at breakfast time point
11343167|NCT02414048|Other|Pimonidazole|All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour
11343168|NCT02414009|Experimental|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
11343169|NCT02414009|Active Comparator|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day
~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
11343170|NCT02413996|Experimental|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
11343171|NCT02413996|Active Comparator|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
11343172|NCT02413983||CI (conventional incision)|The living liver donors underwent hepatectomy using right subcostal incision with a midline extension (conventional incision)
11343173|NCT02413983||MI (midline incision)|The living liver donors underwent hepatectomy using upper midline incision (10cm) without laparoscopic assistance
11343174|NCT02413983||TI (transverse incision)|The living liver donors underwent hepatectomy using transverse incision with laparosocpic assistance
11343175|NCT02413970|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System.
11343176|NCT02413957|No Intervention|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
11343177|NCT02413957|Experimental|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
11343213|NCT02413697|Experimental|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
11343178|NCT02413957|Experimental|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
11343179|NCT02413944|Experimental|healthy volunteers|ACTH stimulation test
11343180|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
11343181|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
11343182|NCT02413905||Senegal|Stool samples on Children with and without severe acute malnutrition in Senegal recruited in 3 locations (Dakar, Dielmo and Ndiop)
11343183|NCT02413905||Niger|Stool samples Children with and without severe acute malnutrition in Niger recruited in Niamey
11343184|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
11343185|NCT02413866|Experimental|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
11343186|NCT02413866|Experimental|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
11343187|NCT02413853|Experimental|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11343188|NCT02413853|Experimental|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11343189|NCT02413840|Experimental|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
11343190|NCT02413840|No Intervention|control group|Psychological counseling only.
11343191|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
11343192|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
11343193|NCT02413814|Experimental|Anger Reduction Treatment|The treatment consists of eight 30-minute IBM sessions. Participants will be presented with ambiguous scenarios and asked imagine themselves in these situations. In the first task, the scenario will be followed by a benign interpretation of the situation. Participants will answer a comprehension question designed to have participants endorse this benign interpretation. In the second task, participants will be presented with a word denoting an interpretation with either a negative/hostile or positive/benign connotation. Following this word, an ambiguous scenario will appear. Participants will indicate whether the word and the scenario were related. They will receive feedback training them to endorse positive interpretations and reject negative interpretations.
11343194|NCT02413814|Placebo Comparator|Control Condition|Participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors (i.e., topics of exercise, diet, hygiene, social support, healthy activities, and sleep, taken from protocols developed from our ongoing research). These participants will also view relaxing videos consisting of brief guided meditation instructions, pictures of nature scenes, and soft music. These sessions (psychoeducation and relaxing videos) will be matched for time with the active treatment condition, lasting 30 minutes each.
11343195|NCT02413801||Psoriasis|Individuals with psoriasis
11343196|NCT02413801||Healthy|Individuals that are healthy
11343197|NCT02413788|Experimental|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
11343198|NCT02413788|Active Comparator|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
11343199|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
11343200|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
11343201|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
11343202|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
11343203|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
11343204|NCT02413749||Stable PsA response to treatment|Individuals with psoriatic arthritis who are being treated standard of care with a stable DMARD or a biologic
11343205|NCT02413749||PsA inadequate response to DMARD|Individuals with psoriatic arthritis who have had an inadequate response to a DMARD and are being treated standard of care with a biologic.
11343206|NCT02413736|Experimental|Imatinib|Imatinib 400 mg/day for 24 months.
11343207|NCT02413736|No Intervention|No imatinib|No further imatinib.
11343208|NCT02413723|Active Comparator|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
11343209|NCT02413723|Placebo Comparator|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
11343210|NCT02413710|Active Comparator|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
11343211|NCT02413710|Experimental|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
11343212|NCT02413697|Active Comparator|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
11343214|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
11343215|NCT02413671|Other|Lupin Protein|Subjects received a test meal rich in carbohydrates and supplemented with lupin protein.
11343216|NCT02413671|Other|Whey Protein|Subjects received a test meal rich in carbohydrates and supplemented with whey protein.
11343217|NCT02413671|Other|Reference|Subjects received a test meal rich in carbohydrates not supplemented with any protein.
11343218|NCT02413658|Active Comparator|Control|Dressings of best current clinical practice, sugar solution.
11343219|NCT02413658|Experimental|Phenytoin 1|Dressings using phenytoin solution 20mg/ml
11343220|NCT02413658|Experimental|Phenytoin 2|Dressings using phenytoin solution 40mg/ml
11343221|NCT02413645|Other|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
11343222|NCT02413645|Other|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
11343223|NCT02413645|Experimental|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
11343224|NCT02413645|Experimental|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
11343225|NCT02413645|Experimental|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.
~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
11343226|NCT02413632|Other|First period|"creation of a STIs score risk
~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
11343227|NCT02413632|Other|Second period|"validation of a STIs score risk
~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
11343228|NCT02413619|Active Comparator|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
11343229|NCT02413619|Active Comparator|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
11343230|NCT02413619|Active Comparator|combined surgery|Combined cataract surgery and vitrectomy at the same time
11343231|NCT02413606|Experimental|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
11343232|NCT02413606|No Intervention|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
11343233|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
11343234|NCT02413580|Experimental|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
11343235|NCT02413567|Experimental|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
11343236|NCT02413554|Experimental|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.
~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
11343237|NCT02413554|No Intervention|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
11343238|NCT02413541|Experimental|High EAA and use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
11343239|NCT02413541|Experimental|High EAA and not use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
11343240|NCT02413541|Active Comparator|Low EAA|EAA level < 0.6 and not use Polymyxin-B Hemoperfusion
11343241|NCT02413528|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.
~Intervention: Inhaler sensor"
11343242|NCT02413528|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.
~Interventions: Inhaler sensor and mobile application for asthma adherence"
11343243|NCT02413515|Experimental|Arm 1|Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
11343244|NCT02413502|Experimental|Bacillus Calmette-Guérin (BCG)|Tice brand BCG used to vaccinate BCG-Naïve adults.
11343245|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
11343246|NCT02413476|Experimental|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
11343247|NCT02413476|Active Comparator|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
11343281|NCT02413255|Placebo Comparator|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
11343248|NCT02413463|Active Comparator|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
11343249|NCT02413463|Active Comparator|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
11343250|NCT02413437|Experimental|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided
11343251|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided
11343252|NCT02413424|Experimental|Drink Sucralose|Subjects will drink sucralose 10 min before drinking a glucose load
11343253|NCT02413424|Placebo Comparator|Drink Water|Subjects will drink water 10 min before drinking a glucose load
11343254|NCT02413424|Experimental|Taste and spit Sucralose|Subjects will taste and spit up sucralose 10 min before drinking a glucose load
11343255|NCT02413411|Experimental|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
11343256|NCT02413411|Active Comparator|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
11343257|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
11343258|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
11343259|NCT02413385|Experimental|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
11343260|NCT02413385|No Intervention|Usual-care wait-list control|No active intervention (usual care).
11343261|NCT02413372|Experimental|Treatment Group A: BMS-986036|Administered as specified on specified days
11343262|NCT02413372|Experimental|Treatment Group B: BMS-986036|Administered as specified on specified days
11343263|NCT02413372|Placebo Comparator|Treatment Group C: Placebo|Administered as specified on specified days
11343264|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
11343265|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
11343266|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
11343267|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
11343268|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
11343269|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
11343270|NCT02413307|Experimental|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
11343271|NCT02413307|No Intervention|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
11343272|NCT02413294|Experimental|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
11343273|NCT02413281|Experimental|ALKS 5461 Dose 1|Sublingual tablets
11343274|NCT02413281|Experimental|ALKS 5461 Dose 2|Sublingual tablets
11343275|NCT02413281|Experimental|ALKS 5461 Dose 3|Sublingual tablets
11343276|NCT02413281|Active Comparator|Buprenorphine Dose 1|Sublingual tablets
11343277|NCT02413281|Active Comparator|Buprenorphine Dose 2|Sublingual tablets
11343278|NCT02413281|Placebo Comparator|Placebo|Sublingual tablets
11343279|NCT02413268|Placebo Comparator|Placebo|Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.
11343280|NCT02413268|Active Comparator|Nitropaste|Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.
11343282|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
11343283|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
11343284|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
11343285|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
11343286|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
11343287|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
11343288|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
11343289|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
11343290|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
11343291|NCT02413255|Placebo Comparator|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
11343292|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
11343293|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
11343294|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
11343295|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
11343296|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
11343297|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
11343298|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.
~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
11343299|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.
~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
11343300|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
11343301|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
11343302|NCT02413216|Experimental|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
11343303|NCT02413216|Active Comparator|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
11343304|NCT02413203|Experimental|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
11343305|NCT02413203|Placebo Comparator|Placebo|Oral administration of a single placebo pill.
11343306|NCT02413177|Active Comparator|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
11343307|NCT02413177|Active Comparator|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
11343308|NCT02413164|Experimental|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
11343309|NCT02413164|No Intervention|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
11343409|NCT02412618|Active Comparator|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
11343310|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
11343311|NCT02413151|Active Comparator|Control|Regular lifestyle
11343312|NCT02413138|Experimental|Phase 2: Somavaratan (VRS-317)|Active treatment arm
11343313|NCT02413138|Experimental|Phase 3: Somavaratan (VRS-317)|Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
11343314|NCT02413125|Experimental|ChitoRino irrigation solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer 1 packet of ChitoRhino irrigation solution (premixed from manufacturer containing sea salt, Chitosan, and sodium bicarbonate). An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
11343315|NCT02413125|Experimental|Normal saline solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer nasal saline (250mL of 0.9% sodium chloride) irrigation solution. An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
11343316|NCT02413112|Experimental|Training once per week|Subjects train once per week in the University gym. All training sessions are supervised by the researchers.
11343317|NCT02413112|Experimental|Training twice per week|Subjects train twice per week in the University gym. All training sessions are supervised by the researchers.
11343318|NCT02413112|Experimental|Thrice per week|Subjects train three times per week in the University gym. All training sessions are supervised by the researchers.
11343319|NCT02413112|No Intervention|Non-training Control group|Subjects continue with their normal daily lives, just performing measurements
11343320|NCT02413099|Experimental|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
11343321|NCT02413099|Placebo Comparator|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
11343322|NCT02413086|Experimental|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
11343323|NCT02413086|Experimental|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
11343324|NCT02413086|Experimental|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
11343325|NCT02413086|Experimental|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
11343326|NCT02413073|Sham Comparator|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
11343327|NCT02413073|Experimental|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
11343328|NCT02413060|Experimental|Resistance training|Patients of treatment group will undergo resistance training every week sessions
11343329|NCT02413060|Other|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
11343330|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
11343331|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
11343332|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
11343333|NCT02413021|Experimental|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
11343334|NCT02413021|Active Comparator|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
11343335|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
11343336|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
11343337|NCT02412995|Experimental|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
11343338|NCT02412995|Experimental|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
11343339|NCT02412995|Experimental|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
11343340|NCT02412995|Experimental|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
11343341|NCT02412995|Experimental|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
11343342|NCT02412995|Experimental|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
11343343|NCT02412982|No Intervention|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level >= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
11343344|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
11343345|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
11343346|NCT02412969|Active Comparator|Lumbar Epidural|Control group will have standard of care Lumbar Epidural
11343347|NCT02412969|Experimental|Dural Puncture Epidural|Will receive Dural Puncture Epidural
11343348|NCT02412956|No Intervention|Control|pamphlet
11343349|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
11343350|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
11343351|NCT02412943|Experimental|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
11343352|NCT02412930|Active Comparator|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
11343353|NCT02412930|Placebo Comparator|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
11343354|NCT02412917|Experimental|FV-100 400 mg QD|FV-100 400mg QD
11343355|NCT02412917|Experimental|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
11343356|NCT02412917|Active Comparator|valacyclovir|valacyclovir 1000mg TID
11343357|NCT02412904|Other|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
11343358|NCT02412904|Other|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
11343359|NCT02412891|Active Comparator|Patients receive active UroShield device|Patients receive active UroShield device
11343360|NCT02412891|Sham Comparator|Patients receive inactive UroShield device|Patients receive inactive UroShield device
11343361|NCT02412878|Experimental|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).
~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
11343362|NCT02412878|Experimental|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).
~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
11343363|NCT02412865|Experimental|Intervention|quit4baby + text4baby
11343364|NCT02412865|Other|Control|text4baby
11343365|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
11343366|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
11343367|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
11343368|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
11343369|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
11343370|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
11343371|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
11343372|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
11343373|NCT02412813|Active Comparator|LEGION OXINIUM femoral component|
11343374|NCT02412813|Active Comparator|LEGION Cobalt Chrome femoral components|
11343375|NCT02412800||Acute lung injury|Postoperative acute lung injury was diagnosed according to the latest 2012 Berlin definition of acute respiratory distress syndrome by the PaO2/FiO2< 300 and acute onset of bilateral infiltrates on the chest radiograph that were not fully explained by cardiac failure during postoperative day 1 to postoperative day 3.
11343376|NCT02412787|Experimental|Idursulfase-IT|Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than [>] 8 months to 30 months of age) and 10 mg (>30 months to 3 years of age) of idursulfase-IT.
11343377|NCT02412774|Experimental|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
11343378|NCT02412774|Experimental|Water|Water after the main meal+ Diet
11343379|NCT02412761|Active Comparator|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
11343380|NCT02412761|Active Comparator|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
11343381|NCT02412761|Active Comparator|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
11343382|NCT02412761|Active Comparator|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
11343408|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
11343444|NCT02412358|Active Comparator|Pulsar|Patients use Pulsar toothbrush for plaque removal
11343383|NCT02412761|Active Comparator|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
11343384|NCT02412761|Active Comparator|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
11343385|NCT02412748|Active Comparator|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
11343386|NCT02412748|Experimental|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
11343387|NCT02412735|Experimental|rexlemestrocel-L|"rexlemestrocel-L alone: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells"
11343388|NCT02412735|Experimental|rexlemestrocel-L + HA|"rexlemestrocel-L + HA: 2.0mL 6 million rexlemestrocel-L cells"
11343389|NCT02412735|Placebo Comparator|Placebo|saline control: 2.0 mL saline solution
11343390|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
11343391|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
11343392|NCT02412722|Experimental|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
11343393|NCT02412722|Experimental|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
11343394|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
11343395|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
11343396|NCT02412709|Experimental|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
11343397|NCT02412709|Active Comparator|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
11343398|NCT02412696|Active Comparator|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
11343399|NCT02412696|Placebo Comparator|Nasal Dilator Strips|Nasal dilator strips during sleep.
11343400|NCT02412670|Experimental|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
11343401|NCT02412670|Experimental|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
11343402|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
11343403|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
11343404|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
11343405|NCT02412644|Active Comparator|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
11343406|NCT02412644|Placebo Comparator|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
11343407|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
11343445|NCT02412358|Active Comparator|Crossaction|Patients use Crossaction toothbrush for plaque removal
11343410|NCT02412618|Placebo Comparator|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
11343411|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
11343412|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
11343413|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
11343414|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
11343415|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
11343416|NCT02412553|Active Comparator|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
11343417|NCT02412553|Active Comparator|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
11343418|NCT02412540|No Intervention|Weight Loss Surgery|Adolescents who will have Weight Loss Surgery and had biopsy-confirmed NASH. The Weight Loss Surgery is not part of the study. The investigators are following the adolescents after the surgery.
11343419|NCT02412540|Experimental|Comprehensive Lifestyle Intervention|Comprehensive Lifestyle Intervention - Dietary, activity and behavioral interventions. Adolescents who have biopsy-confirmed NASH and wish to participate in a Comprehensive Lifestyle Intervention (26+ contact hours) including individual meetings with a study dietitian, group nutrition classes, behavior management modules and physical activity goals.
11343420|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
11343421|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
11343422|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
11343423|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
11343424|NCT02412514|Active Comparator|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
11343425|NCT02412514|Active Comparator|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
11343426|NCT02412501|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
11343427|NCT02412488|Experimental|Out of CathLab setting|Out of cathlab insertion
11343428|NCT02412475|Experimental|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
11343429|NCT02412462|Experimental|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
11343430|NCT02412449|Experimental|Treatment A|AKB-6548
11343431|NCT02412449|Experimental|Treatment B|AKB-6548
11343432|NCT02412449|Experimental|Treatment C|AKB-6548
11343433|NCT02412436|Experimental|Arm A: Depot medroxyprogesterone acetate|At study entry/week 0, participants received depot medroxyprogesterone acetate (DMPA) 150 mg administered intramuscularly as a single dose and co-administered with rifampicin (RIF) and efavirenz (EFV).
11343434|NCT02412423|Experimental|treatment group|post-transplantation cyclophosphamide
11343435|NCT02412410|Experimental|Single|Single arm pilot study analyzing sleep data and calculated efficacy before and after fatigue avoidance education (comparator is same group after intervention)
11343436|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11343437|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11343438|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11343439|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11343440|NCT02412371|Experimental|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
11343441|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
11343442|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
11343443|NCT02412371|Active Comparator|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.
~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
11343447|NCT02412345|Experimental|Extracorporeal Shockwave therapy|Extracorporeal shockwave therapy at the penis. 6 sessions.
11343448|NCT02412345|Sham Comparator|Sham treatment|Extracorporal shockwave therapy with a placebo probe. 6 sessions
11343449|NCT02412332|No Intervention|Group 1 - Control|The patients will be followed during the course of 12 months and evaluated regarding disease progression. No interventions will be performed other than conventional (in-course) treatment.
11343450|NCT02412332|Experimental|Group 2 - BMMC|Patients will be submitted to bone marrow harvesting. Bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation and returned to patients by systemic infusion (1x10^8 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
11343451|NCT02412332|Experimental|Group 3 - ASC|Patients will be submitted to liposuction. The obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) will be returned to patients by systemic infusion (1x10^8 ASC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
11343452|NCT02412332|Experimental|Group 4 - BMMC + ASC|Patients will be submitted to liposuction and the obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) obtained. Patients will be submitted to bone marrow harvesting and bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation. BMMC and ASC will be returned to patients by systemic infusion (5x10^7 ASC + 5x10^7 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
11343453|NCT02412319|Experimental|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
11343454|NCT02412319|Placebo Comparator|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
11343455|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
11343456|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
11343457|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
11343458|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
11343459|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
11343460|NCT02412293|Experimental|Intervention|"Health Education & Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.
~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.
~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
11343461|NCT02412293|No Intervention|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
11343462|NCT02412267|Experimental|O-ICE|"O-ICE:
~Ofatumumab 1000mg intravenous (IV) infusion on Day 1 and Day 8 of cycle 1 of the salvage chemotherapy, and thereafter on Day 1 of each cycle; Ifosfamide 1667 mg/m2 IV infusion over 2 hours on days 1,2,3 of each cycle; Carboplatin 5 x ((25 + Creatinine clearance (CrCl)) IV in 250 ml Normal Saline over 1 hour on day 1 of each cycle; Etoposide 100mg/m2/day IV infusion day 1,2,3 over 45 to 60 minutes of each cycle."
11343463|NCT02412254|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
11343464|NCT02412254|Placebo Comparator|Successful aging intervention|Successful aging intervention
11343465|NCT02412241|Other|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).
~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.
~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
11343466|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18
~Maintenance:
~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
11343467|NCT02412215|Experimental|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
11343468|NCT02412202|Other|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
11343469|NCT02412189|No Intervention|control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
11343470|NCT02412189|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
11343471|NCT02412176|Experimental|Pacing site - right ventricular apex|The intervention will be the implantation of the lead into the right ventricular apex
11343472|NCT02412176|Experimental|Pacing site - septum|The intervention will be the implantation of the lead into the septum.
11343473|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
11343474|NCT02412150|Experimental|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.
~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.
~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.
~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.
~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
11343475|NCT02412150|Placebo Comparator|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.
~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.
~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.
~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
11343476|NCT02412137|Experimental|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
11343477|NCT02412137|Placebo Comparator|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
11343478|NCT02412124|Experimental|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
11343479|NCT02412111|Experimental|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
11343480|NCT02412111|Experimental|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
11343481|NCT02412111|Active Comparator|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
11343482|NCT02412098|Experimental|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
11343483|NCT02412098|Experimental|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
11343484|NCT02412098|Experimental|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
11343485|NCT02412085|Experimental|Golimumab|Subcutaneous golimumab
11343486|NCT02412059|Experimental|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
11343487|NCT02412059|No Intervention|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
11343488|NCT02412046|Active Comparator|Time of the first biopsy: H0|For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
11343489|NCT02412046|Active Comparator|Time of the first biopsy: H1|For a patient in arm H1, it is done after 1 hour lying on the air mattress.
11343490|NCT02412046|Active Comparator|Time of the first biopsy: H2|For a patient in arm H2, it is done after 2 hour lying on the air mattress.
11343491|NCT02412046|Active Comparator|Time of the first biopsy: H3|For a patient in arm H3, it is done after 3 hour lying on the air mattress.
11343492|NCT02412033|Active Comparator|Misoprostol group|Going to receive 400 µg misoprostol vaginally 3 hours before IUD insertion.
11343493|NCT02412033|Placebo Comparator|Placebo group|Going to receive placebo.
11343494|NCT02412020|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 14 days
11343495|NCT02412020|Placebo Comparator|Placebo|Placebo PA101, administered via inhalation three times daily for 14 days
11343496|NCT02412007|Experimental|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.
~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
11343497|NCT02412007|Active Comparator|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to
~Passive stretching exercises for spasticity reduction
~Gait exercises
~Walking on treadmill
~Lower limb strengthening exercises
~Exercises for balance improvenet"
11343988|NCT02408731|Experimental|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
11343498|NCT02411994|Experimental|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
11343499|NCT02411994|Active Comparator|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
11343500|NCT02411981|Other|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.
~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
11343501|NCT02411968||111In-Girentuximab DOTA SPECT|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
11343502|NCT02411955|Experimental|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% (Taro Pharmaceuticals Inc.)
11343503|NCT02411955|Active Comparator|Tazorac®|Tazorac® (tazarotene cream 0.1%) (Allergan LLC)
11343504|NCT02411955|Placebo Comparator|Placebo|Placebo (Vehicle of the test product) (Taro Pharmaceuticals Inc.)
11343505|NCT02411942|Experimental|Adapalene Gel 0.3%|Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)
11343506|NCT02411942|Active Comparator|Differin®|Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)
11343507|NCT02411942|Placebo Comparator|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
11343508|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
11343509|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
11343510|NCT02411916|No Intervention|controls|patients not receiving misoprostol
11343511|NCT02411903|Active Comparator|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
11343512|NCT02411903|Experimental|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
11343513|NCT02411890|Experimental|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
11343514|NCT02411890|Active Comparator|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
11343515|NCT02411877|Active Comparator|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.
11343516|NCT02411877|Experimental|Mild hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.
11343517|NCT02411864||Group 1|Low b=(0,50,150,200)，NEX=(1,3,2,2)
11343518|NCT02411864||Group 2|Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
11343519|NCT02411864||Group 3|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
11343520|NCT02411864||Group 4|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
11343521|NCT02411864||Group 5|Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
11343522|NCT02411851|Active Comparator|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
11343523|NCT02411851|Experimental|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
11343524|NCT02411838|No Intervention|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
11343525|NCT02411838|Experimental|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).
~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).
~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
11343526|NCT02411825|Experimental|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
11343527|NCT02411825|Placebo Comparator|Placebo (healthy subjects)|Once daily SC doses of placebo
11343528|NCT02411825|Experimental|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
11343529|NCT02411825|Placebo Comparator|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
11343530|NCT02411812|Experimental|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
11343531|NCT02411812|Active Comparator|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
11343532|NCT02411812|Active Comparator|Twin-Block appliances|Group treated with Twin-Block appliance.
11343896|NCT02409407|Placebo Comparator|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
11343533|NCT02411786|Experimental|pTVG-AR biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
11343534|NCT02411786|Experimental|pTVG-AR staggered biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
11343535|NCT02411786|Experimental|pTVG-AR with rhGM-CSF biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
11343536|NCT02411786|Experimental|pTVG-AR with rhGM-CSF staggered biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
11343537|NCT02411773|Active Comparator|Exercise Training/Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
11343538|NCT02411773|Active Comparator|Exercise Training/Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
11343539|NCT02411773|Active Comparator|Stretching/Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
11343540|NCT02411773|Placebo Comparator|Stretching/Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
11343541|NCT02411773|No Intervention|Control|Healthy subjects without CKD will not receive any interventions.
11343542|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
11343543|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
11343544|NCT02411721|Experimental|Animal assisted intervention|The Effects of Dog Intervention on Anxiety Levels in Children. The experimental group will receive standard training on the imaging process by the MRI technician plus intervention activity with a dog
11343545|NCT02411721|No Intervention|control group|The control group will receive the standard training on the imaging process by the MRI technician.
11343546|NCT02411708|Experimental|SANGUINATE|320 mg/kg
11343547|NCT02411708|Placebo Comparator|Placebo|Normal saline IV infusion
11343548|NCT02411695|Experimental|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
11343549|NCT02411695|Experimental|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
11343550|NCT02411695|Experimental|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
11343551|NCT02411695|Experimental|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
11343552|NCT02411695|Experimental|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
11343553|NCT02411682|Active Comparator|YesB|On YesB day the patients will consume breakfast , lunch and dinner
11343554|NCT02411682|Experimental|NoB|On NoB Day The patient will consume only lunch and dinner
11343555|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
11343556|NCT02411656|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over approximately 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11343557|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
11343558|NCT02411630||Interactive Questionnaire System (iQS)|An Interactive Questionnaire System (iQS) will be administered twice. First at study entry (ATN 110/113 week 24 visit) and second at week 24 (ATN 110/113 week 48 visit). The questionnaire will assess adherence as well as how structural (physical settings) and partnership factors affect adherence of YMSM to PrEP with FTC/TDF (Truvada®).
11343559|NCT02411617|Active Comparator|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
11343560|NCT02411617|Active Comparator|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
11343561|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.
~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.
~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.
~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
11343562|NCT02411578|Experimental|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).
~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
11343626|NCT02411149|Placebo Comparator|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:
~30 ml normal saline
~3ml 0.5% preservative-free bupivacaine"
11344019|NCT02408562|Experimental|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
11343563|NCT02411578|Active Comparator|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).
~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
11343564|NCT02411565|Active Comparator|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
11343565|NCT02411565|Placebo Comparator|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
11343566|NCT02411552||Intervention schools|These schools were promoting 4 strategies to increase physical activity in students.
11343567|NCT02411552||Control schools|These schools continued with standard programming for activity during year 1, and implemented intervention during years 2 and 3.
11343568|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
11343569|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
11343570|NCT02411526|Experimental|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
11343571|NCT02411526|Experimental|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
11343572|NCT02411526|Experimental|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
11343573|NCT02411526|Active Comparator|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
11343574|NCT02411513|Experimental|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
11343575|NCT02411500|Experimental|Formulation A|
11343576|NCT02411500|Experimental|Formulation B|
11343577|NCT02411500|Experimental|Formulation C|
11343578|NCT02411500|Experimental|Formulation D|
11343579|NCT02411500|Experimental|Formulation E|
11343580|NCT02411500|Experimental|Formulation F|
11343581|NCT02411474||With or without newly diagnosed chronic GVHD after SCT|The patients developed chronic GVHD after SCT/ The patients did not developed chronic GVHD after SCT
11343582|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
11343583|NCT02411461||Healthy siblings|Control group
11343584|NCT02411461||Obese patients|Control group
11343585|NCT02411448|Experimental|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.
~Participants may continue to receive treatment until discontinuation criteria are met.
~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
11343586|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.
~Participants may continue to receive treatment until discontinuation criteria are met."
11343587|NCT02411448|Experimental|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.
~Ramucirumab and gefitinib administered during period 1.
~Ramucirumab and osimertinib administered during period 2."
11343588|NCT02411435|Experimental|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
11343589|NCT02411422|Experimental|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.
~Two kinds of endotracheal tube will be used
~Conventional endotracheal tube
~Reinforced endotracheal tube"
11343590|NCT02411422|Experimental|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.
~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.
~Two kinds of endotracheal tube will be used
~Conventional endotracheal tube
~Reinforced endotracheal tube"
11343591|NCT02411422|Experimental|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.
~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.
~Two kinds of endotracheal tube will be used
~Conventional endotracheal tube
~Reinforced endotracheal tube"
11343592|NCT02411409|Experimental|Intervention group|This group of patients receives the HealtheRx.
11343593|NCT02411409|No Intervention|Control group|This group of patients does not receive the HealtheRx
11343594|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
11343595|NCT02411383|Experimental|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
11343596|NCT02411357|Active Comparator|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
11343597|NCT02411357|Experimental|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
11343598|NCT02411357|Experimental|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
11343599|NCT02411344|Experimental|Pertuzumab, Trastuzumab, Letrozole|
11343600|NCT02411331|Experimental|Experimental group|90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
11343601|NCT02411331|Other|control group|90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study
11410742|NCT01964144|Experimental|Dovitinib arm|
11343602|NCT02411318|Experimental|Cardiovascular Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes. For example, a 30 year old will have a target heart rate zone of 95-162 beats per minute. A baseline blood sample will be acquired before the participant begins exercising. In the following 30 minutes, participants will ride the exercise bike, and their heart rate and general status will be assessed continuously. Specifically, heart rate will be monitored using a chest strap heart rate monitor. Two additional lancet punctures will be performed after the exercise to measure the changes in neutrophil function: one immediately following the 30 minute exercise period and one 30 minutes after the exercise has been completed.
11343603|NCT02411318|Experimental|Caffeine Consumption|Participants will be exposed to a moderate dose of caffeine (200 mg capsule in one sitting) from a common commercial product. After consent and screening, a baseline blood sample will be acquired using the lancet puncture procedure. The participant will then be instructed to swallow a 200 mg caffeine capsule. Two additional lancet punctures will be performed after the caffeine ingestion: one after 30 minutes post-ingestion and another one after 60 minutes.
11343604|NCT02411318|Experimental|Ethanol Ingestion|Participants will be weighed and their required alcohol dose determined according to the equation used by the Madison Police Department during alcohol training workshops: 1 mL of 80 proof (40%) alcohol per pound of body weight. Participants will be permitted to consume the drink at their own pace, although no slower than one drink per hour. Breath Alcohol Concentration (BAC) will be tested 20 minutes after drinking has ceased in order to clear mouth alcohol that may affect the BAC reading. Participants at 0.05 BAC and above will have blood drawn via lancet puncture. In addition to the lancet puncture done once the alcohol level is reached, an additional lancet puncture will be performed 1 hour later.
11343605|NCT02411318|Experimental|Glucose Ingestion|After a baseline blood sample is acquired, participants will consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
11343606|NCT02411318|Experimental|Glucose and Caffeine Ingestion|After a baseline blood sample is acquired, participants will swallow 200mg of caffeine in capsule form and consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the caffeine and glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
11343607|NCT02411305||PCRC Palliative Care Clinicians|
11343608|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
11343609|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
11343610|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
11343611|NCT02411266|Placebo Comparator|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
11343612|NCT02411266|Active Comparator|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
11343613|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,
~1MIU/day for adults.
~Subcutaneous injection every day (5 days) then:
~Regimen A injection every two weeks between D15 and D351,
~Regimen B injections every week between D15 and D351"
11343614|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:
~Regimen A injection every two weeks between D15 and D351
~Regimen B injections every week between D15 and D351"
11343615|NCT02411240|Other|Air filtering in the living room|GENANO tubes, GENANO Benelux; Heusen-Zolder, Belgium
11343616|NCT02411227|Experimental|1|Immediate Intervention
11343617|NCT02411227|No Intervention|2|Wait list
11343618|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
11343619|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
11343620|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
11343621|NCT02411201|Experimental|DOTAREM|
11343622|NCT02411188|Experimental|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
11343623|NCT02411188|No Intervention|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
11343624|NCT02411175|Experimental|20% Ethanol|20% ethanol will be medicated with the individualised homeopathic remedy as determined by the researcher and administered as drops. The potency, dose and frequency of the medicated 20% ethanol drops will be determined for each prescription, in accordance with the laws that govern homeopathic prescribing.
11343625|NCT02411162|Experimental|Open Label Arm|In Cohort 1, study medication (Cream A, 1%) will be applied as a thin layer onto a predefined area of the volar region of the forearm that is large enough to image and collect 3 biopsies (4 mm per biopsy). Vehicle will be applied on Day 1 only, onto a symmetrical location on the opposite forearm from Cream A. In cohort 2, subjects will be enrolled to evaluate Cream A (1%) and a different GSK2894512 Cream, Cream B (1%). Cream A, 1% and Cream B, 1% will be applied as a thin layer to the opposite forearms of the subject. Vehicle will be applied only on Day 1 to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied. Both Cream A and Cream B will continue to be applied OD to the same area of the same forearm for 7 days.
11343866|NCT02409589|Experimental|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
11343627|NCT02411149|Active Comparator|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:
~ropivacaine 0.5% with 1:400,000 epinephrine
~3ml 0.5% preservative-free bupivacaine"
11343628|NCT02411149|Active Comparator|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:
~ropivacaine 0.5% with 1:400,000 epinephrine
~3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
11343629|NCT02411136|Experimental|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
11343630|NCT02411136|Placebo Comparator|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
11343631|NCT02411123|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
11343632|NCT02411123|No Intervention|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
11343633|NCT02411110|Experimental|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
11343634|NCT02411110|Other|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
11343635|NCT02411097|Experimental|femoral nerve block|femoral nerve block will be administered before or after the surgery
11343636|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
11343637|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
11343638|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
11343639|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
11343640|NCT02411058|Experimental|Uninformed|Condition 1
11343641|NCT02411058|Experimental|Informed about Incentives and Purpose|Condition 2
11343642|NCT02411045|Active Comparator|Group 1: Control|Ask participants to take a picture of themselves
11343643|NCT02411045|Experimental|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
11343644|NCT02411045|Experimental|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
11343645|NCT02411032|Experimental|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
11343646|NCT02411032|Experimental|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
11343647|NCT02411032|Experimental|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
11343648|NCT02411032|Experimental|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
11343649|NCT02411032|Experimental|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
11343650|NCT02411019||Observational group|Subjects in the period less than 24 weeks after the final administration of GX-188E
11343651|NCT02411006|No Intervention|Usual care control|No intervention, just usual care from the insurance company
11343652|NCT02411006|Experimental|Reminder control|Send a reminder to subjects every month
11343653|NCT02411006|Experimental|Anonymous prediction|Ask subjects to anonymously predict their upcoming medication adherence
11343654|NCT02411006|Experimental|Anonymous commitment|Ask subjects to anonymously commit to their upcoming medication adherence
11343655|NCT02411006|Experimental|Identified prediction|Ask subjects to predict their upcoming medication adherence and report it
11343656|NCT02411006|Experimental|Identified commitment|Ask subjects to commit to their upcoming medication adherence and report it
11343657|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
11343658|NCT02410980|Experimental|Tretinoin cream 0.1%|Assessment of the skin change
11343659|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
11343660|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
11343661|NCT02410954|Experimental|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
11343662|NCT02410954|Placebo Comparator|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
11343663|NCT02410941|Experimental|Decision-support for MTBI|Clinical decision support will be provided on ordering CT scans for patients suspected to have Minor Traumatic Brain Injury (MTBI) to treating physicians randomized into this group. This arm will also serve as a control for the PE group.
11343664|NCT02410941|Experimental|Decision-support for PE|Clinical decision support will be provided on ordering CT scans for patients suspected to have Pulmonary Embolism (PE) to treating physicians randomized into this group. This arm will also serve as a control for the MTBI group.
11343665|NCT02410928|Experimental|fiberoptic nasal laringoscopy|the vocal cords ill be visualized with fiberoptic nasal laringoscopy
11343666|NCT02410928|Experimental|ultrasonography|the vocal cords ill be visualized with ultrasonography
11343667|NCT02410928|Active Comparator|Direct laringoscopy|the vocal cords ill be visualized with direct laringoscopy
11343668|NCT02410915|Experimental|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
11343669|NCT02410915|Active Comparator|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
11343670|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
11343671|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
11343672|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
11343673|NCT02410876||Controls|No lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
11343674|NCT02410876||Spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.
~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
11343675|NCT02410876||Spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.
~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
11343676|NCT02410876||Prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.
~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
11343677|NCT02410876||Prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
11343678|NCT02410863|Experimental|Cohort A (BRAFi naïve)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily.
11343679|NCT02410863|Experimental|Cohort B (BRAFi / MEKi rechallenge)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily
11343680|NCT02410850||University of Montreal|Patients from University of Montreal in Canada
11343681|NCT02410850||University of Antwerp|Patients from University of Antwerp in Belgium.
11343682|NCT02410850||University of Sydney|Patients from University of Sydney in Australia.
11343683|NCT02410850||Angers University Hospital|Patients from Angers University Hospital in France.
11343684|NCT02410850||University of Gronigen|Patients from University of Gronigen in Netherlands.
11343685|NCT02410850||Kaiser Permanente|Patients from Kaiser Permanente from USA.
11343686|NCT02410850||Stanford University|Patients from Stanford University from USA.
11343687|NCT02410850||Laval University|Patients from Laval University in Canada.
11343688|NCT02410850||Cambridge University|Patients from Cambridge University in UK.
11343689|NCT02410850||Kyushu University|Patients from Kyushu University in Japan
11343690|NCT02410850||Japan Somnology Center|Patients from Japan Somnology Center in Japan.
11343691|NCT02410850||Uniformed Services University|Patients from the Uniformed Services University in USA.
11343692|NCT02410850||University of British Columbia|Patients from the University of British Columbia in Canada.
11343693|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
11343694|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
11343695|NCT02410811||Age Stratum A|"Age 6 to 13.99 years
~Cardiac magnetic resonance imaging (CMR)"
11343696|NCT02410811||Age Stratum B|"Age 14 to 20.99 years
~Detectible and quantifiable TRJV with reported value
~Cardiac magnetic resonance imaging (CMR)"
11343697|NCT02410811||Age Stratum C|"Age ≥21 years
~Detectible and quantifiable TRJV with reported value
~Cardiac magnetic resonance imaging (CMR)"
11343698|NCT02410811||Age Stratum D|"Age ≥6 years.
~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.
~Cardiac magnetic resonance imaging (CMR)"
11343699|NCT02410798|Experimental|TransLoc electrode|Electrode placement
11343700|NCT02410785|Active Comparator|Medical device polyglucosamine|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
11343701|NCT02410785|Placebo Comparator|Placebo|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
11343702|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid
~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
11343703|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid
~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
11343704|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin
~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.
~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
11343705|NCT02410759|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
11343706|NCT02410759|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
11343707|NCT02410746|Active Comparator|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
11343708|NCT02410746|Experimental|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
11343709|NCT02410733|Experimental|Lipo-MERIT|7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts
11343710|NCT02410720|Active Comparator|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
11343711|NCT02410720|Experimental|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
11343712|NCT02410707|Experimental|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
11343713|NCT02410694|Experimental|Ixazomib-Thalidomide-Dexamethasone|"Combination therapy of:
~Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.
~After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months."
11343714|NCT02410668|Active Comparator|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
11343715|NCT02410668|Placebo Comparator|control|dietary and exercise recommendation
11343716|NCT02410655|Active Comparator|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
11343717|NCT02410655|Active Comparator|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
11343718|NCT02410629|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
11343719|NCT02410629|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
11343720|NCT02410616|Experimental|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
11343721|NCT02410616|Active Comparator|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
11343722|NCT02410590|Experimental|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
11343723|NCT02410590|Active Comparator|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
11343724|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
11343725|NCT02410564|Active Comparator|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
11343726|NCT02410564|Placebo Comparator|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
11343727|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
11343728|NCT02410538||"families that received the list of FAQ"|"The intervention consists of the delivery to the relatives of ICU patients a list of 21 key issues in intensive care during the first 48h period of ICU stay, only for intubated and mechanically ventilated patients A formal interview is scheduled to relatives of ICU patients on D3 of inclusion"
11343729|NCT02410538||families that received information as usual|A formal interview is scheduled relatives of ICU patients on D3 inclusion
11343730|NCT02410525|Experimental|[11C]PF-06427878|Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
11343731|NCT02410525|Experimental|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
11343732|NCT02410525|Experimental|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
11343733|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
11343734|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
11343735|NCT02410499|Placebo Comparator|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
11343736|NCT02410499|Experimental|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
11343737|NCT02410499|Experimental|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
11343738|NCT02410499|Experimental|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
11343739|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
11343740|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
11343741|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
11343742|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
11343743|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
11343744|NCT02410460|Other|PKA-BIS (intravenous anesthesia)|"Received the following medications:
~clonidine 0.1-0.2mg glycopyrrolate 0.2mg propofol infusion titrated to BIS of 60-75 ketamine 50mg + additional ketamine not to exceed 200mg aggregate dosage throughout the case local anesthetic (lidocaine/marcaine mix)"
11343745|NCT02410460|Other|Inhalational anesthesia|"Received the following:
~Pre-operatively:
~famotidine 20mg scopolamine 1.5mg transdermal patch midazolam 2mg ondansetron 8mg metoclopramide 10mg glycopyrrolate - dose determined by anesthesiologist
~During the case, medication choices and dosing were dependent on the anesthesiologist - all general anesthesia cases received inhalational anesthetic (type of anesthetic - desfluorane vs. sevofluorane - also varied based on anesthesiologist's choice)"
11343746|NCT02410447|Experimental|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).
~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
11343747|NCT02410434|Experimental|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
11343748|NCT02410421|Experimental|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.
~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.
~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).
~The procedure will be repeated twice a day for 10 days over 2 weeks."
11343749|NCT02410421|Active Comparator|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
~Coil and stimulator will remain the same between individualized and as usual proceedures."
11343750|NCT02410421|Active Comparator|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
11343751|NCT02410408|Active Comparator|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
11343752|NCT02410408|Experimental|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
11343753|NCT02410395|Active Comparator|Conventional technique|Closure of the uterotomy with a conventional two-layer technique
11343754|NCT02410395|Experimental|Modified technique|Closure of the uterotomy with a modified two-layer technique
11343755|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
11343756|NCT02410382|Active Comparator|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
11343757|NCT02410369|Active Comparator|S-588410|Subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
11343758|NCT02410369|Placebo Comparator|Placebo|Subjects with HLA-A*2402 in the placebo arm will receive the subcutaneous administration of placebo.
11343759|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
11343760|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
11343761|NCT02410343|Placebo Comparator|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
11343762|NCT02410343|Experimental|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
11343763|NCT02410330||Group I|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with Therapeutic ultrasound with 20 usec: custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 MI designed for the 1.7 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
11343764|NCT02410330||Group II|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low MI perfusion imaging detected microbubbles within the microvasculature. Treatment will be applied while patient waits for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
11343765|NCT02410330||Group III|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) while few limited diagnostic high MI impulses (n<5 per patient) will be applied to assess myocardial perfusion before and after percutaneous coronary intervention (PCI).
11343766|NCT02410317|Experimental|Continuous wound infusion group|Patients receive analgesia through a multiorifice wound catheter connected to ropivacaine infusion. Saline solution is given in the epidural bolus.
11343767|NCT02410317|Active Comparator|Epidural morphine group|Patients receive epidural analgesia through an epidural bolus of morphine. Saline solution is perfused through the wound catheter.
11343768|NCT02410304|Other|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
11343769|NCT02410304|Other|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
11343770|NCT02410304|Other|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
11343771|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
11343772|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
11343773|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
11343774|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
11343775|NCT02410265|Experimental|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
11343776|NCT02410265|Experimental|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
11343777|NCT02410265|No Intervention|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
11343778|NCT02410252|Experimental|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
11343779|NCT02410239|Experimental|Mesenchymal Stem Cell|Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
11343780|NCT02410226|Active Comparator|Palpation|Double-space combined spinal-epidural anesthesia, Sham ultrasound procedure
11343781|NCT02410226|Experimental|Ultrasound|Double-space combined spinal-epidural anesthesia, Preprocedure spinal ultrasound
11343782|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
11343783|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
11343784|NCT02410187|Active Comparator|Arm 1|systemic therapy+palliative RT
11343785|NCT02410187|Experimental|Arm 2|systemic therapy+SBRT
11343786|NCT02410174|Experimental|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
11343787|NCT02410161|Experimental|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
11343788|NCT02410148|Active Comparator|Papilledema|non-invasive aICP measurement in patientes with papilledema
11343789|NCT02410148|Active Comparator|open angle glaucoma|non-invasive aICP measurement in patients with glaucoma
11343790|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
11343791|NCT02410109|Experimental|SCRIPT intervention|
11343792|NCT02410109|No Intervention|Historical Control|
11343793|NCT02410096|Active Comparator|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
11343794|NCT02410096|Placebo Comparator|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
11343795|NCT02410083|Experimental|Clopirin 1|Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.
11343796|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 1|Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.
11343797|NCT02410083|Experimental|Clopirin 2|Clopirin single-administration. Before this clinical trial Aspirin single-administration.
11343798|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 2|Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.
11343799|NCT02410070|Experimental|Though Volar Minimal Incision|Patients in group A were treated through a small Incision.
11343800|NCT02410070|Active Comparator|Though Convectional Incision|Patients in group B were treated through the conventional Incision
11343801|NCT02410057|Active Comparator|Standard infant formula|Standard infant formula
11343802|NCT02410057|Experimental|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
11343803|NCT02410057|Experimental|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula
11343804|NCT02410057|No Intervention|Breast-feeding|Exclusive breast-feeding
11343805|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
11343806|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.
~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
11343807|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.
~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
11343808|NCT02410005|Active Comparator|Losartan alone|In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.
11343809|NCT02410005|Experimental|Losartan and Calcitriol|In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.
11343810|NCT02409992|Experimental|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting intervention.
11343811|NCT02409992|Active Comparator|Parent Training Only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
11343812|NCT02409979|Active Comparator|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
11343813|NCT02409979|Experimental|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
11343814|NCT02409979|Experimental|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
11343815|NCT02409966|Active Comparator|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
11343816|NCT02409966|Experimental|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
11343817|NCT02409953|Experimental|Bath|
11343818|NCT02409953|Placebo Comparator|Bed|
11343819|NCT02409940|Experimental|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
11343820|NCT02409940|Active Comparator|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
11343821|NCT02409940|No Intervention|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
11343822|NCT02409927|Other|Healthy participant|Each participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
11343823|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
11343824|NCT02409901|Experimental|Exercise Rehabiliation|12 month personalized exercise rehabilitation in addition to standard clinical care
11343825|NCT02409901|No Intervention|Control|Standard clinical care only
11343826|NCT02409888|Experimental|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
11343827|NCT02409888|Experimental|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
11343828|NCT02409875||Risk groups|"For families that both parents have BMI>=24 or at least one of them BMI>=28, then calculated as high-risk group.
~For families that both parents have BMI<24 or one parents with BMI<24 and one with 24<=BMI<28, then grouped as low-risk group."
11343829|NCT02409862|Experimental|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
11343830|NCT02409862|Placebo Comparator|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
11343831|NCT02409849|No Intervention|control group|
11343832|NCT02409849|Experimental|Octreotide LAR treatment|The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression.
11343833|NCT02409836|Active Comparator|Crest Cavity Protection|Marketed Dentifrice
11343834|NCT02409836|Active Comparator|Crest for Kids Hawaiian Punch Paste|Marketed Dentifrice
11343835|NCT02409836|Active Comparator|Crest for Kids Bubble Gum Paste|Marketed Dentifrice
11343836|NCT02409823||patients on atypical antipsychotics|
11343867|NCT02409589|Active Comparator|Conventional|Surface prediction length method
11343989|NCT02408731|Experimental|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
11343837|NCT02409810|Experimental|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
11343838|NCT02409797|Experimental|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
11343839|NCT02409784|Experimental|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).
~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet
~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
11343840|NCT02409771|Experimental|Intervention arm|Bilateral implantation with PRECIZON Presbyopic intraocular lens
11343841|NCT02409758|Active Comparator|VFE voice therapy|Voice therapy: Vocal Function Exercises applied during 6 weeks
11343842|NCT02409758|Experimental|CVRP voice therapy|Voice therapy: Comprehensive Voice Rehabilitation Program applied during 6 weeks
11343843|NCT02409745|Experimental|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
11343844|NCT02409745|Active Comparator|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
11343845|NCT02409745|Experimental|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
11343846|NCT02409745|Active Comparator|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
11343847|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
11343848|NCT02409719|Active Comparator|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
11343849|NCT02409719|Experimental|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
11343850|NCT02409693||Myringotomy with tube insertion|Patients who received surgically inserted ear tubes.
11343851|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
11343852|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
11343853|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
11343854|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
11343855|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
11343856|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
11343857|NCT02409654|Active Comparator|Individualized stroke prevention|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
11343858|NCT02409654|Placebo Comparator|Routine Care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
11343859|NCT02409641|Experimental|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
11343860|NCT02409628|Experimental|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
11343861|NCT02409615|Active Comparator|Hypnosis Group|Hypnosis Group: fifteen participants will receive Hypnosis therapy in addition to the standard postoperative pain management protocol
11343862|NCT02409615|Active Comparator|Healing Touch Group|Healing Touch Group: fifteen participants will receive Healing Touch therapy in addition to the standard postoperative pain management protocol
11343863|NCT02409615|No Intervention|Control Group|Control Group will receive standard postoperative pain management protocol
11343864|NCT02409602||Women with BIIAL|Women who underwent bilateral internal iliac artery ligation due to postpartum hemorrhage within last 2 months
11343865|NCT02409602||Healthy puerperal women|Age-matched healthy puerperal women who delivered within last 2 months
11343868|NCT02409576|Experimental|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
11343869|NCT02409563|Experimental|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
11343870|NCT02409563|Experimental|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
11343871|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
11343872|NCT02409537|Active Comparator|non cholesterolemic individuals|Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
11343873|NCT02409537|Active Comparator|Asymptomatic Hypercholesterolemics|individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
11343874|NCT02409524|Experimental|Treatment|The treatment schedule of AlloVax includes: (1) Priming segment with ID injections of AlloStim on Days 0, 3, 7 and 10. (2) Vaccination segment with ID injections of AlloStim+CRCL on Days 14, 17, 21 and 24. (3) Activation segment with IV push infusion of AlloStim on Day 28. (4) Booster Segment with monthly (every 28 days) ID injections of CRCL alone beginning on Day 56. These injections will continue until all the vaccine is used or the death of the subject
11343875|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
11343876|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
11343877|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
11343878|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
11343879|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
11343880|NCT02409498|Active Comparator|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
11343881|NCT02409498|Placebo Comparator|no pudendal block|Saline
11343882|NCT02409485|Experimental|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
11343883|NCT02409485|No Intervention|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
11343884|NCT02409472|Other|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography* at 8, and 20 months.
11343885|NCT02409472|Other|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
11343886|NCT02409459|Experimental|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
11343887|NCT02409459|Placebo Comparator|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
11343888|NCT02409446|Experimental|Anthocyanin|34 patients will receive anthocyanin. We will analyze their blood samples both prior and after taking anthocyanin.
11343889|NCT02409446|No Intervention|Controls|Healthy Controls, 20 persons. Will be giving blood samples at study start and study end.
11343890|NCT02409433|Experimental|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
11343891|NCT02409433|Active Comparator|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
11343892|NCT02409420|Experimental|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
11343893|NCT02409420|No Intervention|Control|Usual care
11343894|NCT02409407|Experimental|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
11343895|NCT02409407|Experimental|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
11343897|NCT02409394|Experimental|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
11343898|NCT02409394|Experimental|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
11343899|NCT02409381|Experimental|Motore|Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
11343900|NCT02409381|Active Comparator|Alivium|Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
11343901|NCT02409368|Experimental|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
11343902|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
11343903|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
11343904|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
11343905|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
11343906|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.
~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
11343907|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.
~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
11343908|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).
~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
11343909|NCT02409316|Experimental|FES PET/CT|All subjects will receive an [18F]FES PET/CT scan.
11343910|NCT02409303|Experimental|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
11343911|NCT02409303|No Intervention|Control|No intervention received.
11343912|NCT02409290|Active Comparator|Regimen A|Regimen A locally-used WHO-approved MDR-TB regimen in accordance with 2011 WHO MDR-TB treatment guidelines.
11343913|NCT02409290|Active Comparator|Regimen B|"Regimen B is based on the regimen described by Van Deun 2010. With Version 8.0 of the protocol Regimen B (Regimen Bmox) is modified by replacement of moxifloxacin with levofloxacin (Regimen Blev). Regimen B without specification of which fluoroquinolone is in the regimen refers to either (Bmox or Blev).
~Product and dose for [<33 kg, 33-50kg, >50 kg] respectively:
~Moxifloxacin [400mg, 600mg, 800mg] OR Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg,100mg,100mg]; Ethambutol [800mg,800mg,1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid 300mg, 400mg, 600mg]; Prothionamide [250mg,500mg,750mg]; Kanamycin [15mg per kilogram body weight (maximum 1g)]."
11343914|NCT02409290|Experimental|Regimen C|"Regimen C is a 40-week all-oral regimen consisting of bedaquiline, clofazimine, ethambutol, levofloxacin, and pyrazinamide given for 40 weeks supplemented by isoniazid and prothionamide for the first 16 weeks (intensive phase).
~Product and dose for [<33kg, 33-50kg, >50 kg] respectively:
~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg, 100mg, 100mg]; Ethambutol [800mg, 800mg, 1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid [300mg, 400mg, 600mg]; Prothionamide [250mg, 500mg,750mg]."
11343915|NCT02409290|Experimental|Regimen D|"Regimen D is a 28-week regimen consisting of bedaquiline, clofazimine, levofloxacin, and pyrazinamide given for 28 weeks supplemented by isoniazid and kanamycin for the first 8 weeks (intensive phase).
~Product and dose for [<33kg, 33 to<40kg, 40-50kg, >50-60 kg, >60 kg] respectively:
~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin [750mg, 750mg, 750mg, 1000mg, 1000mg]; Clofazimine [50mg, 100mg, 100mg, 100mg, 100mg]; Pyrazinamide [1000mg,1500mg, 1500mg, 2000mg, 2000mg]; Isoniazid [400mg, 500mg, 600mg, 800mg, 900mg]; Kanamycin [15 mg per kilogram body weight (maximum 1g)]."
11343948|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
11343990|NCT02408731|Experimental|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
11343916|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
11343917|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
11343918|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
11343919|NCT02409264|Experimental|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
11343920|NCT02409251|Experimental|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
11343921|NCT02409238|Experimental|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
11343922|NCT02409238|Active Comparator|Standard Level of Care|Standard lifestyle recommendations for the Control groups
11343923|NCT02409225|Experimental|Home Monitoring|Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.
11343924|NCT02409225|Active Comparator|HM option not active.|Regular visits in outpatient clinic. Device: no HM
11343925|NCT02409212|Experimental|Intervention|12 months of aerobic exercise training with behaviour change support
11343926|NCT02409212|Placebo Comparator|Comparison|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
11343927|NCT02409199|Experimental|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11343928|NCT02409199|Active Comparator|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11343929|NCT02409186|Active Comparator|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
11343930|NCT02409186|Placebo Comparator|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
11343931|NCT02409173|Experimental|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
11343932|NCT02409173|No Intervention|Control Group|
11343933|NCT02409160|Experimental|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
11343934|NCT02409160|No Intervention|Control Group|
11343935|NCT02409147|Experimental|Patients|Healthy female volunteers wishing to have a childbirth via uterine transplantation
11343936|NCT02409121|Experimental|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
11343937|NCT02409108|Experimental|Exatherm-TBH system|One treatment of Total Body Hyperthermia
11343938|NCT02409095|Experimental|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
11343939|NCT02409095|Active Comparator|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
11343940|NCT02409069|Experimental|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the ramus auricularis of the vagus nerve (ear)
11343941|NCT02409069|Sham Comparator|Sham stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the earlobe
11343942|NCT02409069|No Intervention|No stimulation|No stimulation
11343943|NCT02409056|Experimental|workplace-tailored CDSMP|Group will receive the CDSMP program which has been modified to fit the unique characteristics of the workplace.
11343944|NCT02409056|Active Comparator|CDSMP usual care|Group will receive the standard CDSMP program which is currently being offered in a variety of community settings.
11343945|NCT02409056|No Intervention|control|Group will receive no intervention for the first 6 months (pre / post), then be randomly assigned to one of the above interventions.
11343946|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
11343947|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
11343949|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
11343950|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.
~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
11343951|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
11343952|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
11343953|NCT02409017|Active Comparator|Protocol A|Our current standard during labor
11343954|NCT02409017|Active Comparator|Protocol B|Another commonly accepted alternative for insulin drip management during labor
11343955|NCT02409004|Experimental|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
11343956|NCT02408991|Experimental|AA and Neopogen|Patient undergoes treatment with Art-assist device and Neupogen
11343957|NCT02408978|Experimental|OXP005|1g naproxen
11343958|NCT02408978|Active Comparator|naproxen|1g naproxen
11343959|NCT02408965|Experimental|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
11343960|NCT02408965|Placebo Comparator|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
11343961|NCT02408952|Experimental|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
11343962|NCT02408952|Experimental|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
11343963|NCT02408952|No Intervention|Usual Care|Care is administered as usual
11343964|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
11343965|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
11343966|NCT02408926|Experimental|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
11343967|NCT02408926|Active Comparator|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
11343968|NCT02408913|Experimental|Group 2|MVA-EbolaZ 1x10(8) PFU
11343969|NCT02408913|Experimental|Group 3|cAd3-EBO 2x10(11) PU followed by MVAEbolaZ 1x10(8) PFU at 8 weeks
11343970|NCT02408913|Experimental|Group1|MVA-EbolaZ 1x10(7) PFU
11343971|NCT02408913|Experimental|Groups 4 to 7|MVA-EbolaZ 1x10(8) PFU administered in VRC 208 to participants who received cAd3-EBO or cAd3-EBOZ in VRC 207.
11343972|NCT02408887|Active Comparator|1|pCND plus TT
11343973|NCT02408887|Active Comparator|2|TT alone
11343974|NCT02408861|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1. Patients in dose level 2 also receive ipilimumab IV over 90 minutes on day 1 of every third cycle of nivolumab, and patients in dose level -2 also receive ipilimumab IV over 90 minutes on day 1 of every sixth cycle of nivolumab. Cycles repeat every 14 days for up to 46 cycles of nivolumab (with ipilimumab if receiving dose level 2 or -2) in the absence of disease progression or unacceptable toxicity.
11343975|NCT02408835|Active Comparator|PICO™|Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.
11343976|NCT02408835|No Intervention|Conventional wound care|Usual wound dressings will be used as comparison group.
11343977|NCT02408822|Active Comparator|PBA (Plain Balloon Angioplasty)|"Patient receiving endovascular treatment of a vascular access stenosis by plain balloon angioplasty (mechanical action, without drug)
~2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure"
11343978|NCT02408822|Experimental|PTX|(PacliTaXel-coated balloon angioplasty) Patient receiving endovascular treatment of a vascular access stenosis by drug-eluting balloon angioplasty (mechanical action + antiproliferative drug - Paclitaxel) 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
11343979|NCT02408809|Active Comparator|Control|
11343980|NCT02408809|Active Comparator|Intervention|
11343981|NCT02408796|Experimental|OTO-201|6 mg OTO-201
11343982|NCT02408770|Experimental|treatment|ulipristal acetate 5mg daily for 3 months
11343983|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
11343984|NCT02408744|Experimental|Pirfenidone|Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
11343985|NCT02408731|Experimental|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
11343986|NCT02408731|Experimental|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
11343987|NCT02408731|Experimental|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
11343991|NCT02408718|Active Comparator|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
11343992|NCT02408718|No Intervention|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
11343993|NCT02408705|Active Comparator|Liraglutide|3-month treatment of liraglutide
11343994|NCT02408705|Placebo Comparator|Placebo|3-month treatment of placebo
11343995|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
11343996|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
11343997|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
11343998|NCT02408679||All subjects|300 eligible subjects will perform a blood sampling for a dosage of serum vitamin D and will fill up a study questionnaire during one visit.
11343999|NCT02408666|Other|Interview|"Interview of epilepsy patients and their family about their experience with epilepsy, EEG registrations and daily life.
~Interview of EEG-technologists and neurologists about their experience with EEG registrations and expections when thinking of a ideal EEG-cap."
11344000|NCT02408653|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
11344001|NCT02408653|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
11344002|NCT02408653|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
11344003|NCT02408640|Experimental|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.
~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
11344004|NCT02408640|No Intervention|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).
~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
11344005|NCT02408627|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
11344006|NCT02408627|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
11344007|NCT02408627|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
11344008|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
11344009|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
11344010|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
11344011|NCT02408601|Active Comparator|Group 1|"split mouth study. one side of the arch that is the lower left permanent 1st molar will be receiving resin based sealants.
~Application of the resin sealants as per the standard instructions of the manufacturer
~Helioseal -F ( Resin based sealant)
~isolate the tooth surface
~etch the fissure anatomy with 37% phosphoric acid for 20 seconds
~wash the tooth surface and dry it. No salivary contamination is accepted
~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.
~light cure the sealant
~check for high points and the occlusion"
11344012|NCT02408601|Experimental|Group 2|"split mouth study. one side of the arch that is the lower right permanent 1st molar will be receiving ART sealants.
~Application of the ART sealants as per the standard instructions of the manufacturer
~isolate the tooth surface
~condition the fissure anatomy using a GC conditioner for 10 seconds
~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.
~dry the tooth surface
~mix the GIC according to the standard powder: liquid ratio
~place the mix onto the fissures using a plastic spatula
~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)
~apply pressure for 10-15 sec and withdraw the finger in a sideways motion
~scrap out the excess material
~check for the high points and the occlusion
~apply petroleum jelly onto the GIC mix
~advice patient not to eat or drink for 30 minutes."
11344013|NCT02408588||Childbirth and epidural|Pregnant women giving childbirth who receive an epidural.
11344014|NCT02408588||Childbirth and general anesthesia|Pregnant women giving childbirth who receive general anesthesia
11344015|NCT02408588||Fetal Intervention and epidural|Pregnant women receiving fetal intervention and an epidural
11344016|NCT02408588||Fetal Intervention and general anesthesia|Pregnant women receiving fetal intervention and general anesthesia
11344017|NCT02408575|Experimental|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
11344018|NCT02408575|Experimental|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3
~No notched filtering
~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
11344020|NCT02408562|Placebo Comparator|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
11344021|NCT02408549|Experimental|Lacosamide|"Start dose
~SP982 completers at V1:
~LCM 10 mg/kg/day for pediatric subjects weighing <30 kg
~LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to <50 kg
~LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg
~SP982 Baseline failures at V1:
~LCM 2 mg/kg/day for pediatric subjects weighing <50 kg
~LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg
~Oral solution (pediatric subjects <50 kg):
~Minimum LCM dose: 4 mg/kg/day
~Maximum LCM dose: 12 mg/kg/day
~Tablets (pediatric subjects ≥50kg):
~Minimum LCM dose: 200 mg/day
~Minimum LCM dose: 600 mg/day
~Tablets (adult subjects):
~Minimum LCM dose: 200 mg/day
~Maximum LCM dose: 800 mg/day"
11344022|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
11344023|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.
~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.)
~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg.)"
11344024|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.
~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.)
~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg.)"
11344025|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
11344026|NCT02408471|Other|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
11344027|NCT02408458|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
11344028|NCT02408445|Experimental|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
11344029|NCT02408445|No Intervention|No treatment|Subjects will not receive any testosterone during the study period.
11344030|NCT02408432|Experimental|Arm I (hMSCs)|Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.
11344031|NCT02408432|Active Comparator|Arm II (standard of care drugs)|Patients receive only standard of care drugs for heart failure.
11344032|NCT02408419|Experimental|Local anesthetic|15 ml. of local anesthetic
11344033|NCT02408419|Placebo Comparator|Saline|15 ml. of saline
11344034|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
11344035|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
11344036|NCT02408393|Placebo Comparator|Placebo|Saline (30 mL maximum)
11344037|NCT02408393|Experimental|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
11344038|NCT02408367||Exercise|30 minutes of active training at 75% of the Maximum heart rate achieved in a cardiopulmonary exercise test
11344039|NCT02408367||Relaxation|30 Minutes of passive relaxation
11344040|NCT02408354|Active Comparator|Triheptanoin|"Triheptanoin/ Placebo Randomized to receive active Triheptanoin first for 12 weeks. At cross-over, participants will receive placebo for 12 weeks.
~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between triheptanoine and placebo phases."
11344041|NCT02408354|Placebo Comparator|Placebo|"Placebo / Triheptanoin Randomized to receive active Placebo first for 12 weeks. At cross-over, participants will receive Triheptanoin for 12 weeks.
~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between placebo and triheptanoin phases."
11344042|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
11344043|NCT02408328|Active Comparator|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
11344044|NCT02408328|Active Comparator|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
11344045|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
11344046|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
11344047|NCT02408302|Active Comparator|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
11344048|NCT02408302|Active Comparator|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
11344049|NCT02408302|Active Comparator|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
11344050|NCT02408289|Placebo Comparator|Lo-Flav|Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage
11344051|NCT02408289|Active Comparator|Hi-Flav|Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
11344052|NCT02408289|Active Comparator|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.
11344053|NCT02408289|Active Comparator|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
11344054|NCT02408276||dGEMERIC MRI technique|All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
11344055|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
11344056|NCT02408237|Active Comparator|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
11344057|NCT02408237|Active Comparator|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
11344058|NCT02408224||one arm|patients on Ticagrelor
11344059|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
11344060|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
11344061|NCT02408185|Experimental|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
11344062|NCT02408185|Experimental|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
11344063|NCT02408172|Experimental|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
11344064|NCT02408172|Experimental|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
11344065|NCT02408159|Experimental|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
11344066|NCT02408159|Placebo Comparator|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.
~A single dose will be administered to subjects at baseline."
11344067|NCT02408146|Experimental|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
11344068|NCT02408146|Experimental|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
11344069|NCT02408146|Experimental|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
11344070|NCT02408133|No Intervention|Control|The control group will be accompanied according to the service routine.
11344071|NCT02408133|Experimental|Exercise|The group will be instructed to perform home exercises autonomously for range of motion and muscular fitness
11344072|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
11344073|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
11344074|NCT02408107|Experimental|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
11344075|NCT02408107|No Intervention|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
11344076|NCT02408081|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
11344077|NCT02408081|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
11344078|NCT02408068|Active Comparator|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
11344079|NCT02408068|Active Comparator|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
11344156|NCT02407496||ADHD|Adults with Attention Deficit Hyperactivity Disorder (ADHD)
11344080|NCT02408068|Active Comparator|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
11344081|NCT02408055|Experimental|Radiolabelled TA-8995|
11344082|NCT02408042|Active Comparator|RICE and Pembrolizumab|non-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
11344083|NCT02408042|Active Comparator|ICE and Pembrolizumab|classical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
11344084|NCT02408042|Active Comparator|brentuximab vedotin and Pembrolizumab|classical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
11344085|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
11344086|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
11344087|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
11344088|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
11344089|NCT02408003|Experimental|Levosimendan|"st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.
~nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
11344090|NCT02408003|Experimental|Milrinone|"st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.
~nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
11344091|NCT02407990|Experimental|BGB-A317 Phase 1A|
11344092|NCT02407990|Experimental|BGB-A317 Phase 1B|
11344093|NCT02407951|Experimental|CBIT group|
11344094|NCT02407951|Placebo Comparator|Psycho-Educational group|
11344095|NCT02407938|Experimental|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
11344096|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
11344097|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
11344098|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
11344099|NCT02407912|Experimental|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
11344100|NCT02407912|No Intervention|Control|No intervention was applied.
11344101|NCT02407899|Experimental|Metformin (and insulin) + saxagliptin|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5mg/d and Metformin 1.5g/d (and insulin at individual dose) for 104-week.
11344102|NCT02407899|Experimental|Metformin(insulin)+saxagliptin +vitamin D3|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg/d, vitamin D drop 2000IU/d, Metformin 1.5g/d (and insulin at individual dose) for 104-week.
11344103|NCT02407899|Active Comparator|Metformin (and insulin)|Patients who have diagnosed LADA are assigned to receive Metformin 1.5g/d(and insulin at individual dose) for 104-week.
11344104|NCT02407873||Cardiac surgery|
11344105|NCT02407860|Experimental|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
11344106|NCT02407860|Active Comparator|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
11344107|NCT02407847|No Intervention|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
11344108|NCT02407847|Experimental|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
11344109|NCT02407834|Experimental|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
11344110|NCT02407834|Experimental|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
11344111|NCT02407834|Experimental|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
11344112|NCT02407834|Placebo Comparator|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
11344113|NCT02407821|Active Comparator|Escitalopram|
11344114|NCT02407821|Placebo Comparator|Placebo|
11344115|NCT02407808|Active Comparator|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
11344116|NCT02407808|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
11344117|NCT02407795|Active Comparator|Arm 1|Conventional radiotherapy, 1x8Gy
11344118|NCT02407795|Experimental|Arm 2|Stereotactic radiotherapy, 1x20Gy
11344119|NCT02407782|Experimental|Ivermectin|
11344120|NCT02407782|Experimental|Permethrin|
11344121|NCT02407769|Experimental|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
11344122|NCT02407769|Sham Comparator|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
11344123|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
11344124|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
11344125|NCT02407743||Surgical patients' clinical progression|Patients undergoing non-ambulatory surgery will be asked questions and complete surveys in an effort to characterize postoperative pain experience profiles. A blood sample will be obtained for genetic markers exploring a variety of pain-related genes.
11344126|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.
~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.
~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
11344127|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.
~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
11344128|NCT02407691|Experimental|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
11344129|NCT02407691|Active Comparator|Standard of care|Primary Care 101 standard version guideline
11344130|NCT02407678|Experimental|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
11344131|NCT02407678|No Intervention|Control|Untreated eye
11344132|NCT02407665|Experimental|Tai Chi|Participants who practice Tai Chi 2X/week for 12-weeks
11344133|NCT02407665|No Intervention|Healthy Control|24 healthy controls
11344134|NCT02407652|Experimental|cognitive control training|internet-delivered, 2 weeks
11344135|NCT02407652|Active Comparator|low cognitive load training|internet-delivered, 2 weeks
11344136|NCT02407639|Active Comparator|co2 arm|insufflation with CO2
11344137|NCT02407639|Placebo Comparator|air arm|insufflation with air
11344138|NCT02407626|Experimental|Sevoflurane|Volatile anesthesia for elective cardiac surgery
11344139|NCT02407626|Active Comparator|Propofol|Total intravenous anesthesia for elective cardiac surgery
11344140|NCT02407613|Experimental|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
11344141|NCT02407600|Active Comparator|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
11344142|NCT02407600|Sham Comparator|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
11344143|NCT02407587|Experimental|unilateral cochlear implants|"Study Group
~PET scans for the mature patients with unilateral cochlear implants and preserved hearing
~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
11344144|NCT02407587|No Intervention|Healthy volunteers|4 states and each state will be repeated 3 times Auditory stimulation Left ear only Auditory stimulation right ear only Binaural auditory stimulation Silence
11344145|NCT02407574|Experimental|Spontaneous rhythm first|Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing.
11344146|NCT02407574|Experimental|Atrial pacing first|Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm.
11344147|NCT02407548|Experimental|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
11344148|NCT02407548|Experimental|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
11344149|NCT02407548|Other|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
11344150|NCT02407535|Experimental|Endometrial carcinoma patient|
11344151|NCT02407522|Experimental|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
11344152|NCT02407522|Placebo Comparator|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
11344153|NCT02407509|Experimental|Twice weekly|RO5126766 will be administered twice weekly in 4 week cycles.
11344154|NCT02407509|Experimental|Three times weekly|RO5126766 will be administered three times weekly in 4 week cycles.
11344155|NCT02407509|Experimental|RO5126766 & Everolimus|RO5126766 and Everolimus will be given in combination once or twice weekly for 3 weeks of a 4 week cycle.
11344158|NCT02407483|Experimental|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
11344159|NCT02407483|Active Comparator|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
11344160|NCT02407470|Active Comparator|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
11344161|NCT02407470|Experimental|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
11344162|NCT02407470|Experimental|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
11344163|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
11344164|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
11344165|NCT02407444|Experimental|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.
~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.
~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
11344166|NCT02407444|Active Comparator|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.
~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
11344167|NCT02407418|Active Comparator|Spinal Manipulation|In a repeated measures, crossover design, all subjects received spinal manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
11344168|NCT02407418|Sham Comparator|Sham Manipulation|In a repeated measures, crossover design, all subjects received the sham manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
11344169|NCT02407405|Experimental|1|selumetinib 50 mg BID daily
11344170|NCT02407392|Active Comparator|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
11344171|NCT02407392|Experimental|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
11344172|NCT02407379|Active Comparator|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
11344173|NCT02407379|Sham Comparator|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
11344174|NCT02407366|Experimental|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
11344175|NCT02407366|Active Comparator|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
11344176|NCT02407353|Experimental|PF-06648671 High dose group|subjects receive a single oral dose of PF-06648671 at 300 mg
11344177|NCT02407353|Experimental|PF-06648671 Low dose group|Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
11344178|NCT02407353|Placebo Comparator|Placebo group|Subjects receive matching placebo
11344179|NCT02407353|Experimental|PF-06648671 Low dose group (2)|Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
11344180|NCT02407340|Active Comparator|Oxytocin|intranasal oxytocin - 40 International Units (IU) dose administered 3 times daily for 1 week
11344181|NCT02407340|Placebo Comparator|Placebo|Intranasal placebo administered 3 times daily for 1 week
11344182|NCT02407314|Sham Comparator|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
11344183|NCT02407314|Experimental|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
11344184|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
11344185|NCT02407288|Active Comparator|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
11344186|NCT02407288|Placebo Comparator|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
11344187|NCT02407275|Other|biological sample|Genomic & culturomic analyses
11344188|NCT02407262|Active Comparator|Treatment|"Black seed oil capsules
~1g/day for 4 weeks"
11344190|NCT02407236|Placebo Comparator|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
11344191|NCT02407236|Experimental|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
11344192|NCT02407236|Experimental|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
11344193|NCT02407236|Other|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
11344194|NCT02407236|Other|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
11344195|NCT02407236|Placebo Comparator|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
11344196|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
11344197|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
11344198|NCT02407236|Other|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
11344199|NCT02407236|Other|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
11344200|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
11344201|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
11344202|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
11344203|NCT02407210|Experimental|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
11344204|NCT02407210|Active Comparator|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
11344205|NCT02407184|No Intervention|Scheduled C-section|Babies that are scheduled to be born in a hospital via standard C-section procedure.
11344206|NCT02407184|No Intervention|Vaginal Delivery|Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.
11344207|NCT02407184|Experimental|Scheduled C-section with Exposure|Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.
11344208|NCT02407171|Experimental|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
11344265|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
11344209|NCT02407171|Experimental|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
11344210|NCT02407171|Experimental|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
11344211|NCT02407171|Experimental|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
11344212|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
11344213|NCT02407132|Active Comparator|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
11344214|NCT02407132|Experimental|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
11344215|NCT02407119|Active Comparator|7 day H.pylori eradication|Treatment: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
11344216|NCT02407119|Placebo Comparator|Placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + Placebo for two antibiotics (clarithromycin and amoxicillin) bid for 7 days
11344217|NCT02407106|Experimental|BLIS K12 treatment|Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month
11344218|NCT02407093|Experimental|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
11344219|NCT02407093|Active Comparator|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
11344220|NCT02407080|Experimental|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.
~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
11344221|NCT02407067|Active Comparator|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
11344222|NCT02407067|Experimental|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
11344223|NCT02407054|Experimental|LY3023414 + Enzalutamide|Lead In- LY3023414 orally twice daily in first week for pharmacokinetics (PK); thereafter LY3023414 orally twice daily in combination with enzalutamide orally once daily for 28-day cycles. Randomization- LY3023414 orally twice daily in combination with enzalutamide orally once daily for 28-day cycles. Participants may remain on treatment until discontinuation criteria are met.
11344224|NCT02407054|Active Comparator|Enzalutamide + Placebo|Enzalutamide orally once daily in combination with matching LY3023414 placebo orally twice daily for 28-day cycles. Participants may remain on treatment until discontinuation criteria are met.
11344225|NCT02407041|Experimental|GR-MD-02|active arm
11344226|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA, no NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
11344227|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA, no NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
11344228|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA, no NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
11344229|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA + NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
11344230|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA + NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
11344231|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA + NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
11344232|NCT02407028|Experimental|Normobaric Hyperoxia (NBH)|Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
11344233|NCT02407028|Active Comparator|Usual care|Usual care for severe TBI
11344234|NCT02407015|Active Comparator|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
11344235|NCT02407015|Active Comparator|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
11344236|NCT02406989|Experimental|MS-553|MS-553 oral tablet BID x 14 days
11344237|NCT02406989|Placebo Comparator|Placebo|Placebo oral tablet BID x 14 days
11344238|NCT02406976|Experimental|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
11344300|NCT02406638||TVT-O Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT Obturator System, inside-out approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation.
11344239|NCT02406976|Experimental|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.
~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
11344240|NCT02406976|Active Comparator|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
11344241|NCT02406963|Active Comparator|TTC|Current standard of care- a telephone call with the NP in the event of a post-operative concern where advice/interventions/reassurance is provided based on information provided by family
11344242|NCT02406963|Experimental|PEC|Experimental arm, the standard telephone call with the NP and the addition of a digital photograph of the surgical site for assessment prior to the administration of advice
11344243|NCT02406950|Experimental|Sitagliptin|All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
11344244|NCT02406950|Placebo Comparator|Placebo|After brachial artery FMD measurement, IR injury for each 15 minutes will be performed, and brachial artery FMD will be measured again. After randomization, placebo group will be treated by nothing. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
11344245|NCT02406950|Other|Sitagliptin and glibenclimide|If sitagliptin treatment show preventive effects of IR injury, the investigator will perform additional experiment to explore the mechanism (Protocol 2 study). Additional 15 healthy volunteers will be treated 5 mg of glibenclamide (Euglucon) 1 hour before administration of 50 m g of sitagliptin. In 2 hours after sitagliptin administration, FMD measurement before and after IR injury will be performed as described above.
11344246|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
11344247|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
11344248|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
11344249|NCT02406924|Experimental|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
11344250|NCT02406924|Active Comparator|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
11344251|NCT02406911|Experimental|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
11344252|NCT02406911|Active Comparator|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
11344253|NCT02406898|Experimental|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.
~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
11344254|NCT02406898|Active Comparator|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.
~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
11344255|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
11344256|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
11344257|NCT02406872|Experimental|Remimazolam Tosilate 1|IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction
11344258|NCT02406872|Experimental|Remimazolam Tosilate 2|intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction
11344259|NCT02406872|Experimental|Remimazolam Tosilate 3|intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction
11344260|NCT02406872|Active Comparator|Propofol|single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction
11344261|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
11344262|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
11344263|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
11344264|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
11344266|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
11344267|NCT02406833|Experimental|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses
~Post-Study Follow-up: until 1 year after administration"
11344268|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
11344269|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
11344270|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
11344271|NCT02406807|Experimental|HVLA manipulation|Osteopathic high velocity, and low amplitude spinal lumbar manipulation
11344272|NCT02406807|Sham Comparator|Sham Spinal lumbar manipulation|Just position in the side lying and not performed the high velocity and low amplitude
11344273|NCT02406794|Experimental|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
11344274|NCT02406794|No Intervention|No Kinesio taping|No Kinesio taping
11344275|NCT02406781|Experimental|Treatment strategy A|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.
11344276|NCT02406781|Experimental|Treatment strategy B|Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.
11344277|NCT02406768||HIV negative unexposed|HIV negative controls
11344278|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
11344279|NCT02406755|No Intervention|Control|This control group will not receive an intervention.
11344280|NCT02406755|Active Comparator|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
11344281|NCT02406755|Active Comparator|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
11344282|NCT02406755|Active Comparator|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
11344283|NCT02406742|Experimental|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
11344284|NCT02406742|Experimental|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
11344285|NCT02406742|Experimental|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
11344286|NCT02406729|Experimental|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
11344287|NCT02406729|Placebo Comparator|Placebo|Placebo Single dose, SC
11344288|NCT02406716||HF|Heart failure patients
11344289|NCT02406716||Controls|Healthy donors
11344290|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
11344291|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
11344292|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
11344293|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
11344294|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
11344295|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
11344296|NCT02406664|Experimental|Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
11344297|NCT02406664|No Intervention|Control patients|15 matched controls receiving Intensive medical therapy
11344298|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
11344299|NCT02406638||TVT Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT 3 years before clinical and 3D pelvic floor ultrasound evaluation.
11414454|NCT01939405|No Intervention|standard physical activity counseling|
11344301|NCT02406638||TVT-S Group|"Women who underwent to stress urinary incontinence surgery using GynecareTVT-Secur System, in U approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation."
11344302|NCT02406625|Experimental|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
11344303|NCT02406625|Experimental|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
11344304|NCT02406625|No Intervention|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
11344305|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
11344306|NCT02406599|Other|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
11344307|NCT02406599|Other|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
11344308|NCT02406586|Experimental|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
11344309|NCT02406586|Experimental|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
11344310|NCT02406586|Placebo Comparator|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
11344311|NCT02406573|Experimental|Crest® Sensi-Stop™ Strips|Professionally Applied
11344312|NCT02406560|Experimental|4 tablets of 12.2 mg tafamdis free acid|
11344313|NCT02406560|Experimental|4 tablets of 12.2 mg tafamidis free acid|
11344314|NCT02406560|Experimental|5 tablets of 12.2 mg tafamidis free acid|
11344315|NCT02406547|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
11344316|NCT02406547|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
11344317|NCT02406534||Normal Pulmonary Function|
11344318|NCT02406534||Reduced Pulmonary Function|
11344319|NCT02406521|Experimental|Arm A: Pazopanib with Radium-223|"No prior targeted therapy
~Pazopanib oral, daily and at predetermined dosage per cycle
~Radium-223 predetermined dosage via IV, per cycle"
11344320|NCT02406521|Experimental|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:
~Sorafenib at predetermined dosage, mouth twice daily
~Radium-223 predetermined dosage via IV, per cycle"
11344321|NCT02406508|Experimental|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.
~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.
~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
11344322|NCT02406495|Experimental|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
11344323|NCT02406482|Experimental|HIVRR + MF|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)) followed by financial literacy, micro-savings and vocational training (Behavioral: Microfinance intervention (MF)).
11344324|NCT02406482|Active Comparator|HIVRR only|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)).
11344325|NCT02406469|Experimental|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
11344326|NCT02406469|Placebo Comparator|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
11344327|NCT02406456|Experimental|Neurofeedback|
11344328|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
11344329|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
11344330|NCT02406417|Experimental|Investigation for pituitary dysfunction|Further investigation for pituitary dysfunction by blood tests, dynamic function tests and pituitary imaging e.g. CT Scan with contrast. Patients identified as being at high risk of having pituitary dysfunction based on preliminary blood tests will have further tests added. If these results point to a likely pituitary dysfunction, the patient will be referred to the Endocrine team for further investigations including dynamic function tests and/or imaging.
11344331|NCT02406404|Experimental|spirometer training group|incentive spirometer training group
11344332|NCT02406404|No Intervention|No intervention group|no intervention group
11344360|NCT02406131|Active Comparator|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
11344333|NCT02406365|Experimental|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.
~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
11344334|NCT02406352|Experimental|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
11344335|NCT02406339|No Intervention|Control|Are not subject to any intervention.
11344336|NCT02406339|Experimental|Electrotherapy|The athletes will be submitted to NMES of bilateral quadriceps. The stimulation will be held in order to induce the move flexion / extension involuntary knee in extension machine, with resistance of 30% of maximum voluntary strength.
11344337|NCT02406339|Experimental|Electrotherapy + Vascular Occlusion|The same as in Electrotherapy group, athletes are subjected to NMES associated total vascular occlusion of the members below the level of the groin.
11344338|NCT02406313|Experimental|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
11344339|NCT02406313|Active Comparator|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
11344340|NCT02406300|Active Comparator|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.
~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
11344341|NCT02406300|Active Comparator|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
11344342|NCT02406287|Experimental|Active|Netarsudil (AR-13324) Ophthalmic Solution
11344343|NCT02406287|Placebo Comparator|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
11344344|NCT02406274|Experimental|Contrast Enhanced Spectral Mammography|
11344345|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;
~20 mg simvastatin, single oral dose on Days 2 and 36;
~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;
~50 mg lanabecestat, single oral dose on Day 4;
~50 mg lanabecestat, single oral dose, Days 10 to 37"
11344346|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;
~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;
~5 mg donepezil, single oral dose on Day 28, Period 2"
11344347|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
11344348|NCT02406222|Active Comparator|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Pomalidomide 4mg orally on days 1-21
~Dexamethasone 40mg orally on days 1, 8, 15 and 22"
11344349|NCT02406222|Experimental|Pomalidomide Dexamethasone Cylcophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.
~Dosing schedule:
~Pomalidomide 4mg orally on days 1-21
~Dexamethasone 40mg orally on days 1, 8, 15 and 22
~Cyclophosphamide 500mg orally on days 1, 8 and 15"
11344350|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
11344351|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
11344352|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
11344353|NCT02406183|Experimental|Treatment (SBRT, Ipilimumab)|"Drug: Ipilimumab Dosage: Ipilimumab will be administered intravenously at 3 mg/kg every 3 weeks for 4 cycles,
~Radiation: Stereotactic Body Radiotherapy Radiation therapy 24 Grays in 8 Grays fractions, Radiation therapy 30 Grays in 10 Grays fractions, Radiation therapy 36 Grays in 12 Grays fractions"
11344354|NCT02406170|Experimental|Regorafenib+Paclitaxel|Regorafenib tolerability will be tested in a dose escalation scheme with a cytotoxic backbone of paclitaxel 80mg/m2.
11344355|NCT02406157|Experimental|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
11344356|NCT02406157|Active Comparator|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
11344357|NCT02406144|Active Comparator|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
11344358|NCT02406144|Experimental|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
11344359|NCT02406131|No Intervention|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
11344361|NCT02406118|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
11344362|NCT02406105|Experimental|Radiosurgical thalamotomy|Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy
11414778|NCT01937325|Active Comparator|Ivacaftor|150mg orally twice daily
11344363|NCT02406092|Experimental|Rituximab|Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP [cyclophosphamide+doxorubicin+vincristine+prednisone], CVP [cyclophosphamide+vincristine+prednisone] or FC [fludarabine+cyclophosphamide]) during induction.
11344364|NCT02406079|Experimental|tracheotomy|
11344365|NCT02406066|Placebo Comparator|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
11344366|NCT02406066|Active Comparator|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
11344367|NCT02406066|Active Comparator|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
11344368|NCT02406066|Active Comparator|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
11344369|NCT02406053||OSAS|Obstructive sleep apnea syndrome
11344370|NCT02406053||COPD|Chronic obstructive pulmonary disease
11344371|NCT02406053||LC|Lung cancer
11344372|NCT02406053||HC|Healthy controls
11344373|NCT02406040|Experimental|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
11344374|NCT02406040|Experimental|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
11344375|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
11344376|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
11344377|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
11344378|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
11344379|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
11344380|NCT02406014|Active Comparator|Treatment Group A|Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
11344381|NCT02406014|Active Comparator|Treatment Group B|Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.
11344382|NCT02406001|Experimental|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
11344383|NCT02406001|Other|Control|Surgical intervention: open flap debridement
11344384|NCT02405988|Experimental|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
11344385|NCT02405975|No Intervention|Control|These participants will not receive the educational intervention
11344386|NCT02405975|Experimental|Intervention|"These participants will receive the online educational intervention SCRIPT"
11344387|NCT02405962|Placebo Comparator|Control group|Parents of children with asthma will receive one session of asthma educational talk as the usual care, plus three weekly sessions of telephone calls to assess the child's asthma symptoms
11344388|NCT02405962|Experimental|ACT group|Parents of children with asthma will receive four sessions of group-based ACT intervention integrated with asthma education (its content will be the same as that of the Control Group).
11344389|NCT02405949||T2D 40%EWL|15 pacients who had type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
11344390|NCT02405949||nonT2D40%EWL|15 pacients without type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
11344391|NCT02405949||T2D75%EWL|35 pacients who had type 2 diabetes befor bariatric surgery and presented with more than 75% of the excess weight loss after 12 month from surgery.
11344392|NCT02405949||nonT2D75%EWL|35 pacients without type 2 diabetes befor bariatric surgery and who presented with more than 75% of the excess weight loss after 12 month from surgery.
11344393|NCT02405923|Experimental|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
11344394|NCT02405923|Placebo Comparator|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
11344395|NCT02405910|Experimental|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
11344396|NCT02405910|Experimental|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
11344397|NCT02405897|Experimental|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
11344398|NCT02405897|Active Comparator|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
11344399|NCT02405884|Other|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
11344400|NCT02405858|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.
11344401|NCT02405845|Other|CT Angiogram|A research CTA scan may be required if there is no change of the imaging on the 3 CTA scans prior.
11344402|NCT02405832|Experimental|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
11344403|NCT02405832|Placebo Comparator|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
11344404|NCT02405819|Other|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
11344405|NCT02405819|Other|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
11344406|NCT02405806|Experimental|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.
~Intervention: Food: Low carbohydrate food"
11344407|NCT02405806|Active Comparator|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
11344408|NCT02405793|Experimental|Meloxicam low dose test capsule|Meloxicam SoluMatrix Capsules - low dose QD
11344409|NCT02405793|Experimental|Meloxicam high dose test capsule|Meloxicam SoluMatrix Capsules - high dose QD
11344410|NCT02405793|Active Comparator|Meloxicam tablets|Meloxicam Tablets QD
11344411|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
11344412|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
11344413|NCT02405767|Experimental|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
11344414|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
11344415|NCT02405728|Experimental|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
11344416|NCT02405728|Active Comparator|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
11344417|NCT02405715|Placebo Comparator|Placebo Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
11344418|NCT02405715|Experimental|Oxytocin Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.
11344419|NCT02405689|Active Comparator|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
11344420|NCT02405689|Active Comparator|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
11344421|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
11344422|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
11344423|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
11344424|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
11344533|NCT02404922|Experimental|CTP-730 High Dose or Matching Placebo|Capsule, once daily.
11344425|NCT02405663|Experimental|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
11344426|NCT02405663|Experimental|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
11344427|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:
~abdominal and pelvic Magnetic Resonance Imaging (MRI) scan
~400 meter walk test for physical fitness"
11344428|NCT02405637|Experimental|SAFE group|simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
11344429|NCT02405637|Placebo Comparator|placebo|distilled water 2.5 ml/kg every 3 hours enterally
11344430|NCT02405624|Experimental|CPAP training|Patients will be instructed and follow the continuous positive airway pressure (CPAP) training procedure
11344431|NCT02405611|Active Comparator|active control|mothers and children are in active control group and only receive the questionnaires
11344432|NCT02405611|Experimental|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
11344433|NCT02405611|Experimental|children|only the children receive the intervention and mothers and children receive the questionnaires
11344434|NCT02405598|Experimental|Salbutamol|"age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)
~age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)
~age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
11344435|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy
~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.
~Post adjuvant therapy: 6 monthly immunizations with HAPa"
11344436|NCT02405572|Active Comparator|Formula 1|infant formula
11344437|NCT02405572|Active Comparator|Formula 2|infant formula
11344438|NCT02405559|Experimental|Lymphatic occlusion pressure lower limb|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
11344439|NCT02405546|Experimental|Pre-Rotated Technique (Group R)|90° counterclockwise rotation of bevel of ETT
11344440|NCT02405546|Active Comparator|No rotation|No rotation of bevel of ETT
11344441|NCT02405533|Experimental|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
11344442|NCT02405533|Placebo Comparator|Group 2|Placebo once a day on an empty stomach x 12 months
11344443|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
11344444|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
11344445|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
11344446|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
11344447|NCT02405507|Experimental|wheat bread with wheat germ|wheat bread with wheat germ supplementation
11344448|NCT02405507|Placebo Comparator|wheat bread without wheat germ|wheat bread without wheat germ supplementation
11344449|NCT02405494|Other|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
11344450|NCT02405494|Other|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
11344451|NCT02405494|Other|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
11344452|NCT02405494|Other|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
11344453|NCT02405494|Other|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
11344454|NCT02405494|Other|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
11344455|NCT02405494|Other|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
11344456|NCT02405494|Other|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
11344457|NCT02405494|Other|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
11344458|NCT02405481|No Intervention|Wait List Control|
11344459|NCT02405481|Experimental|SEPA III Intervention|SEPA brings together two important theoretical perspectives that will be effective and sustainable for HIV/AIDS prevention among Hispanic women in an inner city environment. The content and learning strategies of SEPA are based on the social cognitive theory and of HIV/AIDS prevention that prior research has shown to be the most effective in increasing HIV/AIDS prevention behaviors, modified to take into account the special needs of Hispanic women related to gender inequality and cultural values and practices. SEPA's conceptual framework integrates the Social Cognitive Model of behavioral change with Freire's Pedagogy of the Oppressed that guides the delivery and contextual tailoring.
11344460|NCT02405468||case|patients with a myocardial infarction within one month to one year before the inclusion
11344461|NCT02405468||control|"patients without history of myocardial infarction, free of coronary disease in the view of one of the following test performed within one year before the inclusion : Effort test Echocardiographic stress test Myocardial perfusion scintigraphy Coronarography with >= 2 major cardiovascular risk factors :
~Treated hypertension
~Treated dyslipidemia
~Current smoking
~Diabetes mellitus"
11344462|NCT02405455|Experimental|Cerclage|Cervical cerclage.
11344463|NCT02405455|Experimental|Cervical pessary|Cervical pessary
11344534|NCT02404909||Patients with liver tumors candidate to hepatectomy|
11344535|NCT02404896|Experimental|Metreleptin|Metreleptin, SC
11344536|NCT02404883|No Intervention|control group|care as usual (fertility preservation counseling)
11347531|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
11344464|NCT02405442|Experimental|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
11344465|NCT02405442|Experimental|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
11344466|NCT02405442|Experimental|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
11344467|NCT02405442|Placebo Comparator|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
11344468|NCT02405416|Experimental|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
11344469|NCT02405416|Active Comparator|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
11344470|NCT02405403|Experimental|amyotrophic lateral sclerosis (ALS)|[18F]DPA-714 PET
11344471|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
11344472|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
11344473|NCT02405377|Experimental|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
11344474|NCT02405377|Active Comparator|Control|The control group was hydrated at 1 mL/kg per h.
11344475|NCT02405364|Experimental|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
11344476|NCT02405351|Experimental|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
11344477|NCT02405338|Experimental|WT1/PRAME vaccination|
11344478|NCT02405325|Experimental|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
11344479|NCT02405325|No Intervention|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
11344480|NCT02405312|Experimental|advance care planning|nephrologist empowers social worker to meet with patient and family.
11344481|NCT02405299|Experimental|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
11344482|NCT02405299|Placebo Comparator|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
11344483|NCT02405286||Upeer gastrointestinal bleeding|"Adult Egyptian patients.
~Patients with acute upper G.I hemorrhage.
~Informed consent."
11344484|NCT02405273|Experimental|Interventional Group|Pulmonary rehabilitation
11344485|NCT02405273|Active Comparator|Control Group|Standard Care
11344486|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
11344487|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
11344488|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
11344489|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
11344490|NCT02405247||NSCLC without T790M mutation|NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
11344491|NCT02405234|Experimental|Carbon Modular Radial Head|PyroCarbon Modular Radial Head replacement
11344492|NCT02405234|Active Comparator|Metal Radial Head|Metal Radial Head replacement
11344493|NCT02405221|Experimental|TA-CIN administration via thigh|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
11344494|NCT02405221|Experimental|TA-CIN administration via arm|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
11344495|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
11344607|NCT02404480|Experimental|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
11344496|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
11344497|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
11344498|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
11344499|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
11344500|NCT02405156|Experimental|letrozole + misoprostol|Women will receive three tablets of letrozole vaginal as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for three days and will be followed by 200 mcg vaginal misoprostol or 100mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
11344501|NCT02405156|Placebo Comparator|placebo + misoprostol|Women will receive three tablets of placebo vaginal as a single dose, for three days and will be followed by 200 mcg vaginal misoprostol or 100 mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
11344502|NCT02405143|Experimental|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
11344503|NCT02405143|Sham Comparator|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
11344504|NCT02405130|Active Comparator|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
11344505|NCT02405130|Other|no intracoronary epinephrine|no epinephrine
11344506|NCT02405117|Experimental|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
11344507|NCT02405117|No Intervention|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
11344508|NCT02405104|Active Comparator|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
11344509|NCT02405104|Placebo Comparator|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
11344510|NCT02405104|Active Comparator|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
11344511|NCT02405104|Placebo Comparator|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
11344512|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
11344513|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
11344514|NCT02405078|Experimental|Diagnostic (PET/CT, clonotype, metabolic profile)|"Patients receive standard salvage chemotherapy as determined by the treating physician.
~Patients undergo FDG PET/CT scans at baseline (between days -21 to 0), on day 4 after completion of first high-dose chemotherapy, on day 21 after completion of the first course of chemotherapy, and on day 42 after the end of the second course of chemotherapy. Blood samples are also collected for tumor-specific clonotype and metabolic profile at baseline (days -5 to 0) and on days 4, 8, 21, and 42."
11344515|NCT02405065|Experimental|HM95573|single arm
11344516|NCT02405052||Patients|Emergency department patients with unexplained chest pain
11344517|NCT02405039|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
11344518|NCT02405039|Placebo Comparator|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
11344519|NCT02405026||HIV infected patients|HIV infected patients with asthma
11344520|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
11344521|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
11344522|NCT02405013|Experimental|Sofosbuvir+Ribavirin|Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
11344523|NCT02405013|Experimental|Sofosbuvir+Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
11344524|NCT02405000|Experimental|Intraoperative CT imaging|
11344525|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
11344526|NCT02404974|Experimental|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
11344527|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
11344528|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
11344529|NCT02404935|Experimental|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
11344530|NCT02404935|Other|Arm B observation|observation until progression
11344531|NCT02404922|Experimental|CTP-730 Low Dose or Matching Placebo|Capsule, once daily.
11344532|NCT02404922|Experimental|CTP-730 Mid Dose or Matching Placebo|Capsule, once daily
11344537|NCT02404883|Experimental|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
11344538|NCT02404870|Experimental|Admission 1 or 2|Canagliflozin
11344539|NCT02404870|Placebo Comparator|Admission 2 or 1|Placebo
11344540|NCT02404857|Experimental|Chronic post-stroke|Patients >6 months post-stroke with little to no hand movement. use of EEG based BCI in the neurorehabilitation process
11344541|NCT02404844|Experimental|BKM120 + Tamoxifen|"BKM120 (Buparlisib): 100 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle
~Tamoxifen: 20 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle"
11344542|NCT02404831|Active Comparator|Traditional hospital-based PR|Class based pulmonary rehabilitation
11344543|NCT02404831|Experimental|Web-based PR|web-based pulmonary rehab
11344544|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
11344545|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
11344546|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
11344547|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
11344548|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
11344549|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
11344550|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
11344551|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
11344552|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
11344553|NCT02404779|Experimental|CISATRACURIUM|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
11344554|NCT02404779|Placebo Comparator|PLACEBO|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
11344555|NCT02404766|Experimental|Intervention group|C0-C1 dorsal glide mobilization in the cervical neutral position.
11344556|NCT02404766|Experimental|Intervention group 2|C7-T1 ventral cranial glide mobilization in the cervical neutral position
11344557|NCT02404766|No Intervention|Control group|Not receiving any intervention
11344558|NCT02404753|Experimental|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
11344559|NCT02404753|Active Comparator|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
11344560|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
11344561|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
11344562|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
11344563|NCT02404727|Active Comparator|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
11344564|NCT02404727|Active Comparator|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
11344565|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.
~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
11344566|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.
~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
11344567|NCT02404701|Experimental|Aloe vera with cactus|1 capsule (500 mg), 2 times/day
11344568|NCT02404701|Experimental|Cranberry|3 capsules (810 mg), 2 times/day
11344569|NCT02404701|Experimental|Green tea extract|2 capsules (630 mg), 2 times/day
11344570|NCT02404701|Experimental|Bilberry|1 softgel (1000 mg), 2 times/day
11344571|NCT02404701|Experimental|Cinnamon|1 capsule (500 mg), 2 times/day
11344572|NCT02404701|Experimental|Milk thistle|1 capsule (250 mg), 3 times/day
11344573|NCT02404701|Experimental|Turmeric|1 capsule (450 mg turmeric + 50 mg turmeric extract), 1 time/day
11344574|NCT02404701|Experimental|Aloe vera|1 capsule (470 mg), 2 times/day
11344575|NCT02404688|Experimental|Active THC and Placebo Ethanol|
11344576|NCT02404688|Experimental|Active THC and Active Ethanol|
11344577|NCT02404688|Experimental|Placebo THC and Active Ethanol|
11344578|NCT02404688|Placebo Comparator|Placebo THC and Placebo Ethanol|
11344579|NCT02404675|Experimental|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
11344580|NCT02404675|Active Comparator|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
11344581|NCT02404675|Experimental|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
11344582|NCT02404662|Experimental|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
11344583|NCT02404662|Active Comparator|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
11344584|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
11344585|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
11344586|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
11344587|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
11344588|NCT02404623|Experimental|Intervention Group|800 IU of Vitamin D once daily
11344589|NCT02404623|Other|Control Group|400 IU of Vitamin D once daily, the standard of care
11344590|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
11344591|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
11344592|NCT02404597|Experimental|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure < 65 or a systolic blood pressure < 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.
~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
11344593|NCT02404597|No Intervention|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
11344594|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.
~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
11344595|NCT02404571|Experimental|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
11344596|NCT02404558|Experimental|Sarilumab|Single subcutaneous (SC) dose of sarilumab
11344597|NCT02404558|Active Comparator|Tocilizumab|Single SC dose of tocilizumab
11344598|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
11344599|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
11344600|NCT02404532|Experimental|1|
11344601|NCT02404519|Active Comparator|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
11344602|NCT02404519|Placebo Comparator|Placebo|Placebo tablet, by mouth, daily for 1 year
11344603|NCT02404506|Experimental|Arm: Eribulin mesilate|
11344604|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
11344605|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
11344606|NCT02404480|Experimental|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
11344612|NCT02404480|Experimental|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
11344613|NCT02404467||Patients receiving transfermoral TAVI|TF TAVI
11344614|NCT02404454|Experimental|hysteroscopic metroplasty|women undergoing hysteroscopic metroplasty for uterine septum resection
11344615|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
11344616|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
11344617|NCT02404428|Active Comparator|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
11344618|NCT02404428|Experimental|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
11344619|NCT02404402|Experimental|Active LED|Active LED Treatment
11344620|NCT02404402|Sham Comparator|Sham LED|Inactive (sham) LED Treatment
11344621|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
11344622|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
11344623|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
11344624|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
11344625|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
11344626|NCT02404376|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning + placebo
11344627|NCT02404376|Active Comparator|Combined treatment|Remote Ischemic Conditioning + exenatide
11344628|NCT02404376|Placebo Comparator|Placebo|Sham Remote Ischemic Conditioning + placebo
11344629|NCT02404376|Active Comparator|Exenatide|Sham Remote Ischemic Conditioning + exenatide
11344630|NCT02404363|Experimental|Clopidogrel|Clopidogrel tablets 75 mg for six months:
11344631|NCT02404363|Placebo Comparator|Comparator|Placebo tablet 75 mg for six months:
11344632|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
11344633|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
11344634|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
11344635|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
11344636|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)
~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
11344637|NCT02404337|Experimental|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
11344638|NCT02404337|Experimental|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
11344639|NCT02404324|Experimental|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.
~Intervention: Prescription of spectacles"
11344640|NCT02404311|Active Comparator|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
11344641|NCT02404311|Placebo Comparator|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
11344642|NCT02404311|Active Comparator|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
11344643|NCT02404311|Active Comparator|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
11344644|NCT02404311|Placebo Comparator|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
11344645|NCT02404298|Experimental|IVIg|
11344646|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:
~Lesions will be counted and right, left and forward facing photographs will be taken
~Investigator Global Assessment
~Acne Quality of Life Questionnaire
~Treatment Area Assessment by Investigator"
11344647|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:
~Lesions will be counted and right, left and forward facing photographs will be taken
~Investigator Global Assessment
~Acne Quality of Life Questionnaire
~Treatment Area Assessment by Investigator"
11344648|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
11344651|NCT02404246|Experimental|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
11344652|NCT02404246|No Intervention|Usual Care|Usual Care
11344653|NCT02404233|Experimental|Darunavir/ cobicistat and Rilpivirine|"Single arm study:
~Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food Rilpivirine tablet 25 mg once daily taken with food"
11344654|NCT02404220|Experimental|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response [PR]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
11344655|NCT02404220|Experimental|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
11344656|NCT02404220|Experimental|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
11344657|NCT02404220|Experimental|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.
~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.
~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
11344658|NCT02404207|Active Comparator|Soybean oil|
11344659|NCT02404207|Experimental|High-oleic soybean oil|
11344660|NCT02404207|Experimental|High-oleic soybean oil + fully hydrogenated soybean oil|
11344661|NCT02404207|Active Comparator|Palm olein + palm stearin|
11344662|NCT02404194|Experimental|Targeted Cognitive Training|40 hours of computerized cognitive training
11344663|NCT02404194|Placebo Comparator|Computer Games|40 hours of computer games
11344664|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
11344665|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
11344666|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
11344667|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
11344668|NCT02404155|Experimental|Clozapine|
11344669|NCT02404142|Placebo Comparator|Control group (saline isotonic solution)|saline isotonic solution
11344670|NCT02404142|Experimental|Curar (Atracurium) group|Curar (Atracurium)
11344671|NCT02404129|Other|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
11344672|NCT02404129|Other|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
11344673|NCT02404129|Other|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
11344674|NCT02404116|Experimental|Metacognitive Therapy|12 weeks of Metacognitive Therapy
11344675|NCT02404116|Other|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
11344676|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
11344677|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
11344678|NCT02404077||Clonidine|Patients who received clonidine following prolonged dexmedetomidine infusions
11344679|NCT02404064|Other|Antibiotics perioperative|dose of perioperative antibiotics (cefamezin 1g IV; metronidazole 500 mg IV) This is the standard of care of the department
11344680|NCT02404064|Placebo Comparator|placebo - No Antibiotics perioperative|The intervention is No Antibiotics perioperative
11344681|NCT02404051|Experimental|ARM 1|Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)
11344682|NCT02404051|Experimental|ARM 2|Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)
11344683|NCT02404038|Active Comparator|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
11344684|NCT02404038|Active Comparator|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
11344685|NCT02404038|Active Comparator|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
11344686|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
11344687|NCT02404012|Active Comparator|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
11344688|NCT02404012|Experimental|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
11344689|NCT02403999|Experimental|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
11344690|NCT02403999|Experimental|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
11344691|NCT02403999|Experimental|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
11344692|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
11344693|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
11344694|NCT02403973|Other|Patient hotel group|
11344695|NCT02403973|Other|Ward group|
11344696|NCT02403960|Active Comparator|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
11344697|NCT02403960|Placebo Comparator|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
11344698|NCT02403947|Experimental|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
11344699|NCT02403947|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
11344700|NCT02403908|Experimental|PADN groups (radiofrequency denervation)|An 8-F long sheath will be inserted through the femoral vein and advanced to the main PA (MPA). The nMARQ Circular or Crescent (Biosense Webster) catheter will be advanced along this long sheath. After gently withdrawing the sheath and pushing the PADN catheter, the tip will be released from the sheath. Then, the tip of the catheter will be positioned first at the ostium of the left PA (Level 1 of ablation, <2 mm distal to orifice. After ablation at this level, the catheter tip will be positioned at the ostium of right PA (Level 2 of ablation, <2mm proximal to the bifurcation level). Finally, denervation of main pulmonary artery will be done by pulling the denervation catheter back into Level 3 of ablation (<2 mm proximal to both ostia of right and left PA-s) into main pulmonary artery.
11344701|NCT02403908|No Intervention|SHAM group|non-treated patients (controls)
11344702|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
11344703|NCT02403882|Experimental|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
11344704|NCT02403882|Experimental|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
11344705|NCT02403882|Experimental|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
11344706|NCT02403882|Experimental|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
11344707|NCT02403882|Experimental|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
11344708|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
11344709|NCT02403856|Experimental|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
11344710|NCT02403856|Active Comparator|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
11344711|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
11344712|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
11344784|NCT02403297||Healthy|"Saliva will be collected from 58 subjects determined to be healthy according to the protocol."
11344713|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
11344714|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
11344715|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
11344716|NCT02403804|Other|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.
~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm
~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm
~Week 3: Betaine anhydrous 1000 mg BID"
11344717|NCT02403791|Experimental|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
11344718|NCT02403791|Active Comparator|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
11344719|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
11344720|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
11344721|NCT02403765||Family cases|Family-based Parkinson patients carrying genetic variants associated with the disease
11344722|NCT02403765||Family controls|Family-based Control subjects
11344723|NCT02403752|Experimental|exercise intervention|"Exercise protocol based on the PLIÉ protocol, developed in consultation with experts worldwide, incl. traditional strength-building exercises, yoga, Tai Chi and Feldenkrais, that engage the muscles most needed to maintain independence--including lower body strength, balance, upper body strength, fine motor exercises , and pelvic floor exercises- combined them into a unique integrative exercise program, to be purposeful and to build procedural ('muscle') memory.
~To be practiced at home in dyads of affected individuals and caregivers, called Paired PLIE Program."
11344724|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
11344725|NCT02403713|Experimental|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
11344726|NCT02403713|Active Comparator|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
11344727|NCT02403713|Active Comparator|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
11344728|NCT02403713|Active Comparator|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
11344729|NCT02403713|Active Comparator|Active Comparator 4|Formoterol (12 µg) without spacer
11344730|NCT02403700||All study participants|One group observation study
11344731|NCT02403674|Experimental|MK-1439A|Treatment-naive HIV-infected participants will receive MK-1439A, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
11344732|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding.
11344733|NCT02403661|Active Comparator|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
11344734|NCT02403661|Placebo Comparator|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
11344735|NCT02403648|Experimental|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
11344736|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
11344737|NCT02403648|Active Comparator|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
11344738|NCT02403648|Experimental|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
11344739|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
11344740|NCT02403648|Active Comparator|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
11344741|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
11344742|NCT02403622|Experimental|intervention|open label single arm
11344743|NCT02403609|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) on two consecutive days
11344744|NCT02403596|Experimental|Group 1: Exacyl®: Standard treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 then 1g Exacyl® placebo at H+7 and H+11
11344745|NCT02403596|Experimental|Group 2: Exacyl®: Extended treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 / H+7 and H+11
11344746|NCT02403596|Placebo Comparator|Group 3: Placebo|This group will receive a placebo of Exacyl®: 1g placebo of Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g placebo of Exacyl® at H+3 / H+7 and H+11
11344747|NCT02403583|Other|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
11344748|NCT02403583|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
11344749|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
11344750|NCT02403557|Experimental|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
11344751|NCT02403557|Active Comparator|Waitlist|Weekly check-up.
11344785|NCT02403297||Gingivitis|Saliva will be collected from 58 subjects determined to have gingivitis according to the protocol.
11345083|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
11344752|NCT02403544|Experimental|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
11344753|NCT02403531|Active Comparator|Concurrent chemoradiotherapy|Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
11344754|NCT02403531|Experimental|Induction chemotherapy plus chemoradiotherapy|Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
11344755|NCT02403518|Active Comparator|Back Pain Only|Pain localized to the low back or buttocks.
11344756|NCT02403518|Active Comparator|Leg Pain Only|Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
11344757|NCT02403518|Active Comparator|Back and Leg Pain|Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).
11344758|NCT02403505|Experimental|ABIRATERONE - Group 1|"ZYTIGA - ABIRATERONE ACETATE TABLET
~Combined Chemotherapy
~DELTASONE - PREDNISONE TABLET
~ELIGARD - Leuprolide Acetate Kit"
11344759|NCT02403505|Experimental|ABIRATERONE - Group 2|"ZYTIGA - ABIRATERONE ACETATE TABLET
~Combined Chemotherapy
~DELTASONE - PREDNISONE TABLET
~TRELSTAR - Triptorelin Pamoate Kit"
11344760|NCT02403492|No Intervention|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
11344761|NCT02403492|Experimental|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
11344762|NCT02403492|Experimental|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
11344763|NCT02403479|Experimental|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
11344764|NCT02403479|Experimental|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
11344765|NCT02403466|Experimental|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
11344766|NCT02403440|Experimental|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
11344767|NCT02403427|Experimental|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
11344768|NCT02403427|No Intervention|manual calculation|manula insulin calculation before every main meal; three times per day
11344769|NCT02403401|Experimental|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
11344770|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
11344771|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
11344772|NCT02403375|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
11344773|NCT02403362|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
11344774|NCT02403362|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
11344775|NCT02403362|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
11344776|NCT02403349|Experimental|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
11344777|NCT02403349|Active Comparator|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
11344778|NCT02403349|Active Comparator|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
11344779|NCT02403336|Experimental|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
11344780|NCT02403336|Active Comparator|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
11344781|NCT02403323|Experimental|Part 1: Etrolizumab Open-Label Extension|Participants will receive open-label treatment with etrolizumab once every 4 weeks until commercial availability in their country or sponsor's decision to terminate the study, whichever is earlier (up to approximately 10 years after the first patient is enrolled).
11344782|NCT02403323|No Intervention|Part 2: Safety Monitoring|Participants who have stopped etrolizumab treatment (either by exiting Part 1 of this study or by entering directly from Study GA29144 [NCT02394028]) will be monitored for 92 weeks for progressive multifocal leukoencephalopathy (PML) and other safety events.
11344783|NCT02403310|Experimental|Dose Escalation - Selinexor|"Dose escalation of selinexor with fixed doses of daunorubicin and cytarabine.
~Induction Therapy may be followed by Consolidation Phase and Maintenance Phase as outlined in the Detailed Description and Intervention Descriptions."
11344950|NCT02402270|Active Comparator|Group E|
11344786|NCT02403297||Periodontal disease|Saliva will be collected from 58 subjects determined to have periodontal disease according to the protocol.
11344787|NCT02403284|Experimental|Liraglutide|Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
11344788|NCT02403284|Placebo Comparator|Sugar pill|matching placebo and titration
11344789|NCT02403271|Experimental|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
11344790|NCT02403271|Experimental|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
11344791|NCT02403258|Experimental|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
11344792|NCT02403258|Active Comparator|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
11344793|NCT02403245|Experimental|Psychosocial stimulation|One session of a social stimulation
11344794|NCT02403245|No Intervention|Control group|Residents are in a social controlled condition but without direct stimulation.
11344795|NCT02403232|Experimental|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
11344796|NCT02403219|Experimental|Botulinum toxin type A injection|An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
11344797|NCT02403219|Sham Comparator|Sham injection|An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
11344798|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
11344799|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
11344800|NCT02403193|Experimental|PBF-509_80 mg|
11344801|NCT02403193|Experimental|PBF-509_160 mg|
11344802|NCT02403193|Experimental|PBF-509_320 mg|
11344803|NCT02403193|Experimental|PBF-509_640 mg|
11344804|NCT02403193|Experimental|PBF509_160 mg +PDR001|
11344805|NCT02403193|Experimental|PBF509_320 mg+PDR001|
11344806|NCT02403193|Experimental|PBF509_640 mg +PDR001|
11344807|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
11344808|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
11344809|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
11344810|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
11344811|NCT02403154|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
11344812|NCT02403154|Experimental|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
11344813|NCT02403154|Other|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
11344814|NCT02403154|Other|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
11344815|NCT02403141||Normal glucose tolerance|Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
11344816|NCT02403141||Impaired fasting glycaemia|Patients with blood glucose between 5.6mmol/L - 7mmol/L
11344817|NCT02403141||Type 2 diabetes|Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
11344818|NCT02403141||Type 1 diabetes|Patients on insulin and with positive IA2 and/or GAD antibodies.
11344819|NCT02403128|Experimental|Patients with macular edema from RAM|Intravitreal aflibercept 2.0 mg injection for eyes meeting eligibility criteria will be administered at baseline. Reinjection of the drug for protocol-defined criteria at least two months after previous injection.
11344820|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
11344821|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
11344822|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
11344823|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
11344824|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
11344825|NCT02403089||neonates|neonates 24-41 weeks gestational age
11344826|NCT02403089||children|hematopoietic stem cell transplant recipient children (< 18 years old, donor source: cord blood or genoidentical donor)
11344827|NCT02403063|Active Comparator|sugammadex|Selective relaxant binding agent
11344828|NCT02403063|Active Comparator|neostigmine|Acetylcholinesterase inhibitor
11344829|NCT02403063|Experimental|neostigmine-sugammadex|Acetylcholinesterase inhibitor followed by a selective relaxant binding agent
11344830|NCT02403050||Fiducial Markers Prospective cohort|2 fiducial markers (Visicoils) to be placed in the tumor area at the routine endoscopic ultrasound (EUS) appointment.
11344831|NCT02403050||Retrospective cohort|Images and clinical data from a retrospective group of patients without fiducial markers
11344832|NCT02403037|Experimental|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
11344833|NCT02403037|Sham Comparator|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
11344834|NCT02403037|Other|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
11344835|NCT02403024|Experimental|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
11344836|NCT02403024|Other|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
11344837|NCT02403011|Experimental|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
11344838|NCT02403011|Experimental|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
11344839|NCT02402998|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
11344840|NCT02402985|Other|High animal protein diet group AP|6-weeks diet intervention with high animal protein
11344841|NCT02402985|Other|High plant protein diet group PP|6-weeks diet intervention with high plant protein
11344842|NCT02402972|Experimental|IPC plus AC|"patients treated with intraoperative intraportal chemotherapy (IPC) plus adjuvant chemotherapy (AC; mFOLFOX6).; IPC: During the operation, one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein within 5 minutes just before ligation.
~AC: All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0."
11344843|NCT02402972|Active Comparator|AC|patients treated with adjuvant chemotherapy (AC; mFOLFOX6) alone after surgery; Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0.
11344844|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344845|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344846|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344951|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
11344847|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344848|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344849|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344850|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344851|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344852|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344853|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
11344854|NCT02402946|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
11344855|NCT02402946|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
11344856|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
11344857|NCT02402920|Experimental|Part A (LS-SCLC, pembrolizumab, chemoradiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
11344858|NCT02402920|Experimental|Part B (ES-SCLC, pembrolizumab, radiation therapy)|Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
11344859|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
11344860|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
11344861|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
11344862|NCT02402881|No Intervention|Control|Patients will receive only the standard practices of care
11344863|NCT02402868|Experimental|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
11344864|NCT02402868|Active Comparator|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
11344865|NCT02402855|Experimental|Group Intervention: Financial support|
11344866|NCT02402855|Active Comparator|Group Control: no financial support|
11344867|NCT02402842|Experimental|DCF regimen|docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
11344952|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
11344868|NCT02402829||Hemophilia Patients|Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.
11344869|NCT02402816|Experimental|MPP ON|Patients will be randomized to the MPP-ON Arm vs Standard ICD
11344870|NCT02402816|Active Comparator|Standard ICD|Patients will be randomized to the MPP-ON Arm vs Standard ICD
11344871|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.
~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.
~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
11344872|NCT02402751|Experimental|Acquisition of normative database|Development, implementation and initiation of normative database (image and data) quantitative ultra high field MRI paramaters
11344873|NCT02402738|Experimental|Interpersonal and Social Rhythm Therapy|Participants may be randomized to receive up to 20 outpatient sessions of Interpersonal and Social Rhythm Therapy, provided as an adjunct to community treatment as usual. Intervention sessions begin during pregnancy and continue through 8 weeks postpartum.
11344874|NCT02402738|Active Comparator|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a monthly standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
11344875|NCT02402725|Experimental|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
11344876|NCT02402712|Experimental|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
11344877|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
11344878|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
11344879|NCT02402673|Other|Intervention|
11344880|NCT02402660|Experimental|ALK-001|Daily, oral administration of one capsule. See details below.
11344881|NCT02402660|Placebo Comparator|Placebo|Daily, oral administration of one capsule. See details below.
11344882|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.
~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
11344883|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
11344884|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
11344885|NCT02402621|Active Comparator|Conventional analgesic group|fentanyl
11344886|NCT02402621|Experimental|Model based analgesic group|fentanyl
11344887|NCT02402608|Active Comparator|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
11344888|NCT02402608|Placebo Comparator|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
11344889|NCT02402595|Experimental|Sequence 1 - Period 1|AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
11344890|NCT02402595|Experimental|Sequence 1 - Period 2 (after 3-week washout)|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
11344891|NCT02402595|Experimental|Sequence 2 - Period 1|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
11344892|NCT02402595|Experimental|Sequence 2 - Period 2 (after 3-week washout)|AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
11344893|NCT02402582|Experimental|Family-Centered Empowerment Model|Have the same in-patient, pre-intervention, and post-intervention follow-up care as Control Group. However, rather than routine care and follow-up during the intervention period, they recieved than 4 stage intervention using the Family Centered Empowerment Model.
11344894|NCT02402582|Active Comparator|Control|Same in-patient, pre-intervention, and post-intervention follow-up care as Experimental Group. However, rather than 4 stage intervention they receive routine care and follow-up.
11344895|NCT02402569|Experimental|Multi-electrodes / single electrode|Multi stimulation / single stimulation
11344896|NCT02402569|Experimental|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
11344897|NCT02402556|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
11344953|NCT02402244||Observational (Project: Every Child)|Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of biospecimen samples (e.g., tissue, blood, bone marrow, plasma, serum, saliva, cerebrospinal fluid, or urine).
11344898|NCT02402556|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
11344899|NCT02402543|Placebo Comparator|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
11344900|NCT02402543|Experimental|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
11344901|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
11344902|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
11344903|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
11344904|NCT02402517|Placebo Comparator|Extruded snack control|100% corn flour
11344905|NCT02402517|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
11344906|NCT02402517|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
11344907|NCT02402517|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
11344908|NCT02402517|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
11344909|NCT02402517|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
11344910|NCT02402504|Placebo Comparator|Extruded snack control|100% corn flour
11344911|NCT02402504|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
11344912|NCT02402504|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
11344913|NCT02402504|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
11344914|NCT02402504|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
11344915|NCT02402504|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
11344916|NCT02402491|Active Comparator|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
11344917|NCT02402491|Placebo Comparator|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
11344918|NCT02402478||Stable coronary artery disease|Patients with chest pain
11344919|NCT02402465|Placebo Comparator|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
11344920|NCT02402465|Experimental|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
11344921|NCT02402465|Experimental|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
11344922|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
11344923|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
11344924|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
11344925|NCT02402413|Experimental|PCOS women|
11344926|NCT02402400|Active Comparator|Oral Ticagrelor|
11344927|NCT02402400|Experimental|Sub Lingual Ticagrelor|
11344928|NCT02402387|Active Comparator|Neutral|The patient's head will be in neutral position.
11344929|NCT02402387|Experimental|Flexed|The patient's head will be flexed.
11344930|NCT02402387|Experimental|Extended|The patient's head will be extended.
11344931|NCT02402387|Experimental|Rotated|The patient's head will be rotated.
11344932|NCT02402374|Experimental|PRP gel|Autologous platelet rich plasma gel
11344933|NCT02402374|Placebo Comparator|Placebo|Saline gel
11344934|NCT02402348|Experimental|Metformin|Metformin 850 mg orally once a day for 3 days, then 850 mg orally twice daily starting day 4 until 24hrs before surgery.
11344935|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
11344936|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
11344937|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
11344938|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
11344939|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
11344940|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
11344941|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
11344942|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
11344943|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
11344944|NCT02402283|Experimental|Test Product|Metronidazole benzoate oral granules
11344945|NCT02402283|Active Comparator|Reference Product|Flagyl 400 mg Tablets
11344946|NCT02402270|Experimental|ECP-019 A (Group A)|
11344947|NCT02402270|Experimental|ECP-019 B (Group B)|
11344948|NCT02402270|Experimental|ECP-019 C (Group C)|
11344949|NCT02402270|Active Comparator|Group D|
11344954|NCT02402231|Experimental|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
11344955|NCT02402218|Active Comparator|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
11344956|NCT02402218|Experimental|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
11344957|NCT02402218|Experimental|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
11344958|NCT02402205|Experimental|Web Implementation of TF-CBT|"Web implementation (W)provides only web-based (distance learning) training and consultation to mental health therapists providing TF-CBT treatment to adjudicated youth in RTF. Therapists access the initial 10 hour training course(www.musc.edu/tfcbt) and follow-up consultation (www.musc.edu/tfcbtconsult) at their own convenience and as needed during the course of the study, with RTF administrators guaranteeing that therapists have time to do so. This implementation strategy is free and more convenient to therapists and administrators as it can be accessed whenever desired."
11344959|NCT02402205|Experimental|Web + Live Implementation of TF-CBT|"Web + Live (W+L) implementation provides web-based training and consultation as described in W, and also provides 1) face-to-face training and 2) twice monthly phone consultation with an expert TF-CBT trainer. W+L requires greater resource commitment from therapists and administrators and is less convenient, but provides more specific consultation on the therapists' personal TF-CBT treatment cases."
11344960|NCT02402192|Active Comparator|Corifollitropin alfa|Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.
11344961|NCT02402192|Active Comparator|recombinant FSH|Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.
11344962|NCT02402192|Active Comparator|HP- hMG|Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
11344963|NCT02402179|Experimental|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
11344964|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
11344965|NCT02402153|Other|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
11344966|NCT02402140|Experimental|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.
~No more interventions were applied."
11344967|NCT02402140|No Intervention|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.
~It was not a intervention, it was the control group"
11344968|NCT02402127|Other|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
11344969|NCT02402127|Other|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
11344970|NCT02402127|Other|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
11344971|NCT02402127|Other|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
11344972|NCT02402127|Other|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
11344973|NCT02402127|Other|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
11344974|NCT02402114|Experimental|Intervention|Subject randomized to this group receives 1 oral dose of Hydrocortisone 120 mg
11344975|NCT02402114|Placebo Comparator|Placebo|Subject randomized to this group will receive an oral sugar/placebo pill that looks similar to the Hydrocortisone pill.
11344976|NCT02402101|Active Comparator|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
11345082|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
11344977|NCT02402101|Placebo Comparator|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
11344978|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
11344979|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
11344980|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
11344981|NCT02402075||Brain tumor|patients with glioma
11344982|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
11344983|NCT02402049|Active Comparator|1: Natrum muriaticum 30C|Natrum muriaticum 30C
11344984|NCT02402049|Active Comparator|2: Lachesis 30C|Lachesis 30C
11344985|NCT02402049|Active Comparator|3: Sepia 30C|Sepia 30C
11344986|NCT02402049|Active Comparator|4: Nux vomica 30C|Nux vomica 30C
11344987|NCT02402049|Active Comparator|5: Pulsatilla 30C|Pulsatilla 30C
11344988|NCT02402049|Active Comparator|6 Folliculinum 30C|Folliculinum 30C
11344989|NCT02402049|Placebo Comparator|1: Placebo Natrum muriaticum|Placebo Natrum muriaticum
11344990|NCT02402049|Placebo Comparator|2: Placebo Lachesis|Placebo Lachesis
11344991|NCT02402049|Placebo Comparator|3: Placebo Sepia|Placebo Sepia
11344992|NCT02402049|Placebo Comparator|4: Placebo Nux vomica|Placebo Nux vomica
11344993|NCT02402049|Placebo Comparator|5: Placebo pulsatilla|Placebo pulsatilla
11344994|NCT02402049|Placebo Comparator|6: Placebo Folliculinum|Placebo Folliculinum
11344995|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
11344996|NCT02402023|Active Comparator|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
11344997|NCT02402023|Experimental|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
11344998|NCT02402010|Experimental|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
11344999|NCT02402010|Other|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
11345000|NCT02401997|Active Comparator|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
11345001|NCT02401997|Active Comparator|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
11345002|NCT02401997|Active Comparator|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
11345003|NCT02401984||Screening|A Screening tool will be administered to the participants.
11345004|NCT02401971|Experimental|Arm A (thalidomide+CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.
11345005|NCT02401971|Experimental|Arm B (CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.
11345006|NCT02401958|Experimental|Rheumatoid Arthritis Group|Resistance Training
11345007|NCT02401958|Active Comparator|Healthy control Group|Resistance Training
11345008|NCT02401945|Experimental|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
11345009|NCT02401945|Experimental|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
11345010|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
11345011|NCT02401919|Experimental|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
11345012|NCT02401919|No Intervention|Care as usual|In the control arm, patients will receive care as usual.
11345013|NCT02401880|Active Comparator|Empagliflozin plus Linagliptin|Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
11345014|NCT02401880|Placebo Comparator|Empagliflozin plus Placebo|Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
11345015|NCT02401880|Other|Empagliflozin|Empagliflozin 25mg will be adminstered for 30 days in T2DM patients
11345016|NCT02401841||Sugammadex|Patients treated with Sugammadex
11345017|NCT02401841||Neostigmine|Patients treated with Neostigmine
11345018|NCT02401828|Experimental|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
11345019|NCT02401828|Experimental|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
11345020|NCT02401815|Experimental|Part 1|Open-label, sequential cohort PLX9486 single-agent Dose Escalation in patients with solid tumors.
11345021|NCT02401815|Experimental|Part 2b|Open-label, sequential cohort PLX9486 combined with PLX3397 Dose Escalation in patients with advanced solid tumors (including GIST)
11345022|NCT02401815|Experimental|Part 2e|Open-label, sequential cohort PLX9486 combined with Sunitinib Dose Escalation in patients with solid tumors (including GIST).
11345023|NCT02401802|Experimental|Low-residue diet|The experimental group will receive 4 days of low-residue diet Laxative 4 liters polyethylene glycol 4000 in split fashion.
11345024|NCT02401802|Active Comparator|Usual care|"The control group will receive 3 days of low-residue diet followed by 24 hours of liquid diet.
~Laxative 4 liters polyethylene glycol 4000 in split fashion."
11345025|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
11345026|NCT02401789|No Intervention|control- natural healing|
11345027|NCT02401776|Experimental|small dose monster energy drink|This will be a small dose of monster energy drink
11345028|NCT02401776|Experimental|medium dose monster energy drink|This will be a medium dose of monster energy drink
11345029|NCT02401776|Active Comparator|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
11345030|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
11345031|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
11345032|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
11345033|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
11345034|NCT02401737|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 28 days
11345035|NCT02401737|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
11345036|NCT02401737|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
11345037|NCT02401737|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
11345038|NCT02401724|Active Comparator|Action Training|Training exercise which involves patients lifting up rods of different sizes and shifting their grip if this is too far to one side
11345039|NCT02401724|Experimental|tDCS|A constant 1mA current will be applied to the left (undamaged) side of the scalp with an electrode covered with a damp cotton pad (25 cm2). The current will be applied for 15 minutes per day, with a total of 10 sessions over 3 weeks.
11345040|NCT02401724|Experimental|Action Training + tDCs|This will involve the same procedure as in action training only but with tDCS applied for 15 minutes during the rodlifting.
11345041|NCT02401724|Placebo Comparator|Control training|For the control training, patients will be asked to simply reach for the right hand side of each rod with their right (unaffected) hand and lift it
11345042|NCT02401711|Active Comparator|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
11345043|NCT02401711|Experimental|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
11345044|NCT02401685|Experimental|Adjuvant therapy alone|Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
11345045|NCT02401685|Active Comparator|Adjuvant therapy plus axillary treatment|Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
11345046|NCT02401672|Active Comparator|Active TMS|Repetitive TMS pulse stimulation
11345047|NCT02401672|Sham Comparator|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
11345048|NCT02401659||naïve with CareLink|patients with a first implant of an implanted cardiac device naïve in CareLink or patients with a refill who have not used CareLink until the implant
11345049|NCT02401659||users of CareLink|patients with an implanted cardiac device who have used CareLink for more than one year
11345050|NCT02401646|Experimental|Polygoni Multiflori Radix complex|Participants randomized to the experimental group will take one capsule of Polygoni Multiflori Radix complex extract (250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
11345051|NCT02401646|Placebo Comparator|Starch|Participants randomized to the placebo group will take one capsule of placebo(250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
11345052|NCT02401633|Experimental|CO-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions only
11345053|NCT02401633|Active Comparator|S-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
11345054|NCT02401620||single-group studies|Patients with RA diagnosed
11345055|NCT02401594|Experimental|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
11345056|NCT02401594|Active Comparator|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
11345057|NCT02401581|Experimental|rate of early removal of the catheter|In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .
11345058|NCT02401568|Other|Normal subjects|"No morphologic changes in carpal ligaments or clinical signs of wrist instability.
~Dynamic CT of the wrist will be performed before and after arthrography."
11345059|NCT02401568|Other|Wrist instability|Morphologic ligament changes (e.g. partial or complete rupture) Dynamic CT of the wrist will be performed before and after arthrography.
11345060|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
11345061|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
11345062|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
11345063|NCT02401542|Active Comparator|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.
~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
11345064|NCT02401542|Placebo Comparator|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.
~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
11345065|NCT02401542|Experimental|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.
~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
11345066|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
11345067|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
11345068|NCT02401516|Active Comparator|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
11345069|NCT02401516|Placebo Comparator|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
11345070|NCT02401503|Experimental|Bendamustine + GA101 + ABT-199|Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.
11345071|NCT02401490|Active Comparator|Human albumin|human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.
11345072|NCT02401490|Placebo Comparator|placebo|saline serum 0.9%
11345073|NCT02401477|Experimental|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
11345074|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
11345075|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
11345076|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
11345077|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
11345078|NCT02401451|Experimental|ECG acquisition|"ECG acquisition using the standard ECG machine
~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
11345079|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
11345080|NCT02401425|Active Comparator|letrozole|Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
11345081|NCT02401425|Placebo Comparator|placebo|Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
11345084|NCT02401399|Placebo Comparator|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
11345085|NCT02401399|Active Comparator|high protein formula|The patients receive high protein formula during 15 days before surgery
11345086|NCT02401399|Experimental|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
11345087|NCT02401386|Experimental|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
11345088|NCT02401386|No Intervention|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
11345089|NCT02401373|Experimental|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
11345090|NCT02401373|Experimental|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
11345091|NCT02401360|Experimental|Experimental Group|Oral care regimen
11345092|NCT02401360|Placebo Comparator|Control Group|Toothbrush and toothpaste
11345093|NCT02401347|Experimental|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.
~Participants receive talazoparib 1 mg by mouth daily."
11345094|NCT02401347|Experimental|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:
~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.
~Participants receive talazoparib 1 mg by mouth daily."
11345095|NCT02401334|Experimental|Hernia Repair|Surgical repair for hernia with implantation of the Cook® Antimicrobial Hernia Repair Device.
11345096|NCT02401321|Experimental|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
11345097|NCT02401308|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
11345098|NCT02401308|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
11345099|NCT02401295|Experimental|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.
~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.
~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.
~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
11345100|NCT02401282|Experimental|ABM|Attention bias modification
11345101|NCT02401282|Placebo Comparator|Placebo|Dot-probe task
11345102|NCT02401269|Experimental|Aspirin|Aspirin 325mg daily
11345103|NCT02401269|Placebo Comparator|Placebo|Placebo
11345104|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.
~Included drugs:
~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home
~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
11345105|NCT02401243|Experimental|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
11345106|NCT02401243|Experimental|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
11345107|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
11345108|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
11345109|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
11345110|NCT02401217|Experimental|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
11345111|NCT02401217|Active Comparator|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
11345112|NCT02401217|Experimental|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
11345113|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
11345114|NCT02401191|Experimental|FEX60/PE10|Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
11345212|NCT02400411|Experimental|Rye bread with margarine and ham|Bread-based meal
11345115|NCT02401178||Well baby|"For cross-sectional study design:
~The dependent variables are LCPUFA composition from buccal. The independent variables are 17 SNP from FADS genes.
~For extended cross-sectional study design:
~The dependent variable is atopic dermatitis, while independent variables are:
~17 SNP; LCPUFA and FLG gene mutation"
11345116|NCT02401165|Other|patient|patient
11345117|NCT02401152|Placebo Comparator|Placebo group|Sports drink containing maltodextrin
11345118|NCT02401152|Active Comparator|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
11345119|NCT02401152|Active Comparator|Sports drink 2|Sports drink with a specific source of CHO.
11345120|NCT02401139|Active Comparator|Treatment arm|Ketamine
11345121|NCT02401139|Placebo Comparator|Placebo arm|Placebo
11345122|NCT02401126|Active Comparator|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
11345123|NCT02401126|Placebo Comparator|Placebo|Nitrate-depleted beetroot juice
11345124|NCT02401113|Experimental|UA group|UA group who takes Ursolic acid of Loquat Extract , 500 mg/ day during 12 weeks for treatment of muscle function improvement with relatively health adults
11345125|NCT02401113|Placebo Comparator|placebo group|placebo group who takes a placebo, 500 mg/day for 12 weeks
11345126|NCT02401074|Experimental|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
11345127|NCT02401061|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
11345128|NCT02401048|Experimental|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
11345129|NCT02401048|Experimental|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
11345130|NCT02401035|Experimental|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
11345131|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
11345132|NCT02401022|Active Comparator|AZD8529 high dose|40mg
11345133|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
11345134|NCT02400957|Experimental|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized.
11345135|NCT02400957|Experimental|Placebo|Half of the mouth was applied placebo. Allocation was randomized.
11345136|NCT02400944||patients with bladder cancer|
11345137|NCT02400931|Active Comparator|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
11345138|NCT02400931|Experimental|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
11345139|NCT02400918|Experimental|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
11345140|NCT02400918|No Intervention|Control|Waitlist control
11345141|NCT02400905|Experimental|BioMimics 3D Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Stent System
11345142|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
11345143|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
11345144|NCT02400879|Active Comparator|Remifentanil|For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60
11345145|NCT02400879|Placebo Comparator|sevoflurane and sufentanil|TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60
11345146|NCT02400866|Placebo Comparator|Control|palonosetron + dexamethasone + placebo
11345147|NCT02400866|Experimental|Experimental|palonosetron + dexamethasone + olanzapine
11345148|NCT02400853|Experimental|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
11345149|NCT02400853|Active Comparator|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
11345150|NCT02400840|Experimental|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
11345151|NCT02400840|Active Comparator|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
11345152|NCT02400827||cryopreservation|
11345153|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
11345213|NCT02400411|Experimental|Rye bread with margarine, ham and soup|Bread-based meal
11347532|NCT02384525|Experimental|clinical-based ultrafiltration|
11345154|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
11345155|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11345156|NCT02400801|Active Comparator|oral oestroprogestogen pre-treatment|preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
11345157|NCT02400801|Experimental|gonadotropin-releasing hormone (GnRH) pre-treatment|preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
11345158|NCT02400788|Experimental|Resminostat + Sorafenib|oral administration
11345159|NCT02400788|Active Comparator|Sorafenib|oral administration
11345160|NCT02400775|Experimental|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
11345161|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
11345162|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
11345163|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) Competitive Employment: The IPS intervention assists participants to enter into competitive jobs; 2) Eligibility Based on Client Choice, i.e. zero exclusion; 3) Integration of IPS and Treatment Team, i.e. the PACT; 5) Personalized Benefits Counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) Rapid Job Search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) Systematic Job Development: IPS specialists build an employer network based on Veterans' interests; 8) Time-Unlimited and Individualized Support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
11345164|NCT02400736|Active Comparator|Usual Care/Transitional Work Program (TWP)|Transitional Work Program (TWP) involves 1) Time-limited Set-Aside Employment: short-term transitional work experiences in a brokered or set-aside work setting; 2) Eligibility Criteria: no strict entrance criteria other than general medical clearance; 3) Limited Integration of TWP and Clinical Services: not integrated within PACT; 4) Less Patient-Centered: TWP jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) Personalized Benefits Counseling: TWP specialists help Veterans obtain information about their VA, Social Security, Medicaid, and government entitlements; 6) Job Search: The TWP specialists provide variable and limited guidance for competitive job search; 7) Limited Job Development: TWP specialists do not engage in community based job development for a specific Veteran; 8) Time Limited Support: The TWP specialist does not provide long-term follow-up after the first job is obtained.
11345165|NCT02400723|Experimental|BREATHE|Four weeks of DVD-delivered behavioral intervention. Intervention consists of diaphragmatic breathing and progressive muscle relaxation.
11345166|NCT02400723|Placebo Comparator|Psychoeducation|Four weeks of DVD-delivered psychoeducation as an attention placebo control.
11345167|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
11345168|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
11345169|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
11345170|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
11345171|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
11345172|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
11345173|NCT02400671|Experimental|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
11345174|NCT02400671|Experimental|One-Way SMS|Participants will receive weekly push SMS messaging
11345175|NCT02400671|No Intervention|Control|Participants will receive standard of care (no intervention)
11345176|NCT02400658|Experimental|IORT with CT-Guided HDR Brachytherapy|Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery.
11345177|NCT02400645|Active Comparator|Group A: pre-incisional bupivacaine|Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.
11345178|NCT02400645|Active Comparator|Group B: laparoscope to place TAP block|Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.
11345179|NCT02400632|Experimental|MAGIC-TOUCH Drug-eluting balloon|in-stent restenosis treated with drug-eluting balloon
11345214|NCT02400398||Tube feeding with peptide-base formula|The peptide-based formula (Peptamen) will be administered through a gastrojejunal or jejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered for three 28-day cycles.
11345215|NCT02400385|Experimental|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
11345216|NCT02400372|Experimental|research group|Medihoney Dressing
11345217|NCT02400372|No Intervention|control group|Paraffin gauze with saline Dressing
11345180|NCT02400619|Active Comparator|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
11345181|NCT02400619|Active Comparator|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
11345182|NCT02400606|Experimental|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
11345183|NCT02400606|Active Comparator|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
11345184|NCT02400593|Experimental|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
11345185|NCT02400593|Placebo Comparator|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
11345186|NCT02400580|Experimental|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
11345187|NCT02400580|Placebo Comparator|Normal Saline|The patients in the placebo arm will receive normal saline.
11345188|NCT02400567|Active Comparator|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
11345189|NCT02400567|Experimental|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
11345190|NCT02400554|No Intervention|Wait List Control|Participants wait one year before receiving the intervention. Three assessments are taken over this period: Month 3, Month 9, and Month 12.
11345191|NCT02400554|Experimental|Yappalli|Yappalli: Participants attend a 12-month behavioral intervention.
11345192|NCT02400541|Experimental|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
11345193|NCT02400541|Placebo Comparator|relaxation therapy|10 relaxation sessions during 5 weeks
11345194|NCT02400528|Other|Patients With Profound and Multiple Disabilities|
11345195|NCT02400515|Other|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
11345196|NCT02400502|Experimental|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
11345197|NCT02400476|Experimental|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
11345198|NCT02400476|Experimental|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
11345199|NCT02400476|Experimental|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
11345200|NCT02400476|Experimental|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
11345201|NCT02400476|Experimental|Neratinib Dose Escalation 1|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
11345202|NCT02400476|Experimental|Neratinib Dose Escalation 2|160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.
11345203|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.
~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
11345204|NCT02400450|Experimental|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
11345205|NCT02400450|Placebo Comparator|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
11345206|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity
~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.
~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase
~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase
~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
11345207|NCT02400424|Experimental|SBRT|Study treatment = SBRT for peripheral primary tumor.
11345208|NCT02400411|Experimental|Wheat bread|Bread-based meal
11345209|NCT02400411|Experimental|Wheat bread with margarine and ham|Bread-based meal
11345210|NCT02400411|Experimental|Wheat bread with margarine, ham and soup|Bread-based meal
11345211|NCT02400411|Experimental|Rye bread|Bread-based meal
11345219|NCT02400359|Placebo Comparator|Placebo|Subjects will be randomized to either placebo or Lorcaserin HCl.
11345220|NCT02400359|Active Comparator|Active|Subjects will be randomized to either placebo or Lorcaserin HCl.
11345221|NCT02400346|Experimental|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
11345222|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
11345223|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
11345224|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
11345225|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
11345226|NCT02400320|Active Comparator|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
11345227|NCT02400320|Experimental|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
11345228|NCT02400320|Other|Saline|Saline
11345229|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
11345230|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
11345231|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
11345232|NCT02400281|Experimental|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
11345233|NCT02400281|Experimental|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
11345234|NCT02400268|Experimental|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
11345235|NCT02400268|Active Comparator|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
11345236|NCT02400255|Experimental|Cohort A|Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
11345237|NCT02400255|Experimental|Cohort B|Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
11345238|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
11345239|NCT02400229|Experimental|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
11345240|NCT02400229|Active Comparator|Invasive coronary angiography (ICA)|Invasive coronary angiography
11345241|NCT02400216||Group A|Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)
11345242|NCT02400216||Group B|Patients with minimal fibrosis (Ishak score 0-1).
11345243|NCT02400203|Active Comparator|Control|54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day
11345244|NCT02400203|Experimental|Hemp foods|60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day
11345245|NCT02400190|Experimental|Endocrine therapy alone|Patients receive endocrine therapy alone without radiotherapy
11345246|NCT02400177|Experimental|Emotion regulation training|This is a 4 sessions group workshop and 1 session individual pre-screening about parental emotion regulation and emotion co-regulation. In this study the facilitators will give information about efficient strategies to regulate parent emotions and their children's emotions.
11345247|NCT02400177|No Intervention|Control group|"In this condition we will take all the measurement before and after the waiting list period.
~This group will go through the workshop after the measurements will be taken."
11345248|NCT02400164|Experimental|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
11345249|NCT02400151|Other|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.
~Intervention: Normal control"
11345250|NCT02400151|Experimental|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.
~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
11345251|NCT02400151|Placebo Comparator|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.
~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
11345252|NCT02400138|Experimental|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
11345326|NCT02399540|Active Comparator|Conventional Paired tDCS|Day 1: sham stimulation Day 2: conventional tDCS
11345253|NCT02400138|Sham Comparator|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
11345254|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
11345255|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
11345256|NCT02400112|Experimental|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
11345257|NCT02400112|No Intervention|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
11345258|NCT02400099|Active Comparator|High-protein low calorie diet (HPLC)|900 Kcal; Protein 90 g (39%); CHO 75 g (30%); Lipid 32 g (31%)
11345259|NCT02400099|Placebo Comparator|Control low calorie diet (CLC)|900 Kcal; Protein. 50 g (22%); CHO 119 g (48%); Lipid 31 g (30%)
11345260|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
11345261|NCT02400060|Experimental|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
11345262|NCT02400047|Experimental|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
11345263|NCT02400047|Experimental|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
11345264|NCT02400047|Active Comparator|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
11345265|NCT02400034|Active Comparator|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale >50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is <500 the patient will be discharged WITHOUT a catheter; If PVR is >500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
11345266|NCT02400034|Active Comparator|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids < 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
11345267|NCT02400021|Experimental|Prometrium|Prometrium (progesterone capsules) intervention
11345268|NCT02400021|No Intervention|No treatment|no treatment arm
11345269|NCT02400008|Experimental|Patient with bilateral vocal fold paralysis|Patient with bilateral vocal fold paralysis in a closure position between 6 months to 36 months before et who has been treated by endoscopic treatment without satisfying result (voice or breathing).
11345270|NCT02399995||patients following hepatectomy|
11345271|NCT02399982|Active Comparator|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
11345272|NCT02399982|Experimental|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
11345273|NCT02399969|Experimental|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
11345274|NCT02399969|No Intervention|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
11345275|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.
~Intervention: Survey"
11345276|NCT02399943|Experimental|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.
~Panitumumab: 6 mg/kg, intravenously, Q2W"
11345277|NCT02399917|Experimental|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~5-Azacitidine 75mg/m^2 Lirilumab 1.0 mg/kg"
11345278|NCT02399917|Experimental|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
11345279|NCT02399917|Experimental|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
11345280|NCT02399904|Experimental|1|
11345281|NCT02399891||Retrospective|MI prior to December 11, 2011
11345282|NCT02399891||Prospective|MI on or after December 11, 2011
11345283|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
11345284|NCT02399865|Experimental|YSBNT Group|Six 50 minute YSBNT sessions (delivered by a trained YSBNT practitioner) for over a maximum period of 12 weeks
11345285|NCT02399865|No Intervention|Treatment as Usual Group|Usual care delivered by treatment-as-usual practitioners
11345286|NCT02399826|Other|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
11345287|NCT02399826|Experimental|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
11345288|NCT02399813|Experimental|ADXS11-001|
11345289|NCT02399800|Experimental|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
11345290|NCT02399800|Active Comparator|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
11345291|NCT02399787||infertile patients|Infertile patients with more than 5 oocytes retrieved and no endometriosis
11345292|NCT02399774|Experimental|Post-partum primi and multiparous women|"Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
~Control group: participants will not receive any device for breastfeeding pain control"
11345293|NCT02399774|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
11345294|NCT02399735|Experimental|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
11345295|NCT02399735|Experimental|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
11345296|NCT02399735|Experimental|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
11345297|NCT02399722|Active Comparator|VAC mono therapy|negative pressure wound therapy alone
11345298|NCT02399722|Active Comparator|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
11345299|NCT02399709|Experimental|simvastatin|oral administration, capsule of 20mg.
11345300|NCT02399709|Placebo Comparator|microcrystalline cellulose|oral administration, capsule of 20mg
11345301|NCT02399696|Experimental|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum.
11345302|NCT02399696|Active Comparator|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
11345303|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
11345304|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
11345305|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
11345306|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
11345307|NCT02399657|Experimental|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
11345308|NCT02399644|Experimental|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
11345309|NCT02399644|Experimental|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
11345310|NCT02399644|No Intervention|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
11345311|NCT02399631|Experimental|ERAS group|early recovery program with no preoperative mechanical bowel preparation, early diet initiation, and prevention of postoperative ileus after elective laparoscopic colon cancer surgery
11345312|NCT02399631|No Intervention|Congrol group|Traditional, conventional perioperative treatment
11345313|NCT02399618|Experimental|Capsulized freeze-dried FMT|Reconstitution of normal flora with capsulized freeze-dried fecal inoculum
11345314|NCT02399605|No Intervention|Control|No intervention, group control.
11345315|NCT02399605|Experimental|Stimulation|Subcutaneous Electrical Intervention
11345316|NCT02399592|Experimental|Bevacizumab and Tocotrienol|
11345317|NCT02399579|Experimental|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
11345318|NCT02399566|Experimental|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
11345319|NCT02399566|Active Comparator|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
11345320|NCT02399553|Experimental|Soccer 2G|Soccer players who trained in second generation artificial turf
11345321|NCT02399553|Experimental|Soccer 3G|Soccer players who trained in third generation artificial turf
11345322|NCT02399553|Experimental|Soccer NG|Soccer players who trained in natural grass
11345323|NCT02399553|Experimental|Soccer NON-NG|Soccer players who trained in non-natural grass
11345324|NCT02399553|No Intervention|Control group|
11345325|NCT02399540|Sham Comparator|Sham|Day 1: sham stimulation Day 2: sham stimulation
11345327|NCT02399540|Active Comparator|Conventional Unpaired tDCS|Day 1: conventional tDCS Day 2: sham stimulation
11345328|NCT02399540|Experimental|Late LTP-like Plasticity tDCS|Day 1: late LTP-like Plasticity tDCS Day 2: sham stimulation
11345329|NCT02399514|Other|RePneum coils|Patients who needed lung volume reduction with RePneum coils
11345330|NCT02399501|Experimental|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
11345331|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
11345332|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
11345333|NCT02399462|Experimental|Study Drug Arm|Acthar SC injections
11345334|NCT02399449|Active Comparator|sodium ferric gluconate (brand)|brand-name sodium ferric gluconate
11345335|NCT02399449|Active Comparator|sodium ferric gluconate (generic)|generic sodium ferric gluconate
11345336|NCT02399436|Experimental|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
11345337|NCT02399436|No Intervention|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
11345338|NCT02399436|Experimental|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
11345339|NCT02399423|Other|South Asian participants|30 South Asian male participants
11345340|NCT02399423|Other|European participants|30 European male participants
11345341|NCT02399410|Experimental|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
11345342|NCT02399397|Active Comparator|Control group|Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
11345343|NCT02399397|Experimental|Sepsis group|Adult patients (18-50 years old) ASAII and III with sepsis, systemic inflammatory response syndrome or septic shock submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
11345344|NCT02399397|Experimental|Elderly group|Elderly patients (> 65 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
11345345|NCT02399384||HIV+/CAD+|HIV+/CAD+
11345346|NCT02399384||HIV+/CAD-|HIV+/CAD-
11345347|NCT02399384||HIV-/CAD+|HIV-/CAD+
11345348|NCT02399371|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.
11345349|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
11345350|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
11345351|NCT02399332|Experimental|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.
~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
11345352|NCT02399332|No Intervention|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
11345353|NCT02399319|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal fixator.
11345354|NCT02399319|Experimental|Randomized to Symphyseal Plate|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal plating of the symphysis.
11345451|NCT02398643|Other|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
11345355|NCT02399319|Active Comparator|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and the treating physician selected the internal fixator intervention based on their opinion of how best to treat the specific case.
11345356|NCT02399319|Active Comparator|Observational - Symphyseal Plate|Patient signed consent but did not want to randomize their procedure and the treating physician selected internal plating of the symphysis based on their opinion of how best to treat the specific case.
11345357|NCT02399306|Experimental|Arm A|chemoradiotherapy with Enteral Nutrition intervention
11345358|NCT02399306|Placebo Comparator|Arm B|chemoradiotherapy
11345359|NCT02399293|Experimental|Patient N-back|Patients training the N-back task
11345360|NCT02399293|Active Comparator|Patient Visual Search|Patients training the Visual-Search task
11345361|NCT02399293|Experimental|Non-impaired N-back|Non-impaired training the N-back task
11345362|NCT02399293|Active Comparator|Non-impaired Visual Search|Non-impaired training the Visual-Search task
11345363|NCT02399280|Experimental|Lunch|Lunch as main meal(LM)+ Diet
11345364|NCT02399280|Experimental|Dinner|Dinner as main meal(DM)+ Diet
11345365|NCT02399267|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
11345366|NCT02399267|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
11345367|NCT02399267|Active Comparator|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =< 8 cm H2O with PEEP =< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
11345368|NCT02399267|Active Comparator|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
11345369|NCT02399254||Pulmonary Rehabilitation|Chronic Obstructive Pulmonary Disease (COPD) patients following pulmonary rehabilitation
11345370|NCT02399241|Experimental|Remote telemonitoring of clinical data|Bluetooth enabled nebuliser device (I-neb) providing breathing parameters and adherence data.
11345371|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
11345372|NCT02399215|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11345373|NCT02399202|Experimental|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
11345374|NCT02399189|Experimental|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles
~Auto-HSCT conditioning regimen:
~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
11345375|NCT02399176|Experimental|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
11345376|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
11345377|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
11345378|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
11345379|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
11345380|NCT02399150||Acute Abdominal Pain|patients presenting to the ED with acute abdomen
11345381|NCT02399137|Experimental|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
11345382|NCT02399137|Active Comparator|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
11345383|NCT02399137|No Intervention|Observational Group|
11345384|NCT02399124|Other|single arm, open label, treatment|single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
11345385|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
11345386|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
11345387|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
11345388|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
11345389|NCT02399098|Experimental|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
11345390|NCT02399098|Experimental|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
11345391|NCT02399098|No Intervention|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
11345452|NCT02398630|Other|Open Label|"This is a single arm open label study.
~Its procedures involve:
~Transvaginal Echography
~Conventional Virtual Histerosalpingography
~Virtual Histerosalpingography by MRI
~Blood draw for Antimullerian Hormone Dosing"
11345392|NCT02399085|Experimental|Treatment (MOR00208, lenalidomide)|"MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 week cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.
~Lenalidomide (Revlimid®), PO, daily, 4 week cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity."
11345393|NCT02399072||Geographic Atrophy Participants|Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.
11345394|NCT02399059|Experimental|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
11345395|NCT02399059|Active Comparator|Normal saline lavage|Peritoneal irrigation with normal saline
11345396|NCT02399046|Experimental|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
11345397|NCT02399046|Active Comparator|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
11345398|NCT02399033|No Intervention|the control group|Patients in Control group were not received Xihuang Capsules.
11345399|NCT02399033|Experimental|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
11345400|NCT02399020|Experimental|SCIT group|Social Cognition and Interaction Training intervention group
11345401|NCT02399007|Experimental|Total Hip System made in China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
11345402|NCT02399007|Active Comparator|Total Hip System made outside of China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
11345403|NCT02398994|Active Comparator|Intravenous Methylprednisolone|"Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.
~Adult patients - 1g/day for 5 days."
11345404|NCT02398994|Experimental|Intravenous Immunoglobulin|"Paediatric patients <41.2kg - total dose of 2g/kg in divided doses over 2 days.
~All other patients - total dose of 2g/kg in divided doses over 5 days.
~PLUS Intravenous Methylprednisolone
~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.
~Adult patients - 1g/day for 5 days."
11345405|NCT02398981|No Intervention|Baseline|Baseline data collection ( 20 patients per ICU)
11345406|NCT02398981|Experimental|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
11345407|NCT02398968|Active Comparator|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
11345408|NCT02398968|Active Comparator|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
11345409|NCT02398968|No Intervention|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia followed up for 12 months
11345410|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
11345411|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
11345412|NCT02398929|Other|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily following run-in placebo for 2 weeks
11345413|NCT02398916|Experimental|Music|"Listening to relaxing music for the entire period starting from waiting period in the surgical waiting area until the end of the LEEP procedure
~Undergoing LEEP according to the usual protocol"
11345414|NCT02398916|No Intervention|Control|- Undergoing LEEP according to the usual protocol without listening to music
11345415|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
11345416|NCT02398903||Normal weight women|Normal weight women
11345417|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
11345418|NCT02398877|Experimental|Depression with early trauma|stress
11345419|NCT02398877|Experimental|Depression without early trauma|stress
11345420|NCT02398877|Experimental|Healthy with early trauma|stress
11345421|NCT02398877|Experimental|Healthy without early trauma|stress
11345422|NCT02398864|Experimental|endobronchial ultrasound bronchoscopy|EBUS with TBNA
11345423|NCT02398851|Other|TacTIC care model|Compare the 30-day readmission rate in adult patients who receive care in a trans-disciplinary chronic disease continuity of care model with integrated technology (mobile devices such as tablets, iPads and smartphones)
11345424|NCT02398851|Other|Standard of Care|Compare standard practice (patient-centered, coordinated care model without the integration of technology
11345425|NCT02398838|Experimental|Home administration of mifepristone|Home administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
11345426|NCT02398838|Active Comparator|Clinic administration of mifepristone|Clinic administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
11345427|NCT02398825|Experimental|Ponatinib|
11345428|NCT02398812|Active Comparator|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
11345429|NCT02398812|No Intervention|Usual care|Usual care (reference group).
11345430|NCT02398799|No Intervention|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
11345482|NCT02398422|No Intervention|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
11345483|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
11345484|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
11345485|NCT02398396|Experimental|Open Label: 4CMenB (Bexsero®)|
11345431|NCT02398799|Experimental|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
11345432|NCT02398773|Experimental|Diagnostic (FES PET/CT)|Between 0 to 30 days before start of endocrine therapy, patients receive F-18 16 alpha-fluoroestradiol IV over 2 minutes and undergo PET/CT. Patients may undergo a second FES-PET/CT study at least 24 hours after the first study and no later than 10 days after the initial study.
11345433|NCT02398760|Experimental|Motor Control Exercises|(Costa LOP et al. 2009; Hodges PW et al. 2009)
11345434|NCT02398747|Experimental|AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD|50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
11345435|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
11345436|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
11345437|NCT02398721|Other|FNAC|patients will then be randomized routine FNAC strategy
11345438|NCT02398721|No Intervention|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
11345439|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
11345440|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
11345441|NCT02398695||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
11345442|NCT02398695||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
11345443|NCT02398682|Experimental|After study Intervention arm Heartlands|"The trial has 4 arms in a Before and After design:
~Arm 3. After/Heartlands area patients receiving the experimental intervention
~Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include:
~Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI."
11345444|NCT02398682|Active Comparator|After study Control arm Good Hope|"The trial has 4 arms in a Before and After design:
~Arm 4. After/Good Hope area patients observed whilst receiving active comparator
~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
11345445|NCT02398682|Active Comparator|Before study Heartlands area|"The trial has 4 arms in a Before and After design:
~Arm 1. Before/Heartlands area patients observed whilst receiving active comparator
~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
11345446|NCT02398682|Active Comparator|Before study Good Hope area|"The trial has 4 arms in a Before and After design:
~Arm 2. Before/Good Hope area patients observed whilst receiving active comparator
~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
11345447|NCT02398669|Experimental|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
11345448|NCT02398656|Experimental|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
11345449|NCT02398656|Active Comparator|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
11345450|NCT02398643|Other|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
11345453|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
11345454|NCT02398604|Experimental|Group A - Allo-hMSCs|Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
11345455|NCT02398604|Placebo Comparator|Group B|Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
11345456|NCT02398591|Experimental|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
11345457|NCT02398591|Experimental|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
11345458|NCT02398591|Experimental|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
11345459|NCT02398578|Experimental|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
11345460|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy
~Ventral hernia repair - perioperative factors of interest:
~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,
~Pregnancy and delivery - factors of interest:
~- vaginal vs caesearan section, single vs multiple pregnancy
~Subgroup of patients with mesh repair:
~- subanalysis on main attributes
~Subgroup of patients with sutured repair:
~- mono- vs multifilament, slowly vs rapidly absorbable"
11345461|NCT02398552|Active Comparator|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
11345462|NCT02398552|Experimental|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
11345463|NCT02398539|Active Comparator|Group 1|Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
11345464|NCT02398539|Active Comparator|Group 2|Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
11345465|NCT02398526||Radium-223 dichloride|Male patients with a diagnosis of CRPC with symptomatic bone metastases without known visceral metastases will be enrolled after the decision for treatment with Radium-223 has been made by the attending physician according to his/her medical practice.
11345466|NCT02398513|Experimental|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
11345467|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
11345468|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
11345469|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
11345470|NCT02398487|Active Comparator|Personal Vaporizer|Personal Vaporizer loaded with nicotine
11345471|NCT02398487|Active Comparator|Cigalike|Cigalike loaded with nicotine
11345472|NCT02398487|No Intervention|Usual smoking|
11345473|NCT02398474|Experimental|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
11345474|NCT02398474|Active Comparator|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
11345475|NCT02398461|Experimental|rHIgM22|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
11345476|NCT02398461|Placebo Comparator|Placebo|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
11345477|NCT02398448|Experimental|Zyloprim® 300 mg and three dissolution test formulations|Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3
11345478|NCT02398435|Experimental|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
11345479|NCT02398435|Experimental|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
11345480|NCT02398422|Experimental|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
11345481|NCT02398422|Experimental|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
11347533|NCT02384525|Active Comparator|BIA-based ultrafiltration|
11345486|NCT02398383|Experimental|CF with Normal Glucose Tolerance|Individuals with CF without cystic fibrosis related diabetes
11345487|NCT02398383|Experimental|Cystic Fibrosis Related Diabetes|Individuals with cystic fibrosis and cystic fibrosis related diabetes
11345488|NCT02398383|Active Comparator|Control|Age matched control subjects
11345489|NCT02398370|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.
11345490|NCT02398357|No Intervention|Control|No anticoagulation，just routine follow-up
11345491|NCT02398357|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
11345492|NCT02398344|Experimental|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
11345493|NCT02398344|Experimental|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
11345494|NCT02398331|Experimental|arm|Standardised information and education on sexuality in women with spinal cord injury
11345495|NCT02398331|No Intervention|Control arm|Usual care (no structured information or education on sexuality)
11345496|NCT02398318|Active Comparator|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
11345497|NCT02398318|Sham Comparator|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
11345498|NCT02398305|Active Comparator|TR Band accelerated|Diminishing air pressure in the TR Band using accelerated protocol
11345499|NCT02398305|Other|TR band standard|Diminishing air pressure in the TR band according to standard care
11345500|NCT02398292|Other|M3 Program|Non-randomized experimental group. The program is a six-week multi-modal intervention, including nutrition education and cooking classes, physical activity, and mindfulness. Outcomes will be compared to a non-randomized control group.
11345501|NCT02398292|Other|Control|Non-randomized control group. Outcomes will be compared at same time points (baseline, 6 weeks, 12 weeks).
11345502|NCT02398279|Experimental|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
11345503|NCT02398279|Experimental|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
11345504|NCT02398266|Experimental|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
11345505|NCT02398266|Experimental|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
11345506|NCT02398266|Experimental|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
11345507|NCT02398253|Experimental|CBT + Hypo-energetic Diet|
11345508|NCT02398253|Experimental|Hypo-energetic Diet only|
11345509|NCT02398240|Experimental|Low Risk|Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
11345510|NCT02398240|Experimental|Intermediate Risk|Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
11345511|NCT02398240|Experimental|High Risk|High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
11345512|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
11345513|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
11345514|NCT02398214|Experimental|Sleep hygiene & standard care|Participants receive a light, activity, and sleep training (LAST) intervention consists of behavioral and educational strategies for increasing light exposure and physical activity to minimize sleep disturbance.
11345515|NCT02398214|No Intervention|Standard care|Participants receive usual care.
11345516|NCT02398201|Experimental|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
11345517|NCT02398188|Experimental|LIPO-202|Experimental arm
11345518|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
11345519|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age < 18), (ISS > 16) with thoracic injuries
11345520|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
11345521|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
11345522|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
11345523|NCT02398149||PwMS receiving care at the Mandell Center|
11345524|NCT02398136|Experimental|Ketamine|Intranasal ketamine up to 75 mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
11345525|NCT02398136|Active Comparator|Midazolam|Intranasal midazolam 3.75mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
11345526|NCT02398123|Active Comparator|Transversus abdominis plane block|Transversus Abdominis Plane block
11345527|NCT02398123|Placebo Comparator|Caudal block|Caudal block
11345528|NCT02398110|Experimental|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
11345529|NCT02398110|Active Comparator|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
11345530|NCT02398097|Active Comparator|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
11345531|NCT02398097|Active Comparator|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
11345532|NCT02398097|Active Comparator|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
11345533|NCT02398084|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
11345534|NCT02398071|Experimental|PEP interventon|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
11345535|NCT02398071|Sham Comparator|Sham intervention|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
11345536|NCT02398058|Experimental|Trabectedin plus olaparib|"All patients will be treated with trabectedin and olaparib in an open-label fashion.
~The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment."
11345537|NCT02398045|Experimental|Computerised CBT|Computerised CBT for OCD
11345538|NCT02398032|Experimental|CPAP nasal|Nasal continuous positive airway pressure, during the night
11345539|NCT02398032|Sham Comparator|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
11345540|NCT02398019|Experimental|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
11345541|NCT02398019|No Intervention|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
11345542|NCT02398006|Active Comparator|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
11345543|NCT02398006|Active Comparator|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
11345544|NCT02397993||FNA, blood collection|blood collection prior to fine needle aspiration Endoscopic ultrasonography-guided fine needle aspiration of the pancreas blood collection after to fine needle aspiration
11345545|NCT02397980|No Intervention|Control|Basic information about dementia
11345546|NCT02397980|Active Comparator|Behavioral intervention|"Individual, 90 min a day, with an interval of 2 weeks
~Education about dementia
~psychological counselling
~cognitive behavioral therapy"
11345547|NCT02397967|Experimental|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
11345548|NCT02397967|Placebo Comparator|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
11345549|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
11345550|NCT02397941||non-pregnant women|20 non-pregnant women, BMI < 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
11345551|NCT02397941||pregnant women|40 pregnant women, BMI < 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
11345552|NCT02397941||women who deliverd|20 pregnant women, BMI < 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
11345553|NCT02397928|Experimental|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
11345554|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
11345555|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
11345556|NCT02397902|Experimental|Dairy|Add 4 daily servings of high fat dairy to diet for a period of 4 weeks
11345557|NCT02397902|Active Comparator|Plant-based|Add 4 daily servings of fruit to diet and/or plant-based milk, remove all dairy from diet for a period of 4 weeks
11345558|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
11345559|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
11345560|NCT02397876|Experimental|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
11345561|NCT02397876|No Intervention|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
11345562|NCT02397850|Experimental|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
11345563|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
11345630|NCT02397369|Experimental|Tobacco users:Telephonic counseling|Telephone counseling is a way of providing individual counseling via telephone conversation or telephone hotlines. It can be proactive or reactive.
11345564|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
11345565|NCT02397811|Experimental|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
11345566|NCT02397811|Experimental|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
11345567|NCT02397811|Experimental|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
11345568|NCT02397811|Experimental|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
11345569|NCT02397811|Experimental|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
11345570|NCT02397811|Experimental|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
11345571|NCT02397798|Experimental|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
11345572|NCT02397798|Active Comparator|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
11345573|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
11345574|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
11345575|NCT02397772|Active Comparator|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
11345576|NCT02397772|Experimental|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
11345577|NCT02397772|Experimental|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
11345578|NCT02397759|Experimental|Patients with severe SAH and vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) and presenting vasospasm
11345579|NCT02397759|Experimental|Patients with severe SAH without vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) without vasospasm
11345580|NCT02397759|Active Comparator|Patients with severe SAH without external ventricular derivati|Patients with severe severe SAH from ruptured aneurysm without necessitating a EVD subarachnoid hemorrhage
11345581|NCT02397746||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
11345582|NCT02397733|Active Comparator|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
11345583|NCT02397733|Experimental|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
11345584|NCT02397720|Experimental|Arm I (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11345585|NCT02397720|Experimental|Arm II (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11345586|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
11345587|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
11345588|NCT02397694|Experimental|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.
~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
11345589|NCT02397694|Active Comparator|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.
~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
11345590|NCT02397694|Experimental|Open Label Extension Phase|After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
11345591|NCT02397681|Experimental|Experimental|
11345592|NCT02397668|Experimental|CorMatrix Cor TRICUSPID ECM Valve|Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease. Enrollment will include up to 10 adults subjects and up to 5 pediatric subjects.
11345593|NCT02397642|Active Comparator|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
11345594|NCT02397642|Active Comparator|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
11345595|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
11345596|NCT02397603|Active Comparator|bupivacaine saline group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter
11345597|NCT02397603|Active Comparator|Dexmedetomidine- bupivacaine group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.
11345598|NCT02397590|Other|A Group|Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
11345599|NCT02397590|Other|B Group|Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)
11345600|NCT02397590|Other|C Group|Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
11345601|NCT02397590|Other|D Group|Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
11345602|NCT02397590|Other|E Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)
11345603|NCT02397590|Other|F Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
11345604|NCT02397577|Other|gastric emptying measurements|
11345605|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
11345606|NCT02397551|Active Comparator|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
11345607|NCT02397551|Active Comparator|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
11345608|NCT02397538|Other|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
11345609|NCT02397538|Other|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
11345610|NCT02397525|Experimental|LIPO-202|
11345611|NCT02397512|Experimental|Lactulose group|Subjects will ingest 50g of lactulose once
11345612|NCT02397512|Placebo Comparator|Control group|Subjects will ingest 50g of sucrose once
11345613|NCT02397499|Experimental|LIPO-202|Experimental arm
11345614|NCT02397499|Placebo Comparator|Placebo|Placebo comparator
11345615|NCT02397486|Experimental|Intervention Group|"Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
11345616|NCT02397486|Active Comparator|Control Group|Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
11345617|NCT02397473|Experimental|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
11345618|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
11345619|NCT02397460|Experimental|Gefapixant|Gefapixant 50 mg tablets administered as a single dose
11345620|NCT02397460|Placebo Comparator|Matching placebo for gefapixant|Matching placebo tablets administered as a single dose
11345621|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
11345622|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
11345623|NCT02397434|Experimental|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
11345624|NCT02397421|Active Comparator|Treatment|Dapagliflozin 10mg once daily
11345625|NCT02397421|Placebo Comparator|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
11345626|NCT02397408|Experimental|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
11345627|NCT02397395|Experimental|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
11345628|NCT02397382|Experimental|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
11345629|NCT02397369|Experimental|Tobacco users: Self Help|Self-help intervention is defined as any manual or programme to be used by individuals to assist a quit attempt not aided by counsellors or group support.They include written materials on the health effects of tobacco, audio-or video tape or computer programmes.
11345661|NCT02397187|Active Comparator|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
11345631|NCT02397369|Experimental|Tobacco users:Behavioural therapy Only|Behavioural therapy includes multiple sessions of Focus Group Discussion (FGD) and individual tobacco cessation counseling sessions. The participants in this group will be given advice to quit tobacco via multisession formal cognitive-behavioural therapy as per the Tobacco Cessation Clinic (TCC) guidelines.
11345632|NCT02397369|Experimental|Tobacco users:Pharmacologic|Pharmacotherapy in the form of Nicotine Replacement Therapy based on individual need assessment to relieve withdrawal symptoms in tobacco users when trying to quit.
11345633|NCT02397356|Experimental|Ketamine first AB|Patients in this group will first receive a dose of ketamine in the nebulised form when they ask for pain relief. The second time they ask for pain relief, they will receive physiological salt in the nebulised form.
11345634|NCT02397356|Active Comparator|Placebo first BA|Patients in this group will first receive physiological salt in the nebulised form form when they ask for pain relief. The second time they ask for pain relief, they will receive a dose of ketamine in the nebulised.
11345635|NCT02397343|Other|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
11345636|NCT02397343|Other|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
11345637|NCT02397330|Active Comparator|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
11345638|NCT02397330|Experimental|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
11345639|NCT02397317|Experimental|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
11345640|NCT02397304|Experimental|Pre-exercise food|Pre-exercise food provision
11345641|NCT02397304|Experimental|Post-exercise food|Post-exercise food provision
11345642|NCT02397291|Placebo Comparator|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
11345643|NCT02397291|Active Comparator|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
11345644|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
11345645|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
11345646|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
11345647|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
11345648|NCT02397265|Placebo Comparator|Insulin only|Insulin only closed loop
11345649|NCT02397252|Experimental|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
11345650|NCT02397252|Placebo Comparator|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
11345651|NCT02397252|Placebo Comparator|Physician-collected sampling|Routine colposcopy sample collected by a physician.
11345652|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
11345653|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
11345654|NCT02397226|Active Comparator|Radiofrequency ablation|Treatment with radiofrequency ablation using radiofrequency ablation catheter. This intervention implies tumescent anesthesia.
11345655|NCT02397226|Active Comparator|High ligation/stripping|Treatment with high ligation/stripping using a vein stripping catheter. This intervention implies general anesthesia.
11345656|NCT02397213|Placebo Comparator|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
11345657|NCT02397213|Active Comparator|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.
11345658|NCT02397200|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
11345659|NCT02397200|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals.
11345660|NCT02397187|Experimental|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.
~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
11414779|NCT01937325|Placebo Comparator|Placebo|Matching placebo
11345662|NCT02397174|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
11345663|NCT02397174|Active Comparator|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
11345664|NCT02397161|Experimental|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
11345665|NCT02397161|Experimental|NMT alone|NMT group - will receive a 12-week neuromuscular training
11345666|NCT02397161|Experimental|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
11345667|NCT02397161|No Intervention|Control|Control group - no intervention for 12 weeks
11345668|NCT02397148|Experimental|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
11345669|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
11345670|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
11345671|NCT02397096|Experimental|Immediate Switch to MK-1439A|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to MK-1439A single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
11345672|NCT02397096|Active Comparator|Delayed Switch to MK-1439A|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to MK-1439A single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
11345673|NCT02397083|Experimental|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
11345674|NCT02397083|Experimental|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
11345675|NCT02397070|Experimental|Jaw exercise program|
11345676|NCT02397070|Active Comparator|Occlusal splint and counseling|
11345677|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
11345678|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
11345679|NCT02397044||Implant loading Immediate|Dental implant surgery with immediate loading
11345680|NCT02397044||Implant Loading Early|Dental implant surgery with delayed loading
11345681|NCT02397031|Experimental|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient's attentional control and emotional regulation.
11345682|NCT02397031|Active Comparator|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient's ability to display social effective behavior.
11345683|NCT02397018|Experimental|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
11345684|NCT02397005|Active Comparator|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
11345685|NCT02397005|Placebo Comparator|Placebo|Placebo matching ZL-2102
11345686|NCT02396992|Other|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
11345687|NCT02396979|Experimental|Methadone Maintenance|Methadone induction and management provided
11345688|NCT02396979|Experimental|Holistic Health Recovery Program|Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.
11345689|NCT02396979|Experimental|Methadone Maintenance and Holistic Health Recovery Prorgram|Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).
11345690|NCT02396979|No Intervention|Standard of Care|Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.
11345691|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
11345692|NCT02396940|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
11345693|NCT02396940|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
11345694|NCT02396927|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
11345695|NCT02396927|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
11345696|NCT02396901|Experimental|GDT group|Patients randomized to the GDT Group will care from a protective strategy with the suspension of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 48 hours before surgery and receive hydration with lactated Ringer's solution at the rate of 1 mL/kg/h in the night before the surgery until the surgical procedure and perioperative hemodynamic therapy.
11345697|NCT02396901|Placebo Comparator|Control group|Patients randomized to the control group will be treated in accordance with the care in the institution's routine.
11345698|NCT02396888|Experimental|Insulin|Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized.
11345699|NCT02396888|Placebo Comparator|Placebo|Half of the wound surface was treated daily with normal saline. Allocation was randomized.
11345700|NCT02396875|Experimental|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
11345701|NCT02396875|Active Comparator|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
11345702|NCT02396875|Active Comparator|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
11345703|NCT02396875|Experimental|Group A|"10 patients from Group 1
~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.
~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
11345704|NCT02396875|Active Comparator|Group B|"5 patients form Group 2.
~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
11345705|NCT02396875|Active Comparator|Group C|"5 patients form Group 3
~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
11345706|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
11345707|NCT02396849|Experimental|CPAP|Use of a CPAP machine for at least 5 days per week for 28 days
11345708|NCT02396849|Sham Comparator|CPAP Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
11345709|NCT02396836|Active Comparator|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
11345710|NCT02396836|Experimental|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
11345711|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
11345712|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
11345713|NCT02396810|Placebo Comparator|No intra-operative MRI|Patients undergo transsphenoidal surgery without an intra-operative MRI.
11345714|NCT02396810|Experimental|intra-operative MRI|Patients undergo transspheonidal surgery followed by intra-operative MRI.
11345715|NCT02396797|Experimental|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
11345716|NCT02396797|Active Comparator|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
11345717|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
11345718|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
11345719|NCT02396771|Experimental|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
11345720|NCT02396771|Experimental|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
11345721|NCT02396758|Experimental|APT/2 Hours-r-tPA/2 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 2 mg/hour [hr]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
11345722|NCT02396758|Experimental|APT/4 Hours-r-tPA/1 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
11345723|NCT02396758|Experimental|APT/6 Hours-r-tPA/1 mg/hr/Catheter|A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
11345724|NCT02396758|Experimental|APT/6 Hours-r-tPA/2 mg/hr/Catheter|A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
11345725|NCT02396745|Experimental|TECR & ECM|Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
11345726|NCT02396732|Experimental|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
11345727|NCT02396732|Active Comparator|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
11345728|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
11345729|NCT02396706|Active Comparator|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
11345730|NCT02396706|Placebo Comparator|Placebo|Placebo
11345922|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
11345731|NCT02396693|Experimental|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
11345732|NCT02396693|Placebo Comparator|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
11345733|NCT02396693|Placebo Comparator|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
11345734|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
11345735|NCT02396667||pregnant women with macrosomia|Pregnant wo.en between 37 and 42 weeks with fetal macrosomia as suspected by clinical estimation and 2D ultrasound.
11345736|NCT02396654||normal pregnant women|Normal pregnant women between 37 and 42 weeks gestation.
11345737|NCT02396641|Experimental|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
11345738|NCT02396628|Experimental|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
11345739|NCT02396628|Active Comparator|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
11345740|NCT02396615|Active Comparator|Active|Satin pineapple. Active juice with fibre and ginseng
11345741|NCT02396615|Placebo Comparator|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
11345742|NCT02396602|Experimental|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
11345743|NCT02396602|No Intervention|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
11345744|NCT02396589|Active Comparator|Education Group|Participants in the Education group receive five 90 minute tailored stroke education sessions in the home.
11345745|NCT02396589|Experimental|Home Modifications Group|Participants in the treatment group receive a home assessment and home modifications tailored to functional abilities (pre discharge) and then five 90 minute occupational therapy treatment sessions at home (post discharge) to improve functional abilities and community participation.
11345746|NCT02396576|No Intervention|Usual Care|NEVHC has two main Department of Mental Health (DMH) contracted clinical partners where the majority of the patients are referred to -these are Child and Family Guidance Center (CFGC) in the San Fernando Valley and Child and Family Center (CFC) in the Santa Clarita Valley.
11345747|NCT02396576|Experimental|Telehealth Intervention|The telehealth model will enhance patient coordination as well as clinician communication via live videoconferencing. Developmental behavioral services will be provided by a Developmental Behavioral Pediatrician (DBP) housed at UCLA from Children's Hospital Los Angeles (CHLA). Mental Health services will be provided by Child Family Center (CFC) and Child Family Guidance Center (CFGC). The location of the telehealth visit will be at the same clinic location as the index PCP visit with a telehealth coordinator facilitating the encounter between patient and clinicians.The clinician communication will be enhanced through monthly telehealth topic-based educational sessions as well as case-based educational sessions for the transfer cases.
11345748|NCT02396563||epidural analgesia|women in labor with epidural analgesia
11345749|NCT02396563||no epidural analgesia|
11345750|NCT02396550|Experimental|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
11345751|NCT02396550|Experimental|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
11345752|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
11345753|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
11345754|NCT02396524|Experimental|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
11345755|NCT02396524|No Intervention|Usual-care wait-list control|No active intervention (usual care)
11345756|NCT02396511|Experimental|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
11345757|NCT02396498|Placebo Comparator|D2 radical gastrectomy+Systemic chemotherapy|8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.
11345758|NCT02396498|Experimental|D2 radical gastrectomy+HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
11345759|NCT02396485|Experimental|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
11345760|NCT02396485|No Intervention|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
11345761|NCT02396472|Placebo Comparator|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.
~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
11345762|NCT02396472|Active Comparator|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
11345763|NCT02396472|Active Comparator|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
11345764|NCT02396472|Active Comparator|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
11345765|NCT02396472|Active Comparator|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
11345766|NCT02396459|Experimental|MCT8 deficiency patients|Triac treatment
11345767|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
11345768|NCT02396433|Experimental|Carboplatin, eribulin, and E7449|This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
11345769|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
11345770|NCT02396407|Active Comparator|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
11345771|NCT02396407|No Intervention|Non-intervention arm|None. Households will continue their usual practices.
11345772|NCT02396394|Experimental|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
11345773|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
11345774|NCT02396381|Active Comparator|CC|Ad libitum use of CC
11345775|NCT02396368|Experimental|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.
~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
11345776|NCT02396355||All subjects|This is a single arm study. Samples from each subject will be tested with the Investigational BD FACSPresto System, the BD FACSCalibur flow cytometer, and the Sysmex hematology analyzer KX-21.
11345777|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
11345778|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
11345779|NCT02396329|Experimental|chlorhexidine _based antisepsis|"Including cases undergoing elective&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.
~."
11345780|NCT02396329|Active Comparator|povidone_iodine based antisepsis|Including cases undergoing elective&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
11345781|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
11345782|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
11345783|NCT02396303|Experimental|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
11345784|NCT02396303|Active Comparator|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
11345785|NCT02396290|Experimental|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
11345786|NCT02396290|Active Comparator|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
11345787|NCT02396264|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
11345788|NCT02396264|Active Comparator|normocaloric diet|50% carbohydrates, 30% total lipids and 20% proteins. After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
11345789|NCT02396251|Experimental|HA experimental|HA experimental only
11345790|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
11345791|NCT02396238|Experimental|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
11345792|NCT02396238|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
11345793|NCT02396225|Experimental|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
11345794|NCT02396225|Active Comparator|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
11345795|NCT02396212|Experimental|Canakinumab|All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.
11345796|NCT02396199|Experimental|Endovascular|Endovascular treatment using the Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
11345923|NCT02395185|Experimental|Milk|Milk bottle administration
11345797|NCT02396173|Experimental|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
11345798|NCT02396173|No Intervention|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
11345799|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
11345800|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
11345801|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
11345802|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
11345803|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
11345804|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
11345805|NCT02396121|Experimental|Interventional|Administration of 1 bottle of an oral nutritional supplement, Renutryl® Booster (600 kcal), during 28 days.
11345806|NCT02396108|Experimental|Paclitaxel + Carboplatin + ASLAN001|"Phase I:
~A modified 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdraws consent. In the presence of intolerable toxicities to one or more of the drugs in the regimen (but not all 3), the drug in question may be discontinued and the other drugs continued with the patient remaining in the study, if the patient is deemed to be benefiting, after discussion with the Principal Investigator.
~Phase II:
~Patients with stage I-III HER2-positive breast cancer with a primary breast tumour of 2cm or greater will receive up to 4 cycles of pre-operative ASLAN001 and weekly paclitaxel/ carboplatin delivered in 21-day cycles. Prior to administration of chemotherapy, there will be lead-in dosing of single-agent ASLAN001 administered daily for 2 weeks at the recommended phase II dose."
11345807|NCT02396082|Experimental|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
11345808|NCT02396082|Other|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
11345809|NCT02396069|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
11345810|NCT02396069|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
11345811|NCT02396056|Sham Comparator|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
11345812|NCT02396056|Experimental|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
11345813|NCT02396043|Experimental|Modifed BFM-95|All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate [MTX] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.
11345814|NCT02396030|Active Comparator|Magnesium sulfate 50% - 1g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
11345815|NCT02396030|Experimental|Magnesium sulfate 50% - 2g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours
11345816|NCT02396017|Active Comparator|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
11345817|NCT02396017|Experimental|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
11345818|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
11345819|NCT02395978|Experimental|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
11345820|NCT02395978|Experimental|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
11345821|NCT02395978|Experimental|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
11345822|NCT02395978|Experimental|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
11345823|NCT02395978|Placebo Comparator|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
11345824|NCT02395952|Active Comparator|Lubrication|
11345825|NCT02395952|Active Comparator|Bandage Contact Lens|Acuvue Oasys Contact Lens
11345826|NCT02395952|Active Comparator|Prokera|Wet amniotic membrane mounted on plastic retaining ring
11345827|NCT02395952|Active Comparator|Ambiodisk|Freeze dried amniotic membrane
11345828|NCT02395939|Active Comparator|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
11345829|NCT02395939|Active Comparator|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.
~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
11345830|NCT02395926|Active Comparator|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
11345831|NCT02395926|Experimental|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
11345832|NCT02395926|Experimental|T2|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
11345833|NCT02395913|Active Comparator|R|
11345834|NCT02395913|Experimental|T1|
11345835|NCT02395913|Experimental|T3|
11345836|NCT02395913|Experimental|T4|
11345837|NCT02395900|Active Comparator|Flaxseed|30 grams Flaxseed powder
11345838|NCT02395900|Placebo Comparator|control|dietary and exercise recommendation
11345839|NCT02395887||Intervational|Patients with back or neck pain who are a candidates for operational intervention.
11345840|NCT02395887||Control|Men or women who haven't seek for spine surgery consultation.
11345841|NCT02395874|Experimental|verum-tDCS|verum-tDCS+ speech therapy
11345842|NCT02395874|Sham Comparator|sham-tDCS|sham-tDCS + speech therapy
11345843|NCT02395861|Experimental|Electrophysiologic analyses|
11345844|NCT02395848|Experimental|Fidaxomicin|30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.
11345845|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) > = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.
~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
11345846|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) < 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.
~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
11345847|NCT02395822|Experimental|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide
~IL-15 Activation of Donor NK Cells:
~IL-15 to Facilitate NK Cell Survival and Expansion"
11345848|NCT02395809|Active Comparator|LIS group|Lateral internal shincterotomy: A blade knife (No 11) was inserted between internal and external sphincter. The tip of the blade was angled medially pointing just above the dentate line and IS was divided. When the knife was felt beneath the intact mucosa, it was withdrawn.
11345849|NCT02395809|Active Comparator|TENS group|Posterior tibial nerve stimulation by transcutaneous electrical nerve stimulation by through a stimulating TENS unit.
11345850|NCT02395796|Experimental|Epidural Pressure Waveform|"Study Population:
~Term pregnancy
~in labour
~18 years of age or older."
11345851|NCT02395783|Active Comparator|Melatonin dose1|Melatonin 10 µg
11345852|NCT02395783|Active Comparator|Melatonin dose2|Melatonin 20 µg
11345853|NCT02395783|Placebo Comparator|Placebo|Placebo
11345854|NCT02395770|Experimental|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
11345855|NCT02395757|Experimental|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
11345856|NCT02395744|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
11345857|NCT02395731|Experimental|MIND at Home- Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
11345924|NCT02395185|Experimental|Water|Water bottle administration
11345925|NCT02395185|Experimental|Sucrose|Sucrose bottle administration
11345926|NCT02395172|Experimental|Avelumab|
11345927|NCT02395172|Active Comparator|Docetaxel|
11345858|NCT02395718|Experimental|QDU|Patients will undergo a fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation. Patients will have immediate access to all diagnostic tests and treatments that will be carried out all day (24 hours) on demand from the responsible physician. The QDU is both organisationally and physically integrated in the ED. Point of care ultrasonography can be performed round the clock. Additionally the Department of Radiology provides the QDU with more advanced diagnostic procedures such as e.g. CT scans or MRI scans on a fast track basis. There is access to additional specialist evaluations from the ED staff or from various in house specialists, when needed. Simultaneously to the medical treatment, physical therapists and occupational therapists train and optimise patients' level of functioning, including prevention of loss of function.
11345859|NCT02395718|Active Comparator|DIM|Patients in the control group are treated as conventionally at one of seven wards at the DIM. After initial admission including initial diagnostics and treatment have been carried out in the ED, patients are transferred to the DIM. Usually patients are seen primarily by the on-call physician for evaluation of acute symptoms. The following day, a Chief physician will work out a plan for further diagnostics and treatment. Treatment by physiotherapists and occupational therapists is available on request from a physician. Analyses of blood samples are performed at the central laboratory and radiological procedures at the Department of Radiology.
11345860|NCT02395705|Experimental|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):
~Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
~Surgery:
~2-3weeks after Neo-adjuvant chemotherapy
~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
11345861|NCT02395705|No Intervention|Surgery alone group|"Surgery:
~2-3weeks after Neo-adjuvant chemotherapy
~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.
~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
11345862|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11345863|NCT02395679|Experimental|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
11345864|NCT02395666|Experimental|DFMO twice daily|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
11345865|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
11345866|NCT02395640|Experimental|XELOX|oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
11345867|NCT02395640|Active Comparator|EOX|Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
11345868|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
11345869|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
11345870|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
11345871|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
11345872|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
11345873|NCT02395601|Experimental|CPI-1205|
11345874|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.
~Phone call 48 hours after discharge. Discharge instructions will be reinforced.
~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.
~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
11345875|NCT02395562||OTR and viral reactivation|Organ transplant recipients with and without viral reactivation and skin cancer
11345876|NCT02395549|Experimental|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
11345877|NCT02395549|Experimental|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
11345878|NCT02395549|Experimental|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
11345879|NCT02395549|Placebo Comparator|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
11345880|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
11345881|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
11345928|NCT02395159|Experimental|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
11345882|NCT02395523|Experimental|Proton Beam Therapy|"Definition of target volume:
~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan
~Clinical target volume (CTV) = GTV + internal target volume
~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.
~Radiation dose and planning
~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week
~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
11345883|NCT02395510|Other|Flexible, open label dosing|Flexible dosing 5-20mg
11345884|NCT02395497|Experimental|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
11345885|NCT02395484||constipation|collect stool samples from constipation patients
11345886|NCT02395484||healthy controls|collect stool samples from healthy controls patients
11345887|NCT02395471|Experimental|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
11345888|NCT02395471|Experimental|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
11345889|NCT02395458|Experimental|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
11345890|NCT02395458|Active Comparator|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
11345891|NCT02395445|Active Comparator|Totaltrack|Indirect laryngoscopy
11345892|NCT02395445|Active Comparator|Macintosh Laryngoscope|Direct laryngoscopy
11345893|NCT02395432|Active Comparator|Totaltrack|OTI with Totaltrack
11345894|NCT02395432|Active Comparator|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
11345895|NCT02395419|Active Comparator|Totaltrack|OTI with TotalTrack
11345896|NCT02395419|Active Comparator|Airtraq|OTI with Airtraq
11345897|NCT02395406|Active Comparator|Totaltrack|OTI with Totaltrack
11345898|NCT02395406|Active Comparator|Airtraq|OTI with Airtraq
11345899|NCT02395393|Other|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
11345900|NCT02395380|Experimental|C-reactive protein dosage|
11345901|NCT02395354|Other|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
11345902|NCT02395354|Other|A balloon dilatation|A balloon dilatation
11345903|NCT02395328|Experimental|Care worker home visitation|Care Workers provide biweekly home visits and offer residing caregivers and children information and psychosocial support, and encourage their awareness and accessing of external health and social services.
11345904|NCT02395328|No Intervention|Wait List|Access to homework classes are made available to all participants' children at schools supported by the implementing organization.
11345905|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
11345906|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
11345907|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
11345908|NCT02395289|Experimental|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
11345909|NCT02395289|Active Comparator|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
11345910|NCT02395276|Active Comparator|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
11345911|NCT02395276|Placebo Comparator|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
11345912|NCT02395276|No Intervention|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
11345913|NCT02395263|Experimental|Yuxintine 200mg per day|Yuxintine 200mg oral, once a day, 6 weeks
11345914|NCT02395263|Experimental|Yuxintine 300mg per day|Yuxintine 300mg oral, once a day, 6 weeks
11345915|NCT02395263|Experimental|Yuxintine 400mg per day|Yuxintine 400mg oral, once a day, 6 weeks
11345916|NCT02395263|Placebo Comparator|Placebo|Placebo oral, once a day, 6 weeks
11345917|NCT02395250|Experimental|anti-GPC3 CAR T|
11345918|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
11345919|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
11345920|NCT02395211|Active Comparator|Usual Physiotherapy|
11345921|NCT02395211|Experimental|Gloreha device|
11345929|NCT02395159|Other|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
11345930|NCT02395146|Experimental|Monitoring|intraoperative EBSLN monitoring will take place
11345931|NCT02395146|No Intervention|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
11345932|NCT02395133|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
11345933|NCT02395133|Experimental|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
11345934|NCT02395133|Experimental|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
11345935|NCT02395133|Experimental|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
11345936|NCT02395120|Active Comparator|Standard letter|Modified standard letter will be sent to caregivers.
11345937|NCT02395120|Experimental|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
11345938|NCT02395120|Experimental|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
11345939|NCT02395120|Experimental|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
11345940|NCT02395120|Experimental|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
11345941|NCT02395094|No Intervention|Group 1 (Standard Procedure)|Group 1 (Standard Procedure) will receive BCCH standard care, which consists of topical anesthetic cream, waiting with parents in the playroom in the surgical daycare unit preoperatively, parental presence in the OR, the BCCH 'parent hug' and standard distraction techniques
11345942|NCT02395094|Experimental|Group 2 (Child Life)|Group 2 (Child Life) will receive Child Life intervention applicable to the individual patient, on the day of surgery in addition to standard practices
11345943|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
11345944|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
11345945|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
11345946|NCT02395068|Experimental|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
11345947|NCT02395068|Experimental|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
11345948|NCT02395068|Experimental|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
11345949|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
11345950|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
11345951|NCT02395042|Placebo Comparator|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period (Tx 1): Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 10 and then removed and a second matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 14 and removed on Day 28. Treatment 2 Period (Tx 2): optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and removed on Day 14.
11345952|NCT02395042|Experimental|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period: LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 then removed and a second LiRIS® 400 mg inserted into the bladder on Day 14 and removed on Day 28. Treatment 2 Period: optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and then removed on Day 14.
11345953|NCT02395042|Experimental|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment 1 Period: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 0 and then removed and LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 14 then removed on Day 28. Treatment 2 Period: optional LiRIS® 400 mg inserted into the bladder by cystoscopy on Day 0 then removed on Day 14.
11345954|NCT02395029|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
11345955|NCT02395016|Experimental|Nimotuzumab and Gemcitabine|"nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
11345956|NCT02395016|Placebo Comparator|Placebo and Gemcitabine|"placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
11345957|NCT02395003||High VAT/SAT high Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks
11345958|NCT02395003||Low VAT/SAT|Subjects with a low ratio of visceral to subcutaneous fat
11345959|NCT02395003||Lean Controls|Lean control
11345960|NCT02395003||High VAT/SAT- low Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks
11345961|NCT02394990|Experimental|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
11345962|NCT02394990|Active Comparator|Control|Participants receive only ABI
11345963|NCT02394977|Experimental|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
11345964|NCT02394977|Active Comparator|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
11345965|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
11345966|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
11345967|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
11345968|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
11345969|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
11345970|NCT02394951|Experimental|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
11345971|NCT02394951|Placebo Comparator|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
11345972|NCT02394938|Experimental|MUSIC|In addition to the standard care, heart failure patients assigned to the music group will listen recorded classical music.
11345973|NCT02394938|No Intervention|CONTROL|Heart Failure patients assigned to the control group will receive standard care only. The standard care will consist in nursing and medical counselling, self-care education and medication.
11345974|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
11345975|NCT02394912|Experimental|Single-arm|
11345976|NCT02394899|No Intervention|Control|The control dyad will receive usual care.
11345977|NCT02394899|Experimental|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
11345978|NCT02394886|Experimental|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
11345979|NCT02394873|Experimental|ALLO-ASC-DFU|
11345980|NCT02394860||blood and cardiological examination|
11345981|NCT02394847|Other|propofol|dose of propofol according to the number of therapies
11345982|NCT02394834|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
11345983|NCT02394834|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
11345984|NCT02394821|Experimental|Metronidazole|metronidazole 0.8% solution - topical
11345985|NCT02394821|Experimental|Polihexanide|Polihexanide 2%
11345986|NCT02394808|Experimental|Test Lens 1|senofilcon A (Approved contact lens material)
11345987|NCT02394808|Active Comparator|Test Lens 2|lotrafilcon B (Approved contact lens material)
11345988|NCT02394795|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
11345989|NCT02394795|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
11345990|NCT02394782||Relapsing-remitting Multiple Sclerosis|
11345991|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
11345992|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
11345993|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
11345994|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
11345995|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
11345996|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
11345997|NCT02394743||eGFR > 90|group whose eGFR is more than 90
11345998|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
11345999|NCT02394743||eGFR < 60|group whose eGFR is less than 60
11346000|NCT02394730|Experimental|vorapaxar|2.5mg of vorapaxar po qd
11346001|NCT02394730|Placebo Comparator|Placebo|sugar pill po qd
11346002|NCT02394717|Other|Intervention|All YMCA programs will receive the Healthy Eating and Physical Activity Intervention throughout the study. All programs will receive the HEPA Strategies intervetion to assist them with achievement of the HEPA Standards.
11346178|NCT02393612|Experimental|DP-R202|Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks
11346003|NCT02394704|Experimental|Graded sensory attention training|Sensory stimuli will begin at a maximal tolerable intensity and decrease in intensity throughout the training, to shift from involuntary to voluntary attentional focus.
11346004|NCT02394704|Active Comparator|Non-graded sensory attention training|Sensory stimuli will begin and be maintained at a minimal detectable intensity to maximize voluntary attentional training.
11346005|NCT02394691|Active Comparator|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
11346006|NCT02394691|Placebo Comparator|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
11346007|NCT02394678|Experimental|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
11346008|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;
~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;
~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;
~Adjuvant Temozolomide Therapy for up to 12 cycles."
11346009|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:
~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;
~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;
~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;
~Adjuvant Temozolomide Therapy for up to 12 cycles."
11346010|NCT02394652|Experimental|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.
~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.
~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
11346011|NCT02394652|Active Comparator|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.
~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
11346012|NCT02394639|Active Comparator|conventional video-EEG monitoring|conventional video-EEG monitoring with cup-electrodes and collodion
11346013|NCT02394639|Experimental|video-EEG monitoring with prototype|video-EEG monitoring of 5 hours with EEG-cap with dry electrodes
11346014|NCT02394626|Experimental|Surgery followed by adjuvant second-line therapy|Surgery followed by adjuvant second-line therapy
11346015|NCT02394626|Active Comparator|Second-line therapy alone|Second-line therapy alone
11346016|NCT02394613|Experimental|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
11346017|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
11346018|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
11346019|NCT02394587|Experimental|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
11346020|NCT02394587|Other|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
11346021|NCT02394574|Active Comparator|Clean Cookstove|Subjects will use ethanol stoves using bioethanol
11346022|NCT02394574|Other|Traditional Cookstove|Subjects will use traditional firewood or kerosine cookstove and receive education on how to reduce air pollution exposures
11346023|NCT02394561|Experimental|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
11346086|NCT02394158|Placebo Comparator|Control arm placebo|Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
11346024|NCT02394561|Experimental|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
11346025|NCT02394548|Experimental|Contralateral Esophagus Sparing Technique (CEST)|IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
11346026|NCT02394535|Experimental|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
11346027|NCT02394522|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
11346028|NCT02394522|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
11346029|NCT02394509|Experimental|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
11346030|NCT02394509|Experimental|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
11346031|NCT02394509|Other|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
11346032|NCT02394496|Experimental|ARM 1|Fulvestrant + Placebo Lapatinib
11346033|NCT02394496|Experimental|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
11346034|NCT02394496|Experimental|ARM 3|Fulvestrant + Lapatinib
11346035|NCT02394496|Experimental|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
11346036|NCT02394483|Experimental|Cohort A active|2 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
11346037|NCT02394483|Placebo Comparator|Cohort A placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
11346038|NCT02394483|Experimental|Cohort B active|4 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
11346039|NCT02394483|Placebo Comparator|Cohort B placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
11346040|NCT02394483|Experimental|Cohort C active|6 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
11346041|NCT02394483|Placebo Comparator|Cohort C placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
11346042|NCT02394483|Experimental|Cohort D active|8 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
11346043|NCT02394483|Placebo Comparator|Cohort D placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
11346044|NCT02394483|Experimental|Cohort E active|10 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
11346045|NCT02394483|Placebo Comparator|Cohort E placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
11346046|NCT02394470|Other|Acute heart failure HF,Chronic HF,Advanced chronic HF|patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure
11346047|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
11346048|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
11346049|NCT02394444|Experimental|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :
~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
11346050|NCT02394444|No Intervention|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
11346051|NCT02394444|No Intervention|Full-term control group|Parents with full-term infants without intervention program TRT
11346052|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
11346053|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
11346054|NCT02394418|Active Comparator|Sevoflurane|Treatment of delirium by inhaled sevoflurane
11346055|NCT02394418|Active Comparator|Propofol|Treatment of delirium by propofol i.v. infusion
11346056|NCT02394418|Active Comparator|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
11346057|NCT02394405||valve surgery|valve plasty/replacement surgery
11346058|NCT02394405||off-pump CABG|off-pump CABG
11346059|NCT02394405||CPB-CABG|CABG with CardioPulmonal Bypass
11346060|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
11346061|NCT02394366|Experimental|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
11346062|NCT02394366|Placebo Comparator|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
11346063|NCT02394353|Active Comparator|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
11346064|NCT02394353|Active Comparator|Gastric Bypass|Patients undergoing the gastric bypass surgery
11346173|NCT02393651|Experimental|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
11346065|NCT02394340|Experimental|Luliconazole Cream 1%|Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
11346066|NCT02394327|Active Comparator|Endoscopic nasogallbladder drainage|If GB cannulation was achieved and the wire was coiled in the GB, 5 to 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
11346067|NCT02394327|Active Comparator|Endoscopic gallbladder stenting|If GB cannulation was achieved and the wire was coiled in the GB, 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
11346068|NCT02394314|Placebo Comparator|Placebo|Placebo administered subcutaneously
11346069|NCT02394314|Experimental|MEDI0382|MEDI0382 administered subcutaneously
11346070|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
11346071|NCT02394275|Experimental|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
11346072|NCT02394262|Experimental|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
11346073|NCT02394249|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
11346074|NCT02394249|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
11346075|NCT02394236|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
11346076|NCT02394236|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
11346077|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
11346078|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
11346079|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:
~Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or
~Upon a significant relapse of paraprotein, defined as:
~Duplication of M-component in two consecutive readings taken ≤2 months apart; or
~An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or
~Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
11346080|NCT02394197|Active Comparator|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).
~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
11346081|NCT02394197|Experimental|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).
~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
11346082|NCT02394184||patients with bicuspid aortic valve stenosis|
11346083|NCT02394171|Experimental|Physical Activity|Women completed a physical activity group cohesion intervention which included six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase physical activity. A small team structure was used for peer problem solving and support throughout the intervention. Teams were given weekly physical activity goals, with slowly increasing weekly minutes milestones to gradually meet recommended amounts of physical activity. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a brisk 15-minute walk.
11346084|NCT02394171|Active Comparator|Fruit and Vegetable|Women completed a fruit and vegetable group cohesion intervention which involved six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase fruit and vegetable consumption. A small team structure was used for peer problem solving and support throughout. Teams were given weekly fruit and vegetable consumption goals at each session, with slowly increasing weekly servings milestones to gradually meet recommended amounts of fruit and vegetable consumption. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a fruit and vegetable taste test.
11346085|NCT02394158|Active Comparator|Intervention arm Metformin|Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
11346174|NCT02393638|Experimental|study group|Simulation and lecture
11346175|NCT02393638|Active Comparator|control group|Lecture only
11346087|NCT02394145|Experimental|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
11346088|NCT02394145|Active Comparator|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
11346089|NCT02394145|Active Comparator|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
11346090|NCT02394145|Active Comparator|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
11346091|NCT02394145|Active Comparator|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
11346092|NCT02394132|Experimental|Imiquimod|"Topical imiquimod 5% cream
~application to treatment area for 5 days/week for a total of 12 weeks
~dispensed at baseline visit along with patient diary"
11346093|NCT02394132|Experimental|Radiotherapy|"Radiotherapy
~treatment regimen determined by treating radiation oncologist and as per standard practice at local institution
~treatment to commence within 8 weeks of randomisation"
11346094|NCT02394119|Experimental|Ofatumumab|"Drug Name: Ofatumumab
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities
~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions
~How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.
~When and how much: once; diluted in 1000 ml of normal saline."
11346095|NCT02394119|Active Comparator|Rituximab|"Drug Name: Rituximab (RTX)
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities
~Procedures: the same as for Ofatumumab Arm
~How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
~When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
11346096|NCT02394106|Experimental|Ofatumumab|"Drug Name: Ofatumumab
~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities
~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions
~Who provides: registered nurse
~How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.
~Where: in Hospital
~When and how much: once; diluted in 1000 ml of normal saline
~Tailoring: 1500 mg/1.73m2
~How well: expert nurse would assist administration"
11346097|NCT02394106|Placebo Comparator|Placebo|"Drug Name: Normal Saline (NaCl 0,9%)
~Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.
~Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
11346098|NCT02394093|Experimental|Aspirin dry powder|500 mg Acetylsalicylic Acid (ASA) dry powder
11346099|NCT02394093|Active Comparator|Aspirin coated tablet|500 mg ASA coated tablet
11346100|NCT02394093|Active Comparator|Aspirin effervescent tablet|500 mg ASA effervescent tablet
11346101|NCT02394080|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
11346102|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
11346103|NCT02394054|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
11346104|NCT02394054|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
11346105|NCT02394041|Experimental|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.
~One or more additional session will be performed in the delivery room."
11346106|NCT02394041|Sham Comparator|Sham acupuncture|The same as active arm but with sham needles.
11346107|NCT02394041|No Intervention|control group|Standard care, no acupuncture session.
11346108|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
11346109|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
11346110|NCT02394028|Placebo Comparator|Induction Phase - Cohort 1 (Exploratory): Placebo|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
11346111|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
11346112|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
11346113|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
11346114|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
11346115|NCT02394028|Placebo Comparator|Induction Phase - Cohort 3 (Pivotal): Placebo|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
11346116|NCT02394028|Placebo Comparator|Maintenance Phase - Placebo Responders: Placebo|Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.
11346117|NCT02394028|Placebo Comparator|Maintenance Phase - Etrolizumab Responders: Placebo|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.
11346118|NCT02394028|Experimental|Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.
11346119|NCT02394028|No Intervention|Maintenance Phase - Non-Responders: Safety Follow-Up/GA29145|All participants from Cohorts 1-3 who are considered non-responders after the Induction Phase at Week 14 may be eligible to enter the open-label extension study GA29145 (NCT02403323) and/or undergo a 12-week safety follow-up.
11346120|NCT02394015||Trabectedin+ PLD|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
11346121|NCT02394002|Experimental|Brain surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
11346122|NCT02394002|Experimental|Spine surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
11346123|NCT02394002|Active Comparator|General surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
11346124|NCT02393989|Experimental|Active comparator|posterior restorations
11346125|NCT02393976|Other|CONTROL|STANDARD NUTRITION
11346126|NCT02393976|Experimental|IMMUNONUTRITION|INMUNONUTRITION
11346127|NCT02393963|Experimental|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
11346128|NCT02393963|Placebo Comparator|Placebo|Sodium Chloride
11346129|NCT02393950|Experimental|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
11346130|NCT02393950|Placebo Comparator|Drug: Placebo|Oral capsules given once daily for one day
11346131|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
11346132|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
11346133|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
11346176|NCT02393625|Experimental|Dose Escalation|
11346177|NCT02393625|Experimental|Dose Expansion|
11416309|NCT01927263|Active Comparator|Infliximab|
11346134|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
11346135|NCT02393911|Active Comparator|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
11346136|NCT02393911|Active Comparator|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
11346137|NCT02393911|Active Comparator|Control|Healthy women without LPV, not treated by Low Oxalate Diet
11346138|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
11346139|NCT02393885|Experimental|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
11346140|NCT02393872|Experimental|High-risk families component|School-based intervention and counselling sessions.
11346141|NCT02393872|Experimental|All-families component|School-based intervention.
11346142|NCT02393872|No Intervention|Control|Control group.
11346143|NCT02393859|Active Comparator|High Risk Consolidation 3 (HC3) Chemotherapy|One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m^2/day intravenous [IV] on Days 1-6), vincrisitne (1.5 mg/m^2/day IV on Days 1 and 6), daunorubicin (30 mg/m^2 IV over 24 hours on Day 5), methotrexate (1 g/m^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m^2 IV for 1 hour on Days 2-4), and pegylated [PEG]-asparaginase (1000 U/m^2 IV for 2 hours or intramuscularly [IM] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m^2 IV or IM every 48 hours for a total of 6 doses).
11346144|NCT02393859|Experimental|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
11346145|NCT02393846|Experimental|ketoprofen|Topical ketoprofen (gel) is the experimental drug that is applied to the ankle in a dose of 2 gr.
11346146|NCT02393846|Placebo Comparator|Placebo|Topical placebo (gel) is identical in colour, form and smell with the ketoprofen gel.
11346147|NCT02393833|Active Comparator|Induction chemotherapy|Approved induction CT regimen after randomization
11346148|NCT02393833|Experimental|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
11346149|NCT02393820|Experimental|pazopanib|Pazopanib per os, 800mg daily until progression
11346150|NCT02393807|Experimental|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
11346151|NCT02393794|Experimental|Romidepsin (8mg/m2) + Cisplatin (75mg/m2)|Romidepsin 8mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
11346152|NCT02393794|Experimental|Romidepsin (10mg/m2) + Cisplatin (75mg/m2)|Romidepsin 10mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
11346153|NCT02393794|Experimental|Romidepsin (12mg/m2) + Cisplatin (75mg/m2)|Romidepsin 12mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
11346154|NCT02393794|Experimental|Romidepsin Dose Expansion|Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
11346155|NCT02393768||patients|patients with documented atherosclerosis on a CCTA
11346156|NCT02393768||controls|patients without atherosclerosis on a CCTA
11346157|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
11346158|NCT02393755|Experimental|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
11346159|NCT02393742|Experimental|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
11346160|NCT02393742|Placebo Comparator|Placebo|placebo 2x/day for 3 months
11346161|NCT02393729|Other|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
11346162|NCT02393729|Other|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
11346163|NCT02393729|Other|children with DCD + DD|Neuropsychological assessment and MRI study
11346164|NCT02393729|Other|control children|Neuropsychological assessment and MRI study
11346165|NCT02393716|Other|Endovascular repair|Endurant Evo AAA Stent Graft System
11346166|NCT02393690|Experimental|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
11346167|NCT02393690|Active Comparator|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
11346168|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
11346169|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
11346170|NCT02393664|Experimental|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
11346171|NCT02393664|Active Comparator|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
11346172|NCT02393651|Placebo Comparator|Sham|Motor training of the affected upper extremity combined with sham tDCS.
11416354|NCT01926912||Participants with schizophrenia|
11346179|NCT02393612|Active Comparator|Anplag tab|Patients administrate Anplag tab (Sarpogrelate 100mg) 3 times a day for 12 weeks
11346180|NCT02393599|Experimental|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
11346181|NCT02393599|Placebo Comparator|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
11346182|NCT02393586|Experimental|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
11346183|NCT02393586|Experimental|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
11346184|NCT02393586|Experimental|Rifampicin|Rifampicin 10mg/kg
11346185|NCT02393573|Active Comparator|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
11346186|NCT02393573|Placebo Comparator|Placebo|Placebo will be administered exactly in the similar way to Metformin
11346187|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
11346188|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
11346189|NCT02393534|No Intervention|Usual Care|Eligible patients that are randomized to the usual care arm will have a standard in-person clinic visit with their primary care provider.
11346190|NCT02393534|Experimental|Telephone visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
11346191|NCT02393521|Experimental|Vibration group|Patients in the vibration therapy group received 10 self-administered sessions of vibration therapy (45-50 Hz), one session per day, remaining on their Shindo® vibration mattress at home in supine for 15 min.
11346192|NCT02393521|No Intervention|Control group|Subjects in the control group did not receive vibration therapy
11346193|NCT02393508|Active Comparator|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
11346194|NCT02393508|Active Comparator|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
11346195|NCT02393495|Experimental|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
11346196|NCT02393495|Experimental|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
11346197|NCT02393482|Active Comparator|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
11346198|NCT02393482|Active Comparator|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
11346199|NCT02393469|Placebo Comparator|Group phase 1|Two months of education and self-management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
11346200|NCT02393469|Experimental|Group phase 2|Pulmonary rehabilitation for two months: The same patients enter phase 1 phase 2 performing this two months of pulmonary rehabilitation are also included new patients who participate directly in phase 2
11346201|NCT02393469|Experimental|Group phase 3|Pulmonary rehabilitation for ten months: Participate participants of phases 1 + 2 and 2, as well as new participants enter directly in phase 3
11346202|NCT02393456|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
11346203|NCT02393456|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
11346204|NCT02393443|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
11346205|NCT02393443|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
11346206|NCT02393430|Experimental|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
11346207|NCT02393430|Placebo Comparator|control|The control group were only optimized their life style.
11346208|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
11346209|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
11346210|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
11346211|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
11346212|NCT02393404|Experimental|PT-FMT|Functional movement-power training group
11346213|NCT02393404|Experimental|FMT alone|Functional movement training group
11346214|NCT02393404|No Intervention|Control|No intervention control group
11346351|NCT02392494|Experimental|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
11346352|NCT02392494|Experimental|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
11346215|NCT02393391|Active Comparator|NIBS tDCS/tACS stimulation|Each patient will undergo initial diagnosis with NIBS algorithm utilizing EEG measurements combined with TMS. Initial diagnosis will last 10 minutes in which EEG measurement will be recorded 5 minutes and then in combination with TMS for another 5 minutes with no more than 500 TMS stimuli applied to cortex at low frequency of up to 5Hz. EEG recording will be analyzed by NIBS algorithm which will propose a course of treatment with the following limitations: stimulation of 2mA (32, 33) current after 30 seconds ramp up of 0.1mA increments, 20 min for each session, twice a week
11346216|NCT02393391|Placebo Comparator|inactive electrodes|diagnosis and monitoring will be performed as in active treatment, but during treatment anodal/cathodal/alternate stimulation will begin and automatically stop after 30 seconds leaving subject with an inactive electrodes in place for the remainder of treatment duration
11346217|NCT02393378|Experimental|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
11346218|NCT02393378|Active Comparator|Namilumab 150 mg|Namilumab 150*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
11346219|NCT02393365|Other|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
11346220|NCT02393352|Experimental|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
11346221|NCT02393352|Active Comparator|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
11346222|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
11346223|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
11346224|NCT02393326|Experimental|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
11346225|NCT02393326|Other|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
11346226|NCT02393313|Experimental|Cataract surgery toric intraocular lens|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
11346227|NCT02393300|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
11346228|NCT02393300|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' before the tourniquet deflation and the second dose at 180' after the first dosage
11346229|NCT02393300|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
11346230|NCT02393287||Reproline|this is an observational trial ; there is no intervention
11346231|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
11346232|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
11346233|NCT02393261|Experimental|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
11346234|NCT02393261|Active Comparator|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
11346235|NCT02393248|Experimental|Dose Escalation|"Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.
~Dose Expansion
~Combination therapy:
~Gemcitabine + Cisplatin + Pemigatinib
~Pembrolizumab + Pemigatinib
~Docetaxel + Pemigatinib
~Trastuzumab + Pemigatinib
~INCMGA00012 + Pemigatinib"
11346236|NCT02393235||unexplained infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
11346237|NCT02393235||tubal infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
11346238|NCT02393235||fertile group(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
11346239|NCT02393222||Patients with ESRD on HD|Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
11346240|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
11346241|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
11346242|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
11346243|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
11346244|NCT02393196|Active Comparator|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
11346353|NCT02392481||Healthy subjects|
11346354|NCT02392481||Mild asthma|
11346355|NCT02392481||Moderate asthma|
11346356|NCT02392481||Severe asthma|
11346357|NCT02392468|Experimental|BI 409306 low dose|low dose of BI 409306
11346245|NCT02393196|Active Comparator|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
11346246|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED (ASTED):
~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)
~β- Carotene (3 mg)
~Vit C (100 mg)
~Vit E (Alpha-Tocopherol Acetate): 60 IU
~Vit D (500 IU)
~Zinc (4 mg, elemental)
~Copper (0.5 mg, elemental)
~Selenium 100 µg (as Sodium Selenite)"
11346247|NCT02393183|Active Comparator|Selenium|Selenium (100mic) Twice daily
11346248|NCT02393183|Placebo Comparator|Placebo|Placebo Twice daily
11346249|NCT02393170|Experimental|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
11346250|NCT02393170|Active Comparator|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
11346251|NCT02393157|Experimental|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
11346252|NCT02393157|Experimental|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
11346253|NCT02393144|Other|Spontaneous labor arm|Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
11346254|NCT02393144|Other|Induced labor arm|Women with term pregnancies who are induced for birth before the onset of spontaneous labor. Labor will be induced with either oxytocin infusion for women with high Bishop score, or labor will be induced with dinoprostone pessary for women requiring cervical ripening, i.e. poor. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
11346255|NCT02393131|Experimental|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
11346256|NCT02393131|Active Comparator|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
11346257|NCT02393118|Experimental|BrainPort V200 Device|Single Arm
11346258|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
11346259|NCT02393092|Experimental|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
11346260|NCT02393092|Experimental|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
11346261|NCT02393092|Experimental|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
11346262|NCT02393079|Experimental|Active helmet LED|15 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
11346263|NCT02393079|Sham Comparator|Sham group|15 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
11346264|NCT02393066|Active Comparator|propofol|these patients are sedated with propofol infusion during ICU admission
11346265|NCT02393066|Active Comparator|dexmedetomidine|these patients are sedated with dexmedetomidine infusion during ICU admission
11346266|NCT02393053|Sham Comparator|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
11346267|NCT02393053|Experimental|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
11346358|NCT02392468|Experimental|BI 409306 high dose|high dose of BI 409306
11346359|NCT02392455||A|
11346360|NCT02392442|Experimental|1 - Endotoxin|6 hour lavage post endotoxin
11346268|NCT02393040|Experimental|PRP/Saline|"PRP/Saline
~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.
~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).
~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
11346269|NCT02393027|Experimental|patients|10 idopathic parkinson disease
11346270|NCT02393027|Active Comparator|controls subjects|10 healthy controls (no parkinson disease)
11346271|NCT02393014|Experimental|Low fall risk|low fall risk patients
11346272|NCT02393014|Experimental|Medium fall risk|medium fall risk patients
11346273|NCT02393014|Experimental|High fall risk|high fall risk patients
11346274|NCT02393001||Dermatology patients|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.
11346275|NCT02392988|Placebo Comparator|Group receives sham treatment|Sham treatment will be given on points on the back, points that are not acupuncture points, so that the patient will not be able to know whether she is receiving sham treatment or a real treatment. The treatment will be every 48-72 hours, a maximum of three treatments.
11346276|NCT02392988|Experimental|Group receives acupuncture treatment|The women in this group will receive acupuncture treatment every 48-72 hours, a maximum of three treatments.
11346277|NCT02392988|No Intervention|Group doesn't receive any treatment|The women in this group will come for a follow-up check a week later, unless a spontaneous birth will develop.
11346278|NCT02392975|Experimental|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
11346279|NCT02392962|Experimental|Experimental I|This group performed static stretching
11346280|NCT02392962|Active Comparator|Experimental II|This group performed dynamic stretching
11346281|NCT02392949|Experimental|Experimental group|Passive mobilization on cervical spine
11346282|NCT02392949|Placebo Comparator|Control|Placebo exercise on arms
11346283|NCT02392910|Other|Group A|Placebo
11346284|NCT02392910|Other|Group B|Iron Sucrose
11346285|NCT02392897|Experimental|High Eating Frequency|6 Eating Occasions
11346286|NCT02392897|Experimental|Low Eating Frequency|3 Eating Occasions
11346287|NCT02392884|Active Comparator|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
11346288|NCT02392884|Active Comparator|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
11346289|NCT02392884|No Intervention|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
11346290|NCT02392871|Experimental|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.
~Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.
~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
11346291|NCT02392858|Other|influenza cohort|"Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.
~1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.
~Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms."
11346292|NCT02392845|Experimental|Combination of Docetaxel (DTX) and Epirubicin (EPI)|
11346293|NCT02392832|Experimental|Intervention arm|Fourstar® granule formulation, 90day and 180 day briquettes Bti/Bs in larval habitats of malaria vectors.
11346294|NCT02392832|No Intervention|Control arm|No larvicide application.
11346295|NCT02392819|Experimental|test product|Arm: Panax ginseng
11346296|NCT02392819|Placebo Comparator|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
11346297|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
11346298|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
11346299|NCT02392793|Active Comparator|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
~Arm A is closed to enrollment."
11346361|NCT02392442|Experimental|2 - Endotoxin|24 hour lavage post endotoxin
11346362|NCT02392442|Experimental|3 - Endotoxin|48 hour lavage post endotoxin
11346363|NCT02392442|Placebo Comparator|4 Placebo comparator|6 hour control lavage
11347643|NCT02383771|Experimental|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
11346300|NCT02392793|Active Comparator|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
11346301|NCT02392780|Experimental|Cannabidiol|
11346302|NCT02392767|Active Comparator|Verum|2 times 2 tablets a day for 4 weeks.
11346303|NCT02392767|Placebo Comparator|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
11346304|NCT02392754|Experimental|Screening|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
11346305|NCT02392754|No Intervention|Control|The control group receives standard care for 6 months (including a pulse check and heart auscultation by a physician at 6 months).
11346306|NCT02392741|No Intervention|Control|The control group will follow the IMIP prenatal routine.
11346307|NCT02392741|Experimental|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
11346308|NCT02392728|Experimental|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
11346309|NCT02392728|Active Comparator|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
11346310|NCT02392715|Experimental|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week
~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics
~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
11346311|NCT02392715|Sham Comparator|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week
~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics
~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
11346312|NCT02392702|Active Comparator|C-10355, 25 mg|single oral dose.
11346313|NCT02392702|Active Comparator|C-10358, 25 mg|single oral dose.
11346314|NCT02392702|Active Comparator|C-10355 or C-10358, 75 mg|single oral dose.
11346315|NCT02392702|Active Comparator|C-10355 or C-10358, 150 mg|single oral dose.
11346316|NCT02392702|Active Comparator|Kalydeco, 150 mg|single oral dose.
11346317|NCT02392702|Active Comparator|C-10355 or C-10358, 300 mg|single oral dose.
11346318|NCT02392689|Experimental|PCT-guided|"Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.
~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended"
11346319|NCT02392689|No Intervention|Standard of Care|Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.
11346320|NCT02392676|Experimental|1/OLAPARIB|olaparib 300 mg oral tablets; twice daily
11346321|NCT02392676|Placebo Comparator|2/PLACEBO|placebo matching olaparib 300 mg oral tablets; twice daily
11346322|NCT02392663|Active Comparator|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).
~Both patients and physiotherapist will be blind to the intervention."
11346323|NCT02392663|Active Comparator|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline [7%]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).
~Both patients and physiotherapist will be blind to the intervention."
11346324|NCT02392663|Placebo Comparator|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).
~Both patients and physiotherapist will be blind to the intervention."
11346325|NCT02392637|Experimental|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11346326|NCT02392624|Experimental|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
11346327|NCT02392624|Placebo Comparator|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
11346364|NCT02392429|Experimental|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment.
11346365|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
11346328|NCT02392611|Experimental|GS-5829 (Group 1)|Cohorts will be sequentially enrolled at progressively higher dose levels to receive GS-5829 once daily. Participants in the first 3 cohorts will receive a single dose of GS-5829 and then approximately 7 days later, initiate dosing once daily. Each dose level will enroll 1 participant until a ≥ Grade 2 treatment-related toxicity is observed within the initial dosing period (Day 1 to Day 28). At Dose Level 5 or if a ≥ Grade 2 treatment-related toxicity is observed (whichever occurs first), the dose level will be expanded to 3 participants. Once a dosing level has expanded to 3 participants, a standard 3+3 study design will begin and dose escalation will be performed with cohort sizes of 3 to 6 participants.
11346329|NCT02392611|Experimental|Combination GS-5829 (Group 2)|Participants will receive escalating doses of GS-5829 in combination with either exemestane or fulvestrant.
11346330|NCT02392611|Experimental|Lymphoma Expansion (Group 3)|Participants with aggressive non-hodgkin's lymphoma (NHL) may be enrolled to receive GS-5829 at a dose no higher than the maximum tolerated dose (MTD).
11346331|NCT02392585|Active Comparator|Single tourniquet|
11346332|NCT02392585|Active Comparator|Triple tourniquet|
11346333|NCT02392572|Experimental|Arm A: ONC201 Once Every 3 Weeks|"ONC201 dosed orally once every three weeks. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
11346334|NCT02392572|Experimental|Arm B: ONC201 Once Every 1 Week|"ONC201 dosed orally once every 1 week. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
11346335|NCT02392572|Experimental|Arm C: ONC201 On First Two Consecutive Days of Every Week|"ONC201 dosed orally on the first two consecutive days of every week. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
11346336|NCT02392572|Experimental|Arm D: ONC201 Once Daily|"ONC201 dosed orally once daily. One cycle defined as 21 days (3 weeks).
~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).
~Phase II: Starting dose is MTD dose from Phase I."
11346337|NCT02392572|Experimental|Arm E: ONC201 Once Daily + Cytarabine|"ONC201 orally once daily in combination with low Cytarabine 20 mg subcutaneous twice daily for 10 days. One cycle defined as 28 days (4 weeks).
~Once the highest dose for Arm D (625 mg) are deemed safe (<2/6 DLTs) or the MTD is reached before that, then Phase I part of the study for Arm E will begin. The starting dose of ONC201 will be 625 mg or the MTD with the same schedule as that in Arm D. 3 + 3 algorithm will be applied for dose de-escalation."
11346338|NCT02392559|Placebo Comparator|Placebo|Matching subcutaneous injection every 4 weeks (QM)
11346339|NCT02392559|Experimental|EvoMab 420 mg QM|Evolocumab subcutaneous injection QM
11346340|NCT02392546|Experimental|Elobixibat 10 mg|elobixibat
11346341|NCT02392546|Experimental|Elobixibat 15 mg|elobixibat
11346342|NCT02392546|Experimental|Elobixibat 20 mg|elobixibat
11346343|NCT02392546|Placebo Comparator|Placebo|placebo
11346344|NCT02392533||Pre cohort group|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
11346345|NCT02392533||Post cohort group.|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
11346346|NCT02392520|Experimental|Antagonist|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
11346347|NCT02392520|Placebo Comparator|Conventional|Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.
11346348|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.
~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).
~Participants may continue to receive treatment until discontinuation criteria are met."
11346349|NCT02392494|Experimental|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
11346350|NCT02392494|Experimental|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
11347644|NCT02383771|Sham Comparator|Control|No Drug
11346366|NCT02392390|Experimental|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.
~Intervention: Topical Dynamic Phototherapy (TDP)"
11346367|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).
~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).
~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
11346368|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).
~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.
~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
11346369|NCT02392364|Active Comparator|Variable Treatment Dosing Arm|Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
11346370|NCT02392364|Active Comparator|Monthly Treatment Arm|Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
11346371|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
11346372|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
11346373|NCT02392338|No Intervention|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
11346374|NCT02392338|Active Comparator|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
11346375|NCT02392325|Experimental|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
11346376|NCT02392325|Experimental|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
11346377|NCT02392312||ATF-Fresenius S|intravenous
11346378|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
11346379|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
11346380|NCT02392260|Experimental|Vasculight prototype zero level|
11346381|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
11346382|NCT02392234|Experimental|VX-661/Ivacaftor combination|
11346383|NCT02392234|Experimental|Ivacaftor monotherapy|
11346384|NCT02392234|Placebo Comparator|Placebo|
11346385|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
11346386|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
11346387|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
11346388|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
11346389|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
11346390|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
11346391|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
11346392|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
11346393|NCT02392143|Active Comparator|Printed Education Material|Participants received printed education materials (PEM) sent by first class mail.
11346394|NCT02392143|Active Comparator|Academic Detailing|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices.
11346395|NCT02392143|Active Comparator|Academic Detailing+Telephone Education|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices and participants received tailored telephone education (TTE).
11346396|NCT02392130|Active Comparator|Active Drug|Clobetasol propionate 0.05% ointment
11346397|NCT02392130|Experimental|Experimental Drug|LEO 130852A gel 1%
11346398|NCT02392130|Placebo Comparator|Placebo Drug|LEO 130852A placebo gel
11346399|NCT02392117||Insulin degludec|
11346400|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
11346401|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
11416609|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
11346402|NCT02392052|Experimental|Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
11346403|NCT02392052|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
11346404|NCT02392039|Experimental|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
~Cycle 1 and 3:
~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Cycle 2 and 4:
~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
11346405|NCT02392039|Experimental|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
~Cycle 1 and 3:
~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Cycle 2 and 4:
~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
11346406|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
11346407|NCT02392013|Experimental|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
11346408|NCT02392013|No Intervention|Usual Care Group|Usual care by an Area Agency on Aging
11346409|NCT02392000|Experimental|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
11346410|NCT02391987|Active Comparator|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
11346411|NCT02391987|No Intervention|Standard Care|Standard care is defined as Heart Failure (HF) care based on current American College of Cardiology (ACC) and American Heart Association (AHA) HF guidelines implemented and orchestrated by a cardiologist and support staff at the participating institution.
11346412|NCT02391974|Experimental|PERIOSYAL FILL|n=15
11346413|NCT02391974|No Intervention|No treatment (untreated control)|n=15
11346414|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
11346415|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
11346416|NCT02391935|Experimental|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
11346417|NCT02391935|Placebo Comparator|Placebo|cryomedium
11346418|NCT02391922|No Intervention|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
11346419|NCT02391922|Active Comparator|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
11346420|NCT02391922|Active Comparator|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
11346421|NCT02391922|Active Comparator|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
11346422|NCT02391909||Group A|Vivotif 6.9-10.0 x109 CFU/capsule
11346423|NCT02391909||Group B|Vivotif 4.0-6.8 x109 CFU/capsule
11346424|NCT02391896|Other|Digital Tomosynthesis|Patient will get tomosynthesis scan
11346425|NCT02391896|Other|Dual energy|Patient will get dual energy scan
11346426|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
11346427|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated <24 hours after admission.
11346428|NCT02391870|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
11346429|NCT02391857|Experimental|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
11346430|NCT02391844|Other|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
11346431|NCT02391818||Breast Cancer Patients receiving ACT|Adraimycin/Cytoxan/Taxol
11346432|NCT02391818||Breast Cancer patients receiving RT only|radiation therapy
11346433|NCT02391805|Placebo Comparator|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
11346434|NCT02391805|Placebo Comparator|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
11346435|NCT02391805|Experimental|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
11346436|NCT02391805|Experimental|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
11346437|NCT02391805|Experimental|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
11346438|NCT02391805|Experimental|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
11346439|NCT02391792||patients|patients with septic shock
11346440|NCT02391792||control|patients without septic shock
11346441|NCT02391792||healthy volunteers|
11346442|NCT02391779|Experimental|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
11346443|NCT02391779|Placebo Comparator|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
11346444|NCT02391779|Experimental|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
11346445|NCT02391779|Sham Comparator|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
11346446|NCT02391766|Active Comparator|empowerment group|empowerment intervention by us for us guides
11346447|NCT02391766|Placebo Comparator|no treatment group|dementia patients treatment as usual
11346448|NCT02391727|Other|SYN004|open label study
11346449|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.
~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
11346450|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.
~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
11346451|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
11346452|NCT02391701|No Intervention|Control|No intervention
11346453|NCT02391688|Experimental|Treatment A|"Oral intake of:
~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
11346454|NCT02391688|Experimental|Treatment B|"Oral intake of:
~fexofenadine 25 mg"
11346455|NCT02391688|Experimental|Treatment C|"Oral intake of:
~bupropion 20 mg"
11346456|NCT02391688|Experimental|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):
~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
11346457|NCT02391675||Appendicitis patients|Patients presenting with acute appendicitis
11346458|NCT02391662|Experimental|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 & 15 in a 28 days cycle
11346459|NCT02391649|Experimental|Self-learning program|The participants in the Problem-solving Based Self-learning Program will complete the self-help and problem-solving manual developed by the research team for caregivers of people with psychotic disorders over 20 weeks. In addition to the orientation, understanding about psychosis and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
11346460|NCT02391649|Active Comparator|Psycho-education (in Phase 2)|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for psychosis. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the self-learning program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
11346461|NCT02391649|No Intervention|Routine community care|Participants in the control group (and treatment groups) will receive routine psychiatric outpatient and family services.
11346462|NCT02391636|Experimental|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
11346463|NCT02391636|Active Comparator|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
11346464|NCT02391623|Experimental|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11346465|NCT02391623|Experimental|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11346466|NCT02391623|Experimental|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11346467|NCT02391623|Experimental|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11346468|NCT02391623|Experimental|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11346469|NCT02391623|Experimental|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11346470|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
11346471|NCT02391584|Other|Control|Continued medical management
11346472|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
11346473|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
11346474|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
11346475|NCT02391545|Experimental|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.
~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
11346476|NCT02391545|Experimental|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.
~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
11346477|NCT02391532|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
11346478|NCT02391532|Placebo Comparator|Placebo|Placebo lozenges twice daily for 12 weeks
11346479|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
11346480|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
11346481|NCT02391506|Experimental|Cartiva|Synthetic Cartilage Implant
11346482|NCT02391493|Experimental|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
11346483|NCT02391493|Experimental|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
11346484|NCT02391493|Experimental|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
11346485|NCT02391480|Experimental|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
11346486|NCT02391480|Experimental|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
11346487|NCT02391480|Experimental|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
11346488|NCT02391454|Other|Group A|usual care
11346489|NCT02391454|Experimental|Group B|usual care + RunKeeper app
11346490|NCT02391441||Pulmonary arterial hypertension|Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
11346491|NCT02391441||Control group|Control patients without increased pulmonary artery pressure (i.e. RV peak pressure <35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.
11346492|NCT02391428|Experimental|Children who diagnosed with ADHD|The ADHD children will be asked to consume omega3 capsules for 6 months. Blood will be taken for omega3 analysis in day 0, after 3 and 6 months.
11346493|NCT02391428|Experimental|Control group of children without ADHD|"Blood test:
~The control group of 30 children (age and gender match) without ADHD and related neuropsychiatric syndromes, who were hospitalized due to surgical or orthopedic problems. Only when blood will be taken for clinical purposes, the investigators will ask the children and their parents to allow the collection of an additional small blood tube."
11346494|NCT02391415|Experimental|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
11346495|NCT02391415|Active Comparator|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
11346496|NCT02391415|Experimental|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
11346497|NCT02391415|Active Comparator|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
11346498|NCT02391415|Experimental|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
11346499|NCT02391402|Experimental|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
11346500|NCT02391402|Placebo Comparator|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
11346501|NCT02391389|Experimental|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
11346502|NCT02391376|Experimental|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
11346503|NCT02391376|Experimental|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
11346504|NCT02391376|Experimental|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
11346505|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
11346506|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
11346507|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
11346508|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
11346509|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
11346510|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
11346511|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
11346512|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
11346513|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
11346514|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
11346515|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
11346516|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
11346517|NCT02391298|Experimental|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
11346518|NCT02391285|Experimental|pelvic floor dynamometry|
11346519|NCT02391272|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
11346520|NCT02391259|Experimental|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
11346521|NCT02391259|Placebo Comparator|Placebo|No active drug
11346522|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
11346523|NCT02391233|Experimental|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
11346524|NCT02391233|Active Comparator|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
11346525|NCT02391220|Active Comparator|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
11346526|NCT02391220|Placebo Comparator|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
11346527|NCT02391207||patients having at least one CLM|Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography
11346528|NCT02391194|Experimental|AVB-620|Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.
11346529|NCT02391181|Experimental|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
11346567|NCT02390895|Experimental|Minimally-invasive endoscopic repair|endoscopic repair of myelomeningocele before 26 SA
11346530|NCT02391181|Active Comparator|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
11346531|NCT02391155|Active Comparator|single lumen|Single lumen needle in oocyte retrieval
11346532|NCT02391155|Active Comparator|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
11346533|NCT02391142|Experimental|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
11346534|NCT02391142|No Intervention|non-cardiac sympathetic nerve block|
11346535|NCT02391129||Hyperion Prosthesis|Patients treated with the second generation long-stem revision prosthesis
11346536|NCT02391129||Helios Prosthesis|Patients treated with the first generation long-stem revision prosthesis
11346537|NCT02391129||Locking compression plate|Patients treated with LCP
11346538|NCT02391116|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
11346539|NCT02391103|Experimental|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
11346540|NCT02391103|Sham Comparator|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
11346541|NCT02391090|Experimental|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.
~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
11346542|NCT02391090|Sham Comparator|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).
~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
11346543|NCT02391077|No Intervention|Control Arm|Standard PrePex Procedure
11346544|NCT02391077|Experimental|Arm 1 - Maximal intervention|"Foreskin disinfection with Povidone-Iodine
~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
~Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
11346545|NCT02391077|Experimental|Arm 2 - Medium intervention|"Foreskin disinfection with Povidone-Iodine
~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
11346546|NCT02391064|Experimental|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
11346547|NCT02391064|Experimental|Control|healthy subject
11346548|NCT02391051|Experimental|Focal Brachytherapy|HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy
11346549|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).
~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
11346550|NCT02391025|Experimental|Gallium-68 citrate|
11346551|NCT02391012|Experimental|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
11346552|NCT02390999|No Intervention|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
11346553|NCT02390999|Experimental|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
11346554|NCT02390973|Active Comparator|Sleeve gastrectomy|
11346555|NCT02390973|Active Comparator|Roux-en-Y Gastric Bypass|
11346556|NCT02390973|Active Comparator|Biliopancreatic Diversion|
11346557|NCT02390973|Active Comparator|Control|the best medical management of their diabetes, non-surgical group
11346558|NCT02390960|Active Comparator|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
11346559|NCT02390960|Placebo Comparator|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
11346560|NCT02390947|Experimental|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
11346561|NCT02390947|Placebo Comparator|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
11346562|NCT02390934|Experimental|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
11346563|NCT02390921|Active Comparator|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
11346564|NCT02390921|Experimental|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
11346565|NCT02390908|Experimental|Immediate PLUS intervention|Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
11346566|NCT02390908|Active Comparator|wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
11346568|NCT02390895|Other|surgery at birth for foetal reason|Non eligible pregnant women because of foetal reason
11346569|NCT02390895|Other|surgery at birth for maternal reasons|Non eligible pregnant women because of maternal reason or women refusing the prenatal surgery
11346570|NCT02390882|Placebo Comparator|Placebo|Tamsulosin placebo (12 weeks)
11346571|NCT02390882|Experimental|Treatment 1|HGP0412 capsule (12 weeks)
11346572|NCT02390882|Experimental|Treatment2|HIP1402 capsule (12 weeks)
11346573|NCT02390869|Experimental|R2-MANT|A) Rituximab B) Lenalidomide
11346574|NCT02390869|Active Comparator|R-MANT|A) Rituximab
11346575|NCT02390856|Active Comparator|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
11346576|NCT02390856|Experimental|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
11346577|NCT02390843|Experimental|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
11346578|NCT02390830|Experimental|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
11346579|NCT02390830|Active Comparator|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
11346580|NCT02390817|Active Comparator|Sugammadex|At the wakeup status Sugammadex 2 mg/kg single dose will perform.
11346581|NCT02390817|Placebo Comparator|Neostigmine|At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.
11346582|NCT02390804|Experimental|single-port laparoscopic hysterectomy|total laparoscopic hysterectomy via transumbilical single port
11346583|NCT02390804|Active Comparator|multi-port laparoscopic hysterectomy|total laparoscopic hysterectomy via multi-port (3 port)
11346584|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
11346585|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
11346586|NCT02390778|Experimental|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
11346587|NCT02390778|Placebo Comparator|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
11346588|NCT02390765||All participants|All participants in the study will be evaluated as one group
11346589|NCT02390752|Experimental|Phase I|take oral drug daily for 28 day cycle
11346590|NCT02390752|Experimental|Phase II|take oral drug daily for 28 day cycle
11346591|NCT02390739|Experimental|Single Arm|All patients will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by antithyroglobulin mTCR PBL and aldesleukin.
11346592|NCT02390726|Sham Comparator|Control|Sham FMT and Sham Microbial Maintenance plus standard therapy
11346593|NCT02390726|Experimental|Treatment|FMT and microbial maintenance plus standard therapy
11346594|NCT02390713|Experimental|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
11346595|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
11346596|NCT02390687|Placebo Comparator|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
11346597|NCT02390687|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
11346598|NCT02390674|Active Comparator|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
11346599|NCT02390674|Placebo Comparator|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
11346600|NCT02390661|No Intervention|No drain|Control group
11346601|NCT02390661|Experimental|Penrose drain placement|Placement of a penrose drain after irradiation catheter is removed
11346602|NCT02390648|Experimental|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
11346603|NCT02390648|Placebo Comparator|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
11346604|NCT02390635|Experimental|Diagnostic (18F-FDG PET/CT, whole body PET/MRI)|Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.
11346605|NCT02390622|Other|FMT treatment|Treat the patients by fecal microbiota transplantation
11346606|NCT02390609|Experimental|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.
11347670|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
11346607|NCT02390609|Experimental|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346608|NCT02390609|Experimental|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346609|NCT02390609|Experimental|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346610|NCT02390609|Experimental|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346611|NCT02390609|Experimental|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346612|NCT02390609|Experimental|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346613|NCT02390609|Experimental|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346614|NCT02390609|Experimental|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346615|NCT02390609|Experimental|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
11346616|NCT02390596|Experimental|Anakinra|
11346617|NCT02390583|Active Comparator|control|CBT treatment of internet dependence each two weeks during 3 months
11346618|NCT02390583|Experimental|intervention|CBT treatment of internet dependence plus CBT treatment of sleep disorders during 3 months
11346619|NCT02390570|Experimental|Implementation Arm|
11346620|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
11346621|NCT02390557|Experimental|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
11346622|NCT02390557|Experimental|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
11346623|NCT02390544|Experimental|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.
~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
11346624|NCT02390531|Experimental|Bevacizumab|Dosage if injected Bevacizumab to be studied
11346625|NCT02390518|Experimental|Stereotactic Radiosurgery|
11346626|NCT02390505|Experimental|Vitamin C|Patients receive vitamin C at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
11346627|NCT02390505|Placebo Comparator|Placebo|Patients receive placebo at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
11346628|NCT02390492|Experimental|Ipatasertib/[14C]-ipatasertib|
11346629|NCT02390479|Active Comparator|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.
~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
11346630|NCT02390479|Placebo Comparator|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
11346631|NCT02390466|Experimental|VAC-3S|32µg/ml corresponding to 16µg/vaccination
11346632|NCT02390453|Experimental|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
11346633|NCT02390453|Active Comparator|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
11346634|NCT02390453|Active Comparator|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
11346635|NCT02390453|Sham Comparator|Control|This consists of 45 minutes of group discussion and instruction in health self-management and successful aging, 2 days a week for 12 weeks (24 sessions).
11346636|NCT02390440|Experimental|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
11346637|NCT02390427|Experimental|Arm A|"Arm A
~- Taselisib with Trastuzumab emtansine (also called T-DM1)
~Taselisib administered orally, daily in each treatment cycle (3 weeks).
~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks)."
11346638|NCT02390427|Experimental|Arm B|"Arm B
~-Taselisib with T-DM1 and Pertuzumab
~Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks).
~Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks).
~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
11346639|NCT02390427|Experimental|Arm C|"Arm C:
~Taselisib with Pertuzumab and Trastuzumab
~Cohort C will not open without additional authorization from Genentech
~Taselisib is administered oral, daily in each treatment cycle (3 weeks).
~Trastuzumab administered once via IV per treatment cycle (3 weeks).
~Pertuzumab- administered once via IV per treatment cycle (3 weeks)."
11346640|NCT02390427|Experimental|Arm D|"Arm D
~Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel
~Cohort will not be opened without additional authorization from Genentech
~Taselisib- administered oral, daily in each treatment cycle (3 weeks).
~Pertuzumab- administered once via IV per treatment cycle (3 weeks).
~Trastuzumab administered once via IV per treatment cycle (3 weeks).
~Paclitaxel- administered via IV, weekly for 3 weeks within each cycle."
11346641|NCT02390414||Gets HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT and actually undergo HSCT.
11346642|NCT02390414||No HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT but do not undergo HSCT.
11346643|NCT02390401|Experimental|Vacuum-assisted closure (VAC)|Prevena (VAC) device
11346644|NCT02390401|Active Comparator|Standard sterile dressing|Standard sterile dressing
11346645|NCT02390388|Active Comparator|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
11346646|NCT02390388|Active Comparator|Caudal block group|caudal block performed under general anesthesia
11346647|NCT02390375|Experimental|A|DW-0929
11346648|NCT02390375|Active Comparator|B|Rosuvastatin
11346649|NCT02390362|Experimental|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 & 3.
11346650|NCT02390362|Active Comparator|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
11346651|NCT02390349|Experimental|CuraMed (BCM-95)|67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks
11346652|NCT02390349|Experimental|Curamin|67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks
11346653|NCT02390349|Placebo Comparator|Placebo|67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks
11346654|NCT02390336|Experimental|Real mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.
~Next, the therapist will performed the real mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
11346655|NCT02390336|Sham Comparator|Sham mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.
~Next, the therapist will performed the sham mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
11346656|NCT02390323|Experimental|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
11346657|NCT02390310|Active Comparator|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
11346658|NCT02390310|Active Comparator|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
11346659|NCT02390310|Active Comparator|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
11346660|NCT02390310|Active Comparator|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
11346661|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
11346662|NCT02390284|No Intervention|Abnormal PERG Untreated|Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
11346663|NCT02390284|Experimental|Abnormal PERG Treated|"Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.
~Drugs could be:
~Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.
~If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure."
11346664|NCT02390284|No Intervention|Normal|Patients with a normal PERG test that will go through the study under observation.
11346665|NCT02390271|Experimental|emotion focused therapy training CCT|The general training includes in an individual adjusted way the following techniques: biofeedback-assisted breathing classes that erase negative emotion involving the cardiac and limbic neural pathways, control one's own and other's emotions, mastering positive cognition and enhance self-concept, anchoring positive memories, learning how to recognize psychological reversal in others
11418154|NCT01914952|Active Comparator|HMB free acid gelcap|
11346666|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 1|8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)
11346667|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 2|8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)
11346668|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 3|8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)
11346669|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 4|8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)
11346670|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 5|8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)
11346671|NCT02390258|Experimental|Part 2: Fed-Fasted|17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.
11346672|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 1|10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
11346673|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 2|10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
11346674|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 3|10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)
11346675|NCT02390245|Experimental|Enhanced Intervention Group|Use of patient navigation and social worker: Patients randomized to Group 1 will be referred to a general ophthalmologist close to the current health center or PCP office where they received the undilated eye exam. Prior to all follow-up visits, patients in the enhanced group who have scheduled an appointment will receive a personal phone call reminding them to attend. These patients will receive any necessary interpretation services and educational materials.
11346676|NCT02390245|No Intervention|Usual care group|Patients randomized to Group 2 will be recommended to follow-up for eye care with a local ophthalmologist. These patients will be scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team is able to track outcomes. Group 2 represents a realistic choice currently available for patients. Practice patterns will vary depending on the resources, staff time, and services available within each local ophthalmology practice.
11346677|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
11346678|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
11346679|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
11346680|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
11346681|NCT02390193|Experimental|Hemodialysis|Chronic kidney disease patients undergoing hemodialysis will be recruited consecutively and screened for eligibility using a standardised protocol.
11346682|NCT02390180||Sorting all tastes|This group will receive 15 samples to taste and sort into groups. The samples included: a blank solution, hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, sodium chloride (2), citric acid, acetic acid, quinine, urea, monosodium glutamate, and inosine monophosphate.
11346683|NCT02390180||Sorting bitter tastes|This group will receive 12 samples to taste and sort into groups. The samples included: blank solutions (2), decenoic acid, oleic acid, linoleic acid, quinine (2), urea (2),caffeine, sucrose octaacetate, and propylthiouracil.
11346684|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
11346685|NCT02390154|Experimental|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
11346686|NCT02390154|Experimental|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
11346687|NCT02390141|Experimental|ZP4207|Five multiple doses of ZP4207 in ascending doses
11346688|NCT02390141|Placebo Comparator|Placebo|Five multiple doses of corresponding placebo in ascending doses
11346689|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
11346690|NCT02390115|Active Comparator|Elastic Tape|"Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as paper tension and it is equivalent to 10-15% of the total elastic tape tension."
11346691|NCT02390115|Sham Comparator|Sham|The sham elastic tape will be placed using the same tape to the paretic shoulder. However, the rigid tape will be placed without tension with the upper limb supporting at 90 degree elbow flexion, 0 degrees abduction and adduction of the shoulder.
11346692|NCT02390102|Active Comparator|Erythropoietin|Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.
11346693|NCT02390102|Placebo Comparator|Placebo|Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.
11346694|NCT02390089|Active Comparator|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
11346695|NCT02390089|Experimental|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
11346696|NCT02390089|Experimental|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
11346697|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
11346698|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
11346699|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
11346700|NCT02390063|Experimental|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
11346701|NCT02390063|Experimental|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
11346702|NCT02390063|Active Comparator|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
11346703|NCT02390063|Active Comparator|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
11346704|NCT02390063|Experimental|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
11346705|NCT02390063|Experimental|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
11346706|NCT02390063|Experimental|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
11346707|NCT02390063|Experimental|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
11346708|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
11346709|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
11346710|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
11346711|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
11346712|NCT02390024||Critically ill patients|Mechanical Ventilation
11346713|NCT02390011||MRI|Day 1
11346714|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
11346715|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
11346716|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
11346717|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
11346718|NCT02389959|Experimental|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
11346719|NCT02389959|Placebo Comparator|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
11346720|NCT02389946|Experimental|Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
11346721|NCT02389946|Active Comparator|Xience everolimus coronary stent system|Intervention with a Xience DES.
11346722|NCT02389920|Experimental|Nilotinib|nilotinib 400mg BID for 12 months
11346723|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
11346724|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
11346725|NCT02389894|Active Comparator|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
11346726|NCT02389894|Active Comparator|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
11346727|NCT02389894|No Intervention|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
11346728|NCT02389881|Experimental|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
11346729|NCT02389881|Experimental|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
11346730|NCT02389881|Experimental|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
11346959|NCT02388321|Active Comparator|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
11346731|NCT02389881|Experimental|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
11346732|NCT02389881|Placebo Comparator|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
11346733|NCT02389881|Placebo Comparator|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
11346734|NCT02389881|Placebo Comparator|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
11346735|NCT02389868|Experimental|Lovastatin|
11346736|NCT02389842|Experimental|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
11346737|NCT02389842|Experimental|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
11346738|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
11346739|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.
~Patients can receive second 10mg dose at 1 hour."
11346740|NCT02389816|Placebo Comparator|Placebo|Placebo tablets, orally, once daily for up to Week 8
11346741|NCT02389816|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
11346742|NCT02389816|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
11346743|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
11346744|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
11346745|NCT02389790|Experimental|MT-1303|
11346746|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
11346747|NCT02389777|Active Comparator|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
11346748|NCT02389777|Active Comparator|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
11346749|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
11346750|NCT02389751|Experimental|Treatment (ganetespib, paclitaxel, carboplatin, radiation)|Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
11346751|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.
~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
11346752|NCT02389725|Active Comparator|disposable elastic tourniquet|
11346753|NCT02389725|Active Comparator|manual blood pressure cuff|manual blood pressure cuff inflated to 150 milliliters mercury (mmHg)
11346754|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
11346755|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
11346756|NCT02389699|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
11346757|NCT02389699|Active Comparator|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
11346758|NCT02389686|No Intervention|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
11346759|NCT02389686|Experimental|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
11346760|NCT02389673|No Intervention|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
11346761|NCT02389673|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
11346762|NCT02389660|Experimental|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
11346763|NCT02389660|Active Comparator|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
11346764|NCT02389647||Endovascular group|Subjects undergoing elective endovascular catheterization for coiling of unruptured cerebral aneurysms. Four blood draws of 5mL each: (1) prior to initiation of procedure; (2) at the time of catheterization of major cerebral vessels, (3) immediately after the procedure, and (4) 24-hours after the procedure.
11347166|NCT02386956|Experimental|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
11346765|NCT02389647||Ischemic stroke group|Subjects who present to the emergency department with ischemic infarcts of <6 hours. Four blood draws of 5mL each: (1) at time of enrollment but prior to tPA, (2) 6 hours post-tPA, (3) 12 hours post-tPA, and (4) 24 hours post-tPA.
11346766|NCT02389647||Intracranial hemorrhage|Subjects who present to the emergency department with intracranial hemorrhage. One 5mL blood draw within 24 hours of onset.
11346767|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
11346768|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
11346769|NCT02389608|Experimental|1- tDCS 2--FES|"Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
~Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
11346770|NCT02389595||HIV positive subjects|This group will provide a blood sample.
11346771|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
11346772|NCT02389582|Experimental|Dabigatran|Dabigatran 150mg twice a day for five days
11346773|NCT02389582|Active Comparator|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
11346774|NCT02389569|Experimental|Adhesive system treatment|Four groups ( Two will be treat with Etch-and-Rinse Adhesive System and two will be treated with two step Self-Etch Adhesive System).
11346775|NCT02389569|Experimental|Restoration protocol|Four groups ( Two will be treat with experimental Biosilicate and two will be the control groups).
11346776|NCT02389543|Experimental|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
11346777|NCT02389543|Experimental|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
11346778|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
11346779|NCT02389517|Experimental|Arm I (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
11346780|NCT02389517|Active Comparator|Arm II (lenalidomide)|Patients receive lenalidomide PO as in Arm I.
11346781|NCT02389504|Active Comparator|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
11346782|NCT02389504|Experimental|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
11346783|NCT02389491|Active Comparator|normal density formula (Neocate)|In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days
11346784|NCT02389491|Experimental|high density formula (Infatrini)|In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days
11346785|NCT02389478|Experimental|colostrums|Oropharyngeal administration of colostrums, every 4 hours，continue for 7days
11346786|NCT02389478|Other|Normal saline|Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days
11346787|NCT02389465|No Intervention|Control|This arm is for participants who are not depressed.
11346788|NCT02389465|Experimental|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
11346789|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
11346790|NCT02389439|Experimental|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.
~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.
~20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs"
11346820|NCT02389244|Placebo Comparator|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
11346821|NCT02389231|Experimental|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
11346791|NCT02389426|Experimental|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
11346792|NCT02389426|Experimental|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
11346793|NCT02389413|Experimental|PQ912 oral|PQ912 will be administered orally twice daily for 12 weeks.
11346794|NCT02389413|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 12 weeks.
11346795|NCT02389400|Experimental|Experimental arm|methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5
11346796|NCT02389387|No Intervention|Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
11346797|NCT02389387|Experimental|Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
11346798|NCT02389374|Other|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
11346799|NCT02389374|Other|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
11346800|NCT02389374|Other|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
11346801|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
11346802|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
11346803|NCT02389348|Experimental|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.
~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
11346804|NCT02389335||Group 1a|Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
11346805|NCT02389335||Group 1b|Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
11346806|NCT02389335||Group 1c|Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
11346807|NCT02389335||Control|Healthy subjects
11346808|NCT02389322|Experimental|5μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
11346809|NCT02389322|Experimental|10μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
11346810|NCT02389322|Placebo Comparator|5μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
11346811|NCT02389322|Placebo Comparator|10μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.
11346812|NCT02389309|Experimental|Treatment (dasatinib, cyclophosphamide, temsirolimus)|Patients receive dasatinib PO BID on days 1-21, cyclophosphamide PO QD on days 1-21, and temsirolimus IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing stable disease or better may continue treatment with the approval of the Study Chair.
11346813|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
11346814|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
11346815|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
11346816|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
11346817|NCT02389257|Experimental|MINIMAG / MEG|Cerebral magnetic fields
11346818|NCT02389257|Experimental|MINIMAG / ECG|Cardiac magnetic fields
11346819|NCT02389244|Experimental|Regorafenib|"For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .
~For children Age ≥10 years to <18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
11346822|NCT02389218|Experimental|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
11346823|NCT02389218|Active Comparator|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
11346824|NCT02389205|Placebo Comparator|control group|physical therapy
11346825|NCT02389205|Active Comparator|kinesio group|kinesio taping for ankle joint
11346826|NCT02389192|Experimental|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
11346827|NCT02389179|Active Comparator|25 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
11346828|NCT02389179|Active Comparator|50 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
11346829|NCT02389179|Active Comparator|50 000 IU bi-weekly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
11346830|NCT02389166|Experimental|Optiflow group|
11346831|NCT02389166|Active Comparator|Control group|
11346832|NCT02389153|Experimental|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
11346833|NCT02389153|Active Comparator|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
11346834|NCT02389140|Experimental|Trigger point treatment|Trigger point release
11346835|NCT02389140|Sham Comparator|Ultrasound|Sham US at Trigger point
11346836|NCT02389127||Group A|"Cirrhosis, either clinically- or biopsy-proven
~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)
~Random glucose <200 mg/dL on at least 3 occasions
~No use of insulin or any hypoglycemic agent
~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
11346837|NCT02389127||Group B|"Cirrhosis, either clinically- or biopsy-proven
~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)
~Prior diagnosis of T2DM as based on any of ADA criteria
~Use of insulin or any hypoglycemic agent
~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
11346838|NCT02389127||Control|"Age 18 to 75
~No known chronic liver disease
~Prior diagnosis of T2DM as based on any of ADA criteria
~Use of insulin or any hypoglycemic agent"
11346839|NCT02389114|Active Comparator|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
11346840|NCT02389114|Experimental|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
11346841|NCT02389114|Experimental|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
11346842|NCT02389114|Experimental|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
11346843|NCT02389101|Experimental|Lymphoma|Newly diagnosed lymphoma, all subtypes allowed
11346844|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.
~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
11346845|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.
~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
11346846|NCT02389075||Ankylosing Spondylitis|Subjects with a diagnosis of ankylosing spondylitis undergoing routine colonoscopy or willing to undergo a flexible sigmoidoscopy for research purposes only. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
11346847|NCT02389075||Inflammatory Bowel Disease|Subjects with a diagnosis of inflammatory bowel disease undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
11346848|NCT02389075||Healthy Controls|Subjects without any major autoimmune diseases or pathologies undergoing routine colonoscopy. They will be asked to fill out questionnaires, give blood, perform a rectal swab, and have pinch biopsies taken during endoscopy.
11346849|NCT02389062|Experimental|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
11346850|NCT02389062|Experimental|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
11346917|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
11346851|NCT02389062|Experimental|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
11346852|NCT02389036|No Intervention|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
11346853|NCT02389036|Experimental|SDD intervention group|"The intervention will entail:
~A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
~A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
~A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
11346854|NCT02389023|Other|standard gauze dressing|a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site
11346855|NCT02389023|Other|Prevena Incision Management System|the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.
11346856|NCT02389010|Experimental|Allogeneic Cord Blood Platelet Gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
11346857|NCT02389010|Active Comparator|Standard Local Medications-SLM|1 administration every 3-4 days for 4 weeks. Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
11346858|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
11346859|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
11346860|NCT02388984|Experimental|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
11346861|NCT02388984|Placebo Comparator|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
11346862|NCT02388971|Experimental|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
11346863|NCT02388971|Experimental|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
11346864|NCT02388958||Women with GDM|
11346865|NCT02388958||Women without GDM|
11346866|NCT02388945|Experimental|A APDGroup|PDGO APD machines used in the PD patients for 8 weeks
11346867|NCT02388945|Active Comparator|B CAPDGroup|CAPD used in the PD Patients for 8 weeks
11346868|NCT02388932|Experimental|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.
~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.
~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
11346869|NCT02388919|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
11346870|NCT02388919|Placebo Comparator|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
11346871|NCT02388906|Experimental|Ipilimumab and Placebo matching Nivolumab|
11346872|NCT02388906|Experimental|Nivolumab and Placebo matching Ipilimumab|
11346873|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
11346874|NCT02388867|Experimental|Group I|Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
11346875|NCT02388867|Experimental|Group II|Intervention: Autogenous vein bypass grafting.
11346876|NCT02388854||Endometriosis|Sardinian Women with diagnosis of endometriosis
11346877|NCT02388854||Controls|Healthy blood Sardinian donors
11346878|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
11346879|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
11346880|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
11346881|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
11346918|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
11346882|NCT02388802|Experimental|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
11346883|NCT02388789|Experimental|active movement|use a light treadmill run to raise feet temperature
11346884|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
11346885|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
11346886|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
11346887|NCT02388750|Other|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment
~No previous nausea and vomiting 24 hours prior to radiotherapy"
11346888|NCT02388750|Other|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment
~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
11346889|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.
~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
11346890|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.
~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
11346891|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.
~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
11346892|NCT02388724|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
11346893|NCT02388724|Active Comparator|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
11346894|NCT02388711|Experimental|Usual Care with C-TraC Intervention|Patients/caregivers randomized to this group will receive all routine hospital discharge education/materials (same as usual care group), but will also be enrolled in the C-TraC Program. C-TraC is a low-resource, telephone-based, protocol-driven program designed to reduce 30-day rehospitalizations and to improve care transitions during the early post-hospital period.
11346895|NCT02388711|No Intervention|Usual Care|Usual care group patients will receive all routine University of Wisconsin Hospital and Clinics (UWHC) discharge education/materials. This includes pharmacy-led medication teaching, physician discussions and routine nursing education. No post hospital education/contact is performed by these providers. Caregivers are sometimes, but not always, involved. Patients may receive home health services, depending on their physician's discharge plan.
11346896|NCT02388698|Experimental|Cervical Swab, PET-CT and plasma HPV|Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
11346897|NCT02388685|Experimental|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
11346898|NCT02388685|No Intervention|No exercise|Patients will continue with usual care
11346899|NCT02388672|Experimental|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
11346900|NCT02388672|Placebo Comparator|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
11346901|NCT02388672|Experimental|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
11346902|NCT02388672|Placebo Comparator|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
11346903|NCT02388672|No Intervention|Control|No treatment control group
11346904|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
11346905|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
11346906|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
11346907|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
11346908|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
11346909|NCT02388620|Experimental|Normal Hepatic Function|Normal hepatic function; matched demography to hepatic impairment cohorts
11346910|NCT02388620|Experimental|Mild Hepatic Impairment|Child-Pugh Classification A (score 5-6)
11346911|NCT02388620|Experimental|Moderate Hepatic Impairment|Child-Pugh Classification B (score 7-9)
11346912|NCT02388620|Experimental|Severe Hepatic Impairment|Child-Pugh Classification C (score 10-15)
11346913|NCT02388607||assessing attention span|"Electrophysiological measurements (evocated potentials and spectral densities)
~Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
11346914|NCT02388594|Experimental|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
11346915|NCT02388594|Experimental|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
11346916|NCT02388581|Experimental|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
11346919|NCT02388555||Pre-operative group|Respectively recruited patients with DLS. Patients in this group were not surgically treatment. Only pre-operative radiographic parameters were measured.
11346920|NCT02388555||Surgically treated group|All DLS patients received posterior osteotomy correction of spinal deformity. The immediate post-operative radiographic measurements were performed.
11346921|NCT02388542|Experimental|lifestyle counseling|we will have a trained peer mentor educating employees regarding lifestyle modification for control of cardiovascular disease risk factors and following them up for a duration of 3 months
11346922|NCT02388529|Experimental|Low dose|
11346923|NCT02388529|Experimental|Intermediate dose|
11346924|NCT02388529|Experimental|High dose|
11346925|NCT02388529|Placebo Comparator|Placebo|
11346926|NCT02388516|Placebo Comparator|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
11346927|NCT02388516|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
11346928|NCT02388516|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
11346929|NCT02388516|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
11346930|NCT02388516|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
11346931|NCT02388503|Placebo Comparator|Reference|No added fruit extract
11346932|NCT02388503|Active Comparator|Active 1|lowest dose of fruit extract
11346933|NCT02388503|Active Comparator|Active 2|low dose of fruit extract
11346934|NCT02388503|Active Comparator|Active 3|medium dose of fruit extract
11346935|NCT02388503|Active Comparator|Active 4|high dose of fruit extract
11346936|NCT02388490|Experimental|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
11346937|NCT02388477|Active Comparator|Doxycycline|oral doxycycline, 2 weeks, twice a day,
11346938|NCT02388477|Placebo Comparator|sugar pill|sugar pill, same size, shape, and color as comparator, twice a day for 2 weeks.
11346939|NCT02388464|Experimental|Low dose|
11346940|NCT02388464|Experimental|Intermediate dose|
11346941|NCT02388464|Experimental|High dose|
11346942|NCT02388464|Experimental|Placebo|
11346943|NCT02388451|Experimental|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
11346944|NCT02388438|Experimental|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
11346945|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels.
11346946|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
11346947|NCT02388399||OCT and Pressure wire pullback tracing|This study is pilot study evaluating the feasibility of invasive measurement and estimation of hemodynamic stress acting on plaque as well as co-registration of hemodynamic data with plaque geometric data, which is obtained by optical coherence tomography
11346948|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
11346949|NCT02388373|Active Comparator|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
11346950|NCT02388373|Active Comparator|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
11346951|NCT02388373|Active Comparator|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
11346952|NCT02388360|Other|topical prostaglandin analogs|
11346953|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
11346954|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
11346955|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
11346956|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
11346957|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
11346958|NCT02388321|Experimental|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
11347233|NCT02386449|Experimental|Picoprep|sodium picosulfate, magnesium oxide and citric acid
11346960|NCT02388308||Patient volunteers|Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.
11346961|NCT02388308||Gold fiducial marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
11346962|NCT02388308||Electromagnetic marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
11346963|NCT02388308||General patients|Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
11346964|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
11346965|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
11346966|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.
~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
11346967|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.
~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
11346968|NCT02388256|Experimental|Acupuncture|Manual and electroacupuncture
11346969|NCT02388256|Active Comparator|Enhanced recovery program after surgery|Enhanced recovery program after surgery
11346970|NCT02388243|Experimental|Brief Intervention in Public Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in public clinic.
11346971|NCT02388243|Active Comparator|Screening results in Public Clinic|Written information after screening; No brief intervention; in public clinic.
11346972|NCT02388243|Experimental|Brief Intervention in Private Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in private clinic.
11346973|NCT02388243|Active Comparator|Screening results in Private Clinic|Written information after screening; No brief intervention; in private clinic.
11346974|NCT02388230||Patients 4 or more years post radiotherapy|IMPORT or FAST trial patients who received breast RT previously and are receiving four years (or more) follow-up assessment and have hardening of their breast as a result of breast radiotherapy.
11346975|NCT02388230||Patients 0 to 2 years post breast radiotherapy|Patients who are (1) undergoing, or undergone recently breast RT (general population) and have undergone a clinical assessment either during RT or at 3 month follow-up that found moderate or severe oedema, or (2) IMPORT patients who have received RT and are receiving one or two year follow-up, at which moderate or severe oedema is reported.
11346976|NCT02388204|Experimental|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
11346977|NCT02388204|Experimental|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.
~Intervention: Implantable spinal cord stimulation."
11346978|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
11346979|NCT02388191|Placebo Comparator|Placebo|Placebo
11346980|NCT02388178|Placebo Comparator|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
11346981|NCT02388178|Experimental|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
11346982|NCT02388178|Active Comparator|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
11346983|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
11346984|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
11346985|NCT02388152|Experimental|Lu AF20513, low dose (Cohort 1)|10 Patients with mild Alzheimer's.
11346986|NCT02388152|Experimental|Lu AF20513, medium dose (Cohort 2)|10 Patients with mild Alzheimer's.
11346987|NCT02388152|Experimental|Lu AF20513, high dose (Cohort 3)|15 Patients with mild Alzheimer's.
11346988|NCT02388152|Experimental|Lu AF20513, double high dose (Cohort 4)|15 Patients with mild Alzheimer's.
11346989|NCT02388126|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
11346990|NCT02388113|Experimental|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
11346991|NCT02388113|Active Comparator|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
11346992|NCT02388087|Active Comparator|ROX COUPLER|Iliac arterio-venous anastamosis created by insertion of ROX coupler device.
11346993|NCT02388087|Sham Comparator|ROUTINE CARE|Right heart catheterisation and Routine care of Neurally mediated syncope.
11347033|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
11346994|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
11346995|NCT02388061|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
11346996|NCT02388061|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
11346997|NCT02388048|Experimental|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).
~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.
~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
11346998|NCT02388035|Experimental|SBP-group 1|Spontanous bacterial peritonitis
11346999|NCT02388035|Experimental|CNNA-group 2|Culture negative neutrocytic ascites
11347000|NCT02388035|Experimental|MNBA-group 3|monomicrobial non-neutrocytic ascites
11347001|NCT02388035|No Intervention|group 4|no evidence of ascitic fluid infection
11347002|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
11347003|NCT02388009|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
11347004|NCT02388009|Active Comparator|Flexyn2a plus adjuvant|2 doses of 10 μg of Flexyn2a plus adjuvant will be injected intramuscularly 4 weeks apart
11347005|NCT02388009|Placebo Comparator|Placebo|2 doses of saline buffer plus adjuvant will be injected intramuscularly 4 weeks apart
11347006|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
11347007|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
11347008|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
11347009|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
11347010|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
11347011|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
11347012|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
11347013|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
11347014|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
11347015|NCT02387931|Experimental|Vitamin D|Vitamin D3 2000 IU daily taken for 6 months
11347016|NCT02387931|Experimental|Fish Oil|Fish Oil 1000 mg daily for 6 months
11347017|NCT02387931|Placebo Comparator|Placebo|Placebo taken daily for 6 months.
11347018|NCT02387918|Active Comparator|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
11347019|NCT02387918|Active Comparator|Acupuncture|Acupuncture at point Neiguan (Pericardium-6) bilaterally and at point CV13 (Shang Wen) with acupuncture needles (0.25x25 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed after 20 minutes
11347020|NCT02387905|Active Comparator|Arm I (standard of care)|Patients undergo stereotactic spinal radiosurgery per standard of care.
11347021|NCT02387905|Experimental|Arm II (vertebral body cement augmentation)|Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
11347022|NCT02387892|Placebo Comparator|Control|Cheese & yogurt
11347023|NCT02387892|Experimental|Treatment|Cheese & yogurt + Vitamin D
11347024|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.
~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
11347025|NCT02387866|Experimental|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
11347026|NCT02387866|Experimental|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
11347027|NCT02387866|Experimental|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
11347028|NCT02387853|Experimental|LEO 90100|
11347029|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
11347030|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
11347031|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
11347032|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
11347234|NCT02386449|Active Comparator|Mannitol and Bisacodyl|
11347034|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
11347035|NCT02387827|Experimental|Diet+ short -term physical activity (DST)|
11347036|NCT02387827|Experimental|Diet+ long -term physical activity (DLT)|
11347037|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
11347038|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
11347039|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
11347040|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
11347041|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
11347042|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
11347043|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
11347044|NCT02387775|Experimental|Esophageal temperature control|The Esophageal Cooling Device (ECD) will be inserted and utilized for temperature control for up to 36 hours in this arm. The ECD will be used for all three phases of therapeutic hypothermia; induction, maintenance, and rewarming. Conventional cooling or warming techniques (e.g. cold saline, ice packs, cooling or warming blankets) will still be made available to the treating ICU team to be used at their discretion.
11347045|NCT02387762|Experimental|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
11347046|NCT02387762|Placebo Comparator|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
11347047|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
11347048|NCT02387736|Experimental|Dialectical Behaviour Therapy-6 months|6 months of standard dialectical behaviour therapy treatment.
11347049|NCT02387736|Active Comparator|Dialectical Behaviour Therapy-12 months|12 months of standard dialectical behaviour therapy treatment
11347050|NCT02387723|Experimental|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
11347051|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
11347052|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
11347053|NCT02387697|Experimental|Group A|Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.
11347054|NCT02387697|No Intervention|Group B|Control group (no surgery) with optimal medical treatment.
11347055|NCT02387671|Experimental|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
11347056|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) < 11 mmHg regardless if revascularization is done or not.
11347057|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) > 11 mmHg regardless if revascularization is done or not.
11347058|NCT02387645|Experimental|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
11347059|NCT02387619|Experimental|Group 1 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2
11347060|NCT02387619|Experimental|Group 2 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2
11347061|NCT02387619|Experimental|Group 1 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2
11347062|NCT02387619|Experimental|Group 2 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2
11347063|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
11347064|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
11347065|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
11347066|NCT02387593|Experimental|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
11347067|NCT02387593|No Intervention|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
11347068|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
11347069|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
11347070|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
11347071|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
11347072|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
11347073|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
11347074|NCT02387567|Experimental|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
11347075|NCT02387567|Sham Comparator|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
11347076|NCT02387567|Active Comparator|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
11347077|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
11347078|NCT02387554|Active Comparator|HGP0904|amlodipine
11347079|NCT02387554|Active Comparator|HGP0608|losartan
11347080|NCT02387554|Active Comparator|HGP1405|chlorthalidone
11347081|NCT02387528|Experimental|1- Mindfulness Intervention|"Mindfulness-Based Intervention: The intervention model tested was Breathworks for Stress.The mindfulness intervention used in the study had a total of eight encounters, lasting 120 minutes, that took place once a week. In order to accommodate employees' schedule. There was a recommendation of daily practice lasting an average of 15 minutes, as well as the suggestion to use the tools in everyday life.
~In each session a theme was presented, with distinct practices and well-defined objectives"
11347082|NCT02387528|Placebo Comparator|2- Relaxation Intervention|Relaxation-Based Intervention was composed of four meetings, of two hours duration, held every two weeks. The activities involved mutual help conversations about work situations, psychoeducation on stress and various techniques of stress inoculation, such as: diaphragmatic breathing, progressive muscle relaxation, relaxing visualization and stretching. Each session had its own objective to promote the relaxation response effect.
11347083|NCT02387528|Other|3- Wait List Control Group|The wait list passive control group did not receive any intervention while the study was been enrolling.
11347084|NCT02387515|Experimental|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
11347085|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
11347086|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
11347087|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
11347088|NCT02387489|Active Comparator|NBI|Nurse-delivered Brief Intervention
11347089|NCT02387489|Experimental|CBI|Computerized Brief Intervention
11347090|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
11347091|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
11347092|NCT02387450|Active Comparator|Treated group|Sildenafil, oral, 100mg per day
11347093|NCT02387450|Placebo Comparator|Control group|placebo oral
11347094|NCT02387437|Experimental|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
11347095|NCT02387437|Experimental|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
11347096|NCT02387437|Experimental|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
11347097|NCT02387424|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
11347098|NCT02387424|Active Comparator|OAR|Ongoing Assessment and Referral (OAR)
11347099|NCT02387411|Active Comparator|Interval group|high-intensity interval exercise training
11347100|NCT02387411|Active Comparator|Combined group|combined exercise training
11347101|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
11347102|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
11347103|NCT02387385|Active Comparator|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
11347104|NCT02387385|No Intervention|Standard of Care|Standard of care
11347105|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:
~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours
~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours
~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
11347138|NCT02387177|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
11347106|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
11347107|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
11347108|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
11347109|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
11347110|NCT02387346|Experimental|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
11347111|NCT02387346|Sham Comparator|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
11347112|NCT02387333|Experimental|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
11347113|NCT02387333|Sham Comparator|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
11347114|NCT02387320|Experimental|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
11347115|NCT02387320|No Intervention|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
11347116|NCT02387307|Experimental|Cohort: Dose-Escalation and Expansion|"Dose-Escalation: Dose escalation in solid tumors utilizing a 3+3 design with intra-subject dose escalation. 4 dose levels of rSIFN-co are planned for determining the RD. Dose of rSIFN-co: 15, 21, 24, 27 and 30 ug.
~Dose-Expansion: The Expansion Cohort will be initiated at the RD. Depending on the RD, the lead in period will occur accordingly. After the lead in period, a period from Cycle 1 to the final administration will be performed as the Treatment Phase during which subjects will undergo a standardized evaluation for the safety and efficacy of rSIFN-co at the RD. Follow-up evaluations will be performed 28 days (±5 days) after the last rSIFN-co administration."
11347117|NCT02387294|Experimental|Children and adolescents|"Intervention:
~Vaccination with Fluval AB Novo.
~Dosage:
~Children (3-11 years): 0,25 ml (half dose of) a single intramuscular injection of Fluval AB Novo suspension for injection.
~Adolescents (12-18 years): 0,5 ml (one dose of) a single intramuscular injection of Fluval AB Novo suspension for injection."
11347118|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
11347119|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
11347120|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
11347121|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
11347122|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
11347123|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
11347124|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
11347125|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
11347126|NCT02387242|Experimental|Group 1|10mg/kg Rifampicin
11347127|NCT02387242|Experimental|Group 2|20mg/kg Rifampicin
11347128|NCT02387242|Experimental|Group 3|30mg/kg Rifampicin
11347129|NCT02387229|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg, orally, once daily, preferably at the same time of the day throughout the study.
11347130|NCT02387229|Active Comparator|standard of care|standard of care
11347131|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
11347132|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
11347133|NCT02387203|Experimental|PrevPac|"Study intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)twice daily x 14 days for 2 courses (preoperative and post-operative).
~All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac.
~After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5."
11347134|NCT02387203|No Intervention|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
11347135|NCT02387190|Experimental|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
11347136|NCT02387190|No Intervention|Control group|Placebo is considered as standardized education
11347137|NCT02387177|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
11347139|NCT02387164|Experimental|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
11347140|NCT02387164|Placebo Comparator|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
11347141|NCT02387151|Experimental|mesenchymal stromal cells|allogeneic mesenchymal stromal cell infusion
11347142|NCT02387138|Experimental|SIRINOX|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.
~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).
~Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle G-csf : d8 to d13 systematically"
11347143|NCT02387125|Experimental|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
11347144|NCT02387125|Experimental|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
11347145|NCT02387112|Experimental|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
11347146|NCT02387112|No Intervention|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
11347147|NCT02387099|Active Comparator|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)
~+ further treatment according to standard of care"
11347148|NCT02387099|Experimental|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)
~+ further treatment according to standard of care"
11347149|NCT02387086|Experimental|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
11347150|NCT02387086|Placebo Comparator|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
11347151|NCT02387073||Electrical version|Electrical version patient reported outcome questionnaire was used for patients who had filled-up same questionnaire in a paper version
11347152|NCT02387060|Experimental|H-Bupivacaine 11.5 mg + fentanyl 25 mcg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75% plus fentanyl 25 mcg.
11347153|NCT02387060|Active Comparator|H-Bupivacaine 11.5 mg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75%
11347154|NCT02387034|Experimental|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
11347155|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
11347156|NCT02387021|Active Comparator|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
11347157|NCT02387021|Experimental|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
11347158|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
11347159|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
11347160|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
11347161|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
11347162|NCT02386982|Experimental|HMS5552 dose 1|HMS5552 75mg.Oral administration,twice per day.
11347163|NCT02386982|Experimental|HMS5552 dose 2|HMS5552 75mg.Oral administration,once per day.
11347164|NCT02386969|Experimental|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
11347165|NCT02386969|Experimental|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
11347167|NCT02386956|Experimental|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
11347168|NCT02386956|Placebo Comparator|Control|10 minutes with the patient lying on a machine off of magnetotherapy
11347169|NCT02386943|Experimental|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
11347170|NCT02386943|Experimental|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
11347171|NCT02386943|Experimental|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
11347172|NCT02386930|Experimental|Behavrioal Lifestyle modification|
11347173|NCT02386930|No Intervention|Control|
11347174|NCT02386917|Active Comparator|Gastric bypass|40 patients will undergo gastric bypass
11347175|NCT02386917|Active Comparator|Very low calorie diet|40 patients will undergo a very low calorie diet
11347176|NCT02386917|No Intervention|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
11347177|NCT02386904|Experimental|Phosphate Enema|Phosphate Enema consisting on Monobasic Sodium Phosphate (USP) 19.2 gm /120 ml and Dibasic Sodium Phosphate (USP) 7.2 gm/120 ml Dosage Form: Enema Frequency: One time; 30 minutes before Sigmoidoscopy
11347178|NCT02386891|Experimental|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
11347179|NCT02386891|Experimental|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
11347180|NCT02386878|Experimental|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
11347181|NCT02386878|Experimental|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
11347182|NCT02386878|Experimental|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
11347183|NCT02386878|No Intervention|No Intervention|No intervention
11347184|NCT02386852|Experimental|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
11347185|NCT02386852|Experimental|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
11347186|NCT02386852|Experimental|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
11347187|NCT02386839||Group 1|Participants who had short-term exposure to rhIGF-I/rhIGFBP-3 in previous study ROPP-2008-01 (NCT01096784)
11347188|NCT02386839||Group 2|Participants who received standard neonatal care in previous study ROPP-2008-01(NCT01096784)
11347189|NCT02386826|Experimental|INC280 + Bevacizumab|"Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.
~Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:
~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.
~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
11347190|NCT02386813||Training cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;
~Patients treated with non-anthracycline based therapy as an initial treatment."
11347191|NCT02386813||Validation cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;
~Patients treated with non-anthracycline based therapy as an initial treatment."
11347192|NCT02386800|Experimental|ruxolitinib monotherapy|ruxolitinib monotherapy. Patients are to use the study treatment based on the parent protocol.
11347193|NCT02386800|Experimental|combination of ruxolitinib + panobinostat|combination of ruxolitinib and panobinostat. Patients are to use the study treatment based on the parent protocol.
11347194|NCT02386787|Experimental|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
11347195|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
11347196|NCT02386774|Other|diabetic patients|
11347197|NCT02386761|Experimental|Single Ascending Dose (SAD)|"Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg
~Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg
~Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.
~In case the actual doses are modified, the number of inhalations will be adapted accordingly."
11347198|NCT02386761|Experimental|Multiple Ascending Dose (MAD)|"Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo
~Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo
~Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo
~Duration 14 days b.i.d."
11347199|NCT02386748|Experimental|Chewing gum|Chewing sugarless gum
11347200|NCT02386748|Active Comparator|Oral fluids|Clear oral fluids
11347201|NCT02386748|Other|Intravenous fluids|No chewing gum No oral fluids Only intravenous fluids (Lactated Ringer's solution)
11347202|NCT02386735|Experimental|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
11347203|NCT02386735|Active Comparator|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
11347235|NCT02386436|Experimental|Cohort 1- GSK2330811(0.1 mg/kg)|Subjects will be randomised to receive either 0.1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
11347236|NCT02386436|Experimental|Cohort 2- GSK2330811(0.3 mg/kg)|Subjects will be randomised to receive either 0.3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
11347204|NCT02386722|Experimental|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
11347205|NCT02386722|No Intervention|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
11347206|NCT02386696|Experimental|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:
~Apnea;
~Spontaneous regular breathing;
~Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;
~Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;
~Hyperventilation."
11347207|NCT02386683|Active Comparator|Group L|lung-protective ventilation applied in anesthesia
11347208|NCT02386683|No Intervention|Group T|traditional ventilation applied in anesthesia
11347209|NCT02386670|Experimental|tDCS + CR|"Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions promotes transfer of cognitive gains to everyday tasks."
11347210|NCT02386670|Sham Comparator|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.
~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels."
11347211|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
11347212|NCT02386644|Experimental|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
11347213|NCT02386631|Experimental|Orthotic|Custom made orthotic provided for study
11347214|NCT02386618|Other|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
11347215|NCT02386605|Experimental|Treatment|Motivational Interviewing Treatment group
11347216|NCT02386605|Active Comparator|Control|Relaxation Skills Training group
11347217|NCT02386592|Experimental|Intervention|Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text
11347218|NCT02386579||Diabetics with Charcot foot|
11347219|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
11347220|NCT02386553|Experimental|Nusinersen|Nusinersen administered as an intrathecal injection
11347221|NCT02386540|Experimental|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
11347222|NCT02386540|No Intervention|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
11347223|NCT02386501|Experimental|ADXS31-164|Dose/Potency 5 x 108 CFU; 1 x 109 CFU; 5 x 109 CFU; 1 x 1010 CFU
11347224|NCT02386488|Experimental|Vortioxetine 10 mg single dose|8 men and 8 women
11347225|NCT02386488|Experimental|Vortioxetine 20 mg single dose|8 men and 8 women
11347226|NCT02386488|Experimental|Vortioxetine 10 mg multiple dose|8 men and 8 women
11347227|NCT02386488|Experimental|Vortioxetine 20 mg multiple dose|8 men and 8 women
11347228|NCT02386475|Placebo Comparator|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
11347229|NCT02386475|Active Comparator|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
11347230|NCT02386475|Active Comparator|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
11347231|NCT02386475|Active Comparator|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
11347232|NCT02386462|Experimental|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
11347237|NCT02386436|Experimental|Cohort 3- GSK2330811(1 mg/kg)|Subjects will be randomised to receive either 1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
11347238|NCT02386436|Experimental|Cohort 4- GSK2330811(3 mg/kg)|Subjects will be randomised to receive either 3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
11347239|NCT02386436|Experimental|Cohort 5- GSK2330811(6 mg/kg)|Subjects will be randomised to receive either 6 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
11347240|NCT02386423|Experimental|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
11347241|NCT02386410|Experimental|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
11347242|NCT02386410|Experimental|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
11347243|NCT02386410|No Intervention|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
11347244|NCT02386397|Experimental|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8
~Gemcitabine 900 mg/m² IV in 30 minutes
~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
11347245|NCT02386397|Other|Standard treatment|"mGEMOX: infusion on days 1 and 8
~Gemcitabine 900 mg/m² IV in 30 minutes
~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
11347246|NCT02386384||Control|Normal fertile
11347247|NCT02386384||Implantation Failure|Failure to conceive
11347248|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
11347249|NCT02386371|Experimental|surgery and Intra Operative Radiotherapy|"Surgery :
~Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.
~Intra Operative Radiotherapy (IORT):
~After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure."
11347250|NCT02386358|Active Comparator|Benznidazole|Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
11347251|NCT02386358|Placebo Comparator|Placebo|Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
11347252|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
11347253|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
11347254|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.
~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
11347255|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
11347256|NCT02386306|Experimental|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
11347257|NCT02386306|Placebo Comparator|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
11347258|NCT02386306|Experimental|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
11347259|NCT02386306|Placebo Comparator|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
11347260|NCT02386306|Experimental|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
11347261|NCT02386306|Placebo Comparator|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
11347262|NCT02386293|Placebo Comparator|Placebo|Sugar pill identical to Avapro provided for 7 day prescription
11347263|NCT02386293|Active Comparator|Irbesartan|150 mg of Avapro once daily for 7 days.
11347264|NCT02386280|Experimental|Motivational Interviewing for Change of Parenting Styles|After measured parental style across the scale, the motivational interviewing will be applied in order to modify the parenting styles of risk for involvement with drug use and maintenance of protective factors. This approach will occur in 5 segments .
11347265|NCT02386280|Sham Comparator|Psicoeducation|General information about drugs and ways of prevention
11347266|NCT02386267|Experimental|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
11347267|NCT02386215|Experimental|HIV Self-test|Following a baseline interview, participants in the intervention group will be shown how to correctly use the self-tests and given two HIV self-tests. Subsequently, we will contact participants periodically over a 3 month period to see if they have used the test(s) with their sexual partners and conduct a follow-up interview.
11347268|NCT02386215|No Intervention|Control|Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling & Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
11347269|NCT02386202||Patients with hemorrhagic stroke|All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
11347309|NCT02385903|Other|Standard dressing procedure|One arm receive standard dressing procedure according to the wound
11347270|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
11347271|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
11347272|NCT02386150|Experimental|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
11347273|NCT02386150|Experimental|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
11347274|NCT02386137|Experimental|Patient|Woman aged more than 18 years having one or two symptomatic fibroid with size < 15cm.
11347275|NCT02386124|Other|frailty evaluation|"all consecutive patients admitted to hospital for acute cardiac disease aged more than 69 years will be evaluated with Short Portable Mental Status Questionnaire (SPMSQ), handgrip and Short Physical Performance Battery (SPPB).
~These three tests (SPMSQ, SPPB and handgrip) are the intervention of the study. They are the assays to establish the frailty status"
11347276|NCT02386111|Experimental|Varlilumab and Sunitinib|
11347277|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
11347278|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
11347279|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
11347280|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
11347281|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
11347282|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
11347283|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
11347284|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
11347285|NCT02386059|Placebo Comparator|PLACEBO Group|Received normal saline
11347286|NCT02386059|Active Comparator|DEXAMETHASONE Group|Received 4 mg Dexamethasone.
11347287|NCT02386059|Active Comparator|ONDANSETRON|Received 4 mg Ondansetron
11347288|NCT02386059|Active Comparator|DEXAMETHASONE + ONDANSETRON|Received 4mg Dexamethasone + 4mg Ondansetron
11347289|NCT02386046||Reference Group|Late preterm infants without any pathology. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
11347290|NCT02386046||Study Group|Infants born 26-35 weeks requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital before and after caffeine instituted, and weekly thereafter until 46 weeks postconceptional age.
11347291|NCT02386046||Control Group|Infants born 26-35 weeks not requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
11347292|NCT02386033|Placebo Comparator|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
11347293|NCT02386033|Active Comparator|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
11347294|NCT02386020|Placebo Comparator|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
11347295|NCT02386020|Active Comparator|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
11347296|NCT02386007|Experimental|DW-3101_150mg|150mg a day
11347297|NCT02386007|Experimental|DW-3101_300mg|300mg a day
11347298|NCT02386007|Experimental|DW-3101_600mg|600mg a day
11347299|NCT02386007|Placebo Comparator|a tablet same as experimental agents in formation and shape|Placebo
11347300|NCT02385994|Experimental|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
11347301|NCT02385994|No Intervention|Control|Melasma subjects randomized to non-treatment will receive no treatments.
11347302|NCT02385981|Experimental|Stivax|an intermittent stimulation of afferent vagus nerve at earlap
11347303|NCT02385955|Experimental|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
11347304|NCT02385942|Other|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
11347305|NCT02385929|Experimental|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.
~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
11347306|NCT02385929|No Intervention|Standard Care|Patients in this arm are randomized to usual care / control group
11347307|NCT02385916|Experimental|EstroSense®/MD|3 capsules per day during the study period
11347308|NCT02385916|Placebo Comparator|Placebo|3 capsules per day during the study period
11347310|NCT02385903|Active Comparator|Flammacerium|"Necrosis covering with Flammacerium 3 mm thick each day during one week then one day on two.
~On each dressing, remove excess and add flammacerium. Not to remove crust forming until eliminating furrow appears.
~Cover Flammacerium by compress."
11347311|NCT02385890|Experimental|Bagel control|100% wheat flour
11347312|NCT02385890|Experimental|Bagel with pea flour|Pea flour
11347313|NCT02385890|Experimental|Bagel with pea fibre|Pea fibre
11347314|NCT02385890|Experimental|Bagel with pea protein|Pea protein
11347315|NCT02385890|Experimental|Bagel with pea flour + pea protein|Pea flour + pea protein
11347316|NCT02385890|Experimental|Bagel with pea fibre + pea protein|Pea fibre + pea protein
11347317|NCT02385877|Experimental|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
11347318|NCT02385877|Experimental|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
11347319|NCT02385877|Experimental|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
11347320|NCT02385851|Experimental|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
11347321|NCT02385851|Experimental|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
11347322|NCT02385838|Experimental|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
11347323|NCT02385838|Experimental|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
11347324|NCT02385838|Experimental|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
11347325|NCT02385838|Experimental|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
11347326|NCT02385838|No Intervention|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
11347327|NCT02385825|Experimental|Group 1: 10 μg RVEc|10 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
11347328|NCT02385825|Experimental|Group 2: 50 μg RVEc|50 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
11347329|NCT02385825|Experimental|Group 3: 75 μg RVEc|75 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
11347330|NCT02385812|Experimental|High lung cancer risk|Individuals with lung cancer risk >= 1.5% over 6 years
11347331|NCT02385812|Experimental|Low lung cancer risk|Individuals with lung cancer risk <1.5% over 6 years
11347332|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
11347333|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
11347334|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
11347335|NCT02385773|Experimental|PTM202|PTM202
11347336|NCT02385773|Placebo Comparator|Enfamil Puramino|Formal Placebo
11347337|NCT02385760|Experimental|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
11347338|NCT02385760|Placebo Comparator|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
11347339|NCT02385747|Experimental|women with anbormal bleeding|women with perimenopausal and postmenopausal bleeding who will be evaluated with transvaginal ultrasound, saline sonohysterography,hystroscopy and endometrial currettage
11347340|NCT02385734|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
11347341|NCT02385734|Active Comparator|Coronally Advanced Flap|Periodontal plastic surgery procedure in the treatment of gingival recession
11347342|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
11347343|NCT02385708|Active Comparator|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
11347344|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
11347345|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
11347346|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
11347347|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
11347379|NCT02385474|Experimental|38% SDF annual|annual application of 38% SDF
11347380|NCT02385474|Active Comparator|12% SDF semi-annual|semi-annual application of 12% SDF
11347381|NCT02385474|Active Comparator|12% SDF annual|annual application of 12% SDF
11347382|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
11347348|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.
~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
11347349|NCT02385656|Experimental|Intervention group|Subjects who take modafinil for cancer-related fatigue for 4 weeks.
11347350|NCT02385643|Experimental|Intervention group|This group of subjects receives mobile support system and conventional treatment
11347351|NCT02385643|No Intervention|Control group|This group of patients receive conventional treatment only
11347352|NCT02385630|Experimental|Esophagectomy|"Serial assessment:
~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
11347353|NCT02385630|Experimental|Gastrectomy|"Serial assessment:
~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
11347354|NCT02385617|Experimental|Esophagectomy|Double blind single dose placebo-octreotide crossover
11347355|NCT02385617|Experimental|Total gastrectomy|Double blind single dose placebo-octreotide crossover
11347356|NCT02385617|Active Comparator|Control - no surgery|Double blind single dose placebo-octreotide crossover
11347357|NCT02385617|Experimental|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
11347358|NCT02385591|Experimental|Telephone Support|Participants will receive bi-weekly 20 minute telephone calls from a trained professional facilitator offering physical activity advice with the goal of increasing moderate-to-vigorous intensity physical activity.
11347359|NCT02385591|Experimental|SMS Support|Participants will receive weekly text messages (3-5 text messages per week) offering physical activity advice with the aim of increasing moderate-to-vigorous intensity physical activity.
11347360|NCT02385591|Active Comparator|Attention-control|Participants will receive telephone-based general nutrition advice.
11347361|NCT02385578|No Intervention|The control group|no intervention
11347362|NCT02385578|Experimental|The experimental group|an educational intervention
11347363|NCT02385565|Experimental|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
11347364|NCT02385565|Placebo Comparator|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
11347365|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
11347366|NCT02385539|Active Comparator|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
11347367|NCT02385539|Active Comparator|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
11347368|NCT02385539|Placebo Comparator|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.
~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
11347369|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
11347370|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
11347371|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
11347372|NCT02385513|Active Comparator|6 + 10 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
11347373|NCT02385513|Active Comparator|6 + 14 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule
11347374|NCT02385500|Placebo Comparator|Placebo|Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
11347375|NCT02385500|Experimental|Fesoterodine|Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
11347376|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
11347377|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
11347378|NCT02385474|Experimental|38% SDF semi-annual|semi-annual application of 38% SDF
11418155|NCT01914952|Active Comparator|HMB free acid in water|
11347383|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
11347384|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
11347385|NCT02385448|Experimental|Dienogest|
11347386|NCT02385448|Active Comparator|Combined oral contraceptive pills|
11347387|NCT02385435|Active Comparator|Bupivacaine|single shot caudal plain bupivacaine at a dose of 2mg/kg is used as a reference control drug.
11347388|NCT02385435|Active Comparator|dexmedetomidine 1μg.kg-1|Single shot Caudal dexmedetomidine 1μg.kg-1 used as the second arm intervention
11347389|NCT02385435|Active Comparator|dexmedetomidine 2μg.kg-1|Single shot Caudal dexmedetomidine 2 μg.kg-1 used as the second arm intervention
11347390|NCT02385422|Experimental|Carvedilol|Carvedilol，6.25mg-25mg/d,oral,6 months
11347391|NCT02385422|Active Comparator|Propranolol|Propranolol,30mg-160mg/d,oral,6 months
11347392|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
11347393|NCT02385396|Placebo Comparator|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
11347394|NCT02385396|Experimental|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
11347395|NCT02385396|Placebo Comparator|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
11347396|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
11347397|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
11347398|NCT02385370|Active Comparator|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
11347399|NCT02385370|Active Comparator|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
11347400|NCT02385357|Placebo Comparator|Control|330 ml of commercial protein-enriched drink (2.5 g/100 ml of protein)
11347401|NCT02385357|Experimental|Experimental|330 ml of protein-enriched drink (6 g/100 ml of protein)
11347402|NCT02385318|Experimental|Test Product|Ingenol Mebutate
11347403|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
11347404|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
11347405|NCT02385305|Other|Pressure support ventilation|Usual anesthesia management
11347406|NCT02385292|Experimental|Intranasal application of the device|Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator
11347407|NCT02385292|Active Comparator|Extranasal application of the device|Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator
11347408|NCT02385279|Experimental|MiStent®|Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
11347409|NCT02385279|Active Comparator|XIENCE EES|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
11347410|NCT02385266|Experimental|D-Cycloserine and Acetominophen|D-cycloserine 200mg/bid and Acetaminophen prn
11347411|NCT02385266|Placebo Comparator|Placebo and Acetominophen|Placebo capsules (lactose)/bid and Acetaminophen prn
11347412|NCT02385253|Active Comparator|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
11347413|NCT02385253|No Intervention|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
11347414|NCT02385240|Experimental|Test product|Brimonidine Topical Gel, 0.33 percent
11347415|NCT02385240|Active Comparator|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
11347416|NCT02385240|Placebo Comparator|Placebo gel|Placebo
11347417|NCT02385227|Experimental|Cohort A1|Exclusive blu™ e-cigarette A1
11347418|NCT02385227|Experimental|Cohort A2|Exclusive blu™ e-cigarette A2
11347419|NCT02385227|Experimental|Cohort A3|Exclusive blu™ e-cigarette A3
11347420|NCT02385227|Experimental|Cohort B1|Dual blu™ e-cigarette and usual brand B1
11347421|NCT02385227|Experimental|Cohort B2|Dual blu™ e-cigarette and usual brand B2
11347422|NCT02385227|Experimental|Cohort B3|Dual blu™ e-cigarette and usual brand B3
11347423|NCT02385227|Experimental|Cohort C|Nicotine product cessation C
11347424|NCT02385214|Experimental|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy
~+/- Reconstruction"
11347425|NCT02385214|Active Comparator|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy
~+/- Reconstruction"
11347426|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
11347427|NCT02385188|Experimental|Imiquimod|Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.
11347428|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
11347429|NCT02385162||Observation|Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease
11347430|NCT02385149|Experimental|whole grain wheat|98g whole grain wheat per day for 12 weeks
11347431|NCT02385149|Experimental|refined wheat|coloured refined wheat control intervention
11347432|NCT02385136|Experimental|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
11347433|NCT02385136|No Intervention|WBRT|whole brain radiotherapy (WBRT)
11347434|NCT02385123|Experimental|Seasonal flu vaccine|0.5 ml of seasonal inactivated influenza vaccine (IIV) will be administered intramuscularly (IM) on day 0 of each study season. The study will enroll 10 subjects each season, in years 1, 2, 4 ,5, and 6 of the study for a total of n=50.
11347435|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
~Dexamethasone by vein on Days 1-7 of the induction phase.
~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week during the maintenance phase. Participants who have evidence of budding relapse during the maintenance phase may revert back to receiving Etoposide.
~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
11347436|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2 of the Induction phase. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week during the maintenance phase.
~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
11347437|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
11347438|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
11347439|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
11347440|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
11347441|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
11347442|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
11347443|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
11347444|NCT02385071|Experimental|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3*50 mg capsules of SMV [including 50 mini-tablets of 1 mg each] with water under fed conditions) in Period 2; followed by Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347445|NCT02385071|Experimental|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347446|NCT02385071|Experimental|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347447|NCT02385071|Experimental|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347448|NCT02385071|Experimental|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347449|NCT02385071|Experimental|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347450|NCT02385071|Experimental|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347451|NCT02385071|Experimental|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347452|NCT02385071|Experimental|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347453|NCT02385071|Experimental|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347454|NCT02385071|Experimental|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347455|NCT02385071|Experimental|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11347456|NCT02385058|Experimental|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
11347457|NCT02385058|Experimental|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
11418156|NCT01914952|Active Comparator|CaHMB powder in water|
11347458|NCT02385045|Placebo Comparator|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
11347459|NCT02385045|Experimental|i-scan imaging|i-scan imaging (Pentax endoscopes)
11347460|NCT02385032|Experimental|AB|Ursodiol followed by URSO Forte
11347461|NCT02385032|Experimental|BA|URSO Forte followed by Ursodiol
11347462|NCT02385019|Experimental|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
11347463|NCT02385019|Experimental|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
11347464|NCT02385019|Experimental|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
11347465|NCT02385019|Experimental|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
11347466|NCT02385006|Other|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
11347467|NCT02385006|Other|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
11347468|NCT02384993|Experimental|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
11347469|NCT02384993|No Intervention|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise & Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
11347470|NCT02384980|No Intervention|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
11347471|NCT02384980|Experimental|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
11347472|NCT02384967|Experimental|Darunavir 400mg/d|Tri-therapy containing Darunavir at dose of 400 mg/d.
11347473|NCT02384954|Experimental|Phase I/II ALT-803 w/rituximab for rel/ref iNHL|
11347474|NCT02384941|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
11347475|NCT02384941|Experimental|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
11347476|NCT02384941|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
11347477|NCT02384928|Experimental|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
11347478|NCT02384928|Active Comparator|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
11347479|NCT02384928|Active Comparator|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
11347480|NCT02384915|Experimental|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
11347481|NCT02384915|Active Comparator|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
11347482|NCT02384902|Experimental|low GI|low GI: participants were asked to consume low GI foods (GI<55) in abundant, medium GI in moderate and high GI (GI>70) rarely.
11347483|NCT02384902|Experimental|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
11347484|NCT02384902|Experimental|conventional diet|conventional diet: all carbohydrate were treated as the same.
11347485|NCT02384889|Experimental|Difluoromethylornithine|Subjects may be given daily dose of DFMO
11347486|NCT02384889|Placebo Comparator|Placebo|Subjects may be given daily dose of placebo
11347487|NCT02384876|Experimental|Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Dose escalation: 6 successive cohorts with a maximal increasing dose
11347488|NCT02384876|Active Comparator|Ephedrine, dose : 0.1 mg/kG, reference dose|Reference dose
11347489|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
11347490|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (>=1)
11347491|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
11347492|NCT02384811|Experimental|Radiation group|Radiation therapy
11347493|NCT02384798|Experimental|ventilatory support|noninvasive ventilatory support to 5cmH2O used before the session of interval training and resistance exercises performed three times a week for 12 weeks
11347494|NCT02384798|Active Comparator|interval training|sessions of interval training and resistance exercises performed three times a week for 12 weeks
11347495|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.
~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
11347496|NCT02384759|Experimental|A|Aflibercept + LV5FU2
11347497|NCT02384759|Active Comparator|B|LV5FU2
11347498|NCT02384746|Experimental|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
11347499|NCT02384733|Experimental|Hypofractionated loco-regional RT|40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly
11347500|NCT02384733|Active Comparator|Normofractionated loco-regional RT|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
11347501|NCT02384720||A|Gender: 10 Males, 10 Females
11347502|NCT02384720||B|Gender: 10 Males, 10 Females
11347503|NCT02384720||C|Gender: 10 Males, 10 Females
11347504|NCT02384707|Experimental|allergic food|"Reintroduction procedure for small doses :
~Administration of the first dose the first dose must be allergic food or placebo
~Clinical monitoring for 45 minutes
~Administration of the second dose"
11347505|NCT02384694|Experimental|Intervention|Zumba dance intervention
11347506|NCT02384681||Exposed|Medical regulation assistants working with headset
11347507|NCT02384681||Non-Exposed|Participants working without headset
11347508|NCT02384668|Active Comparator|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
11347509|NCT02384668|Placebo Comparator|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
~The placebo regimen is identical to the vitamin D3 regimen."
11347510|NCT02384655|Experimental|Fenugreek|Mothers will take fenugreek for 14 days
11347511|NCT02384642|Active Comparator|COMPASS|The COMPASS program will involve a structured intervention for girls between the ages of 10-14 that is intended to engage adolescent girls, those who are influential in their lives, service providers and other stakeholders, with the ultimate goal of co-creating environments in which girls are valued and safe. The program is centered on establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
11347512|NCT02384642|Experimental|COMPASS plus parenting|In the COMPASS plus parenting intervention arm, girls will receive the COMPASS intervention, and In addition to the safe spaces for girls, the COMPASS project will also implement structured activities for the parents and caregivers of participants. The study will examine the relative impact of the parenting initiative in addition to the program for adolescent girls. The study will seek to determine whether the structured intervention with girls' parents has an added impact on outcomes improve girls' safety and well-being.
11347513|NCT02384629|Experimental|AXXESS stent1|AXXESS stent (OCT-guided)
11347514|NCT02384629|Experimental|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
11347515|NCT02384629|Active Comparator|AXXESS stent2|AXXESS stent (Angio-guided)
11347516|NCT02384629|Active Comparator|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
11347517|NCT02384616|Active Comparator|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
11347518|NCT02384616|Active Comparator|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
11347519|NCT02384603|Experimental|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
11347520|NCT02384603|Active Comparator|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
11347521|NCT02384590|Experimental|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
11347522|NCT02384590|No Intervention|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
11347523|NCT02384577||Single group prospective treatment|
11347524|NCT02384564|Experimental|Ambu King Vision Video Laryngoscope aBlade System|The trachea will be intubated using the Ambu King Vision Video Laryngoscope with the appropriate sized blade (size 1 or 2) based on manufacturer guidelines and clinical judgement.
11347525|NCT02384564|Active Comparator|Direct Laryngoscope|The trachea will be intubated via direct laryngoscopy using a traditional straight blade laryngoscope, with appropriately sized blade based on manufacturer guidelines and clinical judgement.
11347534|NCT02384499|Experimental|ALLO-ASC group|Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
11347535|NCT02384499|Placebo Comparator|Normal saline group|0.9% normal saline with fibrin glue injection to the anal sphincter
11347536|NCT02384486|Experimental|intervention group|"intervention group will receive the Training to Reduce Stress in Mothers of Children with (ASD)"
11347537|NCT02384486|Other|control group|control group will receive nothing but for ethical purposes will receive the same intervention after the end of the trial for the intervention group
11347538|NCT02384473|Experimental|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
11347539|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
11347540|NCT02384460|Placebo Comparator|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
11347541|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
11347542|NCT02384434|Other|Single Arm|Low Level Laser Therapy
11347543|NCT02384421|Experimental|Activa PC+S Neurostimulator|Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool
11347544|NCT02384408|Placebo Comparator|Control|Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
11347545|NCT02384408|Experimental|Hormone treatment|"Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.
~Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.
~Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study"
11347546|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
11347547|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
11347548|NCT02384369|Experimental|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
11347549|NCT02384369|Placebo Comparator|Placebo|Placebo tablet for oral administration, BID for 8 weeks
11347550|NCT02384343|Active Comparator|Dexmedetomidine|Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
11347551|NCT02384343|Placebo Comparator|Normal saline|NaCl 0,9% 7,5 ml, single intravenous bolus
11347552|NCT02384330||Dysport® (abobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
11347553|NCT02384330||Botox® (onabotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
11347554|NCT02384330||Xeomin® (incobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
11347555|NCT02384317|Experimental|CCX168|BID for 84 days
11347556|NCT02384304|Experimental|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
11347557|NCT02384304|Experimental|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
11347558|NCT02384304|Active Comparator|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
11347559|NCT02384291|Experimental|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
11347560|NCT02384291|Active Comparator|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
11347561|NCT02384278|Experimental|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
11347562|NCT02384265|Experimental|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
11347563|NCT02384265|No Intervention|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
11347564|NCT02384252||obese patients|patients with BMI > 30
11347565|NCT02384252||no obese patients|norma weight patient (BMI<25) overweight patients ( 25< BMI >30)
11347566|NCT02384239|Experimental|Palbociclib 100mg|Treatment arm palbociclib dose 100mg + fulvestrant or tamoxifen
11347567|NCT02384239|Experimental|Palbociclib 125mg|Treatment arm palbociclib dose 125mg + fulvestrant or tamoxifen
11347603|NCT02383979|Sham Comparator|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
11347568|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).
~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
11347569|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
11347570|NCT02384187|Placebo Comparator|Group C|Patients in this group will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
11347571|NCT02384187|Experimental|Group GAB|Patients in this group will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
11347572|NCT02384174|Experimental|Resistant starch (RS)|Resistant starch (RS3)
11347573|NCT02384174|Experimental|Dietary fibre|Dietary fibre (Arabinogalactan, gum guar, pectin)
11347574|NCT02384161|Experimental|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
11347575|NCT02384161|Experimental|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
11347576|NCT02384161|Placebo Comparator|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
11347577|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
11347578|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
11347579|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
11347580|NCT02384148||obese|Obese non diabetic patients with HbA1c<6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
11347581|NCT02384135|Other|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
11347582|NCT02384122|Active Comparator|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
11347583|NCT02384122|No Intervention|Standard of care|Patients receive standard of care without a placebo.
11347584|NCT02384109|Experimental|Intervention|Pharmacist-coordinated shared decision making about treatment for pre-diabetes (lifestyle change and/or metformin), using a decision tool
11347585|NCT02384109|Placebo Comparator|Usual Care|Usual care for patients with a diagnosis of pre-diabetes
11347586|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
11347587|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
11347588|NCT02384083|Experimental|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22
11347589|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
11347590|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
11347591|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
11347592|NCT02384057|Experimental|C8 sciences|cognitive rehabilitation with C8 sciences
11347593|NCT02384057|Active Comparator|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
11347594|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
11347595|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
11347596|NCT02384031|Active Comparator|Traumatic group|Traumatic needle
11347597|NCT02384031|Active Comparator|Atraumatic group|Atraumatic needle
11347598|NCT02384018|No Intervention|Control|Patients will receive standard islet transplantation.
11347599|NCT02384018|Experimental|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
11347600|NCT02384005|Other|Self-anal exam arm|Study only has one arm.
11347601|NCT02383992|Active Comparator|Hydrogen Peroxide|Post-operative wound will be treated with 3% H2O2 solution, Subjects will also clean the sutured wounds with 3% H2O2 solution or twice daily then dress the wounds with petroleum jelly and a bandage.
11347602|NCT02383992|Active Comparator|Saline|Post-operative wound will be treated with 0.9% normal saline. Subjects will also clean the sutured wounds with normal saline twice daily then dress the wounds with petroleum jelly and a bandage.
11347640|NCT02383784|Experimental|Low-GI diet|Low glycemic index diet
11347641|NCT02383784|Experimental|High-GI diet|High glycemic index diet
11347604|NCT02383979|Experimental|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
11347605|NCT02383979|No Intervention|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
11347606|NCT02383966|Experimental|Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil|
11347607|NCT02383966|Active Comparator|Cisplatin/Carboplatin + 5-Flurouracil|
11347608|NCT02383940|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
11347609|NCT02383940|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
11347610|NCT02383927|Experimental|Cohort 1|Thyroid Cancer
11347611|NCT02383927|Experimental|Cohort 2|Squamous Head and Neck Cancer
11347612|NCT02383914||Subscapularis rupture|
11347613|NCT02383888|Placebo Comparator|Matching placebo for each dose groups|
11347614|NCT02383888|Experimental|BI 425809 Active dose group 1|
11347615|NCT02383888|Experimental|BI 425809 Active dose group 2|
11347616|NCT02383888|Experimental|Bi 425809 Active dose group 3|
11347617|NCT02383875|Experimental|Opticourses education intervention|People living in the northern districts of Marseille with in very deprived social situation: very low incomes, heavy financial dependence on social benefits, over-representation of people covered by arrangements for controlling poverty and people covered by free social security
11347618|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
11347619|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
11347620|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
11347621|NCT02383849||Arm 2|Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
11347622|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
11347623|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 14 days of age with birth weight less than or equal to 2500 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
11347624|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
11347625|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
11347626|NCT02383823|Active Comparator|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
11347627|NCT02383823|No Intervention|Menopausal men|comparative to menopausal women, age span 45-55
11347628|NCT02383823|No Intervention|Elderly women|comparative to menopausal women, age span 65-80
11347629|NCT02383823|No Intervention|Elderly men|comparative to menopausal women, age span 65-80
11347630|NCT02383823|Placebo Comparator|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
11347631|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
11347632|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
11347633|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
11347634|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
11347635|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
11347636|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
11347637|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
11347638|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
11347639|NCT02383797|Experimental|Cartilage-hair hypoplasia (CHH)|Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
11347645|NCT02383771|Other|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
11347646|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
11347647|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
11347648|NCT02383732|Experimental|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
11347649|NCT02383732|Active Comparator|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
11347650|NCT02383719|Experimental|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
11347651|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
11347652|NCT02383693|Active Comparator|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
11347653|NCT02383693|Sham Comparator|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
11347654|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
11347655|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
11347656|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.
~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
11347657|NCT02383654|Other|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
11347658|NCT02383641||Observation|Patients with Wolman disease or high-grade suspicion for Wolman disease
11347659|NCT02383615|Active Comparator|DTSNB|Distal transsartorial saphenous nerve block
11347660|NCT02383615|Active Comparator|ACSNB|Adductor canal saphenous nerve block
11347661|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
11347662|NCT02383589|Active Comparator|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
11347663|NCT02383589|Experimental|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
11347664|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
11347665|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
11347666|NCT02383563|Active Comparator|Metformin Treatment Arm|500 mg metformin Extended Release tablets - one tablet daily increased at 4 weeks to 2 tablets (1000 mg) daily.
11347667|NCT02383563|No Intervention|Observational Arm|Observation only
11347668|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
11347669|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
11347671|NCT02383511|Other|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
11347672|NCT02383511|Other|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
11347673|NCT02383511|Other|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
11347674|NCT02383498|Experimental|Vaccine|Radiation + GI-6301 Vaccine + Actigraph
11347675|NCT02383498|Placebo Comparator|Placebo|Radiation + GI-6301 Placebo + Actigraph
11347676|NCT02383485|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
11347677|NCT02383485|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
11347678|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
11347679|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
11347680|NCT02383446|Experimental|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
11347681|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11347682|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
11347683|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
11347684|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
11347685|NCT02383407|Experimental|Stimulation group 2 Hz|Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
11347686|NCT02383407|Experimental|Stimulation group 5 Hz|Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
11347687|NCT02383394||aborted women|women who got pregnant and have 2nd trimesteric abortion, follow up antenatal care by ultrasound and clinical monitoring
11347688|NCT02383394||continued women|women who got pregnant and completed her pregnancy follow up antenatal care by ultrasound and clinical monitoring
11347689|NCT02383368|Experimental|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:
~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
11347690|NCT02383368|Experimental|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
11347691|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
11347692|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
11347693|NCT02383329|Experimental|Oral Nutritional Supplement (ONS)|Diet consultation for the child/family + ONS
11347694|NCT02383329|No Intervention|No Oran Nutritional Supplement (ONS)|Diet consultation for the child/family
11347695|NCT02383316|Experimental|Noonan Syndrome Children|"Children with Noonan Syndrome will be compared with age- and sex-matched healthy children. We hypothesize than Noonan Syndrome children have an increased insulin sensitivity compared to GHD children.
~Study parameters will be collected including: clinical measurements (height, weight, body mass index, waist circumference, and blood pressure), glucose and insulin levels at baseline and after an oral glucose tolerance test (OGTT), body composition measured by dual-energy x-ray absorptiometry (DXA)."
11347696|NCT02383303|Experimental|Program|The program group is eligible to participate in the Individual Development Account savings program.
11347697|NCT02383303|No Intervention|Comparison|The comparison group cannot enter the Individual Development Account program.
11347698|NCT02383290|Experimental|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
11347699|NCT02383277|Experimental|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
11347700|NCT02383277|Sham Comparator|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
11347701|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
11419801|NCT01903681|Active Comparator|Circadin 2 mg|First arm lower dose
11347702|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
11347703|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :
~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.
~Then:
~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.
~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
11347704|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :
~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15
~every 28 days until progression of disease or toxicity"
11347705|NCT02383238|Active Comparator|Dapagliflozin|Dapagliflozin, 10 mg/day, oral administration, 6 weeks
11347706|NCT02383238|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
11347707|NCT02383225|Experimental|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
11347708|NCT02383225|Experimental|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
11347709|NCT02383225|Experimental|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
11347710|NCT02383225|Experimental|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
11347711|NCT02383212|Experimental|Monotherapy Cohort|Cemiplimab will be administered alone
11347712|NCT02383212|Experimental|Dual Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy
~Doses of cemiplimab will be administered in combination with Cyclophosphamide
~Doses of cemiplimab will be administered in combination with Docetaxel"
11347713|NCT02383212|Experimental|Triple Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide
~Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF
~Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel
~Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed
~Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel"
11347714|NCT02383212|Experimental|Quadruple Combination Cohorts|Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
11347715|NCT02383186|Active Comparator|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
11347716|NCT02383186|Active Comparator|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
11347717|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
11347718|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
11347719|NCT02383160|Active Comparator|Active LIPUS Unit|Low-intensity pulsed ultrasound treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
11347720|NCT02383160|Sham Comparator|Sham LIPUS Unit|Sham device treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
11347721|NCT02383147|Experimental|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
11347722|NCT02383147|Active Comparator|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
11347723|NCT02383121||No patients|Study has been withdrawn
11347724|NCT02383108|Active Comparator|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
11347725|NCT02383108|Experimental|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
11347726|NCT02383095|Experimental|Art-therapy|16 Art-therapy sessions
11347727|NCT02383095|Active Comparator|Metacognitive therapy|16 Metacognitive therapy sessions
11347728|NCT02383069|Experimental|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
11347729|NCT02383069|Active Comparator|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
11347730|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
11347731|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
11347732|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
11347733|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
11347734|NCT02383030|Experimental|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
11347735|NCT02383030|No Intervention|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
11347736|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
11347737|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
11347738|NCT02383004|Experimental|Acupuncture|"Same premedication, induction and maintenance protocol as the No Acupuncture (Standard of Care) group.
~The intervention will be placement of 4 acupuncture needles. The needles will be placed after inhalational anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the HT7 point and one in each ear at the shen men point."
11347739|NCT02383004|No Intervention|No Acupuncture (Standard of Care)|"If needed, the patient will receive a standard does of oral midazolam (0.5 mg /kg or less, up to 15mg) plus acetaminophen 12.5 mg/kg (V group). If the patient does not require premedication with midazolam, oral acetaminophen 12.5mg/kg will be given alone (NV group).
~Induction of anesthesia by mask ventilation with sevoflurane in 50% nitrous oxide mixed with 50% oxygen. Sevoflurane will be incrementally titrated from 0% up to 8%. Nitrous oxide will be discontinued after induction. Anesthesia will be maintained with sevoflurane in an oxygen/air mixture. Sevoflurane concentration will be titrated to maintain the adequate depth of anesthesia. Prior to leaving the operating room, a dose of ketorolac 0.5mg/kg will be given intramuscularly."
11347740|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
11347741|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
11347742|NCT02382978|Experimental|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
11347743|NCT02382965|Experimental|ultrasound|
11347744|NCT02382952|Experimental|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
11347745|NCT02382952|Active Comparator|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
11347746|NCT02382939|Experimental|somapacitan|
11347747|NCT02382939|Active Comparator|hGH (somatropin)|
11347748|NCT02382926|Experimental|contactless heart-, breathing rate, ECG|
11347749|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
11347750|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
11347751|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
11347752|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
11347753|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11347754|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11347755|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11347756|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
11347757|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11347758|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
11347759|NCT02382900|Experimental|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
11347760|NCT02382900|Active Comparator|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
11347761|NCT02382900|Active Comparator|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
11347762|NCT02382887|Active Comparator|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
11347763|NCT02382887|Experimental|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
11347764|NCT02382874|Experimental|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
11347765|NCT02382861|Experimental|NAVA group|Management of the difficult weaning from mechanical ventilation by the NAVA.
11347766|NCT02382861|Active Comparator|Control group|Conventional management of the difficult weaning from mechanical ventilation, with the pressure ventilation.
11347796|NCT02382653|No Intervention|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
11347767|NCT02382848|Active Comparator|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
11347768|NCT02382848|Placebo Comparator|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
11347769|NCT02382835||Metal-on-Metal Hip Replacement|
11347770|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
11347771|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
11347772|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
11347773|NCT02382809|Experimental|DC071 (0.2% chlorhexidine digluconate)|
11347774|NCT02382809|Placebo Comparator|Placebo|
11347775|NCT02382796|Experimental|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
11347776|NCT02382783|Other|FLARE Intervention Group|"In the FLARE Intervention Group, we ask that you participate in all of the following, over the course of two years:
~Baseline Study Visit
~Monthly: Complete FLARE Questionnaires, at home, and report results. The last question on this questionnaire will ask you if you feel you are having a flare of your disease.
~FLARE Study Visit (if applicable): We will schedule you to be seen when/if you feel you are having a flare of your disease.
~Follow-up Visits (minimum of every 6 months): These are done as the standard of care for your RA.
~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound
~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year
~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
11347777|NCT02382783|No Intervention|Standard of Care (SOC) Group|"If you are randomized to the SOC Group, your care will not be any different than your usual care of rheumatoid arthritis (RA). You will be seen by a rheumatologist at a minimum of every six months, which is the standard of care for RA.
~Additionally (for research), we ask the following of you...
~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound
~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year
~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
11347778|NCT02382770||Open Abdomen patients|All patients underwent to open abdomen procedure
11347779|NCT02382757||Children|
11347780|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
11347781|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
11347782|NCT02382731|No Intervention|Usual care|Usual care (no intervention)
11347783|NCT02382731|Experimental|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
11347784|NCT02382731|Experimental|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
11347785|NCT02382718|Experimental|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.
~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.
~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
11347786|NCT02382718|Placebo Comparator|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
11347787|NCT02382679|Placebo Comparator|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
11347788|NCT02382679|Experimental|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
11347789|NCT02382666|Experimental|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
11347790|NCT02382666|Experimental|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
11347791|NCT02382666|Experimental|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
11347792|NCT02382666|Experimental|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
11347793|NCT02382666|Experimental|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
11347794|NCT02382666|Experimental|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
11347795|NCT02382653|Other|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
11347797|NCT02382640|Experimental|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
11347798|NCT02382640|Experimental|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
11347799|NCT02382640|Experimental|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
11347800|NCT02382640|Experimental|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
11347801|NCT02382614|Experimental|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
11347802|NCT02382614|No Intervention|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
11347803|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
11347804|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
11347805|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
11347806|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
11347807|NCT02382575|Active Comparator|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
11347808|NCT02382575|Experimental|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
11347809|NCT02382562|Experimental|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
11347810|NCT02382549|Experimental|6MHP and dabrafenib and trametinib|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.
~Dabrafenib is a small molecular BRAF inhibitor and will be administered in accordance with the prescribing information: 150 mg orally twice daily taken at least 1 hour before or at least 2 hours after a meal; the doses will be approximately 12 hours apart. Trametinib is a small molecular MEK1 and MEK2 inhibitor and will be administered in accordance with the prescribing information: 2 mg orally once daily taken at least 1 hour before or at least 2 hours after a meal. The medication will be taken at the same time each day with either the morning or evening dose of dabrafenib."
11347811|NCT02382536||Infusion set|Each subject will receive a total of 4 simultaneous subcutaneous infusions of insulin diluent, two using the investigational device (BD Scarlett Infusion Set) and two using the the comparator (Medtronic QuickSet Infusion Set).
11347812|NCT02382523|Experimental|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
11347813|NCT02382523|Experimental|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
11347814|NCT02382510|Experimental|TRN-157|
11347815|NCT02382510|Placebo Comparator|Placebo|
11347816|NCT02382510|Active Comparator|Tiotropium|
11347817|NCT02382497|Experimental|AN Active tDCS|"Treatment as usual plus experimental treatment"
11347818|NCT02382497|Sham Comparator|AN Sham tDCS|"Treatment as usual plus placebo treatment"
11420131|NCT01901172|Experimental|Part 2: Relative bioavailability|
11347819|NCT02382497|Experimental|BED Active tDCS|"Treatment as usual plus experimental treatment"
11347820|NCT02382497|Sham Comparator|BED Sham tDCS|"Treatment as usual plus placebo treatment"
11347821|NCT02382484|Experimental|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.
~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.
~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
11347822|NCT02382471|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
11347823|NCT02382471|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
11347824|NCT02382458|Experimental|Lifestyle intervention|Participants will receive a year-long comprehensive, dietary, exercise, and stress management intervention. They will be asked to bring a partner of their choosing with them for support. The intervention will include a behavioral program to reduce inflammation.
11347825|NCT02382458|Active Comparator|Information intervention|Participants will receive a year-long intervention that will involve receiving weekly (for the first 3 months) and then monthly (for the following 9 months) newsletters on cancer prevention and control (via e-mail or mail) that will provide the participant with information about cancer prevention and control strategies.
11347826|NCT02382445|Experimental|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
11347827|NCT02382445|Sham Comparator|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
11347828|NCT02382432|Active Comparator|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
11347829|NCT02382432|Active Comparator|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
11347830|NCT02382432|Active Comparator|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
11347831|NCT02382432|Active Comparator|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
11347832|NCT02382419|Experimental|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
11347833|NCT02382419|Placebo Comparator|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
11347834|NCT02382406|Experimental|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles
~Phase I, Cohort 1 Maintenance Therapy:
~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.
~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
11347835|NCT02382406|Experimental|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).
~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.
~*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
11347836|NCT02382393|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) and then a third party validated assessment battery.
11347837|NCT02382393|Experimental|Computerized Assessment, BPT|Participants will take a third party validated assessment battery and then the Brain Performance Test (BPT).
11347838|NCT02382380|Experimental|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
11347839|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
11347840|NCT02382367|Experimental|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
11347841|NCT02382354|Experimental|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
11347842|NCT02382354|Active Comparator|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
11347843|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
11347844|NCT02382328|Experimental|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
11347845|NCT02382328|Placebo Comparator|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
11347846|NCT02382315|Experimental|Intervention Group|Fear of Cancer Recurrence Intervention.
11347847|NCT02382315|No Intervention|Wait-list Control Group|Patients assigned to this arm will be asked to wait 6 weeks before being offered the fear of cancer recurrence intervention.
11347848|NCT02382302|Experimental|Telemedicine system|Telemedicine system
11420132|NCT01901172|Experimental|Part 3: Food effect|
11347849|NCT02382289|Active Comparator|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
11347850|NCT02382289|Active Comparator|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
11347851|NCT02382289|Active Comparator|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
11347852|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
11347853|NCT02382263|Experimental|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
11347854|NCT02382263|Experimental|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
11347855|NCT02382263|Experimental|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
11347856|NCT02382263|Experimental|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
11347857|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
11347858|NCT02382237|Other|PET/TDM|Evaluation by PET/TDM at 2 times
11347859|NCT02382224|Experimental|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
11347860|NCT02382224|Placebo Comparator|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
11347861|NCT02382198|Active Comparator|Active Group|This arm will receive the study drug glycopyrrolate.
11347862|NCT02382198|Placebo Comparator|Placebo Group|Control arm to receive placebo
11347863|NCT02382185|Experimental|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
11347864|NCT02382185|Experimental|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at>10g/dL with blood transfusion as required.
11347865|NCT02382172|Experimental|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
11347866|NCT02382172|Other|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
11347867|NCT02382146|Experimental|dexamethasone and ondansetron|dexamethasone 8 mg with ondansetron 4mg administered in group DO
11347868|NCT02382146|Active Comparator|dexamethasone and dimenhydrinate|dexamethasone 8 mg with dimenhydrinate 1mg/kg administered in group DD
11347869|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
11347870|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
11347871|NCT02382094|Experimental|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
11347872|NCT02382094|Other|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
11347873|NCT02382081|Experimental|Patient-initiated shared care|"Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient.
~Access to nurse-run telephone helpline with direct access to a contact nurse."
11347874|NCT02382081|No Intervention|Control|Traditional, routine hospital reviews every three-fourth month.
11347875|NCT02382068|Experimental|Supportive care (intratympanic dexamethasone)|Patients receive dexamethasone via intratympanic injection in one ear and placebo via intratympanic injection in the other ear. Cisplatin standard of care treatment.
11347876|NCT02382055|Experimental|REACH|Psychotherapy
11347877|NCT02382055|Active Comparator|Supportive Psychotherapy|Psychotherapy
11347878|NCT02382042|Active Comparator|Intensive Referral Intervention|
11347879|NCT02382042|No Intervention|Standard Care|
11347880|NCT02382029|Active Comparator|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
11347916|NCT02381691|Placebo Comparator|no odor|In a second control group, venipuncture was performed to the neonate with an odorless diffusor.
11347917|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
11347918|NCT02381665|Experimental|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
11347881|NCT02382029|Experimental|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).
~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
11347882|NCT02382016|Experimental|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
11347883|NCT02382016|Placebo Comparator|Placebo|Matching placebo tablet once daily.
11347884|NCT02382003|Experimental|Positive Training+Anxious Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
11347885|NCT02382003|Experimental|Positive Training+Neutral Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
11347886|NCT02382003|Active Comparator|50/50 Training+Anxious Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Anxious Imagery Prime
11347887|NCT02382003|Active Comparator|50/50 Training+Neutral Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Neutral Imagery Prime
11347888|NCT02382003|Other|No Scenario+Anxious Imagery Prime|No scenarios paired with a preceding Anxious Imagery Prime
11347889|NCT02382003|Other|No Scenario+Neutral Imagery Prime|No scenarios paired with a preceding Neutral Imagery Prime
11347890|NCT02381964|Placebo Comparator|Placebo|Matched placebo
11347891|NCT02381964|Experimental|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
11347892|NCT02381964|Experimental|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
11347893|NCT02381951|Experimental|Spinal cord stimulation|
11347894|NCT02381938|Experimental|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
11347895|NCT02381938|Other|Control|6-month intervention to educate and improve financial health
11347896|NCT02381912||Hematuria - NMIBC|Primary hematuria due to NMIBC.
11347897|NCT02381912||Hematuria - other cause|Other non-malignant cause of hematuria.
11347898|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
11347899|NCT02381886|Experimental|IDH305|
11347900|NCT02381860|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
11347901|NCT02381860|Active Comparator|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
11347902|NCT02381847|No Intervention|without HIPEC|Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).
11347903|NCT02381847|Experimental|with HIPEC|"Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.
~Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )"
11347904|NCT02381834|Experimental|Bladder stimulation technique|This is a two-person technique. A health care aide or nurse (RN) begins by holding the infant under the axillae with its legs dangling. A second RN or physician then performs bladder stimulation by gentle finger tapping on the lower abdomen in the midline just above the pubic symphysis at a frequency of 100 taps/min. If this is unsuccessful after 30 seconds, lower back stimulation in the lumbar paravertebral zone is performed by light massage in a circular motion using both thumbs. This too is performed for 30 seconds maximum. These two manoeuvres are repeated in succession, for a maximum of 5 minutes total, until urination occurs. Unsuccessful attempts at midstream urine collection will be followed by further feeding/fluid administration and bladder catheterization.
11347905|NCT02381821||pregnant|women undergoing ICSI who became pregnant
11347906|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
11347907|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
11347908|NCT02381769|Experimental|Parenteral Nutrition|Soybean based lipid emulsion
11347909|NCT02381743|No Intervention|Group 1|Weekly non-medical SMS messages
11347910|NCT02381743|Experimental|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
11347911|NCT02381743|Experimental|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
11347912|NCT02381730|Experimental|Aflibercept|
11347913|NCT02381717|Experimental|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
11347914|NCT02381717|Active Comparator|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
11347915|NCT02381691|Experimental|maternal breast milk odor|"In the first group breast milk, venipuncture was performed to the neonate while his mother's milk odor was being diffused."
11348038|NCT02380846|Other|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
11347919|NCT02381665|Placebo Comparator|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
11347920|NCT02381652|Experimental|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
11347921|NCT02381652|Experimental|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
11347922|NCT02381652|Experimental|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
11347923|NCT02381639|Other|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
11347924|NCT02381639|Other|Healthy volunteers|control subjects matched for age and sex with the patients
11347925|NCT02381626|Experimental|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
11347926|NCT02381626|Experimental|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
11347927|NCT02381613|Active Comparator|Baked beef|A meal based on baked beef
11347928|NCT02381613|Experimental|Baked herring|A meal based on baked herring
11347929|NCT02381613|Experimental|Pickled herring|A meal based on pickled herring
11347930|NCT02381600|Experimental|Intervention group- vitamin D|Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment
11347931|NCT02381561|Experimental|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
11347932|NCT02381548|Experimental|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
11347933|NCT02381535|Experimental|Treatment (onalespib, cisplatin, IMRT)|Patient receive onalespib IV over 1 hour on days -7, 3, 10, 24, 31, and 38 and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36 and 43. Patients also undergo IMRT QD, 5 days a week over 7 weeks for a total of 35 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
11347934|NCT02381522|Active Comparator|Remote Ischemic Pre-conditioning|Remote Ischemic Pre-conditioning group will receive 4 cycles of lower extremity occlusion of perfusion by blood pressure cuff inflated to 20 mmHg higher than systolic and confirmed by doppler.
11347935|NCT02381522|Sham Comparator|Sham RIPC|Sham procedure group will receive 4 cycles of inflation of lower extremity blood pressure cuff but it will be 20mmhg lower than systolic BP and hence not occlude the vessel.
11347936|NCT02381509||IVC Filter|IVC filter for the prevention of PE
11347937|NCT02381496|Experimental|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
11347938|NCT02381496|Experimental|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
11347939|NCT02381496|Experimental|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
11347940|NCT02381496|Experimental|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
11347941|NCT02381496|Experimental|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo
~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
11347942|NCT02381496|Experimental|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
11347943|NCT02381496|Experimental|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state
~Six male subjects will receive ACT-453859
~Two male subjects will receive matching placebo"
11347944|NCT02381496|Experimental|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state
~Three male subjects will receive ACT-453859
~Three female subjects will receive ACT-453859
~One male subject will receive matching placebo
~One female subject will receive matching placebo"
11348039|NCT02380846|Active Comparator|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
11420133|NCT01901159|Experimental|RO4995819 capsule|
11347945|NCT02381496|Experimental|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state
~Three male subjects will receive ACT-453859
~Three female subjects will receive ACT-453859
~One male subject will receive matching placebo
~One female subject will receive matching placebo"
11347946|NCT02381496|Experimental|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state
~Three male subjects will receive ACT-453859
~Three female subjects will receive ACT-453859
~One male subject will receive matching placebo
~One female subject will receive matching placebo"
11347947|NCT02381496|Experimental|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)
~Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.
~Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.
~There will be a washout period of 10 days between TPI and TPII"
11347948|NCT02381483|Experimental|Lean|Cold exposure
11347949|NCT02381483|Experimental|Obese|Cold exposure
11347950|NCT02381470|Experimental|Faropenem|Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
11347951|NCT02381470|Experimental|Cefadroxil|Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
11347952|NCT02381470|Active Comparator|Control|Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
11347953|NCT02381457||Pregnancies undergoing prenatal microdeletion screening|"Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.
~No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis."
11347954|NCT02381444||Standard of Care|Participants with advanced Parkinson's Disease
11347955|NCT02381444||Levodopa Carbidopa Intestinal Gel|Participants with advanced Parkinson's Disease
11347956|NCT02381431|Experimental|Thermal Imaging|imaging using a thermal camera
11347957|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
11347958|NCT02381405|Active Comparator|A|Enterade beverage
11347959|NCT02381405|No Intervention|B|Standard of care
11347960|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
11347961|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
11347962|NCT02381379|Active Comparator|Peginterferon-α-2a (Pegasys®)|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year
11347963|NCT02381379|No Intervention|Observation|Stop tyrosine kinase inhibitor that was on and no active medication that might affect CML, for example any immune-modulatory agents, traditional herbs or medications, chemotherapeutic agents, growth factors, or colony stimulating factors is allowed during the trial period.
11347964|NCT02381366|Experimental|PNEUMOSTEM®|Dose A: PNEUMOSTEM® 10 million cells per kg Dose B: PNEUMOSTEM® 20 million cells per kg
11347965|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
11347966|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
11347967|NCT02381327|Experimental|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
11347968|NCT02381327|Experimental|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
11347969|NCT02381314|Experimental|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
11347970|NCT02381301||Venous blood sampling prior to CCTA.|In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.
11347971|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
11347972|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
11347973|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
11347974|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
11348040|NCT02380846|Active Comparator|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
11348041|NCT02380846|Active Comparator|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
11420134|NCT01901159|Experimental|RO4995819 tablet|
11347975|NCT02381262|Experimental|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.
~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
11347976|NCT02381262|No Intervention|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.
~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.
~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
11347977|NCT02381262|No Intervention|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
11347978|NCT02381249|Experimental|Esophagectomy|Double-blind single dose octreotide-placebo crossover
11347979|NCT02381249|Experimental|Gastrectomy|Double-blind single dose octreotide-placebo crossover
11347980|NCT02381249|Active Comparator|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
11347981|NCT02381249|Experimental|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
11347982|NCT02381236|Experimental|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
11347983|NCT02381210||CLINICALLY CONFIRMED PREECLAMPSIA|Pregnant women with clinical diagnosis of preeclampsia (severe, mild or superimposed) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
11347984|NCT02381210||CLINICALLY HEALTHY|Pregnant women admitted to the hospital for delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
11347985|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
11347986|NCT02381184|Active Comparator|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
11347987|NCT02381184|Active Comparator|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
11347988|NCT02381171|Sham Comparator|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
11347989|NCT02381171|Sham Comparator|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
11347990|NCT02381171|Sham Comparator|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
11347991|NCT02381171|Active Comparator|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
11347992|NCT02381158|Experimental|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
11347993|NCT02381145|Placebo Comparator|Placebo|micro-cellulose-filled Placebo
11347994|NCT02381145|Active Comparator|EGCG+RSV-supplementation|EGCG+RSV: 300mg/d + 80mg/d
11347995|NCT02381132|Active Comparator|MNK155|Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
11347996|NCT02381132|Active Comparator|Norco 7.5mg/325mg|Norco 7.5mg/325mg
11347997|NCT02381119|Experimental|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
11347998|NCT02381119|Active Comparator|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
11347999|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
11348000|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
11348001|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
11348002|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
11348003|NCT02381093|Active Comparator|Standard BLS Course|Participants will partake in a standard BLS course.
11348004|NCT02381093|Experimental|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
11348042|NCT02380846|Active Comparator|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
11348043|NCT02380833|Active Comparator|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
11348082|NCT02380664|No Intervention|Sedentary controls|Controls that do not perform swimming or other physical activities
11348005|NCT02381080|Experimental|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
11348006|NCT02381080|Experimental|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
11348007|NCT02381067|Other|NuCel with Allograft Bone|NuCel will be used with allograft bone for the surgical treatment of one, two or three level degenerative disease of the cervical spine.
11348008|NCT02381054||Translation and cross-cultural adaptation phase|In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
11348009|NCT02381054||Test-retest phase|In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.
11348010|NCT02381028|Experimental|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
11348011|NCT02381028|Active Comparator|Control area|Emollient: Apobase creme® (Actavis Norway AS)
11348012|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
11348013|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
11348014|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
11348015|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
11348016|NCT02381002|Experimental|Weight reduction|weight reduction program for 6 months
11348017|NCT02380989|Experimental|Ayurveda|
11348018|NCT02380989|Placebo Comparator|Placebo|
11348019|NCT02380976|Experimental|Test 1|First phase: DW330SR+DW1030 7 days after Second phase: DW340
11348020|NCT02380976|Experimental|Test 2|First phase: DW340 7 days after Second phase: DW330SR+DW1030
11348021|NCT02380963|Experimental|Colorado Diet with soy protein|
11348022|NCT02380963|Active Comparator|Colorado Diet|
11348023|NCT02380950|Other|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
11348024|NCT02380937|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
11348025|NCT02380924|Active Comparator|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
11348026|NCT02380924|Sham Comparator|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
11348027|NCT02380911|Experimental|Intervention Group|The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
11348028|NCT02380911|No Intervention|No Intervention Group|This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health
11348029|NCT02380898|Experimental|Ketorolac|
11348030|NCT02380898|Placebo Comparator|Normal saline 0.9%|
11348031|NCT02380885|Experimental|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
11348032|NCT02380885|Experimental|TAFT|Therapeutic Alliance Focused Therapy
11348033|NCT02380885|No Intervention|TAU|Treatment as Usual
11348034|NCT02380872|Active Comparator|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
11348035|NCT02380872|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
11348036|NCT02380859|Active Comparator|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
11348037|NCT02380859|Sham Comparator|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
11348206|NCT02379910|Experimental|MAD 2|AM1030-CREAM
11348044|NCT02380833|Active Comparator|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
11348045|NCT02380833|Active Comparator|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
11348046|NCT02380833|Active Comparator|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
11348047|NCT02380820|Experimental|AirsoftDuo first|"Patients randomized to this arm will be placed on the Airsoft Duo mattress, and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Softform Premium mattress (in static mode). The patient will then continue his/her stay with the Softform Premium mattress (in static mode) for 1 month.
~Intervention: Airsoft Duo mattress Intervention: Softform Premier mattress (in static mode)"
11348048|NCT02380820|Experimental|Softform Premium first|"Patients randomized to this arm will be placed on the Softform Premium mattress (in static mode), and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Airsoft Duo mattress. The patient will then continue his/her stay with the Airsoft Duo mattress for 1 month.
~Intervention: Softform Premier mattress (in static mode) Intervention: Airsoft Duo mattress"
11348049|NCT02380807|Experimental|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
11348050|NCT02380807|Active Comparator|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
11348051|NCT02380794|Active Comparator|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
11348052|NCT02380794|Placebo Comparator|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
11348053|NCT02380781|No Intervention|Control|Patients will receive current standard postpartum contraceptive counseling.
11348054|NCT02380781|Experimental|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
11348055|NCT02380768|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
11348056|NCT02380768|Active Comparator|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
11348057|NCT02380755|Placebo Comparator|Placebo|One pill every other day during 12 weeks
11348058|NCT02380755|Active Comparator|Clomiphene Citrate|Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks
11348059|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
11348060|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
11348061|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.
~Investigation: First Gene Panel Sequencing and if no mutation ist found > Whole Genome Sequencing (WGS)"
11348062|NCT02380729||Parents of the index patient|"Both parents of the index patient.
~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
11348063|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
11348064|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
11348065|NCT02380690|Experimental|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
11348066|NCT02380690|No Intervention|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
11348067|NCT02380677|Experimental|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
11348068|NCT02380677|Experimental|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
11348069|NCT02380677|Experimental|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
11348070|NCT02380677|Experimental|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
11348071|NCT02380677|Experimental|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
11348072|NCT02380677|Experimental|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
11348073|NCT02380677|Experimental|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
11348074|NCT02380677|Experimental|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
11348075|NCT02380677|Experimental|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
11348076|NCT02380677|Experimental|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
11348077|NCT02380677|Experimental|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
11348078|NCT02380677|Experimental|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
11348079|NCT02380664|No Intervention|Swimmers|Swimmers that continue their normal swimming activity
11348080|NCT02380664|Experimental|WBV swimmers|Swimmers that perform a whole-body vibration training
11348081|NCT02380664|Experimental|Plyometric swimmers|Swimmers that perform a plyometric training
11348083|NCT02380638|Experimental|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
11348084|NCT02380638|No Intervention|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
11348085|NCT02380638|Experimental|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
11348086|NCT02380638|No Intervention|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
11348087|NCT02380625|Experimental|Azithromycin|Azithromycin, IV fluids and laboratory testing
11348088|NCT02380625|Experimental|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
11348089|NCT02380625|Experimental|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
11348090|NCT02380625|Other|IV fluids and laboratory testing|no additional treatment
11348091|NCT02380612|Experimental|Area A|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
11348092|NCT02380612|Experimental|Area B|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
11348093|NCT02380599|Experimental|Experimental Group|Crossover assignment of mid-thoracic spinal manipulation, spinal mobilization, or sham ultrasound
11348094|NCT02380586||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
11348095|NCT02380573|Experimental|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348096|NCT02380573|Placebo Comparator|Healthy Aging Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348097|NCT02380573|Experimental|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348098|NCT02380573|Placebo Comparator|Mild Cognitive Impairment (MCI) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348099|NCT02380573|Experimental|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348100|NCT02380573|Placebo Comparator|Mild Alzheimer's Disease (AD) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348101|NCT02380573|Experimental|Healthy Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348102|NCT02380573|Placebo Comparator|Healthy Middle Age Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
11348103|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
11348104|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
11348105|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
11348106|NCT02380534|Experimental|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
11348107|NCT02380521|Experimental|60 patients with T2DM|These patients will be treated with exenatide once weekly for a period of 8 months
11348108|NCT02380508|Experimental|Group 1|32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10^5 cfu) via Intradermal route.
11348109|NCT02380508|Experimental|Group 2|8-16 control volunteers receiving no vaccination.
11348110|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
11348111|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
11348112|NCT02380482|Other|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients
~Glasgow score < or = 9 or
~Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:
~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
11348113|NCT02380482|Other|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:
~Intubated and mechanically ventilated
~Undergoing urgent non severe surgery"
11348114|NCT02380469|Experimental|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
11348115|NCT02380469|Other|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
11348116|NCT02380443|Experimental|Dosing Schedule A|"The priming step with ID injections of AlloStim on Days 0, 7, and 14
~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21
~The activation step with IV infusion of AlloStim on Day 28
~The booster step with two IV booster infusions of AlloStim on Days 56 and 84
~Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
11348117|NCT02380443|Experimental|Dosing Schedule B|"The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10
~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14
~The activation step with IV infusion of AlloStim on Day 21
~The booster step with two IV booster infusions of AlloStim on Days 49 and 77
~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
11348207|NCT02379897|Experimental|LowGI+ModCarb|Low glycemic index + moderate carbohydrate/moderate fat diet
11348118|NCT02380443|Experimental|Dosing Schedule C|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14
~IV AlloStim on Day 21
~The booster step with two IV booster infusions of AlloStim on Days 49 and 77
~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
11348119|NCT02380443|Experimental|Dosing Schedule D (reducing dose)|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14
~IV AlloStim on Day 21
~The booster step with two IV booster infusions of AlloStim on Days 49 and 77
~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
11348120|NCT02380430||ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
11348121|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
11348122|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
11348123|NCT02380404||Edentulous maxilla|Ibuprofen (600 mg - Film-coated Tablets) 3x/day before the surgery. Duration : 5 days Amoxicilline Teva (500 mg - dispersible tablets) 3x/day before the surgery. Duration : 16 days
11348124|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
11348125|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
11348126|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
11348127|NCT02380365||Outpatients on the Waiting List and after Lung Transplantation|Electrocardiography
11348128|NCT02380352|Experimental|Short-course|5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
11348129|NCT02380352|Active Comparator|Standard|5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID
11348130|NCT02380339|Active Comparator|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
11348131|NCT02380339|Experimental|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
11348132|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
11348133|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
11348134|NCT02380313|Experimental|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
11348135|NCT02380313|Experimental|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
11348136|NCT02380313|Experimental|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
11348137|NCT02380313|Experimental|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
11348138|NCT02380313|Experimental|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
11348139|NCT02380313|Experimental|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
11348140|NCT02380313|Experimental|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
11348141|NCT02380313|Experimental|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
11348142|NCT02380313|Experimental|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
11348208|NCT02379897|Experimental|LowGI+HighCarb|Low glycemic index + high carbohydrate/low fat diet
11348143|NCT02380313|Experimental|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
11348144|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
11348145|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
11348146|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
11348147|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
11348148|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
11348149|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
11348150|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
11348151|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.
~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
11348152|NCT02380274||Patients with CRPC|Patients with CRPC
11348153|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
11348154|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
11348155|NCT02380235|Experimental|PEG-somatropin|0.12mg/kg/w
11348156|NCT02380235|Experimental|PEG-Somatropin|0.20mg/kg/w
11348157|NCT02380222||ASM|
11348158|NCT02380222||SM-AHNMD|
11348159|NCT02380222||MCL|
11348160|NCT02380222||SSM|
11348161|NCT02380222||ISM|
11348162|NCT02380209|Experimental|Optimization|CEST MRI of the breast for estimation of tumor pH.
11348163|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
11348164|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
11348165|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
11348166|NCT02380157|Experimental|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
11348167|NCT02380157|Placebo Comparator|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
11348168|NCT02380144|Experimental|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:
~1st: Orange fruit; 2nd: Orange juice"
11348169|NCT02380144|Experimental|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:
~1st: Orange juice; 2nd: Orange fruit"
11348209|NCT02379897|Experimental|HighGI+ModCarb|High glycemic index + moderate carbohydrate/moderate fat diet
11348210|NCT02379897|Experimental|HighGI+HighCarb|High glycemic index + high carbohydrate/low fat diet
11348170|NCT02380131|Experimental|Herceptin|"drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
~To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis"
11348171|NCT02380118|Experimental|Olanzapine|intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
11348172|NCT02380118|Active Comparator|Haloperidol|intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
11348173|NCT02380118|Active Comparator|Midazolam|intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
11348174|NCT02380105|Experimental|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
11348175|NCT02380105|Active Comparator|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
11348176|NCT02380079|Experimental|SCD-101|SCD-101 dosed TID for 28-days
11348177|NCT02380079|Placebo Comparator|Placebo|Placebo dosed TID for 28-days
11348178|NCT02380066|Experimental|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
11348179|NCT02380066|Experimental|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
11348180|NCT02380066|Experimental|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
11348181|NCT02380066|Experimental|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
11348182|NCT02380066|Placebo Comparator|Placebo|Placebo,oral, twice per day
11348183|NCT02380053|Experimental|Bisoprolol|2.5mg once daily for 2 weeks then 5mg once daily for 2 weeks.
11348184|NCT02380053|Experimental|Celiprolol|200mg once daily for 2 weeks then 400mg once daily for 2 weeks.
11348185|NCT02380040||Term|Normal Term Newborn Intervention: PPG
11348186|NCT02380040||Preterm|Preterm babies admitted to the NICU not suffering from the conditions to be studied Intervention: PPG
11348187|NCT02380040||PDA|Patent Ductus Arteriosus Intervention: PPG
11348188|NCT02380040||PPHN|Persistent Pulmonary Hypertension Intervention: PPG
11348189|NCT02380027|Experimental|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
11348190|NCT02380027|Active Comparator|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
11348191|NCT02380001|Experimental|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
11348192|NCT02380001|Placebo Comparator|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
11348193|NCT02379988|Experimental|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
11348194|NCT02379975|Experimental|rheumatoid arthristis|individuals with rheumatoid arthritis
11348195|NCT02379975|Active Comparator|health|healthy individuals
11348196|NCT02379949|Experimental|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
11348197|NCT02379949|Active Comparator|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
11348198|NCT02379949|No Intervention|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
11348199|NCT02379936|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
11348200|NCT02379936|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
11348201|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
11348202|NCT02379910|Experimental|SAD 1|AM1030-CREAM
11348203|NCT02379910|Experimental|SAD 2|AM1030-CREAM
11348204|NCT02379910|Experimental|SAD 3|AM1030-CREAM
11348205|NCT02379910|Experimental|MAD 1|AM1030-CREAM
11348211|NCT02379871|Experimental|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
11348212|NCT02379871|Sham Comparator|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
11348213|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
11348214|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
11348215|NCT02379845|Experimental|Arm A|NBTXR3 + Radiotherapy
11348216|NCT02379845|Active Comparator|Arm B|Radiotherapy alone
11348217|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
11348218|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
11348219|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
11348220|NCT02379806|Active Comparator|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
11348221|NCT02379806|Placebo Comparator|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
11348222|NCT02379793|Experimental|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
11348223|NCT02379780|Active Comparator|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
11348224|NCT02379780|Active Comparator|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
11348225|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
11348226|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
11348227|NCT02379754|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.
~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
11348228|NCT02379754|No Intervention|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
11348229|NCT02379741|Experimental|ADC-1013 intratumoral|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
11348230|NCT02379741|Experimental|ADC-1013 intravenous|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.
11348231|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
11348232|NCT02379728|Experimental|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
11348233|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
11348301|NCT02379247|Experimental|BYL719 Dose Expansion|"BYL719: MTD from Phase I by mouth daily on day 1-28 of each 28 day cycle
~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
11348341|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
11348234|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.
~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
11348235|NCT02379715|Experimental|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
11348236|NCT02379689|Active Comparator|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
11348237|NCT02379689|Placebo Comparator|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
11348238|NCT02379676|Experimental|Ticagrelor|Ticagrelor 90mg twice daily
11348239|NCT02379676|Active Comparator|Clopidogrel|Clopidogrel 75mg once daily
11348240|NCT02379663|Active Comparator|Oral direct Factor Xa inhibitor|Rivaroxaban
11348241|NCT02379663|Active Comparator|Low molecular weight heparin|Enoxaparin
11348242|NCT02379663|Placebo Comparator|Normal Saline|Normal Saline
11348243|NCT02379650|Experimental|Hydroxychloroquine (HCQ)|Subjects in the experimental arm will take 400 mg hydroxychloroquine pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
11348244|NCT02379650|Placebo Comparator|Placebo|Subjects in the experimental arm will take placebo pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
11348245|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
11348246|NCT02379637|Placebo Comparator|B Placebo|Placebo
11348247|NCT02379624|Placebo Comparator|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
11348248|NCT02379624|Experimental|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
11348249|NCT02379611|Active Comparator|normally hearing children|
11348250|NCT02379611|Experimental|Congenital profound deaf children|
11348251|NCT02379598||Amino acid based formula|
11348252|NCT02379598||Whey protein formula|
11348253|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
11348254|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
11348255|NCT02379572|Experimental|iMRI-guided surgery|Resection of Glioblastomas with iMRI-guidance
11348256|NCT02379572|Active Comparator|5-ALA-guided surgery|Resection of Glioblastomas with 5-ALA-fluorescence-guidance
11348257|NCT02379559|Experimental|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
11348258|NCT02379559|Active Comparator|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
11348259|NCT02379546|Experimental|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
11348260|NCT02379546|Active Comparator|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
11348261|NCT02379533|No Intervention|sedentary control|
11348262|NCT02379533|Experimental|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
11348302|NCT02379234|No Intervention|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
11348303|NCT02379234|Experimental|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
11348449|NCT02378324|Active Comparator|Intervention and control|Intervention arm: screening without fee.
11348263|NCT02379533|Active Comparator|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
11348264|NCT02379520|Experimental|Group A|HPV Specific T Cells
11348265|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
11348266|NCT02379507|Experimental|DEC033 Study Product|Apply twice a day
11348267|NCT02379481|Experimental|NS 550mg|NS 550mg/day
11348268|NCT02379481|Experimental|NS 1100mg|NS 1100mg/day
11348269|NCT02379481|Placebo Comparator|placebo|placebo
11348270|NCT02379468|Experimental|Pedyphar|Ointment
11348271|NCT02379468|Active Comparator|Panthenol|Ointment
11348272|NCT02379455|Experimental|Comprehensive drug review|
11348273|NCT02379455|No Intervention|Control group|"Follow-up by family physician as usual."
11348274|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
11348275|NCT02379429||1|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
11348276|NCT02379429||2|Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
11348277|NCT02379416|Experimental|treatment|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
11348278|NCT02379390|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
11348279|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
11348280|NCT02379377|Experimental|Diagnostic (18F-FSPG PET)|Patients undergo an 18F-FSPG PET scan within 4 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
11348281|NCT02379377|Experimental|Diagnostic (11C-Acetate PET or 18F-FDG PET)|Patients may undergo either carbon-11 (11C)-Acetate PET or 18F-FDG PET scans within 4 weeks of surgery or OLT.
11348282|NCT02379364|Experimental|Intervention group|Diacutaneous Fibrolysis treatment
11348283|NCT02379351|Experimental|In-Home Non-Stress Test Device|Patients with physician-ordered twice-weekly NSTs scheduled in the OB Diagnostic Center at University of Utah Hospital will be eligible for enrollment. After being taught how to use the Airstrip® Sense4Baby™ system machine, participants will use the device on a weekly basis (at home) until the time of delivery. Participants will also receive an in clinic NST once a week.
11348284|NCT02379338|Experimental|Dynamic Brain Cohort|The Dynamic Brain cohort will include up to 10 patients who will undergo a dynamic brain [18F]Fluortriopride PET/CT scan over a period of approximately 2 hours. Subjects in this cohort will also undergo a research brain MRI, generally on a separate day from the PET/CT.
11348285|NCT02379338|Experimental|Biodistribution Cohort|The Biodistribution cohort will include up to10 patients who will undergo a series of whole body biodistribution [18F]Fluortriopride PET/CT scans over a period of approximately 4 hours.
11348286|NCT02379325|Experimental|Lets Quit|Given text message
11348287|NCT02379325|Active Comparator|Pamplets education|Given pamplets on smoking and complication
11348288|NCT02379312|Active Comparator|Very low energy aerated beverage|Very low energy aerated beverage
11348289|NCT02379312|Active Comparator|Normal energy aerated beverage 1|Normal energy aerated beverage 1
11348290|NCT02379312|Active Comparator|Normal energy aerated beverage 2|Normal energy aerated beverage 2
11348291|NCT02379312|Active Comparator|Normal energy aerated beverage 3|Normal energy aerated beverage 3
11348292|NCT02379299|Active Comparator|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
11348293|NCT02379299|Experimental|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
11348294|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
11348295|NCT02379273|Experimental|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
11348296|NCT02379260|Other|Interview|Patients and urologists will be interview by a sociologist.
11348297|NCT02379260|Other|Focus Groups|Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
11348298|NCT02379247|Experimental|Co-hort 1 BYL719 (250mg)+Nab-paclitaxel|"BYL719: 250mg daily on day 1-28
~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
11348299|NCT02379247|Experimental|Co-hort 2 BYL719 (300mg)+Nab-paclitaxel|"BYL719: 300mg by mouth daily on day 1-28 of each 28 day cycle
~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
11348300|NCT02379247|Experimental|Co-hort 3 BYL719 (350mg)+Nab-paclitaxel|"BYL719: 350mg by mouth daily on day 1-28 of each 28 day cycle
~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
11348304|NCT02379221|Experimental|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
11348305|NCT02379195|Experimental|A|"All patients receive the same treatment.
~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.
~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.
~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.
~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days
~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
11348306|NCT02379182|Active Comparator|Control group|Will not receive any treatment procedure. Patients allocated in the control group will be treated according to the standard clinical care of patients with dysphagia at our center, that includes: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary.
11348307|NCT02379182|Experimental|Sensory Group|Patients allocated in the sensory group will be treated with transcutaneous electrical stimulation at sensory level. In addition, they will receive the standard clinical care described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
11348308|NCT02379182|Experimental|Motor Group|Patients allocated in the motor group will be treated with transcutaneous electrical stimulation at motor level. In addition, they will receive the standard clinical care of patients with dysphagia described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
11348309|NCT02379169|Experimental|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
11348310|NCT02379169|Placebo Comparator|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
11348311|NCT02379156|Experimental|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
11348312|NCT02379156|Experimental|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
11348313|NCT02379130|Experimental|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
11348314|NCT02379130|Active Comparator|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
11348315|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion & exclusion criteria.
11348316|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
11348317|NCT02379104||Healthy Volunteers|Healthy volunteers fulfilling inclusion/exclusion criteria for reference interval sample group are tested with ROTEM sigma
11348318|NCT02379104||Patients with expected coagulopathy|Patients with expected bleeding and coagulation problems during elective surgery or at the ICU, or trauma patients are tested with ROTEM sigma and ROTEM delta comparatively
11348319|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
11348339|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
11348340|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
11348450|NCT02378324|No Intervention|Control group|Control arm: screening with the regular fee, 100SEK.
11348320|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
11348321|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
11348322|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
11348323|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers
~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
11348324|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers
~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients
~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
11348325|NCT02379065|Active Comparator|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.
~Interventions:
~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician
~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)
~Arterial blood gas changes - pH, pO2, pCO2"
11348326|NCT02379065|Experimental|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.
~Interventions:
~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician
~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)
~Arterial blood gas changes - pH, pO2, pCO2"
11348327|NCT02379052|Experimental|Dupilumab 300 mg QW|Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
11348328|NCT02379052|Experimental|Placebo|Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
11348329|NCT02379026|Experimental|Exercise & Protein Drink/Diet|High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
11348330|NCT02379026|Active Comparator|Exercise|A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
11348331|NCT02379013|Experimental|Volunteer with MRI|All volunteer will be included in the arm MRI
11348332|NCT02379000|Active Comparator|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
11348333|NCT02379000|Active Comparator|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
11348334|NCT02378987||Typical developmental children|Normal children
11348335|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
11348336|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
11348337|NCT02378974|Other|Cohort 1|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0
11348338|NCT02378974|Other|Cohort 2|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7
11348701|NCT02376621|Active Comparator|Pronovum PRF-048|3 × Pronovum PRF-048
11348342|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
11348343|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
11348344|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
11348345|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
11348346|NCT02378948|Experimental|Early oral feeding|Liquid oral feeding directly after esophagectomy.
11348347|NCT02378948|No Intervention|Delayed oral feeding|Liquid oral feeding 5 days after esophagectomy
11348348|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
11348349|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
11348350|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
11348351|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
11348352|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
11348353|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
11348354|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
11348355|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
11348356|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
11348357|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
11348358|NCT02378922|Experimental|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.
~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.
~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
11348359|NCT02378909|Active Comparator|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
11348360|NCT02378909|No Intervention|Group 2|Diabetic neuropathy with standard of care.
11348361|NCT02378909|Active Comparator|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
11348362|NCT02378909|No Intervention|Group 4|Diabetic neuroischemia with standard of care.
11348363|NCT02378896|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
11348364|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
11348365|NCT02378870|Experimental|A:Osteodex|3.0 mg/kg bodyweight solution for infusion
11348366|NCT02378870|Placebo Comparator|B: Placebo|NaCl 0.9% solution for infusion
11348367|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
11348368|NCT02378857||Control group|Age- and gender-matched healthy individuals
11348369|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
11348370|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
11348371|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
11348372|NCT02378818|Other|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
11348373|NCT02378818|Other|Healthy volunteers (schizophrenia)|35 healthy volunteers
11348374|NCT02378818|Other|Depressive patients|
11348375|NCT02378818|Other|Healthy volunteers (depression)|
11348376|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
11348377|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
11348378|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria >0.3 g/day or per gCreatinine
11348379|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
11348380|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
11348381|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
11348382|NCT02378792|Experimental|Vagus Verve Stimulation is on|
11348383|NCT02378792|Sham Comparator|Placebo Vagus Verve Stimulation is off|
11348384|NCT02378779|Other|Interventional GP : GP trainned in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.
~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.
~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
11420987|NCT01895348|Active Comparator|propofol only|
11348385|NCT02378779|Other|Usual care : GP did not trainnd in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.
~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
11348386|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
11348387|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
11348388|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
11348389|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
11348390|NCT02378740|Placebo Comparator|Placebo|Placebo (.9 sterile normal saline) administered IV
11348391|NCT02378740|Active Comparator|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:
~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
11348392|NCT02378727|Active Comparator|A Standard Care Group (SCG)|Standard Care Conventional Group (SCG): 158 subjects to receive lumbar epidural procedure with the loss of resistance syringe used to identify the epidural space
11348393|NCT02378727|Experimental|Experimental Procedure Group (EPG).|158 of subjects to receive lumbar epidural procedure with the CompuFlo® Epidural System used to identify the epidural space
11348394|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
11348395|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
11348396|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
11348397|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
11348398|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
11348399|NCT02378688|Experimental|MT-1303|
11348400|NCT02378688|Placebo Comparator|Placebo|
11348401|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
11348402|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
11348403|NCT02378662|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
11348404|NCT02378662|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
11348405|NCT02378649|Experimental|Sildenafil|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.
~PDEI or placebo will continue up to 8 days or discharge."
11348406|NCT02378649|Placebo Comparator|Placebo|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.
~PDEI or placebo will continue up to 8 days or discharge."
11348407|NCT02378636|Experimental|600S|Modified 600C (axis marks) monofocal aspheric intraocular lens
11348408|NCT02378623|Active Comparator|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
11348409|NCT02378623|Placebo Comparator|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
11348410|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
11348411|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
11348412|NCT02378597|Active Comparator|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
11348413|NCT02378597|Experimental|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
11348414|NCT02378584|Other|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
11348415|NCT02378584|Active Comparator|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
11348416|NCT02378571|No Intervention|Usual care|Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes. This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later. Participants will not be provided with any advice on heart failure adherence.
11348417|NCT02378571|Experimental|Medication adherence telemonitoring|At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician. A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis. The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
11348448|NCT02378337||Prospective validation cohort|To verify the application of methodology in clinical routine, we conducted a second phase of the study prospectively in 250 subjects (phase 2) using inclusion and exclusion criteria of the retrospective study (phase 1).
11348418|NCT02378558|Experimental|Investigational Device|All patients will undergo breast localization and excision of a lesion using the MagneMark system. The radiologist will insert the MagneMarker clip into the area of concern using the MagneJector device. The surgeon will then locate the MagneMaker clip using the MagneProbe. The clip and breast tissue of concern will then be removed.
11348419|NCT02378545|Active Comparator|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
11348420|NCT02378545|Active Comparator|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
11348421|NCT02378532|Experimental|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.
~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients. Based on the results of the DSMB, an additional level of 300mg was added."
11348422|NCT02378519|Experimental|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
11348423|NCT02378519|Active Comparator|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
11348424|NCT02378506|Experimental|ETN 50mg QW|
11348425|NCT02378493||Exposure: Concordance between tests|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients whose antibiogrammes and Antibiofilmogrammes are concordant will fall into this group (the exposed group).
~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
11348426|NCT02378493||Non exposure: Not concordance between tests.|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients who do not fall into the concordance (exposure) group, will fall into the non exposure group. The latter includes semi-concordance or discordance between antibiogrammes and Antiobiofilmogrammes.
~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
11348427|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
11348428|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
11348429|NCT02378467|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
11348430|NCT02378467|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
11348431|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
11348432|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
11348433|NCT02378441|Experimental|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
11348434|NCT02378441|Experimental|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
11348435|NCT02378428|Experimental|MIBG|Research participants with MIBG avid tumors
11348436|NCT02378415|Placebo Comparator|Normal Saline Infusion|A single IV bolus dose of normal saline solution.
11348437|NCT02378415|Experimental|Subanesthetic IV Bolus Ketamine|a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
11348438|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
11348439|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
11348440|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
11348441|NCT02378389|Experimental|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
11348442|NCT02378376|Experimental|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
11348443|NCT02378376|Experimental|Wheat derived fiber fraction 2|Dietary fiber enriched bran
11348444|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
11348445|NCT02378350|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
11348446|NCT02378350|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
11348447|NCT02378337||Retrospective development cohort|A total of 85 18F-FDG-PET adult studies were gathered over a 3-month period and retrospectively evaluated.
11420988|NCT01895348|Active Comparator|propofol-remifentanil|
11348451|NCT02378311||Cases|Those satisfying the inclusion & exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
11348452|NCT02378311||Controls|Those satisfying the inclusion & exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
11348453|NCT02378298|Active Comparator|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS <2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.
~rituximab and methotrexate"
11348454|NCT02378298|Active Comparator|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
11348455|NCT02378298|Active Comparator|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.
~methotrexate and methylprednisolone"
11348456|NCT02378298|No Intervention|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
11348457|NCT02378298|Active Comparator|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
11348458|NCT02378285|Active Comparator|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
11348459|NCT02378285|Placebo Comparator|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
11348460|NCT02378272|Experimental|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
11348461|NCT02378272|No Intervention|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
11348462|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
11348463|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
11348464|NCT02378246|Experimental|Iodine containing multivitamin|multivitamin tablet containing 150 ug iodine, 1 tablet daily
11348465|NCT02378246|Placebo Comparator|Placebo: non-iodine containing multivitamin|non-iodine containing multivitamin, 1 tablet daily
11348466|NCT02378233|Experimental|iodine|"iodine containing multivitamin
~150 ug, 1 tablet daily"
11348467|NCT02378233|Placebo Comparator|placebo|placebo, 1 tablet Daily of a non-iodine containing multivitamin
11348468|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
11348469|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
11348470|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
11348471|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
11348472|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
11348473|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
11348474|NCT02378194|Placebo Comparator|Placebo group|
11348475|NCT02378194|Experimental|HD-003 (800mg/day)|
11348476|NCT02378194|Experimental|HD-003 (1600mg/day)|
11348477|NCT02378181|Experimental|Toolkit (TK)|Patients in the TK condition will receive counseling sessions from participating counselors who have been trained to use the Health Education Toolkit (TK).
11348478|NCT02378181|Active Comparator|Treatment-as-usual (TAU)|Patients in the treatment-as-usual (TAU) condition will receive the same number of counseling sessions as patients in the TK condition from participating counselors who have not been trained to use the Health Education Toolkit. Counselors working with patients in this condition will receive a control training of the same length and intensity on recovery topics that are covered in the Health Education Toolkit, but will not be equipped with the Toolkit.
11348479|NCT02378168||cohort of RCT (StV 5-2007; NCT00924222)|Patient group with either sevoflurane or propofol sedation of the RCT (StV 5-2007; NCT00924222)
11348480|NCT02378155|Other|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
11348481|NCT02378155|Other|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
11348482|NCT02378142|Experimental|Arm 1|Pazopanib 800mg oral daily
11348483|NCT02378129|Experimental|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
11348484|NCT02378129|Active Comparator|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
11348485|NCT02378116|No Intervention|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
11348486|NCT02378116|Active Comparator|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
11348552|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
11348487|NCT02378103||Case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. Simple aortic aneurysm and pseudoaneurysm were excluded. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
11348488|NCT02378103||Control|As the control group, patients without AD were obtained from the hospitalized patients in the same period.
11348489|NCT02378077|Experimental|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
11348490|NCT02378077|Experimental|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
11348491|NCT02378064|Experimental|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
11348492|NCT02378064|Experimental|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
11348493|NCT02378064|Active Comparator|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
11348494|NCT02378064|Active Comparator|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
11348495|NCT02378051|Experimental|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
11348496|NCT02378051|Placebo Comparator|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
11348497|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
11348498|NCT02378025|Experimental|Yoga Group|Postures, meditation, breathing exercises
11348499|NCT02378025|Active Comparator|Pain Management Wellness Group|Behavioral medicine
11348500|NCT02378012|Active Comparator|GROUP A (participants provide own computer or tablet device)|A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
11348501|NCT02378012|Experimental|GROUP B (Apple BuckiPad)|Participants receive an iPad for days -5 to 10. Participants also receive the BuckiPad manual for instructions on how to use the iPad and Netflix, Skype, and Spotify applications. Participants are also directed to the official Apple's iPad user's manual on their device and have questions answered by research personnel on day -5.
11348502|NCT02378012|No Intervention|GROUP C (no intervention)|Participants do not receive an iPad for days -5 to 10.
11348503|NCT02377999|Experimental|Treatment of genetial warts with Picato|
11348504|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
11348505|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
11348506|NCT02377960|Active Comparator|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
11348507|NCT02377960|Experimental|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive
~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
11348508|NCT02377960|Experimental|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.
~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
11348509|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
11348510|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
11348511|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
11348512|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
11348513|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
11348514|NCT02377856|Active Comparator|intervention|40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'
11348515|NCT02377856|No Intervention|observation|40 patients without treatment will be followed for the clinical course for 1.5 year
11348516|NCT02377843|Experimental|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
11348517|NCT02377843|Experimental|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
11348553|NCT02377583||Diabetic children|"physical examination
~Glucocorticoid sensitivity index
~DNA sample
~Anxiety and depression questionnaires
~depression questionnaire
~MRI"
11348518|NCT02377843|No Intervention|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
11348519|NCT02377830|Experimental|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
11348520|NCT02377830|Active Comparator|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
11348521|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
11348522|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
11348523|NCT02377804|Experimental|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
11348524|NCT02377804|Active Comparator|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
11348525|NCT02377778|Experimental|Propofol|In this arm patients will be receiving propofol for anaesthesia at doses 3-5mg depending on the time needed to complete oocyte retrieval
11348526|NCT02377778|Active Comparator|Thiopental|In this arm patients will receive thiopental for anaesthesia at doses 7mg and a repeat dose of 2-3mg depending on the time needed to completed oocyte retrieval
11348527|NCT02377765|Active Comparator|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
11348528|NCT02377765|Experimental|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
11348529|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m^2) of doxorubicin on Day 1, Day 2, and Day 3 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11348530|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|olaratumab administered IV on Day 1 and Day 8, and 75 mg/m^2 of doxorubicin administered IV on Day 1 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met
11348531|NCT02377752|Experimental|Part A cohort 3 Olaratumab + Doxorubicin|olaratumab administered IV on Day 1 and Day 8, and 75 mg/m^2 of doxorubicin administered IV on Day 1 of every 21-day cycle. Olaratumab doses in cycle 1 are higher than doses in the following cycles (loading dose in cycle 1). Participants may continue to receive treatment until discontinuation criteria are met
11348532|NCT02377752|Experimental|Part B: Olaratumab|olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met
11348533|NCT02377739|Experimental|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
11348534|NCT02377726|Experimental|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
11348535|NCT02377726|Experimental|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
11348536|NCT02377726|Active Comparator|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
11348537|NCT02377713|Experimental|KHK6640|KHK6640
11348538|NCT02377713|Placebo Comparator|Placebo|Placebo
11348539|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
11348540|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
11348541|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
11348542|NCT02377661|No Intervention|Standard Care|Treatment of hypertension according to current guidelines
11348543|NCT02377661|Experimental|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
11348544|NCT02377648|Experimental|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
11348545|NCT02377635|Experimental|Treatment|Drug: Anhydrous selenite (Se-77), single dose 0.8mg, orally administered as a 100 ml purified water solution
11348546|NCT02377635|Placebo Comparator|Control|Drug: Placebo sodium chloride (table salt), orally administered as a 100 ml purified water solution
11348547|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
11348548|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
11348549|NCT02377622|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
11348550|NCT02377622|Active Comparator|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
11348551|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
11348554|NCT02377583||Controls|"physical examination
~Glucocorticoid sensitivity index
~DNA sample
~Anxiety and depression questionnaires
~depression questionnaire
~MRI
~Laboratory tests"
11348555|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
11348556|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
11348557|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
11348558|NCT02377570|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
11348559|NCT02377544|Placebo Comparator|Placebo|Saccharum lactis
11348560|NCT02377544|Experimental|Probiotic|Bifidobacterium animalis lactis
11348561|NCT02377531|Other|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
11348562|NCT02377531|Other|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
11348563|NCT02377518|Experimental|oncologic patients|"Prediction of postoperative pulmonary function.
~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
11348564|NCT02377518|Experimental|lung transplant recipients|"Detection of BOS
~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
11348565|NCT02377505|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
11348566|NCT02377505|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
11348567|NCT02377492|Experimental|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
11348568|NCT02377492|Active Comparator|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
11348569|NCT02377479|Active Comparator|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
11348570|NCT02377479|Active Comparator|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
11348571|NCT02377479|Experimental|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
11348572|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
11348573|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
11348574|NCT02377453||Control|Control: Healthy adult
11348575|NCT02377453||Experimental|Experimental: patients with stroke
11348576|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
11348577|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
11348578|NCT02377414|Experimental|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
11348579|NCT02377414|Experimental|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
11348580|NCT02377401|Experimental|Zanamivir 300 mg|Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour [mL/hr]).
11348581|NCT02377401|Experimental|Zanamivir 600 mg|Subjects will receive a single dose of IV zanamivir 600 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will be receive IV zanamivir 600 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 mL/hr).
11348582|NCT02377388|Active Comparator|treatment: DPP4 -i|"Use of DPP4-i :
~sitagliptin 50 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 100 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)
~OR
~saxagliptin 2,5 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 5 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)"
11348583|NCT02377388|Placebo Comparator|control|placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD
11348584|NCT02377375|Experimental|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
11348585|NCT02377375|Active Comparator|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
11348586|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
11348587|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
11348588|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
11348589|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
11348590|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
11348591|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
11348592|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
11348593|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
11348594|NCT02377336|Experimental|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
11348595|NCT02377336|Placebo Comparator|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
11348596|NCT02377323|Other|Treatment with Rebif|Patients treated with Rebif only, for at least two years, and for up to 18 years
11348597|NCT02377323|Other|Never treated|Patients never treated with a disease-modifying drug (DMD)
11348598|NCT02377310||All patients|All patients will undergo coronary physiological study with measurement of resting Pd/Pa, iFR™, hyperaemic iFR and FFR.
11348599|NCT02377297|Active Comparator|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
11348600|NCT02377297|Experimental|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
11348601|NCT02377297|Experimental|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
11348602|NCT02377284|Experimental|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
11348603|NCT02377284|No Intervention|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
11348604|NCT02377271|Experimental|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
11348605|NCT02377271|Placebo Comparator|Placebo|placebo drug , twice a day, during eight weeks
11348606|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
11348607|NCT02377258||2|with on-going anti-TNF monotherapy
11348608|NCT02377258||3|with thiopurines monotherapy
11348609|NCT02377258||4|with on-going combination therapy
11348610|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
11348611|NCT02377258||6|patients on ustekinumab (alone or on combination therapy)
11348612|NCT02377245||Juvenile Inflammatory Rheumatism|Juvenile Inflammatory Rheumatism patients
11348613|NCT02377232|Active Comparator|Usual Care Outreach for Colon Cancer Screening|Receives standard of care outreach concerning colon cancer screening.
11348614|NCT02377232|Active Comparator|Decision Aid for Colon Cancer Screening|Receives colon cancer screening decision aid intervention in addition to outreach.
11348615|NCT02377219|Experimental|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
11348616|NCT02377206|Experimental|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714
11348617|NCT02377193|Experimental|Simulect|Simulect IV 40 mg D0 and D4
11348618|NCT02377193|Active Comparator|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
11348619|NCT02377180|Experimental|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
11348620|NCT02377180|Active Comparator|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
11348621|NCT02377180|Active Comparator|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
11348622|NCT02377167|Experimental|Early Tracheostomy|"Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 5 days from intubation.
~Intervention: Procedure: Early Tracheostomy"
11348623|NCT02377167|Active Comparator|Prolonged Intubation|"Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy after intubation day 10.
~Intervention: Procedure: Late Tracheostomy"
11348624|NCT02377154|Other|Opthalmologically healthy individuals|Slit lamp, Autorefractor, IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
11348625|NCT02377141|Active Comparator|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
11348626|NCT02377141|Active Comparator|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
11348627|NCT02377128|Experimental|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
11348628|NCT02377128|Active Comparator|Tubal ligation|Cesarean section with tubal ligation
11348629|NCT02377128|No Intervention|No intervention|Cesarean section with no additional intervention
11348630|NCT02377115|Other|Study cohort|Tablet computer application
11348631|NCT02377102|No Intervention|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
11348632|NCT02377102|Active Comparator|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
11348633|NCT02377089|Sham Comparator|Sham|The stimulators are the same device for the active and sham treatment conditions.
11348634|NCT02377089|Active Comparator|Active|The stimulators are the same device for the active and sham treatment conditions.
11348635|NCT02377076|Experimental|DAIRY|Dietary calcium supplementation
11348636|NCT02377076|Placebo Comparator|CONTROL|Control
11348637|NCT02377063|Other|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
11348638|NCT02377050|Active Comparator|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
11348639|NCT02377050|No Intervention|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
11348640|NCT02377037|Experimental|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
11348641|NCT02377037|Experimental|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
11348642|NCT02377037|Experimental|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
11348643|NCT02377024|Experimental|TF 600mg|TF 600mg/day
11348644|NCT02377024|Experimental|TF 1200mg|TF 1200mg/day
11348645|NCT02377024|Placebo Comparator|placebo|placebo
11348646|NCT02377011|Experimental|PS CBT|"Problem solving cognitive behaviour therapy (PS CBT) will be delivered remotely by means of telephone or video calling by a cognitive behaviour therapist in addition to their usual care.
~The duration of the intervention will be 10 sessions. Research measures will be completed at baseline, 3,6,9 and 12 months"
11348647|NCT02377011|No Intervention|Treatment as Usual|Participants will not receive any CBT therapy in addition to their usual care. Research measures will be completed at baseline,3,6,9 and 12 months.
11348648|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
11348649|NCT02376985|Placebo Comparator|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.
~Oral treatment:
~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
11348650|NCT02376985|Experimental|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.
~Oral treatment:
~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.
~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
11348651|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
11348652|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
11348653|NCT02376972|Placebo Comparator|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
11348654|NCT02376972|Active Comparator|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
11348655|NCT02376959|Placebo Comparator|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
11348656|NCT02376959|Active Comparator|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
11348657|NCT02376946|Active Comparator|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
11348658|NCT02376946|Placebo Comparator|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
11348659|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
11348660|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
11348661|NCT02376881|Experimental|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
11348662|NCT02376881|Placebo Comparator|control group|100 ml normal saline in 2 hr for 3 successive days
11348663|NCT02376868|Other|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
11348664|NCT02376868|Other|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
11348665|NCT02376868|Other|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
11348666|NCT02376855|No Intervention|Control|Providers in the Control group followed standard care protocols. If they deemed a patient was in need of cardiology consultation, a referral was created using the standard process. The referral was processed by a referral coordinator and transmitted to an appropriate cardiologist. An appointment was then scheduled for the patient to have an in-person consultation with a cardiologist.
11348667|NCT02376855|Experimental|eConsult|"The intervention consisted of an eConsult pathway and standardized protocol for PCPs to obtain cardiology consults using a secure messaging peer to peer (P2P) module embedded within the EHR. Intervention providers were asked to send all cardiology referrals for their adult patients through the eConsult system. Providers could bypass the eConsult pathway for patients with established relationships with a cardiologist or for whom providers felt a consult was urgent (required a face-to-face visit within a week or less). eConsults contain reason for consult, relevant test results, records or reports but are sent electronically to a Cardiology Consultant for review. eConsults were responded to within two business days. Responses were case-specific and generally contained recommendations for management, additional testing, or a face-to-face cardiology visit. The PCP was responsible for considering/acting upon recommendations and determining when an eConsult was complete."
11348668|NCT02376842|Active Comparator|Severe sepsis early warning best practice alert|Patients in this arm will actively generate the alert.
11348669|NCT02376842|Placebo Comparator|Standard care|This arm will be the current standard of care and will not generate the alert.
11348670|NCT02376829|Experimental|The Invisalign System|Class II correction of malocclusions
11348671|NCT02376816|Experimental|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
11348672|NCT02376816|Experimental|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
11348673|NCT02376803|Experimental|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
11348674|NCT02376803|Active Comparator|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
11348675|NCT02376790|Active Comparator|Methotrexate Monotherapy|Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
11348676|NCT02376790|Experimental|Etanercept Monotherapy|Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
11348677|NCT02376790|Experimental|Methotrexate + Etanercept|Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.
11348678|NCT02376777||Patient receiving NOAC|Follow up of patients receiving new oral anticoagulants (NOAC) medication
11348679|NCT02376777||Patient receiving VKA|Follow up of patients receiving vitamin K antagonist (VKA) medication
11348680|NCT02376725|Active Comparator|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
11348681|NCT02376725|Active Comparator|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
11348682|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:
~Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.
~AKI recovery in less than 72 hours after AKI identification.
~Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
11348683|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:
~Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.
~AKI persistence 72 hours after AKI identification.
~Normal or increased renal blood flow measured by TEE."
11348684|NCT02376699|Experimental|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
11348685|NCT02376699|Experimental|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
11348686|NCT02376699|Experimental|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
11348687|NCT02376699|Experimental|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
11348688|NCT02376699|Experimental|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
11348689|NCT02376699|Experimental|Combination Therapy in Pancreatic Cancer|SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel
11348690|NCT02376686|Experimental|Music intervention|Patient receives Music Intervention before going to sleep.
11348691|NCT02376686|No Intervention|treatment as usual|Patient receives Treatment as usual.
11348692|NCT02376673|Active Comparator|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
11348693|NCT02376673|Experimental|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
11348694|NCT02376660|Experimental|Oats|70 grams oats
11348695|NCT02376660|Placebo Comparator|usual diet and exercise|usual diet and exercise
11348696|NCT02376647|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
11348697|NCT02376647|Active Comparator|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
11348698|NCT02376634|Active Comparator|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
11348699|NCT02376634|No Intervention|Control|This group will receive the standard of care of Nationwide Children's Hospital.
11348700|NCT02376621|Active Comparator|PronovaPure 150:500 triglycerides|3 × PronovaPure 150:500 triglycerides (TG) European Union (EU)
11348702|NCT02376621|Active Comparator|Pronovum PRF-037|3 × Pronovum PRF-037
11348703|NCT02376621|Active Comparator|PronovaPure 500:200 TG|3 × PronovaPure 500:200 TG EU
11348704|NCT02376621|Active Comparator|Pronovum PRF-047|3 × Pronovum PRF-047
11348705|NCT02376608|Active Comparator|Pronova Pure 150:500 EE EU|2 × PronovaPure 150:500 EE EU
11348706|NCT02376608|Active Comparator|Pronovum PRF-037|2 × Pronovum PRF-037
11348707|NCT02376608|Active Comparator|Pronovum PRF-041|2 × Pronovum PRF-041
11348708|NCT02376608|Active Comparator|Eskimo-3|3 × Eskimo-3
11348709|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
11348710|NCT02376582|Experimental|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
11348711|NCT02376582|Active Comparator|Vaccination without S. mansoni infection|DNA Protein
11348712|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
11348713|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
11348714|NCT02376543|Active Comparator|19 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
11348715|NCT02376543|Active Comparator|22 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
11348716|NCT02376530|No Intervention|Usual shopping|No change in condition.
11348717|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
11348718|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
11348719|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
11348720|NCT02376517|Active Comparator|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
11348721|NCT02376517|No Intervention|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
11348722|NCT02376504|Experimental|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
11348723|NCT02376504|Experimental|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
11348724|NCT02376504|No Intervention|Control|Participants will be asked to engage in three 10 min walking bouts each work day
11348725|NCT02376491|Active Comparator|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
11348726|NCT02376491|Experimental|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
11348727|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
11348728|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
11348729|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
11348730|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
11348731|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
11348732|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
11348733|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
11348734|NCT02376452|Experimental|RALIRI|Raltitrexed combined with irinotecan
11348735|NCT02376452|Placebo Comparator|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
11348736|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
11348737|NCT02376426|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
11348738|NCT02376426|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
11348739|NCT02376426|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
11348740|NCT02376426|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
11348741|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
11348742|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.
~Superior pedicle mammoplasty / inverted T
~Superior pedicle mammoplasty / V scar
~Batwing
~Inferior pedicle mammoplasty
~Racquet mammoplasty/radial scar
~vertical-scar mammoplasty"
11348743|NCT02376400|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
11348744|NCT02376400|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
11348745|NCT02376400|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
11348746|NCT02376400|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
11348747|NCT02376374|Experimental|10% OPV|In this arm, 10% of the households in this community will receive OPV.
11348748|NCT02376374|Experimental|30% OPV|In this arm, 30% of the households in this community will receive OPV.
11348749|NCT02376374|Experimental|70% OPV|In this arm, 70% of the households in this community will receive OPV.
11348750|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
11348751|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
11348752|NCT02376348|No Intervention|Control|Individuals receiving the standard Ministry of Health Package
11348753|NCT02376348|Experimental|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
11348754|NCT02376335|Active Comparator|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
11348755|NCT02376335|Placebo Comparator|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
11348756|NCT02376322|Experimental|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
11348757|NCT02376309|Experimental|Leu during inactivity|Leucine supplements
11348758|NCT02376309|Experimental|ND during inactivity|Nandrolone injection
11348759|NCT02376296||hormone naïve|Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.
11348760|NCT02376296||castrate resistant|Subjects with castrate resistant prostate cancer (CRPC) [defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.
11348761|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
11348762|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
11348763|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
11348764|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
11348765|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
11348766|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
11348767|NCT02376270|Experimental|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
11348768|NCT02376270|Placebo Comparator|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
11348769|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
11348770|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
11348771|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
11348772|NCT02376244|Experimental|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.
~Patients will exercise once a week for 8 weeks."
11348773|NCT02376244|Active Comparator|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.
~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.
~Patients will exercise once a week for 8 weeks."
11348774|NCT02376231|No Intervention|Standard Surgery without trial (PJ) device|Standard debulking surgery for EOC without interventional device
11348775|NCT02376231|Active Comparator|Surgery with trial (PJ) device|Debulking surgery for EOC with interventional trial device (PJ)
11348776|NCT02376218|Experimental|Hypertonic 50% dextrose pleurodesis|
11348777|NCT02376205|Experimental|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
11348778|NCT02376205|Placebo Comparator|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
11348779|NCT02376192|Experimental|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
11348817|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
11348818|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
11420989|NCT01895348|Active Comparator|dexmedetomidine-remifentanil|
11348780|NCT02376192|Experimental|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
11348781|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
11348782|NCT02376166|Experimental|Metformin|850 mg PO once daily for 4 weeks
11348783|NCT02376153|Experimental|ABS deployed and active|Air Barrier System (ABS) will be deployed onto the surgical field and activated.
11348784|NCT02376153|Sham Comparator|ABS deployed and NOT active|Air Barrier System (ABS) will be deployed onto the surgical field and NOT activated. This is a sham comparator to reduce the influence of the presence of the device and provide user blinding.
11348785|NCT02376140||Women|Mothers of children 36-59 months old No intervention
11348786|NCT02376140||Children|Children 36-59 months old No intervention
11348787|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
11348788|NCT02376114|Other|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
11348789|NCT02376114|Other|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
11348790|NCT02376101|Active Comparator|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
11348791|NCT02376101|Experimental|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
11348792|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
11348793|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
11348794|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
11348795|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
11348796|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
11348797|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
11348798|NCT02376088||NC|age-matched healthy checkup subjects
11348799|NCT02376075|Placebo Comparator|Placebo|Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment
11348800|NCT02376075|Active Comparator|Linagliptin|Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment
11348801|NCT02376062|Experimental|Bundled Intervention|"On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu
~Weekly case conferences
~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
11348802|NCT02376049|Active Comparator|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
11348803|NCT02376049|Active Comparator|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
11348804|NCT02376049|Active Comparator|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
11348805|NCT02376049|Placebo Comparator|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
11348806|NCT02376036|Experimental|MGD010|Subjects will receive MGD010 through IV infusion.
11348807|NCT02376036|Placebo Comparator|Placebo|Subjects will receive placebo through IV infusion.
11348808|NCT02376036|Experimental|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
11348809|NCT02376036|Placebo Comparator|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
11348810|NCT02376023|Experimental|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
11348811|NCT02376023|No Intervention|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
11348812|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
11348813|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
11348814|NCT02375997|Experimental|Standard oncology care plus palliative care|
11348815|NCT02375997|No Intervention|Standard oncology care|
11348816|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
11348847|NCT02375763|Placebo Comparator|Traditional suggestions|
11348819|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
11348820|NCT02375958|Experimental|Triple Negative Breast Cancer|
11348821|NCT02375958|Experimental|Head and Neck Cancer|
11348822|NCT02375958|Experimental|Esophageal Cancer|
11348823|NCT02375945|Active Comparator|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
11348824|NCT02375945|Experimental|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.
~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.
~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
11348825|NCT02375932|Experimental|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
11348826|NCT02375932|Active Comparator|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
11348827|NCT02375919|No Intervention|Control|Emergency physician will assess low risk patients for PE with conventional strategy, using D-Dimer testing with subsequent CTPA if positive
11348828|NCT02375919|Other|Intervention|PERC based Strategy : Emergency physician will assess low risk patients for PE first with calculation of PERC score. If all PERC criteria are negative, then no further testing for PE is recommended. If at least one criterion is positive, then the patient undergoes D-Dimer testing with subsequent CTPA if positive
11348829|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
11348830|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
11348831|NCT02375880|Experimental|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
11348832|NCT02375880|Experimental|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
11348833|NCT02375880|Experimental|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
11348834|NCT02375867|Active Comparator|prednisolone|This group includes patients with FHF without encephalopathy
11348835|NCT02375867|Active Comparator|methylprednisolone|This group includes patients with FHF with encephalopathy
11348836|NCT02375867|No Intervention|Non-intervention|FHF patients without any of the proposed intervention as controls
11348837|NCT02375854||Preterm infants|Less than 32 weeks' gestation
11348838|NCT02375841||Physicians, Patients, and Caregivers|This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
11348839|NCT02375828|Experimental|Patients with neonatal diabetes|Patients with neonatal diabetes
11348840|NCT02375815|Experimental|Statin Choice Implementation|
11348841|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
11348842|NCT02375789|Active Comparator|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.
~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.
~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.
~The patient remains in the trial until two separate migraines have been treated."
11348843|NCT02375789|Placebo Comparator|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.
~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.
~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.
~The patient remains in the trial until two separate migraines have been treated."
11348844|NCT02375776|Experimental|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
11348845|NCT02375776|No Intervention|Control|Usual Care - The control group will not use the study's mobile health application during the study.
11348846|NCT02375763|Experimental|Sortware suggestions|Children will fill a questionnaire regarding their dietary habits. Afterwards a dietary analysis will be performed using a computer software, and dietary instructions will be given to the children.
11348848|NCT02375750|Experimental|GBO and GBG|0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
11348849|NCT02375750|Active Comparator|Standard treatment|Decontamination of surface of implant
11348850|NCT02375737|Experimental|m-health|Patients will receive text message, emails, and monthly phone calls
11348851|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
11348852|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
11348853|NCT02375711|Experimental|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
11348854|NCT02375698|Experimental|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
11348855|NCT02375698|Placebo Comparator|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
11348856|NCT02375685|Experimental|gevokizumab|
11348857|NCT02375672|Experimental|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:
~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
11348858|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
11348859|NCT02375646|Experimental|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
11348860|NCT02375646|Active Comparator|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
11348861|NCT02375633|Experimental|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
11348862|NCT02375633|Active Comparator|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
11348863|NCT02375620|Experimental|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
11348864|NCT02375620|Experimental|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
11348865|NCT02375607|Other|Algometer|Algometer used patients
11348866|NCT02375594|Experimental|Exercise in park equipment|Participants in the intervention arm will attend a 3-month long program of 2 weekly one-hour exercise sessions in the exercise park equipment, guided by a physical therapist. The sessions will comprise a combination of aerobic, strength, balance and flexibility exercises. Up to 20 participants exercising simultaneously in the equipment under the guidance of an experienced LAPPSET physical therapist.
11348867|NCT02375594|No Intervention|Control|Participants in the control arm will receive usual advice on healthy habits. During the study, they will be offered to attend the talks on healthy living for elderly periodically organised by their primary care centre (CAP Vallcarca - Sant Gervasi). At the end of the study, they will be invited to an exercise session at the exercise park equipment, conducted by the study physical therapist.
11348868|NCT02375581|Experimental|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
11348869|NCT02375581|Active Comparator|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
11348870|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
11348871|NCT02375555|Experimental|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.
~Elotuzumab will be administered by intravenous (IV) infusion
~Bortezomib as a subcutaneous injection
~Lenalidomide single daily oral dose
~Dexamethasone as oral tablets and IV infusion
~Stem cell mobilization will be performed for all subjects at the end of Cycle 4.
~Subjects may elect to stop E-RVD Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive 8 cycles of induction therapy.
~- The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.
~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
11348872|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
11348873|NCT02375529|Experimental|Single Incision Cholesystectomy (SILC)|Single Incision Laparoscopic Cholecystectomy (SILC): The umbilicus is grasped and a 2 cm vertical skin and fascial incision is performed. A multiport (TriPort®) is inserted under direct vision. Principles of cholecystectomy are the same as traditional laparoscopic cholecystectomy.
11348874|NCT02375529|Active Comparator|Four Ports Cholecystectomy (4PCL)|Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
11348875|NCT02375516|Experimental|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions.
11348876|NCT02375516|No Intervention|Control group|Youths assigned to the control arm will receive no intervention.
11348877|NCT02375503|Experimental|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
11348878|NCT02375503|Placebo Comparator|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
11348879|NCT02375490|Experimental|Intervention arm|The intervention arm will participate in Healthy Start.
11348880|NCT02375490|No Intervention|Control arm|Control arm will pursue daily activities at early childcare center as usual.
11348881|NCT02375477|Experimental|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
11421133|NCT01894412|Active Comparator|Enbrel|prefilled syringe
11348882|NCT02375451||Radioiodine|Patients with a history of childhood treatment with radioiodine will be assessed for symptoms of salivary function and measurement of saliva production. These data will be compared to a normal control group.
11348883|NCT02375451||Control|Patients who are similar in age to those in the Radioiodine group, but who did not recieve I-131 therapy.
11348884|NCT02375438||Cohort Group|Patients with a clinical presentation suggestive of mitochondrial cytopathy, in whom mitochondrial deletions above 20% have been found in muscle are considered eligible if they are older than 18 years and are willing and able to give written informed consent.
11348885|NCT02375438||Control Group|Twenty healthy individuals matched for age and gender will be included in the study and considered as controls.
11348886|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
11348887|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
11348888|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
11348889|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
11348890|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
11348891|NCT02375386|Experimental|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
11348892|NCT02375386|Sham Comparator|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
11348893|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
11348894|NCT02375360||Children 8-12- control|Children aged 8-12 years with food allergy who are not undergoing oral immunoterapy
11348895|NCT02375360||Parents 0-12 - control|Parents to children aged 0-12 years with food allergy who are not undergoing oral immunoterapy
11348896|NCT02375360||Children 8-12 - OIT|Children aged 8-12 years with food allergy who are undergoing oral immunoterapy
11348897|NCT02375360||Teenagers 13-17 - OIT|Teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
11348898|NCT02375360||Adults >18 - OIT|Adults> 18 years with food allergy who are undergoing oral immunoterapy
11348899|NCT02375360||Parents 0-12 - OIT|Parents to children aged 0-12 years with food allergy who are undergoing oral immunoterapy
11348900|NCT02375360||Parents 13-17 - OIT|Parents to teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
11348901|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
11348902|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
11348903|NCT02375321|Experimental|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
11348904|NCT02375321|No Intervention|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
11348905|NCT02375308|Experimental|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
11348906|NCT02375308|Experimental|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
11348907|NCT02375295|Experimental|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
11348908|NCT02375295|Active Comparator|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
11348909|NCT02375282|Experimental|Ambulation Orderly Intervention|Patients that are in this group are those randomized to receive visits from the ambulation orderly (ambulation group). The patients in this group will receive the visits from the ambulation orderly in addition to the standard of care that occurs with the rest of the hospital and with the control group.
11348910|NCT02375282|No Intervention|Control Group|This is for the patients who are randomized to receive the standard care of Baystate Medical Center. The standard of care will be nurse-directed ambulation, as is currently done in all other nursing floors at Baystate Medical Center. Nurses will be instructed to walk with the patients as they did before the initiation of the ambulation orderly and as they do when the orderly is on vacation, at conferences, training, or away for illness. These patients will not receive visits from the ambulation orderly.
11348911|NCT02375269|Experimental|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
11348912|NCT02375269|No Intervention|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
11348913|NCT02375256|Experimental|AERAS-402|3 x10^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
11348914|NCT02375256|Active Comparator|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
11348915|NCT02375243|Experimental|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
11348916|NCT02375243|No Intervention|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
11348917|NCT02375230|Placebo Comparator|Control|"Control group
~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
11348918|NCT02375230|Active Comparator|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.
~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
11348919|NCT02375217|Active Comparator|Group 1 : (NS)|"Group 1 Drug combination:
~patients receive half of the recommended dose of sugammadex plus dose of neostigmine
~Sugammadex IV= -1 mg/kg( moderate NMB) or
~2 mg/kg (deep NMB)
~neostigmine IV = 50mcg/kg
~glycopyrrolate 10 mcg/kg"
11348920|NCT02375217|Active Comparator|Group 2 : (S)|"patients receive Full recommended dose of sugammadex
~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)"
11348921|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.
~Cycles 1-4 (1 cycle = 21 days)
~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)
~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol
~cisplatin 25 mg/m^2 IV daily on Days 2-5
~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18
~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
11348922|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.
~Cycles 1-2 (1 cycle = 14 days)
~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)
~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol
~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)
~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1
~Cycles 3-5 (1 cycle = 21 days)
~carboplatin daily on Days 1-3
~etoposide 400 mg/m^2 daily on Days 1-3
~stem cell reinfusion on day 5
~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15
~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
11348923|NCT02375191|Active Comparator|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
11348924|NCT02375191|Experimental|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
11348925|NCT02375178|Active Comparator|Sterile saline solution|sterile Saline solution 0,9%
11348926|NCT02375178|Experimental|chlorhexidine|chlorhexidine 0,12% mouthwash
11348927|NCT02375178|Experimental|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
11348928|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.
11348929|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
11348930|NCT02375152|Experimental|Surgical Intervention|
11348931|NCT02375139|Experimental|DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
11348932|NCT02375139|Experimental|E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
11348933|NCT02375126||Ages 18-35, no antidepressant use|Ages 18-35, up to 15 males and 15 females, no antidepressant use
11348934|NCT02375126||Ages 36-55, no antidepressant use|Ages 36-55, up to 15 males and 15 females, no antidepressant use
11348935|NCT02375126||Ages 18-55, with antidepressant use|Ages 18-55, up to 10 males and 10 females, taking antidepressants
11348936|NCT02375113|Experimental|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
11348937|NCT02375113|Placebo Comparator|Control|Placebo capsules + 25 gram whey protein / day
11348938|NCT02375100|Active Comparator|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
11348939|NCT02375100|Experimental|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
11348940|NCT02375100|Experimental|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
11348941|NCT02375074|Experimental|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
11348942|NCT02375074|Experimental|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
11348978|NCT02374814|Experimental|Rabies vaccine ID 2 dose|This is using alternative dose schedule and administration
11348979|NCT02374814|Placebo Comparator|Placebo IM 1 dose|Albumin and saline comparator
11348980|NCT02374814|Placebo Comparator|Placebo ID 1 dose|Albumin and saline comparator
11349043|NCT02374385|Placebo Comparator|Group 4|Group 4 will receive placebo (normal saline).
11348943|NCT02375061|Experimental|e-BPS intervention|"Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously."
11348944|NCT02375061|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
11348945|NCT02375048|Active Comparator|Hypofractionated WBI|Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).
11348946|NCT02375048|Experimental|Accelerated Partial Breast Irradiation|Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).
11348947|NCT02375022|Experimental|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
11348948|NCT02375009|Experimental|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
11348949|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
11348950|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
11348951|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
11348952|NCT02374983||Research group|The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
11348953|NCT02374970|Experimental|Intervention group|Actual Lumbar stability exercises involving co-contraction of the transversus abdominis and Protocolized Physiotherapy (therapeutic exercises and thermotherapy during 12 sessions)
11348954|NCT02374970|Active Comparator|Control group|Protocolized Physiotherapy treatment: therapeutic exercises and thermotherapy during 12 sessions.
11348955|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
11348956|NCT02374957|No Intervention|Control|No Cilostazol
11348957|NCT02374944|Experimental|Hardware Removal|Removal of hardware at 6 months.
11348958|NCT02374944|No Intervention|Hardware Retention|Retention of hardware at 6 months
11348959|NCT02374931|Experimental|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
11348960|NCT02374918|Experimental|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
11348961|NCT02374918|Placebo Comparator|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
11348962|NCT02374918|Experimental|HC wavelength-1 bright light|30 minutes of light exposure
11348963|NCT02374918|Placebo Comparator|HC wavelength-2 bright light|30 minutes of light exposure
11348964|NCT02374905|Experimental|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
11348965|NCT02374905|Active Comparator|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
11348966|NCT02374892|Experimental|Intervention|"Adolescents will attend a single one-on-one session with a nurse. Sessions will be youth-oriented, interactive, and engaging. They will make a health passport, go over their cardiac anatomy, watch videos among other things.
~The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up."
11348967|NCT02374892|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
11348968|NCT02374879|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
11348969|NCT02374866|No Intervention|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
11348970|NCT02374866|Experimental|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.
~Follow by email or mail is identical to the control group."
11348971|NCT02374853|Experimental|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
11348972|NCT02374853|Placebo Comparator|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
11348973|NCT02374827|Active Comparator|Standard postpartum tubal ligation|In this arm, patients will receive the standard postpartum tubal ligation by accepted methods (procedure names are the following: Modified pomeroy technique or Parkland method). These methods are procedures for completing a partial salpingectomy.
11348974|NCT02374827|Experimental|Complete Salpingectomy|In this arm, patients will receive a complete salpingectomy by documented accepted methods.
11348975|NCT02374814|Active Comparator|Rabies vaccine IM 3 dose|This is standard FDA approved schedule
11348976|NCT02374814|Experimental|Rabies vaccine ID 3 dose|This is using alternative administration method
11348977|NCT02374814|Experimental|Rabies vaccine IM 2 dose|This is using alternative dose schedule
11348981|NCT02374801|Experimental|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
11348982|NCT02374788|Experimental|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
11348983|NCT02374788|Experimental|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
11348984|NCT02374788|No Intervention|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
11348985|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
11348986|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
11348987|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
11348988|NCT02374749|Active Comparator|comorbidities|Evaluation of the prevalence and the presence of the risks factors of the four most frequently observed comorbidities in spondyloarthritis (cardiovascular diseases, cancers, infections osteoporosis and gastro-intestinal) as it is recommended by the French Society of Rheumatology.
11348989|NCT02374749|Active Comparator|self-assessment|"During the initial visit, the clinical research nurse exempt a learning program of assessment of disease activity/severity :
~for assessing the activity in SpA;
~for the calculation of BASDAI and the ASDAS-CRP
~for the transfer technique and for the calculation of the disease activity on a monthly basis during the next 12 months.
~for the risk of tobacco exposure
~for the benefit of an NSAID intake in case of painful episode of the disease
~for the benefit of home exercises
~for the spine and indication of a treatment under the supervision of a physiotherapist in case of severe disease
~for learning the patient to calculate his BASDAI and ASDAS-CRP Then, the patient will return home with his calculator and his notebook. Each month, the patient will be asked to perform the BASDAI and ASDAS-CRP calculations and to report the data on the notebook. 12 months later, the patient comes for a visit in the current practice to assess both such program and comorbidities."
11348990|NCT02374736|Experimental|Human normal immunoglobulin G (IgG > 98 % purity)|"All subjects will be treated for 6 months. The treatment will start the day of inclusion (M0).
~Privigen will be given as 2 g/kg for 2 days/month. The maximum daily dose authorized will be 80g.
~The infusion rates are the recommended rates for Privigen in other indications and are in line with the market authorization for Privigen:
~Infusions should start at a rate of 0.5 mg/kg/min (0.005 mL/kg/min; 0.3 mL/kg/h; 30 mg/kg/h). If well tolerated within 30 min, the rate can be increased in a first step to 1.0 mg/kg/min (0.01 mL/kg/min; 0.6 mL/kg/h; 60 mg/kg/h) for another 30 min.
~If well tolerated, a stepwise increase to a maximum of 8 mg/kg/min (0.08 mL/kg/min; 4.8 mL/kg/h; 480 mg/kg/h) is allowed at the discretion of the investigator."
11348991|NCT02374723|Experimental|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
11348992|NCT02374723|Active Comparator|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
11348993|NCT02374710|Experimental|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
11348994|NCT02374710|Active Comparator|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
11348995|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
11348996|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
11348997|NCT02374684|Experimental|Methosulide|Methosulide, oral administration
11348998|NCT02374684|Placebo Comparator|Placebo|Placebo, oral administration
11348999|NCT02374671|Experimental|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
11349000|NCT02374671|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
11349001|NCT02374671|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
11349002|NCT02374658|Experimental|Arts Intervention|This group will receive the weekly one-hour Living Through the Arts program in addition to their standard program of rehabilitation activities
11349003|NCT02374658|No Intervention|Control Group|This group of patients will only receive their standard program of rehabilitation activities
11349004|NCT02374645|Experimental|Volitinib (AZD6094) 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
11349005|NCT02374645|Experimental|Volitinib (AZD6094) 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
11349006|NCT02374632|Other|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) <50%.
~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
11349007|NCT02374632|Other|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) >70% matched with respect to age, gender and preoperative BMI in the LowEBL group.
~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
11349008|NCT02374619|Experimental|Iron supplement|Oral supplementation
11349009|NCT02374619|Placebo Comparator|Control|Oral supplementation
11349010|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
11349011|NCT02374567|Experimental|Psychiatric drugs|
11349012|NCT02374554|Other|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
11349013|NCT02374541|Experimental|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
11349014|NCT02374541|No Intervention|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
11349015|NCT02374528|Experimental|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
11349016|NCT02374528|Active Comparator|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
11349017|NCT02374515|Active Comparator|Endocuff assisted Colonoscopy|Endocuff assisted Colonoscopy
11349018|NCT02374515|Active Comparator|Standard Colonoscopy|Standard colonoscopy
11349019|NCT02374502|Experimental|Brief Intervention Group|Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
11349020|NCT02374502|No Intervention|Control Group|Participants in this control group will be asked to continue with their current levels of physical activity.
11349021|NCT02374489|Experimental|single-arm studies|"LDK378 in suitable patients:
~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
11349022|NCT02374476|Experimental|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
11349023|NCT02374463|Experimental|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
11349024|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention
11349025|NCT02374450||Active surveillance group and enhanced hospitalisation group|Children <18 months of age at time of enrolment and living in the HDSS area (active surveillance group) and children <5 years of age and hospitalised at any time during the study, living in the HDSS area (enhanced hospitalisation surveillance group).
11349026|NCT02374437|Active Comparator|PART A (single dose)-200 mg|200 mg ARAMCHOL
11349027|NCT02374437|Active Comparator|PART A (single dose)-400 mg|400 mg ARAMCHOL
11349028|NCT02374437|Active Comparator|Part B ( food effect)- -Fasting|600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
11349029|NCT02374437|Active Comparator|Part B ( food effect)- -Fed|600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)
11349030|NCT02374437|Active Comparator|Part C ( multiple doses)- 200 mg|200 mg Aramchol tablets for ten consecutive days.
11349031|NCT02374437|Active Comparator|Part C ( multiple doses)- 400 mg|400 mg Aramchol tablets for ten consecutive days.
11349032|NCT02374437|Active Comparator|Part C ( multiple doses)- 600 mg|600 mg Aramchol tablets for ten consecutive days.
11349033|NCT02374437|Placebo Comparator|Part C ( multiple doses)- Placebo|Placebo tablets for ten consecutive days.
11349034|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).
~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
11349035|NCT02374411||HIPEC surgeons|
11349036|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
11349037|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
11349038|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
11349039|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
11349040|NCT02374385|Experimental|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
11349041|NCT02374385|Experimental|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
11349042|NCT02374385|Experimental|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
11421594|NCT01891305|Experimental|VT-1161 200/50mg|
11349044|NCT02374372|Active Comparator|conventional hemodialysis|conventional hemodialysis
11349045|NCT02374372|Active Comparator|hemodiafiltration On-line|hemodiafiltration On-line
11349046|NCT02374359||atrial tachycardia group|Patients diagnosed of cryptogenic stroke with atrial tachycardia in holter
11349047|NCT02374359||Non atrial tachycardia group (control group)|Patients diagnosed of cryptogenic stroke with a normal holter
11349048|NCT02374333|Experimental|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
11349049|NCT02374320|Experimental|Exparel|20 mL liposomal bupivacaine injected once
11349050|NCT02374307|Experimental|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
11349051|NCT02374307|No Intervention|Control|The control group performs activities as usual.
11349052|NCT02374294|Experimental|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
11349053|NCT02374294|No Intervention|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
11349054|NCT02374281|Experimental|Glucose sucking|"The newborn will receive one minute before the painful care either a compress with sucrose.
~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
~Glucose 30% by oral route (1 ml)."
11349055|NCT02374281|Active Comparator|Water sucking|"The newborn will receive one minute before the painful care either a compress with water.
~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
~Sterile water by oral route (1 ml)."
11349056|NCT02374281|Placebo Comparator|No sucking|The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
11349057|NCT02374268|Experimental|Exercise program alone|There will be 2 site sessions and 1 home session per week for 12 weeks. Each site exercise session will begin and end with a 5-10 minute warm-up and cool-down routine. The first part of the exercise program consists of 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body. To target the development of muscle power in both the lower and upper extremities, participants will be instructed to perform each concentric movement 'as rapidly as possible,' and the eccentric movement in a slow and controlled manner. A 5-minute rest period will be given prior to the start of the second part of the exercise program that consists of aerobic exercises such as ball games using fitballs or Taichi. Participants will be asked to spend an hour/week on home exercise. Thera-Bands and a leaflet showing the exercise procedures will be given to them and their caregivers.
11349058|NCT02374268|Experimental|Exercise program plus nutrition supplement|This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.
11349059|NCT02374268|Other|Waitlist control group|This group will be asked to maintain their usual physical activities and dietary habits during the first 6 months of study period. After they complete the 24-week measurement, they will receive the same 12-week exercise program as of the exercise program alone group.
11349060|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
11349061|NCT02374255|No Intervention|Usual Care|
11349062|NCT02374242|Active Comparator|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
11349063|NCT02374242|Active Comparator|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
11349064|NCT02374242|Active Comparator|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
11349065|NCT02374229|Experimental|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.
~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.
~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.
~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
11349066|NCT02374229|Active Comparator|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.
~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
11349067|NCT02374216|Other|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
11349068|NCT02374203|Experimental|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
11349069|NCT02374190||Hospital Admitted STEMI Patients|The analytical cohort for this study consisted of STEMI patients aged over 18 years admitted directly to '24/7' PPCI-capable hospitals for PPCI. STEMI patients were identified based on their discharge diagnoses and were selected as having received PPCI according to their initial reperfusion strategy. Hospitals performing only sporadic PPCI procedures, which we defined as less than 20 procedures per year, and only performing PPCIs during regular hours were not included in the analysis. Interhospital transfers were not included in the analysis, and we limited our analysis to PPCIs conducted within 6 hours on hospital arrival on the assumption that patients with a DTB time beyond this did not receive PCI as a primary reperfusion strategy. The analysis was conducted for the time period for which data were available-1 January 2007 to 31 December 2012. We conducted a complete-case analysis.
11349070|NCT02374177||Propofol group|Patient anesthetized using propofol
11349071|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
11349072|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
11349073|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
11349074|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
11349075|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
11349076|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
11349077|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
11349078|NCT02374125|Experimental|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
11349079|NCT02374125|Experimental|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
11349080|NCT02374125|Active Comparator|Control Group|Protocolized physiotherapy
11349081|NCT02374112|Experimental|Experimental|Creatine supplementation
11349082|NCT02374112|Placebo Comparator|Control|Placebo supplementation
11349083|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
11349084|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
11349085|NCT02374086|Experimental|Exercise Training|Subjects will exercise for 8 weeks
11349086|NCT02374073|Experimental|Intervention group|Treated with protocolized physiotherapy and functional massage
11349087|NCT02374073|Experimental|Control group|Treated with protocolized physiotherapy
11349088|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0
~Second injection permitted at Week 8 IF:
~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
11349089|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0
~Second injection permitted at Week 8 IF:
~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
11349090|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0
~Second injection permitted at Week 12 IF:
~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
11349091|NCT02374047|Experimental|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
11349092|NCT02374047|Experimental|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
11349093|NCT02374047|Experimental|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
11349094|NCT02374047|Experimental|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
11349095|NCT02374047|Experimental|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
11349096|NCT02374047|Experimental|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
11349097|NCT02374047|Experimental|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
11349098|NCT02374047|Experimental|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
11349099|NCT02374047|Experimental|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
11349100|NCT02374047|Experimental|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
11349101|NCT02374047|Experimental|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
11349102|NCT02374047|Experimental|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
11349263|NCT02373007|Other|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
11349103|NCT02374034|Experimental|Treatment|Experimental group (n=20) completed a corrective exercise routine, as per the Egoscue Method, at least five days per week for two weeks.
11349104|NCT02374034|No Intervention|Control|The control group maintained their current lifestyle for the two-week duration of the study.
11349105|NCT02374021|Active Comparator|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
11349106|NCT02374021|Active Comparator|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
11349107|NCT02374008|Experimental|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
11349108|NCT02374008|Active Comparator|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
11349109|NCT02373995|Active Comparator|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
11349110|NCT02373995|Placebo Comparator|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
11349111|NCT02373956|Experimental|MELECTIS G|"In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.
~Intervention: Usual care Intervention: MELECTIS G"
11349112|NCT02373956|Active Comparator|Usual care|"Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
~Intervention: Usual care"
11349113|NCT02373943|Experimental|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
11349114|NCT02373943|Active Comparator|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
11349115|NCT02373943|Sham Comparator|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
11349116|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
11349117|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
11349118|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
11349119|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
11349120|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
11349121|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
11349122|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349123|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349124|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349125|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349126|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349127|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349128|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349129|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349130|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
11349131|NCT02373917||study group|patient who in the biopsy showed lung cancer
11349132|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
11349133|NCT02373904|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
11349134|NCT02373891|Experimental|T1|
11349135|NCT02373891|Experimental|T0|
11349136|NCT02373878|Active Comparator|Telecoaching plus plate|Telecoaching plus portion control plate
11349137|NCT02373878|Active Comparator|Usual Care|Usual Care
11349138|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
11349139|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
11349140|NCT02373839|Other|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
11349141|NCT02373839|No Intervention|Controls|induction of labour at 37 weeks of gestation.
11349142|NCT02373813|Experimental|etanercept monotherapy|etanercept for injection in pre-filled syringes with placebo for methotrexate
11349143|NCT02373813|Experimental|methotrexate monotherapy|Oral methotrexate with placebo for etanercept
11349144|NCT02373813|Experimental|etanercept plus methotrexate|etanercept for injection in pre-filled syringes and oral Methotrexate
11349145|NCT02373800||The study population|"The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.
~Intervention: Cervical ultrasound with elastography"
11349146|NCT02373787|Experimental|creos xenoprotect|resorbable collagen membrane
11349147|NCT02373787|Active Comparator|Bio-Gide|Bio-Gide, resorbable collagen membrane
11349148|NCT02373774|No Intervention|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
11349149|NCT02373774|Experimental|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
11349150|NCT02373748|Experimental|BioGaming YuGo System|
11349151|NCT02373735|Active Comparator|Group A (SVV <10% group)|"infuse crystalloid (Hartmann's solution) 6-10 ml/kg/hr continuously during surgery
~infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery
~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte)"
11349152|NCT02373735|Experimental|Group B (SVV 10-20% group)|"infuse crystalloid (Hartmann's solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
~infuse colloid (Volulyte) 200 ml if SVV is > 20%
~infuse mannitol 0.5 g/kg or lasix 5 mg if SVV < 10%
~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte), mannitol, lasix"
11349153|NCT02373722|Experimental|Group I (video, text message)|Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
11349154|NCT02373722|Experimental|Group II (educational video)|Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
11349155|NCT02373722|Experimental|Group III (text message)|Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
11349156|NCT02373722|Experimental|Group IV (control)|Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
11349157|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
11349158|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score < 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
11421595|NCT01891305|Experimental|VT-1161 600/150mg|
11349159|NCT02373683|Experimental|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
11349160|NCT02373683|No Intervention|Standard Care|Care dictated by clinical team.
11349161|NCT02373670|Experimental|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
11349162|NCT02373670|Active Comparator|Education|Community health workers providing health education to promote healthy behaviors
11349163|NCT02373657|Experimental|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
11349164|NCT02373657|No Intervention|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
11349165|NCT02373644|Experimental|HVLA Thrust Manipulation and DN|
11349166|NCT02373644|Active Comparator|Conventional Physical Therapy|
11349167|NCT02373631|Experimental|Dry Needling, Conventional PT|
11349168|NCT02373631|Active Comparator|Conventional PT|
11349169|NCT02373618|Experimental|Experimental: DN and Conventional PT|
11349170|NCT02373618|Active Comparator|Active Comparator: Conventional PT|
11349171|NCT02373605|Experimental|Dry Needling,Thrust Manipulation|
11349172|NCT02373605|Active Comparator|Exercise,Non-thrust Mobilization|
11349173|NCT02373592|Placebo Comparator|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.
~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
11349174|NCT02373592|Experimental|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.
~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.
~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
11349175|NCT02373579|Active Comparator|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .
~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
11349176|NCT02373579|Active Comparator|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
11349177|NCT02373566|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
11349178|NCT02373566|No Intervention|STSG alone|STSG alone
11349179|NCT02373553|No Intervention|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
11349180|NCT02373553|Experimental|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
11349181|NCT02373553|Experimental|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
11349182|NCT02373527|No Intervention|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
11349183|NCT02373527|Experimental|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
11349184|NCT02373514|Active Comparator|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
11349185|NCT02373514|Active Comparator|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
11349186|NCT02373501|Experimental|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
11349187|NCT02373501|Experimental|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
11349188|NCT02373488|Other|control|lifestyle advice
11349189|NCT02373488|Active Comparator|intervention-1|connective tissue manipulation
11349190|NCT02373488|Active Comparator|intervention-2|abdominal massage
11349191|NCT02373475|Experimental|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
11349192|NCT02373475|Active Comparator|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
11349193|NCT02373462|Experimental|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP <140/90 mmHg)
11349194|NCT02373462|Active Comparator|other group|other anti-hypertensive drug (titrating BP <140/90 mmHg)
11349195|NCT02373449|Experimental|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
11349196|NCT02373436|Experimental|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.
~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
11349197|NCT02373436|Other|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
11349198|NCT02373423|Experimental|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
11349199|NCT02373423|No Intervention|Control|No intervention program
11349200|NCT02373410|Experimental|Umbilicus|The height of the operating table which set at the needle insertion point, is the level of umbilicus of the anesthesiologist in a standing posture.
11349201|NCT02373410|Active Comparator|Lowest rib margin|The height of the operating table which set at the needle insertion point, is the level of lowest rib margin of the anesthesiologist in a standing posture.
11349202|NCT02373410|Active Comparator|Xiphoid|The height of the operating table which set at the needle insertion point, is the level of xiphoid of the anesthesiologist in a standing posture.
11349203|NCT02373410|Active Comparator|Nipple|The height of the operating table which set at the needle insertion point, is the level of nipple of the anesthesiologist in a standing posture.
11349204|NCT02373397|Experimental|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
11349205|NCT02373397|Placebo Comparator|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
11349206|NCT02373384|Experimental|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;
~Oral alkalinization
~Potassium citrate 20 mEq three times daily
~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.
~Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.
~Dietary recommendations
~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;
~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
11349207|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
11349208|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
11349209|NCT02373358|Experimental|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
11349210|NCT02373332||Healthy subjects|Healthy subjects for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
11349211|NCT02373332||Type 2 diabetes mellitus (T2DM) patients|T2DM patients for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
11349212|NCT02373319|Experimental|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
11349213|NCT02373319|Experimental|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
11349214|NCT02373319|Active Comparator|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
11349215|NCT02373319|Active Comparator|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
11349216|NCT02373306|Active Comparator|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
11349217|NCT02373306|No Intervention|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
11349218|NCT02373280|Active Comparator|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
11349219|NCT02373280|Experimental|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.
11349220|NCT02373280|Experimental|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.
11349264|NCT02373007|Other|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
11349781|NCT02369614|No Intervention|OASIS treatment as usual|OASIS treatment as usual
11349221|NCT02373280|Experimental|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
11349222|NCT02373254|Active Comparator|Ibuprofen 400 mg|Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
11349223|NCT02373254|Active Comparator|Ibuprofen 800 mg|Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
11349224|NCT02373254|Active Comparator|Norco|Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.
11349225|NCT02373241|Active Comparator|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <95th percentile
11349226|NCT02373241|Experimental|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <75th percentile
11349227|NCT02373228|Experimental|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
11349228|NCT02373215|Experimental|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
11349229|NCT02373215|Experimental|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
11349230|NCT02373215|Experimental|Cohort 2|Healthy patients dosing up to 180mg BID
11349231|NCT02373202|Experimental|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
11349232|NCT02373202|Experimental|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
11349233|NCT02373202|Experimental|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
11349234|NCT02373202|Experimental|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
11349235|NCT02373189|Experimental|Bright light|
11349236|NCT02373176|Experimental|[14C] PRC-4016 (Icosabutate)|Investigational medicinal product (IMP), [14C] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 μCi [7.4 MBq]). The radiochemical purity of [14C]PRC-4016 will be at least 97%.
11349237|NCT02373163|Active Comparator|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
11349238|NCT02373163|Active Comparator|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
11349239|NCT02373163|Active Comparator|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
11349240|NCT02373150|Experimental|Group A1|Dose 1 or placebo
11349241|NCT02373150|Experimental|Group A2|Dose 2 or placebo
11349242|NCT02373150|Experimental|Group A3|Dose 3 or placebo
11349243|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
11349244|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
11349245|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
11349246|NCT02373111|Active Comparator|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
11349247|NCT02373111|Placebo Comparator|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
11349248|NCT02373098|Experimental|FTY720|
11349249|NCT02373098|No Intervention|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
11349250|NCT02373085|Experimental|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
11349251|NCT02373085|No Intervention|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
11349252|NCT02373072|Experimental|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
11349253|NCT02373072|Experimental|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
11349254|NCT02373059|Experimental|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
11349255|NCT02373059|Active Comparator|Usual Pharmaceutical care|Usual Care
11349256|NCT02373046|Experimental|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
11349257|NCT02373046|Experimental|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
11349258|NCT02373033|Active Comparator|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
11349259|NCT02373033|Active Comparator|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
11349260|NCT02373033|Placebo Comparator|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
11349261|NCT02373020||group 1|colonoscopic biopsies from patients with colorectal cancer patients
11349262|NCT02373020||(Group 2|colonoscopic biopsies from healthy controls
11349265|NCT02372994|Experimental|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
11349266|NCT02372994|No Intervention|Control Group|Participants receive usual care.
11349267|NCT02372981|Experimental|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
11349268|NCT02372981|Active Comparator|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
11349269|NCT02372955|Experimental|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
11349270|NCT02372955|Active Comparator|glimpiride|glimpiride 4 mg daily for 16 weeks
11349271|NCT02372942|Experimental|Lattoferrin|Use of Lattoferin for prevention of preterm delivery
11349272|NCT02372942|Experimental|Progesterone|Use of Progesterone for prevention of preterm delivery
11349273|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
11349274|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
11349275|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
11349276|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
11349277|NCT02372903|Experimental|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
11349278|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
11349279|NCT02372877|Experimental|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
11349280|NCT02372864|No Intervention|Care as usual|"All participants in the intervention and control group receive the care as usual. The care as usual consists of a clinic appointment with the research nurse. In this appointment the RRSO-induced menopausal complaints will be discussed in more detail. Depending on the complaints at hand, information, reassurance and life style advice will be offered. A leaflet with relevant information will be provided for. Furthermore, the usual medical care may include prescription of (non-)hormonal medicationsTwelve weeks after the clinic appointment, the research nurse will contact all participants per telephone to ask whether there are issues that remain to be addressed.
~Participants are allowed to continue the use of all their current medication."
11349281|NCT02372864|Experimental|Mindfullness based stress reduction|
11349282|NCT02372851|Active Comparator|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
11349283|NCT02372851|No Intervention|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
11349284|NCT02372812|Active Comparator|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
11349285|NCT02372812|Placebo Comparator|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
11349286|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
11349287|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
11349288|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
11349289|NCT02372786|Other|Acne Keloidalis Nuchae|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.
11349290|NCT02372786|Other|Tattoo|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.
11349291|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
11349292|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
11349293|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
11349294|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
11349295|NCT02372760|Experimental|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
11349296|NCT02372760|Active Comparator|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
11349297|NCT02372747|Experimental|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
11349298|NCT02372747|Experimental|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
11421596|NCT01891305|Experimental|VT-1161 1200/300mg|
11349299|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
11349300|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
11349301|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
11349302|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
11349303|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
11349304|NCT02372708||Experimental|diluted dinitrophenyl(DNP) Vaseline (which equaled to 2% DNP 0.1ml) was started to be directly spread on the surfaces of primary or metastatic tumors of malignant melanoma patients since the first day of every circle of chemotherapy, simultaneously laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2. The tumors were wrapped and blocked for two days to induce contact dermatitis. If lymph nodes had been cleared, sensibilization of 2×2cm was performed at occipital region. It was repeated once a week.
11349305|NCT02372708||Control|only diluted DNP Vaseline was spread and the operation were the same with the treatment group
11349306|NCT02372695|Experimental|Treatment|Patient will take one pill of paricalcitol a day.
11349307|NCT02372695|No Intervention|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
11349308|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.
~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
11349309|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
11349310|NCT02372669|Experimental|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
11349311|NCT02372669|Active Comparator|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
11349312|NCT02372656|Placebo Comparator|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
11349313|NCT02372656|Active Comparator|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
11349314|NCT02372656|Active Comparator|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
11349315|NCT02372643|Other|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
11349316|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
11349317|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
11349318|NCT02372617||Group A|bone graft - autologous
11349319|NCT02372617||Group B|bone graft - ceramic
11349320|NCT02372604|Active Comparator|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).
~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
11349321|NCT02372604|Experimental|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).
~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
11349322|NCT02372591|Placebo Comparator|Placebo|
11349323|NCT02372591|Active Comparator|Hydromorphone|
11349324|NCT02372591|Experimental|Buprenorphine|
11349325|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
11349326|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
11349327|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
11349328|NCT02372565|Experimental|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
11349388|NCT02372149|Experimental|IVIg--Washout--0.9% NaCl (CROSSOVER)|"10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)
~Washout period
~0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
11349329|NCT02372565|Active Comparator|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
11349330|NCT02372552|Experimental|CROMA|Microwave coagulation of small blood vessels
11349331|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
11349332|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
11349333|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
11349334|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
11349335|NCT02372500|Experimental|Chewing gum|Patients will chew sugar free gum three times a day
11349336|NCT02372500|No Intervention|Control|Normal post operative care
11349337|NCT02372487|Active Comparator|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
11349338|NCT02372487|Active Comparator|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
11349339|NCT02372474|Experimental|Stem Cell therapy in POF|POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted.
11349340|NCT02372461|Placebo Comparator|Experimental|Placebo
11349341|NCT02372461|Active Comparator|Control|Amoxicillin Liquid
11349342|NCT02372448|Other|ALK-positive|ALK positive analysis on CTCs detected by ISET
11349343|NCT02372448|Other|ALK-negative|ALK negative analysis on CTCs detected by ISET
11349344|NCT02372435|Experimental|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
11349345|NCT02372435|Active Comparator|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
11349346|NCT02372422|Experimental|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
11349347|NCT02372422|Other|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
11349348|NCT02372409|Experimental|Arm A (MRI-guided laser ablation)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
~Participants will undergo DCE and DSC-MRI imaging at the following time points:
~no more than 3 weeks prior to MLA (OPTIONAL)
~within approximately 4 days after MLA
~2-4 weeks after MLA
~Every 12 weeks (+/- 7 days) for the first year or until disease progression"
11349349|NCT02372409|Experimental|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.
~Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes
~Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)
~Participants will undergo DCE and DSC-MRI imaging at the following time points:
~no more than 3 weeks prior to MLA (OPTIONAL)
~within approximately 4 days after MLA
~2-4 weeks after MLA
~every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
11349350|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
11349351|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
11349352|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes
~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)
~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)
~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)
~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
11349353|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).
~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)
~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)
~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)
~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
11349354|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes
~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)
~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)
~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)
~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
11349355|NCT02372370|Active Comparator|Interventions|All participants receive all interventions.
11349420|NCT02371941|Placebo Comparator|Placebo|Subjects randomized to placebo will receive normal saline ampules Subjects 2-12 years of age - 1 ampule 4 times daily Subjects 13-18 years of age - 2 ampules 4 times daily
11349356|NCT02372357|Experimental|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.
~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
11349357|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
11349358|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
11349359|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
11349360|NCT02372331|No Intervention|Conventional perioperative management|"Preop usual biliary drainage
~Preop smoking and alcohol
~Preop parenteral nutrition
~Oral bowel preparation (mechanical bowel preparation )
~Preoperative fasting > 12 hours
~Pre-anesthetic medication
~Anti-thrombotic prophylaxis
~Antimicrobial prophylaxis and skin preparation
~Intravenous analgesia : PCA
~Prevention of postoperative nausea and vomiting (PONV) (X)
~Incision : surgeon direction
~Avoiding hypothermia
~Nasogastric intubation (O)
~Postop glycemic control
~Positive fluid balance
~Perianastomotic drain removal over POD #5
~Somatostatin analogues
~Transurethral catheter removal
~Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)
~Postop routine artificial nutrition (O), soft diet at POD #5
~Early and scheduled mobilization"
11349361|NCT02372331|Experimental|ERAS perioperative management|"behavioral intervention (counselling, audit)
~dietary supplement
~procedure (preoperative and postoperative)
~drug"
11349362|NCT02372318|Experimental|Nalmefene Challenge|Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
11349363|NCT02372318|Placebo Comparator|Placebo|Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
11349364|NCT02372305|Active Comparator|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
11349365|NCT02372305|Active Comparator|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
11349366|NCT02372292|Active Comparator|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
11349367|NCT02372292|Active Comparator|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
11349368|NCT02372279|No Intervention|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
11349369|NCT02372279|Experimental|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
11349370|NCT02372266|Experimental|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
11349371|NCT02372266|Active Comparator|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
11349372|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
11349373|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
11349374|NCT02372240|Experimental|VLX1570 and dexamethasone|"VLX1570 IV (0.05, 0.15, 0.3, 0.6, 1.2, 2.0 mg/kg) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
~Dexamethasone 20 mg PO/IV"
11349375|NCT02372227|Experimental|VS-5584 and VS-6063|
11349376|NCT02372214|No Intervention|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
11349377|NCT02372214|Experimental|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
11349378|NCT02372201|Experimental|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
11349379|NCT02372188|Experimental|Water|125 mL water are administered during or before gastric pH measurement
11349380|NCT02372188|Experimental|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
11349381|NCT02372188|Experimental|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
11349382|NCT02372188|Experimental|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
11349383|NCT02372175|Experimental|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
11349384|NCT02372175|Experimental|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10^4 PFU/mL) inoculated subcutaneously
11349385|NCT02372175|Experimental|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10^5 PFU/mL) inoculated subcutaneously
11349386|NCT02372162||Group A - TACE|"Patients with transarterial chemoembolization (TACE) will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
11349387|NCT02372162||Group B - Sorafenib|"Patients with Sorafenib treatment will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
11349389|NCT02372149|Experimental|0.9% NaCl--Washout--IVIg (CROSSOVER)|"0.9% sodium chloride in water - equal volume to IVIg - Monthly x4
~Washout period
~10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
11349390|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
11349391|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
11349392|NCT02372123|Other|control|lifestyle advice
11349393|NCT02372123|Active Comparator|intervention|connective tissue manipulation
11349394|NCT02372110|Experimental|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
11349395|NCT02372110|Placebo Comparator|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
11349396|NCT02372097|Experimental|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
11349397|NCT02372097|Experimental|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
11349398|NCT02372084|Experimental|osilodrostat (LCI699)|Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).
11349399|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
11349400|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:
~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
11349401|NCT02372032|Experimental|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
11349402|NCT02372032|Active Comparator|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
11349403|NCT02372019|Experimental|CBM With Active Fear Reactivation|
11349404|NCT02372019|Active Comparator|CBM With Inert Fear Reactivation|
11349405|NCT02372019|Placebo Comparator|Inert CBM With Inert Fear Reactivation|
11349406|NCT02372006|Experimental|afatinib|dose escalation
11349407|NCT02371993|Experimental|Choline 650 mg twice daily|See above
11349408|NCT02371993|Placebo Comparator|Placebo|See above
11349409|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
11349410|NCT02371980|Placebo Comparator|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
11349411|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
11349412|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
11349413|NCT02371980|Placebo Comparator|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
11349414|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
11349415|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
11349416|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
11349417|NCT02371954|Experimental|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
11349418|NCT02371954|Active Comparator|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
11349419|NCT02371941|Experimental|Oral cromolyn|"Subjects randomized to the experimental arm will receive oral cromolyn sodium. The dose will be per current package insert for oral cromolyn:
~Subjects 2-12 years of age - 100 mg (1 ampule) 4 times daily Subjects 13-18 years of age - 200 mg (2 ampules) 4 times daily"
11349421|NCT02371928|Active Comparator|Neuromuscular exercise program|"A 12-week physiotherapeutic, supervised exercise program with focus on neuromuscular shoulder control besides incorporation of kinetic chain exercises.
~The exercise program contains the following focal points: Scapula and glenohumeral setting/control, dynamic shoulder stability, muscle co-contractions (weight-bearing upper extremity exercises) and proprioceptive training."
11349422|NCT02371928|Active Comparator|Standard home exercise program|"One physiotherapeutic-supervised instruction in 12 weeks of active exercises for the rotator cuff and scapular muscles.
~Information about the shoulder injury and how to avoid pain provoking movements besides future implications is given. Also, participants receives one phone call after six weeks of training from a physiotherapist to ensure good compliance and answer any questions that the patient may have."
11349423|NCT02371915|Experimental|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
11349424|NCT02371915|No Intervention|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
11349425|NCT02371902|Active Comparator|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
11349426|NCT02371902|Active Comparator|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
11349427|NCT02371889|Experimental|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
11349428|NCT02371889|Placebo Comparator|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
11349429|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
11349430|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
11349431|NCT02371837|Experimental|pilates group|Pilates based protocol for 6 weeks
11349432|NCT02371837|No Intervention|control group|No treatment group
11349433|NCT02371824||MRI Sequence|
11349434|NCT02371811|Experimental|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
11349435|NCT02371811|No Intervention|control group|In this group we will do abdominal hysterectomy without v care.
11349436|NCT02371798|Experimental|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
11349437|NCT02371785|Experimental|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
11349438|NCT02371772|Other|Self-management anticoagulation treatment|Trained to monitor INR and dose warfarin
11349439|NCT02371772|No Intervention|Conventional anticoagulation treatment|Before enrolment
11349440|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
11349441|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
11349442|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
11349443|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
11349444|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
11349445|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
11349446|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
11349447|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
11349448|NCT02371746|Experimental|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
11349449|NCT02371746|Experimental|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
11349450|NCT02371746|Experimental|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
11349451|NCT02371733|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
11349452|NCT02371733|Sham Comparator|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
11349453|NCT02371720|Experimental|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
11349454|NCT02371720|Active Comparator|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
11349455|NCT02371720|Experimental|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
11349456|NCT02371720|Active Comparator|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
11349457|NCT02371707|Experimental|Idalopirdine 60 mg formulation A (test)|
11349458|NCT02371707|Experimental|Idalopirdine 60 mg formulation B (reference)|
11349459|NCT02371694|Experimental|Fat Test drink (50g)|This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
11349460|NCT02371694|Experimental|Fat Test drink (38g)|This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
11349461|NCT02371694|Experimental|Fat Test drink (25g)|This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
11349462|NCT02371694|Experimental|Fat Test drink (13g)|This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
11349463|NCT02371694|Placebo Comparator|Fat Test drink (3g)|This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
11349464|NCT02371694|Active Comparator|Carbohydrate Test drink|This drink contains 20g of glucose from de-gassed lucozade energy.
11349465|NCT02371681|Experimental|1|TB drugs
11349466|NCT02371668|Placebo Comparator|Placebo|Placebo, 5% dextrose (D-glucose) water
11349467|NCT02371668|Experimental|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
11349468|NCT02371655|Active Comparator|Diet included|Diet is included in bowel preparation
11349469|NCT02371655|Experimental|Diet not included|Diet is not included in bowel preparation
11349470|NCT02371629|Experimental|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
11349471|NCT02371629|Experimental|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
11349472|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
11349473|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
11349474|NCT02371603|Experimental|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
11349475|NCT02371603|Experimental|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
11349476|NCT02371590|Experimental|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
11349477|NCT02371577|Experimental|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
11349478|NCT02371564|Active Comparator|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
11349479|NCT02371564|Active Comparator|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
11349480|NCT02371551||1|All patients
11349481|NCT02371538|Experimental|Donor Breastmilk|Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.
11349482|NCT02371525|No Intervention|Standard of Care|
11349483|NCT02371525|Experimental|Prepmate|
11349484|NCT02371512|Experimental|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
11349485|NCT02371512|Active Comparator|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
11349486|NCT02371499|Experimental|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
11349487|NCT02371499|Placebo Comparator|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
11349488|NCT02371486|Experimental|Nich Repair|"Interventions to be administered:
~Ultrasound Scan
~Diagnostic Hysteroscopy
~hysteroscopic repair of cesarean section defect
~IVF cycle"
11349489|NCT02371486|Sham Comparator|No Repair|"Interventions to be administered:
~Ultrasound Scan
~Diagnostic Hysteroscopy
~IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
11349490|NCT02371473|Experimental|#1 (Acetazolamide-placebo)|The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
11349491|NCT02371473|Experimental|#2 (Placebo-acetazolamide)|The arm #2 consists of 6 eligible patients who receive placebo once daily an hour before sleep for first six nights and after two weeks washout they receive acetazolamide 250mg for six nights in the same order. After each six-day period they undergo polysomnography.
11349492|NCT02371460|Experimental|DHA-rich algal oil|1200mg DHA per day
11349493|NCT02371460|Placebo Comparator|Placebo|No supplementation in DHA
11349494|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:
~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)
~Phase 2:
~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)
~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
11349495|NCT02371434|Experimental|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):
~nTregs
~Prednisolone
~MMF
~Tacrolimus"
11349496|NCT02371421||Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
11349497|NCT02371408|Experimental|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
11349498|NCT02371408|Experimental|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
11349499|NCT02371408|Experimental|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
11349500|NCT02371408|Experimental|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
11349501|NCT02371408|Experimental|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
11349502|NCT02371408|Experimental|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
11349503|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
11349504|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
11349505|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
11349506|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
11349507|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
11349508|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
11349509|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
11349510|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
11349511|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
11349512|NCT02371343|Active Comparator|Fish-Oil|"The pregnants with gestational diabetes given fish oil:
~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
11349513|NCT02371343|Placebo Comparator|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:
~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
11349514|NCT02371317|Experimental|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
11349515|NCT02371317|Active Comparator|Stress Management Education|The Stress Management Education intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
11349516|NCT02371317|Other|AHA Recommended Self-Care|All participants will receive the American Heart Association - Understanding and Controlling Your High Blood Pressure Brochure and information on the Dietary Approach to Stop Hypertension from the National Institutes of Health. These brochures describe ways that individuals can improve their lifestyle through better diet and exercise. Participants will get a chance to try and make healthy lifestyle changes on their own, using this information.
11349517|NCT02371304|Active Comparator|Total Mesorectal Excision|After local excision patients will receive additional TME surgery
11349518|NCT02371304|Experimental|Adjuvant chemoradiotherapy|After local excision. Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
11349519|NCT02371291|Experimental|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
11349520|NCT02371291|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
11349521|NCT02371278|Other|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.
~Placebo with meals for 3 days, and leucine with meals for 3 days."
11349522|NCT02371278|Other|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.
~Placebo with meals for 3 days, and leucine with meals for 3 days."
11349523|NCT02371265|Experimental|Adherence and retention intervention|Implementation of adherence and retention package
11349524|NCT02371265|No Intervention|Control|Clusters continue without intervention package
11349525|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
11349526|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
11349527|NCT02371239|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
11349528|NCT02371239|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
11349529|NCT02371239|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
11349530|NCT02371226|Experimental|Cohort 1|1 mg/kg AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) administered once weekly x 8 weeks
11349531|NCT02371226|Experimental|Cohort 2|3 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
11349532|NCT02371226|Experimental|Cohort 3|6-9 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
11349533|NCT02371213|Experimental|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
11349534|NCT02371213|No Intervention|no social networking on mobile phone|usual antenatal care group-health education
11349535|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
11349536|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
11349537|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
11349538|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
11349539|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
11349540|NCT02371161|Experimental|R-DHAP/R-ICE|High-dose myeloablative therapy (R-DHAP or R-ICE) and conditioning therapy (BEAM or FEAM) in elderly patients with relapsed NHL or resistant to firs line therapy
11349541|NCT02371148|Experimental|Bortezomib-Rituximab-Bendamustine|Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.
11349542|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
11349543|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
11349544|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
11349545|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
11349546|NCT02371122|Sham Comparator|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
11349547|NCT02371109||selftaken vs clinical taken swabs|
11349548|NCT02371096|Experimental|RGB-03|
11349549|NCT02371096|Active Comparator|MabThera (rituximab)|
11349550|NCT02371083|No Intervention|Routine|Subjects will continue with regular pessary care every 12 weeks.
11349551|NCT02371083|Experimental|Extended|Subjects will have extended time between pessary care visits which will occur every 24 weeks.
11349552|NCT02371070||Rivaroxaban|N=20
11349553|NCT02371070||Apixaban|N=20
11349554|NCT02371070||Dabigatran|N=20
11349555|NCT02371057||patients under follow-up known to have sleep apnoea|
11349556|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
11349557|NCT02371044||Rivaroxaban|N=20
11349558|NCT02371044||Apixaban|N=20
11349559|NCT02371044||Dabigatran|N=20
11349560|NCT02371031|Experimental|Arm 1: FDOPA-PET/MRI|"Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.
~In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.
~When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
11421597|NCT01891305|Placebo Comparator|Matching placebo|
11349561|NCT02371018|No Intervention|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
11349562|NCT02371018|Experimental|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
11349563|NCT02371018|Experimental|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
11349564|NCT02371005|Other|Measurement of the periodontal ligament space|Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
11349565|NCT02371005|Other|Radiographic analysis of oro-facial manifestations|Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
11349566|NCT02370992||Receiving I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
11349567|NCT02370979|Experimental|Dolutegravir|
11349568|NCT02370966|Placebo Comparator|Potato starch|Potato powder will be incorporated in the placebo product.
11349569|NCT02370966|Active Comparator|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
11349570|NCT02370953|Experimental|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
11349571|NCT02370953|Active Comparator|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
11349572|NCT02370940|Experimental|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
11349573|NCT02370940|Experimental|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
11349574|NCT02370927|Placebo Comparator|Control|100% Wheat Flour
11349575|NCT02370927|Experimental|Cereal w/ pea protein|Pea protein
11349576|NCT02370927|Experimental|Cereal w/ pea starch|Pea starch
11349577|NCT02370927|Experimental|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
11349578|NCT02370927|Experimental|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
11349579|NCT02370927|Experimental|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
11349580|NCT02370914|Experimental|Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a SCAT test.
11349581|NCT02370914|Experimental|Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a SCAT test.
11349582|NCT02370901|Experimental|Helmet|Patients will be referred to a cranial orthotist who will create a custom cranial orthotic device. They will undergo adjustments monthly. At these appointments anthropometric measurements will be done by the cranial orthotist. The orthotist will be blinded and will not be informed of which patient is involved in the study.
11349583|NCT02370901|Experimental|home therapies|Patients will be referred to a physical therapist. They will be offered education, neck stretching exercises, and repositioning techniques, and reassurance.
11349584|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.
~The dose levels of lenalidomide will be as follows:
~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles
~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles
~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles
~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
11349585|NCT02370875|Experimental|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
11349586|NCT02370875|Sham Comparator|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
11349587|NCT02370862|Experimental|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
11349588|NCT02370849|Experimental|NCS|nimotuzumab plus cisplatin and S-1
11349589|NCT02370849|Active Comparator|CS|cisplatin and S-1
11349782|NCT02369588|Experimental|100% Portion Sizes|Food portion size Test meal consists of baseline (100%) portion size of all foods
11349590|NCT02370836|Experimental|Psycho-oncological education|One 60 minute psycho-oncological education session on late effects, fatigue and stress management.
11349591|NCT02370836|No Intervention|Usual Care|Usual care includes completion of a symptom checklist by the nurse practitioner
11349592|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
11349593|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
11349594|NCT02370810|No Intervention|weekly check-in group|will complete weekly measures and commence the treatment once the experimental group completes the intervention
11349595|NCT02370797|Experimental|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
11349596|NCT02370784|Active Comparator|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
11349597|NCT02370784|Placebo Comparator|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
11349598|NCT02370771|Experimental|Patient with hand osteoarthritis|Biological sampling and Radiographic evaluation of patient with erosive and non erosive hand osteoarthritis
11349599|NCT02370758|Active Comparator|Low CMV CMI|Patients that show low levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) continued for an additional 2 months at half dose.
11349600|NCT02370758|No Intervention|High CMV CMI|Patients that show high levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) stopped.
11349601|NCT02370745|Experimental|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.
~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
11349602|NCT02370745|Experimental|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.
~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
11349603|NCT02370745|Experimental|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.
~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
11349604|NCT02370745|Experimental|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.
~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
11349605|NCT02370745|Experimental|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.
~The intervention here is: 15g of mixed essential amino acid drink."
11349606|NCT02370745|Experimental|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.
~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
11349607|NCT02370745|Experimental|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.
~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
11349608|NCT02370745|Experimental|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.
~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
11349609|NCT02370732|Other|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.
~2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.
~2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
11349610|NCT02370719|Experimental|Intervention Group|Mobile application plus standard of care
11349611|NCT02370719|No Intervention|Control Group|Standard of care
11349612|NCT02370706|Experimental|Dose Escalation Arm 1|
11349613|NCT02370706|Experimental|Dose Escalation Arm 2|
11349614|NCT02370706|Experimental|Dose Escalation Arm 3|
11349615|NCT02370706|Experimental|Dose Expansion Arm 1|
11349616|NCT02370706|Experimental|Dose Expansion Arm 2|
11349617|NCT02370706|Experimental|Dose Expansion Arm 3|
11349618|NCT02370693|Active Comparator|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
11349674|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
11421598|NCT01891292|No Intervention|Control|
11349619|NCT02370693|Placebo Comparator|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
11349620|NCT02370680|Experimental|Durlaza™, 1 capsule|Aspirin run-in, followed with Durlaza™, one capsule QD (quaque die), for 14 ± 4 days and an in-patient visit
11349621|NCT02370680|Experimental|Durlaza™, 2 capsules|in a rollover with 10 subjects from the first arm, an aspirin run-in, followed by Durlaza™, two capsules QD, for 14 ± 4 days and an in-patient visit
11349622|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
11349623|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
11349624|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
11349625|NCT02370654|Experimental|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
11349626|NCT02370654|Active Comparator|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
11349627|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
11349628|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
11349629|NCT02370628|Experimental|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
11349630|NCT02370628|Active Comparator|Facet block|injection of anti-inflammatory and analgesic drugs
11349631|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
11349632|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
11349633|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
11349634|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
11349635|NCT02370589|Experimental|Group A|Day 0: Base Dose EBOV GP Vaccine; IM Day 21: Base Dose EBOV GP Vaccine; IM
11349636|NCT02370589|Experimental|Group B|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
11349637|NCT02370589|Experimental|Group C|Day 0: Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
11349638|NCT02370589|Experimental|Group D|Day 0: 2x Base Dose EBOV GP Vaccine; IM Day 21: 2x Base Dose EBOV GP Vaccine; IM
11349639|NCT02370589|Experimental|Group E|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
11349640|NCT02370589|Experimental|Group F|Day 0: 2x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
11349641|NCT02370589|Experimental|Group G|Day 0: 4x Base Dose EBOV GP Vaccine; IM Day 21: 4x Base Dose EBOV GP Vaccine; IM
11349642|NCT02370589|Experimental|Group H|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
11349643|NCT02370589|Experimental|Group J|Day 0: 4x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
11349644|NCT02370589|Experimental|Group K|Day 0: 8x Base Dose EBOV GP Vaccine; IM Day 21: 8x Base Dose EBOV GP Vaccine; IM
11349645|NCT02370589|Experimental|Group L|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM
11349646|NCT02370589|Experimental|Group M|Day 0: 8x Base Dose EBOV GP Vaccine and Matrix-M Adjuvant; IM Day 21: Placebo; IM
11349647|NCT02370589|Placebo Comparator|Group N|Day 0: Placebo; IM Day 21: Placebo; IM
11349648|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
11349649|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
11349650|NCT02370563|Experimental|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
11349778|NCT02369614|Active Comparator|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
11349651|NCT02370550|Experimental|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease >15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
11349652|NCT02370550|Placebo Comparator|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
11349653|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
11349654|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
11349655|NCT02370524|Experimental|[18F]T807|At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807
11349656|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
11349657|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
11349658|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
11349659|NCT02370498|Experimental|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
11349660|NCT02370498|Active Comparator|Paclitaxel|Participants receive 80 mg/m^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
11349661|NCT02370485|Experimental|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
11349662|NCT02370485|Experimental|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
11349663|NCT02370485|Experimental|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
11349664|NCT02370472|No Intervention|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
11349665|NCT02370472|Experimental|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
11349666|NCT02370459|No Intervention|control|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive no AFIX consultation.
11349667|NCT02370459|Experimental|AFIX in-person consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
11349668|NCT02370459|Experimental|AFIX webinar consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff.
11349669|NCT02370446||patient gets personalized medication log|Patients in the intervention group will receive a personalized medication log that includes all treatment medications (IV and oral), days of treatment and medication specific information such as timing or diet restrictions. The personalized medication log and patient education materials (fact cards) will be placed in a clear plastic envelope that the patient can carry with them throughout treatment.
11349670|NCT02370446||patient gets standard of care|Current MSKCC standards of professional nursing practice require the professional nurse to develop a plan of care that includes teaching the patient and support system the prescribed prescriptions / regimen and all doses, route, length of treatment, side effects and safety precautions.
11349671|NCT02370433|Experimental|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
11349672|NCT02370433|Experimental|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
11349673|NCT02370433|Experimental|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
11349779|NCT02369614|Active Comparator|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
11349675|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
11349676|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
11349677|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
11349678|NCT02370394|Experimental|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
11349679|NCT02370394|No Intervention|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
11349680|NCT02370381||Epistaxis|Patients with active anterior epistaxis
11349681|NCT02370368|Experimental|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.
~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
11349682|NCT02370368|Active Comparator|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
11349683|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
11349684|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
11349685|NCT02370342|Experimental|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
11349686|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11349687|NCT02370316|Experimental|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
11349688|NCT02370316|Active Comparator|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
11349689|NCT02370290||Observational (QIM)|Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.
11349690|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
11349691|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
11349692|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
11349693|NCT02370264|Experimental|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
11349694|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
11349695|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.
~continuing from D 1 to Day 21 of 28-day cycle"
11349696|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
11349697|NCT02370225|Experimental|aerobic exercise|Subjects were submitted to a supervised walking, 3 times a week for 16 weeks.
11349698|NCT02370225|No Intervention|no exercise|Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group.
11349699|NCT02370212|Experimental|Creatine|"Creatine will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.05 g/kg body mass of creatine with 0.05 g/kg flavoured dextrose per dose).
~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
11349700|NCT02370212|Placebo Comparator|Placebo|"The placebo will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.1 g/kg flavoured dextrose per dose, isocaloric to the creatine).
~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
11349701|NCT02370199|Experimental|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
11349702|NCT02370173|Experimental|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
11349703|NCT02370173|Placebo Comparator|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
11349704|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
11349705|NCT02370147|Experimental|Smoking reduction intervention arm|Smoking reduction intervention arm (SRI) consisting of a minimal face-to-face individual smoking reduction intervention lasted for about one minute, and five follow-up interventions lasted for about one minute each.
11349780|NCT02369614|Sham Comparator|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
11349706|NCT02370147|Active Comparator|Control arm|Control arm (UC) consisting of a brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and five follow-up interventions lasted for about one minute each with different intervention contents.
11349707|NCT02370134|Experimental|Parkinson's glove|Parkinson's glove 14 days use with 4 times follow-up
11349708|NCT02370134|Placebo Comparator|sham glove|sham glove (with light and sound)14 days use with 4 times follow-up
11349709|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
11349710|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
11349711|NCT02370108|Experimental|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
11349712|NCT02370108|Experimental|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
11349713|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
11349714|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
11349715|NCT02370082|Experimental|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
11349716|NCT02370069|Active Comparator|Previous immunization with PPV23|Participants who have received a previous vaccination with 1 or more dose of PPV23 at least 12 months previously will receive one dose of 0.5 mL Prevnar 13 study vaccine.
11349717|NCT02370069|Active Comparator|Naive to PPV23|Participants who have never received a previous vaccination with PPV23 will receive one dose of 0.5 mL Prevnar 13 study vaccine.
11349718|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.
~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
11349719|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.
~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
11349720|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
11349721|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
11349722|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
11349723|NCT02370030|Active Comparator|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
11349724|NCT02370030|Placebo Comparator|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
11349725|NCT02370017|Experimental|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
11349726|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
11349727|NCT02369978|Experimental|Nifurtimox (NFX)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
11349728|NCT02369978|Active Comparator|Benznidazole (BZN)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
11349729|NCT02369978|Placebo Comparator|Placebo|120 days of treatment with matching placebo
11349730|NCT02369965|Experimental|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
11349731|NCT02369965|Active Comparator|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
11349732|NCT02369939|Active Comparator|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33
11349733|NCT02369939|Experimental|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6
11349734|NCT02369926|Active Comparator|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
11349735|NCT02369926|Active Comparator|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
11349736|NCT02369913||Heart failure subjects|Heart failure subjects undergoing cardiac resynchronization will have a blood drawn for this study.
11349737|NCT02369913||Heart arrhythmia patients|Heart arrhythmia patients undergoing ablation will have a blood drawn for this study.
11349738|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.
~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
11349739|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
11349740|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
11349741|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
11349742|NCT02369874|Active Comparator|Standard of Care|Standard of Care
11349743|NCT02369861|Experimental|ST266|Eye drops
11349744|NCT02369861|Placebo Comparator|Artificial tears|Refresh lubricant eye drops
11349745|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
11349746|NCT02369835|Experimental|Arm I (modified Dakin's solution)|Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
11349747|NCT02369835|Placebo Comparator|Arm II (placebo)|Participants apply placebo solution (saline) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
11349748|NCT02369822|Experimental|Vitamin C supplemented|patients with refractory idiopathic epilepsy will receive vitamin C supplement according to age for 1 month
11349749|NCT02369822|No Intervention|None supplemented|followed up for 1 month
11349750|NCT02369809|Experimental|Neovasculgen®|Single group prospective treatment
11349751|NCT02369809|Active Comparator|standard care|
11349752|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
11349753|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
11349754|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
11349755|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
11349756|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
11349757|NCT02369783|Experimental|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
11349758|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
11349759|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
11349760|NCT02369757|Experimental|Intervention of navigators|Navigators accompany the target population towards OCCS.
11349761|NCT02369757|No Intervention|No Intervention|Population is not accompanied by navigators
11349762|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
11349763|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
11349764|NCT02369731||Translarna|Participants with nmDMD receiving Translarna will be followed for at least 5 years from their date of enrollment, or until participant withdrawal of consent or death, whichever occurs first.
11349765|NCT02369718|Experimental|Implanted subjects|Listening to 12 Fournier's lists of words
11349766|NCT02369718|Active Comparator|Normal hearing subjects|Listening to 48 Fournier's lists of words
11349767|NCT02369679|Experimental|Precast Adjustable Compression Wrap|Precast Adjustable Compression Wrap will be adjusted by the physiotherapist each visit
11349768|NCT02369679|Active Comparator|Multilayer Compression Bandages|Multilayer Compression Bandages will be adjusted by the physiotherapist each visit
11349769|NCT02369666|Experimental|LycoRed (code 40051) product|Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
11349770|NCT02369666|Placebo Comparator|Placebo|Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks.
11349771|NCT02369653|Experimental|Apixaban|"Children aged 1 to <18 years weighing 6 to <35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days.
~Children aged 1 to <18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects < 5years and < 35 kg may be administered 0.5-mg tablets only"
11349772|NCT02369653|Placebo Comparator|No systemic anticoagulant prophylaxis|No systemic anticoagulant prophylaxis
11349773|NCT02369640|Experimental|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
11349774|NCT02369640|Experimental|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
11349775|NCT02369627|Experimental|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
11349776|NCT02369627|Active Comparator|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
11349777|NCT02369627|Active Comparator|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
11349783|NCT02369588|Experimental|133% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 133% the size of baseline portions
11349784|NCT02369588|Experimental|167% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 167% the size of baseline portions
11349785|NCT02369588|Experimental|200% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 200% the size of baseline portions
11349786|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
11349787|NCT02369549|Active Comparator|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.
~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
11349788|NCT02369549|Placebo Comparator|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.
~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
11349789|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
11349790|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
11349791|NCT02369523|Active Comparator|liposomal bupivacaine (LB) (Exparel)|Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
11349792|NCT02369523|Active Comparator|Ropivacaine cocktail (PIC)|400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
11349793|NCT02369523|Active Comparator|continuous femoral nerve blocks (cFNB)|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.
~Sciatic nerve block - 0.125% bupivacaine"
11349794|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
11349795|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
11349796|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
11349797|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
11349798|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
11349799|NCT02369471|Experimental|Group 1a|Subjects on inducer AEDs will administer GWP42006.
11349800|NCT02369471|Active Comparator|Group 2a|Subjects on inhibitor AEDs will administer GWP42006.
11349801|NCT02369471|Experimental|Group 3a|Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
11349802|NCT02369471|Placebo Comparator|Group 1b|Matching placebo control for Group 1a.
11349803|NCT02369471|Placebo Comparator|Group 2b|Matching placebo control for Group 2a.
11349804|NCT02369471|Placebo Comparator|Group 3b|Matching placebo control for Group 3a.
11349805|NCT02369458|Experimental|Arm 1: p16+ OPSCC|"Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).
~Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
11349806|NCT02369458|Experimental|Arm 2: p16- HNSCC|"Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).
~Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
11349807|NCT02369445|Experimental|Moisture Pager (MP) Intervention Group|"This group receives the innovative toilet training intervention comprised of a wireless moisture pager (i.e., an app based on an iPod that communicates via electronic signal with a disposable moisture sensor located in the child's underwear)."
11349808|NCT02369445|Active Comparator|Standard Behavioral Intervention Group|This group receives standard-of-care intervention as presented in the Autism Treatment Network's Toilet Training Tool Kit (https://www.autismspeaks.org/site-wide/atn-tool-kits).
11349809|NCT02369432|Experimental|Group of healthy volunteers and group of patients|"Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed
~Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed"
11349810|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
11349811|NCT02369406|Experimental|Antepartum Cohort|"40 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART < 7 days after birth. This cohort will include at least 15 children who start ART < 3 days after birth.
~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
11349812|NCT02369406|Experimental|Peripartum Cohort|"10 children who test HIV-negative within 96 hours after birth but test HIV-positive <57 days after birth (peripartum HIV infection) and who are able to initiate ART <57 days after birth. This cohort will include at least 10 children who start ART < 21 days after birth.
~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
11349813|NCT02369406|No Intervention|Control Cohort|25 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
11349814|NCT02369393|Experimental|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
11349843|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
11349815|NCT02369393|No Intervention|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
11349816|NCT02369393|Experimental|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
11349817|NCT02369380|Experimental|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
11349818|NCT02369354|No Intervention|Usual Care|Usual medical care at the Duke Kidney Transplant Clinic
11349819|NCT02369354|Other|TALKS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings
11349820|NCT02369354|Other|TALKS PLUS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings plus live donor financial assistance intervention
11349821|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11349822|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11349823|NCT02369328|Experimental|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
11349824|NCT02369328|Active Comparator|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
11349825|NCT02369315|Experimental|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
11349826|NCT02369315|Experimental|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
11349827|NCT02369302|Experimental|DWC20141|multiple dose of DWC20141
11349828|NCT02369302|Experimental|DWC20142|multiple dose of DWC20142
11349829|NCT02369302|Experimental|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
11349830|NCT02369289||vegans|a vegan diet in the last 3 years
11349831|NCT02369289||omnivores|aminal-based diet, comsumption of aminal products at least 3 times a week
11349832|NCT02369276||post SND within 3 months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 3 months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
11349833|NCT02369276||post SND within >3- 6months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within >3- 6months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
11349834|NCT02369276||post SND within 6 months -1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 6 months -1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
11349835|NCT02369276||post SND within more than 1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within more than 1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
11349836|NCT02369276||without shoulder disability|20 Head and Neck Cancer(HNC) post SND without shoulder complication at the control group, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
11349837|NCT02369250|Placebo Comparator|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
11349838|NCT02369250|Active Comparator|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
11349839|NCT02369250|Experimental|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
11349840|NCT02369211|Experimental|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
11349841|NCT02369211|Placebo Comparator|Placebo|Patient receives saline injection instead of the study drug
11349842|NCT02369198|Experimental|Single arm, open label TargomiRs|"TargomiRs are IV injected.
~Phase 1 Planned dose levels
~Dose level 1: 5 billion once a week Dose level 2: 5 billion twice a week Dose level 3: 5 billion once a week with cardiac monitoring Dose level 4: 2.5 billion twice a week with cardiac monitoring Dose level 5: as for dose level #3 with a dexamethasone challenge
~All patients begin on a micro dose of one billion and increase their dose over 2 weeks and reach their phase 1 dose level on week 3.
~Schedule of assessments includes laboratory and physical assessments in the 24 hours after each treatment as well as periodic assessments such as PET and CT scans for tumour assessment.
~100% of the data will be source data verified. Analysis will be simple phase 1 analysis based on a 3+3 model."
11349844|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.
~Subjects ≥12 years will receive a dose of 600 mg.
~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).
~Subjects < 6 months will receive a dose of 8 mg/kg."
11349845|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.
~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).
~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
11349846|NCT02369146|Experimental|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
11349847|NCT02369146|Experimental|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
11349848|NCT02369133|Active Comparator|Group Paracetamol (Group P),|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol
11349849|NCT02369133|Placebo Comparator|Group Saline (Group S)|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline
11349850|NCT02369120|Active Comparator|Normal care by GP|"Control group: Will follow conventional treatment provided by the family physician in primary care. This treatment is based on the clinical guidelines of the Institut Català de la Salut (http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf)."
11349851|NCT02369120|Experimental|Educational intervention using a website|This group of subjects will be given access to our web-site in where they will find information related to CLBP. This information will be provided in different formats: explanatory video by the author, animated video about the neurophysiology of pain, written format using metaphors, and FAQs. All this information will be based on the information provided by the subjects on QUAL. The aim of this educational intervention is to change patient´s misbeliefs about CLBP with the last outcome of reducing pain intensity, improving function, and reducing disability.
11349852|NCT02369107|Experimental|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
11349853|NCT02369107|Sham Comparator|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
11349854|NCT02369094|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
11349855|NCT02369094|Other|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.
~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
11349856|NCT02369081|Active Comparator|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
11349857|NCT02369081|Placebo Comparator|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
11349858|NCT02369081|Active Comparator|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
11349859|NCT02369081|Active Comparator|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
11349860|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.
~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
11349861|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.
~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
11349862|NCT02369055||Stroke survivors in North Norway|Patients with ischemic or heamorrhagic stroke admitted to stroke units in UNN Tromso, Narvik or Harstad (Norway), and living in the defined geographic area of these 3 hospitals.
11349863|NCT02369055||Stroke survivors in Denmark|Patients with ischemic og heamorrhagic stroke admitted to a stroke unit in Aarhus University Hospital and living in the municipalities of Randars or Favrskov in Central Denmark Region
11349897|NCT02368834|No Intervention|control group|This group waited for 3 months, only receiving general consultation.
11349898|NCT02368821||normal pregnancy|placental from normal pregnancy
11421599|NCT01891292|Active Comparator|Enalapril|
11349864|NCT02369042|Experimental|Cohort I|Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.
11349865|NCT02369042|Experimental|Cohort II|Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.
11349866|NCT02369029|Experimental|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
11349867|NCT02369016|Experimental|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
11349868|NCT02369003|Experimental|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
11349869|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
11349870|NCT02368977|Experimental|All subjects|All subjects will undergo examination with a Third Eye Panoramic device in conjunction with a standard colonoscope to evaluate the feasibility of using the study device to provide video imaging of areas of the colon that are difficult to evaluate with the colonoscope alone.
11349871|NCT02368964|Experimental|High dose hCG|The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration
11349872|NCT02368964|Experimental|Double trigger|Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration
11349873|NCT02368951|Experimental|BAY1187982|"Dose-escalation phase:
~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.
~MTD expansion phase:
~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:
~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
11349874|NCT02368938||Several communities in the north of Shanghai|
11349875|NCT02368925|Experimental|Ultherapy™ System|Ultherapy™ System
11349876|NCT02368912|Experimental|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
11349877|NCT02368912|Experimental|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
11349878|NCT02368912|Experimental|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
11349879|NCT02368912|Experimental|4. Food effect (FE), ASP1707 fed|Fed healthy young male
11349880|NCT02368912|Experimental|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
11349881|NCT02368912|Experimental|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
11349882|NCT02368912|Experimental|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
11349883|NCT02368912|Experimental|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
11349884|NCT02368912|Experimental|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
11349885|NCT02368912|Experimental|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
11349886|NCT02368899|Experimental|Computerized Alcohol Misuse Intervention|Arm 1 is a cross-over randomized controlled trial (XRCT) comparing the short-term effects of the computerized alcohol misuse intervention (CAMI) vs. a generic health education attention-control (AC) condition in reducing past 30 day: (a) days of alcohol use, (b) days of heavy episodic drinking, (c) typical number of drinks consumed on a day of drinking, and (d) alcohol use in dangerous situations; (2) investigate changes in (a) patient motivation and (b) perceived norms as mediators of intervention effectiveness.
11349887|NCT02368899|Placebo Comparator|Attention Control (AC)|Arm 2 is not an active intervention but an attention control condition - it is not expected to exert any real intervention effect. Hence, any observed effects for the AC condition can be attributed to natural change via regression-to-the-mean, assessment reactivity, or a placebo effect. The effect size estimate of the intervention, both from an efficacy standpoint (i.e., above and beyond what change would have normally occurred) and an effectiveness standpoint (i.e., the magnitude of behavior change that can be expected in real-world implementation), can be readily calculated.
11349888|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
11349889|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
11349890|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
11349891|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
11349892|NCT02368873|Active Comparator|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
11349893|NCT02368873|No Intervention|Control group|Patients with the straight permanent colostomy without a mesh.
11349894|NCT02368860|Experimental|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
11349895|NCT02368847|Other|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
11349896|NCT02368834|Experimental|intervention group|A psychoeducation program was delivered to the parents/caregivers
11421600|NCT01891292|Active Comparator|N-Acetylcysteine|
11349899|NCT02368821||complacted pregnancy|placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete
11349900|NCT02368808|Experimental|Abangane Support Group|Bereavement support group for adolescents
11349901|NCT02368808|No Intervention|Wait List|Wait-listed adolescents will be able to participate in Abangane at the close of the study.
11349902|NCT02368795|Placebo Comparator|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
11349903|NCT02368795|Active Comparator|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
11349904|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
11349905|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
11349906|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
11349907|NCT02368769||Before tele-expertise|Usual (on site) frozen section
11349908|NCT02368743||mesalazine|Treatment according to standard clinical practice.
11349909|NCT02368730||desmopressin|Treatment according to standard clinical practice.
11349910|NCT02368717|Experimental|Mesalazine|Mesalazine Enema
11349911|NCT02368717|Placebo Comparator|Placebo|Placebo Enema
11349912|NCT02368704||control|"control subjects with :
~Nondiabetic subjects (blood glucose <7.0 mmol/l without hypoglycemic treatment).
~The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
11349913|NCT02368704||case|"Diabetic patients with :
~Having type 2 diabetes for at least 6 months
~HbA1c ≤ 8%
~Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin
~No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
11349914|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
11349915|NCT02368678|Active Comparator|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
11349916|NCT02368678|Active Comparator|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
11349917|NCT02368665|Experimental|AML 5mg|- Amlodipine 5mg, once a day for 8 weeks
11349918|NCT02368665|Experimental|AML 5mg / CC 16mg|- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks
11349919|NCT02368665|Experimental|AML 10mg / CC 16mg|- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
11349920|NCT02368652|Experimental|CC 16mg|Candesartan ceilexetil 16mg, once a day for 8 weeks
11349921|NCT02368652|Experimental|AML 10mg / CC 16mg|Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
11349922|NCT02368639|Experimental|Positive airway pressure (PAP) device|Fisher & Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
11349923|NCT02368626|Experimental|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
11349924|NCT02368613|Placebo Comparator|placebo group|Placebo
11349925|NCT02368613|Active Comparator|test1 group|DW-3102 125mg
11349926|NCT02368613|Active Comparator|test2 group|DW-3102 250mg
11349927|NCT02368613|Active Comparator|test3 group|DW-3102 500mg
11349928|NCT02368600|Experimental|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
11349929|NCT02368600|No Intervention|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
11349930|NCT02368587|Placebo Comparator|Intracoronary infusion WJMSCs|Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure
11349931|NCT02368587|Placebo Comparator|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure.
11349932|NCT02368574|No Intervention|Class III hysterectomy Arm|Class III hysterectomy (radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. Perivesical space and perirectal space should be opened, and the ureteral tunnel is completely separated and pushed down to the junction of ureter and urinary bladder. The uterine arteries are ligated at the level of internal iliac artery, and all the supporting ligaments and connective tissues around the uterus should be separated and abscised. The uterosacral ligament is removed near the sacrum, the cardinal ligament is removed near the pelvic wall, and the vagina is removed after the excision of peivaginal connective tissues, about 3-4cm from the cervical lesion. The pelvic lymph nodes are usually dissected at the same time.
11349933|NCT02368574|Experimental|Class II hysterectomy Arm|Class II hysterectomy (modified radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. The scope of surgery is more extensive than Class I epifascial panhysterectomy, demanding the excision of more parametrium but reservation of the blood supply for distal ureter and urinary bladder. The ureter is separated from the ureteral tunnel, the vesicouterine ligament should be intact, and 1/2 uterosacral ligament and 1cm vagina are excised. The pelvic lymph nodes are usually dissected at the same time.
11349934|NCT02368561|Experimental|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
11349935|NCT02368548|Experimental|Pharmaceutical care program|"Initiated in the Emergency Department (ED):
~Review of home medication and medication reconciliation based on Primary Care data
~Patient interview. Assessment of the patient's knowledge on the pharmacological treatment
~Development of the pharmacological history and registration in the medical record
~Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team
~Pharmacotherapy monitoring
~Treatment validation and medication reconciliation at discharge
~During the hospitalization (if admission from the ED):
~Treatment review and medication reconciliation
~Pharmacokinetics monitoring
~Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team
~Pharmacotherapy monitoring
~Validation and medication reconciliation at discharge
~Patient education at discharge"
11349936|NCT02368548|Other|Standard Care|"Stages:
~Pharmaceutical care program in the episode at the Emergency Department:
~a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.
~During the hospitalization (if admission from the ED):
~Pharmacokinetics monitoring
~Retrospective validation of prescriptions and assessment of drugs appropriateness."
11349937|NCT02368522||Patients treated with and without exposure|
11349938|NCT02368509|Experimental|Bronchial cancer|Patients with bronchial cancer will perform sensory tests before and after a 6-week period of chemotherapy.
11349939|NCT02368509|Placebo Comparator|Control group|Healthy individuals will perform sensory tests before and after a 6-week period without chemotherapy.
11349940|NCT02368496|Experimental|Children and young adults on long-term parenteral nutrition|long-term parenteral nutrition : 2 years
11349941|NCT02368483|Experimental|Neuromuscular training|
11349942|NCT02368470|Active Comparator|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
11349943|NCT02368470|Experimental|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
11349944|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
11349945|NCT02368457|No Intervention|CONTROL|No drug treatment
11349946|NCT02368444|Experimental|Intervention Group|Cognitive Behavioral Therapy and Yoga
11349947|NCT02368431|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
11349948|NCT02368431|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
11349949|NCT02368418||PCP and SRS|participants had received two interventions (PCP and SRS)
11349950|NCT02368418||PCP only|participants had received PCP intervention only
11349951|NCT02368418||SRS only|participants had received SRS intervention only
11349952|NCT02368418||control group|participants had received usual care (neither PCP nor SRS)
11349953|NCT02368405|Active Comparator|Control|Control group will receive standard of care
11349954|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
11349955|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
11349956|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
11349957|NCT02368379|Other|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
11349958|NCT02368366|Experimental|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
11349959|NCT02368366|Experimental|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
11349960|NCT02368366|Experimental|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
11349961|NCT02368353|Experimental|Cognitive behavioral therapy group|weekly group stress-management CBT (SM-CBT) - 1/week 3 months
11349962|NCT02368353|Active Comparator|Reference group|weekly supportive therapy - 1/week 3 months
11349963|NCT02368340||Adults with pulmonary fibrosis|This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.
11349964|NCT02368340||Adults at-risk|"This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.
~Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens."
11349965|NCT02368340||HPS adults not at-risk|"This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.
~Subjects in this group will provide blood and urine specimens."
11349966|NCT02368340||Children with HPS at-risk|This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.
11349967|NCT02368327|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine
11349968|NCT02368327|Active Comparator|Fendrix|Participants receive one dose of Fendrix vaccine
11349969|NCT02368327|Placebo Comparator|Placebo|Participants receive one dose of saline placebo
11349970|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
11349971|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
11349972|NCT02368288|Experimental|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
11349973|NCT02368288|No Intervention|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
11349974|NCT02368275||prospective cohort of patients undergoing mastectomy|Prospective cohort
11349975|NCT02368275||cross sectional cohort of patients|Cross sectional cohort
11349976|NCT02368262||CP- incontinent|Children with CP and daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
11349977|NCT02368262||CP- continent|Children with CP without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
11349978|NCT02368262||NoDev - incontinent|Children with normal development with daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
11349979|NCT02368262||NoDev - continent|Children with normal development without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
11349980|NCT02368249|Placebo Comparator|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
11349981|NCT02368249|Experimental|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
11349982|NCT02368236|Other|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
11349983|NCT02368236|No Intervention|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
11349984|NCT02368236|No Intervention|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
11349985|NCT02368223|Experimental|YouGrabber training|Home-based YouGrabber training
11349986|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
11349987|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
11349988|NCT02368197|Active Comparator|Standard balloon angioplasty|Dilatation of stenosis with standard non drug eluting balloon catheter
11349989|NCT02368197|Experimental|Drug eluting balloon angioplasty|Dilatation of stenosis with paclitaxel eluting balloon catheter
11349990|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo
11349991|NCT02368171||control|patients with AHI<5/h and RVSP<35 mmHg on Echo
11349992|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI>5/h, but RVSP<35 mmHg on Echo
11349993|NCT02368158|Experimental|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
11349994|NCT02368158|Experimental|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
11349995|NCT02368132|No Intervention|Usual Care|Caregivers randomized to UC will be sent general material about VA and community resources for patients with dementia and their CGs. With the exception of this material, individuals in this group will receive usual care and will be contacted again at 3, 6, and 12 months for follow-up research assessments.
11349996|NCT02368132|Active Comparator|Individual Delivered TEP Arm|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
11349997|NCT02368132|Active Comparator|Group Delivered TEP Arm|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
11349998|NCT02368119|Experimental|Group 1|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=10) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=10). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
11349999|NCT02368119|Experimental|Group 2|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=20) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=20). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
11350000|NCT02368106||Radiation Therapy|Participants receiving one of the 11 listed therapy modalities.
11350001|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
11350002|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
11350003|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
11350004|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
11350005|NCT02368067|Active Comparator|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
11350006|NCT02368067|Experimental|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
11350007|NCT02368054|Active Comparator|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
11350008|NCT02368054|Active Comparator|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
11350009|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
11350010|NCT02368028||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
11350011|NCT02368028||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
11350012|NCT02368015|Other|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.
~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
11350013|NCT02368002|Experimental|Behavioral weight loss therapy|Emphasizes 1) identifying behaviors in need of change, 2) setting goals for change, 3) monitoring progress, 4) modifying environmental cues to facilitate change, and 5) modifying consequences to motivate change.
11350014|NCT02368002|Experimental|Meal replacements|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive meal replacements in addition to standard behavioral weight loss therapy.
11350015|NCT02368002|Experimental|Enhanced behavioral weight loss therapy|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive an enhanced version of behavioral weight loss therapy.
11350016|NCT02367989|Placebo Comparator|Control without fibre|"Intervention: 0g barley β-glucan no fibre.
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
11350017|NCT02367989|Experimental|low barley β-glucan|"Intervention: 2g barley β-glucan
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
11350018|NCT02367989|Experimental|medium barley β-glucan|"Intervention: 4g barley β-glucan
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
11350019|NCT02367989|Experimental|high barley β-glucan|"Intervention: 6g barley β-glucan
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
11350020|NCT02367989|Placebo Comparator|control with fibre|"Intervention: 0g barley β-glucan with fibre
~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
11350021|NCT02367976|Experimental|rhprouk|rhprouk to be administrated in 60 minutes.
11350022|NCT02367976|No Intervention|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
11350023|NCT02367963|Experimental|Intervention|A Training period and a Peer-group intervention are asigned to this arm. Peer-group intervention is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
11350024|NCT02367963|Other|Control|"A Training period intervention is asigned to this arm. Once the workshops have been carried out, the control group will be provided with written and visual documentation of risk factors and overall health habits. The members of this group will have access to the study website, where they will be able to find information on risk factors and health habits and links to the same websites related to health as the intervention group.
~They won't participate in the sessions of peer education group dynamics for a period of 12 months."
11350025|NCT02367950|Experimental|Single Arm Study|All participants receive active treatment (exercise) tailored to their level of health ad fitness
11350026|NCT02367937|Experimental|PRC-4016 (Icosabutate)|
11350027|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
11350028|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
11423528|NCT01878578|Experimental|Eslicarbazepine acetate|ESL 600 mg tablets
11350029|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
11350030|NCT02367898|Experimental|Cognitive Training|Lumosity cognitive training program.
11350031|NCT02367898|Active Comparator|Crossword Puzzles|Timed online crossword puzzles
11350032|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
11350033|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
11350034|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
11350035|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
11350036|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350037|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350038|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350039|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350040|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350041|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350042|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
11350043|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
11350044|NCT02367846|Experimental|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
11350045|NCT02367846|Experimental|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
11350046|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
11350047|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
11350048|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
11350049|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
11350050|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
11350051|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
11350086|NCT02367560|Active Comparator|SWT|Participants in this arm of the trial will be referred for Shockwave therapy (SWT) using an Ultrasound device, delivered by a physiotherapist, as their treatment for calcific tendinitis
11350087|NCT02367547|Experimental|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
11350088|NCT02367547|Experimental|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
11350089|NCT02367547|Active Comparator|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
11423529|NCT01878578|Active Comparator|phenytoin|Hidantina® 100 mg tablets
11350052|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
11350053|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
11350054|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants will receive intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants will receive IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
11350055|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants will receive IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
11350056|NCT02367755|Experimental|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
11350057|NCT02367755|Active Comparator|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
11350058|NCT02367742|Other|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
11350059|NCT02367742|Other|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
11350060|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
11350061|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
11350062|NCT02367703|Experimental|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
11350063|NCT02367703|Other|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
11350064|NCT02367690|Experimental|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:
~a) Standard-of-care (SOC) + Selinexor gel, 10 μM
~, b) SOC + vehicle gel c) SOC alone."
11350065|NCT02367690|Experimental|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:
~Standard-of-care (SOC) + Selinexor gel, 30 μM
~SOC + vehicle gel
~SOC alone."
11350066|NCT02367690|Experimental|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:
~Standard-of-care (SOC) + Selinexor gel, 70 μM
~SOC + vehicle gel
~SOC alone."
11350067|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
11350068|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
11350069|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
11350070|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
11350071|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
11350072|NCT02367664|Active Comparator|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
11350073|NCT02367651|Experimental|Pazopanib|Subjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
11350074|NCT02367651|Placebo Comparator|Placebo|Subjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
11350075|NCT02367638|Experimental|MG1111|
11350076|NCT02367638|Active Comparator|VARIVAX|
11350077|NCT02367625|Experimental|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
11350078|NCT02367625|Active Comparator|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
11350079|NCT02367612|Experimental|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
11350080|NCT02367612|Placebo Comparator|Placebo|Placebo
11350081|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
11350082|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
11350083|NCT02367573|Active Comparator|2D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with two dimensional view
11350084|NCT02367573|Experimental|3D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with three dimensional view
11350085|NCT02367560|Active Comparator|NDSSI|Participants in this arm of the trial will be referred for Needle decompression with subacromial steroid (Depo medrol) injection (NDSSI) as their treatment for calcific tendinitis
11350090|NCT02367534|Experimental|Umbilical vein|umbilical vein catheterization
11423530|NCT01878578|Placebo Comparator|Placebo|Placebo tablets
11350091|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
11350092|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
11350093|NCT02367508|Experimental|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
11350094|NCT02367495|Experimental|PCB|Paclitacel-coated balloon (Agent, Boston Scientific)
11350095|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
11350096|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
11350097|NCT02367456|Experimental|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
11350098|NCT02367456|Experimental|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
11350099|NCT02367443|Experimental|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
11350100|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
11350101|NCT02367404|No Intervention|Control|Keigel's exercise
11350102|NCT02367404|Active Comparator|Duloxetine|Duloxetine 60mg for 3 months
11350103|NCT02367404|Active Comparator|Duloxetine + PMFT|Duloxetine 60mg for 3 months PMFT weekly for 3 months
11350104|NCT02367404|Active Comparator|Pelvic Floor Muscle Training|PMFT weekly for 3 months
11350105|NCT02367391|Experimental|Motivational Text Messages|
11350106|NCT02367391|Sham Comparator|Control|
11350107|NCT02367378||MIS|Those who received minimally invasive surgical procedures
11350108|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
11350109|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
11350110|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
11350111|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
11350112|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
11350113|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
11350114|NCT02367326||Patients with Inflammatory Bowel Disease|patients with Crohn's Disease or Ulcerative Colitis meeting clinical, endoscopic and histological criteria and on thiopurines at stable doses for at least 3 months, monotherapy or combined with corticotherapy
11350115|NCT02367313|Placebo Comparator|Placebo|Placebo
11350116|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
11350117|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
11350118|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
11350119|NCT02367261|Experimental|SPI dental implant|Subjects implanted with SPI implant
11350120|NCT02367248|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 500 mg of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water.
11350121|NCT02367248|Active Comparator|Xingnaojing injection|Xingnaojing injection supplied in vials containing 20 ml liquid xingnaojing.
11350122|NCT02367248|Placebo Comparator|Normal Saline|0.9% sodium chloride
11350123|NCT02367235|Experimental|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
11350124|NCT02367235|Experimental|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
11350125|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
11350126|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
11350127|NCT02367196|Experimental|Part A: CC-90002|CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
11350128|NCT02367196|Experimental|Part B: CC-90002 with Rituximab|CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL
11350129|NCT02367183|Experimental|GED-0301 160mg QD 12 WK|GED-0301 160 mg once daily (QD) for 12 weeks
11350130|NCT02367183|Experimental|GED-0301 160 mg QD 8 WK|GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
11351664|NCT02357160|Active Comparator|No choice|Patients not given choice over artwork on wall
11350131|NCT02367183|Experimental|GED-0301 160 mg QD 4 WK|GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
11350132|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
11350133|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
11350134|NCT02367157|Experimental|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
11350135|NCT02367157|No Intervention|No intervention: Control|
11350136|NCT02367131||Jardiance|
11350137|NCT02367118|Experimental|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
11350138|NCT02367118|Placebo Comparator|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
11350139|NCT02367105|Active Comparator|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
11350140|NCT02367105|Placebo Comparator|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
11350141|NCT02367092|Experimental|Exercise Program|The exercise intervention consists of a 30 minute exercise session led by an instructor through a DVD or a video available on the internet.
11350142|NCT02367092|No Intervention|Standard of care|Standard of care which consists of encouragement to exercise by the subject's transplant clinician.
11350143|NCT02367079|Active Comparator|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
11350144|NCT02367079|Sham Comparator|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
11350145|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
11350146|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
11350147|NCT02367053|Experimental|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
11350148|NCT02367053|Active Comparator|native glucagon|single fixed dose of glucagon
11350149|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
11350150|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
11350151|NCT02367027|Experimental|Arm 1 - BAY59-7939|10 mg oral suspension (dry powder) in fasted conditions
11350152|NCT02367027|Experimental|Arn 2 - BAY59-7939|20 mg oral suspension (dry powder) in fed conditions.
11350153|NCT02367027|Experimental|Arm 3 - BAY59-7939|10 mg oral suspension in fasted conditions
11350154|NCT02367027|Experimental|Arm 4 - BAY59-7939|10 mg tablet in fasted conditions.
11350155|NCT02367014|Experimental|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
11350156|NCT02367014|Experimental|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
11350157|NCT02367014|Experimental|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
11350158|NCT02367014|Placebo Comparator|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
11350159|NCT02367001|Other|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)
~Intervention : Normal invitation"
11350160|NCT02367001|Experimental|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)
~Intervention : revised invitation signed by the coordinating doctor"
11350161|NCT02367001|Experimental|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)
~Intervention : Revised invitation signed by the attending physician"
11350162|NCT02366988|Active Comparator|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
11350163|NCT02366988|Active Comparator|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
11350164|NCT02366975|No Intervention|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
11350165|NCT02366975|Active Comparator|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
11350166|NCT02366975|Placebo Comparator|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
11350167|NCT02366962|Experimental|ASP7374 group|
11350168|NCT02366949|Experimental|Arm 1|Experimental Treatment (combination of BAY1217389 with paclitaxel in an intermittent dosing schedule) Expansion Cohort - Maximum tolerated dose of BAY1217389 and Paclitaxel
11350169|NCT02366949|Placebo Comparator|Arm 2|Standard Treatment (Single-agent Paclitaxel )
11350170|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
11350171|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
11350172|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
11350173|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
11424480|NCT01872182|Experimental|Test arm|ALS-L1023 300mg in two tablets
11350174|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
11350175|NCT02366897|Other|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
11350176|NCT02366884|Experimental|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
11350177|NCT02366884|Experimental|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
11350178|NCT02366884|Experimental|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
11350179|NCT02366884|Experimental|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
11350180|NCT02366871|Experimental|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
11350181|NCT02366871|Active Comparator|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
11350182|NCT02366858|Active Comparator|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.
11350183|NCT02366858|Active Comparator|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.
11350184|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.
~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
11350185|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.
~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
11350186|NCT02366832|Experimental|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
11350187|NCT02366819|Experimental|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients undergo conventional surgery.
~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
11350188|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
11350189|NCT02366793|Experimental|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
11350190|NCT02366793|Experimental|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
11350191|NCT02366780|Experimental|Manual expression followed by electric pump|Mothers will be assigned to first express breast milk manually followed by electric pump
11350192|NCT02366780|Experimental|Electric pump followed by manual expression|Mothers will be assigned to first express breast milk by electric pump followed by manual expression
11350193|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
11350194|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
11350195|NCT02366754|Experimental|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
11350196|NCT02366754|Sham Comparator|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
11424624|NCT01871194||Rivaroxaban|This is a non-interventional study
11350197|NCT02366741|Other|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
11350198|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
11350199|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td), 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
11350200|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DC vaccines #1 and #2 with Td pre-conditioning 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
11350201|NCT02366715|Experimental|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
11350202|NCT02366702||Individuals with Bilateral Transfemoral Amputation|
11350203|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
11350204|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
11350205|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
11350206|NCT02366676|Experimental|treatment group|-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd~5th month:once a month)
11350207|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
11350208|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
11350209|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
11350210|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
11350211|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
11350212|NCT02366650||Bern ED|appr 100 patients at Bern ED
11350213|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
11350214|NCT02366637|Experimental|PF-03715455|
11350215|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
11350216|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
11350217|NCT02366598|Experimental|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
11350218|NCT02366598|Experimental|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
11350219|NCT02366598|Active Comparator|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
11350220|NCT02366598|Experimental|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
11350221|NCT02366598|Placebo Comparator|Control shake|non-protein control shake, given once, at beginning of acute trial
11350222|NCT02366585|Experimental|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
11350223|NCT02366572|Placebo Comparator|Cereal control|100% Wheat Flour
11350224|NCT02366572|Experimental|Cereal with pea protein|Pea protein
11350225|NCT02366572|Experimental|Cereal with pea starch|Pea starch
11350226|NCT02366572|Experimental|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
11350227|NCT02366572|Experimental|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
11350228|NCT02366572|Experimental|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
11350229|NCT02366559|Active Comparator|electrocautery|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
11350230|NCT02366559|Active Comparator|532 nm Nd:YAG laser|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
11350231|NCT02366546|Experimental|Low dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
11350232|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
11350700|NCT02363426|Active Comparator|Medical Device: IVF Incubator|5 day oocyte incubation using traditional IVF incubation.
11350233|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 2|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
11350234|NCT02366546|Experimental|TBI-1301 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
11350235|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
11350236|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
11350237|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
11350238|NCT02366494||Androgen blockade|Androgen DeprivationTherapy or Complete Androgen Blockade
11350239|NCT02366494||Chemo Hormonal therapy|Trelstar IM injection with Docetaxel (Taxorere) 75mg/m2 every 3 weeks for 10 cycles.
11350240|NCT02366481|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
11350241|NCT02366481|Active Comparator|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
11350242|NCT02366481|Active Comparator|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
11350243|NCT02366468|Experimental|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
11350244|NCT02366468|Active Comparator|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
11350245|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
11350246|NCT02366429|Experimental|ICBT|Internet-based CBT for antenatal depression
11350247|NCT02366429|Active Comparator|TAU|Treatment as usual provided at antenatal clinics and other health care instances
11350248|NCT02366416|Experimental|Exercise training|12 weeks of one hour exercise training twice weekly
11350249|NCT02366403|Experimental|SKY|a standardized meditation program
11350250|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
11350251|NCT02366390|Experimental|Psychoeducative intervention|A psychoeducative dialogue and one telephone booster session
11350252|NCT02366390|No Intervention|Usual care|Usual care according to current guidelines.
11350253|NCT02366377|Experimental|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
11350254|NCT02366377|Experimental|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
11350255|NCT02366377|Experimental|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
11350256|NCT02366377|Experimental|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
11350257|NCT02366364|Placebo Comparator|Drug: Placebo|Single oral administration on Day 1
11350258|NCT02366364|Experimental|Drug: NRX-1074 375 mg|Single oral administration on Day 1
11350259|NCT02366364|Experimental|Drug: NRX-1074 500 mg|Single oral administration on Day 1
11350260|NCT02366364|Experimental|Drug: NRX-1074 750 mg|Single oral administration on Day 1
11350261|NCT02366351|Experimental|SHR3824 Placebo|once daily, 12 weeks
11350262|NCT02366351|Experimental|SHR3824 5 mg|once daily, 12 weeks
11350263|NCT02366351|Experimental|SHR3824 10 mg|once daily, 12 weeks
11350264|NCT02366351|Experimental|SHR3824 20 mg|once daily, 12 weeks
11350265|NCT02366325|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
11350266|NCT02366325|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
11350267|NCT02366325|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
11350268|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
11350269|NCT02366299|Active Comparator|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
11350270|NCT02366299|Active Comparator|propofol|Treatment of delirium by propofol i.v. infusion
11350271|NCT02366247|Experimental|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
11350272|NCT02366247|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
11350273|NCT02366234||Fracture of Distal Tubercle of Scaphoid|"Questionnaires
~Quick DASH after trauma (< 2 weeks)
~11-point ordinal measure of overall pain intensity 6 months after trauma
~11-point ordinal measure of satisfaction with treatment 6 months after trauma"
11350274|NCT02366221||All subjects|Subjects with a history of complex arm trauma
11350275|NCT02366208|Experimental|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
11424661|NCT01870908||tacrolimus + biological agents|
11350276|NCT02366208|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
11350277|NCT02366195|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
11350278|NCT02366156|Placebo Comparator|Placebo|Inactive capsules
11350279|NCT02366156|Active Comparator|Low Dose Grape Blend|Low dose grape blend providing 375 mg whole grape extract + 375 mg grape seed extract/d (750 mg total botanical extracts/d).
11350280|NCT02366156|Active Comparator|High Dose Grape Blend|High dose grape blend providing 500 mg whole grape extract + 500 mg grape seed extract/d (1000 mg total botanical extracts/d)
11350281|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
11350282|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
11350283|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
11350284|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.
~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
11350285|NCT02366117|Experimental|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.
~This training intervention will be applied to the facilities presenting half the patient sample size."
11350286|NCT02366117|No Intervention|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
11350287|NCT02366091|Experimental|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
11350288|NCT02366091|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
11350289|NCT02366091|Experimental|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
11350290|NCT02366091|Experimental|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
11350291|NCT02366078|Experimental|Stress management|Participants will receive SMART traiing
11350292|NCT02366065|Experimental|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
11350293|NCT02366052|Active Comparator|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
11350294|NCT02366052|Experimental|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
11350295|NCT02366052|Experimental|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
11350296|NCT02366039||EMR|patients undergoing clinically indicated endoscopic mucosal resection as standard of care will be asked to participate for this observational study
11350297|NCT02366026|Experimental|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
11350298|NCT02366026|Placebo Comparator|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
11350299|NCT02366013|Experimental|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
11350300|NCT02366013|Experimental|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
11350301|NCT02366013|Experimental|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
11350302|NCT02366013|Experimental|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
11350303|NCT02366000|Experimental|Brief Parental Training Intervention|Participants will have to attend two 3-hour Brief Parental Training Intervention Programme, with three weeks apart. There will also be two telephone follow-up sessions to reinforce learnt strategies and skills for home practice between workshops.
11350304|NCT02366000|Other|Wait-list Group|Participants will receive the same Brief Parental Training Intervention Programme as the intervention group. However, they will wait until the questionnaires have been completed by the intervention group for the second time (i.e. immediately after intervention) before they receive their programme.
11350305|NCT02365987|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
11350306|NCT02365987|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
11350307|NCT02365974|Active Comparator|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
11350308|NCT02365974|Sham Comparator|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
11350309|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
11350310|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
11350311|NCT02365948|Experimental|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.
~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
11350312|NCT02365948|Experimental|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
11350313|NCT02365948|Experimental|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
11350314|NCT02365948|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
11350315|NCT02365935|Experimental|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
11350316|NCT02365935|Experimental|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
11350317|NCT02365922||Patients with FTLD or family members|Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.
11350318|NCT02365909|Active Comparator|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
11350319|NCT02365909|Placebo Comparator|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
11350320|NCT02365896|Other|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
11350321|NCT02365883||Prostate Cancer Group|
11350322|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
11350323|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
11350324|NCT02365857|Active Comparator|DEX-5|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
11350325|NCT02365857|Active Comparator|DEX-10|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
11350326|NCT02365857|Active Comparator|DEX-15|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
11350327|NCT02365857|Active Comparator|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
11350328|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
11350329|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
11350330|NCT02365818|Experimental|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
11350331|NCT02365805|Active Comparator|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
11350332|NCT02365805|Experimental|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
11350333|NCT02365805|Experimental|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
11350334|NCT02365792|Active Comparator|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
11350335|NCT02365792|Active Comparator|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
11350336|NCT02365792|Placebo Comparator|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
11350337|NCT02365779|Experimental|bilateral laparoscopic salpingectomy|
11350338|NCT02365766|Experimental|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
11350339|NCT02365766|Experimental|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
11350340|NCT02365766|Experimental|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
11350341|NCT02365753|Placebo Comparator|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
11350342|NCT02365753|Active Comparator|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
11350343|NCT02365740|Experimental|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
11350344|NCT02365740|Sham Comparator|Controls|gastric emptying test gut hormones determination
11350345|NCT02365727|Experimental|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
11350346|NCT02365727|Placebo Comparator|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
11350347|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
11350348|NCT02365701|Experimental|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
11350349|NCT02365701|Placebo Comparator|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
11350350|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
11350351|NCT02365675|Active Comparator|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
11350352|NCT02365675|Active Comparator|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
11350353|NCT02365675|Active Comparator|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic 'nanocrystals' of metallic silver.
11350354|NCT02365675|Active Comparator|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
11350355|NCT02365662|Experimental|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
11350356|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
11350357|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
11350358|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
11350359|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
11350360|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
11350361|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
11350362|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
11350363|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
11350364|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
11350365|NCT02365636|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
11350366|NCT02365636|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
11350367|NCT02365636|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
11350368|NCT02365623|Experimental|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
11350369|NCT02365610|Experimental|GWP42006|GWP42006
11350370|NCT02365610|Placebo Comparator|Placebo control|Placebo
11350371|NCT02365597|Experimental|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression.
11350372|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
11350373|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
11350374|NCT02365571|Experimental|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
11350375|NCT02365571|Placebo Comparator|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
11350376|NCT02365571|Experimental|LY3154207 (Part B)|LY3154207 administered once orally.
11350377|NCT02365571|Placebo Comparator|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
11350378|NCT02365571|Experimental|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
11350379|NCT02365571|Experimental|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
11350380|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
11350381|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.
~Evacetrapib will be co-administered once, orally on Day 14."
11350382|NCT02365532|Placebo Comparator|Placebo to match GS-6615|Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
11350383|NCT02365532|Experimental|GS-6615|GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
11350384|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
11350385|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
11350386|NCT02365506|Experimental|Eleclazine Dose Level 1|Eleclazine dose level 1 + placebo to match eleclazine
11350387|NCT02365506|Experimental|Eleclazine Dose Level 2|Eleclazine dose level 2 + placebo to match eleclazine
11350388|NCT02365506|Placebo Comparator|Placebo|Placebo to match eleclazine for 4 days
11350389|NCT02365493|No Intervention|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).
~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
11350390|NCT02365493|Experimental|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
11350391|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
11350392|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
11350393|NCT02365454|Experimental|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
11350394|NCT02365441|Active Comparator|Arm A|imatinib 400mg orally daily continuously
11350395|NCT02365441|Experimental|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
11350396|NCT02365428|Experimental|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
11350397|NCT02365428|Experimental|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
11350398|NCT02365428|Experimental|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
11350399|NCT02365428|Experimental|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
11350400|NCT02365415|Experimental|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
11350401|NCT02365415|No Intervention|Control|No treatment.
11350402|NCT02365402|Experimental|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
11350403|NCT02365402|No Intervention|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
11350404|NCT02365389|Active Comparator|Group A received in situ MTZ vaginal gel|Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
11350405|NCT02365389|Active Comparator|Group B received conventional MTZ vaginal gel|Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
11350406|NCT02365363|Experimental|Bagel control|100% wheat flour
11350407|NCT02365363|Experimental|Bagel with pea flour|Pea flour (30%)
11350408|NCT02365363|Experimental|Bagel with pea fibre|Pea fibre (11g)
11350409|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre|Pea flour (30%) + pea fibre (11g)
11350410|NCT02365363|Experimental|Bagel w/ pea flour + pea protein|Pea flour (30%) + pea protein (24g)
11350411|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre + pea protein|Pea flour (30%) + pea fibre (11g) + pea protein (24g)
11350412|NCT02365350|Experimental|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
11350413|NCT02365350|Active Comparator|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
11350414|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels < 20ng/ ml
11350415|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels >20ng/ ml
11350416|NCT02365324|Experimental|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
11350417|NCT02365324|Other|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
11350418|NCT02365311|Experimental|one lung group|
11350419|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
11350420|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
11350421|NCT02365285|Experimental|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
11350422|NCT02365285|Placebo Comparator|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
11350423|NCT02365272|Active Comparator|amikacin standard dose|amikacin in a single standard dose
11350424|NCT02365272|Active Comparator|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
11350425|NCT02365259|Experimental|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
11350426|NCT02365259|Placebo Comparator|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
11350427|NCT02365246|Experimental|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
11350428|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
11350429|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
11350430|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
11350431|NCT02365220|Active Comparator|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training
11350432|NCT02365220|Experimental|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training"
11350433|NCT02365220|Experimental|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training"
11350434|NCT02365220|Experimental|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training"
11350435|NCT02365207|Experimental|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
11350436|NCT02365194|Other|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
11350437|NCT02365194|Other|Standard Counseling|initial clinic counseling
11350438|NCT02365181|Experimental|IAL|intra-articular local anesthetic infiltration with catheter
11350439|NCT02365181|Active Comparator|ISB|interscalene block with catheter
11350440|NCT02365168|Experimental|Food Challenge with cod|
11350441|NCT02365168|Experimental|Food Challenge with salmon|
11350442|NCT02365168|Experimental|Food Challenge with mackerel|
11350443|NCT02365168|Placebo Comparator|Food Challenge with placebo|
11350444|NCT02365155|Experimental|Intervention group.|Multicomponent training intervention; Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
11350445|NCT02365155|Active Comparator|Control group.|Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
11351665|NCT02357160|Placebo Comparator|No artwork|Patients not receiving any artwork on wall
11350446|NCT02365142|Active Comparator|Platelet Rich Plasma (PRGF)|Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
11350447|NCT02365142|Active Comparator|BMMSC with Platelet Rich Plasma (PRGF)|Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
11350448|NCT02365129|No Intervention|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
11350449|NCT02365129|Experimental|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
11350450|NCT02365129|Experimental|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
11350451|NCT02365116|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
11350452|NCT02365116|Active Comparator|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
11350453|NCT02365103|Other|Test meal I (given with water)|Test meal with water
11350454|NCT02365103|Other|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
11350455|NCT02365103|Other|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
11350456|NCT02365103|Other|Reference Iron Dose|Reference iron dose administered
11350457|NCT02365090|Active Comparator|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
11350458|NCT02365090|Experimental|binocular games|1 hour per day (5 days per week) binocular game play
11350459|NCT02365077||Control|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.
11350460|NCT02365077||Necrosis|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.
11350461|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
11350462|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
11350463|NCT02365051|No Intervention|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
11350464|NCT02365051|Experimental|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
11350465|NCT02365038|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation
11350466|NCT02365038|Active Comparator|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
11350467|NCT02365025|Experimental|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.
~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
11350468|NCT02365025|No Intervention|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.
~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.
~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.
~Step 5: 3 months follow up."
11350469|NCT02365012|Placebo Comparator|Placebo|Placebo given three times a day for 2 weeks
11350470|NCT02365012|Active Comparator|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
11350471|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
11350472|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
11350473|NCT02364986|Experimental|Rebif/Avonex|Rebif® 44µg (day 1, 3, 5 and 8) s.c. Avonex 30µg (day 1 and 8) i.m.
11350474|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
11350475|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|
11350476|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|
11350477|NCT02364947|Placebo Comparator|Placebo|
11350478|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
11350479|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
11350480|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
11350481|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
11350482|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
11350483|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
11350484|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
11350485|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
11350486|NCT02364921|Experimental|Two-layer compression bandage|Two multilayer compression bandage: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.Measure the ankle circumference and choose the correct kit accordingly (ankle size 18-25cm or 25-32cm). Apply one to seven days
11350487|NCT02364921|Active Comparator|crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
11350488|NCT02364908|Other|Patients with Systemic Lupus|
11350489|NCT02364895|Experimental|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
11350490|NCT02364895|Experimental|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
11350491|NCT02364882|Placebo Comparator|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
11350492|NCT02364882|Active Comparator|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
11350493|NCT02364882|Active Comparator|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
11350494|NCT02364882|Active Comparator|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
11350495|NCT02364869|Experimental|Fructooligosaccharide|12g daily, for 12 weeks
11350496|NCT02364869|Placebo Comparator|Maltodextrin|12g daily, for 12 weeks
11350497|NCT02364856||Children with cerebral palsy|
11350498|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
11350499|NCT02364830|Active Comparator|Anise-oil EC|Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks. Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
11350500|NCT02364830|Placebo Comparator|Placebo|Placebo Group: One Placebo Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
11350501|NCT02364830|Active Comparator|Colpermin®|Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
11350502|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).
~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
11350503|NCT02364791|Active Comparator|standard treatment|standard techniques to achieve air leak control after complex thoracic surgical procedures
11350504|NCT02364791|Experimental|standard treatment plus hemopatch|the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures
11350505|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
11350506|NCT02364765|Other|Orthognatic surgery|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour.
11350507|NCT02364752|Experimental|Healthy|Part 1: Blood is obtained from healthy participants on 3 consecutive days, and participants undergo Cardiac Magnetic Resonance Imaging (CMR) and two-dimensional speckle tracking echocardiography (2DSTE) on one of those 3 days.
11350508|NCT02364752|Experimental|Mild/moderate heart failure (HF)|Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
11350509|NCT02364752|Experimental|Severe HF|Part 1: Blood is obtained from participants with severe HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
11350510|NCT02364739|Experimental|Written information|Written information
11350511|NCT02364739|Experimental|Written and oral information|Written and oral information
11350512|NCT02364739|No Intervention|No intervention|Control
11350513|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.
~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
11350514|NCT02364713|Experimental|Arm A (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11350664|NCT02363660|Experimental|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
11351756|NCT02356536|Experimental|Experimental|
11350515|NCT02364713|Active Comparator|Arm B (DOXIL, GEM, TOPA, TAXOL)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15, or paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may also receive bevacizumab IV over 30-90 minutes on days 1 and 15 with pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, or paclitaxel. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11350516|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
11350517|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
11350518|NCT02364674|Experimental|HRCT scans|HRCT scan will be taken
11350519|NCT02364661|Experimental|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
11350520|NCT02364648|Experimental|MitoQ|4 week 20mg oral daily dose of MitoQ
11350521|NCT02364648|Placebo Comparator|Placebo|4 week 20mg oral daily placebo
11350522|NCT02364635|Experimental|Icosabutate dose 1|Dose 1
11350523|NCT02364635|Experimental|Icosabutate dose 2|Dose 2
11350524|NCT02364635|Experimental|Icosabutate dose 3|Dose 3
11350525|NCT02364635|Placebo Comparator|Placebo|Placebo (medium chain triglycerides)
11350526|NCT02364635|Experimental|Icosabutate dose 4|Dose 4
11350527|NCT02364622|Sham Comparator|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
11350528|NCT02364622|Experimental|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
11350529|NCT02364622|Experimental|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
11350530|NCT02364609|Experimental|Arm I (afatinib dimaleate, pembrolizumab)|DOSE DE-ESCALATION COHORT: Patients receive afatinib dimaleate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days (for up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
11350531|NCT02364609|Experimental|Arm II (pembrolizumab, afatinib dimaleate)|EXPANSION COHORT: Patients receive pembrolizumab IV over 30 minutes on day 1 for 2 courses. Beginning course 3, patients receive afatinib dimaleate PO and pembrolizumab IV as in Arm I. Courses repeat every 21 days (up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
11350532|NCT02364596|Experimental|1|SA4Ag vaccine
11350533|NCT02364583|Active Comparator|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
11350534|NCT02364583|Active Comparator|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
11350535|NCT02364583|Active Comparator|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
11350536|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
11350537|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
11350538|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
11350539|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
11350540|NCT02364557|No Intervention|Arm 1 (standard of care)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician.
11350541|NCT02364557|Experimental|Arm 2 (stereotactic radiosurgery, surgery)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician. Patients also undergo stereotactic radiosurgery in 1, 3, or 5 fractions within 3 weeks and/or surgery at the discretion of the treating physician.
11350542|NCT02364544|Other|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program
~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
11350543|NCT02364531||Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
11350544|NCT02364518|Experimental|Snoreplasty|Treatment of Snoring and/or mild obstructive sleep apnea with snoreplasty.
11350545|NCT02364505|Experimental|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
11350546|NCT02364505|Active Comparator|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
11350547|NCT02364492|Experimental|MAG-Tn3 + AS15|"3 escalating doses of MAG-Tn3 in combination with a fixed dose of AS15 adjuvant.
~For each dose patient will receive 6 injections at 3 interval weeks."
11350548|NCT02364479|Experimental|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
11350549|NCT02364479|Experimental|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
11350550|NCT02364479|Placebo Comparator|Placebo|Placebo, Subcutaneous injection per week
11350551|NCT02364453|Experimental|Placebo to PACAP38|Pre-treatment with placebo. PACAP38 8pmol/kg/min
11350552|NCT02364453|Experimental|Clemastin 1 mg/ml to PACAP38 8pmol/kg/min|Pre-treatment with Clemastin 1 mg/ml PACAP38 8 pmol/kg/min
11350553|NCT02364440|Experimental|Ultherapy™ System|Ultherapy™ System
11350554|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
11350555|NCT02364414|Other|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
11350556|NCT02364401|Experimental|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
11350557|NCT02364401|Active Comparator|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
11350558|NCT02364388|Active Comparator|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
11350559|NCT02364388|Other|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
11350560|NCT02364362|Experimental|Famitinib + docetaxel|Low, medium and high dose of famitinib and 60 mg/m^2 docetaxel every 3 weeks
11350561|NCT02364349|Active Comparator|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
11350562|NCT02364349|Experimental|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
11350563|NCT02364336|Experimental|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
11350564|NCT02364336|Experimental|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
11350565|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
11350566|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
11350567|NCT02364310|Experimental|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
11350568|NCT02364310|No Intervention|Best medical care|Best medical care
11350569|NCT02364297|Active Comparator|Early TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.
~Performance of TIPS in the first 5 days following acute gastric variceal bleeding."
11350570|NCT02364297|Placebo Comparator|Control|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.
~Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices)."
11350571|NCT02364284||Urinary Tract Infection (cUTI)|Patients ≥18 years with diagnosis of urinary tract infection.
11350572|NCT02364284||Intra Abdominal Infection(cIAI)|Patients ≥ 18 years with diagnosis of Intra Abdominal Infection
11350573|NCT02364284||Nosocomial Pneumonia (NP)|Patients ≥ 18 years with diagnosis of Hospital acquired pneumonia
11350574|NCT02364271||MACE groups|"Patients with major adverse cardiac events occurred within 30-days or 6-months
~Routine blood test for hs-cTnT and point-of-care test for H-FABP, Coronary CT angiography and Thrombolysis in myocardial infarction score were performed on study patients
~Protocol amendment:
~In October 2014, HEART score of the study patients was determined retrospectively"
11350575|NCT02364271||No MACE group|"Patients with no major adverse cardiac events occurred within 30-days or 6-months
~Routine blood test for hs-cTnT and point-of-care test for H-FABP, Coronary CT angiography and Thrombolysis in myocardial infarction score were performed on study patients
~Protocol amendment:
~In October 2014, HEART score of the study patients was determined retrospectively"
11350576|NCT02364258|Experimental|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
11350577|NCT02364258|Experimental|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
11350578|NCT02364245|Experimental|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
11350579|NCT02364245|Placebo Comparator|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
11350580|NCT02364232|Experimental|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.
~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
11350581|NCT02364232|Active Comparator|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.
~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
11350582|NCT02364219|No Intervention|Standard|"Study arm in which patients are treated according to standard operating procedures. Acting as control arm."
11350583|NCT02364219|Experimental|Standard + Microdialysis|Study arm in which patients are treated according to standard operating procedures but also receive Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue.
11350584|NCT02364219|Experimental|Prewarm|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
11350585|NCT02364219|Experimental|Prewarm + Microdialysis|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia and Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue
11350586|NCT02364206|Experimental|LY2228820 + TMZ + Radiotherapy|"addition of LY2228820 to standard radiotherapy and concomitant treatment by temozolomide (TMZ).
~LY2228820 will be administered orally for two 28 day cycles, from one week before the beginning of radiotherapy, and during standard chemoradiotherapy. Three dose levels of LY2228820 will be tested.
~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
11350587|NCT02364193|Experimental|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:
~Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.
~CO, phase contrast angiography.
~Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).
~DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).
~BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
11350588|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
11350589|NCT02364167|Experimental|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
11350590|NCT02364167|Placebo Comparator|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
11350591|NCT02364167|Active Comparator|Standard therapy|Each patient will receive just standard postoperative analgesia
11350592|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
11350593|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
11350594|NCT02364141|Experimental|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
11350595|NCT02364141|Active Comparator|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
11350596|NCT02364128|No Intervention|Control|Potential bariatric surgery patients who receive both the baseline questionnaire and follow-up questionnaire.
11350597|NCT02364128|Other|Decision Aid|Potential bariatric surgery patients who receive both the baseline questionnaire decision aid/conjoint analysis and follow-up questionnaire.
11350598|NCT02364115|Experimental|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
11350599|NCT02364115|No Intervention|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
11350600|NCT02364089|Experimental|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
11350601|NCT02364089|Active Comparator|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
11350602|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
11350603|NCT02364063|Experimental|Children with CP - Therapy|Children receive incontinence treatment during one year, after which a follow-up period of 6 months will be applied. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
11350604|NCT02364063|No Intervention|Children with CP - Control|Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
11350605|NCT02364063|Active Comparator|Children without CP|Children receive incontinence treatment during 1 year. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
11350606|NCT02364050||Elderly patients with DLBCL|Elderly patients (Age ≥ 65 years) with large B-cell lymphoma classified FIT or UNFIT or FRAIL by Multidimensional Geriatric Assessment (MGA)
11350607|NCT02364037|Other|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
11350608|NCT02364037|Other|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
11350609|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
11350610|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
11350611|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
11350612|NCT02363985|Other|Multiple vitamin A exposer|"55 children who are using
~Mega-dose vitamin A supplementation
~Food diversification (promotion and education on vitamin A rich food consumption)
~Promotion of orange flash sweet potato production and consumption in collaboration with international potato center (CIP) in one of the study area"
11350613|NCT02363985|Other|Only vitamin A supplementation|"55 children who are using
~Mega-dose vitamin A supplementation
~Food diversification (promotion and education on vitamin A rich food consumption)"
11350614|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
11350615|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
11350616|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
11350617|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
11350618|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
11350619|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
11350620|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
11350621|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
11350622|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
11350623|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
11350624|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
11350625|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
11350626|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
11350627|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
11350628|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
11350629|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
11350630|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
11350631|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
11350665|NCT02363660|Experimental|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
11352534|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
11350632|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
11350633|NCT02363920|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
11350634|NCT02363920|Active Comparator|HOF20|the patients will be asked to breathe with HOF of 20 L/min
11350635|NCT02363920|Active Comparator|HOF30|the patients will be asked to breathe with HOF of 30 L/min
11350636|NCT02363920|Active Comparator|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
11350637|NCT02363894||Subjects enrolled in DEFINITIVE AR|
11350638|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
11350639|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
11350640|NCT02363855|Experimental|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
11350641|NCT02363842|Experimental|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
11350642|NCT02363842|Active Comparator|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
11350643|NCT02363829|Experimental|Treatment|Nelfinavir and Cisplatin
11350644|NCT02363803|Placebo Comparator|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
11350645|NCT02363803|Active Comparator|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
11350646|NCT02363790|Other|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)
~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).
~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
11350647|NCT02363790|Other|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
11350648|NCT02363777|Active Comparator|Standard of Care|Epidural placed for postoperative pain control
11350649|NCT02363777|Experimental|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
11350650|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)
~Nasal swab
~Cough swab
~Spontaneous expectorated sputum
~Questionnaire"
11350651|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)
~Nasal swab
~Cough swab
~Induced sputum after inhalation of hypertonic saline (NaCl 6%)
~Questionnaire"
11350652|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)
~Nasal swab
~Cough swab
~Induced sputum after inhalation of hypertonic saline (NaCl 6%)
~Bronchoalveolar lavage (BAL)"
11350653|NCT02363751|Experimental|1|Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinium salt+bevcizumab)
11350654|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
11350655|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
11350656|NCT02363725|Other|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):
~Double anti-aggregation
~IEC (or sartan) at best tolerated dose
~Beta-blocker at best tolerated dose
~High dose statin (usually atorvastatin 80 mg daily)
~If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)
~Any other treatment will be logged."
11350657|NCT02363725|Experimental|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
11350658|NCT02363712|Experimental|APOS|APOS(All Phase Of Step)-shoe
11350659|NCT02363712|Sham Comparator|Sham APOS|Sham APOS(All Phase Of Step)-shoe
11350660|NCT02363699|Active Comparator|Lidocaine|Group treated with lidocaine solution
11350661|NCT02363699|Placebo Comparator|Placebo|Group treated with saline solution
11350662|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
11350663|NCT02363673|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy in aqua distilla according to their symptoms and characteristic manifestations of their disorder. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Remedies will be dispensed in aqua distilla. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing.
11424662|NCT01870895|Experimental|YM060 group|
11350666|NCT02363660|Experimental|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
11350667|NCT02363647|Experimental|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
11350668|NCT02363634|Active Comparator|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
11350669|NCT02363634|Placebo Comparator|Placebo|Those randomized to placebo
11350670|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
11350671|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
11350672|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
11350673|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
11350674|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
11350675|NCT02363595||Papillary Microcarcinoma|This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
11350676|NCT02363582|No Intervention|Breast fed|healthy term infants on exclusively breast feeding , enrollment age: 30-50days old
11350677|NCT02363582|Experimental|Formula fed|healthy term infants on exclusively formula fed , enrollment age: 30-50days old
11350678|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
11350679|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
11350680|NCT02363556|Experimental|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
11350681|NCT02363556|Experimental|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
11350682|NCT02363543|Active Comparator|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
11350683|NCT02363543|Active Comparator|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
11350684|NCT02363530|Experimental|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
11350685|NCT02363530|Placebo Comparator|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
11350686|NCT02363517|No Intervention|Group A|"Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).
~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
11350687|NCT02363517|Active Comparator|Group B|"Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.
~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
11350688|NCT02363517|Active Comparator|Group C|Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
11350689|NCT02363504||Healthy older controls|7 Tesla MRI with memory task and non-invasive neurostimulation
11350690|NCT02363504||Prodromal Alzheimer's disease patients|7 Tesla MRI with memory task and non-invasive neurostimulation
11350691|NCT02363491|Experimental|OPN-305|OPN-305
11350692|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
11350693|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
11350694|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
11350695|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
11350696|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.
~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
11350697|NCT02363452|Experimental|AGS|Reverse transcriptase inhibitors
11350698|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
11350699|NCT02363426|Other|Medical Device: INVOcell Culture Device|5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
11352535|NCT02350985|Active Comparator|Propranolol|Propranolol up to 160 mg/day
11350701|NCT02363413|Active Comparator|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
11350702|NCT02363413|Experimental|IniVAD|Initiation of the NIV at home : experimental care.
11350703|NCT02363400|Experimental|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
11350704|NCT02363400|No Intervention|control arm|closely followed with frequency similar to the experiemental arm
11350705|NCT02363387|Experimental|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
11350706|NCT02363387|Other|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
11350707|NCT02363374|Active Comparator|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
11350708|NCT02363374|Experimental|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
11350709|NCT02363361|Experimental|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
11350710|NCT02363348|Placebo Comparator|Placebo (A)|"were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.
~dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner."
11350711|NCT02363348|Experimental|L arginine (B)|were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
11350712|NCT02363335|Placebo Comparator|Placebo|Randomized, double blind, placebo-controlled cross-over study
11350713|NCT02363335|Experimental|Roflumilast|Randomized, double blind, placebo-controlled cross-over study
11350714|NCT02363335|Experimental|Roflumilast/Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
11350715|NCT02363335|Experimental|Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
11350716|NCT02363322|Active Comparator|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
11350717|NCT02363322|Experimental|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
~ZMapp 50mg/kg IV administered every third day for 3 infusions."
11350718|NCT02363309||Healthy Volunteers|Subjects without liver disease or metabolic syndrome
11350719|NCT02363309||NAFLD subjects|Subjects with Non-Alcoholic Fatty Liver Disease
11350720|NCT02363309||non-NAFLD metabolic syndrome|Subjects who have metabolic syndrome but do not have Non-Alcoholic Fatty Liver Disease
11350721|NCT02363296|Experimental|EEG phase-triggered PAS|TMS triggered to a specific phase of the EEG mu rhythm
11350722|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
11350723|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
11350724|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
11350725|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
11350726|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
11350727|NCT02363231||patients under mechanical ventilation|
11350728|NCT02363218|Experimental|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
11350729|NCT02363205|No Intervention|control|Weekly check-up
11350730|NCT02363205|Experimental|internet-delivered CBT|Tailored Internet-administrated CBT-Treatment
11350731|NCT02363192|Experimental|Pharmacist Intervention Group|
11350732|NCT02363192|No Intervention|Usual Care Group|
11350733|NCT02363179|No Intervention|Non Music Group|500 non-intervention patients will be consented to serve as the control group
11350734|NCT02363179|Experimental|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
11350735|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
11350736|NCT02363153|Experimental|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
11350737|NCT02363140|No Intervention|Group One patients in age group 18--20 years,|"Patients should be aged 18--20 years or 35--45years
~Asymptomatic knee for past 6 months.
~Painless flexion-extension movements at knee joint."
11350934|NCT02361827||B, Vitamin D insufficient|Vitamin D level on the day of HCG administraion 20-29.9 ng/mL Embryo transfer after oocyte retrieval.
11350738|NCT02363140|Active Comparator|Group Two patients in age group 35-45 years,|"Patients should be aged 18--20 years or 35--45years
~Asymptomatic knee for past 6 months.
~Painless flexion-extension movements at knee joint."
11350739|NCT02363140|Active Comparator|Group Three Patients aged 75|"Patients should be aged 75 or older
~Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis
~No clinical suspicion of meniscus tear
~Painless flexion-extension movements at knee joint."
11350740|NCT02363140|Active Comparator|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
11350741|NCT02363127|Experimental|Prolutex|Subcutaneous progesterone
11350742|NCT02363127|Active Comparator|Progeffik|Vaginal progesterone
11350743|NCT02363114||Stroke Prevention Clinic Patients|All consecutive patients presenting to six high volume Regional Stroke Prevention Clinics.
11350744|NCT02363088|No Intervention|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
11350745|NCT02363088|Experimental|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
11350746|NCT02363088|No Intervention|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
11350747|NCT02363088|Experimental|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
11350748|NCT02363088|Experimental|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
11350749|NCT02363088|Experimental|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
11350750|NCT02363088|Experimental|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
11350751|NCT02363088|Other|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
11350752|NCT02363088|Experimental|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
11350753|NCT02363075|Experimental|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
11350754|NCT02363075|Placebo Comparator|placebo|Aspect tablets identical to the active
11350755|NCT02363049|Experimental|colectomy|surgery followed by chemotherapy +/- targeted therapy regime according to each centre
11350756|NCT02363049|Active Comparator|no colectomy|Chemotherapy +/- targeted therapy alone, regime according to each centre.
11350757|NCT02363036||Active labor|Women in active labor normal pregnancy at term.
11350758|NCT02363036||Planned Cesarian Section|Women, normal pregnancy at term who came for elective Cesarean Section without signs of labor (pain/contractions, etc).
11350759|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
11350760|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
11350761|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
11350762|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
11350763|NCT02362997|Experimental|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
11350764|NCT02362997|Experimental|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
11350765|NCT02362997|Experimental|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
11350766|NCT02362984|Placebo Comparator|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
11350767|NCT02362984|Experimental|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
11350768|NCT02362971||Included|Patients included into the randomized controlled trial
11350769|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
11350770|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
11350771|NCT02362958|Experimental|Lapatinib and Capecitabine or Vinorelbine|Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)
11350772|NCT02362945|Experimental|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
11350773|NCT02362945|No Intervention|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
11350774|NCT02362932|Experimental|Intervention|Sanitation
11350775|NCT02362932|No Intervention|Control|No sanitation
11350776|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
11350777|NCT02362906|Experimental|Injection,medications and application|"Intravenous injection:
~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
11350823|NCT02362607|Active Comparator|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
11424663|NCT01870895|Placebo Comparator|Placebo group|
11350778|NCT02362906|Experimental|Injection and medications|"Intravenous injection:
~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
11350779|NCT02362906|Experimental|Injection and application|"Intravenous injection:
~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
11350780|NCT02362893|Experimental|Direct Observed Therapy|Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
11350781|NCT02362893|No Intervention|Control|Standard care
11350782|NCT02362880|Active Comparator|mutation carrier|
11350783|NCT02362880|Sham Comparator|mutation non-carrier|
11350784|NCT02362867|No Intervention|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
11350785|NCT02362854|Active Comparator|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
11350786|NCT02362854|Experimental|DL application in peri-implantitis|Adjunct Diode Laser application.
11350787|NCT02362815|Active Comparator|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
11350788|NCT02362815|No Intervention|Control|Patient are not allowed to drink
11350789|NCT02362802|Active Comparator|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
11350790|NCT02362802|No Intervention|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.
~Apart from that usual standard of care."
11350791|NCT02362789|Experimental|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
11350792|NCT02362789|Placebo Comparator|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
11350793|NCT02362776||breast cancer patients|
11350794|NCT02362776||lung cancer patients|
11350795|NCT02362776||control subjects|
11350796|NCT02362763|Experimental|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
11350797|NCT02362763|Active Comparator|Controls|Controls received five acupuncture sessions designed for sedation
11350798|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
11350799|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:
~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
11350800|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
11350801|NCT02362737|Experimental|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
11350802|NCT02362737|No Intervention|Control|Usual care.
11350803|NCT02362724|Experimental|Sapphire|Subjects randomized to the experimental contact lens over the study duration
11350804|NCT02362724|Active Comparator|Pearl|Subjects randomized to the active comparator contact lens over the study duration
11350805|NCT02362711|Experimental|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
11350806|NCT02362711|Experimental|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
11350807|NCT02362711|Placebo Comparator|Placebo Group|Placebo for NPC-16
11350808|NCT02362698|Experimental|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
11350809|NCT02362698|Active Comparator|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
11350810|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
11350811|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
11350812|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
11350813|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
11350814|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
11350815|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
11350816|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
11350817|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
11350818|NCT02362633|Experimental|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
11350819|NCT02362633|Sham Comparator|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
11350820|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
11350821|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
11350822|NCT02362607|Experimental|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
11350932|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (<0.05ng/ml) We call Event to the onset of ARDS
11350824|NCT02362594|Experimental|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
11350825|NCT02362594|Placebo Comparator|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
11350826|NCT02362581|Experimental|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.
~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
11350827|NCT02362568|No Intervention|Cervical ultrasound exploration|A cervical ultrasound exploration will be performed in all patients admitted for a planned surgery performed under general anesthesia during the stay in the postoperative room.
11350828|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
11350829|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
11350830|NCT02362542|Experimental|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
11350831|NCT02362542|Experimental|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
11350832|NCT02362529|Experimental|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
11350833|NCT02362529|Placebo Comparator|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
11350834|NCT02362529|Other|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
11350835|NCT02362516|Experimental|BI 425809|
11350836|NCT02362503|Experimental|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
11350837|NCT02362503|Active Comparator|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
11350838|NCT02362503|Experimental|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
11350839|NCT02362490|Experimental|peginterferon alpha 2a|in this group, patients who were on treatment of Nucleoside (Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will switch to treatment of peginterferon alpha 2a for 72 week.
11350840|NCT02362490|No Intervention|control group|in this group, patients who were on treatment of Nucleoside(Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will be continue to treatment of Nucleoside(Acid) Analogues for 72 week.
11350841|NCT02362477|Active Comparator|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
11350842|NCT02362477|Experimental|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
11350843|NCT02362464|Experimental|1|intradermally given vaccine given at weeks 3, 6, 9, 12, 15 and 24.
11350844|NCT02362451|Experimental|1-Lead-in TARP DC vaccine treatment|All patients to receive autologous multi-epitopeTARP DC vaccine before randomization
11350845|NCT02362451|Experimental|2-Active TARP DC vaccine treatment|Autologous multi-epitope TARP DC vaccine afterrandomization
11350846|NCT02362451|Placebo Comparator|3-Placebo|Autologous elutriated monocyte vaccine placeboafter randomization
11350847|NCT02362438|Experimental|10X|Highest dose in the escalation scheme
11350848|NCT02362438|Experimental|1X|Lowest dose in the escalation scheme
11350849|NCT02362438|Experimental|3.3X|2nd dose increase in escalation scheme
11350850|NCT02362438|Experimental|5X|3rd dose increase in escalation scheme
11350851|NCT02362425|Active Comparator|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
11350852|NCT02362425|Placebo Comparator|RYR1-RM Patients Administered Placebo|Placebo
11350853|NCT02362425|No Intervention|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
11350854|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
11350855|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
11350856|NCT02362399|Active Comparator|sildenafil citrate|50 mg single oral dose
11350857|NCT02362399|Active Comparator|placebo|single tablet of placebo
11350858|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
11350859|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
11350860|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
11350861|NCT02362347|Active Comparator|Usual care + exercise|Usual care + exercise
11350862|NCT02362347|No Intervention|No care, no exercise|No care, no exercise
11350863|NCT02362347|Experimental|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
11351019|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
11350864|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
11350865|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
11350866|NCT02362308|Other|Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
11350867|NCT02362308|Other|Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
11350868|NCT02362295||census|qualitative interview
11350869|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
11350870|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
11350871|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
11350872|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
11350873|NCT02362256|Experimental|Intervention|"Opioid antagonist induction. Day 4. Duration 12-16 hours.
~Naltrexone gradual increase from 50 µg p/o to a total dose of 12,5 mg according to a predefined protocol:
~st hour 50 µg
~nd hour 50 µg
~rd hour 100 µg
~th hour 100 µg
~th hour 200 µg
~th hour 400 µg
~th hour 800 µg
~th hour 1600 µg
~th hour 3200 µg
~th hour 6000 µg
~Correction of symptoms for opioid abstinence:
~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
11350874|NCT02362256|Active Comparator|Control|"Opioid antagonist induction. Day 4. Duration 12-16 hours. Naltrexone single dose 12,5 mg p/o
~Correction of symptoms for opioid abstinence:
~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
11350875|NCT02362243|Placebo Comparator|Control Group|Participants in the control arm will complete the placebo comparator intervention.
11350876|NCT02362243|Experimental|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
11350877|NCT02362243|Experimental|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
11350878|NCT02362230|Experimental|Icotinib|Icotinib 125 mg BID
11350879|NCT02362217|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.
~Subjects: 8 healthy volunteers."
11350880|NCT02362217|Experimental|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8.
~Subjects: 8 healthy volunteers."
11350881|NCT02362217|Experimental|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8.
~Subjects: 16 healthy volunteers."
11350882|NCT02362191|Experimental|Single Session tACS Across Menstrual Cycle|Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.
11350883|NCT02362178|Experimental|Thromboelastography (TEG)|Patients in the TEG group received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, only if INR was higher than 1.8 and r time longer than 40 minutes. They received platelets at the amount of 1 apheresis Unit, only if platelets count was lower than 50000/μl and MA was shorter than 30 millimeter.
11350884|NCT02362178|Active Comparator|Standard of Care (SOC)|In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.
11350885|NCT02362165|Experimental|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
11350886|NCT02362165|Active Comparator|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
11350887|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
11350888|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
11350889|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
11350890|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
11350891|NCT02362139|Experimental|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
11350892|NCT02362139|No Intervention|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
11350893|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
11350894|NCT02362113||Isfahani adults|GI/GL
11350895|NCT02362100|Placebo Comparator|nonoperative management|"Treatment will consist of sling immobilization for a period of 6 weeks. Details and treatment timeline as follows:
~0 - 3 weeks: immobilization with a shoulder sling, range of motion of elbow, hand and wrist
~3 - 6 weeks: same as 0-3 weeks, with addition of pendulum exercises every two hours
~After 6 weeks: Active mobilization and removal of sling. Light activity permitted and physiotherapy for range of motion permitted as tolerated.
~After 6 months: no further restriction will be placed. Full home and work activity permitted."
11350933|NCT02361827||A, Vitamin D deficient|Vitamin D level on the day of HCG administraion < 20 ng/mL Embryo transfer after oocyte retrieval.
11350896|NCT02362100|Active Comparator|locking plate surgical fixation|"Standardized operative management protocol as follows:
~Pre-operative medical clearance established via anesthesia consults if required for medically complex patients.
~Provision of pre-operative intravenous (IV) antibiotic prophylaxis:
~Administration of general anesthetic.
~Patient positioning and preparation:
~Patient is carefully placed in the beach-chair position,
~Deltopectoral approach Fracture reduction and fixation with confirmation with intraoperative fluoroscopy images."
11350897|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
11350898|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
11350899|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
11350900|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
11350901|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
11350902|NCT02362035|Experimental|Safety Review|The safety and preliminary efficacy of the combination of acalabrutinib and pembrolizumab will be reviewed
11350903|NCT02362022|Placebo Comparator|Group Saline|Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30)
11350904|NCT02362022|Active Comparator|Group Morphine 1|Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30)
11350905|NCT02362022|Active Comparator|Group Morphine 2|Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30)
11350906|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:
~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.
~list of medication timely related to the procedure
~signed informed consent
~exclusion criteria:
~intolerance to contrast agent
~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
~renal failure
~severe arrhythmia
~pregnancy
~reduction of cognitive capabilities to understand the purpose and the extent of the study
~participation in a medical-scientific study using X-rays in the last ten years
~lack of Russian knowledge to fill the forms
~lack of signed study agreement"
11350907|NCT02361996||Coronary Stenting|"inclusion criteria:
~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.
~list of medication timely related to the procedure
~signed informed consent
~exclusion criteria:
~intolerance to contrast agent
~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
~renal failure
~severe arrhythmia
~pregnancy
~reduction of cognitive capabilities to understand the purpose and the extant of the study
~participation in a medical-scientific study using X-rays in the last ten years
~lack of Russian knowledge to fill the forms
~lack of signed study agreement"
11350908|NCT02361996||Aortic Valve Replacement|"inclusion criteria:
~presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%
~list of medication timely related to the procedure
~signed informed consent
~exclusion criteria:
~intolerance to contrast agent
~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
~renal failure
~severe arrhythmia
~pregnancy
~reduction of cognitive capabilities to understand the purpose and the extent of the study
~participation in a medical-scientific study using X-rays in the last ten years
~lack of Russian knowledge to fill the forms
~lack of signed study agreement"
11350909|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
11350910|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
11350911|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
11350912|NCT02361970||volunteer|Health persons
11350913|NCT02361957|Active Comparator|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
11350914|NCT02361957|Placebo Comparator|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
11350915|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
11350916|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
11350917|NCT02361931|Experimental|Treatment group (erythropoietin)|10 patients receive RMD-G1 (gel with 2000 IU/ml of erythropoietin) as an adjunct therapy to standard of care (SOC). Topical application on wound bed, daily for 12 weeks.
11350918|NCT02361931|Placebo Comparator|Control group (standard of care)|10 patients receive SOC alone daily for 12 weeks. A moisturizing gel is applied on wound bed as a part of SOC.
11350919|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
11350920|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
11350921|NCT02361905|Experimental|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
11350922|NCT02361905|Active Comparator|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
11350923|NCT02361892|Experimental|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
11350924|NCT02361879|Experimental|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
11350925|NCT02361879|Active Comparator|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
11350926|NCT02361866|Experimental|GC1107|0.5ml, intramuscular, a single dosing
11350927|NCT02361866|Active Comparator|Tetanus and Diphtheria(Td vaccine)|0.5ml, intramuscular, a single dosing
11350928|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
11350929|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
11350930|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
11350931|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI > or = 0.05ng/ml We call Event to the onset of ARDS
11350935|NCT02361827||C, Vitamin D replete|Vitamin D level on the day of HCG administraion > 30 ng/mL Embryo transfer after oocyte retrieval.
11350936|NCT02361814|Experimental|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
11350937|NCT02361801|Active Comparator|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
11350938|NCT02361801|Active Comparator|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
11350939|NCT02361775|Experimental|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
11350940|NCT02361775|Active Comparator|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
11350941|NCT02361762|Experimental|Training|Computerized executive control training
11350942|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
11350943|NCT02361749|Active Comparator|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
11350944|NCT02361749|Active Comparator|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
11350945|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
11350946|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
11350947|NCT02361723|Experimental|ovarian cancer, fallopian cancer, or primary peritoneal cancer|60mg BID oral.
11350948|NCT02361723|Experimental|Breast Cancer|60mg BID Ora
11350949|NCT02361723|Experimental|Prostate Cancer|60mg BID Oral
11350950|NCT02361723|Experimental|Small Cell Lung Cancer|60mg BID Oral
11350951|NCT02361723|Experimental|Gastric Cancer|60mg BID Oral
11350952|NCT02361710||vitamin D deficient patients|Serum 25- (hydroxide) OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
11350953|NCT02361710||vitamin D sufficient patients|Serum 25- (hydroxide) OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
11350954|NCT02361697|Other|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
11350955|NCT02361684|Experimental|Blended CBT treatment|
11350956|NCT02361684|Active Comparator|Treatment as usual|
11350957|NCT02361645|No Intervention|Control Group|No NSAIDs were administered prior to surgery
11350958|NCT02361645|Experimental|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
11350959|NCT02361645|Experimental|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
11350960|NCT02361645|Experimental|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
11350961|NCT02361645|Experimental|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
11350962|NCT02361632|Experimental|Group 1|"Dietary Supplement. Participants drink coffee with or without milk in following order:
~Black coffee
~Coffee with 20% milk added
~Coffee with 50% milk added"
11350963|NCT02361632|Experimental|Group 2|"Dietary supplement. Participants drink coffee with or without milk in following order:
~Coffee with 20% milk added
~Black coffee
~Coffee with 50% milk added"
11350964|NCT02361632|Experimental|Group 3|"Dietary supplement. Participants drink coffee with or without milk in following order:
~Black coffee
~Coffee with 50% milk added
~Coffee with 20% milk added"
11350965|NCT02361619|Experimental|1|
11350966|NCT02361606|Experimental|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
11350967|NCT02361593|Experimental|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
11350968|NCT02361593|Active Comparator|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
11350969|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
11350970|NCT02361580|No Intervention|No Diary|Control Group
11350971|NCT02361567|Active Comparator|Tramacet|Tramacet 1-2 tabs PO q4h prn
11350972|NCT02361567|Active Comparator|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
11350973|NCT02361554|Experimental|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
11350974|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
11350975|NCT02361528|Experimental|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
11350976|NCT02361528|Placebo Comparator|placebo|placebo, once per day during 5 days by subcutaneous route
11350977|NCT02361515|Active Comparator|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
11350978|NCT02361515|Experimental|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
11350979|NCT02361502|Placebo Comparator|placebo|mirabegron placebo qd
11350980|NCT02361502|Experimental|mirabegron|mirabegron 50mg qd
11350981|NCT02361489|Active Comparator|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
11351020|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
11351021|NCT02361242|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.
11350982|NCT02361489|Active Comparator|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
11350983|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
11350984|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
11350985|NCT02361463|Experimental|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
11350986|NCT02361463|Active Comparator|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
11350987|NCT02361450|Experimental|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
11350988|NCT02361450|Active Comparator|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
11350989|NCT02361437|Placebo Comparator|placebo|placebo
11350990|NCT02361437|Experimental|Vasculera|diosmin
11350991|NCT02361424|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
11350992|NCT02361424|Experimental|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .
~These 2 capsules are taken orally b.i.d. during 8 weeks."
11350993|NCT02361424|Experimental|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .
~These 2 capsules are taken orally b.i.d. during 8 weeks."
11350994|NCT02361424|Placebo Comparator|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .
~These 2 capsules are taken orally b.i.d. during 4 weeks"
11350995|NCT02361398|Experimental|EIT group|the Individualized PEEP titration by EIT was administered to the patients in the EIT group.
11350996|NCT02361398|No Intervention|control group|If patients are assigned to the control group, the Individualized PEEP Setting was by PEEP-FiO2 table based on ARDS-net protocol.
11350997|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
11350998|NCT02361372|Experimental|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
11350999|NCT02361372|Placebo Comparator|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
11351000|NCT02361346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|Phase 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11351001|NCT02361346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|Phase 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11351002|NCT02361346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|Phase 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11351003|NCT02361346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|Phase 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11351004|NCT02361346|Experimental|MT-3724 Phase 1 100 mcg/kg/dose|Phase 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
11351005|NCT02361346|Experimental|MT-3724 Phase 1 75 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
11351006|NCT02361346|Experimental|MT-3724 Phase 1b 50 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724
11351007|NCT02361346|Experimental|MT-3724 Phase 2 50 mcg/kg/dose|Phase 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
11351008|NCT02361333|Experimental|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
11351009|NCT02361333|No Intervention|No Intervention|Patients will not be taught how to install and use a remote monitor
11351010|NCT02361320|Experimental|Computed Tomography Scans (CT)|Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.
11351011|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
11351012|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
11351013|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
11351014|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
11351015|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
11351016|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
11351017|NCT02361268|Experimental|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
11351018|NCT02361268|Active Comparator|Educational program|The active comparator for the study is an educational program.
11351022|NCT02361242|Experimental|PXT00864 Dose 2|1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.
11351023|NCT02361242|Experimental|PXT00864 Dose 3|1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.
11351024|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
11351025|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
11351026|NCT02361203|No Intervention|No Exercise|
11351027|NCT02361203|Experimental|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
11351028|NCT02361190|Placebo Comparator|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
11351029|NCT02361190|Experimental|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
11351030|NCT02361177|Experimental|oxytocin|Intranasal 24 IU oxytocin self-administration.
11351031|NCT02361177|Placebo Comparator|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
11351032|NCT02361164||Mother/child pair|Mother/child pair.
11351033|NCT02361151|Active Comparator|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)
~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
11351034|NCT02361151|Experimental|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website
~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
11351035|NCT02361138|Experimental|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
11351036|NCT02361138|Experimental|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
11351037|NCT02361138|Experimental|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
11351038|NCT02361138|Experimental|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
11351039|NCT02361138|Experimental|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
11351040|NCT02361138|Experimental|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
11351041|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).
~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
11351042|NCT02361112|Experimental|pyrotinib combined with capecitabine|
11351043|NCT02361099|Experimental|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
11351044|NCT02361099|No Intervention|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
11351045|NCT02361086|Experimental|Regimen 1: 7dayPM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week with a 2-week dose titration.
11351046|NCT02361086|Experimental|Regimen 2: 7dayPM-DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week without dose titration.
11351047|NCT02361086|Experimental|Regimen 3: 7dayAM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the morning 7-days a week with a 2-week dose titration.
11351048|NCT02361086|Experimental|Regimen 4: 7dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 7-days a week without dose titration.
11351049|NCT02361086|Experimental|Regimen 5: 5dayPM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the evening before bed 5-days a week without dose titration.
11351050|NCT02361086|Experimental|Regimen 6: 5dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 5-days a week without dose titration.
11351051|NCT02361073||Takotsubo|
11351052|NCT02361073||Healthy|
11351053|NCT02361073||ACS|
11351054|NCT02361060|Experimental|Sugammadex|sugammadex 4 mg/kg
11351055|NCT02361060|Active Comparator|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
11351056|NCT02361047|Experimental|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
11351057|NCT02361047|No Intervention|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
11351058|NCT02361034|Active Comparator|GRC 27864|Test treatment GRC 27864
11351059|NCT02361034|Placebo Comparator|Placebo|Placebo treatment
11351060|NCT02361008|Experimental|TPDC group|Patients who matched inclusion criteria and randomly divided into TPDC group underwent the TEE-guided perventricular device closure without CBP. But of them,who underwent TPDC failure during the procedure would be dropped out of the trial.
11351061|NCT02361008|Experimental|SR group|Patients who matched inclusion criteria and randomly assigned into SR group underwent the surgery repair with CBP.
11351062|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
11351063|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
11351064|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
11351065|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
11351066|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.
~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
11351067|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
11351068|NCT02360956|Experimental|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
11351069|NCT02360956|Active Comparator|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).
~The drug dose must be individualized."
11351070|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
11351071|NCT02360930||Tanner Stage </=2|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
11351072|NCT02360930||Tanner Stage >/= 4|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
11351073|NCT02360917|Experimental|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
11351074|NCT02360917|Other|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
11351075|NCT02360904|Experimental|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
11351076|NCT02360904|Active Comparator|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
11351077|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
11351078|NCT02360891||neurological controls|patients with other neurological disease
11351079|NCT02360891||healthy controls|age matched healthy controls
11351080|NCT02360878||Non-diabetic subjects|Obese (BMI > 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
11351081|NCT02360878||T2DM subjects|Obese (BMI > 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
11351082|NCT02360865|Experimental|COPD|Acute exercise bouts
11351083|NCT02360865|Active Comparator|Healthy|Acute exercise bouts
11351084|NCT02360852|Experimental|A4250|A4250 once daily
11351085|NCT02360839|No Intervention|Early|Study subjects (patients) undergoing endoscopic ultrasound (with or without FNA/TCB) for clinical reasons during 2005-2011.
11351086|NCT02360839|Other|Late|"Study subjects (patients) undergoing endoscopic ultrasound with EUS-guided sampling of various lesions for clinical reasons during 20012-2015.
~Subjects sampled with both EUS-FNA and EUS-FNB on the same lesion. Randomization on first needle order."
11351087|NCT02360826|Experimental|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.
11351088|NCT02360826|Experimental|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.
11351089|NCT02360813|Experimental|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
11351090|NCT02360813|Active Comparator|Treatment as Usual|Usual care.
11351091|NCT02360800|Experimental|TISSEEL|Spray Fibrin Sealant
11351092|NCT02360800|Active Comparator|CONTROL|Traditional hemostasis and chest closure routine
11351093|NCT02360787|Experimental|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
11351158|NCT02360332|Experimental|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
11351094|NCT02360787|Experimental|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
11351095|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
11351096|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
11351097|NCT02360761|Active Comparator|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
11351098|NCT02360761|Experimental|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
11351099|NCT02360748|Experimental|single|Pilot Study in which patients will be adding food items to improve their nutritional status
11351100|NCT02360735|Active Comparator|Control|Patients randomized to this arm will follow the current standard for post-operative care.
11351101|NCT02360735|Experimental|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
11351102|NCT02360722|Experimental|Oral Nutritional Supplement|ONS + Nutritional education
11351103|NCT02360722|Other|Control Group|Nutritional education only
11351104|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
11351105|NCT02360696||Peds/Adol Pts w/ FD - CMH GI APT clinic|"Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.
~Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.
~Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis."
11351106|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
11351107|NCT02360670|Placebo Comparator|Control imaging (NCCT)|Standard imaging
11351108|NCT02360670|Experimental|additional multimodal imaging|CT + CTA + CTP
11351109|NCT02360657|Experimental|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2*5 mg tablet) orally once daily for 4 weeks.
11351110|NCT02360657|Experimental|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
11351111|NCT02360657|Placebo Comparator|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
11351112|NCT02360644|Experimental|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.
~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters [P-gp, MRP2, and MATE1/2K] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
11351113|NCT02360644|Experimental|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled [30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)], as well as 30 healthy controls.
11351114|NCT02360631|Experimental|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
11351115|NCT02360631|Placebo Comparator|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
11351116|NCT02360618|Experimental|Metformin and Simvastatin Treatment|Patients in this group will receive 850 mg of Metformin and 20 mg of Simvastatin daily from the time they are enrolled in the study until the day before their surgery (approximately 12 weeks), in the absence of any safety or tolerability concerns.
11351117|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
11351118|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
11351119|NCT02360592|Active Comparator|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
11351120|NCT02360592|Experimental|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
11351121|NCT02360592|Experimental|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
11351122|NCT02360579|Experimental|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
11351123|NCT02360579|Experimental|Cohort 2|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
11351124|NCT02360579|Experimental|Cohort 3|Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
11351125|NCT02360579|Experimental|Cohort 4|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
11351155|NCT02360358|Active Comparator|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.
~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
11351156|NCT02360345|Experimental|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
11352536|NCT02350985|Active Comparator|Venlafaxine|Venlafaxine up to 150 mg/day
11351126|NCT02360566|Experimental|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
11351127|NCT02360553|Experimental|Intervention|ObeseGO!-web-based intervention
11351128|NCT02360553|Other|Control|Given pamphlets education mainly on diet and physical activity
11351129|NCT02360527||Type 2 diabetic patients with AD|35 patients
11351130|NCT02360527||Type 2 diabetic patients with MCI|35 patients
11351131|NCT02360527||Type 2 diabetic patients controls|35 patients
11351132|NCT02360527||Non-diabetic patients with AD|35 patients
11351133|NCT02360514|Experimental|hantaan virus vaccine|
11351134|NCT02360501|Experimental|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
11351135|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
11351136|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
11351137|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
11351138|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
11351139|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
11351140|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
11351141|NCT02360462|Experimental|Active tDCS|Active tDCS will be applied in the head of the patients in 20 minute sessions, twice. First session will be applied in the night before and the second session, in the morning before the surgical procedure. The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current
11351142|NCT02360462|Sham Comparator|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
11351143|NCT02360449|No Intervention|Wait List|
11351144|NCT02360449|Experimental|Social Initiation Motivation Intervention|
11351145|NCT02360423|Experimental|CRE8 group|CRE8 sirolimus-eluting stent system
11351146|NCT02360423|Active Comparator|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
11351147|NCT02360410|Experimental|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
11351148|NCT02360410|No Intervention|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
11351149|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
11351150|NCT02360384|Placebo Comparator|Sham diet|The placebo intervention will be healthy eating advice in patients with irritable bowel syndrome of the alternating subtype for 28 days.
11351151|NCT02360384|Active Comparator|Lincalotide|All patients with constipation predominant IBS will receive linaclotide 280mcg po od for 28 days.
11351152|NCT02360384|Experimental|FODMAP diet|The FODMAP diet will be introduced in patients with irritable bowel syndrome of the alternating subtype for 28 days.
11351153|NCT02360371|Other|Within-subject design|All participants will complete several sessions and within-subject assessment of double-blind study drug will be examined during the study sessions. Order of sessions will be randomized and counter-balanced, but all participants will undergo the same study conditions. Although this is a clinical trial, it does not have an active intervention/treatment component.
11351154|NCT02360358|Experimental|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
11351157|NCT02360345|Experimental|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
11352603|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
11351159|NCT02360332|No Intervention|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
11351160|NCT02360319|Active Comparator|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
11351161|NCT02360319|Experimental|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
11351162|NCT02360306|Active Comparator|Conventional EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the conventional EBUS scope rather than the hybrid EBUS scope. Subjects in this arm, like in the Hybrid EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
11351163|NCT02360306|Experimental|Hybrid EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the hybrid EBUS scope rather than the conventional EBUS scope. Subjects in this arm, like in the conventional EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
11351164|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
11351165|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
11351166|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
11351167|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
11351168|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
11351169|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
11351170|NCT02360241|Experimental|Robot|A robot will be used and it's position will be evaluated
11351171|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
11351172|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
11351173|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
11351174|NCT02360215|Experimental|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
11351175|NCT02360215|Experimental|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
11351176|NCT02360202|Experimental|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
11351177|NCT02360176|Experimental|Sleeve gastrectomy single port|Sleeve gastrectomy single port
11351178|NCT02360176|Active Comparator|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
11351179|NCT02360163|Active Comparator|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
11351180|NCT02360163|Experimental|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
11351181|NCT02360150|Experimental|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
11351182|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
11351183|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
11351184|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
11351185|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
11351186|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
11351187|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
11351188|NCT02360072||AR group|Allergic rhinitis without any typical asthma symptoms
11351189|NCT02360072||Asthma|Accompanied by typical asthma symptoms and Δ FEV1≥12% in response to a short-acting bronchodilator or bronchial hyperreactivity(BHR) in the methacholine provocation test (PC20≤2.504mg)
11351190|NCT02360072||AR+Asthma|Diagnosed allergic rhinitis concomitant asthma symptoms
11351191|NCT02360072||Control group|non-atopic subjects with neither a history of rhinitis nor asthma
11351208|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
11351192|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.
~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
11351193|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
11351194|NCT02360046|Other|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
11351195|NCT02360046|Other|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
11351196|NCT02360033|Experimental|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
11351197|NCT02360033|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
11351198|NCT02360020|Experimental|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, >70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends >= 90°, or three or more bends of 45-90° proximal to the diseased segment.
11351199|NCT02360007|Experimental|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
11351200|NCT02360007|No Intervention|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
11351201|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
11351202|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.
~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.
~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
11351203|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.
~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
11351204|NCT02359981|Active Comparator|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
11351205|NCT02359981|Experimental|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
11351206|NCT02359968|Active Comparator|FOLFOX|"Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days
~Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1
~Folinic acid 200 mg/m² 2-hr IV infusion on day 1
~3 cycles, q14"
11351207|NCT02359968|Experimental|CarboP-pacliT|"Carboplatin (carboP) AUC=2, given by intravenous infusion
~Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion
~on days 1, 8, 15, 22 and 29"
11351209|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
11351210|NCT02359942|Experimental|Citric acid group|Giving the citric acid (4g) as test meal before UBT
11351211|NCT02359942|No Intervention|Controlled group|No use of test meal
11351212|NCT02359929|Experimental|Dose Level 1: Infusion of MSCs|First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight
11351213|NCT02359929|Experimental|Dose Level 2: Infusion of MSCs|Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight
11351214|NCT02359929|Experimental|Dose Level 3: Infusion of MSCs|Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight
11351215|NCT02359916||A|Snacks sold under equal pricing, no delays
11351216|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
11351217|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
11351218|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
11351219|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
11351220|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
11351221|NCT02359916||G|Snacks sold under equal pricing, no delays
11351222|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
11351223|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
11351224|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
11351225|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
11351226|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
11351227|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
11351228|NCT02359864|Experimental|Cohort One|An initial 15 patients will be enrolled in the first treatment scheme (5 daily fractions of 2 Gy) and will be followed for 12 months after completion of treatment to assess safety and any toxicity/adverse events associated with treatment. 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events.
11351229|NCT02359864|Experimental|Cohort Two|"The second treatment arm will not be used until the last patient in the first dose arm has completed all follow up. At that point patients
~#16-30 will be enrolled in the second dose arm (10 daily fractions of 2 Gy). 15 patients will be enrolled and each will be followed for 12 months to assess safety and toxicity/adverse events."
11351230|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
11351231|NCT02359838|Other|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
11351232|NCT02359838|Active Comparator|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
11351233|NCT02359825|No Intervention|standard epineural repair <24 hours|epineural repair following treatment with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired <24 hours after injury); no medication used
11351234|NCT02359825|No Intervention|standard epineural repair >24 - 72 hours|epineural repair following irrigation with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term chronic injuries (>24-<72 hours after injury); no medication used
11351235|NCT02359825|No Intervention|epineural repair with autografting within 48 hours|epineural repair with auto grafting within 48 hours; no medication used
11351236|NCT02359825|Experimental|epineural repair <24 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired <24 hours after injury); PEG is used during the surgical procedure
11351237|NCT02359825|Experimental|epineural repair >24 but <72 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired >24 hours but < 72 hours after injury); PEG is used during the surgical procedure
11351238|NCT02359825|Experimental|epineural repair with autografting within 48 hours, using PEG|epineural repair with auto grafting within 48 hours
11351239|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
11351240|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
11351241|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
11351242|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
11351243|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
11351244|NCT02359786||Topicals Subjects using topical compounds|
11351245|NCT02359786||Patients undergoing Spinal Surgery using IOM|
11351246|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
11351247|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
11351248|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
11351249|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
11351250|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
11351251|NCT02359760|Experimental|Piezocision group|The experimental group will consist of 14 adults, subjects from 18 to 40 years-old (10 women, 4 men).
11351252|NCT02359760|No Intervention|conventional orthodontics|The control group will consist of 30 matched patients with the same inclusion and exclusion criteria, who have been already treated by conventional orthodontics in the orthodontic clinic of the University of Montreal.
11351253|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
11351254|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
11351255|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
11351256|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
11351257|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
11351258|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
11351259|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
11351260|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
11351261|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
11351262|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
11351263|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
11351264|NCT02359721|Experimental|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
11351265|NCT02359721|No Intervention|control|scaling and root planing
11351266|NCT02359708|Experimental|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
11351267|NCT02359708|Experimental|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
11351268|NCT02359695|Experimental|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
11351269|NCT02359682||Age 20-39|Patients aged from 20 to 39 years old.
11351270|NCT02359682||Age 40-59|Patients aged from 40 to 59 years old.
11351271|NCT02359682||Age 60-79|Patients aged from 60 to 79 years old.
11351272|NCT02359669|Active Comparator|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
11351273|NCT02359669|Placebo Comparator|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
11351274|NCT02359656|Other|non operative treatment|specif non operative treatment protocol
11351275|NCT02359656|Other|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
11351276|NCT02359643|Placebo Comparator|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
11351277|NCT02359643|Experimental|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
11351278|NCT02359630|Active Comparator|EasyTube|Use of EasyTube during general anesthesia
11351279|NCT02359630|Experimental|Endotracheal tube|Use of endotrachel tube during general anesthesia
11351280|NCT02359617|Experimental|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.
~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
11351281|NCT02359604|Other|Single Arm Study -microbiome|This is a single-arm study. The patients will serve as their own controls. The PPI administered for PPI-therapy is already FDA approved. A stool sample will be obtained for intestinal microbiome testing before PPI, under PPI and after PPI therapy.
11351282|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
11351283|NCT02359578|Experimental|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
11351284|NCT02359565|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 34 cycles in the absence of disease progression or unacceptable toxicity.
11351285|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.
~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
11351286|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.
~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
11351287|NCT02359539|Experimental|PRF|Platelets rich fibrin,
11351288|NCT02359539|Experimental|MPP|Marginal periosteal pedicle
11351289|NCT02359526|Experimental|ILUVIEN 190 ug intravitreal implant|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
11351290|NCT02359513|Experimental|boulimic|Analyse of serotoninergic brain activity (determined by positron emission tomography using [18F]MPPF) from bulimic patients treated with serotoninergic antidepressants during 3 months. The serotoninergic brain activity is measured before adnd after the serotoninergic antidepressant treatment.
11351291|NCT02359500|Experimental|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
11351292|NCT02359487|Experimental|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
11351293|NCT02359487|Placebo Comparator|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
11351294|NCT02359474|Experimental|Trabectedin with regional hyperthermia|"Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
~Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs)."
11351295|NCT02359474|Active Comparator|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
11351296|NCT02359461|Experimental|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
11351297|NCT02359461|Other|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
11351298|NCT02359448|Experimental|Melatonin|Patients will be prescribed and dispensed from pharmacy sustained -release Melatonin (Circadin) 2mg. This will be taken every night for twelve weeks.
11351299|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
11351300|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
11351301|NCT02359422|Experimental|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
11351302|NCT02359422|No Intervention|Wait-list control|
11351303|NCT02359409|Active Comparator|water immersion only|Colonoscopy will be performed using the water immersion technique.
11351304|NCT02359409|Experimental|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
11351305|NCT02359396|Experimental|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
11351306|NCT02359396|Experimental|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
11351307|NCT02359396|Experimental|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
11351308|NCT02359383|Active Comparator|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
11351309|NCT02359383|No Intervention|Control grup|Conventional medical treatment
11351310|NCT02359370|Active Comparator|Magnesium Group|Magnesium Sulphate was administered through continuous infusion, immediately before induction of anesthesia
11351311|NCT02359370|Active Comparator|Lidocaine Group|Lidocaine was administered through continuous infusion, immediately before induction of anesthesia
11351312|NCT02359357|Placebo Comparator|Placebo single dose|Placebo administered as a single dose
11351313|NCT02359357|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
11351314|NCT02359357|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
11352673|NCT02349958|Other|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
11351315|NCT02359357|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
11351316|NCT02359357|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
11351317|NCT02359357|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
11351318|NCT02359357|Experimental|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
11351319|NCT02359357|Experimental|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
11351320|NCT02359357|Experimental|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
11351321|NCT02359357|Experimental|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351322|NCT02359357|Experimental|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351323|NCT02359357|Experimental|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351324|NCT02359357|Experimental|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351325|NCT02359357|Experimental|Food effect - fasted|Single dose of FDL169 in fasted conditions
11351326|NCT02359357|Experimental|Food effect - fed|Single dose of FDL169 in fed conditions
11351327|NCT02359357|Placebo Comparator|Placebo - multiple dose|Repeat doses of placebo
11351328|NCT02359357|Experimental|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351329|NCT02359357|Experimental|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351330|NCT02359357|Experimental|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351331|NCT02359357|Experimental|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351332|NCT02359357|Experimental|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351333|NCT02359357|Experimental|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
11351334|NCT02359344|Experimental|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
11351335|NCT02359344|Placebo Comparator|Placebo|Placebo tid 7 days plus a single dose on day 8
11351336|NCT02359331|Active Comparator|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
11351337|NCT02359331|Experimental|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
11351338|NCT02359318|Experimental|Resin infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the no infiltration and de-bonding arm. The teeth that are included in this intervention arm are treated by resin infiltration using Icon (DMG, Germany) according to the manufacturers´ instruction. This is followed by bonding of new brackets (Gemini metal brackets, 3M Unitek). These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.
~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
11351339|NCT02359318|Placebo Comparator|No infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the resin infiltration and de-bonding arm. The teeth that are included in this intervention arm are left untreated new brackets (Gemini metal brackets, 3M Unitek) are bonded. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.
~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
11351340|NCT02359318|Other|Control and de-bonding|"Patients with brackets and without white spots are included in this group. After removal of the old brackets, new brackets (Gemini metal brackets, 3M Unitek) are bonded again. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.
~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
11351341|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
11351342|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
11351343|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI|High Strength fixed combination
11351344|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI|Medium Strength fixed combination
11351345|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|High Strength fixed combination plus Charcoal Block
11351346|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|Medium Strength fixed combination plus Charcoal Block
11351347|NCT02359292|Placebo Comparator|Placebo pMDI|Placebo
11351348|NCT02359279|Experimental|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
11351349|NCT02359266|Experimental|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
11351350|NCT02359266|No Intervention|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
11351406|NCT02358902|Experimental|Group C|tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
11351628|NCT02357407|Experimental|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
11351351|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
11351352|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
11351353|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
11351354|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
11351355|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
11351356|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
11351357|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
11351358|NCT02359214|Active Comparator|Vitamin D3 Supplement|This group will receive a daily dose of 5000IU (125µg) vitamin D3 (which is half of the recommended safe tolerable upper intake level of vitamin D for healthy individuals) for eight weeks.
11351359|NCT02359214|Placebo Comparator|Placebo|This group will receive 100% lactose placebo daily for eight weeks.
11351360|NCT02359201|Experimental|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
11351361|NCT02359201|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
11351362|NCT02359188|Active Comparator|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
11351363|NCT02359188|Sham Comparator|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
11351364|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
11351365|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
11351366|NCT02359162|Experimental|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
11351367|NCT02359162|Active Comparator|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.
~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
11351368|NCT02359149|Experimental|nurse|intravitreal injections with anti-VEGF agents given by a nurse
11351369|NCT02359149|Active Comparator|physician|intravitreal injections with anti-VEGF agents given by a physician
11351370|NCT02359136|Placebo Comparator|LIA placebo|local infiltration anesthesia using saline i addition to multimodal analgesic regimen
11351371|NCT02359136|Experimental|LIA Ropivacaine|local infiltration anesthesia using Ropivacaine and Epinephrine i addition to multimodal analgesic regimen
11351372|NCT02359123|Experimental|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
11351373|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
11351374|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
11351375|NCT02359097|Experimental|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
11351376|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
11351407|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
11351624|NCT02357420|Experimental|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
11351377|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
11351378|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
11351379|NCT02359071||handovers with higher durations|Higher than 20 minutes
11351380|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
11351381|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
11351382|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11351383|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
11351384|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
11351385|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose|ASP6858 arm
11351386|NCT02359032|Placebo Comparator|Part 1: Placebo single ascending dose|Placebo arm
11351387|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
11351388|NCT02359032|Experimental|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
11351389|NCT02359032|Experimental|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
11351390|NCT02359019|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
11351391|NCT02359006|Active Comparator|minocycline|200mg minocycline
11351392|NCT02359006|Placebo Comparator|Placebo|Sugar pill
11351393|NCT02358993|Experimental|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
11351394|NCT02358993|Active Comparator|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
11351395|NCT02358980||Study group|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.
11351396|NCT02358967|Placebo Comparator|Placebo|Standard renal care + 300 mg placebo daily for 1 year
11351397|NCT02358967|Active Comparator|Treatment|Standard renal care + 300 mg TRF daily for 1 year
11351398|NCT02358954|Experimental|Vestibular Pain interactions|
11351399|NCT02358941|Experimental|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.
~Half of the children will be assigned to NF training, the other half to CCT."
11351400|NCT02358941|Experimental|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).
~Half of the children will be assigned to NF training, the other half to CCT."
11351401|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
11351402|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
11351403|NCT02358915|Experimental|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
11351404|NCT02358902|Experimental|Group A|tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
11351405|NCT02358902|Experimental|Group B|AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
11351408|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
11351409|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
11351410|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:
~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
11351411|NCT02358850|Active Comparator|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
11351412|NCT02358850|Active Comparator|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
11351413|NCT02358850|Active Comparator|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
11351414|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
11351415|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
11351416|NCT02358824|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
11351417|NCT02358824|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
11351418|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 70 years old and more
11351419|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI<10) 70 years old and more
11351420|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 18 < Age < 55 years old
11351421|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI<10) 18 < Age < 55 years old
11351422|NCT02358798|Experimental|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
11351423|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
11351424|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
11351425|NCT02358759|Active Comparator|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
11351426|NCT02358759|Active Comparator|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
11351427|NCT02358746|Experimental|combined endo/epicardial approach|combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
11351428|NCT02358746|Active Comparator|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
11351429|NCT02358733|Experimental|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
11351430|NCT02358733|Active Comparator|Control|Intracytoplasmic sperm injection (ICSI)
11351431|NCT02358720|Experimental|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
11351432|NCT02358720|Active Comparator|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
11351433|NCT02358707|Experimental|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
11351434|NCT02358694|Experimental|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
11351435|NCT02358694|Placebo Comparator|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
11351436|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.
~Placebo, intravenous."
11351437|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.
~Placebo, intranasal."
11351438|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
11351439|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
11351440|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
11351441|NCT02358655|Other|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
11351442|NCT02358655|Other|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
11351443|NCT02358655|Other|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
11351444|NCT02358642|Experimental|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
11351445|NCT02358642|Placebo Comparator|Placebo|Placebo
11351446|NCT02358629|Experimental|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
11351447|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
11351625|NCT02357420|Experimental|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
11351448|NCT02358603|Experimental|Case group|At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
11351449|NCT02358603|Placebo Comparator|Control group|Each subject of the control group will do the same test and examination with the subjects in the case group.
11351450|NCT02358590|Experimental|HAPA menu-based mini-video|This group will watch mini-videos, which are multi-target menu-based interventions designed to deliver information about vitamin D adherence and its effect on osteoporosis
11351451|NCT02358590|Active Comparator|Standard care|This group will be advised by the treating physician to take vitamin D
11351452|NCT02358577|Experimental|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
11351453|NCT02358577|Active Comparator|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
11351454|NCT02358564|Active Comparator|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
11351455|NCT02358564|Experimental|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
11351456|NCT02358551|Other|Axillary vein|Lead Placement Through the Axillary Vein Technique
11351457|NCT02358551|Other|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
11351458|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
11351459|NCT02358512|Experimental|Intermittent enteral feeding|The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours).
11351460|NCT02358512|Active Comparator|Continuous enteral feeding|The continuous feeding regimen consists of the total volume of feed administered over 24 hours.
11351461|NCT02358499|Experimental|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
11351462|NCT02358486|Experimental|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
11351463|NCT02358486|Sham Comparator|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
11351464|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.
~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
11351465|NCT02358460|Active Comparator|Pressure-limited ventilation|
11351466|NCT02358460|Active Comparator|Volume-targeted ventilation|
11351467|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
11351468|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
11351469|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
11351470|NCT02358395|Experimental|BBI608 puls Sorafenib|
11351471|NCT02358382|No Intervention|Alpha Stat|Standard CPB blood gas management conditions
11351472|NCT02358382|Experimental|pH Stat|pH stat blood gas management conditions.
11351473|NCT02358369|Experimental|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
11351474|NCT02358369|Experimental|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
11351475|NCT02358369|Active Comparator|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.
~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
11351476|NCT02358356|Active Comparator|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
11351477|NCT02358356|Active Comparator|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
11351478|NCT02358356|Experimental|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
11351479|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
11351480|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
11351502|NCT02358226|No Intervention|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
11351481|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.
~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
11351482|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
11351483|NCT02358343|No Intervention|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
11351484|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
11351485|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
11351486|NCT02358317|Experimental|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
11351487|NCT02358317|Active Comparator|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
11351488|NCT02358304|Active Comparator|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
11351489|NCT02358304|Placebo Comparator|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
11351490|NCT02358291|Active Comparator|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
11351491|NCT02358291|Active Comparator|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
11351492|NCT02358291|Active Comparator|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
11351493|NCT02358265|Active Comparator|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
11351494|NCT02358265|Active Comparator|10 mg Rupatadin|Rupatadine 10 mg, continuously
11351495|NCT02358265|Active Comparator|20 mg Rupatadine|Rupatadine 20 mg, continuously
11351496|NCT02358265|Active Comparator|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
11351497|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).
~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
11351498|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
11351499|NCT02358239|Experimental|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
11351500|NCT02358226|Experimental|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
11351501|NCT02358226|Experimental|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
11351503|NCT02358213|Other|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
11351504|NCT02358200|Experimental|Treatment|BMN-673: Oral, every day, Days 1-21; Carboplatin: intravenous, every week, 750 μg/day; Paclitaxel: intravenous, every week, 0.75 x Maximum Tolerated Dose μg/day
11351505|NCT02358187|Experimental|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
11351506|NCT02358174|Experimental|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
11351507|NCT02358174|Experimental|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
11351508|NCT02358161|Experimental|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
11351509|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
11351510|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
11351511|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
11351512|NCT02358135|Experimental|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
11351513|NCT02358122|Active Comparator|Refined wheat|Refined wheat grain, a variety of cereal foods providing no wholegrain
11351514|NCT02358122|Experimental|Wholegrain wheat|Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
11351515|NCT02358122|Experimental|Wholegrain rye|Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
11351516|NCT02358109|Experimental|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
11351517|NCT02358109|No Intervention|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
11351518|NCT02358096|Experimental|ASP8232|ASP8232 administered once daily
11351519|NCT02358096|Placebo Comparator|Placebo|Placebo administered once daily
11351520|NCT02358083|No Intervention|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
11351521|NCT02358083|Experimental|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
11351522|NCT02358083|Experimental|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
11351523|NCT02358083|Experimental|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
11351524|NCT02358083|Experimental|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
11351525|NCT02358083|Experimental|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
11351526|NCT02358083|No Intervention|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
11351527|NCT02358083|Experimental|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
11351528|NCT02358083|Experimental|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
11351529|NCT02358083|Experimental|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
11351530|NCT02358083|Experimental|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
11351531|NCT02358083|Experimental|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
11351532|NCT02358070||HCC group|
11351533|NCT02358070||control group|
11351534|NCT02358057|Experimental|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.
~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.
~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.
~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine
~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.
~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN > 50.
~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
11351535|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
11351536|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
11351537|NCT02358031|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months.
11351538|NCT02358031|Experimental|Pembrolizumab + Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months; plus cisplatin 100 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
11351539|NCT02358031|Active Comparator|Cetuximab + Chemotherapy (Control)|Participants receive cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each 3-week cycle (6 cycle maximum for platinum-based therapy); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
11351540|NCT02358005|Experimental|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
11351541|NCT02358005|Experimental|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
11351542|NCT02358005|Placebo Comparator|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
11351543|NCT02357992|Experimental|Stereotactic Radiotherapy (SRT)|"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.
~50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor."
11351544|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
11351545|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
11351546|NCT02357966|Experimental|514G3|Phase I of the study will include a single dose of 514G3 at three different dose levels. Phase II utilizes a single dose of 514G3 at the highest dose level. Standard antibiotic therapies will be used in both phases.
11351547|NCT02357966|Placebo Comparator|Placebo|Both Phase I and II will include a single dose of placebo in addition to standard antibiotic therapies.
11351548|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
11351549|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
11351550|NCT02357927|Placebo Comparator|control|simple general telephone call
11351551|NCT02357927|Experimental|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
11351552|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
11351553|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.
~In addition, participants received individual drug counseling (IDC) at least once a week."
11351554|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.
~In addition, participants received individual drug counseling (IDC) at least once a week."
11351555|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).
~In addition, participants received individual drug counseling (IDC) at least once a week."
11351585|NCT02357693|Experimental|aprepitant|aprepitant 80 mg one hour before surgery
11351586|NCT02357693|Placebo Comparator|placebo|oral placebo one hour before surgery
11351626|NCT02357420|Experimental|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
11351556|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.
~In addition, participants received individual drug counseling (IDC) at least once a week."
11351557|NCT02357888|Experimental|Sequence 1|Treatment group sequence: Test Product on Day 1 and Placebo on Day 2
11351558|NCT02357888|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product on Day 2
11351559|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
11351560|NCT02357849|Active Comparator|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
11351561|NCT02357849|Active Comparator|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
11351562|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
11351563|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
11351564|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
11351565|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count < 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
11351566|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count > 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
11351567|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
11351568|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11351569|NCT02357797|Active Comparator|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
11351570|NCT02357797|Placebo Comparator|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
11351571|NCT02357784|Experimental|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
11351572|NCT02357771|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
11351573|NCT02357771|Experimental|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
11351574|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
11351575|NCT02357758|No Intervention|Healthy Population|
11351576|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
11351577|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
11351578|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
11351579|NCT02357732|Experimental|Nivolumab and Dabrafenib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV every 2 weeks (q2 weeks); Dabrafenib 100mg by mouth (PO) twice a day(BID) every day (QD); Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD;
11351580|NCT02357732|Experimental|Nivolumab and Trametinib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Trametinib 2mg PO QD;
11351581|NCT02357732|Experimental|Nivolumab, Dabrafenib and Trametinib Combination (triplet)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD;
11351582|NCT02357719|Experimental|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
11351583|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
11351584|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
11351587|NCT02357680|Experimental|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.
~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.
~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
11351588|NCT02357680|No Intervention|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
11351589|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
11351590|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
11351591|NCT02357654|Experimental|GnRH agonist|
11351592|NCT02357654|Placebo Comparator|Placebo|
11351593|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.
~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
11351594|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
11351595|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
11351596|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
11351597|NCT02357615|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
11351598|NCT02357615|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
11351599|NCT02357602|Experimental|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
11351600|NCT02357602|Experimental|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
11351601|NCT02357602|Experimental|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
11351602|NCT02357589|Active Comparator|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
11351603|NCT02357589|Experimental|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
11351604|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
11351605|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
11351606|NCT02357563|Experimental|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
11351607|NCT02357563|Active Comparator|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
11351608|NCT02357550|Placebo Comparator|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
11351609|NCT02357550|Experimental|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
11351610|NCT02357537|Active Comparator|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).
~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
11351611|NCT02357537|Active Comparator|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.
~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
11351612|NCT02357524|Experimental|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
11351613|NCT02357511|Experimental|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
11351614|NCT02357498|Active Comparator|microscopic|Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)
11351615|NCT02357498|Active Comparator|endoscopic|Fully endoscopic transsphenoidal surgery (350 subjects)
11351616|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
11351617|NCT02357472|Experimental|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
11351618|NCT02357472|Experimental|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
11351619|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
11351620|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
11351621|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
11351622|NCT02357433|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization
11351623|NCT02357433|No Intervention|Control Group|Standard practice
11351627|NCT02357420|Placebo Comparator|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
11351629|NCT02357407|Experimental|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
11351630|NCT02357394|Experimental|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
11351631|NCT02357394|No Intervention|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
11351632|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
11351633|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
11351634|NCT02357368|Experimental|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
11351635|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
11351636|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
11351637|NCT02357355|Active Comparator|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
11351638|NCT02357355|Active Comparator|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
11351639|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
11351640|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
11351641|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
11351642|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
11351643|NCT02357303|Placebo Comparator|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
11351644|NCT02357303|Active Comparator|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
11351645|NCT02357303|Active Comparator|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
11351646|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:
~Subjects ages 5-12:
~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM
~Subjects ages 13-17:
~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM
~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
11351647|NCT02357277|Experimental|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
11351648|NCT02357277|Experimental|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
11351649|NCT02357277|Placebo Comparator|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
11351650|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
11351651|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
11351652|NCT02357251|Active Comparator|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
11351653|NCT02357251|No Intervention|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
11351654|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
11351655|NCT02357225|Experimental|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
11351656|NCT02357225|Experimental|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
11351657|NCT02357212|Other|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
11351658|NCT02357212|Other|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
11351659|NCT02357199|Experimental|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
11351660|NCT02357199|No Intervention|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
11351661|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
11351662|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
11351663|NCT02357160|Experimental|Choice|Patients given choice over artwork on wall
11351666|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin
~Maintenance Phase - Amatuximab"
11351667|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin
~Maintenance Phase - Placebo"
11351668|NCT02357134|Experimental|Arm I (high-flow oxygen)|Patients receive high-flow oxygen via nasal prongs during a structured stationary bicycle exercise session.
11351669|NCT02357134|Experimental|Arm II (high-flow air)|Patients receive high-flow air via nasal prongs during a structured stationary bicycle exercise session
11351670|NCT02357134|Active Comparator|Arm III (low-flow oxygen)|Patients receive low-flow oxygen via a nasal cannula during a structured stationary bicycle exercise session.
11351671|NCT02357134|Active Comparator|Arm IV (low-flow air)|Patients receive low-flow air via a nasal cannula during a structured stationary bicycle exercise session.
11351672|NCT02357121|Experimental|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
11351673|NCT02357108|Active Comparator|Group 1: Video/Doctor Sequence 1|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
11351674|NCT02357108|Active Comparator|Group 2: Video/Doctor Sequence 2|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
11351675|NCT02357108|Active Comparator|Group 3: Video/Doctor Sequence 3|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
11351676|NCT02357108|Active Comparator|Group 4: Video/Doctor Sequence 4|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
11351677|NCT02357095|Experimental|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
11351678|NCT02357095|Experimental|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
11351679|NCT02357095|Experimental|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
11351680|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
11351681|NCT02357069|Experimental|LBEC0101|Etanercept
11351682|NCT02357069|Active Comparator|Enbrel|Etanercept
11351683|NCT02357056|Active Comparator|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
11351684|NCT02357056|Active Comparator|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
11351685|NCT02357056|Active Comparator|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
11351686|NCT02357056|No Intervention|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
11351687|NCT02357043|Experimental|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
11351688|NCT02357030|Experimental|Methyl-P plus GWI Nutrient Formula|Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.
11351689|NCT02357017|Active Comparator|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
11351690|NCT02357017|Active Comparator|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
11351691|NCT02357004|Experimental|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
11351692|NCT02357004|Experimental|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
11351693|NCT02356991|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
11351694|NCT02356991|Placebo Comparator|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
11351695|NCT02356978|Experimental|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.
~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
11351696|NCT02356965|Experimental|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
11351697|NCT02356965|Experimental|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
11351698|NCT02356965|Placebo Comparator|Placebo|Single dose of placebo sublingual wafer
11351699|NCT02356952|Experimental|Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
11351700|NCT02356952|Experimental|Low Glycemic Index Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
11351701|NCT02356952|Experimental|Low Glycemic Index Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
11351702|NCT02356939|Experimental|Intraductal stent (IST)|"For intervention : intraductal removable stent In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.
~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation."
11351703|NCT02356939|Experimental|Without intraductal stent (no IST)|For intervention : stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP) Each center will perform its habitual postoperative follow up.
11351704|NCT02356926||Control|Usual care and routine management
11351705|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
11351706|NCT02356913|Experimental|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
11351707|NCT02356913|Experimental|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
11351708|NCT02356913|Experimental|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
11351709|NCT02356913|Active Comparator|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
11351710|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
11351711|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
11351712|NCT02356887|Experimental|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
11351713|NCT02356874|Experimental|Exercise group|Exercise
11351714|NCT02356874|No Intervention|Control group|Participants in the control group will be asked to continue their usual physical activity habits
11351715|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
11351716|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
11351717|NCT02356848|Experimental|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
11351718|NCT02356848|Placebo Comparator|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
11351719|NCT02356835|Experimental|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
11351720|NCT02356835|Sham Comparator|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
11351721|NCT02356809|Experimental|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
11351722|NCT02356809|No Intervention|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
11351723|NCT02356796|Experimental|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.
~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
11351724|NCT02356796|Active Comparator|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
11351757|NCT02356523||Cardiac Intensive Care Unit Patients|Patients admitted at Cardiac Intensive Care Unit for any condition
11351725|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.
~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
11351726|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.
~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
11351727|NCT02356770|Experimental|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
11351728|NCT02356770|Other|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
11351729|NCT02356757|Experimental|Personalized Behavioral Intervention (PBI)|The PBI is a 12-month long integrated, multicomponent counseling and dermal thermometry intervention targeting foot self-care, foot self-monitoring, diet, medication and physical activity. The intervention is based on self-regulation theory, the Transtheoretical Model and
11351730|NCT02356757|Placebo Comparator|Current Best Practice (CBP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes and foot care, and will also receive counseling regarding preventing general health conditions.
11351731|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
11351732|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
11351733|NCT02356718|Experimental|Experimental|Computerized cognitive training activities
11351734|NCT02356718|Active Comparator|Control|Non-adaptive computerized cognitive training activities
11351735|NCT02356705|Placebo Comparator|Saline Placebo|Control patients will receive intranasal saline
11351736|NCT02356705|Active Comparator|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
11351737|NCT02356705|Active Comparator|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
11351738|NCT02356692|Experimental|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
11351739|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
11351740|NCT02356679|Experimental|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
11351741|NCT02356679|Active Comparator|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
11351742|NCT02356653|Experimental|Expanded access to CliniMACs device for T cell depletion|access for patients who lack a fully HLA matched sibling, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-open protocols that utilize CliniMACs technology for T depletion. Subjects will undergo transplant of stem cells with CD3+/CD19+ depletion.
11351743|NCT02356640|Active Comparator|EUS-guided celiac ganglion neurolysis|Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
11351744|NCT02356640|Active Comparator|Percutaneous celiac plexus neurolysis|Percutaneous celiac plexus neurolysis would be performed
11351745|NCT02356627|Experimental|The Cancer Home Life Intervention|"One or more of the following:
~prioritisation of resources and everyday activities
~adaptation of activities
~adaptation of posture and seating positioning
~provision of assistive devices
~modification of the physical home environment And usual care from hospital and municipality"
11351746|NCT02356627|No Intervention|Control|Usual care from hospital and municipality
11351747|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
11351748|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
11351749|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
11351750|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
11351751|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
11351752|NCT02356549|Active Comparator|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
11351753|NCT02356549|Active Comparator|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
11351754|NCT02356549|Active Comparator|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
11351755|NCT02356549|Active Comparator|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
11351758|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
11351759|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
11351760|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
11351761|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
11351762|NCT02356458|Experimental|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
11351763|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
11351764|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
11351765|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
11351766|NCT02356419|Experimental|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
11351767|NCT02356419|Experimental|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
11351768|NCT02356419|Experimental|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
11351769|NCT02356419|Experimental|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
11351770|NCT02356406|Experimental|Celiac Plexus Radiosurgery|"The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.
~All eligible patients will receive the same protocol of celiac plexus radiosurgery"
11351771|NCT02356380|Experimental|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.
~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
11351772|NCT02356354|Other|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
11351773|NCT02356341||NovaTears®|
11351774|NCT02356328||NovaTears®|
11351775|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
11351776|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
11351777|NCT02356302|Experimental|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|The vicriviroc (MK-4176) IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
11351778|NCT02356302|Experimental|MK-2048 IVR|The MK-2048 IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
11351779|NCT02356302|Experimental|MK-2048A IVR|The MK-2048A IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
11351780|NCT02356302|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
11351781|NCT02356289|Experimental|MYK-461|single-dose, tablet formulation
11351782|NCT02356289|Placebo Comparator|Placebo|single-dose, tablet formulation
11351783|NCT02356276|Experimental|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
~Systemic chemotherapy (XELOX or SOX regimens):
~XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
11351784|NCT02356276|Placebo Comparator|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.
~XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
11351785|NCT02356250||PORTAL HYPERTENSION|PAIEBT WITH PORTAL HYPERTENSION
11351786|NCT02356237|Experimental|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
11351787|NCT02356237|No Intervention|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
11351788|NCT02356224|Experimental|Cohort 1|SHR3824 2.5 mg/day or placebo.
11351789|NCT02356224|Experimental|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11351790|NCT02356224|Experimental|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11351791|NCT02356224|Experimental|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11351829|NCT02355938|Active Comparator|Vancomycin Arm|Oral Vancomycin 125 mg every 6 hours for 10 days
11351792|NCT02356224|Experimental|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11351793|NCT02356224|Experimental|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11351794|NCT02356224|Experimental|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11351795|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
11351796|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
11351797|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
11351798|NCT02356198|Active Comparator|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
11351799|NCT02356172||Healthy Controls|Healthy males or females who are greater than or equal to 18 years old.
11351800|NCT02356172||Patients|Males or females with a diagnosis of IGD (Isolated GnRH Deficiency) who are greater than or equal to 18 years old.
11351801|NCT02356159|Experimental|1/Phase 1: Dose escalation arm|Induction chemotherapy, then palifermin at escalating doses, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
11351802|NCT02356159|Experimental|2/ Phase II arm|Induction chemotherapy, then palifermin at the MTDdetermined in Phase 1, then conditioning chemotherapy, then allogeneic stem cell transplant, then immunosuppression
11351803|NCT02356146||All KT recipient|
11351804|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
11351805|NCT02356107|Experimental|Open label treatment with 5-HTP and Creatine|
11351806|NCT02356094||Cases|Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination
11351807|NCT02356094||Controls|Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination
11351808|NCT02356081|Experimental|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
11351809|NCT02356081|No Intervention|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
11351810|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
11351811|NCT02356055|Experimental|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
11351812|NCT02356055|Active Comparator|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
11351813|NCT02356042||Nursing home residents practicing GIA activity|
11351814|NCT02356042||Nursing home residents no practicing GIA activity|
11351815|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
11351816|NCT02356016|Active Comparator|Whole body Electromyostimulation (WB-EMS)|18 min of WB-EMS/week (one session/week)
11351817|NCT02356016|Active Comparator|WB-EMS and Nutritional Supplements|18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
11351818|NCT02356016|Sham Comparator|Control|Monthly dietary counseling for 6 months
11351819|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
11351820|NCT02355990|Experimental|MIMS|Minimally Invasive Micro Sclerostomy
11351821|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
11351822|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
11351823|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
11351824|NCT02355964|Experimental|exercise|exercise (Aerobe training) 3 times per week
11351825|NCT02355964|Experimental|Diet|A diet with an overall high protein content and a low glycemic index
11351826|NCT02355964|Experimental|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
11351827|NCT02355964|No Intervention|control|Regular lifestyle (no intervention)
11351828|NCT02355938|Experimental|Fidaxomicin Arm|Oral Fidaxomicin 200 mg every 12 hours (Placebo for 2 doses) for 10 days
11351830|NCT02355925|Experimental|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
11351831|NCT02355925|Placebo Comparator|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
11351832|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
11351833|NCT02355912|Experimental|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
11351834|NCT02355899|Experimental|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
11351835|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
11351836|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
11351837|NCT02355873|Experimental|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
11351838|NCT02355873|Active Comparator|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
11351839|NCT02355847|Other|Healthcare Worker Education|Educational Lectures
11351840|NCT02355834|Experimental|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
11351841|NCT02355834|No Intervention|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
11351842|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
11351843|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
11351844|NCT02355808|No Intervention|Non Superfast|
11351845|NCT02355808|Other|Non Superfast GP intervention|
11351846|NCT02355808|Other|Non Superfast Tailored Leaflet|
11351847|NCT02355808|Other|Non Superfast GP + Tailored Leaflet|
11351848|NCT02355808|No Intervention|Superfast|
11351849|NCT02355808|Other|Non Superfast GP|
11351850|NCT02355808|Other|Superfast Tailored Leaflet|
11351851|NCT02355808|Other|Superfast GP + Tailored Leaflet|
11351852|NCT02355795|Experimental|low-fat diet|Participants will be provided low-fat diet for 6 months
11351853|NCT02355795|Experimental|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
11351854|NCT02355795|Experimental|high-fat diet|Participants will be provided high-fat diet for 6 months
11351855|NCT02355756|Experimental|Active|Intradermal injection of maxadilan solution
11351856|NCT02355756|Placebo Comparator|Placebo|Intradermal injection of placebo (=vehicle) solution
11351857|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
11351858|NCT02355730|Experimental|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
11351859|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
11351860|NCT02355704|Active Comparator|Atorvastatin|22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
11351861|NCT02355704|Placebo Comparator|Placebo|22 patients received oral placebo 40 mg 1 time for day for 4 weeks
11351862|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
11351863|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
11351864|NCT02355678|Experimental|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
11351865|NCT02355678|Experimental|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
11351866|NCT02355665|Experimental|Nicotine|Nicotine Spray
11351867|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
11351868|NCT02355652|Active Comparator|Cemented TKA|
11351869|NCT02355652|Active Comparator|Uncemented TKA|
11351870|NCT02355639|Experimental|Clobetasol propionate 0.05 % ointment|Active drug
11351871|NCT02355639|Experimental|Betamethasone dipropionate 0.064 % ointment|Active drug
11351872|NCT02355639|Placebo Comparator|Petrolatum ointment|Placebo drug
11351873|NCT02355613|Active Comparator|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
11351874|NCT02355613|Active Comparator|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
11351912|NCT02355288|Active Comparator|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
11351913|NCT02355275|Experimental|Home Exercise Program|
11351875|NCT02355561|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram [mg] formulation 1 [reference] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 [test] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11351876|NCT02355561|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11351877|NCT02355561|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11351878|NCT02355561|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11351879|NCT02355561|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11351880|NCT02355561|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
11351881|NCT02355548||Outpatient Treatment|All patients eligible for the study will have their PE treated in the outpatient setting.
11351882|NCT02355535|Experimental|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
11351883|NCT02355522|Active Comparator|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
11351884|NCT02355522|Active Comparator|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
11351885|NCT02355522|Placebo Comparator|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
11351886|NCT02355509|Placebo Comparator|Placebo|A placebo drug is given for three months
11351887|NCT02355509|Experimental|Acarbose|Acarbose is given for three months
11351888|NCT02355496|Experimental|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
11351889|NCT02355496|No Intervention|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
11351890|NCT02355470|Experimental|Intervention|Participants will receive the GIFTSS intervention provided by college health center staff and clinicians
11351891|NCT02355470|Active Comparator|Control|Participants will receive a brief alcohol use reduction intervention based on NIAAA guidelines provided by college health center staff and clinicians
11351892|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
11351893|NCT02355444|Experimental|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
11351894|NCT02355444|Placebo Comparator|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
11351895|NCT02355431|Experimental|Itacitinib plus erlotinib|
11351896|NCT02355431|Active Comparator|Placebo plus erlotinib|
11351897|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
11351898|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
11351899|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
11351900|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
11351901|NCT02355379|Experimental|GROUP2- ARM C|Observation
11351902|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
11351903|NCT02355366|Experimental|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
11351904|NCT02355366|Active Comparator|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
11351905|NCT02355353|Experimental|Imaging arm|
11351906|NCT02355340||DXA and pQCT Scan|"Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density
~Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
11351907|NCT02355327|Experimental|Laselle Kegel Exerciser|
11351908|NCT02355327|Active Comparator|Pelvic floor muscle exercises|
11351909|NCT02355314|Experimental|ICU patients requiring mechanical ventilation|
11351910|NCT02355301||patients with orthopedic disorders|Patients with muscular skeletal impairments receiving a treatment (A, B, C...). The investigators compare these treatments (A, B, C...) in function of ICF model in order to improve the quality of care in orthopedic department.
11351911|NCT02355288|Active Comparator|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
11351981|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
11351914|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
11351915|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
11351916|NCT02355249|Experimental|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
11351917|NCT02355249|Active Comparator|B group (OE)|Via traditional three incisions esophagectomy.
11351918|NCT02355236|Experimental|Test Group|Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks
11351919|NCT02355236|Active Comparator|Comparator Group|Celecoxib 200mg and Naxozol-Placebo for 12 weeks
11351920|NCT02355223|Other|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
11351921|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
11351922|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
11351923|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
11351924|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
11351925|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
11351926|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
11351927|NCT02355197|Active Comparator|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
11351928|NCT02355197|No Intervention|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
11351929|NCT02355184|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
11351930|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
11351931|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
11351932|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
11351933|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
11351934|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
11351935|NCT02355119|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
11351936|NCT02355119|Experimental|FOLFOXIRI|
11351937|NCT02355106|Experimental|Treatment|Atrial flutter Ablation
11351938|NCT02355093|Experimental|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
11351939|NCT02355093|Active Comparator|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
11351940|NCT02355080|Experimental|On-site bundled rapid HIV/HCV testing|Participants will receive the on-site bundled rapid HIV/HCV testing intervention. In the intervention group, all patients will receive an offer to participate in rapid HIV/HCV testing. Those who accept this offer will: receive pre-test information about testing procedures and education, be tested, receive results during the same visit as testing, and be provided post-test counseling and support services by trained test counselors. Patients with a preliminary positive (i.e., reactive) HIV and/or HCV test result(s) will be actively linked immediately to a health care provider for further evaluation and confirmatory HIV and/or HCV RNA testing.
11351941|NCT02355080|Active Comparator|Standard of care (SOC)|Participants will receive the standard of care (SOC) at the study sites. The SOC entails venipuncture whole blood HIV testing + venipuncture whole blood HCV testing. Blood draws are sent to an external laboratory for processing, and patients must return for test results in another visit. Patients may not receive pre-test information or results and post-test counseling, especially if non-reactive or negative test result(s). Reflex testing is not standard practice, therefore some patients may require another visit and blood draw for confirmatory HIV and/or HCV RNA testing. Linkage to care in the SOC is accomplished by referral to a health care provider, either within the participating substance use disorder treatment organization or passive referral to other health facilities.
11351942|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
11351943|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
11351944|NCT02355041|Experimental|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
11352040|NCT02354430|Active Comparator|Water-exercise|
11352041|NCT02354430|No Intervention|Control group|
11351945|NCT02355041|Active Comparator|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
11351946|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
11351947|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
11351948|NCT02355002|Experimental|Active Transcranial Magnetic Stimulation (TMS) treatment|In this arm subjects will receive real, active TMS with a standard, water-cooled, figure-8 shaped TMS coil.
11351949|NCT02355002|Sham Comparator|Sham-TMS treatment|This arm serves as the sham/placebo control. In TMS a sham coil is used to create a sensory experience which is similar to active TMS, but in which the magnetic field is blocked by a metal shield built into the coil.
11351950|NCT02354989|Active Comparator|RR on first|Rate Response on first
11351951|NCT02354989|Active Comparator|RR off first|Rate Response off first
11351952|NCT02354976|Placebo Comparator|Placebo|
11351953|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
11351954|NCT02354976|Active Comparator|Fenofibrate 200mg|
11351955|NCT02354963|No Intervention|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
11351956|NCT02354963|Experimental|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.
~Assessment of antral follicle count. IVF treatment."
11351957|NCT02354950|Experimental|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
11351958|NCT02354950|Experimental|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
11351959|NCT02354950|Experimental|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
11351960|NCT02354950|Experimental|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
11351961|NCT02354937|Experimental|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
11351962|NCT02354937|Active Comparator|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
11351963|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
11351964|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
11351965|NCT02354911|Experimental|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
11351966|NCT02354911|Placebo Comparator|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
11351967|NCT02354898|Experimental|BBI503, BBI503 and Sorafenib|
11351968|NCT02354885|No Intervention|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
11351969|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
11351970|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
11351971|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
11351972|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
11351973|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
11351974|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
11351975|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
11351976|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
11351977|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
11351978|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
11351979|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
11351980|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
11351982|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
11351983|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
11351984|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
11351985|NCT02354859|Active Comparator|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
11351986|NCT02354859|Placebo Comparator|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
11351987|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
11351988|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
11351989|NCT02354820|No Intervention|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
11351990|NCT02354820|Experimental|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
11351991|NCT02354807|Experimental|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
11351992|NCT02354794|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.
~Intervention: see below"
11351993|NCT02354781|Experimental|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
11351994|NCT02354768|Experimental|lanreotide and anti-diarrheal treatments|"Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)
~Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)
~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)
~hydration"
11351995|NCT02354768|Active Comparator|Current anti-diarrheal treatments alone|"Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)
~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)
~Hydration"
11351996|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
11351997|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
11351998|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
11351999|NCT02354742|Active Comparator|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
11352000|NCT02354742|Experimental|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
11352001|NCT02354729|Experimental|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
11352002|NCT02354729|No Intervention|Control|Participants received text messages.
11352003|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
11352004|NCT02354703|Experimental|ondansetron|"ondansetron-0.33 mg bid + Brief Behavioral Compliance Enhancement Treatment (BBCET) for 16 weeks arm equally divided between two genetic subgroups
~at Maryland site: carriers of any of the following genotypes
~5-HTTLPR:LL plu rs25531:AA (LALA genotype) in SLC6A4 gene; or
~SLC6A4-rs1042173:TT, or
~HTR3A-rs1150226:AG; or
~HTR3A-rs1176713:GG; or
~HTR3B-rs17619942: AC and carriers of any other genotype
~At Pennsylvania site:
~carriers of HTR3B- rs176744: CC or CT and carriers of HTR3B- rs176744: TT"
11352005|NCT02354703|Placebo Comparator|placebo|"BBCET for 16 weeks arm equally divided between two genetic subgroups
~At Maryland site:
~carriers of any of the following genotypes
~5-HTTLPR:LL plu rs25531:AA (LALA genotype) in SLC6A4 gene; or
~SLC6A4-rs1042173:TT, or
~HTR3A-rs1150226:AG; or
~HTR3A-rs1176713:GG; or
~HTR3B-rs17619942: AC and carriers of any other genotype
~At Pennsylvania site:
~carriers of HTR3B- rs176744: CC or CT and carriers of HTR3B- rs176744: TT"
11352006|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
11352007|NCT02354677|Experimental|Heathy volunteers, smokers and COPD|
11352008|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
11352009|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
11352010|NCT02354651||Pompe subjects receiving NeuDx DPS|Patients will receive pulmonary function testing, resting breathing pattern evaluation, respiratory muscle endurance testing, phrenic nerve stimulation, maximal inspiratory pressure (MIP) testing, forced expiratory testing, and EMG.
11352011|NCT02354638|Experimental|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
11352012|NCT02354638|No Intervention|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
11352013|NCT02354625|Experimental|ahSC transplantation|Autologous human Schwann cells
11352014|NCT02354612|Experimental|TRC105|Weekly or biweekly TRC105 i.v. in combination with companion therapy (if applicable) from the parent trial or single agent TRC105 as per the parent trial. Companion therapy includes but is not limited to: bevacizumab, capecitabine, pazopanib or axitinib
11352015|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352016|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352017|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352018|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352019|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352020|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352021|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
11352022|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
11352023|NCT02354586|Experimental|Niraparib|
11352024|NCT02354573|Active Comparator|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
11352025|NCT02354573|Placebo Comparator|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
11352026|NCT02354560|Experimental|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
11352027|NCT02354547|Experimental|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
11352028|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
11352029|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
11352030|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
11352031|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
11352032|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
11352033|NCT02354495|Experimental|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
11352034|NCT02354482||Diverse, high-risk patient populations|
11352035|NCT02354469||Contact/Collision Sport Athletes|Collegiate athletes who participate in contact or collision sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
11352036|NCT02354469||Non-contact Sport Athletes|Collegiate athletes who participate in non-contact sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
11352037|NCT02354469||Post-Concussion|Collegiate athletes who sustain a concussion will be assessed on a comprehensive battery of tests from the time of injury and incrementally throughout the following year post-injury.
11352038|NCT02354469||Healthy Control|Collegiate athletes who do not sustain a concussion but match the demographic profile of an individual enrolled as a post-concussion subject, will be assessed on the same tests and in a similar timeline as post-concussion subjects.
11352039|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
11352042|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.
~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:
~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.
~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
11352043|NCT02354404|Experimental|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
11352044|NCT02354404|Experimental|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
11352045|NCT02354404|Experimental|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
11352046|NCT02354404|Experimental|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
11352047|NCT02354404|Experimental|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
11352048|NCT02354404|Experimental|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
11352049|NCT02354391|Experimental|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
11352050|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
11352051|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
11352052|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
11352053|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
11352054|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
11352055|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
11352056|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
11352057|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
11352058|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
11352059|NCT02354326||Diagnostic (VNC DECT)|Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.
11352060|NCT02354313|Experimental|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
11352061|NCT02354313|No Intervention|Observation|no therapy is planned but only observation
11352062|NCT02354300||TCD Ultrasound|Transcranial doppler ultrasound monitoring during flow diverter placement.
11352063|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
11352064|NCT02354274|Active Comparator|Standard: Homogeneous dose plan|Treatment will be given over 33 treatments. The dose is 66 Gy.
11352065|NCT02354274|Experimental|Escalation: Inhomogeneous dose plan|"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.
~Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration"
11352066|NCT02354261|Experimental|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
11352067|NCT02354248|Experimental|Stroke patients|The patients will be submitted to a triple stimulation examination.
11352068|NCT02354248|Active Comparator|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
11352069|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
11352070|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
11352071|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
11352072|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
11352073|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.
~The following procedures will be carried out:
~Questionnaire on compliance and adherence
~Clinic Visit
~20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
11352074|NCT02354196||CCTA|Subjects who underwent a CCTA
11352075|NCT02354183|Experimental|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
11352076|NCT02354183|Active Comparator|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
11352077|NCT02354170|Experimental|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
11352078|NCT02354170|Experimental|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
11352079|NCT02354170|Placebo Comparator|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
11352080|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:
~a commercially available gel that contains carrageenan.
~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.
~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
11352081|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:
~a commercially available gel that does not contain carrageenan.
~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.
~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
11352082|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
11352083|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
11352084|NCT02354118|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
11352085|NCT02354118|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
11352086|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
11352087|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include
~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
~Local anesthetic for tenaculum placement
~Sham Paracervical Block done with capped spinal needle
~osmotic dilators placed in the usual fashion
~postprocedural assessment"
11352088|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include
~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
~Local anesthetic for tenaculum placement
~18 ml 1% buffered lidocaine Paracervical Block
~osmotic dilators placed in the usual fashion
~postprocedural assessment"
11352089|NCT02354079|Other|genetic analysis|
11352090|NCT02354066|Experimental|Hallux valgus Surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy, Chevron, SCARF, Austin, etc.)
11352091|NCT02354066|Experimental|Hallux valgus and forefoot surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy; Chevron, Austin, SCARF, etc.) and additional forefoot surgery (PIP arthrodesis, second/third/etc. metatarsal osteotomy, etc.; Peg-in-Hole, WEIL-Osteotomy, etc.)
11352092|NCT02354066|Experimental|Control Run|Measurement of the Brake Response Time by Healthy Participants; control run; brake response time measurement with normal shoe and both foot orthoses
11352093|NCT02354053|Active Comparator|Current ART|Current ART + adherence support
11352094|NCT02354053|Experimental|Triumeq|Triumeq + adherence support
11352095|NCT02354040|Experimental|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
11352096|NCT02354040|No Intervention|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
11352097|NCT02354027|Experimental|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
11352133|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
11352134|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
11352135|NCT02353702|Experimental|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :
~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
11352098|NCT02354014|Experimental|TMC207/Background Regimen (BR)|There will be 4 age-based cohorts. Participants will be enrolled concurrently in Cohorts 1 and 2 followed by sequential enrollment of Cohorts 3, 4. Cohort 1: >= 12 to < 18 years: bedaquiline (TMC207) tablet orally as 400 mg, once daily(qd),for first 2 weeks, followed by TMC207, 200 mg 3 times per week (tiw) for 22 weeks; Cohort 2: >=5 to <12 years: TMC207 tablet given orally as 200 mg, qd, for first 2 weeks, followed by TMC207, 100 mg, tiw for 22 weeks. Cohort 3: >=2 to <5 years: TMC207 8 milligram per kilogram (mg/kg) qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw for 22 weeks. Cohort 4: 0 months to <2 years: TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3. TMC207 will be given in combination with Background Regimen for Multidrug Resistant Tuberculosis (MDR-TB) according to WHO/National Tuberculosis Program (NTP) guidelines/current standard of care.
11352099|NCT02354001|Experimental|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
11352100|NCT02354001|Placebo Comparator|placebo tablet|1 tablet daily for 12 weeks
11352101|NCT02353988|Experimental|bicalutamide|This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
11352102|NCT02353988|Active Comparator|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable
11352103|NCT02353975|Experimental|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
11352104|NCT02353975|Experimental|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
11352105|NCT02353962|Experimental|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
11352106|NCT02353949|Experimental|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
11352107|NCT02353936|Experimental|afatinib group|
11352108|NCT02353923|Experimental|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
11352109|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
11352110|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
11352111|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
11352112|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
11352113|NCT02353858|Experimental|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
11352114|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
11352115|NCT02353845||normal control|
11352116|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
11352117|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
11352118|NCT02353832|Other|No Arm|
11352119|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
11352120|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
11352121|NCT02353793|Experimental|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
11352122|NCT02353793|Active Comparator|Cotton wool blanket|Patient warming with cotton wool blanket
11352123|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
11352124|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
11352125|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
11352126|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
11352127|NCT02353767||Controls|"age ± 7 years from cases
~duration of HIV-1 infection ± 3 years from cases
~HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or > 1000 copies/mL"
11352128|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
11352129|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
11352130|NCT02353741|Experimental|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
11352131|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
11352132|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
11352136|NCT02353702|Placebo Comparator|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :
~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
11352137|NCT02353689|Experimental|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
11352138|NCT02353689|Experimental|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
11352139|NCT02353689|Experimental|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
11352140|NCT02353676|Experimental|BUPIVACAINE GROUP|1.5 ml of 0.5% Bupivacaine solution to be injected into the operative site postoperatively.
11352141|NCT02353676|Placebo Comparator|PLACEBO GROUP|1.5 ml of saline solution to be injected into the opposite site postoperatively.
11352142|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
11352143|NCT02353637|Active Comparator|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
11352144|NCT02353637|Active Comparator|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
11352145|NCT02353611|Experimental|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
11352146|NCT02353611|Active Comparator|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
11352147|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 1|Participants will recieve crenezumab dose level 1 once every 4 weeks.
11352148|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 2|Participants will receive crenezumab dose level 2 once every 4 weeks.
11352149|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 3|Participants will receive crenezumab dose level 3 once every 4 weeks.
11352150|NCT02353598|Placebo Comparator|Double-blind treatment window: Placebo|Participants will receive placebo matched to crenezumab once every 4 weeks.
11352151|NCT02353598|Experimental|Optional OLE window: Crenezumab|Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
11352152|NCT02353585||Intracranial hemorrhage|Intracranial hemorrhage occuring in patients on novel oral anticoagulants (NOAC) or vitamin-K antagonists
11352153|NCT02353585||Acute ischemic stroke|Acute ischemic stroke occuring in patients on novel oral anticoagulants (NOAC) or vitamin K antagonists (VKA)
11352154|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
11352155|NCT02353559|Experimental|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
11352156|NCT02353559|No Intervention|Usual Care|Usual care
11352157|NCT02353546|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
11352158|NCT02353546|No Intervention|Usual Care|
11352159|NCT02353533|Other|EMR|Standard EMR technique
11352160|NCT02353533|Experimental|FTRD|
11352161|NCT02353507|Active Comparator|Opticell Ag+|Absorbent, antibacterial, barrier dressing
11352162|NCT02353507|Active Comparator|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
11352163|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
11352164|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.
~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.
~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
11352165|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.
~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
11352166|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
11352167|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
11352168|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
11352428|NCT02351739|Other|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
11352169|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:
~placebo ultrasound during 5min ;
~scapular squeezing in the sitting position (3x10repetitions);
~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
11352170|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:
~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);
~external rotators strengthening in sidelying positions with load (3x10repetitions);
~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
11352171|NCT02353429|Experimental|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
11352172|NCT02353416|Placebo Comparator|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
11352173|NCT02353416|Active Comparator|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
11352174|NCT02353403|Placebo Comparator|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
11352175|NCT02353403|Experimental|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
11352176|NCT02353390|Active Comparator|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
11352177|NCT02353390|No Intervention|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
11352178|NCT02353364|Experimental|Group A|Transfer of 1 or 2 biopsied euploid embryo of high morphological grade based on NGS testing using CNV-Seq (PGS)
11352179|NCT02353364|No Intervention|Group B|Transfer of 1 or 2 non-biopsied embryo of high morphological grade (no PGS)
11352180|NCT02353338|Experimental|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
11352181|NCT02353338|Active Comparator|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
11352182|NCT02353325|Experimental|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
11352183|NCT02353325|Experimental|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
11352184|NCT02353325|Experimental|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
11352185|NCT02353325|Experimental|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
11352186|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
11352187|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
11352188|NCT02353312|Experimental|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
11352189|NCT02353312|Active Comparator|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
11352190|NCT02353299|Active Comparator|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
11352191|NCT02353299|Placebo Comparator|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
11352192|NCT02353299|Active Comparator|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
11352193|NCT02353299|Placebo Comparator|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
11352194|NCT02353286|Experimental|Post-cholecystecomy bile leak|Endoscopic insertion of biodegradable biliary stent
11352195|NCT02353286|Experimental|Benign biliary stricture|Endoscopic insertion of biodegradable biliary stent
11352196|NCT02353273|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
11352197|NCT02353260|Experimental|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:
~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
~The treatments will be administrated in accord with the guideline for other types of cancer.
~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
11352198|NCT02353260|Active Comparator|Chemotherapy|"Chemotherapy:
~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)
~The treatments will be administrated in accord with the guideline for other types of cancer."
11352199|NCT02353247|Other|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
11352200|NCT02353234|Active Comparator|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
11352201|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
11352202|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
11352226|NCT02353065|Experimental|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
11352429|NCT02351726|Experimental|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
11352203|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
11352204|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
11352205|NCT02353208|Active Comparator|Sham Feeding of Bacon Bits|"In addition to the standard procedure, subjects will be asked to perform sham feeding on two occasions: 1) Immediately after having swallowed the capsule and 2) One hour after having swallowed the capsule.
~Sham feeding will be performed as follows: The patients will be asked to chew 10 times on a piece of bacon over a period of 30 seconds, prior to spitting saliva and bacon into a container. This will be repeated 10 times at one minute intervals.
~The patient will then complete the capsule study as per the standard procedure.
~Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada."
11352206|NCT02353208|Placebo Comparator|Placebo|The control group will not chew bacon bits while undergoing capsule endoscopy.
11352207|NCT02353195|Experimental|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
11352208|NCT02353195|Placebo Comparator|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
11352209|NCT02353182|Experimental|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.
~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed
~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed
~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
11352210|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
11352211|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
11352212|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
11352213|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
11352214|NCT02353156|Experimental|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
11352215|NCT02353156|Active Comparator|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
11352216|NCT02353143|Experimental|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
11352217|NCT02353130||Memantine-XR|Boys ages 8-12 with ASD treated with Memantine-XR daily for 8 weeks
11352218|NCT02353117|Active Comparator|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
11352219|NCT02353117|No Intervention|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
11352220|NCT02353104|Experimental|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
11352221|NCT02353091|No Intervention|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
11352222|NCT02353091|Experimental|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
11352223|NCT02353078|Experimental|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
11352224|NCT02353078|Experimental|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
11352225|NCT02353065|Active Comparator|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
11352227|NCT02353052||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
11352228|NCT02353052||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
11352229|NCT02353039|Experimental|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
11352230|NCT02353039|Experimental|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
11352231|NCT02353039|Experimental|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
11352232|NCT02353039|Placebo Comparator|Placebo|Administer placebo t.i.d for 2 weeks.
11352233|NCT02353026|Experimental|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
11352234|NCT02353013|Active Comparator|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
11352235|NCT02353013|Experimental|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
11352236|NCT02353000|Experimental|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
11352237|NCT02353000|Other|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
11352238|NCT02352987|Experimental|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
11352239|NCT02352987|Active Comparator|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
11352240|NCT02352974|Experimental|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals
~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
11352241|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
11352242|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
11352243|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
11352244|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
11352245|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
11352246|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
11352247|NCT02352935|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
11352248|NCT02352935|No Intervention|Control|The patients without any treatment
11352249|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
11352250|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
11352251|NCT02352909|Active Comparator|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
11352252|NCT02352909|Experimental|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
11352253|NCT02352909|Experimental|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
11352254|NCT02352896|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.
11352255|NCT02352883|Experimental|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
11352256|NCT02352883|Experimental|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
11352257|NCT02352883|Experimental|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
11352258|NCT02352883|Experimental|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
11352259|NCT02352883|Experimental|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
11352260|NCT02352870|Experimental|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:
~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.
~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future
~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
11352261|NCT02352870|Active Comparator|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:
~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.
~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
11352262|NCT02352857|Placebo Comparator|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
11352263|NCT02352857|Experimental|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
11352264|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
11352265|NCT02352831|Experimental|Phase I (tosedostat + capecitabine)|"The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion.
~Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat.
~Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle
~Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain."
11352266|NCT02352831|Experimental|Phase II (tosedostat + capecitabine)|"Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle
~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
11352267|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
11352268|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
11352269|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
11352270|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
11352271|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
11352272|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
11352273|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
11352274|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
11352275|NCT02352792|Active Comparator|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
11352276|NCT02352792|Experimental|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
11352277|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
11352278|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
11352279|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
11352280|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
11352281|NCT02352753|Experimental|Denosumab|Single Arm Study
11352282|NCT02352740|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.
~Intervention : A form arginine and B form arginine"
11352283|NCT02352740|Experimental|Healthy subjects|"Control subjects, i.e. without overweight, elevated waist circumference and elevated fasting triglyceridemia.
~Intervention : A form arginine and B form arginine"
11352284|NCT02352714|Active Comparator|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
11352285|NCT02352714|Sham Comparator|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
11352286|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
11352287|NCT02352688|Active Comparator|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
11352288|NCT02352688|No Intervention|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
11352289|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
11352290|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
11352291|NCT02352662||Study Group|Three blood samples will be collected intra-operatively from each subject enrolled
11352292|NCT02352649|Experimental|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
11352293|NCT02352649|Experimental|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
11352294|NCT02352649|Placebo Comparator|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
11352295|NCT02352636|Active Comparator|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
11352296|NCT02352636|Active Comparator|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
11352297|NCT02352636|Experimental|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
11352298|NCT02352636|Placebo Comparator|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
11352299|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
11352300|NCT02352610|Active Comparator|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
11352301|NCT02352610|Active Comparator|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
11352302|NCT02352597|Active Comparator|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
11352303|NCT02352597|Active Comparator|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
11352304|NCT02352597|Active Comparator|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
11352305|NCT02352584|Experimental|GC3110A(Quadrivalent)|0.5ml, intramuscular, a single dosing
11352306|NCT02352584|Active Comparator|GC Flu (Trivalent)|0.5ml,intramuscular,a single dosing
11352307|NCT02352584|Active Comparator|GC3110A(Trivalent)|0.5ml,intramuscular,a single dosing
11352308|NCT02352571|Experimental|Single group assignment|GC1118 recombinant human anti-EGFR antibody
11352309|NCT02352558|Experimental|Arm 1|Patients with multiple myeloma treated with BBI608
11352310|NCT02352558|Experimental|Arm 2|Patients with lymphoma treated with BBI608
11352311|NCT02352558|Experimental|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
11352312|NCT02352558|Experimental|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
11352313|NCT02352558|Experimental|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
11352314|NCT02352558|Experimental|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
11352315|NCT02352558|Experimental|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
11352316|NCT02352558|Experimental|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
11352317|NCT02352558|Experimental|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
11352318|NCT02352545|Experimental|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
11352319|NCT02352545|Placebo Comparator|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
11352320|NCT02352532|Experimental|Low Back Pain - Dry Needling|
11352321|NCT02352532|Sham Comparator|Low Back Pain - Sham|
11352322|NCT02352532|Active Comparator|Asymmptomatic - Dry Needling|
11352323|NCT02352519|Experimental|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
11352324|NCT02352519|Active Comparator|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
11352325|NCT02352506||AKI|Patients developing AKI during the ICU stay
11352326|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
11352327|NCT02352493|Active Comparator|ALN-CC5|
11352328|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11352329|NCT02352480|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
11352330|NCT02352480|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
11352356|NCT02352285|Placebo Comparator|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
11352331|NCT02352467|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
11352332|NCT02352467|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
11352333|NCT02352454|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
11352334|NCT02352454|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
11352335|NCT02352441|Experimental|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
11352336|NCT02352441|No Intervention|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
11352337|NCT02352428|Experimental|Skin Cancer Screening Training|Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
11352338|NCT02352428|No Intervention|No Skin Cancer Screening Training|Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
11352339|NCT02352402|Experimental|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
11352340|NCT02352402|Placebo Comparator|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
11352341|NCT02352389||Influenza|"Children and young adults identified as having influenza infections by the St. Jude Children's Research Hospital diagnostic microbiology will be approached to participate in the study. Biological samples will be collected on Day 0 within 72 hours of the diagnosis of influenza, and at 7, 14, 21, and 28 days later.
~Interventions: Symptom checklist, Blood sample, Nasal swab, Oropharyngeal swab, Stool sample."
11352342|NCT02352376|Other|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
11352343|NCT02352376|Other|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
11352344|NCT02352363|Experimental|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
11352345|NCT02352363|Other|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
11352346|NCT02352350||Cardiac Arrest Patients|All adult patients with non traumatic cardiac arrest in Alachua County Florida will have blood lactate levels taken and neurological outcomes performed based on the Cerebral Performance Categories (CPC) Scale
11352347|NCT02352337|Active Comparator|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
11352348|NCT02352337|Experimental|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:
~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
11352349|NCT02352337|Experimental|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:
~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over
~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
11352350|NCT02352324|Experimental|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
11352351|NCT02352311|Experimental|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
11352352|NCT02352311|Experimental|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
11352353|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
11352354|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
11352355|NCT02352285|Experimental|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
11352357|NCT02352272|Experimental|Sleep extension|Subject spend 10 hours Time in bed per day during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
11352358|NCT02352272|Sham Comparator|Habitual sleep|Subject respect their habitual Time in bed during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
11352359|NCT02352246|Experimental|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
11352360|NCT02352246|Other|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
11352361|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
11352362|NCT02352207||identification of a pulmonary malformation in the fetus|pregnant women referred to a prenatal Center, because of the identification of a pulmonary malformation in the fetus
11352363|NCT02352194||Assessment|"One part of this study is to quantify physical capacity of patients with Multiple sclerosis.
~Thirty patients will be enrolled in this study and performed assessments."
11352364|NCT02352194||Rehabilitation|A second part of this study is to quantify the benefit of a usual rehabilitation program in the day hospital. Thirty patients will be enrolled in this study and receive rehabilitation. They will be assessed before and after the rehabilitation program (physiotherapy and physical activity)
11352365|NCT02352181|Placebo Comparator|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
11352366|NCT02352181|Experimental|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
11352367|NCT02352168|Active Comparator|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
11352368|NCT02352168|Placebo Comparator|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
11352369|NCT02352155|Active Comparator|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
11352370|NCT02352155|Placebo Comparator|observation only|NO second look endoscopy (Observation)
11352371|NCT02352142|No Intervention|Standard Care|Mothers are given infant care instruction as part of standard care
11352372|NCT02352142|Experimental|Facilitated infant care|Family Nurture Intervention
11352373|NCT02352142|Other|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
11352374|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
11352375|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
11352376|NCT02352116|Experimental|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
11352377|NCT02352116|Active Comparator|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
11352378|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
11352379|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
11352380|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
11352381|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
11352382|NCT02352090|Active Comparator|Progestin-Only|Dienogest
11352383|NCT02352077|Experimental|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
11352384|NCT02352064|Experimental|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
11352385|NCT02352051|Active Comparator|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
11352386|NCT02352051|Active Comparator|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
11352387|NCT02352038|Experimental|LLLT group|LLLT group: orthodontic treatment and low-level laser therapy
11352388|NCT02352038|Placebo Comparator|control group|Control group: orthodontic treatment and no laser treatment.
11352389|NCT02352025|Experimental|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
11352390|NCT02352012|Experimental|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
11352391|NCT02352012|Experimental|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
11352392|NCT02352012|No Intervention|control group|Control group was given to continuous negative pressure drainage
11352393|NCT02351999|Experimental|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
11352394|NCT02351986|Experimental|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
11352395|NCT02351986|No Intervention|Control|Healthy subjects between 18 to 45 years.
11352396|NCT02351973|Active Comparator|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
11352397|NCT02351973|Active Comparator|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
11352398|NCT02351973|Active Comparator|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
11352399|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
11352400|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
11352401|NCT02351947|Experimental|persons with chronic stroke|upper limb rehabilitation for chronic stroke
11352402|NCT02351947|No Intervention|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
11352403|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
11352404|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
11352405|NCT02351921|Experimental|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
11352406|NCT02351921|Experimental|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
11352407|NCT02351921|Sham Comparator|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
11352408|NCT02351908|Experimental|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
11352409|NCT02351908|Experimental|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
11352410|NCT02351908|Experimental|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
11352411|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
11352412|NCT02351882|Active Comparator|Nabilone|Participants randomized into the nabilone arm will be prescribed nabilone for 6 weeks. After one-week placebo washout, they will be taking placebo for an additional 6 weeks.
11352413|NCT02351882|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 6 weeks. After one-week placebo washout, they will be prescribed nabilone for an additional 6 weeks.
11352414|NCT02351869|Active Comparator|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
11352415|NCT02351869|Placebo Comparator|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
11352416|NCT02351856|Experimental|ARRY-371797|
11352417|NCT02351843|Experimental|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
11352418|NCT02351843|Active Comparator|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
11352419|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.
~Baseline product: the subject's usual product
~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces
~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
11352420|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.
~Baseline product: the subject's usual product
~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces
~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
11352421|NCT02351804|Experimental|Ropivacaine + dexamethasone|20 ml ropivacaine 0.5% + 0.5 ml dexamethasone 4 mg7ml
11352422|NCT02351804|Placebo Comparator|Ropivacaine + placebo|20 ml ropivacaine 0.5% + 0.5 ml isotonic saline ad
11352423|NCT02351791|Experimental|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin.
~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
11352424|NCT02351791|Experimental|Patch 2, 4 and 6|"Patch 2, Patch 4 and Patch 6 applied on peristomal skin.
~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
11352425|NCT02351765|Experimental|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.
~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
11352426|NCT02351752|Experimental|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR >60)
11352430|NCT02351713|Experimental|Threshold based method|Exercise Week 1 Heart rate (HR) < first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR < VT1 4 days 25 min/day Week 3 HR < VT1 4 days 30 min/day Week 4 HR < VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to < second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to < VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
11352431|NCT02351713|Experimental|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
11352432|NCT02351713|No Intervention|Control|Non-exercise control group
11352433|NCT02351700|Active Comparator|opioid-sparing group|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
11352434|NCT02351700|Placebo Comparator|standard treatment group|IV Caldolor placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
11352435|NCT02351687|No Intervention|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
11352436|NCT02351687|Experimental|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
11352437|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
11352438|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
11352439|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
11352440|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate>90bpm
11352441|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
11352442|NCT02351648|Experimental|Intervention'|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge
~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge
~Intervention after discharge:
~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
11352443|NCT02351648|Active Comparator|Control'|Patients receive usual standard of care from the internal medicine team
11352444|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
11352445|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
11352446|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
11352447|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
11352448|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
11352449|NCT02351622|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
11352450|NCT02351622|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
11352451|NCT02351609|Experimental|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
11352452|NCT02351609|Active Comparator|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
11352453|NCT02351596|Active Comparator|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).
~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
11352491|NCT02351297|Experimental|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
11352454|NCT02351596|Active Comparator|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
11352455|NCT02351596|Active Comparator|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).
~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
11352456|NCT02351596|Active Comparator|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
11352457|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
11352458|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
11352459|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
11352460|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
11352461|NCT02351544|Experimental|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
11352462|NCT02351544|Experimental|Surgery|Patients in this arm will receive surgery for migraine headaches
11352463|NCT02351531|Experimental|New Thickened Extensively Hydrolyzed formula|
11352464|NCT02351505|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11352465|NCT02351492|Active Comparator|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography (IOC) to investigate bile ducts.
11352466|NCT02351492|Active Comparator|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography (MRCP) first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
11352467|NCT02351479|Other|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
11352468|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
11352469|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
11352470|NCT02351440|Experimental|Duloxetine|duloxetine 60mg PO
11352471|NCT02351440|Placebo Comparator|Placebo|placebo
11352472|NCT02351427|Active Comparator|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7
~with
~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
11352473|NCT02351427|Active Comparator|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
11352474|NCT02351414||Primary Total Knee Arthroplasty|Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts
11352475|NCT02351401|Experimental|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
11352476|NCT02351401|No Intervention|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
11352477|NCT02351388|Active Comparator|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
11352478|NCT02351388|Sham Comparator|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
11352479|NCT02351375|Experimental|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
11352480|NCT02351375|Experimental|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
11352481|NCT02351362|Experimental|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
11352482|NCT02351362|No Intervention|Control Group|Standard of care
11352483|NCT02351349|Experimental|Intervention|frail elderly patients with CKD receiving multidisciplinary intervention
11352484|NCT02351349|No Intervention|Standard care|Frail elderly patients with CKD receive standard of care
11352485|NCT02351336||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :
~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )
~Cervical dilataion >1cm, &/or
~Cervical effacement ≥ 80%"
11352486|NCT02351323|Experimental|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
11352487|NCT02351323|Placebo Comparator|No glutamine + Lifestyle change|Lifestyle change
11352488|NCT02351310|Active Comparator|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
11352489|NCT02351310|Placebo Comparator|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
11352490|NCT02351297|Experimental|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
11352533|NCT02351011|Experimental|Cohort 3|50 x 10^6 MSCs
11352492|NCT02351297|Placebo Comparator|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
11352493|NCT02351271|Experimental|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
11352494|NCT02351271|Active Comparator|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
11352495|NCT02351258|Experimental|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
11352496|NCT02351258|Experimental|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
11352497|NCT02351245||lip hemangiomas|
11352498|NCT02351232|Experimental|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
11352499|NCT02351232|Placebo Comparator|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
11352500|NCT02351219|Experimental|FOLFOXIRI|
11352501|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
11352502|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
11352503|NCT02351193||Group I|poor responder females with age less than 35
11352504|NCT02351193||Group II|poor responder females with age more than 35
11352505|NCT02351180|Experimental|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
11352506|NCT02351180|Placebo Comparator|Placebo|Inhaled placebo twice daily for 180 days.
11352507|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
11352508|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
11352509|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
11352510|NCT02351154|Other|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
11352511|NCT02351141|Other|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
11352512|NCT02351128|Experimental|Only one arm|All patients receive Lanreotide.
11352513|NCT02351115|Experimental|Staccato® Alprazolam, 0.5 mg|Single-dose Staccato® Alprazolam for Inhalation, 0.5 mg
11352514|NCT02351115|Experimental|Staccato® Alprazolam, 1 mg|Single-dose Staccato® Alprazolam for Inhalation, 1 mg
11352515|NCT02351115|Experimental|Staccato® Alprazolam, 2 mg|Single-dose Staccato® Alprazolam for Inhalation, 2 mg
11352516|NCT02351115|Placebo Comparator|Staccato® Placebo (a)|Single-dose inhaled Staccato® Placebo, Inhaler with no drug
11352517|NCT02351115|Placebo Comparator|Staccato® Placebo (b)|Single-dose inhaled Staccato® Placebo, Inhaler with no drug
11352518|NCT02351102|Active Comparator|Valacyclovir|Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
11352519|NCT02351102|Placebo Comparator|Placebo|Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
11352520|NCT02351089|Placebo Comparator|Placebo|capsules containing corn starch
11352521|NCT02351089|Active Comparator|Probiotic low dose|capsules containing probiotic powder and corn starch
11352522|NCT02351089|Active Comparator|Probiotic high dose|capsules containing probiotic powder and corn starch
11352523|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
11352524|NCT02351050|Experimental|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
11352525|NCT02351050|Placebo Comparator|placebo|sham transcranial Doppler monitoring during endovascular procedure
11352526|NCT02351037|Experimental|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
11352527|NCT02351037|Experimental|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
11352528|NCT02351037|Experimental|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
11352529|NCT02351024|Experimental|OXP005|
11352530|NCT02351024|Active Comparator|Naproxen|
11352531|NCT02351011|Experimental|Cohort 1|1 x 10^6 MSCs
11352532|NCT02351011|Experimental|Cohort 2|10 x 10^6 MSCs
11352537|NCT02350972|Experimental|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
11352538|NCT02350959|Experimental|High dose statin|In high dose statin group, atorvastatin 40mg will be used
11352539|NCT02350959|Active Comparator|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
11352540|NCT02350946|Experimental|Cross over Oxytocin and Placebo|fMRI measurement and blood examinations following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14
11352541|NCT02350946|Experimental|Cross over Placebo and Oxytocin|fMRI measurement and blood examinations following placebo on day 1 and following 26 IU Oxytocin (Syntocinon) on day 14
11352542|NCT02350933|Other|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
11352543|NCT02350920|Active Comparator|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
11352544|NCT02350920|No Intervention|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
11352545|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
11352546|NCT02350868|Experimental|Arm 1|Subjects will be treated with oral doses of MPT0E028 in consecutive, 28-day cycles, and will be evaluated regularly for safety. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive MPT0E028 at the discretion of the principal Investigator for up to 6 cycles.
11352547|NCT02350855|Experimental|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
11352548|NCT02350855|Other|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
11352549|NCT02350842|Experimental|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
11352550|NCT02350842|Active Comparator|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
11352551|NCT02350829|Active Comparator|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy
~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
11352552|NCT02350829|Active Comparator|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan
~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
11352553|NCT02350829|Active Comparator|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
11352554|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
~HGT-SAN-093 = NCT02060526"
11352555|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
11352556|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
11352557|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
11352558|NCT02350803|Placebo Comparator|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
11352559|NCT02350803|Active Comparator|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
11352560|NCT02350790|Active Comparator|Robotic ablation|Half of the patients in the study will be randomized to robotic ablation of endometriosis with the argon beam coagulator (ABC).
11352561|NCT02350790|Active Comparator|Robotic Excision|Half of the patients in the study will be randomized to robotic excision of endometriosis.
11352562|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
11352604|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
11352605|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
11352563|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
11352564|NCT02350764|Experimental|Nivolumab|Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease*, withdrawal of consent, or death.
11352565|NCT02350751|Experimental|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
11352566|NCT02350751|Placebo Comparator|Placebo|Solution containing no active ingredients
11352567|NCT02350738|Experimental|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
11352568|NCT02350738|Experimental|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
11352569|NCT02350725|Experimental|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
11352570|NCT02350725|Experimental|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
11352571|NCT02350712|Experimental|All Participants - Period 1|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin) in Period 1 - Initial phase of the trial.
11352572|NCT02350712|Experimental|All Participants - Period 2|Participants deriving clinical benefit enter Period 2 - Extension phase, during which they continue to receive patritumab with cetuximab, but not platinum-based therapy.
11352573|NCT02350699||Control|Nautilus BrainPulse
11352574|NCT02350686|Experimental|capecitabine+oxaliplatin|XELOX every 3 weeks
11352575|NCT02350673|Experimental|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
11352576|NCT02350673|Experimental|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
11352577|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
11352578|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
11352579|NCT02350647|Experimental|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
11352580|NCT02350647|Active Comparator|Twinfix Ultra HA|Suture anchor for rotator cuff repair
11352581|NCT02350634|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
11352582|NCT02350621|Active Comparator|ACDF|Anterior Cervical Discectomy and Fusion
11352583|NCT02350621|Active Comparator|miPCF|minimal invasive Posterior Cervical Foraminotomy
11352584|NCT02350595|Experimental|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
11352585|NCT02350595|Experimental|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
11352586|NCT02350595|No Intervention|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
11352587|NCT02350582|Experimental|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
11352588|NCT02350582|No Intervention|Control group|usual care offered to patients during chemotherapy treatment
11352589|NCT02350569|Experimental|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
11352590|NCT02350556|Other|hemiplegic patients|Dynamic Avoidance Task
11352591|NCT02350556|Other|healthy volunteers|Dynamic Avoidance Task
11352592|NCT02350543|Active Comparator|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
11352593|NCT02350543|No Intervention|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
11352594|NCT02350530|Experimental|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
11352595|NCT02350530|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
11352596|NCT02350517|Experimental|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
11352597|NCT02350504|Experimental|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
11352598|NCT02350504|Placebo Comparator|Partial instruction|Partial instruction which included the booklet only.
11352599|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
11352600|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
11352601|NCT02350491||healthy group|Healthy pregnant woman.
11352602|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
11352606|NCT02350452|Experimental|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
11352607|NCT02350452|Active Comparator|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
11352608|NCT02350439|Experimental|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
11352609|NCT02350426|Experimental|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
11352610|NCT02350426|Experimental|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
11352611|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
11352612|NCT02350400|Experimental|DEBIRI|For unilobar disease, two treatments will be planned, separated by four weeks. For bilobar disease, there will be four treatments planned, alternating between right and left lobe, separated by 2 weeks duration.
11352613|NCT02350387|Experimental|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
11352614|NCT02350387|Experimental|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
11352615|NCT02350374|Other|carbohydrate counting|patients must fill their logbook during 28 days
11352616|NCT02350361|Experimental|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
11352617|NCT02350361|Active Comparator|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
11352618|NCT02350335|Active Comparator|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.
~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.
~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
11352619|NCT02350335|No Intervention|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
11352620|NCT02350335|No Intervention|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
11352621|NCT02350322|Experimental|Schoolmeal with fatty fish|Fatty fish diet
11352622|NCT02350322|Experimental|Schoolmeal without fish|Meat/cheese diet (non-seafood)
11352623|NCT02350322|Experimental|Supplement|Omega-3 capsules
11352624|NCT02350309|Experimental|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
11352625|NCT02350309|Experimental|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
11352626|NCT02350309|Placebo Comparator|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
11352627|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
11352628|NCT02350296|Experimental|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release tablets 40 mg, corresponding to 25 mg of ketoprofen free acid
11352629|NCT02350296|Active Comparator|OKi® 80 mg|OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid)
11352630|NCT02350283|Experimental|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
11352631|NCT02350283|No Intervention|Medical treatment|Standard medical treatment alone.
11352632|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
11352633|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
11352634|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
11352635|NCT02350257|Experimental|ICBT|Internet-based cognitive behavior therapy
11352636|NCT02350257|No Intervention|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
11352637|NCT02350244|Experimental|Experimental group|Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work
11352638|NCT02350244|Other|Control group|Control group patients had no intervention
11352639|NCT02350231|Active Comparator|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
11352640|NCT02350231|Placebo Comparator|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
11352641|NCT02350218|Experimental|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
11352642|NCT02350218|Active Comparator|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
11352643|NCT02350205|Experimental|Treatment (SASS)|All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
11352644|NCT02350205|Active Comparator|Control (split-thickness autograft)|All patients will receive both SASS and Split-thickness autograft (paired samples).
11352645|NCT02350192|Experimental|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
11352646|NCT02350192|No Intervention|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
11352647|NCT02350179|Experimental|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
11352648|NCT02350179|Placebo Comparator|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
11352649|NCT02350166|Experimental|Laparoscopic group|Laparoscopic group, laparoscopic surgery or laparoscopic-assisted small-incision for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis
11352650|NCT02350166|No Intervention|Conventional group|Conventional group, conventional laparotomy for simultaneously resection of both primary colorectal tumor and liver metastasis
11352651|NCT02350153||Patients with verified Cushing's Disease|Patients with verified Cushing's Disease
11352652|NCT02350140|Experimental|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
11352653|NCT02350140|Active Comparator|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
11352654|NCT02350127|Experimental|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
11352655|NCT02350127|Active Comparator|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
11352656|NCT02350114|Experimental|Functional Capacity|6 Minute Walk Test
11352657|NCT02350088|Active Comparator|Fast-track Surgery|probiotics,oral,b.i.d.
11352658|NCT02350088|Active Comparator|Traditional Group|placebo,oral,b.i.d.
11352659|NCT02350075|Experimental|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
11352660|NCT02350075|Other|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
11352661|NCT02350049||Investigational|Cementless Medial Partial Knee
11352662|NCT02350049||Control|Cemented Medial Partial Knee
11352663|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
11352664|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
11352665|NCT02350023|Active Comparator|Topical latanoprost|Topical latanoprost 0.005%
11352666|NCT02350023|Active Comparator|Topical betamethasone|Topical betamethasone 0.05%
11352667|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.
~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.
~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
11352668|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.
~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.
~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
11352669|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
11352670|NCT02349958|Other|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
11352671|NCT02349958|Other|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
11352672|NCT02349958|Other|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
11352674|NCT02349945|Experimental|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
11352675|NCT02349945|Experimental|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
11352676|NCT02349932||Healthy Adults|The following samples will be collected: fecal, blood, and saliva
11352677|NCT02349919|Experimental|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
11352678|NCT02349919|Placebo Comparator|Placebo|Placebo twice daily for 4 weeks
11352679|NCT02349906|Experimental|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.
~The dose has to be calculated as follows:
~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.
~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.
~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
11352680|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
11352681|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
11352682|NCT02349880|Active Comparator|control|5 hour cognitive training
11352683|NCT02349880|Experimental|intervention|5 hour shared decision making training
11352684|NCT02349867|Experimental|Treatment (chemotherapy, chemoradiation)|Patients must receive neoadjuvant chemotherapy (multiple regimens are acceptable) prior to enrollment onto this clinical trial. Chemoradiation study treatment should start within 9 weeks of completing chemotherapy. Patients receive gemcitabine IV infusion over 30 minutes (200 mg/m2 weekly) x 6, concurrent administration of oral sorafenib and oral vorinostat (both per dose-escalation schema), and concurrent RT( 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy) administered at 1.8-Gy fractions to a total dose of 50.4 Gy over 5 ½ weeks (28 daily fractions). Correlative studies will be performed by collecting peripheral blood samples at several time-points for circulating tumor cells (CTC) enumeration and to evaluate CD95 density. Samples will be analyzed by negative-selection techniques (RosetteSep) or with ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device.
11352685|NCT02349854||Cases|patients with scalp itch and seborrheic dermatitis who will get biopsy
11352686|NCT02349854||Controls|patients without scalp itch and without seborrheic dermatitis who will get biopsy
11352687|NCT02349841|Experimental|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
11352688|NCT02349841|Experimental|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
11352689|NCT02349841|Active Comparator|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
11352690|NCT02349828|Active Comparator|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
11352691|NCT02349828|No Intervention|No treatment|standard of care
11352692|NCT02349815||Group 1|Women prescribed JAYDESS in Sweden
11352693|NCT02349802|Experimental|Arm 1|exenatide suspension - 9 mg / 0.85 mL
11352694|NCT02349802|Experimental|Arm 2|exenatide suspension - 9 mg / 0.85 mL
11352695|NCT02349802|Experimental|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
11352696|NCT02349802|Experimental|Arm 4|exenatide suspension - 9 mg / 1.1 mL
11352697|NCT02349802|Experimental|Arm 5|exenatide suspension - 9 mg / 1.5 mL
11352698|NCT02349776|Experimental|All patients for allograft transplant|For the testimonial part all patients who have received an allograft transplant in the last five years will be eligible for participation if they have capacity to consent and can speak English fluently.
11352699|NCT02349763|Active Comparator|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
11352700|NCT02349763|Experimental|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
11352701|NCT02349750|Active Comparator|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
11352702|NCT02349750|No Intervention|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
11352703|NCT02349737||Electromagnetic Interference|
11352704|NCT02349724|Other|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
11352705|NCT02349724|Other|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
11352706|NCT02349724|Other|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
11352707|NCT02349724|Other|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
11352708|NCT02349724|Other|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
11352709|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11352710|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11352711|NCT02349698|Other|Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells targeting CD19.
11352712|NCT02349698|Other|Chronic Lymphcytic Leukemia|Chronic lymphocytic leukemia with chimeric antigen receptor modified T cells targeting CD19.
11352713|NCT02349698|Other|Non-Hodgkin Lymphoma|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells targeting CD19.
11352714|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
11352715|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
11352716|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
11352717|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
11352718|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
11352719|NCT02349659|No Intervention|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
11352720|NCT02349659|Active Comparator|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
11352721|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
11352722|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
11352723|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
11352724|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
11352725|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
11352726|NCT02349620|Active Comparator|A:partialy edutolus patients|In this group surface treated implant with PRF will be inserted.Immediately after the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequency analysis (RFA), using the smart peg type 1, then stability will be measured every 2 weeks up to 3 months .Bone height will be measured in mesial and distal side immediately after placement and in months 3 and 6 with Intra Oral Peri Apical xray (IOPA x-ray)
11352727|NCT02349620|Placebo Comparator|B: partialy edutolus patients|In this group implant with out PRF will be inserted.Immediately after the surgery the implant stability will be measured with the Osstell mentor to verify the resonance frequence analysis (RFA ), using the smartpeg type 1, then stability will be measured every 2 weeks up to 3 months. Bone height was measured in mesial and distal side immediately after placement and in months 3 and 6 with IOPA xray
11352728|NCT02349607|Experimental|PF-05089771 300 mg|
11352729|NCT02349607|Experimental|PF-05089771 300 mg + pregabalin 300 mg|
11352730|NCT02349607|Placebo Comparator|Placebo|
11352731|NCT02349607|Active Comparator|pregabalin 300 mg|
11352732|NCT02349607|Active Comparator|ibuprofen 600 mg|
11352733|NCT02349594|Active Comparator|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
11352734|NCT02349594|Active Comparator|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
11352735|NCT02349581|Experimental|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
11352736|NCT02349581|No Intervention|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
11352737|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
11352738|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
11352739|NCT02349555|Experimental|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
11352740|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
11352741|NCT02349529|Experimental|Psychosocial group intervention|
11352742|NCT02349529|Other|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
11352743|NCT02349516|Experimental|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
11352744|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
11352745|NCT02349516|Experimental|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
11352746|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
11352747|NCT02349503|Experimental|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
11352748|NCT02349503|Experimental|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
11352749|NCT02349503|Experimental|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
11352750|NCT02349490|Active Comparator|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
11352751|NCT02349490|Active Comparator|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
11352752|NCT02349477|Experimental|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
11352753|NCT02349477|Placebo Comparator|placebo|matching placebo
11352754|NCT02349464|Active Comparator|Intervention|For infants receiving pediatric care at one of the seven intervention practices, mothers will receive the Specialized Preterm Infant/Mother Dyad Lactation Support which includes home equipment and pediatric clinic-lactation support to support lactation for four months post-hospital discharge.
11352755|NCT02349464|No Intervention|Control|For infants receiving pediatric care at one of the seven control practices, mothers will receive standard support.
11352756|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
11352757|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
11352758|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
11352759|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
11352760|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
11352761|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
11352762|NCT02349425|Experimental|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
11352763|NCT02349425|Experimental|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
11352764|NCT02349425|Experimental|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
11352765|NCT02349425|Experimental|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
11352766|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
11352767|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
11352768|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
11352769|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
11352770|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
11352771|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
11352772|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
11352773|NCT02349373|Active Comparator|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed >80% VO2max (maximal oxygen uptake).
11352774|NCT02349373|Active Comparator|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.
~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
11352775|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
11352776|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
11352777|NCT02349334|Sham Comparator|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
11352778|NCT02349334|Active Comparator|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
11352779|NCT02349321|Experimental|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
11352798|NCT02349204|No Intervention|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
11352799|NCT02349191|Experimental|Interventional cohort|Omental transposition for mild Alzheimers Disease
11352780|NCT02349321|Experimental|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.
~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
11352781|NCT02349321|No Intervention|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
11352782|NCT02349308||CentrosFLO Long Term Hemodialysis Catheter|Schedule placement of catheter. Arterial tip of the catheter should be placed at or just above the junction of the right atrium and superior vena cava, with the arterial lumen on the left side of the catheter. The venous limb will extend into the right atrium. Catheter will be locked with the usual heparin lock solution for a newly placed catheter (at least 500 units per lumen). Fluoroscopic images will document tip position.
11352783|NCT02349295|Experimental|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
11352784|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
11352785|NCT02349295|Placebo Comparator|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
11352786|NCT02349282|Experimental|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
11352787|NCT02349282|Experimental|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
11352788|NCT02349282|Placebo Comparator|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
11352789|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
11352790|NCT02349243|Experimental|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
11352791|NCT02349243|Placebo Comparator|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
11352792|NCT02349230|Experimental|Astym treatment|Astym treatment is a manual therapy intervention applied by certified therapists with specialized instruments
11352793|NCT02349230|Sham Comparator|Sham Astym|A sham Astym treatment applied with non-therapeutic pressure and
11352794|NCT02349230|No Intervention|Control|12 minutes of rest
11352795|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
11352796|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.
~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
11352797|NCT02349204|Experimental|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
11352979|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
11352800|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
11352801|NCT02349165|Active Comparator|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
11352802|NCT02349165|Experimental|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
11352803|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
11352804|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
11352805|NCT02349139|Experimental|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
11352806|NCT02349126|Experimental|Treatment Group|ARC-520 Injection
11352807|NCT02349113|Experimental|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
11352808|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
11352809|NCT02349074|Experimental|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
11352810|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
11352811|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
11352812|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
11352813|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
11352814|NCT02349035|Experimental|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
11352815|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
11352816|NCT02349009|Placebo Comparator|placebo|C-82 Topical Gel, Placebo
11352817|NCT02349009|Active Comparator|Active|C-82 Topical Gel, 1%
11352818|NCT02348996|Other|Clinical assessment|Patients would have dry weight determined by clinical evaluation (blood pressure levels, peripheral edema, pulmonary auscultation and symptoms).
11352819|NCT02348996|Experimental|Bioimpedance|Patients would have dry weight determined according to volume status with a body composition monitor (BCM)
11352820|NCT02348983|Experimental|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
11352821|NCT02348970|Experimental|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
11352822|NCT02348970|Active Comparator|laboratory devices TALI|The patients will use the laboratory devices TALI
11352823|NCT02348944||15 healthy volunteers|Other: serum and urine sample
11352824|NCT02348931|Active Comparator|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
11352825|NCT02348931|Experimental|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
11352826|NCT02348931|Active Comparator|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
11352827|NCT02348918|Active Comparator|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
11352828|NCT02348918|Active Comparator|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
11352829|NCT02348918|Active Comparator|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
11352866|NCT02348762|Experimental|Cysteine/glycine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
11352830|NCT02348918|Active Comparator|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
11352831|NCT02348918|Active Comparator|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
11352832|NCT02348918|Active Comparator|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
11352833|NCT02348918|Active Comparator|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
11352834|NCT02348918|Active Comparator|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
11352835|NCT02348918|Active Comparator|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
11352836|NCT02348905|Experimental|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
11352837|NCT02348905|Experimental|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
11352838|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
11352839|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
11352840|NCT02348879|Experimental|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
11352841|NCT02348879|Placebo Comparator|Placebo|No active drug
11352842|NCT02348866|Active Comparator|Group 1|home laundered/home-donned
11352843|NCT02348866|Active Comparator|Group 2|Hospital laundered/home-donned
11352844|NCT02348866|Active Comparator|Group 3|Home laundered/hospital donned
11352845|NCT02348866|Active Comparator|Group 4|Hospital laundered/hospital donned
11352846|NCT02348853|Experimental|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
11352847|NCT02348853|Experimental|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
11352848|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
11352849|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
11352850|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
11352851|NCT02348827|Experimental|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
11352852|NCT02348827|Active Comparator|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
11352853|NCT02348814||normal weight|BMI 20-25
11352854|NCT02348814||overweight|BMI 25-30
11352855|NCT02348814||obese|BMI 30-35
11352856|NCT02348814||morbidly obese|BMI > 35
11352857|NCT02348814||non-diabetic|HgbA1c (<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
11352858|NCT02348814||diabetic|HgbA1c (>6.5%) and blood glucose (>100 mg/dL) as defined at UCLA Clinical Lab
11352859|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
11352860|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol >170 mg/dL, LDL >100 mg/dL, HDL >130 mg/dL, triglycerides >150 mg/dL) as defined at UCLA Clinical Lab
11352861|NCT02348801|Active Comparator|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
11352862|NCT02348801|Experimental|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
11352863|NCT02348788|Active Comparator|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet.
~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, <35kg = 0.5mg/kg"
11352864|NCT02348788|Active Comparator|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.
~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, 10-35kg = 0.5mg/kg"
11352865|NCT02348775|Experimental|Cysteine/glycine|Older HIV infected subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 3 months
11352980|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
11352867|NCT02348749|Experimental|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection.
11352868|NCT02348736|Experimental|SensaScope|Time for tracheal intubation with the SensaScope
11352869|NCT02348736|Experimental|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
11352870|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
11352871|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
11352872|NCT02348710|Experimental|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
11352873|NCT02348710|Active Comparator|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
11352874|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
11352875|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
11352876|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
11352877|NCT02348645|Active Comparator|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
11352878|NCT02348645|Active Comparator|Decompression alone|Midline-sparing spinal decompression alone
11352879|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
11352880|NCT02348619|Active Comparator|75, 150, 300 mg of JZP-110|Once Daily Dosing
11352881|NCT02348619|Active Comparator|Placebo|Once Daily Dosing
11352882|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
11352883|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
11352884|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
11352885|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
11352886|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
11352887|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
11352888|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
11352889|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
11352890|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
11352891|NCT02348580|No Intervention|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
11352892|NCT02348580|Experimental|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
11352893|NCT02348567|Active Comparator|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
11352894|NCT02348567|Experimental|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
11352895|NCT02348554|Experimental|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
11352896|NCT02348554|Experimental|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
11352897|NCT02348541|Other|CollaGUARD|
11352898|NCT02348528|Experimental|Lenalidomide and dexamethasone|"Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
~The starting doses of Rd regimen will be the same last doses that the subjects received in Study CC-5013-MM-021, unless event(s) that require dose adjustments (dose modifications, reductions and interruptions) per protocol occurred prior to roll-over."
11352899|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
11352900|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
11352901|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
11352977|NCT02347878|Experimental|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
11352902|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
11352903|NCT02348489|Experimental|SGI-110 (guadecitabine)|Intervention: SGI-110 (guadecitabine)
11352904|NCT02348489|Active Comparator|Treatment Choice|Intervention: Choice of one: cytarabine, decitabine, or azacitidine
11352905|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
11352906|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
11352907|NCT02348450|Experimental|Irinotecan plus Cisplatin|first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
11352908|NCT02348450|Experimental|Etoposide plus Cisplatin|first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
11352909|NCT02348437|Experimental|Repair|Repair of the pronator quadratus muscle
11352910|NCT02348437|Active Comparator|Non-repair|Non-repair of the pronator quadratus muscle
11352911|NCT02348424|Experimental|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
11352912|NCT02348424|Experimental|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
11352913|NCT02348411|Experimental|ExAblate Treatment group|
11352914|NCT02348398|Experimental|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.
~During follow up if disease gets worse, participant called by study staff every 3 months."
11352915|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
11352916|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
11352917|NCT02348372|Placebo Comparator|GSK1278863A Placebo|5, 25 and 100 mg matched
11352918|NCT02348372|Experimental|GSK1278863A 10mg|A round, biconvex, white film coated tablet
11352919|NCT02348372|Experimental|GSK1278863A 25mg|A round, biconvex, white film coated tablet
11352920|NCT02348372|Experimental|GSK1278863A 50mg|A round, biconvex, white film coated tablet
11352921|NCT02348372|Experimental|GSK1278863A 100mg|A round, biconvex, white film coated tablet
11352922|NCT02348359|Experimental|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
11352923|NCT02348359|Experimental|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
11352924|NCT02348359|Experimental|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
11352925|NCT02348359|Placebo Comparator|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
11352926|NCT02348333|Active Comparator|FYU-981|
11352927|NCT02348333|Placebo Comparator|Placebo|
11352928|NCT02348320|Experimental|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
11352929|NCT02348307|Active Comparator|FYU-981|
11352930|NCT02348307|Placebo Comparator|Placebo|
11352931|NCT02348294|Other|Healthy volunteers|Shear- force 19 newton and 3,9 kpa pressure for half an hour
11352932|NCT02348294|Other|Diabetes Mellitus type 2 without neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
11352933|NCT02348294|Other|Diabetes Mellitus type 2 with neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
11352934|NCT02348294|Other|Charcot Osteoarhtopathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
11352935|NCT02348281|Experimental|bicalutamide|150mg, po, qd, d1-28
11352936|NCT02348268|Active Comparator|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
11352937|NCT02348268|Experimental|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
11352938|NCT02348255|Experimental|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
11352939|NCT02348242|Experimental|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
11352940|NCT02348242|Experimental|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
11352941|NCT02348229|Experimental|ERAS group|ERAS protocols
11352942|NCT02348229|Other|conventional pathway group|using conventional pathway
11352978|NCT02347878|No Intervention|control arm|this arm will received nothing 1 hour before lumbar puncture
11352943|NCT02348216|Experimental|Axicabtagene Ciloleucel|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.
11352944|NCT02348203|Experimental|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
11352945|NCT02348203|Placebo Comparator|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
11352946|NCT02348190|Active Comparator|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
11352947|NCT02348190|Placebo Comparator|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
11352948|NCT02348177|Experimental|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
11352949|NCT02348164|Experimental|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
11352950|NCT02348164|Experimental|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
11352951|NCT02348151|Experimental|Treadmill|The Shuttle is going to play on treadmill
11352952|NCT02348151|Active Comparator|Corridor|The Shuttle is going to play on corridor
11352953|NCT02348138|Experimental|Home-based isometric handgrip training|All participants that will be assigned to home-based isometric handgrip training (HBT) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction; however, the training will be performed without daily supervision. Therefore, the subjects will receive a logbook to record the exercise sessions. In addition, visits will be scheduled at weeks 1, 3, 6, 9 and 11 to provide feedback to individuals and discuss potential problems in conducting training.
11352954|NCT02348138|Experimental|Supervised isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training (ST) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction with. The training will be performed with daily supervision.
11352955|NCT02348138|No Intervention|Control group|Subjects randomized to the control group (CG) will be encouraged to increase the level of physical activity and make healthy eating, without, however, receive specific recommendations
11352956|NCT02348125|Experimental|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:
~ubiquinol (liquid form, 150 mg/kg subject weight/day
~carnitine, 50 mg/kg subject weight/day
~alpha-lipoic acid, 100 mg/ day"
11352957|NCT02348112||Altis Sling|Subjects will have an Altis sling placed to treat stress urinary incontinence.
11352958|NCT02348112||Transobturator or Retropubic Sling|Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.
11352959|NCT02348073|Active Comparator|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
11352960|NCT02348073|Placebo Comparator|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
11352961|NCT02348047|Active Comparator|Conventional ventilation|Conventional ventilation - manual mode
11352962|NCT02348047|Experimental|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
11352963|NCT02348034|Experimental|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
11352964|NCT02348034|No Intervention|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
11352965|NCT02348021|Other|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
11352966|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.
~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.
~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
11352967|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
11352968|NCT02347995|Placebo Comparator|Resistive Training|Participants will drink a placebo beverage after each resistance training session.
11352969|NCT02347995|Experimental|Resistive Training + Protein|Participants will drink 30 grams of whey protein after each resistance training session.
11352970|NCT02347969|Experimental|X34|Arm supplemented with X34
11352971|NCT02347956|Experimental|Reduced port group|
11352972|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
11352973|NCT02347917|Experimental|BBI608 puls pemetrexed and cisplatin|
11352974|NCT02347904|Experimental|Adjuvant S-1 and Oxaliplatin|Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer
11352975|NCT02347891|Experimental|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.
~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
11352976|NCT02347891|Active Comparator|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.
~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
11352981|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
11352982|NCT02347839|Experimental|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
11352983|NCT02347813|Other|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
11352984|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
11352985|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
11352986|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
11352987|NCT02347774|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
11352988|NCT02347774|Experimental|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
11352989|NCT02347774|Placebo Comparator|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
11352990|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
11352991|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
11352992|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
11352993|NCT02347748|Experimental|Group A - Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
11352994|NCT02347748|Experimental|Group B - Reading pre-extubation script|Patients will be read a pre-extubation script;
11352995|NCT02347748|Experimental|Group C - Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area Patients will be read a pre-extubation script
11352996|NCT02347748|No Intervention|Group D|Patients will not be read any script
11352997|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
11352998|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
11352999|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
11353000|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
11353001|NCT02347722||Healthy volunteers|Age matched healthy volunteers for comparison with heart failure patients
11353002|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
11353003|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
11353004|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
11353005|NCT02347696|Other|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
11353006|NCT02347696|Other|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
11353007|NCT02347696|Other|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
11353008|NCT02347696|Other|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
11353009|NCT02347696|Other|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
11353010|NCT02347696|Other|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
11353011|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
11353012|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
11353013|NCT02347670|Active Comparator|Group 1M- Community Site|"Participants randomized to Group 1-Main will attend follow-up visits at one of the four main community sites. A glaucoma specialist will perform the comprehensive eye examination and a ophthalmic technician will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.
~Intervention: Efficacy-patient navigator to improve follow-up adherence"
11353014|NCT02347670|Active Comparator|Group 2- Office-Based|"Office-Based, Follow-Up Eye Care with Patient Navigation Protocol: Participants randomized to Group 2 will attend follow-up visits at the Wills Eye Hospital Glaucoma Research Center. A glaucoma specialist will perform the eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.
~Intervention: Efficacy-patient navigator to improve follow-up adherence"
11353015|NCT02347670|Active Comparator|Group 3- Office-Based|"Group 3- follow-up eye care at the Wills Eye Hospital. There will be no charge or co-pay for these visits. Those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire. These participants will receive a phone number to call and schedule their appointment and will receive a reminder phone call similar to the standard appointment-reminding procedure commonly used at the Wills Eye Hospital. Group 3 represents a realistic choice currently available for patients and thus will be used to compare with usual care and will have 2-3 visits over the one-year period depending on diagnosis.
~Intervention: Office-Based Usual Care"
11353016|NCT02347670|Active Comparator|Group 1R- Community Site|"Participants randomized to Group 1-Randomized will attend follow-up visits at one of the four main community sites, these participants were randomized from the 40 community sites to the closest community location. A glaucoma specialist will perform the comprehensive eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.
~Intervention: Efficacy-patient navigator to improve follow-up adherence"
11353017|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
11353018|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
11353019|NCT02347644|Experimental|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
11353020|NCT02347644|No Intervention|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
11353021|NCT02347631|Experimental|Alcon DAILIES TOTAL1|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
11353022|NCT02347631|Active Comparator|ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
11353023|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
11353024|NCT02347605|Experimental|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
11353025|NCT02347605|Placebo Comparator|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
11353026|NCT02347605|Other|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
11353027|NCT02347592|Active Comparator|straight Tenckhoff|The straight Tenckhoff catheter (sT) is the most common used catheter for peritoneal dialysis (PD).
11353028|NCT02347592|Active Comparator|self-locating catheter|A new, more expensive, self-locating catheter (sLC) has been developed by Di Paolo.
11353029|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
11353030|NCT02347579||Patients with CLBP|Patients with chronic low back pain
11353031|NCT02347579||Healthy controls|
11353032|NCT02347566|Experimental|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, [S]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
11353033|NCT02347566|Other|Control|Usual care (control, [C]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
11353034|NCT02347540||PE|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.
~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
11353035|NCT02347540||Control|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
11353036|NCT02347527|Experimental|Active Implicit Priming|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
11353037|NCT02347527|Placebo Comparator|Control Implicit Priming|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
11353038|NCT02347514|Experimental|Diabetes Group Visit|"Subjects in this arm will be asked to attend one group visit at their health center each month for six months. The group visits will involve various staff and providers at the health center who will teach them how to take care of their diabetes. Subjects will be scheduled to attend the same group visit appointments as the other subjects, and health center staff will encourage the group to share their own experiences about living with diabetes with the rest of the group.
~If subjects at the health center additionally implementing the text-messaging intervention consent to enroll in the study, their phone number will also be entered into a secure system that will allow the group visit healthcare team to send them text messages during the course of the six months they are in the program. These text messages are intended to offer the subjects additional support in taking care of their diabetes."
11353039|NCT02347514|No Intervention|Usual care|Patients in the control arm will be selected after the follow-up period is over for the intervention arm. They will receive the care they normally receive at their health center.
11353040|NCT02347501|Experimental|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.
~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
11353041|NCT02347501|No Intervention|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.
~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
11353042|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
11353043|NCT02347462|Experimental|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
11353044|NCT02347462|Active Comparator|Standard care alone|Standard care according to the hospital's severe asthma protocol
11353045|NCT02347449|Experimental|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
11353046|NCT02347436||benign prostatic hypertrophy|patients who are diagnosed with lower urinary tract symptoms caused by prostatic hypertrophy, undergo transurethral resection of the prostate, and post-surgery 24-hr ambulatory blood pressure measurement.
11353047|NCT02347436||inguinal hernia or hydrocele|patients who are diagnosed with lower urinary tract symptoms caused by inguinal hernia or hydrocele, undergo surgical inguinal hernia repair or hydrocele repair, and post-surgery 24-hr ambulatory blood pressure measurement
11353048|NCT02347423|Experimental|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
11353049|NCT02347423|Experimental|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
11353050|NCT02347423|Experimental|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
11353051|NCT02347423|Active Comparator|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
11353052|NCT02347410|Other|SIFS Graft Containment Device|Investigational
11353053|NCT02347397|Experimental|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head & SL-TWIN Stem
11353054|NCT02347397|Active Comparator|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head & SL-PLUS Stem
11353055|NCT02347384|Experimental|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
11353056|NCT02347384|Active Comparator|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
11353057|NCT02347358|Experimental|IV r-tPA with JRecanTM blood FR device|Dual IV r-tPA therapy and adjunctive treatment with JRecanTM blood flow recanalisation device
11353058|NCT02347358|Active Comparator|IV r-tPA|IV infusion of r-tPA
11353059|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
11353060|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
11353061|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
11353062|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
11353063|NCT02347332|Active Comparator|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
11353064|NCT02347319|Experimental|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
11353065|NCT02347319|Active Comparator|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
11353066|NCT02347319|Placebo Comparator|Placebo|This group will treated with Placebo for 12 weeks.
11353067|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
11353068|NCT02347293|Experimental|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
11353069|NCT02347293|Experimental|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
11353070|NCT02347280|Experimental|Loop ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
11353071|NCT02347280|Active Comparator|Total abdominal colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
11353072|NCT02347267|Experimental|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
11353073|NCT02347267|Active Comparator|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
11353074|NCT02347267|No Intervention|All beverages|Beverages were not restricted
11353075|NCT02347254|Experimental|Transcranial ExAblate|Transcranial ExAblate MRgFUS
11353076|NCT02347241|No Intervention|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
11353077|NCT02347241|Experimental|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
11353078|NCT02347228|Experimental|OB318 capsule|
11353079|NCT02347215|Other|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
11353080|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
11353081|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
11353082|NCT02347189|Other|Melody TPV PB1016|
11353083|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
11353084|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
11353085|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
11353086|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
11353087|NCT02347163|Experimental|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
11353088|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
11353089|NCT02347137|Active Comparator|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
11353090|NCT02347137|Experimental|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
11353091|NCT02347137|Experimental|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
11353092|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
11353093|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
11353094|NCT02347111|Experimental|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
11353095|NCT02347111|Experimental|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
11353096|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
11353097|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
11353098|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
11353099|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
11353100|NCT02347072|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
11353101|NCT02347072|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
11353102|NCT02347072|Active Comparator|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
11353103|NCT02347059|Experimental|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
11353104|NCT02347059|Active Comparator|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
11353105|NCT02347046|Experimental|Moderately-decreased group|(eGFR: >=30mL/min/1.73m^2 and < 60mL/min/1.73m^2)
11353106|NCT02347046|Experimental|Slightly-decreased group|(eGFR: >=60mL/min/1.73m^2 and < 90mL/min/1.73m^2)
11353107|NCT02347046|Experimental|Normal group|(eGFR: >=90mL/min/1.73m^2)
11353108|NCT02347033|Active Comparator|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
11353109|NCT02347033|Active Comparator|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
11353110|NCT02347020|Experimental|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
11353111|NCT02347020|Experimental|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
11353112|NCT02347020|Experimental|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
11353113|NCT02347020|Experimental|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
11353114|NCT02347007|Experimental|Almond|
11353118|NCT02346981|Experimental|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
11353119|NCT02346981|No Intervention|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
11353120|NCT02346968||All study participants|Patients with end stage renal disease (ESRD) planned to undergo kidney transplantation.
11353121|NCT02346955|Experimental|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
11353122|NCT02346955|Experimental|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
11353123|NCT02346955|Experimental|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
11353124|NCT02346955|Experimental|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
11353125|NCT02346955|Experimental|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
11353126|NCT02346955|Experimental|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
11353127|NCT02346955|Experimental|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
11353128|NCT02346955|Experimental|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
11353129|NCT02346955|Experimental|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
11353130|NCT02346942||Patients who have no history of bDMARD therapy use|
11353131|NCT02346942||Patients who have a prior history of bDMARD therapy use|
11353132|NCT02346929|Experimental|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
11353133|NCT02346929|No Intervention|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
11353134|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
11353135|NCT02346903|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
11353136|NCT02346890|Experimental|AZD1722 alone|15 mg BID
11353137|NCT02346890|Experimental|AD1722 with Renvela|AZD1722 15 mg BID and Renvela 800 mg TID
11353138|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
11353139|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
11353140|NCT02346864|Experimental|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
11353141|NCT02346864|Other|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
11353142|NCT02346851|Experimental|triggered FES|
11353143|NCT02346851|Active Comparator|conventional FES|
11353144|NCT02346851|No Intervention|control group|
11353145|NCT02346838|Experimental|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
11353146|NCT02346838|Placebo Comparator|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
11353147|NCT02346825|Experimental|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
11353148|NCT02346825|Experimental|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
11353149|NCT02346825|Experimental|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
11353150|NCT02346812|Experimental|Brassica|Brassica vegetables will be consumed daily as part of a controlled diet.
11353151|NCT02346812|Other|Control|Typical American diet will be consumed, without any Brassica vegetables.
11353152|NCT02346799|Experimental|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
11353153|NCT02346799|Experimental|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
11353154|NCT02346799|Experimental|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
11353155|NCT02346799|Experimental|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
11353156|NCT02346799|No Intervention|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
11353157|NCT02346786|Experimental|Mineral Water|mineral water
11353158|NCT02346786|Active Comparator|Tap Water|usual water intake
11353159|NCT02346773|Active Comparator|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
11353160|NCT02346773|Placebo Comparator|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
11353161|NCT02346760|Experimental|UB-621|Intervention drug: UB-621
11353162|NCT02346747|Active Comparator|Group A|Group A will receive 1.0 x 10e7 cells of gene transfected, irradiated, autologous tumor cells via intradermal injection once a month.
11353163|NCT02346747|Placebo Comparator|Group B|"Group B will receive freeze media (10% DMSO, 1% human serum albumin in Plasma-Lyte) via intradermal injection once a month."
11353164|NCT02346734|Active Comparator|MSHAT|The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and the intervention group will receive access to the MSHAT system via a website in which they will utilize each day. The study participants in the intervention group will login to the MSHAT system, go through a pre-exercise symptom diary to determine their eligibility to exercise, perform exercise while watching a video demonstration and report results real-time. The intervention group will also be able to send and receive messages via the MSHAT system. The time to complete the daily exercises will vary from patient to patient ranging for 10-30 minutes.
11353165|NCT02346734|No Intervention|Control|The study participants randomized to group 2 will serve as the control. The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and will be given a paper diary to report their exercise completion. The control group will bring their paper diary showing their exercise completion results to their 3 month and 6 month follow-up visits.
11353166|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11353167|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
11353343|NCT02345499|Active Comparator|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
11353168|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
11353169|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
11353170|NCT02346695||Controls|Normotensive individuals
11353171|NCT02346682|Active Comparator|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.
~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
11353172|NCT02346682|Active Comparator|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.
~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
11353173|NCT02346682|No Intervention|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
11353174|NCT02346669|Active Comparator|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:
~at time 0
~after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
11353175|NCT02346669|Sham Comparator|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:
~at time 0
~after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
11353176|NCT02346669|Active Comparator|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:
~at time 0
~after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
11353177|NCT02346656||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
11353178|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
11353179|NCT02346630|Active Comparator|Levodopa / Carbidopa + Armeo|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
11353180|NCT02346630|Placebo Comparator|Placebo + Armeo|Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
11353181|NCT02346617|Experimental|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
11353182|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
11353183|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
11353184|NCT02346591|Experimental|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
11353185|NCT02346591|Active Comparator|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
11353186|NCT02346578|Experimental|Enzalutamide|Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
11353187|NCT02346578|Active Comparator|Flutamide|Flutamide 125 mg administered orally three times a day as one tablet after meal
11353188|NCT02346565|Other|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, >2mm ST depression on ECG), hypertension (systolic BP>220mmHg), hypotension, pre-syncope or arrhythmia.
11353189|NCT02346565|Other|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.
~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.
~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
11353190|NCT02346552|Experimental|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
11353191|NCT02346552|No Intervention|Group 2|Procedures will be performed with the assistance of human camera holder.
11353192|NCT02346539|Experimental|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.
~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
11353193|NCT02346539|Placebo Comparator|Placebo|Placebo comparator
11353194|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.
~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.
~Blood Tests
~CT scan and bone scan
~FACBC PET/MRI in a subset of participants"
11353195|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)
~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)
~Subgroup A3: Consist of bilateral ceramic on metal THAs"
11353196|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
11353197|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
11353198|NCT02346500|Experimental|Transrectal ultrasound|TRUS and TRUS-Robot will be used during PVP
11353199|NCT02346487|Experimental|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
11353200|NCT02346461|Active Comparator|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
11353201|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
11353202|NCT02346448|Active Comparator|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
11353203|NCT02346448|Active Comparator|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
11353204|NCT02346448|Active Comparator|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
11353205|NCT02346435||Active Surveillance|
11353206|NCT02346435||Immediate Intervention|May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.
11353207|NCT02346435||Crossover (Delayed Intervention)|Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.
11353208|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
11353209|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
11353210|NCT02346409|Experimental|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
11353211|NCT02346409|Active Comparator|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
11353212|NCT02346396|Experimental|Patients with neuropathic chronic pain|
11353213|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
11353214|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
11353215|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
11353216|NCT02346370|Experimental|PEGPH20 + Docetaxel|PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m^2)) was administered on Day 2 of each 21-day cycle.
11353217|NCT02346357|Active Comparator|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
11353218|NCT02346357|Placebo Comparator|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
11353219|NCT02346331|Experimental|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
11353220|NCT02346331|No Intervention|Standard care|This arm will be managed per standard care by the hospital clinicians.
11353221|NCT02346318|Experimental|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
11353222|NCT02346318|No Intervention|Control arm|Radiation and chemotherapy
11353223|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
11353224|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
11353225|NCT02346266|Active Comparator|SMART|The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
11353226|NCT02346266|No Intervention|Usual Care|This group will not receive stroke education.
11353227|NCT02346253|Experimental|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
11353228|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
11353229|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
11353230|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
11353231|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).
~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:
~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.
~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
11353232|NCT02346227|Active Comparator|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
11353233|NCT02346227|Placebo Comparator|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
11353234|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
11353235|NCT02346201|Active Comparator|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
11353236|NCT02346201|Placebo Comparator|Placebo|Matching over-encapsulated placebo and psychosocial intervention
11353237|NCT02346188|Experimental|Ferrous fumarate|Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
11353238|NCT02346188|Experimental|Zinc oxide|Tablet formulated as zinc oxide, 30 mg. Given once daily by mouth for 6 months.
11353239|NCT02346188|Experimental|Ferrous fumarate and zinc oxide|Tablet, formulated as ferrous fumarate 30 mg plus zinc oxide 30 mg. Given once daily by mouth for 6 months.
11353240|NCT02346188|Placebo Comparator|Placebo|Sugar tablet formulated to look like the experimental arms of the study. Given daily by mouth for 6 months.
11353241|NCT02346175|Experimental|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
11353242|NCT02346175|Experimental|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
11353243|NCT02346175|Experimental|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
11353244|NCT02346162|Experimental|Intervention|Weight management intervention
11353245|NCT02346162|Other|Usual Care Control|Usual Care for planning healthy pregnancy
11353246|NCT02346149|Other|Patient with impaired glucose tolerance|Bold-MRI before and after glucose injection
11353247|NCT02346136|Experimental|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice Digital Versatile Disc (DVD), DVD players if necessary, and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
11353248|NCT02346136|Active Comparator|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
11353249|NCT02346123||Single group|Group which contains all the patients of the study.
11353250|NCT02346110|Active Comparator|Bupivacaine-adrenalin + sodium chloride|"Single shot saphenous block:
~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin
~1 mL sodium chloride solution"
11353251|NCT02346110|Experimental|Bupivacaine-adrenaline + Dexamethasone|"Single shot saphenous block:
~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin
~1 mL of 4 mg/mL dexamethasone = 4 mg dexamethasone"
11353340|NCT02345525|Experimental|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.
~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
11353252|NCT02346097|Experimental|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.
~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.
~Programming of the VV interval to obtain the narrowest QRS-width"
11353253|NCT02346097|Active Comparator|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.
~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.
~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
11353254|NCT02346084|Experimental|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences
~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV
~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO
~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR
~3 Biopsy Schedules D8- (~2-hr after the 8th dose) D9- (~24-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
11353255|NCT02346084|Experimental|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules
~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR
~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO
~Biopsy Schedule D8- (~2-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
11353256|NCT02346071|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
11353257|NCT02346071|Experimental|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
11353258|NCT02346058|Experimental|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.
~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.
~Duration: 28 days."
11353259|NCT02346045|Experimental|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
11353260|NCT02346045|Sham Comparator|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
11353261|NCT02346032|Experimental|refametinib|refametinib medication
11353262|NCT02346019|Experimental|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
11353263|NCT02346006|Experimental|Physical activity|Subject from schools with more physical activity.
11353264|NCT02345993|Active Comparator|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation
~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
11353265|NCT02345993|Placebo Comparator|Placebo|"Group receiving placebo additional to standard treatment consisting in:
~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation
~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
11353266|NCT02345980|Active Comparator|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
11353267|NCT02345980|Placebo Comparator|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
11353268|NCT02345967|Experimental|Study Group|Device: Model 100 Sensor
11353269|NCT02345954|Experimental|Supracervical Hysterectomy and Sacropexy|Laparoscopic Supracervical Hysterectomy and Sacropexy
11353270|NCT02345954|Experimental|Hysteropexy|Laparoscopic Hysteropexy
11353271|NCT02345941|Experimental|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
11353272|NCT02345941|Active Comparator|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
11353273|NCT02345928|Experimental|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
11353274|NCT02345928|Experimental|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
11353275|NCT02345928|Experimental|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
11353276|NCT02345928|Experimental|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
11353277|NCT02345928|Experimental|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
11353278|NCT02345928|Experimental|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
11353279|NCT02345928|Experimental|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
11353280|NCT02345928|Experimental|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
11353281|NCT02345928|Experimental|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
11353282|NCT02345928|Experimental|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
11353283|NCT02345928|Experimental|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
11353284|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
11353285|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
11353286|NCT02345915|Other|Young adult acute leukemia-survivor|
11353287|NCT02345902|Experimental|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days
~Non-pharmacologic measures:
~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
11353288|NCT02345902|Active Comparator|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.
~Non-pharmacologic measures:
~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
11353289|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
11353290|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
11353291|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
11353292|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
11353293|NCT02345876||Dyslexic children|Longitudinal follow-up without intervention
11353294|NCT02345876||Normal reading children|Longitudinal follow-up without intervention
11353295|NCT02345863|Experimental|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v
~GA101: 1000 mg iv
~Ibrutinib: 420 mg po daily"
11353296|NCT02345850|Active Comparator|Tacrolimus/Methotrexate Control Arm|"Unmanipulated bone marrow graft with Tacrolimus/Methotrexate GVHD prophylaxis. Tacrolimus will be maintained at therapeutic doses for a minimum of 90 days. Methotrexate will be dosed at 5-15mg/m^2 for a maximum of 4 doses post-transplant.
~Cyclosporine may be substituted for tacrolimus if the patient is intolerant of tacrolimus or per institutional practice."
11353297|NCT02345850|Experimental|CD34 Selection Arm|"Mobilized CD34-selected Peripheral Blood Stem Cell graft
~Following screening and enrollment, the donor of patients randomized to the CD34-selection arm will receive mobilization therapy with once daily Granulocyte Colony Stimulating Factor (G-CSF). Mobilization will begin on Day -5 prior to the patient's transplant date.
~Leukapheresis will be performed on a continuous flow cell separator according to institutional standards and will commence on the morning of the fifth day of G-CSF treatment. The anti-coagulant used for the procedure will be acid citrate dextrose (ACD).
~Decisions concerning the need for further product collection will be based on the known or projected enriched CD34+ cell content of the previously collected products."
11353298|NCT02345850|Experimental|Post Transplant Cyclophosphamide|Unmanipulated Bone Marrow Graft with Cyclophosphamide
11353299|NCT02345837|Active Comparator|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
11353300|NCT02345837|Active Comparator|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
11353301|NCT02345824|Experimental|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
11353302|NCT02345811|Experimental|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
11353303|NCT02345811|Active Comparator|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
11353304|NCT02345798|Active Comparator|Arm I (standard care)|Patients and caregivers receive standard care during routine clinic visits.
11353305|NCT02345798|Experimental|Arm II (video-assisted intervention)|Patients view Parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. Patients then receive an educational handbook and discuss the video with a nurse. After surgery and before hospital discharge, patients view Part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home.
11353306|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
11353307|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
11353308|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
11353309|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
11353310|NCT02345746|Experimental|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
11353311|NCT02345733|Experimental|Ulcerative Colitis Diet|Patients will receive a structured novel diet termed the UCD for 6 weeks, and those in remission at week 6 will receive the step down diet for another 6 weeks.
11353341|NCT02345512|Other|Falls|Wearing of Lycra splinting garment
11353342|NCT02345499|Experimental|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
11353312|NCT02345733|Experimental|Antibiotic Treatment|This antibiotic treatment will be given as an open label for patients who refuse diet therapy or for patients who show no improvement by week 3 , deteriorate by week 6, or patients who are not in full remission by week 6 will receive a 14 day course of antibiotics as previously described by Kato and colleagues.
11353313|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
11353314|NCT02345707|Experimental|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
11353315|NCT02345707|Experimental|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
11353316|NCT02345694|Experimental|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
11353317|NCT02345694|Sham Comparator|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
11353318|NCT02345681|Experimental|Test Furosemide|We will test our furosemide algorithm in one arm
11353319|NCT02345681|No Intervention|Classical Strategy|It's a classical strategy without diuretics
11353320|NCT02345668|Experimental|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
11353321|NCT02345668|Experimental|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
11353322|NCT02345655|Experimental|Urine Drug Testing|GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
11353323|NCT02345655|Other|No test|Patients will not have to performed the OS-UDT test
11353324|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
11353325|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
11353326|NCT02345629|Experimental|Cordotomy Group|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours. Quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call. Participants undergo quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Sensory testing to include sharpness and heat detection.
11353327|NCT02345629|Active Comparator|Comprehensive Medical Management Group|Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
11353328|NCT02345616|Experimental|Nitric oxyde|
11353329|NCT02345603|Experimental|Cryo-therapy|Cryo-therapy of renal arteries
11353330|NCT02345603|No Intervention|Control|No intervention in renal arteries
11353331|NCT02345590|Experimental|Eplerenone|25mg Eplerenone once daily for 12 months
11353332|NCT02345590|Placebo Comparator|Matching placebo|Matching placebo once daily for 12 months
11353333|NCT02345577|Active Comparator|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
11353334|NCT02345577|Sham Comparator|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
11353335|NCT02345564|Other|osteochondral lesions in knee/ankle|patients with traumatic and atraumatic osteochondral lesions in knee/ankle, implantation of MaioRegen fleece into osteochondral lesion
11353336|NCT02345551|Experimental|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
11353337|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
11353338|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
11353339|NCT02345525|Active Comparator|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
11353344|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
11353345|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
11353346|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
11353347|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
11353348|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11353349|NCT02345447|Active Comparator|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.
~Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
11353350|NCT02345447|Placebo Comparator|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
11353351|NCT02345434|No Intervention|No informative letter|This is the control arm and it involves no contact with the prescriber
11353352|NCT02345434|Experimental|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
11353353|NCT02345421||At risk population|
11353354|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
11353355|NCT02345395|Experimental|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
11353356|NCT02345395|Experimental|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
11353357|NCT02345395|Sham Comparator|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
11353358|NCT02345382|Experimental|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353359|NCT02345382|Experimental|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353360|NCT02345382|Experimental|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353361|NCT02345382|Experimental|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353362|NCT02345382|Experimental|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353363|NCT02345382|Experimental|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353364|NCT02345382|Experimental|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
11353365|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
11353366|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
11353367|NCT02345356||Standard-of-Care|the standard clinical approach will be followed
11353368|NCT02345356||Genotype-guided|algorithmically guided personalized therapy of warfarin, using a pharmacogenetic model developed in Caribbean Hispanics
11353369|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
11353370|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
11353371|NCT02345304|Experimental|Treatment 3|single dose of midazolam + BI drug
11353372|NCT02345304|Experimental|Treatment 4|single dose of probe drugs + BI drug
11353373|NCT02345304|Experimental|Treatment 5|single dose of digoxin + BI drug
11353374|NCT02345304|Experimental|Treatment 1|single doses of probe drugs
11353375|NCT02345304|Experimental|Treatment 2|single dose of digoxin
11353376|NCT02345291|Experimental|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
11353377|NCT02345291|Experimental|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
11353378|NCT02345291|Experimental|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
11353379|NCT02345291|Placebo Comparator|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
11353380|NCT02345278|Placebo Comparator|Placebo|once daily sublingual administration for 1 month
11353381|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
11353382|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
11353383|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
11353384|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
11353385|NCT02345265|Experimental|Treatment (olaparib and cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11353386|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
11353387|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
11353388|NCT02345252|Experimental|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
11353389|NCT02345239|Experimental|Pantoprazole|Pantoprazole
11353390|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
11353391|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
11353392|NCT02345226|Experimental|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
11353393|NCT02345213|Experimental|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.
~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
11353394|NCT02345213|Placebo Comparator|Placebo|"Treatment period: Weeks 1-12 placebo
~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
11353395|NCT02345200|Active Comparator|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
11353396|NCT02345200|Active Comparator|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
11353397|NCT02345187|Active Comparator|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
11353398|NCT02345187|Placebo Comparator|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
11353399|NCT02345174|Experimental|Imaging Phase + Continuation Phase|In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
11353400|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
11353401|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
11353402|NCT02345148|Experimental|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
11353403|NCT02345148|Experimental|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
11353404|NCT02345135|Active Comparator|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
11353405|NCT02345135|Active Comparator|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
11353406|NCT02345122|Other|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
11353407|NCT02345122|Experimental|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
11353518|NCT02344459|Experimental|80mL double balloon catheter (Cook catheter®)|
11353408|NCT02345109|Experimental|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
11353409|NCT02345109|Experimental|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
11353410|NCT02345096|Active Comparator|Saccharomyces cerevisiae CNCM I-3856|In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
11353411|NCT02345096|Placebo Comparator|placebo|In this arm, subjects will be asked to consume one capsule of placebo per day.
11353412|NCT02345070|Placebo Comparator|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
11353413|NCT02345070|Experimental|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
11353414|NCT02345070|Experimental|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
11353415|NCT02345057|Experimental|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
11353416|NCT02345057|Experimental|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
11353417|NCT02345057|Experimental|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
11353418|NCT02345057|Experimental|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
11353419|NCT02345057|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
11353420|NCT02345044|Experimental|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
11353421|NCT02345044|Experimental|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
11353422|NCT02345044|Experimental|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
11353423|NCT02345044|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
11353424|NCT02345044|Active Comparator|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
11353425|NCT02345031|Active Comparator|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
11353426|NCT02345031|Placebo Comparator|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
11353427|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
11353428|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
11353429|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
11353430|NCT02344992|Experimental|Biochaperone Insulin Lispro|
11353431|NCT02344992|Active Comparator|Humalog®|
11353432|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
11353433|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
11353434|NCT02344940|Experimental|toremifene|patients who will be treated with toremifene.
11353435|NCT02344940|Active Comparator|tamoxifen|patients who will be treated with tamoxifen.
11353436|NCT02344927|Active Comparator|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice
~Continuance of oral intake (if appropriate)
~Regular (4 hourly) mouth care
~Standard management of pain and other symptoms in the terminal phase."
11353437|NCT02344927|Active Comparator|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice
~Continuance of oral intake (if appropriate)
~Regular (4 hourly) mouth care
~Clinically-assisted hydration
~Standard management of pain and other symptoms in the terminal phase"
11353438|NCT02344914|Experimental|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
11353439|NCT02344914|No Intervention|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
11353440|NCT02344901||atrial fibrillation patients|>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
11353441|NCT02344888|Active Comparator|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
11353442|NCT02344888|Active Comparator|Clomiphene citrate-placebo group|Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
11353443|NCT02344875|Experimental|Male elder subjects|Male 65- Years
11353444|NCT02344875|Experimental|Male non-elder subjects|Male 20-35 Years
11353445|NCT02344875|Experimental|Female elder subjects|Female 65- Years
11353446|NCT02344875|Experimental|Female non-elder subjects|Female 20-35 Years
11353447|NCT02344862|Active Comparator|FYU-981 High dose|
11353448|NCT02344862|Active Comparator|FYU-981 Middle dose|
11353449|NCT02344862|Active Comparator|FYU-981 Low dose|
11353450|NCT02344862|Placebo Comparator|Placebo|
11353451|NCT02344849|Experimental|Mesenchymal stem cell|Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.
11353452|NCT02344836|Active Comparator|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).
~Intervention: podcast + mobile diet app"
11353453|NCT02344836|Experimental|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).
~Intervention: podcast + theory-based mobile diet app"
11353454|NCT02344823|Active Comparator|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
11353455|NCT02344823|Placebo Comparator|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
11353456|NCT02344823|Active Comparator|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
11353457|NCT02344823|Placebo Comparator|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
11353458|NCT02344810|Experimental|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
11353459|NCT02344810|Active Comparator|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
11353460|NCT02344797|Active Comparator|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
11353461|NCT02344797|No Intervention|Control|
11353462|NCT02344758|Experimental|Celiac adult|Patient >16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
11353463|NCT02344758|Experimental|Celiac child|Patient <16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
11353464|NCT02344758|Active Comparator|Healthy adult|Healthy individual > 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
11353465|NCT02344758|Active Comparator|Healthy child|Healthy individual < 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
11353466|NCT02344745|Placebo Comparator|Control|Distilled water
11353467|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
11353468|NCT02344732|Active Comparator|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
11353469|NCT02344732|Experimental|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
11353470|NCT02344719|Active Comparator|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
11353471|NCT02344719|Placebo Comparator|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
11353472|NCT02344706||Mini-EEG, NCSE|Unconscious patients due to seizures, of whom EEG is registered
11353473|NCT02344680||HIV-HBV co-infected|HIV-HBV co-infected patients receiving anti-retroviral therapy
11353474|NCT02344667|Experimental|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
11353475|NCT02344667|Experimental|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
11353476|NCT02344654|Experimental|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
11353477|NCT02344654|Active Comparator|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
11353478|NCT02344641|Experimental|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
11353479|NCT02344641|No Intervention|control group|control group do not receive exenatide
11353480|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
11353481|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
11353482|NCT02344615|Active Comparator|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
11353483|NCT02344615|Experimental|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
11353484|NCT02344602|Experimental|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
11353485|NCT02344589|Experimental|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
11353486|NCT02344589|Experimental|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
11353487|NCT02344589|Experimental|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
11353488|NCT02344589|Active Comparator|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
11353489|NCT02344589|Placebo Comparator|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
11353490|NCT02344576|No Intervention|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
11353519|NCT02344459|Active Comparator|30mL single Foley balloon catheter|
11353689|NCT02343185|Placebo Comparator|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
11353491|NCT02344576|Experimental|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
11353492|NCT02344563|Experimental|Meropem|0.5g/vial,one vial
11353493|NCT02344563|Active Comparator|Mepem|0.25g/vial ,two vials
11353494|NCT02344550|Experimental|Everolimus arm|Everolimus 10mg p.o. daily Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
11353495|NCT02344550|Active Comparator|Control arm|Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
11353496|NCT02344537|Experimental|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
11353497|NCT02344537|No Intervention|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
11353498|NCT02344524|Experimental|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
11353499|NCT02344524|Active Comparator|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
11353500|NCT02344511|Experimental|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.
~• Patients with CrCl < 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.
~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
11353501|NCT02344511|Active Comparator|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label
~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
11353502|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
11353503|NCT02344498||Rural|HBV patients in Harar. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
11353504|NCT02344485|Experimental|OMM treatment|Subject will receive osteopathic manipulative treatment protocol for constipation in Parkinson's disease once a week for 4 weeks, in addition to continuing with their routine care
11353505|NCT02344485|No Intervention|Control|Subjects will continue with their routine care. No OMM will be performed during this study period
11353506|NCT02344472|Experimental|Chemotherapy with docetaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
11353507|NCT02344472|Experimental|Chemotherapy with paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel.Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
11353508|NCT02344472|Experimental|Chemotherapy with vinorelbine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
11353509|NCT02344472|Experimental|Chemotherapy with capecitabine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
11353510|NCT02344472|Experimental|endocrine therapy with exemestane|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus exemestane.
11353511|NCT02344472|Experimental|endocrine therapy with fulvestrant|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus fulvestrant.
11353512|NCT02344472|Experimental|endocrine therapy with anastrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus anastrozole.
11353513|NCT02344472|Experimental|endocrine therapy with letrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus letrozole.
11353514|NCT02344472|Experimental|Chemotherapy with nab-Paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus nab-Paclitaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
11353515|NCT02344472|Experimental|Chemotherapy with eribulin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus eribulin. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
11353516|NCT02344472|Experimental|endocrine therapy with leuprorelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus leuprorelin.
11353517|NCT02344472|Experimental|endocrine therapy with goserelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus goserelin.
11353520|NCT02344446|Experimental|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
11353521|NCT02344433|Experimental|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
11353522|NCT02344433|Active Comparator|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
11353523|NCT02344420|Other|Single Arm|As it is not a randomize trial there is only one study arm. Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
11353524|NCT02344407|Experimental|2|ChAd3-EBO Z
11353525|NCT02344407|Experimental|3|VSVG-ZEBOV
11353526|NCT02344407|Placebo Comparator|1|Placebo (Saline)
11353527|NCT02344394|Other|Hybrid Ablation-cryoballoon alone|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation consisting of pulmonary vein isolation with no further catheter ablation. This will be achieved using the nContact and Medtronic cryoballoon
11353528|NCT02344394|Other|Hybrid ablation-cryoballoon plus RF|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation. Endocardial portion consists of pulmonary vein isolation using the cryoballoon with further catheter ablation, which may consist of ablation of complex fractionated electrograms and linear lesions. This will be achieved using the nContact and Medtronic Cryoballoon plus Thermocool Catheter.
11353529|NCT02344381|Experimental|Sucrose|Sucrose ingestion post-exercise
11353530|NCT02344381|Active Comparator|Glucose|Glucose ingestion post-exercise
11353531|NCT02344368|Experimental|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
11353532|NCT02344368|Experimental|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
11353533|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:
~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions
~Adjuvant therapy:
~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
11353534|NCT02344342|Experimental|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
11353535|NCT02344342|Experimental|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
11353536|NCT02344329|Active Comparator|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
11353537|NCT02344329|Experimental|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
11353538|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
11353539|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
11353540|NCT02344303|Experimental|Part A|Fixed sequence, open label
11353541|NCT02344303|Experimental|Part B|4 way cross over, double blind
11353542|NCT02344290|Experimental|Pitavastatin|Participants will receive pitavastatin once a day for the entire time they are enrolled in the study.
11353543|NCT02344290|Placebo Comparator|Placebo|Participants will receive placebo for pitavastatin once a day for the entire time they are enrolled in the study.
11353544|NCT02344264|Other|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
11353545|NCT02344264|Other|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
11353546|NCT02344251|Other|Group 1|Adherence measured by MEMS Cap
11353547|NCT02344251|Other|Group 2|Adherence measured by ID-Cap technology.
11353548|NCT02344238|Other|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
11353549|NCT02344238|Other|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
11353550|NCT02344238|Other|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
11353551|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
11353552|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
11353553|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
11353554|NCT02344212|Experimental|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
11353555|NCT02344186|Experimental|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
11353556|NCT02344186|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks.
11353557|NCT02344134|Experimental|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
11353558|NCT02344134|Active Comparator|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
11353559|NCT02344108|Experimental|Inspire® Upper Airway Simulation System|Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
11353560|NCT02344095|Experimental|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
11353561|NCT02344095|Experimental|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
11353562|NCT02344082|No Intervention|Standard of Care|The control arm will receive face-to-face pharmacy clinic visits per usual care.
11353563|NCT02344082|Active Comparator|Intervention Arm|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
11353564|NCT02344069|Active Comparator|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
11353565|NCT02344069|Placebo Comparator|Placebo|Saline 0.9%
11353566|NCT02344056|Experimental|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
11353567|NCT02344056|Experimental|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
11353568|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
11353569|NCT02344030|Experimental|standard blade|Standard Blade: tracheal intubation with standard blade
11353570|NCT02344030|Experimental|channeled blade|Channeled Blade: tracheal intubation with channeled blade
11353571|NCT02344017|Experimental|ODM-204 Phase I dose escalation|Dose escalation
11353572|NCT02344017|Experimental|ODM-204 Phase II dose expansion|
11353573|NCT02344004|No Intervention|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] Guidelines)
11353574|NCT02344004|Experimental|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)
~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
11353575|NCT02343991|Experimental|Transcranial ExAblate|MR Guided Focused Ultrasound
11353576|NCT02343978|Experimental|KWA-0711 High dose|
11353577|NCT02343978|Experimental|KWA-0711 Low dose|
11353578|NCT02343965|Experimental|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
11353579|NCT02343965|No Intervention|without touch-massage group|
11353580|NCT02343952|Experimental|Experimental Arm|Pembrolizumab
11353581|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.
~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
11353582|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.
~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
11353583|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.
~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
11353584|NCT02343926|Experimental|Gemigliptin|GEMIGLIPTIN LS15-0444 administered once a day for 24 weeks as add-on therapy to metformin
11353585|NCT02343926|Active Comparator|Vildagliptin|Vildagliptin administered twice a day for 24 weeks as add-on therapy to metformin
11353586|NCT02343913|Experimental|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
11353587|NCT02343887|Active Comparator|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and
~if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12
~or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
11353688|NCT02343185|Experimental|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
11353690|NCT02343172|Experimental|HDM201+LEE011|
11353588|NCT02343887|Experimental|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then
~Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,
~or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
11353589|NCT02343887|Experimental|group with psychological support.|"patients treated with counseling for six months (period 1) and
~Stop if the situation improves with neuropsychological assessment and monitoring to M12,
~or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
11353590|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).
~No intervention is going to be administered but exposure to alcohol will be analysed"
11353591|NCT02343861|Active Comparator|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
11353592|NCT02343861|Placebo Comparator|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
11353593|NCT02343848|Experimental|treatment|smart bracelet.
11353594|NCT02343835|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
11353595|NCT02343835|No Intervention|Control|The patients without treatment
11353596|NCT02343822|Experimental|Multiple PRP Injection|2 PRP Injections 2 months apart
11353597|NCT02343822|Experimental|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
11353598|NCT02343822|Active Comparator|Saline Injection|2 Saline Injections 2 months apart
11353599|NCT02343809|Experimental|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
11353600|NCT02343809|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
11353601|NCT02343809|Other|Control Group|Protocolized Physiotherapy
11353602|NCT02343796|Experimental|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
11353603|NCT02343783|Experimental|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
11353604|NCT02343770|Experimental|idiopathic juvenile arthritis|blood sample
11353605|NCT02343770|Other|control|blood sample
11353606|NCT02343757|Other|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.
~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
11353607|NCT02343744|Experimental|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
11353608|NCT02343731|Experimental|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
11353609|NCT02343718|Experimental|Vinblastine and Temsirolimus|"Vinblastine starting dose:
~Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.
~Temsirolimus starting dose:
~Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
11353610|NCT02343705|Experimental|Latella Knee Implant System|
11353611|NCT02343692|Experimental|Radiofrequency abalation|"Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas
~Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)
~Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.
~Ablation of cystic tumours of the pancreas"
11353612|NCT02343679|Experimental|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
11353613|NCT02343666|Experimental|Treatment (gene modified HPSC)|See Detailed Description.
11353614|NCT02343653|Active Comparator|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
11353615|NCT02343653|Experimental|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
11353616|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
11353617|NCT02343627|Experimental|NVXT Solution|NVXT Solution once daily for 60 days
11353618|NCT02343627|Placebo Comparator|Vehicle of test product|Vehicle of test product, once daily for 60 days
11353619|NCT02343614|Experimental|ARM A|Patients undergoing treatment with oral celecoxib
11353620|NCT02343601|No Intervention|Control group|Control group using a hemodynamic standard protocol
11353621|NCT02343601|Other|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
11353622|NCT02343588|Experimental|The Health Lifestyles Interventions|"Creating a supportive school, family and community environment;
~Health lifestyles educational strategies;
~Instruct and promote school physical education;
~The monitoring and instruction of obesity related behaviors (focus group)"
11353623|NCT02343588|No Intervention|Receive no intervention|Usual practice
11353624|NCT02343575|Experimental|Valproic Acid|"Start:
~VPA PO/NGT 500 mg BID
~If need to increase in 24 or more hours:
~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS
~If need to increase in 24 or more hours:
~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS
~If need to increase in 24 or more hours:
~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
11353625|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID
~Rescue: HAL IV 2-5 mg Q4hr PRN"
11353626|NCT02343562|Active Comparator|Probiotics Group|Will receive Sachet-form probiotics
11353627|NCT02343562|Placebo Comparator|Placebo Group|Will receive off-the-shelf oral multivitamin
11353628|NCT02343549|Experimental|A|All Patients
11353629|NCT02343536|Experimental|Oral Azacitidine (CC-486) and R-CHOP|Will examine four escalating dose-levels of CC- 486 (100 mg, 150 mg, 200 mg and 300 mg).
11353630|NCT02343536|Active Comparator|R-CHOP|R-CHOP, (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) * rituximab, cyclophosphamide, doxorubicin, and vincristine are administered on Day 1; while prednisone is administered Days 1-5
11353631|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
11353632|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
11353633|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
11353634|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
11353635|NCT02343497|Experimental|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
11353636|NCT02343497|Placebo Comparator|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
11353637|NCT02343484|Active Comparator|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
11353638|NCT02343484|Active Comparator|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
11353639|NCT02343471|Experimental|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
11353640|NCT02343471|Placebo Comparator|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
11353641|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
11353642|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
11353643|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
11353644|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
11353645|NCT02343445|Experimental|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
11353646|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
11353647|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
11353648|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
11353649|NCT02343432|Experimental|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
11353650|NCT02343432|Experimental|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
11353651|NCT02343432|Experimental|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
11353652|NCT02343419|Experimental|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
11353653|NCT02343406|Experimental|ABT-414/temozolomide|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks in combination with temozolomide (TMZ) to adult participants
11353654|NCT02343406|Experimental|ABT-414_adult|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to adult participants
11353655|NCT02343406|Active Comparator|Control_lomustine|Adult participants relapsing during temozolomide (TMZ) treatment or within the first 16 weeks after the first day of the last TMZ cycle received lomustine on Day 1 of every 42-day treatment period until one of the treatment withdrawal criteria was met, up to a maximum of 1 year.
11353656|NCT02343406|Active Comparator|Control_ temozolomide|Adult participants relapsing 16 weeks or more after the first day of the last temozolomide (TMZ) cycle received TMZ on Day 1 to Day 5 for the first 28-day cycle, with dose escalation in subsequent cycles in case of adequate tolerance and treatment continuing until one of the treatment withdrawal criteria was met.
11353657|NCT02343406|Experimental|ABT-414_ pediatric|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to pediatric participants. Temozolomide (TMZ) was only allowed for pediatric participants if its use was in accordance with local clinical practice, and was not considered an investigational product for the study (unless this was a local requirement).
11353658|NCT02343393|Experimental|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
11353659|NCT02343393|No Intervention|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
11353660|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
11353661|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
11353662|NCT02343367|Active Comparator|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
11353663|NCT02343367|Experimental|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
11353664|NCT02343354|Experimental|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
11353665|NCT02343341|Experimental|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive a 4-month health promotion education program along with their parents/caregivers and teachers.
11353666|NCT02343341|Other|Control:Standard Curriculum|"The Standard curriculum control arm will receive the standard curriculum in their schools.
~Children randomized to the control arm will receive the health promotion education program for 4 months after the intervention arm has completed it"
11353667|NCT02343328|Active Comparator|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
11353668|NCT02343328|Placebo Comparator|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
11353669|NCT02343315|Experimental|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
11353670|NCT02343315|Experimental|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
11353671|NCT02343315|Active Comparator|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
11353672|NCT02343302|Other|Soft Pancreatic Gland|This arm will be patients with glands felt to have a soft texture during surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
11353673|NCT02343302|Other|Hard Pancreatic Gland|This arm will include patients felt to have a hard gland tecture at the time of surgery. This arm will receive either a suction drain or a gravity drain based on the note inside the sealed envelope.
11353674|NCT02343289|Experimental|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
11353675|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
11353676|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
11353677|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
11353678|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
11353679|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
11353680|NCT02343250|Experimental|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
11353681|NCT02343250|Active Comparator|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
11353682|NCT02343237|Experimental|Osteopathy +|75 patients will make 6 osteopathic sessions
11353683|NCT02343237|Active Comparator|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
11353684|NCT02343224|Experimental|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
11353685|NCT02343211|Experimental|immunoglobulin|
11353686|NCT02343198|Experimental|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
11353687|NCT02343198|Placebo Comparator|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
11353691|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
11353692|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
11353693|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
11353694|NCT02343146|Experimental|Type One Training (TOT)|The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
11353695|NCT02343146|No Intervention|Comparison|The comparison group will receive usual care with the diabetes team.
11353696|NCT02343133|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
11353697|NCT02343133|Placebo Comparator|Placebo|Single subcutaneous dose
11353698|NCT02343120|Experimental|BGB-3111|All patients will undertake 160MG BID of BGB-3111.
11353699|NCT02343107|Experimental|1|Subgroup of subjects who benefit of the e-coaching
11353700|NCT02343107|No Intervention|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
11353701|NCT02343094|Experimental|PBA 7,5g/d|Treatment for 14 days
11353702|NCT02343094|Experimental|PBA 15g/d|Treatment for 14 days
11353703|NCT02343081|Active Comparator|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
11353704|NCT02343081|Experimental|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
11353705|NCT02343055|Experimental|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
11353706|NCT02343055|Placebo Comparator|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
11353707|NCT02343042|Experimental|1: Selinexor, Low-dose Dexamethasone and Pomalidomide (SPd)|"Each cycle is of 28 days
~Cohort 1.1: Selinexor (SEL) 60/80/100 mg orally (PO) once weekly (QW); Dexamethasone (DEX) 40 mg PO once weekly; Pomalidomide (POM) 2/3/4 mg PO Days 1-21.
~Cohort 1.2: SEL 40/60/80 mg PO twice weekly (BIW); DEX 20 mg PO twice weekly; POM 3/4 mg PO Days 1-21.
~Cohort 1.3: Selinexor, Dexamethasone and Pomalidomide will be dosed at RP2D-1.
~Cohort 1.4: SEL 40 mg PO QW; DEX 40 mg PO QW; POM 4mg PO once daily (QD) Days 1-21."
11353708|NCT02343042|Experimental|2: Selinexor, Low-dose Dexamethasone and Bortezomib (SVd)|"Each cycle is of 35 days
~Cohort 2.1: SEL 60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Bortezomib (BOR) 1.3 milligram per meter square (mg/m^2) subcutaneous (SC) once weekly.
~Cohort 2.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.
~Cohort 2.3: Selinexor, Dexamethasone and Bortezomib will be dosed at RP2D-2."
11353709|NCT02343042|Experimental|3: Selinexor, Low-dose DEX, and Lenalidomide (SRd) in RRMM|"Each cycle is of 28 days
~Cohort 3.1: SEL 40/60/80/100 mg PO once weekly; DEX 40 mg PO once weekly; Lenalidomide (LEN) 15/25 mg PO Days 1-21.
~Cohort 3.2: SEL 40/60/80 mg PO twice weekly; DEX 20 mg PO twice weekly; LEN 15/25 mg PO Days 1-21.
~Cohort 3.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-3."
11353710|NCT02343042|Experimental|4:Selinexor, Low-dose dexamethasone, Pomalidomide, Velcade (SPVd)|"PK Run-in Period: Selinexor and Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patients will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days.
~Cohort 4.1:
~SEL 40/60 mg PO once weekly; DEX 40 mg PO once weekly; POM 4 mg PO Days 1-21; BOR 1.3 mg/m^2 subcutaneous (SC) once weekly.
~Cohort 4.3: Selinexor, Dexamethasone, Pomalidomide, Velcade (Bortezomib) will be dosed at RP2D-4."
11353711|NCT02343042|Experimental|5: Selinexor, Low-dose dexamethasone, and Daratumumab (SDd)|"Each cycle is of 28 days
~Cohort 5.1:
~SEL 80/100 mg PO once weekly; DEX 40 mg once weekly (IV or PO); DARA: 16 mg/kg IV infusion Cycle 1-2: Once weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.
~Cohort 5.2:
~SEL: 60 mg PO twice weekly; DEX: 40 mg weekly (IV or PO); DARA: 16 milligram per kilogram (mg/kg) IV infusion Cycle 1-2: Once. weekly, Cycle 3-6: Every other week, Cycle 6 and greater: Once a month.
~Cohort 5.3: Selinexor, Dexamethasone and Daratumumab will be dosed at RP2D-5."
11353712|NCT02343042|Experimental|6: Selinexor, Low-dose dexamethasone, and Carfilzomib (SKd)|"PK Run-in Period: Selinexor and Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-Escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days
~Cohort 6.1:
~SEL 40/60/80/100 mg PO once weekly on days 1, 8, 15, and 22; DEX 40 mg IV or PO once weekly; Carfilzomib (CAR) 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.
~Cohort 6.2:
~SEL 60/80/100 mg PO once weekly on days 1, 8, and 15; DEX 40 mg IV or PO once weekly; CAR 56 or 70 mg/m^2 IV infusion once weekly on days 1, 8, and 15.
~Cohort 6.3: Selinexor, Dexamethasone and Carfilzomib will be dosed at RP2D-6."
11353713|NCT02343042|Experimental|7: Selinexor, Low-dose DEX and Lenalidomide (SRd) in NDMM|"Each cycle is of 28 days
~Cohort 7.1:
~SEL 40/60/80 mg PO once weekly; DEX 40 mg PO once weekly; LEN 25 mg PO Days 1-21.
~Cohort 7.3: Selinexor, Dexamethasone and Lenalidomide will be dosed at RP2D-7."
11353740|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
11353714|NCT02343042|Experimental|8: Selinexor, Low-dose dexamethasone, and Ixazomib (SNd)|"PK Run-in Period: Selinexor & Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-Escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days
~Cohort 8.1:
~SEL 40/60/80/100 mg PO once weekly; DEX 20 mg PO twice weekly; IXA 3/4 mg PO once weekly.
~Cohort 8.3: Selinexor, Dexamethasone and Ixazomib will be dosed at RP2D-8."
11353715|NCT02343042|Experimental|9: Selinexor, Low-dose DEX, Pomalidomide and Elotuzumab (SPEd)|"PK Run-in Period: Selinexor and Clarithromycin:
~For the first 9 patients enrolled into this dose escalation arm
~14 day run-in period after which patient will proceed to Dose-Escalation Phase C1D1
~Selinexor 40 mg will be dosed on Days 1 and 8. Clarithromycin 500 mg will be dosed twice daily on Days 2-8.
~PK samples will be collected on Days 1 and 8 at 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post dose.
~Dose-Escalation Phase:
~All patients enrolled into this Arm
~Each cycle is of 28 days
~Cohort 9.1:
~SEL 20/40/60 mg PO once weekly; DEX 28/20 mg PO twice weekly; POM 4 mg PO QD Days 1-21; Elotuzumab (ELO) 10/20 mg/kg IV will be given once weekly on Days 1,8, 15 and 22 of Cycles 1-2. Starting on Cycle 3 and continuing for future cycles, elotuzumab will be dosed at 20 mg/kg on Day 1 of each cycle only.
~Cohort 9.3: Selinexor, Dexamethasone, Pomalidomide and Elotuzumab will be dosed at RP2D-9."
11353716|NCT02343042|Experimental|10. Selinexor, Dexamethasone, and Belantamab Mafodotin (SBd)|"Each cycle is of 21 days
~Cohort 10.1:
~SEL 40/60/80 mg PO once weekly on Days 1, 8, and 15; DEX 40 mg PO QW on Days 1, 8, and 15; Belantamab Mafodotin (BEL) 2.5 mg/kg IV infusion every 3 weeks (Q3W) Day 1 of each cycle.
~Cohort 10.3:
~Selinexor, Dexamethasone, and Belantamab Mafodotin will be dosed at RP2D-10."
11353717|NCT02343042|Experimental|11. Selinexor, Dexamethasone, Pomalidomide, and Daratumumab (SDPd)|"Each Cycle is of 28 days
~Cohort 11.1 SEL 40/60 mg PO once weekly on Days 1, 8, and 15; DEX total 40 mg weekly (IV or PO) single or divided doses on Days 1, 8, 15, and 22; POM 4 mg PO QW Days 1-21; DARA 16 mg/kg IV or SC QW on Days 1, 8, 15 and 22 of Cycles 1-2 and on Days 1 and 15 of Cycles 3-6, Day 1 of every Cycle greater than (>6).
~Cohort 11.3 Selinexor, Dexamethasone, Pomalidomide, and Daratumumab will be dosed at RP2D-11."
11353718|NCT02343029|Experimental|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
11353719|NCT02343029|Active Comparator|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
11353720|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
11353721|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
11353722|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
11353723|NCT02342990|Experimental|Cluster B|After the first neuropsychological assessment (T1), children will start CogMed working memory training. Children will be retested (T2) about six or seven weeks later.
11353724|NCT02342990|Other|Cluster A|After the first neuropsychological assessment (T1), children will not start any training. Children will be retested (T2) about six or seven weeks later and will start CogMed working memory training. The group will be again retest (T3) after six or seven weeks after ended training.
11353725|NCT02342977|Placebo Comparator|Placebo|Patient will randomly receive a placebo
11353726|NCT02342977|Experimental|Experimental|Patients will randomly receive experimental drug (lacosamide).
11353727|NCT02342964|Other|MUCO-FIBRO|Measures of hepatic elasticity
11353728|NCT02342951|Other|LCI|Measure of lung clearance index
11353729|NCT02342938|Experimental|Patient|
11353730|NCT02342938|Experimental|Volunteers|
11353731|NCT02342925|Experimental|RG1662 plus metformin|
11353732|NCT02342925|Experimental|metformin alone|
11353733|NCT02342912|Experimental|Social Media Targeted Treatment|Participants randomly assigned to this treatment arm will receive weight loss materials via text messages, Facebook postings, on-line videos, and weekly reports. The topics relate to relate to behavioral and lifestyle changes associated with weight-loss (e.g., nutrition, exercise, social support, and self-monitoring). Calorie and physical activity targets also are set. Participants will receive a suggestion to track diet, physical activity, and weight.
11353734|NCT02342912|Experimental|Social Media Tailored Treatment|Participants randomly assigned to this treatment arm receive all of the same weight loss materials (as well as weight, calorie, and physical activity targets) as the Targeted group above. Weekly reports will be more personalized to help participants track diet, physical activity, and weight. Additionally, participants will be asked to report on their weight, exercise and calorie goals, and receive feedback.
11353735|NCT02342912|Active Comparator|Social Media Contact Control|Participants randomly assigned to this treatment arm receive health information via text messages, Facebook postings, on-line videos, and weekly reports. Topics relate to having a healthy body weight through a healthy mind, body, and energy. Some topics include stress management, importance of sleep, and importance of accepting one's body. Participants will receive a suggestion to track stress, body image, and energy levels.
11353736|NCT02342899|Active Comparator|Control Goup|Inpatient initiation of noninvasive ventilation.
11353737|NCT02342899|Active Comparator|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
11353738|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
11353739|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:
~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight
~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight
~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
11353741|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
11353742|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
11353743|NCT02342873|Active Comparator|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
11353744|NCT02342873|Experimental|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
11353745|NCT02342860|Experimental|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
11353746|NCT02342860|No Intervention|Control|Schools in the control group will receive no additional WinS programming.
11353747|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.
~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.
~The follow-up of patients will be performed according to standard clinical practice of each site"
11353748|NCT02342834|No Intervention|Control|"During the control study, each subject ingest 500 ml of water 30 minutes before a standard 75 g Oral Glucose Tolerance Test"
11353749|NCT02342834|Experimental|Small mixed protein and lipid meal|"During the preload study, each subject ingest a small mixed meal 30 minutes before a standard 75 g Oral Glucose Tolerance Test. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
11353750|NCT02342808|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
11353751|NCT02342808|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
11353752|NCT02342795|Experimental|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
11353753|NCT02342795|Experimental|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
11353754|NCT02342795|Experimental|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
11353755|NCT02342795|Experimental|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
11353756|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
11353757|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
11353758|NCT02342756|Experimental|Group 1: CMV - HFOV|"Patients in group 1 will start with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O) and then will be ventilated with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O)
~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
11353759|NCT02342756|Experimental|Group 2: HFOV - CMV|"Patients in group 2 will start with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O) and then will be ventilated with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O).
~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
11353760|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
11353761|NCT02342730|Experimental|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
11353762|NCT02342717|Experimental|Reference|single dose BI 425809
11353763|NCT02342717|Experimental|Test|multiple doses of Itraconazole + single dose BI 425809
11353764|NCT02342704|Experimental|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
11353765|NCT02342704|Active Comparator|fingolimod|Open-label fingolimod 0.5 mg once daily orally
11353766|NCT02342691|Experimental|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
11353975|NCT02341508|Placebo Comparator|Placebo|Saline solution for intravenous infusion
11353767|NCT02342691|Placebo Comparator|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
11353768|NCT02342691|No Intervention|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
11353769|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
11353770|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
11353771|NCT02342665|Experimental|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
11353772|NCT02342652|Experimental|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
11353773|NCT02342652|Placebo Comparator|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
11353774|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
11353775|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
11353776|NCT02342626|No Intervention|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
11353777|NCT02342626|Experimental|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
11353778|NCT02342613|Experimental|MILs treatment|Patients treated with the activated PTCy-MILs
11353779|NCT02342600|Experimental|Trametinib with Pazopanib|Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
11353780|NCT02342587|Experimental|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
11353781|NCT02342574|Experimental|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
11353782|NCT02342574|Placebo Comparator|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
11353783|NCT02342574|Experimental|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
11353784|NCT02342574|Placebo Comparator|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
11353785|NCT02342574|Experimental|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
11353786|NCT02342574|Placebo Comparator|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
11353787|NCT02342574|Experimental|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
11353788|NCT02342574|Placebo Comparator|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
11353789|NCT02342574|Experimental|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
11353790|NCT02342574|Placebo Comparator|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
11353791|NCT02342574|Experimental|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
11353792|NCT02342574|Placebo Comparator|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
11353793|NCT02342574|Experimental|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
11353794|NCT02342574|Placebo Comparator|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
11353795|NCT02342574|Experimental|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
11353796|NCT02342574|Placebo Comparator|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
11353797|NCT02342574|Experimental|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
11353798|NCT02342574|Placebo Comparator|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
11353799|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
11353800|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
11353801|NCT02342548|Experimental|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
11353802|NCT02342548|Experimental|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
11353803|NCT02342535|Other|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.
~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
11353804|NCT02342522|Active Comparator|Remote ischemic conditioning|AutoRIC device will be placed on the upper arm and an active RIC protocol will be delivered (4x5 min cycles of inflation to 200mmHg and deflation) prior to PPCI.
11353805|NCT02342522|Sham Comparator|Sham control|Sham AutoRIC device will be placed on the upper arm and a sham RIC protocol will be delivered prior to PPCI.
11353806|NCT02342509|Experimental|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
11353807|NCT02342509|Experimental|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
11353808|NCT02342509|Active Comparator|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
11353809|NCT02342496|Placebo Comparator|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
11353810|NCT02342496|Active Comparator|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
11353811|NCT02342496|Active Comparator|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
11353812|NCT02342483|Active Comparator|1g|METHYLSULFONYLMETHANE
11353813|NCT02342483|Active Comparator|3g|METHYLSULFONYLMETHANE
11353814|NCT02342483|Active Comparator|6g|METHYLSULFONYLMETHANE
11353815|NCT02342470|Placebo Comparator|Placebo|Placebo Comparator / Bid
11353816|NCT02342470|Experimental|PMK-S005 1|Total 50mg, by mouth, bid
11353817|NCT02342470|Experimental|PMK-S005 2|Total 100mg, by mouth, bid
11353818|NCT02342470|Experimental|PMK-S005 3|Total 150mg, by mouth, bid
11353819|NCT02342457|Experimental|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
11353820|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
11353821|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
11353822|NCT02342431|Active Comparator|Forced air compressible warming|Warming with a compressible forced air mattress
11353823|NCT02342431|Experimental|Forced air non-compressible|Warming with a non-compressible forced air mattress
11353824|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
11353825|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
11353826|NCT02342405|Placebo Comparator|30% oxygen|Inhalation of 30% oxygen
11353827|NCT02342405|Experimental|80% oxygen|Inhalation of 80% oxygen
11353828|NCT02342392|Active Comparator|treatment group|intralesional ranibizumab injected
11353829|NCT02342392|No Intervention|control group|no intralesional ranibizumab injected.
11353830|NCT02342379|Experimental|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
11353831|NCT02342366|Placebo Comparator|Placebo|Placebo
11353832|NCT02342366|Experimental|GHB|GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)
11353833|NCT02342353|Experimental|Phase I (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.
~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.
~A 28-day interval is defined as a cycle"
11353834|NCT02342353|Experimental|Phase II (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.
~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.
~A 28-day interval is defined as a cycle"
11353835|NCT02342340|Active Comparator|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
11353836|NCT02342340|Active Comparator|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
11353837|NCT02342340|Active Comparator|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
11353838|NCT02342340|Active Comparator|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
11353839|NCT02342340|Active Comparator|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
11353905|NCT02341872|No Intervention|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
11353840|NCT02342340|Placebo Comparator|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
11353841|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
11353842|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
11353843|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
11353844|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
11353845|NCT02342314|Placebo Comparator|Placebo (Part A)|Single SC injection of normal saline on Day 1
11353846|NCT02342314|Active Comparator|rGlucagon (Part B)|Single SC injection on Day 1
11353847|NCT02342314|Placebo Comparator|Placebo (Part B)|Single SC injection of normal saline on Day 1
11353848|NCT02342301|Experimental|Standing Desk|Will use standing desk for 3 months
11353849|NCT02342301|Active Comparator|Traditional Desk|Will use traditional desk for 3 months
11353850|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
11353851|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
11353852|NCT02342275|Active Comparator|Propranolol|Propranolol
11353853|NCT02342275|Active Comparator|Atenolol|Atenolol
11353854|NCT02342262|Experimental|Probiotics|EcologicBarrier, 5x10E9 cfu/day
11353855|NCT02342262|Placebo Comparator|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
11353856|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
11353857|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
11353858|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
11353859|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
11353860|NCT02342236|Other|cemented|Primary hip arthroplasty with bone cement use.
11353861|NCT02342236|Other|cementless|Primary hip arthroplasty without bone cement use.
11353862|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.
~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.
~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.
~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.
~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
11353863|NCT02342210|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
11353864|NCT02342210|Other|Group-B - Delayed Intervention|3 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP).
11353865|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
11353866|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
11353867|NCT02342184|Experimental|GB-0998|
11353868|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
11353869|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
11353870|NCT02342158|Experimental|Locally advanced /metastatic cancer|
11353871|NCT02342145|Active Comparator|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
11353872|NCT02342145|Experimental|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
11353873|NCT02342132|Experimental|Respiratoy Therapy Devices|Non-Invasive Bipap Ventilator, Mechanical Insufflator-Exsufflator, and High Frequency Percussive Oscillator are the three respiratory therapy devices that all participants will be using in a random order, in three consecutive days, one device per day.
11353874|NCT02342119|Experimental|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
11353875|NCT02342119|Active Comparator|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
11353903|NCT02341898|Active Comparator|Optimized usual care|Provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives) only
11353904|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
11353876|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
11353877|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.
~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.
~Excellent pregnancy success rates."
11353878|NCT02342093|Active Comparator|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
11353879|NCT02342093|Active Comparator|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
11353880|NCT02342080|Experimental|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
11353881|NCT02342067|Experimental|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
11353882|NCT02342067|Experimental|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
11353883|NCT02342054|Experimental|MRI-TRUS fusion guided Single Frac HDR|Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)
11353884|NCT02342041|Placebo Comparator|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
11353885|NCT02342041|Placebo Comparator|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
11353886|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements
~20~60 years ago, female or males
~Agree participate the study and sign informed consent
~Has not received any treatment for OSA
~No obvious comorbidities (including autoimmune diseases)
~No history of sarcoidosis and tuberculosis
~No use of steroid and immunosuppressant"
11353887|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements
~20~60 years ago, female or males
~Agree participate the study and sign informed consent
~No obvious comorbidities (including autoimmune diseases)
~No history of sarcoidosis and tuberculosis
~No use of steroid and immunosuppressant"
11353888|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
11353889|NCT02342002|Experimental|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
11353890|NCT02342002|Placebo Comparator|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
11353891|NCT02341989|Experimental|Bleomycin-Etoposide-Cisplatin|One course of adjuvant BEP.
11353892|NCT02341989|Active Comparator|Carboplatin|One course of adjuvant carboplatin AUC7
11353893|NCT02341976|Other|Vibratory platform exercises|Vibratory platform exercises: different positions on a vibratory platform in different frequencies
11353894|NCT02341963|Experimental|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
11353895|NCT02341950|Experimental|SCI Hard|This arm plays the SCI HARD game
11353896|NCT02341950|No Intervention|Control|Plays an alternate, publicly available game
11353897|NCT02341924|Experimental|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.
~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
11353898|NCT02341924|Placebo Comparator|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
11353899|NCT02341911|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
11353900|NCT02341911|Active Comparator|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
11353901|NCT02341898|Experimental|Updated original programme|Educational programme for all nurses (90 min. single information session); training and structured support for nominated key nurses (one-day training workshop); provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
11353902|NCT02341898|Experimental|Concise updated programme|Training and structured support for nominated key nurses (one-day training workshop); nurses' training will be carried out by key nurses as facultative option; key nurses receive an additional train-the-trainer module to apply the educational programme; provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
11353906|NCT02341872|Active Comparator|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
11353907|NCT02341872|Experimental|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
11353908|NCT02341872|Experimental|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
11353909|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
11353910|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
11353911|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
11353912|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
11353913|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
11353914|NCT02341833|Active Comparator|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
11353915|NCT02341833|No Intervention|No intervention|No volatile anesthetics during organs procurement
11353916|NCT02341807|Experimental|Dose Group 1|Single, unilateral administration of a single low dose range of AAV2-hCHM.
11353917|NCT02341807|Experimental|Dose Group 2|Single, unilateral administration of a single high dose range of AAV2-hCHM.
11353918|NCT02341794|Experimental|Rosuvastatin|
11353919|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
11353920|NCT02341742||Patients|follow up of patients (children and adolescent) with inflammatory bowel disease in looking for the relationship between the bone mineral density and physical activity.
11353921|NCT02341729|Other|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.
~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
11353922|NCT02341716|Active Comparator|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
11353923|NCT02341716|Active Comparator|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
11353924|NCT02341716|Active Comparator|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
11353925|NCT02341703|Active Comparator|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.
~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
11353926|NCT02341703|Active Comparator|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.
~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
11353927|NCT02341690|Active Comparator|Control|Standard rehabilitation with exercise
11353928|NCT02341690|Experimental|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into
~a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.
~a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.
~After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).
~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
11353929|NCT02341677|Experimental|Biopsy|Single Arm Study. Biopsy Intervention.
11353972|NCT02341534|No Intervention|Control arm|Control group (standard of care)
11353973|NCT02341521|Experimental|OC000459 50 mg|OC000459 50 mg daily for 8 days
11353974|NCT02341508|Experimental|Lpathomab|0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
11353930|NCT02341651|Experimental|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
11353931|NCT02341651|No Intervention|Usual Care|No active intervention
11353932|NCT02341638|Experimental|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
11353933|NCT02341638|Experimental|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
11353934|NCT02341638|Experimental|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
11353935|NCT02341638|Experimental|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
11353936|NCT02341638|Experimental|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
11353937|NCT02341638|Experimental|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
11353938|NCT02341638|Experimental|Part A Panel 7: BMS-986141|Single dose by mouth as specified
11353939|NCT02341638|Experimental|Part A Panel 8: BMS-986141|Single dose by mouth as specified
11353940|NCT02341638|Experimental|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
11353941|NCT02341638|Experimental|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
11353942|NCT02341638|Experimental|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
11353943|NCT02341638|Experimental|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
11353944|NCT02341638|Experimental|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
11353945|NCT02341638|Experimental|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
11353946|NCT02341638|Experimental|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
11353947|NCT02341638|Placebo Comparator|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
11353948|NCT02341638|Experimental|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
11353949|NCT02341625|Experimental|Part 1: Ascending dose of BMS-986148|BMS-986148 Intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer. Alternate dose and schedules may be explored.
11353950|NCT02341625|Experimental|Part 2: Expansion dose of BMS-986148|BMS-986148 Intravenous injection of Maximum tolerated dose (MTD) on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
11353951|NCT02341625|Experimental|Part 3A: Ascending dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at increasing doses on specific days until the maximum tolerated dose is reached. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
11353952|NCT02341625|Experimental|Part 3B: Expansion dose of BMS-986148|Set dose of nivolumab and BMS-986148 intravenous injection at or below maximum tolerated dose on specific days. Five cancers will be studied in this part: mesothelioma, pancreatic, ovarian, gastric, and non-small cell lung cancer.
11353953|NCT02341612|Experimental|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
11353954|NCT02341612|Experimental|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
11353955|NCT02341612|Experimental|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
11353956|NCT02341612|Experimental|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
11353957|NCT02341612|Experimental|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
11353958|NCT02341599|Experimental|Group A: Healthy|Healthy participants with normal renal function (Stage 1: eGFR ≥90 mL/min/1.73m^2).
11353959|NCT02341599|Experimental|Group B: Mild RI|Participants with mild RI (Stage 2: eGFR ≥60 to <90 mL/min/1.73m^2).
11353960|NCT02341599|Experimental|Group C: Moderate RI|Participants with moderate RI (Stage 3: eGFR ≥30 to <60 mL/min/1.73m^2).
11353961|NCT02341599|Experimental|Group D: Severe RI|Participants with severe RI (Stage 4: eGFR <30 mL/min/1.73m^2) not receiving HD.
11353962|NCT02341599|Experimental|Group E: ESRD-HD|Participants with ESRD who are receiving HD for at least 3 months preceding the initial dose in this study (Stage 5).
11353963|NCT02341586|Experimental|Lucky Iron Fish|This group will receive a Lucky Iron Fish to use during cooking.
11353964|NCT02341586|Active Comparator|18 mg iron|This group will receive a daily oral iron supplement.
11353965|NCT02341586|Other|Control group|This group will receive nutrition education
11353966|NCT02341573|Experimental|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
11353967|NCT02341573|Active Comparator|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
11353968|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
11353969|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
11353970|NCT02341560|Sham Comparator|Sham|Sham injection procedure
11353971|NCT02341534|Other|BioMonitor arm|BioMonitor group (standard of care and implantation with investigational device)
11353976|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
11353977|NCT02341482|Experimental|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.
~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
11353978|NCT02341469|No Intervention|Standard-of-care|
11353979|NCT02341469|Experimental|integrated ediagnostic approach|
11353980|NCT02341456|Experimental|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
11353981|NCT02341456|Experimental|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
11353982|NCT02341456|Experimental|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg*min/mL)*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
11353983|NCT02341443|Experimental|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
11353984|NCT02341443|Active Comparator|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
11353985|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.
~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
11353986|NCT02341404|Experimental|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
11353987|NCT02341391|Experimental|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
11353988|NCT02341391|Experimental|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
11353989|NCT02341391|Experimental|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
11353990|NCT02341378|Experimental|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10^6 cells
11353991|NCT02341378|Experimental|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
11353992|NCT02341352|No Intervention|Control|Only behavioral education for Caregiver
11353993|NCT02341352|Experimental|fluoride varnish|fluoride varnish every 6 months
11353994|NCT02341352|Experimental|ImmunoglobulinY|anti-S.mutans Immunoglobulin yolk for everyday use
11353995|NCT02341352|Experimental|Probiotics|Probiotics use for 1 months
11353996|NCT02341339|Experimental|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
11353997|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2
~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.
~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
11353998|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3
~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.
~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
11353999|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3
~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.
~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
11354000|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
11354001|NCT02341300|Experimental|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
11354002|NCT02341300|Placebo Comparator|Aluminum Pot|12 inch nonstick aluminum fry pan
11354003|NCT02341287|Active Comparator|Warming hydrogel glove|"Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
~Warming hydrogel device"
11354104|NCT02340598|No Intervention|control|No intervention, just recording of risk factors and basal metabolic rate.
11354004|NCT02341287|Placebo Comparator|Non thermal hydrogel glove|"Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
~Non thermal hydrogel device"
11354005|NCT02341274|Active Comparator|Fresh Brand Name Tacrolimus (Prograf®)|Oral administration of 5 mg capsule of fresh brand name tacrolimus (Prograf®) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
11354006|NCT02341274|Active Comparator|Fresh Generic Tacrolimus|Oral administration of 5 mg capsule of fresh generic tacrolimus to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
11354007|NCT02341274|Active Comparator|Low Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 10-30% crystallized generic tacrolimus (Low Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
11354008|NCT02341274|Active Comparator|High Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 40-60% crystallized generic tacrolimus (High Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
11354009|NCT02341261|Experimental|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
11354010|NCT02341261|Experimental|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
11354011|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease [children who are found not to have Crohn's disease will not participate further].
~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day] per day"
11354012|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.
~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day]"
11354013|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
11354014|NCT02341235|Experimental|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
11354015|NCT02341235|Active Comparator|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
11354016|NCT02341222|Experimental|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
11354017|NCT02341222|Active Comparator|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
11354018|NCT02341209|Experimental|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
11354019|NCT02341196|Experimental|CEA + Polyester patch|225 Patients
11354020|NCT02341196|Experimental|CEA + Patch Polyurethane|225 Patients
11354021|NCT02341183|Active Comparator|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
11354022|NCT02341183|Active Comparator|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
11354023|NCT02341170|Experimental|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
11354024|NCT02341170|No Intervention|Observation|Observation
11354025|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
11354026|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
11354027|NCT02341131|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes & Reeder, 2005)
11354028|NCT02341131|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
11354029|NCT02341131|No Intervention|Healthy Controls|No intervention
11354030|NCT02341105|Active Comparator|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
11354031|NCT02341105|Active Comparator|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
11354032|NCT02341079|Active Comparator|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
11354033|NCT02341079|Experimental|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
11354034|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
11354035|NCT02341053|Other|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
11354036|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
11354037|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
11354038|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
11354039|NCT02341001|No Intervention|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
11354040|NCT02341001|Experimental|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
11354041|NCT02340988|Experimental|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
11354042|NCT02340988|Experimental|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
11354043|NCT02340975|Experimental|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
11354044|NCT02340975|Experimental|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
11354045|NCT02340975|Experimental|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
11354046|NCT02340975|Experimental|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
11354047|NCT02340975|Experimental|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
11354048|NCT02340975|Experimental|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
11354049|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
11354050|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
11354051|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:
~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².
~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.
~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
11354052|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:
~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².
~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
11354053|NCT02340936|Experimental|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
11354054|NCT02340936|Experimental|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
11354055|NCT02340936|Experimental|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
11354056|NCT02340936|Experimental|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
11354057|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
11354058|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
11354059|NCT02340910|Experimental|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
11354060|NCT02340910|Experimental|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
11354061|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
11354062|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
11354063|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
11354064|NCT02340884|Experimental|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
11354065|NCT02340884|No Intervention|Control|Standard psychosocial supportive care
11354066|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
11354067|NCT02340858|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
11354068|NCT02340858|No Intervention|Control|The patients without treatment
11354069|NCT02340845|Active Comparator|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
11354070|NCT02340845|Active Comparator|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
11354071|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
11354072|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
11354073|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
11354074|NCT02340793|Experimental|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
11354075|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
11354076|NCT02340767|No Intervention|No Device Clinicians|The clinicians will not receive any additional training.
11354077|NCT02340767|Experimental|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
11354078|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
11354218|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
11354079|NCT02340754|Experimental|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
11354080|NCT02340754|Active Comparator|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
11354081|NCT02340741|Other|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.
~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
11354082|NCT02340741|Other|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.
~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
11354083|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
11354084|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
11354085|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
11354086|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
11354087|NCT02340689||Genetic testing|Genetic Analysis
11354088|NCT02340676|Experimental|ECP plus IL-2|"Extracorporeal Photopheresis (ECP) standard-of-care
~Daily subcutaneous (SC) interleukin-2 (IL-2) (Proleukin®) during predetermined weeks of treatment cycle"
11354089|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
11354090|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
11354091|NCT02340650|Experimental|Bladder Cancer Patients|Subjects aged 18 years and older who have a suspicious bladder lesion or clinical presentation identified by a physician who recommends further evaluation with cystoscopy and bladder biopsy or who are undergoing cystoscopy as part of their routine clinical care.
11354092|NCT02340637|Experimental|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.
~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.
~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
11354093|NCT02340637|Active Comparator|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
11354094|NCT02340624|No Intervention|Control group|No intervention(control group)
11354095|NCT02340624|Experimental|condition 2|Intervention:Smokefreemoms texting
11354096|NCT02340624|Experimental|condition 3|Intervention: Quitline referral
11354097|NCT02340624|Experimental|condition 4|Intervention:Smokefreemoms texting and quitline referral
11354098|NCT02340624|Experimental|condition 5|Intervention: Brief intervention
11354099|NCT02340624|Experimental|condition 6|Intervention:Smokefreemoms texting and Brief intervention
11354100|NCT02340624|Experimental|condition 7|Intervention: Quitline referral and Brief intervention
11354101|NCT02340624|Experimental|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
11354102|NCT02340611|Experimental|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
11354103|NCT02340598|Experimental|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
11354105|NCT02340585|Experimental|Next Generation Neuroform Stent System|The Next Generation Stent System is a self-expanding, open cell, nitinol stent designed to provide support of the coil mass within the aneurysm and minimize stent deflection.
11354106|NCT02340572|Experimental|PRS-080#022-DP|hepcidin antagonist, single administration, ascending doses
11354107|NCT02340572|Placebo Comparator|PRS-080-Placebo#001|Comparotor treatment, single administration
11354108|NCT02340559|Experimental|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
11354109|NCT02340559|Active Comparator|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
11354110|NCT02340533|Experimental|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
11354111|NCT02340520|Experimental|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
11354112|NCT02340507|Experimental|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
11354113|NCT02340507|Experimental|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
11354114|NCT02340494|No Intervention|Control group|Women without access to the website.
11354115|NCT02340494|Experimental|Intervention group|Women with access to the website.
11354116|NCT02340481|Experimental|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
11354117|NCT02340481|Active Comparator|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
11354118|NCT02340455|Experimental|Pregabalin_male|
11354119|NCT02340455|Experimental|Pregabalin_female|
11354120|NCT02340455|Active Comparator|Placebo_male|
11354121|NCT02340455|Active Comparator|Placebo_female|
11354122|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
11354123|NCT02340442||High risk group|"40 pregnant women:
~20 Pregnant women with preeclampsia
~20 Obese pregnant women"
11354124|NCT02340442||Healthy control subjects|40 subjects
11354125|NCT02340429|Experimental|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
11354126|NCT02340429|No Intervention|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
11354127|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
11354128|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
11354129|NCT02340390|Experimental|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
11354130|NCT02340390|Experimental|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
11354131|NCT02340364|Experimental|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
11354132|NCT02340364|Active Comparator|Educational Control Arm|- 208 patients randomized to self-care education alone.
11354597|NCT02337179|Experimental|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
11354133|NCT02340351|Active Comparator|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
11354134|NCT02340351|Active Comparator|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
11354135|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
11354136|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
11354137|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
11354138|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
11354139|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
11354140|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
11354141|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
11354142|NCT02340325|Other|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
11354143|NCT02340325|Other|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
11354144|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.
~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.
~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
11354145|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.
~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.
~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
11354146|NCT02340273|Experimental|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
11354147|NCT02340273|Placebo Comparator|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
11354148|NCT02340260|Other|High intensity interval training|High intensity interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 10x1-minute intervals at 90 % of HRmax, with 75 seconds of active recovery at 70 % of HRmax between each interval. Exercise is completed with a three minute cool down. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
11354149|NCT02340260|Other|Sprint interval training|Sprint interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 2x20 seconds of maximum intensity intervals, with 3 minutes and 20 seconds of active recovery at 70 % of HRmax between each interval, followed by 3 minutes cooling down at the same intensity. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
11354150|NCT02340247|Experimental|Placebo|150mL water
11354151|NCT02340247|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
11354152|NCT02340247|Experimental|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
11354153|NCT02340234|Experimental|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
11354154|NCT02340234|Experimental|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
11354155|NCT02340234|Experimental|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
11354215|NCT02339792|Other|Intervention|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
11354156|NCT02340234|Placebo Comparator|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
11354157|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
11354158|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
11354159|NCT02340208|Experimental|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
11354160|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
11354161|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
11354162|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B
~8 patients with moderate renal impairment"
11354163|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B
~8 patients with mild renal impairment"
11354164|NCT02340182|Experimental|Antibiotics|"All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):
~Vancomycin 250mg 3dd2;
~Ciprofloxacin 500mg 2dd1;
~Metronidazole 500mg 3dd1."
11354165|NCT02340169|Experimental|Topicort® Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25%, twice a day for 28 days
11354166|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
11354167|NCT02340143|Active Comparator|Control|Marketed partially hydrolyzed cow's milk protein infant formula
11354168|NCT02340143|Experimental|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
11354169|NCT02340130|Experimental|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
11354170|NCT02340130|Experimental|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
11354171|NCT02340117|Experimental|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. In week 1, SGT-53, at 2.4 mg DNA/infusion, will be administered on day 1 and day 5, 1000 mg/m² gemcitabine and 125 mg/m² nab-paclitaxel will be administered on day 3 of each week except week 4. If the combination is well-tolerated, starting at week 2, 3.6 mg DNA/infusion of SGT-53 will be administered bi-weekly on days 1 and 5 in weeks 2-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive one additional course (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on gemcitabine/nab-paclitaxel alone at investigator discretion.
11354172|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
11354173|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
11354174|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
11354175|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
11354176|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
11354177|NCT02340065|Active Comparator|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
11354178|NCT02340065|Active Comparator|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
11354179|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
11354180|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
11354181|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
11354182|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
11354183|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
11354184|NCT02340039|Experimental|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
11354185|NCT02340039|Experimental|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
11354186|NCT02340039|Placebo Comparator|Control drink|No polyphenols delivered in a low sugar fruit drink
11354216|NCT02339792|Other|Control|e-learning program of medical education, focused on teaching only geriatric pharmacological notions (GPNs)
11354217|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
11355391|NCT02332044|Experimental|Erdosteine 300mg + Bepotastine besilate 10mg|
11354187|NCT02340026|Experimental|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
11354188|NCT02340026|Experimental|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
11354189|NCT02340013|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
11354190|NCT02340013|No Intervention|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
11354191|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
11354192|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
11354193|NCT02339974|Experimental|Severe Tricuspid Regurgitation|
11354194|NCT02339948|Active Comparator|SBRT only|Patients assigned to this arm receive 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
11354195|NCT02339948|Active Comparator|IMRT plus SBRT Boost|Patients assigned to this arm receive 1.8 Gy per fraction for 25 fractions over 5 weeks for a total of 45.0 Gy followed by an SBRT boost of 5.5 Gy per fraction for 4 fractions after IMRT for a total of 22.0 Gy
11354196|NCT02339935|Experimental|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
11354197|NCT02339935|Other|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
11354198|NCT02339922|Experimental|Treatment (ixazomib citrate, rituximab)|Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.
11354199|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
11354200|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
11354201|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
11354202|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
11354203|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
11354204|NCT02339870|Experimental|Arm I (expressive disclosure)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.
11354205|NCT02339870|Experimental|Arm II (benefit finding)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.
11354206|NCT02339870|Sham Comparator|Arm III (control)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
11354207|NCT02339857||No-touch vein grafts to LAD|
11354208|NCT02339844|Active Comparator|antipsychotic treatment|individual doses of aripiprazole for all patients
11354209|NCT02339844|No Intervention|no treatment|no treatment for all healthy controls
11354210|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
11354211|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
11354212|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
11354213|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
11354214|NCT02339805|Experimental|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
11354219|NCT02339766|Sham Comparator|Group 1|Group 1 will receive intrathecal morphine co-administered with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Sham Block be done with 25 mL of saline per side.
11354220|NCT02339766|Active Comparator|Group 2|Group 2 will receive an equivalent volume of intrathecal saline co-administered with the spinal anesthetic. After surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
11354221|NCT02339766|Active Comparator|Group 3|Group 3 will receive will receive intrathecal morphine with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
11354222|NCT02339753|Experimental|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days
~Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days
~MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days
~MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days
~MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
11354223|NCT02339740|Experimental|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
11354224|NCT02339727|Active Comparator|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
11354225|NCT02339727|Active Comparator|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
11354226|NCT02339714|Experimental|Acupuncture combined moxibustion|Acupuncture at Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Needle warming moxibustion at Dazhui(Du14). Patients will be treated once per day for 30 min, 3 times in a weeks for 4 weeks.
11354227|NCT02339714|Active Comparator|loratadine|Loratadine taken orally, 10mg/day in the morning
11354228|NCT02339701|Other|IMRT|Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.
11354229|NCT02339701|Other|SBRT|Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.
11354230|NCT02339688|Other|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
11354231|NCT02339675|Other|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
11354232|NCT02339662|Active Comparator|gabapentin|900 mg per day total, 3 pills of 300mg.
11354233|NCT02339662|Active Comparator|amitriptyline|20 mg total, 1pill
11354234|NCT02339649|Other|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).
~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
11354235|NCT02339649|Other|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:
~Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU
~Duration of ICU stay must be a minimum of 24 hours.
~Mini-Mental State Examination (MMSE) Score of 25 or above
~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
11354236|NCT02339649|Other|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.
~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
11354237|NCT02339636||case group|100 patients with vulgaris psoriasi without arthritis
11354238|NCT02339636||control group|100 age-matched patients with other skin diseases without arthritis
11354239|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :
~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )
~Cervical dilataion >1cm, &/or
~Cervical effacement ≥ 80%"
11354240|NCT02339610||ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:
~(CR FB, CR RP, PS FB, PS RP)."
11354241|NCT02339597|Experimental|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
11354242|NCT02339597|Experimental|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
11354243|NCT02339584|Experimental|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
11354244|NCT02339584|Active Comparator|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
11354245|NCT02339571|Experimental|Arm A (nivolumab, ipilimumab, sargramostim)|"INDUCTION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day 1, and sargramostim SC on days 1-14. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive nivolumab and sargramostim as in Induction therapy. Patients with PR, SC, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity."
11354331|NCT02338960|Experimental|Bremelanotide|Subjects will self-administer a fixed dose of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
11354246|NCT02339571|Experimental|Arm B (nivolumab, ipilimumab)|"INDUCTION THERAPY: Patients receive nivolumab and ipilimumab as in Arm I. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive nivolumab as in Induction therapy. Patients with PR, SD, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity."
11354247|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11354248|NCT02339545||All Enrolled Subjects|All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
11354249|NCT02339532|Experimental|TOP2A amplified|"If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w
~5-Fluorouracil (5-FU) 500 mg/m²
~Epirubicin 100 mg/m²
~Cyclophosphamide 500 mg/m²
~Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:
~Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
~DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w"
11354250|NCT02339532|Experimental|TOP2A not amplified|"If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles
~Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.
~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
~DOCETAXEL 75 mg/m² IV q3w
~CARBOPLATIN AUC 6 IV q3w
~The Calvert formula will be used to calculate the dose of carboplatin:
~Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25] Dose (mg) = 6 x [GFR mL/min + 25] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg."
11354251|NCT02339519|Active Comparator|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
11354252|NCT02339519|Active Comparator|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
11354253|NCT02339519|Active Comparator|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
11354254|NCT02339506|Active Comparator|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
11354255|NCT02339506|Placebo Comparator|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
11354256|NCT02339493|Experimental|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
11354257|NCT02339493|No Intervention|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
11354258|NCT02339480|No Intervention|Healthy volunteers|Healthy volunteers'hypothalamus picture of fMRI will compare with Obesity group' , no intervention and remaining unchanged lifestyle.
11354259|NCT02339480|Active Comparator|Obesity group|An intervention group of patients is put on a waiting list for massage therapy.Observing the Curative effect and hypothalamus picture of fMRI compare with healthy volunteers
11354260|NCT02339467|Experimental|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
11354261|NCT02339467|Active Comparator|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
11354262|NCT02339454|Active Comparator|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.
~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).
~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).
~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
11354263|NCT02339454|Placebo Comparator|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
11354264|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
11354265|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
11354266|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
11354267|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
11354268|NCT02339428|Experimental|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
11354269|NCT02339428|Placebo Comparator|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
11354270|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
11354271|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
11354272|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
11354273|NCT02339376|Experimental|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
11354274|NCT02339376|Experimental|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
11354275|NCT02339376|Sham Comparator|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
11354332|NCT02338960|Placebo Comparator|Placebo Comparator|Subjects will self-administer a fixed dose of placebo subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
11354598|NCT02337166|Active Comparator|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
11354276|NCT02339363|Experimental|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
11354277|NCT02339363|Experimental|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
11354278|NCT02339363|No Intervention|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
11354279|NCT02339350|No Intervention|Rapid early responder group|"RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol
~RER Interim Maintenance #1
~RER Delayed Intensification
~RER Interim Maintenance #2
~RER Maintenance (12 weeks=84 days)"
11354280|NCT02339350|Experimental|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL
~1. SER Consolidation
~Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1
~high dose methotrexate included
~Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1
~Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2
~high dose methotrexate included
~Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2
~Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance
~Intrathecal triple chemotherapy at d0"
11354281|NCT02339337|Experimental|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, < 400000 IU/mL) and RVR (defined asHCV RNA <50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
11354282|NCT02339337|Active Comparator|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
11354283|NCT02339324|Experimental|This study has one arm that consists of 3 phases or steps.|"Induction phase (first 6 weeks): Pembrolizumab and High Dose IFNα-2b (HDI) Pembrolizumab I.V. every 3-4 weeks for 2 doses concurrently with HDI I.V. x 5 consecutive days every week for 4 weeks, followed by S.C. every other day 3x each week for 2 weeks.
~Surgery phase (week 6-8).
~Maintenance phase (following recovery from surgery): Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD (e.g. M,W,F) TIW every week for 46 additional weeks"
11354284|NCT02339298|Active Comparator|Music group|music application
11354285|NCT02339298|Sham Comparator|Control group|only headphones
11354286|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
11354287|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
11354288|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
11354289|NCT02339272||NOA|Infertile males with non obstructive azoospermia
11354290|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
11354291|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
11354292|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
11354293|NCT02339246|Active Comparator|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
11354294|NCT02339246|Active Comparator|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
11354295|NCT02339233|Experimental|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord
11354296|NCT02339220|Experimental|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
11354297|NCT02339220|Experimental|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
11354298|NCT02339220|Active Comparator|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
11354299|NCT02339220|Active Comparator|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
11354300|NCT02339207|Placebo Comparator|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
11354301|NCT02339207|Experimental|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
11354333|NCT02338947|Active Comparator|Off-pump coronary-artery bypass grafting - OPCAB|"Pre-frail and frail patients will be randomly assigned to OPCAB after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
11354513|NCT02337738|Experimental|TVP-1012 0.5mg|TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
11354302|NCT02339194|Experimental|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:
~Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.
~Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.
~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.
~Insertion of finished dentures."
11354303|NCT02339194|No Intervention|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:
~Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.
~Mandibular second impression with border molding using compound and impression rubber in custom tray.
~Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.
~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.
~Finished dentures insertion."
11354304|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11354305|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
11354306|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
11354307|NCT02339142|Experimental|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks
~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
11354308|NCT02339142|Active Comparator|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
11354309|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
11354310|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
11354311|NCT02339116|Experimental|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):
~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
11354312|NCT02339116|Active Comparator|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1
~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):
~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
11354313|NCT02339103|No Intervention|Shivering only|Pt placed in sleeping bag and warmed by shivering only
11354314|NCT02339103|Experimental|Warmed IV fluids|2 Liter of 42 degree celsius normal saline
11354315|NCT02339103|Experimental|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
11354316|NCT02339090|Experimental|somavaratan|somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
11354317|NCT02339090|Active Comparator|Daily rhGH|Daily recombinant growth hormone therapy administered subcutaneously every day
11354318|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
11354319|NCT02339051|Experimental|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
11354320|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
11354321|NCT02339025||Tricare Participants|From WRNMC
11354322|NCT02339012||20-34|age
11354323|NCT02339012||35-49|age
11354324|NCT02339012||50-64|age
11354325|NCT02339012||65-79|age
11354326|NCT02339012||80+|age
11354327|NCT02338999|Experimental|1|Pioglitazone versus placebo crossover
11354328|NCT02338999|Experimental|2|Placebo versus Pioglitazone crossover then radiation
11354329|NCT02338986||Healthy Volunteers|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
11354330|NCT02338973|Experimental|Interferon Gamma-1b|Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks
11354334|NCT02338947|Active Comparator|On-pump coronary-artery bypass grafting - CABG|"Pre-frail and frail patients will be randomly assigned to CABG after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
11354335|NCT02338934|Experimental|Cinacalcet with Vitamin D arm|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
11354336|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor
~Sitagliptin"
11354337|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors
~Dapagliflozin"
11354338|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist
~Lobeglitazone"
11354339|NCT02338908|Experimental|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
11354340|NCT02338908|Active Comparator|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
11354341|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
11354342|NCT02338882|Experimental|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
11354343|NCT02338882|Active Comparator|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
11354344|NCT02338869|Experimental|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
11354345|NCT02338869|No Intervention|Usual care Control group|Participants receive usual rehabilitation and care.
11354346|NCT02338856|Experimental|MB12066 200mg|
11354347|NCT02338856|Placebo Comparator|Placebo|
11354348|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
11354349|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
11354350|NCT02338830|Active Comparator|Progesterone group|Women received vaginal progesterone suppositories
11354351|NCT02338830|No Intervention|No treatment group|Women received no treatment
11354352|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
11354353|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
11354354|NCT02338804|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
11354355|NCT02338804|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
11354356|NCT02338791|Experimental|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
11354357|NCT02338778|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
11354358|NCT02338778|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
11354359|NCT02338765|Experimental|Buddy|Physical activity plus having a buddy
11354360|NCT02338765|Active Comparator|Control|Physical activity only
11354361|NCT02338752|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
11354362|NCT02338752|Active Comparator|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
11354363|NCT02338739|Active Comparator|REC; Outreach if Failure|
11354364|NCT02338739|Active Comparator|REC; SMS + Voucher if Failure|
11354365|NCT02338739|Active Comparator|REC; Navigator if Failure|
11354366|NCT02338739|Active Comparator|SMS; Outreach if Failure|
11354367|NCT02338739|Active Comparator|SMS; Outreach if Failure; Stop SMS if Success|
11354368|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure|
11354369|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure; Stop SMS if Success|
11354370|NCT02338739|Active Comparator|SMS; Navigator if Failure|
11354371|NCT02338739|Active Comparator|SMS; Navigator if Failure; Stop SMS if Success|
11354372|NCT02338739|Active Comparator|Voucher; Outreach if Failure|
11354373|NCT02338739|Active Comparator|Voucher; Outreach if Failure; Stop Voucher if Success|
11354374|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure|
11354375|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
11354376|NCT02338739|Active Comparator|Voucher; Navigator if Failure|
11354377|NCT02338739|Active Comparator|Voucher; Navigator if Failure; Stop Voucher if Success|
11354510|NCT02337764|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.
11354378|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
11354379|NCT02338700|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
11354380|NCT02338700|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
11354381|NCT02338687|Active Comparator|Education|Educational sessions
11354382|NCT02338687|Experimental|Education plus supplement|Educational sessions and 500 mg calcium per day
11354383|NCT02338674|Experimental|COM|COM group receives combination therapy of tenofovir and telbivudine (TDF and LdT) for at least 48 weeks
11354384|NCT02338674|Active Comparator|TDF|TDF group receives single therapy of tenofovir (TDF) for at least 48 weeks
11354385|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
11354386|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
11354387|NCT02338635|Experimental|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
11354388|NCT02338635|Placebo Comparator|Placebo group|Placebo drug 1 tablet tid for 6 months
11354389|NCT02338622|Experimental|Schedule A: 4 days on, 3 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 4 days on, 3 days off
~Schema for dose escalation in schedule A (4-days-on, 3-days-off AZD5363)
~-1. Olaparib: 200mg, AZD5363 240mg
~Olaparib: 300mg, AZD5363 320mg
~Olaparib: 300mg, AZD5363 400mg
~Olaparib: 300mg, AZD5363 480mg"
11354390|NCT02338622|Experimental|Schedule B: 2 days on, 5 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 2 days on, 5 days off
~Schema for dose escalation in schedule B (2-days-on, 5-days-off AZD5363)
~-1. Olaparib: 200mg, AZD5363 400mg
~Olaparib: 300mg, AZD5363 480mg
~Olaparib: 300mg, AZD5363 560mg
~Olaparib: 300mg, AZD5363 640mg"
11354391|NCT02338609|Experimental|Everolimus|All patients will have been previously treated with everolimus as part of CRAD001M2301. Continued treatment with everolimus is allowed but not required for participation in this study. However, the physician may choose to place the patient on another treatment.
11354392|NCT02338609|Experimental|Physician Choice|
11354393|NCT02338596|Experimental|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
11354394|NCT02338596|Active Comparator|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
11354395|NCT02338570|Other|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
11354396|NCT02338557|Experimental|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
11354397|NCT02338557|Active Comparator|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
11354398|NCT02338531|Experimental|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
11354399|NCT02338518|Experimental|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
11354400|NCT02338518|Active Comparator|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
11354401|NCT02338505|Experimental|Telelap ALF-X in obese patients with gynecological disease|
11354402|NCT02338492|Experimental|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
11354403|NCT02338466|Placebo Comparator|rt-PA|"Patients treated by thrombolysis with rt -PA within 4h30 of the onset of symptoms to a proximal middle cerebral artery occlusion visible on a MRI 1 are pre- included. A second MRI ( IRM2 ) is performed between 1 hour and 1.5 hours after administration of rt-PA in the usual way .
~After the treatment by rt-PA, if there is no recanalization (TIMI score: 0,1, 2a), the patient is included. A patient included will be randomized either in the arm rt-PA treatment only or in the arm rt-PA + tenecteplase treatment. If he is included in the arm rt-PA only, he will not receive any other treatment for the study."
11354404|NCT02338466|Active Comparator|rt-PA + tenecteplase|"If patient is in the arm rt-PA + tenecteplase, he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications."
11354405|NCT02338453|Active Comparator|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
11354406|NCT02338453|Placebo Comparator|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
11354511|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
11354407|NCT02338440|Experimental|lipoprostaglandin E1 treatment arm|"lipoprostaglandin E1 1mcg/kg/day, continuous infusion
~lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
11354408|NCT02338427|Experimental|proteomic|
11354409|NCT02338414|Other|Romiplostim|Patients receiving romiplostim due to ITP
11354410|NCT02338401|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
11354411|NCT02338401|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
11354412|NCT02338388|Active Comparator|Single-layer unlocked closure|
11354413|NCT02338388|Active Comparator|Single-layer locked closure|
11354414|NCT02338388|Active Comparator|Double-layer closure|The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture.
11354415|NCT02338375|Experimental|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
11354416|NCT02338375|Active Comparator|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
11354417|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
11354418|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
11354419|NCT02338349|Experimental|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.
~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.
~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.
~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
11354420|NCT02338336|Placebo Comparator|Placebo|Placebo
11354421|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
11354422|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
11354423|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
11354424|NCT02338323|Experimental|Febuxostat|take orally, 40mg per day, for 1 year
11354425|NCT02338323|Experimental|Benzbromarone|take orally, 50mg per day, for 1 year
11354426|NCT02338310|No Intervention|No Aromatase Inhibitor|No aromatase inhibitor given around the time of surgery
11354427|NCT02338310|Experimental|Aromatase Inhibitor|Aromatase Inhibitor given perioperatively for 4 weeks (two weeks before and two weeks after surgery) Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day)
11354428|NCT02338297|Experimental|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
11354429|NCT02338297|Active Comparator|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
11354430|NCT02338271|Other|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study
~: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
11354431|NCT02338258|Experimental|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
11354432|NCT02338258|Placebo Comparator|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
11354433|NCT02338245|Experimental|Treatment Arm A|ASLAN001 + Capecitabine
11354434|NCT02338245|Active Comparator|Treatment Arm B|Lapatinib + Capecitabine
11354435|NCT02338232|Experimental|160 mg Telmisartan|60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days
11354436|NCT02338219|Active Comparator|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
11354437|NCT02338219|Active Comparator|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
11354438|NCT02338219|Active Comparator|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
11354439|NCT02338206|Active Comparator|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
11354440|NCT02338206|No Intervention|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
11354441|NCT02338193|Experimental|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
11354442|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
11354443|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
11354444|NCT02338180|No Intervention|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
11354445|NCT02338180|Experimental|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
11354446|NCT02338180|Experimental|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
11354447|NCT02338167||Advanced/metastatic breast cancer|3,500 patients with locally advanced, inoperable/metastatic breast cancer in any line of treatment (e.g. 1st, 2nd, 3rd, or ≥ 4th line).
11354448|NCT02338167||Early breast cancer|10,000 patients with breast cancer in the neoadjuvant and adjuvant (early breast cancer) setting independent of treatment regimen.
11354449|NCT02338141|Experimental|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
11354450|NCT02338141|Active Comparator|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
11354451|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
11354452|NCT02338102|Experimental|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
11354453|NCT02338102|No Intervention|Control Group|Subjects randomized to this arm receive no intervention.
11354454|NCT02338089|No Intervention|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
11354455|NCT02338089|Active Comparator|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
11354456|NCT02338089|Active Comparator|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
11354457|NCT02338076|Experimental|Interventional arm|petrolatum application under occlusion
11354458|NCT02338063|Experimental|1|Virtual Reality
11354459|NCT02338063|Experimental|2|Health Promotion
11354460|NCT02338050|Experimental|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
11354461|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11354462|NCT02338024|Experimental|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
11354463|NCT02338024|No Intervention|Standard of care|
11354464|NCT02338011|Experimental|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
11354465|NCT02338011|Experimental|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
11354466|NCT02337998|Experimental|Healthy men|each individual will serve as his own control by comparing baseline values to post intervention values
11354467|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
11354468|NCT02337972|Experimental|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
11354469|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
11354470|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
11354471|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
11354512|NCT02337738|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
11354595|NCT02337192|Experimental|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
11354472|NCT02337946|Active Comparator|Group A|Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV), at Day 1, oxaliplatin (OXA) 85 mg/m^2, DIV, at Day 1, levofolinate (l LV) 200 mg/m^2, DIV, at Day 1, fluorouracil (5-FU) 400 mg/m^2, intravenous (IV) at Day 1, 5-FU 2400 mg/m^2, continuous intravenous infusion (CIV), at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
11354473|NCT02337946|Experimental|Group B|Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
11354474|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
11354475|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
11354476|NCT02337907|Placebo Comparator|Placebo comparator|
11354477|NCT02337907|Experimental|BI 409306 dose 1|
11354478|NCT02337907|Experimental|BI 409306 dose 2|
11354479|NCT02337907|Experimental|BI 409306 dose 3|
11354480|NCT02337907|Active Comparator|Active Comparator Donepezil|
11354481|NCT02337907|Experimental|BI 409306 dose 4|
11354482|NCT02337894|Experimental|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
11354483|NCT02337894|Placebo Comparator|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
11354484|NCT02337881|Active Comparator|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
11354485|NCT02337881|Active Comparator|nifedipen only|nifedipine alone in the same regimen and duration described before.
11354486|NCT02337868|Experimental|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
11354487|NCT02337868|Experimental|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
11354488|NCT02337868|Experimental|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
11354489|NCT02337868|Experimental|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
11354490|NCT02337855|Experimental|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
11354491|NCT02337855|Experimental|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
11354492|NCT02337855|Placebo Comparator|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
11354493|NCT02337855|Experimental|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
11354494|NCT02337855|Experimental|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
11354495|NCT02337855|Placebo Comparator|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
11354496|NCT02337855|Experimental|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
11354497|NCT02337855|Experimental|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
11354498|NCT02337855|Placebo Comparator|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
11354499|NCT02337842|Experimental|Cohort 1|N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units and N=1 single oral dose Placebo.
11354500|NCT02337842|Experimental|Cohort 2|N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units and N=1 single oral dose of Placebo.
11354501|NCT02337842|Experimental|Cohort 4|N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo
11354502|NCT02337842|Experimental|Cohort 3|N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units and N=2 single oral dose of Placebo
11354503|NCT02337829|Experimental|Arm A|to undergo superficial lymph node biopsies
11354504|NCT02337829|Experimental|Arm B|to undergo bone marrow biopsies
11354505|NCT02337816||Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
11354506|NCT02337816||Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
11354507|NCT02337803|Experimental|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
11354508|NCT02337803|Active Comparator|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
11354509|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
11354596|NCT02337192|Experimental|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
11354514|NCT02337738|Placebo Comparator|Placebo|One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
11354515|NCT02337725|Experimental|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
11354516|NCT02337725|Placebo Comparator|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
11354517|NCT02337712|Experimental|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and four cycles of etoposide and cisplatin
11354518|NCT02337712|Active Comparator|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and four cycles of etoposide and cisplatin
11354519|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
11354520|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
11354521|NCT02337686|Experimental|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11354522|NCT02337660|Experimental|Healthy, lean|"15 healthy, lean subjects.
~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
11354523|NCT02337660|Experimental|Obese, otherwise healthy|"15 obese, otherwise healthy subjects
~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
11354524|NCT02337647|Other|DCDC app|Subjects will evaluate the DCDC app
11354525|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
11354526|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
11354527|NCT02337621||pectus excavatum surgical candidates|Any person who is eligible to undergo the Nuss procedure for surgical correction of pectus excavatum
11354528|NCT02337608|Experimental|GLPG1205 100mg QD|GLPG1205 100mg daily dosing in the morning
11354529|NCT02337608|Placebo Comparator|Placebo|Placebo daily dosing in the morning
11354530|NCT02337582|Active Comparator|Intervention|
11354531|NCT02337582|Other|Control|
11354532|NCT02337569|Experimental|NPC-02|Oral dose
11354533|NCT02337569|Placebo Comparator|Placebo|Oral dose
11354534|NCT02337556|Experimental|Intervention Group|Peptamen Bariatric
11354535|NCT02337556|Active Comparator|Control Group|Replete
11354536|NCT02337543|Experimental|Active: NEO6860|NEO6860 suspension is the drug under evaluation
11354537|NCT02337543|Placebo Comparator|placebo|Placebo matching NEO6860 suspension formulation
11354538|NCT02337530|Active Comparator|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m^2 & Cisplatin or Carboplatin*: AUC6: 75mg/m^2 given on day 1 Schedule = q 21 days
~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
11354539|NCT02337530|Active Comparator|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days
~**Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
11354540|NCT02337530|Active Comparator|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days
~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
11354541|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
11354542|NCT02337504|No Intervention|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
11354543|NCT02337504|Active Comparator|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
11354544|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle
~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
11354545|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle
~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
11354546|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle
~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
11354547|NCT02337478|Experimental|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11354548|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
11354549|NCT02337452||Observational (family outreach program)|Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.
11354550|NCT02337439|Experimental|Sensory Information Processing Training|Computerized training designed to improve sensory processing
11354551|NCT02337439|Active Comparator|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
11354552|NCT02337426|Experimental|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions
~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
11354553|NCT02337413|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
11354554|NCT02337413|Other|Urothearpy alone|This group will receive standard behavioral urotherapy alone
11354555|NCT02337400|Experimental|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
11354556|NCT02337400|Active Comparator|Counseling Interview|15 minute counseling interview
11354557|NCT02337400|No Intervention|Waiting Control Group|
11354558|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
11354559|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
11354560|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
11354561|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
11354562|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
11354563|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
11354564|NCT02337348|Experimental|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
11354565|NCT02337348|Active Comparator|Conventional coronary intervention|Coronary angiography
11354566|NCT02337322|Active Comparator|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
11354567|NCT02337322|Active Comparator|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
11354568|NCT02337309|Other|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
11354569|NCT02337296|Other|Phase 1 - Intervention|Five patients will be enrolled consecutively for the ADHERE intervention and be followed in order to refine the intervention as needed. This permits the investigation of the process of change at baseline, after the intervention, and across the phases.
11354570|NCT02337296|No Intervention|Phase 2 - Control Group|Following completion of Phase 1 and prior to initiation of enrollment in the intervention group, patients will be enrolled in the control group and will receive usual care.
11354571|NCT02337296|Experimental|Phase 2 - Intervention Group|Following enrollment of all control group patients, the intervention group will be recruited and enrolled and the ADHERE intervention will be conducted by the trained APRN interventionist at cancer center.
11354572|NCT02337283|Experimental|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
11354573|NCT02337283|Placebo Comparator|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
11354574|NCT02337283|Experimental|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
11354575|NCT02337283|Experimental|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
11354576|NCT02337283|Experimental|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
11354577|NCT02337283|Experimental|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
11354578|NCT02337283|Experimental|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
11354579|NCT02337270|Experimental|Group 1 Aerosol|Receive 10^6 Ad5Ag85A by aerosol at day 0
11354580|NCT02337270|Experimental|Group 2 Aerosol|Receive 2x10^6 Ad5Ag85A by aerosol at day 0
11354581|NCT02337270|Experimental|Group 3 Intramuscular|Receive 10^8 Ad5Ag85A by intramuscular injection at day 0
11354582|NCT02337257|Active Comparator|cholecalciferol|Subjects will take 4000 IU per day for 30 days
11354583|NCT02337257|Placebo Comparator|Placebo|Subjects will take placebo everyday for 30 days
11354584|NCT02337231|Other|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
11354585|NCT02337231|Other|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
11354586|NCT02337231|Other|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
11354587|NCT02337218|Active Comparator|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
11354588|NCT02337218|Sham Comparator|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
11354589|NCT02337205|Experimental|KX2-391 Ointment|
11354590|NCT02337192|Experimental|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
11354591|NCT02337192|Experimental|Group 2|Mouthwash with Swish with Curcumin
11354592|NCT02337192|Experimental|Group 3|Moutwash with Swish with Curcumin + SDS
11354593|NCT02337192|Experimental|Group 4|Experiment use dental irradiation with blue light (LED) only.
11354594|NCT02337192|Experimental|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
11355744|NCT02329769|Experimental|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
11354599|NCT02337166|Experimental|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
11354600|NCT02337140|Experimental|Pacemaker|Patient who have been implanted with a pacemaker after TAVI
11354601|NCT02337140|Active Comparator|No Pacemaker|Patient who have not been implanted with a pacemaker after TAVI
11354602|NCT02337127|Active Comparator|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
11354603|NCT02337127|No Intervention|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
11354604|NCT02337114|Experimental|Intervention group|Treatment as Usual and Acceptance & Commitment Therapy
11354605|NCT02337114|Other|Comparison group|Treatment as Usual
11354606|NCT02337101|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
11354607|NCT02337101|Experimental|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
11354608|NCT02337088|Active Comparator|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
11354609|NCT02337088|Experimental|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
11354610|NCT02337075|Experimental|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
11354611|NCT02337075|Active Comparator|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
11354612|NCT02337062|Experimental|APD421 + standard anti-emetic|Single dose of IV APD421
11354613|NCT02337062|Placebo Comparator|Placebo + standard anti-emetic|Single dose of IV placebo
11354614|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
11354615|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
11354616|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
11354617|NCT02337036|Experimental|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
11354618|NCT02337023||healthy subjects|
11354619|NCT02337023||patients with Kleine-Levin Syndrome|
11354620|NCT02337010|Active Comparator|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
11354621|NCT02337010|Experimental|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
11354622|NCT02336997|Experimental|FAT-GRAFT|Fat graft transplantation
11354623|NCT02336997|Experimental|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
11354624|NCT02336997|Placebo Comparator|CONTROL|Same volume saline injection
11354625|NCT02336984|Experimental|Combination Therapy|Combination Therapy: HER-2 pulsed DC1 vaccine with trastuzumab and pertuzumab.
11354626|NCT02336971|Experimental|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.
~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
11354627|NCT02336971|Experimental|Prolonged Exposure|"PE for combat-related stress disorders [13-14] serves as the comparison treatment.
~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE [1-3] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
11354628|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
11354629|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
11354630|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
11354631|NCT02336919|Experimental|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
11354632|NCT02336919|No Intervention|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
11354859|NCT02335255|Active Comparator|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
11354633|NCT02336906|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
11354634|NCT02336906|Other|Urotherapy alone|This group will receive standard behavioral urotherapy alone.
11354635|NCT02336893|No Intervention|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
11354636|NCT02336893|Experimental|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
11354637|NCT02336880|Experimental|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
11354638|NCT02336880|No Intervention|Control group|Care as usual
11354639|NCT02336867|Experimental|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
11354640|NCT02336867|Other|Control group|advancement flap technique
11354641|NCT02336854|Experimental|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
11354642|NCT02336854|Active Comparator|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I & II D1(crossover)
11354643|NCT02336841|Experimental|Intervention|Participants in this condition will receive the guided self-help intervention.
11354644|NCT02336841|Active Comparator|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
11354645|NCT02336828||MEWS alarm and mortality|Reach MEWS Alarm, Not reach MEWS Alarm, With 7 day mortality, Without 7 day mortality
11354646|NCT02336815|Experimental|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
11354647|NCT02336815|Experimental|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
11354648|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
11354649|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
11354650|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
11354651|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
11354652|NCT02336789|Placebo Comparator|placebo|250 ml of normal saline (sham transplantation).
11354653|NCT02336789|Active Comparator|intervention|250 ml of diluted fecal material prepared from a screened donor
11354654|NCT02336776|Experimental|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
11354655|NCT02336776|No Intervention|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
11354656|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
11354657|NCT02336750|Experimental|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
11354658|NCT02336750|Experimental|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
11354659|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.
~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
11354660|NCT02336724|Experimental|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
11354661|NCT02336711|Experimental|Dose escalation|Dose escalation
11354662|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
11354663|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
11354664|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
11354665|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
11354666|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
11354667|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
11354708|NCT02336490|Active Comparator|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
11354709|NCT02336477|Experimental|1|Mexiletine / Placebo
11354668|NCT02336672|No Intervention|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
11354669|NCT02336672|Experimental|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
11354670|NCT02336659|Placebo Comparator|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
11354671|NCT02336659|Experimental|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
11354672|NCT02336659|Experimental|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2
11354673|NCT02336659|Experimental|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2
11354674|NCT02336646|Experimental|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
11354675|NCT02336646|Experimental|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
11354676|NCT02336646|Placebo Comparator|Placebo|normal saline with Intramuscular injection
11354677|NCT02336633|Experimental|1|Resveratrol (80mg/j = 4 capsules/day)
11354678|NCT02336633|Placebo Comparator|2|Placebo (4 capsules/day)
11354679|NCT02336620|Experimental|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
11354680|NCT02336620|Active Comparator|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
11354681|NCT02336607|Experimental|Felodipine tablet (Plendil)|
11354682|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
11354683|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
11354684|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
11354685|NCT02336594|Experimental|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
11354686|NCT02336594|Experimental|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
11354687|NCT02336594|Experimental|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
11354688|NCT02336594|Experimental|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
11354689|NCT02336581|Experimental|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
11354690|NCT02336581|Active Comparator|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
11354691|NCT02336568|Experimental|intervention|intervention: Oxytoine treatments - 20 PTSD patients
11354692|NCT02336568|Placebo Comparator|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
11354693|NCT02336555|Experimental|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
11354694|NCT02336555|Experimental|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
11354695|NCT02336542|Experimental|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
11354696|NCT02336542|Active Comparator|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
11354697|NCT02336529|Experimental|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
11354698|NCT02336529|Placebo Comparator|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
11354699|NCT02336529|Experimental|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
11354700|NCT02336529|Placebo Comparator|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
11354701|NCT02336516|Experimental|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ®
11354702|NCT02336516|Placebo Comparator|Glucose solution 10%|Glucose solution 10%
11354703|NCT02336503|Experimental|BBI-4000 Dose 1|Low concentration of BBI-4000
11354704|NCT02336503|Experimental|BBI-4000 Dose 2|Middle concentration of BBI-4000
11354705|NCT02336503|Experimental|BBI-4000 Dose 3|High concentration of BBI-4000
11354706|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo)
11354707|NCT02336490|No Intervention|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
11354711|NCT02336451|Experimental|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
11354712|NCT02336451|Experimental|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
11354713|NCT02336451|Experimental|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
11354714|NCT02336451|Experimental|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
11354715|NCT02336451|Experimental|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
11354716|NCT02336438|No Intervention|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).
~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
11354717|NCT02336438|Experimental|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).
~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.
~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
11354718|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
11354719|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
11354720|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
11354721|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
11354722|NCT02336412|Experimental|SMS reminder|Daily SMS medication reminder
11354723|NCT02336412|No Intervention|No SMS reminder|No daily SMS medication reminder
11354724|NCT02336386|Experimental|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
11354725|NCT02336386|Active Comparator|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
11354726|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
11354727|NCT02336360|Experimental|Urine Analysis|Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
11354728|NCT02336347|Experimental|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
11354729|NCT02336347|Active Comparator|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
11354730|NCT02336347|Active Comparator|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
11354731|NCT02336347|Experimental|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
11354732|NCT02336334|Experimental|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types
~Interventions:
~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
11354733|NCT02336334|Experimental|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types
~Interventions:
~Positioning measurement Patient feedback Usefulness of a sketch"
11354734|NCT02336321|Experimental|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
11354735|NCT02336308|Active Comparator|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
11354736|NCT02336308|Placebo Comparator|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
11354737|NCT02336295|Other|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
11354770|NCT02336035|Experimental|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.
~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
11354771|NCT02336009|Experimental|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
11354738|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.
~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.
~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
11354739|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.
~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.
~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
11354740|NCT02336256|Experimental|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
11354741|NCT02336256|Active Comparator|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
11354742|NCT02336243|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
11354743|NCT02336243|Placebo Comparator|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
11354744|NCT02336230|Experimental|Active Treatment|
11354745|NCT02336217|Experimental|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
11354746|NCT02336217|Placebo Comparator|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
11354747|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
11354748|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
11354749|NCT02336165|Experimental|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
11354750|NCT02336165|Experimental|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
11354751|NCT02336165|Experimental|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
11354752|NCT02336165|Experimental|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
11354753|NCT02336165|Experimental|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
11354754|NCT02336152|Experimental|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
11354755|NCT02336152|Active Comparator|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
11354756|NCT02336139|Experimental|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
11354757|NCT02336126|Experimental|Biopsychological intervention|
11354758|NCT02336113|No Intervention|Control group|Standard care during hospital stay, without pharmacist involved
11354759|NCT02336113|Experimental|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
11354760|NCT02336100|Experimental|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
11354761|NCT02336100|Experimental|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
11354762|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11354763|NCT02336074|Active Comparator|Control|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
11354764|NCT02336074|Experimental|Intervention|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
11354765|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
11354766|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
11354767|NCT02336048|Active Comparator|Placebo + Obinutuzumab + Chlorambucil|Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
11354768|NCT02336048|Experimental|Tocilizumab + Obinutuzumab + Chlorambucil|Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
11354769|NCT02336035|No Intervention|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.
~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
11354772|NCT02335996|Active Comparator|patients with active hypercortisolism|
11354773|NCT02335996|Active Comparator|Patients in remission of their hypercortisolism after surgery|
11354774|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
11354775|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
11354776|NCT02335983|Experimental|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
11354777|NCT02335983|Experimental|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
11354778|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
11354779|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.
~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
11354780|NCT02335970|Experimental|Training group|Training program: Daily exercises for 3 months
11354781|NCT02335970|No Intervention|Controls|Standard care
11354782|NCT02335957|Other|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
11354783|NCT02335957|Experimental|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
11354784|NCT02335944|Experimental|INC280 plus EGF816|Recruitment in Phase I dose escalation part is completed. Recruitment in Phase II dose expansion is ongoing.
11354785|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
11354786|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
11354787|NCT02335918|Experimental|Varlilumab and Nivolumab|
11354788|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
11354789|NCT02335879|Experimental|Recombinant Human Follitropin|
11354790|NCT02335866|Experimental|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
11354791|NCT02335866|Active Comparator|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
11354792|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:
~Abdominal obesity, defined as a waist circumference in men ≥88 cm
~Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides
~Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C
~Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
~Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
11354793|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
11354794|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
11354795|NCT02335840|Experimental|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
11354796|NCT02335840|Experimental|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
11354797|NCT02335840|Experimental|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
11354860|NCT02335255|Placebo Comparator|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
11354798|NCT02335840|Experimental|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
11354799|NCT02335827|Experimental|Group A|irreversible electroporation with voltage in level A for renal tumors
11354800|NCT02335827|Experimental|Group B|irreversible electroporation with voltage in level B for renal tumors
11354801|NCT02335827|Experimental|Group C|irreversible electroporation with voltage in level C for renal tumors
11354802|NCT02335814|Experimental|FLX925|
11354803|NCT02335788|Other|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
11354804|NCT02335749|Experimental|Fat Reduction|The treatments are designed to see if the fat, on the distal thigh, can be reduced.
11354805|NCT02335736|Active Comparator|Normal|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
11354806|NCT02335736|Active Comparator|Poor responders|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
11354807|NCT02335736|Active Comparator|Polycystic ovarian disease|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
11354808|NCT02335723|Active Comparator|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
11354809|NCT02335723|Placebo Comparator|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
11354810|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
11354811|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
11354812|NCT02335697|Other|Intervention|Attitude change towards female circumcision
11354813|NCT02335697|Other|No intervention|No intervention
11354814|NCT02335684|Experimental|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
11354815|NCT02335671|Experimental|Intra-operative Magnetic Resonance Imaging (MRI)|"Preoperative diagnostic MRI
~Intra-operative MRI
~Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated
~Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
11354816|NCT02335658|Experimental|DSP-5423P|Percutaneous
11354817|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
11354818|NCT02335632|Placebo Comparator|Placebo|For Probiotics, 7 days
11354819|NCT02335632|Active Comparator|Probiotics|Probiotics of 120 mg/day for 7days
11354820|NCT02335619|Active Comparator|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
11354821|NCT02335619|No Intervention|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
11354822|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
11354823|NCT02335593|Experimental|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
11354824|NCT02335593|Active Comparator|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
11354825|NCT02335554|Experimental|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
11354826|NCT02335554|Active Comparator|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
11354827|NCT02335528|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
11354857|NCT02335268|Experimental|Group 3|"Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6
~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
11355073|NCT02333942||Mild Cognitive Impairment|Nautilus NeuroWaveTM System'
11354828|NCT02335528|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
11354829|NCT02335528|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
11354830|NCT02335515|Experimental|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
11354831|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
11354832|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
11354833|NCT02335450|Experimental|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
11354834|NCT02335437||Acute EBV infection|
11354835|NCT02335437||Healthy controls|
11354836|NCT02335424|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to 24 months.
11354837|NCT02335411|Experimental|Cohort 1: Pembro monotherapy, previously treated|Participants receive pembrolizumab (Pembro) 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
11354838|NCT02335411|Experimental|Cohort 2: Pembro combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV Q3W for up to 24 months + cisplatin 80 mg/m^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
11354839|NCT02335411|Experimental|Cohort 3: Pembro monotherapy, treatment naive|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 24 months
11354840|NCT02335398|Experimental|methadone|single group
11354841|NCT02335385|Active Comparator|SIL-V|single incision laparoscopic varicocelectomy
11354842|NCT02335385|Active Comparator|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
11354843|NCT02335372|Experimental|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
11354844|NCT02335359|Experimental|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
11354845|NCT02335359|Placebo Comparator|Placebo|Saline
11354846|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
11354847|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
11354848|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
11354849|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
11354850|NCT02335294|Experimental|TRV130|
11354851|NCT02335294|Active Comparator|Morphine|
11354852|NCT02335294|Placebo Comparator|Placebo|
11354853|NCT02335281|Experimental|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
11354854|NCT02335281|Active Comparator|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
11354855|NCT02335268|Experimental|Group 1|"Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3
~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
11354856|NCT02335268|Experimental|Group 2|"Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2
~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
11354858|NCT02335255|Experimental|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
11354861|NCT02335242|Placebo Comparator|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
11354862|NCT02335242|Experimental|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
11354863|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
11354864|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
11354865|NCT02335203|Experimental|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
11354866|NCT02335203|Placebo Comparator|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
11354867|NCT02335190|Experimental|PSN block and RF ablation|Participants will first undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. On a separate visit, participants will then undergo ablation of the PSN at the lateral crest under ultrasound-guidance.
11354868|NCT02335177|Active Comparator|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
11354869|NCT02335177|No Intervention|Control arm|Control arm : patients with usual care home
11354870|NCT02335164|Experimental|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
11354871|NCT02335164|Experimental|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
11354872|NCT02335164|Experimental|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
11354873|NCT02335164|Experimental|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
11354874|NCT02335164|Experimental|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
11354875|NCT02335164|Experimental|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
11354876|NCT02335164|Experimental|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
11354877|NCT02335164|Experimental|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
11354878|NCT02335164|Experimental|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
11354879|NCT02335151|Experimental|Desflurane|General anesthesia with Desflurane
11354880|NCT02335151|No Intervention|Propofol|General anesthesia with Propofol
11354881|NCT02335138|Placebo Comparator|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
11354882|NCT02335138|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
11354883|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
11354884|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
11354885|NCT02335112|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Head and Neck Neoplasms
11354886|NCT02335112|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Head and Neck Neoplasms
11354887|NCT02335112|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Head and Neck Neoplasms
11354888|NCT02335099|Active Comparator|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
11354889|NCT02335099|Placebo Comparator|Placebo|Placebo drug to be given twice a day for 6 months
11354890|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.
~Clinical and angiographic exclusion criteria as stated in the study protocol."
11354891|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :
~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:
~Symptoms of ischaemia
~Development of pathologic Q waves in the electrocardiogram (ECG)
~New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.
~Identification of an intracoronary thrombus by angiography.
~Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
11354892|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
11354893|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
11354894|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
11354895|NCT02335060|Placebo Comparator|Placebo and Placebo|
11354896|NCT02335047|Other|lower back pain|
11354897|NCT02335034|Experimental|Study group|Intervention: study group will attend two days of classes (two months apart) with the seven professional teams, covering what is the disease arthritis, its causes and treatment options; what is disease, being ill, and the role of the patient in the treatment to obtain behavioral change; the importance of exercise in relieving symptoms, the importance of rest and proper ergonomics at home and at work; proper alimentation; the difference between labor work and regular physical activity as well as the importance of strength resistance and stretching exercises; and the importance of leisure. The second intervention verifies the acquired concepts.
11354898|NCT02335034|Experimental|Control Group|The control group will only make evaluations / consultations with all professional teams without classes for 2 years, then will attend the courses and will be followed by two more years.
11354899|NCT02335021|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
11354900|NCT02335021|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
11354901|NCT02335021|Experimental|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
11354902|NCT02335021|Experimental|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
11354903|NCT02335008|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
11354904|NCT02335008|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
11354905|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
11354906|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
11354907|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
11354908|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
11354909|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
11354910|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
11354911|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
11354912|NCT02334969|Experimental|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
11354913|NCT02334969|Active Comparator|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
11354914|NCT02334956|Experimental|Patient|Patient with addiction
11354915|NCT02334956|Experimental|Control|healthy subject
11354916|NCT02334943|Experimental|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
11354917|NCT02334943|Experimental|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
11354918|NCT02334943|Experimental|Healthy witness|Healthy witness for Blood test
11354919|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
11354920|NCT02334917|Experimental|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
11354921|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
11354922|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
11354923|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
11354924|NCT02334878|Experimental|Stem cells,Mesenchymal|Periurethral injection of autologous bone-marrow derived stem cells.
11354925|NCT02334878|Active Comparator|surgery (TVT)|Tension-free vaginal tape operation: a midurethral sling operation
11354926|NCT02334865|Experimental|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
11354927|NCT02334865|Experimental|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
11354928|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
11354929|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
11354930|NCT02334839||healthy|women without gestational hypertension or preeclampsia
11354931|NCT02334826|Active Comparator|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
11354932|NCT02334826|Active Comparator|CABG|coronary artery bypass grafting
11354933|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
11354934|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
11354935|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
11354936|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
11354937|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
11354938|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
11354939|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
11354940|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
11354941|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
11354942|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
11354943|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
11354944|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
11354945|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
11354946|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
11354947|NCT02334774|Experimental|Participants receiving an SOC Program|Participants following prolonged endotracheal intubation receiving a up to 14-day daily Swallowing and Oral Care Program.
11354948|NCT02334748|Experimental|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
11354949|NCT02334735|Experimental|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:
~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
11354950|NCT02334735|Active Comparator|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:
~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
11354951|NCT02334722|Experimental|1 Week Levetiracetam extended release|Levetiracetam extended release 1000 mg taken by mouth, once daily, for one week.
11354952|NCT02334722|Active Comparator|6 Week Levetiracetam extended release|Levetiracetam extended release 1000 mg taken by mouth, once daily, for six weeks.
11354953|NCT02334709|Experimental|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
11354954|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
11354955|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
11354956|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
11354957|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months.
11354958|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
11354959|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
11354960|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
11354961|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
11354962|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
11354963|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
11354964|NCT02334644|Experimental|1|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
11354965|NCT02334644|Placebo Comparator|2|Placebo
11354966|NCT02334631|Experimental|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
11354967|NCT02334631|Active Comparator|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
11354968|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.
~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
11354969|NCT02334605|Other|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
11354970|NCT02334605|Other|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
11354971|NCT02334592|Experimental|Low Pressure 100W sunbed|
11354972|NCT02334592|Experimental|Low Pressure 160W sunbed|
11354973|NCT02334592|Experimental|High Pressure sunbed|
11354974|NCT02334592|No Intervention|Control group|
11355074|NCT02333942||Frontotemporal Lobar Degeneration|Nautilus NeuroWaveTM System'
11354975|NCT02334579|Experimental|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
11354976|NCT02334566|Experimental|NET TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
11354977|NCT02334566|Active Comparator|Delayed TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis, started following a three-month wait period
11354978|NCT02334553|Active Comparator|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
11354979|NCT02334553|Placebo Comparator|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
11354980|NCT02334540|Other|purses or a calorie/protein matched smoothie|
11354981|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
11354982|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
11354983|NCT02334501|Experimental|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
11354984|NCT02334488|Active Comparator|Everolimus-Tacrolimus|"Tacrolimus (Prograf®) started at 0,1 mg/kg/day since Day0, then adapted to C0 concentration (4-7 ng/ml),
~Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml)."
11354985|NCT02334488|Experimental|Everolimus-Mycophenolate sodium|"Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml),
~Tacrolimus (Prograg®) started at 0,1 mg/kg/day from J0 then to be adapted to C0 concentration (4-7 ng/ml), then replacement by mycophenolate sodium (Myfortic®) at M3 (3 months visit) started at 1440 mg/day."
11354986|NCT02334475|Experimental|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
11354987|NCT02334475|Active Comparator|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
11354988|NCT02334462|Experimental|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
11354989|NCT02334462|Experimental|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
11354990|NCT02334462|Experimental|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
11354991|NCT02334462|Experimental|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
11354992|NCT02334462|Experimental|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
11354993|NCT02334462|Experimental|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
11354994|NCT02334462|Active Comparator|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
11354995|NCT02334449|Experimental|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
11354996|NCT02334449|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
11354997|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
11354998|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
11354999|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
11355000|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
11355001|NCT02334410|No Intervention|Reference|
11355002|NCT02334410|Experimental|Whole body vibration (WBV)|Vibration therapy
11355003|NCT02334397|Active Comparator|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
11355004|NCT02334397|No Intervention|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
11355005|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
11355006|NCT02334384|No Intervention|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
11355007|NCT02334371|Other|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
11355008|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
11355075|NCT02333942||Age-Matched Controls|Nautilus NeuroWaveTM System'
11355009|NCT02334345|Experimental|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
11355010|NCT02334345|Active Comparator|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
11355011|NCT02334332|Active Comparator|Cohort I (standard care)|Participants receive standard post-operative care.
11355012|NCT02334332|Experimental|Cohort II (educational brochure)|Participants receive a 2-page educational brochure after surgery and prior to discharge home.
11355013|NCT02334319|Experimental|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
11355014|NCT02334306|Experimental|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
11355015|NCT02334306|Placebo Comparator|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
11355016|NCT02334293|Other|Omegaven|
11355017|NCT02334280|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
11355018|NCT02334280|No Intervention|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
11355019|NCT02334267|Active Comparator|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
11355020|NCT02334267|Active Comparator|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
11355021|NCT02334254|Experimental|Dual antithrombotic therapy (DAT)|Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban 2.5mg/5mg b.i.d. plus ticagrelor 90mg b.i.d.
11355022|NCT02334254|Active Comparator|Triple antithrombotic therapy (TAT)|Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
11355023|NCT02334241|Experimental|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
11355024|NCT02334241|Active Comparator|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
11355025|NCT02334228|Experimental|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
11355026|NCT02334228|Active Comparator|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
11355027|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
11355028|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
11355029|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
11355030|NCT02334202|Active Comparator|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
11355031|NCT02334202|Experimental|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
11355032|NCT02334189|Experimental|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
11355033|NCT02334189|No Intervention|No letter|Patients receive no letter (this is the usual care).
11355034|NCT02334176|Active Comparator|single injection|Axillary plexus block performed with single injection dorsally to the artery
11355035|NCT02334176|Active Comparator|Double injection|Axillary plexus block performed with 2 injections: one over musculocutaneous nerve the second one dorsally to the artery
11355036|NCT02334163|Experimental|Nitazoxanide group|"12 patients will receive the following for 7 days:
~Oral lactulose
~500 mg nitazoxanide tablets twice daily"
11355037|NCT02334163|Active Comparator|Metronidazole group|"12 patients will receive the following for 7 days:
~Oral lactulose
~250 mg metronidazole tablets every 8 hours"
11355038|NCT02334163|Active Comparator|Rifaximine group|"12 patients will receive the following for 7 days:
~Oral lactulose
~Two 200 mg rifaximine tablets every 8 hours"
11355076|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
11355039|NCT02334150|Experimental|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
11355040|NCT02334150|No Intervention|Control group|Women in the control group were not provided any analgesia during labor.
11355041|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
11355042|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
11355043|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
11355044|NCT02334124|Experimental|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
11355045|NCT02334124|Active Comparator|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
11355046|NCT02334111|No Intervention|(Control)|Patients will receive standard of care
11355047|NCT02334111|Experimental|(Intervention)|Patients will receive RESPECT-Plus intervention
11355048|NCT02334098|Experimental|Omega-3 supplemented drink|A 200 ml. drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
11355049|NCT02334098|Placebo Comparator|Placebo Drink|exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
11355050|NCT02334098|No Intervention|treatment-as-usual controls|No drinks are taken.
11355051|NCT02334085||HOW study participants|
11355052|NCT02334072|Experimental|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
11355053|NCT02334072|Experimental|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
11355054|NCT02334072|Experimental|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
11355055|NCT02334072|Experimental|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
11355056|NCT02334072|Experimental|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
11355057|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
11355058|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
11355059|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
11355060|NCT02334046|Experimental|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
11355061|NCT02334046|Active Comparator|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
11355062|NCT02334020|Experimental|Training course|12 hour training course in Mental Health First-aid
11355063|NCT02334020|Other|Waiting list|Waiting list design, hence delayed offering of Mental Health First-aid
11355064|NCT02334007|Experimental|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
11355065|NCT02334007|Placebo Comparator|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
11355066|NCT02333994|Experimental|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
11355067|NCT02333994|Active Comparator|GROUP B|BALANCE EXERCISES
11355068|NCT02333981|Experimental|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
11355069|NCT02333968|Experimental|Intervention group|Self-management support
11355070|NCT02333968|No Intervention|Control group|Care as usual
11355071|NCT02333955|Experimental|3 mg IV push|GCS-100
11355072|NCT02333942||Alzheimer's Disease|Nautilus NeuroWaveTM System'
11355077|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
11355078|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
11355079|NCT02333916|Experimental|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.
~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).
~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
11355080|NCT02333903|Experimental|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
11355081|NCT02333903|No Intervention|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
11355082|NCT02333890|Experimental|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
11355083|NCT02333890|Placebo Comparator|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
11355084|NCT02333877|Experimental|Skinlink|applying Skinlink on simple laceration (length < 5cm)
11355085|NCT02333877|Other|Nylon|applying conventional suture using nylon on simple laceration (length < 5cm)
11355086|NCT02333864||PWD testing POGO® BGMS|All enrolled persons with diabetes
11355087|NCT02333851|Experimental|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
11355088|NCT02333851|Experimental|Basal-bolus|'Lantus® once daily and Apidra® before meals
11355089|NCT02333838|Experimental|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.
~The conditioning regimen will include:
~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)
~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
~IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)
~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:
~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
~IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
11355090|NCT02333825|Other|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
11355091|NCT02333825|Other|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
11355092|NCT02333812||copd patients|Adult patients with COPD
11355093|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
11355094|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
11355095|NCT02333799|Experimental|Bedaquiline + PA-824 + Linezolid|bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily .
11355096|NCT02333786|Experimental|Infant|Radial artery or posterior tibial artery of patients younger than 1 year old are either cannulated with short-axis/out-of-plane or long-axis/in-plane US-guided arterial catheterization technique.
11355097|NCT02333786|Experimental|Preschool child|Radial artery or posterior tibial artery of patients older than 1 year old and younger than 5 years old are either cannulated with long-axis/in-plane or short-axis/out-of-plane US-guided arterial catheterization technique.
11355098|NCT02333773|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
11355099|NCT02333773|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
11355100|NCT02333773|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
11355101|NCT02333747|Experimental|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
11355102|NCT02333747|Sham Comparator|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
11355103|NCT02333734|Experimental|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
11355104|NCT02333734|Experimental|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
11355392|NCT02332031|Experimental|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
11355105|NCT02333721|Experimental|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
11355106|NCT02333721|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
11355107|NCT02333708||GCA group|
11355108|NCT02333708||Inflammatory syndrome (without GCA) group|
11355109|NCT02333708||Without inflammatory syndrome and without GCA group|
11355110|NCT02333695|Experimental|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
11355111|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
11355112|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
11355113|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
11355114|NCT02333682|Active Comparator|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
11355115|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
11355116|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
11355117|NCT02333656|No Intervention|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
11355118|NCT02333656|Experimental|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
11355119|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
11355120|NCT02333643|Experimental|Digoxin topical formulation|
11355121|NCT02333643|Experimental|Furosemide topical formulation|
11355122|NCT02333643|Placebo Comparator|Vehicle topical formulation|
11355123|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
11355124|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
11355125|NCT02333617|Experimental|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
11355126|NCT02333617|Active Comparator|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
11355127|NCT02333617|Placebo Comparator|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
11355128|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.
~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
11355129|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
11355130|NCT02333591|Placebo Comparator|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
11355131|NCT02333578|Experimental|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
11355132|NCT02333565|Experimental|Combinaison everolimus and octreotide|
11355133|NCT02333539|Experimental|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
11355134|NCT02333539|Experimental|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
11355135|NCT02333539|No Intervention|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
11355136|NCT02333513|Experimental|case group|
11355137|NCT02333500|Experimental|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
11355138|NCT02333500|Active Comparator|other workshop|Influence of other workshop on the rate of oxytocin
11355139|NCT02333500|Other|control group|Rate of oxytocin of the control group
11355140|NCT02333487|Experimental|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
11355141|NCT02333487|Experimental|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
11355393|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
11355142|NCT02333487|Experimental|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
11355143|NCT02333474|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.
11355144|NCT02333474|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given
11355145|NCT02333461|Placebo Comparator|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
11355146|NCT02333461|Experimental|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
11355147|NCT02333461|Experimental|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
11355148|NCT02333461|Experimental|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
11355149|NCT02333461|Experimental|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
11355150|NCT02333448||patients with suspected invasive candidiasis|
11355151|NCT02333435|Experimental|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
11355152|NCT02333435|Experimental|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
11355153|NCT02333422|Experimental|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
11355154|NCT02333409|Active Comparator|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
11355155|NCT02333409|Sham Comparator|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
11355156|NCT02333396|Experimental|PICU Supports|Participants will receive the PICU Supports intervention.
11355157|NCT02333396|Active Comparator|Educational Brochure|Participants will receive an educational brochure about the pediatric intensive care unit.
11355158|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
11355159|NCT02333370|Experimental|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
11355160|NCT02333370|Experimental|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
11355161|NCT02333370|Experimental|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
11355162|NCT02333357|Experimental|Toolkit|Counselors randomized to the toolkit (TK) condition will receive a one to three hour standardized toolkit orientation that will include a description of the overall goal of the toolkit curriculum comprised of five modules, the purpose of each individual element of the toolkit, and an introduction to the toolkit teaching aids such as counselor guides, posters, and patient materials (hand-outs, sampling menus, worksheets, etc). TK counselor participants then conduct group treatment sessions using the toolkit materials with their patient participants.
11355163|NCT02333357|Active Comparator|Treatment as Usual|Counselors assigned to the Treatment as Usual (TAU) attention control condition complete a training that reviews the same five 12-step topics that are included in the toolkit, but they do not receive any toolkit materials. TAU counselor participants then conduct group treatment sessions on the 12-step topics without using toolkit materials.
11355164|NCT02333344|Experimental|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
11355165|NCT02333344|No Intervention|blank|blank group
11355166|NCT02333331|Experimental|BYM338 70 mg|BYM338 70 mg intravenous infusion
11355167|NCT02333331|Experimental|BYM338 210 mg|BYM338 210 mg intravenous infusion
11355168|NCT02333331|Experimental|BYM338 700 mg|BYM338 700 mg intravenous infusion
11355169|NCT02333331|Placebo Comparator|Placebo|Placebo intravenous infusion
11355170|NCT02333318|Experimental|Single Dose_VVZ-149 injection|"Cohort A (50-64 years old), Cohort B (65-84 years old)
~For 2.5, 5mg/kg
~4-hr intravenous infusion of VVZ-149 injection
~6 subjects will be administered within each age group. Total 24 subjects will participate."
11355171|NCT02333318|Experimental|Loading/Maintenance_VVZ-149 injection|"Cohort A (50-64 years old) This trial is conducted only in the Cohort A one week after the single IV infusion.
~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h
~intravenous infusion
~4 subjects will be randomly assigned within each dose group, respectively. Total 8 subjects will participate."
11355172|NCT02333318|Placebo Comparator|Loading/Maintenance_Placebo|"Cohort A (50-64 years old)
~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h
~intravenous infusion
~2 subjects will be randomly assigned within each dose group, respectively. Total 4 subjects will participate."
11355173|NCT02333305|Experimental|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
11355174|NCT02333305|Placebo Comparator|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
11355175|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
11355176|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
11355177|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
11355178|NCT02333266||Candidemia|0
11355179|NCT02333253|Active Comparator|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach >12 mm, HCG was given only if we have at least 3 mature follicles >14 mm and the leading one >17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
11355180|NCT02333253|Active Comparator|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF >12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
11355181|NCT02333240|No Intervention|Usual care|"Women randomised to usual care will have their blood pressure monitored by their community midwife, and will have their anti-hypertensive medication adjusted by their general practitioner. There will be no intervention in this group.
~All women will be followed up at ten days, four and six weeks, then three and six months postpartum and have their blood pressure measured by one of the study team."
11355182|NCT02333240|Experimental|Self-management|Self-management of postnatal anti-hypertensive treatment. Women will be provided with, and taught to use, a validated home blood pressure monitor, and perform daily BP readings. When treatment is discontinued we will ask them to continue daily BP measurements for 1 week. Provided these are <140/90 mmHg they will be asked to check their BP weekly for the remainder of the trial period. The self-monitoring BP data will be collated centrally through the use of a smart phone app or SMS based system. This service will respond to participants regarding the level of their BP and what action is required. Women in the self-management group will have an individualised medication adjustment schedule developed by the research team in conjunction with the participant's obstetric team.
11355183|NCT02333227|No Intervention|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
11355184|NCT02333227|Experimental|Xylitol|Cluster of sites receiving xylitol gum.
11355185|NCT02333214|Experimental|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
11355186|NCT02333214|Active Comparator|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
11355187|NCT02333188|Experimental|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
11355188|NCT02333175|Active Comparator|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
11355189|NCT02333175|No Intervention|Care as usual|Care as usual
11355190|NCT02333162|Experimental|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.
~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
11355191|NCT02333149|Experimental|Melatonin|Dietary supplement: Melatonin 3 mg or 6 mg
11355192|NCT02333149|Placebo Comparator|Placebo|Drug: Placebo
11355193|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
11355194|NCT02333123|Experimental|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
11355195|NCT02333123|Placebo Comparator|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
11355196|NCT02333110|Experimental|GRID radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
11355197|NCT02333084|Experimental|Joint Health Product|natural dietary supplement
11355198|NCT02333084|Placebo Comparator|Placebo|vegetable oil placebo
11355199|NCT02333084|Active Comparator|Combination with Omega-3|combination with omega-3 fish oil
11355200|NCT02333071|Experimental|Bremelanotide|Subjects will self-administer a fixed dose of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
11355201|NCT02333071|Placebo Comparator|Placebo|Subjects will self-administer a fixed dose of placebo subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
11355202|NCT02333058|Experimental|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.
~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.
~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
11355203|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
11355204|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
11355205|NCT02333032|Experimental|hemiplegic patient|
11355206|NCT02333019|Experimental|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
11355207|NCT02333019|Active Comparator|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
11355208|NCT02333006|Other|Traumatic brain injury questionnaires|Traumatic brain injury patients with anosognosia will answer to quetionnaires about Anosognosia compare to the answer of participant without neurological deficits
11355209|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
11355210|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
11355211|NCT02332980|Experimental|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.
~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
11355212|NCT02332967|Active Comparator|Whey predominant starter formula|Whey predominant starter formula
11355213|NCT02332967|Experimental|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
11355214|NCT02332967|Experimental|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
11355215|NCT02332954|Other|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
11355216|NCT02332954|Other|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
11355217|NCT02332941|Experimental|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
11355218|NCT02332928|Active Comparator|20 mg Melatonin|RT (as clinically indicated) + melatonin (Subjects will receive 20-mg oral melatonin the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
11355219|NCT02332928|Placebo Comparator|Placebo|RT (as clinically indicated) + placebo (Subjects will receive 20-mg oral placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
11355220|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
11355221|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
11355222|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
11355223|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
11355224|NCT02332876|Experimental|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
11355225|NCT02332876|Active Comparator|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
11355226|NCT02332863|Active Comparator|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
11355227|NCT02332863|Experimental|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
11355253|NCT02332720|Experimental|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
11355280|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
11355228|NCT02332850|Experimental|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.
~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
11355229|NCT02332850|Experimental|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).
~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
11355230|NCT02332837|Experimental|Digital informed consent|"Traditional digitally signed text based informed consent
~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
11355231|NCT02332837|Experimental|Multi-media informed consent|"Informed consent with images, text and auditory presentation
~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
11355232|NCT02332837|Experimental|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them
~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
11355233|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
11355234|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
11355235|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
11355236|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
11355237|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
11355238|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.
~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
11355239|NCT02332811|Experimental|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
11355240|NCT02332811|Experimental|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
11355241|NCT02332811|Experimental|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
11355242|NCT02332811|Experimental|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
11355243|NCT02332798|Experimental|Cohort 1|Participants received PF-04958242 oral capsule, 0.20 mg, twice a day for 14 days
11355244|NCT02332798|Experimental|Cohort 2|Participants received PF-04958242 oral capsule, 0.35 mg, twice a day for 14 days
11355245|NCT02332798|Placebo Comparator|Matching Placebo|Participants received matching placebo oral capsule, twice a day dosing for 14 days
11355246|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports & electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
11355247|NCT02332772||Data Collection Endoscopy of Colon Polyps|Data collected from endoscopy reports and electronic medical record system to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025.
11355248|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
11355249|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
11355250|NCT02332733|Experimental|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
11355251|NCT02332733|Placebo Comparator|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
11355252|NCT02332720|Experimental|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
11356027|NCT02327819|Active Comparator|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
11355254|NCT02332720|Experimental|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
11355255|NCT02332720|Experimental|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
11355256|NCT02332720|Experimental|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
11355257|NCT02332720|Experimental|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
11355258|NCT02332720|Experimental|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
11355259|NCT02332720|Experimental|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
11355260|NCT02332720|Experimental|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
11355261|NCT02332720|Experimental|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
11355262|NCT02332720|Experimental|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
11355263|NCT02332720|Experimental|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
11355264|NCT02332720|Experimental|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
11355265|NCT02332720|Experimental|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
11355266|NCT02332720|Experimental|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
11355267|NCT02332720|Experimental|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
11355268|NCT02332720|Experimental|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
11355269|NCT02332720|Experimental|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
11355270|NCT02332720|Experimental|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
11355271|NCT02332720|Experimental|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
11355272|NCT02332720|Experimental|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
11355273|NCT02332720|Experimental|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
11355274|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
11355275|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
11355276|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
11355277|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
11355278|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
11355279|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
11356028|NCT02327819|Sham Comparator|non-BCAA protein supplement|non-BCAA protein supplement
11355281|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
11355282|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
11355283|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
11355284|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
11355285|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
11355286|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
11355287|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
11355288|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
11355289|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
11355290|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
11355291|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
11355292|NCT02332694|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
11355293|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
11355294|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
11355295|NCT02332668|Experimental|Melanoma|Participants aged 6 months to <18 years with melanoma receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), intravenously (IV) once every 3 weeks (Q3W). Enrollment of participants aged 6 months to <12 years with melanoma was closed with Amendment 8. Enrollment of participants aged ≥12 years to ≤18 years with melanoma continues.
11355296|NCT02332668|Experimental|Solid Tumors and Other Lymphomas|Participants aged 6 months to <18 years with solid tumors and other lymphomas receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W. Initial enrollment limited to programmed death-ligand 1 (PD-L1)-positive participants. PD-L1-negative participants may enroll if responses are observed. Enrollment of participants with solid tumors and other lymphomas was closed with Amendment 8.
11355297|NCT02332668|Experimental|rrcHL|Participants aged 3 years to <18 years with rrcHL receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
11355298|NCT02332668|Experimental|MSI-H|Participants aged 6 months to <18 years with microsatellite-instability-high (MSI-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
11355299|NCT02332668|Experimental|TMB-H|Participants aged 6 months to <18 years with tumor-mutational burden-high ≥10 mutation/Mb (TMB-H) solid tumors receive pembrolizumab, starting dose 2 mg/kg (maximum dose 200 mg), IV Q3W.
11355300|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
11355301|NCT02332629|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
11355302|NCT02332629|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
11355303|NCT02332616|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
11355304|NCT02332616|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
11355305|NCT02332603|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
11355306|NCT02332603|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
11355307|NCT02332590|Active Comparator|Adalimumab 40 mg|Adalimumab 40 mg subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during randomized treatment period. The dosing frequency of adalimumab may be adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (<20% improvement from baseline tender joint count [TJC] and swollen joint count [SJC] for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
11355308|NCT02332590|Experimental|Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during randomized treatment period. The dosing frequency of placebo for adalimumab may be adjusted to qw dosing in case of participants with inadequate response (<20% improvement from baseline TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
11355309|NCT02332577|Experimental|Pristinamycin + Placebo|Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.
11355310|NCT02332577|Active Comparator|Amoxicillin + Placebo|Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.
11355311|NCT02332564||Coronary Artery Disease|Patient with significant coronary artery disease
11355312|NCT02332564||No Coronary Artery Disease|Patient without significant coronary artery disease
11355313|NCT02332551|Experimental|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
11355314|NCT02332551|No Intervention|Control|
11355315|NCT02332538|Active Comparator|Greenlight (532nm-laser) PVEP|532nm-laser photoselective vapo-enucleation of the prostate)
11355316|NCT02332538|Active Comparator|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prostate
11355317|NCT02332538|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
11355318|NCT02332525|Experimental|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
11355319|NCT02332512|Experimental|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
11355320|NCT02332512|Placebo Comparator|Placebo|Placebo tablet administered orally, once a day until progression
11355321|NCT02332499|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11355322|NCT02332499|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11355323|NCT02332486|Active Comparator|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
11355324|NCT02332486|No Intervention|Blank|There is no intervention for people in the blank group.
11355325|NCT02332473|Active Comparator|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
11355326|NCT02332473|Experimental|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
11355327|NCT02332460||Infliximab|Patients treated with Infliximab
11355328|NCT02332447|Experimental|NALOXONE|
11355329|NCT02332447|Placebo Comparator|PLACEBO|
11355330|NCT02332434|Experimental|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
11355331|NCT02332434|Experimental|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
11355332|NCT02332421|Experimental|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
11355333|NCT02332421|No Intervention|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
11355334|NCT02332408|Experimental|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
11355335|NCT02332408|Active Comparator|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
11355336|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
11355337|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
11355338|NCT02332369|Experimental|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
11355339|NCT02332356|Active Comparator|step up|Procedure: MREC patients receive therapeutic step up
11355340|NCT02332356|No Intervention|observation step up|
11355341|NCT02332356|Active Comparator|step down|Procedure: MREC patients receive therapeutic step down
11355342|NCT02332356|No Intervention|observation step down|
11355343|NCT02332330|Experimental|VEST|
11355344|NCT02332317|No Intervention|Control arm|150 patients will receive standard oncology treatment.
11355345|NCT02332317|Active Comparator|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
11355346|NCT02332304|Other|Preterm fetus|Patients with pregnancies between 26 and 36 6/7 weeks of pregnancy. Before the birth, a sample of amniotic fluid was taken and analyzed using optical density at 650nm. A value above 0.15 was considered an indication of fetal lung maturity.
11355347|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
11355348|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
11355349|NCT02332278|Experimental|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
11355350|NCT02332278|Active Comparator|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
11355351|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).
~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;
~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
11355387|NCT02332057|Active Comparator|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
11355388|NCT02332057|Placebo Comparator|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
11355352|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
11355353|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
11355354|NCT02332252|Active Comparator|Scalpel|Skin incision performed with a scalpel during cesarean section.
11355355|NCT02332252|Experimental|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
11355356|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention
~Eight-week longitudinal tailored CBT-based text-message program"
11355357|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition
~Eight-week longitudinal home safety & nutrition text-message program"
11355358|NCT02332226|Experimental|Representational approach|Four sessions with a nurse. For each session, the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's knowledge of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed.
11355359|NCT02332226|No Intervention|Control|Standard care as per ward protocol.
11355360|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
11355361|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
11355362|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
11355363|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
11355364|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
11355365|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
11355366|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
11355367|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
11355368|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
11355369|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
11355370|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is >10 weeks.
11355371|NCT02332187|Sham Comparator|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
11355372|NCT02332187|Active Comparator|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
11355373|NCT02332174|Experimental|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
11355374|NCT02332174|Experimental|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
11355375|NCT02332174|Experimental|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
11355376|NCT02332174|Experimental|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
11355377|NCT02332148|Experimental|3Vm1001|3VM1001 topical cream containing 10 mg/day of copper, for 30 days
11355378|NCT02332148|Placebo Comparator|Placebo|Placebo for 3VM1001, topical cream without 3VM1001
11355379|NCT02332135|Experimental|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
11355380|NCT02332135|Active Comparator|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
11355381|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.
~Additional for this study are:
~Sputum induction, Skin prick test, Questionnaires"
11355382|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.
~Additional for this study are:
~Sputum induction, Skin prick test, Questionnaires"
11355383|NCT02332109||ODM 5-group|
11355384|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
11355385|NCT02332083|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & Exergame) - T2
11355386|NCT02332083|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
11355394|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
11355395|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
11355396|NCT02332005|Active Comparator|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
11355397|NCT02332005|Active Comparator|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
11355398|NCT02332005|Placebo Comparator|Group 3|Tablet administered twice daily morning and evening containing placebo
11355399|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
11355400|NCT02331979|Experimental|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
11355401|NCT02331979|Experimental|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
11355402|NCT02331979|Experimental|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
11355403|NCT02331953||delirium group|the patients with delirium after spine surgery
11355404|NCT02331953||no delirium group|the patients without delirium after spine surgery
11355405|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
11355406|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
11355407|NCT02331927|No Intervention|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
11355408|NCT02331927|Experimental|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
11355409|NCT02331914||Gastro-intestinal stromal tumors|"A bio-databank consisting of TKI drug level and serum for analysis of mutations in circulating tumor DNA will be set up. This bio-databank will be used to study whether changes in the amount of the primary KIT mutation is an early predictor of treatment response and/of failure. Moreover, secondary TKI resistant mutations in circulating tumor DNA will be assessed.
~To be able to assess those mutations, a tumor biopsy will be performed at the time of radiologic progressive disease. Vena puncture for blood collection will be performed at routine out patient visits."
11355410|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
11355411|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
11355412|NCT02331888|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
11355413|NCT02331875|Experimental|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
11355414|NCT02331862|Experimental|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
11355415|NCT02331862|No Intervention|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
11355416|NCT02331849|Other|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
11355417|NCT02331836|Active Comparator|Arc Endocuff (AEC 110, 120, 130, 140)|Endocuff-assisted colonoscopy Colonoscopy with the Endocuff attached at the distal tip of the scope
11355418|NCT02331836|Active Comparator|Cap|Cap-assisted colonoscopy Colonoscopy with the transparent Cap attached at the distal tip of the scope
11355419|NCT02331836|Active Comparator|Standard Colonoscope|Standard colonoscopy without any additional device
11355420|NCT02331823|Experimental|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
11355421|NCT02331823|Active Comparator|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
11355422|NCT02331810|Experimental|SAR113244|Single subcutaneous dose of SAR113244
11355423|NCT02331810|Placebo Comparator|Placebo|Single subcutaneous dose of placebo
11355424|NCT02331797|Experimental|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
11355425|NCT02331797|Active Comparator|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
11355426|NCT02331784|Experimental|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
11355427|NCT02331784|Active Comparator|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
11355428|NCT02331771|Active Comparator|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
11355429|NCT02331771|Placebo Comparator|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
11356276|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
11355430|NCT02331758|Experimental|Lifestyle counseling|The investigators use several methods to educate patients of controllable factors like lifestyle counseling, and monitor the factors like BMI and other index until the statistics become normal.
11355431|NCT02331758|No Intervention|No treatment|Patients without any intervention and still have abnormal factors like BMI, etc.
11355432|NCT02331745|Experimental|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
11355433|NCT02331745|Active Comparator|standard treatment|Standard treatment alone
11355434|NCT02331732|Active Comparator|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
11355435|NCT02331732|Experimental|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
11355436|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
11355437|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
11355438|NCT02331706|Experimental|Subject Recipients|
11355439|NCT02331706|Experimental|Subject Donors|
11355440|NCT02331693|Experimental|anti-EGFR CAR T|
11355441|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
11355442|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
11355443|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
11355444|NCT02331667|Experimental|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
11355445|NCT02331667|Experimental|Non-seafood|Intervention with meals constisting of non-seafood (meat).
11355446|NCT02331654|Experimental|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
11355447|NCT02331654|Placebo Comparator|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
11355448|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
11355449|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
11355450|NCT02331628|No Intervention|Control|Usual care only will be provided during Baseline period and Follow-up period.
11355451|NCT02331628|Experimental|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
11355452|NCT02331615|Experimental|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
11355453|NCT02331615|Experimental|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
11355454|NCT02331615|Sham Comparator|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
11355455|NCT02331602|Active Comparator|rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
11355456|NCT02331602|Active Comparator|dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
11355457|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
11355458|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
11355459|NCT02331576|Placebo Comparator|rocaine|continuous femoral nerve block with ropivacaine alone.
11355460|NCT02331576|Active Comparator|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
11355461|NCT02331563|Experimental|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
11355462|NCT02331563|Active Comparator|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
11355463|NCT02331550|Experimental|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
11355464|NCT02331550|Experimental|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
11355606|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
11355465|NCT02331537|Experimental|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
11355466|NCT02331537|No Intervention|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
11355467|NCT02331524|No Intervention|Control/Usual Care|Usual care only
11355468|NCT02331524|Experimental|Activity Feedback and Encouragement|Weekly Feedback about daily activity using the FitBit Zip
11355469|NCT02331524|Experimental|Health Coaching/Home Exercise|Weekly contact from physical therapist to develop and progress home exercise program and by health coach for goal setting and support
11355470|NCT02331511|Placebo Comparator|placebo|No antiplatelet drug
11355471|NCT02331511|Active Comparator|Aspirin|Aspirin 80 mg daily
11355472|NCT02331511|Active Comparator|Clopidogrel|Clopidogrel 75mg daily
11355473|NCT02331498|Other|A Pazopanib|Open label study with one group
11355474|NCT02331485|Experimental|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith & Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
11355475|NCT02331485|Active Comparator|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
11355476|NCT02331472||Interstitial cystitis|Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy
11355477|NCT02331472||Control|Adult participants without history of interstitial cystitis/bladder pain syndrome
11355478|NCT02331459|Experimental|Intervention group|"Multicomponent training intervention :
~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
11355479|NCT02331459|Placebo Comparator|Control group|Normal routine during 24 weeks.
11355480|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
11355481|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
11355482|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
11355483|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
11355484|NCT02331433|Experimental|Experimental: 1|
11355485|NCT02331433|Placebo Comparator|Placebo Comparator: 2|
11355486|NCT02331420|Experimental|Bariatric Surgery|Gastric bypass
11355487|NCT02331420|Active Comparator|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
11355488|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
11355489|NCT02331394|Experimental|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer.
11355490|NCT02331381|Experimental|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
11355491|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:
~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.
~Study Treatment:
~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
11355492|NCT02331316|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake
~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355493|NCT02331316|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake
~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355494|NCT02331316|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake
~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355495|NCT02331316|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake
~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355496|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.
~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
11355497|NCT02331290||All patients|20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV
11355498|NCT02331277|Experimental|Multiple dose|Weekly dosing for four weeks
11355499|NCT02331277|Placebo Comparator|Placebo|Placebo
11355500|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
11355501|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
11355502|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
11355503|NCT02331251|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
11355504|NCT02331251|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
11355505|NCT02331251|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
11355506|NCT02331251|Experimental|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
11355507|NCT02331251|Experimental|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
11355508|NCT02331251|Experimental|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
11355509|NCT02331238|No Intervention|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
11355510|NCT02331238|Experimental|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).
~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
11355511|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
11355512|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
11355513|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
11355514|NCT02331212||Ancillary-correlative (role of HAS2+ in CSCs)|Blood and bone marrow samples are collected and analyzed via flow cytometry and PCR. Cells are also transplanted into mice and studied.
11355515|NCT02331199|Experimental|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
11355516|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
11355517|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
11355518|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
11355519|NCT02331160|Experimental|Rebozo|Intervention by Rebozo
11355520|NCT02331160|No Intervention|Control|Standard
11355521|NCT02331147|Sham Comparator|Standard of Care|Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading
11355522|NCT02331147|Active Comparator|Human Dermis|"Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.
~If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion"
11355523|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
11355524|NCT02331121|Active Comparator|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief & first aid
11355525|NCT02331121|Experimental|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief & first aid
11355526|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
11355527|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
11355528|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
11355529|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
11355530|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
11355531|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
11355607|NCT02330601|No Intervention|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
11355532|NCT02331095|Active Comparator|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
11355533|NCT02331095|Experimental|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
11355534|NCT02331082|Active Comparator|Control|Existing healthcare system
11355535|NCT02331082|Experimental|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
11355536|NCT02331069|Active Comparator|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
11355537|NCT02331069|Active Comparator|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
11355538|NCT02331056||thoracoscopic pulmonary lobectomy|to observe a fluid responsiveness in patients who receives scheduled thoracoscopic pulmonary lobectomy
11355539|NCT02331056||open pulmonary lobectomy(thoracotomy)|to observe a fluid responsiveness in patients who receives scheduled open pulmonary lobectomy(thoracotomy)
11355540|NCT02331043|Placebo Comparator|Placebo biscuit|Biscuit without plant stanol ester
11355541|NCT02331043|Experimental|Plant stanol ester biscuit|Biscuit with plant stanol esters
11355542|NCT02331030|Experimental|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
11355543|NCT02331030|Active Comparator|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
11355544|NCT02331017|Experimental|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.
~Administration of Speech perception tests and self-rating questionnaire"
11355545|NCT02331004|Active Comparator|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
11355546|NCT02331004|Placebo Comparator|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
11355547|NCT02330991|Experimental|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
11355548|NCT02330991|Experimental|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
11355549|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
11355550|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
11355551|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
11355552|NCT02330952|Experimental|Prednisone|
11355553|NCT02330952|Placebo Comparator|Placebo|
11355554|NCT02330939|Active Comparator|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
11355555|NCT02330939|Experimental|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
11355556|NCT02330939|Experimental|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
11355557|NCT02330939|Active Comparator|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
11355558|NCT02330939|Experimental|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
11355559|NCT02330939|Experimental|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
11355560|NCT02330926|Experimental|multimodal intervention|standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)
11355561|NCT02330926|Active Comparator|standard care|standard palliative care
11355562|NCT02330913|Experimental|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
11355563|NCT02330900|No Intervention|Study group|Evaluation of interference
11355564|NCT02330887|Experimental|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
11355565|NCT02330887|Active Comparator|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
11355566|NCT02330861|Other|Normal coronary artery|
11355567|NCT02330848|Active Comparator|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
11355568|NCT02330848|Active Comparator|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
11355605|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
11355569|NCT02330835|Experimental|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
11355570|NCT02330835|Active Comparator|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
11355571|NCT02330822|Experimental|Hyaluronic Acid Group|In this Group, Hyaluronic acid will be injected following extraction.
11355572|NCT02330822|No Intervention|Traditional Extraction Group|In this group, traditional extraction procedures will be followed.
11355573|NCT02330809|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355574|NCT02330809|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355575|NCT02330809|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals
~Intervention-B: Drink extra water at anytime over 24 hours"
11355576|NCT02330809|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.
~Intervention-B: Drink extra water at anytime over 24 hours"
11355577|NCT02330796|Experimental|Arm A|Bucillamine (900 mg total dose over 7 days)
11355578|NCT02330796|Experimental|Arm B|Bucillamine (1,800 mg total dose over 7 days)
11355579|NCT02330796|Active Comparator|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
11355580|NCT02330783|Experimental|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
11355581|NCT02330783|Active Comparator|Sorafenib|Sorafenib 400mg Bid
11355582|NCT02330770|Active Comparator|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
11355583|NCT02330770|Active Comparator|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
11355584|NCT02330770|Active Comparator|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
11355585|NCT02330757|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
11355586|NCT02330757|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
11355587|NCT02330744|Experimental|Approach-positive AAT|Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
11355588|NCT02330744|Placebo Comparator|Control AAT|Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
11355589|NCT02330731|Other|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
11355590|NCT02330731|Other|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
11355591|NCT02330731|Other|72% chromated glycerin|injection sclerotherapy for gastric varices
11355592|NCT02330705|Active Comparator|Group A|IUI at time of HCG
11355593|NCT02330705|Active Comparator|Group B|IUI 12 hours after HCG
11355594|NCT02330705|Active Comparator|Group C|IUI 34-36 hours after HCG
11355595|NCT02330679|Other|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
11355596|NCT02330666|No Intervention|Comparison|Standard care
11355597|NCT02330666|Experimental|Intervention|Communication skills training Mission Possible: Parents & Kids Who Listen
11355598|NCT02330653|Experimental|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
11355599|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
11355600|NCT02330640|Experimental|ticagrelor|90mg Bid for 30days after first dose
11355601|NCT02330640|Active Comparator|clopidogrel|75mg Qd for 30days first dose
11355602|NCT02330640|Other|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
11355603|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
11355604|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
11355740|NCT02329782|Experimental|ARP intervention|Adherence counseling intervention
11355608|NCT02330601|Other|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
11355609|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
11355610|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
11355611|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
11355612|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
11355613|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
11355614|NCT02330575|Active Comparator|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
11355615|NCT02330575|Experimental|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
11355616|NCT02330562|Experimental|Phase 1: MRZ + BEV; Phase 2: MRZ alone|"Part1-Phase1: MRZ 10 minute IV infusion on Days 1, 8, and 15 plus BEV IV infusion on Days 1 and 15 of each 28-day cycle.
~Part2-Phase2: MRZ 10 minute IV infusion administered on Days 1, 8, and 15 of each 28-day cycle.
~Part3-Phase2: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion on Days 1, 8, and 15 of every 28-day cycle using intra-patient dose escalation. Starting dose will be 0.8 mg/m2.
~Part4- Phase1: All subjects will receive MRZ enterally by NG tube as a bolus on Days 1, 8 and 15 of the first 28-day cycle and BEV IV infusion on Day 15 of the first 28-day cycle. For subsequent 28-day treatment cycles, MRZ will be administered as an IV at the recommended dose and schedule determined in Part 1, with BEV IV on Days 1 and 15.
~Part5-Phase1: All subjects will receive IV MRZ infusion and IV BEV infusion. MRZ will be administered as a 10-minute, IV infusion at 0.8 mg/m2 on Days 1, 8, and 15 of every 28-day cycle 0.8 mg/m2"
11355617|NCT02330549|Experimental|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
11355618|NCT02330549|Placebo Comparator|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
11355619|NCT02330536|Experimental|Flowrate A|insufflation of carbon dioxide at 8L/min
11355620|NCT02330536|Experimental|Flowrate B|insufflation of carbon dioxide at 16L/min
11355621|NCT02330523|Active Comparator|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
11355622|NCT02330523|Active Comparator|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
11355623|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
11355624|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
11355625|NCT02330497|Experimental|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
11355626|NCT02330484|Experimental|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
11355627|NCT02330484|Experimental|incentives to patients|Give incentives to patients according to their HbA1c improvement
11355628|NCT02330484|Experimental|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
11355629|NCT02330484|No Intervention|Group with no incentives|
11355630|NCT02330471|Experimental|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
11355631|NCT02330471|Active Comparator|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
11355632|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
11355633|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
11355741|NCT02329782|No Intervention|usual care|no intervention, standard care practices regarding adherence support
11355742|NCT02329769|Experimental|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
11355634|NCT02330432|Experimental|Mycobacterium w group|Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
11355635|NCT02330432|Active Comparator|Best standard care|Best standard care for sepsis
11355636|NCT02330419|Placebo Comparator|Placebo|Placebo 50mg, as needed
11355637|NCT02330419|Active Comparator|Naltrexone|Naltrexone 50mg, as needed
11355638|NCT02330406|Active Comparator|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
11355639|NCT02330406|Active Comparator|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
11355640|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
11355641|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is <100Kg or 90mg if the patient is >100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
11355642|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
11355643|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
11355644|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is <80Kg or 35mg if the patient is >80Kg.
11355645|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
11355646|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
11355647|NCT02330367|Experimental|AC0010|Oral AC0010 monotherapy
11355648|NCT02330354|Experimental|Intervention group|Centers in this group will participate in the Healthy Me, Healthy We program.
11355649|NCT02330354|Other|Control Group|Centers in this group will participate in the Healthy Me, Healthy We program after follow-up measures are collected.
11355650|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
11355651|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
11355652|NCT02330328|Experimental|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
11355653|NCT02330328|Active Comparator|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
11355654|NCT02330315|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
11355655|NCT02330315|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
11355656|NCT02330302|Active Comparator|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
11355657|NCT02330302|Active Comparator|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
11355658|NCT02330289|Experimental|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
11355659|NCT02330289|No Intervention|Control arm|Physicians in the control arm will not receive the email or website link.
11355660|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
11355661|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
11355662|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
11355663|NCT02330263|Experimental|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
11355664|NCT02330263|No Intervention|control group|Patients in the control group consume no food or drink after midnight before surgery.
11355665|NCT02330250|Experimental|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
11355666|NCT02330250|Sham Comparator|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
11355667|NCT02330237|Active Comparator|patients|natural gels
11355668|NCT02330237|Placebo Comparator|subjects|These patients will receive that placebo (vehicle) products.
11355669|NCT02330224|Experimental|Hypertension Management Intervention|Multifaceted hypertension management intervention
11355670|NCT02330224|No Intervention|Usual Care|Control group
11355671|NCT02330185|Experimental|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
11355672|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.
~When the end of operation, a injection of neostigmine or sugammadex will be administered."
11355673|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.
~When the end of operation,, a injection of neostigmine or sugammadex be administered."
11355674|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
11355675|NCT02330146|Experimental|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
11355676|NCT02330146|Placebo Comparator|Placebo|cryomedium
11355677|NCT02330133|Experimental|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
11355678|NCT02330133|Active Comparator|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
11355679|NCT02330120|Experimental|propofol|Propofol infusion 0.5-2 mg/kg/h for sedation in mechanically ventilated patients
11355680|NCT02330120|Active Comparator|dexmedetomidine|dexmedetomidine infusion 0.2-0.7 mcg/kg/h for sedation in mechanically ventilated patients
11355681|NCT02330107|Experimental|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
11355682|NCT02330107|Experimental|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
11355683|NCT02330107|Placebo Comparator|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
11355684|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
11355685|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
11355686|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:
~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.
~radio-labeled platelets derived from subjects untreated fresh whole blood."
11355687|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
11355688|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
11355689|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.
~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
11355690|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.
~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
11355691|NCT02330042||Group A|"Patients with:
~Type 1 or Type 2 diabetes mellitus
~severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR)."
11355692|NCT02330042||Group B|"Patients with:
~Type 1 or Type 2 diabetes mellitus
~with or without mild to moderate NPDR"
11355693|NCT02330042||Group C (controls)|Patients without diabetes or evidence of any form of eye disease
11355694|NCT02330029|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
11355695|NCT02330029|Active Comparator|Pinaverium|
11355696|NCT02330029|Placebo Comparator|Placebo|Placebo is blindly given to patients
11355697|NCT02330016|Experimental|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
11355698|NCT02330003|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
11355699|NCT02330003|Active Comparator|TIV PFS|Fluarix Prefilled Syringe
11355700|NCT02329990|Active Comparator|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
11355701|NCT02329990|Placebo Comparator|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
11355702|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
11355703|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
11355743|NCT02329769|Experimental|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
11355704|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group
~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg
~Muscle relaxant agent : Rocuronium 1mg/kg
~After endotracheal intubation : normal saline(0.025 ml/kg)
~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg
~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
11355705|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group
~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg
~Muscle relaxant agent :Succinylcholine 1mg/kg
~After endotracheal intubation : Cisatracurium 0.08mg/kg
~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg
~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
11355706|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
11355707|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
11355708|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
11355709|NCT02329938|Active Comparator|Lichtenstein tension free reair|mesh repair of inguinal hernia
11355710|NCT02329938|Active Comparator|Desarda's repair|non-mesh repair of inguinal hernia
11355711|NCT02329925|Experimental|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
11355712|NCT02329912|Experimental|Patients after abdominal surgery|SmartPill application after abdominal surgery
11355713|NCT02329912|Sham Comparator|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
11355714|NCT02329899||Possible MBD|"Defined by:
~a bleeding score >= 4 in adults;
~a bleeding score >= 2 in children (for girls, up to menses);
~a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;
~a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.
~In this group, the second step of investigations will be performed."
11355715|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.
~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
11355716|NCT02329873|Experimental|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
11355717|NCT02329873|No Intervention|Control group|Control group received usual care and health education.
11355718|NCT02329860|Experimental|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
11355719|NCT02329860|Placebo Comparator|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
11355720|NCT02329847|Experimental|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11355721|NCT02329847|Experimental|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11355722|NCT02329847|Experimental|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11355723|NCT02329847|Experimental|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11355724|NCT02329847|Experimental|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11355725|NCT02329847|Experimental|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11355726|NCT02329834|Experimental|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
11355727|NCT02329834|Experimental|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
11355728|NCT02329821||HCC group|patients with hepatocellular carcinoma
11355729|NCT02329821||donor group|patient for liver transplantation donation
11355730|NCT02329808||Mycophenolic acid|Patients treated for their regular patient care with mycophenolic acid.
11355731|NCT02329808||Cyclosporin|Patients treated for their regular patient care with cyclosporin.
11355732|NCT02329808||Tacrolimus|Patients treated for their regular patient care with tacrolimus.
11355733|NCT02329808||Sirolimus|Patients treated for their regular patient care with sirolimus.
11355734|NCT02329808||Everolimus|Patients treated for their regular patient care with everolimus.
11355735|NCT02329808||Voriconazole|Patients treated for their regular patient care with voriconazole.
11355736|NCT02329808||Posaconazole|Patients treated for their regular patient care with posaconazole.
11355737|NCT02329808||Itraconazole+metabolite|Patients treated for their regular patient care with itraconazole.
11355738|NCT02329808||Fluconazole|Patients treated for their regular patient care with fluconazole.
11355739|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
11355745|NCT02329756|Active Comparator|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
11355746|NCT02329756|Placebo Comparator|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
11355747|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
11355748|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
11355749|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
11355750|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
11355751|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
11355752|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
11355753|NCT02329717|Experimental|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
11355754|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min
~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
11355755|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min
~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
11355756|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
11355757|NCT02329678|Active Comparator|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
11355758|NCT02329678|Active Comparator|Control group|Control Group:No membrane was placed after periapical surgery.
11355759|NCT02329665|Experimental|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
11355760|NCT02329652|Experimental|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
11355761|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
11355762|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
11355763|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.
~Intervention: PET CT 18 FDG"
11355764|NCT02329613|Active Comparator|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.
~Intervention: Standard evening meals."
11355765|NCT02329613|Experimental|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
~Intervention: Improved evening meal"
11355766|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
11355767|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
11355768|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
11355769|NCT02329587|Experimental|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
11355770|NCT02329587|Active Comparator|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
11355771|NCT02329561|Active Comparator|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
11355772|NCT02329561|Placebo Comparator|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
11355773|NCT02329548|Experimental|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
11355774|NCT02329535|Experimental|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
11355775|NCT02329535|No Intervention|No treatment|No treatment. Regular follow up
11355847|NCT02329067|Experimental|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
11355776|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
11355777|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
11355778|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
11355779|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
11355780|NCT02329509|Active Comparator|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
11355781|NCT02329509|Active Comparator|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
11355782|NCT02329496|Experimental|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
11355783|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
11355784|NCT02329470|Experimental|No device, n=50|Withdrawal of device, CPAP, of obstructive sleep apnea treatment during 5 nights
11355785|NCT02329470|No Intervention|Device, CPAP, n=50|Continues with device, CPAP, treatment for obstructive sleep apnea during the study frame
11355786|NCT02329457|Experimental|ID varicella zoster vaccine (VZVv) group|intradermal 0.65 mL Zostavax
11355787|NCT02329457|Active Comparator|SC VZVv group|subcutaneous 0.65 mL Zostavax
11355788|NCT02329457|Placebo Comparator|ID NS Group|intradermal 0.65 mL normal saline
11355789|NCT02329457|Placebo Comparator|SC NS Group|subcutaneous 0.65 mL normal saline
11355790|NCT02329444|Experimental|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
11355791|NCT02329444|Active Comparator|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
11355792|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
11355793|NCT02329431|Active Comparator|support group|Parent-directed support group
11355794|NCT02329418|Experimental|Written document|Accompanying relatives with a written document when discussing withholding and withdrawing life-sustaining therapies . All other procedures are standard.
11355795|NCT02329418|Active Comparator|Standard|Discussing withholding and withdrawing life-sustaining therapies following standard procedure without written document
11355796|NCT02329405|Experimental|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
11355797|NCT02329405|Placebo Comparator|Placebo|Placebo tablet once a day orally for a week.
11355798|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
11355799|NCT02329379|Experimental|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
11355800|NCT02329379|Active Comparator|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
11355801|NCT02329379|No Intervention|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
11355802|NCT02329379|No Intervention|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
11355803|NCT02329379|Experimental|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
11355804|NCT02329379|Active Comparator|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
11355805|NCT02329379|No Intervention|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
11355806|NCT02329379|No Intervention|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
11355807|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
11355808|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
11355809|NCT02329353|Experimental|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
11356277|NCT02326129||Normal weight|Normal weight adolescents
11355810|NCT02329353|Experimental|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
11355811|NCT02329340|Active Comparator|Am Academy of Pediatrics print materials|In-person session to read online version of American Academy of Pediatrics The Injury Prevention Program (TIPP sheets) childhood injury prevention print materials, followed by access to the TIPP sheets for 30 days.
11355812|NCT02329340|Experimental|Family Safety 1-2-3|In-person session to view video and text-based interactive web site on injury prevention information and strategies, followed by 8 emails delivered over a 30-day period inviting participant to view additional child safety videos.
11355813|NCT02329327|Experimental|Single Arm|
11355814|NCT02329301|Experimental|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
11355815|NCT02329301|Experimental|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
11355816|NCT02329301|No Intervention|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
11355817|NCT02329288|Active Comparator|Triamcinolone Acetonide|40mg/1ml
11355818|NCT02329288|Placebo Comparator|placebo|1ml
11355819|NCT02329275||Azoospermic men|
11355820|NCT02329275||Men with proven fertility|
11355821|NCT02329262|Experimental|Mentoring to be Active|Trained teen mentors will deliver the physical activity curriculum to high school students in a school setting. Physical activity will be measured with accelerometers.
11355822|NCT02329262|Active Comparator|Planning to be Active|High school teachers will deliver the physical activity curriculum (usual care) to high school students enrolled in health education courses. Physical activity will be measured with accelerometers.
11355823|NCT02329249|Experimental|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
11355824|NCT02329249|Other|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
11355825|NCT02329236||children with constitutional growth delay|
11355826|NCT02329236||children with Familial short stature|
11355827|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
11355828|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
11355829|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
11355830|NCT02329197|Experimental|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
11355831|NCT02329197|No Intervention|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
11355832|NCT02329184|Experimental|MYK-461|
11355833|NCT02329171|Experimental|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
11355834|NCT02329171|Active Comparator|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
11355835|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
11355836|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
11355837|NCT02329145|Experimental|Active treatment|Renal denervation
11355838|NCT02329145|No Intervention|Observational|
11355839|NCT02329119|Experimental|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
11355840|NCT02329119|Active Comparator|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
11355841|NCT02329106|Experimental|NanoKnife LEDC System|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System, alao called Irreversible electroporation (IRE), 90 pulses of 70 microseconds each in duration will be administered per electrode pair.
11355842|NCT02329106|No Intervention|Control|The patients without treatment
11355843|NCT02329093|Experimental|Bone Signal Changes|
11355844|NCT02329080|Experimental|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 & d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5
~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4
~*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.
~Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 & d-4 ASCT: 5 x 106 CD34+cells/kg d0
~**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 & d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
11355845|NCT02329067|Experimental|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
11355846|NCT02329067|Experimental|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
11356278|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
11355848|NCT02329067|No Intervention|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
11355849|NCT02329054|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
11355850|NCT02329041|Experimental|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
11355851|NCT02329041|Active Comparator|Airtraq|DLT intubation with Airtraq videolaryngoscope
11355852|NCT02329028||Prehospital mini-EEG|Feasibility of prehospital EEG device in unconscious patients.
11355853|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
11355854|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
11355855|NCT02328989|Experimental|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
11355856|NCT02328989|No Intervention|No pessary|No pessary will be placed in the vagina.
11355857|NCT02328976|Experimental|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
11355858|NCT02328976|Experimental|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
11355859|NCT02328963|Experimental|Everolimus|Everolimus + reduced dose of cyclosporine A
11355860|NCT02328963|Active Comparator|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
11355861|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
11355862|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
11355863|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
11355864|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
11355865|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
11355866|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
11355867|NCT02328924|Other|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
11355868|NCT02328924|Other|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
11355869|NCT02328911|Experimental|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
11355870|NCT02328911|Sham Comparator|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
11355871|NCT02328898|Experimental|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
11355872|NCT02328898|Active Comparator|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
11355873|NCT02328885|Experimental|Experimental|DLI of the 20 fraction of the UCBT
11355874|NCT02328872|Experimental|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
11355875|NCT02328872|Active Comparator|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
11355876|NCT02328859|Experimental|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
11355877|NCT02328859|Active Comparator|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
11355878|NCT02328833|Experimental|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
11355879|NCT02328833|No Intervention|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
11355880|NCT02328820|Other|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
11355881|NCT02328807|Experimental|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
11355882|NCT02328794|Active Comparator|Control|Participants randomized to this arm will receive a standardized Vitality program aimed at promoting tobacco cessation. This program includes existing employee benefits for quitting and the use of text/email messages to encourage tobacco cessation. No incentives will be given to participants randomized to this arm. Free cessation aids will not be available to participants in this arm. They will receive compensation for completing study related activities (sample submissions).
11355883|NCT02328794|Experimental|E-cigarette free access|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes only. These products can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
11355918|NCT02328612|Experimental|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
11355919|NCT02328612|Experimental|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
11355920|NCT02328612|Placebo Comparator|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
11355921|NCT02328599||Surgical|Prior Bariatric surgery
11355884|NCT02328794|Experimental|E-cigarette/NRT/Zyban/Chantix Choice|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes, conventional Nicotine Replacement Therapy (NRT), Zyban, or Chantix. Each of these can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
11355885|NCT02328794|Experimental|Outcome Incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition, they will also be able to earn incentives across six months for testing negative for tobacco use (see Incentive payout, below). They will also receive compensation for completing study related activities (sample submissions).
11355886|NCT02328794|Experimental|Loss framing incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition they will also be able to earnincentives across six months through a pre-funded deposit or precommitment account. They will be notified that money has been placed into an account for them. At each time point they will lose a portion (see below) of this initial funding if they do not provide biochemical evidence of abstinence. They will also receive compensation for completing study related activities (sample submissions).
11355887|NCT02328781|Experimental|Experimental|Drug-eluting stent
11355888|NCT02328768|Experimental|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 8-24 hours every day until the patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
11355889|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.
~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
11355890|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)
~Intervention: Hysteroscopy + endometrial biopsy
~Intervention: Telephone call"
11355891|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.
~Intervention: Hysteroscopy + endometrial biopsy
~Intervention: Resection + endometrial biopsy
~Intervention: Follow-up hysteroscopy + endometrial biopsy
~Intervention: Telephone call"
11355892|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.
~Intervention: Hysteroscopy + endometrial biopsy
~Intervention: Resection + endometrial biopsy
~Intervention: Follow-up hysteroscopy + endometrial biopsy
~Intervention: Telephone call"
11355893|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
11355894|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
11355895|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
11355896|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
11355897|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
11355898|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
11355899|NCT02328716|Active Comparator|Comparator|Comparator
11355900|NCT02328716|Experimental|Experimental|Experimental
11355901|NCT02328703|Experimental|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
11355902|NCT02328703|Placebo Comparator|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
11355903|NCT02328690|Experimental|Music with BBT|Music embedded with special tones.
11355904|NCT02328690|Placebo Comparator|Music without BBT|Music not embedded with special tones.
11355905|NCT02328677||ColoCare FHCRC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=611
11355906|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=835
11355907|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=683
11355908|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=294
11355909|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=203
11355910|NCT02328677||University of Washington St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=195
11355911|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=153
11355912|NCT02328664|Other|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
11355913|NCT02328651|Experimental|Ribavirin treatment plus testing drug|
11355914|NCT02328651|Active Comparator|Ribavirin treatment|
11355915|NCT02328638|Active Comparator|Manual-based Behavioral Treatment|up to 16 weekly behavioral therapy sessions (intervention) following the CHANGE obesity manual, lasting approximately 45 minutes and nutritional therapy sessions, lasting approximately 30 to 60 minutes.
11355916|NCT02328638|Placebo Comparator|Parent Education Program|up to 16 weekly behavioral therapy sessions following the parent education program
11355917|NCT02328612|Experimental|First arm|250,000 cells/kg will be administered via intravenous infusion.
11355923|NCT02328586|Experimental|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
11355924|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
11355925|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
11355926|NCT02328560||Paramedical ad consultation|Monitoring will be the same in the 2 groups; That paramedical consultation announcement is made in current practice.
11355927|NCT02328560||No paramedical ad consultation|Monitoring will be the same in the 2 groups
11355928|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
11355929|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
11355930|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by
~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
11355931|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by
~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
11355932|NCT02328521|Experimental|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
11355933|NCT02328521|Placebo Comparator|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
11355934|NCT02328508|Experimental|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
11355935|NCT02328508|No Intervention|Control|The control group received only routine care.
11355936|NCT02328495|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
11355937|NCT02328495|Active Comparator|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
11355938|NCT02328482|Experimental|Arm 1|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
11355939|NCT02328482|No Intervention|Arm 2|no-treatment concurrent control; follow-up over 52 weeks
11355940|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
11355941|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
11355942|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
11355943|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
11355944|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
11355945|NCT02328456|Other|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
11355946|NCT02328456|No Intervention|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
11355947|NCT02328443|Experimental|midazolam alone|midazolam administration alone
11355948|NCT02328443|Experimental|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
11355949|NCT02328443|Experimental|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
11355950|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
11355951|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:
~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
11355952|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
11355953|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
11355954|NCT02328378|Active Comparator|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
11355955|NCT02328378|Placebo Comparator|Control Group|patients will receive a bilateral placebo block
11355956|NCT02328365|No Intervention|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
11355957|NCT02328365|Experimental|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
11355958|NCT02328352|Experimental|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
11355959|NCT02328352|Active Comparator|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.
~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
11355960|NCT02328352|Experimental|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
11355961|NCT02328352|Active Comparator|control group|Five rabbits (R26-R30) will be used as control group.
11355962|NCT02328339|Experimental|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
11355963|NCT02328339|Placebo Comparator|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
11355964|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
11355965|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
11355966|NCT02328313|Experimental|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
11355967|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.
~All participants will receive a FLT PET/MR scan."
11355968|NCT02328287|Experimental|ALLOB® Implantation|
11355969|NCT02328261|Experimental|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
11355970|NCT02328248|Experimental|Biological patch|Use biological patch (Biodesign Surgisis Tissue Graft from Cook Biotech Incorporated) to repair hiatal hernia laparoscopically
11355971|NCT02328248|Placebo Comparator|Plastic patch|Use plastic patch (Parietex Composite from Sofradim Production) to repair hiatal hernia laparoscopically
11355972|NCT02328235|Experimental|High Saturated Fat Diet|Subjects will receive a high fat diet for 5 day following a 2 week lead in diet. Measurements will be made pre-post high fat diet
11355973|NCT02328222|No Intervention|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
11355974|NCT02328222|Experimental|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
11355975|NCT02328209|Experimental|ranibizumab|ranibizumab
11355976|NCT02328183|Experimental|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
11355977|NCT02328170||EUROIMMUN Allergy|Immunoblot assay
11355978|NCT02328170||ImmunoCap|Fluoroallergosorbent test
11355979|NCT02328157|Experimental|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
11355980|NCT02328144|Active Comparator|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
11355981|NCT02328144|Placebo Comparator|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
11355982|NCT02328118|Experimental|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
11355983|NCT02328118|Experimental|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
11355984|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
11355985|NCT02328092|Active Comparator|Real group|The real group received biphasic rSMS using a Magstim Super Rapid (Magstim, Whitland, UK) stimulator connected to a 120-mm outer diameter figure-of-8 air film cooling coil positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2). Stimulation was delivered at 15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upward. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off.
11355986|NCT02328092|Sham Comparator|Sham Group|The control group received sham rSMS stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
11355987|NCT02328079|Active Comparator|Steroid Group|prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
11355988|NCT02328079|Active Comparator|Steroid + Antiviral Group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
11356029|NCT02327806|Other|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
11356279|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
11355989|NCT02328066|Experimental|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
11355990|NCT02328053|Experimental|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
11355991|NCT02328053|Active Comparator|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
11355992|NCT02328040|Placebo Comparator|Part A|Placebo and Insulin monotherapy via CL
11355993|NCT02328040|Active Comparator|Part B|Sitagliptin and insulin/novolog via CL
11355994|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
11355995|NCT02328014|Experimental|Dose Escalation|The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.
11355996|NCT02328014|Experimental|Expansion|Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.
11355997|NCT02328001|No Intervention|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
11355998|NCT02328001|Other|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
11355999|NCT02327988|Experimental|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
11356000|NCT02327988|Experimental|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
11356001|NCT02327988|No Intervention|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
11356002|NCT02327975|Experimental|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
11356003|NCT02327975|Experimental|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
11356004|NCT02327975|Other|Control group|No received intervention.
11356005|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
11356006|NCT02327962||Control|Hemodynamic measurements with PWV
11356007|NCT02327949|Experimental|WP group|WP group:treated with W-Shaped Angular Plate
11356008|NCT02327949|Active Comparator|RP group|RP group:treated with Reconstruction Plate
11356009|NCT02327936|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 4 weeks, for a total of 8 weeks
11356010|NCT02327936|Active Comparator|Oxybutynin XL 10mg|Oxybutynin XL 10 mg Po Die, dose could be increased to 20 mg Po Die after 4 weeks, for a total of 8 weeks
11356011|NCT02327923|Active Comparator|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
11356012|NCT02327923|Active Comparator|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
11356013|NCT02327910|No Intervention|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
11356014|NCT02327910|Experimental|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
11356015|NCT02327910|Experimental|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
11356016|NCT02327897||1|Asthamatic
11356017|NCT02327897||2|Non-asthmatic
11356018|NCT02327884||Group 1|Healthy Volunteers matched with Sjorgren's Syndrome patients
11356019|NCT02327884||Group 2|Family Members, affected and unaffected
11356020|NCT02327884||Group 3|any other cause salivary gland dysfunction
11356021|NCT02327871|Experimental|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
11356022|NCT02327858|Experimental|Supportive text message group|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months .
11356023|NCT02327858|No Intervention|No supportive text message group|Patients in the control group will only receive a text message once every two weeks thanking them for participating in the study. The aim of this will be to help increase the retention rate for the study.
11356024|NCT02327845||Affected|Affected with any of the diseases that are the focus of study by the CReATe Consortium, including ALS, ALS-FTD, HSP, PLS, PMA and MSP.
11356025|NCT02327845||Unaffected|Unaffected family members of enrolled affected individuals.
11356026|NCT02327832|Experimental|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
11356030|NCT02327806|Other|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
11356031|NCT02327806|Other|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
11356032|NCT02327793|No Intervention|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure <100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
11356033|NCT02327793|Experimental|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
11356034|NCT02327793|Experimental|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure >120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
11356035|NCT02327780|Other|FODMAP diet|participants will be put on a low FODMAP diet.
11356036|NCT02327767|Experimental|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
11356037|NCT02327767|No Intervention|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
11356038|NCT02327754|Active Comparator|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
11356039|NCT02327754|Placebo Comparator|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
11356040|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
11356041|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
11356042|NCT02327728|Experimental|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
11356043|NCT02327728|Active Comparator|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
11356044|NCT02327715|Experimental|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
11356045|NCT02327702|Experimental|Chinese naive pregnant chronice hepatitis B|Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
11356046|NCT02327689|Experimental|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
11356047|NCT02327689|Experimental|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
11356048|NCT02327676|Experimental|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
11356049|NCT02327663|Experimental|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
11356050|NCT02327663|Experimental|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
11356051|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
11356052|NCT02327637|No Intervention|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:
~Receive recommendation for bedrest (standard of care).
~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).
~Wear a pedometer to measure activity when out of bed (observational study procedure)."
11356053|NCT02327637|Experimental|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:
~Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).
~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).
~Wear a pedometer to measure activity when out of bed (observational study procedure)."
11356054|NCT02327624|Active Comparator|Clopidogrel|The standard antiplatelet treatment for patients is pretreatment with aspirin and clopidogrel. In this trial patients will be randomised in clopidogrel orTicagrelor of two doses
11356055|NCT02327624|Experimental|Ticagrelor 60|Ticagrelor 60 is a new dosage to be tried in this trial.
11356056|NCT02327624|Experimental|Ticagrelor 90|Ticagrelor 90 is used following clopidogrel as maintenance therapy with aspirin 75 mg daily and clopidogrel 75 mg daily following PCI for at least 1 month.
11356057|NCT02327611|Experimental|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
11356058|NCT02327611|Active Comparator|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
11356128|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
11356280|NCT02326103|Active Comparator|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
11356059|NCT02327585|Experimental|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
11356060|NCT02327559|Experimental|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
11356061|NCT02327559|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
11356062|NCT02327546|Experimental|AKB-6548|AKB-6548
11356063|NCT02327546|Experimental|AKB-6548 plus Ferrous Sulfate|AKB-6548 plus ferrous sulfate
11356064|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
11356065|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
11356066|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
11356067|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
11356068|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
11356069|NCT02327481|Experimental|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
11356070|NCT02327481|Active Comparator|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
11356071|NCT02327455|Experimental|Stress Dobutamine Echocardiographic 4DE Image System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
11356072|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
11356073|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
11356074|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
11356075|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
11356076|NCT02327416|Active Comparator|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
11356077|NCT02327416|Experimental|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
11356078|NCT02327416|Experimental|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
11356079|NCT02327403|Active Comparator|B7-1 positivity on kidney allograft biopsy|Belatacept conversion
11356080|NCT02327403|Active Comparator|B7-1 negativity on kidney allograft biopsy|Belatacept conversion
11356081|NCT02327390|Experimental|X-ACT lymph node cell dose and schedule|"All patients will begin at dose level 1 and will be moved to higher dosing levels as long as the patient does not experience two or more dose limiting toxicities and maintains an acceptable performance status. A minimum of three patients will be enrolled per dose level and no patients will be enrolled on higher dose levels if dose limiting toxicities are encountered.
~Dose level 1: 0.5 x 10^10 X-ACT cells. 2 infusions 4 weeks apart
~Dose level 2: 1.0 x 10^10 X-ACT cells. 1 infusion
~Dose level 3: 0.5 x 10^10 X-ACT cells. 4 infusions 4 weeks apart
~Dose level 4: 1.0 x 10^10 X-ACT cells. 2 infusions 4 weeks apart
~Dose level -1: 0.5 x 10^10 X-ACT cells. 1 infusion (if necessary)"
11356082|NCT02327377|Experimental|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
11356083|NCT02327377|Active Comparator|Online Education|Educational information about pain
11356084|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
11356085|NCT02327338|Experimental|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
11356086|NCT02327338|Experimental|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
11356087|NCT02327338|No Intervention|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
11356088|NCT02327338|Sham Comparator|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
11356281|NCT02326103|Placebo Comparator|Placebo|Oral administration of Placebo pill twice daily
11356089|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
11356090|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
11356091|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
11356092|NCT02327312|Experimental|Surgical|Implantation of two Trabecular Meshwork stents into the study eye
11356093|NCT02327312|Active Comparator|Laser|Laser Trabeculoplasty
11356094|NCT02327299|Experimental|FePP|Bouillon fortified with 4mg FePP
11356095|NCT02327299|Experimental|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
11356096|NCT02327299|Experimental|FeSO4|Bouillon fortified with 4mg FeSO4
11356097|NCT02327299|Experimental|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
11356098|NCT02327286|Experimental|Intervention|Promote and support healthy behaviors
11356099|NCT02327286|No Intervention|Control|Conventional care for women with prior GDM.
11356100|NCT02327273|Experimental|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
11356101|NCT02327273|Experimental|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
11356102|NCT02327260|Experimental|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
11356103|NCT02327260|Experimental|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications.
11356104|NCT02327260|No Intervention|Control group (standard care)|The control group receives standard care while hospitalized.
11356105|NCT02327247|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
11356106|NCT02327247|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
11356107|NCT02327234|Experimental|Ibuprofen|400mg (2X200mg) ibuprofen single dose once
11356108|NCT02327234|Placebo Comparator|Placebo|identical appearing lactose capsules single dose 2 capsules once
11356109|NCT02327221|Active Comparator|Ovasave - Dose 10e4|
11356110|NCT02327221|Active Comparator|Ovasave - Dose 10e6|
11356111|NCT02327221|Active Comparator|Ovasave - Dose 10e7|
11356112|NCT02327221|Placebo Comparator|Placebo|
11356113|NCT02327208|Placebo Comparator|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
11356114|NCT02327208|Active Comparator|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
11356115|NCT02327208|Active Comparator|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
11356116|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
11356117|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
11356118|NCT02327182|Experimental|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
11356119|NCT02327182|Experimental|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
11356120|NCT02327169|Experimental|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
11356121|NCT02327169|Experimental|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
11356122|NCT02327169|Experimental|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
11356123|NCT02327169|Experimental|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m^2 (cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
11356124|NCT02327169|Experimental|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
11356125|NCT02327169|Experimental|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
11356126|NCT02327156|No Intervention|group L|receive 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline
11356127|NCT02327156|Active Comparator|group LD|4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
11356129|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
11356130|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
11356131|NCT02327117|Experimental|Tranexamic acid|
11356132|NCT02327117|Placebo Comparator|Normal Saline|
11356133|NCT02327104|Experimental|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
11356134|NCT02327104|Other|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
11356135|NCT02327091|Placebo Comparator|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
11356136|NCT02327091|Active Comparator|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
11356137|NCT02327078|Experimental|(Phase 1, Part 1) : Nivolumab + Epacadostat|
11356138|NCT02327078|Experimental|(Phase 2): Nivolumab + Epacadostat|
11356139|NCT02327078|Experimental|(Phase 1, Part 2): Nivolumab + Epacadostat + Chemotherapy|
11356140|NCT02327065|Active Comparator|EUS-FNA Group|FNA,Fine needle aspiration
11356141|NCT02327065|Active Comparator|EUS-FNB Group|FNB,Fine needle biopsy
11356142|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
11356143|NCT02327039|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
11356144|NCT02327039|Placebo Comparator|Placebo|Placebo 10 mg tablet once daily for 12 weeks
11356145|NCT02327026|Experimental|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
11356146|NCT02327026|Active Comparator|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
11356147|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.
~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
11356148|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.
~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
11356149|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.
~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
11356150|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
11356151|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
11356152|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 450mg|GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
11356153|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 600mg|GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
11356154|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
11356155|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
11356156|NCT02326987|Active Comparator|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
11356157|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 via IV every 3 weeks for 6 doses and Pertuzumab loading dose via IV on Cycle 1 Day 1 followed by maintenance dose via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor
11356158|NCT02326961|Experimental|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
11356159|NCT02326961|Experimental|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
11356160|NCT02326961|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
11356161|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
11356162|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
11356282|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 1.0%|One drop in each eye
11356163|NCT02326935|Experimental|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection
~Other Names:
~ADSC, mesenchymal cells, stromal cells"
11356164|NCT02326922|Experimental|Metraplant-E First prototype|Metraplant-E (first prototype) levonorgestrel-releasing intrauterine device
11356165|NCT02326922|Experimental|Metraplant-E second prototype|Metraplant-E (second prototype) levonorgestrel-releasing intrauterine device
11356166|NCT02326909|Experimental|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
11356167|NCT02326883|Experimental|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
11356168|NCT02326883|Experimental|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
11356169|NCT02326883|Active Comparator|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
11356170|NCT02326870|Experimental|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
11356171|NCT02326857||Women with breast cancer|Observational study of women with Stage II/III locally advanced breast cancer in Latin America
11356172|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
11356173|NCT02326818|Experimental|E-Stim first|Patients randomized to E-stim first then US
11356174|NCT02326818|Experimental|US first|Patients randomized to US then E-stim
11356175|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
11356176|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
11356177|NCT02326792|Experimental|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
11356178|NCT02326792|Experimental|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
11356179|NCT02326792|No Intervention|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
11356180|NCT02326779|Experimental|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
11356181|NCT02326779|No Intervention|Comparator Arm|Non-aspirin use arm as comparator
11356182|NCT02326766|Experimental|KRG|5g Korea red ginseng (KRG)
11356183|NCT02326766|Placebo Comparator|Placebo|5 g placebo (corn starch)
11356184|NCT02326753|Experimental|No. 7 oral airway|
11356185|NCT02326753|Experimental|No. 8 oral airway|
11356186|NCT02326753|Active Comparator|No. 9 oral airway|
11356187|NCT02326740|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
11356188|NCT02326740|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
11356189|NCT02326740|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
11356190|NCT02326727|Active Comparator|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
11356191|NCT02326727|Active Comparator|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
11356192|NCT02326714|Experimental|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
11356193|NCT02326714|Placebo Comparator|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
11356194|NCT02326688|Experimental|stroke patients|"Kinematic measurement of the amount of trunk displacement during a grasping task
~Two separated measurements are recorded with a 6-hours interval
~A third measurement provided by a second examinator is conducted"
11356195|NCT02326688|Experimental|control patients|"Kinematic measurement of the amount of trunk displacement during a grasping task
~Two separated measurements are recorded with a 6-hours interval
~A third measurement provided by a second examinator is conducted"
11356196|NCT02326675|Active Comparator|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
11356230|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
11356283|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 2.5%|One drop in each eye
11356197|NCT02326675|Active Comparator|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
11356198|NCT02326662|Experimental|Paraplegics Acute|Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
11356199|NCT02326662|Experimental|Paraplegics Sub-chronic|Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
11356200|NCT02326662|Experimental|Paraplegics Chronic|"Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.
~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
11356201|NCT02326662|Experimental|Tetraplegics Acute|Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
11356202|NCT02326662|Experimental|Tetraplegics Sub-chronic|"sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.
~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
11356203|NCT02326662|Experimental|Tetraplegics Chronic|Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation & Biomatrix
11356204|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
11356205|NCT02326623|Experimental|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
11356206|NCT02326623|Other|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
11356207|NCT02326610|Active Comparator|hGH, ZOMACTON® (somatropin)|For infants in the treatment group receiving ZOMACTON® (somatropin) growth hormone by injection
11356208|NCT02326610|No Intervention|No human growth hormone|No growth hormone is given.
11356209|NCT02326597|Active Comparator|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
11356210|NCT02326597|Experimental|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
11356211|NCT02326584|Experimental|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
11356212|NCT02326584|Experimental|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
11356213|NCT02326584|Experimental|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
11356214|NCT02326584|Experimental|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
11356215|NCT02326571||spontaneous intracerebral hemorrhage|
11356216|NCT02326558|Experimental|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
11356217|NCT02326558|Active Comparator|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
11356218|NCT02326545|Experimental|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
11356219|NCT02326545|Active Comparator|Online CBT|Online CBT program for children
11356220|NCT02326532|Experimental|PRO data utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm and provided to the treating physicians.
11356221|NCT02326532|Sham Comparator|PRO data not utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm but will not be provided to the treating physicians.
11356222|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
11356223|NCT02326506|Experimental|Pump speed variation|VA-ELS pump speed variations
11356224|NCT02326493|Experimental|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
11356225|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
11356226|NCT02326480||Familial obesity|Identification of genetic causes of obesity
11356227|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
11356228|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
11356229|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
11356275|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
11356231|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
11356232|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
11356233|NCT02326441|Experimental|KX2-361|
11356234|NCT02326428|Experimental|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
11356235|NCT02326428|Active Comparator|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
11356236|NCT02326415|Active Comparator|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
11356237|NCT02326415|Active Comparator|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
11356238|NCT02326389|Experimental|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
11356239|NCT02326389|Active Comparator|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
11356240|NCT02326376||CAPS patients|CAPS patients treated with anakinra, using the Kineret graduated syringe
11356241|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
11356242|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
11356243|NCT02326350|Experimental|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
11356244|NCT02326350|Placebo Comparator|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
11356245|NCT02326337|Active Comparator|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.
~Other Names:
~Topical Wound Oxygen Therapy
~TWO2"
11356246|NCT02326337|Placebo Comparator|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
11356247|NCT02326311|Active Comparator|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
11356248|NCT02326311|Experimental|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
11356249|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.
~Treatment received from Week 16-48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.
~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
11356250|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
11356251|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.
~PASI75 responders at Week 16 continue to receive Placebo.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
11356252|NCT02326285|Experimental|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
11356253|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.
~Treatment received from Week 16-48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.
~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
11356254|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.
~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
11356255|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).
~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:
~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.
~PASI75 responders at Week 16 continue to receive Placebo.
~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.
~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.
~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
11356256|NCT02326246|Experimental|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
11356257|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
11356258|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
11356259|NCT02326220|Experimental|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
11356260|NCT02326220|Experimental|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
11356261|NCT02326220|Experimental|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
11356262|NCT02326207|Experimental|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
11356263|NCT02326207|Active Comparator|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
11356264|NCT02326194|Placebo Comparator|Placebo group (one shot)|one dose
11356265|NCT02326194|Placebo Comparator|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
11356266|NCT02326194|Experimental|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
11356267|NCT02326194|Experimental|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
11356268|NCT02326181|No Intervention|control group|without inspiratory and expiratory pressure threshold training
11356269|NCT02326181|Experimental|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
11356270|NCT02326181|Experimental|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
11356271|NCT02326168|Experimental|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.
~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
11356272|NCT02326155||Remsima™|Patients who are taking Remsima™ for the treatment
11356273|NCT02326142|Experimental|OBE001|
11356274|NCT02326142|Placebo Comparator|Placebo|
11356284|NCT02326090|Placebo Comparator|Placebo ophthalmic solution|One drop in each eye
11356285|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.
~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.
~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
11356286|NCT02326051|Active Comparator|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
11356287|NCT02326051|Active Comparator|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
11356288|NCT02326038|Experimental|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
11356289|NCT02326038|Placebo Comparator|Placebo|Placebo, capsule, single oral administration
11356290|NCT02326025|Experimental|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).
~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.
~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.
~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
11356291|NCT02326025|Experimental|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV
~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.
~Olaratumab + Doxorubicin:
~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.
~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.
~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
11356292|NCT02326012|Experimental|Emotion Regulation Individual Therapy for Adolescents|
11356293|NCT02325999|Experimental|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
11356294|NCT02325999|No Intervention|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
11356295|NCT02325986|Experimental|Weekly PF with radiation|4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).
11356296|NCT02325973|Other|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
11356297|NCT02325960|Active Comparator|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter
11356298|NCT02325960|Active Comparator|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
11356299|NCT02325947|Experimental|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
11356300|NCT02325947|Sham Comparator|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
11356301|NCT02325934|Active Comparator|Reference|Stribild Standardized breakfast followed by a single dose of STB (whole tablet).
11356302|NCT02325934|Experimental|Intervention I|Stribild, crushed Standardized breakfast followed by a single dose of crushed and suspended STB.
11356303|NCT02325934|Experimental|Intervention II|Stribild, crushed 350 mL of drip feed (type) followed by a single dose of crushed and suspended STB.
11356304|NCT02325921||Renal tumor.|Patients >18 years of age with histopathologically confirmed renal tumor diagnosis.
11356305|NCT02325908||Hemodialysis patients|Dialysis patients will have their estimated dry weight measured with calf segmental bioimpedance. Based on these measurements, their dry weight will be adjusted and the amount of fluid removed during subsequent dialysis treatments will be increased by 200-300mL. The additional fluid removal will occur during 3 consecutive hemodialysis sessions. In addition, these subjects will also use VStim during these treatments. to prevent common intradialytic symptoms by promoting vascular refilling.
11356306|NCT02325908||Healthy Controls|No Intervention was administered. Both groups had their hydration status measured with segmental bioimpedance The group of healthy subjects was studied in order to obtain a range of values for normal hydration status.
11356307|NCT02325895|No Intervention|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
11356308|NCT02325895|Experimental|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
11356309|NCT02325895|Experimental|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
11356310|NCT02325882|Active Comparator|Conventional fentanyl-based epidural PCA|
11356311|NCT02325882|Experimental|dexmedetomidine to fentanyl-based intravenous PCA|
11356312|NCT02325882|Active Comparator|Conventional fentanyl-based intravenous PCA|
11356313|NCT02325869|Experimental|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
11356314|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
11356315|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
11356316|NCT02325843|Experimental|human bone marrow MSC|5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
11356317|NCT02325830|Experimental|Treatment Group|Implantation of the CARILLON Mitral Contour System
11356318|NCT02325830|No Intervention|Control Group|Optimized stable medical therapy
11356319|NCT02325817|Experimental|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
11356320|NCT02325817|Active Comparator|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
11356404|NCT02325362|Experimental|Miglustat then placebo|10 patients will received Miglustat then the placebo
11356405|NCT02325362|Experimental|Placebo then Miglustat|10 patients will received Placebo then Miglustat
11356321|NCT02325804|Active Comparator|Conventional lifestyle counseling|Randomized, open label study to assess effect of 8 weeks of Conventional lifestyle counseling (low calorie diet and exercise) on body composition, physical fitness, and metabolic parameters
11356322|NCT02325804|Active Comparator|Unconventional lifestyle counseling|"Randomized, open label study to assess effect of 8 weeks of unconventional lifestyle counseling (low calorie metabolic stairs diet and circuit-based exercise) on body composition, physical fitness, and metabolic parameters"
11356323|NCT02325791|Experimental|Part A: Suptavumab 30 mg/kg|
11356324|NCT02325791|Experimental|Part B: Placebo Matched to Suptavumab|
11356325|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg- 1 Dose|
11356326|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg - 2 Doses|
11356327|NCT02325778|Experimental|CTI First|CTI ablation prior to left atrial ablation
11356328|NCT02325778|Experimental|CTI second|CTI ablation after left atrial ablation
11356329|NCT02325765||category of RACHS-2 for cardiac surgery|ASD & VSD repair; VSD repair; Tetralogy repair; Tetralogy repair
11356330|NCT02325765||category of RACHS-3 for cardiac surgery|DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation & VSD repair
11356331|NCT02325752|No Intervention|Control|Patients in the control group received usual care by the hospital. There was no contact between the patients in the control group and the study team throughout the 3 months interval. A scheduled telephone call was made at the end of 3 months when they were invited to participate in a telephone survey.
11356332|NCT02325752|Active Comparator|Intervention|Intervention
11356333|NCT02325739|Experimental|FGF401 single agent|Approximately 168 patients enrolled
11356334|NCT02325739|Experimental|FGF401 in combination with PDR001|Approximately 70 patients enrolled
11356335|NCT02325726||Renal Resistive Index/Nephrocheck test|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are at risk to develop postoperative Acute Kidney Injury.
11356336|NCT02325713|Experimental|Sequence A-B-C1-D1|
11356337|NCT02325713|Experimental|Sequence A-B-C1-D2|
11356338|NCT02325713|Experimental|Sequence A-B-C2-D1|
11356339|NCT02325713|Experimental|Sequence A-B-C2-D2|
11356340|NCT02325713|Experimental|Sequence A-B-D1-C1|
11356341|NCT02325713|Experimental|Sequence A-B-D2-C1|
11356342|NCT02325713|Experimental|Sequence A-B-D1-C2|
11356343|NCT02325713|Experimental|Sequence A-B-D2-C2|
11356344|NCT02325713|Experimental|Sequence B-A-C1-D1|
11356345|NCT02325713|Experimental|Sequence B-A-C1-D2|
11356346|NCT02325713|Experimental|Sequence B-A-C2-D1|
11356347|NCT02325713|Experimental|Sequence B-A-C2-D2|
11356348|NCT02325713|Experimental|Sequence B-A-D1-C1|
11356349|NCT02325713|Experimental|Sequence B-A-D2-C1|
11356350|NCT02325713|Experimental|Sequence B-A-D1-C2|
11356351|NCT02325713|Experimental|Sequence B-A-D2-C2|
11356352|NCT02325700||Open aortic repair|145 patients with open aortic repair for abdominal aortic aneurysmal disease (n=139) or abdominal aortic occlusive disease (n=89)
11356353|NCT02325700||Laparoscopic aortic repair|83 patients with Laparoscopic aortic repair for abdominal aortic aneurysmal disease (n=30) or abdominal aortic occlusive disease (n=53)
11356354|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.
~Intervention: Lumbar Puncture (Standard-of-Care)"
11356355|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.
~Intervention: Lumbar Puncture (Standard-of-Care)"
11356356|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.
~Intervention: Lumbar Puncture (Standard-of-Care)"
11356357|NCT02325674||Metreleptin|Generalised lipodystrophy patients treated with Metreleptin
11356358|NCT02325661|Other|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
11356359|NCT02325648||HIPEC cytoreductive surgery|
11356360|NCT02325635|Experimental|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
11356361|NCT02325635|No Intervention|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
11356362|NCT02325596||control|Patients with only nasal septum deviation
11356363|NCT02325596||CRS sNP|Chronic Rhinosinusitis patients without nasal polyps
11356364|NCT02325596||atopic CRS wNP|Chronic Rhinosinusitis patients with allergic constitution and nasal polyps
11356365|NCT02325596||non-atopic CRS wNP|Chronic Rhinosinusitis patients with nasal polyps but not allergic constitution
11356366|NCT02325583|Experimental|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
11356367|NCT02325570|Experimental|KLOX BioPhotonic OraLum Gel + SRP|Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
11356368|NCT02325570|Other|Scaling and Root Planing (SRP)|The second half-mouth will be treated with SRP alone.
11356369|NCT02325557|Experimental|Part A|Patients will receive ADXS31-142 monotherapy. Dosing will start at 1 x 10^9 cfu IV and escalate to 1 x 10^10 if appropriate.
11356446|NCT02325050|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
11356370|NCT02325557|Experimental|Part B/Expansion|Patients will receive ADXS31-142 and pembrolizumab (MK-3475) in combination. Dosing of ADXS31-142 will start at one dose level less that appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate
11356371|NCT02325544|Experimental|CBT+SMC|12 sessions of Cognitive Behavioural Therapy adapted for DS (plus one booster session) plus standardised medical care
11356372|NCT02325544|Active Comparator|SMC|Standardised medical care provide by neurologist and/or psychiatrist
11356373|NCT02325531|Other|Low support|"Low support (toolkit only), includes the following:
~EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and
~BASIC WEBINAR, Annual, 1-hour, topics such as:
~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
11356374|NCT02325531|Other|Medium support|"Medium support (toolkit, staff training), includes the following:
~Same as above (EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation) Plus STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group Plus ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 & 3."
11356375|NCT02325531|Other|High support|"High support (toolkit, training, on-site facilitation), includes the following:
~Same as above (EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, STAFF TRAINING, and ADAPTIVE WEBINARS Plus PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
11356376|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
11356377|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
11356378|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
11356379|NCT02325492|Experimental|Aramchol 400 mg|• One tablet of Aramchol 400 mg and one tablet of Placebo
11356380|NCT02325492|Experimental|Aramchol 600 mg|• One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
11356381|NCT02325492|Placebo Comparator|Placebo|• Two tablet of Aramchol matching placebo.
11356382|NCT02325479|Experimental|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
11356383|NCT02325479|Placebo Comparator|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
11356384|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
11356385|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
11356386|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
11356387|NCT02325453||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
11356388|NCT02325453||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
11356389|NCT02325453||Open Surgery|Patients underwent gastric surgery with open approach.
11356390|NCT02325440|Experimental|Natalizumab - Washout - Fingolimod|One experimental arm: Patients receive one final dose of natalizumab 300mg followed by an 8-week washout Phase and subsequent 32-week treatment Phase with fingolimod 0.5mg o.i.d.
11356391|NCT02325427|Experimental|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
11356392|NCT02325427|Sham Comparator|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
11356393|NCT02325427|No Intervention|no stimulation|Subjects will not received any intervention.
11356394|NCT02325414|Experimental|Zol/Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline and at 12 months.
11356395|NCT02325414|Experimental|Zol/Placebo|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline. Intravenous infusion of placebo at 12 months.
11356396|NCT02325414|Experimental|Placebo/Zol|Intravenous infusion of placebo at baseline. Intravenous infusion of zoledronic acid (zol) 5 mg at 12 months.
11356397|NCT02325414|Sham Comparator|Placebo/Placebo|Intravenous infusion of placebo at baseline and at 12 months.
11356398|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
11356399|NCT02325388|Experimental|Treatment group with ForeSite PT™ system|Inpatients assigned to the treatment group with the ForeSite PT™ system will have its LCD monitor turned on (i.e., real-time images of interface pressure will be displayed on the monitor) during their enrolment in the trial.
11356400|NCT02325388|No Intervention|Control group|Inpatients assigned to the control group will have the ForeSite PT™ system's LCD monitor turned off and hidden (i.e., real-time images of interface pressure will not be displayed on the monitor). As the ForeSite PT™ system will continue to record interface pressure with the display turned off, this enables patients enrolled in the control group to undergo silent monitoring.
11356401|NCT02325375||ALS newly diagnosed|
11356402|NCT02325375||ALS treated|
11356403|NCT02325375||controls|
11356406|NCT02325349|Experimental|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
11356407|NCT02325336|Experimental|bar-code-assisted administration|during administration rounds, nurses will use the BCMA system to help preventing administration errors
11356408|NCT02325336|No Intervention|control|during administration rounds, nurses will administer drugs as usual
11356409|NCT02325310|Experimental|Breastfeeding women|70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
11356410|NCT02325297|Experimental|Letter of condolence|Letter of condolence 15 days after the death of the relative.
11356411|NCT02325297|No Intervention|No letter of condolence|No letter of condolence
11356412|NCT02325284||Healthy adults|
11356413|NCT02325271||Control group|Subjects with normal glucose tolerance
11356414|NCT02325271||Diabetes group|Patients with type 2 diabetes
11356415|NCT02325258|Experimental|Telephone call|Telephone call to physicians in charge of patients who have just had blood cultures drawn. Diagnostic and therapeutic recommendations to physicians in charge.
11356416|NCT02325258|No Intervention|No telephone call|control arm: no intervention
11356417|NCT02325245|Experimental|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
11356418|NCT02325245|Placebo Comparator|Placebo|Placebo tablet three times a day for 16 weeks.
11356419|NCT02325232|Experimental|Enteroscopy|Capsule endoscopy, double balloon enteroscopy sequential use
11356420|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
11356421|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
11356422|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
11356423|NCT02325206|Experimental|dapafliflozin|one administration of 10mg dapagliflozin as tablet
11356424|NCT02325206|Placebo Comparator|placebo|one administration as tablet identical to the experimental drug
11356425|NCT02325180|Experimental|DHA-PQ|One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).
11356426|NCT02325180|Active Comparator|AL|Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).
11356427|NCT02325167|Experimental|EBT|
11356428|NCT02325167|Experimental|Treatment-as-usual|
11356429|NCT02325154||THA Patients|Patients undergoing unilateral total hip arthroplasty
11356430|NCT02325141|Active Comparator|LSG|patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
11356431|NCT02325141|Active Comparator|BTX-LSG|patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
11356432|NCT02325128|Experimental|Post-Exposure Nap|Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
11356433|NCT02325128|Active Comparator|Post-Exposure Wake|At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.
11356434|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
11356435|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
11356436|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
11356437|NCT02325089|Experimental|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
11356438|NCT02325089|Placebo Comparator|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
11356439|NCT02325076|Experimental|Spirodoc|One time during examination at the outpatient unit
11356440|NCT02325063|Experimental|PRP-L Group|"Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).
~Intervention: PRP-L Injection"
11356441|NCT02325063|Active Comparator|Botox Group|"Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).
~Intervention: Botox injection"
11356442|NCT02325063|Active Comparator|Corticoid Group|"Patients randomized to this group will be treated with an injection of Corticoids.
~Intervention: Corticoid injection"
11356443|NCT02325050|Experimental|Group 1|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
11356444|NCT02325050|Experimental|Group 2|Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
11356445|NCT02325050|Experimental|Group 3|Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
11356447|NCT02325050|Experimental|Group 5|Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
11356448|NCT02325050|Experimental|Group 6|Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1*10^8 TCID50) on Day 360.
11356449|NCT02325050|Experimental|Group 7|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
11356450|NCT02325050|Experimental|Group 8|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10^11 vp) on Day 360.
11356451|NCT02325050|Experimental|Group 9|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
11356452|NCT02325050|Experimental|Group 10|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
11356453|NCT02325037|Experimental|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
11356454|NCT02325037|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
11356455|NCT02325037|Experimental|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
11356456|NCT02325037|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
11356457|NCT02325024|Experimental|Renally Impaired Subjects|"Treatment group consists of subjects with severe renal impairment or ESRD and in accordance with the following criteria;
~Clinically significantly abnormal creatinine and creatinine clearance (CLcr <30 mL/min) and not requiring dialysis.
~Onset of renal impairment must have been documented at least 3 months prior to study start."
11356458|NCT02325024|Experimental|Matched subjects with Normal Renal Function|Group consists of healthy subjects (as determined by medical history, physical examination, biochemistry, hematology, urinalysis, hepatitis B and C, and HIV testing) who demonstrate normal renal function (CLcr > 80 mL/min) and are individually matched to renally impaired subjects with respect to age (within the decile or five years, whichever is less), gender, and Body Mass Index (BMI) (+/- 10% BMI).
11356459|NCT02325011|Experimental|Treatment Sequence 1|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.
~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 1 is as follows;
~Visit 2 (Treatment A)
~Visit 3 (Treatment B)
~Visit 4 (Treatment A)
~Visit 5 (Treatment B)
~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
11356460|NCT02325011|Experimental|Treatment Sequence 2|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.
~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 2 is as follows;
~Visit 2 (Treatment B)
~Visit 3 (Treatment A)
~Visit 4 (Treatment B)
~Visit 5 (Treatment A)
~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
11356461|NCT02324998|Experimental|Group A|Olaparib Monotherapy
11356462|NCT02324998|Experimental|Group B|Olaparib in combination with degarelix
11356463|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
11356464|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
11356465|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
11356466|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
11356467|NCT02324959|Active Comparator|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
11356468|NCT02324959|Active Comparator|Computer-based|Computer-based attention training (RehaCom).
11356469|NCT02324959|Experimental|ACoTrain|A combination of computer-based attention training with acupuncture.
11356470|NCT02324946||Study Group|Mass Screening
11356471|NCT02324933|Experimental|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate < 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:
~50% of the hourly dose is given as a basal infusion
~The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using < 1 demand dose per hour, the basal rate is decreased by 20%. In patients using > 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
11356472|NCT02324933|Active Comparator|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain & Palliative Care team in order to make adjustments in pain management as required by the patients."
11356473|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
11356474|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
11356475|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
11356476|NCT02324894|Other|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
11356509|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
11356820|NCT02322606|Other|Cohort 1: TAK-137 5 mg, TAK-137 placebo|Single-dose administration in a fasting state
11356477|NCT02324881|Experimental|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
11356478|NCT02324868|Experimental|Shower patch IV catheter protection|Newly developed waterproof catheter dressing may be used for bathing activities
11356479|NCT02324868|Other|Conventional IV catheter protection|No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.
11356480|NCT02324855|No Intervention|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
11356481|NCT02324855|Experimental|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
11356482|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
11356483|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
11356484|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
11356485|NCT02324829||Total joint replacement|Patients who has undergone lower body total joint replacement surgery.
11356486|NCT02324816|Experimental|Lateral Thigh Treatment Group|CoolSculpting treatment in the lateral thighs for non-invasive subcutaneous fat reduction.
11356487|NCT02324803|Experimental|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
11356488|NCT02324790|Experimental|Treatment|Treated with iNAP® Sleep Therapy System on the treatment PSG night.
11356489|NCT02324777|Experimental|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
11356490|NCT02324777|Experimental|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
11356491|NCT02324777|Experimental|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
11356492|NCT02324777|Experimental|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
11356493|NCT02324777|Experimental|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
11356494|NCT02324777|Placebo Comparator|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
11356495|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
11356496|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
11356497|NCT02324751|Experimental|Vi-TCV|Single intramuscular injection
11356498|NCT02324751|Active Comparator|Vi-PS Vaccine|Single intramuscular injection
11356499|NCT02324751|Other|Control (Men ACWY)|Single intramuscular injection
11356500|NCT02324738|Experimental|Healthy Volunteer|All subjects will receive Mefloquine and Dihydroartemisinin-piperaquine, wash out then will receive Mefloquine
11356501|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
11356502|NCT02324712|Active Comparator|Acupuncture|Acupuncture treatment for TMD
11356503|NCT02324712|Sham Comparator|Sham Acupuncture|Acupuncture treatment for TMD using the non-penetrating Park Sham Acupuncture Device
11356504|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
11356505|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
11356506|NCT02324686|Other|Vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
11356507|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
11356508|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
11356605|NCT02324036|Active Comparator|Routine Coached Care|Patient coaching only
11356510|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
11356511|NCT02324634|Experimental|ES intervention|Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
11356512|NCT02324634|No Intervention|Control|Usual care only
11356513|NCT02324621|Experimental|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11356514|NCT02324608|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes once weekly for 8 weeks.
11356515|NCT02324595|Experimental|Laparoscopic Interval Debulking Surgery|Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
11356516|NCT02324582|Experimental|Intravenous MK-3475/ Intravesical BCG|3 subjects will be treated at a dose of 100 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses 12 subjects will be treated at a dose of 200 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses
11356517|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
11356518|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
11356519|NCT02324556||Laparoscopic total mesorectal excision|Patients operated with laparoscopic total mesorectal surgery for rectal cancer
11356520|NCT02324556||transanal total mesorectal excision|Patients operated with a combined transanal and laparosocopic total mesorectal surgery for rectal cancer
11356521|NCT02324543|Experimental|Dose level 1 - Phase 1|"Gemcitabine - 400 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/twice daily (BID)
~Cisplatin - 15 mg/m^2
~Irinotecan - 20 mg/m^2"
11356522|NCT02324543|Experimental|Dose Level 2 - Phase 1|"Gemcitabine - 400 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 15 mg/m^2
~Irinotecan - 40 mg/m^2"
11356523|NCT02324543|Experimental|Dose Level 3 - Phase 1|"Gemcitabine - 400 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 15 mg/m^2
~Irinotecan - 60 mg/m^2"
11356524|NCT02324543|Experimental|Dose Level 1a - Phase 1|"Gemcitabine - 500 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 20 mg/m^2
~Irinotecan - 20 mg/m^2"
11356525|NCT02324543|Experimental|Dose level 1b - Phase 1|"Gemcitabine - 500 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 20 mg/m^2
~Irinotecan - 40 mg/m^2"
11356526|NCT02324543|Experimental|Phase 2|"Gemcitabine - 500 mg/m^2
~Taxotere - 20 mg/m^2
~Xeloda - 500 mg/BID
~Cisplatin - 20 mg/m^2
~Irinotecan - 20 mg/m^2"
11356527|NCT02324530|Experimental|Lung tumors|Patients with > 1 cm tumor motion simulated using 4DCT with and without CPAP
11356528|NCT02324530|Experimental|Left sided Breast cancer|Patients with heart abutting chest wall will be simulated using 4DCT with and without CPAP
11356529|NCT02324530|Experimental|Abdominal tumors|Patient with liver metastases for SBRT or pancreatic tumors will be simulated using 4DCT with and without CPAP
11356530|NCT02324517||Hemophilia|Patients with Hemophilia A OR B
11356531|NCT02324517||inhibitor patients|Hemophilia or FXI def with inhibitors
11356532|NCT02324517||anticoagulants|patients under therapy with various anticoagulant drugs
11356533|NCT02324517||thrombocytopenia|patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia
11356534|NCT02324517||platelet function disorders|Glanzmann, Bernard Soulier, antiplatelet therapy
11356535|NCT02324517||Fibrinogen disordsers|hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
11356536|NCT02324517||acquired hemophilia|patients with autoimmune Ab's to FVIII
11356537|NCT02324517||RBD|FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF
11356538|NCT02324517||THROMBOLYTICS|Patients treated by thrombolytic agents
11356539|NCT02324517||Hypercoag|thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)
11356540|NCT02324504|Experimental|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
11356541|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
11356542|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
11356543|NCT02324491|Placebo Comparator|Placebo|ZGN-440 Placebo for Injectable Suspension
11356544|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
11356545|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
11356546|NCT02324452|Experimental|heterozygous carrier of DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for one of these SNPs
11356547|NCT02324452|Experimental|wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
11356548|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
11356549|NCT02324426|Experimental|Reduced Glutathione|The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.
11356550|NCT02324413|Active Comparator|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
11356551|NCT02324413|Placebo Comparator|Placebo|
11356552|NCT02324400|Active Comparator|Treatment|
11356553|NCT02324400|Sham Comparator|Control|
11356554|NCT02324387|Experimental|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
11356555|NCT02324374|Experimental|Endocytoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
11356556|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.
~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.
~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
11356557|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.
~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.
~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
11356558|NCT02324348|Placebo Comparator|Immediate coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate coronary stenting group
11356559|NCT02324348|Active Comparator|Deferred coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred after 5-7 days admission in the deferred coronary stenting group.
11356560|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
11356561|NCT02324335|Active Comparator|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
11356562|NCT02324322|Experimental|Exoskeleton training|"To examine the effectiveness of robotic exoskeleton-assisted over ground walking (5 hrs. p/wk, 100 sessions, 20 wks = 100 hrs) to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI. Combined with our current training protocol where people step 1500-2000/session we predict that the 2,000 lower extremity muscle contractions will be sufficient in our proposed exoskeletal study.
~MRI's will be performed to accurately assess muscle CSA of each lower limb to determine individual's muscle thigh and shank volume.
~Muscle Biopsies for the quadricep muscle will be performed to determine changes in BMD and bone structure due to intensive exoskeleton assisted walking."
11356563|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
11356564|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
11356565|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
11356566|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
11356567|NCT02324283|Active Comparator|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
11356568|NCT02324283|Active Comparator|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
11356569|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
11356570|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
11356571|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
11356572|NCT02324257|Experimental|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
11356573|NCT02324257|Experimental|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive RO6958688 with or without obinutuzumab pretreatment QW, Q3W, or according to a combined QW/Q3W step up dosing schedule. Doses will start at 40mg and increase with each administration up to the MTD or 1200mg, whichever is lower.
11356574|NCT02324244||immunocompetent patients underwent heart surgery|
11356575|NCT02324231|Other|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
11356576|NCT02324231|Other|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
11356916|NCT02321956|No Intervention|Formula|Using Cole's formula to choose endotracheal tube size
11356577|NCT02324218||Diabetes mellitus Group|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD database of UK, from the Year 2000 to 2012.
11356578|NCT02324218||Non-Diabetes mellitus Group|All the subjects with hepatitis B who are diagnosed negative diabetes mellitus, reported in the CPRD database of UK, from the Year 2000 to 2012.
11356579|NCT02324205|Experimental|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
11356580|NCT02324192|Other|Normal ultrasonography|Patients with normal ultrasonography findings
11356581|NCT02324192|Other|Inflammatory ultrasonography|Patients with inflammatory ultrasonography findings
11356582|NCT02324179||HIV positive|people with HIV diagnosis
11356583|NCT02324179||Control (HIV negative)|people without HIV
11356584|NCT02324166|Active Comparator|Cefazolin|For the control group, cefazolin will be drawn into a 1 mL syringe and 0.5 mL will be injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery.
11356585|NCT02324166|Active Comparator|Cefazolin + Lidocaine|For the comparator group, the cefazolin and 0.2 mL lidocaine 2% will be mixed together in the same 1 mL syringe and 0.5 mL of the mixed solution injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery surgery.
11356586|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
11356587|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
11356588|NCT02324140||Minimized extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the minimized extracorporeal circulation (MECC, group 1)
11356589|NCT02324140||Conventional extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the conventional extracorporeal circulation (CECC, group 2)
11356590|NCT02324140||Transcatheter aortic valve implantation, transfemoral access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transfemoral access route
11356591|NCT02324140||Transcatheter aortic valve implantation, transapical access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transapical access route
11356592|NCT02324127|Experimental|liver cancer|Detect plasma Hsp90α concentration of liver cancer patients
11356593|NCT02324114|Experimental|Rectal cancer|Detect plasma Hsp90α concentration of patients,
11356594|NCT02324101|Experimental|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
11356595|NCT02324088|Active Comparator|Arm A|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy
11356596|NCT02324088|Experimental|Arm B|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy followed by 4 cycles of D-5FU (D 85 mg/m², day 1 and 5FU 2500 mg/m²/day continuous infusion, days 1-5 every 3 weeks)
11356597|NCT02324075|Experimental|Behavior change|Behavior change messaging with facilitating hardware
11356598|NCT02324075|No Intervention|Control Arm|Standard habits and practices
11356599|NCT02324062||Pathogenic group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~Patients identified with a mutation in a gene not commonly tested for prior to the advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not meet clinical criteria for the underlying syndrome (n = 124). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
11356600|NCT02324062||VUS group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~Patients identified with a variant of unknown significance of any gene of any nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and EPCAM).
~Target accrual is 100. These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
11356601|NCT02324062||Negative Group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~Patients who test negative for all the genes tested. Target goal is 50 for Stanford (100 for the study). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
11356602|NCT02324062||No follow-up intervention group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
~All other participants who do not meet any of the above criteria or fall into one of these groups after the target goal is met for that group."
11356603|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.
~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.
~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
11356604|NCT02324036|Experimental|Coached Care+EMPATHy;|EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
11356606|NCT02324023|Experimental|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
11356607|NCT02324010|Experimental|Sitaglipltin (100mg)|Active drug (sitagliptin)
11356608|NCT02324010|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
11356609|NCT02323984||Hypoactive Delirium - Delirious|Hypoactive delirious patients presenting with lethargy and sedation and are slow to respond to questions and demonstrate little spontaneous movement. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
11356610|NCT02323984||Hyperactive Delirium - Delirious|Hyperactive delirious patients presenting with restlessness, agitation, hyper vigilance, and occaionally hallucinations. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
11356611|NCT02323984||No Delirium - Nondelirious|Patients not presenting any symptoms of hypoactive or hyperactive postoperative delirium. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
11356612|NCT02323958|Experimental|Acupoint stimulation|Electrical stimulation is given through electrodes attached to acupoints
11356613|NCT02323958|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation is given through electrodes attached to non-acupoints
11356614|NCT02323958|Sham Comparator|Control stimulation|Electrode attached but no stimulation is given
11356615|NCT02323945|Active Comparator|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
11356616|NCT02323945|Active Comparator|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
11356617|NCT02323932|Active Comparator|Bilateral Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: each of the CI alone and bilateral (CI/CI) conditions.
11356618|NCT02323932|Active Comparator|Bimodal Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: CI alone, HA alone and bimodal (CI/HA) conditions.
11356619|NCT02323919|Active Comparator|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
11356620|NCT02323919|Active Comparator|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
11356621|NCT02323919|Placebo Comparator|Usual Care|Usual Care
11356622|NCT02323906|Experimental|CC-122 + Fixed-dose Sorafenib|"A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.
~The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part."
11356623|NCT02323893|Experimental|18F-FAraG|A single dose intravenous injection of 18F-FAraG followed by PET scanning.
11356624|NCT02323880|Experimental|Treatment (selinexor)|Patients receive selinexor PO once weekly (days 1, 8, 15, and 22). Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11356625|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment
~11 ATG
~10 ATG
~9 ATG
~8 TBI
~7 TBI
~6 TBI
~5 Thiotepa
~4 Thiotepa
~3 Cyclophosphamide
~2 Cyclophosphamide
~1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
11356626|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment
~9 ATG
~8 ATG
~7 Thiotepa + ATG
~6 Thiotepa
~5 Cyclophosphamide
~4 Cyclophosphamide
~3 TBI
~2 TBI
~1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
11356627|NCT02323867|Experimental|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment
~9 Busulfan + ATG
~8 Busulfan + ATG
~7 Busulfan +ATG
~6 Busulfan
~5 Thiotepa
~4 Thiotepa
~3 Cyclophosphamide
~2 Cyclophosphamide
~1 0 Transplant with alpha beta T cell depleted stem cells"
11356628|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
11356629|NCT02323841|Experimental|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
11356630|NCT02323828|Experimental|Investigational product|"The investigational products are RS starch cookies (40 g resistant starch) from high amylose maize starch.
~Nine young healthy volunteers (males and females) consumed RS rich cookies (40 g RS) in two separate occasions."
11356631|NCT02323828|Placebo Comparator|Placebo|The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
11356632|NCT02323815|Active Comparator|Control|Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
11356633|NCT02323815|Experimental|PROMIS intervention|"Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
~Caregivers with children 6-23 months of age that attend Counselling meetings will be provided with a monthly dose of SQ-LNS (20g/day)"
11356703|NCT02323334|Experimental|LY3202626 Part B High Dose|Single oral dose of LY3202626 in capsule form. Dose determined by Part A.
11356634|NCT02323802|Experimental|educational group intervention|"The group educational food intervention: it provides the delivery of information leaflet and inclusion in groups on a weekly basis for the first 3 meetings, and then, there are other 2 meetings on the third and sixth month by the AMI.
~The meetings will cover education to self-nutrition, physical activity and learning techniques for stimulus control and management of high-risk situations."
11356635|NCT02323802|Active Comparator|prescriptive diet|An objectives food scheme elaborated for each patients will provide the reduction in caloric intake (equivalent to 500-600 calories in deficit if compared to the estimated daily requirement, based on the RDAs) and a reduced intake of lipids, which does not exceed 30% of total calories introduced, with a contribution of saturated fat no more than 7-9% .
11356636|NCT02323789|Experimental|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
11356637|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
11356638|NCT02323737|Active Comparator|Irinotecan and cisplatin|The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
11356639|NCT02323737|Active Comparator|Etoposide and Cisplatin|The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
11356640|NCT02323724||Selected Papillary carcinoma|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.
11356641|NCT02323711|No Intervention|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
11356642|NCT02323711|Experimental|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
11356643|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
11356644|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
11356645|NCT02323698|Active Comparator|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
11356646|NCT02323685|Experimental|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
11356647|NCT02323672||oral premalignant patients|15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.
11356648|NCT02323672||oral malignant patients|15 patients suffering from oral malignant lesions
11356649|NCT02323672||control subjects|15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.
11356650|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
11356651|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
11356652|NCT02323646|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
11356653|NCT02323646|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
11356654|NCT02323646|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
11356655|NCT02323633|Active Comparator|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
11356656|NCT02323633|Sham Comparator|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
11356657|NCT02323620|No Intervention|Standard care|Optimal standard care after myocardial infarction.
11356658|NCT02323620|Experimental|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.
11356659|NCT02323607|Experimental|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
11356660|NCT02323607|Experimental|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11356661|NCT02323594|Experimental|Group 1: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV pediatric chewable tablet
11356662|NCT02323594|Experimental|Group 2: Daclatasvir|Single oral dose of Daclatasvir (DCV) pediatric chewable tablet and single oral dose of DCV pediatric chewable tablet
11356663|NCT02323594|Experimental|Group 3: Asunaprevir|Single oral dose of Asunaprevir (ASV) tablet, single oral dose of ASV pediatric chewable tablet and single oral dose of ASV pediatric chewable tablets
11356664|NCT02323594|Experimental|Group 4: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV tablets
11356665|NCT02323581|Experimental|TAAA (thoracoabdominal aortic aneurysm) Study Arm|"Either the TAAA device or the Physician-Specified TAAA Device will be implanted.
~The TAAA Device is a standard configuration branched stent graft with a combination of two branches for the mesenteric arteries and two fenestrations for the renal arteries.
~The Physician-Specified TAAA Devices are designed on a per patient basis and may include a combination of up to 4 fenestrations and branches for mesenteric and renal arteries. An additional 5th branch or fenestration may be included if there is a large accessory renal artery. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
11356666|NCT02323581|Experimental|Aortic Arch Study Arm|Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.
11356667|NCT02323568|Other|Gynecological consulation|
11356668|NCT02323555|Experimental|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
11356669|NCT02323542|Experimental|High-SDS biscuit|Biscuit with high Slowly Digestible Starch content
11356670|NCT02323542|Active Comparator|Low-SDS cereal product|Cereal product with low Slowly Digestible Starch content
11356671|NCT02323529|Experimental|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
11356672|NCT02323516|Experimental|Acetylsalicylic acid + loperamide|Acetylsalicylic acid + loperamide
11356673|NCT02323516|Active Comparator|diosmectite + loperamide|Acetylsalicylic acid + loperamide
11356674|NCT02323490|Experimental|with microfractures|Standardized meniscal repair with bone marrow stimulation techniques (microfractures)
11356675|NCT02323490|Placebo Comparator|without microfractures|Standardized meniscal repair without augmentation
11356676|NCT02323477|Experimental|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
11356677|NCT02323477|Active Comparator|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
11356678|NCT02323477|No Intervention|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation
11356679|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
11356680|NCT02323464||Open surgery for colorectal cancer|investigated after open surgery of colorectal cancer
11356681|NCT02323464||Laparoscopic or robotic surgery|investigated after laparoscopic or robot surgery of colorectal cancer
11356682|NCT02323464||Control subjects|Controls from the population without colorectal cancer
11356683|NCT02323451|Experimental|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
11356684|NCT02323451|Active Comparator|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
11356685|NCT02323438|Active Comparator|Usual Brand (UB) Cigarettes|Usual Brand Cigarette
11356686|NCT02323438|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 29 mg nicotine)
11356687|NCT02323438|Experimental|Electronic Cigarette #2|VUSE® (menthol flavor, 26 mg nicotine)
11356688|NCT02323438|Experimental|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
11356689|NCT02323425|Experimental|Remote Ischemic Postconditioning|remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.
11356690|NCT02323425|No Intervention|Control|Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).
11356691|NCT02323412|Experimental|Amoxicillin|Amoxicillin (Amoksicillintrihydrat) tablets 750 mg 1x3 for 100 days (oral intake). The tablets will be encapsulated in Capsugel DB-caps AAel Swedish orange.
11356692|NCT02323412|Placebo Comparator|Placebo|Placebo capsules for 100 days of daily (1x3), oral intake. The placebo tablets will also be encapsulated in Capsugel DB-caps AAel Swedish orange.
11356693|NCT02323399|Experimental|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
11356694|NCT02323386|Experimental|ATTUNE knee system|The patients will undergo primary Total Knee Arthroplasty (ATTUNE knee system)
11356695|NCT02323373|Experimental|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
11356696|NCT02323373|Active Comparator|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
11356697|NCT02323373|Placebo Comparator|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
11356698|NCT02323360|Experimental|Stereotactic body radiation therapy|HCC after incomplete TAE or TACE treated by SBRT
11356699|NCT02323360|Active Comparator|TACE/TAE|HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE
11356700|NCT02323334|Experimental|LY3202626 Part A|Single doses of LY3202626 given orally in capsule form administered up to once in each of 4 periods in a crossover fashion. Some participants may also receive multiple doses of 200 mg of Itraconazole orally in 1 period.
11356701|NCT02323334|Experimental|LY3202626 Part B Low dose|Single oral dose of LY3202626 in capsule form. Dose determined by Part A.
11356702|NCT02323334|Experimental|LY3202626 Part B Mid dose|Single oral dose of LY3202626 in capsule form. Dose determined by Part A.
11356704|NCT02323334|Experimental|LY3202626 Part C Low dose|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily, for 14 days. Dose determined by Part B.
11356705|NCT02323334|Experimental|LY3202626 Part C Mid dose|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.
11356706|NCT02323334|Experimental|LY3202626 Part C High dose|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.
11356707|NCT02323334|Experimental|LY3202626 Part D|Multiple oral doses of LY3202626 in capsule form. Drug is given once daily for 14 days. Dose determined by Part B.
11356708|NCT02323334|Placebo Comparator|Placebo Part A|Single oral dose of placebo given in capsule form.
11356709|NCT02323334|Placebo Comparator|Placebo Part B|Single oral dose of placebo given in capsule form.
11356710|NCT02323334|Placebo Comparator|Placebo Part C|Multiple oral doses of placebo given in capsule form. Placebo is given once daily for 14 days.
11356711|NCT02323321|Experimental|OCS Preservation|OCS Preservation and Assessment
11356712|NCT02323308||vaccination|Anti-HBV vaccine injection
11356713|NCT02323295|Experimental|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
11356714|NCT02323295|Experimental|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
11356715|NCT02323282|Other|ropivacine|
11356716|NCT02323269||Treatment naive to dimethyl fumarate|Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
11356717|NCT02323269||Switch to dimethyl fumarate|Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
11356718|NCT02323256|Experimental|newly cochlear implanted adult patients|longitudinal group
11356719|NCT02323256|Experimental|newly cochlear implanted children|longitudinal group
11356720|NCT02323256|Active Comparator|cochlear implanted adult patients (CI>1 year)|transversal group
11356721|NCT02323256|Active Comparator|normal hearing adult subjects|transversal group
11356722|NCT02323243|Experimental|Allium BUS|Temporary urethral stent
11356723|NCT02323230|Experimental|DPX-Survivac + low dose cyclophosphamide|
11356724|NCT02323217|Experimental|Healthy Volunteers|
11356725|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
11356726|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
11356727|NCT02323191|Experimental|Part 1 (Dose-finding): Emactuzumab + Atezolizumab|Participants will receive escalating doses of emactuzumab along with atezolizumab every 3 weeks (q3w).
11356728|NCT02323191|Experimental|Part 2 (Expansion): Emactuzumab + Atezolizumab|Participants will receive emactuzumab at or below the MTDs for the combination treatments that are determined during Part 1 along with atezolizumab.
11356729|NCT02323178|Experimental|eltrombopag|
11356730|NCT02323165||Burns and Wound Care|Blood samples will be taken to detect and identify a molecular detection of bacteria in the bloodstream. In addition, data will be collected from the standard of care blood samples and compared.
11356731|NCT02323152|Experimental|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
11356732|NCT02323152|Active Comparator|Control group|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment.
11356733|NCT02323139|Experimental|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
11356734|NCT02323126|Experimental|Nivolumab and EGF816|Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.
11356735|NCT02323126|Experimental|Nivolumab and INC280|Arm 2 (INC280 + nivolumab) is open and enrolling as planned.
11356736|NCT02323113|Experimental|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
11356737|NCT02323113|Experimental|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
11356738|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
11356739|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
11356740|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
11356741|NCT02323087|Active Comparator|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
11356742|NCT02323087|Active Comparator|Culture|Point of care culture will be performed using ID FlexicultTM
11356743|NCT02323074|Experimental|fBCI-robot|focalized BCI-robot hand training
11356744|NCT02323074|Experimental|gBCI-robot|generalized BCI-robot hand training
11356745|NCT02323074|Sham Comparator|sham-BCI|Sham BCI
11356746|NCT02323061|Experimental|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
11356747|NCT02323061|Experimental|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
11356748|NCT02323061|Placebo Comparator|robot|Training for 20 sessions
11356749|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
11356750|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
11356751|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
11356752|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
11356753|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
11356754|NCT02323035|Experimental|Headgear|Investigative Headgear with CPAP Mask.
11356755|NCT02323022|Experimental|IAC regimen|Patients in this arm will receive an IAC induction therapy
11356756|NCT02323022|Active Comparator|High-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 10mg/msq/d
11356757|NCT02323022|Active Comparator|Intermediate-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 12mg/msq/d
11356758|NCT02323009|Active Comparator|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
11356759|NCT02323009|Active Comparator|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
11356760|NCT02323009|No Intervention|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
11356761|NCT02322996||open label|After the surgery and the onset of moderate-severe pain, QST and PROMIS questionnaires will be repeated. Throughout these procedures, patients will rate their pain perception using a numeric rating scale. Approximately 2-3 hours after surgery at the onset of moderate pain, the rescue analgesic (toradol) will be administered via intramuscular injection. Again, QST and PROMIS protocols will be repeated after the drug is given and when patients report pain relief. A standard naproxen dose of 500 mg will be given to patients upon leaving the clinic and they will be instructed to take one pill orally each day before returning for evaluation after 48 hours.
11356762|NCT02322983|Experimental|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
11356763|NCT02322970||Intracranial Pressure monitoring|Invasive Intracranial Pressure monitoring will be compared to non invasive intracranial monitoring ( through use of transcranial Doppler ).
11356764|NCT02322957|Experimental|Treatment Regimen A|FV-100 400mg OD as a single dose fasted (>/= 8 hours)
11356765|NCT02322957|Experimental|Treatment Regimen B|FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (>/= 8 hours)
11356766|NCT02322944|Experimental|Intervention group|The intervention group will take the treatment quality improvement strategies and tools into implementation.
11356767|NCT02322944|No Intervention|Control group|The control group will maintain the routine practice pattern.
11356768|NCT02322944|Experimental|Process optimization group|The process optimization group's clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process.
11356769|NCT02322931|Experimental|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
11356770|NCT02322918||Participants admitted to BCPP|Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
11356771|NCT02322905|Experimental|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
11356772|NCT02322905|No Intervention|Usual Medical Care|No planned psychotherapy.
11356773|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
11356774|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
11356775|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.
~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.
~The total study time is 6 weeks."
11356776|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.
~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.
~The total study time is 6 weeks."
11356777|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
11356778|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
11356779|NCT02322853|Active Comparator|TAMOXIFEN|"Tamoxifen will be administered daily orally
~Patients will receive study medication until disease progression or unacceptable toxicity"
11356780|NCT02322853|Experimental|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally
~Patients will receive study medication until disease progression or unacceptable toxicity"
11356781|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
11356782|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
11356819|NCT02322619|Active Comparator|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
11356783|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
11356784|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
11356785|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
11356786|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
11356787|NCT02322801||Cohort|
11356788|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
11356789|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
11356790|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
11356791|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
11356792|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
11356793|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
11356794|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
11356795|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
11356796|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
11356797|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
11356798|NCT02322736||WT RAS mCRC|Wild Type RAS metastatic colorectal cancer patients
11356799|NCT02322723||Moderately to severely active RA patients|Moderately to severely active RA patients aged 18 years or older, both male and female
11356800|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
11356801|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
11356802|NCT02322697|Experimental|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
11356803|NCT02322697|No Intervention|control group|No intervention
11356804|NCT02322684|Active Comparator|Group Q|Blind endotracheal intubation will be performed through the air-Q
11356805|NCT02322684|Active Comparator|Group B|Blind endotracheal intubation will be performed through the air-Q with bougie assisted
11356806|NCT02322671|Experimental|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
11356807|NCT02322671|Experimental|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
11356808|NCT02322671|Experimental|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
11356809|NCT02322671|Experimental|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
11356810|NCT02322671|Experimental|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
11356811|NCT02322671|Experimental|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
11356812|NCT02322658|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
11356813|NCT02322658|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
11356814|NCT02322645|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
11356815|NCT02322645|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
11356816|NCT02322632|Experimental|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
11356817|NCT02322632|Experimental|Zemplar Capsules, 4 mcg|Zemplar Capsules, 4 mcg of Abott Laboratories USA
11356818|NCT02322619|Experimental|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
11356821|NCT02322606|Other|Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet|Single-dose administration in a fasting state
11356822|NCT02322606|Other|Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo|Single-dose administration in a fasting state
11356823|NCT02322606|Other|Cohort 4: TAK-137 5mg, TAK-137 placebo|Once daily for 7 days in a fasting state
11356824|NCT02322606|Other|Cohort 5: TAK-137 10 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
11356825|NCT02322606|Other|Cohort 6: TAK-137 15 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
11356826|NCT02322593|Experimental|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
11356827|NCT02322593|Active Comparator|S-1/Cisplatin|S-1 plus Cisplatin
11356828|NCT02322580||Psoriasis patients who receive Enbrel® therapy|
11356829|NCT02322567||LV diastolic dysfunction|
11356830|NCT02322567||No LV diastolic dysfunction|
11356831|NCT02322554||wounds treated with CTPs|All cellular and tissue based products currently reimbursed in the hospital based outpatient department, administered at intervals as determined in the course of clinical practice
11356832|NCT02322541|Experimental|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
11356833|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
11356834|NCT02322515|Experimental|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
11356835|NCT02322515|Placebo Comparator|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
11356836|NCT02322502|Experimental|desflurane|Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
11356837|NCT02322502|Active Comparator|sevoflurane|"Sevoflurane:
~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application"
11356838|NCT02322502|Active Comparator|propofol|Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application
11356839|NCT02322489|Sham Comparator|Sham microcurrent therapy|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but it lasts only for 5 seconds.
11356840|NCT02322489|Experimental|Microcurrent Group|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started.
11356841|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
11356842|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
11356843|NCT02322450|Experimental|A: P1-QGC001 - Washout-placebo - P2-placebo|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
11356844|NCT02322450|Experimental|B: P1-placebo - Washout-placebo - P2-QGC001|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
11356845|NCT02322437|Experimental|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
11356846|NCT02322437|Active Comparator|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
11356847|NCT02322424||Patients who undergo pancreaticoduodenectomy|
11356848|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
11356849|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
11356850|NCT02322398||Group A|Patients who had been stimulated with a starting dose of 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio.
11356851|NCT02322398||Group B|Patients who had been stimulated with a starting dose of 150-300 IU/d hMG.
11356852|NCT02322372|Active Comparator|Group F|"Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
~."
11356853|NCT02322372|Active Comparator|Group S|The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
11356854|NCT02322346|Placebo Comparator|Group S|Preincisional bilateral peritonsillar infiltration of a total of 6 mL of saline
11356855|NCT02322346|Active Comparator|Group LL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.25% (3 mL to each tonsil).
11356856|NCT02322346|Active Comparator|Group HL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.5% (3 mL to each tonsil).
11356857|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
11356858|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
11356859|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
11356860|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
11356861|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
11356862|NCT02322307|Experimental|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
11356863|NCT02322307|Placebo Comparator|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
11356864|NCT02322294|Experimental|Glucodia™|
11356865|NCT02322294|Placebo Comparator|Placebo|
11356866|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
11356867|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
11356868|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed
~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.
~Gemcitabine
~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.
~Docetaxel
~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.
~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.
~Paclitaxel
~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
11356869|NCT02322268|Experimental|Diabetic Cosmos caudatus treated group|Subjects in this arm will receive Cosmos caudatus for 8 weeks.
11356870|NCT02322268|No Intervention|Diabetic control group|Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.
11356871|NCT02322255||All Subjects|All subjects enrolled in the study.
11356872|NCT02322242|Active Comparator|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
11356873|NCT02322242|Other|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
11356874|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
11356875|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
11356876|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
11356877|NCT02322203|Experimental|A|Niacin - 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks.
11356878|NCT02322190|No Intervention|Investigator chosen second line therapy|Investigator chosen second line therapy
11356879|NCT02322190|Experimental|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
11356880|NCT02322177||1|Participants are women with inborn errors of metabolism who have been pregnant
11356881|NCT02322138|Experimental|Experimental 1 Infant Formula|Milk-based infant formula without prebiotics
11356882|NCT02322138|Experimental|Experimental 2 Infant Formula|Milk-based infant formula with prebiotics
11356883|NCT02322138|Other|Human Milk-Fed Reference Group|Breast fed infants
11356884|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
11356885|NCT02322112|Placebo Comparator|Microcrystalline Cellulose (Control)|Microcrystalline cellulose will be used as a placebo control, as it is known to be an insoluble, non-viscous fiber that is essentially not fermented by the human gut microbiota. However, it is important to note that cellulose does have fermentation potential within the gastrointestinal tract and may be associated with improved health benefits; indicating a role as an active comparator.
11357044|NCT02320916|Active Comparator|25Gauge|Arterial blood puncture will be performed using a 25Gauge needle
11356886|NCT02322112|Experimental|Acacia Gum|Acacia gum is composed largely of arabinogalactan, and is considered to be a relatively non-viscous, soluble fiber this is highly fermented by the gut microbiota and well tolerated.
11356887|NCT02322112|Experimental|Resistant Starch Type 4|Cross-linked phosphorylated resistant starch (type IV) is generally insoluble and with low viscosity; yet it tends to have physiologic properties similar to soluble fibers, such as fermentability.
11356888|NCT02322099|Active Comparator|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
11356889|NCT02322099|Placebo Comparator|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
11356890|NCT02322086|Experimental|PH-10|Active treatment
11356891|NCT02322073||Lean healthy controls|Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.
11356892|NCT02322073||Obese healthy|Obese healthy BMI 35-55 Laparoscopic Roux-en-Y gastric bypass
11356893|NCT02322073||Obese kidney disease|Obese kidney disease BMI 35-55 Laparoscopic Roux-en-Y gastric bypass
11356894|NCT02322073||Obese liver disease|Obese liver disease BMI 35-55 Laparoscopic Roux-en-Y gastric bypass
11356895|NCT02322060||Primary ovarian insufficiency|"Primary ovarian insufficiency (POI; also known as premature ovarian failure/dysfunction/insufficiency or premature menopause) is characterised by amenorrhoea, sex hormone (oestrogen, progesterone and testosterone) deficiency and elevated gonadotrophins levels in a woman aged more than two standard deviations below the mean age of menopause estimated for her reference population. POI is defined as a disorder in ovarian function in any woman before the age of 40 years, irrespective of the cause.
~In our study, we mainly recruit POI patients who also desire to have a baby of their own."
11356896|NCT02322060||Ovarian resistance syndrome|We currently also include patients diagnosed with Ovarian resistance syndrome, which means that follicles exist, but do not response to FSH.
11356897|NCT02322047|Experimental|Prazosin and Naltrexone|Prazosin and Naltrexone
11356898|NCT02322047|Active Comparator|Prazosin and Placebo|Prazosin and (Nal)Placebo
11356899|NCT02322047|Active Comparator|Naltrexone and Placebo|Naltrexone and (Praz)Placebo
11356900|NCT02322047|Placebo Comparator|Placebo and Placebo|(Praz)Placebo and (Nal)Placebo
11356901|NCT02322034|Experimental|Interval Training|Hospital outpatient-based regimen (3 times/week for 24 weeks) exercise program will be performed by cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
11356902|NCT02322034|No Intervention|Controls|CHF patients allocated to the control group (no intervention) will undergo biochemical and hormonal sampling, Doppler-echocardiography, cardiopulmonary exercise stress testing at study enrollment and at 24-week follow-up.
11356903|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a low dose of elenbecestat (E609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the Open-Label Extension (OLE) Phase.
11356904|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a middle dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.
11356905|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of elenbecestat will be assessed during the double-blind treatment period and during the OLE Phase for participants meeting OLE eligibility criteria.
11356906|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|During the double-blind portion of the study, two matching placebo tablets will be administered daily. During the OLE Phase, participants will receive the high dose as a single tablet.
11356907|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a low dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.
11356908|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a middle dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.
11356909|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of elenbecestat will be assessed during the double-blind treatment period and during the OLE Phase for participants meeting OLE eligibility criteria.
11356910|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|During the double-blind portion of the study, two matching placebo tablets will be administered daily. During the OLE Phase, participants will receive the high dose as a single tablet.
11356911|NCT02321982|No Intervention|Separate-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation in advance of the day of the procedure.
11356912|NCT02321982|Experimental|Same-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation on the day same day as the procedure.
11356913|NCT02321969|No Intervention|Control|Without green tea extract (GTE) supplementation
11356914|NCT02321969|Experimental|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
11356915|NCT02321956|Experimental|Ultrasound|Using ultrasound measurement of the subglottic area to choose endotracheal tube size
11356917|NCT02321943||Follow-Up Group|"An earlier investigated cohort with first episode psychosis patients from two Norwegian counties. Being between 18 - 65 years old and being consecutive in- or outpatient referred to first adequate treatment for a DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychosis."
11356918|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
11356919|NCT02321917|Active Comparator|Rheoparin coating|MECC system with rheoparin coating
11356920|NCT02321917|No Intervention|No rheoparin coating|MECC system without rheoparin coating
11356921|NCT02321904||Diabetic cases|Children with Type 1 Diabetes 8 to 18 years old followed at the Alberta Children's Hospital Diabetes Clinic with duration of diabetes for at least 5 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
11356922|NCT02321904||Normal controls|Healthy children aged 8 to 18 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
11356923|NCT02321891|Experimental|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
11356924|NCT02321891|Experimental|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
11356925|NCT02321878||Liraglutide|
11356926|NCT02321865|Experimental|NPC-02|
11356927|NCT02321852|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo
11356928|NCT02321852|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
11356929|NCT02321839|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
11356930|NCT02321826|Experimental|Music|Listening to music for 45 minutes at bedtime
11356931|NCT02321826|Active Comparator|Audiobook|Listening to audiobook for 45 minutes at bedtime
11356932|NCT02321826|No Intervention|Control|No intervention control group
11356933|NCT02321813|Experimental|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient's QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
11356934|NCT02321813|Placebo Comparator|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
11356935|NCT02321800|Experimental|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
11356936|NCT02321800|Active Comparator|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
11356937|NCT02321787|No Intervention|Traditional Methods of Assessment|The caudal block will be done using traditional means of assessment, not confirmed by ultrasound.
11356938|NCT02321787|Experimental|Ultrasound for Confirmation|The caudal block will be performed utilizing ultrasound as an additional method of assessment for successful block (in addition to all traditional means of assessment).
11356939|NCT02321761|Experimental|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg
~days 57-70 no drug will be given"
11356940|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
11356941|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
11356942|NCT02321735|Other|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
11356943|NCT02321709|Experimental|SAR113244 cohort 1|Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)
11356944|NCT02321709|Experimental|SAR113244 cohort 2|Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)
11356945|NCT02321709|Experimental|SAR113244 cohort 3|Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)
11356946|NCT02321696|Experimental|Acupuncture and eccentric exercise|Treatment will be performed according to traditional Chinese methods (STRICTA: Standards for reporting interventions in controlled trials of acupunc-ture). Therapists will select points frequently recommended for the treatment of LE. As local point, LI11 and LI10 over the muscular origin of the lateral extensor group of the forearm will be used, and LU5 in the cubical region. LI4 and TE5 will be regional points for pain therapy in the upper limb, GB34 will be used as a distal point for treatment of tendinosis in general, and ST36 for treatment of pain. Needles will be inserted down to the musculature and obtaining De Qi sensation and will remain in situ for 20 min. All patients will receive four treatment sessions; this may be extended to eight depending on patient's pain report and the therapists' clinical evaluation. Maximum treatment period is 4 weeks. Patients will also be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
11356947|NCT02321696|Experimental|Physiotherapy and eccentric exercise|"Manual techniques as gliding mobilization of elbow, therapists are spezialised in manual therapy. At least four treatment sessions will be performed, but depending on the patient's perceived intensity of pain and the therapists' clinical evaluation, a maximum of eight treatment session can be given. All treatment session will be performed during a period of maximum 4 weeks.
~In addition, patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward."
11356948|NCT02321696|Active Comparator|Watchful waiting and eccentric exercise|Patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
11356949|NCT02321683|Experimental|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
11356950|NCT02321683|Active Comparator|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
11356951|NCT02321670|Active Comparator|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
11356952|NCT02321670|Active Comparator|Graft|Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
11356953|NCT02321657|Experimental|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
11356954|NCT02321657|Active Comparator|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
11356955|NCT02321644|Experimental|CC-90001|"Part 1: All subjects will receive the following doses of CC-90001 in the fixed sequence below:
~Treatment A: 60 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment B: 160 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment C: 400 mg of CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days"
11356956|NCT02321644|Experimental|CC-90001 2 X 100mg fasted|Treatment D: 2 x 100 mg CC-90001 as Active-Ingredient-in-Capsule, single oral dose administered under fasted conditions.
11356957|NCT02321644|Experimental|CC-90001 1 X 200mg fasted|Treatment E: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fasted conditions
11356958|NCT02321644|Experimental|CC-90001 1 X 200mg fed|Treatment F: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fed conditions (standard high fat breakfast).
11356959|NCT02321631|Experimental|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
11356960|NCT02321631|Placebo Comparator|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
11356961|NCT02321618|Experimental|BP measurement & pharmacy|BP measurements performed by barber, role model poster exposure in barbershop, and BP medication management visits with study pharmacist
11356962|NCT02321618|Other|BP educational materials|Exposure to hypertension educational materials in barbershop
11356963|NCT02321605|Experimental|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
11356964|NCT02321605|Placebo Comparator|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
11356965|NCT02321592|Active Comparator|Arm A|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.
~Arm A ist closed."
11356966|NCT02321592|Active Comparator|Arm B|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.
~Arm B is closed."
11356967|NCT02321592|Active Comparator|Arm C|AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
11356968|NCT02321579|Placebo Comparator|Negative control|Dextrins
11356969|NCT02321579|Experimental|Supplement 1|50 mg/d vitamin B-6
11356970|NCT02321579|Experimental|Supplement 2|500 mg/d Glutathione
11356971|NCT02321579|Experimental|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
11356972|NCT02321566|Experimental|Treatment Arm|A craniotomy will be performed for the placement of an epidural motor cortex stimulation lead in the context of subjects with chronic facial, upper extremity, and throat pain. If the stimulation is successful during a trial period with externalized lead cabling, the system cabling will be internalized and connected to an internal implantable pulse generator to power and control the system for the duration of the trial.
11356973|NCT02321553|Experimental|Brown Rice|Eat 100g of brown rice cake (3 packets) per day for 5 weeks
11356974|NCT02321553|Experimental|White Rice|Eat 100g of white rice cake (3 packets) per day for 5 weeks
11356975|NCT02321540|Experimental|Ibrutinib|"Participants in Part 1 receive dose level of Ibrutinib depending on study joined. First group of participants receive lowest dose level of Ibrutinib. Each new group receives a higher dose of Ibrutinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ibrutinib is found.
~Participants in Part 2 receive Ibrutinib at highest dose that was tolerated in Part 1 or 840 mg daily.
~Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle."
11356976|NCT02321527|Experimental|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
11356977|NCT02321514|Experimental|Tendyne Mitral Valve System|Transcatheter mitral valve replacement
11356978|NCT02321501|Experimental|Treatment (ceritinib, everolimus)|Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11356979|NCT02321475||Psycho-emotional symptoms, added to cognitive disorders|Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.
11356980|NCT02321462|Experimental|Eziclen|
11356981|NCT02321462|Active Comparator|Fortrans®|
11356982|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
11356983|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
11356984|NCT02321410|Other|Imaging of carotid plaque|Patient undergo contrast enhanced ultrasound of the carotid plaque and dynamic contrast-enhanced carotid plaque MRI
11356985|NCT02321397|Experimental|OXN PR HST|Prolonged release oxycodone/naloxone higher strength tablets
11356986|NCT02321397|Active Comparator|OXN PR LST|Prolonged release oxycodone/naloxone lower strength tablets
11357009|NCT02321202|Active Comparator|Control group|For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
11357535|NCT02317770|Active Comparator|Lidocaine Spray|20 puffs of 10% Lidocaine spray
11356987|NCT02321384|Experimental|A: SAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 6 planned SAD cohorts to receive single dose of RO6889678/matching placebo in fasted state as per anticipated dose escalation sequence (30 milligrams [mg], 100 mg, 300 mg, 600 mg, 1000 mg and 1500 mg). Cohort 1 will be split in 2 groups: 2 participants will be dosed 1 day (1 on RO6889678 and 1 on matching placebo) and 3 participants (2 on RO6889678 and 1 on matching placebo) will be dosed at least 24 hours afterward following satisfactory safety assessment for first 2 participants. Cohort 2 & beyond will include 8 healthy participants with 6 participants randomly assigned to RO6889678 & 2 randomly assigned to placebo. Participants who will tolerate fasted dose and agree to continue in food-effect SAD cohort, will receive single dose (dose level, either 300 mg or 600 mg, decided based on PK and safety data of first 2 SAD cohorts) of RO6889678/matching placebo with US FDA recommended high-fat and high-calorie breakfast on Day 16.
11356988|NCT02321384|Experimental|B: MAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms [mcg]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
11356989|NCT02321384|Experimental|C:RTV-Boosted SAD & MAD Cohorts-RO6889678/Matching Placebo+RTV|Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
11356990|NCT02321371|Experimental|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
11356991|NCT02321371|Active Comparator|Lactulose therapy|
11356992|NCT02321358|Experimental|Two-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention and a booster again six weeks following.
11356993|NCT02321358|Active Comparator|One-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention.
11356994|NCT02321358|Sham Comparator|Sham Comparator Group|Group will receive Canada's Food Guide which contains a small amount of physical activity information.
11356995|NCT02321345|Experimental|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
11356996|NCT02321332|Active Comparator|B-ETS|Bilateral simultaneous endoscopic thoracic sympathectomy: bilateral simultaneous T2-T3 ganglionectomy.
11356997|NCT02321332|Active Comparator|S-ETS|unilateral sequential endoscopic thoracic sympathectomy: unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval
11356998|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
11356999|NCT02321306|Experimental|LUM001|LUM001 administered orally once each day.
11357000|NCT02321293|Experimental|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.
~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)
~Tyrosine Kinase Inhibitors:
~Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .
~Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .
~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
11357001|NCT02321280|Experimental|Single arm single dose of denosumab|Open label = Single dose administration of single dose Denosumab 120 mg subcutaneously
11357002|NCT02321267|Other|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
11357003|NCT02321254|Experimental|The RehaARM-Robot|Receive 45 min of robot-assisted therapy for the shoulder and 1 hour of daily standard rehabilitation therapy.
11357004|NCT02321241||Group 1|According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection
11357005|NCT02321228|Experimental|Salpingectomy with delayed oophorectomy|Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).
11357006|NCT02321228|Active Comparator|Risk-reducing salpingo-oophorectomy|Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).
11357007|NCT02321215|No Intervention|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
11357008|NCT02321215|Active Comparator|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
11357010|NCT02321202|Experimental|Trial group|For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.
11357011|NCT02321189|Placebo Comparator|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
11357012|NCT02321189|Placebo Comparator|placebo|The Effect of placebo on Choroidal Thickness
11357013|NCT02321176|Experimental|pharmacokinetics,trans-resveratrol|tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
11357014|NCT02321163|Experimental|NMES new paradigm|For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
11357015|NCT02321163|Active Comparator|NMES conventional|For NMES conventional, the experimental protocol will be the conventional electrical stimulation protocol i.e frequency: 50 Hz; intensity: maximum intensity tolerated by the subject; duration: 30 min.
11357016|NCT02321163|Sham Comparator|Placebo|For placebo, electrodes will be applied and all conditions will be similar to those in the NMES group, except that the amplitude will be set to 0 mA so that no muscle stimulation occurs.
11357017|NCT02321150|Active Comparator|Sutures|After pterygium removal the conjunctival graft to cover bare sclera will be secured with interrupted 8.0 polyglactin sutures.
11357018|NCT02321150|Experimental|Cautery|After pterygium removal the conjunctival graft to cover bare sclera will be secured with bipolar electrocautery, power set at 25 until whitening of tissue observed.
11357019|NCT02321137|Active Comparator|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
11357020|NCT02321137|Placebo Comparator|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
11357021|NCT02321124|Active Comparator|intervention|we will apply connective tissue manipulation and life style advice.
11357022|NCT02321124|Other|control group|We will apply only life style advice.
11357023|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
11357024|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
11357025|NCT02321111|Active Comparator|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
11357026|NCT02321098|Experimental|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
11357027|NCT02321098|Experimental|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
11357028|NCT02321085|Active Comparator|Sinus Rhythm Control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
~Cardioversion after 1 month
~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
~If AF recur, RFCA"
11357029|NCT02321085|Active Comparator|Pulse Rate Control Group|"No AAD, just anticoagulation
~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
~Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study."
11357030|NCT02321072|Active Comparator|High-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
11357031|NCT02321072|Active Comparator|Low-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
11357032|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
11357033|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
11357034|NCT02321033|Experimental|low glycemic index|palatinose in soft drinks
11357035|NCT02321033|Experimental|high glycemic index|sucrose plus maltodextrin in soft drinks
11357036|NCT02320994||stroke patients|post-rehabilitation stroke patients
11357037|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
11357038|NCT02320968|Experimental|Patients with nocturnal extraesophageal reflux|This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.
11357039|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
11357040|NCT02320942|Experimental|Exercise Intervention|At discharge from the inpatient unit, participants will receive a practical introduction by an exercise specialist and enrolled in the 12-week exercise intervention
11357041|NCT02320929|Experimental|Intraoperative irrigation only|The infected tendon sheath is irrigated intraoperatively, the catheter is removed, and small rubber srains are left in small incisions.
11357042|NCT02320929|Active Comparator|Intra- and postoperative irrigation|The infected tendon sheath is irrigated intraoperatively, the catheter is kept in place, the irrigation is continued postoperatively 3 times a day for 3 days.
11357043|NCT02320916|Active Comparator|23Gauge|Arterial blood puncture will be performed using a 23Gauge needle
11357045|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
11357046|NCT02320890|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 3 days a week for 12 weeks (total of 36 applications)
11357047|NCT02320890|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 3 days a week for 12 weeks (total of 36 applications)
11357048|NCT02320877|Experimental|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
11357049|NCT02320864||Non-surgical group|Adults who have knee osteoarthritis, but do not elect to have a total knee replacement surgery.
11357050|NCT02320864||Surgical group|Adults who have knee osteoarthritis and elect to have total knee replacement surgery.
11357051|NCT02320851|Experimental|SVD-tailored Integrative Psychotherapy (IPT)|IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
11357052|NCT02320851|Active Comparator|Self-help group (SHG)|The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions. Those can be classified as low-level non-placebo control. Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
11357053|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
11357054|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
11357055|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
11357056|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
11357057|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
11357058|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
11357059|NCT02320799|Active Comparator|treatment as usual|Usual Clinic psychosocial treatment
11357060|NCT02320799|Experimental|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
11357061|NCT02320786|Experimental|CoPILOT|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (one hour, four times per week for three weeks).
11357062|NCT02320786|No Intervention|Standard of Care|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair, consisting of 12 hour protocols in a standard power wheelchair (one hour, four times per week for three weeks).
11357063|NCT02320773||1. OAB patients taking Betmiga®|OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
11357064|NCT02320760|Experimental|Physical activity on prescription|
11357065|NCT02320760|No Intervention|Ordinary care|
11357066|NCT02320747|Experimental|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
11357067|NCT02320747|No Intervention|Control Group|
11357068|NCT02320734|Active Comparator|deep neuromuscular relaxation|continuous infusion of rocuronium 0.6 mg/kg/hr (group 1). On demand bolus rocuronium can be given if demanded by anesthesiologist or surgeon
11357069|NCT02320734|No Intervention|on demand neuromuscular relaxation|continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2) On demand bolus of Rocuronium will be given when demanded by anesthesiologist or surgeon.
11357070|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
11357071|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
11357072|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
11357073|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
11357074|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
11357075|NCT02320708|Placebo Comparator|Placebo|
11357076|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
11357077|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
11357078|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
11357079|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
11357080|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
11357081|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
11357082|NCT02320682|Active Comparator|Exeter femur component and Delta TT acetabular component|
11357083|NCT02320682|Active Comparator|SP-CL femur component and Delta TT acetabular component|
11357084|NCT02320682|Active Comparator|SP-CL femoral component and Delta PF acetabular component|
11357085|NCT02320682|Active Comparator|Exeter femoral component and Delta PF acetabular component|
11357086|NCT02320669|Experimental|Triostat|Active Medication - Synthetic Thyroid Hormone
11357087|NCT02320669|Placebo Comparator|Placebo|Placebo Control
11357088|NCT02320656|Experimental|Acute leukemia/myelodysplastic or myeloproliferative disease|
11357089|NCT02320643|Experimental|Seratom® PA mesh|Partially absorbable mesh
11357090|NCT02320630|Experimental|A|Maintenance treatment group
11357091|NCT02320630|Experimental|B|Combination treatment group
11357092|NCT02320630|Experimental|C|Single drug group
11357093|NCT02320617|Experimental|DW-MRI group|To evaluate the efficacy of chemoradiotherapy in lung cancer patients by DW-MRI when compared with conventional imaging modalities(CT, ultrasound et al.)
11357094|NCT02320604|Experimental|Obese Subjects 1mg/kg|8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes
11357095|NCT02320604|Experimental|Obese Subjects 2mg/kg|8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes
11357096|NCT02320591|Experimental|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
11357097|NCT02320591|No Intervention|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
11357098|NCT02320578|Experimental|3D Laparoscopy|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.
~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
11357099|NCT02320578|Active Comparator|Standard Laparoscopy|Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
11357100|NCT02320565|Experimental|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.
~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
11357101|NCT02320565|Active Comparator|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
11357102|NCT02320552||PD patients|Patients receiving peritoneal dialysis. No intervention
11357103|NCT02320552||HD patients|Patients receiving hemodialysis. No intervention
11357104|NCT02320539||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
11357105|NCT02320539||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
11357106|NCT02320539||SAH good grade|SAH without external ventricular drainage
11357107|NCT02320539||Healthy controls|Blood sample in healthy donors registered in the National Donor Registry.
11357108|NCT02320526|Experimental|Control|Control intervention: Subjects will continue their life unaltered during the 14 days intervention period
11357109|NCT02320526|Experimental|Continuous walking|Training intervention: Subjects will perform continuous walking for one hour per day at every weekday during the 14 days intervention period
11357110|NCT02320526|Experimental|Interval Walking|Training intervention: Subjects will perform interval walking for one hour per day at every weekday during the 14 days intervention period. Interval walking will be performed as repeated cycles of three minutes of slow and hree minutes of fast walking during the entire training session
11357111|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
11357112|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
11357113|NCT02320500|Active Comparator|standard physiotherapy|Standard of care physiotherapy for knee osteoarthritis (OA) patients who have been diagnosed with knee OA and may be candidates for total knee replacement (TKA)
11357114|NCT02320500|Experimental|Myofascial-specific therapy|Patient undergo myofascial pain-specific therapy which includes trigger point injections at the same time points as the comparator (1 session every 2 weeks for 8 weeks)
11357115|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
11357116|NCT02320474|Experimental|Aflibercept|
11357117|NCT02320448|Experimental|PIPAC|"PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.
~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy."
11357118|NCT02320435|Experimental|Pertuzumab (Single-Agent or Combination Therapy)|Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.
11357119|NCT02320422|Experimental|Behavioral Telehealth|
11357120|NCT02320409|Experimental|Sulfatinib ,after general diet|First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
11357121|NCT02320409|Experimental|Sulfatinib, before general diet|First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
11357122|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
11357123|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
11357124|NCT02320383|Experimental|B + GA101|"Induction:
~Bendamustine + GA101; a maximum of 6 cycles of BG will be administered; each cycle with a duration of 28 days
~Maintenance:
~GA101 i.v. 1000 mg (flat dose): every 84 days starting on final restaging continued until progression or to a maximum of 2 years"
11357125|NCT02320370|Experimental|Treatment 1|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
11357126|NCT02320370|Experimental|Treatment 2|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
11357127|NCT02320357|Experimental|Clopidogrel|
11357128|NCT02320344|Experimental|Partners in Care|
11357129|NCT02320331|Experimental|PILI Lifestyle Program|
11357130|NCT02320318|Experimental|Ibodutant 10 mg|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
11357131|NCT02320318|Placebo Comparator|Placebo|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
11357132|NCT02320305|Experimental|Arm I (MART-1 antigen and TLR4 antagonist GLA-SE)|Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11357133|NCT02320305|Experimental|Arm II (MART-1 antigen)|Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11357134|NCT02320292|Active Comparator|Arm A (rituximab)|Patients receive rituximab IV on days 1, 8, 15, and 22.
11357135|NCT02320292|Experimental|Arm B (rituximab, yttrium Y-90 ibritumomab tiuxetan)|Patients receive rituximab IV on days 1 and 8 and yttrium Y-90 ibritumomab tiuxetan over 10 minutes on day 8.
11357136|NCT02320279||Women in labor|Pregnant women, women in labor, and women who are admitted to labor and delivery for scheduled c-sections will form the eligible population for recruitment into our study.
11357137|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
11357138|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
11357139|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
11357140|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
11357141|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
11357142|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
11357143|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
11357144|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
11357145|NCT02320240||SNRI Exposure Group|Patients who received a new prescription for an SNRI (duloxetine, venlafaxine, or desvenlafaxine at any dosage) with no prescriptions for either SNRI or SSRI in the prior year.
11357183|NCT02319993|Experimental|TIAN WANG BU XIN DAN|"Drug:TIAN WANG BU XIN DAN CONCENRATED GRANULES CHUANG SONG ZONG"
11357146|NCT02320240||SSRI Exposure Group|Patients who received a new prescription for an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline at any dosage) with no prescriptions for either SSRI or SNRI in the prior year.
11357147|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
11357148|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
11357149|NCT02320201|Experimental|Electrical stimulation|Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
11357150|NCT02320188|Experimental|Eccentric exercise|Thirty sessions of Eccentric training in twelve weeks. Average of two sessions per week without spacing higher than eight days between two sessions.
11357151|NCT02320188|Experimental|Concentric exercise|Thirty sessions of Concentric training in twelve weeks. Average of three sessions per week without spacing higher than eight days between two sessions.
11357152|NCT02320188|No Intervention|No training (control)|Usual activities. No further training during the observation period
11357153|NCT02320175|No Intervention|Pre-intervention|Before implementation of Patient and Family Centered I-PASS.
11357154|NCT02320175|Experimental|Post-intervention|After implementation of Patient and Family Centered I-PASS.
11357155|NCT02320162|Experimental|Experiential learning|Oral health education using experiential learning (EL)
11357156|NCT02320162|Placebo Comparator|Traditional lecturing|Oral health education using traditional lecturing (TL)
11357157|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
11357158|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
11357159|NCT02320136||epilepsy|epilepsy patients
11357160|NCT02320136||tumor with epilepsy|tumor patients with epileptic seizures
11357161|NCT02320136||tumor without epilepsy|tumor patients without epileptic seizures
11357162|NCT02320123|Experimental|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
11357163|NCT02320123|No Intervention|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
11357164|NCT02320097|Other|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.
~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
11357165|NCT02320084||HT-1 patients on Orfadin treatment|HT-1 patients on Orfadin (nitisinone) treatment
11357166|NCT02320071||Patients with incisional hernia|Patients with one or more incisional hernias, combined horizontal fascial defect 3-8 cm, planned for laparoscopic mesh repair. Patients are examined before and one and three months postoperative in regard to abdominal wall function, pain, discomfort, hernia-related quality of life and physical activity level.
11357167|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously
~Maintenance Phase: Nivolumab infusion intravenously"
11357168|NCT02320045|Experimental|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
11357169|NCT02320045|Experimental|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
11357170|NCT02320045|Experimental|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
11357171|NCT02320045|Experimental|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) >30-44 mL/min/1.73 m2
11357172|NCT02320032|Experimental|Aripiprazole Lauroxil - A|Intramuscular (IM) injection Dose and Dosing Sequence A
11357173|NCT02320032|Experimental|Aripiprazole Lauroxil - B|Intramuscular (IM) injection Dose and Dosing Sequence B
11357174|NCT02320032|Experimental|Aripiprazole Lauroxil - C|Intramuscular (IM) injection Dose and Dosing Sequence C
11357175|NCT02320032|Experimental|Aripiprazole Lauroxil - D|Intramuscular (IM) injection Dose and Dosing Sequence D
11357176|NCT02320019|Placebo Comparator|Placebo group|Placebo
11357177|NCT02320019|Experimental|Group A|YH14618 A mg/disc
11357178|NCT02320019|Experimental|Group B|YH14618 B mg/disc
11357179|NCT02320019|Experimental|Group C|YH14618 C mg/disc
11357180|NCT02320019|Experimental|Group D|YH14618 D mg/disc
11357181|NCT02320006|Active Comparator|True acupuncture plus hydrotubation|The treatment group will receive true acupuncture and hydrotubation,Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performedwithin 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles. The points (points used for every participant of treatment group) include bilateral RN4、CV6、CV3、EX-CA1、ST36、SP6,All the needles will be keep in positions for 30 min.Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk)
11357182|NCT02320006|Sham Comparator|control acupuncture plus hydrotubation|The control group will receive control acupuncture and hydrotubation.Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performed within 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles.Two needles will be inserted in each arm, one in each shoulder and one in each upper arm at nonacupuncture pointsAll the needles will be keep in positions for 30 min. Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk).
11357184|NCT02319993|Experimental|Suan Tzao Ren Tang|"Drug:Suan Tzao Ren Tang Granula Subtilae CHUANG SONG ZONG"
11357185|NCT02319993|Placebo Comparator|Placebo|Drug:1/10 TIAN WANG BU XIN DAN
11357186|NCT02319980|Active Comparator|Surgical intervention|All participants in this group will be assigned to receive extracranial-intracranial arterial bypass surgery.
11357187|NCT02319980|No Intervention|Conservative management(medical management)|All participants in this group will be assigned to receive conservative management or medical management which involves drug therapy as considered appropriate for medical symptoms by the treating investigator.
11357188|NCT02319967|No Intervention|Enhanced usual care|Inhaler technique education and distribution of spacers to all participants.
11357189|NCT02319967|Experimental|ED-only|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
11357190|NCT02319967|Experimental|ED-plus-home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
~Home visits by a community health worker (CHW)."
11357191|NCT02319954|Active Comparator|Compression|Each patient will be randomized to receive compression of their nose on either the left or right for 5 continuous minutes after performing a lateral rhinotomy.
11357192|NCT02319954|No Intervention|No compression|Each patient will serve as their own control with the other side not receiving any compression after a lateral rhinotomy.
11357193|NCT02319941|Experimental|Low dose ticagrelor|60mg bid
11357194|NCT02319941|Active Comparator|standard dose ticagrelor|90mg bid
11357195|NCT02319941|Active Comparator|standard dose clopidogrel|75mg qd
11357196|NCT02319928|Active Comparator|Short-term surveillance|Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.
11357197|NCT02319928|Experimental|Long-term surveillance|Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
11357198|NCT02319915|Experimental|Tranexamic acid|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.
11357199|NCT02319915|Active Comparator|Tranexamic acid + adrenalin|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.
11357200|NCT02319902|Placebo Comparator|Standard cold carbon dioxide gas|Standard cold carbon dioxide gas
11357201|NCT02319902|Active Comparator|Heated humidified carbon dioxide gas|Heated humidified carbon dioxide gas
11357202|NCT02319889|Experimental|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11357203|NCT02319876||Severe sepsis|Patients with severe sepsis
11357204|NCT02319876||SIRS patient|Patients after elective surgeries presented with SIRS but without sepsis
11357205|NCT02319876||Volunteer|Volunteers
11357206|NCT02319863|Active Comparator|conventional resection|Perform hepatectomy with conventional method for HCC patients.
11357207|NCT02319863|Experimental|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
11357208|NCT02319850||Reference Group|18 - 29 years of age; apparently healthy younger participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
11357209|NCT02319850||Comparison Group|55 - 75 years of age; apparently healthy older participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
11357210|NCT02319837|Experimental|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks
11357211|NCT02319837|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
11357212|NCT02319837|Active Comparator|Placebo plus leuprolide|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks
11357213|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
11357214|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
11357215|NCT02319798|Active Comparator|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital as usual.
11357216|NCT02319798|Experimental|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
11357217|NCT02319785|Experimental|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
11357218|NCT02319785|Experimental|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
11357219|NCT02319785|Active Comparator|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
11357220|NCT02319785|Experimental|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
11357221|NCT02319785|Active Comparator|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
11357222|NCT02319785|Active Comparator|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
11357223|NCT02319772|Experimental|BCX4430|BCX4430 administered as an IM injection
11357224|NCT02319772|Placebo Comparator|Placebo|Matched placebo administered as an IM injection
11357384|NCT02318758|Active Comparator|Comparison 2|UT-15C 1 mg plus ethanol (simultaneously)
11357385|NCT02318758|Active Comparator|Comparison 3|UT-15C 1 mg administered 1 hour before ethanol
11357225|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
11357226|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
11357227|NCT02319746|Experimental|Experimental group|The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
11357228|NCT02319746|Active Comparator|Control group|The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
11357229|NCT02319733|Experimental|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
11357230|NCT02319720|Experimental|BMA/Cultured Bone Marrow Cells|The subjects in this arm will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. Part of the aspirate will be cultured. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate and up to three applications of cultured cells derived from that aspirate. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by direct application of fresh bone marrow to the wound and up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
11357231|NCT02319720|Experimental|Cultured Bone Marrow Cells|In this group, the bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of up to three applications of cultured cells derived from a single bone marrow aspiration. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
11357232|NCT02319720|Experimental|Bone Marrow Aspirate|The subjects in this group will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate. If the wound has not healed, up to three additional bone marrow biopsies may be performed. If the wound heals at any point during this protocol, no additional bone marrow biopsy procedures will be performed and no additional cells will be applied.
11357233|NCT02319720|Active Comparator|Control|In this arm, subjects will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressing and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
11357234|NCT02319707|Experimental|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
11357235|NCT02319707|Experimental|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
11357236|NCT02319707|Active Comparator|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
11357237|NCT02319681|Experimental|Simple Reminiscence (SR) caregiver|Subjects are caregivers for a persons with EAD and will be administered SR intervention and an attention control treatment four times
11357238|NCT02319681|Experimental|Simple Reminiscence (SR) EAD|Subjects are persons with EAD and will be administered SR intervention and an attention control treatment four times
11357239|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
11357240|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
11357241|NCT02319655|Active Comparator|Air tamponade|Air is injected after vitrectomy/membrane peeling
11357242|NCT02319655|Active Comparator|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
11357243|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.
~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
11357244|NCT02319629|Experimental|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
11357245|NCT02319629|Placebo Comparator|placebo|placebo twice a day
11357246|NCT02319616|Experimental|Clobetasol 0.05% ointment|All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.
11357247|NCT02319616|Placebo Comparator|Placebo|All patients will have one arm assigned to receive the placebo treatment (topical petrolatum ointment) applied daily for a period of fourteen days.
11357386|NCT02318758|Active Comparator|Comparison 4|UT-15C 1 mg administered 1 hour after ethanol
11357536|NCT02317770|Active Comparator|Nebulized Lidocaine|2.5 mL of 10% Lidocaine
11357248|NCT02319603|Active Comparator|Low dose WenXin keli|"Low dose group (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
11357249|NCT02319603|Experimental|High dose WenXin keli|"High dose group(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
11357250|NCT02319590||heart failure, no CAD, QRS < 150ms|no CAD, QRS < 150ms
11357251|NCT02319590||heart failure, CAD QRS < 150ms|CAD, QRS < 150ms
11357252|NCT02319590||heart failure, CAD > 150ms|CAD, QRS > 150ms
11357253|NCT02319590||heart failure, no CAD, > 150ms|no CAD, QRS > 150ms
11357254|NCT02319577|Experimental|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):
~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
11357255|NCT02319577|Active Comparator|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):
~Gefitinib 250 mg daily from day 1 to day 21"
11357256|NCT02319564|Active Comparator|beclomethasone|"beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.
~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
11357257|NCT02319564|Active Comparator|beclomethasone and salbutamol|"beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.
~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
11357258|NCT02319564|Placebo Comparator|Placebo|"placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.
~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
11357259|NCT02319538|No Intervention|Non-surgical treatment only|Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.
11357260|NCT02319538|Active Comparator|Total thyroidectomy performed|Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.
11357261|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
11357262|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
11357263|NCT02319512|Experimental|Chewing gum|Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
11357264|NCT02319512|Sham Comparator|Control|Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum
11357265|NCT02319499|Experimental|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
11357266|NCT02319499|Experimental|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
11357267|NCT02319499|Experimental|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
11357268|NCT02319499|Placebo Comparator|Placebo|No minerals/vitamin
11357269|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
11357270|NCT02319460||Retrospective|Retrospective cohort of adults hospitalized for major bleeding during 2008 to 2013 who receive plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
11357271|NCT02319460||Prospective|Prospective parallel cohort of adults hospitalized for major bleeding during 2014 to 2020 who either receive Kcentra® or plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
11357272|NCT02319447|No Intervention|Usual Care|After randomization, these study participants will receive the Usual Care received by all listed kidney transplant candidates at our center.
11357273|NCT02319447|Experimental|Additional education|These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
11357274|NCT02319421|Experimental|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
11357275|NCT02319408|No Intervention|No radiation|Lobectomy for lung cancer without preoperative radiation
11357276|NCT02319408|Experimental|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
11357277|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
11357278|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
11357279|NCT02319382|Experimental|2 markers: 18F-DPA-714 and 11C-PE2I|PET with the tracer [18F]DPA-714 and second PET with the tracer [11C]-PE2I. [18F]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. [11C]-PE2I allow measures dopaminergic neuronal loss.
11357280|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
11357281|NCT02319369|Experimental|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
11357282|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
11357537|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
11357283|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
11357284|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
11357285|NCT02319356|Active Comparator|Beetroot juice (BRJ)|beetroot juice
11357286|NCT02319356|Placebo Comparator|Placebo (PL)|placebo juice
11357287|NCT02319343|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
11357288|NCT02319343|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
11357289|NCT02319330|Experimental|Phone counseling intervention|Treatment as usual (TAU) plus a nurse-delivered mobile phone counseling intervention delivered at weeks 1 to 12, 14, and 16 post-randomization.
11357290|NCT02319330|Active Comparator|Treatment as Usual|Routine HIV clinic-based counseling
11357291|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
11357292|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
11357293|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:
~FOLFOX: combination of drugs administered in a specific sequence as perscribed below.
~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours
~Leucovorin: 200 mg/m2 IV bolus over 2 hours
~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours
~Part II:
~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
11357294|NCT02319291||Participants|P.F.C. Sigma PS150 RP Total Knee System
11357295|NCT02319278|Active Comparator|Myocarditis|
11357296|NCT02319278|Active Comparator|Cardiac sarcoid|
11357297|NCT02319278|Active Comparator|Cardiac Transplant|
11357298|NCT02319278|Placebo Comparator|Healthy Volunteers|
11357299|NCT02319265|Experimental|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
11357300|NCT02319265|Placebo Comparator|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
11357301|NCT02319252|Active Comparator|Gastric tube|A gastric tube is used
11357302|NCT02319252|Active Comparator|Jejunal tube|A jejunal tube is used
11357303|NCT02319239|Active Comparator|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
11357304|NCT02319239|Experimental|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
11357305|NCT02319239|Experimental|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
11357306|NCT02319213|No Intervention|Group C|The control group (Group C) was not subjected to laparoscopic intervention
11357307|NCT02319213|Experimental|Group L|Intraocular pressure measurement with 9 mmHg insufflation
11357308|NCT02319213|Experimental|Group M|Intraocular pressure measurement with 12 mmHg insufflation
11357309|NCT02319213|Experimental|Group H|Intraocular pressure measurement with 15 mmHg insufflation
11357310|NCT02319200|Experimental|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)
~Metformin daily during 36 months"
11357311|NCT02319200|Placebo Comparator|placebo tablet|2 tablets at morning and 2 tablets at afternoon 4 tablets per day
11357312|NCT02319187|Active Comparator|Arm A|S1
11357313|NCT02319187|Experimental|Arm B|S1 and irinotecan
11357314|NCT02319174|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
11357315|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
11357316|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
11357317|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
11357318|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
11357319|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
11357320|NCT02319135|Active Comparator|fludarabine cytarabine|"Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis> 25 x 109/l), followed by:
~Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR
~Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).
~Treatment cycles every 28 days"
11357321|NCT02319135|Experimental|Azacitidine|Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
11357413|NCT02318563|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
11357322|NCT02319122|Other|Progressive Resistance Training|"The key for the PRT is the timely progression of load, based on the child's individual level of strength, which ensures progressive overload.
~Every training session will consist of a warm up, progressive resistance exercises and a cool down period. During warm up and cool down periods.These exercises will be the same for both training groups.
~The strength training exercises have been chosen to strengthen the main lower extremity muscle groups which are important for the gait: sit-to-stand, lateral step-ups, the half knee rise, heel-rises and bridging.
~All these exercises are performed loaded according to the individual level. Three sets of 8 to 10 repetitions of each exercise will be practiced on 3 non-consecutive days with moderate velocity."
11357323|NCT02319122|Other|High Intensity Interval Training|The High Intensity Circuit Training is a sub form of High Intensity Interval Training. The key feature is the very little rest between the exercises which causes a consistent elevation of the participant's heart rate and a short duration of the whole exercise session. Every training session consists of a warm-up, a circuit of 5 exercises (the same as these in the PRT group) and a cool-down period. The children will be asked to train 3 times a week on non-consecutive days and to perform 3 sets. Exercise workload is controlled by determination of time intervals (30 seconds). The children will be instructed to perform as many repetitions as possible during the exercise interval and to keep the rest between the exercises short (it must not exceed 30 seconds).
11357324|NCT02319096|Experimental|Patients with stress incontinence|Patients who present to urogynaecology clinic with proven stress urinary incontinence who will be offered Whole body vibration therapy.
11357325|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
11357326|NCT02319070||Cohort 1|Adult patients with severe Hemophilia A.(25 patients on Secondary Prophylaxis treatment)
11357327|NCT02319070||Cohort 2|Adult patients with severe Hemophilia A.(50 patients on On Demand treatment)
11357328|NCT02319057|Experimental|Panel 1|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
11357329|NCT02319057|Experimental|Panel 2|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
11357330|NCT02319057|Experimental|Panel 3|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
11357331|NCT02319057|Experimental|Panel 4|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
11357332|NCT02319057|Experimental|Panel 5|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
11357333|NCT02319057|Experimental|Panel 6|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
11357334|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
11357335|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
11357336|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
11357337|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
11357338|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
11357339|NCT02319018|Experimental|Treatment (alisertib, mFOLFOX)|Patients receive alisertib PO BID on days 1-3 and mFOLFOX regimen comprising oxaliplatin IV over 2 hours on day 2, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV continuously over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11357340|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
11357341|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
11357342|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
11357343|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
11357344|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
11357345|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
11357346|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
11357347|NCT02318966|Active Comparator|Glycosade|Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
11357348|NCT02318966|Placebo Comparator|Uncooked corn starch|Participants will be randomised to receive uncooked corn starch as a starch load with a maximum dose of 100g. Uncooked corn starch to be taken as one dose.
11357529|NCT02317796|Placebo Comparator|Placebo|
11357530|NCT02317796|Active Comparator|100 mg q.d.|
11357349|NCT02318953|Experimental|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
11357350|NCT02318953|Active Comparator|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
11357351|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.
~access will be through the femoral vein only"
11357352|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
11357353|NCT02318927|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
11357354|NCT02318914|Experimental|gevokizumab|Solution for subcutaneous injection
11357355|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
11357356|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
11357357|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
11357358|NCT02318888|Experimental|Surgery and Icodextrin|Icodextrin 4% instilled every 30 minutes during surgery and 1000 ml instilled before closure of abdomen
11357359|NCT02318888|Active Comparator|Surgery|No instillations during surgery
11357360|NCT02318875|Experimental|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
11357361|NCT02318875|Placebo Comparator|Placebo group|Subjects take 1 placebo capsule per day
11357362|NCT02318862|Other|GERD|Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
11357363|NCT02318862|Other|non-GERD|Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
11357364|NCT02318849|Experimental|Web intervention|Online intervention that uses information, engaging contests, and advocacy drives to encourage college students to become designated organ donor on driver's license
11357365|NCT02318849|No Intervention|Control|No intervention provided
11357366|NCT02318836|Active Comparator|Normal Hepatic function|
11357367|NCT02318836|Active Comparator|Mild Hepatic Impairment|(Child-Pugh score 5-6)
11357368|NCT02318836|Active Comparator|Moderate Hepatic Impairment|(Child-Pugh score 7-9)
11357369|NCT02318836|Active Comparator|Severe Hepatic Impairment|(Child-Pugh score 10-15)
11357370|NCT02318823|Other|Beer (alcoholic) followed by placebo (non-alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
11357371|NCT02318823|Other|Placebo (non-acoholic beer) followed by Beer (alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
11357372|NCT02318810|Active Comparator|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
11357373|NCT02318810|Active Comparator|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
11357374|NCT02318810|Active Comparator|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
11357375|NCT02318810|Placebo Comparator|Placebo|Patients receive saline
11357376|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
11357377|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
11357378|NCT02318784|Experimental|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.
~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV
~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
11357379|NCT02318771|Experimental|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11357380|NCT02318771|Experimental|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
11357381|NCT02318771|Experimental|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
11357382|NCT02318771|Experimental|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
11357383|NCT02318758|Active Comparator|Comparison 1|UT-15C 1 mg alone
11357387|NCT02318745|Experimental|Culturally Informed Family Treatment for Adolescents|CIFTA focuses on improving parenting practices, parent-adolescent attachment, adolescent ability to meet developmental challenges, increasing family support and decreasing family conflict/negativity, increasing knowledge of drug effects and triggers to use. Parents are taught general parenting and how to help a son or daughter with depression, conduct problems, and/or ADHD. Psycho-educational modules complement the family therapy and culturally relevant information is infused throughout the treatment. In family therapy sessions family members practice the skills and psycho-educational material they have learned. Treatment last approximately 4 months and includes approximately 6 session per month. Session may be family therapy sessions, individual sessions, or psycho-educational modules.
11357388|NCT02318745|Active Comparator|Individual Treatment As Usual|The active comparison condition reflects the typical individually-oriented services that behavior problem youth receive in the community. It was designed to isolate the effects of the CIFTA family interventions. A community agency helped us to standardize the individually-oriented services that were normally provided and a therapist trained by that agency was hired to work on the study to provide continuity to the services. The adolescent individual sessions addressed depression, ADHD, and/or conduct disorder through Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, and assertiveness training. The ITAU therapists were expected to hold 6 sessions per month with the youth.
11357389|NCT02318732|Experimental|Group 1|APPS intervention will be implemented in Group 1 communities prior to implementation in Group 2 communities.
11357390|NCT02318732|Active Comparator|Group 2|APPS intervention will be implemented in Group 2 communities following implementation in Group 1 communities.
11357391|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
11357392|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
11357393|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
11357394|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
11357395|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
11357396|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
11357397|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
11357398|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
11357399|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
11357400|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
11357401|NCT02318680|Experimental|Intervention|Review of follow home visits after discharge from Nykøbing Falster Hospital
11357402|NCT02318680|No Intervention|Control|Standard health care and discharge services
11357403|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
11357404|NCT02318654|Active Comparator|Ice Pack|
11357405|NCT02318654|Active Comparator|Topical EMLA cream|
11357406|NCT02318615|Experimental|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
11357407|NCT02318615|No Intervention|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
11357408|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.
~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.
~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
11357409|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.
~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.
~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
11357410|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.
~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.
~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
11357411|NCT02318576|No Intervention|Control|This group will do nothing for the 12 week program.
11357412|NCT02318576|Experimental|Cognitive Trained Group|This group will train three time a week for one hour on the given computerized cognitive training website for the 12 week program.
11357414|NCT02318563|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
11357415|NCT02318537|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
11357416|NCT02318537|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
11357417|NCT02318511|Experimental|ReNu amniotic allograft|Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
11357418|NCT02318511|Placebo Comparator|Saline|Knee injection with saline. Injectable saline will be used as the placebo control.
11357419|NCT02318511|Active Comparator|HA injection|Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
11357420|NCT02318498|Active Comparator|Prospective MINCA patients|Patients with MINCA prospectively investigated with an early CMR with latest technique
11357421|NCT02318498|Placebo Comparator|Historical MINCA patients|Patients with MINCA investigated earlier with a late CMR (median 12 days)
11357422|NCT02318485|Experimental|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
11357423|NCT02318472|Experimental|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
11357424|NCT02318472|Active Comparator|Immobilization|Treatment as usual using plaster cast immobilization
11357425|NCT02318459|Experimental|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
11357426|NCT02318459|Active Comparator|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
11357427|NCT02318446|Placebo Comparator|Control group|Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
11357428|NCT02318446|Experimental|Test group|Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
11357429|NCT02318433|Experimental|Dexamethasone|Subjects receive dexamethasone (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
11357430|NCT02318433|Placebo Comparator|Saline|Subjects receive sterile saline (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
11357431|NCT02318420|Experimental|Women in labour|"All women in labour during the study period (4 months baseline and the 9th-12th month of the intervention) will be included for this pre- vs. post-study of the PartoMa intervention.
~The following subgroups will be studied in-depth:
~All stillbirths
~All maternal deaths
~All women with severe hypertensive disorders
~A randomized selected group of women delivering a the study site, approximately 300-600 each year."
11357432|NCT02318420|Experimental|Health care providers|All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
11357433|NCT02318407|Experimental|AMG 403|AMG 403 administered as subcutaneous doses
11357434|NCT02318407|Placebo Comparator|Placebo|No active drug
11357435|NCT02318394|Experimental|Monotherapy Arm|MEDI0562 monotherapy
11357436|NCT02318381|No Intervention|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
11357437|NCT02318381|Other|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.
~Arthroscopic dissection of the superior transverse scapular ligament"
11357438|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
11357439|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
11357440|NCT02318355|No Intervention|Control|Control group that receives no intravenous fluid after blood donation
11357441|NCT02318355|Experimental|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
11357442|NCT02318355|Experimental|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
11357443|NCT02318342|Experimental|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
11357444|NCT02318329|Experimental|Part 1A: FPA144 Dose Escalation Solid Tumors|Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
11357445|NCT02318329|Experimental|Part 1B: FPA144 Dose Escalation Gastric Cancer|Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
11357446|NCT02318329|Experimental|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression
11357447|NCT02318316||EBC level|Exhaled breath condensate level of allogeneic stem cell transplantation patients
11357448|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
11357449|NCT02318303|Experimental|GSP 301-1 NS (QD)|
11357450|NCT02318303|Experimental|GSP 301-2 NS (BID)|
11357451|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
11357452|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
11357453|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
11357454|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
11357531|NCT02317796|Active Comparator|100 mg b.i.d.|
11357532|NCT02317796|Active Comparator|200 mg q.d.|
11357455|NCT02318290||Critically ill patients|Mechanically ventilated critically ill patients receiveing opiates for more than 96 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opiates
11357456|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
11357457|NCT02318264|Experimental|Distal to Proximal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting distal by knee and ending proximal by hip.
11357458|NCT02318264|Experimental|Proximal to Distal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting proximal by hip and ending distal by knee.
11357459|NCT02318251|Experimental|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
11357460|NCT02318251|Active Comparator|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
11357461|NCT02318238|Active Comparator|6 minute walking test|walking during 6 minutes
11357462|NCT02318238|Experimental|6 minute step test|stepping during 6 minutes
11357463|NCT02318238|Experimental|4 meter gait speed|walking as fast as possible on 4 meters
11357464|NCT02318225|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
11357465|NCT02318225|Placebo Comparator|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
11357466|NCT02318199||Agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 5-7 during the first 12 hours after surgery.
11357467|NCT02318199||Non-agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 1-4 during the first 12 hours after surgery.
11357468|NCT02318186||0 months - 1 year|
11357469|NCT02318186||11-16 years|
11357470|NCT02318186||7-11 years|
11357471|NCT02318186||4-6 years|
11357472|NCT02318186||1-3 years|
11357473|NCT02318147|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
11357474|NCT02318147|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
11357475|NCT02318134|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
11357476|NCT02318134|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
11357477|NCT02318121|Active Comparator|Amniotomy first|Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.
11357478|NCT02318121|Active Comparator|Oxytocin first|The starting dose will be the low dose rate equal or less than 4 m unit\minute (4 drops\minute doubled every 15 minutes up to 40 drops \minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.
11357479|NCT02318121|Active Comparator|Amniotomy and oxytocin|Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.
11357480|NCT02318108|Experimental|Intervention|Mentored organizational change and feedback.
11357481|NCT02318108|Other|Education only|Education and feedback.
11357482|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
11357483|NCT02318082|Experimental|Interleukin-2 (IL-2)|Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
11357484|NCT02318069|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
11357485|NCT02318069|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
11357486|NCT02318069|Active Comparator|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
11357487|NCT02318069|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
11357488|NCT02318069|Active Comparator|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
11357489|NCT02318056|Experimental|Aquacel® Ag Burn Glove|Application of Aquacel® Ag Burn Glove burn dressing
11357490|NCT02318056|Active Comparator|Mepilex® Transfer Ag|Application of Mepilex® Transfer Ag burn dressing
11357491|NCT02318056|Active Comparator|Xeroform®/Bacitracin®|Application of Xeroform® burn dressing and Bacitracin® topical antibiotic
11357492|NCT02318043|Active Comparator|AMP-BPT|Methods of AMP-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
11357533|NCT02317796|Active Comparator|200 mg b.i.d.|
11357534|NCT02317783|Experimental|FDG-PET, [18F]Flutemetamol Scanning|
11357493|NCT02318043|Active Comparator|His-BPT|Methods of His-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
11357494|NCT02318030||Solid organ transplant|
11357495|NCT02318030||Hematopoietic Stem Cell Transplant|
11357496|NCT02318017|Active Comparator|Methylphenidate|Methylphenidate 0.5mg/kg - once
11357497|NCT02318017|Placebo Comparator|Placebo|Placebo - once
11357498|NCT02318004|Experimental|Home monitoring|Home monitoring via the EarlySense non-invasive nocturnal monitoring system. Movement, heart rate and respiratory rates will be monitored while subject is in his bed. The trends of monitored values will be daily reported to a central repository. No intervention will be attempted and care will be coordinated by the family physician and treating cardiologist as usual.
11357499|NCT02317991|Experimental|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).
~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
11357500|NCT02317978||Subfertility without polycystic ovarian syndrome|The records of all women with infertility who had IVF/ICSI without polycystic ovarian syndrome (PCO) will be reviewed
11357501|NCT02317965||Pregnant Women|"Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure
~Intervention: Single Maternal blood draw of 20mL"
11357502|NCT02317952|Experimental|New Extensively Hydrolyzed Formula|Administered in context of oral food challenge and then for 16 weeks.
11357503|NCT02317952|Active Comparator|Comparator Formula|Administered in context of oral food challenge and then for 16 weeks.
11357504|NCT02317939|Experimental|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
11357505|NCT02317939|Active Comparator|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
11357506|NCT02317926|Active Comparator|Levothyroxine Plus Liothyronine Group|Levothyroxine Plus Liothyronine Group
11357507|NCT02317926|Active Comparator|Levothyroxine Group|Levothyroxine Group
11357508|NCT02317926|Active Comparator|Desiccated Thyroid Extract Group|Desiccated Thyroid Extract Group
11357509|NCT02317900|Experimental|TV005 and rDEN2∆30-7169|Participants will receive one injection of TV005 at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
11357510|NCT02317900|Placebo Comparator|Placebo and rDEN2∆30-7169|Participants will receive one injection of placebo at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
11357511|NCT02317887|Experimental|Group 1|1e9 vg/eye
11357512|NCT02317887|Experimental|Group 2|1e10 vg/eye
11357513|NCT02317887|Experimental|Group 3|1e11 vg/eye
11357514|NCT02317887|Experimental|Group 4|1e11 vg/eye
11357515|NCT02317887|Experimental|Group 5|Not to exceed 3e11 vg/eye
11357516|NCT02317887|Experimental|Group 6|Not to exceed 6e11 vg/eye
11357517|NCT02317874|Experimental|Schedule A (7-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-7, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.
~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
11357518|NCT02317874|Experimental|Schedule B (3-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-3, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.
~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
11357519|NCT02317861|Experimental|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
11357520|NCT02317861|Experimental|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
11357521|NCT02317861|Experimental|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
11357522|NCT02317861|Experimental|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
11357523|NCT02317861|Experimental|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
11357524|NCT02317861|Experimental|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
11357525|NCT02317848|Other|patients with acute heart failure|polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
11357526|NCT02317835|Other|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
11357527|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
11357528|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
11357538|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
11357539|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
11357540|NCT02317731|No Intervention|Routine|Subjects will ingest the bowel preparation from a cup
11357541|NCT02317731|Experimental|Straw|Subjects will ingest the bowel preparation with a straw
11357542|NCT02317718||Normal vitamin D levels group|MORE THAN 20 NG/ML VITAMIN D LEVELS
11357543|NCT02317718||Deficient Vitamin D GROUP|LESS THAN 20 NG/ML LEVELS
11357544|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
11357545|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
11357546|NCT02317679|Experimental|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
11357547|NCT02317666|Experimental|Medication Review|Structured 5-step multidisciplinary medication review (STRIP method) performed by the pharmacist in collaboration with the general practitioner.
11357548|NCT02317666|No Intervention|Delayed Medication Review|Patients in the control group will not undergo a medication review during the study period (delayed medication review).
11357549|NCT02317653||Overweight/Obese|Archive blood, archive breast milk, and clinical assessment data from 15 participants who were considered overweight or obese at enrollment in the Expecting Success study conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent the overweight and obese sample for study investigations.
11357550|NCT02317653||Normal Weight|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior to pregnancy will be enrolled in the study.
11357551|NCT02317640|Active Comparator|Stand Training Alone|Standing training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
11357552|NCT02317640|Experimental|ST with placebo or testosterone|Stand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
11357553|NCT02317640|Experimental|ST with Placebo or Testosterone and ES|"Stand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One RT300 portable stimulator (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation."
11357554|NCT02317640|Experimental|ST with ES|Stand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
11357555|NCT02317627|Experimental|Cohort 1|KD025 will be orally administered to subjects at 400 mg once daily for 12 weeks
11357556|NCT02317627|Experimental|Cohort 2|KD025 will be orally administered to subjects at 200mg twice daily for 12 weeks
11357557|NCT02317627|Experimental|Cohort 3|KD025 will be orally administered to subjects at 400mg twice daily for 12 weeks
11357558|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
11357559|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
11357560|NCT02317601|Active Comparator|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
11357561|NCT02317601|Placebo Comparator|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
11357562|NCT02317588|Active Comparator|Flax Oil|Flax oil 4 grams of ALA per day for 28 days (4 weeks).
11357563|NCT02317588|Active Comparator|Fish Oil|Fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day for 28 days (4 weeks).
11357564|NCT02317575|Experimental|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
11357565|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
11357566|NCT02317575|Experimental|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
11357567|NCT02317575|Experimental|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
11357568|NCT02317575|Experimental|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
11357569|NCT02317575|Experimental|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
11357570|NCT02317562|Experimental|I10E Arm|
11357571|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
11357572|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
11357573|NCT02317536|Experimental|Carnipure Product 1|Carnitine-based product 1, subjects will take one dose once daily for 56 days.
11357574|NCT02317536|Experimental|Carnipure Product 2|Carnitine-based product 2, subjects will take one dose once daily for 56 days.
11357575|NCT02317536|Placebo Comparator|Placebo|Placebo, subjects will take one dose once daily for 56 days.
11357576|NCT02317523|Experimental|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
11357577|NCT02317523|Active Comparator|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
11357578|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
11357579|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
11357580|NCT02317497|Experimental|Moderate sedation (M)|1. Moderate sedation defined by target RASS of >= -3. The intervention (M) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of >= -3 (patient responds to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be deepened below the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the intervention group again.
11357581|NCT02317497|Active Comparator|Deep sedation (D)|2. Deep sedation defined by target RASS of < -3. The control (D) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of < -3 (patient does not respond to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be reduced above the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the control group again.
11357582|NCT02317484||Ipragliflozin (SGLT2 inhibitor)|
11357583|NCT02317471|Experimental|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
11357584|NCT02317471|Other|control group|Oxaliplatin+S-1
11357585|NCT02317458|Experimental|Active arm|One arm with standard of care and C3BS-CQR-1 injection (treatment group) using intramyocardial catheter injection.
11357586|NCT02317458|Sham Comparator|Control arm|One arm with standard of care undergoing a sham procedure (control group)using intramyocardial catheter injection. .
11357587|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
11357588|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
11357589|NCT02317419|Experimental|Part A MAD Phase RO6927005 Monotherapy|RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
11357590|NCT02317419|Experimental|Part A Extension Phase Group 1|RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
11357591|NCT02317419|Experimental|Part A Extension Phase Group 2|RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
11357592|NCT02317419|Experimental|Part B MAD Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
11357593|NCT02317419|Experimental|Part B Extension Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA
11357594|NCT02317406|Active Comparator|Probiotics|Biostime probiotics sachet children's formula, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
11357595|NCT02317406|Placebo Comparator|Probiotics simulation|Biostime probiotics sachet children's formula（placebo）, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
11357596|NCT02317393|Other|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
11357597|NCT02317367||adult women|Women who drink seven or more drinks per week
11357598|NCT02317367||adults a|Individuals who eat fewer than five servings of fruits and vegetables per day, on average, based on an NCI screener for fruit and vegetable consumption.
11357599|NCT02317367||adults b|Individuals who exercise (moderate or vigorous intensity) less than 75 minutes per week.
11357600|NCT02317341|Experimental|1|Single intravenous dose given over 40 minutes
11357601|NCT02317341|Active Comparator|2|Single intravenous dose goven over 40 minutes
11357602|NCT02317328||Affected particpants|Participants with ocular conditions
11357603|NCT02317328||Healthy Volunteers|Healthy Volunteers
11357604|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
11357681|NCT02316860|Other|No history of reflex syncope|Passive tilt test in athletes without history of reflex syncope
11357898|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline
11357605|NCT02317302|Experimental|FDG-PET/CT or FDG-PET/MR|"Standard of care FDG-PET/CT or FDG-PET/MR at baseline
~FDG-PET/CT or FDG-PET/MR after the 2nd but before the 3rd brachytherapy treatment
~Standard of care 3 month post treatment FDG-PET/CT or FDG-PET/MR
~We will perform the research-related FDG-PET on the PET/MR rather than the PET/CT if the patient is safe to undergo MR and agrees to undergo MR.
~The standard of care imaging may be performed on the PET/CT scanner or the PET/MR scanner."
11357606|NCT02317289|Experimental|Detection of freezing|freezing parkinsonian patients
11357607|NCT02317276|Experimental|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
11357608|NCT02317263|Active Comparator|Testosterone gel|Apply gel once a day for 96 weeks
11357609|NCT02317263|Placebo Comparator|Placebo gel|Apply gel once a day for 96 weeks
11357610|NCT02317250|Experimental|prompt amyloid imaging, delayed FDG-PET|Subject's managing physicians will be given the results of amyloid imaging scans immediately. FDG-PET results will be released two years after scanning.
11357611|NCT02317250|Experimental|prompt FDG-PET, delayed amyloid imaging|Subject's managing physicians will be given the results of FDG-PET scans immediately. Amyloid imaging results will be released two years after scanning.
11357612|NCT02317250|Experimental|prompt FDG-PET, prompt amyloid imaging|Both FDG-PET and amyloid imaging scan results will be made immediately available to the managing physician.
11357613|NCT02317250|Active Comparator|delayed FDG-PET, delayed amyloid imaging|Neither FDG-PET nor amyloid imaging scan results will be released to the managing physician for 2 years.
11357614|NCT02317237|No Intervention|General Anesthesia|The patients, who will receive general anesthesia during intervention
11357615|NCT02317237|Experimental|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
11357616|NCT02317224|Experimental|"3-Hole subxiphorid and subcostal approach"|The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole. Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively. Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection. Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
11357617|NCT02317224|Experimental|Trans sternal approach|
11357618|NCT02317224|Experimental|VATS approach|
11357619|NCT02317211|Placebo Comparator|control|placebo 320 mg daily for twelve weeks
11357620|NCT02317211|Experimental|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
11357621|NCT02317198|Experimental|Intervention|Clopidogrel
11357622|NCT02317198|Active Comparator|Control|Ticagrelor/Prasugrel
11357623|NCT02317172|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
11357624|NCT02317159|Experimental|imatinib，Capsule|400mg imatinib qd
11357625|NCT02317146|Experimental|Six Hours Postpartum|The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
11357626|NCT02317146|Active Comparator|Twenty-four hours Postpartum|The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.
11357627|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.
~Intervention: Blood samples Intervention: Stool samples"
11357628|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.
~Intervention: Blood samples Intervention: Stool samples"
11357629|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.
~Intervention: Blood samples Intervention: Stool samples"
11357630|NCT02317107||Concussion|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they receive a diagnosis of concussion, defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. If they agree to participate, they will be placed in the concussion group and assessed at each visit to the clinic. No intervention will be administered.
11357631|NCT02317107||Control|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they come to the clinic for an injury unrelated to brain function or a lower extremity function (which may affect normal gait patterns). If they agree to participate, they will be placed in the control group and assessed at each visit to the clinic. No intervention will be administered.
11357632|NCT02317094|Other|Control|Participants receive care as usual (various DMARDs, different from patient to patient).
11357633|NCT02317094|Experimental|Blood-flow restricted tranining|Participants will receive care as usual (various DMARDs, different from patient to patient) + 12 wks of low-intensity blood-flow restricted training twice per week.
11357634|NCT02317081|Experimental|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
11357635|NCT02317068|Experimental|High Atrial Base Rate Pacing|The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
11357636|NCT02317068|Active Comparator|Device Default|The base rate of pacemaker will be determined 60 beats/minute
11357637|NCT02317055|Other|Patient|Imaging
11357638|NCT02317055|Other|healthy subject|Imaging
11357639|NCT02317042|Other|Phase I: Intellgent Volume Assured Pressure Support (iVAPS)|"iVAPS is a type of respiratory support ventilation. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation. It is commercially available. iVAPS is the predicate therapy for the Experimental therapy: Automatic Expiratory Positive Airway Pressure (AutoEPAP) iVAPS.
~iVAPS delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. Collectively, this optimises ventilation and ensures a target alveolar ventilation is achieved."
11357895|NCT02315404|Active Comparator|Enteroscopy with a cap|Enteroscopy performed with a CAP fitted to the end of the scope
11357640|NCT02317042|Experimental|Phase I: AutoEPAP iVAPS|AutoEPAP iVAPS is a proposed new type of respiratory support ventilation. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation, AND introduces the treatment of upper airway obstruction (i.e. sleep apnea). It is being developed by AutoEPAP iVAPS delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. It is similar to iVAPS, but it introduces an auto-adjusting expiratory pressure to treat airway obstruction.
11357641|NCT02317042|Other|Phase II: Spontaneous Timed (ST) mode|"ST mode is another type of respiratory support ventilation, and is, historically, the commonly used ventilation therapy. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation. It is commercially available.
~ST mode delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. Collectively, this optimises ventilation using pressure ventilation."
11357642|NCT02317042|Experimental|Phase II: AutoEPAP iVAPS|AutoEPAP iVAPS is a proposed new type of respiratory support ventilation. It is used to treat people with respiratory insufficiency, respiratory failure or hypoventilation, AND introduces the treatment of upper airway obstruction (i.e. sleep apnea). It is being developed by AutoEPAP iVAPS delivers two air pressures (one for inspiration and a second for expiration) and provides a back-up breathing rate. It is similar to iVAPS, but it introduces an auto-adjusting expiratory pressure to treat airway obstruction.
11357643|NCT02317029|Experimental|"1 (Standard: Oxygen / LIFEPAK 20)"|"Intervention: Cardioversion with a biphasic truncated exponential waveform
~Intervention: Hyperoxia during cardioversion"
11357644|NCT02317029|Active Comparator|2 (room air / LIFEPAK 20)|"Intervention: Cardioversion with a biphasic truncated exponential waveform
~Intervention: Normoxia during cardioversion"
11357645|NCT02317029|Active Comparator|3 (Oxygen / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform
~Intervention: Hyperoxia during cardioversion"
11357646|NCT02317029|Active Comparator|4 (Room air / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform
~Intervention: Normoxia during cardioversion"
11357647|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
11357648|NCT02317003|Experimental|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
11357649|NCT02317003|Active Comparator|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
11357650|NCT02316990||patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]|"The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study
~)"
11357651|NCT02316964|Experimental|Treatment (decitabine, allogeneic NK cells, aldesleukin)|Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
11357652|NCT02316951||single-arm study group|Study participants will be adult patients recovering from orthopedic surgery. The study group will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room.
11357653|NCT02316925|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
11357654|NCT02316925|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
11357655|NCT02316912|Active Comparator|Single dose level 1 active|Six subjects ATX2417 I mg tablet once.
11357656|NCT02316912|Active Comparator|Single dose level 2 active|Six subjects ATX2417 2x1 mg tablet once.
11357657|NCT02316912|Active Comparator|Single dose level 3 active|Six subjects ATX2417 5 mg tablet once.
11357658|NCT02316912|Active Comparator|Single dose level 4 active|Six subjects ATX2417 4x5 mg tablets once.
11357659|NCT02316912|Active Comparator|Single dose level 5 active|Six subjects ATX2417 to be determined.
11357660|NCT02316912|Active Comparator|Multiple dose level 1 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
11357661|NCT02316912|Active Comparator|Multiple dose level 2 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
11357662|NCT02316912|Placebo Comparator|Single dose level 1 placebo|Two subjects one placebo tablet once.
11357663|NCT02316912|Placebo Comparator|Single dose level 2 placebo|Two subjects one placebo tablet x2 once.
11357664|NCT02316912|Placebo Comparator|Single dose level 3 placebo|Two subjects one placebo tablet once.
11357665|NCT02316912|Placebo Comparator|Single dose level 4 placebo|Two subjects two placebo tablets once.
11357666|NCT02316912|Placebo Comparator|Single dose level 5 placebo|Two subjects four placebo tablets once.
11357667|NCT02316912|Placebo Comparator|Multiple dose level 1 placebo|Two subjects matching placebo(s) once daily for 8 days
11357668|NCT02316912|Placebo Comparator|Multiple dose level 2 placebo|Two subjects matching placebo(s) once daily for 8 days.
11357669|NCT02316912|Active Comparator|Single dose level 6 active|Six subjects ATX2417 to be determined.
11357670|NCT02316912|Active Comparator|Single dose level 7 active|Six subjects ATX2417 to be determined.
11357671|NCT02316912|Placebo Comparator|Single dose level 6 placebo|Six subjects placeboto be determined.
11357672|NCT02316912|Placebo Comparator|Single dose level 7 placebo|Six subjects placebo to be determined.
11357673|NCT02316899|Experimental|ASP0456 (Period I)|Up to 12 weeks
11357674|NCT02316899|Placebo Comparator|Placebo (Period I)|Up to 12 weeks
11357675|NCT02316899|Experimental|ASP0456 (Period II)|From 12 weeks to 52 weeks
11357676|NCT02316886|Experimental|Coronary intervention|Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment
11357677|NCT02316886|Active Comparator|Optimal Medical Treatment|Optimal Medical Treatment
11357678|NCT02316873|Experimental|Music training|twice a week one hour for 30 weeks, music training
11357679|NCT02316873|Active Comparator|Visual arts|twice a week one hour for 30 weeks, visual arts training
11357680|NCT02316860|Other|History of reflex syncope|Passive tilt test in athletes with a history of reflex syncope
11357682|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
11357683|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
11357684|NCT02316834|Experimental|BMN 673|
11357685|NCT02316821|Experimental|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
11357686|NCT02316821|Placebo Comparator|Placebo|Placebo capsules, once daily for 16 weeks
11357687|NCT02316808|Placebo Comparator|Placebo smoothie|
11357688|NCT02316808|Experimental|Plant stanol ester smoothie|
11357689|NCT02316795|Experimental|SLN biopsy with ICG injection|"During the SLN biopsy, the patient will undergo injection of ICG around the breast tumor or melanoma per standard techniques. 1.6 mL of 500 micro-molar ICG will be injected periareolarly (for breast cancer) or peri-tumorly (for melanoma). This will be performed after standard of care technetium-colloid injection. Patients will then undergo the standard SLN biopsy procedure.
~After gamma-probe identification of the SLN, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Findings with the goggles will be recorded but will not change how the SLN biopsy is performed."
11357690|NCT02316782||Non-blinded IVUS assessment|The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
11357691|NCT02316782||Blinded IVUS assessment|After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
11357692|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
11357693|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
11357694|NCT02316756|Experimental|Single Ascending Doses Cohort 1|subjects receive 3 active doses and one placebo
11357695|NCT02316756|Experimental|Single Ascending Doses Cohort 2|subjects receive 3 doses and one placebo
11357696|NCT02316756|Experimental|Cohort 3|optional cohort
11357697|NCT02316743|Experimental|Levothyroxine|Levothyroxine supplementation
11357698|NCT02316730|Experimental|Sanchi-Tongshu Capsule (Enteric coated pellets)|Sanchi-Tongshu Capsule (Enteric coated pellets) is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.35g/capsule, containing 100mg of panaxatriol saponins (PTS).
11357699|NCT02316730|Active Comparator|Sanchi-Tongshu Capsule|Sanchi-Tongshu Capsule is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.2g/capsule, containing 100mg of panaxatriol saponins (PTS).
11357700|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
11357701|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
11357702|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
11357703|NCT02316704|Active Comparator|OsseoTi™ G7 large|OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
11357704|NCT02316704|Active Comparator|OsseoTi™ G7 32|OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
11357705|NCT02316704|Active Comparator|conventional PPS coated G7 large|conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
11357706|NCT02316704|Active Comparator|conventional PPS coated G7 32|conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
11357707|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
11357708|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
11357709|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
11357710|NCT02316665|Experimental|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
11357711|NCT02316665|Sham Comparator|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
11357712|NCT02316652|No Intervention|Healthy sites|Healthy sites with no inflammation; observational only
11357713|NCT02316652|Placebo Comparator|Scaling and root planing sites|Inflamed pocket receiving mechanical instrumentation
11357714|NCT02316652|Active Comparator|Scaling and root planing with solution|Inflamed pocket receiving mechanical instrumentation with sodium hypochlorite solution
11357715|NCT02316639|Experimental|Neuromuscular Training - No Exercise|Subjects will participate in 5 weeks of neuromuscular training followed by 5 weeks of no exercise intervention
11357716|NCT02316639|Experimental|No Exercise - Neuromuscular Training|No exercises will be administered for 5 weeks, followed by 5 weeks of neuromuscular Training.
11357717|NCT02316626|Experimental|Subcutaneous progesterone|Luteal phase support cycles will involve once-daily administration of 25 mg of SC P from the day after insemination for 14 days.
11357718|NCT02316626|Active Comparator|Vaginal Progesterone|Luteal phase support cycles will involve once-daily administration of 90 mg vaginal gel from the day after insemination for 14 days.
11357719|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
11357720|NCT02316600|No Intervention|Control|30 frail volunteers of the control group in the second phase won't be equipped with the smart insole.
11357721|NCT02316600|Experimental|Intervention|30 frail volunteers of the intervention group in the second phase will be equipped with the smart insole for 3 months, to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
11357896|NCT02315391|Experimental|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine
11357722|NCT02316574|Experimental|Cognitive Behavioral Coping Skills|Cognitive Behavioral Coping Skills Therapy is an individual psychotherapy for alcohol use disorders that has been previously shown to reduce drinking. The focus of this treatment is the teaching of coping skills for managing alcohol craving and negative emotions as a way to reduce drinking behavior.
11357723|NCT02316561|Experimental|Single dose ablative radiotherapy|Eligible patients for single dose ablative radiotherapy according to inclusion and exclusion criteria
11357724|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
11357725|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
11357726|NCT02316535|Active Comparator|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
11357727|NCT02316535|Experimental|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
11357728|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
11357729|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
11357730|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
11357731|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
11357732|NCT02316509|Experimental|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
11357733|NCT02316509|Experimental|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
11357734|NCT02316496|Experimental|open label , single arm|cetuximab - irinotecan until progression or unacceptable toxicity
11357735|NCT02316483||Group I: T2D and Charcot foot|Individuals with confirmed diagnosis of type 2 diabetes, using the American Diabetes Association guidelines and confirmed diagnosis of Charcot foot, based on clinical and radiological evidence of Charcot foot.
11357736|NCT02316483||Group II: T2D neuropathy, no charcot|Individuals with type 2 diabetes and presence of neuropathy but the absence of Charcot foot.
11357737|NCT02316483||Group III: Control, non-diabetic|Individuals without history of type 2 diabetes.
11357738|NCT02316470|Active Comparator|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
11357739|NCT02316470|Active Comparator|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
11357740|NCT02316470|Active Comparator|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
11357741|NCT02316470|Placebo Comparator|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
11357742|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the IVAC®WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
11357743|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the IVAC®WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
11357744|NCT02316457|Experimental|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the IVAC®WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
11357745|NCT02316444|Other|HAART exposed|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
11357746|NCT02316444|Other|HAART naive|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
11357747|NCT02316418|Experimental|Hairstetics™ anchoring system|Prosthetic hair implantation using the Hairstetics™ anchoring system, followed by attachment of hair extensions.
11357748|NCT02316405|Experimental|Test Group|5 weeks of arm and leg cycling, 3 times per week for 30 minute of total exercise per session
11357749|NCT02316392||Post transplant subjects|Hyperpolarized Helium-3 MRI. Subjects who have had or are scheduled to have a lung transplant
11357750|NCT02316379|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
11357751|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
11357752|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
11357753|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
11357754|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
11357755|NCT02316340|Experimental|Study Arm - VOR with HCQ|Patients will be given vorinostat 400 mg daily and hydroxychloroquine 600 mg daily in 4 week cycles.
11357756|NCT02316340|Active Comparator|Control Arm - Regorafenib|Patients will be given oral RGF 160 mg daily for 3 weeks in 4 week cycles.
11357757|NCT02316327|Experimental|gemcitabine, cisplatin and bevacizumab|"Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days
~Cisplatin 80 mg/m2 I.V on day 1
~Gemcitabine 1250 mg/m2 I.V on day 1 & 8
~Treatment cycles will be repeated every three weeks up to 6 cycles
~Bevacizumab monotherapy as maintenance allowed in non-progressive tumors"
11357758|NCT02316314||Individuals diagnosed with FRDA|Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
11357759|NCT02316314||Healthy controls|Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
11357760|NCT02316301|Experimental|Long interval misoprostol|A small envelope including two labeled plastic bags (A & B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
11357761|NCT02316301|Active Comparator|Short interval misoprostol|A small envelope including two labeled plastic bags (A& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
11357762|NCT02316288|Experimental|Therapy|Mindfulness and Acceptance Therapy
11357763|NCT02316288|Active Comparator|Education|Health Education
11357764|NCT02316275|Active Comparator|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
11357765|NCT02316275|Experimental|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
11357766|NCT02316262|Experimental|TR|All subjects enrolled in this study will undergo pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally.Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle.
11357767|NCT02316249|Active Comparator|Gellhorn Pessary|Patients who are fitted with a Gellhorn pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
11357768|NCT02316249|Active Comparator|Ring with Support Pessary|Patients who are fitted with a Ring with Support Pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
11357769|NCT02316236|Experimental|dexmedetomidine loading dose|dexmedetomidine is given at load dose
11357770|NCT02316236|Experimental|dexmedetomidine sustaining dose|dexmedetomidine is given at sustaining dose
11357771|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
11357772|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
11357773|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
11357774|NCT02316210|Experimental|Digitimer stimulation|
11357775|NCT02316197|Experimental|MSC2490484A 100 mg QD|Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357776|NCT02316197|Experimental|MSC2490484A 200 mg QD|Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357777|NCT02316197|Experimental|MSC2490484A 150 mg BID|Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357778|NCT02316197|Experimental|MSC2490484A 200 mg BID|Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357779|NCT02316197|Experimental|MSC2490484A 300 mg BID|Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357780|NCT02316197|Experimental|MSC2490484A 400 mg BID|Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357897|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine
11357781|NCT02316197|Experimental|MSC2490484A 400 mg BID RP2D|Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
11357782|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
11357783|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
11357784|NCT02316171|Experimental|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
11357785|NCT02316171|Experimental|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
11357786|NCT02316158|Experimental|Webb-based support and education|It contains of two parts 1) evidence based information (about mental diseases, early signs, coping strategies, what you can do for your relative or close friend, what you can do for yourself, addresses to networks and web sites, relevant juridical issues, etc), 2) FAQ, where you directly can find answers to common questions.
11357787|NCT02316158|Active Comparator|Available support in society|Available support in society for young persons presented in a brochure
11357788|NCT02316145|Other|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
11357789|NCT02316132|Active Comparator|Stress|Injection of corticotropin releasing factor
11357790|NCT02316132|Placebo Comparator|Control|Injection of 0.9% saline 10 ml
11357791|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
11357792|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
11357793|NCT02316106|Experimental|Arm A (Long Intense)|
11357794|NCT02316106|Experimental|Arm B (Intermediate)|
11357795|NCT02316106|Experimental|Arm C (Short Intense)|
11357796|NCT02316093||obese-chronic periodontitis patients|
11357797|NCT02316093||obese-gingivitis patients|
11357798|NCT02316093||obese-periodontally healthy controls|
11357799|NCT02316093||normal weight-chronic periodontitis patients|
11357800|NCT02316093||normal weight-gingivitis patients|
11357801|NCT02316093||normal weight-periodontally healthy controls|
11357802|NCT02316080|Experimental|Desensitizing therapy|14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
11357803|NCT02316080|Experimental|Dental Bleaching|2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
11357804|NCT02316067|Experimental|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
11357805|NCT02316067|No Intervention|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
11357806|NCT02316054||diabetes and MPHI|myocardial perfusion heterogeneity imaging
11357807|NCT02316041|Experimental|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
11357808|NCT02316028|Experimental|decitabine|"administration of decitabine by hepatic arterial infusion
~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.
~Proposed dose levels:
~10 mg/m2 per course
~15 mg/m2 per course
~20 mg/m2 per course"
11357809|NCT02316015|Experimental|Intervention group|Children in the intervention group will receive a protein-energy enriched milk (Infatrini®, or in the case of children on a partial or fully hydrolized milk Infatrini Peptisorb®). The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day). The intervention will be carried out during the first 7 days of hospitalisation, or until the day of discharge (if hospitalized for less than 7 days).
11357810|NCT02316015|No Intervention|Control group|Children in the control group will receive their regular milk. The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day).
11357811|NCT02316002|Experimental|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
11357812|NCT02315989|Other|safety|proton therapy
11357813|NCT02315976|Experimental|Propatyl nitrate|Patients treated with propatyl nitrate 10mg thrice daily
11357814|NCT02315963|No Intervention|No intervention group|Patients in stroke rehabilitation receiving standard therapy
11357815|NCT02315963|Active Comparator|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
11357816|NCT02315950|Other|Arm 1|Botulinum toxin and cineMRI-UDS
11357817|NCT02315924|Experimental|coronary and cerebral stenosis|
11357818|NCT02315924|Active Comparator|coronary or cerebral stenosis|
11357819|NCT02315911|No Intervention|expectancy for mild-moderate OSA|6 months expectancy
11357820|NCT02315911|Experimental|ATE for mild-moderate OSA|adeno-tonsillectomy
11357821|NCT02315911|Experimental|ATE for severe OSA|adeno-tonsillectomy
11357822|NCT02315911|Experimental|APP for severe OSA|adeno-pharyngoplasty
11357823|NCT02315898|Experimental|Treatment-inhaled tPA|All patients with plastic bronchitis enrolled into the study will receive inhaled tPA.
11358120|NCT02313883|Placebo Comparator|SRP and Placebo|Scaling and root planing followed by placebo drug administration
11357824|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
11357825|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
11357826|NCT02315859||All patients|All patients
11357827|NCT02315833|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
11357828|NCT02315833|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for three months
11357829|NCT02315820|Experimental|Induction of Labor (IOL)|Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
11357830|NCT02315820|No Intervention|Expectant|Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
11357831|NCT02315807|Experimental|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
11357832|NCT02315807|Experimental|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
11357833|NCT02315807|Active Comparator|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
11357834|NCT02315794|Experimental|SPI®ART|in test group after a three month healing period a zirconia abutment was connected to the implant to realize the prosthetic restoration
11357835|NCT02315794|Active Comparator|SPI®EASY|in control group a three month healing period a titanium abutment was connected to the implant for the prosthetic restoration
11357836|NCT02315781|Active Comparator|Active tDCS|active tDCS will be used on half of the study participants
11357837|NCT02315781|Sham Comparator|Sham tDCS|Sham tDCS will be used on half of the study participants
11357838|NCT02315768|Experimental|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.
~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:
~Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.
~Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.
~Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.
~Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
11357839|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
11357840|NCT02315742|Experimental|Let's Move Program|Patients will take part in a 12-week exercise program.
11357841|NCT02315716|Experimental|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
11357842|NCT02315716|Active Comparator|ASCT|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
11357843|NCT02315703|Experimental|Group 1|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
11357844|NCT02315703|Experimental|Group 2|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
11357845|NCT02315703|Experimental|Group 3|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + placebo injection at Week 24 and 48.
11357846|NCT02315703|Experimental|Group 4|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by modified Vaccinia Ankara (MVA)-Mosaic vaccine + gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant at Week 24 and 48.
11357847|NCT02315703|Experimental|Group 5|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
11357848|NCT02315703|Experimental|Group 6|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + placebo injection at Week 24 and 48.
11357849|NCT02315703|Experimental|Group 7|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant + placebo injection at Week 24 and 48.
11357850|NCT02315703|Placebo Comparator|Group 8|Participants will receive 1 placebo injection at Week 0 and 12; followed by 2 placebo injections at Week 24 and 48.
11357851|NCT02315690|Active Comparator|Reactive case detection (RACD)|Individuals in RACD Target Areas will be tested by RDT (rapid diagnostic test) and if positive, taken to the nearest health facility for treatment with artemether-lumefantrine per national policy.
11357852|NCT02315690|Experimental|Reactive focal mass drug administration (fMDA)|In the fMDA arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
11357853|NCT02315677|Active Comparator|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
11357854|NCT02315677|Active Comparator|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
11357855|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
11357856|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
11357857|NCT02315651|Experimental|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
11357858|NCT02315651|Placebo Comparator|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
11357859|NCT02315638||Dosed subjects|There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,
11357860|NCT02315625|Experimental|1/ Arm 1 Sunitinib|Sunitinib
11357861|NCT02315625|Experimental|2/ Arm 2 Everolimus|Everolimus
11357862|NCT02315612|Experimental|Arm 1|Dose escalation of CD22-CAR
11357863|NCT02315612|Experimental|Arm 2|Dose expansion of CD22-CAR
11357864|NCT02315599||1|subjects who have participated in POB gene therapy clinical trials
11357865|NCT02315586||1|Participants will be enrolled at the NIH Clinical Center.
11357866|NCT02315586||2|IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program
11357867|NCT02315573|Experimental|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.
~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
11357868|NCT02315573|Experimental|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.
~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
11357869|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
11357870|NCT02315547|Other|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
11357871|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
11357872|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
11357873|NCT02315521||Group 1|Fetuses with LUTO before 18 weeks
11357874|NCT02315521||Group 2|Fetuses with LUTO between 18 and 30 weeks
11357875|NCT02315521||Group 3|Fetuses with LUTO between 30 and 34 weeks
11357876|NCT02315521||Group 4|Fetuses with LUTO after 34 weeks
11357877|NCT02315508|Experimental|AUT00063|4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
11357878|NCT02315508|Placebo Comparator|Placebo|4 capsules of placebo, to take orally with food for 4 weeks.
11357879|NCT02315495|Experimental|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:
~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
11357880|NCT02315495|Experimental|5 mg saxagliptin|"Acute dosing:
~5 mg saxagliptin is given 60 min before a test meal,"
11357881|NCT02315495|Experimental|100 mg acarbose|"Acute dosing:
~100 mg acarbose is given with a test meal"
11357882|NCT02315495|No Intervention|control|
11357883|NCT02315482|Experimental|Group A|after induction of general anesthesia (i) a pneumoperitoneum is induced then (ii) patient is placed in steep trendelenburg position at 25 degrees head down
11357884|NCT02315482|Experimental|Group B|after induction of general anesthesia (i) the patient is placed in steep trendelenburg position at 25 degrees head down then (ii) a pneumoperitoneum is induced
11357885|NCT02315469||Observational (geriatric assessment)|At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
11357886|NCT02315456|Other|Capsule centration|Capsulorhexis made with capsule centration
11357887|NCT02315456|Other|Pupil centration|Capsulorhexis made with pupil centration
11357888|NCT02315443|Experimental|NA-1|2.60 mg/kg of NA-1 (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
11357889|NCT02315443|Placebo Comparator|Placebo|Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
11357890|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11357891|NCT02315417|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
11357892|NCT02315417|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
11357893|NCT02315417|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
11357894|NCT02315404|Placebo Comparator|No cap|enteroscopy performed without a cap
11357899|NCT02315378|Other|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
11357900|NCT02315378|Other|TAU|Treatment as Usual
11357901|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
11357902|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
11357903|NCT02315326|Experimental|Ibrutinib|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A). The defined MTD will then be used in an expansion cohort to further assess toxicity and clinical activity(Arm B). Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX. Patients who have received treatment for >2 years may be able to opt to have MRIs bi-annually if deemed appropriate by the primary investigator.
11357904|NCT02315313||group1|RHR≤60bpm
11357905|NCT02315313||group2|RHR 61-70bpm
11357906|NCT02315313||group3|RHR 71-80bpm
11357907|NCT02315313||group4|RHR >80bpm
11357908|NCT02315300|Experimental|Study Tretament|Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
11357909|NCT02315287|Active Comparator|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
11357910|NCT02315287|Active Comparator|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
11357911|NCT02315274|Experimental|Single arm, remote contact.|Between visit remote contact.
11357912|NCT02315235|Active Comparator|control|The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
11357913|NCT02315235|Active Comparator|stem cell (mononuclear cell)|The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia. The volume of one site injection is 0.5 to 1.0 ml. The depth of needle injection would be 1.5cm.
11357914|NCT02315222|Active Comparator|Test|Dietary Supplementation
11357915|NCT02315222|Placebo Comparator|Control|Placebo Supplementation
11357916|NCT02315196|Experimental|Treatment (doxil, carboplatin, surgery, paclitaxel)|"NEOADJUVANT: Patients receive pegylated liposomal doxorubicin hydrochloride* IV over 90 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~ADJUVANT: Patients undergo definitive surgery at the discretion of the treating physician. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
~*NOTE: If there is a shortage of pegylated liposomal doxorubicin hydrochloride, patients receive epirubicin hydrochloride IV over 15-20 minutes on day 1."
11357917|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
11357918|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
11357919|NCT02315157|Experimental|Bendamustine 200 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).
11357920|NCT02315157|Experimental|Bendamustine 250 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).
11357921|NCT02315144|Experimental|TV48108 - Healthy Volunteers|Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg
11357922|NCT02315144|Placebo Comparator|Placebo - Healthy Volunteers|Placebo
11357923|NCT02315144|Experimental|TV48108 15 µg COPD|Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.
11357924|NCT02315144|Experimental|TV48108 60 µg COPD|Stage 2
11357925|NCT02315144|Experimental|TV48108 120 µg COPD|Stage 2 .
11357926|NCT02315131|Experimental|TV46017- Healthy Volunteers|Stage 1 includes a single-dose treatment period
11357927|NCT02315131|Placebo Comparator|Placebo - Healthy Volunteers|Some healthy subjects will be randomized to receive placebo.
11357928|NCT02315131|Experimental|TV46017 15 μg- COPD|Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered
11357929|NCT02315131|Experimental|TV46017 60 μg- COPD|Stage 2
11357930|NCT02315131|Experimental|TV46017 120 μg- COPD|Stage 2
11357931|NCT02315131|Experimental|TV46017 240 μg- COPD|Stage 2
11357932|NCT02315118|Experimental|T-cell therapy + Rituximab + IL-2|"Patients will undergo apheresis procedure and T cell expansion will be done in the laboratory. All patients will receive Rituximab on day -2 and IL-2 three times per week for one week starting on day -1 (dose 1 of 3). IL-2 dosing will be continued 3 times per week for one week (3 doses total).
~On Day 0, T cell modification in the laboratory and T cell infusion in the patient will be done.
~A disease status evaluation will be conducted approximately 4 weeks post-T cell infusion."
11357933|NCT02315105|Experimental|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
11357934|NCT02315092||Diabetic foot ulcers|Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
11358379|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
11357935|NCT02315079||Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
11357936|NCT02315079||Without eye inflammation|This group will have a regular eye exam with the collection of tears.
11357937|NCT02315066|Experimental|PF-04518600|OX40 agonist
11357938|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
11357939|NCT02315053|Other|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
11357940|NCT02315040|Active Comparator|IUI|standard intrauterine insemination method
11357941|NCT02315040|Experimental|EVIE|Slow release insemination method (SRI)
11357942|NCT02315027|Experimental|autologous mesenchymal stem cells|Administration of autologous mesenchymal stem cells
11357943|NCT02315014|Experimental|whey protein|whey protein micelles
11357944|NCT02315014|Placebo Comparator|placebo|calorie-free placebo
11357945|NCT02315001|Active Comparator|Liraglutide|"Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection
~Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection
~Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection"
11357946|NCT02315001|Placebo Comparator|Saline Placebo|"Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection
~Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection
~Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection"
11357947|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
11357948|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
11357949|NCT02314975|Experimental|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
11357950|NCT02314975|Sham Comparator|Sham AcceleDent device|Fixed appliances with supplementary sham device
11357951|NCT02314975|Active Comparator|Fixed appliance only|Fixed appliances only
11357952|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
11357953|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
11357954|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
11357955|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
11357956|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
11357957|NCT02314923|Experimental|3x10^3 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
11357958|NCT02314923|Experimental|3x10^4 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.
11357959|NCT02314923|Experimental|3x10^5 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.
11357960|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.
11357961|NCT02314923|Experimental|9x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.
11357962|NCT02314923|Experimental|2x10^7 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.
11357963|NCT02314923|Experimental|1x10^8 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.
11357964|NCT02314923|Placebo Comparator|Placebo Cohort 1|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
11357965|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
11357966|NCT02314923|Placebo Comparator|Placebo Cohort 2|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
11357967|NCT02314910||Failed implant|There is only one group, being the group of patients of which the oral implant needed to be removed for clinical reasons.
11357968|NCT02314897|Experimental|LV pacing|Left ventricular pacing lead implanted via coronary sinus
11357969|NCT02314897|Active Comparator|RV pacing|Conventional right ventricular pacing lead.
11357970|NCT02314884|Experimental|Cafusertib Hydrochloride|Cafusertib Hydrochloride d1q3w
11357971|NCT02314871|Active Comparator|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
11357972|NCT02314871|Active Comparator|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
11357973|NCT02314871|Active Comparator|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
11357974|NCT02314858|Experimental|Brief Personalized Video (BPV)|Our BPV intervention focuses on augmenting risk perception and reducing optimistic bias by showing the patient a dramatic video of his/her own apnea (which shows them struggle to breathe), as well as by explaining the physiological processes involved in an apneic event. Specific apneic events are highlighted and associated decreases in blood oxygen levels are demonstrated via oxygen saturation recording superimposed on the video. This group will receive educational information about OSA, its consequences and the need for treatment.
11357975|NCT02314858|Active Comparator|Non-Personalized Video (NPV)|NPV will include a video of someone having apnea, but it will not be personalized. This group will receive educational information about OSA, its consequences and the need for treatment.
11357976|NCT02314858|Placebo Comparator|Treatment As Usual (TAU)|The TAU group will receive no special treatment from study interventionist team and will not view a video.
11357977|NCT02314845|Experimental|Optimal PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using Optimal PEEP determined by Electrical Impedance and FIO2 of 0.5."
11357978|NCT02314845|Other|Low PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure EIT. In this arm, the ventilator will be set with a PEEP=4 cmH2O (Low PEEP) and FIO2 of 0.5 during intraoperative period."
11357979|NCT02314832|Active Comparator|Continuous femoral nerve block|patients receiving continuous femoral nerve block for analgesia after total knee arthroplasty
11357980|NCT02314832|Active Comparator|adductor canal block|adductor canal block group will receive adductor canal block for analgesia after TKA
11357981|NCT02314819|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
11357982|NCT02314819|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
11357983|NCT02314806|Experimental|Irrigation with Gentamicin solution|The surgical bed is irrigated with a gentamicin solution
11357984|NCT02314806|Experimental|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
11357985|NCT02314806|Placebo Comparator|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
11357986|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
11357987|NCT02314793|Placebo Comparator|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
11357988|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
11357989|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
11357990|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
11357991|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
11357992|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
11357993|NCT02314780|Placebo Comparator|Placebo|Placebo 24h prior surgery
11357994|NCT02314780|Active Comparator|Treatment cohort A|heme arginate 1mg/kg 24h prior surgery
11357995|NCT02314780|Active Comparator|Treatment cohort B|heme arginate 3mg/kg 24h prior surgery
11357996|NCT02314767|Active Comparator|Interpersonal Psychotherapy|Interpersonal Psychotherapy treatment for MDD patients was implemented with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention:Interpersonal psychotherapy as ADD-on method. Outcome was compared with patients in treatment as usual group.
11357997|NCT02314767|Active Comparator|Psychoeducational Group Therapy|Psychoeducational Group Therapy arm for MDD patients with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention: Psychoeducational Group Treatment as ADD-on method.
11357998|NCT02314767|No Intervention|Treatment as Usual|Treatment as usual ( consisting of supportive psychodynamic-oriented treatment) with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression
11357999|NCT02314754|Experimental|71-77 days gestational age|Women whose pregnancies are estimated to have a gestational age of 71-77 days.
11358000|NCT02314754|No Intervention|64-70 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days.( Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
11358001|NCT02314741|Experimental|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
11358002|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
11358003|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
11358004|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
11358005|NCT02314715||Controls|Participants without knee osteoarthritis
11358006|NCT02314702||Revision Total Hip Arthroplasty|Single study group previously implanted with a PROFEMUR® L Revision Femoral Stem
11358007|NCT02314689|Experimental|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
11358008|NCT02314676|Experimental|PEG-somatropin|
11358084|NCT02314143|Experimental|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
11358009|NCT02314663|Experimental|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.
~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
11358010|NCT02314663|No Intervention|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
11358011|NCT02314650|Experimental|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
11358012|NCT02314650|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
11358013|NCT02314650|Sham Comparator|Control|patients were with electrodes attached but no stimulation was given
11358014|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
11358015|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
11358016|NCT02314624|Experimental|PracticeGround|Clinicians have access to PracticeGround's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
11358017|NCT02314624|Active Comparator|Care-as-Usual|Usual care without access to PracticeGround.
11358018|NCT02314611||PROFEMUR® Gladiator HA Coated Stem|Single study group previously implanted with a primary PROFEMUR® Gladiator HA Coated Modular Femoral Stem (HA = Hydroxyapatite)
11358019|NCT02314598||No treatment|
11358020|NCT02314585|Other|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
11358021|NCT02314585|Other|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
11358022|NCT02314572|Other|Single-arm|
11358023|NCT02314559|Experimental|Propofol (manual titration)|
11358024|NCT02314559|Active Comparator|Propofol (target controlled infusion)|
11358025|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
11358026|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
11358027|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
11358028|NCT02314533|Experimental|fenofibrate|Fenofibrate 200mg capsule will be administered orally with breakfast once daily according to the Chinese prescription information of Lipanthyl, while previous type and dose of statin will be administered in the evening.
11358029|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
11358030|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
11358031|NCT02314507|Experimental|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
11358032|NCT02314507|Active Comparator|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
11358033|NCT02314494||Infants at risk|Infants identified as at risk of obesity using the ProAsk intervention
11358034|NCT02314494||Infants not at risk|Infants identified as not at risk of obesity using the ProAsk intervention.
11358035|NCT02314481|Experimental|No actionable mutation - MPDL3280A|"MPDL3280A 1200mg IV infusion - 3 weekly for 24 cycles monotherapy
~Or in combination with chemotherapy:
~For non-squamous: Cisplatin or Carboplatin plus pemetrexed & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A and pemetrexed 3 weekly for 20 cycles
~For squamous: Carboplatin plus paclitaxel & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A 3 weekly for 20 cycles
~Until progression, unacceptable toxicity or completion of a total of 24 cycles."
11358036|NCT02314481|Experimental|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
11358037|NCT02314481|Experimental|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
11358038|NCT02314481|Experimental|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD IV infusion
11358039|NCT02314468|Active Comparator|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
11358040|NCT02314468|Active Comparator|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
11358041|NCT02314455|Experimental|D-xylose, water, honey|"25 grams of D-xylose
~10 cc of water
~2 teaspoons of honey"
11358042|NCT02314442|Active Comparator|ALN-PCSSC|
11358043|NCT02314442|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11358044|NCT02314429|Experimental|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
11358045|NCT02314416|Active Comparator|Standard Treatment|Patients in the Control Arm will receive collagen matrix for wound coverage and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
11358046|NCT02314416|Experimental|Amniotic Stem Cells and Collagen Matrix|Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage, and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
11358085|NCT02314143|Experimental|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
11358121|NCT02313883|Experimental|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
11358047|NCT02314403|Experimental|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
11358048|NCT02314390|Experimental|G-MBCT|Group-Mindfulness-Based Cognitive Therapy
11358049|NCT02314390|Experimental|I-MBCT|Individual-Mindfulness-Based Cognitive Therapy
11358050|NCT02314377|Experimental|AVM treatment with Bevacizumab|Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
11358051|NCT02314364|Experimental|SBRT with protons or photons|"Dosage determined by treating physician
~If there is more than one active site of cancer, additional site(s) will be treated with stereotactic treatment courses. The total duration of SBRT courses (from the first day of any SBRT course to the last day of any SBRT course) will not exceed 4 months."
11358052|NCT02314351|Active Comparator|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
11358053|NCT02314351|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
11358054|NCT02314338|Experimental|Pulmonary rehabilitation|Multi-disciplinary pulmonary rehabilitation
11358055|NCT02314325|Active Comparator|Standard prophylaxis|Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days
11358056|NCT02314325|Experimental|Pharmacokinetic tailored prophylaxis|Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
11358057|NCT02314312|Experimental|A: investigation arm|De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
11358058|NCT02314312|Other|B: control arm|De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
11358059|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
11358060|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
11358061|NCT02314286|Placebo Comparator|control|"After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.
~Control group will be treated with placebo."
11358062|NCT02314286|Experimental|treatment|50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.
11358063|NCT02314273|Experimental|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
11358064|NCT02314273|No Intervention|control group|control group
11358065|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
11358066|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
11358067|NCT02314234||Control group|did not receive muscle relaxant during anesthesia
11358068|NCT02314234||Sugammadex group|received single dose of rocuronium for anesthesia and sugammadex at skin incision
11358069|NCT02314221|Experimental|Exoskeletal-Assisted Walking (WALK)|WALK first for 12 weeks (36 sessions)
11358070|NCT02314221|No Intervention|Usual Activities (UA)|Usual activities first for 12 weeks
11358071|NCT02314208|Active Comparator|Xenbilox|Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months
11358072|NCT02314208|Active Comparator|Resveratrol|Resveratrol 80mg capsule by mouth every day for 2 months
11358073|NCT02314208|Active Comparator|Tahor|Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months
11358074|NCT02314195|Active Comparator|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
11358075|NCT02314195|Active Comparator|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
11358076|NCT02314182|Experimental|A Primary tumor resection + chemotherapy|PT resection + systemic chemotherapy +/- target therapy
11358077|NCT02314182|Other|B Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Chemotherapy (+/- target therapy)
11358078|NCT02314169|Experimental|Part A (nivolumab)|Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11358079|NCT02314169|Experimental|Part B Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11358080|NCT02314169|Experimental|Part B Arm II (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11358081|NCT02314156|Experimental|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
11358082|NCT02314156|Active Comparator|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
11358083|NCT02314143|Experimental|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
11358119|NCT02313883|Placebo Comparator|SRP only|Scaling and root planing only
11358757|NCT02309502|Experimental|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms
11358086|NCT02314130|Experimental|Dietary therapy Standardized diet|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
11358087|NCT02314130|No Intervention|Dietary therapy Commercial diet group|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
11358088|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
11358089|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
11358090|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
11358091|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
11358092|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
11358093|NCT02314091|Experimental|Onlay|Onlay mesh repair group
11358094|NCT02314091|Experimental|sublay|Sublay mesh repair group
11358095|NCT02314065|Experimental|Conventional CBT|Cognitive Behavioural Therapy delivered in a conventional manner
11358096|NCT02314065|Experimental|Internet-delivered CBT|Cognitive Behavioural Therapy delivered via the Internet
11358097|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
11358098|NCT02314026|Experimental|Suspected NASH|13C-Octanoate, 13C-Methacetin
11358099|NCT02314013|Active Comparator|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
11358100|NCT02314013|No Intervention|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
11358101|NCT02314000|Active Comparator|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
11358102|NCT02314000|Experimental|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
11358103|NCT02313987||A-Usual care- Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis) and normal Endothelial function as defined by EndoScore.
~These subjects will receive the standard care usually provided in each facility for patients with NOCAD"
11358104|NCT02313987||B1-Usual Care-Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis ) and abnormal Endothelial function as defined by EndoScore.
~These subjects will receive the standard care usually provided in each facility for patients with NOCAD. (Same care as Group A)"
11358105|NCT02313987||B2- Endothelial function guid care|"Subjects with non obstructive CAD and abnormal Endothelial function as defined by EndoScore.
~These subjects will receive the an Endothelial Function-guided Therapy."
11358106|NCT02313961|Experimental|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
11358107|NCT02313961|No Intervention|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
11358108|NCT02313935|Experimental|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
11358109|NCT02313935|Experimental|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
11358110|NCT02313935|Experimental|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
11358111|NCT02313935|No Intervention|Passive|Passive Control Participants do not receive an intervention serving as passive controls
11358112|NCT02313935|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
11358113|NCT02313922|Experimental|etanercept combined with methotrexate|patients treated with etanercept combined with methotrexate
11358114|NCT02313922|Experimental|etanercept as monotherapy|patients treated with etanercept combined with placebo
11358115|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
11358116|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
11358117|NCT02313896|No Intervention|Standard of Care|Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
11358118|NCT02313896|Experimental|Phone calls|On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.
11358122|NCT02313883|Experimental|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
11358123|NCT02313883|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
11358124|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
11358125|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
11358126|NCT02313857|Experimental|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-C/m2 as a single infusion.
~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
11358127|NCT02313844|Experimental|Viralym-B|"Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-B/m2 as a single infusion.
~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
11358128|NCT02313831|Experimental|Exercise training|Patients of this group will be submitted to an interval training
11358129|NCT02313818|Experimental|CPT-C|Cognitive Processing Therapy-Cognitive Only (CPT-C) conducted twice weekly for 4-24 sessions based on good end state functioning.
11358130|NCT02313805|Experimental|With checklist|Students will simulate insulin initiation with the aid of a checklist
11358131|NCT02313805|No Intervention|Without checklist|Students will simulate insulin initiation without the aid of a checklist
11358132|NCT02313792|Active Comparator|Palifermin|The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion
11358133|NCT02313792|Placebo Comparator|Normal saline|The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.
11358134|NCT02313779|Placebo Comparator|Neutral|Reading passage about brain function which is masked as a news article.
11358135|NCT02313779|Experimental|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
11358136|NCT02313779|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
11358137|NCT02313779|Experimental|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
11358138|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.
~End of preoxygenation FEO2=90%"
11358139|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.
~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
11358140|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.
~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
11358141|NCT02313753|Active Comparator|SAFE|Safety Assessment and Follow-up Evaluation Protocol
11358142|NCT02313753|Experimental|CLASP|Coping Long Term with Active Suicide Program Protocol
11358143|NCT02313740||Healthy adults group|Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
11358144|NCT02313740||Elderly group|Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine
11358145|NCT02313727|Active Comparator|pamidronate|pamidronate
11358146|NCT02313727|Placebo Comparator|placebo|placebo
11358147|NCT02313714|Experimental|Neuromuscular stimulation|The patients will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
11358148|NCT02313714|Placebo Comparator|Sham Group|The patients will receive very low electric muscular stimulation with a no biological or clinical effects
11358149|NCT02313701|No Intervention|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
11358150|NCT02313701|Experimental|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
11358175|NCT02313493|Experimental|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
11358176|NCT02313493|No Intervention|Care as usual control group|
11358311|NCT02312492|Experimental|16:0 diet|Palmitic diet - Volunteers will consume palmitic enriched food for a period of 5 weeks.
11358151|NCT02313701|No Intervention|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
11358152|NCT02313701|Experimental|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
11358153|NCT02313701|No Intervention|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
11358154|NCT02313701|Experimental|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
11358155|NCT02313688|Experimental|Group A|Group A: Patients in the Group A will underwent D2 total gastrectomy and with 3±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
11358156|NCT02313688|Experimental|Group B|Patients in the Group B will underwent D2 total gastrectomy and with 5±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
11358157|NCT02313675|Experimental|IV tylenol|One time intra-operative IV acetaminophen administration
11358158|NCT02313675|Experimental|IV toradol|One time intra-operative IV ketorolac thromethamine administration
11358159|NCT02313675|Experimental|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
11358160|NCT02313675|Placebo Comparator|saline|One time intra-operative 50ml IV normal saline administration
11358161|NCT02313623||Patient Scheduled for Prostate Fusion Biopsies|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
11358162|NCT02313610|Experimental|Qinbudan|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months
11358163|NCT02313610|Placebo Comparator|Control Qinbudan Placebo|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months
11358164|NCT02313597|Placebo Comparator|SETON|Seton placement is a method of treatment for complex fistulas in which seton placement method is used.
11358165|NCT02313597|Experimental|VAAFT|Video assisted anal fistula treatment
11358166|NCT02313584|Active Comparator|Short Group|The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
11358167|NCT02313584|Placebo Comparator|Conventional Group|The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
11358168|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
11358169|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
11358170|NCT02313545|Experimental|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
11358171|NCT02313519|Placebo Comparator|Placebo|Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
11358172|NCT02313519|Active Comparator|Probiotics|Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
11358173|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
11358174|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
11358177|NCT02313480|Active Comparator|non-massage group|received exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
11358178|NCT02313480|Experimental|massage group|Received massage, exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
11358179|NCT02313467|Active Comparator|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
11358180|NCT02313467|Sham Comparator|Control|Topical application of sham control per every other day around acne lesions in the face
11358181|NCT02313454|Experimental|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
11358182|NCT02313454|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
11358183|NCT02313441|Active Comparator|RIPC (Remote Ischemic Pre-Conditioning)|Patients used RIPC had a blood pressure cuff placed around their upper arm at < 2 hours before the PCI procedure. The blood pressure cuff was inflated to for 5 minutes, followed by 5 minutes of deflation. This procedure was repeated 3 times
11358184|NCT02313441|Placebo Comparator|Control|Control participants did not experience this procedure of transient upper-limb ischemia.
11358185|NCT02313428|Experimental|Standard of Care with Topical Oxygen Treatment|Medicaid and Dual Medicare/Medicaid patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
11358186|NCT02313428|No Intervention|Standard of Care only|Medicare and Dual Medicare/Medicaid patients that have a chronic wound will receive only their standard of care treatment.
11358187|NCT02313415|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
11358188|NCT02313402|Experimental|EOL (Eye On Line)|training program allowing a gradual acquisition of the eye-writing
11358189|NCT02313389|Experimental|maintenance chemotherapy|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.
~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
11358190|NCT02313389|No Intervention|observation|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.
~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
11358191|NCT02313376|Experimental|GAP3KO|
11358192|NCT02313363|Experimental|PSDCS|using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks
11358193|NCT02313350|Experimental|Chemonucleolysis with Discogel|Discogel® is a class III medical device (CE0459 mark on 28/09/2007) constituted by a radiopaque jellified ethanol. Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia. A volume of 0.9 ml of Discogel® is finally slowly injected during 10 to 15 minutes
11358194|NCT02313350|Active Comparator|Open discectomy|surgery : The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root
11358195|NCT02313337|Experimental|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
11358196|NCT02313337|Experimental|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
11358197|NCT02313337|Experimental|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
11358198|NCT02313337|Experimental|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
11358199|NCT02313324|Experimental|ESWT group|The patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
11358200|NCT02313324|Active Comparator|SWD combined IFC group|The patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
11358201|NCT02313298|Experimental|Stereotactic Body Radiotherapy|An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
11358202|NCT02313285||GZ402668|Patient who received GZ402668 in prior study (TDU13475 or TDU14981)
11358203|NCT02313285||Placebo|Patient who received placebo in prior study (TDU13475 or TDU14981)
11358204|NCT02313272|Experimental|HFSRT with Pembrolizumab and Bevacizumab|Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.
11358205|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
11358206|NCT02313259||Age-matched controls|15 drivers without ocular disease.
11358207|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
11358208|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
11358209|NCT02313246|Experimental|Group Cognitive Behaviour Therapy|Patients will complete an 11-session group cognitive behaviour therapy for IBS that will be led by two clinicians, one of whom will be a registered clinical psychologist, at the Digestive Diseases Clinic at McMaster University Medical Centre. The group cognitive behaviour therapy will include weekly 2-hour sessions for 11 weeks. Sessions will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
11358210|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
11358211|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
11358212|NCT02313220|Experimental|Dapagliflozin and exenatide|Dapagliflozin 10 mg film-coated tablet once daily and exenatide 2 mg once weekly injection combined treatment for 24 weeks
11358213|NCT02313220|Placebo Comparator|Placebo|Placebo film-coated tablet once daily and placebo once weekly injection combined treatment for 24 weeks
11358214|NCT02313207|Active Comparator|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
11358215|NCT02313207|Active Comparator|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
11358216|NCT02313194|Experimental|Stimulation|Determine if epidural stimulation can improve motor function.
11358217|NCT02313181|Experimental|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
11358218|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
11358219|NCT02313168||1|preoperative FRONT score
11358220|NCT02313168||2|intraoperative FRONT score
11358221|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
11358222|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
11358223|NCT02313142|Experimental|Subjects|
11358224|NCT02313129||Rheumatoid Arthritis|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history and detailed menstrual history. They will also have a physical exam and blood tests.
11358225|NCT02313129||Healthy Controls|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history detailed menstrual history, and blood tests.
11358226|NCT02313103|Other|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
11358227|NCT02313103|Other|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
11358228|NCT02313090|Experimental|Welltang|patients using Welltang
11358229|NCT02313090|No Intervention|usual standard care|patients under usual standard of diabetic care
11358230|NCT02313077|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
11358231|NCT02313077|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
11358232|NCT02313077|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
11358233|NCT02313077|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
11358234|NCT02313077|Experimental|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
11358235|NCT02313064|Active Comparator|CXA-10|single dose of CXA-10 oral formulation
11358236|NCT02313064|Placebo Comparator|CXA-10 placebo|single oral doses of CXA-10 placebo
11358237|NCT02313051|Experimental|Everolimus arm|Everolimus+letrozole
11358238|NCT02313051|Active Comparator|Controll arm|letrozole alone, and when progress, followed by everolimus
11358239|NCT02313025|Experimental|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
11358240|NCT02313025|Active Comparator|World-project|This group receives the WORLD intervention for four months.
11358241|NCT02313012|Experimental|Dose Level 1 CC-90003|CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.
11358242|NCT02312999|Experimental|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
11358243|NCT02312999|Active Comparator|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
11358244|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
11358245|NCT02312973|Experimental|Arm 1|Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)
11358246|NCT02312973|Experimental|Arm 2|Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)
11358247|NCT02312973|Experimental|Arm 3|Single oral dose of 75 mg molidustat (fasted) in healthy subjects
11358248|NCT02312960|Other|Arm 1|The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
11358249|NCT02312947|Active Comparator|coblation|coblation adenoidectomy
11358250|NCT02312947|Active Comparator|cold dissection|cold dissection adenoidectomy
11358251|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:
~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
11358378|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
11358252|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
11358253|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.
~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
11358254|NCT02312921||Control|Usual care
11358255|NCT02312908|Experimental|Clonazepam|Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks
11358256|NCT02312908|Placebo Comparator|Placebo|Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks
11358257|NCT02312895|Experimental|Dry Needling|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive dry needling, patient education, and a home exercise program.
11358258|NCT02312895|Experimental|Manual Therapy|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive manual therapy, patient education, and a home exercise program.
11358259|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
11358260|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
11358261|NCT02312843|Active Comparator|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5[HRmax-HRrest] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
11358262|NCT02312843|Placebo Comparator|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
11358263|NCT02312817|No Intervention|Group 1|Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
11358264|NCT02312817|Experimental|Group 2|Individuals randomized to Group 2 will receive mailed outreach invitation.
11358265|NCT02312817|Experimental|Group 3|Individuals randomized to Group 3 will receive mailed outreach invitation and patient navigation.
11358266|NCT02312804|Experimental|Dose Escalation|To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
11358267|NCT02312804|Experimental|Expansion Cervical Cancer|To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
11358268|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
11358269|NCT02312778|Experimental|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation is delivered to the subjects in the side lying position. The more restricted lumbar segment (mobility restriction) will be the target region for the manipulative procedure.
11358270|NCT02312778|No Intervention|Sham Manipulation|Control Group who receives a simulated manipulation.
11358271|NCT02312765|Experimental|Intervention|Study participants will receive a tablet computer with the AirCare system.
11358272|NCT02312765|No Intervention|Control|Standard care
11358273|NCT02312752|Other|Intra-epidermal stimulation|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
11358274|NCT02312739|Active Comparator|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.
~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
11358275|NCT02312739|Experimental|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.
~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
11358276|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
11358277|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
11358278|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
11358279|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
11358280|NCT02312713|No Intervention|Wait list control|no intervention
11358281|NCT02312700|Experimental|Interactive empowerment (IEm) group|Intervention: Patients fill in the questionnaire online and their profile (obtained from their answers) is immediately sent to the physician
11358282|NCT02312700|Sham Comparator|Control|Intervention: Patients fill in the questionnaire online, but their profile (obtained from their answers) is not sent to the physician
11358283|NCT02312687|Experimental|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
11358284|NCT02312674|Experimental|Intervention|Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
11358285|NCT02312674|No Intervention|Control|Patients group which takes no oral nutritional supplements
11358286|NCT02312661|Experimental|Carboplatin / paclitaxel /metformin|Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment
11358287|NCT02312648|Active Comparator|Early mobilization Group|Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
11358288|NCT02312648|Other|Control Group - Respiratory exercise|Respiratory exercises with patient sitting in bed with a high headboard 45, the same breathing exercises will be held
11358289|NCT02312635|Experimental|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
11358290|NCT02312635|Placebo Comparator|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
11358291|NCT02312622|Experimental|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
11358292|NCT02312622|Experimental|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
11358293|NCT02312622|Experimental|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
11358294|NCT02312609|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
11358295|NCT02312609|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
11358296|NCT02312596|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix
11358297|NCT02312596|Active Comparator|Usual and customary practice|Usual and customary practice
11358298|NCT02312583|Sham Comparator|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment.
11358299|NCT02312583|Experimental|iFightDepression online programme.|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
11358300|NCT02312570|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
11358301|NCT02312570|Other|Usual and Customary Practice|Usual and customary practice for non-healing pressure wounds
11358302|NCT02312557|Experimental|Treatment (pembrolizumab)|"INITIAL TREATMENT PHASE: Patients who are progressing on enzalutamide will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily.
~MONITORING PHASE: After completion of the initial treatment phase, patients continue to receive standard of care enzalutamide PO daily for the duration of the trial.
~RETREATMENT PHASE: Patients with disease response or stability after the initial treatment phase will receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for an additional 4 courses in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily for the duration of the trial."
11358303|NCT02312544|Active Comparator|OTX-TP treatment|OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately
11358304|NCT02312544|Active Comparator|Timolol control|Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV).
11358305|NCT02312531|Experimental|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
11358306|NCT02312531|No Intervention|Control group|Mothers in control group had no HBIG injection during pregnancy.
11358307|NCT02312518|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
11358308|NCT02312518|Other|Usual and Customary Practice|usual and customary practice
11358309|NCT02312505|Other|COPFX|cardiac output by PulsioFlex® Monitoring system (COPFX)
11358310|NCT02312492|Experimental|18:1 diet|Oleic Diet - volunteers will consume oleic enriched food for a period of 5 weeks.
11358312|NCT02312492|Experimental|18:0|Stearic Diet - Volunteers will receive Stearic enriched food for a period of 5 weeks.
11358313|NCT02312479|Experimental|Nyxoah SAT therapy|
11358314|NCT02312466||School aged children|
11358315|NCT02312466||Pregnant women|
11358316|NCT02312466||Women of reproductive age|
11358317|NCT02312453|Experimental|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture [Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
11358318|NCT02312440|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
11358319|NCT02312440|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' prior to skin incision and the second dose at 180' after the first dosage.
11358320|NCT02312440|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
11358321|NCT02312427|Experimental|Outpatient arm|After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
11358322|NCT02312427|Experimental|Hospitalization arm 1|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
11358323|NCT02312427|Experimental|Hospitalization arm 2|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
11358324|NCT02312414|No Intervention|IVIR|Patients given IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 1 to week 4
11358325|NCT02312414|Experimental|IVIR Carnitine|Patients given Carnitine (20mg/kg, IV) perior to IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 4 to week 8.
11358326|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
11358327|NCT02312388|Experimental|Catheter-over-the-needle technique|to use the 22G angiocatheter for central venous catheterization
11358328|NCT02312388|Experimental|Thin-wall needle technique|to use the sharp hollow 23G needle for central venous catheterization
11358329|NCT02312375|Experimental|Fimasartan|Expreimental drug is fimasartan.
11358330|NCT02312375|Active Comparator|Amlodipine|Active comparator is amlodipine.
11358331|NCT02312362|Experimental|Combined sclerotomy ab interno and phaco|Combined sclerotomy ab interno and phacoemulsification with IOL implantation
11358332|NCT02312362|Active Comparator|Phacoemulsification with IOL implantation|Phacoemulsification with IOL implantation
11358333|NCT02312336|Placebo Comparator|Cohort A|Cohort A - Room temperature coronary perfusate
11358334|NCT02312336|Active Comparator|Cohort B|Cohort B - Cooled coronary perfusate
11358335|NCT02312323|Experimental|Definitive 65 HPT|The Test product were the Definitive 65 (Filcon V4) lenses with Hydra PEG surface coating. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
11358336|NCT02312323|Active Comparator|Definitive 65|The Control product was the commercially available Definitive 65 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
11358337|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
11358338|NCT02312310|Active Comparator|F 260 mg|"daily consumption of capsules containing 260 mg* cocoa flavanol for 12 weeks
~*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
11358339|NCT02312310|Active Comparator|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
11358340|NCT02312310|Active Comparator|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
11358341|NCT02312297|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
11358342|NCT02312297|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
11358343|NCT02312284||Radiotherapy/Chemoradiotherapy|Pre- or postoperative or palliative radiotherapy/chemoradiotherapy based on 5-fluorouracil or Capecitabine +/-Oxaliplatin
11358344|NCT02312284||Surgery|Transabdominal resection or transanal excision
11358345|NCT02312284||Chemotherapy|Pre- or postoperative chemotherapy including 5-fluorouracil/leucovorin with oxaliplatin, Capecitabine, etc
11358346|NCT02312271||enterally fed adults|adult subjects with established enteral access receiving standard tube feeding formula
11358347|NCT02312258|Experimental|Placebo|Ixazomib placebo-matching capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (Up to data cut-off 12 August 2019).
11358348|NCT02312258|Placebo Comparator|Ixazomib|Ixazomib 3 mg, capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (Up to data cut-off 12 August 2019).
11358349|NCT02312245|Experimental|Arm A (Avatar-directed paclitaxel)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
11358350|NCT02312245|Experimental|Arm B (Avatar-directed gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11358351|NCT02312245|Experimental|Arm C (Avatar-directed liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11358352|NCT02312245|Experimental|Arm D (Avatar-directed topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
11358353|NCT02312232|Experimental|Levodopa formulation A|Levodopa formulation A together with ODM-104 100 mg and carbidopa
11358354|NCT02312232|Experimental|levodopa formulation B|levodopa formulation B together with ODM-104 100 mg and carbidopa
11358355|NCT02312232|Experimental|levodopa formulation C|levodopa formulation C together with ODM-104 100 mg and carbidopa
11358356|NCT02312232|Active Comparator|Sinemet IR 100/25 mg|Sinemet IR 100/25 mg together with ODM-104 100 mg
11358357|NCT02312232|Active Comparator|Half Sinemet CR 100/25 mg|Half Sinemet CR 100/25 mg together with ODM-104 100 mg
11358358|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
11358359|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
11358360|NCT02312206|Experimental|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
11358361|NCT02312206|Placebo Comparator|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
11358362|NCT02312193||Case|Hypertensive subjects
11358363|NCT02312193||Control|Normotensive subjects
11358364|NCT02312180|Experimental|Cohort 1|low dose group of 2 mg/kg Plasminogen (Human) Intravenous
11358365|NCT02312180|Experimental|Cohort 2|mid-dose group of 6 mg/kg Plasminogen (Human) Intravenous
11358366|NCT02312167|Experimental|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
11358367|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.
~(We performed split face study)"
11358368|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
11358369|NCT02312128|Active Comparator|Early Mobilisation|"receives a removable plastic cast for one week and is allowed to move the wrist directly postoperative.
~Interventions:
~Range of Motion measurement (ROM),
~Grip strength measurement,
~VAS Score according to the visual analogue scale ().
~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.
~X- Rays in two planes.
~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
11358370|NCT02312128|Active Comparator|Cast Group|"receives a non removable cast for 5 weeks
~Interventions:
~Range of Motion measurement (ROM),
~Grip strength measurement,
~VAS Score according to the visual analogue scale ().
~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.
~X- Rays in two planes.
~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
11358371|NCT02312115|Active Comparator|Furosemide|Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.
11358372|NCT02312115|Placebo Comparator|Saline|All patients assigned to the saline group will receive saline that is equal in volume as compared to the treatment group. The amount of saline given to the patients in the placebo arm is so small that its effect on these patients is negligible. All other aspects of care for the enrolled patient will be managed per primary team and any consultants.
11358373|NCT02312102|Experimental|Velcade and Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Each treatment cycle lasts 28 days (4 weeks). The first two cycles are called the induction cycles. If the participant respond to treatment during the first two cycles, they can continue on to the maintenance cycles.
~During the induction and maintenance cycles, patients receive up to the MTD of lenalidomide on days 1-21 days only. During days 22-28 (4th week) there is a rest period.
~Bortezomib: During the induction cycles, the medication will be given on days 2, 5, 9, and 12 followed by a 17-day rest period. During the maintenance cycles, bortezomib will be given on days 2, and 5 followed by 23-day rest period."
11358374|NCT02312089|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
11358375|NCT02312089|No Intervention|Control group|No GnRHa administration in luteal phase
11358376|NCT02312076|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
11358377|NCT02312076|No Intervention|Control group|No GnRHa administration in luteal phase
11358380|NCT02312050|Experimental|GCS-100 1 mg|Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
11358381|NCT02312050|Experimental|GCS-100 3 mg|Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
11358382|NCT02312050|Experimental|GCS-100 9 mg|Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
11358383|NCT02312050|Placebo Comparator|Normal Saline Solution 0.9%|Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
11358384|NCT02312024||Patients with severe sepsis/septic shock|Use of CytoSorb adsorber in patients with severe sepsis/septic shock
11358385|NCT02312024||Cardiac surgery with CPB: preemptive use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: preemptive use
11358386|NCT02312024||Cardiac surgery with CPB: postop. use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: postoperative use
11358387|NCT02312024||Patients with other indications|Use of CytoSorb adsorber in patients with other indications
11358388|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.
~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
11358389|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
11358390|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin)|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11358391|NCT02311985|Active Comparator|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
11358392|NCT02311985|Experimental|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
11358393|NCT02311985|Experimental|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
11358394|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
11358395|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
11358396|NCT02311959|Experimental|Invasive or in situ breast carcinoma.|
11358397|NCT02311946|Experimental|Cohort 1|Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid
11358398|NCT02311946|Experimental|Cohort 2|Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3
11358399|NCT02311946|Experimental|Cohort 3|Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.
11358400|NCT02311946|Experimental|Cohort 4|Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.
11358401|NCT02311946|Experimental|Cohort 5|Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.
11358402|NCT02311946|Experimental|Cohort 6|Cohort 6 will receive a 125 mg palbociclib oral solution
11358403|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11358404|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
11358405|NCT02311920|Experimental|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
11358406|NCT02311920|Experimental|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
11358407|NCT02311920|Experimental|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
11358408|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
11358409|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
11358410|NCT02311894|Experimental|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
11358411|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
11358412|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
11358413|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
11358414|NCT02311868|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 day
11358415|NCT02311868|Placebo Comparator|Placebo|patients of this group received 5g of placebo 3 times a day for 30 days
11358416|NCT02311855|Other|Influenza vaccination|all patients are vaccinated per protocol
11358417|NCT02311829|Experimental|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.
~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
11358418|NCT02311829|No Intervention|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist
~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
11358419|NCT02311816||Infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
11358420|NCT02311816||No infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
11358421|NCT02311803|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
11358422|NCT02311803|Active Comparator|Excision of Denonvilliers Fascia|Excision of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
11358423|NCT02311790|Experimental|Trans-C16:1 supplement|Volunteers will take trans-C16:1 supplement for 3 weeks
11358424|NCT02311790|Experimental|Cis-C16:1 supplement|Volunteers will take cis-C16:1 supplement for 3 weeks
11358425|NCT02311777|Active Comparator|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
11358426|NCT02311777|Placebo Comparator|Placebo|Placebo will be given preoperative period
11358427|NCT02311764|Experimental|Carboplatin|Carboplatin will be administered weekly
11358428|NCT02311751|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
11358429|NCT02311751|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
11358430|NCT02311738|Experimental|High intensity training group|"HIE will consist of the following:
~10 minute warm up at 70% of maximal heart rate.
~4 minute exercise intervals at 90-95% of maximal heart rate.
~4 minute interval bouts repeated 4 times.
~Between each bouts there will be a 3 minute active recovery at 70% of maximal heart rate
~After all four bouts are completed; 5 minute cool-down at 70% of maximal heart rate."
11358431|NCT02311738|Experimental|Moderate intensity training group|"MIE will consist of the following:
~10 minute warm up at 50% of maximal heart rate.
~35 minutes exercise at 70% of maximal heart rate.
~4 minute cool-down at 50% of maximal heart rate."
11358461|NCT02311595|Experimental|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
11358462|NCT02311582|Experimental|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
11358821|NCT02309034|Active Comparator|Nutritional guidance|Nutritional counseling classes.
11358432|NCT02311725|Experimental|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.
~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.
~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
11358433|NCT02311725|Active Comparator|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.
~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
11358434|NCT02311712|Active Comparator|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
11358435|NCT02311712|No Intervention|Control|No intervention
11358436|NCT02311699|Experimental|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
11358437|NCT02311699|Experimental|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
11358438|NCT02311699|Experimental|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
11358439|NCT02311699|No Intervention|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
11358440|NCT02311686|Experimental|10 g ethanol|Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
11358441|NCT02311686|Experimental|20 g ethanol|Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
11358442|NCT02311686|Experimental|40 g ethanol|Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
11358443|NCT02311686|Experimental|60 g ethanol|Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
11358444|NCT02311686|Experimental|80 g ethanol|Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
11358445|NCT02311673|Active Comparator|RM-493 Once Daily Dose 1|Dose 1 once daily in the morning
11358446|NCT02311673|Active Comparator|RM-493 Once Daily Dose 2|Dose 2 once daily in the morning
11358447|NCT02311673|Placebo Comparator|Placebo|Placebo in the morning
11358448|NCT02311660|Experimental|vagus nerve stimulation|Patients will have an implanted vagus nerve stimulation device.
11358449|NCT02311647||Post Tamoxifen exposure group|Breast cancer patients receiving or formerly received Tamoxifen for at least 1 year.
11358450|NCT02311647||Control group|Breast cancer patients who did not receive endocrine treatment
11358451|NCT02311634|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of three weeks
11358452|NCT02311634|Active Comparator|Transvaginal ES|At a current intensity of < 60 mA (in 5% increments from 0 mA to the intensity that is sensed without obvious discomfort) and frequencies of 12.5 to 30 Hz, 45 min three times a week for a total of four weeks.
11358453|NCT02311621|Experimental|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.
~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.
~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
11358454|NCT02311621|Experimental|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.
~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.
~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
11358455|NCT02311621|Experimental|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.
~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.
~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
11358456|NCT02311608||High Dose Somatostatin/Octreotide|continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
11358457|NCT02311608||Terlipressin as salvage|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
11358458|NCT02311608||Terlipr+usual dose somato/Octreo|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
11358459|NCT02311608||Control:Usual Dose Somato/Octreo|Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide
11358460|NCT02311608||Control: Initial Terlipressin|Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h
11358523|NCT02311088|Placebo Comparator|Placebo|Matching placebo capsules twice daily orally for 7-10 days.
11358463|NCT02311582|Experimental|Phase II: MK-3475 Only (Arm B)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)
~The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.
~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.
~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will only be performed when clinically warranted."
11358464|NCT02311582|Experimental|Phase II: MK-3475 + MLA (Arm A)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).
~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.
~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.
~--For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA
~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
11358465|NCT02311582|Experimental|Phase II (after amendment #12): MK-3475 + MLA|"After amendment 12, all patients will be enrolled in this arm
~MK-3475 will be given every 3 weeks no more than 1 week after MLA
~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.
~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.
~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA
~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
11358466|NCT02311569|Experimental|Arm Mirabegron|Mirabegron treatment of at least 24 weeks with an initial dose of 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
11358467|NCT02311556|Experimental|DSC-PMR|DSC-PMR (dynamic susceptibility-weighted contrast- enhanced perfusion magnetic resonance imaging) at baseline (screening or time of radiosurgery) and after radiosurgery
11358468|NCT02311543|No Intervention|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
11358469|NCT02311543|Active Comparator|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
11358470|NCT02311530|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
11358471|NCT02311530|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
11358472|NCT02311517|Experimental|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
11358473|NCT02311517|Placebo Comparator|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
11358474|NCT02311504||DiabCheck ophta OCTplus|persons with diabetes undergoing OCT examination
11358475|NCT02311491|Experimental|Ceramic Coated Orthodontic Archwire|Ceramic coated orthodontic archwires will be evaluated in a limited clinical study at the university of North Carolina to test their efficacy in early and intermediate stages of tooth straightening in orthodontic patients.
11358476|NCT02311491|No Intervention|Control|The patients will receive the ordinary archwires. There is no intervention to the standard treatment.
11358477|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
11358478|NCT02311465|Experimental|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
11358479|NCT02311465|No Intervention|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
11358480|NCT02311452||Acute Osteomyelitis|
11358481|NCT02311452||Complicated Pneumonia|
11358482|NCT02311452||Complicated Appendicitis|
11358483|NCT02311439|Experimental|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
11358484|NCT02311426||Norway|500 consecutive patients with stroke from the stroke units at the University Hospital of North Norway located in the cities Narvik, Harstad and Tromsø.
11358485|NCT02311426||Denmark|500 consecutive patients from the stroke unit at Århus Hospital in Denmark.
11358486|NCT02311413|Experimental|Cat-PAD|Subjects will be treated with four monthly doses of Cat-PAD, a peptide immunotherapy product consisting of Fel d 1 synthetic peptide immunoregulatory epitopes (SPIRE).
11358487|NCT02311413|Placebo Comparator|Placebo|Subjects will be treated with 4 monthly doses of Placebo.
11358488|NCT02311374|Sham Comparator|Phase 2|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM-12 PM).
11358641|NCT02310295|Active Comparator|Laser|focal laser therapy
11358489|NCT02311374|Sham Comparator|Phase I|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
11358490|NCT02311361|Experimental|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
11358491|NCT02311361|Experimental|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
11358492|NCT02311361|Experimental|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
11358493|NCT02311361|Experimental|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
11358494|NCT02311361|Experimental|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
11358495|NCT02311361|Experimental|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
11358496|NCT02311335||1|Dyslipidemia patients
11358497|NCT02311322||Children with growth disorders|Children with growth disorders
11358498|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
11358499|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
11358500|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
11358501|NCT02311231|Experimental|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
11358502|NCT02311231|Active Comparator|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
11358503|NCT02311218|Active Comparator|Test group with L. reuteri|Subjects in the test group take one Lactobacillus reuteri DSM 17938 and PTA 5289 containing lozenge in the morning and one in the evening.
11358504|NCT02311218|Placebo Comparator|Placebo group without L. reuteri|Subjects in the placebo group take one placebo lozenges with same look, taste and smell as the test lozenge but lacking the Lactobacillii the morning and one in the evening.
11358505|NCT02311205|Experimental|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
11358506|NCT02311192|Experimental|Ultrasonography B-scan|Patients of uveitis who are included in the study will be imaged using ultrasound B-scan
11358507|NCT02311179|Active Comparator|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
11358508|NCT02311179|Active Comparator|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
11358509|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
11358510|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
11358511|NCT02311140||Cystic Fibrosis patients with G551D mutation|
11358512|NCT02311127|Experimental|SecurAcath|Subcutaneous securement
11358513|NCT02311127|Active Comparator|StatLock|Adhesive securement
11358514|NCT02311114||Telehomecare patients|Observational fieldwork, in depth interviews and surveys up to 4 times will be conducted.
11358515|NCT02311114||Health care providers|In-Depth interviews, observational fieldwork and one time survey will be conducted.
11358516|NCT02311114||Telehomecare administrators|In depth interviews will be conducted
11358517|NCT02311114||Telehomecare technicians|In-depth interviews, observational fieldwork will be conducted.
11358518|NCT02311101|Experimental|Therapy Group MMC 10/BCG Half|"Intravesical Mitomycin C and intravesical BCG
~First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (half dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The first 3 participants received 10mg of MMC and half dose of BCG. The dose was assigned in order of enrollment."
11358519|NCT02311101|Experimental|Therapy Group MMC 10/BCG Full|First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The following 3 participants received 10mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
11358520|NCT02311101|Experimental|Therapy Group MMC 20/BCG Full|First intravesical mitomycin C (20 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The next 3 participants enrolled received 20mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
11358521|NCT02311101|Experimental|Therapy Group MMC 40/BCG Full|First intravesical mitomycin C (40 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The last 3 participants received 40mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
11358522|NCT02311088|Experimental|Caffeine|Caffeine capsules. 200 mg twice daily orally for 7-10 days.
11358524|NCT02311075|Experimental|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
11358525|NCT02311075|Experimental|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
11358526|NCT02311075|Experimental|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
11358527|NCT02311062|Experimental|Eccentric hamstring exercises|Three workouts per week on non-consecutive days for 6 weeks. 1)Assisted Nordic Curl: Kneeling on the ground with ankles fixed by a partner, participant lowering the trunk to the ground by eccentrically contracting the hamstrings. 2) Eccentric single stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the support leg knee and raising the other leg until form an straight line with the trunk4 3) Eccentric double stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the knees until the body parallel with the floor.
11358528|NCT02311062|Experimental|Unistable exercises|Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
11358529|NCT02311062|Active Comparator|Control|Participants did not undergo any resistance training and continued with their regular soccer training.
11358530|NCT02311049|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
11358531|NCT02311049|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
11358532|NCT02311036|Other|Comorbidity_Comprehensive Rehabilitation|Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. For a physician, it is helpful in knowing how aggressively to treat a condition. Higher scores indicating greater comorbidity (patients with a score > 5 have essentially a 100% risk of dying at one year).
11358533|NCT02311036|Other|MRS_Comprehensive Rehabilitation|The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
11358534|NCT02311036|Other|MMSE_Comprehensive Rehabilitation|The mini mental state examination (MMSE) is the most commonly used instrument for screening cognitive function. This examination is not suitable for making a diagnosis but can be used to indicate the presence of cognitive impairment, such as in a person with suspected dementia or following a head injury. The examination has been validated in a number of populations. Scores of 25-30 out of 30 are considered normal; the National Institute for Health and Care Excellence (NICE) classifies 21-24 as mild, 10-20 as moderate and <10 as severe impairment. The MMSE may not be an appropriate assessment if the patient has learning, linguistic/communication or other disabilities (eg, sensory impairments).
11358535|NCT02311036|Other|BSRS_Comprehensive Rehabilitation|Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
11358536|NCT02311023|Experimental|Intermittent fasting|Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.
11358537|NCT02311010|No Intervention|CYP 3 A 5 *3/*3 control group|CYP 3 A 5 *3/*3 control group will receive 0,20 mg/kg of Advagraf®
11358538|NCT02311010|Active Comparator|CYP 3 A 5 *3/*3|CYP 3 A 5 *3/*3 will receive 0,25 mg/kg of Advagraf®
11358539|NCT02311010|Active Comparator|CYP 3 A 5 *1/*3|CYP 3 A 5 *1/*3 will receive 0,30 mg/kg of Advagraf®
11358540|NCT02311010|Active Comparator|CYP 3 A 5 *1/*1|CYP 3 A 5 *1/*1 will receive 0,35 mg/kg of Advagraf®
11358541|NCT02310997|Experimental|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
~Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
11358542|NCT02310997|Experimental|Busulfan + Cyclophosphamide + Melphalan|"Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2"
11358543|NCT02310971|Experimental|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
11358544|NCT02310958||Children with inguinal hernia|Laparoscopic surgical hernia repair in children aged between 1 day and 16 years
11358545|NCT02310945||Knee osteoarthritis|People with moderate/severe symptomatic knee osteoarthritis referred for physiotherapy
11358546|NCT02310932|Experimental|Healthy Living Intervention|The Healthy Living Intervention group will participate in an intervention designed to improve depression, anxiety, diabetes and CVD outcomes. This will be achieved through a 12 month intervention which consists of participation in healthy living groups and integrated collaborative clinic care at their Primary Health Clinic (PHC).
11358547|NCT02310932|Placebo Comparator|Enhanced Standard Care Model|"Patients in control groups will receive an enhanced standard care model, which includes providing referrals for mental health needs."
11358548|NCT02310919|Experimental|Low dose hCG plus FSH co-trigger|On the day of ovulation trigger the patient will receive hCG 1,500 IU SQ plus FSH 450 IU SQ
11360240|NCT02299245|Experimental|randomised to rosuvastatin (20mg/d)|randomised to rosuvastatin (20mg/d)
11358549|NCT02310919|Active Comparator|Standard dose of hCG alone|On the day of ovulation trigger the patient will receive standard dose of hCG (10,000 or 5,000 IU SQ)
11358550|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
11358551|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
11358552|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
11358553|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
11358554|NCT02310893|Active Comparator|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
11358555|NCT02310893|Active Comparator|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
11358556|NCT02310893|Experimental|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
11358557|NCT02310893|No Intervention|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
11358558|NCT02310880||Low vision (virtual street training)|Low vision subjects trained in virtual streets and observed in real streets
11358559|NCT02310880||Low vision (real street training)|Low vision subjects trained in real streets and observed in real streets
11358560|NCT02310867|Experimental|Hand transplant with Belatacept|
11358561|NCT02310854|Active Comparator|ACL Reconstruction|Primary reconstructive surgery of ACL with hamstring autograft (All-inside, Arthrex, Napels, Florida, USA)
11358562|NCT02310854|Experimental|ACL Repair|Primary augmented suture of ACL using Dynamic Intraligament Stabilization (DIS; Mathys Medical Bettlach, Switzerland)
11358563|NCT02310841|Experimental|unilateral transfemoral amputees|
11358564|NCT02310828|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
11358565|NCT02310828|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for one month
11358566|NCT02310802|Experimental|OBE001 dose 1|
11358567|NCT02310802|Experimental|OBE001 dose 2|
11358568|NCT02310802|Experimental|OBE001 dose 3|
11358569|NCT02310802|Placebo Comparator|Placebo|
11358570|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
11358571|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.
~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
11358572|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
11358573|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
11358574|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
11358575|NCT02310750|Experimental|PF-06700841 Tablet|
11358576|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
11358577|NCT02310737|Active Comparator|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
11358578|NCT02310737|Active Comparator|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
11358579|NCT02310724||TODAY cohort|All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2. The study performs long-term observation only and administers no treatment, care, or management.
11358580|NCT02310698||Breast Cancer Screening Patients|"Women presenting for screening full field digital mammography (FFDM) and WBUS on the same day or within 30 days of one another.
~o These women will be offered CEDM instead of the FFDM.
~Women that are scheduled for CEDM alone.
~o These women will be offered WBUS in addition to the CEDM.
~Women scheduled for both CEDM and WBUS on the same day or within 30 days of one another."
11358581|NCT02310685|Active Comparator|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
11358642|NCT02310282||Telemedicine|In-hospital telemedicine by a stroke expert aiming to assess stroke severity using the Unassisted TeleStroke Scale.
11358643|NCT02310269||Pasireotide|
11358644|NCT02310256|No Intervention|Usual care|
11358645|NCT02310256|Active Comparator|Five Plus|Exercise training
11358582|NCT02310685|No Intervention|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
11358583|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
11358584|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score <400
11358585|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
11358586|NCT02310646|Active Comparator|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
11358587|NCT02310646|Active Comparator|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
11358588|NCT02310633|Active Comparator|Memory Strategy Training|This arm involves intervention that teaches participants to use active encoding strategies to learn and remember new information.
11358589|NCT02310633|Active Comparator|Errorless Learning|This arm involves intervention that enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase.
11358590|NCT02310633|Active Comparator|Retrieval Practice|This arm involves intervention that enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue.
11358591|NCT02310620|Experimental|Cognitive Training|
11358592|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
11358593|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
11358594|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
11358595|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
11358596|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
11358597|NCT02310568|Experimental|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
11358598|NCT02310568|Experimental|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
11358599|NCT02310568|Experimental|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
11358600|NCT02310568|Experimental|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
11358601|NCT02310568|Placebo Comparator|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
11358602|NCT02310555|Active Comparator|Gastric bypass|classic Gastric bypass
11358603|NCT02310555|Active Comparator|Modified gastric bypass.|Modified gastric bypass. Resection body and fundus gastric
11358604|NCT02310555|Active Comparator|Slevee Gastrectomy|Slevee Gastrectomy
11358605|NCT02310542|Experimental|MARS-SPAD|Patients will receive first the MARS albumin dialysis system and then, in a second time, the SPAD albumin dialysis system.
11358606|NCT02310542|Experimental|SPAD-MARS|Patients will receive first the SPAD albumin dialysis system and then, in a second time, the MARS albumin dialysis system.
11358607|NCT02310529|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
11358608|NCT02310529|No Intervention|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
11358609|NCT02310516|Experimental|Patient with preoperative device|patients undergoing brain awake surgery with adequate explanations which are provided preoperatively. Preoperative device corresponds to a pre/ perioperative coaching involving the provision of a comprehensive information support on the awake surgery (short video and information brochure) and an interview with an operating room nurse
11358610|NCT02310516|Active Comparator|Patient with standard procedure|patients undergoing brain awake surgery with standard procedure (without adequate explanations)
11358611|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
11358612|NCT02310490|Active Comparator|Right Side DermaVeil, Left Side Sculptra|DermaVeil right with left side Sculptra left side
11358613|NCT02310490|Active Comparator|Left Side DermaVeil, Right Side Sculptra|DermaVeil left with left side Sculptra right side
11358646|NCT02310243|Experimental|Palbociclib|"Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.
~phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest."
11358614|NCT02310464|Experimental|Dose escalation|Each subject will be given a total of 10 doses of OBI-833/OBI-821 subcutaneously at weeks 1,2,3,4,6,8,12,16,20,and 24 (Visits 1,2,3,4,5,6,7,8,9 and 10, respectively). Post treatment, subjects will be continually evaluated for safety and immune response every 4 weeks until the end of study, which is 12 weeks after the last dose, i.e., week 36. Subsequently, subjects will be followed for survival every 8 weeks up to 12 months after the end of study.
11358615|NCT02310464|Experimental|Cohort expansion phase|Each subject will be given OBI-833/OBI-821 at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and every 8 weeks thereafter (Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and every 8 weeks thereafter) until disease progression. For the subjects discontinued treatment because of disease progression, subjects will be continually evaluated for safety and immune response every 8 weeks until the end of the study, which is 24 weeks after the last dose.
11358616|NCT02310451|Experimental|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
11358617|NCT02310438|Experimental|Early intervention music therapy|"music therapy:
~6 stroke patients with hemiparesis begin music therapy treatment in their home as soon as they have completed statutory NHS community rehabilitation."
11358618|NCT02310438|Active Comparator|Delayed intervention music therapy|"music therapy:
~6 stroke patients with hemiparesis begin music therapy treatment in their home 9 weeks after they have been randomised into the wait list group."
11358619|NCT02310425|Active Comparator|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
11358620|NCT02310425|Placebo Comparator|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
11358621|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
11358622|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
11358623|NCT02310399|Experimental|Pre-lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
11358624|NCT02310399|Experimental|Post-Lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age
11358625|NCT02310386|Active Comparator|activated BEMER-device|Activated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
11358626|NCT02310386|Sham Comparator|inactivated BEMER-device|Inactivated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
11358627|NCT02310373|Experimental|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
11358628|NCT02310360||Healthy volunteers|
11358629|NCT02310347|Experimental|Marinol|"generic name: dronabinol
~dosage: 0.1 mg/kg
~frequency: 2 times a single dose
~duration: acute adminstration"
11358630|NCT02310347|Placebo Comparator|Placebo|Empty hard gelatin capsules
11358631|NCT02310334|Experimental|Unguided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the first visit, the participant will partake in an unguided exercise session.
11358632|NCT02310334|Experimental|Guided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
11358633|NCT02310321|Experimental|Phase 1 Dose Evaluation Part|In the dose-evaluation part in Phase 1 part, subjects will receive ASP2215 at assigned single dose for determination of MTD and/or RED. Treatment of AML in this study is composed of 3 periods of therapy: remission induction (42-day cycles x 2 at maximum), consolidation (28-day cycles x 3 at maximum), and maintenance (28-day cycles x 26 at maximum). The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.
11358634|NCT02310321|Experimental|Phase 1 Dose Expansion Part|In the dose expansion part in Phase 1 part, subjects will receive ASP2215 at RED that has been determined in the dose-evaluation part, and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.
11358635|NCT02310321|Experimental|Phase 2 Part|Subjects will receive ASP2215 at the recommended dose established in Phase 1 part.
11358636|NCT02310308|Active Comparator|xylitol chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
11358637|NCT02310308|Experimental|Xylitol-magnolia chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
11358638|NCT02310308|Placebo Comparator|Control chewing gum|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
11358639|NCT02310295|Active Comparator|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
11358640|NCT02310295|Active Comparator|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
11358647|NCT02310230|Other|Blinded Group|Data from the ExSpiron Respiratory Variation Monitor (minute ventilation, tidal volume, and respiratory rate) will not be displayed. The anesthesia provider will care for the patient in the usual manner.
11358648|NCT02310230|Experimental|Monitor Group|The ExSpiron Respiratory Variation Monitor will display continuous real-time measurements of minute ventilation, tidal volume, and respiratory rate, and the anesthesia provider will be instructed to utilize this information in the care of the patient as they deem appropriate.
11358649|NCT02310217||1|Hypertensive
11358650|NCT02310217||2|Normotensive
11358651|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
11358652|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
11358653|NCT02310191||Stenting|Carotid stenting
11358654|NCT02310178|Other|Group/Cohort|all of the current bariatric surgeries are allowed in this prospective cohort study
11358655|NCT02310165|Other|Z-tract Insertion Technique|For this technique, the skin is pulled 2 cm downward before the paracentesis needle is inserted and advanced.
11358656|NCT02310165|Other|Coaxial Insertion Technique|For this technique, the needle is directly inserted to minimize the distance between he cutaneous tissue and ascites
11358657|NCT02310152|Active Comparator|Active Treatment: CBT|Cognitive Behavioral Therapy
11358658|NCT02310152|Experimental|Experimental Treatment: SPACE|Parent-Based Treatment of Childhood and Adolescent Anxiety Disorders
11358659|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
11358660|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
11358661|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
11358662|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
11358663|NCT02310100|Experimental|TactiCath Quartz|TactiCath Quartz treatment
11358664|NCT02310087|Active Comparator|astaxanthin with vitamin E|The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
11358665|NCT02310087|Placebo Comparator|placebo|The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
11358666|NCT02310074|Experimental|Pulsatile Gonadotropin Releasing Hormone|Pulsatile Gonadotropin Releasing Hormone: subjects in the GnRH group initiated a regimen of pulsatile GnRH administered subcutaneously via a portable infusion pump for 18 months.
11358667|NCT02310074|Active Comparator|combination gonadotropin therapy|combined human chorionic gonadotropin (hCG)/urinary Follicle-Stimulating Hormone (uFSH) therapy:HCG treatment was maintained alone for 6 months and then uFSH was added for the next 12 months
11358668|NCT02310061|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
11358669|NCT02310061|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
11358670|NCT02310048|Experimental|MT-1303-FormA|MT-1303, Capsule Formulation A
11358671|NCT02310048|Experimental|MT-1303-FormB|MT-1303, Capsule Formulation B
11358672|NCT02310022|Experimental|Drug Omega 3|4g (4 capsules) once a day, administered with food Other name MAT9001
11358673|NCT02310022|Active Comparator|Drug Omega 3 Comparator|4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
11358674|NCT02310009|Experimental|Control (CON)|Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
11358675|NCT02310009|Experimental|Anakinra (AN)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
11358676|NCT02310009|Experimental|Exercise (EX)|1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
11358677|NCT02310009|Experimental|Anakinra + Exercise (ANEX)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
11358678|NCT02309996|Experimental|Supervisor Training Program|All supervisors from work units randomized to the intervention will receive a supervisor training program, the Supervisor/Manager Accommodation Recognition & Training (SMART) Program. This training program is modeled on a program developed by Shaw and colleagues of the Liberty Mutual Research Institute for Safety (LMRIS). The aim of the training program is to prevent/reduce work disability by improving supervisor communication, response to workplace injury, and problem solving mechanisms. The training program is designed to be administered by two facilitators to groups of 10 to 12 supervisors, during one 4-hour session or two 2-hour sessions. The training program delivery mode includes PowerPoint presentation with supplementary audio or video segments, case studies, and group discussion.
11358679|NCT02309996|No Intervention|No Supervisor Training Program|All supervisors from work units randomized to the control group will not receive the supervisor training program.
11358680|NCT02309983|Active Comparator|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN [Respond Select Neuromuscular Stimulation]. There will be 60 sessions/3x week for 20 weeks.
11358716|NCT02309827|Experimental|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358758|NCT02309502|Experimental|Yellow Pascal|Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management:70%
11358759|NCT02309502|No Intervention|Observation|Observation
11358681|NCT02309983|Placebo Comparator|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
11358682|NCT02309983|Experimental|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
11358683|NCT02309970||Conservative|patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology
11358684|NCT02309970||IV tPA|patient will receive intravenous thrombolysis treatment
11358685|NCT02309970||Endovascular treatment|patient who will receive endovascular treatment
11358686|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
11358687|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
11358688|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
11358689|NCT02309931|Active Comparator|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
11358690|NCT02309931|Active Comparator|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
11358691|NCT02309918|Other|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
11358692|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
11358693|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
11358694|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
11358695|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
11358696|NCT02309892|Experimental|Pemetrexed and Carboplatin plus L-DOS47|Patients will be recruited into cohorts of L DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L DOS47 will be 0.59 µg/kg; further possible dose levels that may be assessed are 0.78, 1.04, 1.38 and 1.84 µg/kg. The standard of care doses of pemetrexed [500 mg/m2] and carboplatin [AUC6], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
11358697|NCT02309879|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
11358698|NCT02309879|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
11358699|NCT02309879|Active Comparator|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
11358700|NCT02309879|Active Comparator|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
11358701|NCT02309866||Genetic Testing|All participants determined eligible for the study will be placed into genetic testing arm.
11358702|NCT02309853|Experimental|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space combined with trunk rotation
11358703|NCT02309853|Active Comparator|Unimodal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training
11358704|NCT02309840|No Intervention|control|Students received standard meals in a standard cafeteria environment
11358705|NCT02309840|Experimental|Chef|Students were exposed to chef-enhanced meals
11358706|NCT02309840|Experimental|choice architecture|"Students were exposed to modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
11358707|NCT02309840|Experimental|Chef and choice architecture|"Students were exposed to both chef-enhanced meals and modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
11358708|NCT02309827|Experimental|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358709|NCT02309827|Experimental|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358710|NCT02309827|Experimental|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358711|NCT02309827|Experimental|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358712|NCT02309827|Experimental|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358713|NCT02309827|Experimental|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358714|NCT02309827|Experimental|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358715|NCT02309827|Experimental|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
11358717|NCT02309814|Experimental|eyelid motion sensor device|all volunteers will wear the monitor eyelid sensor device (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance.
11358718|NCT02309801|Experimental|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).
~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
11358719|NCT02309801|Active Comparator|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
11358720|NCT02309788||RT|Resectable HCC patients adjuvant RT for PVT or NM
11358721|NCT02309788||No RT|Resectable HCC patients adjuvant other treatment for PVT or NM
11358722|NCT02309775|Active Comparator|Auriculotherapy Group|The placement, points according to Souza (1997), will be: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. The point descriptions are: Shen Men, is located in the vertex of the angle formed by the lower root and the upper root of the antihelix; the Sympathetic is situated in the middle of the lower root below the Helix membrane (located at the lower end of the Lobe); the Kidney point is situated in cymba concha, near its junction with the lower root of the antihelix, in the same line as the Shen Men point; the Subcortex is situated on upward curve towards the apex of the antitragus, on the upper edge of the concha; the Adrenal is located at the apex of the tragus, on its projection towards the concha cava; the Cerebral point is situated above the edge of the antitragus. As sessions will held twice a week for a total of 10 sessions.
11358723|NCT02309775|Placebo Comparator|Placebo Grup|The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
11358724|NCT02309762|Experimental|FB825|6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg
11358725|NCT02309762|Placebo Comparator|Placebo|Placebo
11358726|NCT02309749||Naive cohort|
11358727|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
11358728|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
11358729|NCT02309723|No Intervention|No beta amyloid information|
11358730|NCT02309710|Experimental|ShangRing|ShangRing administered to men seeking medical male circumcision
11358731|NCT02309697||Full Term|Children born at full term on or after Jan 1, 2011
11358732|NCT02309697||PreTerm|Children born preterm on or after Jan 1, 2011
11358733|NCT02309684||Study Population|Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
11358734|NCT02309671|Experimental|FE 999049 6 µg|
11358735|NCT02309671|Experimental|FE 999049 9 µg|
11358736|NCT02309671|Experimental|FE 999049 12 µg|
11358737|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
11358738|NCT02309658|Experimental|Interventional|Treatment consisted of gemcitabine at a dose of 1000 mg/m2, followed by cisplatin 35 mg/m2 administered on day 1 and 8, for two cycles. After that, weekly cisplatin 40mg/m2 is administered concomitant with radiotherapy (45-55Gy) in 1,8-2,0 daily fractions and a 10Gy boost when there was parametrial involvement. Low-dose rate brachytherapy, in 4 fractions of 7Gy, in a total of 28Gy will complete the protocol.
11358739|NCT02309645|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
11358740|NCT02309645|Other|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
11358741|NCT02309632|Active Comparator|Pathway 1|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
11358742|NCT02309632|Active Comparator|Pathway2|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
11358743|NCT02309619|Experimental|trans-substernal group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-substernal path.
11358744|NCT02309619|Experimental|trans-esophageal bed group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-esophageal bed path.
11358745|NCT02309606||Migraine without aura|Migraine patients suffering from migraine 0-4 days per month.
11358746|NCT02309606||Healthy controls|Healthy controls with no history of migraine or other primary headaches.
11358747|NCT02309606||Chronic migraine|Migraine patients with chronic migraine
11358748|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, with any type of Acetabular Shells.
11358749|NCT02309580|Experimental|Ibrutinib|This will be a standard dose-escalation study to determine the MTD of ibrutinib in relapsed/refractory PTCL or CTCL. At each dose 6 patients with TCL (PTCL or CTCL) will be enrolled. The first 6 patients will be enrolled at dose level 1. Dose escalation to the next dose level will proceed after DLT assessment of all 6 patients at the end of cycle 1 (28-days).
11358750|NCT02309554|Active Comparator|SILCS Diaphragm alone|Participants will complete a post-coital test cycle with SILCS diaphragm alone.
11358751|NCT02309554|Active Comparator|SILCS Diaphragm with 3% Nonoxynol-9 Gel|Participants will complete a post-coital test cycle with SILCS diaphragm used with 3% nonoxynol-9 gel.
11358752|NCT02309554|Experimental|SILCS Diarphragm with ContraGel|Participants will complete a post-coital test cycle with SILCS diaphragm used with ContraGel.
11358753|NCT02309541|Experimental|Firmware N|New feedback canceller algorithm
11358754|NCT02309541|Active Comparator|Firmware R|Current feedback canceller algorithm (reference)
11358755|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
11358756|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
11358760|NCT02309489|Experimental|Intervention|"Receive standard maternity care
~Woman and partner attend one extra couple counselling session during pregnancy (A)
~Partner attends one group education session for men (B)
~Partner participates in pre-discharge consultation (C)"
11358761|NCT02309489|No Intervention|Control|"Receive standard maternity care
~No active encouragement of partner involvement, no extra sessions offered"
11358762|NCT02309476|Experimental|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
11358763|NCT02309476|Experimental|PASCAL Laser, Green Laser 1 burn|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
11358764|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
11358765|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
11358766|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
11358767|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
11358768|NCT02309450|Experimental|Asunaprevir, Daclatasvir and BMS - 791325|
11358769|NCT02309437|Experimental|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
11358770|NCT02309437|Active Comparator|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
11358771|NCT02309424|Active Comparator|Vinegar|0,50mmol vinegar (6% acetic acid)
11358772|NCT02309424|Placebo Comparator|Placebo|50 ml water
11358773|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
11358774|NCT02309385|Experimental|8% DSP-Visulex|8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
11358775|NCT02309385|Experimental|15% DSP-Visulex|15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
11358776|NCT02309385|Active Comparator|Pred Forte|Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.
11358777|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
11358778|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
11358779|NCT02309359|Placebo Comparator|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
11358780|NCT02309359|Experimental|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
11358781|NCT02309359|Experimental|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
11358782|NCT02309359|Experimental|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
11358783|NCT02309359|Experimental|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.
~The last study drug administration was at the Week 22 visit."
11358784|NCT02309346|Experimental|clindamycin once a day|Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day until clinical improvement
11358785|NCT02309346|Active Comparator|clindamycin thrice a day|Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
11358786|NCT02309320|Experimental|ALX-0171|Inhalation of ALX-0171 during 3 consecutive days
11358787|NCT02309320|Placebo Comparator|Placebo|Inhalation of Placebo during 3 consecutive days
11358788|NCT02309307|Experimental|Arm 1 Tissue Repair Device|Tissue Repair Device
11358789|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
11358790|NCT02309281|Other|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
11358791|NCT02309255||coronary heart disease patients|
11358818|NCT02309047||WHO anovulation|WHO I, II. III anovulation. See inclusion criteria
11358819|NCT02309034|Experimental|Jump exercise|rebound exercises.
11358792|NCT02309242|No Intervention|Neuropsychological assessment, MRI|This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.
11358793|NCT02309229||Cystic fibrosis patients|patients with cystic fibrosis
11358794|NCT02309203|Experimental|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
11358795|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
11358796|NCT02309177|Experimental|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
11358797|NCT02309177|Experimental|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
11358798|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
11358799|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
11358800|NCT02309177|Experimental|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
11358801|NCT02309177|Experimental|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
11358802|NCT02309164|Active Comparator|Acupuncture|acupuncture
11358803|NCT02309164|Sham Comparator|orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
11358804|NCT02309151|Experimental|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
11358805|NCT02309151|No Intervention|Not immediate coronary angiography|Coronary angiography with possible coronary intervention may be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice.
11358806|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
11358807|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
11358808|NCT02309125|Experimental|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
11358809|NCT02309125|Other|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
11358810|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
11358811|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
11358812|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
11358813|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
11358814|NCT02309086|Experimental|Single arm|Autologous dendritic cells transduced with Ad encoding NS3
11358815|NCT02309073||women with a regular indication for ART|In the present proposal we are aiming to include all normo-ovulatory women with a regular indication for ART.
11358816|NCT02309073||women undergoing donor insemination treatment|potential normal fertile control group
11358817|NCT02309060|Experimental|Storytelling Video Intervention (sTVi)|"We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.
~We will add a short, non-narrative, epilogue at the end of each of the 4 episodes that summarizes key messages and provides information on identifying signs of depression and suggestions for efficacious treatments.
~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
11358822|NCT02309021|Other|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
11358823|NCT02309021|Other|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
11358824|NCT02309008|Placebo Comparator|placebo|vehicle cream, dermal administration, multiple dosing
11358825|NCT02309008|Experimental|drug|PAC-14028 cream, dermal administration, multiple dosing, dose escalation
11358826|NCT02308995|Experimental|Cystectomy using barbed sutures|Endometrioma bed is sutured with barbed sutures
11358827|NCT02308995|Active Comparator|Cystectomy using conventional sutures|Endometrioma bed is sutured with conventional sutures
11358828|NCT02308982|Active Comparator|Intravenous immunoglobulin|Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days
11358829|NCT02308982|Placebo Comparator|Placebo|Equivalent volume to 1g/kg of IVIG per day for 2 consecutive days
11358830|NCT02308969|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
11358831|NCT02308956|Experimental|Integrated mental health in primary care|Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders.
11358832|NCT02308956|Active Comparator|Psychiatric nurse-led specialist care|Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
11358833|NCT02308930|Experimental|Vitamins + DHA supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg algal oil (containing 150mg DHA).
11358834|NCT02308930|Other|Vitamins supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg corn oil (free of omega-3 fatty acids).
11358835|NCT02308904|Other|Laboratory Studies for Pituitary-Gonadal Function|"Females: We expect to enroll approximately 15 females ages 12 years and older.
~Males: We expect to enroll approximately 15 males ages 12 years and older."
11358836|NCT02308904|Other|Data on iron burden and chelation history|"Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.
~Iron burden data
~Assay for non-transferrin bound iron (NTBI)
~Chelation data
~Oxidant stress
~History or presence of hypogonadism"
11358837|NCT02308904|Other|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
11358838|NCT02308891|Experimental|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.
~Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP
~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.
~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
11358839|NCT02308891|Active Comparator|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.
~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
11358840|NCT02308878|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for opioid dependence syndrome.
11358841|NCT02308878|Experimental|Mobile health cognitive stimulation|Cognitive stimulation using mobile technology with m-Health applications.
11358842|NCT02308865|No Intervention|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
11358843|NCT02308865|Experimental|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
11358844|NCT02308852|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the brain areas involved in cognitive aptitudes.
~tDCS will be applied during 20 minutes while patients will perform motor bimanual tasks"
11358845|NCT02308852|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
11358846|NCT02308826|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
11358847|NCT02308826|Active Comparator|Cool Little Kids|A 6-week parent psychoeducation group administered over an 8-week period.
11358848|NCT02308813|Experimental|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
11358849|NCT02308813|Experimental|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
11358850|NCT02308800|Active Comparator|Quantum™ Therapy/NPWT with Prontosan|Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
11358851|NCT02308800|Active Comparator|Quantum™ Therapy|Quantum™ Negative Pressure Wound Therapy without irrigant.
11358852|NCT02308761|Experimental|RO6870810|Participants with RR-AML and HMA-refractory MDS will receive RO6870810, as per schedule described in intervention description.
11358853|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
11358854|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
11358855|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
11358856|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
11358857|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
11358858|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
11358859|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
11358860|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
11358861|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
11358862|NCT02308722|Experimental|5-fraction stereotactic body radiation therapy|See intervention
11358863|NCT02308709|Experimental|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
11358864|NCT02308696|Experimental|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
11358865|NCT02308696|Active Comparator|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
11358866|NCT02308683|Experimental|hsCRP, Hgba1c|Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
11358867|NCT02308670||RRMS changing from 20mg to 40mg GA|Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
11358868|NCT02308644|Experimental|Bevacizumab|Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
11358869|NCT02308644|Sham Comparator|Sham|Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
11358870|NCT02308631|Experimental|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
11358871|NCT02308618|Experimental|Traditional Immobilization|45 days of plaster cast immobilization After the immobilization period, subjects received instructions on how to perform a home-based exercise program
11358872|NCT02308618|Experimental|Early mobilization|Six weeks of physical therapy program
11358873|NCT02308618|No Intervention|Control|Subjects had no history of lower limb injury, and were matched in age and anthropometric measurements to subjects that performed physical rehabilitation and to subjects that remained immobilized.
11358874|NCT02308605||Suspected stroke patients and subset|"Blood samples taken on admission and at 24 hours, MRI scan between 24 and 48 hours
~Subset: Blood samples repeated once per hour for six hours"
11358875|NCT02308605||Control participants (relatives)|To donate blood on two occasions, 24 hours apart, to draw comparison with stroke patients
11358876|NCT02308605||Feeding control participants|To donate a baseline blood sample, eat a simple purine rich meal (meat sandwich), then donate 4 more blood samples at 10, 30, 60 and 120 minutes following the meal
11358877|NCT02308592|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
11358878|NCT02308592|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
11358879|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
11358880|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
11358881|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
11358882|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
11358883|NCT02308566|Active Comparator|Conventional Extracorporeal Circulation Technique|Conventional Extracorporeal Circulation Technique
11358884|NCT02308566|Experimental|Minimized Extracorporeal Circulation Technique|Minimized Extracorporeal Circulation Technique
11358885|NCT02308553|Experimental|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
11358886|NCT02308553|Placebo Comparator|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
11358887|NCT02308540|Experimental|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
11358888|NCT02308540|Active Comparator|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
11358889|NCT02308540|Experimental|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
11358890|NCT02308540|Active Comparator|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
11358891|NCT02308540|Experimental|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
11358892|NCT02308540|Active Comparator|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
11358893|NCT02308540|Experimental|Infant Booster Dose SIILPCV 10|One dose of SIILPCV 10 at 9 months of age
11358894|NCT02308540|Active Comparator|Infant Booster Dose Prevenar 13|One dose of SIILPCV 10 at 9 months of age
11358895|NCT02308527|Active Comparator|Temozolomide|Temozolomide Days 1-5 every 4 weeks
11358896|NCT02308527|Experimental|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
11358897|NCT02308527|Experimental|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
11358898|NCT02308527|Experimental|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
11358899|NCT02308527|Experimental|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
11358900|NCT02308527|Experimental|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
11358901|NCT02308527|Experimental|Dinutuximab beta + Temozolomide|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
11358902|NCT02308527|Experimental|Dinutuximab beta + Temozolomide + Topotecan|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
11358903|NCT02308527|Other|Dinutuximab beta + Topotecan + Cyclophosphamide|Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
11358904|NCT02308514|Active Comparator|conservative care|this group of patients will receive the conservative care: myofascial point release and radial head mobilisation
11358905|NCT02308514|Experimental|cryostimulation|this group of patients will receive the conservative care :myofascial point release and radial haed mobilisation and the cryostimulation (30-40 second of cold air application (-70 celsius degree) in order to lower skin temperature around the lateral epicondyle at 4 celsius degree.
11358906|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft® in right eye and one drop Tears Naturale® in left eye once on Day 1 and once on Day 2
11358907|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale® in right eye and one drop Lastacaft® in left eye once on Day 1 and once on Day 2
11358908|NCT02308488|Other|Radiation|The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks. Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions
11358909|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
11358910|NCT02308462|Experimental|CHIMPs intervention|Family-Intervention
11358911|NCT02308462|No Intervention|Control|"The long-term effectiveness of the CHIMPs intervention under conditions of practice will be examined in comparison to a control condition receiving the usual after care (Treatment as usual = TAU); this testing of effectiveness will be performed in due consideration of the health economic aspects.
~The treatment as usual implies that families of the control Group receive the Treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every Family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system."
11358912|NCT02308449|Placebo Comparator|Iron-deficient, given placebo|Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit
11358913|NCT02308449|Active Comparator|Iron-deficient, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
11358914|NCT02308449|Placebo Comparator|Iron-replete, given placebo|Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit
11358915|NCT02308449|Active Comparator|Iron-replete, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
11358916|NCT02308436|Experimental|Candida Mouthwash with Curolox™ Peptide|Repeated applications 2.5 ml or 5 ml twice daily
11358917|NCT02308410||Tourniquet group|This group received a pneumatic tourniquet during total knee arthroplasty.
11358918|NCT02308410||Non-tourniquet group|This group received no tourniquet during total knee arthroplasty.
11358919|NCT02308397|Experimental|Group 1|Begins with Normal gluten containing bread
11358920|NCT02308397|Experimental|Group 2|Begins with Bread with reduced gliadins content
11358921|NCT02308397|Experimental|Group 3|Begins with Bread with reduced ATIs content
11358922|NCT02308397|Experimental|Group 4|Begins with Bread with reduced overall protein content
11358923|NCT02308384|No Intervention|Before intervention|GPs in this group have not yet received intervention.
11358924|NCT02308384|Experimental|After intervention|GPs in this group have received the intervention.
11358925|NCT02308371|Experimental|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV> 13 (in addition to standard clinical data) until PPV < 13.
11359385|NCT02305186|Active Comparator|Neoadjuvant CRT|Standard neoadjuvant chemoradiation treatment (CRT) alone
11358926|NCT02308371|No Intervention|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
11358927|NCT02308358||Allograft Transplantation|Subjects with femoral condyle osteochondral defects ≥10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for allograft transplantation.
11358928|NCT02308358||Microfracture Treatment|Subjects with femoral condyle osteochondral defects <10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for microfracture treatment.
11358929|NCT02308345|Experimental|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
11358930|NCT02308332|Active Comparator|Intervention|patients switching from Atripla to Eviplera
11358931|NCT02308332|No Intervention|Control|patients remaining on Atripla
11358932|NCT02308319|Active Comparator|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
11358933|NCT02308319|Other|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present [defined as HBV DNA >2,000 IU/ml and abnormal ALT (>40 IU/ml)]
11358934|NCT02308306||Opioid analgesics|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
11358935|NCT02308293|Experimental|High intensity exercise|Subjects will preform a high intensity training exercise (3* 30 seconds all out sprint on a cycle ergometer) to raise plasma lactate levels
11358936|NCT02308293|Sham Comparator|Lay down comfortably|As a control conditions, subjects wil lay down comfortably and rest
11358937|NCT02308280|Experimental|Bortezomib post-transplantation|"Non myeloablative allogeneic transplantation followed by Bortezomib for 1 year after a Bortezomib-based induction and autologous stem cell transplantation.
~Bortezomib: 1,3 mg/m2 subcutaneously every 2 weeks for 26 injections."
11358938|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
11358939|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
11358940|NCT02308254|Active Comparator|Lixisenatide|Lixisenatide: 10 mcg, one subcutaneous injection dose
11358941|NCT02308254|Placebo Comparator|Placebo|Matching placebo: one subcutaneous injection dose
11358942|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
11358943|NCT02308228|Experimental|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
11358944|NCT02308228|Placebo Comparator|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
11358945|NCT02308202|Active Comparator|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
11358946|NCT02308202|Active Comparator|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
11358947|NCT02308202|Placebo Comparator|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
11358948|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
11358949|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
11358950|NCT02308176|Experimental|intervention group|health advice and app installation in patient's mobile
11358951|NCT02308176|Placebo Comparator|control group|health advice
11358952|NCT02308163|Placebo Comparator|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
11358953|NCT02308163|Experimental|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
11358954|NCT02308163|Experimental|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
11358955|NCT02308163|Active Comparator|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
11358956|NCT02308137|Experimental|Domperidone|Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year
11358957|NCT02308124|Experimental|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
11358958|NCT02308124|Experimental|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
11358959|NCT02308124|Experimental|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
11358960|NCT02308111|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and Child Pugh Score).
11358961|NCT02308111|Placebo Comparator|Placebo|
11358962|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
11359386|NCT02305173|Active Comparator|dexamethasone group|patients receive one single dose of intravenous dexamethasone 8 mg.
11358963|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
11358964|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
11358965|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh
11358966|NCT02308085|Experimental|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
11358967|NCT02308072|Experimental|Olaparib + Cisplatin + IMRT|"Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5
~Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment."
11358968|NCT02308059||Patients with diabetes mellitus|Group I; the patients with diabetes mellitus who had peripheral neuropathy as diagnosed.
11358969|NCT02308059||Control|Group II; healthy volunteers
11358970|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
11358971|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
11358972|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
11358973|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
11358974|NCT02308020|Experimental|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11358975|NCT02308020|Experimental|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET).
~Participants may continue to receive treatment until discontinuation criteria are met."
11358976|NCT02308020|Experimental|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11358977|NCT02308020|Experimental|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11358978|NCT02308020|Experimental|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with melanoma received 200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11358979|NCT02308020|Experimental|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11358980|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
11358981|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
11358982|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
11358983|NCT02307994|Experimental|75IU uFSH|75IU uFSH (Livzon Pharm Group Inc., China) being injected into severe oligospermia patients or azoospermia patients every 3 days for 6 months
11358984|NCT02307981||Visual field defect with vision teacher|Patients With occipital ischemic stroke and Visual Field defect that live in a geographical region where training With vision teacher is an available service (vision Teachers are a Limited Resource in Norway)
11358985|NCT02307981||Visual field defect without vision teacher|Patients With occipital ischemic stroke and a Visual Field defect, who live in a geographical area where training With vision teacher is not an available service.
11358986|NCT02307968||inner thigh insulin injection|inject insulin at inner thigh site is the intervention arm. So we inject insulin at this site to see if this site is suitable for insulin injection.
11358987|NCT02307968||outer thigh insulin injection|outer thigh site for insulin therapy is the usual site
11358988|NCT02307955|Experimental|firefly|participants treated with firefly device
11358989|NCT02307955|Other|Control|Standard of care
11358990|NCT02307942|Experimental|SURGERY|Patient will be operated for a gastric banding disposal
11358991|NCT02307942|No Intervention|STANDARD|Standard of care for obesity
11358992|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
11358993|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
11358994|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
11358995|NCT02307903||End-stage renal failure (ESRF)|end-stage renal failure (ESRF)
11359047|NCT02307513|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
11358996|NCT02307890||Liver transplantation group|Participants will include all deceased adult liver transplant donors (>16 years of age) whose livers are being utilised for transplantation in the Scottish Liver Transplant Unit in the Royal Infirmary of Edinburgh. Exclusion criteria will include paediatric liver transplant donors (<16 years of age).
11358997|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
11358998|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
11358999|NCT02307864|Experimental|Treatment Sequence 1|Participants will receive treatment A (2*50 milligram [mg] tramadol hydrochloride [HCl] immediate release [IR] tablet + 1 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 2*50 mg tramadol HCl IR tablet + 1 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); treatment B (3*50 mg tramadol HCl IR tablet every 6 hours on Days 1, 2, and 3, along with single dose of 3*50 mg tramadol HCl IR tablet + 1 moxifloxacin placebo on Day 4); treatment C (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); and treatment D (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4) in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
11359000|NCT02307864|Experimental|Treatment Sequence 2|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
11359001|NCT02307864|Experimental|Treatment Sequence 3|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
11359002|NCT02307864|Experimental|Treatment Sequence 4|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
11359003|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
11359004|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
11359005|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
11359006|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
11359007|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
11359008|NCT02307825|Active Comparator|Azithromycin|Patients will receive the active study drug, azithromycin, as well as sinus irrigations with budesonide.
11359009|NCT02307825|Placebo Comparator|Placebo|Patients will receive a placebo as well as sinus irrigations with budesonide.
11359010|NCT02307786||Beta-Thalassemiall -Transplantation|
11359011|NCT02307786||Beta-Thalassemia Supportive Care|
11359012|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
11359013|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
11359014|NCT02307760|Active Comparator|Study Human Milk Fortifier A|Acidified processing method.
11359015|NCT02307760|Experimental|Study Human Milk Fortifier B|Non-acidified processing method.
11359016|NCT02307747|Experimental|trauma patients|Blood samples will be collected every 4 hours during 24 h, between day 2 and day 4 after inclusion
11359017|NCT02307734|Experimental|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately.
11359018|NCT02307734|Active Comparator|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
11359019|NCT02307721|Experimental|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
11359020|NCT02307721|Active Comparator|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
11359021|NCT02307708|Experimental|8° incline shoe|"The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.
~During the walk we will have:
~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).
~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
11359022|NCT02307708|Active Comparator|kinesitherapy|The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish
11359023|NCT02307695|Experimental|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
11359024|NCT02307695|Active Comparator|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
11359025|NCT02307682|Experimental|Brolucizumab 3 mg|Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
11359026|NCT02307682|Experimental|Brolucizumab 6 mg|Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
11359027|NCT02307682|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
11359048|NCT02307513|Experimental|Apremilast|Patients randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
11359049|NCT02307500|Experimental|Regorafenib|Regorafenib 160 mg (40 mg tablets), po, every day for 3 weeks of every 4 week cycle
11359028|NCT02307669|Placebo Comparator|Routine inhaler adherence care|"Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.
~The core features of the usual care group are:
~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.
~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.
~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.
~In follow up, medication changes in response to the above will be directed by these, as suggested by GINA management guidelines using a standardised digital script."
11359029|NCT02307669|Active Comparator|INCA feedback|"The patient's treatment goal is established and used as the focus of the conversation.
~Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.
~Data from the electronic PEF and AQLQ are correlated with digitally recorded adherence so that these can be used to account for improvements or declines in these measures.
~In follow up, medication changes in response to the above (adherence, PEF, ACT and exacerbations) are made using a standardised digital script."
11359030|NCT02307656|Other|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)
~Stage 2:Taste Optimization using API (flavours and sweeteners)
~Stage 3:Prototypes of the API - containing clinical trial materials"
11359031|NCT02307643|Experimental|Part 1|MT-1303 Low dose+Corticosteroid
11359032|NCT02307643|Experimental|Part 2-A|MT-1303 High dose+Corticosteroid
11359033|NCT02307643|Experimental|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
11359034|NCT02307630|Experimental|PET Imaging using 124I-Humanized 3F8|124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
11359035|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
11359036|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
11359037|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
11359038|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
11359039|NCT02307604||Brain cancer|Patients with diagnosis of brain cancer at any stage
11359040|NCT02307591|Active Comparator|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
11359041|NCT02307591|Experimental|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .
~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).
~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.
~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.
~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).
~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:
~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)
~Children < 29 kg: 5 mg/kg 3 times a day"
11359042|NCT02307565|Experimental|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
11359043|NCT02307565|Placebo Comparator|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
11359044|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
11359045|NCT02307539|Experimental|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
11359046|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
11359050|NCT02307487|Experimental|Cohort A2|120 mg MMC in 90ml gel
11359051|NCT02307487|Experimental|Cohort B2|140 mg MMC in 90ml gel
11359056|NCT02307474|Experimental|Treatment (Stereotactic Radiosurgery, pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO daily for up to 60 days. Patients then continue to receive pazopanib hydrochloride PO daily and undergo stereotactic radiosurgery (SBRT) every other day over days 60-65.
11359057|NCT02307461|Experimental|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
11359058|NCT02307461|Experimental|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
11359059|NCT02307461|Experimental|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
11359060|NCT02307448|Active Comparator|PRP Group|Patients will receive weekly PRP treatments
11359061|NCT02307448|Placebo Comparator|Standard of Care|Patients will receive weekly standard of care.
11359062|NCT02307435|Experimental|implantation group|implantation group will receive MSC and HA-CaSo4
11359063|NCT02307422||Case|Diabetic patients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
11359064|NCT02307422||Control|Non-diabeticpatients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
11359065|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
11359066|NCT02307409||Healthy Controls|Healthy Controls will be enrol
11359067|NCT02307396|Experimental|Intervention|"Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (gradual discontinuation, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life."
11359068|NCT02307396|Active Comparator|Control|The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
11359069|NCT02307383|Experimental|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.
~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
11359070|NCT02307370|Experimental|Turbo-Elite Atherectomy|
11359071|NCT02307357|Experimental|newcomball players|active newcomball women players will perform physical fitness tests
11359072|NCT02307357|Experimental|control|not physically active women will perform physical fitness tests
11359073|NCT02307344|Active Comparator|Nigella Sativa Supplement|Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
11359074|NCT02307344|Active Comparator|Patients receiving a placebo tablet|Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
11359075|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
11359076|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
11359077|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
11359078|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
11359079|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
11359080|NCT02307305|Experimental|Duloxetin group|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)
~Phase II (titration): POD#1~6 (30mg for another 6 days)
~Phase III (maintenance): POD#7~13(60mg for 7 days)
~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)
~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)
~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
11359081|NCT02307305|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
11359082|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
11359083|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
11359084|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
11359085|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
11359086|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
11359087|NCT02307253|Experimental|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
11359088|NCT02307240|Experimental|CUDC-907 - five days on/two days off|60 mg/day CUDC-907, oral administration, five days on/two days off until disease progression or other discontinuation criteria are met.
11359089|NCT02307227|Experimental|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):
~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
11359090|NCT02307227|Experimental|Locally advanced HER2- breast cancer pts|"HER2 negative:
~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
11359091|NCT02307214|Other|Coronary X syndrome|BaroReflex Sensitivity, endothelial function measurement
11359092|NCT02307214|Other|Tako-tsubo cardiomyopathy|BaroReflex Sensitivity, endothelial function measurement
11359093|NCT02307214|Other|Healty Volunteers|BaroReflex Sensitivity, endothelial function measurement
11359094|NCT02307201|Experimental|Postpartum Magnesium sulfate|The patient will receive magnesium sulfate as usual for 24 hours postpartum
11359095|NCT02307201|No Intervention|No postpartum treatment|The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum
11359096|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
11359097|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
11359098|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
11359099|NCT02307162|Placebo Comparator|Dummy solution|Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)
11359100|NCT02307162|Experimental|RPL554 suspension|"Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C).
~Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B"
11359101|NCT02307149|Experimental|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
11359102|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
11359103|NCT02307110|Other|1 arm study|cross-sectional observation
11359104|NCT02307097|Experimental|CBB|
11359105|NCT02307097|Experimental|CBT|
11359106|NCT02307097|Active Comparator|WAIT|
11359107|NCT02307084|Experimental|Pre-operative ultrasound imaging|Subjects that are randomly allocated to this group will have ultrasound imaging assessment of the long saphenous vein in both legs. This will allow assessment of the suitability of the long saphenous vein and marking of the distribution prior to heart bypass surgery to allow targeted harvesting of a bypass conduit.
11359108|NCT02307084|No Intervention|Current protocol|This group will not undergo pre-operative ultrasound imaging of the long saphenous vein in accordance with current Trust protocols.
11359109|NCT02307071|Experimental|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
11359110|NCT02307058|Experimental|LEAD RT Group|Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
11359111|NCT02307058|Experimental|HEIGHT RT Group|Participants in this group will receive the Hypofractionated Extended Image-Guided Highly Targeted (HEIGHT) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 7 and a half weeks.
11359112|NCT02307045|Active Comparator|varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
11359113|NCT02307045|Active Comparator|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
11359114|NCT02307019|Experimental|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
11359115|NCT02307019|Active Comparator|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
11359116|NCT02307006|Experimental|Ceftaroline|Experimental comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
11359117|NCT02307006|Active Comparator|Cefazolin / Vancomycin|Standard of care comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
11359118|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
11359119|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
11359120|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
11359121|NCT02306980|Experimental|Colostrum|Colostrum administration
11359122|NCT02306980|No Intervention|Control|Routine care
11359123|NCT02306967|Active Comparator|Standard Resection|Oral resection will be guided by usual practice. This involves identifying the tumour with white light and then marking surgical margins and resection the primary cancer.
11359124|NCT02306967|Experimental|FV Guided Resection|The oral resection will be guided by fluorescent visualization (FV).
11359125|NCT02306954|Active Comparator|High Dose IL-2|"Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
~Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2."
11359126|NCT02306954|Experimental|High Dose IL-2 and SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
11359127|NCT02306941|Experimental|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
11359128|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
11359129|NCT02306915|Experimental|lipegfilgrastim 30|
11359130|NCT02306915|Experimental|lipegfilgrastim 60|
11359131|NCT02306915|Experimental|lipegfilgrastim 100|
11359132|NCT02306902|Experimental|Test|Fenofibrate Capsules, USP 130 mg
11359133|NCT02306902|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
11359134|NCT02306889|Experimental|Test|Fenofibrate Capsules, USP 130 mg
11359135|NCT02306889|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
11359136|NCT02306876|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
11359137|NCT02306876|Placebo Comparator|Placebo|Placebo BID
11359138|NCT02306876|Experimental|PF-06412562 15mg|PF-06412562 15mg BID
11359139|NCT02306863|Experimental|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
11359140|NCT02306863|Sham Comparator|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
11359141|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
11359142|NCT02306837|Experimental|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
11359143|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
11359144|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
11359145|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
11359146|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
11359147|NCT02306798|Experimental|Formulation D|TP05
11359148|NCT02306785|Experimental|Formulation D|TP05 Coating D
11359149|NCT02306785|Experimental|Formulation E|TP05 Coating E
11359150|NCT02306785|Experimental|Formulation H|TP05 Coating H
11359151|NCT02306772|Experimental|Formulation A|TP05 Coating A
11359152|NCT02306772|Experimental|Formulation B|TP05 Coating B
11359153|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
11359154|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
11359155|NCT02306746|Experimental|TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
11359156|NCT02306746|Active Comparator|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
11359157|NCT02306733|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv)
11359158|NCT02306733|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon® Novartis, Switzerland) slowly intravenous.
11359159|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
11359160|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
11359161|NCT02306681||SAQ-Self-Assessment Questionnaire|
11359162|NCT02306668||Ocular surface discomfort|There are no interventions with this observational study
11359163|NCT02306642||Premature Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have experienced acute kidney injury based on the modified KDIGO guidelines for acute kidney injury.
11359164|NCT02306642||Premature No Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have not experienced acute kidney injury in the NICU.
11359165|NCT02306642||Term No Acute Kidney Injury|This group of babies born at term will have not experienced any acute kidney injury.
11359166|NCT02306629|Experimental|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
11359167|NCT02306629|Experimental|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
11359168|NCT02306629|Experimental|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
11359169|NCT02306629|Active Comparator|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
11359170|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
11359171|NCT02306590|Experimental|Study Intervention|High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day
11359172|NCT02306590|Placebo Comparator|Placebo|Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care
11360729|NCT02295787|Experimental|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
11359173|NCT02306577||Vancouver|HIV infected people who are current of recent illicit drug users and receive Stribild for their HIV treatment at Vancouver Infectious Diseases Centre and Regina General Hospital.
11359174|NCT02306564|Experimental|Group A|Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
11359175|NCT02306564|No Intervention|Group B|Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
11359176|NCT02306564|No Intervention|Group C|Group C will serve as a control group and will include age & BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
11359177|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
11359178|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
11359179|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
11359180|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
11359181|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
11359182|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
11359183|NCT02306512|Active Comparator|Standard vs. IF MART-1|"Samples removed with MMS within the first 3 mm margin from the tumor will be the first section. They will be processed as a conventional H&E frozen section and section stained with IHC MART-1. Samples removed with MMS within 3-6 mm from tumor margin will be the second section. They will be processed with fluorescent MART-1 antibodies. Based on the pre-defined characteristics MMS surgeon will evaluate each MART-1 immunofluorescent section as no evident melanoma or possible melanoma or present melanoma. Dermatopathologist will secondarily review each section scoring them in the same manner. If standard H&E, IHC, or immunofluorescence is recorded as present melanoma or possible melanoma a third section from 6-9mm will have the same procedure described before."
11359184|NCT02306512|Active Comparator|IF MART-1 versus IF cocktail|In the second arm of the study, assuming that immunofluorescence with MART-1 proves to be superior or at least equivocal to regular MART-1 IHC, the same method will be applied, but the control sections will be stained with fluorescent MART-1 antibodies and compared to a section stained with a cocktail of fluorescent melanocytic antibodies.
11359185|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH VARICOCELE|ICSI cases using cryopreserved testicular sperm from infertile azoospermic men, with proven diagnosis of varicocele (clinical & sonographic), which will be used for ICSI in an ART program
11359186|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH NO VARICOCELE|ICSI cases using cryopreserved testicular sperms from infertile azoospermic men due to etiologies other than varicocele
11359187|NCT02306486|Placebo Comparator|z250 resin composite|(n=31) Treated with distilled water (placebo) and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
11359188|NCT02306486|Active Comparator|z250 resin composite + oxalic acid|(n=31) treated with 0.5% oxalic acid (Desenssiv, SSWhite)(intervention)// and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
11359189|NCT02306486|Placebo Comparator|p 90 resin composite|(n=31) Treated with distilled water (placebo) and restored with a silorane resin-based-composite.
11359190|NCT02306486|Active Comparator|p 90 resin composite + oxalic acid|(n=31) treated with 0,5% oxalic acid (Desenssiv SSWhite)(Intervention)/ and restored with a silorane resin-based-composite (Filtek Silorane p90, £M ESPE, shade:)
11359191|NCT02306473|Experimental|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
11359192|NCT02306473|Experimental|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
11359193|NCT02306460||left atrial catheter ablation|
11359194|NCT02306460||left atrial appendix closure|
11359195|NCT02306460||paroxysmal atrial fibrillation control group|
11359196|NCT02306460||persistent atrial fibrillation control group|
11359197|NCT02306447|Experimental|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.
~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.
~For stimulation we use MagPro X100 (Medtronic, Denmark)."
11359198|NCT02306434|Active Comparator|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
11359199|NCT02306434|Other|Standard care-Counselling|Counselling for childbirth fear is given by the antenatal care midwife and by specially trained midwives working in collaboration with obstetricians at approximately 3-5 face to face counselling sessions. Often a visit to the delivery unit is included in the program and a care plan for the coming birth.
11359200|NCT02306421|Active Comparator|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
11359201|NCT02306421|Active Comparator|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
11359202|NCT02306421|Active Comparator|R P H|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
11359203|NCT02306421|Active Comparator|P P H|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids-PPH.In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
11359204|NCT02306421|Active Comparator|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
11359205|NCT02306395|Experimental|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
11359206|NCT02306395|No Intervention|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
11359207|NCT02306382|Experimental|ultrasonography, abscess|The experimental group will be treated after examination with 3D ultrasonography. Follow up after two months and one year.
11359208|NCT02306382|Other|Control group with clincial inscision|The control group will have drainage of their perianal abscess in the OR without ultrasound. Follow-up after two months and one year.
11359209|NCT02306369|No Intervention|Treatment as usual|A wait-list control.
11359210|NCT02306369|Experimental|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
11359211|NCT02306356|Experimental|Interventional|Behavioral: Internet-delivered Cognitive Behavior Therapy
11359212|NCT02306343|Experimental|Test (with the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, the InsuPad device was placed on the abdomen of the subject. The InsuPad device was activated and insulin bolus (0.2 units/kg body weight) was injected right before study start. The injection was given to the subject's abdomen through the injection window of the InsuPad device. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.
~In the daily life setting - Up to 12 months with the device (test). Subjects were asked to perform at least 3 blood glucose measurements during the day."
11359213|NCT02306343|No Intervention|Control (without the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, insulin bolus (0.2 units/kg body weight) was injected to the abdomen right before study start. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.
~In the daily life setting - Up to 12 months without the device (control). Subjects were asked to perform at least 3 blood glucose measurements during the day."
11359214|NCT02306330|Experimental|Malditof|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
11359215|NCT02306330|Active Comparator|Routine clinical microbiology|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
11359216|NCT02306317|Active Comparator|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
11359217|NCT02306317|Experimental|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
11359218|NCT02306304|Other|Israeli Arab men|Single arm study. The arm includes all enrolled patients screened by duplex ultra sound for abdominal aortic aneurysms.
11359219|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
11359220|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
11359221|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
11359222|NCT02306278|Placebo Comparator|vitamin capsules|vitamin capsules orally at the night before operation and 2 hours before surgery,respectively
11359223|NCT02306278|Experimental|gabapentin|gabapentin 600mg orally at the night before operation and 2 hours before surgery,respectively
11359224|NCT02306265|Other|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
11359225|NCT02306252|Experimental|CARE Intervention|This group will be contacted to make an appointment for outpatient Occupational and Physical therapy. The therapist will determine the type, frequency and length of treatment. Follow up phone calls will be made to ensure appointments are made, kept and rescheduled as needed.
11359226|NCT02306252|No Intervention|CARE Control|Patients randomized to this arm will receive contact information and a brochure outlining the services available within the supportive care program. The study coordinator will provide the information based on their results and assist the patient with contacting the program if desired.
11359227|NCT02306239|Active Comparator|norepinephrine|patients received norepinephrine
11359228|NCT02306239|Experimental|terlipressin|patients received terlipressin
11359229|NCT02306213|Experimental|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
11359230|NCT02306213|Active Comparator|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
11359231|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
11359232|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
11359233|NCT02306187|Experimental|Non-Alfacaocidol|Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
11359234|NCT02306187|Experimental|Alfacalcidol|Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
11359235|NCT02306174|Experimental|Cognitive Rehabilitation and Exposure-based Class for Compulsi|"Cognitive training is to improve thinking by learning new skills and strategies. The class begins with cognitive training to increase ability to carry out the skills learned later in treatment.
~Exposure therapy for discarding and acquiring helps to improve ability to make choices about possessions and learn to tolerate anxiety. Participants will face making difficult choices about items and potentially letting them go. Through repeated exposure to decisions about discarding and acquiring, distress about letting go or making choices about items will decrease over time."
11359236|NCT02306161|Experimental|Regimen A (VDC/IE)|See Design Details.
11359237|NCT02306161|Experimental|Regimen B (VDC/IE + ganitumab)|"INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.
~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.
~CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A.
~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo definitive SBRT or EBRT over 5 days."
11359238|NCT02306148|Placebo Comparator|Control Group|Group will practice 15 seconds isometric lower limb stretching protocol and must continue practicing running as usual.
11359239|NCT02306148|Experimental|Foot and ankle strengthening|Group will be trained during 2 months by a physiotherapist for foot and ankle strengthening and must continue to exercise at home with a training software supervision. Must continue practicing running as usual.
11359240|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
11359241|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
11359242|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
11359243|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
11359244|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
11359245|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
11359246|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
11359247|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
11359248|NCT02306122|Experimental|Default patient default doctor status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
11359249|NCT02306122|Experimental|Information patient default doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
11359250|NCT02306122|Experimental|Choice patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
11359251|NCT02306122|Experimental|Information patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
11359252|NCT02306122|Experimental|Information patient info doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
11359253|NCT02306109|Active Comparator|Standard motor rehabilitation treatment|
11359254|NCT02306109|Experimental|Intensive motor rehabilitation treatment|
11359255|NCT02306083|Placebo Comparator|Administration of the Placebo|Placebo three times a day.
11359256|NCT02306083|Placebo Comparator|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
11359257|NCT02306070|Experimental|Metformin + lifestyle modification|Metformin + lifestyle modification pre, during and post HCV antiviral therapy
11359258|NCT02306070|Placebo Comparator|No Metformin + Lifestyle modification|No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
11359259|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
11359260|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
11359261|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
11359262|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
11359263|NCT02306031|Placebo Comparator|placebo (ARTIFICIAL TEAR)|control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations.
11359288|NCT02305849|Experimental|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
11359264|NCT02306031|Active Comparator|diclofenac sodium drop|case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.. Theses drops continued up to 6 weeks with the same dose after operations.
11359265|NCT02306018||EV1000™/volumeView™|
11359266|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
11359267|NCT02305992|Experimental|Axillary Block with 0.5% Ropivicaine|Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
11359268|NCT02305992|Experimental|Stellate Ganglion Block with 0.2% Ropivicaine|Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
11359269|NCT02305992|Active Comparator|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
11359270|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
11359271|NCT02305966|Active Comparator|pressfit humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is -pressfit humerus & non-lateralized glenoid.
11359272|NCT02305966|Active Comparator|pressfit humerus & lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is - pressfit humerus & lateralized glenoid.
11359273|NCT02305966|Active Comparator|cemented humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component. Therefore, 4 randomization groups will be created and one of them is cemented humerus & non-lateralized glenoid
11359274|NCT02305966|Active Comparator|cemented humerus & lateralized glenoid.|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is cemented humerus & lateralized glenoid.
11359275|NCT02305953||Frozen serum|The cohort consists of original subjects from the Inno-6025 Trial who previously consented to measuring protein in the blood involved in skin inflammation.
11359276|NCT02305940|Active Comparator|Doxycycline|Doxycycline: oral dose of 100 mg once daily, for a total duration of 52 weeks.
11359277|NCT02305940|Placebo Comparator|Placebo|Placebo: an oral dose of one capsule once daily, for a total duration of 52 weeks.
11359278|NCT02305927|Experimental|Vitamin D3 (cholecalciferol)|
11359279|NCT02305927|Placebo Comparator|Placebo|
11359280|NCT02305914||follow-up visit|Patients who come for follow-up visit will fill in the questionnaire and undergo regular laboratory examination such as liver function test and CRP,faecal elastase-1 as well as CT scanning.Additionally,blood sample of every patient will be collected and sent to the Lab for storage and further experimented.
11359281|NCT02305901|Experimental|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
11359282|NCT02305888|Experimental|LEO 43204, 0.018% once daily for 3 days|
11359283|NCT02305888|Experimental|LEO 43204, 0.037% once daily for 3 days|
11359284|NCT02305888|Experimental|LEO 43204, 0.1% once daily for 3 days|
11359285|NCT02305875|Experimental|MCN scoring|Scoring of the mcn nerve's position in the axillary sheat using MRI
11359286|NCT02305862|Experimental|low dose group (5mg)|low dose Rosuvastatin
11359287|NCT02305862|Experimental|high dose group (20mg)|high dose Rosuvastatin
11359384|NCT02305186|Experimental|Neodjuvant CRT + Pembrolizumab|Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
11359289|NCT02305849|Experimental|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
11359290|NCT02305849|Placebo Comparator|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
11359291|NCT02305836|Experimental|Electroacupuncture combined with donepezil|Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
11359292|NCT02305836|Active Comparator|donepezil|Donepezil will be given once daily before bed-time for the first 4-6 weeks. Based on the treatment effect, the dosage may be increased to 10 mg once daily before bed-time for the next 6-8 weeks. Donepezil will be taken for continuous 24 weeks. The full course of treatment is 36 weeks.
11359293|NCT02305823|Active Comparator|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
11359294|NCT02305823|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
11359295|NCT02305823|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
11359296|NCT02305810|Experimental|Single arm receiving everolimus|single treatment arm receiving everolimus 10 mg daily
11359297|NCT02305797|Experimental|EDG004|EDG004 - Extended release lorazepam capsules
11359298|NCT02305797|Placebo Comparator|Placebo|Placebo
11359299|NCT02305771|Other|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.
~Then will be performed:
~Electroencephalography
~MRI"
11359300|NCT02305758|Experimental|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
11359301|NCT02305758|Placebo Comparator|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
11359302|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
11359303|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
11359304|NCT02305719||Epidural anesthesia|Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
11359305|NCT02305719||Serratus-anterior-plane-Block|"Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery.
~Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered."
11359306|NCT02305719||Local infiltration|Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
11359307|NCT02305706|Experimental|Right|patients will be positioned on the right-lateral position at the start of colonoscopy
11359308|NCT02305706|Active Comparator|Left|patients will be positioned on the left-lateral position at the start of colonoscopy
11359309|NCT02305693|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
11359310|NCT02305693|Active Comparator|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
11359311|NCT02305667|Placebo Comparator|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
11359312|NCT02305667|Active Comparator|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
11359313|NCT02305667|Active Comparator|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
11359314|NCT02305667|Active Comparator|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
11359315|NCT02305654|Active Comparator|Arm A - Standard Surgery (ILND)|"Part of randomisation 1.
~The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery."
11359316|NCT02305654|Experimental|Arm B - neoadjuvant chemotherapy|"Part of randomisation 1.
~Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).
~Administration on an outpatient basis:
~Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5
~Administration on an inpatient basis:
~Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3"
11359317|NCT02305654|Experimental|Arm C - neoadjuvant chemoradiotherapy|"Part of randomisation 1.
~Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.
~Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min."
11359318|NCT02305654|Experimental|Arm P - prophylactic PLND|"Part of randomisation 2.
~Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.
~Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:
~Cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.
~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour
~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:
~Any macroscopic tumour or pathological lymph nodes
~Electively to external iliac nodes in patient with high disease burden
~Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone."
11359319|NCT02305654|No Intervention|Arm Q - Surveillance no prophylactic PLND|"no prophylactic PLND Part of randomisation 2.
~For patients who have NOT received neoadjuvant chemoradiotherapy:
~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour
~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:
~Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden"
11359320|NCT02305641||Cohort|Method of continuous surveillance per standard of care
11359321|NCT02305628||Cohort|Method of continuous surveillance per standard of care
11359322|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
11359323|NCT02305602|Experimental|Post Myocardial Infarction|VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
11359324|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
11359325|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
11359326|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
11359327|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
11359328|NCT02305550|Experimental|electrical synthesis nitric oxide|Participants will breath 20 minutes of electrical pulsed plasma discharge synthesis of nitric oxide at 25 parts per million
11359329|NCT02305537|Experimental|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
11359330|NCT02305537|No Intervention|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
11359331|NCT02305524|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11359332|NCT02305524|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
11359333|NCT02305511|Experimental|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
11359334|NCT02305511|Experimental|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
11359335|NCT02305498|Experimental|Vigorous yoga practice|Supervised vigorous yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
11359336|NCT02305498|Active Comparator|Restorative (gentle) yoga practice|Supervised restorative (gentle) yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
11359337|NCT02305485|Experimental|NeoVas|"The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA- based polymer scaffold and contains the antiproliferative drug sirolimus.
~Intervention: Device: NeoVas BCS"
11359338|NCT02305485|Active Comparator|XIENCE PRIME|XIENCE PRIME Everolimus Eluting Coronary Stent System is a balloon expandable metallic platform stent manufactured from a flexible cobalt chromium alloy with a multicellular design and coated with a thin nonadhesive, durable, biocompatible acrylic, and fluorinated everolimus-releasing copolymer. Intervention: Device: XIENCE PRIME EECSS
11359339|NCT02305472|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
11359340|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.
~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with the Hepatocellular carcinoma (HCC) Module to measure changes in the quality of life of the patient."
11359341|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
11359342|NCT02305433|Experimental|Physiotherapy (physical exercise) for frail elderly|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
11359343|NCT02305433|Experimental|Physiotherapy (physical exercise) for operated hip fracture|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
11359344|NCT02305433|No Intervention|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
11359345|NCT02305433|No Intervention|Usual care for operated hip fracture|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
11359346|NCT02305420|Experimental|EmbryoGen/BlastGen|"EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm
~The intervention is to use EmbryoGen/BlastGen"
11359347|NCT02305420|Active Comparator|Control|Standard Cook sequential media
11359348|NCT02305407|Experimental|surgical revascularization|Patients will be assigned to either surgical or conservative treatment depending on their clinical symptoms and radiological assessment.
11359349|NCT02305407|Experimental|conservative treatment|Normal conservative treatment without surgical intervention.
11359350|NCT02305394|Experimental|PK group (ketamine and propofol)|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
11361156|NCT02292836||non-rosacea patients|Questionnaire testing on routine dermatologist patient population
11359351|NCT02305394|Active Comparator|P group (propofol group)|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
11359352|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
11359353|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
11359354|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
11359355|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
11359356|NCT02305368||Oncogramme|Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
11359357|NCT02305355|Experimental|Omega-3-acids ethylesters 90 4g, any statin|
11359358|NCT02305355|Active Comparator|any statin|
11359359|NCT02305342||Urinary Tract Infections (UTIs)|Uncomplicated UTIs
11359360|NCT02305329|Experimental|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
11359361|NCT02305329|Experimental|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
11359362|NCT02305329|Experimental|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
11359363|NCT02305329|Experimental|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
11359364|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
11359365|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
11359366|NCT02305303|Experimental|Diary|Use of diary
11359367|NCT02305303|No Intervention|Without Diary|
11359368|NCT02305290||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.
11359369|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
~CM - clinical micronized TBM - to-be-marketed"
11359370|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
~CM - clinical micronized TBM - to-be-marketed"
11359371|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
~CM - clinical micronized TBM - to-be-marketed"
11359372|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
~CM - clinical micronized TBM - to-be-marketed"
11359373|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
~CM - clinical micronized TBM - to-be-marketed"
11359374|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
~CM - clinical micronized TBM - to-be-marketed"
11359375|NCT02305264|Experimental|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.
~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
11359376|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
11359377|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
11359378|NCT02305225|Experimental|SDSR|first total then partial Sleep deprivation
11359379|NCT02305225|Experimental|SRSD|first partial then total Sleep deprivation
11359380|NCT02305212|Experimental|Cogmed|Cogmed is a cognitive rehabilitation protocol designed to improve working memory. The Cogmed sessions are on a computer at home for 30-40 min per day, 5 days per week for 5 weeks.
11359381|NCT02305212|No Intervention|Wait list|
11359382|NCT02305199|Active Comparator|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.
~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.
~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
11359383|NCT02305199|Active Comparator|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.
~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.
~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
11359387|NCT02305173|Placebo Comparator|placebo group|patients receive one single dose of intravenous placebo.
11359388|NCT02305160|Experimental|Butantan|The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
11359389|NCT02305160|Active Comparator|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
11359390|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
11359391|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:
~subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50
~subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
11359392|NCT02305147||Controls|Healthy controls: N=50
11359393|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
11359394|NCT02305134|Active Comparator|Tipepidine Hibenzate|Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
11359395|NCT02305134|Placebo Comparator|Placebo|Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
11359396|NCT02305108|Experimental|fascial manipolation and standard|
11359397|NCT02305108|Active Comparator|standard treatment|
11359398|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
11359399|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
11359400|NCT02305082||Fast-track group|Patients treated according to the enhanced recovery pathway. This group is examined prospectively.
11359401|NCT02305082||Control group|Patients treated according to the historic recovery pathway. This group is examined retrospectively.
11359402|NCT02305069|Placebo Comparator|Placebo|"Placebo tablet taken once daily for 12 weeks.
~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
11359403|NCT02305069|Experimental|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.
~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
11359404|NCT02305056|Experimental|C13 N15 Valine|Intervention C13 N15 Valine
11359405|NCT02305030|Experimental|BIA 9-1067 / Warfarin|BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
11359406|NCT02305017|Experimental|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
11359407|NCT02305017|Experimental|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
11359408|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
11359409|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
11359410|NCT02304978|Experimental|Group CRC|patient with a colorectal cancer
11359411|NCT02304978|Experimental|Group control|Control - volunteers
11359412|NCT02304965|Experimental|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
11359413|NCT02304952|Active Comparator|Eccentric exercise|Conservative treatment with eccentric exercise as self-training
11359414|NCT02304952|Active Comparator|Radiofrequency microtenotomy|A minimally invasive surgery (Topaz) and eccentric exercise as postoperative treatment
11359415|NCT02304939|Active Comparator|Quick change|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps at the same speed of the first, wait for a first drop at the end of the tubing.
~Close the first syringe, disconnect it and connect the second syringe, open the valve on and stop the first syringe."
11359416|NCT02304939|Experimental|Double Pumping|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps, open the second syringe while leaving the first syringe open. Wait until the blood pressure rises 5 mmHg (SBP, DBP or MAP).
~Once the blood pressure increased or 2 minutes from the start of the relay if no increase in blood pressure is observed, close the first syringe."
11359417|NCT02304939|Experimental|Smart infusion pump|For this automatic changeover : When the syringe of norepinephrine stops (pre alarm), oversee the progress of the automatic relay.
11359418|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
11359419|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
11359530|NCT02304172|Active Comparator|Thunderbeat (Group A)|Patients submitted to thyroidectomy with the use of the Thunderbeat device.
11359420|NCT02304913|Experimental|Hypoglossal acupuncture|Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.
11359421|NCT02304913|Sham Comparator|Sham acupuncture|Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.
11359422|NCT02304913|Active Comparator|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
11359423|NCT02304900|Experimental|Group 1 : white implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
11359424|NCT02304900|Experimental|Group 2 : yellow implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
11359425|NCT02304887||Bisphosphonate|
11359426|NCT02304887||Selective estrogen receptor modulator|
11359427|NCT02304887||Teriparatide|
11359428|NCT02304887||Senosumab|
11359429|NCT02304874|Other|Phlebotomy|Phlebotomies will be performed every 14 days at the Clinical Investigation Unit (CIU) until the value of ferritin level is below 50 µg/mL and/or the value of hemoglobin level is below 12 g/dL.
11359430|NCT02304861|Active Comparator|Viscoat group|Patients operated using Viscoat OVD
11359431|NCT02304861|Active Comparator|Visthesia group|Patients operated using Visthesia OVD
11359432|NCT02304848|Experimental|DBS (Deep Brain Stimulation)|DBS ( Deep Brain Stimulation) ( both high and low frequency deep brain stimulation will be applied to the subthalamic nucleus)
11359433|NCT02304822|Active Comparator|Multiple-dose of ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
11359434|NCT02304822|Experimental|Single-dose of ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only
11359435|NCT02304822|Experimental|Zero-dose of ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
11359436|NCT02304809|Experimental|VEMURAFENIB|"all eligible patients entering the study will receive oral Vemurafenib as monotherapy.
~Vemurafenib ZELBORAF 240 mg tablets Per OS 960 mg twice daily, to a total daily dose of 1,920 mg Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks Safety will be assessed continuously
~Treatment will be pursed until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal."
11359437|NCT02304796|Experimental|Unified CBT|Group psychotherapy according to the principles of the Cognitive-Behavioral Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011).
11359438|NCT02304796|Experimental|Combined CBT-DMT|Group psychotherapy combining cognitive-behavioral principles and techniques with dance/movement therapy techniques.
11359439|NCT02304783|Active Comparator|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days
11359440|NCT02304783|Placebo Comparator|Placebo|Placebo: one pill per day for five days
11359441|NCT02304783|Active Comparator|paracetamol|paracetamol: 1000mg per day for five days
11359442|NCT02304770|Experimental|cervical persistent high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection
11359443|NCT02304770|Experimental|CIN 1 with high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection
11359444|NCT02304770|Experimental|CIN 2/3|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3
11359445|NCT02304757|Experimental|low dose 99Tc-MDP|Patients with slightly decreased BMD (T or Z-score in lumbar spine or neck region of femur > -2.0 SD by dual energy X-ray) taking suppressive doses of L-T4 to treatment divided into 2 groups of 99Tc-MDP (Technetium [99Tc] methylenediphosphonate) and calcium alone.99Tc-MDP group:10mg Intravenous drip every 1week for ten weeks, every 2weeks for 22 weeks, every 1 month for 4 months.
11359446|NCT02304757|Active Comparator|Caltrate|600mg caltrate containing vitamin D everyday for 12 months.
11359447|NCT02304757|Experimental|high dose 99Tc-MDP|148 patients with obviously decreased BMD (T or Z-score in lumbar spine or neck region of femur≤-2.0 SD) taking suppressive doses of L-T4 divided into 2 groups of 99Tc-MDP and or fosamax. 99Tc-MDP group:15mg 99Tc-MDP Intravenous drip every 1week for ten weeks, every 2weeks for 22 weeks, every 1 month for 4 months (99Tc-MDP) for 12 months.
11359448|NCT02304757|Active Comparator|fosamax|70mg po every week for 12 months.
11359449|NCT02304731|Experimental|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
11359450|NCT02304718|Experimental|exercise intervention group|Pregnant women randomised to the exercise intervention group will complete three supervised, exercise sessions each week, exercise sessions completed on alternate days, and lasts until they give birth by using a stational bike. And also they will have regular prenatal care.
11359451|NCT02304718|No Intervention|control group|Pregnant women randomised to the control group only have regular prenatal care.
11359452|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
11359453|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
11359454|NCT02304692|Sham Comparator|Oticon Medical Machined Abutment|A non surface modified abutment is used
11359455|NCT02304692|Experimental|Oticon Medical Modified Abutment|A surface modified abutment is used
11359456|NCT02304679|Experimental|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).
~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
11361256|NCT02292134|No Intervention|control|
11359457|NCT02304679|Placebo Comparator|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.
~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
11359458|NCT02304666|Experimental|Crohn disease's Patients|Patients with Crohn disease or presenting an ulcerative colitis
11359459|NCT02304666|Other|Control patient|Patients with programmed colonoscopy screening for familial colon cancer history, polyps or for irritbale bowel syndrome
11359460|NCT02304640||Early-stage breast cancer patients|
11359461|NCT02304640||Healthy control|
11359462|NCT02304627|Experimental|Eating meal immediately after dosing|
11359463|NCT02304627|Experimental|Eating meal 30 min after dosing|
11359464|NCT02304627|Experimental|Eating meal 1 hour after dosing|
11359465|NCT02304627|Experimental|Eating meal 6 hour after dosing|
11359466|NCT02304614||Group 1|Patients who have undergone Breast conserving Therapy
11359467|NCT02304601||Comorbid symptoms|
11359468|NCT02304601||No comorbid symptoms|
11359469|NCT02304588|Experimental|Mesenchymal stem cells|Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight).
11359470|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
11359471|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
11359472|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
11359473|NCT02304562|Experimental|UCB Mesenchymal Stem Cells|UCB Mesenchymal Stem Cells treatment of patients with skin injury
11359474|NCT02304549||patients with BPH undergoing TUV-P|patients with Benign Prostatic Hyperplasia undergoing TUV-P
11359475|NCT02304536|Active Comparator|FSH|will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day.
11359476|NCT02304536|Active Comparator|Ovarian drilling|70 women will have laparoscopic ovarian drilling in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
11359477|NCT02304523|Experimental|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.
~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
11359478|NCT02304523|Experimental|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.
~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
11359479|NCT02304523|Active Comparator|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 * 500mL) within 1 hour. After then, take additional 500ml water.
~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
11359480|NCT02304510||females|females aged between 18 and 50 years old living in Beijing
11359481|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
11359482|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
11359483|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
11359484|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
11359485|NCT02304484|Experimental|Evolocumab|Participants received 420 mg evolocumab once a month for up to 2 years.
11359486|NCT02304471||Control|healthy subjects
11359487|NCT02304471||CKD|chronic kidney disease
11359488|NCT02304471||ESRD|end-stage renal disease
11359489|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
11359490|NCT02304445|Active Comparator|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
11359491|NCT02304445|Experimental|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
11359492|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
11359493|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
11359494|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
11359495|NCT02304419|Experimental|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
11359531|NCT02304172|Active Comparator|Harmonic (Group B)|Patients submitted to thyroidectomy with the use of the Harmonic scalpel device
11359773|NCT02302443|Experimental|Cohort 5|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
11359496|NCT02304393|Experimental|Part IA: Selicrelumab (IV) + Atezolizumab|Selicrelumab at a dose of 16 milligrams (mg) will be administered intravenously (IV) on Day 1 of Cycle 1 (first cycle in this group was of 42 days, and subsequent 21-day cycles); and atezolizumab 1200 mg will be administered IV after 6 weeks on Day 1 of Cycle 2, followed by every 3 weeks during Part IA until disease progression, death, loss of follow-up, or withdrawal of consent.
11359497|NCT02304393|Experimental|Part IA: Selicrelumab(SC) + Atezolizumab|Selicrelumab at a starting dose of 1 mg will be administered subcutaneously (SC) on Day 1 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 2, and followed by every 3 weeks during Part IA as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
11359498|NCT02304393|Experimental|Part IB: Selicrelumab + Atezolizumab|Selicrelumab will be administered at a starting dose of 1 mg SC on Day 2 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks during Part IB as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
11359499|NCT02304393|Experimental|Part II: Selicrelumab + Atezolizumab|Atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks; and Selicrelumab will be administered at the dose defined in Part IB (not exceeding 80 mg SC [unless IV administration in Part IB demonstrates better benefit/risk ratio]) on Day 2 (1 day after atezolizumab administration) of every second cycle from Cycles 1 to 7, and every fourth cycle thereafter during Part II as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
11359500|NCT02304367|Experimental|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
11359501|NCT02304354|Experimental|Rituximab|two intravenous infusions of 1000 mg with a two-week interval between them
11359502|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
11359503|NCT02304328||No clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients without clinical signs of brain herniation syndrome
11359504|NCT02304328||Clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients with clinical signs of brain herniation syndrome
11359505|NCT02304315|Experimental|GC1102 50,000 IU|Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.
11359506|NCT02304315|Experimental|GC1102 80,000 IU|Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.
11359507|NCT02304302|Placebo Comparator|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
11359508|NCT02304302|Experimental|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
11359509|NCT02304289|Experimental|Oral Artesunate|The first patient will receive 200 mg Artesunate once-daily for 14 days. If no dose-limiting toxicity (DLT) is observed after 14 days, the next patient will start at a daily dose of 300 mg Artesunate. If no DLT is observed after 14 days, a cohort of 3 patients will receive 400 mg once-daily for 14 days. For each subsequent cohort of 3 patients 200 mg will be added to the dose, until the maximum tolerated dose (MTD) is determined.
11359510|NCT02304276|Active Comparator|1 (Explanted valves)|"10 subjects who are due to undergo repeat aortic valve replacement surgery
~Investigations:
~Baseline 18F-Fluoride PET-CT scan
~Retrieval of explanted bioprosthetic aortic valve at time of surgery for analysis"
11359511|NCT02304276|Experimental|2 (AVR)|"70 subjects with surgical bioprosthetic AVR, to include 10 subjects who have had a valve replacement < 1 month; 20 at 2 years; 20 at 5 years and 20 at >10 years.
~Investigations:
~Baseline 18F-Fluoride PET-CT scan
~Repeat CT calcium score of aortic valve at 2 years
~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
11359512|NCT02304276|Experimental|3 (TAVI)|"50 subjects who have undergone TAVI with the COREVALVE and 50 subjects with the SAPIEN valve. In each group this will include 10 subjects who have had TAVI < 1 month; 20 at 2 years and 20 at 5 years.
~Investigations:
~Baseline 18F-Fluoride PET-CT scan
~Repeat CT calcium score of aortic valve at 2 years
~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
11359513|NCT02304263||Younger (18-35 years old)|iohexol
11359514|NCT02304263||Older (>60 years old)|iohexol
11359515|NCT02304250|Active Comparator|Group D|Group D: dexamethasone group
11359516|NCT02304250|Placebo Comparator|Group S|Group S: saline group
11359517|NCT02304237|Experimental|Vaginal progesterone|Vaginal progesterone(Utrogestan)200mg/day, during 14~21 weeks.
11359518|NCT02304237|Active Comparator|Intramuscular progesterone|Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14~21 weeks.
11359519|NCT02304224|No Intervention|Control|the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
11359520|NCT02304224|Experimental|Eye masks|the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
11359521|NCT02304211|Experimental|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
11359522|NCT02304211|Active Comparator|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
11359523|NCT02304198|Experimental|Udenafil|Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)
11359524|NCT02304185|Experimental|gp140, 50 mcg|
11359525|NCT02304185|Experimental|gp140, 50 mcg + Adjuvant|
11359526|NCT02304185|Placebo Comparator|Placebo 1|
11359527|NCT02304185|Experimental|gp140, 250 mcg|
11359528|NCT02304185|Experimental|gp140, 250 mcg + Adjuvant|
11359529|NCT02304185|Placebo Comparator|Placebo 2|
11359532|NCT02304159|Experimental|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
11359533|NCT02304159|Active Comparator|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
11359534|NCT02304146||High ligation and stripping (surgery)|6-10 years post classical stripping of the great saphenous vein.
11359535|NCT02304146||Foam sclerotherapy|6-10 years post post ultrasound guided foam sclerotherapy of the great saphenous vein.
11359536|NCT02304133|Active Comparator|Intervention|participating in a four-hour course in abdominal POC US
11359537|NCT02304133|Placebo Comparator|Control|no training
11359538|NCT02304120|Experimental|Sensorimotor|"The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device (Posturomed®, see section 3.2). The Posturomed allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured."
11359539|NCT02304120|Active Comparator|Low-intensity activity|Added to conventional therapy, as administered to all participants, the control group will do added treadmill walking. The control intervention will consist of 10 minutes of walking at comfortable pace. The patient will be instructed in treadmill functions and asked to set the speed between 2 and 4 km/h. The speed should be adjusted to the level where the patient would still be able to talk comfortably.
11359540|NCT02304107|Active Comparator|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
11359541|NCT02304107|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
11359542|NCT02304094|Experimental|manipulation|Those in the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique. They will be asked to return once each week for a further five weeks. At each visit the VAS and PTM measurements shall be repeated, as will the manual manipulation. They shall also be asked to return for a review in the sixth week.
11359543|NCT02304094|Active Comparator|Steroid|Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine. They shall then be asked to return for review in six weeks. A second injection may be offered at this point if clinically indicated.
11359544|NCT02304081|Active Comparator|Saxagliptin|Metformin and Dapagliflozin background therapy
11359545|NCT02304081|Placebo Comparator|Placebo|Metformin and Dapagliflozin background therapy
11359546|NCT02304068|Other|Intra-vitreal injection|
11359547|NCT02304055|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
11359548|NCT02304055|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
11359549|NCT02304042|Active Comparator|Carbetocin|125 women will receive carbetocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
11359550|NCT02304042|Active Comparator|Oxytocin|125 women will receive carbetocin oxytocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
11359551|NCT02304029|Experimental|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
11359552|NCT02304016|Experimental|Pelvic floor physical therapy|
11359553|NCT02304016|No Intervention|Observatoin|
11359554|NCT02304003|Experimental|Structured Physiotherapy regimen|Heavy-slow resistance training of rotator cuff . Scapular exercises. Manual mobilisation of glenohumeral joint . Stretching. Low Level Laser therapy
11359555|NCT02304003|Other|Standard care|Standard care offered in primary care while waiting for surgery , this may be but are not limited to : Wait and see, Drugs ( NSAIDS ), Corticosteroid injections, physiotherapy or other conservative treatment options.
11359556|NCT02303990|Experimental|Single arm|Hypofractionated RT and Pembro
11359557|NCT02303964|Active Comparator|Type A Thawed Plasma|"Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders.
~An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained."
11359558|NCT02303964|Placebo Comparator|Normal saline|Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
11359559|NCT02303951|Experimental|vemurafenib + cobimetinib + atezolizumab|"Run-In (week 1-4):
~Day 1-21: vemurafenib 960 mg bid orally + cobimetinib 60 mg od orally
~Day 22-28: vemurafenib 720 mg bid orally
~Triple-Treatment (week 5 ongoing):
~atezolizumab 840 mg Q2W i.v. + vemurafenib 720 mg bid orally + cobimetinib 60 mg od 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)"
11359560|NCT02303938|Experimental|physical exercise|Patients will exercise three times per week for 6 months home-based exercise intervention. Session duration will vary between 20 minutes and 45 minutes.
11359561|NCT02303938|No Intervention|Active control group|Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl
11359562|NCT02303925|Experimental|coils|
11359563|NCT02303912|Other|Open label dose escalation|"Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days.
~Dose escalation will be done using 3+3 dose escalation design"
11359595|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
11359564|NCT02303899|Experimental|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
11359565|NCT02303886|Active Comparator|A Methylene blue 10 mg/ml 2mg/kg|ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
11359566|NCT02303886|Placebo Comparator|B Methylene blue 10 mg/ml 0.02 mg/kg|Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
11359567|NCT02303873|Experimental|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
11359568|NCT02303860|Experimental|Panel 1|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
11359569|NCT02303860|Experimental|Panel 2|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
11359570|NCT02303847|Active Comparator|Active Drug|ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week
11359571|NCT02303847|Placebo Comparator|Placebo|Flavored syrup (without ketamine) by mouth twice daily for 2 weeks
11359572|NCT02303834|No Intervention|Control|The control group will not be fitted with CPAP.
11359573|NCT02303834|Experimental|CPAP group|The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).
11359574|NCT02303821|Experimental|Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.
~Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.
~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
11359575|NCT02303821|Experimental|Dose Escalation 2|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.
~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
11359576|NCT02303808|No Intervention|USUAL CARE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
11359577|NCT02303808|Active Comparator|INHALATION WITH PEP DEVICE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) combined with a PEP device (Acapella Duet) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
11359578|NCT02303795|Active Comparator|Rivaroxaban 20mg|Oral Rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
11359579|NCT02303795|Active Comparator|Warfarin|Warfarin Warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
11359580|NCT02303782|Experimental|OTX015 + azacitidine|
11359581|NCT02303782|Experimental|Azacitidine|
11359582|NCT02303769|Active Comparator|Tamsulosin HCL 0.2mg|Harnal-D tablet (Tamsulosin HCL 0.2mg)
11359583|NCT02303769|Experimental|Tamsulosin HCL 0.4mg|GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)
11359584|NCT02303756|Experimental|Pillcam® COLON Capsule|Detection of neoplastic lesions in colon and rectum compared to colonoscopy
11359585|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
11359586|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
11359587|NCT02303730|Experimental|Exenatide|Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks
11359588|NCT02303730|Active Comparator|Insulin glargine|Insulin glargine subcutaneously, once daily, for 24 weeks
11359589|NCT02303717|Active Comparator|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
11359590|NCT02303717|Experimental|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
11359591|NCT02303704|Active Comparator|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
11359592|NCT02303704|Active Comparator|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
11359593|NCT02303691|Experimental|Computerized Attention Bias Modification|
11359594|NCT02303691|Sham Comparator|Computerized Neutral Training|
11359596|NCT02303665|No Intervention|The control group|No Intervention
11359597|NCT02303665|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
11359598|NCT02303665|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
11359599|NCT02303639|Experimental|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
11359600|NCT02303639|Active Comparator|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
11359601|NCT02303626|Experimental|BCX4161 300 mg three times daily|Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
11359602|NCT02303626|Experimental|BCX4161 500 mg three times daily|Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
11359603|NCT02303626|Placebo Comparator|Placebo three times daily|Five placebo capsules to be taken three times daily by mouth
11359604|NCT02303600|Experimental|biomarker treatment arm|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate).
11359605|NCT02303600|Active Comparator|standard treatment arm|Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
11359606|NCT02303587|Experimental|low dose group|methylprednisolone 2mg-4mg/Kg
11359607|NCT02303587|Experimental|high dose group|methylprednisolone 10mg/Kg
11359608|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
11359609|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
11359610|NCT02303561|Experimental|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
11359611|NCT02303561|Active Comparator|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
11359612|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
11359613|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
11359614|NCT02303535||Congenital|"All patients with congential and acquired heart disease treated by cardiac surgery and therapeutic cardiac catheterisations procedures .
~For acquired heart disease, the audit covers all arrhythmias & cardiomyopathies in patients less than 16 years old only.
~For congenital heart disease, the audit collects data on both children and adult patients."
11359615|NCT02303522||All subjects|All subjects will be included in a unique cohort
11359616|NCT02303509|Experimental|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
11359617|NCT02303509|Experimental|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
11359618|NCT02303496|Experimental|PRP Cream Application|Application of Cream Containing Platelet Rich Plasma and Oleaginous Base
11359619|NCT02303496|Active Comparator|SW Cream Application - Placebo|Application of Cream Containing Sterile Water and Oleaginous Base
11359620|NCT02303483|Placebo Comparator|Placebo|lime tablets
11359621|NCT02303483|Experimental|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
11359622|NCT02303470|Experimental|Vigorous Exercise|High-intensity interval training for 15 minutes daily, 5 days per week for 8 weeks
11359623|NCT02303470|Experimental|Moderate Exercise|Brisk walking for 30 minutes daily, 5 days per week for 8 weeks
11359624|NCT02303457|Experimental|CO2 laser surgery|CO2 Laser surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved. All patients, under general anesthesia, underwent endoscopic excision of the lesion using a carbon dioxide (CO2) laser (Sharplan 100) coupled with a microscope (Zeiss) set to an output power of between 5 and 12 W in superpulse mode. The lesion's resection was accomplished in a radical fashion, with a free margin of 2 mm. For lesions which involved the anterior commissure, the excision plane always uncovered the cartilage.
11359625|NCT02303457|Other|Open surgery|"Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved.
~open surgery :Frontolateral Vertical Partial Laryngectomy or laryngofissure with cordectomy was accomplished in a radical fashion, with a free margin of 2 mm."
11359626|NCT02303444||MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
11359627|NCT02303444||non-MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
11359628|NCT02303431|Experimental|Cohort 1a|12 to < 18 years of age: edoxaban low dose group
11359629|NCT02303431|Experimental|Cohort 1b|12 to < 18 years of age: edoxaban high dose group
11359630|NCT02303431|Experimental|Cohort 2a|6 to < 12 years of age: edoxaban low dose group
11359631|NCT02303431|Experimental|Cohort 2b|6 to < 12 years of age: edoxaban high dose group
11359632|NCT02303431|Experimental|Cohort 3a|2 to < 6 years of age: edoxaban low dose group
11359633|NCT02303431|Experimental|Cohort 3b|2 to < 6 years of age: edoxaban high dose group
11359634|NCT02303431|Experimental|Cohort 4a|6 months to <2 years of age: edoxaban low dose group
11359635|NCT02303431|Experimental|Cohort 4b|6 months to <2 years of age: edoxaban high dose group
11359636|NCT02303431|Experimental|Cohort 5a|0 to 6 months of age: edoxaban low dose group
11359637|NCT02303431|Experimental|Cohort 5b|0 to 6 months: edoxaban high dose group
11359638|NCT02303418|Active Comparator|Carbetocin|100 µgm of Carbetocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
11359679|NCT02303093||Panzyga|Patient receiving panzyga
11359680|NCT02303080|Placebo Comparator|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
11359639|NCT02303418|Active Comparator|Oxytocin|5 mg of oxytocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
11359640|NCT02303405|Experimental|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
11359641|NCT02303405|Active Comparator|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
11359642|NCT02303392|Experimental|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11359643|NCT02303379|Active Comparator|Continuous Endurance training|Endurance training with constant work load 31min at 65-75% maximal heart rate (HRmax)
11359644|NCT02303379|Experimental|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
11359645|NCT02303379|Experimental|High-intensity intervall training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
11359646|NCT02303366|Experimental|SABR + MK-3475|SABR treatment (20Gy in 1 fraction) to at least one metastases (to a maximum of 5 metastases) followed by 8 cycles of 3 weekly treatment with MK-3475 (200mg IV per dose).
11359647|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
11359648|NCT02303340||Study Group|Any patient who enrolled and signed informed consent will be sent to bone mineral density DEXA Scan, and for blood testing for PTH, Phosphor, Calcium ,Vitamin D and Creatinine levels. Density measurements will be done in specific sites on the CBCT's of the jaws.
11359649|NCT02303327|Other|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
11359650|NCT02303327|Active Comparator|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
11359651|NCT02303314|Other|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
11359652|NCT02303314|Other|Drug: Placebo|in this group patients use placebo twice daily.
11359653|NCT02303301|Active Comparator|Probiotics|Patients gurgle twice a day with a suspension of two probiotic strains of bacteria- Contains also a filling material - maltodextrin
11359654|NCT02303301|Placebo Comparator|Control|Patients gurgle twice a day with a suspension of the filling material - maltodextrin
11359655|NCT02303275|Other|Lifestyle Change|Lifestyle Change
11359656|NCT02303262|Experimental|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
11359657|NCT02303249|Experimental|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
11359658|NCT02303249|No Intervention|Control|Standard health care services
11359659|NCT02303223|Other|Propofol|Single intravenous bolus dose of Propofol 2.5mg/kg for induction of anesthesia
11359660|NCT02303210|Other|hearing aid NaidaUP|Within subject design: compare frequency lowering one with frequency lowering two.
11359661|NCT02303210|Other|hearing aid NaidaSP|Within subject design: compare frequency lowering one with frequency lowering two.
11359662|NCT02303197|Experimental|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
11359663|NCT02303197|No Intervention|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
11359664|NCT02303184|Experimental|suprachoroidal CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
11359665|NCT02303184|Active Comparator|suprachoroidal sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
11359666|NCT02303171|Active Comparator|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
11359667|NCT02303171|Active Comparator|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
11359668|NCT02303145||Breast cancer survivor Group|Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
11359669|NCT02303145||Control Group|Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
11359670|NCT02303132|Other|Active MC|Patients with active MC will be included
11359671|NCT02303132|Other|MC in remission|Patients with MC in remission will be included
11359672|NCT02303132|Other|Controls|Patients without MC will be included
11359673|NCT02303119|Active Comparator|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
11359674|NCT02303119|Experimental|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
11359675|NCT02303119|Experimental|Arm C : Rituximab SC first cycle|8 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
11359676|NCT02303106|Active Comparator|lamotrigine|lamotrigine alone
11359677|NCT02303106|Experimental|Lamotrigine + paracetamol|Lamotrigine + paracetamol
11359678|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
11359681|NCT02303080|Active Comparator|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
11359682|NCT02303080|Active Comparator|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
11359683|NCT02303080|Active Comparator|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
11359684|NCT02303054|Experimental|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on an Prostatic multi-parametric MRI (mpMRI) of the prostate will be considered for enrollment. If followed by a positive MRI-US targeted biopsy of the prostate, men who be offered enrollment into the study. All men enrolled in the study will undergo bipolar radiofrequency ablation. Efficacy will be assessed through MRI-US biopsy after focal bipolar RFA.
11359685|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
11359686|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
11359687|NCT02303028|Experimental|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
11359688|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
11359689|NCT02303002|Experimental|Dose A|Dose A: Botulinum Toxin Type A
11359690|NCT02303002|Experimental|Dose B|Dose B: Botulinum Toxin Type A
11359691|NCT02303002|Experimental|Dose C|Dose C: Botulinum Toxin Type A
11359692|NCT02303002|Active Comparator|Dose D|Dose D: Botulinum Toxin Type A
11359693|NCT02303002|Placebo Comparator|Dose E|Dose E: Placebo
11359694|NCT02302989|No Intervention|Observation|No treatment. Observation only
11359695|NCT02302989|Active Comparator|Quarterly Ranibizumab 0.5|Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg
11359696|NCT02302976|Experimental|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
11359697|NCT02302976|Experimental|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
11359698|NCT02302976|Placebo Comparator|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
11359699|NCT02302976|Placebo Comparator|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
11359700|NCT02302963|Experimental|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
11359701|NCT02302963|Placebo Comparator|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
11359702|NCT02302950||women that picked up raltegravir 2013|minority women that picked up raltegravir at Thomas street Health Center 2013
11359703|NCT02302937|Active Comparator|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
11359704|NCT02302937|Active Comparator|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
11359705|NCT02302911||Early intensive behavioral intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive behavioral Intervention at one of the participating centres.
11359706|NCT02302911||Early intensive eclectic intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive eclectic Intervention at the participating centre.
11359707|NCT02302911||Control group|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving treatment as usual or no treatment at all.
11361327|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
11359708|NCT02302898||Wt maintenance|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
11359709|NCT02302898||Wt Regain|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
11359710|NCT02302872|Experimental|ARTO system|
11359711|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.
~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.
~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.
~Participants complete saliva cotinine test 3 months after intervention."
11359712|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.
~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.
~Participants complete saliva cotinine test 3 months after intervention."
11359713|NCT02302846|Experimental|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
11359714|NCT02302833|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11359715|NCT02302820|Active Comparator|Make Your Wishes Known|"A Decision Aid that uses interactions, videos, vignettes.
~A formatted Advance Directive; saved data that may be revisited to produce a revised Advance Directive"
11359716|NCT02302820|Active Comparator|Mayo Clinic-Advance Health Care Planning|"Not an online decision aid
~Written instructions, worksheets, and Advance Directive to complete"
11359717|NCT02302820|Active Comparator|Mydirectives.com|"Online decision aid that uses interactions, videos, and vignettes.
~An electronically stored Advance Directive that may be printed."
11359718|NCT02302820|Active Comparator|Prepare|"An online decision aid that uses interactions, videos and vignettes.
~A printed summary useful for transposing values and treatment wishes into an Advance Directive; a list of action steps."
11359719|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
11359720|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
11359721|NCT02302794|Active Comparator|open surgery|Conventional procedure
11359722|NCT02302794|Experimental|laparoscopic surgery|Minimum invasive procedure
11359723|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
11359724|NCT02302768|Placebo Comparator|Placebo|Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.
11359725|NCT02302768|Active Comparator|80-Semet|Patients randomized to receive selenomethionine at 80 mcg per day.
11359726|NCT02302768|Active Comparator|160-Semet|Patients randomized to receive selenomethionine at 160 mcg per day.
11359727|NCT02302755|Experimental|Screening/ Active Treatment Arm|"Screening Period: This includes diagnosis confirmation, consent, required tests and vaccinations.
~Treatment Period: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific TP10 dose-escalation scheme during the Induction Period and subsequent dose adjustments based on complement levels during the Maintenance Period"
11359728|NCT02302742||Triple Negative Breast Cancer patients|No intervention
11359729|NCT02302742||Germline HBOC Mutation Carriers|No intervention
11359730|NCT02302729|Experimental|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
11359731|NCT02302729|Placebo Comparator|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
11359732|NCT02302729|Experimental|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
11359733|NCT02302729|Placebo Comparator|Placebo and No responsive caregiving|Placebo and No responsive caregiving
11359734|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
11359735|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
11359736|NCT02302703|Active Comparator|the low FODMAP diet|
11359737|NCT02302703|Active Comparator|Gluten free diet|
11359738|NCT02302664|Active Comparator|PRP Injection|Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
11359739|NCT02302664|Sham Comparator|Imitation Injection|Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
11359740|NCT02302651|Other|Osteoid Osteoma|MR guided High Intensity focused ultrasound
11359741|NCT02302638|Active Comparator|Sage 1-step|"Embryo culture in different single-step media:
~Half of each patient's oocytes will be randomly allocated to be cultured in Sage 1-step medium for up to six days following oocyte retrieval."
11359742|NCT02302638|Active Comparator|CSCM|"Embryo culture in different single-step media:
~Half of each patient's oocytes will be randomly allocated to be cultured in CSC medium for up to six days following oocyte retrieval."
11359743|NCT02302625|Experimental|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
11359744|NCT02302612|Experimental|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE disease management program.
11359745|NCT02302612|Active Comparator|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
11359746|NCT02302599|Experimental|Umbilical cord mesenchymal stem cells|Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
11359747|NCT02302599|Experimental|Controlled suspension liquid|Patients receive Controlled suspension liquid
11359748|NCT02302586|Active Comparator|Patient Controlled Analgesia (IV PCA)|Postoperative intravenous (IV) morphine PCA is being used for acute pain control: Basal infusion: 0.3 mg/kg/h Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
11359749|NCT02302586|Active Comparator|Thoracic Paravertebral Block (TPVB)|Preoperative thoracic paravertebral block (TPVB) at 4 levels from T4 to T8 is being performed and total of 20 mL Bupivacaine 0.5% is deposited (5 mL per level by using landmark technique)
11359750|NCT02302573|Experimental|placenta accreta|contast-enhanced ultrasound with sonovue
11359751|NCT02302560||Patients with elective hip surgery|Patients with elective hip surgery (implementation or replacement of hip joint endoprotheses).
11359752|NCT02302547|Active Comparator|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
11359753|NCT02302547|Experimental|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
11359754|NCT02302534|Experimental|patients|"2 groups with MRI :
~- 8 right thoracic AIS participants (Cobb angle between 20 and 40°)"
11359755|NCT02302534|Experimental|controls subjects|- 8 healthy controls (no clinical scoliosis)
11359756|NCT02302521||Healthy Younger Adults|Age: 20-30. Gender: male or female. No neurological conditions.
11359757|NCT02302521||Healthy Older Adults|Age: 50-70. Gender: male or female. No neurological conditions.
11359758|NCT02302521||Parkinson's disease|Gender: male or female. Tremor dominant Parkinson's disease.
11359759|NCT02302521||Healthy Children|Age: 4-8. Gender:male or female. No neurological conditions.
11359760|NCT02302508|Experimental|T2D patients with A1C ≤7.0|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
11359761|NCT02302508|Experimental|T2D patients with A1C>7.5|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
11359762|NCT02302508|Experimental|Insulino-treated|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
11359763|NCT02302508|Active Comparator|Non-diabetic healthy subjects|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
11359764|NCT02302495|Other|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
11359765|NCT02302482|Experimental|Functional autonomy level collection|Collection of the Functional autonomy level every 6 - 12 months by phone
11359766|NCT02302469|Other|revlimid|a dose-escalation of revlimid
11359767|NCT02302456|Experimental|TXA|Intravenous administration of 1g of tranexamic acid within 2 minutes after birth and prophylactic oxytocin administration
11359768|NCT02302456|Placebo Comparator|Placebo|Intravenous administration of placebo within 2 minutes after birth and prophylactic oxytocin administration
11359769|NCT02302443|Experimental|Cohort 1|Very low dose of HM12470 (single dose, subcutaneous injection)
11359770|NCT02302443|Experimental|Cohort 2|Low dose of HM12470 (single dose, subcutaneous injection)
11359771|NCT02302443|Experimental|Cohort 3|Intermediate dose of HM12470 (single dose, subcutaneous injection)
11359772|NCT02302443|Experimental|Cohort 4|High dose of HM12470 (single dose, subcutaneous injection)
11359774|NCT02302443|Experimental|Cohort 6|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
11359775|NCT02302430|Experimental|Treatment|Treatment group will receive either 20IU or 40IU intranasal oxytocin
11359776|NCT02302430|Placebo Comparator|Placebo|Placebo group will receive a saline nasal spray
11359777|NCT02302417|Other|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
11359778|NCT02302404|Experimental|Cohort 1: GSK2982772 Single Ascending Dose (Part A) (0.1-10mg)|Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through approximately 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 0.1, 0.5, 2.5, and 10mg. A sequential design will be used including approximately weekly dose escalations while allowing for a sufficient washout period. The proposed doses may be adjusted based on emerging safety and PK
11359779|NCT02302404|Experimental|Cohort 2: GSK2982772 Single Ascending Dose (Part A) (40-240mg)|Eight subjects will be randomized equally to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having 4 dose periods (3 active dose of GSK2982772 +1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 40, 100, 180, and 240 mg. A sequential design with weekly dose escalations and sufficient washout period will be used. The proposed doses may be adjusted based on emerging safety and PK. After the completion of the fasted treatment periods, subjects will receive a high fat meal within 30 minutes of dosing with GSK2982772 during a final treatment period.
11359780|NCT02302404|Experimental|Cohort 3: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A data
11359781|NCT02302404|Experimental|Cohort 4: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in Part A or any preceding repeat dose cohorts in Part B
11359782|NCT02302404|Experimental|Cohort 5: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A or any preceding repeat dose cohorts in Part B.
11359783|NCT02302404|Experimental|Cohort 6: GSK2982772 Single Ascending Dose (Part A)|This additional cohort in Part A of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied. Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
11359784|NCT02302404|Experimental|Cohort 7: GSK2982772 Repeat Dose (Part B)|This additional cohort in Part B of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
11359785|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
11359786|NCT02302378|Active Comparator|Taylor's approach|This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
11359787|NCT02302378|Active Comparator|Lumbar approach|This arm will have the procedure of spinal anesthetic performed via a paramedian 'Lumbar approach' at interspace L3-L4. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
11359788|NCT02302352|Active Comparator|Probiotic|Oral probiotic 1g, once/day, containing: Lactobacillus paracasei, 10x9 CFU; Lactobacillus rhamnosus,10x9 CFU; Lactobacillus acidophillus, 10x9 CFU; Bifidobacterium lactis 10x9 CFU per sachet
11359789|NCT02302352|Placebo Comparator|Placebo|Maltodextrin 1g per sachet, once/day
11359790|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
11359791|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
11359792|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
11359793|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
11359794|NCT02302326|Experimental|Metformin|PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.
11359795|NCT02302326|Experimental|Myo-inositol + folic acid|PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks
11359796|NCT02302326|No Intervention|Healthy women|Healthy untreated women adjusted for age and body mass index
11359797|NCT02302313|Other|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
11359798|NCT02302300|Experimental|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
11359799|NCT02302300|No Intervention|Control Group|Standard preparation
11359800|NCT02302287|Experimental|Group A|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
~Mediterranean diet and ketoacids for 6 months"
11359801|NCT02302287|Experimental|Group B|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day;
~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
~Mediterranean diet and ketoacids for 6 months"
11359802|NCT02302287|Other|Group control|Free diet: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day
11359803|NCT02302274||flecainide infusion test|Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
11359804|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
11359805|NCT02302248|Experimental|Crowdsourced Reappraisal|Participants received the web-based crowdsourcing reappraisal intervention.
11359806|NCT02302248|Active Comparator|Expressive Writing|Participants received the web-based expressive writing intervention.
11359807|NCT02302235|Active Comparator|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
11359808|NCT02302235|Other|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
11359809|NCT02302222|Active Comparator|Standard of Care|dry sterile dressing/gauze and steristrips
11359810|NCT02302222|Experimental|Customizable|Prevena Customizable Dressing with ActiV.A.C. Therapy Unit
11359811|NCT02302209|Experimental|Oxytocin|40 IU Oxytocin Intranasal
11359812|NCT02302209|Placebo Comparator|Placebo|Saline Nasal Spray
11359813|NCT02302196||Autologous Fat Grafting of the breast|Approximately 100 women who have had a lumpectomy and qualify, will be offered Autologous Fat Grafting (AFG) procedure. Patients will be assessed 3 months post grafting for safety and efficacy by Breast-Q survey, mammography BIRADS scoring and physical assessment. The AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. Repeat mammogram will be done 1 year post AFG.
11359814|NCT02302196||Control arm standard treatment|Retrospective chart review will be done in 100 women who have undergone standard treatment for breast contour defect after lumpectomy.The control group will be measured by compiling BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy.
11359815|NCT02302183|Experimental|Experimental: device FreeO.|Automatic adjustment of oxygen
11359816|NCT02302183|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
11359817|NCT02302170|Experimental|H. pylori vaccine in children|H. pylori vaccine (15mg/dose) in children between 6-15 years of age
11359818|NCT02302170|Placebo Comparator|placebo in children|placebo (0mg/dose) in children between 6-15 years of age
11359819|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
11359820|NCT02302144|Experimental|Early Multi-Ex-PD|Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
11359821|NCT02302144|Experimental|Late Multi-Ex-PD|Three months after enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
11359822|NCT02302131||pulmonary valve replacement|SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
11359823|NCT02302118||Surgical approach|Group A: Esophagogastrectomy Group B: Extended gastrectomy
11359824|NCT02302105|Active Comparator|Prostate Only|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV
11359825|NCT02302105|Experimental|Whole Pelvis|66-68 Gray (Gy) in 25 fractions will be prescribed for the prostate PTV and 50 Gy in 25 fractions to nodal region .
11359826|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
11359827|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
11359828|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
11359829|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
11359830|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
11359831|NCT02302066|Experimental|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 365.
11359832|NCT02302066|Experimental|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 91 and 365.
11359833|NCT02302066|Experimental|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 91.
11359834|NCT02302066|Placebo Comparator|Group 4 (Placebo Control)|Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
11359835|NCT02302053|Active Comparator|New Viviscal Professional Supplement|New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
11359836|NCT02302053|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
11359837|NCT02302040|Experimental|AIM2ACT|AIM2ACT uses existing mHealth technology developed by the study team to elucidate tailored intervention targets for each family. AIM2ACT then facilitates collaborative caregiver/adolescent asthma management by automatically guiding dyads through a structured process that includes the supportive behavioral management strategies of goal setting, contingency management, and problem solving communication. Skills-training videos for adolescents and caregivers provide guidance on how to complete each collaborative asthma management component.
11359838|NCT02302040|Active Comparator|Self-Guided|Participants in the self-guided control condition will be given general information on supportive behavioral management techniques they can use to target improvement in asthma self-management behaviors. The control condition will serve as an attention control and is designed to optimize recruitment and sustain interest while concurrently having a minimal impact on asthma management.
11359839|NCT02302027|Experimental|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
11359840|NCT02302014|Experimental|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
11359841|NCT02302014|No Intervention|Usual Care|Usual Care
11359842|NCT02302001|Experimental|Primary Breast Augmentation|
11359843|NCT02301988|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
11359844|NCT02301988|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
11359845|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
11359846|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
11359847|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
11359848|NCT02301962|Experimental|Panitumumab arm|Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
11359849|NCT02301949|Active Comparator|Thalidomide Retreatment Group|
11359850|NCT02301949|Placebo Comparator|Placebo Group|
11359851|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
11359852|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
11359853|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
11359854|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
11359855|NCT02301910|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
11359856|NCT02301910|Active Comparator|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)
~55 to <60 30 mg 6 ml
~60 to <70 35 mg 7 ml
~70 to <80 40 mg 8 ml
~80 to <90 45 mg 9 ml
~90 50 mg 10 ml"
11359857|NCT02301897|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
11359858|NCT02301897|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
11359859|NCT02301897|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
11359860|NCT02301884|Experimental|Allergen extract|"Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.
~Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection"
11359861|NCT02301871|Active Comparator|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
11359862|NCT02301871|Experimental|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
11359863|NCT02301871|Experimental|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
11359864|NCT02301858|Other|Study arm|Genome analysis of tissue samples.
11359865|NCT02301845|Experimental|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
11359866|NCT02301819|Active Comparator|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
11359867|NCT02301819|Active Comparator|Conservative|Early conservative therapy according to standard practice
11359868|NCT02301806|Experimental|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
11359869|NCT02301806|Active Comparator|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
11359870|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.
~Intervention: Nurse education in contemporary format"
11359871|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.
~Intervention: Nurse education in traditional format"
11359872|NCT02301780|Placebo Comparator|Control Group|Placebo
11359873|NCT02301780|Active Comparator|Intervention Group|Aspirin
11359874|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
11359875|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
11359876|NCT02301754|Experimental|INVAC-1|"INVAC-1 at escalating doses of 100, 400 and 800 µg will be given as a single agent by intradermal injection (Q 4 weeks x 3 cycles), always combined with electroporation.
~Each patient will receive 3 cycles, unless motivated treatment interruption."
11359877|NCT02301741|Experimental|Game Condition|Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
11359878|NCT02301741|No Intervention|Control Condition|Participants in the CONTROL condition will complete baseline and post-test standardized reaching tasks, but will not play the game in the intervening three days.
11359879|NCT02301715|Active Comparator|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
11361328|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
11359880|NCT02301715|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
11359881|NCT02301702|Experimental|Tdap Vaccine|Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
11359882|NCT02301702|Active Comparator|Td Vaccine|Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
11359883|NCT02301689||Heart Failure patients|
11359884|NCT02301676|Active Comparator|General anesthesia & Control|"After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention Korean version of telephone interview for cognitive status (TICS). The test will be administered to spouse simultaneously by telephone."
11359885|NCT02301676|Active Comparator|Sevoflurane & Propofol & Dexmedetomidine|The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
11359886|NCT02301663|Experimental|Women w/microvascular disease|10 women with microvascular disease
11359887|NCT02301663|Experimental|Normal controls|10 age-matched women with no evidence of microvascular disease
11359888|NCT02301663|Experimental|calibration|10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
11359889|NCT02301650||group A|The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
11359890|NCT02301650||group B|The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
11359891|NCT02301650||group C|The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
11359892|NCT02301650||group D|The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy
11359893|NCT02301624|Experimental|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams [mg]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.
~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.
~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
11359894|NCT02301624|Experimental|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.
~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.
~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
11359895|NCT02301611|Experimental|Treatment|autologous TLPLDC (active vaccine)
11359896|NCT02301611|Placebo Comparator|Placebo|unloaded YCWP + autologous DC (control)
11359897|NCT02301598|Experimental|FS-ALK|Femtosecond laser-assisted maximum thickness anterior lamellar keratoplasty (FS-ALK) was performed for 11 eyes of 11 patients with advanced keratoconus and 2 eyes of 2 patients with superficial corneal scattering.
11359898|NCT02301585|Experimental|Passive Leg Raising|Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
11359899|NCT02301585|Active Comparator|Standard of care|Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.
11359900|NCT02301572||Aggressive onset MS|Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
11359901|NCT02301559|Experimental|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
11359902|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
11359903|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
11359904|NCT02301533|Experimental|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
11359905|NCT02301533|Other|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
11359906|NCT02301507|Experimental|SMS (texting) Arm|texts received
11359907|NCT02301494|Experimental|Fluocinonide (Vanos) cream 0.1%|Fluocinonide (Vanos) cream 0.1% will be applied as currently approved by the FDA for treatment of corticosteroid responsive disorders of the skin. Treatment will continue for 4 months with a follow up at 6 and 12 months.
11359908|NCT02301494|Experimental|3.75% Imiquimod (Zyclara) Cream|3.75% Imiquimod (Zyclara) Cream will be used as currently labeled by the FDA for treatment of actinic keratoses. Treatment will continue for 4 months with follow up at 6 and 12 months.
11359909|NCT02301481|Experimental|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
11359910|NCT02301481|Active Comparator|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
11359936|NCT02301312|Experimental|POSS-PCU graft|POSS-PCU vascular graft will be used to create vascular access for dialysis.
11359965|NCT02301117|Experimental|Mild Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11359911|NCT02301468|Experimental|Dry needling|Dry needling (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained
11359912|NCT02301468|Experimental|Ischemic compression|Ischemic compression (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
11359913|NCT02301455|No Intervention|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
11359914|NCT02301455|Experimental|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
11359915|NCT02301455|No Intervention|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
11359916|NCT02301442|Experimental|Exercise + behaviour change intervention|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
11359917|NCT02301442|Active Comparator|Exercise + control education|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
11359918|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
11359919|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
11359920|NCT02301416|No Intervention|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
11359921|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
11359922|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
11359923|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
11359924|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
11359925|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
11359926|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
11359927|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
11359928|NCT02301351|Other|Graphic Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with FDA-approved graphic warning labels.
11359929|NCT02301351|Other|Text Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with standard text warning labels.
11359930|NCT02301338||Usual Care|"The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon
~The patient will answer questions on:
~Social support
~Quality of life"
11359931|NCT02301338||Phone Calls|"In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.
~The patient will answer questions on:
~Social support
~Quality of life"
11359932|NCT02301325|Other|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
11359933|NCT02301325|Other|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
11359934|NCT02301325|Other|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
11359935|NCT02301325|Other|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
11360209|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|
11359937|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
11359938|NCT02301286|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
11359939|NCT02301286|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
11359940|NCT02301273|Active Comparator|Usual Physiotherapy|Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
11359941|NCT02301273|Experimental|Enhanced Physiotherapy|Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
11359942|NCT02301260|Experimental|Speed of Processing Training (SPT)|SPT will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11359943|NCT02301260|Placebo Comparator|Placebo control group|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 sessions)
11359944|NCT02301247|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11359945|NCT02301247|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11359946|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
11359947|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
11359948|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
11359949|NCT02301221|Experimental|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
11359950|NCT02301208|Active Comparator|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
11359951|NCT02301208|Active Comparator|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
11359952|NCT02301208|Experimental|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
11359953|NCT02301208|Experimental|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
11359954|NCT02301195|Experimental|Therapeutic Horseback Riding|Ten-weekly one-hour manualized small group Therapeutic Horseback Riding intervention led by certified THR instructor.THR intervention taught riding and horsemanship skills.
11359955|NCT02301195|Active Comparator|Barn Activity Intervention|Ten-weekly one-hour manualized small group Barn Activity Intervention led by THR instructor, teaching horsemanship skills without horses present.
11359956|NCT02301182|Active Comparator|ADM X3-MoP Cup|THA: ADM dual-mobility hydroxyapatite coated cups with X3TM HXLPE liners on 28mm BIOLOX® delta femoral heads (Stryker) with femoral stems being 2nd generation Accolade stems of the taper lock type, proximal circumferential coated with a 50µm plasma-spray PureFix HA coating to aid the mechanical engagement in bone coating (Stryker)
11359957|NCT02301182|Active Comparator|CoC Cup|THA: CoC BIOLOX® delta-delta large-head single-mobility cementless fiber-mesh titanium coated acetabular system from Zimmer (Zimmer TrilogyIT cup/CLS spotorno stem) with a grit-blasted osteophilic titanium alloy CLS® Spotorno femoral stems (Zimmer) that has a three-dimensional wedge shape and sharpened ribs in the proximal region
11359958|NCT02301169|Active Comparator|T4P1001|
11359959|NCT02301169|Sham Comparator|Placebo|
11359960|NCT02301156|Experimental|Ublituximab + ibrutinib|"Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions
~Ibrutinib: Fixed oral daily dose"
11359961|NCT02301156|Active Comparator|Ibrutinib|- Ibrutinib: Fixed oral daily dose
11359962|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.
~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR
~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR
~Surgical intervention"
11359963|NCT02301130|Experimental|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.
~Part 1 (Dose Escalation Phase)
~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.
~Part 2 (Cohort Expansion Phase)
~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
11359964|NCT02301130|Experimental|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.
~Part 1 (Dose Escalation Phase)
~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.
~Part 2 (Cohort Expansion Phase)
~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
11360210|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|
11359966|NCT02301117|Experimental|Moderate Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11359967|NCT02301117|Experimental|Severe Renal Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
~The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts"
11359968|NCT02301117|Experimental|Normal Renal Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11359969|NCT02301104|Experimental|Mild Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11359970|NCT02301104|Experimental|Moderate Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11359971|NCT02301104|Experimental|Severe Hepatic Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
~The dose level of severe cohort, if enrolled, will be determined based on the Interim Assessment of mild and moderate cohorts."
11359972|NCT02301104|Experimental|Normal Hepatic Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
11359973|NCT02301091|Experimental|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
11359974|NCT02301091|Active Comparator|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
11359975|NCT02301078||Percutaneous Needle Aponeurotomy|Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
11359976|NCT02301078||Xiaflex|Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
11359977|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
11359978|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
11359979|NCT02301052|Placebo Comparator|placebo|placebo topical cream 2 cc twice daily for 3 weeks
11359980|NCT02301052|Active Comparator|Anti-hemorrhoid topical cream drug|Anti hemorrhoid topical cream as a standard drug 2 cc twice daily for 3 week
11359981|NCT02301052|Active Comparator|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
11359982|NCT02301039|Experimental|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
11359983|NCT02301039|Experimental|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
11359984|NCT02301039|Experimental|Expansion|Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
11359985|NCT02301013|Experimental|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
11359986|NCT02301000|Experimental|Intestinal microbiota therapy|The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
11359987|NCT02301000|Active Comparator|Metronidazole|The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
11359988|NCT02300987|Active Comparator|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
11359989|NCT02300987|Placebo Comparator|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
11359990|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
11359991|NCT02300948|Experimental|PregVit-Folic 5®-5 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
11359992|NCT02300948|Active Comparator|PregVit®-1.1 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit® contains 1.1 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
11359993|NCT02300935|Experimental|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
11359994|NCT02300922|Experimental|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:
~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
11359995|NCT02300909|Experimental|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
11359996|NCT02300909|Other|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
11361329|NCT02291588|Experimental|AMG 811|AMG 811 administered as subcutaneous and intravenous doses
11359997|NCT02300896|Experimental|Intervention|Group-based exercise training during hospitalization Procedure: Exercise training. Individual program training 5 days a week during hospitalization
11359998|NCT02300896|No Intervention|Control|Usual care including rehabilitation when necessary
11359999|NCT02300883||no treatment|no treatment
11360000|NCT02300870||Heart Transplant Rejection|Patients presenting with acute cellular rejection
11360001|NCT02300870||Heart Transplant Control|Patients presenting for routine office visit
11360002|NCT02300857|Active Comparator|Low carbohydrate diet|
11360003|NCT02300857|Active Comparator|Moderate carbohydrate diet|
11360004|NCT02300857|Active Comparator|High carbohydrate diet|
11360005|NCT02300844|Experimental|NNC0174-0833 10 mg/mL|
11360006|NCT02300844|Placebo Comparator|Placebo|
11360007|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
11360008|NCT02300818|Active Comparator|Pulsed Electromagnetic Field Therapy|"Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
~PEMF has also proved to be beneficial in vision acuity of patients with low vision. In 50 per cent of the cases, values improved. Patients with vision acuity of 0.2 diopters showed improvement from 46 before treatment to 75 after treatment.
~Different studies on varied diseases have proved that Pulsed Electromagnetic Field Therapy (PEMF) treatment is a safe, non-invasive and effective option for curing ocular conditions."
11360009|NCT02300818|Active Comparator|Seawater eyedrops|instantly soothes and clears the eye irritation caused by pollution, pollen, smoke, etc. It is a very practical system for eye daily hygiene · enables efficient therapeutic help in basic eye conditions such as: · · internal and external stye blepharitis and keratoconjunctivitis · · Conjuntiviti Episcleritis and scleritis
11360010|NCT02300792|Active Comparator|honey|Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
11360011|NCT02300792|Placebo Comparator|molasses|Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
11360012|NCT02300779|Experimental|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
11360013|NCT02300779|Active Comparator|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
11360014|NCT02300766||Posterior fossa tumor patients|Children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th ventricle/brainstem ) requiring surgery or open biopsy at one of the participating centres.
11360015|NCT02300740|Experimental|low dose|500 mg nicotinamide riboside oral
11360016|NCT02300740|Experimental|high dose|1000 mg nicotinamide riboside oral
11360017|NCT02300727|Active Comparator|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.
~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
11360018|NCT02300727|Experimental|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
11360019|NCT02300727|Other|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).
~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
11360020|NCT02300714|Active Comparator|AP group|oblique view approach during transforaminal epidural block
11360021|NCT02300714|Active Comparator|OB group|oblique view approach during transforaminal epidural block
11360022|NCT02300701|Experimental|Xolair/Omalizumab|
11360023|NCT02300701|Placebo Comparator|Placebo|
11360024|NCT02300688|Experimental|Arm 1|Period 1 (Treatment A) - Wash out - Period 2 (Treatment B)
11360025|NCT02300688|Experimental|Arm 2|Period 1 (Treatment B) - Wash out - Period 2 (Treatment A)
11360026|NCT02300675|No Intervention|control arm|Patients follow the classic support prescription of hormonotherapy
11360027|NCT02300675|Experimental|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
11360028|NCT02300662|Experimental|Cycle Ergometer|Conventional physiotherapy and cycle ergometer 20 minutes, at 20 cycles per minute, once per day for as long as they remain on invasive mechanical ventilation
11360029|NCT02300662|Sham Comparator|Conventional Physiotherapy|Upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method and manual bronchial hygiene exercises.
11360030|NCT02300649|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
11360031|NCT02300649|Placebo Comparator|Control group|Saline will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
11360032|NCT02300636|Experimental|Training: open kinetic|"Co-contraction training in open kinetic chain position
~8 weeks, 3 days in a week"
11360033|NCT02300636|Experimental|Training: closed kinetic|"Co-contraction training in closed kinetic chain position
~8 weeks, 3 days in a week"
11360034|NCT02300636|Active Comparator|Training: Standard ACL rehabilitation|"Standard ACL rehabilitation
~8 weeks, 3 days in a week"
11360035|NCT02300623|Active Comparator|Control|Antiretroviral therapy alone
11360036|NCT02300623|Experimental|Treatment|Antiretroviral therapy plus Interleukin-2'
11360037|NCT02300610|Experimental|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
11361330|NCT02291588|Placebo Comparator|Placebo|No active drug
11360038|NCT02300610|Experimental|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
11360039|NCT02300597|Experimental|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
11360040|NCT02300597|No Intervention|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
11360041|NCT02300584|Experimental|Prototype Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
11360042|NCT02300584|Experimental|Field Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Based on the feedback from the prototype program, the videos may vary. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
11360043|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
11360044|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
11360045|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
11360046|NCT02300532||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
11360047|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
11360048|NCT02300506||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg, and enrolled in study GLI01S.
11360049|NCT02300493|Experimental|Experimental|weigh themselves daily
11360050|NCT02300493|Active Comparator|Control|Weigh themselves every six months
11360051|NCT02300480|Experimental|CTB group|Participants in this group will receive a single injection for calot's triangle block combined with PCIA post-operatively. CTB will be conducted by bile duct needle and 1.0% 10 ml ropivacaine will be injection in calot's triangle when before surgical dissection.Participants in this group will also receive PCIA after surgery,the regimens of PCIA are included tramadol 800 mg, flurbiprofenaxetil 100 mg with normal saline added up to a volume of 80 ml in total.
11360052|NCT02300480|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with normal saline added up to a volume of 80ml in total ) .The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
11360053|NCT02300467|Experimental|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
11360054|NCT02300454|Active Comparator|Non-slip element balloon (NSE)|Lacrosse® NSE dilatation before use of SeQuent® Please drug coated balloon (DCB)
11360055|NCT02300454|Placebo Comparator|Balloon|Non-compliant balloon dilatation before use of SeQuent® Please drug coated balloon (DCB)
11360056|NCT02300428||1-year cohort|"Patients with at least 1 prescription of any oral iron preparation in the last 2 years and who have at least 1 year of follow up data post-prescription.
~It is anticipated that ca. 123,000 patients in CPRD fulfil this criteria."
11360057|NCT02300428||10-year cohort|"All pre-menopausal women (18-45 years old) with at least 1 prescription of one ferrous iron salt (i.e. sulphate, fumarate and gluconate) since January 2000.
~It is anticipated that ca. 299,000 patients in CPRD fulfil this criteria."
11360058|NCT02300415||patient with sepsis|Patients admitted to the emergency department and with criteria of sepsis.
11360059|NCT02300389|Experimental|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
11360060|NCT02300389|Active Comparator|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
11360061|NCT02300376|Experimental|Calcium edetate de sodium versus inulin|The designing a Bayesian model of the plasma clearance of Calcium edetate de sodium is compared to the renal clearance of Inulin.
11360062|NCT02300363|Experimental|Treatment A|10 mg oral rosuvastatin administration
11360063|NCT02300363|Experimental|Treatment B|400 mg oral LX4211 qd administration
11360064|NCT02300363|Experimental|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
11360065|NCT02300350|Experimental|Treatment A|0.5 mg single-dose oral digoxin administration
11360066|NCT02300350|Experimental|Treatment B|400 mg oral LX4211 qd administration
11361429|NCT02290990|Experimental|Multiple Sclerosis patients|Patients with MS
11360067|NCT02300350|Experimental|Treatment C|0.5 mg single-dose oral digoxin administration + 400 mg oral LX4211 qd administration
11360068|NCT02300337|Experimental|Reduce Cuff Pressure|Cuff Pressure difference between inspiration and expiration is measured.
11360069|NCT02300324|Experimental|Standard v Beneforte v Beneforte Extra|This is a randomized, double-blinded, three-phase crossover trial investigating the bioavailability of SF following consumption of three types of broccoli + stilton soup containing different concentrations of glucoraphanin. The three types of soup are standard broccoli and stilton soup, beneforte broccoli and stilton soup, and beneforte extra broccoli and stilton soup.
11360070|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
11360071|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
11360072|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
11360073|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
11360074|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
11360075|NCT02300272||Typically healthy older adults|Adults 65 years and older with only common late-life medical conditions who will complete a screening that includes a Polysomnograph and assessment that includes Actiwatch.
11360076|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
11360077|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
11360078|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
11360079|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
11360080|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
11360081|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
11360082|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
11360083|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
11360084|NCT02300246|Experimental|Test Group|Alveolar socket post-extraction covered with PRF
11360085|NCT02300246|No Intervention|Control Group|Only clot (spontaneous healing)
11360086|NCT02300233|Active Comparator|volanesorsen|
11360087|NCT02300233|Placebo Comparator|Placebo|
11360088|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
11360089|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
11360090|NCT02300207|No Intervention|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
11360091|NCT02300207|Experimental|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
11360092|NCT02300194|Active Comparator|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
11360093|NCT02300194|Placebo Comparator|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
11360094|NCT02300181|Placebo Comparator|Placebo (flour)|5 placebo capsules for each test (4.88 kcal/5 cap)
11360095|NCT02300181|Experimental|Bacillus subtilis var natto DC-15|5 experimental capsules for each test (4.96 kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
11360096|NCT02300155|Experimental|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
11360097|NCT02300155|Active Comparator|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
11360098|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
11360099|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
11360100|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
11360101|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
11360102|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
11361430|NCT02290990|Experimental|Insomnia patients|Patients with insomnia
11360103|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
11360104|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:
~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)
~Period 2 (cross-over design):
~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
11360105|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:
~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
~Period 2 (cross-over design):
~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
11360106|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:
~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
~Period 2 (cross-over design):
~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
11360107|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:
~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
~Period 2 (cross-over design):
~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
11360108|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
11360109|NCT02300090||Intervention group|This group of patients (n=250) will receive the digital service (smart phone application and bluetooth inhaler device) in addition to current best care from their healthcare professional.
11360110|NCT02300090||Control group|This group of patients (n=250) will receive current best care alone. Control patients will not have access to the digital service.
11360111|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
11360112|NCT02300077|Active Comparator|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
11360113|NCT02300077|Active Comparator|Treatment methadone 0.15 mg/kg|
11360114|NCT02300064|Experimental|Healthy volunteers|Healthy volunteers will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
11360115|NCT02300064|Experimental|COPD patients|Patients with Chronic Obstructive Pulmonary Disease (COPD) will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
11360116|NCT02300051|Experimental|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
11360117|NCT02300051|Active Comparator|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
11360118|NCT02300051|Experimental|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
11360119|NCT02300038|Active Comparator|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
11360120|NCT02300038|Placebo Comparator|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
11360121|NCT02300025|Experimental|Cohort 1: Normal function|
11360122|NCT02300025|Experimental|Cohort 2: Mild Hepatic Impairment|
11360123|NCT02300025|Experimental|Cohort 3: Moderate Hepatic Impairment|
11360124|NCT02300025|Experimental|Cohort 4: Severe Hepatic Impairment|
11360125|NCT02300012|No Intervention|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
11360126|NCT02300012|Experimental|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
11360127|NCT02300012|No Intervention|Non-operation|Patients with ACL rupture not requiring operation
11360128|NCT02300012|No Intervention|Control|Healthy age matched volunteers - No operation
11360129|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
11360211|NCT02299492|Experimental|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
11360130|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
11360131|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
11360132|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
11360133|NCT02299986||Single arm Ultrasound measurement|Ultrasound measurement
11360134|NCT02299973|Placebo Comparator|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
11360135|NCT02299973|Experimental|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
11360136|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
11360137|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
11360138|NCT02299960||AH|patients with hypertension
11360139|NCT02299960||Nephropathy|patients with diabetic nephropathy
11360140|NCT02299947|Experimental|Haemocomplettan P|Study patients that receive Haemocomplettan P
11360141|NCT02299947|Placebo Comparator|NaCl 0.9%|Study patients that receive NaCl 0.9%
11360142|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
11360143|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
11360144|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
11360145|NCT02299908|Experimental|TAP block with Bupivacaine at 0.25%|Intervention: Injection of local anesthetics in the transverses abdominal plane
11360146|NCT02299908|Placebo Comparator|Placebo saline solution|Placebo: Injection of saline solution in the transverses abdominal plane
11360147|NCT02299882|Experimental|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
11360148|NCT02299882|No Intervention|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
11360149|NCT02299869|Other|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
11360150|NCT02299869|Other|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
11360151|NCT02299869|Other|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
11360152|NCT02299869|Other|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
11360153|NCT02299856||Myocarditis|Patients with strong clinical evidence for acute myocarditis (recent infection, elevated troponin and white blood cell count).
11360154|NCT02299856||Healthy Controls|Healthy volunteers without any signs of cardiac disease.
11360155|NCT02299843|Active Comparator|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
11360156|NCT02299843|Experimental|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
11360157|NCT02299830|Experimental|cryotherapy|give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
11360158|NCT02299830|Experimental|argon plasma coagulation|give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
11360159|NCT02299830|Experimental|stent|give the cases whose central airway stricture were caused by neoplasm compression stent placement
11360160|NCT02299830|Experimental|snare|give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
11360161|NCT02299817|Active Comparator|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
11360162|NCT02299817|Placebo Comparator|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
11360163|NCT02299804|Experimental|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
11360164|NCT02299804|Experimental|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
11360165|NCT02299804|Placebo Comparator|Placebo arm|Have no any active component
11360166|NCT02299791|Active Comparator|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
11360167|NCT02299791|Active Comparator|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
11360168|NCT02299778|Experimental|1mg of 13C6-p-aminobenzoic acid|
11360169|NCT02299765|Experimental|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.
~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
11360170|NCT02299765|Active Comparator|Arm B|Gefitinib 250mg/d until disease progression
11360171|NCT02299752|Experimental|Catheterization|Blood vessel Catheterization during resuscitation with single and double - gloving system. Catheterization was performed using simulation mannikin
11360172|NCT02299726|Experimental|Active|spironolactone
11360173|NCT02299726|Placebo Comparator|Placebo|matching placebo to active study drug
11360174|NCT02299713|Sham Comparator|placebo/sham acupuncture|There are different types of controls used in acupuncture trials. We used the control described as sham and by some as minimal acupuncture. This group had the same schedule as the electro-acupuncture group. Sham acupuncture was administered, with the same duration and frequency and by the same specialist who performed the non-sham acupuncture. Retractable needles were placed into small adhesive cylinders, so that the needles were supported but did not perforate the skin. The acupuncturist placed the needles at the same points as the non-sham group and used the same pairs of electrodes to simulate the electrical connection.
11360175|NCT02299713|Active Comparator|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat knee pain. The points selected were local points St 34, St 35, St 36,Liv 8, Sp 10. One distal point St 44.A total of six needles were inserted into each leg by the acupuncturist (the out come measures were not specifically targeted to whether the patient had one or both knees involved). All patients belonging to this group experienced a De Qi sensation, which is a tingling and numbness sensation upon needling of specific points.
11360176|NCT02299700||Autism Spectrum Disorder (ASD) Participants (6-9 years)|Participants with ASD aged 6 to 9 years will be observed for the usability of the Janssen Autism Knowledge Engine (JAKE) personal healthcare record (pHR) and biosensors in stage 1 and stage 2 (at laboratory sites).
11360177|NCT02299700||ASD Participants (13-17 years)|Participants with ASD aged 13 to 17 years will be observed for the usability of the JAKE pHR and biosensors in stage 1 and stage 2 (at laboratory sites).
11360178|NCT02299700||ASD Participants (3 or greater than 3 years)|Participants with ASD aged 3 or greater than 3 years will be observed for the usability of the JAKE pHR and biosensors in stage 2 (at clinical sites).
11360179|NCT02299687|Experimental|CYP2C19 EM|CYP2C19 EM
11360180|NCT02299687|Experimental|CYP2C19 IM|CYP2C19 IM
11360181|NCT02299687|Experimental|CYP2C19 PM|CYP2C19 PM
11360182|NCT02299674||Persons with unilateral transfemoral amputation|
11360183|NCT02299661|Experimental|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
11360184|NCT02299661|Experimental|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
11360185|NCT02299661|Experimental|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
11360186|NCT02299648|Other|Single arm|molecular profiling, patient derived cells
11360187|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
11360188|NCT02299609|Active Comparator|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
11360189|NCT02299609|Sham Comparator|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
11360190|NCT02299596|Experimental|Pre and postoperative exercise|"The intervention is prehabilitation preoperatively and physical training postoperatively. During the hospital stay both groups will be treated in the same manner.
~Preoperative intervention:
~One half hour of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.
~Inspiratory muscle training. Thirty breaths x two twice daily. Postoperative intervention is mainly the same as preoperatively."
11360191|NCT02299596|No Intervention|Control|Standard treatment with one exception, patients will fill in a physical activity diary
11360192|NCT02299583|Experimental|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
11360193|NCT02299583|No Intervention|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
11360194|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
11360195|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
11360196|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
11360197|NCT02299557|Experimental|Treatment|Intra-anal Oxymetazoline gel once daily
11360198|NCT02299557|Placebo Comparator|Placebo|Intra-anal Placebo gel once daily
11360199|NCT02299544|Experimental|OAB|"Patients with overactive bladder (OAB) with or without urge incontinence.
~Two patient populations will be enrolled in the study:
~Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) [de novo patient group] and Patients with a documented success on PTNS therapy [prior-PTNS group]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review.
~All patients will be treated with BlueWind Medical System."
11360200|NCT02299531|Experimental|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
11360201|NCT02299531|Experimental|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
11360202|NCT02299531|Experimental|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
11360203|NCT02299531|Experimental|High Energy Density, Small Portions|High meal energy density and small portion sizes
11360204|NCT02299531|Experimental|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
11360205|NCT02299531|Experimental|High Energy Density, Large Portions|High meal energy density and large portion sizes
11360206|NCT02299518|Experimental|Cohort A (mitoxantrone, etoposide, cytarabine, selinexor)|Patients receive mitoxantrone hydrochloride IV, etoposide IV, and cytarabine IV QD on days 1-6 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment continues for 1 course (28 days). Further treatment is based on disease response. Patients achieving CR/CRi are evaluated for stem cell transplant; patients who do not proceed to transplant may receive selinexor as monotherapy in the absence of disease progression or unacceptable toxicity.
11360207|NCT02299518|Experimental|Cohort B (etoposide, selinexor)|Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
11360208|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|
11360212|NCT02299492|No Intervention|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
11360213|NCT02299479|Experimental|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
11360214|NCT02299453|Experimental|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
11360215|NCT02299453|No Intervention|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
11360216|NCT02299440|Experimental|Ketamine|"Patients randomized to this group will be treated via Ketamine infusion.
~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions"
11360217|NCT02299440|Placebo Comparator|Placebo/Control|"Patients randomized to this group will be treated via saline solution infusion.
~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions"
11360218|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
11360219|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
11360220|NCT02299414|Experimental|Anti-hypertensive therapy to goal <140/90 mmHg|Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
11360221|NCT02299414|Active Comparator|No anti-hypertensive unless BP is severe (≥160/105 mmHg|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used
11360222|NCT02299401|Experimental|Buccal|Women randomized to receive three 800 mcg doses of misoprostol taken buccally in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
11360223|NCT02299401|Experimental|Sublingual|Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
11360224|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
11360225|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
11360226|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
11360227|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
11360228|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
11360229|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
11360230|NCT02299336|Other|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
11360231|NCT02299310|Experimental|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
11360232|NCT02299310|Active Comparator|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
11360233|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
11360234|NCT02299284|Experimental|Hand-Arm Bimanual Intensive Therapy (HABIT)|HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
11360235|NCT02299284|Experimental|Intensive Functional Lower-Limb Training|lower-limb function, strength training, balance, PT, OT, rehab
11360236|NCT02299271|Active Comparator|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
11360237|NCT02299271|Placebo Comparator|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
11360238|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
11360239|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
11360241|NCT02299245|Active Comparator|randomised to rosuvastatin (10mg/d)|randomised to rosuvastatin (10mg/d)
11360242|NCT02299232|Active Comparator|dexmedetomidine 3mcg/kg|dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
11360243|NCT02299232|Active Comparator|dexmedetomidine 4mcg/kg|dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI
11360244|NCT02299219|Experimental|Taking Charge Experimental Group|
11360245|NCT02299219|Active Comparator|Control Group|
11360246|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
11360247|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
11360248|NCT02299193|Experimental|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
11360249|NCT02299193|Sham Comparator|Healthy Sleep Habits|online sessions about healthy sleep practices
11360250|NCT02299180|No Intervention|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
11360251|NCT02299180|Experimental|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
11360252|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
11360253|NCT02299154|Experimental|Patient with memory disorders|psychological questionnaires
11360254|NCT02299154|Experimental|Accompanier|psychological questionnaires
11360255|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle
11360256|NCT02299128|Sham Comparator|Minimally Therapeutic Treatment|Non-differential, prescriptive protocol of physical therapy treatment with minimal to no therapeutic benefit.
11360257|NCT02299128|Experimental|Skilled Treatment|Differential treatment based on the results from the assessment. Physical Therapy treatment in this arm will be pragmatically designed and modified by the treating therapist. Treatments will include manual therapy to the cervical spine, neuromotor retraining (position sense and movement sense), habituation and adaptation exercises.
11360258|NCT02299115|Experimental|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
11360259|NCT02299115|Active Comparator|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
11360260|NCT02299102|Other|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
11360261|NCT02299102|Other|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
11360262|NCT02299089|Experimental|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
11360263|NCT02299089|Experimental|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
11360264|NCT02299089|Experimental|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
11360265|NCT02299089|Experimental|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
11360266|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
11360267|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
11360268|NCT02299063|Placebo Comparator|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
11360269|NCT02299063|Experimental|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
11360270|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day
~Other Names:
~Bromocriptine Mesylate Quick Release"
11360271|NCT02299024|No Intervention|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
11360272|NCT02299024|Experimental|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
11360273|NCT02299011|Experimental|Orsiro drug eluting stent|Orsiro drug eluting stent
11360274|NCT02299011|Active Comparator|Biomatrix drug eluting stent|Biomatrix drug eluting stent
11360275|NCT02298998||Intervention|The intervention group refers to surveillance based on the EAU guidelines.
11360276|NCT02298998||Control|The control group refers to surveillance based on the AUA guidelines.
11360277|NCT02298985|Active Comparator|curcumin|curcumin 3 g/day for 6 months
11360278|NCT02298985|Placebo Comparator|placebo|curcumin 3 g/day for 6 months
11360279|NCT02298972|No Intervention|Comparison group|The comparison group will receive standard care.
11360315|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
11360280|NCT02298972|Active Comparator|Intervention group|After completion of the comparison group, new patients starting chemotherapy treatment will be offered this study. Study participants will receive the nurse support and selfmanagement intervention.
11360281|NCT02298959|Experimental|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab IV over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Cycles repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11360282|NCT02298946|Experimental|DL1 - CTX, SBRTx1 day, & AMP-224|Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses
11360283|NCT02298946|Experimental|DL2 - CTX, SBRTx3 days, and AMP-224|Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
11360284|NCT02298933|Experimental|Eculizumab|1200 mg IV infusion over 30-40 min
11360285|NCT02298920|Experimental|Single Group|Open Label ADME Study
11360286|NCT02298881||Dry eye group|People with dry eye symptoms
11360287|NCT02298881||Non-dry eye group|People with no dry eye symptoms
11360288|NCT02298868|Experimental|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
11360289|NCT02298855|No Intervention|Conventional follow-up|Treatment as usual will involve: one post treatment appointment then 3 monthly appointments with a Dr. At appointments: medical history; investigations to monitor disease progression including CA125 tumour marker blood test if this were raised at diagnosis. A physical examination may be performed.
11360290|NCT02298855|Experimental|Individualised follow-up|Follow-up is delivered by a nurse and frequency and type (telephone or face-to-face) is negotiated to suit their individual situation. Assessment by holistic guide. The intervention is informed by a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to help patients manage symptoms and psychological discomfort.
11360291|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
11360292|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
11360293|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
11360294|NCT02298816||new B-Cell Hematologic Malignancy diagnosis|All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).
11360295|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
11360296|NCT02298790|Experimental|Early Meals|Meals are eaten early in the wake episode
11360297|NCT02298790|Experimental|Late Meals|Meals are eaten late in the wake episode
11360298|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)
~Biological samples (skin, urine and blood):
~1st point at patient's inclusion visit
~2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
11360299|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
11360300|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
11360301|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
11360302|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)
~Biological samples (skin, urine and blood):
~- 1single point at patient's inclusion visit"
11360303|NCT02298764|Active Comparator|standard + 10 psychotherapeutic sessions|- standard back pain treatment plus 10 psychotherapeutic sessions, that will include the shock-trauma method 'Somatic Experiencing'.
11360304|NCT02298764|Active Comparator|Standard back pain treatment|Standard back pain treatment
11360305|NCT02298751|Experimental|CET via smartphone|Cue Exposure Treatment
11360306|NCT02298751|Experimental|CET via group sessions|Cue Exposure Treatment
11360307|NCT02298751|No Intervention|Aftercare as usual|
11360308|NCT02298738||New onset Atrial fibrillation|New-onset AF was defined as patients with hypertension and atrial fibrillation which was identified for the first time by an electrocardiogram or ambulatory holter monitoring.
11360309|NCT02298738||control|Hypertensive patients without atrial fibrillation.
11360310|NCT02298725|Experimental|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
11360311|NCT02298725|Experimental|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
11360312|NCT02298712||Observation|Patients with Hurler disease or high-grade suspicion for Hurler disease
11360313|NCT02298699||Observation|Patients with Sly disease or high-grade suspicion for Sly disease
11360314|NCT02298686||Observation|Patients with Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease
11360316|NCT02298660|Experimental|BOTOX|BOTOX® Total dose per patient: 200U Number of cycles:1 cycle Treatments will be conducted according to established protocol, 200 BOTOX® units with intradetrusor injections under cystoscopic guided injections into 20 sites, trigone sparing. One month later, urodynamics with continuous arterial blood pressure and electrocardiogram measurements will be repeated, as well as 24 hour ambulatory blood pressure monitoring. AD- HR QoL and I-QOL questionnaires will be administered to evaluate the effect of Botox on AD HR-QoL and bladder-related QoL.
11360317|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
11360318|NCT02298634||Observation|Patients with Farber disease or high-grade suspicion for Farber disease
11360319|NCT02298621|Experimental|pomegranate juice|pomegranate juice: 500 ml
11360320|NCT02298621|Placebo Comparator|placebo|sugar + aroma+ color: 500ml
11360321|NCT02298608|Experimental|Irreversible Electroporation|Percutaneous, CT guided, Irreversible Electroporation of renal mass
11360322|NCT02298595|Experimental|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
11360323|NCT02298595|Experimental|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
11360324|NCT02298595|Experimental|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
11360325|NCT02298582|Experimental|Intranasal fentanyl|
11360326|NCT02298569|No Intervention|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
11360327|NCT02298569|Experimental|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
11360328|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
11360329|NCT02298543||coronary spasm|
11360330|NCT02298530|Experimental|Combination of caffeine and theanine|250 mg caffeine + 200 mg theanine
11360331|NCT02298530|Placebo Comparator|Caffeine|250 mg caffeine
11360332|NCT02298517|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
11360333|NCT02298517|Experimental|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
11360334|NCT02298517|Experimental|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
11360335|NCT02298517|Experimental|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
11360336|NCT02298517|Experimental|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
11360337|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
11360338|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
11360339|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
11360340|NCT02298491|Experimental|H.P. Acthar Gel|
11360341|NCT02298478|Experimental|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
11360342|NCT02298478|Experimental|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
11360343|NCT02298478|Other|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.
~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
11360344|NCT02298465|Active Comparator|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
11360345|NCT02298465|Experimental|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
11360346|NCT02298452|Other|Hearing aid|172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.
11360347|NCT02298426|Experimental|health management and product|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
11360348|NCT02298426|Experimental|general management and product|"We provide general information about health. Information is provided through telephones and materials.
~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
11360349|NCT02298426|Experimental|health management and placebo|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
~Meanwhile, we use placebo to replace the dietary supplement products."
11360350|NCT02298426|Placebo Comparator|general management and placebo|"We provide general information about health. Information is provided through telephones and materials.
~Meanwhile, we use placebo to replace the dietary supplement products."
11360351|NCT02298400|Active Comparator|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
11360352|NCT02298400|Active Comparator|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
11360353|NCT02298400|Active Comparator|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
11360354|NCT02298387|Experimental|OMP-305B83|The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
11360355|NCT02298374|Experimental|Homecare reablement|Receives comprehensive assessment and individualized follow-up according to a plan with short and longterm goals.
11360356|NCT02298374|Active Comparator|Usual care|Receives normal care
11360357|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
11360358|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
11360359|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
11360360|NCT02298348|Other|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
11360361|NCT02298335|Experimental|prednisone|First,full-dose induction period, then protracted tapering period.
11360362|NCT02298322|Experimental|CoolSculpting Treatment|The intervention is the CoolSculpting System.
11360363|NCT02298309|No Intervention|Usual Care|Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa
11360364|NCT02298309|Active Comparator|Test-and-Treat Intervention|Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.
11360365|NCT02298296||No treatment|
11360366|NCT02298283|Experimental|study treatment|"induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks
~radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks
~Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
11360367|NCT02298270|Experimental|Relaxation Response Resiliency Program|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
11360368|NCT02298270|Placebo Comparator|Health Education|Participants will receive and 8-week general stress and health education program, with none of the active relaxation and resiliency-based components being tested in the experimental condition.
11360369|NCT02298257|Experimental|Treatment (BV + combination chemotherapy)|Patients receive doxorubicin hydrochloride given IV , vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11360370|NCT02298244|Active Comparator|PV isolation + GP Ablation|
11360371|NCT02298244|Active Comparator|PV isolation + GP ablation + Pulmonary GP ablation|
11360372|NCT02298231|Experimental|Group 1|Standard of Care Balance (SCB) Treatment
11360373|NCT02298231|Experimental|Group 2|Mystic Isle (MI) Balance Training
11360374|NCT02298231|Experimental|Group 3|Mystic Isle (MI) Dual Task Training
11360375|NCT02298218|Experimental|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
11360376|NCT02298218|No Intervention|No intervention|During 6 months, without meloxicam, the maintenance will be decided by the comparison of liver stiffness score comparing the intervention group.
11360377|NCT02298205|Other|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
11360378|NCT02298205|Active Comparator|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
11360379|NCT02298192|Experimental|Once weekly titration|
11360380|NCT02298192|Experimental|Twice weekly titration|
11360381|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
11360382|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
11360383|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
11360410|NCT02298036|No Intervention|Treatment as Usual|Participants do not receive remote therapy and remain in usual care
11360447|NCT02297750|Active Comparator|single wire technique|single wire technique in patients undergoing ERCP with biliary cannulation
11360384|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
11360385|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
11360386|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
11360387|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
11360388|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
11360389|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
11360390|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
11360391|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
11360392|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
11360393|NCT02298166|Placebo Comparator|Standard arm|chemotherapy (MC) in combination with placebo
11360394|NCT02298166|Experimental|Experimental arm|chemotherapy (MC) in combination with crenolanib
11360395|NCT02298153|Experimental|atezolizumab (MPDL3280A) + epacadostat (INCB024360)|atezolizumab (MPDL3280A) 1200 mg given every 3 weeks + epacadostat (INCB024360) 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
11360396|NCT02298140|Experimental|SMS reminders|This arm will receive automated mobile phone text message reminders for health workers in outpatient departments of public and private health facilities on issues related to care of malaria patients and suspected patients.
11360397|NCT02298127|Experimental|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
11360398|NCT02298127|Experimental|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
11360399|NCT02298127|Sham Comparator|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
11360400|NCT02298114|Experimental|neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine. The electrodes will be placed over the motor points of the following muscles: pectoral muscles (fibres of the pectoralis major muscle) and rectus abdominis muscles (bilaterally) The first training session will have a duration of 30 minutes , which will then be extended by 1 minute for every 2 days of administration. The intensity will be increased until muscle contraction is visible or palpable or, intensity will be adjusted according to tolerance associated conventional physiotherapy. Neuromuscular electrical stimulation will be applied held until extubation end conventional respiratory and motor physiotherapy until discharge from the ICU.
11360401|NCT02298114|Sham Comparator|Conventional physiotherapy|Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
11360402|NCT02298101|Active Comparator|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
11360403|NCT02298101|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
11360404|NCT02298088|Active Comparator|Ticagrelor 180 mg|Patients assigned to Ticagrelor will receive oral Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
11360405|NCT02298088|Active Comparator|Clopidogrel|"Patients will take the 300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.
~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
11360406|NCT02298062|Experimental|Infliximab|For one group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them infliximab (5mg/kg) once.
11360407|NCT02298062|Active Comparator|IVIG|For the other group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them IVIG (2g/kg) once.
11360408|NCT02298049|Other|Scanning|"Repeated measures:
~Satiation scan + Pre-meal scan
~All participants undertook both scans"
11360409|NCT02298036|Experimental|Remote Therapy Offered|Participants randomised to this arm receive 6-10 sessions of remote CBT
11360411|NCT02298023|Experimental|allogenic adipose stem cell treatment|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
11360412|NCT02298023|Placebo Comparator|Placebo Comparator (Fibrin glue) group|Normal saline 0.5cc + Fibrin glue 0.5cc + range of motion exercise
11360413|NCT02298023|No Intervention|Exercise comparator group|Normal saline 0.5cc + Normal saline 0.5cc + range of motion exercise
11360414|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
11360415|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
11360416|NCT02297997|Experimental|1.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 1.5mg will be taken daily for two weeks.
11360417|NCT02297997|Experimental|3mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 3mg will be taken daily for two weeks.
11360418|NCT02297997|Experimental|4.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 4.5mg will be taken daily for two weeks.
11360419|NCT02297997|Experimental|6mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 6mg will be taken daily for two weeks.
11360420|NCT02297997|Placebo Comparator|Control|Placebo will be taken daily for two weeks.
11360421|NCT02297984||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
11360422|NCT02297945|Experimental|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
11360423|NCT02297932|Experimental|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
11360424|NCT02297932|Active Comparator|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
11360425|NCT02297919|Experimental|web based intervention|Web based intervention: Students will have access to the educational content through the learning management system on the web site (genc-e-saglik) created for this project.
11360426|NCT02297919|Active Comparator|classic preprepared lesson|Training at the control group,lectures will be presented on the basis of the classic preprepared lesson by educator and at the end of the training, will be answered student's questions.
11360427|NCT02297906|Experimental|Intranasal ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intranasal route using a mucosal atomization device.
11360428|NCT02297906|Active Comparator|Intravenous ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
11360429|NCT02297893|Experimental|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
11360430|NCT02297893|Active Comparator|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
11360431|NCT02297880|Experimental|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners (flavour)
11360432|NCT02297880|Active Comparator|Still water|Still water (no flavour)
11360433|NCT02297867|Experimental|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
11360434|NCT02297854|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
11360435|NCT02297854|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
11360436|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
11360437|NCT02297828|Experimental|Boussignac CPAP|"Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
11360438|NCT02297828|Active Comparator|Ventury face mask|"Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
11360439|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
11360440|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
11360441|NCT02297789|Experimental|Headgear 1|Full Face Mask with Headgear 1
11360442|NCT02297789|Experimental|Headgear 2|Full Face Mask with Headgear 2
11360443|NCT02297776||CPC score 1 to 2|The patients with CPC score 1 to 2 judged half a year after cardiac arrest
11360444|NCT02297776||CPC scores 3 to 5|The patients with CPC score 3 to 5 judged half a year after cardiac arrest
11360445|NCT02297763|Active Comparator|quetiapine|quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
11360446|NCT02297763|Placebo Comparator|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
11360448|NCT02297750|Active Comparator|Double wire technique|double-wire technique in patients undergoing ERCP with biliary cannulation
11360449|NCT02297737|Experimental|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
11360450|NCT02297737|Active Comparator|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
11360451|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
11360452|NCT02297711|Experimental|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
11360453|NCT02297711|Active Comparator|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
11360454|NCT02297698|Experimental|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
11360455|NCT02297698|Active Comparator|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
11360456|NCT02297685|Sham Comparator|Sham Transcutaneous nerve stimulation|The group with sham TENS did not receive any current. Four surface electrodes (5×5 cm Prim-Trode®, Spain) were symmetrically placed over the L1 and L5 transverse processes with respect to the spine. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
11360457|NCT02297685|Experimental|Transcutaneous nerve stimulation|The group with TENS received current at a frequency of 80 Hz and with a pulse width of 150 μs with two channels, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
11360458|NCT02297685|Experimental|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
11360459|NCT02297672|Experimental|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
11360460|NCT02297659|Active Comparator|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
11360461|NCT02297659|Active Comparator|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
11360462|NCT02297646|Experimental|Carbohydrates|50 grams of carbohydrates 4 times a week for each training session
11360463|NCT02297646|Placebo Comparator|Control|no carbohydrate intake
11360464|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
11360465|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
11360466|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
11360467|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
11360468|NCT02297620||Suglat group|
11360469|NCT02297607|Experimental|Tube Feeding|Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
11360470|NCT02297607|No Intervention|Standard of Care|Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,
11360471|NCT02297594|Experimental|AK0529|Generic name: AK0529 Dosage Form: capsule
11360472|NCT02297594|Placebo Comparator|Placebo|Sugar placebo
11360502|NCT02297360|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
11360503|NCT02297334|Active Comparator|With CytoSorb device|Patients randomised to this arm are treated with the CytoSorb device during bypass.
11360504|NCT02297334|No Intervention|Withouot device|Patients randomised to this arm are treated without the CytoSorb device during bypass.
11360473|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center
~A GFC is defined as follows:
~General geriatrician or ortho-geriatrician available in trauma/orthopaedic department
~Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)
~Local medical guidelines, consented by orthopedic surgeons and geriatrician
~Pre-defined order set for assessing laboratory values
~Pre-defined patient pathway to guarantee a fast track in the emergency room
~Daily communication among involved specialists
~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):
~Daily patient visit by geriatrician
~Daily patient visit by orthopedic surgeon in combination with nurse
~Daily therapy by physiotherapists, except for weekends
~Access to social workers, if required"
11360474|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center
~A UCC is defined as follows:
~No geriatrician available in trauma/orthopaedic department
~No pre-operative visit by a geriatrician as a standard
~No pre-defined medical guidelines for geriatric fracture patients
~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):
~No daily patient visits by a geriatrician as a standard"
11360475|NCT02297568|Active Comparator|Calciferol,1800 IU/d supplement|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to 1,800 IU/d .
11360476|NCT02297568|Placebo Comparator|Placebo|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to receive placebo.
11360477|NCT02297555|No Intervention|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
11360478|NCT02297555|Experimental|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
11360479|NCT02297542|Active Comparator|Flu Vaccine SD|Fluzone Standard Dose Influenza Vaccine
11360480|NCT02297542|Active Comparator|Flu Vaccine HD|Fluzone High Dose Influenza Vaccine
11360481|NCT02297516|Experimental|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
11360482|NCT02297516|Experimental|Filler as single treatment|Filler as single treatment at initial treatment
11360483|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
11360484|NCT02297503|Experimental|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
11360485|NCT02297490|Placebo Comparator|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
11360486|NCT02297490|Experimental|Allergovit 6-grasses immunotherapy|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
11360487|NCT02297477|Active Comparator|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
11360488|NCT02297477|Active Comparator|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
11360489|NCT02297464|Experimental|Eggs - 2 per day for breakfast|Participants will consume 2 eggs per day for breakfast for 4 weeks of the study.
11360490|NCT02297464|Experimental|Oatmeal - 1 packet per day for breakfast|Participants will consume 1 packet of oatmeal per day for breakfast for 4 weeks of the study.
11360491|NCT02297451|No Intervention|Brachial artery inflow|Elbow fistula created with brachial artery as inflow (ie. either brachiocephalic or brachiobasilic fistulas)
11360492|NCT02297451|Active Comparator|Proximal radial/ulnar artery as inflow|Elbow fistula created with either proximal radial or ulnar artery as inflow
11360493|NCT02297438|Experimental|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
11360494|NCT02297438|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
11360495|NCT02297425|Experimental|Single agent - study drug|The study will evaluate single-agent PF-06459988
11360496|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11360497|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11360498|NCT02297399|Experimental|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
11360499|NCT02297399|Active Comparator|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
11360500|NCT02297386|Experimental|[18F] DIHYDRO-TESTOSTERONE PET|"The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely quantitative, that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass)."
11360501|NCT02297360|Active Comparator|Viviscal Extra-Strength Supplement|Viviscal Extra-strength tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
11360505|NCT02297321|Experimental|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
11360506|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
11360507|NCT02297295|Experimental|Physiotherapy|Comparing the patients to themselves (spontaneus evolution) before intervention.
11360508|NCT02297282|Experimental|Behavioural Activation|Originally a component of Cognitive Therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
11360509|NCT02297282|No Intervention|Wait List (Control Group)|The Control group (waitlist) will receive treatment as usual while they are waiting to start the BA intervention at the end of the Intervention Group Therapy time (28 sessions over an 18 week period). In addition to usual care, the control group will be assessed by clinical staff that offers treatment as usual for mood symptoms and quality of life measures during the waiting time.
11360510|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
11360511|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
11360512|NCT02297256|Active Comparator|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
11360513|NCT02297256|Active Comparator|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
11360514|NCT02297243|Experimental|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
11360515|NCT02297230|Experimental|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
11360516|NCT02297230|Experimental|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
11360517|NCT02297230|Experimental|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
11360518|NCT02297230|Experimental|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
11360519|NCT02297217|Experimental|Chemotherapy with Concurrent Radiation|Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
11360520|NCT02297204|Experimental|aflibercept|"2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.
~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.
~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
11360521|NCT02297191|Experimental|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.
~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
11360522|NCT02297178||Cystoscopy Alone|Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
11360523|NCT02297178||Cystoscopy & Urethral Dilatation|Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
11360524|NCT02297165|Experimental|Program|olfactory stimulation program
11360525|NCT02297165|No Intervention|Control|normal follow-up
11360526|NCT02297152|Other|FLIP HOLE|The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation
11360527|NCT02297139|Experimental|Dasatinib|This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
11360559|NCT02296918|Experimental|Double combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
11360528|NCT02297126|No Intervention|Control Arm|4,000 patients receiving a new prescription for targeted medication(s) randomized into the control arm receive standard care (no intervention affecting drug selection, dosage, dosage form, frequency and duration of therapy). Healthcare costs and adverse events data collected and analyzed for 12 months from time of entry into study. List of targeted medications: codeine, amitriptyline, aripiprazole, atazanavir, atomoxetine, azathioprine, citalopram, clopidogrel, cyclophosphamide, doxepin, efavirenz, escitalopram, esomeprazole, fluconazole, simvastatin, fluorouracil, phenytoin, quetiapine, glyburide, lansoprazole, mercaptopurine, methadone, methotrexate, nortriptyline, omeprazole, pantoprazole, rasburicase, tacrolimus, thioguanine, tramadol, venlafaxine, voriconazole and warfarin
11360529|NCT02297126|Experimental|Pharmacogenetic Intervention Arm|2,000 patients receiving new prescription for targeted medication(s) identified in the control arm will be randomized to the intervention arm, consented and a tests will be performed from a blood sample. The treating physicians will be provided with the pharmacogenetic information and will determine if intervention is appropriate. Physician may elect to stay the course of therapy or alter drug selection, dosage, dosage form, frequency or duration of therapy based on the pharmacogenetic test results and input from clinical pharmacology consultations (if requested). Patients in the intervention arm will have their overall healthcare costs and clinical outcomes (specifically adverse events) followed and analyzed for a 1 year period from the time that they are entered into the study
11360530|NCT02297113|Active Comparator|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
11360531|NCT02297113|Active Comparator|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
11360532|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
11360533|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
11360534|NCT02297087|Other|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
11360535|NCT02297074|Experimental|Ordinary White Bread|Ordinary white bread bread is characterised by a white crumb with regular soft alveoli and a slightly soft thin crust.
11360536|NCT02297074|Experimental|Precooked-Frozen White Bread|Precooked-Frozen white bread is characterized by white crumb with regular soft alveoli and bright crusty crust
11360537|NCT02297074|Experimental|Candeal-flour White Bread|Candeal-flour white bread has a thick crust of between one and two millimetres, which is smooth and crisp, golden to light brown in colour and which tastes of toasted cereal. The crumb of the bread is white and its texture is smooth, spongy and consistent, with little regular alveolus and with an intense cereal aroma with a pleasant and slightly sweet taste
11360538|NCT02297074|Experimental|Alfacar White Bread|Alfacar white bread is made according to its protected designation of origin and protected geographical indication (D.O. Alfacar, Granada, Spain). The bread has a creamy white, flexible and soft crumb, with many randomly scattered holes. The crust is medium-thick to thick, golden, slightly shiny and quite smooth
11360539|NCT02297074|Experimental|Organic Wholemeal Bread|The Organic wholemeal bread only includes organic whole grain flours as the unique difference compared with the Ordinary bread. The resulting dark brown bread is characterized by compact crumb free of alveoli and hard thin crust
11360540|NCT02297074|Active Comparator|Glucose|Glucose is used to calculate glycemic index, glycemic load and insulinemic index
11360541|NCT02297061||TEG group|200 consecutive hip fracture patients, Thrombelastography is performed on admission.
11360542|NCT02297048|Experimental|RU 486 (mifepristone)|Subjects will receive 400 mg once a day of RU486
11360543|NCT02297048|Placebo Comparator|Placebo|Subjects will receive placebo once a day
11360544|NCT02297035|Experimental|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
11360545|NCT02297035|Experimental|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
11360546|NCT02297022|Experimental|Deep Brain Stimulation|Patients with Prader-Willi syndrome to receive DBS.
11360547|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
11360548|NCT02296996|Experimental|Dabrafenib + trametinib|Single arm study with dabrafenib + trametinib combination therapy
11360549|NCT02296983|Experimental|Low dose arm|The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
11360550|NCT02296983|Experimental|Full dose arm|The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
11360551|NCT02296957|Experimental|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
11360552|NCT02296957|No Intervention|Control|Usual Care
11360553|NCT02296944||Children aged under 7 years old when tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
11360554|NCT02296944||Children aged 7 to 10 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
11360555|NCT02296944||Children aged 11 to 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
11360556|NCT02296944||Children aged over 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
11360557|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
11360558|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
11360560|NCT02296918|Experimental|Double combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
11360561|NCT02296918|Experimental|Triplet combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with rituximab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
11360562|NCT02296918|Experimental|Triplet combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
11360563|NCT02296905|Experimental|Group I|Subjects with mild hepatic impairment
11360564|NCT02296905|Experimental|Group II|Subjects with moderate hepatic impairment
11360565|NCT02296905|Experimental|Group III|Subjects with severe hepatic impairment
11360566|NCT02296905|Experimental|Group IV|Subjects with normal hepatic function
11360567|NCT02296892|Experimental|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
11360568|NCT02296892|Placebo Comparator|Placebo|"Double-blind placebo arm as inactive control
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
11360569|NCT02296892|Active Comparator|Midazolam|"Open-label Midazolam arm: 1.75 mg* iv for sedation induction and 1.0 mg* iv for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.
~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
11360570|NCT02296879|Experimental|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.
~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
11360571|NCT02296853|Experimental|TAF - Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single dose of TAF.
11360572|NCT02296853|Active Comparator|TAF - Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of TAF.
11360573|NCT02296840|Experimental|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
11360574|NCT02296840|Active Comparator|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
11360575|NCT02296814|Active Comparator|Sinusitis Hevert SL Tablet|two weeks treatment
11360576|NCT02296814|Placebo Comparator|Placebo for Sinusitis Hevert SL Tablet|two weeks treatment
11360577|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
11360578|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
11360579|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
11360580|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
11360581|NCT02296788|No Intervention|No Exercise Control|Healthy Living Control Group
11360582|NCT02296788|Experimental|Aerobic Exercise Group|8 kcal/kg of body weight/week (KKW) (~900 kcal/wk)
11360583|NCT02296788|Experimental|Aerobic Exercise Group 2|20 KKW (~2250 kcal/wk)
11360584|NCT02296775|Experimental|DRL_RI|
11360585|NCT02296775|Active Comparator|Rituxan|
11360586|NCT02296775|Active Comparator|MabThera|
11360587|NCT02296762|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
11360588|NCT02296762|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
11360589|NCT02296749|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
11360590|NCT02296749|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
11360591|NCT02296736||Pancreatic malignancy|All patients who have undergone surgery for presumed pancreatic malignancy in Derriford Hospital between Jan 2006 and Jan 14 and had a Computerised tomography (CT) scan.
11360592|NCT02296723|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
11360593|NCT02296723|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
11360594|NCT02296710|Experimental|Echocardiographic and sleep apnea test|Echocardiographic Evaluation of systolic and diastolic function of both ventricles and evaluation of apnea-hypopnea index and type of apnea
11360595|NCT02296697|Active Comparator|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
11360596|NCT02296697|Active Comparator|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
11360597|NCT02296697|Placebo Comparator|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
11360630|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
11360631|NCT02296489||Healthy volunteers|
11360598|NCT02296684|Experimental|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.
~Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:
~risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)
~optional image-guided radiation therapy
~risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course
~MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based on 's surgical pathology from standard of care surgery shows high risk features (positive margins or extracapsular extension). These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
11360599|NCT02296684|Experimental|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery
11360600|NCT02296671|Experimental|PEMOX|"Pemetrexed will be given intravenously (IV) on an outpatient basis on Day 1 of each 14-day cycle over 10 minutes. Oxaliplatin will be given (IV) on an outpatient basis on Day 1 of each 14-day cycle at a dose over 120 minutes. Drugs may be given in either order.
~-Oxaliplatin will be administered on Day 2 for Cycle 1 only. **"
11360601|NCT02296671|Experimental|FOLFOX|"The modified FOLFOX-6 regimen is the following drugs given every 14 days:
~Oxaliplatin on Day 1 of each cycle
~Leucovorin over 120 minutes on Day 1 of each cycle
~5-FU bolus and continuous infusion over 46 hours beginning on Day 1 of each cycle
~Oxaliplatin will be administered on Day 2 for Cycle 1 only and the 5-FU infusion will be interrupted at 20 hours so that the FLT-PET scan can be performed (only for FLT-PET scan eligible patients)."
11360602|NCT02296658|Experimental|S-1 based chemoradiotherapy|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy in a standard manner.
11360603|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
11360604|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
11360605|NCT02296619|Experimental|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
11360606|NCT02296619|Sham Comparator|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
11360607|NCT02296580|Experimental|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
11360608|NCT02296567|Active Comparator|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
11360609|NCT02296567|Active Comparator|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
11360610|NCT02296567|Active Comparator|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
11360611|NCT02296567|Active Comparator|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
11360612|NCT02296567|Active Comparator|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
11360613|NCT02296567|Active Comparator|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
11360614|NCT02296567|Active Comparator|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
11360615|NCT02296567|Active Comparator|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
11360616|NCT02296567|Active Comparator|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
11360617|NCT02296567|Active Comparator|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
11360618|NCT02296554|Experimental|SLAP Repair|Patient will receive SLAP repair for their SLAP tear.
11360619|NCT02296554|Experimental|Biceps Tenodesis Repair|Patient will receive biceps tenodesis repair for their SLAP tear.
11360620|NCT02296541|Experimental|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
11360621|NCT02296541|Placebo Comparator|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
11360622|NCT02296541|Experimental|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
11360623|NCT02296541|Placebo Comparator|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
11360624|NCT02296541|Experimental|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
11360625|NCT02296541|Placebo Comparator|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
11360626|NCT02296528|Other|Swallowing Expansion Device|Titanium swallowing expansion device
11360627|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
11360628|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
11360629|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
11360632|NCT02296489||Asthma patients|
11360633|NCT02296476|Experimental|MK-8628 80 mg|Participants received 80 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
11360634|NCT02296476|Experimental|MK-8628 120 mg|Participants received 120 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
11360635|NCT02296476|Experimental|MK-8628 160 mg|Participants received 160 mg of oral MK-8628 administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
11360636|NCT02296463|Experimental|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
11360637|NCT02296463|Experimental|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
11360638|NCT02296463|Experimental|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
11360639|NCT02296463|Experimental|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
11360640|NCT02296463|Placebo Comparator|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
11360641|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
11360642|NCT02296437|Experimental|tDCS + CT|
11360643|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
11360644|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
11360645|NCT02296411|Experimental|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
11360646|NCT02296411|Placebo Comparator|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
11360647|NCT02296398||Romidepsin therapy|Patients who received romidepsin per standard of care practice or included in other clinical trials (when receiving romidepsin therapy).
11360648|NCT02296385|Experimental|Supplementation|Supplementation
11360649|NCT02296372|Other|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score < 7 at first day of measurement.
~Intervention: Measuring continuous glucose monitoring."
11360650|NCT02296372|Other|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score > 7 at first day of measurement.
~Intervention: Measuring continuous glucose monitoring."
11360651|NCT02296359||Asthma Discordant Monozygotic Twins|This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
11360652|NCT02296359||Non-Asthma Concordant Monozygotic Twins|This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.
11360653|NCT02296346|Active Comparator|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
11360654|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:
~ECP will be administered according to the following schedule:
~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
11360655|NCT02296333|Active Comparator|ondansetron|ondansetron iv, 8 mg, skin closure time
11360656|NCT02296333|Placebo Comparator|isotonic|isotonic 2ml, once, skin closure time
11360657|NCT02296320|Active Comparator|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
11360658|NCT02296320|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
11360659|NCT02296320|Active Comparator|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
11360660|NCT02296307||DOvEE Participants|"All symptomatic women who are eligible for participation in the DOvEE trial receive the same interventions:
~Blood test: CA-125 biomarker at day 1 and week 6-8. Second Test: Transvaginal Ultrasound at day 1. Follow-up Phone Call: Confirms continuing health 6 months after last visit."
11360661|NCT02296294|Active Comparator|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.
~Body Composition Monitoring every 10 minutes for 6hours."
11360662|NCT02296294|Placebo Comparator|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
11360663|NCT02296281|Experimental|treatment group|
11360664|NCT02296268||Pre-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
11360665|NCT02296268||Post-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
11360666|NCT02296268||Stroke Rehabilitation Physiotherapists|Physiotherapists whose current practice involves working full-time or part-time on in- or out-patient stroke service at the NSRC. Their self-efficacy regarding the clinical utilization of aerobic exercise post-stroke will be conducted prior to, and after, implementation of the Aerobics Clinic.
11360667|NCT02296255|No Intervention|no HPV vaccine|No delivery of HPV vaccine
11360668|NCT02296255|Experimental|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
11360669|NCT02296242|Experimental|BVD-523|
11360670|NCT02296229|Experimental|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
11360671|NCT02296216|Active Comparator|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
11360672|NCT02296216|Placebo Comparator|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
11360673|NCT02296203|Experimental|cetuximab and irinotecan|
11360674|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
11360675|NCT02296190|Placebo Comparator|Placebo|1 dose of water and disodium ethylenediaminetetraacetic acid solution via 4 intranasal applications at time 0
11360676|NCT02296177|No Intervention|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
11360677|NCT02296177|Active Comparator|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
11360678|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
11360679|NCT02296151|Placebo Comparator|Group A|Four iliotibial band stretches; to be completed 3 days per week.
11360680|NCT02296151|Active Comparator|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
11360681|NCT02296151|Experimental|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
11360682|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
11360683|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
11360684|NCT02296125|Experimental|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
11360685|NCT02296125|Active Comparator|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
11360686|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11360687|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
11360688|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
11360689|NCT02296086||Group I|"Study sites in which patients perform early mobilization as per local standard of care, which is as follows:
~2 days (at the latest) after surgery: Transfer from the bed to a sitting chair for the first time
~4 (± 2) days after surgery: Stand up and put both feet on the ground for the first time (walking aids allowed)
~5 (± 2) days after surgery: Walking (at least partial weight bearing, walking aids allowed)
~The patients are instructed by the investigator at the hospital about a standardized mobilization program to be followed at home"
11360690|NCT02296086||Group II|Study sites in which patients start walking (i.e. partial weight bearing, walking aids allowed) more than 7 days after surgery as per local standard of care
11360691|NCT02296073|Experimental|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
11360692|NCT02296073|Experimental|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
11360693|NCT02296073|Experimental|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
11360694|NCT02296073|Experimental|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
11360695|NCT02296060|Experimental|6 minutes walking test|
11360728|NCT02295800||Healthcare workers|Facility based healthcare workers
11360696|NCT02296047|Experimental|Group A|The medication order: subjects inhaled placebo,ipratropium bromide 80μg, salbutamol 400μg in sequence.
11360697|NCT02296047|Experimental|Group B|The medication order: subjects inhaled placebo, salbutamol 400μg, ipratropium 80μg in sequence.
11360698|NCT02296021|Experimental|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
11360699|NCT02296021|Active Comparator|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
11360700|NCT02296008|Other|surgery for Hirschsprung's disease|children after surgery for Hirschsprung's disease will undergo 3D high resolution anorectal manometry procedure
11360701|NCT02296008|Other|surgery for anorectal malformation|children after surgery for anorectal malformation will undergo 3D high resolution anorectal manometry procedure
11360702|NCT02296008|Other|surgery for other disorders|children after surgery for other disorders will undergo 3D high resolution anorectal manometry procedure
11360703|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
11360704|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
11360705|NCT02295982|Placebo Comparator|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
11360706|NCT02295982|Active Comparator|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
11360707|NCT02295956|Experimental|Home Based Exercise and Nutrition Program|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete. Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Exercise instructional booklet given to all participants describing all exercises. Participants to walk 20-30 minutes at least 3 times a week. Nutrition program discussed with participants. Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
11360708|NCT02295943|Other|Positioning measuring device|The supine time during the first postoperative day is measured
11360709|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:
~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
~l-LV 200 mg/sqm IV over 2-h, day 1 followed by
~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
~Surgical revaluation will be performed after the induction phase (8 cycles).
~Patients deemed unsuitable for surgery will received maintenance treatment as follows:
~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
11360710|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:
~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
~l-LV 200 mg/sqm IV over 2-h, day 1 followed by
~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
~Surgical revaluation will be performed after the induction phase (8 cycles).
~Patients deemed unsuitable for surgery will received maintenance treatment as follows:
~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
11360711|NCT02295891|Experimental|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.
~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
11360712|NCT02295878|Active Comparator|Treatment|400mg capsule containing seaweed extract (treatment)
11360713|NCT02295878|Placebo Comparator|Placebo|400mg capsule containing maltodextrin (placebo)
11360714|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
11360715|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
11360716|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
11360717|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
11360718|NCT02295852|Experimental|Group A: LOW-SODIUM LOW LIPID CALCIUM RICH DIET|Experimental Group A: patients will change their diet in a diet similar for total daily calories, sodium and macronutrients but enriched in calcium (1200 mg/daily) and will be followed up to 1 year with an intermediate control after the first 3 months;
11360719|NCT02295852|Active Comparator|Group B: LOW-SODIUM LOW LIPID DIET|Experimental Group B: patients will continue the low-lipid, low-sodium diet up to 1 year with an intermediate control after the first 3 months.
11360720|NCT02295839|No Intervention|Usual care|
11360721|NCT02295839|Experimental|Sleep Hygiene and Relaxation Education|
11360722|NCT02295826|Experimental|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients >80 years of age and/or an eGFR of 30-50 ml/min)
11360723|NCT02295826|Active Comparator|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
11360724|NCT02295813|Experimental|FBF001|"FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.
~FBF001 is administered once during 1 day or once per day during 5 days."
11360725|NCT02295813|Placebo Comparator|Placebo|The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
11360726|NCT02295800||Mothers|HIV Infected mothers
11360727|NCT02295800||Infants|HIV exposed infants
11360730|NCT02295787|Placebo Comparator|Placebo|Intranasal saline solution administered six times over three weeks.
11360731|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
11360732|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
11360733|NCT02295761|Active Comparator|Lifestyle counseling|12-weeks
11360734|NCT02295761|Active Comparator|Lifestyle counseling + activity watch|12-weeks
11360735|NCT02295748|Experimental|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
11360736|NCT02295735|Experimental|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
11360737|NCT02295735|No Intervention|Control|Standard pressure ulcer prevention according to hospital standard
11360738|NCT02295722|Experimental|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -
~IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.
~immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.
~Day 0
~•Stem cell infusion
~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
11360739|NCT02295709|Experimental|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
11360740|NCT02295709|Experimental|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
11360741|NCT02295709|Experimental|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
11360742|NCT02295696|Experimental|Intervention group|Intervention arm : EMMA consultations
11360743|NCT02295696|No Intervention|Control group|Control arm: Usual care/consultations
11360744|NCT02295670|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
11360745|NCT02295670|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11360746|NCT02295657|Experimental|ETI intubation|endotracheal intubation in manikin
11360747|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
11360748|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
11360749|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
11360750|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
11360751|NCT02295631|Experimental|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
11360752|NCT02295631|Experimental|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
11360753|NCT02295618|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11360754|NCT02295618|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
11360755|NCT02295605|Experimental|Land-based exercises|Land-based muscle strengthening exercises protocol
11360756|NCT02295605|Experimental|Water-based exercises|Water-based muscle strengthening exercises protocol
11360757|NCT02295592|Experimental|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
11360758|NCT02295592|Active Comparator|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
11360759|NCT02295566|Active Comparator|Nitric Oxide Group|Inhaled Nitric Oxide delivered via nasal canulae at 10ppm for 8 hours a night for 7 nights.
11360760|NCT02295566|Placebo Comparator|Control Group|Air/oxygen mix (according to clinical need) delivered via nasal canulae for 8 hours a night for 7 nights.
11360761|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
11360762|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
11360763|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
11360764|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
11360765|NCT02295540|Experimental|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
11360766|NCT02295527|Experimental|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
11360767|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
11360768|NCT02295514|Experimental|PTP1B dosage|PTP1B dosage during sepsis
11360769|NCT02295501|Experimental|EBOV convalescent donors|EBOV convalescent donors for passive immune therapy in subjects with acute EVD
11360770|NCT02295488|Experimental|Desensitization|Blood intake for biological sampling during validated desensitization protocol (Alyostall®)
11360771|NCT02295475|Experimental|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
11360772|NCT02295475|Active Comparator|Warfarin|Subjects will receive warfarin for the duration of the study, with the dose and frequency adjusted per clinician discretion to achieve an INR (International Normalized Ratio) between 2 and 4.
11360773|NCT02295462|Experimental|Person-centered Care|Medication Review + Person-centered Care
11360774|NCT02295462|Active Comparator|Optimised Treatment|Medication Review
11360775|NCT02295449|Experimental|1|
11360776|NCT02295436|Experimental|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
11360777|NCT02295436|Experimental|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
11360778|NCT02295436|Experimental|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
11360779|NCT02295436|Experimental|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
11360780|NCT02295410||Engaged in Home-Based CPT|Home-Based Telemental Health-Patients undergoing Home-Based CPT for PTSD
11360781|NCT02295410||Comparison|Treatment as Usual (TAU) Patients NOT receiving regular CPT or other evidence-based therapy for PTSD.
11360782|NCT02295397|Experimental|food provocation|open and placebo-controlled food challenges
11360783|NCT02295384||Audit Group|"Patients attending HHMP in Darlinghurst, Sydney, New South Wales with documented HIV-1 infection from 1st January 2005 to 31st July 2014, who were considered linked to care (Attendance during the study period for at least 2 visits >3 months and <12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site))."
11360784|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
11360785|NCT02295345|Experimental|CBT for Insomnia|Participants attend 5 weekly sessions of Cognitive Behavioural Therapy for Insomnia for pregnant women, administered by licensed clinical psychologist.
11360786|NCT02295332|Experimental|Cohort A|
11360787|NCT02295332|Experimental|Cohort B|
11360788|NCT02295319|Experimental|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
11360789|NCT02295319|No Intervention|Control|Usual discharge procedures
11360790|NCT02295293|Experimental|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
11360791|NCT02295293|Placebo Comparator|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
11360792|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
11360793|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
11360794|NCT02295267|Experimental|walnut allergy provocation|inclusion of walnut allergic patients, food provocation with walnut
11360795|NCT02295254||Research group|The study contain only one group: travelers who intended to travel to tropical destinations. The participants will give a feces sample before and after the travel.
11360796|NCT02295228||Adults undergoing total hip arthroplasty|No intervention will be administered, this is an observational trial. The study population includes adults 50+ who are undergoing elective total hip arthroplasty for osteoarthritis.
11360797|NCT02295215|No Intervention|Sedentary Group|The patients will not do exercise training
11360798|NCT02295215|Experimental|Trained Group|The patients will do exercise training for sixteen weeks.
11360799|NCT02295202|Experimental|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
11360800|NCT02295202|Placebo Comparator|Placebo|Nasal Strips
11360801|NCT02295189|Active Comparator|Visual analogue scale|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
11360802|NCT02295189|Active Comparator|Treatment|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
11360803|NCT02295176|Experimental|Armolipid Plus|Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
11360804|NCT02295176|Placebo Comparator|Placebo|1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
11360805|NCT02295163|Sham Comparator|Sham procedure|injection of NACL 0,9% in the stellate ganglion
11360806|NCT02295163|Experimental|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
11361431|NCT02290990|Experimental|Health professionists|Health professionists as healthy volunteers
11360807|NCT02295150|Experimental|Nadroparin|patients above 140 kg will receive a dose of 2850 IU nadroparine pre-operatively, anti-Xa factor will be determined 3 days after nadroparin use. After surgery patients receive 5700 IU nadroparin (our standard treatment). Three days after surgery and 4 weeks after surgery anti-Xa factor will be measured again.
11360808|NCT02295137|Experimental|pre-procedure image guidance|
11360809|NCT02295124|Active Comparator|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
11360810|NCT02295124|Active Comparator|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
11360811|NCT02295111|Active Comparator|EA treatment and TCM health consult|Participants randomized to the EA treatment will receive 2 EA +TCM health consult once a week x 4 weeks (8 total)
11360812|NCT02295111|Experimental|TCM health consult|Participants randomized to TCM health consult will receive 2 TCM health consult once a week x 4 weeks ( 8 total)
11360813|NCT02295111|Active Comparator|Usual care|Participants randomized to usual care will continue with their usual care
11360814|NCT02295098|Active Comparator|Thoracic epidural catheter|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
11360815|NCT02295098|Active Comparator|Paracostal catheter|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
11360816|NCT02295072|No Intervention|Control group|2 Usual Physical Education sessions/week
11360817|NCT02295072|Experimental|Intervention Group|A 5-months physical exercise-based program (3-5 Physical Education after school sessions/week + 2 Usual Physical Education sessions/week)
11360818|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
11360819|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
11360820|NCT02295046|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
11360821|NCT02295046|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
11360822|NCT02295033|Experimental|Boost irradiation|
11360823|NCT02295033|No Intervention|No boost irradiation|
11360824|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
11360825|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
11360826|NCT02295007|Other|text message|all families will receive text messages to which they can respond to report symptoms
11360827|NCT02294994|Experimental|half dose tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.075 µg per kilogram per minute for 24 to 36 hours.UFH heparin was administered as a bolus of 100 U/kg before PCI.
11360828|NCT02294994|Active Comparator|recommended-dose Tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours. UFH heparin was administered as a bolus of 100 U/kg before PCI.
11360829|NCT02294994|Placebo Comparator|none tirofiban|Tirofiban was not administered ,UFH heparin was administered as a bolus of 100 U/kg before PCI.
11360830|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
11360831|NCT02294981|Experimental|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
11360832|NCT02294968|Experimental|Family Startup|Family Startup plus usual pre- and postnatal care
11360833|NCT02294968|No Intervention|Control|Usual pre- and postnatal care
11360834|NCT02294955|Active Comparator|Catheterablation|Pulmonary vein isolation with Cryo-energy using a Arctic Front™ Cardiac CryoAblation Catheter or an irrigated radiofrequency ablation catheter, with an optional roof line.
11360835|NCT02294955|Active Comparator|Antiarrhythmic drug Class IC or III.|Serial testing of oral antiarrhythmic drugs; amiodarone 600 mg once daily 7-10 days, then 100-200 mg once daily; sotalol: 80-160 mg twice daily; flecainide 100 to 150 mg twice daily or entire dose as slow-release formula once daily; propafenone 300 mg twice daily; disopyramide 250-375mg twice daily, or dronedarone 400 mg twice Daily.
11360836|NCT02294942|Experimental|RANCAD 500mg|RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.
11360837|NCT02294942|Experimental|RANCAD 1000mg|RANCAD 2 tabs (500 mg), twice daily
11360838|NCT02294942|Active Comparator|Placebo|2 tabs, twice daily
11360839|NCT02294929|Other|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
11360840|NCT02294916|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11360841|NCT02294916|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11360842|NCT02294903|Experimental|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
11360843|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.
~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
11360844|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.
~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
11360845|NCT02294864|Experimental|Pulsed Radiofrequency|Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
11360846|NCT02294864|Active Comparator|Physical Therapy|This group will receive standard of care outpatient physical therapy weekly for 3-4 weeks with therapist instructions to reduce knee pain.
11360847|NCT02294851|Experimental|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
11360848|NCT02294851|Placebo Comparator|Placebo|BMS-986168 Placebo
11360849|NCT02294838|Experimental|MRI with parotid gland stimulation|All participants will have MRI imaging of the parotid gland with IV Gadovist pre and post parotid stimulation with lemon juice. 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered. Approximately three minutes after scan commencement, the salivary glands will be stimulated by orally administering a small portion (≈5 ml) of Citric acid.
11360850|NCT02294812|Active Comparator|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
11360851|NCT02294812|Experimental|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
11360852|NCT02294812|Active Comparator|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
11360853|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
11360854|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
11360855|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
11360856|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
11360857|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
11360858|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
11360859|NCT02294760|Active Comparator|Subsensory, OFF, subsensory|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then turned OFF for the next 4 weeks and finally set subsensory for the last 4 weeks.
11360860|NCT02294760|Active Comparator|Subsensory, subsensory, OFF|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then set subsensory for another 4 weeks and finally turned OFF for the last 4 weeks.
11360861|NCT02294747|Active Comparator|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
11360862|NCT02294747|Active Comparator|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
11360863|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
11360864|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
11360865|NCT02294721|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
11360866|NCT02294721|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
11360867|NCT02294708|Experimental|supine|postoperative postures: patients in this arm are assigned to adopt supine position for 24 hours after the surgery
11360868|NCT02294708|Experimental|temporal lateral|postoperative postures: patients in this arm are assigned to adopt temporal lateral position for 24 hours after the surgery
11360869|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
11360870|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
11360871|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
11360872|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
11360873|NCT02294669|Experimental|Turris Facet Fuser|
11360874|NCT02294656|Experimental|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
11360875|NCT02294656|Active Comparator|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
11360876|NCT02294643|Active Comparator|aspirin, clopidogrel & sarpogrelate|the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (Anplag®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily
11360877|NCT02294643|Placebo Comparator|aspirin, clopidogrel & placebo|the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily
11360878|NCT02294630|Active Comparator|Surfactant Dose - 100|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg.
11360879|NCT02294630|Active Comparator|Surfactant Dose - 200|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg.
11360880|NCT02294617|Active Comparator|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
11360881|NCT02294617|Active Comparator|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
11360882|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
11360883|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
11360884|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
11360885|NCT02294591|Active Comparator|NAC group|Receiving N-acetylcysteine as add-on treatment
11360886|NCT02294591|Placebo Comparator|Placebo group|Receiving placebo as add-on treatment
11360887|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
11360888|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
11360889|NCT02294565|Other|VST-1001 & 99mTc-labeled sulfur colloid|"VST-1001 (with medical devices) and 99mTc-labeled sulfur colloid are used together during a SLNB procedure in a single subject. Both drugs are evaluated for lymphatic mapping and localization of lymph nodes. The current standard of care for lymphatic mapping and lymph node localization during a SLNB procedure is a combined-modality technique that employs both a radiotracer (99mTc-labeled sulfur colloid is the radiotracer used in this study) and a vital blue dye (a patient receives both drugs). In this study, the vital blue dye is replaced with VST-1001 and companion medical devices.
~VST-1001 is excited by a medical device (blue-light LED illuminator) to fluoresce; the surgeon is wearing blue-light filtering eyewear to improve visualization of the relevant tissue structures."
11360890|NCT02294552|Experimental|Matched bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv
11360891|NCT02294552|Experimental|Matched peripheral blood stem cells graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
11360892|NCT02294552|Experimental|Mismatched peripheral blood stem cells or bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
11360893|NCT02294539|Experimental|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
11360894|NCT02294539|Experimental|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
11360895|NCT02294539|Active Comparator|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
11360896|NCT02294539|Active Comparator|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
11360897|NCT02294526|Experimental|Sardine diet|Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
11360898|NCT02294526|No Intervention|Control diet|Subjects only follow general dietary recommendations for diabetes.
11360899|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
11360900|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
11360901|NCT02294487||Subjects|Individuals over 50 who are going to get the seasonal flu vaccine, pneumococcal, HIB, and/or meningococcal vaccination and either have multiple myeloma or do not have multiple myeloma.
11360902|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
11360903|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
11360904|NCT02294461|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once a day until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
11360905|NCT02294461|Experimental|Placebo|Participants received matching placebo orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
11360906|NCT02294448|Experimental|cohort 1|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)
11360907|NCT02294448|Experimental|cohort 2|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
11361716|NCT02289287|Active Comparator|Standard Care|Participants will receive Standard Care only
11360908|NCT02294448|Experimental|cohort 3|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)
11360909|NCT02294435|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
11360910|NCT02294435|Experimental|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
11360911|NCT02294422|Experimental|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
11360912|NCT02294422|Placebo Comparator|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
11360913|NCT02294409|Experimental|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
11360914|NCT02294409|Active Comparator|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
11360915|NCT02294396|Experimental|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
11360916|NCT02294396|Experimental|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
11360917|NCT02294396|Experimental|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
11360918|NCT02294396|Experimental|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
11360919|NCT02294383||Pre/post surgery pelvic floor assessment|
11360920|NCT02294383||Conservative treatmen monitoring|
11360921|NCT02294383||Pelvic floor muscle contrictions|
11360922|NCT02294383||Imaging reproducibility|
11360923|NCT02294370||subjects at the early stages of diabetes|Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test >7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose > 7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (<3 years)
11360924|NCT02294357|Experimental|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
11360925|NCT02294357|Experimental|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
11360926|NCT02294357|Experimental|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
11360927|NCT02294357|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
11360928|NCT02294357|Experimental|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
11360929|NCT02294344|Experimental|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)
11360930|NCT02294344|Active Comparator|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
11360931|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
11360932|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
11360966|NCT02294123|Experimental|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
11360967|NCT02294110||diabetes mellitus|spinal anesthesia
11361590|NCT02289976|Active Comparator|core decompression|Core decompression and nonvascularized autograft from the iliac crest
11360933|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
11360934|NCT02294305|Experimental|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
11360935|NCT02294305|Placebo Comparator|Placebo|Placebo PO QD for 12 weeks.
11360936|NCT02294292|Experimental|Carvedilol + Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
~if carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
11360937|NCT02294292|Active Comparator|Endoscopic Variceal Ligation (EVL)|
11360938|NCT02294279|Experimental|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
11360939|NCT02294279|No Intervention|Placebo|Blinded placebo inhaler
11360940|NCT02294266|Experimental|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration
~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
11360941|NCT02294266|Active Comparator|Mephedrone|"Mephedrone 200 mg, single dose, oral administration
~Lemon-flavoured water (350 ml), single dose, oral administration"
11360942|NCT02294266|Active Comparator|Alcohol|"Lactose 200 mg, single dose, oral administration
~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
11360943|NCT02294266|Placebo Comparator|Placebo|"Lactose 200 mg, single dose, oral administration
~Lemon-flavoured water (350 ml), single dose, oral administration"
11360944|NCT02294253|Experimental|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
11360945|NCT02294240|Experimental|Arm One|Energy dense biscuits will be provided throughout pregnancy after enrolment
11360946|NCT02294240|Placebo Comparator|Arm Two|Wheat Flour,oil, iron and folic acid will be provided fortnightly throughout pregnancy after enrolment
11360947|NCT02294227|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
11360948|NCT02294227|Experimental|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
11360949|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
11360950|NCT02294214|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
11360951|NCT02294214|Active Comparator|Intervention|Spatial Repellent product with active ingredient
11360952|NCT02294201|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
11360953|NCT02294201|Active Comparator|Intervention|Spatial Repellent product with active ingredient
11360954|NCT02294188|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
11360955|NCT02294188|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
11360956|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
11360957|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
11360958|NCT02294162|Experimental|0.5 mg/kg body weight Ketamin|Patients allocated to this arm will receive an iv dose of 0.5 mg/kg body weight ketamine.
11360959|NCT02294162|Placebo Comparator|5 ml normal saline as placebo|Patients allocated to this arm will receive an iv dose of 5ml saline as placebo.
11360960|NCT02294149|Placebo Comparator|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
11360961|NCT02294149|Experimental|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
11360962|NCT02294136|Experimental|Prep-C|Four session nurse administered behavioral intervention.
11360963|NCT02294136|Active Comparator|Educational Control|Attention Control
11360964|NCT02294123|Experimental|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
11360965|NCT02294123|Experimental|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
11360968|NCT02294097|No Intervention|Non-biopsy|Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
11361717|NCT02289274|Experimental|NVP-1203|NVP-1203
11360969|NCT02294097|Experimental|Protocol biopsy|Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
11360970|NCT02294084|Experimental|Sitagliptin|Subjects will receive Sitagliptin in a dosage of 100 mg/day p.o. for 12 weeks. The dosage corresponds to 1 gift/day.
11360971|NCT02294084|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks. Placebo will be given in 1 gift/day
11360972|NCT02294071|Experimental|acetaminophen|acetaminophen 15mg/kg (max 975mg)
11360973|NCT02294071|Experimental|ibuprofen|ibuprofen 10mg/kg (max 600mg)
11360974|NCT02294071|Experimental|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
11360975|NCT02294058|Active Comparator|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
11360976|NCT02294058|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
11360977|NCT02294058|Experimental|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
11360978|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
11360979|NCT02294019|Experimental|Ibuprofen caplet arm|
11360980|NCT02294006|Experimental|everolimus+octreotide LAR+metformin|
11360981|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
11360982|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
11360983|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
11360984|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
11360985|NCT02293980|Experimental|Part 1: PT2385 Tablets|PART 1: Multiple Dose/Dose-Escalation
11360986|NCT02293980|Experimental|Part 2: PT2385 Tablets and nivolumab|PART 2: PT2385 Tablets in combination with nivolumab
11360987|NCT02293980|Experimental|Part 3: PT2385 and cabozantinib tablets|PART 3: PT2385 Tablets in combination with cabozantinib tablets
11360988|NCT02293967|Experimental|MT-1303|[14C] MT-1303 after a single oral dose
11360989|NCT02293954|Experimental|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
11360990|NCT02293941|Experimental|JKB-122 5mg|5mg, oral, once daily
11360991|NCT02293941|Experimental|JKB-122 15 mg|15mg, oral, once daily
11360992|NCT02293941|Experimental|JKB-122 35 mg|35mg, oral, once daily
11360993|NCT02293941|Placebo Comparator|placebo|comparable capsule, oral, once daily
11360994|NCT02293928||Elective hybrid coronary revascularization|All patients are treated with non-enteric coated aspirin 75 mg once daily prior to study participation. Aspirin treatment is discontinued 8-10 days prior to surgery and resumed 6-9 hours after surgery. Left internal mammary grafting of the left descendent coronary artery is performed off-pump through an inferior J-hemisternotomy (JOPCAB). All patients receive an oral loading dose of aspirin 300 mg 6-9 hours after surgery followed by daily maintenance doses of 75 mg aspirin. An oral loading dose of clopidogrel 300 mg 12 hours prior to PCI is followed by daily maintenance doses of 75 mg for 12 months. Patients are followed for 1 year.
11360995|NCT02293915|Experimental|sodium oligo-mannurarate 900mg|
11360996|NCT02293915|Placebo Comparator|Placebo|
11360997|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
11360998|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
11360999|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
11361000|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
11361001|NCT02293889|Experimental|Vitamin D|Vitamin D3 2000IU/daily 3 months
11361002|NCT02293889|Experimental|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
11361003|NCT02293889|Experimental|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
11361004|NCT02293889|Placebo Comparator|Placebo|Placebo capsule: edible oil
11361005|NCT02293876|Sham Comparator|Eye drop|Eye drop LACRIBELL® - two drops each eye, three times a day, after eye cleansing.
11361006|NCT02293876|Sham Comparator|Ocular gel|Ocular gel LIPOSIC® applied three times a day at the lower palpebra from medium line to the lateral border.
11361007|NCT02293876|Sham Comparator|Glad wrap|Occlusion of the orbital area with a Glad wrap, turning the area into a moisture chamber.
11361008|NCT02293876|No Intervention|Control group|Ocular cleansing three times a day.
11361009|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
11361010|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
11361011|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
11361012|NCT02293850|Experimental|single intra-tumoral injection|OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
11361013|NCT02293837|Experimental|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
11361014|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
11361015|NCT02293824||Premature infants|Premature infants <29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.
11361016|NCT02293811|Other|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )
~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:
~healthy patients;
~patients with colonic Crohn disease in acute phase;
~patients with colonic Crohn disease in chronic phase;
~patients with ulcerative colitis in acute phase;
~patients with ulcerative colitis in chronic phase;
~patients with colon cancer"
11361017|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
11361018|NCT02293772|Active Comparator|Hypoxic ambulatory|Ambulatory in normobaric hypoxia
11361019|NCT02293772|Experimental|Hypoxic Bedrest|Bedrest in normobaric hypoxia
11361020|NCT02293772|Active Comparator|Normoxic bedrest|Bedrest in normobaric normoxia
11361021|NCT02293759|Active Comparator|HoLEP|Holmium laser enucleation of the prostate
11361022|NCT02293759|Active Comparator|Greenlight laser PVP|Phtoselective vaporization of the prostate
11361023|NCT02293746|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
11361024|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
11361025|NCT02293720|Experimental|EndoBarrier Device|Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
11361026|NCT02293707|Experimental|GX301 Regimen A (8 administrations)|Administration time frame: Day 1 to Day 63.
11361027|NCT02293707|Experimental|GX301 Regimen B (4 administrations)|Administration time frame: Day 1 to Day 63.
11361028|NCT02293707|Experimental|GX301 Regimen C (2 administrations)|Administration time frame: Day 1 to Day 63.
11361029|NCT02293694|Active Comparator|self-injection|Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
11361030|NCT02293694|Active Comparator|provider injection|Women randomized to this arm will received Sayana press from a family planning provider every three months.
11361031|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
11361032|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
11361033|NCT02293668|Active Comparator|Combined 450|Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
11361034|NCT02293668|Active Comparator|Combined 300|Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
11361035|NCT02293668|Active Comparator|Letrozole and hMG|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
11361091|NCT02293317|Experimental|M-001 0.5mg & TIV|M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
11361036|NCT02293655|Placebo Comparator|MPH Discontinuation|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.
~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.
~DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
11361037|NCT02293655|Active Comparator|Sustained MPH|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.
~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.
~DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
11361038|NCT02293629|Placebo Comparator|A1: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
11361039|NCT02293629|Placebo Comparator|A2: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
11361040|NCT02293629|Placebo Comparator|A3: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
11361041|NCT02293629|Active Comparator|B1: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
11361042|NCT02293629|Active Comparator|B2: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
11361043|NCT02293616|Experimental|Nitrate Rich|A nitrate rich beetroot juice supplement (Beet It Shot®, James White Drinks, UK) high in nitrates will be provided to the subjects. Subject's diet will be supplemented once daily while hospitalized up to 14 days with one 70 ml bottle containing 300 mg of dietary nitrate.
11361044|NCT02293616|Placebo Comparator|Nitrate Depleted|This group will consume a beetroot juice supplement (Beet It Shot®, James White Drinks, UK) that has had the nitrate removed from the beverage by the manufacturer. Patient's diet will be supplemented once daily with one 70 ml bottle while hospitalized up to 14 days.
11361045|NCT02293603|Experimental|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
11361046|NCT02293603|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
11361047|NCT02293590|Experimental|intensive, adapted treatment strategy|"Experimental: intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200mg every 2 weeks after loading d 400mg at Weeks 0, 2 and 4
~DMARD:
~Patients without sufficient treatment response will be taken to the next step according to the therapeutic algorithm or next drug, for example: 15=>25mg Metoject (R)/week => Leflunomide Gebro (R)20mg/d => Salazopyrine EN(R) 2000mg/d
~Glucocorticoids:
~At Week, 0 patients will be initiated on Spiricort (R) 20mg/d and tapered every 5 days
~Joint injections:
~Starting at Week 0 up to 5 joint injections may be conducted into synovitic joints at every visit of the study.
~The maximum cumulative Lederlon (R) dose is 100mg/visit. Joints are to be infiltrated with the following doses of triamcinolone and lidocaine"
11361048|NCT02293590|Active Comparator|fixed-dosed program|"Intervention:
~Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.
~DMARD:
~Patients are to continue to receive their stable weekly dose of DMARD as noted at study entry for the duration of the study (24 weeks)
~Glucocorticoids:
~Prednisolone (Spiricort (R)) daily dose of ≤ 10 mg
~Joint injections:
~None"
11361049|NCT02293564|Experimental|gevokizumab|
11361050|NCT02293551|Experimental|Part A: Lispro (A)|Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
11361051|NCT02293551|Experimental|Part A: Lispro (B)|Formulation B: Single dose of lispro administered SC in one of five periods.
11361052|NCT02293551|Experimental|Part A: Lispro (C)|Formulation C: Single dose of lispro administered SC in one of five periods.
11361053|NCT02293551|Experimental|Part A: Lispro (D)|Formulation D: Single dose of lispro administered SC in one of five periods.
11361054|NCT02293551|Experimental|Part A: Lispro (Reference)|Reference formulation: Single dose of lispro administered SC in one of five periods.
11361055|NCT02293551|Experimental|Part B: Lispro|Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
11361056|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
11361057|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
11361058|NCT02293525|Active Comparator|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
11361059|NCT02293525|Placebo Comparator|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
11361060|NCT02293512|Experimental|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
11361092|NCT02293317|Experimental|M-001 1.0mg & TIV|M-001 (1.0mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
11361625|NCT02289781||Zirconia posterior crowns|Monolithic zirconia crowns which are polished and non-glazed
11361061|NCT02293512|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
11361062|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
11361063|NCT02293512|No Intervention|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
11361064|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
11361065|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
11361066|NCT02293486|No Intervention|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
11361067|NCT02293486|Experimental|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
11361068|NCT02293486|Experimental|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
11361069|NCT02293473|Experimental|Protocol Group|"Using multimodal monitoring to optimise the patients' haemodynamic status, namely, the use of LiDCO Rapid, BIS-Bispectral Index Monitor and INVOS-Cerebral Oxygenation Monitor monitors to assess and fine tune the patient, as described in the study protocol in detail."
11361070|NCT02293473|Active Comparator|Control Group|Using current standard of care
11361071|NCT02293460|Experimental|I10E Arm|
11361072|NCT02293447|No Intervention|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
11361073|NCT02293447|Experimental|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
11361074|NCT02293447|Experimental|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
11361075|NCT02293434||All Children (1 month to 18 years)|All children (1 month to 18 years) admitted to all PICUs in France during three one-week periods (February, June, October) in the course of a year
11361076|NCT02293421|Other|STOP BANG|STOP BANG screening questionnaire and a snore question
11361077|NCT02293408||Component 1|Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.
11361078|NCT02293408||Component 2|Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).
11361079|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
11361080|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
11361081|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
11361082|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
11361083|NCT02293369|Active Comparator|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
11361084|NCT02293369|Active Comparator|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
11361085|NCT02293356|Experimental|Nimotuzumab Injection|200mg,Once a week，Intravenous infusion over 60 minutes
11361086|NCT02293343||control group|healthy subjects
11361087|NCT02293343||IgE positive|patients with high IgE level in serum
11361088|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
11361089|NCT02293330|Experimental|C group|continuous infusion of levobupivacaine
11361090|NCT02293330|Experimental|B group|Intermittent bolus infusion of levobupivacaine
11361713|NCT02289300|Experimental|DCB-BO1202+Placebo|
11361093|NCT02293317|Placebo Comparator|Placebo & TIV|0.3ml Saline administered Intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
11361094|NCT02293304|Experimental|Self-etch approach|Application of universal adhesive as self-etch mode
11361095|NCT02293304|Experimental|Etch-and-rinse approach|Application of universal adhesive as etch-and-rinse mode
11361096|NCT02293291|Active Comparator|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.
~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
11361097|NCT02293291|Placebo Comparator|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.
~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
11361098|NCT02293278|Experimental|Physical Activity Intervention|"The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention.
~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
11361099|NCT02293278|No Intervention|Control Group|"Day cares randomly assigned to the control group will continue with their existing programming. Day care providers will receive the PA intervention upon completion of their involvement in the 6 month trial, including: 2 three hour educational workshops, Healthy Opportunities for Preschoolers manual and program outlining the ideal implementation of activities from the manual.
~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
11361100|NCT02293265|Other|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
11361101|NCT02293252|Experimental|Interventional group|Remote patient monitoring system (Motiva)
11361102|NCT02293252|No Intervention|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
11361103|NCT02293239|No Intervention|Control Group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
11361104|NCT02293239|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
11361105|NCT02293226|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11361106|NCT02293226|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions
11361107|NCT02293213|Active Comparator|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
11361108|NCT02293213|Experimental|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
11361109|NCT02293200|Experimental|Traditional learning|chest compression group learning without CPR feedback device. After a month of quality control of chest compressions is made also without the device.
11361110|NCT02293200|Experimental|Experimental learning|Training is done using TrueCPR feedback device. After a month of quality control of chest compressions is made without the device. To do this will be indicated on the impact of the use of feedback devices for improving the effectiveness of training in CPR.
11361111|NCT02293187|Active Comparator|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
11361112|NCT02293187|Placebo Comparator|Placebo|Placebo, microcrystalline cellulose
11361113|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
11361114|NCT02293161|Experimental|Cohort A GSK2618960|Subjects will receive GSK2618960 0.6 milligram per kilogram (mg/kg)
11361115|NCT02293161|Placebo Comparator|Cohort A Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
11361116|NCT02293161|Experimental|Cohort B GSK2618960|Subjects will receive GSK2618960,planned dose being 2mg/kg. However, actual dose level for Cohort B may be adjusted based on the emerging data on safety, tolerability, PK and RO from Cohort A. The maximum dose will not exceed 2.4 mg/kg (i.e. a 4-fold dose escalation from 0.6 mg/kg)
11361117|NCT02293161|Placebo Comparator|Cohort B Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
11361118|NCT02293148|Experimental|GSK1278863 (Part A)|All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A
11361155|NCT02292836||rosacea patients|Questionnaire testing on routine dermatologist patient population
11361119|NCT02293148|Experimental|GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)|Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule
11361120|NCT02293135|Experimental|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
11361121|NCT02293135|Experimental|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
11361122|NCT02293122||Observational|Observational group exposure to three test devices and one comparative device. The test Konan Non-con Robo Pachy F&A Specular Microscope.
11361123|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11361124|NCT02293096|Other|Metoprolol succinate|The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol and groups the following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.
11361125|NCT02293096|Experimental|Genotyping|Subjects compared on the outcome of metoprolol effectiveness for SBP decline stratified by CYP2D6 genotype.
11361126|NCT02293096|Experimental|CYP2D6 Phenotyping|Subjects compared on the outcome of metoprolol effectiveness for SBP decline stratified by CYP2D6 phenotype.
11361127|NCT02293096|Other|Clinical Factors|Subjects compared on the outcome of metoprolol effectiveness for SBP based upon clinical factor prediction alone.
11361128|NCT02293083|Experimental|Lidocaine|Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
11361129|NCT02293083|Experimental|Hyaluronidase|Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml
11361130|NCT02293070|Experimental|Repeat Cardiac MRI Post Cryoablation|All subjects in this study receive a follow up delayed enhanced cardiac MRI 2-6 weeks after they undergo a cryoablation procedure.
11361131|NCT02293057|Active Comparator|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
11361132|NCT02293057|Placebo Comparator|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
11361133|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
11361134|NCT02293031|Experimental|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
11361135|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
11361136|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
11361137|NCT02293018|Experimental|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
11361138|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
11361139|NCT02292992|Experimental|Nasal pillow CPAP|Nasal pillow CPAP
11361140|NCT02292979|Active Comparator|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
11361141|NCT02292979|Experimental|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
11361142|NCT02292966|Experimental|Hepatitis C treatment|12 weeks of DCV/ASV/BCV therapy.
11361143|NCT02292927|No Intervention|Pre-intervention|Patients treated as standard before intervention
11361144|NCT02292927|Active Comparator|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
11361145|NCT02292914|Experimental|Robot-Assisted Surgery|patients undergoing robot assisted surgery for the treatment of cancer
11361146|NCT02292914|Active Comparator|Conventional Surgery|patients undergoing conventional surgery for the treatment of cancer
11361147|NCT02292901|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
11361148|NCT02292901|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
11361149|NCT02292888|Active Comparator|patients with LVEF >40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
11361150|NCT02292888|Active Comparator|patients with LVEF < or equal to 40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
11361151|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
11361152|NCT02292862||MG Main Group|lymph node and blood sampling
11361153|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
11361154|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
11361157|NCT02292810|Experimental|Inspiratory muscle exercise|Patients will exercise the inspiratory muscle using a load of 60% of maximum inspiratory mouth pressure (MIP 60%).
11361158|NCT02292810|Placebo Comparator|Inspiratory muscle exercise placebo|Patients will exercise the inspiratory muscle using a load of 2% of maximum inspiratory mouth pressure (MIP 2%).
11361159|NCT02292784|Placebo Comparator|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous [IV] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
11361160|NCT02292784|Experimental|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram [mg] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
11361161|NCT02292784|Active Comparator|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter [mL] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
11361162|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
11361163|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
11361164|NCT02292758|Experimental|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11361165|NCT02292758|Active Comparator|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11361166|NCT02292745|Experimental|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
11361167|NCT02292732|Experimental|Trametinib/ ORTHO-NOVUM® tablet|Subjects in treatment period 1will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 21 days (Days 1 through 21), followed by one placebo tablet once daily at approximately the same time each day for 7 days (Days 22 through 28). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for a total of 17 days (Days 12 through 28). Subjects in treatment period 2 will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 11 days (Days 1 through 11). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for 11 days (Days 1 through 11).
11361168|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
11361169|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
11361170|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
11361171|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
11361172|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
11361173|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
11361174|NCT02292693|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
11361175|NCT02292680||NICU Tooth Study Cohort|All study subjects will have been cared for in the Mount Sinai NICU and have had the same hospital environment exposure.
11361176|NCT02292667|Experimental|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.
~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).
~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
11361177|NCT02292667|Active Comparator|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.
~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
11361178|NCT02292654|Experimental|GZ402665|Olipudase alfa, dose (up to 3.0 mg/kg body weight) once every 2 weeks for 64 weeks
11361179|NCT02292641|Other|Patients with advanced or recurrent rectal cancer|Provide these patients with a compartmentalized radiology report which will provide surgeons with data on optimal exenterative surgery
11361180|NCT02292628|Experimental|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
11361181|NCT02292628|Placebo Comparator|Ringer lactate solution|Ringer lactate solution
11361182|NCT02292615||cervical cancer|Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
11361183|NCT02292615||endometrial cancer|Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
11361184|NCT02292615||ovarian cancer|Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
11361185|NCT02292602|Experimental|Family-Based Weight Control Intervention|Families will receive the FBWC
11361186|NCT02292602|No Intervention|Control|Families will continue with standard of care at WIC
11361187|NCT02292589|Experimental|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
11361188|NCT02292589|Experimental|Temporal Stimulation|Left temporal cortex stimulation
11361189|NCT02292589|Experimental|Sham Stimulation|Sham stimulation
11361190|NCT02292576|Experimental|Acute dose/Chronic dose|Acute dose/Chronic dose.
11361191|NCT02292576|Experimental|Chronic dose/Acute dose|Chronic dose/Acute dose.
11361192|NCT02292563|Experimental|endoscopist only|Single inspection by endoscopist during colonoscopy
11361193|NCT02292563|Experimental|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
11361194|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
11361195|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
11361196|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
11361197|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
11361198|NCT02292550|Experimental|Ribociclib 300 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
11361199|NCT02292537|Experimental|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
11361200|NCT02292537|Sham Comparator|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
11361201|NCT02292524|No Intervention|Arm I: Control|Men in this group consumed a tomato free diet for the duration of the study (less than or equal to 5 mg lycopene/day) and, thus, did not consume a tomato intervention product.
11361202|NCT02292524|Experimental|Arm II: Juice|Commercially-available tomato food product: men in this group consumed V8® juice (11-16.5 fl. oz./day).
11361203|NCT02292524|Experimental|Arm III: Soup|Commercially-available tomato food product: men in this group consumed Campbell's® Tomato Soup (2-2 ¾ cups/day).
11361204|NCT02292524|Experimental|Arm IV: Sauce|Commercially-available tomato food product: men in this group consumed Prego® spaghetti sauce (5-7 oz./day).
11361205|NCT02292511|Experimental|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
11361206|NCT02292511|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
11361207|NCT02292498|Experimental|FLIR ONE thermal camera|Thermal camera (FLIR ONE)
11361208|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
11361209|NCT02292472|Experimental|Medytoxin®|Botulinum toxin type A
11361210|NCT02292472|Placebo Comparator|Normal Saline|Normal Saline
11361211|NCT02292459|Experimental|PEG 3350|Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
11361212|NCT02292459|Active Comparator|PEG 4000|Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
11361213|NCT02292446|Experimental|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
11361214|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
11361215|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
11361216|NCT02292407|Experimental|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
11361217|NCT02292394|Experimental|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
11361218|NCT02292394|Experimental|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
11361219|NCT02292394|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
11361220|NCT02292381||Glaucoma Patients|Patients with primary open angle glaucoma
11361221|NCT02292381||Healthy controls|age- and sex matched controls
11361222|NCT02292368|Experimental|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
11361223|NCT02292368|Experimental|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
11361224|NCT02292355|Experimental|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
11361225|NCT02292355|No Intervention|Occlusal splint|Control group who receive conventional treatment with occlusal splint
11361226|NCT02292342|Active Comparator|0.1 mg/ kg BW pure (-)-epicatechin|0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
11361227|NCT02292342|Active Comparator|0.5 mg/ kg BW pure (-)-epicatechin|0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
11361228|NCT02292342|Active Comparator|1.0 mg/ kg BW pure (-)-epicatechin|1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
11361229|NCT02292342|Placebo Comparator|0.0 mg/ kg BW pure (-)-epicatechin|Water only (3 ml/kg BW)
11361230|NCT02292329|Active Comparator|150g of acai fruit|150g of acai fruit in fruit smoothie form
11361231|NCT02292329|Placebo Comparator|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
11361232|NCT02292316|Experimental|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
11361233|NCT02292316|Sham Comparator|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
11361234|NCT02292303|Experimental|zinc-enriched yeast|zinc-enriched yeast capsules
11361235|NCT02292303|Active Comparator|zinc oxide|zinc oxide capsules
11361236|NCT02292303|Active Comparator|zinc gluconate|zinc gluconate capsules
11361237|NCT02292290|Active Comparator|Monotherapy 2|addition of Sulfonylurea or Pioglitazone to Metformin
11361238|NCT02292290|Experimental|Dual Therapy 1|Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)
11361239|NCT02292290|Active Comparator|Dual therapy 2|Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)
11361240|NCT02292290|Experimental|Monotherapy|Addition of Liraglutide to Metformin
11361241|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
11361242|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
11361243|NCT02292264||Surgical treatment of ventral hernia|Adult patients who underwent a ventral hernia Repair at Zealand University hospital
11361244|NCT02292251|Active Comparator|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
11361245|NCT02292251|Active Comparator|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
11361246|NCT02292238|Experimental|Benfotiamine|The patients in this arm will be treated with benfotiamine
11361247|NCT02292238|Placebo Comparator|Placebo|The patients in this arm will be treated with placebo
11361248|NCT02292225|Experimental|IPI-145 in Combination with Obinutuzumab|
11361249|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
11361250|NCT02292199|Experimental|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
11361251|NCT02292199|Active Comparator|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
11361252|NCT02292199|Placebo Comparator|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
11361253|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
11361254|NCT02292173|Experimental|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.
~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.
~Sorafenib: Twice daily, according to dose level upon entry.
~Each cycle is repeated every 28 days."
11361255|NCT02292134|Experimental|earplug and sleep mask|
11361257|NCT02292121|Experimental|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
11361258|NCT02292121|Active Comparator|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
11361259|NCT02292121|No Intervention|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
11361260|NCT02292108|Experimental|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
11361261|NCT02292108|Other|dietetic counselling|Patient will only benefit of usual dietetic counselling
11361262|NCT02292095|Experimental|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
11361263|NCT02292095|Active Comparator|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
11361264|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively
~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
~Surgeon will perform the periarticular injections:
~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
~Intravenous sedation with midazolam and propofol."
11361265|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively
~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
~Adductor canal block technique:
~Supine position, after IV sedation
~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
~Local anesthetic will be delivered periarterial between 12 and 6 o'clock
~Intravenous sedation with midazolam and propofol.
~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
11361266|NCT02292069|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
11361267|NCT02292069|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
11361268|NCT02292056|Experimental|Counseling Group|Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
11361269|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
11361270|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
11361271|NCT02292030||cardioversion+HTEA|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion+HTEA.
11361272|NCT02292030||only cardioversion|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion, but not with HTEA.
11361273|NCT02292017|Experimental|Embolization of intracranial aneurysm|Embolization with Target Coils
11361274|NCT02292004|Experimental|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
11361275|NCT02292004|Active Comparator|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
11361276|NCT02291991|Experimental|Group A|"Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo
~(1 subject : GX-E2, 1 subject : Placebo)
~Subjects in group A will be injected drug, So we observe safety. After three days, Subject in group B will be injected drug."
11361277|NCT02291991|Experimental|Group B|Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo (7 subjects : GX-E2, 1 subject : Placebo)
11361278|NCT02291978|Experimental|ExAblate 2100 Treatment|The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
11361279|NCT02291952|Experimental|Experimental|During Forced Desynchrony sleep and wake will occur at different circadian phases, while meals are restricted to the biological day.
11361280|NCT02291952|Other|Control|During Forced Desynchrony sleep and wake, as well as meals, will occur at different circadian phases.
11361281|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
11361282|NCT02291926|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
11361283|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
11361284|NCT02291900|Active Comparator|medial femoral condyle|Patients in this arm receive core decompression followed by free vascularized medial femoral condyle graft
11361285|NCT02291900|Active Comparator|core decompression|Patients in this arm receive core decompression followed by osseous autograft from the iliac crest
11361286|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
11361287|NCT02291874|Experimental|Ipragliflozin group|Ipragliflozin treatment
11361288|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
11361289|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
11361714|NCT02289300|Placebo Comparator|Placebo|
11361290|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
11361291|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
11361292|NCT02291848|Experimental|Group A|Patients receiving TAA-specific CTLs as therapy for Myeloma
11361293|NCT02291848|Experimental|Group B|Patients receiving TAA-Specific CTLs as adjunctive therapy following autologous or syngeneic transplant for myeloma
11361294|NCT02291809|Experimental|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
11361295|NCT02291809|Placebo Comparator|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
11361296|NCT02291796|Experimental|Bezafibrate group|Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment
11361297|NCT02291796|No Intervention|Control group|Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment
11361298|NCT02291783|Experimental|HTL0009936|HTL0009936 single and multiple ascending oral doses.
11361299|NCT02291783|Placebo Comparator|HTL0009936 Placebo|HTL0009936 matching placebo
11361300|NCT02291770|Active Comparator|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:
~MSC+prednisone+cyclosporine;
~MSC+prednisone+tacrolimus;
~MSC+prednisone+mycophenolate mofetil."
11361301|NCT02291770|Placebo Comparator|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:
~Placebo+prednisone+cyclosporine;
~Placebo+prednisone+tacrolimus;
~Placebo+prednisone+mycophenolate mofetil."
11361302|NCT02291757|Active Comparator|NEM brand eggshell membrane|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits.
11361303|NCT02291757|Placebo Comparator|Placebo|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.
11361304|NCT02291744|Experimental|XELOX plus surgery|Eight cycles of XELOX chemotherapy plus surgery:Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle. After 4 cycles, the patients are randomized to surgery group. Then the rest four cycles are administrated.
11361305|NCT02291744|Active Comparator|XELOX|Eight cycles of XELOX chemotherapy: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
11361306|NCT02291731|Experimental|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
11361307|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
11361308|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
11361309|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
11361310|NCT02291705|Experimental|rectus sheath block|rectus sheath block
11361311|NCT02291705|Active Comparator|tramadol|tramadol control group
11361312|NCT02291692|Active Comparator|Paravertebral blockade|Paravertebral blockade
11361313|NCT02291692|No Intervention|Paracetamol|The patients was given 15 mg/kg of paracetamol.
11361314|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
11361315|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
11361316|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
11361317|NCT02291666|Experimental|T2D patients with A1C ≤7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
11361318|NCT02291666|Experimental|T2D patients with A1C>7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
11361319|NCT02291666|Active Comparator|Non T2D subjects|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
11361320|NCT02291653|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11361321|NCT02291653|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11361322|NCT02291640|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11361323|NCT02291640|Experimental|Child ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
11361324|NCT02291627|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
11361325|NCT02291614|Experimental|AMG 211|comparison of different dosages of drug
11361326|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
11361331|NCT02291575|Experimental|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
11361332|NCT02291575|Active Comparator|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
11361333|NCT02291562|Experimental|Tetrahydrocannabinol|10 mg of Tetrahydrocannabinol as capsule (once)
11361334|NCT02291562|Experimental|Cannabidiol|600 mg Cannabidiol capsule (once)
11361335|NCT02291562|Placebo Comparator|placebo|placebo capsule (once)
11361336|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
~Mometasone furoate nasal spray (200mcg) once daily"
11361337|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure
~Mometasone furoate nasal spray (200mcg) once daily"
11361338|NCT02291536|Experimental|tetrahydrocannabinol|oral administration of 10mg of tetrahydrocannabinol, once
11361339|NCT02291536|Experimental|cannabidiol|oral administration of cannabidiol, 600mg, once
11361340|NCT02291536|Placebo Comparator|placebo|oral administration of placebo, once
11361341|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
11361342|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
11361343|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
11361344|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
11361345|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
11361346|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
11361347|NCT02291484|Experimental|Comprehensive cardiac CT|"Tiered cardiac CT protocol:
~CT calcium scan
~CT angiography (if calcium scan positive or high pre-test probability)
~CT perfusion (if >50% stenosis on CTA, or cannot be ruled out)"
11361348|NCT02291484|No Intervention|Standard care|Standard diagnostic management of suspected CAD, using stress testing
11361349|NCT02291471|Experimental|T0001|
11361350|NCT02291458|Experimental|L-arginine|Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
11361351|NCT02291458|Placebo Comparator|Placebo|Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
11361352|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
11361353|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
11361354|NCT02291432|Experimental|AMDC-USR|Cell treatment
11361355|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
11361356|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
11361357|NCT02291406|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
11361358|NCT02291406|Active Comparator|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
11361359|NCT02291393|Other|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
11361360|NCT02291393|Other|Healthy volunteers|Aged and gender matched healthy controls.
11361361|NCT02291380|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose, dextran and gelatin.
11361362|NCT02291380|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but includes sucrose, dextran and gelatin.
11361363|NCT02291367|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|
11361364|NCT02291367|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
11361365|NCT02291354|Placebo Comparator|FMT + Placebo|Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.
11361366|NCT02291354|Experimental|FMT + Pectin|Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.
11361367|NCT02291341|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
11361368|NCT02291341|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
11361369|NCT02291328|Experimental|High Brassica|Participants will be asked to consume 3x 84g portions of frozen broccoli, 3x 84g portions of frozen cauliflower, and 3x 300g portions of frozen broccoli and sweet potato soups a week for a total of 2 weeks.
11361370|NCT02291328|Experimental|Low Brassica|Participants will be asked to consume 1x 84g portion of either frozen broccoli or frozen cauliflower in week one, and the remaining 84g portion of Brassica in week two.
11361371|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
11361372|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
11361373|NCT02291302|Placebo Comparator|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
11361374|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
11361375|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
11361376|NCT02291289|Experimental|Cohort 1: 5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
11361377|NCT02291289|Experimental|Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
11361378|NCT02291289|Experimental|Cohort 3: capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
11361379|NCT02291289|Experimental|Cohort 4: Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
11361380|NCT02291289|Active Comparator|Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
11361381|NCT02291289|Active Comparator|Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
11361382|NCT02291289|Active Comparator|Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
11361383|NCT02291289|Active Comparator|Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
11361384|NCT02291289|Other|Cohort 1: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
11361385|NCT02291289|Other|Cohort 2: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
11361386|NCT02291289|Other|Cohort 3: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
11361387|NCT02291289|Other|Cohort 4: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
11361388|NCT02291276||Female cancer patients with ascites|Primary epithelial ovarian female cancer patients with ascites (> 500 ml ascites in the preoperative sonographic examination)
11361389|NCT02291276||Female cancer patients aged > 70 years|"Primary epithelial ovarian female cancer patients aged > 70 years with at least one of the following secondary diagnoses:
~Status Post stent placement due to coronary heart disease respectively Status Post-myocardial infarction
~existing arterial Hypertension for more than 5 years
~chronic heart failure (New York Heart Association (NYHA) class II-III)
~peripheral arterial disease"
11361390|NCT02291263|Active Comparator|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
11361391|NCT02291263|Active Comparator|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
11361392|NCT02291263|Active Comparator|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
11361432|NCT02290990|Active Comparator|Waiting list MS|pw MS filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
11361393|NCT02291250|Experimental|Sugar matched water with polycal OGTT|"Control: sugar matched (matched to currant sugar content) water with polycal
~Blackcurrants (200grams) with polycal
~Blackcurrants (200grams) with glucose
~Greencurrants (200grams) with polycal Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load.
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
11361394|NCT02291250|Experimental|Blackcurrants with polycal OGTT|"Blackcurrants (200grams) with polycal
~Blackcurrants (200grams) with glucose
~Greencurrants ( 200grams) with polycal
~Control: sugar matched (matched to currant sugar content) water with polycal
~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
11361395|NCT02291250|Experimental|Blackcurrants with glucose OGTT|"Blackcurrants (200grams) with glucose
~Greencurrants (200grams) with polycal
~Control: sugar matched (matched to currant sugar content) water with polycal
~Blackcurrants (200grams) with polycal
~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
11361396|NCT02291250|Experimental|Greencurrants with polycal OGTT|"Greencurrants (200grams) with polycal
~Control: sugar matched (matched to currant sugar content) water with polycal
~Blackcurrants (200grams) with polycal
~Blackcurrants (200grams) with glucose
~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.
~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments."
11361397|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
11361398|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
11361399|NCT02291224|Other|Control|The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
11361400|NCT02291224|Experimental|Intervention|"Enrollment
~Interactive multimedia platform focused on DP strategies.
~Intervention arm counseling by a health care provider to select DP strategy.
~Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.
~Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.
~6 month visit
~Abbreviated version of the interactive multimedia platform on DP strategies and adherence.
~Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.
~Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care."
11361401|NCT02291211|Experimental|S-1 plus cisplatin HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after palliative operation gastric cancer of stage IV limited peritoneal metastasis. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
11361402|NCT02291172|Experimental|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry. The comprehensive communication intervention: (a) teaches foundational social communicative behaviors, (b) related skills that predict long term language outcomes, (c) a range of communicative functions, (d) spoken language skills, (e) provides children with an immediate mode of communication, (f) incorporates instructional methods, contexts, and partners that increase both the critical skills for spoken language and social use of language. Because parents are essential partners for young children with ASD who are learning to communicate, we (g) include parents
11361403|NCT02291172|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
11361404|NCT02291159|Experimental|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
11361405|NCT02291159|Sham Comparator|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
11361433|NCT02290990|Active Comparator|Waiting list arm Insomnia|pw INS Insomnia Subject filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
11361406|NCT02291146|Experimental|LA Sprouts intervention|"The intervention classes will be taught during a 90-minute session once a week for 12 weeks. Participants will receive a 45-minute gardening lesson, taught by a Master Gardener (supervised by Dr. Gatto). This lesson will include learning how to plant, maintain and harvest various fruits and vegetables. Supplementing the gardening lesson, a USC nutrition educator, with help from various graduate students (supervised by PI Dr. Davis), will lead a 45-minute cooking activity and nutrition education lesson. Every participant will participate in the cooking activity and sample the food. The program will include lessons on growing crops that have cultural significance to Latino youth such as nopales, beans, corn and squash (the latter three crops are commonly referred to as the three sisters)."
11361407|NCT02291146|No Intervention|control|Approximately 200 students in the second region who are enrolled in LA's Best will serve as control participants. After the 12-week intervention is conducted and all post-testing measures are collected on controls, a vegetable/fruit garden will be built at both control schools and the LA Sprouts program will be taught to all 3rd, 4th and 5th graders in LAs Best and their parents at the control school as a delayed intervention.
11361408|NCT02291133|Experimental|Electrochemotherapy treatment|
11361409|NCT02291120|Active Comparator|MTA|ProRoot® MTA is a root canal repair material that is a unique improvement over other materials used for root canal repair. Made up of fine hydrophilic particles that set in the presence of water, ProRoot® MTA seals off all pathways between the root canal system and surrounding tissues, significantly reducing bacterial migration. Its excellent compatibility with the dentinal wall allows for a predictable clinical healing response.
11361410|NCT02291120|Experimental|MedCem Portland Cement (PC)|MedCem PC is an excellent capping material for cariology on permanent teeth (direct and indirect capping) and in milk tooth endodontics (milk tooth amputation). Is characterized by excellent colour stability and neutrality and does not contain any additional ingredients
11361411|NCT02291107|Experimental|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
11361412|NCT02291107|Active Comparator|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
11361413|NCT02291094|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
11361414|NCT02291094|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
11361415|NCT02291068|Other|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy.
11361416|NCT02291055|Experimental|Arm A|ADXS11-001& Medi4736, IV Infusion
11361417|NCT02291055|Experimental|Arm B|Medi4736, IV Infusion vs. ADXS11-001 & Medi4736, IV Infusion
11361418|NCT02291042|Experimental|Suppository|Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
11361419|NCT02291042|No Intervention|Control|Patients will be provided with routine care.
11361420|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
11361421|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
11361422|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
11361423|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
11361424|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
11361425|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
11361426|NCT02291016|Active Comparator|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.
~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
11361427|NCT02291016|Active Comparator|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.
~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
11361428|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
11361434|NCT02290990|Active Comparator|Waiting list arm Health professionists|Health professionist filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated.
11361435|NCT02290977|Experimental|Scheduled TACE-RT|RT will be delivered at two weeks after TACE for HCC combined PVTT.
11361436|NCT02290964|No Intervention|Control group|After general anesthesia is applied, surgery is performed. Whenever transfusion is indicated, the patients will received allogenic blood transfusion
11361437|NCT02290964|Active Comparator|ANH group|After general anesthesia is applied, blood from patients in this group were withdrawn. the volume of blood withdrawn was determined based on Gross equation. The blood obtained was then stored in the operating room at temperature between 23 - 25 Celsius degree, and given back to the patient whenever transfusion is indicated.
11361438|NCT02290951|Experimental|Experimental cohorts N|Experimental cohorts N (participants with CD20+NHL) will receive multiple dose levels of REGN1979 Rituximab lead-in cohort N will receive multiple dose regimens of REGN1979
11361439|NCT02290951|Experimental|Experimental cohorts C|Experimental cohorts C (participants with CLL) will receive multiple dose levels of REGN1979
11361440|NCT02290938|Active Comparator|Community Wellness Gatherings|All youth will attend a CWG, which is a monthly gathering focused on making healthy choices and learning about Native American culture
11361441|NCT02290938|Experimental|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
11361442|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
11361443|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
11361444|NCT02290912|Experimental|Treatment|Health education program; informational website, experiential classes in various help domains, custom smart phone application, and wearable technology
11361445|NCT02290912|No Intervention|Control|No intervention
11361446|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
11361447|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
11361448|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
11361449|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
11361450|NCT02290873|Experimental|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.
~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
11361451|NCT02290873|Placebo Comparator|Placebo|"Inactive control arm
~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
11361452|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill
~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
11361453|NCT02290860|Other|Intervention|Type 2 diabetes diagnosis test.
11361454|NCT02290847|Active Comparator|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
11361455|NCT02290847|Active Comparator|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
11361456|NCT02290847|Active Comparator|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
11361457|NCT02290834|Active Comparator|ARM 1|"Breast cancer patients treated with chemotherapy
~Cognitive, functional and subjective assessments (Pre and Post Treatment)
~Imaging (Pre and Post Treatment)
~Magnetic Resonance Imaging (MRI) Scan
~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
11361458|NCT02290834|Active Comparator|ARM 2|"Non-treated breast cancer patient control
~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later
~Imaging (Post Enrollment and at 8-14 months later)
~Magnetic Resonance Imaging (MRI) Scan
~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
11361459|NCT02290834|Active Comparator|ARM 3|"Healthy control subjects
~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later
~Imaging (Post Enrollment and at 8-14 months later)
~Magnetic Resonance Imaging (MRI) Scan
~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
11361460|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
11361461|NCT02290821|Placebo Comparator|Placebo|Placebo
11361462|NCT02290808|Experimental|Theory-based group|The theory-based intervention group will receive strategies based on the Theory of Planned Behaviour to help increase physical activity among couples. Parents will receive materials on how to work together.
11361463|NCT02290808|No Intervention|Information group|The information group will serve as the control group and will receive informational materials on the benefits of physical activity.
11361464|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
11361465|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
11361466|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
11361467|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
11361468|NCT02290782|Experimental|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor > 3.5 cm, lobular cancer, resection margin < 2 mm*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.
~* In case of positive margins (<2 mm resection margin) a re-resection should be done"
11361469|NCT02290769|Experimental|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
11361470|NCT02290769|Active Comparator|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
11361552|NCT02290210|Experimental|URC102 0.5mg|0.5mg URC102 x 2weeks
11361553|NCT02290210|Placebo Comparator|URC102 1.0mg|1.0mg URC102 x 2weeks
11361471|NCT02290756|Active Comparator|Parenting program and toolkit|The intervention arm of the study will have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy and the parenting program delivered to the newborn for 12 months.
11361472|NCT02290756|Other|Control- toolkit|The control arm of the study will only have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy.
11361473|NCT02290743|Experimental|Kinesio tape|Kinesio tape on quadriceps femoris
11361474|NCT02290743|No Intervention|Control|No intervention
11361475|NCT02290730|Experimental|Kinesio tape|Kinesio tape on lower trapezius
11361476|NCT02290730|No Intervention|Control|No intervention
11361477|NCT02290717|Experimental|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
11361478|NCT02290717|Experimental|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
11361479|NCT02290717|Active Comparator|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
11361480|NCT02290704||controls|People without eye disease
11361481|NCT02290704||GO patients|patients with Graves' ophthalmopathy
11361482|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
11361483|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
11361484|NCT02290678|Experimental|Intervention|Participate in a two day Adventure-based Programming retreat and team building exercises.
11361485|NCT02290665|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
11361486|NCT02290665|Experimental|Saline enema|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
11361487|NCT02290652||Prospective|Prospective - Factors affecting sexual function pre-THR
11361488|NCT02290652||Retrospective|Retrospective- Factors affecting sexual function post-THR
11361489|NCT02290639|Experimental|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
11361490|NCT02290639|Active Comparator|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
11361491|NCT02290626|Experimental|Elemental diet|"Study 1: Elemental diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.
~Study 2: Elemental diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
11361492|NCT02290626|Active Comparator|Semi-solid diet|"Study 1: Semi-solid diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.
~Study 2: Semi-solid diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
11361493|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
11361494|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
11361495|NCT02290600||type 1 diabetes|type 1 diabetes with continuous glucose monitor (CGM)
11361496|NCT02290587|Experimental|Patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
11361497|NCT02290587|Experimental|Control|healthy subject
11361498|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
11361499|NCT02290548|Experimental|high flow nasal cannula|High flow nasal cannula immediately use after extubation
11361500|NCT02290548|Placebo Comparator|stanrd oxygen therapy|Oxygen cannula or mask after extubation
11361501|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
11361502|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
11361503|NCT02290522|Experimental|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
11361504|NCT02290509|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
11361505|NCT02290509|Active Comparator|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
11361506|NCT02290496|Experimental|CBT for Insomnia (CBT-I)|Cognitive behavior therapy to improve sleep and depression.
11361507|NCT02290496|Placebo Comparator|Sleep Hygiene (SH)|Attention control placebo comprising sleep hygiene therapy
11361508|NCT02290470|Experimental|olanzapine Days 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment
~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:
~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (16 mg intravenously on the day of chemotherapy), plus
~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
11361509|NCT02290470|Experimental|olanzapine+Dexamethasone d 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment
~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:
~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus
~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
11361554|NCT02290210|Placebo Comparator|URC102 2.0mg|2.0mg URC102 x 2weeks
11361589|NCT02289976|Active Comparator|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
11361510|NCT02290470|Active Comparator|dexamethasone days 1-3|"Dexamethasone + Chemotherapy + Antiemetic treatment
~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:
~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus
~Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy"
11361511|NCT02290457|Experimental|CSTS|core strength training performed on stable surfaces
11361512|NCT02290457|Experimental|CSTU|core strength training performed on unstable surfaces
11361513|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
11361514|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
11361515|NCT02290431|Experimental|LBH589 + bortezomib + dexamethasone|Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
11361516|NCT02290418|Active Comparator|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass and routine care.
11361517|NCT02290418|Active Comparator|Omega-Loop Gastric Bypass|Laparoscopic Omega-Loop Gastric Bypass and routine care.
11361518|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
11361519|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
11361520|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
11361521|NCT02290379|Experimental|TNX-201 35 mg|Drug: TNX-201 35 mg
11361522|NCT02290379|Experimental|TNX-201 70 mg|Drug: TNX-201 70 mg
11361523|NCT02290379|Experimental|TNX-201 140 mg|Drug: TNX-201 140 mg
11361524|NCT02290379|Active Comparator|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
11361525|NCT02290379|Placebo Comparator|Placebo|Drug: Placebo
11361526|NCT02290366|Experimental|Focal Therapy|
11361527|NCT02290353|Experimental|Adult (Stroke) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
11361528|NCT02290353|Experimental|Teenagers (Cerebral Palsy) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
11361529|NCT02290340|Placebo Comparator|Placebo|Participants will receive placebo intramuscularly.
11361530|NCT02290340|Experimental|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
11361531|NCT02290340|Experimental|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
11361532|NCT02290340|Experimental|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
11361533|NCT02290327|Placebo Comparator|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
11361534|NCT02290327|Active Comparator|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
11361535|NCT02290314|Other|minimally invasive MID-line Lumbar Fusion (MIDLF)|MIDLF surgery involves a minimally invasive midline laminectomy posterior approach to the lumbar spine. An incision that is smaller than the standard incision is made in the midline of the low back directly over the spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed as described in the PLIF procedure.
11361536|NCT02290314|Other|posterior lumbar interbody fusion (PLIF)|PLIF surgery involves a standard incision in the midline of the low back directly over the involved spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed in between the vertebral bodies where the disc usually lies. This will allow bone fusion (healing) to occur from one vertebral body to the other.
11361537|NCT02290301||Type 2 Diabetes Mellitus|
11361538|NCT02290288|Active Comparator|SSF|1. vaginal surgery arm (SSF)
11361539|NCT02290288|Active Comparator|LSC|laparoscopic surgery arm (LSC)
11361540|NCT02290275|Placebo Comparator|Placebo|The subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
11361541|NCT02290275|Experimental|Creatine|The subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
11361542|NCT02290275|Experimental|Walking Exercise|The subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
11361543|NCT02290262|Experimental|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education plus usual care.
11361544|NCT02290262|No Intervention|Usual care|The control group will receive usual care alone.
11361545|NCT02290249|Active Comparator|normal airway|İntubation with glidescope or airtraq in normal airway
11361546|NCT02290249|Active Comparator|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
11361547|NCT02290249|Active Comparator|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
11361548|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
11361549|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
11361550|NCT02290210|Placebo Comparator|Placebo|Placebo x 2weeks
11361551|NCT02290210|Placebo Comparator|URC102 0.25mg|0.25mg URC102 x 2weeks
11361555|NCT02290197|Experimental|Hinged External Fixator|Hinged external fixator allows early and aggressive joint mobility in the sagittal plane only. Flexion and extension are permitted, but rotational movements, translations in the anterior-posterior plane, lateral (varus) and medial (valgus) openings are not allowed. Thus protective stability is ensured for ligament reconstruction procedures. Simultaneously we allow immediate joint mobilization, reducing the risk of arthrofibrosis, joint stiffness and postoperative ligament laxity.
11361556|NCT02290197|Active Comparator|Cast Immobilization|In these patients we used cast postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
11361557|NCT02290184|Experimental|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
11361558|NCT02290184|Active Comparator|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
11361559|NCT02290171|Active Comparator|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
11361560|NCT02290171|No Intervention|Delayed intervention group|The control groups will start intervention with 6 months delay
11361561|NCT02290158|Active Comparator|Orthodontic finishing|Patients receiving a complete orthodontic finishing protocol according to the ABO-OGS
11361562|NCT02290158|No Intervention|No orthodontic finishing|Patients receiving orthodontic treatment without the finishing protocol according to the ABO-OGS
11361563|NCT02290145|Experimental|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
11361564|NCT02290145|Other|surgery group|surgery with post-operative radiotherapy
11361565|NCT02290132||highly aggressive T cell tumors|The study is to research the outcome of Rabbit Anti-human Thymocyte Globulin (ATG)based myeloablative conditioning regimen after allo-HSCT in patients with highly aggressive T-cell tumors.
11361566|NCT02290119|Sham Comparator|Control - Without the use of Verasense|Total Knee Replacement without the use of intraoperative sensors
11361567|NCT02290119|Active Comparator|Sensor-assisted TKR (Verasense)|Total Knee Replacement with the use of intraoperative sensors
11361568|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
11361569|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
11361570|NCT02290093|Active Comparator|Standard full-volume PEG|
11361571|NCT02290093|Experimental|Split-dose full-volume PEG|
11361572|NCT02290093|Experimental|Split-dose low-volume PEG|
11361573|NCT02290080|Experimental|Oxygen|"For patients randomized to oxygen therapy:
~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)
~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
11361574|NCT02290080|No Intervention|No oxygen|"For patients randomized to withholding oxygen treatment
~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)
~all patients receive standard acute coronary syndrome treatment including reperfusion strategies
~observation duration 12 hours"
11361575|NCT02290067|Active Comparator|Omnitest 3|Blood glucose monitoring system
11361576|NCT02290067|Experimental|Omnitest 5|Blood glucose monitoring system
11361577|NCT02290067|Experimental|Omnitest 5D|Blood glucose monitoring system
11361578|NCT02290054|Sham Comparator|Control|A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
11361579|NCT02290054|Experimental|Treated|"A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Auriculotherapy is performed while the patient is sleeping but before thoracic incision.
~Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles."
11361580|NCT02290041|Experimental|Mesenchymal stem cells|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
11361581|NCT02290041|Placebo Comparator|Placebo|Intravenous infusion of 4 doses of Placebo
11361582|NCT02290028|Other|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
11361583|NCT02290015|Experimental|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
11361584|NCT02290015|Sham Comparator|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
11361585|NCT02290002|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
11361586|NCT02290002|Active Comparator|group B|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
11361587|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
11361588|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
11361718|NCT02289274|Active Comparator|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
11361591|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
11361592|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
11361593|NCT02289950|Experimental|Farletuzumab|All subjects will receive a loading dose for the first 2 weeks of 10 mg/kg farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV)
11361594|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
11361595|NCT02289937|Experimental|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
11361596|NCT02289937|Placebo Comparator|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
11361597|NCT02289924||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy
11361598|NCT02289911|Active Comparator|Class|Traditional learning form
11361599|NCT02289911|Active Comparator|Web|Didactic training using internet
11361600|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
11361601|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
11361602|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
11361603|NCT02289885|Experimental|normal model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
11361604|NCT02289885|Experimental|ascites positive model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
11361605|NCT02289872|Experimental|Scenario A|The control scenario, where neither chest compression nor cervical stabilization was applied during intubation.
11361606|NCT02289872|Experimental|Scenario B|The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.
11361607|NCT02289872|Experimental|Scenario C|The chest compression with cervical stabilization scenario, where both chest compression using Lucas-2 and cervical stabilization were applied. A correctly fitting standard cervical immobilization collar (StifNeck Select, Laerdal, Stavanger, Norway) was applied to the manikin's neck to prevent movement of the cervical spine.
11361608|NCT02289859|Active Comparator|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
11361609|NCT02289859|Active Comparator|Wound Closure without Undermining|One side of the wound will remain un-undermined.
11361610|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
11361611|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
11361612|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
11361613|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
11361614|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
11361615|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
11361616|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
11361617|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
11361618|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
11361619|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
11361620|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
11361621|NCT02289807|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone
11361622|NCT02289807|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
11361623|NCT02289794|Active Comparator|E.coli bioconjugate vaccine|E.coli bioconjugate vaccine in saline buffer
11361624|NCT02289794|Placebo Comparator|Placebo|Saline buffer
11361626|NCT02289781||Metal-Ceramic posterior crowns|Metal-supported glass-ceramic veneered crowns which are polished and non-glazed
11361627|NCT02289768|Experimental|5-fluorouracil/salicylic acid|Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
11361628|NCT02289768|Placebo Comparator|Vehicle|Vehicle solution applied to the affected area once-daily for 12 weeks
11361629|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria
~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
11361630|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
11361631|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
11361632|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
11361633|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
11361634|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
11361635|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
11361636|NCT02289703|Experimental|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
11361637|NCT02289703|Experimental|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
11361638|NCT02289690|Experimental|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.
~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
11361639|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
11361640|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
11361641|NCT02289690|Active Comparator|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
11361642|NCT02289677|Experimental|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
11361643|NCT02289664|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11361644|NCT02289664|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11361645|NCT02289651|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11361646|NCT02289651|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11361647|NCT02289638|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11361648|NCT02289638|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11361649|NCT02289625|Active Comparator|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
11361650|NCT02289625|Active Comparator|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.
~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
11361651|NCT02289612|Placebo Comparator|Tapioca Starch - Low-Fibre|Tapoica starch pudding without added fibre
11361652|NCT02289612|Placebo Comparator|High Maltose Corn Syrup - Low-Fibre|High maltose corn syrup pudding without added fibre
11361653|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#1)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at first treatment study visit.
11361654|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#2)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at final treatment study visit.
11361655|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - Tapioca Starch|Yellow mustard gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
11361656|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - High Maltose Corn Syrup|Yellow mustard gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
11361657|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - Tapioca Starch|Soluble flaxseed gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
11361658|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - High Maltose Corn Syrup|Soluble flaxseed gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
11361659|NCT02289612|Active Comparator|Fenugreek Gum Fibre - Tapioca Starch|Fenugreek gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
11361660|NCT02289612|Active Comparator|Fenugreek Gum Fibre - High Maltose Corn Syrup|Fenugreek gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
11361661|NCT02289599|Experimental|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
11361662|NCT02289599|Experimental|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
11361663|NCT02289599|Experimental|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
11361664|NCT02289599|Experimental|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
11361665|NCT02289599|Experimental|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
11361666|NCT02289599|Experimental|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
11361667|NCT02289599|Experimental|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
11361668|NCT02289599|Experimental|Part B: Elderly cohort|One dose level below MTD from Part A
11361669|NCT02289586|Active Comparator|hypoxemia, central airway stenosis.|"Inclusion Criteria:
~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;
~Exclusion Criteria:
~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
11361670|NCT02289586|Experimental|hypoxemia, central airway stenosis|"Inclusion Criteria:
~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;
~Exclusion Criteria:
~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
11361671|NCT02289573|Experimental|neurally adjusted ventilatory assist|
11361672|NCT02289573|Sham Comparator|pressure support ventilation|
11361673|NCT02289560|Experimental|Transcranial ExAblate|Transcranial ExAblate
11361674|NCT02289547|No Intervention|Group A|observational arm
11361675|NCT02289547|Experimental|Group B|arm of capecitabine maintenance treatment
11361676|NCT02289521|Active Comparator|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation
~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
11361677|NCT02289521|Sham Comparator|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation
~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).
~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
11361678|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
11361679|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
11361680|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
11361681|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
11361682|NCT02289495|Experimental|GSK2838232 without RTV|Subjects will receive 20 mg of GSK2838232/ placebo (3:1) in cohort 1 and 50 mg of GSK2838232/ placebo (3:1) in cohort 2, administered QD for 8 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
11361715|NCT02289287|Experimental|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
11361683|NCT02289495|Experimental|GSK2838232 with RTV|Subjects will receive 10 mg of GSK2838232/ placebo (3:1) in cohort 3, 20 mg of GSK2838232/ placebo (3:1) in cohort 4 and 50 mg of GSK2838232/ placebo (3:1) in cohort 5, co administered with RTV 100 mg, QD for 11 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
11361684|NCT02289482|Experimental|GSK2838232 Part A: Single Dose Escalation|During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
11361685|NCT02289482|Experimental|GSK2838232 Part B: Single Dose, 3-Period Crossover, Relative B|During Part B, subjects will receive GSK2838232/ placebo, in an open-label, unbalanced, 3-period, cross-over design; subjects will be randomized (1:1) to each sequence. The relative bioavailability of single 100 mg doses of powder in a bottle (PIB) Active Pharmaceutical Ingredient (API) of GSK2838232 versus PIB Spray-Dried Dispersion (SDD) will be assessed (Period 1: SDD GSK2838232 100 mg vs GSK2838232 API 100 mg; period 2: GSK2838232 API 100 mg Vs SDD GSK2838232 100 mg ). A single dose of GSK2838232 will be co-administered on the 10th day of RTV dosing (period 3:GSK2838232 10 mg + RTV 100 mg); RTV dosing will continue for an additional 4 days (total of 14 days).
11361686|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
11361687|NCT02289469|No Intervention|Usual care|Usual medication history process
11361688|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle
~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
11361689|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
11361690|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
11361691|NCT02289430|Experimental|Crestor+Ezetrol|rosuvastatin+ezetimibe
11361692|NCT02289430|Active Comparator|Ezetrol|ezetimibe
11361693|NCT02289430|Active Comparator|Crestor|rosuvastatin
11361694|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks
~After 12 weeks:
~Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)
~Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)
~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
11361695|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks
~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)
~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
11361696|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)
~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
11361697|NCT02289404|Experimental|NVP-1203(fed then fasting)|Subjects will receive a oral dose of NVP-1203 under fed conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fasting conditions in period 2
11361698|NCT02289404|Experimental|NVP-1203(fasting then fed)|Subjects will receive a oral dose of NVP-1203 under fasting conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fed conditions in period 2
11361699|NCT02289391|Placebo Comparator|non-asthma group|"Non-asthma history
~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of normal saline at 10 minutes before the end of surgery."
11361700|NCT02289391|Experimental|Dexmedetomidine A|"With a history of asthma
~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
11361701|NCT02289391|Experimental|Dexmedetomidine B|"With a history of asthma
~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
11361702|NCT02289391|Placebo Comparator|Control group|"With a history of asthma
~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.
~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.
~Stop infusion of normal saline at 10 minutes before the end of surgery."
11361703|NCT02289378|Experimental|Docetaxel, Oxaliplatin and 5-Fu|Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks
11361704|NCT02289365|Placebo Comparator|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
11361705|NCT02289365|Experimental|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
11361706|NCT02289365|Experimental|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
11361707|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
11361708|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
11361709|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
11361710|NCT02289339||TAVI patients|all patients undergoing transcatheter aortic valve prostheses implantation
11361711|NCT02289313|Experimental|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
11361712|NCT02289300|Experimental|DCB-BO1202|
11361719|NCT02289261|Active Comparator|Control|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
11361720|NCT02289261|Active Comparator|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
11361721|NCT02289248|Experimental|Ketamine/CBT Group|Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
11361722|NCT02289235|Experimental|Ginger|Ginger powder capsule 500 mg
11361723|NCT02289235|Placebo Comparator|Placebo|Placebo powder capsule
11361724|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
11361725|NCT02289209|Experimental|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
11361726|NCT02289196|Experimental|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
11361727|NCT02289196|Experimental|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
11361728|NCT02289196|Experimental|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
11361729|NCT02289196|Experimental|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
11361730|NCT02289183|Experimental|Totally laparoscopic distal gastrectomy|The totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy will be performed for the treatment of patients with distal gastric cancer assigned to this group.
11361731|NCT02289183|Active Comparator|Laparoscopy-assisted distal gastrectomy|The laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis will be performed for the treatment of patients with distal gastric cancer assigned to this group.
11361732|NCT02289170|Experimental|Heating and cooling combination therapy|The patients in this group received heating and cooling combination therapy by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. Doctor press 8 acupuncture points which is treated in LBP patients and select the most painful 2 acupuncture points. Device's probe is attached to the acupuncture points in 15 minutes. Probe's temperature is changed 5 cycles from maximum 45℃ to minimum 15℃.
11361733|NCT02289170|Sham Comparator|Sham heating and cooling therapy|The patients in this group received sham heating and cooling combination therapy in same conditions of treatment group except the temperature. Before the treatment begin, caregiver measure the patient's skin temperature. Then probe's temperature is changed 5 cycles from 1℃ over the skin temperature to 1℃ under the skin temperature.
11361734|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
11361735|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
11361736|NCT02289144|Experimental|Ceritinib|
11361737|NCT02289131|Experimental|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
11361738|NCT02289131|Experimental|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
11361739|NCT02289131|Experimental|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
11361740|NCT02289118||Diagnostic Imaging|[18F]T807 imaging tracer.
11361741|NCT02289105|Experimental|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
11361742|NCT02289105|No Intervention|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
11361743|NCT02289092|Experimental|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
11361744|NCT02289092|No Intervention|Control|Control families will receive services as usual that are being provided to the families within their school
11361745|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
11361746|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
11361747|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
11361748|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
11361749|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
11361750|NCT02289027|Experimental|Deployed volunteers - Group 1|Low dose cAd3-EBOZ (2.5x10e10 vp)
11361751|NCT02289027|Experimental|Deployed volunteers - Group 2|High dose cAd3-EBOZ (5x10e10 vp)
11361752|NCT02289027|Experimental|Not deployed volunteers - Group 3|Low dose cAd3-EBOZ (2.5x10e10 vp)
11361753|NCT02289027|Experimental|Not deployed volunteers - Group 4|High dose cAd3-EBOZ (5x10e10 vp)
11361755|NCT02289014|No Intervention|Wait-list control group|Wait-list control group
11361756|NCT02289014|Experimental|Active treatment group|online stress Management program
11361757|NCT02289001|Experimental|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
11361758|NCT02289001|No Intervention|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
11361759|NCT02288988|Other|GERD patients with Short Esophagus|Patients with True Short Esophagus diagnosed intra-operatively: The length of the intra-abdominal portion of the esophagus < 2.5 cm measured intra-operatively using a combined endoscopic-laparoscopic method. Minimally invasive antireflux surgery was performed (Collis gastroplasty + Nissen fundoplication).
11361760|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
11361761|NCT02288975||Control|Patients with septic shock will get routine ICU care.
11361762|NCT02288962|Experimental|cabergoline|"Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.
~Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study"
11361763|NCT02288962|No Intervention|observation|visits and controls as usual
11361764|NCT02288949||Prospective cohort|Stratification of patients admitted into a network of Spanish ICUs.
11361765|NCT02288936|Experimental|Enzalutamide|Enzalutamide 160 mg/day
11361766|NCT02288923|Active Comparator|Femoral nerve block|Femoral nerve block with 20ml 0.375% Levobupivacaine
11361767|NCT02288923|Active Comparator|Local Infiltration Analgesia|Local infiltration of knee joint using 40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
11361768|NCT02288897|Experimental|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
11361769|NCT02288897|Active Comparator|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
11361770|NCT02288884|Active Comparator|Silver containing dressing|Subjects will have a silver containing dressing (Acticoat PostOp) applied at the time of elective cesarean section.
11361771|NCT02288884|Placebo Comparator|Standard dressing|Subjects will have a standard dressing (OpSite PostOp) applied at the time of elective cesarean section.
11361772|NCT02288871|Other|"Sutureless valve"|"Patients who underwent aortic valve replacement with a sutureless aortic valve.
~An echocardiogram and a cardiac CT-scan will be conducted."
11361773|NCT02288871|Other|"Sewed-in valve"|"Patients who underwent aortic valve replacement with a sewed-in aortic valve. An echocardiogram and a cardiac CT-scan will be conducted."
11361774|NCT02288858|Active Comparator|Test product|Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
11361775|NCT02288858|Placebo Comparator|Placebo|Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
11361776|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
11361777|NCT02288832|Experimental|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold > 105.copies per ml and/or G. vaginalis > 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
11361778|NCT02288832|Other|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
11361779|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
11361780|NCT02288780||Control|BPH patients with normal diastolic function
11361781|NCT02288780||Diastolic dysfunction|BPH patients with preoperative diastolic dysfunction
11361782|NCT02288767|Active Comparator|Control group|For the traditional method group, crystalloid and colloid (maximum 50 ml/kg) are provided through the traditional method of assessing the blood pressure, heart rate and urine volume.
11361783|NCT02288767|Experimental|SVV group|The method of fluid administration to be employed (traditional or SVV via a FloTrac/ EV1000™ monitor) is determined based on the group. Fluid administration is performed in accordance with the group; in general, about 10 ml/kg/h is administered although it may vary for each patient depending on the preoperative fasting, fluid loss during surgery (evaporation, emanation, urination, surgical area, etc.), and blood loss. Crystalloid is administered in the SVV-monitored group with a target below SVV 12%, and a 200-300 ml of colloid (maximum 50 ml/kg) is loaded when SVV is above 12%. If the patient shows hypertension even when SVV is below 12%, a vasoconstrictor should be administered intermittently or consistently.
11361784|NCT02288754||Stage II or III curative surgery (closed to accrual)|Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
11361785|NCT02288754||Stage II or III neoadjuvant therapy cohort (closed to accrual)|Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
11361786|NCT02288754||Metastatic disease|Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
11362877|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
11361787|NCT02288741|Experimental|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
11361788|NCT02288741|Active Comparator|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
11361789|NCT02288741|Other|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
11361790|NCT02288728|Experimental|Group B (double-track anastomosis)|Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
11361791|NCT02288728|Other|Group A (Gastric tube anastomosis)|Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.
11361792|NCT02288715||SAE|patient who develop encephalopathy in the progress of sepsis
11361793|NCT02288715||non-SAE|patient who do not develop encephalopathy in the progress of sepsis
11361794|NCT02288702||Normal|This is the group with no neurological problems or syndrome
11361795|NCT02288702||Down syndrome|This is the group with Down syndrome
11361796|NCT02288676||Case Group|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
11361797|NCT02288676||Control Group|Participants must not be under investigation for any pre-cancerous or cancerous lesions of the genital tract, and must be scheduled for a hysterectomy, bilateral salpingectomy with/without bilateral oopherectomy for presumed benign condition.
11361798|NCT02288663|Other|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
11361799|NCT02288650|Experimental|Liberal group|Early refeeding
11361800|NCT02288650|Sham Comparator|Control group|Refeeding in the day case ward (usual practice)
11361801|NCT02288637|Experimental|Conventional Olyset LLIN|High coverage (>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
11361802|NCT02288637|Experimental|Olyset Plus LLIN|High coverage (>80% access) of Olyset Plus LLIN
11361803|NCT02288637|Experimental|Conventional Olyset LLIN and IRS|High coverage (>80% access) of conventional Olyset LLIN and high coverage IRS (>80% of the household sprayed) with pirimiphos methyl CS
11361804|NCT02288637|Experimental|Olyset Plus LLIN and IRS|High coverage (>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (>80% of the household sprayed) with pirimiphos methyl CS
11361805|NCT02288624|Placebo Comparator|Control|Water control (240 ml)
11361806|NCT02288624|Experimental|Orange Juice|Orange juice, 240 ml. Commercial orange juice
11361807|NCT02288624|Experimental|Whole orange|Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
11361808|NCT02288624|Experimental|processed orange juice|Processed orange juice, 240 ml. Experimental orange juice processing
11361809|NCT02288611|Placebo Comparator|Maltodextrin/Dextrose mix|"Twenty-two healthy human individuals were randomly assigned to consume a control (maltodextrin-dextrose, 40.2g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
~P.S. placebo is called control in this study, where the bioactive comparator is a fruit."
11361810|NCT02288611|Active Comparator|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume date fruits (approx. 50g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
11361811|NCT02288598|Experimental|Anodal TDCS|Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
11361812|NCT02288598|Sham Comparator|Sham TDCS|Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
11361813|NCT02288585|Active Comparator|Plant sterols|Plant sterols
11361814|NCT02288585|Placebo Comparator|Placebo product|Placebo product
11361815|NCT02288572|Active Comparator|Lactobacillus plantarum PCS 26|Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
11361816|NCT02288572|Placebo Comparator|Placebo|Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
11361817|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
11361818|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
11361819|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
11361820|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
11361821|NCT02288546||Vegans|Vegans' data are compared with those of sex-and age-matched non vegetarians
11361822|NCT02288546||Non-vegans|Non-vegans are age and sex-matched controls
11361823|NCT02288533|Experimental|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
11361824|NCT02288507|Experimental|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
11361825|NCT02288494||hypoalbuminemia|The primary purpose was to describe the acid base balance of ICU patients with severe hypoalbuminemia using Stewart's approach for acid base disorders, before and after an human albumin perfusion
11361826|NCT02288481|Experimental|Cohort 1 10 mg TBA-354|
11361827|NCT02288481|Placebo Comparator|Cohort 1 placebo|Placebo Suspension
11361838|NCT02288468|Experimental|STN|"Deep Brain Stimulation of Nucleus subthalamicus with Vercise™ Deep Brain Stimulation System.
~The STN will be typically reached with the most distal contacts of the DBS electrode (8 contact). Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located in the STN. We expect the STN to be typically covered by contacts 1-4 of the Vercise™ DBS lead. Typically, only the most superficial contacts (3,4) will be activated after a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction, reduction of rigidity and bradykinesia. Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
11361839|NCT02288468|Experimental|Vim/DRT|"Deep Brain Stimulation of Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.
~The thalamic target (Vim/DRT) will be typically reached with the proximal contacts. Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located the thalamic target. We expect the thalamic target to be typically covered by contacts 5-8 of the Vercise™ DBS lead. We will perform a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction and the occurrence of side effects (typically capsular e.g. facial contraction). Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
11361840|NCT02288468|Experimental|STN+Vim/DRT|"Combined Deep Brain Stimulation of Nucleus subthalamicus and Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.
~STN+Vim/DRT stimulation is essentially a combination of the previously described procedure."
11361841|NCT02288455|Experimental|RELIEF II - GTU AUS|Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU Artificial Urinary Sphincter device in males with stress urinary incontinence.
11361842|NCT02288442|No Intervention|control|
11361843|NCT02288442|Experimental|exercise|exercise intervention during 8 weeks
11361844|NCT02288429||Colistin|"Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection
~Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
11361845|NCT02288416|Active Comparator|Group I (standard of care)|Patients receive standard of care following LCS consisting of routine visits and telephone contact with the LCS program nurse practitioner and coordinator.
11361846|NCT02288416|Experimental|Group II (video-based intervention)|Patients undergo a video-based intervention prior to undergoing LCS. Patients watch a 5-minute video that focuses on preparing patients for LCS by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. Patients also receive an educational handbook. Patients with positive scans (a Lung-RADS 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results.
11361847|NCT02288403|Experimental|Aerobic interval training|"Interval exercise at an intensity between 90-95% of maximum heart rate (15x30 s), with recoveries at an equivalent speed to 50-55 % of maximal oxygen consumption at baseline (14x60 s).
~24 training sessions, 3x weekly (on alternate days)."
11361848|NCT02288403|Active Comparator|Continuous training|"40 minutes of continuous exercise at an intensity between 65-75% of maximum heart rate.
~24 training sessions, 3x weekly (on alternate days)."
11361849|NCT02288390|Active Comparator|Miswak (Sewak)|Miswak (sewak) oral care applied 4 hourly for oral care in mechanically ventilated patients.
11361850|NCT02288390|Active Comparator|Chlorhexidine/ toothbrush|Chlorhexidine 0.12 % plus toothbrushing oral care applied 4 hourly for oral care in mechanically ventilated patients.
11361851|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
11361852|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
11361853|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
11361854|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
11361855|NCT02288351|Other|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
11361856|NCT02288338|Experimental|1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)|"Three treatment
~atorvastatin calcium 40mg will be administration to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
11361857|NCT02288338|Experimental|2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)|"Three treatment
~ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
11361858|NCT02288338|Experimental|3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)|"Three treatment
~atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
11361859|NCT02288338|Experimental|4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)|"atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
11361860|NCT02288338|Experimental|5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)|"ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
11361897|NCT02288143|Experimental|COOL-COS|All women will receive the intervention: Letrozole, Clomiphene, and low-dose hMG for the controlled ovarian stimulation.
11361898|NCT02288130|Active Comparator|GnRHa and placebo tablets|11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily)
11361861|NCT02288338|Experimental|6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)|"atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days
~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
11361862|NCT02288325|Experimental|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release [ER]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
11361863|NCT02288325|Placebo Comparator|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
11361864|NCT02288325|Experimental|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
11361865|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
11361866|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
11361867|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
11361868|NCT02288299|Experimental|non invasive mechanical ventilation|Patients suffering from neuromuscular disease with NIV indication and cough inefficiency
11361869|NCT02288286|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
11361870|NCT02288286|Experimental|2.5IU/ml in humans aged 21-50|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
11361871|NCT02288286|Experimental|2.5IU/ml in humans aged 51-60|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
11361872|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
11361873|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 21-50 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
11361874|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 51-60 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
11361875|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
11361876|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
11361877|NCT02288260||Part A|PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST
11361878|NCT02288260||Part B|Patients on ticagrelor at the time of discharge from hospital
11361879|NCT02288247|Experimental|Enzalutamide with docetaxel + prednisolone|Continued treatment with enzalutamide after adding docetaxel and prednisolone
11361880|NCT02288247|Placebo Comparator|Placebo with docetaxel + prednisolone|Treatment with placebo after adding docetaxel and prednisolone
11361881|NCT02288234||Vibativ|This is an observational study for patients who were already prescribed Vibativ.
11361882|NCT02288221|Experimental|With non pharmacological therapeutic|Installation of ICT at patient's home
11361883|NCT02288221|Active Comparator|Without non pharmacological therapeutic|No change at patient's home
11361884|NCT02288208|Experimental|Antiviral Therapy & Birinapant|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.
11361885|NCT02288208|Placebo Comparator|Antiviral Therapy & Placebo|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.
11361886|NCT02288195|Experimental|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
11361887|NCT02288195|Experimental|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
11361888|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
11361889|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
11361890|NCT02288169|Experimental|COPE|The experimental group will receive usual care plus the COPE intervention. This group will receive 3 individual intervention sessions. During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom. Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home. Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms. In addition they will get 2 phone calls encouraging them to apply COPE.
11361891|NCT02288169|Sham Comparator|Support|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
11361892|NCT02288169|No Intervention|Control|The control group will receive usual care and no additional attention from our interventionists.
11361893|NCT02288156|Active Comparator|0,1mM|
11361894|NCT02288156|Experimental|0,01mM|
11361895|NCT02288156|Experimental|0.001mM|
11361896|NCT02288156|Placebo Comparator|Placebo|
11361899|NCT02288130|Active Comparator|Ulipristal|Three months of Ulipristal 5 mg once daily combined with a single saline injection at the onset of pretreatment (produced as placebo of Leuproreline)
11361900|NCT02288130|No Intervention|Control|No pre-treatment prior to laparoscopic myomectomy
11361901|NCT02288104|Other|needle based confocal endomicroscopy|The patient, scheduled for a standard liver or kidney percutaneous biopsy or ablation will undergo a needle-based confocal laser endomicroscopy procedure during the procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
11361902|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
11361903|NCT02288078|Active Comparator|Treatment group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), test drug capsule (dexamethasone 2 mg) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.
~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.
~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medicatiob check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
11361904|NCT02288078|Placebo Comparator|Placebo group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), placebo capsule (lactose) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.
~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.
~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medication check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
11361905|NCT02288065||responders|amelioration of dyspnea radiological amelioration after sterile talc pleurodesis
11361906|NCT02288065||failed intervention|unchanged symptoms and radiology after sterile talc pleurodesis
11361907|NCT02288052|Experimental|Writing program|The program will train participants in maintaining writing amplitude, writing speed, writing fluently and automatization of writing.
11361908|NCT02288052|Placebo Comparator|Stretch & Relaxation program|The program will learn participants to alleviate tension in the upper limbs and will consist of exercises performed while lying down or sitting.
11361909|NCT02288039|Experimental|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
11361910|NCT02288039|No Intervention|Standard Care|Participants will receive usual standard treatment
11361911|NCT02288026||Arm I|Patients undergo lobectomy
11361912|NCT02288026||Arm II|Patients undergo a wedge resection or anatomical segmentectomy
11361913|NCT02288013|Other|Stratafix Tissue control device|Closure of Uterine incision at C section
11361914|NCT02288013|Other|Vicryl suture|Closure of uterine incision at C section
11361915|NCT02288000|Active Comparator|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
11361916|NCT02288000|Placebo Comparator|Placebo|The placebo will be presented as capsule comparable to memantine
11361917|NCT02287987|Active Comparator|Clamp|Laparoscopic robot-assisted partial nephrectomy with clamping the renal pedicle during the resection of the tumor
11361918|NCT02287987|Experimental|Off clamp|Laparoscopic robot-assisted partial nephrectomy without clamping the renal pedicle during the resection of the tumor
11361919|NCT02287974|Experimental|Autologous mononuclear stem cell from the bone marrow|Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
11361920|NCT02287974|Experimental|Autologous endothelial stem cell from the bone marrow|Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
11361921|NCT02287974|Experimental|Autologous mesenchymal stem cells from the adiposite tissue|Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
11361922|NCT02287974|Active Comparator|Current medication for the disease|Current medication for the disease
11361923|NCT02287961|Other|Subjects|"Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
~High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
~Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy
~High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
11361924|NCT02287948||MS subjects group|Multiple sclerosis subjects wiht mild-moderate gait disability with EDSS score not higher than 5.5
11361925|NCT02287948||Healthy subjects group|Healthy subjects age-matched with multiple sclerosis subjects.
11361926|NCT02287935|Active Comparator|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique
11361927|NCT02287935|Active Comparator|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis procedure
11361928|NCT02287922|Experimental|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
11361929|NCT02287922|Experimental|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
11361930|NCT02287922|Experimental|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
11361931|NCT02287922|Active Comparator|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
11362878|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
11361932|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
11361933|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
11361934|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
11361935|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
11361936|NCT02287896|Experimental|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.
~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.
~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.
~The postnatal dose must still be given even when antenatal prophylaxis has been administered.
~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
11361937|NCT02287896|Experimental|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.
~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.
~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.
~The postnatal dose must still be given even when antenatal prophylaxis has been administered.
~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
11361938|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.
~Observational: Patient Activation and Engagement (PAE)"
11361939|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.
~Observational: Patient Activation and Engagement (PAE)"
11361940|NCT02287870|Experimental|Chloroprocaine Group|Epidural anesthesia with 3% chloroprocaine.
11361941|NCT02287870|Active Comparator|Lidocaine Group|Epidural anesthesia with 2% lidocaine.
11361942|NCT02287857|Experimental|Domestic Tenofovir Disoproxil Fumarate Tablets|
11361943|NCT02287857|Active Comparator|Tenofovir Disoproxil Fumarate Tablets of Gilead|
11361944|NCT02287844|Experimental|XOS group|Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.
11361945|NCT02287844|Experimental|INU-XOS group|Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.
11361946|NCT02287844|Active Comparator|Placebo|Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.
11361947|NCT02287831|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
11361948|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
11361949|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
11361950|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
11361951|NCT02287805||qualitative survey|"parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery
~12 patients aged over 15 years, operated more than 10 years before"
11361952|NCT02287805||quantitative survey 2|"100 parents of patients 1 year after surgery
~100 parents of patients, 5 years after the operation
~100 patients aged over 15 years and operated over 10 years ago"
11361953|NCT02287792|Experimental|18-FDG PET/CT scan|All patients will undergo a whole body PET/CT scan
11361954|NCT02287779|Experimental|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
11361955|NCT02287779|Placebo Comparator|Placebo|Three subjects per cohort will take a matched placebo
11361956|NCT02287766||Control|Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
11361957|NCT02287766||Metabolic Syndrome Diagnosis Group|Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
11361958|NCT02287753|Experimental|Vascular occlusion test (VOT)|Pediatric patients aged under 8 years old are enrolled in this study. VOT is performed in 3 times : after induction of anesthesia, during cardiopulmonary bypass (CPB) for main surgical procedure and after weaning from CPB. The relationship between postoperative outcome variables and the dynamic parameters from VOT, such as desaturation and reoxygenation rate, and reactive hyperemic area, will be evaluated.
11361959|NCT02287740|Experimental|Tai Ji Quan: Moving for Better Balance|This protocol involves training 2 times a week for 6 months.
11361960|NCT02287740|Active Comparator|Multimodal Exercise|This protocol involves training 2 times a week for 6 months.
11361961|NCT02287740|Sham Comparator|Stretching|This protocol involves participation of 2 times a week for 6 months.
11361962|NCT02287727|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11361963|NCT02287714|Active Comparator|Instep without Gastrocnemius Recession|Patient will receive an instep plantar fascial release but not a gastrocnemius recession.
11361964|NCT02287714|Experimental|Instep with Gastrocnemius Recession|Patient will receive an instep plantar fascial release as well as a gastrocnemius recession.
11361965|NCT02287701|Experimental|PET/MRI|Patient receives MRI
11361966|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
11361967|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
11361968|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:
~In adults, to assist in the:
~localization of lymph nodes draining a primary tumor in patients with
~breast cancer or malignant melanoma when used with a hand-held gamma counter.
~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
11361969|NCT02287662|Experimental|Vancouver 3M Clinical Pathway|The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
11361970|NCT02287649|Other|patients with rituximab treatment|blood sample intake
11361971|NCT02287636|Experimental|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
11361972|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
11361973|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
11361974|NCT02287597||Cohort|
11361975|NCT02287584|Placebo Comparator|DSP-5423P Placebo|Percutaneous
11361976|NCT02287584|Experimental|DSP-5423P 40mg|Percutaneous
11361977|NCT02287584|Experimental|DSP-5423P 80mg|Percutaneous
11361978|NCT02287571|Active Comparator|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
11361979|NCT02287571|Experimental|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
11361980|NCT02287558|Experimental|Pomalidomide|Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.
11361981|NCT02287545||Glaucoma, primary|Glaucoma patients undergoing trabeculectomy
11361982|NCT02287532|Experimental|DIABEO software alone|Patient will have an introductory training session in the use of DIABEO by the investigating physician an will return for an on site consultation at 6 mounths (optional), 12 mounths and 24 mounths
11361983|NCT02287532|Experimental|DIABEO+paramedical telemonitoring|"Patient will have an on site introductory training session in the use of DIABEO, by his/her telemedicine nurse from his/her region. The nurse will then follow up the patient according to a delegated tasks protocol written by the investigating physician with the nurse. Patient will be asked to return to see the investigator at 6 mounths (optional), 12 mounths and 24 mounths"
11361984|NCT02287532|No Intervention|Usual Follow up|Patient will continue his/her usual follow up and return to see the investigator at 6 mounths (optional) and at the one year end of follow up for the study
11361985|NCT02287519|Experimental|Support Group|"One group educational session will include information on resources, self-help strategies, and relaxation techniques.
~One telephone coaching session after the group session Or
~Pilot webinar format of the educational session"
11361986|NCT02287506|Experimental|ODS from enrolment|Optimised Diagnostic Strategy used from enrolment to study
11361987|NCT02287506|No Intervention|ODS at end of study|ODS fed back at the end of the participants involvement with the study
11361988|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
11361989|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
11361990|NCT02287480|Experimental|VSV-ZEBOV lower dose|"One intramuscular (deltoid) injection of a lower dose (10^7 plaque-forming units) of VSV-ZEBOV.
~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10^5 plaque-forming units) of VSV-ZEBOV"
11361991|NCT02287480|Experimental|VSV-ZEBOV higher dose|"One intramuscular (deltoid) injection of a higher dose (5 x 10^7 pfu) of VSV-ZEBOV.
~Study amendment (01.2015) : interrupted"
11361992|NCT02287480|Placebo Comparator|Placebo|One intramuscular (deltoid) injection of normal saline (0.5 ml)
11361993|NCT02287467|Experimental|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
11361994|NCT02287467|Placebo Comparator|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
11361995|NCT02287454|Experimental|Cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
11361996|NCT02287454|No Intervention|Control group|No intervention was administered.
11361997|NCT02287441|Placebo Comparator|Raw Group|Vegetables Prepared Raw (raw)
11361998|NCT02287441|Experimental|Tomato Group|Tomato Products (tomato)
11361999|NCT02287428|Experimental|Coh 1 (Original Cohort): Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):
~~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.
~During that time, participant NeoAntigen Vaccine-Preparation is created (process takes ~ 12 weeks)
~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:
~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
11362000|NCT02287428|Experimental|Coh 1a: Pembrolizumab w Std RT Followed by NeoVax + Pembro|"RT: Standard RT (60Gy) over 6 weeks
~Pembrolizumab: Starts within 2 weeks after start of RT, and continues every 3 weeks for up to 2 years
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
11362001|NCT02287428|Experimental|Coh 1b: Std RT Followed by NeoVax + Pembrolizumab|"RT: Standard RT (60Gy) over 6 weeks
~Pembrolizumab: Starts 2-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
11362002|NCT02287428|Experimental|Coh 1c: Std RT (+ 1 dose Pembro) Followed by NeoVax & Pembo|"RT: Standard RT (60Gy) over 6 weeks
~Pembrolizumab: Single dose of pembrolizumab administered within 2 weeks after start of RT; re-starts 2-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years.
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
11362003|NCT02287428|Experimental|Coh 1d: Std RT+TMZ Followed by 6 Cyc TMZ + NeoVax + Pembro|"• RT: Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks. Concurrent TMZ @ 75 mg/m2/day for 6 weeks.
~Followed by:
~6 cycles of Adjuvant temozolomide (TMZ): Starts 4-6 weeks after completion of RT. TMZ (150-200 mg/m2/day) on days 1-5 of each 28-day cycle for 6 cycles.
~Pembrolizumab: Starts 2-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years
~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
11362004|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
11362005|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
11362006|NCT02287389|Experimental|balloon dilation|give the cases balloon dilation as the intervention
11362007|NCT02287389|Experimental|balloon dilation plus cryotherapy|give the cases balloon dilation plus cryotherapy as the intervention
11362008|NCT02287389|Experimental|BD plus spiculiform electrosurgery|give the cases balloon dilation plus spiculiform electrosurgery as the intervention
11362009|NCT02287389|Experimental|BD plus mitomycin C|give the cases Balloon dilation plus mitomycin C as the intervention
11362010|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
11362011|NCT02287363||TPP group|TPP patients(between episodes of paralysis), the inclusion criteria consisted of a certain history of acute limb muscle weakness, hypokalemia and decreased TSH with elevated free FT4, FT3. Subjects who suffered from hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease were excluded.
11362012|NCT02287363||hyperthyroidism group|Control group, we included subjects with evidence of aberrant thyroid function (decreased TSH, elevated FT4, FT3) without paralysis. Graves' disease(GD) was preferred which required information concerning either increased thyrotrophin receptor antibody(TRAb) level, ophthalmopathy or diffusively enlarged goiter. Individuals with pure thyroid associated ophthalmopathy, history of thyroidectomy due to malignancy or adenoma as well as subacute thyroiditis and pituitary hyperthyroidism were excluded.
11362013|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
11362014|NCT02287337|Experimental|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
11362015|NCT02287337|Other|Exercise|Patients will receive 5 visits of therapeutic exercises
11362016|NCT02287324|Active Comparator|Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine
11362017|NCT02287324|Placebo Comparator|Manual Contact|Manual contact to suboccipital region of the cervical spine for 5 minutes
11362018|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.
~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.
~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
11362059|NCT02286999|Placebo Comparator|Placebo|Infants in the experimental arm will have two doses of placebo (powdered maltodextrin) on Day 7 and Day 14 of life.
11362060|NCT02286986|Other|Cannabidiol|open label administration
11362019|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.
~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.
~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
11362020|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.
~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.
~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
11362021|NCT02287298||2006 TO 2010 PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
11362022|NCT02287298||CURRENT PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
11362023|NCT02287285|Experimental|Exendin9|Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
11362024|NCT02287272|Active Comparator|Treatment period R|single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
11362025|NCT02287272|Active Comparator|Treatment period T|Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
11362026|NCT02287259|Experimental|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
11362027|NCT02287259|Active Comparator|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
11362028|NCT02287246|Experimental|Extended-Release liposomal bupivacaine|20mL Extended-release liposomal bupivacaine injected into the posterior vaginal wall following surgery
11362029|NCT02287246|Active Comparator|Placebo (normal saline)|20mL normal saline injected into the posterior vaginal wall following surgery
11362030|NCT02287233|Experimental|Venetoclax + Low-Dose Cytarabine (LDC)|Participants will receive various doses of Venetoclax
11362031|NCT02287220||Newborn Infants|0-12 months old Male or female Any ethnicity
11362032|NCT02287207|Active Comparator|Anodal tDCS|20 minutes, 1.0 mA unilateral-anodal motor cortex (M1) tDCS stimulation
11362033|NCT02287207|Sham Comparator|Sham tDCS|20 minutes, sham tDCS stimulation
11362034|NCT02287194||SpyGlass Direct Visualization System|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of biliary tract diseases.
11362035|NCT02287181|Active Comparator|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
11362036|NCT02287181|Active Comparator|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
11362037|NCT02287168|Experimental|dissemination of cancer cells|conversion of negative result of pre-gastrectomy peritoneal washing cytology to positive cytology after gastrectomy
11362038|NCT02287168|Experimental|elimination of cancer cells|elimination of peritoneal cancer cells occurred before (pre-gastrectomy peritoneal washing cytology) or after gastrectomy (post-gastrectomy peritoneal washing cytology) by intra operative peritoneal lavage ('post-lavage peritoneal washing cytology)
11362039|NCT02287155|Experimental|occupation based health promotion|"The description of the health promotion intervention is provided in the detailed description of the study. It's a single arm study."
11362040|NCT02287142|Active Comparator|Interscalene|Single-shot Interscalene Nerve Block with ropivacaine 0.5%
11362041|NCT02287142|Active Comparator|Supraclavicular|Single-shot Supraclavicular Nerve Block with ropivacaine 0.5%
11362042|NCT02287142|Active Comparator|Suprascapular|Single-shot Suprascapular Nerve Block with ropivacaine 0.5%
11362043|NCT02287129|Experimental|Non-Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy
11362044|NCT02287129|Active Comparator|Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy
11362045|NCT02287116|No Intervention|nasal mask and nasal prongs|
11362046|NCT02287103|Experimental|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
11362047|NCT02287103|Active Comparator|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
11362048|NCT02287077|No Intervention|Immediate cord clamping|At birth, neonate will be held at the level of placenta and umbilical cord will be clamped immediately (standard of care for depressed neonates).
11362049|NCT02287077|Experimental|Umbilical cord milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
11362050|NCT02287064|Experimental|Intravenous Immune Globulin (IVIG)|
11362051|NCT02287051||colonoscopy population|
11362052|NCT02287038|Active Comparator|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
11362053|NCT02287038|Placebo Comparator|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
11362054|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
11362055|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
11362056|NCT02287012||Pre-Plerixafor era|The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
11362057|NCT02287012||Plerixafor era|The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
11362058|NCT02286999|Experimental|B.infantis|Infants in the experimental arm will have two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis) on Day 7 and Day 14 of life.
11362170|NCT02286362||Cohort|
11362061|NCT02286973|Active Comparator|Only Intravenous Group|Only Intravenous Injection During Operation, 10mg/kr
11362062|NCT02286973|Active Comparator|Intravenous + Topical 1g Group|"Intravenous Injection During Operation, 10mg/kr
~After Capsule Closure, Tranexamic acid Topical Injection 1g"
11362063|NCT02286973|Active Comparator|Intravenous + Topical 2g Group|"Intravenous Injection During Operation, 10mg/kr
~After Capsule Closure, Tranexamic acid Topical Injection 2g"
11362064|NCT02286973|Active Comparator|No Intravenous, Only Topical 2g Group|Only Topical Injection 2g
11362065|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
11362066|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
11362067|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
11362068|NCT02286934|Experimental|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd
~Day 4 to 8 : Carvedilol 25 mg qd
~Day 9 to 11 : Carvedilol 12.5 mg qd
~Isoproterenol Sensitivity Test
~Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.
~Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.
~Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol."
11362069|NCT02286921|Experimental|Arm A: Testosterone cypionate or testosterone enanthate|Patients on BAT will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
11362070|NCT02286921|Experimental|Arm B: Enzalutamide|Patients randomized to enzalutamide will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
11362071|NCT02286895|Active Comparator|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
11362072|NCT02286895|Experimental|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
11362073|NCT02286882|Experimental|Cohort 1: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362074|NCT02286882|Experimental|Cohort 2: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362075|NCT02286882|Experimental|Cohort 3: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362076|NCT02286882|Experimental|Cohort 4: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362077|NCT02286882|Experimental|Cohort 5: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362078|NCT02286882|Experimental|Cohort 6: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362079|NCT02286882|Experimental|Cohort 7: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362080|NCT02286882|Experimental|Cohort 8: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362081|NCT02286882|Experimental|Cohort 9: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
11362082|NCT02286869|Experimental|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.
~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.
~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
11362083|NCT02286869|Experimental|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.
~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.
~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
11362084|NCT02286869|Experimental|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.
~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.
~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
11362085|NCT02286856|Other|control group|Usual care followed bij diet intervention after 6 months
11362086|NCT02286856|Active Comparator|intervention group|diet intervention
11362087|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
11362088|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
11362089|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
11362090|NCT02286817|Experimental|Single arm of 30 subjects|Subjects will be administered single dose of NFC-1 to assess safety, tolerability, and pharmacokinetics, then proceed to continuous, daily administration of NFC-1 for 4 weeks to assess safety, tolerability, and impact on ADHD severity.
11362091|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
11362092|NCT02286791|Experimental|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
11362093|NCT02286791|Active Comparator|Health Education Program|18 sessions of health education program focusing on healthy living topics
11362094|NCT02286778|Active Comparator|Acetogenins|Dietary Supplement: Acetogenins BID for 12 months
11362095|NCT02286778|Placebo Comparator|Placebo|Dietary Supplement: No Acetogenins BID for 12 months
11362096|NCT02286778|No Intervention|Control|Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
11362097|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
11362098|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
11362099|NCT02286752|Active Comparator|neostigmine|
11362100|NCT02286752|Active Comparator|sugammadex|
11362101|NCT02286739|Sham Comparator|Group A TKA without VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
11362102|NCT02286739|Active Comparator|Group B TKA with VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.
11362103|NCT02286726|Experimental|Arm I (lower-dose CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
11362104|NCT02286726|Experimental|Arm II (intermediate-dose CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
11362105|NCT02286726|Experimental|Arm III (standard-dose CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
11362106|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
11362107|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
11362108|NCT02286700|Active Comparator|Desonide Group|Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
11362109|NCT02286700|Experimental|Amino Acid Group|Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
11362110|NCT02286687|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11362111|NCT02286674|Experimental|Tablet for watching movie|The study group will receive standard of care in addition to a tablet to watch movies and/or TV
11362112|NCT02286674|No Intervention|Standard of care - no tablet|The control group will receive standard of care only.
11362113|NCT02286661|Active Comparator|Short Arm Cast|Short arm cast below the elbow
11362114|NCT02286661|Active Comparator|Long Arm Cast|Long arm cast above the elbow
11362115|NCT02286648|Experimental|Mineral Trioxide Aggregate|pulpotomy with MTA
11362116|NCT02286648|Active Comparator|Formocresol|pulpotomy with FC
11362117|NCT02286635|Experimental|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
11362118|NCT02286635|Experimental|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
11362119|NCT02286622|Experimental|Renal Impairment|Eight (8) subjects with ESRD on HD will receive one 18 mg dose of deflazacort.
11362120|NCT02286622|Experimental|Healthy Volunteers|Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the ESRD cohort. Subjects will receive one 18 mg dose of deflazacort.
11362121|NCT02286609|Experimental|Hepatic Impairment|Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
11362122|NCT02286609|Experimental|Healthy Volunteer|Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
11362123|NCT02286596||heparin-induced extracorporeal LDL precipitation|Lipid apheresis treatment for 3 hours
11362124|NCT02286596||dextran sulfate adsorption|Lipid apheresis treatment for 3 hours
11362125|NCT02286583|No Intervention|Microwave Thermography RTM-01-RES|Microwave thermography with sensitive probe that can detect skin and up to 8 cm microwave radiation deep tissues
11362126|NCT02286570|Active Comparator|face-to-face intubation of Glidescope|patients were intubated using glidescope by face-to-face approach
11362127|NCT02286570|Active Comparator|face-to-face intubation with Airtraq|patients were intubated using the Airtraq by face-to-face approach
11362128|NCT02286570|Active Comparator|face-to-face intubation with fastrach|patients were intubated using the Fastrach by face-to-face approach
11362171|NCT02286349|Experimental|Real rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 blocks of real stimulation intensity of 10 Hz, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average).
11362129|NCT02286557|Experimental|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
11362130|NCT02286557|Experimental|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
11362131|NCT02286544|Active Comparator|Salmonella typhi vaccine|0.5 mL Salmonella typhi vaccine
11362132|NCT02286544|Experimental|Salmonella typhi vaccine + oxygen|0.5 mL Salmonella typhi vaccine + 6l/min oxygen
11362133|NCT02286544|Experimental|S. typhi vaccine + oxygen + Atorvastatin|0.5 mL Salmonella typhi vaccine + 6l/min oxygen + 80mg Atorvastatin
11362134|NCT02286531|Experimental|FET imaging|FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2[18F]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
11362135|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
11362136|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
11362137|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
11362138|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
11362139|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
11362140|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
11362141|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
11362142|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
11362143|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
11362144|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
11362145|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
11362146|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
11362147|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
11362148|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
11362149|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
11362150|NCT02286505|Experimental|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
11362151|NCT02286505|Other|Standard radiological assessment.|Standard neuroradiological report of the structural MRI only.
11362152|NCT02286479|Active Comparator|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
11362153|NCT02286479|Experimental|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
11362154|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
11362155|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
11362156|NCT02286453|Experimental|1|Benjakul
11362157|NCT02286453|Active Comparator|2|diclofenac
11362158|NCT02286440|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on test results
11362159|NCT02286440|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
11362160|NCT02286427|Active Comparator|Standard Dressing|J0 to J42 : once a week, primary dressing with Mepitel®
11362161|NCT02286427|Experimental|Amniotic Membrane|J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
11362162|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
11362163|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
11362164|NCT02286388|Experimental|Partial excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
11362165|NCT02286388|Active Comparator|Complete excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
11362166|NCT02286388|Experimental|Antibacterial dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
11362167|NCT02286388|Active Comparator|Conventional dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
11362168|NCT02286375|Experimental|Intervention group|Interventions include providing comprehensive assessment from Omaha system, giving information regarding the self-care management, assisting and coordinating self-regulating skills and abilities, and providing social support from health-social care team to community-dwelling older adults for three months
11362169|NCT02286375|Placebo Comparator|customary care group|Customary care includes receiving community services from the community center in the district, providing monthly social call by a reserch assistant for three months
11362172|NCT02286349|Sham Comparator|Sham rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 stimulation sham blocks, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average)
11362173|NCT02286349|Experimental|Real tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of real anodal transcranial direct current stimulation with intensity of 1 mA + 20 minutes of neuropsychological reassessment (on average).
11362174|NCT02286349|Sham Comparator|Sham tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of sham transcranial direct current stimulation + 20 minutes of neuropsychological reassessment (on average)
11362175|NCT02286336|Experimental|middle aged group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
11362176|NCT02286336|Active Comparator|young group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
11362177|NCT02286323|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
11362178|NCT02286323|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11362179|NCT02286310|Experimental|Group A|Kinetic Chain Exercises
11362180|NCT02286310|Active Comparator|Group B|Traditional Exercises
11362181|NCT02286297|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
11362182|NCT02286297|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11362183|NCT02286284|Experimental|Apheresis arm|Apheresis for extracorporal removal of sFlt-1
11362184|NCT02286258|Experimental|Inuline - Calcium EDTA|Calcium EDTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
11362185|NCT02286258|Experimental|Inuline - Gd-DOTA|Gd-DOTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
11362186|NCT02286245|Experimental|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
11362187|NCT02286245|Active Comparator|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
11362188|NCT02286232|Experimental|Stretching exercise|A series of 12 standardized, weekly stretching exercise classes will be held at the Wilton Family YMCA, designed for people with chronic low back pain unaccustomed to stretching. Participants will be asked to practice the identical routine of that week's stretching exercise class on off days and will be given handouts and CD's to assist in this.
11362189|NCT02286232|Active Comparator|Self-care book|The Back Pain Helpbook (Moore JE, Lorig K, Von Korff M, Gonzalez VM, Laurent DD. The Back Pain Helpbook. Reading, MA: Perseus Books; 1999)provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
11362190|NCT02286219|Experimental|FS102|Dose escalation of either weekly or Q3W of FS102
11362191|NCT02286206|Experimental|Clozapine bid|"Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.
~Intervention: Days 1-14"
11362192|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
11362193|NCT02286167|Other|Single arm diet|Intermittent, modified Atkins diet
11362194|NCT02286154|Experimental|Hydroxyurea|"All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the New Cohort or Old Cohort New Cohort participants include those who are not receiving hydroxyurea therapy upon study entry. Old Cohort participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines."
11362195|NCT02286141||Intervention|Patients receiving care at primary care clinics randomized to receive the supplemental training on stratified care for back pain through the use of the StartBack Tool will be considered to be a part of the intervention group. Randomization is done at the clinic level and not at the individual patient level.
11362196|NCT02286141||Control|Patients receiving care at primary care clinics randomized to receive the standard Group Health training on the updated Guidelines for Back Pain Care will be considered to be a part of the control group. Randomization is done at the clinic level and not at the individual patient level.
11362197|NCT02286128||Non-diabetic controls|Age-matched non-diabetic subjects
11362198|NCT02286128||Type 2 diabetes|Type 2 diabetes with metformin monotherapy failure
11362199|NCT02286115|Experimental|Life-Stress Interview|The Life-Stress Interview is an experiential assessment technique
11362200|NCT02286115|No Intervention|Wait-list Control|Wait-list Control
11362201|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
11362202|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
11362203|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
11362234|NCT02285868||Hip and lower extremity injuries|Pre- and post-treatment outcomes of care as measured by the Lower Extremity Functional Scale via physical therapy
11362204|NCT02286063|Active Comparator|ambulatory oxygen cylinders|Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
11362205|NCT02286063|No Intervention|no oxygen cylinders|Subjects randomised to be on air for the first two weeks of the treatment period.
11362206|NCT02286050|Experimental|CF Nursing Intervention|
11362207|NCT02286011|Experimental|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.
~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
11362208|NCT02286011|Placebo Comparator|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
11362209|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
11362210|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
11362211|NCT02285985|Experimental|Saxagliptin|Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
11362212|NCT02285985|Placebo Comparator|Placebo|Sugar pill
11362213|NCT02285972|Placebo Comparator|saline|
11362214|NCT02285972|Active Comparator|dexketoprofen|
11362215|NCT02285972|Active Comparator|tenoxicam|
11362216|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
11362217|NCT02285933|Experimental|VRT|sitting balance exercises delivered via virtual reality training
11362218|NCT02285933|Active Comparator|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
11362219|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
11362220|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
11362221|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
11362222|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
11362223|NCT02285907|Experimental|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
11362224|NCT02285907|Experimental|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
11362225|NCT02285907|Experimental|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
11362226|NCT02285907|Experimental|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
11362227|NCT02285894|Experimental|Inspiratory hold|Mechanical inspiratory pressure held for 10 seconds at a time.
11362228|NCT02285881|Experimental|shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
11362229|NCT02285881|No Intervention|control group|Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
11362230|NCT02285868||Arm, Shoulder and Hand injuries|Pre- and post-treatment outcomes of care as measured by the DASH (Disabilities of the Arm, Shoulder and Hand) via physical therapy
11362231|NCT02285868||Lumbar spine injuries|Pre- and post-treatment outcomes of care as measured by the Modified Oswestry (lumbar spine) via physical therapy
11362232|NCT02285868||Knee injuries|Pre- and post-treatment outcomes of care as measured by the Knee Outcome Survey via physical therapy
11362233|NCT02285868||Foot and ankle injuries|Pre- and post-treatment outcomes of care as measured by the Foot & Ankle Ability Measure via physical therapy
11362235|NCT02285868||Neck injuries|Pre- and post-treatment outcomes of care as measured by the Neck Disability Index Questionnaire via physical therapy
11362236|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
11362237|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
11362238|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
11362239|NCT02285829||T4/T1=0.1-0.25|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
11362240|NCT02285829||T4/T1=0.25-0.50|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
11362241|NCT02285829||T4/T1=0.50-0.75|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
11362242|NCT02285829||T4/T1=0.75-0.90|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
11362243|NCT02285816|Experimental|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
11362244|NCT02285816|Experimental|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10^10 pfu administered IM on day (-14). No dose escalation is planned.
11362245|NCT02285816|Experimental|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 & 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
11362246|NCT02285803|Active Comparator|TRT and real tDCS|
11362247|NCT02285803|Sham Comparator|TRT and sham tDCS|
11362248|NCT02285790|Experimental|RCM-OSS procedure|The Vivascope 1500 will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed for intended use only and interpreted on the Vivascope workstation by two investigators independently at both study locations. The investigators will be blinded to the results of the reference standard. After RCM imaging subjects will receive OSS surgical excision according to subtype. Clinically suspected primary BCCs that are not confirmed by RCM will also receive surgical treatment with a margin of 3mm.
11362249|NCT02285790|Active Comparator|Standard of care procedure|Clinical suspected primary BCCs, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most elevated part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. HE stained sections of the punch biopsies will be evaluated by an experienced board certified pathologist. Subjects will receive surgical excision according to subtype within 6 weeks after punch biopsy has been performed. Clinically suspected new primary BCCs that are not confirmed by punch biopsy will also receive surgical treatment with a margin of 3mm.
11362250|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
11362251|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
11362252|NCT02285764|Experimental|Nutritional Supplement|One 237 ml oral supplement consumed two times a day; Not commercially available.
11362253|NCT02285764|Other|Standard of Care|As determined by the study site
11362254|NCT02285751|Experimental|200mg acetylsalicylic acid per os|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os"
11362255|NCT02285751|Experimental|100mg acetylsalicylic acid intravenous|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously."
11362256|NCT02285751|Experimental|81 mg chewable acetylsalicylic acid|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid"
11362257|NCT02285751|Active Comparator|75mg clopidogrel|"control group for patients with high on treatment platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day"
11362258|NCT02285751|Experimental|60mg prasugrel|"Loading dose of prasugrel for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel"
11362259|NCT02285751|Experimental|600mg clopidogrel|"additional loading dose for 24 patients tested with high on treatment platelet reactivity to clopidogrel"
11362290|NCT02285556|No Intervention|ATS diagnosis and evaluation for normal people|Do the same initial and follow-up assessment as ATS abusers who stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community .
11362260|NCT02285751|Experimental|180mg ticagrelor|"Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity after being treated with 10mg prasugrel daily"
11362261|NCT02285751|Active Comparator|prasugrel 10mg|patients treated with 10mg prasugrel daily
11362262|NCT02285738|Active Comparator|Aspirin+Asprin/Simvastatin+Observation (ASO)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation
11362263|NCT02285738|Experimental|Aspirin+Observation+Asprin/Simvastatin (AOS)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin
11362264|NCT02285738|Experimental|Aspirin/Simvastatin+Observation+Asprin (SOA)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day
11362265|NCT02285738|Experimental|Aspirin/Simvastatin+Asprin+Observation (SAO)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.
11362266|NCT02285738|Experimental|Observation+Aspirin/Simvastatin+Asprin (OSA)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.
11362267|NCT02285738|Experimental|Observation+Aspirin+Asprin/Simvastatin (OAS)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.
11362268|NCT02285725|Experimental|Augmented Microdrilling Surgery|
11362269|NCT02285712|No Intervention|Classical method of peripheral venous catheterization|Classical method will be applied only on arm and forearm.
11362270|NCT02285712|Experimental|Ultrasound guided peripheral venous catheterization|Nurse will use a vascular ultrasound system to orient the catheter toward the peripheral vein. Ultrasound method will be applied only on arm and forearm.
11362271|NCT02285699|Other|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
11362272|NCT02285673|Experimental|Umbilical Cord Mesenchymal Stem Cell|
11362273|NCT02285660|Other|Routine CT scan plus 4D PET-CT scan|
11362274|NCT02285660|Other|Routine CT scan|
11362275|NCT02285647|Experimental|Rolapitant - Oral|Investigational Product: Rolapitant Dose: 200 mg (4 x 50mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
11362276|NCT02285647|Experimental|Rolapitant - IV|Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
11362277|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
11362278|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
11362279|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
11362280|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
11362281|NCT02285621|Experimental|Optimized brace|Test group: Patient will receive optimized brace (3D computer assisted design of the brace)
11362282|NCT02285621|Active Comparator|Standard brace|Control goup: Patient will receive the Boston Thoracolumbosacral orthosis (TLSO) (conventional design method)
11362283|NCT02285608|Experimental|PIMM/SAM|Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
11362284|NCT02285608|No Intervention|Standard Prescribing Practice(SPP)|Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
11362285|NCT02285595|Other|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
11362286|NCT02285556|No Intervention|general information|use cross-sectional study to collect 1000 ATS abuse or dependence patients' general information and 5 ml blood,get their blood plasma and DNA sample in order to explore the possible addict mechanism.
11362287|NCT02285556|No Intervention|ATS diagnosis and evaluation for abusers|Use cohort study design to establish ATS abuse induced craving experiment.Do the initial and follow-up assessment from start smoking to stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community . Thus compare with normal group to explore the possible psychological abuse mechanism.
11362288|NCT02285556|Active Comparator|psychological training intervention|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
11362289|NCT02285556|Active Comparator|brain stimulation intervention|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
11362542|NCT02283931|Active Comparator|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
11362291|NCT02285556|Active Comparator|physical and neurological rehabilitation|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
11362292|NCT02285556|Placebo Comparator|fake brain stimulation intervention|fake transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
11362293|NCT02285543|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.
~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
11362294|NCT02285543|Other|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
11362295|NCT02285530|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.
~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
11362296|NCT02285530|Other|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
11362297|NCT02285517|Active Comparator|modified Meek technique|Intervention: modified Meek skin grafting technique. Patients with third degree of burns without infected wounds are included and the modified Meek results are studied , measured and compared to other group which is operated lesions by mesh technique
11362298|NCT02285517|Active Comparator|mesh technique|Intervention: mesh skin grafting technique. patients with third degree of burns without infected wounds are included and the mesh skin grafting technique results are studied , measured and compared to other group which is operated lesions by modified Meek skin grafting technique
11362299|NCT02285504|Experimental|SAGE-547|
11362300|NCT02285491|Experimental|bupivacaine group|This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision
11362301|NCT02285491|Placebo Comparator|saline group|This group will receive saline injections as placebo into both angles of the rectus sheath incision
11362302|NCT02285491|Experimental|bupivacaine and saline group|This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle.
11362303|NCT02285465|Experimental|ASP3700 multiple ascending dose cohort|
11362304|NCT02285465|Placebo Comparator|Placebo cohort|
11362305|NCT02285452|Active Comparator|Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)|Thorax wrap with ginger flour, duration max. 20 minutes
11362306|NCT02285452|Active Comparator|Thorax wrap with mustard flour (Sinapis nigrea semen)|Thorax wrap with mustard flour, duration max 20 minutes
11362307|NCT02285452|Placebo Comparator|Thorax wrap with warm water (placebo)|Thorax wrap with warm water (placebo), duration: 20 minutes
11362308|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
11362309|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
11362310|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
11362311|NCT02285426||suspected lungcancer|"Patients will undergo a bronchoscopy with the Pentax EB1990i HD-bronchoscope investigating the entire bronchial tree. The HD+ bronchoscopy needs to be performed in a standardized way using 3 different imaging modes:
~HD+bronchoscopy
~HD+bronchoscopy + i-Scan 1
~HD+bronchoscopy + i-Scan 2"
11362312|NCT02285413|Experimental|DC vaccination|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase
11362313|NCT02285413|Experimental|DC vaccination with cisplatinum|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase. each DC vaccine will be preceded by cisplatin infusion: 50 mg/m2, 1-2h before DC injection.
11362314|NCT02285400|Experimental|Moderate COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
11362315|NCT02285400|Experimental|Severe COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
11362316|NCT02285387|Experimental|Rhythm control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
~Cardioversion after 1 month
~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
~If AF recur, RFCA"
11362317|NCT02285387|Active Comparator|Rate control group|"No AAD, just anticoagulation
~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
11362318|NCT02285374|Experimental|Arm 1|Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily
11362319|NCT02285374|Experimental|Arm 2|Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily
11362320|NCT02285361||GIOTRIF|
11362321|NCT02285348|Other|Ataxia Telangiectasia|20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
11362322|NCT02285348|Other|Healthy Control|20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
11362323|NCT02285335|Experimental|Low group|GINST15 3g/day
11362324|NCT02285335|Experimental|High group|GINST15 6g/day
11362325|NCT02285322||BP control reached|Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to <140/90mmHg if aged less than 60 years old, and <150/90mmHg for those of ≥60 years
11362326|NCT02285322||BP control not reached|Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
11362327|NCT02285309||Cardiac surgery|
11362328|NCT02285296|No Intervention|control arm|usual care
11362329|NCT02285296|Experimental|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
11362330|NCT02285283|Placebo Comparator|Placebo|2 capsules by mouth twice a day for 24 weeks
11362331|NCT02285283|Active Comparator|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
11362332|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
11362333|NCT02285244|Experimental|Treatment (sotrastaurin acetate)|Patients receive sotrastaurin acetate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11362334|NCT02285231|Experimental|TEST|Arginyl-fructose Supplementation
11362335|NCT02285231|Experimental|Placebo|Placebo Supplementation
11362336|NCT02285218||1) Normal control|metabolically healthy with no obesity
11362337|NCT02285218||2) dyslipidemia|high triglyceride levels or LDL-C levels
11362338|NCT02285218||3) type 2 diabetes|defined in 'inclusion criteria'
11362339|NCT02285218||4) non-alcoholic fatty liver disease|defined in 'inclusion criteria'
11362340|NCT02285205|Experimental|Lobeglitazone|
11362341|NCT02285192|Experimental|intracervical 18F-FDG injection during a dynamic PET/CT|The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
11362342|NCT02285179|Experimental|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
11362343|NCT02285179|Placebo Comparator|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
11362344|NCT02285166||Oral administration of 2 g of omega-3-acid ethyl esters|Oral administration of 2 g of omega-3-acid ethyl esters once daily or twice daily immediately after meals
11362345|NCT02285166||Standard antihyperlipidemic therapy|Standard antihyperlipidemic therapy other than omega-3 fatty acid ethyl esters (Lotriga) administration.
11362346|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
11362347|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
11362348|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
11362349|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
11362350|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
11362351|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
11362352|NCT02285127|Active Comparator|Short nail implant|used to treat pertrochanteric fractures
11362353|NCT02285127|Active Comparator|Long nail implant|used to treat pertrochanteric fractures
11362354|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age will switch their current 2-NRTI containing regimen to F/TAF while continuing on their 3rd ARV agent for 48 weeks.
11362355|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF while continuing on their boosted PI for 48 weeks.
11362356|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age must be on a boosted protease inhibitor (PI) or other protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF while continuing their 3rd ARV agent for 48 weeks.
11362357|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
11362358|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
11362359|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
11362360|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
11362361|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
11362417|NCT02284724|Experimental|Needling|Insertion of solid mono-filament needle into lumbar multifidus muscle at both sides of L4/5 segment
11362362|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
11362363|NCT02285101|Experimental|Cohort 1|PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
11362364|NCT02285101|Experimental|Cohort 2|PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
11362365|NCT02285101|Experimental|Cohort 3|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
11362366|NCT02285101|Experimental|Cohort 4|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
11362367|NCT02285101|Experimental|Cohort 5|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
11362368|NCT02285101|Experimental|Cohort 6|PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
11362369|NCT02285088|Experimental|GBT440|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
11362370|NCT02285088|Placebo Comparator|Placebo|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
11362371|NCT02285075|Other|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
11362372|NCT02285062|Experimental|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
11362373|NCT02285062|Active Comparator|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
11362374|NCT02285049||Urticaria Control Test|"Evaluation by UAS28, PatGA-LS, PhyGA-LS
~Fill the UCT and DLQI questionnaire"
11362375|NCT02285036|Experimental|A newly PPV23|The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
11362376|NCT02285036|Active Comparator|PNEUMOVAX 23|PNEUMOVAX 23 is an established US-licensed vaccine and manufactured by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
11362377|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)
~Fill the DLQI and CU-Q2oL questionnaire"
11362378|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
11362379|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
11362380|NCT02284997|Experimental|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
11362381|NCT02284997|No Intervention|Control|No treatment
11362382|NCT02284984|Experimental|Rituximab with belimumab|Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.
11362414|NCT02284750|Active Comparator|Provisional stenting technique|Percutaneous coronary intervention with Provisional stenting technique. Stenting of the side branch was required if TIMI flow was <3, or ≥ type B dissection after kissing balloon inflation.
11362415|NCT02284737|Experimental|PADN + sildenafil|Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
11362416|NCT02284737|Sham Comparator|sham PADN + sildenafil|The radiofrequency ablation catheter placed, no ablations.
11362383|NCT02284971|Experimental|Arm A: CDX1127 & SBRT Concurrent|"SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).
~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
11362384|NCT02284971|Experimental|Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).
~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
11362385|NCT02284971|Experimental|Arm C: CDX1127 & SBRT Sequential; SBRT upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).
~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
11362386|NCT02284958|Active Comparator|Standard/Control group|Each participant will receive a one-off individualized educational session regarding the management of chronic low back pain with a Physical Therapist: includes a physical examination, standardized advice & provision of the 'Back Book'.
11362387|NCT02284958|Experimental|Walking group|Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
11362388|NCT02284945|Experimental|Posterior percutaneous instrumentations|
11362389|NCT02284945|Other|Traditional open surgery with pedicle screw fixation|
11362390|NCT02284932||COPD patients|Group : COPD patients No specific intervention for this study
11362391|NCT02284932||Healthy controls|Group : healthy volunteers No specific intervention for this study
11362392|NCT02284919|Experimental|ISO-1 PET/CT|All subjects will receive an [18F]ISO-1 PET/CT scan
11362393|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
11362394|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
11362395|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
11362396|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
11362397|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
11362398|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
11362399|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
11362400|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
11362401|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
11362402|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
11362403|NCT02284841|Experimental|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
11362404|NCT02284841|No Intervention|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
11362405|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
11362406|NCT02284815|Active Comparator|Glutenfree diet|Self-chosen glutenfree diet
11362407|NCT02284815|Placebo Comparator|Normal diet|Those not following the glutenfree diet
11362408|NCT02284802|Experimental|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
11362409|NCT02284789|Other|CAJAS evaluation|
11362410|NCT02284776|No Intervention|Témoin|No treatment.
11362411|NCT02284776|Experimental|Action|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
11362412|NCT02284763|Experimental|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
11362413|NCT02284750|Experimental|Two-stenting technique|Percutaneous coronary intervention with DK crush, or culotte technique
11362541|NCT02283931|Active Comparator|two handed uterine displacement|Uterine displacement using two hands
11362418|NCT02284724|Other|Sham|The plastic tube containing the mono-filament needle will be pressed into the skin over the lumbar multifidus muscle at both sides of L4/5 segment - without insertion through the skin
11362419|NCT02284711|Active Comparator|Bipolar|Coagulation during salpingectomy using conventional bipolar electric energy
11362420|NCT02284711|Active Comparator|Ultrasound|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
11362421|NCT02284698||Study Group|Study Group will have the field workers and active health education with referral mechanism
11362422|NCT02284698||Control Group|Control group will not have field workers and active health education. They will follow routine health care
11362423|NCT02284685|Experimental|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
11362424|NCT02284685|Experimental|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
11362425|NCT02284685|Experimental|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
11362426|NCT02284685|Experimental|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
11362427|NCT02284685|Experimental|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
11362428|NCT02284685|Experimental|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
11362429|NCT02284685|Experimental|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
11362430|NCT02284685|Experimental|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
11362431|NCT02284672|Placebo Comparator|control|"After preoxygenation for 3 minutes, normal saline would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.
~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
11362432|NCT02284672|Experimental|dexmedetomidine|"After preoxygenation for 3 minutes, dexmedetomidine would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.
~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
11362433|NCT02284659|Sham Comparator|FES-sham|Functional Electro Stimulation (FES-sham)
11362434|NCT02284659|Active Comparator|Intervention (FES)|functional electro stimulation
11362435|NCT02284646|Experimental|Personalized physical training|9-week personalized physical training program (ergometric bicycle)
11362436|NCT02284646|No Intervention|Information about physical activity|2 sessions of information on physical activity
11362437|NCT02284620|Experimental|CFNB group|Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
11362622|NCT02283346|Experimental|HDR Brachytherapy + EBRT|HDR brachytherapy + hypofractionated EBRT
11362438|NCT02284620|Active Comparator|LWI group|Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
11362439|NCT02284607|Experimental|MHAA4549A higher dose|
11362440|NCT02284607|Experimental|MHAA4549A lower dose|
11362441|NCT02284607|Placebo Comparator|Placebo|
11362442|NCT02284594|Experimental|text message|Receipt of series of text messages regarding influenza vaccination
11362443|NCT02284594|No Intervention|usual care|
11362444|NCT02284581||Retrospective cohort|All consecutive metastatic breast cancers patients treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from Feb 2014 retrospectively back until 2000.
11362445|NCT02284581||Prospective cohort|All new consecutive metastatic breast cancers patients will be treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from March 2014 to December 2016.
11362446|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
11362447|NCT02284568|Experimental|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
11362448|NCT02284568|Experimental|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
11362449|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
11362450|NCT02284542||Patients with successful trial implant|Patients who have had a successful SCS trial and are indicated for permanent implantation will be approached to participate in this study prior to permanent implantation. Patients will be recruited and enrolled by physicians at any one of the involved sites. Each Investigator will only use one method (awake or non-awake) according to his/her typical practice. Patients will receive treatment from their enrolling physician.
11362451|NCT02284529|Experimental|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8~12 cycles
11362452|NCT02284516|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
11362453|NCT02284516|Placebo Comparator|Placebo|Placebo to match active treatment, BID for 84 days
11362454|NCT02284503|Experimental|40mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.
11362455|NCT02284503|Experimental|20mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.
11362456|NCT02284503|Experimental|no statin group|The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.
11362457|NCT02284490|Experimental|Treatment Arm|Pemetrexed 900 mg/m² every 21 days until disease progression.
11362458|NCT02284477|Experimental|non- PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in glass bottle for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
11362459|NCT02284477|Experimental|PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
11362460|NCT02284477|No Intervention|Only lunch and dinner|Participant received food for lunch and dinner After 1 week, participant get over to each experimental arms.
11362461|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
11362462|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
11362463|NCT02284451|Active Comparator|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
11362464|NCT02284451|Active Comparator|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
11362465|NCT02284451|Active Comparator|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
11362466|NCT02284451|Active Comparator|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
11362467|NCT02284438|Other|Biofilm formation on ETT|Three different endotracheal tubes uses on intubated mechanical ventilated patients will after extubation be examined regarding biofilm, structure and presence of microbes on the ETTs The different tubes will be used during consecutive time periods The study does not include any interventions concerning the treatment of these critically ill patients
11362468|NCT02284425|Experimental|Part A|Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
11362469|NCT02284425|Experimental|Part B|Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
11362470|NCT02284412|Active Comparator|neostigmine|Neostigmine will be dosed as 60 μg/kg, and glycopyrrolate 12 μg/kg (commercially available 5:1 co-formulation), as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
11362471|NCT02284412|Experimental|Sugammadex|Sugammadex will be dosed 15 mg/kg, as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
11362472|NCT02284412|Placebo Comparator|Water for injection|Water will be dosed arbitrarily as a 1 mL single iv bolus administered over 10sec.
11362473|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
11362474|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
11362475|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
11362476|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
11362477|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
11362478|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
11362479|NCT02284360|Experimental|Group A: Low dose|"Each volunteer in group A will receive both Verum and Placebo.
~The Verum lyophilized APOSEC™ is derived from 12.5*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.
~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
11362480|NCT02284360|Experimental|Group B: High dose|"Each volunteer in group B will receive both Verum and Placebo.
~The Verum lyophilized APOSEC™ is derived from 25*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.
~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
11362481|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
11362482|NCT02284334||Low GI-High GI|"Two study visits are separate by around one month.
~For this arm, test meal (Visit 1): low-glycemic index; test meal (Visit 2): high-glycemic index"
11362483|NCT02284334||High GI-Low GI|"Two study visits are separate by around one month.
~For this arm, test meal (Visit 1): high-glycemic index; test meal (Visit 2): low-glycemic index"
11362484|NCT02284308|Active Comparator|Concurrent RCHT|"Etoposide (day 1, 2 and 3) and cisplatin (day 1) every 3 weeks, 3 cycles)
~Etoposide (day 1, 2 and 3) and carboplatin (every 3 weeks, 3 cycles)
~Cisplatin (daily)
~Pemetrexed/Alimta and cisplatin (day 1 every 3 weeks, 3 cycles)
~Pemetrexed/Alimta and carboplatin (day 1 every 3 weeks, 3 cycles)
~Radiation schedule:
~Radiotherapy in both arms is delivered to a minimal total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the mininimal TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
11362485|NCT02284308|Active Comparator|Sequential RCHT|"Pemetrexed/Alimta and cisplatin day 1 every 3 weeks, 3 cycles,
~Pemetrexed/Alimta and carboplatin (every 3 weeks, 3 cycles),
~Gemcitabine (day 1 and 8) and cisplatin (day 1) every 3 weeks, 3 cycles)
~Gemcitabine (day 1 and 8) and carboplatin, (day 1 every 3 weeks, 3 cycles)
~Radtiation schedule:
~Radiotherapy in both treatment arms is delivered to a minimum total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the minimum TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
11362486|NCT02284295||occupational COPD|"Consists of 2 subgroups
~COPD patients with history of exposure to respirable silica dust
~COPD patients with history of exposure to aromatic hydrocarbons"
11362487|NCT02284295||smokers with COPD and healthy control|"patients with COPD, history of tobacco smoke and no history of occupational exposure
~healthy subjects"
11362488|NCT02284282|Active Comparator|Spinal injection|Patients receive spinal injection Bupivacaine/Morphine
11362489|NCT02284282|Placebo Comparator|Subcutaneum injection|Placebo subcutaneum injections
11362490|NCT02284256|Experimental|Fibrocaps|"Human fibrinogen and thrombin powder. Single application during surgery
~Other Names:
~Raplixa
~PRO-0601
~Fibrin sealant
~Device: Gelatin sponge. Single application during surgery
~Other Name: Spongostan"
11362491|NCT02284256|Active Comparator|TachoSil|Human fibrinogen and thrombin powder. Single application during surgery
11362492|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
11362493|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
11362494|NCT02284230|Active Comparator|Liraglutide treatment|Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
11362495|NCT02284230|Placebo Comparator|Placebo treatment|Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
11362496|NCT02284217|Experimental|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
11362497|NCT02284204|Active Comparator|Midazolam and Ketamine|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
11362498|NCT02284204|Experimental|Midazolam, Ketamine and Sevoflurane|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.
11362499|NCT02284191|Active Comparator|CT Coronary Angiogram|CT Coronary Angiogram plus standard care
11362500|NCT02284191|No Intervention|Standard Care|Standard care only
11362501|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
11362502|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
11362503|NCT02284152|Experimental|Typical versus Infant-Led feeding|This is a within-subject study; all infants and mothers will be exposed to both conditions (typical feeding versus infant-led feeding conditions). Order of presentation will be counterbalanced across infant/mother dyads.
11362504|NCT02284139|Placebo Comparator|Placebo|Placebo ointment dose not contain EGF.
11362505|NCT02284139|Active Comparator|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
11362506|NCT02284139|Active Comparator|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
11362507|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
11362508|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
11362509|NCT02284113|Experimental|Treatment|Treatment with focused cold therapy.
11362510|NCT02284113|Sham Comparator|Sham|Sham treatment with focused cold therapy device
11362511|NCT02284100|Experimental|animal assisted therapy group|the dog was present during post-operative awakening (2 hours after surgery)
11362512|NCT02284100|No Intervention|standard group|children had standard post-operative medical care
11362513|NCT02284087||V_PAS|Visuomotor paired associative stimulation protocol
11362514|NCT02284087||Sham V_PAS|Placebo group of Visuomotor paired associative stimulation protocol
11362515|NCT02284087||CER_PAS|cerebellar-motor associative stimulation protocol
11362516|NCT02284087||Sham CER_PAS|Placebo group of cerebellar-motor associative stimulation protocol
11362517|NCT02284074|Experimental|Nasal LPS spray|"This is a 5-way crossover, randomised, placebo-controlled study.
~Arms consists of the following nasal challenges:
~placebo, 1, 10, 30 and 100µg LPS."
11362518|NCT02284061|Experimental|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
11362519|NCT02284061|Other|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
11362520|NCT02284048|Placebo Comparator|control|nitrate,beta blocker
11362521|NCT02284048|Active Comparator|ticagrelor|ticagrelor 90mg qd
11362522|NCT02284035|Experimental|Group 1 Raltegravir / 3TC (MK0518B|Raltegravir / 3TC (MK0518B ) (50 patients)
11362523|NCT02284035|Active Comparator|Group 2 standard combination therapy|"NNRTI-Based Regimen:
~• EFV/TDF/FTC
~PI-Based Regimens:
~ATV/r + TDF/FTC or DRV/r + TDF/FTC
~INSTI-Based Regimens:
~DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
~NNRTI-Based Regimens:
~EFV plus ABC/3TC or RPV/TDF/FTC
~PI-Based Regimen:
~ATV/r plus ABC/3TC
~PI-Based Regimens:
~DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
~INSTI-Based Regimen:
~RAL plus ABC/3TC
~And other ART regimens"
11362524|NCT02284022||Brain Computer Interface|Patients will test the brain computer interface system
11362525|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
11362526|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
11362527|NCT02283996|Experimental|Physical Therapy with Steroid Injection|Patients will undergo regular physical therapy as defined by the standard of care at Massachusetts General Hospital for Adhesive Capsulitis (Frozen Shoulder). If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
11362528|NCT02283996|Experimental|Watchful Waiting with Steroid Injection|Patients will undergo no therapeutic intervention outside of steroid injection. If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
11362529|NCT02283983|Active Comparator|Standard cryoprotection|Proposal helmet without mittens and booties
11362530|NCT02283983|Experimental|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
11362531|NCT02283970||BAV and aortic regurgitation|BAV Diagnosis, Aortic Regurgitation with surgical indication (according to current clinical guidelines or best clinical practice), normal ascending aorta
11362532|NCT02283970||BAV and Ascending aorta dilatation|BAV diagnosis, no or trivial Aortic Regurgitation, ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice)
11362533|NCT02283970||BAV, aortic regurgitation and dilatation|BAV diagnosis, Aortic Regurgitation and ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice).
11362534|NCT02283970||BAV with aortic stenosis in pts>60yrs|BAV diagnosis, Aortic stenosis with surgical indication (according to current clinical guidelines or best clinical practice). Normal ascending aorta
11362535|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
11362536|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
11362537|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
11362538|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
11362539|NCT02283944|Experimental|TMS electrochemotherapy|Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
11362540|NCT02283931|Active Comparator|One handed uterine displacement|Uterine displacement using one hand
11362543|NCT02283918||Participants with education less than bachelor's degree|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
11362544|NCT02283918||Participants with bachelor's degree or equivalent|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
11362545|NCT02283905|Other|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. ~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
11362546|NCT02283892|Experimental|Checklist|2 checklists available for consultation by the attending physician: (1) dyspnea evaluation checklist and (2) cough evaluation checklist. The checklists are available on computers and mobile devices (smartphone, PDA or tablet computer).
11362547|NCT02283892|Active Comparator|Conventional assessment|Evaluation of patients reporting dyspnea or cough made by the attending physician, without the use of the checklists for dyspnea or cough evaluation.
11362548|NCT02283879|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
11362549|NCT02283866|Experimental|Administering desflurane according to the patient's BIS value|The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
11362550|NCT02283866|Experimental|Administering desflurane at 1 MAC|The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
11362551|NCT02283853|Experimental|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
11362552|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
11362553|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
11362554|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
11362555|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
11362556|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
11362557|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
11362558|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
11362559|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
11362560|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
11362561|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A
~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;
~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days
~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
11362562|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;
~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;
~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
11362563|NCT02283801|Experimental|Group A|"Group A
~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;
~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
11362564|NCT02283801|Experimental|Group B|"Group B
~Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;
~Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;
~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days
~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
11362565|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
11362566|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
11362623|NCT02283333|Experimental|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
11362567|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
11362568|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
11362569|NCT02283775|Experimental|PomdeSAR|"Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression
~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression"
11362570|NCT02283762|Experimental|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
11362571|NCT02283762|Placebo Comparator|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
11362572|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
11362573|NCT02283736|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one tablet containing Lactobacillus rhamnosus SP1 per day during 3 months.
11362574|NCT02283736|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
11362575|NCT02283723|Experimental|Patient Group 1|This patient group will begin receiving the Health TAPESTRY intervention from time zero.
11362576|NCT02283723|Active Comparator|Patient Group 2|Using a step-wedge approach, this patient group will receive the intervention after a six month waiting period where they will be used as a comparable group. In the first six months, they will receive usual care.
11362577|NCT02283710|Experimental|Pentoxifylline + lifestyle modification|Pentoxifylline for 6 months plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
11362578|NCT02283710|Experimental|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity.
11362579|NCT02283697|Experimental|Dietary Counseling|Apart from standard care, an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the DASH (Dietary Approach to Stop Hypertension) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
11362580|NCT02283697|Other|Control: Standard Care|A standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
11362581|NCT02283684|Active Comparator|Greenlight laser PVP|Greenlight (532-nm) laser Photoselective vaporization of the prostate using (XPS) 180W system
11362582|NCT02283684|Active Comparator|Bipolar TUVP|Bipolar transurethral vaporization of the prostate using bipolar system
11362583|NCT02283671|Experimental|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.
~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.
~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
11362584|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11362585|NCT02283645|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the chest.
11362586|NCT02283645|Placebo Comparator|Placebo|Placebo lotion is applied twice daily to the chest.
11362587|NCT02283632|Experimental|Jejunal Diversion|all subjects who receive jejunal diversion surgery
11362588|NCT02283619||Patients with LBBB being evaluated for ACS|Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.
11362589|NCT02283580|Experimental|Single limb resistance training|"Low load, high-repetitive resistance training.
~single limb at a time (e.g., one arm or one leg)
~elastic bands"
11362590|NCT02283580|Active Comparator|Two limb resistance training|"Low load, high-repetitive resistance training.
~two limbs at a time (e.g., both arms or both legs)
~elastic bands"
11362591|NCT02283554|Placebo Comparator|ARM1- open flap debridement (OFD)|open flap debridement done for 30 subjects. After debridement, Metformin or PRF was not added into the intrabony defect.
11362592|NCT02283554|Experimental|ARM2- open flap debridement plus PRF(Platelet rich fibrin)|"After open flap debridement, PRF( Platelet rich fibrin) was added into the intrabony defect.
~No. of subjects= 30"
11362593|NCT02283554|Experimental|ARM3- open flap debridement plus 1%Metformin|After open flap debridement, 1% metformin was added into the intrabony defect No. of subjects= 30
11362594|NCT02283554|Experimental|ARM4- open flap debridement plus PRF plus metformin|"After open flap debridement, PRF and 1% metformin was added into the intrabony defect.
~No. of subject- 30"
11362624|NCT02283333|Active Comparator|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
11362625|NCT02283320|Experimental|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
11362626|NCT02283307|Experimental|Reduced contrast DECT scan|Reduced Contrast Dual Energy CT
11362627|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
11362595|NCT02283541|Experimental|ASTM|Participants in Automatic self-transcending meditation (ASTM) arm will complete a 12 week meditation training program in addition to their existing treatment plan. This involves participating in 120-minute sessions on each of four consecutive days of the first week. Participants will individually be given a mantra on day one, and then be instructed in use of the mantra according to specific criteria over the four session program. This will be followed by weekly 60-minute follow up sessions for the 11 subsequent weeks. In addition, participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12.
11362596|NCT02283541|No Intervention|TAU|Participants in TAU arm will continue with their existing treatment schedule as usual. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12. However, no assessments will be done or information collected on the TAU arm from week 12 onwards. After week 12, TAU arm participants will be offered the opportunity to learn ASTM and attend follow up meditation.
11362597|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
11362598|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
11362599|NCT02283515|Active Comparator|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
11362600|NCT02283515|Placebo Comparator|group II - placebo|placebo-placed locally in intrabony defects.
11362601|NCT02283502|Experimental|Intervention: MRgHIFU, Surgery|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
11362602|NCT02283489|Experimental|Combination therapy A|Recombinant human endostatin adenovirus (EDS01), 5.0 × 1011 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
11362603|NCT02283489|Experimental|Combination therapy B|Recombinant human endostatin adenovirus (EDS01), 1.0 × 1012 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
11362604|NCT02283489|Experimental|Chemotherapy|Paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
11362605|NCT02283476|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with Gemcitabine and Cisplatin
11362606|NCT02283476|Active Comparator|Endostar routine intravenous infusion|Endostar routine intravenous infusion in combination with Gemcitabine and Cisplatin
11362607|NCT02283463|Active Comparator|Standard Cervical Tenaculum|Single tooth tenaculum, pierces the tissue of the cervix to allow provider to stabilize and place traction on the cervical cal/uterus
11362608|NCT02283463|Experimental|Bioceptive Cervical Retraction Device|Suction based method for stabilizing the cervix and uterus. Achieves suction 360 degrees around cervical os creating a portal through which instruments can be passed into the cervical canal and uterus. Provider can still place traction on uterus with this device just as with tenaculum.
11362609|NCT02283450||the experimental group|The patients in experimental group received the relevant tests and inspections before the beginning of experiment，signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，we evaluated the symptoms，the function of heart，blood pressure，heart rate and keep blood specimens. Three and six month later，electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
11362610|NCT02283450||the placebo group|The placebo group was followed up in the same way.
11362611|NCT02283437|Experimental|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program (PSBPF) using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living' (p.11).
11362612|NCT02283437|Active Comparator|Behavioral Management and Education Program|The Behavioral Management and Education group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) psycho-education and McFarlane et al.'s (2003) family behavioral management programs for schizophrenia.
11362613|NCT02283437|No Intervention|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
11362614|NCT02283424|Active Comparator|chemotherapy|Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
11362615|NCT02283424|Experimental|Icotinib|Icotinib, 125mg,3/D,2years
11362616|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
11362617|NCT02283398|Experimental|with RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
11362618|NCT02283398|Sham Comparator|without RIPC|the cuff will be placed around the left arm without being inflated
11362619|NCT02283385|Experimental|PROTECT Intervention|Participants will receive a brief psychotherapy that builds on Problem Solving Therapy (PST)
11362620|NCT02283372|Experimental|nab-Paclitaxel + Gemcitabine + IMRT|"Prior to initiation of chemoradiation, patients will undergo 1 full cycle of gemcitabine and nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
~Both gemcitabine and nab-paclitaxel will be given intravenously on an outpatient basis during the one-month lead-in period and during Weeks 1 and 2 (and, if enrolled to Dose Level or 2, Weeks 4 and 5) of radiotherapy. There may be up to 21 days between the last dose of lead-in chemotherapy (given on Day 15) and initiation of chemoradiation (inclusive of the week following Day 15, the fourth week of the lead-in cycle (an off-week), and an additional week following that).
~Intensity modulated radiation (IMRT) - the prescribed dose will range from 40-67.5 Gy over 15 to 25 fractions."
11362621|NCT02283359|Experimental|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m^2; Level 1: 40 mg/m^2; Level 2: 50 mg/m^2; Level 3: 65 mg/m^2.
~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m^2."
11362628|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
11362629|NCT02283281|Experimental|Nabiximols high dose|"Single-dose, before anesthetic induction:
~21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, oromucosal spray.
~Dummy 50 ml vial containing 0.9% sodium chloride solution, intravenous.
~Prefilled dummy 2ml syringe containing 0.9% sodium chloride solution, intravenous."
11362630|NCT02283281|Experimental|Nabixomols low dose|"Single-dose, before anesthetic induction:
~10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, oromucosal spray.
~Dummy 50 ml vial containing 0.9% sodium chloride solution, intravenous.
~Prefilled dummy 2ml syringe containing 0.9% sodium chloride solution, intravenous."
11362631|NCT02283281|Active Comparator|Active placebo|"Single-dose, before anesthetic induction:
~Dummy oromucosal spray containing alcohol vehicle without nabiximols.
~Prefilled 50 ml vial containing 1 g acetaminophen, intravenous.
~Prefilled 2 ml syringe containing 2 mg midazolam, intravenous."
11362632|NCT02283281|Placebo Comparator|Control|"Single-dose, before anesthetic induction:
~Dummy oromucosal spray containing alcohol vehicle without nabiximols.
~Dummy 50 ml vial containing 0.9% sodium chloride solution, intravenous.
~Prefilled dummy 2ml syringe containing 0.9% sodium chloride solution, intravenous."
11362633|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
11362634|NCT02283255|Active Comparator|Physical Activity 1|Aerobic Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months.
11362635|NCT02283255|Active Comparator|Physical Activity 2|Respiratory Training: muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
11362636|NCT02283255|Active Comparator|Physical Activity 3|Aerobic and Respiratory Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months and respiratory muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
11362637|NCT02283255|No Intervention|Physical Activity 4|No Physical Activity: Control group (usual care)
11362638|NCT02283242|Experimental|Galantamine|"8 mg of Galantamine for 4 weeks
~16 mg Galantamine for 8 weeks"
11362639|NCT02283242|Placebo Comparator|Placebo|"8 mg of placebo for 4 weeks
~16 mg placebo for 8 weeks"
11362640|NCT02283229|Active Comparator|Active|Newborns with preventive caring advices
11362641|NCT02283229|Placebo Comparator|Surveillance|Newborns with normal caring advices
11362642|NCT02283216|Experimental|Acoustic, Body, Cortical|Acoustic corresponds to noise sound stimulation. Body corresponds to body electrical stimulation. Cortical corresponds to transcranial magnetic stimulation. Acoustic is presented together with body and cortical stimulation. Different body locations and timing among acoustic, body, and cortical stimulation are presented across testing sessions.
11362643|NCT02283203|Active Comparator|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
11362644|NCT02283203|Placebo Comparator|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
11362645|NCT02283190|Experimental|Ewwinase|Six doses of Erwinase given three times weekly (Monday-Wednesday-Friday) for two weeks. Possible dose levels used are 20.000 IU/m2/day, 25,000IU/m2/day, and 30,000IU/m2/day.
11362646|NCT02283177|Experimental|Cohort A|Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
11362647|NCT02283177|Experimental|Cohort B|Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
11362648|NCT02283164|Experimental|Treatment|Hazardous materials online education and study feedback
11362649|NCT02283164|Active Comparator|Control then treatment|Hazardous materials online education and study feedback
11362650|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
11362651|NCT02283151|Experimental|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
11362652|NCT02283099|Experimental|rVSVΔ-ZEBOV-GP (BPSC1001)|Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
11362653|NCT02283086|No Intervention|Control|
11362654|NCT02283086|Experimental|Intervention|The intervention consisted of quarterly performance feedback reports sent via e-mail.
11362655|NCT02283073||Idiopathic Parkinson's disease|Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.
11362656|NCT02283073||Differential Diagnosis Group|MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls
11362657|NCT02283060|Experimental|Stribild switch arm|Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
11362658|NCT02283060|Active Comparator|Atripla control arm|Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
11362659|NCT02283047|Active Comparator|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
11362660|NCT02283047|Experimental|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
11362697|NCT02282826|Experimental|Dose 5 SC|GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362661|NCT02283047|Experimental|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
11362662|NCT02283047|Experimental|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
11362663|NCT02283034|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
11362664|NCT02283034|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
11362665|NCT02283021||NSCLC Patients|Sample biopsies from normal and cancerous lung tissue.
11362666|NCT02283021||Patients without NSCLC|Sample biopsies from normal lung tissue.Control group.
11362667|NCT02283008|No Intervention|Standard care|This arm will receive standard care which involves informal education on how to use metered dose inhalers
11362668|NCT02283008|Active Comparator|Structured education|This arm will receive structured education on the use of inhalers. At 6 weeks post education inhaler technique will be re-assessed. Participants who fail to achieve a set level of competence may be chosen for semi structured interview.
11362669|NCT02282995||•FDR-Relatives of FD patients|"Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.
~Up to 20 ml of fasting blood sample will be collected
~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
11362670|NCT02282995||•FDC-Healthy control|"Healthy control. Controls who are self-referred to this study will be recruited.
~Up to 20 ml of fasting blood sample will be collected
~Fasting glucose test will be performed for FD patients
~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
11362671|NCT02282995||•FD-Patients with FD|"Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.
~Up to 20 ml of fasting blood sample will be collected
~Fasting glucose test will be performed for FD patients"
11362672|NCT02282995||•FDCR-Relatives of healthy controls|"Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.
~Up to 20 ml of fasting blood sample will be collected
~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
11362673|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
11362674|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
11362675|NCT02282956|Experimental|study group|single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
11362676|NCT02282956|Other|controll Group|After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
11362677|NCT02282943|Active Comparator|Laser|vapourisation/excision of endometriosis using CO2 laser
11362678|NCT02282943|Experimental|Harmonic scalpel|excision of endometriosis using Harmonic scalpel
11362679|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
11362680|NCT02282917|Experimental|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
11362681|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
11362682|NCT02282891|Active Comparator|Propofol|Induction of general Anesthesia using propofol 2mg/kg
11362683|NCT02282891|Experimental|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
11362684|NCT02282878|Experimental|High/Low Sodium Diet|All MS patients will receive 2 weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
11362685|NCT02282878|Active Comparator|High/Low Sodium Diet Control|Age matched controls will receive two weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
11362686|NCT02282865||Visual analogue scale (VAS) >5|The degree of surgery-related anxiety assessment using VAS
11362687|NCT02282865||Visual analogue scale (VAS) ≤5|The degree of surgery-related anxiety assessment using VAS
11362688|NCT02282852|Experimental|Wireless Capsule Endoscopy|Wireless capsule endoscopy is the investigation modality of choice for suspected diseases of the small bowel. A small pill-sized capsule contianing a camera is swallowed by the patient. The procedure is safe and non-invasive. Normally, the pill camera travels through the gut an exits the bowel via natural means. In a small number of cases the capsule is maintained. If the capsule is still in the stomach, mobilisation is encouraged followed by an intramuscular pro-kinetic injection if this fails.
11362689|NCT02282852|Active Comparator|Magnetically steerable capsule endoscopy|A handheld magnet (manufactured by Intromedic Ltd.) has been developed to allow some control of the pill camera (that contains a small amount of magnetic material) in the upper GI tract. We propose that this could be used, alongside positional changes, to expedite capsule transit through the stomach thus improving completion rates and avoiding the risks of unnecessary medication.
11362690|NCT02282839|Active Comparator|Study group|Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy
11362691|NCT02282839|Placebo Comparator|Control group|Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy
11362692|NCT02282826|Experimental|Dose 1 IV|GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362693|NCT02282826|Experimental|Dose 2 IV|GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362694|NCT02282826|Experimental|Dose 3 IV|GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362695|NCT02282826|Experimental|Dose 3 SC|GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362696|NCT02282826|Experimental|Dose 4 SC|GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362698|NCT02282826|Placebo Comparator|Placebo SC|placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362699|NCT02282826|Placebo Comparator|Placebo IV|placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
11362700|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
11362701|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
11362702|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
11362703|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
11362704|NCT02282800||Case group|Case group include patients with generalized AgP were the tissue samples taken to analyse the number of vitamin D receptor present.
11362705|NCT02282800||Control group|Ethnically matched, systemically and periodontally healthy individuals were included in control group were also gingival tissue taken for analysis of number of receptors present in nucleus and cytoplasm
11362706|NCT02282787|Experimental|5 micron dex arm|
11362707|NCT02282787|Experimental|10 micron dex arm|
11362708|NCT02282774|Experimental|SB|receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture
11362709|NCT02282774|Sham Comparator|C|receive subtenon block of 4mL saline
11362710|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
11362711|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
11362712|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
11362713|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
11362714|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
11362715|NCT02282709|Experimental|Daclatasvir and asunaprevir|daclatasvir 60 mg once daily asunaprevir 100 mg BID
11362716|NCT02282696|Experimental|cancer patients|Questionnaire, focus group participation
11362717|NCT02282683|Experimental|Prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months.
11362718|NCT02282683|No Intervention|Control|Maximum tolerated guideline-directed medical therapy
11362719|NCT02282670|Experimental|DA-5204|DA-5204 administered two times daily for two weeks
11362720|NCT02282670|Active Comparator|Stillen tab.|Stillen tab. administered three times daily for two weeks
11362721|NCT02282657|Experimental|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
11362722|NCT02282644|Experimental|CellSearch|
11362723|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
11362724|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
11362725|NCT02282618||heart failure with HTEA|Heart failure patients are treated with the world-wide accepted medicine, plus HTEA for 4 weeks.
11362726|NCT02282618||heart failure with medicine|Heart failure patients are treated with the world-wide accepted medicine.
11362727|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
11362728|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
11362729|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
11362730|NCT02282592||Cases|newly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
11362731|NCT02282592||Controls|patients without any malignant disease, matched for age an menopausal status with cases.
11362732|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
11362733|NCT02282566|Placebo Comparator|Protein-nutrition beverage - Placebo|: 8 oz protein-nutrition beverage 1
11362734|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 2|8 oz protein-nutrition beverage 2
11362735|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 3|8 oz protein-nutrition beverage 3
11362736|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 4|8 oz protein-nutrition beverage 4
11362762|NCT02282397|Other|Phase 1: CGM|Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management. RT-CGM (Continuous Glucose Monitoring) is the intervention.
11362763|NCT02282397|No Intervention|Phase 2: CGM/MDI|Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
11362764|NCT02282397|No Intervention|Phase 2: CGM/CSII|Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
11362765|NCT02282384|Experimental|oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
11362737|NCT02282553|Experimental|Magnetically steerable pill camera|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet. This technique will be compared to conventional gastroscopy which uses a flexible endoscope. Both techniques will be used to diagnose upper gastrointestinal pathology in patients with recurrent/refractory iron deficient anemia.
11362738|NCT02282540|Experimental|Iodixanol to the Eustachian tube|Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
11362739|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
11362740|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
11362741|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
11362742|NCT02282501|Active Comparator|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
11362743|NCT02282501|Active Comparator|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
11362744|NCT02282488|Experimental|Group 1: Low protein formula|Low protein formula
11362745|NCT02282488|Experimental|Group 2: high protein formula|High protein formula
11362746|NCT02282488|No Intervention|Group Breastfeeding|Breastfeeding
11362747|NCT02282475||Cohort study of pregnant women|"Participants will complete the following at 12-16 weeks gestation and again at 32-36 weeks gestation:
~Fasting glucose, insulin and insulin sensitivity testing;
~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;
~Measurements of body fat using air displacement technology and MRI;
~Ultrasound to measure placental blood flow, visceral fat thickness (12-16 weeks only) and to estimate fetal weight (32-36 weeks only);
~24 hour diet recalls
~Questionaires regarding activity level"
11362748|NCT02282475||Case-control study Gestational Diabetes|"Participants diagnosed with gestational diabetes (cases) and without gestational diabetes (controls) will complete the following at 32-36 weeks gestation:
~Fasting glucose, insulin and insulin sensitivity testing;
~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;
~Measurements of body fat by using air displacement technology and MRI;
~Ultrasound to measure placental blood flow and to estimate fetal weight;
~24 hour diet recalls
~Questionaires regarding activity level"
11362749|NCT02282462|Experimental|Reg pressure, Active suction (Dig)|Regulated pleural pressure with active suction
11362750|NCT02282462|Experimental|Reg pressure, Passive drainage (Dig)|Regulated pleural pressure with passive drainage
11362751|NCT02282462|Experimental|Unreg pressure, Active suction (Trad)|Unregulated pleural pressure with active suction
11362752|NCT02282462|Experimental|Unreg pressure, Passive drainage (Trad)|Unregulated pleural pressure with passive drainage
11362753|NCT02282449|Experimental|Power Injectable Port|The subjects randomized to this group will receive the newer, power injectable port.
11362754|NCT02282449|Active Comparator|Non-Power Injectable Port|The subjects randomized to this group will receive the older, non-power injectable port.
11362755|NCT02282436||COPD exacerbation|No specific intervention for this study
11362756|NCT02282423|Experimental|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
11362757|NCT02282423|Experimental|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
11362758|NCT02282423|Experimental|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
11362759|NCT02282423|Experimental|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.
~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
11362760|NCT02282410|Experimental|ADVATE standard prophylaxis|This study is a prospective, open-label, interventional, multicenter study in a total of 15 PTPs with hemophilia A (FVIII≤2 %).The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
11362761|NCT02282397|No Intervention|Phase 1: SMBG|Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management. No intervention to be administered
11362766|NCT02282384|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
11362767|NCT02282371|Experimental|Cetuximab + BYL719 + IMRT|Cetuximab loading dose, 400 mg/m2 intravenously (IV). IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days Cetuximab 250 mg/m2 weekly IV X 7 weeks Daily BYL719, according to dose escalation scheme followup clinic visits every 3 months for 2 years,every 6 months for the next 3 years, and annually thereafter.
11362768|NCT02282358|Experimental|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
11362769|NCT02282345|Experimental|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.
~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
11362770|NCT02282332|Experimental|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
11362771|NCT02282319|Experimental|A chloro|spinal chloroprocaine 40 mg
11362772|NCT02282319|Experimental|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
11362773|NCT02282319|Experimental|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
11362774|NCT02282306|Other|TTIP-PRO|"Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the Personal Feedback Report, which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the Personal Risk Factors Report which is mailed to the participant with some other helpful information."
11362775|NCT02282293|Active Comparator|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
11362776|NCT02282293|Placebo Comparator|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
11362777|NCT02282280||Study Group|All patients included in the study
11362778|NCT02282267|Experimental|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
11362779|NCT02282254|Active Comparator|Single-hormone closed-loop strategy|
11362780|NCT02282254|Active Comparator|Dual-hormone closed-loop strategy|
11362781|NCT02282241|Placebo Comparator|Placebo|Patients given once daily placebo (cellulose) orally in the evening, for 14 days.
11362782|NCT02282241|Experimental|Melatonin|Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.
11362783|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
11362784|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
11362785|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
11362786|NCT02282215|Active Comparator|G-CSF|Randomized
11362787|NCT02282202|Other|Off/on for 3 weeks followed by on/off for 3 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device (Aerobika ®) or no device for three weeks, then crossover for the following three weeks.
11362788|NCT02282189|Other|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
11362789|NCT02282176|Experimental|Azithromycin|10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
11362790|NCT02282176|Placebo Comparator|Placebo|Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
11362791|NCT02282163|Experimental|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
11362792|NCT02282150|Other|Conventional vs modified hydrocortisone;|5 weeks of conventional hydrocortisone followed by 16 weeks of modified-release hydrocortisone (Plenadren)
11362793|NCT02282137|Experimental|68Ga-PSMA|Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.
11362794|NCT02282124|Experimental|Intervention|"The intensity of the intervention follows a defined algorithm during the first eight months after renal transplantation. Behaviours are classified in three groups:
~Group 1: Patients with optimal behaviour in all three behaviours.
~Group 2: Patients with slight deviation (defined) from optimal behaviour in one or more behaviours.
~Group 3: Patients with larger deviation (defined) from optimal behaviour in one or more behaviours.
~All patients (group 1-3) will receive an assessment, education and a monthly reassessment.
~Patients from group 2 und 3 will receive additionally behavioral education and peer involvement. Patients from group 3 will receive additionally a consilium of specialized healthcare professionals such as a nutritionist, physiotherapist, or psychologist."
11362795|NCT02282124|Other|Control|
11362796|NCT02282111|Active Comparator|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
11362831|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
11362832|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
11362797|NCT02282111|Active Comparator|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
11362798|NCT02282098|Experimental|Active Colchicine|The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months
11362799|NCT02282098|Placebo Comparator|Placebo Colchicine|The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.
11362800|NCT02282085|Experimental|Aripiprazole Once-Monthly|Switch to 400 mg aripiprazole once-monthly injection
11362801|NCT02282085|Active Comparator|Standard of Care|Continue current SOC oral antipsychotic medication
11362802|NCT02282072|Active Comparator|Deep Brain Stimulation|Stimulator is ON
11362803|NCT02282072|Sham Comparator|Placebo|Stimulator is OFF
11362804|NCT02282059||sunitinib group|patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
11362805|NCT02282046||non-diabetic group|patients without diagnosed type 2 diabetes, having an HbA1c level below 6.0%
11362806|NCT02282046||type 2 diabetes group|patients diagnosed with type 2 diabetes of over 1 year duration.
11362807|NCT02282033|Experimental|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.
~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
11362808|NCT02282020|Experimental|1/OLAPARIB|olaparib 300mg oral tablets; twice daily
11362809|NCT02282020|Active Comparator|2/CHEMOTHERAPY|Physician's choice single agent chemotherapy
11362810|NCT02282007|No Intervention|No Intervention:Control group|
11362811|NCT02282007|Experimental|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
11362812|NCT02281994|Active Comparator|Active PEMF|Active device emits Pulsed Electromagnetic Field (PEMF)
11362813|NCT02281994|Placebo Comparator|Control/no PEMF|control/placebo device does not emit Pulsed Electromagnetic Field (PEMF)
11362814|NCT02281981|Experimental|Curcumin supplement|200 mg, curcuminoids, 7d of supplementation in capsular form
11362815|NCT02281981|Placebo Comparator|Placebo|sucrose, capsular
11362816|NCT02281968|Experimental|NSAID cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
11362817|NCT02281968|Placebo Comparator|Placebo cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
11362818|NCT02281955|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
11362819|NCT02281942|Experimental|Yoga|Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension.
11362820|NCT02281942|Placebo Comparator|Education|A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress).
11362821|NCT02281929|Active Comparator|amoxicillin+ prednisolone|Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
11362822|NCT02281929|Placebo Comparator|Placebo + prednisolone|Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
11362823|NCT02281916|Experimental|P28GST treatment|P28GST as a parasite enzyme
11362824|NCT02281903|Experimental|Chest compression of manikins chest|Compression of pediatric manikins chest according European Resuscitation Council 2010 guidelines for cardiopulmonary resuscitation.
11362825|NCT02281890||Proven sepsis|Children included in the INIS trial in whom pathogenic organisms (i.e. bacteria or fungi) were cultured from blood and/or cerebrospinal fluid during the sepsis period at the time of study inclusion
11362826|NCT02281890||Clinical sepsis|Children included in the INIS trial in whom no pathogenic organisms (i.e. bacteria or fungi) were cultured from blood or cerebrospinal fluid during the sepsis period at the time of study inclusion
11362827|NCT02281877|Experimental|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.
~Standard Rehabilitation Protocol"
11362828|NCT02281877|Active Comparator|Control|Standard Rehabilitation Protocol
11362829|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
11362830|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
11362833|NCT02281838|Experimental|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
11362834|NCT02281838|Active Comparator|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
11362835|NCT02281825||Control|Adolescents without any psychiatric disorder
11362836|NCT02281825||Study|Adolescents with psychiatric disorder of the following: Attention-Deficit and Hyperactivity Disorder, Conduct, Oppositional defiant Disorder, Anxiety, Depression, Disruptive Mood Dysregulation Disorder
11362837|NCT02281812|Experimental|RFA group|A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
11362838|NCT02281812|No Intervention|Control group|Normal excision of the tumor according to the protocol
11362839|NCT02281799|Experimental|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.
~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
11362840|NCT02281786|Experimental|Cohort 1|8 volunteers (6 active, 2 placebo)
11362841|NCT02281786|Experimental|Cohort 2|8 volunteers (6 active, 2 placebo)
11362842|NCT02281786|Experimental|Cohort 3|8 volunteers (6 active, 2 placebo)
11362843|NCT02281786|Experimental|Cohort 4|8 volunteers (6 active, 2 placebo)
11362844|NCT02281786|Experimental|Cohort 5|8 volunteers (6 active, 2 placebo)
11362845|NCT02281786|Experimental|Cohort 6|8 volunteers (6 active, 2 placebo)
11362846|NCT02281773|Experimental|dose 1|
11362847|NCT02281773|Experimental|dose 2|
11362848|NCT02281773|Experimental|dose 3|
11362849|NCT02281773|Experimental|dose 4|
11362850|NCT02281773|Placebo Comparator|placebo|
11362851|NCT02281760|Experimental|1-ECD|All subjects enrolled in this trial will receive combination therapy of dabrafenib and trametinib for up to 12 months.
11362852|NCT02281760|Experimental|2-ECD|All subjects enrolled in this trial will receive combination therapy of dabrafenib and trametinib for up to 12 months.
11362853|NCT02281747||affected with arthritis|arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis
11362854|NCT02281747||unaffected with arthritis|in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritisstatus by clinically relevant subgroups.
11362855|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
11362856|NCT02281708|No Intervention|low risk|low risk; observation
11362857|NCT02281708|No Intervention|high risk; observation group|high risk: observation
11362858|NCT02281708|Experimental|high risk; adjuvant chemotherapy group|high risk. vinorelbine plus cisplatin
11362859|NCT02281695|Active Comparator|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.
~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
11362860|NCT02281695|Active Comparator|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
11362861|NCT02281682|Active Comparator|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
11362862|NCT02281682|Active Comparator|5-Fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
11362863|NCT02281682|Active Comparator|Ingenol mebutate 0.015%|during 3 (consecutive) days once daily. Prior to treatment: curettage
11362864|NCT02281682|Active Comparator|MAL-PDT|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
11362865|NCT02281669||Research group|The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery [as our current policy].
11362866|NCT02281656|Experimental|Reverse End-to-side|"Surgery: a reverse end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or babysitting these muscles during the time period until this occurs."
11362867|NCT02281656|Active Comparator|Surgery:standard care|Surgery: the anterior interosseous (AIN) to motor branch of the ulnar nerve transfer has been established as an effective means to reinnervate ulnar innervated intrinsic hand muscles (without loss of function from using the AIN) when nerve injury is too proximal for recovering axons to reach the hand by 18 months. . The procedure (surgery) is presently the standard of care
11362868|NCT02281643|Experimental|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
11362869|NCT02281643|Active Comparator|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
11362870|NCT02281630|Experimental|KWA-0711 High dose|
11362871|NCT02281630|Experimental|KWA-0711 Low dose|
11362872|NCT02281630|Placebo Comparator|Placebo|
11362873|NCT02281604||0.2/1.2 microliter filter|Use of 0.2/1.2 microliter filters for intravenous drug administration
11362874|NCT02281604||5 mircroliter filter|Use of 5 microliter filters for intravenous drug administration
11362875|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
11362876|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
11362879|NCT02281578|Experimental|Combination prevention|Community-based, combination HIV prevention intervention package
11362880|NCT02281578|Active Comparator|Standard of care|Locally run standard of care HIV prevention, treatment and care services
11362881|NCT02281552|Experimental|tofacitinib modified release tablet|
11362882|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
11362883|NCT02281539|Experimental|Treatment using myoelectric signals|Virtual- and augmented reality, are controlled by the patient's phantom limb using muscle (myoelectric) signals from the stump. The patient learns to reactivate areas in the brain related to motor control of the missing limb. The medical device is non-invasive and based on surface electromyography
11362884|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
11362885|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
11362886|NCT02281513|Other|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
11362887|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
11362888|NCT02281487|Active Comparator|Hysterectomy|standard hysterectomy
11362889|NCT02281487|Experimental|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
11362890|NCT02281474|Active Comparator|150mg dosing|This arm will take 150mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
11362891|NCT02281474|Active Comparator|300mg dosing|This arm will take 300mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
11362892|NCT02281461|Experimental|Early ifants|Intervention Male circumcision using a non-surgical device
11362893|NCT02281461|Experimental|Cildren|Intervention Male circumcision using a non-surgical device
11362894|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
11362895|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
11362896|NCT02281435|Experimental|PrePex with Incision|Adult male circumcision by the PrePex™ device using foreskin incision
11362897|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
11362898|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
11362899|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
11362900|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
11362901|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
11362902|NCT02281409|Experimental|Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin. Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
11362903|NCT02281396|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
11362904|NCT02281396|Experimental|2.5IU/ml in humans aged 21-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
11362905|NCT02281396|Active Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
11362906|NCT02281396|Active Comparator|2.5IU/ml in humans(from 21-60 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
11362907|NCT02281383|Experimental|Bacillus Calmette-Guérin (BCG)|Patients will be treated with an induction course (6 intravesical instillations) of BCG followed by a second induction course (6 intravesical instillations), with a recovery period between the 2 treatment courses.
11362908|NCT02281370|Experimental|SEQUENCE D0, D1, D2|Participants will receive treatment D0 in treatment period 1, D1 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 milligram (mg), D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
11362909|NCT02281370|Experimental|SEQUENCE D1, D0, D2|Participants will receive treatment D1 in treatment period 1, D0 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
11362910|NCT02281370|Experimental|SEQUENCE D1, D2, D0|Participants will receive treatment D1 in treatment period 1, D2 in treatment period 2 and D0 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
11362911|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
11362912|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
11362913|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
11362914|NCT02281331|Active Comparator|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
11362915|NCT02281331|Placebo Comparator|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
11363006|NCT02280642||Both doses delayed|A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
11362916|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
11362917|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
11362918|NCT02281305|Experimental|Colchicine Active treatment group|Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
11362919|NCT02281305|Placebo Comparator|Control group|Drug: Placebo
11362920|NCT02281292|Experimental|LKA651 (Part 1)|LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
11362921|NCT02281292|Placebo Comparator|Sham injection (Part 1)|Sham injection in the study eye
11362922|NCT02281292|Experimental|LKA651 and Lucentis (Part 2)|LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
11362923|NCT02281292|Placebo Comparator|Sham injection and Lucentis (Part 2)|Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
11362924|NCT02281279|Experimental|Treatment (rituximab, romidepsin, lenalidomide)|Patients receive rituximab IV over 90 minutes on day 1; romidepsin IV over 4 hours on either day 1, days 1 and 8, or days 1, 8, and 15; and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11362925|NCT02281266|Experimental|treatment (T)|"The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.
~Nucleoside analog plan to give to HBV DNA positive patients."
11362926|NCT02281266|Other|control (C)|"The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.
~Nucleoside analog plan to give to HBV DNA positive patients."
11362927|NCT02281253|Experimental|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
11362928|NCT02281253|Experimental|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
11362929|NCT02281240||With hemostatic complications|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
11362930|NCT02281227|Active Comparator|compression group|skin compression with an indicator for determination of needle entry point
11362931|NCT02281227|Active Comparator|non-compression group|non skin compression with an indicator for determination of needle entry point
11362932|NCT02281214|Experimental|blood sample, biopsy|
11362933|NCT02281201|Experimental|BE1116|Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
11362934|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
11362935|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
11362936|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
11362937|NCT02281162||Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
11362938|NCT02281162||No Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
11362939|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
11362940|NCT02281123||Patient suspected of being infected by chikungunya|Patient (>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
11362941|NCT02281110||iFR/FFR assessment|Patients enrolled into this prospective registry will be derived from Stable Coronary Artery disease or Acute Coronary Syndrome (ACS) population undergoing cardiac catheterization. Patients with ACS may be evaluated by functional assessment in the non-culprit stenosis during the index PCI revascularization or in a staged procedure. The registry will enroll patients in whom physiological assessment (iFR/FFR) is particularly helpful in identifying haemodynamically significant stenosis: MVD patients defined by patients with lesions > 40% and <100% in 2 or more vessels.
11362942|NCT02281097|Active Comparator|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.
~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
11362943|NCT02281097|Placebo Comparator|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.
~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
11362944|NCT02281084|Experimental|Monotherapy: Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
11363007|NCT02280629|Experimental|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
11362945|NCT02281084|Experimental|Combination Therapy: Oral Azacitidine and Durvalumab|Oral Azacitidine 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous (IV) infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
11362946|NCT02281071|Experimental|laterally moved coronally advanced flap microsurgical|For the test group (LMCAF-M), the surgical procedures were performed with the aid of a galilean loupe, under 2.5x magnification vision, microsurgical instruments and microsurgical suture material .
11362947|NCT02281071|Active Comparator|laterally moved coronally advanced flap macrosurgical|For the control group (LMCAF), LMCAF was performed with conventional instruments (detaylı) and materials (stur). Loupe magnification, microsurgical instruments and suture material were not used in the control group.
11362948|NCT02281058|Experimental|intervention group|Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
11362949|NCT02281045|Experimental|EVODIAL dialyzer and Selectbag citrate|Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
11362950|NCT02281045|Active Comparator|Regional citrate anticoagulation|Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.
11362951|NCT02281032|Other|interRAI Palliative Care|"15 experimental nursing homes:
~Caregivers of 15 participating nursing homes receive a training about the interRAI PC and the BelRAI webapplication
~Caregivers of 15 experimental nursing homes fill out the interRAI PC multidisciplinary every three months during one year for all nursing home residents with palliative care needs. Based on the results (Client Assessment Protocols and Scales) of the interRAI PC instrument, care plans are being evaluated, adapted and designed."
11362952|NCT02281032|No Intervention|No interRAI Palliative Care|"15 control nursing homes:
~- Caregivers of control nursing homes do not receive the intervention and provide care as usual"
11362953|NCT02281019||Indeterminate strictures or undefined filling defects|
11362954|NCT02281019||Biliary stone cases|
11362955|NCT02281019||Other indications|
11362956|NCT02281006|Experimental|Treated ear|Trans-tympanic injection of a sodium thiosulfate gel
11362957|NCT02281006|No Intervention|Control ear|No intervention
11362958|NCT02280993|Experimental|DHAP-BV|Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation
11362959|NCT02280980|Experimental|Combined rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department is supplemented with a three weeks home protocol of oculomotor and gaze stability exercises.
11362960|NCT02280980|No Intervention|Usual rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department for patients after stroke.
11362961|NCT02280967|Experimental|Education about HPV by school nurse|The educational intervention consists of education about HPV and a special designed leaflet and self-reported questionnaires. The educational intervention is included in the regular health interview with the school nurse (scheduled for about one hour) and includes information about HPV; facts about the virus, transmission, what it can cause and prevention (i.e. safe sex with condom use and HPV vaccination), facts about HPV vaccine and the importance of attending future cervical cancer screening controls. Students complete questionnaires before the health interview at baseline and after three months. A follow-up with parts of the boys will be performed with qualitative interviews. Participants (n=40)
11362962|NCT02280967|No Intervention|Control group 1|Students allocated to control group 1 receives standard treatment, the regular health interview with the school nurse. Students complete questionnaires before the health interview at baseline and after three months (n=400).
11362963|NCT02280954|Experimental|ICG injection group|This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
11362964|NCT02280941|Experimental|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
11362965|NCT02280928|Experimental|Single-task motor training group|The participants will receive only balance training which will progress from stance activities, to stance activities plus hand manipulation, then gait activities, and finally gait activities plus hand manipulation.
11362966|NCT02280928|Experimental|Single-task cognitive training group|The participants will receive cognitive training that will involve executive function, attention, and working memory.
11362967|NCT02280928|Experimental|Dual-task motor-cognitive training group|The participants assigned to the dual-task motor-cognitive training group will receive the same exercises as single-task motor training while simultaneously performing secondary tasks as those in the single-task cognitive training group.
11362968|NCT02280928|Experimental|Dual-task cognitive-cognitive training group|The participants in the dual-task cognitive-cognitive trainings group will receive two cognitive tasks at the same time.
11362969|NCT02280915|Experimental|Fortified savoury food product 1|Savoury food product fortified with iron
11362970|NCT02280915|Experimental|Fortified savoury food product 2|Savoury food product fortified with iron
11362971|NCT02280915|Experimental|Fortified savoury food product 3|Savoury food product fortified with iron
11362972|NCT02280915|Experimental|Fortified savoury food product 4|Savoury food product fortified with iron
11362973|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
11362974|NCT02280876|Active Comparator|1 - Andrographis paniculata p/st extract|1 - Andrographis paniculata extract. Active comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the active test product (Andrographis paniculata p/st extract, oral lozenges, one BID, for 12 months), in addition to base medication (Interferon).
11362975|NCT02280876|Placebo Comparator|2 - Excipients|2 - Excipients. Placebo comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the placebo formulation (Only the excipients of the active test product, in oral lozenges of same shape, one BID, for 12 months), in addition to base medication (Interferon).
11362976|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
11362977|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
11362978|NCT02280850|Experimental|Guanxin Shutong Capsule|3 capsules once, tid, Oral Duration: 4 weeks
11362979|NCT02280850|Placebo Comparator|Placebo Capsule|"Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.
~3 capsules once, tid, Oral Duration: 4 weeks"
11362980|NCT02280837||Patients with suspected or diagnosed coronary artery disease|
11362981|NCT02280824|Experimental|A|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
11362982|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
11362983|NCT02280798||pilot study|"A total of 5 volunteers from our egg donation program were included in the study with 4 endometrial biopsies for each one after 4 diferente protocols
~Endometrial biopsy after Stimulated cycle
~Endometrial biopsy after Natural Cycle
~Endometrial biopsy after Natural modified cycle: the biopsy is taken seven days after the hCG
~Endometrial biopsy after Hormone Replacement Therapy Cycle"
11362984|NCT02280785|Experimental|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.
~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
11362985|NCT02280772|Experimental|Glucomannan|Glucomannan orally, 3g/day (in three divided doses), for 12 weeks
11362986|NCT02280772|Placebo Comparator|Maltodextrin|Maltodextrin orally, 3g/day (in three divided doses), for 12 weeks
11362987|NCT02280759|Active Comparator|Gelatin Tannate|"Gelatin Tannate:
~4 times 250 mg/daily for 5 days for children under 3. years old or 4 times 500mg/daily for 5 days for children older then 3. years and under 5 years."
11362988|NCT02280759|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
11362989|NCT02280746|Experimental|A - gluten challenge group|Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
11362990|NCT02280746|No Intervention|B - gluten-free diet|Continuation of GFD.
11362991|NCT02280720|Active Comparator|CoCr-BAS|Stenting using Optimax™ cobalt-chromium alloy platform with a titanium-nitride-oxide coating
11362992|NCT02280720|Active Comparator|PtCr-EES|Stenting using PROMUS Element™ Plus durable polymer everolimus-eluting stent built on a platinum-chromium platform.
11362993|NCT02280707|Experimental|Intervention|
11362994|NCT02280707|No Intervention|Control|
11362995|NCT02280694|Experimental|capecitabine, cyclophosphamide, methotrexate, celecoxib|"The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment
~Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal)
~Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals)
~Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal)
~Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)"
11362996|NCT02280681||Couples with ovarian failure|Heterosexual couples confronted with infertility due to ovarian failure between the age of 18 and 44 years old treated in the K.U.Leuven and
11362997|NCT02280681||Clinicians|Clinicians who indicated an interest in reproductive medicine in their membership of the Belgian Society for Reproductive Medicine (BSRM).
11362998|NCT02280668|Active Comparator|Control Group|Will perform the eccentric muscle damage exercise and will not perform any icing interventions post damage. These participants will be the control group.
11362999|NCT02280668|Experimental|Icing Protocol 1|Will perform the eccentric muscle damage exercise and will begin the icing intervention immediately after the muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
11363000|NCT02280668|Experimental|Icing Protocol 2|Will perform the eccentric muscle damage exercise and will begin the icing intervention 6 hours post muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
11363001|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
11363002|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
11363003|NCT02280642||Both doses on time|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
11363004|NCT02280642||Dose 2 delayed|A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
11363005|NCT02280642||Dose 3 delayed|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
11363008|NCT02280629|Placebo Comparator|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
11363009|NCT02280629|Active Comparator|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
11363010|NCT02280616|Experimental|Low dose budesonide tablet|
11363011|NCT02280616|Experimental|High dose budesonide tablet|
11363012|NCT02280616|Experimental|High dose budesonide suspension|
11363013|NCT02280616|Placebo Comparator|Placebo|
11363014|NCT02280603|Experimental|DA-4001C|DA-4001C is administered
11363015|NCT02280603|Active Comparator|5% minoxidil|5% minoxidil is administered
11363016|NCT02280590|Experimental|Cresnon®|Rosuvastatin 10mg, tablet, q.d.
11363017|NCT02280590|Active Comparator|Crestor®|Rosuvastatin 10mg, tablet, q.d.
11363018|NCT02280564|No Intervention|Control|Standard diabetes care
11363019|NCT02280564|Experimental|Health coaching with technology support|Behavioral strategies including problem solving skills building, family communication counseling, technology support, motivational interviewing support.
11363020|NCT02280551||Adolescents|1927 Grade 7 high school students
11363021|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
11363022|NCT02280538|Experimental|Intra-Articular Hyaluronic Acid|"hylan G-F 20 (high molecular weight hyaluronic acid):
~intra-articular administration
~6 mL
~administered every 6 months
~for 2 years"
11363023|NCT02280538|Placebo Comparator|Placebo|"Saline solution:
~intra-articular administration
~6 mL
~administered every 6 months
~for 2 years"
11363024|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #1|"Preferred regimen for CLL and low grade lymphoma
~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Days -5 to -3. Cyclophosphamide 200 mg/m2 by vein over 3 hours on Days -5 to -3. Rituximab 375 mg/m2 by vein over 3-6 hours on Day -5 for participants with B-cell cancer.
~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.
~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
11363025|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #2|"For all malignancies if able to tolerate higher dose cyclophosphamide per the discretion of the treating physician
~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2. Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.
~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.
~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
11363026|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #3|"For myeloid malignancies
~Lenalidomide 2.5 mg by mouth once a day on Days -2 to Day +14. Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2. Cytarabine 2 mg/m2 by vein on Days -6 to -2.
~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.
~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
11363027|NCT02280512||elderly with fractures|patients more than 65 years old accepting surgeries for lower extremities fracture
11363028|NCT02280486|Active Comparator|Saxagliptin|The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
11363029|NCT02280486|Active Comparator|Glimepiride|Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
11363030|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
11363031|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
11363032|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
11363033|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
11363034|NCT02280447|Experimental|1/3 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL suspension for injection for intramuscular use"
11363035|NCT02280447|Experimental|1/5 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL suspension for injection for intramuscular use"
11363036|NCT02280447|Experimental|1/10 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL suspension for injection for intramuscular use"
11363037|NCT02280447|Active Comparator|IPV SSI|"Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)
~1 X 0.5 mL solution for injection for intramuscular use"
11363038|NCT02280434|Active Comparator|CBP-307|Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
11363039|NCT02280434|Placebo Comparator|Placebo|Participants will receive a single dose or once daily dose of matching placebo for 28 days.
11363040|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
11363041|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
11363042|NCT02280408|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0 and Day 28.
11363043|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0 and Day 28.
11363044|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0 and Day 28.
11363045|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
11363046|NCT02280395|Experimental|RUT058-60|
11363047|NCT02280395|Placebo Comparator|Sterile Saline for Irrigation|
11363048|NCT02280382|Other|Femmeze®|Femmeze® will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
11363049|NCT02280369||automated abdominal binder|automated abdominal binder with waist and thigh accelerometers, and ActivPAL
11363050|NCT02280356|Experimental|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate & seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, & treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) & every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal & sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
11363051|NCT02280330|Active Comparator|MNP group|The MNP group will receive 60 sachets of MNP in a period of 6 months or 10 sachets per month equivalent to 3-4 sachets in a week.
11363052|NCT02280330|Placebo Comparator|Placebo group|The placebo group will receive 60 sachets of placebo (with same characteristics) as the MNP or 10 sachets per month equivalent to 3-4 sachets in a week.
11363053|NCT02280317|Experimental|VAL201: Laboratory & Clinical Assessment|VAL201-001 Sub-cutaneous injection.
11363054|NCT02280304|Experimental|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
11363055|NCT02280304|Active Comparator|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
11363056|NCT02280291|Active Comparator|Ankle Single Shot Block (SSB)|
11363057|NCT02280291|Experimental|Ankle OnQ (Continuos Sedation OnQ Pump)|
11363058|NCT02280291|Experimental|DR SSB|
11363059|NCT02280291|Experimental|DR OnQ|
11363060|NCT02280278|Experimental|CIK group|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.
11363061|NCT02280278|Active Comparator|Control group|Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.
11363062|NCT02280265|Experimental|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight every 48 ± 6 hours) with Recombinant Human Coagulation Factor VIII for injection(ADVATE) for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
11363063|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:
~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule
~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule
~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:
~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
11363064|NCT02280239|Placebo Comparator|Control Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
11363065|NCT02280239|Experimental|Acetaminophen Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
11363066|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
11363067|NCT02280213|Experimental|Intubation without chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) during resuscitation without chest compressions.
11363068|NCT02280213|Experimental|Intubation with chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
11363069|NCT02280200|Experimental|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
11363070|NCT02280200|No Intervention|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
11363071|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
11363072|NCT02280174|Experimental|Drug: linagliptin|linagliptin 5 mg/d for 12 weeks
11363073|NCT02280174|No Intervention|Drug: standard treatment|sulfonylurea treatment for 12 weeks
11363074|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
11363075|NCT02280148|Experimental|Endoscopy of Intravenous Anesthesia|20-70 year-old volunteers who hold legitimate licenses were recruited to have gastroscopy or colonoscopy under intravenous anesthesia with propofol
11363076|NCT02280135|Experimental|Intravitreal injection of Autologous bone marrow Stem Cell|"Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.
~The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline."
11363077|NCT02280135|Placebo Comparator|Subconjunctival injection of saline|Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.
11363142|NCT02279719|Experimental|BBI608 and Sorafenib|
11363078|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm
~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites
~no Intervention provided"
11363079|NCT02280122||periodontally healthy|"PPD ≤ 3 mm
~PAL-V ≤ 2 mm at < 30% of sites
~BOP < 20%
~No radiographically detectable bone loss: distance cemento-enamel junction to provided
~no Intervention but aMMP-8 test"
11363080|NCT02280109|Active Comparator|Tenofovir Gel|Women will receive a single dose of tenofovir gel (1%;equivalent to 40 mg in 4ml's of gel) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
11363081|NCT02280109|Active Comparator|Tenofovir Film|Women will receive a single dose of tenofovir film (1.3%;40 mg) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
11363082|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
11363083|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
11363084|NCT02280083|Experimental|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
11363085|NCT02280083|Placebo Comparator|placebo|excipient
11363086|NCT02280070|Active Comparator|SOX (S-1 + L-OHP)|"S-1 (80 mg/m2, p.o.) (day1-14）, L-OHP (130 mg/m2)(day 1): repeated every 3 weeks until 4 courses or meet discontinuation criteria.
~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
11363087|NCT02280070|Active Comparator|mFOLFOX6|"L-OHP (85 mg/m2) and l-LV (200 mg/m2) by IV infusion drip for 2hr at day 1. 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards (day 1-2: repeated every 2 weeks until 6 courses or meet discontinuation criteria.
~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
11363088|NCT02280057|Active Comparator|Metformin|Metformin 850 mg x 2 in six months
11363089|NCT02280057|Placebo Comparator|Placebo|Placebo 2 tablets daily for six months
11363090|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
11363091|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
11363092|NCT02280031|Active Comparator|Experimental|Acetylsalicylic Acid 80mg administered daily at bedtime
11363093|NCT02280031|Placebo Comparator|Control|Identical placebo administered daily at bedtime
11363094|NCT02280018|Experimental|JNJ-49122944, 5 milligram (mg)|Single dose of 5 mg JNJ-49122944, administered as a 22.2 milliliter (mL) intravenous (IV) infusion over 45 minutes in the morning following an overnight fast.
11363095|NCT02280018|Placebo Comparator|Placebo|Placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes in the morning following an overnight fast.
11363096|NCT02280005|Experimental|WAK Treatment|Use of experimental device.
11363097|NCT02279992|Experimental|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
11363098|NCT02279992|Active Comparator|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
11363099|NCT02279979|Experimental|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
11363100|NCT02279966|Experimental|Vortioxetine 10 mg|daily, encapsulated, orally
11363101|NCT02279966|Other|Paroxetine 20 mg (active reference)|daily, encapsulated, orally
11363102|NCT02279966|Placebo Comparator|Placebo|capsules, orally
11363103|NCT02279953|Experimental|Vortioxetine 10-20 mg|daily, encapsulated, orally
11363104|NCT02279953|Experimental|Vortioxetine 10-20 mg + SSRI|daily, encapsulated, orally
11363105|NCT02279953|Experimental|SSRI|licensed doses, encapsulated, orally
11363106|NCT02279927|Experimental|Low energy high frequency|Ureteroscopy with laser settings of low energy & high frequency with aim of stone dusting
11363107|NCT02279927|Active Comparator|High energy low frequency|Ureteroscopy with laser settings of low energy high frequency with aim of stone fragmentation and basket extraction of fragments
11363108|NCT02279914|Experimental|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
11363109|NCT02279914|Experimental|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
11363110|NCT02279901|No Intervention|Traditional|Patients will attend a 1 hour OSA Class where OSA education is provided and home sleep testing is set up. These patients return the next day for individual appointments where study is scored and test results are discussed with patient. If study is consistent with OSA based on AHI4% at least 5/hour, patients undergo a 1 week autoCPAP trial. During this week, wireless remote monitoring is performed and troubleshooting is provided via telephone if problems with CPAP use are identified. The autoCPAP is returned during an individual visit, and CPAP is ordered for long-term use based on trial results and patient feedback. Patients are scheduled a 3 month follow-up appointment but are also instructed to call their sleep center case manager prior to that visit if there are problems with CPAP use.
11363111|NCT02279901|Experimental|Telemedicine Education Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are emailed a link to view the Emmi OSA program within 2 weeks prior to their initial OSA class. If the patient tests positive for OSA and agrees to an autoCPAP trial, the patient is emailed a link to view the Emmi CPAP program. These patients are also scheduled for a 3 month follow-up visit to check CPAP usage.
11363143|NCT02279719|Experimental|BBI503 and Sorafenib|
11363144|NCT02279719|Active Comparator|Sorafenib|
11363145|NCT02279693|Other|CBCT|cone beam computed tomography (CBCT) repositioning
11363112|NCT02279901|Experimental|Telemedicine IVR Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. Additionally, if CPAP is ordered for long-term therapy, the patient is enrolled into an IVR protocol that automatically analyzes the patient's CPAP use. If specific provider-defined thresholds are met, the platform will automatically deliver feedback messages to the patient (phone call, text messaging, or email) with the intention of encouraging better CPAP use. Patients are instructed to contact the sleep center for any issues with their therapy. This platform also includes a method for patients to track their own usage online. Automated messaging mechanism will be active for 3 months after CPAP is ordered, after which the messaging will stop. These patients are also scheduled for a 3 month follow-up visit.
11363113|NCT02279901|Experimental|Telemedicine Both Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are provided both Emmi education programs and IVR follow-up as previously outlined. These patients are also scheduled for a 3 month follow-up.
11363114|NCT02279888||CardioMEMS HF System Group|Patients implanted with a CardioMEMS HF System.
11363115|NCT02279875|Experimental|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
11363116|NCT02279875|Experimental|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
11363117|NCT02279875|Experimental|Linezolid 600 mg once per day (A)|600mg (scored) tablet
11363118|NCT02279875|Experimental|Linezolid 600 mg once per day (B)|600mg (scored) tablet
11363119|NCT02279875|Experimental|Linezolid 600 mg twice per day|600mg (scored) tablet
11363120|NCT02279875|Experimental|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
11363121|NCT02279875|Experimental|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
11363122|NCT02279875|Active Comparator|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the
~Subject's weight as follows:
~30-37 kg: 2 tablets;
~38-54 kg: 3 tablets;
~55-70 kg: 4 tablets;
~71 kg and over: 5 tablets."
11363123|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
11363124|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
11363125|NCT02279849|Experimental|Communications|These 6 stores received the communications intervention. Communications materials were developed for each program phase; 1) Healthier Drinks, 2) Healthier Essentials, and 3) Healthier Snacks. Each phase's materials included posters, recipe cards, educational handouts, shelf talkers, price tags, door signs, educational displays, and promotional giveaways (i.e., drink tumblers, re-usable shopping bags) to encourage healthy food purchasing and consumption. Stores receiving the communications intervention also received either a small refrigerator or freezer to help provide the environmental supports needed to stock perishable fruits and vegetables.
11363126|NCT02279849|No Intervention|Control|These 6 stores received no intervention.
11363127|NCT02279849|Experimental|Pricing|These 6 stores received a pricing intervention. 10-30% with discounts for specific foods contingent on price elasticity of demand, initial wholesale price, and projected store-level sales. Items were given the minimum discount needed to increase store supply and consumer demand. For example, brand name frozen vegetables were discounted 30% at the wholesaler, in order to provide the storeowner with enough incentive to stock the item. The % discount passed from the storeowner to the consumer was ultimately a decision made by the storeowner, but was suggested to be at least 50% in order to increase consumer demand. Discounts were automatically applied at wholesaler registers to stores receiving the pricing intervention.
11363128|NCT02279849|Experimental|Combined (Communications & Pricing)|These 6 stores received communications materials as well as pricing incentives as intervention (see Communications & Pricing Arms Descriptions).
11363129|NCT02279836|Other|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
11363130|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
11363131|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
11363132|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
11363133|NCT02279810||Medical students, medical staff|Survey about Knowledge, Attitude and Practice About Organ Transplantation
11363134|NCT02279784|Experimental|Freeway|angioplasty with Freeway drug-eluting balloon
11363135|NCT02279784|Experimental|Lutonix|angioplasty with Lutonix drug-eluting balloon
11363136|NCT02279771|Active Comparator|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
11363137|NCT02279771|Active Comparator|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
11363138|NCT02279758|Experimental|METFORMIN|850mg of metformin every 12 hours.
11363139|NCT02279745|Experimental|Ralinepag|Ralinepag immediate release (IR) capsules of 0.01, 0.02, 0.03, 0.04 mg, and 0.10 mg per capsule or extended release (XR) tablets of 50, 250, and 400 mcg (0.05, 0.25 and 0.4 mg) for oral administration. The starting dose and titration schedule will be determined for each subject in accordance with the starting dose and titration schedule optimized from Study APD811-003.
11363140|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)
~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
11363141|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO
~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
11363146|NCT02279693|Other|fiducial markers|kV imaging of fiducial marker repositioning
11363147|NCT02279680|Other|Patients|Adults between 18 and 30 years old right handing Patients with ASD
11363148|NCT02279680|Other|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
11363149|NCT02279667|Experimental|Group A|"st period - 16 mL oral suspension 50 mg/mL
~nd period - Four 200 mg tablets
~rd period - One 800 mg tablet"
11363150|NCT02279667|Experimental|Group B|"st period - One 800 mg tablet
~nd period - 16 mL oral suspension 50 mg/mL
~rd period - Four 200 mg tablets"
11363151|NCT02279667|Experimental|Group C|"st period - Four 200 mg tablets
~nd period - One 800 mg tablet
~rd period - 16 mL oral suspension 50 mg/mL"
11363152|NCT02279654||Lenalidomide Population|Patients with transfusion-dependent, low- or intermediate (int)-1risk MDS and isolated del (5q) who receive at least 1 dose of lenalidomide after 15th June 2007 and have been followed up for on the registry for 3 years or until death/consent withdrawal
11363153|NCT02279654||Background Population|All MDS patients who have been diagnosed on 15th June 2007 or later, have never been exposed to lenalidomide and have been followed up on the registry for 3 years or until death/consent withdrawal
11363154|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
11363155|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
11363156|NCT02279628|Experimental|Continuous wound infiltration alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 1 ml sodium chloride 0.9% (without morphine). Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
11363157|NCT02279628|Active Comparator|Intrathecal moprhine alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of sodium chloride 0.9% 8 ml/H via a preperitoneal catheter.
11363158|NCT02279628|Experimental|Intrathecal morphine&wound infiltration|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
11363159|NCT02279615|Active Comparator|Treatment Group|(Mirabegron + Tamsulosin)
11363160|NCT02279615|Placebo Comparator|Control Group|(Placebo + Tamsulosin)
11363161|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
11363162|NCT02279589|Active Comparator|Group A|"Description :
~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,1
~Route : Intramuscular vaccination schedule : M0, M2, M12"
11363163|NCT02279589|Active Comparator|Group B|"Description 15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,1
~Route : Intramuscular vaccination schedule : M0, M2, M12"
11363164|NCT02279589|Active Comparator|Group C|"Description :
~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,5
~Route : Intramuscular vaccination schedule : M0, M2, M12"
11363165|NCT02279589|Active Comparator|Group D|"Description:
~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,5
~Route : Intramuscular vaccination schedule : M0, M2, M12"
11363166|NCT02279576|Experimental|Pazopanib plus weekly paclitaxel|Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.
11363167|NCT02279563|Experimental|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.
~Batch Number KL1981, Expiry Date Mar 2015."
11363168|NCT02279563|Active Comparator|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.
~Batch Number G30349, Expiry Date Mar 2015."
11363169|NCT02279563|Placebo Comparator|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.
~Batch Number KL0781, Expiry Date Mar 2015."
11363170|NCT02279550||hip fracture|aged >65 with hip fracture
11363171|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
11363172|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
11363173|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
11363174|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
11363175|NCT02279511|Experimental|24 hours infusion of ATP|
11363176|NCT02279511|Experimental|6 hours infusion of ATP|
11363177|NCT02279511|Placebo Comparator|24 hours infusion of placebo|
11363178|NCT02279511|Placebo Comparator|6 hours infusion of placebo|
11363179|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
11363180|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
11363181|NCT02279485|Experimental|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.
~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.
~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
11363182|NCT02279485|Experimental|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.
~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.
~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
11363183|NCT02279472|Other|laser peripheral iridotomy|Laser peripheral iridotomy (LPI) is widely regarded as the first-line intervention for either acute or chronic types of angle-closure glaucoma in early stage ,which relieves pupil block and thus flattening the iris contour and widening the drainage angle,performd by Nd.YAG LASER
11363184|NCT02279459||Patient|Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
11363185|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
11363186|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
11363187|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
11363188|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
11363189|NCT02279433|Experimental|DS-6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
11363190|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
11363191|NCT02279407|Placebo Comparator|placebo|
11363192|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
11363193|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
11363194|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
11363195|NCT02279381|Experimental|Intervention group A|"Essential Neonatal Care
~Kangaroo mother Care
~Application of 4% Chlorhexidine
~Education and counseling for mothers and care providers"
11363196|NCT02279381|Experimental|Intervention group B|"Essential Neonatal Care
~Application of 4% Chlorhexidine
~Education and counseling for mothers and care providers"
11363197|NCT02279381|Active Comparator|Control group|"Essential Neonatal Care
~Education and counseling for mothers and care providers"
11363198|NCT02279368|Experimental|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
11363199|NCT02279368|No Intervention|Control Group|Control group families were followed in usual care.
11363200|NCT02279355||pressure ulcer group|Patient who developing pressure ulcer categorized as stage more than II after surgery
11363201|NCT02279355||Control group|Patients has identical values on the matching factors such as age, sex and surgical procedures of control group
11363202|NCT02279342|No Intervention|Non febuxostat treatment group|No febuxostat treatment
11363203|NCT02279342|Experimental|Febuxostat treatment group|once daily after breakfast
11363204|NCT02279329|Other|COPD and Bronchiectasis Patients|All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at up to 8 visits over 2-3 years.
11363205|NCT02279316|Experimental|Jaques-Dalcroze eurhythmics|Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
11363206|NCT02279316|Experimental|Home exercise program|Home exercise strength program (3x30min/wk) + 800 IU vitamin D
11363207|NCT02279316|Other|Vitamin D only|800 IU Vi-De 3
11363208|NCT02279303|Experimental|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
11363209|NCT02279303|Active Comparator|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
11363210|NCT02279290|Experimental|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
11363211|NCT02279290|Active Comparator|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
11363212|NCT02279277|No Intervention|No physical therapy|No prescribed, supervised physical therapy prior to total knee replacement
11363213|NCT02279277|Active Comparator|Physical Therapy|Prescribed, supervised physical therapy prior to total knee replacement
11363214|NCT02279251|Active Comparator|Brief CBT (VÅG)|This is a brief five session CBT group intervention developed at Uni Research. The intervention include self-help material (Psychological First Aid) for the adolescents to use at home between sessions.
11363215|NCT02279251|Active Comparator|Established CBT program (CHILLED)|An established, 10 session CBT group program (school version) developed by researchers at Macquarie University, Australia. The intervention has previously not been evaluated with Norwegian adolescents.
11363216|NCT02279251|No Intervention|Waitlist|Waiting period is ten weeks, then participants are randomized to one of the two active interventions
11363217|NCT02279225|Placebo Comparator|placebo (P)|Intervention without radiation
11363218|NCT02279225|Experimental|phototherapy (FT)|Intervention only with phototherapy radiation
11363219|NCT02279225|Experimental|phototherapy+Physical activity (FT+A)|Intervention associated
11363220|NCT02279225|Experimental|Physical activity (A)|Intervention with physical activity: the gold standard of treatment in fibromyalgia
11363221|NCT02279199||Control|Normative data from standardized assessment
11363222|NCT02279199||Hemophilia|Persons aged 4-21 with any severity of hemophilia A or B
11363223|NCT02279186|Active Comparator|group A|receiving tranexamic acid
11363224|NCT02279186|No Intervention|group B|does not receive tranexamic acid
11363225|NCT02279173|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
11363226|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
11363227|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
11363228|NCT02279147|Experimental|raceanisodamine & neostigmine|Patients receive immediately raceanisodamine（10mg）by intramuscular injection after operation.Then the patients will be receive 50mg raceanisodamine and 0.15mg neostigmine within 24hs by slow injection into vein for three consecutive days.
11363229|NCT02279147|No Intervention|blank|Patients do not receive special treatment after operation.
11363230|NCT02279134|No Intervention|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
11363231|NCT02279134|Experimental|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
11363232|NCT02279134|Active Comparator|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
11363233|NCT02279121|Experimental|TauroLock|solution of taurolidine-citrate
11363234|NCT02279121|Other|Control|saline solution
11363235|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
11363236|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
11363237|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Subjects received weight-adjusted doses of palovarotene equivalent to 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days for an eligible flare-up (Part A).
11363238|NCT02279095|Experimental|Palovarotene dose level 2|Subjects with at least 90% skeletal maturity received 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
11363239|NCT02279095|Experimental|Palovarotene dose level 3|Subjects with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
11363240|NCT02279095|Experimental|Palovarotene dose level 4|All subjects will receive 5 mg palovarotene once daily for up to 36 months; and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Doses are adjusted for weight in skeletally immature subjects
11363241|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
11363242|NCT02279069|Active Comparator|4-point canne|Stroke patients walk with 4-point canne
11363243|NCT02279069|Experimental|4-roll canne|Stroke patients walk with 4-roll canne
11363244|NCT02279056|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
11363245|NCT02279056|Placebo Comparator|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
11363246|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
11363247|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
11363248|NCT02279043|No Intervention|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
11363249|NCT02279017|Other|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
11363250|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
11363251|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
11363252|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
11363253|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
11363254|NCT02278991||Lutonix Drug Coated Balloon|Paclitaxel coated balloon catheter
11363255|NCT02278978|Experimental|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
11363256|NCT02278978|Experimental|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
11363257|NCT02278978|Experimental|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
11363258|NCT02278965|Experimental|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
11363259|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
11363260|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
11363261|NCT02278926||Patients ultrasound lypo-hypertrophy identification|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
11363262|NCT02278926||Control group|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
11363425|NCT02277782|Experimental|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
11363263|NCT02278913|Experimental|Basal Bolus (Glargine and Glulisine)|Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.
11363264|NCT02278913|Active Comparator|Human Insulin|Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal
11363265|NCT02278900|Experimental|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
11363266|NCT02278900|No Intervention|Control group|No intervention.
11363267|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
11363268|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
11363269|NCT02278874||Multiple gestation high risk pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
11363270|NCT02278861|Active Comparator|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
11363271|NCT02278861|Active Comparator|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.
~If there were any clinical adverse events the drug could be reduced to twice a week."
11363272|NCT02278848|Experimental|Diagnosis of ICAH|"One arm: patients with chronic adult hydrocephalus.
~All patients have: Computerised gait analysis, Ultrasound measurement of cerebral pulsatility, MRI flow, Urinary incontinence scale"
11363273|NCT02278835|Other|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
11363274|NCT02278835|Other|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
11363275|NCT02278822|Experimental|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
11363276|NCT02278822|Experimental|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
11363277|NCT02278809|No Intervention|waitlist control group|The waitlist control group parents received the online videos when the intervention period was over.
11363278|NCT02278809|Experimental|intervention group|
11363279|NCT02278796|Experimental|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
11363280|NCT02278796|Active Comparator|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
11363281|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
11363282|NCT02278757|Placebo Comparator|Low protein diet (LPD)|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
11363283|NCT02278757|Experimental|High protein diet (HPD)|HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
11363284|NCT02278744|Experimental|single-fraction radiosurgery|
11363285|NCT02278731|No Intervention|Control Group|The elderly in Control Group suffered no intervention and continued with their daily activities.
11363286|NCT02278731|Active Comparator|Pilates Group|Pilates group (PG), which underwent one-month (three times per week) training program with the Pilates method. This protocol consisted of Pilates exercises on the ground.Stretches were performed on upper trunk and lower limbs before the exercises. Subsequently, exercises that included the range of motion and strength of the upper limbs, trunk and lower limbs were performed, always associated with breathing and contraction of transversus abdominis muscles, in different positions, increasing repetitions and resistance in the weeks of the study, using the Swiss ball, thera-band and the magic circle.
11363287|NCT02278731|Active Comparator|PNF Group|PNF group that underwent one-month (three times per week) training program using the propriocptive neuromuscular facilitation method.The selected PNF diagonal patterns were chosen with all the basic procedures to the facilitation and according to three specific principles of PNF: rhythmic initiation, sustain and relax and reversal of antagonists. During the first week, one set of ten repetitions for each diagonal was performed; in the second week, two sets of ten repetitions and in the third and fourth weeks, three sets of ten repetitions were performed.
11363288|NCT02278718|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.
11363289|NCT02278718|Active Comparator|Standard of Care|Non surgical and Surgical Debridement
11363329|NCT02278419|Experimental|Group A1|Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.
11363290|NCT02278705||Weight-status improved|"Cases, termed, weight-status improved, are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile decreases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later)."
11363291|NCT02278705||Weight-status unchanged/worse|Controls are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile remains unchanged or increases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later).
11363292|NCT02278692|Active Comparator|Vitamin K|Vitamin K1 (phytonadione) 10 mg orally three times a week after dialysis for 12 weeks
11363293|NCT02278692|Placebo Comparator|Placebo|Identical appearing placebo orally three times a week after dialysis for 12 weeks
11363294|NCT02278679||Anesthitized patient|First, it will be validated on 120 anesthetized patients undergoing prostate surgery comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports.
11363295|NCT02278679||Standardized patients|During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.
11363296|NCT02278679||Clinic patient|The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.
11363297|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
11363298|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
11363299|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
11363300|NCT02278653||Study group|The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
11363301|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
11363302|NCT02278627|Experimental|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
11363303|NCT02278627|No Intervention|Usual treatment|
11363304|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
11363305|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
11363306|NCT02278601|Experimental|VAMB variable automated|variable frequency automated mandatory bolus (VAMB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
11363307|NCT02278601|Experimental|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
11363308|NCT02278601|Active Comparator|patient controlled epidural analgesia|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
11363309|NCT02278588||PD-R|Parkinson's disease receiving rasagiline
11363310|NCT02278588||PD-NMAO|Parkinson's disease not receiving any MAO-B inhibitors
11363311|NCT02278588||HC|Healthy Controls
11363312|NCT02278575|Other|Consisting of treatment with Atenativ|During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin
11363313|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
11363314|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
11363315|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
11363316|NCT02278549||Asymptomatic|Individuals between 30 and 50 years old that have had no episode of low back pain in the last two years requiring medical attention
11363317|NCT02278549||Patients with Low Back Pain|Individuals between 30 and 50 years old that present with non-specific low back pain for more than 3 months
11363318|NCT02278536||Multiple high risk gestation pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
11363319|NCT02278536||Multiple low risk gestation pregnancies|women pregnant with twins or triplets at low risk for aneuploidy
11363320|NCT02278523|Experimental|Inspiratory muscle training group|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
11363321|NCT02278523|Active Comparator|control group|normal volunteers use Inspiratory muscle trainer(Threshold IMT®)
11363322|NCT02278510|Experimental|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
11363323|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
11363324|NCT02278484|Other|Balloon Sinus Dilation|
11363325|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
11363326|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.
~Polypill will be taken once daily."
11363327|NCT02278458|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
11363328|NCT02278445|Experimental|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
11363330|NCT02278419|Experimental|Group A2|Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
11363331|NCT02278419|Experimental|Group B|Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
11363332|NCT02278406|Experimental|Parkinson's patients with DBS|Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
11363333|NCT02278393|Active Comparator|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
11363334|NCT02278393|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
11363335|NCT02278380|Other|Arm 1|"To compare the Glycemic Index value of seven test foods:
~Low GI standard Breakfast Medium GI standard Breakfast Nutritional pregnant milk supplement Nutritional product for diabetics Pregnant and lactation women milk powder Nutritional drinks for diabetics Test product"
11363336|NCT02278367|Experimental|Flortaucipir PET Scans|
11363337|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
11363338|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
11363339|NCT02278341|Experimental|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
11363340|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
11363341|NCT02278328|Experimental|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.
~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
11363342|NCT02278328|Experimental|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.
~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
11363343|NCT02278328|Experimental|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.
~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
11363344|NCT02278315|Experimental|Single|I-131-CLR1404 with or without concurrent dexamethasone
11363345|NCT02278302|Experimental|Aggrenox®|treatment alone or in combination with Ethanol
11363346|NCT02278302|Placebo Comparator|Placebo|treatment alone or in combination with Ethanol
11363347|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
11363348|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
11363349|NCT02278276|Placebo Comparator|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
11363350|NCT02278276|Active Comparator|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
11363351|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
11363352|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
11363353|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
11363354|NCT02278250|Experimental|Part A: M4344 BIW|Dose escalation of M4344 administered BIW as a single agent.
11363355|NCT02278250|Experimental|Part A2: M4344 BID or once daily|Dose escalation of M4344 administered BID or once daily as a single agent.
11363356|NCT02278250|Experimental|Part A3: M4344 Drug holiday schedule|Dose escalation of M4344 administered in a drug holiday schedule (different schedule with either 3 days once daily (QD) or BID followed by 4 days of pausing, 5 days of QD or BID followed by 2 days of pausing, 7 days of QD or BID dosing followed by 7 days of pausing or 14 days of QD or BID dosing followed by 7 days of pausing may be explored. Other dosing holiday schedules may be explored if agreed by the sponsor and Investigators).
11363357|NCT02278250|Experimental|Part B1: M4344 + Carboplatin|Dose escalation of M4344 in combination with carboplatin.
11363358|NCT02278250|Experimental|Part C1: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
11363359|NCT02278250|Experimental|Part C2: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
11363424|NCT02277782|Active Comparator|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
11363360|NCT02278250|Experimental|Part C3: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
11363361|NCT02278250|Experimental|Part C4: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
11363362|NCT02278250|Experimental|Part C5: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
11363363|NCT02278250|Experimental|Part C6: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
11363364|NCT02278237|Experimental|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
11363365|NCT02278224|Experimental|Rumination Focused CBT|11 sessions of manualised group based Rumination Focused CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
11363366|NCT02278224|Active Comparator|Cognitive Behavioral Therapy|11 sessions of manualised group based CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
11363367|NCT02278211||Study Cohort|Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease
11363368|NCT02278198|Experimental|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.
~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).
~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.
~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
11363369|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
11363370|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
11363371|NCT02278172|Active Comparator|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
11363372|NCT02278172|Placebo Comparator|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
11363373|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
11363374|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
11363375|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
11363376|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
11363377|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
11363378|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
11363379|NCT02278133|Experimental|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
11363380|NCT02278120|Experimental|Ribociclib (LEE011) + NSAI/tamoxifen + goserelin|LEE011 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
11363381|NCT02278120|Placebo Comparator|LEE011 placebo+NSAI/tamoxifen+goserelin|LEE011 Placebo 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
11363382|NCT02278107|Experimental|Tidal Assist Ventilator System|Lightweight, portable, positive pressure ventilator system with proprietary nasal interface. Ventilator is powered by compressed oxygen delivered by cylinder, concentrator, or wall source.
11363383|NCT02278107|Active Comparator|Nasal Cannula Oxygen|Nasal Cannula Oxygen Standard nasal cannula oxygen at 2-5 liters per minute (LPM) based on patient requirement. Oxygen sources includes cylinder, concentrator, or wall source.
11363384|NCT02278094|Experimental|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
11363385|NCT02278094|Active Comparator|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
11363386|NCT02278081|Experimental|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
11363387|NCT02278081|Placebo Comparator|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
11363388|NCT02278068|Experimental|Metabolic Neuromodulation System (MNS)|Hepatic sympathetic denervation therapy to aid in glycemic control
11363389|NCT02278055|Experimental|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
11363390|NCT02278042|Active Comparator|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
11363391|NCT02278042|Active Comparator|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
11363392|NCT02278042|Active Comparator|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
11363393|NCT02278042|Active Comparator|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
11363394|NCT02278042|Active Comparator|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
11363395|NCT02278029||Concussed|those subjects with a concussion
11363396|NCT02278029||Controls|those subjects without a concussion
11363397|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.
~measure the amnesic effects of propofol."
11363398|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
11363399|NCT02277990|Active Comparator|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
11363400|NCT02277990|No Intervention|Control|No TYRX™ envelope, bare CIED
11363401|NCT02277977|Experimental|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
11363402|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.
~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
11363403|NCT02277951||Participants|The Bonfils Intubation Fibrescope the Video Rigid Flexing Laryngoscope the C-MAC® S Video Laryngoscope the Macintosh Laryngoscope
11363404|NCT02277938||Amantadine|Lung cancer patients being prescribed chemotherapy
11363405|NCT02277925|Active Comparator|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
11363406|NCT02277925|Experimental|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
11363407|NCT02277912|Experimental|Transcranial Magnetic Stimulation I|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the motor cortex
11363408|NCT02277912|Experimental|Transcranial Magnetic Stimulation II|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the secondary somatosensory cortex
11363409|NCT02277912|Sham Comparator|Sham Stimulation|Intervention: Repetitive sham Transcranial Magnetic Stimulation with SHAM block of the motor cortex
11363410|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.
~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:
~Communication regarding child's high weight status
~Counseling regarding cardiovascular risk factor screening and assessment
~Behavioral counseling
~Interval follow-up to readdress weight, and
~Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
11363411|NCT02277886|Experimental|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
11363412|NCT02277886|Active Comparator|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
11363413|NCT02277873||No Treatment|Defined population (pregnant women) compared on a environmental moon luminosity influence
11363414|NCT02277860|Experimental|Exercise|Aerobic and strength training using the Wii Fit Plus for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
11363415|NCT02277847|Experimental|IDA 8mg/M2|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
11363416|NCT02277847|Active Comparator|IDA 10mg/M2|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
11363417|NCT02277834||pancreatic adenocarcinoma|15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
11363418|NCT02277834||chronic pancreatitis|15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
11363419|NCT02277834||non-pancreatic, non-neoplastic disorders|15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
11363420|NCT02277821|Experimental|Stendo pulsating suit System|One 20 minutes Stendo pulsating suit session will be applied to the patient.
11363421|NCT02277808|Active Comparator|Respirgard II|Determination of pulmonary deposition
11363422|NCT02277808|Active Comparator|Isoneb|Determination of pulmonary deposition
11363423|NCT02277795|Experimental|AccuCirc|"The AccuCirc procedure is performed according to manufacturer instructions: http://www.clinicalinnovations.com/site_files/files/AccuCirc_IFUs.pdf
~Before the surgery, the mother (and father, if available) will be counseled on benefits and risks of EIMC in their language of choice (English, Kiswahili, DhoLuo). At least one parent/guardian will provide documented informed consent using IRB-approved Consent Form. Providers will record demographic and locator information and EIMC eligibility criteria. If the infant is eligible for EIMC, the provider will perform the procedure and document the outcome of the surgery on a post-operative form. Information recorded will include: amount and type of anesthesia provided, intra-operative adverse event and outcome, and procedure start and end time."
11363426|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
11363427|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
11363428|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
11363429|NCT02277756|Experimental|high functioning Autism|Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
11363430|NCT02277756|Placebo Comparator|witness|Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness
11363431|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
11363432|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
11363433|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
11363434|NCT02277730|Experimental|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
11363435|NCT02277730|Active Comparator|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
11363436|NCT02277717|Experimental|SYD985 (trastuzumab vc-seco-DUBA)|HER2-targeting Antibody-Drug Conjugate
11363437|NCT02277704|Placebo Comparator|Treatment A|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
11363438|NCT02277704|Active Comparator|Treatment B|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
11363439|NCT02277704|Active Comparator|Treatment C|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
11363440|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.
~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
11363441|NCT02277678|Experimental|Oxycodone|Epidural oxycodone 3mg single dose as opioid administration
11363442|NCT02277678|Active Comparator|Morphine|Epidural morphine 3mg single dose as opioid administration
11363443|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
11363444|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
11363445|NCT02277652|Experimental|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
11363446|NCT02277652|Experimental|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
11363447|NCT02277652|Experimental|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
11363448|NCT02277652|Experimental|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
11363449|NCT02277652|Experimental|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
11363450|NCT02277652|Experimental|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
11363451|NCT02277639|Experimental|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
11363452|NCT02277639|Experimental|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
11363453|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
11363454|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
11363455|NCT02277613|Experimental|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
11363456|NCT02277613|Sham Comparator|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
11363457|NCT02277600|Experimental|Cohort 1, Treatment A, B|"Treatment A:
~BMS-663068 orally twice daily (BID) on Days 1 through 4
~Treatment B:
~BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14"
11363458|NCT02277600|Experimental|Cohort 2, Treatment C, D|"Treatment C:
~BMS-663068 orally BID on Days 1 through 4
~Treatment D:
~BMS-663068 orally BID plus COBI QD on Days 5 through 14"
11363459|NCT02277587|Experimental|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
11363489|NCT02277366||Routine Bronchoscopy|All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
11363460|NCT02277587|Active Comparator|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.
~The total daily dose and timing is not changed during the study period."
11363461|NCT02277587|No Intervention|Healthy volunteers|Healthy volunteers will be enrolled as control group
11363462|NCT02277574|Experimental|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
11363463|NCT02277574|Experimental|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
11363464|NCT02277561|Experimental|Diagnostic (VB-DTI, MRI)|Patients undergoing WBRT for a total of 10 fractions also undergo VB-DTI MRI at baseline, 1 week after WBRT initiation, and 7-11 days after completion of WBRT. Patients undergoing SRS without WBRT also undergo VB-DTI MRI at baseline and 7-11 days after completion of SRS.
11363465|NCT02277548|Experimental|Lyrica at 300 mg per day|
11363466|NCT02277548|Placebo Comparator|Placebo|
11363467|NCT02277535|Experimental|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.
~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
11363468|NCT02277535|No Intervention|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
11363469|NCT02277522|Experimental|RNA autologous T cells (anti CD19 CAR T cells)|
11363470|NCT02277509|Experimental|Chinese DPP|Our Chinese DPP intervention includes: 1) skills development core adapted from the DPP core curriculum, 2) stress reduction counseling and activities, 3) physical activity sessions, 4) self-monitoring tools for diet and physical activity, 5) barriers assessment linked to tool box, and 6) post-core support intervention.
11363471|NCT02277509|Active Comparator|Minimal Intervention Control|The minimal control intervention will consist of providing patients with publically available materials on diabetes prevention, which are produced in Chinese.
11363472|NCT02277496|Experimental|HC toolkit intervention students|HC students will receiveeExperimental wellness education via a toolkit approach to address the 2010 Dietary Guidelines for reducing obesity in youth. The specific recommendations include: 1) reducing intake of sugary beverages, 2) increasing intake of fruits and vegetables, 3) increasing frequency of eating breakfast, 4) decreasing fast and junk food choices, 5) increasing physical activity to 1 hour/day, and 6) decreasing screen time to 2 hours per day.
11363473|NCT02277496|No Intervention|Comparison Schools|During the 2014-2015 school year, control schools were utilized to compare outcomes.
11363474|NCT02277483|Active Comparator|active treatment|LAIS® Mites Sublingual tablets + rescue medication
11363475|NCT02277483|No Intervention|control|Rescue medication
11363476|NCT02277470||Golimumab|Patients who are eligible for golimumab therapy.
11363477|NCT02277457|Experimental|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
11363478|NCT02277457|Experimental|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
11363479|NCT02277444|Experimental|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m^2 per week for participants with BSA less than [<] 1.67 meter square (m^2), or minimum of 15 mg/week for participants with BSA greater than or equal to [>=] 1.67 m^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m^2 every 8 weeks after completion of the Week 252 assessments.
11363480|NCT02277431|Experimental|Probiotic dietary supplement|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:
~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])
~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)
~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
11363481|NCT02277431|Placebo Comparator|Placebo|The placebo capsules utilized in this study will be indistinguishable from the probiotic dietary supplement capsules as they will be identical in appearance, odor, weight, and taste. Furthermore, the same sunflower oil matrix will be in both the probiotic dietary supplement and placebo. The only difference between the dietary supplement and placebo capsules will be the probiotic bacteria.
11363482|NCT02277418|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11363483|NCT02277418|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11363484|NCT02277418|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
11363485|NCT02277418|Experimental|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
11363486|NCT02277405|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
11363487|NCT02277405|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
11363488|NCT02277366||Fluorescence/Narrow Band Bronchoscopy|All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
11363490|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
11363491|NCT02277340|Experimental|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
11363492|NCT02277327|Experimental|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
11363493|NCT02277327|Placebo Comparator|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
11363494|NCT02277314|Other|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
11363495|NCT02277301|Experimental|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
11363496|NCT02277301|No Intervention|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
11363497|NCT02277288|No Intervention|Emptied bladder arm|No instillation of fluid into bladder.
11363498|NCT02277288|Experimental|Filled bladder arm|Instilled bladder with fluid.
11363499|NCT02277275|Placebo Comparator|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
11363500|NCT02277275|Experimental|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
11363501|NCT02277275|Placebo Comparator|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
11363502|NCT02277262|Experimental|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
11363503|NCT02277262|Active Comparator|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
11363504|NCT02277249|Other|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
11363505|NCT02277249|Other|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
11363506|NCT02277236||Younger Veterans|Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
11363507|NCT02277236||Young-Old Veterans|Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
11363508|NCT02277223|Experimental|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<30kg: 500 milligram, twice daily, weight>30kg: 1 gram twice daily
11363509|NCT02277223|Placebo Comparator|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
11363510|NCT02277210|Placebo Comparator|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
11363511|NCT02277210|Active Comparator|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
11363512|NCT02277197|Experimental|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.
~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
11363513|NCT02277184|Experimental|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.
~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.
~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
11363514|NCT02277171|Experimental|Nitric oxide impregnated catheter|
11363515|NCT02277158|Experimental|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
11363516|NCT02277145|Experimental|treatment group|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
11363517|NCT02277132|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
11363518|NCT02277132|Placebo Comparator|Placebo|Placebo tablets three times daily orally from randomization until delivery
11363519|NCT02277119|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
11363520|NCT02277119|Experimental|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
11363521|NCT02277119|Experimental|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
11363522|NCT02277106|Experimental|SAGE-547|Intravenous
11363523|NCT02277106|Placebo Comparator|Placebo|Intravenous sterile saline
11363524|NCT02277093|Experimental|Pacritinib|"Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)
~Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
11363525|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
11363526|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
11363527|NCT02277067|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
11363528|NCT02277067|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
11363529|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
11363530|NCT02277041|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
11363531|NCT02277041|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
11363532|NCT02277028|Experimental|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension. The priming (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total priming for one day is 30 minutes. Total task specific training for one day is 90 minutes"
11363533|NCT02277028|Active Comparator|Health Education|The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as above. The health education (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total time on health education website for one day is 30 minutes. Total task specific training for one day is 90 minutes
11363534|NCT02277015|Experimental|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
11363535|NCT02277015|Experimental|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
11363536|NCT02277002|Placebo Comparator|Placebo|Participants are exposed to unfiltered cabin air
11363537|NCT02277002|Active Comparator|Cabin Air Filter|Participants are exposed to filtered cabin air
11363538|NCT02276989|Experimental|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
11363539|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
11363540|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
11363541|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
11363542|NCT02276937|Placebo Comparator|Placebo (0 ciu/limb)|Placebo control
11363543|NCT02276937|Active Comparator|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
11363544|NCT02276937|Active Comparator|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
11363545|NCT02276924|Experimental|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
11363546|NCT02276911|Active Comparator|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
11363547|NCT02276911|Placebo Comparator|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
11363548|NCT02276898|Active Comparator|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
11363549|NCT02276898|Placebo Comparator|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
11363550|NCT02276885|Experimental|PBI Radiotherapy 6 Gy|Prone partial breast irradiation of 6 Gy x 5 over 5 days, on five consecutive days
11363551|NCT02276885|Experimental|PBI Radiotherapy 8 Gy|Prone partial breast irradiation of 8 Gy x 3 over 5 days, every other day
11363729|NCT02275650|No Intervention|control|No nbUVB illumination will be given for the control group.
11363552|NCT02276872|Experimental|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
11363553|NCT02276872|Experimental|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
11363554|NCT02276872|Experimental|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
11363555|NCT02276859|Experimental|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.
~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
11363556|NCT02276859|Experimental|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.
~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.
~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
11363557|NCT02276833|Experimental|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
11363558|NCT02276820|Experimental|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-A/m2 as a single infusion.
~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
11363559|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
11363560|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
11363561|NCT02276794|Experimental|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.
~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.
~A single treatment will be provided."
11363562|NCT02276794|Experimental|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.
~A single treatment will be provided"
11363563|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
11363564|NCT02276768|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
11363565|NCT02276768|Experimental|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
11363566|NCT02276768|Active Comparator|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
11363567|NCT02276768|Active Comparator|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
11363568|NCT02276768|Placebo Comparator|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses
~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
11363569|NCT02276755|Active Comparator|Intervention: 1|Dietary Supplement: Cholecalciferol (vitamin D3)
11363570|NCT02276755|Placebo Comparator|Placebo Comparator: 2|Dietary Supplement: Placebo
11363571|NCT02276742|No Intervention|Usual Care (UC)|Participants randomized to UC will receive baseline advice about the value of losing weight, becoming more physically active, and limiting intake of sodium and inorganic phosphates followed by 12 mos of UC. We have elected not to use a control group in which we provide equivalent attention to both study arms. Behaviors are difficult to change and there is no reason to believe that simply giving participants attention would create behavioral changes sufficient to result in weight loss, reduce sodium excretion, or reduce serum phosphorus. Numerous weight loss studies, including Look AHEAD, have used attention control groups that did not demonstrate weight loss.
11363572|NCT02276742|Active Comparator|Social Cognitive Theory (SCT)|Participants will be exposed to a group behavioral intervention that is based on SCT, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Mastery experiences will include emphasizing past successes; setting incremental, easily achievable goals; identifying modifiable barriers to healthy behavior; receiving positive feedback on goal achievement; and practicing problem solving skills around barriers to adherence.
11363573|NCT02276742|Active Comparator|Monitoring|Participants will be taught how to use a lifestyle self-monitoring program to reduce information processing requirements, make readily available the information required to make good self-management decisions, deliver automated, real-time feedback about achievement of behavioral goals, and permit individualized guidance from an interventionist who uses the MyNetDiary® electronic log to provide targeted education and advice. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
11363609|NCT02276495|Experimental|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
11363574|NCT02276742|Active Comparator|Combined|Participants randomized to COMBINED will receive all aspects of the SCT and MONITORING intervention conditions. Social Cognitive Theory based behavioral intervention in complex patients is strengthened when technology is used to manage information complexity, and weakened in its absence. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
11363575|NCT02276729|Experimental|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
11363576|NCT02276729|No Intervention|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
11363577|NCT02276716|Experimental|Phosphatidylserine|"Phosphatidylserine titration from 300, 600 and 800 mg/day
~duration: 6 months"
11363578|NCT02276690|Experimental|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
11363579|NCT02276690|Active Comparator|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
11363580|NCT02276677|Experimental|Oxytocin|Oxytocin 24 IU x 1
11363581|NCT02276677|Placebo Comparator|Placebo|Placebo 24 IU x 1
11363582|NCT02276664|No Intervention|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
11363583|NCT02276664|Experimental|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
11363584|NCT02276664|Active Comparator|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
11363585|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
11363586|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
11363587|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
11363588|NCT02276625|Experimental|A - ID|Intradermal administration. 20% dose in a single visit.
11363589|NCT02276625|Experimental|B - ID|Intradermal administration. 40% dose in a single visit.
11363590|NCT02276625|Experimental|C - ID|Intradermal administration. 60% dose in a single visit.
11363591|NCT02276625|Active Comparator|D - IM|1x IM
11363592|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.
~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
11363593|NCT02276599||Cardiac catheterization|Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.
11363594|NCT02276586|Active Comparator|Group 1|Horizontal Tooth preparation
11363595|NCT02276586|Experimental|Group 2|Vertical tooth preparation
11363596|NCT02276573|Experimental|Oral lichen planus disease|buccal cavity sample
11363597|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
11363598|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
11363599|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
11363600|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
11363601|NCT02276534|Experimental|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
11363602|NCT02276534|Experimental|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
11363603|NCT02276521||Zero dose group|Participants that did not received any HPV vaccine previously.
11363604|NCT02276521||One dose group|Participants that received one dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
11363605|NCT02276521||Two dose group|Participants that received two dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
11363606|NCT02276521||Three dose group|Participants that received three dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
11363607|NCT02276508|Experimental|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
11363608|NCT02276495|Experimental|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
11363610|NCT02276495|Experimental|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
11363611|NCT02276482|Experimental|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
11363612|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
11363613|NCT02276469|Experimental|peer support|peer support is delivered on individual basis for half a year, the frequency depends on the patients requirement, but at least 3 sessions has to occur
11363614|NCT02276469|No Intervention|usual care|usual care was delivered to the patients
11363615|NCT02276456|Experimental|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
11363616|NCT02276456|No Intervention|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
11363617|NCT02276443|Experimental|Treatment (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 courses, and after 4 courses of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
11363618|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
11363619|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
11363620|NCT02276417||Sepsis|Blood Collection. Urine collection. Bioimpedance analysis. Quality-of-life questionnaires, physical function tests and cognitive function tests.
11363621|NCT02276417||Healthy Controls|Blood Collection.
11363622|NCT02276404|Experimental|relaxation training|Each participant of the experimental group 1 receives 2 one-hour sessions of guided relaxation training prior to surgery.
11363623|NCT02276404|Experimental|acupuncture|Each participant of the experimental group 2 receives 3 acupuncture treatments with a semi-standardized acupoint scheme: once a week over 2 weeks and the day before surgery.
11363624|NCT02276404|Experimental|relaxation training and acupuncture|Each patient of the experimental group 3 receives 3 acupuncture treatments with a semi-standardized acupoint scheme and 2 one-hour sessions of guided relaxation training prior to surgery.
11363625|NCT02276404|No Intervention|usual care|Patients receive usual senological treatment
11363626|NCT02276391|Experimental|Telmisartan/HCTZ fixed-dose combination|
11363627|NCT02276391|Active Comparator|Telmisartan|
11363628|NCT02276378|Experimental|Telmisartan low / HCTZ fixed-dose combination, fed|
11363629|NCT02276378|Experimental|Telmisartan high / HCTZ fixed-dose combination, fed|
11363630|NCT02276378|Active Comparator|Telmisartan low /HCTZ fixed-dose combination, fasted|
11363631|NCT02276378|Active Comparator|Telmisartan high /HCTZ fixed-dose combination, fasted|
11363632|NCT02276365|Experimental|Sequence ABC|"Treatment A: 50 mg BI 10773 once daily from day 1 to 5
~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
~Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out"
11363633|NCT02276365|Experimental|Sequence CAB|"Treatment C: 45 mg pioglitazone once daily from day 1 to 7
~Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out
~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7"
11363634|NCT02276352|Experimental|Meloxicam low dose - one tablet|
11363635|NCT02276352|Experimental|Meloxicam high dose - two tablets|
11363636|NCT02276352|Active Comparator|Meloxicam high dose - one tablet|
11363637|NCT02276339|Experimental|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
11363638|NCT02276326|Experimental|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
11363639|NCT02276300|Experimental|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
11363640|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
11363641|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
11363642|NCT02276261|Experimental|Vertical|Vaginal cuff closure performed in a vertical manner.
11363643|NCT02276261|Active Comparator|Horizontal|Vaginal cuff closure performed in a horizontal manner.
11363644|NCT02276248|Experimental|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
11363645|NCT02276235|Experimental|catgut embedding group|Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks
11363646|NCT02276235|Sham Comparator|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.
~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)
~The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks"
11363647|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
11363648|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
11363649|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
11363650|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
11363651|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
11363652|NCT02276196|Experimental|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
11363653|NCT02276196|Active Comparator|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
11363654|NCT02276183|Experimental|Arm1, Nutrition intervention, test formula and activity|
11363655|NCT02276170||Aminophylline per standard of care|
11363656|NCT02276157||Direct peroral cholangioscopy|Patients with bile duct disease that is eligible to direct peroral cholangioscopy
11363657|NCT02276131|Experimental|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
11363658|NCT02276118|Experimental|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
11363659|NCT02276118|Active Comparator|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
11363660|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
11363661|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
11363662|NCT02276079|Experimental|mTBI Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily aerobic exercise intervention lasting 1-week.
11363663|NCT02276079|Experimental|mTBI Non-Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily non-aerobic exercise intervention lasting 1-week.
11363664|NCT02276079|No Intervention|Non-injured Reference Group|Non-injured, healthy participants will serve as a reference group for functional outcome measures.
11363665|NCT02276066|Active Comparator|Inhospital group at day 14|This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
11363666|NCT02276066|Other|Released from hosptial prior to day 14|This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
11363667|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
11363668|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
11363669|NCT02276027|Experimental|BYL719|20 NSCLC patients. Patient's tumor must have molecular alteration of the PIK3CA gene.
11363670|NCT02276027|Experimental|INC280|20 NSCLC patients. Patient's tumor must have molecular alteration of the c-MET gene.
11363671|NCT02276027|Experimental|LDK378|25 NSCLC patients.Patient's tumor must have ALK or ROS1 gene rearrangement.
11363672|NCT02276027|Experimental|MEK162|20 NSCLC patients. Patient's tumor must have KRAS, NRAS or BRAF mutation.
11363673|NCT02276014|Other|Supplement A|Beta-carotene 7mg formulation A
11363674|NCT02276014|Other|Supplement B|Beta-carotene 7mg formulation B
11363675|NCT02276014|Other|Supplement C|Beta-carotene 7mg formulation C
11363676|NCT02276001|Experimental|K-877|K-877
11363677|NCT02276001|Experimental|K-877 with Cyclosporine|K-877 with Cyclosporine
11363678|NCT02275988|Experimental|K-877|K-877
11363679|NCT02275988|Experimental|K-877 with Clarithromycin|K-877 with Clarithromycin
11363680|NCT02275975|Experimental|K-877|K-877
11363681|NCT02275975|Experimental|K-877 with Fluconazole|K-877 with Fluconazole
11363682|NCT02275962|Experimental|K-877|K-877
11363683|NCT02275962|Experimental|K-877 with Rifampin|K-877 with Rifampin
11363684|NCT02275949|Experimental|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
11363685|NCT02275949|Sham Comparator|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
11363686|NCT02275936|Experimental|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
11363687|NCT02275936|Experimental|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
11363688|NCT02275936|Experimental|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
11363689|NCT02275936|Placebo Comparator|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
11363690|NCT02275923|Experimental|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
11363691|NCT02275910|Experimental|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
11363692|NCT02275897|Experimental|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
11363693|NCT02275897|Experimental|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
11363694|NCT02275884|Active Comparator|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
11363695|NCT02275884|Sham Comparator|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
11363696|NCT02275871|Experimental|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
11363697|NCT02275858|Experimental|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
11363698|NCT02275858|Placebo Comparator|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
11363699|NCT02275845|Experimental|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
11363700|NCT02275845|Active Comparator|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
11363701|NCT02275832|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
11363702|NCT02275832|Placebo Comparator|Placebo|Placebo is applied twice daily to beard.
11363703|NCT02275819||control|Will not receive intervention with exercise
11363704|NCT02275819||Intervention group|2 groups will receive 2 different types of exercise
11363705|NCT02275806|Other|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8
~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
11363706|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
11363707|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
11363708|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
11363709|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
11363710|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
11363711|NCT02275767|Experimental|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
11363712|NCT02275767|Active Comparator|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
11363713|NCT02275767|Active Comparator|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
11363714|NCT02275754|Experimental|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
11363715|NCT02275754|Active Comparator|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
11363716|NCT02275728|Experimental|Pelvic Floor Muscle Training(PFMT)|The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
11363717|NCT02275728|Active Comparator|EMG Biofeedback treatment|In this group, the same protocol of the TMAP will be held, however, emg biofeedback is used during training for 20 minutes, 2 times a week, 8 sessions.
11363718|NCT02275728|No Intervention|no treatment|In this group, will be held only the initial assessment, you will not receive treatment for a month and will be reevaluated after being serviced this period.
11363719|NCT02275715|Experimental|Parent Training Program (PT-F)|Treatment group
11363720|NCT02275715|No Intervention|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
11363721|NCT02275702|Placebo Comparator|Group 1|saline solution IV, bolus
11363722|NCT02275702|Active Comparator|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
11363723|NCT02275689|Active Comparator|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
11363724|NCT02275689|Active Comparator|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
11363725|NCT02275689|No Intervention|Physical therapy|Muscle strength training, home trainings programme
11363726|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
11363727|NCT02275663|Experimental|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1
~G-CSF 5 mcg/kg subcut on days 0 to + 6
~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5
~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
11363728|NCT02275650|Experimental|nbUVB|2 SED dose of nbUVB will be given every other week for this intervention group.
11363730|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
11363731|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
11363732|NCT02275598|Experimental|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
11363733|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
11363734|NCT02275572|Experimental|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
11363735|NCT02275572|No Intervention|Control|Usual procedure.
11363736|NCT02275559|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
11363737|NCT02275559|Active Comparator|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
11363738|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
11363739|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
11363740|NCT02275533|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity.
11363741|NCT02275533|Active Comparator|Arm II (observation)|Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I.
11363742|NCT02275520|Other|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
11363743|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
11363744|NCT02275494||shortening group|Shortening group where the operated leg was more than 5mm shorter compared with the contralateral side
11363745|NCT02275494||Restoration group|the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side
11363746|NCT02275494||Lengthening group|The lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.
11363747|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
11363748|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
11363749|NCT02275468|Placebo Comparator|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.
11363750|NCT02275468|Experimental|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
11363751|NCT02275455|Experimental|Participants with autism|
11363752|NCT02275455|Experimental|Aged-matched controls|
11363753|NCT02275429|Other|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
11363754|NCT02275416|Experimental|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
11363755|NCT02275403|Experimental|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
11363756|NCT02275403|Active Comparator|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
11363757|NCT02275390|Experimental|Nurse-led Psycho-education [SPBB: Self-learning program]|"The Nurse-led Psychoeducation Program is comprised of eight 2-hour sessions held at every two weeks (over 4 months). The program consists of five themes: (a) orientation and engaging and understanding of mental health/illness, its related behaviors and community support resources; (b) working collaboratively and empowering and minimizing resistance and challenges using motivational interviewing approach; (c) effective interpersonal and communication skills; (d) strategies in coping with mental illness, sleep hygiene and allaying anxiety; and (e) self-review and evaluation and establishing a realistic plan for future.
~[Note: The participants in the SPBB will complete the self-help and problem-solving manual (5 modules) for caregivers of people with psychotic disorders over 20 weeks, together with an orientation, understanding about psychosis and its care and 4 review sessions.]"
11363758|NCT02275390|Active Comparator|Usual Psychiatric Outpatient Care|"Routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study
~[Note: for SPBB trial, routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study]"
11363759|NCT02275377|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
11363760|NCT02275377|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
11363761|NCT02275377|No Intervention|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
11363762|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
11363763|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
11363764|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
11363765|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
11363766|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
11363767|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
11363768|NCT02275325|Experimental|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
11363769|NCT02275325|No Intervention|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
11363770|NCT02275299|Experimental|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
11363771|NCT02275299|Active Comparator|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
11363772|NCT02275286|Experimental|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
11363773|NCT02275273||Patients with adnexal masses|Every patient that are at least 18 years old with a planned pelvic magnetic resonance imagery and an adnexectomy within the institution.
11363774|NCT02275260|Experimental|All patients|All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing
11363775|NCT02275247|Experimental|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
11363776|NCT02275247|No Intervention|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
11363777|NCT02275234||Retrospective|Patients who survived cardiac arrest >3 months prior to the start of the study and a close family/friend,will be invited to attend an outpatient clinic
11363778|NCT02275234||Prospective- psychological intervention|In patients who survived cardiac arrest and a close family/friend,will be invited to attend an outpatient clinic
11363779|NCT02275221||Hepatitis B and C|Hepatitis B and C
11363780|NCT02275182|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
11363781|NCT02275182|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
11363782|NCT02275169|Experimental|Treated|Urofollitropin 150 IU ampoules three times a week for three months
11363783|NCT02275169|Placebo Comparator|Controls|Placebo ampoules three times a week for three months
11363784|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
11363785|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
11363786|NCT02275130|Experimental|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
11363787|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
11363788|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
11363789|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
11363790|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
11363791|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
11363792|NCT02275104||Ventricular arrhythmias|
11363793|NCT02275104||Persistent atrial fibrillation|
11363794|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
11363795|NCT02275091||Healthy|Healthy children 12-21 years old
11363796|NCT02275078|Other|Interventional|The program consists of 3 components: 1) COPD self-management using an Action Plan; 2) Telesystem-Phone self-assessment/reporting system; and 3) Nurse case manager support.
11363797|NCT02275065|Experimental|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
11363798|NCT02275065|Experimental|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
11363799|NCT02275065|Experimental|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
11363800|NCT02275065|Experimental|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
11363801|NCT02275065|Placebo Comparator|Placebo|Placebo matched to bictegravir tablet for 10 days
11363802|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
11363803|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
11363804|NCT02275039|Experimental|Treatment (MVA-p53 vaccine and gemcitabine hydrochloride)|Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
11363805|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
11363806|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
11363807|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
11363808|NCT02275000|Experimental|Intervention|5 Day physiotherapy programme at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK.
11363809|NCT02275000|Active Comparator|Treatment as usual|Participants are referred to their local neuro-physiotherapy service and if appropriate placed on a waiting list for inpatient rehabilitation.
11363810|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
11363811|NCT02274974|Active Comparator|lidocaine|20 ml of 2% lidocaine.
11363812|NCT02274974|Experimental|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
11363813|NCT02274961|Experimental|S-pantoprazole 10mg|S-pantoprazole 10mg Tablet once daily for 4 weeks
11363814|NCT02274961|Placebo Comparator|Placebo|Placebo tablet for the test drug
11363815|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
11363816|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.
~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
11363817|NCT02274935|Experimental|Gait and balance exercise|Traditional exercises focusing on gait and balance
11363818|NCT02274935|Experimental|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
11363819|NCT02274909|No Intervention|control group|The subjects received no intervention and continued with their daily activities.
11363820|NCT02274909|Active Comparator|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
11363821|NCT02274909|Active Comparator|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
11363822|NCT02274896|Experimental|PD catheter group|All patients will receive the Bayston PD catheter
11363823|NCT02274883|Experimental|Enriched Protein Fractions|This group is given Infant formula with enriched protein fractions.
11363824|NCT02274883|Active Comparator|Protein Fractions|This group is given Infant formula with protein fractions.
11363825|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
11363826|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
11363827|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
11363828|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
11363829|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
11363830|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
11363831|NCT02274831|Experimental|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
11363832|NCT02274831|No Intervention|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
11363833|NCT02274818|No Intervention|Standard Duty Hour Schedule|IM programs randomized to the currently mandated duty 16 hour standards (maximum work duration of 16 hours for interns and 28 hours for PGY2-3); this schedule may involve night float.
11363834|NCT02274818|Experimental|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:
~No more than 80 hours of work per week (when averaged over 4 weeks)
~1 day off in 7 (when averaged over 4 weeks)
~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
11363835|NCT02274805||Adults presenting for surgery in the neck area|
11363836|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
11363904|NCT02274233|Experimental|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
11363837|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy
~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy
~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.
~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
11363838|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
11363839|NCT02274766|Placebo Comparator|Placebo|Placebo
11363840|NCT02274740|Experimental|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).
~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
11363841|NCT02274740|No Intervention|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
11363842|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
11363843|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
11363844|NCT02274701|Experimental|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
11363845|NCT02274701|No Intervention|Control|The control group entails standard care - routine consultation between the patient and clinician.
11363846|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
11363847|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
~Randomized and will be blindly assessed."
11363848|NCT02274675|Experimental|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
11363849|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
11363850|NCT02274649|Active Comparator|Control|Control group receiving general peer support
11363851|NCT02274636|No Intervention|Data collection|This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
11363852|NCT02274636|Active Comparator|Intervention|In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
11363853|NCT02274623|Experimental|CTAP101 Capsules|CTAP101 Capsules daily
11363854|NCT02274610|Experimental|Group A|Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
11363855|NCT02274610|Experimental|Group B|Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
11363856|NCT02274597||Environmental impact on epitympanic temperature measurment|volunteers exposed to different environmental factors to simulate field settings
11363857|NCT02274584|Experimental|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
11363858|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
11363859|NCT02274571|Placebo Comparator|Placebo|Non active comparator
11363860|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
11363861|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
11363862|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
11363863|NCT02274545|Experimental|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
11363864|NCT02274532|Experimental|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
11363900|NCT02274259|Active Comparator|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
11363901|NCT02274259|Active Comparator|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
11363902|NCT02274246|Experimental|Gadobutrol|Gadobutrol in Healthy volunteers
11363903|NCT02274233|Experimental|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
11363865|NCT02274532|Other|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
11363866|NCT02274519|Experimental|Tai Chi|Group randomized to participate in Tai Chi intervention
11363867|NCT02274519|Active Comparator|Educational|Group randomized to participate in educational intervention
11363868|NCT02274506|Experimental|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.
~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
11363869|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
11363870|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
11363871|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
11363872|NCT02274467|Active Comparator|Uniport catheter|19 gauge uniport epidural catheter
11363873|NCT02274467|Active Comparator|Multiport catheter|19 gauge multiorifice epidural catheter
11363874|NCT02274454|Active Comparator|1.25mM Calcium-NO oxytocin pretreatment|
11363875|NCT02274454|Active Comparator|2.5mM Calcium-NO oxytocin pretreatment|
11363876|NCT02274454|Active Comparator|5.0mM Calcium-NO oxytocin pretreatment|
11363877|NCT02274454|Active Comparator|1.25mM Calcium-WITH oxytocin pretreatment|
11363878|NCT02274454|Active Comparator|2.5mM Calcium-WITH oxytocin pretreatment|
11363879|NCT02274454|Active Comparator|5.0mM Calcium-WITH oxytocin pretreatment|
11363880|NCT02274428|Other|pneumostem group|single arm, pneumostem treated infants
11363881|NCT02274415|Experimental|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
11363882|NCT02274415|Active Comparator|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
11363883|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
11363884|NCT02274389||Bedaquiline Patient Registry (BPR)|
11363885|NCT02274376||Cohort|
11363886|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
11363887|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
11363888|NCT02274337|Experimental|AC0010|patients receiving avitinib treatment Qd, at different dose stages
11363889|NCT02274324|Active Comparator|PD patients- Diet B first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet B and then crossover to diet C.
11363890|NCT02274324|Active Comparator|PD patients- Diet C first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet C and then crossover to diet B.
11363891|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
11363892|NCT02274298|Active Comparator|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
11363893|NCT02274298|No Intervention|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
11363894|NCT02274285|Experimental|Group A (SP0204)|Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
11363895|NCT02274285|Active Comparator|Group B (control)|Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
11363896|NCT02274285|Experimental|Group C|Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly
11363897|NCT02274272|Placebo Comparator|Placebo Capsules|
11363898|NCT02274272|Experimental|ADR-1|Lactobacillus reuteri GMNL-89
11363899|NCT02274272|Experimental|GMNL-263|Lactobacillus reuteri GMNL-263
11364033|NCT02273505|Experimental|Asasantin (ER)|
11363905|NCT02274233|Experimental|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
11363906|NCT02274233|Experimental|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
11363907|NCT02274233|Experimental|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
11363908|NCT02274233|Experimental|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
11363909|NCT02274220|Experimental|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
11363910|NCT02274220|Experimental|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
11363911|NCT02274220|No Intervention|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
11363912|NCT02274207|Experimental|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
11363913|NCT02274207|Active Comparator|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
11363914|NCT02274194|Active Comparator|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
11363915|NCT02274194|Experimental|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
11363916|NCT02274181|Experimental|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
11363917|NCT02274168|Other|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
11363918|NCT02274168|Other|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
11363919|NCT02274155|Experimental|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
11363920|NCT02274155|Experimental|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
11363921|NCT02274155|Experimental|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
11363922|NCT02274142|Experimental|Restorations with Encapsulated material|Restorations performed with encapsulated glass ionomer cement (EQUIA - GC Corp). Capsules with glass ionomer will be activated and applied after selective carious tissue removal in primary molars.
11363923|NCT02274142|Active Comparator|Restorations with Hand-Mixed material|Restorations will be performed with hand-mixed glass ionomer cement (Fuji IX - GC Corp) after selective carious tissue removal in primary molars.
11363924|NCT02274129|Experimental|Use of Healing cap II|Single arm study using a new healing cap as intervention
11363925|NCT02274116|Active Comparator|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.
~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes"
11363926|NCT02274116|Sham Comparator|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.
~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes"
11363927|NCT02274103|Active Comparator|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
11363928|NCT02274103|Active Comparator|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
11363929|NCT02274090|Placebo Comparator|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
11363930|NCT02274090|Active Comparator|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
11363931|NCT02274077|Active Comparator|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
11363932|NCT02274077|Placebo Comparator|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
11363933|NCT02274064|Experimental|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
11363934|NCT02274064|No Intervention|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
11363935|NCT02274051|Experimental|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.
~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
11363936|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
11363937|NCT02274012|Experimental|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
11363938|NCT02273999|No Intervention|Control Group (no device)|No devices were delivered after third molar tooth extraction
11363939|NCT02273999|Placebo Comparator|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
11363940|NCT02273999|Experimental|Test (activated device)|Activated devices were delivered after third molar tooth extraction
11363941|NCT02273986|Experimental|Digoxin|Digoxin
11363942|NCT02273986|Experimental|Digoxin with K-877|Digoxin with K-877
11363943|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
11363944|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
11363945|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
11363946|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
11363947|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
11363948|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
11363949|NCT02273947|Experimental|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363950|NCT02273947|Experimental|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363951|NCT02273947|Experimental|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363952|NCT02273947|Experimental|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363953|NCT02273947|Experimental|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363954|NCT02273947|Experimental|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363955|NCT02273947|Experimental|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363956|NCT02273947|Experimental|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
11363957|NCT02273947|Experimental|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363958|NCT02273947|Experimental|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363959|NCT02273947|Experimental|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363960|NCT02273947|Experimental|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363961|NCT02273947|Experimental|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363962|NCT02273947|Experimental|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363963|NCT02273947|Experimental|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363964|NCT02273947|Experimental|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363965|NCT02273947|Experimental|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363966|NCT02273947|Experimental|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363967|NCT02273947|Experimental|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363968|NCT02273947|Experimental|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363969|NCT02273947|Experimental|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
11363970|NCT02273934|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to adults, and there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the person on a daily basis focusing on self-help.
11363971|NCT02273934|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
11363972|NCT02273921|No Intervention|EEG|A non-invasive EEG recording
11363973|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
11363974|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
11363975|NCT02273895|Active Comparator|Control|Scopolamine
11363976|NCT02273895|Active Comparator|MCI|Scopolamine
11363977|NCT02273895|Active Comparator|AD|Scopolamine
11363978|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation <12 months of age
11363979|NCT02273856||Treatment naïve patients with CLL|
11363980|NCT02273856||Treatment naïve patients with iNHL|
11363981|NCT02273856||Relapsed/refractory patients with CLL|
11363982|NCT02273856||Relapsed/refractory patients with iNHL|
11363983|NCT02273843|Experimental|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
11363984|NCT02273843|Active Comparator|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
11363985|NCT02273830|Active Comparator|oxygen adjusted|oxygen adjusted to get SpO2> 90% during the walking test
11363986|NCT02273830|Placebo Comparator|control group|oxygen at 3L/min
11363987|NCT02273817|Experimental|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray
~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.
~Strength: 50 μg per actuation.
~Batch/Lot number (Expiry date): JM6697 (May 2012)
~Manufacturer: Apotex, Inc."
11363988|NCT02273817|Active Comparator|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,
~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide
~Strength: 50 μg per actuation
~Batch/Lot number (Expiry date): 131657 (03/2012)
~Manufacturer: Sepracor, Inc."
11363989|NCT02273817|Placebo Comparator|Placebo|"Placebo
~Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.
~Batch/Lot number (Expiry date): JR3808 (Nov 2012)
~Manufacturer: Apotex, Inc."
11363990|NCT02273804|Experimental|topiramate|pill
11363991|NCT02273804|Placebo Comparator|placebo|Sugar pill
11363992|NCT02273791||HRT group|Women will be subjected to HRT using Estradiol valerate before FET
11363993|NCT02273791||MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
11363994|NCT02273778|Other|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
11363995|NCT02273778|Other|Routine radiotherapy treatment|
11363996|NCT02273765|Active Comparator|Raltegravir|Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID
11363997|NCT02273765|Experimental|Efavirenz|Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD
11363998|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
11363999|NCT02273739|Experimental|AG-221|
11364000|NCT02273726|Experimental|Roxadustat (FG-4592)|Roxadustat will be dosed orally three times a week.
11364001|NCT02273726|Active Comparator|Epoetin Alfa|Epoetin alfa will be dosed intravenously three times a week.
11364002|NCT02273713|Experimental|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
11364003|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.
~Intervention: Rivaroxaban"
11364004|NCT02273687|Experimental|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.
~Intervention: Diaphragmatic ultrasound"
11364005|NCT02273674|Experimental|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
11364006|NCT02273674|Experimental|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
11364007|NCT02273661|Placebo Comparator|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
11364008|NCT02273661|Experimental|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
11364009|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with
~Diabetes (all types) at least 300 subjects should be included and analyzed in this segment
~Small vessels (≤2.75 mm) approx. 150 subjects
~Chronic total occlusion (CTO) approx. 50 subjects
~Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects
~Multivessels approx. 250 subjects
~In stent restenosis approx. 100 subjects
~Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months"
11364010|NCT02273635|Experimental|andrographolides|Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.
11364011|NCT02273635|Placebo Comparator|sugar tablets|Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.
11364012|NCT02273622|Experimental|hydroxytyrosol 5 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
11364013|NCT02273622|Experimental|hydroxytyrosol 20 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
11364014|NCT02273622|Placebo Comparator|placebo|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
11364015|NCT02273596|Experimental|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.
~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. Up-titration was permitted if NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 was administered for up to 36 months."
11364016|NCT02273583|Experimental|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
11364017|NCT02273583|No Intervention|Control|31 weeks of MAP.
11364018|NCT02273570|Active Comparator|control|Control group: standard care. The iPTH target in this group is 300-540 pg/ml
11364019|NCT02273570|Experimental|Optimal CKD-MBD control|Optimal CKD-MBD control: in this group the PTH target is150-300 pg/ml to be achieved with a therapeutic algorithm
11364020|NCT02273557|Experimental|Asasantin ER (new formulation I - low)|
11364021|NCT02273557|Experimental|Asasantin ER (new formulation III - medium)|
11364022|NCT02273557|Experimental|Asasantin ER (new formulation II - high)|
11364023|NCT02273557|Active Comparator|Asasantin ER (present commercial formulation)|
11364024|NCT02273544|Experimental|Asasantin ER (new formulation - low)|
11364025|NCT02273544|Experimental|Asasantin ER (new formulation - medium)|
11364026|NCT02273544|Experimental|Asasantin ER (new formulation- high)|
11364027|NCT02273544|Active Comparator|Asasantin ER - commercial formulation|
11364028|NCT02273531|Experimental|Asasantin ER, new formulation|
11364029|NCT02273531|Active Comparator|Asasantin ER, present commercial formulation|
11364030|NCT02273518|Experimental|Asasantin ER, new formulation I|
11364031|NCT02273518|Experimental|Asasantin ER, new formulation II|
11364032|NCT02273518|Active Comparator|Asasantin ER, present commercial formulation|
11364035|NCT02273492|Experimental|Asasantin ER after a standardized breakfast|
11364036|NCT02273492|Active Comparator|Asasantin ER at fasted state|
11364037|NCT02273479|Experimental|Asasantin®|
11364038|NCT02273479|Placebo Comparator|Placebo|
11364039|NCT02273466|Active Comparator|Desipramine alone|
11364040|NCT02273466|Experimental|Desipramine with Crobenetine|
11364041|NCT02273453|Experimental|Songha® Night|
11364042|NCT02273453|Active Comparator|Placebo + Oxazepam|
11364043|NCT02273453|Placebo Comparator|Placebo|
11364044|NCT02273440|Experimental|BIIL 284 BS with theophylline|
11364045|NCT02273440|Placebo Comparator|Placebo with theophylline|
11364046|NCT02273427|Active Comparator|BIIL 284 BS fasted|
11364047|NCT02273427|Experimental|BIIL 284 BS with high fat meal|
11364048|NCT02273427|Experimental|BIIL 284 BS with low fat meal|
11364049|NCT02273414|Experimental|BIIL 284 BS - rising dose|
11364050|NCT02273414|Placebo Comparator|Placebo|
11364051|NCT02273401|Experimental|BI 11054 CL|
11364052|NCT02273401|Placebo Comparator|Placebo|
11364053|NCT02273388|Experimental|Volasertib|
11364054|NCT02273375|Experimental|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
11364055|NCT02273375|Placebo Comparator|Placebo|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
11364056|NCT02273362|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
11364057|NCT02273349|Experimental|Treatment|Patients with Alpha-1-Antitrypsin deficiency treated with endoscopic lung volume reduction using Lung Volume Reduction Coils (PneumRx Inc.)
11364058|NCT02273336||Ancillary-Correlative (comprehensive genomic analysis)|Tissue and blood samples are analyzed via next generation sequencing and whole exome sequencing.
11364059|NCT02273323|Experimental|Tea|Black tea
11364060|NCT02273323|Placebo Comparator|Placebo|Placebo
11364061|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
11364062|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
11364063|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
11364064|NCT02273284|Experimental|Buzzy|Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
11364065|NCT02273284|No Intervention|control - no Buzzy|Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy
11364066|NCT02273271|Experimental|Imaging arm|18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
11364067|NCT02273258|Experimental|Test (T)|SAR342434: single dose injection
11364068|NCT02273258|Active Comparator|Reference 1 (R1)|US-approved Humalog®: single dose injection
11364069|NCT02273258|Active Comparator|Reference 2 (R2)|EU-approved Humalog®: single dose injection
11364070|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age>18) patients presenting with symptoms of AAS.
11364071|NCT02273232|Active Comparator|Supervised Exercise Group|All PVD patients will get the standard advice regarding exercises but this group will have a constructed exercise program under supervision of Dr. Micheál Newell who is qualified Sports and Exercise Scientist with a Doctorate degree in Integrated Biology. This include six minute walk test, Chair Stand Test and symptoms free distance.
11364072|NCT02273232|Active Comparator|RIPC and supervised Exercise Group|This group will have structured intermitting periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be applied for 5 minutes alternatively with 5 minutes rest to the total of 4 cycles, which needs 40 minutes per day. The RIPC group will receive an exercise program identical to the first group. The total number of days for each participant will be 28 days.
11364073|NCT02273232|Active Comparator|RIPC with Standard Care Group|The patients in this group will receive standard care advice regarding exercise in addition to RIPC as in the 2nd group.
11364074|NCT02273232|Sham Comparator|Control Group (Standard Care)|This group will get the standard advice regarding exercise for PVD patients and all the information available in Out patients clinic settings.
11364075|NCT02273219|Experimental|AEB071 and BYL719|AEB071, oral, 100-400 mg twice daily BYL719, oral, 200-350 mg daily
11364076|NCT02273206|Active Comparator|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
11364077|NCT02273206|Experimental|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.
~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
11364078|NCT02273193||Pregnant Women|Pregnant Women in the first trimester (<13 weeks) of pregnancy and the second trimester of pregnancy.
11364079|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
11364080|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
11364081|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
11364082|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
11364083|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
11364084|NCT02273154|Experimental|paroxetine and buspirone group|receive paroxetine (20-60mg/d) and buspirone(30mg/d)
11364085|NCT02273154|Active Comparator|paroxetine group|receive paroxetine (20-60mg/d)
11364086|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
11364087|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
11364088|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD>-2.5) and Chronic Periodontitis (>3mm Pocket Probing Depth)
11364089|NCT02273115|Active Comparator|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
11364090|NCT02273115|Active Comparator|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
11364091|NCT02273115|Active Comparator|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
11364092|NCT02273115|Active Comparator|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
11364093|NCT02273102|Experimental|TCP Dose Level 1|20mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
11364094|NCT02273102|Experimental|TCP Dose Level 2|40mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
11364095|NCT02273102|Experimental|TCP Dose Level 3|60mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
11364096|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
11364097|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
11364098|NCT02273063|Experimental|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
11364099|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
11364100|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
11364101|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
11364102|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
11364103|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
11364104|NCT02273024|Experimental|Exercise|Individuals will participate in weekly supervised and unsupervised exercise sessions prior to HSCT, during hospitalization and till 100 days from HSCT. Exercise will consist of endurance and resistance exercise 3-5 days a week.
11364105|NCT02273024|No Intervention|Usual Care|Usual care will have continue with standard of care treatment without any specific exercise instruction or guidance other than what is provided by the patient education team at the cancer centre.
11364106|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
11364107|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
11364108|NCT02272998|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11364109|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
11364110|NCT02272972||Retrospective group|One x-ray image per patient is assessed by the surgeon. The surgeon undergoes an educational intervention (video/poster) and applies the achieved knowledge during the second assessment of the same image. The intervention is not administered to patients, only to an image.
11364111|NCT02272972||Prosp.group (Application of knowledge)|No direct intervention at the patient. The surgeon applies the achieved knowledge during the performance of the fluoroscopy in the operating room. This image is assessed.
11364112|NCT02272959|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
11364113|NCT02272959|Placebo Comparator|Placebo Group|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
11364114|NCT02272946|Other|Safety Arm|In Stage 1: all 10 subjects will receive 150 mg Canakinumab subcutaneous injection. This will be a preliminary safety study (before Stage II).
11364115|NCT02272946|Experimental|Canakinumab|In Stage II: About 67 subjects will receive 150mg Canakinumab subcutaneous injection.
11364116|NCT02272946|Placebo Comparator|Placebo|In Stage II: About 33 subjects will receive 150mg placebo subcutaneous injection
11364117|NCT02272933|Experimental|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
11364118|NCT02272920|Experimental|Renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation: Medtronic Symplicity Flex, Medtronic Symplicity Spyral or St Jude EnligHTN.
~Renal denervation is performed within seven days after PCI in patients with acute myocardial infarction and hypertension."
11364119|NCT02272920|No Intervention|Control: Standard of care|Standard-of-care follow-up after ACS. Including nurse and physician out-patient visits.
11364120|NCT02272907|Experimental|Non-buttressed, non-imbricated oversewing|Along the staple line, the surgical attending will oversew the length of the staple line using a 2-0 Vicryl suture in a continuous fashion.
11364121|NCT02272907|Experimental|Non-buttressed, imbricated suture line|Along the staple line, the surgical attending will oversew the staple line using a 2-0 Vicryl suture in a continuous, imbricating fashion.
11364122|NCT02272907|Experimental|Buttressed stapling|"The specimen will be stapled utilizing the same stapling device, with Seamguard applied as a buttress. We will use the standard methodology to apply Seamguard as illustrated in the company's Instructions for Use."
11364123|NCT02272907|Active Comparator|No reinforcement|Data will be collected on staple lines without any reinforcement as a baseline for leak pressure.
11364124|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
11364125|NCT02272894||Group B|D2 Radical Gastrectomy
11364126|NCT02272881|Experimental|immediate surgical intervention|immediate surgical reconstruction of the pressure ulcer via flap closure or comparable procedure
11364127|NCT02272881|Other|wound care|conservative wound management directed by certified wound care experts
11364128|NCT02272868|Experimental|Fecal microbiome transplant|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Fecal Microbial Transplant
11364129|NCT02272868|Placebo Comparator|Normal saline|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Normal saline
11364130|NCT02272855|Experimental|HF10 plus ipilimumab|
11364131|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
11364132|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
11364133|NCT02272829|Active Comparator|Active|Participants in this arm will receive the study intervention (sessions with the BHC and the PCP).
11364134|NCT02272829|Placebo Comparator|Health Education|Participants in this arm will receive study sessions about various health topics.
11364135|NCT02272816|Experimental|Carboplatin AUC-10|
11364136|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide
~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Drug: Dexamethasone
~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Biological: Elotuzumab (BMS-901608)
~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
11364137|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide
~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
~Drug: Dexamethasone
~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
11364138|NCT02272790|Experimental|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
11364139|NCT02272790|Experimental|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
11364201|NCT02272439||male factor (female/control)|Women of couples with a diagnosis of male factor infertility (n=15)
11364140|NCT02272790|Experimental|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.
~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
11364141|NCT02272790|Experimental|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
11364142|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
11364143|NCT02272777|Experimental|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
11364144|NCT02272764|Other|Itraconazole|Itraconazole or placebo
11364145|NCT02272764|Experimental|ALKS 5461|ALKS 5461 or placebo Sublingual tablet
11364146|NCT02272751|Experimental|Exercise Intervention|"Subjects allocated to the Exercise arm will aim to undertake a personal prescribed home exercise programme for half an hour three times a week.
~Exercises will be progressed at 6 weeks as subjects progress. All exercise sessions will be documented in the logbooks provided.
~Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
11364147|NCT02272751|Experimental|Relaxation Intervention|"Subjects allocated to the Relaxation arm will aim to undertake a guided relaxation programme on a CD for half an hour three times a week.
~All relaxation sessions will be documented in the logbooks provided. Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
11364148|NCT02272738|Experimental|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.
~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.
~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.
~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
11364149|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
11364150|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
11364151|NCT02272712|Experimental|Cognitive Behavioural Therapy|A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
11364152|NCT02272712|No Intervention|Control Condition|The online attention matched control arm will provide education about sleep without any focus on the active ingredients that constitute the intervention group.
11364153|NCT02272699|Experimental|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.
~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.
~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
11364154|NCT02272699|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
11364155|NCT02272699|Active Comparator|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
11364156|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
11364157|NCT02272660|Experimental|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
11364158|NCT02272660|Placebo Comparator|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
11364159|NCT02272647|Experimental|IM Plac - Oral Plac - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
11364160|NCT02272647|Experimental|IM Plac - Oral Prog - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
11364161|NCT02272647|Experimental|IM E2 - Oral Plac - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)
11364162|NCT02272647|Experimental|IM E2 - Oral Prog - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
11364163|NCT02272634|Experimental|YPL-001 low dose|Active arm including patients who receive the YPL-001 low dose
11364164|NCT02272634|Experimental|YPL-001 high dose|Active arm including patients who receive the YPL-001 high dose
11364165|NCT02272634|Placebo Comparator|placebo|Control arm including patients who receive the placebo drug
11364166|NCT02272621|Experimental|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
11364167|NCT02272621|Experimental|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
11364168|NCT02272608||control|patients WHO do not have sleep apnea
11364169|NCT02272608||mild OSAS|mild apnea patients (AHI: 5-15)
11364170|NCT02272608||moderate OSAS|moderate apnea patients (AHI: 16-30)
11364171|NCT02272608||severe OSAS|severe OSAS patients (AHI: more than 30)
11364202|NCT02272439||PCOS (female)|Women of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
11364172|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
11364173|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
11364174|NCT02272582|Experimental|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
11364175|NCT02272582|Active Comparator|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
11364176|NCT02272569|Experimental|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space
11364177|NCT02272556|Active Comparator|Subjects with Type 2 Diabetes|Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination
11364178|NCT02272556|Active Comparator|Non-Diabetic Obese|Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals
11364179|NCT02272556|Active Comparator|Lean, healthy control subjects|Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)
11364180|NCT02272543|Active Comparator|Fish surimi peptide powder|Fish surimi peptide powder
11364181|NCT02272543|Placebo Comparator|Placebo|Placebo
11364182|NCT02272530||Healthy|100 healthy volunteers in age of 20-75 years
11364183|NCT02272530||Patients|100 patients with stable coronary artery disease and accordingly endothelial dysfunction
11364184|NCT02272517|Active Comparator|Escitalopram 10-20 mg|Encapsulated tablets once daily for 8 weeks
11364185|NCT02272517|Experimental|Vortioxetine 10-20 mg|Encapsulated tablets once daily for 8 weeks
11364186|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
11364187|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
11364188|NCT02272491|Experimental|ZrO2|"Straumann CARES Variobase Abutment RN
~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
11364189|NCT02272491|Active Comparator|PFM crown|Straumann Gold Abutment RN Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
11364190|NCT02272478|Active Comparator|Arm A|"Patients not known adverse karyotype
~Randomise between
~Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy
~Versus
~CPX-351 100 units/m2 on days 1, 3 and 5"
11364191|NCT02272478|Active Comparator|Arm B|"Patients with known adverse karyotype
~5 cycles of Vosaroxin and Decitabine therapy"
11364192|NCT02272478|Active Comparator|Arm C|"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1
~Randomise between
~Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)
~Versus
~Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive
~Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive
~Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)
~And Randomisation to receive AC220 or not"
11364193|NCT02272478|Active Comparator|Arm D|"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1
~Randomisation to receive AC220 or not"
11364194|NCT02272478|Active Comparator|Arm E|"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1
~Randomisation between
~CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)"
11364195|NCT02272478|Active Comparator|Arm F|"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1
~Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)
~versus
~Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)"
11364196|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
11364197|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
11364198|NCT02272439||Unexplained (male)|Men of couples with a diagnosis of Unexplained infertility (n=15)
11364199|NCT02272439||Unexplained (female)|Women of couples with a diagnosis of Unexplained infertility (n=15)
11364200|NCT02272439||male factor (male)|Men of couples with a diagnosis of male factor infertility (n=15)
11364203|NCT02272439||PCOS (male/control)|Men of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
11364204|NCT02272439||healthy volunteer (male/control)|Men with a history of no reproductive dysfunction and proven fertility (n=15)
11364205|NCT02272439||healthy volunteer (female/control)|Women with a history of no reproductive dysfunction and proven fertility (n=15)
11364206|NCT02272426|Experimental|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
11364207|NCT02272426|Sham Comparator|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
11364208|NCT02272413|Experimental|BI 695502|
11364209|NCT02272413|Active Comparator|Avastin|
11364210|NCT02272400|Experimental|IGRT of prone partial breast|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy.
11364211|NCT02272387|Active Comparator|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
11364212|NCT02272387|Placebo Comparator|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
11364213|NCT02272374|Experimental|e-AVF group|120 elderly with end stage renal disease will undergo AVF creation.
11364214|NCT02272374|Experimental|e-TCC group|120 elderly with end stage renal disease will undergo TCC placement.
11364215|NCT02272374|Experimental|e-AVG group|60 elderly with end stage renal disease will undergo AVG creation.
11364216|NCT02272374|Experimental|ve-AVF group|80 very elderly with end stage renal disease will undergo AVF creation.
11364217|NCT02272374|Experimental|ve-TCC group|80 very elderly with end stage renal disease will undergo TCC placement.
11364218|NCT02272374|Experimental|ve-AVG group|40 very elderly with end stage renal disease will undergo AVG creation.
11364219|NCT02272361|Other|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
11364220|NCT02272361|Other|vaginal mesh surgery|vaginal mesh surgery
11364221|NCT02272348|Experimental|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
11364222|NCT02272348|Other|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
11364223|NCT02272335|Experimental|CB Stress Management|The Cognitive-Behavioral Stress Management (CBSM) intervention arm is a closed, structured group intervention that offers 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the Cancer Wellness and Education (CW) condition as well. i.e. Group Sessions
11364224|NCT02272335|Active Comparator|Cancer Wellness (CW)|Enhanced Breast Cancer Wellness and Education (CW). The CW condition consists of 10 weekly sessions that are roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain (e.g., National Cancer Institute, Susan G. Komen Foundation, American Cancer Society).i.e. Group Sessions
11364225|NCT02272309|Experimental|Healthy volunteers|Healthy volunteers
11364226|NCT02272309|Experimental|Patients with LUTS|Patients with LUTS
11364227|NCT02272309|Experimental|Patients with LUTS and treatment|Patients with LUTS and treatment
11364228|NCT02272296|Active Comparator|Jet Injector_main study|Administration of insulin or placebo injection in main study
11364229|NCT02272296|Placebo Comparator|conventional pen, NovoPen IV|Administration of insulin or placebo injection in main study
11364230|NCT02272296|Active Comparator|jet injector_sub study|Administration of insulin or placebo injection in sub study
11364231|NCT02272283|Active Comparator|Angio-guided PCI|"Patients allocated to angio-guided PCI are having Percutaneous Coronary Intervention (PCI) with stent implantation guided by routine angiography alone.
~Documentary (comparator) intravascular imaging with Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) is performed. The PCI-operator is blinded to the image aquisitions, and the analysis is performed offline later."
11364232|NCT02272283|Experimental|OCT-guided PCI|"After obtaining an angiographic optimal result, patients allocated to OCT-guided PCI have guiding Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) performed. Online image interpretation is performed by a dedicated OCT-analyst and the PCI-operator. If the OCT reveals; 1) under expansion of the stent with a minimal stent area (MSA) <90% of the distal/proximal reference vessel lumen area and/or; 2) significant acute incomplete stent apposition (defined as more than or equal to 3 stent struts detached >140 microns from the underlying vessel wall), and/or; 3) edge dissection(s) causing significant reduction in minimal lumen area(s) (MLA <4 mm2) and/or, 4) significant residual stenosis (MLA <4 mm2) at the proximal and/or distal reference segment(s), additional intervention is encouraged. The degree of optimization based upon OCT findings is left to the judgement of the PCI-operator."
11364233|NCT02272270|Experimental|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID
~Followed by 28 day break followed by
~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles
~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:
~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
11364234|NCT02272257|Experimental|Early Direct Access Physical Therapy|All care will be administered by one or more physical therapists employed by Temple University. This arm will be early, direct access, physical therapy (immediately evaluation following contacting the front desk administrator or reporting a work injury). Intervention will include interventions matched to their stratified risk category incorporating biopsychosocially oriented education, therapeutic exercise, and manual therapy tailored to the patient's needs.
11364269|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
11364235|NCT02272257|Active Comparator|Physician management|All usual care by physician will be administered by one or more employee health physicians employed by Temple University. Recommendations may or may not include referral to physical therapy.
11364236|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
11364237|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
11364238|NCT02272218|Other|LAGB|There is only one arm for this study, since this study involves a single cohort receiving the same intervention, laparoscopic gastric banding (LAGB) surgery.
11364239|NCT02272192|Experimental|ESDM15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
11364240|NCT02272192|Experimental|ESDM 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
11364241|NCT02272192|Experimental|EIBI 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using Early Intensive Behavioral Intervention (EIBI) and following the Manual A Work in Progress"
11364242|NCT02272192|Experimental|EIBI 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using EIBI and following the Manual A Work in Progress"
11364243|NCT02272179|Experimental|ASAP Treatment and Brite|Participants in the experimental arm received the ASAP treatment, during their transition from inpatient to outpatient care, as well as the Brite app for distress tolerance/emotion regulation and safety planning.
11364244|NCT02272179|Active Comparator|Treatment as Usual|Participants in this grouping were studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants completed paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
11364245|NCT02272166|Active Comparator|propofol|Hypnotic used in this arm is exclusively intra-venous propofol.
11364246|NCT02272166|Active Comparator|sevoflurane|Hypnotic used in this arm is exclusively inhaled sevoflurane.
11364247|NCT02272153|Active Comparator|Egg refined grain|Eggs with white toast
11364248|NCT02272153|Active Comparator|Egg whole grain|Eggs with whole grain toast
11364249|NCT02272153|Active Comparator|Cereal Refined grain|rice cereal with white toast
11364250|NCT02272127|Experimental|intercalated treatment|Patients will receive 4 cycles treatment: chemotherapy(day 1) plus intercalated icotinib(day 8-21) every 3 weeks, and then oral icotinib continuously for 2 years or until disease progression or unacceptable toxic effects
11364251|NCT02272101|Experimental|Vitamin D|Vitamin D 4,000 I.U. orally
11364252|NCT02272101|Placebo Comparator|Placebo|Placebo orally
11364253|NCT02272088|Experimental|physical activity-moderate|participants will be walking during 60 minutes in a moderate pace
11364254|NCT02272088|Experimental|intense physical activity|participants will be running during 60 minutes in na intense pace.
11364255|NCT02272075|No Intervention|mobile colposcope|
11364256|NCT02272062|No Intervention|Preferences Not Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, but these preferences will NOT be shared with the treating clinicians.
11364257|NCT02272062|Experimental|Preferences Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, and these preferences WILL be shared with the treating clinicians.
11364258|NCT02272049|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
11364259|NCT02272036|Active Comparator|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
11364260|NCT02272036|Active Comparator|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
11364261|NCT02272023|Experimental|9 sessions of Intensive Motivational Interviewing|Experimental condition will consist of 9 1-hour intensive motivational interviewing sessions.
11364262|NCT02272023|Active Comparator|1 Standard Motivational Interview plus 8 nutrition classes|The standard MI intervention will consist of a commonly used, single session of MI (50 minutes) plus 8 hours of nutrition education to achieve time and attention equivalence of study conditions.
11364263|NCT02272010|Experimental|Experimental diet|Altered n-6 and n-3 fatty acid intake.
11364264|NCT02272010|Active Comparator|Comparator Diet|Diet standardized to usual n-6 and n-3 intake.
11364265|NCT02271997|Active Comparator|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
11364266|NCT02271997|Active Comparator|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
11364267|NCT02271997|Active Comparator|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
11364268|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
11364270|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
11364271|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
11364272|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
11364273|NCT02271971|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
11364274|NCT02271971|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.
11364275|NCT02271958|Experimental|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
11364276|NCT02271958|Experimental|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
11364277|NCT02271958|Experimental|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
11364278|NCT02271958|Experimental|Group 4|Oral administration of mifepristone placebo daily for 3 months
11364279|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
11364280|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
11364281|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
11364282|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
11364283|NCT02271919|Experimental|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
11364284|NCT02271919|Placebo Comparator|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
11364285|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
11364286|NCT02271893|Experimental|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
11364287|NCT02271893|Placebo Comparator|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
11364288|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
11364289|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
11364290|NCT02271867|Active Comparator|Levobupivacaine 0,5%|Levobupivacaine 0,5% 15 ml once
11364291|NCT02271867|Active Comparator|Levobupivacaine 0,5% with epinephrine|Levobupivacaine 0,5% with 1/200000 epinephrine 15 ml once
11364292|NCT02271867|Active Comparator|Ropivacaine 0,75%|Ropivacaine 0,75% 15 ml once
11364293|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
11364294|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
11364295|NCT02271841||Before introduction of PVI|Physicians' practices
11364296|NCT02271841||After introduction of PVI|Physicians' practices
11364297|NCT02271828|Active Comparator|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
11364298|NCT02271828|No Intervention|No sentinel lymph node procedure|No sentinel lymph node procedure
11364299|NCT02271815||Oral Hygiene|Oral Hygiene
11364300|NCT02271802|Experimental|Butyrate|Enema containing sodium butyrate
11364301|NCT02271802|Placebo Comparator|Placebo|Enema containing NaCl
11364302|NCT02271776|Active Comparator|Galactooligosaccharide|5g 3x per day for 12 weeks
11364303|NCT02271776|Placebo Comparator|maltodextrin|3x per day for 12 weeks (isocaloric to intervention)
11364304|NCT02271763|Active Comparator|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
11364305|NCT02271763|Experimental|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
11364306|NCT02271750||Dementia|
11364307|NCT02271750||controls|
11364308|NCT02271737|Experimental|Experimental|Improve infection control in health centers; improve home hygiene; improve newborn danger signs recognition by the HC staff, VHSG, and mothers; and improve care coordination between community and health facilities. The above improvements will be through the training of health center staff and VHSG; HC staff and VHSG provide health education to mothers at the health centers and at home respectively; and provide supportive supervision to both HC and VHSG. VHSG will conduct three home visits to the mothers/newborns on the first 24 hours, the 3rd day, and the 7th day after delivery.
11364309|NCT02271737|No Intervention|No Intervention|We do not make any interventions.
11364310|NCT02271724||CIDP/MMN newly diagnosed (drug naive)|"Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients.
~Lumbar puncture Blood sample"
11364311|NCT02271724||CIDP/MMN treated|"All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital.
~We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital."
11364312|NCT02271724||Other peripheral neuropathies|Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
11364313|NCT02271724||Syptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls
11364314|NCT02271711|Experimental|Treatment (autologous ex vivo-expanded NK cells)|Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
11364315|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
11364316|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
11364317|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
11364318|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
11364319|NCT02271685|Experimental|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
11364320|NCT02271685|Experimental|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
11364321|NCT02271685|Experimental|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
11364322|NCT02271685|Experimental|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
11364323|NCT02271672|Experimental|XP1000 RF group|Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
11364324|NCT02271672|Sham Comparator|Sham group|Subjects in the Sham group will be treated with the sham XP1000 RF device.
11364325|NCT02271659|Experimental|Brachytherapy boost|Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique
11364326|NCT02271659|Active Comparator|Exclusive external beam irradiation|Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
11364327|NCT02271646|Experimental|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
11364328|NCT02271633|Active Comparator|Sodium nitrate|Dietary supplement: 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
11364329|NCT02271633|Active Comparator|Beetroot juice|Dietary supplement: 800 mg of nitrate in concentrated beetroot juice (Beet-IT)
11364330|NCT02271633|Active Comparator|Spinach|Dietary supplement: 800 mg of nitrate in a spinach based beverage
11364331|NCT02271633|Active Comparator|Rocket salad|Dietary supplement: 800 mg of nitrate in a rocket salad based beverage
11364332|NCT02271620|Other|nonallergic rhinitis|nonallergic rhinitis nasal allergen provocation test
11364333|NCT02271607|Experimental|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
11364334|NCT02271607|No Intervention|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
11364335|NCT02271594|Active Comparator|Intensive Training|The intervention consists of instructing patients in whom lipohypertrophy (LH) is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
11364363|NCT02271425|Experimental|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)[¹³C₈] evacetrapib administered over a 4 hour infusion.
11364364|NCT02271412|Experimental|LY03005|LY03005 40, 80, 120, or 160 mg
11364365|NCT02271412|Placebo Comparator|Placebo|Placebo at 40, 80, 120, or 160 mg
11364366|NCT02271399|Active Comparator|acetylsalicylic acid|aspirin 300mg tablet by mouth, every 24 hours for postoperatively 10 days
11364336|NCT02271594|No Intervention|Standard Care|Standard care means affording the patients randomized to the control arm the customary education and follow-up usually given at the centre. This would include appraising them of the presence of LH (if they were not previously aware) and stating that injections should not be given into that area. The training approach, tools and intensive follow-up given the Intervention arm patients will not be given to the Controls. Additionally, at their return visit (3 and 6 months), Control patients will be asked if they did indeed change their injection habits (e.g. stopped injecting into LH) since entering the study. Those who did and those who did not will be analysed separately to see if there is a difference in outcomes and both groups will be compared to the Intervention arm patients.
11364337|NCT02271568||Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
11364338|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
11364339|NCT02271555|Active Comparator|sevoflurane-remifentanil (Group SR)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
11364340|NCT02271555|Placebo Comparator|sevoflurane-saline (Group SS)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.
11364341|NCT02271542|Experimental|between 1-10 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
11364342|NCT02271542|Experimental|under 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
11364343|NCT02271542|Experimental|upper 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
11364344|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
11364345|NCT02271516|Experimental|188Re-BMEDA-liposome|"Stage I:
~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose
~Stage II:
~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)
~0.42±0.04 mCi/kg
~0.63±0.06 mCi/kg
~0.84±0.08 mCi/kg
~1.05±0.11 mCi/kg
~1.26±0.13 mCi/kg
~1.47±0.15 mCi/kg"
11364346|NCT02271503|Other|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
11364347|NCT02271503|Other|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
11364348|NCT02271503|Other|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
11364349|NCT02271490|Active Comparator|micoinjection according to classical protocole|incubation of sperm in incubation medium
11364350|NCT02271490|Experimental|incubation in follicular fluid|incubation of sperm in follicular fluid prior to microinjection
11364351|NCT02271477|No Intervention|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
11364352|NCT02271477|Experimental|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
11364353|NCT02271464|Experimental|Maintenance:BEVACIZUMAB|Induction: FOLFOXIRI; Manteinance: Bevacizumab
11364354|NCT02271464|Experimental|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Induction: FOLFOXIRI; Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE(Metronomic Chemotherapy)
11364355|NCT02271451|Experimental|Q collar|subjects wearing the q collar
11364356|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
11364357|NCT02271438|Experimental|Part 1: Ibrutinib 840 milligram (mg)|Participants will receive ibrutinib 840 mg (6*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.
11364358|NCT02271438|Experimental|Part 1: Ibrutinib 1680 mg|Participants will receive ibrutinib 1680 mg (12*140 mg capsules) on Day 1 of Part 1, Period 2.
11364359|NCT02271438|Experimental|Part 2: Treatment A|Participants will receive ibrutinib, 1680 mg (12*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.
11364360|NCT02271438|Experimental|Part 2: Treatment B|Participants will receive ibrutinib, 840 mg (6*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.
11364361|NCT02271438|Experimental|Part 2: Treatment C|Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.
11364362|NCT02271438|Experimental|Part 2: Treatment D|Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.
11364367|NCT02271399|Experimental|rivaroxaban|xarelto 10mg tablet by mouth, every 24 hours for postoperatively 10 days
11364368|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
11364369|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
11364370|NCT02271373|Experimental|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
11364371|NCT02271373|No Intervention|control group|The control school did not have any interventions.
11364372|NCT02271360|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
11364373|NCT02271360|Active Comparator|group B|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat day of HCG injection and for 8 days .
11364374|NCT02271347|Experimental|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
11364375|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
11364376|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
11364377|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
11364378|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
11364379|NCT02271321|No Intervention|control group|The control group will receive usual care
11364380|NCT02271321|Experimental|experimental group|The experimental group will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
11364381|NCT02271308|No Intervention|Control group|Residents in control group will receive regular activity in nursing homes.
11364382|NCT02271308|Experimental|Experimental group|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
11364383|NCT02271295|Experimental|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
11364384|NCT02271295|No Intervention|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
11364385|NCT02271282|Experimental|Oral Toremifene/Oral Placebo|"Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.
~After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
11364386|NCT02271282|Experimental|Oral Placebo/Oral Toremifene|"Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.
~After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
11364387|NCT02271269|No Intervention|Usual Care (UC)|"Patients receiving Usual Care for Glaucoma comprising:
~Education on effective glaucoma treatment
~Routine check-ups with an ophthalmologist and prescription of glaucoma eye drops
~Glaucoma counselling [Can be recommended by ophthalmologist for non-adherent patients] covering:
~Glaucoma risk factors and symptoms
~Management and treatment
~Medications and optimal dosage windows
~Risks of medication non-adherence
~Formulation of a dosing schedule that compliments each patient's lifestyle"
11364388|NCT02271269|Experimental|Value Pricing (VP)|Patient receiving Usual Care for Glaucoma and given the opportunity to receive Value Pricing Subsidies.
11364389|NCT02271256|Experimental|Functional intimate apparel|A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
11364390|NCT02271256|No Intervention|Control|Monitoring and observation will be provided during the 6-9 months wearing period.
11364391|NCT02271243||Subject with suspected MBI|
11364392|NCT02271243||Subjects without suspected MBI|
11364393|NCT02271230|Experimental|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
11364394|NCT02271230|Placebo Comparator|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
11364395|NCT02271230|Experimental|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
11364396|NCT02271230|Placebo Comparator|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
11364397|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
11364398|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
11364399|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
11364400|NCT02271191|Active Comparator|Nicardipine and Remifentanil|intravenous nicardipine and remifentanil during deliberate hypotension
11364401|NCT02271191|Placebo Comparator|Remifentanil|intravenous remifentanil during deliberate hypotension
11364402|NCT02271178|Experimental|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
11364403|NCT02271178|Other|Conventional treatment|Usual therapy
11364404|NCT02271165|Active Comparator|IVIg naive|Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
11364405|NCT02271165|Active Comparator|non-IVIg naive|Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
11364406|NCT02271152|Experimental|FAST ablation + PVI|FAST mapping and ablation will be performed in addition to PVI
11364407|NCT02271152|Active Comparator|PVI|Pulnonary vein isolation will be performed
11364408|NCT02271126|Experimental|TEG|TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG. Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
11364409|NCT02271126|Active Comparator|APTT|APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
11364410|NCT02271113|Experimental|GMI-1271|IV GMI-1271
11364411|NCT02271113|Placebo Comparator|Placebo|IV Placebo
11364412|NCT02271113|Active Comparator|Enoxaparin Sodium (Lovenox®)|SC Lovenox®
11364413|NCT02271100|Placebo Comparator|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
11364414|NCT02271100|Active Comparator|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
11364415|NCT02271074|No Intervention|Standard of Care|The role of this arm is to provide a baseline measure that can be used to assess the effectiveness of the combination interventions in improving the proportion of individuals entering care within 3 months. Participants in this arm only receive standard post-test counselling after they are issued with a positive HIV result. They are counselled on possible emotional resources, and given information on how to reduce risk of HIV transmission, ongoing positive living, nutrition and healthy lifestyles. These clients are given referral letters and referred to health facilities of their choice that offer HIV care/treatment. They are then followed up at the designated study time points to ascertain entry into care.
11364416|NCT02271074|Experimental|Point of care CD4 testing|Participants in this arm will receive point of care (POC) cluster differentiation 4 (CD4) testing using the PIMA™ CD4 test system.
11364417|NCT02271074|Experimental|Care facilitation|Participants receive a combination of POC CD4 testing and care facilitation.
11364418|NCT02271074|Experimental|Transport support|Participants receive a combination of POC CD4 testing and transport support.
11364419|NCT02271061|Experimental|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
11364420|NCT02271061|Sham Comparator|Control tape|Apply tape in same technique without tension.
11364421|NCT02271048|Experimental|Group I|"The raters in this group one firstly review ultrasound images numbered from one to 50 using LCD monitor of ultrasound machine and after mandatory rests of 20 minutes, review the remaining ultrasound examinations numbered from 51 to 100 using iPhone display with CubeView at their first visit.(Remote ultrasonography interpretation using the smartphone)
~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
11364422|NCT02271048|Experimental|Group II|"The raters in this group II firstly review the ultrasound images numbered from one to 50 using iPhone with CubeView (Remote ultrasonography interpretation using the smartphone) and 51 to 100 with the LCD monitor.
~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
11364423|NCT02271035|Active Comparator|Deflux|In each patient, Deflux will be injected into one of the ureteral orifices using the the HIT technique.
11364424|NCT02271035|Active Comparator|Vantris|Vantris will be injected into the other ureteral orifice using the same technique and the same amount of implant.
11364425|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
11364426|NCT02271009|Placebo Comparator|Placebo without Al(OH)3|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
11364427|NCT02271009|Active Comparator|AllerT (10 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
11364428|NCT02271009|Active Comparator|AllerT (25 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
11364429|NCT02271009|Active Comparator|AllerT (50 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:
~First three SC injections at weekly intervals.
~Fourth SC injection two weeks after the third injection.
~Fifth SC injection four weeks after the fourth injection."
11364430|NCT02270996||NO Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) BEFORE the implementation of the Antimicrobial Stewardship Program.
11364431|NCT02270996||WITH Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) WITH the implementation of the Antimicrobial Stewardship Program.
11364432|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
11364433|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
11364434|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
11364435|NCT02270970|Active Comparator|Responders to Belimumab|This Arm is defined as patients who complete 6 months of belimumab without and meet the primary endpoint
11364436|NCT02270970|Active Comparator|Non Responders to Belimumab|This Arm is defined as patients who complete 6 months of study and do not meet the primary endpoint
11364437|NCT02270957|Active Comparator|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
11364438|NCT02270957|Placebo Comparator|Placebo|Patients receive placebo instead of Abatacept in a double blind fashion. Otherwise participation is the same, including that at the time of treatment failure they may elect any standard of care treatment and/or to begin taking open label abatacept but this rescue will define non-response in the primary endpoint at six months.
11364439|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
11364440|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
11364441|NCT02270918|Active Comparator|Apixaban with Kcentra|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
11364442|NCT02270918|Placebo Comparator|Apixaban with placebo|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline
11364443|NCT02270905|Experimental|dCELL® Meniscus|
11364444|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
11364445|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
11364446|NCT02270879||Main group|Patients having performed bilateral consecutive cataract surgery between 1st October 2012 and 24th April 2014 in a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal).
11364447|NCT02270866|Experimental|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
11364448|NCT02270853|Other|sleep apnea screening with ApneaLinkTM|This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
11364449|NCT02270840||CRT-D|Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.
11364450|NCT02270840||Only ICD|"In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.
~Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only)."
11364451|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:
~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by
~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by
~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle
~Cisplatin or carboplatin may be given at the discretion of the investigator.
~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:
~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle
~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
11364452|NCT02270801|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
11364453|NCT02270788|Experimental|Study Participants|"All participants who consent and are enrolled on the study.
~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
11364454|NCT02270775||Fibromyalgia Patients|"The central Sensitization questionnaire will be filled in by each patients included.
~After One week, patients will filled it the questionnaire again to study the reliability."
11364455|NCT02270775||Ankle sprain Patients|The central Sensitization questionnaire will be filled in by each patients included.
11364456|NCT02270775||Healthy Volunteers|"The central Sensitization questionnaire will be filled in by each volunteer included.
~After One week, volunteers will filled it the questionnaire again to study the reliability."
11364457|NCT02270762|Experimental|1) Rest in bed|First evaluation of EIT with patient in bed at 30º of head inclination during 5 minutes.
11364458|NCT02270762|Experimental|2) Passive Verticalization|Second evaluation of EIT with patient in tilt table at 60º of verticalization during 10 minutes.
11364459|NCT02270762|Experimental|3) Rest in bed|Last evaluation of EIT with patient in bed at 30º of head inclination during 20 minutes.
11364586|NCT02269891|Experimental|Nu Femme|Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
11364460|NCT02270749|Active Comparator|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
11364461|NCT02270749|Active Comparator|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
11364462|NCT02270736|Experimental|IncobotulinumtoxinA (Xeomin)|"Main and extension period: subjects to receive on average 2 units incobotulinumtoxinA per kg body weight per treatment cycle (subjects with a body weight ≥ 30 kg to receive a fixed total dose of 75 U per cycle).
~Mode of administration: Four injections at the beginning of each treatment cycle (parotid and submandibular glands, bilateral)"
11364463|NCT02270736|Placebo Comparator|Placebo|"For subjects aged 6-17 years only.
~Main period (1 treatment cycle): Subjects to receive placebo injection.
~Extension period (3 treatment cycles): Subjects to receive on average 2 Units IncobotulinumtoxinA per kg body weight per treatment cycle (subjects with a body weight ≥ 30 kg to receive a fixed total dose of 75 U per cycle).
~Mode of administration: Four injections at the beginning of each treatment cycle (parotid and submandibular glands, bilateral)"
11364464|NCT02270723|Active Comparator|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
11364465|NCT02270723|Placebo Comparator|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
11364466|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
11364467|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
11364468|NCT02270697||Regular Diagnosis|Difficult in regular diagnosis specimens, assistance with array.
11364469|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
11364470|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
11364471|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
11364472|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
11364473|NCT02270658|Experimental|Continuous positive airway pressure|Continuous positive airway pressure therapy (CPAP)
11364474|NCT02270658|Placebo Comparator|Nasal strips|Nasal strips applied to the outside surface of the nose with adhesive.
11364475|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.
~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.
~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
11364476|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.
~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.
~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
11364477|NCT02270632|Placebo Comparator|Arm 1|Placebo
11364478|NCT02270632|Experimental|Arm 2|F8IL10, 30 μg/kg
11364479|NCT02270632|Experimental|Arm 3|F8IL10, 160 μg/kg
11364480|NCT02270619|Placebo Comparator|Uninterrupted sleep & placebo|Uninterrupted sleep followed by placebo
11364481|NCT02270619|Experimental|Uninterrupted sleep & endotoxin|Uninterrupted sleep followed by endotoxin 0.8 ng/kg of body weight IV bolus
11364482|NCT02270619|Experimental|Partial sleep deprivation & placebo|Partial sleep deprivation followed by placebo
11364483|NCT02270619|Experimental|Partial sleep deprivation & endotoxin|Partial sleep deprivation followed by endotoxin 0.8 ng/kg of body weight IV bolus
11364484|NCT02270606|Experimental|Treatment(IMRT,fluorouracil,chemotherapy,surgery)|"CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours.
~PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity.
~SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery.
~POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity."
11364485|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
11364486|NCT02270580|Experimental|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
11364487|NCT02270580|Active Comparator|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
11364488|NCT02270554|Experimental|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
11364489|NCT02270541|No Intervention|Control|Standard pre-hospital emergency care by the Paramedic Intervention Team, in accordance with their standing operating procedures.
11364490|NCT02270541|Experimental|Telemedicine|In-ambulance teleconsultation by a stroke expert aiming to support the Paramedic Intervention Team by focusing on patient identification, obtaining homeostasis (optimal control of blood pressure, blood oxygenation, temperature, heart rate and rhythm, glycemia), assessment of the patient's neurological status, stroke diagnosis, hospital notification, and patient selection for specific stroke treatment.
11364491|NCT02270528|Experimental|HIT1|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. The second attempt, prior to the WCST, this group will perform a warm-up and 5-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
11364492|NCT02270528|Experimental|HIT2|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and a 5-minute stationary period. The second attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
11364493|NCT02270528|Other|CON|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt and second attempt, prior to the WCST, this group will participate in a 15-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
11364494|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
11364495|NCT02270502||Adult patients on the SICU|Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
11364496|NCT02270489|Experimental|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
11364497|NCT02270489|Experimental|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
11364498|NCT02270489|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks
~1 administration 36 weeks after first injection"
11364499|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
11364500|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
11364501|NCT02270463|Experimental|SL-401|
11364502|NCT02270450|Experimental|Arm I (randomized to surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician.
11364503|NCT02270450|Experimental|Arm II (randomized to non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician.
11364504|NCT02270450|Experimental|Arm III (no randomization, surgery)|Patients undergo therapeutic conventional surgery (abdominal) as defined by the treating physician as in Arm I.
11364505|NCT02270450|Experimental|Arm IV (no randomization, non-surgical management)|Patients are offered gastrointestinal complications management/prevention (non-surgical management) as determined by the treating physician as in Arm II.
11364506|NCT02270437|Experimental|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
11364507|NCT02270437|No Intervention|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
11364508|NCT02270424|Experimental|Conventional medicine+ placebo TCM|Patients in this group will be given conventional medicine, Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three placebo TCM treatment, which are which are placebo Bufeijianpi granule, placebo Bufeiyishen granule and placebo Yiqizishen granule corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
11364509|NCT02270424|Experimental|conventional medicine+ TCM|Patients in this group will receive Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three types of TCM treatment, which are Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule. A herbal extract twice daily for 52 weeks for lower dosage. The three granules are corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
11364510|NCT02270411||Healthy Subjects|Healthy subjects.
11364511|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
11364512|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
11364513|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
11364514|NCT02270411||Psoriasis|Patient has a history of psoriasis for at least 6 months.
11364515|NCT02270411||Hidradenitis Suppurativa (HS)|Patient has a history of HS for at least 6 months.
11364516|NCT02270398|Experimental|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
11364517|NCT02270398|Active Comparator|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
11364518|NCT02270398|Active Comparator|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
11364519|NCT02270385|Experimental|Experimental group|The experimental group will be implemented a 16-week PU prevention programme. The PU prevention programme includes an intensive training on knowledge and skills ono PU prevention and also a PU prevention protocol. The purpose of the programme is to equip care staff with PU knowledge and skills and to guide especially health workers and personal care workers in PU prevention.
11364520|NCT02270385|Other|control group|The control group will be provided with the usual PU prevention care
11364521|NCT02270372|Experimental|Drug Combination|The drug combination of ONT-10 and varilumab
11364522|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
11364523|NCT02270346|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device.
11364524|NCT02270346|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
11364525|NCT02270333|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
11364526|NCT02270333|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
11364527|NCT02270320|No Intervention|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
11364528|NCT02270320|Active Comparator|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
11364529|NCT02270307|Experimental|MSC+CY|Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery
11364530|NCT02270294|Experimental|Thai traditional massage|
11364531|NCT02270294|Sham Comparator|No massage|
11364532|NCT02270281|Other|Dexmedetomidine|Before dexmedetomidine infusion
11364533|NCT02270268|Experimental|pectin|a kind of soluble dietary fiber
11364534|NCT02270268|Placebo Comparator|Placebo|maltodextrin
11364535|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
11364536|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
11364537|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
11364538|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
11364539|NCT02270229||Healthcare providers|
11364540|NCT02270229||PD patients|
11364541|NCT02270229||Primary caregivers of the PD patients|
11364542|NCT02270229||Laboratory personnel|
11364543|NCT02270216|Active Comparator|elderly with isolated systolic hypertension|over 60 years of age with essential isolated systolic hypertension (stage I-II base on recommendation of JNC-VII) for the hypertension group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
11364544|NCT02270216|Active Comparator|healthy elderly|over 60 years of age with normal blood pressure in the healthy group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
11364545|NCT02270190|Other|tenesmus patients|Percutaneous Tibial Nerve Stimulation (PTNS) will be applied to all patients in the study
11364546|NCT02270177|No Intervention|Regular consultation|Regular headache consultations
11364547|NCT02270177|Other|Videoconsultation|Headache consultations through telemedicine technology
11364548|NCT02270164|Experimental|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
11364549|NCT02270164|Placebo Comparator|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
11364550|NCT02270151|Active Comparator|MyDiagnostick|Everyone aged 65 years or over, who visits the GP practice will be screened for AF with the MyDiagnostick. When the device indicates a positive result, the single lead ECG will be assessed to confirm/reject the diagnosis. Every new case of diagnosed AF will be evaluated for further treatment by the general practitioner.
11364551|NCT02270151|No Intervention|Control|Control arm will perform care as usual with selective screening by feeling the pulse.
11364552|NCT02270138|Experimental|Movement-to-music|Three movement-to-music video programs will be used by the participants. First and second videos last about 10 minutes including two songs and their movement preparation. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
11364553|NCT02270138|No Intervention|No movement-to-music|Another group will not receive movement-to-music video during intervention. However, their physical activity will be objectively measured as well.
11364554|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
11364555|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
11364556|NCT02270112||Paroxysmal Af|No Intervention is planned. All patients receive a 5 Minute ECG and have their pulse recordes by an iPhone.
11364557|NCT02270099||Subjects with suspected HSV Lesions|
11364558|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
11364585|NCT02269904|Active Comparator|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
11364559|NCT02270073|Experimental|TAU + mindfulness intervention|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together the brief intervention with mindfulness elements. Participants sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The text is standardized and spoken by Dr. Thomas Heidenreich. During the exercise, participants are instructed to observe their breathing and body sensations. After completion of the mindfulness intervention, the regular therapy session begins.
~Intervention: Cognitive behavior therapy of trainee therapists"
11364560|NCT02270073|Active Comparator|TAU + progressive muscle relaxation|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together a short version of progressive muscle relaxation (PMR). Both patient and therapist sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The PMR text is standardized and spoken by Dr. Thomas Heidenreich. Wording is as similar as possible to the mindfulness interventions.During the exercise, participants are instructed to tense and relax arms, face, body and legs. After completion of PMR, the regular therapy session begins.
~Intervention: Cognitive behavior therapy of trainee therapists"
11364561|NCT02270073|Other|Treatment as usual|"No specific intervention is conducted at the beginning of therapy sessions. Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions.
~Intervention: Cognitive behavior therapy of trainee therapists"
11364562|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
11364563|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
11364564|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
11364565|NCT02270047|Active Comparator|A|Orange nectar with NAXUS fibre, 5g/100mL
11364566|NCT02270047|Placebo Comparator|B|Orange nectar
11364567|NCT02270034|Experimental|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
11364568|NCT02270021|Experimental|Provider Mobile Application (ProvAPP)|Mobile phone application for providers.
11364569|NCT02270021|Experimental|ProvAPP + Patient Educational Tool (Tab)|Patient educational tool; plus the Mobile phone application for providers.
11364570|NCT02270021|No Intervention|ProvAPP Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
11364571|NCT02270021|No Intervention|ProvAPP+Tab Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
11364572|NCT02270008|Active Comparator|Pelvic floor training|The intervention group will undergo an in-person standardized training session by a trained nurse practitioner. The intervention is the pelvic floor training session. They will then be asked to continue muscle training at home at regular intervals and asked to log their exercises on a standardized exercise diary that is provided to them.
11364573|NCT02270008|No Intervention|Literature-only group|The literature-only group will receive a pamphlet with instructions for pelvic floor muscle exercises; however, no in-person training will be administered.
11364574|NCT02269995||E7040|
11364575|NCT02269982||men with mCRPC prior to enzalutamide/abiraterone|
11364576|NCT02269969|Experimental|Once daily aminoglycoside|Once daily dosing of Tobramycin
11364577|NCT02269956|Active Comparator|Intervention|The 2 NH's not used in the focus groups will receive the intervention, a 12-week feasibility study. At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for 3 meals over 2 days at baseline and again at week 6 and 12, and a medical record review will be conducted. After baseline data is collected, the training program will be delivered in 5 weekly modules with group coaching sessions completed the same week.
11364578|NCT02269956|No Intervention|Focus Groups|Year 1 focus groups will aim to identify how nursing staff feel about usual interventions for feeding behaviors of PWD and staff responses when a PWD displays difficult eating behaviors. Year 2 focus groups will evaluate the revised dementia feeding skills training program, the coaching interventions, and case scenarios, and indicate how realistic and compatible the intervention is with their work environment.
11364579|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
11364580|NCT02269930|Experimental|Group 1|Treatment Sequence 1: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41 Treatment Sequence 2: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29
11364581|NCT02269930|Experimental|Group 2|Treatment Sequence 1: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29 Treatment Sequence 2: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41
11364582|NCT02269917|Experimental|Experimental Treatment Regimen|Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
11364583|NCT02269917|Active Comparator|Current Treatment Regimen|Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
11364584|NCT02269904|Active Comparator|Fluorouracil Implants and Xelox regimes|"Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
~Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished."
11364587|NCT02269891|Placebo Comparator|Placebo|Two capsules taken once daily in the morning after breakfast for 24 weeks
11364588|NCT02269878||people with MPM with Thymine/Thymine,Thymine/cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
11364589|NCT02269878||people with MPM, Cytosine/Cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
11364590|NCT02269852|Experimental|trivalent seasonal influenza vaccine|"Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine
~60 infants: two-dose regimen with a 28-day interval;
~60 adults: single-dose regimen;
~60 seniors: single-dose regimen;"
11364591|NCT02269839|Active Comparator|theta-burst rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
11364592|NCT02269839|Sham Comparator|Control arm|The control (sham) stimulation will consist of stimulating with the rTMS coil held at right angles to the participants' head. This will result in no active stimulation of brain tissue but would feel similar to the patient. Each treatment session will therefore last approximately 20 minutes.
11364593|NCT02269826|Experimental|Vagisan® Moisturising Cream|non-hormonal vaginal cream for the treatment of vulvovaginal dryness
11364594|NCT02269826|Active Comparator|Gynomunal® vaginal gel|non-hormonal gel
11364595|NCT02269813||ET/GOOD|Endocrine therapy only.
11364596|NCT02269813||CT/POOR|Chemoendocrine therapy according to national guidelines.
11364597|NCT02269800|Experimental|Benzalkonium chloride solution|Tid, for 7 days.
11364598|NCT02269800|Active Comparator|Normal saline|Tid, for 7 days.
11364599|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
11364600|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
11364601|NCT02269774|Other|Pulmonary vein isolation|Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index > 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
11364602|NCT02269774|No Intervention|No intevention|Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index < 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.
11364603|NCT02269748|Experimental|Root coverage with Tunnel (TT)|The tunnel technique with subepithelial connective tissue graft (TT+SeCTG) will be utilized to cover the denude root surface
11364604|NCT02269748|Active Comparator|Coronally advanced flap (CAF+SeCTG)|The Coronally advanced flap with subepithelial connective tissue graft (CAF+SeCTG) will be utilized to cover the denude root surface
11364605|NCT02269735|Experimental|Part I: MK-2640 (Panel A)|Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364606|NCT02269735|Experimental|Part I: MK-2640 (Panel B)|Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364607|NCT02269735|Experimental|Part I: MK-2640 (Panel C)|Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364608|NCT02269735|Experimental|Part I: MK-2640 (Panel D)|Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364609|NCT02269735|Experimental|Part I: MK-2640 (Panel E)|Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364610|NCT02269735|Experimental|Part I: MK-2640 (Panel F)|Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364611|NCT02269735|Experimental|Part I: MK-2640 (Panel G)|Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
11364612|NCT02269735|Experimental|Part II: MK-2640 followed by RHI|Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
11364613|NCT02269735|Experimental|Part II: RHI followed by MK-2640|Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
11364614|NCT02269735|Experimental|Part III: MK-2640 followed by RHI|Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
11364615|NCT02269735|Experimental|Part III: RHI followed by MK-2640|Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
11364643|NCT02269540|Experimental|Citalopram and n-acetylcysteine|Citalopram and n-acetylcysteine for seven weeks of treatment
11364616|NCT02269722|Experimental|Short Clamp time|Radial clamp applied at full pressure for 20 minutes. At the end of 20 minutes, the clamp will be loosened ¼ turn every 5 minutes over 20 minutes and then removed.
11364617|NCT02269722|Experimental|Long Clamp Time|Radial clamp applied at full pressure for 60 minutes. At the end of 60 minutes, the clamp is to be loosened and removed under the same instruction as those patients in arm one.
11364618|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
11364619|NCT02269696|Experimental|Metoprolol|Metoprolol infusion
11364620|NCT02269696|Placebo Comparator|Normal saline|Equal volume of saline.
11364621|NCT02269683|Experimental|Robot-assisted|Distal pancreatectomy via robot-assisted minimally-invasive approach
11364622|NCT02269683|Active Comparator|Laparoscopic|Distal pancreatectomy via a conventional laparoscopic approach
11364623|NCT02269670|Experimental|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
11364624|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
11364625|NCT02269644|Experimental|Dalbavancin|Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
11364626|NCT02269644|Active Comparator|Linezolid|Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
11364627|NCT02269644|Other|Linezold Placebo IV and Oral Capsules|Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
11364628|NCT02269644|Other|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
11364629|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
11364630|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
11364631|NCT02269618|Active Comparator|Control group (Group A)|The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed
11364632|NCT02269618|Other|Intervention group (Group B)|"Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:
~Home-based telehealth program
~Home-based rehabilitation"
11364633|NCT02269605|Placebo Comparator|Group 1|Patients receiving placebo (sodium chloride) at single dose
11364634|NCT02269605|Active Comparator|Group 2|Patients receiving Bryostatin 1 (10ug/m2) at single dose
11364635|NCT02269605|Active Comparator|Group 3|Patients receiving Bryostatin 1 (20ug/m2) at single dose
11364636|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
11364637|NCT02269579|Experimental|CPX-351|Study Drug CPX-351 will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
11364638|NCT02269566|Active Comparator|Allergen extract|0.1 ml of allergen extracts
11364639|NCT02269566|Placebo Comparator|Placebo|Normal saline, 0.1 ml
11364640|NCT02269553|Active Comparator|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
11364641|NCT02269553|Active Comparator|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
11364642|NCT02269540|Experimental|Sertraline and n-acetylcysteine|Sertraline and n-acetylcysteine for seven weeks of treatment
11364644|NCT02269540|Experimental|Existing medication treatment & NAC|Existing depression medication treatment and n-acetylcysteine for seven weeks of treatment
11364645|NCT02269527|Other|Live music|1-hour live music 5 days/week
11364646|NCT02269514|Active Comparator|Own Brand Cigarette|Own Brand Cigarette
11364647|NCT02269514|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 14mg nicotine)
11364648|NCT02269514|Experimental|Electronic Cigarette #2|VUSE® (original flavor, 29mg nicotine)
11364649|NCT02269514|Experimental|Electronic Cigarette #3|VUSE® (original flavor, 36mg nicotine)
11364650|NCT02269514|Active Comparator|Leading U.S. Nicotine Gum|Leading U.S. Nicotine Gum
11364651|NCT02269501|Experimental|Exercise treatment|Exercise treatment
11364652|NCT02269501|No Intervention|No treatment|No treatment
11364653|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
11364654|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
11364655|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
11364656|NCT02269462||Pregnant women - efavirenz|Pregnant women taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health
11364657|NCT02269462||Nursing mothers - efavirenz|Nursing mothers taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
11364658|NCT02269462||Pregnant women - nevirapine|Pregnant women taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health
11364659|NCT02269462||Nursing mothers - nevirapine|Nursing mothers taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
11364660|NCT02269449|Experimental|6Fr Glidesheath Slender sheath|TRI will be performed using a new 6Fr sheath (Glidesheath slender: GSS).
11364661|NCT02269449|Active Comparator|5Fr contemporary sheath|TRI will be performed using a contemporary safety of 5Fr sheath.
11364662|NCT02269449|Experimental|Hemostasis with TR band|Hemostasis is achieved by randomization of using TR band (TERUMO) Patent hemostasis.
11364663|NCT02269449|Active Comparator|Any hemostasis procedure|Hemostasis is achieved by randomization of any hemostasis of each hospital's routine procedure.
11364664|NCT02269436|Experimental|sNN0029 infusion solution|
11364665|NCT02269423|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
11364666|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
11364667|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
11364668|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
11364669|NCT02269410|Active Comparator|GBP-SPS|GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day)
11364670|NCT02269410|Experimental|GBP-HPS|GBP High PRO-S (1.2g protein/ kg ideal body weight/ day)
11364671|NCT02269410|Active Comparator|VSG-SPS|VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day)
11364672|NCT02269410|Experimental|VSG-HPS|VSG High PRO-S (1.2g protein/ kg ideal body weight/ day)
11364673|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
11364674|NCT02269384|Sham Comparator|No History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
11364675|NCT02269384|Active Comparator|History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
11364676|NCT02269371|Experimental|Group 1|Group 1: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
11364677|NCT02269371|Sham Comparator|Group 2|Group 2: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
11364678|NCT02269358|Experimental|Addition of methotrexate|Addition SC methotrexate at 15 mg/m2, not to exceed 25 mg/m2 . Patients in remission after 4 weeks will reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
11364679|NCT02269345|Experimental|Battlefield Acupuncture|BFA at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
11364680|NCT02269345|Placebo Comparator|Standard Treatment|Standard Treatment alone
11364681|NCT02269332||Screening Colonoscopy|Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
11364682|NCT02269319|Experimental|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
11364683|NCT02269319|Active Comparator|Linezolid|Linezolid 600 mg given twice a day for 10 days
11364684|NCT02269306|Experimental|clomiphen citrate(cc)|Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles.
11364685|NCT02269293|Experimental|Regimen 1|Paclitaxel 175 mg/m^2 IV, Day 1 (administered over approximately 3 hours) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
11364686|NCT02269293|Experimental|Regimen 2|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
11364687|NCT02269293|Experimental|Regimen 3|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once weekly on days 1, 8, and 15 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
11364815|NCT02268383|Experimental|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
11364688|NCT02269293|Experimental|Regimen 4|Paclitaxel and carboplatin will be delivered intravenously (IV) on day 1 of each cycle. Selinexor will be taken orally once a week on days 1, 8 and 15 of each chemotherapy cycle.
11364689|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 3|Azacitidine (AZA) Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
11364690|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 5|Azacitidine (AZA) 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
11364691|NCT02269280|Experimental|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
11364692|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
11364693|NCT02269267||Discontinuation of TKI medication|Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years.
11364694|NCT02269254|Experimental|Persona PS|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
11364695|NCT02269254|Active Comparator|NexGen PS|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
11364696|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
11364697|NCT02269228|Experimental|Asasantin ER|Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)
11364698|NCT02269228|Experimental|Asasantin ER, administered twice daily from day 1 to day 14|
11364699|NCT02269228|Placebo Comparator|Placebo|
11364700|NCT02269215|Experimental|BIII 890 CL single rising dose|
11364701|NCT02269215|Placebo Comparator|Placebo|
11364702|NCT02269202|Experimental|Midazolam and crobenetine|
11364703|NCT02269202|Placebo Comparator|Midazolam and placebo|
11364704|NCT02269189|Experimental|BIIL 284 BS, high dose in adult patients|
11364705|NCT02269189|Experimental|BIIL 284 BS, low dose in pediatric patients|
11364706|NCT02269189|Placebo Comparator|Placebo|
11364707|NCT02269176|Experimental|Telmisartan|Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
11364708|NCT02269176|Active Comparator|Losartan|Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
11364709|NCT02269163|Active Comparator|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
11364710|NCT02269163|Experimental|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
11364711|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
11364712|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
11364713|NCT02269124|No Intervention|Conventional measures arm|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
11364714|NCT02269124|Experimental|Conventional measures + hearing aid arm|In the second arm, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by a Massachusetts Eye and Ear Infirmary (MEEI) audiologist. The subject will be instructed wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
11364715|NCT02269111|Experimental|Diagnostic (hybrid MRI)|Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
11364716|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.
~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
11364717|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
11364718|NCT02269085|Experimental|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m^2, 20/36 mg/m^2, 20/45 mg/m^2 or 20/56 mg/m^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.
~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.
~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
11364719|NCT02269072|Active Comparator|Testosterone|Testosterone cream applied daily
11364720|NCT02269072|Placebo Comparator|Placebo|Identical placebo cream applied daily
11364721|NCT02269059|Experimental|GT1 Participants|Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
11364722|NCT02269059|Experimental|GT3 Participants|Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
11364723|NCT02269046|Experimental|Acupuncture and moxibustion|"therapeutic lifestyle change
~Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)
~Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
~Group I and II will change alternatively every other week .
~Once per day five days per week."
11364724|NCT02269046|Active Comparator|Simvastatin|"therapeutic lifestyle change
~simvastatin
~oral administration with 10mg per day
~seven days per week for 12 weeks."
11364725|NCT02269046|Other|waiting list|- therapeutic lifestyle change
11364726|NCT02269033|Experimental|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
11364727|NCT02269033|Active Comparator|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
11364728|NCT02269020|Experimental|3 patients cancer of the epi larynx|"3 patients with squamous cell carcinoma of the epi-larynx
~Intervention: Neck Dissection"
11364729|NCT02269007|Experimental|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
11364730|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
11364731|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
11364732|NCT02268981|Experimental|Oxymizer® compared to CNC|"From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.
~The intervention will be performed on consecutive days and twice during study period."
11364733|NCT02268968|Experimental|Lidocaine|Intervention: Topical lidocaine gel 2% (0.3 ml/kg) will be applied once only to the nostrils and nasal CPAP prong 5 minutes prior to the application of nasal CPAP
11364734|NCT02268968|No Intervention|Control|No topical lidocaine will be used prior to application of nasal CPAP
11364735|NCT02268955|Placebo Comparator|Control Group: Adults age 18-55 years|Saline-only control group
11364736|NCT02268955|Active Comparator|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
11364737|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
11364738|NCT02268929|Other|Control Group|Patients treated by usual customary medical practice (Usual Care)
11364739|NCT02268929|Other|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
11364740|NCT02268916|Experimental|Intervention|OT-led counseling based on home activity pattern
11364741|NCT02268916|Placebo Comparator|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
11364742|NCT02268903|Active Comparator|Diuretics|
11364743|NCT02268903|Placebo Comparator|Placebo|
11364744|NCT02268890|Experimental|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
11364745|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
11364746|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
11364747|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
11364748|NCT02268851|Experimental|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Each Cycle = 28 days
~TGR-1202 (oral): Starting on Day 1 administered daily.
~Ibrutinib (oral): Starting on Day 1 administered daily."
11364749|NCT02268851|Experimental|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Each Cycle = 28 days
~TGR-1202 (oral): Starting on Day 1 administered daily.
~Ibrutinib (oral): Starting on Day 1 administered daily."
11364810|NCT02268435|Experimental|Dovitinib plus Imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
11364750|NCT02268838|Experimental|50 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
11364751|NCT02268838|Experimental|100 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
11364752|NCT02268838|Experimental|200 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
11364753|NCT02268838|Experimental|400 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
11364754|NCT02268838|Experimental|200 mg E6007 fed condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
11364755|NCT02268825|Experimental|MK-3475 treatment arm, all patients|
11364756|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.
~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
11364757|NCT02268799||DC Cardioversion|Patients undergoing DC cardioversion
11364758|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
11364759|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
11364760|NCT02268773|Experimental|Acetylsalicylic acid low dose with Asasantin®|
11364761|NCT02268773|Active Comparator|Acetylsalicylic acid high dose|
11364762|NCT02268760|Experimental|BILN 2061 ZW single rising doses|
11364763|NCT02268760|Placebo Comparator|Placebo|
11364764|NCT02268760|Experimental|BILN 2061 ZW fixed dose fed|
11364765|NCT02268760|Active Comparator|BILN 2061 ZW fixed dose fasted|
11364766|NCT02268747|Experimental|Dacomitinib|"Patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).
~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
11364767|NCT02268734||Sporadic Medullary Thyroid Cancer|Patients with diagnosis of locally relapsed and or metastatic sporadic MTC surgically treated (total thyroidectomy)
11364768|NCT02268721|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records before discharge, and at six and twelve weeks, as the intervention group. The control group receives no special treatment or care after discharge.
11364769|NCT02268721|Other|App for food delivery|"Intervention: Tablet Computer
~Patients in the intervention group receives a tablet upon discharge from the hospital. The tablet contains an app, which the patients in the intervention group can use for ordering meals for delivery from the kitchen at the hospital three times a week. The app also ask the patients to register their own dietary intake, and give them feedback on their daily energy and protein intake.
~Baseline measurements and records are taken at prior to discharge from the hospital, and after six and twelve weeks."
11364770|NCT02268708||COPD|"Patients:
~>18 years old COPD: FEV/FEV1<80% in respiratory evaluation who have un oncological pulmonary resection in Cochin Hospital Paris France"
11364771|NCT02268695|Active Comparator|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).
~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.
~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
11364772|NCT02268695|Experimental|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).
~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.
~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.
~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
11364773|NCT02268682|No Intervention|Standard of Care (Control)|Patients randomized to the standard of care condition will not receive any educational materials from our program and will only participate in the survey portion of the investigation. Dialysis providers will be asked to continue their current practices throughout the study period without change. While Control patients will be free to ask additional questions or solicit more information from their dialysis educators at any point during the study period, no additional educational interventions will be added to what is currently being done.
11364774|NCT02268682|Experimental|Patient-Guided|Over an 8-month period, patients in the Patient-Guided intervention condition will receive four educational modules and twelve transplant education postcards in the mail. Modules will be mailed once every other month and consist of an introductory letter, a transplant video, and printed resources. Transplant education postcard will be mailed every two weeks following the mailing of each module, for a total of three postcards over the course of 6-weeks.
11364811|NCT02268422|Experimental|7 day patch|Buprenorphine transdermal system (BTDS) 2nd generation
11364812|NCT02268422|Active Comparator|7 Day Patch|1st Generation BTDS: Butrans
11364813|NCT02268409|Experimental|ACE-536 0.8 mg/kg once every 3 weeks SC|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
11364814|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
11364775|NCT02268682|Experimental|Educator-Guided|Patients in the Educator-Guided intervention condition will receive the same intervention components as those in the Patient-Guided condition; however, the key difference in this condition is that Educator-Guided patients will also receive telephonic support from an experienced clinical social worker in the role of a Transplant Educator to maximally facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 minutes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an educational text messaging service designed to supplement the ET education they are receiving in the mail.
11364776|NCT02268669|Active Comparator|Primary angioplasty|Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations
11364777|NCT02268669|Active Comparator|Post-thrombolysis angioplasty|Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering >50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization
11364778|NCT02268656|Other|concentration in male|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
11364779|NCT02268656|Other|concentraion in female|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
11364780|NCT02268643||group 1|ultrasound plus clinical breast examination
11364781|NCT02268630||Group A|Patients treated with Warfarin for VTE
11364782|NCT02268630||Grup B|Patients treated with Rivaroxaban for VTE
11364783|NCT02268617|Experimental|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
11364784|NCT02268604|Experimental|BIIB 722 CL|
11364785|NCT02268604|Placebo Comparator|Placebo|
11364786|NCT02268591|Active Comparator|Transcranial Stimulator|We will apply oscillating current at a slow frequency of 0.5-1.5 Hz during early sleep, which is rich in slow waves [ie non-REM sleep]. The peak intensity of stimulation which allows for optimal phase entrainment will be determined in pilot studies. However, peak stimulation intensities will not exceed 2 mA (as discussed above). The current will be applied over the left and right prefrontal cortex (F3, F4), corresponding to the predominant region of slow oscillations, during the onset of deep sleep to the first REM episode (early non-REM-rich sleep).
11364787|NCT02268591|No Intervention|Sham Stimulation|The EEG and stimulation electrodes will be placed as in the stimulation sessions, but stimulation will not be administered.
11364788|NCT02268578|Active Comparator|Transcranial Direct Current Stimulation|Subjects will receive a total of 5 sessions on consecutive days. During each session, 2 mA of tDCS will be applied for 20 minutes over the left DLPFC (active or sham). The electrodes will have the size of 35cm2 each. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes and delivered b y a specially developed, battery driven, constant current stimulator with a maximum output of 2mA.
11364789|NCT02268578|Sham Comparator|Sham TDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
11364790|NCT02268565|Placebo Comparator|Insomnia symptom induction/placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
11364791|NCT02268565|Experimental|Insomnia symptom induction/aspirin|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
11364792|NCT02268552|Experimental|branaplam|branaplam Treatment
11364793|NCT02268539|Active Comparator|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
11364794|NCT02268539|Active Comparator|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
11364795|NCT02268539|Active Comparator|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
11364796|NCT02268539|Active Comparator|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
11364797|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
11364798|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
11364799|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
11364800|NCT02268513||MASALA study|"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study.
~Objective of MASALA study:
~The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers."
11364801|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
11364802|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
11364803|NCT02268487|Experimental|Sertraline|Patients using Sertraline with any dose will be evaluated about Early Improvement
11364804|NCT02268474|Experimental|532nm KTP Laser|Cutera® Excel V
11364805|NCT02268474|Active Comparator|595nm Pulse Dye Laser|Candela/Syneron Vbeam
11364806|NCT02268461|Active Comparator|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
11364807|NCT02268461|Sham Comparator|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
11364808|NCT02268448|Experimental|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
11364809|NCT02268448|Experimental|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
11364816|NCT02268370|Other|Dasatinib|"This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.
~Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.
~If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.
~If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib."
11364817|NCT02268357|Experimental|Propranolol|capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
11364818|NCT02268357|Placebo Comparator|Placebo|capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
11364819|NCT02268344|Active Comparator|Grass SD9 Stimulator|Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection.
11364820|NCT02268344|No Intervention|No Stimulation|No stimulation will be performed in this group, and patients will simply have the neck dissection as planned. No sham stimulation is required, as all outcome measures are performed by individuals not present in the operating room, and therefore, blinded to the treatment arm.
11364821|NCT02268331|Experimental|Active Surveillance|"For 60 consecutive pediatric visits, patients will be asked to complete a PRE & POST form to capture adverse events (AEs) that occur up to 1 week after treatment. The PRE-treatment form will be completed prior to the start of the visit. The POST-treatment form will be completed after the treatment visit and mailed directly to the investigative team.
~The providers will collect data on the treatment provided on the same 60 pediatric patients. The treatment provided is at the discretion of the doctors. If a moderate, serious, or severe AE occurs, the provider will complete the AE form with detailed information about potential risk factors and patient outcomes."
11364822|NCT02268331|Active Comparator|Passive Surveillance|"All doctors allocated to this arm will be provided with a username and password with an established chiropractic passive surveillance reporting and learning online system (CPiRLS) in the UK. If a patient safety incident occurs in their office or an adverse event (AE), the provider will complete a report on the CPiRLS website. The providers can record events that occur during the time period of 60 pediatric visits.
~Treatment provided during these treatments is at the doctor's discretion."
11364823|NCT02268318|Experimental|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols
11364824|NCT02268318|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 1 bottle of dairy product/day with no Phytosterols
11364825|NCT02268305|Experimental|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
11364826|NCT02268305|Placebo Comparator|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
11364827|NCT02268292|Experimental|Bicycle Exercise|Bicycle Exercise for 12 weeks
11364828|NCT02268279|Experimental|solithromycin|oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day
11364829|NCT02268266|Other|Single-arm study|Early mobilization of patients after stroke or spinal cord injury. Monitoring of vital parameters during mobilization of healthy subjects
11364830|NCT02268253|Experimental|Tagraxofusp (SL-401)|
11364831|NCT02268240|Experimental|Experimental|Stepped Care
11364832|NCT02268240|No Intervention|Control|Usual Care
11364833|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
11364834|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
11364835|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
11364836|NCT02268201|Experimental|ADV group|Once daily
11364837|NCT02268201|Experimental|PRG group|Twice daily
11364838|NCT02268188|Experimental|Supportive Care (Harvesting Health program)|Participants undergo a series of 10 education and training sessions over 1 hour every 2 weeks, comprising education on current research, evidence-based health guidelines, application techniques, reference materials specific to extended-stage cancer survivors, and recommendations and personal health goals for survivorship. The guidelines described in class are part of a nutrition intervention and an exercise intervention with personal and group goal setting over the course of the study.
11364839|NCT02268175|Experimental|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).
~Participants will receive the assigned study treatment per cycle
~Enzalutamide- Once daily at prespecified dose, orally
~Abiraterone Acetate- Once daily at prespecified dose, orally
~Prednisone-Once daily at prespecified dose, orally
~Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
11364840|NCT02268175|Experimental|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).
~Participants will receive the assigned study treatment per cycle.
~Enzalutamide- once daily at prespecified dose, orally
~Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
11364841|NCT02268162|No Intervention|Routine Bronchoscopy|Participants in the group will receive routine bronchoscopy.
11364842|NCT02268162|Experimental|Routine Bronchoscopy with a guiding equipment|Participants in the group will receive routine bronchoscopy combined with a guiding equipment. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
11364843|NCT02268162|Experimental|Routine Bronchoscopy with two or more guiding equipments|Participants in the group will receive routine bronchoscopy combined with two or more guiding equipments. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
11364844|NCT02268149|Experimental|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
11364845|NCT02268149|Placebo Comparator|Placebo|
11364846|NCT02268136|Experimental|BIII 890 CL|single increasing doses
11364847|NCT02268136|Placebo Comparator|Placebo|
11364958|NCT02267395||(Yes-PRMSDs)|Group 2: Playing Related Musculoskeletal Injury
11364848|NCT02268110|Experimental|Supervised exercise therapy|Participants will receive 12 sessions with a physiotherapist where they will receive instructions on body mechanics, and be given a progressive abdominal exercise program
11364849|NCT02268110|Experimental|Abdominal binding|Participants will be fitted for an abdominal binder and asked to wear it for a period of 12 weeks.
11364850|NCT02268110|Experimental|Exercise therapy and Abdominal Binding|Participants will attend 12 sessions with a physiotherapist, and receive an abdominal binder
11364851|NCT02268110|No Intervention|Control|Participants will not receive an intervention during the study period
11364852|NCT02268097|Experimental|Freehand|Patellar resurfacing with freehand technique:Using freehand technique for patella preparation during total knee arthroplasty.
11364853|NCT02268097|Active Comparator|Resection guide|Patellar resurfacing with resection guide technique: Using patellar resection guide technique for patella preparation during total knee arthroplasty.
11364854|NCT02268084|Sham Comparator|Sham|
11364855|NCT02268084|Experimental|Experimental|
11364856|NCT02268071|Experimental|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
11364857|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.
~Patient and family received standard education on concussion management in the Emergency department."
11364858|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.
~Patient and family received standard education on concussion management in the Emergency department."
11364859|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.
~Patient and family received standard education on concussion management in the Emergency Department."
11364860|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.
~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
11364861|NCT02268045|Experimental|RTXM83|Active Ingredient: Rituximab (Biosimilar)
11364862|NCT02268045|Active Comparator|MabThera|Active Ingredient: Rituximab
11364863|NCT02268032|Experimental|Vaginal ring 1 (VRD)|20 women using DHEA (VRD) for 2 menstrual cycles
11364864|NCT02268032|Experimental|Vaginal ring 2 (VRaA)|20 women using another androgenic agent (VRaA) for 2 menstrual cycles
11364865|NCT02268032|Experimental|Vaginal ring 3 (VR2A)|20 women using fixed combination of 2 androgenic agents (VR2A) for 2 menstrual cycles
11364866|NCT02268019|Experimental|Hypospadiasis repair|
11364867|NCT02268006|Other|IMRT-SIB|
11364868|NCT02267993|Experimental|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
11364869|NCT02267993|Experimental|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
11364870|NCT02267980|Active Comparator|Group SK|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
11364871|NCT02267980|Placebo Comparator|Group SS|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.
11364872|NCT02267967|Experimental|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
11364873|NCT02267954|Experimental|50% Prices/50% Calories|"The participant is exposed to the baseline menu, but the prices are edited to be at 50% of the actual price (e.g., a $1 coffee is listed as costing $.50) and the calorie labels are edited to be at 50% of the actual content (e.g., a 500 calorie Large Fries is listed as having 250 calories). In addition, the baseline mistakes are still included.
~This is the Menu edited intervention."
11364874|NCT02267941||case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. According to the Stanford classification system, type A aortic dissection was defined as any dissection that involves the ascending aorta and type B as any that does not. Acute stage was confined to initial 14 days after symptom onset. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
11364875|NCT02267941||control|As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period. Types of disease in the control group included congenital heart disease (632), coronary heart disease (467), adult valve disease (375), pulmonary artery hypertension (292), appendicitis (234), pneumonia (197), fracture (189), intestinal polyps (167), gallstone (156), esophagus cancer (51). Patients in the control group were derived from Department of Cardiovascular Surgery, Department of General Surgery, Department of Thoracic Surgery, and Department of Respiration, respectively.
11364876|NCT02267928|Experimental|Check/Experience|Participants are asked to check the symptoms that they have experienced in the last 6 weeks.
11364877|NCT02267928|Experimental|Un-check/Experience|Participants are asked to un-check the symptoms that they have experienced in the last 6 weeks.
11364878|NCT02267928|Experimental|Check/Not Experienced|Participants are asked to check the symptoms that they have NOT experienced in the last 6 weeks.
11364879|NCT02267928|Experimental|Un-check/Not Experienced|Participants are asked to un-check the symptoms that they have NOT experienced in the last 6 weeks.
11364880|NCT02267915|Experimental|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
11364881|NCT02267902|Experimental|Part 1|Single oral therapeutic dose of 5mg DA-1229 as a tablet + An IV dose of 20㎍ [14C]-DA-1229
11364882|NCT02267902|Experimental|Part 2|Single oral therapeutic dose of 5mg [14C]-DA-1229
11364883|NCT02267889|Experimental|Image guided GP ablation|Use of cardiac nuclear imaging data to guide GP ablation procedures.
11364884|NCT02267863|Experimental|Dose Escalation and Expansion|APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.
11364885|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
11364886|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
11364887|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
11364888|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
11364889|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
11364890|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
11364891|NCT02267811|Experimental|Fixed Orthodontic Treatment with OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
11364892|NCT02267811|Experimental|Fixed Orthodontic Treatment|Subjects assigned to this group receive orthodontic treatment with no OrthoPulse™ treatment.
11364893|NCT02267798|Experimental|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes and will focus on repetitive tasks that incorporate multidirectional reaching actions. In this robot-assisted therapy a robot manipulator applies forces to the paretic arm during goal-directed movements.
~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists of a battery powered programmable stimulator and a forearm-wrist-hand orthosis containing 5 electrodes positioned to provide reliable activation of muscles. The intensity of stimulation will be set to a level that provided comfortable and consistent activation of the extensor and flexor muscles to achieve whole hand opening and functional grasping."
11364894|NCT02267798|Active Comparator|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence, Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques based on neuro-developmental treatment.
11364895|NCT02267785|Experimental|Skill-Based Exercise|Participants assigned to this arm will complete the Skill-Based Exercise Intervention
11364896|NCT02267785|Experimental|Aerobic Exercise|Participants assigned to this arm will complete the Aerobic Exercise Intervention
11364897|NCT02267785|Experimental|Social Contact Group|Participants assigned to this arm will complete the Social Contact Intervention
11364898|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
11364899|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
11364900|NCT02267759|Experimental|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
11364901|NCT02267759|Active Comparator|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
11364902|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
11364903|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
11364904|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
11364905|NCT02267733|Experimental|Early Disease|Patients not requiring anti-tumor therapy
11364906|NCT02267733|Experimental|Disease Requiring Anti-tumor therapy|Patients that have disease requiring anti-tumor therapy at any time
11364907|NCT02267720|Active Comparator|Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
11364908|NCT02267720|Experimental|Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
11364909|NCT02267707|Experimental|Cohort 1 - Bilirubin level > 1.5 x ULN to 3 x ULN|4 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
11364910|NCT02267707|Experimental|Cohort 2 - Bilirubin level > 3 x ULN to 5 x ULN|6 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2 nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
11364911|NCT02267694|Other|Black raspberry powder|Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
11364912|NCT02267681|Experimental|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
11364913|NCT02267681|Experimental|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
11364914|NCT02267681|Active Comparator|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
11364915|NCT02267668|Experimental|STEP arm|"The Baseline Evaluation Session will include formal neuropsychological evaluation, postural stability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).
~Intervention includes exercise tolerance evaluations, 3 times per week exercise by physical therapist. Self report of symptoms and exertion."
11365046|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
11364916|NCT02267668|Active Comparator|Control|"The Baseline Evaluation Session will include formal neuropsychological evaluation, posturalstability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).
~Control protocol includes instructions for stretching, instructions for restricting physically demanding activity during first 3 weeks of study; instructions for light, self-guided daily exercise in last 3 weeks of study. Self report of symptoms and exertion."
11364917|NCT02267655|Active Comparator|inhaled Nitric Oxide 30 mcg/kg IBW/hr|30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
11364918|NCT02267655|Active Comparator|inhaled nitric oxide 75 mcg/kg IBW/hr|Part 2: 75mcg/Kg IBW/hr
11364919|NCT02267655|Active Comparator|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
11364920|NCT02267655|Placebo Comparator|Placebo|Placebo for 75 mcg/kg IBW/hr
11364921|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
11364922|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
11364923|NCT02267616|Experimental|Continued Use Implant Group|Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.
11364924|NCT02267616|Active Comparator|New Implant Group|Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.
11364925|NCT02267616|No Intervention|Observational Continued Use Group|Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).
11364926|NCT02267603|Experimental|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.
~* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
11364927|NCT02267590||MCL: 80-100 samples from 60- 70 patients|Mantle Cell lymphoma patients
11364928|NCT02267590||CLL: 15-20 samples from 10-15 patients|Chronic lymphocytic leukaemia patients
11364929|NCT02267577|Experimental|Healthy Adults Volunteers|Men and women over the age of 18 will have their blood pressure measured with both the Sphygmo: Automatic Blood Pressure Monitor device and the GE Dinamap ProCare automatic blood pressure monitor.
11364930|NCT02267564|Experimental|MPFLR without tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction without tibial tubercle transfer.
11364931|NCT02267564|Active Comparator|MPFLR with tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction with tibial tubercle transfer.
11364932|NCT02267551|Other|Mimic dV-Trainer|
11364933|NCT02267551|Other|daVinci Skills Simulator|
11364934|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
11364935|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
11364936|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
11364937|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
11364938|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
11364939|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
11364940|NCT02267512|Experimental|ATG-F single dosing group|Intravenous (IV)
11364941|NCT02267512|Experimental|ATG-F continuous dosing group|Intravenous (IV)
11364942|NCT02267499|Experimental|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
11364943|NCT02267499|No Intervention|Passive Control|Participants do not receive an intervention serving as passive controls
11364944|NCT02267486||Alzheimer Dementia (AD)|Patients with dementia caused by Alzheimer's disease
11364945|NCT02267486||Non-dementia|Patients with cognitive concern without dementia
11364946|NCT02267460|Active Comparator|AA4500 with investigator modeling and vacuum therapy|AA4500 with investigator modeling and home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
11364947|NCT02267460|Active Comparator|AA4500 without investigator modeling/with vacuum therapy|AA4500 without investigator modeling but with home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
11364948|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
11364949|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
11364950|NCT02267434|Experimental|Low dose AFFITOPE® PD03A + Adjuvant|"4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
11364951|NCT02267434|Experimental|High dose AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks
~1 boost immunization 36 weeks after first injection"
11364952|NCT02267434|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks
~1 administration 36 weeks after first injection"
11364953|NCT02267421|Experimental|Home based aerobic exercise|Home based aerobic exercise on cycle ergometer. Three times per week, 30-60 minutes per session.
11364954|NCT02267421|No Intervention|Usual Care group|These patients will continue with their normal activities of daily living and will not be provided with equipment or coaching for home based exercise during the study period .
11364955|NCT02267408|Experimental|Fearon algorithm dosing|Warfarin adjustment using the Fearon algorithm
11364956|NCT02267408|Active Comparator|Standard dosing|Warfarin adjustment using standard dosing
11364957|NCT02267395||(No-PRMSDs)|Group 1 : No Playing Related Musculoskeletal Injury
11364959|NCT02267382|Experimental|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
11364960|NCT02267382|Experimental|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
11364961|NCT02267382|Experimental|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
11364962|NCT02267382|Experimental|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
11364963|NCT02267382|Placebo Comparator|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
11364964|NCT02267369|Active Comparator|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
11364965|NCT02267369|Experimental|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
11364966|NCT02267369|Experimental|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
11364967|NCT02267356|Experimental|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
11364968|NCT02267356|Experimental|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
11364969|NCT02267356|Experimental|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
11364970|NCT02267356|Experimental|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
11364971|NCT02267356|Placebo Comparator|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
11364972|NCT02267343|Experimental|ONO-4538 Arm|ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11364973|NCT02267343|Placebo Comparator|Placebo Arm|Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11364974|NCT02267330||Standard of care, Exposure recording|Patient will undergo fracture surgery as per standard of care, and will have radiation exposure recording.
11364975|NCT02267317|Active Comparator|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
11364976|NCT02267317|Active Comparator|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
11364977|NCT02267317|Active Comparator|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
11364978|NCT02267317|Active Comparator|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
11364979|NCT02267291|Experimental|All patients|Ventilatory support to alter intrathoracic pressure
11364980|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.
~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
11364981|NCT02267265|Experimental|Treatment intervention|The treatment group will complete a demographics questionnaire and the knowledge survey before the intervention. Participants will then view the 10 minute TMW-Newborn Intervention video around the time of the newborn hearing screening. Participants whose newborn does not pass the hearing screen will view an additional 3 minute video detailing the importance of following up for an outpatient re-screening. The participant will complete the knowledge survey again before discharge, and after approximately four to six weeks.
11364982|NCT02267265|Active Comparator|Control intervention|The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
11364983|NCT02267239|Active Comparator|Essential Oils, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the essential oils antiseptic solution
11364984|NCT02267239|Active Comparator|Chlorhexidine, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the chlorhexidine antiseptic solution
11364985|NCT02267239|Other|baseline|Professional oral cleaning Plaster cast IDODS Disk in basal conditions.
11364986|NCT02267239|Active Comparator|Essential Oils, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the essential oils antiseptic solution
11364987|NCT02267239|Active Comparator|Chlorhexidine, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the chlorhexidine antiseptic solution
11364988|NCT02267226|Experimental|Octafibrin|
11364989|NCT02267213|Experimental|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
11364990|NCT02267200||reversible PAH group|reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
11364991|NCT02267200||irreversible PAH group|irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
11364992|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
11364993|NCT02267174|Other|Standardized OR to ICU handoff|A standardized handoff process for conducting OR to ICU handoffs will be implemented in two intensive care units without a standard process.
11364994|NCT02267161|Experimental|neuropsycological tests|Psychometric scales for infants at 3 years of age
11364995|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
11364996|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
11364997|NCT02267122|Experimental|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound.
11364998|NCT02267122|Experimental|Mupirocin ointment application|After placing the staples, a Mupirocin ointment application was placed covering the wound.
11364999|NCT02267122|No Intervention|Conventional dressing|After placing the staples, a conventional dressing, without application of any special gauze or ointment, was placed covering the wound
11365000|NCT02267109|Experimental|2.5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 2.5 x 10(10):
11365001|NCT02267109|Experimental|5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 5 x 10(10):
11365002|NCT02267109|Experimental|1.0 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(10):
11365003|NCT02267109|Experimental|1.0 x 10(11) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(11):
11365004|NCT02267109|Experimental|Booster-MVA-BN® Filo or saline placebo|MVA-BN® Filo or saline placebo
11365005|NCT02267096|Experimental|Telephone Counseling (TC)|The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.
11365006|NCT02267096|Active Comparator|Minimal Treatment|The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.
11365007|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
11365008|NCT02267070|Experimental|Cognitive Training and Exercise|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
11365009|NCT02267070|Active Comparator|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
11365010|NCT02267057|Active Comparator|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
11365011|NCT02267057|Placebo Comparator|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
11365012|NCT02267044|Active Comparator|Ropivacaine Single Shot Block|Single Shot Interscalene block patients will receive a single shot of 30ml of 0.5% Ropivacaine prior to surgery
11365013|NCT02267044|Active Comparator|Ropivacaine Continuous block|Continuous Interscalene block patients will receive a shot of up to 30ml of 0.5% Ropivacaine and then a catheter is placed. The catheter is secured with Dermabond and Tegaderm. Once surgery is complete, the catheter is connected to a pain ball system which holds 400ml of 0.2% Ropivacaine local anesthetic. The rate is locked in at 8ml/hr. Catheter is pulled once the pain ball is empty.
11365014|NCT02267031|Active Comparator|normoxia and normocapnia|Normoxia PaO2 of 70-140 mm Hg Normocapnia PaCO2 of 35-48 mmHg
11365015|NCT02267031|Active Comparator|hyperoxia and normocapnia|Hyperoxia 150-300 mm Hg Normocapnia PaCO2 of 35-48 mmHg
11365016|NCT02267031|Active Comparator|normoxia and hypocapnia|Normoxia PaO2 of 70-140 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
11365017|NCT02267031|Active Comparator|hyperoxia-hypocapnia|Hyperoxia 150-300 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
11365018|NCT02267018|Active Comparator|nCPAP|Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
11365019|NCT02267018|Active Comparator|NIHFV|Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality is has not been well studied to date.
11365020|NCT02267005|Experimental|Treatment|patients on this arm will be treated with creapure supplements
11365021|NCT02267005|Placebo Comparator|Placebo|patients on this arm will be given a placebo glucose tablet supplement
11365022|NCT02266992|Experimental|Fluenz Tetra|Live attenuated influenza vaccine- Fluenz tetra. Intra-nasal administration of 0.2ml (0.1ml in each nostril).
11365023|NCT02266966|Experimental|F2695|Single dose - 2 capsules / Day on Day 1 and Day 8
11365024|NCT02266966|Placebo Comparator|placebo|Single dose - 2 capsules / Day on Day 1 and Day 8
11365025|NCT02266953|Experimental|Use of communication tool about diet|The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices. This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
11365026|NCT02266953|Active Comparator|Treatment as usual|The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet. The consultations are carried out when the child is 10-, 12- and 15-18 months old.
11365027|NCT02266940|Experimental|200mg DS-1971a oral suspension fasted|200 mg DS 1971a given as oral suspension in fasted condition
11365028|NCT02266940|Experimental|200 mg DS-1971a tablet fasted|single 200 mg DS 1971a oral tablet in fasted condition
11365029|NCT02266940|Experimental|200 mg DS-1971a tablet fed|single 200 mg DS 1971a oral tablet given in fed condition
11365030|NCT02266927|Active Comparator|Flovent® HFA 440µg|Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg
11365031|NCT02266927|Experimental|OPTINOSE™ FLUTICASONE 400µg intranasal|OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally
11365032|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
11365033|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
11365034|NCT02266888|Experimental|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
11365035|NCT02266888|Placebo Comparator|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
11365036|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).
~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
11365037|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).
~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
11365038|NCT02266862||Study Group|The purpose of this study is to evaluate the location within the renal artery of maximal angular displacement before and after fenestrated endovascular aortic repair (FEVAR) using CT with end-inspiration and end-expiration CT images before and after repair.
11365039|NCT02266849|Active Comparator|Loperamide|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
11365040|NCT02266849|Placebo Comparator|Placebo|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
11365041|NCT02266836|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
11365042|NCT02266823|Active Comparator|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.
~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
11365043|NCT02266823|Other|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.
~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
11365044|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
11365045|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
11365047|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
11365048|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
11365049|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
11365050|NCT02266784|Experimental|Contingency Management (CM)|ADHD (N=20) & CTRL (N=20). Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system. This level of compensation will increase by the same amount each visit based upon abstinence. In addition, escalating bonus payments will be available for evidence of continued abstinence. The first 10 visits will be daily weekdays. The following 9 visits will be over three weeks. The final 3 treatment visits will occur weekly. The 2nd & 3rd type visits CM payments will be based upon monitoring participants' cotinine levels. A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day. If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days. Also follow-up visits at 3 and 6 months.
11365051|NCT02266784|Other|Treatment as Usual|ADHD (N=20). Transdermal nicotine skin patches (i.e. Habitrol) will be used along with supportive counseling in the treatment as usual groups. Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8). A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d. Also follow-up visits at 3 and 6 months.
11365052|NCT02266771|Active Comparator|NPWT with Instillation|Negative Pressure Wound Therapy with Instillation.
11365053|NCT02266771|Placebo Comparator|NPWT without Instillation|Negative Pressure Wound Therapy without Instillation
11365054|NCT02266758|Other|GDM Screening Method 1|GDM Screening Methods
11365055|NCT02266758|Other|GDM Screening Method 2|GDM Screening Methods
11365056|NCT02266745|Experimental|PT-112 injection|PT-112 Injection, administered by intravenous infusion
11365057|NCT02266732|Other|Interscalene block|
11365058|NCT02266732|Other|Femoral block|
11365059|NCT02266719|Experimental|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
11365060|NCT02266719|Experimental|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
11365061|NCT02266706|Experimental|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to <18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
11365062|NCT02266706|Experimental|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to <12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
11365063|NCT02266706|Experimental|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to <7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
11365064|NCT02266706|Experimental|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to <2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
11365065|NCT02266706|Experimental|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (>32 weeks gestation, 7 days postnatal) to <3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
11365066|NCT02266706|Experimental|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to <3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.
11365067|NCT02266693|Experimental|ICBT Group|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
11365068|NCT02266693|No Intervention|Waitlist Group|Upon completion of the 8-week study wait-list period (i.e. their study participation), the opportunity to participate in iCBT, outside the study framework will be provided.
11365069|NCT02266680|Experimental|Yoga Treatment Group|BFY will be taught by a trained yoga instructor. Group sessions will be offered twice a week for 60 minutes each (i.e., a total of 2 hours per week), for 8 weeks.
11365070|NCT02266680|No Intervention|Waitlist Group|Waitlisted participants will receive BFY at the next available group after their waitlist period is completed
11365071|NCT02266667|Experimental|Progressive scoliosis|Children with progressive scoliosis
11365072|NCT02266667|Experimental|Neuromuscular scoliosis|Children with neuromuscular scoliosis
11365111|NCT02266420|Other|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size < or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
11365151|NCT02266186|No Intervention|Care as usual|Childbirth preparation according to local routine
11365152|NCT02266173||Pertuzumab|Participants for whom the treating physician has decided to administer pertuzumab according to standard of care and in line with the current summary of product characteristics (SmPC)/local labeling, will be observed.
11365073|NCT02266654|Experimental|Prehospital-directed therapy arm|Patients who are hypotensive or whose lactate is ≥ 2.5, prehospital providers will provide a notification to the receiving hospital (Hospital Notification), establish an IV, and provide 1 liter normal saline (NS) bolus of IV fluids. An additional 1 liter normal saline bolus will be given for systolic blood pressure less than 100. Patients who have a history of end-stage renal disease or congestive heart failure would receive only 20 milliliters/kilogram of fluid. If the patient remains hypotensive, Emergency Medical Services will continue providing fluids as is standard of care.
11365074|NCT02266654|Experimental|Control Arm|Prehospital providers will obtain a point of care lactate, establish an IV, and provide IV fluids as judged necessary.
11365075|NCT02266641|Active Comparator|healthy pregnant women|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
11365076|NCT02266641|Experimental|healthy pregnant women's lineal relative with cancer|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
11365077|NCT02266641|Experimental|pregnant women or lineal relative with overweight/obesity|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
11365078|NCT02266641|No Intervention|healthy pregnant women's lineal relative with diabetes|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
11365079|NCT02266628|Experimental|Treatmetn Group A|RSV-F vaccine (0.5mL Injection)
11365080|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
11365081|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
11365082|NCT02266602|Other|Treatment|Patients treated with intraoperative radiation therapy at the time of partial mastectomy.
11365083|NCT02266589|Experimental|Hydrocortisone|little doses of hydrocortisone
11365084|NCT02266589|No Intervention|Placebo|Placebo
11365085|NCT02266576|Active Comparator|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
11365086|NCT02266576|Experimental|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
11365087|NCT02266563||Traumatic Brain Injury (TBI) Group|TBI subjects will have a history of one or more concussions and have a memory complaint and objective decline that is considered to be worse than others of the same age (in the absence of an acute medical event). Severity classifications of the subjects selected for past history of TBI will be based upon established criteria used in TBI research (i.e., traumatically induced physiologic disruption of brain function as indicated by at least one of the following: any period of loss of consciousness, any loss of memory for events immediately before or after the accident, any alteration in mental state at the time of the accident, focal neurologic deficits that may or may not be transient). TBI cases will be those with mTBI (single or multiple concussion). Most recent injury must have occurred at least 1 year prior to study enrollment.
11365088|NCT02266563||Mild Cognitive Impairment (MCI) Group|MCI Subjects will have MMSE scores between 24-30 (inclusive), a CDR of 0.5, have no depression, no history of TBI, and no dementia.
11365089|NCT02266563||Healthy Control Group|Healthy control subjects will have no self or informant-reported problems with cognition, no depression, no history of TBI, and no dementia.
11365090|NCT02266537|Experimental|Tamsulosin|
11365091|NCT02266537|Experimental|Alfuzosin|
11365092|NCT02266537|Experimental|Doxazosin|
11365093|NCT02266537|Placebo Comparator|Placebo|
11365094|NCT02266524|Experimental|Tamsulosin hydrochloride, very low dose|
11365095|NCT02266524|Experimental|Tamsulosin hydrochloride, low dose|
11365096|NCT02266524|Experimental|Tamsulosin hydrochloride, medium dose|
11365097|NCT02266524|Experimental|Tamsulosin hydrochloride, high dose|
11365098|NCT02266511|Experimental|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
11365099|NCT02266511|Experimental|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
11365100|NCT02266498|Experimental|BIBB 515 BS after a standard breakfast|
11365101|NCT02266498|Active Comparator|BIBB 515 BS|
11365102|NCT02266485|Experimental|BIBB 515 BS|
11365103|NCT02266485|Active Comparator|Pravastatin|
11365104|NCT02266485|Placebo Comparator|Placebo|
11365105|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
11365106|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
11365107|NCT02266446|Experimental|Attention & Interpretation Modification|The final product will be web-delivered, so it may be completed at the clinic or home. Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session
11365108|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.
~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine
~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
11365109|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.
~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
11365110|NCT02266420|Other|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size < or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
11365112|NCT02266407|Active Comparator|ASEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
11365113|NCT02266407|Active Comparator|SEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
11365114|NCT02266394|Active Comparator|Mesenchymal stem cell delivery|To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
11365115|NCT02266394|Active Comparator|Mesenchymal stem cell delivery with stent placement|To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.
11365116|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
11365117|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
11365118|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
11365119|NCT02266368|No Intervention|Control group|This arm will include patients with non-coated stents
11365120|NCT02266368|Active Comparator|Antimicrobeal group|This arm will include patients with antimicrobeal coated stents
11365121|NCT02266355|Experimental|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
11365122|NCT02266329|Active Comparator|prazosin|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
11365123|NCT02266329|Placebo Comparator|placebo|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
11365124|NCT02266316|Experimental|Mask|Using mask that warms air at the mouth by utilising body heat
11365125|NCT02266316|No Intervention|No mask|Not using any mask that warms air at the mouth by utilising body heat
11365126|NCT02266303|Experimental|With checklist|Doctors will initiate insulin with the aid of a checklist
11365127|NCT02266303|No Intervention|Without checklist|Doctors will initiate insulin without the use of the checklist
11365128|NCT02266290|Experimental|Kinesio-Tape group|In this study, Sport tex® kinesiotape over lateral ankle (6cm*2.5m) is used.
11365129|NCT02266290|Placebo Comparator|Placebo Tape Group|In the placebo group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used. With patient in the same position described above, horizontal strips were placed covering the sural region with no defined direction.
11365130|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
11365131|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
11365132|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
11365133|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
11365134|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
11365135|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
11365136|NCT02266264|Experimental|100 milligrams of hydrocortisone|100 milligrams per day of hydrocortisone is the starting dosage.
11365137|NCT02266264|Active Comparator|200 milligrams of hydrocortisone|200 milligrams per day of hydrocortisone is the starting dosage.
11365138|NCT02266251||Surgical AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the Transcatheter Valve Therapies (TVT) Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS Adult Cardiac Surgical DAtabase (ACSD) (Jan 2011-Dec 2013).
11365139|NCT02266251||Transcatheter AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the TVT Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS ACSD (Jan 2011-Dec 2013).
11365140|NCT02266238|Experimental|Group 1|DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
11365141|NCT02266238|Experimental|Group 2|Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
11365142|NCT02266238|Experimental|Group 3|Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula
11365143|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
11365144|NCT02266212|Active Comparator|Smoke|Fagerstrom test for nicotine dependence
11365145|NCT02266212|Active Comparator|Pain|pain during post-operation Day1 to Day4
11365146|NCT02266212|Active Comparator|Morphine|Morphine consumption during post-operation Day1 to Day4
11365147|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
11365148|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
11365149|NCT02266186|Experimental|Internet CBT|Intervention:Internet-based cognitive behavioural therapy.
11365150|NCT02266186|Active Comparator|Traditional CBT|Intervention:Traditional CBT given by a therapist following given modules.
11365153|NCT02266160|Experimental|1|"71 tinnitus patients treated with 2 gram EMLA 5% cream a day for 4 days, 4 hours a day.
~we will compare the questionnaires results before and after 4 days of treatment to see whether EMLA cream changes the degree of suffer from tinnitus"
11365154|NCT02266160|Sham Comparator|2|71 tinnitus patients using cetomacrogol cream (lotion cream, does not contain any drug) for 4 days. these patients will fulfill the questionnaires as the investigational group.
11365155|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1
~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1
~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29
~PART 2
~Cycle 1: Required
~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1
~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29
~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29
~Cycle 2: Optional
~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181
~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209
~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
11365156|NCT02266134|Experimental|Standardized Implementation|Sites randomized to the standardized condition will be expected to use the Patient Health Questionnaire prior to each session with a depressed client and they will work as a team to maximize fidelity. Sites in this arm will receive the standard implementation of measurement based care intervention.
11365157|NCT02266134|Experimental|Tailored Implementation|Sites randomized to the tailored condition will develop a site-specific protocol for use of the Patient Health Questionnaire and they will work as a team to maximize the fit of measurement based care to this clinic. Sites in this arm will receive the tailored implementation of measurement based care intervention.
11365158|NCT02266121|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.
~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
11365159|NCT02266121|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
11365160|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
11365161|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
11365162|NCT02266095|Active Comparator|Oval-8 Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.
~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee). Oval-8 splints are not commonly used for treatment of thumb CMC arthritis.
~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
11365163|NCT02266095|Active Comparator|Tee Pee Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.
~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).
~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
11365164|NCT02266095|Active Comparator|Forearm Based Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.
~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).
~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
11365165|NCT02266069|Other|Research cluster 1: Antwerp|The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
11365166|NCT02266069|Other|Research cluster 2: Mons|The first French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from November 2014.
11365167|NCT02266069|Other|Research cluster 3: Brussels|The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
11365168|NCT02266069|Other|Research cluster 4: Limburg|The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
11365169|NCT02266069|Other|Research cluster 5: ?|A second French-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2015.
11365170|NCT02266056|Experimental|Deep neuromuscular relaxation|
11365171|NCT02266056|Active Comparator|Moderate neuromuscular relaxation|
11365172|NCT02266030|Experimental|Cilostazol|Cilostazol 100-200 mg qd
11365173|NCT02266030|Active Comparator|Aspirin|Asprin 100mg qd for active comparator
11365174|NCT02266017|Experimental|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
11365175|NCT02266017|Active Comparator|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
11365176|NCT02266004|Experimental|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
11365177|NCT02265978|Experimental|CopeSmart|
11365178|NCT02265978|No Intervention|Control|
11365179|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
11365180|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
11365181|NCT02265952|Experimental|Open-label|Open-label REGN1500
11365182|NCT02265939|Placebo Comparator|0% NPO-13|Placebo
11365183|NCT02265939|Active Comparator|0.2% NPO-13|Low dose
11365184|NCT02265939|Active Comparator|0.4% NPO-13|Medium dose
11365185|NCT02265939|Active Comparator|0.8% NPO-13|High dose
11365186|NCT02265926|Experimental|N95|Intervention: N95 mask material
11365187|NCT02265913|Experimental|Test Product|acyclovir cream
11365188|NCT02265913|Active Comparator|Reference Product|acyclovir cream
11365189|NCT02265913|Placebo Comparator|Placebo Product|Placebo cream
11365190|NCT02265900|Active Comparator|Exercise 1|One type of exercise
11365191|NCT02265900|Placebo Comparator|Exercise 2|A different type of exercise
11365192|NCT02265874|Active Comparator|Treatment|Habitrol Nicotine patch - 7,14,21 mg patches Qd
11365193|NCT02265874|Placebo Comparator|Control|Placebo patch
11365194|NCT02265861|Experimental|Group 1|typical PCOS
11365195|NCT02265861|Experimental|Group 2|PCOS without PCO
11365196|NCT02265861|Experimental|Group 3|PCOS without HA
11365197|NCT02265861|Experimental|Group 4|Control
11365198|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
11365199|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
11365200|NCT02265835||Cases of anastomotic airway complication|Cases of anastomotic airway complication
11365201|NCT02265835||Patients with normal anastomotic healing|Patients with normal anastomotic healing
11365202|NCT02265822|Experimental|melatonin|0.5 mg/kg (max 20 mg) oral melatonin premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding water in a syringe without needle.
11365203|NCT02265822|Active Comparator|midazolam|0.5 mg/kg (max 20 mg) oral midazolam premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding 5% dextrose in a syringe without needle.
11365204|NCT02265809|Experimental|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2.
11365205|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
11365206|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
11365207|NCT02265783|Other|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
11365208|NCT02265770|Experimental|Stratum 1 arm A|Conformal radiotherapy followed by 16 weeks of VEC + CDDP.
11365209|NCT02265770|Active Comparator|Stratum 1 arm B|Conformal radiotherapy.
11365210|NCT02265770|Experimental|Stratum 2 arm A|VEC + HD-MTX followed by conformal radiotherapy +/- boost
11365211|NCT02265770|Active Comparator|Stratum 2 arm B|VEC followed by conformal radiotherapy +/- boost
11365212|NCT02265770|Experimental|Stratum 3 arm A|Chemotherapy + Valproate.
11365213|NCT02265770|Active Comparator|Stratum 3 arm B|Chemotherapy
11365214|NCT02265757|Experimental|No Cognitive Rehabilitation|Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Support Group, Wellness Education and Physical Exercise.
11365215|NCT02265757|Experimental|No Computer Brain Fitness Training|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Support Group, Wellness Education and Physical Exercise
11365216|NCT02265757|Experimental|No Support Group|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Wellness Education and Physical Exercise
11365217|NCT02265757|Experimental|No Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Physical Exercise
11365218|NCT02265757|Experimental|No Physical Exercise|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Wellness Education
11365219|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
11365220|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
11365221|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
11365222|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
11365223|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
11365224|NCT02265731|Experimental|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
11365225|NCT02265731|Experimental|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
11365523|NCT02264002|Active Comparator|Metoprolol succinate|1 tablet on day 1, day 2 followed by two tablets from day 3 to day 14
11365226|NCT02265731|Experimental|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
11365227|NCT02265731|Experimental|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
11365228|NCT02265718||(Amyloid Negative)|
11365229|NCT02265718||Amyloid Positive|
11365230|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.
~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
11365231|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.
~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
11365232|NCT02265679|Experimental|BIIL 284 BS, low dose in pediatric patients|
11365233|NCT02265679|Experimental|BIIL 284 BS, medium dose in pediatric patients|
11365234|NCT02265679|Experimental|BIIL 284 BS, high dose in pediatric patients|
11365235|NCT02265679|Experimental|BIIL 284 BS, low dose in adult patients|
11365236|NCT02265679|Experimental|BIIL 284 BS, medium dose in adult patients|
11365237|NCT02265679|Experimental|BIIL 284 BS, high dose in adult patients|
11365238|NCT02265679|Placebo Comparator|Placebo|
11365239|NCT02265666|Experimental|BIIL 284 BS Tablet FF|
11365240|NCT02265666|Active Comparator|BIIL 284 BS tablet C|
11365241|NCT02265653|Experimental|BIIL 284 BS tablet C|
11365242|NCT02265653|Experimental|BIIL 284 BS tablet D|
11365243|NCT02265653|Active Comparator|BIIL 284 BS WIF tablet|
11365244|NCT02265640|Experimental|BIIL 284 BS boli - fasted|
11365245|NCT02265640|Experimental|BIIL 284 BS boli - fed|
11365246|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fasted|
11365247|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fed|
11365248|NCT02265627|Experimental|BIIL 284 BS, normal hepatic function|
11365249|NCT02265627|Experimental|BIIL 284 BS, mild hepatic impairment|
11365250|NCT02265627|Experimental|BIIL 284 BS, moderate hepatic impairment|
11365251|NCT02265614|Experimental|PGS|blastocyst biopsy and chromosomal analysis
11365252|NCT02265614|No Intervention|control|regular IVF
11365253|NCT02265601|Experimental|computer-based decision aid|"Making Your Wishes Known: Planning Your Medical Future- Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team."
11365254|NCT02265601|Active Comparator|standard care|paper/pencil living will form
11365255|NCT02265588|No Intervention|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
11365256|NCT02265588|Experimental|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
11365257|NCT02265575|Experimental|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
11365258|NCT02265562|Experimental|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
11365259|NCT02265562|Placebo Comparator|Placebo|60 minutes before the surgery 2 tablets of placebo tablets inserted rectally
11365260|NCT02265536|Experimental|LY3022855 - 1.25 mg/kg Dose A|1.25 milligram per kilogram (mg/kg) LY3022855 administered intravenously (IV), once every two weeks. Treatment is 6 week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
11365261|NCT02265536|Experimental|LY3022855 - Dose B|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
11365262|NCT02265536|Experimental|LY3022855 - Dose C|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
11365263|NCT02265536|Experimental|LY3022855 - Dose D|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
11365264|NCT02265523|No Intervention|Standard Post-op Exercise Group|The standard post-operative exercises are already currently recommended to patients. Briefly, they include deep breathing and coughing, ankle pumping, buttock contractions, and static quadriceps strengthening. These are performed on a daily basis , 2-3 times per day, 30 repetitions.
11365265|NCT02265523|Experimental|Viscus Group|The Viscus (intervention) group will complete the standard post-operative exercises and will also have access to a Viscus V1.5 cycle ergometer 24 hours per day in their recovery room to use at their leisure.
11365266|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
11365267|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
11365268|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
11365269|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
11365270|NCT02265484|Experimental|Lactulose + Rifaximin + Bromocriptine|
11365271|NCT02265484|Active Comparator|Lactulose+Rifaximin+Placebo|
11365272|NCT02265471||university hospital|university hospital
11365273|NCT02265471||large or small public hospitals|large or small public hospitals
11365274|NCT02265471||private HCFs|private HCFs
11365275|NCT02265471||referral centers for cancer|referral centers for cancer
11365276|NCT02265471||chirurgical facilities, clinic|chirurgical facilities, clinic
11365277|NCT02265471||mixed group|local hospitals, long term care and post-op and rehabilitation facilities, and nursing homes
11365452|NCT02264314|Experimental|Intervention|This group received an audiological rehabilitation program with a tele-educative intervention boost
11365278|NCT02265458|Experimental|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
11365279|NCT02265458|Active Comparator|Sensory isolation|Sensory isolation
11365280|NCT02265458|No Intervention|Standard of care|Standard of care
11365281|NCT02265445|Active Comparator|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
11365282|NCT02265445|Active Comparator|Deescalation therapy|Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy
11365283|NCT02265432|Experimental|Mobile technology intervention|"General physical activity educational materials
~Wearable activity tracking devices to enable the intervention participants to self-monitor their physical activity behavior and receive real-time feedback
~Access to an online map of Singapore providing location based information about leisure time physical activity opportunities
~Personalized text messages which include, educational information, tailored theory-based motivational messages, as well as compliance enhancing reminders"
11365284|NCT02265432|Other|Control|1.General physical activity educational materials
11365285|NCT02265419|Experimental|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
11365286|NCT02265406|Experimental|Ceftriaxone|
11365287|NCT02265406|Placebo Comparator|Sodium Chloride|
11365288|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
11365289|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
11365290|NCT02265380|Experimental|Treatment with OptiVein|The patient will have an IV catheter placed with the use of OptiVein device.
11365291|NCT02265380|Active Comparator|Treatment with Vasofix Certo|The patient will have an IV catheter placed with the use of Vasofix Certo device.
11365292|NCT02265367|Experimental|Levomilnacipran|In this three week period, baseline measures are obtained during the first week, levomilnacipran will be started during the second week and effects on smoking behavior will be assessed during the third week
11365293|NCT02265367|Placebo Comparator|Placebo|In this three week period, baseline measures are obtained during the first week, placebo will be started during the second week and effects on smoking behavior will be assessed during the third week
11365294|NCT02265354|Experimental|Collective-Intelligence computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a collective intelligence recommender systems algorithm for up to 6 months
11365295|NCT02265354|Active Comparator|Rule-based computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a rule-based algorithm for up to 6 months
11365296|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11365297|NCT02265328|Experimental|Bovine colostrum + prednisolone|"Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
~Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. If Lilli score > 0.45 after 7 days, then GC would be stopped and patients will be counselled for liver transplantation.
~Oral Bovine colostrum (200 ml (20 gram) TDS × 2 months."
11365298|NCT02265315|Sham Comparator|LSVT +sham TMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS)
11365299|NCT02265315|Active Comparator|LSVT +left rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to left side of head
11365300|NCT02265315|Active Comparator|LSVT + right rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to right side of brain
11365301|NCT02265302|Experimental|BIIL 284 BS oral solution|
11365302|NCT02265302|Experimental|BIIL 284 BS WIF tablets|
11365303|NCT02265302|Placebo Comparator|Placebo|
11365304|NCT02265289|Experimental|Lefradafiban with clopidogrel|"All patients received the same treatment:
~Lefradafiban only (day 1-4)
~Lefradafiban in combination with Clopidogrel (day 5-8)
~Clopidogrel only (day 9-12)"
11365305|NCT02265276|Active Comparator|Saroglitazar Group|Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks
11365306|NCT02265276|Placebo Comparator|Pioglitazone Group|Tab Pioglitazone 30 mg daily fixed dose for 24 weeks
11365307|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck
~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within two years after initial hospital stay."
11365308|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at maximum n= 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 104 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 years in Berlin.
~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
11365309|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.
11365310|NCT02265263||Surgical patients - 7 Tesla MRI|A study Group of at maximum n= 80 should be collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
11365311|NCT02265250||Asymptomatic, CACS <300|"5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) <300
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)"
11365312|NCT02265250||Asymptomatic, CACS ≥300|"5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
11365313|NCT02265250||Stable angina|"5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
11365314|NCT02265250||Recent acute MI|"5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram
~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
11365315|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
11365316|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
11365317|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
11365318|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
11365319|NCT02265224|Experimental|NAC 600 mg uncoated tablet|single dose of one tablet
11365320|NCT02265224|Active Comparator|NAC 600 mg coated tablet|single dose of one tablet
11365321|NCT02265211|Experimental|Self-Help App|Smartphone app designed to teach cognitive defusion.
11365322|NCT02265198||PC Group|patients with Pulmonary Contusion on chest computed tomography (CT)
11365323|NCT02265198||Control Group 1|Uninjured patients undergoing elective surgical procedures that will require intubation and mechanical ventilation
11365324|NCT02265198||Control Group 2|Trauma patients without chest injury who are mechanically ventilated
11365325|NCT02265198||MICU group|Patients in the Medical ICU who are mechanically ventilated with acute respiratory failure
11365326|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
11365327|NCT02265172|Experimental|Physiotherapy screening|"Screening consisted of a 60-min appointment including assessment, diagnosis and management. The patients received advice regarding ergonomics, exercises and/or treatment when needed. Management options were;
~Referral for orthopaedic surgeon consultation.
~Referral back to the patient's General Practitioner.
~Referral for further investigation.
~Referral to the physiotherapy or the occupational therapy clinic."
11365328|NCT02265172|Active Comparator|Standard practice (orthopaedic surgeon)|"Appointment was 15 min, including assessment, diagnosis and management. The patients received advice, prescriptions or injections when needed. Management options were;
~Referral for orthopaedic intervention.
~Referral back to the patient's General Practitioner.
~Referral for further investigation.
~Referral to the physiotherapy or the occupational therapy clinic."
11365329|NCT02265159|Other|Focal Therapy Using High Intensity Focused Ultrasound|
11365330|NCT02265120|Experimental|primary care providers by region|A questionnaire will be given to a randomized sample of primary care providers who care for patients in the 194 federally designated regions of Primary Care provider shortage within California will be studied.
11365331|NCT02265107|Experimental|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
11365332|NCT02265094|Experimental|Patients|Electroencephalography and neuropsychological tests in children with autism
11365333|NCT02265094|Experimental|Control|Electroencephalography and neuropsychological tests in children without autism
11365334|NCT02265081|Active Comparator|nulliparous women|internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
11365335|NCT02265081|Experimental|parous women|those who had vaginal delivery in the past; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
11365336|NCT02265081|Experimental|parous women - VBAC|those with previous LSCS and no vaginal births; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
11365337|NCT02265055|Active Comparator|transfer early cleavage embryos (EC)|transfer early cleavage embryos
11365338|NCT02265055|Active Comparator|transfer non early cleavage embryo (NEC)|transfer non early cleavage embryos
11365339|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
11365340|NCT02265029|Active Comparator|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
11365341|NCT02265029|Sham Comparator|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
11365342|NCT02265016||Patients with CAD|Patients with stable coronary artery disease
11365343|NCT02265016||Patients with ACS|Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
11365344|NCT02265016||healthy control group|healthy control group without clinical apparent arteriosclerosis
11365345|NCT02265003||Healthy young age|Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
11365346|NCT02265003||Healthy middle age|Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
11365347|NCT02265003||Healthy old|Healthy subjects in age of >70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
11365348|NCT02265003||Patients|Patients with atherosclerosis
11365349|NCT02264990|Experimental|Veliparib/Carboplatin/Paclitaxel|veliparib on Days -2 to 5 (7days) and carboplatin and paclitaxel on Day 1 of a 21 day cycle
11365350|NCT02264990|Active Comparator|Investigator's choice of platinum doublet|Either carboplatin and paclitaxel, cisplatin and pemetrexed, or carboplatin and pemetrexed on Day 1 of a 21 day cycle.
11365351|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
11365352|NCT02264964|Experimental|internal jugular vein catheterization|900 patients will be received temporary central vena catheterization in right internal jugular vein with non-cuff GamCath® catheter.They will undergo AVF creation.
11365353|NCT02264964|Experimental|femoral vein catheterization|500 patients will be received temporary central vena catheterization in femoral vein with non-cuff GamCath® catheter, which are unsuitable for right internal jugular vein catheterization.They will undergo AVF creation.
11365354|NCT02264951|Active Comparator|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
11365355|NCT02264951|Active Comparator|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
11365356|NCT02264951|Active Comparator|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
11365357|NCT02264951|Placebo Comparator|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
11365358|NCT02264938|No Intervention|Observation|Patients with AREDS category 2 and 3 AMD are observed during 1 year
11365359|NCT02264938|Active Comparator|Antioxidant|Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
11365360|NCT02264925|Experimental|Deep Brain Stimulation|All of included patients will receive a standard deep brain stimulation of the thalamus in order to reduce their essential tremor
11365361|NCT02264912||stent-PCI patients|Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
11365362|NCT02264899|Experimental|Alzheimer's disease and related disorders|
11365363|NCT02264886|Experimental|Arm 1: Stereotactic body radiation therapy|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.
~All patients will undergo MRI simulation in positioning appropriate for the specific treatment site. When medically feasible and applicable, patients will be simulated with IV and small bowel contrast (for non-thorax cases)."
11365364|NCT02264873|Other|Decitabine|This is a 3+3 design of dose escalation
11365365|NCT02264860|Other|Nutritional Supplements Zinc and SAMe|All men subjects will be started on 30 mg/day and women will be started on 25mg of elemental zinc plus 1600 mg/day of SAMe.
11365366|NCT02264847|Active Comparator|Clomiphene citrate plus hCG|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response could be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size . Women will receive 5,000 IU human chorionic gonadotrophin trigger in the morning between 9 and 10 a.m. and the couple will be advised to have intercourse the following night, about 36 hours later.
11365367|NCT02264847|Active Comparator|Clomiphene Citrate alone|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response will be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size , the women will be advised to have intercourse frequently over the next few days.
11365368|NCT02264834|Active Comparator|Control group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
11365369|NCT02264834|Experimental|Ambulatory group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
11365370|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
11365371|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
11365372|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
11365373|NCT02264808||Developmental outcomes|A developmental assessment (Bayley-III) of children 18-20 months who already enrolled in Florida Neonatal Neurologic Network. As part of this previous study, these children were born with Hypoxic Ischemic Encephalopathy (HIE) and underwent therapeutic cooling after birth.
11365374|NCT02264795|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline.
11365375|NCT02264795|Active Comparator|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
11365376|NCT02264782|Experimental|Group I (PreView)|Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.
11365377|NCT02264782|Active Comparator|Group II (educational video)|Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.
11365378|NCT02264769|Active Comparator|Carbetocin 20mcg|Patient is given carbetocin 20 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
11365379|NCT02264769|Active Comparator|Carbetocin 100mcg|Patient is given carbetocin 100 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
11365380|NCT02264756||Ward CAP|Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
11365381|NCT02264743|Experimental|Femoston Conti 0.5mg/2.5mg|"Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg & dydrogesterone 2.5 mg
~Once a day
~The duration is six months.
~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
11365453|NCT02264314|Placebo Comparator|Control|This group received no intervention
11365454|NCT02264301|Active Comparator|Puerarin injection 400 mg|Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks
11365382|NCT02264743|Active Comparator|EVOREL® CONTI transdermal patches|"EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .
~The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .
~The duration is six months.
~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
11365383|NCT02264730|Experimental|Clot Foam|Application of Clotfoam
11365384|NCT02264717|Active Comparator|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
11365385|NCT02264717|Active Comparator|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
11365386|NCT02264704|Experimental|High intensity exercise|High intensity exercise Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks.
11365387|NCT02264704|Experimental|Moderate intensity exercise|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks.
11365388|NCT02264704|No Intervention|Usual Care|Participants receive usual medical care.
11365389|NCT02264691||Normal (healthy volunteers)|No Research Intervention. Clinically indicated interventions only.
11365390|NCT02264691||Mild Asthmatics|No Research Intervention. Clinically indicated interventions only.
11365391|NCT02264691||Mild to Moderate Asthmatics|No Research Intervention. Clinically indicated interventions only.
11365392|NCT02264691||Severe Asthmatics|No Research Intervention. Clinically indicated interventions only.
11365393|NCT02264678|Experimental|Module 1 Part A|Module 1 Part A: ascending doses of ceralasertib in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).
11365394|NCT02264678|Experimental|Module 1 Part B|Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive ceralasertib and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.
11365395|NCT02264678|Experimental|Module 2 Part A1|Module 2 Part A1: ascending doses of ceralasertib will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.
11365396|NCT02264678|Experimental|Module 2 Part A2|Module 2 Part A2: ascending doses of ceralasertib will be administered in combination with olaparib to patients to define the dose, frequency and schedule of ceralasertib and olaparib to take into Module 2 Part B.
11365397|NCT02264678|Experimental|Module 2 Part B1|Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
11365398|NCT02264678|Experimental|Module 2 Part B2|Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
11365399|NCT02264678|Experimental|Module 2 Part B3|Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
11365400|NCT02264678|Experimental|Module 2 Part B4|Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.
11365401|NCT02264678|Experimental|Module 3 Part A|Module 3 Part A: cohort escalation of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients to define the dose, frequency and schedule of ceralasertib and durvalumab to take into Module 3 Part B. Additionally, Module 3 Part A will include a serial tumour biopsy cohort to evaluate the Proof of Mechanism of ceralasertib in HNSCC and NSCLC patients.
11365402|NCT02264678|Experimental|Module 3 Part B|Module 3 Part B: cohort expansions of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.
11365403|NCT02264678|Experimental|Module 2 Part B5|Patients with BRCA mutant (either germline or somatic) epithelial ovarian, fallopian tube, or primary peritoneal cancer according to local testing. Patients must be platinum sensitive and previously progressed on a licensed PARPi. The cohort will be split into 2 groups: Cohort 1: (without intervening chemotherapy following progression on a PARPi): Cohort 2: (with intervening chemotherapy following progression on a PARPi). Patients will receive ceralasertib and olaparib, at a dose, frequency and schedule recommended from Module 2 Part A2.
11365404|NCT02264665||Sunitinib|
11365405|NCT02264665||Afinitor|
11365406|NCT02264665||other treatment (chémotherapy, SSA..)|
11365407|NCT02264652|Experimental|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS approximately 2mA will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the central cathodal electrode placed over the identified target and surrounding return electrodes forming approximately a 5-cm radius ring.
11365408|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
11365409|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
11365410|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
11365411|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
11365412|NCT02264626|Experimental|acutely ill patients|administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.
11365413|NCT02264613|Experimental|Dose Regimen A (DR-A)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.
11365414|NCT02264613|Experimental|Dose Regimen B (DR-B)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle
11365415|NCT02264613|Experimental|Dose Regimen C (DR-C)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle
11365455|NCT02264301|Experimental|Qingkailing injection 40 ml|Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks
11365416|NCT02264613|Experimental|Combination with palbociclib|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle
11365417|NCT02264587|Experimental|mosapride|mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days
11365418|NCT02264587|Active Comparator|domperidone|domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days
11365419|NCT02264574|Experimental|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
11365420|NCT02264574|Experimental|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.
~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
11365421|NCT02264561|Placebo Comparator|Placebo|Mannitol administered at visit 1 and at visit 2
11365422|NCT02264561|Active Comparator|caffeine|caffeine administered at visit 1 and at visit 2
11365423|NCT02264548|Experimental|Arm 1|Radiation: Radio-Ablation
11365424|NCT02264535|Experimental|0.1mg/ml Ginkgolides Meglumine Injection|Injection, 0.1mg/ml.
11365425|NCT02264535|Experimental|1mg/ml Ginkgolides Meglumine Injection|Injection, 1mg/ml.
11365426|NCT02264535|Experimental|5mg/ml Ginkgolides Meglumine Injection|Injection, 5mg/ml.
11365427|NCT02264522|Experimental|Single Arm|"All patients will be enrolled in the same intervention arm. Interventions are implemented based in 1-4 event levels on the device. Interventions include: Place dialysis chair into position 3, Decrease dialysate temperature, Decrease ultrafiltration rate by 25%, and Decrease ultrafiltration rate by 50%."
11365428|NCT02264509||Arterial insufficiency and HIV|Of a cohort of 206 HIV patients will be randomly selected 206 for Ankle-brachial index to identify wich suffer symptomatic or asymptomatic arterial insufficiency
11365429|NCT02264496|No Intervention|Control|Standard pre-operative care
11365430|NCT02264496|Experimental|Exercise|A 2-4 week low volume, moderate intensity, supervised, one to one, individualised exercise programme. '
11365431|NCT02264483||COPD exacerbation|"No intervention.
~The subjects will be divided in 2 subgroups according to the image study:
~COPD exacerbation with pneumonia
~COPD exacerbation without pneumonia"
11365432|NCT02264483||COPD stable patients|
11365433|NCT02264470||Patients with clinical stroke|All patients with stroke, 18 years or older, are asked for participation.
11365434|NCT02264457|Other|First eye closed loop haptic|subjects implanted with the Closed loop haptic during first eye surgery and the plate haptics toric intraocular lens during second eye surgery
11365435|NCT02264457|Other|First eye plate haptic|subjects implanted with the plate haptic toric during first eye surgery and the closed loop haptic toric intraocular lens during second eye surgery
11365436|NCT02264444|Experimental|Cholecystectomy visualization|All patients will undergo a standard single site cholecystectomy and will have their operation recorded and scored for visualization.
11365437|NCT02264418|Experimental|ODM 203|Oral capsules given once daily dosage 50-800mg
11365438|NCT02264418|Experimental|ODM-203|Oral tablets given once daily 200-1600mg
11365439|NCT02264392|Active Comparator|Ultrasound Guided|Ultrasound Guided Incision and Drainage- Patients will undergo ultrasound guided drainage of the abscess using bedside ultrasound
11365440|NCT02264392|Active Comparator|Blind I&D|Blind Incision and Drainage- Patients will undergo drainage of the abscess using physical exam.
11365441|NCT02264379||normal fractionated irradiation|
11365442|NCT02264379||hypo fractionated irradiation|
11365443|NCT02264366|Experimental|At Risk Group: ACCELERATION program|"This At Risk Group will include ;People at risk of cancer referred from UHN partners and community practices. Also included in this group are; First Nations population of BC, Asians and South Asian populations from Greater Vancouver and the working population of the City of Richmond employees. At the Montreal site users of the YMCA with risk factors for, or family history of, cancer and other chronic diseases will be targeted. And finally, in Nova Scotia the At Risk Group will be identified as being at risk of cancer and other chronic diseases referred from community practices and from the workplace population of the Capital District Health Authority (CDHA).
~Intervention: Motivational Communication for Health Behavior management"
11365444|NCT02264366|Experimental|Friends & Family -ACCELERATION Program|This group includes family and friends of cancer survivors and family and friends of cardiac & COPD rehab patients. The intervention includes Motivational Communication for Health Behavior management
11365445|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
11365446|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
11365447|NCT02264340|Active Comparator|Control|Relaxation technique
11365448|NCT02264340|Experimental|Experimental|Combined treatment
11365449|NCT02264327|Experimental|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.
~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
11365450|NCT02264327|Active Comparator|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.
~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
11365451|NCT02264327|Active Comparator|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.
~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
11365456|NCT02264288|Experimental|3 x 10^6 cells|Human Placenta Derived cells (PDA-002) administered intramuscularly (IM) on Study Days 1 and 8
11365457|NCT02264288|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
11365458|NCT02264288|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
11365459|NCT02264288|Placebo Comparator|Placebo|Identically matching placebo administered IM on Study Days 1 and 8
11365460|NCT02264275|Experimental|Aerobic Exercise Training|An 8-week Nintendo Wii at-home dancing exergame Intervention
11365461|NCT02264262|Experimental|Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
11365462|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
11365463|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
11365464|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
11365465|NCT02264236|Experimental|P10s-PADRE vaccine|Subjects will be immunized by administration of either three or four doses of P10s-PADRE vaccine over a six-week period at a dose level of 500 micrograms (µg) per injection depending on the slandered of care therapy they receive for their lung cancer.
11365466|NCT02264223|Active Comparator|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.
~Fermented red clover isoflavones in aglycone form"
11365467|NCT02264223|Active Comparator|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.
~Fermented red clover isoflavones in aglycone form"
11365468|NCT02264223|Active Comparator|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt
~Fermented red clover isoflavones in aglycone form"
11365469|NCT02264223|Active Comparator|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid
~Fermented red clover isoflavones in aglycone form"
11365470|NCT02264223|Active Comparator|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones
~Unfermented glycosides (as aglycone equivalents)"
11365471|NCT02264210|Experimental|Intervention group|Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
11365472|NCT02264210|No Intervention|Observation group|Observation.
11365473|NCT02264197|Experimental|BIBX 245 CL - fed|after a light breakfast with 40 g fat
11365474|NCT02264197|Active Comparator|BIBX 245 CL - fasted|
11365475|NCT02264184|Experimental|Tamsulosin + Paroxetine|"Tamsulosin: q.d on day 1
~Paroxetine: higher dose q.d. on days -7 to 2 q.d., lower dose on days -10 to -8 and 3 to 5"
11365476|NCT02264184|Active Comparator|Tamsulosin|Tamsulosin: q.d on day 1
11365477|NCT02264171|Experimental|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
11365478|NCT02264171|Active Comparator|Tamsulosin HCl|Tamsulosin HCl given at day 1
11365479|NCT02264158|Experimental|Telmisartan high|
11365480|NCT02264158|Experimental|Telmisartan low|
11365481|NCT02264158|Active Comparator|Lacidipine high|
11365482|NCT02264158|Active Comparator|Lacidipine low|
11365483|NCT02264158|Experimental|Telmisartan+Lacidipine|
11365484|NCT02264158|Placebo Comparator|Placebo|
11365485|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - low|
11365486|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - medium|
11365487|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - high|
11365488|NCT02264145|Experimental|Ethanolic Solution From Respimat®|
11365489|NCT02264132|Experimental|Pramipexole ER tablet versus Pramipexole IR tablet|
11365490|NCT02264132|Experimental|Pramipexole IR tablet versus Pramipexole ER tablet|
11365491|NCT02264119|Experimental|Lefradafiban tablet with Pantoprazole|
11365492|NCT02264119|Active Comparator|Lefradafiban tablet without Pantoprazole|
11365493|NCT02264119|Experimental|Lefradafiban double chamber sachet with Pantoprazole|
11365494|NCT02264119|Active Comparator|Lefradafiban double chamber sachet without Pantoprazole|
11365495|NCT02264106|Experimental|Lefradafiban tablet with pantoprazole|
11365496|NCT02264106|Active Comparator|Lefradafiban tablet|
11365497|NCT02264106|Experimental|Lefradafiban double chamber sachet with pantoprazole|
11365498|NCT02264106|Active Comparator|Lefradafiban double chamber sachet|
11365499|NCT02264093|Experimental|Talsaclidine with Propranol|
11365500|NCT02264093|Active Comparator|Propranolol|
11365501|NCT02264093|Active Comparator|Talsaclidine|
11365502|NCT02264080|Experimental|WAL2014|
11365503|NCT02264080|Placebo Comparator|Placebo|
11365504|NCT02264067|Experimental|Talsaclidine|single rising doses
11365505|NCT02264067|Placebo Comparator|Placebo|
11365506|NCT02264054|Experimental|[14C]talsaclidine, oral|single dose of 20 mg oral solution
11365507|NCT02264054|Active Comparator|[14C]talsaclidine, iv|single dose of 20 mg intravenous (iv) infusion
11365508|NCT02264041|Experimental|Cilobradine, low dose plus itraconazole|Pre-study
11365509|NCT02264041|Active Comparator|Cilobradine, low dose|Pre-study
11365510|NCT02264041|Experimental|Cilobradine, high dose plus itraconazole|main study
11365511|NCT02264041|Active Comparator|Cilobradine, high dose|main study
11365512|NCT02264028|Active Comparator|[14C]-DK-AH 269 CL intravenous|
11365513|NCT02264028|Experimental|[14C]-DK-AH 269 CL oral|
11365514|NCT02264015|Experimental|Cilobradine low|
11365515|NCT02264015|Placebo Comparator|Placebo|
11365516|NCT02264015|Active Comparator|Moxifloxacin|
11365517|NCT02264015|Experimental|Cilobradine high|
11365518|NCT02264002|Experimental|Cilobradine low dose 1|
11365519|NCT02264002|Experimental|Cilobradine low dose 2|
11365520|NCT02264002|Experimental|Cilobradine medium dose|
11365530|NCT02263963|Experimental|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
11365531|NCT02263963|No Intervention|No TAP Block|
11365532|NCT02263950|Experimental|LON002|(Artemether sublingual spray)
11365533|NCT02263937|Active Comparator|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
11365534|NCT02263937|Sham Comparator|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
11365535|NCT02263924|Experimental|Experimental: Tocotrienol|Mixed tocotrienol 200mg twice a day for 6 months
11365536|NCT02263924|Placebo Comparator|Placebo (for tocotrienol)|Placebo capsules, 1 capsule twice a day for 6 months
11365537|NCT02263911|Experimental|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
11365538|NCT02263911|Experimental|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
11365539|NCT02263911|Experimental|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
11365540|NCT02263911|Experimental|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
11365541|NCT02263911|Experimental|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
11365542|NCT02263898|Experimental|Treatment (LGX818, MEK162)|Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
11365543|NCT02263885|Experimental|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
11365544|NCT02263872|Experimental|Minocycline|Minocycline 200mg perday
11365545|NCT02263872|Placebo Comparator|comparison group with placebo|Placebo provide
11365546|NCT02263859|Experimental|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
11365547|NCT02263859|Other|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
11365548|NCT02263846||Postmenopausal group|Patients at the age ≥ 60 years with more than one year of menopause, or patients having undergone bilateral oophorectomy.
11365549|NCT02263846||Premenopausal group|Patients with regular menses during recent 3 months and having never received luteinizing hormone-releasing hormone analogue therapy.
11365550|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
11365551|NCT02263807|Experimental|MPFL group|Arthroscopy and MPFL reconstruction
11365552|NCT02263807|Active Comparator|Control|Arhroscopy and rehabilitation
11365553|NCT02263794|Experimental|Image guided bronchial thermoplasty|At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
11365554|NCT02263794|Active Comparator|Conventional bronchial thermoplasty|Patients in this group will undergo conventional 3 stage bronchial thermoplasty (during 3 separate bronchoscopies).
11365555|NCT02263781|Experimental|Control Blood|Patients on routine postinfectious control, blood draw
11365556|NCT02263781|Experimental|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
11365557|NCT02263781|Experimental|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
11365558|NCT02263781|Experimental|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
11365559|NCT02263781|Experimental|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
11365560|NCT02263781|Experimental|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
11365561|NCT02263768|Other|Group 1 - Recall Interval of 12 months|"Oral clinical conditions:
~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
11365562|NCT02263768|Other|Group 2 - Recall Interval of 18 months|"Oral clinical conditions:
~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
11365563|NCT02263755||chronic hepatitis B subjects|Subjects who have been diagnosed with chronic hepatitis B.
11365564|NCT02263742|Experimental|Peer whole health|Peer whole health intervention will be compared to the treatment as usual at Wellness Center to assess healthcare choice and outcomes
11365565|NCT02263742|Active Comparator|EBPs at Wellness Center|EBPs at Wellness Center will be the active comparative to measure healthcare choice and outcomes with the peer whole health intervention
11365566|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
11365567|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
11365568|NCT02263716||Accelerometer|Utilize accelerometers to measure activity in a diverse population of patients with medical or surgical critical illness.
11365569|NCT02263703|Experimental|HPV vaccine|Quadrivalent HPV vaccine
11365570|NCT02263690|Active Comparator|Group Drops|"proparacaine 0.5% drops (Group Drops)
~Patients from group Drops received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.
~Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%."
11365571|NCT02263690|Active Comparator|Group SC|"proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)
~Patients from group SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.
~For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe."
11365572|NCT02263690|Active Comparator|Group Gel|"Lidocaine gel 2% on the eye (Group Gel)
~Patients from Group Gel received 1 mL of 2% lidocaine gel on the eye before receiving the drop of povidone iodine 5%.
~For the patients from Group Gel, 1 mL of 2% lidocaine gel was applied on the eye before receiving the drop of povidone iodine 5%."
11365573|NCT02263677|Experimental|Sitagliptin|60 day supply of 100mg Sitagliptin
11365574|NCT02263651|Active Comparator|Closure with conventional technique with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
11365575|NCT02263651|Experimental|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.
11365576|NCT02263638|Experimental|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period
11365577|NCT02263612||Danish Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
11365578|NCT02263599||Conservatively treated ventral hernias|
11365579|NCT02263599||Surgically treated ventral hernias|
11365580|NCT02263573|Experimental|PEP'C-R|Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
11365581|NCT02263573|Active Comparator|Control group|Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.
11365582|NCT02263560||Post-stroke patients|Patients who experienced stroke and who already recover gait abilities.
11365583|NCT02263560||Control population|Participants matching the criterion (age and gender) of the patients' group.
11365584|NCT02263547|Other|teriflunomide elimination with colestipol|
11365585|NCT02263534|Experimental|minisling|patients in this arm will undergo single incision minisling
11365586|NCT02263534|Sham Comparator|tension free vaginal tape|patients in this arm will undergo tension free vaginal tape
11365587|NCT02263521||physicians|Nationally-representative sample of physicians in all specialties who have direct or indirect patient care responsibilities
11365588|NCT02263521||resident physicians|Nationally-representative of resident physicians in all specialties
11365589|NCT02263521||medical students|Nationally-representative sample of 4th year medical students in all US allopathic medical schools.
11365590|NCT02263508|Experimental|Phase 1b;|Phase 1b: talimogene laherparepvec and pembrolizumab (MK-3475)
11365591|NCT02263508|Experimental|Phase 3 Arm 1;|Phase 3 Arm 1: talimogene laherparepvec and pembrolizumab (MK-3475)
11365592|NCT02263508|Experimental|Phase 3 Arm 2;|Phase 3 Arm 2: placebo and pembrolizumab (MK-3475)
11365593|NCT02263495|Active Comparator|Paclitaxel & Gemcitabine(PG)|Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1& Day8 every 3weeks
11365594|NCT02263495|Experimental|Eribulin & Gemcitabine(EG)|Eribulin 1.0 mg/m2, 2-5min iv ,Day1& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1& Day8 every 3weeks
11365595|NCT02263482|Other|Control group|patients awaiting for evaluation to cardiac rehabilitation or transplantation
11365596|NCT02263482|Experimental|moderate-intensity group|Patients will be submitted to a 8-weeks training program, with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with upper and lower exercises (50% of the 1-maximum repetition test).
11365597|NCT02263482|Active Comparator|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 Kg each).
11365598|NCT02263469|Experimental|Replenine®-VF|
11365599|NCT02263456|Active Comparator|Current Factor IX|
11365600|NCT02263456|Experimental|Replenine®-VF|
11365601|NCT02263443|Experimental|Soap sus enema (S.S.E.)|Patients in S.S.E. group will receive bowel preparation by soap suds enema until clear at night before surgery.
11365602|NCT02263443|Experimental|sodium chloride enema|Patients in unison enema group will receive Unison enema 100 ml per rectal at night before surgery.
11365603|NCT02263443|Placebo Comparator|no enema|Patients will receive none of bowel preparation. NPO after midnight
11365604|NCT02263430|Experimental|Deep Brain Stimulation|Stimulation is on.
11365605|NCT02263430|Sham Comparator|Placebo|Stimulation is off.
11365606|NCT02263417|Active Comparator|Deep Brain Stimulation|Stimulation is on
11365607|NCT02263417|Sham Comparator|Placebo|Stimulation is off
11365608|NCT02263404|Experimental|Deep Brain Stimulation|DBS Implant and stimulation Intervention: Device: Deep Brain Stimulation
11365609|NCT02263391|Experimental|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
11365641|NCT02263196|Experimental|combination of alcohol and betadin|the efficacy of combination of alcohol and povidone iodine on infection related to vascular access
11365642|NCT02263183|Active Comparator|red palm olein(labelled A)|red palm olein (labelled A)
11365643|NCT02263183|Placebo Comparator|palm olein(labelled B)(control)|palm olein(labelled B)(control)
11365644|NCT02263170||All study participants|Healthy (m/f), normal weighted
11365645|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
11365646|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
11365610|NCT02263391|Experimental|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
11365611|NCT02263378|Experimental|supplement|
11365612|NCT02263378|Placebo Comparator|not intervention|
11365613|NCT02263365|No Intervention|Control|
11365614|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
11365615|NCT02263352|Experimental|Lycored soft gels , Scaling and Rootplaning.|Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline
11365616|NCT02263352|Experimental|Scaling and Rootplaning only.|Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.
11365617|NCT02263339|Experimental|Aerobic Exercise|
11365618|NCT02263339|Active Comparator|Stretching Program|
11365619|NCT02263339|Active Comparator|Aerobic Exercise, Healthy Subjects|
11365620|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
11365621|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
11365622|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
11365623|NCT02263300||Supine- Supine|Group A (supine-supine) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global rating scale and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the supine, then Upright position. At the end of one week,the same medical student will then perform the intubation with the mannequin in both positions.
11365624|NCT02263300||Upright-upright|Group B (upright-upright) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position.At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
11365625|NCT02263300||Supine -upright|Group C( supine -upright) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position. At the end of one week, The same medical student will then perform the intubation with the mannequin in both positions.
11365626|NCT02263300||Upright - supine|Group D( upright - supine) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright,then supine position. At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
11365627|NCT02263287|Other|Alzheimer disease (AD)|Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
11365628|NCT02263287|Other|Dementia with Lewy Bodies (DLB)|Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
11365629|NCT02263287|Other|Probable AD and possible DLB|Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale
11365630|NCT02263274|Experimental|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
11365631|NCT02263261|Other|Flex HD Pliable Perforated HADM|Single Arm
11365632|NCT02263248|Experimental|venlafaxine XR plus buprenorphine|Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.
11365633|NCT02263248|Placebo Comparator|venlafaxine XR plus placebo|Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks
11365634|NCT02263235|Experimental|Group 1|60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
11365635|NCT02263235|Experimental|Group 2A|20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
11365636|NCT02263235|Experimental|Group 2B|30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
11365637|NCT02263222|Experimental|MDT-10013|Subjects will receive MDT-10013.
11365638|NCT02263209|Experimental|Bioguard Group|Randomised study to either Bioguard or control stock
11365639|NCT02263209|Active Comparator|Control Group|Randomised study to either Bioguard or control stock
11365640|NCT02263196|Experimental|alcohol and povidone iodine|the efficacy of combination of alcohol and povidone iodine on inflammation related to vascular access
11365647|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
11365648|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
11365649|NCT02263144||histologically-verified <10mm polyps|histologically-verified <10mm polyps, analyzed by virtual chromo-endoscopy using FICE Fujifilm Technology
11365650|NCT02263131|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
11365651|NCT02263131|Active Comparator|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
11365652|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
11365653|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
11365654|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
11365655|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
11365656|NCT02263105|Experimental|CDDP plus Temozolomide|"Patients were treated with CDDP and TMZ. CDDP was administered iv from Day 1 to 3 with everyday dose of 30mg. TMZ was orally administered from Day 1 to 7 and Day 15 to 21, with everyday dose of 125mg/m2 (Level 2). The period of one chemotherapy cycle is 28 days. TMZ dose levels were listed in Table 1.
~Table 1 TMZ dose levels Dose levels Daily TMZ dose( mg/m2/d ) TMZ dose per cycle(mg/m2)
~150 2100
~125 1750
~100 1400
~75 1050"
11365657|NCT02263092|Experimental|15 minutes of physical exercise|the subjects will do physical exercise on a treadmill with 64 to 74% of maxHR
11365658|NCT02263092|Experimental|10 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 77 to 95% of maxHR.
11365659|NCT02263092|Experimental|30 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 57 to 63% of maxHR.
11365660|NCT02263092|Experimental|Rest/control|the subjects will be on 15 or 30 minutes seat without move the legs.
11365661|NCT02263092|Experimental|Anodal tDCS + physical exercise 1|the subjects will be undergo to anodal tDCS + physical exercise 1
11365662|NCT02263092|Experimental|Anodal tDCS + physical exercise 2|the subjects will be undergo to anodal tDCS + physical exercise 2
11365663|NCT02263092|Experimental|Cathodal tDCS + physical exercise 1|the subjects will be undergo to cathodal tDCS + physical exercise 1
11365664|NCT02263092|Experimental|Cathodal tDCS + physical exercise 2|- the subjects will be undergo to cathodal tDCS + physical exercise 2
11365665|NCT02263092|Experimental|Sham tDCS + physical exercise 1|the subjects will be undergo to sham tDCS + physical exercise 1
11365666|NCT02263092|Experimental|Sham tDCS + physical exercise 2|the subjects will be undergo to sham tDCS + physical exercise 2
11365667|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
11365668|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
11365669|NCT02263079|Experimental|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
11365670|NCT02263066||Group 1|Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013
11365671|NCT02263053|Active Comparator|Posterior Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
11365672|NCT02263053|Active Comparator|Caudal Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
11365673|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
11365674|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
11365675|NCT02263027|Experimental|Vaccine, then placebo|1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment followed by 1 injection of normal saline placebo, 0.5mL/dose, 28 days later
11365676|NCT02263027|Experimental|Placebo, then vaccine|1 injection of normal saline placebo, 0.5mL/dose followed by 1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment, 28 days later
11365677|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after the surgery is completed.
11365678|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after unilateral mastectomy or breast conserving surgery is completed.
11365679|NCT02263001|Experimental|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
11365680|NCT02263001|Active Comparator|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
11365681|NCT02262988|Experimental|Autologous cells and knee arthroplasty|Regenerative cells recovered from the patient's infrapatellar fat pad will be processed using the Transpose RTTM system (InGeneron, Inc., Houston, TX, USA). The processed cells are injected into the knee as adjuvant treatment for total knee arthroplasty (TKA).
11365682|NCT02262988|Placebo Comparator|Control|Standard total knee arthroplasty (no fat cells harvested).
11365683|NCT02262975||donepezil (Aricept)|
11365684|NCT02262962|No Intervention|Usual Well-Child Care|No change in Well-Child Visits.
11365685|NCT02262962|Experimental|Redesigned Well-Child Care|The Redesigned Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and text messaging services (HealthyTxt).
11365686|NCT02262949|Experimental|LifeStent Vascular Stent|This is a single arm study and all subjects receive PTA and implantation of one Life Stent Vascular Stent.
11365687|NCT02262936|Active Comparator|Desmopressin|Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
11365688|NCT02262936|Active Comparator|Fesoterodine|Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
11365689|NCT02262923|No Intervention|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.
~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
11365690|NCT02262923|Experimental|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.
~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
11365691|NCT02262910|Experimental|ES414|Cohorts 1-3 of the dose escalation stage of the study (Stage 1) will test weekly doses of 0.2 mcg/kg to 2 mcg/kg. Cohorts 4-9 of the dose escalation stage of the study (Stage 1) will test continuous infusion at flat doses of 25 mcg to 300 mcg per day delivered continuously over 24 hours. The maximum tolerated dose from Stage 1 of the study will be further examined in Stage 2. Patients in cohorts 1-3 will receive ES414 weekly via intravenous (IV) infusion during the first three 28-day cycles and then on Day 1 and 15 of each subsequent cycle until disease progression, intolerable toxicity occurs, or the patient withdraws consent. Patients in cohorts 4-9 will receive ES414 as a continuous IV infusion for 6 months until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
11365692|NCT02262897|Experimental|Nab-paclitaxel single agent|Nab-paclitaxel single agent, either in 130mg/m2 weekly regimen, d1,8,15 every 4 weeks or in 230mg/m2 d1 every 3 weeks
11365693|NCT02262884|Active Comparator|AIS @ 12mmHg pressure|SurgiQuest AirSeal Insufflation System (AIS) set at 12mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
11365694|NCT02262884|Active Comparator|AIS @ 15mmHg pressure|SurgiQuest AirSeal insufflation System (AIS) set at 15 mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
11365695|NCT02262884|Active Comparator|CIS @ 15mmHg pressure|Conventional Insufflation System (CIS) set at 15mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephectomy.
11365696|NCT02262871|Experimental|CF patients HFN|CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
11365697|NCT02262871|Experimental|CF patients NIV|CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
11365698|NCT02262858|Experimental|Telmisartan and HCTZ (fix dose combination)|
11365699|NCT02262858|Active Comparator|Telmisartan and HCTZ (monocomponent)|
11365700|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
11365701|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
11365702|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
11365703|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
11365704|NCT02262845||Group E: Other|In subjects with other indications
11365705|NCT02262832|Other|Leptin study drug|Administration of study drug SQ BID
11365706|NCT02262806|Other|Leptin therapy|leptin administered via SC injections BID
11365707|NCT02262793|Experimental|telmisartan and ASA/ER-DP (concomitant)|
11365708|NCT02262793|Active Comparator|ASA/ER-DP alone|
11365709|NCT02262793|Experimental|telmisartan and ASA/ER-DP (consecutively)|
11365710|NCT02262793|Active Comparator|telmisartan|
11365711|NCT02262780|Experimental|Single low dose Telmisartan with HCTZ|
11365712|NCT02262780|Experimental|Single high dose Telmisartan with HCTZ|
11365713|NCT02262780|Experimental|Multiple high dose Telmisartan with HCTZ|
11365764|NCT02262520|Experimental|Treatment B: Apixaban and Digoxin|Apixaban and Digoxin tablets by mouth on specified days
11365765|NCT02262507|Experimental|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study.
11365902|NCT02261610|Other|PCT group|In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
11365714|NCT02262767|Experimental|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
11365715|NCT02262767|Experimental|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
11365716|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
11365717|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
11365718|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
11365719|NCT02262741|Experimental|MEDI4736 + tremelimumab|
11365720|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
11365721|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
11365722|NCT02262715|Experimental|Part 1|Participants will receive in random order Treatment A (VX-787, 600 mg tablet 2 times a day on Day 1 to 4, followed by VX 787, 600 mg tablet on Day 5); Treatment B (Oseltamivir, 75 mg capsule 2 times a day on Day 1 to 4, followed by oseltamivir 75 mg capsule in the morning on Day 5) or Treatment C (VX-787, 600 mg tablet, 2 times a day orally + oseltamivir, 75 mg capsule, 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + oseltamivir, 75 mg capsule on Day 5). Each participant will receive all three treatments (Treatment A, B and C) in a random sequence.
11365723|NCT02262715|Experimental|Part 2 VX-787|Participants will receive VX-787, 600 mg, tablet 2 times a day, orally on Day 1 to Day 9, followed by single dose of VX-787, 600 mg on Day 10.
11365724|NCT02262715|Experimental|Part 2 Placebo|Participants will receive placebo matching to VX-787, 2 times a day, orally on Day 1 to Day 9, followed by single dose of matching placebo on Day 10.
11365725|NCT02262702||Extended Release Paracetamol|Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
11365726|NCT02262702||Standard Paracetamol|Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
11365727|NCT02262689|Experimental|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
11365728|NCT02262689|Placebo Comparator|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
11365729|NCT02262676||Rivaroxaban|Patients with Atrial fibrillation treated with Rivaroxaban
11365730|NCT02262663|Experimental|Vilaprisan [0.5mg]|0.5 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
11365731|NCT02262663|Experimental|Vilaprisan [1mg]|1 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
11365732|NCT02262663|Experimental|Vilaprisan [2mg]|2 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
11365733|NCT02262663|Experimental|Vilaprisan [4mg]|4 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
11365734|NCT02262650|Active Comparator|Telmisartan alone|
11365735|NCT02262650|Experimental|Telmisartan + Clopidogrel (concomitantly)|
11365736|NCT02262650|Experimental|Telmisartan + Clopidogrel (consecutively)|
11365737|NCT02262650|Active Comparator|Clopidogrel alone|
11365738|NCT02262637||Hypertensive patients - Cardiologists|
11365739|NCT02262637||Hypertensive patients - Nephrologists|
11365740|NCT02262637||Hypertensive patients - Diabetologists|
11365741|NCT02262624|Experimental|Telmisartan/HCTZ fixed combination|
11365742|NCT02262624|Active Comparator|Telmisartan and HCTZ monocomponents|
11365743|NCT02262611||Hypertension patients - Pneumology|
11365744|NCT02262611||Hypertension patients - Cardiology|
11365745|NCT02262611||Hypertension patients - Nephrology|
11365746|NCT02262611||Hypertension patients - Diabetology|
11365747|NCT02262598|Experimental|Telmisartan/HCTZ fixed dose|
11365748|NCT02262598|Active Comparator|Telmisartan and HCTZ monocomponents|
11365749|NCT02262585|Experimental|BIBR 277 tablet|(Mannitol based)
11365750|NCT02262585|Active Comparator|BIBR 277 capsule|
11365751|NCT02262572|Experimental|Telmisartan /HCTZ - compression tablet (DC)|
11365752|NCT02262572|Experimental|Telmisartan /HCTZ - dry granulation tablet (DG)|
11365753|NCT02262572|Active Comparator|Telmisartan /HCTZ - present commercial formulation|
11365754|NCT02262559|Experimental|BIBR 277 tablet|
11365755|NCT02262559|Active Comparator|BIBR 277 capsule|
11365756|NCT02262546|Experimental|Pramipexole|
11365757|NCT02262546|Active Comparator|Moxifloxacin|
11365758|NCT02262546|Placebo Comparator|Pramipexole Placebo|
11365759|NCT02262546|Placebo Comparator|Moxifloxacin Placebo|
11365760|NCT02262533|Experimental|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
11365761|NCT02262533|Experimental|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
11365762|NCT02262533|Experimental|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
11365763|NCT02262520|Experimental|Treatment A: Digoxin|Digoxin tablet by mouth on specified days
11365798|NCT02262234|Experimental|Education Program Type 1|
11365766|NCT02262494|Other|Suspected first episode of DVT|"The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.
~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs"
11365767|NCT02262481|Active Comparator|Dydrogesterone|tocolytic + corticosteroids + Dydrogesterone 10 mg/tablet prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
11365768|NCT02262481|Placebo Comparator|Placebo|tocolytic + corticosteroids + Placebo prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
11365769|NCT02262468||MOM total hip replacements|all patients with MOM 36mm hip replacements
11365770|NCT02262455|Experimental|STM 434|
11365771|NCT02262455|Experimental|STM 434 and Liposomal Doxorubicin|
11365772|NCT02262442|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
11365773|NCT02262442|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
11365774|NCT02262429||ONS QIP|Two (2) hospitals will administer the new rapid, comprehensive oral nutritional supplementation (ONS) QIP.
11365775|NCT02262429||ONS Standard Feeding|"Two (2) hospitals will use their current standard ONS feeding protocol."
11365776|NCT02262416|Placebo Comparator|controls|Normal saline of equivalent volume
11365777|NCT02262416|Active Comparator|case|0.5mg Leuprolide acetate injection
11365778|NCT02262403|Experimental|Hookworm infected|The amount, phenotype and function of Treg will be explored at several time points. Cultures with environmental antigen will be subsequently performed.
11365779|NCT02262403|Active Comparator|Non infected (hookworms) healthy subjects|All the tests done in the experimental hookworm infected group will be also done in the comparator non infected group.
11365780|NCT02262390|Active Comparator|Standard of Care|Partner notification slip is given to the pregnant female participant on the day she receives her syphilis test results to give to their sexual partner encouraging them to come to the STI clinic and be screened for syphilis. The partner notification slip will have a code number, but no identifiable features (no names).
11365781|NCT02262390|Active Comparator|SMS reminders and notification slip for partner screening|Participants will receive weekly SMS reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and on the SMS reminders.
11365782|NCT02262390|Active Comparator|Phone call reminders and notification slip for partner scree|Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
11365783|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
11365784|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
11365785|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
11365786|NCT02262351|Experimental|Screening|"Subjects will undergo three screening methods for atrial fibrillation:
~30 Second Pulse Check Watch BP Home A HeartCheck Hand-held ECG device"
11365787|NCT02262338|Experimental|Treated subjects|AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
11365788|NCT02262325|Experimental|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
11365789|NCT02262312||Patients with myelodysplastic syndrome|Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable
11365790|NCT02262299|Placebo Comparator|Placebo|Receive placebo tablets
11365791|NCT02262299|Active Comparator|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
11365792|NCT02262286||Brain Injury|Brain Injury
11365793|NCT02262286||Control|Healthy, or Head Trauma, or Orthopedic Trauma, or Poly-Trauma
11365794|NCT02262273||Serous ovarian cancer:|Women with platinum-sensitive recurrent serous ovarian cancer
11365795|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
11365796|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
11365797|NCT02262247||Transoral Visualization & Access|Subjects ≥ 22 yrs requiring transoral procedures
11365800|NCT02262221|No Intervention|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
11365801|NCT02262221|Other|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
11365802|NCT02262208|Other|Patients with type 2 diabetes|
11365803|NCT02262208|Other|Healthy|
11365804|NCT02262195||Carboxyhemoglobin|Induced carboxyhemoglobin levels up tp 15 percent.
11365805|NCT02262195||Methemoglobin|Induced methemoglobin levels up to 15 percent.
11365806|NCT02262182|Experimental|KP group|PEP delivery by EzPAP® device with manual chest physiotherapy .
11365807|NCT02262182|Placebo Comparator|KM group|Manual chest physiotherapy only;
11365808|NCT02262169|Active Comparator|Treatment I|2 Omeprazole capsules 20 mg once daily and 1 placebo caplet of DLBS2411, twice daily
11365809|NCT02262169|Experimental|Treatment II|1 DLBS2411 caplet 250 mg twice daily and 2 placebo capsules of Omeprazole once daily
11365810|NCT02262156|Experimental|Cognitive behavioral Therapy|"CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.
~12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks."
11365811|NCT02262156|Active Comparator|Selective serotonin euptake inhibitor|Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.
11365812|NCT02262143|Experimental|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
11365813|NCT02262143|Active Comparator|Comparator|Rosuvastatin 10 mg
11365814|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
11365815|NCT02262117|Placebo Comparator|standard care|No specific treatment (standard care)
11365816|NCT02262117|Experimental|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
11365817|NCT02262104|Experimental|Intensive exercise|Intensive strengthening and balance exercises 1 hour twice a week 12 weeks. Lead by physiotherapists.
11365818|NCT02262104|Placebo Comparator|Control|Control group activities: Social activities one hour twice a week. Light physical activities, reading, conversation, games. Lead by occupational therapist or nursing staff
11365819|NCT02262091|Placebo Comparator|Placebo group|
11365820|NCT02262091|Experimental|Food fibers|
11365821|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
11365822|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
11365823|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
11365824|NCT02262065||Controls|Patients with well tolerated arthroplasties
11365825|NCT02262052|Other|Phase 4 cohort study|MRDTI
11365826|NCT02262039|Active Comparator|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
11365827|NCT02262039|Experimental|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
11365828|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
11365829|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
11365830|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
11365831|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
11365832|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
11365833|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
11365834|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
11365835|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
11365836|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
11365837|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
11365838|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
11365839|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
11365840|NCT02262013|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
11365841|NCT02262013|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program.
11365842|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
11365843|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
11365844|NCT02261987|Active Comparator|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
11365845|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
11365846|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
11365847|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
11365848|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
11365849|NCT02261961|Experimental|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
11365850|NCT02261961|Placebo Comparator|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
11365851|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
11365852|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
11365853|NCT02261935|Active Comparator|Existing Home Care Nursing Practice|Home care nurses provide care based on existing home care practice
11365854|NCT02261935|Experimental|Practice Support Tool Intervention|"The practice support tool intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.
~Update - December 22, 2016 - In some home care offices only, a study nurse will meet with family caregivers who are in the intervention group to deliver the CSNAT intervention. Information arising from the CSNAT about family caregivers' support needs will be communicated by the study nurse to the home care nurse, and incorporated by the home care nurse into the home care plan for the patient and patient's family."
11365855|NCT02261922|Experimental|ticagrelor|ticagrelor treatment
11365856|NCT02261922|Active Comparator|prasugrel|prasugrel treatment
11365857|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
11365858|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
11365859|NCT02261896|Experimental|Placebo|1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
11365860|NCT02261896|Active Comparator|Antibiotic|Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
11365861|NCT02261883|Active Comparator|IV Remodulin|IV Remodulin will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
11365862|NCT02261883|Placebo Comparator|Placebo|Placebo will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
11365863|NCT02261870|Experimental|ALL_patients|MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
11365864|NCT02261857|Experimental|Intervention Arm|Intervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
11365865|NCT02261857|No Intervention|Historical Control Arm|Pre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.
11365866|NCT02261844|Experimental|resveratrol|Resveratrol 1 g daily for 10 days
11365867|NCT02261844|Placebo Comparator|Placebo|Placebo 1 pill daily for 10 days
11365868|NCT02261831|Experimental|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
11365869|NCT02261831|Experimental|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
11365870|NCT02261831|Experimental|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
11365871|NCT02261831|Experimental|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
11365872|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
11365873|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
11365874|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
11365875|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
11365876|NCT02261792|Active Comparator|A : 24 hours bed rest|24 hours bed rest
11365877|NCT02261792|Experimental|B : 24 hours Trendelenburg position|24 hours Trendelenburg position
11365878|NCT02261779|Experimental|Tretinoin & Tranylcypromine|Tretinoin started with 45mg/m2 on day 7 for one year, administered orally as soft capsules, Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets
11365879|NCT02261753|Active Comparator|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
11365880|NCT02261753|No Intervention|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
11365881|NCT02261740|Experimental|Yoga Therapy Group|Participants will attend twice-weekly group yoga classes and be instructed to practice yoga at home one additional hour a week, using a written manual.
11365882|NCT02261727|Placebo Comparator|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
11365883|NCT02261727|Active Comparator|Low-dose theophylline arm|Theophylline 100 mg twice daily
11365884|NCT02261727|Active Comparator|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
11365885|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
11365886|NCT02261701|Experimental|Early mobilization|Intervention is early mobilization, four weeks immobilization postsurgery with collar´n cuff only.
11365887|NCT02261701|Other|Post surgery shoulder lock|Post surgery shoulder lock with abduction cushion 3 weeks and after this period collar´n cuff 3 weeks
11365888|NCT02261688|Other|Subjects in study|All subjects in study are in a cross-over study with 3 interventions sequentially (low salt diet, low salt diet + IV normal saline, liberal salt diet)
11365889|NCT02261675|No Intervention|control group|children undergoing selective lower abdominal surgery received saline before induction
11365890|NCT02261675|Experimental|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
11365891|NCT02261675|Experimental|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
11365892|NCT02261662|Experimental|Ribavirin and Betamethasone|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
~It will be used along with Topical steroids; Betamethasone"
11365893|NCT02261662|Experimental|Betamethasone alone|Topical steroids alone will be used; Betamethasone.
11365894|NCT02261649||Cerebellar Tumor Surgically Removed|"Quantitative Sensory Testing and Neuroimaging
~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)
~Cold water bath
~MRI scanner
~Questionnaires"
11365895|NCT02261649||Healthy Volunteer|"Quantitative Sensory Testing and Neuroimaging
~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)
~Cold water bath
~MRI scanner
~Questionnaires"
11365896|NCT02261636||Pentasa|Treatment according to standard clinical practice.
11365897|NCT02261623||Palliation|Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery
11365898|NCT02261623||Curative intent surgery|Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy
11365899|NCT02261623||Benign biliary strictures|Treatment of benign biliary strictures
11365900|NCT02261623||Other indication|Other indication
11365901|NCT02261610|Experimental|clinical group|In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
11365977|NCT02261116|Placebo Comparator|Placebo|
11365903|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
11365904|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
11365905|NCT02261584|Experimental|Microwave Thermal Coagulation|MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
11365906|NCT02261584|Experimental|Partial Splenic Embolization Catheter|Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has been considered first-line therapy for hypersplenism in many institutions, and has been proposed as an effective alternative to splenectomy for improving peripheral blood cell counts. However, PSE is associated with many complications, including intermittent fever, abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic infarction rate needs to be greater than 50% (8). Thus, severe complications can ensue.
11365907|NCT02261571|Experimental|Moxibustion|A series of moxibustion sessions within six weeks from baseline with adjuvant chemotherapy.
11365908|NCT02261571|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 6 weeks while receiving adjuvant chemotherapy
11365909|NCT02261558|Experimental|Clinical Improvisation Instrumental Music Therapy|Clinical Music Therapy session, 20 minutes. Focus on instrumental improvisation
11365910|NCT02261558|Experimental|Clinical Vocal Improvisation|Clinical Music Therapy session, 20 minutes. Focus on vocal improvisation
11365911|NCT02261558|No Intervention|Control Group|Participants enrolled in control group will complete the same study design, without having a clinical music improvisation
11365912|NCT02261545|Active Comparator|n-3 Fatty Acid Supplemetation|patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
11365913|NCT02261545|Placebo Comparator|Placebo|patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
11365914|NCT02261532|Experimental|TAS-102|
11365915|NCT02261519|Experimental|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
11365916|NCT02261519|Placebo Comparator|Placebo|The control treatment is placebo.
11365917|NCT02261506|Active Comparator|7 days|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
11365918|NCT02261506|Active Comparator|14 days|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
11365919|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
11365920|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
11365921|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
11365922|NCT02261480||Group A: Documented Prior History|"Pediatric and adult participants with sickle cell disease (SCD) with a documented prior history of parvovirus B19 infection (aplastic crisis).
~Group A participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group A."
11365923|NCT02261480||Group B: No Prior History|"Pediatric and adult participants with SCD who have never had a documented parvovirus B19 infection (aplastic crisis).
~Group B participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group B."
11365924|NCT02261480||Group C: Suspected and/or Confirmed|"Sickle cell disease patients with suspected and/or confirmed acute parvovirus B19 infection, the latter defined as febrile illness with anemia without adequate compensatory reticulocytosis.
~Group C participants will have blood draw and nasopharyngeal wash on day 1, day 7±4 days, day 30±7 days, and day 120±14 days."
11365925|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
11365926|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
11365927|NCT02261454|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
11365928|NCT02261454|Active Comparator|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
11365929|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
11365930|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
11365931|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
11365932|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
11365978|NCT02261103|Active Comparator|Pramipexole IR, fasted|Pramipexole immediate release (IR) tablets
11365933|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
11365934|NCT02261402|Experimental|Medisinstart|Patients in this arm will receive the service; Medisinstart
11365935|NCT02261402|No Intervention|Current Practice|Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
11365936|NCT02261389|No Intervention|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
11365937|NCT02261389|Experimental|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
11365938|NCT02261376|Experimental|Caucasian men, aged 18-55 years|
11365939|NCT02261376|Experimental|Caucasian men, aged 65 years or older|
11365940|NCT02261376|Experimental|Japanese men, aged 18-55 years|
11365941|NCT02261376|Experimental|Caucasian women, aged 18-55 years|
11365942|NCT02261363||Ecig group 1|
11365943|NCT02261363||Ecig group 2|
11365944|NCT02261350|Experimental|Food Fortification|Food Fortification
11365945|NCT02261350|Experimental|Oral Nutritional Supplements|Oral Nutritional Supplements - Fortisip Compact
11365946|NCT02261350|No Intervention|Usual Care|
11365947|NCT02261311||Quality of Life, tissue collection|All participants will complete the GAD-7 and Cancer Locus of Control Scale - Course of Illness Subscale questionnaires and additional tissue will be collected at the time of the diagnostic biopsy.
11365948|NCT02261298|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle
11365949|NCT02261298|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle
11365950|NCT02261298|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle
11365951|NCT02261285|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
11365952|NCT02261285|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
11365953|NCT02261285|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
11365954|NCT02261272|Experimental|CBT for insomnia|Cognitive-behavioral therapy for insomnia
11365955|NCT02261272|Active Comparator|Sleep Hygiene|Psychoeducational intervention based on standard sleep hygiene advices
11365956|NCT02261259|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
11365957|NCT02261259|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
11365958|NCT02261259|No Intervention|Healthy control (no neck pain)|In this arm, healthy controls are tested at baseline.
11365959|NCT02261246|Experimental|Immediate treatment|This arm receives spinal manipulation treatment shortly after enrollment
11365960|NCT02261246|Experimental|Delayed treatment|This arm receives spinal manipulation treatment approximately 4 weeks after enrollment
11365961|NCT02261246|No Intervention|Healthy control (no low back pain)|In this arm, healthy controls are tested at baseline.
11365962|NCT02261233|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
11365963|NCT02261233|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
11365964|NCT02261220|Experimental|MEDI4736 + Tremelimumab|Subjects with multiple tumor types.
11365965|NCT02261207|Experimental|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
11365966|NCT02261194|Experimental|Self-Care Tools|The tool binder includes 3 core tools and 4 supplemental tools. The tools that will be provided include a variety of self-care approaches to manage depression including audio-visual, internet, and paper-based tools that might appeal to individuals with different learning styles. The 3 core tools consist of the Antidepressant Skills Workbook, a Mood Monitoring Tool, and a DVD on depression.
11365967|NCT02261194|No Intervention|Delayed Self-Care Tools|This group will receive the self-care tools at the conclusion of the study.
11365968|NCT02261181|Experimental|XONRID|"Patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients.
~Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines. The use of other topical medications for the treatment of dermatitis will be not permitted during the study."
11365969|NCT02261168|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
11365970|NCT02261155|Other|Hypnosis|hypnotic induction followed by relaxation and pleasant imagery
11365971|NCT02261142|Experimental|Multifocal TENS|Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient
11365972|NCT02261142|Sham Comparator|Sham treatment|Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient
11365973|NCT02261129|Experimental|Telmisartan, film-coated tablet|one tablet of telmisartan
11365974|NCT02261129|Active Comparator|Telmisartan, conventional tablet|Two tablets of telmisartan
11365975|NCT02261116|Experimental|Telmisartan|
11365976|NCT02261116|Active Comparator|Candesartan|
11365979|NCT02261103|Experimental|Pramipexole ER, fasted|Pramipexole extended release (ER) tablets
11365980|NCT02261103|Experimental|Pramipexole ER, fed|Pramipexole extended release tablets with a high-fat meal 30 min before drug administration
11365981|NCT02261090|Experimental|Formulation B|Slow release (SR) tablet
11365982|NCT02261090|Experimental|Formulation C|SR tablet
11365983|NCT02261090|Experimental|Formulation D|SR tablet
11365984|NCT02261090|Experimental|Formulation E|SR tablet
11365985|NCT02261090|Experimental|Formulation F|SR tablet
11365986|NCT02261090|Experimental|Formulation G|SR tablet
11365987|NCT02261090|Experimental|Formulation H|SR tablet
11365988|NCT02261090|Active Comparator|immediate release (IR) formulation|
11365989|NCT02261077|Experimental|Buscopan, single rising doses|
11365990|NCT02261077|Experimental|Buscopan, multiple rising doses|
11365991|NCT02261077|Placebo Comparator|Placebo|
11365992|NCT02261064|Experimental|Telmisartan/Amlodipine low dose, fed|Telmisartan low dose/Amlodipine fixed-dose combination
11365993|NCT02261064|Active Comparator|Telmisartan/Amlodipine low dose, fasted|Telmisartan low dose/Amlodipine fixed-dose combination
11365994|NCT02261064|Experimental|Telmisartan/Amlodipine high dose, fed|Telmisartan high dose/Amlodipine fixed-dose combination
11365995|NCT02261064|Active Comparator|Telmisartan/Amlodipine high dose, fasted|Telmisartan high dose/Amlodipine fixed-dose combination
11365996|NCT02261051||Non-concurrent control group|"A group of advanced cancer patients who received care at our Center before implementation of the LCCM model. They will receive current standard of care.
~This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase)."
11365997|NCT02261038|Other|Kanekasu radiographs|No drugs or devices are used in this study. Commonly available radiological techniques such as radiographs and CT are used. All patients undergo a CT of the knee and a special radiograph (Kanekasu technique).
11365998|NCT02261025|Experimental|Aspirin group|Aspirin 75-100mg,per day，oral
11365999|NCT02261025|No Intervention|non-aspirin group|No interventions
11366000|NCT02261012||30 healthy probands|group without the condition of interest
11366001|NCT02261012||30 CRPS patients|group with condition of interest
11366002|NCT02261012||30 CTS patients|group with a different type of pain on the upper limbs
11366003|NCT02260999||healthy|> 18 years old sufficient language knowledge
11366004|NCT02260999||chronic pain patients|
11366005|NCT02260999||patients with injury at the upper etxremity|
11366006|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
11366007|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
11366008|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
11366009|NCT02260973|Active Comparator|Omega-3|re esterified TG omega-3
11366010|NCT02260973|Placebo Comparator|Safflower Oil|vegetable oil
11366011|NCT02260960|Experimental|Omega-3|Reesterified Triglyceride form omega 3
11366012|NCT02260960|Placebo Comparator|Placebo|safflower oil
11366013|NCT02260947|Experimental|1|
11366014|NCT02260947|Experimental|2|
11366015|NCT02260947|Active Comparator|3|
11366016|NCT02260947|Active Comparator|4|
11366017|NCT02260947|Placebo Comparator|5|
11366018|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
11366019|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.
~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
11366020|NCT02260921|Experimental|Treatment|iovera Treatment
11366021|NCT02260921|Sham Comparator|Sham|Sham Treatment
11366022|NCT02260908|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
11366023|NCT02260908|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo (normal saline) 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
11366024|NCT02260895|No Intervention|Control|Standard 2-hour 75-gram oral glucose tolerance test
11366025|NCT02260895|Experimental|Almond Pre-test snack|1/2 ounce (14 g) almond snack 30 minutes prior to a 2-hour 75-gram oral glucose tolerance test
11366026|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
11366027|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
11366028|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
11366029|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
11366030|NCT02260856|Active Comparator|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
11366031|NCT02260856|Experimental|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
11366032|NCT02260843|No Intervention|Control|Subjects in this group do not received any intervention.
11366033|NCT02260843|Active Comparator|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
11366034|NCT02260843|Placebo Comparator|Generic Fitness Intervention|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
11366035|NCT02260830|Experimental|Treatment Period A|1 reference treatment (2 mg Lu AF11167 immediate release hard capsule) + 5 different test prototype formulations of Lu AF11167
11366036|NCT02260830|Experimental|Treatment Period B|Food interaction and multiple dosing of Lu AF11167
11366037|NCT02260817|Experimental|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.
~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
11366038|NCT02260817|Experimental|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.
~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
11366039|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
11366040|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
11366041|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
11366042|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
11366043|NCT02260778|Experimental|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
11366044|NCT02260778|No Intervention|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
11366045|NCT02260765|Active Comparator|HCP dTMS|this arm will receive dTMS treatment
11366046|NCT02260765|No Intervention|HCP TAU|this arm will continue with the same drugs that they are using usually, which mean treatment as usual
11366047|NCT02260752||Medical|Patients who receive medical therapy only for treatment of their uterine fibroids
11366048|NCT02260752||Procedure|Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.
11366049|NCT02260739|Other|chronic myelomonocytic leukemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
11366050|NCT02260739|Other|essential thrombocytemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
11366051|NCT02260739|Other|myelofibrosis|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
11366052|NCT02260726|Experimental|Surgical group|Subjects already scheduled to undergo surgical correction of a symptomatic cam-type hip impingement deformity. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound investigation prior to surgery.
11366053|NCT02260726|Other|Control|Asymptomatic subjects with normal hip morphometry, as determined by MRI. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound imaging.
11366054|NCT02260713|No Intervention|Control|control subjects with acute complete spinal cord injury who would not receive any bone marrow transplantation.
11366181|NCT02259972|Experimental|BI 113823 solution|single rising doses, dose group 5 twice (fed and fasted)
11366055|NCT02260713|Experimental|Transplantation via intrathecal route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via lumber puncture
11366056|NCT02260713|Experimental|Transplantation via intralesional route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via durotomy and injection at the lesional site .
11366057|NCT02260700|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
11366058|NCT02260700|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
11366059|NCT02260700|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed by Treatment A (single oral dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
11366060|NCT02260700|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed byTreatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
11366061|NCT02260700|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
11366062|NCT02260700|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
11366063|NCT02260687||Group 1|Decision of treatment is made by attending investigator according to the Japanese Package Insert
11366064|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
11366065|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
11366066|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
11366067|NCT02260661|Experimental|Part A|AZD8835 single agent dose escalation
11366068|NCT02260661|Experimental|Part B|Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene.
11366069|NCT02260661|Experimental|Part C|AZD8835 in combination with fulvestrant dose escalation
11366070|NCT02260661|Experimental|Part D|Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D).
11366071|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
11366072|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
11366073|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
11366074|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
11366075|NCT02260635|Placebo Comparator|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
11366076|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
11366077|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
11366078|NCT02260609|Other|Open-Label|Grafix®: Cryopreserved Placental Membrane
11366079|NCT02260596||Cohort Population|Pediatric SOT/HSCT recipients
11366108|NCT02260401|No Intervention|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
11366109|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
11366110|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
11366080|NCT02260583|Experimental|extracorporeal CO2 removal device|"the patients will be enroll to start a one shot session of extracorporeal CO2 removal. The patient will be connected to the device via a double lumen catheter inserted in the femoral vein An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used. Blood flow is driven by a roller nonocclusive pump (0-450 mL/min) through a polypropylene oxygenator ; priming volume, 100 mL; contact surface area, 1.35 m2; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter."
11366081|NCT02260570|Experimental|Functional MRI Arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
11366082|NCT02260557|Experimental|Selexipag|Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.
11366083|NCT02260557|Experimental|Placebo|Placebo matching selexipag tablets is administered according to the same schedule as selexipag
11366084|NCT02260544|Experimental|Test Product - T|"doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )
~Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks."
11366085|NCT02260544|Active Comparator|Reference Product - R|"doxorubicin hydrochloride liposome ( Sun Pharma )
~Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks."
11366086|NCT02260531|Experimental|ARM 1|"HER2-positive
~Cabozantinib- orally administered daily per treatment cycle
~Trastuzumab- IV administered once per cycle
~MRI- Baseline, Cycle 2 Day 1, and every 2 cycles
~Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"
11366087|NCT02260531|Experimental|ARM 2|"Hormone receptor-positive (ER+ and/or PR+)
~Cabozantinib- orally administered daily per treatment cycle
~MRI- Baseline, Cycle 2 Day 1, and every 2 cycles
~Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"
11366088|NCT02260531|Experimental|ARM 3|"Triple negative (ER-, PR-, HER2-)
~Cabozantinib- orally administered daily per treatment cycle
~MRI- Baseline, Cycle 2 Day 1, and every 2 cycles
~Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"
11366089|NCT02260518|Experimental|Lifestyle Intervention|The intervention will focus on women gaining the recommended amount of weight, increasing physical activity to 150 minutes per week, and meeting healthy eating guidelines.
11366090|NCT02260518|Other|Standard Care|Women in the standard care group will attend their regularly scheduled obstetric (OB) visits with their prenatal care providers and will receive monthly mailings and matched number of podcasts.
11366091|NCT02260505|Experimental|Imatinib maintenance|Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).
11366092|NCT02260505|No Intervention|Imatinib Interruption|Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
11366093|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
11366094|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
11366095|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
11366096|NCT02260479|Active Comparator|Preheated chlorhexidine|Preheated skin disinfection with 36ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
11366097|NCT02260479|No Intervention|Room temperature chorhexidine|Room temperature skin disinfection with 20ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
11366098|NCT02260466|Other|elderly patients with Aortic steNosis valvular replacement|
11366099|NCT02260453|Active Comparator|A - Coronary angiography|All the patients receive preoperative coronary angiography followed, if needed, by percutaneous intervention (PCI) or bypass (CABG)
11366100|NCT02260453|Active Comparator|B - standard cardiac workup|Standard cardiac workup
11366101|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles
~Pembrolizumab will be given at 200 mg every 21 days.
~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
11366102|NCT02260427|Experimental|the i-gel group|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
11366103|NCT02260427|Active Comparator|the Air-Q sp group|After induction of general anesthesia, the air-Q sp will be inserted according to randomly allocated group.
11366104|NCT02260414|Experimental|Patients with multiple myeloma|Patient with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
11366105|NCT02260414|Active Comparator|Patients with agressive lymphoma|Patient hospitalized for aggressive lymphoma treated with chemotherapy treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
11366106|NCT02260414|Active Comparator|Patients with acute medical condition|Patient older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
11366107|NCT02260401|Experimental|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
11366111|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
11366112|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
11366113|NCT02260375|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.
11366114|NCT02260375|No Intervention|No treatment.|
11366115|NCT02260362||HTAP of Congenital Heart Disease|
11366116|NCT02260349|Experimental|patient with Indocyanine green infusion|Infusion of Indocyanine Green 0,25 mg/Kg 24h before prostatic surgery
11366117|NCT02260336|Experimental|Panax Notoginseng Powder 1g|Panax Notoginseng Powder 1g, daily
11366118|NCT02260336|Experimental|Panax Notoginseng Powder 5g|Panax Notoginseng Powder 5g,daily
11366119|NCT02260336|Experimental|Panax Notoginseng Powder 10g|Panax Notoginseng Powder 10g,daily
11366120|NCT02260336|Experimental|Panax Notoginseng Powder 15g|Panax Notoginseng Powder 15g,daily
11366121|NCT02260336|Active Comparator|Celecoxib Capsule 400 mg daily|Celecoxib Capsule 400 mg daily
11366122|NCT02260323|Experimental|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
11366123|NCT02260323|Active Comparator|patient-tailored DMARDs|Patients use tailored DMARDs
11366124|NCT02260310|Experimental|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
11366125|NCT02260310|Active Comparator|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
11366126|NCT02260284|Experimental|Yaotong points acupuncture|patients under the treatment of Yaotong ponts penetration mode
11366127|NCT02260284|Active Comparator|standardized acupuncture|patients under the treatment of standardized acupuncture
11366128|NCT02260284|Other|the usual care|In the usual care group, participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS)).
11366129|NCT02260271||Database Entry/Biospecimen Collection|Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected.
11366130|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous I.V. infusion as per standard intensive care unit practice.
~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
11366131|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
11366132|NCT02260245|Other|Team training|All participating affiliates will undergo team training using the TeamSTEPPS model
11366133|NCT02260232|Experimental|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
11366134|NCT02260232|No Intervention|control|
11366135|NCT02260219|Active Comparator|S2|Surgically Implant an Ahmed Glaucoma Drainage Device Model S2 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
11366136|NCT02260219|Active Comparator|M4|Surgically Implant an Ahmed Glaucoma Drainage Device Model M4 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
11366137|NCT02260206|Experimental|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
11366138|NCT02260206|No Intervention|No intervention|No intervention
11366139|NCT02260193|Experimental|AKB-6548, starting dose 1|
11366140|NCT02260193|Experimental|AKB-6548, starting dose 2|
11366141|NCT02260193|Experimental|AKB-6548, starting dose 3|
11366142|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
11366143|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
11366144|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
11366145|NCT02260167|Experimental|Treatment with MIND|
11366146|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
11366147|NCT02260141|Experimental|Treatment with d-ribose|Treatment with ribose 5 gm TID
11366148|NCT02260128|Experimental|Gum chewing|"This intervention group will receive chewing gum four times daily following surgery. Each of which they are encouraged to chew for 30 minutes.
~Gum chewing is terminated when one of the primary end points occurs."
11366149|NCT02260128|No Intervention|Control group|This group will receive the normal postoperative treatment. Occurence of primary end points are registrered.
11366150|NCT02260115|Experimental|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
11366151|NCT02260115|Sham Comparator|Surgical Control|Laproscopic Surgery Only
11366152|NCT02260102|Active Comparator|urinary tract infections|Children requiring antibiotic treatment for urinary tract infections. Intervention: blood sampling for assay of temocillin
11366153|NCT02260102|Active Comparator|cholangitis|"Cirrhotic children requiring antibiotic treatment due to suspicion of cholangitis.
~Intervention: blood sampling for assay of temocillin"
11366154|NCT02260102|Active Comparator|hepatic transplant|Children requiring antibiotic prophylaxis following a hepatic transplant. Intervention: blood sampling for assay of temocillin
11366155|NCT02260089|Experimental|Low dose of telmisartan|4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
11366156|NCT02260089|Experimental|High dose of telmisartan|After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
11366157|NCT02260076|Experimental|PEG 400|multiple rising doses
11366158|NCT02260076|Placebo Comparator|Placebo|
11366186|NCT02259946|Experimental|BI 1744 CL - single rising dose + Tiotropium|Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
11366187|NCT02259946|Placebo Comparator|Placebo|
11366188|NCT02259933|Experimental|KUC 7483 CL|increasing repeated oral doses
11366189|NCT02259933|Placebo Comparator|Placebo|
11366190|NCT02259920|Active Comparator|Treatment A|KUC 4783 CL, immediate release tablets
11366191|NCT02259920|Experimental|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
11366192|NCT02259920|Experimental|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
11366193|NCT02259920|Experimental|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
11366194|NCT02259920|Experimental|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
11366195|NCT02259907|Experimental|KUC 7483 CL|single rising doses
11366196|NCT02259907|Experimental|KUC 7483 CL, fed|dosing after high fat meal
11366197|NCT02259907|Placebo Comparator|Placebo|
11366198|NCT02259894|Experimental|BIRT 2584|single rising doses
11366199|NCT02259894|Placebo Comparator|Placebo|
11366200|NCT02259881|Experimental|Low dose of BIBT 986 CL|
11366201|NCT02259881|Experimental|Medium dose of BIBT 986 CL|
11366202|NCT02259881|Experimental|High dose of BIBT 986 CL|
11366203|NCT02259881|Placebo Comparator|Placebo|
11366204|NCT02259868|Experimental|Group A|randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout
11366205|NCT02259868|Experimental|Group B|randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout
11366206|NCT02259868|Experimental|Group C|randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout
11366207|NCT02259868|Experimental|Group D|randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout
11366208|NCT02259855|Experimental|Mild hepatic insufficiency|
11366209|NCT02259855|Experimental|Moderate hepatic insufficiency|
11366210|NCT02259855|Experimental|Healthy subjects|
11366211|NCT02259842|Experimental|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
11366212|NCT02259842|Experimental|BI 34021 FU2 tablet|dose group 4 only
11366213|NCT02259842|Placebo Comparator|Placebo|
11366214|NCT02259829|Experimental|Telmisartan/Amlodipine fixed dose combination|
11366215|NCT02259829|Active Comparator|Telmisartan and Amlodipine monocomponents|
11366216|NCT02259816|Active Comparator|Telmisartan|
11366217|NCT02259816|Experimental|Telmisartan and amlodipine|
11366218|NCT02259803|Experimental|Telmisartan/amlodipine fixed-dose combination|
11366219|NCT02259803|Active Comparator|Telmisartan and amlodipine mono-components|
11366220|NCT02259790|Experimental|Telmisartan/amlodipine fixed-dose combination|
11366221|NCT02259790|Active Comparator|Telmisartan tablet and amlodipine tablet|
11366222|NCT02259777|Experimental|Telmisartan/Amlodipine, fed|
11366223|NCT02259777|Active Comparator|Telmisartan/Amlodipine, fasted|
11366224|NCT02259764|Experimental|KUC 7483 CL - single rising dose|"Treatment 1: KUC 7483 CL - low dose
~Treatment 2: KUC 7483 CL - medium dose
~Treatment 3: KUC 7483 CL - high dose
~In treatment 3 the same subjects as in treatment 2 received drug immediately after the ingestion of a standardized high fat meal"
11366225|NCT02259764|Placebo Comparator|Placebo|
11366226|NCT02259751|Experimental|KUC 7483 CL|
11366227|NCT02259751|Placebo Comparator|Placebo|
11366228|NCT02259738|Experimental|Human urinary kallidinogenase and Shuxuening injection|Human urinary kallidinogenase 0.15PNA and Shuxuening injection 20mg, every day for 7 days.
11366229|NCT02259725|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11366230|NCT02259712|Active Comparator|Pelviperineal physiotherapy|"The treatment duration is 2 days per week during 8 weks (two months). The aproximate duration of the season is 45 minutes. The protocol consists in:
~Anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity).
~Hygienic and behavioral advises preventing pelvic floor dysfunctions.
~Awareness of the pelvic floor muscles.
~Strengthening the pelvic floor muscles and the entire abdominal pelvic cavity. Use of electrostimulation and biofeedback in different positions if deemed necessary.
~Treatment the abdominal-pelvic cavity pain if it requires."
11366231|NCT02259712|Experimental|Hiporessive and Pelviperineal PT|The treatment duration is 2 days per week, 8 weeks (two months). The session is about 45 minutes. All women are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle. The participants are also treated by doing Hipopressive exercises and by specific physicaltherapy for the strengthening the pelvic floor muscles.
11366232|NCT02259712|Experimental|Hipopressive exercises|The treatment is done 2 times per week for 8 weeks (2 months). The session duration is about 45 minutes. All participants are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity). The participants are also treated by doing Hipopressive exercises in standing, sitting, and supine fours.
11366233|NCT02259699|Experimental|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
11366234|NCT02259699|No Intervention|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
11366235|NCT02259686|Experimental|Protocol 1. Apelin 1mg doses|5 Healthy volunteers
11366236|NCT02259686|Experimental|Protocol 2. Apelin 5mg doses|5 Healthy volunteers
11366237|NCT02259686|Experimental|Protocol 3. Apelin 10mg single dose|5 Healthy volunteers
11366238|NCT02259673|Experimental|Fun exercise|effect of fun physical exercise on sarcopenia
11366239|NCT02259673|Experimental|fun exercise|effect of fun physical exercise on interest in exercise
11366240|NCT02259660|Active Comparator|Active Group|Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.
11366241|NCT02259660|Placebo Comparator|Sham Training|The intervention in the sham training arm will be identical in every way to that of the active arm with the exception of the trainer that is provided. Subjects in the sham training arm will have inspiratory and expiratory muscle strength trainers which have had the pressure threshold spring removed and are therefore unable to provide a load to the muscles being trained.
11366242|NCT02259647|Experimental|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
11366243|NCT02259647|Active Comparator|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
11366244|NCT02259634|Experimental|Patient Navigation|Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
11366245|NCT02259634|No Intervention|Treatment as Usual|Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic
11366246|NCT02259621|Experimental|Nivolumab|"Nivolumab administration:
~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
11366247|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
11366248|NCT02259595|Experimental|HPN-07 500 mg / Placebo|Single dose of 500mg HPN-07 plus placebo in oral capsules.
11366249|NCT02259595|Experimental|HPN-07 1000 mg / Placebo|Single dose of 1,000mg HPN-07 plus placebo in oral capsules
11366250|NCT02259595|Experimental|HPN-07 1500 mg / Placebo|Single dose of 1,500mg HPN-07 plus placebo in oral capsules
11366251|NCT02259595|Experimental|HPN-07 MTD plus NAC 1200mg|Single dose of maximum tolerated dose of HPN-07 plus 1,200 mg NAC in oral capsules. Dose selection will be determined from safety data of previous cohorts by Data Assessment Committee (DAC).
11366252|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
11366253|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
11366254|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
11366255|NCT02259569|Experimental|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
11366256|NCT02259569|Active Comparator|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
11366257|NCT02259556|Experimental|anti-CD30 CAR T cells|Patients receive CART30 cell infusions with an escalation dose.
11366258|NCT02259543|No Intervention|G0|Root decontamination performed by scaling and root planing followed by rinsing with saline solution during the treatment of recession defects by subepithelial connective tissue graft (SCTG). Control group.
11366259|NCT02259543|Active Comparator|G90|Root conditioning with citric acid+tetracycline solution (1:1) for 90 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
11366260|NCT02259543|Active Comparator|G180|Root conditioning with citric acid+tetracycline solution (1:1) for 180 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
11366261|NCT02259530|Experimental|Integrated Psychotherapeutic Intervention|Integrated treatment of khat use disorder and PTSD
11366262|NCT02259517|Experimental|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
11366263|NCT02259517|Experimental|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
11366264|NCT02259491|Experimental|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
11366265|NCT02259491|No Intervention|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
11366266|NCT02259465|Active Comparator|Oligofructose|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with oligofructose, 7grams twice daily
11366267|NCT02259465|Placebo Comparator|Maltodextrin|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with maltodextrin, 7grams twice daily
11366268|NCT02259426|Active Comparator|Dihydroartemisínin-piperaquine (Artekin)|Dihydroartemisínin-piperaquine combination alone
11366269|NCT02259426|Experimental|Dihydroartemisinin-piperaquine, Primaquine|Dihydroartemisinin-piperaquine with single-dose 0.25mg/kg Primaquine
11366270|NCT02259413|Experimental|Exercise Rehabilitation|"Participants will receive baseline exercise counseling as per Standard Care group. Participants will then participate in a 26-week exercise rehabilitation program incorporating 3 components:
~One-to-one self-management/resistance education once per week during the first 4 weeks of intervention. Participants will subsequently receive resistance training material to allow for home exercise for the remaining 22 weeks of the intervention.
~Intradialytic aerobic exercise on a cycle ergometer 3 times weekly for 26 weeks at their usual hemodialysis sessions.
~Four additional one-to-one standardized education sessions will be completed during the intervention period."
11366271|NCT02259413|No Intervention|Standard Care|Participants will receive one exercise counseling session as part of their baseline assessment. Participants in the control group will not undergo any other exercise counseling or formal exercise intervention, but will not be prohibited from participating in exercise outside of the study protocol.
11366272|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
11366273|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
11366274|NCT02259387||Cases|Children with migraines will be placed into this group.
11366275|NCT02259387||Controls|Children without migraines or headaches will be placed into this group.
11366276|NCT02259374|Active Comparator|TAP BLOCK 0.2% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy.
~Intervention: TAP block Dose: 20 ml 0.2% ropivacaine"
11366277|NCT02259374|Active Comparator|TAP BLOCK 0.4% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy.
~Intervention: TAP block Dose: 20 ml 0.4% ropivacaine"
11366278|NCT02259361|Active Comparator|Experimental|Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
11366279|NCT02259361|Placebo Comparator|Placebo|Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
11366280|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
11366281|NCT02259335|Experimental|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise>20% of baseline and/or a rapid shallow-breathing index >100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
11366282|NCT02259322|Active Comparator|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
11366283|NCT02259322|Experimental|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
11366284|NCT02259322|Experimental|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
11366285|NCT02259309|Experimental|Misoprostol administration - buccal then vaginal|Vaginal or buccal administration
11366286|NCT02259309|Experimental|Misoprostol administration - vaginal then buccal|Vaginal or buccal administration
11366287|NCT02259296|Experimental|Lower eGFR for AVF creation|
11366288|NCT02259296|Active Comparator|Higher eGFR for AVF creation|
11366289|NCT02259283|Experimental|Achalasia|Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.
11366290|NCT02259270||ASTRA-1|"All patients discharged from the participating hospitals between July 2012 and July 2013.
~Determination of long term use of AST before, during and after hospitalisation based on dispensing data, no record review."
11366291|NCT02259270||ASTRA-2|Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
11366292|NCT02259244|Experimental|Mediterranean diet+physical activity|Mediterranean diet based on 1573 kcal/day with the goal of consumption of 30 ml/day of olive oil, 56g/week of nuts, 3-4 servings/week of fish, 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat
11366293|NCT02259244|Active Comparator|Hypolipemic reduction diet+physical activity|Hypolipemic reduction diet based on 1287 kcal/day with the goal of consumption of 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat, non-fat or low-fat dairy products
11366294|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
11366295|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
11366296|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
11366297|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
11366298|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
11366375|NCT02258711|No Intervention|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
11366299|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
11366300|NCT02259231|Experimental|Omaveloxolone Dose5 TBD & nivolumab|Omaveloxolone (RTA 408) capsules, Dose5 TBD taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
11366301|NCT02259231|Experimental|Omaveloxolone Dose6 TBD & nivolumab|Omaveloxolone (RTA 408) capsules, Dose6 TBD taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
11366302|NCT02259218||Ancillary-Correlative|Prospectively collected blood, urine, and tissue samples are analyzed for potential predictive biomarkers via metabolomic and other molecular profiling.
11366303|NCT02259205|Experimental|Enriched Yogurt|150 g yogurt enriched with approximately 0.5 g bioactive lipids extract from olive oil mill provided daily for 8 weeks
11366304|NCT02259205|Placebo Comparator|Plain Yogurt|150 g not enriched yogurt provided daily for 8 weeks
11366305|NCT02259205|No Intervention|Control|No yogurt consumption
11366306|NCT02259192|Experimental|Open-label|Cochlear Implant
11366307|NCT02259179|Active Comparator|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
11366308|NCT02259179|Active Comparator|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
11366309|NCT02259166|Experimental|EHFP+|Group receiving the intervention EHFP+, in addition to MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
11366310|NCT02259166|No Intervention|Control|MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
11366311|NCT02259153|Active Comparator|Lean red meat diet|Participants were given 350 g per day of lean red meat to incorporate to their usual diet for ten days.
11366312|NCT02259153|Active Comparator|Fat red meat diet|Participants were given 350 g per day of fat red meat to incorporate to their usual diet for ten days.
11366313|NCT02259140|Active Comparator|Proximal Femoral Resection Arthroplasty|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The abductors of the hip are detached with sharp dissection. A capsulotomy is performed. The femur is exposed in a supra-periosteal manner (2 cm distal to the lesser trochanter) at the level of the ischium; transverse osteotomy will then be performed. The joint capsule will be sutured to itself. The iliopsoas tendon and the abductor tendons are attached to the capsule. The quadriceps will be brought around the proximal femoral stump and sutured to medial tissues.
11366314|NCT02259140|Experimental|Subtrochanteric Valgus Osteotomy|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The medial half of the abductors may be incised off the greater trochanter for repair. The femoral head is resected at the base of the neck. The ligamentum teres is incised off the head and preserved. A lateral closing wedge osteotomy is performed below the lesser trochanter. 3.5 or 4.5 5 hole locking/non-locking surgeon-contoured plate ( 45⁰) will be used to stabilize the osteotomy. Femoral torsion will be corrected. The psoas tendon will attach the ligamentum teres to the lesser trochanter. The anterior and posterior capsule is sutured together creating interposition tissue. If the ligamentum teres was sutured to the lesser trochanter, the capsule will not close, but will be covered by the psoas tendon.
11366315|NCT02259127|Active Comparator|SOC arm|SOC for ODYSSEY A is defined as a PI or non nucleoside transcriptase inhibitors + 2 or 3 nucleoside transcriptase inhibitor SOC for ODYSSEY B is defined as a PI or non nucleoside transcriptase inhibitor+ 2 nucleoside transcriptase inhibitors
11366316|NCT02259127|Experimental|DTG arm|DTG + 2 nucleoside transcriptase inhibitors
11366317|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive MK-8628 capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
11366318|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive MK-8628 capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
11366319|NCT02259101|Experimental|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
11366320|NCT02259101|Active Comparator|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
11366321|NCT02259088|Experimental|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
11366322|NCT02259088|Active Comparator|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
11366323|NCT02259075|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.
11366324|NCT02259062|Active Comparator|Music listening|
11366325|NCT02259062|Experimental|Music listening with brief mindfulness|
11366326|NCT02259062|Placebo Comparator|Audio book intervention|
11366327|NCT02259049|Active Comparator|L-Tyrosine|We will administer 1,000 mg of L-tyrosine BID for 24 hours and record BP and HR.
11366328|NCT02259049|Placebo Comparator|Sugar Pill|We will administer a sugar pill BID for 24 hours and record BP and HR.
11366329|NCT02259036|Other|SmartCAT Enhanced Treatment|Cognitive Behavioral Therapy enhanced with an ecological momentary treatment enhancement smartphone app called SmartCAT.
11366330|NCT02259023|Experimental|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
11366331|NCT02259023|Experimental|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
11366374|NCT02258711|Experimental|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
11366332|NCT02259010|Experimental|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
11366333|NCT02258997||HbSS|Subjects are homozygous for the sickle hemoglobin mutation (HbS).
11366334|NCT02258997||HbS-beta thalassemia|Subjects are heterozygous for the HbS mutation and beta thalassemia
11366335|NCT02258984|Other|Open physician access to Venus 1000 CVP data|
11366336|NCT02258984|Other|No open physician access to Venus 1000 CVP data|
11366337|NCT02258971|Experimental|BEA 2180 BR oral|
11366338|NCT02258971|Active Comparator|BEA 2180 BR infusion|
11366339|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
11366340|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
11366341|NCT02258932||Continuous subcutaneous insulin infusion|This group will consist of patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
11366342|NCT02258919|Experimental|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
11366343|NCT02258919|Active Comparator|Best medical treatment|Best medical treatment
11366344|NCT02258906|Experimental|Ulinastatin group|Patients in the ulinastatin group are given ulinastatin during operation.
11366345|NCT02258906|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
11366346|NCT02258893|Experimental|NO2 Scrubber, then HEPA filter, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
11366347|NCT02258893|Experimental|NO2 Scrubber, then Control, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
11366348|NCT02258893|Experimental|HEPA filter, then NO2 scrubber, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
11366349|NCT02258893|Experimental|HEPA filter, then Control, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
11366350|NCT02258893|Experimental|Control, then HEPA filter, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
11366351|NCT02258893|Experimental|Control, then NO2 scrubber, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
11366352|NCT02258880|Experimental|SUN13837|Drug: SUN13837 daily for 28 days.
11366353|NCT02258880|Placebo Comparator|Placebo|Placebo: Matching Placebo daily for 28 days
11366354|NCT02258867|Placebo Comparator|Placebo|
11366355|NCT02258867|Experimental|Gevokizumab|
11366356|NCT02258854|Experimental|Dose 2 gevokizumab|
11366357|NCT02258841|Experimental|Personalized online Safety Decision Aid|Setting priorities for safety; Danger Assessment; Personalized Action Plan
11366358|NCT02258841|Active Comparator|General Online Risk/Safety Information|General Risk and Safety Information; Basic Emergency Safety Plan
11366359|NCT02258828|Experimental|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
11366360|NCT02258828|Placebo Comparator|Placebo|Patient received matched placebo
11366361|NCT02258815|Experimental|ch14.18|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.
~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
11366362|NCT02258802|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
11366363|NCT02258802|No Intervention|Usual food practices|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
11366364|NCT02258789|Experimental|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
11366365|NCT02258776|Active Comparator|Pomegranate Extract|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
11366366|NCT02258776|Active Comparator|Pomegranate Juice|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
11366367|NCT02258776|Placebo Comparator|Placebo|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
11366368|NCT02258763|Experimental|Amoxicillin-Potassium Clavulanate|Patient will be on amoxicillin-clavulanate 22.5mg/kg/dose bd for 10 days
11366369|NCT02258763|Active Comparator|Placebo|Patient will be on amoxicillin-clavulanate 22.5mg/kg/bd for 3 days followed by another 7 days of placebo medication given at the same dose and frequency
11366370|NCT02258750|Experimental|Polydextrose|Tomato soup enriched with added polydextrose
11366371|NCT02258750|Placebo Comparator|Control|Tomato soup without added polydextrose
11366372|NCT02258737|Experimental|transitional case management|
11366376|NCT02258698||Elective on-pump cardiac surgery|Observation of perioperative Insulin resistance in patients undergoing elective on-pump cardiac surgery (CABG and/or valve repair)
11366377|NCT02258685||Cohort A1|ART-treated HIV-infected individuals with lipodystrophy
11366378|NCT02258685||Cohort A2|ART-treated HIV-infected individuals without lipodystrophy
11366379|NCT02258685||Cohort A3|HIV-1 infected individuals naïve to ART
11366380|NCT02258685||Cohort A4|HIV-1 seronegative individuals who are at a high risk for infection
11366381|NCT02258685||Cohort B1|A subset of subjects from Cohort A: ART-treated HIV-infected individuals with HIV-associated dysbiosis
11366382|NCT02258685||Cohort B2|A subset of subjects from Cohort A: ART-treated HIV-infected individuals without HIV-associated dysbiosis
11366383|NCT02258672|Experimental|Prehabilitation program|Participants will be physically trained before undergoing surgery
11366384|NCT02258672|No Intervention|Control|Patients will follow the normal course of care provided by the hospital
11366385|NCT02258659|Experimental|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
11366386|NCT02258659|Experimental|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11366387|NCT02258659|Experimental|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*
~*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
11366388|NCT02258646|Experimental|Telerehabilitation|Exercise training at home, telemonitoring, and education/self-management
11366389|NCT02258646|Experimental|Unsupervised exercise training at home|Unsupervised exercise training at home
11366390|NCT02258646|No Intervention|Usual care|Usual care
11366391|NCT02258633|Experimental|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
11366392|NCT02258633|No Intervention|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
11366393|NCT02258620|Experimental|dinitrate isosorbide (intra venous)|dinitrate isosorbide by continuous intra venous injection (1 à 5 mg/h)
11366394|NCT02258620|Experimental|dinitrate isosorbide (intra arterial)|dinitrate isosorbide 5 mg by direct administration intra arterial
11366395|NCT02258620|Experimental|nitroglycerine (transdermic)|nitroglycerine dermal patch15 mg/24h soit 67,2 mg/21 cm2
11366396|NCT02258607|Experimental|Momelotinib (MMB) dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.
11366397|NCT02258607|Experimental|Trametinib dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.
11366398|NCT02258607|Experimental|Momelotinib (MMB)+trametinib|Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.
11366399|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units
~Usual Care on four Oncology units"
11366400|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units
~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
11366401|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
11366402|NCT02258568|Experimental|Smoking abstinence counseling|Telephone motivational counseling sessions supporting smoking abstinence
11366403|NCT02258568|No Intervention|Control|Do not receive telephone motivational counseling sessions supporting smoking abstinence
11366404|NCT02258555|Experimental|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
11366405|NCT02258542|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
11366406|NCT02258542|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
11366407|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
11366408|NCT02258516|Experimental|behavioral intervention|"Patient education for self-management called CHIME 3-M will be delivered"
11366409|NCT02258516|Active Comparator|control|attention control arm received phone calls to discuss non-heart failure related health topics
11366410|NCT02258503||numerical scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and then taken care according to the usual practice of the emergency department.
11366411|NCT02258503||algoplus scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and by Algoplus® scale then taken care according to the usual practice of the emergency department.
11366412|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
11366413|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
11366414|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
11366415|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
11366478|NCT02258035||DBP/Gc1f-1f genotype|Human volunteers homozygous for the 1f-1f (fast) genotype of DBP.
11366416|NCT02258464|Experimental|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
11366417|NCT02258464|Placebo Comparator|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
11366418|NCT02258451|Experimental|Radium-223 dichloride + exemestane/everolimus|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) (randomized) + All patients will receive exemestane and everolimus
11366419|NCT02258451|Placebo Comparator|Placebo + exemestane/everolimus|Up to 6 cycles of saline injection (placebo) (randomized) + All patients will receive exemestane and everolimus
11366420|NCT02258438|Experimental|Uninterrupted sitting|Patient will refrain from any structured activity and reduce any daily life activity. The patient will spend 24 hours in the calorimeter room. During the 24 hours the patient will remain sedentary for the 24 hours but will be able to watch TV, computer work or read.
11366421|NCT02258438|Experimental|Sitting + 1 bout of activity|The patient will be asked to perform the 45 minutes of moderate-exercise intervention in the morning once per day for two days in their daily life. This bout of exercise will be supervised by study staff on one of the treadmills On day 3 the patient will report at the Clinical and Translational Research Center (CTRC) of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, you will be asked to sit quietly in a chair, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity walking on a treadmill.
11366422|NCT02258438|Experimental|Sitting + microbursts of activity|The patient will be asked to refrain from any structured exercise running, swimming, lifting weights, yoga, dancing, etc.) for two days but to walk for the 5 minute intervention each hour between 1000 and 1800. On day 3, The patient will report at the CTRC of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, the patient will be asked to rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5 min moderate-intensity walking on a treadmill, which represents a total of 45 min.
11366423|NCT02258425|Experimental|FEM-CARE|Six specialized nurse case managed and health education sessions and coach-facilitated mentoring
11366424|NCT02258425|Active Comparator|Health Promotion|One brief basic health education session and coach-facilitated mentoring
11366425|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
11366426|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
11366427|NCT02258399|Active Comparator|Breakfast Rest|
11366428|NCT02258399|Active Comparator|Breakfast Exercise|
11366429|NCT02258399|Experimental|Fasted Exercise|
11366430|NCT02258373|Experimental|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.
~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
11366431|NCT02258373|Active Comparator|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
11366432|NCT02258360|Active Comparator|24 hours hypothermia|Therapeutic hypothermia for 24 hours after reaching target temperature
11366433|NCT02258360|Experimental|48 hours hypothermia|Therapeutic hypothermia for 48 hours after reaching target temperature
11366434|NCT02258347|Experimental|Single arm|
11366435|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
11366436|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
11366437|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
11366438|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
11366439|NCT02258321|Experimental|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
11366440|NCT02258321|Experimental|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
11366441|NCT02258308|Experimental|CHW intervention|"The CHW intervention is in-home education and support by a community health worker (CHW). At the first home visit, the CHW assesses the participant's knowledge and skills related to asthma self-management, current status of the child's asthma, and resources and support for asthma self-management using a baseline questionnaire. The CHW will inspect the home environment using an Environmental Home Checklist to identify environmental triggers that can cause asthma symptoms and affect asthma control. The CHW makes up to three follow-up visits and two telephone visits during the year the participant is in the study. Participants receive resources to help them control asthma: vacuum cleaner, dust covers for a pillow and mattress and a green cleaning kit with cleaning supplies."
11366479|NCT02258035||DBP/Gc1s-1s genotype|Human volunteers homozygous for the 1s-1s (slow) genotype of DBP.
11366442|NCT02258308|No Intervention|control|The control group receives standard asthma care, as provided by a primary health care provider. When the intervention period is over, the control group receives one visit with a CHW and the resources provided to the intervention group participants.
11366443|NCT02258295|Experimental|Intragel|Intragel (IBSA) has an average size of 800-1200 kDaltons. Intragel will give given with a concentration of 16mg/2cc. Each injection (2cc) injection will be given at baseline, then 2 weeks and 4 weeks from the baseline.
11366444|NCT02258295|Active Comparator|Saline|Saline injections will be given similar to the active hyaluronic injections. Each injection (2cc) will be given at baseline, then 2 weeks and 4 weeks from the baseline.
11366445|NCT02258282|Experimental|Etanercept|Patients under the treatment of 50 mg Etanercept
11366446|NCT02258282|Sham Comparator|Control|Patients under the treatment of traditional DMARDs
11366447|NCT02258269|Experimental|SQ|Patients with rheumatoid arthritis exercise square dance
11366448|NCT02258269|Sham Comparator|Control|Patients with rheumatoid arthritis listen to accompany music of square dance at home
11366449|NCT02258256|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
11366450|NCT02258230|Active Comparator|2D mode LSC|2D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
11366451|NCT02258230|Active Comparator|3D mode LSC|3D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
11366452|NCT02258230|Active Comparator|2D mode PVR|2D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
11366453|NCT02258230|Active Comparator|3D mode PVR|3D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
11366454|NCT02258217|Experimental|Single arm|Acthar 80 units subcutaneously for five consecutive days.
11366455|NCT02258204|Placebo Comparator|tPA-placebo|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.
~Saline infusion : 0.15 mL/kg IV bolus (maximum 15 mL) followed by an IV infusion of 0.15 mL/kg over 60 minutes (maximum 15 mL)."
11366456|NCT02258204|Experimental|tPA-ketamine|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.
~Ketamine infusion : 0.15 mg/kg IV bolus (maximum 15 mg) followed by an IV infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg)."
11366457|NCT02258191|Active Comparator|NIV treatment with telemonitoring|telemonitoring is used to manage NIV treatment
11366458|NCT02258191|Sham Comparator|NIV treatment with sham telemonitoring|sham telemonitoring (data not used for NIV management)
11366459|NCT02258178||1, Flucelvax|Flucelvax exposure in pregnancy
11366460|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
11366461|NCT02258152|Placebo Comparator|Placebo|
11366462|NCT02258152|Experimental|SYN120|
11366463|NCT02258139|Experimental|Study Group 1|1st overnight visit with no contact lens; 2nd overnight visit randomized to either left or right eye for B&L Investigational Contact Lens
11366464|NCT02258126|Active Comparator|Control group|healthy lifestyle education including healthy lifestyle education, supportive therapy and behavioral advice for both children and parents to improve nutrition and physical activity
11366465|NCT02258126|Experimental|Exercise group|multidisciplinary intervention program including healthy lifestyle education, supportive therapy and behavioral advice for for both children and parents to improve nutrition and physical activity and supervised exercise.
11366466|NCT02258113|Other|LEA numbers, Pelli-Robson, Octopus|Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
11366467|NCT02258100||Paper|Patients receiving care documented via paper anesthesia record.
11366468|NCT02258100||AIMS|Patients receiving care documented via electronic anesthesia record.
11366469|NCT02258087|Active Comparator|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
11366470|NCT02258087|Experimental|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
11366471|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
11366472|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
11366473|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
11366474|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
11366475|NCT02258061|Experimental|DDD-80 pacing|To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).
11366476|NCT02258061|Sham Comparator|DDD-60 pacing|To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).
11366477|NCT02258048||Patients with cirrhosis|
11366480|NCT02258035||DBP/Gc 2-2 genotype|Human volunteers homozygous for the 2-2 genotype of DBP.
11366481|NCT02258009|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
11366482|NCT02258009|Experimental|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
11366483|NCT02257996|Experimental|Interventional Group|Online Systematic Brief Psychodynamic Psychotherapy
11366484|NCT02257996|No Intervention|Control Group|Waiting list
11366485|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
11366486|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
11366487|NCT02257970|Experimental|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally
~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
11366488|NCT02257970|Experimental|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally
~Open-label group: 75 mgs, three times daily, for four months"
11366489|NCT02257970|Placebo Comparator|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally
~Placebo: 1 capsule, three times daily, for four months"
11366490|NCT02257970|Active Comparator|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally
~Ketoprofen: 1 capsule, three times daily, for four months"
11366491|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
11366492|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
11366493|NCT02257944|Experimental|Motivational Interviewing|Receive brief hospital-based intervention
11366494|NCT02257944|Other|Treatment as Usual|Treatment as Usual
11366495|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
11366496|NCT02257918|Experimental|Group 1|N = 70 subjects receive single oral dose , 2000 mg of AZD0914
11366497|NCT02257918|Experimental|Group 2|N =70 subjects receive single oral dose , 3000 mg of AZD0914
11366498|NCT02257918|Active Comparator|Group 3|N = 40 subjects receive single intramuscular dose, 500 mg of ceftriaxone
11366499|NCT02257905||AL Amyloidosis patients who received allo HSCT|
11366500|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
11366501|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
11366502|NCT02257879||Sequence A|water - GFJ - supplement
11366503|NCT02257879||Sequence B|GFJ - supplement - water
11366504|NCT02257879||Sequence C|supplement - water - GFJ
11366505|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
11366506|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
11366507|NCT02257853|No Intervention|Control Group|No Intervention Group
11366508|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
11366509|NCT02257827|Experimental|IMRT- Hypofractionated schedule 70 Gy/25 fx|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
11366510|NCT02257827|Active Comparator|3DCRT-Hypofractionated schedule 70 Gy/25 fx|The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
11366511|NCT02257814|No Intervention|Control Group|Control group
11366512|NCT02257814|Experimental|Incredible Years|incredible years intervention
11366513|NCT02257814|Experimental|Preschool PATHS|Preschool PATHS (Promoting Alternative Thinking Strategies)
11366514|NCT02257814|Experimental|Tools of the Mind|Tools of the Mind
11366515|NCT02257801|Experimental|Nutritional beverage fortified with 6mg lutein/day|
11366516|NCT02257801|Experimental|Nutritional beverage fortified with 12mg lutein/day|
11366517|NCT02257801|Placebo Comparator|Nutritional beverage fortified with 0mg lutein/day|
11366518|NCT02257788|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
11366519|NCT02257788|Active Comparator|Treatment Arm 2|PRO 140: one SC loading dose, 700 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
11366520|NCT02257788|Active Comparator|Treatment Arm 3|PRO 140: one SC loading dose, 700 mg (day 1), followed by one single SC dose 350 mg (day 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
11366521|NCT02257788|Active Comparator|Treatment Arm 4|PRO 140: one SC dose, 700 mg (day 1) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
11366522|NCT02257762|Experimental|Lipid-based nutrient supplement (LNS)|LNS added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
11366523|NCT02257762|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge, eaten over 6 months, age 6-12 months to age 11-17 months
11366524|NCT02257762|Active Comparator|Sprinkles|Sprinkles added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
11366525|NCT02257762|No Intervention|Control|Plain borbor and thereafter family foods, eaten over 6 months, age 6-12 months to age 11-17 months
11366526|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
11366527|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
11366564|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
11366565|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
11366528|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
11366529|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
11366530|NCT02257710||Orsiro|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
11366531|NCT02257697|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
11366532|NCT02257697|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).
~All study subjects will receive standard steroid therapies during the study."
11366533|NCT02257684|Experimental|Pegcrisantaspase|
11366534|NCT02257671|Active Comparator|Oral contraceptive|oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks
11366535|NCT02257671|Placebo Comparator|Placebo|Oral placebo capsule daily during 11 weeks
11366536|NCT02257658|Experimental|Doxycycline|Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.
11366537|NCT02257658|Active Comparator|Incentive|Subjects in the incentive arm will receive escalating payments for remaining STI free at Weeks 12, 24 and 36.
11366538|NCT02257645||Euforvac-Hib vaccine|
11366539|NCT02257632|Experimental|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
11366540|NCT02257632|Experimental|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
11366541|NCT02257619|Experimental|Itacitinib plus docetaxel|
11366542|NCT02257606|No Intervention|Control group (persons with MS)|no training
11366543|NCT02257606|Experimental|Experimental group (persons with MS)|Robot-assisted training
11366544|NCT02257593|Experimental|10 % Protein|10% Dietary protein energy
11366545|NCT02257593|Experimental|15% Protein|15% Dietary protein energy
11366546|NCT02257593|Experimental|25% Protein|25% Dietary protein energy
11366547|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
11366548|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
11366549|NCT02257567|Experimental|Arm A (Phase II Randomization): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
11366550|NCT02257567|Active Comparator|Arm B (Phase II Randomization): BR in FL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
11366551|NCT02257567|Experimental|Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
11366552|NCT02257567|Active Comparator|Arm D (Phase II Randomization): BR in DLBCL|Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
11366553|NCT02257567|Experimental|Arm E (Phase II Expansion): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
11366554|NCT02257567|Experimental|Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
11366555|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
11366556|NCT02257567|Experimental|Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL|Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
11366557|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
11366558|NCT02257567|Experimental|Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL|Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
11366559|NCT02257567|Experimental|Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
11366560|NCT02257567|Experimental|Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL|In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
11366561|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
11366562|NCT02257528|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
11366563|NCT02257502|Experimental|aflibercept|intravitreal injection of aflibercept (EYLEA)
11366566|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
11366567|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
11366568|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
11366569|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
11366570|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
11366571|NCT02257476|Experimental|Carfilzomib|Patients will receive single agent carfilzomib on a weekly dosing schedule (days 1, 8, 15) in a 21 day cycle. The initial dose will be 20 mg/m² for cycle 1, day 1. Dose escalation will proceed in a standard 3+3 fashion with the requirement that dose escalation to the next level can only proceed if 0 of 3 or ≤ 1 of 6 patients experience a dose limiting toxicity (DLT). Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
11366572|NCT02257463|Active Comparator|Study group (group A)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training) inspiratory muscle training: (at intensity that progressively increased from 30% to 60% of patients' maximal inspiratory pressure)"
11366573|NCT02257463|Active Comparator|control positive group (group B)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training)"
11366574|NCT02257463|Active Comparator|control negative group (group C)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations"
11366575|NCT02257437|Experimental|LNS + borbor|Lipid-based nutrient supplement (LNS) added to borbor
11366576|NCT02257437|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge
11366577|NCT02257437|Active Comparator|Sprinkles|Sprinkles added to borbor
11366578|NCT02257437|Active Comparator|LNS snack|LNS eaten as snack
11366579|NCT02257424|Other|Phase 1/2|
11366580|NCT02257411|Active Comparator|Ear-sized based and weight based formula|the sizes of the PLMA determined with the ear-based compared with the sizes according to the manufacturer's weight-based formula
11366581|NCT02257398|Experimental|Sequence ABDC|Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
11366582|NCT02257398|Experimental|Sequence BCAD|Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
11366583|NCT02257398|Experimental|Sequence CDBA|Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
11366584|NCT02257398|Experimental|Sequence DACB|Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
11366585|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
11366586|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
11366587|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
11366588|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
11366589|NCT02257359|Experimental|Epelsiban Cohort 1|Subjects will receive 300 mg of epelsiban administered orally twice (every 12 hr) on Day 1 (total daily dose of 600 mg)
11366590|NCT02257359|Experimental|Epelsiban Cohort 2|Epelsiban dose for Cohort 2 will be determined based on data from Cohort 1, but will not exceed a total daily dose of 900 mg, administered orally in divided doses (450 mg every 12 hrs or 300 mg every 8 hrs).
11366591|NCT02257359|Experimental|Additional Cohorts TBD (to be decided)|Subjects will be enrolled if determined necessary, based on data collected in Epelsiban Cohort 1 and Cohort 2
11366592|NCT02257346|Active Comparator|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
11366593|NCT02257346|Placebo Comparator|Normal Saline|Intravenous normal saline infusion
11366594|NCT02257320|Other|Feasibility|Assessing EMG activity with Bruxoff(TM) device
11366595|NCT02257294|Placebo Comparator|Control Arm|two placebo vials
11366596|NCT02257294|Active Comparator|Arm A|Alteplase 10mg and placebo vial
11366597|NCT02257294|Active Comparator|Arm B|Alteplase 10mg and alteplase 10mg
11366598|NCT02257281|Experimental|Active Therapeutic Ultrasound|The three inflammatory forearm spots on the same side induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with active therapeutic ultrasound .
11366599|NCT02257281|Placebo Comparator|Non-active Therapeutic Ultrasound|The contralateral three inflammatory forearm spots induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with non-active therapeutic ultrasound .
11366600|NCT02257268|Experimental|Change behavior group|Change behavior group = Group of change behavior including physical activity and healthy habits promotion.
11366601|NCT02257268|No Intervention|Control group|Control group = Group that will not receive the VAMOS program as intervention.
11366602|NCT02257255|Active Comparator|Pfannenstiel cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by Pfannenstiel technique. Pain assessment on postoperative hours 6, 12 and 24.
11366603|NCT02257255|Experimental|Misgav-Ladach cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by minimally invasive technique. Pain assessment on postoperative hours 6, 12 and 24.
11366604|NCT02257242|Experimental|Dose-escalation cohort|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
11366605|NCT02257229||Surgical|Corrective Surgery only
11366606|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
11366607|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
11366608|NCT02257216|Active Comparator|Sequence 1: Treatment/Treatment|Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®
11366609|NCT02257216|Active Comparator|Sequence 2: Placebo/Treatment|Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®
11366610|NCT02257216|Placebo Comparator|Sequence 3: Placebo/Placebo|Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo
11366611|NCT02257203|Experimental|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
11366612|NCT02257203|Active Comparator|Reading Education|Parents will receive an educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
11366613|NCT02257190|Experimental|Control (Con)|No exercise intervention.
11366614|NCT02257190|Experimental|Interval Walking - 3 min intervals (IW3)|One hour of classical interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking.
11366615|NCT02257190|Experimental|Interval Walking - 1 min intervals (IW1)|One hour of fast alternating interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking
11366616|NCT02257177|Placebo Comparator|HV placebo arm|placebo
11366617|NCT02257177|Active Comparator|HV treatment arm|inhaled TD139 single dose escalation
11366618|NCT02257177|Placebo Comparator|IPF patient placebo arm|placebo
11366619|NCT02257177|Active Comparator|IPF patient treatment arm|Inhaled TD139 od 2 weeks
11366620|NCT02257164|Active Comparator|femoral nerve block|20 ml injection of 2 mg/ml ropivacaine in femoral nerve
11366621|NCT02257164|Experimental|obturator nerve block and intraarticular injection|10 ml injection of 2 mg/ml ropivacaine in obturator nerve intraarticular injection : 10 ml of chlorhydrate ropivacaine (2 mg/ml) and 10ml of magnesium sulfate
11366622|NCT02257151|Experimental|Group 1: BMS-986142 or placebo|BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified
11366623|NCT02257151|Experimental|Group 2: BMS-986142 or placebo|BMS-986142 or placebo Multiple dose oral Solution as specified
11366624|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine)|Patients receive ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11366625|NCT02257125|Experimental|high incentive|game version including visual effects and monetary rewards
11366626|NCT02257125|Active Comparator|low incentive|game version without visual effects or monetary rewards
11366627|NCT02257112|Experimental|Multistage low-energy stimulation|Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
11366628|NCT02257073|Experimental|CBT|Cognitive-behavioral treatment
11366629|NCT02257073|Sham Comparator|WLT|Waiting in list
11366630|NCT02257060|Experimental|Endocardial Ablation|
11366631|NCT02257047|Experimental|RYR|Patients under the treatment of red yeast rice
11366632|NCT02257047|Sham Comparator|Control|Patients under the treatment of tea
11366633|NCT02257034|Experimental|Taichi|patients exercise with Tai chi
11366634|NCT02257034|Sham Comparator|Control|patients under exercise of dance
11366635|NCT02257021|Experimental|Tipranavir and high dose of ritonavir plus BILR 355 BS|
11366636|NCT02257021|Experimental|BILR 355 BS with low dose of ritonavir|
11366637|NCT02257008|Experimental|Single rising dose of BILR 355 BS with grapefruit juice|
11366638|NCT02257008|Experimental|Single rising dose of BILR 355 BS with nelfinavir|
11366639|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir|
11366640|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir, ritonavir|
11366641|NCT02256995||Pregnant Women (>22 weeks gestation)|Biomarkers tracked over 3 antenatal care visits via standard of care (dipstick, manually/visually assessed) and via uChek (automated assessment via computer application)
11366642|NCT02256982|Experimental|Resectable Disease|"Consent and Registration
~3 cycles of gemcitabine + cisplatin
~Evaluate for surgery* (weeks 10-15)
~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.
~Proceed to surgery
~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
11366643|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration
~3 cycles of gemcitabine + cisplatin
~Evaluate for surgery* (weeks 10-15)
~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.
~Proceed to radiation therapy with protons or photons, determined by available resources
~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
11366644|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.
~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
11366645|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.
~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
11366646|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.
~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
11366647|NCT02256956|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
11366648|NCT02256956|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
11366649|NCT02256943|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
11366650|NCT02256943|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
11366651|NCT02256930|Experimental|M518101|M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
11366652|NCT02256930|Placebo Comparator|M518101 Vehicle|M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
11366653|NCT02256930|Active Comparator|Sodium lauryl sulfate|The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
11366654|NCT02256930|Sham Comparator|Saline|The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
11366655|NCT02256917|Experimental|Human-cl rhFVIII|
11366656|NCT02256904|Experimental|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
11366657|NCT02256904|Active Comparator|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
11366658|NCT02256891|Experimental|Double Row|Double Row
11366659|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
11366660|NCT02256878|Experimental|BIRT 2584 XX + Amitriptyline|"BIRT 2584 XX:
~Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)
~Amitriptyline:
~Single dose on day -8, day 1, and day 15"
11366661|NCT02256865|Placebo Comparator|Placebo and Drug Group 2|Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day.
11366662|NCT02256865|Active Comparator|Drug and Placebo Group 1|Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day
11366663|NCT02256852|Experimental|QBKPN SSI|Individualized maintenance dose administered subcutaneously for 12 weeks
11366664|NCT02256839||non TB infection|Group tested with CST_001
11366665|NCT02256839||low exposure risk|Group tested with CST_001
11366666|NCT02256826|Experimental|Group A|
11366667|NCT02256826|Experimental|Group B|
11366668|NCT02256813|Experimental|BIRT 2584 XX + PK-cocktail|
11366669|NCT02256800|Experimental|UGT1A1 genotyping (6,6)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
11366670|NCT02256800|Experimental|UGTA1T1 genotyping (6,7)|The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
11366671|NCT02256800|Experimental|UGTA1T1 genotyping (7,7)|The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
11366672|NCT02256800|Experimental|UGT1A1 non-genotyping|The investigators will maintain the dosage of irinotecan by 180mg/m2
11366673|NCT02256787|Experimental|BILB 1941 ZW - single rising dose|Single rising dose part
11366674|NCT02256787|Placebo Comparator|Placebo|Single rising dose part
11366675|NCT02256787|Experimental|BILB 1941 ZW - tablet - fasted|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
11366676|NCT02256787|Experimental|BILB 1941 ZW - solution|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
11366677|NCT02256787|Experimental|BILB 1941 ZW - tablet - fed|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
11366678|NCT02256774|Experimental|Combivir® plus BILR 355/Ritonavir|
11366679|NCT02256774|Experimental|BILR 355/Ritonavir|
11366680|NCT02256761|Experimental|BIRT 2584 XX - single dose|"Part 1 - bioavailability/food effect
~two single doses, 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served"
11366681|NCT02256761|Placebo Comparator|Placebo|Part 2
11366682|NCT02256761|Experimental|BIRT 2584 XX - multiple escalating dose|Part 2 - multiple escalating dose, 14 days and 28 days
11366683|NCT02256748|Experimental|BIRT 2584 XX + Midazolam|"BIRT 2584 XX: Multiple doses for 12 days (bid on days 1 and 2, qd from days 3 to 12)
~Midazolam: Administration on days -2, 1, 3, and 12"
11366684|NCT02256735|Experimental|Treatment A|
11366685|NCT02256735|Experimental|Treatment B|
11366686|NCT02256735|Experimental|Treatment C|
11366687|NCT02256735|Experimental|Treatment D|
11366688|NCT02256735|Placebo Comparator|Placebo|
11366689|NCT02256735|Active Comparator|Moxifloxacin|
11366690|NCT02256722|Experimental|Treatment A|
11366691|NCT02256722|Experimental|Treatment B|
11366692|NCT02256722|Experimental|Treatment C|
11366693|NCT02256722|Experimental|Treatment D|
11366694|NCT02256722|Active Comparator|Treatment E|
11366695|NCT02256709|Experimental|single rising dose BIBP 5371 CL|
11366696|NCT02256709|Experimental|BIBP 5371 CL tablet high dose|to be compared with same daily dose level from single rising dose arm
11366697|NCT02256709|Experimental|BIBP 5371 CL tablet low dose|to be compared with same daily dose level from single rising dose arm
11366698|NCT02256709|Placebo Comparator|Placebo drinking solution|
11366699|NCT02256709|Experimental|BIBP 5371 CL drinking solution|
11366700|NCT02256709|Experimental|BIBP 5371 CL tablet high dose with food|
11366701|NCT02256709|Experimental|BIBP 5371 CL tablet low dose with food|
11366702|NCT02256709|Placebo Comparator|Placebo tablet|
11366703|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
11366704|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
11366705|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
11366706|NCT02256683|Experimental|Dabigatran|Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
11366707|NCT02256683|Active Comparator|Phenprocoumon|Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response
11366708|NCT02256670|Experimental|Text Message Application Intervention|The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
11366709|NCT02256657|Experimental|Step 1: Toolkit Implemented in Month 4|Quality Improvement Toolkit
11366710|NCT02256657|Experimental|Step 2: Toolkit Implemented in Month 8|Quality Improvement Toolkit
11366711|NCT02256657|Experimental|Step 3: Toolkit Implemented in Month 12|Quality Improvement Toolkit
11366712|NCT02256657|Experimental|Step 4: Toolkit Implemented in Month 16|Quality Improvement Toolkit
11366713|NCT02256657|Experimental|Step 5: Toolkit Implemented in Month 20|Quality Improvement Toolkit
11366714|NCT02256644||Million Veteran Program (MVP) participants|Veterans who are currently enrolled in the Million Veteran Program.
11366715|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 will receive a single VRC01 20 mg/kg injection less than 72 hours after birth.
11366716|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 will receive a single VRC01 40 mg/kg injection less than 72 hours after birth.
11366717|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 will receive a VRC01 40 mg/kg injection less than 5 days after birth. They will then receive a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
11366718|NCT02256631|Experimental|Dose Group 4|Infants in Cohort 1 will receive a single VRC01LS injection less than 72 hours after birth. Dose is based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. Infants in Cohort 2 will receive an initial VRC01LS injection no longer than 5 days after birth, with dose based on weight. A second dose of 100 mg VRC01LS will be administered at Week 12 if an infant is still breastfeeding.
11366719|NCT02256631|Experimental|Dose Group 5|Infants in Cohort 1 will receive a single VRC07-523LS injection less than 72 hours after birth. Dose is based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. Infants in Cohort 2 will receive an initial VRC07-523LS injection no longer than 5 days after birth, with dose based on weight. A second dose of 100 mg VRC07-523LS will be administered at Week 12 if an infant is still breastfeeding.
11366720|NCT02256618|Experimental|Cell therapy|Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion
11366721|NCT02256605||Insufficient Group|D-3 Chewable Wafer - 14,000 IU/wafer weekly Vitamin D-3 Caps - 2,000 IU/Cap daily Vitamin D-3 Liquid - 5,000 IU/ml (0.4) ml daily
11366722|NCT02256605||Deficient Group|D-3 Chewable Wafer - 50,000 IU/wafer weekly Vitamin D-3 Liquid - 5,000 IU/ml daily
11366723|NCT02256592|Experimental|Fecal microbiota transplant (FMT)|Donor fecal suspension will be delivered during colonoscopy to HIV+ individuals.
11366724|NCT02256566|Experimental|emotional memory training exercise|study training exercise - Emotional Faces Memory Task (EFMT)
11366725|NCT02256566|Active Comparator|memory training exercise|an active control exercise (CT)
11366726|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
11366727|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
11366904|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
11366728|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
11366729|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
11366730|NCT02256527||Promus Premier|observational data
11366731|NCT02256514|Experimental|Daily oral dose of hepcortespenlisimut-L|Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
11366732|NCT02256501|Experimental|Mono Nunlear Cell (MNC)|The patients with idiopathic dilated cardiomyopathy who underwent intracoronary injection of autologous bone marrow-derived mononuclear cells .
11366733|NCT02256501|No Intervention|Control|The patients with cardiomyopathy that are under observe during the study.
11366734|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
11366735|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
11366736|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
11366737|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
11366738|NCT02256475|Experimental|Adolescents Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
11366739|NCT02256475|Experimental|Adolescents Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
11366740|NCT02256475|Experimental|Adolescents Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
11366741|NCT02256475|Experimental|Children Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
11366742|NCT02256475|Experimental|Children Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
11366743|NCT02256475|Experimental|Children Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
11366744|NCT02256462|Experimental|Interventional|Adalimumab levels and antibodies will be obtained with every laboratory examination (every 2 months, except for the first 2 visits). Dose or interval adjustment will be performed as followed:when trough levels results taken prior to ADA injection are above 5 µg/ml no change in dosing is required. Detectable levels below 5 µg/ml will result in interval decrease to every week. If levels are still below 5 µg/ml dose will be increased to 40 mg (in patients receiving less than 40 mg). Undetectable levels below 0.3µg/ml will be followed by antibodies (ATAs) measurement. If ATAs are persistently above 8 µg/ml the patient will discontinue the study. If ATAs are below 8 µg/ml ADA intervals will be decreased to every week.
11366745|NCT02256462|No Intervention|Clinical|"Adalimumab levels and antibodies will be requested based on physician judgment when there are signs of loss of response (LOR). Dose and interval adjustment will be performed according to clinical measures: Following physician decision trough levels and ATAs will be collected and further adjustment may be considered according to results. Interval adjustment will be performed as described for the interventional arm.
~LOR is defined as PCDAI equal or higher than 10 or CRP higher than 0.5 mg/dl (5mg/l) and/or Fecal calprotectin higher than 150 mcg/gr (If lower than 150 at randomization)."
11366746|NCT02256449||BVS patients|Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.
11366747|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
11366748|NCT02256436|Active Comparator|Active Comparator|Participants receive paclitaxel 175 mg/m^2 IV or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 Q3W
11366749|NCT02256423|Active Comparator|REFERENCE 1: Nurofen® 200 mg tablet|Single group 3-way crossover study
11366750|NCT02256423|Active Comparator|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|Single group 3-way crossover study
11366751|NCT02256423|Experimental|ibuprofen 200 mg soft gel capsule|single group, 3-way cross
11366752|NCT02256410|Experimental|Stimulation|Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
11366753|NCT02256410|Sham Comparator|sham stimulation|Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
11366754|NCT02256397|Active Comparator|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
11366755|NCT02256397|Experimental|Enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:
~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller
~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
11366756|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
11366757|NCT02256371|Experimental|Hypnotic analgesia|"Hypnosis sessions:
~Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist"
11366758|NCT02256371|Experimental|Relaxation|"Relaxation group:
~Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist."
11366759|NCT02256371|No Intervention|Routine care|The patients will receive their usual pain treatments throughout the study
11366760|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
11366761|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
11366762|NCT02256345|Active Comparator|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
11366763|NCT02256345|Placebo Comparator|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
11366764|NCT02256332|Active Comparator|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
11366765|NCT02256332|Active Comparator|High dose plant based ingredient|Reference food with high dose of plant based ingredient
11366766|NCT02256332|Placebo Comparator|Reference food format|Reference food without plant-based ingredient
11366767|NCT02256319|Experimental|Dexmedetomidine recording|Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.
11366768|NCT02256319|Active Comparator|Propofol recording|Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.
11366769|NCT02256319|No Intervention|Basal recording|Recording registered through the deep brain stimulation electrodes with no sedation .
11366770|NCT02256306|Experimental|Young Donor Plasma|Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
11366771|NCT02256293|Experimental|Group Therapy|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
11366772|NCT02256280|Experimental|S Group|Sugammadex 2 or 4 mg/kg iv once at the end of surgery
11366773|NCT02256280|Active Comparator|N Group|Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery
11366774|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
11366775|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
11366776|NCT02256254|Active Comparator|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
11366777|NCT02256254|Placebo Comparator|Placebo|2 placebo capsules every evening for 14 days
11366778|NCT02256241||The role of RING ubiquitin ligases in osteogenic progenitors|Bone marrow (BM) will be collected from healthy patients undergoing orthopedic surgery. BM will be collected from disposable tissue that is removed during the normal sequence of the surgery.
11366779|NCT02256241||The role of RING ubiquitin ligases in musculoskeletal cancer|Collection of connective tissue from patients with tumors of musculoskeletal origin - a part of the resected tumor specimens.
11366780|NCT02256228|Active Comparator|Group R|Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
11366781|NCT02256228|Placebo Comparator|Group P|Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
11366782|NCT02256215|Experimental|Vitamin D|• All patients will have their serum vitamin D levels measured at the baseline visit. Those assigned to the treatment arm (group A) will receive either 50,000 international units of vitamin D3 by mouth once or more per week for six to eight weeks, then 800 to 1000 (or more) international units of vitamin D3 daily thereafter, this is according to the recommendations of the Endocrine Society clinical practice guideline 2011. Group B patients will receive placebo supplements identical in appearance to the vitamin D supplements.
11366783|NCT02256215|Placebo Comparator|Placebo|
11366784|NCT02256189|Other|Sitagliptin first, then placebo|Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks
11366785|NCT02256189|Other|Placebo first, then sitagliptin|Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks
11366786|NCT02256150|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
11366787|NCT02256150|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).
~All study subjects will receive standard steroid therapies during the study."
11366788|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
11366789|NCT02256124|Experimental|Lamotrigine|"Lamotrigine during 28 consecutive weeks:
~8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily
~18 weeks target-dose phase: 100mg twice daily
~2 weeks decline-phase: 100mg once daily."
11366790|NCT02256124|Placebo Comparator|Placebo|Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.
11366791|NCT02256111|Experimental|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
11366792|NCT02256111|Experimental|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
11366793|NCT02256098|Experimental|ATTUNE™|Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy
11366794|NCT02256098|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
11366795|NCT02256085|Sham Comparator|Sham rTMS|"Daily rTMS with Sham coil
~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil"
11366796|NCT02256085|Experimental|Active rTMS|"Daily rTMS with Active coil
~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
11366797|NCT02256085|Experimental|Open Active rTMS|"Open Label Daily rTMS with Active coil
~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
11366798|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
11366799|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
11366800|NCT02256059||Plate osteosynthesis|Patients with fracture of the lateral clavicle and indication for surgical treatment
11366801|NCT02256046|Experimental|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
11366802|NCT02256033|Experimental|Istradefylline|One 40-mg tablet of istradefylline administered on Day 1.
11366803|NCT02256020|Other|Original lifestyle|Original lifestyle, watching TV 50 minutes, three times a week for 6 months.
11366804|NCT02256020|Experimental|Wheel-chair music aerobic exercise|Wheel-chair music aerobic exercise with 3 times of 50-minute session (10 minutes warm up, 30 minutes exercise and 10 minutes cool down) a week for 6 months.
11366805|NCT02256007|Active Comparator|Standardized Assessments|"Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:
~Line Bisection Test
~Patient Reported Outcomes
~Trial Making A and B
~Usability Questionnaire"
11366806|NCT02256007|Experimental|Videogame Assessments|"Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:
~Line Crossing
~Patient Reported Outcomes
~Trial Making A & B-Asteroid Adventure Game
~Usability Questionnaire"
11366807|NCT02255994|Experimental|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
11366808|NCT02255994|Active Comparator|No MESH|Patients in this arm had subvesical plication without reinforcement.
11366809|NCT02255981|Experimental|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months
~."
11366810|NCT02255968|Experimental|EDP-788|Multiple doses with dose escalation to continue in successive cohorts
11366811|NCT02255968|Placebo Comparator|Placebo|Multiple doses with dose escalation to continue in successive cohorts
11366812|NCT02255955|Experimental|550 mg naproxen sodium and 30mg codeine|Preoperatively patients received oral naproxen sodium codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
11366813|NCT02255955|Active Comparator|300 mg paracetamol and 30 mg codeine|Preoperatively patients received oral paracetamol codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
11366814|NCT02255955|Placebo Comparator|Placebo|Preoperatively patients received oral placebo tablet, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
11366815|NCT02255942|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
11366816|NCT02255929|Experimental|Gamma Knife Radiosurgery|Gamma Knife treatment is conducted in one day and takes approximately 70 to 90 minutes.
11366817|NCT02255916|No Intervention|Controll|No sound-bed intervention
11366818|NCT02255916|Experimental|Music|live sound-bed music intervention
11366819|NCT02255903||Group 1(Control Group):|ultrasound and Doppler examination: of 100 pregnant females with gestational age 37-40 weeks.
11366820|NCT02255903||Group 2 (post date Group)|ultrasound and Doppler examination:will be done for 100 pregnant females with gestational age 41 weeks or more
11366821|NCT02255877|Active Comparator|Zip Surgical Skin Closure|Subjects randomized to receive one knee (left or right) closed with ZipSurgical Skin Closure and the other knee closed with standard staples
11366822|NCT02255877|Active Comparator|Steel Staples|Subjects randomized to receive one knee (left or right) closed with Staples and the other knee closed with ZipSurgical Skin Closure
11366823|NCT02255864|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
11366824|NCT02255851||Treatment Group|TAVR + SENTINEL (Cerebral Protection System)
11366825|NCT02255838|Experimental|Bronchoscope disposable, aScope IV|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
11366866|NCT02255617|Experimental|Fecal Microbiota Transplant|Single arm open label FMT administered at Week 0 by colonoscopy and at Weeks 1-4 by enema
11366905|NCT02255422|Experimental|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
11366906|NCT02255422|Experimental|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
11366826|NCT02255838|Active Comparator|Bronchoscope reusable Storz 8402 2x|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
11366827|NCT02255825|Active Comparator|Control Group|Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.
11366828|NCT02255825|Experimental|Intervention Group|Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.
11366829|NCT02255812|Placebo Comparator|200 mL tap water|Single intragastric instillation of 200 mL tap water via nasogastric tube
11366830|NCT02255812|Active Comparator|2 g citric acid|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
11366831|NCT02255812|Active Comparator|2 g salt|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
11366832|NCT02255812|Active Comparator|0.017 g quinine|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
11366833|NCT02255812|Active Comparator|1 g monosodium glutamate|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
11366834|NCT02255812|Active Comparator|25 g glucose|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
11366835|NCT02255799|Active Comparator|Donepezil|Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.
11366836|NCT02255799|Placebo Comparator|Placebo|Placebo capsules once daily for 70 days.
11366837|NCT02255786|Experimental|ACT Parent Group|Participants will complete a total of five Acceptance and Commitment Therapy - Parent Group Sessions First four are held weekly, last session held one month from 4th session.
11366838|NCT02255786|No Intervention|Treatment as Usual|Treatment as usual-Control
11366839|NCT02255773|Other|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
11366840|NCT02255773|Other|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
11366841|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
11366842|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
11366843|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
11366844|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
11366845|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
11366846|NCT02255747|Active Comparator|anal dilatation|
11366847|NCT02255747|Active Comparator|Oral Lactulose|
11366848|NCT02255734|Active Comparator|Zovirax|
11366849|NCT02255734|Experimental|Virless|
11366850|NCT02255721|Experimental|SHIP Intervention|SHIP is a health behavior change intervention to give parents the knowledge, motivation, and skills necessary to set goals, problem-solve, and improve their child's sleep.
11366851|NCT02255721|Active Comparator|SHIP Control Arm|The active control arm uses the same strategies as the SHIP intervention arm, but for child health topics unrelated to sleep or outcome measures.
11366852|NCT02255708|Other|Healthy group.|Group formed by healthy patients.
11366853|NCT02255708|Other|Group with demyelinating polyneuropathy|Group formed by patients with demyelinating polyneuropathy.
11366854|NCT02255695|No Intervention|Control group|Control group
11366855|NCT02255695|Experimental|School-based exercise program|School-based exercise program
11366856|NCT02255682|Placebo Comparator|Simvastatin and Q10-placebo|Simvastatin 40 mg orally administered daily and Q10-placebo for 8 weeks
11366857|NCT02255682|Active Comparator|Simvastatin and Q10|Simvastatin 40 mg orally administered daily for 8 weeks in combination with Q10 supplementation of 400 mg/daily
11366858|NCT02255669|Active Comparator|partially covered SEMS|Deployment of Partially covered biliary self expandable metal stent
11366859|NCT02255669|Active Comparator|fully covered SEMS|Deployment of Fully covered biliary self expandable metal stent
11366860|NCT02255656|Experimental|GZ402673 alemtuzumab|Intravenous infusion for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course
11366861|NCT02255643|Experimental|-10% of effective PMT|Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
11366862|NCT02255643|Active Comparator|former setting (+/- 0% of PMT)|Patients are set to their original PMT at start of study, Changes in PMT settings
11366863|NCT02255643|Experimental|+10% of effective PMT|Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
11366864|NCT02255630|Experimental|Salbutamol inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
11366865|NCT02255630|Experimental|Placebo inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
11366867|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.
~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
11366868|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.
~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
11366869|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.
~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
11366870|NCT02255591|Experimental|Shamrock|Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
11366871|NCT02255591|Active Comparator|Lumbar Ultrasound Trident|Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.
11366872|NCT02255578|Other|IVF treatment|Fertility, as determined by egg quality parameters, as well as metabolic parameters, will be assessed following Endobarrier treatment in PCOS during IVF treatment.
11366873|NCT02255578|Other|clomiphene citrate treatment|Ovulation rate in response to clomiphen citrate after Endobarrier treatment in PCOS.
11366874|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
11366875|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
11366876|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
11366877|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
11366878|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
11366879|NCT02255526||Healthy Volunteers|Healthy volunteers between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
11366880|NCT02255526||Heart Failure|Heart failure patients between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
11366881|NCT02255513|Experimental|HLD200 (methylphenidate)|Generic name: Methylphenidate hydrochloride (MPH) Dosage form: Capsules (20,40,60,80,100 mg) Frequency: Once per day during the evening Duration: 7 weeks
11366882|NCT02255513|Placebo Comparator|Placebo|Placebo capsules will be filled with microcrystalline cellulose (MCC) beads in place of MPH containing beads found in the HLD200 capsules
11366883|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
11366884|NCT02255487|Experimental|IrriSept System|IrriSept device used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen
11366885|NCT02255487|Active Comparator|Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
11366886|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
11366887|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
11366888|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
11366889|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
11366890|NCT02255448|Other|SV1, SV2|SV1 intervention: stroke volume using transthoracic echo SV2 intervention: stroke volume measured using the esCCO device.
11366891|NCT02255435|Experimental|Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
11366892|NCT02255435|Experimental|Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks
11366893|NCT02255435|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
11366894|NCT02255435|Experimental|Omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks
11366895|NCT02255435|Experimental|Omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks
11366896|NCT02255435|Experimental|Omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks
11366897|NCT02255435|Experimental|Omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks
11366898|NCT02255435|Experimental|Omaveloxolone Capsules 300 mg|omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks
11366899|NCT02255435|Experimental|Omaveloxolone Capsules 150 mg|omaveloxolone (RTA 408) Capsules, 150 mg taken orally once daily for 24 weeks
11366900|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
11366901|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
11366902|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
11366903|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
11367041|NCT02254538|Experimental|BILR 355 BS|escalating doses
11366907|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
11366908|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
11366909|NCT02255383|Other|PERSONA TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
11366910|NCT02255370|Experimental|CURCUMIN|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
11366911|NCT02255370|Placebo Comparator|PLACEBO|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
11366912|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
11366913|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
11366914|NCT02255344||ST-Elevation Myocardial Infarction|Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
11366915|NCT02255344||Non ST Segment Elevation|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
11366916|NCT02255331||Retrieval Analysis|"You qualify for this Retrieval Analysis study if you:
~Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation.
~Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or
~Have a metal-on-polyethylene total hip replacement greater than 1 year old, or
~Have an infected total hip replacement (any surface bearing)
~You do not qualify for this arm of the study if you:
~Have occupational exposure to cobalt or chromium
~Presence of a metal-on-metal (MOM) implant, or a recalled implant
~Have had a prior revision of your total hip
~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
11366917|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:
~Have a total hip replacement with a ceramic component
~Have a metal-on-polyethylene total hip replacement.
~Have your original or revised total hip replacement.
~You do not qualify for this arm of the study if you:
~Have occupational exposure to cobalt or chromium
~Have cemented components.
~Presence of a metal-on-metal (MOM) implant, or a recalled implant
~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
11366918|NCT02255318|Experimental|Taurolock|Patients received Taurolock lock for 3 months administration.
11366919|NCT02255318|Placebo Comparator|Placebo|Patients received placebo lock (physiological serum) for 3 months administration.
11366920|NCT02255305|Experimental|FMT Group (Intervention Arm)|Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
11366921|NCT02255305|Active Comparator|Antimicrobial Group (Control Arm)|Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.
11366922|NCT02255292|Experimental|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study.
11366923|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
11366924|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
11366925|NCT02255266||A|
11366926|NCT02255253|Experimental|Telmisartan|capsule,40mg per day,2 months
11366927|NCT02255253|Experimental|Hydrochlorothiazide|tablet, 25mg per day, 2 months
11366928|NCT02255240|Experimental|Physical activity intervention|This arm will receive the physical activity intervention, which consists of three individual meetings, weekly brief counseling phone calls for 6 weeks, and provision of a video game console with three active video games.
11366929|NCT02255227|Active Comparator|1 dose Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
11366930|NCT02255227|Experimental|2 doses Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
11366931|NCT02255214||Surgical Patient|These are the results from the blood samples taken from the study participants.
11366932|NCT02255201|Active Comparator|Beverage A|Single dose, Pre-Workout Master Performance Blend Dose 1
11366933|NCT02255201|Active Comparator|Beverage B|Single dose, Pre-Workout Master Performance Blend Dose 2
11366934|NCT02255201|Active Comparator|Beverage C|Single dose, Pre-Workout Performance Energy Blend
11366935|NCT02255201|Active Comparator|Beverage D|Single dose, Pre-Workout Energy Blend
11366936|NCT02255201|Placebo Comparator|Beverage E|Single dose, Pre-Workout Placebo
11366937|NCT02255188||Graft type - PCL|PCL - polycaprolactone
11366938|NCT02255188||Graft type - PCL/ gelatin|polycaprolactone/ gelatin/poorly permeable layer;
11366939|NCT02255188||Graft type - PLGA/PCL/gelatin|PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
11366940|NCT02255188||Graft type - nylon 6|
11366941|NCT02255175|Experimental|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
11366942|NCT02255175|Active Comparator|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
11367042|NCT02254538|Placebo Comparator|Placebo|
11366943|NCT02255162|Experimental|Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Participants will receive the following:
~Cytarabine-intravenous, fixed dosage, given 5 times during cycle
~HLA-mismatched stem-cell microtransplantation
~Lenalidomide-administered daily per cycle"
11366944|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
11366945|NCT02255136|Experimental|Individualized homeopathic medicines|Psorinum, Tuberculinum, Medorrhinum, Calcarea carbonica, Natrum sulphuricum etc. as indicated; Rescue medicines, e.g. Aralea racemosa, Arsenicum album, Histamine hydrochloride, House dust, Ipecacuanha, Antimonium tartaricum, Grindelia robusta etc. as indicated; 5 ml dose of indicated homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; administered twice daily for 1 year
11366946|NCT02255136|Placebo Comparator|Intervention placebo|5 ml dose made up of single drop of rectified spirit in 5 ml distilled water, identical in appearance of homeopathic medicine, to be administered twice daily for 1 year
11366947|NCT02255110|Experimental|TH-302 and doxorubicin|
11366948|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
11366949|NCT02255084|Experimental|Group 1|"Group 1 remove self sample kit at gp consulting room or perform pap smear :
~Study coordinators send mail inviting women to remove a kit for vaginal self-sampling at their general practitioner s consulting room.
~Either a pap smear is perform or, at home, women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
11366950|NCT02255084|Experimental|Group 2|"Group 2 perform self sample at home or pap smear :
~Kit for vaginal self-sampling sent at women home. Women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
11366951|NCT02255071|Experimental|Acupressure|Patients will band a acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
11366952|NCT02255071|Sham Comparator|Sham-Acupressure|Patients will band a sham wristband over wrist but no acupressure for seven days.
11366953|NCT02255045|Experimental|Dose 1 of meloxicam in vaginal ring|2.4 g of meloxicam in a vaginal ring
11366954|NCT02255045|Experimental|Dose 2 of meloxicam in vaginal ring|3.0 g of meloxicam in a vaginal ring
11366955|NCT02255045|Active Comparator|Oral non-steroidal anti-inflammatory drug|Diclofenac potassium
11366956|NCT02255045|Placebo Comparator|Placebo vaginal ring and oral pill|Placebo vaginal ring and placebo oral pill
11366957|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
11366958|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
11366959|NCT02255019||IBD, CD, UC|All patients should either have a known IBD diagnose or suspect of having IBD.
11366960|NCT02255006|Experimental|active acupuncture|The participants in this group receive real acupuncture treatment at first. Afterwards crossover study is scheduled to be performed.
11366961|NCT02255006|Sham Comparator|Sham acupuncture|The participants in this group receive sham acupuncture treatment at first. afterwards crossover study is scheduled to be performed
11366962|NCT02255006|Experimental|Euglycon|Glibenclamide (Euglucon, Roche Pharma) is administered 3 hours before FMD measurement.
11366963|NCT02255006|Experimental|Celebrex|Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.
11366964|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
11366965|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
11366966|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
11366967|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
11366968|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
11366969|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
11366970|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
11366971|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
11366972|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:
~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL
~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL
~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
11366973|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:
~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume
~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
11366974|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
11366975|NCT02254980|Experimental|Vitamin-E group|Vitamin-E diffused polyethylene
11366976|NCT02254980|Active Comparator|Control group|Standard polyethylene
11366977|NCT02254967|Experimental|Fidaxomicin Extended Pulsed Regimen (EPFX)|Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
11366978|NCT02254967|Experimental|Vancomycin|Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
11366979|NCT02254954|Experimental|Macitentan in combination with RT & TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
11366980|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
11366981|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
11366982|NCT02254928|Other|Group 1|First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)
11366983|NCT02254928|Other|Group 2|First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)
11366984|NCT02254915|Experimental|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
11366985|NCT02254915|Active Comparator|Bacillus Calmette-Guérin|Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
11366986|NCT02254902|Experimental|Physical Activity|Participants in the Physical Activity intervention arm of the study receive culturally-modified, materials through participation in 12 weekly 1-.5-hour sessions focused on increasing daily step counts and bouts of moderate intensity physical activity. The group sessions include participation in different forms of physical activity as well as group discussions on the barriers and opportunities for increasing physical activity in daily life.
11366987|NCT02254902|No Intervention|Wait List Control|Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
11366988|NCT02254889|Active Comparator|pre-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) before ESD.
11366989|NCT02254889|Placebo Comparator|post-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) after ESD.
11366990|NCT02254876|Active Comparator|Standard physical therapy program|Standard physical therapy program is delivered for four rehabilitation sessions for a period of about 45 minutes each.
11366991|NCT02254876|Experimental|NeuroMuscular Taping (NMT)|"NeuroMuscular Taping is delivered in addiction to the Standard Treatment for four rehabilitation sessions. The sessions were spaced apart about five days to ensure the optimum adhesion of the NMT."
11366992|NCT02254863|Experimental|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
11366993|NCT02254850|Experimental|Mesoglycan|"The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml and inactive ingredients: sodium chloride, chlorocresol, water for injections.
~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg and Inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
~Patients also performed Flow Mediated Dilation (FMD)."
11366994|NCT02254850|Placebo Comparator|Placebo|"The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
~Patients also performed Flow Mediated Dilation (FMD)."
11366995|NCT02254837|Experimental|Zilver PTX|
11366996|NCT02254824|Active Comparator|Normal-dose statin|Lifestyle modification with Normal-dose statin
11366997|NCT02254824|Active Comparator|Lifestyle modification + Xuezhikang|Lifestyle changes with Xuezhikang
11366998|NCT02254824|Active Comparator|Lifestyle modification|Lifestyle modification
11366999|NCT02254811|Experimental|Delivery via capsule|Fecal microbiota transplant is delivered by oral capsules
11367000|NCT02254811|Experimental|Delivery via colonoscopy|Fecal microbiota transplant delivered by colonoscopy
11367001|NCT02254798||Transplanted patients|No intervention Prospective registration of patients receiving an allogeneic hematopoietic stem cell transplant
11367002|NCT02254785|Experimental|Cabazitaxel|
11367003|NCT02254785|Active Comparator|Abiraterone or enzalutamide|
11367004|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
11367005|NCT02254759|Other|IV Midazolam Alone|A single 1 milligram (mg) dose of IV Midazolam on Day 1.
11367006|NCT02254759|Other|Oral Midazolam Alone|A single 5 mg oral dose of midazolam on Day 2.
11367007|NCT02254759|Experimental|RO5186582 Alone|RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.
11367008|NCT02254759|Experimental|RO5186582 Plus IV Midazolam|RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.
11367009|NCT02254759|Experimental|RO5186582 Plus Oral Midazolam|RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.
11367010|NCT02254746|Experimental|Phase I (dose escalation)/ Phase II|"Phase I
~Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.
~Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.
~Phase II
~Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study."
11367011|NCT02254733|Experimental|ACT + CBSST|Implementing Cognitive Behavioral Social Skills Training in an Assertive Community Treatment model
11367012|NCT02254733|Active Comparator|ACT only|Assertive Community Treatment only
11367013|NCT02254720|Experimental|BEA 2180 BR IV|Rising doses
11367014|NCT02254720|Placebo Comparator|Placebo|
11367015|NCT02254720|Experimental|BEA 2180 BR inhalation|
11367016|NCT02254707|Experimental|BILB 1941 ZW|Escalating Doses
11367017|NCT02254707|Placebo Comparator|Placebo|
11367018|NCT02254694|Experimental|high heeled shoes|see detailed description
11367145|NCT02253953|Experimental|D7|
11367019|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
11367020|NCT02254668|Experimental|Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
11367021|NCT02254668|Active Comparator|Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
11367022|NCT02254655|Experimental|Puerarin injection 400 mg|Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
11367023|NCT02254655|Sham Comparator|Control|Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
11367024|NCT02254642|Experimental|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
11367025|NCT02254642|Other|Control patients|Usual surgery assigned to control patients
11367026|NCT02254629|Experimental|laxative-probiotic sequential|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
11367027|NCT02254629|Active Comparator|probiotic|Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
11367028|NCT02254629|Active Comparator|Laxative followed by Probiotic 2 weeks later|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.
11367029|NCT02254616|Experimental|Mirror therapy with tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
11367030|NCT02254616|Active Comparator|Mirror Therapy|The MT only group will receive a 60-minute MT per session followed by a 30-minute functional training. Participant will go through the same protocol as that for the MT+tDCS and MT+sham tDCS groups with no tDCS presented in setting. This group is for evaluating placebo effect of the present of tDCS application.
11367031|NCT02254616|Active Comparator|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training. During the 60-mimute conventional training, interventions will include passive range of movement and muscle tone normalization techniques of the affected arm, and gross motor training (e.g., shoulder ladder activity), fine motor training (e.g., grasping cones), and muscle strength training in a unilateral and bilateral manners. During the 30-minute functional training, the same principles to those in the MT groups will be applied.
11367032|NCT02254616|Active Comparator|Mirror Therapy with sham-tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
11367033|NCT02254603|Other|Acupuncture controls|Acupuncture group will receive 30-minutes treatment three times a week for 3 months.
11367034|NCT02254603|Experimental|acupuncture and yoga exercise|Subject will receive a combination of acupuncture and yoga exercise three times a week for 3 months.
11367035|NCT02254590|Experimental|IEDL|Endoscopic decompression of spinal stenosis
11367036|NCT02254577|Experimental|Endometrin® plus Progesterone in Oil (PIO)|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.
11367037|NCT02254577|Active Comparator|Progesterone in Oil (PIO) Alone|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.
11367038|NCT02254564||Positive Scrapings|Skin scrapings that are positive for scabies
11367039|NCT02254564||Negative Controls|collect negative controls from patients in whom tinea (superficial fungal infection) was clinically suspected. Samples from patients with demodex folliculitis (a mite that is commonly found in oil glands on the face) are also intended to be used as negative controls as well.
11367040|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.
~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.
~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
11367043|NCT02254525|Experimental|800 mg intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.
11367044|NCT02254525|Placebo Comparator|200 ml of saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.
11367045|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
11367046|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
11367047|NCT02254473|Experimental|Wedge Insert|Patients will receive a wedge insert
11367048|NCT02254473|Placebo Comparator|Flat insert|Patients will receive a flat insert
11367049|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
11367050|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
11367051|NCT02254447|Experimental|Sequence ABC|Subjects in this arm will receive single dose of treatment A in period 1, treatment B in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
11367052|NCT02254447|Experimental|Sequence ACB|Subjects in this arm will receive single dose of treatment A in period 1, treatment C in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
11367053|NCT02254447|Experimental|Sequence BAC|Subjects in this arm will receive single dose of treatment B in period 1, treatment A in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
11367054|NCT02254447|Experimental|Sequence BCA|Subjects in this arm will receive single dose of treatment B in period 1, treatment C in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
11367055|NCT02254447|Experimental|Sequence CAB|Subjects in this arm will receive single dose of treatment C in period 1, treatment A in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
11367056|NCT02254447|Experimental|Sequence CBA|Subjects in this arm will receive single dose of treatment C in period 1, treatment B in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
11367057|NCT02254434|Experimental|Eltrombopag 50 mg|Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions
11367058|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
11367059|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
11367060|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
11367061|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
11367062|NCT02254395|Experimental|Deep Brain Stimulation|Stimulation is on.
11367063|NCT02254395|Sham Comparator|Placebo|Sham Stimulation: Stimulation is off.
11367064|NCT02254382|Experimental|Adaptive servo ventilation (ASV)|This group will receive ventilation therapy (AutoSet CS, ASV device)
11367065|NCT02254369|Experimental|Cohort 1- GC021109|single dose, 0.0014 mg/kg GC021109
11367066|NCT02254369|Experimental|Cohort 2- GC021109|single dose, 0.014 mg/kg GC021109
11367067|NCT02254369|Experimental|Cohort 3-GC021109|single dose, 0.14 mg/kg GC021109
11367068|NCT02254369|Experimental|Cohort 4- GC021109|single dose, 1.4 mg/kg GC021109 subjects will receive GC021109 under fasting then under fed conditions separated by a washout of 14 (± 1) days after the first dose.
11367069|NCT02254369|Experimental|Cohort 5- GC021109|single dose, 4.2 mg/kg GC021109
11367070|NCT02254369|Placebo Comparator|Cohort 1- placebo|single dose, 0.0014 mg/kg matching placebo
11367071|NCT02254369|Placebo Comparator|Cohort 2- placebo|single dose, 0.014 mg/kg matching placebo
11367072|NCT02254369|Placebo Comparator|Cohort 3- placebo|single dose, 0.14 mg/kg matching placebo
11367073|NCT02254369|Placebo Comparator|Cohort 4- placebo|single dose, 1.4 mg/kg subjects will receive matching placebo under fasting then under fed conditions separated by a washout of 14 (+/- 1) days after the first dose.
11367074|NCT02254369|Placebo Comparator|Cohort 5- placebo|single dose, 4.2 mg/kg matching placebo
11367075|NCT02254356|Experimental|Zilver|
11367076|NCT02254343|Experimental|proximal robot-assisted therapy|treatment programs will target to shoulder and elbow portions of upper extremity via the InMotion2 robotic system
11367077|NCT02254343|Experimental|distal robot-assisted therapy|the InMotion3 robot system will be used to execute treatment programs focus on wrist movements. It includes three degrees of freedom to allow wrist flexion/extension, abduction/adduction, and pronation/supination.
11367146|NCT02253953|Experimental|D8|
11367147|NCT02253953|Experimental|D10|
11367078|NCT02254343|Active Comparator|individualized intensive therapy|individualized occupational therapy which is dose-match to robot-assisted therapy, based on task-oriented principle.
11367079|NCT02254317|Placebo Comparator|0 mg placebo|Not containing GSE (Placebo)
11367080|NCT02254317|Active Comparator|300 mg GSE|Containing 300 mg of GSE
11367081|NCT02254317|Active Comparator|600 mg GSE|Containing 600 mg of GSE
11367082|NCT02254317|Active Comparator|900 mg GSE|Containing 900 mg of GSE
11367083|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
11367084|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
11367085|NCT02254291|Experimental|Semaglutide 0.5 mg|
11367086|NCT02254291|Experimental|Semaglutide 1.0 mg|
11367087|NCT02254291|Active Comparator|Sitagliptin 100 mg|
11367088|NCT02254278|Experimental|IMRT 6 weeks + cisplatin|IMRT 6 weeks with concurrent cisplatin
11367089|NCT02254278|Experimental|IMRT 5 weeks|IMRT 5 weeks
11367090|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
11367091|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
11367092|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
11367093|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
11367094|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
11367095|NCT02254239|Experimental|Treatment (everolimus, brentuximab vedotin)|"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or QOD on days 1-21. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity. Patients then receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or every other day on days 1-84 for 1 course.
~MAINTENANCE THERAPY: Beginning on course 17, patients receive everolimus PO QD, QOD, twice weekly, or thrice weekly on days 1-84. Courses repeat every 84 days in the absence of disease progression and unacceptable toxicity."
11367096|NCT02254226|Experimental|Salmeterol MDI low|
11367097|NCT02254226|Active Comparator|Salmeterol MDI high|
11367098|NCT02254226|Experimental|Salmeterol Diskus low|
11367099|NCT02254226|Experimental|Salmeterol Diskus high|
11367100|NCT02254200|Experimental|Fatmax group|Group who performed a continuous training program at the intensity eliciting the maximal fat oxidation
11367101|NCT02254200|Experimental|HIIT group|Group who performed a continuous training program with high intensity interval
11367102|NCT02254187|Experimental|Salmeterol capsule via Handihaler - low|
11367103|NCT02254187|Experimental|Salmeterol capsule via Handihaler - high|
11367104|NCT02254187|Active Comparator|Salmeterol via Serevent® Diskus®|
11367105|NCT02254174|Experimental|Tiotropium/Salmeterol|
11367106|NCT02254174|Active Comparator|Serevent® Diskus®|
11367107|NCT02254174|Active Comparator|Spiriva®|
11367108|NCT02254174|Active Comparator|Spiriva® and Serevent® Diskus®|
11367109|NCT02254161|Experimental|BI 1181181 healthy young|Medium doses as tablets q.d. for 10 days
11367110|NCT02254161|Experimental|BI 1181181 healthy elderly|Medium doses as tablets q.d. for 10 days
11367111|NCT02254161|Placebo Comparator|Matching placebo in healthy young|Matching placebo for 10 days
11367112|NCT02254161|Placebo Comparator|Matching placebo in healthy elderly|Matching placebo for 10 days
11367113|NCT02254148|Experimental|Treatment|single dose of CYP 450 substrates and a P-gp substrate + multiple doses of BI 187004
11367114|NCT02254135|Experimental|BEA 2180 BR solution - rising dose|
11367115|NCT02254135|Placebo Comparator|Placebo|
11367116|NCT02254122|Experimental|BEA 2180 BR|
11367117|NCT02254122|Placebo Comparator|Placebo|
11367118|NCT02254109|Experimental|BEA 2180 BR - rising dose|
11367119|NCT02254109|Placebo Comparator|Placebo|
11367120|NCT02254096|Experimental|BIRT 1696 BS|single escalating dose phase
11367121|NCT02254096|Experimental|BIRT 1696 BS + GFJ|single dose grapefruit effect arm
11367122|NCT02254096|Experimental|BIRT 1696 BS + HFM|single dose food effect arm
11367123|NCT02254096|Placebo Comparator|Placebo|
11367124|NCT02254083|Experimental|BIBT 986 BS - low|
11367125|NCT02254083|Experimental|BIBT 986 BS - high|
11367126|NCT02254083|Placebo Comparator|Placebo|
11367127|NCT02254070|Experimental|BIBT 986 BS|
11367128|NCT02254057|Experimental|BIBT 986 BS - single rising dose|
11367129|NCT02254057|Placebo Comparator|Placebo|
11367130|NCT02254044|Experimental|bivatuzumab mertansine|dose escalation
11367131|NCT02254031|Experimental|bivatuzumab mertansine|dose escalation
11367132|NCT02254018|Experimental|bivatuzumab mertansine|single dose escalation
11367133|NCT02254005|Experimental|single dose escalation|
11367134|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab
~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
11367135|NCT02253979|Placebo Comparator|standard double lumen tube|Intervention: Standard double lumen tube
11367136|NCT02253979|Experimental|VivaSight double lumen tube|Intervention: VivaSight double lumen tube
11367137|NCT02253966|Active Comparator|Methylprednisoloneacetate|"Administration of:
~1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery."
11367138|NCT02253966|Placebo Comparator|Sodium chloride|"Administration of:
~5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery."
11367139|NCT02253953|Experimental|D1|
11367140|NCT02253953|Experimental|D2|
11367141|NCT02253953|Experimental|D3|
11367142|NCT02253953|Experimental|D4|
11367143|NCT02253953|Experimental|D5|
11367144|NCT02253953|Experimental|D6|
11367149|NCT02253940|Experimental|Dose Group 1 - low dose|Treatment sequences ABC / CAB / BCA
11367150|NCT02253940|Experimental|Dose Group 2 - high dose|Treatment sequences DE / ED
11367151|NCT02253927|Experimental|BILR 355 (dose escalation) + Ritonavir|escalating dose groups, for food effect evaluation lowest dose group (D1) with high fat meal breakfast after wash-out period
11367152|NCT02253914|Experimental|BILR 355 BS, solution|escalating doses
11367153|NCT02253914|Experimental|BILR 355 BS, tablet|escalating doses
11367154|NCT02253914|Placebo Comparator|Placebo|
11367155|NCT02253901|Experimental|TRUVADA with BILR 355 BS and ritonavir|
11367156|NCT02253901|Active Comparator|BILR 355 BS in combination with ritonavir|
11367157|NCT02253888|Experimental|TPV/r - Room condition|
11367158|NCT02253888|Experimental|TPV/r - Refrigerated conditions|
11367159|NCT02253875|Experimental|TPV + RTV + Omeprazole|
11367160|NCT02253862|Experimental|Sequential treatment|
11367161|NCT02253849|Experimental|CBZ - TPB/r+CBZ|"Days 1-14: carbamazepine (CBZ) twice daily
~Days 15-22: CBZ twice daily plus TPV/r twice daily"
11367162|NCT02253836|Experimental|TAZ/RTV - TPV/RTV - TPV/RTV+TAZ|"Days 1-9: single dose TAZ/RTV
~Days 16-23: morning and evening dose TPV/RTV
~Days 24-32: TPV/RTV + TAZ"
11367163|NCT02253823|Experimental|TPV+RTV - low dose|
11367164|NCT02253823|Experimental|TPV+RTV - high dose|
11367165|NCT02253810|Experimental|Tranexamic Acid|Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.
11367166|NCT02253810|Placebo Comparator|Placebo|Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.
11367167|NCT02253797|Experimental|TPV/r followed by 14C-radiolabeled TPV|Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir
11367168|NCT02253784|Active Comparator|Group I (ISB-P)|Four nerve blocks with perineural injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
11367169|NCT02253784|Active Comparator|Group II (ISB-S)|Four nerve blocks with systemic injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
11367170|NCT02253784|Active Comparator|Group III (ISB-C)|Four nerve blocks without dexamethasone
11367171|NCT02253771|Experimental|shockwave therapy|shockwave therapy
11367172|NCT02253771|Placebo Comparator|Placebo treatment|sham shockwave therapy by an identically looking device without any function
11367173|NCT02253758|Experimental|Sedation|Volunteers will be sedated to Ramsay score 4-5 with propofol, and data will be recorded during arousal
11367174|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
11367175|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
11367176|NCT02253732|Experimental|'3 months exercise intervention program'|all participants will be subjected to 3 months supervised exercise intervention programme
11367177|NCT02253719||HIV positive women|500 HIV women will be recruited from the hospital's current patient base as well as the community
11367178|NCT02253719||HIV negative women|500 HIV women will be recruited from the hospital's current patient base as well as the community
11367179|NCT02253706|Active Comparator|Low flow nasal oxygen supplementation|Low flow nasal oxygen supplementation as per routine standard of care(control arm)
11367180|NCT02253706|Experimental|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35
11367181|NCT02253693||Patients with haemophilia|Adult patients with haemophilia A presenting joint disease.
11367182|NCT02253680|No Intervention|Routine care|Wool and crepe bandage for 24 hours post-operatively
11367183|NCT02253680|Experimental|Compression bandage|Actico, inelastic, short-stretch compression bandage worn 24 hours post-operatively
11367184|NCT02253667|Experimental|HFONC|Patient will use HFONC with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
11367185|NCT02253667|Other|Conventional oxygen|Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
11367186|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
11367187|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
11367188|NCT02253641|Active Comparator|Standard Weight Loss Intervention|"Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program. Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention."
11367189|NCT02253641|Experimental|Stress-Focused Weight Loss Intervention|Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al.. The participants in this arm will receive all of the content that the comparison group receives (just moderately condensed to allow time for additional components) plus a stress-reduction intervention woven into each of the sessions. The stress-reduction content aims to reduce stress by helping participants: (1) identifying and reducing exposure (to the degree possible) of current stressors, (2) change their perceptions of current stressors and (3) use healthier stress-coping techniques (e.g. yoga, meditation, etc.)
11367190|NCT02253628|Experimental|Trial 1|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
11367191|NCT02253628|Experimental|Trial 2|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
11367192|NCT02253628|Experimental|Trial 3|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
11367193|NCT02253628|Experimental|Trial 4|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
11367194|NCT02253615|Active Comparator|Machine resistance training (MRT)|The machine resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
11367195|NCT02253615|Experimental|Elastic resistance training (ERT)|The elastic resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
11367196|NCT02253602|Experimental|Ferumoxytol Dose optimization|"We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg).
~Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once"
11367197|NCT02253602|Experimental|Before Surgery|Twenty patients will be measured directly before surgery. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study. MR parameters will be correlated with pathology data.
11367198|NCT02253602|Experimental|Before Neoadjucant therapy|Ten patients will be measured before start of neoadjuvant chemoradiation. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study. MR parameters will be correlated with pathology data.
11367199|NCT02253589|No Intervention|Waiting list|Participants will assessment only during study, same intervention after posttest
11367200|NCT02253589|Experimental|Intervention|Participants assigned to this arm will receive the modified ASSIST-linked Brief Intervention
11367201|NCT02253576|Experimental|inhaled 7% hypertonic saline|Three consecutive 4ml doses of 7% NaCl solution with salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
11367202|NCT02253576|Active Comparator|inhaled nebulized normal saline|Three consecutive 4ml doses of 0.9 NaCl solution added to salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
11367203|NCT02253563|Experimental|Resistance Training|Group performing resistance training.
11367204|NCT02253563|Experimental|Balance Training|Group performing balance training.
11367205|NCT02253550|Experimental|Cirrhosis|Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
11367206|NCT02253550|Experimental|Non-Cirrhotic|Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
11367207|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
11367208|NCT02253524|Active Comparator|Dimenhydrinate|50 mg Dimenhydrinate with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
11367209|NCT02253524|Active Comparator|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
11367210|NCT02253511|Experimental|Cidan capsule|Patients who undergone operation and TACE were administered 1.35 g cidan capsules (Weida Pharmaceutical Co., Ltd., Beijing, China) three times a day for 3 months.
11367211|NCT02253511|No Intervention|Control group|Patients were only accepted operation and TACE.
11367212|NCT02253498|Experimental|Deep Brain Stimulation|Deep Brain Stimulation is on
11367213|NCT02253498|Sham Comparator|Sham Stimulation|placebo
11367214|NCT02253485||telbivudine treated entire pregnancy|mothers in this group were treated with antiviral therapy during entire pregnancy for hepatitis, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
11367215|NCT02253485||telbivudine treated in late pregnancy|mothers with high serum HBV DNA load were treated with antiviral therapy in late pregnancy, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
11367216|NCT02253485||HBV DNA positive control|infants in this group born to mother with high serum HBV DNA load and receive standard immunoprophylaxis or additional HBIG injection at 1 month after birth for preventing MTCT of HBV.
11367217|NCT02253485||HBV DNA negative control|infants in this group born to a HBsAg positive and serum HBV DNA negative mothers and receive standard immunoprophylaxis for preventing MTCT of HBV
11367220|NCT02253459|Experimental|UTD1 Injection plus capecitabine|"UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.
~Number of Cycles: until progression or unacceptable toxicity develops."
11367221|NCT02253459|Active Comparator|capecitabine|"Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.
~Number of Cycles: until progression or unacceptable toxicity develops."
11367222|NCT02253446|Experimental|Piroksikam|20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
11367223|NCT02253446|Experimental|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
11367224|NCT02253433|Experimental|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
11367225|NCT02253433|Experimental|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
11367226|NCT02253420|Experimental|Copanlisib with and without concomitant Itraconazole (Arm A)|"To evaluate the effect of Itraconazole on the pharmacokinetics of Copanlisib (BAY80-6946) and safety in patients with advanced solid tumor. Cycle 1 of the study will be conducted in 2 parts: Part 1 and part 2:
~Part 1 of Cycle 1: 6 patients will be enrolled and will receive 12 mg of copanlisib on Day 1 and Day 15. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.
~Part 2 of Cycle 1: 20 patients will be enrolled and receive copanlisib doses of either 12 mg, 30 mg or 60 mg on Days 1 and 15 with the same dose administered on both days. Copanlisib dose for Part 2 will be based on safety and copanlisib pharmacokinetics in Part 1. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.
~Cycle 2 and subsequent cycles: All patients will receive copanlisib doses of 60 mg on Days 1, 8 and 15."
11367227|NCT02253420|Experimental|Copanlisib with and without concomitant Rifampin (Arm B)|"To evaluate the effect of Rifampin on the pharmacokinetics of Copanlisib (BAY 80-6946) and safety in patients with advanced solid tumor or non-Hodgkin's lymphoma in Cycle 1. Approximately 30 subjects will receive 60mg of copanlisib on Cycle 1 Day 1 and Cycle 1 Day 15. Rifampin will be administered once a day from Cycle 1 Day 10 to Day 21. Holter monitoring will be performed on Cycle 1 Day -1 and Cycle 1 Day 1 to evaluate the effect of copanlisib on the QT/QTc assessment.
~Cycle 2 and subsequent cycles, all patients will receive copanlisib dose of 60 mg on Days 1, 8 and 15. Holter monitoring will be performed on Cycle 3 Day 1 and Cycle 6 Day 1."
11367228|NCT02253407|Experimental|Disposable syringe jet injector|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
11367229|NCT02253407|Active Comparator|Needle-Syringe|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe
11367230|NCT02253394|Active Comparator|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
11367231|NCT02253394|Placebo Comparator|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
11367232|NCT02253381|Active Comparator|Right lateral decubitus position|Right lateral decubitus position during spinal anesthesia
11367233|NCT02253381|Active Comparator|Left lateral decubitus position|Left lateral decubitus position during spinal anesthesia
11367234|NCT02253368|Active Comparator|Sleep Arm 1|Sleep Arm 1
11367235|NCT02253368|Active Comparator|Sleep Arm 2|Sleep Arm 2
11367236|NCT02253355|Experimental|Deep Brain Stimulation|Stimulation is on
11367237|NCT02253355|Sham Comparator|Placebo|Stimulation is off
11367238|NCT02253342|Experimental|WCK 2349|Subjects will receive oral doses of WCK 2349 administered twice-daily for five days starting on Day 1
11367239|NCT02253329|Active Comparator|Treatment during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
11367240|NCT02253329|Active Comparator|Treatment prior to sleep|Protein ingestion directly after one-legged NMES, directly prior to sleep
11367241|NCT02253316|Experimental|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, & dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 55 mg of lenalidomide will be administered on daily on Days 1-21.
11367242|NCT02253316|Experimental|Maintenance Arm 1: Ixazomib|"Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxcity.
~09/23/2019: Upon review of the interim analysis that suggested inferior progression-free survival in the ixazomib maintenance arm, there will be no further randomizations into the maintenance portion of the trial. All patients will be enrolled into the lenalidomide arm with the exception of those who discontinue lenalidomide during the consolidation phase due to toxicity. Patients who discontinue lenalidomide may be enrolled into the ixazomib arm following approval from the principal investigator."
11367243|NCT02253316|Experimental|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
11367244|NCT02253303|Experimental|Midline incision|The extraction-site incision in laparoscopic colectomy is middline
11367245|NCT02253303|Active Comparator|off-midline incision|The extraction-site incision in laparoscopic colectomy is off-middline
11367246|NCT02253290||Neuromuscular disease|Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
11367280|NCT02253082|Placebo Comparator|Standard fresh frozen plasma|replacement to bleeding
11367281|NCT02253069|Experimental|PHMB-based antiseptic|Applying Prontosan antiseptic solution to tie-over dressings
11367282|NCT02253069|Placebo Comparator|Control|Applying water to tie-over dressings
11367283|NCT02253056|Experimental|Fasting|Intermittent fasting over 8 weeks (one day per week)
11367284|NCT02253056|Active Comparator|Healthy diet|Regular healthy diet according to current German (DGE) guidelines for healthy nutrition.
11367285|NCT02253043|Experimental|Deep Brain Stimulation|DBS Implant and stimulation
11367247|NCT02253277|Experimental|Nilotinib and Ruxolitinib|The study included two strata, which were to be treated in parallel. The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
11367248|NCT02253264|Experimental|Intrathecal rituximab|25 mg of rituximab will be administered intrathecally by direct infusion over 10 minutes at two time points, two weeks apart.
11367249|NCT02253251||Family Registry|For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
11367250|NCT02253251||KRAS-variant BRCA negative Breast Cancer|Women with breast cancer who are BRCA negative will be tested for the KRAS-variant, to determine the associations as well as the prevalence.
11367251|NCT02253251||Double primary breast cancer|Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
11367252|NCT02253251||Autoimmunity|We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
11367253|NCT02253238|Other|Standard of Care Group|Surveys administered in person or by telephone interview and are audio-recorded.
11367254|NCT02253238|Experimental|CYCORE Group + Standard of Care|"Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer).
~Surveys administered in person or by telephone interview and are audio-recorded."
11367255|NCT02253225||Bipolar Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).
11367256|NCT02253225||Major Depressive Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).
11367257|NCT02253225||Healthy Control|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.
11367258|NCT02253212|Experimental|SonoCloud + carboplatin|SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
11367259|NCT02253199|Active Comparator|1-6 months (Group 1)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
11367260|NCT02253199|Active Comparator|7-12 months (Group 2)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
11367261|NCT02253199|Active Comparator|13-24 months (Group 3)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
11367262|NCT02253199|Active Comparator|25-36 months (Group 4)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
11367263|NCT02253186|Experimental|Group I|Patients wear, for 90 days, the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
11367264|NCT02253186|No Intervention|Group II|Patients wear, for 30 days, only a usual custom-made compressive armsleeve during Day-time and no garment during night-time. Then, for the next 60 days, patients wear the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
11367265|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
11367266|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
11367267|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
11367268|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
11367269|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
11367270|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
11367271|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
11367272|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
11367273|NCT02253121|Experimental|Dapagliflozin + sliding scale insulin.|Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
11367274|NCT02253121|Placebo Comparator|Placebo + sliding scale insulin|Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
11367275|NCT02253108|Experimental|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
11367276|NCT02253108|Experimental|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
11367277|NCT02253095|Experimental|Multiple Intervention Arm|single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
11367278|NCT02253095|Placebo Comparator|Placebo|three placebos
11367286|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
11367287|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
11367288|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
11367289|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
11367290|NCT02253017||Children operated on for cataract|
11367291|NCT02253004|Experimental|Active|Cilostazol 200 mg single dose
11367292|NCT02253004|Placebo Comparator|Placebo|Placebo capsule
11367293|NCT02252991|Other|Arm A with physical activity during the treatment|In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
11367294|NCT02252991|Other|Arm B with physical activity after the treatment|In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.
11367295|NCT02252978|Experimental|Arm I (ciprofloxacin)|Patients receive ciprofloxacin PO BID for 2 weeks.
11367296|NCT02252978|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 2 weeks.
11367297|NCT02252965|Active Comparator|Metformin IR|
11367298|NCT02252965|Experimental|Metformin XR|
11367299|NCT02252952|Experimental|Sugar Sweetened Beverages|Any beverage from a range of caffeine free, sugar sweetened drinks. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
11367300|NCT02252952|Experimental|Diet Beverage|Any beverage from a range of caffeine free drinks sweetened with non-caloric sweetener. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
11367301|NCT02252952|Active Comparator|Water|12 oz of water. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
11367302|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
11367303|NCT02252926|Active Comparator|Bupivacaine lozenge|The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
11367304|NCT02252926|Other|Standard treatment|The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.
11367305|NCT02252913|Experimental|Volitinib+docetaxel|"Dose escalation stage: oral administration, Volitinib 600mg/800 QD + docetaxel 75mg/m2.
~If the dose of docetaxel 75mg/m2 is not tolerable, docetaxel dose will be reduced to 60mg/m2 while keep volitinib at 600mg QD as the initial dose. Volitinib dose escalation will be re-started and end at the dose of 800mg QD.
~Dose expansion Stage:Volitinib with docetaxel. Use the prefer dose from escalation stage"
11367306|NCT02252900|Experimental|cerebral MRI during follow-up of IE|All patients will undergo the diagnostic test specific to the study (Magnetic resonance imaging)
11367307|NCT02252887|Experimental|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it < 6 weeks prior to Cycle 1 Day 1.
11367308|NCT02252874|Placebo Comparator|Control Group|Receive leisure activities (e.g. reading, web-surfing, playing chess/ Mahjong) Twenty hours (2-3 sessions per week, 1.5 hours per session)
11367309|NCT02252874|Active Comparator|Intervention Group 1|Receive slow motion Nintendo Wii video games Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
11367310|NCT02252874|Active Comparator|Intervention Group 2|Receive fast motion Nintendo Wii video games (e.g. shooting game) Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
11367311|NCT02252861||Left Atrial Appendage Closure|Patients with atrial fibrillation and counter-indication to anticoagulant therapy referred for percutaneous Left Atrial Appendage Closure in routine care
11367312|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
11367313|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
11367314|NCT02252822|Experimental|The Overcoming Bulimia Online Programme|This treatment incorporates a combination of cognitive-behavioral, motivational and education strategies. The program will be presented in 8 collaborative, multi-media, web based CBT sessions for BN.
11367315|NCT02252809|Active Comparator|adalimumab|adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
11367316|NCT02252809|Active Comparator|methylprednisolone|methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
11367317|NCT02252809|No Intervention|control|no intervention, 7 days before endotoxin inhalation
11367318|NCT02252796|Experimental|Sub-group 1|HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
11367319|NCT02252796|Experimental|Sub-group 2|Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
11367320|NCT02252783|Experimental|BFPET|BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
11367321|NCT02252770|Active Comparator|Nitric oxide supplement arm|During this arm, subjects will receive a lozenge with nitric oxide supplement
11367322|NCT02252770|Placebo Comparator|Placebo Arm|During this arm, subjects will receive placebo
11367323|NCT02252731|Experimental|warfarin and FG-4592|Single dose of warfarin and Multiple doses of FG-4592 in combination with a single dose of warfarin
11367359|NCT02252523|Experimental|DEXMEDETOMIDINE|
11367324|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
11367325|NCT02252705||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
11367326|NCT02252705||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
11367327|NCT02252692|Active Comparator|Enalapril|Renitec® 2 x 5 mg tablets administered at once, to be entirely swallowed with 240 ml water
11367328|NCT02252692|Experimental|Enalapril ODMT|10 x 1mg of Enalapril ODMT, swallowed entirely with 240ml of water
11367329|NCT02252692|Experimental|Enalapril ODMT dispersed|10 x 1mg of Enalapril ODMT, dispersed on tongue
11367330|NCT02252679||Osteoporosis|Postmenopausal women, men > age 50 years, or other patients with well-established causes of secondary osteoporosis (incl. glucocorticoid-induced osteoporosis, transplantation-related osteoporosis, disuse osteoporosis, etc.) N=20 treated with antiresorptive drugs N=10 treated with osteoanabolic drugs (e.g. teriparatide, Forsteo)
11367331|NCT02252679||Calcium malabsorption|N=10 Patients with clinically obvious potential causes of calcium malabsorption (incl. severe vitamin D-deficiency, Scopinaro or other bariatric surgery, exocrine pancreatic insufficiency/steatorrhea, cystic fibrosis, inflammatory bowel disease, celiac disease, anorexia nervosa/eating disorders, malnutrition, etc.), with or without bone pains, muscle weakness and other typical osteomalacia symptoms. Confirmed by 24h urine collection showing calciuria <100 mg/24h.
11367332|NCT02252679||Various disorders|Exploratory, heterogeneous group of calcium-related disorders (incl.hypercalcemia, hypocalcemia, primary/secondary/tertiary hyperparathyroidism, hypoparathyroidism, vitamin D deficiency, X-linked/autosomal dominant hypophosphatemic rickets, familial hypocalciuric hypocalcemia,etc.) N=20
11367333|NCT02252679||Normal control subjects|N=40 Men and women ≤ 40 years recruited from the population
11367334|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
11367335|NCT02252653||Familial Amyloidotic Cardiomyopathy (FAC)|
11367336|NCT02252640|Active Comparator|Group 1|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
11367337|NCT02252640|Active Comparator|Group 2|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
11367338|NCT02252640|Active Comparator|Group 3|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
11367339|NCT02252640|Active Comparator|Group 4|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
11367340|NCT02252640|No Intervention|Group 5|Week 11: Controlled Human Malaria Infection
11367341|NCT02252640|No Intervention|Group 6|Week 31-39: Controlled Human Malaria Infection
11367342|NCT02252627||Group 1|Healthy volunteers
11367343|NCT02252614|Active Comparator|Naproxen sodium codein|Preoperative Naproxen sodium codein administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
11367344|NCT02252614|Experimental|Paracetamol codein|Preoperative paracetamol codein administrered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
11367345|NCT02252614|Placebo Comparator|Placebo tablet|Preoperative placebo tablet administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
11367346|NCT02252601|Experimental|Well patients aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
11367347|NCT02252601|Experimental|Acute exacerbation aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
11367348|NCT02252601|Experimental|Children with CF aged 5-10 years|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
11367349|NCT02252601|Active Comparator|Healthy Control Children age 5-10 years.|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
11367350|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
11367351|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
11367352|NCT02252575|Experimental|Electromagnetic field|Exposure to the elctromagnetic field of an electric motor
11367353|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
11367354|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
11367355|NCT02252549|Active Comparator|A|SPIES+WLI assisted TURB
11367356|NCT02252549|Active Comparator|B|WLI assisted TURB
11367357|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
11367358|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
11367360|NCT02252497|Active Comparator|Tranexamic acid|"1g Intra Venous just before surgery
~Then infusion of 1g of Exacyl over eight hours."
11367361|NCT02252497|Placebo Comparator|Physiologic serum|"1g Intra Venous, just before surgery
~Then infusion of 1g of physiologic serum over eight hours."
11367362|NCT02252484|Experimental|Weight loss intervention Group|Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
11367363|NCT02252484|Active Comparator|Comparison Group|All patients who are unwilling or not ready to engage in a weight loss program will be offered entry into the comparison group arm.
11367364|NCT02252471|Experimental|Choices-Teen Intervention|A three session intervention with two counseling sessions with a master's level therapist and a counseling session with a physician. The counseling with the master's level therapist utilizes a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, smoking and HIV risk behaviors. This part of the intervention (a) provides norms-based-but personalized-feedback; (b) encourages participating in the smoking cessation program; (c) increases motivation to change each of the target behaviors; (d) decreases temptation to engage in risk behaviors; (e) increases confidence to avoid risk behaviors; and (f) develops a personalized, tailored change plan. The physician session provides individualized contraception and HIV risk reduction counseling.
11367365|NCT02252458|Experimental|Fentanyl high dose|Fentanyl 10mcg/kg of bodyweight
11367366|NCT02252458|Active Comparator|Fentanyl low dose|Fentanyl 1mcg/kg of bodyweight
11367367|NCT02252445|Active Comparator|Propofol|Propofol will be administered as the anesthetic maintenance agent.
11367368|NCT02252445|Experimental|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
11367369|NCT02252432|Active Comparator|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
11367370|NCT02252432|Active Comparator|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
11367371|NCT02252432|Experimental|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
11367372|NCT02252419|Active Comparator|Dexamethasone|Dexamethasone will be administered 30 minutes before the anesthetic induction.
11367373|NCT02252419|Experimental|Dexamethasone+ Paracetamol (DP)|Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
11367374|NCT02252406|Experimental|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
11367375|NCT02252406|Placebo Comparator|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
11367376|NCT02252393|Experimental|Arm I (RARC with IUD)|Patients undergo RARC with IUD.
11367377|NCT02252393|Experimental|Arm II (RARC with EUD)|Patients undergo RARC with EUD.
11367378|NCT02252380|Experimental|Transcranial ExAblate System|Transcranial ExAblate System (MRgFUS)
11367379|NCT02252367|Experimental|Tadalafil|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.
11367380|NCT02252367|Placebo Comparator|Placebo|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.
11367381|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
11367382|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
11367383|NCT02252341|Placebo Comparator|placebo|"Dietary Supplement: N-Acetyl-Cysteine Phase 4 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study
~Primary Outcome Measure:
~Hamilton Depression Rating Scale [Time Frame: baseline, 1, 2, 3 months] [Designated as safety issue: Yes]
~Secondary Outcome Measures:
~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]
~Other Pre-specified Outcome Measures:
~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers N-Acetyl-cysteine 1800 mg / day will be taken for 12 weeks versus placebo 12 weeks."
11367384|NCT02252341|Placebo Comparator|N-Acetyl-Cysteine|"Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study
~Official Title: Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder
~Primary Outcome Measure:
~Hamilton Depression Rating Scale [Time Frame: baseline] [Designated as safety issue: Yes]
~Secondary Outcome Measures:
~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]
~Other Pre-specified Outcome Measures:
~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers
~Placebo will be taken for 12 weeks."
11367385|NCT02252328|Experimental|Simvastatine|Group of patients receiving simvastatin 80mg once daily in addition to standard care
11367386|NCT02252328|Placebo Comparator|Placebo|Group of patients receiving placebo once daily in addition to standard care
11367387|NCT02252315|Active Comparator|Written Education|
11367388|NCT02252315|Active Comparator|Verbal Education|
11367389|NCT02252302|Active Comparator|Resting in diesel exhaust following salbutamol inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
11367390|NCT02252302|Placebo Comparator|Resting in diesel exhaust following placebo inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
11367415|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
11367391|NCT02252302|Active Comparator|Cycling in diesel exhaust following salbutamol inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
11367392|NCT02252302|Placebo Comparator|Cycling in diesel exhaust following placebo inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
11367393|NCT02252302|Sham Comparator|Resting in filtered air following salbutamol inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
11367394|NCT02252302|Placebo Comparator|Resting in filtered air following placebo inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
11367395|NCT02252302|Sham Comparator|Cycling in filtered air following salbutamol inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
11367396|NCT02252302|Placebo Comparator|Cycling in filtered air following placebo inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
11367397|NCT02252289||Problematic severe asthmatics|"Approximately 75 Children aged 5 to 17 years with problematic severe asthma (PSA). Two groups of PSA children will be recruited: those who have already been assessed as part of the Difficult Asthma protocol and classified as DA (difficult asthma)/ STRA (severe therapy resistant asthma) (training set) and those newly referred to the protocol (validation set).
~Previous enrolment or new referral to the Royal Brompton Hospital Difficult Asthma Protocol."
11367398|NCT02252289||Control group of moderate asthmatics|A control group of 30 children aged 5 to 17 years with mild to moderate asthma.
11367399|NCT02252276|Experimental|Experimental|performed the same exercises and manual therapy during 4 weeks
11367400|NCT02252276|Active Comparator|Control|performed proprioceptive and strengthening exercises during 4 weeks
11367401|NCT02252263|Experimental|Arm 1: Elotuzumab + Lirilumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Lirilumab every 4 wks Intravenous solution for Up to 2 yrs, depending on response
11367402|NCT02252263|Experimental|Arm 2: Elotuzumab + Urelumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Urelumab every 4 wks Intravenous solution for Up to 26 weeks, depending on response
11367403|NCT02252250|Active Comparator|conventional laparoscopic|conventional laparoscopic total mesentery excision surgery for rectal cancer.
11367404|NCT02252250|Experimental|Transanal hybrid-laparoscopic|Transanal hybrid-laparoscopic total mesentery excision surgery for rectal cancer.
11367405|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
11367406|NCT02252224||T2DM patients treated with Forxiga|Korean patients who are at least 18 years old, diagnosed with type2 diabetes and treated with Forxiga according to the approved lable
11367407|NCT02252211|Experimental|DS-8895a|Patients received infusions with DS-8895a on Days 1, 8, 22, and 36. Infusions on Days 1 and 36 were trace labelled with ^89Zr (^89Zr-Df-DS-8895a). The Day 1 dose was 0.2 mg/kg, followed by subsequent doses calculated based on individual patient body weight and dosing cohort assignment.
11367408|NCT02252198||Investigational|• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
11367409|NCT02252185|Experimental|China made spine fusion system|patents in this arm will be implanted with Johnson&Johnson Medical Suzhou made Spine Fusion System.
11367410|NCT02252185|Active Comparator|Imported spine fusion system|patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .
11367411|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
11367412|NCT02252172|Active Comparator|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
11367413|NCT02252159||Cohort A|"Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:
~Watchful waiting (with or without aspirin)*, or
~Phlebotomy (PHL) alone (with or without aspirin)* - or
~HU alone (without concomitant PHL, with or without aspirin).
~(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)"
11367414|NCT02252159||Cohort B|"Patients with clinically overt PV, with one or more of the following disease characteristics:
~Treatment with HU and PHL in combination or
~Treatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or
~A history of thrombosis (venous or arterial) or
~A history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or
~Presence of documented splenomegaly (clinically assessed by palpation) or
~Presence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)
~Tiredness
~Difficulty sleeping
~Itching
~Muscle aches and/or bone pain
~Night sweats
~Sweats while awake
~Other"
11367416|NCT02252133|Other|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
11367417|NCT02252133|Other|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
11367418|NCT02252120|Active Comparator|Supreme|Supreme LMA
11367419|NCT02252120|Active Comparator|Laryngeal Tube|Laryngeal tube LTSII
11367420|NCT02252107|Experimental|Decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
11367421|NCT02252094|Active Comparator|Conventional lung protective ventilation|Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
11367422|NCT02252094|Experimental|Ultra-protective ventilation|Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
11367423|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
11367424|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
11367425|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
11367426|NCT02252068|Experimental|I-CBT randomized trial|I-CBT in randomized trial.
11367427|NCT02252068|Active Comparator|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
11367428|NCT02252055|Experimental|ATDC Treatment|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation.
~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below :
~Prednidolone :
~D 0: 500 mg IV
~D 1: 125 mg IV
~D 2 to 14: 20.0 mg/d
~Wk 3 to 4: 15.0 mg/d
~Wk 5 to 8: 10.0 mg/d
~Wk 9 to 12: 5.0 mg/d
~Wk 13 to 14: 2.5 mg/d
~Wk 15 to End:Cessation
~MMF (or biologic equiv.):
~D -7 to -2: 500 mg/d (250mg 2x/d)
~D -1 to 14: 2000 mg/d
~Wk 3 to 36: 1000 mg/d
~Wk 37 to 40: 750 mg/d
~Wk 41 to 44: 500 mg/d
~Wk 45 to 48: 250 mg/d
~Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction.
~Tacrolimus :
~≤ 48 h pre-Tx to D 14: 3-12 ng/ml
~Wk 3 to 12: 3-10 ng/ml
~Wk 13 to 36: 3-8 ng/ml
~Wk 37 to End: 3-6 ng/ml"
11367429|NCT02252042|Experimental|Pembroliziumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
11367430|NCT02252042|Active Comparator|Active Comparator|Participants receive methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
11367431|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
11367432|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
11367433|NCT02252003|Experimental|Pain scales testing|
11367434|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
11367435|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
11367436|NCT02251977|Experimental|Adjuvant Chemotherapy plus GM1|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
11367437|NCT02251977|Placebo Comparator|Adjuvant Chemotherapy plus placebo|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4).
11367438|NCT02251964|Other|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
11367439|NCT02251951|Experimental|nab-Paclitaxel|Abraxane
11367440|NCT02251938|Experimental|DE-109 Sirolimus|DE-109 440 μg
11367441|NCT02251925|Experimental|Natural cycle|In natural cycle without hCG, daily monitoring of urinary LH is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of LH surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos.
11367442|NCT02251925|Experimental|Natural cycle + hCG for ovulation induction|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
11367443|NCT02251925|Experimental|Hormonally controlled cycle with GnRH-a|In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
11367553|NCT02251223|Experimental|TPV/r high dose|
11367554|NCT02251210|Experimental|BIIL 284 BS low dose|
11367555|NCT02251210|Experimental|BIIL 284 BS medium dose|
11367556|NCT02251210|Experimental|BIIL 284 BS high dose|
11367444|NCT02251925|Experimental|Hormonally controlled cycle without GnRH-a|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
11367445|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
11367446|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
11367447|NCT02251899|Experimental|Disease-Management intervention|Behavioral: Disease-Management intervention The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
11367448|NCT02251899|No Intervention|No Intervention: Control arm|Control group not receiving any in
11367449|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
11367450|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
11367451|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
11367452|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
11367453|NCT02251873|Experimental|TPV + RTV (low dose)+ ddI|
11367454|NCT02251873|Experimental|TPV+ RTV (high dose)+ ddI|
11367455|NCT02251860||Participants with Rheumatoid Arthritis|Participants with active rheumatoid arthritis who are prescribed tocilizumab treatment according to the marketing authorization by their physician will be followed under routine conditions over an observation period of up to 2 years if baseline and disease characteristics data are available.
11367456|NCT02251847|Active Comparator|R5|Rosuvastatin 5mg
11367457|NCT02251847|Active Comparator|R10|Rosuvastatin 10mg
11367458|NCT02251847|Active Comparator|R20|Rosuvastatin 20mg
11367459|NCT02251847|Experimental|R5/E10|Rosuvastatin 5mg/ezetimibe 10mg
11367460|NCT02251847|Experimental|R10/E10|Rosuvastatin 10mg/ezetimibe 10mg
11367461|NCT02251847|Experimental|R20/E10|Rosuvastatin 20mg/ezetimibe 10mg
11367462|NCT02251834|Experimental|Community Health Worker|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .
11367463|NCT02251834|Other|Usual Care|usual care and health education brochures every 4 months.
11367464|NCT02251821|Experimental|Treatment (ruxolitinib, transplant)|Patients receive a ruxolitinib and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.
11367465|NCT02251795|Experimental|Tipranavir/Ritonavir|500 mg Tipranavir / 200 mg Ritonavir 10 days BID
11367466|NCT02251795|Active Comparator|Darunavir/Ritonavir|600 mg Darunavir /100 mg Ritonavir 10 days BID
11367467|NCT02251795|Active Comparator|Ritonavir|100 mg Ritonavir 10 days BID
11367468|NCT02251782||Epi proColon Group|Subjects assigned to the Epi proColon Group will be offered the Epi proColon test for colorectal cancer screening.
11367469|NCT02251782||FIT Group|Subjects in the FIT Group will be offered a fecal immunochemical test (FIT test) for colorectal cancer screening.
11367470|NCT02251782||Usual Care Group|For the purpose of comparison to usual care, participating health systems will build an anonymized group of patients meeting study eligibility criteria, who do not participate in the study. This group will serve as a passive control and their CRC screening activity will be monitored via Medical Record.
11367471|NCT02251769|Experimental|Sequential administration|
11367472|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 1application|Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
11367473|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 2 applications|Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
11367474|NCT02251756|Experimental|Actinica, 2 mg/cm2, 1 application|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
11367475|NCT02251756|Experimental|Actinica, 2 mg/cm2, 2 applications|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
11367476|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
11367477|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
11367478|NCT02251730|Experimental|Refer for smoking cessation|Refer for smoking cessation
11367479|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
11367480|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
11367481|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
11367482|NCT02251691|Experimental|Advagraf|Take Advagraf once daily
11367483|NCT02251691|Active Comparator|Prograf|Take tacrolimus twice daily
11367484|NCT02251678|Experimental|Elimune capsules|Elimune capsules 2 capsules BID (four total capsules per day)
11367485|NCT02251665||Acute ischemic stroke, acute ICH, TIA|Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
11367486|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
11367487|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
11367557|NCT02251210|Placebo Comparator|Placebo|
11367558|NCT02251197|Experimental|BIII 890 CL|escalating doses
11367559|NCT02251197|Placebo Comparator|Placebo|
11367560|NCT02251184|Experimental|Aggrenox|extended release
11367561|NCT02251184|Active Comparator|dipyridamole+aspirin|immediate release
11367488|NCT02251639|Experimental|Oral Imaging and Cytology|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
11367489|NCT02251626|Experimental|Coenzyme Q10 (ubiquinol)|Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day
11367490|NCT02251626|Placebo Comparator|Placebo for CoQ10 (ubiquinol)|Placebo group will be given placebo only
11367491|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
11367492|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
11367493|NCT02251600|Experimental|Deflazacort|This is an open label and single period study , dosed with 0.9mg/kg Deflazacort.
11367494|NCT02251587|Active Comparator|Standard Weight Management Program|Participants will be given information on diet and exercise. Participants will attend meetings to discuss barriers to exercise and nutrition and ways to solve these problems. Participants will be given healthy snack ideas and planning tools.
11367495|NCT02251587|Experimental|$ensible Weigh Program|Participants will be given information on diet and exercise with an emphasis on food security. Participants will be provided with additional information on community resources such as those for food, transportation, and safe places to exercise. A weekly cooking demonstration will be provided using inexpensive ingredients and common food pantry items.
11367496|NCT02251574|Experimental|Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 1200-1500 calories per day.
11367497|NCT02251574|Experimental|Very Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 520-800 calories per day.
11367498|NCT02251574|Active Comparator|Standard Care|Participants will receive normal care.
11367499|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
11367500|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
11367501|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-
~Oral, daily during each cycle
~fludarabine-administered at standard dosing for up to 6 cycles
~cyclophosphamide-administered at standard dosing for up to 6 cycles
~rituximab-administered at standard dosing for up to 6 cycles"
11367502|NCT02251535|Experimental|test group 1|Retrospective test group 1 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining) with intraoperative high level rollback
11367503|NCT02251535|Experimental|test group 2|Retrospective test group 2 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining)with intraoperative low level rollback
11367504|NCT02251535|Experimental|control group|Control group (n=10, PFC® SIGMA® Knee System, rotatinq platform, cruciate retaininq)
11367505|NCT02251522||ConforMIS iTotal Knee Replacement System|Patients who have had an iTotal knee replacement at least 6 months prior to testing
11367506|NCT02251522||Off-the-Shelf Knee Replacement System|Patients who have had an off-the-shelf knee replacement at least 6 months prior to testing
11367507|NCT02251509|Experimental|Carvedilol|carvedilol BID for 2 weeks
11367508|NCT02251509|Experimental|Metoprolol tartrate|Metoprolol tartrate BID for 2 weeks
11367509|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
11367510|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
11367511|NCT02251483|Other|SBI|Group 1: SBI (N=30) - one packet daily
11367512|NCT02251483|Placebo Comparator|Placebo|Group 2: Placebo (N=30) - one packet daily
11367513|NCT02251470|Experimental|HBE Wii (EG)|Participants receive an introduction of using the Nintendo Wii by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (wii-fit balances games) at home (instruction: min. 3 times a week for each 30 minutes).
11367514|NCT02251470|Active Comparator|HBE Control (CG)|Participants receive an introduction for conventional/traditional balance exercise by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (exercises in standing and walking) at home (instruction: min. 3 times a week for each 30 minutes).
11367515|NCT02251457|Experimental|ranolazine|ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
11367516|NCT02251444|Experimental|outpatient rehabilitation program|whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
11367517|NCT02251444|Active Comparator|physical therapy|prescribed physical therapy
11367518|NCT02251431|Experimental|Exenatide-extended release|Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks
11367519|NCT02251431|Placebo Comparator|Placebo|Matching placebo subcutaneously once per week x 38 weeks
11367520|NCT02251418|Experimental|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
11367521|NCT02251418|No Intervention|Control|Standard care treatment
11367522|NCT02251405|Placebo Comparator|One big bag, no stainless container|No stainless container
11367523|NCT02251405|Active Comparator|One big bag with two stainless containers|Two stainless containers
11367524|NCT02251392|Experimental|Chamomila recutita Gel|Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
11367525|NCT02251392|Experimental|Chamomila recutita Infuse 2,5%|Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
11367526|NCT02251392|Active Comparator|Urea cream based|Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
11367527|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
11367528|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
11367529|NCT02251366|No Intervention|SOC Examination Based Cohort|Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
11367530|NCT02251366|Active Comparator|Physician-Guided Diagnostic|Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
11367531|NCT02251353||lung and/or hepatic metastasis|intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
11367532|NCT02251340|Experimental|Intervention|Families in the intervention group will receive an Eczema Care Plan
11367533|NCT02251340|No Intervention|Control|Families in the control group will not receive an Eczema Care Plan
11367534|NCT02251327||Case detection group|Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
11367535|NCT02251327||Drug resistance risk group|Confirmed pulmonary tuberculosis cases with documented rifampin resistance, who have received anti-tuberculosis drugs for 31 days or less and/or history of prior tuberculosis PLUS ongoing signs and/or cases with symptoms of pulmonary tuberculosis PLUS suspected drug resistance and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
11367536|NCT02251301|Active Comparator|Macronutrient isoenergetic control|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of macro nutrient matched isoenergetic control (whey/casein protein and dextrose/lactose) consumed immediately and 1 h after each training session
11367537|NCT02251301|Experimental|Skim Milk|Participants will also engage in twelve weeks of High intensity interval training with consumption of one serving (250 mL) of fat-free fluid milk immediately and 1 h after each training session
11367538|NCT02251301|Placebo Comparator|Placebo|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of placebo (water) consumed immediately and 1 h after each training session.
11367539|NCT02251288|Experimental|Group 1|12 patients receive Intramuscular (IM) A/H7N9 15 mcg on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of Intranasal (IN) sprayer 10^7 FFU H7 N9 pLAIV on Day 29
11367540|NCT02251288|Experimental|Group 2|12 patients receive A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer10^7 FFU H7 N9 pLAIV on Day 85
11367541|NCT02251288|Experimental|Group 3|12 patients receive S A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer 10^7 FFU H7 N9 pLAIV on Day 169
11367542|NCT02251288|Experimental|Group 4|8 patients receive A/H7N9 15 mcg IM on Day 1, 8 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1
11367543|NCT02251288|Experimental|Group 5|12 patients receive A/H7N9 15 mcg plus MF59 adjuvant on Day 1 and Day 29
11367544|NCT02251275|Experimental|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:
~Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.
~Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.
~Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
11367545|NCT02251262|Experimental|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
11367546|NCT02251249|Experimental|STEMI Group|
11367547|NCT02251249|Other|Stable patient Group|Patient referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI)
11367548|NCT02251236|Other|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
11367549|NCT02251236|Other|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
11367550|NCT02251236|Other|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
11367551|NCT02251223|Experimental|TPV/r low dose|
11367552|NCT02251223|Experimental|TPV/r medium dose|
11367562|NCT02251171|Experimental|TPV/RTV - Rifabutin|"Day 1: single dose Rifabutin
~Days 8-20: morning and evening doses of Tipranavir/Ritonavir
~Day 15: single dose Rifabutin"
11367563|NCT02251158|Experimental|TPV/r with food|Tipranavir/Ritonavir paediatric/oral solution
11367564|NCT02251158|Experimental|TPV/r|Tipranavir/Ritonavir paediatric/oral solution
11367565|NCT02251158|Active Comparator|TPV/r capsules|
11367566|NCT02251145|Experimental|tipranavir/ritonavir low dose|
11367567|NCT02251145|Experimental|tipranavir/ritonavir high dose|
11367568|NCT02251132|Experimental|TPV/RTV Low 1|
11367569|NCT02251132|Experimental|TPV/RTV Low 2|
11367570|NCT02251132|Experimental|TPV/RTV Low 3|
11367571|NCT02251132|Experimental|TPV/RTV Medium 1|
11367572|NCT02251132|Experimental|TPV/RTV Medium 2|
11367573|NCT02251132|Experimental|TPV/RTV High 1|
11367574|NCT02251132|Experimental|TPV/RTV High 2|
11367575|NCT02251132|Experimental|TPV/RTV High 3|
11367576|NCT02251119|Experimental|TPV|"Administration of LOP on days 1, 9 and 22
~Administration of TPV on days 4-9
~Administration of TPV/RTV on days 12-22"
11367577|NCT02251119|Experimental|RTV|"Administration of LOP on days 1, 9 and 22
~Administration of RTV on days 4-9
~Administration of TPV/RTV on days 12-22"
11367578|NCT02251106|No Intervention|-LBP/-Brace|Subjects in this arm did not have back pain nor did they wear brace (asymptomatic controls). Subjects had their spine function measured before and after a two week period.
11367579|NCT02251106|Active Comparator|-LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm did not have back pain but wore a brace for a two week period (asymptomatic intervention). Subjects had their spine function measured before and after a two week period.
11367580|NCT02251106|Experimental|+LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm had back pain and wore a brace for a two week period (symptomatic intervention). Subjects had their spine function measured before and after a two week period.
11367581|NCT02251093|Experimental|Lcr Regenerans|
11367582|NCT02251093|Placebo Comparator|Placebo|
11367583|NCT02251080||Internet-based Survey|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF); and responses to a weekly Internet-based questionnaire of adherence and disease severity.
11367584|NCT02251080||Standard-of-Care|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF);
11367585|NCT02251067|Active Comparator|VPI-2690B low dose|6 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
11367586|NCT02251067|Active Comparator|VPI-2690B medium dose|18 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
11367587|NCT02251067|Placebo Comparator|Placebo|6 or 18 mg Placebo, administered subcutaneously every 2 weeks for 48 weeks
11367588|NCT02251067|Active Comparator|VPI-2690B high dose|48 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
11367589|NCT02251054|Experimental|Avatar group|"Intervention group viewed two avatar coaches: a generic avatar coach (GAC) and a self-avatar, peer mentor (SAP)."
11367590|NCT02251054|Active Comparator|No Avatar group|The control group version (voice only) observed the identical program, including introductions, question asking, narration of animations, delivery of key points, and summary of each section with identical pre-recorded voices without the avatars.
11367591|NCT02251041|Active Comparator|cases|the group receives a combination of drugs
11367592|NCT02251041|Placebo Comparator|controles|the group do not receive a combination of drugs, but a placebo (sodium chloride solution)
11367593|NCT02251028|Active Comparator|Group A|Group A receives value-based cognitive behavior therapy after randomization.
11367594|NCT02251028|Active Comparator|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
11367595|NCT02251015|Active Comparator|therapeutic exercises|13 as control group - The control group got only orientation related to therapeutic exercises.The orientation for therapeutic exercises seek to correctly position the jaw in the resting position. Maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
11367596|NCT02251015|Experimental|occlusal plate group|36 getting occlusal splints - the splinted group was subjects that used occlusal plate under the occlusal stability criteria. The patients also received therapeutic exercises too. The plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
11367597|NCT02251002||Control|no history of TBI or neurologic disorder
11367598|NCT02251002||mTBI|documented past mild to moderate TBI
11367599|NCT02250989||Hyperinsulinemia/Euglycaemia|In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
11367600|NCT02250989||Hyperinsulinemia/Hyperglycemia|In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
11367601|NCT02250989||Hypoinsulinemia/Hyperglycemia group|In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
11367602|NCT02250976|Experimental|Livasupril Cap.160/2mg|"Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
~once a day"
11367603|NCT02250976|Active Comparator|Lipilfen cap.160mg, Livaro tab. 2mg|"Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg
~Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day"
11367604|NCT02250963||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
11367605|NCT02250963||CTCA|Computed tomography coronary angiography is going to perform with a 64-slice system (Brilliance 64, Philips Healthcare, Best, the Netherlands).
11367606|NCT02250950|Experimental|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
11367607|NCT02250950|Sham Comparator|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
11367608|NCT02250937|Experimental|Arm I (busulfan days -13 and -12 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
11367609|NCT02250937|Experimental|Arm II (busulfan days -20 and -13 before PBSCT)|"PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0."
11367610|NCT02250924|Placebo Comparator|Placebo|Subjects will wear a silicone bracelet for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
11367611|NCT02250924|Sham Comparator|Sugar-less Gum|Subjects will chew one stick of sugar-less gum for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
11367612|NCT02250924|Experimental|Caffeinated Gum|Subjects will chew one stick of caffeinated gum (100mg caffeine per stick) for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
11367613|NCT02250911|Experimental|This web-based CCC Workshop|The Care for the Cancer Caregivers (CCC) workshop is composed of six webcasts. The Introductory Webcast is based upon Sessions 1 and 2 of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and provides participants with an introduction to the CCC Workshop, an overview of the different meaning-centered modules (i.e., legacy, choice, creativity, and connectedness), and a discussion about identity and how caregivers' identities have or have not changed since taking on this role.
11367614|NCT02250911|Active Comparator|Waitlist Control|"Participants randomized to the waitlist control arm will be offered what is considered usual care at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop."
11367615|NCT02250898|Experimental|Experimental/Myofascial|The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
11367616|NCT02250898|Active Comparator|Control/Global Relaxation|The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
11367617|NCT02250885|Experimental|Selinexor (KPT-330)|Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.
11367618|NCT02250872|Active Comparator|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
11367619|NCT02250872|Placebo Comparator|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
11367620|NCT02250859|Experimental|FMX101 Minocycline 4% foam|FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
11367621|NCT02250846|Experimental|arm a|EGFR exon 19 mutation with EGFR-TKI
11367622|NCT02250846|Experimental|arm b|EGFR exon 21 mutation with EGFR-TKI
11367623|NCT02250833|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
11367624|NCT02250833|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
11367625|NCT02250820|Experimental|Nasal Dexmedetomidine and oral placebo|If the patient is assigned to the dexmedetomidine arm, they will receive dexmedetomidine through the nose. In order to keep the assignment blinded, the patient will also receive an oral placebo.
11367626|NCT02250820|Experimental|Nasal placebo and oral pentobarbital|If the patient is assigned to the pentobarbital arm, they will receive pentobarbital through the mouth. In order to keep the assignment blinded, the patient will also receive an nasal placebo.
11367627|NCT02250807|Experimental|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
11367628|NCT02250794|Active Comparator|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
11367629|NCT02250794|Experimental|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
11367630|NCT02250781|Experimental|Treatment (Oral ONC201)|Patients receive Oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11367631|NCT02250768|Experimental|GM-CSF|Injected oocytes were cultured in GM-CSF supplemented media until day of transfer
11367632|NCT02250755|Experimental|MRI T1 T2 sequences|comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
11367633|NCT02250742|Experimental|low back pain group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utielized. The needles will be left in situ for 10 minutes.
11367634|NCT02250742|Active Comparator|healthy group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utilized. The needles will be left in situ for 10 minutes.
11367635|NCT02250729|Experimental|cases with NMBA anaphylaxis|Patients who experienced NMBA anaphylaxis during anesthesia
11367636|NCT02250729|Other|controls|Patients who underwent anesthesia with NMBA injection but did not experience anaphylaxis
11367637|NCT02250716|Experimental|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
11367638|NCT02250716|No Intervention|Arm 2|12 month cytology and histology follow-up
11367639|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
11367640|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
11367641|NCT02250690|Experimental|experimental group - tDCS|The tDCS intervention occur at 10 sessions of intervention where electrodes are connected to head specifically in supplementary motor area placed at 2 cm in front of vertex. The clinical stimulator (NeuroConn, Germany) provided the direct current using two silicon-sponge electrodes with a surface area of 35 cm2 (5 × 7cm) embedded in a saline-soaked solution. Immediately after 13 minutes of tDCS application, patient was submitted to gait training three times a week during 4 weeks with visuals cues. The patients were asked to walk along at a 7 meters rubber carpet to at different speed, forward and backward gait, side walk during thirty minutes with three intervals of two minutes. The patient may be at on state of drug administration and the training is applied by another physiotherapist.
11367642|NCT02250690|Sham Comparator|Control group (tDCS sham)|The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
11367643|NCT02250677||Patients with myalgia|Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
11367644|NCT02250677||Patients without myalgia|Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
11367645|NCT02250677||Control group|Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
11367646|NCT02250664|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
11367647|NCT02250664|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
11367648|NCT02250664|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
11367649|NCT02250651|Experimental|Bimatoprost SR Dose A|Study Eye: bimatoprost sustained-release (SR) Dose A administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
11367650|NCT02250651|Experimental|Bimatoprost SR Dose B|Study Eye: bimatoprost SR Dose B administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
11367651|NCT02250651|Sham Comparator|Sham|Both Eyes: sham administered on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.
11367652|NCT02250612|Experimental|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
11367653|NCT02250612|Experimental|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
11367654|NCT02250612|Experimental|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
11367655|NCT02250612|Experimental|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
11367656|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
11367657|NCT02250599|Active Comparator|carboplatin and paclitaxel|carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
11367658|NCT02250599|Experimental|AVASTIN and carboplatin and paclitaxel|AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
11367659|NCT02250586|Experimental|CBT-CSO|"The CBT-CSO program will be based on concepts from cognitive-behavioral therapy and motivational interviewing, and is specifically developed for use with CSOs of treatment refusing problem gamblers. The program resembles the community reinforcement and family training approach that has been successfully used with CSOs of substance abusers.
~The program will be given as guided self-help with guidance given via email and telephone. There are 8 modules, which all contain homework exercises and about 5-10 pages of text."
11367660|NCT02250586|No Intervention|Wait-list|The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options-in their area and web-based-for the problem gambler.
11367661|NCT02250573|Experimental|Replenine®-VF|
11367662|NCT02250560|Experimental|Replenine®-VF|
11367663|NCT02250534|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
11367664|NCT02250534|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
11367665|NCT02250534|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
11367666|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
11367667|NCT02250508|Experimental|Optivate®|
11367668|NCT02250508|Active Comparator|Haemate P®|
11367669|NCT02250495|Experimental|Sympara Therapeutic System|All subjects will wear for the Sympara device for 30 days
11367670|NCT02250482|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
11367671|NCT02250469|Active Comparator|Axium SCS System|Implantation with the Axium Neurostimulator
11367672|NCT02250469|Active Comparator|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
11367673|NCT02250456||Turner syndrome patients and vascular abnormalities|
11367674|NCT02250443|Experimental|BYM338|BYM338 Group
11367675|NCT02250430|Experimental|Topical SB204|Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
11367676|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
11367677|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
11367678|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
11367679|NCT02250391|Experimental|NPB-06|1,500 unit, 5 days continuous-infusion
11367680|NCT02250391|Placebo Comparator|Placebo|0 unit, 5 days continuous-infusion
11367681|NCT02250378|Experimental|Treatment (stereotactic radiosurgery, wedge resection)|Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.
11367682|NCT02250365|Experimental|Continuous, suprasensory ESS|
11367683|NCT02250365|Active Comparator|Intermittent, suprasensory ESS|
11367684|NCT02250352||Cohort I (newly diagnosed, surgery before systemic therapy)|Patients undergo baseline and, if applicable, follow-up core needle biopsies of breast cancer in the breast, regional nodes, and distant metastases. Patients who experience a recurrence or progression after therapy undergo additional core biopsies at the time of recurrence. Clinical and blood specimens will also be gathered.
11367685|NCT02250352||Cohort II (newly diagnosed, systemic therapy before surgery)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients also undergo biopsies at a specific time point following the initiation of standard systemic therapy.
11367686|NCT02250352||Cohort III (patients with suspicious breast mass)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
11367687|NCT02250352||Cohort IV (breast cancer recurrence or progression)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients may also undergo 1-3 extra core biopsies.
11367688|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
11367689|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
11367690|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
11367691|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
11367692|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
11367693|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
11367694|NCT02250313||Case|All patients will have the tissue from their previous negative biopsy tested with the assay. Cases are defined as those subjects who receive the ConfirmMDx assay results.
11367695|NCT02250313||Control|All patients will have the tissue from their previous negative biopsy tested with the assay. Controls are defined as subjects who will be blinded to the ConfirmMDx assay results.
11367696|NCT02250300|Experimental|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
11367805|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
11367697|NCT02250300|Experimental|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
11367698|NCT02250300|Experimental|MLN9708 Phase I|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
11367699|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
11367700|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
11367701|NCT02250261|Experimental|KÄPY group|Workplaces, which are supported to promote employees' ACW.
11367702|NCT02250261|No Intervention|Comparison group|Workplaces, which are not supported to promote employees' ACW but will be offered support to do so after the study.
11367703|NCT02250248|Active Comparator|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
11367704|NCT02250248|Active Comparator|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
11367705|NCT02250235|Experimental|Self-affirmation|In the self-affirmation arm, the patients completed a 10 item questionnaire about their past acts of kindness (self-affirmation) prior to reading the health risk information.
11367706|NCT02250235|No Intervention|Control|Control patients completed 10 matched control questions with no self-affirming properties, prior to reading the health risk information.
11367707|NCT02250222|Experimental|Part 1: LGD-6972 15 mg|15 mg LGD-6972 administered once daily (QD) for 14 days.
11367708|NCT02250222|Placebo Comparator|Part 1: Placebo (Captisol ®)|Placebo administered once daily (QD) for 14 days.
11367709|NCT02250222|Experimental|Part 2: LGD-6972 5 mg|5 mg LGD-6972 administered orally QD for 14 days.
11367710|NCT02250222|Experimental|Part 2: LGD-6972 10 mg|10 mg LGD-6972 administered orally QD for 14 days.
11367711|NCT02250222|Experimental|Part 2: LGD-6972 15 mg|15 mg LGD-6972 administered orally QD for 14 days.
11367712|NCT02250222|Placebo Comparator|Part 2: Placebo (Captisol ®)|Placebo administered orally QD for 14 days.
11367713|NCT02250209|Experimental|Trastuzumab,Capecitabine,Oxaliplatin|"Patients receive eight 3-week cycles of oral capecitabine (800-1000 mg/m2 twice daily on days 1-14 of each cycle) ,intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) plus intravenous Trastuzumab (440mg on day 0 of each cycle).
~Number of cycle:capecitabine and oxaliplatin --8 cycles; Trastuzumab--14-16 cycles."
11367714|NCT02250196|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
11367715|NCT02250196|Active Comparator|SPMC 2|group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
11367716|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
11367717|NCT02250170|Experimental|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
11367718|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
11367719|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
11367720|NCT02250144|Experimental|Morpho-specific foot orthoses|"Morpho-specific thermo-molded foot orthoses are designed according to the patient's morphotype.
~Orthoses are custom-molded from different materials such as BIOFLUX resin, Covercuir MF, EVA300/60, EVA400/70, PE255/55, ABSORB Dur and CAPITON PU."
11367721|NCT02250144|Placebo Comparator|Placebo foot orthoses|The placebo foot orthoses will be made with the same principle of molding and with the same materials as for the experimental group. The only difference is that they involve no active corrective insert element : they will be made without morphotype correction.
11367722|NCT02250131|No Intervention|Control|Routine cardiopulmonary bypass technique. Flow adjusted on BSA and temperature
11367723|NCT02250131|Active Comparator|Goal Directed Perfusion|Perfusion targeted at oxygen delivery
11367724|NCT02250118|Experimental|Bevacizumab|Intrapleural use: range 0.5 - 5 mg/kg
11367725|NCT02250105|Active Comparator|ARI-3037MO|ARI-3037MO 3g bid orally for 12 weeks
11367726|NCT02250105|Placebo Comparator|Placebo|Matching placebo 3g bid orally for 12 weeks
11367727|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
11367728|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
11367729|NCT02250079|Experimental|Polyethilene body bag group|The intervention group infants were provided the same care as control infants, but were dressed with the polyethylene body bag immediately after birth. The bag had an upper opening for the head and a seal at the bottom. The intervention group infants remained in the plastic bag for the first 10 minutes after birth. The same process was done in surgery room in case of cesarean. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process were done in surgery room in case of cesarean
11367806|NCT02249572|Experimental|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
11367807|NCT02249572|No Intervention|Expectation|No active treatment given for vestibular schwannoma
11367730|NCT02250079|Active Comparator|Conventional group|): Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
11367731|NCT02250066|Other|Study group 1|Received high monounsaturated fat diet
11367732|NCT02250066|Other|Study group 2|Received high carbohydrate diet
11367733|NCT02250066|No Intervention|Control Group|Control group was encouraged to follow the Food Guide Pyramid
11367734|NCT02250053|Experimental|exercise|aerobic exercise on soluble intercellular adhesion molecules
11367735|NCT02250040|Active Comparator|Control group|Conventional physiotherapy for stroke.
11367736|NCT02250040|Experimental|Target group|Techniques based on patients' functional level were added.
11367737|NCT02250027|Experimental|experimental A (0.6g/day)|HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days
11367738|NCT02250027|Experimental|experimental B (1.2g/day)|HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days
11367739|NCT02250027|Experimental|experimental C (1.8g/day)|HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days
11367740|NCT02250027|Placebo Comparator|Placebo|placebo: 2 capsules at once, 3 times a day, for 7 days
11367741|NCT02250014|Experimental|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
11367742|NCT02250014|Active Comparator|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
11367743|NCT02250001||Treatment with DCV/ASV|Patients who are beginning to receive the treatment with DCV/ASV under the approved indications, dosage, and administration will be included in this study
11367744|NCT02249988|Experimental|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
11367745|NCT02249988|No Intervention|Group 2 - Control arm|NUCs background therapy only
11367746|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
11367747|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
11367748|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
11367749|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
11367750|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
11367751|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11367752|NCT02249936|Experimental|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
11367753|NCT02249936|Experimental|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
11367754|NCT02249936|Experimental|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
11367755|NCT02249923||Pulmonary Arterial Hypertension|
11367756|NCT02249910|Experimental|Semaglutide|
11367757|NCT02249897|Placebo Comparator|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
11367758|NCT02249897|Active Comparator|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
11367759|NCT02249884|Experimental|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
11367760|NCT02249884|Experimental|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
11367761|NCT02249884|Experimental|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
11367762|NCT02249884|Experimental|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
11367763|NCT02249884|Experimental|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
11367764|NCT02249884|Experimental|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
11367765|NCT02249871|Experimental|Semaglutide|
11367766|NCT02249871|Experimental|Semaglutide + Omeprazole|
11367767|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
11367768|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
11367769|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
11367770|NCT02249832|Experimental|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (>0.8m/sec) functioning.
11367771|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
11367772|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
11367773|NCT02249806||PH target therapy|Patients receiving PH target therapy
11367774|NCT02249793||Study group|Healthy volunteers
11367775|NCT02249780|Experimental|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
11367776|NCT02249780|Active Comparator|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
11367777|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
11367778|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
11367779|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
11367780|NCT02249754|Active Comparator|Routine health education|Routine health education alone
11367781|NCT02249754|Experimental|Nutrition education package|Nutrition education package and routine health education
11367782|NCT02249741|Experimental|Patients with osteoporosis|Treated with Ibandronic acid as per protocol
11367783|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
11367784|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
11367785|NCT02249715|Experimental|rDTMS|
11367786|NCT02249702|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
11367787|NCT02249702|Active Comparator|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
11367788|NCT02249689|Experimental|Definitive 65|The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
11367789|NCT02249689|Active Comparator|Definitive 74|The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
11367790|NCT02249676|Experimental|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .
~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
11367791|NCT02249676|Placebo Comparator|Control group|Patients with progressive and refractory NMO treated with regular methods
11367792|NCT02249663|Experimental|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
11367793|NCT02249663|Active Comparator|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
11367794|NCT02249663|Placebo Comparator|Placebo|Placebo Nasal Spray
11367795|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
11367796|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
11367797|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
11367798|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
11367799|NCT02249611|Experimental|MT and life counseling|To improve physical activity, body composition, physiological parameters and quality of life by using MT (mobile physical activity promotion tool) and lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination will be conducted for 3 months in intervention periods.
11367800|NCT02249611|Active Comparator|Standard care|Lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination based on the booklet of metabolic syndrome prevention which is edited by Health Promotion Administration, Ministry of Health and Welfare in Taiwan only once in this period (3 months).
11367801|NCT02249598|Experimental|Univeristy of Sheffield|lactamica
11367802|NCT02249598|Placebo Comparator|Hallam University|Phosphate Buffered Saline (PBS)
11367803|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
11367804|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
11367911|NCT02248883|Experimental|low TPV/RTV|
11367808|NCT02249559||GK subthalamotomy|Evaluate the safety and efficacy of unilateral GK subthalamotomy for PD in patients deemed poor candidates for DBS.
11367809|NCT02249546|Experimental|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
11367810|NCT02249546|Active Comparator|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
11367811|NCT02249533|Experimental|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).
~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
11367812|NCT02249533|No Intervention|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
11367813|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
11367814|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
11367815|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
11367816|NCT02249507|No Intervention|Control|sited rest for 45 minutes
11367817|NCT02249507|Experimental|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
11367818|NCT02249507|Experimental|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
11367819|NCT02249494|Experimental|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
11367820|NCT02249494|Placebo Comparator|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
11367821|NCT02249481|Active Comparator|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
11367822|NCT02249481|Experimental|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
11367823|NCT02249468||Mild and Moderate Alzheimer's Disease|
11367824|NCT02249468||Cognitively intact healthy people|
11367825|NCT02249455|Experimental|Acapella|Acapella is given to the patients twice daily for 20 min.
11367826|NCT02249455|Experimental|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
11367827|NCT02249455|Active Comparator|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
11367828|NCT02249442|Experimental|Scheme A, mild hepatic subjects|multi-dose
11367829|NCT02249442|Experimental|Scheme B, moderate hepatic subjects|single dose
11367830|NCT02249429|Experimental|bimiralisib (PQR309)|
11367831|NCT02249416|Experimental|TPV/RTV low + ZDV|
11367832|NCT02249416|Experimental|TPV/RTV high + ZDV|
11367833|NCT02249403|Experimental|Talsaclidine, 6 mg tid|
11367834|NCT02249403|Experimental|Talsaclidine, 12 mg tid|
11367835|NCT02249403|Experimental|Talsaclidine, 24 mg tid|
11367836|NCT02249403|Experimental|Talsaclidine, 36 mg tid|
11367837|NCT02249403|Experimental|Talsaclidine, 36 mg bid|
11367838|NCT02249403|Placebo Comparator|Placebo|
11367839|NCT02249390||Anyone|Any individual may complete this survey
11367840|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
11367841|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
11367912|NCT02248883|Experimental|high TPV/RTV|
11367913|NCT02248883|Experimental|Placebo/RTV|
11367842|NCT02249364|Active Comparator|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
11367843|NCT02249364|Experimental|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
11367844|NCT02249351|Experimental|Talsaclidine|
11367845|NCT02249351|Placebo Comparator|Placebo|
11367846|NCT02249338|Experimental|BIIL 284 BS|
11367847|NCT02249338|Placebo Comparator|Placebo|
11367848|NCT02249325|Experimental|Probiotic dietary supplement|Florajen3 oral probiotic (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum) taken daily beginning at 28 weeks gestation.
11367849|NCT02249325|No Intervention|Placebo|Women in the comparison group did not take a placebo.
11367850|NCT02249312|Experimental|BIIIL|
11367851|NCT02249312|Placebo Comparator|Placebo|
11367852|NCT02249299|Active Comparator|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
11367853|NCT02249299|Placebo Comparator|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
11367854|NCT02249286|Experimental|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
11367855|NCT02249286|No Intervention|No intervention|
11367856|NCT02249260|Experimental|Behavioral|Group-based high intensity interval training and lifestyle counseling
11367857|NCT02249247|Experimental|Low dose of BIIL 284 BS|
11367858|NCT02249247|Experimental|Medium dose of BIIL 284 BS|
11367859|NCT02249247|Experimental|High dose of BIIL 284 BS|
11367860|NCT02249247|Placebo Comparator|Placebo|
11367861|NCT02249234|Experimental|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
11367862|NCT02249234|Placebo Comparator|Saline|Saline 10ml of normal saline for a one-time injection
11367863|NCT02249221|Experimental|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
11367864|NCT02249221|Active Comparator|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
11367865|NCT02249208|Active Comparator|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
11367866|NCT02249208|Experimental|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
11367867|NCT02249208|Experimental|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
11367868|NCT02249182|Experimental|12 to < 18 Years Old|"Participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).
~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.
~United Kingdom:
~HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks
~United States/Australia/New Zealand:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
11367869|NCT02249182|Experimental|6 to < 12 Years Old|"Participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).
~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.
~United Kingdom:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks
~United States/Australia/New Zealand:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
11367870|NCT02249182|Experimental|3 to < 6 Years Old|"Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing < 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).
~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.
~United Kingdom:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks
~United States/Australia/New Zealand:
~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks
~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks
~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
11367871|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
11367872|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
11367873|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
11367874|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
11367875|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
11367876|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
11367877|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
11367878|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
11367879|NCT02249130|Experimental|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
11367880|NCT02249117|Experimental|BIWH 3|single escalating dose
11367881|NCT02249117|Placebo Comparator|Placebo|
11367882|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily
~Cetaphil Acne Regimen:
~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application
~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
11367883|NCT02249091|Experimental|Selinexor in combination with cytarabine and idarubicin|"All enrolled patients will be treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m² iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycles is applied idarubicin is only given on day 1 and 3.
~Selinexor will be administered at a dose of 40 mg/m² twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
11367884|NCT02249078|Experimental|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
11367885|NCT02249078|Experimental|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
11367886|NCT02249078|Experimental|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
11367887|NCT02249078|Experimental|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
11367888|NCT02249078|Placebo Comparator|Placebo|Placebo 2-mL vial solution for injection
11367889|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
11367890|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
11367891|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
11367892|NCT02249039|Experimental|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
11367893|NCT02249026|Experimental|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
11367894|NCT02249026|Active Comparator|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
11367895|NCT02249013|Experimental|HIPEC|Neoadjuvant Chemotherapy (NACT) followed by Cytoreductive Surgery (CRS) under a Fast-track recovery strategy plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and thus, Adjuvant Chemotherapy
11367896|NCT02249000|Experimental|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
11367897|NCT02248987||Clozapine|stable patients treated with clozapine
11367898|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
11367899|NCT02248987||Healthy volunteer|healthy controls
11367900|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
11367901|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
11367902|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
11367903|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
11367904|NCT02248948|Placebo Comparator|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
11367905|NCT02248948|Experimental|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
11367906|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
11367907|NCT02248922|Experimental|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
11367908|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
11367909|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
11367910|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
11367914|NCT02248870|Placebo Comparator|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
11367915|NCT02248870|Experimental|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
11367916|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
11367917|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.
~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.
~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
11367918|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
11367919|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
11367920|NCT02248831|Experimental|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
11367921|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
11367922|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
11367923|NCT02248805|Experimental|Does Escalation Arm A|MGD007 treatment once weekly
11367924|NCT02248805|Experimental|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
11367925|NCT02248805|Experimental|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
11367926|NCT02248805|Experimental|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
11367927|NCT02248792|Experimental|Group A|Methotrexate 10mg orally once weekly
11367928|NCT02248792|Active Comparator|Group B|Methotrexate 25mg orally once weekly
11367929|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:
~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.
~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.
~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
11367930|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:
~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.
~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.
~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
11367931|NCT02248766|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
11367932|NCT02248766|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
11367933|NCT02248753|Active Comparator|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
11367934|NCT02248753|Experimental|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
11367935|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).
~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
11367936|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).
~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
11367937|NCT02248727|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
11367938|NCT02248727|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
11367939|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
11367940|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
11367941|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
11367942|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
11367943|NCT02248688|Other|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
11367944|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
11367945|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
11367946|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
11367947|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
11367948|NCT02248649|Experimental|Physical Activity|Structured walking program
11367949|NCT02248649|Active Comparator|Control|Health education attention control
11367950|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
11367951|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
11367952|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
11367953|NCT02248597|Experimental|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2
~TRANSPLANT: Patients undergo stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
11367954|NCT02248584|Experimental|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
11367955|NCT02248584|Placebo Comparator|Placebo|Capsule containing only lactose
11367956|NCT02248571|Experimental|Arm A|"Bevacizumab plus Capecitabine (1st treatment phase) followed by Everolimus plus Exemestane (2nd treatment phase)
~Dosing (treatment cycle: 21days):
~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)
~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet
~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
11367957|NCT02248571|Experimental|Arm B|"Everolimus plus Exemestane (1st treatment phase) followed by Bevacizumab plus Capecitabine (2nd treatment phase)
~Dosing (treatment cycle: 21days):
~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet
~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)
~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
11367958|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
11367959|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
11367960|NCT02248545||Non-celiac Wheat Sensitivity Patients|Consecutive adult patients with irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
11367961|NCT02248545||Celiac Disease Patients|Celiac disease adult patients, sex- and age-matched, diagnosed according to standard criteria, during the same study period, chosen at random and enrolled as first control group.
11367962|NCT02248545||Irritable Bowel Syndrome Patients|"Irritable Bowel Syndrome adult patients, sex- and age-matched, diagnosed according to Rome II criteria, and unrelated to NCWS or other food intolerance, during the same study period, chosen at random and enrolled as second control group."
11367963|NCT02248532|Active Comparator|Group A|Repetitive stem cell administration
11367964|NCT02248532|Active Comparator|Group B|Single stem cell administration
11367965|NCT02248519|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
11367966|NCT02248519|Experimental|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
11367967|NCT02248506|Other|Clotrimazole|Clotrimazole 500 mg
11367968|NCT02248493|Experimental|paracetamol and ketoprofen|"paracetamol 20 mg/kg (1% 2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.
~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
11367969|NCT02248493|Placebo Comparator|placebo and ketoprofen|"0.9% sodium chloride (2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.
~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
11367970|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
11367971|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
11367972|NCT02248467||eugonadal|50 eugonadal subjects
11367973|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
11367974|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
11367975|NCT02248454|Experimental|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
11367976|NCT02248441|Experimental|Daily RIC|Daily ischemic conditioning treatment
11368185|NCT02246972|Experimental|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
11367977|NCT02248428|Experimental|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.
~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.
~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
11367978|NCT02248428|Active Comparator|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.
~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.
~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.
~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
11367979|NCT02248415|Experimental|No pump group|Blood cardioplegia administration without roller pump
11367980|NCT02248415|Other|Pump group|Blood cardioplegia administration with roller pump
11367981|NCT02248402|Experimental|Vax-DC/MM|
11367982|NCT02248389|Experimental|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
11367983|NCT02248376|Experimental|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
11367984|NCT02248376|No Intervention|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
11367985|NCT02248350|Experimental|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
11367986|NCT02248350|Active Comparator|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
11367987|NCT02248337|Active Comparator|4 Liter PEG|Colon preparation for colonoscopy: PEG 4 Liter before endoscopy
11367988|NCT02248337|Experimental|2 Liter PEG plus bisacodil|Colon preparation for colonoscopy: PEG 2 L before endoscopy
11367989|NCT02248311||Patients/Control Group|Observational
11367990|NCT02248311||Patients/Group Control|Observational
11367991|NCT02248298|Experimental|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
11367992|NCT02248298|Active Comparator|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
11367993|NCT02248298|Active Comparator|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
11367994|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
11367995|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
11367996|NCT02248272|Experimental|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
11367997|NCT02248272|Experimental|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
11367998|NCT02248272|Experimental|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
11367999|NCT02248259|Experimental|Reference treatment|Single oral dose of BI 409306
11368000|NCT02248259|Experimental|Test treatment|Single oral dose of BI 409306 and Administration of Itraconazole
11368001|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
11368002|NCT02248233|Experimental|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
11368047|NCT02247830|No Intervention|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
11368003|NCT02248233|Experimental|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.
~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
11368004|NCT02248220||Parkinson's disease patients|
11368005|NCT02248207||Parkinson Disease patients|
11368006|NCT02248194|Experimental|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
11368007|NCT02248194|Active Comparator|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
11368008|NCT02248181||Idiopathic PD patients|
11368009|NCT02248168||Idiopathic Parkinson's disease patients|
11368010|NCT02248155||RLS patients|
11368011|NCT02248142||RLS patients|
11368012|NCT02248129||Hypertensive patients|
11368013|NCT02248116|Experimental|Alzheimer|
11368014|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
11368015|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
11368016|NCT02248090|Experimental|AZD9496|AZD9496 dose escalation and expansion(s)
11368017|NCT02248077|Active Comparator|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
11368018|NCT02248077|Other|Usual and Customary Care (UCC)|Standard of care
11368019|NCT02248064|No Intervention|Fixed flow oxygen|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
11368020|NCT02248064|Experimental|Auto-titrating arm|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
11368021|NCT02248051|Experimental|CXA-10|
11368022|NCT02248038|Active Comparator|open surgery|Conventional procedure
11368023|NCT02248038|Experimental|laparoscopic surgery|Minimum invasive procedure
11368024|NCT02248012|Experimental|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
11368025|NCT02247999||Cohort|HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.
11368026|NCT02247973|Experimental|Mesenchymal stem cells|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
11368027|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
11368028|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
11368029|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
11368030|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
11368031|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
11368032|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
11368033|NCT02247921|Experimental|Rehabilitation|nurse-led caregiver-delivered rehabilitation
11368034|NCT02247921|No Intervention|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
11368035|NCT02247908|Experimental|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
11368036|NCT02247908|Active Comparator|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
11368037|NCT02247895|Sham Comparator|Sham Treatment|Sham stimulation twice daily
11368038|NCT02247895|Active Comparator|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
11368039|NCT02247882|Experimental|Patient Education|Health Education.
11368040|NCT02247882|Active Comparator|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
11368041|NCT02247869|Experimental|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
11368042|NCT02247856|Active Comparator|Control Group|Noninvasive ventilation+ jet nebulizer
11368043|NCT02247856|Experimental|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
11368044|NCT02247843|Experimental|βAS3-FB vector transduced peripheral blood CD34+ cells|This is a single arm study without randomization. All subjects will receive the intervention of BetaAS3 lentiviral vector-modified autologous peripheral blood stem cell transplant.
11368045|NCT02247830|Experimental|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
11368046|NCT02247830|Experimental|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
11368048|NCT02247817|Experimental|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
11368049|NCT02247804|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
11368050|NCT02247804|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
11368051|NCT02247804|Active Comparator|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
11368052|NCT02247791|Active Comparator|Cemented femoral stem|Patient undergoing total hip arthroplasty surgery
11368053|NCT02247791|Active Comparator|Uncemented femoral stem|Patients undergoing total hip arthroplasty
11368054|NCT02247778|Active Comparator|conventional plate osteosynthesis|Standard procedure
11368055|NCT02247778|Active Comparator|mini-incision-type osteosynthesis|mini-incision
11368056|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
11368057|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
11368058|NCT02247752|Other|Inactive carriers|
11368059|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
11368060|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
11368061|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
11368062|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
11368063|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
11368064|NCT02247713||Retrospective cohort|Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
11368065|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
11368066|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
11368067|NCT02247687|Other|Counseling arm|Counseling without antiretroviral treatment modification
11368068|NCT02247687|Active Comparator|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
11368069|NCT02247687|Active Comparator|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm
~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
11368070|NCT02247674|Placebo Comparator|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
11368071|NCT02247674|Experimental|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
11368072|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
11368073|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
11368074|NCT02247648|Experimental|treatment|treatment: tramadol group
11368075|NCT02247648|Placebo Comparator|control|control: placebo group
11368076|NCT02247635|No Intervention|Conventional medical treatment|Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
11368077|NCT02247635|Active Comparator|Healthy lifestyle and adherence|1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
11368078|NCT02247622||Healthy control|
11368079|NCT02247622||IBD|patients with inflammatory bowel disease, study group
11368080|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
11368081|NCT02247609|Experimental|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
11368082|NCT02247596|Placebo Comparator|Placebo|Sugar pill 1g tds for 2 weeks
11368083|NCT02247596|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
11368084|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
11368085|NCT02247570|Experimental|Vestibular Rehabilitation|Vestibular Rehabilitation
11368086|NCT02247557|Experimental|Group A: Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
11368087|NCT02247557|Experimental|Group B: BoNT-A 200 U in Normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
11368088|NCT02247557|Placebo Comparator|Group C: Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
11368122|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368123|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368089|NCT02247544|Experimental|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).
~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
11368090|NCT02247531|Experimental|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
11368091|NCT02247531|Experimental|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
11368092|NCT02247531|Sham Comparator|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
11368093|NCT02247518|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg*1t/day for 5days, Treatment B : Tadarafil 5mg*1t/day and Tamsulosin 0.2mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
11368094|NCT02247518|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
11368095|NCT02247505|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
11368096|NCT02247505|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
11368097|NCT02247492||Orsiro|
11368098|NCT02247479|Experimental|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
11368099|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
11368100|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
11368101|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
11368102|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
11368103|NCT02247453|Experimental|Screening|Healthy heavy smokers aged 50-75 years
11368104|NCT02247440|Experimental|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week
~Ribavirin initial dosing in the morning and in the evening:
~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).
~For genotypes 1, 4, 5 and 6:
~800 mg/day, if bodyweight <65 kg,
~1000 mg/day, if bodyweight between 66-80 kg,
~1200 mg/day, if bodyweight between 81-105 kg,
~1400 mg/day, if bodyweight >105 kg.
~Duration: 48 weeks"
11368105|NCT02247427|Experimental|Off-pace group|Deactivated device group
11368106|NCT02247427|No Intervention|On-Pace group|Ongoing device activity group
11368107|NCT02247414|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
11368108|NCT02247414|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
11368109|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
11368110|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
11368111|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
11368112|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
11368113|NCT02247388|No Intervention|Standard Care|Standard Care
11368114|NCT02247375|Experimental|Low dose of BIIL 284 BS|
11368115|NCT02247375|Experimental|High dose of BIIL 284 BS|
11368116|NCT02247375|Placebo Comparator|Placebo|
11368117|NCT02247362|Experimental|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
11368118|NCT02247362|Experimental|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
11368119|NCT02247362|Experimental|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
11368120|NCT02247362|Placebo Comparator|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
11368121|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose -1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368156|NCT02247154|Experimental|Vigam® Liquid|
11368124|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 3|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368125|NCT02247349|Experimental|Dose Escalation (Monotherapy) Dose 4|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368126|NCT02247349|Experimental|Dose Expansion (Monotherapy)- Cohort A (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368127|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort B (Refractory)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368128|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort C (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368129|NCT02247349|Experimental|Dose Expansion (Monotherapy) Cohort D (Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity
11368130|NCT02247349|Experimental|Dose Escalation (Combination) Dose 1|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
11368131|NCT02247349|Experimental|Dose Escalation (Combination) Dose 2|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
11368132|NCT02247349|Experimental|Dose Expansion (Combination)- (Refractory and Sensitive)|BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days
11368133|NCT02247336|Experimental|Immediate|Patients will complete MeTree at enrollment
11368134|NCT02247336|Active Comparator|Delayed|Patients will complete MeTree 12 months following enrollment
11368135|NCT02247323||premenopausal women|premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
11368136|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
11368137|NCT02247297||Pregnant Women|Healthy pregnant women and women with preeclampsia, HELLP syndrom, amniotic infection syndrome, or preterm premature rupture of membranes
11368138|NCT02247284|Experimental|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
11368139|NCT02247271|Other|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
11368140|NCT02247258|Active Comparator|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
11368141|NCT02247258|Active Comparator|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
11368142|NCT02247245|Placebo Comparator|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
11368143|NCT02247245|Active Comparator|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
11368144|NCT02247245|Experimental|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
11368145|NCT02247232|Placebo Comparator|Placebo|
11368146|NCT02247232|Experimental|Z-100|
11368147|NCT02247219|Experimental|Intervention|'Counselling and education individually and in groups'
11368148|NCT02247219|Other|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
11368149|NCT02247206|Experimental|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
11368150|NCT02247206|No Intervention|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
11368151|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
11368152|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
11368153|NCT02247180|Experimental|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
11368154|NCT02247180|Active Comparator|Cognitive Training|standardized cognitive training in the domesticity
11368155|NCT02247167|Experimental|adenotonsillectomy (AT)|Children with SDB studied before and after before adenotonsillectomy.
11368158|NCT02247128|Active Comparator|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
11368159|NCT02247128|Active Comparator|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
11368160|NCT02247128|Active Comparator|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
11368161|NCT02247128|Active Comparator|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
11368162|NCT02247102|Experimental|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
11368163|NCT02247102|Active Comparator|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
11368164|NCT02247076|Placebo Comparator|Grazing|"Participants will eat meals spread over the course of the day (grazing)."
11368165|NCT02247076|Experimental|Time-restricted feeding (early eating)|Participants will eat meals only in the early part of the day (early lunch and very early dinner).
11368166|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
11368167|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
11368168|NCT02247050|Experimental|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
11368169|NCT02247050|Experimental|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
11368170|NCT02247050|Experimental|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
11368171|NCT02247050|Experimental|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
11368172|NCT02247050|Experimental|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
11368173|NCT02247050|Experimental|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation
~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
11368174|NCT02247037||Triple Negative Breast Cancers|All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
11368175|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
11368176|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
11368177|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
11368178|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
11368179|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
11368180|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
11368181|NCT02246985|Experimental|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
11368182|NCT02246985|Experimental|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
11368183|NCT02246985|Experimental|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
11368184|NCT02246985|Experimental|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
11368186|NCT02246972|Active Comparator|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
11368187|NCT02246959|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive electronic pill bottles for their statin medication but are not enrolled in the sweepstakes.
11368188|NCT02246959|Experimental|Process Arm|Arm 2 will be a Process incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
11368189|NCT02246959|Experimental|Outcome Arm|Arm 3 will be an Outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group may receive incentives if they lower their LDL.
11368190|NCT02246959|Experimental|Process Plus Outcome Arm|Arm 4 will be a process plus outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication and receive additional incentives for lowering their LDL cholesterol.
11368191|NCT02246946|Experimental|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
11368192|NCT02246946|Active Comparator|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.
~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
11368193|NCT02246946|Placebo Comparator|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.
~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
11368194|NCT02246933|Experimental|PUFA Diet|
11368195|NCT02246933|Placebo Comparator|Control Diet|
11368196|NCT02246920|Experimental|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
11368197|NCT02246920|Active Comparator|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
11368198|NCT02246920|Placebo Comparator|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
11368199|NCT02246907|No Intervention|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
11368200|NCT02246907|Other|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
11368201|NCT02246894|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
11368202|NCT02246881|Active Comparator|Current Factor VIII|Optivate® (Human Coagulation Factor VIII)
11368203|NCT02246881|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
11368204|NCT02246868|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
11368205|NCT02246855|Experimental|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
11368206|NCT02246855|Experimental|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
11368207|NCT02246855|Experimental|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
11368208|NCT02246842|Experimental|D-Gam®|D-Gam® (human anti-D immunoglobulin)
11368209|NCT02246842|Active Comparator|Rhophylac®|Human Anti-D Immunoglobulin
11368210|NCT02246829|Other|Aflibercept 2mg Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
11368211|NCT02246816|Experimental|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
11368212|NCT02246803|Active Comparator|CABG+pulmonary vein isolation|CABG+pulmonary vein isolation procedure
11368213|NCT02246803|Active Comparator|Isolated CABG|Isolated CABG procedure
11368214|NCT02246790|Active Comparator|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
11368215|NCT02246790|Active Comparator|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
11368216|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
11368217|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
11368218|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
11368219|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
11368220|NCT02246751|Experimental|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
11368221|NCT02246738||Cohort1|
11368222|NCT02246738||Cohort 2|
11368223|NCT02246738||Cohort 3|
11368224|NCT02246738||Cohort 4|
11368225|NCT02246738||Cohort 5|
11368226|NCT02246738||Cohort 6|
11368227|NCT02246738||Cohort 7|
11368228|NCT02246738||Cohort 8|
11368229|NCT02246738||Cohort 9|
11368230|NCT02246725||Contact with palliative care unit versus contact when needed.|
11368231|NCT02246712|Active Comparator|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G>T in CYP2B6 gene (CYP2B6 genotype).
11368232|NCT02246712|Experimental|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).
~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
11368233|NCT02246712|Experimental|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).
~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
11368234|NCT02246699|Experimental|KiOnutrime®-Cs|The product is presented as a capsule containing chitosan as ingredient supporting the activity.
11368235|NCT02246699|Placebo Comparator|Placebo|Placebo is presented as a capsule containing inactive ingredients.
11368236|NCT02246686|Experimental|STW5-II|Half of study population, assigned randomly
11368237|NCT02246686|Placebo Comparator|Placebo|Half of study population, assigned randomly
11368238|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
11368239|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
11368240|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
11368241|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
11368242|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
11368243|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
11368244|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
11368245|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
11368246|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
11368247|NCT02246634|Experimental|Diffusion Weighted MRI scan|Patients in the study will get a DW-MRI of the liver in addition to their standard treatment imaging prior to their surgery.
11368248|NCT02246621|Experimental|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
11368249|NCT02246621|Placebo Comparator|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
11368250|NCT02246608|Active Comparator|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
11368251|NCT02246608|Experimental|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
11368252|NCT02246595|Active Comparator|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
11368253|NCT02246595|Placebo Comparator|Placebo|dose escalation mimicing i.v. placebo treatment:
11368254|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
11368255|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
11368256|NCT02246556|Active Comparator|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
11368257|NCT02246556|Active Comparator|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
11368258|NCT02246556|Experimental|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
11368259|NCT02246543|Placebo Comparator|Treatment 1 - Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
11368260|NCT02246543|Active Comparator|Treatment 2 - HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
11368261|NCT02246543|Active Comparator|Treatment 3 - LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
11368262|NCT02246543|Active Comparator|Treatment 4 - HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
11368263|NCT02246543|Active Comparator|Treatment 5 - LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
11368264|NCT02246530|Active Comparator|PRP injection into PTRCT|Treatment - PRP injection
11368265|NCT02246530|Active Comparator|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
11368266|NCT02246517|Experimental|N2O&Oxygen|70% N2O & 30% Oxygen by Aspiration for 5 min
11368267|NCT02246517|Placebo Comparator|Oxygen|100% Oxygen by Aspiration for 5 min
11368268|NCT02246504|Experimental|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
11368269|NCT02246491|Other|iPSCs without gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
11368270|NCT02246491|Other|iPSCs with gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
11368271|NCT02246478|Placebo Comparator|Placebo|
11368272|NCT02246478|Active Comparator|TAS-205 low dose|
11368273|NCT02246478|Active Comparator|TAS-205 middle dose|
11368274|NCT02246478|Active Comparator|TAS-205 high dose|
11368275|NCT02246465|Experimental|RXI-109|RXI-109 dosed at the site of the revised hypertrophic scar
11368276|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
11368277|NCT02246439|Placebo Comparator|Placebo|Placebo
11368278|NCT02246426|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
11368279|NCT02246426|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
11368280|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
11368281|NCT02246413|No Intervention|Usual Care|Usual Care.
11368282|NCT02246400|Active Comparator|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
11368283|NCT02246400|Experimental|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
11368284|NCT02246387||Manchester Operation|Manchester Operation: Native tissue repair
11368285|NCT02246374|Experimental|ExAblate Treated Arm|ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
11368286|NCT02246374|Sham Comparator|ExAblate Sham Treated Arm|ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
11368287|NCT02246361|No Intervention|Phase 1 (without PIL)|No particular intervention during consultation for the patient
11368288|NCT02246361|Experimental|Phase 2|Patient Information Leaflet is given to the patient during the consultation
11368289|NCT02246348|Experimental|Doppler ultrasound|
11368290|NCT02246335|Active Comparator|Control group|Hemiarthroplasty
11368291|NCT02246335|Active Comparator|Treatment group|Total hip arthroplasty
11368292|NCT02246322|Experimental|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
11368293|NCT02246322|Experimental|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
11368294|NCT02246309|Experimental|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
11368295|NCT02246309|Active Comparator|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
11368296|NCT02246296|Active Comparator|Standard F75 Milk|F75 with 63% of total energy from carbohydrates, including 10% of energy from lactose (standard F75).
11368297|NCT02246296|Experimental|Modified F75 Milk|F75 milk with 43% of total energy from carbohydrates, without any lactose, and providing the same amount of energy as standard F75 by increased lipid in the form of medium chain triglycerides.
11368298|NCT02246270|Experimental|Intravesical heparin|Recurrent UTI subject receives intravesical heparin once every week for 6 weeks
11368299|NCT02246270|Active Comparator|Placebo|Recurrent UTI subject receives intravesical saline once every week for 6 weeks
11368300|NCT02246257|Other|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.
~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
11368334|NCT02246049|Experimental|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.
~[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
~[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
11368301|NCT02246257|Other|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.
~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
11368302|NCT02246244|Experimental|Escitalopram|10 mg once per day
11368303|NCT02246244|Placebo Comparator|Placebo|
11368304|NCT02246231|Experimental|NF2 who has an auditory implant|
11368305|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
11368306|NCT02246205|Experimental|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
11368307|NCT02246205|Active Comparator|DPC UN|Child reconstruction after pancreaticoduodenectomy
11368308|NCT02246192|Experimental|control group|sinus pilonidal excision and standard cares
11368309|NCT02246192|Experimental|PRGF group|sinus pilonidal excision+ PRGF
11368310|NCT02246179|Experimental|1: AFXL + AHES|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
11368311|NCT02246179|Experimental|2: AFXL + EMLA|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
11368312|NCT02246179|Sham Comparator|3: Sham AFXL + AHES|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will then be applied at this test region on the intact skin at t1. Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
11368313|NCT02246179|Sham Comparator|4: Sham AFXL + EMLA|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will then be applied at this test region on the intact skin at t1. Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
11368314|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
11368315|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
11368316|NCT02246153|Experimental|Laparoscopic gastrectomy|Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11368317|NCT02246153|Active Comparator|Open gastrectomy|Open distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11368318|NCT02246140|Experimental|Cannabis users|Cerebral MRI and MRA
11368319|NCT02246140|Active Comparator|healthy volunteers|Cerebral MRI and MRA
11368320|NCT02246127|Active Comparator|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
11368321|NCT02246127|Experimental|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
11368322|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
11368323|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
11368324|NCT02246101||WTC responders|WTC responders who were enrolled in the WTC-CHEST program.
11368325|NCT02246088|Experimental|MT + NE|A manual therapy (MT) intervention combined with neuroscience education (NE)
11368326|NCT02246088|Active Comparator|MT + E|Manual therapy (MT) intervention plus an educational program based on a traditional patho-anatomical or biomedical model (E)
11368327|NCT02246075|Experimental|EVP-6124, low dose|Low dose, Tablet, Once Daily, Day 1 through Day 168
11368328|NCT02246075|Experimental|EVP-6124, high dose|High dose, Tablet, Once Daily, Day 1 through Day 168
11368329|NCT02246075|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 168
11368330|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
11368331|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
11368332|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
11368333|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
11368335|NCT02246036|Experimental|APD probe|Placement of a duodenal probe during 24 hours.
11368336|NCT02246023|Active Comparator|Fractionated propofol administration|"Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response.
~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy"
11368337|NCT02246023|Experimental|Propofol-TCI|"Flexible bronchoscopy in moderate sedation with TCI propofol perfusor:
~Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation.
~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively."
11368338|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
11368339|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
11368340|NCT02245997|Experimental|patients with high-risk neuroblastoma|Patients undergo external beam radiation therapy using IMRT or proton beam RT twice daily for 5-6 weekdays (10-12 treatments). Patients will be evaluated by physical exams, CT scan or MRI of the primary site, and MIBG at, 6, 12, 18 and 24 months (+/- 6 weeks).
11368341|NCT02245984|Experimental|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
11368342|NCT02245984|Experimental|electronic nursing process|for two weeks students in this group will be implemented electronic nursing process for patients.
11368343|NCT02245971|Active Comparator|Whole precutting group|
11368344|NCT02245971|Active Comparator|Partial precutting group|
11368345|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
11368346|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
11368347|NCT02245945|Experimental|TFV 1% gel|"Participants will be instructed to use TFV 1% vaginal gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.
~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.
~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
11368348|NCT02245945|Placebo Comparator|hydroxyethylcellulose (HEC) placebo gel|"Participants will be instructed to use HEC placebo gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.
~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.
~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
11368349|NCT02245932|Experimental|Resveratrol supplementation|150 mg of resveratrol for 4 weeks (split over two doses of 75 mg/day)
11368350|NCT02245932|Placebo Comparator|Placebo supplementation|Placebo for 4 weeks (split over two doses per day)
11368351|NCT02245919|Experimental|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
11368352|NCT02245906|Placebo Comparator|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
11368353|NCT02245906|Experimental|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
11368354|NCT02245906|Placebo Comparator|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
11368355|NCT02245893|Active Comparator|Screw|"In the SCREW Group (standard surgery technique), surgical treatment will be by closed reduction utilizing intraoperative fluoroscopy to visualize the reduction and percutaneous syndesmosis screw insertion. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.
~'open reduction internal fixation (ORIF)"
11368356|NCT02245893|Active Comparator|Anatomic repair technique (ART)|"In the ART group (study group) surgical treatment will be by open reduction and internal fixation. In order to stabilize the syndesmosis, direct visual anatomic alignment will be conducted and a syndesmotic screw inserted. In addition, fixation of the anterior ligament will be performed with use of a 2.7 to 4.0 mm suture anchor. Repair of the intact portion of the ligament will be made using a modified Mason -Allen repair. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.
~'open reduction internal fixation (ORIF)"
11368357|NCT02245880|Active Comparator|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
11368358|NCT02245880|Active Comparator|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
11368359|NCT02245867|Experimental|Phase Ia|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:
~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks."
11368360|NCT02245867|Experimental|Phase Ib|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:
~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12."
11368361|NCT02245854|Experimental|Colonic polyps|Exacto™
11368362|NCT02245841|Experimental|H.P Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
11368363|NCT02245828|Placebo Comparator|Placebo|Placebo comparator
11368364|NCT02245828|Experimental|QCC374|Single and multiple ascending doses of QCC374
11368365|NCT02245815|Experimental|use probiotics Boucardii|group A will be administered the lactobacillus boucardii probiotic (1x109 colonies forming units (UFC) per day for 3 weeks).
11368366|NCT02245815|Experimental|use probiotics Multi-species|Group B will be administered multi-species probiotic (1x109 colonies forming units (UFC) per day for 3 weeks).
11368367|NCT02245802||Low risk group|CU Prediction model < 3
11368368|NCT02245802||High risk group|CU Prediction model >=3
11368369|NCT02245789|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope. All patients will received propofol and remifentanil anesthesia.
11368370|NCT02245789|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope. All patients will received propofol and remifentanil anesthesia.
11368371|NCT02245776|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
11368372|NCT02245750|No Intervention|Routine Invistigations|ICSI with long luteal phase protocol
11368373|NCT02245750|Experimental|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
11368374|NCT02245737|Experimental|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
11368375|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
11368376|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
11368377|NCT02245724|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
11368378|NCT02245711|Experimental|Stem Cell|
11368379|NCT02245698|Experimental|Stem Cell|Bone marrow mononuclear cells
11368380|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
11368381|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
11368382|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
11368383|NCT02245659|Experimental|CPAP|
11368384|NCT02245659|Other|Nasal dilator strip|Control
11368385|NCT02245646||Control group|No indication for stapedotomy
11368386|NCT02245646||Distortion positive|Subjects after stapedotomy perceiving sound distortions
11368387|NCT02245646||Distortion negative|Subjects after stapedotomy not perceiving sound distortions.
11368388|NCT02245633||vitamin D levels deficient|Diabetic hemodialysis patients with vitamin D levels deficient
11368389|NCT02245633||vitamin D levels sufficient|Diabetic hemodialysis patients with vitamin D levels sufficient
11368390|NCT02245620|Experimental|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
11368391|NCT02245620|Placebo Comparator|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
11368392|NCT02245607|Experimental|Compensatory Cognitive Training|Compensatory Cognitive Training
11368393|NCT02245607|Active Comparator|Recreational Therapy|Recreational Therapy
11368394|NCT02245594||Gl motility and sleep pattern|
11368395|NCT02245581|Active Comparator|SVV-guided fluid management|SVV : Stoke volume variation
11368396|NCT02245581|Active Comparator|CVP-guided fluid management|CVP : Central venous pressure
11368397|NCT02245568|Experimental|LMTM|
11368398|NCT02245555||Patients with benign prostatic hyperplasia|
11368399|NCT02245542||BPH patients|
11368400|NCT02245529||Patients with benign prostatic hyperplasia (BPH)|
11368401|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
11368402|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
11368403|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
11368404|NCT02245490|Experimental|Tamsulosin|
11368405|NCT02245490|Placebo Comparator|Placebo|
11368406|NCT02245477||Obstetric Ultrasoud|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
11368407|NCT02245477||Serum Vascular Endothelial Growth Factor|Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
11368408|NCT02245464||Patients with essential hypertension|
11368409|NCT02245451|Experimental|TPV/r with methadone|
11368410|NCT02245438|Experimental|TPV/RTV low dose|
11368411|NCT02245438|Experimental|TPV/RTV high dose|
11368412|NCT02245425|Active Comparator|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
11368413|NCT02245425|Active Comparator|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
11368414|NCT02245412|Experimental|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
11368415|NCT02245412|Experimental|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
11368416|NCT02245412|Experimental|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
11368417|NCT02245399|Experimental|A canola oil enriched mediterranean diet|Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
11368418|NCT02245399|Active Comparator|A high wheat fiber diet|Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
11368419|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
11368420|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
11368421|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
11368422|NCT02245373||Antidepressants|Naturalistic assignment: Patients whose physician decides to indicate antidepressants.
11368423|NCT02245373||Active Monitoring|Naturalistic assignment: Patients whose physician considers starting an Active Monitoring intervention.
11368424|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
11368425|NCT02245360|Placebo Comparator|Placebo|Placebo
11368426|NCT02245347||Patients with expected MDR TB|
11368427|NCT02245334|Experimental|Povidone-iodine|povidone iodine pill
11368428|NCT02245334|No Intervention|no intervention|no intervention
11368429|NCT02245321|Placebo Comparator|Letter Group- No information|Receive a thank you letter after each blood donation.
11368430|NCT02245321|Experimental|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
11368431|NCT02245321|Placebo Comparator|Ferrous gluconate- 0 mg|Receive pills to take daily that contain no iron (a placebo or inert pill).
11368432|NCT02245321|Experimental|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
11368433|NCT02245321|Experimental|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
11368434|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
11368435|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
11368436|NCT02245295||EBUS-TBNA|EBUS-TBNA for enlarged mediastinal/hilar lymph nodes
11368437|NCT02245269|Experimental|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
11368438|NCT02245256|Placebo Comparator|Normal saline|same infusion rate as experimental group (dexmedetomidine)
11368439|NCT02245256|Experimental|dexmedetomidine|0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.
11368440|NCT02245243|Experimental|Delafloxacin|Single Dose 300 mg IV
11368441|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
11368442|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
11368443|NCT02245217|Experimental|PET/CT Imaging arm|
11368444|NCT02245204|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
11368445|NCT02245191|Experimental|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
11368446|NCT02245191|Experimental|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
11368447|NCT02245191|Experimental|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
11368448|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
11368449|NCT02245165|Experimental|Nitric oxide synthase (NOS) inhibition|After a control period of 4 hours, intervention with L-NMMA (10 mg/kg IV) is done and recording continued for 4 hours.
11368450|NCT02245165|Sham Comparator|Saline|After a control period of 4 hours, intervention with saline is done and recording continued for 4 hours.
11368451|NCT02245152|Experimental|PROMIS intervention|"Small group behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly well-baby visits for children 0-17 months of age
~Caregivers with children 0-17 months of age that attend the well-baby visit will be provided with a monthly dose of LNS (20g/day)"
11368452|NCT02245152|Active Comparator|control|Monthly well-baby visits as prescribed by national policy This arm is the basic comparison arm. Caregivers are invited to frequent the health center once a month for well-baby visits. During these visits necessary vaccinations are administered, child growth and nutrition status is evaluated and preventive counseling on child nutrition and health is provided in large groups of caregivers.
11368453|NCT02245126|Experimental|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)
~3-3-4 mix was administered"
11368454|NCT02245126|Active Comparator|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
11368455|NCT02245113|Experimental|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
11368456|NCT02245113|Experimental|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
11368457|NCT02245113|Experimental|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
11368458|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
11368459|NCT02245087|Experimental|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
11368460|NCT02245087|No Intervention|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
11368461|NCT02245074|Other|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
11368462|NCT02245074|Other|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
11368463|NCT02245074|Other|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
11368464|NCT02245061|Experimental|paired pulses cortical electrical stimulation|
11368465|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
11368466|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
11368467|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
11368468|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
11368469|NCT02245022|Experimental|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
11368470|NCT02245022|Active Comparator|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
11368471|NCT02245009||Pacemaker patients|Patients with pacemaker, presenting for cardioversion.
11368472|NCT02245009||ICD patients|Patients with ICD, presenting for cardioversion.
11368473|NCT02245009||CRT patients|Patients with CRT device, presenting for cardioversion.
11368474|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
11368475|NCT02244996|Placebo Comparator|Placebo|Placebo
11368476|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
11368477|NCT02244970|Experimental|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
11368478|NCT02244970|Active Comparator|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
11368479|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
11368480|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
11368481|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
11368482|NCT02244931|Experimental|Phase 1: Performance evaluation on ergometer|"The 3 devices are experimented in random order to compare them on performance using an ergometer wheelchair:
~Servomatic™ assisting device
~E.Motion© assisting device
~Standard manual Wheelchair"
11368483|NCT02244931|Experimental|Phase 2: Comparison of maneuverability|"The 3 devices are experimented in random order to compare them on maneuverability:
~Servomatic™ assisting device
~E.Motion© assisting device
~Standard manual Wheelchair"
11368484|NCT02244931|Experimental|Phase 3: Comparison of the autonomy|"The 3 devices are experimented in random order to compare them on the autonomy they afford to patients:
~Servomatic™ assisting device
~E.Motion© assisting device
~Standard manual Wheelchair"
11368485|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
11368486|NCT02244918|Experimental|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
11368487|NCT02244905|Experimental|Positive Deviance Intervention Arm|Three hospital wards received Positive Deviance intervention.
11368488|NCT02244905|Other|Control Arm|Three hospital wards randomized to control arm received the Standard-of-Care Infection Control approach.
11368489|NCT02244879|Placebo Comparator|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
11368490|NCT02244879|Experimental|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
11368491|NCT02244879|Experimental|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
11368492|NCT02244866|Active Comparator|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
11368493|NCT02244866|Active Comparator|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
11368494|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
11368495|NCT02244827|Experimental|WCK 2349|Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.
11368496|NCT02244814|Experimental|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
11368497|NCT02244814|Active Comparator|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
11368498|NCT02244801|Other|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.
~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
11368499|NCT02244801|Other|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.
~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
11368500|NCT02244762|Experimental|Mild Renal Impairment|20 mg HC-ER
11368501|NCT02244762|Experimental|Moderate Renal Impairment|20 mg HC-ER
11368502|NCT02244762|Experimental|Severe Renal Impairment|20 mg HC-ER
11368503|NCT02244749||skin specimen|skin specimen
11368504|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
11368505|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
11368506|NCT02244736||Diabetics|Subjects with abnormal OGTT
11368507|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.
~For each patient a lung ultrasound examination will be performed."
11368508|NCT02244710|Experimental|Ticagrelor|180mg initial dose next day 90mg BID
11368509|NCT02244710|Active Comparator|Clopidogrel|600mg po initial dose and 75mg qd starting next day
11368510|NCT02244697||Experimental: laryngeal ultrasound stridor|Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre.
11368511|NCT02244697||Other: laryngeal ultrasound -control|Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx.
11368512|NCT02244684||Pregnant women|
11368513|NCT02244671|Experimental|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
11368514|NCT02244658|Experimental|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
11368515|NCT02244658|No Intervention|control|no thrombopoietic agents
11368516|NCT02244645|Other|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
11368517|NCT02244645|Experimental|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
11368518|NCT02244632|Experimental|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
11368519|NCT02244632|Experimental|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
11368520|NCT02244632|Experimental|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
11368521|NCT02244632|Experimental|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
11368522|NCT02244632|Experimental|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
11368523|NCT02244632|Experimental|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
11368524|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
11368525|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
11368526|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
11368527|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
11368528|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
11368529|NCT02244593|No Intervention|Mammography screening only|"This group will receive their standard of care mammogram only. Participants in this arm will not receive the FAST MRI.
~Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram."
11368530|NCT02244593|Experimental|FAST MRI and mammogram screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram. The intervention is the addition of the FAST Breast MRI.
11368531|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
11368532|NCT02244567|Active Comparator|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
11368533|NCT02244567|Active Comparator|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
11368534|NCT02244567|Active Comparator|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
11368535|NCT02244554|Experimental|enLighten Laser Picosecond Pulse|Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
11368536|NCT02244554|Experimental|enLighten Laser Nanosecond Pulse|Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
11368537|NCT02244541|Experimental|Anavex2-73 oral then the Anavex2-73 intravenous formulation|Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
11368538|NCT02244541|Experimental|Anavex2-73 intravenous then the Anavex2-73 oral formulation|Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
11368539|NCT02244541|Experimental|Anavex2-73 30 mg oral formulation|Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
11368540|NCT02244541|Experimental|Anavex2-73 50 mg oral formulation|Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
11368541|NCT02244528|Experimental|Treatment|sildenafil treatment
11368542|NCT02244515|Placebo Comparator|Group C|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered 10 ml NaCI 0.9%.
11368543|NCT02244515|Experimental|Group D|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
11368544|NCT02244502|Experimental|TTFields in combination with weekly paclitaxel|Patients will be treated continuously with the NovoTTF-100L(O) device, in addition to weekly paclitaxel.
11368545|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine|Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.
11368546|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine+oxaliplatin|Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.
11368547|NCT02244463|Experimental|MLN0128|Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
11368548|NCT02244450|Experimental|Screened patients|SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
11368549|NCT02244450|No Intervention|Control group|SCID children diagnosed without screening by pediatricians local referents DIP
11368550|NCT02244437|Active Comparator|Ibuprofen|Ibuprofen has been shown to prevent AMS from previous studies.
11368551|NCT02244437|Experimental|Acetaminophen|Acetaminophen has not been tested yet in AMS prevention.
11368552|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
11368553|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
11368598|NCT02244112|Experimental|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
11368599|NCT02244099|Experimental|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
11368600|NCT02244086|No Intervention|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
11369102|NCT02240875|Experimental|Group 1c|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
11368554|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
11368555|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
11368556|NCT02244398|Experimental|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
11368557|NCT02244398|Active Comparator|FP services|VHTs in the control arm only provide family planning services.
11368558|NCT02244385||Observation|No intervention
11368559|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
11368560|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
11368561|NCT02244372|Placebo Comparator|Placebo|Placebo
11368562|NCT02244359|Experimental|Training|Online tutorial, decision aid and interactive workshop
11368563|NCT02244359|Other|Usual care|Usual care
11368564|NCT02244346||Benign prostatic hyperplasia patients|
11368565|NCT02244333||Patients with symptomatic BPS|
11368566|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
11368567|NCT02244307||Patients with BPH treated with alpha-andrenergic blockade|
11368568|NCT02244294|Experimental|FLOMAX®|
11368569|NCT02244294|Placebo Comparator|Placebo|
11368570|NCT02244281|Experimental|FLOMAX®|
11368571|NCT02244281|Placebo Comparator|Placebo|
11368572|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
11368573|NCT02244255|Experimental|FLOMAX®|
11368574|NCT02244255|Active Comparator|HYTRIN®|
11368575|NCT02244242|Experimental|Tamsulosin hydrochloride|modified release capsules
11368576|NCT02244229|Experimental|Tamsulosin|
11368577|NCT02244229|Active Comparator|Finasteride|
11368578|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
11368579|NCT02244203|Experimental|Single rising doses of BI 60732|
11368580|NCT02244203|Placebo Comparator|Placebo|
11368581|NCT02244190|Experimental|new Tipranavir + Ritonavir|
11368582|NCT02244190|Active Comparator|current Tipranavir + Ritonavir|
11368583|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
11368584|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
11368585|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.
~Until 11,March, 2015, 59 cases are collected."
11368586|NCT02244164|Active Comparator|Sulfonylurea|Patient will received metformine with sulfonylurea
11368587|NCT02244164|Active Comparator|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
11368588|NCT02244164|Active Comparator|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
11368589|NCT02244151|Experimental|DECAPEPTYL® diario|Group 1: DECAPEPTYL® diario,OPU 24 hours after GnRHa administration.
11368590|NCT02244151|Experimental|Decapeptyl® diaro|Group 2:Decapeptyl® diario OPU 30 hours after GnRHa administration.
11368591|NCT02244151|Experimental|Decapeptyl® diario.|Group 3: Decapeptyl® diario, OPU 40 hours after GnRHa administration.
11368592|NCT02244151|Active Comparator|Decapeptyl® daily|Group 4: Decapeptyl® daily OPU 36 hrs after GnRH administration
11368593|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
11368594|NCT02244125|Other|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:
~The treatment phase:
~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The consolidation phase:
~Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)
~2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The maintenance phase: Until progression or discontinuation for any other reason
~Pomalidomide and Dexamethasone"
11368595|NCT02244125|Other|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:
~The treatment phase:
~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The consolidation phase:
~5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)
~The maintenance phase: Until progression or discontinuation for any oher reason
~Pomalidomide and Dexamethasone"
11368596|NCT02244112|Experimental|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:
~Diet A: Fasted conditions
~Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat
~Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
11368597|NCT02244112|Experimental|Part II: Drug-Drug Interaction (DDI)|"Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4
~Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
11368712|NCT02243306|Experimental|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
11369103|NCT02240875|Experimental|Group 2|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly
11368601|NCT02244086|Experimental|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
11368602|NCT02244073|Experimental|Individualized blood glucose target|Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
11368603|NCT02244073|Active Comparator|Conventional blood glucose target|Maintain blood glucose bellow 10 mmol/l.
11368604|NCT02244060|Experimental|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
11368605|NCT02244060|No Intervention|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
11368606|NCT02244047|Active Comparator|Bifidobacterium breve|Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
11368607|NCT02244047|Active Comparator|Placebo|Placebo in the same powder packages as Bifidobacterium breve
11368608|NCT02244034||1250 patients who had cardiac surgery wit|
11368609|NCT02244021|Experimental|BRENTUXIMAB VEDOTIN|1 arm for all patients
11368610|NCT02244008|Experimental|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
11368611|NCT02244008|Placebo Comparator|manual contact|
11368612|NCT02243995|Experimental|Physical training|
11368613|NCT02243982|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile. Radiopharmaceutical tracer
11368614|NCT02243969|Experimental|flaxseed oil (rich in α-linolenic acid )|
11368615|NCT02243969|Placebo Comparator|high oleic sunflower oil|
11368616|NCT02243956|Experimental|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
11368617|NCT02243956|Placebo Comparator|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
11368618|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
11368619|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
11368620|NCT02243930|Experimental|Cap|Sigmoidoscopy with cap
11368621|NCT02243930|No Intervention|No cap|Sigmoidoscopy without cap
11368622|NCT02243917|Experimental|Dose Escalation Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles; subjects who have completed at least one cycle may optionally participate in a food effect week, wherein CB-5083 will be orally administered once daily, on days 1 and 4, and thereafter return to the original dosing schedule
11368623|NCT02243917|Experimental|Dose Expansion Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles
11368624|NCT02243917|Experimental|Food Effect Stage - CB-5083|CB-5083 will be orally administered once daily, on days 1 and 4 of week 1, cycle 1, and orally administered daily, 4 days on and 3 days off, for the remaining 3 weeks of cycle 1; for subsequent 28 day cycles, CB-5083 will be orally administered daily, 4 days on and 3 days off
11368625|NCT02243904||Lead exposure|
11368626|NCT02243891|Active Comparator|Control|Atrial fibrillation ablation only
11368627|NCT02243891|Experimental|ROX Coupler|Atrial fibrillation ablation with concurrent ROX Coupler insertion
11368628|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.
~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
11368629|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.
~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
11368630|NCT02243865|Experimental|Chordate System S200 + CT100 (active treatment)|
11368631|NCT02243865|Placebo Comparator|Chordate System S200 + CT100 (placebo treatment)|
11368632|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
11368633|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
11368634|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.
~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
11369425|NCT02238730|Active Comparator|Ultrabrief Right Unilateral|Ultrabrief (0.25 ms) Right Unilateral Electroconvulsive Therapy
11368635|NCT02243839|Active Comparator|Thrombolytic therapy|In the first arm, thrombolytic therapy (TT) is performed to the patients with obstructive prosthetic valve thrombosis. The TT regimen depends on the functional status of the patient. In patients with NYHA class III-IV dyspnea low dose, relatively faster TT regimen (25 mg tPA/6 hours) is performed. In patients with NYHA class I-II dyspnea TT with low dose and ultra-slow infusion of tPA (25 mg tPA/25 hours) is performed. During TT, patients are followed up with transesophageal echocardiography in every 24 hours.
11368636|NCT02243839|Active Comparator|Surgery|In the second arm, redo valve surgery is performed for obstructive valve thrombosis. Intraoperative and postoperative results are recorded
11368637|NCT02243826|Experimental|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
11368638|NCT02243826|Other|compressed air|The second group will inhale compressed air during the same period of time
11368639|NCT02243813|Experimental|Delayed Participation|Participants will begin the psilocybin intervention 6 months after study enrollment.
11368640|NCT02243813|Experimental|Immediate Participation|Participants will begin psilocybin intervention immediately after study enrollment.
11368641|NCT02243800|Experimental|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
11368642|NCT02243800|Placebo Comparator|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
11368643|NCT02243787|Experimental|COVA322|single i.v. infusion
11368644|NCT02243787|Placebo Comparator|Placebo|single i.v. infusion
11368645|NCT02243774|No Intervention|No letter|Individuals randomized to the control group who will not receive any of the four letters
11368646|NCT02243774|Experimental|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
11368647|NCT02243774|Experimental|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
11368648|NCT02243774|Experimental|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
11368649|NCT02243774|Experimental|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
11368650|NCT02243761|Experimental|DBT Based Skills Groups for Families|Family members of youth with concurrent disorder participate in a 12-week DBT based skills group led by therapists and/or peer facilitators.
11368651|NCT02243748|Active Comparator|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
11368652|NCT02243748|Experimental|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
11368653|NCT02243735|Active Comparator|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
11368654|NCT02243735|Active Comparator|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
11368655|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
11368656|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
11368657|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
11368658|NCT02243683|Experimental|Cohort A|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
11368659|NCT02243683|Experimental|Cohort B|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
11368660|NCT02243670|Experimental|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
11368661|NCT02243657|Placebo Comparator|1: Placebo dose level|
11368662|NCT02243657|Experimental|2: ASP3652 lowest dose level twice daily|
11368663|NCT02243657|Experimental|3:ASP3652 low dose level twice daily|
11368664|NCT02243657|Experimental|4: ASP3652 medium dose level twice daily|
11368665|NCT02243657|Experimental|5: ASP3652 high dose level twice daily|
11368666|NCT02243657|Experimental|6: ASP3652 highest dose level once daily|
11368667|NCT02243644|Active Comparator|Group A|7 days of albendazole 15 mg/kg/day
11368668|NCT02243644|Active Comparator|Group B|28 days of albendazole 15 mg/kg/day
11368669|NCT02243631|Experimental|Probenecid|These patients will receive 5 days of probenecid.
11368670|NCT02243631|No Intervention|No intervention|These patients will receive no intervention.
11368671|NCT02243618|Active Comparator|Rebamipide group|
11368672|NCT02243618|Active Comparator|Polaprezinc group|
11368673|NCT02243605|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11368713|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
11370110|NCT02233868|Experimental|Phase I|PET scan with [11C] PBR28 followed by PET scan with FDG and MRI.
11368674|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
11368675|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
11368676|NCT02243566||Essential hypertension|
11368677|NCT02243553|Experimental|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
11368678|NCT02243553|Experimental|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
11368679|NCT02243553|Experimental|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
11368680|NCT02243553|Experimental|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
11368681|NCT02243527|Experimental|Inspiratory Muscle Training|
11368682|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
11368683|NCT02243514||Resistant hypertension|
11368684|NCT02243514||Essential hypertension|
11368685|NCT02243514||Chronic heart failure|
11368686|NCT02243514||Control|
11368687|NCT02243501|Experimental|Intervention Group|The Intervention Group receives access to the BNBD intervention, and can access alternative resources while enrolled in the study. The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
11368688|NCT02243501|No Intervention|Usual Care Group|The Usual Care Group will receive no treatment until after the 8 month follow-up assessment. The Usual Care Group can access alternative resources and additional programs and services while enrolled in the study.
11368689|NCT02243488|Experimental|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
11368690|NCT02243488|Experimental|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
11368691|NCT02243462|Other|No pre-op warming|No pre-warming in bay before surgery.
11368692|NCT02243462|Active Comparator|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
11368693|NCT02243449|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
11368694|NCT02243449|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
11368695|NCT02243436|Experimental|BV-ESHAP|"- 3 cycles every 21 days:
~Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)
~Etoposide 40 mg/m2/day, on days 1 to 4
~Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4
~Cisplatin 25 mg/m2/day, on days 1 to 4
~Ara C (cytarabine) 2 g/m2, on day 5
~- A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.
~- Autologous peripheral blood stem cell transplant
~- A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
11368696|NCT02243423|Experimental|SUPINE group|The surgical table will remain horizontal after intrathecal (spinal) anesthesia injection for cesarean section. Choosing to position the patient supine is the intervention.
11368697|NCT02243423|Active Comparator|TILT group|The surgical table will be turned to 15° of left lateral tilt after patients are laid supine after spinal anesthesia injection. The tilted group is the control group.
11368698|NCT02243384|Experimental|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
11368699|NCT02243384|Active Comparator|Radiofrequency Ablation|Radiofrequency Ablation
11368700|NCT02243371|Experimental|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
11368701|NCT02243371|Experimental|Arm B: CY/ GVAX/ CRS-207|
11368702|NCT02243345||Delayed|Time from surfacing to recompression >=48 hours
11368703|NCT02243345||Early|Time from surfacing to recompression <48 hours
11368704|NCT02243332|Experimental|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
11368705|NCT02243319|Experimental|Group 1|"A → B → C
~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
11368706|NCT02243319|Experimental|Group 2|C → A → B
11368707|NCT02243319|Experimental|Group 3|B → C → A
11368708|NCT02243319|Experimental|Group 4|C → B → A
11368709|NCT02243319|Experimental|Group 5|B → A → C
11368710|NCT02243319|Experimental|Group 6|A → C → B
11368711|NCT02243306|Experimental|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
11370391|NCT02231866|Experimental|Group 2|cAd3-EBO at 2x10(11)PU IM
11368714|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368715|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368716|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
11368717|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368718|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368719|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368720|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368721|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368722|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368723|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
11368724|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
11368725|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
11368726|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
11368727|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
11368728|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
11368729|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
11368730|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
11368731|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
11368732|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
11368733|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
11368734|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
11368735|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
11368736|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
11368737|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
11368738|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
11368739|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
11368740|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
11368741|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
11368742|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
11368743|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
11368744|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
11368745|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
11368746|NCT02243254|Placebo Comparator|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
11368747|NCT02243254|Placebo Comparator|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
11368748|NCT02243254|Active Comparator|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
11368749|NCT02243254|Active Comparator|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
11368750|NCT02243241|Experimental|HYD|
11368751|NCT02243241|Other|Moxifloxacin|Moxifloxacin is the positive control.
11368752|NCT02243241|Placebo Comparator|Placebo|Placebo for HYD and placebo for moxifloxacin
11368753|NCT02243228|Experimental|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
11368754|NCT02243215|Experimental|Offsite training|Access to a portable trainer for laparoscopic skills
11368755|NCT02243215|No Intervention|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
11368756|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
11368757|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
11368758|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
11368759|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
11368760|NCT02243189|Experimental|JNJ-43260295 (Healthy Participants)|Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
11368761|NCT02243189|Placebo Comparator|Placebo (Healthy Participants)|Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
11368762|NCT02243189|Experimental|JNJ-43260295 (Asthmatic Participants)|Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.
11368763|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
11368764|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
11368765|NCT02243163|Experimental|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
11368766|NCT02243150|Experimental|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
11368767|NCT02243150|Experimental|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
11368768|NCT02243150|Experimental|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
11368769|NCT02243150|Experimental|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
11368770|NCT02243150|Experimental|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
11368771|NCT02243150|Experimental|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
11368772|NCT02243150|Experimental|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
11368773|NCT02243137|Active Comparator|prasugrel and acetylsalicylic|single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
11368774|NCT02243137|Experimental|lysine acetylsalicylate and prasugrel|single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous
11368775|NCT02243124|Active Comparator|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
11368776|NCT02243124|Active Comparator|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
11368777|NCT02243124|Active Comparator|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
11368778|NCT02243111|Experimental|Doppler ultrasound|Recording Doppler signals from the lungs
11368779|NCT02243098|Experimental|Semaglutide|
11368780|NCT02243085||photoselective vaporization|
11368781|NCT02243072|Experimental|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
11368782|NCT02243072|No Intervention|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
11368783|NCT02243059|Experimental|GDF-MRI|"In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.
~Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset)."
11368784|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
11368785|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
11368786|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
11368787|NCT02243033||Visualase|MR-guided laser focal therapy
11368788|NCT02243020|Experimental|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
11368789|NCT02243020|Active Comparator|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
11368790|NCT02243007|Experimental|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel
~Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.
~After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.
~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
11368791|NCT02243007|Experimental|Gemcitabine/nab-Paclitaxel- Arm B|"Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).
~Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.
~After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine
~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
11368792|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
11368793|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
11368794|NCT02242968||Healthy Volunteers|Male and Female healthy volunteers between aged 18 and 65 years.
11368795|NCT02242955|Active Comparator|"AD = as-usual diazepam"|Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
11368796|NCT02242955|Experimental|"PD = prolonged diazepam"|Diazepam will be slowly tapered to be stopped at day 30
11368797|NCT02242942|Experimental|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
11368798|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
11368799|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
11368800|NCT02242929|Active Comparator|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
11368801|NCT02242929|Experimental|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
11368802|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
11368803|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
11368804|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
11368805|NCT02242890|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
11368806|NCT02242877||Isolated systolic hypertension|
11368807|NCT02242877||Systolic and diastolic hypertension|
11368808|NCT02242864||Patients with hypertension and diabetes mellitus|
11368809|NCT02242851||Hypertensive patients|
11368810|NCT02242838||Hypertensive patients|
11368811|NCT02242825||Patients with hypertension and diabetes mellitus|
11368812|NCT02242812|Experimental|Telmisartan|MICARDIS®
11368813|NCT02242812|Active Comparator|Metoprolol succinate|BELOC ZOK®
11368814|NCT02242799|Experimental|Study A Sequence 1|Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
11368815|NCT02242799|Experimental|Study A Sequence 2|Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
11368816|NCT02242799|Experimental|Study B Sequence 1|Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
11368817|NCT02242799|Experimental|Study B Sequence 2|Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
11368818|NCT02242786|Experimental|EBRT|
11368819|NCT02242773|Experimental|Active Surveillance|Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.
11368820|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
11368821|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
11368822|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
11368823|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
11368824|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
11368825|NCT02242747|Other|ingenol mebutate|Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area
11368826|NCT02242747|Other|5% 5-FU|Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area
11368827|NCT02242734|Experimental|Mild Hepatic Impairment|20 mg HC-ER
11368828|NCT02242734|Experimental|Moderate Hepatic Impairment|20 mg HC-ER
11368829|NCT02242734|Experimental|No Hepatic Impairment|20 mg HC-ER
11368830|NCT02242721||Intensive care unit patients needing renal replacement therapy|Male and female patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs.
11368831|NCT02242708|No Intervention|Normal breathing|The control group will do normal breathing.
11368832|NCT02242708|Experimental|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
11368833|NCT02242695|Experimental|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
11368834|NCT02242695|Active Comparator|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
11368835|NCT02242682|No Intervention|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
11368836|NCT02242682|Experimental|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
11368837|NCT02242669||AIM 1|200 current DBSA participants.
11368838|NCT02242669||AIM 2|60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
11368839|NCT02242669||AIM 3|100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
11368840|NCT02242656|Experimental|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
11368841|NCT02242656|Experimental|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
11368842|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.
~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
11368843|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.
~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
11368844|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
11368845|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
11368846|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
11368847|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
11368848|NCT02242617|Active Comparator|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
11368849|NCT02242617|Active Comparator|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
11368850|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
11368851|NCT02242591|Active Comparator|ACB_active/placebo|"Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0).
~The measurements for baseline and outcome will be made in following order:
~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
11368908|NCT02242227|Experimental|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
11368909|NCT02242227|Active Comparator|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
11368910|NCT02242227|Placebo Comparator|Placebo|
11368911|NCT02242214||Misoprostol 200 µg VDS|At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
11368852|NCT02242591|Placebo Comparator|ACB_placebo/active|"Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0).
~The measurements for baseline and outcome will be made in following order:
~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
11368853|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
11368854|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
11368855|NCT02242565|Other|Control: all-sizes of ShangRing|All-sizes of ShangRings will be available.
11368856|NCT02242565|Active Comparator|Reduced-sizes|7 adult sizes of ShangRings will be available
11368857|NCT02242539|Experimental|Height measurement poster|
11368858|NCT02242539|Experimental|Community-based monitoring|
11368859|NCT02242539|No Intervention|Control|
11368860|NCT02242526|Active Comparator|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
11368861|NCT02242526|Active Comparator|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
11368862|NCT02242513|Active Comparator|pulsed mode radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. One dose of PRF was given in tibial nerve behine the medial ankle in intervention group.
11368863|NCT02242513|Placebo Comparator|Xylocaine|2 c.c xylocaine was given in tibial nerve behind the medial ankle in control group.
11368864|NCT02242500|Experimental|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
11368865|NCT02242500|Other|Coronally advanced flap|Coronally advanced flap procedure alone
11368866|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
11368867|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
11368868|NCT02242474|Active Comparator|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
11368869|NCT02242474|Experimental|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
11368870|NCT02242461|Placebo Comparator|Rhodiola placebo capsules|starch
11368871|NCT02242461|Experimental|Rhodiola Crenulata|Rhodiola Crenulata
11368872|NCT02242435|Experimental|Ampion 4ml|4 mL intra-articular injection of Ampion
11368873|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
11368874|NCT02242422||transobturator tape|
11368875|NCT02242409|Experimental|Gemcitabine/abraxane|Gemcitabine and Abraxane
11368876|NCT02242396||Hypertensive patients|
11368877|NCT02242383||Essential hypertension|
11368878|NCT02242370|Experimental|Telmisartan low dose|
11368879|NCT02242370|Experimental|Telmisartan high dose|
11368880|NCT02242357||Patients with hypertension|
11368881|NCT02242344|Experimental|telmisartan - low dose|
11368882|NCT02242344|Experimental|telmisartan - high dose|
11368883|NCT02242344|Placebo Comparator|Placebo|
11368884|NCT02242331||essential hypertension patients|
11368885|NCT02242318|Experimental|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
11368886|NCT02242318|Active Comparator|Valsartan|low dose for two weeks, then up titration to high dose, once daily
11368887|NCT02242318|Placebo Comparator|Placebo|
11368888|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
11368889|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
11368890|NCT02242292|Experimental|Hyoscine butylbromide|"5 tablets taken in a 24-hour period/each episode:
~for up to 7 episodes, or
~over a period of up to 6 weeks"
11368891|NCT02242292|Placebo Comparator|Placebo|
11368892|NCT02242279|Experimental|BEA 2180 - low dose|
11368893|NCT02242279|Experimental|BEA 2180 - medium dose|
11368894|NCT02242279|Experimental|BEA 2180 - high dose|
11368895|NCT02242279|Active Comparator|Tiotropium|
11368896|NCT02242279|Placebo Comparator|Placebo|
11368897|NCT02242266|Experimental|Tiotropium low dose|oral inhalation via the blue HandiHaler®
11368898|NCT02242266|Experimental|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
11368899|NCT02242266|Active Comparator|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
11368900|NCT02242266|Placebo Comparator|Placebo|
11368901|NCT02242253|Experimental|Tiotropium+salmeterol QD|free combination of tiotropium and salmeterol
11368902|NCT02242253|Active Comparator|Tiotropium+salmeterol BID|free combination of tiotropium and salmeterol
11368903|NCT02242253|Active Comparator|Tiotropium QD|
11368904|NCT02242253|Active Comparator|Salmeterol BID|
11368905|NCT02242240|Experimental|Tiotropium with single dose of formoterol|
11368906|NCT02242240|Experimental|Tiotropium with double dose of formoterol|
11368907|NCT02242240|Experimental|Tiotropium with Placebo|
11368912|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
11368913|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
11368914|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
11368915|NCT02242188|Experimental|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.
~The intervention will last from 4 months to 9 months of age."
11368916|NCT02242188|Placebo Comparator|Placebo|"Maltodextrin prepared in sachets. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.
~The intervention will last from 4 months to 9 months of age."
11368917|NCT02242175|Other|normal group|
11368918|NCT02242175|Other|irritable bowel syndrome group|
11368919|NCT02242162||neuromuscular diseases|
11368920|NCT02242149|Placebo Comparator|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
11368921|NCT02242149|Experimental|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
11368922|NCT02242136|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1,5 and 2 hrs depending on the needs of the participant.
11368923|NCT02242136|No Intervention|Waiting list|
11368924|NCT02242123||Study group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of mild intestinal histology damage (grade 1-2) at first evaluation.
11368925|NCT02242123||Control group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of intestinal villous atrophy (intestinal histology damage grade 3) at first evaluation.
11368926|NCT02242110|Experimental|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
11368927|NCT02242097|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
11368928|NCT02242084|Experimental|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
11368929|NCT02242071|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
11368930|NCT02242058||High frequency pain group|39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
11368931|NCT02242058||Low Pain Frequency group|39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
11368932|NCT02242058||Healthy control group|39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
11368933|NCT02242058||Pain Crisis group|30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
11368934|NCT02242058||Pain Service group|10 patients without sickle cell disease admitted to the pain service.
11368935|NCT02242045|Experimental|Idelalisib|- Idelalisib cohort: Idelalisib 150 mg in participants with iNHL or CLL
11368936|NCT02242032|Experimental|P-321|P-321 Ophthalmic Solution
11368937|NCT02242032|Placebo Comparator|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
11368938|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
11368939|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
11368940|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
11368941|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
11368942|NCT02241993||Type 1 diabetic|
11368943|NCT02241980||Medicare Part D patients|Survey
11368944|NCT02241980||Physician Providers|Survey
11368945|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
11368946|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
11368947|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
11368948|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
11368949|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
11368950|NCT02241941|Experimental|Daptomycin|
11368951|NCT02241928|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
11368952|NCT02241915|Active Comparator|Microbial Sealant|Integuseal (Kimberly Clark)
11368956|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
11368957|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
11368958|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
11368959|NCT02241876|Placebo Comparator|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
11368960|NCT02241876|Experimental|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
11368961|NCT02241863|Experimental|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
11368962|NCT02241863|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
11368963|NCT02241850|Other|High intensity training|9 weeks of supervised training
11368964|NCT02241824|Active Comparator|Elastic abdominal binder|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an elastic abdominal binder.
11368965|NCT02241824|No Intervention|No brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen with no brace (control).
11368966|NCT02241824|Experimental|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
11368967|NCT02241811|Placebo Comparator|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
11368968|NCT02241811|Experimental|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
11368969|NCT02241798|Experimental|Pre-oxygenation first|"st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated
~nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
11368970|NCT02241798|Experimental|Standard practice first|"st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).
~nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
11368971|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
11368972|NCT02241772|Experimental|10mg TA-8995|10mg TA-8995 once daily
11368973|NCT02241772|Experimental|2.5mg TA-8995|2.5mg TA-8995 once daily
11368974|NCT02241772|Placebo Comparator|Placebo to TA-8995|Placebo to TA-8995 once daily.
11368975|NCT02241759|Experimental|TA-8995|Single oral dose of 150mg TA-8995
11368976|NCT02241759|Experimental|Placebo|Single oral dose of placebo to TA-8995
11368977|NCT02241759|Active Comparator|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
11368978|NCT02241746||malnutrition|
11368979|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
11368980|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
11368981|NCT02241720|Experimental|Regorafenib treatment|
11368982|NCT02241694||survey|
11368983|NCT02241681|Other|Peptamen 1.5|500 mL of Peptamen 1.5
11368984|NCT02241668|Experimental|FLT PET Scan + 3'-Deoxy-3'-18f-Fluorothymidine|After a magnetic resonance imaging (MRI) scan of brain performed, an FLT PET scan using 3'-Deoxy-3'-18f-Fluorothymidine solution performed. After solution is injected into a vein, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. The entire procedure should last about 60-70 minutes.
11368985|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
11368986|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
11368987|NCT02241642|Experimental|Treatment|VIVASURE CLOSURE DEVICE™
11368988|NCT02241629|Experimental|levo phencynonate hydrochloride 1mg|levo phencynonate hydrochloride tablet 1mg
11368989|NCT02241629|Placebo Comparator|placebo|Placebo
11368990|NCT02241629|Experimental|levo phencynonate hydrochloride 2mg|levo phencynonate hydrochloride 2mg
11368991|NCT02241616|Experimental|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
11368992|NCT02241603|Experimental|Weight loss|Obese Veterans will aim to lose 5-10% body weight
11368993|NCT02241603|No Intervention|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
11368994|NCT02241590|Placebo Comparator|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
11368995|NCT02241590|Experimental|Entecavir + Fuzheng Huayu Tablet|Tablet with Entrcavir+ Tablet with Fuzheng Huayu
11368996|NCT02241577|Experimental|Surgical treatment|Surgical access for scaling and disinfection of dental implant
11368997|NCT02241577|Experimental|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of dental implant
11368998|NCT02241564||Malignancy post transplantation|
11368999|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
11369000|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
11369104|NCT02240875|Experimental|Group 2b|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
11369001|NCT02241538|Experimental|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
11369002|NCT02241538|Experimental|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
11369003|NCT02241538|Experimental|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
11369004|NCT02241538|Active Comparator|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group will not receive additional exercise.
11369005|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
11369006|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
11369007|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
11369008|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
11369009|NCT02241499|Experimental|Radiotherapy and chemotherapy (oxaliplatin and fluorouracil).|Radiotherapy (5 x 4 Gy) will be given. After completion of radiotherapy, 4 cycles of chemotherapy will be administered, cycle length 14 days. Each patient will receive oxaliplatin as infusion at a dose of 85 mg/m2, followed by a bolus injection of fluorouracil at a dose of 400 mg/m2, and a long time infusion (44 hours) of fluorouracil at a dose of 2 400 mg/m2.
11369010|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
11369011|NCT02241473|Experimental|CH training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion.
11369012|NCT02241473|Active Comparator|CN training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) condition in a single-blind fashion.
11369013|NCT02241460|Active Comparator|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
11369014|NCT02241460|Placebo Comparator|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
11369015|NCT02241447||Observation|the nurse identifies cases with severe AS and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
11369016|NCT02241447||Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
11369017|NCT02241434|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
11369018|NCT02241421|Placebo Comparator|Placebo|No intervention: Placebo 3x2 capsules per day during 7 consecutive days.
11369019|NCT02241421|Experimental|Treatment Antibiotics: Amoxicillin|Experimental: Amoxicillin (broad spectrum antibiotics) 1500 mg/day (3x2 capsules of 250 mg) during 7 consecutive days.
11369020|NCT02241421|Experimental|Treatment Antibiotics: Vancomycin|Experimental: Vancomycin (small spectrum antibiotics) 1500mg/day (3x2 capsules of 250 mg) during 7 consecutive days
11369021|NCT02241395|Experimental|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
11369022|NCT02241382|Active Comparator|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a > 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
11369023|NCT02241382|Experimental|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
11369024|NCT02241369|Experimental|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
11369025|NCT02241369|Experimental|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
11369026|NCT02241356|Active Comparator|single vision glasses|single vision glasses
11369027|NCT02241356|Experimental|bifocals|bifocal glasses
11369028|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
11369029|NCT02241330|Placebo Comparator|Control|Control wheat used for meal, level of zinc is usual
11369030|NCT02241330|Active Comparator|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
11369031|NCT02241330|Active Comparator|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
11369032|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
11369033|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
11369034|NCT02241278|Placebo Comparator|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
11369035|NCT02241278|Experimental|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
11369036|NCT02241265||Past Bronchial Thermoplasty data|Data will be collected from records of patients who, in the past, have undergone bronchial thermoplasty.
11369037|NCT02241252|Other|iPhone ECG QT recording|iPhone ECG
11369038|NCT02241239||participants|healthy adults without stroke and coronary heart disease
11369039|NCT02241226|Experimental|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
11369040|NCT02241226|No Intervention|Resort group|Resort group at the La Costa resort
11369041|NCT02241213|Active Comparator|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (> 1 Hz), low frequency (<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency <1 Hz with repetitive pulses.
11369042|NCT02241213|Placebo Comparator|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
11369043|NCT02241200|Experimental|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
11369044|NCT02241200|Experimental|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
11369045|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
11369046|NCT02241174|Experimental|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
11369047|NCT02241174|Placebo Comparator|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
11369048|NCT02241161|Active Comparator|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
11369049|NCT02241161|Active Comparator|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
11369050|NCT02241161|Active Comparator|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
11369051|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream +rejuvenating serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
11369052|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream + antioxidant serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
11369053|NCT02241148|Active Comparator|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
11369054|NCT02241148|Experimental|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
11369055|NCT02241135|Experimental|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
11369056|NCT02241135|Experimental|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
11369057|NCT02241135|Experimental|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
11369058|NCT02241135|Experimental|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
11369059|NCT02241135|Experimental|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
11369060|NCT02241135|Experimental|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
11369061|NCT02241135|Experimental|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
11369062|NCT02241135|Experimental|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
11369063|NCT02241122|Experimental|MRI guided prostate biopsy|prostate biopsy after MR-imaging
11369064|NCT02241109|Other|All patients|Compare patients with high calcification propensity do have faster valve-stenosis progression
11369065|NCT02241096|Experimental|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
11369066|NCT02241083|Active Comparator|dopamine group|vasopressor dosage individually titred according to the mean arterial pressure
11369067|NCT02241083|Active Comparator|norepinephrine group|vasopressor dosage individually titred according to the mean arterial pressure
11369068|NCT02241083|Active Comparator|control group|no medication
11369069|NCT02241070|Experimental|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
11369070|NCT02241070|No Intervention|waiting-list control|passive control group
11369071|NCT02241057|Experimental|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
11369072|NCT02241057|Experimental|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
11369073|NCT02241044|Active Comparator|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
11369074|NCT02241044|Placebo Comparator|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
11369075|NCT02241031|Experimental|MPs|MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
11369076|NCT02241031|Active Comparator|Non-MPs|Patients can receive platelet infusion but can not receive platelet stimulating factors.
11369077|NCT02241018|Experimental|Mesenchymal stem cells|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.
11369078|NCT02241018|Experimental|CD25 Mc Ab & calcineurin inhibitors|CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given.
11369079|NCT02241005|Active Comparator|Theraworx™|Participants are randomized to use the Theraworx™ bath wipes.
11369080|NCT02241005|Active Comparator|Standard|Participants are randomized to use standard bath wipes.
11369081|NCT02240992|Experimental|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
11369082|NCT02240992|Experimental|MSCs|MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
11369083|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
11369084|NCT02240953|Active Comparator|Warfarin|In the first arm only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
11369085|NCT02240953|Active Comparator|Warfarin + ASA 100 mg + PPI|In the second arm 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
11369086|NCT02240953|Active Comparator|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
11369087|NCT02240953|Active Comparator|Observational Warfarin|This arm is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
11369088|NCT02240940|Experimental|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
11369089|NCT02240927|Active Comparator|Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
11369090|NCT02240927|Active Comparator|Enoxaparine and 2.5 mg warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1.0). Full dose warfarin is continued after first trimester and dose is regulated according to INR (between 2.5-4)
11369091|NCT02240927|Active Comparator|Enoxaparine and 4 mg warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
11369092|NCT02240927|Active Comparator|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
11369093|NCT02240914||Vascular USG and IVUS imaging diagnosis|
11369094|NCT02240901|Experimental|Laryngeal mask airway|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
11369095|NCT02240901|Experimental|Endotracheal intubation group（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
11369096|NCT02240888|Active Comparator|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
11369097|NCT02240888|Active Comparator|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
11369098|NCT02240888|Active Comparator|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
11369099|NCT02240888|Active Comparator|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
11369100|NCT02240875|Experimental|Group 1|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly
11369101|NCT02240875|Experimental|Group 1b|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
11369105|NCT02240875|Experimental|Group 2c|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
11369106|NCT02240875|Experimental|Group 3|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly
11369107|NCT02240875|Experimental|Group 3b|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
11369108|NCT02240875|Experimental|Group 3c|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
11369109|NCT02240875|Experimental|Group 4|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 7
11369110|NCT02240875|Experimental|Group 5|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 14
11369111|NCT02240875|Experimental|Group 6|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 7
11369112|NCT02240875|Experimental|Group 7|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 14
11369113|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
11369114|NCT02240849|Experimental|Functional pillow|cervical pillow, designed functionally to decrease neck pain and help to ensure the right support of the cervical curve, was applied to patients' posterior neck area.
11369115|NCT02240849|Placebo Comparator|General pillow|Applicants Randomly allocated to this group were issued by placebo-general pillow. There is not any specific intervention for their neck discomfort except for that.
11369116|NCT02240836|Experimental|Intervention. Exercise|The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
11369117|NCT02240836|No Intervention|Control group|Control group, standard treatment regimen
11369118|NCT02240823|Experimental|adipose derived stem cells|
11369119|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
11369120|NCT02240797||Anorexia Nervosa - Recovered (AN-REC)|Anorexia Nervosa - Recovered (AN-REC)
11369121|NCT02240797||Healthy Control (HC)|Healthy Control (HC)
11369122|NCT02240784||Acute Hepatic Porphyria|
11369123|NCT02240771|Active Comparator|Transarterial chemotherapy|Doxorubicin 50mg, Cisplatin 100mg
11369124|NCT02240771|Placebo Comparator|Oral chemotherapy|Thalidomide---50-300mg once a day Capecitabine---- 500-1500mg once a day
11369125|NCT02240758|Experimental|surgical removal of the tumors+stereotaxic biopsy|
11369126|NCT02240745||All patients|Patients with a suspicion of coronary heart disease
11369127|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.
~Observational with imaging."
11369128|NCT02240719|Experimental|Everolimus + Bendamustine|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11369129|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
11369130|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
11369131|NCT02240693|Experimental|BI 409306 dose 1|
11369132|NCT02240693|Experimental|BI 409306 dose 2|
11369133|NCT02240693|Experimental|BI 409306 dose 3|
11369134|NCT02240693|Experimental|BI 409306 dose 4|
11369135|NCT02240693|Placebo Comparator|Placebo|
11369136|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
11369137|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
11369138|NCT02240667||Subjects with atrial fibrillation|
11369139|NCT02240654||Dabigatran etexilate|
11369140|NCT02240641||hypertension treatment strategies|
11369141|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
11369142|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
11369143|NCT02240615|Experimental|Sinopsys Lacrimal Stent|All enrolled patients will receive a Sinopsys Lacrimal Stent inserted from the caruncle to the ethmoid sinus. Discharge instructions will include administration of sterile saline and ophthalmic drops as well as assessments for device patency.
11369144|NCT02240602|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
11369145|NCT02240602|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
11369146|NCT02240602|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
11369147|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
11369148|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
11369149|NCT02240563|Experimental|Low-level laser therapy|This group of patients was treated with a continuous wave diode laser device (830 nanometer, infrared) with a beam area of 0.002827 cm2 using the punctual method on the continuous emission mode at an output power of 50 milliwatts and a fluence of 707 Joules/cm2 six years before.
11370699|NCT02229760|Experimental|TPV/r (Tipranavir co-administered with low dose ritonavir)|
11369150|NCT02240563|Placebo Comparator|Non laser ordinary red light|This group of patients was treated using the same method and equipment, except that a non laser ordinary red light, an output power of 0.1 Watt and a fluence of 1.41 Joules/cm2 and an irradiance value of 0.0002827 Watts/cm2 (the placebo), indistinguishable from the laser beam, was used. Therefore, the patients were blinded to which treatment they received.
11369151|NCT02240550|Active Comparator|ProFlor Hernia Repair System|A 3-D hernia mesh
11369152|NCT02240550|Active Comparator|Lichtenstein Hernia Repair|Using flat polypropylene mesh
11369153|NCT02240537|Experimental|Open Label Treatment Arm|BB-MPI-03 peptides plus montanide plus sargramostim
11369154|NCT02240524|Experimental|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.
~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.
~Systemic chemotherapy (XELOX):
~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
11369155|NCT02240524|Placebo Comparator|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.
~Systemic chemotherapy (XELOX):
~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
11369156|NCT02240511|Active Comparator|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
11369157|NCT02240511|Experimental|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator
~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
11369158|NCT02240498|Experimental|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
11369159|NCT02240498|Experimental|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 10 minutes.
11369160|NCT02240498|Experimental|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 15 minutes.
11369161|NCT02240498|Experimental|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 20 minutes.
11369162|NCT02240498|Experimental|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 25 minutes.
11369163|NCT02240498|Experimental|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 30 minutes.
11369164|NCT02240485|Experimental|Behavioral Couple Therapy|"Already described in the Intervention Description section"
11369165|NCT02240485|Active Comparator|Usual individual/group treatment|Well described in the Intervention section
11369166|NCT02240472|No Intervention|Axillary clearance|Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis
11369167|NCT02240472|Experimental|No axillary clearance|Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis
11369168|NCT02240459|Experimental|Fesoterodine 4mg daily|fesoterodine 4mg oral
11369169|NCT02240459|Experimental|Fesoterodine 8mg|Fesoterodine 8mg in form of 2, 4mg tablets
11369170|NCT02240459|Active Comparator|oxybutynin|oxybutynin immediate release, encapsulated 2, 5mg capsules daily
11369171|NCT02240459|Placebo Comparator|placebo capsule|placebo capsule, 2 per day
11369172|NCT02240446|Experimental|Active tDCS|Active tDCS
11369173|NCT02240446|Placebo Comparator|Sham tDCS|Sham tDCS
11369174|NCT02240433|Experimental|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
11369175|NCT02240420|Active Comparator|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
11369176|NCT02240420|No Intervention|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
11369177|NCT02240407|Experimental|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
11369207|NCT02240160|Experimental|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
11369208|NCT02240160|Experimental|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
11369178|NCT02240407|Sham Comparator|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
11369179|NCT02240381|Experimental|Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)|Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
11369180|NCT02240368||Group 1|Children age between 1 month to 12 months
11369181|NCT02240368||Group 2|Children age between 13 months and 36 months
11369182|NCT02240368||Group 3|Children age between 37 months to 144 months
11369183|NCT02240355|Experimental|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
11369184|NCT02240355|Experimental|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
11369185|NCT02240355|Experimental|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
11369186|NCT02240342|Experimental|Poor ovarian reserve women|
11369187|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
11369188|NCT02240316||Follicular NHL Cohort|
11369189|NCT02240316||DLBCL Cohort|
11369190|NCT02240303||Chronic Pain Group|Participants that experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
11369191|NCT02240303||No Chronic Pain Group|Participants that do not experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
11369192|NCT02240290|Experimental|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
11369193|NCT02240264|Active Comparator|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.
~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
11369194|NCT02240264|Placebo Comparator|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
11369195|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
11369196|NCT02240238|Experimental|NC-6004 and Gemcitabine|
11369197|NCT02240212|Experimental|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
11369198|NCT02240212|Experimental|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
11369199|NCT02240212|Experimental|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
11369200|NCT02240199|Experimental|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
11369201|NCT02240199|Active Comparator|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
11369202|NCT02240199|Active Comparator|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
11369203|NCT02240199|Placebo Comparator|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
11369204|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
11369205|NCT02240173|Experimental|Jobelyn + Haloperidol|Combination of the conventional drugs and Jobelyn
11369206|NCT02240173|Active Comparator|Haloperidol + Placebo|Combination of the conventional drug + Placebo
11369417|NCT02238821||resectable colorectal cancer|
11369418|NCT02238808|Experimental|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
11369209|NCT02240160|Experimental|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
11369210|NCT02240147|Experimental|home-based exercise training|
11369211|NCT02240147|No Intervention|Control group|
11369212|NCT02240134|Experimental|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
11369213|NCT02240134|Active Comparator|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
11369214|NCT02240134|Sham Comparator|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
11369215|NCT02240121|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
11369216|NCT02240121|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
11369217|NCT02240108|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
11369218|NCT02240108|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
11369219|NCT02240095|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, students will be offered all 3 online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
11369220|NCT02240095|Experimental|Interventions A + B|"See Interventions Description. In this arm, students will be offered the 2 following interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach"
11369221|NCT02240095|Experimental|Interventions A + C|"In this arm, students will be offered the 2 following online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention C - Online Audit and Feedback"
11369222|NCT02240095|Experimental|Interventions B + C|"See Interventions Description. In this arm, students will be offered the 2 following online interventions combined:
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
11369223|NCT02240095|Experimental|Intervention A alone|"See Interventions Description. In this arm, students will be offered only the following intervention:
~* Intervention A - Online Clinical Questions Recorder"
11369224|NCT02240095|Experimental|Intervention B alone|"See Interventions Description. In this arm, students will be offered only the following intervention:
~* Intervention B - Online Evidence Retrieval Coach"
11369225|NCT02240095|Experimental|Intervention C alone|"See Interventions Description. In this arm, students will be offered only the following intervention:
~* Intervention C - Online Audit and Feedback"
11369226|NCT02240095|No Intervention|No intervention|In this arm, students will be offered none of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
11369227|NCT02240082|Experimental|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
11369228|NCT02240082|No Intervention|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
11369229|NCT02240069|Experimental|Education (Tx1)|Education on best burn practices
11369230|NCT02240069|Active Comparator|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
11369231|NCT02240069|Sham Comparator|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
11369232|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
11369233|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
11369234|NCT02240056||healthy subjects|healthy postmenopausal women without coronary artery disease
11369235|NCT02240043|Other|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
11369236|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
11369237|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
11369238|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
11369239|NCT02240017|Active Comparator|Carboplatin/Gemcitabine|
11369240|NCT02240017|Experimental|Fractionated Cisplatin/Gemcitabine|
11369241|NCT02239991|No Intervention|Historical control|Group of patients that had their coagulopathy secondary to the liver transplant treated based on conventional laboratory tests. Before the implementation of thromboelastometry.
11369242|NCT02239991|Experimental|Intervention|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
11369243|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
11369244|NCT02239978||Control|Age-matched healthy adults
11369245|NCT02239965||Anaesthesia personnel|Anaesthesiologists and nurse anaesthetists
11369246|NCT02239952|Experimental|sunitinib|
11369247|NCT02239952|Experimental|vandetanib|
11369248|NCT02239952|Experimental|Erlotinib|
11369419|NCT02238795||Purpura fulminans|Patients diagnosed with Purpura fulminans in association with sepsis
11370700|NCT02229747|Experimental|Meloxicam suspension|
11369249|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
11369250|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
11369251|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
11369252|NCT02239926|Placebo Comparator|Placebo|Placebo
11369253|NCT02239913|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11369254|NCT02239913|Experimental|Topiramate Dose 1|Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11369255|NCT02239913|Experimental|Topiramate Dose 2|Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11369256|NCT02239900|Experimental|Group 1 Liver: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 1: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
11369257|NCT02239900|Experimental|Group 2 Liver: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 2: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
11369258|NCT02239900|Experimental|Group 3 Lung: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
11369259|NCT02239900|Experimental|Group 4 Lung: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 29 - 33 of each 21 day cycle.
11369260|NCT02239900|Experimental|Group 5 Liver/Lung Metastasis: (late) Ipilimumab and SBRT|Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
11369261|NCT02239900|Experimental|Thyroid Expansion Cohort|"Participants enrolled in this arm treated to a total dose of 50 Gy in 4 fractions, 60 Gy in 10 fractions, or 20 Gy in 5 fractions with stereotactic radiotherapy to a liver or lung lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.
~Participants receive Ipilimumab every 21 days for a total of 4 doses."
11369262|NCT02239887||WaveCrest LAA occlusion device|Left Atrial Occlusion
11369263|NCT02239874|Placebo Comparator|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
11369264|NCT02239874|Active Comparator|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
11369265|NCT02239874|Active Comparator|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
11369266|NCT02239874|Active Comparator|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
11369267|NCT02239861|Experimental|TAA-Specific CTLs|"4 different dosing schedules will be evaluated. 2 to 4 patients will be evaluated on each dosing schedule. The first 2 patients on each dose level will be staggered by 4 weeks (which starts when the first infusion is given, Day 0). No subjects between the ages of 2-18 will be enrolled to a dose level on this protocol, until an adult has been enrolled to and treated on that dose level on one of the protocols being conducted under this same IND. Each patient will receive 2 injections at the same dose,14 days apart: The expected volume of infusion will be 1 to 10 cc.
~Dose Level One:
~Day 0 and 14: 5 x 10^6 cells/m^2
~Dose Level Two:
~Day 0 and 14: 1 x 10^7 cells/m^2
~Dose Level Three:
~Day 0 and 14: 2 x 10^7 cells/m^2
~Dose Level Four:
~Day 0 and 14: 4 x 10^7 cells/m^2"
11369268|NCT02239835|Experimental|TPV low dose + RTV low dose|
11369269|NCT02239835|Experimental|TPV high dose + RTV low dose|
11369270|NCT02239835|Active Comparator|SQV + RTV high dose|
11369271|NCT02239822|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
11369272|NCT02239822|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
11369273|NCT02239809|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
11369274|NCT02239809|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
11369275|NCT02239796|Experimental|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.
~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
11369420|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
11369276|NCT02239796|Sham Comparator|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.
~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.
~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
11369277|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
11369278|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
11369279|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
11369280|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
11369281|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
11369282|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
11369283|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
11369284|NCT02239757|Experimental|Right radial approach|Primary PCI performed through right radial approach.
11369285|NCT02239757|Experimental|Left radial approach|Primary PCI performed through left radial approach.
11369286|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
11369287|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
11369288|NCT02239731|Experimental|FDX104 (4% Doxycycline)|Active ingredient: Doxycycline Concentration: 4% Route: Topical Dosage schedule: Twice daily, morning and evening. Prophylactic treatment to prevent the rash associated with EGFRI treatment. patients will apply a thin layer of the drug twice daily for five weeks to one half of face
11369289|NCT02239731|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Twice daily, morning and evening. Patients will apply a thin layer of the placebo twice daily for five weeks to the opposite half of the face of which they received active treatment.
11369290|NCT02239718|Experimental|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
11369291|NCT02239718|Active Comparator|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
11369292|NCT02239705||Fluid challenge|Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output
11369293|NCT02239705||Inotropic infusion|Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output
11369294|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
11369295|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
11369296|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
11369297|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
11369298|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
11369299|NCT02239666||Moderate to Severe Plaque Psoriasis|Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
11369300|NCT02239653|Experimental|Physician communication|"The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption."
11369301|NCT02239653|No Intervention|Usual care|
11369302|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
11369303|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
11369304|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
11369305|NCT02239614|Experimental|Group 1: LAV (T=0), PIV (T=28)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.
~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study."
11369306|NCT02239614|Experimental|Group 2: PIV (T=0), LAV (T=28)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.
~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study."
11369307|NCT02239614|Experimental|Group 3: LAV (T=0), PIV (T=180)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.
~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study."
11370701|NCT02229747|Active Comparator|Diclofenac suspension|
11369308|NCT02239614|Experimental|Group 4: PIV (T=0), LAV (T=180)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.
~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study."
11369309|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
11369310|NCT02239588|Experimental|Pure Canterbury milk powder|Oral consumption of infant formula (0-6 months) milk powder
11369311|NCT02239588|Active Comparator|Other infant formula milk powder|"Oral consumption of milk powder (other than the experimental product) selected by subjects' parents. The products including:
~Yashili Ambery Infant Formula Milk Powder (Stage 1: 0-6 months)
~Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)
~Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)
~Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)
~Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)
~Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
11369312|NCT02239588|Placebo Comparator|Breast milk|Oral consumption of breast milk
11369313|NCT02239562|Experimental|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
11369314|NCT02239562|Experimental|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
11369315|NCT02239562|Experimental|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
11369316|NCT02239562|Experimental|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
11369317|NCT02239562|Experimental|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
11369318|NCT02239562|Experimental|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
11369319|NCT02239549|Experimental|Jumbo cold forceps polypectomy group|Polypectomy conducted with jumbo cold forceps
11369320|NCT02239549|Experimental|Cold snare polypectomy group|Polypectomy conducted with cold snare
11369321|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
11369322|NCT02239536|Experimental|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
11369323|NCT02239523|Active Comparator|Letter Group|Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.
11369324|NCT02239523|Experimental|Intervention Group|Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.
11369325|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
11369326|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
11369327|NCT02239497|Experimental|femoral block by US and NE and intravenous analgesia|preincisional femoral block by ultrasound and neurostimulation, with 20 ml bupivacaine 0,5% and epinephrine. ketoprofen, dipyrone and dexamethasone IV. Morphine IV to rescue analgesia
11369328|NCT02239497|Experimental|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and morphine. IV morphine to rescue analgesia
11369329|NCT02239484|Experimental|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
11369330|NCT02239484|Experimental|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
11369331|NCT02239484|Experimental|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
11369332|NCT02239458|Placebo Comparator|Placebo|Placebo intake during 3 months
11369333|NCT02239458|Active Comparator|Saxagliptin 5mg|Saxagliptin dose of 5mg for 3 months
11369334|NCT02239445|Active Comparator|chloral hydrate group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
11369335|NCT02239445|Experimental|low dose dexmedetomidine Group|"Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
11369336|NCT02239445|Experimental|high dose dexmedetomidine group|"Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
11369337|NCT02239432||Suspected Adenocarcinoma of the Lung|Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
11369338|NCT02239432||Healthy Control|Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
11369339|NCT02239432||Age-matched controls with proven solid lung malignancy|Patients with biopsy-proven advanced solid malignancy of the lung
11369340|NCT02239419|Experimental|CO2-Enriched Tap Water (Carbothera)|CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C. Tap water will be enriched with CO2 by the investigational Carbothera device.
11369341|NCT02239419|Placebo Comparator|Non-CO2-Enriched Tap Water|Non-CO2-enriched tap water (i.e. normal tap water) maintained at a temperature of 37˚C.
11369342|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
11369343|NCT02239393|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
11369344|NCT02239393|Experimental|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
11369345|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
11369346|NCT02239367|Experimental|Depression Decision Aid protocol|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
11369347|NCT02239354|Experimental|Cohort 1|2 VC-01™ Combination Product implants
11369348|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01™ Combination Product implants
11369349|NCT02239341|Active Comparator|Music Intervention (M)|The M intervention will be 30 minutes (same amount of time as E group), but the participants will simply be listening to the same music in bed with no exercise component. They will be wearing the heart rate monitor as in the E group. The M group will act as a control group for the E group.
11369350|NCT02239341|Experimental|Muscle Conditioning Intervention (E)|E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.
11369351|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
11369352|NCT02239315|Experimental|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
11369353|NCT02239289|Experimental|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
11369354|NCT02239250|Experimental|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
11369355|NCT02239250|No Intervention|Control|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
11369356|NCT02239237||Compound Kuh-seng Injection|Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
11369357|NCT02239224|Experimental|ATYR1940|ATYR1940 : IV; 0.3, 1.0, or 3.0 mg/kg; once a week; Up to 12 weeks
11369358|NCT02239224|Placebo Comparator|Placebo|Placebo: IV; 0.3, 1.0, or 3.0 mg/kg; once a week; Up to 12 weeks
11369359|NCT02239211|Experimental|BTT1023|BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
11369360|NCT02239198|Experimental|C|Nutrition bar without omega-3 fatty acids
11369361|NCT02239198|Experimental|B|Nutrition bar without added minerals and vitamins
11369362|NCT02239198|Active Comparator|A|Complete nutrition bar
11369363|NCT02239185|Other|Hernial sac ligation in continuity|laparoscopic closure of hernia sac in continuity using 3 - 0 non-absorbable purse-string suture. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying.
11369364|NCT02239185|Other|Hernial sac disconnection|circumferential incision on the peritoneum at internal inguinal ring (IIR) with separation of hernia sac from the peritoneum. The proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
11369365|NCT02239172|Experimental|12.5 µg + Alhydrogel|vaccine
11369366|NCT02239172|Experimental|25 µg + Alhydrogel|vaccine
11369367|NCT02239172|Experimental|50 µg + Alhydrogel|vaccine
11369368|NCT02239172|Experimental|100 µg + Alhydrogel|vaccine
11369369|NCT02239159|No Intervention|Control|Electrodes will be attached, but stimulation will not be given
11369370|NCT02239159|Sham Comparator|Non-acupoint TES|TES is for transcutaneous electric stimulation.Stimulation will be given through electrodes attached to non-acupoints
11369371|NCT02239159|Experimental|Acupoint TES|Transcutaneous stimulation will be given through acupoints
11369372|NCT02239146|Experimental|rFXIII|
11369373|NCT02239146|Placebo Comparator|Placebo|
11369374|NCT02239133|Experimental|ProVATE vaginal pessary|"The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse (POP). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only."
11369375|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
11369421|NCT02238769||Hepatocellular Carcinoma|18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue
11369376|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
11369377|NCT02239107|Experimental|N-Acetyl cysteine|Laparoscopic ovarian drilling followed by NAC 1200mg daily in two divided doses for five days starting cycle day 2 for 6 month
11369378|NCT02239107|Active Comparator|laparoscopic drilling group|laparoscopic drilling only will be done
11369379|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
11369380|NCT02239081|Experimental|CTP-730, 5 mg|oral suspension, once daily.
11369381|NCT02239081|Experimental|CTP-730, 10 mg|Oral Suspension, once daily.
11369382|NCT02239081|Experimental|CTP-730, 20 mg|Oral Suspension, once daily.
11369383|NCT02239081|Experimental|CTP-730, 30 mg|Oral Suspension, once daily.
11369384|NCT02239081|Experimental|CTP-730, 40 mg|Oral Suspension, once daily.
11369385|NCT02239081|Experimental|CTP-730, 50 mg|Oral Suspension, once daily.
11369386|NCT02239081|Experimental|CTP-730, 60 mg|Oral Suspension, once daily.
11369387|NCT02239055||Focus Group 1|Staff Perceptions
11369388|NCT02239055||Focus Group 2|Staff Perceptions
11369389|NCT02239042|Sham Comparator|Low-level laser therapy (LLLT) Sham|LLLT Sham on the palatal donor site of connective tissue graft
11369390|NCT02239042|Experimental|Low-level laser therapy (LLLT)|LLLT on the palatal donor site of connective tissue graft
11369391|NCT02239029|Active Comparator|Platelet rich plasma|"Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side."
11369392|NCT02239029|Placebo Comparator|normal saline|Normal saline was injected into the other side of knee as the control group.
11369393|NCT02239003|Experimental|DAOIB|250-1500 mg/day, oral, for 24 weeks
11369394|NCT02239003|Placebo Comparator|Placebo|placebo, oral, for 24 weeks
11369395|NCT02238977|Active Comparator|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
11369396|NCT02238977|Experimental|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
11369397|NCT02238964|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
11369398|NCT02238964|Active Comparator|Standard closure|"Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures.
~Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon."
11369399|NCT02238951|Experimental|Mobile Health (mHealth)|Care coordination using mHealth technology enhancements
11369400|NCT02238951|Active Comparator|No mHealth|Care coordination without mHealth enhancements
11369401|NCT02238938|Experimental|en-bloc resection|En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
11369402|NCT02238938|Active Comparator|piecemeal resection|"Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.
~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy."
11369403|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):
~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.
~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.
~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
11369404|NCT02238912|Experimental|Kandhaga Rasayanam- single arm|Kandhaga Rasayanam- 2grams twice a day for 45 days
11369405|NCT02238886|Experimental|Parenteral nutrition|Patients receives a goal-directed nutritional intervention combining oral intake and parenteral nutrition
11369406|NCT02238886|No Intervention|Standard treatment|patients receives a standard nutritional strategy of resting the bowel till clear signs of bowel recovery and feeding orally after bowel recovery
11369407|NCT02238873|Active Comparator|Pegfilgrastim +1|Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
11369408|NCT02238873|Experimental|Pegfilgrastim +3|Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
11369409|NCT02238860|Active Comparator|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
11369410|NCT02238860|Active Comparator|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
11369411|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)
~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
11369412|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).
~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
11369413|NCT02238834|Experimental|SAD Cohorts 1-8 Experimental Arm|
11369414|NCT02238834|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
11369415|NCT02238834|Experimental|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
11369416|NCT02238834|Placebo Comparator|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
11369426|NCT02238730|Active Comparator|Brief Pulse Bitemporal|Brief Pulse (0.5 ms) Bitemporal Electroconvulsive Therapy
11369427|NCT02238717|Experimental|PF-06372865 (65mg)|
11369428|NCT02238717|Experimental|PF-06372865 (15mg)|
11369429|NCT02238717|Active Comparator|Pregabalin|
11369430|NCT02238717|Placebo Comparator|Placebo|
11369431|NCT02238704|Experimental|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
11369432|NCT02238704|Active Comparator|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
11369433|NCT02238691|Experimental|Mask ventilation with PEEP|15 subjects will undergo anesthetic induction with application of PEEP of 10 cm H2O during mask ventilation.
11369434|NCT02238691|No Intervention|Mask ventilation without PEEP|15 subjects will undergo anesthetic induction without PEEP during mask ventilation.
11369435|NCT02238678||Deep endometriosis patients|
11369436|NCT02238665||Ulcerative colitis|
11369437|NCT02238665||Crohn's disease|
11369438|NCT02238652|No Intervention|Control|
11369439|NCT02238652|Active Comparator|Intervention|Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety
11369440|NCT02238639|Experimental|Active search for pulmonary embolism|All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.
11369441|NCT02238639|No Intervention|Standard management|All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.
11369442|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
11369443|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
11369444|NCT02238613|Experimental|radioactive stent|The radioactive stent carrying seeds iodine 125 is made of Polytetrafluoroethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the irradiation group patients.
11369445|NCT02238613|Other|plastic stent|The plastic stent is made of polyethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the conventional group patients.
11369446|NCT02238587|Placebo Comparator|Placebo/Ganoderma|In control group, oral placebos for 6 weeks. Then the patients in control groups are switched, Ganoderma Spores Powder Capsules are given for 6 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
11369447|NCT02238587|Experimental|Ganoderma|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
11369448|NCT02238574|Experimental|follow up & surgery|CIN positive with surgery and intensified follow up
11369449|NCT02238574|Active Comparator|follow up|CIN positive, only intensified outpatient follow up
11369450|NCT02238561||Elective major abdominal surgery|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth Hospitals National Health Service (NHS) Trust (PHNT)
11369451|NCT02238548|Placebo Comparator|Control group|Regular cholera vaccination
11369452|NCT02238548|Experimental|Milk bolus|Cholera vaccination - raw milk - bolus
11369453|NCT02238548|Experimental|Milk controlled|Cholera vaccination - raw milk - controlled intake
11369454|NCT02238535|Active Comparator|Ventavis + Warfarin|Patients in this group will receive drug treatment - ventavis (2,0 ml - 6 time per day - during 5 days). Warfarin - INR=2,0-3,0
11369455|NCT02238535|Active Comparator|Warfarin|Patients in this group will receive drug treatment according to up-to-date guidelines (Warfarin - INR=2,0-3,0)
11369456|NCT02238522|Experimental|Dose Escalation Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
11369457|NCT02238522|Experimental|Dose Expansion Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
11369458|NCT02238509|Experimental|lapatinib and trastuzumab|ARM A: Lapatinib and trastuzumab (experimental arm). Patients with hormone receptor (HR) positive breast cancer will also receive endocrine therapy at the physician's discretion (preferred choice with fulvestrant).
11369459|NCT02238509|Experimental|trastuzumab plus chemotherapy|ARM B: Trastuzumab plus chemotherapy (control arm). Any type of chemotherapy in combination with trastuzumab will be allowed at the physician's discretion.
11369460|NCT02238496|Other|Surgical Cohort - cytoreductive surgery|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
11369461|NCT02238496|Other|Medical Cohort - no cytoreductive surgery|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
11369462|NCT02238483|Experimental|AZD7624|Active treatment
11369463|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
11369464|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
11369465|NCT02238457|Active Comparator|Low dose losartan|Low dose losartan
11369466|NCT02238457|Active Comparator|High dose losartan|High dose losartan
11369467|NCT02238444|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
11369468|NCT02238444|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
11369469|NCT02238431|Experimental|Lucrin depot, artificial cycle start|intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval
11369470|NCT02238431|Active Comparator|OCP active, artificial cycle start|to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days
11369471|NCT02238431|Experimental|Natural, menstrual period|to wait for the second bleed to commence the artificial FET cycle
11369472|NCT02238418|Experimental|Usual vitamin D supplementation|
11369473|NCT02238405|Experimental|Counseling|Intensive anti-smoking counseling
11369474|NCT02238405|No Intervention|Standard Care|Control group will receive current standard of care.
11369475|NCT02238392|Active Comparator|Group A|Adenosine testing after PVI and elimination of dormant conduction
11369476|NCT02238392|Active Comparator|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
11369477|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
11369478|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
11369479|NCT02238366||Prostate cancer patients|Patients recently diagnosed with prostate cancer requiring ADT.
11369480|NCT02238353|Experimental|azelastine + fluticasone|azelastine 137 µg + fluticasone 50 µg combined applied twice daily one puff in each nostril duration: 4 weeks
11369481|NCT02238353|Placebo Comparator|placebo|twice daily one puff in each nostril duration: 4 weeks
11369482|NCT02238340|Experimental|Extended-release oxycodone 10mgr|Extended-release oxycodone 10 mgrs , started 12 hours before orthopaedic surgery
11369483|NCT02238340|Experimental|Extended-release oxycodone 20 mgr|Extended-release oxycodone 20 mgr , started 12 hours before orthopaedic surgery
11369484|NCT02238327||HIV positive normal pulmonary function|HIV positive DLCO percent predicted >=.80 FEV1/FVC percent predicted >=0.70
11369485|NCT02238327||HIV positive with pulmonary dysfuntion|HIV positive DLco percent predicted <=0.80% FEV1/FVC percent predicted<=0.70%
11369486|NCT02238314|Experimental|Tipranavir low dose|
11369487|NCT02238314|Experimental|Tipranavir high dose|
11369488|NCT02238301|Other|"Patients test (pregnant women with a eutrophic fetus)"|Test the type of mask, oxygen flow and duration of oxygenation, adjustment of MRI machine Adjustment of MRI machine (choice of antenna calibration, verifying Settings of each sequence, adaptation of the number of cuts for the duration of each sequence, checking the correct execution of the succession of sequences, settings of total examination time)
11369489|NCT02238301|Active Comparator|Pregnant women with a diagnosis of IUGR fetuses|Measure of the BOLD effect in the feto-placental units of IUGR fetuses
11369490|NCT02238301|Active Comparator|Pregnant women with eutrophic fetuses|Measure of BOLD effects of fetal-placental unit eutrophic fetuses
11369491|NCT02238288|Active Comparator|aminocaproic acid|Crushed tablets inserted in the dental socket post-extraction
11369492|NCT02238288|Other|Routine care after dental extraction|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
11369493|NCT02238275||Patients with hypertension|
11369494|NCT02238262||essential hypertension patients|
11369495|NCT02238249||paediatric patients with urticaria|
11369496|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
11369497|NCT02238223||Patients without experience in treatment with epinastine|
11369498|NCT02238210|Experimental|Atrovent® - common cold group|Treatment duration for common cold group - three time daily for 4 days
11369499|NCT02238210|Experimental|Experimental: Atrovent® - allergy group|Treatment duration for allergy group - three time daily for 14 days
11369500|NCT02238197||Chronic Obstructive Pulmonary Disease|
11369501|NCT02238184||Chronic Obstructive Pulmonary Disease|patients receiving Atrovent®
11369502|NCT02238184||Cronic Obstructive Pulmonary Disease|patients receiving Ventilat®
11369503|NCT02238171||Chronic Obstructive Pulmonary Disease|
11369504|NCT02238158||Chronic Obstructive Pulmonary Disease|
11369505|NCT02238145||Chronic Obstructive Airways Disease|
11369506|NCT02238132||Chronic Obstructive Airways Disease|
11369507|NCT02238119|Experimental|tiotropium + formoterol|
11369508|NCT02238119|Active Comparator|tiotropium|
11369509|NCT02238119|Active Comparator|formoterol|
11369510|NCT02238106|Experimental|Salmeterol inhalation powder, medium dose|administered via HandiHaler®
11369511|NCT02238106|Active Comparator|Salmeterol inhalation powder, low dose|administered via HandiHaler®
11369512|NCT02238106|Active Comparator|Salmeterol inhalation powder, high dose|administered via HandiHaler®
11369513|NCT02238106|Active Comparator|Serevent® Diskus®|administered via Diskus®
11369514|NCT02238106|Placebo Comparator|Placebo|administered via Diskus® or HandiHaler®
11369515|NCT02238093||Dialysis Patients|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.
11369890|NCT02235467|Active Comparator|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
11369516|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
11369517|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
11369518|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
11369519|NCT02238041||GlucoClear System|
11369520|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
11369521|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
11369522|NCT02238015||surgery group|patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
11369523|NCT02238015||control group|patients' other eye that did not have surgery
11369524|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
11369525|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
11369526|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
11369527|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
11369528|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
11369529|NCT02237976|Active Comparator|Routine practice|No specific intervention
11369530|NCT02237963||Posterolateral thoracotomy|Surgeons perform a posterolateral thoracotomy
11369531|NCT02237963||Axillary thoracotomy|Surgeons perform an axillary thoracotomy
11369532|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
11369533|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
11369534|NCT02237937|Experimental|Normal dosage|"Selected antidepressants that are substrates of the P-glycoprotein:
~Dosage:
~paroxetine < 40 mg/d
~sertraline < 100 mg/d
~citalopram < 40 mg/d
~escitalopram < 20 mg/d
~venlafaxine < 225 mg/d
~amitriptyline < 150 mg/d
~amitriptylinoxide < 150 mg/d
~nortriptyline < 150 mg/d
~trimipramine < 150 mg/d"
11369535|NCT02237937|Experimental|High dosage|"Selected antidepressants that are substrates of the P-glycoprotein:
~Dosage:
~paroxetine < 80 mg/d
~sertraline < 200 mg/d
~citalopram < 80 mg/d
~escitalopram < 40 mg/d
~venlafaxine < 450 mg/d
~amitriptyline < 300 mg/d
~amitriptylinoxide < 300 mg/d
~nortriptyline < 300 mg/d
~trimipramine < 300 mg/d"
11369536|NCT02237924|Experimental|endostar + IMRT|
11369537|NCT02237924|Active Comparator|DDP + IMRT|
11369538|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
11369539|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
11369540|NCT02237911|No Intervention|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
11369541|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
11369542|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
11369543|NCT02237885|Experimental|Neurofeedback|
11369544|NCT02237859|Experimental|Vancomycin|Vancomycin 125 mg PO QD vs Placebo
11369545|NCT02237846|Active Comparator|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
11369546|NCT02237846|Active Comparator|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
11369547|NCT02237833||Septic shock and vasopressor|Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.
11369548|NCT02237820|Experimental|Dexamethasone|
11369549|NCT02237820|Active Comparator|Prednisone|
11369550|NCT02237807|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
11369551|NCT02237807|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
11369552|NCT02237794||Patients Without Acute Heart Conditions|Patients without acute heart conditions who were hospitalized for other medical indications.
11369553|NCT02237781|Experimental|AMH levels|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.
11369554|NCT02237768|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
11369555|NCT02237768|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
11369556|NCT02237755|Active Comparator|Clomiphene citrate|Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
11369557|NCT02237755|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
11369558|NCT02237742|Experimental|PF-06427878|
11369559|NCT02237729|Experimental|PF-06410293|
11369560|NCT02237729|Active Comparator|Adalimumab-US|
11369561|NCT02237729|Active Comparator|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
11369562|NCT02237703||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
11369563|NCT02237703||Trauma Control (TC)|Trauma Control (TC)
11369564|NCT02237703||Healthy Control (HC)|Healthy Control (HC)
11369565|NCT02237690|Experimental|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
11369566|NCT02237690|Active Comparator|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
11369567|NCT02237677||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
11369568|NCT02237677||Healthy Controls (HC)|Healthy Controls (HC)
11369569|NCT02237664|Active Comparator|Patient-controlled paravertebral analgesia (PC-PVB)|Patient-controlled paravertebral analgesia
11369570|NCT02237664|Placebo Comparator|Continuous paravertebral analgesia (C-PVB)|Continuous paravertebral analgesia
11369571|NCT02237651||topical anesthesia multi-use device|anesthesia with multi-use device (Laryngeal atomizer, Karl Storz, Tuttlingen, Germany
11369572|NCT02237651||topical anesthesia Intranasal Mucosal Atomization|single-use product (LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Teleflex medical, Kernen Germany) for topical anesthesia
11369573|NCT02237638|Experimental|hVEGF26-104/RFASE vaccination|hVEGF26-104/RFASE is investigated in dose escalation in which hVEGF26-104 is escalated from 62.5 ug to 500 ug and RFASE is given in a fixed dose of 20 mg. Three patients are treated at each dose level. If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort. If 1 of the 3 patients shows DLT, 3 additional patients are treated at that dose level. If none of these show DLT, the dose level is escalated for the next cohort; otherwise, the prior dose level is defined as the MTD. At the highest dose level 6 patients will be treated. The recommended dose for a phase II trial will be the lowest dose that results in the most effective VEGF neutralization, together with acceptable safety and toxicity.
11369574|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
11369575|NCT02237612|Experimental|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
11369576|NCT02237586|Experimental|Group IA|"Adults with naturally acquired immunity and HbAA (Group IA, n=10)
~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
11369577|NCT02237586|Experimental|Group IS|"Adults with naturally acquired immunity and HbAS (Group IS, n=10)
~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
11369578|NCT02237586|Experimental|Group NI|"Adults without previous exposure to malaria and HbAA (Group NI, n=5)
~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
11369579|NCT02237573|Experimental|Intervention|Written medical report and standardized medical advices
11369580|NCT02237573|Active Comparator|Control|Standardized medical advice only
11369581|NCT02237560|Experimental|Cybercycle-Game|Combined aerobic & cognitive exercise for 6 months, 3-5x/week.
11369582|NCT02237560|Active Comparator|Cybercyle-Tour|Aerobic exercise only for 6 months, 3-5x/week.
11369583|NCT02237560|Active Comparator|Game Only|Cognitive exercise only 6 months, 3-5x/week.
11369584|NCT02237547|Experimental|IV and IT UC-MSC and BMMC|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
11369585|NCT02237534|Active Comparator|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.
11369586|NCT02237534|Experimental|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
11369587|NCT02237521||End-stage renal disease|Patients with normal glucose tolerance and end-stage renal disease
11369588|NCT02237521||Controls|Healthy controls with normal kidney function and normal glucose tolerance
11369589|NCT02237508|Experimental|Z7200|single dose (two inhalations)
11369590|NCT02237508|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
11369591|NCT02237508|Experimental|Z7200 with charcoal|single dose (two inhalations)
11369592|NCT02237508|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
11369593|NCT02237508|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
11369594|NCT02237495|Placebo Comparator|Saline|Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
11369595|NCT02237495|Experimental|dexmedetomidine|dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
11369596|NCT02237482|Experimental|Small periacetabular bone defects|Patients with cup loosening and small periacetabular bone defects
11369597|NCT02237482|Experimental|Large periacetabular bone defects|Patients with cup loosening and large periacetabular bone defects
11369598|NCT02237469||Prone and supine simulation|Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
11369599|NCT02237443|Other|Post-induction|Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
11369600|NCT02237430|Active Comparator|Manuel compression|Conventional manual compression
11369601|NCT02237430|Experimental|MynxGrip closure device|Closure device for femoral artery access closure
11369602|NCT02237417|Other|Healthy Control|
11369603|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
11369604|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
11369605|NCT02237404|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
11369606|NCT02237404|Experimental|Remote monitoring of pacemakers|"Telemedicine System:
~Patients have not to go to the hospital to be monitorized"
11369607|NCT02237391|Experimental|CIPAP Program|Complex Interdisciplinary Pain Assessment Program
11369608|NCT02237391|Other|Treatment as Usual (TAU)|Treatment as usual control group
11369609|NCT02237378|Experimental|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
11369610|NCT02237365|Experimental|81mg aspirin|Aspirin 81mg daily for 60 days
11369611|NCT02237365|Experimental|1000mg aspirin|Aspirin 1000mg daily for 60 days
11369612|NCT02237365|Placebo Comparator|Placebo|Visually matched placebo daily for 60 days
11369613|NCT02237352||Control|Subjects without diabetic nephropathy
11369614|NCT02237352||Diabetic nephropathy|Subjects with diabetic nephropathy
11369615|NCT02237339|Active Comparator|Allopurinol|Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.
11369616|NCT02237339|Placebo Comparator|Placebo tablet|Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.
11369617|NCT02237326|Active Comparator|Visual Inspection with Lugol's Iodine|Participants underwent colposcopic exam, followed by Visual Inspection with Lugol's Iodine (VILI) by a second, blinded clinician (the order of exams was reversed to eliminate potential interference with exam results due to iodine staining). Biopsy was done after the VILI.
11369618|NCT02237326|Active Comparator|Visual Inspection with Acetic Acid|Participants underwent Visual Inspection with Acetic Acid followed by colposcopy by a second clinician who was blinded to the screening test result.
11369619|NCT02237313|Experimental|prevalent cases|"40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.
~8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program"
11369620|NCT02237300|Experimental|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
11369621|NCT02237300|Active Comparator|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
11369622|NCT02237287|Sham Comparator|wound dressing with VAC|After wound debridement wounds are treated for 2 weeks with VAC dressing alone
11369623|NCT02237287|Other|wound dressing with VAC and sNAG under Antiaggregation|In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
11369624|NCT02237287|Experimental|wound dressing with VAC and sNAG without antiaggregation|In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG
11369625|NCT02237274|Experimental|Patients with Fontan circulation|High altitude exposition
11369626|NCT02237274|Other|Age and gender-matched healthy volunteers|High altitude exposition
11369760|NCT02236377|Active Comparator|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
11369627|NCT02237261|Experimental|Bendamustine, Bortezomib, Prednisone|Induction: Bortezomib: 1.3 mg/m2 subcutaneous for 7 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison: : 60 mg/m2 per os for 4 days Consolidation: Bortezomib: 1.3 mg/m2 subcutaneous for 4 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison 60 mg/m2 per os for 4 days
11369628|NCT02237235|Experimental|MMFS-202 -302|"MMFS-202: evening dose
~MMFS-302: morning dose"
11369629|NCT02237235|Placebo Comparator|Placebo|Placebo
11369630|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.
~Frequency and intensity are individually assigned."
11369631|NCT02237209|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
11369632|NCT02237209|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
11369633|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.
~Cat immunotherapy will be administered weekly."
11369634|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.
~Cat immunotherapy will be administered weekly."
11369635|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.
~Placebo for Cat immunotherapy will be administered weekly."
11369636|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.
~Placebo for cat immunotherapy will be administered weekly."
11369637|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
11369638|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
11369639|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
11369640|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
11369641|NCT02237170||Castration Resistant Metastatic Prostate Cancer|Castration Resistant Metastatic Prostate Cancer with no history of prior systemic chemotherapy
11369642|NCT02237157|Other|Gemcitabine, Local Delivery|Gemcitabine; 4 cycles, two doses per cycle; dose escalation
11369643|NCT02237144|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
11369644|NCT02237144|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
11369645|NCT02237144|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
11369646|NCT02237144|Experimental|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
11369647|NCT02237144|Experimental|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
11369648|NCT02237131|Experimental|Oral contraceptives cyclic|Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free. The regimen will be repeated for the duration of the trial.
11369649|NCT02237131|Active Comparator|Oral contraceptives continuous|Oral contraceptives containing 0.030 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for the duration of the trial.
11369650|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
11369651|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
11369652|NCT02237105|Experimental|Cognitive Behavioral Therapy Group|This group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery
11369653|NCT02237105|No Intervention|control group|This group will not undergo any psychological intervention before the spinal surgery.
11369654|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
11369655|NCT02237079|Experimental|Bazedoxifene/Conjugated Estrogens (BZA/CE)|"Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications."
11369656|NCT02237079|Placebo Comparator|Placebo|"Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind."
11369657|NCT02237066|Experimental|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
11369658|NCT02237066|Active Comparator|Standard PTA Balloon|Standard PTA Balloon Angioplasty
11369659|NCT02237053|Active Comparator|Glucagon with Octreotide and insulin|Overnight (10 hours) infusion of glucagon, then 3 hours infusion of glucagon with concurrent infusions of Octreotide and insulin.
11369660|NCT02237053|Placebo Comparator|Placebo, Glucagon with Octreotide and Insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of glucagon with concurrent infusions of Octreotide and insulin.
11369761|NCT02236377|Active Comparator|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
11369661|NCT02237053|Placebo Comparator|Placebo, with Octreotide and insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of saline with concurrent infusions of Octreotide and insulin.
11369662|NCT02237040|Experimental|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
11369663|NCT02237027|Experimental|TasP group|HIV positive female sex workers receiving TasP using ART regimen as per Benin guidelines
11369664|NCT02237027|Experimental|PrEP group|HIV negative female sex workers receiving PrEP using Truvada
11369665|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
11369666|NCT02236988|Experimental|Formulation of apremilast + test formulations 1, 2, and 3|A single oral 60 mg reference formulation of apremilast, given as 30 mg twice a day (BID), and single oral doses of 75 mg of each test formulation numbers 1, 2, and 3 given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. There will be at least 7, and not more than 10 days between each dose
11369667|NCT02236988|Experimental|Formulation of apremilast + test formulations 4, 5, and 6|A single oral 60 mg reference formulation (given as 30 mg twice a day),and single oral doses of 75 mg of each test formulation #s 4, 5, and 6 given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. There will be at least 7, and not more than 10 days between each dose. If only 2 test formulations are available, there will be 6 possible sequences (AEF, EFA, FAE, AFE, EAF, FEA).
11369668|NCT02236988|Experimental|Formulation of apremilast + test formulations: 7 and 8|A single oral 60 mg reference formulation (given as 30 mg twice a day),and single oral doses of 75 mg of each test formulation #s 7 and 8 given in 6 possible sequences (AHI, HIA, IAH, AIH, HAI, and IHA). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. If only 1 test formulation is available, there will be 2 possible sequences (AH and HA).
11369669|NCT02236988|Experimental|Formulation of Apremilast + test formulations: 11, 12, 13, 14|A single oral 60 mg reference formulation (given as 30 mg twice a day),and single oral doses of 75 mg of each test formulation #s 11, 12, 13, and 14 given in 10 possible sequences (ALOMN, LMANO, MNLOA,NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, and MLNAO). Each subject will be randomly assigned to a sequence which will determine the order in which each formulation is given. There will be at least 7, and not more than 10 days between each dose.
11369670|NCT02236975|Experimental|BuMA Supreme Biodegradable drug coating coronary stent system|Implant BuMA Supreme stent only
11369671|NCT02236975|Active Comparator|Resolute Integrity durable polymer stent system|Implant Resolute stent
11369672|NCT02236962|Placebo Comparator|Placebo|lactose powder in equivalent capsule
11369673|NCT02236962|Experimental|Drug treatment|sympathetic agonist and thiazolidinedione
11369674|NCT02236949|Experimental|Pain Practice Change Booster|Pain Practice Change Booster Intervention: 12 months after the EPIQ intervention, and every 4 months for 2 years, a 30-60 minute standardized booster session was delivered to a small group of champions in each hospital unit randomized to the intervention group. Two co-facilitators familiar with the EPIQ intervention conducted all booster sessions via teleconference. Booster sessions included reviewing the effectiveness knowledge translation strategies champions implemented over the past four months to sustain and improve targeted pain practices; determining the sustainability of the pain practice changes, developing a commitment to change plan of action for the next four months.
11369675|NCT02236949|No Intervention|Usual Care Group|No interventions associated with the study were conducted on these units.
11369676|NCT02236936|Active Comparator|Arm A - Standard of care|"Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.
~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
11369677|NCT02236936|Experimental|Arm B - Parenteral over night nutrition|"Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss >5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.
~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
11369678|NCT02236923||Group A: Single procedure|Group A consists of patients recorded as having only had an ascending aortic dissection repair procedure.
11369679|NCT02236923||Group B: Multiple procedures|Group B consists of patients who had an ascending aortic dissection repair procedure together with any other surgical intervention.
11369680|NCT02236910|Experimental|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
11369681|NCT02236910|Experimental|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
11369682|NCT02236897|Experimental|PET Scanning|Imaging of mGluR5 using PET scanning
11369683|NCT02236884|Experimental|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
11369684|NCT02236871|No Intervention|Control|Maintain current milk and milk product intakes.
11369685|NCT02236871|Active Comparator|2 servings|Participants will be asked to consume 1 milk (250 ml) plus a yogurt (100-175 g) or cheese (up to 50 g) to reach an average of 2 servings of milk or milk products/d.
11369686|NCT02236871|Active Comparator|4 servings|Participants will be asked to consume recommended servings of milk or milk products/d for their age, so they will receive 1 milk (250 ml), a yogurt (175 g) and cheese (50 g) or more. This would provide ≥ 3 servings/d.
11369687|NCT02236858|Sham Comparator|Sham HEPA Air Cleaner|Sham HEPA Air Cleaner and Delayed Intervention. Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
11369762|NCT02236377|Active Comparator|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
11369891|NCT02235467|No Intervention|ABA parent training control|
11369688|NCT02236858|Active Comparator|HEPA Air Cleaner|HEPA Air Cleaner also containing carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time. These air cleaners are suitably sized to provide clean air delivery rates for the rooms in which they will be placed. Participants will be instructed to run the air cleaners continually during the course of the study and the units will be modified to prevent them from being turned off by the participants.
11369689|NCT02236845|Experimental|Lacrima medical active device|
11369690|NCT02236845|Sham Comparator|Lacrima medical sham device|
11369691|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
11369692|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
11369693|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
11369694|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
11369695|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
11369696|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
11369697|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
11369698|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
11369699|NCT02236806|Placebo Comparator|Arm 4|Placebo
11369700|NCT02236793|Experimental|BioChaperone PDGF-BB|BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
11369701|NCT02236793|Placebo Comparator|Standard of Care|Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
11369702|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
11369703|NCT02236754|Other|Healthy Controls|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
11369704|NCT02236754|Other|Patients with T1D|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
11369705|NCT02236741||users of anti-parkinsonian drugs|
11369706|NCT02236728||Parkinson's disease patients|
11369707|NCT02236715||Chronic Obstructive Airways Disease|
11369708|NCT02236702||Asymptomatic control|Asymptomatic control
11369709|NCT02236702||Mildly symptomatic with depressive symptoms|Mildly symptomatic with depressive symptoms
11369710|NCT02236702||Moderately symptomatic with depressive symptoms|Moderately symptomatic with depressive symptoms
11369711|NCT02236702||Severely symptomatic with depressive symptoms|Severely symptomatic with depressive symptoms
11369712|NCT02236689|Active Comparator|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
11369713|NCT02236689|Placebo Comparator|Non Operative|control group will not undergo a second portal or muscle release.
11369714|NCT02236663|Experimental|App Based Safety Decision Aid|Personalized App-Based Safety Decision Aid
11369715|NCT02236663|Active Comparator|Control App|Usual Care Safety Plan
11369716|NCT02236650|Experimental|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
11369717|NCT02236650|Active Comparator|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
11369718|NCT02236637||mCRPC patients|Patients with metastatic castration-resistant prostate cancer treated according to routine clinical practice
11369719|NCT02236624|Experimental|Aerobic Exercise|
11369720|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
11369721|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
11369722|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
11369723|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months
~Subjects will be instructed to take the pills"
11369724|NCT02236585|Active Comparator|Patient-controlled epidural analgesia|Patient-controlled epidural analgesia
11369725|NCT02236585|Placebo Comparator|Continuous epidural analgesia|Continuous epidural analgesia
11369726|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
11369727|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.
~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
11369763|NCT02236364|Experimental|New device for OPTICAL determination of blood glucose level|
11369728|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.
~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
11369729|NCT02236546|Experimental|FDG-PET/CT|Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
11369730|NCT02236533|Placebo Comparator|Control pasta|Volunteers were fed with control pasta, without B-glucans and spores of B. coagulans once a day for 12 weeks.
11369731|NCT02236533|Experimental|Probiotic Whole Grain Pasta|Volunteers were fed with probiotic fortified pasta, including B-glucans and spores of B. coagulans once a day for 12 weeks.
11369732|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
11369733|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
11369734|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
11369735|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
11369736|NCT02236507|Other|children without anorectal disorders|All children will be investigated by 3D high resolution anorectal manometry procedure
11369737|NCT02236494|Active Comparator|General Health Information Pamphlet|This group will not receive a brief intervention in the ED. They will receive a pamphlet with general health information for older adults, as well as contact information for an outpatient alcohol treatment center where they have the option to follow-up for alcohol treatment at their discretion. The patient's readiness to change their alcohol habits will be measured using a 1-10 scale with a visual cue.
11369738|NCT02236494|Experimental|Brief Negotiated Interview|The BNI will follow standard steps (7, 63): 1. The research assistant (RA) will ask permission to discuss the patient's alcohol use with them. 2. They will provide feedback regarding the patient's alcohol use, and will review guidelines drinking in older adults. Where relevant, the RA will discuss how the patient's current visit may relate to their alcohol use. 3. The RA will assess the patient's readiness to change using a 1-10 scale, and will enhance motivation. 4. The RA will negotiate a goal for the patient's drinking and give advice. The patient will be asked to sign a drinking agreement.
11369739|NCT02236481|Experimental|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
11369740|NCT02236481|Active Comparator|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
11369741|NCT02236468|Experimental|new EHFP|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
11369742|NCT02236468|Experimental|old EHFP+WASH|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication since 2014
11369743|NCT02236468|Other|new EHFP+WASH|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014 + WASH/malaria behavior change communication since 2014
11369744|NCT02236468|Other|old EHFP+WASH+LNS distribution|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication and distribution of LNS since 2014
11369745|NCT02236455|Experimental|Audio Relaxation technique|Relaxation is a process that decreases the effects of stress on your mind and body. Relaxation techniques can help you cope with everyday stress and with stress related to various health problems, such as cancer and pain.
11369746|NCT02236455|Experimental|Medical Music Intervention|Music intervention is use to assist with relaxation and reduce stress levels in patients.
11369747|NCT02236455|Experimental|Nature Therapy without Music|Ecotherapy is the use of nature to reduce stress and to increase levels of well-being in patients.
11369748|NCT02236455|Experimental|Nature Therapy with Music|Nature therapy videos were produced with and without music for surgical patients.
11369749|NCT02236442|No Intervention|Usual care|First arm : Passive recording head pain, linked symptoms, treatment used and diagnosis.
11369750|NCT02236442|Experimental|After protocol recommendation care|Recording head pain, linked symptoms, treatment used and diagnosis after intervention that is recommendation to use global headache treatment protocol
11369751|NCT02236429|Experimental|recurrent bacterial vaginitis|
11369752|NCT02236416|Experimental|Intervention group|Physical exercise
11369753|NCT02236416|Other|Control group|Posture Education/Unchanged condition
11369754|NCT02236403|Experimental|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
11369755|NCT02236403|Placebo Comparator|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
11369756|NCT02236390|Active Comparator|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
11369757|NCT02236390|Active Comparator|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
11369758|NCT02236390|Active Comparator|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
11369759|NCT02236377|Active Comparator|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
11370702|NCT02229747|Active Comparator|Nimesulide suspension|
11369764|NCT02236351|Placebo Comparator|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
11369765|NCT02236351|Experimental|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
11369766|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).
~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
11369767|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).
~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
11369768|NCT02236325|Experimental|DBT Brief Suicide Intervention|
11369769|NCT02236325|Active Comparator|Relaxation Training|
11369770|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
11369771|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
11369772|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
11369773|NCT02236312|Placebo Comparator|Placebo|I.M. injection
11369774|NCT02236299|Placebo Comparator|saline placebo infusion|30 minute infusion of a saline placebo Right coronary artery percutaneous coronary intervention
11369775|NCT02236299|Experimental|GLP-1 infusion|30 minute infusion of GLP-1 Right coronary artery percutaneous coronary intervention
11369776|NCT02236286|Experimental|Exercise|Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions). The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD. The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
11369777|NCT02236286|Active Comparator|Chronic Disease Management Education|Subjects will also receive (cross-over) six weeks of educational classes. The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism. Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks. Subject will do an additional 120 minutes of relaxation at home/week.
11369778|NCT02236273|Experimental|Conventional Text Message|Conventional text message reminder
11369779|NCT02236273|Experimental|Enhanced reminders|Enhanced text message reminders
11369780|NCT02236260|Active Comparator|Local anesthesia alone|
11369781|NCT02236260|Experimental|Local Anesthesia + Electroacupuncture|
11369782|NCT02236247|Experimental|ivabradine|I(f) inhibitor, heart rate controller
11369783|NCT02236247|Placebo Comparator|placebo|placebo pill will be administered orally twice daily
11369784|NCT02236234|Experimental|Vaccine|one group with HPV vaccine
11369785|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
11369786|NCT02236182|Experimental|Ipratropium Bromide low|delivered via RESPIMAT®
11369787|NCT02236182|Experimental|Ipratropium Bromide high|delivered via RESPIMAT®
11369788|NCT02236182|Placebo Comparator|Placebo|delivered via RESPIMAT®
11369789|NCT02236169|Experimental|Ipratropium bromide|
11369790|NCT02236169|Active Comparator|ATROVENT|
11369791|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
11369792|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
11369793|NCT02236143||MRI|Subjects undergoing MRI
11369794|NCT02236130|Active Comparator|General|General Anesthesia only
11369795|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
11369796|NCT02236117|Experimental|Intervention: Aerobic Training|The children included in the experimental group will make 10 weeks of aerobic training. The intensity of the race will be based on individual speed obtained in the last stage completed the progressive test, known as the maximal aerobic speed (MAV) in km/h. The running speed of the exercise protocol will be minimum 80% of the MAV in the protocol of continuous training. The intermittent progressive training is n * (10*15 s) to 100% MAV, and n from 2 to 6 series between the first and tenth week. The training protocol was adapted from previously described (Mandigout et al, 2002, Gamelin et al, 2009.). Acceptance of the exercise in a pediatric population has been previously observed by pilot study.
11369797|NCT02236117|No Intervention|physical education classes|
11369798|NCT02236104|Experimental|cough assist session|Mechanical insufflation-exsufflation contains 15 cycles durea 2-3 seconds. pressure level fixed +/-30 cm H2O.
11369799|NCT02236091||Inpatients|
11369800|NCT02236078|Experimental|High dose isoniazid|INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing <45 kg)
11369801|NCT02236065|Experimental|UCB + G-CSF|UCB + G-CSF
11369802|NCT02236052|Experimental|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
11369803|NCT02236052|Experimental|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
11369804|NCT02236052|Experimental|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
11369805|NCT02236052|Experimental|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
11369806|NCT02236052|Experimental|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
11369807|NCT02236052|Placebo Comparator|Placebo|A single dose of Placebo
11369808|NCT02236039|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by a bronchoscopy 24 hours post exposure.
11369809|NCT02236039|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by a bronchoscopy 24 hours post exposure.
11369810|NCT02236026|Experimental|Supratherapeutic dose of Nestorone|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
11369811|NCT02236026|Placebo Comparator|Placebo|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
11369812|NCT02236026|Experimental|Moxifloxacin|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
11369813|NCT02236013|Experimental|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
11369814|NCT02236013|Experimental|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
11369815|NCT02236013|Experimental|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
11369816|NCT02236013|Experimental|Continuous ASP2215 Exposure during Consolidation (Part 4)|During Consolidation, ASP2215 will be given daily on day 1 up to day 56.
11369817|NCT02236000|Experimental|Neratinib and T-DM1|
11369818|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
11369819|NCT02235974|Experimental|Acute/Early|Intervention: A 20-hour dose of early intensive upper extremity motor training therapy will be initiated within 30 days post-stroke.
11369820|NCT02235974|Experimental|Sub-acute/Outpatient|Intervention: A 20-hour dose of sub-acute intensive upper extremity motor training therapy will be initiated within 2 to 3 months post-stroke.
11369821|NCT02235974|Experimental|Chronic|Intervention: A 20-hour dose of chronic intensive upper extremity motor training therapy will be initiated 6 to 9 months post-stroke
11369822|NCT02235974|Placebo Comparator|Control|Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
11369823|NCT02235961|Experimental|Part 1|
11369824|NCT02235961|Experimental|Part 2|
11369825|NCT02235948|Experimental|folic acid|folic acid supplementation placebo controlled
11369826|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
11369827|NCT02235922|Experimental|Dual task training|Dual task training
11369828|NCT02235922|Experimental|Conventional training|Conventional training
11369829|NCT02235909|Experimental|Azilsartan Medoxomil 10 mg|Once a day dosing
11369830|NCT02235909|Experimental|Azilsartan Medoxomil 20 mg|Once a day dosing
11369831|NCT02235909|Experimental|Azilsartan Medoxomil 40 or 80 mg|Once a day dosing
11369832|NCT02235909|Active Comparator|Losartan 25 or 50 mg|Once a day dosing
11369833|NCT02235896|Other|Education/Behavior Modification|Education/Behavior modification program
11369834|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
11369835|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
11369836|NCT02235857|Experimental|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
11369837|NCT02235844|Experimental|Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells
11369838|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
11369839|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
11369840|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
11369841|NCT02235818|Active Comparator|Kinesiotape (KT)|Kinesiotape was used only on the affected side as per the manufacturer instructions. With the elbow extended, wrist fully flexed and fingers pointed down 24, KT was applied with slight stretch (10-15%) and paper off tension to the lateral arm beginning just above the bony portion of lateral epicondyle. Once the top strand was anchored, KT was applied along the side of elbow such that hole in the tape was over lateral epicondyle of the elbow. Two strands of tape followed the lateral forearm and ended at around beginning of the distal one third of forearm. Once the support was applied, KT was gently rubbed to activate the glue.
11369842|NCT02235818|Active Comparator|Counterforce elbow brace|The counterforce brace was approximately 5cm wide with velcro attachment for adjustable girth. It had gel pack for extra support on extensor muscle mass. With the elbow extended, brace was applied 2.5cms below the lateral epicondyle. A feeling of comfortable compression, as reported by the patients was used to adjust the brace.
11369843|NCT02235805|Experimental|Magnesium Citrate|
11369844|NCT02235805|Placebo Comparator|Placebo|
11369845|NCT02235792|Experimental|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
11369846|NCT02235779|Other|Cryobiopsy|
11369847|NCT02235766||CRT candidates patients|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.
11369848|NCT02235753|Experimental|High-intensity interval training, HIT-S|High-intensity aerobic interval training, short interval (HIT-S)
11369849|NCT02235753|Experimental|High-intensity interval training, HIT-L|High-intensity aerobic interval training, long interval (HIT-L)
11369850|NCT02235753|No Intervention|Usual care|control group
11369851|NCT02235740|Experimental|Afuresertib 125 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive Afuresertib 125 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg (increased dosage of 27 mg/meter (m)^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
11369852|NCT02235740|Experimental|Afuresertib 150 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive oral Afuresertib 150 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
11369853|NCT02235740|Experimental|Afuresertib 100 mg+ Carfilzomib (Part 1)|An additional arm with 100 mg of afuresertib may be evaluated if the other 2 arms are not tolerated. Approximately 8 subjects will receive Afuresertib 100 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
11369854|NCT02235740|Experimental|Afuresertib/carfilzomib (Part 2)|Approximately 50 subjects will receive Afuresertib Recommended Phase 2 Dose (RP2D) daily starting Cycle 1 Day 1 + Carfilzomib 20 mg/m^2 Cycle 1, Day 1, 2. Carfilzomib 27 mg (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15 and 16; Cycle Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9 and 15 and 16 of each cycle.
11369855|NCT02235740|Active Comparator|Carfilzomib (Part 2)|Approximately 50 subjects will receive Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9 15, and 16; Cycle 2, Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9, 15 and 16 of each cycle.
11369856|NCT02235727|Experimental|GBR 900|Test treatment GBR 900
11369857|NCT02235727|Placebo Comparator|Placebo|Placebo Treatment
11369858|NCT02235714||Tetraplegia|Individuals with chronic tetraplegia
11369859|NCT02235714||Asthma|Individuals with mild asthma
11369860|NCT02235714||Able-bodied controls|Age matched able-bodied (AB) controls with no history of lung disease
11369861|NCT02235701|Experimental|aldoxorubicin|
11369862|NCT02235688|Experimental|aldoxorubicin|
11369863|NCT02235675|Experimental|Tack-It|Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
11369864|NCT02235662|Experimental|TFV IVR|TFV IVR is an intravaginal ring 55.0 mm in diameter, consisting of single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. Used for one month, the IVR delivers 8-10 mg/day TFV.
11369865|NCT02235662|Experimental|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm: a longer segment containing white TFV paste and a shorter one (20 mm) with a white LNG core. Used for one month, the IVR delivers 8-10 mg/day TFV and 20 μg/day LNG.
11369866|NCT02235662|Placebo Comparator|Placebo Intravaginal Ring|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month.
11369867|NCT02235649|No Intervention|TAU|Treatment as usual
11369868|NCT02235649|Active Comparator|SOC+TAU|Social Cognition intervention + Treatment as Usual
11369869|NCT02235636||Laparoscopic group|
11369870|NCT02235636||Robotic group|
11369871|NCT02235623|Other|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
11369872|NCT02235623|Other|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
11369873|NCT02235610|No Intervention|Standard Group|"Recipients receive standard donor lungs as per current clinical practice.
~No experimental procedures will be carried out."
11369874|NCT02235610|Experimental|EVLP Group|Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.
11369875|NCT02235597||Patients and Staff of Community Clinics|Patients and Staff of Community Clinics who shared strategies and solutions to overcome barriers to accessing health care
11369876|NCT02235584|Experimental|Dexamethasone|This is a before-after study. All subjects are administered dexamethasone 2mg BID for 5 days.
11369877|NCT02235571|No Intervention|Control|These subjects are receiving standard patient education
11369878|NCT02235571|Experimental|iChoose Kidney Decision Aid|These subjects receive iChoose Kidney Decision Aid along with standard patient education
11369879|NCT02235558|Experimental|Verapamil|Super-selective intra-arterial administration of 10 mg verapamil immediately following successful intra-arterial thrombolysis
11369880|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
11369881|NCT02235532|Experimental|Foramen Herbal Aloe toothpaste|test group was asked to brush the teeth with Foramen Herbal Aloe toothpaste for 30 days once a day.
11369882|NCT02235532|Active Comparator|use of fluoride toothpaste (signal)|use of a fluoride toothpaste (signal) in control group once a day for 30 days .
11369883|NCT02235519|Active Comparator|Azilsartan low dosage|Patients will take azilsartan 40 mg during 12 weeks
11369884|NCT02235519|Active Comparator|Azilsartan high dosage|Patients will take azilsartan 80 mg during 12 weeks
11369885|NCT02235506|Experimental|epidural infusion|In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation,
11369886|NCT02235506|Experimental|femoral sciatic|In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr.
11369887|NCT02235493||Retrospective Case Only|
11369888|NCT02235480|Experimental|Tazarotene Gel|once daily
11369889|NCT02235480|Placebo Comparator|Placebo Gel|once daily
11369892|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
11369893|NCT02235441|Experimental|Cardiopulmonary Fitness|All eligible subjects will participate in treadmill exercise to measure cardiopulmonary fitness during chemoradiation therapy.
11369894|NCT02235428|Experimental|Ipratropium bromide|
11369895|NCT02235428|Active Comparator|Salbutamol|
11369896|NCT02235415||Motens|
11369897|NCT02235402|Experimental|Lacidipine|
11369898|NCT02235402|Active Comparator|Bendrofluazide|
11369899|NCT02235402|Placebo Comparator|Placebo|
11369900|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
11369901|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
11369902|NCT02235376||critical care|
11369903|NCT02235363|Experimental|facelift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
11369904|NCT02235350|Experimental|Action Observation Treatment (AOT)|Conventional physiotherapy + Action Observation Treatment
11369905|NCT02235350|Sham Comparator|Observation of videos with no motor content (MNO)|Conventional physiotherapy + Observation of videos with no motor content (MNO)
11369906|NCT02235337|Experimental|Riboflavin|
11369907|NCT02235324|Experimental|Treatment (ziv-aflibercept, leucovorin calcium, fluorouracil)|"PHASE I:
~Patients receive ziv-aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients proceed to Phase II.
~PHASE II:
~Patients receive ziv-aflibercept IV over 1 hour, leucovorin calcium IV over 1 minute, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
11369908|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
11369909|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
11369910|NCT02235298|Experimental|Dapagliflozin|Dapaglifozin will be administered the dose of 5 mg once daily. Metformin regimen will be continued.
11369911|NCT02235298|Active Comparator|Metformin|Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl.
11369912|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
11369913|NCT02235272|Experimental|XG-102|
11369914|NCT02235272|Placebo Comparator|Placebo|
11369915|NCT02235259|Experimental|XG-104 low dose|
11369916|NCT02235259|Experimental|XG-104 intermediate dose|
11369917|NCT02235259|Experimental|XG-104 high dose|
11369918|NCT02235259|Placebo Comparator|Placebo|Placebo
11369919|NCT02235246|Experimental|normal saline|
11369920|NCT02235246|Active Comparator|magnesium sulfate|
11369921|NCT02235233|Experimental|Patients with NASH|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
11369922|NCT02235233|Active Comparator|Healthy Normal Volunteers|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
11369923|NCT02235220|Experimental|Composite resin restoration|A canine guidance is reestablished by additive composite resin restorations of the canine cusp.
11369924|NCT02235207|Experimental|Neuromuscular exercise|The exercise group will participate in Fustra20 Neck & Back neuromuscular exercise program.
11369925|NCT02235207|No Intervention|Control group|Participants are encouraged to continue there usual physical activity and exercise
11369926|NCT02235194|Active Comparator|Amino Acids, Chromium - Picolinate|Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
11369927|NCT02235194|Placebo Comparator|Placebo Drink|Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
11369928|NCT02235181|No Intervention|Standard Treatment|Women will be allocated to standard treatment, currently this is no treatment.
11369929|NCT02235181|Active Comparator|Arabin pessary|The Arabin cervical pessary will be inserted between 18 and 20+6 days gestation and removed between 35 and 36+6 weeks gestation unless Labour occurs sooner.
11369930|NCT02235168|Experimental|With rollator|Six minutes walking test with rollator
11369931|NCT02235168|Active Comparator|Without rolator|Six minutes walking test without rollator
11369932|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
11369933|NCT02235142|Experimental|Localised prostat cancer and androgen deficiency|
11369934|NCT02235129|Experimental|6 minutes walking test|
11369935|NCT02235116||Patients who responded to the survey|
11369936|NCT02235103||Clinical Pregnancy|Patients who are clinically pregnant after first treatment cycle with intra-uterine insemination.
11369937|NCT02235103||No Clinical Pregnancy|Patients who are not clinically pregnant after first treatment cycle with intra-uterine insemination.
11369938|NCT02235090|Sham Comparator|Zero-strength of direct current stimulation|Sham transdermal direct current stimulation of cervical spinal cord
11369939|NCT02235090|Experimental|100 microamperes direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
11369940|NCT02235090|Experimental|1 milliampere direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
11369941|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
11369942|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
11369943|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
11369944|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
11369945|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
11369946|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
11369947|NCT02235038|Active Comparator|Low carbohydrate diet|
11369948|NCT02235038|Active Comparator|Moderate carbohydrate diet|
11369949|NCT02235038|Active Comparator|High carbohydrate diet|
11369950|NCT02235025|Other|Asymptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score equal to zero and are free of respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze.
11369951|NCT02235025|Other|Symptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score > 0.
11369952|NCT02235025|Other|Healthy controls|Healthy controls have normal baseline spirometry (FEV1 > 80% predicted, FEV1/FVC > 0.7). They don't have any health problems, including cardiovascular, metabolic, neuromuscular, musculoskeletal, or respiratory diseases that could contribute to breathlessness or exercise limitation. They have a mMRC score equal to zero and do not complain any respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze and/or chronic respiratory related medication.
11369953|NCT02235012|Experimental|Ketamine then placebo|Infusion of low dose Ketamine then infusion of a saline solution
11369954|NCT02235012|Experimental|Placebo then ketamin|Infusion of a saline solution then infusion of low dose Ketamine
11369955|NCT02234999|Experimental|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg [14C]-CC-122. given as a suspension under fasting conditions on Day 1
11369956|NCT02234986|Experimental|ENMD-2076|ENMD-2076, oral capsule Once daily dose 250 mg/day
11369957|NCT02234973||11 First Nations Community and Clinical Teams|11 Community & Clinical Teams in each First Nation community participated in the intervention.
11369958|NCT02234960||Cohort of RA Participants|Participants with RA treated with tocilizumab at a dose and duration at the discretion of physician in accordance with the summary of product characteristics as per routine clinical practice were observed for a period of 6 months with the length of entire study for 24 months.
11369959|NCT02234947||New onset of Type 1 Diabetes|The subjects with new onset of Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
11369960|NCT02234947||Antibody Positive Risk for Diabetes|The subjects with single or double antibody positive risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
11369961|NCT02234947||Antibody Negative Risk for Diabetes|The subjects with antibody negative risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
11369962|NCT02234947||Healthy Control|The subjects has no family history for Type 1 Diabetes. They will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
11369963|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
11369964|NCT02234921|Experimental|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
11369965|NCT02234908|Experimental|Contacts|Contacts are the household contacts of confirmed TB and drug-resistant TB patients.
11369966|NCT02234908|Other|Index|Index subjects are confirmed TB and drug-resistant TB patients who distribute referral cards to their household contacts.
11369967|NCT02234895|Experimental|Lateral wedge plus medial arch support|The lateral wedge plus medial support orthotic will be custom-made and designed using a 3D volumetric cast of the foot with the participant's foot in a subtalar joint neutral position. The cast will be balanced so that it rests in a neutral position then smoothed to address any irregularities and to allow for soft tissue splay. Polypropylene sheets of 3mm or 4mm thickness will be vacuum formed or milled directly to produce a ¾ length shell. An ethyl-vinyl-acetone (EVA) lateral post in the heel and forefoot of 5 degrees will be incorporated into the orthotic. The orthotic will be finished with a neoprene cover for improved comfort and patient compliance.
11369968|NCT02234895|Experimental|Lateral wedge|The lateral wedge only orthotic will be constructed of EVA, made to full length of the subject's footwear and incorporate a 5 degree posting. The wedge will be finished with a neoprene cover for improved comfort and patient compliance.
11369969|NCT02234882|Experimental|Rosuvastatin and BMS-663068|Treatment A: Rosuvastatin, single dose (SD) Treatment B: BMS-663068 administered on specified days Treatment C: Combination BMS-663068 and Rosuvastatin administered on specified days
11369970|NCT02234869|Experimental|Peginterferon beta-1a|Participants will receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks during the 6-month comparator period of the study and during the 12-month extension period.
11369971|NCT02234869|Active Comparator|Interferon-β|Participants will continue to receive their standard-of-care interferon beta treatment for the first six months. During the 12-month extension period participants will switch to receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks.
11369972|NCT02234856|No Intervention|conventional residency training|no intervention
11370042|NCT02234336||Subjects with HCM|All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
11369973|NCT02234856|Experimental|Laparoscopic Hysterectomy trainer|Intervention: An educational video and web-based e-module will be created. The final product will be reviewed by the expert contributors. Once approved, these tools will be showcased to a voluntary focus group of Obstetrics and Gynecology residents at the University of Toronto. A quantitative assessment of effectiveness of this tool will be performed through the use of pre- and post-tests of knowledge. A qualitative needs assessment will also be performed using post-viewing surveys. If found to be effective, this educational tool will be incorporated in the University of Toronto Obstetrics and Gynecology residency curriculum.
11369974|NCT02234843|Experimental|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
11369975|NCT02234843|Experimental|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
11369976|NCT02234830|Experimental|Exoseal closure device|Closure device for femoral artery access closure
11369977|NCT02234830|Active Comparator|Angio-Seal closure device|Closure device for femoral artery access closure
11369978|NCT02234804|Experimental|Medtronic Resolute Integrity stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
11369979|NCT02234804|Experimental|OCT|OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
11369980|NCT02234804|Active Comparator|Angiography|Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
11369981|NCT02234804|Active Comparator|Xience Prime stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
11369982|NCT02234791||gene mutation|
11369983|NCT02234778|Experimental|Study Treatment|Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
11369984|NCT02234765|Active Comparator|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
11369985|NCT02234765|Experimental|Primary Care|Patients diagnosed and followed up in the Primary Care.
11369986|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
11369987|NCT02234739|Experimental|active treatment|Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
11369988|NCT02234726|Experimental|Early Childhood Development Program|"Treatment clusters will be assigned a trained Child Development Agent (CDA) who will have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases including malaria, diarrhea, and pneumonia and referral for diagnosis and treatment; and 4) organization and mentoring of biweekly caregiver meetings to discuss parenting and promote early childhood cognitive stimulation.
~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
11369989|NCT02234726|No Intervention|Control|Children residing in comparison health zones will only receive baseline and end line evaluations of their health and developmental status. There will be no active intervention in the comparison areas during the course of the study.
11369990|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
11369991|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
11369992|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
11369993|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
11369994|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
11369995|NCT02234674|Active Comparator|Standard intensive CDP|This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit.
11369996|NCT02234674|Experimental|Stendo group|This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions.
11369997|NCT02234661|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
11369998|NCT02234661|No Intervention|Control Standard of CAP|Control participants access to CAP array of service
11369999|NCT02234648|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
11370000|NCT02234648|Active Comparator|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
11370001|NCT02234635|Other|monofocal IOLs group|monofocal IOLs group were implantation with Tecnis® ZCB00
11370002|NCT02234635|Active Comparator|Diffractive multifocal IOLs group|Diffractive multifocal IOLs group were implantation with Tecnis® ZMB00
11370003|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
11370108|NCT02233894||Chronic obstructive pulmonary disease patients|
11370004|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
11370005|NCT02234609|Other|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
11370006|NCT02234596|Experimental|Nintedanib|
11370007|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
11370008|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
11370009|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
11370010|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
11370011|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
11370012|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
11370013|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
11370014|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
11370015|NCT02234557|Experimental|Tai Chi|Tai Chi instruction, 1 hour, twice per week Home Tai Chi practice with video, requesting 15-30 minutes, 3 times per week, monitored by practice log
11370016|NCT02234544|Placebo Comparator|Placebo + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
11370017|NCT02234544|Active Comparator|Ezetimibe + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
11370018|NCT02234531|Experimental|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
11370019|NCT02234531|Other|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
11370020|NCT02234518|Experimental|High quantity fiber food product|
11370021|NCT02234518|Experimental|Low quantity fiber food product|
11370022|NCT02234518|Placebo Comparator|Placebo|
11370023|NCT02234505|Experimental|Trans-tibial prosthesis users|prosthetic alignment perturbation
11370024|NCT02234492|Active Comparator|Rosuvastatin|Rosuvastatin 10mg once daily for 6 months.
11370025|NCT02234492|No Intervention|No rosuvastatin|No rosuvastatin- this group will continue with their current medical therapy for 6 months.
11370026|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
11370027|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
11370028|NCT02234466|Active Comparator|Oral Dexamethasone|"Oral dexamethasone- two 4mg tabs and one 2mg tab contained within a gelatin capsule Administered a single time, 2 hours pre-induction
~Ondansetron 6mg IV will be administered at skin closure"
11370029|NCT02234466|Placebo Comparator|Gelatin pill|"Gelatin capsule contained within second gelatin capsule. Administered a single time, 2 hours pre-induction
~Ondansetron 6mg IV will be administered at skin closure"
11370030|NCT02234453|Experimental|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
11370031|NCT02234440|Experimental|Metformin|Metformin- 500 mg once daily as a starting dose, can be escalated to 2 g/day to control diabetes
11370032|NCT02234440|Active Comparator|Insulin|
11370033|NCT02234427|Experimental|Aspirin|
11370034|NCT02234401|Experimental|Non invasive ventilation (NIV)|Non invasive ventilation used for the first 7 days of study
11370035|NCT02234401|Active Comparator|Standard Care|High Flow Controlled Oxygen Therapy
11370036|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
11370037|NCT02234375|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
11370038|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
11370039|NCT02234349|Experimental|pancreas kidney transplant|Patients with pancreas kidney transplantation
11370040|NCT02234349|Experimental|kidney transplant subjects|Patients with kidney transplantation
11370041|NCT02234349|No Intervention|Control|
11370043|NCT02234323|Experimental|rFVIIIFc|Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (>=) 50 exposure days (ED: 24-hour period in which >=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (>=5.00 Bethesda Units per milliliter [BU/mL]) or positive low titer inhibitor (>=0.60 and <5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.
11370044|NCT02234310|Experimental|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
11370045|NCT02234297|Experimental|BLZ-100|
11370046|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
11370047|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
11370048|NCT02234271|Active Comparator|Health Educator Arm|Health Educator for contraception information
11370049|NCT02234271|Experimental|Mobile Health Application Arm|Plan A Birth Control - iPad based application for contraception information
11370050|NCT02234258|Experimental|Cognitive behavioral social skills|In Cognitive behavioral social skills training (CBSST), skills-based CBT is used to teach individuals how to correct inaccurate dysfunctional thoughts that interfere with goal-directed activities, including defeatist expectancies, low self-efficacy beliefs, and anomalous beliefs. SST focuses on behaviorally-based instruction of interpersonal social skills, utilizing role-modeling, rehearsal, corrective feedback, and positive reinforcement to facilitate learning. In the modified version of CBSST used in this project: 1) we will strengthen the focus on corrective feedback from successful social interactions; 2) focus on normalization and destigmatization of attenuated psychotic symptoms; 3) add motivational interviewing techniques to promote treatment engagement; and 4) use examples and role plays. CBSST will be delivered in three 6-session modules (i.e., Cognitive Skills, Social Skills, and Problem Solving Skills), a total of 18 90-minute group sessions.
11370051|NCT02234258|Active Comparator|Psychoeducation|The purpose of this alternative treatment is to match CBSST for the nonspecific effects of therapist contact and interest, social interaction and support. Common factors include client expectancy, providing a rationale for change, therapist factors and therapeutic alliance. The psychoeducation group will meet weekly, for a total of 18 90-minute sessions. Therapists will follow brief guidelines as to what they can and cannot do. In each session the therapists will ask how the previous week had been. Any crises will be dealt with, and advice will be offered to help with any immediate problems. No active CBT or SST techniques will be taught or used. Psychoeducational information about high risk for psychosis will be offered. There will be a focus on listening, reflecting and empathizing, and demonstrating uncritical acceptance and genuineness. Social exchanges amongst participants will be encouraged.
11370052|NCT02234245|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
11370053|NCT02234245|Experimental|Remote monitoring of pacemakers|"Telemedicine System:
~Patients have not to go to the hospital to be monitorized"
11370054|NCT02234232|Experimental|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
11370055|NCT02234232|Experimental|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
11370056|NCT02234232|Experimental|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
11370057|NCT02234232|Active Comparator|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
11370058|NCT02234219|Active Comparator|Circular Anastomosis|
11370059|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
11370060|NCT02234206|Experimental|Chandrakanthi choornam|"Chandrakanthi Choornam (CKC) - 12gm in milk
~OD dose; Oral route
~3 Months - duration
~Intervention Drug: Chandrakanthi Choornam (CKC)"
11370061|NCT02234193|Active Comparator|Micro biopsies 2mm x control|2 mm diameter micro biopsies will be performed on all subjects.
11370062|NCT02234193|Active Comparator|Micro biopsies 1mm x control|1 mm diameter micro biopsies will be performed on all subjects.
11370063|NCT02234193|Active Comparator|Micro biopsies 0.8 mm x control|0.8 mm diameter micro biopsies will be performed on all subjects.
11370064|NCT02234193|Active Comparator|Micro biopsies 0.6 mm x control|0.6 mm diameter micro biopsies will be performed on all subjects.
11370065|NCT02234193|Active Comparator|Micro biopsies 0.5 mm x control|0.5 mm diameter micro biopsies will be performed on all subjects.
11370066|NCT02234193|Active Comparator|Micro biopsies 0.40 mm x control|0.4 mm diameter micro biopsies will be performed on all subjects.
11370067|NCT02234193|Active Comparator|Micro biopsies 0.20 mm x control|0.2 mm diameter micro biopsies will be performed on all subjects.
11370068|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11370069|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11370070|NCT02234167|Other|Risk behaviour and infectious diseases|.(among IDU)
11370071|NCT02234154|Other|TOPS System|Post Marketing Study
11370072|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
11370073|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
11370074|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
11370075|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
11370076|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
11370077|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
11370078|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
11370079|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
11370080|NCT02234102|Active Comparator|Paroxysmal Atrial Fibrillation (PAF)|Endoscopically guided laser ablation
11370081|NCT02234102|Active Comparator|Persistent Atrial Fibrillation|Endoscopically guided laser ablation
11370082|NCT02234089||Degarelix|
11370083|NCT02234089||LHRH agonist|
11370084|NCT02234076|Experimental|VRET|"Virtual Reality Exposure Therapy (VRET)
~The experimental treatment VRET is offered with the Multi-Modal Memory Restructuring System (3MR system) and a therapy manual. Participants can use this system at home. Note: The 3MR system is offered via a computer screen, no head-mounted display (HMD) equipment is used in this study."
11370085|NCT02234076|Active Comparator|TAU|Treatment As Usual
11370086|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
11370087|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
11370088|NCT02234050|Experimental|Trabectedin|Patient will be treated with trabectedin
11370089|NCT02234050|Other|Local standard of care|Treatment in the control arm is left to the discretion of the investigator, according to the local standard of care.
11370090|NCT02234037|Experimental|Decitabine and Exercise|8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.
11370091|NCT02234024|Experimental|Supplementation of gangliosides|Supplementation of dairy-derived concentrated gangliosides
11370092|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
11370093|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
11370094|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
11370095|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
11370096|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
11370097|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
11370098|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
11370099|NCT02233972|Experimental|Midazolam and Ginkgolides Meglumine Injection|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Ginkgolides Meglumine Injection: 25mg, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
11370100|NCT02233972|Placebo Comparator|Midazolam and placebo|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Placebo: Sodium Chloride Injection, 250 ml, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
11370101|NCT02233959||Healthy Adults|
11370102|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
11370103|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
11370104|NCT02233933|Active Comparator|argon plasma coagulation|argon plasma coagulation of radiation proctitis
11370105|NCT02233933|Experimental|argon plasma coagulator and hemospray|treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
11370106|NCT02233920||Chronic obstructive bronchitis patients|
11370107|NCT02233907||Chronic obstructive pulmonary disease patients|
11370111|NCT02233868|Experimental|Phase II|After 3 weeks of abstinence or nonabstinence, PET scan with [11C]PBR28 followed by PET scan with FDG and MRI are repeated.
11370112|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
11370113|NCT02233829|Active Comparator|Evening MRI/PET/Raclopride/IV Methylphenidate Session|The PET [11C] raclopride scan will be done between 5-7 PM. After iv catheters are inserted blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plus-infusion method for [11C]raclopride and the administration of intravenous MP (0.5 mg/kg) forty-five minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
11370114|NCT02233829|Active Comparator|Morning MRI/PET/Raclopride/IV Methylphenidate Session|Morning Session [11C]raclopride PET scan: To be started between 7-8 AM. After iv catheters are inserted, genetic blood samples are drawn and then blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plusinfusion method for [11C]raclopride and the administration of intravenous MP (0.25 mg/kg) fortyfive minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
11370115|NCT02233816|Experimental|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
11370116|NCT02233816|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
11370117|NCT02233816|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
11370118|NCT02233816|Placebo Comparator|Placebo|A single dose of Placebo
11370119|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
11370120|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
11370121|NCT02233790|Experimental|Ticagrelor|
11370122|NCT02233790|Active Comparator|Clopidogrel|
11370123|NCT02233777|Experimental|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg pregabalin.
11370124|NCT02233777|Active Comparator|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg pregabalin.
11370125|NCT02233764|Experimental|FeZnPM|The FeZnPM arm will consume iron- and zinc-biofortified pearl millet (ICTP8203-Fe).
11370126|NCT02233764|Active Comparator|CtrlPM|The CtrlPM arm will consume conventional pearl millet three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
11370127|NCT02233751|Experimental|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
11370128|NCT02233751|Experimental|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
11370129|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
11370130|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
11370131|NCT02233725|Active Comparator|Definity Perflutren Suspension|Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.
11370132|NCT02233712|Experimental|Group 1|G17DT; 250 µg dose administered at 0, 1, and 3 weeks.
11370133|NCT02233712|Experimental|Group 2|G17DT; 100 µg dose administered at 0, 1, and 3 weeks.
11370134|NCT02233712|Experimental|Group 3|G17DT; 500 µg dose administered at 0, 1, and 3 weeks.
11370135|NCT02233712|Experimental|Group 4|G17DT; 500 µg dose administered at 0, 2, and 6 weeks.
11370136|NCT02233699|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
11370137|NCT02233699|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
11370138|NCT02233686|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
11370139|NCT02233686|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
11370140|NCT02233673|Experimental|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
11370141|NCT02233673|No Intervention|Standard care|Participants receive standard obstetrical care from their provider
11370142|NCT02233660|Experimental|Physical Therapy Group.|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
11370143|NCT02233660|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
11370144|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
11370145|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.
~Placebo will be administered acutely during low dose phendimetrazine maintenance."
11370146|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.
~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
11370147|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.
~Placebo will be administered acutely during high dose phendimetrazine maintenance."
11370148|NCT02233634|Active Comparator|CAD Patients|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
11370149|NCT02233634|Active Comparator|Healthy Volunteers (Control Group)|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
11370150|NCT02233621|Experimental|PET with [18F]-FES|PET with [18F]-FES compared to histological analysis performed at least on one biopsy done during coelioscopy.
11370151|NCT02233608|No Intervention|Usual Care|The usual care group will receive generic pelvic floor muscle exercise (PMFX) instructions and demonstrations by the research coordinator at the initial post-operative time point. This will include instruction on how to engage the pelvic floor and specific PFMX prescription. Repetition volume will start at 20 repetitions per day during weeks 1-2; 60/day during weeks 3-4; and 90/day during weeks 5-6, and 100+/day for weeks 7-26. The total number of repetitions will be divided equally between rhythmic (contract and relaxed over one second) and sustained contractions (contract and hold for up to 10 seconds).
11370152|NCT02233608|Experimental|Advanced Pelvic Floor Exercise (APFX)|Participants in this group will receive detailed week-by-week description of the program. The program progresses participants through stages of training every two weeks, starting the introduction of basic PFMX, and slowly incorporates Pfilates and Hypopressives exercises until week 8, where patients will maintain the final stage of training until week 26 or urinary incontinence is completely resolved.
11370153|NCT02233595||Adjuvant chemotherapy|
11370154|NCT02233582|Experimental|ibuprofen plus ascent to high altitude|subjects randomized to this arm will take ibuprofen 200 mg 3 times daily during ascent and at altitude.
11370155|NCT02233582|Placebo Comparator|sugar pill plus ascent to high altitude|subjects randomized to this arm will receive the placebo
11370156|NCT02233569|Active Comparator|PH|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
11370157|NCT02233569|Active Comparator|VS|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
11370158|NCT02233556|Experimental|Memantine|This study has only one arm. i.e. Single dose of memantine 20mg
11370159|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
11370160|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
11370161|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.
~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
11370162|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
11370163|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
11370164|NCT02233491|Placebo Comparator|Control|This group will be counselled in clinic by clinicians about the risks of glucose intolerance and will receive leaflets outlining lifestyle modification advice. The leaflets include advice on healthy eating, exercise and the importance of weight loss. However there will be no dietician referral, psychosocial intervention or focused exercise and weight loss monitoring programme. Follow up will be at routine clinic visits only where lifestyle modification advice will be reinforced as per usual clinical practise.
11370165|NCT02233491|Active Comparator|Active intervention|This group will receive active lifestyle modification intervention and will consist of dietician referral, graded exercise programme and weight loss advice. The dietician will be supported by Clinical Psychology services and our collaboration with a recognised expert in behavioural change therapy. The dietician will be trained with motivational interviewing skills and psychological tools will be utilised to support the active lifestyle intervention.
11370166|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
11370167|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
11370168|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
11370169|NCT02233465|Experimental|IPOM Mesh-repair parastomal hernia|Mesh-repair of para-stomal hernia. Patients with para-stomal hernia requiring surgery are offererd enrollment in the study. Preoperatively a CT-scan of the abdomen and or a 3D ultrasonography of the stoma is performed. All patients in the stydy are operated with IPOM-mesh designed for treatment of parastomal hernia.
11370170|NCT02233465|No Intervention|No mesh-repair|Patients not attending the study
11370171|NCT02233452|Active Comparator|Methadone|Group treated with methadone solution.
11370172|NCT02233452|Active Comparator|Ketamine|Group treated with ketamine solution
11370173|NCT02233452|Active Comparator|Methadone plus ketamine|Group treated with methadone plus ketamine solution
11370174|NCT02233439|Placebo Comparator|Placebo|a placebo identical in appearance to the galactagogue product
11370175|NCT02233439|No Intervention|No treatment|Usual care and breastfeeding support
11370176|NCT02233439|Experimental|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
11370177|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
11370178|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
11370179|NCT02233400|Experimental|Treatment|Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
11370180|NCT02233400|No Intervention|Control|Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
11370181|NCT02233387|Experimental|[18F] HX4 PET imaging|injection with [18F] HX4 and PET imaging at baseline and after 20 Gy radiotherapy
11370182|NCT02233374|Experimental|Assessing response with MRI + PET.|"Pre-operative chemo/RT as per standard treatment. Intensity Modulated Radiotherapy (IMRT) / Volumetric Arc Therapy (VMAT) 45Gray/25 fractions with simultaneous integrated Boost of 50Gray/25 fractions + concurrent capecitabine chemotherapy.
~Intervention 1 'Early MRI and PET/CT - 2 weeks after commencing chemo/RT' involves additional Multiparametric MRI + PET/CT 2 weeks into chemo/RT Intervention 2 :\'Late MRI and PET/CT 6 weeks post chemo/RT' involves additional Multiparametric MRI + PET/CT 6 weeks post chemo/RT"
11370183|NCT02233361|Experimental|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
11370184|NCT02233361|No Intervention|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
11370185|NCT02233348||ASD group|Subjects with DSM-IV ASD diagnosis
11370186|NCT02233348||Control group|Controls without lifetime ASD or a family history of ASD
11370187|NCT02233322|Experimental|iron supplements|all subjects will receive iron supplementation based on iron levels in blood
11370188|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.
~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
11370189|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
11370190|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
11370191|NCT02233283|Active Comparator|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
11370192|NCT02233283|Experimental|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
11370193|NCT02233283|Active Comparator|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
11370194|NCT02233283|Experimental|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
11370195|NCT02233244|Other|CTX-4430 and midazolam|Midazolam 2 mg solution once, CTX-4430 100 mg tablet once per day for 7 days, Midazolam 2 mg solution once
11370196|NCT02233231|Active Comparator|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
11370197|NCT02233231|Placebo Comparator|Placebo|Placebo tablets equivalent to IMP.
11370198|NCT02233218|Experimental|telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 40 subjects. Telmisartan80mg + Amlodipine 10mg 9 days, Telmisartan80mg + Amlodipine 10mg , Rosuvastatin 20mg 5days Total 14days administration of investigational products to healthy male volunteers
11370199|NCT02233218|Experimental|Telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 20 subjects. Rosuvastatin 20mg 5 days, Rosuvastatin 20mg , Telmisartan80mg + Amlodipine 10mg 9days, Total 14days administration of investigational products to healthy male volunteers
11370200|NCT02233205|Experimental|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
11370201|NCT02233179|Experimental|Removable Cast Walker|An offloading device that can be removed by the patients
11370202|NCT02233179|Active Comparator|Irremovable Cast Walker|A removable cast rendered irremovable using instant total contact cast, so patients cannot remove offloading device.
11370203|NCT02233153||Pre-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
11370204|NCT02233153||Post-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
11370205|NCT02233153||Pre-Elder Friendly Surgical Control Group|Elder Acute Care and Emergency Surgery patients
11370206|NCT02233153||Post-Elder Friendly Surgical Control Group|
11370207|NCT02233140|Experimental|Shockwave with manual manipulation|A shockwave (EPAT) therapy with two supervised manual manipulation per week
11370208|NCT02233140|Active Comparator|Manual manipulation|A Placebo (no) shockwave with two supervised manual manipulations per week
11370209|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
11370210|NCT02233114|Experimental|Yogic exercises|Yogic exercises for lung disorders
11370211|NCT02233114|Active Comparator|physiotherapy|Physiotherapy during the yogic exercises
11370212|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
11370213|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
11370214|NCT02233088|Experimental|ELM Group|A 6-month group lifestyle intervention, consisting of 12 weekly and 6 bi-weekly 2-hour sessions. The sessions consist of 30-min physical activity, 30-min meal demonstration, and 60-min group behavioral intervention, with a focus on experiential learning in naturalistic setting. Sessions are facilitated by dietitian/personal trainer and behavioral specialist.
11370215|NCT02233088|Other|ELM Classes|A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
11370216|NCT02233088|Active Comparator|ELM Individual|A 6-month intervention, that consists of educational manuals on physical activity, diet and stress reduction and recommended 3 medical visits every 3 months for medical counseling and feedback using 5A (Ask, Advise, Assess, Assist, and Arrange) framework . These Metabolic syndrome care materials and provider documentation will be embedded in electronic medical record system, and will be accessible to medical providers by usual means. This enhanced usual care by participant's usual health care provider focuses on metabolic syndrome and lifestyle modifications to reduce the risk of chronic disease.
11370217|NCT02233075|Experimental|REP 2139-Ca + Pegasys (TM)|REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.
11370218|NCT02233062|Experimental|Semen quality|
11370219|NCT02233049|Experimental|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
11370220|NCT02233049|Experimental|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
11370221|NCT02233049|Experimental|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
11371472|NCT02224235|Experimental|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
11370222|NCT02233049|Experimental|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
11370223|NCT02233023|Experimental|Pramixpexole|
11370224|NCT02233023|Active Comparator|Bromocriptine and other dopamine agonists|
11370225|NCT02233010||kidney function normal group|kidney function normal group : defined by the normal level of NGAL after post operation 4hrs
11370226|NCT02233010||kidney function decreased group|kidney function decreased group : defined by the increased level of NGAL after post operation 4hrs
11370227|NCT02232997|Active Comparator|Long Hydration|Long term hydration at routine speed(12h before and after procedure)
11370228|NCT02232997|Active Comparator|Short Hydration|Short term hydration at high speed(1h before and 4h after procedure)
11370229|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
11370230|NCT02232971|Placebo Comparator|Placebo|Isotonic Saline
11370231|NCT02232971|Experimental|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
11370232|NCT02232971|Experimental|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
11370233|NCT02232971|Experimental|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
11370234|NCT02232958|Experimental|Hyperbaric Oxygen treatment|administration of 100% Oxygen at 2 Atmospheres Absolute for 1 hour 1 daily, 5 days a week for 2 weeks
11370235|NCT02232945|Placebo Comparator|placebo|placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.
11370236|NCT02232945|Experimental|Banlangen granules & placebo|Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate
11370237|NCT02232945|Active Comparator|oseltamivir phosphate & placebo|oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules
11370238|NCT02232932|Experimental|CAPECITABINE-Radiotherapy -Liver Transplantation|Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)
11370239|NCT02232932|Active Comparator|RESECTION|Liver resection
11370240|NCT02232919|Experimental|Deep Brain Stimulation|The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index [BMI] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
11370241|NCT02232906|Experimental|intravenous ferric carboxymaltose|
11370242|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
11370243|NCT02232893|Placebo Comparator|Placebo|Placebo TID
11370244|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.
~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
11370245|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.
~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
11370246|NCT02232867|Experimental|Arm and Leg Cycling Exercise Program|Multiple baseline test sessions will be used for the same participant to establish a meaningful baseline thus confirming consistency of all outcome measures prior to the intervention.
11370247|NCT02232854|Experimental|Depression training/supervision program|"A complex intervention, which will include:
~Primary Health Care team training in depression
~A focus group, after training
~Telephone monitoring of patients
~Web-based supervision of clinicians"
11370248|NCT02232854|No Intervention|Usual Care|Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.
11370249|NCT02232841||Mechanical ventilation|Hospitalized adult patients with lung injury receiving mechanical ventilation and who also have received or will receive a CT scan as part of their standard care
11370250|NCT02232828|Experimental|Selective removal|
11370251|NCT02232828|Active Comparator|Stepwise removal|
11370252|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
11370253|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
11370254|NCT02232789|Experimental|Mephedrone|Mephedrone 200 mg, single dose, oral administration
11370255|NCT02232789|Active Comparator|3,4-methylenedioxymethamphetamine|3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
11370256|NCT02232789|Placebo Comparator|Lactose|Placebo, single dose, oral administration
11370257|NCT02232776|Experimental|Losartan treatement|All patients had received losartan treatment for 24 weeks.
11370258|NCT02232763|Experimental|Losartan|12 weeks of losartan or placebo with crossover to the other
11370259|NCT02232763|Experimental|Placebo|12 weeks of losartan or placebo with crossover to the other
11370260|NCT02232737|Experimental|0.8 mg nicotine|0.8 mg nicotine cigarettes
11370261|NCT02232737|Experimental|0.12 mg nicotine|0.12 mg nicotine cigarettes
11370262|NCT02232737|Experimental|0.03 mg nicotine|0.03 mg nicotine cigarettes
11370263|NCT02232724|Experimental|Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
11370264|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
11370265|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
11370266|NCT02232685|Experimental|Choline PET/CT|18F-Choline PET/CT
11370267|NCT02232672|Experimental|MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
11370268|NCT02232659|Experimental|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
11370269|NCT02232659|Experimental|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
11370270|NCT02232646|Experimental|BBI503|
11370271|NCT02232633|Experimental|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
11370272|NCT02232620|Experimental|BBI503|
11370273|NCT02232607|Experimental|Lacidipine, low dose|
11370274|NCT02232607|Experimental|Lacidipine, medium dose|
11370275|NCT02232607|Experimental|Lacidipine, high dose|
11370276|NCT02232607|Active Comparator|Placebo|
11370277|NCT02232594||chronic obstructive respiratory tract disease patients|
11370278|NCT02232581|Experimental|Alovudine - low|
11370279|NCT02232581|Experimental|Alovudine - medium|
11370280|NCT02232581|Experimental|Alovudine - high|
11370281|NCT02232581|Placebo Comparator|Placebo|
11370282|NCT02232568|Experimental|Feedback Arm|Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb <8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
11370283|NCT02232568|No Intervention|Control Arm|Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.
11370284|NCT02232555|Experimental|Duloxetine|
11370285|NCT02232555|Placebo Comparator|Placebo|
11370286|NCT02232542|Experimental|Duloxetine - low dose|
11370287|NCT02232542|Experimental|Duloxetine - high dose|
11370288|NCT02232542|Placebo Comparator|Placebo|
11370289|NCT02232529|Experimental|Part 1: MIN-101|"MIN-101
~modified release formulation (MR),single oral dose between 16 and 64 mg"
11370290|NCT02232529|Experimental|Part 2: MIN-101 low dose|"MIN-101
~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
11370291|NCT02232529|Placebo Comparator|Part 2: placebo|"placebo MIN-101
~daily oral dose from Day 1 to Day 7"
11370292|NCT02232529|Experimental|Part 2: MIN-101 high dose|"MIN-101
~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
11370293|NCT02232516|Experimental|Treatment (romidepsin, lenalidomide)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11370294|NCT02232490|Experimental|hepcortespenlisimut-L|Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
11370295|NCT02232490|Placebo Comparator|placebo|placebo
11370296|NCT02232477|Experimental|Open-label treatment|laronidase 1.74 mg IT q 3 months for five years
11370297|NCT02232464||ADHD group|Adults with clinical diagnosis of ADHD according to the DSM-IV criteria
11370298|NCT02232464||Control group|Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD
11370299|NCT02232451|Experimental|ERCP with loop tip wire|ERCP with loop tip wire is an endoscopic procedure to treat biliary disease. Wire guide cannulation with loop-tip is a new procedure to improve rate of biliary cannulation and reduce complication, as post-procedure pancreatitis.
11370300|NCT02232451|Active Comparator|ERCP for cannulation|ERCP for cannulation of CBD with traditional technique
11370301|NCT02232438|Experimental|Behavioral activation therapy|Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.
11370302|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
11370303|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
11370304|NCT02232399|Active Comparator|Milrinone|In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg
11370305|NCT02232399|Experimental|Levosimendan|In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg
11370306|NCT02232386|Experimental|Treatment|"Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Treatment duration with Ibrutinib will be based on what comes first of the following three options:
~Treatment until progression or toxicity
~Treatment until MRD negativity for 6 months
~Treatment for 6 years. Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1."
11370307|NCT02232373|Sham Comparator|Normal FODMAP arm|Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
11370308|NCT02232373|Experimental|Low FODMAP arm|Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
11370309|NCT02232360|Experimental|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
11370310|NCT02232360|Active Comparator|Rosuvastatin alone|Rosuvastatin 10 mg per day
11370311|NCT02232347|Experimental|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
11370312|NCT02232347|Active Comparator|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
11370313|NCT02232334|Experimental|Osteopathic manual treatment|Global Osteopathic Manual treatment: each subject will be treated according to what restrictions or areas of poor mobility are found individually. No two subjects will receive the same overall treatment.
11370314|NCT02232334|No Intervention|Control--no change in current treatment of subject|The population will act as their own control prior to intervention of osteopathy, their will be a control period where the subject maintains current treatment of their gastroparesis. During that period they will fill out the GCSI measuring tool at the beginning of the control period and at the end. Those measurements will be compared to the GSCI results during the intervention period.
11370315|NCT02232321|Other|PsA MDA|
11370316|NCT02232308|Experimental|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
11370317|NCT02232308|Experimental|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
11370318|NCT02232308|Experimental|Nizatidine plus Lisinopril|Nizatidine (150 mg) and Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
11370319|NCT02232308|Placebo Comparator|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
11370320|NCT02232295|Active Comparator|Conventional group|Conventional group consist of Upper extremity task oriented functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities.
11370321|NCT02232295|Experimental|Graded Motor imagery group and Conventional group|"Graded Motor imagery is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:
~Left Right discrimination training (Implicit Motor Imagery) - 2 weeks
~Explicit Motor Imagery (Imagined movements) - 2 weeks
~Mirror Therapy - 2 weeks"
11370322|NCT02232282|Sham Comparator|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
11370323|NCT02232282|Active Comparator|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
11370324|NCT02232269|Placebo Comparator|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
11370325|NCT02232269|Active Comparator|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
11370326|NCT02232269|Experimental|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour
~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
11370327|NCT02232269|Active Comparator|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour
~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
11370328|NCT02232256|Experimental|CALPXT96|"1st treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)
~2 week wash out period
~2nd treatment period: 4 weeks placebo (two capsules hs at bedtime)"
11370329|NCT02232256|Placebo Comparator|Placebo|"1st treatment period: 4 weeks placebo (two capsules hs at bedtime)
~2 week wash 'out' period
~2nd treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)"
11370330|NCT02232243|Experimental|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
11370331|NCT02232243|Experimental|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
11370332|NCT02232243|Experimental|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
11370333|NCT02232217|Experimental|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
11370334|NCT02232217|Active Comparator|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
11370335|NCT02232204|Active Comparator|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
11370336|NCT02232204|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
11370337|NCT02232191|Active Comparator|Nonoperative|Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
11370338|NCT02232191|Active Comparator|Angioembolization|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
11370339|NCT02232191|Active Comparator|Splenectomy|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
11370340|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
11370341|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
11370342|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
11370343|NCT02232165|Experimental|Hypotension avoidance (MAP >= 65 mmHg)|Mean arterial blood pressure is maintained >= 65 mmHg for 7 days following acute SCI.
11371771|NCT02222415|Placebo Comparator|Training + placebo drink|Exercise + non-caloric placebo drink
11370344|NCT02232165|Active Comparator|Induced hypertension (MAP >= 85 mmHg)|Induced hypertension with mean arterial blood pressure >= 85 mmHg for 7 days following acute SCI.
11370345|NCT02232152|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
11370346|NCT02232139|No Intervention|Standard therapy group|Participant who will not receive midazolam for pharmacological anxiolytic premedication before general surgery
11370347|NCT02232139|Experimental|Midazolam group|Participant who will receive midazolam for pharmacological anxiolytic premedication before general surgery
11370348|NCT02232126|No Intervention|Usual Care|
11370349|NCT02232126|Experimental|Intervention|
11370350|NCT02232113|Experimental|CERA|We included HD patients with stable hematocrit (between 30~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
11370351|NCT02232100|Experimental|10AMG|Attentional bias modification group - 10 training sessions
11370352|NCT02232100|Placebo Comparator|10ACG|Attentional control group - 10 placebo sessions
11370353|NCT02232100|Experimental|18AMG|Attentional bias modification group - 18 training sessions
11370354|NCT02232100|Placebo Comparator|18ACG|Attentional control group - 18 placebo sessions
11370355|NCT02232087|Experimental|test product A|salmeterol and fluticasone propionate, 2 puffs
11370356|NCT02232087|Active Comparator|reference product D|salmeterol and fluticasone propionate, 2 puffs
11370357|NCT02232087|Experimental|test product B|salmeterol and fluticasone propionate, 6 puffs
11370358|NCT02232087|Active Comparator|reference product E|salmeterol and fluticasone propionate, 6 puffs
11370359|NCT02232087|Experimental|test product C|salmeterol and fluticasone propionate, 12 puffs
11370360|NCT02232087|Active Comparator|reference product F|salmeterol and fluticasone propionate, 12 puffs
11370361|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
11370362|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
11370363|NCT02232061|Other|Fingolimod|
11370364|NCT02232048||Corticosteroid Treatment|Patients in the internal medicine department who are being treated with corticosteroids will undergo Transthoracic Echocardiogram to determine change in heart function.
11370365|NCT02232035|Placebo Comparator|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
11370366|NCT02232035|Experimental|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
11370367|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
11370368|NCT02232009|Other|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
11370369|NCT02231996||gene mutation|
11370370|NCT02231983||Severe Combined Immunodeficiency|Case histories were analyzed to grasp important characteristics of the diseases. Distribution of lymphocyte subsets from peripheral blood were examined by flow cytometry. Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
11370371|NCT02231970|Experimental|Endoscopic sleeve gastroplasty|The intervention is an endoscopic procedure: to perform endoscopic sleeve gastroplasty we used a cap-based flexible endoscopic suturing system (OverStitch™, Apollo, Inc. Austin, Texas) mounted on a double-channel endoscope (GIF-2T160; Olympus Medical Systems Corporation, Tokyo, Japan) to achieve full-thickness, running sutures through the gastric wall from antrum to fundus.
11370372|NCT02231957|Experimental|educational text message reminders|receipt of education-embedded text message vaccine reminders
11370373|NCT02231957|Active Comparator|conventional text message reminders|receipt of conventional text message vaccine reminders
11370374|NCT02231944|Experimental|Replenine®-VF|
11370375|NCT02231931|Experimental|A (Reference 1) Digoxin|1 tablet as single dose, fasted
11370376|NCT02231931|Experimental|B (Reference 2) Furosemide|oral solution, as single dose, fasted
11370377|NCT02231931|Experimental|C (Reference 3) Metformin hydrochloride|1 film-coated tablet as single dose, fasted
11370378|NCT02231931|Experimental|D (Reference 4) Rosuvastatin|1 film-coated tablet as single dose, fasted
11370379|NCT02231931|Experimental|E (Test) 1|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
11370380|NCT02231931|Experimental|F (Test 2)|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted
11370381|NCT02231931|Experimental|G (Test 3)|Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
11370382|NCT02231918|Experimental|MIRAPEX® - low|
11370383|NCT02231918|Experimental|MIRAPEX® - medium|
11370384|NCT02231918|Experimental|MIRAPEX® - high|
11370385|NCT02231905|Experimental|BI-Sifrol®|Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.
11370386|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
11370387|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
11370388|NCT02231879|Active Comparator|Year 1 crossover|G-CSF or plerixafor, blinded
11370389|NCT02231879|Active Comparator|Year 2 crossover|G-CSF or plerixafor, blinded
11370390|NCT02231866|Experimental|Group 1|cAd3-EBO at 2x10(10)PU IM
11370392|NCT02231866|Experimental|Group 3|cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
11370393|NCT02231866|Experimental|Group 4A|cAd3-EBOZ at 1x10(10)PU IM
11370394|NCT02231866|Experimental|Group 4B|cAd3-EBOZ at 1x10(11)PU IM
11370395|NCT02231866|Experimental|Group 5|cAd3-EBO at 2x10(11)PU IM
11370396|NCT02231853|Experimental|-1|1x10e4 MVST/kg infusion
11370397|NCT02231853|Experimental|1|1x10e5 MVST/kg infusion
11370398|NCT02231853|Experimental|2|5x10e5 MVST/kg infusion
11370399|NCT02231853|Experimental|3|1x10e6 MVST/kg infusion
11370400|NCT02231853|Experimental|3B|1x10e6 MVSTr/kg infusion
11370401|NCT02231853|Experimental|4|5x10e6 MVSTr/kg infusion
11370402|NCT02231840||ANA participants|Addictions Neuroclinical Assessment (ANA) Substudy
11370403|NCT02231840||Not treatment-seeking participants|NTSP
11370404|NCT02231840||Treatment-seeking Patients|TSP
11370405|NCT02231827|Experimental|Gait analysis|
11370406|NCT02231814|Experimental|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
11370407|NCT02231814|Experimental|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
11370408|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
11370409|NCT02231788|Experimental|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
11370410|NCT02231788|Active Comparator|Telmitrend®Tab. 80mg|Telmitrend®Tab.(Telmisartan) 80mg
11370411|NCT02231775|Experimental|Treatment (dabrafenib, trametinib, surgery)|Patients receive dabrafenib PO BID and trametinib PO QD for 8 weeks. After completion of 8 weeks of dabrafenib and trametinib, patients undergo surgery. Approximately 1 week after surgery, patients receive dabrafenib PO BID and trametinib PO QD for 44 additional weeks in the absence of disease progression or unacceptable toxicity.
11370412|NCT02231762|Experimental|Lanreotide Autogel 120mg & Temozolomide|"Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.
~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment."
11370413|NCT02231749|Experimental|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11370414|NCT02231749|Active Comparator|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
11370415|NCT02231736||Type 2 diabetes, HbA1c>7.5|
11370416|NCT02231736||Type 2 diabetes, HbA1c<7.5|
11370417|NCT02231723|Experimental|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
11370418|NCT02231723|Experimental|B: BBI608 in combination with modified FOLFIRINOX|
11370419|NCT02231723|Experimental|C: BBI608 in combination with FOLFIRI|
11370420|NCT02231723|Experimental|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
11370421|NCT02231710|Experimental|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
11370422|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
11370423|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
11370424|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
11370425|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
11370426|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
11370427|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
11370428|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
11370429|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
11370430|NCT02231684|Experimental|i.v. 0.25 mg (1 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
11370431|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by i.v. 0.25 mg (1 mg/ml)|
11370432|NCT02231671|Experimental|Part 1: Absolute Bioavilability|Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg [14C]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
11370433|NCT02231671|Experimental|Part 2: Mass Balance|Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg [14C]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range.
11370434|NCT02231658|Experimental|Liraglutide|The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
11370435|NCT02231658|Experimental|Lixisenatide|The highest injected once daily dose will be 20µg s.c. for lixisenatide.
11370436|NCT02231645|Experimental|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
11370437|NCT02231645|No Intervention|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
11370438|NCT02231632|Experimental|Live attenuated Poliomyelitis vaccine (human diploid cell)|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
11370439|NCT02231632|Experimental|Poliomyelitis（Live）Vaccine(Monkey Kidney Cell),Oral|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
11370440|NCT02231619|No Intervention|Demonstration of LSUPT at baseline|This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker.
11370441|NCT02231619|Active Comparator|Baseline verbal instruction of LSUPT|Verbal instruction on how to do LSUPT at baseline
11370442|NCT02231606|No Intervention|Group 1: Pure Control|Provision of glasses prescription only
11370443|NCT02231606|Experimental|Group 2: Free Glasses|Free glasses for all, no upgrade glasses offered
11370444|NCT02231606|Experimental|Group 3: Free + Upgrade Glasses 1|Free glasses for all, optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
11370445|NCT02231606|Experimental|Group 4: Free + Upgrade Glasses 2|Free glasses for all, optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
11370446|NCT02231593||Acromegalic patients|
11370447|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
11370448|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
11370449|NCT02231567|Experimental|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
11370450|NCT02231567|Active Comparator|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
11370451|NCT02231554|Experimental|Feldenkrais|The Feldenkrais method is a self education method that uses the somatic sensory-motor learning to enhance the functions of people in daily life activities through the awareness of their motor habits and the experience of more efficient alternatives.
11370452|NCT02231554|Active Comparator|Back School|The Back School teaches the patient, with theoretical and practical knowledge, how to defend his own back from the pain and how to prevent their disease, considering awareness and education as important parts of the therapeutic process .
11370453|NCT02231541|Experimental|Very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
11370454|NCT02231541|Placebo Comparator|Turned off very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
11370455|NCT02231528|Experimental|Use of ultrasound with active GPS|
11370456|NCT02231528|Active Comparator|Use of ultrasound with inactive GPS|
11370457|NCT02231515|Experimental|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty
11370458|NCT02231515|Active Comparator|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty (SLT)
11370459|NCT02231502|Experimental|Vegetable-based convenience food|"One time ingestion of a vegetable-based convenience product. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).
~At least 7 days wash-out between each assessment visit."
11370460|NCT02231502|Active Comparator|Vegetable meal|"One time ingestion of a minimally processed vegetable meal. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).
~At least 7 days wash-out between each assessment visit."
11370461|NCT02231489|Experimental|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram [mg] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
11370462|NCT02231489|Experimental|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
11370463|NCT02231463||ultrasound measurement|"measuring subclavian vein Diameter in six Groups:
~neutral positioning, PEEP 0 cm H2O, neutral positioning, PEEP 5cm H2O, neutral positioning, PEEP 10cm H2O, Trendelenburg positioning -20°, PEEP 0 cmH2O, Trendelenburg positioning -20°, PEEP 5 cmH2O, Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure."
11370464|NCT02231450|Experimental|Patients with mild hepatic impairment (Group1)|8 patients with mild hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054
11370465|NCT02231450|Experimental|Patients with moderate hepatic impairment (Group 2)|8 patients with moderate hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054.
11370466|NCT02231450|Experimental|Healthy subjects (Group 3)|8 healthy subjects will be administered a single oral dose of 60 mg Lu AE58054.
11370467|NCT02231437||chronic obstructive respiratory tract disease patients|
11370468|NCT02231424||chronic obstructive respiratory tract disease patients|
11370469|NCT02231411|Active Comparator|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
11370470|NCT02231411|Active Comparator|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
11370471|NCT02231398||Women who participated in nuMoM2b|
11370472|NCT02231385|Experimental|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.
~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
11370586|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
11370473|NCT02231385|No Intervention|Control Group|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.
~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
11370474|NCT02231372||chronic obstructive airways disease patients|
11370475|NCT02231359||chronic obstructive airways disease patients|
11370476|NCT02231346||chronic obstructive pulmonary disease patients|
11370477|NCT02231333|Experimental|S-adenosylmethionine (SAMe)|
11370478|NCT02231333|Active Comparator|pentoxiphylline (PTX)|
11370479|NCT02231320||Chronic Obstructive Pulmonary Disease patients|
11370480|NCT02231307|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
11370481|NCT02231307|Experimental|SUBLIVAC FIX Birch 40,000 AUN/ml|
11370482|NCT02231294||Idiopathic Parkinson's Disease Patients|
11370483|NCT02231281|Experimental|cART(TDF/AZT+3TC+LPV/r)|cART(TDF/AZT+3TC+LPV/r)
11370484|NCT02231281|Experimental|CTL infusion|cART plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
11370485|NCT02231268||Depressive patients|
11370486|NCT02231255||Idiopathic Parkinson's disease patients|
11370487|NCT02231242|Experimental|Intrathecal Autologous Bone Marrow TNC|Procedure/Surgery: Intrathecal Autologous Bone Marrow TNC. Other Names: Autologous Stem Cell Transplantation Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) (10mcgr/kg of body weight) for 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the autologous TNC concentrate of 10 mL will be infused intrathecally.
11370488|NCT02231242|No Intervention|Control group|"Patients will be evaluated with the Gross Motor Functional Classification System initially, at one, three and six months, and then cross to the intervention arm."
11370489|NCT02231229|Experimental|PCR-based strategy|PCR-based strategy: after testing for isoniazid and rifampin resistance using a molecular testing with PCR (GenoType ®MTB DR plus), patients will receive HRZ combination therapy (INH , RIF, PZA) if no resistance is detected
11370490|NCT02231229|Active Comparator|conventional therapy|Conventional therapy: based on the standard of care in France: initiation of the standard 4 drug regimen INH, RIF, PZA, and EMB, until drug susceptibility testing (DST) results are available.
11370491|NCT02231216|Experimental|Rhinoseptoplasty and turbinectomy|Patients submitted to rhinoseptoplasty associated to Endoscopic partial turbinectomy.
11370492|NCT02231216|Active Comparator|Rhinoseptoplasty|Patients submitted only to rhinoseptoplasty, without turbinectomy procedure.
11370493|NCT02231203|Placebo Comparator|Placebo|2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
11370494|NCT02231203|Active Comparator|Omegaven|2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
11370495|NCT02231190|Experimental|GSK1278863|Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
11370496|NCT02231190|Placebo Comparator|Placebo|Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
11370497|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
11370498|NCT02231177|Active Comparator|BI 1744 CL|
11370499|NCT02231177|Active Comparator|Tiotropium|
11370500|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
11370501|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
11370502|NCT02231151|Experimental|Pediatric Acute Care Professionals|Individuals must work in ER or ICU setting regularly or rotate through this setting with up to date BLS/PALS/ACLS certification. The participants will be required to rate the CPR based on accuracy for each video shown. The type of CPR error(s) shown to the individuals will be randomized.
11370503|NCT02231138|Experimental|Abelmoschus manihot (AM)|"age above 12 years old (including 12)：huangkui capsule are given orally at 2.5 g three times per day
~age between 6-12 years old(including 6):huangkui capsule are given orally at 1.5 g three times per day
~age under 6 years old：huangkui capsule are given orally at 1.0 g three times per day"
11370504|NCT02231125|Experimental|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huangkui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
11370505|NCT02231125|Experimental|Losartan|Losartan potassium (Hangzhou MSD Pharmaceutical Co., Ltd.), 100 mg × 7 capsules/box.
11370506|NCT02231112|Experimental|Prone position whole breast RT|
11370507|NCT02231099|Experimental|prolift + m|surgery with mesh (prolift+M)
11370508|NCT02231099|Active Comparator|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
11370509|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
11370510|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
11370584|NCT02230579|Experimental|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
11370585|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
11370693|NCT02229786|Placebo Comparator|Placebo|
11370511|NCT02231073|Experimental|Exercise: Agility Boot Camp-Cognitive|Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
11370512|NCT02231073|Active Comparator|Education: Living with Parkinson's disease|The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
11370513|NCT02231060||AIE after Cardiac Arrest|Male and female patients with AIE following CA.
11370514|NCT02231047|Experimental|64N Nutraceutical|Powdered 64N Nutraceutical 40 mg/kg/day mixed in 12 ounces of a culturally appropriate warm drink for 1 week (7 days).
11370515|NCT02231047|Sham Comparator|No 64N Nutraceutical|Culturally appropriate 12 ounce warm drink daily for 1 week (7 days).
11370516|NCT02231021|Experimental|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
11370517|NCT02231021|Active Comparator|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
11370518|NCT02231021|Active Comparator|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
11370519|NCT02231008|Experimental|Tasimelteon|Single dose oral capsule, daily dosage, for 21 weeks
11370520|NCT02231008|Placebo Comparator|Placebo|Placebo comparator
11370521|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
11370522|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
11370523|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
11370524|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
11370525|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
11370526|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
11370527|NCT02230930|Active Comparator|Massage with a spiky ball|Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
11370528|NCT02230930|Active Comparator|Hydrocortisone cream 1%|Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
11370529|NCT02230930|Active Comparator|Subcutaneous hydrocortisone 10mg|Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
11370530|NCT02230930|Active Comparator|Apomorphine 0.25% (2.5mg/ml)|Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.
11370531|NCT02230917|Experimental|Sotatercept|Sotatercept 0.2 mg/kg will be administered every 21 days for 12 doses subcutaneously into the upper arm, abdomen or thigh.
11370532|NCT02230917|Placebo Comparator|Placebo|0.2 mg/kg of normal saline will be administered subcutaneously in the upper arm, abdomen or thigh for 21 days for 12 doses.
11370533|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
11370534|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
11370535|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
11370536|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
11370537|NCT02230891|No Intervention|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
11370538|NCT02230878|Experimental|JNJ-42847922, 5 milligram (mg) and Placebo|Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
11370539|NCT02230878|Experimental|JNJ-42847922, 10 mg and Placebo|Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
11370540|NCT02230878|Experimental|JNJ-42847922, 20 mg and Placebo|Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
11370541|NCT02230878|Experimental|JNJ-42847922, 40 mg and Placebo|Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
11370542|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
11370543|NCT02230839|Experimental|Exercise training protocol|
11370544|NCT02230839|Experimental|Energy restriction-induced weight loss|
11370545|NCT02230839|No Intervention|Health Education|
11370546|NCT02230826||Patients with Hip arthroplasty|Patients with Tornier implants.
11370547|NCT02230813||Oral antibiotic therapy|Consecutive adult patients attending the study Emergency Departments with cellulitis will be considered eligible for recruitment to the study. Only those patients deemed suitable for oral antibiotic therapy and planned for discharge will be recruited to the study. Oral antibiotic therapy prescribed will be dependent on local institutional prescribing guidelines. For the purposes of the sites enrolling participants, the antibiotic of choice is oral flucloxacillin 500 milligrams four times daily for seven days. We will be assessing the treatment failure rate for this cohort of patients; namely, the number of patients requiring the primary outcome (change from oral to intravenous antibiotic therapy). We will also assess this group of patient for the secondary outcomes listed above.
11370548|NCT02230800|Experimental|Tocovid SupraBio plus pentoxifylline (PTX)|Tocovid SupraBio* 200mg po bd plus pentoxifylline (PTX) 400mg po bd for 12 months.
11370549|NCT02230800|Placebo Comparator|Matching placebos|Matching placebos bd for 12 months.
11370550|NCT02230787|Active Comparator|Recession coverage without Emdogain|
11370551|NCT02230787|Experimental|Recession coverage with Emdogain|
11370552|NCT02230774||medical staff|Nurses and doctors oncall
11370553|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
11370554|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
11370555|NCT02230735|Experimental|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
11370556|NCT02230735|Placebo Comparator|Normal Saline|Total of 14 ml of normal saline, 7ml into the right uterosacral ligament and 7ml into the left uterosacral ligament
11370557|NCT02230722|Active Comparator|Attention Control|The neutral 10-15 minute visit with the Care Manager will consist of a brief review of ATHENA-OT safety education and the patient's Pain Care Plan. The CM will answer patient questions, but will avoid using Motivational Interviewing communication. The Care Manager will review upcoming telephone check-in and assessment sessions.
11370558|NCT02230722|Experimental|Collaborative Care|Collaborative Care intervention in which one of two Care Managers delivering both interventions will assist primary care providers (PCPs) by using Motivational Interviewing to communicate computer-based ATHENA-OT (opioid therapy) decision support guidelines to veterans with chronic pain.
11370559|NCT02230709|Experimental|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
11370560|NCT02230709|Active Comparator|"TENS and dry needling"|Application of TENS current after dry needling treatment.
11370561|NCT02230696|Experimental|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
11370562|NCT02230696|Active Comparator|Reference Product|
11370563|NCT02230696|Placebo Comparator|Placebo Product|Placebo nasal spray
11370564|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
11370565|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
11370566|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
11370567|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
11370568|NCT02230670|Placebo Comparator|Placebo|Placebo BID
11370569|NCT02230657|Active Comparator|Same day Discharge|
11370570|NCT02230657|Active Comparator|Next day discharge|
11370571|NCT02230644|Experimental|Audio enhanced|Enhanced Clinical Environment: participants wait for their operation in the enhanced audio-visual booth.
11370572|NCT02230644|Active Comparator|Other distraction method|Participants wait for their operation in a booth with another distraction such as the news on television
11370573|NCT02230644|No Intervention|Ordinary|Participants wait for their operation in an ordinary, unenhanced booth
11370574|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
11370575|NCT02230631||Part 2 (prospective observational evaluation)|
11370576|NCT02230618||Ryzodeg™|
11370577|NCT02230605|Experimental|Cognitive Exercise|The cognitive exercises will consist of a series of computer games focusing on five categories: memory, speed, attention, flexibility and problem-solving. Participants will be expected to complete 1 hour of Lumosity exercise daily for a minimum of 8 days prior to surgery. Participants will be instructed to complete no less than 15 minutes of exercise at a time throughout each day. Each hour of exercise, participants will work through at least 1 game under each category. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
11370578|NCT02230605|Placebo Comparator|Normal Activity|Participants randomized into the Normal Activity group will be encouraged to maintain their normal activity level prior to surgery. These participants are asked not to alter their normal daily routine of mental exertion (i.e. watching television, reading, puzzles, etc.) and not permitted to subscribe to Lumosity while in the research study. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
11370579|NCT02230579|Experimental|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
11370580|NCT02230579|Experimental|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
11370581|NCT02230579|Experimental|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
11370582|NCT02230579|Experimental|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
11370583|NCT02230579|Experimental|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
11370694|NCT02229773|Experimental|BIBB 1464 MS low dose|
11370587|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
11370588|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
11370589|NCT02230553|Experimental|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
11370590|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.
~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
11370591|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.
~Catheterization with SelfCath (comparator) followed by measurement of residual urine.
~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
11370592|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
11370593|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
11370594|NCT02230514|Experimental|XCEL-MT-OSTEO-ALPHA and surgery|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue"
11370595|NCT02230514|Other|Autologous iliac crest and surgery|Standard treatment
11370596|NCT02230501|Experimental|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner
~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
11370597|NCT02230501|Experimental|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner
~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
11370598|NCT02230488|Active Comparator|Intensive Diabetes Case Management|Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
11370599|NCT02230488|No Intervention|Control :Standard/ usual care|
11370600|NCT02230462|Experimental|Viewing of cancer excision defect|Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
11370601|NCT02230462|No Intervention|No viewing of cancer excision defect|Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.
11370602|NCT02230436|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 72)
11370603|NCT02230436|Experimental|Late drain removal|Removing drain(s) on postoperative day 4 or later (n = 72)
11370604|NCT02230423|Experimental|Patients receiving nose surgery|"Patients in need of nose surgery, before and after surgery; or only after successful surgery, then with or without Empty Nose Syndrome."
11370605|NCT02230410|Experimental|focal cryo ablation|in this pilot study 10 subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
11370606|NCT02230397|Other|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
11370607|NCT02230397|Other|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
11370608|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
11370609|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
11370610|NCT02230371|Experimental|Granisetron|Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
11370611|NCT02230371|Placebo Comparator|Control (placebo)|Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.
11370612|NCT02230358|Other|Regional anesthesia (RA)|Regional anesthesia (RA) for a carotid endarterectomy Interventions: Regional anesthesia (RA), blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, Near-infrared spectroscopy (NIRS) monitoring, oxygen supply (not invasive 'Vigileo')
11370613|NCT02230358|Other|General anesthesia (GA)|General anesthesia (GA) for a carotid endarterectomy Interventions: General anesthesia, blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, NIRS monitoring, oxygen supply (not invasive 'Vigileo')
11370614|NCT02230345|Experimental|Probiotic yogurt|Daily administration, during two weeks, of two probiotic yogurts (200 mL each)
11370615|NCT02230345|Active Comparator|Acidified milk|Daily administration, over two consecutive weeks, of an isocaloric dose (compared to probiotics) of unfermented acidified milk
11370616|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
11370617|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
11370695|NCT02229773|Placebo Comparator|Placebo|
11370696|NCT02229773|Active Comparator|Pravastatin|
11370697|NCT02229773|Experimental|BIBB 1464 MS medium dose|
11370618|NCT02230319|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
11370619|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.
~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
11370620|NCT02230293|Active Comparator|Conventional Group|Conventional treatment and follow up
11370621|NCT02230293|Experimental|Multidisciplinary Group|Multidisciplinary assistance
11370622|NCT02230280|Other|The intervention cohort.|A community transition and rehabilitation intervention that includes a mobile health solution
11370623|NCT02230267|Experimental|High intensity boot camp|Each of the two HIBCs will have 10 participants (20 total) with a 1:5 physical therapist-to-patient ratio. Each HIBC session will last 1.5 hours and will be held on 4 days of the week. Participants will be required to attend 3 of those 4 days but may attend all. Because this is a pragmatic trial, therapists will have some leeway to control the intensity and the modality of the exercise. However, the basic format of the HIBC will consist of the following exercise components: A. 30 minutes of moderate-high intensity aerobic exercise at 70%+ of estimated maximum heart rate; B. 15 minutes of strengthening the major muscle groups of the trunk and upper/lower extremities; C. 15 minutes of balance training; and, D. 15 minutes of rest and stretching. Participants will rotate through these four different exercise components in a circuit fashion.
11370624|NCT02230267|Active Comparator|Usual care arm|The low intensity exercise group will participate in the Fitness Counts Exercise Program (FCEP) which is a basic low intensity, sitting and standing exercise program (10 minutes of stretching, 10 minutes of aerobic exercise (60% of heart rate maximum), and 10 minutes of strengthening). This exercise program was developed by the National Parkinson Foundation and is commonly used in PD exercise classes. The physical therapist-to-patient ratio will be 1:5. As there are two clinical sites, there will be 10 participants in each of the two boot camps (20 total). The FCEP will be 1 hour daily on four days of the week. Participants will be required to attend 3 days per week but may attend more if they are able.
11370625|NCT02230254|Experimental|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
11370626|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
11370627|NCT02230228|Experimental|ALK-001 capsules|
11370628|NCT02230215|Experimental|Patient-Specific Instrumentation|Patients to have a total knee replacement surgery completed using Patient-Specific Instrumentation
11370629|NCT02230215|No Intervention|Traditional Instrumentation|Patients to have a total knee replacement surgery done using traditional instrumentation.
11370630|NCT02230202||Healthy control|Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
11370631|NCT02230202||Stage III or IV CKD patients|Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
11370632|NCT02230202||Post-transplant patients|Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
11370633|NCT02230189|Experimental|Non-allergic/Non-asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with neither asthma nor allergy (as established by skin prick testing)
11370634|NCT02230189|Experimental|Allergic/Non-asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with allergy (as established by skin prick testing) but without asthma
11370635|NCT02230189|Experimental|Allergic/Asthmatic subjects|Intervention: Segmental airway allergen challenge Group: Volunteers with both asthma and allergy (as established by skin prick testing)
11370636|NCT02230176|Experimental|177Lu-DOTA0-Tyr3-Octreotate or OCLU|7.4 GBq per injection (max: 4 injections)
11370637|NCT02230176|Active Comparator|Sunitinib|37.5 mg/day
11370638|NCT02230137|Experimental|Text message arm|
11370639|NCT02230137|No Intervention|No text message arm|
11370640|NCT02230124|Experimental|MRE|
11370641|NCT02230111|Experimental|Energy restriction plus CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. They will be told that they are on a low-calorie diet and strategies to increase CDR will be used.
11370642|NCT02230111|Experimental|Energy restriction without CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
11370643|NCT02230098|Experimental|Remote Ischemic Conditioning|By use of short-term obstruction of the blood supply to the arm
11370644|NCT02230098|No Intervention|Before Remote Ischemic Conditioning|
11370645|NCT02230085||CPAP therapy|
11370646|NCT02230072|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
11370647|NCT02230059||Metastatic Castration-resistant Prostate Cancer|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
11370648|NCT02230046|Experimental|Sequence 1 (ABC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
11370698|NCT02229773|Experimental|BIBB 1464 MS high dose|
11370649|NCT02230046|Experimental|Sequence 2 (BCA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
11370650|NCT02230046|Experimental|Sequence 3 (CAB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
11370651|NCT02230046|Experimental|Sequence 4 (ACB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
11370652|NCT02230046|Experimental|Sequence 5 (BAC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
11370653|NCT02230046|Experimental|Sequence 6 (CBA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
11370654|NCT02230033|Experimental|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1.
11370655|NCT02230033|Experimental|Treatment B|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
11370656|NCT02230033|Experimental|Treatment C|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
11370657|NCT02230020||Nasal High Flow|All subjects are in this group
11370658|NCT02230007|Experimental|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
11370659|NCT02230007|No Intervention|Without MEOPA|Physiotherapit care without MEOPA
11370660|NCT02229994||Adults patients with chronic respiratory diseases|"- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.
~Sample 1 (n=110 patients) with COPD
~Sample 2 (n=30 patients) with Diffuse interstitial lung diseases
~Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).
~Sample 4 (n=30 patients) Adult with Cystic fibrosis"
11370661|NCT02229981|Experimental|ABC294640|Patients will receive ABC294640 orally in gelatin capsules BID.
11370662|NCT02229968|Experimental|Amicar (ε-aminocaproic acid)|Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.
11370663|NCT02229968|Placebo Comparator|normal saline|Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.
11370664|NCT02229955|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
11370665|NCT02229955|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
11370666|NCT02229942|Experimental|Rituximab|Rituximab induction (two infusions two weeks apart) and maintenance (infusions at 3, 6, 9 and 12 months)
11370667|NCT02229942|Placebo Comparator|Placebo|Saline (with added albumin), two infusions two weeks apart, followed by infusions at 3, 6, 9 and 12 months.
11370668|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
11370669|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
11370670|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
11370671|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
11370672|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
11370673|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
11370674|NCT02229903|Active Comparator|Active DTMS Treatment|Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
11370675|NCT02229903|Sham Comparator|Sham Treatment|The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
11370676|NCT02229890||Acute ischemic stroke within three hours after symptom onset|
11370677|NCT02229877|Experimental|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days
~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
11370678|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
11370679|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
11370680|NCT02229851|Active Comparator|Daily hGH|
11370681|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
11370682|NCT02229838|Experimental|BIBB 1464 MS single rising dose fed|
11370683|NCT02229838|Experimental|BIBB 1464 MS tablet fasted|
11370684|NCT02229838|Active Comparator|BIBB 1464 MS solution fasted|
11370685|NCT02229838|Placebo Comparator|BIBB 1464 MS placebo|
11370686|NCT02229825|Experimental|Duloxetine low|
11370687|NCT02229825|Experimental|Duloxetine high|
11370688|NCT02229812||thrombolytic therapy in stroke|
11370689|NCT02229799||Stroke patients|
11370690|NCT02229786|Experimental|Buscopan® plus|
11370691|NCT02229786|Active Comparator|Buscopan®|
11370692|NCT02229786|Active Comparator|Paracetamol|
11370703|NCT02229734|Experimental|Radiation plus Androgen Supression|Radiation plus Androgen Suppression give as stereotactic radiation 7gray (Gy) per week x 5 weeks and leuprolide 45mg every 6 months for 18 months
11370704|NCT02229721|Active Comparator|Syntocinon Nasalspray 32 IU|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
11370705|NCT02229721|Placebo Comparator|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
11370706|NCT02229708|No Intervention|Usual Care|The Usual Obstetric Care group will receive usual advice about nutrition and activity during pregnancy from their obstetrician along with some additional information about pregnancy and childbirth through readings from The American College of Obstetricians and Gynecologists. In addition, participants will receive weekly text messages to maintain contact and ensure follow-up.
11370707|NCT02229708|Experimental|Healthy Lifestlye Group|The Healthy Lifestyle Group will take part in an individual, technology-based behavioral intervention program which will include specific information about nutrition and physical activity, and strategies for helping them make changes to their diet, physical activity, and weight-related behaviors during pregnancy. Participants will receive information through print materials, text messages, a private Facebook group, and in-person visits and phone calls from a health coach who is part of our research team.
11370708|NCT02229682|Experimental|Mild-dose IMRT|"Experimental: Mild-dose of 46Gy with IMRT
~Drug:
~gemcitabine：1250mg/m2 (iv drip) on days 1, oxaliplatin: 85 mg/m2 (iv drip) on day 1, and pegaspargase: 2500 IU/m2 (intramuscular injection) on day 1. Cycle is repeated every 14 days
~IMRT： IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions."
11370709|NCT02229669|Experimental|Horizontal incisions|Coronally advanced flap was performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted extending beyond the mucogingival junction, to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed.
11370710|NCT02229669|Experimental|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
11370711|NCT02229656|Experimental|radiotherapy and olaparib|Radiotherapy will be given with accelerated fractionation following the DAHANCA schedule Olaparib: dose escalation
11370712|NCT02229643||Traumatic brain injury|Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
11370713|NCT02229630|Experimental|Pregnant women|Foetuses with intra-uterine growth restriction, between 28 and 32 weeks of gestation, with an estimated foetal weight < 5th percentile (Hadlock calculator)
11370714|NCT02229617|Active Comparator|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
11370715|NCT02229604|Experimental|EA group|Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
11370716|NCT02229604|Active Comparator|drug group|Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.
11370717|NCT02229591||EFL patients|Patients with Expiratory Flow Limitation undergoing surgery
11370718|NCT02229591||Control group|Patients withouth Expiratory Flow Limitation undergoing surgery
11370719|NCT02229578||Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
11370720|NCT02229578||Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
11370721|NCT02229565||Caucasian|Caucasian subjects having a biopsy or prostatectomy.
11370722|NCT02229565||African American|African American subjects having a biopsy or prostatectomy.
11370723|NCT02229552|Other|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
11371859|NCT02221908||Patients brought to Hahnemann Hospital ED|
11370724|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.
~Patients will complete the Oral Symptoms booklet per the protocol."
11370725|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.
~Patients will complete the Oral Symptoms booklet per the protocol."
11370726|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.
~Patients will complete the Oral Symptoms booklet per the protocol."
11370727|NCT02229526|Active Comparator|Low dose fish oil|
11370728|NCT02229526|Placebo Comparator|Low dose olive oil|
11370729|NCT02229526|Experimental|High dose fish oil|
11370730|NCT02229526|Placebo Comparator|High dose olive oil|
11370731|NCT02229513|No Intervention|Control|Normal cesarean technique.
11370732|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
11370733|NCT02229500|Active Comparator|Control|Inulin control, 10g/d for 7 days. Isotope and appetite measurements on day 7
11370734|NCT02229500|Experimental|Delivery system 1|Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
11370735|NCT02229500|Experimental|Delivery system 2|Delivery system, 54% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
11370736|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
11370737|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
11370738|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
11370739|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
11370740|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
11370741|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
11370742|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
11370743|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
11370744|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
11370745|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
11370746|NCT02229448||IgG4 UKN diagnosis|who ever been found with IgG4 sub class in blood sample or in his byposy
11370747|NCT02229435||eGFR <60ml/min|Patients with CKD with eGFR <60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.
11370812|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
11370986|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
11370748|NCT02229422|Experimental|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.
~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.
~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.
~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.
~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
11370749|NCT02229409|No Intervention|Control|Observation only, no behavioral intervention
11370750|NCT02229409|Experimental|Intervention|Intervention Walkadoo.
11370751|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
11370752|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
11370753|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
11370754|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
11370755|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
11370756|NCT02229370||ECAA|all patients diagnosed with an extracranial carotid artery aneurysm
11370757|NCT02229357|Experimental|OrniFlu® inactivated vaccine|
11370758|NCT02229344||Newly Diagnosed Moderate to Severe Ulcerative Colitis|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
11370759|NCT02229331||gait analysis|gait analysis
11370760|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
11370761|NCT02229305|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
11370762|NCT02229305|Experimental|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
11370763|NCT02229292|Active Comparator|Tranexamic acid|The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
11370764|NCT02229292|Placebo Comparator|Saline|The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
11370765|NCT02229279|Active Comparator|Teleconsulting|Teleconsulting
11370766|NCT02229279|No Intervention|No Teleconsulting|
11370767|NCT02229266|Experimental|NK cells|Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
11370768|NCT02229266|Active Comparator|Control Intervention|1 cycle of consolidation chemotherapy with high-dose cytarabine
11370769|NCT02229253||Degarelix|Treatment according to standard clinical practice.
11370770|NCT02229240|Experimental|Albiglutide|Subjects will receive once-weekly subcutaneous injections of albiglutide 30 mg (with forced uptitration to albiglutide 50 mg at Week 4) in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms.
11370771|NCT02229240|Placebo Comparator|Matching albiglutide placebo|Subjects will receive once-weekly subcutaneous injections of matching albiglutide placebo in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms
11370772|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
11370773|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
11370774|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)
~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)
~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)
~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
11370775|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
11370776|NCT02229201|Experimental|Propofol|intravenous anaesthetic
11370777|NCT02229201|Active Comparator|Sevoflurane|volatile anaesthetic
11370778|NCT02229188|Active Comparator|Problem Solving Therapy|Problem Solving Therapy is an evidence-based behavioral treatment for late life depression proven effective with different geriatric groups including ambulatory; medically ill; older adults with executive dysfunctions; and more recently, low-income, disabled older adults.
11370779|NCT02229188|Experimental|Evolution|Evolution is a plasticity intervention in the form of a video driving game that targets the cognitive conflict network.
11370780|NCT02229188|Placebo Comparator|Words|Words is a challenging crosswords type of game that will serve as the placebo comparator to Evo.
11370781|NCT02229175|Experimental|IVB + laser|Intravitreal bevacizumab (IVB) will be administered at baseline, month 1, and month 2, consistent with previous DME trials. Subvisible laser treatment will be administered at baseline. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB and laser therapy every 3 months if defined retreatment criteria are met, as described below.
11370813|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
11371184|NCT02226237|No Intervention|Control Group|in which patients received no specific treatment, only the usual general guidelines
11370782|NCT02229175|Active Comparator|IVB only|IVB monthly at baseline, month 1, and month 2. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB if defined retreatment criteria are met, as described below. Patients will also undergo sham laser treatment (patient will be placed in front of laser but no laser will be activated) to mask the patient to the treatment.
11370783|NCT02229162||90 seconds DCC|the initial 15-20 subjects (15 enrolled subjects who complete study) will have cord clamped at 90 seconds. Then data will be analyzed and evaluated by DSMB
11370784|NCT02229162||Two minutes DCC|If Data Safety Monitoring Board (DSMB) concurs, DCC will then be practiced for 2 minutes for second group, which is the minimum amount of time recommended to be defined as DCC.
11370785|NCT02229149|Experimental|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab
~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND
~physician's choice of chemotherapy:
~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
~Docetaxel 75 mg/m2 IV every 3 weeks; OR
~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.
~AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
11370786|NCT02229149|Active Comparator|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab
~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND
~physician's choice of chemotherapy:
~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
~Docetaxel 75 mg/m2 IV every 3 weeks; OR
~Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
11370787|NCT02229136|Experimental|Miracle Mouthwash plus Hydrocortisone|Miracle Mouthwash plus Hydrocortisone, swish and expectorate 10cc (10 mLs) 4 times per day, every day for 12 weeks.
11370788|NCT02229136|Active Comparator|Prednisolone|Prednisolone oral solution 15 mg/5 ml; swish and expectorate 10cc (10 mL) 4 times per day, every day for 12 weeks.
11370789|NCT02229123|Experimental|Intravenous levetiracetam|1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.
11370790|NCT02229110|Active Comparator|Signal|In addition to usual care, there will be an automatic signal in the electronic medical record (EMR) upon opening that will show the reader that the patient is currently not treated in the correct treatment setting and it simultaneously will give advice to which treatment allocation this patient should be transferred to.
11370791|NCT02229110|No Intervention|No signal|Patients receive usual care, consisting of 4 office visits yearly
11370792|NCT02229097|Experimental|Normal then Coordinated|normal bolus during 2 weeks then coordinated bolus during 2 weeks
11370793|NCT02229097|Experimental|Coordinated then Normal|coordinated bolus during 2 weeks then normal bolus during 2 weeks
11370794|NCT02229084|Active Comparator|Chemovax Schedule A|Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
11370795|NCT02229084|Active Comparator|Chemovax Schedule B|Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
11370796|NCT02229084|Active Comparator|Chemovax Schedule C|Chemovax Schedule C: Subjects will receive three weekly injections of vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
11370797|NCT02229084|Active Comparator|Chemovax Schedule D|Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
11370798|NCT02229084|Active Comparator|Chemovax Schedule E|Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
11370799|NCT02229071|Experimental|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
11370800|NCT02229071|Active Comparator|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
11370801|NCT02229058|Experimental|Albumin Bound Paclitaxel plus S-1|Abraxane 120 mg/m2, D1,D8;S-1 40~60mg QD D1-D14,every 3 weeks until disease progress or intolerable toxicity.
11370802|NCT02229045|Experimental|Albumin Bound Paclitaxel With 5-FU/CF|Albumin Bound Paclitaxel 150 mg/m2 (on day 1),5FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
11370803|NCT02229032||Dravet Sydrome|Patients with Dravet Syndrome who are self-seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy
11370804|NCT02229019|Experimental|Volunteer mealtime assistance|Trained volunteers will provide mealtime assistance to older hospital inpatients at one mealtime each weekday.
11370805|NCT02229006||Aneurysm surveillance|Radiation: 18F-NaF PET-CT
11370806|NCT02229006||Control patients|Radiation: 18F-NaF PET-CT
11370807|NCT02228993||Awake Craniotomy|
11370808|NCT02228993||General Anesthesia Craniotomy|
11370809|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
11370810|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
11370811|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
11370814|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:
~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.
~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.
~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
11370815|NCT02228954||Renal Cell Cancer|
11370816|NCT02228941||gene mutation|
11370817|NCT02228928|Experimental|CAPNP, 50 ug/cm2 capsaicin patch|50 ug/cm2 capsaicin patch, 49cm2, 1patch/4days
11370818|NCT02228928|Experimental|CAPNP, 100 ug/cm2 capsaicin patch|100ug/cm2 capsaicin patch, 49cm2, 1patch/4days
11370819|NCT02228928|Active Comparator|0.075% capsaicin cream|capsaicin cream qc/day
11370820|NCT02228928|Placebo Comparator|Placebo patch|
11370821|NCT02228902|Active Comparator|ferrous fumarate|12 patients receive ferrous fumarate, 12 patients receive ferrous gluconate
11370822|NCT02228902|Active Comparator|ferrous gluconate|12 patients receive ferrous fumarate and 12 patients receive ferrous gluconate
11370823|NCT02228889|Experimental|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
11370824|NCT02228889|Experimental|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
11370825|NCT02228863|Experimental|Early Inmotion and Botox|Concomitant use of Inmotion and botulinum toxin from the baseline
11370826|NCT02228863|Active Comparator|Botox, then Inmotion|Inmotion training 4 weeks after botulinum toxin injection
11370827|NCT02228863|Active Comparator|Inmotion, then Botox|From the baseline Inmotion, then Botox injection at 4 weeks after baseline
11370828|NCT02228863|Active Comparator|Late Inmotion and Botox|No intervention, then Inmotion and Botox injection at 4 weeks from the baseline
11370829|NCT02228850|Experimental|Alprostadil Cream (300mcg)|300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
11370830|NCT02228850|Experimental|Alprostadil Cream (1000mcg)|1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
11370831|NCT02228850|Experimental|Alprostadil Cream (3000mcg)|3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration
11370832|NCT02228837|Placebo Comparator|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
11370833|NCT02228837|Experimental|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
11370834|NCT02228824|Experimental|Very low nicotine content cigarettes|
11370835|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
11370836|NCT02228811|Experimental|DCC-2701 tablet|DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11370837|NCT02228798||Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require surgery or a procedure.
11370838|NCT02228798||Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require surgery or a procedure.
11370839|NCT02228798||Apixaban|Patients currently taking apixaban that have atrial fibrillation and require surgery or a procedure.
11370840|NCT02228785|Experimental|100µg dose of G17DT|Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
11370841|NCT02228785|Experimental|200µg dose of G17DT|Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
11370842|NCT02228785|Experimental|500µg dose of G17DT|Patients in this arm received a 500µg dose of G17DT via intramuscular injection.
11370843|NCT02228772|Experimental|MLN 9708|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~MLN 9708 will be given with standard multi-drug regimen for ALL . MLN 9708 will be administered on determined days during Induction therapy cycle and Consolidation cycle. If remission occurs and if eligible, the next stage with be either Stem Cell or Bone Marrow Transplant.
~If not eligible to receive a transplant, the participant will continue on this study for the next 3 stages.
~CNS Therapy
~Consolidation 2
~Continuation Therapy
~No further MLN9708, the investigational drug, will be given after Consolidation 1 Standard chemotherapy -Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate"
11370916|NCT02228213|Placebo Comparator|Saline|Saline administered i.v. once weekly for 52 weeks
11370917|NCT02228200|Experimental|Nurse-led care|Subjects in the nurse-led care arm received nurse-led care and routine care.
11370918|NCT02228200|Active Comparator|Routine care|Subjects in the routine care arm received routine care provided by the study hospital.
11370844|NCT02228759|Experimental|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
11370845|NCT02228746|Experimental|Alpha-galacto-oliosaccharides|
11370846|NCT02228746|Placebo Comparator|Placebo|
11370847|NCT02228733|Experimental|KBP-5074: Cohort 1|Healthy Volunteers will receive one dose of KBP-5074
11370848|NCT02228733|Experimental|KBP-5074: Cohort 2|Healthy Volunteers will receive one dose of KBP-5074
11370849|NCT02228733|Experimental|KBP-5074: Cohort 3|Healthy Volunteers will receive one dose of KBP-5074
11370850|NCT02228733|Experimental|KBP-5074: Cohort 4|Healthy Volunteers will receive one dose of KBP-5074
11370851|NCT02228733|Experimental|KBP-5074: Cohort 5|Healthy Volunteers will receive one dose of KBP-5074
11370852|NCT02228733|Experimental|KBP-5074: Fed Group|Healthy Volunteers will receive one dose of KBP-5074
11370853|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
11370854|NCT02228707|Experimental|BIIB061|Participants receive BIIB061
11370855|NCT02228707|Placebo Comparator|Placebo|Participants receive matched placebo
11370856|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
11370857|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
11370858|NCT02228655|Other|FMX-8|FMX-8 for injection, 15mg/kg, twice weekly, 29 days
11370859|NCT02228629|Experimental|Typical house shoe|Subject's typical shoes worn in and around home
11370860|NCT02228616|Experimental|Prucalopride plus Polyethylene glycol or lactulose|
11370861|NCT02228603|Experimental|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
11370862|NCT02228603|Active Comparator|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
11370863|NCT02228603|Other|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
11370864|NCT02228590|Other|APL-130277|open label baseline comparison
11370865|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
11370866|NCT02228551|Other|ARC PPS|Augmented renal clearance Point prevalence study
11370867|NCT02228538||Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers
11370868|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
11370869|NCT02228512|Active Comparator|1|Treatment naive PEL (main cohort)
11370870|NCT02228512|Active Comparator|2|Treatment na(SqrRoot) ve large cell lymphoma arising in KSHV-MCD
11370871|NCT02228512|Active Comparator|3|Previously treated KSHV-NHL
11370872|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
11370873|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
11370874|NCT02228486|Active Comparator|Cue Exposure Therapy and verum tDCS|During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
11370875|NCT02228486|Placebo Comparator|Cue Exposure Therapy and sham tDCS|During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
11370876|NCT02228486|No Intervention|Waiting list control group|The Cue-Reactivity of patients assigned to this arm will be measured twice with an interval of 5 weeks. Afterwards, patients will take part in the cue exposure therapy like subjects assigned to the active arms of the study
11370877|NCT02228473|Experimental|Glycopyrrolate|Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
11370878|NCT02228473|Active Comparator|Atropine|Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
11370879|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
11370880|NCT02228447|No Intervention|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
11370881|NCT02228447|Experimental|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
11370882|NCT02228434|Experimental|Tailored intervention group|"For the monitoring session, physical activity was assessed by accelerometer and dietary was assessed by diary. Based on the monitoring information, the individual tailored prescription, including the normative feedback and process feedback, were formed and delivered to children and parents. Children were encouraged to modify the behaviors according to the prescription.
~Then, next monitoring circle was followed. In total, 7 monitoring round were completed."
11370883|NCT02228434|Experimental|Happy 10 exercise group|All the schools participating in this group were encouraged to take two Happy 10 sessions on each school day.
11370884|NCT02228434|Experimental|Nutrition education group|The nutrition intervention was mainly conducted based on the nutrition knowledge through health education lectures given by researchers. The lectures were given for eight times to students and twice to parents. Each lecture session lasted no less than 40 min.
11370885|NCT02228434|No Intervention|Control group|Receive no intervention
11370886|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
~Allowable Dosage Forms:
~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
11370887|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
11370888|NCT02228395|Experimental|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
11370889|NCT02228395|Experimental|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
11370890|NCT02228395|Experimental|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
11370891|NCT02228382|Experimental|Bosutinib|
11370892|NCT02228369|Experimental|Daily dose of AZD3759|Daily oral dose of AZD3759
11370893|NCT02228369|Experimental|Daily Dose of AZD9291|Daily oral dose of AZD9291
11370894|NCT02228343|Experimental|Ayurveda|Ayurvedic therapy
11370895|NCT02228330|Experimental|uni-lateral obturator nerve block|"Patients scheduled for TUR for bladder tumor Intervention: uni-lateral obturator nerve block.
~non-blocked obtorator side of each patient will be used as control"
11370896|NCT02228317|Experimental|Telemedicine consultation|EMTs will systematically establish teleconsultation by either telephone or video with the EMDC-physician in all cases of non-critical illness
11370897|NCT02228304|Experimental|NT-503-3 ECT implantation|
11370898|NCT02228304|Active Comparator|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
11370899|NCT02228291|Placebo Comparator|Placebo|Cellulose
11370900|NCT02228291|Experimental|Citric flavonoid|Citric flavonoid
11370901|NCT02228278|Experimental|Group A|Group A will receive the typical clinic visits plus daily text messages
11370902|NCT02228278|Other|Group B|Group B will act as the control and will receive the typical clinic visits.
11370903|NCT02228265||Ancillary-Correlative (genetic analysis)|Patients undergo collection of blood and tissue samples at baseline, during administration of enzalutamide and after the time of disease progression for analysis via immunohistochemistry, comparative genome hybridization, and sequencing.
11370904|NCT02228252|Experimental|20 g whey protein (-15 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
11370905|NCT02228252|Experimental|20 g whey protein (-30 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 30 min prior to the main meal.
11370906|NCT02228252|Experimental|20 g casein|20 g casein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
11370907|NCT02228252|Experimental|20 g gluten protein|21.5 g gluten protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
11370908|NCT02228239|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
11370909|NCT02228239|Experimental|Sequence 2 (BCA)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
11370910|NCT02228239|Experimental|Sequence 3 (CAB)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
11370911|NCT02228239|Experimental|Sequence 4 (CBA)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
11370912|NCT02228239|Experimental|Sequence 5 (ACB)|Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
11370913|NCT02228239|Experimental|Sequence 6 (BAC)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
11370914|NCT02228226||MG-1treated group|MG-1treated group: Patients those who underwent arthroscopic Bankart repair for glenohumeral instability using MG-1
11370915|NCT02228213|Experimental|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
11370919|NCT02228187|Active Comparator|BCI Intervention|Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
11370920|NCT02228187|No Intervention|Waitlist Control Group|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
11370921|NCT02228174|Experimental|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
11370922|NCT02228161|Experimental|Yoga exercise|Participatants will receive regular 60-minutes yoga classes twice a week for 3 months.
11370923|NCT02228161|No Intervention|Regular schedule of daily living|Participants will maintain regular schedule as usual.
11370924|NCT02228148|Experimental|NFS|Cochlear Nucleus Fitting Software
11370925|NCT02228148|Active Comparator|CSS|Cochlear Nucleus Custom SoundTM Suite
11370926|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
11370927|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
11370928|NCT02228122|Experimental|Aquacel® Ag+ Extra|
11370929|NCT02228109|Experimental|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
11370930|NCT02228109|Experimental|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
11370931|NCT02228109|Experimental|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
11370932|NCT02228096|Experimental|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
11370933|NCT02228083|Active Comparator|Safety of dental anesthesia|Application of local dental anesthesia with two cartridges (5,6 mL) of the lidocaine 2% with epinephrine 1:100.000 in heart failure patients in functional class III or IV.
11370934|NCT02228083|Other|Oral health profile|An oral health profile of patients with heart failure will be described based in oral clinical examination.
11370935|NCT02228070|Experimental|strabismus video goggles|
11370936|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
11370937|NCT02228044|Experimental|Prevention Program|This is a cognitive-behavioral substance abuse, suicide, and HIV prevention program delivered in a workshop format to adolescent participants and their parents/legal guardians.
11370938|NCT02228044|No Intervention|Assessment Only|
11370939|NCT02228031|Experimental|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.
11370940|NCT02228031|Placebo Comparator|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
11370941|NCT02228018|Experimental|CALSA and FRI repeatability|CT-Scan No medication used
11370942|NCT02228005|Experimental|Depression|Sertraline 50- 200mg
11370943|NCT02228005|No Intervention|Comparison group (non-depressed)|No intervention
11370944|NCT02227992|Experimental|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
11370945|NCT02227992|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
11370946|NCT02227979|Experimental|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
11370947|NCT02227979|Active Comparator|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
11370948|NCT02227966|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
11370949|NCT02227966|Sham Comparator|sham-YBand (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
11370950|NCT02227953|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
11370951|NCT02227953|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
11370952|NCT02227940|Experimental|Arm 1 (ceritinib MTD then with gemcitabine alone)|"Dose Escalation Cohort 1: Patients with advanced solid tumors for whom gemcitabine hydrochloride-based therapy is clinically appropriate receive ceritinib PO (QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Expansion Cohort 1E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors who previously progressed on gemcitabine hydrochloride-based therapy receive ceritinib and gemcitabine hydrochloride as in the dose escalation cohort 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11370953|NCT02227940|Experimental|Arm 2 (ceritinib MTD then with gemcitabine and nab-paclitaxel)|"Dose Escalation Cohort 2: Patients with advanced pancreatic cancer receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Expansion Cohort 2E: Once the MTD of ceritinib has been determined, patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation as in the dose escalation cohort 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11370984|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
11370985|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
11371860|NCT02221895|Experimental|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
11370954|NCT02227940|Experimental|Arm 3 (ceritinib MTD then with gemcitabine and cisplatin)|"Dose Escalation Cohort 3: Patients with advanced solid tumors for whom gemcitabine hydrochloride and cisplatin-based therapy is clinically appropriate receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Expansion Cohort 3E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and cisplatin as in the dose escalation cohort 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11370955|NCT02227914|Experimental|Oprozomib with Sorafenib|"Phase 1b:
~Oprozomib doses will be escalated in sequential groups of at least 2 subjects. Study subjects will receive oprozomib at dose levels of 90, 120, 150, 180, 210, or 240 mg + sorafenib to reach the dose levels of 600 or 800 mg total daily dose until the maximum tolerated dose (MTD) is reached.
~Phase 2:
~Study subjects who meet the entry criteria will receive oprozomib + sorafenib at the RP2D (recommended Phase 2 dose) established in the Phase 1b portion of the study."
11370956|NCT02227914|Active Comparator|Sorafenib|"Phase 2:
~Study subjects who meet the entry criteria will receive sorafenib 400 mg twice a day (800 mg total daily dose)."
11370957|NCT02227901|Experimental|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.
~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
11370958|NCT02227888|Experimental|N91115|Every 12 hour oral dosing of 50 mg N91115 for 14 days
11370959|NCT02227875|Experimental|Mylan's insulin Glargine|receive Mylan's insulin Glargine
11370960|NCT02227875|Active Comparator|Lantus®|receive Lantus®
11370961|NCT02227862|Experimental|Mylan's Insulin Glargine|Receive Mylan's Insulin Glargine plus insulin lispro.
11370962|NCT02227862|Active Comparator|Lantus®|Receive Lantus® plus insulin lispro
11370963|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
11370964|NCT02227836|Experimental|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:
~2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.
~Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits
~The patches will be removed at 48 hours, and results read at 72 and 120 hours after application
~Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
11370965|NCT02227823|Experimental|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
11370966|NCT02227823|No Intervention|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
11370967|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
11370968|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
11370969|NCT02227797|Experimental|Voriconazole|
11370970|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
11370971|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
11370972|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
11370973|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
11370974|NCT02227771||Patient with chronic total occlusion|
11370975|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
11370976|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
11370977|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
11370978|NCT02227732|Other|New Indwelling Pleural Catheter|
11370979|NCT02227719|Experimental|Test: CTI|CTI is titanium mesh
11370980|NCT02227719|Active Comparator|Control: Collagen membrane|Collagen membrane is used for ridge augmentation
11370981|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
11370982|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
11370983|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
11370987|NCT02227680|Active Comparator|Music Therapy|Patients randomized to the music therapy group will receive 1-3 10-40 minute music therapy sessions during each of the days of their stay on the inpatient unit. Each participant randomized to the music therapy intervention will be given a personalized CD and one portable CD player with headphones which they may keep after the study has ended.
11370988|NCT02227680|Active Comparator|Massage Therapy|Patients randomized to the massage therapy group will receive 1-3 10-40 minute massage treatments during each of the days of their stay on the inpatient unit.
11370989|NCT02227680|No Intervention|Usual Care|The control group will continue to receive usual care while on the Family Medicine Inpatient Unit.
11370990|NCT02227667|Experimental|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
11370991|NCT02227654|Experimental|Abnormal Ovarian Ultrasound|Abnormal Ovarian Ultrasound
11370992|NCT02227641|Experimental|Adoptive transfer of CMV/EBV specific T-cells|Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.
11370993|NCT02227641|No Intervention|Control|Observation only.
11370994|NCT02227628|Placebo Comparator|Sugary Beverage|Sugary Beverage
11370995|NCT02227628|Experimental|Acai beverage|Acai Polyphenolics
11370996|NCT02227615|Placebo Comparator|Sugary beverage|Sugary beverage
11370997|NCT02227615|Experimental|Mango beverage|Mango polyphenolics
11370998|NCT02227602|Experimental|Mango|Mango polyphenolics
11370999|NCT02227589|Experimental|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
11371000|NCT02227589|Active Comparator|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
11371001|NCT02227589|Active Comparator|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
11371002|NCT02227576|Experimental|Romiplostim|Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.
11371003|NCT02227563|Experimental|Active tDCS|active tDCS
11371004|NCT02227563|Sham Comparator|control|sham (placebo) tDCS condition
11371005|NCT02227550|Experimental|Apixaban|Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)
11371006|NCT02227550|Active Comparator|Vitamin K antagonist|VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine
11371007|NCT02227537||Adolescence idiopathic scoliosis|Patients must be at least 10 years of age with a risser score of 0, 1, or 2
11371008|NCT02227524|Experimental|No Device|Assistive device conditions
11371009|NCT02227524|Experimental|Single Point Cane|Assistive device condition
11371010|NCT02227524|Experimental|Four-Point Cane|Assistive device condition
11371011|NCT02227524|Experimental|Trekking Pole|Assistive device condition
11371012|NCT02227511|Active Comparator|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
11371013|NCT02227511|Active Comparator|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
11371014|NCT02227498|Experimental|Effect of Argus II on Functional Vision|All subjects enrolled in the study will be implanted with the Argus II Retinal Prosthesis. To evaluate safety and effectiveness of Argus II on visual function.
11371015|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
11371016|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
11371017|NCT02227472||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study will complete evaluation of cognitive and pre-academic skills, and parent questionnaires.
11371018|NCT02227459|Experimental|Experimental: Arm A|Once a week dosing
11371019|NCT02227459|Experimental|Experimental: Arm B|Twice a week dosing
11371020|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.
~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
11371021|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
11371022|NCT02227433|Experimental|brentuximab vedotin (BV)|
11371023|NCT02227420|Experimental|Anakinra|Anakinra 100mg s.c. x 5
11371024|NCT02227407|Experimental|Energy expenditure, gait pattern, RGOs|using motion capture system and forceplates to monitor gait pattern while wearing reciprocating gait orthoses to calculate the mechanical energy cost
11371025|NCT02227394|Experimental|Z7200|"Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.
~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
11371026|NCT02227394|Active Comparator|Symbicort® Turbohaler|Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).
11371027|NCT02227381||Microarray / NGS test|
11371028|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
11371029|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
11371030|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) <70 years of age.
11371031|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
11371032|NCT02227342|Experimental|Fecal Microbiota Transplantation|serial Fecal Microbiota Transplantation
11371033|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
11371034|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
11371035|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
11371036|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
11371037|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
11371038|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
11371039|NCT02227303|Other|Lifestyle counseling|
11371040|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
11371041|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
11371042|NCT02227277|Experimental|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
11371043|NCT02227277|Experimental|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
11371044|NCT02227277|No Intervention|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
11371045|NCT02227264|Experimental|Cinacalcet|"Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.
~Second intervention: Parathyroid adenomectomy."
11371046|NCT02227251|Experimental|Selinexor (KPT-330)|Fixed milligram dose of 60 mg selinexor orally, twice weekly on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1-4 of each four week (28 day) cycle (total of 8 doses per cycle).
11371047|NCT02227238|Experimental|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
11371048|NCT02227238|Active Comparator|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
11371049|NCT02227225||Postoperative Delirium|
11371050|NCT02227212|Experimental|Insulin glargine U300|Once daily subcutaneous injection for 4 weeks
11371051|NCT02227199|Experimental|Treatment (brentuximab, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin IV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
11371052|NCT02227186|No Intervention|Control arm|No school-located influenza vaccination clinic
11371053|NCT02227186|Experimental|School-located influenza vaccination clinics|School-located influenza vaccination clinics
11371054|NCT02227173|Experimental|Single-Sequence, A B C|"Treatment A:
~Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1
~Treatment B:
~BMS-986020 orally twice daily (BID) on Day 8 through Day 10
~Treatment C:
~BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17"
11371055|NCT02227160|Experimental|Psychosocial group intervention|Subjects will seek outpatient counseling, support groups, in addition to 10 weekly group meetings
11371056|NCT02227160|Active Comparator|Control|Subjects will seek outpatient counseling and support groups only
11371057|NCT02227147|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
11371058|NCT02227147|Placebo Comparator|Placebo|Vehicle: formulation containing anti-oxidant
11371059|NCT02227134|Other|Difficult Airway|Children with a history of difficult airway intubation.
11371060|NCT02227134|Other|Obstructive Sleep Apnea|Children with a history of obstructive sleep apnea.
11371061|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
11371062|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
11371063|NCT02227095|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
11371064|NCT02227095|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
11371065|NCT02227082|Experimental|radiotherapy and olaparib|radiotherapy: 61.18 Gy olaparib: dose escalating
11371066|NCT02227069|Experimental|M518101|M518101 is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
11371067|NCT02227069|Placebo Comparator|M518101 Vehicle|M518101 vehicle is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
11371068|NCT02227069|Active Comparator|sodium lauryl sulfate|A solution of 0.2% sodium lauryl sulfate is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
11371069|NCT02227069|Sham Comparator|Saline|A solution of 0.9% saline is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
11371070|NCT02227056|Experimental|Methylphenidate treatment|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
11371071|NCT02227056|No Intervention|Control|On three different days each participant will be re-evaluated without recieveing Methylphenidate.
11371072|NCT02227030|Experimental|BIIB 722 CL single rising dose|
11371073|NCT02227030|Experimental|BIIB 722 CL cross over|
11371074|NCT02227030|Placebo Comparator|Placebo solution|
11371075|NCT02227030|Placebo Comparator|Placebo tablet|
11371076|NCT02227017|Experimental|TPV/RTV capsules fed|
11371077|NCT02227017|Experimental|TPV/RTV capsules fasted|
11371078|NCT02227017|Active Comparator|TPV/RTV solutions fed|
11371079|NCT02227017|Active Comparator|TPV/RTV solutions fasted|
11371080|NCT02227004||MRI in patients with Pacemaker or ICD|Perform MRI in patients with pacemaker or ICD and evaluate patient and device safety
11371081|NCT02226991|Experimental|TPV/RTV/EFV|tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23
11371082|NCT02226978|Experimental|TPV/r with valaciclovir|VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)
11371083|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
11371084|NCT02226952|Experimental|Group 1|BILN 2061 W, medium dose, in patients with genotype 1, minimal fibrosis
11371085|NCT02226952|Experimental|Group 2|BILN 2061 W, high dose, in patients with genotype 1, minimal fibrosis
11371086|NCT02226952|Experimental|Group 3|BILN 2061 W, high dose, in non-genotype 1 patients, minimal fibrosis
11371087|NCT02226952|Experimental|Group 4|BILN 2061 W, low dose, in patients with genotype 1, minimal fibrosis
11371088|NCT02226952|Experimental|Group 5|BILN 2061 W, medium dose, in patients with genotype 1, advanced fibrosis
11371089|NCT02226952|Placebo Comparator|Placebo|
11371090|NCT02226939|Experimental|BILN 2061 ZW|
11371091|NCT02226939|Placebo Comparator|Placebo|
11371092|NCT02226926|Experimental|Aggrenox|Dipyridamole extended release / Acetylsalicylic acid
11371093|NCT02226926|Active Comparator|Persantin Retard|Dipyridamole extended release
11371094|NCT02226926|Active Comparator|Acetylsalicylic acid|
11371095|NCT02226913|Experimental|lidocaine & sodium bicarbonate|2% lidocaine with 1: 80,000 epinephrine buffered with 0.18 mL of 8.4% sodium bicarbonate
11371096|NCT02226913|Active Comparator|lidocaine & placebo|2% lidocaine with 1:80,000 epinephrine with 0.18 mL of sterile distilled water
11371097|NCT02226900|Experimental|Hybrid Revascularization|The hybrid myocardial revascularization group will be accomplished by a two-step scheme, comprised by off-pump LIMA-to-left anterior descending grafting, followed by percutaneous coronary interventions with Promus Element (everolimus second generation drug eluting stent) for the remaining coronary lesions.
11371098|NCT02226900|Other|Conventional Surgical Coronary Bypass Grafting|Conventional Coronary Artery Bypass Grafts with in pump technique.
11371099|NCT02226887|Experimental|MESH|
11371100|NCT02226887|Active Comparator|NO MESH|
11371101|NCT02226861|Experimental|1|Subjects will receive CD34-selected stem cells followed by fixed dose ULG IL-2 (100,000 IU/m2) given subcutaneously for 12 weeks+Sirolimus until Day +60
11371102|NCT02226822||Adult patients with documented T2DM|Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
11371103|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
11371104|NCT02226796|Active Comparator|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes prior to naming treatment, while the subject sits quietly and comfortably in a chair. After the 20-minute priming period, the a-tDCS will be removed and the participant will receive naming treatment for 60 minutes.
11371105|NCT02226796|Active Comparator|Non-Prime Condition|The non-prime (NONPRIME) condition is an intervention that will consist of 40 minutes of naming treatment only, followed by an additional 20 minutes of concurrent naming treatment with a-tDCS.
11371106|NCT02226783|Experimental|Treatment A AZD1722 salt tablet (fasted)|Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner
11371107|NCT02226783|Experimental|Treatment B AZD1722 salt tablet (fed)|Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner
11371108|NCT02226783|Experimental|Treatment C AZD1722 salt tablet (fasted)|Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption
11371109|NCT02226783|Experimental|Treat D AZD1722 free-base tablet (fast)|Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner
11371110|NCT02226783|Experimental|Treat E AZD1722 free-base+Omeprazole|Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
11371111|NCT02226770|Other|ICD|Implantation of an Implantable Cardioverter Defibrillator (ICD) in patients with heart failure
11371112|NCT02226757|Experimental|Paclitaxel-trastuzumab|Paclitaxel-trastuzumab weekly
11371113|NCT02226744|Active Comparator|Focused breathing|Focused deep breathing techniques used to produce specific physiological and psychological states
11371114|NCT02226744|Active Comparator|Focused breathing 2|Focused deep breathing techniques used to produce specific physiological and psychological states
11371115|NCT02226731|Experimental|Early Belfort-Dildy balloon device|
11371116|NCT02226731|Other|Late Belfort-Dildy balloon device|
11371117|NCT02226718||questionnaire|
11371118|NCT02226705|Experimental|Multiple Surgeries|Patients undergoing transnasal endoscopic surgery
11371119|NCT02226692||nonspecific chronic low back pain|Physical examination and follow-up assessment by questionnaires at 2, 4, 6, and 12 months
11371120|NCT02226679|Experimental|Algisyl-LVR device implantation|Algisyl-LVR™ employed as a method of left ventricular augmentation and restoration in patients with dilated cardiomyopathy. Algisyl-LVR™ will be injected into the myocardium under direct visualization during the surgical procedure.
11371121|NCT02226666||Patients having MRI with Eovist|Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
11371122|NCT02226666||Patients having MRI with Multihance|Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
11371123|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
11371124|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
11371125|NCT02226640||Non-Diabetic Lean Athletes|Athletes with a Body Mass Index (BMI) less than or equal to 25 kg/m2.
11371126|NCT02226640||Non-Diabetic Lean No Diabetes History|Adults with a BMI < 25 kg/m2 and no family history of diabetes
11371127|NCT02226640||Non-Diabetic Lean Yes Diabetes History|Adults with a BMI < 25 kg/m2 and family history of diabetes
11371128|NCT02226640||Non-Diabetic Obese|Adults with BMI greater than or equal to 30 kg/m2.
11371129|NCT02226640||Non-Diabetic Obese Female PCOS|Female adults with BMI > 30 kg/m2 and Polycystic Ovarian Syndrome (PCOS).
11371130|NCT02226640||Diabetic No Medication|Have diabetes and currently receiving no medication or early treatment with one medication. Some participants receiving insulin may also be included in this study
11371131|NCT02226640||Diabetic GAD Ab+|Have diabetes with Latent Autoimmune Diabetes in Adults (LADA).
11371132|NCT02226640||Diabetic With NASH|Have diabetes with Nonalcoholic Steatohepatitis (NASH), which is chronic liver disease with fat in the liver, inflammation, and damage not associated with drinking alcohol.
11371133|NCT02226614|Experimental|head cooling|head cooling
11371134|NCT02226601|Active Comparator|Aprepitant|"Aprepitant
~40 mg IV pre-operatively
~40 mg PO post-op day #1
~40 mg PO post-op day #2"
11371135|NCT02226601|Placebo Comparator|Placebo|"electrolyte (0.9% NaCl) infusion) pre-operatively
~capsule without medication on post-op day #1
~capsule without medication on post-op day #2"
11371136|NCT02226588|Experimental|Secondary prevention|Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
11371137|NCT02226588|Active Comparator|Universal prophylaxis|Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby
11371138|NCT02226575|Experimental|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
11371139|NCT02226575|No Intervention|Control|Controls only dilivery standard care
11371140|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
11371141|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
11371142|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
11371143|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
11371144|NCT02226536|Placebo Comparator|control|Diet group Control group
11371145|NCT02226536|Active Comparator|fractioned diet without glucose|Fractioned diet without glucose
11371146|NCT02226523||ACS|subjects with final diagnosis of ACS, or non-ACS
11371147|NCT02226510|Placebo Comparator|Placebo|Placebo capsules (with an identical appearance to the active drug) and containing only microcrystalline cellulose PhEur
11371148|NCT02226510|Active Comparator|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day (metformin XL 500mg x2/day). They will continue on Metformin XL 500mg x2/day for two weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day (and stopped if this cannot be tolerated).
11371149|NCT02226497|Active Comparator|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
11371185|NCT02226237|Experimental|group of pelvic floor exercises|in which patients were instructed to perform home exercises daily
11371150|NCT02226497|Experimental|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
11371151|NCT02226484|Experimental|Quercetin|Two 250 mg capsules of oral quercetin (Q) twice-a-day (BID) one hour before meals with a glass of water for 6 weeks.
11371152|NCT02226471||NW-NBP group|normal weight and blood pressure subjects
11371153|NCT02226471||NW-HTN group|Normal weight with hypertension subjects
11371154|NCT02226471||OB-NBP group|obese-normal blood pressure subjects
11371155|NCT02226471||OB-HTN group|Obese-hypertension subjects
11371156|NCT02226458|Experimental|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
11371157|NCT02226445||ADHD medication and psychosocial counseling|
11371158|NCT02226432|Sham Comparator|Kinesics|- Classic Rehabilitation and Kinesic Therapy
11371159|NCT02226432|Sham Comparator|surgery|"- Surgery:
~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
11371160|NCT02226432|Active Comparator|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
11371161|NCT02226419|Experimental|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
11371162|NCT02226406|Experimental|Legs Cycloergometer Group (A)|Patients randomized in this group will do 10 minutes of legs cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
11371163|NCT02226406|Experimental|Hands Cycloergometer Group (B)|Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
11371164|NCT02226406|Experimental|Walk in place (C)|Patients randomized in this group will do 10 minutes of active walk in place. Continuously evaluated with electric impedance tomography.
11371165|NCT02226393|Experimental|Prolonged exposure|See intervention description
11371166|NCT02226393|Active Comparator|Child-parent Play Therapy|see intervention description
11371167|NCT02226380|Experimental|mFOLFOX6,chemotherapy regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
11371168|NCT02226367|Active Comparator|prazosin hydrochloride|Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.
11371169|NCT02226367|Placebo Comparator|placebo|Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.
11371170|NCT02226354|Active Comparator|Flaxseed oil|9.73ml Flaxseed oil once daily, for 28 days
11371171|NCT02226354|Experimental|Ahiflower oil|9.73ml Ahiflower oil once daily, for 28 days
11371172|NCT02226341|Active Comparator|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
11371173|NCT02226341|Active Comparator|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
11371174|NCT02226328|Experimental|Propofol sedation|"Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.
~Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.
~Maintenance with 10-20 mg of propofol in case of discomfort."
11371175|NCT02226328|Active Comparator|Midazolam and Fentanyl sedation|"1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.
~Maintenance with 1 mg Midazolam in case of discomfort."
11371176|NCT02226315||Multiple gestations|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have passed their Estimated Date of Delivery (EDD).
11371177|NCT02226302||Female Group 2|Females with BMI >30 kg/m2 who are having a hysterectomy for benign conditions
11371178|NCT02226302||Females Group 1|Females with BMI <30 kg/m2 who are having a hysterectomy for benign conditions
11371179|NCT02226302||Males|2 males with BMI <30 kg/m2 and 2 males with BMI >30 kg/m2
11371180|NCT02226289|Experimental|bevacizumab-containing|bevacizumab with the latest received cytotoxic regimen
11371181|NCT02226276|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
11371182|NCT02226263|Experimental|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
11371183|NCT02226250|Experimental|3 Placebo Beverages|Sugar beverage 2 hr before meal and with meal and 2 hr after meal
11371186|NCT02226237|Experimental|anal electrostimulation group|in which patients, and are instructed to perform the exercises mentioned in the group of pelvic floor exercises, also underwent anal electrostimulation
11371187|NCT02226224||early gastric cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
11371188|NCT02226224||Locally Advanced Gastric Cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
11371189|NCT02226224||early esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
11371190|NCT02226224||locally advanced esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
11371191|NCT02226211|Experimental|air-Q group|
11371192|NCT02226211|Experimental|aura-i group|
11371193|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
11371194|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
11371195|NCT02226185|Experimental|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
11371196|NCT02226185|Placebo Comparator|placebo|identical-appearing placebo supplements for 2-3 years
11371197|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
11371198|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
11371199|NCT02226159|Active Comparator|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
11371200|NCT02226159|Experimental|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
11371201|NCT02226146|Experimental|Bertilimumab|Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
11371202|NCT02226133|Experimental|Exclusion of Left Atrial Appendage|Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,
11371203|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
11371204|NCT02226107|Experimental|Peer-PN|Peer Patient Navigation
11371205|NCT02226107|Active Comparator|Pro-PN|Professional Patient Navigation
11371206|NCT02226094|Experimental|DWT device dose A|Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments).
11371207|NCT02226094|Active Comparator|Ellex Tango SLT machine|Selective Laser Trabeculoplasty (SLT)
11371208|NCT02226094|Sham Comparator|DWT Sham|Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface.
11371209|NCT02226094|Experimental|DWT device dose B|Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments).
11371210|NCT02226068|Other|CsA-ECP|Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given
11371211|NCT02226068|Other|ECP-CsA|Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given
11371212|NCT02226055||Arterial stiffness: CKDu patients|Cohort of 50 patients with CKD of unknown aetiology Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
11371213|NCT02226055||Arterial stiffness: CKD known cause|Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
11371214|NCT02226055||Arterial Stiffness: Healthy Sri Lankan volunteers|Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
11371215|NCT02226055||2nd aim: 250 CKDu patients for investigation of aetiology|"To recruit a cohort of up to 250 CKDu patients from specific CKDu clinics in Anuradhapura and Padavi-Sri Pura for detailed history, basic anthropometric tests, and further analysis of serum, and urine. Analysis for biomarkers of kidney damage, proteomics, exosomes, and DNA adducts will be used to seek information that may complement already collected data and help refine aetiological hypotheses.
~Inclusion and Exclusion criteria as per CKDu cases in cohort 1"
11371216|NCT02226042|Experimental|Mindfulness-based Cognitive Therapy|Individuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
11371217|NCT02226042|No Intervention|Non-MBCT arm|Individuals currently in remission from depression will choose not to undergo the 8 week MBCT group programme
11371218|NCT02226042|No Intervention|Healthy volunteers|Individuals who have never experienced major depression
11371219|NCT02226029|Experimental|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
11371220|NCT02226029|Experimental|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
11371221|NCT02226016|Experimental|Ptosis|Device (measurement of levator strength in patients with upper lid ptosis)
11371222|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
11371223|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
11371224|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
11371225|NCT02225990|Active Comparator|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
11371226|NCT02225990|Active Comparator|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
11371227|NCT02225990|Experimental|Experimental Group, Sub-Acute|This group consists of sub-acute stroke patients who are between three weeks and six months post-stroke and will receive the QualPro protocol. If the participant is an inpatient at Shands Rehabilitation Hospital at the beginning of the study, his/her first three weeks of research therapy sessions will take place at the Shands Rehabilitation Hospital. After being discharged, the remainder of the study sessions will take place at either UF Health Rehab Center- Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
11371228|NCT02225990|Experimental|Experimental Group, Chronic|This group consists of chronic stroke patients who are greater than six months post-stroke and will receive the QualPro protocol. The study sessions will take place at either UF Health Rehab Center-Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
11371229|NCT02225977||Gilenya treated - 1 month|Patient's taking continuous oral Gilenya at prescribed dose for 1 month.
11371230|NCT02225977||Gilenya treated - 3 months|Patient's taking continuous oral Gilenya at prescribed dose for 3 months.
11371231|NCT02225977||Gilenya treated - 6 months|Patient's taking continuous oral Gilenya at prescribed dose for 6 months.
11371232|NCT02225977||Gilenya treated - 12 months|Patient's taking continuous oral Gilenya at prescribed dose for 12 months.
11371233|NCT02225977||Gilenya qualified - untreated|Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.
11371234|NCT02225964||aMCIp,aMCIs|progressive aMCI,stable aMCI
11371235|NCT02225951|Active Comparator|Test group|Nutritional product as breakfast.
11371236|NCT02225951|Other|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
11371237|NCT02225938||Intensive care survivors|Patients surviving an admission to an intensive care unit
11371238|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
11371239|NCT02225912|Experimental|PrevinC|PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.
11371240|NCT02225912|Placebo Comparator|Control solution|The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.
11371241|NCT02225899||Subjects with Cystic Fibrosis|Cross-sectional, observational study
11371242|NCT02225899||healthy volunteers|Cross-sectional, observational study
11371243|NCT02225899||Subjects with CF in a vitamin D study|This is a longitudinal observational study in subjects enrolled in a high-dose vitamin D study. The investigator (Jessica Alvarez) does not assign the intervention to the subjects of the study.
11371244|NCT02225886|Experimental|Ascorbic acid|Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.
11371245|NCT02225886|Placebo Comparator|Control group|Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.
11371246|NCT02225873|Experimental|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
11371247|NCT02225873|Placebo Comparator|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
11371248|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
11371249|NCT02225860|No Intervention|Control|Continue with usual diet
11371250|NCT02225847|Active Comparator|Control|Members of this group will continue with their daily life activities and will not receive gardening intervention. The control group will be given a set of psychometric assessments for health and quality of life evaluations and undergo a Functional Magnetic Resonance Imaging (fMRI) brain scan, followed by a second round of psychometric assessments and a fMRI brain scan administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
11371251|NCT02225847|Experimental|Gardening|Members of this group will be given a set of psychometric assessments for health and quality of life evaluations and a Functional Magnetic Resonance Imaging (fMRI) brain scan prior to receiving the gardening activities intervention. The gardening intervention will consist of twice weekly group sessions lasting 60 minutes in duration that will take place in a greenhouse. The duration of the experimental intervention will be six weeks for a total of 12 individual gardening activity sessions. Following the completion of the gardening intervention, a second round of psychometric assessments and a fMRI brain scan will be administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
11371252|NCT02225834|Experimental|early Atorvastatin treatment|Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
11371253|NCT02225834|No Intervention|no early treatment with atorvastatin|Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge
11371254|NCT02225821|Active Comparator|antibiotic prophylaxis|a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
11371255|NCT02225821|Placebo Comparator|No antibiotic prophylaxis|a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
11371256|NCT02225808|Experimental|CBT for anxiety in autism|Cognitive-behavioral therapy (CBT) teaches skills for coping with anxiety and consist of 12 weekly sessions. CBT is conducted with child and parent.
11371257|NCT02225795|Experimental|Single Arm: All subjects|Hematopoietic stem cell transplantation
11371258|NCT02225782|Active Comparator|1.0 mg alteplase (tPA)|1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
11371259|NCT02225782|Experimental|2.0 mg alteplase (tPA)|2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
11371260|NCT02225769|Experimental|e-POCT|Febrile children managed using the e-POCT tool. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
11372225|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
11371261|NCT02225769|Active Comparator|ALMANACH|Febrile children managed using the ALMANACH algorithm. ALMANACH is an improved Integrated Management of childhood Illness (IMCI) algorithm based on mobile phones and tablets that has already been assessed for safety and efficacy.
11371262|NCT02225769|No Intervention|Routine practice|Febrile children managed according to routine care such as provided by routine health facility health workers.
11371263|NCT02225756|Experimental|Cyclosporine A dose 1|
11371264|NCT02225756|Experimental|Cyclosporine A dose 2|
11371265|NCT02225756|Placebo Comparator|Placebo|
11371266|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
11371267|NCT02225717|Experimental|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
11371268|NCT02225717|Experimental|Preterm Labor|Pregnant women admitted for preterm labor
11371269|NCT02225717|Experimental|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
11371270|NCT02225704|Experimental|Radium-223 and enzalutamide|Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
11371271|NCT02225691|Experimental|paired testing of blood glucose|Patient will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Paired testing arm will undergo paired testing of blood glucose.
11371272|NCT02225691|No Intervention|control arm|Non-insulin patients will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Patients in the control arms will not undergo paired testing and will be managed as before.
11371273|NCT02225665|Experimental|Cohort 1|
11371274|NCT02225665|Experimental|Cohort 2|
11371275|NCT02225652|Experimental|FEC + filgrastim x 3 cycles q 14-21 days and Weekly Paclitaxel|"FEC (FLUOROURACIL 500 mg/m2 IV infusion of 30 minutes + EPIRUBICIN 60 mg/m2 IV infusion of 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion of 30 minutes).
~From day 7 until hematological recovery = Filgrastim 300 microg s.c. After 21 days from the last FEC cycle = Paclitaxel 100 mg/m2 IV infusion of 1hour (weekly for 8 cycles, at day 1)."
11371276|NCT02225639|Active Comparator|PRC-063|
11371277|NCT02225639|Placebo Comparator|Placebo|
11371278|NCT02225626|Experimental|BI 1060469 fed|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
11371279|NCT02225626|Experimental|BI 1060469 fasted|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
11371280|NCT02225613|Active Comparator|Usual protocol|2 weeks conventional rehabilitation 3 weeks conventional rehabilitation
11371281|NCT02225613|Active Comparator|Spa protocol|2 weeks conventional rehabilitation 3 weeks aquatic rehabilitation
11371282|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
11371283|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
11371284|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
11371285|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
11371286|NCT02225574|Experimental|Advanced CML + Philadelphia positive Acute Leukemia-Group 1|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.
~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
~Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.
~Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle."
11371287|NCT02225574|Experimental|Chronic Phase CML - Group 2|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.
~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
~Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.
~Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
11371288|NCT02225561|Experimental|Intervention arm|Pharmaco- mechanical optimization
11371289|NCT02225561|Active Comparator|Mechanical optimization only|Mechanical optimization only
11371290|NCT02225548|Experimental|Selegiline and Tadalafil|Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
11371291|NCT02225535|Placebo Comparator|Usual Care (NP)|Rural NP with client in-person, usual care
11371292|NCT02225535|Active Comparator|PT in-person|Urban PT travels to rural area to manage patient's back pain in-person.
11371293|NCT02225535|Active Comparator|PT/NP Telehealth|Intervention: Rural NP is joined by PT via Telehealth for interprofessional videoconference with patient
11371294|NCT02225522|No Intervention|Standard Care|Patients in this arm receive standard genetic evaluation without the addition of next generation sequencing for the diagnosis of their presumed genetic condition
11371295|NCT02225522|Experimental|Rapid whole genome sequencing (StatSeq)|Patients in this arm will receive standard of care genetic evaluation and next generation sequencing of their genome to achieve rapid diagnosis of genetic conditions.
11371296|NCT02225509|Other|Patients with thyroid nodules|Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.
11371324|NCT02225314|Active Comparator|Active Control|An active control arm is necessary to model practice effects in an untreated group. Participants in this group will view and complete quizzes on a computerized learning program designed to improve knowledge about literature, art, and history.
11371325|NCT02225301|Experimental|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
11372494|NCT02217904|Experimental|Islatravir 2 mg|Single oral dose of islatravir 2 mg
11371297|NCT02225496|Experimental|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow [MBS] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.
11371298|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
11371299|NCT02225470|Experimental|Arm A, E7389 (Eribulin Mesylate)|The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
11371300|NCT02225470|Active Comparator|Arm B, Vinorelbine injection|The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
11371301|NCT02225457|Experimental|Hypercaloric diet and polyphenols|"polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
~Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
11371302|NCT02225457|Active Comparator|Hypercaloric diet and placebo|"Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
~Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
11371303|NCT02225444||OsteoAMP treatment group|The OsteoAMP treatment group contains patients randomized to receive their own bone (retrieved from the surgical site) augmented with the OsteoAMP growth factor to assist with posterolateral arthrodesis at 1 or 2 adjacent levels between L1-S1.
11371304|NCT02225431|Active Comparator|Standard saline infusion|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
11371305|NCT02225431|Experimental|Double saline infusion|All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)
11371306|NCT02225418|Sham Comparator|Placebo TQL block|30 ml single shot TQL block with saline 0,9%
11371307|NCT02225418|Active Comparator|Active TQL block|30 ml single shot TQL block with ropivacaine 0,75%
11371308|NCT02225405|Experimental|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
11371309|NCT02225392|Active Comparator|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.
~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
11371310|NCT02225392|Experimental|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.
~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
11371311|NCT02225379|Experimental|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference method and data generated by the non- invasive study device (Hypo Sense) during approximately 4 hours, in which a hypoglycemic event will be induced.
11371312|NCT02225366|Experimental|Intra-Tumoral Injection of LL37|LL37 administered intratumorally in cutaneous or subcutaneous tumors at least 1 cm in diameter. Patients will receive weekly intratumoral injections of LL37 for up to 8 weeks. The injections will be given every 7 days (+/- 48 hours). Starting dose 250 µg/tumor.
11371313|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
11371314|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
11371315|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
11371316|NCT02225340||Controls|
11371317|NCT02225340||Familial hypercholesterolemia|
11371318|NCT02225327|Active Comparator|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
11371319|NCT02225327|Active Comparator|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
11371320|NCT02225327|Active Comparator|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
11371321|NCT02225327|Active Comparator|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
11371322|NCT02225314|Experimental|Brain Fitness|Brain Fitness is a computer-based cognitive training programs designed to augment auditory processing speed and accuracy over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
11371323|NCT02225314|Experimental|InSight|InSight is a computer-based cognitive training programs designed to augment visual processing and working memory over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
11371326|NCT02225288|Experimental|Group A|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group A: 48 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
11371327|NCT02225288|Experimental|Group B|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group B: 72 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
11371328|NCT02225288|Experimental|Group C|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group C: 96 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
11371329|NCT02225288|Experimental|Group D|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group D: 120 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
11371330|NCT02225275|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
11371331|NCT02225262|Experimental|CyberKnife Radiosurgery|
11371332|NCT02225236|Experimental|Classroom Intervention|The intervention focuses on training executive functioning (e.g., working memory and inhibition) and metacognition (i.e., the ability to predict, check, monitor, coordinate and control cognitive operations) using play activities and structured language and reinforcement.
11371333|NCT02225236|No Intervention|No treatment control|No intervention
11371334|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
11371335|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
11371336|NCT02225210|Experimental|Group dexmedetomidine ,dexmedetomidine|Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
11371337|NCT02225210|Active Comparator|Group midazolam,midazolam,fentanyl|Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05~0.1mg.kg-1.h-1 and fentanyl 0.5~1μg.kg-1.h-1 separately.
11371338|NCT02225197|Experimental|CyberKnife Radiosurgery|
11371339|NCT02225171||Physicians|15 physicians each will be interviewed from the specialties of reproductive endocrinology and obstetrics/gynecology.
11371340|NCT02225132|Experimental|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
11371341|NCT02225119||Affected|Participants with macular disease
11371342|NCT02225119||Unaffected|Healthy volunteers
11371343|NCT02225106|Experimental|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
11371344|NCT02225093|Experimental|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
11371345|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
11371346|NCT02225067|Experimental|C13-CAC|
11371347|NCT02225054|Placebo Comparator|Ropivacaine,Normal Saline,Saline Bolus|Ropivacaine 15 mL 0.5% Normal Saline mL 0.9% Saline Bolus
11371348|NCT02225054|Experimental|Ropivacaine,Dexmedetomidine,Saline Bolus|Ropivacaine15 mL 0.5% Dexmedetomidine0.5 u/kg Saline Bolus
11371349|NCT02225054|Active Comparator|Ropivacaine,Saline,Dexmedetomidine|Ropivacaine 15 mL 0.5% Normal Saline 1 mL 0.9% Dexmedetomidine single IV bolus 0.5 u/kg over 30 minutes
11371350|NCT02225028|Active Comparator|Physical Activity Counseling|Participants who are randomized to the physical activity counseling intervention group will work with a physical activity coach over the course of 6 months to come up with a physical activity program that works for each individual. Participants will have 16 phone calls and discuss goals and values, track physical activity, troubleshoot barriers, and work on keeping exercise interesting and motivating. Participants will also learn strategies for managing stress and battling unhelpful thoughts that may get in the way of activity. By the end of the intervention, the goal is to be regularly doing 150 minutes of physical activity each week. The physical activity coach will work with participants to ensure that they are increasing activity safely in order to prevent injuries.
11371430|NCT02224521|Experimental|Cohort 1|Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
11371351|NCT02225028|No Intervention|Usual Care|Participants randomized to the usual care control group will receive a packet of exercise related-information at the end of the baseline assessment as well as a letter from study staff informing them of their randomization status and their test results. The letter will provide information on biological markers that are in the at-risk range, advice to seek medical advice regarding lifestyle changes such as diet and exercise and information on how to contact study staff regarding test results. We will offer to forward test results to their health care provider provided they furnish written release of information We will emphasize our interest in providing them with a follow-up assessment in 6 months.
11371352|NCT02225015|Active Comparator|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
11371353|NCT02225015|No Intervention|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
11371354|NCT02224989|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
11371355|NCT02224976|Experimental|Intensified training|Volunteers will increase exercise training by 30% from baseline
11371356|NCT02224963|Experimental|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
11371357|NCT02224963|Active Comparator|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
11371358|NCT02224950|Placebo Comparator|Control|"Non-medicated Emollient with no Clothing Covering Upper Limb - Baseline/Control Cells"
11371359|NCT02224950|Active Comparator|Sleeve 2|Non-medicated Emollient plus Lyocell/Chitosan Sleeve
11371360|NCT02224950|Placebo Comparator|Placebo Sleeve|Non-medicated Emollient plus Cotton Sleeve
11371361|NCT02224937|Experimental|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
11371362|NCT02224937|Placebo Comparator|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
11371363|NCT02224924|Active Comparator|autologous blood patch injection (ABPI)|
11371364|NCT02224924|Experimental|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
11371365|NCT02224911||Laser Interstitial Thermal Therapy|This is a minimally invasive procedure for focal treatment of prostate cancer.
11371366|NCT02224898||Definite/Suspected Chronic Pancreatitis|Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
11371367|NCT02224898||Healthy Control Group|Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
11371368|NCT02224885|Other|addition of nCLE to help target biopsy|The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
11371369|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
11371370|NCT02224859|Other|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place
~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
11371371|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
11371372|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
11371373|NCT02224833|Experimental|Intervention|
11371374|NCT02224833|No Intervention|Control|
11371375|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
11371376|NCT02224807|Active Comparator|Progressive Resistance Training (PRT) and a healthy diet|PRT will be done with resistance bands; participants will receive instruction on three resistance band exercises (triceps, biceps, and shoulder overhead) from an American College of Sports Medicine (ACSM) certified exercise specialist. Participants also will receive dietary counseling from a registered dietitian on correcting nutrient deficiencies that are detected during analysis of their 2-day dietary recalls.
11371431|NCT02224521|Experimental|Cohort 2|The selected formulation will be dosed with GSK2190915 capsule formulation at 20mg (fasted), 100mg (fasted), 100mg (fed) and 200mg (fasted).
11371432|NCT02224521|Experimental|Cohort 3|Cohort 3 will be a 4-way complete crossover study with single doses of 20mg and 200mg of up to two capsule formulations taken forward from cohort 2 in 10 healthy adult subjects in the fasted state.
11371377|NCT02224807|Experimental|PRT and a healthy diet, plus weight loss|This arm will receive all components of the active comparator arm, plus counseling to achieve a weight loss of 1.5-2 pounds/week. Participants will be trained on how to achieve this caloric deficit through both dietary restriction and increased physical activity. Weight loss will be promoted via a healthy, nutritionally adequate diet consistent with American Cancer Society guidelines. Protein levels will be based on 0.8 g/kg body weight. The distribution of food groups will be customized for preferences. An exercise program will be tailored taking into account kcal expenditure for various activities at a specific body weight; expenditures of 200-400 kcal/day will serve as a goal. Aerobic training of large muscles (legs) will be emphasized to achieve a greater kcal deficit; ramping of intensity and volume over time will be pursued as per the ACSM guidelines. Participants will train once weekly while supervised by an exercise physiologist and daily at home.
11371378|NCT02224794||Fast-Track Group|includes subjects who complete the Fast-Track EVAR protocol
11371379|NCT02224794||Standard P-EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access
11371380|NCT02224794||Standard EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair)
11371381|NCT02224781|Experimental|Arm A (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C."
11371382|NCT02224781|Experimental|Arm B (BRAF inhibitor therapy)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.
11371383|NCT02224781|Experimental|Arm C (BRAF inhibitor therapy)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11371384|NCT02224781|Experimental|Arm D (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.
~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
11371385|NCT02224768||HCP and Patient inclusion|"HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools
~Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials"
11371386|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
11371387|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
11371388|NCT02224742|Experimental|LeucoPatch|Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
11371389|NCT02224742|Active Comparator|Usual care|Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
11371390|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
11371391|NCT02224716||Pre-intervention All patients admitted with a diagnosis of CAP|
11371392|NCT02224716||Post intervention All patient admitted with a diagnosis of CAP|
11371393|NCT02224703|Experimental|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter [mL] cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
11371394|NCT02224703|Experimental|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
11371395|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
11371396|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
11371397|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
11371398|NCT02224677||Children with Craniofacial Microsomia|125 children with craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for children at the first visit include: assessment of development, video, photographs, and a hearing evaluation. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, saliva sample, hearing evaluation, speech assessment.
11371399|NCT02224677||Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 children without craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for the first visit include: assessment of development, video, and photographs. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, and speech assessment.
11371400|NCT02224677||Parents of Children with Craniofacial Microsomia|125-250 parents of children with craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete more questionnaires, have their picture taken, and donate saliva.
11371401|NCT02224677||Parents of Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
11371402|NCT02224677||Teacher/Day Care Provider|When the children participants are around 36 months old, we will ask parents for permission to contact their child's teacher/day care provider. We would like the teacher/day care provider to fill out a questionnaire.
11371403|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
11371404|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
11371405|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
11371406|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
11371407|NCT02224651|Experimental|(1-1000mg) Immediate Release formulation|
11371408|NCT02224651|Placebo Comparator|Immediate Release Placebo arm|
11371409|NCT02224651|Experimental|(10-500) mg Modified Release formulation|
11371410|NCT02224651|Placebo Comparator|Modified Release Placebo arm|
11371411|NCT02224638|Active Comparator|TheraHoney HD|Honey product
11371412|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
11371413|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
11371414|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
11371415|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
11371416|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
11371417|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
11371418|NCT02224612|Active Comparator|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask
~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
11371419|NCT02224612|Active Comparator|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask
~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
11371420|NCT02224612|Active Comparator|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask
~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
11371421|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
11371422|NCT02224586||light treatment|clinical routine treatment according to the doctor's advice
11371423|NCT02224573|Experimental|GWP42003-P|
11371424|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
11371425|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
11371426|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
11371427|NCT02224547|Experimental|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
11371428|NCT02224534|Experimental|Ticagrelor and Clopidogrel.|The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
11371429|NCT02224534|Active Comparator|Clopidogrel|The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
11371471|NCT02224235|Active Comparator|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
11371433|NCT02224521|Experimental|Cohort 4|The regimen for Cohort 4 will be either the highest dose (200mg) of the capsule formulation (A, B or C) taken forward from the previous cohorts or the solution formulation (200mg).
11371434|NCT02224521|Experimental|Cohort 5|Subjects will take milled and micronised tablet formulations of GSK2190915 in the fasted state in periods 1 and 2, and will take milled and micronised tablet formulations of GS2190915 in the fed state in periods 3 and 4.
11371435|NCT02224521|Experimental|Cohort 6|Tablet formulations (milled and micronised, different to the Cohort 5 formulations) of GSK2190915 will be dosed in the fasted and fed (after a light breakfast) states.
11371436|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
11371437|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
11371438|NCT02224495|Placebo Comparator|Control|Standard of care
11371439|NCT02224495|Experimental|Structured exercise training|8-week outpatient exercise-training program, encompassing 3 sessions per week, including endurance and resistance training
11371440|NCT02224482|No Intervention|Control|Print materials
11371441|NCT02224482|Active Comparator|Intervention Group|PROGRESS
11371442|NCT02224469|Experimental|ECoG (electrocorticography) sensing|Use ECoG-based Brain Computer interface to control assistive technology
11371443|NCT02224456|Experimental|Tenofovir|Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
11371444|NCT02224443|Experimental|Group A, dexmedetomidine , 0.3µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
11371445|NCT02224443|Experimental|Group B,dexmedetomidine , 0.5µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
11371446|NCT02224443|Placebo Comparator|Group C ,normal saline|Normal saline infusion will be given with the same infusion volume as group A and B
11371447|NCT02224430|Experimental|schizophrenia/schizoaffective disorder|Participants with schizophrenia/schizoaffective disorder.
11371448|NCT02224417|Other|Diabetes Educational Program (DEP) only|Participants will receive the Diabetes Educational Program, as required, which is part of usual care at the Polyclinic. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one).
11371449|NCT02224417|Other|DEP + Process Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified process goals.
11371450|NCT02224417|Other|DEP + Outcome Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified outcome goals.
11371451|NCT02224404|Experimental|Fast Gelling Dressing|
11371452|NCT02224391|Experimental|Arm I (ABM training)|Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
11371453|NCT02224391|Sham Comparator|Arm II (sham training)|Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
11371454|NCT02224378|Experimental|peep induced CVP|
11371455|NCT02224378|Active Comparator|passive leg raising(PLR)|
11371456|NCT02224365|Experimental|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
11371457|NCT02224365|Placebo Comparator|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
11371458|NCT02224352|Experimental|Single-Arm Study|Functional neuromuscular electrical stimulation of abdominal-wall muscles triggered by an airway pressure signal
11371459|NCT02224339||plaque neovascular and stress echo|After the SE and CEUS examination, patients will be grouped per the result of SE and CEUS as follows: group I: plaque neovascularization and normal wall motion; group II: plaque neovascularization and abnormal wall motion; group III: no plaque neovascularization and abnormal wall motion; group IV: no plaque neovascularization and normal wall motion.
11371460|NCT02224313|No Intervention|1.Premenopausal women|No treatment
11371461|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
11371462|NCT02224300|Experimental|Education|"Intervention group will receive the ELC for six weeks (15.9. - 26.10.2014) and comparison group will not receive it.
~Members of the intervention group in will work in teams of 10 nurses with weekly questions (released in Mondays) based on patient-description existing in Moodle. One member of the team will send the solutions to questions once a week (in Thursdays) Moodle. Researcher will download the model-answer to Moodle once a week (in Fridays) and nurses will compare their answer to model answer (self-evaluation)."
11371463|NCT02224287|Other|Fluoroscopy|Technologist control of fluoroscopy Surgeon control of fluoroscopy
11371464|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
11371465|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
11371466|NCT02224261|Experimental|Physical Therapy|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords and patient education."
11371467|NCT02224261|Active Comparator|Control|Control protocol includes standard progressive active and action-assisted arm exercises & patient education.
11371468|NCT02224248|Experimental|Health checks with fitness testing|
11371469|NCT02224248|Active Comparator|Health checks without fitness testing|
11371470|NCT02224235|Experimental|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
11371473|NCT02224222||Patients undergoing vascular procedures|Including all non-interventional surgical procedures, excluding varix surgery
11371474|NCT02224222||Patients undergoing cardiac procedures|Including all non-interventional surgical procedures, excluding HTX
11371475|NCT02224209|Experimental|Staged angioplasty|"Using Abbott EPD systems (Accunet/Emboshield), a balloon, stent
~Method of stage-1 angioplasty
~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device; Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.
~Method of stage-2:
~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
11371476|NCT02224209|Active Comparator|Routine single-stage CAS|"Using a balloon, stent
~Routine stenting procedure:
~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
11371477|NCT02224196|Experimental|manual ventilation|
11371478|NCT02224196|Active Comparator|pressure-controlled ventilation|
11371479|NCT02224183|Active Comparator|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
11371480|NCT02224183|Active Comparator|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
11371481|NCT02224170|Experimental|Lidocaine group|
11371482|NCT02224170|Active Comparator|Dexamethasone group|
11371483|NCT02224157|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
11371484|NCT02224157|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
11371485|NCT02224144|Experimental|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months
~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
11371486|NCT02224144|Placebo Comparator|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months
~1 pill of placebo (sugar pill) per day for 12 months"
11371487|NCT02224131|Experimental|Monitoring Arm|dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay(TEG)
11371488|NCT02224131|Active Comparator|Conventional Arm|fixed dose regiment of both aspirin and clopidogrel in all patients following stent deployment according to international guidelines
11371489|NCT02224118|Experimental|CNTO 3649 10 mcg/kg (single dose)|A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
11371490|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (single dose)|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
11371491|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (single dose)|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
11371492|NCT02224118|Experimental|CNTO 3649 300 mcg/kg (single dose)|A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
11371493|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
11371494|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
11371495|NCT02224118|Placebo Comparator|Placebo|Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
11371496|NCT02224105|Experimental|BI 653048 BS|escalating doses
11371497|NCT02224105|Active Comparator|Prednisolone low|
11371498|NCT02224105|Active Comparator|Prednisolone high|
11371499|NCT02224105|Placebo Comparator|Placebo|
11371500|NCT02224092|Active Comparator|Active|Active is a multivitamin multimineral with phytonutrient product.
11371501|NCT02224092|Placebo Comparator|Placebo|Placebo is a sugar pill.
11371502|NCT02224079|Experimental|BIIB 722 CL|
11371503|NCT02224079|Placebo Comparator|Placebo|
11371504|NCT02224066|Experimental|Ticagrelor|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
11371505|NCT02224066|Active Comparator|Aspirin/Clopidogrel|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
11371506|NCT02224066|No Intervention|Registry arm|Patients with normal-on-treatment platelet reactivity (PRU < 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.
11371507|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
11371508|NCT02224040|Experimental|Ceftriaxone I.V|The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
11371542|NCT02223806|Experimental|Midwife uterine tonus assessment|Uterine tonus assessment every 15 minutes for 2 hours by midwive.
11371695|NCT02222805|Other|Early cord clamping (ECC)|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
11371509|NCT02224040|Experimental|Ceftriaxone I.V+Azithromycin P.O|The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
11371510|NCT02224040|Experimental|Azithromycin P.O|The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
11371511|NCT02224040|Experimental|Azithromycin P.O+Cefixime P.O|The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
11371512|NCT02224027|Active Comparator|i-gel|Each novice performs i-gel insertion in difficult laryngoscopy scenario.
11371513|NCT02224027|Active Comparator|proceal laryngeal mask airway|Each novice performs proceal laryngeal mask airway insertion in difficult laryngoscopy scenario.
11371514|NCT02224027|Active Comparator|tracheal tube|Each novice performs tracheal intubation in difficult laryngoscopy scenario.
11371515|NCT02224014||Lendormin D tablets|
11371516|NCT02224001|Experimental|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts
~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
11371517|NCT02223988|Experimental|subglottic secretion drainage|
11371518|NCT02223975||Vulval Disease|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.
11371519|NCT02223962|Experimental|Physical activity|The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
11371520|NCT02223962|Placebo Comparator|Usual Care|During the hospital stay, the patients in the control group will be informed about the beneficial effects of being physically inactive.They will not receive feedback about their activities performed and will not be stimulated to become more active.
11371521|NCT02223949|Experimental|Cook double balloon catheter|Insertion of the Cook double balloon catheter to the cervix until both balloons are properly located in the cervical canal. After properly located it is inflated with 20 ml of saline. Then both balloons are additionally inflated to a total of 80 ml each balloon. Twelve hours later the balloons are deflated and the device is removed.
11371522|NCT02223949|Active Comparator|PGE1 tablet insertion|Insertion of 25 mg PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix. The patient woll the be instructed to stay in bed for the next 60 minutes. After six hours a repeated dose will be administered. Total of 4 PGE1 doses within 24 hours.
11371523|NCT02223936|Other|children with Prenatal enlarged nuchal transluce|
11371524|NCT02223936|Other|Control|
11371525|NCT02223923|Experimental|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
11371526|NCT02223923|Experimental|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
11371527|NCT02223923|Experimental|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
11371528|NCT02223923|Experimental|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
11371529|NCT02223910|Active Comparator|Motor Cortex|Feedback training of functional connectivity between motor cortex and the rest of the brain
11371530|NCT02223910|Placebo Comparator|Control region|Feedback training of functional connectivity between medial prefrontal cortex of healthy hemisphere and the rest of the brain
11371531|NCT02223897|Experimental|Conventional treatment, huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
11371532|NCT02223897|Placebo Comparator|Conventional plus placebo|Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).
11371533|NCT02223884|Experimental|weekly docetaxel and carboplatin|
11371534|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
11371535|NCT02223858|Experimental|Positive Activities (PA)|Positive Activities (PA) Program
11371536|NCT02223858|Active Comparator|Attention Control (AC)|Attention Control (AC) Program
11371537|NCT02223845|Experimental|Music|Played music during embryo transfer
11371538|NCT02223845|No Intervention|Control|No music played during embryo transfer
11371539|NCT02223832|Experimental|ACT-128800|"A single oral dose of 40 mg ACT-128800 will be administered as
~1 capsule given in the fasted state in the morning"
11371540|NCT02223819|Experimental|Crizotinib|Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
11371541|NCT02223806|Active Comparator|Self-assessment of uterine tonus|Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
11371543|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
11371544|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
11371545|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
11371546|NCT02223780|Placebo Comparator|control|standard management
11371547|NCT02223780|Active Comparator|early palliative care|early palliative care
11371548|NCT02223767|Experimental|Verum TMS|10 Hz TMS over medial prefrontal cortex
11371549|NCT02223767|Experimental|Sham TMS|10 Hz sham TMS over medial prefrontal cortex
11371550|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
11371551|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
11371552|NCT02223741||Korean medicine conjugate rehabilitation|those with more than 30 days of herbal drugs or more than 12 times of acupuncture (Korean medical treatment) within six months in addition to conventional rehabilitation
11371553|NCT02223741||Conventional rehabilitation|those with one of the treatments; physical, occupational, speech-language or cognitive-behavioral therapies
11371554|NCT02223728|Experimental|Treatment Condition|Telehealth Lifestyle Program
11371555|NCT02223728|Sham Comparator|Attention Control Condition|Health Education Program
11371556|NCT02223715||CDI|
11371557|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
11371558|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
11371559|NCT02223689|Experimental|Skin Affix|Surgical adhesive
11371560|NCT02223676|Experimental|Intervention|Clinical pharmacists conduct medication history
11371561|NCT02223676|No Intervention|Control|standard procedures for admission is followed
11371562|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
11371563|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
11371564|NCT02223637||Exposure group|"Pregnant women who were exposed to
~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
11371565|NCT02223624|Experimental|eccentric aerobic exercise group|Eccentric aerobic exercise group: Participants in this group will participate in an eccentric aerobic exercise rehabilitation program for a total of eight weeks, two sessions per week. Outcome measurements will be taken post exercise program and also after a 3 month follow-up period. Each session will be approximately 60 minutes in duration and include approximately 10 minutes of warm up (stretches), eccentric stepper aiming for 20 minutes, walking and light weights, followed by a five minute cool-down period.
11371566|NCT02223624|Active Comparator|Concentric aerobic exercise group|"Concentric aerobic exercise group (usual care): The length of the concentric aerobic exercise based rehabilitation program will be the same as the study group- twice weekly exercise sessions for 8 weeks. Outcome measurements will also be taken after a 3-month follow-up period.
~Participants in the concentric aerobic exercise group will participate in the same warm-up and cool down period as the eccentric group. They will also complete walking and light weights. To replace the 20 minutes of eccentric exercise, concentric participants will complete approximately 20 minutes of exercise bike, stair climbing and rowing as able with required rests."
11371567|NCT02223624|No Intervention|Waiting list control|Waiting list (no exercise): Participants assigned to this group will not receive any intervention during the study period. They will be assessed like other participants at baseline and after eight weeks, but not at three-month follow-up due to ethical concerns around withholding care known to be effective. Given that there is a waiting list for the current exercise program of 4-12 weeks, it is felt that delaying care for a set period of eight weeks is not of ethical concern. Following the completion of assessments, waiting list participants will be able to complete the traditional exercise program as usual but not as participants of the study's experimental groups.
11371568|NCT02223611|Experimental|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)<1.25 m2, 50mg; bid when 1.25 m2≤BSA<1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.
~3 weeks/4cycles"
11371569|NCT02223611|Active Comparator|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.
~3 weeks/4cycles"
11371570|NCT02223598|Experimental|Dose Escalation - CB-5083|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies
11371571|NCT02223598|Experimental|Dose Expansion - CB-5083, Dexamethasone|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)
11371572|NCT02223598|Experimental|Dose Expansion - CB-5083|CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor
11371573|NCT02223585|Experimental|Cross-over single arm|
11371574|NCT02223572|Experimental|osteoporotic hip fracture|
11371575|NCT02223559||right heart catheterization patients|
11371576|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
11371577|NCT02223533|Experimental|Wound catheter|analgesia with wound catheter after colon surgery
11371578|NCT02223533|Active Comparator|morphine|analgesia with morphine after colon surgery
11372495|NCT02217904|Experimental|Islatravir 10 mg|Single oral dose of islatravir 10 mg
11371579|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
11371580|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
11371581|NCT02223507|Experimental|BIIR 561 CL|
11371582|NCT02223507|Placebo Comparator|Placebo|
11371583|NCT02223494|Experimental|Terbogrel|
11371584|NCT02223481|Experimental|Terbogrel low dose|
11371585|NCT02223481|Experimental|Terbogrel high dose|
11371586|NCT02223481|Placebo Comparator|Placebo|
11371587|NCT02223468||CASE-CONTROL|CASE: Liver transplant recipients (n=20) CONTROL: A healthy person with a similar age (±10 years) to the control selected from the same family setting (n=20)
11371588|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
11371589|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
11371590|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
11371591|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
11371592|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
11371593|NCT02223416|Experimental|RGB-10|
11371594|NCT02223416|Active Comparator|Forsteo|
11371595|NCT02223403|Experimental|submaximal steady state exercise|90 minutes after respective beetroot juice ingestion, subjects walked on treadmill at a pre-determined steady state workload for a total of 15 minutes with oxygen consumption recorded for the last 10 minutes
11371596|NCT02223403|Experimental|six minute walk test|subjects performed six-minute walk at self-determined pace 30 minutes after treadmill exercise was performed
11371597|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
11371598|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
11371599|NCT02223377|Active Comparator|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).
~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
11371600|NCT02223377|Active Comparator|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).
~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
11371601|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
11371602|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
11371603|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
11371604|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
11371605|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
11371606|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:
~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
11371644|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
11371645|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
11372496|NCT02217904|Experimental|Islatravir 30 mg|Single oral dose of islatravir 30 mg
11371607|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:
~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
11371608|NCT02223325||Elderly, acute pancreatitis|No intervention
11371609|NCT02223325||Adults <65 y, acute pancreatitis|No intervention
11371610|NCT02223312|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
11371611|NCT02223299|Experimental|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
11371612|NCT02223299|Placebo Comparator|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
11371613|NCT02223286||ASGES (Treatment Group)|Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
11371614|NCT02223286||Non-ASGES (Control Group)|Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
11371615|NCT02223273|Experimental|Multifaceted Strategy|"Multifaceted Intervention
~Simulation Based Team Training
~Case Manager
~Check lists
~Reminders
~Educational Materials"
11371616|NCT02223273|No Intervention|Usual Care|Hospital Standard Treatment
11371617|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
11371618|NCT02223247|Experimental|TVB-2640|Oral TVB-2640 capsules or tablets of various dose strengths administered QD for 21 - 28 day dosing cycles, alone or in combination with certain standard chemotherapy agents
11371619|NCT02223234|Active Comparator|Control|Control- monthly mailed information on children's health
11371620|NCT02223234|Experimental|Email and 4 Home Visits|Weekly emails and 4 home visits with a health educator
11371621|NCT02223234|Experimental|Email and 2 Home Visits|Weekly emails and 2 home visits
11371622|NCT02223221|Experimental|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.
~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
11371623|NCT02223221|Active Comparator|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.
~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
11371624|NCT02223208|Experimental|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
11371625|NCT02223182|Experimental|Viaskin Milk 150 mcg|
11371626|NCT02223182|Experimental|Viaskin Milk 300 mcg|
11371627|NCT02223182|Experimental|Viaskin Milk 500 mcg|
11371628|NCT02223182|Placebo Comparator|Viaskin Placebo|
11371629|NCT02223169|Experimental|Egg albumin-derived peptide|Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.
11371630|NCT02223169|Placebo Comparator|Placebo|Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.
11371631|NCT02223156||MediYoga|
11371632|NCT02223156||Music relaxation|
11371633|NCT02223156||No treatment|
11371634|NCT02223130|Experimental|Intervention Group|Participants will attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys. After their baseline interview and before their first follow-up interview, participants attend the Intervention Group, which consist of 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who uses Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions, and behaviors in response to stressful/discrimination experiences.
11371635|NCT02223130|No Intervention|Waitlist Control|"Participants are not given the Intervention Group while they are enrolled in the study. Instead, they only attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys.
~After they have completed the study, participants from the first two cohorts are offered the option of attending an intervention group that is identical in content to the intervention group being studied.The third cohort is offered the intervention group after they have completed the first follow-up but before they complete the final follow-up due to timing and budgetary restraints. No data is collected and no incentives are given during these intervention groups."
11371636|NCT02223117|Experimental|Intervention|Thrombosomes
11371637|NCT02223117|Placebo Comparator|Placebo|Buffer/placebo Control
11371638|NCT02223104|Active Comparator|Sensura|Ostomy pouch
11371639|NCT02223104|Experimental|Flexima Active|Ostomy pouch
11371640|NCT02223091|Experimental|Consultation by a trained physician|The physicians of this group receive a free consultation training program on skills regarding consultations on complementary medicine for breast-cancer patients. The training was developed by a multi-professional team and is comprised of three parts: (1) online-training, (2) on-site-training, and (3) consultation manual. Each of the physicians will counsel 10 patients. The patients in this group therefore receive a consultation by a trained physician.
11371641|NCT02223091|Active Comparator|Consultation by an untrained physician|The physicians of the control arm receive no training. Each will counsel 10 patients. The patients in this group therefore receive a consultation by an untrained physician.
11371642|NCT02223078|Experimental|G17DT|Three 250 µg injections over a six week period (weeks 0,2 and 6)
11371643|NCT02223078|Placebo Comparator|Placebo|Three 250 µg injections of a placebo over a six week period (weeks 0,2 and 6)
11371646|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1|Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
11371647|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1|One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
11371648|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
11371649|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
11371650|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
11371651|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
11371652|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
11371653|NCT02223026|Experimental|Linagliptin/metformin fed|
11371654|NCT02223026|Active Comparator|Linagliptin/metformin fasted|
11371655|NCT02223013|Active Comparator|BIBV 308 SE solution|
11371656|NCT02223013|Experimental|BIBV 308 SE capsule L|
11371657|NCT02223013|Experimental|BIBV 308 SE capsule S|
11371658|NCT02223000|Active Comparator|BIBV 308 SE solution|
11371659|NCT02223000|Experimental|BIBV 308 SE capsule 1|
11371660|NCT02223000|Experimental|BIBV 308 SE capsule 2|
11371661|NCT02222987|Active Comparator|Terbogrel|
11371662|NCT02222987|Experimental|Terbogrel with Clopidogrel|
11371663|NCT02222987|Active Comparator|Clopidogrel|
11371664|NCT02222974|Experimental|BIIR 561 CL|
11371665|NCT02222974|Placebo Comparator|Placebo|
11371666|NCT02222961|Experimental|BIIR 561 CL|
11371667|NCT02222961|Placebo Comparator|Placebo|
11371668|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
11371669|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
11371670|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
11371671|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
11371672|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
11371673|NCT02222935|Experimental|Balance exercise training|Balance exercise training - thrice week, 2 weeks, 10 repetition Maximum/ set, 2 sets
11371674|NCT02222935|Active Comparator|Routine Back exercise Program|Routine Back exercise Program - 10 Repetition Maximum / set, 2 sets, three times weekly, 2 weeks
11371675|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
11371676|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
11371677|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
11371678|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
11371679|NCT02222909|Experimental|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
11371680|NCT02222909|No Intervention|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
11371681|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
11371682|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
11371683|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
11371684|NCT02222883||patients with primary diagnosis|patients with primary diagnosis of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
11371685|NCT02222883||patients with platinum-sensitive recurrence|patients with platinum-sensitive recurrence of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
11371686|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
11371687|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
11371688|NCT02222844|No Intervention|Preoperative CT scan|CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
11371689|NCT02222844|Experimental|Preoperative MRI scan|Standard treatment plus an additional MRI scan before surgery
11371690|NCT02222844|No Intervention|Observational|Observational only
11371691|NCT02222831|Experimental|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:
~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).
~The embryo culture media will be collected at day 2-5."
11371692|NCT02222831|No Intervention|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.
~The embryo culture media will be collected at day 2-5."
11371693|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
11371694|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
11371696|NCT02222805|Other|Delayed cord clamping (DCC)|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
11371697|NCT02222792||Septic patient group|The septic patient group will be comprised of patients presenting with bone and joint prosthetic device infection confirmed by intraoperative microbiological culture (at least 2 deep positive samples for the same bacterial strain).
11371698|NCT02222792||Non-septic patient group|The non-septic patient group will be comprised of prosthetic patients presenting with symptoms of mechanical loosening, and whose deep intraoperative samples have all proved negative
11371699|NCT02222792||Intermediate group|An intermediate group will be comprised of patients with only one deep positive sample.
11371700|NCT02222779||Patients with Parkinson´s Disease|
11371701|NCT02222779||Patient´s with Alzheimer´s Disease|
11371702|NCT02222779||Patients with Multiple Sclerosis|
11371703|NCT02222779||Patients with any other neurodegenerative diseases|
11371704|NCT02222766|Experimental|Parents and Tots Together Program|9-week group-based parenting program
11371705|NCT02222766|Active Comparator|Control|Minimal attention control- weekly mailed information on general child development for 9 weeks
11371706|NCT02222740|Experimental|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
11371707|NCT02222740|Experimental|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
11371708|NCT02222727|Active Comparator|Donepezil|Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
11371709|NCT02222727|No Intervention|Control|Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.
11371710|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
11371711|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
11371712|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
11371713|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
11371714|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
11371715|NCT02222701||Replacement|Composite resins with Alpha values for the marginal adaptation criteria were used as the positive control and were made with resin composite (Filtek Supreme, 3M ESPE), eith rubber dam isolation and the adhesive system L-Pop Prompt (3M-ESPE)
11371716|NCT02222701||No treatment|Composite resin restorations (Z100, 3M ESPE) in general clinically acceptable, did not receive treatment.
11371717|NCT02222701||Refurbishing|For this group, The dentists finished the occlusal, lingual or facial surfaces of defective RBC restorations with the medium series of aluminum oxide disks (Sof-Lex,3M ESPE) or carbide burs (12 and 30 blades,Brasseler USA, Dental Instrumentation,Savannah, Ga.) and then polished them with afine series of aluminum oxide disks (Sof-Lex, 3M ESPE) and diamond-impregnated composite polisher (ComposiPro Diacomp, Brasseler). For restorations in which proximal surface areas were affected, the clinicians smoothed them with interproximal aluminum oxide finishing strips (Sof-Lex Finishing Strips, 3M ESPE).
11371718|NCT02222688|Experimental|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
11371719|NCT02222688|Experimental|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
11371720|NCT02222688|Experimental|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
11371721|NCT02222688|Experimental|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
11371722|NCT02222688|Experimental|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
11371723|NCT02222688|Experimental|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
11371724|NCT02222688|Experimental|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
11371725|NCT02222675|Experimental|Sonographically assisted breast surgery|Sonographically assisted breast surgery
11371726|NCT02222675|Active Comparator|Conventional breast surgery|Conventional breast surgery
11371727|NCT02222662|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
11371728|NCT02222662|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
11371729|NCT02222649|Experimental|Vitamin D3|Group supplemented with high single dose of 200,000 IU of vitamin D3 (cholecalciferol)
11371730|NCT02222649|Placebo Comparator|placebo group|Placebo capsules with starch
11371731|NCT02222636|Placebo Comparator|Group 1,Normal saline,1 milliliter|Patients will be assigned to receive intranasal normal saline 1 milliliter
11371732|NCT02222636|Experimental|Group 2,dexmedetomidine 1μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter
11371733|NCT02222636|Experimental|Group 3,dexmedetomidine 2μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter
11371734|NCT02222623|Active Comparator|glargine insulin|Basal glargine given once daily in the morning before breakfast plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
11371735|NCT02222623|Active Comparator|NPH insulin|Basal NPH given twice daily before breakfast and at bedtime plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
11371767|NCT02222441|Experimental|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
11371768|NCT02222428|Experimental|BI 1744 CL/BI 54903 XX FDC|
11371769|NCT02222428|Active Comparator|BI 54903 XX|
11371770|NCT02222428|Active Comparator|BI 1744 CL|
11371736|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.
~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on SD-OCT. The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
11371737|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.
~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
11371738|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.
~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
11371739|NCT02222597||positive infrascanner finding|
11371740|NCT02222584||IBD group|patients with with inflammatory bowel disease who are visiting the out-patient clinic of severance hospital from July 2014 to February 2015
11371741|NCT02222571|Active Comparator|Control|9-week parenting group focused on safety
11371742|NCT02222571|Experimental|Parents and Tots Together Program|Parents and Tots Together Program is a 9-week, group-based parenting intervention
11371743|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
11371744|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
11371745|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
11371746|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
11371747|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
11371748|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.
~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
11371749|NCT02222545|Experimental|OMS721 low dose|Administration of OMS721 at a low dose
11371750|NCT02222545|Experimental|OMS721 medium dose|Administration of OMS721 at a medium dose
11371751|NCT02222545|Experimental|OMS721 high dose|Administration of OMS721 at a high dose
11371752|NCT02222532|Experimental|Tetronine|Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
11371753|NCT02222532|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
11371754|NCT02222519||Statin use group|patients taking statins for at least 3 months
11371755|NCT02222519||non statin use|no history of taking statin
11371756|NCT02222506|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.
11371757|NCT02222493|Experimental|PF-06438179|
11371758|NCT02222493|Active Comparator|Infliximab|
11371759|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg
11371760|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 60/25mg
11371761|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg
11371762|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 120/25mg
11371763|NCT02222480|Placebo Comparator|Placebo|placebo
11371764|NCT02222467|Experimental|Klox BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for venous leg ulcers.
11371765|NCT02222454|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.
11371766|NCT02222441|Experimental|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
11371772|NCT02222415|Experimental|Exercise + Protein drink|exercise + Drink containing Protein, Carbohydrates and Fat
11371773|NCT02222402|Experimental|INTRA-DIALYTIC EXERCISE TRAINING|"Using a modified cycle ergometer, aerobic exercise will be performed in a semi-recumbent position, 3 times per week during the first two hours of haemodialysis. The initial prescription will be set in the moderate intensity range of 40-60% of peak aerobic capacity, progressing to 75% level by the end of the intervention.
~Twice per week patients will also complete lower extremity muscular conditioning exercise, using ankle weights, after the aerobic cycling exercise."
11371774|NCT02222402|No Intervention|HAEMODIALYSIS RENAL REPLACEMENT THERAPY|"Haemodialysis is the most common dialysis (renal replacement) treatment for kidney failure.
~They may also receive dietary advice, counselling, input from social workers, and other forms of educational support."
11371775|NCT02222389|Experimental|CM for alcohol|CM for alcohol
11371776|NCT02222389|Experimental|CM for drugs|CM for drugs
11371777|NCT02222389|Experimental|CM for both substances|CM for both substances
11371778|NCT02222389|Other|Non-Contingent group|No CM for either substance, the Non-Contingent (NC) group
11371779|NCT02222376|Active Comparator|Conventional treatment|Weekly ulcer debridement and daily cleansing
11371780|NCT02222376|Experimental|Pirfenidone|Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
11371781|NCT02222363|Experimental|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
11371782|NCT02222350|Experimental|DS-8500a 10mg once daily|10mg DS-8500a tablet given orally once daily
11371783|NCT02222350|Experimental|DS8500a 75 mg once daily|75mg DS-8500a tablet given orally once daily
11371784|NCT02222350|Placebo Comparator|placebo to match DS-8500a tablet|placebo matching DS-8500a tablet
11371785|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
11371786|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
11371787|NCT02222324|Placebo Comparator|Treatment A|Placebo
11371788|NCT02222324|Experimental|Treatment B|E2609 Low dose
11371789|NCT02222324|Experimental|Treatment C|E2609 High dose
11371790|NCT02222324|Active Comparator|Treatment D|Moxifloxacin
11371791|NCT02222311||Autistic Children|Children diagnosed with autism spectrum disorder according to the criteria of the Diagnostic Statistical Manual-V will have blood samples taken for laboratory analysis.
11371792|NCT02222311||Healthy Children|Children with no developmental or physical diseases will have blood samples taken for laboratory analysis.
11371793|NCT02222311||Children with Attention Deficit Disorder|Blood samples from children with Attention Deficit Disorder will be measured for Vitamin D and oxidative stress markers.
11371794|NCT02222298|Experimental|VAAPS group|patients undergoing video assisted ablation of pilonidal sinus
11371795|NCT02222298|Active Comparator|conventional treatment group|patients undergoing conventional off-midline Bascom cleft lift procedure
11371796|NCT02222285|Placebo Comparator|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
11371797|NCT02222285|Active Comparator|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
11371798|NCT02222285|Active Comparator|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
11371799|NCT02222259|Experimental|GA and Integrated Care Plan|Participants allocated to the intervention group will be seen in the geriatric oncology clinic where they will be assessed using a geriatric assessment. Based on the issues identified in the geriatric assessment, a care plan will be developed with the participant to address the issues.
11371800|NCT02222259|No Intervention|Standard oncology care|Participants randomized to standard oncology care will receive usual care from their oncology team.
11371801|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
11371802|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
11371803|NCT02222233|Experimental|BI 671800 HEA delayed release (enteric coated) tablet|
11371804|NCT02222233|Experimental|BI 671800 HEA solution released in jejunum|BI 671800 HEA solution in the Enterion® capsule released in the jejunum
11371805|NCT02222233|Experimental|BI 671800 HEA solution released in ascending colon|BI 671800 HEA solution in the Enterion® capsule released in the ascending colon
11371806|NCT02222233|Experimental|BI 671800 HEA solution released in descending colon|BI 671800 HEA solution in the Enterion® capsule released in the descending colon
11371807|NCT02222233|Experimental|BI 671800 HEA particulate released in ascending colon|BI 671800 HEA as particulate in the Enterion® capsule released in the ascending colon
11371808|NCT02222220|Placebo Comparator|metoclopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
11371809|NCT02222220|Experimental|metocliopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
11371810|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
11372497|NCT02217904|Experimental|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
11371811|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
11371812|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
11371813|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
11371814|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
11371815|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
11371816|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
11371817|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
11371818|NCT02222194||VAM|"Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.
~Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice."
11371819|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
11371820|NCT02222168|Experimental|1 BI 409306|tablet, fasted, oral administration with 240 ml water
11371821|NCT02222168|Experimental|2 BI 409306|tablet, fed, oral administration with 240 ml water
11371822|NCT02222168|Experimental|3 BI 409306|tablet, oral administration with 240 ml water at bed time
11371823|NCT02222155|Active Comparator|CCX168 low dose plus standard of care|Capsule, 10mg, twice daily, 12 weeks
11371824|NCT02222155|Active Comparator|CCX168 high dose plus standard of care|Capsule, 30 mg, twice daily, 12 weeks
11371825|NCT02222155|Placebo Comparator|Placebo BID plus standard of care|Capsule, placebo, twice daily, 12 weeks
11371826|NCT02222142||Isoflurane group|Isoflurane inhalational anesthesia during OPCAB
11371827|NCT02222142||Propofol group|Total intravenous anesthesia with propofol during OPCAB
11371828|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
11371829|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
11371830|NCT02222116|Experimental|MGuard Prime|MGuard Prime
11371831|NCT02222116|Active Comparator|Control|BMS or DES
11371832|NCT02222103||Suspected obstructive sleep apnea in adults|Already scheduled in-lab sleep study
11371833|NCT02222090||patients who have been prescribed warfarin|
11371834|NCT02222090||patients who have been prescribed apixaba|
11371835|NCT02222064|Experimental|Mindfulness|8 week self-managed mindfulness based intervention
11371836|NCT02222051|Experimental|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
11371837|NCT02222051|Active Comparator|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
11371838|NCT02222051|No Intervention|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
11371839|NCT02222038|Other|skin biopsy|4mm punch biopsy
11371840|NCT02222025|Experimental|Injury Prevention Programme|see intervention prescription
11371841|NCT02222025|No Intervention|Control|The coaches of the control group will receive the instruction to regularly perform a common warm-up consisting of running and ball-based exercises (sham treatment, no neuromuscular and stability exercises).
11371842|NCT02222012|Active Comparator|single channel|
11371843|NCT02222012|Experimental|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|
11371844|NCT02221999|Active Comparator|Chemotherapy only|Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles
11371845|NCT02221999|Experimental|GnRHa|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously
11371846|NCT02221999|Experimental|letrozole|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day
11371847|NCT02221986|Experimental|Interdisciplinary rehabilitation|"The intervention consists of 6 weeks intensive outpatient physiotherapy in conjunction with 0-6 weeks of occupational therapy if need is indicated. The physical intervention contains supervised group exercise of 90 minutes three times a week in groups up to four patients included continuously.
~The occupational therapy intervention consists of individual training 60 minutes twice a week for patients having deficits in activity or participation levels measured by the Assessment of Motor and Process Skills (AMPS)."
11371848|NCT02221986|No Intervention|Care as usual|The control group receives usual standard of care (e.g. no training, individual training or group training in the municipality). The amount of training in this group is based on a questionnaire at the follow-up trials.
11371849|NCT02221973|Experimental|milk with 1.2g/d sterols and 8g/d hawthorn powder|
11371850|NCT02221973|Experimental|milk with 1.8g/d sterols and 8g/d hawthorn powder|
11371851|NCT02221973|Active Comparator|milk without sterols and hawthorn powder|
11371852|NCT02221960|Experimental|Monotherapy Arm|MEDI6383
11371853|NCT02221960|Experimental|Combination Arm|MEDI6383 and MEDI4736
11371854|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
11371855|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
11371856|NCT02221934|Experimental|Signal more likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
11371857|NCT02221934|Active Comparator|Signal less likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
11371858|NCT02221921|Experimental|MicroPort's Transcatheter Aortic Valve and Delivery System|single arm with intervention that percutaneous implantation of the MicroPort's Transcatheter Aortic Valve and Delivery System
11371861|NCT02221895|Active Comparator|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
11371862|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11371863|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
11371864|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
11371865|NCT02221856|Experimental|Motion View|
11371866|NCT02221856|Active Comparator|Conventional Orthodontic Treatment|
11371867|NCT02221830|Placebo Comparator|Placebo|Normal Saline (standard of care)
11371868|NCT02221830|Experimental|Treatment|normal saline + oxytocin
11371869|NCT02221817|Active Comparator|Blind|Trochanter injection
11371870|NCT02221817|Experimental|Ultrasound|Trochanter injection
11371871|NCT02221804|Experimental|COPD - reduced activity levels|COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
11371872|NCT02221804|Experimental|Healthy - reduced activity levels|Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
11371873|NCT02221804|No Intervention|COPD - unchanged activity levels|
11371874|NCT02221791|Active Comparator|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
11371875|NCT02221791|Active Comparator|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
11371876|NCT02221791|Placebo Comparator|Placebo|Participants will consume 70g white chocolate + placebo capsules
11371877|NCT02221778|Experimental|SBRT|SBRT according to the intervention description
11371878|NCT02221765|Experimental|Arm 1|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.
~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.
~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg."
11371879|NCT02221765|Experimental|Arm 2|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.
~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously."
11371880|NCT02221752|Experimental|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
11371881|NCT02221752|Experimental|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
11371882|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
11371883|NCT02221726|Experimental|JNJ-35684-AAA-023: 5.5 cm^2 Patch|
11371884|NCT02221726|Experimental|JNJ-35684-AAA-023: 44 cm^2 Patch|
11371885|NCT02221713||Group A: perforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with perforated diverticulitis (i.e., Hinchey III or IV).
11371886|NCT02221713||Group B: unperforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with unperforated diverticulitis (Hinchey I or II).
11371887|NCT02221713||Group C: asymptomatic diverticulosis|Patients with asymptomatic diverticulosis will be recruited from the 2-week wait (2ww) colorectal cancer pathway. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
11371888|NCT02221713||Group D: normal controls|Patients with or without haemorrhoids, and no other colonic pathology will be recruited from the 2ww colorectal cancer pathway. These will be the normal controls. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
11371889|NCT02221700|Experimental|Group I (leg massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
11371890|NCT02221700|Experimental|Group II (leg massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
11371891|NCT02221700|Experimental|Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
11371892|NCT02221700|Experimental|Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
11371893|NCT02221687|Experimental|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain
~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.
~Route : oral, ad libitum
~Duration of product intake:
~Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)
~Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
11371894|NCT02221687|Placebo Comparator|Control formula|"Control formula : standard formula without pre and probiotic
~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.
~Route: oral, ad libitum
~Duration of product intake:
~Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)
~Control FoF : 6 months of consumption (from 6 to 12 months of age)"
11371895|NCT02221687|No Intervention|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.
~Dose:
~Breast milk : on demand
~Route : oral, ad libitum
~Duration of product intake:
~Breast milk : at least 4 month (from birth until at least 4 months of age)"
11371896|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
11371897|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
11371898|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
11371899|NCT02221635||rTMS+Risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.At the same time,risperidone (2-4mg) was took orally.
11371900|NCT02221635||Risperidone|Risperidone (2-4mg) was took orally.
11371901|NCT02221622|Experimental|Allopregnanolone 2 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
11371902|NCT02221622|Experimental|Allopregnanolone 4 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
11371903|NCT02221622|Experimental|Allopregnanolone 6-18 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
11371904|NCT02221622|Placebo Comparator|Placebo|Drug: Placebo injection (intravenous solution) once per week for 12 weeks
11371905|NCT02221609|Experimental|Treatment based on Movement System Impairment based model|Treatment based on Movement System Impairment based classification model is composed by patient education, analysis and modification of daily living activities and prescription of specific exercises
11371906|NCT02221609|Active Comparator|General exercise|The general exercise program consists of stretching exercises of the trunk and lower limbs muscles and strengthening exercises of the trunk muscles (Hayden et al., 2005; Rainville et al., 2004).
11371907|NCT02221596|Experimental|vitamin D + aerobic training|vitamin D capsules every weekday (10,000IU/day) and exercise
11371908|NCT02221596|Active Comparator|vitamin D + no aerobic training|vitamin D capsules every weekday (10,000IU/day) and no exercise
11371909|NCT02221596|Active Comparator|placebo + aerobic training|placebo capsule every weekday and exercise
11371910|NCT02221596|No Intervention|placebo + no aerobic training|placebo capsule every weekday and no exercise
11371911|NCT02221583|Experimental|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
11371912|NCT02221583|Experimental|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
11371913|NCT02221570|Active Comparator|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
11371914|NCT02221570|Placebo Comparator|Placebo|placebo of baclofen
11371915|NCT02221557|Experimental|New alloplastic bone graft material|
11371916|NCT02221544|Experimental|rTMS treatment followed by Sham|A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment
11371917|NCT02221544|Experimental|Sham treatment followed by rTMS|A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS
11371918|NCT02221531|Experimental|Short infusion|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
11371919|NCT02221531|Other|Bolus application|Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds
11371920|NCT02221518|Experimental|Patients with OCD|Behavioral: Exposure & Response Prevention (EX/RP)
11371921|NCT02221505|Experimental|LOP628 - Solid Tumor|with LOP628
11371922|NCT02221505|Experimental|LOP628 - AML|With LOP628
11371923|NCT02221505|Experimental|LOP628 - Solid Tumor Expansion|With LOP628
11371924|NCT02221492|Active Comparator|granulocyte colony-stimulating factor alone|G-CSF administered up to 8 days
11371925|NCT02221492|Experimental|granulocyte colony-stimulating factor plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
11371926|NCT02221479|Active Comparator|Granulocyte colony-stimulating factor (G-CSF) alone|G-CSF administered up to 8 days
11371927|NCT02221479|Experimental|G-CSF plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
11371928|NCT02221466||diabetic patients|Diabetic patients given HBOT
11371929|NCT02221466||None diabetic patients|None diabetic patients given HBOT
11371930|NCT02221453|Other|Triamcinolone Acetonide Treatment|Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection
11372226|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
11371931|NCT02221440|Placebo Comparator|air, second stage of labor|"Patients randomized to the group will receive sham administered by nasal catheter.
~The therapy will continue until after delivery"
11371932|NCT02221440|Experimental|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by low flow nasal oxygen at a flow rate of 2 L/min.
~The therapy will continue until after delivery"
11371933|NCT02221427|Active Comparator|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
11371934|NCT02221427|Experimental|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
11371935|NCT02221414|Experimental|Treatment A (FDC)|
11371936|NCT02221414|Active Comparator|Treatment B (single agents)|
11371937|NCT02221401|Experimental|Treatment A (FDC)|
11371938|NCT02221401|Active Comparator|Treatment B (single agents)|
11371939|NCT02221388|Active Comparator|BI 671800 ED capsules|
11371940|NCT02221388|Experimental|BI 671800 HEA tablet in fasted state|
11371941|NCT02221388|Experimental|BI 671800 HEA EC tablet in fasted state|
11371942|NCT02221388|Experimental|BI 671800 HEA tablet in fed state|
11371943|NCT02221388|Experimental|BI 671800 HEA EC tablet in fed state|
11371944|NCT02221388|Experimental|BI 671800 HEA, 50 mg tablet in fasted state|
11371945|NCT02221375|Experimental|BHT low|
11371946|NCT02221375|Experimental|BHT medium|
11371947|NCT02221375|Experimental|BHT high|
11371948|NCT02221375|Experimental|BI 54903 XX low|
11371949|NCT02221375|Experimental|BI 54903 XX medium 1|
11371950|NCT02221375|Experimental|BI 54903 XX medium 2|
11371951|NCT02221375|Experimental|BI 54903 XX high|
11371952|NCT02221375|Experimental|BI 54903 XX medium single dose|
11371953|NCT02221375|Active Comparator|Ciclesonide|
11371954|NCT02221362||Observational|No interventions
11371955|NCT02221349|Other|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
11371956|NCT02221349|Other|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
11371957|NCT02221336|Placebo Comparator|Non-MONARCA II system|Use of smartphone for normal communicative purposes only. No self-monitoring and no feedback loop.
11371958|NCT02221336|Experimental|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
11371959|NCT02221323|Experimental|Insulin lispro|
11371960|NCT02221310|Experimental|Gemtuzumab Ozogamicin|Conditioning therapy with Gemtuzumab Ozogamicin in combination with busulfan and cyclophosphamide chemotherapy followed by allogeneic stem cell transplantation.
11371961|NCT02221297|Experimental|Supplement product with plant stanol ester|
11371962|NCT02221297|Placebo Comparator|Placebo supplement product|
11371963|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
11371964|NCT02221271|Experimental|NPB-01|
11371965|NCT02221258|Experimental|FURESTEM-RA Inj.+DMARDs|FURESTEM-RA Inj. 1. 2.5x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 2. 5.0x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 3. 1.0x10^8 stem cells+DMARDs after registration
11371966|NCT02221245||Patients with Esophageal Cancer|Tumor Biopsy via Ultrasound Endoscopy
11371967|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
11371968|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
11371969|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
11371970|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
11371971|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
11371972|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
11371973|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
11371974|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
11371975|NCT02221206|Active Comparator|Treatment|mini-screw implant anchorage-assisted retraction of maxillary incisors
11371976|NCT02221206|No Intervention|Control|regular maximum anchorage
11371977|NCT02221193|Experimental|site specific vs panoral disinfection|
11372030|NCT02220842|Experimental|Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
11372298|NCT02219009|Experimental|MIND1 System|
11371978|NCT02221180|Experimental|Treatment Sequence ABDC|Treatment A (1 immediate release (IR) fixed dose combination [FDC] tablet containing canagliflozin 150 milligram [mg] and metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11371979|NCT02221180|Experimental|Treatment Sequence BCAD|Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11371980|NCT02221180|Experimental|Treatment Sequence CDBA|Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11371981|NCT02221180|Experimental|Treatment Sequence DACB|Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11371982|NCT02221167|No Intervention|Exclusive breastfeeding|Infants in the exclusive breastfeeding group will continue to breastfeed.
11371983|NCT02221167|Active Comparator|Donor Milk|"Infants in this arm will continue to breastfeed and will be given 10 ml of donor breast milk by syringe after each breastfeeding until their mother's milk comes in. (until the onset of lactogenesis II)"
11371984|NCT02221154|Experimental|Inofolic®|standard ovarian stimulation and Inofolic®
11371985|NCT02221154|Active Comparator|Gonadotropins;Folic Acid|standard ovarian stimulation without Inofolic®
11371986|NCT02221115|Other|Google Glass|Investigators using Google Glass during clinic visit
11371987|NCT02221115|No Intervention|No Google Glass|Investigator will not be using Google Glass during clinic visit
11371988|NCT02221102|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
11371989|NCT02221102|Experimental|edoxaban 30mg|Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
11371990|NCT02221102|Experimental|edoxaban 60mg|Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
11371991|NCT02221089|Experimental|Retaron|
11371992|NCT02221089|Placebo Comparator|Placebo|
11371993|NCT02221076|Experimental|Confocal Laser Endomicroscopy (CLE)|The patient will undergo a 10 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs.
11371994|NCT02221063|Active Comparator|low [thiamin] fortified fish sauce|Fish sauce will contain 2 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
11371995|NCT02221063|Active Comparator|higher [thiamin] fortified fish sauce|Fish sauce will contain 8 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
11371996|NCT02221063|Placebo Comparator|Placebo fish sauce|Fish sauce will contain only iron (as NaFeEDTA), no thiamin
11371997|NCT02221037|Experimental|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
11371998|NCT02221037|Placebo Comparator|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
11371999|NCT02221024|Experimental|Flushing every 24 hours|Flushing with positive pressure with normal saline every 24 hours
11372000|NCT02221024|Active Comparator|Flushing every 12 hours|Flushing with positive pressure with normal saline every 12 hours
11372001|NCT02221011|Experimental|shock wave (three times)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks
11372002|NCT02221011|Sham Comparator|Sham shock wave|E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle
11372003|NCT02221011|Experimental|Shock wave (one time)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose
11372004|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
11372005|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
11372095|NCT02220361|Experimental|hemabate+high dose dexmedetomidine group|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
11372006|NCT02220985|Experimental|Arm A (MRD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
11372007|NCT02220985|Experimental|Arm B (MRD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
11372008|NCT02220985|Experimental|Arm C (MUD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
11372009|NCT02220985|Experimental|Arm D (MUD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.
~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.
~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
11372010|NCT02220972|Experimental|Arm A: First on Perampanel with a crossover to Placebo|Treatment Arm A will initially receive perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD with a crossover to placebo.
11372011|NCT02220972|Experimental|Arm B: First on Placebo with a crossover to Perampanel|Treatment Arm B will initially receive placebo with a crossover to perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD.
11372012|NCT02220959|Experimental|walk test|morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
11372013|NCT02220946|Active Comparator|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. Each patient received a 20 minute session once a week for total 8 sessions
11372014|NCT02220946|Placebo Comparator|plasebo|sham electrical stimulation
11372015|NCT02220933|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
11372016|NCT02220933|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
11372017|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
11372018|NCT02220920|Placebo Comparator|Placebo＋insulin|
11372019|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
11372020|NCT02220894|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
11372021|NCT02220894|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
11372022|NCT02220881|Experimental|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
11372023|NCT02220881|Other|Observation|This group will follow the physician instruction of care for the hallux valgus
11372024|NCT02220868|Other|Sofossbuvir, Riabvirin, Stribild|Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild
11372025|NCT02220855|Experimental|BKM120|BKM120, 100mg capsule for oral use, taken once daily for two or more months for a maximum of one year. Each cycle is 28 days.
11372026|NCT02220842|Experimental|Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab|Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression.
11372027|NCT02220842|Experimental|Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
11372028|NCT02220842|Experimental|Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
11372029|NCT02220842|Experimental|Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression.
11372096|NCT02220348|Experimental|linaclotide|Linaclotide 145 μg or 290 μg capsules, once daily for 3 days, oral administration
11372031|NCT02220829|Active Comparator|Preventive administration of Rapaflo|Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
11372032|NCT02220829|Other|Standard care|Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
11372033|NCT02220816|Experimental|Competitive Training|The patients will receive only competitive activities designed to restore attention abilities. These include pencil-and-paper tasks completed under competitive circumstances and competitive virtual games specifically designed to treat different aspects of attention (divided, selective, sustained, etc).
11372034|NCT02220816|Active Comparator|Non-Competitive Training|The patients will receive conventional attentional training. Pencil and paper tasks focused on different aspects of attention (divided, selective, sustained, etc.) will be completed by all participant under individual or group-therapy sessions. No competitive training will be allowed.
11372035|NCT02220803|Active Comparator|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.
~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
11372036|NCT02220803|Active Comparator|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
11372037|NCT02220803|Experimental|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
11372038|NCT02220777|Experimental|1. ASP8477 and placebo|Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
11372039|NCT02220777|Experimental|2. ASP8477 alone|Part 3, fasted or fed
11372040|NCT02220777|Experimental|3. omeprazole alone|Part 4, Drug-Drug Interaction
11372041|NCT02220777|Experimental|4. ASP8477 + omeprazole|Part 4: Drug-Drug Interaction
11372042|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
11372043|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
11372044|NCT02220751|Placebo Comparator|chronic periodontitis|Non-surgical periodontal therapy.
11372045|NCT02220751|Active Comparator|Chronic periodontitis + type 2 diabetes|Non-surgical periodontal therapy + systemic doxycycline non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before first scaling and root planning session.
11372046|NCT02220751|No Intervention|Control|Periodontal- and systemically healthy patients were included as control group.
11372047|NCT02220738|Experimental|ABT-957|ABT-957 administered twice-daily for 7 days
11372048|NCT02220738|Placebo Comparator|Placebo|Placebo administered twice-daily for 7 days
11372049|NCT02220725|Experimental|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
11372050|NCT02220725|Experimental|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
11372051|NCT02220712|Experimental|Drug: OPC-14597 IMD|
11372052|NCT02220686|Experimental|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
11372053|NCT02220686|No Intervention|Usual Care|Physician will follow their institution's standard of care for smoking cessation.
11372054|NCT02220673|Experimental|BHT 0.1%|
11372055|NCT02220673|Experimental|BHT 0.5%|
11372056|NCT02220673|Placebo Comparator|Placebo for RMT-B|
11372057|NCT02220673|Placebo Comparator|Placebo for HFA-MDI|
11372058|NCT02220660|Active Comparator|Free dose combination|
11372059|NCT02220660|Experimental|Fixed dose combination|
11372060|NCT02220647|Experimental|Treatment A (FDC)|
11372061|NCT02220647|Active Comparator|Treatment B (single agents)|
11372062|NCT02220634|Experimental|Regadenoson|Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.
11372063|NCT02220621|Experimental|Treatment|After the hysteroscopic adhesiolysis, crosslinked hyaluronic acid gel is applied into the uterine cavity, then a Foleys balloon catheter is inserted into the uterine cavity.
11372064|NCT02220621|Active Comparator|Control|After hysteroscopic adhesiolysis, a Foleys balloon catheter is inserted into the unterine cavity.
11372129|NCT02220140|No Intervention|Control|Service as usual
11372130|NCT02220140|Experimental|Intervention group|Participants are offered access to the web based resilience program and are invited to join a short introduction course.
11372131|NCT02220127|Experimental|8 mm collimator|GKR with a single shot of the 8 mm collimator
11372132|NCT02220127|Experimental|4 mm collimator|GKR with a single shot of the 4 mm collimator
11372065|NCT02220608|Experimental|Arm 1: Dose Level 1 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
11372066|NCT02220608|Experimental|Arm 2: Dose Level 2 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
11372067|NCT02220595|Experimental|Carotid stenting|Carotid artery stenting for treatment of carotid artery stenosis
11372068|NCT02220595|Active Comparator|Carotid endarterectomy|Carotid artery endarterectomy for treatment of carotid artery stenosis
11372069|NCT02220543|Experimental|Back on Track intervention|Back on Track intervention is a biopsychosocial primary care intervention
11372070|NCT02220543|Active Comparator|Primary care as usual|Primary care as usual comprises maximally 12 individual regular physical therapy sessions for a maximum of 8 weeks.
11372071|NCT02220530||Sedation group|Colonoscopies performed with conscious sedation with iv midazolam and fentanyl
11372072|NCT02220530||Control group|Colonoscopies performed without sedation.
11372073|NCT02220517|Experimental|A: MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
11372074|NCT02220517|Experimental|B: MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
11372075|NCT02220504|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
11372076|NCT02220504|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
11372077|NCT02220491|Active Comparator|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.
~The Brain contour will be generated using the segmentation wizard and edits as required.
~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
11372078|NCT02220491|Experimental|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of < 0.7 mm (CT field of view < 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
11372079|NCT02220478|Active Comparator|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
11372080|NCT02220478|Active Comparator|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
11372081|NCT02220465|Experimental|PA+ Smoking Cessation (LMPA)|This intervention integrates low-to-moderate physical activity (PA) with evidence based smoking cessation programming. Over the 4-week treatment period, the intervention (1 in-person and 3 phone counseling sessions) focuses on (a) gradually increasing routine PA during the pre-quit period and maintaining PA post quit day (b) increasing daily PA (steps/day) using a weekly tailored algorithm with the goal of achieving 10,000 steps by Week 4 (quit day) and (c) training participants to use PA as a primary urge management strategy, thereby embedding PA within evidence-based smoking cessation counseling. Other components include additional smoking urge management skills, increasing motivation to quit, overcoming barriers and maintaining PA for quitting and staying smoke-free .
11372082|NCT02220465|Active Comparator|Standard Care Smoking Counseling (SCC)|The control intervention parallels the format of the LMPA intervention with focus only on behavioral and cognitive urge management strategies (avoiding/escaping high-risk situations, stimulus control) and minimizing the probability that participants in the control group would increase increase/use PA during the intervention period. Participants are provided a pedometer without any instructions or encouragement around increasing walking/steps during the 8-week intervention period.
11372083|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
11372084|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
11372085|NCT02220439||Case: non-rotavirus seroconverters|Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti-RV Immunoglobulin A < 20 U/ml
11372086|NCT02220439||Control: rotavirus seroconverters|Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti-rotavirus Immunoglobulin A > 20 U/ml
11372087|NCT02220426|Other|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
11372088|NCT02220400|Experimental|Ketamine|Ketamine infusion group
11372089|NCT02220400|Placebo Comparator|Placebo|Normal saline infusion
11372090|NCT02220387||occupational COPD|"Consists of 2 subgroups
~COPD patients with history of exposure to respirable silica dust
~COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust"
11372091|NCT02220387||smokers with COPD and healthy control|"Consists of 2 subgroups
~patients with COPD, history of tobacco smoke and no history of occupational exposure
~healthy subjects"
11372092|NCT02220374|Experimental|Supportive Finger Tape|Participants will be randomised to either placebo or supportive taping
11372093|NCT02220361|Placebo Comparator|placebo group|received 20 ml intravenous physiological saline
11372094|NCT02220361|Experimental|low dose dexmedetomidine group|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
11372097|NCT02220335|Experimental|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
11372098|NCT02220335|Active Comparator|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
11372099|NCT02220309||Anxiety and mood disorders|
11372100|NCT02220296|Experimental|Part 1 insulin 338|
11372101|NCT02220296|Placebo Comparator|Part 1 placebo|
11372102|NCT02220296|Experimental|Part 2 insulin 338|
11372103|NCT02220296|Active Comparator|Part 2 insulin glargine|
11372104|NCT02220270||patient with PDA or ASD|
11372105|NCT02220257||Newly diagnosed type 1 diabetes|
11372106|NCT02220244|Experimental|MD1003|MD1003 100mg capsule, 1 capsule TID for 12 months
11372107|NCT02220244|Placebo Comparator|Placebo|Placebo capsule, 1 capsule TID for 6 months, then switch to MD1003 100mg capsule, 1 capsule TID for 6 months
11372108|NCT02220231|Experimental|capnothorax group|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
11372109|NCT02220218|Experimental|Treatment Sequence ABDC|Treatment A (canagliflozin and metformin immediate release [IR] fixed dose combination [FDC] tablet 50 milligram [mg]/500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11372110|NCT02220218|Experimental|Treatment Sequence BCAD|Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11372111|NCT02220218|Experimental|Treatment Sequence CDBA|Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11372112|NCT02220218|Experimental|Treatment Sequence DACB|Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
11372113|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
11372114|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
11372115|NCT02220192|Experimental|Focal LEEP|All patients will undergo focal treatment of high-grade cervical intraepithelial neoplasia using LEEP. A two-week follow-up assessment will evaluate the side effects of the treatment and any unusual symptoms. This will be done through a phone survey. At six months a clinic visit is required to assess whether there are any precancerous cells of the patient's cervix.
11372116|NCT02220179|No Intervention|control|service as usual
11372117|NCT02220179|Experimental|Intervention group 1|Participants are offered access to the web based resilience program
11372118|NCT02220179|Experimental|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
11372119|NCT02220166|Experimental|Triticum monococcum|60 days of daily administration of 100 grams of water biscuits of Triticum monococcum
11372120|NCT02220153|Experimental|UCB7665 Intravenous 1|Single dose calculated based on body weight for 60 minutes intravenous infusion.
11372121|NCT02220153|Experimental|UCB7665 Intravenous 2|Single dose calculated based on body weight for 60 minutes intravenous infusion.
11372122|NCT02220153|Experimental|UCB7665 Intravenous 3|Single dose calculated based on body weight for 60 minutes intravenous infusion.
11372123|NCT02220153|Experimental|UCB7665 Intravenous 4|Single dose calculated based on body weight for 60 minutes intravenous infusion.
11372124|NCT02220153|Experimental|UCB7665 Intravenous 5|Single dose calculated based on body weight for 60 minutes intravenous infusion.
11372125|NCT02220153|Experimental|UCB7665 Subcutaneous 1|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
11372126|NCT02220153|Experimental|UCB7665 Subcutaneous 2|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
11372127|NCT02220153|Placebo Comparator|Intravenous Placebo|Single dose placebo comparator for each active arm of intravenous infusion.
11372128|NCT02220153|Placebo Comparator|Subcutaneous Placebo|Single dose placebo comparator for each active arm of subcutaneous infusion.
11372133|NCT02220114|Other|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days.
~Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks."
11372134|NCT02220088|Experimental|TAI of FOLFOX|Retreatment With Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin
11372135|NCT02220088|Active Comparator|Sorafenib|treatment with sorafenib
11372136|NCT02220075||spontaneous group|maintain spontaneous breathing during the operation, and recording tidal volume, ET CO2, respiratory rate, peak airway pressure, SpO2
11372137|NCT02220075||controlled group|controlled ventilation(tidal volume 8ml/kg, ET CO2 35~40mmHg) during the operation, recording peak airway pressure, SpO2
11372138|NCT02220062|Active Comparator|EUS-CPN group|Group that be performed by Endoscopic ultrasound guided bilateral celiac plexus neurolysis
11372139|NCT02220062|Experimental|EUS-CGN group|Group that be performed by Endoscopic ultrasound guided celiac ganglia neurolysis
11372140|NCT02220049|Experimental|Velcade|Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
11372141|NCT02220036|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
11372142|NCT02220036|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
11372143|NCT02220023|Experimental|Nitric Oxide|40 ppm, one time administration, inhaled.
11372144|NCT02220010|Experimental|Pancreatic stent|If POPF grade B or C is detected on post operative day 3 or more, a pancreatic stent is endoscopically positioned in the pancreatic duct.
11372145|NCT02220010|No Intervention|Drain only|If POPF grade B or C is detected on post operative day 3 or more, only the per-operatively placed drain is used as treatment
11372146|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
11372147|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
11372148|NCT02219984||patients anticoagulated|
11372149|NCT02219971|Experimental|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
11372150|NCT02219971|Experimental|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
11372151|NCT02219971|Experimental|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
11372152|NCT02219971|Experimental|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
11372153|NCT02219971|Experimental|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
11372154|NCT02219971|Experimental|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
11372155|NCT02219971|Experimental|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
11372156|NCT02219958||RAMP-HT and Non-RAMP-HT|
11372157|NCT02219945|Experimental|Group 1 - 20 PTB patients aged >18yrs|Group 1 - 20 TB patients aged > 18 yrs 5 min exhaled breath sampling with nose clamp
11372158|NCT02219945|Experimental|Group 2 - 20 TB suspects > 18 yrs|Group 2 - 20 non-TB patients > 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp
11372159|NCT02219945|Experimental|group 3 - 20 lung patients, non-TB|Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp
11372160|NCT02219945|Experimental|Group 4 - 20 healthy controls|Group 4 - 20 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp
11372161|NCT02219945|Experimental|Group 5 - 7 newly diagnosedMDR PTB pts|Group 5 - 7 newly diagnosed MDRTB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp
11372162|NCT02219945|Experimental|group 6 - cohort of TB suspects|300 more individuals, suspected to have TB - final diagnosis by standard procedures plus sputum culture plus follow-up for >2 years 5 min exhaled breath sampling with nose clamp
11372163|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
11372164|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
11372165|NCT02219919|Experimental|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
11372166|NCT02219919|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
11372167|NCT02219906|Placebo Comparator|Placebo|Placebo capsule given three times daily X 3 weeks
11372168|NCT02219906|Experimental|Resveratrol|Resveratrol 1 gram three times daily X 3 weeks
11372169|NCT02219893|Experimental|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
11372170|NCT02219880|Placebo Comparator|Placebo|Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
11372171|NCT02219880|Experimental|Kava - standardised 240mg kavalactones|Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day
11372172|NCT02219867|Experimental|Ketamine|Active Comparator
11372173|NCT02219854|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11372174|NCT02219854|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11372175|NCT02219841||No intervention group|Receive general life-style advice and information on heart healthy diet Undergo catheter ablation for AFib
11372176|NCT02219841||Life-style intervention|patients will receive personilized low-calorie diet menu and undergo supervised exercise in the cardiac rehabilitation facility for 3 months before ablation with an aim of loosing >10% of body weight. They will continue diet and exercise for 1 year following ablation procedure Will receive catheter ablation for AFib
11372177|NCT02219828|Placebo Comparator|Placebo|placebo sc
11372178|NCT02219828|Active Comparator|Anakinra|Anakinra 2mg/Kg up to 100mg (maximum dose)
11372179|NCT02219815|No Intervention|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
11372180|NCT02219815|Experimental|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
11372181|NCT02219802|Active Comparator|Drug-eluting stent|Treatment of infarct related laesion with a drug-eluting stent
11372182|NCT02219802|Experimental|Drug-coated balloon|After treatment of the infarct related artery with a drug-coated ballon, an additional BMS is advised to be used in case of residual stenosis > 50% or coronary artery dissection type > B.
11372183|NCT02219789|Experimental|Treatment (alisertib, fulvestrant)|Patients receive fulvestrant IM on day 1 (days 1 and 15 of course 1 only) and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11372184|NCT02219776|Active Comparator|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
11372185|NCT02219776|Experimental|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
11372186|NCT02219750|Active Comparator|Preprandial premix therapy|switch twice-daily insulin Preprandial premix therapy mean that transition of advance insulin based on the basal insulin daily total dose at study entry divided into two equal dose of preprandial NovoMix 30. Patient discontinued all pre-study oral antidiabetic drug(OAD), including sulfonylureas, glinides, Thiazolidinedione(TZD) and Dipeptidyl peptidase-4(DPP-4) inhibitor but left metformin alone
11372187|NCT02219750|Active Comparator|Basal-plus insulin|switch twice-daily insulin Basal-plus insulin consisted of continued previous basal insulin and add-on once-daily insulin aspart(NovoRapid) before breakfast. The starting dose of insulin aspart was 4 unit(U) before breakfast and continued under previous basal insulin dose.
11372188|NCT02219737|Experimental|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11372189|NCT02219724|Experimental|MOXR0916: Dose Escalation Stage|Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days.
11372190|NCT02219724|Experimental|MOXR0916: Expansion Stage|Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years).
11372191|NCT02219711|Experimental|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
11372192|NCT02219698|Experimental|Symptomatic treatment|
11372193|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
11372194|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
11372195|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
11372196|NCT02219672|Experimental|Triptolide group|cART for 6 months, and the experimental group will take Triplitode 2 tabs tid po for another 12 months
11372197|NCT02219672|Active Comparator|Comparator group|combined antiretroviral therapy (cART): TDF+3TC+LPV/r+RAL for 18 months
11372198|NCT02219659|Active Comparator|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
11372199|NCT02219659|Active Comparator|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
11372200|NCT02219659|Active Comparator|Fentanyl push first|This arm attempts to manage patient's pain and agitation with analgesia first. Fentanyl intravenous (IV) pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and titrated to target RASS score up to 6 hours.
11372201|NCT02219646|Experimental|Vardenafil|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Study Group were treated with vardenafil 10 mg twice/daily.
11372202|NCT02219646|Placebo Comparator|Control|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Control Group were treated with tablets twice/daily identical to the Study Group, but containing placebo.
11372203|NCT02219633|Experimental|LEO 39652 cream|Topical application
11372204|NCT02219633|Placebo Comparator|LEO 39652 cream vehicle|Topical application
11372205|NCT02219620|Experimental|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
11372206|NCT02219620|Active Comparator|Social Control|social control/interaction group
11372207|NCT02219607||epidural|
11372208|NCT02219607||general anesthesia|
11372209|NCT02219594|Experimental|Gemstone CT|Gemstone CT ：Discovery CT750 HD（high definition） ，GE（General Electric Co.） Healthcare, Milwaukee； CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient
11372210|NCT02219594|Active Comparator|320-detector row spiral CT|320-detector row spiral CT：Aquilion One, Toshiba, Nasu, Japan. CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient .
11372211|NCT02219581|Placebo Comparator|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
11372212|NCT02219581|Experimental|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
11372213|NCT02219581|Experimental|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
11372214|NCT02219568|Experimental|obscure gastrointestinal bleeding|Those patients who developed obscure gastrointestinal bleeding either overt or occult bleeding who will then undergo video capsule endoscopy and CT enterography.
11372215|NCT02219555|Placebo Comparator|Randomized Placebo/salt water injection|1ml of 0.9% NaCl and 2 ml of 1% lidocaine placebo/salt water injection at the time of enrollment into the study. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
11372216|NCT02219555|Active Comparator|Randomized Active medication injection|a mixture of one ml of triamcinolone acetonide, 240 mg/ml, and 2 ml of 1% lidocaine, active medication injection. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
11372217|NCT02219555|No Intervention|None Randomized observational medication injection|Observational: Active medication injection Patients without randomization where any type of injection as prescribed by the physician is accepted If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection, surgery or any other choice that they and their doctor agree to
11372218|NCT02219555|No Intervention|Observational: Surgical|"Patients who are going to have carpel tunnel release surgery are eligible for this arm.
~If patient has ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome."
11372219|NCT02219542|Placebo Comparator|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
11372220|NCT02219542|Experimental|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
11372221|NCT02219529|Experimental|MCE|patients were assigned to swallow MCE first, followed by the gastroscopy
11372222|NCT02219529|Active Comparator|Standard gastroscopy|patients were assigned to swallow MCE first, followed by the gastroscopy
11372223|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
11372224|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
11372227|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
11372228|NCT02219490|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
11372229|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
11372230|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
11372231|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
11372232|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
11372233|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
11372234|NCT02219451|Experimental|exercise training|We studied twenty-six chronic heart failure outpatients and they were assigned to 2 groups: Untrained (n=13) and trained (n=13).
11372235|NCT02219438|Experimental|Bolus|ropivacaine 0.2% administration as repeated, scheduled (one/h) bolus doses (8 mL) x8 h
11372236|NCT02219438|Active Comparator|basal|ropivacaine 0.2% administration as a continuous basal infusion (8 mL/h) x8 h
11372237|NCT02219425|Other|endometrial biopsy|
11372238|NCT02219412|Experimental|ticagrelor mono-therapy|Take ticagrelor 90 mg Bid for 2 weeks.
11372239|NCT02219412|Active Comparator|aspirin/ticagrelor dual-therapy|Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
11372240|NCT02219399|Experimental|300 mg DHA|300 mg DHA
11372241|NCT02219399|Placebo Comparator|Placebo|olive oil or high oleic acid sunflower oil placebo
11372242|NCT02219399|Experimental|600 mg DHA|600 mg DHA
11372243|NCT02219386|Active Comparator|Deep dry needling|The group of DDN receive this treatment and stretch
11372244|NCT02219386|Other|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
11372245|NCT02219373|Experimental|Gabapentin|
11372246|NCT02219373|Experimental|Oxcarbazepine|
11372247|NCT02219373|Placebo Comparator|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
11372248|NCT02219347|Other|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of < 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
11372249|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
11372250|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
11372251|NCT02219321|Active Comparator|Lidocaine infusion|A continuous intravenous infusion of lidocaine
11372252|NCT02219321|Placebo Comparator|Saline infusion|A continuous intravenous infusion of saline
11372253|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.
~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
11372254|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.
~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
11372255|NCT02219295|Experimental|sweet -block|application of different sugars, artificial sweeteners and sweet-taste antagonists in a single dose in 300 ml tap water every week up to 7 times and collection of blood samples over 3 hours
11372256|NCT02219295|Experimental|bitter block|application of purified bitter tasting ingredients of vegetables and hop in 300 ml tap water , collection of blood samples for 3h (-15,0,15,30,60,120,180 min)
11372257|NCT02219295|Experimental|umami-block|"application of glutamate and glutamate +IMP
~same procedure as above"
11372258|NCT02219295|Other|gastroscopy|gastroscopy with and without oral intervention with artificial sweetener saccharin to take tissue samples from the upper bowel for the investigation of taste receptor cells in the upper bowel in human beings
11372259|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
11372260|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
11372261|NCT02219269||Medically complex contraception users|Cohort includes women of reproductive age with diverse medical conditions (listed in inclusion criteria) who are referred to Family Planning felowship-trained physicians, seeking contraception counseling and administration.
11372262|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
11372263|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
11372264|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
11372265|NCT02219243|No Intervention|Waitlist Control|This is a 1-month waitlist control to be compared with the active online interpretation training interventions. This is a no intervention control group
11372299|NCT02218996||Psychosocial treatment|Children and adolescents with anxiety disorders
11372266|NCT02219243|Experimental|Active Interpretation Training|Online Interpretation Training Condition 2 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
11372267|NCT02219243|Experimental|Placebo Interpretation Training|Online Interpretation Training Condition 1 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
11372268|NCT02219230|Experimental|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
11372269|NCT02219217|Experimental|No arms|All participants will be administered Tivicay® (dolutegravir 50 mg once daily) for 10 days, then will undergo a nine-day wash out period and then take Stribild® (245 mg of tenofovir disoproxil, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.
11372270|NCT02219204|Active Comparator|Acupuncture treatment|"This will be performed twice weekly for 30 days. There will be 8 sessions of acupuncture treatments in total.
~The needles to be use around the eyes will have the dimensions of 0.25 (diameter) x 13mm (length), while 0.25 x 25mm needles will be used behind the ear (feng chi) and 0.30 X 25mm needles on the upper and lower limbs. These needles will remain in the points for 20 minutes. The depth of penetration will be about 1-2 mm."
11372271|NCT02219204|Active Comparator|Herbal treatment|"This formulation is called qi ju gan lu yin or Lycium berry, a chrysanthemum beverage. This is a modified version of qi ju di huang wan published previously. The senior TCM collaborator, Prof Wei QP has made this modification in order to treat the dry eye patients with lung-kidney yin deficiency."
11372272|NCT02219204|No Intervention|Eye drops|
11372273|NCT02219191|Experimental|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
11372274|NCT02219191|Active Comparator|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
11372275|NCT02219178|Experimental|RsqVD|Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
11372276|NCT02219165|Experimental|IVIG 2 g/kg|Intravenous human immunoglobulin Day 1: As soon as there is suspicion of TSS, randomisation will be performed in order for the study treatment to be administered within the 12h following PICU admission (or following the manifestation of the first signs of shock). Concurrently, the TSS antibiotherapy following Surviving Sepsis Campaign recommendations is given
11372277|NCT02219165|Placebo Comparator|Albumin 4%|Same study scheduling as the first arm. Only the study treatment given is different (albumin instead of IGIV)
11372278|NCT02219152|Experimental|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
11372279|NCT02219152|Placebo Comparator|saline|the saline will be administrated using an infusion during the biopsy.
11372280|NCT02219139|Other|ESTA abutment Roxolid|"One study abutment per patient will be placed. After healing for 6 to 7 weeks, patients will be asked to stop oral hygiene at the study site for 2 weeks.
~Sulcus fluid and plaque samples will be taken at the abutment site at several visits before and during abdication of oral hygiene.
~The study finishes with biopsy visit. Afterwards a regular abutment will be placed and the patients will be treated according to the standard protocol of the clinic to obtain their final restoration."
11372281|NCT02219126|Experimental|Homogenized and pasteurized milk|Milk that has undergone homogenization ans pasteurization treatment
11372282|NCT02219126|Experimental|Nonhomogenized and nonpasteurized milk|Unhomogenized and unpasteurized milk (raw milk)
11372283|NCT02219113|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
11372284|NCT02219100|Experimental|Home administration of mifepristone|This arm consisted of women who chose home administration of 200 mg mifepristone.
11372285|NCT02219100|No Intervention|Clinic administration of mifepristone|This arm consisted of women who underwent clinic administration of 200 mg mifepristone.
11372286|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
11372287|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
11372288|NCT02219074|Experimental|Sebacia microparticle and laser treatment|
11372289|NCT02219074|Sham Comparator|Vehicle and laser treatment|
11372290|NCT02219061||GMT|
11372291|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
11372292|NCT02219048|Experimental|PF-03715455|PF-03715455
11372293|NCT02219035||stroke-ischaemic|no interventions
11372294|NCT02219035||stroke -haemorrhagic|no intervention
11372295|NCT02219035||stroke: not confirmed|no intervention
11372296|NCT02219022|Active Comparator|Control group|Patient remain with their usual clinical treatment.
11372297|NCT02219022|Experimental|Experimental group|"Patients in experimental group participated in a 12-week progressive resistance training using a maximum repetition exercise in which patients performed 1 Maximum Repetition with the maximum bearable weight. Once the 1 Maximum Repetitionwas determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1 Maximum Repetition.
~The exercises were knee extension and flexion and hip abduction and adduction, elbow extension and flexion, wrist extension and flexion and shoulder abduction and adduction and spine extension and flexion all performed in machines. The 1 Maximum Repetition load was reevaluated every 6 weeks.
~Patient remain with their usual clinical treatment."
11372300|NCT02218983|Experimental|Limited transthoracic echocardiogram (LTTE)|LTTE (SonoSite Ultrasound), which will be performed every 10 - 30 minutes, after each fluid challenge or transfusion, until two consecutive equivalent measurements are reached without fluid challenge or transfusion
11372301|NCT02218983|Active Comparator|Usual care|measurements on :blood pressure, heart rate, urine output, lactate, lactate clearance (after 6 hrs), base deficit, creatinine
11372302|NCT02218970|Experimental|strength training|Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
11372303|NCT02218970|Other|control|patients treated for substance-related disorder but not participating in strength training intervention (no training control group)
11372304|NCT02218957|Active Comparator|Standard RYGB|Standard RYGB
11372305|NCT02218957|Experimental|Extended Pouch RYGB|Restrictive/extended pouch RYGB
11372306|NCT02218944|Experimental|Response Inhibition Training: A|In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
11372307|NCT02218944|Active Comparator|Response Inhibition Training: B|In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
11372308|NCT02218944|Placebo Comparator|Benign|A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
11372309|NCT02218931|Experimental|Targeted ESTEEM diet|"The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia.
~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
11372310|NCT02218931|No Intervention|Current clinical practice|The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
11372311|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
11372312|NCT02218918|Active Comparator|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
11372313|NCT02218918|Experimental|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
11372314|NCT02218905|Experimental|Sit to stand test|One minute sit to stand in 40 inches armless chair. Fatigue, breathlessness and failure to maintain tempo will lead to decease the test
11372315|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
11372316|NCT02218879||Patients with relapsing MS|
11372317|NCT02218866||Group 1|All participants will be examined by a neurologist to test sensation, reflexes, and strength and complete a few questionnaires. Tests will be performed to measure nerve function and small punch skin biopsies will be taken to assess nerve fiber density. Blood and urine tests will measure various markers of interest. Participants will be seen before and after their bariatric surgery.
11372318|NCT02218866||Group 2|"In addition to the procedures described for Group 1, participants in Group 2 will have the following procedures:
~During bariatric surgery, a small biopsy from the liver and abdominal fat will be taken to examine how fat is processed within the body.
~At the first visit, after a skin biopsy is taken, a small capsaicin patch will be placed on the lower thigh. The patch will remain in place for 48 hours and will cause the nerves in the immediate area to pull back from the skin. A biopsy will be taken from the patch area 48 hours, 1 month, and 3 months after the initial biopsy. This procedure will be repeated after surgery.
~MRIs may be performed before and after bariatic surgery.
~Participants may be asked to complete additional tests to evaluate nerve function"
11372319|NCT02218866||Group 3|Group 3 will comprise of individuals who are not overweight. Participants in this group will undergo a similar evaluation to Group 2.
11372320|NCT02218853||Bipolar I disorder, with psychosis|Individuals diagnosed with Bipolar I disorder, with psychotic features
11372321|NCT02218853||Bipolar I disorder, without psychosis|Individuals diagnosed with Bipolar I disorder, without psychotic features
11372322|NCT02218853||Healthy Controls|Must have no personal history of any psychotic or mood disorder, or a family history of psychotic or recurrent mood disorder among their first-degree relatives
11372323|NCT02218840||Behavioral|Evaluation of cigar smoking topography
11372324|NCT02218827|Experimental|dry eye patients|Loteprednol Etabonate (FML) topical treatment 1 drop 4 times daily for 1 month then Loteprednol Etabonate (FML) 1 drop 2 times daily for 1 month
11372325|NCT02218814|Experimental|Adductor Canal Block:|Adductor Canal Nerve Block: The patient is placed in a supine position with the extremity to be blocked slightly externally rotated. On the medial thigh, at the midpoint between the inguinal crease and the medial condyle, 13-6-MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) is placed in a transverse orientation to visualize the femoral artery in short axis deep to the sartorius muscle. Sterile field and patient sedation achieved. A 21-gauge,100 mm, short-bevel needle (Stimuplex; B Braun) is inserted under ultrasound guidance in in-plane technique to position the needle tip anterolateral to the artery and just deep to the posterior fascia of the sartorius muscle. Once in position, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
11372378|NCT02218528|Active Comparator|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
11372379|NCT02218528|Active Comparator|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
11372380|NCT02218515|Other|Open Flap Debridement|Open Flap Debridement (Control Group)
11372381|NCT02218515|Experimental|Enamel Matrix Derivative|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)
11372326|NCT02218814|Active Comparator|Femoral Nerve Block|Femoral Nerve Block. The procedure is conducted with the patient in a supine position with a 13-6 MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) applied to the skin at the level of the inguinal crease. The femoral artery, fascia iliac, and femoral nerve are visualized. Sterile field and patient sedation achieved. A 22-gauge, 50-mm, short-bevel stimulating needle (Stimuplex; B Braun, Bethlehem, Pennsylvania) connected to twitch monitor B/Braun Stimuplex DIG RC is inserted under ultrasound guidance using an in-plane technique from lateral to medial until a quadriceps motor response is elicited at a current between 0.5 and 0.2 mA with a pulse width of 0.1millisecond from a twitch monitor . After negative aspiration, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral nerve and deep to the fascia iliac, with intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
11372327|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
11372328|NCT02218775|Experimental|LY2456302|LY2456302 dosed orally at 10 mg daily for 2 weeks in healthy volunteers
11372329|NCT02218762|Experimental|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
11372330|NCT02218762|Experimental|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
11372331|NCT02218749|Experimental|Initially triaged to physiotherapist|Initially triaged to physiotherapist
11372332|NCT02218749|Active Comparator|Initially triaged to physician|Initially triaged to physician
11372333|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
11372334|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
11372335|NCT02218723|Active Comparator|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF [100 microgram (mcg) per blister from 0.6% blend] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372336|NCT02218723|Active Comparator|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372337|NCT02218723|Active Comparator|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372338|NCT02218723|Active Comparator|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372339|NCT02218723|Active Comparator|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372340|NCT02218723|Active Comparator|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372341|NCT02218723|Active Comparator|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372342|NCT02218723|Active Comparator|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372343|NCT02218723|Active Comparator|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372344|NCT02218723|Active Comparator|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
11372345|NCT02218710||Growth hormone deficiency|
11372346|NCT02218710||healthy controls|
11372347|NCT02218697|Experimental|Co-Ad Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
11372348|NCT02218697|Experimental|Control Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
11372349|NCT02218684|Experimental|Telmisartan + Lacidipine - low dose|
11372350|NCT02218684|Experimental|Telmisartan + Lacidipine - medium dose|
11372351|NCT02218684|Experimental|Telmisartan + Lacidipine - high dose|
11372352|NCT02218684|Placebo Comparator|Placebo|
11372353|NCT02218671|Experimental|WE 941 OD under deglutition|
11372354|NCT02218671|Experimental|WE 941 OD under non-deglutition|
11372355|NCT02218658|Experimental|WE 941 OD|
11372356|NCT02218658|Active Comparator|Brotizolam|
11372357|NCT02218645|Experimental|WE 941 OD|
11372358|NCT02218645|Active Comparator|Brotizolam|
11372359|NCT02218632|Active Comparator|lactose-free diet|lactose-free diet (standard therapy) vs. lactose-free diet plus temporary oral galactose supplements
11372360|NCT02218632|Active Comparator|lactose free diet|lactose-free diet (standard therapy)
11372361|NCT02218619|Experimental|Taurourodeoxycholic Acid (TUDCA)|TUDCA 1750 mg/day x 12 months
11372362|NCT02218619|Placebo Comparator|Sugar pill (placebo)|Placebo at same dose, frequency, and duration as experimental treatment
11372363|NCT02218606|Experimental|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
11372364|NCT02218606|Experimental|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
11372365|NCT02218593|Experimental|WREX orthosis|WREX Orthosis
11372366|NCT02218580|Experimental|Massage therapy & standard care|"Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.
~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen."
11372367|NCT02218580|Active Comparator|Standard care|Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
11372368|NCT02218567|Other|Patients|
11372369|NCT02218567|Other|Caregivers|
11372370|NCT02218554|Experimental|Study Group|Subject has been diagnosed with BRONJ
11372371|NCT02218554|No Intervention|Control Group|Subject has not developed any signs or symptoms of BRONJ
11372372|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
11372373|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
11372374|NCT02218528|Placebo Comparator|Starchy meal|No Plant-based ingredient added to a starchy meal
11372375|NCT02218528|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
11372376|NCT02218528|Placebo Comparator|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
11372377|NCT02218528|Active Comparator|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
11372382|NCT02218515|Experimental|Enamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
11372383|NCT02218502|Other|If simple rules are conclusive|All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
11372384|NCT02218502|Other|If simple rules are inconclusive|If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
11372385|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
11372386|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
11372387|NCT02218476|Other|APS Patient|
11372388|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
11372389|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
11372390|NCT02218437|Experimental|MSC+ATG|The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.
11372391|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
11372392|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
11372393|NCT02218411|Experimental|Exercise|Exercises routine based on the Otago exercise programme
11372394|NCT02218398|Experimental|Bronchodilator|Albuterol 3-4 times per day, steroids when necessary.
11372395|NCT02218398|No Intervention|No drug|No drug
11372396|NCT02218385||ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
11372397|NCT02218372|Experimental|Fidaxomicin|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
11372398|NCT02218372|Active Comparator|Vancomycin|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
11372399|NCT02218359|Experimental|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.
11372400|NCT02218359|Placebo Comparator|Aerosolized Placebo|Aerosolized placebo to be administered by aerosol using the AFIS Inline System.
11372401|NCT02218346|Active Comparator|Treatment A (unfed)|Treatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
11372402|NCT02218346|Active Comparator|Treatment B (fed)|Treatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
11372403|NCT02218333|Placebo Comparator|Control drink|An isocaloric drink to milk
11372404|NCT02218333|Experimental|Milk|Protein enriched milk (Styrk)
11372405|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
11372406|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
11372407|NCT02218307|Active Comparator|Mupirocin|topical antibiotic
11372408|NCT02218307|Placebo Comparator|Placebo|Placebo control for mupirocin
11372409|NCT02218294|Experimental|[14C] BCX4161|Includes a radiolabelled dose of [14C] BCX4161 and unlabelled BCX4161
11372410|NCT02218281|Experimental|C2Q-Teen app|Smoking cessation treatment delivered through a smartphone app via mindfulness training.
11372411|NCT02218281|Active Comparator|NCI's QuitSTART app|Smoking cessation treatment delivered through a smartphone app by NCI, without mindfulness training.
11372412|NCT02218281|Active Comparator|Written smoking cessation materials only|Receipt of written smoking cessation materials.
11372413|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.
~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
11372414|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.
~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
11372415|NCT02218255|Active Comparator|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
11372416|NCT02218255|Active Comparator|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
11372417|NCT02218255|No Intervention|Day 5 eSET with Traditonal Morphology|
11372418|NCT02218242|Experimental|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
11372419|NCT02218229|Experimental|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
11372420|NCT02218229|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
11372421|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
11372422|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
11372423|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
11372424|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
11372425|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
11372426|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
11372427|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
11372428|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
11372429|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
11372430|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
11372431|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
11372432|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
11372433|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
11372434|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
11372435|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
11372436|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
11372437|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
11372438|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
11372439|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
11372440|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
11372441|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
11372442|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
11372443|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
11372444|NCT02218164|Experimental|Capecitabine or 5-FU with Pegylated Interferon alpha-2b|"Participants will start the Capecitabine pills on day 1 thru day 14 and be off for 7 days (day 15-day 21).
~Participants will receive 5-FU days 1-4 of each 21 day cycle.
~Participants will receive the Interferon alpha-2b injection weekly every week. The three week period is referred to as one cycle.
~After three cycles, new imaging studies will be performed that will measure how the disease is responding to treatment. Participants whose disease is stable or improved will undergo an additional 3 cycles of therapy and the imaging studies will be repeated. Again, participants whose disease is stable or improved will undergo a final 3 cycles of treatment (a total 27 weeks of treatment)."
11372445|NCT02218151|Experimental|Patient-Centered Medical Home (PCMH)|"Day-to-Day Care:
~Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
11372446|NCT02218151|Active Comparator|Standard Care|"These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self.
~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
11372447|NCT02218138|Experimental|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
11372448|NCT02218138|Experimental|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
11372493|NCT02217904|Experimental|Islatravir 1 mg|Single oral dose of islatravir 1 mg
11372449|NCT02218125|Experimental|Group 1- MVA Mosaic|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
11372450|NCT02218125|Placebo Comparator|Group 2 - Placebo|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
11372451|NCT02218125|Experimental|Group 3 - MVA Mosaic|Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
11372452|NCT02218125|Placebo Comparator|Group 4- Placebo|Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
11372453|NCT02218112||OB - Bariatric surgery (gastric bypass)|Obese patients who will undergo a bariatric surgery (gastric bypass)
11372454|NCT02218112||OB- Control group|Obese patients who will not undergo surgery - Control group
11372455|NCT02218099|Experimental|1: Single dose of ASP8232|Subjects receive a single oral dose of ASP8232
11372456|NCT02218099|Experimental|2: Multiple doses of ASP8232 or placebo|Subjects receive multiple oral doses of ASP8232 or placebo
11372457|NCT02218086|Experimental|professionals|balancing on the slackline / wobbling board 3 times by 30 seconds balancing on the slackline with a fix visual anchor / moving visual anchor 3 times by 30 seconds
11372458|NCT02218086|Experimental|beginners|balancing on the slackline / wobbling board 3 times by 30 seconds pre-training compared to post-training
11372459|NCT02218073|Experimental|Treatment Sequence AB|Participants will receive 10 milligram (mg) JNJ-42756493 tablet orally on Day 1 of Period 1 and 100 microgram (mcg) of JNJ-61818549 as intravenous injection 2 hours after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 2.
11372460|NCT02218073|Experimental|Treatment Sequence BA|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 1 and JNJ-42756493 10 mg tablet orally on Day 1 of Period 2.
11372461|NCT02218060|Experimental|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
11372462|NCT02218060|Other|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
11372463|NCT02218047|Active Comparator|Best available therapy (BAT)|Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study
11372464|NCT02218047|Experimental|Pegylated-Proline-interferon alpha-2b|AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study
11372465|NCT02218034|Experimental|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
11372466|NCT02218034|Experimental|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
11372467|NCT02218034|Active Comparator|TAZORAC® Gel 0.1%|TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
11372468|NCT02218034|Active Comparator|TAZORAC® Cream 0.1%|TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
11372469|NCT02218021|Experimental|Samidorphan Dose 1|
11372470|NCT02218021|Experimental|Samidorphan Dose 2|
11372471|NCT02218021|Experimental|Samidorphan Dose 3|
11372472|NCT02218021|Placebo Comparator|Placebo|
11372473|NCT02218021|Active Comparator|Oxycodone Dose 1|
11372474|NCT02218021|Active Comparator|Oxycodone Dose 2|
11372475|NCT02218008|Experimental|High Dose|
11372476|NCT02218008|Experimental|Low Dose|
11372477|NCT02218008|Placebo Comparator|Placebo|
11372478|NCT02217995|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in ten 2.5 hour group sessions with 15 participants per group.
11372479|NCT02217995|No Intervention|Waitlist|Wait list as per usual.
11372480|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
11372481|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
11372482|NCT02217969|Experimental|Electronic alert to SLUScore increase|Patients whose anesthesia care team members are receiving alerts to increments in their SLUScore (progressive hypotensive exposures) are anticipated to be given interventions aimed at minimizing further hypotensive exposures. The decision of whether or not to intervene as well as the type(s) of interventions will be at the sole discretion of the patient's anesthesia care team
11372483|NCT02217969|No Intervention|Control (no alert)|Routine anesthesia care at the discretion of the anesthesia care team
11372484|NCT02217956|Experimental|HCIP + bevacizumab|"4 dose level of cisplatin are planned: Level 1 : 50 mg/m2 (start level) Level 2 : 60 mg/m2 Level 3 : 70 mg/m2 Level 4 : 80 mg/m2 Level -1: 40 mg/m2 (in case of DLT at level 1)
~bevacizumab: Treatment starts between week 10 and 14 after HCIP. Dosage: 15 mg/kg for a total of 22 injections every 3 weeks for 15 months"
11372485|NCT02217943|Active Comparator|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
11372486|NCT02217943|Active Comparator|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
11372487|NCT02217930|Placebo Comparator|Placebo|"Placebo matched to WCK 2349, oral tablet(s)
~Placebo matched to moxifloxacin overencapsulated tablet"
11372488|NCT02217930|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg positive control (overencapsulated tablet)
11372489|NCT02217930|Experimental|WCK 2349|WCK 2349 supratherapeutic dose determined in Part 1, oral tablet(s)
11372490|NCT02217917|Experimental|Cohort 1|Single ascending dose in 3 period cross-over design (with optional 4th period)
11372491|NCT02217917|Experimental|Cohort 2|Multiple ascending dose
11372492|NCT02217917|Experimental|Cohort 3|Multiple ascending dose
11372498|NCT02217904|Experimental|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
11372499|NCT02217904|Experimental|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
11372500|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.
~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
11372501|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
11372502|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
11372503|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
11372504|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
11372505|NCT02217852|Experimental|A1 nitrendipine|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and nitrendipine will be added (dose range 10mg-20mg bid).
11372506|NCT02217852|Experimental|A2 hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and hydrochlorothiazide will be added (dose range 12.5mg-25mg)
11372507|NCT02217852|Experimental|B1 captopril plus Hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and captopril plus Hydrochlorothiazide will be added (dose range：captopril 25mg-50mg tid, Hydrochlorothiazide 12.5mg-25mg qd).
11372508|NCT02217852|Experimental|B2 Beijing hypotensive No.0|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and Beijing hypotensive will be added (dose range：Beijing hypotensive No.0 one pile qd or less ).
11372509|NCT02217839|Experimental|DG3173|
11372510|NCT02217839|Experimental|DG3173+Octreotide|
11372511|NCT02217826|Experimental|DG3173|
11372512|NCT02217826|Placebo Comparator|Saline|
11372513|NCT02217826|Active Comparator|Octreotide|
11372514|NCT02217813|Experimental|1. Tafamidis|
11372515|NCT02217813|Experimental|2. Tafamidis|
11372516|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
11372517|NCT02217787|Other|fasted condition|
11372518|NCT02217787|Other|fed condition|
11372519|NCT02217774|Experimental|MGUIDE assisted implant placement|Implant placement, using MGUIDE MORE system for implant planning and placement
11372520|NCT02217748|Experimental|Survey questionnaire version 1|Name generator order: leisure, money, support
11372521|NCT02217748|Experimental|Survey questionnaire version 2|Name generator order: leisure, support, money
11372522|NCT02217748|Experimental|Survey questionnaire version 3|Name generator order: money, leisure, support
11372523|NCT02217748|Experimental|Survey questionnaire version 4|Name generator order: money, support, leisure
11372524|NCT02217748|Experimental|Survey questionnaire version 5|Name generator order: support, leisure, money
11372525|NCT02217748|Experimental|Survey questionnaire version 6|Name generator order: support, money, leisure
11372526|NCT02217735|Experimental|Writing Intervention - Expressive Arm|Participants are asked to write about the most traumatic or stressful experience of their entire lives in three, 20 minute writing sessions.
11372527|NCT02217735|Active Comparator|Writing Intervention - Neutral Arm|Participants are asked to write about what they did the day before, refraining from including emotional details.
11372528|NCT02217722|Experimental|Ulcerative Colitis Diet counseling|Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
11372529|NCT02217722|Experimental|Antibiotic Treatment|Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
11372530|NCT02217709|Experimental|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade < or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
11372531|NCT02217696|Experimental|Computerized reading training first|Cross-over design: group first receives the intervention
11372532|NCT02217696|Experimental|Waiting Control First|Cross-over design: group first serves as waiting control
11372533|NCT02217683|No Intervention|Young blood transfusion|The first group of patients (n=30) will be randomized to receive leukoreduced blood transfusion stored for less than 10 days
11372534|NCT02217683|No Intervention|Old blood transfusion|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days
11372535|NCT02217683|Active Comparator|Old blood transfusion and Nitric Oxide|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days while breathing nitric oxide (80 part per million) and oxygen
11372536|NCT02217670|Experimental|Metformin (test)|single oral dose of Metformin 1000 mg granules
11372537|NCT02217670|Active Comparator|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
11372538|NCT02217657|Active Comparator|operator informed to contact force|Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)
11372539|NCT02217657|Experimental|operator blinded to contact force|Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)
11372540|NCT02217644|Experimental|BI 653048 H3PO4 solution|single rising doses
11372541|NCT02217644|Experimental|BI 653048 H3PO4 low dose capsule|
11372542|NCT02217644|Experimental|BI 653048 H3PO4 high dose capsule|
11372543|NCT02217644|Placebo Comparator|Placebo|
11372544|NCT02217631|Experimental|BI 653048 BS H3PO4|dose escalation
11372545|NCT02217631|Active Comparator|Prednisolone low dose|
11372546|NCT02217631|Active Comparator|Prednisolone high dose|
11372547|NCT02217631|Placebo Comparator|Placebo|
11372548|NCT02217618|Experimental|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
11372549|NCT02217605|Experimental|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) followed by 75 minutes 31P MRS
11372550|NCT02217579|Placebo Comparator|Control|Isocaloric food without the test protein and prebiotic fiber.
11372551|NCT02217579|Experimental|Protein|Dietary protein consumed as two daily servings of 5 grams protein/serving.
11372552|NCT02217579|Experimental|Fiber|Prebiotic fiber consumed as two daily servings of 8 grams protein/serving.
11372553|NCT02217579|Experimental|Protein plus prebiotic fiber|Protein and prebiotic fiber consumed as two daily servings of 5 grams protein/serving plus 8 grams fiber/serving.
11372554|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
11372555|NCT02217553|Experimental|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
11372556|NCT02217540|Experimental|Experimental Group|Experimental Group consist of the physiotherapy standard protocol and active movement plus accessory mobilizations of the humeral head using Mulligan Concept Mobilisation with Movement.
11372557|NCT02217540|Active Comparator|Control Group|Standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
11372558|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
11372559|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
11372560|NCT02217514|Experimental|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
11372561|NCT02217514|Experimental|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
11372562|NCT02217514|Experimental|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
11372563|NCT02217514|Experimental|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
11372564|NCT02217514|Experimental|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
11372565|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
11372566|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
11372567|NCT02217488|Experimental|DG3173|
11372568|NCT02217488|Placebo Comparator|Vehicle|
11372569|NCT02217475|Experimental|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
11372570|NCT02217475|Experimental|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
11372571|NCT02217475|Placebo Comparator|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
11372572|NCT02217462||Pregnant women|
11372573|NCT02217449||HD|Prediction of histology
11372574|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
11372575|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
11372576|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
11372577|NCT02217423|Experimental|Obstructive increased AC|"Patient with obstructive respiratory disease with increased abdominal circumference.
~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
11372578|NCT02217423|Experimental|Obstructive disfunction with normal AC|"Patients with obstructive respiratory disease with normal abdominal circumference.
~Patient with obstructive respiratory disease with increased abdominal circumference.
~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
11372579|NCT02217423|Experimental|Restrictive increased AC|"Patients with restrictive respiratory disease with increased abdominal circumference. chest physiotherapy chest wall expansion.
~The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
11372621|NCT02217072|Experimental|Parents as Tutors|Educational support intervention
11372580|NCT02217423|Experimental|Restrictive disfunction with normal AC|"Patients with restrictive respiratory disease with normal abdominal circumference.
~Chest physiotherapy chest wall expansion. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
11372581|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
11372582|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
11372583|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction]
11372584|NCT02217397|Experimental|OA, CPAPm, combination therapy|
11372585|NCT02217371|Experimental|ADHD patient|
11372586|NCT02217371|Active Comparator|Healthy volunteers|
11372587|NCT02217358|Experimental|NBI endoscopy|150 patients with suspected lesion in larynx and hypopharynx on standard ENT white light endoscopy examination will undergo NBI endoscopy in order to compare the outcomes of these two examination methods
11372588|NCT02217345|Experimental|Growth hormone|Growth hormone (somatropin) administered by daily injection at 0.3 mg daily for women and 0.2 mg daily for men given for the duration of the 6 month study
11372589|NCT02217345|Placebo Comparator|Placebo|Placebo will be administered by daily injection in this double blind study design.
11372590|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
11372591|NCT02217319|Active Comparator|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
11372592|NCT02217319|Placebo Comparator|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
11372593|NCT02217306||Contrast Sensitivity|Determine changes in contrast sensitivity frequences and visual function (visual acuity) after one month of treatment photocoagulation in macular edema
11372594|NCT02217293|Active Comparator|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
11372595|NCT02217293|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
11372596|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
11372597|NCT02217267|Placebo Comparator|Placebo group|Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times
11372598|NCT02217267|Active Comparator|Lidocaine group|Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times
11372599|NCT02217254|Active Comparator|two 3-minute cryoablations|two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure
11372600|NCT02217254|Active Comparator|One 3-minute cryoablation|One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure
11372601|NCT02217241|Experimental|Intervention|Students in the intervention group participated in a one-hour interactive, small-group handoff workshop facilitated by a study investigator. The workshop focused on the importance of specific handoff skills to patient safety.
11372602|NCT02217241|No Intervention|Control|
11372603|NCT02217228|Experimental|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
11372604|NCT02217228|Experimental|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
11372605|NCT02217228|Experimental|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
11372606|NCT02217215||Negative and Referral Cytology Results|CNDS Advanced Cervical Scan Colposcopy
11372607|NCT02217202|Experimental|ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
11372608|NCT02217189|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
11372609|NCT02217189|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
11372610|NCT02217176||endotracheal intubation|
11372611|NCT02217176||laryngeal mask airway|
11372612|NCT02217163|Experimental|Single Arm|The combination therapy of Carfilzomib, cyclophosphamide and dexamethasone (KCyd) will be used to treat eligible patients for up to 6 cycles.This will be followed by an autologous bone marrow transplantation and 2 further consolidation cycles of KCyd. Depending on their disease response, patients will be managed expectantly or be started on maintenance.
11372613|NCT02217150||Metastatic Lesions to the spine|Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
11372614|NCT02217124|Experimental|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
11372615|NCT02217124|Placebo Comparator|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
11372616|NCT02217111|Experimental|voice therapy|
11372617|NCT02217098|Active Comparator|GIC Restorations|Restorations using Glass Ionomer Cement
11372618|NCT02217098|Experimental|Compomer Restorations|Restorations using Compomer
11372619|NCT02217098|Experimental|Carbomer Restorations|Restorations using Glass Carbomer
11372620|NCT02217072|No Intervention|Control|Control
11372622|NCT02217072|Experimental|school intervention|Educational support intervention
11372623|NCT02217059||Prehypertension|Using the JNC7 definition
11372624|NCT02217059||Stage I Hypertension|Using the JNC7 definition
11372625|NCT02217059||Stage II Hypertension|Using the JNC7 definition
11372626|NCT02217046|Experimental|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
11372627|NCT02217046|No Intervention|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
11372628|NCT02217033|Placebo Comparator|Purified Water|"In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.
~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days."
11372629|NCT02217033|Experimental|'R' (Electro-kinetically altered beverage)|"Patients randomized to this arm will begin to consume R (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.
~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days."
11372630|NCT02217020|Experimental|FOLFOXIRI|patients received FOLFOXIRI alone for 4 cycles before surgery.
11372631|NCT02217007|Experimental|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
11372632|NCT02216994|Other|surgery treatment|The patients with a predicting score of more than 5 are diagnosed with HD, and are performed surgery to remove the aganglionic bowel. The patients with a score less than 5 are mostly indicative of HAD, and receive conservative treatments that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments. one stage pull through procedure to remove the dysganglionic bowel segments.
11372633|NCT02216981|Experimental|Intensive Cognitive Behavioural Therapy|Intensive CBT (an average of 12-18 hours of CBT offered in an intensive format, delivered on 2-3 days per week over a period of 3 weeks)
11372634|NCT02216981|Active Comparator|Weekly Cognitive Behavioural Therapy|Weekly CBT (an average of 12-18 hours of CBT delivered in 60-90 minute sessions on a weekly basis)
11372635|NCT02216981|No Intervention|Wait list|Wait list (3 months). Participants randomized to wait list will commence treatment after 3 months, in the treatment condition to which they are re-randomized (either Intensive or Weekly CBT).
11372636|NCT02216968|Experimental|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.
~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
11372637|NCT02216968|Experimental|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.
~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
11372638|NCT02216942|Active Comparator|Vitapex|Endodontic treatment using Vitapex
11372639|NCT02216942|Experimental|Guedes Pinto Paste|Endodontic treatment using Guedes Pinto
11372640|NCT02216916|Experimental|HM781-36B|
11372641|NCT02216903||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
11372642|NCT02216890|Experimental|SGN-CD70A|
11372643|NCT02216877|Placebo Comparator|Placebo|Oral placebo twice daily for 8 weeks. 12 subjects.
11372644|NCT02216877|Experimental|Mablet 360 mg once daily|Oral Mablet 360 mg once daily and oral placebo once daily for 8 weeks. 12 subjects.
11372645|NCT02216877|Experimental|Mablet 360 mg twice daily|Oral Mablet 360 mg twice daily for 8 weeks. 12 subjects.
11372646|NCT02216864|Experimental|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
11372647|NCT02216864|No Intervention|Control|Subjects will receive no intervention control on the other side of the face.
11372648|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
11372649|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
11372650|NCT02216838|Experimental|botulinum toxin A|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
11372651|NCT02216838|Placebo Comparator|Saline Control|This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.
11372652|NCT02216825|Experimental|Delayed release capsule, L. reuteri NCIMB 30242|
11372653|NCT02216825|Experimental|Standard vegetarian capsule, L. reuteri NCIMB 30242|
11372654|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
11372655|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
11372790|NCT02215863|Active Comparator|PCV13 and Fluad|437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
11372656|NCT02216799|Active Comparator|Regular Insulin incorporated in parenteral nutrition|Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk, will be added to parenteral nutrition to run over 24 hours as 80% of the total insulin requirement of the preceding day administered via subcutaneous sliding scale
11372657|NCT02216799|Active Comparator|Insulin glargine|Insulin glargine adminstred at daily night, calculated as 80% of the total insulin requirement of the preceding day from the insulin administered via subcutaneous sliding scale
11372658|NCT02216786|Experimental|Fulvestrant and AZD2014 (continuous)|Experimental arm
11372659|NCT02216786|Active Comparator|Everolimus and Fulvestrant|Comparator arm
11372660|NCT02216786|Active Comparator|Fulvestrant|Control 1
11372661|NCT02216786|Experimental|Fulvestrant +AZD2014 (intermittent)|Experimental arm
11372662|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.
~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
11372663|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.
~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
11372664|NCT02216760|Active Comparator|Ripple Mapping guided VT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to identify conduction channels within the ventricular scar substrate to guide ablation lesions in patients with monomorphic VT.
11372665|NCT02216760|Active Comparator|Conventional VT Ablation|Standard substrate ablation as per local operator preference will be used to guide ablation in the ventricular scar in patients with monomorphic VT.
11372666|NCT02216747|Active Comparator|prednisone 60 mg/meter square Body Surface Aera|A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.
11372667|NCT02216747|Active Comparator|prednisone 45 mg/meter square BSA|B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.
11372668|NCT02216747|Active Comparator|prednisone 30 mg/meter squer BSA|C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.
11372669|NCT02216734|Experimental|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
11372670|NCT02216734|No Intervention|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
11372671|NCT02216721||Non primary aldosteronism|Non primary aldosteronism patients undergoing usual anti hypertensive treatment
11372672|NCT02216721||Primary Aldosteronism|Patients with confirmed primary aldosteronism undergoing treatment
11372673|NCT02216708|Experimental|intravenous fluid for rehydration rapidly over 6 hours|intravenous fluid for rehydration rapidly over 6 hours
11372674|NCT02216708|Experimental|receive slow rehydration recommended by WHO (12 hours)|receive intravenous fluid followed by ORS (slow rehydration recommended by WHO) over 12 hours
11372675|NCT02216669|Experimental|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
11372676|NCT02216656|Placebo Comparator|Plascebo|
11372677|NCT02216656|Experimental|KHK7580 low dose|
11372678|NCT02216656|Experimental|KHK7580 middle dose|
11372679|NCT02216656|Experimental|KHK7580 high dose|
11372680|NCT02216656|Active Comparator|KRN1493|
11372681|NCT02216643|Experimental|thrombectomy|mechanical thrombectomy with stentriever Solitaire FR® and/or thromboaspiration with Penumbra System® in patients with large vessel occlusion in cerebral anterior circulation vessels
11372682|NCT02216643|No Intervention|best medical treatment|best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion
11372683|NCT02216630|Experimental|Adipose-Derived Stem Cell (ADSC) Therapy|This arm, as the sole arm, will consist of the ADSC treatment procedure. Intervention will consist of Adipose Derived Stem Cell (ADSC) Therapy
11372684|NCT02216617|Experimental|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)
~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)
~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
11372685|NCT02216604|Experimental|Intervention group|Multimodal Exercise intervention (console-based training, age-specific resistance training and body awareness)
11372686|NCT02216604|No Intervention|Control|age, disease and gender matched
11372791|NCT02215863|Active Comparator|Fluad alone|437 Fluad recipients: one vaccine injection administered on Day 0
11372792|NCT02215863|Active Comparator|PCV13 alone|437 PCV13 recipients: one vaccine injection administered on Day 0
11372793|NCT02215850|Experimental|SLC-0111|
11372869|NCT02215408|No Intervention|Control|Patient received usual care from the provider in the local clinic.
11372687|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
11372688|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
11372689|NCT02216578|Experimental|cabozantinib|cabozantinib 60 mg oral daily
11372690|NCT02216565|Other|Medical treatment|Conventional medical non-interventional treatment
11372691|NCT02216565|Other|Endovascular treatment|Conventional medical treatment plus endovascular treatment
11372692|NCT02216552|Experimental|Resveratrol|Intervention: Resveratrol Oral supplementation of resveratrol (ResVida) 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days.
11372693|NCT02216552|Placebo Comparator|Placebo|Intervention: Placebo Control Oral supplementation of placebo twice daily (with breakfast and dinner) for a total duration of 30 days.
11372694|NCT02216539|Experimental|Self-hypnosis|Patients trained to self-hypnosis before surgery
11372695|NCT02216539|Active Comparator|Usual pain management|Patients receiving the usual post-operative pain management protocols
11372696|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
11372697|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
11372698|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
11372699|NCT02216513|Active Comparator|Desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
11372700|NCT02216513|Placebo Comparator|placebo|normal saline IV for 4 hours for 5 consecutive days
11372701|NCT02216500|Experimental|Ketogenic Therapy|Ketogenic Therapy will be administered.
11372702|NCT02216487|Experimental|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
11372703|NCT02216474|Sham Comparator|Sham transcranial direct current stimulation (frontal cortex)|Transcranial direct current stimulation will be ramped up over 60 seconds and then ramped down gradually to encourage blinding to condition.
11372704|NCT02216474|Experimental|Anodal transcranial DC stimulation (frontal cortex)|Anodal transcranial direct current stimulation to prefrontal cortex for approximately 15 minutes plus ramp up and down time
11372705|NCT02216461|Experimental|Low dose of BIBW 2948 BS|
11372706|NCT02216461|Experimental|Medium dose of BIBW 2948 BS|
11372707|NCT02216461|Experimental|High dose of BIBW 2948 BS|
11372708|NCT02216461|Placebo Comparator|Placebo|
11372709|NCT02216448|Other|simulator training|Training knee simulator in Lab
11372710|NCT02216448|Other|OR training|Training in the OR - 2 knee arthroscopies.
11372711|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
11372712|NCT02216409|Experimental|Treatment (Hu5F9-G4)|Hu5F9-G4 monotherapy
11372713|NCT02216383|Experimental|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
11372714|NCT02216383|Active Comparator|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
11372715|NCT02216383|Active Comparator|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
11372716|NCT02216370||Cryptogenic Stroke or TIA|
11372717|NCT02216370||Healthy Volunteers|Healthy Volunteers as comparative group adjusted to investigated group by age and gender
11372718|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
11372719|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
11372720|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
11372721|NCT02216331|Experimental|Group 1 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
11372722|NCT02216331|Experimental|Group 1 TMC207 and rifapentine|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifapentine administered as 4 tablets of 150 mg per tablet on each of Study Days 20-41.
11372723|NCT02216331|Experimental|Group 2 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
11372724|NCT02216331|Experimental|Group 2 TMC207 and rifampicin|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifampicin administered as 4 capsules of 150 mg per capsule on each of Study Days 20-41.
11372725|NCT02216318|Placebo Comparator|red light|red light during the whole day
11372726|NCT02216318|Active Comparator|Blue light|Blue light during early day
11372727|NCT02216305|Active Comparator|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
11372728|NCT02216305|Active Comparator|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
11372729|NCT02216292||Preterm Single Donor Milk Group|The prospective study group = preterm single donor milk group (PSDM-Group) from June 2012 - April 2013
11372730|NCT02216292||Control Group|Retrospective control group receiving no donor milk = control group from March 2011 - May 2012
11372731|NCT02216279|Experimental|Pulmonary Hypertension Patients|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
11372732|NCT02216279|Active Comparator|Control Non-Smoking Participants|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
11372733|NCT02216266|Active Comparator|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
11372734|NCT02216266|Placebo Comparator|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
11372735|NCT02216253|Active Comparator|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|The combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract will be administered in tablet twice a day 7 days before and after surgery
11372736|NCT02216253|Placebo Comparator|Placebo|Placebo tablet twice a day 7 days before and after surgery
11372737|NCT02216240|Active Comparator|Accident and emergency|Patients randomised to A&E were treated as per standard care and given no information other than that pertaining to the study.
11372738|NCT02216240|Experimental|Paramedic|Treatment at the scene by a paramedic. Valsalva manoeuvre with subsequent administration of 6mg and 12mg of adenosine unless the supraventricular tachycardia terminated. Patients were taken to accident and emergency if the tachycardia did not terminate, restarted, or the patient had continuing symptoms, a persistently abnormal ECG (other than T wave inversion) or was heamodynamically unstable. Prior to discharge from the ambulance patients received an information pack and a referral letter for their GP to refer them to an arrhythmia clinic.
11372739|NCT02216227|Experimental|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):
~ecolonize with intranasal Mupirocin ointment BID x 5 days
~hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)
~efazolin plus Vancomycin (no Vanco for MSSA positive)
~Patient has a known negative Staph aureus pre-op screening result:
~HG bathing (night before & morning of surgery using wipes or liquid)
~efazolin
~Patient was not screened or results are unknown at time of surgery:
~ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)
~HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before & morning of surgery using wipes or liquid)
~efazolin plus Vancomycin"
11372740|NCT02216214|Placebo Comparator|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
11372741|NCT02216214|Experimental|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
11372742|NCT02216188|Experimental|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
11372743|NCT02216188|Experimental|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
11372744|NCT02216188|Other|Control|Untreated control group
11372745|NCT02216175|Experimental|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
11372746|NCT02216175|Active Comparator|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
11372747|NCT02216175|Placebo Comparator|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
11372748|NCT02216162|Experimental|A: Interventional adapted physical activity + enhanced geriatr|Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment. Weekly Taï-Chi exercises.
11372749|NCT02216162|Other|Arm B: control|Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
11372750|NCT02216149|Experimental|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
11372751|NCT02216149|Active Comparator|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
11372752|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
11372753|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
11372754|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
11372755|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
11372756|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
11372757|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
11372758|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
11372759|NCT02216097|Experimental|Treatment|
11372760|NCT02216097|Placebo Comparator|Placebo|
11372761|NCT02216084|Experimental|Recombinant ADAMTS13|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
11372762|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
11372763|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
11372764|NCT02216058|Experimental|NOYA|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
11372765|NCT02216045|Active Comparator|Peginterferon ,Ribavirin|drug :Peginterferon, Ribavirin,
11372766|NCT02216045|Experimental|Peginterferon, Ribavirin, camel milk|drug :Peginterferon, Ribavirin, camel milk
11372767|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
11372768|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
11372769|NCT02216019||study cohort|Patient undergoing planned heart surgery with cardiopulmonary bypass
11372770|NCT02216006|Active Comparator|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.
~Initial ventilatory settings are also done in a conventional manner."
11372771|NCT02216006|Active Comparator|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.
~Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver."
11372772|NCT02215993|Active Comparator|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
11372773|NCT02215993|Active Comparator|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
11372774|NCT02215980|Experimental|A|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.
~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
11372775|NCT02215980|Experimental|B|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21
~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.
~Maintenance until progression or intolerance:
~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
11372776|NCT02215967|Experimental|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
11372777|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
11372778|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
11372779|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
11372780|NCT02215941|Experimental|TV-45070 7%|twice daily topical application to 7% body surface area for 7.5 days (15 applications)
11372781|NCT02215941|Experimental|TV-45070 21%|twice daily topical application to 21% body surface area for 7.5 days (15 applications)
11372782|NCT02215941|Experimental|TV-45070 53%|twice daily topical application to 53% body surface area for 7.5 days (15 applications)
11372783|NCT02215941|Placebo Comparator|Placebo|
11372784|NCT02215928||Ancillary-correlative (tumor genomic profiling)|Tissue samples are collected at baseline and blood for liquid biopsy is collected at baseline and every 6-8 weeks during active treatment. Tissue samples are analyzed via sequencing for tumor genomic profiling.
11372785|NCT02215915|Experimental|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
11372786|NCT02215915|Active Comparator|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
11372787|NCT02215902|Experimental|Hemopurifier|Affinity plasmapheresis
11372788|NCT02215889|Experimental|Surgery|
11372789|NCT02215876|Experimental|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
11372794|NCT02215837|Sham Comparator|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
11372795|NCT02215837|Experimental|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
11372796|NCT02215824|Experimental|BIWH 3|in escalating doses
11372797|NCT02215824|Placebo Comparator|Placebo|
11372798|NCT02215811|Experimental|Mesenchymal stromal cells|
11372799|NCT02215798||Cymbalta|
11372800|NCT02215785|Experimental|kiwifruit cohort|Patients that presented at Primary Care Centres with registered -Roma III criteria based- constipation and who accepted to participate in the study were followed-up for two weeks before intervention and three weeks under 3-daily kiwifruit intake.
11372801|NCT02215772|Experimental|BI 44370 BS|200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity
11372802|NCT02215759|Experimental|BI 44370 TA|
11372803|NCT02215759|Placebo Comparator|Placebo|
11372804|NCT02215746|Experimental|Treatment A|BI 44370 TA drinking solution 100 mg fasted
11372805|NCT02215746|Experimental|Treatment B|BI 44370 TA drinking solution 100 mg fed
11372806|NCT02215746|Experimental|Treatment C|BI 44370 TA drinking solution 200 mg fasted
11372807|NCT02215746|Experimental|Treatment D|BI 44370 TA drinking solution 200 mg fed
11372808|NCT02215746|Experimental|Treatment E|100 mg BI 44370 BS as two tablets 50 mg fasted
11372809|NCT02215746|Experimental|Treatment F|100 mg BI 44370 BS as two tablets 50 mg fed
11372810|NCT02215733||Patients prescribed antihypertensives|
11372811|NCT02215720|Experimental|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
11372812|NCT02215707|Experimental|Group 1|"Group 1: 5 doses of 2.7x10^5 PfSPZ Vaccine; homologous 3D7 CHMI
~Grp 1 (n=15) gets 5 doses of 270,000 PfSPZ per dose (4 doses at 4 wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 and 2 start immunizations together.
~1 subj in each of Grps 1 and 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/Grp 2 pilot subjects: 1st subject will be immunized, observed on site for minimum 1 hr; the 2nd subject may be immunized, will also be observed for minimum 1 hr. If no safety concerns are identified after 24 hrs that trigger the stopping rules, then rest of subjects in Grps 1 and 2 will be immunized.
~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (Pf3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
11372813|NCT02215707|Experimental|Group 2|"Grp 2: 5 doses of 2.7x10^5 PfSPZ Vaccine; heterologous 7G8 CHMI
~Grp 2 (n=15) gets 5 doses of 270,000 PfSPZ/dose (4 doses at 4wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 / 2 start immunizations together.
~1 subj in each of Grps 1 / 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/ 2 pilot subj: 1st subj will be immunized, observed on site for min 1 hr; 2nd subj may be immunized, will also be observed for min 1 hr. If no safety concerns after 24 hrs that trigger stopping rules, then rest of Grps 1 / 2 will be immunized.
~Approx 3 wks after final dose, Grps 1/3 have homologous CHMI; 2-3 days later, Grp 2 will undergo heterologous CHMI (Pf7G8) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1/3 have 2nd homologous CHMI; 2-3 days later, Grp 2 will undergo 2nd heterologous CHMI (7G8 strain) with 6 Infectivity Controls. Subj will be followed for 8 wks after last CHMI for safety purposes."
11372814|NCT02215707|Experimental|Group 3|"Grp 3 (n=15) will receive 3 doses by DVI of 450,000 PfSPZ/dose (of PfSPZ Vaccine) at 8 wk intervals (starting approx. 4 wks after Grps 1 and 2 get 1st immunization).
~3 subjects in Grp 3 will be immunized approx 24 hrs prior to rest of grp (pilot subjects). The 3 subjects will be immunized sequentially with min 2 hr observation period between subjects (and a 2 hr observation of 3rd subject as well). If no safety concerns identified in pilot subjects after 24 hours that trigger the stopping rules, the rest of subjects in Grp 3 will be immunized as scheduled.
~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
11372815|NCT02215707|No Intervention|CHMI Controls.1|n = 6, infectivity controls for 1st homologous CHMI (3D7) occurring approximately 3 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
11372816|NCT02215707|No Intervention|CHMI Controls.2|n = 6, infectivity controls for 1st heterologous CHMI (7G8) occurring approximately 3 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
11372817|NCT02215707|No Intervention|CHMI Controls.3|n = 6, infectivity controls for 2nd homologous CHMI (3D7) occurring approximately 24 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
11372818|NCT02215707|No Intervention|CHMI Controls.4|n = 6, infectivity controls for 2nd heterologous CHMI (7G8) occurring approximately 24 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
11372819|NCT02215694|Experimental|probiotic group|consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
11372820|NCT02215694|Placebo Comparator|placebo group|consumed 2g of powder daily without probiotics
11372821|NCT02215681|Experimental|acupuncture|acupuncture treatment
11372822|NCT02215681|No Intervention|standard treament|watchful waiting
11372823|NCT02215668|No Intervention|No physical exercise|Women are never subjected to any exercise prior to mammography.
11372824|NCT02215668|Experimental|Physical exercise (Upper limb)|Women will be subjected to physical exercise on upper limb prior to mammography.
11372825|NCT02215668|Active Comparator|Group 2|Women are subjected to physical exercise in the lower limbs prior to mammography
11372826|NCT02215655|Active Comparator|Motivational interviewing|Motivational interviewing counselling will be administered to the subjects
11372827|NCT02215655|No Intervention|No intervention: control group|No motivational interviewing counselling will be administered to the subjects
11372828|NCT02215629|Experimental|Experimental VS4718|Oral VS-4718 administered BID during a 28 day cycle.
11372829|NCT02215616|Placebo Comparator|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
11372830|NCT02215616|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
11372831|NCT02215616|Experimental|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
11372832|NCT02215616|Experimental|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.
~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
11372833|NCT02215603|No Intervention|Prolonged sitting|9 h of prolonged sitting
11372834|NCT02215603|Experimental|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
11372835|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
11372836|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
11372837|NCT02215590|Experimental|Re-Step|"The system consists of a pair of special shoes whose sole height and angles change in a specific given order, thereby facilitating motor learning and problem solving in real time.
~This unpredictable change will introduce a situation of necessary adaptation to keep balance."
11372838|NCT02215577|Experimental|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
11372839|NCT02215577|Active Comparator|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
11372840|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
11372841|NCT02215551||Study Group|"Younger than 90 years old. no communication barriers (e.g., English speaking, household telephone) Affirmative response to each of the three following questions: a) Do patients have pain, weakness, numbness, or tingling in their legs when walking standing? b) Does this pain, weakness, numbness or tingling in their legs interfere with their daily activities? c) Have patients tried at least one non-surgical treatment for their leg symptoms (e.g., physical therapy, pain medications, spinal injection)? Have been scheduled for surgery on lower back for a condition called lumbar spinal stenosis.
~Whom have non degenerative causes of LSS such as tumor, infection, trauma, hemorrhage, or epidural lipomatosis, Prior lumbar spinal surgery, spondylolisthesis with spinal instability, significant cognitive impairment."
11372842|NCT02215538|Experimental|OROS methylphenidate|This was a 4-week double-blind arm. Medication was initiated at 18 mg/day and increased every 2 or 3 days by 9 mg based on treatment response and side effects. Maximum dose - 90 mg/day. Patients were seen weekly. Generally a stable dose was seen in 2 weeks and maintained the last 2 weeks of the arm. Side effects were assessed at each visit.
11372843|NCT02215538|Placebo Comparator|placebo|This arm was identical to the active medication arm except that placebo replaced the active medication.
11372844|NCT02215525|Experimental|UVA and Herbal|Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
11372845|NCT02215525|Experimental|Herbal|Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
11372846|NCT02215512|Experimental|RRx-001 + WBRT|RRx-001 administered intravenously twice a week (10, 17, 33, 55 mg) in subjects with brain metastases receiving whole brain radiation therapy (WBRT).
11372847|NCT02215499|Active Comparator|Xyrem®|Oral suspension
11372848|NCT02215499|Experimental|JZP-386|Oral suspension
11372849|NCT02215499|Placebo Comparator|Placebo|Oral suspension
11372850|NCT02215473|Experimental|gingivitis mouth rinse|
11372851|NCT02215473|Experimental|periodontitis mouth rinse|
11372852|NCT02215473|Active Comparator|gingivitis no mouth rinse|
11372853|NCT02215473|Active Comparator|periodontitis no mouth rinse|
11372854|NCT02215460|Experimental|Full-mouth scaling (FMS)|
11372855|NCT02215460|Experimental|FMS chlorhexidine rinse|
11372856|NCT02215460|Experimental|FMS azithromycin tablets|
11372857|NCT02215460|Placebo Comparator|FMS placebo rinse|
11372858|NCT02215460|Experimental|Quadrant scaling (QS)|
11372859|NCT02215460|Experimental|QS chlorhexidine rinse|
11372860|NCT02215460|Experimental|QS azithromycin tablets|
11372861|NCT02215460|Placebo Comparator|QS placebo tablets|
11372862|NCT02215460|Placebo Comparator|FMS placebo tablets|
11372863|NCT02215460|Placebo Comparator|QS placebo rinse|
11372864|NCT02215447|Experimental|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
11372865|NCT02215434|Placebo Comparator|Biolipid B2 (blanked/placebo)|"The study is a single-center, single-blind, placebo-controlled, parallel group trial.
~It consists of a 4-week screening period plus a 12-week treatment phase. At the screening visit, all participants underwent a physical examination including vital signs and breast and pelvic examination.
~They were randomly assigned in a 1:1 ratio to receive a transdermal vehicle biolipid B2 (identical placebo) provided by Evidence Pharmaceuticals Inc, SP,BRAZIL.
~The testosterone and placebo emulsion were alcohol-free matrixes that were applied topically to the forearm daily for the period of 12 weeks."
11372866|NCT02215434|Active Comparator|Testosterone, Transdermal, Behavior|Testosterone 0.5%, daily, 3 months
11372867|NCT02215421|Experimental|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
11372868|NCT02215421|No Intervention|No game play|No intervention control.
11372870|NCT02215408|Experimental|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
11372871|NCT02215395|Experimental|CVR treatment cycle|Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
11372872|NCT02215382|Active Comparator|sugammadex|
11372873|NCT02215382|Active Comparator|neostigmine + atropine|
11372874|NCT02215369|Experimental|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
11372875|NCT02215356|Active Comparator|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5, cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles, while chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times). Progressive patients will be administered oral icotinib 125 mg three times daily.
11372876|NCT02215356|Experimental|Icotinib with concurrent radiotherapy|Chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times), while icotinib 125mg three times daily (375 mg per day) by mouth. Maintenance icotinib will be administered after radiotherapy. Progressive patients will receive chemotherapy, using the platinum-based two-drug chemotherapy regimen.
11372877|NCT02215343|Experimental|High fibre diet (wheat bran extract)|
11372878|NCT02215343|Experimental|High PUFA diet (fish oil supplement)|
11372879|NCT02215330|Placebo Comparator|Sugar pill|"Maltodextrin filled into capsules.
~1 Pill starting dosage
~Follow-up visits (every two weeks, beginning at week 4):
~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.
~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.
~If no subretinal fluid is present and the patient takes no medication everything stays the same.
~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
11372880|NCT02215330|Experimental|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.
~1 Pill starting dosage
~Follow-up visits (every two weeks, beginning at week 4):
~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.
~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.
~If no subretinal fluid is present and the patient takes no medication everything stays the same.
~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
11372881|NCT02215317||OSA group|Patients found to have OSA based on an overnight sleep study
11372882|NCT02215317||Non-OSA group|Patients found not to have OSA based on an overnight sleep study
11372883|NCT02215304|Active Comparator|Bifidobacterium longum R0033|Bifidobacterium longum ssp infantis R0033, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
11372884|NCT02215304|Active Comparator|Lactobacillus helveticus R0052|Lactobacillus helveticus R0052, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
11372885|NCT02215304|Active Comparator|Bifidobacterium bifidum R0071|Bifidobacterium bifidum R0071, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
11372886|NCT02215304|Placebo Comparator|Placebo|potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
11372887|NCT02215291||Patients undergoing EGD or esophagoscopy|The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance
11372888|NCT02215278|Experimental|low phytic acid bean (lpa variety)|
11372889|NCT02215278|Experimental|high iron biofortified bean variety|
11372890|NCT02215278|Experimental|normal iron, normal phytic acid bean|
11372891|NCT02215265|No Intervention|A: No adjuvant treatment|Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.
11372892|NCT02215265|Active Comparator|B1: Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.
~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
11372893|NCT02215265|Experimental|B2: Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.
~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
11372894|NCT02215265|Active Comparator|C1: Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.
~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
11372925|NCT02215057|Experimental|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
11372926|NCT02215057|Experimental|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
11372927|NCT02215044|Experimental|BI 2536 in combination with gemcitabine|
11372895|NCT02215265|Experimental|C2: Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).
~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
11372896|NCT02215252|Experimental|PF-05089771|
11372897|NCT02215252|Experimental|Placebo|
11372898|NCT02215252|Experimental|Pregabalin|
11372899|NCT02215252|Experimental|PF-05089771 + Pregabalin|
11372900|NCT02215239|Experimental|Working type A & Workplace intervention|Participants: Workers tend to be seated during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
11372901|NCT02215239|No Intervention|Working type A & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
11372902|NCT02215239|Experimental|Working type B & Workplace intervention|Participants: Workers tend to be standing during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
11372903|NCT02215239|No Intervention|Working type B & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
11372904|NCT02215213|Active Comparator|Intervention Group|Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
11372905|NCT02215213|Active Comparator|Arm 2 intervention group|Arm 2 is receiving vitamin D supplementation in 4000/IU per day
11372906|NCT02215213|Active Comparator|Arm 3 control group|Arm 3 is receiving vitamin D supplementation in 400 IU/day
11372907|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.
~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
11372908|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.
~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
11372909|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
11372910|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
11372911|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
11372912|NCT02215174|Experimental|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
11372913|NCT02215174|Experimental|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
11372914|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11372915|NCT02215148||Brain injured patients with hyponatremia|Patients with acute brain injury who develop hyponatremia and are administered tolvaptan via the nasogastric tube, deemed necessary by the primary medical team.
11372916|NCT02215135|Experimental|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
11372917|NCT02215122|Experimental|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
11372918|NCT02215122|Experimental|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
11372919|NCT02215122|Experimental|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
11372920|NCT02215109||BRVO, Retinal vessel diameter|The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
11372921|NCT02215096|Experimental|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
11372922|NCT02215096|Experimental|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
11372923|NCT02215083|Experimental|L-Glutamine|All patients will receive 20-30 grams of l-glutamine daily for 9 weeks (+/- 1 week)
11372924|NCT02215070|Experimental|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
11372937|NCT02214992|Experimental|Telmisartan/Ramipril|Fixed dose combination tablet
11372938|NCT02214992|Active Comparator|Telmisartan + Ramipril capsule|
11372939|NCT02214992|Active Comparator|Telmisartan + Ramipril tablet|
11372940|NCT02214979|Experimental|Telmisartan/Ramipril|
11372941|NCT02214979|Active Comparator|Telmisartan + Ramipril capsule|
11372942|NCT02214979|Active Comparator|Telmisartam + Ramipril tablet|
11372943|NCT02214966|Experimental|Telmisartan/Ramipril, fed|
11372944|NCT02214966|Active Comparator|Telmisartan/Ramipril, fasted|
11372945|NCT02214953|Experimental|BI 11634 ER formulation A|
11372946|NCT02214953|Experimental|BI 11634 ER formulation B|
11372947|NCT02214953|Experimental|BI 11634 ER formulation M|
11372948|NCT02214953|Experimental|BI 11634 ER formulation C|
11372949|NCT02214953|Active Comparator|BI 11634 IR tablet|
11372950|NCT02214940|Experimental|BI 11634|multiple rising dose
11372951|NCT02214940|Placebo Comparator|Placebo|
11372952|NCT02214927|Experimental|BI 11634 single rising dose|tablet
11372953|NCT02214927|Experimental|BI 11634 cross-over|sequence: 1. tablet 2. drinking solution
11372954|NCT02214914|Experimental|BI 11634 drinking solution|single rising dose
11372955|NCT02214914|Placebo Comparator|Placebo|
11372956|NCT02214914|Experimental|BI 11634 tablet|
11372957|NCT02214901|Experimental|BIBW 2948 BS in single rising doses|
11372958|NCT02214901|Placebo Comparator|Placebo|
11372959|NCT02214888|Experimental|BIRB 796 BS, low dose|
11372960|NCT02214888|Experimental|BIRB 796 BS, high dose|
11372961|NCT02214888|Placebo Comparator|Placebo|
11372962|NCT02214875|Experimental|CQI/BTS|"Experimental: CQI/BTS
~CQI/BTS interventions will be applied through rapid structured cycles of data collection, testing of solutions and review of changes will be done. At each site, Quality Improvement Teams (QIT) will be established among facility staff. Local Government/State QI teams will provide oversight function of facility based QI initiatives. Break Through Collaborative Series (BTS) will hold quarterly in each study state at a central location with participants from intervention sites. Sessions will provide opportunity for teams to learn from each other; adapt and implement changes using the Plan-Do-Study-Act (PDSA) model. Process indicators will be used to measure quality improvement from the intervention sites and collaboratives."
11372963|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
11372964|NCT02214862|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
11372965|NCT02214849|Experimental|LATCH Intervention|Women enrolled in the WIC program and receiving breastfeeding peer counseling services will receive text messages to support them with their breastfeeding intentions. They will start receiving automated text messages starting in pregnancy and continuing throughout the first 6 months after giving birth. Messaging during pregnancy will emphasize what to expect in the hospital, the onset of lactation, skin-to-skin contact with baby, early and often breastfeeding in post-partum period, milk transfer (suck & swallow), positioning (with links), common breastfeeding problems and how to seek help. Throughout the study, participants will be able to respond to automated text messages with specific questions that will be received and answered by their WIC program peer counselors. Texting will also have prompts to respond occasionally (at minimum once every two weeks) to ensure that phone is still in service and that the participant in the intervention arm are receiving intervention.
11372966|NCT02214836|Experimental|Kidney stones|"Device: Verasonics Data Acquisition System (VDAS)
~Other Names:
~Verasonics Data Acquisition System (VDAS) Verasonics Ultrasound Engine Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified.
~Subjects in this arm will be imaged by ultrasound by the VDAS. Stone location and size will be determined and compared to clinical determination of stone location and size."
11372967|NCT02214823|Experimental|FES-Cycling|"Timeframe: Within 72 hours of ICU admission. Program: Standard care physiotherapy AND up to one hour of supine cycling daily using a cycle ergometer (RT300 supine model Restorative Therapies, Ltd or Letto 300.) attached to a six channel stimulator (SAGE) and 2 additional RT50 wireless stimulator channels.
~One leg will undergo cycling alone without the electrodes turned on (sham) and the other leg will undergo cycling and muscle stimulation. Electrodes will be placed on all major lower limb muscles. Intervention will be provided individually and supervised by a physiotherapist in ICU only. Duration /Intensity: Up to 1 hour at least 5 times a week for 28 days or ICU discharge, if 20 sessions have not occurred at this time, intervention will continue until this is achieved. Intensity of muscle stimulation will be delivered at a level able to cause visible muscle contractions, confirmed by palpation.
~A subgroup of 10 individuals will be involved in biomarker analyses."
11372968|NCT02214823|Active Comparator|Standard Care|"Both groups will receive usual medical and nursing care in the ICU and ward. Both groups (control and intervention) will receive standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
~A subgroup of 10 individuals will be involved in biomarker analyses. This will involve collection of muscle biopsy, blood and urine analyses at baseline and ICU discharge."
11372969|NCT02214810|Active Comparator|Control- Marcain|Group 1 will receive non-liposomal bupivacaine introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
11372970|NCT02214810|Experimental|Experimental- Exparel|Group 2 will receive a mixture of non-liposomal bupivacaine and Exparel introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
11372971|NCT02214797|Other|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D
~Control lens : Lotrafilcon B and Senofilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
11373012|NCT02214589|Active Comparator|Facilitated Tucking and NNS|Facilitated tucking and NNS
11373232|NCT02213172|Experimental|Lactobacillus paracasei HA-196|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
11373233|NCT02213172|Placebo Comparator|Placebo|1 capsule daily for 8 weeks
11372972|NCT02214797|Other|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D
~Control lens : Lotrafilcon B and Senofilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
11372973|NCT02214797|Other|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D
~Control lens : Lotrafilcon B and Senofilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
11372974|NCT02214797|Other|Non-presbyopic group|"18 to 39 years old No Add
~Control lens : Lotrafilcon B and Etafilcon A
~Test lens: Etafilcon A
~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
11372975|NCT02214784|Active Comparator|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
11372976|NCT02214784|Placebo Comparator|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
11372977|NCT02214771||1: CDI in patients treated with fidaxomicin|Diagnosed with a CDI and treated with fidaxomicin
11372978|NCT02214771||2: CDI in patients receiving treatment other than fidaxomicin|Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)
11372979|NCT02214758|Other|Dietary counseling|
11372980|NCT02214758|Other|Oral health counseling|
11372981|NCT02214758|No Intervention|nutrition no counseling|
11372982|NCT02214758|No Intervention|oral health no counseling|
11372983|NCT02214745||Mentally retarded Israeli Arab children|
11372984|NCT02214745||Israeli Arab children with cerebral palsy|
11372985|NCT02214745||Israeli Jewish children with cerebral palsy|
11372986|NCT02214745||Mentally retarded Israeli Jewish children|
11372987|NCT02214732|Experimental|MBCT + Treatment as Usual (TAU)|"Behavioural: Mindfulness Based Cognitive Therapy
~Participants in the MBCT group attend an 8 week course of a modified MBCT program for pregnant women, delivered by a licensed clinical psychologist."
11372988|NCT02214732|No Intervention|Treatment as Usual (TAU)|Participants in the TAU group access community resources for pregnant women experiencing psychological distress.
11372989|NCT02214719|Experimental|Baseline observation for EASI-IDM use|Baseline observation period to gather information on current practice about diabetes care
11372990|NCT02214706|Experimental|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
11372991|NCT02214706|Experimental|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
11372992|NCT02214706|Experimental|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
11372993|NCT02214706|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
11372994|NCT02214693|Experimental|Group 1(Severe decrease in GFR)|Severe decrease in GFR
11372995|NCT02214693|Experimental|Group 2(Moderate decrease in GFR)|Moderate decrease in GFR
11372996|NCT02214693|Experimental|Group 3(Mild decrease in GFR)|Mild decrease in GFR
11372997|NCT02214693|Experimental|Group 4(Normal GFR)|Normal GFR
11372998|NCT02214680|Experimental|Combination of Brimonidine and Timolol|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
11372999|NCT02214667|Experimental|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
11373000|NCT02214667|Active Comparator|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
11373001|NCT02214654||ticagrelor，clopidogrel，antiplatelet drugs|
11373002|NCT02214641|Experimental|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
11373003|NCT02214641|Active Comparator|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
11373004|NCT02214628|Experimental|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
11373005|NCT02214628|Experimental|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
11373006|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
11373007|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
11373008|NCT02214602|Experimental|Study group(Epirubicin)|in this arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
11373009|NCT02214602|No Intervention|Control group|in this arm -control group- : patients will not receive immediate intravesical instillation of of epirubicin after compete transurethral resection of bladder tumor.
11373010|NCT02214589|Active Comparator|Oral glucose and NNS|Oral glucose and NNS
11373011|NCT02214589|Active Comparator|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
11373521|NCT02211170|Experimental|BIBR 796 BS, high dose|
11373013|NCT02214563|Active Comparator|Thrice-weekly cholecalciferol|Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
11373014|NCT02214563|Active Comparator|Monthly cholecalciferol|Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
11373015|NCT02214563|Placebo Comparator|Thrice-weekly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
11373016|NCT02214563|Placebo Comparator|Monthly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
11373017|NCT02214550|No Intervention|Pain Discovery Aim|"255 Reproductive age women (18-45) will be identified and divided into 5 groups
~Healthy Controls
~Chronic Pain (Positive Controls)
~Dysmenorrhea (D)
~Dysmenorrhea with Cross Organ Sensitization (D+COS)
~Painful bladder syndrome (PBS)/interstitial cystitis (IC)
~After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
11373018|NCT02214550|No Intervention|D+COS-no OC|For Aim #2, ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
11373019|NCT02214550|Active Comparator|D+COS-cyclic microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
11373020|NCT02214550|Active Comparator|D+COS-continuous microgestin 1/20|For Aim #2, 26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
11373021|NCT02214550|Active Comparator|PBS-continuous microgestin 1/20|For Aim #2, 26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. Aim #1 testing will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
11373022|NCT02214537|Experimental|MACS|Patients with MACS Selection
11373023|NCT02214524|Experimental|Bair hugger forced air warming therapy|Use of Bair Hugger forced-air warming system perioperatively to keep patient normothermia
11373024|NCT02214524|No Intervention|conventional warming care|conventional warming care
11373025|NCT02214511||MDD patients|emotional facial stimuli cyberball game
11373026|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
11373027|NCT02214498|Active Comparator|Enalapril/hydrochlorothiazide|This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
11373028|NCT02214498|Placebo Comparator|Placebo|This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
11373029|NCT02214485|Experimental|integrated care (IC)|Subjects will receive such care twice weekly for 12 weeks.
11373030|NCT02214485|Experimental|lower extremity strength training (LEST)|Subjects will receive training twice weekly for 12 weeks
11373031|NCT02214472|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
11373032|NCT02214472|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
11373033|NCT02214459|Experimental|mhealth counseling|DASH Mobile mhealth enhanced coaching
11373034|NCT02214446||primary caregivers of children newly diagnosed with cancer|Explore Factors related to Truth Telling in Primary Caregivers of Children Newly Diagnosed with Cancer
11373035|NCT02214433|Experimental|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
11373036|NCT02214433|Experimental|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
11373037|NCT02214433|Experimental|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
11373038|NCT02214433|Experimental|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
11373039|NCT02214433|Placebo Comparator|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
11373040|NCT02214433|Experimental|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
11373041|NCT02214433|Experimental|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
11373042|NCT02214433|Experimental|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
11373043|NCT02214433|Experimental|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
11373044|NCT02214433|Experimental|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
11373045|NCT02214433|Experimental|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
11373046|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
11373047|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
11373136|NCT02213783|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 2-5 days
11373048|NCT02214407|Experimental|ARM A: DECITABINE (DACOGEN)|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days.
~Allopurinol, 300mg/d, will be started at the time of inclusion; hydration during treatment will be administered to all patients. In (the rare) case of necessity, prophylactic anti-emetics could be given.
~Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L."
11373049|NCT02214407|Experimental|ARM B: HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.
~Dose escalation will be performed by steps of 0.5 g/d, up to 4 g/d, if the WBC has been reduced by less than 20% and remains > 15 G/L. HY will then be adapted to maintain a WBC count between 5 and 10 G/L. HY will be lowered if platelets decrease by > 30 X 109/L (if initially below 100 X 109L). HY will be discontinued in cases of grade 4 thrombocytopenia or neutropenia, and reintroduced at a lower dose after recovery to grade ≤ 3. Persistent grade 4 thrombocytopenia or neutropenia after a 4 week discontinuation will mandate bone marrow evaluation."
11373050|NCT02214394|Experimental|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
11373051|NCT02214381|Active Comparator|Mycet/Cyclophosphamid|4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile.
11373052|NCT02214381|Active Comparator|Myocet/Cyclophosphamide/Paclitaxel|2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile.
11373053|NCT02214368|Experimental|NIV bundle group|early use of NIV, and combination fiberoptic bronchoscopy and sedation
11373054|NCT02214368|Other|Conventional treatment group|standard supplemental oxygen, and conventional application of noninvasive ventilation.
11373055|NCT02214342|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
11373056|NCT02214342|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
11373057|NCT02214329|Experimental|Sensor-based exercise training|The intervention group receives sensor-based balance training with real-time joint feedback through an interactive interface on LC monitor screen.
11373058|NCT02214329|Active Comparator|In-home balance training|The control group performs similar exercise as intervention group at home without use of sensor or any joint feedback from sensor data.
11373059|NCT02214316|Experimental|Interventional 1|Interventional experimental arm with hypertonic saline
11373060|NCT02214303||Allergic asthma|Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
11373061|NCT02214303||Allergic rhinitis|allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
11373062|NCT02214303||Control group|Healthy subjects
11373063|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
11373064|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
11373065|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 g) provided by NOW FOODS
11373066|NCT02214277|Experimental|Test Arm|
11373067|NCT02214277|Active Comparator|Control Arm|
11373068|NCT02214277|Other|Safety Arm|
11373069|NCT02214264|Experimental|Loving-Kindness training|Participants receive Loving-Kindness meditation training for approximately 12 minutes.
11373070|NCT02214264|Experimental|Breath Awareness training|Participants receive Breath Awareness meditation training for approximately 12 minutes.
11373071|NCT02214264|Experimental|Gratitude training|Participants will receive Gratitude training for approximately 12 minutes.
11373072|NCT02214264|Other|Control|Participants write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
11373073|NCT02214251|Experimental|PK-16CH EXG system|PK-16CH EXG is a wireless physiological signal acquisition system for monitoring the bio-signals, such as EEG, ECG, and EMG. The system can concomitant EEG and EMG recording during ambulation.
11373074|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
11373075|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
11373076|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
11373077|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
11373078|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
11373079|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:
~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
11373080|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:
~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
11373081|NCT02214199|Active Comparator|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
11373137|NCT02213783|Experimental|Extended infusion arm|Infusion of 0.5 g of imipenem for 4 hr every 6 hr for 2-5 days
11373138|NCT02213770||Intervention group|Group that followed high- intensity interval training program in TEX study.
11373139|NCT02213770||Control group|Followed up on a regular basis for HTx recipients in Norway.
11373082|NCT02214199|Experimental|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
11373083|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
11373084|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
11373085|NCT02214173|Experimental|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
11373086|NCT02214173|Placebo Comparator|placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
11373087|NCT02214160|Experimental|UX007|Participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
11373088|NCT02214147|Experimental|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN.
11373089|NCT02214147|Experimental|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin > 1.5-3 x ULN and any ALT level.
11373090|NCT02214147|Experimental|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin > 3 x ULN and any ALT level.
11373091|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
11373092|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
11373093|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
11373094|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
11373095|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
11373096|NCT02214108|Experimental|Phisical activity with Nintendo Wii|3 hours of weekly of physical activity, divided in 1 hour interday with Nintendo WII. games applied: Wii Boxing, Wii Tennis; Wii Bowling
11373097|NCT02214108|No Intervention|phisical activity with phisiotherapist|3 hours of weekly physical activity, divided in 1 hour interday. applying cardiovascular and muscular endurance static exercises.
11373098|NCT02214095|Active Comparator|glucosamine sulphate capsules|500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
11373099|NCT02214095|Placebo Comparator|lactose capsules|lactose capsules three times daily for 3 months
11373100|NCT02214082|No Intervention|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
11373101|NCT02214082|Experimental|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
11373102|NCT02214069||Patients with Atrial Fibrillation|Patients with Atrial Fibrillation admitted to the hospital for drug loading with Dofetilide or Sotalol willing to record and transmit heart rhythm using AliveCor.
11373103|NCT02214056||The study population|"There is only one group in this study. Please see the inclusion/exclusion criteria.
~Intervention: Patient recruitment Intervention: Mobile team exam"
11373104|NCT02214043||Group 2|
11373105|NCT02214043||group 1|
11373106|NCT02214030|Active Comparator|Assiut Femoral Compression Device|the sheaths were removed 2 hours after PCI instead of conventional 6hours. To standardize compression times, AFCD were applied to patient and complete femoral artery compression were applied for 5 minutes, followed by a gradual release of pressure over the ensuing 8 minutes. Therefore each patient received a minimum of 13 minutes of compression, with further compression applied only if full hemostasis had not been achieved at that point with maximum of 30 minutes.
11373107|NCT02214030|Placebo Comparator|Manual compression|The intra-arterial sheaths were removed 6 hours after PCI in the MC group according to the standard local protocols.
11373108|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
11373109|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
11373110|NCT02214004|Experimental|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
11373111|NCT02213991|Experimental|Intraoperative Radiotherapy|"Intervention:
~Intraoperative Radiotherapy
~* Operation day
~Breast conservative surgery + Intraoperative radiotherapy 20 Gy
~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done.
~* Postoperative period
~± Chemotherapy
~WBRT (46 Gy) for 4~5 weeks
~± Endocrine therapy or target therapy"
11373112|NCT02213965||Vasofix® Safety|Peripheral IV catheter Vasofix® Safety
11373113|NCT02213965||Introcan Safety®|Peripheral IV catheter Introcan Safety® IV catheter
11373114|NCT02213952|Experimental|Platelet-Rich Plasma|Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
11373115|NCT02213952|Active Comparator|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
11373116|NCT02213939||CPB + Cytosorb|On pump myocardial revascularization with the use of the cytokine adsorbing circuit (Cytosorb)
11373117|NCT02213939||CPB / Control|Controll group; on pump myocardial revascularization
11373118|NCT02213939||OPCAB / Control|Controll Group; off-pump myocardial revascularization
11373119|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
11373120|NCT02213913|Experimental|Treatment (lenalidomide, DA-EPOCH-R)|"INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months."
11373121|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
11373122|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
11373123|NCT02213887|Experimental|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.
~Intervention: Days 2-8"
11373124|NCT02213887|Experimental|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.
~Intervention: Days 2-8"
11373125|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
11373126|NCT02213861|Experimental|1.0% SHAPE Gelled Solution once daily|
11373127|NCT02213861|Experimental|0.5% SHAPE Gelled Solution twice daily|
11373128|NCT02213861|Experimental|1.0% SHAPE Gelled Solution twice daily|
11373129|NCT02213848|Experimental|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
11373130|NCT02213848|Placebo Comparator|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
11373131|NCT02213835|Experimental|Specific Carbohydrate diet (SCD)|"The treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include Breaking the Vicious Cycle by Elaine Gottschall and Recipes for the Specific Carbohydrate Diet by Raman Prasad."
11373132|NCT02213822||Pts with Solid Tumors/ Hematological Cancer|Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.
11373133|NCT02213809|Experimental|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
11373134|NCT02213809|Active Comparator|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
11373135|NCT02213796|Other|1h infusion of 1 g meropenem|
11373140|NCT02213757|Experimental|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
11373141|NCT02213757|Placebo Comparator|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
11373142|NCT02213744|Experimental|MM-302 + trastuzumab|MM-302 + trastuzumab
11373143|NCT02213744|Active Comparator|Chemotherapy of Physician's Choice plus trastuzumab|Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine
11373144|NCT02213731|Other|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
11373145|NCT02213718|Experimental|Desflurane|desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
11373146|NCT02213718|Active Comparator|propofol|intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
11373147|NCT02213705|Experimental|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide
11373148|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
11373149|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
11373150|NCT02213679|Experimental|Guanidinoacetic acid|Supplementation with dietary guanidinoacetic acid
11373151|NCT02213679|Placebo Comparator|Placebo|Supplementation with cellulose
11373152|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
11373153|NCT02213653|Experimental|Concomitant iron and I.V. epoietin zeta|
11373154|NCT02213653|Experimental|Iron and I.V. epoietin zeta sequential|
11373155|NCT02213653|Active Comparator|Epoietin zeta|
11373156|NCT02213640|Experimental|Arm A Anodal tDCS and prismatic adaptation|anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
11373157|NCT02213640|Placebo Comparator|Arm B: control|Prismatic adaptation with placebo stimulation
11373158|NCT02213627|Experimental|Corifollitropin alfa|From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
11373159|NCT02213627|Experimental|Recombinant FSH|From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
11373160|NCT02213627|Experimental|HP-hMG|From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
11373161|NCT02213614|Experimental|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.
~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
11373162|NCT02213614|Experimental|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
11373163|NCT02213601|Experimental|Yoga|8-week Gentle Vinyasa Flow yoga intervention
11373164|NCT02213601|No Intervention|Wait-list Control Group|
11373165|NCT02213588|Active Comparator|AOX blend|Rosemary:Quercetin:Turmeric (300 mg total)
11373166|NCT02213588|Placebo Comparator|Placebo|Maltodextrin
11373167|NCT02213575|Other|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
11373168|NCT02213562|Experimental|200 mg CFO|200 mg of chrysanthemum flower oil
11373169|NCT02213562|Experimental|300 mg CFO|300 mg of chrysanthemum flower oil
11373170|NCT02213562|Experimental|400 mg CFO|400 mg of chrysanthemum flower oil
11373171|NCT02213549|Placebo Comparator|Placebo|3 placebo capsules/day for 12 weeks
11373172|NCT02213549|Experimental|Ume paste and ginger powder|3 experimental capsules/day for 12 weeks.
11373173|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
11373174|NCT02213523|Experimental|Plant concentrate A|Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
11373175|NCT02213523|Experimental|Plant concentrate B|Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
11373176|NCT02213523|Experimental|Plant concentrate C|Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
11373177|NCT02213523|Experimental|Plant concentrate D|Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
11373178|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
11373179|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
11373180|NCT02213484||Marfan syndrome|Individuals with a clinical diagnosis of Marfan syndrome
11373181|NCT02213484||Aortopathy syndrome|Individuals with one of the following clinical diagnoses: Loeys-Dietz syndrome, Turner syndrome, Ehlers-Danlos type IV syndrome, Thoracic Aortic Aneurysm and Dissection syndromes.
11373182|NCT02213471||Elevated risk for melanoma|Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
11373183|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
11373184|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
11373185|NCT02213432|Experimental|Day 1 vaccination|"Different timing of influenza vaccination: Day 1
~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts."
11373186|NCT02213432|Active Comparator|Day 11 vaccination|"Different timing of influenza vaccination: Day 11
~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts"
11373187|NCT02213419|Experimental|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
11373188|NCT02213406|Experimental|intervention group|Fat detection threshold test, intake of high and low fat yogurt, fMRI-measurements
11373189|NCT02213393|Experimental|Protein enriched products|The intervention group receives protein enriched products (CwC products) in the hospital and receives these also after discharge during 12 weeks.
11373190|NCT02213393|Active Comparator|Usual menu|The control group receives the usual protein and energy rich menu in the hospital and receives regular products, no protein enrichment, after discharge during 12 weeks.
11373191|NCT02213380|Other|group GA|Method of anesthesia: general anesthesia
11373192|NCT02213380|Other|group RA|Method of anesthesia: regional anesthesia
11373193|NCT02213367|Active Comparator|20 mg Bilastin|20mg Bilastine once daily
11373194|NCT02213367|Active Comparator|Bilastin 40mg|40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
11373195|NCT02213367|Active Comparator|Bilastin 80mg|80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
11373196|NCT02213354|Experimental|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
11373197|NCT02213354|Experimental|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
11373198|NCT02213354|Experimental|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
11373199|NCT02213354|Experimental|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
11373200|NCT02213354|Experimental|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
11373201|NCT02213354|Experimental|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
11373202|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
11373203|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
11373204|NCT02213328|Experimental|Truvada|All participants will take Truvada, once daily by mouth for the first 12 weeks of the study. After Week 12 of the study, only participants who indicate a willingness to use Truvada PrEP and who do not have any medical reasons not to do so will continue to receive the Truvada tablets through Week 52.
11373205|NCT02213315|Experimental|100mg arm|100mg dose
11373206|NCT02213315|Experimental|150mg arm|150mg dose
11373207|NCT02213315|Placebo Comparator|Placebo|Placebo
11373208|NCT02213302|Placebo Comparator|Isotonic serum|placebo administration
11373209|NCT02213302|Active Comparator|Midazolam|midazolam intravenous administration 0.02mg/kg
11373210|NCT02213289|Experimental|HER2 Group|Trastuzumab
11373211|NCT02213289|Experimental|MET group|
11373212|NCT02213289|Experimental|EGFR Arm|ABT-806
11373213|NCT02213289|Experimental|FGFR2 Arm|TBD2
11373214|NCT02213289|Experimental|VEGFR2 Arm|Ramucirumab
11373215|NCT02213289|Experimental|MSI-H Arm|Nivolumab
11373216|NCT02213276|Experimental|Healthy males|Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
11373217|NCT02213263|Experimental|PF-05280586|
11373218|NCT02213263|Active Comparator|MabThera®|
11373219|NCT02213250|Experimental|BeneFIX|
11373220|NCT02213224|Experimental|Perindopril|Perindopril 4mg qd taken in the morning;
11373221|NCT02213224|Experimental|Telmisartan|Telmisartan 80mg qd taken in the morning;
11373222|NCT02213224|Placebo Comparator|Amlodipine|Amlodipine；5mg qd taken in the morning.
11373223|NCT02213211|Experimental|Diagnosis and treatment of malaria|"School-based diagnosis and treatment of uncomplicated malaria using malaria RDTs and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers.
~Drug: Artemether lumefantrine (artemisinin-based combination therapy [ACT], Coartem). Three-day doses of 20mg/120mg, 40mg/240mg, 60mg/360mg and 80mg/480mg Coartem are provided, according to weight, upon a positive rapid diagnostic test (RDT) result."
11373224|NCT02213211|No Intervention|No intervention|No intervention provided
11373225|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
11373226|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
11373227|NCT02213185|Experimental|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
11373228|NCT02213185|Active Comparator|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
11373229|NCT02213185|Placebo Comparator|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
11373230|NCT02213185|Placebo Comparator|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
11373231|NCT02213172|Experimental|Bifidobacterium longum R0175|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
11373234|NCT02213159|Active Comparator|Dexmedetomidine|prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes
11373235|NCT02213159|Active Comparator|Morphine|prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
11373236|NCT02213146|Experimental|BioChaperone human insulin|BioChaperone Human Insulin
11373237|NCT02213146|Active Comparator|Human insulin|Huminsulin® Normal
11373238|NCT02213146|Active Comparator|Insulin lispro|Humalog®
11373239|NCT02213133|Experimental|Selinexor (KPT-330)|oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly for the first 3 weeks of each 4-week cycle. Duration of treatment is open-ended and patients will dose as long as the dose is tolerated and participation is voluntarily given, until disease progression occurs.
11373240|NCT02213120||Dizziness|Patients with Dizziness
11373241|NCT02213107|Experimental|Enzalutamide and dutasteride|Two oral drugs.
11373242|NCT02213094|Experimental|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
11373243|NCT02213094|Experimental|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
11373244|NCT02213081|Experimental|Ulipristal|25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
11373245|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:
~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.
~Tacrolimus tapered over one month as follows:
~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue
~MPA: administered according to SOC"
11373246|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.
~Tacrolimus tapered over one month as follows:
~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
11373247|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:
~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.
~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
11373248|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
11373249|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
11373250|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who are hormone receptor positive, an aromatase inhibitor of the investigator's choice is required.
11373251|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive will receive an aromatase inhibitor at the discretion of the investigator.
11373252|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who are hormone receptor positive, an aromatase inhibitor of the investigator's choice is required.
11373253|NCT02213029|Experimental|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
11373254|NCT02213029|Experimental|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges.
11373255|NCT02213029|Experimental|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
11373256|NCT02213016|Sham Comparator|Transcranial magnetic stimulation|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
11373257|NCT02213016|Active Comparator|Transcraneal magnetic stimulation|Active repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
11373258|NCT02213016|Sham Comparator|Sham Comparator|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
11373259|NCT02213016|Active Comparator|Active Comparator|Active repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
11373260|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
11373261|NCT02212990|Active Comparator|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
11373262|NCT02212990|Placebo Comparator|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
11373263|NCT02212990|Active Comparator|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
11373264|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
11373265|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
11373266|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
11373267|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
11373268|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
11373269|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
11373270|NCT02212938|Experimental|BI 14332 CL fasted|
11373271|NCT02212938|Experimental|BI 14332 CL fed|
11373272|NCT02212925|Experimental|BI 14332 CL|
11373273|NCT02212925|Placebo Comparator|Placebo|
11373274|NCT02212912|Other|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
11373275|NCT02212912|Other|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
11373276|NCT02212886|Experimental|GA Depot 80mg|Monthly IM injection
11373277|NCT02212886|Experimental|GA Depot 40mg|Monthly IM injection
11373278|NCT02212873|No Intervention|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
11373279|NCT02212873|Experimental|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
11373280|NCT02212860|Experimental|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (single dose, 21 Gy) followed by lumpectomy for stage I or IIA early stage breast carcinoma
11373281|NCT02212847|Experimental|vestibular stimulation|
11373282|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
11373283|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
11373284|NCT02212821|Placebo Comparator|Placebo|intravenous infusion
11373285|NCT02212821|Experimental|Erythromycin|intravenous infusion
11373286|NCT02212808|Experimental|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
11373287|NCT02212808|Experimental|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
11373288|NCT02212795|Experimental|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
11373289|NCT02212795|Experimental|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
11373290|NCT02212795|Experimental|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
11373291|NCT02212782|Experimental|A Group|1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg
11373292|NCT02212782|Experimental|B Group|1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
11373522|NCT02211170|Placebo Comparator|Placebo|
11373293|NCT02212769|Experimental|A Group|1st oral administration of Losartan 50mg and 2nd oral administration of Losartan 50mg and DW1029M 1200mg
11373294|NCT02212769|Experimental|B Group|1st oral administration of DW1029M 1200mg and Losartan 50mg and 2nd oral administration of Losartan 50mg
11373295|NCT02212756|Experimental|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
11373296|NCT02212756|Experimental|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
11373297|NCT02212730|Experimental|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
11373298|NCT02212730|Experimental|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
11373299|NCT02212717|Active Comparator|EUS-guided gallbladder drainage|
11373300|NCT02212717|Active Comparator|Percutaneous cholecystomy|
11373301|NCT02212704|Experimental|Vestibular stimulation|This is the experimental paradigm applied in all participants
11373302|NCT02212691||Sickle cell disease|Patients diagnosed with sickle cell disease
11373303|NCT02212691||Healthy control|Healthy individuals recruited through fliers and have no history of cognitive disorders
11373304|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
11373305|NCT02212665|Experimental|High intense interval training (HIIT)|3 x 20 sec, 3 x week
11373306|NCT02212665|Experimental|Increased daily activity detected by the pedometer|10.000 steps a day
11373307|NCT02212665|Experimental|Increased daily activity detected by te pedometer+HIIT|10.000 steps + 3 x 20 sec, 3 x week
11373308|NCT02212665|Experimental|Increased daily activity (pedometer)+group intervention|10.000 steps + group intervention
11373309|NCT02212665|No Intervention|Control group|
11373310|NCT02212652|Active Comparator|Standard of Care plus Vitamin D|If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
11373311|NCT02212652|Placebo Comparator|Standard of Care plus Placebo|If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
11373312|NCT02212639|Experimental|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
11373313|NCT02212626|Experimental|Rotarex|After assessment of the lesion by angiography the occlusion is intraluminally crossed with the wire according to physician's discretion. The device is introduced and the catheter is activated while its tip is still proximal to the occlusion to allow lubrication of the spiral inside the catheter with the aspirated blood. The catheter is advanced into the occlusion with occasional retraction into the already recanalized lumen. Care must be taken to achieve sufficient cooling of the catheter tip and evacuation of the debris to get an appropriate blood flow along the catheter. In order to minimize peripheral embolization of clot the distal end of the occlusion should not be passed too fast before all loose material has been sucked back into the catheter. Several passages of the occlusion may be needed to clean out all wall-adherent thrombotic material. If residual underlying stenosis of >30% persist further endovascular treatment can be performed according to the physician's discretion.
11373314|NCT02212613|Experimental|Brexpiprazole|Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally
11373315|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
11373316|NCT02212587|Experimental|TOBI Podhaler|
11373317|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.
~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
11373318|NCT02212561|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
11373319|NCT02212548|Experimental|Hydrogel|The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.
11373320|NCT02212535|Experimental|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
11373321|NCT02212522||Isis-Diab patients|French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
11373322|NCT02212522||Isis-Diab controls|French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
11373323|NCT02212496||Cancer-associated stroke|Cryptogenic embolic stroke with active cancer
11373324|NCT02212496||Cryptogenic embolic stroke|Cryptogenic embolic stroke without active cancer
11373325|NCT02212483|Experimental|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
11373326|NCT02212483|Active Comparator|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.
~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
11373327|NCT02212483|Other|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
11373328|NCT02212470|Active Comparator|Drug Eluting Balloon|Admiral In.Pact Drug Eluting Balloon
11373329|NCT02212470|Active Comparator|Nitinol Stent|Complete SE Self-expandible Nitinol stent
11373330|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
11373331|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
11373332|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
11373333|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
11373334|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
11373335|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
11373336|NCT02212444|Experimental|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
11373337|NCT02212444|Active Comparator|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
11373338|NCT02212431|Experimental|Cysteamine|"Dosing will be in accordance with licensed use of cysteamine for cystinosis, i.e. 450mg qds.
~Dose will be escalated:
~450mg od for one week 450mg bd for one week 450mg tds for one week 450mg qds for two weeks"
11373339|NCT02212418|Experimental|Abdominal hypopressive technique|
11373340|NCT02212405|Sham Comparator|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
11373341|NCT02212405|Experimental|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
11373342|NCT02212405|Experimental|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
11373343|NCT02212392|No Intervention|control|This arm was not given any prophylactic antibiotics. Patients were managed in the surgical ward by post graduate residents under the supervision of consultants
11373344|NCT02212392|Experimental|Antibiotics|this arm was given IV antibiotics, prophylactically, right from the day of admission. They were given intravenous broad spectrum (MEROPENEM) twice daily at 12 hours interval for 7-10 days
11373345|NCT02212379|Experimental|raltegravir and etravirine|
11373346|NCT02212366|Experimental|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
11373347|NCT02212366|Sham Comparator|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
11373348|NCT02212353||Site 1 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 1 in delivering to care to neck of femur patients.
11373349|NCT02212353||Site 2 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 2 in delivering to care to neck of femur patients.
11373350|NCT02212353||Site 3 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 3 in delivering to care to neck of femur patients.
11373351|NCT02212340|Experimental|TIVA group|Anesthesia is maintained with fresofol and remifentanil
11373352|NCT02212340|Active Comparator|Des group|Anesthesia is maintained with desflurane and remifentanil
11373353|NCT02212327||PD subjects|
11373354|NCT02212327||Controls|
11373355|NCT02212314|Experimental|Response Inhibition Training|Treatment group will receive immediate treatment after pre-test.
11373356|NCT02212314|No Intervention|Waitlist Crossover|Waitlist group will not receive intervention while treatment group is active, but waitlist group will be offered treatment after post-test is completed.
11373357|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
11373523|NCT02211157|Experimental|BIBR 796 BS, fasted|dose escalation
11373358|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
11373359|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
11373360|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
11373361|NCT02212275|Experimental|Dextromethorphan in ASD|8-12 years old: > 30 boys will be recruited who have a known or suspected diagnosis of ASD confirmed by DSM-5 checklist and the ADOS-2 at screening. They will have the cortical metric measured 20 min prior to receiving DXM and 2 hours after receiving a single age and weight appropriate dose of DXM. The outcome reported is the difference in the cortical metric after the DXM dose and before the DXM dose.
11373362|NCT02212275|Active Comparator|Dextromethorphan in controls|30 typically developing boys 8-12 years old who have the cortical metric measured 20 min before receiving a single age and weight appropriate dose of DXM and 2 hours after the single dose of DXM. The reported value will be the difference between the cortical metric 2hrs after the single dose of DXM and the cortical metric 20 minutes prior to the single dose of DXM.
11373363|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
11373364|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
11373365|NCT02212249|Active Comparator|Systemic sclerosis|patients with systemic sclerosis
11373366|NCT02212249|Sham Comparator|primary raynaud disease|patients with primary raynaud disease
11373367|NCT02212236|Experimental|Psychological preparation + TAU|TAU=treatment as usual
11373368|NCT02212236|No Intervention|Treatment as usual|Usual care including medication, nursing, and psychologist support.
11373369|NCT02212223|Experimental|Group 1: Somali immigrant group, 10 µg (400 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months
11373370|NCT02212223|Experimental|Group 2: Somali immigrant group, 20 µg (800 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months
11373371|NCT02212223|Placebo Comparator|Group 3: Somali immigrant group, 0 µg vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months
11373372|NCT02212223|Experimental|Group 4: Original Finnish group, 10 µg (400 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months.
11373373|NCT02212223|Experimental|Group 5: Original Finnish group, 20 µg (800 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months.
11373374|NCT02212223|Placebo Comparator|Group 6: Original Finnish group, 0 µg vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months.
11373375|NCT02212210|Active Comparator|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
11373376|NCT02212210|Placebo Comparator|Normal saline|2cc preservative free normal saline
11373377|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
11373378|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
11373379|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
11373380|NCT02212184|Sham Comparator|Control Group|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
11373381|NCT02212184|Experimental|Intevention Group|"All patients will receive the Manual Diaphragm Release Technique, during 6 days of treatment. They will undertake four evaluations throughout treatment: before and immediately after the Day 1 (Baseline 1 and Post 1) and before and after Day 6 (Baseline 6 and Post 6).
~In the other Days (2nd to 5th) patients will only receive the intervention and won't be evaluated."
11373382|NCT02212171|Experimental|TRIAP intervention|
11373383|NCT02212171|No Intervention|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
11373384|NCT02212158|Experimental|motivational interviewing group|"Motivational Group Intervention:
~Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies."
11373385|NCT02212145||Screened group|Screened group is defined as those individuals who were willing to participate in the cardiovascular prevention program and all the individuals who lived in Sollentuna during the intervention.
11373386|NCT02212145||Relatives to the screened group|Relatives to individuals included in the screened group, who lived in Stockholm County at least during one year at the time of the intervention.
11373387|NCT02212145||Control group|"Matched controls is going to be selected randomly from the population of Stockholm County minus Sollentuna Municipality with relevant background factors. The whole population will be used as a comparison group when evaluating the result from all the municipality of Sollentuna during 1988-1993."
11373388|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
11373389|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
11373390|NCT02212119|Placebo Comparator|Saline|Saline injection up to 5 cc in arm with paratonia (one time injection)
11373524|NCT02211157|Experimental|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
11373391|NCT02212119|Active Comparator|Botulinum Toxin|Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
11373392|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
11373393|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
11373394|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
11373395|NCT02212080|Experimental|BAY1214784|Dose 1 to 7 of BAY1214784
11373396|NCT02212080|Placebo Comparator|Placebo|Placebo Dose 1 to 7 of BAY1214784
11373397|NCT02212067|Experimental|Semaglutide|Total of 12 visits
11373398|NCT02212067|Placebo Comparator|Placebo|Total of 12 visits
11373399|NCT02212067|No Intervention|Healthy subjects|Total of 2 visits
11373400|NCT02212054|Experimental|conservative & operative treatment|anal dilation; colon lavage; probiotics
11373401|NCT02212054|Active Comparator|operative treatment|one stage pull- through radical colectomy
11373402|NCT02212041|Experimental|Electronic cigarettes|Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
11373403|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
11373404|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
11373405|NCT02212015|Experimental|Pazopanib + Paclitaxel|
11373406|NCT02212002||Control|Control group: infants born to GBS-negative mothers, who thus did not receive any antibiotic treatment before/at delivery.
11373407|NCT02212002||IAP|IAP group: infants born to GBS-positive mothers who have received adequate intrapartum antibiotic prophylaxis (IAP). According to the Institutional treatment protocol for GBS prophylaxis (derived from CDC guidelines), intravenous ampicillin is given every 4 hours until delivery (first dose 2 g, following doses 1 g each). IAP is considered adequate when the mother received at least two doses of ampicillin before delivery.
11373408|NCT02211989|Experimental|BI 14332 CL|single rising dose
11373409|NCT02211989|Placebo Comparator|Placebo|
11373410|NCT02211976|Experimental|Bisacodyl|
11373411|NCT02211976|Experimental|Simeticone|
11373412|NCT02211976|Experimental|Bisacodyl and simeticone|
11373413|NCT02211963|Experimental|BI 44847|
11373414|NCT02211963|Placebo Comparator|Placebo|
11373415|NCT02211950|Experimental|Treatment A|single dose BI 44847 administered to white subjects
11373416|NCT02211950|Experimental|Treatment B|100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
11373417|NCT02211950|Experimental|Treatment C|single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
11373418|NCT02211950|Experimental|Treatment D|single dose BI 44847 administered to asian subjects
11373419|NCT02211950|Experimental|Treatment E|single dose BI 44847 administered to african subjects
11373420|NCT02211937|Active Comparator|Treatment A|BI 44847 suspension high dose, fasted
11373421|NCT02211937|Experimental|Treatment B|BI 44847 tablet high dose, fasted
11373422|NCT02211937|Experimental|Treatment C|BI 44847 tablet high dose, fed
11373423|NCT02211937|Active Comparator|Treatment D|BI 44847 solution low dose, fasted
11373424|NCT02211937|Experimental|Treatment E|BI 44847 tablet low dose, fasted
11373425|NCT02211924|Experimental|BI 44847|single rising dose
11373426|NCT02211924|Placebo Comparator|Placebo|
11373427|NCT02211911|Experimental|Bisacodyl|
11373428|NCT02211911|Experimental|Sodium picosulfate|
11373429|NCT02211898|Experimental|BNS003|
11373430|NCT02211872|Experimental|Treatment A|BI 2536 BS single rising dose
11373431|NCT02211872|Experimental|Treatment B|BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
11373432|NCT02211859|Experimental|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
11373433|NCT02211846|Experimental|Mirabegron|Administered under fed and fasted conditions
11373434|NCT02211833|Experimental|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
11373435|NCT02211807||Patients initiating an Efavirenz|Patients initiating an Efavirenz-containing antiretroviral regimen
11373436|NCT02211807||Patients initiating an Efavirenz-free regimen|
11373437|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
11373438|NCT02211768|Experimental|1/FDG and FLT PET scans|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
11373439|NCT02211768|Other|2/FDG-PET scan|Subjects will undergo FDG-PET scan
11373440|NCT02211755|Experimental|1|Starting doses are clofarabine at 1 mg/m(2) IV on days 1 through 5 of a 21-day cycle, and bortezomib at 0.8 mg/m2 subcutaneously on days 1 and 4 of a 21-day cycle.
11373441|NCT02211742|Active Comparator|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
11373442|NCT02211742|Placebo Comparator|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
11373443|NCT02211729|Active Comparator|Seasonal malaria chemoprevention|Sulphadoxine-Pyrimethamine Amodiaquine Placebo Azithromycin
11373444|NCT02211729|Experimental|seasonal malaria chemoprevention plus AZ|Sulphadoxine-Pyrimethamine+ Amodiaquine + Azithromycin 4 rounds during malaria transmission season
11373445|NCT02211716|Experimental|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
11373446|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
11373525|NCT02211157|Placebo Comparator|Placebo|
11373447|NCT02211690|Experimental|dolutegravir 50mg with co-formulated emtricitabine-tenofovir|One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days
11373448|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
11373449|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
11373450|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
11373451|NCT02211664|Experimental|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:
~pre-dilation of the lesion with a Passeo-18 balloon (mandatory)
~dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)
~stenting of the lesion with a Pulsar-18 stent (mandatory)
~post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
11373452|NCT02211651||ObeseDYS|Obese subjects with dysfunctional vascularization and inflammation of placenta.
11373453|NCT02211651||ObeseNL|Obese subjects with normal vascularization and inflammation of placenta
11373454|NCT02211651||LeanNL|Lean subjects with normal vascularization and inflammation of placenta.
11373455|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
11373456|NCT02211625|Experimental|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
11373457|NCT02211625|Active Comparator|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
11373458|NCT02211612|Experimental|Saturated fatty acids (SFA)-group|Weight gain created by addition of muffins baked on saturated fat
11373459|NCT02211612|Experimental|Polyunsaturated fatty acids (PUFA)-group|Weight gain created by addition of muffins baked on polyunsaturated fat
11373460|NCT02211599|Experimental|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
11373461|NCT02211599|Experimental|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
11373462|NCT02211573|No Intervention|Control group|Patients of this group don't performed physical training
11373463|NCT02211573|Experimental|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
11373464|NCT02211560|Placebo Comparator|Placebo|Identical looking cellulose capsules
11373465|NCT02211560|Experimental|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
11373466|NCT02211547|No Intervention|Control|No treatment to be rendered following separator placement.
11373467|NCT02211547|Placebo Comparator|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
11373468|NCT02211547|Experimental|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
11373469|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
11373470|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
11373471|NCT02211521|Experimental|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
11373472|NCT02211521|Active Comparator|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
11373473|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
11373474|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
11373475|NCT02211495|Active Comparator|No device|Treated with best medical therapy
11373476|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
11373477|NCT02211482|Other|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
11373478|NCT02211469|Experimental|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
11373479|NCT02211469|Experimental|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
11373480|NCT02211469|Experimental|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
11373481|NCT02211469|Experimental|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
11373482|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
11373526|NCT02211144|Experimental|BIRB 796 BS|in escalating doses
11373527|NCT02211144|Placebo Comparator|Placebo|
11373483|NCT02211443|Experimental|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:
~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg
~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
11373484|NCT02211430|Experimental|Cognitive-Behavioral Counseling (CBC)|Cognitive-Behavioral Counseling (CBC) consists of two 45-minute on-site intervention sessions (session 1 and 3), one 15 minute on-site session (session 2), and one 15-minutes phone session (booster session).
11373485|NCT02211430|Active Comparator|Best Practice (BP) Control|Best Practice (BP) Control Condition consists of two 10-15 min, on-site intervention sessions (session 1 and 3), one brochure pick-up (session 2), and receipt of a newsletter by mail (booster session).
11373486|NCT02211417|Experimental|DS107G|DS107G 2g capsules taken by mouth daily for 56 days.
11373487|NCT02211417|Placebo Comparator|Placebo|Placebo capsules 2g taken by mouth daily for 56 days.
11373488|NCT02211391|Experimental|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
11373489|NCT02211391|Placebo Comparator|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
11373490|NCT02211378|Experimental|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
11373491|NCT02211378|Active Comparator|Hotseat|Trainees are in the 'hotseat' actively participating during all 3 simulation sessions
11373492|NCT02211352|Active Comparator|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
11373493|NCT02211352|Placebo Comparator|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
11373494|NCT02211339|Experimental|Peer-led intervention group|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
11373495|NCT02211339|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
11373496|NCT02211326|Experimental|genotype-guided group|Interventions：on day1~day3, patients received dose according to IWPC formula (PGx-1) included clinical variables and genotype data for VKORC1, CYP2C9*1, CYP2C9*2, and CYP2C9*3; on day4~day7, patients received dose according to Lenzini formula consisted of clinical variables, VKORC1, CYP2C9*2, CYP2C9*3 and previous INR and dosing information (PGx-2); and on day8, the clinicians adjusted the dose according to observed INR.The overall follow-up period is 12 weeks.
11373497|NCT02211326|Active Comparator|control group|Interventions：on day1~day3, patients were given initial dose (2.25mg); and starting from day4, the clinicians began to adjust the dose for patients according to observed INR.The overall follow-up period is 12 weeks.
11373498|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
11373499|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
11373500|NCT02211300|Experimental|Optiscanner values vs YSI|Matched samples up to 12 times per 24 hour period
11373501|NCT02211287|Experimental|Intervention|The intervention will include five key elements: a Project Nurse - ACP facilitator; family education on comfort care at the end of life for individuals with dementia using the 'Comfort Care at the end of life for persons with dementia' booklet; a family meeting with follow-up telephone call; documentation of ACP decisions, and orientation and education directed towards General Practitioners (GPs) and nursing home staff about the intervention.
11373502|NCT02211287|No Intervention|Usual care|Care will continue as usual for the nursing home residents
11373503|NCT02211274|Experimental|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
11373504|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
11373505|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
11373506|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
11373507|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
11373508|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
11373509|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
11373510|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
11373511|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
11373512|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
11373513|NCT02211248|Active Comparator|Conventional Group|Conventional treatment and follow up
11373514|NCT02211248|Experimental|Multidisciplinary Group|Multidisciplinary assistance
11373515|NCT02211209|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
11373516|NCT02211209|Experimental|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
11373517|NCT02211196|Experimental|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
11373518|NCT02211183|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
11373519|NCT02211183|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
11373520|NCT02211170|Experimental|BIBR 796 BS, low dose|
11373528|NCT02211131|Other|Surgery|Surgical resection of melanoma tumor lesion(s)
11373529|NCT02211131|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).
11373530|NCT02211118|Experimental|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
11373531|NCT02211105||Laparoscopic Nissen Fundoplication|Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
11373532|NCT02211105||Transoral Incisionless Fundoplication|Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
11373533|NCT02211092|Experimental|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
11373534|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
11373535|NCT02211079|Experimental|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2*50 mg tablets), midazolam 2 mg (1 milliliter [mL], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
11373536|NCT02211066|Active Comparator|Clopidogrel|Clopidogrel 75 mg will be administered daily for 1 year
11373537|NCT02211066|Experimental|Ticagrelor|Ticagrelor 90 mg will be administered daily for 1 year
11373538|NCT02211053|Active Comparator|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
11373539|NCT02211053|Placebo Comparator|Placebo|Infusion matched to intervention arm
11373540|NCT02211040|Experimental|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
11373541|NCT02211040|Experimental|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
11373542|NCT02211027|Experimental|Vaccine|The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
11373543|NCT02211014|Experimental|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
11373544|NCT02211014|Experimental|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
11373545|NCT02211001|Experimental|Pilates Group|The individuals were treated with Mat Pilates Method.
11373546|NCT02211001|Experimental|Segmented Dynamic Exercises Group|The individual were treated with ball exercises.
11373547|NCT02211001|Experimental|Global Postural Reeducation Group|The individuals were treated with postures of Souchard Method.
11373548|NCT02210988|Experimental|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
11373549|NCT02210975|Experimental|Electrical Stimulation Therapy|
11373550|NCT02210962|Experimental|essential fatty acids|The experimental treatment is a food supplement containing fish oil. The daily dose of 4 capsules provides 1320 mg of eicosapentaenoic acid and 880 mg of docosahexaenoic acid, 26 weeks intervention
11373551|NCT02210962|Placebo Comparator|olive oil|Placebo capsules contain olive oil and trace amount of fish oil to assure comparable taste, 26 weeks intervention
11373552|NCT02210949|Other|Erythropoietin Iron|"Erythropoietin and iron:
~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .
~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once."
11373553|NCT02210936|Other|PDMP Data|
11373554|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:
~20 Hz, 3 Volts, 480 microseconds
~20 Hz, 6 Volts, 480 microseconds
~50 Hz, 3 Volts, 480 microseconds
~50 Hz, 6 Volts, 480 microseconds
~90 Hz, 3 Volts, 480 microseconds
~90 Hz, 6 Volts, 480 microseconds"
11373555|NCT02210910|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
11373556|NCT02210910|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair, and placement of the InSpace™ system.
11373557|NCT02210884|Experimental|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
11373558|NCT02210884|Placebo Comparator|Placebo|Placebo capsule containing no vitamin D
11373559|NCT02210871|Experimental|Normal hepatic function|
11373560|NCT02210871|Experimental|Mild hepatic impairment|
11373561|NCT02210871|Experimental|Moderate hepatic impairment|
11373562|NCT02210871|Experimental|Severe hepatic impairment|
11373563|NCT02210858|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11373564|NCT02210845|Active Comparator|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
11373565|NCT02210845|Placebo Comparator|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
11373566|NCT02210845|Active Comparator|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
11373567|NCT02210832|Experimental|Best practices for pregnant smokers|Five As plus referral to pregnancy-specific tobacco quit line
11373568|NCT02210832|Experimental|Best practices plus financial incentives|Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
11373569|NCT02210832|No Intervention|Never-smoker comparison condition|We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum
11373570|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
11373571|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
11373572|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
11373573|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
11373574|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
11373575|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
11373576|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
11373577|NCT02210793|Active Comparator|Transepithelial PRK|20 eyes to undergo a no touch , all-laser advanced surface ablation technique termed transepithelial PRK using the Amaris laser platform (Schwind eye-tech solutions Gmbh, Germany)
11373578|NCT02210793|Active Comparator|Conventional LASIK|20 eyes to undergo LASIK using a mechanical microkeratome (M2, Moria Surgical, Antony, France) and the Mel 80 excimer laser system(Carl Zeiss Meditec)
11373579|NCT02210780|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
11373580|NCT02210780|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
11373581|NCT02210767|Experimental|Walnut Diet|Provides ~2 oz. walnuts/day (2-3% of total calories from alpha-linolenic acid [ALA])
11373582|NCT02210767|Active Comparator|Walnut Control Diet|Provides same fatty acid profile (<7% SFA, 9% MUFA, 14-15% PUFA, 2-3% ALA) as Walnut Diet, but is devoid of walnuts and their bioactives
11373583|NCT02210767|Placebo Comparator|Low ALA Diet|Provides similar macronutrient and linoleic acid profile but replaces ALA with oleic acid (<7% SFA, 12% MUFA, 12% PUFA, 0.5% ALA)
11373584|NCT02210754|Experimental|E-cigarette 1|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
11373585|NCT02210754|Experimental|E-cigarette 2|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/propylene glycol (PG) vehicle)
11373586|NCT02210754|Experimental|E-cigarette 3|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
11373587|NCT02210754|Experimental|E-cigarette 4|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
11373588|NCT02210754|Experimental|E-cigarette 5|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
11373589|NCT02210754|Active Comparator|Combustible Cigarette|Marlboro Cigarette
11373590|NCT02210728|Active Comparator|Medication only|Stimulant medication (methylphenidate or amphetamine product approved for clinical use in Canada), with dose optimized for each patient based on report of efficacy and side effects.
11373591|NCT02210728|Active Comparator|Cognitive behavioral therapy + medication|Patients are first titrated to an optimal dose of stimulant medication. They then undergo the 12 weeks of group cognitive behavioral therapy.
11373592|NCT02210728|Experimental|Cognitive behavioral therapy alone|12 weeks of structured group cognitive behavioral therapy, focusing on acquisition of skills in organization, time management, goal attainment, cognitive restructuring, stress management, anger management, impulse control, self-esteem, and relationship management.
11373593|NCT02210715|Experimental|switch to Isentress|28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
11373594|NCT02210715|Active Comparator|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
11373595|NCT02210702|Experimental|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
11373596|NCT02210702|Experimental|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
11373597|NCT02210702|No Intervention|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
11373598|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
11373599|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
11373600|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
11373601|NCT02210676|Experimental|Patients with Mallet Finger|All enrolled patients
11373602|NCT02210663|Experimental|veliparib (ABT-888)|
11373603|NCT02210650|Other|Ureteral stone removal|Group 1 will receive the standard treatment of having only the ureteral stone removed
11373604|NCT02210650|Other|Asymptomatic kidney stones and ureteral stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the ureteral stone
11373605|NCT02210637||Retrospective Cohort|Retrospective Cohort of scheduled outpatient appointment
11373606|NCT02210624|Experimental|Single arm|"Experimental: HYNR-CS inj.
~Treatment group with HYNR-CS inj."
11373607|NCT02210611|Active Comparator|36 hours|Intrauterine insemination 36 hours after ovulation induction
11373608|NCT02210611|Active Comparator|42 hours|Intrauterine insemination 42 hours after ovulation induction
11373609|NCT02210598|Active Comparator|inpatient Foley balloon induction|"Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley blindly by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded."
11373695|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
11373610|NCT02210598|Experimental|outpatient Foley balloon induction|Patients randomized to the experimental group will undergo outpatient Foley induction of labor. Either of the above two described methods will be used to place an 18 French Foley catheter transcervically and its balloon filled with 60mL of sterile saline. The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours. When the patient returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
11373611|NCT02210585|Active Comparator|Kneehab|5 sessions per week
11373612|NCT02210585|Placebo Comparator|Placebo|5 sessions per week
11373613|NCT02210572|Experimental|Bimuno Galacto-oligosaccharide|Dietary intervention
11373614|NCT02210572|Placebo Comparator|Low- FODMAPs diet|Dietary intervention
11373615|NCT02210559|Experimental|Arm A|FG-3019 + Gemcitabine + Nab-paclitaxel
11373616|NCT02210559|Other|Arm B|Gemcitabine + Nab-paclitaxel
11373617|NCT02210546|Experimental|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
11373618|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
11373619|NCT02210520|Experimental|laser|3 J/cm², 2 minutes in 6 points around the back spine
11373620|NCT02210520|Experimental|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine
11373621|NCT02210520|Experimental|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
11373622|NCT02210520|No Intervention|control|no treatment.
11373623|NCT02210507|Experimental|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
11373624|NCT02210507|Experimental|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
11373625|NCT02210507|Experimental|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
11373626|NCT02210494|Experimental|Secretrol|
11373627|NCT02210481||GLUC-MAC-COHORT|post vitrectomy for retinal detachment or epimacular membrane patients
11373628|NCT02210468|Experimental|APIC-CF 4cc,|APIC-CF 4cc, once at first day
11373629|NCT02210468|Experimental|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
11373630|NCT02210468|Placebo Comparator|Saline|
11373631|NCT02210455|Experimental|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
11373632|NCT02210455|Active Comparator|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
11373633|NCT02210442|Experimental|Educaguia intervention|Implementation of practice clinical guidelines with educational games
11373634|NCT02210442|Active Comparator|Control group|Implementation of clinical practice guidelines with standard practice care
11373635|NCT02210429|Active Comparator|IV Opioids|
11373636|NCT02210429|Active Comparator|Supraclavicular Single-Shot Block|
11373637|NCT02210429|Active Comparator|Supraclavicular Catheter|
11373638|NCT02210429|Active Comparator|Supraclavicular Angiocath|
11373639|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
11373640|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
11373641|NCT02210403|Active Comparator|Upper limb motor function training + tDCS|Bi-hemispheric tDCS with motor function training
11373642|NCT02210403|Sham Comparator|upper limb motor function training + sham tDCS|sham tDCS with motor function training
11373643|NCT02210390|Experimental|Intervention|Psycho-education Sessions will be offered weekly basis
11373644|NCT02210390|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
11373645|NCT02210377|Experimental|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
11373646|NCT02210377|Placebo Comparator|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
11373647|NCT02210364|Experimental|lurbinectedin (PM01183) and capecitabine|
11373648|NCT02210351|Experimental|MRI test|
11373649|NCT02210338|Experimental|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
11373650|NCT02210338|Experimental|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
11373651|NCT02210325|Active Comparator|Ceftriaxone plus Azithromycin|A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin
11373652|NCT02210325|Experimental|Solithromycin|A single oral dose of 1000 mg solithromycin
11373653|NCT02210312||elective non-cardiac surgery and non-neurosurgical procedures|300 Patients aged 60 years and older undergoing elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia with a duration of operation of 120 minutes or longer. 80 age-, gender- and education-matched healthy controls.
11373654|NCT02210299|Other|Exposure study|2-6 months-old children and 12-18 months-old children
11373655|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
11373656|NCT02210273|Experimental|Treatment|Subjects undergoing treatment with the Solace Bladder Control (Vesair) Balloon on day 0
11373657|NCT02210273|Sham Comparator|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control (Vesair) Balloon at 3 months
11373658|NCT02210260|Active Comparator|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
11373659|NCT02210260|Experimental|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
11373660|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
11373661|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
11373662|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
11373663|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
11373664|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
11373665|NCT02210234|Active Comparator|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat brand cereal during the day for 3 weeks.
11373666|NCT02210234|Active Comparator|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat brand cereal the day for 3 weeks.
11373667|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
11373668|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
11373669|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
11373670|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
11373671|NCT02210182|Experimental|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
11373672|NCT02210182|Placebo Comparator|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
11373673|NCT02210169|No Intervention|Intermittent infusion of vancomycin|Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
11373674|NCT02210169|Active Comparator|Continuous infusion of vancomycin|A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.
11373675|NCT02210156|Placebo Comparator|Placebo|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
11373676|NCT02210156|Experimental|Omniplus Supreme|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
11373677|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
11373678|NCT02210143||AERSA-II gingival recession|AERSA > 15 mm2 named as AERSA-II (high risk group).
11373679|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
11373680|NCT02210130||patients HIV+ CSVD+|patients with HIV and cerebral small vessel disease
11373681|NCT02210130||control HIV+ CSVD-|patients with HIV and without cerebral small vessel disease
11373682|NCT02210117|Experimental|Arm A (nivolumab, surgery)|"Patients receive nivolumab IV over 60 minutes on day 1 every 2 weeks for 6 weeks. Approximately 4 weeks later, patients undergo nephrectomy, metastasectomy or biopsy.
~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
11373683|NCT02210117|Experimental|Arm B (nivolumab, bevacizumab, surgery)|"Patients receive nivolumab IV over 60 minutes and bevacizumab IV over 90 minutes on day 1 every 2 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.
~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
11373684|NCT02210117|Experimental|Arm C (nivolumab, ipilimumab, surgery)|"Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1 every 3 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.
~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
11373685|NCT02210104|Experimental|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10^10 cells/m^2.
11373686|NCT02210091|Experimental|<6 years old|
11373687|NCT02210091|Experimental|≥6 to <12 years|
11373688|NCT02210078|Experimental|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
11373689|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
11373690|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
11373691|NCT02210039|Experimental|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
11373692|NCT02210026|Experimental|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
11373693|NCT02210013||Caucasian women|200 Caucasian infertile women undergoing their first or second IVF cycle
11373694|NCT02210013||Indian women|200 Indian women undergoing their first or second IVF cycle.
11373696|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
11373697|NCT02209987|Experimental|GS-5745 SC|Participants will receive a single dose of GS-5745 by SC injection.
11373698|NCT02209987|Experimental|GS-5745 IV|Participants will receive a single dose of GS-5745 by IV infusion.
11373699|NCT02209974|Placebo Comparator|Inhaled Placebo|Inhaled placebo administered to healthy (n=7) and to a half (n=8) of COPD patients
11373700|NCT02209974|Experimental|Inhaled corticosteroids (Fluticasone, 0.5 mg)|Inhaled corticosteroids administered to the other half (n=8) of COPD patients
11373701|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
11373702|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
11373703|NCT02209948|No Intervention|Without treatment|
11373704|NCT02209935|Active Comparator|Usual Care|Typically, usual care is when therapies are not initiated until the treating team places an order for each element of care (physical, occupational, speech, and emotional therapy consultation).
11373705|NCT02209935|Experimental|Early Rehabilitation Protocol|Physical, occupational, speech, and emotional evaluation and support personalized to the subject's severity of illness and developmental status.
11373706|NCT02209922|Active Comparator|Transcranial direct current stimulation|"ARM1: Transcranial direct current stimulation (tDCS) intervention and simultaneous balance training.
~Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week."
11373707|NCT02209922|Sham Comparator|ARM 2|ARM2: Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
11373708|NCT02209909|Experimental|aspirin continuation|Intervention : Low-dose aspirin (< 100mg/day) is used before OPCAB surgery in the aspirin continuation group.
11373709|NCT02209909|Experimental|aspirin discontinuation|Intervention: Low-dose aspirin is stopped more than 4 days before OPCAB surgery in the aspirin discontinuation group.
11373710|NCT02209896|Experimental|BlueWind Reprieve System|The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.
11373711|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
11373712|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
11373713|NCT02209870||E-checklist group|The patients after CPR team using E-checklist system
11373714|NCT02209844|Experimental|BI 44847 powder|single rising dose reconstituted with natrosol solution
11373715|NCT02209844|Placebo Comparator|Placebo|reconstituted with natrosol solution
11373716|NCT02209831|Experimental|BIBR 796 BS + pantoprazole|
11373717|NCT02209831|Active Comparator|BIBR 796 BS without pantoprazole|
11373718|NCT02209818|Experimental|Laser Irradiation One Dose|Laser irradiation will be applied in one dose for patients in this group, but only on one side of the jaw. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
11373719|NCT02209818|Experimental|Laser Irradiation Two doses|Laser irradiation will be applied in two doses for patients in this group, but only on one side of the jaw. The second dose will be given after 24 hour of the first one. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
11373720|NCT02209805|Experimental|BIRB 796 BS, low dose|
11373721|NCT02209805|Experimental|BIRB 796 BS, high dose|
11373722|NCT02209805|Placebo Comparator|Placebo|
11373723|NCT02209805|Experimental|BIRB 796 BS, medium dose|
11373724|NCT02209792|Placebo Comparator|Placebo|
11373725|NCT02209792|Experimental|BIRB 796 BS, low dose|2 x 5 mg b.i.d.
11373726|NCT02209792|Experimental|BIRB 796 BS, medium dose 1|20 mg b.i.d.
11373727|NCT02209792|Experimental|BIRB 796 BS, medium dose 2|2 x 5 mg + 20 mg b.i.d.
11373728|NCT02209792|Experimental|BIRB 796 BS, high dose|3 x 20 mg b.i.d.
11373729|NCT02209779|Experimental|BIBR 796 BS, low dose|twice daily doses of 5 mg for 4 weeks
11373730|NCT02209779|Experimental|BIBR 796 BS, medium dose 1|twice daily doses of 10 mg for 4 weeks
11373731|NCT02209779|Experimental|BIBR 796 BS, medium dose 2|twice daily doses of 20 mg for 4 weeks
11373732|NCT02209779|Experimental|BIBR 796 BS, high dose|twice daily doses of 30 mg for 4 weeks
11373733|NCT02209779|Active Comparator|Placebo|
11373734|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
11373735|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
11373736|NCT02209753|Experimental|BIRB 796 BS, low dose|
11373737|NCT02209753|Experimental|BIRB 796 BS, medium dose 1|
11373738|NCT02209753|Experimental|BIRB 796 BS, medium dose 2|
11373739|NCT02209753|Experimental|BIRB 796 BS, high dose|
11373740|NCT02209753|Placebo Comparator|Placebo|
11373741|NCT02209740||Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
11373742|NCT02209727|Experimental|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
11373743|NCT02209714|Experimental|BIIF 1149 BS|
11373744|NCT02209714|Placebo Comparator|Placebo|
11373745|NCT02209701|Experimental|Porfiromycin|
11373746|NCT02209688|Experimental|ESR 1150 CL dose escalation fasted|
11373747|NCT02209688|Experimental|ESR 1150 CL fed|
11373748|NCT02209688|Placebo Comparator|Placebo|
11373749|NCT02209675|Other|patients with elevated liver enzymes|Patients with elevated liver enzymes and/or hyperbilirubinemia post transplantation for hepatitis C virus related disease will have liver biopsy
11373750|NCT02209662|Experimental|APIC-PRP and Standard of Care|APIC-PRP
11373751|NCT02209662|Placebo Comparator|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
11373752|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation A|
11373753|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation B|
11373754|NCT02209649|Active Comparator|Lacidipine and Telmisartan, mono|
11373816|NCT02209233|No Intervention|Control|If randomized to the control group, patients will not be receiving massage therapy.
11373755|NCT02209636|Experimental|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
11373756|NCT02209636|Placebo Comparator|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
11373757|NCT02209623||Pregnant Women receiving TDAP|
11373758|NCT02209610|Other|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
11373759|NCT02209610|Other|Health Control Subjects and Neuromuscular Function|Health Control Subjects
11373760|NCT02209597|Experimental|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a
~Subjects will be studied in 4 phases for a total of approximately 28 weeks:
~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
11373761|NCT02209571|Experimental|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
11373762|NCT02209571|Active Comparator|Control|Breath test and venous blood markers in healthy subjects
11373763|NCT02209558|No Intervention|Standard Written Sternal Precautions|"Patients will receive education that is the standard of care at North Shore Long Island Jewish Health Systems in their post-operative sternal precautions."
11373764|NCT02209558|Experimental|Visual Sternal Precautions|"Patients will receive both standard of care written sternal precautions, as well as visual sternal precautions."
11373765|NCT02209545|Experimental|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
11373766|NCT02209545|Placebo Comparator|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
11373767|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
11373768|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
11373769|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
11373770|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
11373771|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
11373772|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
11373773|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
11373774|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
11373775|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
11373776|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
11373777|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
11373778|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
11373779|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
11373780|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
11373781|NCT02209493|Experimental|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
11373782|NCT02209493|Sham Comparator|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
11373783|NCT02209480|Experimental|Alexander Technique|5 lessons of AT, each lasting up to 45 minutes, weekly intervals The lessons aimed at sensory awareness of everyday movements and movement sequences, such as sitting, walking, lying, or lifting in order to replace habitual patterns using conscious control; and different techniques were applied, such as demonstration, verbal instructions, hands on techniques and others
11373784|NCT02209480|Active Comparator|Heat pad application|5 treatments by means of a heat pad, 15-0 minutes, sitting or lying position, quiet room Heat pad: Zapp-Sack® contained certain grains and a ginger extract, and could be heated up in the microwave.
11373785|NCT02209480|Active Comparator|guided imagery|guided imagery relaxation technique , 45 minutes, 5 sessions in weekly rhythm including body scan, breathing relaxation, visualization
11373786|NCT02209467|No Intervention|Group balance training late start|Participants randomized to late start act as No intervention group during the study period.
11373787|NCT02209467|Experimental|Group balance training early start|Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
11373788|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
11373789|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
11373790|NCT02209428|Active Comparator|IDH wild type|Patients with IDH wild type, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
11373791|NCT02209428|Experimental|IDH mutation|Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
11373792|NCT02209415|Active Comparator|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
11373793|NCT02209415|Experimental|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
11373794|NCT02209402|No Intervention|Usual Care|
11373795|NCT02209402|Experimental|Exercise Training|
11373796|NCT02209389||Positive OctavaPink|Following a positive OctavaPink result, an MRI is performed and any additional testing (required by the MRI).
11373797|NCT02209389||Negative OctavaPink - control|"For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and recalled for an MRI and any additional testing (required by the MRI).
~MRI won't be performed to all negative OctavaPink results. Only one negative control will be assigned to each OctavaPink positive result."
11373798|NCT02209376|Experimental|Arm 1|
11373799|NCT02209363|Experimental|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
11373800|NCT02209363|Sham Comparator|nasal dilator strips|Sham treatment
11373801|NCT02209350|Active Comparator|Group 1|Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
11373802|NCT02209350|Active Comparator|Group 2|Standard endovascular treatment (stenting) in patients with the iliac segment occlusive disease. Medication: after stenting all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
11373803|NCT02209337|Experimental|SRS-I|Implantation of SRS-I
11373804|NCT02209324|Experimental|ASP2151|
11373805|NCT02209311|Experimental|Tissue engineered construction implantation|
11373806|NCT02209298||CoreValve Transcatheter Valve|Medtronic CoreValve SystemTM is designed to replace the native or surgical bioprosthetic aortic heart valve without open heart surgery and without concomitant surgical removal of the failing valve. The support frame is manufactured by Nitinol, which has multi-level, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from a single layer of porcine pericardium into a tri-leaflet configuration. The bioprosthesis is processed with alpha-amino oleic acid (AOA™), which is a compound derived from oleic acid, a naturally occurring long-chain fatty acid. AOA™ is an antimineralization treatment shown to reduce both early and late valvular calcification.
11373807|NCT02209285|No Intervention|Control group|The control group will receive usual care, which is provided by the community care access centre (CCAC). Usual care may include in-home visits by regulated health care providers, personal support workers, and care coordination through the community care access centre. Case conferences may occur on an as-needed basis.
11373808|NCT02209285|Active Comparator|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month self-management intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
11373809|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
11373810|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
11373811|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
11373812|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
11373813|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
11373814|NCT02209246|Experimental|Intervention|The intervention group will be comprised of patients who will complete the PROMIS- CAT for pain interference, pain behavior and physical function prior to the encounter with the physician and then will complete the MISS-21 after the encounter.
11373815|NCT02209246|Experimental|Control|The control group will complete the PROMIS- CAT for pain interference, pain behavior and physical function after the encounter and after completing a satisfaction questionnaire (MISS-21).
11373817|NCT02209233|Experimental|Massage Therapy|If randomized to the intervention group, patients will receive massage therapy of the hand, arm, shoulder, and neck by the licensed massage therapist on duty. The massage will be given in a manner that is congruent with standard of care practices by the Heart and Surgical Hospital and the licensed massage therapist.
11373818|NCT02209220|Active Comparator|Automatic positive airway pressure|Automatic positive airway pressure treatment of obstructive sleep apnea
11373819|NCT02209220|Active Comparator|Continuous positive airway pressure|Continuous positive airway pressure for the treatment of obstructive sleep apnea
11373820|NCT02209207|Active Comparator|Continuous walking training|n=10 patients with COPD Walking intensity 60 percent of 6-minute walking test speed
11373821|NCT02209207|Active Comparator|Interval walking training|n=10 patients with COPD Walking intensity 120 percent of 6-minute walking test speed for 1 minute alternating with 1 minute of rest
11373822|NCT02209194||Aortoiliac Aneurysms Iliac Aneurysms|Endovascular repair of aortoiliac or iliac aneurysms
11373823|NCT02209181|Experimental|JNJ-10450232 250 mg|
11373824|NCT02209181|Experimental|JNJ-10450232 1000 mg|
11373825|NCT02209181|Placebo Comparator|Placebo|
11373826|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
11373827|NCT02209168||Infertile Indian Population|200 Infertile Indian population
11373828|NCT02209168||Infertile arabian population|200 Infertile Arabian population
11373829|NCT02209168||Infertile caucasian population|200 Infertile Caucasian population
11373830|NCT02209155|Active Comparator|R-verapamil 75 mg tablet|375 mg/day; one in the morning, two in the afternoon and two at bedtime daily
11373831|NCT02209155|Placebo Comparator|Placebo|one in the morning, two in the afternoon and two at bedtime daily
11373832|NCT02209142|Experimental|pan-genomic screen|A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,
11373833|NCT02209142|Sham Comparator|control|a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject
11373834|NCT02209129||women at high risk for breast cancer|
11373835|NCT02209116|Active Comparator|QB Open|Participants and their clinician will receive results of the Qb Test
11373836|NCT02209116|Other|Qb Blind|Participants and their clinician will be blind to the results of the Qb test
11373837|NCT02209103|Experimental|Citrus flavonoid|Citrus flavonoid
11373838|NCT02209103|Experimental|Citrus flavonoid formulation|Citrus flavonoid formulation
11373839|NCT02209103|Placebo Comparator|Placebo|Placebo
11373840|NCT02209090|Experimental|maternal modified sims position|"Women in this group will adopt the modified Sims position, lying on the side of the foetal back.
~This position is maintained for the greater part of labour, at least 40 minutes, every hour. The mother can use other positions during resting time of no more than 20 minutes each hour, but never use a lateral position against the side of the foetal back."
11373841|NCT02209090|Sham Comparator|maternal free positions|Women can adopt the position they wish and which is most comfortable, except for lateral positions which can only be used for a maximum of 20 minutes each hour to avoid confounding factors.
11373842|NCT02209077|Experimental|Healthy Volunteers|OCT performed to collect data from the back of the eye
11373843|NCT02209077|Experimental|Glaucoma group|OCT performed to collect data from the back of the eye
11373844|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
11373845|NCT02209051|Active Comparator|AMNIOEXCEL|Human Amniotic Membrane Allograft
11373846|NCT02209051|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading of wound.
11373847|NCT02209038|Experimental|Expanded AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?
~4 answer choices:
~Yes, I would like to complete a comprehensive version of an advance directive.
~Yes, I would like to complete an expanded version of an advance directive.
~Yes, I would like to complete a brief version of an advance directive.
~No, I do not wish to complete an advance directive."
11373848|NCT02209038|No Intervention|Standard AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?
~2 answer choices:
~Yes, I would like to complete an AD.
~No, I do not wish to complete an advance directive."
11373849|NCT02209038|Experimental|Expanded Life-sustaining therapy Choice|"For each hypothetical illness state described in the living will:
~4 answer choices:
~No, I would not want life support.
~Yes, I would want life support.
~I would want life support if my doctor believes it could help, but I want to stop receiving life support if at any time my doctor believes it is only delaying the moment of my death.
~I do not wish to specify a preference at this time."
11373850|NCT02209038|No Intervention|Standard Life-sustaining Therapy Choice|"For each hypothetical illness state described in the living will:
~3 answer choices:
~No, I would not want life support.
~Yes, I would want life support.
~I do not wish to specify a preference at this time."
11373851|NCT02209025|Placebo Comparator|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
11373852|NCT02209025|Experimental|Theobromine|500mg theobromine in a drink
11373853|NCT02209012||ALA|Subjects who received ALA in CP0108
11373854|NCT02209012||Vehicle|Subjects who received Vehicle in CP0108
11373855|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
11373856|NCT02208986|Active Comparator|0.2mg Triptorelin|Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
11373857|NCT02208986|Active Comparator|0.3mg Triptorelin|Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
11373858|NCT02208986|Active Comparator|Active Comparator: 0.4mg Triptorelin|Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
11373859|NCT02208973|Experimental|PBF-680 (5 mg)|5 mg of PBF-680
11373860|NCT02208973|Experimental|PBF-680 (10 mg)|10 mg of PBF-680
11373861|NCT02208973|Experimental|PBF-680 (20 mg)|20 mg of PBF-680
11373862|NCT02208973|Experimental|PBF-680 (40 mg)|40 mg of PBF-680
11373863|NCT02208973|Experimental|PBF-680 (60 mg)|60 mg of PBF-680
11374291|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
11373864|NCT02208973|Placebo Comparator|Placebo|Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo
11373865|NCT02208960|Experimental|Neonatal Kit|Mothers in the neonatal kit clusters will receive a neonatal kit and training on how to use the kit components during their third trimester of pregnancy. The kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Community Health Workers will be equipped with a hand-held battery operated scale to identify low birth weight newborns.
11373866|NCT02208960|Experimental|Neonatal Stimulation|During home visits in the 3rd trimester, mothers in the neonatal stimulation clusters will be taught 3 core messages pertaining to neonatal stimulation. First, mothers will be taught how to make eye contact and talk to their child. This type of interaction encourages social inclusion, attachment, and development of social-communication skills. Second, mothers will be taught techniques to foster responsive feeding and caregiving. Finally, mothers will be encouraged to sing songs and nursery rhymes, including those with gentle touch in order to support the development of communication skills, and introduce a tactile component to caregiving. These messages will be reiterated at subsequent home visits by the CHW after the baby is born.
11373867|NCT02208960|Experimental|Neonatal Kit and Neonatal Stimulation|Participants in this arm of the study will receive both a neonatal kit (described in Arm 1) and neonatal stimulation (described in Arm 2).
11373868|NCT02208960|No Intervention|Control (Standard Care)|"In control clusters, CHWs will visit the home according to the regular schedule (same as in the intervention clusters) and deliver the standard CHW post-natal care that consists of talking to mothers about:
~Exclusive breastfeeding and proper nutrition for both the mother and the baby.
~Ensuring warmth to the baby.
~Full immunization and growth monitoring of newborn.
~Hygiene and sanitation practices.
~Family Planning and promote the proper use of Insecticides Treated Nets.
~Identifying any danger sign/complication for both mothers and new-borns and refer for prompt treatment (within 24 hours) for management and treatment.
~Promoting the use of services such as birth registration.
~Giving advice on proper care of the umbilical cord."
11373869|NCT02208947|Active Comparator|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
11373870|NCT02208947|Experimental|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
11373871|NCT02208934|Experimental|PBF-999 (5 mg)|5 mg of PBF-999
11373872|NCT02208934|Experimental|PBF-999 (10 mg)|10 mg of PBF-999
11373873|NCT02208934|Experimental|PBF-999 (20 mg)|20 mg of PBF-999
11373874|NCT02208934|Experimental|PBF-999 (40 mg)|40 mg of PBF-999
11373875|NCT02208934|Placebo Comparator|Placebo|Placebo for the 5, 10, 20 and 40 mg dose
11373876|NCT02208921||T2DM patients with Chronic Kidney Disease|T2DM patients with Chronic Kidney Disease
11373877|NCT02208908||Patient with cancer hospitalize inpalliative situation|"An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
~An assessment of the traceability of clinical assessment and appropriate treatment prescribed or will be conducted on day 3 and repeated the day of the release of hospitalization (or day 15) from information recorded in the patient record"
11373878|NCT02208895||iSTAT Study Group|Measure glucose of pleural fluid via glucometer, in the laboratory, and using the iSTAT device to see if the three methods give a similar reading or not.
11373879|NCT02208882|Experimental|Panel 1: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
11373880|NCT02208882|Experimental|Panel 2: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
11373881|NCT02208882|Experimental|Panel 3: BMS-986120 or Placebo + Midazolam|BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
11373882|NCT02208882|Experimental|Panel 4: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
11373883|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.
~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
11373884|NCT02208856|Placebo Comparator|Placebo|
11373885|NCT02208856|Experimental|BIBR 796 BS food effect|
11373886|NCT02208856|Experimental|BIBR 796 BS|
11373887|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
11373888|NCT02208830|Experimental|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
11373889|NCT02208830|Experimental|pulmonary rehabilitation|Duration of 8 week, twice weekly exercise program with: lower limb strength training and aerobic training per 30 minutes.
11373890|NCT02208817||Ill patients|Ill patients who require Paediatric Intensive Care or Paediatric High Dependency Care
11373891|NCT02208817||Well Controls|Matched controls who are well (PEWS<3)
11373892|NCT02208817||Parent feedback|Feedback from parents/carers of children recruited into the PRefill study
11373893|NCT02208817||Healthcare professionals feedback|Feedback from healthcare professionals who have cared for a child with the device on
11373894|NCT02208804|Experimental|Surefire Infusion System|Hepatic arterial administrations using the Surefire Infusion System
11373895|NCT02208804|Active Comparator|Standard End-hole Microcatheter|Hepatic arterial administrations using the standard end-hole microcatheter
11373896|NCT02208791|Active Comparator|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
11373897|NCT02208791|Experimental|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
11373898|NCT02208778|Experimental|Duloxetine|Duloxetine 30 mg a day (2 weeks), then 60 mg a day (4weeks), taken by mouth
11373899|NCT02208778|Placebo Comparator|Placebo (for Duloxetine)|Sugar pill: 1 capsule a day (2 weeks), then 2 capsules a day (4 weeks) taken by mouth
11373900|NCT02208778|Experimental|Remifentanil|Intravenous infusion with maximum estimated plasma target of 1.0 ng/ml, during less than 20 minutes
11373901|NCT02208778|Placebo Comparator|Placebo (for Remifentanil)|Intravenous infusion of normal saline, during less than 20 min
11373902|NCT02208765|Other|Study cohort|Any patient referred to the Nuclear Cardiology Laboratory of the University Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis evaluation of suspected or know coronary artery disease
11373903|NCT02208752|Active Comparator|Exercises|exericises on motor control and strengthening exercises on the Rotator Cuff
11373904|NCT02208752|Placebo Comparator|Control group- No exercises|No exercises
11373905|NCT02208739|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy was given to all patients at baseline
11373906|NCT02208739|Active Comparator|Oral hygiene instructions|Oral hygiene instructions were given to all patients at baseline
11373907|NCT02208726|Placebo Comparator|Sucrose pillules|Unmedicated sucrose pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
11373908|NCT02208726|Experimental|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH. Pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
11373909|NCT02208713|Experimental|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
11373910|NCT02208700|Experimental|Oxepa|Other: Therapeutic nutrition with EPA, GLA and antioxidants.
11373911|NCT02208700|Active Comparator|Jevity 1.5|Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .
11373912|NCT02208687|Experimental|Energetic|Self management group program aimed at reconditioning and social participation
11373913|NCT02208687|Other|Control group|Usual care
11373914|NCT02208674|No Intervention|Usual Care|Primary care provider-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per usual care.
11373915|NCT02208674|Experimental|Protocolized, pharmacist-delivered CKD Action Plan|Protocolized, pharmacist-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per KDIGO and JNC-8 recommendations.
11373916|NCT02208648||Deceased|"Peri-operative mortality (within 90 days). Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
11373917|NCT02208648||Matched control|"Patients who survived beyond 90 days peri-operatively. Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
11373918|NCT02208635|Experimental|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (~30 µg Zn/g).
11373919|NCT02208635|Experimental|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
11373920|NCT02208635|Active Comparator|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
11373921|NCT02208622|Experimental|Study 1: Whey Supplement Day 1|Children in this arm received the whey supplement as part if their diet on day 1.
11373922|NCT02208622|Experimental|Study 1: Whey Supplement Day 2|Children in this arm received whey supplement as part of their diet on day 2.
11373923|NCT02208622|Experimental|Study 2: Whey Supplement|Children in this arm received a whey supplement as part of their diet.
11373924|NCT02208622|No Intervention|Study 2: Control|Children in this arm did not receive a whey supplement as part of their diet.
11373925|NCT02208609|Experimental|Maize Tortillas with 20% Amaranth|Children in this arm were fed maize tortillas fortified with 20% amaranth
11373926|NCT02208609|Experimental|Maize Tortillas without 20% Amaranth|Children in this arm were fed maize tortillas without amaranth
11373927|NCT02208596|Experimental|Group A|In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
11373928|NCT02208596|Experimental|Group B|In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
11373929|NCT02208596|Experimental|Group C|In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
11374107|NCT02207387|Experimental|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
11373930|NCT02208583|Active Comparator|AR dependent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:
~CRPC patients without druggable gene mutations: Docetaxel & Prednisone; CRPC patients with druggable gene mutations: DP & Targeted drugs"
11373931|NCT02208583|Active Comparator|AR independent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:
~CRPC patients without druggable gene mutations: cisplatin & Etoposide; CRPC patients with druggable gene mutations: EP & Targeted drugs"
11373932|NCT02208570|Experimental|P(+)V(+)|PPV>14% before anesthesia induction, HES 6ml/kg infused
11373933|NCT02208570|Experimental|P(+)V(-)|PPV>14% before anesthesia induction, no additional volume infused
11373934|NCT02208570|Experimental|P(-)V(+)|PPV<14% before anesthesia induction, HES 6ml/kg infused
11373935|NCT02208570|Experimental|P(-)V(-)|PPV<14% before anesthesia induction, no additional volume infused
11373936|NCT02208557|Active Comparator|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
11373937|NCT02208557|Experimental|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
11373938|NCT02208544|Experimental|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:
~negative: watchful waiting including confirmatory ultrasound
~positive: diagnostic thyroid surgery as planned"
11373939|NCT02208544|Other|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
11373940|NCT02208531|No Intervention|Control|
11373941|NCT02208531|Experimental|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
11373942|NCT02208518||Elastography analysis|Consecutive patients undergoing for upper endoscopy ultrasound
11373943|NCT02208505|Experimental|Dexmedetomidine|we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).
11373944|NCT02208505|Active Comparator|Remifentanil|we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.
11373945|NCT02208492|Experimental|Levetiracetam|
11373946|NCT02208492|Active Comparator|Carabamazepine|
11373947|NCT02208479||cardiac surgery|
11373948|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
11373949|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
11373950|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
11373951|NCT02208453|Experimental|InSpace implantation|InSpace device implantation
11373952|NCT02208440|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
11373953|NCT02208440|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
11373954|NCT02208427|Experimental|3M_RH|Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
11373955|NCT02208427|Active Comparator|9M_INH|Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
11373956|NCT02208414|Experimental|Crab or shrimp|Intervention: treated with crab and shrimp energy signature vial using NAET
11373957|NCT02208414|Placebo Comparator|Placebo|Treated with water vial
11373958|NCT02208401|Active Comparator|conventional cold snare polypectomy|conventional cold snare polypectomy
11373959|NCT02208401|Experimental|Cold snare polypectomy with suction|Cold snare polypectomy with suction
11373960|NCT02208388|Experimental|Computed tomography perfusion|Patients with Computed tomography perfusion
11373961|NCT02208388|Active Comparator|Fractional flow reserve|Patients with Fractional flow reserve
11373962|NCT02208375|Experimental|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
11373963|NCT02208375|Experimental|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
11373964|NCT02208375|Experimental|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
11373965|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018.
~Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
11373966|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions
11373967|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
11373968|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
11373969|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
11373970|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
11373971|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
11373972|NCT02208336||Observational (electronic medical record review)|Patients' electronic medical records are reviewed for adherence, severe myelosuppression, and patient morbidity retrospectively and prospectively.
11373973|NCT02208323|Experimental|Bubble CPAP|Bubble CPAP for 28 days
11373974|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
11373975|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
11373976|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
11373977|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
11373978|NCT02208284|Experimental|Cohort 1-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
11373979|NCT02208284|Experimental|Cohort 2-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
11373980|NCT02208284|Experimental|Cohort 3-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
11373981|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
11373982|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
11373983|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
11373984|NCT02208245|Active Comparator|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
11373985|NCT02208245|Active Comparator|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
11373986|NCT02208232||MC 6125 AS IOL|cataract surgery with implantation of intraocular lens MC 6125 AS in one eye
11373987|NCT02208219|Experimental|Music-supported Therapy (n=40)|Participants in this group will receive a Music-supported Therapy training at the Hospital during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
11373988|NCT02208219|Experimental|home-based Music-supported Therapy(n=40)|Participants in this group will receive a Music-supported Therapy training at home during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
11373989|NCT02208219|Active Comparator|Conventional treatment (n=40)|Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
11373990|NCT02208193|Experimental|healthy controls group|Healthy volunteers
11373991|NCT02208193|Experimental|Alzheimer subjects group|"Group A Alzheimer group: patients with mild to severe stages of Alzheimer's disease: subgroup A1 Alzheimer group hospitalized at the Paul Spillmann Centre (Centre Paul Spillmann, CPS) (CHU de Nancy, France); subgroup A2 Alzheimer group monitored at the Resource and Research Memory Centre (Centre Mémoire de Ressources et de Recherche, CMRR) (CHU de Nancy, France)"
11373992|NCT02208180|Experimental|Return of genomic results on cardiovascular disease risk|Participants will receive genomic cardiovascular disease risk information.
11373993|NCT02208180|Active Comparator|Return of lifestyle results on cardiovascular disease risk|Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
11373994|NCT02208167|Other|Chronic HIV infection|HXTC infusion
11373995|NCT02208167|Other|Acute HIV infection|HXTC infusion
11373996|NCT02208154|Active Comparator|Standard care|"Standard infection prevention measurements will be implemented before the baseline period and carried out throughout the entire trial. They consist of:
~Chlorhexidine 2% body washings (CHX-BW) for all ICU patients. The face and neck of the patient will not be cleansed with Chlorhexidine to prevent irritation of the eyes and face.
~A hand hygiene improvement program (HHIP) based on the program designed by the World Health organisation (WHO).
~Standard oropharyngeal care consists of oral washing with sterile water (3-4 times daily) and tooth brush twice daily."
11373997|NCT02208154|Experimental|Chlorhexidine oral care (CHX-Oro)|Chlorhexidine digluconate oromucosal gel 1%, 2cm, to be administered 4 times daily, during invasive mechanical ventilation.
11373998|NCT02208154|Experimental|Selective oropharyngeal decontamination|Selective oropharyngeal decontamination (SOD) mouth paste containing colistin and tobramycin in a 2% concentration and nystatin 1 x 10^5 units, dosage 0.5g , to be administered 4 times daily during the entire period of invasive mechanical ventilation.
11373999|NCT02208154|Experimental|Selective digestive decontamination|Selective digestive decontamination (SDD), suspension via the nasogastric tube containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u., dosage 10ml, to be administered together with SOD (see above) 4 times daily during entire period of mechanical ventilation.
11374000|NCT02208141||lean and obese children and adolescents|study cohort may be stratified for lean (definded as BMI <1.28 SDS) and overweight/obese (definded as BMI>= 1.28 SDS) children for posthoc analyses no intervention
11374001|NCT02208128|No Intervention|Receptor-Tyrosinkinase-Inhibitor|Guidelines-oriented therapy with approved systemic medications for renal cell carcinoma individually for each patient (Receptor-Tyrosinkinase-Inhibitor) (e.g.Sunitinib, Pazopanib, Bevacizumab, Everolimus, Axitinib, Temsirolimus). With 1.progression turning to second line treatment with one of the upper mentioned medications. Third line therapy due to the individual molecular modifications for each patient.
11374002|NCT02208115|Experimental|Meal composition - High GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
11374003|NCT02208115|Experimental|Meal composition - Low GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
11374004|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
11374005|NCT02208089|Active Comparator|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
11374006|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
11374007|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
11374008|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
11374009|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
11374010|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
11374011|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
11374012|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
11374013|NCT02208024|Experimental|Stereotactic Body Radiation Therapy|5 fractions of 6.6 Gy delivered twice weekly with each fraction separated by greater than 48 hours over 15 days
11374014|NCT02207998|Experimental|Homeopathic complex and physiotherapy|"Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.
~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist."
11374015|NCT02207998|Placebo Comparator|Placebo and physiotherapy|"Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.
~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist ."
11374016|NCT02207985|Experimental|Hematopoetic stem cell transplantation|Patients with pancreatic adenocarcinoma that have undergone Whipple surgery and show no sign of disease recurrence can be treated with hematopoietic stem cell transplantation to achieve an immunological anti-tumor effect.
11374017|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
11374018|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
11374019|NCT02207959|Experimental|Surveillance Endoscopy|White light examination, vital-dye enhanced fluorescence examination (VFI), High Resolution Microendoscope (HRME)
11374020|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
11374021|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
11374022|NCT02207933|Experimental|AP shifting group|
11374023|NCT02207933|Active Comparator|gait training group|
11374024|NCT02207920|Experimental|Group 1|"At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid."
11374025|NCT02207920|Experimental|Group 2|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
~At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
11374026|NCT02207920|Experimental|Group 3|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.
~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
11374027|NCT02207920|Experimental|Group 4|At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
11374028|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
11374029|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
11374030|NCT02207881|Placebo Comparator|placebo|placebo gel, 25mg, 3 times up to 10 days
11374031|NCT02207881|Experimental|VDO gel|VDO gel 25mg, 3 times a day up to 10 days
11374032|NCT02207868||no treatment|
11374033|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
11374034|NCT02207842||Volatile anesthesia exposure|
11374035|NCT02207842||No volatile anesthesia exposure|
11374036|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
11374037|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
11374038|NCT02207816|Experimental|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
11374039|NCT02207816|Active Comparator|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
11374040|NCT02207816|Active Comparator|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
11374041|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
11374042|NCT02207803|No Intervention|Control|Control
11374043|NCT02207790|Experimental|E2609 low-dose and placebo in healthy Japanese subjects|Cohort 1 will consist of Japanese subjects randomized to a low-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
11374044|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy Japanese subjects|Cohort 2 will consist of Japanese subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
11374108|NCT02207387|Experimental|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
11374357|NCT02205710|Placebo Comparator|Computerized game training|Series of gamified tasks.
11374045|NCT02207790|Experimental|E2609 high-dose and placebo in healthy Japanese subjects|Cohort 3 will consist of Japanese subjects randomized to a high-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
11374046|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy White subjects|Cohort 4 will consist of White subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
11374047|NCT02207777|Experimental|Roux-en-Y gastric bypass (RYGB)|Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain approximately 16-18% (with a range of 16-25%) weight loss.
11374048|NCT02207777|Active Comparator|Low-calorie diet|Subjects in this group will participate in a low-calorie diet intervention to obtain approximately 16-18% (with a range of 16-25%) weight loss.
11374049|NCT02207764|Experimental|Reiki Intervention|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
11374050|NCT02207764|No Intervention|nursing presence control|Each patient in the control group will receive usual care including the study nurse presence for the 15-minute period.
11374051|NCT02207738|Experimental|microneedling radiofrequency device|microneedling radiofrequency
11374052|NCT02207738|Active Comparator|bipolar radiofrequency device|bipolar radiofrequency treatment
11374053|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
11374054|NCT02207725|Placebo Comparator|Placebo|Placebo
11374055|NCT02207712|Active Comparator|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
11374056|NCT02207712|Experimental|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
11374057|NCT02207699|Experimental|Benzonatate 200 mg|
11374058|NCT02207699|Experimental|Benzonatate 800 mg|
11374059|NCT02207699|Active Comparator|Moxifloxacin 400 mg|
11374060|NCT02207699|Placebo Comparator|Placebo|
11374061|NCT02207686||von Hippel-Lindau disease|Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
11374062|NCT02207673|Active Comparator|Spikes as biomarker|"In arm  spikes the resection of epileptogenic tissue is guided by epileptiform spikes in the aECoG (current standard). (Independent of the randomisation ictiform spike patterns will always be resected.)"
11374063|NCT02207673|Experimental|HFOs as biomarker|"In arm HFOs resection of epileptogenic tissue is guided by HFOs in the aECoG (new). (Independent of the randomisation ictiform spike patterns will always be resected.)"
11374064|NCT02207660||Cisplatin,P-HDFL|The general principles for patients schedule for P-HDFL regimen treatment were as followings: patients must have had white cell count > 3000/mm3, platelet count > 100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance ([urine creatinine level (mg/dL) X 24-hr urine amount (mL)]/[serum creatinine level (mg/dL) X 1,440 min]) of ≧ 40 mL/min [12,15], total bilirubin ≦ 2 mg/dL, and transaminase (≦3X the upper normal limits). Also, patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
11374065|NCT02207647||Patients with syndromes requiring lumbar puncture|
11374066|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
11374067|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
11374068|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
11374069|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
11374070|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
11374071|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
11374072|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
11374073|NCT02207595|Experimental|UCB5857 Cohort 1|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
11374074|NCT02207595|Experimental|UCB5857 Cohort 2|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
11374075|NCT02207595|Experimental|UCB5857 Cohort 3|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
11374076|NCT02207595|Experimental|UCB5857 Cohort 4|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
11374077|NCT02207595|Experimental|UCB5857 Cohort 5|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
11374078|NCT02207582|Experimental|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
11374079|NCT02207582|Placebo Comparator|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
11374080|NCT02207569|Experimental|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:
~Evolut R Transcatheter Aortic Valve (TAV)
~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
~EnVeo R Loading System (LS)"
11374081|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
11374082|NCT02207543|Experimental|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
11374083|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
11374084|NCT02207517|Experimental|Office-based verg/accomm therapy (OBVAT)|OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
11374085|NCT02207517|Placebo Comparator|Office-based placebo therapy (OBPT)|"Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures.
~The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT"
11374086|NCT02207504|Experimental|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.
~Crizotinib- given orally daily-28 day cycle
~Enzalutamide- given orally daily-28 day cycle"
11374087|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
11374088|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
11374089|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
11374090|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
11374091|NCT02207465|Experimental|Single Arm|
11374092|NCT02207452|Other|Salbutamol + Ipratropium|Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose.
11374093|NCT02207452|Other|Ipratropium + Salbutamol|Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose.
11374094|NCT02207439|Experimental|Single Arm Phase 2|
11374095|NCT02207426|Experimental|TobrAir® 6.0|Tobramycin 75mg inhalation solution
11374096|NCT02207426|Experimental|TOBI® / PARI LC® PLUS Nebulizer|Tobramycin 300mg nebulizer solution
11374097|NCT02207426|Experimental|TOBI® Podhaler™|Tobramycin 112mg (4x28mg) inhalation powder
11374098|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
11374099|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
11374100|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
11374101|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
11374102|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
11374103|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
11374104|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
11374105|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
11374106|NCT02207387|Experimental|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
11374109|NCT02207387|Experimental|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.
~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
11374110|NCT02207387|Experimental|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.
~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
11374111|NCT02207374|Experimental|Semaglutide 0.5 mg|
11374112|NCT02207374|Experimental|Semaglutide 1.0 mg|
11374113|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
11374114|NCT02207361|Experimental|Paclitaxel, Carboplatin，injection|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
11374115|NCT02207361|Active Comparator|Paclitaxel, Epirubicin，injection|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
11374116|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with FlexPen®|
11374117|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with the PDS290 pen-injector|
11374118|NCT02207335|Experimental|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
11374119|NCT02207335|Active Comparator|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
11374120|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)
~-- Complete baseline data collection, and registration
~Patient Randomization
~Standard transplant oncology care
~-- Palliative care consults only upon request
~Longitudinal Data Collection (patient & family caregivers)
~Week-2 of hospitalization
~3-months, and 6-months post HSCT"
11374121|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care
~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)
~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits
~Longitudinal Data Collection (patient & family caregivers)
~Week-2 of hospitalization
~3-months, and 6-months post HSCT"
11374122|NCT02207309|Active Comparator|Pazopanib|800mg, oral, 24 months
11374123|NCT02207309|Placebo Comparator|Placebo|800mg, oral, 24 months
11374124|NCT02207296|Other|PVI group|Fluid optimisation using PVI
11374125|NCT02207296|No Intervention|Control group|Standard care using a hemodynamic protocol during general anesthesia
11374126|NCT02207270|Experimental|Same day discharge|Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
11374127|NCT02207270|Other|Overnight stay standard care|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.
11374128|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
11374129|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
11374130|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
11374131|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
11374132|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
11374133|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
11374134|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
11374135|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
11374168|NCT02206984|Active Comparator|Anastrozole|1mg given orally daily for 21 days
11374136|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
11374137|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
11374138|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
11374139|NCT02207218||NovoEight®|
11374140|NCT02207205|Other|Catheter vs venipuncture blood samples|Evaluation of whether there is any difference in results of whole blood clotting time in blood samples drawn from an indwelling catheter versus direct venipuncture
11374141|NCT02207192||Morbidly obese|Consecutive morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric surgery were prospectively recruited.Subjects with respiratory and cardiac history (asthma, Chronic obstructive pulmonary disease, heart failure) were excluded.
11374142|NCT02207179|No Intervention|Single Arm|LumaScan Image Guided Surgery
11374143|NCT02207166||user group|volunteers who are willing to receive 40 minutes video monitoring and questionnaires while operation a electronic blood pressure measuring machines.
11374144|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
11374145|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
11374146|NCT02207140|Experimental|probiotic|HOWARU Restore
11374147|NCT02207140|Placebo Comparator|placebo|microcrystalline cellulose
11374148|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
11374149|NCT02207114|No Intervention|Observational|9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
11374150|NCT02207114|Experimental|Biomarker Algorithm Intervention|"The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics.
~The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs."
11374151|NCT02207101|Active Comparator|E-OJ-01 (OXYJUN)|E-OJ-01 (OXYJUN). Dose: 01 capsule to be taken orally daily after lunch.
11374152|NCT02207101|Placebo Comparator|Placebo|Matching placebo capsules [for E-OJ-01 (OXYJUN)] composed of microcrystalline cellulose. Dose: 01 capsule to be taken orally daily after lunch.
11374153|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
11374154|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.
~SPMS subjects will have two baseline [11C]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
11374155|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline [C11]PK-1195 PET scans and 1 MRI.
11374156|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
11374157|NCT02207049|Active Comparator|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
11374158|NCT02207049|Active Comparator|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
11374159|NCT02207049|Active Comparator|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
11374160|NCT02207036|Experimental|Facebook intervention|Assignment to private group on Facebook with 3 months of content delivered to the group.
11374161|NCT02207036|Active Comparator|Referral|Referral to smokefree.gov website
11374162|NCT02207023|No Intervention|Memory Training Program|Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
11374163|NCT02207023|Experimental|Healthy Lifestyle Training Program|Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
11374164|NCT02207010|Experimental|AZD1775|Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
11374165|NCT02206997||Passive Insulation standard treatment|no active warming before start of anesthesia and no active warming at PACU
11374166|NCT02206997||Active prewarming treatment|active warming before start of anesthesia and active warming at PACU following recommendations of S3-guideline
11374167|NCT02206984|Active Comparator|tamoxifen|Tamoxifen is administered orally, at a dose of 20 mg,daily, for 21 days
11374169|NCT02206984|Active Comparator|fulvestrant|500 mg, administered as two 250 mg IM injections, given on days 1 and 14
11374170|NCT02206971|Active Comparator|Feedback Group|receive a Smoking Cessation Manual, the opportunity for smoking cessation counseling on the phone, and urine analyses feedback via the mail plus a phone call to discuss the information
11374171|NCT02206971|No Intervention|Standard Care|receive a Smoking Cessation Manual and the opportunity for smoking cessation counseling on the phone
11374172|NCT02206958|Other|No treatment control group|No treatment control group
11374173|NCT02206958|Experimental|Behavioral Urinary Incontinence Treatment|12 week program combining behavioral treatments for urinary incontinence and physical activity
11374174|NCT02206945|Experimental|neurofeedback|Two imaging sessions of neurofeedback.
11374175|NCT02206945|Placebo Comparator|control feedback|Two imaging sessions of feedback
11374176|NCT02206932|Other|Sofosbuvir + Simeprevir|Subjects will be enrolled and treated with simeprevir 150 mg and sofosbuvir 400 mg once daily for 12 weeks
11374177|NCT02206906||Study Participants|All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
11374178|NCT02206893|Experimental|Mobile: Professional and peer support|A mobile app that provides both professional support and peer support
11374179|NCT02206893|Experimental|Mobile: Peer support|A mobile app that provides peer support, but not professional support
11374180|NCT02206893|Experimental|Mobile: Professional Support|A mobile app that provides professional support, but no peer support
11374181|NCT02206893|Active Comparator|Mobile: No Support|A mobile app that provides neither peer support nor professional support
11374182|NCT02206893|Active Comparator|Web: No Support|A web app that provides neither peer support, nor professional support
11374183|NCT02206867|Experimental|LBAL|Developed by LG Life Sciences
11374184|NCT02206867|Active Comparator|Humira®|Abbvie
11374185|NCT02206854|Experimental|R-flurbiprofen|200 mg R-flurbiprofen in gelatine capsules once
11374186|NCT02206841||NAFLD|Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as targeted SNP arrays, super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, metabolomics, fecal microbiome, metabolite, metagenome/metatranscriptome analyses.
11374187|NCT02206828||1 GROUP|Only 1 group not predetermined
11374188|NCT02206815|Active Comparator|Ticagrelor+Warfarin|Ticagrelor:Plain, round, yellow, film-coated tablet, 90mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
11374189|NCT02206815|Active Comparator|Clopidogrel+Aspirin+Warfarin|Clopidogrel:Light red bisulfate tablets, containing one 75mg; Aspirin:Plain, round, white, film-coated tablet, 100mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
11374190|NCT02206802||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
11374191|NCT02206802||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
11374192|NCT02206789|Active Comparator|penetrating keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators.
~3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years
~."
11374193|NCT02206789|Active Comparator|therapeutic keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators. (For all patients with fungal keratitis topical steroids will be administered only after 2 weeks post keratoplasty.) Until then diclofenac sodium0.1% may be used 3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years
~."
11374194|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
11374195|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
11374196|NCT02206763|Experimental|Momelotinib (MMB)+erlotinib|Participants will receive momelotinib (MMB) plus erlotinib.
11374197|NCT02206750|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11374198|NCT02206750|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11374199|NCT02206737|Experimental|E-Cigarette|3 doses of e-cigarette to be given No nicotine Low dose nicotine High dose nicotine
11374200|NCT02206724|Experimental|STEREOTACTIC BODY RADIOTHERAPY|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
11374201|NCT02206711|Experimental|Single oral dose of [14C] BMS 955176|A single 180 mg oral dose of [14C] BMS-955176 containing approximately 80 microcurie of total radioactivity.
11374202|NCT02206711|Experimental|Nasoduodenal (ND) Tube Cohort|A single dose of [14C] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.
11374203|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
11374204|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
11374205|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
11374206|NCT02206659|Experimental|Telmisartan|2-week placebo run-in period followed by 6 weeks of treatment with telmisartan
11374207|NCT02206646||Metalyse|weight-adjusted dose
11374208|NCT02206633||Elderly, assisted living residents|Hydration Monitor ultrasound measurements
11374209|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
11374210|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
11374211|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
11374212|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
11374213|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
11374214|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
11374215|NCT02206594|Experimental|Descemetorhexis|
11374216|NCT02206581||young healthy adult athletes|Hydration Monitor measurement of the ultrasound velocity and measures of hydration status including urine specific gravity, plasma and urine osmolality in male and female young adults after undergoing 3% acute dehydration and a 2-hr rehydration period
11374217|NCT02206568|Experimental|URAL vs. Insulin lispro|Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.
11374218|NCT02206555|Experimental|Treatment group (TRUVADA)|Homosexual men and heterosexual men and women at high risk of HIV infection
11374219|NCT02206542|Experimental|Robot-assisted group|Electroacupuncture, physical therapy and upper limb rehabilitation robot
11374220|NCT02206542|Active Comparator|Control group|Electroacupuncture and physical therapy
11374221|NCT02206529|Active Comparator|Social Network Engagement+Std Treatment|"Social Network Engagement = content and activities to help the parent engage his/her social network in supporting healthy lifestyle behaviors.
~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
11374222|NCT02206529|Other|Standard Treatment|"This comparator arm consists of historical controls, participants in the FOCUS trial who received standard treatment.
~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
11374223|NCT02206516|Experimental|patients|Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
11374224|NCT02206503|Experimental|Cyclophosphamide; Lenalidomide; Dexamethasone|"MM Patients who experienced biochemical progression during Rd treatment without CRAB (signs of organ damage, multiple myeloma-related, as renal impairment and/or anemia and/or new bone lesions and/or hypercalcemia), will continue:
~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days.
~Dexamethasone orally at the dose of 40 mg once a week.
~Adding:
~· Cyclophosphamide orally at the dose of 50 mg/day on days 1-21 every 28 days. CRd combination will be continued for 9-4week cycles. Patients will not receive any maintenance therapy."
11374225|NCT02206490|Active Comparator|Naltrexone Study Drug|Subjects will take naltrexone 4.5 mg daily for three months.
11374226|NCT02206490|Placebo Comparator|Naltrexone placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
11374227|NCT02206490|Active Comparator|dextromethrophan study drug|subjects will take a sustained release dextromethorphan pill twice a day.
11374228|NCT02206490|Placebo Comparator|dextromethoprhan placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
11374229|NCT02206477|Experimental|DMSO treatment group|The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
11374230|NCT02206477|Placebo Comparator|the control group|The control group will be treated with the same post-operative protocol, but with 0.9% saline instead of DMSO. On the seventh post-operative day, the patient will be guided to set 10 cc 0.9% saline soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
11374231|NCT02206464|Experimental|Group 1|H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
11374232|NCT02206464|Experimental|Group 2|H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
11374233|NCT02206464|Experimental|Group 3|H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
11374234|NCT02206438|Experimental|1)C-LMA group|
11374235|NCT02206438|Active Comparator|2)Air-Q group|
11374236|NCT02206425|Experimental|bortezomib + melphalan + prednisone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374237|NCT02206425|Experimental|bortezomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374287|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
11374288|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
11374238|NCT02206425|Experimental|carfilzomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374239|NCT02206425|Experimental|bortezomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374240|NCT02206425|Experimental|carfilzomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374241|NCT02206425|Experimental|bortezomib + cyclophosphamide + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374242|NCT02206425|Experimental|bortezomib + cyclophosphamide + ascorbic acid|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.
11374243|NCT02206425|Experimental|bortezomib + PLD + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374244|NCT02206425|Experimental|bortezomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374245|NCT02206425|Experimental|carfilzomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
11374246|NCT02206412||HMGB1 group|
11374247|NCT02206386|Experimental|MentalHealthTraining-Net|MHTraining-Net is an implementation strategy that uses a web-based platform with several long distance tools (e.g. e-learning modules, consultation, telephone calls, toolkits, and discussion boards) to deliver four types of implementation activities: infrastructure development, training and education, quality improvement, and social networking.
11374248|NCT02206386|Active Comparator|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded trainings in the use of the protocol and depression screening posted by Brightree.
11374249|NCT02206360||Individuals at elevated risk for pancreatic cancer|Individuals with an elevated risk of developing pancreatic cancer as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk.
11374250|NCT02206347|Other|attention focus|
11374251|NCT02206334|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.
11374252|NCT02206321||Navigation total knee arthroplasty|Navigation total knee arthroplasty
11374253|NCT02206321||Conventional total knee arthroplasty|Conventional total knee arthroplasty
11374254|NCT02206308|Experimental|single arm|Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;
11374289|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
11374290|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
11374255|NCT02206295|Experimental|Treatment Sequence AB|"Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.
~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.
~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
11374256|NCT02206295|Experimental|Treatment Sequence BA|"Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.
~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.
~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
11374257|NCT02206269||Alair System|This is a single arm study with Alair system used.
11374258|NCT02206256|Active Comparator|Low calorie diet|Low calorie diet 2 weeks pre-operatively
11374259|NCT02206256|Active Comparator|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
11374260|NCT02206243||Embozene|Patients receiving Embozene microspheres
11374261|NCT02206230|Experimental|Hypofractionated radiation therapy|Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
11374262|NCT02206230|Active Comparator|Standard radiation therapy|Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
11374263|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
11374264|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
11374265|NCT02206204|Experimental|Group A|Subjects in Group A receive selexipag on Days 3 to 23 and moxifloxacin-matching placebo on Days 2 and 24. Selexipag administered orally, twice a day, for 21 days according to the following multiple dose up-titration regimen: 400 μg on Days 3-5, 600 μg on Days 6-8, 800 μg on Days 9-11, 1000 μg on Days 12-14, 1200 μg on Days 15-17, 1400 μg on Days 18-20, and 1600 μg on Days 21-23 (only morning dose on Day 23).
11374266|NCT02206204|Experimental|Group B1|Subjects in Group B1 receive 400 mg moxifloxacin, orally on Day 2 and moxifloxacin-matching placebo, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
11374267|NCT02206204|Experimental|Group B2|Subjects in Group B2 receive moxifloxacin-matching placebo, orally on Day 2 and 400 mg moxifloxacin, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
11374268|NCT02206191||Mothers of 6-11 year olds|
11374269|NCT02206178|Experimental|acetaminophen|"The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.
~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine
~- decrease the antinociceptive effect of acetaminophen in comparison to a group control
~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
11374270|NCT02206178|Placebo Comparator|placebo|"- decrease the antinociceptive effect of acetaminophen in comparison to a group control
~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
11374271|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 5mg|Candesartan 8mg + Amlodipine 5mg, po, q.d.
11374272|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 10mg|Candesartan 8mg + Amlodipine 10mg, po, q.d.
11374273|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
11374274|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
11374275|NCT02206165|Active Comparator|Candesartan 8mg|Candesartan 8mg, po, q.d.
11374276|NCT02206165|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
11374277|NCT02206165|Active Comparator|Amlodipine 5mg|Amlodipine 5mg, po, q.d.
11374278|NCT02206165|Active Comparator|Amlodipine 10mg|Amlodipine 10mg, po, q.d.
11374279|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
11374280|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
11374281|NCT02206126|Experimental|Energy restriction group|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
11374282|NCT02206126|No Intervention|Control group|The control group was advised not to change their food intake.
11374283|NCT02206113|Experimental|Standing workstation - 16 weeks|This arm, Standing workstation - 16 weeks, received the intervention of a standing workstation for 16 weeks. For the first 8 weeks, the participants were instructed how long to stand per hour for an 8 hour shift. The second 8 weeks their use was monitored for sustainability.
11374284|NCT02206113|Active Comparator|Standing workstation - second 8 weeks|This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
11374285|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
11374286|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
11374292|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
11374293|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
11374294|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
11374295|NCT02206074|Active Comparator|T2DM|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
11374296|NCT02206074|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
11374297|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.
~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
11374298|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
11374299|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
11374300|NCT02206048|Experimental|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
11374301|NCT02206035|Experimental|Tacrolimus, Methotrexate and Tocilizumab (Tac/MTX/Toc)|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant. Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
11374302|NCT02206022|Experimental|Remifentanil|Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
11374303|NCT02206022|Placebo Comparator|Placebo|Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion
11374304|NCT02206009|Experimental|Collagen membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
11374305|NCT02205996|Active Comparator|Controls|Weight-matched healthy controls. Euglycaemic Hypoglycaemic insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
11374306|NCT02205996|Active Comparator|Type 2 diabetes|People with a known diagnosis of type 2 diabetes. Euglycaemic Hypoglycaemic Insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
11374307|NCT02205983|Experimental|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
11374308|NCT02205983|Experimental|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
11374309|NCT02205983|Experimental|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
11374310|NCT02205983|Placebo Comparator|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
11374311|NCT02205970|Active Comparator|TENS active|TENS (interactive): frequency (90 and 150 pps) and pulse duration (300 and 400μs)
11374312|NCT02205970|Sham Comparator|TENS sham|Placebo lasting 35 minutes.
11374313|NCT02205957||Training quality|Tunisian residents in anesthesiology and intensive care
11374314|NCT02205944|No Intervention|Control Group|The control group will receive routine vascular access pre-op teaching and care.
11374315|NCT02205944|Experimental|Normal Exercise Group|"Group 1 (Normal Exercise Group): progressive handgrip exercise
~Group 2 (Restricted Blood Flow Exercise Group): progressive handgrip exercise with controlled tourniquet"
11374316|NCT02205931|Experimental|Ketogenic diet|8 week trial of the ketogenic diet (KD) therapy. Children allocated to KD therapy will have their diets individually calculated by a paediatric dietitian with consideration of daily calorie requirements, adequate protein intake for growth and vitamin and mineral supplementation. All diets will be implemented according to a classical KD protocol, i.e. based on a ratio of fat to carbohydrate and protein that will usually be between 2:1 and 4:1.
11374317|NCT02205931|Active Comparator|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug (AED) for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy according to a standardised manual (consensus document) written following the initial workshop of the paediatric neurologists from all the trial centres.
11374318|NCT02205918||Sham TMS|"Participants in this group will receive one, 30 minute session of inactive (sham) TMS."
11374319|NCT02205918||Active TMS|Participants in this group will receive one, 30 minute session of 1hz TMS.
11374320|NCT02205905|Experimental|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
11374321|NCT02205892|Active Comparator|Lupeol|
11374322|NCT02205892|Placebo Comparator|Vehicle|
11374323|NCT02205879|Experimental|pregabalin|
11374324|NCT02205879|Placebo Comparator|Placebo|
11374325|NCT02205866|Active Comparator|Group A|Non Obese patients
11374326|NCT02205866|Experimental|Group B|Obese patients
11374327|NCT02205853|Other|The patient-directed (PD) strategy|A single-faceted patient-directed (PD) strategy that will embed the change at patient level.
11374328|NCT02205853|Other|The multi-faceted (MF) strategy|A multi-faceted (MF) strategy that will embed the change at the patient, professional and organizational levels.
11374329|NCT02205840|Experimental|SI-614|
11374330|NCT02205840|Placebo Comparator|Placebo Vehicle|
11374331|NCT02205827|No Intervention|Single-arm|healthy volunteers
11374332|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
11374333|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
11374334|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
11374335|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
11374336|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
11374337|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
11374338|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
11374339|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
11374340|NCT02205775|Placebo Comparator|twice placebo before PCI|
11374341|NCT02205775|Experimental|atorvastatin 80 + 40 mg pre PCI|
11374342|NCT02205775|Experimental|rosuvastatin 40 + 40 mg before PCI|
11374343|NCT02205775|Experimental|rosuvastatin 5 + ezetimibe 10 mg twice before PCI|
11374344|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).
~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
11374345|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
11374346|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.
~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
11374347|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
11374348|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH
~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
11374349|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.
~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.
~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.
~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
11374350|NCT02205749|Other|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
11374351|NCT02205749|Other|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
11374352|NCT02205749|Other|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
11374353|NCT02205736|Other|Living Room Visit participants|Latino women who received breast health education while attending a Living Room Visit.
11374354|NCT02205723|Experimental|Smartphone Asthma Control|Smartphone Asthma Control
11374355|NCT02205723|Active Comparator|Control|Control group
11374356|NCT02205710|Experimental|Computerized cognitive training|Series of gamified tasks.
11374358|NCT02205697|Experimental|Implementation intention|The entire cohort will be asked to create an implementation intention to increase their intake of fruit and vegetables over the study period.
11374359|NCT02205684|Experimental|Physical activity|Aerobic High Intensity Training (HIT)
11374360|NCT02205684|Active Comparator|Computer game skills training|Playing Nintendo Wii Sports
11374361|NCT02205671|Experimental|Intervention|Building Better Caregivers Small-group Workshop
11374362|NCT02205658||Autism|Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder.
11374363|NCT02205658||Sensory Processing|Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder
11374364|NCT02205658||Typical|Typically functioning individuals aged 13-95 years
11374365|NCT02205645|Experimental|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
11374366|NCT02205632|Other|High myopic patients with lacker craks|
11374367|NCT02205632|Other|High myopic patients without lacker cracks|
11374368|NCT02205619|Experimental|Ultrasonic instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic instrumentation (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) treatment group
11374369|NCT02205619|Experimental|Hand instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into hand curette (Gracey curettes, American Eagle, Missoula, MT, USA) treatment group hand instrumentation (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA)
11374370|NCT02205619|Experimental|subgingival airpolishing with glycine|"Prior to extraction, the teeth (N = 12) were randomly included into air-polishing (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) with the glycine powder (Air-flow® Powder Perio, EMS) treatment group.
~subgingival airpolishing with glycine(Air-flow® Powder Perio, EMS SA, Nyon, Swiss)"
11374371|NCT02205619|Experimental|ultrasonic following airpolishing|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic following airpolishing ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) with the glycine powder treatment group
11374372|NCT02205606|Active Comparator|HGP0816 5mg|
11374373|NCT02205606|Active Comparator|HGP0816 10mg|
11374374|NCT02205606|Active Comparator|HGP0816 20mg|
11374375|NCT02205606|Experimental|HCP1306 5/10mg|
11374376|NCT02205606|Experimental|HCP1306 10/10mg|
11374377|NCT02205606|Experimental|HCP1306 20/10mg|
11374378|NCT02205593|Placebo Comparator|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
11374379|NCT02205593|Active Comparator|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
11374380|NCT02205580|Experimental|Sufentanil infusion rate 0.02μg•kg-1•h-1|Sufentanil infusion rate 0.02μg•kg-1•h-1 lasted for 48 hours
11374381|NCT02205580|Experimental|Sufentanil infusion rate 0.03μg•kg-1•h-1|Sufentanil infusion rate 0.03μg•kg-1•h-1 lasted for 48 hours
11374382|NCT02205580|Experimental|Sufentanil infusion rate 0.04μg•kg-1•h-1|Sufentanil infusion rate 0.04μg•kg-1•h-1 lasted for 48 hours
11374383|NCT02205567||Group 2|1000 mg/day of Bergamot-derived product
11374384|NCT02205567||Group 1|500 mg/day of Bergamot-derived product
11374385|NCT02205554|Active Comparator|Omnitram-Tramadol-Placebo|Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.
11374386|NCT02205554|Active Comparator|Tramadol-Placebo-Omnitram|Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.
11374387|NCT02205554|Active Comparator|Placebo-Omnitram-Tramadol|Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.
11374388|NCT02205541|Experimental|Eculizumab|"300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.
~Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection."
11374389|NCT02205541|Placebo Comparator|Placebo|"Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.
~Placebo will be administrated intravenously as a 30-minute injection."
11374390|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
11374391|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
11374392|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
11374393|NCT02205515|Other|Radiotherapy|SBRT or EBRT
11374394|NCT02205502|Experimental|Lidocaine|"Proper amount of lidocaine will be injected lacerated wound.
~dosage form: fluid
~dosage: not exceeding 1mg/kg
~frequency: once
~duration: n/a"
11374395|NCT02205502|Placebo Comparator|Normal saline|Normal saline will be used as a placebo for lidocaine
11374396|NCT02205489|Experimental|GZ402673 LEMTRADA|First course: Intravenous infusion for 5 consecutive days. Second course (will occur 12 months after the first course of treatment): Intravenous infusion for 3 consecutive days.
11374397|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
11374398|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
11374431|NCT02205320|Experimental|Treatment Sequence IV (A, B, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
11374645|NCT02203734|Experimental|Moderate Pressure Massage|Moderate Pressure Massage Therapy
11374399|NCT02205463|Experimental|KD019|Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
11374400|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
11374401|NCT02205437||Controls|Healthy subjects without psychotic disorder.
11374402|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
11374403|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
11374404|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
11374405|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
11374406|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
11374407|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
11374408|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
11374409|NCT02205411|Experimental|HeartAssist 5® VAD System|Implant of the HeartAssist 5® VAD System
11374410|NCT02205411|Active Comparator|Control VAD|
11374411|NCT02205398|Experimental|c-MET positive mCRC and HNSCC|c-MET positive and K/NRAS WT mCRC and c-MET positive HNSCC patients
11374412|NCT02205385|Active Comparator|Traditional Traction Neurectomy|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the current standard of care surgical treatment.
~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). In the active comparator arm, gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally. It may be buried in healthy muscle to further pad the nerve ending. The intention is to place the inevitable recurrent end-neuroma away from superficial locations in which it is likely to become mechanically irritated."
11374413|NCT02205385|Experimental|Targeted Muscle Reinnervation|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the experimental surgical treatment.
~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle."
11374414|NCT02205372|Experimental|MT-3995|
11374415|NCT02205372|Placebo Comparator|Placebo|
11374416|NCT02205359|Experimental|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
11374417|NCT02205359|Active Comparator|aCRT OFF|Standard CRT
11374418|NCT02205346||no treatment|no treatment
11374419|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
11374420|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
11374421|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
11374422|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
11374423|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
11374424|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
11374425|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
11374426|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
11374427|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
11374428|NCT02205320|Experimental|Treatment Sequence I (DRL, A, B)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
11374429|NCT02205320|Experimental|Treatment Sequence II (DRL, B, A)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
11374430|NCT02205320|Experimental|Treatment Sequence III (A, DRL, B)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
11374432|NCT02205320|Experimental|Treatment Sequence V (B, A, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
11374433|NCT02205320|Experimental|Treatment Sequence VI (B, DRL, A)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
11374434|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
11374435|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
11374436|NCT02205294|No Intervention|Assessment Only|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
11374437|NCT02205294|Active Comparator|Assessment and Treatment|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
11374438|NCT02205281|No Intervention|Standard Care|
11374439|NCT02205281|Experimental|Lifestyle Intervention|
11374440|NCT02205268|Experimental|Neurofeedback training|20 sessions of near infrared spectroscopy neurofeedback training to increase activation to bilateral prefrontal cortex. Two sessions per week.
11374441|NCT02205255|Experimental|Azithromycin|N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
11374442|NCT02205255|Placebo Comparator|Placebo|N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
11374443|NCT02205242|Experimental|Azithromycin|"N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
11374444|NCT02205242|Placebo Comparator|Placebo|"N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
11374445|NCT02205229||Patients receiving a topical compounded medication|
11374446|NCT02205216|Active Comparator|Active tDCS|Active tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
11374447|NCT02205216|Sham Comparator|Sham tDCS|Sham tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
11374448|NCT02205203|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
11374449|NCT02205203|Experimental|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
11374450|NCT02205190|Other|Treatment AB|"Treatment A (1 day) → wash-out(7days) → Treatment B (1 day)
~Treatment A : Fimasartan and Rosuvastatin
~Treatment B : Fimasartan/Rosuvastatin combination"
11374451|NCT02205190|Other|Treatment BA|"Treatment B (1 day) → wash-out(7days) → Treatment A (1 day)
~Treatment A : Fimasartan and Rosuvastatin
~Treatment B : Fimasartan/Rosuvastatin combination"
11374452|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
11374453|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
11374454|NCT02205164|Experimental|Palonosetron + Aprepitant|Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
11374455|NCT02205164|Active Comparator|Palonosetron|multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
11374456|NCT02205151|Other|Treatment AB|"Treatment A (1 day) → wash-out(14days) → Treatment B (1 day)
~Treatment A : Fimasartanm and Amlodipine
~Treatment B : Fimasartan/Amlodipine combination"
11374644|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
11374457|NCT02205151|Other|Treatment BA|"Treatment B (1 day) → wash-out(14days) → Treatment A (1 day)
~Treatment A : Fimasartanm and Amlodipine
~Treatment B : Fimasartan/Amlodipine combination"
11374458|NCT02205138|Experimental|ALLOB® cells with ceramic scaffold|ALLOB® cells with ceramic scaffold Implantation
11374459|NCT02205112|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL, intravenous administration, once daily for 7~14 days
11374460|NCT02205112|Active Comparator|Levofloxacin 500mg|Levofloxacin: 500mg/100mL, intravenous administration, once daily for 7~14 days
11374461|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
11374462|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
11374463|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
11374464|NCT02205099|Placebo Comparator|Placebo|Placebo
11374465|NCT02205086|Other|Diagnosis|Test diagnostic decision support software
11374466|NCT02205073|Placebo Comparator|Dosing Period 1|
11374467|NCT02205073|Active Comparator|Dosing Period 2|
11374468|NCT02205073|Experimental|Dosing Period 3|
11374469|NCT02205060|Experimental|virtual reality exposure therapy (VRET)|
11374470|NCT02205060|Experimental|cognitive and behavioral approaches therapy without VRET|
11374471|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
11374472|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
11374473|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
11374474|NCT02205034|Active Comparator|first arm|4IU of oxytocin every other day
11374475|NCT02205034|Active Comparator|second arm|4 IU of oxytocin daily
11374476|NCT02205034|Active Comparator|third arm|4 IU of oxytocin twice daily
11374477|NCT02205021||All subjects|
11374478|NCT02205008|Active Comparator|Arm A|curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1
11374479|NCT02205008|Placebo Comparator|Arm B|curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1
11374480|NCT02204995|Active Comparator|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
11374481|NCT02204995|Active Comparator|Trapeziectomy|Trapeziectomy
11374482|NCT02204982|Experimental|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
11374483|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.
~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
11374484|NCT02204969|Sham Comparator|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
11374485|NCT02204969|Placebo Comparator|lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water
~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
11374486|NCT02204956|Experimental|Sustained Care|A 40-minute, in-hospital motivational counseling session about smoking cessation, 8 Interactive Voice Response (IVR) phone calls and/or texts over 90 days, including the possibility of a warm transfer to a telephone tobacco quit line and up to 8-weeks of free transdermal nicotine patches.
11374487|NCT02204956|Active Comparator|Usual Care|A brief 5-10 minute tobacco education session that all hospitalized smokers will receive, delivered by a hospital nurse. During this session, they will be provided with written handouts describing the stages of readiness for change in quitting, self-monitoring of smoking, self-management of smoking situations, relapse prevention, managing stress, other quitting tips and use of nicotine replacement therapy.
11374488|NCT02204943|Experimental|Bone Biopsy and Circulating Tumor Cell Samples|
11374489|NCT02204930|Experimental|Haemostat|PeproStat
11374490|NCT02204917|Experimental|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
11374491|NCT02204904||Allo-HSCT prospective|Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
11374492|NCT02204904||Allo-HSCT partial prospective/retrospective|Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
11374493|NCT02204904||Allo-HSCT retrospective|Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.
11374494|NCT02204891|Experimental|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
11374495|NCT02204891|Active Comparator|Probiotics|Administration of probiotics in patients with IBS without SIBO
11374496|NCT02204878|Placebo Comparator|A|1ml of saline was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. 1ml saline Q12h will be given within 72 hours after surgery
11374581|NCT02204202||Grade A0|Double-lung transplant recipients with no evidence of rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
11374497|NCT02204878|Experimental|AT|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
11374498|NCT02204865||Pacemaker/ICD with ApneaScan|Patients with HFREF due to receive a pacemaker or ICD with ApneaScan function
11374499|NCT02204852|Experimental|Iloprost+eptifibatide|Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
11374500|NCT02204852|Placebo Comparator|Saline|Double dummy 0.9% saline as 48h continuous i.v infusion
11374501|NCT02204839|Experimental|Basal dose reduction|Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.
11374502|NCT02204826|Experimental|V + KRG group (n = 20)|three capsules of KRG (500 mg/dose) daily and varicocelectomy.
11374503|NCT02204826|Active Comparator|non-V + KRG group|three capsules of KRG (500 mg/dose) daily
11374504|NCT02204826|Active Comparator|V + P group (n = 20)|placebo capsules and varicocelectomy
11374505|NCT02204826|Placebo Comparator|non-V + P group|non-V + P group (n = 20) placebo capsules
11374506|NCT02204813|Experimental|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
11374507|NCT02204800||Small clear cell renal tumors (Wild Type)|No specific chromatin remodeling gene (CRG) alteration
11374508|NCT02204800||Small clear cell renal tumors (Mutant)|Specific chromatin remodeling gene (CRG) alteration
11374509|NCT02204787|Experimental|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
11374510|NCT02204787|Sham Comparator|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
11374511|NCT02204774||Dilatated or aneurysmatic Aorta|Complete cohort, which will be followed over 3 years
11374512|NCT02204761|Experimental|Treatment|Proton beam radiation therapy
11374513|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
11374514|NCT02204735|Experimental|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
11374515|NCT02204735|Experimental|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
11374516|NCT02204722|Experimental|Group B|the group who has more than 10% of the BCR-ABL(IS) level for three months will receive 600mg/day of Imatinib after three months.
11374517|NCT02204722|Experimental|Group A|the group who has more than 10% of the BCR-ABL(IS) level for three months will maintain the dose, 400mg/day of Imatinib, after three months.
11374518|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
11374519|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
11374520|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
11374521|NCT02204696||Tonsillectomy|All participants will undergo baseline sleep study, a second preoperative sleep study after a period of watchful waiting, and a postoperative sleep study.
11374522|NCT02204683|Other|Aflibercept|Subjects who have had a vitrectomy previously
11374523|NCT02204683|Other|Aflibercept in Non-Vitrectomized eyes|Patients who have not had vitrectomy.
11374524|NCT02204670||Overweight Adolescents Performing Resistance Training|Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period. Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training. This will be the primary exposure variable. After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks. During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
11374525|NCT02204657|Active Comparator|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
11374526|NCT02204657|No Intervention|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
11374527|NCT02204644|Experimental|Flumatinib mesylate tablets|Flumatinib mesylate tablets 600mg qd for 12 months
11374528|NCT02204644|Active Comparator|Imatinib mesylate tablets|Imatinib mesylate tablets 400mg qd for 12months
11374529|NCT02204631|Experimental|Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).
~After enrollment and baseline data collection, the participant will be given the handbook. The clinician giving out the handbook will give an overview of the handbook and flip through the important sections. The clinician will encourage the participant to bring it back and forth.
~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception)."
11374582|NCT02204202||Grades A2-3|Double-lung transplant recipients with mild to moderate rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
11374530|NCT02204631|No Intervention|Non Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).
~The first group of participants will not receive the handbook but will receive the current standard care in the head and neck disease center.
~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception).
~At completion of Phase I, all 30 participants will also be given a copy of the handbook and an accompanying questionnaire."
11374531|NCT02204618|Experimental|cochlear implantation|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
11374532|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
11374533|NCT02204605|No Intervention|Control|Visits are not videotaped
11374534|NCT02204605|Experimental|Videoed Patients|Patients will have their visit videotaped.
11374535|NCT02204579|Experimental|NPSP795|intravenous
11374536|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
11374537|NCT02204540|Experimental|Monitoring by webcam|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming food) while being recorded and monitored by webcam.
11374538|NCT02204540|Active Comparator|In-person monitoring|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming good) while being monitored in-person.
11374539|NCT02204527|Experimental|vitamin D3|supplementation of 100.000 IU of vitamin D3
11374540|NCT02204527|Placebo Comparator|Placebo pill|Placebo
11374541|NCT02204514||Surgery for external snapping hip|
11374542|NCT02204501|Experimental|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
11374543|NCT02204501|Experimental|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
11374544|NCT02204488|Active Comparator|Total Joint Arthroplasty|Total Joint Arthroplasty
11374545|NCT02204488|Active Comparator|Trapeziectomy|Trapeziectomy
11374546|NCT02204475|Active Comparator|BOC/PR|All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
11374547|NCT02204475|Experimental|Grazoprevir/Elbasvir|Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
11374548|NCT02204462|Experimental|Newly diagnosed breast cancer|Patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e. index cancer). Patients will undergo FBnTP PET imaging for detection of malignant breast cancer.
11374549|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
11374550|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
11374551|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
11374552|NCT02204423|Experimental|Trans-Radial PCI|
11374553|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
11374554|NCT02204397|Experimental|INGAP Peptide, Ustekinumab|INGAP Peptide, Ustekinumab subcutaneous
11374555|NCT02204384|Experimental|HFD Meal: high fiber from food|HFD Meal: high amount of fiber from diet food sources (total fiber 9.7g; soluble fiber 5.4g)
11374556|NCT02204384|Experimental|HFS Meal: High fiber from supplement|HFS Meal: high amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - Fiber Mais, Nestlé
11374557|NCT02204384|Experimental|UF Meal: usual amount of fiber|UF Meal: usual amount of fiber (total fiber 2.4g; soluble fiber 0.8g)
11374583|NCT02204189|Experimental|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
11374641|NCT02203760|Experimental|Pazopanib plus Gemcitabine|Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
11374642|NCT02203760|Active Comparator|Pazopanib|Pazopanib 800 mg orally once daily
11374643|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
11374558|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
11374559|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
11374560|NCT02204358|Experimental|autologous bone marrow stem cells|Using collagen scaffold loaded with autologous bone marrow stem cells to treat severe intrauterine adhesions or endometrial dysplasia.
11374561|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
11374562|NCT02204332|Experimental|Cabazitaxel|"Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).
~Besides, patient will be treated with BSC."
11374563|NCT02204332|Other|Best Supportive Care|Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
11374564|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
11374565|NCT02204306|Other|TSER *2/*2 *2/*3|Patients with TSER *2/*2 *2/*3 genotypes will be assigned to this group and receive standard chemotherapy contains fluorouracil. (FOLFOX 6/XELOX/SOX)
11374566|NCT02204306|Other|TSER*3/*3 (fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
11374567|NCT02204306|Other|TSER*3/*3 (non-fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
11374568|NCT02204293|Experimental|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
11374569|NCT02204293|Placebo Comparator|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
11374570|NCT02204280||Type 2 Diabetic|Patiens with type 2 diabetic which conform to the WHO in 1999 diabetes diagnostic criteria.
11374571|NCT02204280||Diabetic With macro-or Microalbuminuria|Patients with diabetic with macro-or microalbuminuria.
11374572|NCT02204280||proteinuria,nondiabetic renal disease|Patients with proteinuria due to nondiabetic renal disease,such as IgA nephropathy,FSGS,Hypertensive renal damage and MN.
11374573|NCT02204280||healthy controls|Healthy person.
11374574|NCT02204267|Experimental|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
11374575|NCT02204267|No Intervention|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
11374576|NCT02204254|Experimental|Radiofrequence|3 sessions of radiofrequency at 3 weeks intervals V1, V2 (W3 or W4) and V3 (between W6 and W8), with clinical examination, evaluation of tolerance, adverse events report, photos, surface biopsy (SSSB), and confocal microscopy (V1 and V3). Follow up visit V4 (M6) with clinical evaluation, photos, SSSB, confocal microscopy, adverse events report and treatment satisfaction.
11374577|NCT02204254|Placebo Comparator|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
11374578|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:
~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.
~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).
~Treatment schedule for maintenance until progression or intolerance:
~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
11374579|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
11374580|NCT02204215|Experimental|electric acupuncture & conservative|Electric acupuncture therapy on four limbs 30 min each time, twice per day; or conservative treatment without electric acupuncture.
11374584|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
11374585|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
11374586|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
11374587|NCT02204163|Experimental|Eutropin|Eutropin 0.24mg/kg/week
11374588|NCT02204163|Active Comparator|Genotropin|Genotropin 0.24mg/kg/week
11374589|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
11374590|NCT02204137||Completion of Questionnaires|"Participants will complete an assessment consisting of the Falls Risk Questionnaire, a primarily self-administered geriatric assessment (GA) developed by the Cancer and Aging Research Group, a quality of life scale (FACT GOG/NTX) and the Falls Efficacy Scale-International.
~Each questionnaire contains approximately 150 questions and will take between 30 minutes and one hour to complete."
11374591|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
11374592|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
11374593|NCT02204111||Control Cluster|Care as usual
11374594|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
11374595|NCT02204098|Active Comparator|Cohort 1:Neoadjuvant endocrine therapy alone|"Will be treated with standard of care adjuvant endocrine therapy as determined by their treating physician
~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy"
11374596|NCT02204098|Experimental|Cohort 2:Neoadjuvant endocrine + mammaglobin-A DNA vaccine|"Will be treated with standard of care adjuvant endocrine therapy
~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy
~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)
~All study injections will be administered using a TriGrid electroporation device"
11374597|NCT02204098|Active Comparator|Cohort 3: Neoadjuvant chemotherapy alone|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician
~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28
~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in cohort 3"
11374598|NCT02204098|Experimental|Cohort 4: Neoadjuvant chemotherapy + mammoglobin-A DNA vaccine|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician
~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28
~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)
~All study injections will be administered using a TriGrid electroporation device
~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in either cohort 4"
11374599|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
11374600|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
11374601|NCT02204072|Experimental|BI 836845 & Enzalutamide|
11374602|NCT02204072|Active Comparator|Enzalutamide|
11374603|NCT02204059|Experimental|hMAb BIWA 4|Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4
11374604|NCT02204046|Experimental|BIWA 4|"Generic Name: Bivatuzumab
~186Re-labelled humanised monoclonal antibody BIWA 4"
11374605|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - low dose|
11374606|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - medium dose|
11374607|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - high dose|
11374608|NCT02204033|Experimental|186 Re - labelled hMAb BIWA 4 - escalating dose|
11374609|NCT02204020|Experimental|5-azacytidine|5-aza SC or IV 32mg/m2 - 75mg/m2 (based on dose escalation)
11374610|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
11374611|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
11374612|NCT02203994|Experimental|extracorporeal shock wave therapy (ESWT)|"one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 T-Top (Storz Medical AG, Tägerwilen, Switzerland))"
11374613|NCT02203968|Placebo Comparator|Normal saline|Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
11374614|NCT02203968|Active Comparator|Fibrinogen concentrate|Fibrinogen concentrate (RiaSTAP™) is a freeze-dried lyophilised plasma product presented in powdered form. The powder is reconstituted with water for intravenous injection at a concentration of 20 mg fibrinogen per ml. The concentrate is formulated with human albumin, L-arginine, sodium citrate and sodium chloride. RiaSTAP™ is supplied as a purified lyophilisate in a 1g dosage form and is reconstituted in 50 ml of sterile water. The final volume of RiaSTAP™ to be infused in this study will therefore be 300 ml.
11374615|NCT02203955|Active Comparator|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
11374616|NCT02203955|Placebo Comparator|Maltodextrin|4 chews (maltodextrin) daily for 12 months
11374617|NCT02203942||Vaginal Infections (BV, VVC, trich)|NAAT testing Amsel criteria Nugent score yeast culture TV culture
11374618|NCT02203929||Phakic eyes|Phakic eyes will be monitored with 4 preoperative optical coherence tomography scans as these patients will undergo phacoemulsification and intraocular lens implantation prior to their macular hole surgery
11374619|NCT02203929||Pseudophakic eyes|Phakic eyes will be monitored with 2 preoperative optical coherence tomography scans as there is no surgical intervention prior to the macular hole treatment.
11374620|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
11374621|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
11374622|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
11374623|NCT02203903|Experimental|Tumor associated antigen lymphocytes (TAA-T)|"For Arm A Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first.
~For Arm B Patients (pre-HSCT): TAA-T will be infused any time > 7 days after previous therapy for relapsed disease.
~For Arm C Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT.
~Five different dosing levels will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.
~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2 Dose Level Five: 1 x 108 cells/m2 (ONLY applicable to Arm A patients)
~Arm C patients will ONLY be enrolled at: Dose Level Four (4 x 107 cells/m2)"
11374624|NCT02203890||Apparently Healthy|Apparently healthy preschool children who attend 3 daycare centers of the Secretariat of Beneficials Works of the First Lady in Guatemalan Western Highlands
11374625|NCT02203877|Placebo Comparator|Maltodextrin|1 capsule/day for 16 weeks
11374626|NCT02203877|Experimental|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
11374627|NCT02203864|Experimental|BIBW2 with IL-2 secreting cell line|
11374628|NCT02203864|Experimental|BIBW2 without IL-2 secreting cell line|
11374629|NCT02203851|Experimental|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
11374630|NCT02203851|Experimental|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved <90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
11374631|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
11374632|NCT02203825|Experimental|CM-CS1 T-cell infusion|"The treatment will consist of a single infusion of CM-CS1 cells.
~The following dose levels will be evaluated:
~Cohort 1: 1x 10^6 CM-CS1 T-cells Cohort 2: 3x 10^6 CM-CS1 T-cells Cohort 3: 1x 10^7 CM-CS1 T-cells Cohort 4: 3x 10^7 CM-CS1 T-cells"
11374633|NCT02203812|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
11374634|NCT02203812|Placebo Comparator|Placebo Arm|Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
11374635|NCT02203799|Experimental|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
11374636|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).
~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules
~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.
~Response measured to 15 min session of a commercial slot machine game."
11374637|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).
~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules
~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.
~Response measured to 15 min session of a commercial slot machine game."
11374638|NCT02203773|Experimental|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
11374639|NCT02203773|Experimental|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
11374640|NCT02203773|Experimental|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
11374646|NCT02203734|Sham Comparator|Light Pressure Massage|Light Pressure Massage Therapy
11374647|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
11374648|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
11374649|NCT02203708|Active Comparator|BPD prevention|Supportive Program for Mother with BPD (SuPMother-B) : BPD mothers participate to prevention program in groups or/and house calls.
11374650|NCT02203708|No Intervention|Usual care of BPD mothers|BPD mothers don't participate to Supportive Program (SuPMother-B).
11374651|NCT02203695|Experimental|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT [Intensity-modulated radiation therapy]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
11374652|NCT02203695|Placebo Comparator|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
11374653|NCT02203682|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
11374654|NCT02203682|Placebo Comparator|Placebo|Tablet placebo for 12 weeks
11374655|NCT02203669|Active Comparator|Structured In-Office Therapy|Structured In-Office Therapy: Study subjects will receive structured, therapist-supervised occupational/physical therapy twice per week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Patients in this arm will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These patients will also receive exercise and stretching handouts to use at home between therapy visits. Will complete the DASH at week 1 and week 4.
11374656|NCT02203669|No Intervention|No therapy|Study subjects in this arm will not receive post-operative occupational /physical therapy. Will complete the DASH at week 1 and week 4.
11374657|NCT02203669|Active Comparator|Home Therapy|Home Therapy: Study subjects will receive a handout of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist to complete independently at home for four (4) weeks. Will complete the DASH at week 1 and week 4.
11374658|NCT02203656|Placebo Comparator|Placebo Supplement|Daily placebo supplement for 30 days after discharge.
11374659|NCT02203656|Experimental|Nutritional Supplement|Daily nutritional supplement for 30 days after discharge.
11374660|NCT02203656|Experimental|In-home exercise + placebo|in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
11374661|NCT02203656|Experimental|In-home exercise + nutrition|in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
11374662|NCT02203656|Experimental|Testosterone|Single testosterone injection within 24 hours of hospital discharge.
11374663|NCT02203643|Experimental|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.
~After the end of consolidation all patients will be randomized to receive:
~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
11374664|NCT02203643|Experimental|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.
~After the end of consolidation all patients will be randomized to receive:
~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
11374665|NCT02203643|Experimental|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.
~After that all patients will be randomized to receive:
~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
11374666|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
11374667|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
11374668|NCT02203617|Experimental|educational baby books|books embedded with educational information (pediatric anticipatory guidance)
11374669|NCT02203617|Active Comparator|non-educational baby books|baby books given with same illustrations but no educational information
11374670|NCT02203617|No Intervention|no books|not given any baby books
11374671|NCT02203604|Experimental|Treatment (aldesleukin, ipilimumab)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.
~MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity."
11374672|NCT02203591|Experimental|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
11374673|NCT02203591|Experimental|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
11374674|NCT02203591|Active Comparator|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
11374675|NCT02203591|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
11374676|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11374677|NCT02203565|Experimental|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
11374795|NCT02202915|Experimental|Fidelity Checklist Arm|Therapists are receiving training using the fidelity Checklist
11374678|NCT02203552|Experimental|Arm I (minocycline hydrochloride)|Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
11374679|NCT02203552|Placebo Comparator|Arm II (placebo)|Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
11374680|NCT02203539|Experimental|bright light|Intervention: exposure to bright light
11374681|NCT02203539|Experimental|blue-enriched light|Intervention: exposure to blue-enriched light
11374682|NCT02203539|Experimental|normal light|Intervention: exposure to normal light
11374683|NCT02203526|Experimental|Arm 1-A (First Cohort; original study design)|TEDD-R and IT therapy
11374684|NCT02203526|Experimental|Arm 1-B (Second Cohort; original study design)|TEDDI-R and IT therapy
11374685|NCT02203526|Experimental|Arm 2 (Dose Escalation; Amendment I)|TEDDI-R and IT therapy with antifungals
11374686|NCT02203526|Experimental|Arm 3 (Dose Expansion; Amendment I)|TEDDI-R and IT therapy with antifungals
11374687|NCT02203513|Experimental|1-prexasertib|Prexasertib monotherapy treatment
11374688|NCT02203500|Experimental|Lacidipine|
11374689|NCT02203500|Experimental|Telmisartan|
11374690|NCT02203500|Experimental|Lacidipine + Telmisartan|
11374691|NCT02203487|Experimental|BIIF 1149 BS - single rising dose|
11374692|NCT02203487|Placebo Comparator|Placebo|
11374693|NCT02203474|Experimental|Tiotropium HFA BAI 5 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
11374694|NCT02203474|Experimental|Tiotropium HFA BAI 10 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
11374695|NCT02203474|Experimental|Tiotropium HFA BAI 15 mcg|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
11374696|NCT02203474|Active Comparator|SPIRIVA HandiHaler|2 inhalations from one 18 mcg capsule daily
11374697|NCT02203474|Placebo Comparator|Placebo|1 inhalation from each of 3 inhalers containing either Tiotropium HFA BAI 5 mcg or placebo daily
11374698|NCT02203461|Experimental|Group I|STRIBILD® Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
11374699|NCT02203461|Active Comparator|Group II|Truvada®/Kaletra® Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
11374700|NCT02203461|Experimental|Group III|Truvada®/Prezista®/Norvir® Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
11374701|NCT02203448||FACET WEDGE spinal system|The FACET WEDGE spinal system provides additional stability to a spinal segment to enhance fusion conditions.
11374702|NCT02203422|Experimental|combination treatment group|60 enrolled patients are randomly picked up to take cyclosporin A in combination with rhTPO at the indicated dose.
11374703|NCT02203422|Active Comparator|single treatment group|60 enrolled patients are randomly picked up to take cyclosporin A at the indicated dose.
11374704|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
11374705|NCT02203396|Experimental|Severe Aplastic Anemia|Drug: rabbit ATG, Cyclosporine, Levamisole
11374706|NCT02203383||Pts with CSA for CRT implantation|Patients with heart failure (EF<40%) and moderate to severe CSA (>15 events per hour, >50% Central)
11374707|NCT02203383||No Sleep Apnoea for CRT implantation|Heart failure (EF < 40%) but no significant sleep apnoea (<5 events per hour).
11374708|NCT02203370||all patients|All patients will be measured throughout the procedure with both devices. There no further separation into groups as both sensors can be placed on the same patient.
11374709|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
11374710|NCT02203357|Experimental|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
11374711|NCT02203357|Experimental|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
11374712|NCT02203344||Light sedation|Light sedation is defined as RASS of +1 to -2.
11374713|NCT02203344||Deep sedation|Deep sedation is defined as RASS of -3 to -5
11374714|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
11374715|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
11374716|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
11374717|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
11374718|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
11374719|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
11374720|NCT02203318||control|healthy children with normal bilateral testis
11374721|NCT02203318||undescended palpable testis|patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area
11374722|NCT02203318||non-paplpable testis|patient whose affected testis is not palpable during the physical examination
11374723|NCT02203305|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
11374724|NCT02203305|Other|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
11374725|NCT02203305|Experimental|Cochlear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
11375251|NCT02199886|Experimental|BIBH 1|dose escalation: 0.5, 2, 10 or 20mg/m**2, 7 days prior to surgery
11374726|NCT02203292|Active Comparator|Liberal|Liberal transfusion strategy. Patients will have red blood cells transfused only if Hb < 9.0 g/dL
11374727|NCT02203292|Experimental|Restrictive|Restrictive transfusion strategy. Patients will have red blood cells transfused only if Hb < 7.0 g/dL
11374728|NCT02203279|Experimental|Rebase II Fast|The direct chair-side relining materiel 'Rebase II Fast' will be used.
11374729|NCT02203279|Experimental|Flexacryl|The direct chair-side relining material Flexacryl will be used
11374730|NCT02203279|Experimental|Vertex|Vertex is a heat-cured resin material which is going to be used for indirect relining
11374731|NCT02203266|Experimental|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
11374732|NCT02203266|Active Comparator|Demonstration|Current best practice - inhaler technique education
11374733|NCT02203266|No Intervention|Control|Usual care in the community pharmacy setting
11374734|NCT02203253|Active Comparator|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
11374735|NCT02203253|Placebo Comparator|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
11374736|NCT02203240|Experimental|Cocoa|3 servings of polyphenol-rich cocoa beverage consumed per day.
11374737|NCT02203240|Placebo Comparator|Placebo|3 servings of non-cocoa beverage consumed per day.
11374738|NCT02203227|Placebo Comparator|Placebo|Capsule containing 250 mg of placebo, two times a day
11374739|NCT02203227|Experimental|BioTurmin|Capsule containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
11374740|NCT02203227|Experimental|BioTurmin-WD|Capsule containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
11374741|NCT02203227|Experimental|MaQxan|Capsule containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
11374742|NCT02203214||Ligamys|All patients treated with Ligamys can be included in the study. Patients must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled.
11374743|NCT02203201||Study group|NCWS patients who had showed a negative celiac disease serology and a Marsh 0-1 duodenal histology, but who had displayed a positive EmA assay in the culture medium of the duodenal biopsies (EmA-biopsy).
11374744|NCT02203201||Control group|NCWS patients with negative EmA-biopsy.
11374745|NCT02203188|Experimental|Lid debridgement scaling|Perform lid debridgement scaling
11374746|NCT02203188|No Intervention|Control|No Treatment
11374747|NCT02203175|Placebo Comparator|Group C (plasebo): no pretreatment|saline injection
11374748|NCT02203175|Active Comparator|propofol and fentanyl|propofol 50 mg with fentanyl 50 mcgr iv during anesthesia induction ones time
11374749|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
11374750|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
11374751|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
11374752|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
11374753|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
11374754|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
11374755|NCT02203136||Muscle Invasive Bladder Cancer (MIBC)|During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
11374756|NCT02203123|Other|Ultrasound, inferior vena cava, aorta, normal saline|
11374757|NCT02203097|Experimental|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
11374758|NCT02203084||Children with Chronic Medical Conditions|The Social Determinants Questionnaire will be administered to the three groups of children with chronic diseases (cystic fibrosis, diabetes mellitus type I, or chronic renal insufficiency). The questionnaire questions will be asked by a research assistant. Each participant will have the same general and background information questions then will have questions specific to their chronic medical condition.
11374759|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
11374760|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
11374761|NCT02203058|Experimental|Pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) with pursed-lips breathing.
11374762|NCT02203058|Placebo Comparator|No pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) without pursed-lips breathing.
11374796|NCT02202902|Experimental|Group 1 : 1H magnetic resonance spectroscopy and CMRI|Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance
11375252|NCT02199873|Experimental|BIIX 1 XX - single rising dose|
11374763|NCT02203045|Active Comparator|Tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
11374764|NCT02203045|Experimental|Non- tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
11374765|NCT02203032|Experimental|Open-label ustekinumab|
11374766|NCT02203032|Experimental|Double-blind guselkumab|
11374767|NCT02203032|Experimental|Double-blind ustekinumab|
11374768|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
11374769|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
11374770|NCT02203006|Other|OVIHD|Cohort and a blood sample collection will be done with data and blood of HIV infected patients
11374771|NCT02202993|Experimental|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.
~This will be given concurrently with hypofractionated radiation therapy."
11374772|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
11374773|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
11374774|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
11374775|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
11374776|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
11374777|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
11374778|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
11374779|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
11374780|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
11374781|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
11374782|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
11374783|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
11374784|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
11374785|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
11374786|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
11374787|NCT02202967|Active Comparator|Misoprostol|Misoprostol
11374788|NCT02202967|Placebo Comparator|Placebo|Placebo
11374789|NCT02202954|Active Comparator|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.
~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
11374790|NCT02202954|No Intervention|Conventional rehabilitation|conventional therapy in the community
11374791|NCT02202941|Experimental|Procalcitonin guided treatment|Patients who will be randomized to this arm will receive antibiotics therapy based on procalcitonin-guided algorithm.
11374792|NCT02202941|Active Comparator|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
11374793|NCT02202928|Sham Comparator|Chemo-radiotherapy|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.
11374794|NCT02202928|Experimental|DC-CIK|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.
11375253|NCT02199873|Placebo Comparator|Placebo|
11374797|NCT02202902|Experimental|Group 2 : 1H magnetic resonance spectroscopy and CMRI|Group 2: Cushing's syndrome patients with normal glucose intolerance
11374798|NCT02202902|Experimental|Group 3 : 1H magnetic resonance spectroscopy and CMRI|age-, sex- and BMI-matched healthy volunteers
11374799|NCT02202876|Active Comparator|Aim 1: Children with Cystic Fibrosis|Cystic Fibrosis children aged 1 to 9 years with normal glucose tolerance receiving Oral Glucose Tolerance Test
11374800|NCT02202876|Active Comparator|Aim 1: Control Children|Children with out Cystic Fibrosis aged 1 to 9 years controls with normal glucose tolerance receiving Oral Glucose Tolerance Test
11374801|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - High Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating High Glycemic Index Meal
11374802|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - Low Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating Low Glycemic Index Meal
11374803|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Test Soda|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of a test soda. A week later these participants will have an Oral Glucose Tolerance Test.
11374804|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Fruit Juice|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of fruit juice. A week later these participants will have an Oral Glucose Tolerance Test.
11374805|NCT02202863|Experimental|Red Wine Grape Pomace Flour (WGPF)|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
11374806|NCT02202863|No Intervention|Control|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks.
11374807|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
11374808|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
11374809|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
11374810|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
11374811|NCT02202824|Experimental|Survey questionnaire version 1|Study participants will receive version 1 of the survey questionnaire
11374812|NCT02202824|Experimental|Survey questionnaire version 2|Study participants will receive version 2 of the survey questionnaire
11374813|NCT02202824|Experimental|Survey questionnaire version 3|Study participants will receive version 3 of the survey questionnaire
11374814|NCT02202811|Experimental|Obstructive Sleep Apnea|Forced Desynchrony, OSA
11374815|NCT02202811|Placebo Comparator|Control|Forced Desynchrony, Control
11374816|NCT02202798||Syringe device|Endotracheal tube cuff pressure measured by 2 new syringe devices.
11374817|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
11374818|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
11374819|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
11374820|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
11374821|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
11374822|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
11374823|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
11374824|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
11374825|NCT02202746|Experimental|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
11374826|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
11374827|NCT02202733|Other|Cooking|A skill-based cooking intervention for caretakers of an overweight/obese child aged 3-10 years.
11374828|NCT02202720|Experimental|sevoflurane|
11374829|NCT02202707|Other|Gabapentin|Open label single arm study. All participants will receive Gabapentin.
11374830|NCT02202694|Experimental|Intervention|Culturally Adapted Cognitive Behavior Therapy
11374831|NCT02202694|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
11374832|NCT02202681|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
11374833|NCT02202668|Experimental|TRS|
11374876|NCT02202434|Active Comparator|CoreValve TAVR System - Randomized|Transcatheter aortic valve replacement (TAVR) with CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
11374834|NCT02202642|Experimental|limbal stem cells|"Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of limbal stem cells need special cell-cell contact and cell-extracellular matrix interaction to support their survival"
11374835|NCT02202629|Placebo Comparator|Cherry flavoured beverage 1|10floz cherry flavoured test article
11374836|NCT02202629|Experimental|Cherry flavoured beverage 2|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
11374837|NCT02202629|Experimental|Cherry flavoured beverage 3|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
11374838|NCT02202629|Experimental|Cherry flavoured beverage 4|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
11374839|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
11374840|NCT02202603|Active Comparator|Teriparatide group 1|Subcutaneous injection of Teriparatide
11374841|NCT02202603|Placebo Comparator|excipients|Oral pill without API
11374842|NCT02202603|Experimental|API|Oral administration of pill with API
11374843|NCT02202603|Experimental|API optimization 1|Oral administration of pill with API, for PK optimization #1
11374844|NCT02202603|Experimental|API optimization 2|Oral administration of pill with API, for PK optimization #2
11374845|NCT02202603|Experimental|API optimization 3|Oral administration of pill with API, for PK optimization #3
11374846|NCT02202603|Experimental|API optimization 4|Oral administration of pill with API, for PK optimization #4
11374847|NCT02202603|Experimental|API optimization 5|Oral administration of pill with API, for PK optimization #5
11374848|NCT02202603|Experimental|API optimization 6|Oral administration of pill with API, for PK optimization #6
11374849|NCT02202603|Experimental|API optimization 7|Oral administration of pill with API, for PK optimization #7
11374850|NCT02202603|Active Comparator|Teriparatide group 2|Subcutaneous injection of Teriparatide
11374851|NCT02202603|Experimental|Excipients|Oral pill without API
11374852|NCT02202603|Experimental|API Optimized|expanded group size with API in optimized dosage and administration form.
11374853|NCT02202590|Experimental|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
11374854|NCT02202577|Experimental|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
11374855|NCT02202577|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
11374856|NCT02202564|Experimental|LT+ADV-TK|Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.
11374857|NCT02202564|Active Comparator|LT|Orthotopic liver transplantation
11374858|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
11374859|NCT02202538|Experimental|Indego|Indego
11374860|NCT02202525||Essential arterial hypertension|Patients with essential arterial hypertension needing a new antihypertensive therapy
11374861|NCT02202512|Experimental|BI 1060469 low dose|Low-Dose,Tablet,oral administration with 240 ml water,over 10 days
11374862|NCT02202512|Experimental|BI 1060469 high dose|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
11374863|NCT02202512|Active Comparator|Cimetidine|
11374864|NCT02202512|Active Comparator|Naproxen|
11374865|NCT02202512|Experimental|BI 1021958|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
11374866|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
11374867|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
11374868|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
11374869|NCT02202486||Migraine with aura|Brain MRI
11374870|NCT02202486||Migraine without aura|Brain MRI
11374871|NCT02202486||Chronic migraine|Brain MRI
11374872|NCT02202473|Active Comparator|Lamivudine|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd
11374873|NCT02202473|Experimental|Lamivudine+Oxymatrine Capsules|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.
11374874|NCT02202447|Experimental|EC1169|"PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
~PART A: EC1169 given as IV bolus QW on Weeks 1 and 2 of a 3 week cycle. Dose based on dose escalation plan starting with 0.2 mg/m2
~PART B: EC1169 cohort 1 - taxane naive mCRPC patients that have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible).
~PART B: EC1169 cohort 2 - taxane exposed mCRPC patients who have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and who have progressed subsequent to receiving > 2 cycles of a taxane-based regimen for mCRPC."
11374875|NCT02202434|Experimental|Lotus Valve System - Randomized|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
11374877|NCT02202434|Experimental|Lotus Valve Sytem - Single-arm 21mm Cohort|Transcatheter aortic valve replacement (TAVR) with 21mm Lotus Valve System
11374878|NCT02202434|Experimental|Lotus Valve System - Single-arm Continued Access Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
11374879|NCT02202434|Experimental|Lotus Valve System - Single-arm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
11374880|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm Edge Nested Registry|"Transcatheter aortic valve replacement (TAVR) with 23mm, 25mm and 27mm LOTUS Edge Valve System.
~This arm is recruiting."
11374881|NCT02202421|Active Comparator|T-ABA Parent Training Only|Participants in the T-ABA Parent Training Only group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
11374882|NCT02202421|Experimental|T-ABA Parent Group + Individual Therapy|Participants in the T-ABA Parent Group plus Individual Therapy group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions.
11374883|NCT02202408|Experimental|SKI2670|"Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group
~-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4"
11374884|NCT02202408|Placebo Comparator|Placebo|Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)
11374885|NCT02202395|Active Comparator|0.25mg|LTS 0.25mg,qd MTX qw
11374886|NCT02202395|Active Comparator|0.5mg|LTS 0.5mg, qd MTX qw
11374887|NCT02202395|Active Comparator|1.0mg|LTS 1.0mg,qd MTX qw
11374888|NCT02202395|Placebo Comparator|Placebo|Placebo qd MTX qw
11374889|NCT02202382|Placebo Comparator|non-V + P group|no surgery and placebo (12 weeks)
11374890|NCT02202382|Active Comparator|V + P group|Surgery with placebo (12 weeks)
11374891|NCT02202382|Active Comparator|non-V + KRG group|no surgery with KRG (korean red ginseng, 1.5 gm daily 12weeks)
11374892|NCT02202382|Experimental|V + KRG group|Surgery with KRG (1.5 gm daily 12weeks)
11374893|NCT02202369|Experimental|Multimodal Analgesia (MMA) Treatment|
11374894|NCT02202369|Active Comparator|Standard of Care Pain Managment Protocol|
11374895|NCT02202356|Experimental|ALS-008176 Single Dose|Single dose of ALS-008176 administered orally as a suspension
11374896|NCT02202356|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally as a suspension
11374897|NCT02202356|Experimental|ALS-008176 Multiple Doses|Multiple doses of ALS-008176 administered orally as a suspension
11374898|NCT02202356|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo administered orally as a suspension
11374899|NCT02202343|Experimental|School-based health and nutrition education|
11374900|NCT02202330|Placebo Comparator|Standard Care, Organized Discharge|Stroke patients are given instructions before discharge regarding diet, need for rehabilitation, possible complications, medication use and information booklets are also handed out. This information is imparted by a multidisciplinary team consisting of a neuro physician, a stroke nurse, a dietitian and a physiotherapist. These are verbal instructions and handouts are written in English. On the day of discharge, or 24 hours prior to discharge, a discharge coordinator details the skills learnt . A detailed written discharge summary is given out detailing all aspects of care, follow-up, medications and test results.
11374901|NCT02202330|Experimental|Video Arm, Standard Discharge|"Intervention is as follows:
~5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)
~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.
~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
11374902|NCT02202317|Experimental|Y90 Based PET/CT Scan|
11374903|NCT02202304|Experimental|Chlorhexidine/Thymol varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by painting it over the surfaces of these teeth."
11374904|NCT02202304|Placebo Comparator|Placebo varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush and painting it on all the surfaces of these teeth.."
11374905|NCT02202291|Experimental|Patient with Raynaud's phenomenon|
11374906|NCT02202278||ovarian hyperstimulation patients|Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit >45%, weight gain >2 kg, white blood cell count >15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of >50 ml/min, liver dysfunction.
11374907|NCT02202278||without ovarian hiperstimulation|Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS
11374908|NCT02202265|Active Comparator|Control diet (standard dietary)|Patients will receive a control diet based on standard dietary guidelines
11374909|NCT02202265|Experimental|Olive oil (30ml a day)|Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day
11374910|NCT02202265|Experimental|Nuts (30g a day)|Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day
11374911|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.
~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
11374912|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.
~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
11374913|NCT02202239|Experimental|Group E|Etomidate was used in both induction and maintenance of anesthesia.
11374914|NCT02202239|Active Comparator|Group P|Propofol was used in both induction and maintenance of anesthesia.
11374915|NCT02202226|Experimental|Lu AF35700 oral solution (1 mg/mL)|Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
11374916|NCT02202226|Placebo Comparator|Matching placebo|Oral solution
11374917|NCT02202213|Experimental|Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg|"Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone
~Three times daily oral dosing for 14 days."
11374918|NCT02202213|Placebo Comparator|Matching placebo|Daily oral dosing matching the experimental arm.
11374919|NCT02202200|Experimental|PD-0332991|
11374920|NCT02202187|Experimental|GSK2140944|Dose range 100mg to 3000mg single dose
11374921|NCT02202187|Placebo Comparator|Matching Placebo|Placebo
11374922|NCT02202174||Supraglottic Airway Device|Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
11374923|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
11374924|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
11374925|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
11374926|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
11374927|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
11374928|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
11374929|NCT02202148||alcohol withdrawal|
11374930|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
11374931|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
11374932|NCT02202122||Study Group|OSA Scoring
11374933|NCT02202109|Active Comparator|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
11374934|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
11374935|NCT02202096|Experimental|Intervention (plus usual care)|Patient education: One-on-one visit Discharge planning: Assessment of barriers to discharge Medication reconciliation: Patient medication review Appointment before discharge: Additional measure to ensure awareness of next clinic visit Transition coach Patient-centered discharge instructions: Enhanced Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology Timely follow-up: Barriers to clinic follow-up visits will be discussed Timely PCP communication Follow-up telephone call Patient hotline: 24 hour follow-up following call to Ask My Nurse number
11374936|NCT02202096|No Intervention|Usual Care|Usual care-Standard of care that all colorectal cancer patients normally receive
11374937|NCT02202083|Experimental|oxytocin|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.
~This group is term gestaion,with bishop score less than 6."
11374938|NCT02202070|Experimental|Botox injection first, followed by placebo|50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
11374939|NCT02202070|Experimental|Placebo injection first, followed Botox|Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
11374940|NCT02202057||Parkinson's disease|Men and women with Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation and Fluoroscopic swallowing evaluation.
11374941|NCT02202057||Healthy adults|Men and women without Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation.
11374942|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
11374943|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
11374944|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
11374945|NCT02202018|Experimental|Active KT Intervention|CKD clinics receiving the active knowledge translation intervention.
11374946|NCT02202018|No Intervention|Usual standard of care|Clinics will continue their standard of care education and approach to use of home dialysis.
11374947|NCT02202005|Experimental|Nevirapine|
11374948|NCT02202005|Active Comparator|Viramune®|
11374995|NCT02201719||Hysterectomy Adenomyosis|Adenomyosis present
11374996|NCT02201719||Hysterectomy no adenomyosis|Adenomyosis not present
11374949|NCT02201992|Experimental|Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11374950|NCT02201992|Active Comparator|Arm B (observation)|Patients undergo observation.
11374951|NCT02201979||Breast lift in combination with implants.|Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
11374952|NCT02201966||Female gymnasts with low back pain|Subset of competitive female gymnasts who report significant low back pain that affects their ability to perform gymnastics.
11374953|NCT02201966||Female gymnasts without low back pain|Subset of competitive female gymnasts who deny significant low back pain that affects their ability to perform gymnastics.
11374954|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
11374955|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
11374956|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
11374957|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
11374958|NCT02201927|Experimental|patient with right parietal lobe lesion|Patient with right parietal lobe lesion
11374959|NCT02201927|Experimental|patient stroke|patient with cerebral vascular accident
11374960|NCT02201927|Experimental|healthy volunteers|healthy volunteers
11374961|NCT02201914|Experimental|Clomiphene citrate|
11374962|NCT02201914|Experimental|Daily FSH and LH plus Cetrorelix|
11374963|NCT02201914|Experimental|Triptorelin plus daily FSH and LH|
11374964|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
11374965|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
11374966|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
11374967|NCT02201888|Experimental|Computer-assisted cognitive training|Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
11374968|NCT02201888|Active Comparator|Computerized active condition|Patients allocated to this condition completed the same number of sessions as the cognitive training group but followed a computerized typing program (www.rapidtyping.com). This had similar design characteristics to the CRT condition, in that it was hierarchically organized with exercise level of difficulty being adjusted to the individual's level of performance and feedback being given at the end of each exercise. Additionally, patients in this condition played computerized games requiring typing (crosswords, word puzzles, etc) and were taught basic internet navigation by a supervisor. Exposure to the computer was of equivalent duration to the CRT condition.
11374969|NCT02201888|Placebo Comparator|Treatment as usual|Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities
11374970|NCT02201875||Healthy subjects|male, aged 18-65 moderately trained healthy, no treatment
11374971|NCT02201875||obstructive sleep apneas|patients with apnea/hypopnea index > 15 BMI < 30 Age < 50 yrs
11374972|NCT02201875||cardiac failure|NYHA class I to III ejection fraction < 40% age < 65 yrs BMI < 30
11374973|NCT02201862||Euploid Subjects|Subject's with fetal euploidy confirmed by chromosome analysis
11374974|NCT02201862||Aneuploid Subjects|Subject's with fetal aneuploidy confirmed by chromosome analysis
11374975|NCT02201849|Experimental|Study Drug|Oral capsules
11374976|NCT02201849|Active Comparator|Active Control|Oral capsules
11374977|NCT02201849|Placebo Comparator|Placebo|Oral capsules
11374978|NCT02201836|Active Comparator|One time music therapy session|One time music therapy session which consists of music meditation, including as assessment/evaluation of confined body breathing function as expressed through drawing and coloring post music imagery session. This is followed by an entrainment wind playing/breath expansion music therapy intervention. At the end of the session, the subjects are given a donated wind instrument for play at home.
11374979|NCT02201836|Active Comparator|Weekly group music therapy intervention|The weekly group music therapy intervention consists of children and teens using guided visualization and expressing their fears and or fantasies related to breathing with one another. This is followed by creative music improvisations with part-playing on flutes, slide whistles, recorders and melodicas.
11374980|NCT02201836|No Intervention|Control|
11374981|NCT02201823|Experimental|ABTL0812|ABTL0812 oral
11374982|NCT02201810|Experimental|2nd level intervention: Rate Reduction|Rate reduction intervention
11374983|NCT02201810|Experimental|2nd level intervention: Recycling|Recycling Group
11374984|NCT02201810|Experimental|2nd level intervention: Choice|Choice Group
11374985|NCT02201797|Experimental|DCE and DWI MRI|MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
11374986|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
11374987|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
11374988|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
11374989|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
11374990|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
11374991|NCT02201758|Placebo Comparator|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
11374992|NCT02201758|Experimental|flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
11374993|NCT02201732|Experimental|Arm A : Operative hysteroscopy|operative hysteroscopy with direct visualization
11374994|NCT02201732|Active Comparator|Arm B : Aspirative curettage|curettage is the standard surgical treatment in most centers
11374997|NCT02201706|Experimental|Multi-electrocoagulation retinectomy|Retinal re-detachment in eyes with silicone oil filled,a modified surgery named Multi-electrocoagulation retinectomy will be used to re-attach the retina.
11374998|NCT02201693|Experimental|Cyclic exclusive MODULEN IBD|Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
11374999|NCT02201693|Experimental|MODULEN IBD supplementation (25% of caloric requirements)|MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
11375000|NCT02201680||parents and children|Anxiety tests
11375001|NCT02201667|Experimental|Ticagrelor group|Patients wil be given 180 mg loading dose of ticagrelor and 300mg loading dose of aspirin followed by PCI, then will receive 90 mg ticagrelor twice daily with aspirin maintenance dose to 30 days after randomization.
11375002|NCT02201667|Active Comparator|Clopidogrel group|Patients will be given clopidogrel 300mg loading dose and 300mg loading dose of aspirin followed by PCI, then will receive 75mg clopidogrel once with aspirin maintenance dose to 30 days after randomization.
11375003|NCT02201654|Other|EBUS patients|All patients in our study are in the same arm, as each patient serves as their own internal control. More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
11375004|NCT02201641|Experimental|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
11375005|NCT02201641|Experimental|Cone Beam computed tomography (CBCT)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
11375006|NCT02201641|Active Comparator|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
11375007|NCT02201641|Active Comparator|Glass ionomer cement ( Fuji IX™)|Glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
11375008|NCT02201628|Experimental|Nasopharyngeal and oesophageal temperatures|An oesophageal and nasopharyngeal temperature probe will be placed and temperature will be measured at these site
11375009|NCT02201615|Experimental|Perineal Massage & Control|"Perineal Massage every 30 min, a 10 min 4 times in the first stage of labour, 1 times in the second stage of labour.
~Control routine care procedure at the clinic."
11375010|NCT02201602|Experimental|Gliclazide|Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
11375011|NCT02201602|Active Comparator|Glibenclamide|Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks
11375012|NCT02201589|Experimental|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
11375013|NCT02201576|Experimental|Bortezomib|Five plasma exchanges, two cycles of bortezomib + dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
11375014|NCT02201576|Active Comparator|Control|Five plasma exchanges, dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
11375015|NCT02201563|Experimental|Minocycline|oral Minocycline 100 mg twice a day for 3 months.
11375016|NCT02201550||Liraglutide|Patients with type 2 diabetes undertaking treatment with liraglutide
11375017|NCT02201537|Other|Imag-NCT|"The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant.
~The functional imaging examinations will be held as follows:
~1st stage - the conventional Doppler ultrasound:
~2nd stage - the elastography:.
~Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound.
~Renal biopsy will be performed after the functional ultrasound at 3 and 12 months."
11375018|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
11375019|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
11375020|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
11375021|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
11375022|NCT02201511|Experimental|Arm 1|
11375023|NCT02201511|Experimental|2|
11375024|NCT02201511|Experimental|3|
11375025|NCT02201511|Experimental|4|
11375026|NCT02201498|Active Comparator|Formocresol/OZE|Conventional pulpotomy technique, with formocresol and zinc oxide eugenol
11375027|NCT02201498|Active Comparator|Biodentine|New technique, with biodentine
11375028|NCT02201485|Active Comparator|PTA in combination with stent-placement|In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
11375029|NCT02201485|Active Comparator|PTA alone|In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
11375030|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
11375031|NCT02201459|Active Comparator|Nilotinib|Control arm, this compound been licensed in this indication.
11375032|NCT02201459|Experimental|Peg-IFN alfa 2a (Pegasys®) and Nilotinib|Arm testing the efficacy of a combination of nilotinib and Peg-IFN alfa 2a as frontline therapy for first line chronic phase CML patients.
11375033|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
11375034|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
11375035|NCT02201433||medical staff and member of an association|"members of medical staff and member of an association of parents of premature infants.
~This cohort is necessary to build protocol interview for part 2 of the study"
11375036|NCT02201433||fathers|fathers of preterm newborns
11375037|NCT02201433||fathers or médical staff|This cohort is build for data validation. We will include fathers who have experienced this situation. Caregivers of NICU who are not participating in the first part
11375038|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
11375039|NCT02201407||CHB Participants Treated With Peginterferon alfa-2a|As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with local labeling and not directed by the protocol. Participants with CHB who are receiving peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics, and in line with the local labeling will be followed for the duration of treatment with peginterferon alfa-2a (48 weeks) and up to 24 weeks after peginterferon alfa-2a treatment (72 weeks in total).
11375040|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
11375041|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
11375042|NCT02201381|Experimental|Metabolic Treatment|"Subjects will take the following treatments and have their data collected from their medical records every 3 months.
~Oral atorvastatin up to 80mg uid, for study duration.
~Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.
~Oral doxycycline 100mg uid, for study duration.
~Oral Mebendazole 100mg uid, for study duration."
11375043|NCT02201368|Experimental|Triheptanoin|
11375044|NCT02201368|Active Comparator|MCT (Medium-Chain Triglycerides)|
11375045|NCT02201355|Experimental|chemoradiation|Hypofractionated, PET-directed, Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy
11375046|NCT02201342|Experimental|Udenafil Dose Level 1 qd|Udenafil tablet dose Level 1 daily for 5 days
11375047|NCT02201342|Experimental|Udenafil Dose Level 1 bid|Udenafil Dose Level 1 twice daily for 5 days.
11375048|NCT02201342|Experimental|Udenafil Dose Level 2 qd|Udenafil tablet dose level 2 once daily for 5 days.
11375049|NCT02201342|Experimental|Udenafil Dose Level 2 bid|Udenafil tablet dose level 2 twice daily for 5 days
11375050|NCT02201342|Experimental|Udenafil Dose Level 3 qd|Udenafil tablet dose level 3 daily for 5 days
11375051|NCT02201342|No Intervention|No Drug|No drug
11375052|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
11375053|NCT02201316|Experimental|Sequence 1 (ABC)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
11375054|NCT02201316|Experimental|Sequence 2 (ACB)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
11375055|NCT02201316|Experimental|Sequence 3 (BAC)|Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
11375056|NCT02201316|Experimental|Sequence 4 (BCA)|Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
11375057|NCT02201316|Experimental|Sequence 5 (CAB)|Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
11375058|NCT02201316|Experimental|Sequence 6 (CBA)|Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
11375059|NCT02201303|Experimental|Part 1|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
11375060|NCT02201303|Experimental|Part 2|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
11375061|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
11375062|NCT02201277|Experimental|Denali|Denali IVC Filter
11375063|NCT02201277|Experimental|Option|Option Elite IVC Filter
11375064|NCT02201264||Primary PCI for STEMI patients|Primary PCI for patients presenting with ST elevation MIs
11375065|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
11375066|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
11375177|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
11375067|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in tube)|1% diclofenac sodium plus 3% menthol gel (in 30g aluminium tube). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
11375068|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in roll-on device)|1% diclofenac sodium plus 3% menthol gel (in roll-on applicator device supplied in 30g plastic bottles). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
11375069|NCT02201238|Active Comparator|Diclofenac sodium tablets|50mg diclofenac sodium tablets administered orally, three times daily for three consecutive days with 6h between adjacent doses on the same day
11375070|NCT02201238|Active Comparator|Voltaren gel|Voltaren gel supplied in 100g aluminium tube. Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
11375071|NCT02201225|Active Comparator|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
11375072|NCT02201225|Sham Comparator|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
11375073|NCT02201212|Experimental|Everolimus|"Everolimus
~Fixed doses orally once a day per each 28 day cycle
~Participants will stay on study as long as they do not progress for a maximum of 24 months.
~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
11375074|NCT02201199|Active Comparator|insulin glargine U100|1 single dose
11375075|NCT02201199|Experimental|insulin glargine U200|1 single dose
11375076|NCT02201199|Experimental|insulin glargine U500|1 single dose
11375077|NCT02201186|Experimental|manuka honey enema treatment|Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.
11375078|NCT02201173|Experimental|Locomotor Training|
11375079|NCT02201160|Active Comparator|omega 3|The subjects will take 4 capsules/day during 6 months. Each capsule of the active n-3 PUFA supplement contained 500 mg of fish oil (each capsule provides 300 mg of n-3 PUFA (EPA+DHA) with 3.75 U vitamin E to prevent peroxidation).
11375080|NCT02201160|Placebo Comparator|Sun Flower|The subjects will take 4 capsules/day during 6 months. The placebo capsule contained 500 mg of sunflower oil with 3.75 U vitamin E.
11375081|NCT02201147|Experimental|cold biopsy polypectomy|
11375082|NCT02201147|Experimental|Cold snare polypectomy|
11375083|NCT02201134|Other|sevoflurane|
11375084|NCT02201121|Experimental|phenylephrine group, dopamine group, ephedrine group|"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.
~dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level."
11375085|NCT02201108|Placebo Comparator|Placebo|Matching placebo tablets
11375086|NCT02201108|Experimental|Teriflunomide|Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
11375087|NCT02201095|No Intervention|Normal care|Normal care - no active warming
11375088|NCT02201095|Active Comparator|Forced air warming|Underbody forced air warming blanket
11375089|NCT02201095|Active Comparator|Conduction warming mattress|Underbody conduction warming mattress
11375090|NCT02201082|Experimental|Nebulization and airway clearance technique|nebulization combined to airway clearance
11375091|NCT02201082|Active Comparator|Nebulization|nebulization
11375092|NCT02201069|Experimental|health coaching|12 weeks of health coaching using weekly contact in the first month and biweekly contacts in months 2-3.
11375093|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
11375094|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
11375095|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
11375096|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
11375097|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
11375098|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
11375099|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
11375100|NCT02201043|Active Comparator|Thalidomide 150mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd.po.to the end
11375101|NCT02201043|Active Comparator|Thalidomide 100mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end
11375102|NCT02201043|Placebo Comparator|Placebo|Placebo po.
11375103|NCT02201030|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
11375104|NCT02201030|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
11375105|NCT02201004|Experimental|tofogliflozin|Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
11375106|NCT02201004|Placebo Comparator|placebo|Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
11375107|NCT02200991|Experimental|Lixisenatide|"Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.
~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
11375108|NCT02200991|Active Comparator|Sitagliptin - Januvia|"50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.
~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
11375178|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
11375213|NCT02200185|Placebo Comparator|IV titrated morphine|"patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).
~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS > 50%, 30 minutes after the beginning of the protocol."
11375109|NCT02200978|Active Comparator|ATO and chemotherapy|"Induction:
~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).
~Consolidation 1:
~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20 mg (1-3 years), or 30 mg ( > 3 years), dexamethasone 2mg.
~Consolidation 2:
~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Consolidation 3:
~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Maintenance:
~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance."
11375110|NCT02200978|Experimental|RIF and chemotherapy|"Induction:
~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).
~Consolidation 1:
~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20mg (age 1-3 years), or 30mg (age > 3 years), dexamethasone 2mg.
~Consolidation 2:
~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Consolidation 3:
~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.
~Maintenance:
~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment."
11375111|NCT02200965|Active Comparator|Received a letter on 3 occasions|"My Diabetes, My Information, My Plan Document:
~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.
~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
11375112|NCT02200965|Active Comparator|Received letter on 1 occasion|"My Diabetes, My Information, My Plan Document:
~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.
~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
11375113|NCT02200952||Patients at risk of OHSS|Patients at risk of OHSS on the oocytes triggering day with an oestradiol > 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm
11375114|NCT02200939|Experimental|Partial-thickness tear|Medium or large partial-thickness tear or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
11375115|NCT02200939|Experimental|Full-thickness tear|Medium or large full-thickness tear of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
11375116|NCT02200926|Experimental|Placebo|The breathing was performed normally in this groups.
11375117|NCT02200926|Experimental|Loaded breathing training|subjects will trained to inspire deeply against the resistance setting by using BreathMAX® at the loaded of 18 cmH2O with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
11375118|NCT02200926|Experimental|Unloaded breathing training|subjects will trained to inspire deeply (no resistance) with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
11375119|NCT02200913|Experimental|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
11375120|NCT02200913|Experimental|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
11375121|NCT02200900|Active Comparator|Group 1 ( CPAP followed by HFNC)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.
11375122|NCT02200900|Active Comparator|Group 2 (HFNC followed by CPAP)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.
11375123|NCT02200887||Advanced Parkinsons Disease|Polysomnogram
11375124|NCT02200887||Parkinsons Disease with Dyskinesia|Polysomnogram
11375125|NCT02200887||De novo Parkinsons Disease|Polysomnogram
11375126|NCT02200887||Healthy Volunteers|Polysomnogram
11375127|NCT02200874||before NST-implementation (group A)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: Before implementation of Nutrition Support Team (NST).
11375128|NCT02200874||After NST-implementation (group B)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: After implementation of Nutrition Support Team (NST).
11375129|NCT02200848|Experimental|Lenalidomide, Ibrutinib, Rituximab|Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.
11375130|NCT02200822|No Intervention|non-intervention arm|continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)
11375131|NCT02200822|Active Comparator|withdrawal of beta blockers|"Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.
~(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:
~bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop
~metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop
~nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop
~carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop"
11375248|NCT02199912|Experimental|Patients with colorectal surgery|
11375132|NCT02200822|Active Comparator|withdrawal of RAAS blockers|"intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)
~first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop
~after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:
~captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop
~enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop
~lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop
~ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop
~candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop
~valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop"
11375133|NCT02200822|Active Comparator|withdrawal of RAAS - and beta blockers|"intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)
~First: spironolactone/eplerenone cfr reduction schedule supra
~After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra
~After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra"
11375134|NCT02200809|Experimental|MR-guided focal laser ablation|
11375135|NCT02200796|Experimental|Low Protein Meal|Low Protein Test Meal (15 g)
11375136|NCT02200796|Experimental|Moderate Protein Meal|Moderate Protein Meal (30 g)
11375137|NCT02200796|Experimental|High Protein Meal|High Protein Meal (45g)
11375138|NCT02200796|Experimental|Control Meal|High Carbohydrate Control Meal (7 g of protein)
11375139|NCT02200783|Active Comparator|Radial|Cardiac catheterization and coronary angioplasty performed via standard radial artery technique.
11375140|NCT02200783|Active Comparator|Femoral|Cardiac catheterization and coronary angioplasty performed via standard femoral artery technique.
11375141|NCT02200783|Experimental|TripTable|Cardiac catheterization and coronary angioplasty performed with standard transradial technique plus using the TRIPTable device.
11375142|NCT02200770|Placebo Comparator|Total Placebo|Aquaporin-4-antibody (AQP4- IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15 in OLP and will be followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP.
11375143|NCT02200770|Experimental|Total Inebilizumab|AQP4-IgG sero positive and sero negative participants will receive IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who entered OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15 of OLP and will be followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP.
11375144|NCT02200757|Experimental|Aldoxorubicin|
11375145|NCT02200757|Active Comparator|Topotecan|
11375146|NCT02200744||Dislocation reduction using propofol|
11375147|NCT02200731|Experimental|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience.
11375148|NCT02200731|No Intervention|Control|In Denmark, standard care after treatment does not include systematic psychosocial support. Families are able to seek support on their own or contact a support group offered by the Danish Cancer Society. However support specializing the families with childhood cancer survivors and their siblings after ending medial treatment is limited.
11375149|NCT02200718|Experimental|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant
11375150|NCT02200718|Placebo Comparator|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion
11375151|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
11375152|NCT02200692||plasma transfusion|Patients receiving plasma transfusion.
11375153|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
11375154|NCT02200653|Experimental|Low dose of MICARDIS®|
11375155|NCT02200653|Experimental|High dose of MICARDIS®|
11375156|NCT02200653|Active Comparator|Low dose of COZAAR® / LORZAAR®|
11375157|NCT02200653|Active Comparator|High dose of COZAAR® / LORZAAR®|
11375158|NCT02200640|Experimental|Low dose of Micardis®|
11375159|NCT02200640|Experimental|High dose of Micardis®|
11375160|NCT02200640|Active Comparator|Low dose of COZAAR®|
11375161|NCT02200640|Active Comparator|High dose of COZAAR®|
11375162|NCT02200614|Experimental|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
11375163|NCT02200614|Placebo Comparator|Placebo|Participants received matching placebo 2 tablets twice daily with food.
11375164|NCT02200601|Experimental|Seipher Wellness|
11375165|NCT02200588||Patients|Patients followed in the First Episode Psychosis Clinical Program (PAFIP) with psychotic disorder
11375166|NCT02200588||Controls|Healthy subjects without psychotic disorder
11375167|NCT02200575||Patients with non-secondary, essential hypertension|
11375168|NCT02200562|Experimental|Ipilimumab and Dabrafenib|
11375169|NCT02200549|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
11375170|NCT02200549|Experimental|Cycle training group|A 30-minute cycling training session is performed 3 days a week using calibrated cycle ergometer.
11375171|NCT02200549|Experimental|Combined group|A 30-minute Combined training session is performed 3 days a week using calibrated cycle ergometer and threshold loading device.
11375172|NCT02200536|Experimental|Test|Infant oral health promotion package
11375173|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
11375174|NCT02200536|No Intervention|Control 2|
11375175|NCT02200523|Experimental|SARA electrode|new electrode
11375176|NCT02200523|Active Comparator|Gold cup|gold standard
11375179|NCT02200484|Experimental|Parent Training/Obesity Prevention|Mother-child dyads randomized to the active intervention in the pilot study will be administered 8 weeks of a combined parenting training and obesity prevention program that was adapted through analysis of formative research interviews with adolescent mothers with feedback from an expert panel of multidisciplinary research team members and community members.
11375180|NCT02200484|Active Comparator|8-week Wellness Program (Control)|Participants randomized to control condition during intervention piloting will receive print-based health and wellness materials once weekly for 8-weeks + 2 follow up telephone calls at the beginning and conclusion of the 8-week program.
11375181|NCT02200471|Experimental|VeinViewer|VeinViewer will be used in conjunction with routine cosmetic dermatology procedures. Patients and physicians will complete questionnaires.
11375182|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
11375183|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).
~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.
~The dose levels will be as follows:
~Cohort 1: 0.3x10^6 IU/m^2/day.
~Cohort 2: 1.0x10^6 IU/m^2/day.
~Cohort 3: 1.5x10^6 IU/m^2/day.
~Up to 6 subjects will be recruited to each dose cohort.
~Once the maximum tolerated dose has been identified, a further 10 subjects will receive IL-2 at the maximum tolerated dose."
11375184|NCT02200432|No Intervention|Control|The study's current rule-based CTHC system is embedded within the Decide2Quit.org web service. Control smokers will receive the current Decide2Quit.org system, including informational web pages, an interactive quit plan, plus pushed email messages. The messages will be selected using the current rule-based CTHC system. The CTHC selects messages based on decision rules (e.g: readiness to quit, gender) using information from a smoker's baseline profile. Participants will receive one message per day for 30 days
11375185|NCT02200432|Experimental|Intervention|The PERSPeCT intervention smokers will receive all components of the Decide2Quit.org web service, but persuasive email messages will be selected by the PERSPeCT recommender system developed in Aim 2. PERSPeCT will use data (see Figure 1) to predict messages that would be most influential to the participant. Intervention smokers will receive one PERSPeCT-generated message per day for 30 days. With each message rating, the PERSPeCT system will further adapt to patient preferences.
11375186|NCT02200419|Other|Transfusion Algorithm|Hospitals will be randomized to the intervention arm of the study in a stratified manner.
11375187|NCT02200406|Other|Desvenlafaxine|"Open-label pilot study
~Desvenlafaxine will be administered during 56 consecutive days
~Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks."
11375188|NCT02200393|Experimental|Abdominal FES|Participants in the Abdominal Functional Electrical Stimulation (AFES) group will receive AFES 5 times per week (20 to 40 mins per day), on four alternate weeks.
11375189|NCT02200380|Experimental|CDX-301|
11375190|NCT02200380|Experimental|CDX-301 and plerixafor|
11375191|NCT02200367|Experimental|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
11375192|NCT02200367|Other|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
11375193|NCT02200354|Experimental|pemetrexed with bevacizumab|pemetrexed rechallenge with bevacizumab pemetrexed (500mg/m2 day1) bevacizumab (15mg/kg day1)
11375194|NCT02200341|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) 8-week intervention
11375195|NCT02200341|Active Comparator|Progressive Relaxation Training - Psychoeducation|Progressive Relaxation Training and Psychoeducation (PRT-PsyEd) 8-week intervention
11375196|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
11375197|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
11375198|NCT02200315|Experimental|No Antimicrobial prophylaxis|No use of antimicrobial prophylaxis during surgery
11375199|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
11375200|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
11375201|NCT02200263|Experimental|Lutein plus Zeaxanthin|Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
11375202|NCT02200263|Placebo Comparator|Placebo softgels|Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
11375203|NCT02200250||Post Barretts Excision|Patients who have undergone an EMR for Barretts Oesophagus
11375204|NCT02200237|Placebo Comparator|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
11375205|NCT02200237|Experimental|EV71 with adjuvant aluminium phosphate|Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 μg/0.5ml
11375206|NCT02200224|Experimental|Rapid Testing/Treatment Group|All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED.
11375207|NCT02200224|No Intervention|Control|All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED.
11375208|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
11375209|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
11375210|NCT02200198|Active Comparator|Inspiratory group|Inspiratory muscle training
11375211|NCT02200198|Sham Comparator|Sham group|Sham training
11375212|NCT02200198|Experimental|Expiratory group|Expiratory muscle training
11375249|NCT02199899|Experimental|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
11375214|NCT02200185|Experimental|Low dose nebulised morphine|"patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.
~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo"
11375215|NCT02200185|Experimental|High dose nebulised morphine|"patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.
~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo."
11375216|NCT02200172|Active Comparator|Melatonin|A single daily sublingually administered tablet of 3mg non-animal synthetic source melatonin (immediate-release) at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
11375217|NCT02200172|Placebo Comparator|Placebo|A single daily sublingually administered tablet of placebo at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
11375218|NCT02200159||dexmedetomidine|
11375219|NCT02200146|Active Comparator|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
11375220|NCT02200146|Experimental|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
11375221|NCT02200133|Experimental|Individualized Survivorship Care Plan (SCP)|"Participant information sheet and instructions on how to use the SCP
~Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)
~Newest Vital Sign nutrition label to measure health literacy and its instructions
~Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
11375222|NCT02200133|No Intervention|Usual care (no SCP)|"Materials that their transplant center routinely provides to patients for follow-up care
~Newest Vital Sign nutrition label to measure health literacy and its instructions
~Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
11375223|NCT02200107|Experimental|self management education|self management education program delivered by family doctor in primary care clinics and during and physical therapy design
11375224|NCT02200107|No Intervention|control|Routine follow up according to standard practice
11375225|NCT02200094||Outpatients with essential hypertension|
11375226|NCT02200081|Experimental|MGN1703|MGN1703, solution in Dulbecco's Phosphate-Buffered Saline (DPBS), 2 mL of 60 mg/4 mL (15 mg/mL), administered SC at 2 application sites twice weekly
11375227|NCT02200081|Other|Standard of care|Continous first line therapy
11375228|NCT02200068|Active Comparator|PHR Group|This group will have access to a personal health record website SANOIA in addition to all resources they use or find online
11375229|NCT02200068|No Intervention|Non-PHR Group|This group will not be informed of the Personal Health Record Website and will use Internet as they usually do.
11375230|NCT02200055|Experimental|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.
~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.
~Bioimpedance Assessment"
11375231|NCT02200042|Experimental|Radiation therapy|Liver-directed radiation therapy
11375232|NCT02200042|No Intervention|Observation|No radiation therapy
11375233|NCT02200029|Experimental|Ademetionine IV|
11375234|NCT02200029|Experimental|Ademetionine oral|
11375235|NCT02200016|Experimental|SAX|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
11375236|NCT02200016|Active Comparator|LAX|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
11375237|NCT02200003|Experimental|Attention Bias Modification|640 Trials (20 minutes) four times over four weeks
11375238|NCT02200003|Sham Comparator|Sham Attention bias modification|640 Trials (20 minutes) four times over four weeks
11375239|NCT02199977|Other|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
11375240|NCT02199977|Other|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
11375241|NCT02199977|Other|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
11375242|NCT02199977|Other|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
11375243|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
11375244|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
11375245|NCT02199951||Dihydroartemisinin and piperaquine|The patients will take Eurartesim® (DHA/PQP) with a dose regimen of one administration every 24 hours over a period of three days, i.e. at Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3) from the first administration. The dose will be based on body weight. Two strengths of Eurartesim® will be provided for dosing in children and adults: 20/160mg and 40/320mg of DHA and PQP respectively. Body weight (kg) Daily dose (mg) Number of tablets per dose 20/160mg DHA/PQ 40/320mg DHA/PQ 5 to <7 10 mg DHA and 80 mg PQP ½ tablet 7 to <13 20 mg DHA and 160 mg PQP 1 tablet 13 to < 24 40 mg DHA and 320 mg PQP 1 tablet 24 to < 36 80 mg DHA and 640 mg PQP 2 tablets 36 to < 75 120 mg DHA and 960 mg PQP 3 tablets 75 to < 100 160 mg DHA and 1280 mg PQP 4 tablets > 100.
11375246|NCT02199938||musculoskeletal tumors|Patients with suspected or confirmed bone or soft tissue tumors undergoing biopsy or surgery
11375247|NCT02199925|Experimental|Gammaplex 5% IGIV|Gammaplex 5% IGIV administered intravenously
11375260|NCT02199834|Experimental|Peer group|24 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support to this group under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
11375261|NCT02199834|Other|Refused peer group|Patients who fit the criteria of peers but refuse to be contacted by peer supporters will be signed as refused group. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
11375262|NCT02199834|Experimental|Report group|Patients in this group will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values twice a year through mails.
11375263|NCT02199834|No Intervention|Usual care|Patients will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
11375264|NCT02199821|Active Comparator|Soybean oil formula commonly used in the hospita|
11375265|NCT02199821|Experimental|Formula with soybean oil, medium-chain triglyce|
11375266|NCT02199808||7-9 year olds|These are children who are between 7 and 9 years old when they are tested.
11375267|NCT02199808||10-12 year olds|These are children who are between 10 and 12 years old when they are tested.
11375268|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
11375269|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
11375270|NCT02199782|Active Comparator|Welsh|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
11375271|NCT02199782|Active Comparator|English|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
11375272|NCT02199769|Experimental|Clinical Decision Support|Visit-based, EMR-enabled case identification and real-time decision support to identify patients without diabetes who have a RBG>= 125mg/dL and no resulted diabetes screening.
11375273|NCT02199769|No Intervention|Usual care|Diabetes screening/testing and diagnosis per usual care at the discretion of the treating physician.
11375274|NCT02199756||Cesarean section|Women with cesarean section
11375275|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
11375276|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
11375277|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
11375278|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
11375279|NCT02199704|Other|No control or comparison arm.|This case series study has no control or comparison arm. There is only one arm being evaluated (the self directed parenting intervention).
11375280|NCT02199691|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
11375281|NCT02199691|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
11375282|NCT02199691|Experimental|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
11375283|NCT02199691|Active Comparator|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
11375284|NCT02199678|Placebo Comparator|Placebo|Placebo
11375285|NCT02199678|Active Comparator|ketamine 25 mg|ketamine
11375286|NCT02199678|Active Comparator|ketamine 35 mg|ketamine
11375287|NCT02199678|Active Comparator|ketamine 50 mg|ketamine
11375288|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11375289|NCT02199652|Placebo Comparator|placebo|placebo pill
11375290|NCT02199652|Experimental|prazosin|prazosin pill
11375291|NCT02199639||Spain|Group of patients with hemophilia recruited in the Region of Murcia (Spain) and evaluated in the Universidad Católica San Antonio between June and July 2014.
11375292|NCT02199639||El Salvador|"Group of patients with hemophilia recruited in the city of San Salvador (El Salvador) and evaluated in the Hospital Nacional Rosales and the Hospital Nacional de niños Benjamín Bloom from San Salvador in April 2014."
11375293|NCT02199639||Bolivia|Group of patients with hemophilia recruited in the city of Santa Cruz (Bolivia) and evaluated at the Hospital Nacional de niños in Santa Cruz August 2014.
11375294|NCT02199626|Experimental|CCE-2|Second generation of Colon capsule endoscopy in pediatric Crohn's disease
11375295|NCT02199613|Experimental|Treatment simplification|Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food
11375296|NCT02199600|Other|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
11375297|NCT02199587|Active Comparator|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
11375298|NCT02199587|No Intervention|Endocrine test without medical clown|
11375299|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
11375300|NCT02199561|Experimental|Fecal Microbiota Transplant|Open label single arm delivering fecal transplant to each participant
11375301|NCT02199548||Study Participants|All enrolled participants will take part in a face-to-face interview.
11375302|NCT02199522|Experimental|titration induction of propofol|titration induction of propofol by Fresenius pump at the speed of 1 mg•kg-1•min-1
11375303|NCT02199522|No Intervention|convention induction of propofol|propofol 2mg•kg-1 intravenously by Fresenius pump at the speed of 250mg•min-1
11375304|NCT02199496|Experimental|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
11375305|NCT02199496|Experimental|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
11375306|NCT02199470||C-peptide minimal detectable|C-peptide level between 0,01-0,08 ng/mL
11375307|NCT02199470||C-peptide sustained|C-peptide level between higher or equal to 0,08 ng/mL
11375308|NCT02199470||C-peptide not detectable|C- peptide level equal to or lower than 0,01 ng/mL
11375309|NCT02199457|Other|SVSS and reference devices|Vital signs will be measured on the same subject with the reference devices and with the SVSS. The subject will have blood pressure, pulse, blood oxygen, body temperature and respiration rate measured using standard equipment. The same subject will then use the investigational device which measures all vital signs at the same time, by placing the index finger on a sensor.
11375310|NCT02199444|Experimental|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
11375311|NCT02199444|Placebo Comparator|Placebo|The patients received placebo three times a day
11375312|NCT02199431|Experimental|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
11375313|NCT02199431|Experimental|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
11375314|NCT02199418|Experimental|Paclitaxel and Cisplatin|"Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
~Trastuzumab (only for human epidermal growth factor receptor-2(HER2)-positive patients): Loading dose: 4 mg/kg, Maintenance dose: 2 mg/kg, day 1 q day 8 for 16 weeks. Post-surgery: up to a total duration of 1 year"
11375315|NCT02199405|Experimental|massage and Sishi Daoyin|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
11375316|NCT02199405|Active Comparator|conventional massage and cervical traction|Conventional massage , 15 minutes, three times one week for 4 weeks Cervical traction , 15 minutes, three times one week for 4 weeks
11375317|NCT02199392|Experimental|Lenvatinib 24 mg|The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
11375318|NCT02199379|Experimental|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
11375319|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
11375320|NCT02199353|Experimental|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.
~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.
~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
11375321|NCT02199353|Active Comparator|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.
~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
11375322|NCT02199340|Experimental|Cystic fibrosis|"iStep exercise test
~CPET exercise test"
11375323|NCT02199340|Active Comparator|Healthy control|- iStep exercise test
11375324|NCT02199327|Active Comparator|Mitomycin C|Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
11375325|NCT02199327|Active Comparator|Interferon alfa 2b|Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
11375326|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
11375327|NCT02199301|Experimental|BMTKT|Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)
11375328|NCT02199288||Cohort|
11375329|NCT02199262|Experimental|control groupe|agitation diagnosis and management according to implemented guidelines= reminder implementation
11375330|NCT02199262|Experimental|music intervention + reminder|agitation diagnosis and management according to implemented guidelines+ music intervention
11375331|NCT02199262|Experimental|reflexology + reminder|agitation diagnosis and management according to implemented guidelines + reflexology
11375332|NCT02199249|Active Comparator|Open Reduction Tightrope fixation (OT)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
11375333|NCT02199249|Active Comparator|Open Reduction screw fixation (OS)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
11375334|NCT02199236|Experimental|endorectal brachytherapy, concurrent chemo and questionnaires|This is a phase I, dose-escalation study to evaluate the safety of endorectal brachytherapy with concurrent capecitabine or 5-fluoruracil (5-FU) in the management of locally recurrent/residual rectal or anal cancer in patients who have received pelvic external beam radiation therapy (EBRT) +/- chemotherapy. We will use magnetic resonance imaging (MRI) with dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI) series to contribute to the assessment of tumor response.
11375335|NCT02199223|Experimental|panitumumab + regorafenib|
11375336|NCT02199210|Experimental|Prompting forethought|"A demographic questionnaire will be filled out by each participant. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:
~participants forethought will be prompted and each participant will be asked to report his/her forethought,
~participants then will be asked to manage a simulated massive transfusion scenario,
~at completion of the scenario, each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
11375337|NCT02199210|No Intervention|No prompting|"A demographic questionnaire will be filled out by each participants. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:
~participants will sit and wait for a predetermined time before entering into the simulator,
~participants then will be asked to manage a simulated massive transfusion scenario,
~at completion of the scenario, each participant will be interviewed about their thought process before entering to the simulation room,
~each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
11375338|NCT02199197|Experimental|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
11375339|NCT02199197|Active Comparator|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
11375340|NCT02199184|Experimental|Treatment (DA-EPOCH and ofatumumab or rituximab)|Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
11375341|NCT02199171|Experimental|HIPEC carboplatin|"Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.
~Doses as appropriate for assigned dose level in 500 cubic centimeters (cc)"
11375342|NCT02199158|Experimental|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
11375343|NCT02199145|Other|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria /creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
11375344|NCT02199132||Nasopharyngeal Carcinoma|
11375345|NCT02199119|Experimental|Control|Sitting quietly for 30 min No TV No exercise
11375346|NCT02199119|Experimental|TV viewing only|watching TV for 30 min
11375347|NCT02199119|Experimental|Exercise only|exercising for 30 min
11375348|NCT02199119|Experimental|TV viewing and Exercise|30 min of moderate exercise on a treadmill while watching TV
11375349|NCT02199106|Experimental|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)
~Intervention: Left temporal verum cTBS"
11375350|NCT02199106|Experimental|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings
~Intervention: Left temporal placebo cTBS"
11375351|NCT02199093|Experimental|Functional Rehabilitation of apraxia|The participants will be randomly assigned to an experimental group, to receive intervention in upper limb apraxia at home since two approaches, a rehabilitative and another compensatory (providing adaptive strategies at home). The treatment will be performed three times a week, 30 minutes a day, during a 4-week period.
11375682|NCT02196792|Active Comparator|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
11375352|NCT02199093|Active Comparator|Traditional health educative protocol|Control group will receive treatment with a traditional health educative protocol to improve his functionality in activities of daily living. The treatment will be performed twice in two month.
11375353|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
11375354|NCT02199054|Placebo Comparator|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
11375355|NCT02199054|Active Comparator|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
11375356|NCT02199054|Active Comparator|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
11375357|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.
~Cells for infusion are prepared using the CliniMACS System."
11375358|NCT02199028|Experimental|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.
~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
11375359|NCT02199028|Experimental|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.
~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.
~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
11375360|NCT02199015|Experimental|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
11375361|NCT02199002|Other|healthy volunteers|healthy volunteers (no gastric complains)
11375362|NCT02199002|Other|PPI responders|proven reflux, good symptom relief upon PPI therapy
11375363|NCT02199002|Other|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
11375364|NCT02199002|Other|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
11375365|NCT02199002|Other|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
11375366|NCT02198989|Experimental|peer support and yoga music therapy|"Patients in the group will receive peer support and yoga music therapy before bed.
~Patients in the group will received the group education courses and clinical medical therapy."
11375367|NCT02198989|No Intervention|Control group|Patients in the group will received the group education courses and clinical medical therapy.
11375368|NCT02198976||Barrett's Oesophagus|Patients with Barrett's Oesophagus with either high grade dysplasia (HGD) or intramucosal cancer (IMC)
11375369|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
11375370|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
11375371|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
11375372|NCT02198950||ICU patients|all patients admitted into the ICU
11375373|NCT02198937||Smokers|Healthy smokers
11375374|NCT02198937||Non-Smokers|Healthy non-smokers
11375375|NCT02198924|Experimental|Parecoxib and Celecoxib|"Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3."
11375376|NCT02198924|Placebo Comparator|placebo|"Patients in the control group are supplied with the corresponding placebo with the same instructions.
~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3."
11375377|NCT02198911|Active Comparator|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
11375378|NCT02198911|Active Comparator|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
11375379|NCT02198911|Active Comparator|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
11375380|NCT02198898|No Intervention|GUARDIX|no guadix
11375381|NCT02198898|Experimental|guadix|guadix treatment
11375715|NCT02196571|No Intervention|Control|Standard antenatal care
11375382|NCT02198885||Control|This group receives the standard prehospital care en route to hospital, and they do not receive the FAST ultrasound en route.
11375383|NCT02198885||FAST|This group receives the FAST ultrasound en route to hospital.
11375384|NCT02198872|Experimental|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
11375385|NCT02198872|Active Comparator|Land Group|Patients of this group perform physical training on bicycle.
11375386|NCT02198859|Experimental|Lithium|Oral lithium carbonate dose escalation: Level 1 of 600 mg/day, then escalating to Level 2 of 900 mg/day, then the final Level 3 of 1200 mg/day.
11375387|NCT02198846|Experimental|Insulin pump|insulin pump
11375388|NCT02198846|Active Comparator|conventional treatment|intensification of conventional treatment
11375389|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
11375390|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
11375391|NCT02198820||General|All patients included who underwent surgery with general anesthesia
11375392|NCT02198820||Loco Regional|All patients included who underwent surgery with loco regional anesthesia
11375393|NCT02198807|Experimental|Fosmidomycin-Piperaquine|Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days
11375394|NCT02198794|Experimental|SD-809- Part A|Dose titration for 6 weeks to determine a subject's optimal dose. Subject's dose is then maintained for the duration of the study.
11375395|NCT02198794|Experimental|SD-809- Part B|I week period of randomized withdrawal
11375396|NCT02198794|Experimental|Placebo- Part B|I week period of randomized withdrawal
11375397|NCT02198781||Cohort|Basic science study
11375398|NCT02198768||Ankle Fracture|Patients with isolated ankle fractures.
11375399|NCT02198768||Ankle Fracture-Dislocation|Patients with ankle fracture-dislocations.
11375400|NCT02198755|Active Comparator|High Resolution Ultrasound|High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner
11375401|NCT02198755|Active Comparator|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI)
11375402|NCT02198742|Active Comparator|Miller blade|Subjects must have >500 intubations in order to participate in this study. There is no placebo group, and each subject wil be his or her own control.
11375403|NCT02198742|Active Comparator|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable. There is no placebo group, and each subject wil be his or her own control.
11375404|NCT02198742|Active Comparator|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacterer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
11375405|NCT02198729|Active Comparator|Endoscopic Mucosal Resection|Participants randomised to this arm will receive standard of care Endoscopic Mucosal Resection for removal of their lesions.
11375406|NCT02198729|Experimental|Endoscopic Submucosal Dissection|Participants randomised to this arm will receive Endoscopic Mucosal Dissection to remove their lesion.
11375407|NCT02198716|Other|Drug eluting stent|Percutaneous coronary intervention
11375408|NCT02198716|Other|Bare Metal Stent|Percutaneous Coronary Intervention
11375409|NCT02198703|Experimental|AB-Life|1 capsule of AB-Life daily during 12 weeks consumed immediately before, after or during the breakfast. The daily dose corresponds to the intake of 1.8E+10 CFU. According to the product's stability and the duration of the experiment, all participants receive at least 1.2E+09 CFU/capsule/day by the end of the study.
11375410|NCT02198703|Placebo Comparator|Placebo|1 capsule of placebo daily during 12 weeks consumed immediately before, after or during the breakfast.
11375411|NCT02198690|Experimental|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women >75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
11375412|NCT02198690|Placebo Comparator|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
11375413|NCT02198677|Experimental|AP|Anterior to posterior pressures 5x10 seconds per set with 10 seconds rest between each set
11375414|NCT02198677|Experimental|Lateral glides|Lateral glides 5x10 seconds per set with 10 seconds rest between each set
11375415|NCT02198664|Experimental|Peanut Protein Capsule|Biological: Capsules containing peanut flour, oral immunotherapy, will be used for dose escalation build-up, and maintenance phase
11375416|NCT02198651|Experimental|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
11375417|NCT02198651|Active Comparator|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
11375418|NCT02198651|Placebo Comparator|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
11375419|NCT02198651|Experimental|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
11375420|NCT02198638|Other|Patients or healthcare workers|
11375421|NCT02198625|No Intervention|FiO2 80%,Nonprotective Lung Ventilation|
11375422|NCT02198625|Experimental|FiO2 30%,Nonprotective Lung Ventilation|FiO2 30%,Nonprotective Lung Ventilation
11375423|NCT02198625|Experimental|FiO2 80%,protective Lung Ventilation|FiO2 80% and protective Lung Ventilation
11375424|NCT02198625|Experimental|FiO2 30%,protective Lung Ventilation|FiO2 30% and protective Lung Ventilation
11375425|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
11375426|NCT02198599|Experimental|Mobility-enhancing-nursing intervention|A 30 day mobility enhancing-nursing intervention for patients with Multiple Scerosis and stroke to expand kinaesthetic competence in order to increase compensation of limitations, improve functionality, and quality of life
11375427|NCT02198599|No Intervention|Standard usual rehabilitation care|Participants in the control group will receive usual care, which is based on the principles of rehabilitation nursing. Based on patients functional ability (EBI data) the nursing process is used to determine objectives and interventions. The main focus is on providing a therapeutic environment and supporting and advancing abilities to perform the Activities of Daily Living, support mobility and kinesthetic perception.
11375428|NCT02198586||No treatment|The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
11375429|NCT02198560||Normal (Eyes without pathology)|
11375430|NCT02198547|Experimental|Ropivacaine Magnesium sulfate|"Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg.
~Sciatic block at popliteal level."
11375431|NCT02198547|Active Comparator|Ropivacaine|Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG
11375432|NCT02198534||ophthalomogically normal subjects|
11375433|NCT02198521||Bilateral Carpal Tunnel Syndrome (CTS)|
11375434|NCT02198508|Active Comparator|DFX single treatment|a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
11375435|NCT02198508|Active Comparator|DFP single treatment|single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
11375436|NCT02198508|Experimental|combination treatment|sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
11375437|NCT02198495|Active Comparator|Ferric carboxymaltose|Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30
11375438|NCT02198495|Active Comparator|Iron sucrose|Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38
11375439|NCT02198482|Active Comparator|Daunorubicin, Cytarabine (DA)|"DA
~Induction I:
~Daunorubicin 60 mg/m² i.v., d 1-3
~Cytarabine 100 mg/m² cont. i.v., d 1-7
~Induction II:
~Daunorubicin 50 mg/m² i.v. d 1-3
~Cytarabine 100 mg/m² cont. i.v., d 1-5
~Consolidation therapy:
~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).
~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. infusion on day 1.
~Intermediate-dose cytarabine:
~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT."
11375440|NCT02198482|Experimental|Volasertib, Daunorubicin, Cytarabine|"VDA
~Induction I
~Volasertib i.v., d1
~Daunorubicin 60 mg/m² i.v., d 2-4
~Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II
~Volasertib i.v., d1
~Daunorubicin 50 mg/m² i.v. d 2-4
~Cytarabine 100 mg/m² cont. i.v., d 2-6
~Consolidation therapy:
~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).
~Volasertib i.v., d1
~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 2.
~Intermediate-dose cytarabine:
~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT."
11375441|NCT02198482|Experimental|Daunorubicin, Cytarabine, Volasertib|"DAV
~Induction I
~Volasertib i.v., d7
~Daunorubicin 60 mg/m² i.v., d 1-3
~Cytarabine 100 mg/m² i.v., d 1-7 Induction II
~Volasertib i.v., d5
~Daunorubicin 50 mg/m² i.v. d 1-3
~Cytarabine 100 mg/m² cont. i.v., d 1-5
~Consolidation therapy:
~Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).
~Volasertib i.v., d4
~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 1.
~Intermediate-dose cytarabine:
~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT."
11375442|NCT02198469|Experimental|Er:YAG AFL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
11375443|NCT02198469|Active Comparator|MAL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
11375444|NCT02198456||3D echocardiography|
11375445|NCT02198443|Active Comparator|Tenofovir+emtricitabine|
11375446|NCT02198443|Experimental|Elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|
11375447|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
11375448|NCT02198430||Control group|Children without hemophilia
11375449|NCT02198417|Experimental|Metformin|Metformin ER 1500 mg per day treatment for 12 weeks
11375450|NCT02198404|Experimental|sedation with propofol|propofol injection: induction with propofol at 20 mg/kg/h. When patient is sleeping, the dosage is deceased to 6 mg/kg/h
11375451|NCT02198391||3 x 1 tablet per day|Echinaforce Junior tablets (low dose)
11375452|NCT02198391||5 x 1 tablet per day|Echinaforce Junior tablets (high dose)
11375453|NCT02198378|Active Comparator|Morphine|Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
11375454|NCT02198378|Experimental|MEOPA and paracetamol|"The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.
~During the same time, an intravenous injection of 1 g paracetamol will be administered."
11375455|NCT02198365||Group 2|Group 1: normal pap smear Group 2: cervical neoplasia
11375456|NCT02198352|Experimental|BIBN 4096 BS - in single rising doses|
11375457|NCT02198352|Placebo Comparator|Placebo|
11375458|NCT02198339|Experimental|BIBN 4096 BS - ranging dose|"sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance
~IV infusion over 10 minutes"
11375459|NCT02198339|Placebo Comparator|Placebo|IV infusion over 10 minutes
11375460|NCT02198326|Experimental|BIBN 4096 BS - in single rising doses|
11375461|NCT02198326|Placebo Comparator|Placebo|
11375462|NCT02198313|Experimental|BIIX 1 XX - D1|
11375463|NCT02198313|Experimental|BIIX 1 XX - D2|
11375464|NCT02198313|Experimental|BIIX 1 XX - D3|
11375465|NCT02198313|Placebo Comparator|Placebo|
11375466|NCT02198300|Active Comparator|rDES Group|regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
11375467|NCT02198300|Experimental|BiOSS LIM Group|BiOSS LIM® stent implantation into coronary lesion within bifurcation.
11375468|NCT02198287|Experimental|BIIX 1 XX, rising doses|
11375469|NCT02198287|Placebo Comparator|Placebo|
11375470|NCT02198274|Experimental|BIBH 1|
11375471|NCT02198261||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
11375472|NCT02198261||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
11375473|NCT02198248|Experimental|Low-dose glucocorticoid|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).
~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy."
11375474|NCT02198248|Active Comparator|High-dose glucocorticoid|"Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).
~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering."
11375475|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
11375476|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
11375477|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
11375478|NCT02198209|Other|single arm|"Liraglutide (Victoza)
~acute study: one injection of 0.6 mg s.c. before IVGTT
~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
11375479|NCT02198196|Experimental|Weight Talk-Mindfulness|WT-M retain the evidence-based elements of WT-S (control condition), including the DASH diet, physical activity components, and an emphasis on self-monitoring. However, each call in WT-M will include an emphasis on mindfulness and stress management that will not be included in the control condition.
11375480|NCT02198196|No Intervention|Weight Talk-Standard|Weight Talk-Standard is a phone and web-based weight loss intervention offered by employers as a benefit to their employees. Weight Talk is based on the NIH Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in Adults and utilizes the curriculum developed for the Diabetes Prevention Program. Weight Talk-S contains no additional stress management techniques.
11375481|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
11375482|NCT02198170|Experimental|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period
11375483|NCT02198170|Experimental|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
11375484|NCT02198157|Active Comparator|intermittent urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will receive intermittent catheterization
11375485|NCT02198157|Active Comparator|continuous urinary catheter|nullipara women with epidural anaesthesia who pose urination difficulty will receive continuous catheterization
11375486|NCT02198144|Other|barbershop-based BP measurement|BP monitoring by barbershop based Barbers and BP lowering medication(s)
11375487|NCT02198131|Experimental|Supportive Care (pulsed dye laser)|Patients undergo pulsed dye laser monthly for three months.
11375488|NCT02198118|No Intervention|Control Group|Control group (CG) subjected only to evaluations and to no exercises.
11375489|NCT02198118|Experimental|Study Group|Study group (SG) instructed to perform domiciliary exercises for the upper limbs
11375490|NCT02198105||Femoropopliteal stenosis|"Consecutive patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis/occlusion.
~Intervention with Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon-PTA."
11375879|NCT02195505||Usual treatment of knee|nonsteroidal antiinflammatory drugs, antalgics
11375491|NCT02198092||Patient Group FAP|"Clinical diagnosis of familial adenomatous polyposis (FAP).
~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.
~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
11375492|NCT02198092||Patient Group Lynch Syndrome|"Clinical diagnosis of Lynch Syndrome, also known as HNPCC.
~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.
~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
11375493|NCT02198092||Patient Group MAP / MYH|"Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.
~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.
~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
11375494|NCT02198092||Control Group (FAP Genetically-Related)|"Genetically related family member of enrolled FAP patient.
~Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.
~The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.
~If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.
~Blood draws in FAP patients should always be accompanied by blood draws in their family member controls."
11375495|NCT02198079||Cystic Fibrosis|Children with Cystic Fibrosis
11375496|NCT02198066|Other|Dry Sterile Dressing|Subjects in this study arm received a dry sterile dressing (Primapore®, Smith & Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
11375497|NCT02198066|Active Comparator|Metallic Silver Dressing|Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith & Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
11375498|NCT02198066|Active Comparator|Ionic Silver Dressing|Subjects in this arm received an ionic silver dressing (Dermanet Ag®, DeRoyal), a semi-transparent dressing that includes silver, alginate, and maltodextrin. The dressing was cut to fit the incision and then covered with a transparent dressing (Transseal®, DeRoyal). This dressing should not be used on patients with known sensitivity to alginates (a seaweed based component).
11375499|NCT02198053||Ticagrelor2|Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
11375500|NCT02198053||Ticagrelor1|Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
11375501|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
11375502|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
11375503|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
11375504|NCT02198027|Experimental|Bupivacaine infiltration|10 ml of 0.25 % Bupivacaine
11375505|NCT02198027|Placebo Comparator|Normal saline infiltration|10 ml of normal saline
11375506|NCT02198014|Experimental|Manual Therapy group|We employed joint traction, passive muscle stretching and isometric exercises, active resisted and proprioception exercises. The treatment in this group consisted of two sessions per week for one hour each.
11375507|NCT02198014|Experimental|Educational gruop|"This group received educational sessions and home exercises. The exercises are aimed at improving quadriceps strength, flexibility, range of motion and knee proprioception.
~Each educational session of 90 minute every two weeks, with exercises daily home"
11375508|NCT02198014|No Intervention|Control group|The control group (group C) did not receive any treatment. The patients of this group were assessed by the same reviewers and under the same conditions as the subjects of the two intervention groups.
11375509|NCT02198001|Active Comparator|tooth extraction and insertion of PRF|Experimental: Atraumatic tooth extraction with antibiotics( amoxicillin clavulanate combination) .Insertion of PRF membrane in tooth-extraction site.
11375510|NCT02198001|Placebo Comparator|No PRF|Atraumatic extraction with antibiotic without PRF insertion
11375511|NCT02197988|Active Comparator|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block Exparel 1.33% (20ml Volume)
11375512|NCT02197988|Active Comparator|Thoracic Epidural Anesthesia|Thoracic Epidural Anesthesia 0.125% bupivicaine with 2 mcg/ml Fentanyl
11375513|NCT02197975|Experimental|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
11375514|NCT02197975|Experimental|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
11375515|NCT02197975|Placebo Comparator|Placebo MDI|Placebo MDI. Administered as 2 inhalations
11375516|NCT02197962|Experimental|Extracorporeal radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
11375517|NCT02197962|Placebo Comparator|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
11375518|NCT02197949||Breast cancer patients with infiltrated axillary l|
11375519|NCT02197936||Peristalsis adenomyosis|with adenomyosis
11375520|NCT02197936||Peristalsis control|No adenomyosis
11375521|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
11375522|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
11375523|NCT02197910|Active Comparator|High content of wheat bioactive peptides|100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
11375524|NCT02197910|Placebo Comparator|Low dose of wheat bioactive peptides|100 gr pasta/day, containing around 3 mg bioactive peptides
11375525|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
11375526|NCT02197884|Experimental|Itraconazole + JNJ-54861911 (Part 1)|Single dose of JNJ-54861911, 25 milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
11375527|NCT02197884|Experimental|Clarithromycin + JNJ-54861911 (Part 2)|Single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
11375528|NCT02197871|No Intervention|blank control|usual diet
11375529|NCT02197871|Experimental|nutrition supplementation|In addition to usual diet,the patients will be given enteral nutrition emulsion, which is a oral nutrition liquid composed of proteins,omega-3 fatty acids,carbohydrate,vitamins.Every package contains 200ml and provides 260 kcal energy.
11375530|NCT02197845|Experimental|Phase I: Recruitment into Specialty Care|Participants in the Phase I Experimental Arm are enrolled into SCD specialty care. PN's will contact patient up to 3 times to assure patients have had an initial visit by 3 months time.
11375531|NCT02197845|Experimental|Phase II: Patient Navigator Arm|Participants in the Phase II Experimental Arm follow routine clinical care and are assigned a Patient Navigator. A specially trained (SCD specefic)PN will work with participants for one year. Participants will be contacted by their Navigator weekly for the first 6 months, then biweekly for the second 6 months.
11375532|NCT02197845|No Intervention|Phase II: Passenger Arm|No Intervention. Participants in the Phase II Passenger Arm follow routine clinical care.
11375533|NCT02197832|Experimental|EA|in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
11375534|NCT02197832|Placebo Comparator|Control|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.
11375535|NCT02197819|Experimental|External Rotation Brace|Shoulder placed in an external rotation brace for 4 weeks
11375536|NCT02197819|Active Comparator|Traditional Sling|Patient placed in traditional sling
11375537|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
11375538|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
11375539|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
11375540|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
11375541|NCT02197793|Experimental|Community Mobilization Program|Intervention activities will map onto six mobilization domains identified as key components for communities to mobilize for change around testing, linkage and retention in care (Treatment as Prevention (TasP)).
11375542|NCT02197793|No Intervention|Control Arm|The control arm does not receive the Community Mobilization Intervention.
11375543|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
11375544|NCT02197754|Experimental|Polyphenol Diet|After 2 weeks of adaptation to a controlled diet, polyphenol-rich fruits (berries and apple) and beverages (tea) will be fed (8 wks) as part of a controlled diet (10 wks total).
11375545|NCT02197741||opiate without bolus|continuous opiate administration without bolus application
11375546|NCT02197741||opiate with bolus|continuous opiate administration with additional bolus application
11375547|NCT02197728|Active Comparator|Hohl uterine manipulator ®|Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®
11375548|NCT02197728|Active Comparator|Colpo-Probe™ Vaginal Fornix Delineator|Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator
11375549|NCT02197715|Experimental|computer-adaptive SAFE|Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
11375880|NCT02195492||Synvisc®|
11375550|NCT02197715|Experimental|Face-to-face SAFE|Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques. Each session will be led by an experienced counselor. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods. Session 4 will focus on effective strategies to communicate with a sexual partner.
11375551|NCT02197715|Active Comparator|Usual Care|Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
11375552|NCT02197702|Placebo Comparator|Placebo|2 ml identical placebo taken by mouth at baseline and 3.5 months.
11375553|NCT02197702|Active Comparator|Vitamin D|Vitamin D (100,000IU) given in a 2 ml oral dose at baseline and 3.5months.
11375554|NCT02197689|Experimental|SMS Medication Reminder|763 patients were assigned to experimental group
11375555|NCT02197689|No Intervention|No SMS Reminder|435 patients were assigned to control group as no SMS reminder
11375556|NCT02197676|Experimental|SGI-110|
11375557|NCT02197663|Experimental|Acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
11375558|NCT02197663|Sham Comparator|sham acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
11375559|NCT02197637|Experimental|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle
11375560|NCT02197611||Validation group|Group of patients who we will consult the characteristics of the scale designed and will be made the statistical calculations of validity, reliability and reproducibility
11375561|NCT02197598|Experimental|Selincro® (nalmefene) 18 mg, tablets|One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.
11375562|NCT02197585|Experimental|Glue|Mesh fixation with glue
11375563|NCT02197585|Active Comparator|Suture|Mesh fixation with suture
11375564|NCT02197572|Experimental|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
11375565|NCT02197559||BMS group, DES group|All the participants in this group will be performed with bare-metal stents or drug -eluting stents
11375566|NCT02197546|Other|acupuncture plus local anesthesia|Bilateral acupuncture with 1.5 mm long indwelling fixed needles
11375567|NCT02197546|No Intervention|Local anesthesia alone|Standard therapy - local anesthesia alone without acupuncture
11375568|NCT02197533|Experimental|Written list|Patients in the intervention group will receive both verbal information and a written supplement (Appendix 1), produced during the discussion by CM or a fellow (not the individual who obtained consent), on treatment recommendations for OAB. They will leave clinic with this written list of recommendations and will be able to take it home with them.
11375569|NCT02197533|No Intervention|Control|Patients in the control group will receive the same verbal information on the treatment recommendations for OAB, however, these patients will not receive the written list of management strategies for their condition.
11375570|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
11375571|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
11375572|NCT02197507|Experimental|RA patients|
11375573|NCT02197494|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
11375574|NCT02197494|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
11375575|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
11375576|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
11375577|NCT02197468||Probiotics|"Preterm infants given probiotics: GA 24-27 weeks/Birth weight < 1000 g
~Preterm infants not given probiotics: GA 28-31 weeks/Birth weight 1000-1500 g
~Full-term infants not given probiotics (control)"
11375578|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
11375579|NCT02197442|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
11375580|NCT02197442|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
11375581|NCT02197429|Experimental|Acupuncture|Acupuncture
11375582|NCT02197429|No Intervention|Wait-list Control|Wait-list Control
11375583|NCT02197416|Experimental|dabigatran etexilate|
11375584|NCT02197403|Experimental|alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
11375585|NCT02197403|Active Comparator|alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
11375586|NCT02197403|Active Comparator|Non-alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
11375587|NCT02197403|Active Comparator|Non-alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
11375613|NCT02197221|Experimental|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
11375614|NCT02197221|Active Comparator|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
11375588|NCT02197390|Experimental|Health Care plus Public Health|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs). The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
11375589|NCT02197390|Experimental|Health Care|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs).
11375590|NCT02197390|Experimental|Public Health|The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
11375591|NCT02197390|Experimental|Control|No intervention.
11375592|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
11375593|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
11375594|NCT02197364||ILD, Other respiratory diseases, Healthy control group|"ILD: those with interstitial lung disease.
~Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.
~Healthy control group: those who is healthy."
11375595|NCT02197351|Experimental|Gastric Symptoms|Patients with gastric symptoms including dyspepsia undergoing upper endoscopy will undergo white light biopsy narrow band imaging guided biopsy protocolled biopsy
11375596|NCT02197338|Experimental|Short Wire, Small Tome|Short wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
11375597|NCT02197338|Active Comparator|Short Wire, Standard Tome|Short wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
11375598|NCT02197338|Active Comparator|Long Wire, Small Tome|Long wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
11375599|NCT02197338|Active Comparator|Long Wire, Standard Tome|Long wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
11375600|NCT02197325|Active Comparator|PICSO|Participants enrolled in the PICSO treatment Group will be treated with PICSO concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction
11375601|NCT02197325|No Intervention|Parallel control|Participants enrolled in will receive treatment based on the standard guidelines for treatment of a myocardial infarction.
11375602|NCT02197312|Other|NobelProcera Bridge Shaded Zirconia|posterior region
11375603|NCT02197299|Experimental|Carnitine|Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks
11375604|NCT02197299|Placebo Comparator|Sugar pill|Oral administration of placebo sugar pill
11375605|NCT02197286|Experimental|Vitamin D (cholecalciferol)|Intervention: Capsules containing the active ingredient, cholecalciferol @ 4,000 international units (IU). One capsule daily, oral administration for 10 weeks.
11375606|NCT02197286|Placebo Comparator|Placebo|"Daily matching placebo gelatin capsule (also contains microcrystalline cellulose).
~Capsules are identical in size, color and taste to experimental drug."
11375607|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):
~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine
~Injection into capsular tissue after placement of the acetabular component:
~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline
~Total Knee Arthroplasty (TKA):
~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc
~Injection into posterior capsule of the knee:
~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline
~Total Shoulder Arthroplasty (TSA):
~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
11375608|NCT02197273|Experimental|Liposomal bupivacaine|"THA:
~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue
~TKA:
~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue
~TSA:
~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.
~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
11375609|NCT02197260|Experimental|Protocol A|Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
11375610|NCT02197260|Active Comparator|Protocol B|Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)
11375611|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
11375612|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
11376301|NCT02192892|Active Comparator|Commercial porridge flour|Porridge from commercial porridge flour
11375615|NCT02197208|Active Comparator|Spontaneous NC|Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
11375616|NCT02197208|Experimental|hCG induced NC|Timing by giving hCG when the dominant follicle reaches >=17mm in diameter on ultrasound monitoring
11375617|NCT02197195|Experimental|Chocolate Milk Beverage|Chocolate milk beverage and sitting quietly
11375618|NCT02197195|Experimental|Chocolate Milk Beverage and Exercise|Chocolate milk beverage and exercising
11375619|NCT02197195|Experimental|Fruit Drink Beverage|Fruit drink beverage and sitting quietly
11375620|NCT02197195|Experimental|Fruit Drink Beverage and Exercise|Fruit drink beverage and exercising
11375621|NCT02197182|Experimental|LUXSOL Cream|LUXSOL Cream is a copper containing cream to be administered intravaginally before bedtime for 10 consecutive nights.
11375622|NCT02197182|Active Comparator|Metronidazole cream|Metronidazole cream is the active comparator drug to be self-administered intravaginally each night before bedtime for 10 consecutive nights. Dosage is per package insert.
11375623|NCT02197169|Experimental|DNX-2401 alone|Single intratumoral injection of DNX-2401
11375624|NCT02197169|Experimental|DNX-2401 + Interferon gamma (IFN-γ)|Interferon gamma (IFN-γ) beginning at Day 14
11375625|NCT02197156|Experimental|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
11375626|NCT02197156|Experimental|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
11375627|NCT02197156|Experimental|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
11375628|NCT02197156|Experimental|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
11375629|NCT02197156|Active Comparator|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
11375630|NCT02197156|Placebo Comparator|Placebo|Matching placebo
11375631|NCT02197143|Experimental|Esomeprazole|40 mg Esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
11375632|NCT02197143|Experimental|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
11375633|NCT02197143|Experimental|placebo|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
11375634|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
11375635|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
11375636|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
11375637|NCT02197117|Active Comparator|Remote ischemic conditioning|Standard blood pressure cuff placed on upper arm and inflated to 200 mmHg. The cuff is left inflated at this level for 5 minutes and then rapidly deflated to 0 mmHg left deflated for 5 minutes0 this cycle is repeated 4 times in total.
11375638|NCT02197117|Sham Comparator|Control|Standard blood pressure cuff placed on upper arm and left un-inflated for 40 minutes, and then cuff is removed.
11375639|NCT02197104|Experimental|Citocoline|
11375640|NCT02197091||Observational (communication in oncology treatment)|Patients complete questionnaires, including the FACIT-TS-G, the FACIT-Sp12, the MOS-SSS, and the DT. Doctors also complete a questionnaire. Patients' medical records may be reviewed, if necessary.
11375641|NCT02197078||Glitazones|
11375642|NCT02197078||Linagliptin|
11375643|NCT02197078||Sulfonylurea|
11375644|NCT02197078||Within-class comparators|
11375645|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
11375646|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
11375647|NCT02197052||Computer Based Survey Arm|Participants randomized to the computer based self-completed survey arm were issued a tablet computer to answer survey questions. All participants were encouraged to ask for technical assistance if needed at any point, and like in the face-to-face interviews, electronic survey could be re-initiated at the point of discontinuation after any interruption. Those in the tablet survey arm also could complete the survey in their preferred language and all were additionally given headsets so they could use audio assist with identical, pre-recorded questions in the selected language.
11375648|NCT02197052||Face-to-face interview arm|Participants randomized to this condition were interviewed in-person by a fully bilingual (English-Spanish), bi-cultural research assistant trained in cultural humility, standard research protocols and interviewing practices. Interviews were conducted in clinical rooms in respondent's preferred language, were easily interrupted for medical care, and the survey could be re-initiated at the point of discontinuation after any interruption. Participant responses during face-to-face interviews were recorded by the research assistant on paper and later recorded electronically.
11375649|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.
~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.
~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
11375650|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.
~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.
~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
11375651|NCT02197026|Experimental|Synvisc group|injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments
11375652|NCT02197026|Active Comparator|Osteoarthritis standard treatment group|Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product
11375653|NCT02197013||Introcan Safety 3|Closed IV Catheter
11375654|NCT02197013||Introcan Safety|IV catheter
11375655|NCT02197000|Experimental|DIM-Avail 100mg|women will receive DIM 100mg*1/d, a nutritional supplement for 24 months.
11375656|NCT02196987||Urination, urethral catheterisation|Act of urination during urethral catheterisation in males
11375657|NCT02196987||Lie, catheterisation, urethra|Urethral catheterisation without medical professional guidance
11375658|NCT02196974|Experimental|cryobiopsy|
11375659|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
11375660|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
11375661|NCT02196948|Experimental|Electrolysis Percutaneous Therapeutic (EPTE)|Electrolysis Percutaneous Therapeutic (EPTE) consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon, to initiate a local inflammatory process allowing phagocytosis and repair of the affected tissue. The technique is pain-free since the electrical intensity is adapted to each patient. In addition, patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
11375662|NCT02196948|Experimental|Eccentric exercise|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
11375663|NCT02196935||ERCP/EUS|All patients who undergo ERCP and EUS for clinical indications will undergo a detailed prospective assessment of clinical course.
11375664|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
11375665|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
11375666|NCT02196909|Active Comparator|HIBM patient|motor function, muscle strength, NMR, 24h urine and serum collections at baseline, then annually
11375667|NCT02196909|Active Comparator|Controls|motor function, muscle strength, 24h urine and serum collections at baseline only
11375668|NCT02196896|Experimental|deprexis®|Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
11375669|NCT02196896|Placebo Comparator|Information|Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
11375670|NCT02196883|Active Comparator|MRI Pathology|
11375671|NCT02196883|Active Comparator|Physical Exam Pathology|
11375672|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
11375673|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
11375674|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
11375675|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.
~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.
~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
11375676|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
11375677|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
11375678|NCT02196818||Mpact Acetabular Shell|Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
11375679|NCT02196805|Experimental|1|
11375680|NCT02196805|Experimental|2|
11375681|NCT02196792|Active Comparator|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
11375683|NCT02196792|Active Comparator|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
11375684|NCT02196792|Active Comparator|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
11375685|NCT02196779||Patients undergoing abdominoplasty|Skin circulation to abdominal flap is evaluated during surgery using laser fluorescent imaging.
11375686|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
11375687|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
11375688|NCT02196753||CIED related infection|"All patients will undergo standard diagnostic process that will consist of: medical interview, physical examination, laboratory tests, blood cultures (3 sets, 1 hour apart, repeated after 24 hours and -if applicable - with fever peak above 38°C); imaging studies (echocardiography: transthoracic, and if there are no contraindications transesophageal, in case of negative or equivocal result repeated after 7-10 days, or in series if necessary, computed tomography scan for pulmonary embolism if indicated); if there are abnormalities in other systems, decisions concerning further diagnostics will be made by the physician in charge.
~Apart from standard diagnostic procedures patients will undergo whole body PET CT scan to localize infection or inflammation.
~Then the investigators team will make a decision concerning further treatment (antibiotics and complete device removal vs conservative treatment)."
11375689|NCT02196753||Non-infective|Control group consisting of 20 pts with implanted CIEDs who underwent PET CT due to non infectious indications and have no data for infectious process in follow-up
11375690|NCT02196740|Active Comparator|creosote|Creosote ，once，three weeks Triple Antibiotic Paste ，none
11375691|NCT02196740|Experimental|Triple Antibiotic Paste|Triple Antibiotic Paste,once,three weeks creosote,none
11375692|NCT02196727||Patients undergoing Bascom operation|
11375693|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
11375694|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
11375695|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
11375696|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
11375697|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
11375698|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
11375699|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
11375700|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
11375701|NCT02196662|Experimental|Treatment A|IBD98-M: mesalamine-sodium hyaluronate 200mg-28.75mg X2
11375702|NCT02196662|Experimental|Treatment B|IBD98-M without HA: Mesalamine 200mg X2
11375703|NCT02196662|Experimental|Treatment C|Delzicol 200 mg X2
11375704|NCT02196649|Experimental|Endoscopic Clipping|Participants randomised to the arm will receive endoscopic clips to their defect following EMR.
11375705|NCT02196649|No Intervention|No Endoscopic Clipping|These participants will receive standard of care practice only.
11375706|NCT02196636|Experimental|Part 1: Single Ascending Dose (SAD)|Adaptive model per protocol
11375707|NCT02196636|Experimental|Part 2: Food Effect (FE)|Fasted versus Fed
11375708|NCT02196623|Experimental|Hypoxic Exercise|Supervised, progressive aerobic exercise for 8 weeks under hypoxic conditions
11375709|NCT02196623|Sham Comparator|Normoxic exercise|Supervised, progressive aerobic exercise for 8 weeks under normoxic conditions
11375710|NCT02196610||HEALTHY SUBJECTS group|A group of 20 healthy staff volunteers identified from the Division of Nephrology, Dept. of Medicine and the Kidney Research Centre at the Ottawa Hospital Research Institute will be invited to participate. Measurements of arterial stiffness will be performed by Applanation tonometry. Healthy status will be defined by a self-reporting questionnaire obtained over the phone prior to enrolment and 2 subsequent non-invasive measurements of arterial blood pressure (BP) prior to testing. Subjects will be included if diastolic BP is ≤ 90 mm Hg and systolic BP ≤ 140 mm Hg on 2 consecutive measurements.
11375711|NCT02196610||END-STAGE RENAL DISEASE (ESRD) group|A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate <15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
11375712|NCT02196597||resection with RCT|rectal resection in the case of rectal carcinoma with preoperative radiochemotherapy
11375713|NCT02196597||resection without RCT|patients with rectal resection without preoperative radiochemotherapy
11375714|NCT02196571|Experimental|Exercise and lifestyle change|Women in the experimental group will be included in structured exercise programme two times per week with duration of 50 minutes.Participants will start with training sessions right after they are diagnosed with GDM and they will exercise until the end of the pregnancy or occurence of contraindications. Programme will consist of aerobic exercises (20 minutes), resistance exercises (20 minutes), plevic floor, stretching and relaxation exercises (10 minutes). Women in control group will receive standard antenatal care.
11375716|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
11375717|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
11375718|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
11375719|NCT02196545|Experimental|Exercise|Exercise, patients train on a specifically programmed movement trainer three times a week for 30 minutes (total duration 12 weeks)
11375720|NCT02196545|No Intervention|Treatment as usual|Treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without movement trainer exercise
11375721|NCT02196532||migraine group|Patients with migraine
11375722|NCT02196532||healthy control|Sex- and agematched healthy subjects
11375723|NCT02196519|Experimental|Test|All test arm subjects received Sylys Surgical sealant around anastomotic junction after closure.
11375724|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
11375725|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
11375726|NCT02196493|Experimental|Azithromycin|250mg azithromycin three times weekly for 12 weeks
11375727|NCT02196480|No Intervention|Methotrexate|JIA patients on stable dose of methotrexate vaccinated with PPV23
11375728|NCT02196480|Experimental|anti-TNF|JIA patients refractory to methotrexate immediately before the association of anti-TNF vaccinated with PPV23
11375729|NCT02196467|Experimental|Myoblast transplantation & strength|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
11375730|NCT02196467|Sham Comparator|Saline injection & strength|The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
11375731|NCT02196454|No Intervention|Vaccine Information Statement|Study participants will receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
11375732|NCT02196454|Experimental|Video & Vaccine Information Statement|Participants will view an educational video about the HPV vaccine with a male or female narrator. Participants will also receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
11375733|NCT02196441|Experimental|Group 2|0.5% bupivacaine Deep topical fornix nerve block anaesthesia (DTFNB)
11375734|NCT02196441|Experimental|Group 1|2% tetracaine local anaesthetic drops
11375735|NCT02196428|Other|Telemonitoring and Teleconsultation|
11375736|NCT02196402||study population|"Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications (screening, symptoms, surveillance).
~Exclusion criteria:
~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer
~patients with inadequate bowel preparation
~patients in which cecal intubation was not achieved or scheduled for partial examinations
~polyps could not be resected due to ongoing anticoagulation or could not be retrieved for pathologic assessment"
11375737|NCT02196389|Active Comparator|Nozovent|Nasal Dilator
11375738|NCT02196389|Active Comparator|Nasanita|Nasal Dilator
11375739|NCT02196389|Active Comparator|Breath Right|Nasal Dilator
11375740|NCT02196389|Active Comparator|Airmax|Nasal Dilator
11375741|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
11375742|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
11375743|NCT02196363||Pregnant mothers|No intervention
11375744|NCT02196350|Experimental|Intervention A: Diet|Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).
11375745|NCT02196350|Experimental|Intervention B: Exercise|"Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes).
~Healthy isocaloric diet."
11375746|NCT02196350|Experimental|Intervention C: Diet and Exercise|"Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet.
~One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)"
11375747|NCT02196350|No Intervention|Control - Historical data|Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.
11375748|NCT02196337||Women of reproductive age|Age: 18-44 years
11375749|NCT02196337||Pregnant women|Age: 18-44 years
11375750|NCT02196337||Lactating women|Age: 18-44 years
11375751|NCT02196337||Young infants|Age: younger than 6 months
11375752|NCT02196337||Toddlers|Age: between 6 and 24 months
11375753|NCT02196337||School-aged children|Age: 6-12 years
11375754|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
11375755|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
11375756|NCT02196311||Supracondylar humerus fractures|We are looking to compare open reduction internal fixation versus circular external fixation for supracondylar humerus fractures.
11375757|NCT02196298|Experimental|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
11375758|NCT02196298|Active Comparator|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
11375759|NCT02196285|Experimental|Double viral vaccine (MR)|Measles and rubella vaccine
11375760|NCT02196272|Experimental|Nurse-led email program through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse care manager (NCM).
11375761|NCT02196272|No Intervention|Management of diabetic patients|Usual care, educational program and usual management of Diabetic patients
11375762|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
11375763|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
11375764|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
11375765|NCT02196207|Experimental|Eloctate Prophylaxis|Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
11375766|NCT02196207|Experimental|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
11375767|NCT02196207|Experimental|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
11375768|NCT02196207|Active Comparator|Eloctate ITI Alone|Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
11375769|NCT02196194||tiotropium|
11375770|NCT02196181|Experimental|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
11375771|NCT02196181|Experimental|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
11375772|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
11375773|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
11375774|NCT02196155|Active Comparator|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
11375775|NCT02196155|Active Comparator|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
11375776|NCT02196155|Placebo Comparator|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
11375777|NCT02196142|Active Comparator|Cortisol first, Placebo second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
11375778|NCT02196142|Active Comparator|Placebo first, Cortisol second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
11375779|NCT02196129|Experimental|Sinbaro-3|1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions
11375780|NCT02196129|Placebo Comparator|Hwangryun(distillation)|1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention
11375781|NCT02196116|Active Comparator|Group 1|Controls
11375782|NCT02196116|Experimental|Group 2|Cognitively-impaired subjects without dementia and without memory
11375783|NCT02196116|Experimental|Group 3|Cognitively-impaired subjects without dementia and with memory
11375784|NCT02196103|Experimental|Expectant management|
11375785|NCT02196090|Experimental|Single arm|Study uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
11375786|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
11375787|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
11375788|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
11375789|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
11375790|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
11375791|NCT02196064||Safety of the three-drug combination TDF/FTC/RPV|A total of 176 patients will be included in this study, as well as 352 patients naive for RPV who initiated any ART that does not include RPV, who will serve as control group.
11375844|NCT02195726|Sham Comparator|Sham remote ischemic preconditioning'|In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline
11375908|NCT02195284|Experimental|Sub-study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA inhaler
11375909|NCT02195271|Active Comparator|Melatonin|0,25mg/Kg sl before tDCS
11375792|NCT02196051|Experimental|Exercise Training|Participants will engage in a single bout of elliptical exercise for 45 minutes (3X15 spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Participants will then take part in six weeks of exercise training on an elliptical trainer 3 times per week each time for 45 minutes. Hepatic de novo lipogenesis will be compared pre and post to examine wether improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
11375793|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
11375794|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
11375795|NCT02196025|Experimental|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
11375796|NCT02196012|Experimental|Lifestyle counseling|The intervention condition will contain multiple components: nutrition education, physical activity, social support, social media (Pinterest and Facebook), and smartphone applications for self-monitoring. Students in this condition will have access to the private study website, which will be the central platform for delivery of the program materials and social support. The website, developed using Wordpress.com, will include nutrition materials, exercise videos, a forum, and links to the study's Facebook and Pinterest pages
11375797|NCT02196012|Active Comparator|attention control condition|Students randomized to the attention control condition will receive educational emails three times per week. Nutrition materials will be sent once a week, and links to the YouTube exercise videos will be sent twice a week. At the start of the program, students will be emailed a link to the Pandora workout station. The materials sent to the control group will be the same materials posted on the website for the intervention group. Participants will access the emailed lessons and videos each week at their own convenience. Individuals in the attention control condition will not have access to the study website or social media pages.
11375798|NCT02195999||Individuals with DMD|"Magnetic Resonance Imaging is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
~Pulmonary Function testing (PFT) are a series of non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
~Metabolic exercise testing using stationary bicycle (exercise capacity and MVO2) evaluates global cardiopulmonary functional status.
~Echocardiogram with multiple-echo Dixon method helps to assess cross-sectional and longitudinal variations in myocardial structure."
11375799|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
11375800|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
11375801|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
11375802|NCT02195973|Experimental|Paclitaxel + LDE225|Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
11375803|NCT02195960|Placebo Comparator|placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
11375804|NCT02195960|Active Comparator|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
11375805|NCT02195947|Experimental|Antagonist and Growth hormone|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
11375806|NCT02195947|No Intervention|Antagonist|HMG IM daily was administrated from day 2 of the cycle. The GnRH antagonist (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
11375807|NCT02195934|Other|Standard orange juice (OJ) followed by blood OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
11375808|NCT02195934|Other|Blood orange juice followed by standard OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
11375809|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
11375810|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
11375875|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
11375876|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
11375877|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
11375811|NCT02195921|Experimental|Matching points ST36+CV12|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
11375812|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
11375813|NCT02195908|Experimental|Single point PC6|"choose single point: Neiguan(PC6).Neiguan(PC6): On the anterior aspect of the forearm,between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
11375814|NCT02195908|Experimental|Single point CV12|"choose another single point Zhongwan（CV12）. Zhongwan(CV12): On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line. Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
11375815|NCT02195908|Experimental|Matching points PC6+CV12|"Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
11375816|NCT02195908|Active Comparator|only antiemetic|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.
11375817|NCT02195895|Experimental|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months
~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
11375818|NCT02195882|Experimental|Exercise program|
11375819|NCT02195869|Experimental|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
11375820|NCT02195869|Experimental|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
11375821|NCT02195869|Experimental|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
11375822|NCT02195869|Experimental|Phase 2|Subjects receive daily dose of recommended phase 2 dose
11375823|NCT02195856|Active Comparator|Diseased condition|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
11375824|NCT02195856|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
11375825|NCT02195843|Active Comparator|Emperical|Anatomical optimization of device and leads
11375826|NCT02195843|Active Comparator|Electrical|Electrical optimization by RVLV Conduction Time with VectSelect
11375827|NCT02195830|Other|Single arm - Ultrasound|All participants will have an Ultrasound measurement of their inferior vena cava at enrolment as described in the intervention
11375828|NCT02195817|Other|Selincro® 18 mg with continuous psychosocial support: Cohort A|Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support
11375829|NCT02195817|Other|Initial psychosocial support: Cohort B|Initial psychosocial support followed by usual care practice, 12-week Observational Period
11375830|NCT02195804|Experimental|Ranitidine HCL ODT Vanilla-Mint|
11375831|NCT02195804|Experimental|Ranitidine HCL ODT RM Vanilla-Mint|
11375832|NCT02195804|Active Comparator|Ranitidine HCL|Maximum Strength ZANTAC 150®
11375833|NCT02195791|Active Comparator|Pioglitazone|
11375834|NCT02195791|Placebo Comparator|Placebo|
11375835|NCT02195778||Young, 18 to 30|
11375836|NCT02195778||Middle, 31 to 50|
11375837|NCT02195778||Older, 51 to 70|
11375838|NCT02195765|Experimental|enamel matrix derivative|Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
11375839|NCT02195765|Active Comparator|Open flap debridment|Open flap debridement
11375840|NCT02195752||Prescribed Compounded Pain Cream|The study is limited to patients who have been prescribed treatment with a topical compounded pain cream as a component of their ordinary care by a qualified physician.
11375841|NCT02195739||Nicotine replacement therapy cohort|Cohort defined as patients in whom nicotine replacement therapy (in any preparation) was initiated at the index smoking cessation attempt as the first recorded smoking cessation intervention.
11375842|NCT02195739||Other smoking cessation therapy|Cohort defined as patients in whom other (non-nicotine replacement therapy) smoking cessation pharmacotherapy's were initiated at the index smoking cessation attempt (e.g. bupropion, varenicline) as the first recorded smoking cessation intervention
11375843|NCT02195739||Smoking cessation advice cohort|Cohort (control patients) defined as patients whose first recorded smoking cessation intervention involved smoking cessation advice leading to a quit attempt unassisted by pharmacological smoking cessation aids, at the index smoking cessation attempt.
11375845|NCT02195726|Experimental|Remote ischemic preconditioning|"In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion.
~In subjects presenting with BMI > 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation"
11375846|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
11375847|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
11375848|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
11375849|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
11375850|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
11375851|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
11375852|NCT02195661|Active Comparator|Melatonin sleep EEG induced group|"All children who were referred to the neurophysiology department who were either unable to keep still for their EEG, or required a sleep EEG as part of their epilepsy work-up and whose caregivers agreed to the administering of sedation with melatonin. Melatonin by mouth (3mg for children < 15kg, 6mg for those > 15kg) 1 hour before the scheduled EEG by the unit nurse. Children who can swallow the capsules directly, those who cannot are given the contents of the powder in the capsule mixed in a few millilitres of water. If the child fails to fall asleep within one hour of administration of the melatonin then a second dose 3mg is given) ."
11375853|NCT02195661|Other|Comparison group for children sedated using previous practice|Since the choral hydrate had been withdrawn a direct comparison group was not possible. However a study performed the previous year in the department measured a several parallel useful outcomes. This study had addressed the usefulness of electroencephalograms in a South African population. A proportion of this group screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). These patients were drawn from the same regional pool, with the same disease demographics, and the same sleep deprivation and procedural techniques to the current group. This group was screened for several common denominators to the current study themes, and comparison will be made between these, namely the proportion of patients with successful attainment of sleep studies, the proportion of studies with excessive artifact (precluding interpretation) and the usefulness of the data attained detailing whether the studies were able to assist or alter patient management.
11375854|NCT02195648|Experimental|Suboccipital inhibition|The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
11375855|NCT02195648|No Intervention|Control|No intervention will be done to the participants during the study. After study completion, the participants will be offered to receive the therapy.
11375856|NCT02195635|Experimental|Period 1|Single oral dose of 500 mg telotristat etiprate on Day 1
11375857|NCT02195635|Other|Period 2|Subcutaneous injections of 200 µg octreotide acetate three times daily with a single oral dose of 500 mg telotristat etiprate on Day 6
11375858|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
11375859|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
11375860|NCT02195609|Other|Omega-3|600 mg (EPA, DHA and Omega-3) twice a day
11375861|NCT02195609|Other|Soy Isoflavones|54.4mg oral twice a day
11375862|NCT02195596|Experimental|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient."
11375863|NCT02195596|Active Comparator|Low intensity aerobic exercise+strength|The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
11375864|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
11375865|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
11375866|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
11375867|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
11375868|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
11375869|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
11375870|NCT02195570|Experimental|QSN with CM (QSN-CM).|Women will receive standard of care Quit Smoking Now tobacco education and support plus prize-based contingency management. Their smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Women will earn chances to win prizes each time they test negative for smoking according to biochemical measures.
11375871|NCT02195570|Active Comparator|QSN Only|Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
11375872|NCT02195557||Synvisc®|
11375873|NCT02195544||Synvisc®|
11375874|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
11375881|NCT02195479|Active Comparator|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
11375882|NCT02195479|Experimental|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
11375883|NCT02195466|Experimental|TPV + RTV + FCZ|
11375884|NCT02195453|Experimental|Yangzhengxiaoji Capsule|"Gemcitabine or Pemetrexed
~Cisplatin
~Yangzhengxiaoji Capsule four granules t.i.d po"
11375885|NCT02195453|Placebo Comparator|Placebo Capsule|"Gemcitabine or Pemetrexed
~Cisplatin
~Placebo Capsule four granules t.i.d po"
11375886|NCT02195440|Experimental|PRI-724|
11375887|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
11375888|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
11375889|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
11375890|NCT02195401||Sleeping in a cleanroom|Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
11375891|NCT02195388||CR with AH|Patients after ACS with arterial hypertension treat with comprehensive cardiac rehabilitation
11375892|NCT02195388||N-CR with AH|Patients after ACS with arterial hypertension don't treat with comprehensive cardiac rehabilitation.
11375893|NCT02195388||CR without AH|Patients after ACS without arterial hypertension treat with comprehensive cardiac rehabilitation
11375894|NCT02195375|Experimental|Flutiform 500/20 µg BID|Flutiform 250/10 (2 puffs BID)
11375895|NCT02195375|Experimental|Flutiform 250/10 µg BID|Flutiform 125/5 (2 puffs BID)
11375896|NCT02195375|Active Comparator|Seretide Accuhaler 50/500 µg BID|Seretide Accuhaler 50/500 (BID)
11375897|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
11375898|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
11375899|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
11375900|NCT02195336|Experimental|dMRT, Bevacizumab, Chemotherapy|"dMRT: Magnetic Resonance Tomograph, Baseline, day 8, day 28, day 92, progression/relapse.
~Bevacizumab: 7.5mg/kg every 3 weeks for 3 cycles. Standard of care NSCLC first-line chemotherapy, doublets containing paclitaxel and carboplatin are preferred, every 3 weeks for 3 cycles.
~Thereafter Bevacizumab 7.5mg/kg every 3 weeks until progression/relapse or unacceptable toxicity."
11375901|NCT02195323|Experimental|MSC recipient|The patients with CKD who underwent intravenous injection of MSC.
11375902|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
11375903|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
11375904|NCT02195297|Active Comparator|ANTICELLULITE GMG GIULIANI|Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
11375905|NCT02195297|Active Comparator|SOMATOLINE|Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
11375906|NCT02195284|Experimental|Sub-study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler
11375907|NCT02195284|Experimental|Sub-study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI (metered-dose inhaler) or use MDI first and then ELLIPTA inahler
11375910|NCT02195271|Experimental|tDCS|Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
11375911|NCT02195258||salbutamol|
11375912|NCT02195245|No Intervention|Control|Control - Observational (non interventional) data is collected from current state of the art absorber devices.
11375913|NCT02195245|Experimental|memsorb|New CO2 filter - data is collected using the new CO2 absorber.
11375914|NCT02195232|Experimental|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days
~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
11375915|NCT02195232|Experimental|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days
~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
11375916|NCT02195219|Experimental|open reduction internal fixation|open reduction internal fixation
11375917|NCT02195219|Active Comparator|non operative treatment|'sling rest and early functional recovery
11375918|NCT02195206||Healthy|Adult
11375919|NCT02195193|No Intervention|Usual Care (UC)|"The standard interventions from Clinical Pathway for Acute Coronary Syndromes in China-Phase 3 (CPACS-3) study that are limited to in-patient ACS care (refer to Usual Care [UC]), will be implemented in the participating hospitals, and hence will be received by all patients in both intervention (IC) and control (UC) groups; standardized cardiovascular disease education also will be provided to all participants.CPACS-3 registration number is NCT01398228"
11375920|NCT02195193|Experimental|Intervention Care (IC)|Besides of the UC, an nurse-coordinated integrated care model for Acute Coronary Syndromes(ACS) and depression will be delivered to intervention group, including ACS secondary prevention therapies at and after discharge, screening and treatment of depression during hospitalization and after discharge.
11375921|NCT02195180|Experimental|standard of care combined with ERY001|standard of care = Gemcitabine or folfox
11375922|NCT02195180|Sham Comparator|standard of care alone|standard of care = Gemcitabine or folfox
11375923|NCT02195167|Experimental|Dasotraline|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
11375924|NCT02195154|Experimental|18F-DTBZ for Vascular Parkinsonism|This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
11375925|NCT02195141|Active Comparator|conventional fraction|Radiotherapy (25x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily
11375926|NCT02195141|Experimental|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
11375927|NCT02195115|Active Comparator|Laparoscopic cholecystectomy|surgical removal of gallbladder
11375928|NCT02195115|Active Comparator|Non-operative treatment|Administration of amitriptyline 25mg daily, Low Fat-Low Cholesterol Diet
11375929|NCT02195102||transcatheter aortic valve Replacement|Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses.
11375930|NCT02195089|Experimental|BLS_ILB_E710c 500mg|"Drug: BLS_ILB_E710c 500mg
~Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 & 8)"
11375931|NCT02195089|Experimental|BLS_ILS_E710c 1000mg|"Drug: BLS_ILS_E710c 1000mg
~Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 & 8)"
11375932|NCT02195089|Experimental|BLS_ILS_E710c 1500mg|"Drug: BLS_ILS_E710c 1500mg
~Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 & 8)"
11375933|NCT02195076||Breast Cancer patients|
11375934|NCT02195076||Lung cancer patients|
11375935|NCT02195076||Healthy controls|
11375936|NCT02195063||Pain management|patients undergoing transdermal treatment for pain
11375937|NCT02195063||Scar care|patients undergoing transdermal treatment for scars
11375938|NCT02195063||Wound care|patients undergoing transdermal treatment for wounds
11375939|NCT02195063||UDT|patients receiving urinary drug tests
11375940|NCT02195050||Therapeutic target arm|Statin treated patients with and without raised triglycerides who do not have diabetes or dysglycemia. Statin treated patients with type 2 diabetes.Statin treated patients with CKD stages 4 and 5 (eGFR ≤30mL/min).
11375941|NCT02195050||Nerve function arm|Patients with severe hypertriglyceridaemia (fasting TG > 5.5mmol/l.) are recruited for nerve function assessment and corneal confocal microscopy.
11375942|NCT02195050||Genetic screening arm|For LAL deficiency screening, patients will be recruited over a 5 year period with a documented triglyceride level of more than 10 mmol/l at any time, low HDLC, raised ALT, combined hyperlipidaemia, or non-alcoholic fatty liver disease. Patients recruited from Manchester will be offered additional genetic testing for familial hypercholesterolaemia.
11375943|NCT02195024|Active Comparator|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
11375944|NCT02195024|No Intervention|No MRI group|Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
11375945|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.
~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
11376003|NCT02194673|Experimental|Trans free palm margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
11375946|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.
~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
11375947|NCT02194998|Experimental|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
11375948|NCT02194998|Experimental|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
11375949|NCT02194998|Experimental|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
11375950|NCT02194998|Experimental|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
11375951|NCT02194985|Experimental|migalastat HCl 150 mg|Migalastat HCl is a capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on days between migalastat HCl.
11375952|NCT02194972|Experimental|soluble dietary fiber|pectin, a kind of soluble dietary fiber
11375953|NCT02194972|No Intervention|Placebo|Placebo
11375954|NCT02194959|Experimental|Peer PN|A scheduling phone call will be made to all patients within 14 days of their initial referral to the study. Following the scheduling of their appointment, each patient will be mailed an informational pamphlet with written instructions for the colonoscopy once they have scheduled the procedure. The first reminder PPN phone call will be made two weeks before a patient's scheduled colonoscopy. The second reminder PPN call will be made three days before the scheduled colonoscopy. For all calls, at least three attempts (at different times of the day and different days of the week) will be made to reach patients. All telephone calls will be audio-recorded to facilitate fidelity monitoring. All colonoscopy appointments will be made within the Division of Gastroenterology at each of the hospital sites. The Project Coordinator will be responsible for confirming completion (and no-shows) for all colonoscopy appointments.
11375955|NCT02194959|Active Comparator|Pro PN|Participants randomized to standard patient navigation received care that they would normally receive if they were not participating in the study with navigation from the GI staff, and three phone calls that involved scheduling and reminding the participant about their colonoscopy appointment.
11375956|NCT02194946|Active Comparator|CKD-related management group|"Patients in basic care group are provided with basic western medicine treatment according to Kidney Disease: Improving Global Outcomes(KDIGO) and The National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guidelines but not prescribed any Chinese herbal medicine.
~The basic western medicine treatment mainly includes dietary protein restriction(0.6g/kg·d, for Chinese), Blood pressure control, treating anemia with erythropoietin,treatment of abnormal calcium-phosphate metabolism, and treatment of fluid, electrolyte and acid-base disorders."
11375957|NCT02194946|Experimental|CM therapies group|Participants will receive CM therapies and CKD-related management concurrently. One or several the following CM patterns will be allowed: a. Chinese herbal formula via oral administration; b. Chinese patent medicine via oral administration; c. Chinese herbal formula via colonic administration; d. Chinese patent medicine via colonic administration.
11375958|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
11375959|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
11375960|NCT02194920||Parathyroid reimplantation|
11375961|NCT02194907|Active Comparator|Anterior insula cortex activation|Participants will receive training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain, while thinking of and viewing emotional faces, scenes, and text.
11375962|NCT02194907|Active Comparator|Primary auditory cortex activation|Participants will have training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain while thinking of and viewing emotional faces, scenes, and text.
11375963|NCT02194894|Active Comparator|NAFLD patients|Twenty patients with NAFLD will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
11375964|NCT02194894|Active Comparator|Healthy controls|Twenty healthy controls will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
11375965|NCT02194881||Ivacaftor 1|patients with CF who are homozygous or heterozygous for the G551D mutation and treated with Ivacaftor
11375966|NCT02194868||donors of hematopoietic stem|Adult and minor donors of hematopoietic stem
11375967|NCT02194868||patients requiring allogeneic hema|Adult and minor patients (recipients) requiring allogeneic hema
11375968|NCT02194855|Experimental|laparoscopic operation on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
11375969|NCT02194855|Experimental|laparoscopic operation on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
11376004|NCT02194673|Experimental|Interesterified palm based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
11375970|NCT02194855|Experimental|conventional open surgery on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
11375971|NCT02194855|Experimental|conventional open surgery on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
11375972|NCT02194842|Active Comparator|Enzalutamide|Enzalutamide will be given at a dose of 160 mg daily
11375973|NCT02194842|Experimental|Enzalutamide and Ra223|Ra223 will be administered 50kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.
11375974|NCT02194829|Experimental|Arm A (phase I, dose level 1)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 PO daily on days 1, 2, 8, 9, 15, and 16.
11375975|NCT02194829|Experimental|Arm B (phase I, dose level 2)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.
11375976|NCT02194829|Active Comparator|Arm C (phase II, placebo)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily on days 1, 2, 8, 9, 15, and 16.
11375977|NCT02194829|Experimental|Arm D (phase II, WEE1 inhibitor MK-1775)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 (recommended phase II dose) as in Arm A.
11375978|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
11375979|NCT02194803||Cohort with routine OCT monitoring|
11375980|NCT02194803||Cohort without routine OCT monitoring|
11375981|NCT02194790|Experimental|community-based Integrated CKD care|Standard CKD care + multidisciplinary team and home visit by community care team
11375982|NCT02194790|No Intervention|Conventional CKD care|standard CKD care
11375983|NCT02194777|Experimental|BIBN 4096 BS - in single rising doses|
11375984|NCT02194777|Placebo Comparator|Placebo|
11375985|NCT02194764|Experimental|Expirimental Formulation|Participants will be administered a single encapsulated dose of the test formulation (Model Naltrexone 50mg containing 2-butanol). Breath samples will be taken over 90 minutes (-5, 0, 5, 10, 20, 40, 60, 90). Subjects will then be randomly crossed over to the four interventions (Formulation 1, Formulation 2, Formulation 3, Formulation-free positive control) three formulations from the first part of the study and a control administration (a capsule-in-capsule design).
11375986|NCT02194751|Experimental|Oncoquest-L vaccine|Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
11375987|NCT02194738|Experimental|A081105 Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
11375988|NCT02194738|Placebo Comparator|A081105 Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
11375989|NCT02194738|Experimental|A081105 Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11375990|NCT02194738|Active Comparator|A081105 Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
11375991|NCT02194738|Active Comparator|A081801 Arm A (platinum doublet, observation)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONTINUANCE THERAPY: Patients then undergo observation."
11375992|NCT02194738|Experimental|A081801 Arm B (platinum doublet, sequential pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles in the absence of disease progression or unacceptable toxicity."
11375993|NCT02194738|Experimental|A081801 Arm C (platinum doublet, combination pembrolizumab)|"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles in the absence of disease progression or unacceptable toxicity."
11375994|NCT02194738|Experimental|E4512 Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11375995|NCT02194738|Active Comparator|E4512 Arm B (observation)|Patients undergo observation.
11375996|NCT02194738|Experimental|EA5142 Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
11375997|NCT02194738|Active Comparator|EA5142 Arm II (observation)|Patients are followed serially with imaging for 1 year.
11375998|NCT02194712||travellers|travellers with recent (<12 weeks) high risk water contact are included in the study and asked to provide samples for CAA testing
11375999|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
11376000|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
11376001|NCT02194686|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
11376002|NCT02194686|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
11376005|NCT02194673|Experimental|IE soybean oil-based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
11376006|NCT02194660||M- main hospital|Patient enrolled in the main hospital
11376007|NCT02194660||B- Beihu branch|Patients enrolled in the Beihu branch
11376008|NCT02194634|Experimental|Conbercept treatment group|Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the subjects need to get repeated treatment according to monthly assessment.
11376009|NCT02194634|Active Comparator|Laser treatment group|Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months.
11376010|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
11376011|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
11376012|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
11376013|NCT02194608|Experimental|Telemedicine system|Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits.
11376014|NCT02194608|No Intervention|Usual care|Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits.
11376015|NCT02194595|Experimental|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
11376016|NCT02194595|Active Comparator|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
11376017|NCT02194595|Active Comparator|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
11376018|NCT02194569|Experimental|High citrate group|Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
11376019|NCT02194569|Experimental|Low citrate group|Blood flow according to weight. Target citrate concentration is 2.5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 1.3-1.6 mg/dL.
11376020|NCT02194556|Experimental|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
11376021|NCT02194556|Active Comparator|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib (125 mg three times per day) as maintenance treatment until disease progression or intolerable toxicity.
11376022|NCT02194543||HD 3D|The patients received surgeries with HD 3D on their left eyes.
11376023|NCT02194543||Conventional|The patients received surgeries with conventional method on the other eye.
11376024|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
11376025|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
11376026|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
11376027|NCT02194517|No Intervention|control (B)|Patients performing CHO and FP exchanges calculation with standard method.
11376028|NCT02194517|Experimental|ELKa (A)|Patients counting CHO and FP exchanges with ELKa toolset.
11376029|NCT02194504|No Intervention|No dietary advice|No dietary intervention
11376030|NCT02194504|Experimental|Dietary advice, Targeted|12-wk dietary advice
11376031|NCT02194504|Experimental|Dietary advice, Western|12-wk dietary advice
11376032|NCT02194491|Experimental|[11C]AS2471907 administration (Part 1)|Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.
11376033|NCT02194491|Experimental|ASP3662 administration (Part 2)|The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.
11376034|NCT02194478|Other|8 Week Meditation|Allina Health employees undergoing 8 week meditation intervention
11376035|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
11376036|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
11376037|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
11376038|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
11376039|NCT02194465|Experimental|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
11376040|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
11376041|NCT02194465|Placebo Comparator|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
11376042|NCT02194452|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|"Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.
~Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis"
11376043|NCT02194439||hematopoietic stem cell transplant|procedure
11376044|NCT02194426|Experimental|MP0250|"see section intervention description below"
11376045|NCT02194413|Experimental|Arm 1 (healing touch)|"Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital (therapeutic touch).
~Interventions: therapeutic touch, quality-of-life assessment, and questionnaire administration"
11376046|NCT02194413|Active Comparator|Arm II (usual care)|"Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital.
~Interventions: quality-of-life assessment, and questionnaire administration"
11376047|NCT02194400|Placebo Comparator|Placebo|Saline infusion
11376048|NCT02194400|Experimental|RSLV-132|0.3 - 10 mg/kg experimental drug
11376049|NCT02194387|Experimental|Supportive care (energy balance interventions)|"TELEPHONE COACHING VS EMAIL COACHING: Participants receive telephone coaching once per week for 16 weeks or 1 email per week for 16 weeks (with follow-up responses if the participant responds) from a coach trained in motivational interviewing.
~TEXT MESSAGES: Participants receive daily text messages promoting adherence to diet and exercise recommendations daily 1-3 times per day or no text messages.
~SOCIAL NETWORKING: Participants are invited to an online forum for study participants available for 16 weeks or do not receive an invitation for social networking.
~SELF-MONITORING: Participants are asked to record their dietary intake 4-7 days per week or 1 day per week on a website or smartphone app."
11376050|NCT02194374|Experimental|ROR1R-CAR-T Cells|"Peripheral blood mononuclear cells (PBMC) collected via venipuncture and/or steady state leukapheresis at discretion of PI. Participants receive a cycle of lympho-depleting chemotherapy as chosen by treating physician 4 to 5 days before ROR1R-CAR-T cell infusion : Fludarabine, Cyclophosphamide, and Rituximab (FCR), Bendamustine and Rituximab (BR), or Fludarabine, Bendamustine, and Rituximab (FBR).
~Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.
~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
11376051|NCT02194361|Experimental|Anthocyan capsules|
11376052|NCT02194361|Placebo Comparator|Placebo|
11376053|NCT02194348|Experimental|BIBN 4096 BS - in single rising doses|
11376054|NCT02194348|Placebo Comparator|Placebo|
11376055|NCT02194335|Experimental|BIBN 4096 BS - in single rising doses|
11376056|NCT02194335|Placebo Comparator|Placebo|
11376057|NCT02194322|Experimental|BIBN 4096 BS - in single rising doses|
11376058|NCT02194322|Placebo Comparator|Placebo|
11376059|NCT02194309|Experimental|Telmisartan low + amlodipine|
11376060|NCT02194309|Experimental|Telmisartan high + amlodipine|
11376061|NCT02194296|Experimental|Ambroxol hydrochloride - lozenge|
11376062|NCT02194296|Active Comparator|Ambroxol hydrochloride - syrup|Mucosolvan®
11376063|NCT02194283|Experimental|Ambroxol - in single rising doses|
11376064|NCT02194283|Placebo Comparator|Placebo|
11376065|NCT02194270|Experimental|Ambroxol hydrochloride - soft pastille|
11376066|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - low dose|
11376067|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - high dose|
11376068|NCT02194257|Experimental|[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge|
11376069|NCT02194257|Experimental|[14C]-benzyl ambroxol oral solution + ambroxol lozenge|
11376070|NCT02194244|Experimental|Granules Fasted|
11376071|NCT02194244|Experimental|Granules Fed|
11376072|NCT02194244|Active Comparator|Tablet Fasted|
11376073|NCT02194244|Active Comparator|Tablet Fed|
11376074|NCT02194231|Experimental|Trabectedin|Patients will receive trabectedin treatment
11376075|NCT02194218|Experimental|Nevirapine XR 4 doses|
11376076|NCT02194218|Active Comparator|Nevirapine XR 2 doses|
11376077|NCT02194205|Experimental|COMBIVENT HFA|
11376078|NCT02194205|Placebo Comparator|Placebo HFA|
11376079|NCT02194205|Active Comparator|COMBIVENT (CFC)|
11376080|NCT02194205|Placebo Comparator|Placebo CFC|
11376081|NCT02194192|Experimental|Group E|Ephedrine 10 mg in Normal Saline 10 ml
11376082|NCT02194192|Active Comparator|Group O|Ondansetron 8 mg in Normal saline 10 ml
11376083|NCT02194192|Placebo Comparator|Group P|Normal saline 10 ml
11376084|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fasted|
11376085|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fed|
11376086|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fasted|
11376087|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fed|
11376088|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fasted|
11376089|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fed|
11376090|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fasted|
11376091|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fed|
11376092|NCT02194179|Active Comparator|NVP IR 200 mg (Viramune®)|
11376093|NCT02194166|Experimental|Pre-Randomization (Trastuzumab IV)|Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
11376094|NCT02194166|Experimental|Group A: Trastuzumab SC (First Vial Formulation, then SID)|Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
11376139|NCT02193919||Ornish Diet + UVB|Ornish Diet + UVB
11376140|NCT02193906|Experimental|Intervention group|Cognitive training.
11376095|NCT02194166|Experimental|Group B: Trastuzumab SC (First SID, then Vial Formulation)|Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
11376096|NCT02194153||Metalyse|Metalyse weight-adjusted
11376097|NCT02194140|Other|oral contrast|oral iodinated contrast material
11376098|NCT02194127|Experimental|Anthocyan capsules|capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)
11376099|NCT02194127|Placebo Comparator|Placebo|
11376100|NCT02194114|Experimental|Dietary Protein Intake|One treatment Arm; Protein Diet: All patients will be fed the following five diets, in random order, each for 17-19 days: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
11376101|NCT02194101||Supernormal oxygen delivery goal therapy|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.
11376102|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
11376103|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
11376104|NCT02194075|Active Comparator|Fluvoxamine+Methylphenidate Hydrochloride|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.
~Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks."
11376105|NCT02194075|Placebo Comparator|Fluvoxamine+sugar pill|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.
~sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks."
11376106|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
11376107|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
11376108|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
11376109|NCT02194049|Experimental|BKM 120, cisplatin, etoposide|Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11376110|NCT02194036|Experimental|Learning oriented physiotherapy|Learning oriented physiotherapy is a treatment approach based on knowledge from neuroscience and particularly aimed to curb physical symptoms and ailments, but also to regain a sense of better physical balance and mental control. Therapy sessions are normally given every 2 weeks with individual homework lessons between. The therapy will last between 6 to 12 months depending on learning process and individual needs.
11376111|NCT02194036|Active Comparator|Widely Recognized Psychiatric Treatment|Standard Outpatient Treatment within the Psychiatric clinic
11376112|NCT02194023|Placebo Comparator|Placebo (PCB)|Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)
11376113|NCT02194023|Experimental|0.12%NF|0.12% Chlorhexidine digluconate new formulation
11376114|NCT02194023|Experimental|0.03%NF|0.03% Chlorhexidine digluconate new formulation
11376115|NCT02194023|Active Comparator|PAT (Perio-Aid Treatment)|Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)
11376116|NCT02194010||Participants evaluated at INC sites|Participants being evaluated at the INC sites will participate in both the DSI and HMSN-R-ODS by completing these PROs during their visit.
11376117|NCT02194010||INC Contact Registry|INC Contact Registry completes the HMSN-R-ODS on web http://rarediseasesnetwork.epi.usf.edu/INC/
11376118|NCT02193997|Experimental|Fiber 1|Fiber bar containing inulin as fiber soucre taken once daily for 4 weeks
11376119|NCT02193997|Experimental|Fiber 2|Fiber bar containing soluble corn as fiber soucre taken once daily for 4 weeks
11376120|NCT02193997|Placebo Comparator|Placebo|Bar with low fiber content (placebo) once daily for 4 weeks
11376121|NCT02193984|Experimental|Peer support|Study participants are assigned a volunteer peer supporter who has been trained to offer support on diabetes management.
11376122|NCT02193984|No Intervention|Control|No intervention
11376123|NCT02193971|Active Comparator|BS-DES with prasugrel 10mg daily|BS-DES with prasugrel 10mg daily
11376124|NCT02193971|Active Comparator|BS-DES with prasugrel 5mg daily|BS-DES with prasugrel 5mg daily
11376125|NCT02193971|Experimental|BD-DES with prasugrel 10mg daily|BD-DES with prasugrel 10mg daily
11376126|NCT02193971|Experimental|BD-DES with prasugrel 5mg daily|BD-DES with prasugrel 5mg daily
11376127|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
11376128|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
11376129|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
11376130|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
11376131|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
11376132|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
11376133|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
11376134|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
11376135|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
11376136|NCT02193932|Experimental|EEG Triggered fMRI using Micro Maglink|EEG Triggered fMRI to be performed using the Micro Maglink
11376137|NCT02193919||cohort 1 placebo + UVB|cohort 1 placebo + UVB
11376138|NCT02193919||South Beach Diet + UVB|South Beach DIet + UVB
11376142|NCT02193893|Active Comparator|Stem/progenitor cells transplantation.|Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.
11376143|NCT02193893|Sham Comparator|Standard treatment of ALS|Symptomatic treatment of ALS without biologic cell-based treatment
11376144|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
11376145|NCT02193867|Experimental|Open-Label Sebelipase Alfa|All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (United Kingdom only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.
11376146|NCT02193854|Experimental|Mobile phone|"General practitioners (GPs) received TD consultation through Sana system.
~Mobile phones with Sana system installed were provided to 10 rural GPs from three different districts of Mongolia."
11376147|NCT02193841|Active Comparator|C & P|Curettage with puncture (C & P) will be performed alone
11376148|NCT02193841|Active Comparator|C & P with Vitoss|A predetermined amount of Vitoss morsels will be injected following the curettage and puncture (C & P)
11376149|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
11376150|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
11376151|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
11376152|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
11376153|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
11376154|NCT02193802|Other|Endoscopy|"CHANCE is a single arm study: all patients will undergo one capsule endoscopy ( PillCam® COLON 2 capsule and PillCam Crohn's) of the whole intestine AND one ileocolonoscopy.
~The patients will be then treated according to the preference of their physician and a second capsule endoscopy AND an ileoconoscopy will be performed 6 at 12 months later.
~Both exams will be evaluated locally by two independent investigators and all the recorded films will be evaluated and compared by four central readers."
11376155|NCT02193789|Experimental|Anastomosis site stricture|anastomosis site stricture after subtotal gastrectomy with Billroth-I anastomosis
11376156|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
11376157|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
11376158|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
11376159|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
11376160|NCT02193763|Experimental|90 days and under--Interventional|Neonates aged 90 days and under randomized to ultrasound assisted lumbar puncture
11376161|NCT02193763|No Intervention|90 days and under--control|Neonates aged 90 days and under randomized to lumbar puncture using the anatomical landmark approach
11376162|NCT02193763|Experimental|Over 90 days--Interventional|Neonates aged over 90 days randomized to ultrasound assisted lumbar puncture
11376163|NCT02193763|No Intervention|Over 90 days--Control|Neonates aged over 90 days randomized to lumbar puncture using the anatomical landmark approach
11376164|NCT02193750|Placebo Comparator|Placebo|1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
11376165|NCT02193750|Experimental|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
11376166|NCT02193750|Experimental|High Oligosaccharide Group|1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)
11376167|NCT02193737|Experimental|Early oral fluid recovery.|
11376168|NCT02193737|Active Comparator|Delayed oral fluid recovery.|
11376169|NCT02193724||Retinoblastoma|Participants identified with heritable retinoblastoma will undergo a skin biopsy or blood draw to collect cells for processing and analysis.
11376170|NCT02193711|Experimental|Topical Arthritis Cream|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
11376171|NCT02193711|Placebo Comparator|Placebo|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
11376172|NCT02193698|Experimental|Lenalidomide+Dexamethasone|Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
11376173|NCT02193685||Subjects with HAEC|There is no intervention involvement. The clinical data and biologic specimens collected during the study will serve as an invaluable resource for a wide spectrum of clinical and translational ancillary studies directly related to the aims and goals of the study.
11376174|NCT02193685||Subjects without HAEC|A subgroup of children who have Hirschsprung Disease may or may not develop enterocolitis; therefore we will be identifying the bio-markers in children with or without associated enterocolitis.
11376220|NCT02193334|Active Comparator|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
11376302|NCT02192892|Active Comparator|Commercial porridge bar|Porridge from commercial porridge bar
11376175|NCT02193672|Experimental|PET/CT + [18F]Fluciclatide|"At baseline: Participants have PET/CT imaging within 7 days prior to initiation of chemotherapy treatment. Participants monitored at 24 hours post scan via telephone.
~On treatment: Participants have PET/CT imaging at end of the first cycle and prior to the initiation of the second cycle of chemotherapy. Participants assessed at 24 hours post scan via telephone call.
~Baseline and on treatment PET/CT imaging performed with agent [18F] Fluciclatide."
11376176|NCT02193659|Experimental|Cereals|For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet. The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
11376177|NCT02193633|Experimental|AZD2014 3 on/4 off & weekly paclitaxel|3 days on, 4 days off AZD2014 BD administered orally Days 1-3 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
11376178|NCT02193633|Experimental|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 BD administered orally Days 1-2 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
11376179|NCT02193620|Placebo Comparator|Placebo group|Placebo soft capsules
11376180|NCT02193620|Experimental|Study group|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
11376181|NCT02193607|Active Comparator|No TVT-O|Improved reconstruction pelvic surgery
11376182|NCT02193607|Experimental|Combined surgery group|Improved reconstruction pelvic surgery TVT-O procedure
11376183|NCT02193594|Experimental|CCRT group|The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.
11376184|NCT02193594|Active Comparator|CT group|The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.
11376185|NCT02193581||Suspicious skin lesions.|Patients with a suspicious skin lesion referred for a biopsy are tested using MDS
11376186|NCT02193568|Experimental|Arm I (light sedation)|Patients receive light sedation (awake) and undergo craniotomy.
11376187|NCT02193568|Active Comparator|Arm II (intubated general anesthesia)|Patients receive intubated general anesthesia and undergo craniotomy.
11376188|NCT02193555|Other|Non-presbyopic group|"Non-presbyopic group: age ranging from 7 to 39 years
~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.
~For each fitting visit, lenses will be fitted bilaterally."
11376189|NCT02193555|Other|Presbyopic group|"Presbyopic group: age 40 and above
~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.
~For each fitting visit, lenses will be fitted bilaterally."
11376190|NCT02193542||Pregnant patient|Pregnant woman presenting for vaginal or cesarean delivery
11376191|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
11376192|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
11376193|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
11376194|NCT02193477|No Intervention|Control|Patients were given no TEAS.
11376195|NCT02193477|Experimental|TEAS Treatment|Patients were given 30min of TEAS before general anesthesia induction, 1th day and 2nd day after surgery.
11376196|NCT02193477|Sham Comparator|Sham TEAS|Patients were given 30min of sham TEAS before general anesthesia induction,1th day and 2nd day after surgery.
11376197|NCT02193464||inflammatory bowel disease|
11376198|NCT02193451|Experimental|Urodynamics|Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
11376199|NCT02193451|Active Comparator|Usual care|Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
11376200|NCT02193438|Active Comparator|Spice 1|Red chili pepper extract
11376201|NCT02193438|Active Comparator|Spice 2|Cinnamon extract
11376202|NCT02193438|Active Comparator|Spice 3|Refreshing agent
11376203|NCT02193438|Placebo Comparator|Placebo|Tomato juice
11376204|NCT02193425|Experimental|PET FDG &amp; MRI Scans|The test-retest reproducibility of the gender and aging effects on FC measures (lFCD, C, L and S) acquired in RS and TS conditions.
11376205|NCT02193412|Experimental|patients|"noxious stimulus
~change in operating table slope: head-down tilt position
~change in operating table slope: head-up tilt position"
11376206|NCT02193399|Experimental|Physiotherapy exercises|Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
11376207|NCT02193399|No Intervention|Control group|Patients undergoing allogeneic transplantation without treatment of physiotherapy
11376208|NCT02193386|Active Comparator|Usual Care|No intervention, no follow-up, only registration of usual therapy
11376209|NCT02193386|Experimental|Intervention period|Predefined, evidence-based program and support
11376210|NCT02193373|Active Comparator|Sub-Occipital Release|Osteopathic Manual Medicine
11376211|NCT02193373|Active Comparator|Rib-Raising|Osteopathic Manual Medicine
11376212|NCT02193373|Active Comparator|Stellate Ganglion Release|Osteopathic Manual Medicine
11376213|NCT02193373|Active Comparator|All techniques|Osteopathic Manual Medicine
11376214|NCT02193373|Sham Comparator|All Techniques-S|Sham Osteopathic Manual Medicine
11376215|NCT02193373|Sham Comparator|Sub-Occipital Release-S|Sham Osteopathic Manual Medicine
11376216|NCT02193373|Sham Comparator|Rib-Raising-S|Sham Osteopathic Manual Medicine
11376217|NCT02193373|Sham Comparator|Stellate Ganglion Release -S|Sham Osteopathic Manual Medicine
11376218|NCT02193360|Experimental|Single arm Dose Escalation|
11376219|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
11376221|NCT02193334|Placebo Comparator|Placebo|Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
11376222|NCT02193321|Experimental|Amniotic membrane patch placement|One amniotic membrane patch will be placed on the epicardial surface of the heart immediately following a CABG procedure prior to wound closure.
11376223|NCT02193321|No Intervention|Control|Amniotic membrane patch will not be placed after CABG procedure prior to wound closure.
11376224|NCT02193308|Experimental|Telmisartan/Amlodipine FDC|
11376225|NCT02193308|Active Comparator|Telmisartan + Amlodipine mono|
11376226|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction.
11376227|NCT02193295|Experimental|NAFLD|Placebo or ACC inhibitor treatment for 12 weeks
11376228|NCT02193282|Experimental|Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
11376229|NCT02193282|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
11376230|NCT02193282|Experimental|Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11376231|NCT02193282|Active Comparator|Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
11376232|NCT02193269|Placebo Comparator|sugar pill|0.0mg
11376233|NCT02193269|Active Comparator|Minocycline|200mg
11376234|NCT02193256|Active Comparator|Varenicline plus Prazosin|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
11376235|NCT02193256|Placebo Comparator|Varenicline plus Placebo|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Placebo: placebo will be given instead of prazosin (Weeks 1-3)
11376236|NCT02193217|Experimental|MT-1303-Low|MT-1303-Low dose
11376237|NCT02193217|Experimental|MT-1303-High|MT-1303-High dose
11376238|NCT02193217|Active Comparator|Fingolimod|Fingolimod
11376239|NCT02193217|Placebo Comparator|Placebo|Placebo
11376240|NCT02193204|Experimental|Social Drinkers Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers with depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
11376241|NCT02193204|Experimental|Social Drinkers No Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers without depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
11376242|NCT02193204|Experimental|Alcohol Dependent, Non-Depressive|30 treatment-engaged 28-day abstinent, alcohol dependent (AD) smokers, without Depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
11376243|NCT02193204|Experimental|Alchohol Dependent Depressive Symptoms|30 treatment-engaged 28-day abstinent, alcohol dependent smokers with depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
11376244|NCT02193191|Experimental|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
11376245|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
11376246|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
11376247|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
11376248|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
11376249|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.
~One cycle of pazopanib is 28 days."
11376250|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
11376251|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
11376252|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
11376253|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
11376254|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
11376255|NCT02193126|Experimental|Treatment|
11376256|NCT02193126|No Intervention|Comparison|
11376257|NCT02193113|Experimental|KVD001 Injection Dose 1|Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
11376258|NCT02193113|Experimental|KVD001 Injection Dose 2|Single 100uL intravitreal injection KVD001 injection Dose 2
11376259|NCT02193113|Experimental|KVD001 Injection Dose 3|Single 100uL intravitreal injection of KVD001 injection Dose 3
11376260|NCT02193100||13C-glucose|experimental (13C-glucose)
11376261|NCT02193100||No glucose|control (no glucose)
11376262|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
11376263|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
11376264|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
11376265|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
11376266|NCT02193074|Experimental|nusinersen|
11376267|NCT02193074|Sham Comparator|Sham procedure|
11376268|NCT02193061|Active Comparator|ROTA 1|two doses of monovalent vaccine Rotarix followed by one dose of sterile water
11376269|NCT02193061|Active Comparator|ROTA 2|three doses of pentavalent vaccine RotaTeq
11376270|NCT02193061|Active Comparator|ROTA 3|one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
11376271|NCT02193061|Active Comparator|ROTA 4|one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
11376272|NCT02193061|Active Comparator|ROTA 5|two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
11376273|NCT02193061|Active Comparator|ROTA 6|one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
11376274|NCT02193061|Active Comparator|ROTA 7|a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix
11376275|NCT02193048||Patients newly diagnosed with Crohn's disease|This study will evaluate a new clinical scoring system in patients receiving routine treatment
11376276|NCT02193035|Experimental|Single group|Patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Microparticle levels will be measured before and after TAVR.
11376277|NCT02193022|Experimental|Miltefosine|
11376278|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
11376279|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
11376280|NCT02192996|Other|Probiotics supplementation|"Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight < 1300 g and gestational age < 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of Bifidobacterium breve and Lactobacillus salivarius , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10^9 colony forming units (CFU) per doses of each one of the probiotic bacteria."
11376281|NCT02192983||chemotherapy regimen|those with XELOX regimen and those with EOX regimen
11376282|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
11376283|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
11376284|NCT02192957|Other|Ottawa AF Cardioversion|elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
11376285|NCT02192944|Active Comparator|Chloroquine|Chloroquine base 600 mg single dose
11376286|NCT02192944|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose
11376287|NCT02192931|Active Comparator|Creatine monohydrate|5 grams of daily creatine monohydrate for 8 weeks
11376288|NCT02192931|Placebo Comparator|Placebo|5 g of placebo for 8 weeks
11376289|NCT02192931|No Intervention|Healthy Control|
11376290|NCT02192918|Experimental|Airbrush|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Participants will receive access to one of each of the following after the 6-month assessment at no cost: massage, pedicure, yoga class, and dance class. Participants will schedule these activities on their own and the study staff will arrange for payment for the appointment.
11376291|NCT02192918|Experimental|Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class. These activities are being given as healthy alternatives to the relaxation sensation of indoor tanning.
11376292|NCT02192918|Active Comparator|Delayed Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
11376293|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
11376294|NCT02192892|Experimental|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from Corn Soy Blend drum dried with α-amylase
11376295|NCT02192892|Placebo Comparator|CSB drum dried - α-amylase|CSB drum dried - α-amylase: Porridge from Corn Soy Blend drum dried without α-amylase
11376296|NCT02192892|Experimental|CSB + α-amylase|CSB + α-amylase: Porridge from Corn Soy Blend with α-amylase
11376297|NCT02192892|Placebo Comparator|CSB - α-amylase|CSB - α-amylase: Porridge from Corn Soy Blend without α-amylase
11376298|NCT02192892|Experimental|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
11376299|NCT02192892|Placebo Comparator|RSB - α-amylase|RSB - α-amylase: Porridge from Rice Soy Blend without α-amylase
11376300|NCT02192892|Active Comparator|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
11376303|NCT02192892|Experimental|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from Corn Soy Blend PLUS drum dried with α-amylase
11376304|NCT02192892|Placebo Comparator|CSB PLUS drum dried - α-amylase|CSB PLUS drum dried - α-amylase: Porridge from Corn Soy Blend PLUS drum dried without α-amylase
11376305|NCT02192892|Experimental|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
11376306|NCT02192892|Placebo Comparator|CSB PLUS - α-amylase|CSB PLUS - α-amylase: Porridge from Corn Soy Blend PLUS without α-amylase
11376307|NCT02192892|Experimental|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
11376308|NCT02192892|Placebo Comparator|RSB PLUS - α-amylase|RSB PLUS - α-amylase: Porridge from Rice Soy Blend PLUS without α-amylase
11376309|NCT02192892|Experimental|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
11376310|NCT02192892|Placebo Comparator|WSB PLUS - α-amylase|WSB PLUS - α-amylase: Porridge from Wheat Soy Blend PLUS without α-amylase
11376311|NCT02192892|Active Comparator|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
11376312|NCT02192879|Active Comparator|Thoracic Epidural|
11376313|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
11376314|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
11376315|NCT02192866||Peanut allergic|No intervention(s) to be administered.
11376316|NCT02192866||Other food allergic|No intervention(s) to be administered.
11376317|NCT02192866||Controls|No intervention(s) to be administered.
11376318|NCT02192853|Experimental|Sitagliptin|Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.
11376319|NCT02192853|Placebo Comparator|placebo|
11376320|NCT02192840|Active Comparator|rDES Group|"Regular drug-eluting stent implantation, one of the following:
~Device: LucChopin (Balton, Poland) Device: Prolim (Balton, Poland) Device: Xience Pro (Abott Vascular) Device: Biomatrix (Biosensors) Device: Promus (Boston Scientific) Device: Cypher (Cordis) Device: Taxus (Boston Scientific) Device: Coroflex Please (BBraun) Device: Resolute Integrity (Medtronic)"
11376321|NCT02192840|Experimental|BiOSS Group|New dedicated bifurcation stent BiOSS Expert (Balton, Warsaw, Poland) implantation
11376322|NCT02192827|Experimental|Single Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once
11376323|NCT02192827|Experimental|Two Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.
11376324|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.
~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.
~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
11376325|NCT02192788|Experimental|SBRT|Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
11376326|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
11376327|NCT02192762|Experimental|Withdrawal regulation training|Withdrawal coping skills
11376328|NCT02192762|Active Comparator|Relaxation training|Relaxation skills instruction
11376329|NCT02192749|Experimental|Umbilical cord mesenchymal stem cells|
11376330|NCT02192736|Other|Intra-nasal infusion of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally
11376331|NCT02192723|Experimental|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day) for 8 weeks.
11376332|NCT02192723|Active Comparator|Risperidone|Risperidone, 2~6mg/day, twice day, 8 weeks
11376333|NCT02192723|Active Comparator|Olanzapine|5~20mg/day
11376334|NCT02192723|Active Comparator|Quetiapine|400~750mg/day
11376335|NCT02192723|Active Comparator|Aripiprazole|Aripiprazole, 10~30mg/day, twice per day, 8 weeks
11376336|NCT02192723|Active Comparator|Ziprasidone|Ziprasidone, 80~160mg/day, twice per day, 8 weeks
11376337|NCT02192710|Active Comparator|Hypnovel® (midazolam)|Midazolam oral intake before anesthesia
11376338|NCT02192710|Experimental|Electronic tab|
11376339|NCT02192697|Experimental|Phase I dose-escalation group|Oral administration
11376340|NCT02192697|Experimental|Phase I EGFR-T790M mutation group|Oral administration
11376341|NCT02192697|Experimental|Phase II group|Oral administration
11376342|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
11376343|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
11376344|NCT02192671|Experimental|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
11376345|NCT02192671|Active Comparator|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
11376346|NCT02192658||People with Disability (PWD) (N= 850)|"PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).
~A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria."
11376347|NCT02192658||Non-Disabled People (control group) (N= 850)|For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
11376348|NCT02192645|Experimental|Sanfujiu|"Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time.
~Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time."
11376349|NCT02192645|Placebo Comparator|placebo|"Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint .
~Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time."
11376350|NCT02192645|No Intervention|waiting list|No intervention in the first year. Accept Sanfujiu in the second and the third years.
11376351|NCT02192632|Experimental|Epiduo- dermatologist's detailed instruction|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist
11376352|NCT02192632|Experimental|Epiduo- drug insert only gruop|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group
11376353|NCT02192632|Placebo Comparator|BPO group|After randomly assigned to side of BPO application, patients apply BPO during 12 week
11376354|NCT02192619||observational|
11376355|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
11376356|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
11376357|NCT02192593|Experimental|Computer CBT|A 10-session computerized cognitive-behavioral therapy intervention
11376358|NCT02192593|No Intervention|Usual Care|
11376359|NCT02192580|Active Comparator|Omega-3|omega-3 (DHA+EPA) in divided 3 times/day in addition to standard regimens: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
11376360|NCT02192580|No Intervention|Control|control group received just standard regimens without omega-3
11376361|NCT02192567|Experimental|DS-5573a does escalation (step 1) and expansion (step 2)|"Step 1 of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg.
~Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg Step 2: 30 subjects will be enrolled and treated at the dose determined in Step 1."
11376362|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
11376363|NCT02192528||cardiac surgical patients|patients undergoing a cardiac surgical procedure
11376364|NCT02192515|Experimental|APD356 10 mg|Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
11376365|NCT02192515|Experimental|APD356 20 mg|Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
11376366|NCT02192515|Experimental|APD356 XR-20 mg|Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
11376367|NCT02192515|Experimental|APD356 10 mg and APD356 XR-20mg (orange tablet)|"Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.
~Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed)
~Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted)"
11376368|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
11376369|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
11376370|NCT02192489|Experimental|CC-220 0.3mg|CC-220 0.3 mg capsules by mouth (PO) daily for 12 weeks
11376371|NCT02192489|Experimental|CC-220 0.6mg|CC-220 0.6mg capsules by PO daily for 12 weeks
11376372|NCT02192489|Placebo Comparator|Placebo|Identically matching placebo PO daily for 12 weeks
11376373|NCT02192476|Active Comparator|conventional|15 participants are allotted in this arm and each participants received conventional neuro rehabilitation programme 5 days a week for 6 weeks.
11376374|NCT02192476|Experimental|intervention|15 participants allotted in this arm and each participants received California tri-pull taping method along with conventional neuro rehabilitation was given 5 days a week for 6 weeks
11376375|NCT02192463|Experimental|Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release|
11376376|NCT02192463|Experimental|NVP ER 300 mg (KCR 25%) Medium Release|
11376377|NCT02192463|Experimental|NVP ER 300 mg (KCR 30%) Slow Release|
11376378|NCT02192463|Experimental|NVP ER 400 mg (KCR 25%) Medium Release|
11376379|NCT02192463|Experimental|NVP ER 300 mg (KCR 40%) Slow Release|
11376380|NCT02192463|Experimental|NVP ER 300 mg (ECR 20%) Fast Release|
11376381|NCT02192463|Experimental|NVP ER 400 mg (KCR 20%) Medium Release|
11376382|NCT02192463|Experimental|NVP ER 400 mg (KCR 30%) Slow Release|
11376383|NCT02192463|Experimental|NVP ER 400 mg (KCR 40%) Slow Release|
11376384|NCT02192463|Experimental|NVP ER 400 mg (ECR 20%) Fast Release|
11376385|NCT02192463|Active Comparator|Nevirapine IR 1 tablet|
11376386|NCT02192463|Active Comparator|Nevirapine IR 2 tablets|
11376387|NCT02192450|Active Comparator|Insulin glargine|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.
~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.
~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.
~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
11376420|NCT02192268|Active Comparator|Assisted Coughing|The children in the control group will be subjected to two daily sessions of assisted coughing.
11377197|NCT02187250|Active Comparator|roflumilast|In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.
11376388|NCT02192450|Experimental|Insulin degludec|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.
~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.
~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.
~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
11376389|NCT02192437|Experimental|Methionine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine). Control diet for 4 weeks followed by a washout for 3-4 weeks, then a methionine restricted diet (70%) for 4 weeks, followed by 3-4 weeks washout period and then a methionine restricted diet (90%) for 4 weeks.
11376390|NCT02192437|Experimental|Methionine and cysteine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine and cysteine). Control diet for 4 weeks followed by a washout for 3-4 weeks then a methionine and cysteine restricted diet (50%) followed by 3-4 weeks washout period and then a methionine and cysteine restricted diet (65%) for 4 weeks.
11376391|NCT02192424|Active Comparator|Metformin alone|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
11376392|NCT02192424|Experimental|Metformin + Intermittent Insulin Therapy|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.
11376393|NCT02192411|Active Comparator|Standard Lidocaine|50mL 1% lidocaine in 450mL normal saline
11376394|NCT02192411|Experimental|1/4 dose lidocaine|12.5mL 1% lidocaine in 487.5mL normal saline
11376395|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:
~guanfacine (2mg)
~guanfacine (1mg)
~placebo
~Subjects will be instructed to take one capsule in the evening for 4 weeks."
11376396|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:
~guanfacine (2mg)
~guanfacine (1mg)
~placebo
~Subjects will be instructed to take one capsule in the evening for 4 weeks."
11376397|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:
~guanfacine (2mg)
~guanfacine (1mg)
~placebo
~Subjects will be instructed to take one capsule in the evening for 4 weeks."
11376398|NCT02192372||metabolic syndrome|Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference > 102 cm in men and > 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (<40 mg/dl in men and <50 mg/dl in women).
11376399|NCT02192372||control|Age and sex adjusted control subjects
11376400|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11376401|NCT02192346|Experimental|2.4 mg/kg α-TEA|Patients will receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
11376402|NCT02192346|Experimental|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
11376403|NCT02192346|Experimental|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
11376404|NCT02192346|Experimental|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
11376405|NCT02192346|Experimental|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
11376406|NCT02192346|Experimental|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
11376407|NCT02192346|Experimental|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
11376408|NCT02192346|Experimental|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
11376409|NCT02192346|Experimental|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
11376410|NCT02192333|No Intervention|Arm I (usual care)|Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.
11376411|NCT02192333|Experimental|Arm II (survivorship care)|Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
11376412|NCT02192320|Experimental|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;
~Dexamethasone: 0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
11376413|NCT02192320|Active Comparator|Atorvastatin|Atorvastatin: 20 mg (every evening orally) for 5 weeks
11376414|NCT02192307|Experimental|potassium oxalate gel|Professional application
11376415|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
11376416|NCT02192294|Experimental|Bosutinib|
11376417|NCT02192281|Experimental|Playworks|Playworks was implemented during the entire school year, and outcome measures were collected in spring of the school year.
11376418|NCT02192281|No Intervention|Control|Playworks was not implemented at these schools.
11376419|NCT02192268|Active Comparator|HFOO|Children of the HFOO group will be subjected to two daily sessions of this resource which should be the same throughout her hospitalization with Shaker equipment.
11376421|NCT02192268|Active Comparator|PEP|The children will be subjected to PEP group two daily sessions of this resource which should be the same throughout her hospitalization with facial mask and valve Spring load with expiratory pressure of 10cmH2O.
11376422|NCT02192255|Experimental|Intervention phone call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
11376423|NCT02192255|No Intervention|Control arm - usual care|Those in the control arm received usual care.
11376424|NCT02192242|Experimental|Acute ischemic pain|acute ischemic pain was induced by treadmill testing in all patients investigated
11376425|NCT02192229|Active Comparator|intervention group|The intervention group will be supplemented with 50.000 IU vitamin D3 every week for 12 consecutive weeks
11376426|NCT02192229|Placebo Comparator|Placebo group|The placebo group will receive placebo Tablet which will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
11376427|NCT02192216|Experimental|Exercise & Chemotherapy|Following a control period during active chemotherapy the patients undergo ten weeks of supervised exercise comprised of resistance and aerobic training in combination with protein supplementation during ongoing chemotherapy.
11376428|NCT02192203|Experimental|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
11376429|NCT02192203|Active Comparator|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
11376430|NCT02192203|Active Comparator|Menthol Only Gel|3% menthol
11376431|NCT02192203|Placebo Comparator|Placebo Only Gel|0.09% menthol
11376432|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
11376433|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
11376434|NCT02192190|Experimental|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
11376435|NCT02192190|Experimental|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
11376436|NCT02192190|Experimental|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
11376437|NCT02192190|Experimental|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
11376438|NCT02192177||Group 1|Pregnant subjects diagnosed with obstetric cholestasis who didn't have any foreknown systemic disease.
11376439|NCT02192177||Group 2|entirely healthy pregnant subjects, the control group.
11376440|NCT02192138|Experimental|Therapeutic thoracentesis|Patients with pleural effusion who require therapeutic thoracentesis will be enrolled into the study
11376441|NCT02192125|Experimental|REWIRE-System|The training system consists of a so-called Tymoplate® (Tyromotion, Austria), a medical device class 1 with CE certification and approval by the FDA for use in neurorehabilitation after stroke. The Tymoplate® is connected to a computer and allows by means of a base plate with integrated pressure sensors and custom-developed training software different postural biofeedback exercise.
11376442|NCT02192099|Experimental|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
11376443|NCT02192086|Experimental|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).
~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
11376444|NCT02192086|Active Comparator|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).
~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
11376445|NCT02192073|Active Comparator|Suprapectoral Biceps Tenodesis|Suprapectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the superior border of the pectoralis major insertion
11376738|NCT02190123||ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
11376446|NCT02192073|Active Comparator|Subpectoral Biceps Tenodesis|Subpectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the inferior border of the pectoralis major insertion
11376447|NCT02192060|Experimental|Test|Using of a suspension containing Triclosan
11376448|NCT02192060|Placebo Comparator|Control|Using of a suspension without Triclosan or other active ingredient
11376449|NCT02192047|Experimental|palm olein margarine|8 weeks
11376450|NCT02192047|Experimental|IE palm olein margarine|8 weeks
11376451|NCT02192047|Experimental|IE soybean oil-based margarine|8 weeks
11376452|NCT02192034|Experimental|Navigation Group|This group will receive standard clinic instructions for the colonoscopy and two additional phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure.
11376453|NCT02192034|Placebo Comparator|Control|This group will receive only clinic instructions without intervention from the patient navigator.
11376454|NCT02192021|Experimental|Micro needle array-Doxorubicin (MNA-D)|MNA-D application for all subjects
11376455|NCT02192008|Active Comparator|Part A|Cohort naive to typhoidal Salmonella challenged with either S. Typhi or S. Paratyphi
11376456|NCT02192008|Active Comparator|Part B|Cohort previously challenged with S. Typhi or Paratyphi re-challenged with either S. Typhi or S. Paratyphi.
11376457|NCT02191995|Experimental|body awareness yoga|body awareness yoga session prior to breakfast meal
11376458|NCT02191995|No Intervention|Control Arm|No intervention
11376459|NCT02191982|Experimental|Intervention|This arm will begin the Walk With Ease program after the completion of chemotherapy.
11376460|NCT02191982|Active Comparator|Wait List Control|The arm will begin the Walk With Ease program three months after completion of chemotherapy.
11376461|NCT02191969|No Intervention|Control|This group will be receiving adjuvant chemotherapy for colorectal cancer. They will not participate in the Walk With Ease program. They will be followed up using standard of care.
11376462|NCT02191969|Experimental|Intervention|"This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day.
~Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy."
11376463|NCT02191956|Active Comparator|Behavioral Parent Training|Standard of care intervention
11376464|NCT02191956|Experimental|Behavioral Parent Training - Enhanced|Standard of Care Behavioral Parent Training plus new delivery methods
11376465|NCT02191943|Active Comparator|Control (fluoride varnish)|
11376466|NCT02191943|Experimental|resin infiltration (Icon)|
11376467|NCT02191930|Experimental|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
11376468|NCT02191930|Experimental|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
11376469|NCT02191917|Experimental|Measurement of Respiratory Muscle Strength|
11376470|NCT02191904|Active Comparator|Truview EVO2®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively.
11376471|NCT02191904|Active Comparator|Airtraq®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
11376472|NCT02191904|Active Comparator|Direct laryngoscopy|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
11376473|NCT02191891|Experimental|BI 836845 + afatinib|BI 836845 low or high dose (weekly IV infusion), afatinib 30mg or 40mg (once daily oral dosing)
11376474|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.
~Phase 2 - dose expansion at the MTD."
11376475|NCT02191865|Experimental|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
11376476|NCT02191865|Experimental|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
11376477|NCT02191865|Experimental|Healthy volunteers|Healthy control subjects
11376478|NCT02191852|Experimental|Seresis®|2 capsules per day for a period of 16 consecutive weeks
11376479|NCT02191839|Active Comparator|alpha 1 antitrypsin|patients receive 4 grams of IV alpha 1 antitrypsin preoperatively
11376480|NCT02191839|Placebo Comparator|placebo|10 patients will randomely receive placebo
11376481|NCT02191826|Experimental|SOM0226 single dose|
11376482|NCT02191826|Experimental|SOM0226 multiple doses|
11376483|NCT02191813|Experimental|Seresis®|
11376484|NCT02191813|Placebo Comparator|Placebo|
11376485|NCT02191787|Experimental|Seresis® + Placebo|"2 capsules Seresis® o.d. for 5 days
~2 capsules Placebo o.d. the day before treatment with Seresis®"
11376486|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
11376487|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
11376488|NCT02191761|Experimental|SM04755|
11376888|NCT02189226|Active Comparator|chromoendoscopy (CE) group|
11376489|NCT02191748|Active Comparator|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site.
11376490|NCT02191748|Experimental|Needling and Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site.
11376491|NCT02191748|No Intervention|No treatment|No treatment will be done to these vitiligo patches as a control.
11376492|NCT02191735||Troponin I|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
11376493|NCT02191735||Myoglobin|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP Myoglobin test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
11376494|NCT02191735||CK-MB|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP CK-MB test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
11376495|NCT02191735||NT-proBNP|Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
11376496|NCT02191722|Experimental|JIA patients|All participants will be evaluated before and after reading the comics booklet
11376497|NCT02191709|Experimental|Dextromethorphan syrup|Bisoltussin® Syrup
11376498|NCT02191709|Active Comparator|Dextromethorphan soft pastilles|Silomat® DMP soft pastilles
11376499|NCT02191683||Health of women before conception|Tanzanian women aged 18-40 years focusing on prevalence of anaemia, infections, nutritional status, and NCDs.
11376500|NCT02191683||480 women during pregnancy|"Describe how 1st and 2nd trimester anaemia compared to 3rd trimester anaemia alters foetal growth and newborns' body composition.
~Evaluate anaemia's effect on villous branching in placenta, and uterine and umbilical artery blood flow.
~Evaluate effect on vascular endothelial growth factor A/placental growth factor balance and insulin-like growth factor axis.
~Determine which markers for foetal programming such as methylation of regulatory genes related to metabolism and haematopoiesis may be discovered early after exposure to anaemia."
11376501|NCT02191670||METALYSE®|
11376502|NCT02191657|Experimental|Cohort 1|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
11376503|NCT02191657|Experimental|Cohort 2|Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
11376504|NCT02191657|Experimental|Cohort 3|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.
11376505|NCT02191644|Placebo Comparator|Refined rice|
11376506|NCT02191644|Experimental|Whole grains and legumes|
11376507|NCT02191631|Experimental|Internet-delivered CBT|Participants will receive 12 weeks of internet-delivered cognitive behavior therapy with psychologist support.
11376508|NCT02191631|No Intervention|Wait list|Participants will receive no treatment for 12 weeks. After that period participants will receive Internet-delivered Cognitive Behavior Therapy.
11376509|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
11376510|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
11376511|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
11376512|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
11376513|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
11376514|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
11376515|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
11376516|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
11376517|NCT02191566|Experimental|S-1/Oxaliplatin|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
11376735|NCT02190136|Active Comparator|Protein whole foods|Ingestion of 20-25 grams per serving consumed 4-6 times per day; 1 within an hour of waking in the morning and the other 2.5-3 hours apart during the day.
11376518|NCT02191553|Active Comparator|Control Group: Relaxation Techniques|Relaxation techniques which do not involve either formal or informal mindfulness training. Subjects in this group practice Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
11376519|NCT02191553|Experimental|Loving Kindness Meditation (Metta)|Loving-kindness meditation following Kristin Neff protocol
11376520|NCT02191553|Experimental|Body Scan|Body scan as described in standard MBSR protocol
11376521|NCT02191553|Experimental|Sitting Practice|Sitting practice as mindfulness meditation described in standard MBSR protocols.
11376522|NCT02191540|Experimental|Abnoba Viscum F 20mg|
11376523|NCT02191527|Experimental|Point of Care Testing|The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.
11376524|NCT02191527|No Intervention|Laboratory Testing - Standard of care|Samples sent to the laboratory for analysis, (standard of care)
11376525|NCT02191501|Experimental|Pyloric restriction|Endoscopic method of pyloric restriction in order to decrease gastric emptying. The hypothesis is that this will cause and early and prolonged satiety which will inturn lead to decreased food consumption and lead to weight loss.
11376526|NCT02191488|Experimental|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
11376527|NCT02191475|Active Comparator|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.
11376528|NCT02191475|Experimental|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.
11376529|NCT02191462|Experimental|Niagen 100mg|1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
11376530|NCT02191462|Experimental|Niagen 300mg|3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
11376531|NCT02191462|Experimental|1000mg Niagen|10 Niagen capsules (10 x 100mg capsule)
11376532|NCT02191436||Patients with haemophilia|Hemophilia patients (children, youth and adults) and parents of children with hemophilia under 18
11376533|NCT02191423|Experimental|postpartum depression|"Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy
~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).
~All women in this group participate in 8-weeks of dyadic psychotherapy (DP) at the outpatient Psychiatric Department, Tel-Aviv Medical Center.
~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
11376534|NCT02191423|Other|normal controls|"Normal control women not suffering from postpartum depression assessed by fMRI
~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).
~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
11376535|NCT02191410|Active Comparator|High Frequency Positive Pressure Ventilation|
11376536|NCT02191410|Placebo Comparator|Continuous Positive Airway Pressure|
11376537|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
11376538|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
11376539|NCT02191384|Experimental|Orcinoside 25mg per day|
11376540|NCT02191384|Experimental|Orcinoside 50mg per day|
11376541|NCT02191384|Experimental|Orcinoside 100mg per day|
11376542|NCT02191384|Experimental|Orcinoside 200mg per day|
11376543|NCT02191384|Experimental|Orcinoside 400mg per day|
11376544|NCT02191384|Experimental|Orcinoside 600mg per day|
11376545|NCT02191384|Placebo Comparator|placebo|
11376546|NCT02191371|Experimental|propofol|Propofol is used as a maintenance anesthetic to patients in the propofol group. Intervention: propofol infusion by target-controlled infusion for maintaining anesthesia propofol (Fresofol MCT 2%) target effect site concentration: 4~5 mcg/ml, during general anesthesia
11376736|NCT02190136|Experimental|Protein Resistance Exercise Training|Ingestion of 4-6 protein-rich meals per day and 3 times per week of resistance functional training.
11376547|NCT02191371|Experimental|desflurane|"Desflurane is used as a maintenance anesthetic to patients in the desflurane group.
~Intervention: Desflurane administration for maintaining anesthesia desflurane (Suprane) inhalation as 6~8 vol% during general anesthesia"
11376548|NCT02191358||"Tested patients (prospective)"|Patients whose providers decide to have them undergo testing via the YouScript Personalized Prescribing System will be recruited for the study. Data will be gathered at baseline and 120 days later. The decision to utilize YouScript and all treatment decisions will be made at the discretion of the provider in accordance with their usual care practice, and will be made prior to the decision to participate in the study.
11376549|NCT02191358||"Untested patients (retrospective)"|Patients for comparison to the prospectively followed patients will be derived from Inovalon's MORE2 healthcare database. Patients meeting the same enrollment criteria (excluding the YouScript testing) will be matched on key characteristics to the tested patients. Outcomes will be compared between the prospectively enrolled patients undergoing pharmacogenetic testing with the YouScript Personalized Prescribing System at the discretion of their treating physician.
11376550|NCT02191345|No Intervention|10 minute break|Participants asked to take a 10 minute break as usual 3 times per week for 4 weeks
11376551|NCT02191345|Experimental|Guided Imagery|Participants listen to one of 6 pre-recorded guided imagery tracks 3 times per week for 4 weeks
11376552|NCT02191332||Viramune|
11376553|NCT02191319||Viramune®|Patients switching from protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) containing antiretroviral regimen to Viramune®
11376554|NCT02191306||HIV Positive Patients (Study Group)|
11376555|NCT02191306||Non HIV Positive Patients (Control)|
11376556|NCT02191293||Viramune®|
11376557|NCT02191280|Experimental|Antistax®, low dose|
11376558|NCT02191280|Experimental|Antistax®, high dose|
11376559|NCT02191280|Placebo Comparator|Placebo|
11376560|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
11376561|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
11376562|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
11376563|NCT02191254|Experimental|Antistax®|1 tablet per day for 12 weeks
11376564|NCT02191254|Placebo Comparator|Placebo|
11376565|NCT02191241|Experimental|Red Vine Leaf Extract|
11376566|NCT02191228|Experimental|Group 1|Linagliptin in subjects with normal renal function
11376567|NCT02191228|Experimental|Group 2|Linagliptin in patients with mild renal insufficiency (RI)
11376568|NCT02191228|Experimental|Group 3|Linagliptin in patients with moderate RI
11376569|NCT02191228|Experimental|Group 4|Linagliptin in patients with severe RI
11376570|NCT02191228|Experimental|Group 5|Linagliptin in patients with end-stage renal disease (ESRD)
11376571|NCT02191228|Experimental|Group 6|Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
11376572|NCT02191228|Experimental|Group 7|Linagliptin in patients with normal renal function and T2DM
11376573|NCT02191215||Nevirapine (Viramune®)|
11376574|NCT02191202||Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
11376575|NCT02191189|Active Comparator|Treatment A, p.o.|50 mg Nevirapine administered orally in 100 mL water
11376576|NCT02191189|Experimental|Treatment B, ascending colon|50 mg Nevirapine administered to the ascending colon via Enterion™ capsule
11376577|NCT02191189|Experimental|Treatment C, jejunum|50 mg Nevirapine administered to the jejunum via Enterion™ capsule
11376578|NCT02191189|Experimental|Treatment D, ileum|50 mg Nevirapine administered to the ileum via Enterion™ capsule
11376579|NCT02191189|Experimental|Treatment E, descending colon|50 mg Nevirapine administered to the descending colon via Enterion™ capsule
11376580|NCT02191176|Experimental|Dextromethorphan syrup - low dose|
11376581|NCT02191176|Experimental|Dextromethorphan syrup - high dose|
11376582|NCT02191176|Placebo Comparator|Placebo|
11376583|NCT02191163|Experimental|Antistax®|1 x 360 mg for 42 days
11376584|NCT02191163|Placebo Comparator|Placebo|
11376585|NCT02191150||Cohort 1|Patients with CKD
11376586|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
11376587|NCT02191124|Experimental|measurement-based care|MBC allows psychiatrists to individualize treatment decisions for each patient based on the change of psychopathology and tolerance toward antidepressants. Treatment decisions were made by treating psychiatrists according to ratings of self-report scales obtained at each treatment visit. Paroxetine was started at 20mg/day and then raised to 30mg/day by week 4, 40mg/day by week 6, 50mg/day by week 8 and 60mg/day by week 10. Mirtazapine was started at 15mg/day and raised to 30mg/day by week 1 and 45mg/day by week 4. Dose adjustments were dependent on how long a patient had received a particular dose, symptom changes and side effects.
11376588|NCT02191124|Active Comparator|Standard treatment|Patients in the ST group are treated by their psychiatrists according to their clinical needs as judged at each outpatient visit, receiving either open-label paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) within the therapeutic dose range.
11376589|NCT02191111|Experimental|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
11376590|NCT02191111|No Intervention|Control|These sites will continue practice as usual, with no contact from study staff.
11376591|NCT02191098|Experimental|ALT-803|ALT-803
11376622|NCT02190851|Experimental|electrical nerve stimulation (TENS)|"Two electrodes are attached around the internal malleolus and connected to the TENS unit, by UROSTIM 2.
~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
11376737|NCT02190136|Experimental|Protein Stretching/Yoga Training|Ingestion of Protein-rich diet 4-6 meals/day and stretching/yoga training 3 times per week
11376592|NCT02191085|No Intervention|Standard Management|"Patients in the Standard Management arm will be assessed without any interventions.Patients will be assessed by a sleep respirologist and follow a management plan that is determined by the sleep physician and patient. This plan may involve polysomnography or the initiation of PAP therapy. If further testing is ordered, follow-up may occur with the physician or with an ACP, at the physician's discretion. For patients initiating PAP therapy, the decision to delegate follow-up to an ACP will be left up to the physician, as the intent of this study is to observe real-world practice and not to change the management of individual patients."
11376593|NCT02191085|Active Comparator|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient."
11376594|NCT02191072|Experimental|omalizumab|omalizumab 300mg subcutaneously once
11376595|NCT02191059|Experimental|Intermittent High Dose of Icotinib|"Intermittent High Dose of Icotinib in Combination With Docetaxel:
~Icotinib 625mg tablet b ymouth three times per day for day1-2, Docetaxel 75mg/m2 injection intravenous drip for day 3, 3 weeks as 1 cycle"
11376596|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
11376597|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
11376598|NCT02191033|Experimental|Text messaging|Smoking counseling, nicotine patch, text messaging
11376599|NCT02191033|Active Comparator|Standard of care|Smoking counseling, nicotine patch
11376600|NCT02191020|Experimental|Total glucosides of paeony & Acitretin Capsules|During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d
11376601|NCT02191020|Active Comparator|Acitretin Capsules|20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.
11376602|NCT02191007|Experimental|Calcipotriol/Betamethasone and Calcipotriol|Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;
11376603|NCT02191007|Sham Comparator|Calcipotriol/Betamethasone and urea cream|alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period
11376604|NCT02191007|Active Comparator|Calcipotriol/Betamethasone|Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period
11376605|NCT02190994|No Intervention|A. Normal function, non-GC replacement|No glucocorticoid replacement will be given perioperatively.
11376606|NCT02190994|Active Comparator|B. Normal function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
11376607|NCT02190994|Active Comparator|C. Impaired function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
11376608|NCT02190994|Active Comparator|D. Impaired function, high-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3.
11376609|NCT02190981||Ultrasound for Small Bowel Obstruction|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected small bowel obstruction
11376610|NCT02190968|Experimental|Mindful Mood Balance|An 8 session internet intervention targeting residual depressive symptoms.
11376611|NCT02190968|Active Comparator|Usual Depression Care|Usual Depression Care through Kaiser Permanente Colorado
11376612|NCT02190955||NEPTUNE contact registry patients|Patients and caregivers will be recruited from the Nephrotic Syndrome Study Network (NEPTUNE) Patient Contact Registry. Over 1000 patients and caregivers are members of the registry and have already provided permission to be contacted for future research studies. Analysis of the one-time online questionnaire will be done in collaboration with investigators from the NEPTUNE Consortium.
11376613|NCT02190942||Vasculitis Contact Registry Patients|Consent will be obtained from at least 20 randomly selected patients with each of the following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care providers to request that the providers complete an online version of this questionnaire (or print copy, if they prefer), and request specific chart items from their office to further verify the data.
11376614|NCT02190929||Vasculitis Contact Registry Patients|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.
11376615|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
11376616|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
11376617|NCT02190890|Experimental|Dry needling: 4 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 4 local twitch responses were elicited.
11376618|NCT02190890|Experimental|Dry needling: 6 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 6 local twitch responses were elicited.
11376619|NCT02190890|Experimental|Dry needling: Until no more local twitch responses elicited|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until no more local twitch responses were elicited.
11376620|NCT02190890|Active Comparator|Control|The needle was inserted 1.5 cm away from the trigger point in the trapezius muscle and withdrawn without any consecutive insertion.
11376621|NCT02190877||Cohort 1: Subjects taking diuretic medication|All subjects will be in the same group, Cohort 1
11376623|NCT02190851|Placebo Comparator|Control group|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
11376624|NCT02190838|Experimental|Dacarbazine with Metformin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Metformin 850 mg BID.
11376625|NCT02190838|Experimental|Dacarbazine and Melatonin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Melatonin 3 mg before sleep daily.
11376626|NCT02190838|Active Comparator|Dacarbazine|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days
11376627|NCT02190812|Experimental|Forearm supporter|This study measured the effect of proper forearm supporter to alleviate pain and improve the wrist and grip strength in the subjects with tennis elbow.
11376628|NCT02190812|Experimental|Grip ball|In this study a portable grip ball training system is developed. This study use the grip ball to train the wrist muscle. It's expected to reduce the risk of injury of the elderly in their daily lives.
11376629|NCT02190799|Experimental|Convalescent plasma|Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria
11376630|NCT02190786|Experimental|KUX-1151, Low dose|
11376631|NCT02190786|Experimental|KUX-1151, Middle dose|
11376632|NCT02190786|Experimental|KUX-1151, High dose|
11376633|NCT02190773||Chronic periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment
11376634|NCT02190773||Agressive periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment.
11376635|NCT02190773||Control group|Periodontally healthy individuals
11376636|NCT02190760|Active Comparator|Group I (ISB-P)|Interscalene block with perineural injection of dexamethasone 0.1 mg/kg
11376637|NCT02190760|Active Comparator|Group II (ISB-S)|Interscalene block with systemically injection of dexamethasone 0.1 mg/kg.
11376638|NCT02190760|Active Comparator|Group III - ISB-C|Interscalene block without adjuvant.
11376639|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
11376640|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
11376641|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
11376642|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
11376643|NCT02190734|Other|wheelchair, walking on treadmill, walking overground|Sitting in wheel chair Gait training on treadmill Gait training overground
11376644|NCT02190721|Experimental|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
11376645|NCT02190708|Experimental|PQ912 & Midazolam & Omeprazole|day2 - day6 800mg PQ912 twice per day po day1 / day6 2.5 mg Midazolam once per day day1 / day6 20 mg Omeprazole once per day
11376646|NCT02190695|Active Comparator|Decitabine|Decitabine 20mg/m2 IV over 1hour daily times 5 days every 28 days
11376647|NCT02190695|Experimental|Decitabine and Carboplatin|Decitabine 20mg/m2 IV over 1hour daily times 5 days, plus Carboplatin AUC 5 IV over 1hour on day 8. repeat every 28 days.
11376648|NCT02190695|Experimental|Decitabine and Arsenic|Decitabine 20mg/m2 IV over 1 hour daily for 5 days plus Arsenic Trioxide 0.15mg/kg IV daily for 5 days. repeat every 28 days
11376649|NCT02190669||exercise in individuals without diabetes|exercise in individuals without diabetes
11376650|NCT02190669||exercise in type 1 diabetes|exercise in type 1 diabetes
11376651|NCT02190669||exercise in type 2 diabetes|exercise in type 2 diabetes
11376652|NCT02190656||Anterior resection|Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery
11376653|NCT02190643|Experimental|Adherence condition|Brief smoking cessation counseling session (based on 5 A's approach) that includes a module focused on improving adherence to using the nicotine patch, plus 8-week supply of nicotine patches.
11376654|NCT02190643|Active Comparator|Standard condition|Brief smoking cessation counseling session (based on 5 A's approach) that does not include a module focused on improving nicotine patch adherence, plus 8-week supply of nicotine patches.
11376655|NCT02190630|Active Comparator|Part time (12hour) wear|the' Modified Clark Twin Block' will be worn part time
11376656|NCT02190630|Active Comparator|Full time (24hour) wear|the ' Modified Clark Twin Block' will be worn full time
11376657|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Management Plan|"Patients in study arm will receive:
~Enhanced Clinic Intervention
~Enhanced Health Plan
~Unified Management Plan"
11376658|NCT02190617|Active Comparator|CHW Home Visit Only|"Patients in study arm will receive:
~CHW Home Visit
~Usual clinic care with enhanced health plan"
11376659|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Plan+ CHW|"Patients in study arm will receive:
~CHW Home Visit
~Enhanced Clinic intervention
~Enhanced health plan
~Unified asthma management plan"
11376660|NCT02190617|No Intervention|Usual Care|-Usual clinic care with enhanced healthplan
11376661|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376662|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376663|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11377018|NCT02188381||Controlled hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
11376664|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376665|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376666|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376667|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376668|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376669|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376670|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
11376671|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
11376672|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
11376673|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
11376674|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
11376675|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
11376676|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
11376677|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
11376678|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
11376679|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
11376680|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
11376681|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
11376682|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
11376683|NCT02190578|Experimental|Diagnostic: Reveal G4|Subjects tested with investigational devices and approved comparator assay algorithms for HIV
11376684|NCT02190565|Placebo Comparator|Placebo|Placebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
11376685|NCT02190565|Active Comparator|Food supplement|Food supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
11376686|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
11376687|NCT02190539|Experimental|Homeopathic treatment|A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
11376688|NCT02190526|Experimental|Mesalazine(asacol 800 mg)|patients receive asacol (800 mg/TDS) and a placebo agent similar to amitriptyline (10 mg/HS) for 8 weeks
11376689|NCT02190526|Experimental|Amitriptyline|patients receive amitriptyline (10 mg/HS) and a placebo like asacol (800 mg/ TDS) for 8 weeks
11376690|NCT02190526|Placebo Comparator|placebo group|patients receive placebo like asacol (800 mg/TDS) and placebo similar to amitriptyline (10 mg/HS) for 8 weeks
11376691|NCT02190500|Active Comparator|Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
11376692|NCT02190500|No Intervention|Standard Management|Acute ischemic stroke patients receiving standard management
11376693|NCT02190487||TAS group|patients who had thoracic aortic surgery due to dissection
11377198|NCT02187237|Experimental|Laser therapy|
11376694|NCT02190474|Experimental|Mindfulness Group|These adolescents will be invited to participate in a group mindfulness meditation program based on a protocol refined by the investigative team. The weekly group meetings will be taught by an MBSR teacher at the Yale School of Medicine, with experience teaching mindfulness interventions to adults, children, and adolescents.
11376695|NCT02190461|Experimental|Early Respiratory Rehabilitation|Starting the Early Respiratory Rehabilitation programme during the admission and continues it at home immediately after discharge for a period of 3 months.
11376696|NCT02190461|Active Comparator|Conventional Respiratory Rehabilitation|Started a conventional Respiratory Rehabilitation programme at home one month after discharge from hospital and continues for 3 months.
11376697|NCT02190448|Experimental|study herbal tea|Supplementation of 3-5, 8 oz cups of study tea daily for 4 weeks.
11376698|NCT02190448|Placebo Comparator|herbal placebo tea|Supplementation of 3-5, 8oz cups of tea daily for 4 weeks.
11376699|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
11376700|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
11376701|NCT02190409|Experimental|Test, Control|Test: Minimum two tapered implants (Ankylosis, Dentsply Friadent) were placed to each patient. After surgical preparation of implant sockets, PRF that was prepared preoperatively was placed randomly to one of the sockets (PRF+). Acellular plasma portion of PRF was used to wet the implant placed into the PRF-coated socket Control: Other socket was selected as a control group (No Platelet Rich Fibrin used): In the control group no extra intervention used and the conventional procedure was done. Thus the readings of the experimental arm compared with this control.
11376702|NCT02190396||Group 1|Placental calcification of Grade 3
11376703|NCT02190396||Group 2|No placental calcification noted, the control group.
11376704|NCT02190383|Experimental|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
11376705|NCT02190370|Experimental|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
11376706|NCT02190357|Experimental|rifaximin|400 mg bid,orally
11376707|NCT02190357|No Intervention|controlled group|no intervention
11376708|NCT02190344|Experimental|Functionality of 8-channel paddle coil system|
11376709|NCT02190331|Experimental|Interventional program|The training protocol is constituted by 4 strengthening exercises (Side Lying External Rotation, Prone Horizontal Abduction with External Rotation, Y to I exercise and Chin Tuck) and 3 stretching exercises(one- Sided Unilateral Self Stretch Exercise, one-sided Unilateral Self Stretch Exercise, Static Sternocleidomastoid Stretch and Static Levator Scapulae Stretch
11376710|NCT02190331|Active Comparator|Control group|The control group will only participate in the Physical Education classes
11376711|NCT02190318|Experimental|Losartan|Losartan is taken orally 100mg/d
11376712|NCT02190318|Experimental|spirolactone|spirolactone is taken orally 20mg/d
11376713|NCT02190318|Experimental|losartan in combination with spirolactone|Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d
11376714|NCT02190318|Sham Comparator|blank control|patients with antihypertensives besides ACEI/ARBs and spirolactone.
11376715|NCT02190305|Experimental|Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg|Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
11376716|NCT02190292||PANS group|All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.
11376717|NCT02190292||Psychiatric controls|60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.
11376718|NCT02190292||Healthy controls|25 age and sex matched children to the PANS group will be recruited.
11376719|NCT02190279|Experimental|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
11376720|NCT02190279|Experimental|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
11376721|NCT02190279|Experimental|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
11376722|NCT02190266||Patients|Patiens with confirmes refractory and/or disseminated coccidioidomycosis.
11376723|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
11376724|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
11376725|NCT02190227|Other|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
11376726|NCT02190201|Experimental|videolaryngoscope|DLT intubation with McGrath videolaryngoscope
11376727|NCT02190201|Active Comparator|Direct laryngoscope|DLT intubation with Macintosh laryngoscope
11376728|NCT02190188|No Intervention|No specific treatment|No specific treatment after partial meniscectomy
11376729|NCT02190188|Other|Wedge Insole with 5mm wedge angel|Participants wear a wedge insole after partial meniscectomy
11376730|NCT02190188|Other|Knee Brace|Participants wear a knee brace after partial meniscectomy
11376731|NCT02190162|Active Comparator|Tantum Verde® mouthwash|solution of Tantum Verde
11376732|NCT02190162|Placebo Comparator|placebo mouthwash|saline with mint flavor
11376733|NCT02190149||ADVATE (Factor VIII)|Participants will remain on their current (pre-study) treatment regimen of ADVATE throughout the study period
11376734|NCT02190149||RIXUBIS (Factor IX)|Participants will remain on their current (pre-study) treatment regimen of RIXUBIS throughout the study period
11376739|NCT02190110||Suspected pulmonary embolism patients|Adult patients (more than 18 years old) suspected of PE will be recruited at the time of the medical evaluation and before a final diagnosis is established
11376740|NCT02190097|Experimental|paleolithic diet|subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
11376741|NCT02190097|Active Comparator|American Diabetes Association diet|subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
11376742|NCT02190084|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
11376743|NCT02190084|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.
11376744|NCT02190058|Experimental|DS-1971a|DS-1971a suspension, up to 4650mg/day
11376745|NCT02190058|Placebo Comparator|placebo|matching DS-1971a suspension
11376746|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
11376747|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
11376748|NCT02190032|Active Comparator|Control group|"Intubating a manufacturer-provided-angled double-lumen tube (=Conventional-angled group,MallinckrodtTM endotracheal tube, Covidien)"
11376749|NCT02190032|Experimental|Tube angle modification|The angle of the double lumen tube(MallinckrodeTM endotracheal tube) is modified individually.At sniffing position, the distal tip of the tube is placed at the patient's cricoid cartilage level and the tube is bent at the intersection point of the two airway axes (oropharyngeal axis and tracheal axis) with an angle between the two axes.
11376750|NCT02190019|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
11376751|NCT02190019|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 10 treatments identical in duration will be administered over a two week period.
11376752|NCT02190006||Polycystic ovarian syndrome|Women with polycystic ovarian syndrome undergoing ICSI
11376753|NCT02189993||Total Parenteral Nutrition Use|The cohort investigated consisted of patients with intestinal failure requiring total parenteral nutrition use.
11376754|NCT02189980|Placebo Comparator|Saline & nasal clip|Saline and nasal clip inhaled post-operatively
11376755|NCT02189980|Experimental|Aromatherapy blend & nasal clip|Aromatherapy blend and nasal clip inhaled post-operatively
11376756|NCT02189967|Active Comparator|conventional fractionation|radiotherapy with conventional fractionation (5 x 2Gy per week)
11376757|NCT02189967|Active Comparator|accelerated fraction|radiotherapy with accelerated fraction (7 x 2 Gy per week)
11376758|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
11376759|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
11376760|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
11376761|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
11376762|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
11376763|NCT02189928|Experimental|With per-CID protocol|Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
11376764|NCT02189928|Other|Without per-CID protocol|Usual care patients (thrombolysis or not).
11376765|NCT02189915|Experimental|Creatine monohydrate|
11376766|NCT02189902|Active Comparator|4000 IU/d of D3 by mouth for 12 weeks|4000 IU/d of D3 by mouth for 12 weeks
11376767|NCT02189902|Experimental|7000IU/d of D3 by mouth for 12 weeks|7000IU/d of D3 by mouth for 12 weeks
11376768|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
11376769|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
11376770|NCT02189876|Experimental|FemAALES|Females of African American Legacy Empowering Self Intervention. A nine session, theoretically grounded small group intervention.
11376771|NCT02189876|Active Comparator|Standard of Care|A one-time STD/family planning testing and counseling session provided to all study participants.
11376772|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
11376773|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
11376774|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
11376775|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
11376776|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
11376777|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
11376778|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
11376779|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
11376780|NCT02189824|Experimental|Infusion of partially matched unrelated donor cells|
11376781|NCT02189811|Experimental|IPV|IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
11376782|NCT02189811|Experimental|bOPV|bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
11376783|NCT02189811|Experimental|bOPV and IPV|bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
11376784|NCT02189811|Experimental|bOPV and IPV and IPV2|bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
11376785|NCT02189811|Active Comparator|tOPV|tOPV at birth, 6, 10, 14, 18 and 22 weeks of age
11376786|NCT02189798|Experimental|Newly Implanted Group|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness. Patients retaining considerable low frequency acoustic hearing after the surgery, will be fitted with the EAS sound processor.
11376787|NCT02189798|Experimental|Existing Implanted Group|Adults unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness will be fitted with the EAS sound processor.
11376788|NCT02189798|Experimental|EAS Extended Use Arm|Adults who are unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness and completed the 12 Month visit using the EAS sound processor in either the Newly Implanted Group or Existing Implanted Group.
11376789|NCT02189785||Healthy Controls|Healthy men and women ages 18-25 years
11376790|NCT02189772|Experimental|MDX (metadoxine extended release)|"Route of administration: oral
~The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:
~40-49 kg 700 mg consisting of a 700 mg tablet
~50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet
~65-100 kg 1400 mg consisting of two 700 mg tablets"
11376791|NCT02189772|Placebo Comparator|placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
11376792|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
11376793|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
11376794|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
11376795|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
11376796|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to 1 hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
11376797|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
11376798|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
11376799|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
11376800|NCT02189733|Experimental|Caplacizumab - Treatment A|Single s.c. dose of reconstituted lyophilized solution of caplacizumab followed by single s.c. dose of liquid formulation of caplacizumab
11376801|NCT02189733|Experimental|Caplacizumab - Treatment B|Single s.c. dose of liquid formulation of caplacizumab followed by single s.c. dose of reconstituted lyophilized solution of caplacizumab
11376802|NCT02189707|Experimental|Probiotic Bifidobacterium 1x1010 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
11376803|NCT02189707|Experimental|Probiotic Bifidobacterium 1x109 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
11376804|NCT02189707|Placebo Comparator|Placebo powder in capsules|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
11376805|NCT02189694|Active Comparator|Insulin pump therapy|Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
11376806|NCT02189694|Active Comparator|Single-hormone closed-loop strategy|Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
11376807|NCT02189694|Active Comparator|Dual-hormone closed-loop strategy|Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
11376808|NCT02189681|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthesia.
11376809|NCT02189681|Experimental|Group P|This group had pre-procedure ultrasound guided L5S1 paramedian spinal anaesthesia performed
11376810|NCT02189668|Experimental|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
11376811|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
11376812|NCT02189655|No Intervention|Group Control|Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
11376813|NCT02189655|Experimental|Group Diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
11376814|NCT02189642||Genito-Urinary/Urology Surgical Procedure Types|Pediatric patients undergoing circumcision, orchidopexy, hypospadias repair, hernia repair, cystoscopy, pyeloplasty, and ureteral reimplants or ureteral stents.
11376815|NCT02189642||Otolaryngology Surgical Procedure Types|Pediatric patients undergoing tonsil and/or adenoid removal, tympanostomy, tympanoplasty, and mastoidectomy.
11376816|NCT02189642||Orthopaedics Surgical Procedure Types|Patients undergoing hip and knee arthroscopies, hardware removal, and tendon lengthening.
11376817|NCT02189642||Plastic Surgery Surgical Procedure Type|Pediatric patients undergoing alveolar cleft repair.
11376818|NCT02189629|Experimental|CD5789 (trifarotene) cream|
11376819|NCT02189616|Other|regular care group|receive regular care which contains filling a paper asthma diary daily.
11376820|NCT02189616|Experimental|SMS reminder group|receive weekly mobile phone short message reminders for 3 months
11376821|NCT02189616|Experimental|SMS reminder and SMS consultation group|receive weekly mobile phone short message reminders and can consult asthma nurse by mobile phone short message when needed for 3 months
11376822|NCT02189603|Experimental|Senior group(over 65 years old)-HE|Anti-HEV IgG seronegative participants over 65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
11376823|NCT02189603|Active Comparator|Younger groups(16-65 years old)|Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
11376824|NCT02189603|No Intervention|Senior group(over 65 years old)-Cont|Anti-HEV IgG seropositive participants over 65 years old were enrolled. This is the safety control group, without any intervention.
11376825|NCT02189590|Experimental|air-Q|Patients will receive the air-Q with size based on manufacturer recommendations of body weight
11376826|NCT02189590|Experimental|i-gel|Patients will receive the i-gel with size based on manufacturer recommendations of body weight
11376827|NCT02189577|Experimental|CHF 5259|CHF 5259
11376828|NCT02189577|Placebo Comparator|Placebo|Placebo
11376829|NCT02189564|Active Comparator|Intrinsic reward|Feedback about good performance
11376830|NCT02189564|Experimental|Intrinsic and extrinsic reward|Feedback about good performance + money
11376831|NCT02189564|Experimental|Intrinsic reward (average performance)|Feedback about random selection of trials
11376832|NCT02189551|Active Comparator|Lokomat Pro|gait robot established on the market
11376833|NCT02189551|Experimental|Lokomat Pro FreeD|gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market
11376834|NCT02189538|Experimental|ω-3 PUFA|Modular low fat diet (18%) including 9% as ω-3 PUFA
11376835|NCT02189538|Active Comparator|Low fat enteral diet|Modular low fat (18%)
11376836|NCT02189525||Sports induced concussion|Exposure to sports induced concussion
11376837|NCT02189525||Routine Athletic Exertion|Exposure to routine athletic exertion without sports-induced concussion (non-concussion control)
11376838|NCT02189512|Other|brain death organ donors|cases - blood sampling
11376839|NCT02189512|Other|abdominal aortic aneurysm repair|controls - blood sampling
11376840|NCT02189499|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
11376841|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
11376842|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
11376843|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
11376844|NCT02189460||Healthy adults|20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.
11376845|NCT02189447|Experimental|Refractive surgery|Patients with keratoconus treated with simultaneous photorefractive keratectomy and Corneal collagen cross-linking.
11376846|NCT02189434||Cytoreductive surgery|Patients having undergone cytoreductive surgery with or without HIPEC will have serum procalcitonin lab draws
11376847|NCT02189421|Other|Direct peroral cholangioscopy|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
11376848|NCT02189408|Experimental|PRP|one intraoperative application of PRP in the interventional group
11376849|NCT02189408|No Intervention|Control|No application of any substance during knee arthroscopy
11376850|NCT02189395|Experimental|NPH and regular insuline group|For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
11376851|NCT02189395|Active Comparator|glargine and humalog group|Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.
11376852|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
11376853|NCT02189382|Other|Water|Self Applied
11376854|NCT02189369|Experimental|Day 3 embryo-Own-above cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
11376855|NCT02189369|Experimental|Day 5 embryo-Own-above cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
11376856|NCT02189369|Experimental|Day 3 embryo-Donor-above cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
11376857|NCT02189369|Experimental|Day 5 embryo-Donor- above cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
11376858|NCT02189369|Experimental|Day 3 embryo-Donor-lower cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
11376859|NCT02189369|Experimental|Day 5 embryo-Donor-lower cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
11376860|NCT02189369|Experimental|Day 3 embryo-own-lower cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
11376861|NCT02189369|Experimental|Day 5 embryo-own-lower cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
11376862|NCT02189356|Experimental|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
11376863|NCT02189356|Other|contol group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
11376864|NCT02189343|Experimental|Dose Escalation Cohort|Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
11376865|NCT02189330|Experimental|Tafamidis|
11376866|NCT02189330|Experimental|Tafamudus Free Acid|
11376867|NCT02189330|Experimental|20 mg new soft gelatin capsule|
11376868|NCT02189330|Experimental|4 capsules of 20 mg tafamidis of commercial formulation|
11376869|NCT02189330|Experimental|4 capsules of 12.2 mg tafamidis of free acid tablet|
11376870|NCT02189317|Experimental|Exparel|This arm will receive Exparel
11376871|NCT02189317|No Intervention|Control|
11376872|NCT02189304|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
11376873|NCT02189304|Experimental|PT009|PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
11376874|NCT02189304|Active Comparator|Symbicort Turbohaler|Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations
11376875|NCT02189291|Experimental|Immediate catheter removal|The indwelling Foley catheter will be removed prior to exiting the operating room.
11376876|NCT02189291|Active Comparator|Post op day 1 catheter removal|Patients assigned to this group will follow the standard of care at present, with removal of indwelling catheter on the morning of postoperative day 1.
11376877|NCT02189278|Experimental|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
11376878|NCT02189278|No Intervention|Treatment as usual|Treatment as usual control.
11376879|NCT02189265||Full cohort|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
11376880|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
11376881|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
11376882|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
11376883|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
11376884|NCT02189239|Active Comparator|Zeller Entspannung film coated tablets|Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.
11376885|NCT02189239|Placebo Comparator|Placebo tablets|Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.
11376886|NCT02189239|Sham Comparator|No Treatment|No medication intake.
11376887|NCT02189226|Experimental|probe-based confocal laser endomicroscopy (pCLE) group|
11376889|NCT02189213|Active Comparator|Sertraline, Fluoxetine, or Escitalopram|"Sertraline, Fluoxetine, or Escitalopram will be administered PO to treat anxiety disorders in children and adolescents. One of the following dosing schedules will be used:
~Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks, or
~Fluoxetine will be titrated from 10mg once a day orally up to 40mg once a day orally, for 12 weeks or
~Escitalopram will be titrated from 10mg once a day orally up to 40mg once a day orally, for 12 weeks.
~The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration."
11376890|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
11376891|NCT02189200|Active Comparator|Oat bran group|oat bran (40g per day)
11376892|NCT02189200|Placebo Comparator|Placebo group|refined rice flour (40g per day)
11376893|NCT02189187|Experimental|Mindfulness Based Stress Reduction (MBSR) program|Mindfulness Based Stress Reduction (MBSR) is an 8-week program that consists of training in mindfulness practices, the application of mindfulness to daily life, and information about healthy living and the role played by thoughts and emotions in health.
11376894|NCT02189187|Active Comparator|Healthy Living Course (HLC)|Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
11376895|NCT02189174|Experimental|CLR457|
11376896|NCT02189161|Experimental|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
11376897|NCT02189148||Cohort|"Each participant will :
~give consent
~provide a blood sample (10 ml)
~be measured (weight and height for BMI calculation)
~undergo a blood pressure measurement
~have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)
~answer to a short questionnaire (5 pages)"
11376898|NCT02189135|No Intervention|Usual care|Usual care from physician/ doctor
11376899|NCT02189135|Experimental|Telemedicine|Mobile wireless glucometer with feedback from physicians
11376900|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
11376901|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
11376902|NCT02189109|Experimental|Dose Escalation|NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.
11376903|NCT02189096||No change from current practice|"Phase 1 (4 months)
~No change from current practice. Each Paramedic crew routinely documents patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be electronically captured. The data will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria [signs of systemic inflammation] and suspicion of infection) by the study investigators. An estimate will be made of the time of completion of the ePRF in relation to patient transport."
11376904|NCT02189096||NEWS and Sepsis Screening|"Phase 2 (4 months)
~The ten crews will undertake implementation of NEWS and Sepsis Screening. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, the patients transfer will be as per normal protocol but receiving ED staff will receive the information about NEWS score and Sepsis screening as part of a structured handover."
11376905|NCT02189096||Point of care lactate measurement|"Phase 3 ( 4 months)
~The ten crews will undertake Point of Care Lactate measurement when NEWS ≥ 4 or when the patient screens positive for Sepsis. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection).
~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge. The lactate level, along with the NEWS score and sepsis screening, will be given to the receiving ED staff as part of a structured handover."
11376906|NCT02189083|Experimental|High dose TSD|Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
11376907|NCT02189083|Active Comparator|Low dose TSD|Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
11376908|NCT02189070||Responders|Responding participants
11376909|NCT02189070||Non-responders|Non-responding participants
11376910|NCT02189057|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
11376911|NCT02189057|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
11376912|NCT02189044|Other|exercises; muscle strength|Evaluate the effects of Pilates exercises on respiratory muscle strength in elderly women before and after eleven weeks of training
11376913|NCT02189031||Upper Extremity Amputee|Robust custom tactor to facilitate embodiment and proprioception
11376914|NCT02189031||Able Bodied|Bypass tactor
11376915|NCT02189018|Active Comparator|Control|Ad lib activity at home
11376916|NCT02189018|Experimental|Active Exercise|Active exercise on treadmill
11376917|NCT02189018|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
11376918|NCT02189018|Experimental|Weight loss and active exercise|Weight loss plus active exercise on treadmill
11376919|NCT02189005|Experimental|PreCrea|Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.
11376920|NCT02189005|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
11376921|NCT02188992||Cohort 1|Patients with sepsis syndrome, without criteria for severe sepsis/septic shock. These patients are recruited from the emergency department.
11376922|NCT02188992||Cohort 2|Patients with community acquired sepsis syndrome REQUIRING critical care admission due to severity of sepsis. These patients are recruited from the critical care areas (ICU/HDU).
11376923|NCT02188992||Cohort 3|Patients without sepsis syndrome. Age and gender matched to cohort 1, and recruited from Emergency Department.
11376924|NCT02188966|Experimental|Geographical Information System|Availability of Geographical Information System data from ambulances destined for the Emergency Department of Regional Hospital Horsens.
11376925|NCT02188953|Experimental|ACCS100|Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
11376926|NCT02188953|Placebo Comparator|Calcium carbonate|Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.
11376927|NCT02188940|Active Comparator|Exercise, dietary and behavioral therapy|The interventions of active comparator will be education program, dietary and behavioral therapy and exercise training.
11376928|NCT02188940|Sham Comparator|Dietary and behavioral therapy|The intervention in sham comparator will be education program, dietary and behavioral therapy and stretching and breathing exercise.
11376929|NCT02188927|Experimental|Implementation of ANL|"Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure
~Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)"
11376930|NCT02188927|Active Comparator|No included ANL|Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy
11376931|NCT02188914||Inhalant use disorder group|Subjects must have a diagnosis of inhalant use disorder, according to the DSM-5, who are under a treatment program for addictive disorders.
11376932|NCT02188914||Normal control group|Normal control without a history of drug abuse or dependency.
11376933|NCT02188901|Other|single arm|
11376934|NCT02188888||Tachycardic patients|Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
11376935|NCT02188875|Experimental|SMS Text Messages & Fitbit One|All study participants were provided a Fitbit One to facilitate self-monitoring of PA. Those who were randomly assigned to the intervention group were asked to indicate 3 preferred times of the day to receive text message prompts to do PA throughout the 6-week study period.
11376936|NCT02188875|Active Comparator|Fitbit One Only|An active control group was also provided the Fitbit One to facilitate self-monitoring of PA throughout the 6-week study period.
11376937|NCT02188862||Rheumatic heart disease cases|Patients with rheumatic heart disease as defined in the case criteria
11376938|NCT02188862||Population controls|Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)
11376939|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
11376940|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
11376941|NCT02188836|Experimental|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
11376942|NCT02188836|Placebo Comparator|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
11376943|NCT02188823|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.
~Participants will also be taught information about exercise, sleep, mindfulness, and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
11376944|NCT02188810|Active Comparator|Group 1|Single dose of control vaccine (a single dose of 0.5 mL TIV).
11376945|NCT02188810|Experimental|Group 2|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
11376946|NCT02188810|Experimental|Group 3|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 1x PAL, i.e. 60 μg).
11376947|NCT02188810|Experimental|Group 4|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 2x PAL (i.e., 120 μg).
11376948|NCT02188810|Experimental|Group 5|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 4x PAL (i.e., 240 μg).
11376949|NCT02188810|Experimental|Group 6|Single dose of the test article (0.125 mL of TIV with 4x PAL i.e., 240 μg).
11376950|NCT02188797|Experimental|Group MI risk reduction program|Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
11376951|NCT02188797|No Intervention|Usual care control|Participant receive HIV information brochure and Community Resource Guide.
11376952|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
11376953|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
11376954|NCT02188771|Experimental|RegenoGel SP 2ml|"RegenoGel-SP is a new viscosupplement intended for the intra-articular treatment of OA.
~Following signing the Informed Consent form (Visit 1), subjects who conform to the inclusion criteria will be evaluated for vital signs, blood hematology, chemistry, INR, aPTT and ECG, and will be subjected to a 30-40ml blood withdrawal that will be used for the production of autologous RegenoGel-SP. Subjects randomized to receive RegenoGel-SP will receive a single, intra-articular injection (Visit 2)."
11376955|NCT02188758||Adults - CFPE Treatment|Other: CF Pulmonary Exacerbation (CFPE) Treatment
11376956|NCT02188745|Experimental|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.
~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.
~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.
~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.
~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
11376957|NCT02188732|Experimental|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):
~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
11376958|NCT02188732|Active Comparator|CBHH+SMT|"CBHH+SMT Community-Based Health Home (CBHH) PLUS Self-Management Training (SMT) of I-IMR
~I-IMR integrates psychiatric illness self-management with strategies for medical illness self-management . The psychiatric component includes psychoeducation about illness and treatment, cognitive behavioral approaches to increase medication adherence, training and relapse prevention, teaching coping skills to manage persistent symptoms, and social skills training. The medical illness component consists of an individually tailored curriculum focused on managing physical illnesses using parallel skills and strategies taught for psychiatric illness self-management, as well as a nurse health care manager to facilitate coordination of necessary preventive and ongoing health care. The I-IMR curriculum consists of 10 modules delivered by an I-IMR specialist through eight months of weekly sessions customized to the specific needs and disorders of each client."
11376959|NCT02188732|Active Comparator|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
11376960|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
11376961|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
11376962|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
11376963|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
11376964|NCT02188693||Gemcitabine, Experimental|Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause
11376965|NCT02188693||Observational|Observation for every 12 weeks until disease progression or the date of first documented death from any cause
11376966|NCT02188680|Active Comparator|Low FODMAPS diet and positive breath testing for fructose|Patients with breath testing positive have a low FODMAPS diet. The test will be considered as positive if we observe an increase of more than 20 ppm of H2 and/or CH4 on a sample with regard to the basal concentration
11376967|NCT02188680|Sham Comparator|negative breath testing for fructose|patients with negative breath test have a low FODMAPS diet
11376968|NCT02188667|Active Comparator|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
11376969|NCT02188667|Sham Comparator|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
11376970|NCT02188654|Experimental|Metformin|500 mg metformin
11376971|NCT02188654|Placebo Comparator|Placebo|500 mg of placebo tablets
11376972|NCT02188641|Other|Diet|Low-fat diet
11376973|NCT02188641|Other|Exercise|3-day/week exercise programme
11376974|NCT02188641|Other|Diet and exercise|healthy low fat diet and 3day/week exercise programme
11376975|NCT02188641|Other|Healthy lifestyle (Control) group|Control group was provided with health education using videotaped presentation
11376976|NCT02188628|Experimental|H-Man|H-Man is a novel, portable, inexpensive end-effector upper limb robot.
11376977|NCT02188628|Active Comparator|Additional Conventional Therapy|Repetitive goals based arm therapy
11376978|NCT02188615|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
11376979|NCT02188615|Active Comparator|Radical Chemoradiotherapy|only Radical Chemoradiotherapy
11376980|NCT02188615|Active Comparator|Mckeown MIE|only Mckeown MIE
11376981|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
11376982|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
11376983|NCT02188589|Experimental|Nasal implant group|Bilateral or unilateral INEX nasal implants
11376984|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.
~A higher dose of tranexamic acid will be given to this arm as follows:
~50 mg/kg loading dose and 5 mg/kg/h infusion"
11377334|NCT02186353|Experimental|Highly processed whole grains|Partial feeding study
11376985|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.
~A lower dose of TXa will be given as follows:
~10 mg/kg loading dose and 5 mg/kg/h infusion"
11376986|NCT02188563|Experimental|Comprehensive intervention|New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
11376987|NCT02188563|Active Comparator|Enhanced usual care|Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
11376988|NCT02188550|Experimental|Single|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
11376989|NCT02188537|Experimental|Nelfinavir, Bortezomib, Dexamethasone|"The trial is designed as an add-on therapy, where nelfinavir is added to the approved bortezomib-containing therapy. Bortezomib and dexamethasone background treatment will be given in the Swissmedic-approved dose and schedule and according to international therapeutic standard."
11376990|NCT02188524|No Intervention|Control Group|No exercise program
11376991|NCT02188524|Experimental|Exercise Group|exercise program
11376992|NCT02188511|Experimental|Group A|Electronic cigarette (nicotine/placebo) - Day 8 Intervention: Electronic cigarette exposure will be limited to one day.
11376993|NCT02188511|Experimental|Group B|Electronic cigarette (nicotine/placebo) - Days 7 through 8 Electronic cigarette exposure will be limited to two days
11376994|NCT02188511|Experimental|Group C|Electronic cigarette (nicotine/placebo) - Days 6 through 8 Electronic cigarette exposure will be limited to 3 days
11376995|NCT02188511|Experimental|Group D|Electronic cigarette (nicotine/placebo) - Days 5 through 8 Electronic cigarette exposure will be limited to 4 days
11376996|NCT02188511|Experimental|Group E|Electronic cigarette (nicotine/placebo) - Days 4 through 8 Electronic cigarette exposure will be limited to 5 days.
11376997|NCT02188498||Polysomnography with Holter monitoring|Patients will undergo resting electrocardiogram (ECG) test at the beginning of the night and be monitored by a Holter device for the duration of the sleep study.
11376998|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
11376999|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
11377000|NCT02188472|Active Comparator|Penicillin V|Penicillin V 2 tablets of 330 mg twice dayly for 7 days
11377001|NCT02188472|Active Comparator|Trimethoprim|2 Tablet Trimethoprim of 100 mg twice daily for 7 days
11377002|NCT02188472|Placebo Comparator|Placebo|2 Placebo Tablets twice daily for 7 days
11377003|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
11377004|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
11377005|NCT02188446|Experimental|Smoking and alcohol cessation education|
11377006|NCT02188446|No Intervention|Standard treatment|Standard treatment is information about benefits of stopping drinking and smoking before surgery and if wanted, advice about who to contact to get support.
11377007|NCT02188433|Experimental|Cut down to quit (CDTQ)|"For those subjects who claim that they cannot quit smoking ≤7 days, they will receive a leaflet (i.e. include a roadmap of smoking reduction strategy) plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit as quitting can greatly reduce risks, and participants will be advised to cut down cigarette consumption at their own pace, but the process should not exceed 3 months. (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention and encourage smokers who fail to quit or relapse to reduce again during each telephone follow-up.
~For the subjects have intention to quit smoking ≤7 days, the investigator will follow-up them after a week. For those who report quitted, they will be followed up as other participants. However, if they report failed to quit, they will receive the same interventions and will be followed-up as other participants in the experimental group."
11377008|NCT02188433|Active Comparator|Quit Immediately (QI)|QI group subjects will receive a smoking cessation booklet (provided by COSH) plus brief intervention using AWARD model similar to CDTQ group. For the subsequent telephone follow-up repeat the health warning that 'one in two smokers will be killed by smoking' and encourage smokers who fail to quit or relapse to try again.
11377009|NCT02188420|Experimental|Latency minus 3ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
11377010|NCT02188420|Experimental|Latency minus 5ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
11377011|NCT02188420|Experimental|Latency minus 7ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
11377012|NCT02188420|Active Comparator|Latency plus 100ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency + 100ms), known to have no effect, where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
11377013|NCT02188407|Experimental|Sevoflurane|Sevoflurane group (S group)- The group anaesthesied with sevoflurane
11377014|NCT02188407|Active Comparator|Propofol|Propofol 4-6 mg/kg/h iv
11377015|NCT02188394|Experimental|Anesthetic blockades with bupivacaine|Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
11377016|NCT02188394|Placebo Comparator|Isotonic saline injection|Patients will receive a bilateral occipital injection with isotonic saline
11377017|NCT02188381||Normal controls without hypertension|Control subjects will have a systolic BP <140mmHg with no cardiovascular disease. These subjects will provide a one time stool sample and a blood sample.
11377335|NCT02186353|Active Comparator|Refined grains|Partial feeding study
11377019|NCT02188381||Resistant hypertension|Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg despite ≥3 anti-hypertensive medications of different classes. These subjects will provide a one time stool sample and a blood sample.
11377020|NCT02188381||Prior enrolled in NCT 02133872|These subject will be asked to provide two stool samples and two blood samples. One at baseline and one after 3 months of therapy.
11377021|NCT02188381||Remodeled Resistent Hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
11377022|NCT02188368|Experimental|A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)|"POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
11377023|NCT02188368|Experimental|B: POM 3mg+PLD with or without steroids|"POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).
~PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
11377024|NCT02188368|Experimental|C: POM MTD + other drugs|"Phase 1:
~POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed
~Phase 2:
~POM at the MTD All other agents, at the same dose and on the same days as phase 1"
11377025|NCT02188342|Experimental|HIT exercise training|
11377026|NCT02188329||Households with children under 13|Interviews were conducted with the parent or guardian of a child or children under age 13.
11377027|NCT02188329||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own.
11377028|NCT02188329||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
11377029|NCT02188329||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
11377030|NCT02188316|Active Comparator|Jumbo forceps polypectomy|89 patients were randomized to jumbo forceps arm and 120 diminutive colorectal polyps were removed by jumbo forceps polypectomy.
11377031|NCT02188316|Active Comparator|Hot biopsy electrocauterization|90 patients were randomized to hot biopsy forceps arm and 117 diminutive colorectal polyps were removed by hot biopsy electrocauterization.
11377032|NCT02188303|Experimental|LY2944876 (Single Dose)|Single escalating dose of LY2944876 administered subcutaneous (SC) on Day 1
11377033|NCT02188303|Placebo Comparator|Placebo (Single Dose)|Single dose of placebo matching LY2944876 administered SC on Day 1
11377034|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|LY2944876 administered once daily SC on Days 1 - 7
11377035|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1 - 7
11377036|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses administered once daily SC on Days 1, 4, 6, 8, 10 and 12
11377037|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
11377038|NCT02188290||HAPLO group|Control group of all eligible patients who received an HSCT from a haploidentical donor without ATIR administration between 1 January 2006 and 30 June 2013
11377039|NCT02188290||MUD group|Control group of eligible patients who received an HSCT from a fully matched unrelated donor between 1 January 2010 and 31 December 2012
11377040|NCT02188290||MMUD group|Control group of eligible patients who received an HSCT from a 1-locus mismatched unrelated donor between 1 January 2010 and 31 December 2012
11377041|NCT02188290||UCB group|Control group of eligible patients who received a double umbilical cord blood transplantation between 1 January 2010 and 31 December 2012
11377042|NCT02188277|Experimental|Xeomin®|4-8 Units per kg body weight. Single injection cycle.
11377043|NCT02188277|Active Comparator|Botox®|4-6(8) Units per kg body weight. Single injection cycle.
11377044|NCT02188264|Experimental|Treatment (selumetinib and cyclosporine)|Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11377045|NCT02188251|Experimental|Activamp|Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks
11377046|NCT02188251|Placebo Comparator|Placebo|1 capsule taken twice daily for 12 weeks
11377047|NCT02188238||Saliva Sample Collection|Collection of stimulated whole mouth saliva . Whole mouth saliva is collected through stimulation by inert gum, and collecting saliva in a sterile tube.
11377048|NCT02188225|Experimental|Acupuncture|12 sessions of acupuncture / 3 sessions weekly/ 20 minutes each session
11377049|NCT02188225|Active Comparator|fluoxetine|10 mg daily
11377050|NCT02188212|Other|NobelProcera Crown Shaded Zirconia|NobelProcera Crown Shaded Zirconia molar
11377051|NCT02188199||Knee Replacement|Patients undergoing knee replacement surgery
11377052|NCT02188199||Hip Replacement|Patients undergoing hip replacement
11377053|NCT02188186|Active Comparator|Conventional treatment|"Initial dual combination therapy with sulfonylurea and metfomin. Dose of sulfonylurea (glimepride 2-8 mg) and metfomin (500-2550 mg) can be ecalated at investigator's discreition at every visit.
~Insulin therpy can be added as a rescue therapy at investigator's discreition."
11377054|NCT02188186|Experimental|Initial triple combination treatment|"Initial dual combination therapy with metformin, sitagliptin (Januvia 100 mg), and lobeglitazone (Duvie 0.5 mg).
~Insulin therpy can be added as a rescue therapy at investigator's discreition."
11377088|NCT02187887|No Intervention|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
11377336|NCT02186340|Experimental|Inspiratory muscle training|
11377055|NCT02188173||dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
11377056|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
11377057|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
11377058|NCT02188147|Experimental|SWD 1000|Short Term Wearable Defibrillator
11377059|NCT02188134||65 and older|No intervention will be administered
11377060|NCT02188121|Experimental|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
11377061|NCT02188121|No Intervention|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
11377062|NCT02188108|Experimental|Survey|Wisconsin Stone-QOL survey. Patients with kidney stones or a history thereof will complete a kidney stone-specific health-related survey at enrollment and post-enrollment at 3 months, 12 months, 24 months, and 36 months.
11377063|NCT02188095||Excia T®|
11377064|NCT02188082|Experimental|IvabRadine hemisulfate Sustained-release Tablets|5-15mg qd
11377065|NCT02188082|Placebo Comparator|placebo|5-15mg qd
11377066|NCT02188043|Other|Relay Model|"AUDIT score 8+: Brief Motivational Intervention with alcohol therapist. AUDITscore16+:Brief Motivational Intervention and appointment at Alcohol Treatment Clinic
~-"
11377067|NCT02188043|No Intervention|Usual Referral Procedure|Hospital staff refer patient to Alcohol Treatment Clinic according to usual procedure
11377068|NCT02188030|Active Comparator|Group Exercise Training (GET).|Group Exercise Program. The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum 12. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
11377069|NCT02188030|Active Comparator|Individual Exercise Training|Individual Exercise Program. The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al. and Sundstrup et al . During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
11377070|NCT02188017|Active Comparator|80 units|80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading
11377071|NCT02188017|Active Comparator|40 units|40 units of ACTHAR gel will be given twice a week for 22 weeks after loading
11377072|NCT02187991|Active Comparator|ER+/HER2- Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
11377073|NCT02187991|Experimental|ER+/HER2- Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
11377074|NCT02187991|Active Comparator|Triple Negative Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
11377075|NCT02187991|Experimental|Triple Negative Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
11377076|NCT02187978|Experimental|Early total enteral feeding (ETEF)|"Feeding will be initiated on D1 with 80ml/kg/day of expressed breast milk or LBW formula milk.
~No intravenous fluid will be provided. Feeds will be advanced till 150ml/kg/day is attained."
11377077|NCT02187978|Active Comparator|Conventional enteral feeding (CEF)|"Feeding will be initiated on D1of life with 20ml/kg of expressed breast milk or LBW formula milk.
~Remaining requirement as intravenous fluids. Feeds advanced by 20ml/kg/day for next 2 days and then 30ml/kg/day for the next three days until 150ml/kg/day is reached."
11377078|NCT02187952|Experimental|Behavioral feeding intervention|Behavioral feeding intervention will be conducted as usual. The intervention will not be altered for purposes of the study.
11377079|NCT02187952|No Intervention|Waitlist control|
11377080|NCT02187939|Active Comparator|Summer wellness program - nutrition & physical activity|The GROOVE condition uses conventional means to address health-related activities and content within the context of a science museum summer enrichment program. The emphasis is on nutrition, physical activity, and healthy lifestyle.
11377081|NCT02187939|Experimental|Summer program plus virtual world technology|The GROOVE+ condition enhances the conventional approach to address health-related activities and content within the context of a science museum summer enrichment program by employing technology and a 3-D virtual world as a key educational strategy. The emphasis is on nutrition, physical activity, and healthy lifestyle.
11377082|NCT02187926||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved label in Greece.
11377083|NCT02187913|Experimental|Resistant starch|The test snack bar consumed has the resistant starch
11377084|NCT02187913|Experimental|Control|The control bar uses maltodextrin rather than the resistant starch.
11377085|NCT02187900|Experimental|TWH for the treatment of IgAN|Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
11377086|NCT02187900|Active Comparator|MMF for IgAN|MMF for the treatment of IgAN for 6 months
11377087|NCT02187887|Experimental|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
11377199|NCT02187224|Experimental|Progesterone|For the three days prior to each test day every participant in this arm will receive progesterone.
11377089|NCT02187874|Active Comparator|early umbilical cord occlusion|Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.
11377090|NCT02187874|Experimental|delayed umbilical cord occlusion|"One of the paediatricians will hold the newborn ( in vaginal deliveries between 20-30 cm under the mother, in C-sections between the legs of the mother) until clamping of the umbilical cord is indicated by a second paediatrician who will be controlling the time and overall state of the baby. The baby will be wrapped during this time in a thermal blanket in a flexed lateral decubitus position to minimise stress and heat loss. Time of clamping: after 30 to 60 seconds( preferably 60). If loss of the baby's wellbeing is suspected, the paediatrician will assess the newborn's heart rate , stopping the procedureif this falls under 100ppm, initiating at that moment the necessary reanimation procedures.
~60 second after the delivery of the new born 10 IU of oxytocin will be administered intramuscularly."
11377091|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
11377092|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
11377093|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
11377094|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
11377095|NCT02187848|Experimental|SAR408701 Main Dose Escalation Cohort|Dose escalation administered intravenously, once every two weeks
11377096|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC)|Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
11377097|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
11377098|NCT02187848|Experimental|SAR408701 Expansion Cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
11377099|NCT02187848|Experimental|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
11377100|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
11377101|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
11377102|NCT02187848|Experimental|SAR408701 Expansion Cohort small cell lung cancer (SCLC)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
11377103|NCT02187848|Experimental|SAR408701 Dose Escalation every 3 weeks cohort|Dose escalation administered intravenously, once every three weeks
11377104|NCT02187835||schizophrenia|patients with a diagnosis of schizohrenia
11377105|NCT02187835||control|healthy control group
11377106|NCT02187822|Experimental|Dose Escalation + Dose Expansion|"Dose Escalation followed by Dose Expansion.
~Dose Escalation Phase: The maximum tolerated dose (MTD) for TPI 287 given concurrently with Fractionated Stereotactic Radiotherapy (FSRT) will be determined using the standard 3+3 study design.
~Dose Expansion Phase: Participants will be treated with TPI 287 at MTD given concurrently with FSRT to further assess toxicity and tumor response."
11377107|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
11377108|NCT02187796||Normal Cognition|HIV+ individuals with no detectable neurocognitive impairment
11377109|NCT02187796||ANI (asymptomatic neurocognitive impairment)|"HIV+ individuals where impairment involves at least two cognitive domains, and results in neuropsychological testing performance at least 1 Standard Deviation (SD) below the appropriate mean age/education norm for:
~Information processing speed
~Sensory/motor skills
~Short-term and long-term memory
~Ability to learn new skills and solve problems
~Attention, concentration, and distractibility
~Logical and abstract reasoning functions
~Ability to understand and express language
~Visual-spatial organization Visual-motor coordination
~Planning, synthesizing and organizing abilities"
11377110|NCT02187796||MCD (Mild Cognitive Disorder)|HIV+ individuals with cognitive impairment same as ANI but patient or caregivers report that cognitive deficit interferes with mental acuity, work efficiency, home making or social activity
11377111|NCT02187796||HAD (HIV-associated dementia)|"HIV+ individuals where impairment involves at least two cognitive domains and results in neuropsychological testing at least 2 SD below the appropriate mean age/education norm for:
~Information processing speed
~Short-term and long-term memory
~Ability to learn new skills and solve problems
~Attention, concentration, and distractibility
~Logical and abstract reasoning functions
~Ability to understand and express language
~Visual-spatial organization Visual-motor coordination
~Planning, synthesizing and organizing abilities Cognitive impairment significantly interferes with work, home life, social activities or ADL's."
11377154|NCT02187510|Experimental|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
11377399|NCT02185937|Active Comparator|cola|imatinib intake with cola
11377112|NCT02187796||Healthy Controls (HIV-)|Our P300 COGNISION apparatus has been used only in subjects over the age of 60, whereas our participants in the HAND study will all be younger than 60. So, we cannot use COGNISION normative data base for comparison. We will add 10 HIV- healthy controls to our planned 40 HIV+ subjects. These HIV- participants will be age- and gender-matched to the HIV- Asymptomatic Neurocognitive Impairment (ANI) patients, and will undergo all the same assessments
11377113|NCT02187783|Experimental|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
11377114|NCT02187757|Experimental|PreLipid|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.
11377115|NCT02187757|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
11377116|NCT02187744|Experimental|PF-05280014|
11377117|NCT02187744|Active Comparator|Herceptin®|
11377118|NCT02187718|Other|SNPGA|Sentinel Node Procedure under General Anaesthesia
11377119|NCT02187718|Other|SNPLA|Sentinel Node Procedure under Local Anaesthesia
11377120|NCT02187705||Patients with normotension at baseline|
11377121|NCT02187705||Patients with essential hypertension at baseline|
11377122|NCT02187705||Patients with isolated hypertension at baseline|
11377123|NCT02187692|No Intervention|TAU|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
11377124|NCT02187692|Experimental|MCT|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
11377125|NCT02187679|Experimental|Abobotulinum toxin A|Abobotulinum toxin A Injection
11377126|NCT02187666||Lumbar|Patients undergoing lumbar spinal surgery
11377127|NCT02187666||Cervical|Patients undergoing cervical spine surgery
11377128|NCT02187653||Lumbar|Patients undergoing lumbar surgery
11377129|NCT02187653||Cervical|Patients undergoing cervical surgery
11377130|NCT02187640|Experimental|Self-administered acupressure|A 10-day self-administered acupressure program was implemented by the participants who were adult psychiatric in-patients and randomly assigned into this treatment group. The patients would receive a 3-session training of this therapy conducted by a qualified acupressure therapist and each session lasted about an hour. They would be assessed by the trainer to ensure that they are able to identify the five acupoints and applied a constant and an appropriate pressure on each acupoint before actual implementation.
11377131|NCT02187640|Sham Comparator|Sham control group|Sham control group: Patients would receive 3-session training and be assessed by the trainer. However, they would be trained to locate five non-acupoints adjacent to the actual acupoints and with minimal pressure applied.
11377132|NCT02187627|Experimental|Part 1: Tracer Selection|Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2.
11377133|NCT02187627|Experimental|Part 2A: Test-Retest|Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
11377134|NCT02187627|Experimental|Part 2B: Dosimetry|Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry.
11377135|NCT02187614|Experimental|Diclofenac and Placebos|Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
11377136|NCT02187614|Active Comparator|Morphine and Placebos|Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
11377137|NCT02187614|Active Comparator|Paracetamol and Placebos|participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.
11377138|NCT02187601|Experimental|CLD with MPBA and BID|Chronic Liver Disease (CLD) patients of all degrees will be offered to be tested on the MPBA (multi purpose breath analyzer) and BID (BreathID) on a walk- in basis with , proving they meet inclusion/exclusion criteria.
11377139|NCT02187601|Experimental|HV with MPBA and BID|Healthy volunteers (HV) with no known liver disease will undergo the breath test with the MPBA and the BID before and after substrate ingestion.
11377140|NCT02187588|Experimental|Eschscholtzia Californica - low dose|
11377141|NCT02187588|Experimental|Eschscholtzia Californica - high dose|
11377142|NCT02187588|Active Comparator|Ibuprofen|
11377143|NCT02187588|Placebo Comparator|Placebo|
11377144|NCT02187575|Experimental|UHAC 62 XX tablet|
11377145|NCT02187575|Active Comparator|UHAC 62 XX capsule|
11377146|NCT02187562|Experimental|Meloxicam/Aspirin|Meloxicam days 1-10 / Aspirin days 5-10
11377147|NCT02187562|Active Comparator|Aspirin|Aspirin 2 days
11377148|NCT02187549|Experimental|HYMOVIS|HYADD(TM) 4 Hydrogel Intra-Articular Injection
11377149|NCT02187549|Placebo Comparator|Placebo|Saline Intra-Articular Injection
11377150|NCT02187536|Experimental|Telmisartan combined with Simvastatin|Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)
11377151|NCT02187536|Active Comparator|Simvastatin and telmisartan placebo|Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)
11377152|NCT02187523|Experimental|Telmisartan/HCTZ FDC|
11377153|NCT02187523|Active Comparator|Telmisartan and HCTZ individual tablets|
11377155|NCT02187510|Active Comparator|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
11377156|NCT02187497|Experimental|Low dose of BIBR 277|
11377157|NCT02187497|Experimental|Medium dose of BIBR 277|
11377158|NCT02187497|Experimental|High dose of BIBR 277|
11377159|NCT02187484|Experimental|Single rising doses of BIBR 277|
11377160|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
11377161|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
11377162|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
11377163|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
11377164|NCT02187445|Experimental|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
11377165|NCT02187432||ADPKD|EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).
11377166|NCT02187419|Active Comparator|5 Therapist-Delivered Hypnosis Session|Participants will complete five therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
11377167|NCT02187419|Active Comparator|3 Therapist-Delivered Hypnosis Session|Participants will complete three therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
11377168|NCT02187419|Active Comparator|5 Phone Calls; Hypnosis Recordings Only|Participants will complete five phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
11377169|NCT02187419|Active Comparator|3 Phone Calls; Hypnosis Recordings Only|Participants will complete three phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
11377170|NCT02187406|No Intervention|Control|
11377171|NCT02187406|Experimental|Traditional ankle athletic taping|Described by Purcell and Schuckman (2009)
11377172|NCT02187406|Experimental|modified ankle athletic taping|Described by Montag and Asmussen (1992)
11377173|NCT02187380||Control group|Pharmacists received no depression training, delivered usual care to patients starting a new treatment with depression.
11377174|NCT02187380||Intervention group|Pharmacists received a depression training day and provided structured medication counselling to patients starting a new treatment with antidepressants
11377175|NCT02187367|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
11377176|NCT02187367|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
11377177|NCT02187341|Experimental|5-HTP|200 mg 5-HTP capsule will be ingested 2h prior to reporting to the laboratory.
11377178|NCT02187341|Placebo Comparator|Placebo|For these visit subjects will ingest placebo (Sugar pill) capsule 2 hours before reporting to the laboratory.
11377179|NCT02187328|Experimental|Grapefruit juice|12.5 OZ Grapefruit juice: Subject will ingest grapefruit juice 12.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon prior to their evening visit
11377180|NCT02187328|Placebo Comparator|Apple juice|10.5 OZ Apple juice: Subject will ingest apple juice 10.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon 3 hours prior to their evening visit.
11377181|NCT02187315|Experimental|Melodie group|Induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
11377182|NCT02187315|Other|Routine-chemotherapy group|Induction chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
11377183|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:
~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;
~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
11377184|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
11377185|NCT02187289|Active Comparator|Standard care|Weeks 1-12, Standard Care only (Compression Sleeve, daytime wear)
11377186|NCT02187289|Experimental|Standard Care plus Night-time Compression Bandages|Weeks 1 - 12, Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered Compression Bandages.
11377187|NCT02187289|Experimental|Standard Care Plus Night-time Compression System Garment|Weeks 1 - 12, Standard care (day-time sleeve) plus night-time use of a custom-made Night-time Compression System Garment
11377188|NCT02187276||Alzheimer disease or mixed dementia|Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
11377189|NCT02187263||hereditary DCM|
11377190|NCT02187263||inflammatory DCM|
11377191|NCT02187263||LVNC|
11377192|NCT02187263||HCM|
11377193|NCT02187263||ARVC|
11377194|NCT02187263||acute myocarditis|
11377195|NCT02187250|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
11377196|NCT02187250|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
11377930|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
11377200|NCT02187224|Placebo Comparator|Placebo|For the three days prior to each test day every participant in this arm will receive placebo.
11377201|NCT02187211|Experimental|Minocycline Low Dose|Participants in this arm will receive a low dose (200mg/day) of Minocycline for 10 days
11377202|NCT02187211|Experimental|Minocycline High Dose|Participants in this arm will receive a high dose (400mg/day) of Minocycline for 10 days
11377203|NCT02187211|Placebo Comparator|Placebo|Participants in this arm will receive the Placebo for 10 days
11377204|NCT02187198|Experimental|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
11377205|NCT02187198|Experimental|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
11377206|NCT02187185|Active Comparator|Sonicare Elite-Flexcare|Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
11377207|NCT02187185|Active Comparator|Manual Toothbrush|Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
11377208|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
11377209|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
11377210|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
11377211|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
11377212|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
11377213|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
11377214|NCT02187146||ART population|Patients undergoing IVF/ICSI/FET treatment at the Birmingham Womens Fertility Centre 2013-2014
11377215|NCT02187133|Experimental|Treatment|Patients receive carfilzomib IV over 30 minutes twice weekly on days 1, 2, 8, 9, 15, and 16 or weekly on days 2, 9, and 16; bendamustine hydrochloride IV over 60 minutes on days 1 and 2; and rituximab IV over 30-90 minutes on day 9 (course 1 only) and day 1 (subsequent courses). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11377216|NCT02187120|Experimental|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.
~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
11377217|NCT02187120|Placebo Comparator|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).
~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
11377218|NCT02187107|Experimental|TMC114 + rtv|Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours
11377219|NCT02187094|Placebo Comparator|Placebo|One capsule of placebo administered as a single dose.
11377220|NCT02187094|Experimental|2 mg TC-6499|One capsule of 2 mg TC-6499 administered as a single dose.
11377221|NCT02187094|Experimental|5 mg TC-6499|One capsule of 5 mg TC-6499 administered as a single dose.
11377222|NCT02187094|Experimental|10 mg TC-6499|One capsule of 10 mg TC-6499 administered as a single dose.
11377223|NCT02187081|Experimental|Sorafenib+RFA|We give radiofrequency ablation plus Sorafenib for the treatment of HCC
11377224|NCT02187081|Active Comparator|RFA alone|We give Radiofrequency ablation alone for the treatment of HCC
11377225|NCT02187068|Experimental|Dexmedetomidine obese 1|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
11377264|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
11377226|NCT02187068|Experimental|Dexmedetomidine obese 2|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
11377227|NCT02187068|Experimental|Dexmedetomidine non-obese 1|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
11377228|NCT02187068|Experimental|Dexmedetomidine non obese 2|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
11377229|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
11377230|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
11377231|NCT02187055|Active Comparator|Adalimumab with methotrexate|
11377232|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
11377233|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
11377234|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
11377235|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
11377236|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
11377237|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
11377238|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
11377239|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
11377240|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
11377241|NCT02187003|Experimental|Rivipansel Treatment Arm|
11377242|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
11377243|NCT02186990|Active Comparator|propofol|
11377244|NCT02186990|Active Comparator|etomidate|
11377245|NCT02186990|Active Comparator|propofol-etomidate|
11377246|NCT02186977|Active Comparator|Intramuscular group|These subjects will receive one intramuscular injection of 1.0cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur-MSD) with syringe and needle in the deltoid region.
11377247|NCT02186977|Experimental|Intradermal group (Mantoux)|These subjects will receive one intradermal injection with mantoux technique in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur-MSD) will be injected.
11377248|NCT02186977|Experimental|Intradermal group (VAX-ID) A|These subjects will receive one intradermal injection with the newly developed intradermal injection device VAX-ID in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
11377249|NCT02186977|Experimental|Intradermal group (VAX-ID) B|These subjects will receive two intradermal injections with two newly developed intradermal injection devices VAX-ID in both forearms each 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
11377250|NCT02186964|Experimental|tension free primary closure|patients treated by tension free primary closure
11377251|NCT02186964|Experimental|karydakis|patients treated by Karydakis method
11377252|NCT02186964|Experimental|Limberg flap|patients treated by Limberg flap procedure
11377253|NCT02186951|Experimental|Amoxicillin clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
11377254|NCT02186951|Placebo Comparator|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
11377255|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
11377256|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
11377257|NCT02186925||Bladder, Kidney and Prostate Cancer Patients|
11377258|NCT02186912|Experimental|mandible|Nobel Active Nobel Procera IBO
11377259|NCT02186912|Experimental|maxilla|Nobel Active Nobel Procera IBO
11377260|NCT02186899|Active Comparator|General Anesthesia Femoral continuous|General anesthesia plus continuous femoral nerve block
11377261|NCT02186899|Active Comparator|General anesthesia Femoral bolus|General anesthesia plus single shot femoral nerve block
11377262|NCT02186899|Active Comparator|Femoral Sciatic Obturator Nerve block|Ultrasound guided femoral plus sciatic plus obturator nerve block
11377263|NCT02186886|Other|Golimumab|Golimumab: Patients with body weight less than 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter // Patients with body weight greater than or equal to 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter
11377931|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
11377265|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
11377266|NCT02186860|Experimental|Third generation CAR-T cells|Patients receive third generation CAR-T cells transduced with a lentiviral vector on days 0, 2, 4 and 6 in the absence of disease progression or unacceptable toxicity Intervention: Genetic: CAR-T Cells
11377267|NCT02186847|Active Comparator|Chemoradiation|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
11377268|NCT02186847|Experimental|Metformin + Chemoradiation|Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
11377269|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).
~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
11377270|NCT02186821|Experimental|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
11377271|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
11377272|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
11377273|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
11377274|NCT02186782|Active Comparator|Clomiphene citrate-Estradiol group|Women will receive clomiphene citrate and estradiol
11377275|NCT02186782|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate and placebo
11377276|NCT02186769|Active Comparator|Risperdal® Consta®|25 Mg or 50 mg
11377277|NCT02186769|Experimental|L03004|25 mg or 50 mg
11377278|NCT02186756|Experimental|EMG-Biofeedback and Usual Care|"Patients in the intervention group started EMG-biofeedback training within three days after inclusion. In total 14 sessions of EMG-biofeedback training were applied. They started with three sessions of therapy in week 1-3 and had one session per week in week 4-8.
~Patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 minutes per day. Additionally, they should try to apply the techniques in stressful situations, for example appointments at the dentist's."
11377279|NCT02186756|No Intervention|Usual care|The patients in the control group had only two encounters with the therapist in the eight week interval. At these encounters pain was assessed by a visual analogue scale and their trapezius muscle activity was measured during 5 minutes analogously to the intervention group. However, afterwards they did not continue with muscle straining and relaxation.
11377280|NCT02186743|Experimental|Intervention Diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
11377281|NCT02186743|Active Comparator|Active control diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
11377282|NCT02186730|Experimental|Stressbsuters|"Computerised Cognitive Behaviour package consisting of eight 30-45 minute sessions of CBT designed for 12-18 year olds. Each Stressbusters session is an interactive presentation featuring narration synchronised with videos, animations, graphics and printouts.
~The programme has a narrator guiding individuals through each of the eight sessions in a linear progression. Each session builds on the knowledge gained in previous sessions and on tasks carried out at home. Sessions contain flexible add-ons such as written fact sheets (for example about bullying, sleep problems) which can be printed out and taken away together with home practice related handouts from the programme (for example mood diary sheets). Session topics include getting activated, relapse prevention, challenging negative thoughts and problem solving"
11377283|NCT02186730|Active Comparator|Websites|Any individuals randomised to arm 2 of the trial will spend the equivalent time accessing currently available self help websites that provide information about low mood/depression. These four websites will be the same as those used in our initial feasibility study of which, based on our preliminary data, there is evidence for their usefulness.
11377284|NCT02186717|Experimental|Chewing gum|Chewing gum
11377285|NCT02186717|No Intervention|No Chewing Gum|No Chewing Gum
11377286|NCT02186704||ICD with DX system|Implantable cardioverter-defibrillator recipients with DX system
11377287|NCT02186704||Dual chamber ICD|Dual chamber implantable-cardioverter-defibrillator recipients (retrospective cohort from IMPACT study)
11377288|NCT02186704||Single chamber ICD|Single chamber implantable cardioverter-defibrillator recipients (retrospective cohort from Cornell registry)
11377289|NCT02186691|Experimental|RV and LV ejection fraction assesment|assesment RV and LV ejection fraction after PVR measured by MRI
11377290|NCT02186678|Experimental|assesment by 68Ga-DOTATATE PET-CT|
11377291|NCT02186665|Experimental|calcitriol ointment|calcitriol 3 mcg/g ointment
11377292|NCT02186665|Placebo Comparator|placebo|placebo comparator
11377293|NCT02186652|Other|Pantoprazole|
11377294|NCT02186639||COPD|40 COPD patients (20 non-frequent and 20 frequent-exacerbators). No intervention.
11377295|NCT02186639||Controls|"Subjects with no apparent lung disease and normal lung function testing. Matched for age, gender and smoking history (pack years).
~No intervention."
11377333|NCT02186353|Experimental|Intact/minimally processed whole grains|Partial feeding study
11377296|NCT02186626|Experimental|WN/DEN4Δ30 Vaccine|Participants will receive one dose of the WN/DEN4Δ30 vaccine at study entry and one dose at Day 180.
11377297|NCT02186626|Placebo Comparator|Placebo|Participants will receive one dose of the placebo at study entry and one dose at Day 180.
11377298|NCT02186613|Experimental|Experimental|These mothers and their babies will receive Primary Care standard care (office visits at 1, 2, 4 and 6 months) plus the telephone support
11377299|NCT02186613|No Intervention|No intervention|Standard care (office visits at 1, 2, 4 and 6 months)
11377300|NCT02186600|Active Comparator|Control|Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have ~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
11377301|NCT02186600|Experimental|Risedronate|"Subjects in the risedronate group will take 35 mg of the bisphosphonate risedronate weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes."
11377302|NCT02186600|Experimental|Exercise|Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.
11377303|NCT02186587|Other|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
11377304|NCT02186574|Active Comparator|Pre-emptive tenofovir|Tenofovir disoproxil
11377305|NCT02186574|Placebo Comparator|Placebo|Placebo
11377306|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
11377307|NCT02186548|Active Comparator|Closed surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo closed surgical exposure, which is an intervention to correct the position of PDC:s.
11377308|NCT02186548|Active Comparator|Open surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo open surgical exposure, which is an intervention to correct the position of PDC:s.
11377309|NCT02186535|Other|Daily dosing|Daily oral capsule of Vitamin D in 4000 IU/day with daily oral capsules of 1000mg of calcium
11377310|NCT02186535|Other|weekly dosing|Oral capsule Vitamin D 50,000 IU/week with a oral capsule of 1000mg of calcium, daily
11377311|NCT02186522||Critical Care Patients|Patients staying in the ICU for at least 48 hours, requiring external support of one or more organs (invasive ventilation, inotropes/vasopressors or renal replacement therapy) and who are not expected to die within 48 hours of study entry.
11377312|NCT02186509|Experimental|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
11377313|NCT02186496|Experimental|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
11377314|NCT02186496|Experimental|CKD-330|CKD-330 8/5mg, PO, 1days or 22days
11377315|NCT02186483|Experimental|Metformin|Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration
11377316|NCT02186483|Experimental|Rosuvastatin|Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin
11377317|NCT02186483|Experimental|Co-administration|Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin
11377318|NCT02186470|Experimental|Treatment (image-guided intensity-modulated APBI)|Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
11377319|NCT02186457|Experimental|Polymyxin B in Normal Saline|Polymyxin B (500,000 U) in 1 liter of 0.9% Normal Saline
11377320|NCT02186457|Placebo Comparator|Placebo: Normal Saline|0.9 % Normal Saline
11377321|NCT02186444||PHI Navigator|Personalized Health Information Navigator (PHIN).
11377322|NCT02186444||NCI Information Booklets (IB)|National Cancer Institute (NCI) Information Booklets (IB).
11377323|NCT02186431|Experimental|history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events
11377324|NCT02186431|Active Comparator|without a history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers without a history of corneal infiltrative events.
11377325|NCT02186418|Experimental|ARU-1801|Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
11377326|NCT02186405|Experimental|LEVOTHYROXINE|administration of levothyroxine
11377327|NCT02186392|No Intervention|Control department|The control department where the conventional light is installed.
11377328|NCT02186392|Experimental|Circadian Light luminaries|The department where the special circadian light is installed. The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
11377329|NCT02186379|Experimental|RePace Intervention Group|"Re-Pace intervention-five weekly intervention sessions lasting about 1 hour each.
~Lab Test Meal-2 test meals 6-8 weeks apart."
11377330|NCT02186379|Active Comparator|Usual Care Control Group|One 25 minute education session (week 6) 2 lab test meals 6-8 weeks apart (baseline and week 6)
11377331|NCT02186366|Experimental|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
11377332|NCT02186366|Active Comparator|Buspirone|Buspirone by mouth 5mg three times per day for 6week
11377932|NCT02182479|Experimental|Berodual® via Respimat®, high dose|
11377337|NCT02186327|No Intervention|Standard care|The control arm will continue to receive standard care as they did prior to enrollment.
11377338|NCT02186327|Experimental|Integrative health coaching|Subjects in this arm will receive 6 sessions of integrative health coaching over a 3 month period, in addition to standard care.
11377339|NCT02186314|Active Comparator|Apical stimulation|Pacemaker Biotronik: apical stimulation
11377340|NCT02186314|Active Comparator|Bifocal stimulation|Pacemaker Biotronik: bifocal stimulation
11377341|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
11377342|NCT02186301|Experimental|Rociletinib Mono-Therapy|
11377343|NCT02186288||Adult ICU patients|
11377344|NCT02186275|Experimental|Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day|"3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UIday as maintenance therapy for 48 weeks.
~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
11377345|NCT02186275|Active Comparator|Vitamin D3 800 UI/day then 800 UI/day|800 UI/day as induction therapy for 4 weeks, then 800 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).
11377346|NCT02186262||Primary gliomas, Recurrent gliomas|
11377347|NCT02186236||Lung and Colorectal cancer patients|Eligible people who consent to participation will provide urine (both in lung cancer and colorectal cancer) and blood (in lung cancer only) samples at pre-specified times.
11377348|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
11377349|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
11377350|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
11377351|NCT02186197||Shock and/or Respiratory Failure|
11377352|NCT02186184|Experimental|Orthokeratology in the first year|The participants would wear orthokeratology in the first year and then switch to spectacle in the second year
11377353|NCT02186184|Active Comparator|Spectacle in the first year|The participants would wear spectacle in the first year and then changed to orthokeratology in the second year
11377354|NCT02186171|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
11377355|NCT02186171|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
11377356|NCT02186158|Experimental|Vitamin C|Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime.
11377357|NCT02186158|Placebo Comparator|Placebo|Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime.
11377358|NCT02186145|Experimental|Association of metronidazole; nystatin and dexamethasone|Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
11377359|NCT02186145|Active Comparator|Flagyl|Vaginal cream of metronidazole 500 mg, nystatin 100.000 UI - once a day. Period: 10 days
11377360|NCT02186132|Experimental|Atropine 0.6 mg|Atropine 0.6 mg intravenous
11377361|NCT02186132|Active Comparator|Atropine 1.2 mg intravenous|Atropine 1.2 mg intravenous
11377362|NCT02186119|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, and 20, followed by a sham procedure at weeks 12, 16, and 24.
11377363|NCT02186119|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
11377364|NCT02186119|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
11377365|NCT02186119|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
11377366|NCT02186106|Experimental|Loading dose substitution|Substituted with a highdose of cholecalciferol at study start
11377367|NCT02186106|No Intervention|Historic controls|Control subjects from journal archive
11377368|NCT02186093||Korea|patients in South of Korea
11377369|NCT02186093||United Kingdom|patients in England
11377370|NCT02186093||Spain|patients in Spain
11377371|NCT02186093||United State of America|patients in USA
11377372|NCT02186080|Experimental|Gemigliptin|Gemigliptin 50mg qd added to subjects current diabetes treatment
11377373|NCT02186080|Placebo Comparator|Placebo|Placebo (identical in appearance to gemigliptin)
11377374|NCT02186067|Experimental|Referral System|"Referral System:
~Primary Level Secondary Level Tertiary Level"
11377375|NCT02186067|No Intervention|Control|Usual/routine care will be provided to the patients
11377376|NCT02186054|Other|Imaging- MRI examinations|Liver MRI imaging will be performed on 50 patients.
11377377|NCT02186041||De-Novo patients|Patients tested and de novo implanted with Interstim®. These patients will be followed-up for 5 years after the implant visit.
11377378|NCT02186041||Device replacement|Patients implanted with Interstim® for a device replacement. These patients will be followed-up for 5 years after the implant visit.
11377379|NCT02186041||Not-implanted patients|Patients who are tested and are not implanted with the Interstim® system. The data of the follow up of the test will be captured up to one year after the end-test visit
11377380|NCT02186028|Experimental|Vitamin D 400 IU|"Vitamin D-400IU/ml- 1ml daily
~Neonates will be administered Vitamin D 400 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
11377400|NCT02185924|Experimental|CONTINUOUS FEMORAL BLOCK AND PARECOXIB|Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib
11377381|NCT02186028|Active Comparator|Vitamin D 200IU|"Vitamin D 400IU/ml : 0.5ml daily
~Neonates will be administered Vitamin D 200 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
11377382|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
11377383|NCT02186002|Experimental|Group 1|A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
11377384|NCT02186002|Experimental|Group 2|A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
11377385|NCT02186002|Experimental|Group 3|A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
11377386|NCT02186002|Experimental|Group 4|A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
11377387|NCT02186002|Experimental|Group 5|A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
11377388|NCT02186002|Experimental|Group 6|A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
11377389|NCT02185989|Active Comparator|Electrical muscle stimulation and bicycling|Patients will undergo early electrical stimulation of the quadriceps and early leg bicycling in addition to routine care (which comprises early standard mobilization)
11377390|NCT02185989|No Intervention|Standard early passive/active rehabilitation|In this control group, patients will undergo routine care that comprises standard early passive/active rehabilitation delivered by physiotherapist with the assistance of ICU nurses
11377391|NCT02185976|Active Comparator|cartoon|paediatric patients undergoing general anesthesia. This group will choose a cartoon movie to watch throughout the preparation until the induction of anesthesia
11377392|NCT02185976|No Intervention|routine|paediatric patients undergoing general anesthesia
11377393|NCT02185963|Experimental|Rosuvastatin|Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors
11377394|NCT02185950|Experimental|Ultrasound group|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm, and the application parameters with a matched control side of the patient, in a region with contralateral uninjured skin.
11377395|NCT02185950|Experimental|Group paraffin|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.
11377396|NCT02185950|Experimental|Ultrasound group + endermotherapy|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm. The application of endermotherapy will be held shortly after the therapeutic ultrasound in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
11377397|NCT02185950|Experimental|Group paraffin + endermotherapy|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.The application of endermotherapy will be held shortly after the paraffin therapy in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
11377398|NCT02185937|No Intervention|water|imatinib intake with water
11377401|NCT02185924|Placebo Comparator|CONTINUOUS FEMORAL BLOCK AND PLACEBO|Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%
11377402|NCT02185911||Cohort 1|Patients with CKD
11377403|NCT02185898|Active Comparator|Leading U.S. tobacco-burning non-menthol cigarette|Leading U.S. non-menthol cigarette
11377404|NCT02185898|Active Comparator|Leading U.S. tobacco-burning menthol cigarette|Leading U.S. menthol cigarette
11377405|NCT02185898|Experimental|Electronic cigarette #1|VUSE® (menthol flavor, 29 mg nicotine)
11377406|NCT02185898|Experimental|Electronic cigarette #2|VUSE® (original flavor, 29 mg nicotine)
11377407|NCT02185898|Experimental|Electronic cigarette #3|VUSE® (original flavor, 14 mg nicotine)
11377408|NCT02185898|Experimental|U.S. Market-sample electronic cigarettes (two brands)|blu™ (any variety) and NJOY® (any variety)
11377409|NCT02185885|Experimental|Increased bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted according to department guidelines with the modification that MAP is kept between 70 and 80 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
11377410|NCT02185885|No Intervention|Regular bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted in accordance with departmental guidelines, where MAP is sought to be ≥ 45 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
11377411|NCT02185872|Active Comparator|Aerobic and Resistance Training|Participants completed 24 exercise sessions based on current guidelines. Aerobic exercise (50 min) was performed on machines every session and resistance training (20 min) was performed on machines two sessions per week. Aerobic intensity was prescribed at 40-50% of heart rate reserve (HRR) Weeks 1-4 and 50-60% HRR Weeks 5-8. Resistance training was supervised by an ACE certified personal trainer. One-repetition maximums (1-RM) were assessed Week 1 (i.e., seated bicep curl, military press, seated lat pulldown, seated leg extension, triceps pulldown, bench press, reverse leg curl, seated leg press). For Weeks 2-3 participants completed, 3 sets of 15 reps at 50% 1-RM; Weeks 4-5, 3 sets of 12 reps at 60% 1-RM; Weeks 6-7, 3 sets of 10 reps at 70% 1-RM; Week 8, 3 sets of 8 reps at 75% 1-RM. Three sets of 15 unweighted crunches were completed each day. One minute of rest was taken between each set and each exercise.
11377412|NCT02185872|Experimental|High-intensity functional training|Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
11377413|NCT02185859|Experimental|Perioperative lidocaine infusion|
11377414|NCT02185859|Experimental|Perioperative magnesium infusion|
11377415|NCT02185859|Active Comparator|Noraml saline infusion|
11377416|NCT02185846|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
11377417|NCT02185846|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.Ve Tic. A. Ş., Turkey, one tablet, once
11377418|NCT02185833|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
11377419|NCT02185833|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
11377420|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:
~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).
~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.
~Treatment schedule for maintenance until progression or intolerance:
~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.
~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
11377421|NCT02185807|Active Comparator|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians, and receive face- to face discussion with their physicians as well.
11377422|NCT02185807|Placebo Comparator|control group|The control patients receive verbal information and discussion from their physicians.
11377423|NCT02185794|Placebo Comparator|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
11377424|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
11377425|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
11377426|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
11377427|NCT02185794|Placebo Comparator|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
11377428|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
11377429|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
11377430|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
11377460|NCT02185638|Placebo Comparator|Placebo|"Placebo (2 capsules). Each capsule contains:
~Rice Flour"
11377431|NCT02185794|Placebo Comparator|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
11377432|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
11377433|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
11377434|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
11377435|NCT02185794|Experimental|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
11377436|NCT02185794|Experimental|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
11377437|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
11377438|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
11377439|NCT02185781|Experimental|Autologous NK Cells infusions|
11377440|NCT02185768|Experimental|DC-BEADS + Idarubicin|Chemoembolization with DC BEAD loaded with idarubicin
11377441|NCT02185755|Active Comparator|Internet-Based Glucose Monitoring System|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
11377442|NCT02185755|Other|Normal Medication Positive Control|The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
11377443|NCT02185742|Experimental|Strength Based Case Management|Strength Based Case Management
11377444|NCT02185742|No Intervention|Contemporary, HIV+ Jail Detainees|No intervention
11377445|NCT02185729|Active Comparator|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
11377446|NCT02185716|Active Comparator|local infiltration|Group L (n=25) will be given total 30 ml 0.25 % levobupivacaine infiltration around trocar-site with injector in sterilized conditions without administering TAP block at the end of the operation
11377447|NCT02185716|No Intervention|Control|Only routine general anesthesia will be applied
11377448|NCT02185716|Experimental|TAP|Group T (n=25) will be given bilateral total 30 ml 0.25 % levobupivacaine administering TAP block under the guidance of ultrasound at the preoperative period.
11377449|NCT02185703|Experimental|Chordate System S020 in treatment mode|
11377450|NCT02185703|Sham Comparator|Chordate System S020 in placebo mode|
11377451|NCT02185690|Other|Binimetinib efficacy/safety|"This is a Phase I/Ib, open-label, dose-escalation, multi-center, non-randomized study designed to evaluate the safety and tolerability of oral Binimetinib in combination with carboplatin and pemetrexed.
~Phase I part A standard 3+3 dose-escalation will be used to determine the maximum administered dose (MAD) and the RP2D for the combination in subjects with advanced non-squamous lung carcinoma.
~Phase Ib part Once RP2D has been identified, an expansion cohort will be accrued; these patients will be stratified by KRAS genotype.
~The RP2D will be expanded by enrolling additional patients, stratified by KRAS genotype, to a total of 30 patients eligible for the safety set (including those treated at the same dose combination in the dose-escalation phase of the study who are eligible for the safety set) to be evaluated for safety, tolerability, pharmacokinetics and biologic activity of MEK162."
11377452|NCT02185677||MSA-P|
11377453|NCT02185677||MSA-C|
11377454|NCT02185664|Active Comparator|Landmark technique|The landmark technique is the standard technique used for internal jugular vein cannulation.
11377455|NCT02185664|Experimental|Static Ultrasound technique|Static ultrasound technique was used to assist internal jugular vein cannulation.
11377456|NCT02185651|Active Comparator|Zavesca® 100 mg|"3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.
~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
11377457|NCT02185651|Active Comparator|Zavesca® 300 mg|"3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.
~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
11377458|NCT02185638|Experimental|A20-50|"A20-50 (2 capsules). Each capsule contains:
~Yerba Mate (Ilex paraguariensis), Guarana seed (Paullinia cupana), Magnesium Oxide , Caffeine , Damiana (Turnera microphylla), Green tea (Camellia sinensis), Ginger (Zingiber Officinale), Kola nut (Cola acuminate or nitida), Pyridoxine Hydrochloride, Tibetan Ginseng root (Rhodiola crenulata), Schisandra (Schisandra Chinensis), Jujube (Ziziphus Jujuba) , Cocoa nut (Theobroma cacao), Chinese Skullcap (Scutellaria Baicalensis), Black tea leaf (Thea sinensis), Rice flour (to fill)
~Dose = 2 capsules have a total of 200 mg of caffeine"
11377459|NCT02185638|Active Comparator|YGD|"YGD blend (2 capsules). Each capsule contains:
~Yerba Maté (leaf) , Guarana (seed) , Damiana (leaf) , Rice flour: to fill ,
~The 2 capsules of the YGD blend contain about 40 mg xanthines (caffeine and caffeine-like stimulants)."
11377463|NCT02185612|No Intervention|Control|Participants will be randomized to a 1 year wait list. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
11377464|NCT02185612|Experimental|Savings program|Participants will be randomized to the EARN.org online savings program for 6 months. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
11377465|NCT02185599||Colposcopy with DySIS|The prospective arm will recruit patients referred for colposcopy and will be examined using DySIS.
11377466|NCT02185599||Standard colposcopy|The retrospective arm will collect historical data from colposcopy examinations performed using a standard colposcope.
11377467|NCT02185586|Experimental|LALC|lower abdominal laparoscopic cholecystectomy
11377468|NCT02185586|Experimental|SLC|single laparoscopic cholecystectomy
11377469|NCT02185586|Placebo Comparator|UALC|upper abdominal laparoscopic cholecystectomy
11377470|NCT02185573|No Intervention|Conventional Technique|Multi-layer filling technique
11377471|NCT02185573|Active Comparator|Bulk fill technique|Bulk fill technique
11377472|NCT02185573|Experimental|SonicFill technique|SonicFill technique
11377473|NCT02185560||BAY43-9006|NEXAVAR treatment group
11377474|NCT02185547|Experimental|ICBT in combination with sertraline treatment|Internet cognitive behavioral therapy in combination with sertraline treatment
11377475|NCT02185547|Active Comparator|ICBT|Only Internet cognitive behavioral treatment, no additional depression treatment
11377476|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
11377477|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
11377478|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
11377479|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.
~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
11377480|NCT02185508||Lumbar spine surgery with IONM|Patients diagnosed with 1 or 2 level lumbar disk disease and radicular symptoms who underwent decompressive surgery, and for whom IONM records exist.
11377481|NCT02185495|Experimental|High-risk individuals|"The elder and heavy smokers, which are high-risk individuals for early lung cancer. These subjects will be examined using Observer nodule detection and  Computer-aided nodule detection."
11377482|NCT02185482|Experimental|Physician Supported Care|The intervention is an individualized, stepped-care depression treatment program provided by a depression clinical specialist primary care physician.
11377483|NCT02185482|Other|Usual care|Usual care patients will be advised to consult with their primary care physician regarding depression. Primary care physicians prescribe antidepressant medication and can refer patients to the Mental Health Services.
11377484|NCT02185469|Active Comparator|pneumatic retinopexy group|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
11377485|NCT02185469|Active Comparator|vitrectomy group|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
11377486|NCT02185456|No Intervention|Healthy|Patients with no history of bacterial vaginosis. These women will be monitored monthly and with daily self swabs.
11377487|NCT02185456|Active Comparator|G1 BV in clinical & molecular remission|Patients will receive standard of care intervention, oral metronidazole 500 mg twice a day for 7 days. They will then be monitored to confirm that initial BV treatment was effective by Nugent and Amsel, and by the qPCR test (LbRC). These will be monitored with monthly visits and daily self swabs. Those who recur with symptomatic BV may enroll in the B2 arm for more aggressive treatment.
11377488|NCT02185456|Experimental|G2. Molecular conversion subarm|Half of G1 patients who convert to poor qPCR test results while remaining asymptomatic will be randomized into this G2 arm and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days, with continued monthly visits and daily swabs.
11377489|NCT02185456|Active Comparator|B1 Initially poor qPCR responders|The B1 arm are patients who enter remission after standard of care treatment, oral metronidazole 500 mg twice a day for 7 days, but who have poor initial qPCR scores. Half of such patients will be randomized into B1, half into B2. B1 patients will be monitored with monthly visits and via daily swabs, but will receive no further treatment while BV negative. Patients who recur with BV may enroll as B2 patients for more aggressive treatment.
11377490|NCT02185456|Experimental|B2 BV Remission to conversion|A subgroup of B1 patients who convert to consistently poor qPCR scores during the study (conversion) will be randomized into Arm B2 and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days. These patients will continue monthly visits and daily self swabs. B2 patients who recur with symptomatic BV will be dropped from the study and given other options for therapy.
11377491|NCT02185443|Experimental|SBRT|
11377492|NCT02185430|Placebo Comparator|Control group|saline solution
11377493|NCT02185430|Active Comparator|dexmedetomidine group|dexmedetomidine
11377494|NCT02185417|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study
11377495|NCT02185417|Active Comparator|Chlorthalidone|Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study
11377516|NCT02185261|Experimental|interferon Alfa-2b group|Acute leukemia patients who are minimal residual disease positive after hematopoietic stem cell transplantation receive interferon Alfa-2b
11377933|NCT02182479|Experimental|Berodual® via Respimat®, low dose|
11377496|NCT02185404|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
11377497|NCT02185391|Experimental|fact-finding group|Intervention: Audience Response System and motivational telephone interview
11377498|NCT02185391|No Intervention|control group|
11377499|NCT02185378|Active Comparator|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
11377500|NCT02185378|Active Comparator|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
11377501|NCT02185365||Developmental dysplasia of the hip (DDH)|Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
11377502|NCT02185352|Experimental|Inductional BEEP regimen|"Induction BEEP regimen:
~Every 3 weeks a cycle for a total of 3 cycles (around 2 months)
~Bevacizumab 15mg/kg IVF on D1
~Etoposide 70 mg/m2 IVF QD, D2-4
~Cisplatin 70 mg/m2 IVF on D2
~WBRT:
~3000cGy in 10 fractions"
11377503|NCT02185352|No Intervention|WBRT alone|"standard WBRT:
~3000cGy in 10 fractions"
11377504|NCT02185339|Experimental|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is > or < than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
11377505|NCT02185339|Active Comparator|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count >2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is > or < than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
11377506|NCT02185326|Experimental|Microflare and growth hormone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
11377507|NCT02185326|No Intervention|Microflare protocol alone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later
11377508|NCT02185313|Experimental|gaze holding|
11377509|NCT02185300|Experimental|Sequence ABCDE|Subject will be administered treatments in the sequence ABCDE where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 minutes(mins), re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 minutes, re-dispersed, and then taken by subject
11377510|NCT02185300|Experimental|Sequence BCDEA|Subject will be administered treatments in the sequence BCDEA where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
11377511|NCT02185300|Experimental|Sequence CDEAB|Subject will be administered treatments in the sequence CDEAB where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
11377512|NCT02185300|Experimental|Sequence DEABC|Subject will be administered treatments in the sequence DEABC where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
11377513|NCT02185300|Experimental|Sequence EABCD|Subject will be administered treatments in the sequence EABCD where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
11377514|NCT02185287||Lower urinary tract dysfunction, female, age: 18-40 years|
11377515|NCT02185287||Healthy female subjects, age: 18-40 years|
11377596|NCT02184637|Experimental|Cohort 5 - TQ alone|A single dose of Tafenoquine will be administered on Day 1
11377517|NCT02185248|No Intervention|Control Group|General clinical counseling in regards to child's BMI category and necessary changes to diet and activity regimen.
11377518|NCT02185248|Experimental|Wellness Plan|Received a wellness action plan. The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
11377519|NCT02185235|Experimental|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
11377520|NCT02185235|Active Comparator|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
11377521|NCT02185222|Experimental|Cholecalciferol 100 000 UI (Unité Internationale)|Oral solution in single-dose : 100 000 UI per month
11377522|NCT02185222|Placebo Comparator|Placebo|Oral solution in single-dose per month
11377523|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
11377524|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
11377525|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
11377526|NCT02185196|Active Comparator|Vitamin D3|Vitamin D3, Doses form: 20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
11377527|NCT02185196|Placebo Comparator|Miglyol-oil|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
11377528|NCT02185183|Experimental|AlequelTM|AlequelTM
11377529|NCT02185170|Experimental|Fluorescence assesment|"All patients undergo a transurethral resection.
~There are four different steps in the study:
~the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,
~the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,
~the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,
~the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner."
11377530|NCT02185157|Experimental|Experimental: Dual Task exercises|Dual-task training, includes 18 sessions model of cognitive and 12 motor dual-task exercises model, were administered in groups of four participants in a comfortable environment, without distraction effects. The 50-minute sessions included 30 minutes of motor dual-task exercises, and then, the participants were divided into pairs. The first pair performed free walks during 10 minutes at their maximal speeds, while the other received individual cognitive dual-task training for the same time, and these activities will be exchanged, so that all pairs could walk and receive cognitive training.
11377531|NCT02185157|Other|Control intervention: Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
11377532|NCT02185144|Experimental|PATH for Triples (PFT)|The Nurse Health Navigator (NHN) meets at least weekly with the experimental participants to implement the adherence component of PFT using approaches tailored to the communication and comprehension of the person that includes memory aids, education regarding side effects and other treatment aspects, engagement with participants' social networks and treatment providers, and active community outreach. PFT will be implemented for 6 months and participants will be followed for an additional 3 months to allow examination of potential decay of the intervention after it is withdrawn.
11377533|NCT02185144|Placebo Comparator|Treatment as Usual (TAU)|Participants in the the Treatment as Usual (TAU) group receive usual treatment after inpatient care.
11377534|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
11377535|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
11377536|NCT02185118|Experimental|oxygen plus isoflurane/sevoflurane|"All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.
~The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients."
11377537|NCT02185105|Experimental|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
11377538|NCT02185105|Active Comparator|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
11377539|NCT02185092|Placebo Comparator|Sugar Pill|1 pill orally daily
11377540|NCT02185092|Active Comparator|Lactobacillus GG|1 pill (2 x 10x 9 CFU) daily orally
11377541|NCT02185079|Active Comparator|Group C|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
11377542|NCT02185079|Experimental|Group M|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be subjected to training to proficiency based on the metrics developed for labor epidural catheter placement in a epidural simulator.
11377543|NCT02185066|Experimental|Group 1|"Single-dose crossover
~Reference: Atorvastatin 20mg and Metformin XR 500mg
~Test: CJ-30056 20/500mg
~Once daily Oral administration with 7days of washout period"
11377544|NCT02185066|Experimental|Group 2|"Single-dose crossover
~Test: CJ-30056 20/500mg
~Reference: Atorvastatin 20mg and Metformin XR 500mg
~Once daily Oral administration with 7days of washout period"
11377545|NCT02185053|Experimental|CPC-201|
11377546|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
11377690|NCT02184000||3. pacients with liver cirrhosis type B or C|
11377547|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)
~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
11377548|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days
~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
11377549|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
11377550|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
11377551|NCT02185027||complications and compliance with GIHP recommendations|Description at 1 month post-intervention of an potential event
11377552|NCT02185014|Other|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
11377553|NCT02185001|Active Comparator|Surgical Treatment Group|Direct Medial Patellofemoral Ligament (MPFL) Repair
11377554|NCT02185001|Active Comparator|Conservative Treatment Group|Immobilization, stabilization bracing, and physical therapy
11377555|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
11377556|NCT02184975|Experimental|Stitches|Cold Knife Conization with stitches
11377557|NCT02184975|Active Comparator|No stitches|Cold Knife Conization without stitches
11377558|NCT02184949||Primary Sample|All percutaneous coronary intervention patients who meet the primary eligibility criteria for this study.
11377559|NCT02184949||Subsample|Patients drawn from the main sample who specifically underwent a primary percutaneous coronary intervention procedure.
11377560|NCT02184936||acute ischemic stroke|
11377561|NCT02184923|Experimental|verticality measurements|
11377562|NCT02184910||gastritis and pepsinogen|
11377563|NCT02184897|Active Comparator|AM group|Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
11377564|NCT02184897|Experimental|PM group|Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
11377565|NCT02184884||MACE group|the patients with MACE after OPCAB
11377566|NCT02184884||no MACE group|the patients without MACE after OPCAB
11377567|NCT02184871||intrahepatic cholangiocarcinoma|Patients committed to surgery and stratified according to exposure to different risk factors for ICC, basing on modified ReNaM questionnaire.
11377568|NCT02184858|Experimental|lisinopril|dose titration of investigational product (lisinopril) dependant on blood pressure, levels of renin and aldosterone and on adverse events.
11377569|NCT02184845|Experimental|NobelActive 3.0|
11377570|NCT02184832|Experimental|Low tryptophan diet|2 days of a low tryptophan diet
11377571|NCT02184832|Experimental|High tryptophan diet|2 days of a high tryptophan diet
11377572|NCT02184819|Active Comparator|levosimendan|study drug
11377573|NCT02184819|Placebo Comparator|placebo|placebo group
11377574|NCT02184806|Experimental|1- orthotopic graft|
11377575|NCT02184806|Experimental|2- heterotopic graft|
11377576|NCT02184793|Other|EMD (Inclinomax) then usual care|"EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.
~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h."
11377577|NCT02184793|Other|usual care then EMD (Inclinomax)|"Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.
~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h."
11377578|NCT02184780||GUSTO Neurocognitive Cohort|This study involves retrospective analysis of data from an existing cohort of 600 infants who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in Singapore, where subjects were followed up from in-utero up to 36 months of age and beyond. The infants have already undergone a rigorous battery of neurocognitive tests at 6, 18, 24 and 36 months of age and their detailed demographic and medical information are available.
11377579|NCT02184767|Experimental|ADASUVE®|oral inhalation using a single-use, hand-held, inhaler; dosage determined by the investigator according the participants weight
11377580|NCT02184754||MEI|
11377581|NCT02184741|Placebo Comparator|Placebo|Infusion of normal saline
11377582|NCT02184741|Experimental|GB-0998|Infusion of GB-0998 (Immunoglobulin)
11377583|NCT02184728|No Intervention|EMMA(TM)|"A small capnograph for measuring ET-CO2 - the EMMA capnometer
~1"
11377584|NCT02184715|Active Comparator|Virtual reality video game|Participants received rehabilitation treatment and additional virtual reality system (30 minutes of interactive virtual reality system play, two times per week, in eight sessions over a 4-week span) for 1 month, followed by rehabilitation treatment for 1 month
11377585|NCT02184715|Placebo Comparator|Virtual reality system|received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system (30 minutes of interactive video game play, two times per week, in eight sessions over a 4-week span) during the one month of intervention period.
11377586|NCT02184702||shoulder arthroscopy|
11377587|NCT02184689|Experimental|Fexinidazole|
11377588|NCT02184676|Other|Children born to mother/father with type 1 diabetes|
11377589|NCT02184663|Active Comparator|Standard care without APA program|
11377590|NCT02184663|Experimental|standard care with APA program|
11377591|NCT02184650||Premature infants|Premature infants with a GA < 32 weeks
11377592|NCT02184637|Experimental|Cohort 1- TQ w/DHA+PQP|Tafenoquine (TQ) will be co-administered with Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) on Day 1. DHA+PQP alone will be administered at 24 hours (h) (Day 2) and 48 h (Day 3) post first dose administration.
11377593|NCT02184637|Experimental|Cohort 2 - TQ w/AL|Tafenoquine co-administered with Artemether + Lumefantrine (AL) on Day 1. AL alone will be administered at 8h (Day 1), 24h and 36h (Day 2), 48h and 60 h (Day 3) post first dose administration.
11377594|NCT02184637|Experimental|Cohort 3 - DHA+PQP alone|Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration
11377595|NCT02184637|Experimental|Cohort 4 - AL alone|Artemether + Lumefantrine will be administered on Day 1 and 8h, 24 and 36h (Day 2), 48h and 60 h(Day 3) post first dose administration
11377782|NCT02183389|Active Comparator|Treatment A: Warfarin|Warfarin as single dose
11377597|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
11377598|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
11377599|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
11377600|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
11377601|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
11377602|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
11377603|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
11377604|NCT02184598|Placebo Comparator|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
11377605|NCT02184598|Experimental|Cognitive training|Cognitive training with 6 different games each of which gets progressively more difficult as children obtain proficiency.
11377606|NCT02184585|Experimental|Cohort 1: Fasted state|Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
11377607|NCT02184585|Experimental|Cohort 2 : Fed state|Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
11377608|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
11377609|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
11377610|NCT02184559|Experimental|TAP block|
11377611|NCT02184559|Active Comparator|infiltration continues|
11377612|NCT02184533|Experimental|Treatment (sodium selenite and radiation therapy)|Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
11377613|NCT02184520|Active Comparator|TRANSITION|Stabilization System
11377614|NCT02184520|Active Comparator|REVERE|Stabilization System
11377615|NCT02184507|Experimental|Supplement pre CABG|Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
11377616|NCT02184507|Experimental|Supplement post CABG|Consumption of placebo 7 days before surgery and supplement 30 days post surgery
11377617|NCT02184507|Experimental|Supplement pre and post CABG|Consumption of the supplement 7 days before and 30 days post surgery
11377618|NCT02184507|Placebo Comparator|Placebo|Consumption of placebo 7 days before and 30 days post surgery
11377619|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
11377620|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
11377621|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
11377622|NCT02184481|Experimental|Working memory training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level adapted to the working memory capacity of the participant.
11377623|NCT02184481|Placebo Comparator|Placebo training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level in the placebo condition was easy and did not adapt to the working memory capacity of the participant.
11377624|NCT02184468|Other|Dual dispatch|Simultaneously dispatching of EMS, firefighters and/or police in OHCA
11377625|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
11377626|NCT02184442|Experimental|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
11377627|NCT02184442|Active Comparator|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
11377628|NCT02184429|Experimental|Single Ascending Dose-1|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
11377629|NCT02184429|Experimental|Single Ascending Dose-2|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
11377630|NCT02184429|Experimental|Multiple Ascending Dose-1|Daily dose of PF-06669571 in healthy volunteers
11377631|NCT02184429|Experimental|Multiple Ascending Dose-2|Daily dose of PF-06669571 in healthy volunteers
11377632|NCT02184429|Experimental|Multiple Ascending Dose-3|Daily dose of PF-06669571 in healthy volunteers
11377633|NCT02184429|Experimental|Multiple Ascending Dose-4|Daily dose of PF-06669571 in healthy volunteers
11377634|NCT02184429|Experimental|Multiple Ascending Dose-5|Daily dose of PF-06669571 in healthy volunteers
11377635|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:
~Sutent (prospective) - Inlyta
~Sutent (retrospective) - Inlyta
~Sutent - not further active treatment (supportive care)
~Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
11377636|NCT02184390|Experimental|tutorial|Parents who receive access to the tutorial immediately
11377637|NCT02184390|No Intervention|wait list control|Parents who are assessed at the same time points as the intervention arm, but do no receive access to the tutorial
11377638|NCT02184377||RLN+SLN paralysis|unilateral recurrent laryngeal and superior laryngeal nerve paralysis
11377639|NCT02184377||RLN paralysis|unilateral recurrent laryngeal nerve paralysis
11377640|NCT02184364|Experimental|Low dose of Klimadynon®|
11377641|NCT02184364|Experimental|Medium dose of Klimadynon®|
11377642|NCT02184364|Experimental|High dose of Klimadynon®|
11377643|NCT02184364|Active Comparator|Oestrofeminal®|
11377644|NCT02184364|Placebo Comparator|Placebo|
11377645|NCT02184351|Experimental|Roxanes's clotrimazole troches|
11377646|NCT02184351|Active Comparator|Mycelex® troches|
11377647|NCT02184338|Experimental|BIRB 1017 BS in single rising doses|
11377648|NCT02184338|Placebo Comparator|Placebo|
11377649|NCT02184325|Experimental|Kiddi® Pharmaton Fizz, effervescent tablets|with reduced amount of minerals
11377650|NCT02184325|Active Comparator|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
11377651|NCT02184325|Active Comparator|Comparator product|in the form of a product that is a market leader
11377652|NCT02184312|Experimental|Nevirapine XR low dose|
11377653|NCT02184312|Experimental|Nevirapine XR medium dose|
11377654|NCT02184312|Active Comparator|Nevirapine XR high dose|
11377655|NCT02184312|Active Comparator|Nevirapine (VIRAMUNE®)|commercial product
11377656|NCT02184299|Experimental|Nevirapine + Prednisone|"week 1-2: Nevirapine + Prednisone
~week 3-24: Nevirapine alone"
11377657|NCT02184299|Active Comparator|Nevirapine|week 1-24: Nevirapine
11377658|NCT02184286|Experimental|Nevirapine + Saquinavir-sgc|
11377659|NCT02184273|Experimental|Magnesium metamizol|
11377660|NCT02184273|Placebo Comparator|Placebo|
11377661|NCT02184260|Experimental|Metamizole|
11377662|NCT02184260|Placebo Comparator|Placebo|
11377663|NCT02184247|Experimental|anhydrous theophylline, 350 mg|
11377664|NCT02184247|Active Comparator|anhydrous theophylline, 300 mg|
11377665|NCT02184234|Experimental|Antistax film coated tablets|
11377666|NCT02184221|Experimental|High frequency stimulation|alpha burst, 8~12Hz, run 2 seconds, rest 8 seconds, lasts 20 minutes each time
11377667|NCT02184221|Active Comparator|Low frequency stimulation|0.5Hz, run 0.5 seconds, rest 1.5 seconds, lasts 20 minutes each time
11377668|NCT02184208||Device utlization following extubation|
11377669|NCT02184208||Pulmonary mechanics|
11377670|NCT02184195|Experimental|Olaparib|Olaparib tablets po. 300 mg twice daily
11377671|NCT02184195|Placebo Comparator|Placebo|Placebo tablets twice daily
11377672|NCT02184182|Experimental|VLS ablation/portal ligation/hepatectomy|"Step1:
~exploratory laparoscopy to exclude extrahepatic disease
~right portal vein ligation if surgically feasible
~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)
~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1
~Step 2: only if FRL/body weight > 0.5
~- laparoscopic/laparotomic right trisectionectomy"
11377673|NCT02184169|Experimental|HLHS|Patients undergoing palliative repair.
11377674|NCT02184169|Active Comparator|TGA|Surgical repair of TGA.
11377675|NCT02184156|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL intra-articular injection of Ampion
11377676|NCT02184156|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
11377677|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
11377678|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
11377679|NCT02184130|Experimental|TMS|
11377680|NCT02184117||All patients|Entire cohort undergoes paired testing
11377681|NCT02184104|Active Comparator|Aeroshot|A single 100 mg caffeine dose administered using the Aeroshot device.
11377682|NCT02184104|Active Comparator|Energy Drink|A single 100 mg caffeine dose administered as an oral solution.
11377683|NCT02184091|Experimental|Nevirapine|Single dose administration
11377684|NCT02184078|Experimental|single group|"Nevirapine:
~Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)
~Rifabutin:
~Study Days 0 to 42"
11377685|NCT02184065||Meloxicam|
11377686|NCT02184052||Meloxicam|
11377687|NCT02184026|Experimental|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
11377688|NCT02184000||1. the control group healthy adult volunteers|
11377689|NCT02184000||2. patients with chronic hepatitis B or C|
11377691|NCT02183987|Experimental|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
11377692|NCT02183987|No Intervention|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
11377693|NCT02183974|Experimental|Peptest|44 children at the age between 1 to 7 years diagnosed with bilateral or unilateral OME who underwent adenoidectomy and myringotomy with insertion of ventilation tube. Effusion was collected and analysed using Peptest, which contains monoclonal antibodies targeted against pepsin. Result of the Peptest was stated as positive (2 lines), negative (1 line) and invalid (no line).
11377694|NCT02183961|Experimental|Laryngopharyngeal reflux|EER was detected using three methods: oropharyngeal pH was monitored for 24 hours using the Restech system; detection of pepsin in middle ear fluid obtained during myringotomy was done using Peptest, and detection of pepsin in adenoid specimen was done immunohistochemically using antibody P3635Rb-h.
11377695|NCT02183948|Experimental|oxytocin|nasal spray
11377696|NCT02183948|Placebo Comparator|Placebo|nasal spray
11377697|NCT02183935|No Intervention|Lifestyle counseling, metformin|Age, gender and BMI matched controls will be managed by lifestyle counseling and metformin if indicated.
11377698|NCT02183935|Active Comparator|Duodeno - jejunal liner|Duodeno-jejunal liner (Endobarrier) will be implanted for the duration of 12 months. During this time subjects will be regularly monitored for investigated parameters. In addition, subjects will be carefully monitored upon device removal for additional 12 months.
11377699|NCT02183922|Placebo Comparator|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
11377700|NCT02183922|Experimental|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
11377701|NCT02183922|Experimental|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid group received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
11377702|NCT02183909|Experimental|Study intervention|
11377703|NCT02183896|Experimental|Platelet-rich plasma (PRP)|Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.
11377704|NCT02183896|Placebo Comparator|Saline|Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.
11377705|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
11377706|NCT02183870|Experimental|Crizotinib|Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
11377707|NCT02183857|Other|Ultrasound|Patients in group Ultrasound will have their femoral arterial lines inserted under the guidance of US. The Ultrasound equipment used is a SonoSite 180 PLUS with an L25/10- to 5-MHz linear array transducer (SonoSite, Inc., Bothell, WA)
11377708|NCT02183857|Other|Landmark|No Device is used. Patients in group Landmark will have their femoral line inserted using the blinded, external landmark-guided technique. After localization of the femoral artery by identifying the pulse in the femoral triangle immediately distal to the inguinal ligament.
11377709|NCT02183844|Experimental|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
11377710|NCT02183831||Capsular tension ring non insertion group|The patients who had same cataract surgery procedure without CTR insertion
11377711|NCT02183831||Capsular tension ring insertion group|The patients who underwent capsular tension ring insertion just before IOL implantation during cataract surgery
11377712|NCT02183818||Healthy nonsmokers|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
11377713|NCT02183818||Smokers with COPD|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
11377714|NCT02183805|Experimental|Metastatic triple negative breast cancer|Abraxane,Cyclophosphamide,Carboplatin
11377715|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
11377716|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
11377717|NCT02183779|Experimental|Reynaud|patients with reynaud phenomena
11377718|NCT02183779|Experimental|Healthy|Healthy volunteers
11377719|NCT02183766|Placebo Comparator|Maltodextrin|6 mL once a day diluted in juice during 30 days.
11377720|NCT02183766|Active Comparator|Galactooligosaccharide prebiotic|6 mL once a day diluted in juice during 30 days.
11377721|NCT02183753|Active Comparator|Wood smoke|The dose of WSP to be used (500 µg/m3 for 2 hours) is based on prior studies which indicate the exposure is well tolerated, and is similar to that found in some indoor exposures in homes heated by wood burning (24-26). The route of administration (breathing air containing WSP at rest, nasally) is intended to mimic natural exposures.
11377722|NCT02183753|Placebo Comparator|clean air|Chapel Hill air which has been filtered to remove ambient air pollutants.
11377723|NCT02183740|Experimental|Multifaceted educational program|"A multifaceted educational program for nursing home staff consisting of:
~One seven hours educational meeting (interactive workshop) conducted in the nursing home. Theoretical input and case-base discussions considering guidelines for nurse led assessment og interventions of patients fecal incontinence.The content will be made available as educational material.
~Recruitment of one local opinion leader per nursing home unit.
~Seven educational outreach meetings (1 hour 30 minutes per meeting) during the three months intervention period."
11377724|NCT02183740|No Intervention|Control|The control arm will not receive any educational program and will continue with usual care. Data with information about ordinary care will be gathered as part of the data collection procedure in the study.
11377783|NCT02183376|Experimental|BI 1356 - healthy subjects|
11377784|NCT02183376|Experimental|BI 1356 - mild liver impairment|
11377725|NCT02183727|Experimental|L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
11377726|NCT02183727|Active Comparator|Hamstring Autograft|Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.
11377727|NCT02183714|Experimental|Songha Night ®|
11377728|NCT02183714|Placebo Comparator|Placebo|
11377729|NCT02183701|Experimental|Telmisartan|4 weeks placebo run-in, 6-weeks fixed dose period
11377730|NCT02183701|Active Comparator|Losartan + Hydrochlorothiazide|4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
11377731|NCT02183688|Experimental|ASA + paracetamol + caffeine|
11377732|NCT02183688|Active Comparator|ASA + paracetamol|
11377733|NCT02183688|Active Comparator|ASA|
11377734|NCT02183688|Active Comparator|Paracetamol|
11377735|NCT02183688|Active Comparator|Caffeine|
11377736|NCT02183688|Placebo Comparator|Placebo|
11377737|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
11377738|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
11377739|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
11377740|NCT02183662|Experimental|BI 224436|
11377741|NCT02183662|Placebo Comparator|Placebo|
11377742|NCT02183649|Experimental|pentoxyverine citrate vs. placebo|All subjects were allocated to receive both verum and placebo in randomised order
11377743|NCT02183636|Experimental|Treatment 1 (T1)|Linagliptin/pioglitazone, FDC formulation C5
11377744|NCT02183636|Experimental|Treatment 2 (T2)|Linagliptin/pioglitazone, FDC formulation C8
11377745|NCT02183636|Active Comparator|Reference (R)|Linagliptin tablet and pioglitazone tablet (Actos®)
11377746|NCT02183623|Experimental|BI 1356 BS and Simvastatin|
11377747|NCT02183610|Experimental|[14C] BI 1356 as oral (p.o.) solution|
11377748|NCT02183610|Experimental|[14C] BI 1356 solution for i.v. infusion|
11377749|NCT02183597||Advanced breast cancer|Women with advanced breast cancer
11377750|NCT02183584|Experimental|Rifampicin and Linagliptin|
11377751|NCT02183571|Experimental|Glucophage® high dose|Part I: Treatment A + B
11377752|NCT02183571|Experimental|Glucophage® low dose|Part II: Treatment C+ D
11377753|NCT02183558|Experimental|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
11377754|NCT02183558|Experimental|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
11377755|NCT02183545|Experimental|BI 1060469|single rising doses given as tablet
11377756|NCT02183545|Placebo Comparator|Placebo|given as tablet (matching placebo of BI 1060469)
11377757|NCT02183532|Experimental|BI 1356 BS|
11377758|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
11377759|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
11377760|NCT02183506|Active Comparator|Metformin|
11377761|NCT02183506|Experimental|BI 1356 BS and metformin|Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
11377762|NCT02183493|Experimental|Fed administration of BI 1356|
11377763|NCT02183493|Active Comparator|Fasted administration of BI 1356|
11377764|NCT02183480|Experimental|Linagliptin, low dose|
11377765|NCT02183480|Experimental|Linagliptin, medium dose|
11377766|NCT02183480|Active Comparator|Linagliptin, high dose|
11377767|NCT02183467|Experimental|BI 1356, low dose|
11377768|NCT02183467|Experimental|BI 1356, high dose|
11377769|NCT02183467|Placebo Comparator|Placebo|
11377770|NCT02183467|Active Comparator|Moxifloxacin|
11377771|NCT02183441|Experimental|BI 1356 plus ritonavir|Treatment A: 3 days of ritonavir, 1 day BI 1356
11377772|NCT02183441|Active Comparator|BI 1356|Treatment B: BI 1356 alone
11377773|NCT02183428|Experimental|BI 1356|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
~Treatment B: 1 day of combined treatment of BI1356 and glyburide
~Treatment C: 1 day of treatment with glyburide alone"
11377774|NCT02183428|Active Comparator|Glyburide|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by
~Treatment B: 1 day of combined treatment of BI1356 and glyburide
~Treatment C: 1 day of treatment with glyburide alone"
11377775|NCT02183415|Experimental|BI 1356 BS, low dose|
11377776|NCT02183415|Experimental|BI 1356 BS, medium dose|
11377777|NCT02183415|Experimental|BI 1356 BS, high dose|
11377778|NCT02183415|Placebo Comparator|Placebo|
11377779|NCT02183402|Experimental|Digoxin with BI 1356|
11377780|NCT02183402|Active Comparator|Digoxin|
11377781|NCT02183389|Experimental|Treatment B: BI 1356 and Warfarin|BI 1356 for 12 days combined with a single dose of warfarin on day 6
11377792|NCT02183337|Experimental|BI 1356|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days BI 1356 until steady state followed by
~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days
~Treatment C: 7 days of treatment with Pioglitazone alone"
11377793|NCT02183337|Active Comparator|Pioglitazone|"Treatment sequence AB_C or C_AB
~Treatment A: 5 days BI 1356 until steady state followed by
~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days
~Treatment C: 7 days of treatment with Pioglitazone alone"
11377794|NCT02183324|Experimental|Low dose of BI 1356 BS|
11377795|NCT02183324|Experimental|Medium dose of BI 1356 BS|
11377796|NCT02183324|Experimental|High dose of BI 1356 BS|
11377797|NCT02183324|Placebo Comparator|Placebo|
11377798|NCT02183311|Experimental|BI 1356 BS - single rising dose|
11377799|NCT02183311|Experimental|BI 1356 BS - multiple rising dose|
11377800|NCT02183311|Active Comparator|Placebo|
11377801|NCT02183298|Experimental|BI 1356 BS - single rising dose|
11377802|NCT02183298|Placebo Comparator|Placebo|
11377803|NCT02183285|Experimental|PHL 00747 capsules|
11377804|NCT02183285|Experimental|PHL 00747 tablets|
11377805|NCT02183285|Placebo Comparator|Placebo|
11377806|NCT02183272|Active Comparator|Intranasal Ketamine|0.2 mg / kg dose of intranasal ketamine for treatment of suicidality will be given in two separate doses on the day of admission to the hospital.
11377807|NCT02183272|Placebo Comparator|Intranasal Saline Placebo|0.2 mg / kg dose saline intranasal will be given in two separate doses on the day of hospital admission.
11377808|NCT02183259|Experimental|ESR 1150 CL capsule|
11377809|NCT02183259|Experimental|ESR 1150 CL ampoule|
11377810|NCT02183246|Experimental|Porfiromycin + Radiotherapy|
11377811|NCT02183246|Placebo Comparator|Placebo + Radiotherapy|
11377812|NCT02183233|Experimental|Eschscholtzia Californica|
11377813|NCT02183233|Placebo Comparator|Eschscholtzia Californica Placebo|
11377814|NCT02183220|Experimental|Metamizol high & Placebo|
11377815|NCT02183220|Experimental|Metamizol low & Placebo|
11377816|NCT02183220|Active Comparator|Acetylsalicylic acid & Placebo|
11377817|NCT02183220|Placebo Comparator|Placebo|
11377818|NCT02183207|Experimental|PEG insertion arm via EG Scan|Percutaneous endoscopic insertion of gastrostomy via visualization through E.G. ScanTM
11377819|NCT02183194|Experimental|Lutonix Paclitaxel Drug Coated Balloon|
11377820|NCT02183181|Experimental|Meloxicam capsule|Capsules 15 mg
11377821|NCT02183181|Active Comparator|Meloxicam tablet|Tablets 15 mg
11377822|NCT02183168|Experimental|Meloxicam suppository|
11377823|NCT02183168|Experimental|Meloxicam tablet|
11377824|NCT02183168|Active Comparator|Indomethacin suppository|
11377825|NCT02183155|Experimental|Meloxicam - low|
11377826|NCT02183155|Experimental|Meloxicam - medium|
11377827|NCT02183155|Experimental|Meloxicam - high|
11377828|NCT02183155|Placebo Comparator|Placebo|
11377829|NCT02183155|Active Comparator|Extended-release indomethacin|
11377830|NCT02183142|Active Comparator|Mobic Germany|
11377831|NCT02183142|Experimental|Mobic China|
11377832|NCT02183129|Experimental|Meloxicam|
11377833|NCT02183129|Active Comparator|Diclofenac|
11377834|NCT02183116|Experimental|Meloxicam|
11377835|NCT02183103|Active Comparator|meloxicam rapid release tablet after an overnight fast|
11377836|NCT02183103|Experimental|meloxicam rapid release tablet after high fat breakfast|
11377837|NCT02183090|Experimental|Meloxicam ampoule|
11377838|NCT02183090|Active Comparator|Meloxicam tablet|
11377839|NCT02183077|Experimental|Meloxicam gel|
11377840|NCT02183077|Active Comparator|Meloxicam tablet|
11377841|NCT02183064|Experimental|Meloxicam|
11377842|NCT02183064|Active Comparator|Usual care prescription NSAID|
11377843|NCT02183051|Experimental|Meloxicam 15 mg|
11377844|NCT02183051|Experimental|Meloxicam 7.5 mg|
11377845|NCT02183051|Experimental|Meloxicam 3.75 mg|
11377846|NCT02183051|Experimental|Meloxicam 1.875 mg|
11377847|NCT02183051|Active Comparator|Ibuprofen 400 mg|
11377848|NCT02183051|Active Comparator|Ibuprofen 200 mg|
11377849|NCT02183051|Placebo Comparator|Placebo|
11377850|NCT02183038|Experimental|Meloxicam low & Placebo|
11377851|NCT02183038|Experimental|Meloxicam high & Placebo|
11377852|NCT02183038|Active Comparator|Naproxen sodium & Placebo|
11377853|NCT02183025|Experimental|Meloxicam 7.5 mg|
11377854|NCT02183025|Experimental|Meloxicam 15 mg|
11377855|NCT02183025|Active Comparator|Mefenamic acid 1500 mg|500 mg three times daily
11377856|NCT02183012|Experimental|A: Ibuprofen extrudate, fed state|
11377857|NCT02183012|Experimental|B: Ibuprofen extrudate, fasted state|
11377858|NCT02183012|Active Comparator|C: Ibuprofen lysinate tablet, fed state|
11377859|NCT02183012|Active Comparator|D: Ibuprofen lysinate tablet, fasted state|
11377860|NCT02183012|Active Comparator|E: Ibuprofen tablet, fed state|
11377861|NCT02183012|Active Comparator|F: Ibuprofen tablet, fasted state|
11377862|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
11377863|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
11377864|NCT02182986||Subjects Enrolled Pre-Transplant|"Subjects (N=approximately 357) Enrolled Pre-Transplant
~Subjects with evidence of EBV infection prior to transplant
~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
11377865|NCT02182986||Subjects Enrolled Post-Transplant|"Subjects (N=approximately 588) Enrolled 3 Yrs Post-Transplant
~Subjects with evidence of EBV infection prior to transplant
~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
11377934|NCT02182479|Active Comparator|Berodual® via MDI, high dose|
11377866|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
11377867|NCT02182960|Experimental|Ibuprofen|
11377868|NCT02182960|Active Comparator|Brufen|
11377869|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
11377870|NCT02182934|Experimental|Ginsana|
11377871|NCT02182934|Placebo Comparator|Placebo|
11377872|NCT02182908|Other|Non surgical aneurysm of abdominal aorta|PET-Scan
11377873|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
11377874|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
11377875|NCT02182882|Experimental|GINSANA|
11377876|NCT02182882|Placebo Comparator|Placebo|
11377877|NCT02182869|Experimental|Combivent® HFA|
11377878|NCT02182869|Active Comparator|Combivent® CFC|
11377879|NCT02182856|Experimental|Ipratropium bromide/salbutamol sulphate|"Randomised sequence of four different treatments
~Ipratropium bromide 500 µg/salbutamol sulphate 3 mg
~Ipratropium 500 µg
~Salbutamol sulphate 3 mg
~Salbutamol sulphate 6 mg"
11377880|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
11377881|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
11377882|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
11377883|NCT02182817||GA-Exposed Group|Exposure to general anaesthesia below 15 months of age
11377884|NCT02182817||Unexposed Group|Children not exposed to general anaesthesia or surgery from GUSTO cohort. (GUSTO: Growing Up Towards Healthy Outcomes in Singapore: a prospective longitudinal study providing normative data from the local population)
11377885|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
11377886|NCT02182791|Experimental|Nevirapine tablets|"once a day (q.d.) Day 2-15,
~twice a day (b.i.d.) Study day 16-30"
11377887|NCT02182791|Active Comparator|EE/NET tablets|Single dose on Study Day 0 and 30
11377888|NCT02182778|Experimental|Gemcitabine/Cisplatin group|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
11377889|NCT02182778|Experimental|Gemcitabine/Cisplatin /S-1 group|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
11377890|NCT02182765|Experimental|Nevirapine|"Part I: Study days 15-43
~Part II: Study day 44 to end of trial"
11377891|NCT02182765|Active Comparator|Amprenavir|"Part I: Study days 0 to 43
~Part II: Study day 44 to end of trial"
11377892|NCT02182765|Active Comparator|Abacavir|"Part I: Study days 0 to 43
~Part II Study day 44 to end of trial"
11377893|NCT02182752|Active Comparator|Ropivacaine - Tramadol|
11377894|NCT02182752|Active Comparator|Ropivacaine|
11377895|NCT02182739||Meloxicam|
11377896|NCT02182726||MOBEC|
11377897|NCT02182713|Experimental|Arm 1 - CombiventTM followed by Salbutamol|
11377898|NCT02182713|Active Comparator|Arm 2 - Salbutamol followed by CombiventTM|
11377899|NCT02182700|Experimental|Combivent® aerosol|
11377900|NCT02182687|Other|Arm A|Stereotactic Body Radiation Therapy (SBRT)
11377901|NCT02182687|Other|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
11377902|NCT02182674|Experimental|Combivent HFA|
11377903|NCT02182674|Active Comparator|Combivent (CFC)|
11377904|NCT02182661|Experimental|Ba253BINEB|
11377905|NCT02182648|Experimental|etomidate group|infusion of etomidate at 2 minutes before anesthesia induction
11377906|NCT02182648|Active Comparator|propofol group|infusion of propofol at 2 minutes before anesthesia induction
11377907|NCT02182648|Active Comparator|sevoflurane group|inhale sevoflurane for anesthesia induction and maintenance
11377908|NCT02182635|Experimental|Ba253BINEB|
11377909|NCT02182622|Experimental|Dose Level -1|Docetaxel 60mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 200mg oral daily
11377910|NCT02182622|Experimental|Dose Level 1|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice a day LDE225 200mg oral daily
11377911|NCT02182622|Experimental|Dose Level 2|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 400mg oral daily
11377912|NCT02182622|Experimental|Dose Level 3|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 800mg oral daily
11377913|NCT02182609|Experimental|99mTc-rhAnnexin V-128|
11377914|NCT02182596|Experimental|DAUNORUBICINE - ARACYTINE - MYLOTARG -|"Adaptive Bayesian method for dose-finding in phase I/II clinical trials based on treatment efficacy and toxicity (Thall, Russel, 1998), with successive patients cohorts and three combined dose levels:
~DNR 45 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.
~DNR 60 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.
~DNR 60 mg/m2 IV days 1 to 3 + AraC 200 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.
~Two consolidation courses for CR patients:
~Amsacrine: 90 mg/m2 IV Day 1 Cytarabine: 1g/m2 twice a day IV Days 1 to 4 Mylotarg: 3 mg/m2 IV Day 1."
11377915|NCT02182583|Experimental|Ba253BINEB|
11377916|NCT02182583|Active Comparator|Ba253MDI|
11377917|NCT02182570|Experimental|WAL 801 CL|
11377918|NCT02182557|Experimental|WAL 801 CL Dry Syrup + Placebo|
11377919|NCT02182557|Active Comparator|Ketotifen Fumarate Dry Syrup + Placebo|
11377920|NCT02182544|Experimental|WAL801CL dry syrup + Placebo|
11377921|NCT02182544|Active Comparator|Ketotifen fumarate dry syrup + Placebo|
11377922|NCT02182531|Experimental|Epinastine and Pseudoephedrine combination|
11377923|NCT02182531|Active Comparator|Epinastine|
11377924|NCT02182531|Active Comparator|Pseudoephedrine|
11377925|NCT02182518|Experimental|Epinastine + Pseudoephedrine|
11377940|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
11377941|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
11377942|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
11377943|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
11377944|NCT02182414|Active Comparator|BI 207127 NA (TF-I)|trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
11377945|NCT02182414|Experimental|BI 207127 NA (TF-II)|trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
11377946|NCT02182414|Experimental|BI 207127 NA delayed release|trial part 1: 800 mg BI 207127 NA TF-II, delayed release
11377947|NCT02182414|Experimental|BI 207127 NA extended release (10% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
11377948|NCT02182414|Experimental|BI 207127 NA extended release (15% PEO)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
11377949|NCT02182414|Experimental|BI 207127 NA extended release (20% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
11377950|NCT02182414|Experimental|BI 207127 (TF-II), fed|trial part 2
11377951|NCT02182414|Experimental|BI 207127 (TF-II), fasted|trial part 2
11377952|NCT02182401|Experimental|BI 207127 NA|fixed sequence
11377953|NCT02182388|Experimental|BI 207127 NA|single rising dose part
11377954|NCT02182388|Placebo Comparator|Placebo|
11377955|NCT02182388|Experimental|BI 207127 NA, fasted or fed|
11377956|NCT02182375|Experimental|BI 201335 NA|"400 mg raltegravir (bid) from day 1-14 and once on day 15;
~240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15"
11377957|NCT02182362|Experimental|BI 201335 NA in rising doses|single dose of BI 201335 NA on day 1, multiple dosing days 4-24
11377958|NCT02182362|Placebo Comparator|Placebo|
11377959|NCT02182362|Experimental|BI 201335 NA|highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
11377960|NCT02182349|Experimental|BI 201335 NA|multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of [14C]-BI 201335 NA radiolabelled drug on day 9
11377961|NCT02182336|Experimental|BI 201335 NA|
11377962|NCT02182323|Experimental|BI 201335 in single rising doses|
11377963|NCT02182323|Placebo Comparator|Placebo|
11377964|NCT02182323|Experimental|BI 201335 NA fasted or fed|"two randomized sequences:
~BI 201335 NA or placebo fasted
~BI 201335 NA or placebo after high-fat breakfast"
11377965|NCT02182310|Placebo Comparator|BI 201335 placebo|crossover part
11377966|NCT02182310|Experimental|BI 201335 low dose|crossover part
11377967|NCT02182310|Experimental|BI 201335 high dose|crossover part
11377968|NCT02182310|Active Comparator|Moxifloxacin|crossover part
11377969|NCT02182310|Experimental|BI 201335 or Placebo|tolerability part in female subjects
11377970|NCT02182297|Experimental|BI 201335 NA in single rising doses|
11377971|NCT02182297|Placebo Comparator|Placebo|
11377972|NCT02182284|Experimental|BI 201335 NA - low dose|
11377973|NCT02182284|Experimental|BI 201335 NA - high dose|
11377974|NCT02182271|Experimental|BI 201335 ZW - single rising dose|
11377975|NCT02182271|Placebo Comparator|Placebo|
11377976|NCT02182258|Placebo Comparator|Placebo|
11377977|NCT02182258|Active Comparator|BIBF 1120 intravenous|
11377978|NCT02182258|Experimental|BIBF 1120 capsule|
11377979|NCT02182245|Experimental|Combination Therapy|
11377980|NCT02182245|Experimental|Monotherapy|
11377981|NCT02182232|Experimental|BIBF 1120 with paclitaxel and carboplatin|
11377982|NCT02182232|Experimental|BIBF 1120 monotherapy|
11377983|NCT02182219|Experimental|BIBF 1120|
11377984|NCT02182206|Experimental|BIBF 1120|
11377985|NCT02182193|Experimental|BIBF 1120 capsules charge 1|
11377986|NCT02182193|Experimental|BIBF 1120 capsules charge 2|
11377987|NCT02182193|Active Comparator|BIBF 1120 drinking solution|
11377988|NCT02182180||Protocol participants|All participants enrolled on the protocol
11377989|NCT02182167|Experimental|IV NAC|"Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .
~Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours."
11377990|NCT02182167|Placebo Comparator|Placebo|Water
11377991|NCT02182154|Experimental|BIBF 1120 ES|
11377992|NCT02182141|Experimental|BIBF 1120|
11377993|NCT02182128|Experimental|BIBF 1120|
11377994|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
11377995|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.
~Chlorhexidine gluconate soap applied for bathing daily.
~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.
~Nasal mupirocin to applied inside nostrils twice daily."
11377996|NCT02182102|Experimental|BIBF 1120 + Pemetrexed|
11377997|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:
~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
11377998|NCT02182089||Patients with less than 10% IDH|"Study Population:
~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
11377999|NCT02182076|Active Comparator|fasted administration of BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules in fasting state
11378000|NCT02182076|Experimental|fed administration of BIBF 1120|three 50 mg BIBF 1120 soft gelatine capsule immediately after a high fat, high caloric meal
11378008|NCT02182024|Experimental|Dabigatran high dose in healthy subjects|healthy subjects with a creatinine clearance of >80 mL/m
11378009|NCT02182024|Experimental|Dabigatran high dose in mild renal impairment|patients with a creatinine clearance of >50 up to 80 mL/min
11378010|NCT02182024|Experimental|Dabigatran high dose in moderate renal impairment|patients with a creatinine clearance of >30 up to 50 mL/min
11378011|NCT02182024|Experimental|Dabigatran high dose in severe renal impairment|patients with a creatinine clearance of up to 30 mL/min
11378012|NCT02182024|Experimental|Dabigatran low dose in haemodialysis patients|patients requiring haemodialysis
11378013|NCT02182011|Experimental|Tenecteplase|Single i.v. bolus followed by infusion, weight adjusted
11378014|NCT02182011|Active Comparator|Alteplase|Single i.v. bolus followed by infusion
11378015|NCT02182011|Active Comparator|Streptokinase|I.V. infusion
11378016|NCT02181998|Active Comparator|tenecteplase + unfractioned heparin|
11378017|NCT02181998|Experimental|tenecteplase + enoxaparin|
11378018|NCT02181985|Active Comparator|TNK-tPA + heparin|
11378019|NCT02181985|Experimental|TNK-tPA + enoxaparin|
11378020|NCT02181985|Experimental|TNK-tPA + abciximab + heparin|
11378021|NCT02181972|Experimental|Gingko biloba|
11378022|NCT02181972|Placebo Comparator|Placebo|
11378023|NCT02181959|Experimental|Pharmaton® with DMAE|
11378024|NCT02181959|Active Comparator|Pharmaton® without DMAE|
11378025|NCT02181959|Placebo Comparator|Placebo|
11378026|NCT02181946|Experimental|Fluconazole with and without Nevirapine|
11378027|NCT02181933|Experimental|Nevirapine|Mother: two doses, Infant: one dose
11378028|NCT02181933|Active Comparator|Zidovudine (ZDV) + Lamivudine (3TC)|
11378029|NCT02181920|Experimental|Metamizole - Diclofenac|metamizole followed by diclofenac
11378030|NCT02181920|Experimental|Diclofenac - Metamizole|diclofenac followed by metamizole
11378031|NCT02181920|Experimental|Metamizole - Placebo|metamizole followed by placebo
11378032|NCT02181920|Experimental|Placebo - Metamizole|placebo followed by metamizole
11378033|NCT02181907|Experimental|UH-AC 62 XX tablet|
11378034|NCT02181907|Active Comparator|UH-AC 62 XX capsule|
11378035|NCT02181894||Orally intubated infants|Subjects will be <72 hours of age and orally intubated. Following consent, four measures will be reported (i.e. body weight, nasal to tragus length, suprasternal notch to xyphoid process and shoulder to elbow length). Measures will be compared against a chest x-ray and placement of ETT at the subjects lip to identify the most accurate method to place endotracheal tubes in the newborn.
11378036|NCT02181881|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
11378037|NCT02181881|Active Comparator|Life Steps|A 3-session HIV medication adherence support program for individuals.
11378038|NCT02181881|No Intervention|Treatment as usual (TAU)|HIV positive individuals will continue to follow their current HIV treatment plan.
11378039|NCT02181855|Other|Atypical GERD syptoms treated with GERD-X|Patients treated by means of full-thickness gastroplication
11378040|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
11378041|NCT02181829|Experimental|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
11378042|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
11378043|NCT02181803|Experimental|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
11378044|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
11378045|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
11378046|NCT02181803|Experimental|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
11378047|NCT02181803|Placebo Comparator|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
11378048|NCT02181803|Placebo Comparator|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
11378049|NCT02181803|Placebo Comparator|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
11378050|NCT02181790|Experimental|First Group|excimer laser treatment to one palm and/or one sole
11378051|NCT02181790|Experimental|Second Group|excimer laser treatment to both palms and/or soles
11378052|NCT02181777|Experimental|GRASP|GRoup trAining for Social skills in Psychosis
11378053|NCT02181777|Active Comparator|Standard care|Treatment as usual as provided by care team
11378054|NCT02181764|Experimental|KRN23|Single SC administration on day 1
11378055|NCT02181751|Experimental|Treatment Group|Children in the Treatment Group will receive treatment between 0 and 4 months from the study start date. The intervention will be a Trauma Focused Cognitive Behavioural Therapy Group.
11378056|NCT02181751|Other|Waitlist Group|Children in the wait-list group will receive treatment from 5-8 months of the studies start date. The intervention once this group receives treatment will be a Trauma Focused Cognitive Behavioural Therapy Group
11378581|NCT02178319|Active Comparator|open group|the patients under go the open esophagogastric devascularization and splenectomy
11378057|NCT02181738|Experimental|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: Specified dose on specified days
~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days"
11378058|NCT02181725|Experimental|Multimodal Rehabilitation Program|Multimodal Rehabilitation Program, consisting of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM)
11378059|NCT02181725|Active Comparator|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
11378060|NCT02181712|Experimental|Mesenchymal Stem cells|Subjects who have never received Mesenchymal Stem Cells
11378061|NCT02181712|Experimental|Booster Mesenchymal Stem Cells|Subjects who have previously received Mesenchymal Stem Cells
11378062|NCT02181699|Experimental|KHK2823|single agent KHK2823 administered at selected dose levels
11378063|NCT02181686||Sentus QP group|Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.
11378064|NCT02181686||VR-T/DR-T group|Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family
11378065|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
11378066|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
11378067|NCT02181660|Experimental|Dose Escalation Cohort|ASP2215
11378068|NCT02181647|Experimental|Intervention|Safe Touches Personal Safety Training for Children
11378069|NCT02181647|Other|Comparison|Received Safe Touches after week-1 assessment completed (delayed intervention).
11378070|NCT02181634|Experimental|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
11378071|NCT02181621|Placebo Comparator|Solosite gel|Hydrogel with preservatives, used to create a moist wound environment.
11378072|NCT02181621|Active Comparator|Iodosorb|Cadexomer iodine gel
11378073|NCT02181582|Experimental|Emapunil Administration|Single Arm Study
11378074|NCT02181569||Treatment seeking participants with alcohol dependence|Treatment seeking individuals with alcohol dependence who are admitted into a 28-day inpatient treatment program.
11378075|NCT02181556|Experimental|FOLFIRI and aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
11378076|NCT02181543|Experimental|Clonidine|Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
11378077|NCT02181543|No Intervention|No Clonidine|Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.
11378078|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
11378079|NCT02181517|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
11378080|NCT02181517|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
11378081|NCT02181517|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
11378082|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
11378083|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
11378084|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
11378085|NCT02181491|Experimental|P943 PET Scan|
11378086|NCT02181478|Experimental|Treatment (intra-osseous UCB with hMSC co-transplant)|"REDUCED INTENSITY CONDITIONING (RIC):
~Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.
~Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.
~GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.
~TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
11378087|NCT02181465|Experimental|Group 1|One injection of G17DT followed by up to three booster injections depending on antibody response over 16 week period
11378088|NCT02181465|Experimental|Group 2|Three injections of G17DT with option of one booster after 16 weeks
11378089|NCT02181439|Other|Right irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the right maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.
~The same procedure will be applied to the left non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
11378145|NCT02181127|Active Comparator|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
11378090|NCT02181439|Other|Left irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the left maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.
~The same procedure will be applied to the right non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
11378091|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
11378092|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
11378093|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
11378094|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
11378095|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
11378096|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
11378097|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
11378098|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
11378099|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
11378100|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
11378101|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
11378102|NCT02181361||hirudin plus aspirin|14 days after stroke onset, patients in the hirudin plus aspirin group received natural hirudin 0.75g, three times a day and aspirin 100mg, once daily.
11378103|NCT02181361||Warfarin|14 days after stroke onset, patients in warfarin group were given an initial dose of 1.25mg of warfarin,once daily. 3 days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
11378104|NCT02181348|Active Comparator|Intervention (Vitamin E supplementation)|Vitamin E 400 mg once daily for 3 months
11378105|NCT02181348|Placebo Comparator|placebo (edible oil)|
11378106|NCT02181335|Experimental|Respimat ® Budesonide low dose + Turbohaler® Placebo|
11378107|NCT02181335|Experimental|Respimat ® Budesonide high dose + Turbohaler® Placebo|
11378108|NCT02181335|Active Comparator|Turbohaler® Budesonide + Respimat Placebo®|
11378109|NCT02181322|Experimental|Meloxicam - low dose, fasted|
11378110|NCT02181322|Experimental|Meloxicam - medium dose, fasted|
11378111|NCT02181322|Experimental|Meloxicam - high dose, fasted|
11378112|NCT02181322|Experimental|Meloxicam - high dose, fed|
11378113|NCT02181309|Experimental|Meloxicam low dose, fasted|
11378114|NCT02181309|Experimental|Meloxicam medium dose, fasted|
11378115|NCT02181309|Experimental|Meloxicam high dose, fed|
11378116|NCT02181309|Active Comparator|Meloxicam high dose, fasted|
11378117|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
11378118|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
11378119|NCT02181283|Active Comparator|W+W|Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
11378120|NCT02181283|Active Comparator|W+P|Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
11378121|NCT02181283|No Intervention|Enhanced Usual Care|Enhanced usual care.
11378122|NCT02181270|Experimental|high intensity exercise|High-intensity interval exercise (HIIE): Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
11378123|NCT02181270|Experimental|Continuous moderate exercise group|Continuous moderate exercise group (CME): Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
11378124|NCT02181257|Other|Newly Diagnosed Bronchiolitis Obliterans|"Participants with newly diagnosed Bronchiolitis Obliterans Syndrome will be randomized to Early Photopheresis Intervention or Control (Standard of Care). Participants randomized to Early Photopheresis Intervention will receive Extracorporeal Photopheresis Treatments. The patient has 24 treatments in a 6 month period and may continue maintenance treatments.
~The Control group will receive local Standard of Care for the management of Bronchiolitis Obliterans Syndrome. Therapy will involve changes in immunosuppressive agents."
11378146|NCT02181127|Placebo Comparator|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
11378147|NCT02181114|Experimental|Expert System Coaching|Patients in the intervention group will receive coaching based off the answers provided in the computer-based Expert System that is designed to track their readiness level to pursue a living donor kidney transplant.
11378693|NCT02177500|Experimental|Telmisartan + hydrochlorothiazide and matching placebo|
11378125|NCT02181257|Other|Refractory Bronchiolitis Obliterans|Participants with Refractory Bronchiolitis Obliterans Syndrome are electronically assigned to either Extracorporeal Photopheresis treatment or Observation based on the participant's Forced Expiratory Volume. Values from pulmonary function tests from the preceding 12 months will be entered into a web-based treatment allocation which will perform an automated calculation. Patients who have a statistically significant rate of decline within the preceding 6 months, and a derived protocol defined slope, will be assigned to the Extracorporeal Photopheresis Treatment Cohort. If a patient does not meet these criteria, the participant will be assigned to the Observation Cohort.
11378126|NCT02181244|Experimental|Egg, one a day, for breakfast|The intervention consists in feeding the subjects egg, one a day for breakfast during 5 weeks. At the end of the intervention, blood will be obtained to measure plasma lipids, glucose, insulin and inflammatory markers. All measurements will be finished 24 weeks after the intervention is finished. All data will be reported 1 year after completion of the study.
11378127|NCT02181244|Experimental|Oatmeal, one cup a day|In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
11378128|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
11378129|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
11378130|NCT02181218|Experimental|Dose Level 0 (starting dose) (8 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;
~Gemcitabine IV over 30 minutes on Day 1
~Oxaliplatin IV over 2 hours on Day 1
~Dexamethasone orally on Days 1-4
~Pegfilgrastim subcutaneously on Day 3
~Drugs may be administered in any order on Day 1.
~Each cycle is 21 days.
~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
11378131|NCT02181218|Experimental|Dose Level 1 (10 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;
~Gemcitabine IV over 30 minutes on Day 1
~Oxaliplatin IV over 2 hours on Day 1
~Dexamethasone orally on Days 1-4
~Pegfilgrastim subcutaneously on Day 3
~Drugs may be administered in any order on Day 1.
~Each cycle is 21 days.
~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
11378132|NCT02181218|Experimental|Dose Level 2 (12 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;
~Gemcitabine IV over 30 minutes on Day 1
~Oxaliplatin IV over 2 hours on Day 1
~Dexamethasone orally on Days 1-4
~Pegfilgrastim subcutaneously on Day 3
~Drugs may be administered in any order on Day 1.
~Each cycle is 21 days.
~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
11378133|NCT02181205|Experimental|placebo|sphenopalatine ganglion block performed with normal saline as the placebo
11378134|NCT02181205|Active Comparator|bupivacaine|sphenopalatine ganglion block performed with bupivacaine
11378135|NCT02181192|Experimental|delayed radiotherapy|PET/CT and Radiotherapy after achievement of PSA marginal value Additive imaging
11378136|NCT02181192|Active Comparator|instant radiotherapy|Instant Radiotherapy according to guidelines
11378137|NCT02181179|Active Comparator|Yoga|This will involve participating in at least two 60-minute Vinyasa yoga sessions each week for eight weeks (weeks 1-8). This will begin the week following a baseline laboratory appointment. These sessions will be conducted at a local Austin studio that has numerous locations in the area.
11378138|NCT02181179|No Intervention|Waitlist|If randomized to this group, participants will complete weekly assessments only and not yoga during their time in the study. Following full completion of the study (i.e., after week 10), participants will be compensated with a voucher for 2 free months of yoga.
11378139|NCT02181166|Experimental|kinesiotherapy + High voltage electrical stimulation|Same protocol group kinesiotherapy + high voltage electrial stimulation with two rectangular electrodes (3x5 cm) active silicon-carbon and an electrode rectangular dispersive (10x18cm) aluminum wrapped with a damp felt in water. The active electrodes are positioned in central myofascial trigger point of the upper trapezius muscle after application of water soluble gel. The dispersive electrode was placed in the lumbar region. The following parameters will be use: frequency of 10 Hz, twin pulses of 20μs to 100ms between pulses and the maximum voltage tolerated by voluntary until the motor threshold (visible muscle contraction) to increase every five minutes, totaling 30 minutes of stimulation. The negative polarity will be use.
11378140|NCT02181166|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: These exercises involve stretching of the cervical, anterior and posterior chain of the upper trunk and active mobilization of the cervical, shoulder movements of flexion, extension, abduction and adduction of the shoulder and upper limb. The exercises lasted 50 minutes, with 10 minutes of walking, and stretching was performed with two repetitions of 20 seconds, and active mobilization exercises of three sets of eight repetitions and final relaxation of 10 minutes were performed.
11378141|NCT02181166|Experimental|kineshioterapy + isquemic compression|The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
11378142|NCT02181153|Other|siblings of patients with IBD|Blood and fecal samples from 100 siblings of children affected with IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form.
11378143|NCT02181153|Other|patients without family history of IBD|Blood and fecal samples of 100 healthy children without a family history of IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form
11378144|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
11378204|NCT02180776|Placebo Comparator|Group B|Patients assigned to group B started four weeks of observation (control) in phase 1, followed by four weeks of summit 456 TLSO (intervention) in phase 2 of the study.
11378148|NCT02181114|No Intervention|Control|Patients in the control group will only receive the standard of care education that is offered at the UCLA Kidney and Pancreas Transplant Center which consists of a powerpoint presentation on their Evaluation Day appointment.
11378149|NCT02181101|Experimental|AA-BA|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years
11378150|NCT02181101|Experimental|AB-BA|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years
11378151|NCT02181101|Experimental|AA-BB|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years
11378152|NCT02181101|Active Comparator|AB-BB|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years
11378153|NCT02181088|Experimental|Group 1 (ChAd63 RH5 low dose)|1 dose of ChAd63 RH5 5 x 10^9 vp intramuscularly
11378154|NCT02181088|Experimental|Group 2A (ChAd63 RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly
11378155|NCT02181088|Experimental|Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later intramuscularly
11378156|NCT02181088|Experimental|Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later intramuscularly
11378157|NCT02181075|Experimental|Part I|"All participants in Part I received:
~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour
~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
11378158|NCT02181075|Experimental|Part II|"All participants in Part II received:
~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour
~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
11378159|NCT02181062|Experimental|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.
~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.
~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.
~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
11378160|NCT02181062|No Intervention|Wait-list control|After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
11378161|NCT02181036|Experimental|family work shop|2 to 3 hours per session, one session per week, for a total of 6 weeks of family work shop
11378162|NCT02181023|Experimental|Aclidinium - Glycopyrronium|Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
11378163|NCT02181023|Experimental|Glycopyrronium - Aclidinium|Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).
11378164|NCT02181010|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in low-income, urban, minority neighborhoods. Intervention components will occur at the policy level; food wholesaler level; small food retail outlet level; neighborhood level; household level.
11378165|NCT02181010|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
11378166|NCT02180997|Experimental|Tamsulosin 1|Volunteers will be taken Tamsulosin and solifenacin
11378167|NCT02180997|Experimental|Solifenacin 1|Volunteers will be taken Tamsulosin and solifenacin
11378168|NCT02180997|Experimental|Co-administration 1|Volunteers will be taken Tamsulosin and solifenacin
11378169|NCT02180997|Experimental|Tamsulosin 2|Volunteers will be taken Tamsulosin and solifenacin
11378170|NCT02180997|Experimental|Solifenacin 2|Volunteers will be taken Tamsulosin and solifenacin
11378171|NCT02180997|Experimental|Co-administration 2|Volunteers will be taken Tamsulosin and solifenacin
11378205|NCT02180763|Experimental|Gammanorm® 165 mg/mL|
11378206|NCT02180750|Experimental|Intervention: Memory Work Therapy|Residential week intervention consisting of memory box, memory book, tree of life, Active Citizen book, all activities facilitated.
11378207|NCT02180750|Active Comparator|Control: standard care|Usual care services.
11378208|NCT02180737|Experimental|Dexmeditomedine|Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
11378209|NCT02180724|Experimental|Previously Treated|Previously treated, N=92
11378210|NCT02180724|Experimental|Treatment Naïve|Treatment Naïve, N=14
11378211|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1
11378172|NCT02180984|Active Comparator|BED randomized to rTMS|"30 obese individuals currently diagnosed with BED and meeting criteria for the study will be randomized to active rTMS treatment.
~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).
~Proposed schedule of treatment:
~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. For the real treatment condition, stimulation will target the left DLPFC at 110% of the resting motor threshold. Each session of 10 Hz stimulation will apply 1000 pulses to the left hemisphere, with a duty cycle of 5s on and 55s off, for a total stimulation time of 20 min."
11378173|NCT02180984|Sham Comparator|Sham BED TMS|"30 obese individuals currently diagnosed with BED will be randomized to receive sham TMS treatment. Blinded to participants and study staff, except to the doctor applying the TMS treatment.
~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).
~Proposed schedule of treatment:
~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. Sham treatment condition, will follow the same protocol however no real TMS will be delivered."
11378174|NCT02180984|No Intervention|Control (obese non BED)|15 controls, obese but without a current or past diagnosis of BED will complete the baseline measurements only.
11378175|NCT02180984|No Intervention|Controls (normal weight)|15 controls, normal weight and without a current or past diagnosis of BED will complete baseline measures only.
11378176|NCT02180971|Experimental|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
11378177|NCT02180971|Experimental|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
11378178|NCT02180958||Cerebral Arteriovenous Malformations|Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.
11378179|NCT02180945||Intracranial Dural Arteriovenous Fistula|Adult patients requiring endovascular treatment of Intracranial Dural Arteriovenous Fistulae.
11378180|NCT02180932|Experimental|periodontal disease|Saliva samples
11378181|NCT02180919|No Intervention|Control period|All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
11378182|NCT02180919|Experimental|Telemonitoring|telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
11378183|NCT02180906||Patients with NSTI|Definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and are spreading along tissue structures.
11378184|NCT02180893|Experimental|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
11378185|NCT02180893|Placebo Comparator|No block|Patients who did not receive PVB
11378186|NCT02180880|Experimental|Pregabalin and Oxcarbazpepine|Pregabalin and Oxcarbazepine
11378187|NCT02180867|Experimental|Regimen A (pazopanib, chemoradiation)|See Regimen A Detailed Description.
11378188|NCT02180867|Experimental|Regimen B (chemoradiation)|See Regimen B Detailed Description.
11378189|NCT02180867|Experimental|Regimen C (pazopanib, radiation therapy)|"INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.
~SURGERY: Patients undergo surgery on week 10.
~CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13."
11378190|NCT02180867|Experimental|Regimen D (radiation therapy)|"INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.
~SURGERY: Patients undergo surgery on week 10.
~CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13."
11378191|NCT02180854|Experimental|Intervention (8 hours)|EWS every 8 hours
11378192|NCT02180854|Active Comparator|Control (12 hours)|EWS every 12 hours
11378193|NCT02180841|Experimental|Soy 25g|Soy protein powder (25g/day)
11378194|NCT02180841|Experimental|Soy 50g|Soy protein powder 50 g/day
11378195|NCT02180841|Placebo Comparator|Control|Control powder
11378196|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
11378197|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
11378198|NCT02180815||ReVENT implanted group|
11378199|NCT02180802|Experimental|motivational intervieing group|The behavioral intervention targets were improved eating and physical activity behavior in order to reduce obesity levels. Each adolescent was encouraged to eat a variety of foods from each of the four major food groups and low-fat alternatives . Moreover, each adolescent was encouraged to achieve at least 60 minutes of moderate-to-vigorous intensity physical activity daily as recommended by the World Health Organization
11378200|NCT02180802|Experimental|motivational interviewi group with parental involvement|an additional single session with parents or guardians over 60 minutes in the clinic
11378201|NCT02180802|Active Comparator|Control|The patients received routine care
11378202|NCT02180789|Experimental|Harnalidge® OCAS®|
11378203|NCT02180776|Active Comparator|Group A|Patients assigned to group A wore the Summit 456 TLSO (intervention) for four weeks in phase 1 of the study, followed by four weeks of observation (control) in phase 2.
11378694|NCT02177500|Experimental|Telmisartan and matching placebo|
11378212|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects
11378213|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
11378214|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
11378215|NCT02180711|Experimental|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
11378216|NCT02180698|Experimental|Treatment (TLR4 agonist GLA-SE, radiation therapy)|Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
11378217|NCT02180685|Other|Anchor fixation|Medial fixation of the reconstruction at the medial femural condyle with suture anchors.
11378218|NCT02180685|Other|Screw fixation|Medial fixation of the reconstruction at the medial femural condyle with a screw.
11378219|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
11378220|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
11378221|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
11378222|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
11378223|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
11378224|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
11378225|NCT02180633||Fellow Eyes|Patients that suffer from unilateral idiopathic macular hole, and whose fellow eyes don't show any sign of retinal pathology.
11378226|NCT02180633||Controls|Healthy subjects age-matched to the other group, with no visible retinal pathologies.
11378227|NCT02180620|Experimental|No exercise|participants will remain sedentary during testing
11378228|NCT02180620|Experimental|Meal then exercise|45 min of resistance training will be performed after a standard meal
11378229|NCT02180620|Experimental|exercise then meal|45 min of resistance training will be performed prior to a standard meal
11378230|NCT02180607||Healthy Controls|Response to social feedback, monetary incentive delay, and go/no-go tasks
11378231|NCT02180607||MDD patients|Response to social feedback, monetary incentive delay, and go/no-go tasks
11378232|NCT02180581|Experimental|Probiotic (2 * 10^9 cfu/d)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12) and Lactobacillus Rhamnosus GG (LGG) in a dosage of 10^9 cfu/day of each strain. The probiotics are provided as powder in a sachet, and can be added to food or drink
11378233|NCT02180581|Placebo Comparator|Placebo|provided as powder in a sachet, and can be added to food or drink
11378234|NCT02180568|Experimental|Lipiodol|Lipiodol-guided lung localization technique
11378235|NCT02180568|Active Comparator|Hookwire|Hookwire-guided lung localization technique
11378236|NCT02180555||ICU patients|
11378237|NCT02180542||Ischemic stroke patients|Patients admitted with ischemic stroke from march 2012 to april 2014
11378238|NCT02180529|Experimental|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
11378239|NCT02180529|Placebo Comparator|Placebo|Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
11378240|NCT02180516||Meloxicam|
11378241|NCT02180516||Other NSAIDs|
11378242|NCT02180503|Experimental|BI 1356 BS - low dose|
11378243|NCT02180503|Experimental|BI 1356 BS - high dose|
11378244|NCT02180490|Experimental|UHAC 62 XX tablet|
11378245|NCT02180490|Active Comparator|UHAC 62 XX capsule|
11378246|NCT02180477|Experimental|UHAC 62 XX TF1 tablet|
11378247|NCT02180477|Experimental|UHAC 62 XX TF2 tablet|
11378248|NCT02180477|Active Comparator|UHAC 62 XX capsule|
11378249|NCT02180464|Experimental|LAS41004|Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily
11378250|NCT02180464|Active Comparator|control|Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily
11378251|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
11378252|NCT02180425||Healthy Group|The subjects in this group do not have a history of acne.
11378253|NCT02180425||Acne Group, Topical Retinoid|These subjects have been prescribed a topical retinoid for their acne. They will participate in the study for a period of 1 month.
11378254|NCT02180425||Acne Group, Isotretinoin|These subjects have been prescribed isotretinoin for their acne. They will participate in the study for a period of 5-6 months.
11378255|NCT02180412|Experimental|Panhematin|Panhematin plus glucose
11378256|NCT02180412|Placebo Comparator|Placebo|Placebo (saline) plus glucose
11378257|NCT02180386|Experimental|Experimental group|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
11378258|NCT02180373||vein graft bypass|patients who have had peripheral bypass
11378259|NCT02180373||SFA stent|Patients who have had SFA stenting
11378297|NCT02180139|Experimental|Primary motor cortex (M1) stimulation|Treatment by transcranial direct current stimulation will be targeted to the motor cortex for all treatment sessions with Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral M1, 15 minutes (Goal: decrease contralateral M1 excitability)
11378260|NCT02180360|Experimental|Capoeira training group|"The Capoeira training was performed during eight weeks, twice a week with duration of 60min each session, divided in 1) initial part: 10min warm-up with activities of low intensity or the ginga used in Capoeira; 2) main part: from the Basic Programmed Lesson (40min) and ; 3) final part: Capoeira presentation of 10min. In this last moment, the participants remained in a circle and, in pairs, executed the movements practiced earlier in the sessions. In order to perform the Basic Programmed Lesson, the activities were divided in four stages, composed by ginga and other movements: dodging, unbalancing, traumatizing and acrobatic. The volunteers would perform the initial part of the basic lesson (ex. 1st stage) and afterwards, when performing the subsequent part (ex. 2nd stage), would first repeat the 1st basic lesson, with the purpose of continuing the learning process and improving the previous lesson."
11378261|NCT02180360|No Intervention|Control group|The Control group did not perform any physical exercise during the intervention period (eight weeks).
11378262|NCT02180347||Multifocal contact lenses|Coopervision Proclear Multifocal
11378263|NCT02180347||Single vision contact lenses|Coopervision Proclear Sphere
11378264|NCT02180334|Experimental|Mosapride|"Mosapride citrate 5 mg (Gasmotin®): 1 tablet (5 mg) will be administered 1 hour before MMTT.
~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.
~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
11378265|NCT02180334|Placebo Comparator|Control|"Placebo drug: 1 tablet will be administered 1 hour before MMTT.
~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.
~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
11378266|NCT02180321|Active Comparator|Control|
11378267|NCT02180321|Experimental|Tranexamic acid|
11378268|NCT02180308||PET/MRI|Patient receives PET/MRI
11378269|NCT02180295|Experimental|V212 Lot 1|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
11378270|NCT02180295|Experimental|V212 Lot 2|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
11378271|NCT02180295|Experimental|V212 Lot 3|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
11378272|NCT02180282|Experimental|Acne Treatment|Acne treatment using the M22-IPL acne filter
11378273|NCT02180269|Experimental|Cohort A|Single oral dose of either JNJ-54861911, 25 milligram (mg) tablet or matched placebo tablet on Day 1.
11378274|NCT02180269|Experimental|Cohort B|Single oral dose of either JNJ-54861911, 50 mg (2*25 mg tablets) or matched placebo tablets on Day 1.
11378275|NCT02180269|Experimental|Cohort C|Single oral dose of either JNJ-54861911, 100 mg (4*25 mg tablets) or matched placebo tablets on Day 1.
11378276|NCT02180256|Experimental|Endoscratching, non-RIF|Endometrial scratching. Women with no more than 1 previous unsuccessful embryo transfer. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
11378277|NCT02180256|No Intervention|Control, non-RIF|No intervention. Women with no more than 1 previous unsuccessful embryo transfer.
11378278|NCT02180256|Experimental|Endoscratching, RIF|Endometrial scratching. Women with 2 or more previous unsuccessful embryo transfers. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
11378279|NCT02180256|No Intervention|Control, RIF|No intervention. Women with 2 or more previous unsuccessful embryo transfers.
11378280|NCT02180243|Experimental|Yoga/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
11378281|NCT02180243|Active Comparator|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
11378282|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
11378283|NCT02180217|Experimental|osilodrostat (LCI699)|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then osilodrostat during a double-blind, placebo controlled RW Period.
11378284|NCT02180217|Placebo Comparator|LCI699 Placebo|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then placebo during a double-blind, placebo controlled RW Period.
11378285|NCT02180204|Experimental|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg
11378286|NCT02180204|Active Comparator|Alteplase|Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg
11378287|NCT02180191||Obesity|27 obese individuals (20 men and 7 women with mean BMI: 39.98±5.56 kg/m2)
11378288|NCT02180191||Diabetes|26 patients with newly diagnosed type 2 diabetes (18 men and 8 women with mean BMI: 28.63±5.08 kg/m2)
11378289|NCT02180191||Control|Healthy control subjects (22 men and 6 women with mean BMI: 23.02±1.70 kg/m2)
11378290|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
11378291|NCT02180165|Experimental|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
11378292|NCT02180165|Active Comparator|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
11378293|NCT02180165|Experimental|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
11378294|NCT02180165|Active Comparator|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
11378295|NCT02180152|Experimental|Postprandial walk|
11378296|NCT02180152|No Intervention|sedentary pregnant women|
11378417|NCT02179385|Experimental|Health coaching|Patients receive health coaching via the phone, face to face or group support, according to patients' choice
11378418|NCT02179385|Placebo Comparator|Standard of Care|
11378298|NCT02180139|Experimental|Cerebellum stimulation|Treatment with transcranial direct current stimulation will be targeted to the cerebellum at every session with anode to ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits)
11378299|NCT02180139|Experimental|Combined M1 and Cerebellum stimulation|Treatment with transcranial direct current stimulation will be placed with M1 anode contralateral + cerebellum anode. M1 will first be 'primed' with anode on contralateral M1, cathode on face, for 10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the contralateral M1 with increased excitability to engage a potentially larger effect from the following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect on the motor circuits including M1)
11378300|NCT02180139|Placebo Comparator|Sham stimulation|transcranial direct current stimulation will be given in placebo form. Sham stimulation: electrode placement will be same as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds following standard practice for sham tDCS.
11378301|NCT02180126||Positive ANCA|Patients with borderline positive ANCA results.
11378302|NCT02180113|Other|Fibroscan®|Fibroscan® is an active non implantable medical device using ultrasound. It has been designed to measure liver stiffness in a painless, rapid and non invasive manner. It is a diagnostic aid tool. In this study, Spleen Stiffness Measurement will be assessed using a dedicated FibroScan® device which has been developed specifically to assess spleen stiffness.
11378303|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
11378304|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
11378305|NCT02180087|Placebo Comparator|placebo group|Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours
11378306|NCT02180087|Other|ketopofen quarter dose|"Group 2 : Ketoprofen quarter dose (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours."
11378307|NCT02180087|Other|ketoprofen half-dose|"Group 3 : Ketoprofen half-dose (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours."
11378308|NCT02180087|Other|Ketoprofen full dose|"Group 4 : Ketoprofen full dose (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours"
11378309|NCT02180074||I|Women without PAD (ABI >1.0 and <1.4) or CAD, and < 2 risk factors for cardiovascular disease (to serve as healthy controls)
11378310|NCT02180074||II|Women without PAD (ABI>1.0 and <1.4) or CAD and > 2 risk factors for cardiovascular disease
11378311|NCT02180074||III|Women with PAD as defined by ABI <0.9 and a coronary angiogram without any significant coronary artery disease.
11378312|NCT02180074||IV|Women with CAD without PAD, as defined by >50% stenosis by coronary angiography and ABI >1.0 and <1.4.
11378313|NCT02180074||V|Women with both CAD and PAD.
11378314|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
11378315|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
11378316|NCT02180048|Active Comparator|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
11378317|NCT02180048|Active Comparator|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
11378318|NCT02180048|Placebo Comparator|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
11378319|NCT02180035|Experimental|Symbiotic & Nutritional intervention|Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
11378320|NCT02180035|Placebo Comparator|Maltodextrin & Nutritional intervention|Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
11378321|NCT02180022|Placebo Comparator|Placebo|Patients treated with placebo for 12 weeks
11378322|NCT02180022|Experimental|Onion peel extract|Patients treated with onion peel extract for 14 days
11378323|NCT02180009||normal control|healthy people
11378324|NCT02180009||sepsis|mild response to infection
11378325|NCT02180009||severe sepsis|infection with at least one organ dysfunction
11378326|NCT02180009||septic shock|patients with septic shock
11378327|NCT02179996|Active Comparator|Three vaccine injections|Infants in this study arm will receive three vaccine injections at two, three and four months after birth (vaccine: DTP-pertussis-Hib).
11378328|NCT02179996|Experimental|Two vaccine injections|Infants in this study arm will receive two vaccine injections at two and four months after birth (vaccine: DTP-pertussis-Hib).
11378329|NCT02179983|No Intervention|Standard care|Standard care for exacerbation and follow-up without rehabilitation
11378330|NCT02179983|Experimental|Pulmonary rehabilitation|6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)
11378331|NCT02179970|Other|Plerixafor (Mozobil)|Plerixafor (Mozobil), continuous 7 day IV infusion. Starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
11378332|NCT02179957||CT and FFR|Coronary stenoses which have been analysed with both CT and FFR
11378333|NCT02179944||Participants|
11378334|NCT02179931|Experimental|Flupentixol/melitracen film-coated tablet|test treatment - 0.5 mg/10 mg; oral as a single dose
11378335|NCT02179931|Other|Flupentixol/melitracen coated tablet (Deanxit®)|reference treatment - 0.5 mg/10 mg, oral as a single dose
11378336|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
11378337|NCT02179905||Irritable bowel syndrome, Control|
11378338|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
11378339|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
11378419|NCT02179372|Experimental|Eicosapentaenoic acid|Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months
11378340|NCT02179879||Video validation group|This will include video taping of experts (defined as one who has performed more than 500 labor epidurals in preceding 5 year period) and novices (defined as one who has done less than 50 epidurals in preceeding 2 years) perfoming labor epidural
11378341|NCT02179866|Experimental|[14C]-labeled RO5285119|Single oral dose - drinking solution
11378342|NCT02179853|Experimental|Anakinra|This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).
11378343|NCT02179840|Active Comparator|Intravenous|Anesthesia is maintained via intravenous agents. Mechanical ventilation adjustment will be performed.
11378344|NCT02179840|Active Comparator|Inhalational|Anesthesia is maintained via inhalational agents. Mechanical ventilation adjustment will be performed.
11378345|NCT02179814|Experimental|AMPT|"Experimental:
~alpha-methyl-paratyrosine (AMPT, trade name: Demser), body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 time points over 24 hours"
11378346|NCT02179814|Sham Comparator|Diphenhydramine & placebo|Diphenhydramine (25mg, trade name in Switzerland: Benocten) at the first medication intake time point, placebo at the second to fourth intake time point (medication intake over 24 hours)
11378347|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
11378348|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:
~Days 1-7, take 1 capsule with evening meal
~Days 8-14, take 3 capsules with evening meal
~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal
~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
11378349|NCT02179775|Active Comparator|propranolol|
11378350|NCT02179775|Active Comparator|Quince's oxymel|
11378351|NCT02179775|Placebo Comparator|placebo|
11378352|NCT02179762|Experimental|Arm I (moderate intensity exercise)|Patients perform moderate intensity exercise on a stationary bike for 20-50 minutes, three days a week for 16 weeks.
11378353|NCT02179762|Experimental|Arm II (HIIT exercise on a standard stationary bike)|Patients perform HIIT exercise on a standard stationary bike, three days a week for 16 weeks.
11378354|NCT02179762|Experimental|Arm III (HIIT exercise on a cybercycle)|Patients perform HIIT exercise on a cybercycle using racing or other games, three days a week for 16 weeks.
11378355|NCT02179749|Active Comparator|Experimental: mifepristone 600 mg daily|600 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
11378356|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
11378357|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
11378358|NCT02179736|Experimental|Active treatment|
11378359|NCT02179723|Experimental|Leukosan Adhesive|Leukosan Adhesive applied to one wound (left or right)
11378360|NCT02179723|Active Comparator|Transcutaneous suture|Transcutaneous suture applied to second wound (left or right)
11378361|NCT02179710||Motivational Interviewing|Review of adherence dashboard by the investigator with the patient to facilitate and engage intrinsic motivation within the client in order to change behavior.
11378362|NCT02179697|Active Comparator|Surgery + Bracing vs. Bracing Alone|"Randomize between 2 treatments:
~Treatment 1: Surgery + Bracing Treatment 2: Bracing alone"
11378363|NCT02179697|Other|Patient's choice|Patient will decide which group is best for him/her. The patient will be followed at the same points as Group 1.
11378364|NCT02179684|Experimental|Early surgery|Patienst with Bell´s Palsy with an early surgical intervention (< 3month), according to 'baby-sitter' method
11378365|NCT02179684|Active Comparator|Conventional treatment and follow-up|Patienst with Bell´s Palsy treated with conventional treatment and standardized physiotherapy according to Jaqueline Diels model.
11378366|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
11378367|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
11378368|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
11378369|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
11378370|NCT02179658|Experimental|OPT-80 group|Oral
11378371|NCT02179658|Active Comparator|Vancomycin group|Oral
11378372|NCT02179645|Experimental|GRC 27864|Test Treatment GRC 27864
11378373|NCT02179645|Active Comparator|Celecoxib|Active Comparator Treatment
11378374|NCT02179645|Placebo Comparator|Placebo|Placebo Treatment
11378375|NCT02179632|Experimental|Disclosure intervention zero|Treatment Group 1: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. A. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. A, according to manufacturer, in 2012. Dr. A will be a physician the researchers have chosen who does not appear on the website and therefore did not receive any payments in 2012. Participants should report $0/not listed as the response. Following this stage, participants will be told that Dr. A does not appear on the website and therefore did not receive any payments.
11378376|NCT02179632|Experimental|Disclosure intervention low|"Treatment Group 2: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. B. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. B, according to manufacturer, in 2012. Dr. B will be a physician the researchers have chosen who received an aggregate amount that is a low payment (below $100) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. B in 2012."
11378695|NCT02177487|Experimental|Telmisartan + Hydrochlorothiazide|
11378377|NCT02179632|Experimental|Disclosure intervention high|"Treatment Group 3: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. C. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. C, according to manufacturer, in 2012. Dr. C will be a physician the researchers have chosen who received an aggregate amount that is a high payment (above $250) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. C in 2012."
11378378|NCT02179632|No Intervention|Control group|Control Group: The control group will not be exposed to the disclosure website, but will participate in another online information-seeking task. These participants will visit the Farmer's Almanac website and be asked to search for temperature reports.
11378379|NCT02179619|Experimental|Dermalax(Deep)|subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
11378380|NCT02179619|Active Comparator|Restylane|Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
11378381|NCT02179606|Experimental|Dermalax Implant Plus|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
11378382|NCT02179606|Active Comparator|Restylane Sub-Q|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
11378383|NCT02179593|Other|2-Segment SARPE|Maxilla expansion using one sagittal section of the maxilla.
11378384|NCT02179593|Other|3-Segment SARPE|Maxilla Expansion using two parasagittal section of the maxilla.
11378385|NCT02179580|Experimental|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days
11378386|NCT02179580|Placebo Comparator|Placebo|Placebo at a rate of 3.0 g three times per day for 28 days
11378387|NCT02179567|Experimental|Doc/Bev|Docetaxel/Bevacizumab
11378388|NCT02179554||cardiopulmonary bypass|Patients undergoing elective surgery requiring cardiopulmonary bypass
11378389|NCT02179541||Group 1|All Group 1 patients were diagnosed with OME, diagnoses made by endoscopic-otoscopic examination findings and type-B tympanograms. They were all scheduled for ventilation tube insertion. Diagnosis of OME was confirmed during this surgery. All patients were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements. Viscosity was measured by the Brookfield DV-II+ProCP Viscometer.
11378390|NCT02179541||Group 2|Children in Group 2 had totally normal tympanic membranes and type A tympanograms. They had no hearing loss, Eustachian tube dysfunction, or any other ear-related problem, and were included in the study as healthy controls. Excluded from the study were patients presenting with acute otitis media, tympanosclerotic plaques, mental retardation, and children who were difficult to cooperate with. All subjects were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements.
11378391|NCT02179541||Group 1a|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion below the mean viscosity value of 450 cP (centipoise) were assigned to Group 1a.
11378392|NCT02179541||Group 1b|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion above the mean viscosity value of 450 cP (centipoise) were assigned to Group 1b.
11378393|NCT02179528|Active Comparator|etoposide,maintenance therapy|etoposide,25mg qd d1-20，repeat every 28 days
11378394|NCT02179528|No Intervention|blank control|blank control
11378395|NCT02179515|Experimental|A|Three cohorts will receive MVA-brachyury-TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/ 4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
11378396|NCT02179502|Experimental|GLPG1690 single dose|Single oral dose of GLPG1690 suspension or solid formulation - ascending doses
11378397|NCT02179502|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension or solid formulation
11378398|NCT02179502|Experimental|GLPG1690 multiple doses|Multiple oral doses of GLPG1690 suspension - ascending doses
11378399|NCT02179502|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
11378400|NCT02179489|No Intervention|Control|surgery alone
11378401|NCT02179489|Experimental|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
11378402|NCT02179476|Experimental|Glyder|Glyder Facet Restoration Device
11378403|NCT02179463||Neoadjuvant Chemotherapy|undergo neoadjuvant chemotherapy before surgery
11378404|NCT02179450||Blepharospasm|Patients suffering from Blepharospasm
11378405|NCT02179450||Cervical Dystonia|Patients suffering from cervical dystonia
11378406|NCT02179450||Bilateral facial palsy|Patients suffering from bilateral facial palsy of inflammatory origin
11378407|NCT02179450||Healthy Control|Control subjects
11378408|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
11378409|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
11378410|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
11378411|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
11378412|NCT02179411|Active Comparator|healthy volunteers|healthy volunteers
11378413|NCT02179411|Active Comparator|renal transplant recipients|renal transplant recipients
11378414|NCT02179411|Active Comparator|renal transplant recipients grave|renal transplant recipients grave
11378415|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.
~(WBC and band counts blinded to the physician in charge of the patient)"
11378416|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.
~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
11378420|NCT02179372|Placebo Comparator|Medium chain fatty acid (placebo)|Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months
11378421|NCT02179359|Experimental|Reduced Toxicity Ablative Regimen|For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are <12 years and/or have mild/moderate iron exposure.
11378422|NCT02179359|Experimental|Reduced Intensity Preparative Regimen|For use in patients with unrelated donor bone marrow and for DBA patients who are >12 years and/or have significant iron exposure.
11378423|NCT02179359|Experimental|Myeloablative Preparative Regimen|For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
11378424|NCT02179346||Cartilage defects in the hip joint|NOVOCART® Inject Autologous Chondrocyte Implantation
11378425|NCT02179333||Subjects with Ataxia|Patients with a diagnosis of ataxia (Friedreich's ataxia or Spinocerebellar ataxia type 1-30) aged 18-80 years old will be recruited for the study.
11378426|NCT02179320|Active Comparator|Dry needling|Dry needling for myofascial pain syndrome, in the trapezius muscle.
11378427|NCT02179320|Sham Comparator|Sham needling|Superficial dry needling in the trapezius muscle
11378428|NCT02179307|Experimental|Arm label 1-Set, 3-Set|12-week progressive strength training protocol of different volumes
11378429|NCT02179294|Active Comparator|Pethidine|Pethidine is pain relief in labour
11378430|NCT02179294|Active Comparator|Remifentanil|Remifentanil intravenous patient controlled analgesia
11378431|NCT02179281|Experimental|Suspend Before Low feature turned ON|"MiniMed™ 640G system with the Suspend Before Low feature turned ON; continuously set on at 3,6 mmol/L (65 mg/dL). Suspend On Low Alert and Resume Basal Alert for the SmartGuard group should be set OFF.
~Administered intervention: Medtronic MiniMed™ 640G system"
11378432|NCT02179281|Active Comparator|Suspend Before Low feature turned OFF|"MiniMed™ 640G system with the Suspend Before Low and Suspend On Low features are both turned OFF; Alert On Low is set at 65 mg/dL (3,6 mmol/L). Resume Basal Alert should be set OFF as well.
~Administered intervention: Medtronic MiniMed™ 640G system"
11378433|NCT02179268|Active Comparator|sertraline & control|sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
11378434|NCT02179268|Active Comparator|citalopram & Control|citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
11378435|NCT02179268|Active Comparator|venlafaxine & control|venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
11378436|NCT02179268|Active Comparator|reboxetine & control|reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
11378437|NCT02179255|Experimental|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) plus FSH 450 to 600 units per day administered subcutaneous (SQ) daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
11378438|NCT02179255|Active Comparator|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
11378439|NCT02179242|No Intervention|Control arm|This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
11378440|NCT02179242|Experimental|Cardiac rehab|This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.
11378441|NCT02179229|Placebo Comparator|CONTROL|Patient in the CONTROL arm will receive a powder containing only tapioca-resistant starch comparable in colour, texture and taste to the synbiotic.
11378442|NCT02179229|Experimental|SYNBIOTIC|Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
11378443|NCT02179216|Active Comparator|Hydration|•Group 1: First day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl). Second day, Orthostatic Hypotension test with venous contention in the morning.
11378444|NCT02179216|Active Comparator|Venous contention|•Group 2: First day, Orthostatic Hypotension test after implementation of venous contention in the morning. Second day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl).
11378445|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
11378446|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
11378447|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
11378448|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
11378449|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
11378450|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
11378451|NCT02179138|Other|TFV 1% Gel|TFV 1% gel with the user-filled paper applicator
11378452|NCT02179125|Experimental|Bronchoscopic LVR-coil treatment|Bronchoscopic lung volume reduction with coil treatment
11378453|NCT02179099|Experimental|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
11378454|NCT02179086|Active Comparator|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11378455|NCT02179086|Experimental|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11378456|NCT02179086|Active Comparator|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11378457|NCT02179086|Experimental|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.
~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11378458|NCT02179073||neurogenic bladder dysfunction|
11378459|NCT02179060||Cooling group|The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation
11378460|NCT02179060||Control group|Standard care, no cooling during pre-hospital care
11378461|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
11378462|NCT02179047||placebo|healthy subject
11378463|NCT02179034|Placebo Comparator|Tobacco Flavor|In this arm, subjects will receive tobacco flavor- without nicotine (placebo). Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
11378464|NCT02179034|Active Comparator|Low Dose Nicotine|In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
11378465|NCT02179034|Active Comparator|High Dose Nicotine|In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
11378466|NCT02179008|Experimental|DE-117 Low Dose ophthalmic solution|One drop Low Dose DE-117 in each eye QD for 90 days
11378467|NCT02179008|Experimental|DE-117 Low/Middle Dose ophthalmic solution|One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days
11378468|NCT02179008|Experimental|DE-117 Middle Dose ophthalmic solution|One drop Middle Dose DE-117 in each eye QD for 90 days
11378469|NCT02179008|Experimental|DE-117 Middle/High Dose ophthalmic solution|One drop Middle/High Dose DE-117 in each eye QD for 90 days
11378470|NCT02179008|Experimental|DE-117 High Dose ophthalmic solution|One drop High Dose DE-117 in each eye QD for 90 days
11378471|NCT02179008|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop latanaprost in each eye QD for 90 days
11378472|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.
~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
11378473|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
11378474|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
11378475|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
11378476|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
11378477|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
11378478|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
11378479|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.
~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:
~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
11378480|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
11378481|NCT02178982||standard treatments of ARDS|
11378482|NCT02178982||protocol treatment of ARDS|
11378483|NCT02178956|Experimental|BBI608 plus Paclitaxel|
11378484|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
11378485|NCT02178943||Heart Transplant Recipients|Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.
11378486|NCT02178930|Other|Integrated self management support|The intervention involves the introduction of an interactive chronic disease support platform into doctor-patient consultations, in addition to a self-management support program. Specifically, the intervention comprises the following interlinked components: within consultation engagement; at home exploration; phone and web-based health coaching.
11378487|NCT02178930|No Intervention|Usual care|The control group will receive usual care from study sites until all study participants have completed 12 months of follow up from their Baseline Visits. At this point access to the study intervention will be expanded to include control sites.
11378488|NCT02178917|Experimental|patients with central neuropathic pain|Randomised to 20 neurofeedback therapy sessions
11378489|NCT02178917|Other|Control: patients with central neuropathic pain|Randomised to no neurofeedback treatment
11378490|NCT02178917|No Intervention|patients with no central neuropathic pain|Observed for development of central neuropathic pain
11378491|NCT02178904||Suspected Coronary Artery Disease|Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test
11378492|NCT02178891|Other|short implants|
11378493|NCT02178878||Progress, Pain|Progress, Pain
11378494|NCT02178865||translocation carrier|balanced translocation carriers who have undergone IVF
11378495|NCT02178852|Experimental|TNS-active|TRIGEMINAL NERVE STIMULATION (TNS)
11378496|NCT02178852|Placebo Comparator|TNS-sham|TRIGEMINAL NERVE STIMULATION (TNS) - sham
11378497|NCT02178839|Experimental|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
11378498|NCT02178839|Placebo Comparator|Maltodextrin|8.5 g/d Maltodextrin
11378499|NCT02178826|Experimental|Rapid Maxillary Expansion|A Rapid Maxillary Expander will be fitted and the palate will be expanded approximately 5mm.
11378500|NCT02178826|Placebo Comparator|Placebo group|A Sham appliance is fitted and activated for 10-14 days. The patients in this group will after it has been revealed they were randomized into the placebo group have a true Rapid Maxillary Expander fitted and the palate will be expanded approximately 5 mm.
11378501|NCT02178813|Experimental|Administration of minocycline|"All patients in the study will receive minocycline periprocedurally with the following schedule:
~Day prior to procedure: 800mg p.o., 700mg p.o.
~Day of procedure: 600mg i.v., 500mg p.o.
~Day after procedure: 400mg p.o., 400mg p.o."
11378502|NCT02178800|Experimental|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
11378503|NCT02178800|Placebo Comparator|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
11378504|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
11378505|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
11378506|NCT02178774||parturients|tissue oxymetry
11378507|NCT02178761|Active Comparator|Angioplasty alone|plain old balloon angioplasty alone
11378508|NCT02178761|Active Comparator|Stenting|Balloon angioplasty plus stenting
11378509|NCT02178761|Active Comparator|drug-eluting balloon|Balloon angioplasty with drug-eluting balloon
11378510|NCT02178761|Active Comparator|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stent
11378511|NCT02178748|Experimental|Group 1|Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
11378512|NCT02178748|Experimental|Group 2|Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
11378513|NCT02178735|Experimental|Anterior compartment prolapse|Woman with cystocele who underwent anterior vaginal tailored mesh surgery
11378703|NCT02177448|Active Comparator|Enalapril and placebo matching BIBR277|
11378514|NCT02178735|Experimental|Posterior compartment prolapse|Woman with rectocele, enterocele, uterine prolapse, vaginal stump prolpase who underwent posterior vaginal tailored mesh surgery
11378515|NCT02178735|Experimental|anterior and posterior prolapse|Woman with cystocele and rectocele/uterine prolapse/vaginal vault prolapse/enterocele who underwent anterior and posterior vaginal tailored mesh surgery
11378516|NCT02178722|Experimental|Phase 1: MK-3475 + INCB024360|Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
11378517|NCT02178722|Experimental|Phase 2: MK-3475 + INCB024360|(recommended phase 2 dose)
11378518|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:
~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle
~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle
~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle
~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.
~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
11378519|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
11378520|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
11378521|NCT02178683|No Intervention|Tacrolimus and Mycophenolate Mofetil|Non-myeloablative allogeneic SCT from an HLA-Identical or non-identical family onor or unrelated donors, with fludarabine and low-dose TBI, with immunosuppression utilizing tacrolimus and MMF.
11378522|NCT02178670|Placebo Comparator|non-cancer stem cell vaccine|There is no cancer stem cell vaccine in this group
11378523|NCT02178670|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11378524|NCT02178670|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11378525|NCT02178670|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11378526|NCT02178657|Experimental|Bone marrow transplantation low dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10^6 per kilogram)
11378527|NCT02178657|Experimental|Bone marrow transplantation high dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10^6 per kilogram)
11378528|NCT02178657|No Intervention|Control|
11378529|NCT02178644|Experimental|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
11378530|NCT02178631|Experimental|Deprexis|Online self-help
11378531|NCT02178631|Active Comparator|CAU|Care as usual
11378532|NCT02178618|Active Comparator|Partially covered biliary self expandable metal stent|
11378533|NCT02178618|Active Comparator|Uncovered biliary self expandable metal stent|
11378534|NCT02178605||Cervical arthrodesis candidates|Patients scheduled to undergo cervical arthrodesis to treat their spinal pathology will undergo cervical arthrodesis with rhBMP-2
11378535|NCT02178592|Experimental|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
11378536|NCT02178592|Active Comparator|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
11378537|NCT02178579||Multiple Myeloma (MM) treatment with bortezomib|No intervention planned.
11378538|NCT02178579||Multiple Myeloma (MM) treatment with carfilzomib|No intervention planned.
11378539|NCT02178566|Placebo Comparator|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
11378540|NCT02178566|Active Comparator|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
11378541|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
11378580|NCT02178332|Active Comparator|Two theoretical lectures|Teachers receive two theoretical lectures on development of children's socio-emotional skills (3 hours in November 2013 and 3 hours in March 2014 ).
11378704|NCT02177435|Experimental|Telmisartan plus Hydrochlorothiazide|
11378542|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
11378543|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
11378544|NCT02178527|Experimental|Mulitfaceted podiatry Intervention|Foot and ankle exercises, foot orthoses, footwear provision
11378545|NCT02178527|Placebo Comparator|Usual podiatry care|Continued provision of usual NHS (National Health Service) podiatry care
11378546|NCT02178514|Experimental|Formula Feeding group by BabyNes Nutrition System|In this arm, all infants will be fed with BabyNes Nutrition System since enrollment until 12 month of age
11378547|NCT02178514|No Intervention|Breastfeeding group|used as reference to compare with formula feeding group
11378548|NCT02178501|Experimental|Omega-3 PUFA|OMEGA-3 PUFA 2000 mg once daily (1000 mg EPA and 1000 mg DHA)
11378549|NCT02178501|Placebo Comparator|Placebo|Placebo once daily
11378550|NCT02178488|Active Comparator|Cholecalciferol|150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month
11378551|NCT02178488|Placebo Comparator|Sugarpill|150 patients with MRSA resistent Placebo daily 12 month
11378552|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
11378553|NCT02178462||Primary ovarian cancer patients|Intervention will not be administered.
11378554|NCT02178462||Primary endometrial cancer patients|Intervention will not be administered.
11378555|NCT02178462||Benign gynecological disease patients|Intervention will not be administered.
11378556|NCT02178462||Healthy controls|Intervention will not be administered.
11378557|NCT02178449|Experimental|Verum|Dexamethasone and Ropivacaine
11378558|NCT02178449|Active Comparator|Placebo|Ropivacaine and Saline
11378559|NCT02178436|Experimental|Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)|Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11378560|NCT02178436|Experimental|Group II: Phase II Group I (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
11378561|NCT02178436|Experimental|GroupIII: Phase II Group II (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11378562|NCT02178423|Experimental|Ultrasound|Ultrasound for diagnosis of CVC position in children
11378563|NCT02178410|Active Comparator|Vitamin D + fish oil|
11378564|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
11378565|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
11378566|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11378567|NCT02178397|Experimental|EXPERIMENTAL ARM B|"INDUCTION chemotherapy: 4 cycles of
~pemetrexed with cisplatin or carboplatin
~or gemcitabine with cisplatin or carboplatin in combination with erlotinib
~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib"
11378568|NCT02178397|Active Comparator|STANDARD ARM A|"INDUCTION chemotherapy: 4 cycles of
~pemetrexed with cisplatin or carboplatin
~or gemcitabine with cisplatin or carboplatin
~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed"
11378569|NCT02178384|Experimental|Altered-cast technique|Removable partial dentures will be made using altered-cast technique for free saddles.
11378570|NCT02178384|Active Comparator|Precision attachments|Removable partial dentures will be made using precision attachments which will be located on the distal abutment teeth.
11378571|NCT02178384|Active Comparator|Resilient layer|Removable partial dentures will be made using a resilient-layer on the distal extension of each appliance.
11378572|NCT02178371|Experimental|UTWC (control group)|the control group performs the same tasks than the experimental group, but without healthy hand constraint/containment.
11378573|NCT02178371|Experimental|mCIMT|"The study is conducted over a period of 5 weeks of treatment, using a movement restriction time healthy upper extremity of 2 hours daily.
~The restriction applied in the study is performed with the closed hand position and thumb inside the fist through a transparent film that reaches the wrist joint.
~In periods mCIMT, monitored the activities designed to enhance their functionality, based on motivation, avoiding frustrations are made."
11378574|NCT02178358|Experimental|LY2157299|150 milligrams (mg) LY2157299 administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles).
11378575|NCT02178358|Experimental|LY2157299 + Sorafenib|"80 or 150 mg LY2157299 administered orally, BID for 14 days followed by 14 days with no study drug (28 day cycles).
~400 mg sorafenib administered orally BID for 28 days."
11378576|NCT02178358|Placebo Comparator|Placebo + Sorafenib|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles).
~400 mg sorafenib administered orally BID for 28 days."
11378577|NCT02178345||Surgical patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
11378578|NCT02178345||surveillance management patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
11378579|NCT02178332|Experimental|Yhteispeli, whole school programme|Yhteispeli-programme aims to support children's socio-emotional skills and well being at schools. Schools receive the Yhteispeli manual and teachers receive 3 and head masters 2 lecture days about use of Yhteispeli methods including group discussions and exercises. In addition every school is visited 4 times to support the use of Yhteispeli methods. (Lectures for the head masters March 2013 - November 2013, teachers August 2013 - January 2014)
11378705|NCT02177435|Experimental|Telmisartan|
11378582|NCT02178319|Experimental|laparoscopic group|the patients under go the laparoscopic esophagogastric devascularization and splenectomy
11378583|NCT02178306|Experimental|Telmisartan|
11378584|NCT02178293|Active Comparator|Benzidamine hydrochloride|
11378585|NCT02178293|Experimental|Ketoprofen lysine salt|
11378586|NCT02178280|No Intervention|unresectable hilar cholangiocarcinoma|control group
11378587|NCT02178280|Experimental|liver transplantation|liver transplantation combined with neoadjuvant radiochemotherapy
11378588|NCT02178267|Experimental|Lactobacillus reuteri|The study was performed by two groups. And these groups were constituted from the newborn preterm infants who are received probiotics (Lactobacillus reuteri) and no probiotics.
11378589|NCT02178254|Experimental|Sequence 3|N=10 subjects receive 3grams oral sachet of Monurol in Period 1; 1.0gram of Intravenous (IV) ZTI-01 for Period 2 (1-hour infusion); and 8.0 grams IV ZTI-01 for Period 3.
11378590|NCT02178254|Experimental|Sequence 1|N=10 subjects receive 1.0gram of Intravenous (IV) ZTI-01 for Period 1 (1-hour infusion); 8.0 grams IV ZTI-01 for Period 2 (1-hour infusion); and 3grams oral sachet of Monurol in Period 3.
11378591|NCT02178254|Experimental|Sequence 2|N=10 subjects receive 8.0 grams IV ZTI-01 for Period 1(1-hour infusion); 3grams oral sachet of Monurol in Period 2 and 1.0gram of IV ZTI-01 for Period 3 (1-hour infusion)
11378592|NCT02178241|Experimental|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11378593|NCT02178228||Subjects over age 18|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are over the age of 18
11378594|NCT02178228||Subjects age 15-17|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are age 15-17 with one permission of one parent.
11378595|NCT02178215|Placebo Comparator|Placebo shower gel|•Wash forearm by prepared placebo shower gel twice a day
11378596|NCT02178215|Active Comparator|Holly Mangrove Shower Gel|•Wash forearm by Holly Mangrove Showver gel twice a day
11378597|NCT02178189|Active Comparator|Standard-calorie infant formula|Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
11378598|NCT02178189|Experimental|High-calorie infant formula|Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
11378599|NCT02178176|Experimental|Education, encouragement, card sort|
11378600|NCT02178176|Active Comparator|Education, encouragement|
11378601|NCT02178163|Experimental|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
11378602|NCT02178150|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 8 weeks, every day 1 tablet
11378603|NCT02178150|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 8 weeks, one tablet every day
11378604|NCT02178137|Active Comparator|Glucosamine/Chondroitin|"Glucosamine/Chondroitin twice a day for a daily total dose of 1500 mg of Glucosamine and 1200 mg of Chondroitin.
~Tablets will have 750 mg Glucosamine Sulphate and 600 mg of Chondroitin Sulphate. These will be taken twice a day after breakfast and dinner."
11378605|NCT02178137|Active Comparator|Diacerien|Diacerien 50 mg twice a day in capsule form. To be taken twice a day after breakfast and dinner
11378606|NCT02178137|Placebo Comparator|Placebo pill|Placebo tablets with Zinc sulfate twice a day. These will contain pharamacologically non active ingredients (Usually expedients).
11378607|NCT02178124|Experimental|dosage 1|drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)
11378608|NCT02178124|Experimental|dosage 2|"dosage2 period 1 : oral administration drug : 12 people(10mg)
~dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)"
11378609|NCT02178111|Experimental|Never perform episiotomy|In this group the birth attendant will sought to avoid the use of episiotomy, and try not to carry out the procedure unless considered absolutely needed
11378610|NCT02178111|Active Comparator|Selective episiotomy|Patients will be subjected to the usual routine (selective episiotomy, ie, in the presence of indications described in the literature, according to the discretion of the physician or nurse assisting the birth)
11378611|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
11378612|NCT02178098|Placebo Comparator|Placebo|Placebo control
11378613|NCT02178085|Experimental|Flow imaging|Glaucoma patients and healthy subjects who will undergo ocular flow imaging
11378614|NCT02178072|Other|HPV positive|HPV positive patients
11378615|NCT02178072|Other|HPV negative|HPV negative patients
11378616|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
11378617|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
11378618|NCT02178046||Gingivitis|optical measurements
11378619|NCT02178033|Other|low-volume (2L) PEG|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, both doses are taken the day before colonoscopy, starting on the evening at about 18:00. Solution intake should be completed before 22.00 h.
11378620|NCT02178033|Active Comparator|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, the first dose is taken on the evening before colonoscopy (at about 20:00 h), the second one is taken early in the morning on the day of the procedure, starting about 4 h before the scheduled procedure time.
11378621|NCT02178020||knee arthroplasty, standard polyethylene|total knee arthroplasty with Standard Compression Molded tibial Polyethylene Liner
11378622|NCT02178020||knee arthroplasty, Highly Cross-Linked (XLP) polyethylene|knee arthroplasty with Highly Cross-Linked tibial Polyethylene Liner
11378623|NCT02177994|Experimental|Group A ceftriaxone after cord clamping|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive
~1 gm. ceftriaxone via l intravenous infusion single dose after cord clamping."
11378624|NCT02177994|Active Comparator|Group B ceftriaxone before skin incision|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive
~1 gm. ceftriaxone vial intravenous infusion single dose 30-60 minutes before skin incision."
11378625|NCT02177981|Active Comparator|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
11378626|NCT02177981|Sham Comparator|Control|The cuff will be placed around the arm but not inflated.
11378627|NCT02177968||Elderly fallers or non-fallers|characteristics of these groups
11378628|NCT02177955|Placebo Comparator|midazolan|7.5 mg midazolan 45 minutes before the surgery
11378629|NCT02177955|Placebo Comparator|diazepam|10 mg diazepam 45 minutes before the surgery
11378630|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
11378631|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
11378632|NCT02177929|Experimental|adapted canoeing, handbike, conventional physiotherapy|Individuals are divided into three groups: one group adapted canoeing, one group of handbike and one grup of conventional physiotherapy.
11378633|NCT02177916|Experimental|Traditional teaching|
11378634|NCT02177916|Experimental|DVD|
11378635|NCT02177903|Other|Bair PawsPatient Adjustable Warming System|Bair PawsPatient Adjustable Warming System for active pre-warming
11378636|NCT02177903|Other|Passive pre-warming|Passive pre-warming
11378637|NCT02177890|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve
11378638|NCT02177890|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.
11378639|NCT02177864|Experimental|Fiber|
11378640|NCT02177864|Placebo Comparator|Placebo|
11378641|NCT02177851|Experimental|Single oral iron supplement per day (120 mg)|Single oral iron dose of 120 mg per day for 3 consecutive days
11378642|NCT02177851|Active Comparator|B.i.d. oral iron supplement (2x 60 mg)|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
11378643|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
11378644|NCT02177825|Experimental|Imatinib Mesylate|Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
11378645|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
11378646|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
11378647|NCT02177799||gastroenteritis|
11378648|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
11378649|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
11378650|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
11378651|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
11378652|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
11378653|NCT02177760|Experimental|Sirolimus|Sirolimus (0.05 mg/kg/day) day -5 for aGVHD prophylaxis through day +100 or until T-regulatory cells >9% of CD4 effector cells; whichever comes first.
11378654|NCT02177747|Experimental|Diabet patients|Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy
11378655|NCT02177734|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 1 at a 21 day interval
11378656|NCT02177734|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 2 at a 21 day interval
11378657|NCT02177734|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 3 at a 21 day interval
11378658|NCT02177734|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 4 at a 21 day interval
11378659|NCT02177734|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3277509A H7N9 vaccine formulation 5 at a 21 day interval
11378660|NCT02177734|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
11378696|NCT02177474|Experimental|Telephone based peer support|The telephone based peer support was delivered by 11 women with chd aged 54 to 73 years, living all over Germany. Participants could call according to their needs during scheduled times on workdays.
11378697|NCT02177474|Other|Waitlist Group|Waitlist condition with delayed telephone based peer support starting at 5 months
11378698|NCT02177461|Experimental|Telmisartan|
11378661|NCT02177721|Experimental|Raxibacumab arm|"This is an open-label, single arm study. The study will be implemented for subjects who receive FDA-approved raxibacumab as part of medical treatment of anthrax or for post-exposure prophylaxis.
~Intervention: Sampling of subjects or use of subjects salvaged standard of care samples may be considered for the following assessments (if available/applicable): pregnancy test, pharmacokinetics (PK) sampling, protective antigen, toxin neutralizing antibody (TNA), anti-raxibacumab antibodies."
11378662|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
11378663|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
11378664|NCT02177682|Experimental|Afuresertib|"Three subjects will be enrolled and given afuresertib 125 mg orally and monitored for toxicity. After completion of PK sampling in 3 days (Cycle 0), daily repeated dose of 125 mg will be given for 21 days (Cycle 1). If no DLT event is found after 21 days of repeated dosing, up to 6 subjects will be enrolled and given afuresertib 150 mg. If afuresertib 150 mg is assessed to be tolerable, up to 6 subjects can be enrolled and given afuresertib 200 mg. If afuresertib 200 mg is assessed to be intolerable, up to 6 subjects will be enrolled and given afuresertib 150mg or 175 mg. In any Dose levels, if DLT occurs in more than 2 subjects, that Dose level will be considered as intolerable."
11378665|NCT02177669||Normals without ocular disease|
11378666|NCT02177656|No Intervention|Usual care|Patients in the usual care group received six patient educational materials in the hospital, a baseline and follow-up phone call by blinded research assistants.
11378667|NCT02177656|Experimental|MI tailored intervention|The MI intervention was provided by a heart failure specialist nurse. The nurse conducted a home-based motivational interviewing intervention followed up by three phone calls over the course of 90 days. The intervention began with a conversation about the participant's self-identified goals. In the home intervention, the nurse focused on self-care areas that the participant identified as high priority. During the home-based intervention, the participant also set specific goals, which the nurse followed up with and reinforced over the follow-up phone calls.
11378668|NCT02177643|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.
11378669|NCT02177643|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
11378670|NCT02177630||Magnetic resonance imaging and endomyocardial biopsy|Magnetic resonance imaging and endomyocardial biopsy
11378671|NCT02177617|Active Comparator|Botox only|Participants randomized to receive Botox injections alone.
11378672|NCT02177617|Active Comparator|Botox plus Physical Therapy|Participants randomized to receive Botox injection combined with Physical Therapy
11378673|NCT02177604|Experimental|Wingate HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction 3 supervised sessions of Wingate High-intensity Interval Training.
11378674|NCT02177604|Experimental|Modified HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction with 3 supervised sessions of Modified High-Intensity Interval Training
11378675|NCT02177604|Active Comparator|No Exercise Control|7 days of high-fat overfeeding (50% excess calories) with no supervised exercise
11378676|NCT02177591||CAD and MI|Patients with a history of coronary artery disease who have had a myocardial infarction in the past.
11378677|NCT02177591||CAD, no MI|Patients who have a history of coronary artery disease and have not had a myocardial infarction in the past.
11378678|NCT02177591||no CAD|Patients with no documented history of coronary artery disease.
11378679|NCT02177578|Experimental|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions
~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
11378680|NCT02177578|Active Comparator|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.
~Will be prescribed to 46 Gy in 2 Gy fractions
~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.
~Will be prescribed to 14 Gy in 2 Gy fractions"
11378681|NCT02177565|Experimental|carrier plus BMSCs|carrier plus in vitro expanded autologous BMSCs
11378682|NCT02177565|Placebo Comparator|carrier alone (control).|Carrier alone
11378683|NCT02177552|Experimental|Experimental chemotherapy|Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.
11378684|NCT02177552|Other|Standard chemotherapy|Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks
11378685|NCT02177539|Active Comparator|Cyclopentolate|
11378686|NCT02177539|Experimental|Cyclopentolate+tropicamide+phenylephrine|
11378687|NCT02177526|Other|Imaging - CT and MRI examinations|Abdominal and pelvic CT and pelvic MRI imaging will be performed in 30 patients.
11378688|NCT02177513|Active Comparator|1|
11378689|NCT02177513|Active Comparator|2|
11378690|NCT02177513|Active Comparator|3|
11378691|NCT02177513|Placebo Comparator|4|
11378692|NCT02177513|Active Comparator|5|
11378707|NCT02177409|Experimental|Telmisartan|4-week placebo run-in, 8-week fixed dose period
11378708|NCT02177409|Active Comparator|Amlodipine|4-week placebo run-in, 8-week fixed dose period
11378709|NCT02177396|Experimental|Telmisartan|
11378710|NCT02177396|Active Comparator|Valsartan|
11378711|NCT02177383|Experimental|Docosahexaenoic acid|1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek) provides 1.14 g DHA/daily
11378712|NCT02177383|Placebo Comparator|Olive oil|1 liter/day of placebo beverage (containing 0.8% olive oil)
11378713|NCT02177370|Experimental|Fenoterol metered dose inhaler (MDI)|
11378714|NCT02177370|Active Comparator|DSCG MDI|
11378715|NCT02177357|Experimental|Pramipexole - escalation dose|
11378716|NCT02177357|Placebo Comparator|Placebo|
11378717|NCT02177344|Experimental|Low dose of ipratropium bromide|
11378718|NCT02177344|Experimental|High dose of Ipratopium bromide|
11378719|NCT02177344|Active Comparator|Atrovent|
11378720|NCT02177344|Placebo Comparator|Placebo|
11378721|NCT02177331|Experimental|Lacidipine|
11378722|NCT02177318||Patients with COPD|
11378723|NCT02177305|Experimental|Tiotropium dose group 1|0.02 mcg tiotropium solution
11378724|NCT02177305|Experimental|Tiotropium dose group 2|0.04 mcg tiotropium solution
11378725|NCT02177305|Experimental|Tiotropium dose group 3|0.08 mcg tiotropium solution
11378726|NCT02177305|Experimental|Tiotropium dose group 4|0.16 mcg tiotropium solution
11378727|NCT02177305|Experimental|Tiotropium dose group 5|0.28 mcg tiotropium solution
11378728|NCT02177305|Experimental|Tiotropium dose group 6|0.40 mcg tiotropium solution
11378729|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
11378730|NCT02177279|Other|Visit A- 120g wheat bran cereals|A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
11378731|NCT02177279|Other|Visit B-40g wheat bran cereals|A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
11378732|NCT02177279|Other|Follow up-40g (8days), 120g (1day) wheat bran cereals|Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
11378733|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
11378734|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
11378735|NCT02177253|Experimental|Ipratropium bromide / Salbutamol Inhalation solution|
11378736|NCT02177253|Placebo Comparator|Placebo Inhalation solution|
11378737|NCT02177253|Experimental|Ipratropium bromide Inhalation solution|
11378738|NCT02177253|Active Comparator|COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)|
11378739|NCT02177253|Placebo Comparator|Placebo Inhalation Aerosol|
11378740|NCT02177240|Active Comparator|GRS (GlideRite®)|GlideScope® intubation with GRS® stylet of a simulated difficult airway
11378741|NCT02177240|Active Comparator|FIS (Flex-it® )|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
11378742|NCT02177227|Experimental|Total Knee Arthroplasty with PSI|Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation
11378743|NCT02177227|No Intervention|Total Knee Replacement|Total Knee Replacement, as per Standard of Care
11378744|NCT02177214||ventral hernia|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with inclusion of primary and incisional hernias. Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
11378745|NCT02177201|Sham Comparator|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
11378746|NCT02177201|Active Comparator|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
11378747|NCT02177188|Experimental|Haemorrhage simulation|
11378748|NCT02177175|Experimental|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
11378749|NCT02177175|Placebo Comparator|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
11378750|NCT02177149|Active Comparator|Standard of Care|DBS using standard of care.
11378751|NCT02177149|Experimental|DBS Clinical Support System|DBS using Clinical Support System.
11378752|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Subjects randomized to 1.5 mg OCA will take 1.5 mg OCA daily for 12 weeks. If tolerated, the dose will be increased to 3 mg OCA daily for an additional 12 weeks.
11378753|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Subjects randomized to 5 mg OCA will take 5 mg OCA daily for 12 weeks. If tolerated, the dose will be increased to 10 mg OCA daily for an additional 12 weeks.
11378754|NCT02177136|Experimental|Placebo|Subjects randomized to placebo will take placebo for 24 weeks.
11378755|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in a primary open angle glaucoma subject using an ab externo subconjunctival/subTenons access with direct connection to the anterior chamber of the eye.
11378756|NCT02177110||Study|Patients who have fresh frozen and FFPE tissue taken prior to treatment
11378757|NCT02177110||Control|Fresh frozen tissue and FFPE tissue is available
11378758|NCT02177097||40 patients (uTHA)|Patients undergoing primary uncemented total hip arthroplasty surgery.
11378759|NCT02177097||40 patients (hTHA)|40 patients undergoing primary hybrid total hip replacement surgery.
11378760|NCT02177097||40 patients (TKA)|40 patients undergoing total knee replacement surgery.
11378837|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
11379300|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
11378761|NCT02177084|Experimental|PTNS + conservative treatment|"PTNS consists in the insertion of a small electrode above the medial malleolus adjacent to the posterior tibial nerve. An adhesive surface electrode is placed under th arch of the foot. Both electrodes are connected to the neurostimulator that generates electricity. A neuromodulation session lasts 30 minutes.
~The treatment plan includes 12 weekly sessions, followed by two sessions at 2-week intervals and the last one after one month. Two additional sessions of reinforcement (top-up) are provided at intervals of 6 months or earlier in case of worsening of symptoms"
11378762|NCT02177084|No Intervention|conservative treatment|
11378763|NCT02177071|No Intervention|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
11378764|NCT02177071|Other|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
11378765|NCT02177071|Other|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
11378766|NCT02177058|Experimental|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
11378767|NCT02177058|Active Comparator|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
11378768|NCT02177058|No Intervention|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
11378769|NCT02177045|Experimental|Microbubbles contrast media for US|Sonovue, Bracco, microbubbles contrast media
11378770|NCT02177032|Experimental|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
11378771|NCT02177032|Experimental|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
11378772|NCT02177032|Active Comparator|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
11378773|NCT02177032|Active Comparator|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
11378774|NCT02177019|Experimental|Development of personal health plan|Personal Health Plan
11378775|NCT02177006||Caregivers|Caregivers of children 2-6 years of age
11378776|NCT02177006||Pediatric clinicians|Pediatricians and nurse practitioners at Lake Forest Pediatric Associates
11378777|NCT02176993||Application of surface cooling|Surface cooling during 60 minutes.
11378778|NCT02176980|Active Comparator|Medical provider (MP) brief alcohol counseling & referral|"Screening of HCV-infected patients for alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT).
~Patients self-administer the AUDIT.
~HCV providers review the AUDIT with the patient.
~If the patient is using any alcohol, the HCV provider conducts brief alcohol counseling using the FRAMES model, based on the evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) method.
~Medical provider will explain the importance of alcohol abstinence in the presence of HCV infection.
~Patient is referred to an alcohol treatment programs outside the liver clinic. Typical counseling will take the form of individual and group therapy."
11378779|NCT02176980|Experimental|Brief alcohol counseling & 6 months of HCV-alcohol treatment|"Steps 1 through 5 as described in comparator arm above.
~6 months of group therapy, offered weekly.
~6 months of individual therapy, in person or by phone, offered every two weeks.
~Therapy content emphasizes interplay between alcohol use and liver health/HCV.
~Informal collaboration between HCV providers and addictions therapists.
~Shared EMR charting.
~Referral to study-provided psychiatry as needed."
11378780|NCT02176967|Experimental|Group A (clinical observation)|Patients undergo clinical observation for 96 weeks in the absence of disease progression.
11378781|NCT02176967|Experimental|Group B (clinical observation, first-line chemotherapy)|Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
11378782|NCT02176967|Experimental|Group C (clinical observation, first-line chemotherapy)|Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
11378783|NCT02176954|Experimental|Test A, Test B, Comparator|The subjects first test Coloplast Test A followed by Coloplast Test B and finally Comparator.
11378784|NCT02176954|Experimental|Test A, Comparator, Test B|The subjects first test Coloplast Test A followed by Comparator and finally Coloplast Test B.
11378785|NCT02176954|Experimental|Test B, Test A, Comparator|The subjects first test Coloplast Test B followed by Coloplast Test A and finally Comparator.
11378786|NCT02176954|Experimental|Test B, Comparator, Test A|The subjects first test Coloplast Test B followed by Comparator and finally Coloplast Test B.
11378787|NCT02176954|Experimental|Comparator, Test A, Test B|The subjects first test Comparator followed by Coloplast Test A and then Coloplast Test B
11378788|NCT02176954|Experimental|Comparator, Test B, Test A|The subjects first test Comparator followed by Coloplast Test B and then Coloplast Test A.
11378789|NCT02176941||ATHEROMA group|"ATHEROMA group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease"
11378790|NCT02176941||Control Surgery group|"Control Surgery group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease."
11378791|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
11378915|NCT02176122|Active Comparator|Meropenem|Meropenem 1g adm every 8 hours IV up to study day 4.
11379301|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
11378792|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
11378793|NCT02176915|Experimental|Group program|8-session group weight loss program and 4 follow-up phone counseling sessions
11378794|NCT02176915|Active Comparator|Print Materials|8 weekly mailings of print materials covering weight loss topics through US mail.
11378795|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
11378796|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.
11378797|NCT02176889|Experimental|Lactospore|One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days
11378798|NCT02176889|Placebo Comparator|Placebo|One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.
11378799|NCT02176876|Experimental|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
11378800|NCT02176876|Placebo Comparator|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
11378801|NCT02176863|Experimental|Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 2 g/kg body weight administered via intravenous infusion over 2 consecutive days (1 g/kg infused on Day 1 and 1 g/kg infused on Day 2) every 4 weeks for 52 weeks
11378802|NCT02176863|Experimental|Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 1 g/kg body weight administered via intravenous infusion on Day 1 every 4 weeks for 52 weeks
11378803|NCT02176863|Placebo Comparator|Stage 1 Arm 3: Placebo|Normal Saline Solution of matching volume, administered via intravenous infusion either over 1 day or 2 consecutive days every 4 weeks for 52 weeks
11378804|NCT02176863|Experimental|Stage 2 Arm 1: Flebogamma 5% DIF|The dose of Flebogamma® 5% DIF selected from Stage 1 will be administered every 4 weeks over 2 consecutive days during a 52-week treatment period.
11378805|NCT02176863|Placebo Comparator|Stage 2 Arm 1: Placebo|A total dose of 40 mL/kg of body weight of Normal Saline Solution will be administered over 2 consecutive days (20 mL/kg infused on Day 1 and 20 mL/kg infused on Day 2).
11378806|NCT02176850||Micardis®|
11378807|NCT02176837|Experimental|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
11378808|NCT02176824|Experimental|Triple Chronotherapy|Total Sleep Deprivation, Sleep phase advance, and Bright Light Therapy. Carex Health Brands Day-Light Classic 10,000 Lux
11378809|NCT02176824|Sham Comparator|Sham Triple Chronotherapy|Total sleep deprivation, Three day fixed wake schedule, and sham light therapy.
11378810|NCT02176824|Active Comparator|Treatment As Usual|Normal inpatient care including pharmacotherapy, psychotherapy, milieu therapy, and social work interventions.
11378811|NCT02176811||Non-alcoholic Fatty Liver Disese|no treatment
11378812|NCT02176811||healthy controls|no treatment
11378813|NCT02176785|Sham Comparator|Sham tDCS|tDCS will be applied, but then turned off after 30 seconds.
11378814|NCT02176785|Experimental|Anodal tDCS 2mA 10 Minutes|Anodal tDCS will be applied bi-frontally for 10 minutes at 2mA
11378815|NCT02176785|Experimental|Cathodal tDCS 2mA 10 Minutes|Cathodal tDCS will be applied Bi-Frontally for 10 minutes at 2mA
11378816|NCT02176772||Tuberculosis, no HIV and severe anemia|
11378817|NCT02176759|Experimental|Regular FePP|Rice (50g dry weight) fortified with 4mg regular FePP
11378818|NCT02176759|Experimental|Regular FePP with citrate added during extrusion|Rice (50g dry weight) fortified with 4mg regular FePP and citrate added during the extrusion process
11378819|NCT02176759|Experimental|Regular FePP with citrated added at consumption|Rice (50g dry weight) fortified with 4mg regular FePP and citrate shortly added before consumption
11378820|NCT02176759|Active Comparator|Ferrous sulphate|Rice (50g dry weight) fortified with 4mg ferrous sulphate
11378821|NCT02176746|Placebo Comparator|non-cancer stem cell vaccine|This is no cancer stem cells vaccine in this group
11378822|NCT02176746|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11378823|NCT02176746|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11378824|NCT02176746|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11378825|NCT02176733|Experimental|cyclosporine|
11378826|NCT02176720|No Intervention|Standard diagnostics without PET|Standard of care brain imaging modalities, predominantly MRI
11378827|NCT02176720|Experimental|FDOPA PET-CT|PET-CT with administration of FDOPA as an experimental radiopharmaceutical. This arm includes standard of care imaging plus FDOPA PET-CT
11378828|NCT02176707||Idiopathic pulmonary fibrosis sufferers|
11378829|NCT02176694|No Intervention|Standard Care|Aside from the asthma education provided at enrollment and placement of the SmartInhaler (i.e.,electronic monitoring device), adolescents will continue to receive usual care through their primary care providers.
11378830|NCT02176694|Experimental|Text Messaging|A technology based system which allows adolescents to compose, schedule and send one-time or recurring text messages to their own cell phones.
11378831|NCT02176681|Active Comparator|Insulin alone|Use the usual frequency and dose
11378832|NCT02176681|Experimental|Insulin and Vildagliptin|vildagliptin 50 mg/day during 3 months
11378833|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
11378834|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal,
11378835|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
11378836|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
11378838|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg before meal
11378839|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
11378840|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
11378841|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
11378842|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
11378843|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
11378844|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
11378845|NCT02176629|Experimental|Condition virtual reality (VR)|The subject is placed in front of a Barcotm screen capable of displaying high quality images.
11378846|NCT02176629|Active Comparator|Condition classic cognitive stimulation (CSC)|It is proposed about using the test dam Zazzo suitable for elderly. This classic test measures sustained attention.
11378847|NCT02176616|Active Comparator|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
11378848|NCT02176616|Experimental|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
11378849|NCT02176603||Patients with Phenylketonuria|Patients with Phenylketonuria due to phenylalanine hydroxylase deficiency
11378850|NCT02176603||Control group|Control group of healthy volunteers
11378851|NCT02176590|Experimental|Power PATH|Classroom PATHS Social Emotional Learning Curriculum (for preschool classrooms) plus Coping Power parent intervention (teaches parents what children are learning in the classroom PATHS program and also provides parents with mental health intervention and parenting topics to promote family well-being)
11378852|NCT02176590|Active Comparator|Head Start as usual|Head Start as usual (will measure the effects of Head Start programming as usual on the primary outcomes)
11378853|NCT02176577|Experimental|Product 0405|Topically Active Investigational Product 0405
11378854|NCT02176564||Chronic obstructive pulmonary disease|Patients with COPD treated with inhaled bronchodilators
11378855|NCT02176551|Experimental|Product 0405|Topical active investigational Product 0405
11378856|NCT02176551|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
11378857|NCT02176538|Experimental|Product 0405|Topical active investigational Product 0405
11378858|NCT02176538|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
11378859|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
11378860|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
11378861|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
11378862|NCT02176512|Experimental|Sequence 1|"four treatment periods:
~Treatment A
~Treatment B
~Treatment B
~Treatment A"
11378863|NCT02176512|Active Comparator|Sequence 2|"four treatment periods:
~Treatment B
~Treatment A
~Treatment A
~Treatment B"
11378864|NCT02176499|Experimental|Telmisartan, low dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
11378865|NCT02176499|Experimental|Telmisartan, high dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
11378866|NCT02176499|Placebo Comparator|Placebo|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
11378867|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
11378868|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
11378869|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
11378870|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
11378871|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
11378872|NCT02176473|Experimental|Computerized Cognitive Behavioral Therapy|A computerized version of CBT has been developed in an effort to more widely disseminate the powerful effects of this psychotherapy modality, with studies showing efficacy comparable to that of traditional CBT.8 The present study aims to further investigate the feasibility of combining ECT and computerized CBT (c-CBT).
11378873|NCT02176460|Experimental|colchicine|0.5mg twice daily for 16 weeks
11378874|NCT02176460|Placebo Comparator|placebo tablet|1 tablet twice daily for 16 weeks
11378875|NCT02176434|Experimental|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
11378876|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
11378877|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment
~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
11378916|NCT02176122|Experimental|Piperacillin-tazobactam combination product|Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
11378878|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment
~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
11378879|NCT02176395|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
11378880|NCT02176395|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
11378881|NCT02176395|No Intervention|healthy volunteer|
11378882|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
11378883|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
11378884|NCT02176369|Experimental|vinorelbine|50 mg three times a week for a three weeks cycle
11378885|NCT02176369|No Intervention|Close observation/Best Supportive Care|Close observation/Best Supportive Care (BSC)
11378886|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
11378887|NCT02176343|Experimental|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
11378888|NCT02176330|Active Comparator|Usual care|ePAQ-PF followed by a face to face consultation.
11378889|NCT02176330|Experimental|Virtual Clinic|ePAQ-PF followed by a telephone consultation.
11378890|NCT02176317|Experimental|Autologous Umbilical Cord Blood (UCB)|All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
11378891|NCT02176304|Active Comparator|Suprapatellar Knee Injection Site|Patients will be injected specified dose of lidocaine and depomedrol through suprapatellar-lateral knee entry site.
11378892|NCT02176304|Active Comparator|Anterolateral knee injection|Patients will be injected specified dose of lidocaine and depomedrol through anterolateral knee entry site.
11378893|NCT02176291|Experimental|Buprenorphine|Buprenorphine
11378894|NCT02176291|Placebo Comparator|Placebo|Placebo
11378895|NCT02176278|No Intervention|Usual Care Group|"Usual care (UC) group:
~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
11378896|NCT02176278|Experimental|Empowered Care Group|"Empowered care (EC) group:
~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
11378897|NCT02176278|Experimental|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:
~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
11378898|NCT02176265|Experimental|Qvanteq bioactive coronary stent system|Open-label, single arm, non-randomized study
11378899|NCT02176252|Experimental|AZD1722|Dose escalation from 5 mg to 90 mg BID
11378900|NCT02176239||Gammaplex® IVIg|
11378901|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
11378902|NCT02176213|Experimental|Pomalidomide, Cyclophosphamide, Dexamethasone|Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)
11378903|NCT02176200|Experimental|Berodual® Respimat®|
11378904|NCT02176200|Active Comparator|Berodual® HFA-MDI|
11378905|NCT02176187|Experimental|natural technique, without instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
11378906|NCT02176187|Experimental|optimal technique, with instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
11378907|NCT02176174||White|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
11378908|NCT02176174||Black|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
11378909|NCT02176174||South Asian|Self-reported ethnic group of South Asian, using the United Kingdom Census categories, as recorded in electronic health records.
11378910|NCT02176174||Mixed/Other|Self-reported ethnic group of Mixed or other, using the United Kingdom Census categories, as recorded in electronic health records.
11378911|NCT02176161|Experimental|Surgical Prostate Cancer Patients|"Radical Prostatectomy patients with:
~High risk surgical pathology (Gleason 8 or higher, positive surgical margins, evidence of extra capsular extension or seminal vesicle invasion)
~Prior Radiation Therapy OR
~Prior Radiation Therapy with rising PSA.
~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
11378912|NCT02176161|Experimental|Radiation Patients|"Radiation Patients with Biochemical Recurrence (rising PSA).
~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
11378913|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
11378914|NCT02176135|Experimental|Dose escalation|Auranofin 3 to 6 mg/day oral administration for 12 weeks
11378917|NCT02176096|Experimental|Glycosade|
11378918|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
11378919|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
11378920|NCT02176057|Experimental|Antibiotic|Azithromycin, suspension (liquid), 1 gram, one-time dose
11378921|NCT02176057|No Intervention|Observation|
11378922|NCT02176044|Placebo Comparator|Glucose infusion|Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
11378923|NCT02176044|Active Comparator|Sodium Nitroprusside infusion|Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
11378924|NCT02176031|Experimental|Natalizumab|"Natalizumab-
~(Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion
~At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.
~If participants have no response after one dose, they will be not be given a second dose.
~Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.
~Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.
~Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
11378925|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
11378926|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
11378927|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
11378928|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
11378929|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
11378930|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
11378931|NCT02175979|Placebo Comparator|standard|standard of care
11378932|NCT02175979|Experimental|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
11378933|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:
~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks
~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
11378934|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy
~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks
~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
11378935|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks
~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks
~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
11378936|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks
~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks
~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
11378937|NCT02175953|Experimental|Interventiongroup|Psychotherapy
11378938|NCT02175953|No Intervention|Waitling list group|waiting list
11378939|NCT02175940||Myopic Choroidal Neovascularization patients|
11378940|NCT02175940||Control patients undergoing cataract surgery|
11378941|NCT02175927|Experimental|High Dose Amoxicillin|High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid
11378942|NCT02175927|Active Comparator|Tetracycline|Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
11378943|NCT02175914|Experimental|Erythromycin|Oral treatment with Erythromycin 500mg twice daily.
11378944|NCT02175901|Experimental|Amoxicillin/metronidazole|Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
11378945|NCT02175901|Active Comparator|Amoxicillin/clarithromycin|Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
11378946|NCT02175888|Experimental|Oral iron supplement every day for 14 days|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days
11378947|NCT02175888|Active Comparator|Oral iron supplement every second day for 28 days|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
11378948|NCT02175875||comatose patients|180 mg ticagrelor followed by 90 mg BID for comatose patients after cardiac arrest
11378949|NCT02175862||Trauma patients before PS-HEMS|"The before period was between december 1 2009 to april 30 2010 (five months)."
11378950|NCT02175862||Traume patients after PS-HEMS|"The after period was between may 1 2010 to april 30 2011 (12 months)."
11378951|NCT02175849||Drug resistant TB patients|Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
11378952|NCT02175849||Contacts|Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
11378953|NCT02175836||SCD possitive versus SCD negative group|The total Heart Failure patients subgroup experiencing Sudden Cardiac Death surrogate end-points during follow up versus the patients subgroup that is free from Sudden Cardiac Death surrogate end-points.
11378954|NCT02175797|Other|Pacemaker + leads|all patients must have a MRI exam after pacemaker implantation
11378955|NCT02175784|Experimental|ipragliflozin group|oral
11378956|NCT02175784|Experimental|placebo group|oral
11378978|NCT02175680|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
11378957|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378958|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378959|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378960|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378961|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378962|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378963|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378964|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.
~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11378965|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to < 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
11378966|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to < 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
11378967|NCT02175758|Experimental|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to < 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
11378968|NCT02175758|Experimental|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to < 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
11378969|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
11378970|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
11378971|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
11378972|NCT02175732|Experimental|KnowIt|Please see the 'KnowIt' intervention description below. Diabetes education, behavioral management
11378973|NCT02175732|Experimental|OnTrack|Please see the 'OnTrack' intervention description below. Diabetes Distress Reduction, Problem Solving Therapy
11378974|NCT02175719||E2014|
11378975|NCT02175706|Active Comparator|Resolute Integrity®|The coating of Resolute Integrity consists of zotarolimus as antiproliferative agent and the BioLinx® polymer system. This polymer system consists of a blend of three different polymers: (1) the hydrophobic C10 polymer, which aids in the control of drug release; (2) the hydrophilic C19 polymer, which supports biocompatibility; and (3) polyvinyl pyrro-lidinone, which increases the initial drug burst and enhances the elution rate.
11378976|NCT02175706|Active Comparator|Promus Element®|"Promus Element utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation.
~Promus Element is composed of the Element platform, a thin fluoropolymer coating, and Everolimus."
11378977|NCT02175693||E2014|
11378979|NCT02175667|Experimental|Global Postural Reeducation|Participants receiving GPR treatment during 45 minutes to stretch muscular chains
11378980|NCT02175667|No Intervention|Control|Participants not receiving GPR treatment
11378981|NCT02175654|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks, followed by one week of rest, according to the 3/1 regimen
11378982|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
11378983|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
11378984|NCT02175628|Experimental|Acoustic Angiography|All breast patients will be included in the experimental group.
11378985|NCT02175628|Experimental|Healthy Volunteers|A volunteer group was added to the study to perfect the image acquisition techniques.
11378986|NCT02175602|Experimental|Cohort 2|Sertraline (50 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Sertraline (50 milligrams each morning) days 23-29
11378987|NCT02175602|Experimental|Cohort 1|Escitalopram (10 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Escitalopram (10 milligrams each morning) days 23-29
11378988|NCT02175589|Other|Study group|Colchicine Cessation in FMF patients with one MEFV mutation
11378989|NCT02175589|No Intervention|Control group|The control group includes FMF patients that will be kept on a daily colchicine treatment
11378990|NCT02175576|Experimental|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
11378991|NCT02175576|Active Comparator|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
11378992|NCT02175563|No Intervention|Without feedback|Participants compress the chest of the manikin without smartphone based feedback app.
11378993|NCT02175563|Experimental|With feedback|Participants compress the chest of the manikin with a smartphone based feedback app.
11378994|NCT02175550|Experimental|NR CC|
11378995|NCT02175537|Experimental|Microclinic social induction training|BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
11378996|NCT02175537|No Intervention|Controls|Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
11378997|NCT02175524||Case|Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing.
11378998|NCT02175524||Control|Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing.
11378999|NCT02175511|Experimental|Cloud-based home BP monitoring|170 were assigned to the experimental group
11379000|NCT02175511|No Intervention|Traditional Care|212 patients were assigned to the traditional care group (paper-based data)
11379001|NCT02175498|Experimental|Homoeopathic medicines|4 pills once a week of the indicated similium for a period of one year
11379002|NCT02175485|Experimental|Fexofenadine HCl|2 tablets of Dellegra Combination Tablets (Fexofenadine Hydrochloride 30 mg+Pseudoephedrine Hydrochloride 60 mg/tablet), oral, administrated 2 hours after start of exposure with 8,000 grains/cubic meter of Japanese cedar pollen
11379003|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
11379004|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
11379005|NCT02175446|Experimental|Experimental1|"Bevacizumab and eribulin
~In this study all patients will receive:
~Eribulin 1.23 mg/m2 on days 1, 8 every 3 weeks intravenously
~Bevacizumab 15 mg/kg every 3 weeks intravenously or Bevacizumab 10 mg/kg every 2 weeks intravenously"
11379006|NCT02175433|Experimental|Dose Escalation of AGS67E 0.05 mg/kg Without GF|Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.
11379007|NCT02175433|Experimental|Dose Escalation of AGS67E 0.1 mg/kg Without GF|Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
11379008|NCT02175433|Experimental|Dose Escalation of AGS67E 0.3 mg/kg Without GF|Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
11379009|NCT02175433|Experimental|Dose Escalation of AGS67E 0.6 mg/kg Without GF|Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
11379010|NCT02175433|Experimental|Dose Escalation of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
11379011|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg Without GF|Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
11379012|NCT02175433|Experimental|Dose Expansion of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
11379013|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg With GF|Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
11379014|NCT02175433|Experimental|Dose Escalation of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
11379015|NCT02175433|Experimental|Dose Escalation of AGS67E 1.8 mg/kg With GF|Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
11379016|NCT02175433|Experimental|Dose Expansion of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
11379017|NCT02175420|Active Comparator|TFV alone|Typhim Vi
11379018|NCT02175420|Experimental|BCG+TFV|BCG (SSI, Denmark) followed after 14 days by Typhim Vi
11379019|NCT02175407|Experimental|ASP1707 alone|
11379020|NCT02175407|Experimental|ASP1707 + itraconazole|
11379021|NCT02175394|Active Comparator|Microgynon®|Microgynon® once daily during period 1 (day 1 to day 14)
11379302|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
11379022|NCT02175394|Experimental|Microgynon® and BI 1356|Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)
11379023|NCT02175381|Experimental|Carbo/GEM|
11379024|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
11379025|NCT02175355|Experimental|Low dose of Micardis®|
11379026|NCT02175355|Experimental|Medium dose of Micardis®|
11379027|NCT02175355|Experimental|High dose of Micardis®|
11379028|NCT02175355|Active Comparator|Hydrochlorothiazide|
11379029|NCT02175355|Placebo Comparator|Placebo|
11379030|NCT02175342|Experimental|Tiotropium-1.25 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff
11379031|NCT02175342|Experimental|Tiotropium-2.5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff
11379032|NCT02175342|Experimental|Tiotropium-5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff
11379033|NCT02175342|Experimental|Tiotropium-10 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff
11379034|NCT02175342|Experimental|Tiotropium-20 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff
11379035|NCT02175342|Placebo Comparator|Placebo Respimat|
11379036|NCT02175342|Active Comparator|Tiotropium-18 lactose powder Handihaler|
11379037|NCT02175342|Placebo Comparator|Placebo lactose powder Handihaler|
11379038|NCT02175329|Experimental|CAD/CAM veneering|CAD/CAM manufactured e.max CAD veneers on zirconia framework
11379039|NCT02175329|Active Comparator|manually layered|Manually layered veneering on CAD/CAM fabricated zirconia bridge framework
11379040|NCT02175316|Experimental|Experimental: EECP for DOMS|All enrolled subjects will receive EECP treatment Delayed Onset Muscle Soreness.
11379041|NCT02175303|Experimental|Decidual stromal cell therapy for toxicity and inflammation|Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
11379042|NCT02175290||Spinocerebellar Ataxia 3 Yemenite Jews patients|
11379043|NCT02175277|Experimental|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
11379044|NCT02175264||Patients and Families with isolated non syndromic CDH cases|
11379045|NCT02175251|Active Comparator|low frequency (1Hz)|low frequency
11379046|NCT02175251|Sham Comparator|Sham Comparator|Sham Comparator
11379047|NCT02175251|Experimental|high frequency (20Hz)|high frequency
11379048|NCT02175238|Experimental|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
11379049|NCT02175238|Active Comparator|BI 691751 fasted|single dose BI 691751 in fasted state
11379050|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
11379051|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
11379052|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
~Bicalutamide 50 mg tablet every day for 2 months
~High dose conformal radiotherapy
~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
11379053|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
~Bicalutamide 50 mg tablet every day for 2 months
~High dose conformal radiotherapy"
11379054|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
11379055|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
11379056|NCT02175186|Experimental|ALBIS|Albis Tab 2 tab twice a day 12weeks
11379057|NCT02175186|Placebo Comparator|Placebo|placebo Tab 2 tab twice a day 12weeks
11379058|NCT02175173||E2080|Children ages >= 4 years: Patients weighing 15.0-30.0 kg: oral daily dose of 200 mg in two divided doses after meals for the first 2 days. The dose will be increased by up to 200 mg/day every two days. The maintenance dose should be 1000 mg/day in two divided doses after meals. The dose can be increased or decreased within a range not exceeding 1000 mg/day, and should be increased by up to 200 mg/day at intervals not less than 2 days. Patients weighing >= 30.1 kg: Adults: oral daily dose of 400 mg in two divided doses after meals for the first 2 days, then increased by up to 400 mg/day every two days. The maintenance dose should be 1800 mg/day for patients weighing 30.1-50.0 kg, 2400 mg/day for patients weighing 50.1-70.0 kg, and 3200 mg/day for patients weighing 70.1 kg or over in two divided doses after meals. Dose can be increased or decreased within a range not exceeding the above maintenance dose, and should be increased by up to 400 mg/day at intervals not less than 2 days.
11379059|NCT02175160|Experimental|Braking and functionality with right knee osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right knee osteoarthritis
11379060|NCT02175160|Experimental|Braking and functionality with right knee arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right total knee arthroplasty
11379061|NCT02175134|No Intervention|conventional diagnostic flow arm|Perform the laparoscopic biopsy as a discretion of attending physician's decision
11379062|NCT02175134|Experimental|two-step algorithm-based approach|"Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.
~Blood ELISPOT >= 6 spots or ascites adenosine deaminase > 20 IU/L, and
~Ascites ELISPOT/Blood ELISPOT rato > 3"
11379063|NCT02175121|Placebo Comparator|Treatment A- Placebo|
11379064|NCT02175121|Experimental|Treatment B- PF-06291874|
11379065|NCT02175121|Experimental|Treatment C- PF-06291874|
11379066|NCT02175121|Experimental|Treatment D- PF-06291874|
11379067|NCT02175121|Experimental|Treatment E- PF-06291874|
11379098|NCT02174900|Active Comparator|G6PD deficient receiving AL only|G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
11379068|NCT02175095|Experimental|Regorafenib and FLT-PET|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional [18F]FDG-PET will be performed before treatment and at 8 weeks (just once at the point of first response evaluation).
11379069|NCT02175082|Active Comparator|Forced exercise cycling|Cycling exercise at approximately 90 rpm
11379070|NCT02175082|Active Comparator|Self-selected pace cycling|Cycling at self selected rate, with same aerobic level as forced cycling group
11379071|NCT02175069|Experimental|Interscalene Nerve Block - 5ml|"ultrasound guided interscalene plexus block (UISB)
~Ropivacaine 0.75%, 20ml Gadopentetate-Dimeglumine 0.05 mmol Shoulder Surgery"
11379072|NCT02175069|Active Comparator|Interscalene Nerve Block - 20ml|"ultrasound guided interscalene plexus block (UISB)
~Ropivacaine 0.75%, 5ml Gadopentetate-Dimeglumine 0.0125 mmol Shoulder Surgery"
11379073|NCT02175056|Experimental|HL2351|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
11379074|NCT02175056|Placebo Comparator|Placebo|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
11379075|NCT02175056|Active Comparator|Kineret(Anakinra)|100 mg (SC) / Single-Dose
11379076|NCT02175043|Experimental|the operation to add in CFAE to conventional liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
11379077|NCT02175043|Active Comparator|only doing conventional liner ablation|The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
11379078|NCT02175030|Active Comparator|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
11379079|NCT02175030|Active Comparator|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
11379080|NCT02175017|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
11379081|NCT02175004|Experimental|IONIS-TTR Rx|
11379082|NCT02174991|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
11379083|NCT02174991|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
11379084|NCT02174978|Experimental|Group 1: 10 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
11379085|NCT02174978|Experimental|Group 2: 30 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
11379086|NCT02174978|Other|Infectivity control|Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
11379087|NCT02174965|Experimental|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
11379088|NCT02174965|Active Comparator|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
11379089|NCT02174952|Experimental|TAU+SH|Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician. They will also receive an introductory DVD aimed at highlighting key components of the intervention.
11379090|NCT02174952|No Intervention|TAU|Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child & Adolescent Mental Health Services (CAMHS) during the trial phase. Families in the TAU condition will be offered the self-help manual at the end of the trial.
11379091|NCT02174939|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
11379092|NCT02174939|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
11379093|NCT02174926|Active Comparator|Conservative treatment|Written lifestyle guidance and fiber supplements
11379094|NCT02174926|Experimental|Elective laparoscopic sigmoid resection|
11379095|NCT02174913|Active Comparator|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
11379096|NCT02174913|Placebo Comparator|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
11379097|NCT02174900|Experimental|G6PD deficient 0.25 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
11379303|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
11379099|NCT02174900|Active Comparator|G6PD normal 0.25 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
11379100|NCT02174900|Active Comparator|G6PD normal 0.4 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
11379101|NCT02174900|Experimental|G6PD-deficient 0.4 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
11379102|NCT02174887|Experimental|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days The patients will receive 2 cycles of treatment every 28 days
11379103|NCT02174874||Oral Ondansetron|Arm that receive oral solution .8 mgms per ml ondansetron - Apotex Brand DIN 02291967
11379104|NCT02174874||Oral disintegrating tablets|Arm that receives the disintegrating tablets either 4mg or 8 mgs Glaxo Brand 4 mg DIN 02239372, 8 mg DIN 02239373
11379105|NCT02174861|Experimental|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
11379106|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
11379107|NCT02174835|Experimental|Cohort A - Period 1|Twice daily dosing orally for 7 days
11379108|NCT02174835|Active Comparator|Cohort A - Period 2|Twice daily dosing orally for 7 days
11379109|NCT02174835|Experimental|Cohort A - Period 3|Twice daily dosing orally for 7 days
11379110|NCT02174835|Experimental|Cohort B - Period 1|Twice daily dosing orally for 7 days
11379111|NCT02174835|Active Comparator|Cohort B - Period 2|Twice daily dosing orally for 7 days
11379112|NCT02174835|Experimental|Cohort B - Period 3|Twice daily dosing orally for 7 days
11379113|NCT02174822|Experimental|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
11379114|NCT02174822|Experimental|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
11379115|NCT02174822|Experimental|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
11379116|NCT02174822|Experimental|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
11379117|NCT02174809|Experimental|5As|Physicians' use of the 5As tool to discuss gestational weight gain with their pregnant patients
11379118|NCT02174809|Active Comparator|Usual care|Usual care by physicians in addressing gestational weight gain with their pregnant patients
11379119|NCT02174796|Experimental|Surgical treatment group|"patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
~intervention: surgical correction (Ravitch or Nuss type intervention)."
11379120|NCT02174796|Experimental|Orthopedic treatment group|patients who chose an orthopedic treatment by vacuum bell. intervention : orthopedic treatment by vacuum bell.
11379121|NCT02174783|Active Comparator|Control group|Standard of care group
11379122|NCT02174783|Experimental|Mediterranean diet|Mediterranean diet for 6 months
11379123|NCT02174783|Experimental|Protein-Sparing Modified Fast (PSMF)|PSMF for 6 months
11379124|NCT02174770|Experimental|ACL BFR group|This group is patients with post-op from ACL reconstruction who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
11379125|NCT02174770|Active Comparator|ACL Standard Therapy|This group is patients with post-op from ACL reconstruction who are randomized into the standard therapy arm. They will receive ACSM guided-strength training as part of their post-operative physical therapy program.
11379126|NCT02174770|Other|Chronic Muscle Weakness|This is a crossover group where all subjects will be randomized to begin with either standard or blood flow restriction therapy for 4 weeks. After completion of the initial training, each subject will be switched to the opposite in an AB/BA crossover design.
11379127|NCT02174770|Experimental|Knee Arthroscopy BFR|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
11379128|NCT02174770|Active Comparator|Knee Arthroscopy Standard|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the standard physical therapy arm. They will receive ACSM-guided strength training as part of their post-operative physical therapy program during normal post-op rehab.
11379129|NCT02174757|Experimental|Inersan|Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2.
11379130|NCT02174757|Experimental|Inersan and Doxycycline together|"Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
~Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2."
11379131|NCT02174757|Active Comparator|Doxycycline|Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
11379132|NCT02174744||numerical scale|
11379133|NCT02174731|Experimental|Roxadustat|
11379134|NCT02174731|Active Comparator|Epoetin alfa|
11379135|NCT02174718|Experimental|Daily 4000IU transdermal D patch|Only in the stage 2, Efficacy Study
11379136|NCT02174718|Active Comparator|Daily placebo patch plus oral placebo|Only in the stage 3, non-inferiority Study
11379137|NCT02174718|Active Comparator|Daily placebo patch plus oral vitamin D|Only in the stage 3 Non-inferiority Study
11379138|NCT02174718|Active Comparator|Daily 4000IU topical patch plus oral placebo|Only for the 3rd Stage of the study, Non-inferiority Study
11379139|NCT02174718|Placebo Comparator|Daily transdermal placebo patch|Only in the stage 2, Efficacy Study
11379140|NCT02174705|Experimental|Sucrose|Sucrose prior to vaccine injections
11379141|NCT02174705|Active Comparator|Rotavirus|Rotavirus prior to vaccine injections
11379142|NCT02174692|Experimental|Elderly|"Exercise One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum
~2 minutes rest between sets"
11379215|NCT02174172|Experimental|Arm E: Atezolizumab with Obinutuzumab|Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.
11379143|NCT02174692|Experimental|Young|"Exercise
~One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum
~2 minutes rest between sets"
11379144|NCT02174666|Active Comparator|Red clover extract|Group recieving daily red clover extract containing isoflavones (80 mg/d), along with calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
11379145|NCT02174666|Placebo Comparator|Placebo group|Group recieving daily placebo extract (with no isoflavone content), calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
11379146|NCT02174653|Active Comparator|EPs® 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet
~During the common cold free period: One film-coated tablet (20 mg) three times a day
~During a common cold episode: Two film-coated tablets (1 x 20 mg and 1x placebo) three times a day (in the morning, midday and evening; total daily dose 60 mg) over the individual treatment duration of 14 consecutive days."
11379147|NCT02174653|Active Comparator|EPs(R) 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet
~During the common cold free period: One film-coated tablet (20 mg) three times a day
~During a common cold episode: Two film-coated tablets (2 x 20 mg = 40 mg) three times a day (in the morning, midday and evening; total daily dose 120 mg) over the individual treatment duration of 14 consecutive days."
11379148|NCT02174653|Placebo Comparator|Placebo|"During the common cold free period: One film-coated tablet (placebo) three times a day
~During a common cold episode: Two film-coated tablet (placebo) three times a day (in the morning, midday and evening) over the individual treatment duration of 14 consecutive days."
11379149|NCT02174640|Active Comparator|Coffee|Coffee Beverage
11379150|NCT02174640|Placebo Comparator|Water|Water
11379151|NCT02174627|Experimental|Roxadustat|
11379152|NCT02174627|Placebo Comparator|Placebo|
11379153|NCT02174614|Active Comparator|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
11379154|NCT02174614|Experimental|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment
11379155|NCT02174614|Experimental|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized games 3 times per week for the first 4 weeks.
11379156|NCT02174601||colonoscopy group|
11379157|NCT02174588|Experimental|balanced propofol group|
11379158|NCT02174588|Active Comparator|propofol alone group|
11379159|NCT02174575|Active Comparator|Sevoflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
11379160|NCT02174575|Active Comparator|Desflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
11379161|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
11379162|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
11379163|NCT02174549|Experimental|Tirapazamine|Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.
11379164|NCT02174536|Active Comparator|Decidual Stromal cell therapy|Decidual stromal cell therapy (approximately 1x10^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.
11379165|NCT02174536|Placebo Comparator|Placebo|Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).
11379166|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
11379167|NCT02174523|Placebo Comparator|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
11379168|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
11379169|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
11379170|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
11379171|NCT02174497||Control|Three day Bowel Preparation
11379172|NCT02174497||Study Arm|One day Bowel Preparation
11379173|NCT02174484||Pacemaker recipients|Patients implanted with a single or dual pacemaker and with Home-Monitoring system activated and periodic IEGM activated
11379174|NCT02174458||Bariatric Surgery only|Patients after Bariatric Surgery but no secondary reconstructive procedures
11379175|NCT02174458||Body Contouring surgery|Post-bariatric patients and patients with no history of bariatric surgery but after natural weight loss
11379176|NCT02174445|Experimental|Imatinib|Imatinib 400-800mg, daily, maximum 6 years
11379177|NCT02174445|Active Comparator|Nilotinib|Nilotinib, 300mg, twice daily, maximum 6 years
11379178|NCT02174432|Experimental|nalbuphine HCl ER|nalbuphine HCl ER
11379179|NCT02174419|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
11379180|NCT02174419|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
11379181|NCT02174419|Placebo Comparator|Sugar pill|Placebo tablets BID
11379297|NCT02173574|Experimental|Open-Label Single Arm Cohort|
11379182|NCT02174406||women scheduled for breast screening|"Each patient will have the following:
~Screening whole breast ultrasound
~DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
11379183|NCT02174393|Experimental|Microneedling Plus Universal Peel|"(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each.
~Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11."
11379184|NCT02174380|No Intervention|Passive Household Contact Evaluation|Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
11379185|NCT02174380|Experimental|Active Household Contact Evaluation|The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district. During the home visit health staff will evaluate all household contacts for symptoms of active TB. Any person reporting cough for >14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation. All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required. Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
11379186|NCT02174367||Psoriasis|Patients with moderate to sever psoriasis attending a tertiary referral center. patients will be evaluated with a questionnaire, measurement of height,weight, waist circumference, fasting bloods, abdominal ultrasound and transient elastography.
11379187|NCT02174354||Psoriasis|Patients with psoriasis taking methotrexate
11379188|NCT02174328|Experimental|acetylsalicylic acid|This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
11379189|NCT02174328|Placebo Comparator|Placebo|This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36
11379190|NCT02174315|Experimental|Contingency Management|
11379191|NCT02174315|No Intervention|Non-Contingent Control Group|
11379192|NCT02174289|Active Comparator|Active Bi-ventricular Pacing|
11379193|NCT02174289|Placebo Comparator|No Biventricular pacing|
11379194|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
11379195|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
11379196|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
11379197|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
11379198|NCT02174263|Experimental|Supportive care (tocilizumab)|Patients receive tocilizumab IV over 1 hour every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11) and then every 4 weeks for 12 weeks (weeks 13, 17, and 21).
11379199|NCT02174250|Experimental|Istradefylline 40mg|Period 1: Day 1, istradefylline 40mg then crossover to Period 2
11379200|NCT02174250|Experimental|Rifampin 300mg BID + istradefylline 40mg|Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only
11379201|NCT02174237|Experimental|LNP1892|Dosage Form: Tablet Two Parts. Part A: Single Ascending Dose (SAD) starting with 25 mg (Maximum 5 cohorts). Part B: Multiple Ascending Dose (MAD), 10 days dosing, Maximum 3 cohorts. Six subjects in each cohort will receive LNP1892
11379202|NCT02174237|Placebo Comparator|Placebo|Two subjects in each cohort will receive matching placebo.
11379203|NCT02174224|Experimental|SMC + BI + Case Management|This arm will include all interventions in Standard Medical Care + Brief Intervention Arm. Case management will also be given to this arm. General needs based assessments will be conducted by the outreach worker. These assessments will be done at the hospital or at the youth's home, whichever they prefer. This assessment tool addresses education, vocational training, employment, housing, medical insurance, follow-up care and pro-social activities. Although each youth in this arm will receive the same needs-based assessment, individual youth will have variable needs, which will guide each unique and individualized case management plan.
11379204|NCT02174211|Active Comparator|Arm A: Ranibizumab (Lucentis)|Previous Vitrectomy
11379205|NCT02174211|Active Comparator|Arm B: Ranibizumab (Lucentis)|Non-vitrectomised, PVD / no PVD
11379206|NCT02174211|Active Comparator|Arm C: Aflibercept (Eylea)|Non-vitrectomised, PVD / no PVD
11379207|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
11379208|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
11379209|NCT02174185||bladder cancer, conduit diversion|new patients with bladder cancer scheduled for radical cystectomy and subsequent conduit diversion
11379210|NCT02174185||bladder cancer, orthotopic neobladder|new patients with bladder cancer scheduled for radical cystectomy and subsequent orthotopic neobladder
11379211|NCT02174172|Experimental|Arm A: Atezolizumab with Ipilimumab|Participants will receive atezolizumab along with ipilimumab.
11379212|NCT02174172|Experimental|Arm B: Atezolizumab with Interferon alfa-2b|Participants will receive atezolizumab along with Interferon alfa-2b.
11379213|NCT02174172|Experimental|Arm C: Atezolizumab with PEG- interferon alfa-2a|Participants will receive atezolizumab along with PEG- interferon alfa-2a.
11379214|NCT02174172|Experimental|Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab|Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.
11379216|NCT02174159|Experimental|Panel A: MK-8507 600 mg|Single oral dose of MK-8507 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
11379217|NCT02174159|Experimental|Panel B: MK-8507 150 mg|Single oral dose of MK-8507 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
11379218|NCT02174159|Experimental|Panel C: MK-8507 <=600 mg|Single oral dose of MK-8507 <=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
11379219|NCT02174146|Other|non-surgical therapy|non-surgical periodontal therapy with ultrasonic scalers and periodontal curettes
11379220|NCT02174133||patients after HTX|
11379221|NCT02174133||patients after LVAD implantation|
11379222|NCT02174133||patients with coronary heart disease|
11379223|NCT02174133||healthy volunteers|
11379224|NCT02174120|Experimental|Group A|During maintenance of anesthesia, etomidate was give by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml to keep bispectral index between 40 to 60.
11379225|NCT02174120|Experimental|Group B|During maintenance of anesthesia, Propofol was give by target controlled infusion, the effect-site concentration is 2 to 4 micrograms/ml to keep bispectral index between 40 to 60.
11379226|NCT02174120|Experimental|Group C|During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
11379227|NCT02174107|Experimental|Arm A|Percutaneous vertebroplasty
11379228|NCT02174107|Experimental|Arm B|External radiotherapy
11379229|NCT02174094|Experimental|Clobazam|Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
11379230|NCT02174094|Placebo Comparator|Placebo|Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
11379231|NCT02174068|Experimental|paracetamol|drug interaction between paracetamol and nefopam in healthy volunteers.
11379232|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. The study is divided in three phases. In Phase 1, approximately 15 depressed patients (as determined clinically) and approximately 15 non-depressed patients will undergo individual interviews. In Phase 2, the team will use the themes and subthemes obtained in Phase 1 to write a set of indicators into questionnaire form. In Phase 3, the newly developed questionnaire will be given to a sample of approximately 150 cancer patients who meet the eligibility criteria. Survey results obtained from this sample of 150 patients will be used to assess internal consistency, conduct item analysis, and determine the unique content of the proposed instrument.
11379233|NCT02174042|Experimental|Tangning Tongluo Capsule|Type 2 diabetes
11379234|NCT02174029||Ventilation- mandatory mode only|those patient ventilator days during which they had only received a mandatory mode of ventilation
11379235|NCT02174029||Ventilation- voluntary mode only|Those patient days on a mechanical ventilator who have not received prior mandatory ventilation during this episode of mechanical ventilation.
11379236|NCT02174029||voluntary with preceding mandatory|Those patient ventilator days where the patient had at least one prior day of mandatory mechanical ventilation during this episode of respiratory support.
11379237|NCT02174016|Experimental|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
11379238|NCT02174003||Open Treatment Group|The Open Treatment Group (all participants in this study) will receive the active / WBH treatment in an open fashion.
11379239|NCT02173990|Experimental|Aflibercept-FOLFIRI|On day 1 of each cycle patients will receive aflibercept followed by irinotecan, 5-FU and leucovorin (FOLFIRI regimen). This treatment will be repeated every 2 weeks until RECIST progression or intolerance.
11379240|NCT02173977|Active Comparator|ARM A- Agonist/Antagonist protocol|The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
11379241|NCT02173977|Active Comparator|ARM B- Antagonist protocol|The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
11379242|NCT02173964|Experimental|pinaverium bromide|pinaverium bromide 50 mg tablet per oral administration one time
11379243|NCT02173964|Placebo Comparator|water|water ~100mL
11379244|NCT02173951|Active Comparator|arm 1 iron chelation|Active Comparator arm : iron chelation Included 32 thalassemia major patients with low serum ferritin (≥500) . They will receive low dose Deferiprone( DFP )on 50 mg/kg/d.
11379245|NCT02173951|Placebo Comparator|arm 2 blood transfusion|Placebo Comparator arm: blood transfusion only Included 32 thalassemia patients with low serum ferritin (≥500). They receive blood transfusion with no chelation. Patients will start deferiprone 75 mg/kg/d when reaching Primary end point which is elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6
11379246|NCT02173938||Treatment seekers|
11379247|NCT02173925||Functional dyspepsia group|Patients who had epigastric pain or discomfort with normal upper endoscopy and no organic evidence for explaining these symptoms
11379248|NCT02173925||Control group|Subjects with normal endoscopic finding who do not have any gastrointestinal symptoms
11379249|NCT02173912|Experimental|Sequence 1|"Single-dose crossover
~Test: CJ-30059
~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg
~Once daily Oral administration with at least 14 days of washout period"
11379250|NCT02173912|Experimental|Sequence 2|"Single-dose crossover
~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg
~Test: CJ-30059
~Once daily Oral administration with at least 14 days of washout period"
11379251|NCT02173899|Experimental|varicella-1|The second varicella vaccine and 1 year of the interval time between 2 doses
11379252|NCT02173899|Experimental|varicella-3|The second varicella vaccine and 3 years of the interval time between 2 doses
11379253|NCT02173899|Experimental|varicella-5|The second varicella vaccine and 5 years of the interval time between 2 doses
11379254|NCT02173886|Experimental|Bupropion|Bupropion SR and XL, single dosages of each separated by a wash-out period
11379298|NCT02173561|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
11379299|NCT02173561|Experimental|Individual Cognitive Processing Therapy-Cognitive Only|
11379255|NCT02173873|Experimental|one injection of ziv aflibercept intravitreal route|Intervention: Inject 0.05 ml of zaltrap into the vitreous of blind eyes with various diseases (AMD, CRVO) and monitor vision and OCT 1 day and 1 week after injection
11379256|NCT02173860|Active Comparator|FFR-guided revascularization|Patients with valvular heart disease scheduled for elective cardiac surgery and concomitant significant coronary artery disease will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions in vessels pre-specified as suitable for surgical revascularization. If the FFR is ≤0.80, then CABG will be performed. If the FFR is >0.80 then no graft will be placed in that particular vessel. Patients in whom FFR of a particular lesion is not possible can be included if at least one additional lesion is suitable for FFR measurement and grafting.
11379257|NCT02173860|Active Comparator|Angio-guided revascularization|Concomitant CABG will be performed as per clinical routine in all vessels with at least one stenosis > 50%. The vessel should be pre-specified as suitable for surgical revascularization before randomization. An internal mammary graft to the LAD should be attempted in all cases, if possible. Further revascularization strategy is left to the discretion of each center.
11379258|NCT02173847|Experimental|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Diode laser welding of the flap in its final position. 12 months follow up study
11379259|NCT02173834|Other|Lean subjects|Lean, young, healthy, Caucasian, male subjects
11379260|NCT02173834|Other|Obese subjects|Obese, Young, Healthy, Caucasian, male subjects
11379261|NCT02173808|Experimental|Contraceptive|
11379262|NCT02173795|Experimental|Berodual® Respimat® - Berodual® MA HFA|"randomized sequence
~Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)
~Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)"
11379263|NCT02173782|Experimental|Berodual® Respimat ® high dose|
11379264|NCT02173782|Active Comparator|Berodual® MDI|
11379265|NCT02173782|Experimental|Berodual® Respimat® low dose|
11379266|NCT02173782|Placebo Comparator|Placebo|
11379267|NCT02173769||Adults with COPD|
11379268|NCT02173756|Experimental|oral morphine gel|1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
11379269|NCT02173756|Placebo Comparator|placebo gel|1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
11379270|NCT02173743|Experimental|PRP group|PRP during barbotage
11379271|NCT02173743|Other|Control group|Regular barbotage
11379272|NCT02173730|Experimental|BIBR 1048 MS without Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day
11379273|NCT02173730|Experimental|BIBR 1048 MS with Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.
11379274|NCT02173717|Experimental|Dabigatran etexilate|"Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.
~Single oral administration of dabigatran etexilate on Day 1;
~Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;
~Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;
~Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout"
11379275|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
11379276|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
11379277|NCT02173691|Experimental|Tiotropium|
11379278|NCT02173691|Active Comparator|Salmeterol|
11379279|NCT02173691|Placebo Comparator|Placebo|
11379280|NCT02173678|Experimental|COMBIVENT® HFA|
11379281|NCT02173678|Active Comparator|COMBIVENT® CFC|
11379282|NCT02173678|Placebo Comparator|Placebo HFA-MDI (metered dose inhaler)|
11379283|NCT02173665|Experimental|BI 1356 BS - Powder in bottle (PIB)|
11379284|NCT02173665|Experimental|BI 1356 BS - Tablet|
11379285|NCT02173665|Active Comparator|Placebo|
11379286|NCT02173652|Experimental|BI 1356, high dose|Treatment A: 7 days of BI 1356 treatment given once daily
11379287|NCT02173652|Active Comparator|BI 1356, low dose|Treatment B: 7 days of BI 1356 treatment given twice daily
11379288|NCT02173639|Experimental|BI 1356/metformin|
11379289|NCT02173639|Experimental|BI 1356 + Metformin|
11379290|NCT02173626|Other|GSH Medical Staff|Volunteers from the Good Samaritan Hospital medical staff were included on a first come first serve basis
11379291|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
11379292|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
11379293|NCT02173600|Experimental|Group-level Intensive Dietary Counselling|Active learning through 4-6 60-minute sessions workshop, enrolling 8-12 people each time.
11379294|NCT02173600|Active Comparator|Individual-level Intensive Dietary Counselling|Individualised dietary counselling delivered at the health-care point
11379295|NCT02173587|Experimental|Mussel oil capsules|Four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) per day for first two months and two mussel oil capsules (containing 400mg mussel oil and 400mg corn oil) per day thereafter for four months.
11379296|NCT02173587|Placebo Comparator|Corn oil capsuels|Four corn oil capsules (containing 1600mg corn oil) for first two months and two mussel oil capsules (containing 800mg corn oil) per day thereafter for four months.
11379307|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
11379308|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
11379309|NCT02173509|Experimental|Educational multifaceted intervention|Multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense, in physicians and pharmacists.
11379310|NCT02173496||Colour contrast sensitivity|Colour contrast sensitivity
11379311|NCT02173483|Other|Quadriceps graft|Proximally from patella the Quadriceps graft is harvested and used as a knew anterior cruciate ligament after rupture.
11379312|NCT02173483|Other|Hamstrings Graft|The Hamstrings graft is harvested and used as a knew anterior cruciate ligament after rupture.
11379313|NCT02173470|No Intervention|Control|Routine clinical care (which includes a conventional chest X-ray).
11379314|NCT02173470|Experimental|CT scan|Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).
11379315|NCT02173457|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 24 weeks
11379316|NCT02173457|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 24 weeks
11379317|NCT02173457|Active Comparator|Arm 3|Patients administrate Sitagliptin 100mg once daily for 24 weeks
11379318|NCT02173431||BMI 20 to 24.99|30 patients
11379319|NCT02173431||BMI 25 to 29.99|30 patients
11379320|NCT02173431||BMI 30 to 34.99|30 patients
11379321|NCT02173431||BMI 35 to 39.99|30 patients
11379322|NCT02173431||BMI 40 to 44.99|30 patients
11379323|NCT02173431||BMI 45 to 49.99|30 patients
11379324|NCT02173431||BMI more than 50|30 patients
11379325|NCT02173418|Experimental|Ropivacaine|Phrenic nerve block with Ropivacaine
11379326|NCT02173418|Placebo Comparator|Placebo|Phrenic nerve block with Sodium chloride
11379327|NCT02173405|Active Comparator|Treatment Group|20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.
11379328|NCT02173405|Placebo Comparator|Placebo group|20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.
11379329|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
11379330|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
11379331|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
11379332|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
11379333|NCT02173366|Experimental|Change Club Intervention|
11379334|NCT02173353|Experimental|Pancreas cancer|Develope a stand, cradle or robotic arm to hold the ultrasound probe, to obtain an ultrasound just before a standard radiation therapy treatment is given.
11379335|NCT02173327|Other|Continuously Helm CPAP|Continuously helm CPAP for 6 hours
11379336|NCT02173327|Other|Intermittent Mask CPAP|Intermittent Mask CPAP for 10minuttes every 2 hours in a 18 hours period postoperative.
11379337|NCT02173314|Experimental|Treatment|
11379338|NCT02173314|No Intervention|Comparison|
11379339|NCT02173301|Experimental|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
11379340|NCT02173301|Experimental|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
11379341|NCT02173301|Experimental|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
11379342|NCT02173301|Placebo Comparator|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
11379343|NCT02173288|Active Comparator|Standard medical therapy|Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
11379344|NCT02173288|Active Comparator|Midodrine group|Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
11379345|NCT02173288|Active Comparator|Tolvaptan group|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
11379346|NCT02173288|Experimental|Tolvaptan plus midodrine arm|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day
11379347|NCT02173275||derivation cohort|n = 309
11379348|NCT02173275||validation cohort|n = 309
11379349|NCT02173262|Other|G-CSF|Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.
11379350|NCT02173262|Other|Ciprofloxacin|Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.
11379351|NCT02173249|Experimental|AC 170 0.24%|
11379352|NCT02173236|Experimental|platform-switched implants|platform-switched implants vs. platform-matched implants
11379353|NCT02173236|Active Comparator|platform-matched implants|platform-switched implants vs. platform-matched implants
11379386|NCT02173015|Experimental|High Fall Risk, Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, and qualify for compensatory step training."
11379387|NCT02173002|Active Comparator|Standard care|Standard care
11379388|NCT02173002|Experimental|myIBDcoach|myIBDcoach
11379389|NCT02172976|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery
11379390|NCT02172976|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery
11379391|NCT02172963|Experimental|Decidual Stromal Cell therapy for Hemorrhagic Cystitis|
11379354|NCT02173223|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
11379355|NCT02173223|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
11379356|NCT02173210||Prior preterm birth|Pregnant women with a prior preterm birth, eligible to receive 17 hydroxyprogesterone caproate (17OHPC)
11379357|NCT02173197||OT arm|"Through the initial evaluation of the complex patients' needs, the OT will propose a targeted intervention to the needs emerged and decide which approach will use to achieve the goal (i.e. compensatory or restorative).
~We will describe the characteristics of the population included and identify common needs and problems of the complex patients through the COPM.
~The needs and problems identified will be grouped into macro-areas, and the OT will propose the appropriate treatment on the basis of the area identified, the patient's needs and the available resources regardless of the origin of the disease."
11379358|NCT02173184|Placebo Comparator|Placebo|Placebo vehicle (0.9% NaCl solution)
11379359|NCT02173184|Experimental|Gynevac|Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution
11379360|NCT02173171||Previously treated with T-VEC|Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
11379361|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
11379362|NCT02173145|Active Comparator|Azithromycin first, Placebo second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo.
11379363|NCT02173145|Active Comparator|Placebo first, Azithromycin second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo. Placebo will be capsulated similar to verum and given 3 times a week.
11379364|NCT02173132|Active Comparator|acetyl-L-carnitine|2 g acetyl-L carnitine twice a day for 90 days
11379365|NCT02173132|Placebo Comparator|sugar pill|Placebo twice a day for 90 days
11379366|NCT02173119||HCC patients having MRI post-TACE|HCC patients who have undergone conventional lipiodol based chemoembolization.
11379367|NCT02173106|Experimental|Group A: steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.
11379368|NCT02173106|No Intervention|Group B: no steroid & Cyclosporin|no steroid and cyclosporin and waiting for spontaneous remission for 6 months
11379369|NCT02173093|Experimental|Treatment (IL-2, GM-CSF, GD2Bi-aATC)|Patients receive IL-2 SC daily on days -2 to 35, GM-CSF SC twice weekly x 5 weeks, and GD2Bi-aATC IV over 30 minutes twice weekly x 4 weeks for a total of 8 infusions. Laboratory evaluations of immune responses are obtained prior and after immunotherapy.
11379370|NCT02173080||Polycystic liver disease patients|will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36
11379371|NCT02173080||ADPKD group without PLD|will receive PLD-Q
11379372|NCT02173080||Healthy controls|receive PLD-Q
11379373|NCT02173080||PLD patient focus group|to discuss and improve PLD-Q
11379374|NCT02173080||PLD clinical expert focus group|to discuss and improve PLD-Q
11379375|NCT02173067||2% lidocaine|35 patients received 5.4 mL of 2% lidocaine.
11379376|NCT02173067||2% lidocaine with epinephrine|35 patients recieved 5.4 mL of 2% lidocaine with 1:100,000 epinephrine.
11379377|NCT02173054|Placebo Comparator|Adapalene gel|"Evening
~Wash face by prepared facial foam and dry your face
~Apply adapalene gel all over the face"
11379378|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning
~Wash face by prepared facial foam and dry their face
~Apply placebo cream all over the face
~Evening
~Wash face by prepared facial foam and dry your face
~Apply adapalene gel all over the face
~Apply placebo cream all over the face"
11379379|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning
~Wash face by prepared facial foam and dry their face
~Apply Eucerin cream all over the face
~Evening
~Wash face by prepared facial foam and dry your face
~Apply adapalene gel all over the face
~Apply Eucerin cream all over the face"
11379380|NCT02173041|Other|Standard Usual Care|Community program which follows with referral services
11379381|NCT02173041|Experimental|Prevention Awareness Groups (PAG)|Prevention Awareness Groups (PAG) is a community based integrated substance abuse prevention program targeting vulnerable populations. It comprises of community programs, physician led counseling followed by treatment follow up in community based clinic.
11379382|NCT02173028||Optimal beta blocker titration|We will compare the efficacy of two management strategies for beta-blocker up-titration: Standard in-office visits vs. Remote follow-up.
11379383|NCT02173028||Without optimal titration of beta blocker|This analysis will be conducted within the Cardiac Resynchronization Therapy observational study Modular Registry (CRT MORE - ClinicalTrials.gov Identifier: NCT01573091).
11379384|NCT02173015|No Intervention|Low Fall Risk|"Individuals who have a functional reach greater than 8 and a unipedal stance time greater than 5 s."
11379385|NCT02173015|No Intervention|High Fall Risk, No Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, but do not qualify for compensatory step training due to health concerns."
11379392|NCT02172950|Experimental|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
11379393|NCT02172950|Experimental|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
11379394|NCT02172937|Experimental|Decidual Stromal Cells as last line treatment|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.
11379395|NCT02172937|Active Comparator|Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.
11379396|NCT02172924|Active Comparator|Early Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.
11379397|NCT02172924|Active Comparator|Late Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.
11379398|NCT02172911|Experimental|INO-3112|1.1 ml of INO-3112 (6 mg of VGX-3100 and 1 mg of INO-9012)
11379399|NCT02172898||Heavily Drinking Controls|Heavy alcohol drinking will be defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment. Heavy drinkers, who have just become abstinent within prior 2 weeks, including those we convince to seek treatment as part of the recruiting process, are eligible for enrollment. Control subjects must meet the following criteria: (1) AST, ALT, and total bilirubin levels must be within normal range; (2) no prior history of known alcoholic liver disease; and (3) absence of hepatosplenomegaly (from physical examination or radiographic imaging) or stigmata of liver disease.
11379400|NCT02172898||Subjects with AH|Diagnosis of AH will be established on published criteria based on history of heavy alcohol consumption (defined as > 40 grams per day on average in women and > 60 grams per day on average for men for a minimum of 6 months and within the 6 weeks prior to study enrollment), clinical evaluation and appropriate laboratory testing (as defined as total bilirubin > 2 mg/dL and AST > 50 U/L). When diagnosis of AH remains in question, a liver biopsy (if clinically feasible and subject has no contraindications) will be required. We plan to enroll patients with AH in special population infected with hepatitis B (HBV), hepatitis C (HCV), or HIV.
11379401|NCT02172885|Experimental|Mesenchymal stem cells|Five Mesenchymal Stem Cell infusions
11379402|NCT02172872|Active Comparator|standard combination chemotherapy|
11379403|NCT02172872|Experimental|decitabine|
11379404|NCT02172859|Active Comparator|lumiVida™|lumiVida™ (2 x 0.5 g sachets to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days.
11379405|NCT02172859|Placebo Comparator|Placebo|Placebo (2 x 0.5 g sachets of casein hydrolysate to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days
11379406|NCT02172846|Experimental|Treatment (PBT, paclitaxel, and carboplatin)|"CHEMORADIATION THERAPY:
~PBT daily 5 days a week over 3 weeks for a total of 15 fractions
~Paclitaxel intravenously (IV) over 1 hour weekly for 3 weeks
~Carboplatin intravenously (IV) over 30 minutes weekly for 3 weeks.
~CONSOLIDATION CHEMOTHERAPY (B=beginning 4-6 weeks after completion of radiation therapy, patients may receive):
~Paclitaxel IV over 1 hour on day 1
~Carboplatin IV over 30 minutes on day 1
~At the discretion of the treating physician
~Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
11379407|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
11379408|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
11379409|NCT02172807|Experimental|Tiotropium low & Placebo|Tiotropium 18 µg inhalation capsule and Placebo MDI
11379410|NCT02172807|Experimental|Tiotropium high & Placebo|Tiotropium 36 µg inhalation capsule and Placebo MDI
11379411|NCT02172807|Active Comparator|Oxitropium & Placebo|Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules
11379412|NCT02172794|Experimental|tiotropium|
11379413|NCT02172794|Active Comparator|salmeterol|
11379414|NCT02172781|Experimental|Ipratropium - unit dose vial|
11379415|NCT02172781|Experimental|Tiotropium - inhalation capsule - low dose|
11379416|NCT02172781|Placebo Comparator|Placebo matching tiotropium - inhalation capsule|
11379417|NCT02172781|Placebo Comparator|Placebo matching to ipratropium - unit dose vial|
11379418|NCT02172781|Experimental|Tiotropium - inhalation capsule - high dose|
11379419|NCT02172768|Experimental|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
11379420|NCT02172768|Active Comparator|daily dosing|micafungin daily for 8 days
11379421|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
11379422|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
11379423|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate
~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
11379424|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo
~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
11379425|NCT02172729|Experimental|ACB with lidocaine 5 mg/ml|Adductor canal block (ACB) with 20 ml lidocaine 5 mg/ml, single bolus
11379426|NCT02172729|Experimental|ACB with lidocaine 15 mg/ml|Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
11379427|NCT02172716|Experimental|Nonsurgical periodontal treatment|Nonsurgical periodontal treatment will be conducted following a full-mouth approach; no antibiotics or chemical plaque control will be provided.
11379428|NCT02172703|Other|Non-invasive ICP measurement|non-invasive ICP measurement with NON-INVASIVE ICP ABSOLUTE VALUE METER (carried out simultainusly with standard invasive ICP measurement catheter and probes)
11379429|NCT02172690|Experimental|Laparoscopic Staging|For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
11379430|NCT02172677|Experimental|Healthy participants|Structural and functional MRI and memory assessment
11379431|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
11379432|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
11379433|NCT02172651|Experimental|Vitamin D3 - Blinded Registration|One capsule of vitamin D3 10,000 IU orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative vitamin D3 for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
11379434|NCT02172651|Placebo Comparator|Placebo - Blinded Registration|One placebo capsule orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative placebo for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
11379435|NCT02172638|Experimental|FAST-TRACK Group|Patients in this group will be managed according to an specifically designed FAST-TRACK protocol which will include: Preoperatory nutritional management and coaching by surgeon, anesthetist, nutritionist and specifically trained nurse personnel, reduced preoperatory fasting, avoiding use of intraabdominal drainages, specific anesthetic management to reduce intraoperative stress, avoiding use of Nasogastric tube, avoiding the need for major opioid in postoperatory analgesia and use of an standardized postoperatory management protocol directed to obtain an early oral intake and mobilization with a the goal of normal diet and deambulation in the 3rd day after surgery.
11379436|NCT02172638|Active Comparator|Classical management group|Patients assigned to this group will receive the standard management preformed in our center until now. This management includes a preoperatory control exclusively by the surgeon and anesthetist, minimum of 8h fasting previous to surgery, loose use of intraabdominal drainage , systematic use of nasogastric tube whenever rectum resection or omentectomy is performed, Postoperative analgesia following standing Vall d'Hebron protocols for Moderate-severe postoperative pain, which include use of combined analgesia with non opioids drugs and major Opioids, and usual flexible, non standardized postoperatory management with mobilization and oral intake progression depending on perceived evolution by attending surgeon.
11379437|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
11379438|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
11379439|NCT02172612|Experimental|Arm 1 - Intervention|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
11379440|NCT02172612|No Intervention|Arm 2 - Control|Those included in the control group will receive a generic brochure about medication safety and inappropriate medication use in the elderly.
11379441|NCT02172599|Experimental|multi-component intervention|"Sit-stand workstation provision
~The multi-component intervention will align with the World Health Authority's promotion of a healthy workplace model, which emphasises that best-practice workplace health interventions should involve an integrated approach involving organisation and individual level approaches to behaviour change (WHO, 2010). Thus, participants will receive a sit-stand workstation with additional support to use the sit-stand workstation."
11379442|NCT02172599|Experimental|Sit-stand workstation only|"Sit-stand workstation provision
~Participants in this arm will receive a sit-stand workstation. They will not receive any support to use the sit-stand workstation, except some health and safety advice upon installation."
11379443|NCT02172599|No Intervention|Usual practice (seated workstation)|This arm is the control group. They will continue to use their usual seated workstation for the duration of the study.
11379444|NCT02172586|Experimental|Telmisartan|
11379445|NCT02172586|Experimental|Telmisartan + Hydrochlorothiazide|
11379446|NCT02172586|Active Comparator|Losartan|
11379447|NCT02172586|Active Comparator|Losartan + Hydrochlorothiazide|
11379448|NCT02172573|Experimental|Pramipexole|
11379449|NCT02172573|Experimental|Bromocriptine|
11379450|NCT02172573|Placebo Comparator|Placebo|
11379451|NCT02172560||Premature withdrawal from tiotropium|
11379452|NCT02172547||COPD patients who stopped smoking during treatment|
11379453|NCT02172534|Experimental|Tiotropium bromide low|Single dose: 2.5 µg Tiotropium
11379454|NCT02172534|Experimental|Tiotropium bromide medium|Single dose: 5 µg Tiotropium
11379455|NCT02172534|Experimental|Tiotropium bromide high|Single dose: 10 µg Tiotropium
11379456|NCT02172534|Experimental|Tiotropium bromide low (28 days)|multiple dose: 2.5 µg Tiotropium
11379457|NCT02172534|Experimental|Tiotropium bromide medium (28 days)|Multiple dose: 5 µg Tiotropium
11379458|NCT02172534|Placebo Comparator|Placebo|single or multiple dose of Placebo
11379459|NCT02172521||COPD and proven hyperinflation|Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram
11379460|NCT02172508|Experimental|Tiotropium|
11379461|NCT02172508|Placebo Comparator|Placebo|
11379462|NCT02172495||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
11379463|NCT02172482||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
11379464|NCT02172469|Experimental|Tiotropium & Placebo|
11379465|NCT02172469|Active Comparator|Atrovent & Placebo|
11379466|NCT02172456|Experimental|Tiotropium|
11379467|NCT02172443|Experimental|tiotropium inhalation capsules|
11379468|NCT02172443|Active Comparator|Atrovent MDI|
11379469|NCT02172430|Experimental|Tiotropium|
11379470|NCT02172430|Active Comparator|Oxitropium bromide|
11379471|NCT02172417|Experimental|Cimetidine + Tiotropium followed by Tiotropium|
11379472|NCT02172417|Experimental|Ranitidine + Tiotropium followed by Tiotropium|
11379473|NCT02172404|Experimental|HandiHaler® vs. MDI|sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
11379474|NCT02172404|Experimental|MDI vs. HandiHaler®|sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
11379475|NCT02172391|Experimental|Tiotropium|Tiotropium inhalation powder capsules 18 mcg, one capsule once daily for 28 days
11379476|NCT02172391|Placebo Comparator|Placebo|Placebo inhalation powder capsules, one capsule once daily for 28 days
11379477|NCT02172378|Experimental|Tiotropium inhalation capsules|
11379478|NCT02172378|Placebo Comparator|Placebo inhalation capsules|
11379479|NCT02172352|Experimental|Ba 679 BR low dose|
11379480|NCT02172352|Placebo Comparator|Placebo inhalation powder|
11379481|NCT02172352|Experimental|Ba 679 BR middle dose|
11379482|NCT02172352|Experimental|Ba 679 BR high dose|
11379483|NCT02172339|Experimental|Tiotropium|group comparison (healthy, renal impairment)
11379484|NCT02172326|Experimental|Tiotropium inhalation capsules|
11379485|NCT02172313|Experimental|Fed conditions|Fasting for 10 hours overnight followed by a high-fat, high-calorie meal, after the meal dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
11379486|NCT02172313|Experimental|Fasting conditions|Fasting for 10 hours overnight followed by dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
11379487|NCT02172313|Experimental|Reference dosing condition|Fasting for 6 hours overnight followed by dosing of the tablet with 120 mL of water and a post-dose fasting period of 30 min
11379488|NCT02172300|Experimental|Tiotropium|Tiotropium inhalation capsules via HandiHaler
11379489|NCT02172300|Placebo Comparator|Placebo|Placebo inhalation capsules via HandiHaler
11379490|NCT02172287|Experimental|Tiotropium (Ba679 BR)|Tiotropium capsule once daily by oral inhalation
11379491|NCT02172287|Active Comparator|Salmeterol|Salmeterol inhalation aerosol twice daily
11379492|NCT02172287|Placebo Comparator|Placebo|"Tiotropium (Ba679 BR)- placebo one capsule once daily by inhalation
~Salmeterol- placebo, inhalation aerosol twice daily"
11379493|NCT02172274|Experimental|[14C]-BI 10773 - oral solution|
11379494|NCT02172261|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and glimepiride once on day 1
~Treatment C: Glimepiride once on day 1"
11379495|NCT02172261|Experimental|Sequence CAB|"Treatment C: Glimepiride once on day 1
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and glimepiride once on day 1"
11379496|NCT02172248|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4
~Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4"
11379497|NCT02172248|Experimental|Sequence CAB|"Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4"
11379498|NCT02172235|Active Comparator|Pioglitazone|
11379499|NCT02172235|Experimental|Pioglitazone + BI 10773 low|
11379500|NCT02172235|Experimental|Pioglitazone + BI 10773 medium|
11379501|NCT02172235|Experimental|Pioglitazone + BI 10773 high|
11379502|NCT02172235|Experimental|Pioglitazone low + BI 10773 medium|
11379503|NCT02172235|Experimental|Pioglitazone + BI 10773 1 hour after Pioglitazone|
11379504|NCT02172222|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI10773 and linagliptin once daily from day 1 to 7
~Treatment C: Linagliptin once daily from day 1 to 7"
11379505|NCT02172222|Experimental|Sequence CAB|"Treatment C: Linagliptin once daily from day 1 to 7
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI10773 and linagliptin once daily from day 1 to 7"
11379506|NCT02172209|Experimental|BI 10773 tablet administered with food|50 mg BI 10773 after a standardised high fat breakfast
11379507|NCT02172209|Active Comparator|BI 10773 tablet administered to fasted subjects|50 mg BI 10773 p.o. after an overnight fast of at least 10 hours
11379508|NCT02172196|Experimental|Treatment sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5
~Treatment C: Sitagliptin once daily from day 1 to 5"
11379509|NCT02172196|Experimental|Treatment sequence CAB|"Treatment C: Sitagliptin once daily from day 1 to 5
~Treatment A: BI 10773 once daily from day 1 to 5
~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5"
11379510|NCT02172183|Experimental|CBT group|This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
11379511|NCT02172183|Active Comparator|Psychopharmacological treatment|Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
11379512|NCT02172170|Experimental|BI 10773 single rising dose|
11379513|NCT02172170|Placebo Comparator|Placebo|
11379514|NCT02172157|Experimental|BI 1744 CL i.v. (intravenous) infusion|
11379515|NCT02172157|Active Comparator|BI 1744 CL Oral solution|
11379516|NCT02172144|Experimental|BI 1744 CL|
11379517|NCT02172144|Placebo Comparator|Placebo|
11379518|NCT02172144|Active Comparator|Moxifloxacin (Avalox®)|
11379519|NCT02172131|Experimental|BI 1744 CL|Single rising dose of BI 1744 CL as intravenous (i.v.) infusion
11379520|NCT02172131|Placebo Comparator|Placebo|
11379521|NCT02172118|Experimental|severely renally impaired patients|
11379522|NCT02172118|Experimental|healthy volunteers|
11379523|NCT02172105|Experimental|BI 1744 CL|
11379524|NCT02172105|Placebo Comparator|Placebo|
11379525|NCT02172092|Experimental|Ketoacidosis|Patients treated for diabetic ketoacidosis at the Intensive care unit, Vrinnevi Hospital, Norrköping.
11379526|NCT02172079|Experimental|Real mobilization-with-movement (MWM)|For the MWM group, an accessory posterior-lateral gliding movement in the humeral head combined with a movement of active shoulder flexion will be applied. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior aspect of the head of the humerus
11379527|NCT02172079|Sham Comparator|Sham mobilization-with-movement (MWM)|The sham condition will replicate the treatment condition except for the hand positioning. The therapist locates one hand over the belly of the pectoralis major muscle and the other over scapula without applying any pressure. The patient will be asked to move the arm in a similar manner as in the MWM group
11379528|NCT02172066|Experimental|Narrative Exposure Therapy (NET)|During NET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for emotions, cognitions, sensory information, and physiological reactions to link the traumatic events to an autobiographical context, namely time and place. In total the Individuals receive 6 sessions of NET, every session lasting between 1,5 and 2 hr depending on the needs of the participant.
11379529|NCT02172066|No Intervention|No treatment control|
11379530|NCT02172053|Active Comparator|Compensatory Workplace Exercise (CWE)|Comparative Group will receive a light training protocol including warming up, stretching and resisted exercise using elastic bands.
11379531|NCT02172053|Experimental|Individual Resistance Exercise (IRE)|Intervention group will receive training protocol including warming up, stretching a specific resistance training with increase progressive load.
11379532|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
11379533|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
11379534|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
11379535|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
11379536|NCT02172027||Lung Cancer, Pleural effusion|
11379537|NCT02172014|Experimental|Fentanyl|midazolam and fentanyl citrate infusion
11379538|NCT02172014|Placebo Comparator|Control|midazolam and normal saline infusion
11379539|NCT02172001|Experimental|Iron isomaltoside 1000|Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
11379540|NCT02172001|Placebo Comparator|Placebo (NaCl 0,9%)|Sodium Chloride. Dose: 100 ml or 5 ml
11379541|NCT02171988|Active Comparator|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
11379542|NCT02171988|Active Comparator|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
11379543|NCT02171988|Active Comparator|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
11379544|NCT02171988|Active Comparator|Bisoprolol+pyridostgmine|start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
11379545|NCT02171975|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthetic.
11379546|NCT02171975|Experimental|Group P|This group had their spinal anaesthetic done based on pre-procedure ultrasound guided paramedian spinal
11379547|NCT02171962|Experimental|Zilver® PTX® VI|
11379548|NCT02171949|No Intervention|Control group|
11379549|NCT02171949|Active Comparator|Bone marrow mononuclear cell therapy|
11379550|NCT02171936||chronic pain|
11379551|NCT02171923||Remitted depressed patients|Formerly depressed patients in remission for 6 months or more
11379552|NCT02171923||healthy controls|healthy subjects with no history of mental disorders
11379553|NCT02171910|Active Comparator|Doxapram|Propofol sedation with a doxapram 1mg/kg i.v. bolus at induction and an i.v. infusion 1mg/kg/h) during the procedure
11379554|NCT02171910|Placebo Comparator|Placebo|Propofol sedation with a placebo i.v. bolus at induction and a placebo i.v. infusion during the procedure
11379555|NCT02171897|Experimental|Patients treated with osteosynthesis|
11379556|NCT02171897|Experimental|Patients treated with total hip replacement|
11379557|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
11379558|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
11379559|NCT02171884||Group T1|Singletons conceived naturally
11379560|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
11379633|NCT02171416|Experimental|Rilonacept 160mg|Rilonacept s.c every 7 days
11379634|NCT02171403||Lactose intolerance|Patients with a positive lactose-breath test and complaints during the test
11379561|NCT02171871|Experimental|CONTROL GROUP|"Healthy non-smoking volunteers (18-40 years old) will be subject, after giving their brief medical history, to IOS and to the nitrogen washout test. The IOS will be conducted in four positions (standing, sitting, right and left lateral decubitus), whereas the nitrogen washout test in two (sitting and decubitus).
~Then the subjects will be exposed to a smoking environment for 20 minutes."
11379562|NCT02171858||stroke|Patients admitted to hospital who are diagnosed with stroke will be treated as usually a our center by observation, venous or arterial thrombolysis depending on extension, condition, thrombolysis feasibility.
11379563|NCT02171845||Foetus|
11379564|NCT02171832|Experimental|Mildly liver impaired patients|
11379565|NCT02171832|Experimental|Moderately liver impaired patients|
11379566|NCT02171832|Experimental|Healthy volunteers|
11379567|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
11379568|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
11379569|NCT02171819|Placebo Comparator|Placebo|Phosphate buffered saline
11379570|NCT02171806|Experimental|BI 1744 CL multiple rising doses|
11379571|NCT02171806|Placebo Comparator|Placebo|
11379572|NCT02171806|Experimental|BI 1744 CL medium dose, females|
11379573|NCT02171793|Experimental|BI 1744 CL|
11379574|NCT02171793|Placebo Comparator|Placebo|
11379575|NCT02171780|Experimental|BI 1744 CL single rising doses|
11379576|NCT02171780|Placebo Comparator|Placebo|
11379577|NCT02171767|Experimental|BIBW 2992 MA2 - single rising dose|
11379578|NCT02171754|Experimental|BIBW 2992 + Ritonavir|
11379579|NCT02171754|Active Comparator|BIBW 2992|
11379580|NCT02171741|Experimental|Docetaxel + BIBW 2992|
11379581|NCT02171728|Experimental|BIBW 2992|dose escalation
11379582|NCT02171715|Experimental|BIBW 2992 MA2, final formulation|
11379583|NCT02171715|Experimental|BIBW 2992 MA2, trial formulation II|
11379584|NCT02171715|Active Comparator|BIBW 2992 MA 2 drinking solution|
11379585|NCT02171702|Experimental|BIBW 2992|dose escalation
11379586|NCT02171702|Experimental|BIBW 2992, fasted|food effect part: maximum tolerated dose of BIBW 2992
11379587|NCT02171702|Experimental|BIBW 2992, fed|food effect part: maximum tolerated dose of BIBW 2992
11379588|NCT02171689|Experimental|BIBW 2992 MA2|
11379589|NCT02171676|Experimental|Docetaxel + BIBW 2992|Dose escalation
11379590|NCT02171663|Experimental|BIBW 2992|
11379591|NCT02171650|Experimental|BIBW 2992|
11379592|NCT02171637|Experimental|BIBW 2992|
11379593|NCT02171624|Experimental|dabigatran etexilate|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
11379594|NCT02171624|Experimental|quinidine|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
11379595|NCT02171611|Experimental|Dabigatran etexilate pellets|
11379596|NCT02171611|Experimental|Dabigatran etexilate powder|
11379597|NCT02171611|Active Comparator|Dabigatran etexilate capsule|
11379598|NCT02171598|Experimental|Fixed sequence 1|multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
11379599|NCT02171598|Experimental|Crossover|clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
11379600|NCT02171598|Experimental|Fixed sequence 2|intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
11379601|NCT02171585|Experimental|Dabigatran without Clarithromycin|
11379602|NCT02171585|Experimental|Dabigatran with Clarithromycin|
11379603|NCT02171572|Experimental|Dabigatran etexilate low|
11379604|NCT02171572|Experimental|Dabigatran etexilate high|
11379605|NCT02171559|Experimental|Dabigatran etexilate capsules after enoxaparin ampoules|
11379606|NCT02171559|Active Comparator|Dabigatran etexilate capsules without enoxaparin|
11379607|NCT02171546|Active Comparator|Dabigatran etexilate capsules|
11379608|NCT02171546|Experimental|Dabigatran etexilate capsules and quinidine sulfate tablets|
11379609|NCT02171546|Active Comparator|Fexofenadine tablets|
11379610|NCT02171546|Experimental|Fexofenadine and quinidine sulfate tablets|
11379611|NCT02171533|Experimental|Fixed sequence|Treatments will be given in a fixed sequence
11379612|NCT02171533|Experimental|Crossover|Treatments will be given in randomized sequences
11379613|NCT02171520|Experimental|Dabigatran etexilate generation I|
11379614|NCT02171520|Active Comparator|Dabigatran etexilate generation II|
11379615|NCT02171507|Active Comparator|Dabigatran etexilate|
11379616|NCT02171507|Active Comparator|Diclofenac|
11379617|NCT02171507|Experimental|Dabigatran etexilate + diclofenac|
11379618|NCT02171494|Experimental|IVAX warfarin|Treatment A: IVAX warfarin
11379619|NCT02171494|Active Comparator|BMS coumadin|Treatment B: BMS coumadin tablets
11379620|NCT02171481|Experimental|Dabigatran etexilate polymorph II|
11379621|NCT02171481|Active Comparator|Dabigatran etexilate polymorph I|
11379622|NCT02171468|Experimental|Dabigatran high dose|
11379623|NCT02171468|Experimental|Dabigatran low dose|
11379624|NCT02171455|Experimental|Dabigatran etexilate low dose|
11379625|NCT02171455|Experimental|Dabigatran etexilate medium dose|
11379626|NCT02171455|Experimental|Dabigatran etexilate high dose|
11379627|NCT02171442|Experimental|BIBR 953 ZW Intravenously|
11379628|NCT02171442|Active Comparator|BIBR 1048 Oral Solution|
11379629|NCT02171429|Active Comparator|Adalimumab + Etrolizumab Placebo|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
11379630|NCT02171429|Experimental|Etrolizumab + Adalimumab Placebo|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
11379631|NCT02171429|Placebo Comparator|Etrolizumab Placebo + Adalimumab Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
11379632|NCT02171416|Placebo Comparator|Placebo|Placebo s.c every 7 days
11379635|NCT02171403||Lactose malabsorption|Patients with a positive lactose-breath test and no complaints during the test
11379636|NCT02171403||Healthy controls|Subjects with a negative lactose-breath test
11379637|NCT02171390|Active Comparator|Daily testosterone transdermal gel|
11379638|NCT02171390|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
11379639|NCT02171377|Experimental|Group 2 : quadricipital electrical stimulation|stimulation in addition to rehabilitation (30 min bilateral quadricipital electrical stimulation pd, 5 days per week, 8 weeks)
11379640|NCT02171377|Active Comparator|Group 1 : Pulmonary rehabilitation|Pulmonary rehabilitation 3 to 5 times per week, 8 weeks
11379641|NCT02171364|Experimental|virtual simulation|This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape.
11379642|NCT02171364|Active Comparator|conventional ablation|The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation.
11379643|NCT02171351|Experimental|effect of neuromuscular electrostimulation (NMES)|
11379644|NCT02171351|Experimental|effect of neuro electrostimulation (NES)|
11379645|NCT02171351|Experimental|effect of voluntary contractions (VC)|
11379646|NCT02171338|Other|Antibiotic treatment based on PCT-level|"Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).
~With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started."
11379647|NCT02171338|No Intervention|Control|"Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.
~PCT-level will be measured but the treating doctor has no access to the result."
11379648|NCT02171325|Experimental|irinotecan|irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
11379649|NCT02171312||Concussion Cohort|Participants with possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
11379650|NCT02171312||Healthy Controls|Participants without possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
11379651|NCT02171299|Experimental|intervetional group (local anaesthetic)|intraoperative wound infiltration with ropivacaine 10%.
11379652|NCT02171299|No Intervention|control (no local anesthetic)|no infiltration of the wound with local anaesthetic
11379653|NCT02171286||No Treatment|
11379654|NCT02171273|Experimental|Chronic circadian disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
11379655|NCT02171273|Experimental|Chronic sleep restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
11379656|NCT02171273|Active Comparator|Control (sleep extension)|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
11379657|NCT02171260|Experimental|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m^2.
11379658|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
11379659|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
11379660|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
11379661|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
11379662|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
11379663|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
11379664|NCT02171221|Experimental|Oral DFP-11207|DFP-11207: daily oral dosing, 28 day treatment cycle
11379665|NCT02171208|Active Comparator|Reference, Test, Reference (RTR)|Doses will be separated by a washout period
11379666|NCT02171208|Active Comparator|Test, Reference, Reference (TRR)|Doses will be separated by a washout period
11379667|NCT02171195|Experimental|Group 1 (20 mg)|
11379668|NCT02171195|Experimental|Group 2 (50 mg)|
11379669|NCT02171195|Experimental|Group 3 (100 mg)|
11379670|NCT02171195|Experimental|Group 4 (200 mg)|
11379671|NCT02171195|Experimental|Group 5 (400 mg)|
11379672|NCT02171195|Experimental|Group 6 (600 mg)|
11379673|NCT02171195|Experimental|Group 7 (900 mg)|
11379674|NCT02171195|Experimental|Group 8 (1200 mg)|
11379675|NCT02171182||Qutenza patients w/ post-operative peripheral neuropathic pain|
11379676|NCT02171169||Transsacral lumbar interbody fusion|
11379677|NCT02171169||Transforaminal lumbar interbody fusion|
11379678|NCT02171143|Experimental|ASP2409 Dose Escalation|
11379679|NCT02171143|Placebo Comparator|Placebo Dose Escalation|
11379680|NCT02171130|Experimental|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
11379681|NCT02171117|No Intervention|CT-group|standard induction and consolidation chemotherapy only, without microtransplantation
11379682|NCT02171117|Experimental|MST-group|standard induction and consolidation chemotherapy with microtransplantation
11379683|NCT02171104|Experimental|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical
~See intervention descriptions."
11379684|NCT02171104|Experimental|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical
~See intervention descriptions."
11379685|NCT02171104|Experimental|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)
~-Haplo-Identical Only
~See intervention descriptions."
11379686|NCT02171104|Experimental|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
11379687|NCT02171104|Experimental|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
11379688|NCT02171104|Experimental|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
11379689|NCT02171104|Experimental|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
11379690|NCT02171091||study arm|One tracheal sample will be obtained using sterile (5 ml) sterile saline solution using irrigation and wall suction from each patient every day for 72 hours, total sampling time is approximately 10 seconds per specimen. Lung samples or fiberoptic obtained samples will be collected at same time intervals as the tracheal samples when possible and if they are done as standard of care. Samples will not be collected for research only and the time for this procedure will not be extended to collect extra tissue. A blood sample (10ml) will be collected simultaneously with the airway samples and also will be used for baseline control measurements.
11379691|NCT02171078||Alliance for Clinical Trials Database|Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
11379692|NCT02171078||National Cancer Database|Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
11379693|NCT02171078||Stakeholder Engagement|Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.
11379694|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
11379695|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
11379696|NCT02171052|Experimental|Dabigatran etexilate plus digoxin|
11379697|NCT02171052|Active Comparator|Dabigatran etexilate|
11379698|NCT02171052|Active Comparator|Digoxin|
11379699|NCT02171039|Experimental|dabigatran plus atorvastatin|
11379700|NCT02171039|Active Comparator|dabigatran|
11379701|NCT02171039|Active Comparator|atorvastatin|
11379702|NCT02171026|Experimental|Dabigatran etexilate + Amiodarone|
11379703|NCT02171026|Active Comparator|Amiodarone|
11379704|NCT02171013|Experimental|Dabigatran etexilate batch A|
11379705|NCT02171013|Experimental|Dabigatran etexilate batch B|
11379706|NCT02171000|Experimental|BIBR 1048|BIBR 1048 MS
11379707|NCT02170987|Experimental|Dabigatran etexilate low|
11379708|NCT02170987|Experimental|Dabigatran etexilate high|
11379709|NCT02170987|Placebo Comparator|Placebo to dabigatran etexilate|
11379710|NCT02170987|Active Comparator|Moxifloxacin|
11379711|NCT02170974|Experimental|BIBR 1048 MS polymorph II|
11379712|NCT02170974|Active Comparator|BIBR 1048 MS polymorph I|
11379713|NCT02170961||acute heart failure (AHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
11379714|NCT02170961||Non acute heart failure (NAHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
11379715|NCT02170948|Experimental|Dex 0.5|Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
11379716|NCT02170948|Experimental|Dex 1.0|Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline
11379717|NCT02170935|Experimental|BIBR 1048 capsule|
11379718|NCT02170922|Experimental|Sequence 1|BIBR 1048 MS tablet (fasted) - BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet after high fat meal
11379719|NCT02170922|Experimental|Sequence 2|BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet (fasted) - BIBR 1048 MS tablet after high fat meal
11379720|NCT02170909|Experimental|BIBR 1048 MS low dose|
11379721|NCT02170909|Experimental|BIBR 1048 MS medium dose|
11379722|NCT02170909|Experimental|BIBR 1048 MS high dose|
11379723|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule A+Pantoprazole|
11379724|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule B+Pantoprazole|
11379725|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule C+Pantoprazole|
11379726|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule D+Pantoprazole|
11379727|NCT02170896|Active Comparator|Period 1: BIBR1048 MS solution+Pantoprazole|
11379728|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule C|
11379729|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule D|
11379730|NCT02170896|Active Comparator|Period 2: BIBR1048 MS solution|
11379731|NCT02170883|Experimental|Interactive SMS|"Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement I follow my asthma medication plan and pharmacist follow-up"
11379732|NCT02170883|Active Comparator|Usual care|Pharmacist conducted patient education, counseling and action-plan
11379733|NCT02170870|Experimental|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
11379734|NCT02170870|Placebo Comparator|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
11379735|NCT02170870|Experimental|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
11379736|NCT02170870|Placebo Comparator|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
11379737|NCT02170870|Experimental|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
11379738|NCT02170870|Placebo Comparator|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
11379739|NCT02170857|No Intervention|Open Curettage Only|patients will be treated by the conventional surgical method, i.e. open curettage without injecting any material.
11379740|NCT02170857|Experimental|Open Curettage with Hyaluronic Acid|Hyaluronic Acid injection will be employed in conjunction with the ordinary surgical procedure.
11379741|NCT02170844|Experimental|BIBR 1048 MS (Japanese)|Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
11379742|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Japanese)|Japanese subjects will receive placebo of BIBR 1048 MS
11379743|NCT02170844|Experimental|BIBR 1048 MS (Caucasian)|Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
11379744|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Caucasian)|Japanese subjects will receive placebo of BIBR 1048 MS
11379745|NCT02170831|Experimental|BIBR 1048 MS low dose|
11379746|NCT02170831|Experimental|BIBR 1048 MS medium dose 1|
11379747|NCT02170831|Experimental|BIBR 1048 MS medium dose 2|
11379748|NCT02170831|Experimental|BIBR 1048 MS high dose|
11379749|NCT02170831|Placebo Comparator|BIBR 1048 Placebo|
11379750|NCT02170818|Experimental|Educational Workshop on Speaking-Up|Educational Workshop on Speaking-Up Before Simulated Case
11379751|NCT02170818|Sham Comparator|Unrelated Education|Unrelated Education (CPR) before simulated case (Educational Workshop on Speaking-up after case and debriefing)
11379752|NCT02170805|Experimental|Substudy 1|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence
~BIBR 1048 MS capsule formulation A without pantoprazole;
~BIBR 1048 MS capsule formulation A with coadministration of 40 mg pantoprazole (bid);
~BIBR 1048 MS powder plus solution without pantoprazole"
11379753|NCT02170805|Experimental|Substudy 2|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence
~BIBR 1048 MS capsule formulation B without pantoprazole;
~BIBR 1048 MS capsule formulation B with coadministration of 40 mg pantoprazole (bid);
~BIBR 1048 MS powder plus solution without pantoprazole"
11379754|NCT02170792|Experimental|BIBR 1048 MS with ranitidine|Low, medium or high dose in combination with ranitidine
11379755|NCT02170792|Experimental|BIBR 1048 MS without ranitidine|Low, medium or high dose
11379756|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
11379757|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
11379758|NCT02170766|Experimental|BIBR 1048 low1|"Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole
~BIBR 1048 12.5 mg without Pantoprazole
~BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)"
11379759|NCT02170766|Experimental|BIBR 1048 low2|"Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole
~BIBR 1048 25 mg without Pantoprazole
~BIBR 1048 25 mg with 40 mg Pantoprazole (bid)"
11379760|NCT02170766|Experimental|BIBR 1048 medium|"Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole
~BIBR 1048 50 mg without Pantoprazole
~BIBR 1048 50 mg with 40 mg Pantoprazole (bid)"
11379761|NCT02170766|Experimental|BIBR 1048 high|"Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole
~BIBR 1048 100 mg without Pantoprazole
~BIBR 1048 100 mg with 40 mg Pantoprazole (bid)"
11379762|NCT02170753|Experimental|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy
11379763|NCT02170753|Active Comparator|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
11379764|NCT02170740|Experimental|BIBR 1048 MS|
11379765|NCT02170740|Experimental|BIBR 1048 MS + Pantoprazole|
11379766|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
11379767|NCT02170714||ASC|Consecutive children hospitalized for an episode of acute ASC, defined as a PUCAI > 65. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms. A follow-up of 2 years for the colectomy risk was evaluated for all patients.
11379768|NCT02170701|Experimental|BIBR 1048|Ascending doses (in mg) given twice daily
11379769|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
11379770|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
11379771|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.
~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
11379772|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.
~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
11379806|NCT02170454|Placebo Comparator|Placebo|Sham rTMS on pharyngeal cortical area in healthy subjects
11379807|NCT02170441||Patients at risk for drug-resistant TB|No intervention
11379808|NCT02170428||growth and development|Growth and development of a random sample of healthy Danish infants
11379773|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
11379774|NCT02170675|Experimental|Dabigatran etexilate + Ketoconazole|"Period 1 - Dabigatran etexilate
~Period 2 - Dabigatran etexilate and single dose of 400 mg Ketoconazole on Day 8 and 9
~Period 3 - Dabigatran etexilate and multiple doses of 400 mg Ketoconazole on Day 10 to 16"
11379775|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
11379776|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
11379777|NCT02170649|Experimental|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
11379778|NCT02170636|Experimental|Period 1: BIBR 1048 MS + Pantoprazole|"Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence.
~BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole"
11379779|NCT02170636|Experimental|Period 2: BIBR 1048 MS|"Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).
~BIBR 1048 MS Capsule E without pantoprazole;
~BIBR 1048 MS Tablet H without pantoprazole;
~BIBR 1048 MS Drinking solution without pantoprazole"
11379780|NCT02170623|Experimental|Period 1: BIBR 1048 MS with Pantoprazole|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.
~BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);
~BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);
~BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)"
11379781|NCT02170623|Experimental|Period 2: BIBR 1048 MS|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.
~BIBR 1048 MS Capsule K (bid for 3 days);
~BIBR 1048 MS Drinking solution (bid for 3 days)"
11379782|NCT02170610|Experimental|BIBR 1048 MS capsule|
11379783|NCT02170610|Experimental|BIBR 1048 capsule with pantoprazole|
11379784|NCT02170610|Experimental|BIBR 1048 capsule with food|
11379785|NCT02170597|Experimental|BIBR 1018 MS HPMC capsule fasted|
11379786|NCT02170597|Experimental|BIBR 1048 MS HPMC capsule after high fat meal|
11379787|NCT02170597|Active Comparator|BIBR 1048 MS gelatine capsule fasted|
11379788|NCT02170584|Experimental|BIBR 953 ZW IV|
11379789|NCT02170584|Active Comparator|BIBR 1048 MS oral solution|
11379790|NCT02170584|Experimental|BIBR 1048 MS tablet|
11379791|NCT02170584|Placebo Comparator|BIBR 953 ZW IV Placebo|
11379792|NCT02170571|Experimental|Dabigatran etexilate|
11379793|NCT02170558||Patients implanted w/TM-Ardis|Patients who are receiving a TM-Ardis implant for degenerative disc disease will have a CT scan immediate post op (2 weeks) and again at 6 months to determine if fusion can be assessed with the study metal reduction software. Will utilize TM- Ardis implant and Metal Reduction CT software
11379794|NCT02170545||Multi-Part Proximal Humerus Fracture|All participants that meet the entry criteria will be included in the study cohort.
11379795|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
11379796|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
11379797|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
11379798|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
11379799|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
11379800|NCT02170519|Experimental|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.
~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
11379801|NCT02170519|Experimental|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.
~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
11379802|NCT02170506|Experimental|submental sensitive transcutaneous electrical stimulation.|Each Healthy subjects will be his own witness. Urostim 2 stimulation Arm
11379803|NCT02170467|Experimental|Control|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in controls and camparison with pateints with anorexia nervosa.
11379804|NCT02170467|Experimental|patients with anorexia nervosa|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in patients with anorexia nervosa before and after re-feeding.
11379805|NCT02170454|Active Comparator|rTMS|rTMS on pharyngeal cortical area in healthy subjects
11379809|NCT02170415|Active Comparator|Intervention limb|"Medical review and analgesic optimisation.
~Pain education (in the form of leaflet and website recommendations)
~Psychological input for patients with evidence of psychological morbidity.
~Protective analgesia - one pre-procedure dose of 150mg oral pregabalin.
~Five days post-procedure oral pregablin twice daily at a dose of 75mg twice a day.
~Patients offered a paravertebral block, local anaesthetic infiltrated around the wound by the surgeon.
~Daily, focused visits from the hospital pain team.
~Any patient displaying concerning pain symptoms, behaviour or who underwent prolonged (>3 hours surgery) may be booked for early 'preemptive' review in pain clinic."
11379810|NCT02170415|No Intervention|Usual care|These partcipants will receive usual care before, during and after their breast surgery
11379811|NCT02170402|Experimental|Previously Treated Patients (PTPs)|"PTPs will participate sequentially with:
~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:
~12 adults (>12 years of age)
~12 children (≤12 years of age)
~Part 2: On-demand treatment with ADVATE for 6 months
~Part 3: Prophylaxis regimen with ADVATE for 6 months"
11379812|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
11379813|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
11379814|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
11379815|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
11379816|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
11379817|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
11379818|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
11379819|NCT02170350|Experimental|Brief mindful meditation practice|Patients use brief mindful meditation practice (sitting meditation in which the mind is guided to focus in the present, thinking of your existence, and allowing sensations to arise with an openness and curiosity) over 12 minutes daily for 14 days during radiation therapy.
11379820|NCT02170337|Experimental|AMG 282|AMG 282 administered as subcutaneous and intravenous doses.
11379821|NCT02170337|Placebo Comparator|Placebo|No active drug
11379822|NCT02170324|Experimental|GLP-1 agonism group|Exenatide injection 10 ug twice daily for 10 days subcutaneously.
11379823|NCT02170324|Placebo Comparator|Placebo group|0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
11379824|NCT02170311|Experimental|Z-213 100mg|Group/Cohort Label: 100 mg iron Z-213 will be administered by intravenous infusion.
11379825|NCT02170311|Experimental|Z-213 500mg|Group/Cohort Label: 500 mg iron Z-213 will be administered by intravenous infusion.
11379826|NCT02170311|Experimental|Z-213 800mg|Group/Cohort Label: 800 mg iron Z-213 will be administered by intravenous infusion.
11379827|NCT02170311|Experimental|Z-213 1000mg|Group/Cohort Label: 1000 mg iron Z-213 will be administered by intravenous infusion.
11379828|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.
~Drug: Placebo"
11379829|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.
~Drug: Lisdexamfetamine"
11379830|NCT02170285|Experimental|Interventional tDCS|The primary intervention will be cathodal (inhibitory) tDCS (see below).
11379831|NCT02170285|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
11379832|NCT02170272|Experimental|Home-based Lymphedema Care Program|Home-based Lymphedema Care Program (HBLCP): Participants will undergo one training session with a lymphedema therapist, and then receive a self-care video and educational manual to review at home. After completion of training session, follow-up measures occur at 1, 2, and 3 months.
11379833|NCT02170259|Experimental|suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region.
11379834|NCT02170259|Experimental|The articulatory technique|- The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases.
11379835|NCT02170259|Experimental|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT.
11379836|NCT02170259|No Intervention|Control group|Control group. The control group was not applied a treatment technique
11379837|NCT02170246|No Intervention|Antiretroviral Therapy (ART) only|Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
11379838|NCT02170246|Experimental|ART + Telmisartan|Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).
11379839|NCT02170233||Sepsis|This group will contain patients meeting criteria for sepsis for enrollment in the study (target population).
11379840|NCT02170233||Normals|This group will be healthy patients who will have data points recorded for controls for the study to assess the reliability of these measures on healthy patients.
11379841|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
11379842|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
11379843|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
11379844|NCT02170194|Experimental|Resilience Enhancement Group|The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
11379845|NCT02170194|Placebo Comparator|Control Group|"The control group will be provided with an initial informational session providing them with details of where they can get help if they have worsened symptoms over time. In addition, the psychologist will briefly review the apps, but not provide the same pscyhoeducational detail given to the resilience enhancement group. They will receive daily texts with inspirational aphorisms (e.g., Early to bed and early to rise makes a man healthy, wealthy, and wise.) for 6 weeks."
11379846|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
11379847|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
11379848|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
11379849|NCT02170181||RE-IRRADIATION ARM|
11379850|NCT02170168||Orkdal region patients|cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
11379851|NCT02170168||Romsdal county patients|control palliative care cancer patients in standard care, i.e. a local hospital in the county of Møre and Romsdal, Molde Hospital, and nine districts
11379852|NCT02170168||Orkdal region carers|carers of cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
11379853|NCT02170168||Romsdal county carers|carers of cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
11379854|NCT02170168||Orkdal region health care providers|Health care providers for cancer patients participating in a integrated palliative care program for diagnostics, treatment, care and follow-up in and between hospital care and 13 municipalities
11379855|NCT02170168||Romsdal county health care providers|Health care providers for cancer patients receiving standard care, i.e. in a local hospital in the county of Møre and Romsdal, Molde Hospital, and community care in nine districts
11379856|NCT02170155||Patients with CSM|
11379857|NCT02170155||Patients with spinal injury (SCI)|
11379858|NCT02170155||Healthy controls|
11379859|NCT02170142||No treatment|All subjects studied are normal healthy neonates without a condition. MRI will be used to assess normal brain development.
11379860|NCT02170129|Active Comparator|100% AAB|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 100% AAB (Bio-Oss) followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
11379861|NCT02170129|Active Comparator|50% AAB plus 50% autologous bone|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 50% AAB (Bio-Oss) plus 50% autologous bone harvested locally with a bone scraper followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
11379862|NCT02170116|Experimental|BIBR 1048 MS dose 1|
11379863|NCT02170116|Experimental|BIBR 1048 MS dose 2|
11379864|NCT02170116|Experimental|BIBR 1048 MS dose 3|
11379865|NCT02170116|Experimental|BIBR 1048 MS dose 4|
11379866|NCT02170116|Experimental|BIBR 1048 MS dose 5|
11379867|NCT02170116|Placebo Comparator|Placebo|
11379868|NCT02170103|Experimental|Ultrasound and microbubbles|Patients who provide emergent consent will be randomized to either conventional therapy for a heart attack, or conventional therapy and ultrasound with microbubbles. The ultrasound will be applied both before and after emergent heart catheterization, in order to break up the blood clots that are not only in the artery supplying the heart muscle, but also in the small branches (capillaries) that are fed by this artery.
11379869|NCT02170103|Other|Standard of care|Emergent PCI/antithrombotic/antiplatelet therapy with Echocardiogram to assess LVEF (Left Ventricular Ejection Fraction) and Aspirin, Plavix, or Direct Thrombin Inhibitor.
11379988|NCT02169323|Experimental|Step-down|Step-down of the inhaled corticosteroid (ICS) dose
11379989|NCT02169310||1|Healthy adult volunteers
11379870|NCT02170090|Experimental|Gemcitabine plus Cisplatin|"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles)
~and Observation
~Second randomisation for R1 resected patients: 8 cycles Cisplatin and Gemcitabin or 6 cycles Cisplatin and Gemcitabin followed by IMRT with capecitabine"
11379871|NCT02170090|Active Comparator|Capecitabine|"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles)
~and Observation
~Second randomisation for R1 resected patients: 8 cycles capecitabine or 6 cycles capecitabine followed by IMRT with capecitabine"
11379872|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
11379873|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
11379874|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
11379875|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
11379876|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
11379877|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.
~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
11379878|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
11379879|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
11379880|NCT02170038|Experimental|Arm 1|Healthy premenopausal subjects will receive multiple oral doses of Microgynon for 21days
11379881|NCT02170038|Experimental|Arm 2|Healthy premenopausal subjects will receive a single intramuscular dose of Noristerat
11379882|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
11379883|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
11379884|NCT02170012|Experimental|Cohort 1-PF-06743649 or placebo|
11379885|NCT02170012|Experimental|Cohort 2-PF-06743649 or placebo|
11379886|NCT02170012|Experimental|Cohort 3-PF-06743649 or placebo|
11379887|NCT02170012|Experimental|Cohort 4-PF-06743649 or placebo|
11379888|NCT02170012|Experimental|Cohort 5-PF-06743649 or placebo|
11379889|NCT02169999|Experimental|Personalized Diabetes Care Website|Subjects are exposed to Personalized Diabetes Care website.
11379890|NCT02169999|No Intervention|No Exposure To Website|Subjects are not exposed to Personalized Diabetes Care website
11379891|NCT02169986|No Intervention|control group|Parents/caregivers will receive the standard of care.
11379892|NCT02169986|Experimental|electronic reminders|In this group, the parents/caregivers will receive two daily electronic reminders in addition to the standard of care.
11379893|NCT02169973|Experimental|Part A|3 to 5 participants will undergo Positron Emission Tomography (PET)/computed tomography scan after administration of 11C-MK-3168 on Day 1.
11379894|NCT02169973|Experimental|Part B|3 to 12 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive 2 single doses of JNJ-42165279: 100 mg on Days 1 and up to 250 mg on Day 8. Participants will undergo PET scans after 1 hour of each administration of JNJ-42165279 on Days 1 and 8, with 11C-MK-3168 administration.
11379895|NCT02169973|Experimental|Part C|4 to 8 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive once daily dose of JNJ-42165279 (up to 100 mg) from Day 1 to Day 7. Participants will undergo PET scans after 24 hour of administration of JNJ-42165279 on Days 1 and 7, with 11C-MK-3168 administration.
11379896|NCT02169960|Active Comparator|Middle School, General|OVK Resiliency Training Program - Cognitive Behavioral Therapy designed to modify negative thoughts and feelings. This program also includes a social problem-solving component.
11379897|NCT02169960|No Intervention|High School, General|No intervention - no Resiliency training, no online intervention for high school students who do not score at risk for development of mental health issues
11379898|NCT02169960|Active Comparator|Middle School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues. OVK Resiliency Training is also provided.
11379899|NCT02169960|Active Comparator|High School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues.
11379900|NCT02169947|Active Comparator|Weight loss core|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program.
11379901|NCT02169947|Experimental|Weight loss core plus maintenance|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program PLUS 12 maintenance sessions.
11379902|NCT02169934|Experimental|Radiolabeled TRV130|
11379903|NCT02169921|Experimental|TurboHawk|This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk
11379904|NCT02169908|Other|Occurrence of painful neuropathy|Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.
11379905|NCT02169895|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~Every period with concomitant single oral administration of Prolopa® 100-25"
11379906|NCT02169895|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~Every period with concomitant single oral administration of Prolopa® 100-25"
11379907|NCT02169895|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~Every period with concomitant single oral administration of Prolopa® 100-25"
11379908|NCT02169895|Active Comparator|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~Every period with concomitant single oral administration of Prolopa® 100-25"
11379909|NCT02169882|Active Comparator|Rifampicin 450 mg (standard dose)|"Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).
~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.
~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
11379910|NCT02169882|Experimental|Rifampicin 900 mg per oral|"Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.
~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
11379911|NCT02169882|Experimental|Rifampicin 1350 mg per oral|"Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.
~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
11379912|NCT02169869|Experimental|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
11379913|NCT02169869|Active Comparator|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
11379914|NCT02169856|Other|control group|"control group was not given any EFTs (emotional freedom techniques) therapy for postoperative nausea and vomiting.
~Following medications were given to both groups. details are in respective interventions.
~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
11379915|NCT02169856|Experimental|EFTs study group|"EFTs (emotional freedom techniques) was applied to the patietns. one session of 5 to 10 min at 6 hours postoperatively.
~Following medications were given to both groups. details are in respective interventions.
~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
11379916|NCT02169843|Experimental|Sevoflurane & Dexmedetomidine|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Dexmedetomidine 0.2µg/kg/h.
11379917|NCT02169843|Active Comparator|Sevoflurane & Placebo|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Placebo(for Dexmedetomidine )0.05ml/kg/h.
11379918|NCT02169830|Active Comparator|nortriptyline|Diet modification - nortriptyline and then if necessary topiramate
11379919|NCT02169830|Active Comparator|topiramate|Diet Modification topiramate and then nortriptyline if necessary
11379920|NCT02169817|Experimental|Enterogermina + Enterolyte|2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation
11379921|NCT02169804|Experimental|70 years or older|Non-smoking healthy adult males >or equal to 70 years of age.
11379922|NCT02169804|Experimental|Under 60 years of age|Non-smoking healthy adult males<60 years of age.
11379923|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
11379951|NCT02169570|Experimental|Vitamin D and Calcium|Vitamin D and Calcium supplementation Anti TuberculosisTreatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks with daily 1000 mg calcium carbonate for 3 months
11379952|NCT02169557|Experimental|Fexinidazole|
11379953|NCT02169544||RA patients who are prescribed Abatacept|Abatacept
11379924|NCT02169778|Experimental|Intermittent energy restricted diet|The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
11379925|NCT02169778|Experimental|Continuous energy restricted diet|The continuous energy restricted group will be prescribed a low calorie diet (LCD) with 33% energy restriction, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. The diets' macronutrient composition of the two groups will be matched (50% carbohydrates, 20% protein and 30% fat).
11379926|NCT02169765|Active Comparator|Hepatic resection|Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
11379927|NCT02169765|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
11379928|NCT02169752|Active Comparator|Ambrisentan|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
11379929|NCT02169752|Placebo Comparator|Placebo|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
11379930|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
11379931|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
11379932|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
11379933|NCT02169713|Experimental|Treatment Sequence 1|Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
11379934|NCT02169713|Experimental|Treatment Sequence 2|Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
11379935|NCT02169700|Experimental|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling.
11379936|NCT02169700|Sham Comparator|Sham Ischemic compression. Dry Needling|Sham Ischemic compression was carried out after dry needling.
11379937|NCT02169700|No Intervention|Control group|No intervention. Control group
11379938|NCT02169687|Experimental|Hifu|
11379939|NCT02169674|Active Comparator|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
11379940|NCT02169674|Active Comparator|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
11379941|NCT02169661|Experimental|Burger and Beetroot Study|
11379942|NCT02169648|Experimental|ranibizumab|Experimental: Intravitreal injection of Ranibizumab
11379943|NCT02169635|Experimental|Macula buckle|Macular buckle: perform episcleral macular buckle surgery using a three-armed silicone capsule to support the posterior staphyloma in high myopia.
11379944|NCT02169609|Experimental|Dinutuximab. Immunotherapy|"Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours.
~Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward).
~Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if < 12kg) PO divided into 2 doses daily x 14 days.
~Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3"
11379945|NCT02169596|Other|Coronary Artery Disease|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
11379946|NCT02169596|Other|Healthy Normals|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
11379947|NCT02169583|Experimental|Part A (Cohort 1)|Approximately 8 subjects (6 Active, 2 Placebo) will be randomized to receive single escalating IV doses i.e.10 milligrams (mg), 25 mg and 100 mg, plus one oral 100 mg dose (on the last occasion) of GSK1325756 or matching placebo, with a 7-days washout between doses. Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 100 mg. Additional subjects/Cohorts may be enrolled.
11379948|NCT02169583|Experimental|Part B (Cohorts 2 and 3)|Approximately 8 subjects (6 Active, 2 Placebo) per cohort will be randomized to receive escalating repeated IV doses of GSK1325756 or matching placebo (Cohort 2: 25 mg, Cohort 3: 50 mg) for 5 days. Repeated (BID) doses of GSK1325756 will begin the morning of Day 1 and continue through the morning of Day 5 (9 total doses). Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 50 mg BID. Additional subjects/Cohorts may be enrolled.
11379949|NCT02169570|Active Comparator|Vitamin D|Vitamin D supplementation Anti Tuberculosis Treatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks and color and taste matched placebo for calcium for 3 months
11379950|NCT02169570|Placebo Comparator|Placebo|Anti Tuberculosis Treatment with placebo color matched for vitamin D and color and taste matched placebo for calcium
11379990|NCT02169310||2|TBI patients
11379955|NCT02169531|Experimental|ex vivo activated immune cells|Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
11379956|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
11379957|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
11379958|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).
~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
11379959|NCT02169479|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
11379960|NCT02169479|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
11379961|NCT02169479|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
11379962|NCT02169479|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
11379963|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
11379964|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
11379965|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
11379966|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
11379967|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
11379968|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
11379969|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg
~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
11379970|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg
~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
11379971|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
11379972|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
11379973|NCT02169427|Experimental|Opicapone (OPC)|100 mg OPC
11379974|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
11379975|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
11379976|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
11379977|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
11379978|NCT02169401||Treated subjects|All subjects recruited and treated with the Axium Neurostimulator
11379979|NCT02169388|Experimental|Probiotic|Microbial composition using Probiotic，3 capsules / times, 2 times / day for 4 weeks
11379980|NCT02169388|Placebo Comparator|placebo|Microbiota modulation using placebo，3 capsules / times, 2 times / day for 4 weeks
11379981|NCT02169375|Experimental|Mu Rhythm with adaptation|
11379982|NCT02169375|Experimental|Mu Rhythm without adaptation|
11379983|NCT02169362|Experimental|Platelet Rich Plasma - Bio-Bandage™|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
11379984|NCT02169362|Sham Comparator|Saline Spray, Standard of Care|
11379985|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
11379986|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
11379987|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
11379991|NCT02169297|Experimental|Ultrasound-Guided Sub-Paraspinal Block|Patients allocated to the treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location and an intravenous PCA post-operatively
11379992|NCT02169297|Placebo Comparator|PCA only|Patients allocated to the control group had two sham multi-perforated soaker catheters taped to their back and received intravenous PCA post-operatively
11379993|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
11379994|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
11379995|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
11379996|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
11379997|NCT02169258|Placebo Comparator|Selective Strategy|non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia
11379998|NCT02169258|No Intervention|Registry|Clinical decisions are reached by consensus of operators, patients and family as usual care
11379999|NCT02169258|Active Comparator|Systemic Strategy|Routine coronary angiography before PTA without a previous non-invasive stress test
11380000|NCT02169245|Experimental|Average Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and fiber for this age group for 2 weeks.
11380001|NCT02169245|Experimental|Average Protein and High Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and higher than average amount of fiber for this age group for 2 weeks.
11380002|NCT02169245|Experimental|High Protein and Average Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of fiber and higher than average amount of protein for this age group for 2 weeks.
11380003|NCT02169245|Experimental|Higher Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with a higher than average amount of protein and fiber for this age group for 2 weeks.
11380004|NCT02169232|Active Comparator|Videolaryngoscope|Intubation by videolaryngoscope
11380005|NCT02169232|Active Comparator|Fiberoptic|Intubation by fibroscope
11380006|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
11380007|NCT02169206|Other|shoulder radiography|Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
11380008|NCT02169193|Experimental|99mTc-Rhenium Sulfide Nanocolloid|99mTc-Rhenium Sulfide Nanocolloid
11380009|NCT02169180|Experimental|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
11380010|NCT02169167|Experimental|Resin salve treatment|The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
11380011|NCT02169167|Active Comparator|Octenidine treatment|Octenidine treatment is implemented with the similar manner as resin salve treatment by using sterile gauze that is impregnated with the octenidine dihydrochloride.
11380012|NCT02169154|Experimental|Diclofenac Sodium/Menthol Gel|1% diclofenac sodium + 3% menthol
11380013|NCT02169154|Active Comparator|Diclofenac Gel|1% diclofenac sodium + 0.09% menthol
11380014|NCT02169154|Active Comparator|Menthol Gel|3% menthol
11380015|NCT02169154|Placebo Comparator|Placebo Gel|0.09% menthol
11380016|NCT02169154|Active Comparator|Voltaren Gel|1% diclofenac sodium
11380017|NCT02169154|Placebo Comparator|Sodium lauryl sulfate|0.2% Sodium lauryl sulfate
11380018|NCT02169154|Placebo Comparator|Saline|0.9% saline
11380019|NCT02169141||PK of Levofloxacin-Capreomycin|Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
11380020|NCT02169128||Patients and their significant others|Patients affected by necrotizing fasciitis and their significant others
11380021|NCT02169115|Experimental|Omalizumab 150mg|
11380022|NCT02169115|Experimental|Omalizumab 300mg|
11380023|NCT02169115|Placebo Comparator|Placebo|
11380024|NCT02169102|Other|Control|
11380025|NCT02169102|Sham Comparator|Sham Laser|
11380026|NCT02169102|Experimental|Laser 1|Low Power Laser applied at 0.16 Joules/point. 2 points of laser irradiation
11380027|NCT02169102|Experimental|Laser 2|Low Power Laser applied at 16 Joules/point. 2 points of laser irradiation
11380028|NCT02169089|Experimental|Spironolactone|Spironolactone
11380029|NCT02169089|Placebo Comparator|Placebo|Placebo
11380030|NCT02169076|Active Comparator|CRT-On|Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device
11380031|NCT02169076|Sham Comparator|CRT-Off|Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device
11380032|NCT02169063|Experimental|Diagnostic (11C-acetate, 18F-fluoride, PET)|Patients receive carbon-11 acetate IV and fluorine F 18 sodium fluoride IV over 1 minute and undergo PET at baseline and at 6-12 weeks after systemic therapy starts.
11380033|NCT02169050||No intervention|There is no intervention to subjects in this study. All subjects are morbidly women seeking bariatric surgeries.
11380034|NCT02169037|Experimental|FIRM ablation|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM) alone.
11380035|NCT02169037|Active Comparator|Conventional AF ablation with PVI|These patients will treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
11380036|NCT02169024|Experimental|Expect With Me group prenatal care|receiving prenatal care through an Expect With Me group
11380037|NCT02169024|Active Comparator|Individual Care Only|Standard of Care- individual prenatal care
11380038|NCT02169011|Active Comparator|Latissimus Dorsi Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the Latissimus Dorsi flap and if needed an implant.
11380039|NCT02169011|Active Comparator|TAP Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the TAP-flap and if needed an implant in combination with an acellular dermal matrix.
11380040|NCT02168998|No Intervention|No clown|Routine venipuncture without distraction
11380041|NCT02168998|Active Comparator|Clown|A medical clown is present in the procedure room during venipuncture
11380042|NCT02168985|Experimental|Attend TFH Program|Couples attend the three-day Faithful House Training program immediately
11380043|NCT02168985|No Intervention|Wait-listed for TFH Program|Couples attend The Faithful House program three-months after the initial group
11380044|NCT02168972|Experimental|Global mapping and ablation device|
11380045|NCT02168959|Active Comparator|Femoral nerve block|bupivacaine
11380046|NCT02168959|No Intervention|No femoral nerve block|No block
11380047|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
11380048|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
11380049|NCT02168933|Experimental|active excimer laser|308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.
11380050|NCT02168933|Sham Comparator|Sham excimer laser|Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.
11380051|NCT02168920|Experimental|Aripiprazole, 2 mg/day|
11380052|NCT02168920|Experimental|Aripiprazole, 3 mg/day|
11380053|NCT02168920|Experimental|Aripiprazole, 6 mg/day|
11380054|NCT02168920|Placebo Comparator|Placebo|
11380055|NCT02168907|Experimental|Treatment (CPI-613, bendamustine hydrochloride, rituximab)|Patients receive 6,8-bis(benzylthio)octanoic acid intravenously IV over 2 hours on days 1-4 (week 1) and days 1 and 4 (weeks 2 and 3). Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 and rituximab on day 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11380056|NCT02168894|Experimental|Group 1 - Acupuncture With Electrical Stimulation|Participants in Group 1 have acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
11380057|NCT02168894|Experimental|Group 2 - Acupuncture Sessions Without Electrical Stimulation|Participants in Group 2 have acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
11380058|NCT02168894|Active Comparator|Group 3 - Waitlist Group|Participants in Group 3 have acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
11380059|NCT02168881|Active Comparator|misoprostol|oral misoprostol in solution 25 microgram every 2 hours
11380060|NCT02168881|Active Comparator|dinoprostone|3 mgs dinoprostone vaginally every six hours
11380061|NCT02168868||Control Group of Children|Control Group of Children
11380062|NCT02168868||Children-Autism Spectrum Disorder|Children-Autism Spectrum Disorder
11380063|NCT02168855|Active Comparator|Active nicotine gum|
11380064|NCT02168855|Placebo Comparator|Inactive gum|
11380065|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
11380066|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
11380067|NCT02168829|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg daily
11380068|NCT02168829|Active Comparator|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
11380069|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
11380070|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
11380071|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
11380072|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
11380073|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
11380074|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
11380075|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
11380076|NCT02168790|Experimental|Amniotic membrane ring|Application of amniotic membrane device for 6-7 days.
11380110|NCT02168595|Experimental|Cohort 2|5 mg/kg GMI-1271 or matching placebo
11380111|NCT02168595|Experimental|Cohort 3|10 mg/kg GMI-1271 or matching placebo
11380112|NCT02168582||low back pain|
11380077|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
11380078|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
11380079|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
11380080|NCT02168764|Experimental|Treatment|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
11380081|NCT02168764|Active Comparator|Control|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
11380082|NCT02168751|Active Comparator|propofol|propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
11380083|NCT02168751|Experimental|sevoflurane|Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
11380084|NCT02168738|Active Comparator|13-C labeled PC-DHA|
11380085|NCT02168738|Active Comparator|13-C labeled TG-DHA|
11380086|NCT02168738|Experimental|13-C labeled AceDoPC-DHA|
11380087|NCT02168725|Experimental|briciclib|The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.
11380088|NCT02168712|Active Comparator|Moderate continuous exercise training|Moderate intensity continuous exercise training
11380089|NCT02168712|Experimental|Interval exercise training|High intensity interval exercise training
11380090|NCT02168699|Other|Ultrasound examination|Ultrasound examination of the axillary region in children
11380091|NCT02168686|Experimental|Part A: Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
11380092|NCT02168686|Experimental|Part A: Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
11380093|NCT02168686|Experimental|Part A: Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
11380094|NCT02168686|Experimental|Part A: Dose 4|ADVM-043 administered at a dose that will be determined
11380095|NCT02168686|Experimental|Part B (optional): Intrapleural administration|ADVM-043 administered intrapleurally at a dose that will be determined
11380096|NCT02168673||Group 1|Healthy non-smokers
11380097|NCT02168673||Group 2|Healthy non-smokers
11380098|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
11380099|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
11380100|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
11380101|NCT02168647|Experimental|Behavioral Lifestyle counseling|Intervention group participants will take part in behavioral lifestyle counseling provided by a Registered Dietitian Nutritionist from week 14 of gestation through childbirth.
11380102|NCT02168647|Active Comparator|Control|Participants in the control arm will receive no form of lifestyle intervention.
11380103|NCT02168634|Experimental|Botulinum toxin|5U Botulinum toxin in 1cc normal saline, administered in one of the two itchy points
11380104|NCT02168634|Placebo Comparator|Normal Saline|1cc normal saline, administered in the other itchy point
11380105|NCT02168621|Active Comparator|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
11380106|NCT02168621|Active Comparator|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval. Follow-up 2-4 weeks after the last session of SRP for oral hygiene control and re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
11380107|NCT02168608|Experimental|Remote ischemia precondition|patients in this arm accepted RIPC procedure after induction of anesthesia
11380108|NCT02168608|Experimental|None remote ischemia precondition|patients in this arm didn't accept RIPC procedure after induction of anesthesia
11380109|NCT02168595|Experimental|Cohort 1|2 mg/kg GMI-1271 or matching placebo
11380113|NCT02168569|Active Comparator|Cohort 1|5 sites, namely Manhiça, Dondo, Montepuez, Tete and Chokwe
11380114|NCT02168569|Active Comparator|Cohort 2|3 sites, namely Montepuez, Dondo and Chokwe
11380115|NCT02168556|Placebo Comparator|Standard of Care|Patient underwent urodynamic testing by receiving only standard of care with mailed information and during test teaching.
11380116|NCT02168556|Active Comparator|Music|Patient underwent urodynamic testing while listening to music that was 60 beats per minute and received standard of care information and teaching.
11380117|NCT02168556|Active Comparator|Video|Patient watched an informational video prior to urodynamic testing.
11380118|NCT02168543|Experimental|Alendronate|1% Alendronate gel once in periodontal pocket (Gums)
11380119|NCT02168543|Placebo Comparator|Placebo|Placebo gel once in periodontal pocket (Gums)
11380120|NCT02168530|Placebo Comparator|Placebo|
11380121|NCT02168530|Experimental|Vismodegib|
11380122|NCT02168517||Group I|Overweight osteoarthritis patients
11380123|NCT02168517||Group II|Normal weight osteoarthritis patients.
11380124|NCT02168517||Group III|Overweight healthy men.
11380125|NCT02168517||Group IV|Normal weight healthy men.
11380126|NCT02168504||Healthy controls|Healthy male and female subjects older than 18 years of age without the symptoms of Parkinson's disease. The ages of subjects in this group will be matching to the ages of subjects in Parkinson's disease group
11380127|NCT02168504||Parkinson's disease patients|male and female subjects older than 18 years of age at the early stage the disease
11380128|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
11380129|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.
~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
11380130|NCT02168465|Other|teaching self-management of intermittent catheter|Single group pre-post test of feasibility, teaching self-management
11380131|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
11380132|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
11380133|NCT02168426|Active Comparator|Guardix|6g per body
11380134|NCT02168426|Active Comparator|Seprafilm|1 sheet per body
11380135|NCT02168400|Experimental|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
11380136|NCT02168400|Sham Comparator|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
11380137|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
11380138|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
11380139|NCT02168374|Experimental|Chlorhexidine - CHX|Deciduous teeth were filled with GIC containing 1.25% chlorhexidine.
11380140|NCT02168374|Experimental|Doxycycline - DOX|Deciduous teeth were filled with GIC containing 4.5% doxycycline.
11380141|NCT02168374|Placebo Comparator|Glass ionomer cement - GIC|Deciduous teeth were filled with GIC without chlorhexidine or doxycycline.
11380142|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
11380143|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
11380144|NCT02168348||Diabetic patients with a lesion on the foot|
11380145|NCT02168335|Experimental|Treatment group|"OrasaltsTM
~1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
11380146|NCT02168335|Placebo Comparator|Control group|"Sea salt
~1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
11380147|NCT02168322|Experimental|collagen membranes|collagen barrier that help in isolating unwanted tissues in periodontal regneration
11380148|NCT02168309|Other|Labetalol|Labetalol 200mg PO BID starting dose
11380149|NCT02168309|Other|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
11380150|NCT02168296|Placebo Comparator|No added Plant-based ingredient|No Plant-based ingredient added to starchy meal
11380151|NCT02168296|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
11380152|NCT02168296|Active Comparator|High dose added to starchy meal|Plant-based ingredient in high dose added to starchy meal
11380153|NCT02168296|Active Comparator|Low dose added to liquid|Plant-based ingredient in low dose added to liquid
11380154|NCT02168296|Active Comparator|High dose added to liquid|Plant-based ingredient in high dose added to liquid
11380155|NCT02168283|Experimental|treatment arm|active fluid management includes 3 components: dietary counseling, diuretics, and intensive dialysis regimen
11380156|NCT02168283|Active Comparator|control arm|dietary counseling alone
11380157|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11380158|NCT02168257|Experimental|RAM Cannula CPAP|CPAP provided by RAM Cannula
11380159|NCT02168257|Active Comparator|Binasal Prong CPAP|CPAP provided by binasal prong
11380160|NCT02168244|Active Comparator|Ice pack|Pre-treatment with ice - Ice applied to the skin 2-3 minutes before injecting biologic drug injection
11380161|NCT02168244|Active Comparator|Heating Pack|Pre-treatment with heat - Heat applied to the skin 2-3 minutes before injecting biologic drug injection
11380162|NCT02168244|No Intervention|No treatment before injection|No treatment applied to the skin 2-3 minutes before injecting biologic drug injection
11380163|NCT02168231||Complex abdominal wall repair Strattice|Complex abdominal wall repair Strattice
11380164|NCT02168218|Experimental|high protein|20% protein diet
11380165|NCT02168218|Active Comparator|low protein|7.5% protein diet
11380166|NCT02168205|Experimental|4 mg Pomalidomide - Fed|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
11380167|NCT02168205|Experimental|4 mg Pomalidomide - Fasted|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
11380168|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Non-smoking|Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
11380169|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Smoking|Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
11380170|NCT02168192|Placebo Comparator|Traditional Lecture|These subjects received a 10 minute power point lecture on BBN skills.
11380171|NCT02168192|Experimental|Simulation-Debrief|These subjects received a formal debrief process, reviewing their prior baseline simulation.
11380172|NCT02168179|Experimental|Supportive Care (KeraStat Skin Therapy)|Patients apply KeraStat Skin Therapy topically BID during radiation therapy.
11380173|NCT02168166|Active Comparator|Executive Function Training|"Two weeks of training of cognitive domain of executive functioning
~Using online program (Scientific Brain Training Pro)
~Four exercises"
11380174|NCT02168166|Placebo Comparator|Placebo Training|"Two weeks of training with exercises not affecting working memory, information processing speed, or cognitive load
~Exercises maintain other traditional progressive aspects to preserve appearance of dynamic titration of difficulty levels
~Using online program (Scientific Brain Training Pro)
~Four exercises"
11380175|NCT02168153|Active Comparator|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
11380176|NCT02168153|Placebo Comparator|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
11380177|NCT02168140|Experimental|Treatment (CPI-613 and bendamustine hydrochloride)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 of week 1 and on days 1 and 4 of weeks 2 and 3. Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11380178|NCT02168127|Experimental|Active drug group|PRC-063 - Active methylphenidate hydrochloride extended-release capsules drug group
11380179|NCT02168114|Experimental|Duchenne Muscular Dystrophy|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
11380180|NCT02168114|Experimental|Non-affected Subjects|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
11380181|NCT02168101|Experimental|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
11380182|NCT02168101|Experimental|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
11380183|NCT02168101|Experimental|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
11380184|NCT02168088||Index case|Subjects who have died of sudden unexplained death
11380185|NCT02168088||Biologically related family member|Biologically related family member of the deceased individual
11380186|NCT02168075|Experimental|Group 1|0.25g/kgof 20% mannitol administered at drilling of skull.
11380187|NCT02168075|Experimental|Group 2|0.5g/kg of 20% mannitol administered at drilling of skull.
11380188|NCT02168075|Experimental|Group 3|1.0 g/kg of 20% mannitol administered at drilling of skull.
11380189|NCT02168075|Experimental|Group 4|1.5g/kg of 20% mannitol administered at drilling of skull.
11380190|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
11380191|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
11380192|NCT02168049|Experimental|Heart and Lung Function Monitioring|
11380193|NCT02168036||Patients with lung disease|General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
11380194|NCT02168023|Experimental|DACC impregnated dressing|Patients undergoing elective or emergency caesarean section with DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
11380195|NCT02168023|Active Comparator|Standard surgical dressing|Patients undergoing elective or emergency caesarean section with standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
11380196|NCT02168010|Experimental|Experiment|Test Drug Group: 2 times a day; 4 tablets per time (2 tablets of Analgecine and 2 tab. of placebo)
11380197|NCT02168010|Active Comparator|PosCtrl|PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
11380198|NCT02168010|Placebo Comparator|Placebo|Placebo Group: 2 times a day; 4 tablets / time (4 placebo tablets).
11380199|NCT02167984||at term newborns|Infant with GE >=37w
11380200|NCT02167984||preterm newborns|Infant with GE <37w
11380201|NCT02167971|Experimental|Active Coil|The patients assigned to this group will undergo repetitive Transcranial Magnetic Stimulation over 10 sessions (each one with 2,000 pulses) on left dorsolateral prefrontal cortex.
11380202|NCT02167971|Sham Comparator|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
11380203|NCT02167958|Experimental|Treatment|"Day -6, -5 Fludarabine 30 mg/M2 IV over 30-60 minutes Cyclophosphamide 14.5 mg/kg IV over 1-2 hours*, Mesna 14.5 mg/kg IV in 4 divided doses
~Day -4 through -2 Fludarabine 30 mg/M2 IV over 30-60 minutes
~Day -1 Total Body Irradiation 200 cGy, donor apheresis
~Day 0 T cell replete PBSC
~Days 3, 4 Cyclophosphamide 50 mg/kg IV Mesna 50 mg/kg IV in 4 divided doses
~Day 5 Begin tacrolimus ,mycophenolate, and G-CSF"
11380204|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
11380205|NCT02167932||Breast Cancer Patients|Breast Cancer patients undergoing chemotherapy will participate in the Walk with Ease program during their treatment.
11380206|NCT02167919|Experimental|Prostatic artery embolization|Microspheres measuring 100-300 microns will be injected under fluoroscopic guidance into the left and right prostatic arteries for embolization.
11380207|NCT02167906|Experimental|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
11380208|NCT02167906|Active Comparator|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
11380209|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
11380210|NCT02167867|Experimental|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
11380211|NCT02167867|Experimental|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
11380212|NCT02167854|Experimental|LJM716, BYL719 AND TRASTUZUMAB|A treatment cycle will consist of 28 days. Treatment doses for trastuzumab and LJM716 will be fixed at trastuzumab 2mg/kg weekly, and LJM716 20mg/kg weekly. The exception to this is if dose de-escalation results in treatment of patients at dose level 1, where LJM will be dosed at 10mg/kg weekly. On Arm A, BYL719 was administered orally once daily continuously at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. On Arm B, BYL719 will be administered orally once daily during 4 of 7 days in a week, at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. This means BYL719 will be given to patients on Arm B during days 1-4, 8-11, 15-18, and 22-25 of each cycle. The dose-finding phase will follow a Continuous Reassessment Methods (CRM) phase I biostatistical design.
11380213|NCT02167841|Experimental|Knee-Chest position|In this arm, the women will perform daily the Knee-Chest position between weeks 32-37. In week 37 the investigators will check via ultra sound if there was a successful version (if not, the woman would go to External Cephalic Version)
11380214|NCT02167841|No Intervention|External Cephalic Version|In this group the women will perform External Cephalic Version without doing maternal Knee-Chest position before.
11380215|NCT02167828|Experimental|Social Support|Participants will be trained to give one another ongoing, theory-based but personally-tailored advice, recommendations, and support to encourage entry to HIV medical care, remaining in care, and adhering to medication regimens when they are prescribed. The intervention's intent is to increase mutual support, positive attitudes, intentions, plans, and collective self-efficacy for care engagement.
11380216|NCT02167828|No Intervention|No Intervention|Participants in this arm will not receive an intervention.
11380217|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
11380218|NCT02167815|Experimental|Intervention ( Mepilex XT)|
11380219|NCT02167789|No Intervention|PhD|
11380220|NCT02167776|Experimental|Church-based teaching|Teaching about male circumcision provided to church leaders in addition to standard teaching available from Ministry of Health.
11380221|NCT02167776|No Intervention|No church-based teaching|Standard of care. Teaching about male circumcision provided by Ministry of Health.
11380222|NCT02167763|Experimental|VeraCept Intrauterine Contraceptive|The VeraCept low-dose Intrauterine Copper Contraceptive
11380223|NCT02167763|Active Comparator|TCu380|A commercial standard T-shaped copper IUD (TCu380)
11380224|NCT02167750|Placebo Comparator|Cherry flavored beverage - Mix 1|Mix 1 flavored still beverage
11380225|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 2|Mix 2 flavored still beverage with phytochmicals and caffeine
11380226|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 3|Mix 3 flavored still beverage with phytochemicals and caffeine
11380227|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 4|Mix 4 flavored still beverage with phytochemicals and caffeine
11380228|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 5|Mix 5 flavored still beverage with phytochemicals and caffeine
11380229|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 6|Mix 6 flavored still beverage with caffeine
11380230|NCT02167737|Experimental|Bedside Decision Aid Group|This arm will include study participants who are randomized to the group utilizing the bedside decision aid, which has hospital staff arrange fall-risk reduction interventions (e.g., home safety checks, exercise programs, vision checks, etc.).
11380327|NCT02167035|Active Comparator|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
11380328|NCT02167035|Active Comparator|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
11380231|NCT02167737|Active Comparator|Control Arm|"Participants in the control/comparator arm will experience the same study procedures with the exception of not using the Bedside Decision Aid and instead being given the Centers for Disease Control (CDC) brochure, What You Can Do to Prevent Falls, and arranging for their own fall prevention strategies."
11380232|NCT02167724|Experimental|Patients with schizophrenia|
11380233|NCT02167711|Experimental|SIRT|
11380234|NCT02167698|Experimental|Airway pressure release ventilation arm|"This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.
~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups."
11380235|NCT02167698|Active Comparator|Low-tidal volume ventilation arm|Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
11380236|NCT02167685||CMX001|Subjects who have previously participated in CMX001-301 or other CMX001 study.
11380237|NCT02167672||Consumers|Women who have had a Hysterectomy in the previous 2 years
11380238|NCT02167672||Doctors|Obstetricians and Gynaecologists
11380239|NCT02167659|Experimental|BIS Assessment|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include L-Dex, skin assessment and self-report forms. Patients with < 6.5 L-Dex units change will continue follow-up for 36 months. Patients with an L-Dex value change ≥ 6.5 will undergo circumference measurement and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.
~*At discretion of the site PI or attending physicians."
11380240|NCT02167659|Active Comparator|Tape Measure|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include arm volume (tape measure), skin assessment and self-report forms. Patients with no volume increase will continue follow-up for 36 months. Patients with a volume change of between ≥ 5% and < 10% in the at-risk limb will undergo L-Dex testing and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.
~*At discretion of the site PI or attending physicians."
11380241|NCT02167646|Other|Bilaterally innervated flap|Two nerve branches attached with the flap for sensory reconstruction.
11380242|NCT02167633|Active Comparator|Decompression surgery plus fractionated radiotherapy|
11380243|NCT02167633|Experimental|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in one fraction to cover as large a fraction as possible the defined target volume
11380244|NCT02167620|Placebo Comparator|Metformin|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
11380245|NCT02167620|Placebo Comparator|Placebo|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
11380246|NCT02167607|Active Comparator|Purple Potato|Active Comparator
11380247|NCT02167607|Placebo Comparator|White Potato|Placebo Comparator
11380248|NCT02167594|Experimental|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
11380249|NCT02167594|Experimental|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
11380250|NCT02167594|Experimental|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
11380251|NCT02167581||epithelial odontogenic tumours|
11380252|NCT02167568||Corpus callosum agenesis/dysgenesis|patients with Corpus callosum agenesis/dysgenesis
11380253|NCT02167568||parents|parents of patients with corpus callosum agenesis/dysgenesis
11380254|NCT02167555|Active Comparator|Wild Bluberries|Active Comparator
11380255|NCT02167555|Placebo Comparator|Placebo|Placebo Comparator
11380256|NCT02167542|Experimental|NPPV group|Patients assigned to noninvasive positive pressure ventilation (NPPV) are connected to the ventilator through a face mask (VBM Endoscopy Mask) that is secured to the patient's face by the investigator.
11380257|NCT02167542|Active Comparator|CPAP valve group|Patients assigned to CPAP valve (Boussignac valve, Vygon, Inc) are connected to this device through a standard face mask that is secured to the patient's face with elastic straps.
11380258|NCT02167516|Experimental|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
11380259|NCT02167516|Active Comparator|glucosamine sulfate capsule|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
11380260|NCT02167490|Active Comparator|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
11380261|NCT02167490|No Intervention|Arm 2: observation|No axillary staging
11380262|NCT02167477|Active Comparator|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
11380263|NCT02167477|Active Comparator|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
11380264|NCT02167464|Active Comparator|Aldosterone Antagonist|Prescribe an aldosterone antagonist such as Spironolactone 12.5-25 mg daily as a starting dose with a maximum recommended dose of 50 mg daily.
11380265|NCT02167464|Active Comparator|Referral Hypertension specialist|Referral to a hypertension specialist
11380266|NCT02167464|Active Comparator|Renin treatment-guided therapeutics|Renin treatment-guided therapeutics. A treatment algorithm is provided to guide treatment based upon renin levels.
11380267|NCT02167464|Active Comparator|Renin-guided therapeutics and referral|Renin treatment-guided therapeutics and referral to hypertension specialist. Treatment based upon algorithm for treatment related to renin level in addition to referral to a hypertension specialist.
11380268|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
11380269|NCT02167438|Experimental|Investigational|Application of the Hem-Avert device.
11380270|NCT02167438|No Intervention|Control|No Application of the Hem-Avert device.
11380271|NCT02167425||Late Post-IMAT Cohort|Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
11380272|NCT02167425||Early Post-IMAT Cohort|Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
11380273|NCT02167425||Late Pre-IMAT Cohort|Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
11380274|NCT02167425||Early Pre-IMAT Cohort|Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
11380275|NCT02167412||Syncope without POTS|Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
11380276|NCT02167399||smart phone inclinometer|For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
11380277|NCT02167399||2-D video analysis|two dimensional video analysis by first placing markers on the subject at the midpoint of the femoral condyles, midpoint of the ankle malleoli, and the proximal thigh along a line from the anterior superior iliac spine (ASIS) to the knee marker. Testing will take place in front of a digital video camera with tape on the floor to give a reference point for the subject being tested. Participants will be tested twice on day 1 and then again 5-9 days later. Subjects will be allowed 2-3 practice trials prior to each test in order to allow the subject to feel comfortable with each test. Following the practice trials the subject will perform 3 trials of each test on bilateral lower extremities. This set up was consistent with the set up by Munro et al.
11380278|NCT02167386|Experimental|Enhanced PrEP Adherence|Enhanced PrEP Adherence: peer navigators, PrEP support group, on-line support group, text message reminders
11380279|NCT02167386|Active Comparator|Standard PrEP Adherence|Standard PrEP Adherence: support groups, case management
11380280|NCT02167373|No Intervention|Control|
11380281|NCT02167373|Experimental|Intervention|Cogito Companion Intervention. Participants will be provided with a mobile phone application that provides feedback on their mental health. The participants' clinicians will be provided with a desktop application to review their patients' results.
11380282|NCT02167360|Experimental|Single Arm|
11380283|NCT02167347|Experimental|Family Intervention|Culturally Adapted Family intervention for Psychosis Sessions will be offered weekly basis
11380284|NCT02167347|No Intervention|Control|"Caregiver ' s Patients who will be randomized to the treatment as usual arm will receive routine care"
11380285|NCT02167334|Experimental|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
11380286|NCT02167334|Active Comparator|Oxygenation with simple breathing mask|spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
11380287|NCT02167321|Active Comparator|Arm A|"Arm A; standard neoadjuvant chemoradiotherapy group
~fluoropyrimidine based concurrent chemoradiotherapy-> TME -> adjuvant chemotherapy (Low risk: fluoropyrimidine-based chemotherapy, High risk: FOLFOX)"
11380288|NCT02167321|Experimental|Arm B|"Arm B : adjuvant FOLFOX group
~Total mesorectal excision (TME) --> 12 cycles of FOLFOX every 2 weeks (or Total mesorectal excision (TME) --> Concurrent chemoradiotherapy + 12 cycles of FOLFOX every 2 weeks)"
11380289|NCT02167308|Active Comparator|Laser acupuncture group|Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
11380290|NCT02167308|Sham Comparator|Control group|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. Acupuncture points, application duration, and total number of treatments will be identical to the Laser acupuncture group.
11380291|NCT02167295||Focus group|The focus groups will consist of 6 to 8 persons each (N = 32). The focus group discussions will last for about 60 to 90 minutes. The discussion topics will be based on previous literature and experience and will include reasons for betel quid chewing or for quitting, pros and cons of betel quid chewing, barriers to and facilitators of abstinence, health beliefs and experiences about betel quid chewing and other issues.
11380292|NCT02167295||In-depth interviews.|We will conduct 15 one-to-one interviews, each lasts for about 45 to 60 minutes. Participants will be interviewed by a trained interviewer using a structured interview. The interview will be designed to collect information on socio-demographic background, current and/or former betel quid use, other substance use (smoking and/or alcohol consumption), as well as other variables including usage parameters, psychosocial and environmental influences on betel quid chewing, barriers to and interest in quitting, and knowledge of adverse effects on health.
11380365|NCT02166788|Other|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
11380293|NCT02167295||Self-report questionnaire|This study is expected to enroll 30 participants who have smoking and betel nut chewing behaviors.Participants will complete 4 separate visits to CMUH, during which they will complete the same self-report questionnaire designed to measure withdrawal symptoms relating to betel quid chewing. To better measure betel quid withdrawal symptoms and to distinguish the 6 symptoms from those of smoking withdrawal, Participants will be required to attend one visit regular cigarette smoking and betel nut chewing behavior without restriction (as control), one visit after 12 hours of overnight betel quid deprivation (no cigarette deprivation), one visit after 12 hours of overnight cigarette deprivation (no betel quid deprivation), and one visit after 12 hours of both overnight betel quid and cigarette deprivation.
11380294|NCT02167269|Active Comparator|Baby EAR-JR|The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
11380295|NCT02167269|Active Comparator|JR-Baby EAR|The subjects receive Jackson-Rees (JR) circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Baby EAR circuit and the procedure will be repeated.
11380296|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
11380297|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
11380298|NCT02167243|Experimental|Reinforcement for performing BG testing|Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
11380299|NCT02167243|Active Comparator|No reinforcement for BG testing|Subjects will receive standard of care without reinforcement for Self Monitoring Blood Glucose
11380300|NCT02167230|Experimental|Jailed-balloon technique|Apply jailed-balloon technique to protect the side branch during coronary bifurcation PCI
11380301|NCT02167230|Active Comparator|Jailed-wire technique|Apply jailed-wire technique to protect the side branch during coronary bifurcation PCI
11380302|NCT02167217|Experimental|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
11380303|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
11380304|NCT02167191|Experimental|HIT|High intensity interval training sessions on an cycle ergometer
11380305|NCT02167178||Volunteers receiving 0.9% NaCl|Volunteers receiving 0.9% NaCl to optimise stroke volume
11380306|NCT02167178||Volunteers receiving gelofusine|Volunteers receiving gelofusine to optimise stroke volume
11380307|NCT02167165||Digoxin and AF|Patients consulting the emergency deprtment (ED) for AF and receiving Digoxin treatment
11380308|NCT02167152|Experimental|Ischemic Preconditioning Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
11380309|NCT02167152|Active Comparator|Control Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
11380310|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
11380311|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
11380312|NCT02167126|Experimental|Kinesio Taping|Kinesio Taping was applied as experimental group.
11380313|NCT02167126|Placebo Comparator|Micropore|Micropore Tape was used as placebo tape
11380314|NCT02167113||study population|
11380315|NCT02167100||Retained in Care|Each patient who had at least 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring until 31st of March 2014.
11380316|NCT02167100||Lost to follow-up (LTFU)|Each patient who had at 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring but did not maintain regular attendance at HHMP until 31st March, 2014.
11380317|NCT02167087|Experimental|Sentinel node mapping|Sentinel node mapping with indocyanine green injected orally and anally to the tumor.
11380318|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
11380319|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
11380320|NCT02167061|Experimental|(Part 1) DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
11380321|NCT02167061|Experimental|(Part 1) E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
11380322|NCT02167061|Experimental|(Part 2) DA-1229_01 fast → fed|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
11380323|NCT02167061|Experimental|DA-1229_01 fed → fast|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
11380324|NCT02167048|Experimental|Normal-dose Psychostimulant, Low-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
11380325|NCT02167048|Active Comparator|Low-dose Psychostimulants, Normal-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
11380326|NCT02167048|No Intervention|No intervention, No intervention|This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).
11380329|NCT02167022|Experimental|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
11380330|NCT02167022|Experimental|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
11380331|NCT02167009|Experimental|Prostate Artery Embolization|Embospheres microspheres
11380332|NCT02166996|Active Comparator|A|Suture removal time 7 days.
11380333|NCT02166996|Experimental|B|Suture removal time 14 days.
11380334|NCT02166983|Experimental|Arm IA (Lumosity, relaxation, compensatory strategies)|Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
11380335|NCT02166983|Experimental|Arm IB (Active Journaling, relaxation, compensatory strategy)|Participants complete Active Journal cognitive exercises. Active Journaling requires participants to keep a written diary or journal where she discusses what her thoughts and feelings about various events with a focus on describing the meaning of the activities and experiences, particularly new things that were learned. Active Journaling is a method of practicing various cognitive skills including communication, organization, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises and compensatory strategies as in Arm IA.
11380336|NCT02166983|Experimental|Arm II (Lumosity only)|Participants complete Lumosity exercises as in Arm IA.
11380337|NCT02166970|Experimental|Single stent deployment|Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
11380338|NCT02166970|Active Comparator|Multiple stent deployment|Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
11380339|NCT02166957||Long disruption > 5cm +/- loss of SES|
11380340|NCT02166957||Short disruption < 5cm|
11380341|NCT02166944|Experimental|tamoxifen|tamoxifen 40 mg daily for one year
11380342|NCT02166944|Placebo Comparator|placebo|placebo drugs
11380343|NCT02166931|Placebo Comparator|placebo|placebo with the same color, order, taste as BRAND'S® Essence of Chicken , 70cc daily for 2weeks
11380344|NCT02166931|Experimental|Chicken Essence|BRAND'S® Chicken Essence 70cc, daily for 2 weeks
11380345|NCT02166918||patients with schizophrenia|320 patients with a diagnosis of schizophrenia according to Diagnostic and Statistical Manual IV edition (DSM-IV) criteria, confirmed by the Structured Clinical Interview for DSM-IV - Patient Version (SCID -IP), will be included in the study.
11380346|NCT02166918||unaffected first-degree relatives|240 unaffected first-degree relatives of the recruited patients (120 unaffected parents and 120 unaffected siblings)
11380347|NCT02166918||healthy control|320 healthy control subjects.
11380348|NCT02166905|Experimental|Arm I (CDX-1401, poly ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC as in Phase I.
11380349|NCT02166905|Experimental|Arm II (CDX-1401, poly ICLC, IDO1 inhibitor INCB024360)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 as in Phase I.
11380350|NCT02166892|Active Comparator|Normal weight|Normal weight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
11380351|NCT02166892|Active Comparator|Overweight children|Overweight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
11380352|NCT02166879||Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Chart review from patients undergoing elective surgery.
11380353|NCT02166866||Experimental arm|
11380354|NCT02166853|Experimental|conventional group|"a conventional group, in which intravenous sedation with midazolam will be administered"
11380355|NCT02166853|Experimental|sevoflurane group|"a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices"
11380356|NCT02166840|Experimental|Self expanding metal stent|Patients with self expanding metal stent inserted into bile duct.
11380357|NCT02166840|Active Comparator|Plastic stent|Patients with obstructive jaundice who got a plastic stent inserted into bile duct.
11380358|NCT02166827|Active Comparator|NeuroAD|NeuroAd Treatment, synchronized TMS and cognitive training stimulation
11380359|NCT02166827|Sham Comparator|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
11380360|NCT02166814|Experimental|Fimasartan and Rosuvastatin|Combination of Fimasartan and Rosuvastatin
11380361|NCT02166814|Active Comparator|Fimasartan|Fimasartan monotherapy
11380362|NCT02166814|Active Comparator|Rosuvastatin|Rosuvastatin monotherapy
11380363|NCT02166801|Active Comparator|Early intervention for infants|A 30w intensive intervention according to the small step program, with daily practice sections conducted by parents at home, with weekly support by therapists.
11380364|NCT02166801|Active Comparator|Usual care|Usual care means that the Children in this arm of the study participate in the established follow up program that is established at the Astrid Lindgrens Children's Hospital and offered to all Children that displays a delayed early gross and fine motor development.
11380399|NCT02166489|Experimental|mesenchymal stem cell transplantation|Intravenous injection of mesenchymal stem cell in patients with PKD
11380366|NCT02166788|Other|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
11380367|NCT02166762|Experimental|QLV interval measurement|QLV measurements collected during implantation of CRT-D device
11380368|NCT02166749||Subtotal abdominal hysterectomy|107 women
11380369|NCT02166749||Total abdominal hysterectomy|105 women
11380370|NCT02166736|Experimental|Instantaneous wave-free ratio (iFR)|
11380371|NCT02166736|Active Comparator|Fractional Flow Reserve (FFR)|
11380372|NCT02166723||CRYOABLATION|Cryoballoon ablation will be applied to all patients with persistent atrial fibrillation. It consists on applying the Arctic Front Cryoballoon to the pulmonary veins and freezing the antrum. In addition debulking of the atrial roof will be performed by a single application of the cryoballoon to the left and right roof, the septal wall and the lateral ridge wall.
11380373|NCT02166710|Experimental|Adductor canal femoral nerve blockade|Patients will receive continuous adductor canal femoral nerve blockade for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
11380374|NCT02166710|Placebo Comparator|Simulated nerve blockade|Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
11380375|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
11380376|NCT02166684|Experimental|Do-it-yourself devices|All subjects will use do-it-yourself devices for self-monitoring health parameters
11380377|NCT02166671|Experimental|HBV booster vaccination|
11380378|NCT02166658|Experimental|Single Arm|Patients receive Cabazitaxel 25 mg/m2 i.v. infusion. This trial is a single arm trial.
11380379|NCT02166645|Experimental|Prone position|Prone position per 48 hours after extubation
11380380|NCT02166645|Active Comparator|Supine position|Supine position per 48 hours after extubation
11380381|NCT02166632|Experimental|Intracapsular Injection|Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
11380382|NCT02166632|Active Comparator|Periarticular Injection|Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.
11380383|NCT02166619|Experimental|tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
11380384|NCT02166619|Sham Comparator|Sham tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric sham tDCS will be applied. Anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds. After bihemispheric sham tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
11380385|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
11380386|NCT02166593|Experimental|Pravastatin 40mg/Fenofibrate160mg|Pravastatin (40mg/day) Fenofibrate (160mg/day)
11380387|NCT02166593|Active Comparator|Atorvastatin Sodium|Atorvastatin Sodium (10mg/day)
11380388|NCT02166567|Experimental|YoPro and FACS|Spermatozoa to be used for ICSI will be stained with the YoPro Dye and then be sorted with FACS to select non-YoPro stained spermatozoa, known to have significantly less fragmented DNA.
11380389|NCT02166567|Active Comparator|Swim-up|Spermatozoa will be processed using the conventional swim-up me
11380390|NCT02166554|Placebo Comparator|Control Arm|Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery
11380391|NCT02166554|Experimental|Cross-linked Hyaluronan Hydrogel Arm|HyaRegen
11380392|NCT02166541|Experimental|INRS with BCSK|"Intensive Neurophysiological Rehabilitation System (INRS) including the Biomechanical correction of the spine according to Kozyavkin (BCSK).
~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
11380393|NCT02166541|Sham Comparator|INRS, traditional spinal manipulation|"Intensive Neurophysiological Rehabilitation System (INRS) including spinal manipulation by the traditional technique.
~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
11380394|NCT02166528||experiment group|patients with FPFD
11380395|NCT02166528||control group|patients without FPFD
11380396|NCT02166515||experiment group|patients with cervical cancer, endometrial cancers or ovary cancer
11380397|NCT02166515||control group|postmenopausal women with benign tumor
11380398|NCT02166502||Nevirapine|The patients in this study are newborn infants clinically prescribed combination antiretroviral treatment with nevirapine for prevention of mother-to-child HIV transmission.
11380652|NCT02164617|No Intervention|control|routine care
11380400|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
11380401|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
11380402|NCT02166463|Active Comparator|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over 1-15 minutes on days 1-2, bleomycin sulfate IV over 10 minutes or SC on days 1 and 8, vincristine sulfate IV over 1 minute on days 1 and 8, etoposide IV over 60-120 minutes on days 1-3, prednisone PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV over 30-60 minutes on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
11380403|NCT02166463|Experimental|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV over 1 minute on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
11380404|NCT02166450||Control group|Denture wearers without clinical signs of denture-related stomatitis confirmed with negative Candida swabs.
11380405|NCT02166450||Denture-related stomatitis group|"Denture wearers with clinical signs of denture-related stomatitis, confirmed with positive Candida swabs.
~Treated for fungal infection, with nystatin [100 000 IU every 6 h for 3 weeks, applied on the infected area of the mucous membrane of the palate and cheeks]."
11380406|NCT02166437||Alendronate|Patients treated with alendronate
11380407|NCT02166437||Minodronate|Patients treated with minodronate
11380408|NCT02166437||Denosmab|Patients treated with denosmab
11380409|NCT02166424|Active Comparator|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
11380410|NCT02166424|Placebo Comparator|olive oil|2880mg olive oil daily
11380411|NCT02166411|Experimental|myomectomy using barbed sutures|.Myoma bed is sutured with barbed sutures
11380412|NCT02166411|Active Comparator|myomectomy using conventional sutures|Myoma bed is sutured with conventional sutures
11380413|NCT02166398|Active Comparator|Amosartan 5/50 tab|Amosartan 5/50 tab given by oral administration
11380414|NCT02166398|Experimental|UI15AML055MT tab|UI15AML055MT tab given by oral administration
11380415|NCT02166372||Obese diabetic patients|Diabetic patients with BMI over 25 Age 20 to 67 Diabetes medically controlled at our center for at least six months
11380416|NCT02166359|Active Comparator|Glucose group|Glucose use of 2.5% or 4.25% dextrose solution at least 4 hours
11380417|NCT02166359|Experimental|Extraneal (Icodextrin) group|Extraneal (Icodextrin) use at least 8 hours
11380418|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
11380419|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
11380420|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
11380421|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
11380422|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
11380423|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
11380424|NCT02166320|Active Comparator|Partially covered SEMS|Boston Scientific Ultraflex SEMS
11380425|NCT02166320|Experimental|Fully covered SEMS|Boston Scientific Wallflex Esophageal SEMS.
11380426|NCT02166294|Experimental|NEOX® CORD 1K|Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
11380427|NCT02166294|Active Comparator|Pressure bandage|Standard of Care Pressure bandage with off-loading instructions
11380428|NCT02166294|Experimental|Standard of Care Cross over to NEOX|Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
11380429|NCT02166268|Active Comparator|Avanz Phleum pratense|Avanz Phleum pratense 15,000 SQ+ (standardised quality), suspension for subcutaneous injection.
11380430|NCT02166268|Placebo Comparator|Placebo|Placebo, suspension for subcutaneous injection.
11380431|NCT02166255|Experimental|Treatment (APN401)|Patients receive autologous siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes.
11380432|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
11380433|NCT02166229|Experimental|Divalproex sodium|Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.
11380434|NCT02166216||Healty subjects|Healthy subjects that participate in a high intensity, endurance bicycle race.
11380435|NCT02166190|Experimental|Radiofrequency Ablation (EndoHbp probe)|Radiofrequency Ablation using EndoHPB Probe
11380436|NCT02166190|Active Comparator|Stenting only|Stenting only
11380437|NCT02166177|Experimental|Autologous Regulatory T cell therapy|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)
11380438|NCT02166164|Experimental|Experiemental pain models|all study participants will be tested with the same experimental pain models: Brief thermal sensitization, Long thermal stimulation, and Heat-pain-detection threshold.
11380439|NCT02166151|Experimental|Omalizumab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
11380440|NCT02166138|Experimental|Laser treated Group|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits. Thus, patients in this group will be getting the Non-Abilative laser treatment.
11380441|NCT02166138|Placebo Comparator|Not Laser treated Group|Patients in this group will be given the laser treatment with the 1540 non-abilative laser device, but the device will not be set to provide treatment. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
11380442|NCT02166125||Endoscopic suturing|Any patient who has undergone clinically indicated and/or standard of care endoscopic suturing within the Gastrointestinal tract.
11380443|NCT02166112||Permacol mesh placement|No intervention performed
11380444|NCT02166099||SpyGlass Choledochoscopy procedure|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of a pancreatico-biliary disorder
11380445|NCT02166086||Endoscopic imaging|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment of a pancreatico-biliary disorder.
11380446|NCT02166060|Experimental|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
11380447|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
11380448|NCT02166047|Experimental|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
11380449|NCT02166047|Experimental|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
11380450|NCT02166047|Experimental|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
11380451|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
11380452|NCT02166047|Experimental|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
11380453|NCT02166047|Experimental|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
11380454|NCT02166047|Experimental|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
11380455|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
11380456|NCT02166047|Experimental|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
11380457|NCT02166047|Experimental|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
11380458|NCT02166047|Experimental|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
11380459|NCT02166034|Experimental|garden intervention|Schools assigned to the garden intervention receive raised bed garden kits and access to a toolkit of garden-based curriculum
11380460|NCT02166034|No Intervention|Control|Wait-list control (no garden intervention + lessons) until end of the study.
11380461|NCT02166021|Experimental|IT- Treated|Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
11380462|NCT02166021|Experimental|IV - Treated|Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
11380463|NCT02166021|Placebo Comparator|Placebo|Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.
11380464|NCT02166008|Active Comparator|Repamipide|Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
11380465|NCT02166008|Placebo Comparator|placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.
11380466|NCT02165995|Experimental|Navigated Transcranial Magnetic Stimulation (nTMS)|Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
11380467|NCT02165982||Patients controles|Inpatients suffering from anorexia nervosa at Institut Mutualiste Montsouris
11380468|NCT02165982||Individus sains témoins|Healthy controls selected from the general population
11380469|NCT02165969|Experimental|endoscopic endonasal surgery with UPSIT|endoscopic endonasal surgery with UPSIT prior to surgery and at months 1, 3, 6, and 12 after surgery.
11380470|NCT02165956|Experimental|New Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
11380471|NCT02165956|Active Comparator|Standard Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
11380472|NCT02165943||Vitoss Bone Graft with BMA|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage age was recommended and who received Vitoss bone graft with BMA to fill the cavity.
11380473|NCT02165943||Vitoss bone graft|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage was recommended and who received Vitoss bone graft to fill the cavity.
11380474|NCT02165930|Experimental|Treatment A|
11380475|NCT02165930|Experimental|Treatment B|
11380476|NCT02165917|Placebo Comparator|Excision only|Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration
11380477|NCT02165917|Active Comparator|Excision plus hyaluronic acid gel|Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration
11380478|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
11380479|NCT02165891|Other|Urokinase|insertion of a chest drain with urokinase instillation
11380480|NCT02165891|Other|VATS|primary video-assisted thorascopic surgery Other interventions except drainage procedure are the same in both arms
11380481|NCT02165878||Children and adolescent|children and adolescent CKD patients of any etiology
11380482|NCT02165865|Experimental|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
11380483|NCT02165852|Experimental|Papillectomy without injection|Conventional snaring mucoal resection without submucosal injection
11380484|NCT02165852|Active Comparator|Papillectomy with injection|Conventional mucosal resction method following injeciton of diluted epinephrine mixture.
11380485|NCT02165839|Active Comparator|Healthy Eating Education Learning (HEAL)|Healthy Eating Education Learning (HEAL) control group.
11380486|NCT02165839|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|Brief Behavioral Therapy for Insomnia (BBT-I).
11380487|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
11380488|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
11380489|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
11380490|NCT02165813|Active Comparator|Nitazoxanide|oral nitazoxanide suspension twice daily for 3 days
11380491|NCT02165813|Placebo Comparator|Placebo|oral placebo suspension twice daily for 3 days
11380492|NCT02165800|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
11380493|NCT02165800|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
11380494|NCT02165787||patients|
11380495|NCT02165787||healthy control subjects|
11380496|NCT02165774|Active Comparator|sacral neuromodulation ON|active sacral neuromodulation (neuromodulator ON)
11380497|NCT02165774|Placebo Comparator|sacral neuromodulation OFF|placebo sacral neuromodulation (neuromodulator OFF)
11380498|NCT02165761|Active Comparator|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
11380499|NCT02165761|Other|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
11380500|NCT02165735|Experimental|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
11380501|NCT02165735|Experimental|Usual Care|Usual care for HIV
11380502|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
11380503|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
11380504|NCT02165709|Experimental|Salpingectomy|Participants will be offered a risk-reducing salpingectomy, and if they choose this options the surgeon will proceed with a salpingectomy.
11380505|NCT02165709|Active Comparator|Traditional sterilization|Participants will be offered a risk-reducing salpingectomy, and those that choose a traditional sterilization will be in this treatment arm.
11380506|NCT02165696|Experimental|Manual lymphatic drainage and compression bandaging|Experimental group: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
11380507|NCT02165696|Active Comparator|Manual lymphatic drainage|Control group: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
11380508|NCT02165670||Ischemic heart disease|Patients undergoing percutaneous coronary intervention (PCI)
11380509|NCT02165657|Experimental|Excimer laser|Excimer laser treatment
11380510|NCT02165644|Experimental|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with current standard of care which is Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
11380511|NCT02165644|Active Comparator|Standard of care|Subjects will receive only standard of care for subarachnoid hemorrhage which will include Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
11380512|NCT02165631||Group A-Simbinza|Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
11380653|NCT02164604|Experimental|Ranibizumab|All eyes receive one intravitreal injection with 0.03ml ranibizumab
11380513|NCT02165631||Group B-Timolol|Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
11380514|NCT02165618|No Intervention|GCT|In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
11380515|NCT02165618|Active Comparator|GCT-RASP|Medication review, based on but not limited to the RASP list
11380516|NCT02165605|Experimental|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
11380517|NCT02165605|Placebo Comparator|Placebo|The patient is her own control.
11380518|NCT02165592||Patients with hemophilia|Patients with hemophilia who meet the inclusion criteria
11380519|NCT02165579||Age > 21, diabetes, osteomyelitis|1 Cohort, standard care, observational patients are: Diagnosis of diabetes mellitus Age ≥ 21 years Infectious Disease Society of America stage 3 infection
11380520|NCT02165566|Experimental|Regular-insulin,|regular-insulin or lispro-insulin at 0.04 units/kg/hour continuous infusion crossover and random assignement
11380521|NCT02165566|Experimental|Lispro insulin|patients randomly assigned in a crossover way to one of the 2 treatments
11380522|NCT02165553|Experimental|Hibiscus sabdariffa calyces extract as a cold drink|Subjects are asked to consume 250 ml of Hibiscus calyces drink after a high fat breakfast
11380523|NCT02165553|Placebo Comparator|Water|Subjects are asked to consume 250 ml of water after a high fat breakfast
11380524|NCT02165540|Experimental|Doula|Patients will have a doula support person during their procedure.
11380525|NCT02165540|No Intervention|Routine care/No Doula|Patients will have routine care with clinical staff only.
11380526|NCT02165527|Experimental|x-ray with iXDA scan|Tota body scan taken by the Lunar iXDA. During the scan, subject will be asked to lay on their back. Following the Lunar iDXA scan, the computer of the Luna iXDA will calculate bone length. The calculation of bone length will be compared to a calculation from the subject's conventional x-ray to determine accuracy.
11380527|NCT02165514|Experimental|Lunar iDXA (DEXA) scan|Spinal scans taken by DEXA scanner
11380528|NCT02165475|Experimental|Biofeedback|
11380529|NCT02165475|Experimental|medical treatment|
11380530|NCT02165475|Experimental|combination of the two treatments|
11380531|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
11380532|NCT02165449|Experimental|Ketamine|
11380533|NCT02165436|Placebo Comparator|Control|No gum
11380534|NCT02165436|Active Comparator|Chewing Gum|Bubble gum-flavored sugar-free gum - chew for 15-30 minutes 5 times/day
11380535|NCT02165423|Experimental|Control|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
11380536|NCT02165423|Experimental|Intervention|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
11380537|NCT02165410|Experimental|Eye tracking and RMI|
11380538|NCT02165397|Experimental|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
11380539|NCT02165397|Experimental|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
11380540|NCT02165397|Experimental|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
11380541|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
11380542|NCT02165371|Experimental|Sinovuyo Caring Families Programme|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly 3 hour sessions. Program is manualized.
11380543|NCT02165371|No Intervention|No intervention|Control group receives not intervention
11380544|NCT02165358||Patients|Patients verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
11380545|NCT02165358||Controls|Healthy controls matched for age and gender.
11380546|NCT02165345|Experimental|Tocilizumab|Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.
11380547|NCT02165332|Placebo Comparator|Part 1: Placebo|Saline solution, given as a minimum of a 2 hour infusion
11380548|NCT02165332|Experimental|Part 1: RO7033877|Single ascending dose
11380549|NCT02165332|Experimental|Part 2: RO7033877|Single-dose 4-way crossover
11380550|NCT02165319|Active Comparator|Barrel|Endotracheal tube with barrel-shaped cuff will be used during general anesthesia.
11380551|NCT02165319|Active Comparator|Tapered|Endotracheal tube with tapered-shaped cuff will be used during general anesthesia.
11380552|NCT02165306|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
11380553|NCT02165306|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the neurologist/neurosurgeon and nurses.
11380554|NCT02165293|Experimental|RO7033877|
11380555|NCT02165280|Active Comparator|Guided IMagery (GIM)|If randomized to GIM, they will then be given an audio Compact Disc. Patients will be instructed to listen to the recording least once per day in a calm location during the week leading up to surgery. They will then be seen prior to surgery in the surgical waiting area where they will evaluated for anxiety, preparedness and study compliance.
11380654|NCT02164578|Experimental|Rivaroxaban|Patients receive IMP in 5mg b.i.d. for 20 weeks.
11380655|NCT02164578|Active Comparator|Aspirin|Patients receive IMP in a dosage of 100mg once daily for 20 weeks.
11380656|NCT02164565|Experimental|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
11380707|NCT02164253|Experimental|Deferiprone|Deferiprone, 25 to 30 mg/kg per day, oral use
11380556|NCT02165280|No Intervention|Standard of Care (SOC)|"Each participant will complete a baseline set of questionnaires. The Pelvic Floor Distress Inventory (PFDI) is a 20 question self-administered questionnaire on the presence and both of pelvic floor symptoms .
~The Pelvic Organ Prolapse Quantification System (POPQ) measures the topography of the vagina and is considered to be gold standard for quantifying prolapse .
~The State-Trait Anxiety Inventory (STAI) has been used extensively in research and clinical practice since its introduction in 1966 and is the most widely cited measure of anxiety.
~New measurements at the 6-week follow-up appointment will include the Patient Global Impression of Improvement (PGII), and a postoperative questionnaire eliciting overall satisfaction and development of new pelvic symptoms."
11380557|NCT02165267|Experimental|Arm 1: VRC01 (6 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0, followed by IV infusions of 20 mg/kg of VRC01 administered in 100 mL of normal saline over at least 30 minutes to 1 hour at Days 28, 56, 84, 112, and 140.
11380558|NCT02165267|Experimental|Arm 2: VRC01 (3 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0 and over at least 30 minutes to 1 hour at Days 56 and 112.
11380559|NCT02165267|Experimental|Arm 3a: VRC01 (1 IV infusion plus multiple SC injections)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of 5 mg/kg of VRC01 administered every 2 weeks for 20 weeks.
11380560|NCT02165267|Placebo Comparator|Arm 3b: Placebo for VRC01 (infusion plus injections)|Participants will receive an IV infusion of sodium chloride placebo administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of placebo for VRC01 administered every 2 weeks for 20 weeks.
11380561|NCT02165267|Experimental|Arm 4: 10 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 10 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
11380562|NCT02165267|Experimental|Arm 5: 30 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 30 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
11380563|NCT02165254|Other|high dose tai chi intervention|
11380564|NCT02165254|Other|standard dose tai chi intervention|
11380565|NCT02165228|Experimental|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
11380566|NCT02165228|Active Comparator|Nutrition Enhancement|Nutrition education class and behavioral intervention
11380567|NCT02165228|No Intervention|Control|No class or behavioral intervention
11380568|NCT02165215|Experimental|Open-Label Induction Phase: Etrolizumab|All participants will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) up to Week 10.
11380569|NCT02165215|Experimental|Double-Blind Maintenance Phase: Etrolizumab|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive etrolizumab 105 mg SC injection Q4W from Week 12 up to Week 62.
11380570|NCT02165215|Placebo Comparator|Double-Blind Maintenance Phase: Placebo|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive placebo (matched to etrolizumab) SC injection Q4W from Week 12 up to Week 62.
11380571|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
11380572|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
11380573|NCT02165189|Experimental|Simeprevir plus Sofosbuvir plus Ribavirin (Arm 1)|Participants will be administered simeprevir capsule 150 milligram (mg), sofosbuvir 400 mg tablet, and ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram [kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg weight), orally once daily up to 12 weeks.
11380574|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 2)|Participants will be administered simeprevir capsule 150 mg and sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
11380575|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 3)|Participants will be administered simeprevir 150 mg capsule and sofosbuvir 400 mg tablet orally once daily 24 weeks.
11380576|NCT02165176|Experimental|10mg acute oral cannabis|10mg acute oral cannabis
11380577|NCT02165176|Experimental|25mg acute oral cannabis|25mg acute oral cannabis
11380578|NCT02165176|Experimental|50mg acute oral cannabis|50mg acute oral cannabis
11380579|NCT02165163|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
11380580|NCT02165163|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
11380581|NCT02165150|Experimental|Wheelchair-bound Senior Elastic Band|WSEB interventions three times per week, 40 minutes per practice
11380582|NCT02165150|No Intervention|Control|routine care
11380583|NCT02165137||trauma patients|type and severity of patients, circumstances and trauma pre- and post-injury / -quality initiative
11380584|NCT02165124|Experimental|Intervention/Bariatric Embolization|
11380657|NCT02164565|Experimental|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
11380658|NCT02164552||Vitamin D3 pills|Vitamin D3 (cholecalciferol) supplementation (50,000 IU/week for 8 weeks) followed by 1000 IU/day for 16 weeks
11380659|NCT02164552||Placebo pill|Placebo pills will be given 1 per week for 8 weeks followed by 1 per day for 16 weeks
11380806|NCT02163629|No Intervention|Usual medical care|
11380585|NCT02165111|Experimental|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).
~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
11380586|NCT02165111|Placebo Comparator|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).
~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
11380587|NCT02165098|Experimental|Cariprazine PR tablet B|Cariprazine prolonged release tablet B - fed
11380588|NCT02165098|Experimental|Cariprazine PR tablet A|Cariprazine prolonged release tablet A - fed
11380589|NCT02165098|Experimental|Cariprazine capsule|Cariprazine capsule - fasted
11380590|NCT02165098|Experimental|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
11380591|NCT02165098|Experimental|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
11380592|NCT02165085||Vascular-Ehlers Danlos syndrome|N=50 patients with vascular Ehlers-Danlos syndrome
11380593|NCT02165085||Spontaneous arterial dissection(s)|N=50 patients
11380594|NCT02165085||Healthy volunteers|n=100 Healthy volunteers
11380595|NCT02165059||Study Group|Patients undergoing surgical full thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder.
11380596|NCT02165059||Control Group|"Patient undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, Whipple surgery, transplant surgery.
~Patients who are organ donors and undergoing surgery are also part of the control group."
11380597|NCT02165046|Experimental|SYN006 HFA MDI, 180/10 mcg/dose|SYN006 HFA MDI(Budesonide/Procaterol Hydrochloride, 180/10mcg), Single dose, 4 puffs
11380598|NCT02165046|Active Comparator|Pulmicort pMDI|Budesonide 200mcg, single dose, 4 puffs
11380599|NCT02165046|Active Comparator|Meptin Air 10mcg|Procaterol hydrochloride 10mcg, single dose, 4 puffs
11380600|NCT02165033|Experimental|Budesonide/Procaterol 180/10 X 4 puffs|Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days
11380601|NCT02165020|Experimental|Rectal toxicities after prostate hypofractionated radiotherapy|Rectal toxicities after prostate hypofractionated radiotherapy with hyaluronic acid
11380602|NCT02165007|Experimental|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
11380603|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
11380604|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
11380605|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
11380606|NCT02164968||Obstructive bronchitis|1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
11380607|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
11380608|NCT02164942||Single Arm|Specimen Collection
11380609|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
11380610|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
11380611|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
11380660|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
11380612|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
11380613|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
11380614|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11380615|NCT02164903||Imatinib|Patients in first line treatment with imatinib for no more than 3 years.
11380616|NCT02164903||Dasatinib|Patients in first line treatment with dasatinib for no more than 3 years.
11380617|NCT02164890|Other|Pharmacokinetics of micafungin|
11380618|NCT02164877|Experimental|pectin|Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
11380619|NCT02164877|Placebo Comparator|control|Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks
11380620|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
11380621|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
11380622|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
11380623|NCT02164838|Experimental|Axitinib|
11380624|NCT02164825|Experimental|Single-shot nerve block|Efficacy compared to epidural
11380625|NCT02164825|Active Comparator|Continuous epidural|Continuous epidural perfusion
11380626|NCT02164812|Experimental|Moxifloxacin, Placebo, Efavirenz|Moxifloxacin, Placebo, Efavirenz single dose as specified
11380627|NCT02164799||Shock|Patients found to have persistent hypotension after resuscitation or vasopressor requirement
11380628|NCT02164799||Pre-shock|Patients with markedly abnormal vital signs (Heart Rate (HR)>130, Respiratory Rate (RR)>24, Shock Index >1, Lactate > 4.0mmol/L, or Systolic Blood Pressure (SBP) <90mm/hg) without shock, as defined previously.
11380629|NCT02164786||Acute severe disease|
11380630|NCT02164773|Active Comparator|magnesium sulfate|magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.
11380631|NCT02164773|Placebo Comparator|o.9%normal saline|0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.
11380632|NCT02164760|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
11380633|NCT02164760|No Intervention|STSG alone|STSG alone
11380634|NCT02164747||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
11380635|NCT02164747||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
11380636|NCT02164747||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
11380637|NCT02164747||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
11380638|NCT02164734|Active Comparator|Endotracheal intubation|Endotracheal intubation for surfactant administration, following remifentanil and atropine pre-medication
11380639|NCT02164734|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
11380640|NCT02164721|Other|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
11380641|NCT02164708|Experimental|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
11380642|NCT02164695|Active Comparator|PPCI plus RIPC|The patients randomized to PPCI plus RIPC group will receive RIPC during PPCI.
11380643|NCT02164695|Sham Comparator|PPCI only|The patients randomized to PPCI only group will receive PPCI only but the sham procedure of RIPC.
11380644|NCT02164682||IV PCA group|
11380645|NCT02164682||IV PCA+ caudal block group|
11380646|NCT02164656|Experimental|mindfulness training|8 week course in mindfulness for smokers
11380647|NCT02164643|Experimental|Florbetapir (18F)|
11380648|NCT02164643|Experimental|Flutemetamol (18F)|
11380649|NCT02164630|Experimental|Hope Therapy|Patients assigned to this arm will receive Hope Therapy in three individual intervention sessions. Intervention will be administered by an experienced therapist.Training focuses on effective goal setting and augmenting hopeful thinking.
11380650|NCT02164630|Other|Pain Education|Patients assigned to this arm will receive Pain Education in three individual intervention sessions. Intervention will be administered by an experienced therapist. Training will focus on understanding TMD-related pain and learning pain management techniques.
11380651|NCT02164617|Experimental|Wheelchair-bound Senior Elastic Band|Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
11380661|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
11380662|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
11380663|NCT02164526||No treatment|
11380664|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
11380665|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
11380666|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
11380667|NCT02164500|Experimental|Ruxolitinib|
11380668|NCT02164487||B1 blood levels|
11380669|NCT02164474|Experimental|High-Intensity Interval Training (HIIT)|Participants will perform a series of high-intensity intervals with an interval length of 60-seconds at 90% of peak aerobic capacity workload, and a rest length of 60-seconds.
11380670|NCT02164474|Active Comparator|Moderate-Intensity Continuous Exercise|Participants will engage in exercise at 45% of peak aerobic capacity workload.
11380671|NCT02164461|Experimental|ADXS11-001|
11380672|NCT02164448|Experimental|dexmedetomidine group|
11380673|NCT02164448|Placebo Comparator|control group|
11380674|NCT02164435|Other|Renal Denervation|
11380675|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
11380676|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
11380677|NCT02164422|Placebo Comparator|Placebo|Placebo
11380678|NCT02164409||Patient|Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
11380679|NCT02164409||Control|A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
11380680|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
11380681|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
11380682|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
11380683|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
11380684|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:
~How effective is the following intervention:
~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
11380685|NCT02164370||non-pregnant controls|Acid-base in healthy non-pregnant women in childbearing age
11380686|NCT02164370||healthy pregnant control group|healthy pregnant volunteers matched in gestational age to cases
11380687|NCT02164370||severe pre-eclampsia|Acid-base in severe pre-eclampsia
11380688|NCT02164357||EVT|Patients receiving endovascular treatment (EVT) within 4.5 hours after onset because intravenous thrombolytic therapy (IVT) is contraindicated
11380689|NCT02164357||IVT + EVT|Patients receiving intravenous thrombolytic therapy (IVT) followed by endovascular treatment (EVT) within 4.5 hours after onset
11380690|NCT02164357||IVT (intravenous thrombolytic therapy)|Patients that will received IVT only within 4.5 hours after onset
11380691|NCT02164344|Experimental|Probiotics|HIV-1 infected patients take daily dietary supplement with probiotics for at least 3 months
11380692|NCT02164331|Experimental|JNC guideline training|Providers will receive current JNC guideline training for treating patients with uncontrolled hypertension.
11380693|NCT02164331|No Intervention|Control|Provider patient panels will be assessed for number of uncontrolled hypertensives before receiving the JNC guidelines training. These baseline characteristics will serve as their control conditions.
11380694|NCT02164318|No Intervention|Control group|Standard of care
11380695|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
11380696|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
11380697|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
11380698|NCT02164305|Experimental|Strengthening group|4-week exercise training, 3 times a week, 30 minutes per visit.
11380699|NCT02164305|Experimental|Neuromuscular group|4-week exercise training, 3 times a week, 30 minutes per visit
11380700|NCT02164305|Sham Comparator|Control|Only have 2 assessments.
11380701|NCT02164292||ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
11380702|NCT02164279||Progressor (ND)|Group of patients with an albuminuria > 100mg/L, by Urinary sample collection
11380703|NCT02164279||Non-Progressor (non-ND)|Group of patients without an albuminuria > 100mg/L, by Urinary sample collection
11380704|NCT02164266|Experimental|Part 1: Healthy Volunteers|
11380705|NCT02164266|Experimental|Part 2: Patients with T2D, Group A|Low dose daily oral administration of RO6799477
11380706|NCT02164266|Experimental|Part 2: Patients with T2D, Group B|High dose daily oral administration of RO6799477
11380708|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
11380709|NCT02164227|Experimental|respiratory pattern|Deep and slow inspiration is used in the initial and active stages, at which time the contractions vary from uncomfortable to strong, lumbosacral pain and cervical dilation may occur between 3 and 8 cm in this case the mother is driven to inspire slowly and the level of inspiratory reserve volume followed by slow exhalation to functional residual capacity; Sigh with post-expiratory pause that corresponds to a small spontaneous exhalation to relax occurs in tidal volume; Expiratory delay that corresponds to a prolonged propelled with the lips during the lull and expiration in the expiration time that corresponds to a slow inspiration followed by two or three puffs with the short lips will be used propelled.
11380710|NCT02164227|No Intervention|Control|Follows the service routine
11380711|NCT02164214|Experimental|patients PSORIATIC ARTHRITIS|etanercept Treatment
11380712|NCT02164214|Active Comparator|patients RHEUMATOID ARTHRITIS|etanercept Treatment
11380713|NCT02164188|No Intervention|control|Initially this control group will not receive an intervention (wait list). After 8 weeks this goup will receive the Flourishing protocol (cross over).
11380714|NCT02164188|Experimental|Flourishing protocol|This group will receive the intervention Flourishing protocol and after that it will not receive any other intervention (cross over).
11380715|NCT02164175||HeRO Graft|End stage renal disease patients who receive HeRO Graft implant for dialysis access
11380716|NCT02164162|Experimental|Experimental group|"Participants received 12 sessions of robotic assisted body weight-supported treadmill training on the Lokomat. Training occurred approximately 3 days/ week for 4 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support.
~Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session."
11380717|NCT02164162|Active Comparator|Control group|Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
11380718|NCT02164149||Quality of colon cancer surgery|Patients with primary colon cancer
11380719|NCT02164136|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
11380720|NCT02164136|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
11380721|NCT02164123|Experimental|Spinal mobilization|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute. The subject will be comfortable prone lying.
11380722|NCT02164123|Active Comparator|Spinal Mobilization II|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
11380723|NCT02164123|Placebo Comparator|Placebo|20 subjects will be randomized to this arm. Only manual contact will be applied, without any oscillation. The subject will be comfortable prone lying. The intervention time is the same of the other arms.
11380724|NCT02164110|Experimental|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2
~Method of administration: oral administration
~Dose of drug to be administered: 1.5 mL/dose"
11380725|NCT02164110|Active Comparator|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2
~Method of administration: oral administration
~Dose of drug to be administered: 1.5 mL/dose"
11380726|NCT02164097|Experimental|ODSH and ICE Chemotherapy|"Patients will receive standard doses of ICE Chemotherapy:
~Ifosfamide 1800 mg/m2 mixed with Mesna 360 mg/m2 IV over 2 hours on days 1, 2, 3, 4, and 5
~Carboplatin 400 mg/m2 IV over 1 hour on days 1 and 2
~Etoposide 100 mg/m2 IV over 1 hour on days 1, 2, 3, 4, and 5
~ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first ifosfamide dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for five consecutive days, on days 1-5, for a total of 120 hours of continuous ODSH infusion."
11380727|NCT02164084|Experimental|SB204|SB204 8% topically twice daily for 4 days and once on Day 5
11380728|NCT02164084|Placebo Comparator|Vehicle Gel|Vehicle Gel topically twice daily for 4 days and once on Day 5
11380729|NCT02164071||Multiple Myeloma (MM)|Patients with Myltiple Myeloma, symptomatic or asymptomatic
11380730|NCT02164071||Myelodysplastic Syndromes or Acute Myeloid Leukemia|Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
11380731|NCT02164071||Chronic Lymphocytic Leukemia (CLL)|Patients with Chronic Lymphocytic Leukemia
11380732|NCT02164058|Experimental|TandemHeart System + PCI|TandemHeart System prior to percutaneous coronary intervention
11380733|NCT02164058|Active Comparator|PCI|Percutaneous coronary intervention
11380734|NCT02164045|Experimental|BMS-663068- Fasted|BMS-663068 tablet twice a day by mouth on specified days
11380735|NCT02164045|Experimental|BMS-663068- Fed|BMS-663068 tablet twice a day by mouth on specified days
11380736|NCT02164032|Placebo Comparator|Insulin dilution buffer|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.
~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
11380737|NCT02164032|Active Comparator|Intranasal Insulin administration|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.
~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
11380738|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
11380739|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
11380740|NCT02164006|Experimental|TGR-1202 + brentuximab vedotin|TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
11380741|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
11380742|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
11380743|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
11380744|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
11380745|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
11380746|NCT02163980|Placebo Comparator|Caudal ropivacaine + normal saline|1.5ml kg-1 ropivacaine 0.15% with normal saline (Control group, n=40).
11380747|NCT02163980|Experimental|Caudal ropivacaine + dexmedetomidine|1.5ml kg-1 ropivacaine 0.15% with dexmedetomidine 1 μg kg-1 (DEX group, n=40)
11380748|NCT02163967|Other|Dose sequence: Sham, Low, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
11380749|NCT02163967|Other|Dose sequence: Sham, High, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
11380750|NCT02163967|Other|Dose sequence: Low, Sham, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
11380751|NCT02163967|Other|Dose sequence: Low, High, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
11380752|NCT02163967|Other|Dose sequence: High, Sham, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
11380753|NCT02163967|Other|Dose sequence: High, Low, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation
11380754|NCT02163954|Active Comparator|Clopidogrel|Patients treated with clopidogrel for 14 days
11380755|NCT02163954|Experimental|Ticagrelor|Patients treated with ticagrelor for 14 days
11380756|NCT02163941|Experimental|Compassion Training|8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
11380757|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
11380758|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
11380759|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
11380760|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
11380761|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
11380762|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
11380763|NCT02163902|Experimental|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
11380764|NCT02163902|Placebo Comparator|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
11380765|NCT02163889||Candida Positive Patients|Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida
11380766|NCT02163876|Experimental|HuCNS-SC cells|Intramedullary transplantation of HuCNS-SC cells in the cervical spine
11380767|NCT02163876|No Intervention|non-surgery arm|non-surgery arm
11380768|NCT02163863|Experimental|BioMimics 3D|The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
11380769|NCT02163863|Active Comparator|Control|CR Bard LifeStent System, delivering a self-expanding Nitinol stent
11380770|NCT02163850|Experimental|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
11380771|NCT02163850|Active Comparator|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
11380772|NCT02163837|Experimental|rifaximine|
11380773|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
11380774|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
11380775|NCT02163824|Placebo Comparator|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
11380776|NCT02163824|Placebo Comparator|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
11380777|NCT02163811|Experimental|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
11380778|NCT02163811|Active Comparator|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
11380779|NCT02163798|Experimental|Tai Chi Group|Participants in this group received a 12-week instructor-led Tai Chi training program.
11380780|NCT02163798|Experimental|Walking Group|Participants in this group received a 12-week instructor-led brisk walking training program.
11380781|NCT02163798|No Intervention|Control Group|Participants in the control group did not receive intervention during the 12 weeks, and were told that they would be provided two sessions of free health and fitness evaluation with an interval of three months (12 weeks).
11380782|NCT02163785|Active Comparator|Supine position|Abdominoperineal resection - perineal time- in supine position
11380783|NCT02163785|Experimental|Prone position|Abdominoperineal resection - perineal time- in prone position
11380784|NCT02163772|Experimental|Intracordal hyaluronate injection (HI)|The intervention of Intracordal hyaluronate (Restylane) injection is given in this group No other therapies are given
11380785|NCT02163772|No Intervention|Conservative management (CM)|In this arm, only observation is arranged. No therapy is given.
11380786|NCT02163759|Active Comparator|Adalimumab + Etrolizumab Placebo|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
11380787|NCT02163759|Experimental|Etrolizumab + Adalimumab Placebo|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
11380788|NCT02163759|Placebo Comparator|Etrolizumab Placebo + Adalimumab Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
11380789|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
11380790|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
11380791|NCT02163733|Other|Fasted|AZD9291 tablets following a period of fasting
11380792|NCT02163733|Other|High-fat meal|AZD9291 tablets following a high-fat meal.
11380793|NCT02163720||Yondelis®-Caelyx®-relapse ovarian cancer|Yondelis®-Caelyx®-relapse ovarian cancer
11380794|NCT02163707|Other|Psilocybin Dose 1|0.3 mg/kg (approximately 20mg/70kg)
11380795|NCT02163707|Other|Psilocybin Dose 2|0.45 mg/kg (approximately 30 mg/70 kg)
11380796|NCT02163707|Other|Psilocybin Dose 3|0.6 mg/kg (approximately 40 mg/70 kg)
11380797|NCT02163694|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Veliparib Placebo on Day -2 through 5 of a 21-day cycle. Carboplatin on Day 1 of a 21-day cycle and paclitaxel on Day 1, 8, and 15 of a 21-day cycle.
11380798|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib on Day -2 through 5 of a 21-day cycle. Carboplatin on Day 1 of a 21-day cycle and paclitaxel on Day 1, 8, and 15 of a 21-day cycle.
11380799|NCT02163681|Experimental|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
11380800|NCT02163668|Experimental|Yoga group|8 months of progressive Yoga training
11380801|NCT02163668|No Intervention|Control group|No training, just pre and post testing
11380802|NCT02163655|Placebo Comparator|PLACEBO|PLACEBO: placebo, oral, every 24 hours for maximum 5 days
11380803|NCT02163655|Experimental|FUROSEMIDE|FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
11380804|NCT02163642||Non-CF Bronchiectasis|Cyranose® 320
11380805|NCT02163629|Experimental|psychotherapeutic intervention|"The psychotherapeutic intervention stress management is based on therapeutic, behavioral and cognitive strategies. They are active and put the patient actor of his adaptation of the heart transplantation entire process. The approached components are emotional, cognitive and behavioral (techniques of communication and problem solving)."
11380807|NCT02163616|Experimental|PPH Treatment|800mcg sublingual misoprostol
11380808|NCT02163603||Pelvic osteotomy|
11380809|NCT02163590|Experimental|2Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 2Hz frequency.
11380810|NCT02163590|Experimental|0,5Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 0,5Hz frequency.
11380811|NCT02163590|Placebo Comparator|Placebo|A simulation technique, that mimic the other groups, in this case only manual contact will be applied, without any oscillation.
11380812|NCT02163577|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W). Dose was determined by the participant's weight and prescribed dose by their study doctor.
11380813|NCT02163577|Experimental|Burosumab Q4W Then Q2W|Burosumab SC injections every 4 weeks (Q4W). Dose was determined by the participant's weight and prescribed dose by their study doctor. Participants in Q4W were to switch to Q2W beginning with Week 64 dosing.
11380814|NCT02163564|No Intervention|Focus groups|The first part of the study is to conduct focus groups of adolescents with insomnia and depression. The treatment arm is informed by responses provided by teens in the focus group portion.
11380815|NCT02163564|Active Comparator|Treatment|A modified cognitive behavioral therapy for insomnia is the treatment intervention in this treatment arm.
11380816|NCT02163551||Spinal Cord Injury|Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
11380817|NCT02163551||Controls|Twenty healthy age-matched adults will also participate.
11380818|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
11380819|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
11380820|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
11380821|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
11380822|NCT02163512||Non-refractory ascites|
11380823|NCT02163512||Refractory ascites|
11380824|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
11380825|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
11380826|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
11380827|NCT02163473||Septic patients|Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
11380828|NCT02163473||Healthy Control|The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
11380829|NCT02163460|Experimental|Drain|In group 1(Drain), a 4.8 mm diameter continuous closed-suction tubular drain : was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
11380830|NCT02163460|Experimental|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
11380831|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
11380832|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
11380833|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
11380868|NCT02163174|Active Comparator|Pentoxyfilline arm|Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
11381131|NCT02161471||TGA arterial switch|Patients with transposition of the great arteries after arterial switch operation
11380834|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
11380835|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
11380836|NCT02163434|Experimental|gabapentin|1800-2400mg/day divided tid or qid, orally.
11380837|NCT02163434|Experimental|metoclopramide|45-60mg/day divided tid or qid, orally
11380838|NCT02163421|Experimental|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
11380839|NCT02163421|Experimental|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
11380840|NCT02163421|Experimental|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
11380841|NCT02163421|Active Comparator|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
11380842|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
11380843|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
11380844|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
11380845|NCT02163382|Experimental|Neurovent Monitor XIII|1 hour Ventilation with NAVA
11380846|NCT02163369|Experimental|Peppermint and Lavender Essential Oils|
11380847|NCT02163356|Experimental|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
11380848|NCT02163343||No treatment|
11380849|NCT02163330|Active Comparator|Acetazolamide|active comparator group will receives 500 mg azetazolamide daily
11380850|NCT02163330|Placebo Comparator|sugar pill|placebo comparator group will receives placebo daily.
11380851|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
11380852|NCT02163304|Active Comparator|Artificial Sweetner|Artificial Sweetener
11380853|NCT02163304|Placebo Comparator|Tasteless Solution|12 oz tasteless solution
11380854|NCT02163304|Active Comparator|Sucrose|12 oz 75 g sucrose beverage
11380855|NCT02163291|Experimental|paclitaxel liposome|S-1 plus paclitaxel liposome
11380856|NCT02163278|Experimental|DBPR108|
11380857|NCT02163278|Placebo Comparator|matching placebo|
11380858|NCT02163265|Experimental|Surgery|Patients suffering from Pectus excavatum and Pectus carinatum will be surgically treated
11380859|NCT02163252|Active Comparator|Standard|A 12-week internet-based weight loss program that involves weekly video lessons, a self-monitoring platform where participants submit their weight, calorie, and activity information, and weekly automated feedback.
11380860|NCT02163252|Experimental|Early intervention|Participants randomized to Early Intervention will receive the same internet-based weight loss program compared to the Standard group. In addition, Early Intervention participants achieving less than optimal weight loss following several weeks of treatment will be given the opportunity to come to the Weight Control and Diabetes Research Center for an individual visit. At this visit, an interventionist will discuss with the participant any barriers that he or she may be experiencing and recommend alternate strategies to assist in their weight loss. One such strategy would be to recommend the use of meal replacement products or portion controlled meals. In addition to this one-time visit, the interventionist will follow up with the participant via phone weekly, for 2 weeks following this in-person visit.
11380861|NCT02163239||10mm Cannula|Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator
11380862|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
11380863|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
11380864|NCT02163213|Other|Serum Bovine Immunoglobulin|"Serum-Derived Bovine Immunoglobulin (SBI) 5.0 g by mouth twice daily;
~Effects of SBI will be compared with observations and measurements performed at baseline PRIOR to starting the SBI treatment"
11380865|NCT02163200||pressure of total hip replacement|Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA
11380866|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
11380867|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
11380869|NCT02163174|Placebo Comparator|Placebo arm|Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
11380870|NCT02163161|Experimental|Treatment A|
11380871|NCT02163161|Experimental|Treatment B|
11380872|NCT02163161|Experimental|Treatment C|
11380873|NCT02163148||Public Speaking Anxiety|Intervention to be administered: One speech exposure session.
11380874|NCT02163122|Experimental|NAC Followed by EEC|This arm will undergo allergy assessment first by NAC. After a rest and washout period, the same individuals will undergo assessment in an EEC.
11380875|NCT02163122|Experimental|EEC Followed by NAC|This arm will undergo allergy assessment first in an EEC. After a rest and washout period, the same individuals will undergo assessment by NAC.
11380876|NCT02163122|Experimental|Dose-finding Phase|An initial group of 6 to 12 participants with cat allergy as defined by the eligibility criteria will undergo a single-visit, stepwise dose-escalating nasal allergen challenge only, with the aim of estimating the most appropriate single dose of allergen to use in the randomized phase. Eligible participants who participate in the dose-finding phase may proceed to the randomized phase of the trial after a minimum 28-day washout period.
11380877|NCT02163109||Critically-ill patients|Adult patients requiring intubation and mechanical ventilation on an intensive care unit, predicted to require a further 48 hours of artificial ventilation
11380878|NCT02163096||History of Wheezing, Benign Joint Hypermobility Syndrome|
11380879|NCT02163096||Asthma, Benign Joint Hypermobility Syndrome|
11380880|NCT02163083|No Intervention|Lymphadenectomy using standard Methods|Lymphadenectomy will be performed as a standard procedure
11380881|NCT02163083|Experimental|Lymphadenectomy using ICG|A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.
11380882|NCT02163070|Experimental|whey drink|consumption of 220 milliliters of whey drink three times a week,
11380883|NCT02163070|Experimental|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
11380884|NCT02163070|Experimental|vitaminE|consumption of 400 milligrams of vitamin E three times a week,
11380885|NCT02163070|No Intervention|D- control|control group: no intervention,
11380886|NCT02163057|Other|Surgery Cohort|1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device
11380887|NCT02163057|Other|Chemoradiation|1.1 mL of INO-3112 (VGX-3100 and INO-9012) delivered IM via CELLECTRA-5P device
11380888|NCT02163044||Statin|Patients on statin treatment
11380889|NCT02163031|Active Comparator|right radial approach|devices used in the coronary angiography by right radial approach
11380890|NCT02163031|Active Comparator|left radial approach|devices used in the coronary angiography by left radial approach
11380891|NCT02163018|Experimental|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1.
11380892|NCT02163018|Placebo Comparator|Placebo|Subcutaneous administration of placebo
11380893|NCT02163005|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
11380894|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
11380895|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
11380896|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
11380897|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
11380898|NCT02162966|Experimental|High Dose Colistin|High dose colistin protocol
11380899|NCT02162966|Active Comparator|Standard Dose Colistin|Standard dose of colistin
11380900|NCT02162940||patients taking statins|Visual anlogue score vas used to evaluate pain. The SF 36 test was used to evaluate quality of life.
11380901|NCT02162940||patients not taking statins|Visual anlogue score vas used to evaluate pain.The SF 36 test was used to evaluate quality of life.
11380902|NCT02162927|Experimental|Potassium Nitrate (N)|This involves 1 serving (2 pills) of potassium nitrate KNO3- (N) (8 mmols NO3-). The supplementation period is six days. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
11380903|NCT02162927|Placebo Comparator|Potassium Chloride|This involves 1 serving (2 pills) of the nitrate-free placebo (PL) potassium chloride (8 mmol KCl) for a six-day supplementation period. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
11380904|NCT02162914|Active Comparator|Regorafenib/active|Subjects randomized to be treated with Regorafenib (active product) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
11380905|NCT02162914|Placebo Comparator|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib (placebo) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
11380906|NCT02162901|Experimental|Choice-Class with IVR Calls|Participants enrolled in this arm of the study will have chosen to attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months.
11380907|NCT02162901|Experimental|Choice-DVD with IVR calls|Participants enrolled in this arm of the study will have chosen to watch a DVD at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
11380908|NCT02162901|Experimental|Random-Class with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
11380974|NCT02162511|Experimental|ARM C Non-malignant|Non-malignant diseases Chemotherapy based conditioning
11380975|NCT02162498|Experimental|Feeding buddies intervention|Sites receiving a comprehensive feeding buddy program implemented by the Window of Opportunity program.
11380909|NCT02162901|Experimental|Random-DVD with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will be given a DVD to watch at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
11380910|NCT02162901|Active Comparator|Random-Class only|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the intervention and will receive a workbook to use at home.
11380911|NCT02162888|Other|Eagle-BDM; Teva-BDM; Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
11380912|NCT02162888|Other|Teva-BDM; Eagle-BDM;Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
11380913|NCT02162888|Other|Teva-BDM, Teva-BDM, Eagle-BDM|Eagle-BDM: IV Teva-BDM: IV
11380914|NCT02162875|Experimental|MDA once a year|Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
11380915|NCT02162875|Experimental|MDA 2nd year CWT follwed by 2 years SBT|Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
11380916|NCT02162875|Experimental|Praziquantel every second year CWT|Treatment with praziquantel given every second year as CWT
11380917|NCT02162875|Experimental|MDA once a year SBT|Treatment with praziquantel as above given as 4 years of SBT
11380918|NCT02162875|Experimental|MDA given for 2 years as SBT|Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
11380919|NCT02162875|Experimental|MDA as SBT 1year and 1 year without MDA|Treatment with praziquantel given as one years of SBT alternating with one year without treatment
11380920|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
11380921|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
11380922|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
11380923|NCT02162849|Experimental|Varenicline + Placebo Patch|"Varenicline dosing follows the recommended 12 week course: 0.5 milligram mg/day by mouth for Days 1-3, 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter. Participant takes Varenicline 1-10 days after Visit 1.
~Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day.
~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.
~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo. Some of the counseling sessions may be recorded by video and/or audio tape.
~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
11380924|NCT02162849|Experimental|Nicotine Patch + Placebo Tablet|"Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
~Starting on Day 8, and then every day after that, participant applies 1 nicotine patch.
~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.
~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo.
~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
11380925|NCT02162836|Experimental|Cohort 1|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
11380926|NCT02162823||Pancreatic cancer|Patients with pancreatic cancer and age&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
11380927|NCT02162810|Active Comparator|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
11380928|NCT02162810|Placebo Comparator|placebo-controlled|Simple Syrup will be used as the placebo
11380929|NCT02162797|Experimental|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
11380930|NCT02162797|Experimental|zinc supplementation|Intervention group A. Patients who will orally receive zinc for 3 months.
11380931|NCT02162784|Experimental|Budesonide/procaterol 180/10mcg X1|HFA MDI, oral inhalation, 180/10mcg, one puff
11380932|NCT02162784|Experimental|Budesonide/Procaterol, 180/10mcg X2|HFA MDI, oral inhalation, two puffs
11380933|NCT02162784|Active Comparator|Albuterol HFA MDI 100 mcg X2|HFA MDI, oral inhalation, 100mcg, two puffs
11380934|NCT02162771|Experimental|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.
~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
11381091|NCT02161679|Experimental|IMMU-132|IMMU-132 infusion is administered
11381132|NCT02161471||Normal|Normal controls
11380935|NCT02162771|Active Comparator|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.
~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
11380936|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
11380937|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
11380938|NCT02162745|Experimental|Isotonic solution (NaCl 0.9%)|Single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril
11380939|NCT02162745|Experimental|Hypertonic solution (NaCl 3%)|Single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril
11380940|NCT02162745|No Intervention|Supportive care|Wiping the nose, positioning the child, changing a wet diaper, feeding.
11380941|NCT02162732|Experimental|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
11380942|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib and paclitaxel in cycles of 28 days (4 weeks) each and study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
11380943|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo and paclitaxel in cycles of 28 days (4 weeks) each and study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
11380944|NCT02162693|Experimental|Mesenchymal progenitor cells|Administrated for intra-articular use of Mesenchymal progenitor cells
11380945|NCT02162693|Active Comparator|Sodium Hyaluronate|Administrated for intra-articular use of Sodium Hyaluronate.
11380946|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
11380947|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
11380948|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
11380949|NCT02162667|Experimental|CT-P6|
11380950|NCT02162667|Active Comparator|Trastuzumab|
11380951|NCT02162654|Active Comparator|Remote ischemic preconditioning|Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
11380952|NCT02162654|Sham Comparator|Sham preconditioning|Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
11380953|NCT02162641||SCC of the anus|
11380954|NCT02162628||Exair for Total Repair|Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair
11380955|NCT02162628||Total Native Tissue Repair|Total repair with native tissue only
11380956|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
11380957|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
11380958|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
11380959|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
11380960|NCT02162589||POEM for Achalasia|Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia.
11380961|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
11380962|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.
~Intervention: FOLFOXIRI with bevacizumab"
11380963|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.
~Intervention: FOLFOX/FOLFIRI with bevacizumab"
11380964|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.
~Intervention: FOLFOX/FOLFIRI with panitumumab"
11380965|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.
~Intervention: FOLFOX/FOLFIRI with bevacizumab"
11380966|NCT02162550|Experimental|Bydureon|injectable medication Bydureon
11380967|NCT02162550|Placebo Comparator|Placebo|a similar looking injectable
11380968|NCT02162537|Other|Arm A (standard arm)|Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)
11380969|NCT02162537|Other|Arm B (experimental arm)|Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain
11380970|NCT02162524|No Intervention|No Exercise Control|Healthy Living Group
11380971|NCT02162524|Active Comparator|Aerobic Exercise Group|Persons are aerobically exercising.
11380972|NCT02162511|Experimental|ARM A Malignant TBI|Malignant diseases Conditioning including total body irradiation and chemotherapy
11380973|NCT02162511|Experimental|ARM B Malignant Non-TBI|Malignant diseases chemotherapy based conditioning
11381244|NCT02160743|Experimental|CJ-30056 20mg/500mg|fasting, fed
11380976|NCT02162498|No Intervention|Standard of care|Sites from Window of Opportunity program who are not yet receiving the comprehensive feeding buddies program and are only receiving standard of care PMTCT support.
11380977|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler|Single dose of Salmeterol/fluticasone Easyhaler
11380978|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)
11380979|NCT02162485|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
11380980|NCT02162485|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)
11380981|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
11380982|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
11380983|NCT02162459||whey beverage|consumption of 52 grams of whey protein supplement following resistance exercise
11380984|NCT02162459||chocolate milk beverage|consumption of chocolate flavored milk following resistance exercise
11380985|NCT02162446|Experimental|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
11380986|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
11380987|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
11380988|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
11380989|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
11380990|NCT02162420|Experimental|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
11380991|NCT02162420|Experimental|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
11380992|NCT02162407|Experimental|Insulin detemir 60 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
11380993|NCT02162407|Experimental|Insulin detemir 120 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
11380994|NCT02162407|Active Comparator|Human insulin 6 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
11380995|NCT02162394||Referred for Holter monitoring|
11380996|NCT02162381|Experimental|methylphenidate provided|the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
11380997|NCT02162381|Active Comparator|control|control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation
11380998|NCT02162355|Experimental|GLPG0634 in Japanese subjects|Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days
11380999|NCT02162355|Placebo Comparator|Placebo in Japanese healthy subjects|Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days
11381000|NCT02162355|Experimental|GLPG0634 in Caucasian subjects|In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days
11381001|NCT02162355|Placebo Comparator|Placebo in Caucasian healthy subjects|In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days
11381002|NCT02162342||Rehabilitative intervention|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
11381003|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
11381004|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
11381005|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.
~After 8 week follow up visit, Wait-List Group offered meditation program."
11381006|NCT02162316|Active Comparator|H.Pylori eradication therapy|A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
11381007|NCT02162316|Experimental|Motilitone®|30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
11381008|NCT02162303|Experimental|Colchicine|Colchicine 0.6 mg tablets,once daily, for 6 months
11381009|NCT02162303|Placebo Comparator|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment.
11381010|NCT02162290|Experimental|Interval exercise|Exercise bouts in low and high intensities
11381011|NCT02162290|Experimental|Continuous exercise|Exercise continuously with moderate intensity
11381012|NCT02162277||Osteoporosis diagnostic kit|
11381013|NCT02162264||E2020|
11381014|NCT02162251||E2020|
11381015|NCT02162238|Placebo Comparator|purified water|Filtered water Pump water purified by the LSF-filtering device Intervention: Device: LSF-filtering device
11381016|NCT02162238|Experimental|zinc enriched purified water|Zinc water water purified and zinc-enriched by the LSF-filtering device Intervention: Device: LSF-filtering device
11381017|NCT02162225|Experimental|Beet Juice|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.
~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
11381018|NCT02162212|Active Comparator|ADA guideline Instructed|The control intervention will be instruction in basic wellness activities according to the American Diabetes Association guidelines
11381019|NCT02162212|Experimental|Optimized Shoulder Movement Program|"The experimental intervention is the Optimized Shoulder Movement Program. Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation, and active shoulder motion based on the participant's baseline activity count ."
11381020|NCT02162199|Experimental|Debio 1450|Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions
11381021|NCT02162199|Placebo Comparator|Placebo|Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions
11381022|NCT02162173|Experimental|Endoscopy|All patients underwent the same endoscopy.
11381023|NCT02162160|Experimental|Probiotic creme|Women receing probiotic creme
11381024|NCT02162160|Placebo Comparator|placebo|Women receiving a moisturizer
11381025|NCT02162134|Other|no chewing gum.|the no chewing gum group was control and receive no chewing gum postoperatively. While they received all other medications like anesthesia, antibiotics etc
11381026|NCT02162134|Experimental|sugar free chewing gum|sugar free chewing was given to patients 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started.
11381027|NCT02162134|Experimental|sugared chewing gum|sugared chewing gum will be given 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started
11381028|NCT02162121|Experimental|Stimulating catheter|"After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
11381029|NCT02162121|Active Comparator|Non-stimulating catheter|"After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
11381030|NCT02162095||Chronic obstructive pulmonary disease|Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
11381031|NCT02162095||Control|Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
11381032|NCT02162082|Experimental|stent or scaffold|implantation of stents or scaffolds after recanalization of coronary chronic total occlusions
11381033|NCT02162069|Experimental|transcatheter aortic valve replacement|Patients receive transcatheter aortic valve replacement.
11381034|NCT02162056|Experimental|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffold for coronary artery disease.
11381035|NCT02162043||Usability assessment|Patients without any experience with visual field testing will be recruited and tested with different versions of the developed self-test. This will help identify usability features that will make the test user-friendly.
11381036|NCT02162043||Hospital-based clinical trial|The new test will be evaluated on patients attending Manchester Royal Eye Hospital to provide an estimate of its diagnostic performance.
11381037|NCT02162043||Community-based trial|Patients attending Manchester Royal Eye Hospital's outpatient clinics will be recruited to trial the new test on their friends and family in order to evaluate the uptake and performance of the new test in a home environment without any researchers/clinicians presence.
11381038|NCT02162030|Other|Full ACT|Acceptance and Commitment Therapy
11381039|NCT02162030|Other|Modified ACT|Acceptance and Commitment Therapy
11381040|NCT02162017|Experimental|The lying flat intervention|Patients in lying flat intervention to be nursed lying flat (0°) immediately after diagnosis of acute stroke is made and to remain in this position for 24 hours
11381041|NCT02162017|Active Comparator|The sitting-up intervention|Patients in the sitting up intervention to be nursed with their head elevated (≥30°) by raising the head of the bed (or with extra pillows or wedge) immediately after the diagnosis of acute stroke is made, and to remain in this position for the next 24 hours
11381042|NCT02162004|Experimental|Continuous correction|The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
11381043|NCT02162004|No Intervention|Control|Regular sensor-augmented pump therapy.
11381044|NCT02161991|Experimental|aprepitant group|Patients assigned to aprepitant group should receive aprepitant for the control of CINV, aprepitant 125 mg for day1, 80mg for day2 and day3.
11381045|NCT02161991|Placebo Comparator|placebo|Patients assigned to placebo group should receive placebo for the control of CINV compared with aprepitant group.
11381046|NCT02161965|Experimental|Rivaroxaban|"Rivaroxaban (oral tablet) for patients with atrial fibrillation:
~20 mg once daily for patients with GFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml.
~Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
11381047|NCT02161965|Active Comparator|vitamin K antagonists|Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
11381048|NCT02161952|Experimental|Pirfenidone|Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
11381049|NCT02161952|Placebo Comparator|Matched equivalent placebo|Matched equivalent placebo
11381050|NCT02161926|Experimental|obese men from 60 to 70 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
11381051|NCT02161926|Active Comparator|obese men from 30 to 40 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
11381052|NCT02161913|Active Comparator|SCI Education Control Group|The SCIEC condition is a 16-session, highly structured educational intervention that provides information on how SCI affects the body; methods for maximizing function, coping, and living with SCI; and staying healthy with SCI. It also includes general guidelines for improving health behavior. Each SCIEC session follows the same structure, beginning with a presentation of the objectives for the current session and a brief review of material from the previous session before introducing the session's topic and presenting information on one or two key problem areas. SCIEC utilizes a traditional didactic model with information delivered by an expert SCI educator in a classroom or lecture setting.
11381053|NCT02161913|Experimental|Multi-family Group Treatment|The MFG Program uses a structured problem-solving and skills training program to provide participants with SCI and their caregivers with tools and information to improve coping and help family members to connect through positive behavioral exchanges. MFG educators are health professionals with experience in management of SCI, such as physical therapists, recreational therapists, occupational therapists, and psychologists. MFG will last for 16 sessions across 9 months.
11381054|NCT02161900|Active Comparator|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
11381055|NCT02161900|Experimental|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
11381056|NCT02161887||Complementary Medicine Group|Patients receiving chiropractic care, acupuncture, or meditation for chronic pain
11381057|NCT02161887||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management) for chronic pain.
11381058|NCT02161874|Experimental|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
11381059|NCT02161874|Active Comparator|Nanotite certain tapered implant|Nanotite Certain tapered implant
11381060|NCT02161861|Experimental|group cFEE|"The group cFEE will be similarly inseminated with 100000/ml motile spermatozoa and will be supplemented with cFEE 100µM during 18 hours.
~The cFEE will increase the fusiogenic capacities of a gamete,"
11381061|NCT02161861|No Intervention|untreated group|control group
11381062|NCT02161848||Patients|Patients with verified singe large-scale mtDNA deletions and chronic progressive external ophthalmoplegia.
11381063|NCT02161848||Controls|Healthy controls matched for age and gender.
11381064|NCT02161848||Patient group as Controls|Patients with mitochondrial DNA 3243A>G mutations
11381065|NCT02161835|Experimental|Training|Participants exercise 3 times a week, 30 minute, on an ergometer bike.
11381066|NCT02161835|No Intervention|Control|Participants is tested with the 4 objective myotonia test and measurements of self-assessed myotonia by the Myotonia Behavior Scale is collected.
11381067|NCT02161822|Experimental|Simvastatin|single arm : Simvastatin
11381068|NCT02161809|Experimental|Physical Activity Intervention|This arm (10 summer day camps) will receive the Physical Activity intervention the first year and both healthy eating and physical activity the second and thrid years.
11381069|NCT02161809|Other|Healthy EAting Intervention|This arm (10 summer day camps) will receive the Healthy Eating intervention the first year and both healthy eating and physical activity the second and thrid years.
11381070|NCT02161796|Experimental|1: young male subjects|3x single dose of FG-4592 and a placebo
11381071|NCT02161796|Experimental|2: young female subjects|3x single dose of FG-4592 and a placebo
11381072|NCT02161796|Experimental|3: elderly male subjects|3x single dose of FG-4592 and a placebo
11381073|NCT02161796|Experimental|4: elderly female subjects|3x single dose of FG-4592 and a placebo
11381074|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
11381075|NCT02161770|Other|Normal hepatic function|Patients without a history or presence of hepatic disease
11381076|NCT02161770|Other|Mild hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh A
11381077|NCT02161770|Other|Moderate hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh B
11381078|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
11381079|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
11381080|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
11381081|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
11381082|NCT02161744|Experimental|ADSCs administration|Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
11381083|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
11381084|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
11381085|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
11381086|NCT02161718|Placebo Comparator|Placebo + olanzapine|
11381087|NCT02161705|Experimental|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
11381088|NCT02161705|Placebo Comparator|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
11381089|NCT02161692|Experimental|High dose chemotherapy|"Characterized by the following sequence:
~High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin
~1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue"
11381090|NCT02161692|Active Comparator|Conventional dose chemotherapy|Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles
11381092|NCT02161679|Active Comparator|IMMU-132 plus Carboplatin|IMMU-132 infusion and Carboplatin infusion are administered to the participants in this arm of study.
11381093|NCT02161666||Patients|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
11381094|NCT02161666||Controls|Age, sex and BMI-matched healthy controls
11381095|NCT02161653|No Intervention|Prednisone|Prednisone 40 mg daily by mouth during 30 days.
11381096|NCT02161653|No Intervention|Pentoxifylline|Pentoxifylline 400 mg thrice in day by mouth during 30 days
11381097|NCT02161653|Experimental|Prednisone plus metadoxine|Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
11381098|NCT02161653|Experimental|Pentoxifylline plus metadoxine|Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
11381099|NCT02161640||Control|Age/sex matched control participants, not suffering from inflammatory bowel disease or any other chronic inflammatory disease
11381100|NCT02161640||Inflammatory Bowel Disease|Patients with active or remissive inflammatory bowel disease
11381101|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
11381102|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
11381103|NCT02161614|Placebo Comparator|Placebo|Patients will use placebo for 30 days
11381104|NCT02161614|Experimental|Estradiol Valerate|patients will use estradiol valerate 1mg/day during 30 days
11381105|NCT02161601|Experimental|Correctly and incorrectly applied cricoid pressure|
11381106|NCT02161588|Experimental|Semaglutide|
11381107|NCT02161588|Placebo Comparator|Placebo|
11381108|NCT02161575|Experimental|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
11381109|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
11381110|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
11381111|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
11381112|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
11381113|NCT02161536|Experimental|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
11381114|NCT02161536|Experimental|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
11381115|NCT02161536|Experimental|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
11381116|NCT02161510|Experimental|Part I: MK-2248 200 mg (Panel A)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
11381117|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel B)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381118|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel C)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.
11381119|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel D)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381120|NCT02161510|Experimental|Part II: MK-2248 200 mg (Panel E)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
11381121|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel F)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381122|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel G)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381123|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel H)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381124|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel I)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381125|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel J)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
11381126|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
11381127|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
11381128|NCT02161471||Aortic coarctation|Patients after repair of coarctation of the aorta
11381129|NCT02161471||Tetralogy of Fallot|Patients after repair of tetralogy of Fallot
11381130|NCT02161471||TGA atrial switch|Patients with transposition of the great arteries after atrial switch (Senning procedure)
11381133|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
11381134|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
11381135|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
11381136|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
11381137|NCT02161445||AHF group|patients with AHF diagnosed based on clinical, biological and echocardiographic findings. Two sub-groups of patients were identified within HF group: Patients with reduced (<45%) LVEF (HFrEF) and those with preserved (≥45%) LVEF (HFpEF).
11381138|NCT02161445||non AHF group|we included patients with acute dyspnea and for whom acute heart failure was excluded
11381139|NCT02161432|Experimental|Treatment A|single dose of BI 187004 in fasted state
11381140|NCT02161432|Experimental|Treatment B|single dose of BI 187004
11381141|NCT02161432|Experimental|Treatment C|single dose of BI 187004 in fed state
11381142|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
11381143|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
11381144|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
11381145|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
11381146|NCT02161393|Experimental|Physical Activity Intervention|12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
11381147|NCT02161393|Active Comparator|Pulmonary Rehabilitation Programme|6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
11381148|NCT02161380|Experimental|1(Chronic)|injection of scAAV2-P1ND4v2
11381149|NCT02161380|Experimental|2(Acute)|injection of scAAV2-P1ND4v2
11381150|NCT02161380|Experimental|3(Presymptomatic)|injection of scAAV2-P1ND4v2
11381151|NCT02161367|Experimental|Simethicone, OVOL|Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
11381152|NCT02161367|Placebo Comparator|Oral Suspending Vehicle, Ora-Plus|Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
11381153|NCT02161354|Experimental|2mg dose of NTC-510 or placebo|Subjects will be dosed with 2 mg of NTC-510 or placebo.
11381154|NCT02161354|Experimental|4 mg dose of NTC-510 or placebo|Subjects will be dosed as a split dose of 2 mg followed by 2 mg an hour later of NTC-510 or placebo.
11381155|NCT02161354|Experimental|6 mg dose of NTC-510 or placebo|Subjects will be dosed with 6 mg of NTC-510 or placebo.
11381156|NCT02161354|Experimental|2 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 2mg of NTC-510A or placebo
11381157|NCT02161354|Experimental|4 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 4 mg of NTC-510A or placebo
11381158|NCT02161354|Experimental|6 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 6 mg of NTC-510A or placebo
11381159|NCT02161328||ICU patients undergoing a dilatative tracheotomy.|
11381160|NCT02161315||Observation group|Steroid Aromatase Inhibitors
11381161|NCT02161315||Control group|Non-Steroid Aromatase Inhibitor
11381162|NCT02161302|Experimental|Active tDCS|tDCS will be applied in the head of the patients in 20 minute sessions, daily from Monday to Friday for 2 weeks (10 sessions total). The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current.
11381163|NCT02161302|Sham Comparator|tDCS Sham|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
11381164|NCT02161276|Experimental|TNTL capsule and Placebo|3-4 capsules 3 times a day Used before meals
11381165|NCT02161263||Quality of Vision after LASIK surgery|Questionnaire
11381166|NCT02161250|Experimental|Resistant starch|The test beverage consumed has the resistant starch.
11381167|NCT02161250|Experimental|Control|The control beverage uses maltodextrin rather than the resistant starch.
11381168|NCT02161237|Experimental|standard dose group|Oral
11381169|NCT02161237|Experimental|optimized dose group|Oral
11381170|NCT02161224|Experimental|1: FG-4592 in subjects with moderate hepatic impairment|
11381171|NCT02161224|Experimental|2: FG-4592 in healthy subjects|
11381172|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
11381173|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
11381174|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
11381175|NCT02161198|Experimental|Y-75|volunteers receive 3 packages twice a day up to 14 weeks
11381176|NCT02161198|Placebo Comparator|Placebo|volunteers receive 3 packages twice a day up to 14 weeks
11381177|NCT02161185|Other|USL261|
11381178|NCT02161172||Mild traumatic brain injury|Traumatic brain injury patients with Glasgow coma score (GCS) of 13-15.
11381179|NCT02161159||Patients With Urinary Incontinence Due to iOAB|Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
11381180|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
11381181|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
11381182|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
11381183|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
11381184|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
11381185|NCT02161133|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
11381186|NCT02161133|Active Comparator|Health Education|Health education provides didactic information about Gulf War Illness
11381187|NCT02161120|Active Comparator|Traditional rye bread|As part of habitual diet participants are expected to consume 100-200 grams of traditional Finnish rye bread daily
11381188|NCT02161120|Experimental|Low-FODMAP rye bread|As part of habitual diet participants are expected to consume 100-200 grams of low-FODMAP rye bread daily
11381189|NCT02161107|Experimental|Grass-SPIRE 1|Grass-SPIRE regimen 1 given 2 weeks apart
11381190|NCT02161107|Experimental|Grass-SPIRE 2|Grass-SPIRE regimen 2 given 2 weeks apart
11381191|NCT02161107|Placebo Comparator|Placebo|Placebo given 2 weeks apart
11381192|NCT02161094|Experimental|Group 1: Physicians|Give incentives to physicians based on their patient's HbA1c improvement
11381193|NCT02161094|Experimental|Group 2: Diabetic patients|Give incentives to patients based on their own HbA1c improvement
11381194|NCT02161094|Experimental|Group 3: Both Physicians and Patients|Give incentives to both based on the HbA1c improvements from the physicians' patients
11381195|NCT02161094|No Intervention|Group 4: Control group|Receive no incentive but will be provided diabetes education booklet and group education courses for DM control as usual
11381196|NCT02161081|Experimental|Myocardial CT perfusion (21-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 21-second scan duration.
11381197|NCT02161081|Active Comparator|Myocardial CT perfusion (30-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 30-second scan duration.
11381198|NCT02161055|Experimental|Strict control group|"Intensive insulin therapy: Keep Target blood glucose levels between 4.4-7.0 mmol/L;
~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
11381199|NCT02161055|Experimental|Moderate control group|"Intensive insulin therapy: Keep target blood glucose levels between 7.1 and 10.0 mmol/L.
~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours"
11381200|NCT02161055|Experimental|Slight control group|"Intensive insulin therapy: Keep target blood glucose levels between 10.1 and 13.0 mmol/L.
~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
11381201|NCT02161055|Active Comparator|Non-intensive insulin therapy|Rapid blood glucose levels were measured once every 2 hours. When blood glucose levels were ≤ 13.0 mmol/L, no intervention was performed; When blood glucose levels were > 13.0 mmol/L, regular insulin was subcutaneously injected separately. During fasting, insulin was injected once every 8 hours. During venous or enteral nutrition infusion, insulin was infused at 30 minutes before nutrition infusion. When blood glucose levels were ≤ 13.0 mmol/L, insulin infusion was terminated.
11381202|NCT02161042||fresh blood Transfusion|
11381203|NCT02161042||Old blood transfusion|
11381204|NCT02161029|Active Comparator|New drill biopsy instrument|To take biopsies from gastric submucosal tumors with a new drill biopsy instrument used with flexible endoscopes.
11381205|NCT02161029|Active Comparator|Conventional biopsy instrument|To take biopsies from gastric submucosal tumors with conventional biopsy forceps used with flexible endoscopes
11381206|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
11381207|NCT02161003|Experimental|Stem Cells Isolation|"Stem cell isolation technique and Stem Cells Injection Technique The method of isolation of MSC from bone marrow will be carried out using the Ficoll-Paque technique for the isolation of mononucleated cells followed by the separation of MSC by adherence to plastic. Finally, the cells will be resuspended and counted using a hemocytometer.
~Mononucleated cells will be cultured and incubated at 37°C in an atmosphere of 95% relative humidity and 5% CO2."
11381208|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
11381209|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
11381210|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
11381211|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
11381212|NCT02160951|Experimental|LGH447|LGH447, QD
11381213|NCT02160938||3 year follow-up cohort|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.
~At as close to the age of 3 as possible, the following exams will be performed and are described below:
~The Vineland-II Adaptive Behavior Scale (VABS)
~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)
~Children will also be photographed (for review by the study dysmorphologist)"
11381214|NCT02160938||Limited follow-up cohort|Women with children who will not reach the age of 2 years 6 months by the end of our study but have a prenatally diagnosed CNV will be recruited into the limited follow-up study. Each center will describe the study to eligible women and will verbally obtain their permission to be contacted by the Study Follow-up Specialist. The Study Follow-Up Specialist will contact the patient, explain the study, and obtain full written informed consent.
11381215|NCT02160925|Experimental|Preoperative 99mTc-Sestamibi SPECT/CT|
11381216|NCT02160912||Ectoin Mund- & Rachenspray|treatment with Ectoin Mund- & Rachenspray 1%
11381217|NCT02160912||Emser Pastillen|treatment with Emser Pastillen
11381218|NCT02160899|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
11381219|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
11381220|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
11381221|NCT02160899|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
11381222|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
11381223|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
11381224|NCT02160886|Experimental|Child-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the children themselves, using the Swedish version of the Perceived Efficacy and Goal Setting System (PEGS).
~A PEGS interview will be performed with the children. The children identifies tasks they find difficult to perform and prioritize three tasks, they want to perform better, as goals for intervention."
11381225|NCT02160886|Experimental|Parent-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the parents using the Canadian Occupational Performance Measure (COPM).
~Using the COPM interview technique, the parents are encouraged to talk about an ordinary day to identify occupational performance issues their child is not able to perform. Identified performance issues are rated for importance and the parents selects the three most important issues as goals for intervention."
11381226|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
11381227|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
11381228|NCT02160860||Children|Children
11381229|NCT02160847|Experimental|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
11381230|NCT02160847|No Intervention|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
11381231|NCT02160834|Experimental|B-MOBILE smartphone-based intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
11381232|NCT02160834|Experimental|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
11381233|NCT02160834|No Intervention|Control|
11381234|NCT02160821|Experimental|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block TAPB Ultrasound guided TAPB
11381235|NCT02160821|Experimental|Caudal Epidural Block|Caudal Epidural Block Caudal Block Neuraxial Block Ultrasound Guided Caudal Block
11381236|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
11381237|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
11381238|NCT02160782|Experimental|LUM001|LUM001 will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.
11381239|NCT02160782|Placebo Comparator|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
11381240|NCT02160756|Active Comparator|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) softgel capsule on Day 1.
11381241|NCT02160756|Experimental|Treatment B|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
11381242|NCT02160756|Experimental|Treatment C|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
11381243|NCT02160756|Experimental|Treatment D|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
11381246|NCT02160730|Experimental|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
11381247|NCT02160717||Turner Syndrome|Female with Turner Syndrome
11381248|NCT02160717||Healthy Controls|Healthy Female
11381249|NCT02160704|Experimental|Arm 1(IP)|Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks
11381250|NCT02160704|Placebo Comparator|Arm 2 (Placebo)|Placebo capsule 1x daily for 16 weeks
11381251|NCT02160691|Experimental|Anxiety Meter|The Anxiety Meter (experimental) group will receive a real-time display of physiological arousal on the Anxiety Meter during the intervention period in visit #4.
11381252|NCT02160691|No Intervention|No Anxiety Meter|The control group will have the Anxiety Meter during the intervention period, but the marker will not move.
11381253|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
11381254|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
11381255|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
11381256|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
11381257|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
11381258|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
11381259|NCT02160652||Patients|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
11381260|NCT02160639|No Intervention|usual care|usual care includes diabetes self management education
11381261|NCT02160639|Active Comparator|diabetes self management support|diabetes self management support in addition to usual care, which includes diabetes self management education
11381262|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
11381263|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
11381264|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
11381265|NCT02160613|Other|Open flap for periodontitis patients|Open flap debridement
11381266|NCT02160600|Experimental|split bolus|Patients will undergo diagnostic Split bolus DECT scan
11381267|NCT02160600|Experimental|Standard|Patients will undergo routine multiphase diagnostic CT
11381268|NCT02160587|Active Comparator|ZuraPrep|Irritation scores of the following applied to test sites will be compared: ZuraPrep, ZuraPrep without IPA, ChloraPrep, and 0.9% Physiological Saline.
11381269|NCT02160574|Active Comparator|ZuraPrep|ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.
11381270|NCT02160561|Experimental|Intervention Arm|Experimental - Intervention Arm patients who are in critical illness with acute respiratory failure and are mechanically ventilated will be placed in an upright reverse trendelenburg position
11381271|NCT02160548|Placebo Comparator|'Standard care'|Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.
11381272|NCT02160548|Experimental|'Standard care+ 2.5 mg Salbutamol'|Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care
11381273|NCT02160548|Experimental|'Standard care+ 5 mg Salbutamol'|Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care
11381274|NCT02160535|Experimental|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
11381275|NCT02160522||Cuffed ETT|Patients that are intubated with a cuffed endotracheal tube.
11381276|NCT02160509||- The patients who undergo ultrasonography in the ED|
11381277|NCT02160496|Active Comparator|20% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
11381278|NCT02160496|Active Comparator|27% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 27% protein, 30% fat and 43% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
11381279|NCT02160496|Active Comparator|35% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 35% protein, 30% fat and 35% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
11381280|NCT02160483|Experimental|Magnetic resonance imaging|Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis
11381281|NCT02160470|Experimental|Exposure with Retrieval|Exposure Therapy with Retrieval
11381282|NCT02160470|Experimental|Exposure with Compounding|Exposure Therapy with Compound Extinction
11381283|NCT02160470|Experimental|Exposure with Retrieval and Compounding|Exposure Therapy with Retrieval and Compound Extinction
11381284|NCT02160470|Active Comparator|Therapist-Guided Exposure Therapy|Therapist-guided Exposure Therapy
11381285|NCT02160457|Experimental|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis (IGA)
11381286|NCT02160457|No Intervention|Intervention without IGA|'Care as usual' - Individually tailored interdisciplinary interventions based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations BUT NOT (IGA).
11381287|NCT02160444|Experimental|CBT plus Parent as CBT Coach Training|CBT plus Parent as CBT Coach Training
11381288|NCT02160431|Experimental|CBT for pediatric OCD|Participants complete standard CBT for OCD
11381289|NCT02160418|No Intervention|Control|36 Participants will be sent a new toothbrush and will be asked to use it in place of their current brush. They also receive twice daily reminders via sms to brush their teeth.
11381290|NCT02160418|Experimental|Financial Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. They will also be offered financial incentives twice a day to brush their teeth.
11381291|NCT02160418|Experimental|Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
11381292|NCT02160418|Experimental|Financial and Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice daily they receive financial incentives to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
11381293|NCT02160405|Experimental|Normal diet|
11381294|NCT02160392||Endometrial biopsy|HIV + and HIV negative women underwent lower and upper genital tract sampling.
11381295|NCT02160379||post Roux-en-Y-gastric bypass|Formerly obese females 1-5 years after gastric bypass
11381296|NCT02160379||matched controls|non-operated females age-and weight-matched to post Roux-en-Y-gastric bypass subjects
11381297|NCT02160379||healthy young controls|non overweight (BMI between 19 and 25 kg/m2) healthy females
11381298|NCT02160366||Biomarker/Molecular Data Collection and Analyzation|Advanced cancer participants
11381299|NCT02160353|Experimental|Combined hormonal therapy|Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days Prednisolone; 5mg/day (1 tablet orally once a day, concomitant to abiraterone acetate) for 126 days GnRh agonist for 4 injections (at 28 day intervals)
11381300|NCT02160340||Vitreomacular adhesion|Male or female subjects aged over 40 years with vitreomacular adhesion
11381301|NCT02160314|Placebo Comparator|pad|absorbent pad control
11381302|NCT02160314|Experimental|pessary|disposable, single-use pessary
11381303|NCT02160301|Experimental|Multimodal pain control|Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.
11381304|NCT02160301|Active Comparator|Standard pain control|Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.
11381305|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
11381306|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
11381307|NCT02160275|Active Comparator|Open Loop|4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring
11381308|NCT02160275|Experimental|Closed Loop|4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)
11381309|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
11381310|NCT02160249|Experimental|Community-based rehabilitation and facility based care|"Community-based rehabilitation is delivered to participants and their caregivers at their home by a specialist CBR worker. It comprises psychoeducation, adherence support, rehabilitation (including self-care and social skills), family support groups and accessing existing community organisations. It also involves community awareness raising and education and mobilisation of community leaders.
~Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education."
11381311|NCT02160249|Active Comparator|Facility-based care|Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education.
11381312|NCT02160236|Active Comparator|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
11381313|NCT02160236|Active Comparator|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
11381314|NCT02160236|Placebo Comparator|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
11381315|NCT02160223|Experimental|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at the end of surgery
11381316|NCT02160223|Active Comparator|Neostigmine|Group N patients will receive 50 µg kg-1 neostigmine and 05 mg atropin at the end of surgery
11381317|NCT02160210|Experimental|Ultrafine Endoscope|The ultrafine endoscope for colonoscopy with water method is performed in screening the colorectal diseases.
11381318|NCT02160197|No Intervention|No Immobilisation|No immobilisation post op, allowing patients to weight bear as tolerated.
11381319|NCT02160197|Active Comparator|Functional Bracing|Immobilise patients in Functional brace, allowing patients to weight bear as tolerated.
11381320|NCT02160197|Active Comparator|Plaster Immobilisation|Immobilise patients in plaster, allowing patients to weight bear as tolerated.
11381321|NCT02160171||Term neonates|Term neonates who are undergoing continuous video amplified Electroencephalogram (aEEG)/Electroencephalogram (EEG) monitoring for clinical purposes (e.g. because seizures were suspected, or the neonate is being treated with therapeutic hypothermia). EEGs will be analysed off line by 'Algorithm for Neonatal Seizure Recognition'
11381322|NCT02160158|Experimental|Cohort 1|
11381323|NCT02160158|Experimental|Cohort 2|
11381324|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
11381325|NCT02160145|Placebo Comparator|Placebo|Placebo
11381326|NCT02160132|Experimental|A 1-2-3Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
11381327|NCT02160132|Active Comparator|B 1-3-5Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
11381328|NCT02160119||Healthy Controls|
11381329|NCT02160119||Autism Spectrum Disorders|
11381330|NCT02160106|Experimental|TEW-7197|Dose Escalation of TEW-7197: TEW 7191 tablets will be given once daily (QD) or twice daily (BID) for 5 days followed by 2 days without treatment in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
11381331|NCT02160080|Experimental|Boc+Peg-int alfa+Rbv|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
11381332|NCT02160067|Experimental|Treatment A|Second generation patch BTDS 12.6mg
11381333|NCT02160067|Experimental|Treatment B|Second generation patch BTDS 3.15mg
11381334|NCT02160067|Active Comparator|Treatment C|First generation patch BuTrans 20mg
11381335|NCT02160067|Active Comparator|Treatment D|First generation patch BuTrans 5mg
11381336|NCT02160054||Group 1|patients with kidney transplantation who converted the immunosuppressant from cyclosporine to Graceptor ®
11381337|NCT02160041|Experimental|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
11381338|NCT02160028|Active Comparator|Standard information|This group is given anesthetics and standard information before dental treatment about the anesthetics.
11381339|NCT02160028|Experimental|Extended information|This group is given anesthetics and extended information before dental treatment about the anesthetics.
11381340|NCT02160015|Experimental|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11381341|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
11381342|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
11381343|NCT02159989|Experimental|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11381344|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
11381345|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
11381346|NCT02159963|Experimental|Supervised training|8 weeks of high intensity training three times a week, once supervised. Followed by 8 weeks home based, unsupervised optional training.
11381347|NCT02159963|Experimental|Unsupervised training|"Participants have 8 weeks of non-intervention Control period, followed by 8 weeks of home based, unsupervised high intensity interval training."
11381348|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
11381349|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
11381350|NCT02159937||Patients with metastatic cancer|Blood sampling by vena punction.
11381351|NCT02159924||Asymptomatic|
11381352|NCT02159911||200 mcg misoprostol|Misoprostol administered orally one hour before surgery
11381353|NCT02159911||400 mcg misoprostol|Misoprostol administered orally one hour before surgery
11381354|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
11381355|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
11381356|NCT02159885|Experimental|Telemonitoring|In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment.
11381357|NCT02159885|No Intervention|Usual Care|"Subjects in this arm will receive usual care for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure."
11381358|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
11381359|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
11381360|NCT02159846||Test Group and Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
11381361|NCT02159846||Test Group & Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
11381362|NCT02159833|Experimental|Intervention|Intranasal challenge with food protein or vehicle control
11381363|NCT02159820|Active Comparator|DTC Arm|Patients are randomly assigned to receive lower-dose decitabine treatment followed by TC regimen (ie, DTC arm).
11381364|NCT02159820|Active Comparator|TC regimen|Patients were randomly assigned to receive carboplatin plus paclitaxel (ie, TC arm).
11381365|NCT02159807|Active Comparator|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
11381366|NCT02159807|Active Comparator|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
11381367|NCT02159807|Active Comparator|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
11381368|NCT02159794|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
11381369|NCT02159781|Experimental|periodontal treatmnent|
11381370|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
11381371|NCT02159755|Experimental|Treatment (ibrutinib, palbociclib)|Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11381372|NCT02159742||Cohort 1|
11381373|NCT02159729|Placebo Comparator|Placebo|Participants treated with placebo in previous ATX-101 studies
11381374|NCT02159729|Experimental|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm^2) in previous phase 2 studies
11381375|NCT02159729|Experimental|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm^2) in previous phase 2 studies
11381376|NCT02159729|Experimental|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm^2) in previous phase 2 studies
11381377|NCT02159716|Experimental|Metastatic Pancreatic (ductal) adenocarcinoma (PDA)|
11381378|NCT02159716|Experimental|Serious Epithelial Ovarian Cancer|
11381379|NCT02159716|Experimental|Malignant Epithelial Pleaural Mesothelioma|
11381380|NCT02159703|Experimental|Single Arm Phase 2|
11381381|NCT02159677||Healthy Subjects|Healthy subjects aged 21-80 years with no history of present or past disabling back or neck pain, sciatica, cervical radiculopathy, or any generalized neuromuscular condition except for mild polyneuropathy or common mononeuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy at the elbow.) Additionally, subjects cannot have any history of any moderate-to-severe ongoing medical condition producing generalized disability, such as advanced cardiac or renal disease, or metal spine implants of any type.
11381382|NCT02159677||Radiculopathy Subjects|Subjects aged 21-80 years with a history consistent with radiculopathy based on clinical, radiologic, and standard electrophysiological criteria, as determined by spine expert.
11381383|NCT02159677||Musculoskeletal Back Pain Subjects|Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.
11381384|NCT02159677||Undiagnosed Lower Back or Neck Pain Subjects|Subjects aged 21-80 years with a major complaint of lower back or neck pain.
11381385|NCT02159664|Experimental|didgeridoo practice|
11381386|NCT02159651||1: Dermatomyositis group|patients with interstitial pneumonia associated with dermatomyositis
11381387|NCT02159651||2: Polymyositis group|patients with interstitial pneumonia associated with polymyositis
11381388|NCT02159638|Other|comparisson CGM accuracy|Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose
11381389|NCT02159625|Experimental|Abdominal Compression Elastic Support|To compress the abdomen at 15 mmHg for 3 hours during the course of hemodialysis treatment.
11381390|NCT02159612||FSHD|A cohort of adult danish patients with facioscapulohumeral muscular dystrophy is invited to perform a MRI scan.
11381391|NCT02159599|Active Comparator|Darunavir/Ritonavir + 2 nucleos(t)idos|Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
11381392|NCT02159599|Experimental|Darunavir/ritonavir + Lamivudine|Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
11381393|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
11381394|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
11381395|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
11381396|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
11381397|NCT02159534|Experimental|Primebrain|"' Stimulation ' Infants group will receive Primebrain stimulation whose items were selected according to a Delphi process and discussed at the European Academy of Childhood Disability (2013).
~This sensorimotor stimulation programme is administered at home by parents (trained and monitored by a physical therapist), once a day between term-age and 6 months of corrected age.
~In addition, these infants undergo systematic monitoring for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
11381398|NCT02159534|Other|usual care|"Infants in the comparison group receive usual care for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
11381399|NCT02159521|Experimental|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
11381400|NCT02159508|No Intervention|Individualised on-demand counselling|Individualized on-demand counselling group was assigned to receive baseline nutritional counselling, that consisted of one dietetic consultation before (chemo)radiotherapy. During (chemo)radiotherapy on-demand counselling group patients received further counselling only on demand.
11381401|NCT02159508|Experimental|Intensive nutritional counselling|Intensive nutritional counselling consisted of protocolled counselling given by a dietitian once at baseline and on the 2nd and 4th week of treatment and at the end of chemoradiotherapy.
11381402|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
11381403|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
11381789|NCT02156687|Active Comparator|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
11381404|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
11381405|NCT02159456|Experimental|Continuous enteral feeding|Continuous enteral feeding via infusion pump is applied for at least 7 days after the start of enteral feeding
11381406|NCT02159456|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via gravity-based infusion is applied for at least 7 days after the start of enteral feeding.
11381407|NCT02159443||Study Participants|Those who meet eligibility criteria and consent to participate in the study.
11381408|NCT02159430||HereditaryAngioEdema|Patients from the Eastern Sicily HAE register
11381409|NCT02159417|Experimental|Therapeutic Education|Intensive training individual or collective teaching
11381410|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
11381411|NCT02159404||Healthy controls|
11381412|NCT02159391|No Intervention|Usual Intervention|A standard intervention will be performed by nursing staff during hospital admission. Written information about the consequences of driving under the influence of alcohol and/or drugs will be provided. No psychological intervention.
11381413|NCT02159391|Experimental|Brief Motivational Interview|A Brief Motivational Interviewing will be performed during hospital admission by a psychologist experienced with this intervention.
11381414|NCT02159378|Other|GD with Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
11381415|NCT02159378|Other|GD without Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
11381416|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
11381417|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days
~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
11381418|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days
~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
11381419|NCT02159339||gene-methylation|"gene-low-level of methylation: patients with early stage gastric carcinoma containing low-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.
~gene-middle-level of methylation: patients with early stage gastric carcinoma containing middle-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.
~gene-high-level of methylation: patients with early stage gastric carcinoma containing high-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.
~gene-without of methylation: patients with early stage gastric carcinoma NOT containing methylated E-cadherin,GFRA1,p16,SRF or ZNF382 CpG island."
11381420|NCT02159326|Experimental|Arm1|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
11381421|NCT02159326|Experimental|Arm2|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
11381422|NCT02159313|Experimental|BAY63-2521 with Non sparkling water|Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature
11381423|NCT02159313|Experimental|BAY63-2521 with applesauce|Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)
11381424|NCT02159313|Experimental|BAY63-2521 with water|Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)
11381425|NCT02159313|Experimental|BAY63-2521 after breakfast|Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature
11381426|NCT02159300||Patients|Patients with fibromyalgia pain Intervention: experience brain activity recording
11381427|NCT02159300||Healthy Controls|Healthy controls without chronic pain of any type.
11381428|NCT02159287|Experimental|Low molecular-weight heparin|these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.
11381429|NCT02159287|Active Comparator|unfractionated heparin|This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).
11381430|NCT02159274||BCS without oncoplastic techniques|BCS without oncoplastic techniques
11381431|NCT02159274||BCS with oncoplastic techniques|BCS with oncoplastic techniques.
11381432|NCT02159261||Cohort 1|Female patients ≥ 18 years old requiring contraception.
11381433|NCT02159248|Experimental|Tolfenamic acid + gemcitabine + radiation|
11381434|NCT02159235||AIHD-patients (ICD-10 I21)|Patients suffering from acute ischemic heart disease according to ICD-10 I21
11381435|NCT02159235||CIHD-patients (ICD-10 I25)|patients suffering from chronic ischemic heart disease according to ICD-10 I25
11381436|NCT02159222|Experimental|Additional physical therapy|
11381437|NCT02159209||Drug Induced Renal Injury (DIRI)|This is a prospective observational cohort study of patients who have developed acute kidney injury Stage 2 or a glomerular disorder following exposure to specific drugs that have been associated with DIRI.
11381438|NCT02159196|Active Comparator|acetylcysteine and salbutamol|Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
11381601|NCT02158013|Active Comparator|Diltiazem, calcium channel blocker|Diltiazem gel 2% applied twice daily for 8 weeks
11381439|NCT02159196|Experimental|acetylcysteine or salbutamol|"Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.
~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm."
11381440|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
11381441|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
11381442|NCT02159170|Experimental|NGF|injection of 50 µl NGF, once into the left volar forearm and injection of 50 µl NaCl (sodium chloride) once into the right volar forearm
11381443|NCT02159157|No Intervention|Arm A|"Physical Therapy consult for post op care and general physical activity recommendation 1-4 weeks prior to starting chemotherapy.
~Phone calls designed to support the patient to maintain current activity level."
11381444|NCT02159157|Placebo Comparator|Arm B|"Physical Therapy consult for post-op care 1-4 weeks prior to starting chemotherapy.
~Exercise prescription aimed at increasing physical activity by a minimum of 10 MET hours/week.
~Motivational phone calls aimed at encouraging the patient to adhere to their exercise prescription."
11381445|NCT02159144|Experimental|healthy adults|
11381446|NCT02159131|Experimental|OC containing levonorgestrel and ethinyl estradiol + GSK126574|Eligible subjects will enter a run-in-period of 21 days (may extend to 49 days) to stabilize on OC containing levonorgestrel and ethinyl estradiol in order to synchronize the menstrual cycles of multiple subjects. Subjects completing run-in-period will enter Treatment period 1 and will be dosed OC once daily on Days 1 to 10. At day 11 subjects will enter Treatment period 2 and will be dosed with OC containing levonorgestrel and ethinyl estradiol + 744 once daily on Day 12 to 19. Subjects completing Treatment period 2 will have 7 OC free days (Day 22 to 28) during which withdrawal menses should occur. Subjects will then be followed up for 7 to 14 days (Day 28 to 35/49).
11381447|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
11381448|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
11381449|NCT02159105||Women undergoing cesarean delivery|"FAST scan and non-invasive hemoglobin measurement
~Women undergoing cesarean delivery will undergo a non-invasive hemoglobin measurement both before and after surgery. An abdominal ultrasound will be performed to establish normal levels of intra-abdominal fluid after cesarean delivery."
11381450|NCT02159092|Experimental|Contingency Management|Monetary incentives are given for submitting negative saliva cotinine tests.
11381451|NCT02159092|No Intervention|Fixed Rate Control|Fixed amounts of payments are provided for submitting saliva samples
11381452|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
11381453|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
11381454|NCT02159066|Experimental|LGX818 + MEK162|
11381455|NCT02159066|Experimental|LGX818 + MEK162 + LEE011|
11381456|NCT02159066|Experimental|LGX818 + MEK162 + BGJ398|
11381457|NCT02159066|Experimental|LGX818 + MEK162 + BKM120|
11381458|NCT02159066|Experimental|LGX818 + MEK162 + INC280|
11381459|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
11381460|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
11381461|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
11381462|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
11381463|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
11381464|NCT02159027|Placebo Comparator|placebo|placebo identical in appearance to maraviroc 150 and 300 mg tablets will be added to each subjects antiretroviral regimen at doses as recommended by the package insert
11381465|NCT02159027|Experimental|maraviroc|Maraviroc Tablets are available as 150 mg and 300 mg tablets. Each subject will add maraviroc to their current antiretroviral regimen with dosage based on recommendations as per maraviroc package insert
11381466|NCT02159014|Experimental|Phase 1|Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).
11381467|NCT02159014|Active Comparator|Phase 2|Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.
11381468|NCT02159001|Active Comparator|ECT treatment right after recruitment|This group receives electroconvulsive therapy treatment right after they are recruited.
11381469|NCT02159001|Placebo Comparator|ECT after 4 weeks period.|This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
11381489|NCT02158871|Active Comparator|Mental health literacy training|"Mental Health First Aid training consists of twelve hours of standardized, module-based mental health literacy training offered in a group format. It will be offered as 2 full-day training sessions (or four half-day sessions)."
11381600|NCT02158026||infertility without polycystic ovarian syndrome|1000 women with infertility without polycystic ovarian syndrome who are already decided to be treated with ICSI will be recruited
11381743|NCT02157090|Active Comparator|Herpes vesicle patch of Compeed®|
11381470|NCT02158988|No Intervention|without HIPEC|"Preoperative chemotherapy 3 cycles, each cycle 21 days. Patients with negative or unknown HER-2 status receive Epirubicin 50 mg/m² infusion (maximum 100mg/d). Oxaliplatin 130 mg/m² infusion (maximum 260 mg/d) and capecitabine oral 625 mg/m² two times a day (maximum 2500 mg/d).
~Patients with positive HER-2 status receive:
~Cisplatin : 80 mg/m² infusion (maximum of 160 mg/d). Capecitabine: oral 1000 mg/m2 (two times a day maximum of 4000 mg/d), on day 1-14.
~Trastuzumab: 8 mg/kg infusion (on cycle 1 and 6 mg/kg on cycle 2 and 3). CRS is performed and 4-12 weeks after CRS 3 cycles of postoperative chemotherapy have to be applied. In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
11381471|NCT02158988|Experimental|With HIPEC|"Patients will be treated with a preoperative chemotherapy as described for the control group. EOX or CCT depending on the HER-2 status.
~CRS will be performed 2 to 3 weeks after end of last chemotherapy cycle. HIPEC with mitomycin C and cisplatin either at the time of CRS or a delayed HIPEC within 5-7 days.
~HIPEC:
~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.
~Patients may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs can be excluded.
~In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
11381472|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
11381473|NCT02158962|Experimental|Behavioral - Education|"3 Educational Sessions
~Session 1 - Reducing Risk for Intimate Partner Violence (IPV); Session 2 - Reducing risk for Sexually Transmitted Infections including HIV (STI/HIV) Session 3 - A group session which reinforces skills for reducing IPV and STI/ HIV risk reduction."
11381474|NCT02158962|Active Comparator|Behavioral - Education|"3 Educational Sessions
~Session 1 - Breast Health Education and Developing A Breast Cancer Risk Reduction Plan Session 2 - Reducing risk for overweight and obesity and Developing a Healthy Eating and Activity Plan Session 3 - A group session which integrates and reinforces skills from Sessions 1 and 2."
11381475|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
11381476|NCT02158949|No Intervention|Usual Care|Usual care in ED
11381477|NCT02158936|Experimental|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
11381478|NCT02158936|Placebo Comparator|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
11381479|NCT02158923|Experimental|Individualized ventilation|Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
11381480|NCT02158923|Experimental|Individualized vent. + postop. CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed. Postoperatively a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
11381481|NCT02158923|No Intervention|Standard ventilation|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed.
11381482|NCT02158923|Active Comparator|Standard vent. + postoperative CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed. Postoperatively, a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
11381483|NCT02158910||Aricept Group 1|Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
11381484|NCT02158910||Aricept Group 2|Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
11381485|NCT02158897|No Intervention|Control|Participants will consume their normal diet. Body weight and physiological change at two time points (approximately 2-3 months apart) will be examined. The participants will be crossed over to the diet group.
11381486|NCT02158897|Experimental|Prolon Diet|Participants will be provided with a 5-day supply of fasting-mimicking diet, including energy bars, soups, drink packets and dietary supplements. Participants will diet for 3 cycles. Each one-month cycle consists of 5 days of dieting with a calorie intake estimated at 600-1200 calories per day. The rest of the month participants will eat normally. After 3 cycles, participants will be examined again after consuming their normal diet after 2-3 months.
11381487|NCT02158884|Other|IDEO brace|IDEO brace
11381488|NCT02158871|Experimental|Contact-based mental health education|"The Beyond Silence' program is 12 hours in length: six 1.5-2 hour in-person group sessions every other week, plus five online sessions between each of the in-person sessions."
11381557|NCT02158377|Experimental|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
11381490|NCT02158858|Experimental|Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm|"Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi.(CPI-0610 alone)
~Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)"
11381491|NCT02158858|Experimental|Arm 2: Prior JAKi Combination Arm|"Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)
~Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)"
11381492|NCT02158858|Experimental|Arm 3: JAKi Naïve Combination Arm|• Open to patients with MF who are anemic (i.e., Hemoglobin (Hgb) <10g/dL) and who have not previously received a JAKi. (CPI-0610 + Ruxolitinib)
11381493|NCT02158845|Active Comparator|LNG-IUS|LNG-IUS: levonorgestrel intrauterine system
11381494|NCT02158845|Active Comparator|GnRHa|GnRHa: leuprolide
11381495|NCT02158832|Experimental|Acupuncture + Electrical Stimulation|Acupuncture needles are inserted beneath the skin and electrical stimulation applied for 20 minutes.
11381496|NCT02158832|No Intervention|Control|Participants who are randomized to receive no intervention will still receive physical assessment.
11381497|NCT02158819|No Intervention|TKA with standard instrumentation|This arm consists of the Genesis II Total knee implant system or the Legion Primary total knee system with standard instrumentation
11381498|NCT02158819|Active Comparator|Total knee arthroplasty with Visionaire|This arm will consist of the Genesis II Total Knee Implant System or Legion Primary Total Knee System with the Visionaire patient-matched instrumentation
11381499|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
11381500|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
11381501|NCT02158793|Experimental|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
11381502|NCT02158780|Experimental|Scrotal Orchidopexy|Single incision
11381503|NCT02158780|Other|Inguinal Orchidopexy|Double Incision (Standard)
11381504|NCT02158754||Corus CAD (ASGES)|Subjects receiving CorusCAD (ASGES) gene expression test as part of their diagnostic workup for typical and/or atypical symptoms of obstructive coronary artery disease.
11381505|NCT02158754||Control|Matched subjects in the same practice that did NOT receive Corus CAD (ASGES) as part of their diagnostic workup.
11381506|NCT02158741|No Intervention|Usual Primary Care|Usual Primary Care will be received by half the participants during the course of the Study
11381507|NCT02158741|Active Comparator|Home Visits and educational support|Intervention comprised of Home Visits and group educational sessions. Home Visits and will be conducted by Diabetes Education staff in lieu of usual care conducted at the Diabetes clinic. Lifestyle support and educational will be offered in the form of monthly Diabetes Wellness Days offered in the community where nutrition, exercise and support will be given to help improve self-management of diabetes.
11381508|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).
~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
11381509|NCT02158715||Smartphone positioning during Chest compression|
11381510|NCT02158702|Experimental|Pomalidomide and Dexamethasone|"PO pomalidomide 4mg from D1-21 and PO dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.
~PO or IV cyclophosphamide 300mg/m2 on D1, 8 and 15 can be added at the discretion of the treating physician to induce added response under the following circumstances: 1) If there is less than a MR after 3 cycles in the absence of disease progression, or 2) If there is disease progression within the first 3 cycles of Pomalidomide and Dexamethasone treatment.
~Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
11381511|NCT02158689|Active Comparator|human menopausal gonadotropin (hMG)|hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
11381512|NCT02158689|Active Comparator|Letrozole|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
11381513|NCT02158676|Experimental|Prebiotic|6 g/day of prebiotic (fructooligosaccharides) for 15 days.
11381514|NCT02158676|Experimental|Synbiotic|6 g/day of synbiotic (fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019) for 15 days.
11381515|NCT02158676|Placebo Comparator|Placebo|6 g/day of placebo (maltodextrin) for 15 days.
11381516|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
11381517|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
11381518|NCT02158650|Experimental|Video Group|Patients randomized to Group II will be emailed the educational video, pre- and post- knowledge assessments, and patient satisfaction survey with instructions on what order to fill them out. Group II patients will report to the treatment visit and undergo discussion of options and treatment as per standard of care. An additional knowledge assessment survey will be administered to Group II patients after discussion with treating physician.
11381519|NCT02158650|No Intervention|Control Group|Patients randomized to Group I will be come to the clinic for the treatment visit and discuss options and treatment as per standard of care. Pre- and post- discussion knowledge assessments and satisfaction surveys will be administered at the time of the treatment visit.
11381520|NCT02158637||Cancer patients receiving treatment|Patients receiving active treatment for cancer or initiating treatment for cancer in the next 7 days
11381521|NCT02158624|Experimental|Ranibizumab|
11381522|NCT02158611|Other|Lifestyle counseling|
11381523|NCT02158598|No Intervention|wash-out|2 months
11381524|NCT02158598|Experimental|Vitamin D chewable tablet supplementation|A chewable vitamin D tablet containing 1000 IU to be taken once a day for 2 months.
11381525|NCT02158598|Experimental|Vitamin D pill supplementation|A vitamin D pill containing 1000 IU to be taken once a day for 2 months.
11381526|NCT02158585|Placebo Comparator|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
11381527|NCT02158585|Active Comparator|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day, or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
11381528|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
11381529|NCT02158559|Experimental|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
11381530|NCT02158559|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
11381531|NCT02158546|Experimental|ALKS 5461|
11381532|NCT02158546|Placebo Comparator|Placebo|
11381533|NCT02158533|Experimental|High Dose|
11381534|NCT02158533|Experimental|Low Dose|
11381535|NCT02158533|Placebo Comparator|Placebo|
11381536|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
11381537|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
11381538|NCT02158507|Experimental|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
11381539|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
11381540|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
11381541|NCT02158481|Active Comparator|Dietary ingredients: polyphenols and carotenoids|Dietary ingredients: polyphenols and carotenoids
11381542|NCT02158481|Placebo Comparator|Placebo product|Placebo product
11381543|NCT02158468|Active Comparator|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
11381544|NCT02158468|Active Comparator|Postconditioning|4 cycles of postconditioning (30s ischemia, 30s reperfusion) after primary PCI/stenting
11381545|NCT02158468|No Intervention|Control group|Standard infarction treatment without conditioning intervention
11381546|NCT02158455|Experimental|NT SVG grafts|NT SVG randomized for revascularization of left or right coronary territory
11381547|NCT02158455|Active Comparator|RA grafts|RA grafts randomized for revascularization of left or right coronary territory
11381548|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
11381549|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
11381550|NCT02158429|Active Comparator|3 Dimensional ultrasound|an additional 5-10 minutes of ultrasound using three dimensional technique
11381551|NCT02158429|Active Comparator|2 dimensional|an additional 5-10 minutes of ultrasound using standard two-dimensional technique
11381552|NCT02158416||Hematology-oncology|hematology-oncology outpatients requiring platelet transfusion
11381553|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
11381554|NCT02158390|Experimental|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC
~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
11381555|NCT02158390|No Intervention|Community treatment as usual|Children access educational and speech-language interventions available to them through schools and community resources.
11381556|NCT02158377|Active Comparator|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
11381558|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
11381559|NCT02158351||Simple steatosis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
11381560|NCT02158351||Non-alcoholic steato-hepatitis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
11381561|NCT02158338||Asthma|Mothers of children thought to have asthma
11381562|NCT02158338||Non-asthma|Mothers of children without diagnosed respiratory problems
11381563|NCT02158325|Active Comparator|3.0-3.9 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0-3.9 mm in diameter)
11381564|NCT02158325|Experimental|4.0-5.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (4.0-5.0 mm in diameter)
11381565|NCT02158325|Active Comparator|5.1-6.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (5.1-6.0 mm in diameter)
11381566|NCT02158312|Experimental|transcranial direct current stimulation|bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, for 20 minutes
11381567|NCT02158312|Placebo Comparator|sham stimulation|same as the experimental stimulation condition but only for 2 minutes
11381568|NCT02158299|Experimental|Avitene,Drainaging,reexamine|
11381569|NCT02158299|Experimental|Sapylin,Drainaging,reexamine|
11381570|NCT02158299|Active Comparator|Drainaging,reexamine|
11381571|NCT02158286||Esophagectomy, Emptying from gastric tube|Validate paracetamol clearance technique to scintigraphy for measuring emptying rate from the gastric tube.
11381572|NCT02158273|Active Comparator|TRICOR (fenofibrate)|
11381573|NCT02158273|Placebo Comparator|Sugar Pill|
11381574|NCT02158260|Experimental|position changing|During the examination, subjects changed position in the following sequence: left lateral head-down position, supine position, prone head-down position, right lateral head-down position, supine position, left lateral position, prone position, prone hip-high position, right lateral position and sitting position.
11381575|NCT02158260|No Intervention|free position|
11381576|NCT02158247||Conventional group, Touch and Read group|
11381577|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
11381578|NCT02158221|Active Comparator|Migraine patients with high genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
11381579|NCT02158221|Active Comparator|Migraine patients with low genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
11381580|NCT02158208||Patients with HD|
11381581|NCT02158208||Controls|
11381582|NCT02158195||Patients|
11381583|NCT02158195||controls|
11381584|NCT02158182|Experimental|lactulose|
11381585|NCT02158182|Experimental|L-ornithine L-aspartate|
11381586|NCT02158182|Experimental|Rifaximin|
11381587|NCT02158182|Placebo Comparator|Placebo|
11381588|NCT02158156|Experimental|Excercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
11381589|NCT02158143|Experimental|vitamin D3|
11381590|NCT02158130||Healthy Living|non exercise healthy living control group
11381591|NCT02158130||General Health|Exercise Group (8 KKW) One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. We will recruit 1 year post study intervention.
11381592|NCT02158130||Weight Loss|Exercise Group (20 KKW) Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session. We will recruit 1 year post study intervention.
11381593|NCT02158117|Experimental|nasal naloxone|8 and 16 mg/ml, comparator 1 mg/ml. Three daily occasions with at least 3 days washout between treatment (min 8 days).
11381594|NCT02158104||Latent trigger point in the upper trapezius muscle|
11381595|NCT02158091|Experimental|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.
~Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.
~Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
11381596|NCT02158065|No Intervention|Usual care|Patients will receive information (leaflet) and guidance on the benefits associated with increased physical activity in COPD patients and their health status
11381597|NCT02158065|Experimental|Coaching program|In addition to usual care, patients will receive the coaching program
11381598|NCT02158052|Experimental|Transplantation|Single arm combined bone marrow and kidney transplantation
11381599|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
11381602|NCT02158013|Experimental|Levorag, Hibiscus plant extract|Levorag Emulgel applied twice daily for 8 weeks
11381603|NCT02158000|Active Comparator|Group A|In group A , 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles are allocated to receive one tab / 8 hs of Diosmin ( 500mg) beginning from the day of ovum retrieval and for 3 days (till the day of embro trasfer) in addition to aspiration of the fluid by an IUI catheter.
11381604|NCT02158000|No Intervention|Group B|In group B (control group) 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles, no thing will be done
11381605|NCT02157987|Experimental|bevacizumab|bevacizumab spray
11381606|NCT02157974|Experimental|PCOS, medication naive + Byetta|PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
11381607|NCT02157974|No Intervention|Control|Up to 25 girls without PCOS
11381608|NCT02157974|No Intervention|PCOS medication naive|Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
11381609|NCT02157974|No Intervention|PCOS on COCPs|Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
11381610|NCT02157974|No Intervention|PCOS on metformin|Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
11381611|NCT02157961||General Practitioner / Family Physician in German Primary care|
11381612|NCT02157961||Medical Specialists|Working in the ambulatory setting
11381613|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
11381614|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
11381615|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
11381616|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
11381617|NCT02157922|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
11381618|NCT02157922|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
11381619|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
11381620|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
11381621|NCT02157896||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
11381622|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
11381623|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
11381624|NCT02157844||COPD|Subjects with diagnosis of COPD
11381625|NCT02157844||OSA|Subjects with diagnosis of OSA
11381626|NCT02157844||controls|Gender, age, BMI matched controls
11381627|NCT02157831|Experimental|Subjects from UPCC 10903|
11381628|NCT02157818|Active Comparator|midazolam|midazolam IV bolus 0.05ml/kg bolus in 1minute. rescue drug(Midazolam) 1 mg, IV boluses for double blinding setting, we use saline, 0.4 mcg/kg IV bolus in 10 minutes and 0.5 mcg/kg/h, as placebo.
11381629|NCT02157818|Experimental|Dexmedetomidine|"Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.25-0.75 mcg/kg/h for RSS 3-5. Midazolam 1mg bolus IV pro re nata (PRN).
~for double blinding setting, IV bolus 0.05ml/kg bolus in 1minute."
11381630|NCT02157805|Active Comparator|rare beef meat|beef meat cooked during 5 minutes at 55°C
11381631|NCT02157805|Active Comparator|well cook beef meat|beef meat cooked during 30 minutes à 90°C
11381632|NCT02157792|Experimental|Part A|This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.
11381633|NCT02157792|Experimental|Part B|This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.
11381634|NCT02157792|Experimental|Part B2|This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.
11381635|NCT02157792|Experimental|Part C1|This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.
11381636|NCT02157792|Experimental|Part C2|This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.
11381637|NCT02157792|Experimental|Part C3|This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.
11381638|NCT02157779|Experimental|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
11381639|NCT02157779|Active Comparator|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
11381640|NCT02157766|Active Comparator|MNP with Asthma: Mindfulness Based Stress Reduction|
11381641|NCT02157766|No Intervention|MNP w/ Asthma: Wait List Control|
11381642|NCT02157766|Active Comparator|MNP, no asthma - Mindfulness Based Stress Reduction|
11381643|NCT02157766|Active Comparator|MNP, no asthma: Health Enhancement Program|
11381644|NCT02157766|No Intervention|MNP, no asthma - Wait List Control|
11381645|NCT02157766|Active Comparator|Long Term Meditator|
11381646|NCT02157740||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
11381647|NCT02157740||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
11381648|NCT02157740||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
11381649|NCT02157740||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
11381650|NCT02157727||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
11381651|NCT02157727||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
11381652|NCT02157727||Control group, Prior Tele-expertise|
11381653|NCT02157727||Control group, during Tele-expertise|Infants hospitalized in health facilities not performing Tele-expertise while the exposed group use Tele-expertise
11381654|NCT02157714|Experimental|PRX002|PRX002
11381655|NCT02157714|Placebo Comparator|Placebo|Placebo
11381656|NCT02157701|Experimental|Polyherbal capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
11381657|NCT02157701|Placebo Comparator|Placebo capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
11381658|NCT02157688||case|Patient with a folliculitis Decalvans
11381659|NCT02157688||control|Control without folliculitis decalvans
11381660|NCT02157675|Experimental|Polyherbal capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
11381661|NCT02157675|Placebo Comparator|Placebo capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
11381662|NCT02157662||No coronary disease and risk factors >=3|
11381663|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
11381664|NCT02157662||No coronary disease and risk factors 0-1|
11381665|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
11381666|NCT02157649|Experimental|ER Tablet under Fasted Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, to subjects under fasted conditions.
11381667|NCT02157649|Active Comparator|IR Tablet under Fasted conditions|IR Tablet combination tablet of Codeine/Guaifenesin 20mg/400mg administered under fasted conditions as a single tablet every 4 hours during a 12 hour study [three doses]
11381668|NCT02157649|Experimental|ER Tablet under Fed Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, following a standard high-fat breakfast.
11381669|NCT02157636|Experimental|CPI-0610|
11381670|NCT02157623|Experimental|Red Light PDT and Blue Light PDT|The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.
11381671|NCT02157610|Experimental|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
11381672|NCT02157610|Experimental|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
11381673|NCT02157597|Active Comparator|Control Arm|"The control patients will have open display of the NIRS monitor in the OR, but recording without display in the CICU, along with a request to the surgical and intensive teams to react to the data in their usual way. The disparity between the OR and CICU reflect the current opinions of the clinicians in these different environments regarding the necessity of NIRS monitoring within their sphere of practice.
~In this way, continuous recording of cerebral and somatic oximetry will be made in all patients. However for control patients the monitor display will be switched off in the CICU using a pre-programmed research mode, which permits both ongoing recording and also the display of technical error messages (such as inadvertent disconnections or probe displacement)."
11381674|NCT02157597|Experimental|NIRS based management|The trial interventions of NIRS based management consists of provision to the cardiac surgical and intensive care teams of a protocol to guide their interpretation of cerebral and somatic NIRS monitoring and interventions to try in the event of monitored desaturation during the pre- and post-bypass periods (when the circulation is perfused by the beating of the native heart). The investigators believe that there is insufficient data to inform an evidence-based protocol for the bypass phase of surgery, particularly regarding the interpretation of NIRS data under conditions of hypothermia.
11381675|NCT02157584|Experimental|Treatment A|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
11381676|NCT02157584|Experimental|Treatment B|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
11381677|NCT02157571|Experimental|Prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.
~Placebo of levofloxacin hydrochloride tablet, without active components."
11381787|NCT02156700||Liver tumors|Measurement of tumor stiffness by Shear wave elastography - SWE™
11381678|NCT02157571|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.
~Placebo of prulifloxacin film-coated tablet without active components."
11381679|NCT02157558|Experimental|All subjects|All subjects will receive a single oral dose of fexofenadine on Day 1 while fasting. Days 2 to 5 will be Washout days. On Day 6, subjects will begin a 5 day telotristat etiprate regimen. On Day 10 subjects will be given the morning telotristat etiprate dose concomitantly with a single dose of fexofenadine while fasting.
11381680|NCT02157545||pyridostigmine|administration of rocuronium to determine its potency.
11381681|NCT02157545||control arm (no pyridostigmine)|determination of potency of rocuronium in patients not taking pyridostigmine
11381682|NCT02157532|Active Comparator|Best standard treatment|intravenous r-tPA or any other medical management
11381683|NCT02157532|Active Comparator|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
11381684|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
11381685|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
11381686|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
11381687|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
11381688|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
11381689|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
11381690|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
11381691|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
11381692|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
11381693|NCT02157493|Experimental|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
11381694|NCT02157493|Active Comparator|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
11381695|NCT02157480|No Intervention|control|usual follow-up for 6 weeks
11381696|NCT02157480|Experimental|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
11381697|NCT02157480|Experimental|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
11381698|NCT02157467|Experimental|Arm 1: NGMN/EE + BMS-955176|"Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28
~Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)"
11381699|NCT02157454|Experimental|Website access|Two-week access to the colorectal cancer module of the website www.krankheitserfahrungen.de
11381700|NCT02157454|No Intervention|Control|Participants who are randomized to the control group don't have access to the website until they have finished the last questionnaire at 6 weeks follow up.
11381701|NCT02157441|Experimental|all patients|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
11381702|NCT02157428|Placebo Comparator|saline|patients received 20 ml of saline during 1 minute, after end of surgery.
11381703|NCT02157428|Active Comparator|flumazenil|patients received 1 mg of flumazenil, after end of surgery
11381704|NCT02157415|Experimental|Long-term catherized patients|Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
11381705|NCT02157402|Experimental|Intervention Group|The intervention group will received activities and social events designed according 8 social marketing Benchmark criteria to promote healthy lifestyles.
11381706|NCT02157402|No Intervention|Control Group|The control group will not received any intervention activities and social events to promote healthy lifestyles.
11381707|NCT02157389|Experimental|placebo|Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect
11381708|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
11381788|NCT02156687|Active Comparator|Cololast, Inc. Restorell Y mesh|Y mesh
11381709|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
11381710|NCT02157363|Active Comparator|Repositioning Group|The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
11381711|NCT02157363|Experimental|Single positioning|The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.
11381712|NCT02157350|Experimental|Panretinal Laser Photocoagulation|See interventional description.
11381713|NCT02157337|Experimental|atrovastatin|
11381714|NCT02157337|Placebo Comparator|placebo|
11381715|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
11381716|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
11381717|NCT02157311|Experimental|Four consecutive days on treatment and 3 days off|All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
11381718|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
11381719|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
11381720|NCT02157285|No Intervention|Routine Counseling|Subjects randomized to receive routine counseling before selecting a method of contraception
11381721|NCT02157285|Experimental|Peer Mentor counseling|Subjects randomized to receive peer counseling before selecting a method of contraception
11381722|NCT02157272|Experimental|Rivaroxaban|Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
11381723|NCT02157272|Active Comparator|Warfarin|To Keep an INR between 2.0 and 3.0
11381724|NCT02157246|Other|Group A, pimonidazole, no CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole
11381725|NCT02157246|Other|Group B, CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI
11381726|NCT02157233|Experimental|Hot environment|Subjects will perform the intervention in a hot environment (33°C)
11381727|NCT02157233|Sham Comparator|Neutral environment|Subjects will perform the intervention in a neutral environment (22°C)
11381728|NCT02157220|Experimental|Randomised group 1|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
11381729|NCT02157220|Experimental|Randomised group 2|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
11381730|NCT02157207|Placebo Comparator|Placebo|Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
11381731|NCT02157207|Experimental|Antioxidant|"Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.
~of vitamin E."
11381732|NCT02157181|Experimental|HCL, 2CdA +/- Rituximab|"Risk stratification
~HCL variant will be treated with cladribine plus rituximab, independent of previous therapy
~Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is < 3 years.
~All repeated relapses (> 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.
~Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion
~Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is > 3 years.
~Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection"
11381733|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
11381734|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.
~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
11381735|NCT02157155|Experimental|Intervention|Insulin reduction and mimic infection with LPS
11381736|NCT02157155|No Intervention|Control|Normal insulin and no LPS
11381737|NCT02157142|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
11381738|NCT02157129|Experimental|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
11381739|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
11381740|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
11381741|NCT02157103|Experimental|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
11381742|NCT02157090|Active Comparator|Herpes Patch SOS (Hansaplast®)|
11381744|NCT02157077|Experimental|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
11381745|NCT02157051|Experimental|Arm 1 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 1 injection ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
11381746|NCT02157051|Experimental|Arm 2 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/M2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
11381747|NCT02157051|Experimental|Arm 3 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 3 injections ID every 28 days for 3 months. Patients may also receive 2 additional booster STEMVAC vaccines at 3 and 9 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
11381748|NCT02157051|Experimental|Arm 4 (STEMVAC)|Patients receive CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine with rhuGM-CSF as 2 injections ID every 28 days for 3 months. Patients may also receive 1 additional STEMVAC vaccine at 3 months after the third vaccine in the absence of unacceptable toxicity or disease progression.
11381749|NCT02157038|Experimental|Procedures|RNA/DNA blood sample will be collected. Participant will complete questionnaires, MRI and strength and reflex testing.
11381750|NCT02157025|Experimental|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
11381751|NCT02157025|Active Comparator|Usual Care|Usual care procedures for Humphrey perimetry in young children
11381752|NCT02157012|Experimental|The condition of rheumatoid arthritis|
11381753|NCT02156999|Experimental|Osteoporosis|
11381754|NCT02156986||9 month old infant|
11381755|NCT02156986||12 month old infant|
11381756|NCT02156986||18 month old toddler|
11381757|NCT02156986||24 month old toddler|
11381758|NCT02156986||36 month old toddler|
11381759|NCT02156973|No Intervention|Group One Usual care|Patients attending for CT coronary angiography all receive an information leaflet with their appointment letter, and a brief verbal description of the scan by the radiographer immediately before it is undertaken, as standard care. All patients attending will be offered the opportunity to complete a short questionnaire (until all patients are recruited - anticipated to be 4 weeks). The Speilberger State-Trait Anxiety Index has been abbreviated and validated for use in outpatient settings to gauge levels of pre-procedural anxiety. This will be undertaken on arrival and repeated immediately before the scan, to see if patients feel better prepared after the standard interaction with staff.
11381760|NCT02156973|Experimental|Group Two Video information|The patient video will be introduced to Group Two once Group One has been completed. In addition to the information sheet these patients (again, for four weeks or until recruitment is complete) will be sent an internet hyperlink to its presence on YouTube (video-sharing website) and the Hospital website with their appointment letter. Patients who do not have internet access will be offered the opportunity to see the video in the preparation room while waiting for their scan. Questionnaires will be administered as before, again done twice to examine any late impact of the information on patient anxiety, and the patient will undergo their test.
11381761|NCT02156960|Experimental|Denosumab and/or teriparatide treatment|Denosumab and/or teriparatide treatment in osteoporotic patients
11381762|NCT02156947||Chronic cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
11381763|NCT02156947||Acute cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
11381764|NCT02156934|Experimental|Muscle derived stem cell|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
11381765|NCT02156921|No Intervention|Control group|Self-guided training without app-based training (written hand-outs)
11381766|NCT02156921|Active Comparator|Intervention group|Self-guided training with app-based training
11381767|NCT02156908|Experimental|D-serine|D-serine
11381768|NCT02156882||TB patients and Tb suspects|Patients with confirmed tuberculosis who are treated by the National TB Programme
11381769|NCT02156869|Experimental|Intervention arm|The intervention was the use of a decision aid.
11381770|NCT02156869|No Intervention|Control arm|Usual care
11381771|NCT02156856||Hemodynamic optimisation|
11381772|NCT02156856||No hemodynamic optimisation|
11381773|NCT02156843|Experimental|Pyridorin|Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
11381774|NCT02156843|Placebo Comparator|Placebo|Placebo Oral Capsule taken BID (twice daily, every 12 hours)
11381775|NCT02156817||Late Preterm Infants (LPT)|34 weeks and 0-6 days gestational age
11381776|NCT02156817||Moderate preterm infants (MPT)|32 weeks and 0-6 days gestational age
11381777|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
11381778|NCT02156791|Experimental|gpASIT+TM|
11381779|NCT02156778|Active Comparator|Extended Standard Care (Stroke Card)|
11381780|NCT02156778|Active Comparator|Standard Care|
11381781|NCT02156752|Experimental|ACT|Behavioral weight loss plus techniques from Acceptance and Commitment Therapy
11381782|NCT02156752|Active Comparator|SR|Behavioral weight loss plus self-regulation techniques
11381783|NCT02156752|Active Comparator|WLO|Behavioral weight loss plus cooking tips and demonstrations
11381784|NCT02156739|Experimental|Diagnostic (contrast-enhanced MRI)|Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.
11381785|NCT02156726||Low dose FCR in Elderly/Comorbid CLL|low dose FCR
11381786|NCT02156713|Experimental|CIMT Camp|Members of this study will participate in the group CIMT camp.
11381790|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
11381791|NCT02156661|Active Comparator|Oxytocin|"Oxytocin: Syntocinon-Spray, Novartis
~intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT"
11381792|NCT02156661|Placebo Comparator|Placebo|Placebo nasal spray
11381793|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
11381794|NCT02156635|Experimental|Active tdcs / CIMT|Participants in the acute post-stroke stage will receive active tDCS associate to rehabilitation (CIMT)
11381795|NCT02156635|Sham Comparator|Sham stimulation / CIMT|Participants in the acute post-stroke stage will receive sham stimulation associate to rehabilitation (CIMT)
11381796|NCT02156622||Depression Care Manager|All enrolled in AIM 3 received decision support from Depression Care Manager
11381797|NCT02156609|Experimental|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
11381798|NCT02156596|Active Comparator|Intravenous NSAI|patients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
11381799|NCT02156596|Experimental|Nebulised Morphine|patients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
11381800|NCT02156583||Older, left ventricular assist device|Older heart failure patients undergoing left ventricular assist device implantation
11381801|NCT02156570|Experimental|Sofosbuvir and ribavirin|"Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily
~Treatment will be for 6 weeks in all participants."
11381802|NCT02156557|Experimental|peptide application|"Investigational Agent Administration
~KCCFPAQ-GGGSK-(5-FITC)-NH2
~1.2 mg lyophilized powder per single-use amber vial
~Lyophilized powder reconstituted with 10 mL of 0.9% NaCl
~Final concentration of 76.4 μM for single, one-time topical application
~The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)"
11381803|NCT02156544|Experimental|CKD-519 25mg|CKD-519 25mg or placebo
11381804|NCT02156544|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
11381805|NCT02156544|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
11381806|NCT02156544|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
11381807|NCT02156544|Experimental|CKD-519 400mg|CKD-519 400mg or placebo
11381808|NCT02156531|Placebo Comparator|Attention Control Condition|3.c.14.5. Arm 1: Attention Control Condition. The minimally effective attention-control group procedure is identical to the active CBM procedure except that during the presentation of the trials where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. Thus, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active versions of CBM in Arms 2 and 3.
11381809|NCT02156531|Experimental|Arm 2: Self-administered CBM only|3.c.14.6. Arm 2: Self-Administered CBM Only. Youth assigned to this arm will receive the self-administered active CBM intervention. As described above in detail, in the 80% of CBM trials where a neutral and disgust face are both presented, the probe always replaces the neutral face. Thus, participants are trained to disengage their attention from threat. These youth do not receive Adherence Promotion telephone calls.
11381810|NCT02156531|Experimental|Arm 3: Self-administered CBM + Adherence Promotion|3.c.14.7. Arm 3: Self-Administered CBM + Adherence Promotion. Youth assigned to this arm will receive both the self-administered active CBM intervention and the telephone coach calls to deliver the Adherence Promotion (AP) procedures. AP procedures are intended to compensate for the important nonspecific 'scaffolding' provided by research staff when CBM has been traditionally delivered in laboratories. This includes technical assistance with use of the program, support/encouragement, motivational enhancement, and brainstorming solutions to barriers to regular sessions. The addition of AP to the 3rd arm of this trial attempts to recreate much of this nonspecific, yet likely important, support of in-person interventions, which we hypothesize will lead to greater participant adherence to the program and therefore better clinical outcomes.
11381811|NCT02156518|Experimental|Vocal Function Exercises|Vocal Function Exercises
11381812|NCT02156518|Active Comparator|Vocal hygiene|Vocal hygiene
11381813|NCT02156505|Experimental|DoubleBare stent|Placement of double bare stent
11381814|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
11381815|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
11381816|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
11381817|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
11381818|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
11381819|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
11381820|NCT02156479||Allo-HSCT recipients|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive
11381821|NCT02156466|Experimental|MSB0010841 30 mg|
11381822|NCT02156466|Experimental|MSB0010841 60 mg|
11381823|NCT02156466|Experimental|MSB0010841 120 mg|
11381824|NCT02156466|Experimental|MSB0010841 240 mg|
11381825|NCT02156466|Placebo Comparator|Placebo|
11381826|NCT02156453||Total knee arthroplasty|Patients undergoing uncomplicated total knee replacement
11381827|NCT02156440|Placebo Comparator|Placebo|Placebo capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
11381954|NCT02155673|Experimental|High Dose GCS-100|GCS-100 High dose
11381828|NCT02156440|Experimental|SierraSil Joint Formula 14|SierraSil Joint Formula 14 capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
11381829|NCT02156427|Experimental|VITICELL|In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
11381830|NCT02156427|Placebo Comparator|PLACEBO|In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
11381831|NCT02156414||Clinically Localized Prostatic Neoplasm|Radical Prostatectomy Extended Lymphadenectomy
11381832|NCT02156401||Cohort 1: Suspect of Pulmonary Embolism (PE)|
11381833|NCT02156401||Cohort 2: Suspect of Deep Vein Thrombosis (DVT)|
11381834|NCT02156401||Cohort 3: Incidental Venous Thromboembolism (VTE)|
11381835|NCT02156388|Experimental|Ia-GW003 50μg/kg|2-3 subjects
11381836|NCT02156388|Experimental|Ia-GW003 150μg/kg|2-3 subjects
11381837|NCT02156388|Experimental|Ia-GW003 300μg/kg|3-6 subjects
11381838|NCT02156388|Experimental|Ia-GW003 400μg/kg|3-6 subjects
11381839|NCT02156388|Experimental|Ia-GW003 500μg/kg|3-6 subjects
11381840|NCT02156388|Experimental|Ia-GW003 600μg/kg|3-6 subjects
11381841|NCT02156388|Experimental|Ib-GW003 150μg/kg|6-8 subjects
11381842|NCT02156388|Experimental|Ib-GW003 300μg/kg|6-8 subjects
11381843|NCT02156375|Experimental|Ustekinumab 90 mg/mL|
11381844|NCT02156375|Experimental|Ustekinumab 5 mg/mL|
11381845|NCT02156362|Other|follow up|
11381846|NCT02156349|Other|Control Group|Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
11381847|NCT02156349|Other|Intervention group|"Patients are treated according to the concept Integrated personalized diabetes management."
11381848|NCT02156336|Placebo Comparator|PLACEBO|"500 mg PLACEBO PO 2 times a day for 1 week (Week 1)
~1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
11381849|NCT02156336|Active Comparator|RANOLAZINE|"500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)
~1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
11381850|NCT02156323|Experimental|Treatment Sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
11381851|NCT02156323|Experimental|Treatment Sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
11381852|NCT02156297||Induction Group|
11381853|NCT02156297||Consolidation Group|
11381854|NCT02156297||Salvage Group|
11381855|NCT02156297||Maintenance Group|
11381856|NCT02156297||Alleviatitive Group|
11381857|NCT02156284|Experimental|Empathic behaviour by nurses|Patients who received empathic behaviour was performed by a trained nurse.
11381858|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
11381859|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
11381860|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
11381861|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
11381862|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
11381863|NCT02156245|Experimental|"Conventional group"|
11381864|NCT02156245|Experimental|"Combined group"|
11381865|NCT02156232|Active Comparator|TIPS,Emboliaztion|The covered stents were used for TIPS The SPSS will be embolized during the procedure of TIPS
11381866|NCT02156232|Active Comparator|TIPS alone|The covered stents were used for TIPS No embolization of SPSS will be performed during TIPS
11381867|NCT02156219||Under separation|Exposure to the separation of women and men in the metro of Mexico City.
11381868|NCT02156219||No treatment|Non exposure to the separation of women and men in the metro of Mexico City.
11381869|NCT02156206||123 women line|Women who call the 123 emergency line and have also immediate services from the 123 women emergency line
11381870|NCT02156206||No treatment|Women who call the 123 emergency line and do not have immediate services from the 123 women emergency line
11381871|NCT02156193|Experimental|Prophylactic clip|Before conventional snare polypectomy, hemoclips will be applied on the base of stalk.
11381872|NCT02156193|Active Comparator|No prophylactic management|Conventional snare polypectomy will be performed without any preventive management.
11381873|NCT02156180||Early stage oral cavity / oropharyngeal cancer|Exhaled breath
11381874|NCT02156167|Experimental|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
11381875|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
11381876|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
11381877|NCT02156141|Experimental|Supervised high intensity training|"8 weeks of supervised high intensity training, 10 minutes, 3 times a week (once a week supervised) on a cycle ergometer followed by 8 weeks of unsupervised optional training.
~Participants: Patients with Kennedy's disease or healthy control subjects (individually matched with patients).
~Participants: Patients with Kennedys disease and healthy control subjects."
11381878|NCT02156141|Experimental|Unsupervised High intensity training|"8 week control period with no training followed by 8 weeks of unsupervised high intensity training on a cycle ergometer.
~Participants: Patients with Kennedy's disease."
11382025|NCT02155244||CBDS|treated with ERCP combined with surgery
11381879|NCT02156128|Experimental|Cogmed|Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
11381880|NCT02156128|Active Comparator|Control group|These subjects will participate in the vocational rehabilitation program for 3,5 weeks. The program includes cognitive therapy (ACT) and physical activity, but no working memory training.
11381881|NCT02156115||healthy volunteers|healthy volunteers
11381882|NCT02156115||lymphatic patients|lymphatic patients
11381883|NCT02156115||relatives|relatives
11381884|NCT02156102||Microbiome with active leg ulcer|We will recruit and obtain microbiome samples from male or female adult participants with active leg ulcers and sickle cell disease. The total sample size will be no more than 250.
11381885|NCT02156102||Microbiome with no active leg ulcer|We will recruit and obtain mircobiome samples from male or female adult participants without active leg ulcers but do not have sickle cell disease. The total sample size will be no more than 250.
11381886|NCT02156102||non-microbiome participants|We will recruit but not obtain microbiome samples from participants with sickle cell disease
11381887|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
11381888|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
11381889|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
11381890|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
11381891|NCT02156063|Experimental|NT100|NT100 Dose 1
11381892|NCT02156063|Placebo Comparator|Placebo|Placebo
11381893|NCT02156050|Active Comparator|OBLOO device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
11381894|NCT02156050|Experimental|BBLOO Device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
11381895|NCT02156037|Experimental|dashboard team care intervention|Dashboard team
11381896|NCT02156037|Active Comparator|usual diabetes team control|usual clinical diabetes team with no access to the diabetes dashboard
11381897|NCT02156024|Placebo Comparator|placebo|placebo drink, 1 dose at a time, twice a day, duration: 4 weeks
11381898|NCT02156024|Active Comparator|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
11381899|NCT02156011||Instrumented knee implant|"4-6 subjects with an instrumented TKA, that has been implanted within the study Kniemessprothese: Belastungsmessung bei Patienten mittels einer instrumentierten Knie-Endoprothese (EA4/069/06) approved and conducted at the Charité- Universitätsmedizin in Berlin, Germany, will be involved in this project."
11381900|NCT02155998||PREVENT study patients|Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation.
11381901|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
11381902|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
11381903|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
11381904|NCT02155972|Active Comparator|Bifidobacterium infantis|Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily
11381905|NCT02155972|Placebo Comparator|Placebo|Placebo capsule once daily
11381906|NCT02155959||one group|one group receiving a toric intraocular lens during cataract surgery.
11381907|NCT02155946|Experimental|Arm 1|Group receives active brain stimulation plus memory rehabilitation
11381908|NCT02155946|Sham Comparator|Arm 2|Group receives sham brain stimulation plus memory rehabilitation
11381909|NCT02155946|Active Comparator|Arm 3|Group receives active brain stimulation plus reminiscence training
11381910|NCT02155946|Active Comparator|Arm 4|Group receives sham brain stimulation plus reminiscence training
11381911|NCT02155933||Hyperandrogenemia|Peripubertal girls with hyperandrogenemia
11381912|NCT02155933||Controls|Peripubertal girls without hyperandrogenemia
11381913|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
11381914|NCT02155907||Rtest, Atrial fibrillation|Patients with ischemic stroke or TIA within the last week. Sinus rhythm on the surface ECG. Age ≥ 60 years. Given written informed consent
11381915|NCT02155894|Experimental|Disease control, Telemedicine, doctor|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a doctor at week 13, 26, 39.
11381916|NCT02155894|Experimental|Disease control, Telemedicine, nurse|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a nurse at week 13, 26, 39.
11381917|NCT02155894|No Intervention|Usual care|Usual care: control of disease activity with consultations in the outpatient clinic.
11381918|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
11381919|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
11381920|NCT02155868|Experimental|Intervention|"Cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C.
~Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it."
11382026|NCT02155231||previous enrolled|
11381921|NCT02155868|Placebo Comparator|Control|Only cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C during cardiac surgery and the first six hours after it.
11381922|NCT02155855|Experimental|Telemedicine|"Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit."
11381923|NCT02155855|Active Comparator|Control|Control Subjects will continue routine care which requires blood glucose testing at least 4 times a day. Parents will use customary ways to communicate (pager, email, fax or phone) with the Diabetes team, if they are concerned about glycemic control..
11381924|NCT02155842|Experimental|High intensity endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume high intensity endurance exercise, followed by 6 months non-supervised endurance exercise
11381925|NCT02155842|Active Comparator|Moderate continuous endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume moderate intensity endurance exercise, followed by 6 months non-supervised endurance exercise
11381926|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks
~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
11381927|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks
~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
11381928|NCT02155816|Placebo Comparator|Placebo|MCT (medium chain triglyceride)
11381929|NCT02155816|Experimental|Omega 3|Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.
11381930|NCT02155816|Experimental|Omega 7 + 3|210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3
11381931|NCT02155803|Experimental|Sarcoidosis related Calcium Dysregulation|Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
11381932|NCT02155790|Experimental|Renal Denervation by Neurolysis|Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
11381933|NCT02155777|No Intervention|No intervention|No intervention.
11381934|NCT02155777|Active Comparator|OrthoNovum 1/35|OrthoNovum 1/35
11381935|NCT02155764|Experimental|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
11381936|NCT02155764|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
11381937|NCT02155764|Active Comparator|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
11381938|NCT02155751|Experimental|Full NELIP group|"These women (n=10) will receive the full NELIP intervention and will be introduced to both the dietary program and the exercise program as described above under detailed description."
11381939|NCT02155751|Experimental|Exercise program only/ELIP|These women (n=10) will only be given the exercise component (ELIP) of NELIP, as outlined below in interventions. Once dietary intake has been assessed, this group will not be given any dietary intervention but will be encouraged to eat a healthy, balanced diet. Access to the nutritionist in the clinic is available and encouraged.
11381940|NCT02155751|Experimental|Nutrition program only/NLIP|These women (n=10) will only be given the nutrition program (NLIP) of NELIP as outlined below in intervention. They will be encouraged to be more active but will not be given an exercise intervention.
11381941|NCT02155751|No Intervention|Control|A control group (n=30) of obese pregnant women will also be recruited and will be matched by pre-pregnancy BMI, maternal age and parity, with no intervention, but will attend the clinic for standard obstetric care and follow-up.
11381942|NCT02155738|Placebo Comparator|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
11381943|NCT02155738|Experimental|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
11381944|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
11381945|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
11381946|NCT02155712|Active Comparator|Triathlon Tritanium Knee|Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
11381947|NCT02155712|Active Comparator|Triathlon Knee|Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
11381948|NCT02155699|Experimental|Exercise 1|65% of V02 Max, 3x per week, 3 months
11381949|NCT02155699|Experimental|Exercise 2|85% of VO2 Max, 2x per week, 3 months
11381950|NCT02155699|No Intervention|Waitlist|Waitlist (three months)
11381951|NCT02155686|Experimental|Biosensors|Participants in this arm are equipped both with home telecare/automation and with biometric sensors
11381952|NCT02155686|Active Comparator|Automation|Participants in this arm are equiepd with home automation only
11381953|NCT02155673|Experimental|Low Dose GCS-100|Low dose of GCS-100
11381955|NCT02155660|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
11381956|NCT02155660|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
11381957|NCT02155660|Experimental|Benralizumab Arm C|Benralizumab administered subcutaneously
11381958|NCT02155660|Placebo Comparator|Placebo|Placebo administered subcutaneously
11381959|NCT02155647|Experimental|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
11381960|NCT02155647|Experimental|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
11381961|NCT02155634|Experimental|Lenalidomide|Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
11381962|NCT02155634|No Intervention|Observation|Observation until disease progression. Long term follow-up 5 years post last patient randomized.
11381963|NCT02155621|Experimental|Genome Sequencing|There is only one arm to this study.
11381964|NCT02155608|Experimental|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
11381965|NCT02155608|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
11381966|NCT02155595||500 with BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
11381967|NCT02155595||500 without BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed
11381968|NCT02155582|Experimental|Arm 1|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients
11381969|NCT02155582|Experimental|Arm 2|45 mg and 60 mg for the diabetic patients
11381970|NCT02155569|Active Comparator|Transperitoneal Cesarean|
11381971|NCT02155569|Active Comparator|Extraperitoneal Cesarean|
11381972|NCT02155556||Healthy volunteers|
11381973|NCT02155543|Experimental|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
11381974|NCT02155543|Experimental|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
11381975|NCT02155543|Experimental|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
11381976|NCT02155543|Experimental|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
11381977|NCT02155543|Placebo Comparator|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
11381978|NCT02155543|Experimental|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
11381979|NCT02155543|Placebo Comparator|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
11381980|NCT02155530|Experimental|High efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
11381981|NCT02155530|Active Comparator|Low efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
11381982|NCT02155517|Experimental|Propofol Infusion|"Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..
~The study will make in two stages:
~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
~STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
11381983|NCT02155504|Experimental|ASP3700 single ascending dose cohort|Part 1
11381984|NCT02155504|Placebo Comparator|Placebo single ascending dose cohort|Part 1
11381985|NCT02155504|Experimental|ASP3700 alone|Part 2
11381986|NCT02155504|Active Comparator|ASP3700 and itraconazole|Part 2
11381987|NCT02155491||Prospective cohort 1|In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
11382027|NCT02155231||New Enrolled|
11382068|NCT02154932|Active Comparator|double dose misoprostol|2 doses, 3 and 1 hours, prior surgery (group B, 35 cases).
11381988|NCT02155491||Prospective cohort 2|In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
11381989|NCT02155478|Other|AMO ZCB00|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
11381990|NCT02155478|Active Comparator|ISERT 250|ISERT 250 (HOYA, Japan): a standard IOL
11381991|NCT02155465|Experimental|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.
~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
11381992|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
11381993|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
11381994|NCT02155439|Active Comparator|Triamcinolone|kortikosteroid
11381995|NCT02155439|Active Comparator|5-fluorouracil|antimitotic drug
11381996|NCT02155426||Treatment|Treatment: Chemotherapy or targeted therapy
11381997|NCT02155400|Experimental|Prototype development|10 patients (this phase will be terminated once prototype is confirmed ready) Intervention: prototype device
11381998|NCT02155400|Active Comparator|Treatment arm - Prototype|- 18 patients Intervention: Prototype device (heating both sole of foot and popliteal fossa with compression)
11381999|NCT02155400|Active Comparator|Control arm - Forced Air Warming Blanket|18 patients Intervention: Forced air warming blanket (Bair hugger)
11382000|NCT02155400|Active Comparator|Comparison - Sole of foot only|9 patients heating sole of foot only Intervention: prototype device
11382001|NCT02155400|Active Comparator|Comparison - Popliteal fossa only|9 patients heating popliteal fossa only Intervention: prototype device
11382002|NCT02155387||Coronary artery bypass graft surgery|with cardiopulmonary bypass
11382003|NCT02155387||Pulmonary metastasectomy by thoracotomy|with one lung ventilation
11382004|NCT02155387||Minimal invasive mitral valve surgery|with cardiopulmonary bypass and one lung ventilation
11382005|NCT02155374|Active Comparator|Sliding scale insulin|Sliding scale insulin Glucose 7.8-12 mmol/l --> 2 IU insulin, glucose 12.1-17 mmol/l --> 4 IU insulin, glucose ≥17.1 mmol/l --> 6 IU insulin. In case of insufficient control, insulin doses will be increased
11382006|NCT02155374|Experimental|Intermediate acting insulin|Intermediate acting insulin, 0.01 IU / mg prednison / kg body weight with a maximum of 0.5 unit insulin per kg body weight. In case of age > 70 years or diminished renal function (GFR <30ml/min)
11382007|NCT02155361|Active Comparator|Topical Citrullus colocynthis fruit oil|Topical Citrullus colocynthis fruit oil (1%) 1 cc twice daily
11382008|NCT02155361|Placebo Comparator|Placebo (Vehicle)|Topical vehicle oil 1 cc twice daily
11382009|NCT02155348|Active Comparator|Multifocal group|Bilateral cataract surgery with implantation of multifocal IOLs
11382010|NCT02155348|Active Comparator|Monovision|Bilateral cataract surgery with monovision
11382011|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
11382012|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
11382013|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
11382014|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
11382015|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
11382016|NCT02155296|Experimental|Schools receiving RPI|"This arm contains schools receiving RPI. RPI offers a continuum of practices that range from informal (e.g., using affective statements that communicate feelings) to formal (e.g., hosting a restorative circle where participants are encouraged to express emotions and form emotional bonds). The circles or group meetings that are designed to take place between school staff and students, are the crux of RPI. School staff are encouraged to use the restorative practices to build relationships and resolve staff issues (restorative staff community), as well as when interacting with parents (restorative approach with families). All restorative practices encourage acting with youth and setting high expectations. When a school becomes proficient in all 11 essential practices it is officially recognized as a Restorative Practices School."
11382017|NCT02155296|Experimental|Schools not receiving RPI|This arm is the control arm and consists of schools that are not receiving RPI.
11382018|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
11382019|NCT02155270|Active Comparator|Precut|A corneal precut of 600µm will be performed.
11382020|NCT02155270|Active Comparator|Stab incision|A stab incision without corneal precut will be performed.
11382021|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
11382022|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
11382023|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
11382024|NCT02155244||Common bile duct stones|Common bile duct stones traeted with ERCP
11382028|NCT02155218|Active Comparator|Standard Injection Rate|Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size, given at an injection rate of 2 - 2.5 cc/second.
11382029|NCT02155218|Experimental|Patient Tailored Injection Rate|"Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the contrast - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves. The injection rate will vary from 1 to 3 cc/second."
11382030|NCT02155205|Experimental|Telotristat etiprate|Single dose of telotristat etiprate followed by a 7-day washout.
11382031|NCT02155205|Active Comparator|Moxifloxacin|Single dose of moxifloxacin followed by a 7-day washout.
11382032|NCT02155205|Placebo Comparator|Placebo|Single dose of placebo with a 7-day washout to follow.
11382033|NCT02155192||Cohort 1|Participants who participated in NCT01483599 (X-PLORE) study.
11382034|NCT02155192||Cohort 2|Participants who participated in NCT00267969 (PHOENIX 1) study.
11382035|NCT02155192||Cohort 3|Participants who participated in NCT00307437 (PHOENIX-2) study.
11382036|NCT02155192||Cohort 4|Participants who participated in NCT00454584 (ACCEPT) study.
11382037|NCT02155179||Good prognosis|Sperm samples >15mill/ml >30% progresive sperms
11382038|NCT02155179||bad prognosis|Sperm samples <5mill/ml <5% progresive sperms
11382039|NCT02155166|Active Comparator|intracervical anesthesia|Intracervical anesthesia with lidocaine 2%
11382040|NCT02155166|Active Comparator|ibuprofen|ibuprofen 400 mg
11382041|NCT02155153|Experimental|Sugar Free Chewing Gum|All patients receiving sugar free gum
11382042|NCT02155153|No Intervention|Control|Patients receiving no intervention
11382043|NCT02155140|Active Comparator|Jejunal feeding|Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
11382044|NCT02155140|No Intervention|No jejunal feeding|No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks
11382045|NCT02155127|Experimental|walking intervention|Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
11382046|NCT02155127|No Intervention|usual care|these subjects receive information on walking program, however do not receive any coaching over 12 weeks
11382047|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
11382048|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
11382049|NCT02155088|Experimental|Combination Therapy: BYL719, Gemcitabine, (Nab)-Paciltaxel|Dose escalation, followed by expansion, of BYL719 in combination with Gemcitabine and (Nab)-Paclitaxel. BYL719: once daily. Gemcitabine: Days 1,8, 15 of 28-day cycle. (Nab)-Paclitaxel: Days 1,8, 15 of 28-day cycle.
11382050|NCT02155075|Experimental|Arm 1|"Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant.
~All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI."
11382051|NCT02155075|Experimental|Arm 2|Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
11382052|NCT02155062|Experimental|Whole grain rye|3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
11382053|NCT02155062|Experimental|Whole grain wheat|3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
11382054|NCT02155062|Placebo Comparator|Refined cereal|No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
11382055|NCT02155049|Experimental|Prostaglandin Analogues|The patients will receive a single daily drop of bimatoprost for six months.
11382056|NCT02155036|No Intervention|Usual care|Usual care
11382057|NCT02155036|Active Comparator|Exercise|exercise intervention
11382058|NCT02155023|Experimental|Insulin dosing and glucose sensors|To test the glucose sensors different levels of glycemia are needed. To provoke different glycemic levels the following intervention will be performed: Lunch (with fast glucose absorption characteristics) will be served. Up to 30 minutes after the usual insulin dosing time, the subjects will take his/her lunch dose of insulin adjusted to the chosen lunch plus additional approximately 25% (in the range of 0-50% according to the discretion of the Investigator) of insulin - in order to provoke moderate postprandial hypoglycaemia with glucose values < 70 mg/dl.
11382059|NCT02155010|Experimental|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
11382060|NCT02155010|Active Comparator|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
11382061|NCT02154997||Type 1 and Type 2 Diabetes|pregnant women which have a known condition of type 1 or type 2 diabetes
11382062|NCT02154997||Gestational diabetes|pregnant women which have developed Gestational diabetes
11382063|NCT02154997||Control group|Pregnant women whom do not suffer from any altered glucose metabolism
11382064|NCT02154984|Experimental|Behavioral (time restricted diet)|Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
11382065|NCT02154971||Patients|HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
11382069|NCT02154932|Active Comparator|single dose Misoprostol|intra-vaginal single dose of 400 microgram Misoprostol 1 hour pre-operatively (group A, 34 cases)
11382070|NCT02154919||complete revascularization group|this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
11382071|NCT02154919||conservative pharmacotherapy group|patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
11382072|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
11382073|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
11382074|NCT02154893|Experimental|Device and exercise|Device with ultrasound and laser associated with therapeutic exercise
11382075|NCT02154893|Experimental|Device|Device with ultrasound and laser
11382076|NCT02154893|Placebo Comparator|Placebo|Without any treatment
11382077|NCT02154880||HIV positive under 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
11382078|NCT02154880||HIV negative under 50 yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
11382079|NCT02154880||HIV positive over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
11382080|NCT02154880||HIV negative over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
11382081|NCT02154867|Experimental|Fecal transplantation|Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
11382082|NCT02154867|Placebo Comparator|Placebo fecal transplantation|Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.
11382083|NCT02154854|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.
~Drug: Tacrolimus targeted half-dose"
11382084|NCT02154854|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
11382085|NCT02154841|Experimental|Questionnaire, taste test, visual food test|The participants will complete a questionnaire that asks them about their taste preferences. They will also will be shown photos of various food stuffs and asked to choose their preferred meal. They will also be asked to put five sponge sticks (a single use item commonly used for mouth care) dipped in one of a five different liquids into their mouths and give their comments what each taste was and on how much they enjoyed it. These five liquids represent the four well-described tastes (sweet, sour, salty, bitter) and a more recently proposed taste, savoury. The intention of this part of the trial is to assess the patient's ability to detect alteration in pure taste and to identify if any of these tastes are preferred.
11382086|NCT02154828||Integrative practices|"Children included in this project are children 3 to 6 years with diagnosis F84.0 F84.1 according to CIM-10.
~these children must be supported in care units that meet the criteria defined integrative practices."
11382087|NCT02154815||PPT|Patients with a pre-emptive kidney transplantation from deceased or living donors
11382088|NCT02154815||PDT|Patients who have experienced a pre-transplant dialysis period of less than 36 months
11382089|NCT02154802|Experimental|video: community member|Participant watches video of a community member
11382090|NCT02154802|Experimental|video: physician|Participant watches video of a physician
11382091|NCT02154802|Experimental|video: choice of video|Participant can choose to watch video of either the community member of the physician
11382092|NCT02154802|No Intervention|no video|
11382093|NCT02154789|Experimental|polidocanol|
11382094|NCT02154789|Active Comparator|cryotherapy|
11382095|NCT02154789|Active Comparator|infra-red coagulation|
11382096|NCT02154776|Experimental|LEE011 + buparlisib + letrozole|open label, dose escalation evaluating max tolerated dose of the triple combination
11382097|NCT02154763|Placebo Comparator|Intraperitoneal Normal Saline|Intraperitoneal Normal Saline: 100mL (Milliliter) normal saline administered as in intervention arm
11382098|NCT02154763|Experimental|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (Milliliter) (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL (Milliliter) of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
11382099|NCT02154750|Active Comparator|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
11382100|NCT02154750|Experimental|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled
11382101|NCT02154737|Experimental|erlotinib and gemcitabine|"Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg
~Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle."
11382102|NCT02154724|Other|aDBS|The aDBS (adaptive Deep Brain Stimulation) device is applied both in aDBS and in DBS modality, for two hours in random order for two days. The aDBS can be programmed to deliver aDBS controlled by local fields potential or conventional DBS.
11382103|NCT02154711||Mitochondrial Disease|Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease
11382104|NCT02154711||Unaffected|Healthy individuals, without mitochondrial disease
11382105|NCT02154698|Active Comparator|22-gauge Standard Needle|Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)
11382580|NCT02151656|Experimental|F17464|Oral administration - During 6 weeks - 4 capsules daily
11382106|NCT02154698|Active Comparator|22-gauge ProCore Needle|Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)
11382107|NCT02154685|Other|Retrieval-Extinction: Smoking Cues|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
11382108|NCT02154685|Other|Non-Retrieval Extinction: Neutral Cues|This is the group that will not receive retrieval-extinction training and will be exposed to neutral cues.
11382109|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
11382110|NCT02154659|Other|postprandial reflux group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
11382111|NCT02154659|Other|normal group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
11382112|NCT02154646|Experimental|LY2157299 + Gemcitabine|150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days without study drug (28 day cycle.) Gemcitabine 1000 milligram per square meter will be administered intravenously (IV) on Days 8, 15, and 22 in each cycle (28 day cycle). Participants may continue to receive treatment until discontinuation criteria are met.
11382113|NCT02154633|Experimental|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
11382114|NCT02154633|Active Comparator|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
11382115|NCT02154620|No Intervention|Plaster cast|The patient will be treated in a dorsal plaster cast for 4 weeks following the injury to the wrist
11382116|NCT02154620|Experimental|Volar plate|The patient will undergo surgery to the injured wrist with a Synthes Two-column plate (TCP) with a volar approach. Cast will be worn 2 weeks after surgery.
11382117|NCT02154607|No Intervention|Symptomatic treatment|Symptomatic analgetic Treatment only was performed without any Manipulation of OLP lesions.
11382118|NCT02154607|Active Comparator|CO2-Laser Treatment|CO2-Laser Vaporisation was performed of OLP lesions under local anaesthesia.
11382119|NCT02154594|Experimental|Acacia|Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days
11382120|NCT02154594|Active Comparator|Chlorhexidine gluconate|Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days
11382121|NCT02154594|Placebo Comparator|Distilled water|Rinse with 10 ml distilled water twice daily for 15 days.
11382122|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
11382123|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
11382124|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
11382125|NCT02154555|No Intervention|no debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During all three postoperative visits, no debridement will be performed.
11382126|NCT02154555|Experimental|debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During the one week postoperative visit, the randomized unilateral debridement will be performed. Debridement includes removing any crust or mucous in the nose. During the one month and three month visit, the PI will only examine the nose.
11382127|NCT02154542|Active Comparator|Experimental A|NAVA then standard mode
11382128|NCT02154542|Active Comparator|Experimental B|Standard mode then NAVA
11382129|NCT02154529|Experimental|Phase 1b, Arm 1|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 150mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
11382130|NCT02154529|Experimental|Phase 1b, Arm 2|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 250mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
11382131|NCT02154529|Experimental|Phase 1b, Arm 3|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 300mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
11382132|NCT02154529|Experimental|Phase 1b, Arm 4|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 350mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
11382133|NCT02154529|Experimental|Phase 1b, Arm 5|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 400mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
11382134|NCT02154529|Experimental|Phase 2a, Group 1|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive breast cancer and brain metastases that have progressed after radiation therapy.
11382135|NCT02154529|Experimental|Phase 2a, Group 2|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive metastatic breast cancer who do not have brain metastases, or who have asymptomatic brain metastases, or who have minimally symptomatic brain metastases that do not require immediate radiation therapy or neurosurgery.
11382155|NCT02154490||S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382136|NCT02154529|Experimental|Phase 2a, Group 3|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will be limited to those with HER2-positive metastatic breast cancer with pathologically confirmed leptomeningeal metastases with or without brain metastases. Brain metastases do not have to have progressed after radiation therapy in this group.
11382137|NCT02154516|Active Comparator|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:
~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem
~OXINIUM heads on polyethylene liners or
~Ceramic heads on ceramic liners (all uncemented components)"
11382138|NCT02154516|Experimental|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:
~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem
~R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)
~R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)
~Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
11382139|NCT02154503|Experimental|Microneedling|"By randomization, the side for treatment will be determined. Topical anaesthetic will be then placed onto the treatment area under occlusion for thirty minutes to one hour. This will then be removed with 70% alcohol. The area will be rolled with microneedles in two planes: coronally and sagitally. In each plane, five passes will be made. Patients will restart application of Minoxidil the following day to both sides of the lesion.
~The same half of the scalp will be treated for the rest of the sessions, with topical anaesthetic applied by patient 30 minutes to an hour prior to start of treatment session. Patients will undergo microneedling on alternate weeks for a total of six treatments in 12 weeks. If there is >30% growth seen after six weeks, then the entire area will be treated."
11382140|NCT02154490||S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
11382141|NCT02154490||S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
11382142|NCT02154490||S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
11382143|NCT02154490||S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382144|NCT02154490||S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
11382145|NCT02154490||S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382146|NCT02154490||S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11382147|NCT02154490||S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
11382148|NCT02154490||S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11382149|NCT02154490||S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382150|NCT02154490||S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
11382151|NCT02154490||S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382152|NCT02154490||S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
11382153|NCT02154490||S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
11382154|NCT02154490||S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
11382156|NCT02154490||S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11382157|NCT02154490||S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11382158|NCT02154477|Active Comparator|diabetes|All patient will receive insulin at one visit and saline at another visit
11382159|NCT02154477|Active Comparator|control|All patient will receive insulin at one visit and saline at another visit
11382160|NCT02154464|Active Comparator|Paracetamol|
11382161|NCT02154464|Placebo Comparator|Placebo|
11382162|NCT02154438|Experimental|ketamine|ketamine 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
11382163|NCT02154438|Placebo Comparator|Placebo|normal saline 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
11382164|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
11382165|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
11382166|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
11382167|NCT02154399|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection.
11382168|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
11382169|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
11382170|NCT02154360|Experimental|Aprepitant|"Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days.
~6 participants will be receiving an antiretroviral regimen containing atazanavir/ritonavir (300/100 mg) daily plus two other antiretrovirals.
~6 participants will be receiving an antiretroviral regimen containing darunavir/ritonavir (800/100 mg) daily plus two other antiretrovirals."
11382171|NCT02154347|Experimental|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
11382172|NCT02154347|Other|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
11382173|NCT02154334|Experimental|Cohort 1|One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
11382174|NCT02154334|Experimental|Cohort 2: Sequence 1|One Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A) and pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 2 (Treatment C).
11382175|NCT02154334|Experimental|Cohort 2: Sequence 2|Pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1 (Treatment C) and 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 2 (Treatment A).
11382176|NCT02154321||Attention Deficit Hyperactivity Disorder|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
11382177|NCT02154321||Healthy Control|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
11382325|NCT02153385|Experimental|Yoga group|Two yoga sessions per week for 8 weeks
11382178|NCT02154308|Experimental|IL-YANG influenza vaccine|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
11382179|NCT02154295|Active Comparator|Eagle Eye Platinum|Eagle Eye Platinum Catheter as the comparator.
11382180|NCT02154295|Active Comparator|Revolution|Revolution Catheter as the comparator
11382181|NCT02154295|Active Comparator|TVC Insight 40MHz|TVC Insight as comparative catheter.
11382182|NCT02154295|Active Comparator|Atlantis Pro|Atlantis Pro catheter as comparator
11382183|NCT02154282|Experimental|ipod games|Administered ipod games with cognitive testing before and after
11382184|NCT02154269|Experimental|G-CSF|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
11382185|NCT02154269|Placebo Comparator|Saline|Subjects will be randomly assigned to receive saline for five days, during 4 cicles.
11382186|NCT02154256|Experimental|Increasing incentives|The investigators will offer incentives to users that begin low, and get higher over time.
11382187|NCT02154256|Experimental|Decreasing incentives|The investigators will offer incentives to users that start high, and decrease over time.
11382188|NCT02154256|Experimental|Stable incentives|The investigators will offer incentives that stay stable over time.
11382189|NCT02154256|No Intervention|Usual care control|The investigators will offer incentives that are identical to the incentives normally offered by the investigators' partner company.
11382190|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
11382191|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
11382192|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
11382193|NCT02154230|Experimental|sulphate-bicarbonate-calcium water and low-calorie diet (SW-D)|"Experimental arm: Those patients assigned to this interventional arm of the study will be asked to follow a low-calorie diet. For the first 12 weeks, the diet will cover only basal metabolism expenditure ± 10%. At the end of this 12 weeks, for the following 12 weeks, patients will follow a maintenance diet which will cover both basal metabolism and physical activity expenditure. Patients will be invited to maintain the same level of physical activity preceding enrollment throughout the entire study period. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
11382194|NCT02154230|Active Comparator|tap water and low-calorie diet (TW-D)|Active comparator: Those patients assigned to this interventional arm of the study will be asked to follow the same low-calorie diet of the experimental arm. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Rome tap water at room temperature.
11382195|NCT02154217|Experimental|Bimatoprost|once daily
11382196|NCT02154217|Experimental|Latanoprost/Timolol|once daily
11382197|NCT02154191|Experimental|Surgical Intervention Group|The Surgical Intervention Group will undergo the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
11382198|NCT02154191|No Intervention|Non-Intervention Group (Control)|No Intervention.This group will consist of patients wait listed for surgery but further back in the queue.
11382199|NCT02154178|Experimental|Biomarker group|"Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.
~Biomarker group"
11382200|NCT02154178|No Intervention|Control group|Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).
11382201|NCT02154165|Active Comparator|Blue light wavelenght 460 nm|
11382202|NCT02154165|Active Comparator|Turquoise light wavelength 499 nm|
11382203|NCT02154152|Experimental|Homoeopathic Medicine Causticum|The drug namely Causticum 200C potency shall be administered as 4 globules, prescribed once a week for 3 months with placebo to follow for the remaining period.
11382204|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
11382205|NCT02154126|Other|Accuracy assessment|
11382206|NCT02154113|Active Comparator|Velashape II device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
11382207|NCT02154113|Active Comparator|Ultrashape|The UltraShape Contour I V3 uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
11382208|NCT02154100|Experimental|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
11382209|NCT02154100|Placebo Comparator|Placebo|12 weeks tart cherry juice taken in two doses of 240 ml per day.
11382210|NCT02154087|Experimental|HP802-247|
11382211|NCT02154074|Active Comparator|N1 group: Isoflurane & saline|for normal patients: inhale Isoflurane + the same volume of saline during operation
11382212|NCT02154074|Experimental|N2 group: Isoflurane & Dexmedetomidine|for normal patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
11382213|NCT02154074|Active Comparator|D1 group: Isoflurane & saline|for diabetes patients: inhale Isoflurane + the same volume of saline during operation
11382214|NCT02154074|Experimental|D2 group: Isoflurane & Dexmedetomidi|for diabetes patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
11382215|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
11382216|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
11382217|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
11382218|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
11382219|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
11382220|NCT02154035||Group 1|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
11382221|NCT02154035||Group 2|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
11382222|NCT02154022||1|Patients with cancer who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
11382223|NCT02154009||Healthy Volunteers|Volunteers will be studied for Fellows to practice and gain normative values for pupillometric function.
11382224|NCT02154009||Patients|Referred patients with known or suspected abnormalities of one or more components of the autonomic nervous system
11382225|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Placebo|Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation
11382226|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Colchicine|Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation
11382227|NCT02153983|Experimental|Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine|Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.
11382228|NCT02153983|No Intervention|Evaluation Only Non-obese Adults|Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
11382229|NCT02153983|No Intervention|Evaluation Only Obese Adults Not Randomized|Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.
11382230|NCT02153983|No Intervention|Evaluation Only Adults with Type 2 Diabetes|Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
11382231|NCT02153957|Experimental|1|Enhanced PA home intervention group for the first 12weeks; followed by 12 weeks of PA maintenance ontheir own.
11382232|NCT02153957|Active Comparator|2|Usual physical activity (no intervention) for 12 weeks;followed by the enhanced PA home intervention for 12 weeks.
11382233|NCT02153944|Experimental|1|Methylphenidate
11382234|NCT02153944|Placebo Comparator|2|Placebo
11382235|NCT02153931||Volunteers|Parents of children with NF1
11382236|NCT02153918|Experimental|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
11382237|NCT02153905|Experimental|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
11382238|NCT02153905|Experimental|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
11382239|NCT02153892|Other|Multi-center, prospective, single-arm study|To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
11382240|NCT02153879|Experimental|Fenofibrate|Fenofibrate 145 mg/day for 12 weeks
11382241|NCT02153879|Experimental|Niacin plus Laropiprant|Niacin 2g/day plus Laropiprant for 12 weeks
11382242|NCT02153866|Placebo Comparator|rotavirus|vaccinate one dose rotavirus vaccine for each of 700 participants aged 8~9months
11382243|NCT02153866|Placebo Comparator|measles-rubella|vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8~9 months.
11382244|NCT02153866|Placebo Comparator|measles-mumps-rubella|vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8~9 months.
11382245|NCT02153866|Experimental|rotavirus, measles-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8~9 months.
11382246|NCT02153866|Experimental|rotavirus, measles-mumps-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8~9 months.
11382247|NCT02153853||Rectal cancer|Patients undergoing laparoscopic surgery for rectal cancer at the Department of Gastrointestinal Surgery, Hvidovre Hospital, Copenhagen, Denmark.
11382248|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule|PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
11382249|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule low dose group|PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
11382250|NCT02153840|Placebo Comparator|placebo|Placebo granule 1.1g os once a day for 12weeks.
11382251|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
11382252|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
11382253|NCT02153814|Sham Comparator|Control|Will undergo sham procedure twice
11382254|NCT02153814|Experimental|One Endometrial Scratch Procedure|Will undergo one sham procedure and one endometrial scratch procedure
11382255|NCT02153814|Experimental|Two Endometrial Scratch Procedures|Will undergo endometrial scratch procedure twice
11382256|NCT02153801|Active Comparator|Low Inferior Mesenterci Artery Ligation|The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
11382326|NCT02153385|No Intervention|Control group|Usual level of physical activity; no involvement in any yoga practice during the course of the study
11382257|NCT02153801|Other|High Inferior Mesenterci Artery Ligation|"For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.
~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
11382258|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
11382259|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
11382260|NCT02153775|Experimental|Progressive muscle relaxation|Progressive muscle relaxation: single 20-minutes session
11382261|NCT02153775|No Intervention|Reading newspaper of the day|Reading newspaper of the day : single 20-minutes session
11382262|NCT02153762|Experimental|Right side|Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.
11382263|NCT02153762|Active Comparator|Left first|Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.
11382264|NCT02153749|Experimental|Cognitive Regulation of Craving|Training in craving regulation component of Cognitive Behavioral Therapy(CBT) for addictions.
11382265|NCT02153749|Experimental|Mindfulness-Based Regulation of Craving|Training in craving regulation component of Mindfulness Based Therapy(MBT) for addiction.
11382266|NCT02153749|No Intervention|No training control|No training sessions will be provided in this arm.
11382267|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
11382268|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
11382269|NCT02153723|Experimental|Copaxone|"Dose escalation:
~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
11382270|NCT02153710|Experimental|Phonomotor therapy|Experimental group
11382271|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
11382272|NCT02153697|Experimental|Pigmanorm Cream, Q-switched Ruby laser,solar lentigines|Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.
11382273|NCT02153684||Mild COPD, symptomatic|Smokers fitting GOLD 1B criteria for COPD
11382274|NCT02153684||Mild COPD, asymptomatic|Smokers fitting GOLD 1A criteria for COPD
11382275|NCT02153684||Symptomatic smokers, at risk for COPD|Smokers who do not meet spirometric criteria for COPD
11382276|NCT02153684||Healthy, non-smoking controls|Non-smokers, matched to smoking groups for age (>40 yrs of age) and gender
11382277|NCT02153671|Experimental|Primed with H5N2|Subjects who received A(H5N1) inactivated influenza vaccine as well as primed with H5N2 live attenuated influenza vaccine approximately 1.5 years before
11382278|NCT02153671|Active Comparator|Did not receive A(H5N2)|Subjects who received A(H5N1) inactivated influenza vaccine and did not receive A(H5N2) live attenuated influenza vaccine in a previous study.
11382279|NCT02153658|No Intervention|Arm 1|Subjects followed the current hygiene instructions, standard washing in a shower with soap.
11382280|NCT02153658|Active Comparator|Arm 2|Subjects cleaned the foreskin with soapy water using a syringe once a day.
11382281|NCT02153658|Active Comparator|Arm 3|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
11382282|NCT02153645|Experimental|240mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 240mg daily for 12 weeks post two week titration phase.
11382283|NCT02153645|Experimental|320mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 320mg daily for 12 weeks post a two week dose titration phase.
11382284|NCT02153645|Placebo Comparator|Placebo tablets|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 16 weeks.
11382285|NCT02153632|Experimental|240mg amantadine HCl ER tablets|amantadine HCl ER, 240 mg tablets, once daily, 22 weeks
11382286|NCT02153632|Experimental|320mg amantadine HCl ER tablets|amantadine HCl ER, 320 mg tablets, once daily, 22 weeks
11382287|NCT02153632|Placebo Comparator|Placebo Tablets for Amantadine|Placebo, tablets, once daily, 26 weeks.
11382288|NCT02153619|Experimental|Meaning-Centered Grief Therapy (MCGT)|Part 1: Open Trials. Participants (n = 5 for Step 1 & n = 5 for Step 2) will receive 16 1-hour (approx) weekly sessions MCGT, & all therapy sessions will be audio recorded. Will make every effort to complete 16 sessions in 16 weeks, due to normal life activities, this is considered an approximation (i.e. there may be weeks where sessions don't take place &/or weeks where more than 1 session takes place in a week). If participant provides us with permission, we will also video record the sessions. Assessments will be administered at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). They will provide their feedback about MCGT & the measures. PI will review the open trial sessions to help refine the MCGT manual & treatment integrity forms. Sessions for Step 1 participants in Part 1 will be held at the MSK Counseling Center. Sessions for Step 2 participants in Part 1 will be conducted via videoconferencing.
11382327|NCT02153372|Experimental|BMC2012|The large bone defect was then be bridged as per clinical standard, filled with a clinically established scaffold (ß-TCP), and 1.3 x106/ml BMC were loaded per 1 ml ß-TCP in situ.
11382355|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
11382581|NCT02151656|Placebo Comparator|Placebo|Oral administration - During 6 weeks - 4 capsules daily
11382289|NCT02153619|Experimental|MCGT or Supportive Psychotherapy|Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation & therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, & d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
11382290|NCT02153606|Active Comparator|Glycerin Suppository|
11382291|NCT02153606|Sham Comparator|Sham Suppository|
11382292|NCT02153593|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
11382293|NCT02153593|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
11382294|NCT02153593|Active Comparator|Usual hemostasia|Electrocauterization
11382295|NCT02153580|Experimental|Treatment (lymphodepletion,cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of, and not limited to, any of the following agents: cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide. CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T cells >= 28 days post T cell infusion.
~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
11382296|NCT02153580|Experimental|Treatment (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of, and not limited to, any of the following agents: cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide. CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.
~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
11382297|NCT02153567|Placebo Comparator|Control (Placebo) group|"Identical looking placebo (once daily)
~Double blinding of study medication is achieved by repacking Escitalopram 5mg and 10mg as blue and green capsules respectively.. Identical appearing placebos packed in blue and green capsules will be used for the control group."
11382298|NCT02153567|Experimental|Escitalopram|Escitalopram 5mg & 10mg daily
11382299|NCT02153554|Experimental|Trained|Training civil servants in Medellin (Colombia) on attention to violence against women.
11382300|NCT02153554|No Intervention|Non trained|
11382301|NCT02153541|Placebo Comparator|Mineral oil|For those participants who receive mineral oil placebo, we do not anticipate any change in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
11382302|NCT02153541|Active Comparator|Antipyrine-benzocaine otic solution|Will be used on 50% of participants.
11382303|NCT02153528|Active Comparator|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
11382304|NCT02153528|Experimental|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
11382305|NCT02153515|Experimental|Fingerprick of autologous blood (FAB)|Fingerprick of autologous blood (FAB) four times a day for 2 months
11382306|NCT02153502|Experimental|AVP-786|
11382307|NCT02153502|Placebo Comparator|Placebo|
11382308|NCT02153489|Experimental|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
11382309|NCT02153489|Placebo Comparator|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
11382310|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
11382311|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
11382312|NCT02153463|Experimental|Activity Counselling|Physical Activity Counselling weekly for 8 weeks
11382313|NCT02153463|No Intervention|Standard Care|Standard care with no change in medications for 8 weeks
11382314|NCT02153450|Experimental|Treatment (stereotactic radiosurgery, metformin hydrochloride)|"Patients receive metformin hydrochloride PO daily or BID on days -11 to -1. Patients then undergo stereotactic radiosurgery 5 days a week for 5 weeks and receive concurrent metformin hydrochloride* PO BID for 5 weeks. Patients undergo laparotomy on week 6 (or weeks 5-7). Systemic therapy continues as soon as it is considered feasible by the treating physicians.
~*NOTE: Metformin hydrochloride should be stopped 2 days before laparotomy."
11382315|NCT02153437|Experimental|Arm A: BMS-919373|BMS-919373 oral Solution/tablet single dose for one day
11382316|NCT02153437|Active Comparator|Arm B: Sotalol|Sotalol oral Tablet single dose for one day
11382317|NCT02153437|Placebo Comparator|Arm C: Placebo for BMS-919373|Oral solution/tablet one single dose for one day
11382318|NCT02153424||NVAF patients in Mexico treated with Apixaban|All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
11382319|NCT02153411||8645 asthmatic patients|Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
11382320|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
11382321|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
11382322|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
11382323|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
11382324|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
11382328|NCT02153359|Experimental|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
11382329|NCT02153359|Sham Comparator|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
11382330|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
11382331|NCT02153333||HRV Group|Subjects who had received 2 doses of HRV vaccine in previous studies.
11382332|NCT02153333||Placebo Group|Subjects who had received 2 doses of placebo in previous studies.
11382333|NCT02153320|Experimental|HBsAg + adjuvant 1 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).
11382334|NCT02153320|Experimental|HBsAg + adjuvant 2 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).
11382335|NCT02153320|Experimental|HBsAg + adjuvant 3 Group|Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).
11382336|NCT02153307|Experimental|Implantable loop recorders Reveal ICM LINQ®,|
11382337|NCT02153294|Experimental|Ventilation with lower tidal volumes|Use of low tidal volume (4 to 6 ml/kg PBW) after intubation and during all mechanical ventilation
11382338|NCT02153294|Other|Ventilation with higher tidal volumes|Use of high tidal volume (8 to 10 ml/kg PBW) after intubation and during all mechanical ventilation
11382339|NCT02153281|Experimental|Phenelzine treatment|Subjects will undergo a PET and MRI scan before and after the treatment.
11382340|NCT02153268|Experimental|single arm, Liposuction, BonoFill Transplantation|"Liposuction - will be performed on Visit 2 for all eligible subjects
~BonoFill Transplantation - will be performed on Visit 6 for all eligible subjects"
11382341|NCT02153255||Children With Mucopolysaccharidosis Type IVa|
11382342|NCT02153242||Supra Ventricular Tachycardia (SVT)|Patients undergoing SVT studies
11382343|NCT02153229|Experimental|patients who undergo RP plus photofrin-based PDT|
11382344|NCT02153229|Experimental|patients who undergo RP alone|
11382345|NCT02153203|Experimental|Behavioral approach|The Prevent-Teach-Reinforce Model will be implemented with families in their home settings.
11382346|NCT02153203|Active Comparator|Educational approach|Each child's parent will participate in one 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior in children with autism spectrum disorders.
11382347|NCT02153190|Experimental|HYBRID-OPEN|"Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
~During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
11382348|NCT02153190|Experimental|OPEN-HYBRID|"Patients are randomized on the schedule: open period and after hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
~During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
11382349|NCT02153177|Active Comparator|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
11382350|NCT02153177|Active Comparator|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
11382351|NCT02153151||In vitro effect of AMP-514|Patients undergo blood sample collection at baseline, during the second week of RT, at the end of RT, and at 1 month after the end of RT
11382352|NCT02153125|Experimental|Eplerenone|25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment
11382353|NCT02153125|Placebo Comparator|Placebo|
11382354|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
11382479|NCT02152358|Active Comparator|Aciclovir|Patients with a PCR positive for HSV
11382356|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
11382357|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
11382358|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
11382359|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
11382360|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
11382361|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
11382362|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
11382363|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
11382364|NCT02153099|Experimental|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
11382365|NCT02153099|Experimental|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
11382366|NCT02153099|Experimental|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
11382367|NCT02153099|Experimental|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
11382368|NCT02153099|Experimental|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
11382369|NCT02153099|Experimental|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
11382370|NCT02153099|Placebo Comparator|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
11382371|NCT02153086||Ramelteon 8 mg Tablets|
11382372|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
11382373|NCT02153060|Experimental|20mg dexamethasone group|Dexamethasone 20 mg per day, 4 consecutive days
11382374|NCT02153060|Experimental|40mg dexamethasone group|Dexamethasone 40 mg per day, 4 consecutive days
11382375|NCT02153047|Experimental|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
11382376|NCT02153047|No Intervention|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
11382377|NCT02153034||Buruli ulcer patients, no intervention|Buruli ulcer patients administered standard standard care by the attending physician
11382378|NCT02153034||Healthy contacts, no intervention|Healthy volunteers who will be contacts of patients recruited or non-endemic controls. No intervention will be administered
11382379|NCT02153021|Placebo Comparator|Lifestyle counseling|alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.
11382380|NCT02153021|Active Comparator|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.
~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
11382381|NCT02153008||Symptomatic population for GAS|This study is a diagnostic study to aid in the detection of Strep throat. No intervention or medication is a part of this study.
11382382|NCT02152995|Experimental|Treatment (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
11382480|NCT02152358|Placebo Comparator|Aciclovir placebo|Patients with a positive PCR for HSV
11383126|NCT02148107|Experimental|BI 691751 Dose 4|multiple dose given over 14 days
11382383|NCT02152982|Experimental|Arm I (temozolomide, veliparib)|Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression (confirmed progression) or unacceptable toxicity.
11382384|NCT02152982|Placebo Comparator|Arm II (temozolomide, placebo)|Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression (confirmed progression) or unacceptable toxicity.
11382385|NCT02152969|Other|Part B|Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
11382386|NCT02152969|Other|Part A|Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
11382387|NCT02152956|Experimental|Flotetuzumab|CD123 x CD3 bispecific DART® antibody
11382388|NCT02152943|Experimental|Treatment (everolimus, letrozole, trastuzumab)|Patients receive everolimus PO QD and letrozole PO QD. Patients also receive trastuzumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382389|NCT02152930|Active Comparator|Supervised Exercise Therapy|Standard treatment: Supervised Exercise Therapy during 12 weeks
11382390|NCT02152930|No Intervention|Controlled group|
11382391|NCT02152917|Active Comparator|Tranexamic acid|A dose of tranexamic acid (10mg/Kg) will be administered 20 minutes before inflating the pneumatic tourniquet and another dose 15 minutes after the tourniquet release.
11382392|NCT02152917|Active Comparator|Floseal®|Floseal® will be applied in regions of potential bleeding before the release of the pneumatic tourniquet.
11382393|NCT02152917|No Intervention|Control group|
11382394|NCT02152904||Peptic ulcer bleeding patients|Endoscopy
11382395|NCT02152891|Experimental|CHAP-EMS/CP@clinic Program Intervention|12 month implementation of the intervention
11382396|NCT02152891|No Intervention|Control|Will complete a survey at baseline and at 1 year, no program or intervention provided
11382397|NCT02152878|Active Comparator|Active stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
11382398|NCT02152878|Placebo Comparator|Sham stimulation|For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
11382399|NCT02152865|Active Comparator|Lupeol|Patients are supposed to apply lupeol on one side of face two times per day for 8 weeks
11382400|NCT02152865|Placebo Comparator|Control vehicle|Patients are supposed to apply vehicle control to another side of face two times per day for 8 weeks
11382401|NCT02152852|Experimental|Community Health Worker Intervention|Community Health Worker Intervention-home visits from community health workers providing education and support for self-management of type 2 diabetes, resources for diabetes control, and assistance in effective communication with medical providers
11382402|NCT02152852|No Intervention|Usual Care Control Group|Usual Care Control Group- Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support diabetes self-management (such as classes and support groups) and educational pamphlets.
11382403|NCT02152839|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
11382404|NCT02152839|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
11382405|NCT02152826|Experimental|potassium oxalate gel|Professional application
11382406|NCT02152826|Active Comparator|Potassium oxalate liquid|Professional application
11382407|NCT02152813|Active Comparator|1. Bilateral TENS (Bi-TENS) group|Subjects having bilateral electrical stimulation and task-orientated exercises
11382408|NCT02152813|Placebo Comparator|Unilateral TENS (Uni-TENS) group|Subjects having unilateral TENS over their affected lower limb only, and task-oriented exercises
11382409|NCT02152800|Experimental|Vacyless® 1000 mg|one Vacyless® 1000 mg tablets, 3 times daily for 7days
11382410|NCT02152800|Experimental|Vacyless® 500mg|Two Vacyless® 500mg tablets, 3 times daily for 7 days
11382411|NCT02152800|Active Comparator|Valtrex® 500 mg|Two Valtrex® 500 mg tablets, 3 times daily for 7days
11382412|NCT02152787|Experimental|1) propofol 1.0mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
11382413|NCT02152787|Experimental|2) propofol 0.5mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
11382414|NCT02152787|Placebo Comparator|3) normal saline group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
11382415|NCT02152774|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
11382416|NCT02152774|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
11382417|NCT02152761|Experimental|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
11382615|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
11382418|NCT02152761|Experimental|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
11382419|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
11382420|NCT02152761|Experimental|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
11382421|NCT02152748||Glioblastoma|The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
11382422|NCT02152735|Active Comparator|Cleaning the uterine cavity|Cleaning the uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
11382423|NCT02152735|No Intervention|Not cleaning the uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
11382424|NCT02152722||Total Body Irradiation Subjects|Subjects undergoing total body irradiation prior to chemotherapy. It is expected that all of these subjects will be receiving ablative radiation prior to bone marrow transplant. Breath will be collected before and after the first radiation exposure on each day of total body irradiation.
11382425|NCT02152709|Experimental|10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
11382426|NCT02152709|Active Comparator|5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.
11382427|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
11382428|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
11382429|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
11382430|NCT02152683|Experimental|long protocol|Renova
11382431|NCT02152683|Experimental|short protocol|Renova
11382432|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
11382433|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
11382434|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
11382435|NCT02152657|Experimental|Mesenchymal stem cell transplantation|
11382436|NCT02152644||amyloid|unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
11382437|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
11382438|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
11382439|NCT02152618|Experimental|Treatment|
11382440|NCT02152618|No Intervention|Comparison|
11382441|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
11382442|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
11382443|NCT02152592|No Intervention|PCM/NAPR group|paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
11382444|NCT02152592|Active Comparator|PCM/Oxy1 group|Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
11382445|NCT02152592|Active Comparator|PCM/Oxy2 group|CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
11382446|NCT02152579|Experimental|Isosorbide-5-mononitrate, tablet|Single treatment arm.
11382447|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
11382448|NCT02152553|Active Comparator|Hydrocortisone|Near-physiologic doses of Hydrocortisone are being given to subjects. The first day between 09.00 and 12.00 0,024 mg Hydrocortisone/kg per hour. The first day between 12.00 and 20.00 0,012 mg Hydrocortisone/kg per hour. The first day between 20.00 and 24.00 0,008 mg Hydrocortisone/kg per hour. The second day between 00.00 and 11.00 0,030 mg Hydrocortisone/kg per hour. Hydrocortisone infusion: 0,4 ml Solu Cortef 100 mg (50 mg/ml) added in 999,6 ml sodium chloride 0,9% solution (1 mg Solu Cortef/ 50 ml total solution volume).
11382616|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
11382449|NCT02152553|Placebo Comparator|Placebo|The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
11382450|NCT02152540|Experimental|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
11382451|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
11382452|NCT02152527||Trimetazidine|Patients for coronary artery bypass grafting surgery who had preoperative trimetazidine usage in standard ischemic coronary disease therapy.
11382453|NCT02152527||Control|Patients for coronary artery bypass grafting surgery who had standard therapy for ischemic coronary disease without trimetazidine.
11382454|NCT02152514|Active Comparator|Intrathecal Morphine/Sufentanil and PCA|Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
11382455|NCT02152514|Placebo Comparator|PCA alone|Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.
11382456|NCT02152501|Experimental|Exercise Energy Expenditure 300 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 300 kcal/day.
11382457|NCT02152501|Experimental|Exercise Energy Expenditure 600 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 600 kcal/day.
11382458|NCT02152475|Experimental|PDT with blue light and curcumin|PDT treatment was performed with light and curcumin.The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence. The curcumin concentration of 30 mg/L was used.
11382459|NCT02152475|Active Comparator|Curcumin|The curcumin concentration of 30 mg/L was used.
11382460|NCT02152475|Active Comparator|Blue light|The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence.
11382461|NCT02152462|Other|Exergaming|Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
11382462|NCT02152462|No Intervention|Control|Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
11382463|NCT02152449|No Intervention|Control group|"Control group: systematic advice on swallowing, plus:
~If no weight loss compared to usual weight: no intervention
~if weight loss <5%: advice on a fat- and protein-enriched diet
~if weight loss ≥5%: advice on a fat- and protein-enriched diet + 1 unit of ONS/day per os"
11382464|NCT02152449|Experimental|oral nutritional supplementation|"Experimental ONS Group: systematic advice on swallowing + systematic advice on a fat- and protein-enriched diet, plus:
~if no weight loss compared to usual weight: 1 ONS/day per os
~if weight loss <5% compared to usual weight: 2 ONS/day per os
~if weight loss ≥5% compared to usual weight: 3 ONS/day per os"
11382465|NCT02152436||Before simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured before simulation-based curriculum
11382466|NCT02152436||After simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured after simulation-based curriculum
11382467|NCT02152423|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
11382468|NCT02152423|Active Comparator|ENOXAMED|patients are given a curative dose of Enoxaparin (ENOXAMED)
11382469|NCT02152410|Experimental|acupuncture group|The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
11382470|NCT02152410|Active Comparator|Morphine group|Each patient must receive a bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement (VAS> 30).
11382471|NCT02152397|Active Comparator|Therapist-led brief intervention (TBI)|"Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
11382472|NCT02152397|No Intervention|Enhanced usual care|Participants will receive therapist-led, computer-assisted control sessions with a therapist.
11382473|NCT02152384|Experimental|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
11382474|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
11382475|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
11382476|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
11382477|NCT02152358|Active Comparator|Ganciclovir|Patients with a positive CMV PCR
11382478|NCT02152358|Placebo Comparator|Ganciclovir placebo|Patients with a positive CMV PCR
11382481|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
11382482|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
11382483|NCT02152332|Experimental|Treatment Sequence Group ADBC|Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
11382484|NCT02152332|Experimental|Treatment Sequence Group BACD|Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).
11382485|NCT02152332|Experimental|Treatment Sequence Group CBDA|Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
11382486|NCT02152332|Experimental|Treatment Sequence Group DCAB|Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).
11382487|NCT02152319|Experimental|KHV reporting|Clinicians will view the motor symptom severity reports and videoconference to titrate medications.
11382488|NCT02152319|Active Comparator|Standard care|Subjects in this group will still use KHV at home to minimize any placebo effects that could be attributed to using the system; however, clinicians will view the motor symptom severity reports and videoconference to titrate medications solely for the experimental subjects.
11382489|NCT02152306|Experimental|Fimasartan and Amlodipine|Combination of Fimasartan and Amlodipine
11382490|NCT02152306|Active Comparator|Fimasartan|Fimasartan Monotherapy
11382491|NCT02152280|Experimental|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
11382492|NCT02152280|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
11382493|NCT02152267|Experimental|tDCS 1mA|the parameters used in the TDCS will be 1mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
11382494|NCT02152267|Experimental|tDCS 2mA|the parameters used in the TDCS will be 2mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
11382495|NCT02152267|Sham Comparator|tDCS Sham|the parameters used in the TDCS will be sham, cathodal over right DLPFC and anodal over supraorbital contralateral area.
11382496|NCT02152254|Active Comparator|Arm A: Targeted Therapy|Personalized treatment, targeted therapy against the alteration based on molecular profiling.
11382497|NCT02152254|Experimental|Arm B: Standard-of-Care Therapy|Standard-of-Care treatment not selected on basis of alteration analysis.
11382498|NCT02152241||Patients with IBD|Adult patients with IBD diagnosed during childhood
11382499|NCT02152228|Experimental|Oral Parathyroid Hormone (1-34)|Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)
11382500|NCT02152215|Active Comparator|Acellular dermal matrix membrane|An acellular dermal matrix membrane will be used as a barrier between the osseous graft and the soft tissue flap.
11382501|NCT02152215|Experimental|Polylactic acid membrane|A polylactic acid membrane will be used as a barrier between the osseous graft and the soft tissue flap.
11382502|NCT02152202|Experimental|Semi-upright position|Semi-upright position defined as 45 degrees incline from horizontal of the patients bed during nocturnal sleep, for two postoperative nights. Daytime naps will be excluded. A regular pillow may be used by the patients based upon the level of comfort and also to support the head in a neutral position.
11382503|NCT02152202|Other|Control group (Supine position)|In this group patients' bed will be set into Supine/0 degree angle during sleep in the night time. Patient will be managed according to routine care
11382504|NCT02152189||Screening population|
11382505|NCT02152176|Experimental|Patient Controlled Analgesy group|Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
11382506|NCT02152176|No Intervention|Control group|titration will be perform in the usual manner in accordance with the recommendations : a nurse will assess pain using a visual analog scale in the control group to assess the need for a new bolus of morphine
11382507|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
11382508|NCT02152163|Placebo Comparator|IV Saline|IV Saline
11382509|NCT02152150|Experimental|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content)
11382510|NCT02152150|Active Comparator|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content)
11382511|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11382512|NCT02152124||Controlled on LA-SMSA|Patients with controlled acromegaly on long-acting somatostatin analogs
11382513|NCT02152124||Controlled on LA-SMSA and pegvisomant|Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant
11382514|NCT02152124||Controlled after surgery|Controlled acromegaly patients without need for medical therapy after surgery
11382515|NCT02152124||Healhy controls|Healthy volunteers
11382516|NCT02152124||Uncontrolled on LA-SMSA|Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage
11382517|NCT02152111|Experimental|Dietary Supplement: Coconut flour|Diet hipoernergetic plus 26g/day coconut flour during three months (12weeks).
11382518|NCT02152111|Active Comparator|Nutritional Treatment|All patients received an individualized diet plan and balanced. The diet was calculated to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of total energy value
11382519|NCT02152098|Experimental|Chronic Exercise|Chronic Exercise
11382520|NCT02152098|Experimental|Acute Early onset of rehabilitation|Acute Early onset of rehabilitation
11382521|NCT02152098|Experimental|Chronic control|Chronic control
11382522|NCT02152098|Experimental|Acute Delayed onset of rehabilitation|Acute Delayed onset of rehabilitation
11382523|NCT02152085|Experimental|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
11382524|NCT02152085|Experimental|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
11382525|NCT02152072||medical students|
11382526|NCT02152059|Experimental|BIBF1120|BIBF1120 200 mg twice daily continuously
11382527|NCT02152046||Spring loaded retractor|The Alfonso Eyelid Speculum, newborn size
11382528|NCT02152046||Screw retractor|Cook Eyelid Speculum, infant size
11382529|NCT02152033|Experimental|Home-based Continuing Care|The components of Home-based Continuing Care (HCC) include brief parent training, brief Young Adult (YA) orientation and recovery planning, telephone-based continuing care (TCC) and home-based contingency management. Both parent and YA participants will attend sessions with a family specialist.
11382530|NCT02152033|Other|Services as Usual|YAs completing residential care usually are referred to continuing outpatient services and/or self-help groups.
11382531|NCT02152020||Cancer survivors|
11382532|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
11382533|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
11382534|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
11382535|NCT02151981|Experimental|Osimertinib|Osimertinib 80 mg, orally, once daily
11382536|NCT02151981|Active Comparator|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
11382537|NCT02151968|Active Comparator|Traditional blind peribulbar block|
11382538|NCT02151968|Experimental|Ultrasound-guided peribulbar block|
11382539|NCT02151955|Experimental|Individual parent infant intervention|Children and parents will be offered an assessment and then a tailored individual 10 to 15 week based attachment and parent intervention to promote parent child relationship.
11382540|NCT02151942||Control group|Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal
11382541|NCT02151942||Rehearsal group|Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal
11382542|NCT02151929|Experimental|Bioresorbable Vascular Scaffold|Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI
11382543|NCT02151929|Active Comparator|Everolimus Eluting stent|Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI
11382544|NCT02151916|Experimental|Dental care, AG, MI & fluoride varnish|The intervention comprises four components; provision of dental care to the mother during pregnancy (2nd trimester), preventive treatment with fluoride varnish to the teeth of children, and two behavioral interventions, namely oral health anticipatory guidance and motivational interviewing with the caregiver/mother.
11382545|NCT02151916|Other|Delayed intervention|Three fluoride varnish applications to the teeth of children and oral health anticipatory guidance and motivational interviewing for the caregiver when the child is aged 24, 30 and 36 months. Dental care also will be offered to the mothers/caregivers in the delayed intervention group when their children are aged 2 to 3 years old. Before the children are aged 2 years, standard dental care will be the comparator, which usually involves provision of dental care only if the participant is in pain.
11382546|NCT02151903|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
11382547|NCT02151903|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
11382578|NCT02151669|Experimental|Mediterranean Diet Group|Nutritional intervention to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
11382579|NCT02151669|No Intervention|Control group|Participants of control group will be referred to your doctor or nurse with reference to a report on specific according to your personal situation dietary recommendations.
11382548|NCT02151890|Experimental|Laparoscopic Stem Cell Transplantation.|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS)Laparoscopic injected of stem cell Sample in the ovaries.. Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.
11382549|NCT02151877|Experimental|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
11382550|NCT02151877|Placebo Comparator|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
11382551|NCT02151864|Experimental|LDE225|LDE225 200mg-800mg oral daily
11382552|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.
~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
11382553|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.
~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
11382554|NCT02151825|Experimental|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
11382555|NCT02151825|Placebo Comparator|Placebo|3 capsules of Maltodextrin per day
11382556|NCT02151812|Experimental|Agent Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
11382557|NCT02151812|Active Comparator|SeQuent Please Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
11382558|NCT02151799|Experimental|Body contouring surgery|
11382559|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
11382560|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
11382561|NCT02151760|Experimental|18F-DCFPyL|
11382562|NCT02151747||Sanger|BRCA 1/2 test results by Sanger sequencing
11382563|NCT02151747||NGS|BRCA 1/2 test results by NGS
11382564|NCT02151734|Experimental|KALOMIN™ Tab.|KALOMIN™ Tab./Placebo to Umckamin syrup
11382565|NCT02151734|Active Comparator|Umckamin syrup|Umckamin syrup/Placebo to KALOMIN™ Tab.
11382566|NCT02151721|Experimental|vorinostat, gefitinib, combination|single arm vorinostat plus gefitinib
11382567|NCT02151708|Active Comparator|motilitone 90mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
11382568|NCT02151708|Active Comparator|motilitone 180mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
11382569|NCT02151708|Placebo Comparator|placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
11382570|NCT02151695|Active Comparator|Panretinal photocoagulation|
11382571|NCT02151695|Experimental|Aflibercept intravitreal injections|
11382572|NCT02151682|Active Comparator|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.
~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
11382573|NCT02151682|Experimental|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.
~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
11382574|NCT02151682|Experimental|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
11382575|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
11382576|NCT02151682|No Intervention|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
11382577|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
11382582|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
11382583|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
11382584|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
11382585|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
11382586|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.
~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
11382587|NCT02151630|Active Comparator|Pyruvic acid|Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
11382588|NCT02151630|Active Comparator|Salicylic acid|Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
11382589|NCT02151617|Experimental|Cohort 1-PF-06743649 or placebo|Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
11382590|NCT02151617|Experimental|Cohort 2-PF-06743649 or placebo|
11382591|NCT02151617|Experimental|Cohort 3-PF-06743649 or placebo|
11382592|NCT02151617|Experimental|Cohort 4-PF-06743649 or placebo|
11382593|NCT02151617|Experimental|Cohort 5-PF-06743649 or placebo|
11382594|NCT02151604|Experimental|129 Xenon MR Imaging|Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
11382595|NCT02151591|Experimental|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
11382596|NCT02151591|Other|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
11382597|NCT02151578|No Intervention|nothing at home level|No intervention at community level. The study drugs (arthemeter/Lumefantrine and Cotrimoxazole) available at the health facility drug stores level and prescribed exclusively to sick children attending to the health facility for care seeking. No Community Heath Worker /Key Opinion leader (CHWs/KOLs) selected in those clusters
11382598|NCT02151578|Experimental|Home management of malaria|"At the community level, the Community health workers/ keay opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc"
11382599|NCT02151578|Experimental|Home management of malaria and pneumonia|"At the community level, the Community health workers/ key opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) or antibiotic (Cotrimoxazole) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc. The treatment decision making for the CHWs/KOLs based on the algorithm"
11382600|NCT02151565|Experimental|HTEMS|High-tone external muscle stimulation 5 times within 10 days
11382601|NCT02151565|Active Comparator|TENS|Transcutaneous electrical nerve stimulation 5 times within 10 days
11382602|NCT02151552|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
11382603|NCT02151539||Observational (medical chart review)|Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.
11382604|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
11382605|NCT02151513||Cancer Pain|Placement of an intrathecal pump
11382606|NCT02151500|Experimental|Stress and Health Interview|Stress and Health Interview is an experiential assessment technique
11382607|NCT02151500|No Intervention|Wait-list Control|Standard medical care until the 6-week follow-up is completed
11382608|NCT02151487||Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
11382609|NCT02151487||Ropivacaine and dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
11382610|NCT02151487||Ropivacaine and clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
11382611|NCT02151487||Ropivacaine, dexamethasone and clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
11382612|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
11382613|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
11382614|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
11382617|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
11382618|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
11382619|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
11382620|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before & after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days & CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed & Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
11382621|NCT02151435||Patients with IPF|Observation of longitudinal biomarkers in IPF patients
11382622|NCT02151422|Experimental|Breathing exercises|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
11382623|NCT02151409|Experimental|NNC 0151-0000-0000 i.v.|Dose escalation trial
11382624|NCT02151409|Experimental|NNC 0151-0000-0000 s.c.|Dose escalation trial
11382625|NCT02151409|Placebo Comparator|Placebo|
11382626|NCT02151396|Experimental|Cogmed Working Memory Training|Cogmed (TM) working memory training following standard, recommended administration procedures
11382627|NCT02151383|Experimental|Serelaxin|Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.
11382628|NCT02151370||Cohort|
11382629|NCT02151357|Experimental|DCBCI0901|DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20
11382630|NCT02151344|Experimental|Cohort 1|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
11382631|NCT02151344|Experimental|Cohort 2|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
11382632|NCT02151344|Experimental|Cohort 3|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
11382633|NCT02151344|Experimental|Cohort 4|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
11382634|NCT02151344|Experimental|Cohort 5|Participants will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28.
11382635|NCT02151331|Experimental|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
11382636|NCT02151331|Experimental|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
11382637|NCT02151305|Experimental|Total intravenous anesthesia group|This group received propofol and remifentanil for the maintenance of general anesthesia.
11382638|NCT02151305|Experimental|Inhalation anesthesia group|This group received sevoflurane for the maintenance of general anesthesia.
11382639|NCT02151279|Placebo Comparator|control group|Chitosan as wine fining agent
11382640|NCT02151279|Active Comparator|Shrimp allergic patients|Chitosan as wine fining agent
11382641|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
11382642|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
11382643|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
11382644|NCT02151253|Experimental|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.
~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
11382645|NCT02151253|Placebo Comparator|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.
~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
11382646|NCT02151240|Experimental|Arm I|Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV
11382737|NCT02150694|Experimental|Apelin agonist infusion|Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.
11382647|NCT02151240|Active Comparator|Arm II|First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV
11382648|NCT02151227||magnesium intake categories|comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake
11382649|NCT02151214|Experimental|Parenteral nutrition|Parenteral nutrition will be administered to the patients
11382650|NCT02151214|No Intervention|Normal per os nutrition|The patients will eat orally
11382651|NCT02151201|Experimental|Influenza vaccination video education|Influenza vaccination video education
11382652|NCT02151201|Placebo Comparator|Hand Washing video education|Hand Washing vaccination video education
11382653|NCT02151188|Other|Bread and water|co-ingestion control session
11382654|NCT02151188|Experimental|bread with cow milk co-ingestion|co-ingestion bread with cow milk
11382655|NCT02151188|Experimental|bread with soy milk co-ingestion|co-ingestion bread with soy milk
11382656|NCT02151188|Experimental|preload cow milk|preload cow milk 30 min, then bread
11382657|NCT02151188|Experimental|preload soy milk|preload soy milk 30 min, then bread
11382658|NCT02151175|Experimental|LIFUP|
11382659|NCT02151162|Experimental|Stress management plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
11382660|NCT02151162|Active Comparator|Stress management plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
11382661|NCT02151162|Active Comparator|Psychoeducation leaflet plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
11382662|NCT02151162|Active Comparator|Psychoeducation leaflet plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
11382663|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
11382664|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
11382665|NCT02151136|Experimental|24% sucrose + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml 24% sucrose will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
11382666|NCT02151136|Placebo Comparator|Sterile water + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml sterile water will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
11382667|NCT02151123||Diagnosed colon cancer patients|Patients undergoing colectomy for colonic adenocarcinoma.
11382668|NCT02151110|Placebo Comparator|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
11382669|NCT02151110|Experimental|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
11382670|NCT02151110|Experimental|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
11382671|NCT02151110|Experimental|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
11382672|NCT02151110|Experimental|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
11382673|NCT02151110|Experimental|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
11382674|NCT02151110|Experimental|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
11382675|NCT02151110|Experimental|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
11382676|NCT02151097||High risk prostate cancer|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage ≥T2c, or Prostate Specific Antigen (PSA)>20 ng/ml, or Gleason Score 8-10, scheduled to have radical prostatectomy.
11382677|NCT02151084|Experimental|Arm A (Continuous Dosing)|"Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)
~On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
11382678|NCT02151084|Experimental|Arm B (Sequential Dosing)|"Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout
~On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.
~Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
11382679|NCT02151084|Experimental|Arm C (Standard Care)|Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.
11382680|NCT02151071|Other|Breast conserving surgery|Females ≥ 30 years of age with a diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS), scheduled for BCS +/- SLNB or ALND
11382681|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
11382682|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
11382683|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
11382684|NCT02151045|Active Comparator|Non target epidural infiltration at L3-L4 stage|"In this control arm, there are patients with a non target posterior epidural space infiltration of corticoids done at L3-L4 stage on scan control.
~These patients must have a discal hernia confirmed by scanner or RMI"
11382685|NCT02151045|Experimental|Epidural infiltration on contact of disco radicular conflict|"In this experimental arm, there are patients with an epidural infiltration of corticoids done in lateral on contact of disco radicular conflict on scan control.
~These patients must have a discal hernia confirmed by scanner or RMI"
11382686|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
11382687|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
11382688|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
11382689|NCT02151019|Experimental|Experimental Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
11382690|NCT02151019|No Intervention|Control Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique
11382691|NCT02151006|Active Comparator|DHEA|women will receive DHEA 6 weeks before starting IVF/ICSI
11382692|NCT02151006|No Intervention|Control|
11382693|NCT02150993|Experimental|Arm A : TDF + FTC (or 3TC) + ZDV|Tenofovir + Emtricitabine or Lamivudine + Zidovudine
11382694|NCT02150993|Experimental|TDF+FTC (or 3TC) +LPV/r|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
11382695|NCT02150993|Experimental|Arm C : TDF +FTC (or 3TC) + RAL|Tenofovir + Emtricitabine or Lamivudine + Raltegravir
11382696|NCT02150967|Experimental|BGJ398 (infigratinib)|To estimate anti-tumor activity of BGJ398
11382697|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
11382698|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
11382699|NCT02150941|Experimental|BioVac Direct Suction Device|Experimental arm
11382700|NCT02150941|Active Comparator|Standard Endoscopy Suction|Control arm
11382701|NCT02150928|Experimental|Erwinaze / Erwinase|
11382702|NCT02150915|Experimental|new acupoint|Subjets in this arm receive acupuncture therapy in a new acupoint (leopard spot needling technique)
11382703|NCT02150915|Active Comparator|classical acupoint|Subjects in this arm receive acupuncture therapy in a classical acupoint in the pericardial conduit (leopard spot needling technique)
11382704|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
11382705|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
11382706|NCT02150889|No Intervention|Lean Trained|Metabolic control
11382707|NCT02150889|Experimental|Obese or Overweight|Running Program Yoga Program
11382708|NCT02150863|Active Comparator|Ultrapulse laser alone|
11382709|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
11382710|NCT02150863|No Intervention|Control|
11382711|NCT02150850||Registry|Patients who have who have sustained an AFF that consent to participating in the registry only.
11382712|NCT02150850||Cases|Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.
11382713|NCT02150850||Controls|For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.
11382714|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 & 2 & 2 Meal Replacement Plan for weight loss.
11382715|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 & 2 & 1 Meal Replacement Plan for weight loss.
11382716|NCT02150824|Experimental|BI 187004 low dose mono QD|patient to receive one tablet containing low dose of BI 187004 or matching placebo
11382717|NCT02150824|Experimental|BI 187004 medium dose mono QD|patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
11382718|NCT02150824|Experimental|BI 187004 high dose mono QD|patient to receive one tablet containing high dose of BI 187004 or matching placebo
11382719|NCT02150824|Experimental|BI 187004 high dose QD add on|patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
11382720|NCT02150811||Hunner's ulcer|
11382721|NCT02150798|Experimental|High fat and low carbohydrate diet|High fat low carbohydrate diet composition was 40 % of carbohydrates, 40 % of lipids (12 % saturated, 18 % monounsaturated and 10% polyunsaturated, ) and 20 % of protein for two months
11382722|NCT02150798|Active Comparator|Control diet|the standard diet composition was 50 % of carbohydrates, 30 % of lipids (10 % saturated, 10 % polyunsaturated, and 10 % monounsaturated) and 20 % of protein for two months
11382723|NCT02150785|Experimental|Adminstering Streptokinase|treatment with 15,000 units/Kg of streptokinase in ischemic stroke patients with symptoms onset for less than 3 hours
11382724|NCT02150772|Other|Shear Wave Elastography|All included patients have SWE performed
11382725|NCT02150759|Experimental|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
11382726|NCT02150759|Active Comparator|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
11382727|NCT02150746||Pancreatic Cancer CTC|Peripheral/Central Venous Blood Draw Peritoneal Wash
11382728|NCT02150733|Experimental|Group 1 - Normal hepatic function|Subjects with normal hepatic function
11382729|NCT02150733|Experimental|Group 2 - Mild hepatic impairment|Subjects with mild hepatic impairment by Child-Pugh classification scores
11382730|NCT02150733|Experimental|Group 3 - Moderate hepatic impairment|Subjects with moderate hepatic impairment by Child-Pugh classification scores
11382731|NCT02150733|Experimental|Group 4 - Severe hepatic impairment|Subjects with severe hepatic impairment by Child-Pugh classification scores
11382732|NCT02150720|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
11382733|NCT02150720|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,
11382734|NCT02150720|Active Comparator|Usual hemostasia|Electrocauterization
11382735|NCT02150707||Dipeptidyl-Peptidase IV Inhibitors|Newly started on DPP4 inhibitor for hyperglycaemia
11382736|NCT02150707||Glucagon-Like Peptide 1|Newly started on GLP-1 for hyperglycaemia or obesity
11382738|NCT02150694|Experimental|Apelin receptor antagonist infusion|Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent
11382739|NCT02150694|Experimental|Apelin agonist/antagonist co-infusion|Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.
11382740|NCT02150681|Experimental|Mindfulness-based cognitive therapy|8 class sessions of mindfulness therapy given in a group setting, with one 2-hr session per week for 8 weeks.
11382741|NCT02150668|Experimental|HOPS Intervention|School counselors deliver HOPS intervention to students during the school day. This includes 16, 20-minute sessions with the student and two joint family meetings.
11382742|NCT02150668|Active Comparator|HSI Intervention|School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
11382743|NCT02150655|Experimental|Probiotic|Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 oral capsules
11382744|NCT02150655|Placebo Comparator|Placebo|Sugar pill
11382745|NCT02150642||Neurological Injury|
11382746|NCT02150642||No Neurological Injury|
11382747|NCT02150629||SCI patients|
11382748|NCT02150629||Healthy subjects|
11382749|NCT02150616|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
11382750|NCT02150616|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
11382751|NCT02150616|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
11382752|NCT02150616|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
11382753|NCT02150603||Adults with congenital heart disease|
11382754|NCT02150590|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
11382755|NCT02150590|Placebo Comparator|Sham oxygen|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
11382756|NCT02150577|Experimental|Implementation|Evidence Based Quality Improvement
11382757|NCT02150577|No Intervention|Control|Usual Quality Improvement
11382758|NCT02150564|Other|Navigation only group|Sonowand system will be used for navigation control arm as well as sononavigation experimental arm.Navigation will be used to plan the craniotomy and throughout the procedure as desired by the operating surgeon. At no point of time however will the Ultrasound be used.
11382759|NCT02150564|Experimental|SonoRCT Test group|Surgery to resect the tumor with the aid of sononavigation. In addition to the navigation function, the Ultrasound will be available at all times. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue.
11382760|NCT02150551|Experimental|Mesenchymal Stromal Cells (MSCs)|A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
11382761|NCT02150538|Active Comparator|Right ventricular stimulation|patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
11382762|NCT02150538|Experimental|Biventricular Stimulation|Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
11382763|NCT02150525|Experimental|Arm I (oral omega-3 fatty acid)|Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
11382764|NCT02150525|Placebo Comparator|Arm II (placebo)|Patients received equivalent, matched oral placebo (seven capsules) daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
11382765|NCT02150512|Experimental|Transpulmonary thermodilution (TPTD)|The intervention group (TPTD guided therapy) follows a fluid resuscitation protocol based on stroke volume variation (SVV) and extravascular lung water (EVLW). Initial trigger for fluid loading when circulatory insufficiency is present will be SVV.
11382766|NCT02150512|Active Comparator|Surviving Sepsis Guidelines (SSG)|The standard group (SSG guided therapy) follows a fluid resuscitation protocol based on the Surviving Sepsis Campaign recommendations. Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg).
11382767|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
11382768|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
11382769|NCT02150473|Experimental|Adalimumab|receive adalimumab 40 mg eow injections in combination with MTX for 24 weeks
11382770|NCT02150473|Placebo Comparator|Placebo|receive placebo injections in combination with MTX for 24 weeks
11382771|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
11382772|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
11382773|NCT02150447|Active Comparator|Intervention group|Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
11382774|NCT02150447|Placebo Comparator|Placebo group|Placebo for the prevention of gastric cancer bleeding
11382775|NCT02150434|Sham Comparator|Compressed Air|compressed air delivered at a fixed flow of 2 L/min
11382776|NCT02150434|Active Comparator|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
11382777|NCT02150434|Experimental|Automated oxygen titration|oxygen at a variable flows delivered by the FreeO2
11382778|NCT02150421||e-book|study the course materials by using e-book
11382779|NCT02150408|Experimental|assesment by 68Ga-DOTATATE PET-CT|
11382780|NCT02150395|Experimental|music therapy|pt received a protocolized music therapy intervention that included altered state induction, music driven guided visualiztion, and psychoeducation on relaxation techniques to be used during simulation for radiation therapy. Prescribed pre-recorded music program provided to be used during simulation.
11382781|NCT02150395|No Intervention|control|no intervention
11382782|NCT02150369||Patient, care partner, primary nurse case|In Phase I of this pilot, a case is comprised of the metastatic RCC patient receiving IL-2, their care partner, and their primary nurse. In Phase II, the IL-2 patient can either have MM or metastatic RCC. The care partner for this study will be the family member or friend staying with the IL-2 patient throughout treatment.
11382783|NCT02150356|Experimental|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
11382784|NCT02150356|Placebo Comparator|Control|Diet based on refined cereal products for a period of 8 weeks.
11382785|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
11382786|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
11382787|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
11382788|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
11382789|NCT02150330|Active Comparator|DHEAS in DOR Group|Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
11382790|NCT02150330|Active Comparator|Normal Control|Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
11382791|NCT02150330|Active Comparator|Shame DOR Group|Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.
11382792|NCT02150317|Active Comparator|TACE+Sorafenib|TACE followed by Sorafenib
11382793|NCT02150317|Experimental|TACE|TACE alone
11382794|NCT02150304||intravenous aminophylline|intravenous aminophylline use during spinal anesthesia
11382795|NCT02150304||no intravenous aminophylline|no use of intravenous aminophylline during spinal anesthesia
11382796|NCT02150291|Active Comparator|Group A|one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
11382797|NCT02150291|Active Comparator|Group B|Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
11382798|NCT02150291|Active Comparator|Group C|Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
11382799|NCT02150291|Placebo Comparator|Group D|Patients will receive matching placebo capsule to take during hepatitis C treatment
11382800|NCT02150278|Experimental|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
11382801|NCT02150265|No Intervention|Waiting list control group|6 week waiting list
11382802|NCT02150265|Experimental|Individual cognitive behavioral therapy with SMART|SMART manual cognitive behavioral therapy individual weekly sessions for 6 weeks
11382803|NCT02150252|Experimental|BY HWT，placebo-BY HWT ， Gait parameter|
11382804|NCT02150239||postoperative pain|
11382805|NCT02150226|Experimental|Experimental: Zirconia monolithic crowns and bridges|Evaluation of Lava Plus zirconia dental crowns and bridges
11382806|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
11382807|NCT02150200|Other|A group : Conventional hospitalization|Patients discharged after 3 days hospital stay after laparoscopic hysterectomy
11382808|NCT02150200|Experimental|B group : shorter stay|Patients going home within 24 hours discharged the first day after laparoscopic hysterectomy.
11382809|NCT02150187|Experimental|HCap Formula|Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.
11382810|NCT02150187|Placebo Comparator|Placebo|Same as treatment with placebo pills
11382811|NCT02150174|Experimental|Patients with schizophrenia|
11382812|NCT02150174|Active Comparator|Healthy subjects|
11382813|NCT02150161|Experimental|lidocaine/ ketamine infusion|lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
11382814|NCT02150161|Active Comparator|fentanyl|iv fentanyl, 3ug/kg bolus
11382815|NCT02150148|Experimental|Mentored Gardening Intervention|Participants in this arm will be provided with either a raised bed garden or 4 earthboxes, gardening supplies, and plants and seeds. A master gardener from the Cooperative Extension will mentor them over the course of a year to plant three gardens (spring, summer and fall).
11382816|NCT02150148|Other|Wait-List|Participants in this arm will be provided with the same gardening supplies as the other group, but will receive them one year after enrollment in the study. They also will receive instruction from a master gardener from the Cooperative Extension at this time as well.
11382817|NCT02150135|Experimental|Oncothermia group|Patients were treated with oncothermia 2 or 3 times a week. Treatment was performed for about 1 hours per each visits.
11382818|NCT02150122|Experimental|10 micrograms (400 IU) vitamin D3|Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.
11382819|NCT02150122|Experimental|20 micrograms (800 IU) vitamin D3|Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.
11382820|NCT02150122|No Intervention|Placebo|Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.
11382821|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
11382822|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
11382823|NCT02150096|Active Comparator|Continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
11383127|NCT02148107|Experimental|BI 691751 Dose 5|multiple dose given over 14 days
11382824|NCT02150096|Active Comparator|Pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
11382825|NCT02150096|Active Comparator|low level laser therapy group|the group will be treated with 3J during 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
11382826|NCT02150096|No Intervention|control group|group of women no treated, only evaluated in two moments and this group will be compared with orthers: laser, pulsed ultrasound and continuous ultrasound.
11382827|NCT02150083|Experimental|OR retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is NOT replaced for the duration of the surgery. The surgery is completed and the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will be instructed to void. The voided volume and residual volume will be recorded.
11382828|NCT02150083|No Intervention|PACU retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is replaced for the duration of the surgery and when complete the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will undergo a retrograde bladder fill with 300 mL of normal saline. The foley catheter will be removed and she will be instructed to void. The voided volume and residual volume will be recorded.
11382829|NCT02150070|Experimental|Intravenous ASP2408|
11382830|NCT02150070|Experimental|Subcutaneous ASP2408 low dose|
11382831|NCT02150070|Experimental|Subcutaneous ASP2408 middle dose|
11382832|NCT02150070|Experimental|Subcutaneous ASP2408 high dose|
11382833|NCT02150070|Placebo Comparator|Intravenous Placebo|
11382834|NCT02150070|Placebo Comparator|Subcutaneous Placebo|
11382835|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
11382836|NCT02150057|Active Comparator|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
11382837|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
11382838|NCT02150031|Other|Control|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).
~No prophylactic Chlorhexidine regimen.
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
11382839|NCT02150031|Active Comparator|CHX-Mouthwash|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).
~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
11382840|NCT02150031|Active Comparator|CHX-MW/SUB_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).
~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
11382841|NCT02150031|Active Comparator|CHX-MW/SUPRA_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).
~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.
~Local anesthesia with lidocaine plus adrenaline (1:100,000).
~Tooth extraction."
11382842|NCT02150018||non invasive ventilation (NIV)|
11382843|NCT02150005|Experimental|Periodontal treatment|The test group received oral hygiene instructions, supragingival and subgingival scaling and root planning using curettes and an ultrasonic appliance.
11382844|NCT02150005|No Intervention|Control|
11382845|NCT02149992|Experimental|Myo-inositol, folic acid|"myo-inositol, oral, 2g, two times per day for 5 total days
~folic acid, oral 200 micrograms, two times per day for 7 days
~Continuous Glucose Monitoring Surveillance device for 7 days during study period
~Capillary glucose monitoring 4 times per day"
11382846|NCT02149979|Experimental|Temperature Controlled Laser Soldering|Efficacy and safety of Temperature Controlled Laser Soldered wound incisions closure
11382847|NCT02149966|Experimental|AG-348|Multiple oral doses of AG-348
11382848|NCT02149966|Placebo Comparator|Placebo|Multiple oral doses of placebo.
11382849|NCT02149953|Experimental|Glycine intake|Dietary supplement: Glycine intake
11382850|NCT02149940|Experimental|clinical pharmacy intervention|
11382851|NCT02149927|Experimental|Sevoflurane|Single arm: dose escalation of study medication
11382852|NCT02149914|Experimental|PPI treatment|Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
11382853|NCT02149901|Experimental|Pseudoephedrine + 480 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 480 ml
11382854|NCT02149901|Placebo Comparator|Pseudoephedrine + 50 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 50 ml
11382855|NCT02149901|Experimental|Placebo + 480 ml water (optional)|Placebo PO 45 minutes before water 480 ml
11382856|NCT02149901|Placebo Comparator|Placebo + 50 ml water (optional)|Placebo PO 45 minutes before water 50 ml
11382857|NCT02149888|Experimental|Tenofovir/emtricitabine|MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis
11382858|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
11382859|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
11382860|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
11382861|NCT02149862|Experimental|cancer|patients with an indication of partial or total bladder resection will have urine infrared analysis
11382862|NCT02149862|Placebo Comparator|control group|"Lithiasic patients should be operated a urinary calculation, without catheter double J, will have urine infrared analysis"
11382863|NCT02149849|No Intervention|Standard lateral positioning|
11382864|NCT02149849|Experimental|Modified lateral positioning|Modified lateral positioning. This will ensure less pressure and stretch on shoulder than standard lateral positioning.
11382865|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
11382866|NCT02149823|Active Comparator|Intranasal Oxytocin Group 1|Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3
11382867|NCT02149823|Active Comparator|Intranasal Oxytocin Group 2|oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3
11382868|NCT02149823|Active Comparator|Intranasal Oxytocin Group 3|oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.
11382869|NCT02149823|Active Comparator|Intranasal Oxytocin Group 4|after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit
11382870|NCT02149823|Active Comparator|Intranasal Oxytocin Group 5|after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit
11382871|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
11382872|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
11382873|NCT02149797|Active Comparator|Four port laparoscopic cholecystectomy|This group of patients undergone classical four port laparoscopic cholecystectomy
11382874|NCT02149797|Active Comparator|SILC-Pick'n roll-Beginning (group I)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's beginning arm."
11382875|NCT02149797|Active Comparator|SILC-Pick'n roll-Experienced (group II)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's experienced arm."
11382876|NCT02149784|Experimental|Surgical treatment group|Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.
11382877|NCT02149784|No Intervention|Chemotherapy group|Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.
11382878|NCT02149771|Experimental|TACE&Stents|chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
11382879|NCT02149771|Active Comparator|TACE|Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
11382880|NCT02149758|Experimental|Etoricoxib|Etoricoxib 60 mg once daily
11382881|NCT02149758|Placebo Comparator|matching placebo|matching placebo once daily
11382882|NCT02149745|Experimental|Calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by calling the patient's name
11382883|NCT02149745|Experimental|Not calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by giving verbal stimulus other than the patient's name
11382884|NCT02149719|Experimental|Desensitisation to peanut|Desensitisation using boiled peanut
11382885|NCT02149719|Experimental|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
11382886|NCT02149706|Experimental|NeuroVax|NeuroVax
11382887|NCT02149706|Placebo Comparator|IFA Incomplete Freund's Adjuvant|Incomplete Freund's Adjuvant IFA
11382888|NCT02149693|Experimental|high-fidelity simulation and teamwork training|high-fidelity simulation and teamwork training
11382889|NCT02149693|Active Comparator|traditional resuscitation training|traditional resuscitation training
11382890|NCT02149680||Experimental group|Patient who has had an epidural blood patch following accidental dura puncture during pregnancy
11382891|NCT02149680||Control Group|Women in the same group, equal numbers of those with or without epidurals, without accidental dural puncture, similar parity would constitute the control group. They would be chose at random, 10 times the number in the experimental group (n = 600).
11382892|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
11382893|NCT02149641||Nasopharyngeal cancers|Intensitiy modulated radiotherapy with chemotherapy
11382894|NCT02149628|Active Comparator|desflurane|use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)
11382895|NCT02149628|Experimental|propofol|propofol infusion with target-controlled infusion(TCI) device guided by BIS
11382896|NCT02149615|Experimental|isotretinoin|Retinal nerve fibre layer measurement in patients under isotretinoin treatment
11382897|NCT02149615|Active Comparator|lymecycline|Retinal nerve fibre layer measurement in patients under lymecycline treatment
11382898|NCT02149615|Active Comparator|minocycline|Retinal nerve fibre layer measurement in patients under minocycline treatment
11382899|NCT02149615|Active Comparator|doxycycline|Retinal nerve fibre layer measurement in patients under doxycycline treatment
11382900|NCT02149602||oropharyngeal and hypopharyngeal HNSCC|Intensity Modulated Radiotherapy HPV positive and HPV negative
11382901|NCT02149589|Experimental|Focal ARDS|In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt.
11382902|NCT02149589|Other|non focal ARDS|In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used
11382938|NCT02149355||congenital fourth nerve palsy|teeth molding in patients suffering from congenital fourth nerve palsy
11382978|NCT02149030|No Intervention|A2|A2) infrequent information of screening results, only at the age 30 years.
11382903|NCT02149576|Active Comparator|LDCT Surveillance Program Group|This cohort will follow a strict schedule of Low Dose Computed Tomography Imaging scans and clinical visits 3, 6, and 12 months after surgery. At each encounter, a history, physical examination, and review of the LDCT results will be performed. Patients with normal clinical and imaging findings will proceed to the next scheduled clinical encounter. Patients with abnormal findings will be managed according to predetermined algorithms.
11382904|NCT02149576|Other|Historical Control Group|The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
11382905|NCT02149563|Active Comparator|Treatment|One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.
11382906|NCT02149563|Placebo Comparator|Placebo|100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month
11382907|NCT02149550|Active Comparator|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
11382908|NCT02149550|Experimental|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
11382909|NCT02149550|Experimental|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
11382910|NCT02149550|Active Comparator|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
11382911|NCT02149550|Experimental|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
11382912|NCT02149550|Experimental|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
11382913|NCT02149537|Experimental|hydroxyurea|500mg of hydroxyurea/day during 6 months
11382914|NCT02149537|No Intervention|No treatment|No hydroxyurea treatment during 6 months
11382915|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
11382916|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
11382917|NCT02149511||SCI subjects|
11382918|NCT02149511||healthy control subjects|
11382919|NCT02149498||Parkinson Disease (PD)|Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)
11382920|NCT02149498||Healthy Controls|Healthy individuals
11382921|NCT02149472||Pregnant women with PPH|All pregnant women in participating hospitals are asked for their informed consent (n = 9.500). All women will complete a bleeding score generating questionnaire during their pregnancy. Only from women developing postpartum haemorrhage > 1000 cc blood samples will be drawn (n = 600).
11382922|NCT02149459|Experimental|treatment arm|Partial brain re-irradiation combined with metabolic intervention (low carbohydrate diet and/or metformin treatment)
11382923|NCT02149446|Experimental|Surgisis reinforcement of staple line|The stapler used to divide the pancreas is reinforced with Surgisis (COOK Medical).
11382924|NCT02149446|No Intervention|No reinforcement of staple line|The stapler used to divide the pancreas is not reinforced with any material
11382925|NCT02149433|Experimental|Prednisone versus placebo|Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days
11382926|NCT02149420|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
11382927|NCT02149420|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
11382928|NCT02149420|Placebo Comparator|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
11382929|NCT02149407|Active Comparator|Glycerin group (GG)|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
11382930|NCT02149407|Active Comparator|Rectal stimulation group (SG)|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
11382931|NCT02149407|Sham Comparator|Control group (CG)|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
11382932|NCT02149394|Experimental|Ice|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale.The experimental group received an ice popsicle made of 10 mL mineral water.The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice was supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
11382933|NCT02149394|Active Comparator|Water|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
11382934|NCT02149381|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy is a manual-based group intervention for chr depression (20 weeks).
11382935|NCT02149381|Active Comparator|Befriending|Befriending is a social support intervention
11382936|NCT02149381|Active Comparator|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
11382937|NCT02149355||controls|teeth molding in subjects without congenital fourth nerve palsy
11382939|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
11382940|NCT02149329|Experimental|Short treatment|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
11382941|NCT02149329|No Intervention|Extended treatment|Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature <38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC > 0,5 x10^9/L), whichever comes first.
11382942|NCT02149316|Experimental|RIPC+RIPostC|
11382943|NCT02149316|Sham Comparator|control|
11382944|NCT02149303||Dabigatran|
11382945|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
11382946|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
11382947|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
11382948|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
11382949|NCT02149251||Pre-genetic diagnosis|Women in this group had ICSI and PGD to exclude genetically affected children or for sex selection
11382950|NCT02149251||Control group|This group will include women who had IVF without PGD
11382951|NCT02149238|Active Comparator|flavanol rich drink intervention|flavanol rich drink
11382952|NCT02149238|Active Comparator|methylxanthine rich drink intervention|methylxanthine rich drink
11382953|NCT02149238|Active Comparator|flavanol + methylxanthine rich drink intervention|flavanol + methylxanthine rich drink
11382954|NCT02149225|Experimental|APVAC1 and 2 vaccine plus polyICLC and GMCSF concurrent to TMZ|
11382955|NCT02149212|Active Comparator|Clinical Treatment|Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
11382956|NCT02149212|Active Comparator|Iliac vein stenting|Wallstent
11382957|NCT02149199|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
11382958|NCT02149199|Active Comparator|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
11382959|NCT02149199|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
11382960|NCT02149186|Experimental|Rehabilitation|
11382961|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
11382962|NCT02149160|Experimental|FRM-0334; Arm 1|low dose, Capsule, Once Daily, Day 1 through Day 28
11382963|NCT02149160|Experimental|FRM-0334; Arm 2|high dose, Capsule, Once Daily, Day 1 through Day 28
11382964|NCT02149160|Placebo Comparator|Placebo Comparator; Arm 3|Placebo, Capsule, Once Daily, Day 1 through Day 28
11382965|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
11382966|NCT02149134|Experimental|New extensively hydrolyzed casein formula|Subjects with cow's milk allergy treated with a new formula
11382967|NCT02149121|Experimental|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
11382968|NCT02149121|Active Comparator|Rituxan|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
11382969|NCT02149121|Active Comparator|MabThera|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
11382970|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
11382971|NCT02149108|Placebo Comparator|Placebo + BSC|
11382972|NCT02149095|Experimental|TransCon PEG treprostinil|Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
11382973|NCT02149082||Infrascanner exam|Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
11382974|NCT02149056||Impaired Glucose Tolerance|
11382975|NCT02149043||Ulcerative Colitis patients|30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
11382976|NCT02149043||Healthy volunteers|30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
11382977|NCT02149030|Active Comparator|A1|A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
11382979|NCT02149030|Other|A3|A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
11382980|NCT02149017|Experimental|SNUBH-NM-333(18F), Safety, Efficacy|10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients
11382981|NCT02149004||Site Bonn|
11382982|NCT02149004||Site Heidelberg|
11382983|NCT02149004||Site Munich|
11382984|NCT02149004||Site Hamburg|
11382985|NCT02149004||Site Hannover|
11382986|NCT02149004||Site Cologne|
11382987|NCT02149004||Site Freiburg|
11382988|NCT02149004||Site Frankfurt|
11382989|NCT02149004||Site Essen|
11382990|NCT02148991||Irbesartan|Patients on irbesartan treatment
11382991|NCT02148978|Experimental|Saxagliptin administration|Saxagliptin Administration- The participants in this study will undergo an OGTT (Oral Glucose Tolerance Test) at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin. After 6 weeks of treatment the participants will return to perform a second OGTT.
11382992|NCT02148965|Experimental|Lifestyle intervention|Physical Exercise / Physical Activity. Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
11382993|NCT02148965|No Intervention|Control Group|A group of eligible women, twice as large as the intervention group, will not receive the exercise intervention but will be followed-up equally to compare outcomes in the future.
11382994|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
11382995|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
11382996|NCT02148913|Active Comparator|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
11382997|NCT02148913|Active Comparator|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
11382998|NCT02148913|Active Comparator|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
11382999|NCT02148913|Active Comparator|Cohort 3: Carfilzomib 27mgm2|Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
11383000|NCT02148900||Marfan|Diagnosis of Marfan syndrome, according to Ghent criteria.
11383001|NCT02148900||Marfan Related Disorders|Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.
11383002|NCT02148900||Control Subjects|Unaffected by Marfan or Marfan related disorders.
11383003|NCT02148887||SCI patients with upper limb impairment - Upper limb training|
11383004|NCT02148887||SCI patients with lower limb impairment - Lower limb training|
11383005|NCT02148887||Healthy controls - Upper limb training|
11383006|NCT02148887||Healthy controls - Lower limb training|
11383007|NCT02148887||Healthy controls - No intervention|
11383008|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
11383009|NCT02148861|Experimental|Insulin 287 + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
11383010|NCT02148861|Active Comparator|Insulin degludec + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
11383011|NCT02148848|Active Comparator|Early bisphosphonate use|"Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients.
~Risedronate (35 mg) 1 tablet orally once a week"
11383012|NCT02148848|No Intervention|Late bisphosphonate use|"Give only calcium and vitamin D supplementation during the first 3 months after the surgery.
~Bisphosphonate, risedronate (Actonel), will be given at 3 months after surgery for an osteoporotic femoral neck fracture."
11383013|NCT02148835|Active Comparator|Triomeg|Sausage: Triomeg
11383014|NCT02148835|Placebo Comparator|Control sausage|Sausage: Control
11383015|NCT02148822||Malnourished|Children with either height for age z score or body mass index for age z score below 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
11383016|NCT02148822||Not malnourished|Children with either height for age z score or body mass index for age z score equal or higher than 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
11383017|NCT02148809|Experimental|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
11383018|NCT02148796|Active Comparator|Broncho-Vaxom|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
11383019|NCT02148796|Placebo Comparator|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
11383020|NCT02148783|Experimental|methylphenidate administration|All participants will receive oral methylphenidate 60 mg before the second TMS study. The participants will receive oral methylphenidate 60 mg before the second PET scan. Subjects will then be treated with oral methylphenidate, using a forced titration. Dose titration will be incremental within 6 days (dose-escalation phase) , starting at 5 mg orally twice daily for 3 days, and 10 mg twice daily for the next 3 days. Then the dose will be increased to 30 mg twice daily starting from day 7 given twice daily for additional 3 weeks.
11383021|NCT02148770|Experimental|Neurofeedback|Neurofeedback training: Up-regulation of DLPFC.
11383022|NCT02148770|Sham Comparator|Neurofeedback SHAM|Neurofeedback training: Sham-regulation of DLPFC.
11383023|NCT02148757|Other|DVT|Doppler Ultrasound
11383024|NCT02148744|Experimental|XmAb7195 or Placebo|
11383124|NCT02148107|Experimental|BI 691751 Dose 2|multiple dose given over 14 days
11383025|NCT02148731||Comprehensive Geriatric Assessment (CGA)|Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
11383026|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
11383027|NCT02148705|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (~ surface of an adult palm) for four hours.
11383028|NCT02148705|Placebo Comparator|Gel Vehicle|Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (~ surface of an adult palm) for four hours.
11383029|NCT02148705|Active Comparator|Standard of Care (SOC)|Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.
11383030|NCT02148692|Experimental|Higher PEEP|PEEP of 12 cmH2O or higher and lung recruitment maneuvers
11383031|NCT02148692|Active Comparator|Lower PEEP|PEEP of 4 cmH2O without lung recruitment maneuvers
11383032|NCT02148679|Experimental|DASH/SRD|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge
~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions
~Intervention: pre-prepared, home delivered DASH/SRD-compliant meals for 4 weeks after hospital discharge"
11383033|NCT02148679|Placebo Comparator|Attention Control|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge
~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions"
11383034|NCT02148666||experimental : intracoronary stem cells|intracoronary stem cells will be injected in infarct related artery.
11383035|NCT02148653|Experimental|Multifunctional diet (MFD)|Subjects eat a diet designed according to the Nordic Nutrition Recommendations with the addition of important amounts of various functional food concepts: Low GI and GI-modulating food items; Natural antioxidant-rich items, Long chain omega-3 fatty acid-rich fish; Betaglucan-rich barley and oat food/drinks; Cholesterol-modulating foods.
11383036|NCT02148653|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Nutrition Recommendations but lacking the functional items included in the MFD.
11383037|NCT02148640|Experimental|CT-P13|Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
11383038|NCT02148640|Active Comparator|INX|Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion
11383039|NCT02148627|Experimental|LY3041658 (IV)|Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.
11383040|NCT02148627|Experimental|LY3041658 (SC)|Single dose of LY3041658 administered subcutaneously (SC).
11383041|NCT02148627|Placebo Comparator|Placebo|Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.
11383042|NCT02148614|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
11383043|NCT02148614|Active Comparator|Libramed|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
11383044|NCT02148601|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation from healthy donors will be infused by colonoscopy
11383045|NCT02148601|Active Comparator|Standard Antibiotic Therapy|Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients
11383046|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire
~Sensory mapping of the affected limb
~Quantitative Sensory Testing
~Patients will have a peripheral nerve blockade"
11383047|NCT02148575|Experimental|Self-Management Group|"Managing Cancer Care: A Personal Guide (MCC) is a set of magazine-format, printed modules that includes information about key self-management topics, worksheets, conversation starters, and targeted links to local and internet resources, among other features."
11383048|NCT02148575|Active Comparator|Symptom Management Group|Participants in the Symptom Management Group will be given a symptom management toolkit that provides information on the most commonly experienced symptoms and side effects of cancer treatment, including fatigue, nausea, and sleep problems, among others. Each chapter includes information on when and why the symptom may occur, how the symptom can be managed, and when to call a provider.
11383049|NCT02148562||Chronic Hepatitis B|Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
11383050|NCT02148562||End stage liver disease|Diagnosis of advanced liver disease related to Hepatitis B
11383051|NCT02148549|Experimental|Optimal chemotherapy courses|Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients
11383052|NCT02148536||HPS-TIPS group|
11383053|NCT02148523|Experimental|Weekly Adherence Report|Adherence report to subject every 7 days.
11383054|NCT02148523|Experimental|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
11383055|NCT02148523|Other|Usual Care|Usual care with GlowCap.
11383056|NCT02148510|Experimental|Monobloc|Treatment with an appliance that holds the lower jaw in a fixed protruded position
11383057|NCT02148510|Active Comparator|Bibloc|Bibloc device where a maxillary splint is connected to a mandibular splint by a connector allowing a slight opening of the jaw without compromizing the protrusion (Narval)
11383058|NCT02148497|Other|Dry Eye Disease or Sjogren's Disease|Capturing images of the tear surface using the multi-colored Placido disk
11383059|NCT02148497|Other|Control|Capturing images of the tear surface using the multi-colored Placido disk
11383060|NCT02148484|Experimental|1|Prolonged exposure for adolescents
11383061|NCT02148484|Active Comparator|2|Client centered therapy
11383062|NCT02148471||Healthy controls|Healthy living liver donors with healthy liver on imaging and/or liver histology
11383063|NCT02148471||Simple steatosis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
11383064|NCT02148471||Nonalcoholic steatohepatitis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
11383125|NCT02148107|Experimental|BI 691751 Dose 3|multiple dose given over 14 days
11383065|NCT02148471||Minimal findings|Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.
11383066|NCT02148458|Other|Control group|Western diet for 8 weeks, followed by 8 weeks of Western diet with intermittent fasting.
11383067|NCT02148458|Experimental|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting.
11383068|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
11383069|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
11383070|NCT02148432|Experimental|dexmedetomidine 0.5 mcg/kg/hr|
11383071|NCT02148432|Active Comparator|dexmedetomidine 1.0 mcg/kg/hr|
11383072|NCT02148406|Experimental|Arm I (YST intervention)|Patients undergo YST intervention comprising four individualized, 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation during outpatient chemotherapy sessions in weeks 2, 4, 6, and 8. Patients practice awareness - noticing the current state and establishing relaxed breathing for 5 minutes; movement - 7 minutes of gentle movements coordinated with the breath (such as raising and lowering the arms); breathing practice - 3 minutes of inhaling cool air as if through a straw; and meditation - 5 minutes of focus on letting go of physical and mental tension. Patients review a handout describing the YST and to encourage patients to practice daily with strategies to increase adherence to home practice. Patients also receive an audio recording of the YST and devices to play the recording and are asked to keep a home practice log.
11383073|NCT02148406|Active Comparator|Arm II (attention control)|Patients attend four 30-minute sessions with an interventionist in weeks 2, 4, 6, and 8. During these sessions, patients are encouraged to discuss their experiences while receiving chemotherapy and do not receive instruction of movement, meditation or breathing practices. Patients will also be asked to write brief diary entries daily at home.
11383074|NCT02148393|Active Comparator|Control|In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.
11383075|NCT02148393|Experimental|Intervention|"Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.
~On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible."
11383076|NCT02148380|Experimental|chemotherapy group(B)|pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
11383077|NCT02148380|Experimental|combination therapy group(A)|pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
11383078|NCT02148380|Experimental|gefitinib group (group C)|received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death
11383079|NCT02148367|Active Comparator|Erythropoietin (EPO)|Participants (n=20) will receive EPO with a dose of 40,000 IU EPO subcutaneously (s.c.) once weekly for 4 weeks.
11383080|NCT02148367|Placebo Comparator|placebo|Participants (n=10) will receive placebo s.c. once weekly for 4 weeks
11383081|NCT02148354|Experimental|Group with support by the therapist.|Intervention group that do the Smiling is Fun program and receives support by the therapist (a brief weekly two-minute call without clinical content).
11383082|NCT02148354|Experimental|Group without support by the therapist|Intervention group that do the Smiling is Fun program and does not receive support by the therapist.
11383083|NCT02148354|Other|Waiting list control group|"Control group that could access the Smiling is Fun program after waiting for 12 weeks.
~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
11383084|NCT02148341|Experimental|Community of Practice Facilitation|Medical Centers assigned to this arm will recieive the communtiy of practice facilitation. In this process we will contact existing members of the community of practice (called the Heart Failure Network) at the facility as well as attempt to identify new providers and other staff at the facility with an interest in improving heart failure care. The facilitation includes: describing the national H2H program, providing talking points and strategies for local providers to obtain support from their local facility to initiate local projects related to H2H, providing a forum for successful sites to describe how they initiated projects to sites yet to initiate projects.
11383085|NCT02148341|Experimental|Usual Care|Medical centers in this arm will hear of H2H through usual routs (calls with facilty Directors and Chiefs of staff).
11383086|NCT02148328|Experimental|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants.
11383087|NCT02148328|Active Comparator|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
11383088|NCT02148328|Experimental|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
11383089|NCT02148328|Active Comparator|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
11383090|NCT02148315|Experimental|garden intervention|garden kit and access to garden-based lessons
11383091|NCT02148315|No Intervention|no garden|control - receives garden and lessons at end of study
11383092|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.
~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.
~A run-in period of two weeks followed by twelve weeks of active treatment"
11383093|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
11383094|NCT02148289|Active Comparator|Nitrate rich beverage|Nitrate rich beverage will contain 140ml nitrate rich beetroot juice + 200ml blackcurrant juice containing 12.7mmol nitrate
11383095|NCT02148289|Placebo Comparator|Nitrate free beverage|Nitrate free beverage will 140ml water + 200ml blackcurrant juice containing <0.5mmol nitrate
11383096|NCT02148276||Research Participants|All participants will complete two measures of social harm at monthly research appointments for a three month period. The social harms assessments will be (1) the ACASI-SHQ that was developed in Phase 1 and (2) the HIV Vaccine Trials Network (HVTN) Social Impact Assessment.
11383097|NCT02148263|Experimental|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
11383098|NCT02148263|Experimental|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
11383099|NCT02148250|Experimental|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
11383100|NCT02148250|Experimental|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
11383101|NCT02148237|No Intervention|Treatment as Usual|Participants in Treatment as Usual (TAU) will receive standard breastfeeding (BF) services from the WIC program and participate in research assessments. Standard services include an on-site and home-visiting lactation consultant, occasional one-on-one peer counseling, and an enhanced food package for BF women.
11383102|NCT02148237|Experimental|Contingency Management|These participants will receive usual WIC care. The frequency, duration, content, and size of the meetings and participation requirements will be the same as for the TAU group, except that this group will also receive contingency management (CM). Members will demonstrate breastfeeding and receive cash incentives weekly if they breastfeed.
11383103|NCT02148224||healthy without diabetes|
11383104|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
11383105|NCT02148198|Active Comparator|1g NWT-03, then placebo|7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
11383106|NCT02148198|Placebo Comparator|placebo, then 1g NWT-03|7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period
11383107|NCT02148198|Active Comparator|2g NWT-03, then placebo|7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
11383108|NCT02148198|Placebo Comparator|placebo, then 2g NWT-03|7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period
11383109|NCT02148198|Active Comparator|5g NWT-03, then placebo|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
11383110|NCT02148198|Placebo Comparator|placebo, then 5g NWT-03|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
11383111|NCT02148185|Experimental|MT-1303|
11383112|NCT02148172|Active Comparator|Standard Plyometric Training|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice delivered at a standard dosage of sets and repetitions.
11383113|NCT02148172|Experimental|Plyometric Training with BWS|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
11383114|NCT02148159|Experimental|Cachexia Acupuncture-A|"Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period.
~Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture"
11383115|NCT02148159|Sham Comparator|General Acupuncture-B|"General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted.
~Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture"
11383116|NCT02148146|Other|Omegaven|No placebo or comparator arm. Only intervention arm with Omegaven.
11383117|NCT02148133|Experimental|Eltrombopag|Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
11383118|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6, 1 puff|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
11383119|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6 µg, 4 puffs|Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg
11383120|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 1 puff|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
11383121|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 4 puffs|Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg
11383122|NCT02148120|Placebo Comparator|Placebo NEXThaler|Placebo
11383123|NCT02148107|Experimental|BI 691751 Dose 1|multiple dose given over 14 days
11383128|NCT02148107|Experimental|BI 691751 Dose 6|multiple dose given over 14 days
11383129|NCT02148107|Placebo Comparator|Placebo|Placebo
11383130|NCT02148094|Experimental|Truvada|Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP.
11383131|NCT02148081||Critically ill children|
11383132|NCT02148068||Bariatric Surgery - Gastric Bypass|This population will undergo a laparoscopic roux-en-y gastric bypass
11383133|NCT02148068||Bariatric Surgery - Sleeve Gastrectomy|This group will undergo a laparoscopic sleeve gastrectomy
11383134|NCT02148055|Other|A group of 20 pregnant patients.|20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.
11383135|NCT02148042||Anorexics|
11383136|NCT02148042||Controls|
11383137|NCT02148029|Active Comparator|Control|Standard care: anticoagulation, compression & ad-lib ambulation
11383138|NCT02148029|Experimental|Exercise|Standard care + Interventional Exercise therapy
11383139|NCT02148016|Experimental|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.
~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
11383140|NCT02148016|Active Comparator|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
11383141|NCT02148016|Experimental|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.
~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
11383142|NCT02148016|Active Comparator|PRK only (Traditional Technique)|PRK alone will be performed.
11383143|NCT02148003|Active Comparator|RFA at 90 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 90 degrees Celsius
11383144|NCT02148003|Active Comparator|RFA at 80 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 80 degrees Celsius
11383145|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
11383146|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
11383147|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
11383148|NCT02147977|Active Comparator|dietary supplement: n-3 PUFA|"n-3 polyunsaturated fatty acids from fish oil
~capsules of 500 mg. 2 g a day."
11383149|NCT02147977|Placebo Comparator|olive oil|Capsules of 500 mg. 2 g a day.
11383150|NCT02147964|Experimental|Acyline; T Gel; placebo dutasteride, placebo ketoconazole|"All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
11383151|NCT02147964|Experimental|Acyline; T gel; Ketoconazole; placebo|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
11383152|NCT02147964|Experimental|Acyline; Tgel; Ketoconazole; Dutasteride|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
11383153|NCT02147964|Experimental|Acyline; Tgel; HCG|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.
~Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
11383154|NCT02147938||1: early conversion from Prograf® to Advagraf®|patients converted during the first 6 months post-transplantation
11383155|NCT02147938||2: late conversion from Prograf® to Advagraf®|patients converted between 6 and 12 months post-transplantation
11383156|NCT02147925|Active Comparator|Liraglutide|Liraglutide combined with metformin
11383157|NCT02147925|Active Comparator|Insulin glargine|Insulin glargine combined with metformin
11383158|NCT02147925|Active Comparator|Sitagliptin|Sitagliptin combined with metformin
11383159|NCT02147912|Active Comparator|Aerobic exercise|A six week aerobic exercise intervention in COPD depressed population.
11383160|NCT02147912|No Intervention|Control sample|"Only participants randomized in the arm named Aerobic exercise will receive a six weeks aerobic exercise intervention."
11383161|NCT02147899|Experimental|SYM-1219 Low Dose|Administered orally
11383162|NCT02147899|Experimental|SYM-1219 High Dose|Administered orally
11383163|NCT02147899|Placebo Comparator|Placebo|Administered orally
11383164|NCT02147886|Experimental|Cabaletta 15gr|Cabaletta 15gr
11383165|NCT02147886|Experimental|Cabaletta 30gr|Cabaletta 30gr
11383166|NCT02147873|Active Comparator|azacitidine with birinapant|Azacitidine 75 mg/m2 IV on days 1-5, 8 & 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 & 4) for 3 out of 4 weeks
11383167|NCT02147873|Placebo Comparator|Azacitidine and placebo|Azacitidine 75mg/m2 IV days 1-5, 8 & 9 OR days 1-7 and placebo IV twice a week (days 1 & 4) for 3 out of 4 weeks
11383168|NCT02147860|Placebo Comparator|Sensor Augmented Pump Therapy|Each camp participant will be randomized to full day and night CLC or sensor augmented pump therapy for up to 7 days/6 nights. The subject will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
11383169|NCT02147860|Experimental|Diabetes Assistant (DiAs) with USS Virginia|"With the use of the UVA Artificial Pancreas (DiAs), the study will assess safety and feasibility and are not powered for statistical significance. These studies are intended to train staff on system function and obtain data regarding safe and feasible system use.
~Camp participants will be randomized to either closed-loop control using the DiAs or sensor-augmented pump therapy only. These studies would generate up to 120 days of closed-loop data and 120 comparable days of open-loop data."
11383170|NCT02147847|Experimental|Video game based training 1|Video Game play with training strategy 1
11383171|NCT02147847|Experimental|Video game based training 2|Video Game play with training strategy 2
11383172|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
11383173|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet
~500mg tablet two times per day for 7 days then,
~500mg tablet (1000mg) two times per day for 15 weeks"
11383174|NCT02147821|No Intervention|Standard|Standard treatment will be defined as current practice whereby two mediastinal chest tubes are used for drainage, as well as an additional pleural tube if the pleura is opened during surgery. As part of current standard practice, the pleural and mediastinal spaces will be suctioned during the achievement of hemostasis prior to the insertion of chest tubes.
11383175|NCT02147821|Experimental|Intervention|The treatment arm of the study will involve standard placement of the mediastinal tubes with the exclusion of the pleural tube.
11383176|NCT02147808|Experimental|All subjects|All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
11383177|NCT02147795||Control cohort|Standard care before implementation (pre-implementation)
11383178|NCT02147795||PBM cohort|After implementation of PBM program (post-implementation)
11383179|NCT02147782||control|Healthy people from physical examination centers are recruited as controls.
11383180|NCT02147782||CKD1|"with clinical one or more symptoms and signs of kidney injury listed as below：
~Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)
~urinary sediments abnormality
~renal tubular lesions
~renal histological abnormalities
~abnormal structure showed by imaging
~history of renal transplantation
~GFR≥90（ml/min/1.73m²)"
11383181|NCT02147782||CKD2|with clinical symptoms and signs of kidney injury, and 60<=GFR<=89（ml/min/1.73m²)
11383182|NCT02147782||CKD3|with clinical symptoms and signs of kidney injury, and 30<=GFR<=59（ml/min/1.73m²)
11383183|NCT02147782||CKD4|with clinical symptoms and signs of kidney injury, and 15<=GFR<=29（ml/min/1.73m²)
11383184|NCT02147782||CKD5|with clinical symptoms and signs of kidney injury, and GFR<15（ml/min/1.73m²)
11383185|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
11383186|NCT02147756|Active Comparator|CO2RE|Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
11383187|NCT02147756|Active Comparator|RePair|Fractional CO2 system that comprises an infrared laser controlled by an embedded processor and a handpiece that directs the laser treatment. The device laser has a wavelength of 10.6μm and its tissue chromophore is water. It delivers multiple low energy pulses in microscopic spots as the handpiece glides over the skin surface. The selected energy determines the depth and width for each microscopic treatment zone (MTZs).
11383188|NCT02147743|Experimental|CCP+MDFT|Multidimensional Family Therapy (MDFT) is a multisystemic, flexible intervention system (Liddle, 2002). It is a strengths-based approach promoting protective factors and reducing risk factors for delinquency, substance use, and school problems. MDFT organizes interventions in key areas of the teen's life: self of the adolescent (includes HIV-STD risk behaviors), parenting, family environment, and school/vocational functioning.
11383189|NCT02147743|Other|CCP+SAU|Services as Usual (SAU) are determined on a case-by-case basis by the CCP Case Manager. SAU includes a variety of services offered by a number of community partners.
11383190|NCT02147730||surgical patients|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, hallux valgus surgery, hernia repair, saphenectomy, cesarean section,colectomy, hysterectomy, nephrectomy mastectomy during study period
11383191|NCT02147717|Experimental|Laser stimulation|"Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.
~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
11383192|NCT02147717|Placebo Comparator|fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
11383193|NCT02147704|Other|Goup I|Group I: Fimasartan 60 mg in a low-sodium intake period --> Fimasartan 60 mg in a high-sodium intake period
11383194|NCT02147704|Other|Group II|Group II: Fimasartan 60 mg in a high-sodium intake period --> Fimasartan 60 mg in a low-sodium intake period
11383195|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%
~Azelaic acid 15% to the face each PM"
11383196|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
11383197|NCT02147678|Experimental|Group E|Etomidate/remifentanil group. Patients in group E will be given etomidate and remifentanil during the operation, the speeds are 10~15 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
11383198|NCT02147678|Experimental|Group P|Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50~75 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
11383199|NCT02147665|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after Hookah smoking.
11383200|NCT02147652|Experimental|Personalized music|
11383201|NCT02147639|Experimental|Sodium Nitrate|Patients will ingest a single oral dose of sodium nitrate (~8.4 mmol)
11383202|NCT02147639|No Intervention|Baseline|This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
11383203|NCT02147639|Experimental|Dose-escalation trial|This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (~16.8 mmol).
11383204|NCT02147639|Placebo Comparator|Placebo-control trial|This is an optional study visit, where patients will ingest a placebo.
11383205|NCT02147639|Experimental|Increased exercise intensity|This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
11383206|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the AHA Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) DASH website, and the NIH smoking cessation website
11383207|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
11383208|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
11383209|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
11383210|NCT02147600||Chronic plaque psoriasis|Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
11383211|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
11383212|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
11383213|NCT02147574|Experimental|antiperistaltic ileosigmoid anastomosis|To assess the operative results after laparoscope subtotal colectomy with antiperistaltic ileosigmoid anastomosis for the slow-transit constipation.
11383214|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
11383215|NCT02147548|Experimental|etifoxine (Anxiolytic)|etifoxine, 100 mg, a single oral intake
11383216|NCT02147548|Active Comparator|lorazepam|lorazepam, 2 mg, a single oral intake
11383217|NCT02147548|Placebo Comparator|Placebo|2 capsules of Placebo, a single oral intake
11383218|NCT02147535|Experimental|Methylphenidate|
11383219|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
11383220|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.
~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
11383221|NCT02147509|Experimental|Severe dry eye|"0.02% Fm, SH
~0.02% Fm, SH, AS
~0.02% Fm, SH, 0.05% CsA
~0.02% Fm, SH, tBCL (0.05% CsA: 0.05% cyclosporin A; tBCL: therapeutic bandage contact lenses; 0.02% Fm: 0.02% Fluorometholone; AS: Autologous Serum; SH: Sodium Hyaluronate)"
11383222|NCT02147496|Experimental|2% M.F. Milk|Dietary treatment: 2% m.f. milk
11383223|NCT02147496|Experimental|1% M.F. Chocolate Milk|Dietary treatment: 1% m.f. chocolate milk
11383224|NCT02147496|Experimental|1.5% M.F. Drinkable Yogurt|Dietary treatment: 1.5% m.f. drinkable yogurt
11383225|NCT02147496|Experimental|Tropical Punch|Dietary treatment: fruit-flavoured beverage
11383226|NCT02147496|Experimental|Water|Dietary treatment: calorie-free control
11383227|NCT02147483|Active Comparator|Treatment as usual|Treatment as usual as prescribed by clinician.
11383228|NCT02147483|Experimental|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
11383229|NCT02147470|Other|prerenal AKi, acute tubular necrosis and hepatorenal syndrome|All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.
11383230|NCT02147457||ELBW (CASES)|Extremely low birth weights, born in 2000-2005, birth weight below 1000 grams, who were initially admitted (2000-2005) at the Neonatal Intensive Care Unit, UZ Leuven Belgium and have been well characterized and documented in the postnatal period.
11383231|NCT02147457||CONTROLS|Survivors (CASES) (n = 140) will be matched with two healthy controls. One control will be matched to sex, birth year and residential area and will be suggested by the index patient (e.g. school friend, neighbor), the second control will be age and sex matched from the area of the field.
11383232|NCT02147444||Non-valvular atrial fibrillation|"Patients diagnosed with non-valvular atrial fibrillation
~Patients who are treated or will be treated with rivaroxaban"
11383233|NCT02147431|Experimental|Semaglutide|
11383234|NCT02147431|Placebo Comparator|Placebo|
11383235|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
11383236|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
11383237|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
11383238|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
11383239|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
11383240|NCT02147379|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
11383241|NCT02147379|No Intervention|Treatment as usual|Patients randomized to this arm will continue their usual treatment.
11383242|NCT02147366|Experimental|Behavioral (Lifestyle)|Only standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
11383243|NCT02147366|Experimental|Behavioral (Music & lifestyle changes)|Experimental: Music along with standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
11383244|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
11383245|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
11383246|NCT02147340||Heart failure patients with ICD|Heart failure patients with ICD and RPM system equipped with sensors for the measurement of weight and pressure
11383247|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):
~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
11383248|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
11383249|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
11383250|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
11383251|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
11383252|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
11383253|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
11383254|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
11383255|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
11383256|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
11383257|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
11383258|NCT02147275||hypertension disease|patients have hypertension disease, whether well-controlled or uncontrolled, more than 3 year
11383259|NCT02147262|Active Comparator|ACA-doxy 14 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
11383260|NCT02147262|Active Comparator|ACA-doxy 28 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
11383261|NCT02147249|Experimental|erythema migrans patients treated with antibiotics|adult patients with erythema migrans will be treated with oral antibiotics
11383262|NCT02147223|Active Comparator|Flavanol rich product A|250 mg flavanols
11383263|NCT02147223|Active Comparator|Flavanol rich product B|500 mg flavanols
11383264|NCT02147223|Active Comparator|Flavanol rich product C|750 mg flavanols
11383265|NCT02147223|Placebo Comparator|Flavanol free product|flavanol free
11383266|NCT02147210||1-Case|patients who developed CTG secondary to antibody-mediated kidney rejection (AMR), diagnosed by microscopic analysis.
11383267|NCT02147210||2-Control|patients with antibody-mediated kidney rejection (AMR) but without CTG
11383268|NCT02147197|Experimental|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
11383269|NCT02147197|Experimental|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
11383270|NCT02147197|Placebo Comparator|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
11383271|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
11383272|NCT02147184||Unmedicated Group|No treatment with SSRIs
11383273|NCT02147171|Active Comparator|Active lutein group|44 participants taking VisionAce daily for a period of 1 year
11383274|NCT02147171|Placebo Comparator|Placebo group|44 participants taking placebo daily for a period of 1 year
11383275|NCT02147158|Experimental|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
11383276|NCT02147158|Experimental|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
11383277|NCT02147158|Experimental|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
11383278|NCT02147158|Experimental|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
11383279|NCT02147158|Experimental|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
11383280|NCT02147158|Experimental|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
11383281|NCT02147145||Observation Cohort|
11383282|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
11383283|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
11383284|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
11383285|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
11383286|NCT02147119||Patients post- cardiac catheterisation|
11383287|NCT02147106||Videoconsultation|Performing two videoconsulations with the treating medical oncologist
11383288|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
11383289|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
11383290|NCT02147080|Experimental|Tailored Intervention|Subject has access to the tailored web intervention
11383291|NCT02147080|Active Comparator|Skin Cancer Foundation Website|Subject has access to the pre-existing Skin Cancer Foundation website
11383292|NCT02147080|No Intervention|Assessment Only Condition|Subjects will only complete assessments
11383293|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
11383294|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
11383295|NCT02147054|Active Comparator|Rocuronium with >95% inhibition|"IV Rocuronium to be given:
~Bolus dose of Rocuronium 0.3 mg/kg to achieve >95% inhibition as indicated by Train of Four monitoring
~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition
~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
11383296|NCT02147054|Active Comparator|Rocuronium with 50% inhibition|"IV Rocuronium to be given:
~Bolus dose of Rocuronium 0.3 mg/kg to achieve 50% inhibition as indicated by Train of Four monitoring
~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition
~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
11383297|NCT02147054|No Intervention|No Rocuronium|No Rocuronium will be given
11383298|NCT02147041|Experimental|EGCG(Epigallocatechin Gallate)|EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
11383299|NCT02147041|Placebo Comparator|placebo|cellulose (500mg, three times a day, 12 weeks)
11383300|NCT02147028|Experimental|Hippocampal sparing whole brain RT|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
11383301|NCT02147028|Active Comparator|Control: Conventional whole brain RT|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
11383302|NCT02147015|Experimental|Personalized variable dose of glucocorticoids arm|Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
11383303|NCT02147015|Other|Fixed dose of glucocorticoids arm|Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
11383304|NCT02147002|Active Comparator|omega 3 acids 1|Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)
11383305|NCT02147002|Active Comparator|omega 3 acids 2|Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)
11383306|NCT02147002|Active Comparator|omega 3 acids 3|Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)
11383307|NCT02147002|Active Comparator|omega 3 acids 4|Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum
11383308|NCT02146989||Cerebral Palsy|Children and adolescents with spastic unilateral Cerebral Palsy (with perinatal acquired hypoxic ischemic incidents), aged 7 to 18 years, MACS levels I-III.
11383309|NCT02146989||Healthy controls|Children and adolescents without Cerebral Palsy
11383310|NCT02146976|Experimental|Propofol|introvenious infusion of propofol
11383642|NCT02144857|Active Comparator|Anti IL12/23 regimen|ustekinumab 45 mg
11383311|NCT02146976|Experimental|Inhaled anaesthetic (Sevoflurane)|sevoflurane (1.0-1.3% Minimum Alveolar Concentration)
11383312|NCT02146963||alcohol withdrawal|
11383313|NCT02146950||LCS12|New users of LCS12
11383314|NCT02146950||Mirena|New users of Mirena
11383315|NCT02146950||Copper IUD|New users of copper IUDs
11383316|NCT02146950||Kyleena|New users of Kyleena
11383317|NCT02146950||Other hormonal IUD (OHIUD)|New users of other hormonal IUDs (e.g. Levosert, Fibroplant)
11383318|NCT02146937|Experimental|Combination therapy- bicalutamide and finasteride|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
11383319|NCT02146924|Experimental|Arm I (cellular immunotherapy closed to accrual January 2019)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
11383320|NCT02146924|Active Comparator|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells after 28 days.
11383321|NCT02146911|Experimental|Bupropion|Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
11383322|NCT02146911|Experimental|Varenicline|Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
11383323|NCT02146898|Active Comparator|Lateral|patient placed in the lateral postion for spinal anesthesia
11383324|NCT02146898|Active Comparator|Sitting|patient placed in the sitting position for spinal anestheisa, then supine
11383325|NCT02146898|Active Comparator|Recline|patient placed in the sitting position for spinal anesthesia administration. After spinal placed, the patient turned to a 30-degree upperbody tilt, followed by a slow recline to supine over 5 minutes
11383326|NCT02146885||Weight Control|Weight Control
11383327|NCT02146872||Very Premature CAD|Patients who have received a coronary intervention procedure on the basis of atherosclerosis before the age of 40
11383328|NCT02146872||Healthy middle-aged 1st degree relatives|Healthy 1st degree relatives aged 30-65 years of patients with very premature CAD.
11383329|NCT02146872||PCAD families|Families severely affected by premature CAD
11383330|NCT02146859||general anesthesia|Patient having general anesthesia
11383331|NCT02146846||Imatinib, CML|Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
11383332|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
11383333|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
11383334|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
11383335|NCT02146820|Experimental|Picosecond Laser System|
11383336|NCT02146807|Experimental|Picosecond Laser System|
11383337|NCT02146794|Experimental|Renal denervation|renal denervation
11383338|NCT02146781|Placebo Comparator|0.80 mL Saline Placebo Cohort 1|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan and are skin test positive or negative at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens.
~Cohort # 1: Subjects will receive four 0.200 mL volume intradermal injections of saline control as a placebo control using the Biojector device.
~Intervention: Saline Control via Intradermal route."
11383339|NCT02146781|Experimental|2.16 mg of CryJ2-DNA-LAMP plasmid vaccine Cohort 2|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.
~Cohort # 2: Subjects receive four (4) injections of 0.200 mL volumes (2.7 mg/mL) for a single dose of 2.16 mg of CryJ2-DNA-LAMP plasmid vaccine; intradermally (ID) administered using the Biojector device (each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B
~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
11383340|NCT02146781|Experimental|1.08 mg CryJ2-DNA-LAMP plasmid vaccine Cohort 3|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.
~Cohort # 3: Subjects will receive two (2) injections of 0.200 mL (2.7 mg/mL) for a single dose intradermally (ID) for a single dose of 1.08 mg CryJ2-DNA-LAMP plasmid vaccine administered using the Biojector device, each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B
~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
11383341|NCT02146742|Experimental|1. ASP1707 lowest dose|
11383342|NCT02146742|Experimental|2 ASP1707 higher dose|
11383343|NCT02146742|Experimental|3. ASP1707 Highest dose|
11383344|NCT02146729|Experimental|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
11383345|NCT02146729|Active Comparator|Open Treatment|Midline posterior incision with instrumentation.
11383346|NCT02146716|No Intervention|Control|
11383347|NCT02146716|Experimental|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
11383348|NCT02146703|Experimental|gemcitabine and S-1|
11383349|NCT02146690|Other|osteopathic manipulative treatment|newborns will receive osteopathic manipulative evaluation and treatment during the entire period of hospitalization plus usual care
11383350|NCT02146690|Other|sham|newborns will receive sham treatment for the entire period of hospitalization plus usual care
11383351|NCT02146690|Other|usual care|newborns allocated in the usual care arm will receive standard care only
11383352|NCT02146677|Other|Sham|newborns will be osteopathically evaluated and softly touched
11383353|NCT02146677|Other|Usual care|newborns will be undergone usual routine neonatology care
11383354|NCT02146677|Other|OMT|newborns will receive osteopathic evaluation and treatment according to international guidelines. Osteopathic treatment use will be indirect techniques.
11383355|NCT02146664|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for eight weeks of study period
11383356|NCT02146664|Placebo Comparator|Placebo|Placebo is administered one tablet three times daily, everyday for eight weeks of study period
11383357|NCT02146651|Experimental|BioChaperone insulin lispro 0.2U/Kg|BioChaperone insulin lispro 0.2U/Kg
11383358|NCT02146651|Experimental|BioChaperone insulin lispro 0.1U/Kg|BioChaperone insulin lispro 0.1U/Kg
11383359|NCT02146651|Experimental|BioChaperone insulin lispro 0.4U/Kg|BioChaperone insulin lispro 0.4U/Kg
11383360|NCT02146651|Active Comparator|Humalog® 0.2U/Kg|Humalog® 0.2U/Kg
11383361|NCT02146638|Active Comparator|Morphine|Patients received morphine 0.02 mg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
11383362|NCT02146638|Experimental|Fentanyl|Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
11383363|NCT02146625|Experimental|Dose level 1 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
11383364|NCT02146625|Experimental|Dose level 2 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
11383365|NCT02146625|Experimental|Dose level 3 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
11383366|NCT02146625|Experimental|Dose level 4 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
11383367|NCT02146625|Experimental|Dose level 5 of CJ-40002|"Single dose
~8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
11383368|NCT02146612||Group Receiving Supplement|Amino acid supplement group
11383369|NCT02146599||Pseudophakic|
11383370|NCT02146586||Dystrophinopathies|
11383371|NCT02146586||Gold Standard Clinical Evaluators (GS-CEs)|
11383372|NCT02146586||Sites Clinical Evaluators (CEs)|
11383373|NCT02146573|Experimental|CCI Provider for Parent-patient dyad|Parents and patients are randomly assigned to a Continuity Care Intensivist (CCI) Provider who has received specialized communication training. The parent-patient dyad will receive standardized care from the CCI throughout their time in the PICU in addition to being assigned a rotating physician of record.
11383374|NCT02146573|No Intervention|Usual Care for Parent-patient dyad|Patients and parents randomly assigned to usual care in the PICU which includes the rotation of the physician of record approximately every 7 days. There is no standardized process by which patients may be assigned a primary attending who would follow them throughout their stay. In the usual care arm it may never happen that they are assigned a primary intensivist, regardless of the length of their hospitalization.
11383375|NCT02146547|Active Comparator|aripiprazole oral|the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.
11383376|NCT02146547|Active Comparator|Aripiprazole depot|"The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).
~After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.
~If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered."
11383377|NCT02146547|Active Comparator|Paliperidone|The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
11383378|NCT02146547|Active Comparator|Paliperidone palmitate|The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.
11383379|NCT02146534|Experimental|fampridine|extended release fampridine 10mg BID PO for 14 weeks
11383380|NCT02146534|Placebo Comparator|placebo|placebo pill BID PO for 14 weeks
11383381|NCT02146521||patients undergoing CT|Emergency department's patients undergoing CT scanning for evaluation of acute abdominal pain and tenderness
11383382|NCT02146508|Experimental|Endoscopic treatment|Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
11383383|NCT02146495|Active Comparator|Amygdala EEG-NF|Amygdala activity based EEG-NF
11383384|NCT02146495|Placebo Comparator|Sham EEG-NF|Sham EEG-NF
11383385|NCT02146495|No Intervention|Change in drug therapy|Pain and sleep quality measured after a change in drug therapy performed by the treating physician irrespective of the study - an observational arm
11383386|NCT02146495|Active Comparator|A/T EEG-NF|EEG-NF based on alpha/Theta ratio
11383549|NCT02145481|Active Comparator|CAD Education|Patient with coronary artery disease will be given a general educational handout on coronary artery disease.
11383387|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
11383388|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
11383389|NCT02146469|Experimental|None varicella vaccine history|2 doses with an 3 months interval
11383390|NCT02146469|Experimental|1 year after first dose|A second dose with an 1 year interval
11383391|NCT02146469|Experimental|3 years after first dose|A second dose with an 3 year interval
11383392|NCT02146469|Experimental|5 years after first dose|A second dose with an 5 year interval
11383393|NCT02146469|Experimental|Testing group for conbined immunization|1 dose Varicella vaccine and 1 dose MMR given at the same time
11383394|NCT02146469|Placebo Comparator|Control group for conbined immunization|1 dose MMR
11383395|NCT02146456|No Intervention|Colloid|During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
11383396|NCT02146456|Experimental|Tranexamic acid|"During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
~In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion."
11383397|NCT02146443|Active Comparator|Baseline|Completion of the star shaped manual dexterity test, five rounds clockwise and five rounds counter clockwise without any intervention. Time and number of errors are recorded. Measurement of static arm strength with the stretched arm test. test subject is asked to hold a 2.5 kg weight in stretched arm for as long as possible. Maximum endurance time is recorded.
11383398|NCT02146443|Active Comparator|Fatigue|Prior to completion of the star shaped manual dexterity test, the test subject is asked to stand up still and hold a 2.5-kg weight with the dominant arm fully extended as long as possible without moving. Maximum endurance time is recorded. After this, the test subject completes the the star shaped manual dexterity test and time and number of errors are recorded.
11383399|NCT02146443|Active Comparator|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test. Completion time and number of errors are recorded.
11383400|NCT02146443|Active Comparator|Fatigue and Stress|The test subject will be fatigued prior to the test (as detailed in the fatigue arm), and asked to identify cards during completion of the star shaped manual dexterity test (as detailed in the stress arm). Completion time and number of errors are recorded.
11383401|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
11383402|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
11383403|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
11383404|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
11383405|NCT02146417|Active Comparator|Normal pressure pneumoperitoneum & deep neuromuscular block|Normal pressure pneumoperitoneum
11383406|NCT02146417|Experimental|Low pressure pneumoperitoneum & deep neuromuscular block|Low pressure pneumoperitoneum
11383407|NCT02146404|Active Comparator|Euglycemia|Plasma glucose levels will be clamped at a constant value of ~5.0 mmol/l
11383408|NCT02146404|Experimental|Hypoglycemia|Plasma glucose levels will be clamped at a stable value of ~3.0 mmol/l
11383409|NCT02146391|Experimental|Androxal 25 mg|
11383410|NCT02146378||Vyndaqel|
11383411|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
11383412|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
11383413|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
11383414|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
11383415|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
11383416|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
11383417|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
11383418|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
11383419|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
11383420|NCT02146339|Experimental|Unfortified-3g-5g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
11383421|NCT02146339|Experimental|Unfortified-5g-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
11383422|NCT02146339|Experimental|3g-5g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
11383423|NCT02146339|Other|3g-Unfortified-5g milk polar lipid fortified cheese product|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.
~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
11383424|NCT02146339|Experimental|5g-unfortified-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
11383425|NCT02146339|Other|5g-3g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
11383426|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
11383427|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
11383428|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
11383429|NCT02146326|Active Comparator|BREATHE-Clients|
11383430|NCT02146313|Experimental|Dose-escalation Cohort|DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
11383431|NCT02146313|Experimental|Platinum-resistant Ovarian Cancer Dose-expansion Cohort|Platinum-resistant Ovarian Cancer participants will be administered with the identified RP2D during the Dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
11383432|NCT02146313|Experimental|Unresectable Pancreatic Cancer Dose-expansion Cohort|Unresectable pancreatic cancer participants will be administered with the identified RP2D during the dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
11383433|NCT02146300|Experimental|Allergen and xylometatsolin|Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
11383434|NCT02146287|Active Comparator|Early Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 28 weeks PMA
11383435|NCT02146287|Active Comparator|Late Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 36 weeks PMA
11383436|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
11383437|NCT02146261|Experimental|1|Subcutaneous administration of E6011 50 mg
11383438|NCT02146261|Experimental|2|Subcutaneous administration of E6011 100 mg
11383439|NCT02146261|Experimental|3|Subcutaneous administration of E6011 200 mg
11383440|NCT02146261|Experimental|4|Subcutaneous administration of E6011 400 mg
11383441|NCT02146261|Placebo Comparator|5|Subcutaneous administration of placebo
11383442|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).
~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
11383443|NCT02146235|Experimental|Treatment Group - Music Therapy|The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
11383444|NCT02146235|No Intervention|Standard Pulmonary Rehabilitation|"Pulmonary rehabilitation is a program to people with chronic lung diseases like COPD, emphysema, and chronic bronchitis lead full, satisfying lives and restore them to their highest functional capacity. Pulmonary rehab is aimed to improve quality of life by:
~Decreasing respiratory symptoms and complications Encouraging self-management and control over daily functioning Improving physical conditioning and exercise performance Improving emotional well-being Reducing hospitalizations
~Pulmonary rehab programs include:
~Medical management Exercise Breathing retraining Education Emotional support Nutrition counseling"
11383445|NCT02146222|Experimental|Arm I (high dose X-82, docetaxel)|Patients receive high dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15. Beginning course 2, patients also receive docetaxel IV over 60 minutes on day 1.
11383446|NCT02146222|Experimental|Arm II (low dose X-82, docetaxel)|Patients receive low dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15 and docetaxel IV as in Arm I.
11383447|NCT02146209|Experimental|Test Product Formula A|Metronidazole benzoate
11383448|NCT02146209|Active Comparator|Reference Product Formula B|Flagyl 125 mg/5 ml oral suspension
11383449|NCT02146209|Active Comparator|Reference Product Formula C|Flagyl 400 mg Tablets
11383450|NCT02146196|Experimental|Heart failure, robotic assisted training|4 weeks robotic assisted training with the Lokomat®
11383451|NCT02146196|Experimental|Post cardiac surgery|One week robotic assisted gait training with the Lokomat®
11383452|NCT02146183|Placebo Comparator|placebo / Corn starch|Carbohydrate-containing composition that comprises 2 g carbohydrate per kg of body weight. This composition will be 500 mg placebo starch corn.
11383453|NCT02146183|Active Comparator|Carbohydrate steviol glycosides|500 mg steviol glycosides.
11383454|NCT02146170||Single group|Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET
11383455|NCT02146157|Active Comparator|herb and mineral combination product|Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
11383456|NCT02146157|Placebo Comparator|placebo|Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
11383457|NCT02146144|No Intervention|no peeling|where the ILM peeling will not be made
11383458|NCT02146144|Active Comparator|active peeling|where the ILM peeling will be made
11383459|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
11383460|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.
~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
11383461|NCT02146118|Experimental|Erlotinib and Silibin|
11383462|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
11383463|NCT02146092|Active Comparator|Standard physiotherapy|Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
11383464|NCT02146092|Experimental|Incentive Spirometry|"Patients in the Incentive Spirometry arm will receive standard physiotherapy care in addition to training and use of an incentive spirometer. The physiotherapy care includes routine care as per current institutional standards.
~They will also receive an incentive spirometer on the first postoperative day and will be taught how to use it with an accompanying instructional sheet for later reference. Teaching will emphasize slow deep breathing, sustained vacuum pressure, and gradual increase in difficulty. Patients will be instructed to use the spirometer 10 times every hour until 30 days after surgery."
11383465|NCT02146079|Experimental|Semaglutide 0.5 mg|Dose-escalation trial
11383466|NCT02146079|Placebo Comparator|Semaglutide placebo 0.5 mg|
11383467|NCT02146079|Experimental|Semaglutide 1.0 mg|Dose-escalation trial
11383468|NCT02146079|Placebo Comparator|Semaglutide placebo 1.0 mg|
11383469|NCT02146053|Active Comparator|Ferrous sulfate|ferrous sulfate taken at mealtimes twice daily during 1 week of the treatment period.
11383470|NCT02146053|Placebo Comparator|Placebo|placebo taken at mealtimes twice daily during 1 week of the treatment period.
11383471|NCT02146027|Experimental|Fermented Milk Drink Yakult 40|"Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40
~Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks."
11383472|NCT02146027|Placebo Comparator|Placebo|"The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.
~Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and"
11383473|NCT02146014|Experimental|Transcranial Direct Current Stimulation|These subjects will receive real transcranial direct current stimulation.
11383474|NCT02146014|Placebo Comparator|Sham tDCS|These subjects will receive sham transcranial direct current stimulation (placebo)
11383475|NCT02146001|Active Comparator|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
11383476|NCT02146001|Experimental|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
11383477|NCT02145988|Experimental|DLBS1033|DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
11383478|NCT02145988|Placebo Comparator|Placebo|Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period
11383479|NCT02145975|Experimental|Fentanyl|"Procedure: Fentanyl for rescue of acute postoperative pain in the postanesthesia care unit
~Intervention:
~The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
11383480|NCT02145975|Active Comparator|Morphine|"Procedure: Morphine for rescue of acute postoperative pain in the postanesthesia care unit
~Intervention:
~The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
11383481|NCT02145962|Active Comparator|Forearm tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the medical services site of the Autonomous University of Nuevo Leon, Monterrey, Mexico. These study patients should receive treatment in the forearm region.
11383482|NCT02145962|Active Comparator|Thorax tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
11383550|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
11383551|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
11383483|NCT02145949|Experimental|Essential Amino Acids (EAA)|"Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.
~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).
~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.
~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%)."
11383484|NCT02145949|Placebo Comparator|Placebo (Alanine)|"Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.
~The placebo supplement consists of 20 g (100%) alanine.
~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.
~The placebo supplement consists of 23 g (100%) alanine."
11383485|NCT02145936|Experimental|oleic acid diet|Participants are provided with meals enriched in oleic acid (18:1)
11383486|NCT02145936|Experimental|palmitic acid diet|Participants are provided with meals enriched in palmitic acid (18:0)
11383487|NCT02145936|Experimental|stearic acid diet|Participants are provided with meals enriched in stearic acid (18:0)
11383488|NCT02145923|Other|allogeneic MMSCs infusion|Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion.
11383489|NCT02145910|Experimental|WBRT + Vemurafenib|Patients undergo WBRT once daily (QD) for 10 doses
11383490|NCT02145910|Experimental|SRS + Vemurafenib|Patients undergo SRS (gamma knife, tomotherapy, cyberknife, or megavoltage LINAC radiation therapy) on day 1
11383491|NCT02145897|Experimental|Autologous Stromal Vascular Fraction|single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
11383492|NCT02145897|Experimental|Autologous Adipose Derived MSCs|One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
11383493|NCT02145897|Active Comparator|Control|
11383494|NCT02145884|Experimental|timolol maleate 0.5% gel|timolol gel 1 to 2 drops twice a day to lesions for 4 months
11383495|NCT02145871|Active Comparator|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
11383496|NCT02145871|Experimental|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
11383497|NCT02145845|Experimental|Treatment|Injectable SIS
11383498|NCT02145832|Experimental|Fluconazole|"Fluconazole Kabi, Fresenius 2mg/ml
~Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg once daily, depending of corrected gestational age (GA) at the beginning of treatment:
~12 mg/kg/day for neonates corrected GA (GA + postnatal age) < 30 weeks
~20 mg/kg/day for neonates corrected GA (GA + postnatal age) ≥ 30 weeks
~The infusion will last two hours."
11383499|NCT02145832|Experimental|Micafungin|"Mycamine 50mg - 10 mg/mL of micafungin
~Micafungin will be administered as a loading dose of 15 mg/kg on the first day of treatment and followed by a maintenance dose of 10 mg/kg once daily.
~The infusion will last two hours."
11383500|NCT02145819|Placebo Comparator|A: spontaneous LH peak|In group A, embryos are thawed 4 days after LH surge, with a re-evaluation and transfer 5 days after LH surge.
11383501|NCT02145819|Active Comparator|B: hCG|In group B, embryos are thawed 5 days after hCG administration, with a re-evaluation and transfer 6 days after hCG.
11383502|NCT02145793|Active Comparator|ADHD Group Curriculum|Participants assigned to the group visit intervention agree to participate in 5 group visits every 3 months rather than individual ADHD follow-up visits to the clinic. Parents and children participate in separate but simultaneously run groups. Group portion is 60 minutes and then parent-child dyads complete individual visits for medication titration and physical exam.
11383503|NCT02145793|No Intervention|Control|Participants continue to go to the clinic for 5 routine ADHD follow-up visits to the clinic every 3 months as usual clinical protocol.
11383504|NCT02145780|Experimental|2g of grape polyphenol extract supplement|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
11383505|NCT02145780|Placebo Comparator|2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
11383506|NCT02145767|Experimental|Progesterone|Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.
11383507|NCT02145767|Placebo Comparator|Placebo|Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.
11383508|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
11383509|NCT02145741|Experimental|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
11383510|NCT02145728|Experimental|Individual Cognitive Functional Therapy|The intervention being tested has four main components: (1) a cognitive component, for each patient, their vicious cycle of pain will outlined in a diagram based on their findings from the examination and the Orebro Musculoskeletal Pain Screening Questionnaire; (2) specific movement exercises designed to normalize maladaptive movement behaviours; (3) targeted functional integration of activities in their daily life previously, reported to be avoided or provocative by the patient; and (4) a physical activity and lifestyle programme.
11383552|NCT02145455|Active Comparator|Mechanical alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes mechanical alignment via measured resection to establish knee alignment.
11383511|NCT02145728|Active Comparator|Group Exercise Classes|6 classes will take place in total. The class has 3 components each week. First, a 30 minute talk and discussion on chronic pain, and some tips for participants. Second, a 40 minute exercise circuit, involving aerobic exercise, and gentle stretching and strengthening exercises. Finally, a 5 minute relaxation/mindfulness session will take place at the end. The total time involved is approximately 1 hour and 15 minutes.
11383512|NCT02145715|Experimental|Velcade, Thalidomide, Dexamethasone (VTD) + Panobinostat|"Up to 16 cycles of VTD+Panobinostat followed by panobinostat maintenance for 1 year or until disease progression.
~Induction - Cycles 1-16 (21-day cycle)
~Velcade: 1.3mg/m2 (subcutaneous) on days 1 and 8
~Thalidomide: 100mg (PO)on days 1 -21
~Dexamethasone: 20 mg (PO) on days 1, 2, 8 and 9
~Panobinostat: 10mg, 15mg or 20mg days 1, 3, 5, 8, 10 and 12 Dose depends on cohort entry at registration during the dose escalation phase. The recommended dose will be used during the expansion phase.
~Panobinostat monotherapy maintenance for 1 year. Panobinostat will be given at the same dose as the recommended dose during expansion phase"
11383513|NCT02145702|Experimental|Exercise Group|Subjects randomized to this group will start 12 weeks of supervised aerobic exercise after baseline testing.
11383514|NCT02145702|Experimental|Control Group|Subjects randomized to this group will continue with 12 weeks of Standard Care. After 12 weeks, the subjects will cross over to the exercise arm and undergo baseline testing again and then start 12 weeks of exercise intervention.
11383515|NCT02145689|Experimental|onabotulinumtoxinA Dose 1|Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.
11383516|NCT02145689|Experimental|onabotulinumtoxinA Dose 2|Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.
11383517|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
11383518|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
11383519|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
11383520|NCT02145650||All Participants|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study.
11383521|NCT02145637|Experimental|Afatinib plus Ruxolitinib combination (single arm)|
11383522|NCT02145624|Active Comparator|Repevax|Repevax in pregnancy
11383523|NCT02145624|Active Comparator|Boostrix-IPV|Boostrix-IPV in pregnancy
11383524|NCT02145624|No Intervention|unvaccinated|unvaccinated mothers
11383525|NCT02145611|Active Comparator|vildagliptin|Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks
11383526|NCT02145611|Active Comparator|glibenclamide|Glibenclamide: Dosage: 5 mg to 20 mg; Duration: 12 weeks
11383527|NCT02145598|Experimental|Lenalidomide|Lenalidomide 10mg/day
11383528|NCT02145598|Placebo Comparator|Placebo|Placebo
11383529|NCT02145585||Robotic pharmacological system|Robotic pharmacological system/Automated anesthesia delivery system
11383530|NCT02145572||Obese adolescents with type 2 diabetes|No intervention
11383531|NCT02145572||Obese adolescents without diabetes|No intervention
11383532|NCT02145572||Healthy non-obese adolescents|No intervention
11383533|NCT02145559|Experimental|Metformin XR|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will recieve metformin XR (500 mg daily with the evening meal)(through day 21). On day 15, patients randomized to metformin XR will have their dose increased to 1000 mg daily if there is no grade ≥ 2 toxicity due to metformin XR. Patients who develop grade 2 toxicity due to metformin will be maintained on metformin XR 500 mg daily for the rest of the study, while patients who develop > grade 2 toxicity will be taken off study. From day 22 onwards, all patients will be on combination of sirolimus and metformin.
11383534|NCT02145559|Active Comparator|Delayed Metformin|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
11383535|NCT02145546|Experimental|Amiodarone|Patient will take Amiodarone orally
11383536|NCT02145546|Experimental|Sotalol|Patients will take sotalol orally
11383537|NCT02145546|Experimental|Propafenone|Patients will take propafenone orally
11383538|NCT02145546|No Intervention|Control|Patients will take no antiarrhythmic drugs except β-blocker
11383539|NCT02145533||Group I|patient with ruptured aneurysms
11383540|NCT02145533||Group II|patients with non-ruptured aneurysms
11383541|NCT02145533||Group III|Healthy volunteers
11383542|NCT02145520|Experimental|Magnesium sulfate|Magnesium sulfate. Single dose intravenous over one hour.
11383543|NCT02145520|Placebo Comparator|placebo|"Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).
~•All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.•Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
11383544|NCT02145507|Other|Arm 1: Room Temperature Storage/Filtration|In vitro whole blood storage, leukoreduction and processing of donated whole blood.
11383545|NCT02145507|Other|Arm 2 : Cold storage|In vitro analysis of whole blood following refrigerated storage for > 66 hours prior to leukoreduction and subsequent processing of packed red blood cells.
11383546|NCT02145494|Experimental|Treatment|Radiotherapy
11383547|NCT02145481|No Intervention|Survey development|Patients with coronary artery disease will be given a survey to complete assessing their knowledge, communication with physicians, involvement, and treatment preferences after completing the treatment decision-making process.
11383548|NCT02145481|Experimental|Decision Aid|Patients with stable coronary artery disease will be given a decision aid to review prior to making a treatment decision.
11383643|NCT02144857|Active Comparator|Cyclosporine regimen|Cyclosporine 2.5-3 mg/kg
11383553|NCT02145455|Active Comparator|Anatomic alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes anatomic alignment via ligament balancing with the tibial cut perpendicular to the tibial anatomic axis.
11383554|NCT02145442|Experimental|Obex|Obex®, two oral sachets daily during three months.
11383555|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
11383556|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
11383557|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
11383558|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);
~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;
~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;
~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;
~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);
~International Prostate Symptom Score (IPSS)."
11383559|NCT02145377|Experimental|PXVX0200 10E8 then placebo|PXVX0200 10E8 on day 0; Placebo on day 14
11383560|NCT02145377|Experimental|Placebo, then PXVX0200 10E8|Placebo on day 0; PXVX0200 10E8 on day 14
11383561|NCT02145377|Experimental|PXVX0200 10E9 then Placebo|PXVX0200 10E9 on day 0; Placebo on day 14
11383562|NCT02145377|Experimental|Placebo then PXVX0200 10E9|Placebo on day 0; PXVX0200 10E9 on day 14
11383563|NCT02145377|Active Comparator|Shanchol|Two doses of Shanchol, on day 0 and day 14
11383564|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
11383565|NCT02145351|Active Comparator|Pacing off|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
11383566|NCT02145351|Experimental|Pacing on|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
11383567|NCT02145338|Experimental|Antibiotic prophylaxis|Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
11383568|NCT02145338|Other|No prophylaxis|The control arm will be a strategy of no prophylaxis. Participants will self-monitor their symptoms as usual and report to their General Practitioner if they develop symptoms and signs suggestive of UTI requiring treatment.
11383569|NCT02145325|Experimental|Expanded Tregs|Immune cells in the blood will be removed by leukopheresis procedure and stored for later manufacture of subject's Expanded Tregs cellular product. Two months following subject's kidney transplantation, subject will be given an Expanded Tregs infusion intravenously in the Northwestern Clinical Research Unit.
11383570|NCT02145312|Experimental|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
11383571|NCT02145299|Experimental|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
11383572|NCT02145299|Active Comparator|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
11383573|NCT02145286|Experimental|Radiation Therapy|Stereotactic Body Radiation Therapy
11383574|NCT02145273|Experimental|Intervention|Subjects screen positive for depression and are offered a group Therapy intervention for depression: Interpersonal Psychotherapy for Depression Group.
11383575|NCT02145273|No Intervention|Control|Subjects screen positive for depression and are offered Treatment as usual: External referral.
11383576|NCT02145273|No Intervention|comparison|Subjects screen negative for depression: no referral or intervention.
11383577|NCT02145260|Active Comparator|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
11383578|NCT02145260|Experimental|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
11383579|NCT02145247|Active Comparator|Normal adult women|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.
~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.
~Blood samples will be obtained at T = -0.5, 0, and +24 hours.
~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.
~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
11383580|NCT02145247|Active Comparator|Women with PCOS|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.
~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.
~Blood samples will be obtained at T = -0.5, 0, and +24 hours.
~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.
~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
11383644|NCT02144857|Active Comparator|anti-interleukin 17 A regimen|secukinumab 300 mg
11383581|NCT02145234|Experimental|SAD Panel 1:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
11383582|NCT02145234|Experimental|SAD Panel 2:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
11383583|NCT02145234|Experimental|SAD Panel 3:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
11383584|NCT02145234|Experimental|SAD Panel 4:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
11383585|NCT02145234|Experimental|SAD Panel 5:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration
~OR
~Placebo matching with BMS-986089 in a single subcutaneous administration"
11383586|NCT02145234|Experimental|MAD Panel 1:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 multiple subcutaneous administrations weekly"
11383587|NCT02145234|Experimental|MAD Panel 2:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
11383588|NCT02145234|Experimental|MAD Panel 3:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
11383589|NCT02145234|Experimental|MAD Panel 4:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
11383590|NCT02145234|Experimental|MAD Panel 5:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administration every 2 weeks
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
11383591|NCT02145234|Experimental|MAD Panel 6:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
11383592|NCT02145234|Experimental|MAD Panel 7:BMS-986089/Placebo|"BMS-986089 a single subcutaneous administrations weekly
~OR
~Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks"
11383593|NCT02145221|Experimental|Music therapy|Music therapy post surgery
11383594|NCT02145221|No Intervention|No intervention|
11383595|NCT02145208|Experimental|Medi-Tate iTind|TIND System
11383596|NCT02145195|Experimental|Vitamin D (10 microgram/day)|Tablets with 10 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
11383597|NCT02145195|Experimental|Vitamin D (20 microgram/day)|Tablets with 20 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
11383598|NCT02145195|Placebo Comparator|Placebo control|Tablets with 0 microgram vitamin D daily for 20 weeks.
11383599|NCT02145182|Experimental|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
11383600|NCT02145182|Placebo Comparator|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
11383601|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
11383602|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
11383603|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
11383604|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
11383605|NCT02145143|Experimental|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that > or = 2000 cGy can be achieved in at least one tumor with < 300 mCi of 131I, Thyrogen-stimulated standard dosimetry & therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued & tumor assessments will be conducted with serial radiologic scan(s) & thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, & 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, & the patient will be taken off the study.
11383606|NCT02145130|Experimental|denovoDerm|Autologous tissue-engineered dermal substitute
11383607|NCT02145130|Experimental|denovoSkin|Autologous tissue-engineered dermo-epidermal skin substitute
11383608|NCT02145117|Other|MBSR Training|Mindfulness Based Stress Reduction (MBSR) Training
11383609|NCT02145104|Experimental|Arm A|cilinidpine 10mg + valsartan 160mg
11383610|NCT02145104|Experimental|Arm B|cilnidipine 5mg + valsartan 160mg
11383611|NCT02145104|Active Comparator|Arm C|valsartan 160mg
11383612|NCT02145091|Experimental|One all-day session|"Participants will complete on all-day study session with a moderately-high dose of psilocybin.
~Preparation will include two days of screening, and an additional 8 hours of session preparation over at least 2 days. Follow-up will consist of an interview and MRI scan one day after the all-day session, a questionnaire follow-up 2 months after the all-day session, and a final follow-up 12-18 months after the all-day session."
11383613|NCT02145091|Experimental|Two all-day sessions|"Participants will complete two all-day study sessions, the first with placebo and the second with a moderately-high dose of psilocybin.
~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the second all-day session."
11383640|NCT02144870|Active Comparator|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
11383641|NCT02144857|Active Comparator|Anti-TNFa regimen|Etanercept 50 mg
11383614|NCT02145091|Experimental|Three all-day sessions|"Participants will complete three all-day study sessions, the first two with placebo and the third with a moderately-high dose of psilocybin. The majority of participants (over 90%) will be assigned to either one or two all-day sessions. A small minority of participants (less than 10%) will be assigned to three all-day sessions.
~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the third all-day session."
11383615|NCT02145091|Experimental|MRI of the acute effects of psilocybin|This is an optional arm consisting of two sessions where either placebo, a very-low dose of psilocybin, or a moderately-low dose of psilocybin will be administered. During each session, participants will undergo MRI scanning shortly after the administration of each dose. Study sessions may occur over one or two days. Participants who have previously completed an all-day session with psilocybin in this study will be eligible to volunteer for this arm.
11383616|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
11383617|NCT02145065|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty
11383618|NCT02145065|Experimental|microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation
11383619|NCT02145052|Active Comparator|Continuous suture|0 non-looped PDS using a tapered needle starting at the superior and the inferior portions of the wound. Fascia is then approximated with at least 1cm distance from the edge of the fascia and 1cm advancement. The two sutures are then knotted in the center with 8 square knots.
11383620|NCT02145052|Active Comparator|Interrupted Suture|Using a tapered needle, 0 non-looped PDS interrupted figure of eight suture 1cm from the edge and advancing 1cm between each suture.
11383621|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
11383622|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
11383623|NCT02145013||Portal hypertension|Hepatectomy
11383624|NCT02145013||No portal hypertension|Hepatectomy
11383625|NCT02145000|Experimental|Rotavirus vaccine (BRV-PV)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
11383626|NCT02145000|Placebo Comparator|Placebo|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
11383627|NCT02144974||Patients undergoing total pelvic exenteration|Patients undergoing total pelvic exenteration for gynecological malignancies and reconstruction of the pelvic floor with a TMG flap.
11383628|NCT02144961||Ultrasound|Breast ultrasound in female patients who are post-mastectomy pursuing autologous tissue breast reconstruction surgery.
11383629|NCT02144948|Experimental|E.-coli-Nissle|10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd
11383630|NCT02144935||myelitis, transverse or acute flaccid myelitis|Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
11383631|NCT02144922|Placebo Comparator|Control|Patients continue taking their antihypertensive medication alone.
11383632|NCT02144922|Active Comparator|Pitavastatin|Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
11383633|NCT02144909|Experimental|Partners in Care with Semi-Structured Support Group|Partners in Care with Semi-Structured Support Group: participants will receive the Partners in Care intervention followed by 6 semi-structured support groups, conducted every other week for 3 months. Half of the support groups will be conducted by professionals with diabetes specific knowledge, e.g., pharmacists, physicians, nutritionists. While the other half will be conducted by the trained diabetes self-management facilitator.
11383634|NCT02144909|No Intervention|Partners in Care Standard Follow-up|Participants will receive the Partners in Care intervention followed by monthly healthy lifestyle tips related to diabetes self-management
11383635|NCT02144896|Experimental|Ankle splinting|Older adults will have one leg randomly assigned to ankle splinting for 4 weeks. The non-splinted leg will serve as the control.
11383636|NCT02144896|No Intervention|No Ankle Splinting|The non splinted leg will serve as the control
11383637|NCT02144883|Active Comparator|Materials|Self-help materials mailed to subjects home.
11383638|NCT02144883|Experimental|Telephone Counseling and Materials|Subjects received up to 9 telephone counseling calls plus self-help quit kit and 5 additional mailings
11383639|NCT02144870|Active Comparator|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
11383645|NCT02144857|Active Comparator|inhibitor of phosphodiesterase-4|apremilast 30mg
11383646|NCT02144844|Experimental|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
11383647|NCT02144844|No Intervention|Treatment as Usual (TAU)|Treatment as Usual (TAU) Control
11383648|NCT02144831|Active Comparator|anti-thrombotic treatment|10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
11383649|NCT02144831|Active Comparator|anti-thrombotic|30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
11383650|NCT02144818|Active Comparator|GnRH agonist|
11383651|NCT02144818|Active Comparator|hCG|
11383652|NCT02144818|Active Comparator|dual triggering: GnRH agonist and hCG|
11383653|NCT02144805|Active Comparator|Suturing in a single layer|The technique used for single layer to close the uterine incision following cesarean sectio
11383654|NCT02144805|Active Comparator|Suturing in two layer|The technique used for two layer technie to close the uterine incision following cesarean sectio
11383655|NCT02144792|Active Comparator|Control group (healthy persons)|Normal controls take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
11383656|NCT02144792|Active Comparator|Patients with drug-resistant epilesy|Patients with drug-resistant epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
11383657|NCT02144792|Active Comparator|Patients with drug-sensitive epilepsy|Patients with drug-sensitive epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
11383658|NCT02144779|Active Comparator|Usual care|No treatment for this group
11383659|NCT02144779|Experimental|Assigned to palliative care team|The intervention group will be assigned to a palliative care team member that will facilitate communication and meetings between families and the medical team
11383660|NCT02144766|Experimental|Ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
11383661|NCT02144766|Placebo Comparator|saline|caudal block with 1 ml/kg of saline
11383662|NCT02144753|Experimental|NTX-1|NTX-1 (18 g)
11383663|NCT02144753|Active Comparator|Psyllium|psyllium (15 g)
11383664|NCT02144740|Other|NWT-03, then placebo|4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period
11383665|NCT02144740|Other|Placebo, then NWT-03|4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period
11383666|NCT02144727|Active Comparator|D2 distal subtotal gastrectomy|D2 distal subtotal gastrectomy D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
11383667|NCT02144727|Experimental|D1+ distal subtotal gastrectomy|D1+ distal subtotal gastrectomy D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
11383668|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
11383669|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
11383670|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
11383671|NCT02144701|Experimental|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
11383672|NCT02144701|No Intervention|No intervention|Patients receive no intervention.
11383673|NCT02144688|Experimental|Change in ARVs to improve cognition|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
11383674|NCT02144675|Experimental|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
11383675|NCT02144675|Active Comparator|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
11383676|NCT02144662|Experimental|Ranibizumab|Ranibizumab
11383677|NCT02144649|No Intervention|Group I (control, no juice)|Patients consume no tomato juice.
11383678|NCT02144649|Experimental|Group II (tangerine tomato juice)|Patients will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks)
11383679|NCT02144649|Experimental|Group III (red tomato juice)|Patients consume two cans of red tomato juice daily until their scheduled surgery (approximately 4 weeks).
11383680|NCT02144636|Experimental|treament|herbalife protein shake along with exercise
11383681|NCT02144636|No Intervention|control|diet and exercise only
11383682|NCT02144623|Experimental|Valproate|
11383683|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
11383684|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
11383685|NCT02144597|Active Comparator|2-week LCD|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
11383686|NCT02144597|Active Comparator|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
11383687|NCT02144597|Active Comparator|Control diet|A conventional food diet will be followed for 2 weeks prior to Roux-en-Y gastric bypass. The diet, prescribed as a standard of care at Imperial Weight Centre by the bariatric dietitian will provided 800-1000kcal/day.
11383688|NCT02144584|Placebo Comparator|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
11383689|NCT02144584|Active Comparator|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
11383690|NCT02144571|Experimental|Lifestyle|Diet and physical activity intervention group. Measurements taken at baseline, 12 weeks and 1 year.
11383691|NCT02144571|No Intervention|Wait-list control|No-treatment control group. Measurements taken at baseline, 12 weeks and 1 year. People in the control condition can elect to take the intervention after 1 year.
11383692|NCT02144558|Experimental|Spinal cord injured (SCI) men, para or tetraplegic|SCI men will have 4 medical visits associated to sperm retrieval (penile vibratory stimulation (PVS) or masturbation)
11383693|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 33Fr bougie size and 2 cm distance from the pylorus.
11383694|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 33Fr bougie size and 5 cm distance from the pylorus
11383695|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
11383696|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
11383697|NCT02144532|Experimental|Patients with EDS hypermobility type|Patients with EDS hypermobility type wearing compression garment then compression garment removal
11383698|NCT02144519|Experimental|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
11383699|NCT02144519|Experimental|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
11383700|NCT02144506|Experimental|T&E|"Home-based exercises program T&E.This exercise program proposes 50 exercises with a booklet, cards and an electronic tablet. The participants choose their exercises on the basis of a rating scale of perception of exercise difficulty."
11383701|NCT02144506|Active Comparator|OTAGO|"Programm OTAGO is a home-based exercises program."
11383702|NCT02144493||Patients with recurrent CBD stone|
11383703|NCT02144493||Patients without recurrent CBD stone|
11383704|NCT02144480|Experimental|Intensive training|intensive aerobic training in moderate intensity day5 postoperatively. 30 minutes per sessions, 2 sessions per day, 10 sessions per week. There will be 20 sessions in total.
11383705|NCT02144480|Sham Comparator|traditional training|traditional rehabilitation
11383706|NCT02144467||Large-sample healthy participants|MRI scanning.
11383707|NCT02144454|Active Comparator|Meal rich in saturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in saturated fats
11383708|NCT02144454|Experimental|Meal rich in monounsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in monounsaturated fats
11383709|NCT02144454|Experimental|Meal rich in n-6 polyunsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in n-6 polyunsaturated fats
11383710|NCT02144441|Experimental|Patient self-administered insulin|The study's only arm
11383711|NCT02144428||Cow's milk allergy|Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet
11383712|NCT02144415|Experimental|EB-1020 400 mg|EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
11383713|NCT02144415|Experimental|EB-1020 800 mg|EB-1020 800 mg, administered as eight 100-mg IR capsules
11383714|NCT02144415|Active Comparator|lisdexamfetamine 150 mg|lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
11383715|NCT02144415|Active Comparator|d-amphetamine 40 mg|d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
11383716|NCT02144415|Placebo Comparator|Placebo|Placebo, administered as 8 matching placebo capsules
11383717|NCT02144402|Active Comparator|infant formula with DHASCO|standard infant formula with docosahexaenoic acid (DHA)
11383718|NCT02144402|Experimental|infant formula with DHASCO-B|standard infant formula with DHA-B
11383719|NCT02144389|Active Comparator|Praziquantel (PZQ)|A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
11383720|NCT02144389|Experimental|Arachidonic acid (ARA)|A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
11383721|NCT02144389|Experimental|PZQ + ARA|A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.
11383722|NCT02144376|Placebo Comparator|Maltodextrin|7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
11383723|NCT02144376|Active Comparator|Ispaghula|7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
11383724|NCT02144350|Experimental|Intervention|patients will undergo daily hyperbaric oxygen sessions in addition to IV steroids for 10 days.
11383725|NCT02144350|Sham Comparator|Sham|Patients will undergo sham hyperbaric air sessions in addition to IV steroids for 10 days
11383762|NCT02144142|Experimental|Moisturizer with each subject's own antimicrobial bacteria|Each subject will have a moisturizer containing their own antimicrobial bacteria species spread over their arms in the clinic
11383763|NCT02144129|Experimental|active WB-EMS|2 sessions/week with 20 min of active WB-EMS application
11383726|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
11383727|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
11383728|NCT02144324|Experimental|Tandem Appliance|This group of patients will receive the new appliance which is called the Tandem Appliance
11383729|NCT02144324|No Intervention|Traditional Treatment|Patients in this group will be treated by the traditional Face Mask appliance.
11383730|NCT02144311|Experimental|MRI with DW-MRI & DCE-MRI & FDG PET/CT|Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
11383731|NCT02144298||cold blood cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cold blood cardioplegia.
11383732|NCT02144298||cristalloid cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cristalloid cardioplegia.
11383733|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
11383734|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
11383735|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
11383736|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
11383737|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
11383738|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
11383739|NCT02144272|Experimental|LY3114062 (SC)|LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.
11383740|NCT02144272|Experimental|LY3114062 (IV)|LY3114062 given once intravenous (IV).
11383741|NCT02144272|Placebo Comparator|Placebo|Placebo (sodium chloride injection) given as a single SC dose.
11383742|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
11383743|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
11383744|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
11383745|NCT02144246|Other|Pre-intervention|Patients will act as their own controls. Will have no hormones for 3 months
11383746|NCT02144246|Experimental|Post-intervention|Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
11383747|NCT02144233|Experimental|Occlusal adjustment therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
11383748|NCT02144233|Placebo Comparator|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
11383749|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
11383750|NCT02144207|Active Comparator|Glidescope: Unrestricted View|Unrestricted view of the larynx.
11383751|NCT02144207|Active Comparator|Glidescope: Restricted View|Restricted view of the larynx.
11383752|NCT02144194|Experimental|Maintenance treatment|"Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles
~Followed by:
~Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
11383753|NCT02144194|Experimental|Observation arm|"Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles
~Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
11383754|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
11383755|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
11383756|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
11383757|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
11383758|NCT02144168|Active Comparator|prebiotics-free enteral formula|Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal
11383759|NCT02144168|Experimental|prebiotics containing enteral formula|Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days
11383760|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
11383761|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
11383764|NCT02144129|Experimental|Passive WB-EMS|2 sessions/week with 20 min of passive WB-EMS application in a resting supine position
11383765|NCT02144129|No Intervention|Inactive Control Group|sedentary non-training control group
11383766|NCT02144116|Experimental|Experimental group|Patients with fibromyalgia included in a dance-movement therapy programme
11383767|NCT02144116|Active Comparator|Control group|Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
11383768|NCT02144103|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
11383769|NCT02144090|Experimental|Fractional flow reserve|Fractional flow reserve measurement
11383770|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
11383771|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
11383772|NCT02144064|Active Comparator|Group A(heparin group)|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
11383773|NCT02144064|No Intervention|Group B|group B (n = 100) receive no thing
11383774|NCT02144051|Experimental|AZD5312|"AZD5312 will be given intravenously (IV) as an infusion, over one hour. For the purpose of planning, each 4 week period (28 days) will be called a Cycle. AZD5312 will initially be administered 4 times within the first 11 days, (on Days [1, 4, 8 and 11]± 2), with no dosing on sequential days. Patients will receive weekly treatments on Days 15 and 22 to complete Cycle
~1. During the subsequent cycles, patients will receive weekly treatment on Days 1, 8, 15 and 22 (±2)."
11383775|NCT02144038|Experimental|Phase Ib: LGH447 + BYL719|Dose-escalation, LGH447 in combinatinon with BYL719
11383776|NCT02144038|Experimental|Phase II: LGH447 + BYL719|LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
11383777|NCT02144038|Experimental|Phase II: LGH447 alone|LGH447 alone (dosing according to single-agent RDE)
11383778|NCT02144025|Experimental|Topical cyclosporine|This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen. In this arm, patients who are candidates to this trial, will receive topical cyclosporine twice a day for 12 months to prevent ocular graft versus host disease.
11383779|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
11383780|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
11383781|NCT02143999||Cohort|
11383782|NCT02143986||Macrophagic activation syndrome|
11383783|NCT02143986||Still's disease|
11383784|NCT02143986||Hyperferritinemia|
11383785|NCT02143986||Sepsis|
11383786|NCT02143973|Experimental|nalbuphine HCl ER|nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
11383787|NCT02143960|Active Comparator|Velashape III device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
11383788|NCT02143960|Active Comparator|Noninvasive Cryolipolysis Device|A noninvasive device that reduces fat by freezing fat cells
11383789|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
11383790|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
11383791|NCT02143934|Active Comparator|Primaquine|Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
11383792|NCT02143934|Placebo Comparator|Placebo|Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
11383793|NCT02143921|Experimental|Training Intervention|One service provider group received training
11383794|NCT02143921|No Intervention|Control|Control group service providers did not received intervention training
11383795|NCT02143908|Placebo Comparator|placebo supplementation|2000 mg placebo tablets/day
11383796|NCT02143908|Active Comparator|Supplementation|lysine 2000 mg tablets/day supplementation
11383797|NCT02143882|Experimental|LAIV|All children will receive LAIV, currently available as the marketed product Fluenz
11383798|NCT02143856|Experimental|100 mg GLPG1205 fasted|Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast
11383799|NCT02143856|Experimental|100 mg GLPG1205 fed|Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast
11383800|NCT02143843|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
11383801|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
11383843|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
11383802|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
~The maximum number of patients enrolled in this arm will be 10."
11383803|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
11383804|NCT02143817|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
11383805|NCT02143817|Experimental|Whole body vibration training plus L-citrulline|Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)
11383806|NCT02143817|Experimental|Whole body vibration training & placebo|Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)
11383807|NCT02143817|Experimental|L-citrulline supplementation|(6g per day)containing L-citrulline
11383808|NCT02143804|Experimental|CG0070|oncolytic virus genetically modified to express GM-CSF
11383809|NCT02143791||Burst stimulation|At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation
11383810|NCT02143778|Experimental|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
11383811|NCT02143765|Experimental|Mitiglinide|Mitiglinide 10 mg three times a day, orally, for 12 weeks
11383812|NCT02143765|Active Comparator|Acarbose|Acarbose 50 mg three times a day, orally, for 12 weeks
11383813|NCT02143752||Mindfulness|Smokers enter a Mindfulness Training for Smokers course
11383814|NCT02143752||Quit Line|Smokers attempt smoking cessation with the help of the Wisconsin Tobacco Quit Line
11383815|NCT02143739||Newly diagnosed asthma patients|The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.
11383816|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11383817|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11383818|NCT02143713|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
11383819|NCT02143713|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
11383820|NCT02143700||Stable and exacerbated patients|Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation. Cognitive assessment of these patients will be performed.
11383821|NCT02143687|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
11383822|NCT02143687|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
11383823|NCT02143687|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
11383824|NCT02143687|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
11383825|NCT02143674|Experimental|INTERVENTION|Muscle stretching and Strength Training
11383826|NCT02143674|Experimental|Educated about physical exercises|
11383827|NCT02143661||Critically ill patients in the newly designed ICU rooms|Critically ill patients treated in one of the newly designed ICU rooms.
11383828|NCT02143661||Critically ill patients in the conventional ICU rooms|Critically ill patients treated in one of the conventional rooms on the same ICU.
11383829|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
11383830|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
11383831|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
11383832|NCT02143635|Experimental|Arm A|
11383833|NCT02143635|Experimental|Arm B|
11383834|NCT02143635|Experimental|Arm C|
11383835|NCT02143635|Experimental|Arm D|
11383836|NCT02143622|Experimental|LJM716+cetuximab|
11383837|NCT02143609|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
11383838|NCT02143609|Placebo Comparator|Sham oxygen|sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
11383839|NCT02143596|Active Comparator|Bun/Cr based hydration|receive intravenous normal saline infusion and adjust infusion rate by Bun/Cr followed in the first 72 hours
11383840|NCT02143596|No Intervention|control|receive intravenous normal saline infusion as clinician's adjustment
11383841|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
11383842|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
11383879|NCT02143336|Active Comparator|Skin staples|Standard skin staples for wound closure
11383844|NCT02143570|Experimental|Darifenacin + Physiotherapy|Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms.
11383845|NCT02143570|Active Comparator|Physiotherapy|Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill.
11383846|NCT02143557|Experimental|Fat-Modified Breast Milk|Infants in this arm of the study were fed their own mother's breast milk where the fat layer was removed by centrifugation. Prior to feeding, extra energy and nutrients were added to the defatted breast milk.
11383847|NCT02143557|Active Comparator|MCT-formula group|Infants in this arm of the study were fed a MCT-containing medical food which is the current standard of care.
11383848|NCT02143544|Active Comparator|Preoperative intra-aortic balloon pump.|Intervention: Preoperative placement of the intra-aortic balloon pump.
11383849|NCT02143544|No Intervention|Control|No preoperative placement of the intra-aortic balloon pump.
11383850|NCT02143531|Active Comparator|Group I|Patients will receive 4 mg of Ondansetron IV upon occurrence of nausea or vomiting
11383851|NCT02143531|Active Comparator|Group II|Patients will receive 1mg of Haloperidol IV upon occurrence of nausea or vomiting
11383852|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel|High Dose Na-GST-1/Alhydrogel® Only
11383853|NCT02143518|Experimental|30 µg Na-GST-1/Alhydrogel + CpG 10104|Low Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
11383854|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel + CpG 10104|High Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
11383855|NCT02143505|Experimental|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements for 3 years
11383856|NCT02143505|Placebo Comparator|placebo|identical-appearing placebo supplements for 3 years
11383857|NCT02143479||1:early conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
11383858|NCT02143479||2:late conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation
11383859|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
11383860|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
11383861|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
11383862|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
11383863|NCT02143453|Experimental|High intensity interval training|
11383864|NCT02143453|Experimental|Endurance training|
11383865|NCT02143440|Other|Newly diagnosed type 2 patients|The initial assessment of daily insulin dose.
11383866|NCT02143427|Experimental|Social Skills Training|Social Skills Training child-focused and subsequent social competence training which combines patient- and parent-/teacher and peer-focused interventions
11383867|NCT02143427|Active Comparator|Treatment Program with techniques to activate resources|Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training child-focused
11383868|NCT02143414|Experimental|Cohort I (blinatumomab, POMP)|"INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Patients not achieving CR or CRi after Induction, receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity.
~POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive prednisone PO on days 1-5, vincristine sulfate IV on day 1, mercaptopurine PO on days 1-28, and methotrexate PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 18 cycles in the absence of disease progression or unacceptable toxicity. (Closed to accrual 06/29/17)"
11383869|NCT02143414|Experimental|Cohort II (dasatinib, prednisone, blinatumomab)|"INDUCTION: Patients receive dasatinib PO BID on days 1-84 and prednisone PO on days 1-24 with tapering on days 25-32 in the absence of disease progression or unacceptable toxicity.
~RE-INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 2 cycles in the absence of disease progression or unacceptable toxicity.
~POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 and dasatinib PO QD on days 1-42. Treatment repeats every 42 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive dasatinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive prednisone PO on days 1-5. Treatment repeats every 28 days for 18 cycles in the absence of disease progression or unacceptable toxicity."
11383870|NCT02143401|Experimental|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 cycle of 1 only) and sorafenib tosylate PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11383871|NCT02143388|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
11383872|NCT02143388|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
11383873|NCT02143375|Experimental|810 Diode Laser|810 nm Diode Laser, contact, continuous wave,320micron,
11383874|NCT02143362|Experimental|Dexmedetomidine group|"Infusion of dexmedetomidine(0.8μg/kg) at10 minutes before anesthesia induction.
~Infusion of dexmedetomidine at 0.4 μg•kg-1•h-1during anesthesia maintenance.
~The infusion rate of dexmedetomidine was reduced to 0.1 μg•kg-1•h-1 for awaken test."
11383875|NCT02143362|Placebo Comparator|Control group|"Infusion normal saline(0.8μg/kg) at 10 minutes before anesthesia induction.
~Infusion normal saline at 0.4 μg•kg-1•h-1 during anesthesia maintenance.
~The infusion rate of normal saline was reduced to 0.1 μg•kg-1•h-1 for awaken test."
11383876|NCT02143349|Experimental|Coleus forskohlii extract|Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks
11383877|NCT02143349|Placebo Comparator|Placebo|Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks
11383878|NCT02143336|Experimental|Subcuticular suture|Subcuticular suture (absorbable) for skin closure
11383880|NCT02143323|Active Comparator|Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild|Augmentin tablet
11383881|NCT02143323|Active Comparator|GSTT1/GSTM1 wild/null type|Augmentin tablet
11383882|NCT02143323|Active Comparator|GSTT1/GSTM1 null/wild type|Augmentin tablet
11383883|NCT02143323|Active Comparator|GSTT1/GSTM1 null/null type|Augmentin tablet
11383884|NCT02143310|Experimental|EVP|Subject who use the EVP for up to 2 years
11383885|NCT02143297||SAHS negative|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
11383886|NCT02143297||SAHS positive|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
11383887|NCT02143284|Experimental|Endoscopy exploratory single arm|Exploratory single arm, the system will be used in otherwise standard procedures, and will be reviewed in terms of performance, usability, ease of use and safety.
11383888|NCT02143271|Experimental|KHK7580|
11383889|NCT02143258|Experimental|Neurointerventional|Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
11383890|NCT02143245|Active Comparator|Revision Population|"The study population is both men and women who have had previous shoulder surgery with symptoms suggestive of deep infection.These include the presence of pain, stiffness, and radiologic signs of infection including implant lucencies or migration.
~Patients in this population will undergo a synovial biopsy, in addition to undergoing an open tissue biopsy at the time of their procedure."
11383891|NCT02143245|Active Comparator|Primary TSA Population|A subset of patients undergoing native total shoulder replacements will have open tissue biopsy at the time of their procedure.
11383892|NCT02143232|Experimental|Remote patient monitoring (Telus RPM)|The remote monitoring device (Telus RPM) is used by every patient in the study post operatively at home.
11383893|NCT02143219|Other|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
11383894|NCT02143206||Exercise Method|Patients attend exercise 80 minute exercise sessions of which 30 minutes includes aerobic exercise on a NuStep and Biodex elliptical machine. Patients pain levels are scored when using the NuStep then when using the Biodex and these scores are compared to determine which machine give the best outcome for pain management
11383895|NCT02143193|Experimental|Skin to Skin Contact|implement mother-baby Skin-to-Skin contact immediately after vaginal birth
11383896|NCT02143193|No Intervention|Standard of Care|standard care for newborn and mother immediately after vaginal birth
11383897|NCT02143167|Experimental|SR-fampridine/placebo|24 weeks of SR-fampridine followed by four weeks of inactive placebo.
11383898|NCT02143167|Experimental|Placebo/SR-fampridine|24 weeks of inactive placebo followed by four weeks of SR-fampridine
11383899|NCT02143154||GBS positive women|Women wih GBS positive bacteruria with plan for treatment with vancomycin in labor, or women with positive GBS screening cultures with a plan to receive vancomycin in labor
11383900|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
11383901|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
11383902|NCT02143128||ESScore reliability|Same patients evaluated by two or more health professionals
11383903|NCT02143128||ESScore|Tool used for evaluation of patients after surgery
11383904|NCT02143128||ESScore without evaluation|Scored by tool, but not evaluated by it
11383905|NCT02143128||No ESScore|Regular ward routines
11383906|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
11383907|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
11383908|NCT02143089|Active Comparator|Group 1|Use of urinary catheterization in Cesarean section
11383909|NCT02143089|No Intervention|Group 2|NO urinary catheterization during Cesarean section
11383910|NCT02143076||Sickle Cell Disease|Participants will complete three questionnaires during the course of the study: Demographic Questionnaire, Medical Adherence Measure Questionnaire, and Acceptability Questionnaire. All questionnaires will be completed in a private clinic room.
11383911|NCT02143063|Active Comparator|standard care|standard care
11383912|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
11383913|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
11383914|NCT02143050|Experimental|Dabrafenib, Trametinib and Metformin|Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.
11383915|NCT02143037|Active Comparator|Control Group|usual care
11383916|NCT02143037|Experimental|Experimental Group|usual care plus prize contingency management for attending treatment
11383917|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
11383918|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
11383919|NCT02143011|Other|orange juice|no sugar
11383920|NCT02143011|Other|sugar beverage|no sugar
11383921|NCT02142998|Active Comparator|GERD Symptoms|
11383922|NCT02142998|Active Comparator|No GERD Symptoms|
11383923|NCT02142985|Experimental|colloid solution|vascular filling with 500 ml of colloid solution (Plasmagel) over 30 minutes
11383924|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
11383925|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
11383926|NCT02142959|Placebo Comparator|Lotion vehicle/Placebo|Lotion vehicle/placebo will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
11383927|NCT02142946||RIS MS patients|Radiologically Isolated Syndrome (RIS) MS patients
11383928|NCT02142946||CIS MS patients|Clinically Isolated Syndrome (CIS) patients during a stable phase
11383929|NCT02142946||RRMS patients|Relapsing-remitting (RR) MS patients during a stable phase
11383930|NCT02142946||SPMS Patients|Secondary progressive MS patients (SPMS)
11383931|NCT02142946||PPMS Patients|Primary progressive MS patients (PPMS)
11383932|NCT02142946||Controls|Age and gender matched controls
11383933|NCT02142946||CI Patients|Cochlear Implant patients pre- and post-operatively
11383934|NCT02142946||UVL Patients|Unilateral vestibular loss patients in acute and compensated state
11383935|NCT02142946||Chronic UVL|Chronic unilateral vestibular loss patients
11383936|NCT02142946||Phobic|Phobic vertigo patients
11383937|NCT02142933|Other|rectal swab and vagino-perineal swab|single-arm
11383938|NCT02142920|Experimental|[14C] PF 05212384|Receive PF-05212384 89 mg Dose
11383939|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
11383940|NCT02142881|Experimental|Antihypertensive medication intensification|
11383941|NCT02142881|Other|Usual care|
11383942|NCT02142855|No Intervention|Old Control|Older individuals (65-75 y) with no exercise intervention
11383943|NCT02142855|Experimental|Old Concentric|Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training
11383944|NCT02142855|Experimental|Old Eccentric|Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training
11383945|NCT02142855|No Intervention|Young Control|Young individuals (18-30 y) with no exercise intervention
11383946|NCT02142855|Experimental|Young Concentric|Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training
11383947|NCT02142855|Experimental|Young Eccentric|Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training
11383948|NCT02142842|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3 radiographic OA severity with 16 patients as control.
11383949|NCT02142829|Active Comparator|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
11383950|NCT02142829|Active Comparator|On-Q Pain Ball|Device for delivering bupivacaine.
11383951|NCT02142816|Active Comparator|Doppler|Fluid directed by oesophageal doppler
11383952|NCT02142816|Active Comparator|PVI|Fluid therapy directed by Pleth Variability Index
11383953|NCT02142803|Experimental|Treatment (TORC1/2 inhibitor INK128, bevacizumab)|Patients receive TORC1/2 inhibitor INK128 PO QD on days 1-28 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11383954|NCT02142790|Experimental|paclitaxel liposome injection weekly|paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable
11383955|NCT02142790|Experimental|paclitaxel liposome injection every 3 weeks|paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable
11383956|NCT02142777|Experimental|Investigational|All study subjects will take a 10mg pill by mouth twice daily over a 6 week period. Subjects will receive either placebo or S -Equol. They will not know which they are receiving.
11383957|NCT02142764|Experimental|Multiple Sclerosis|Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed
11383958|NCT02142764|Other|Control|HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
11383959|NCT02142764|Experimental|Multiple Sclerosis patients treated|HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
11383960|NCT02142751|Experimental|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
11383961|NCT02142751|Active Comparator|Meropenem intravenous|1g every 8 hours (15-30 min infusion)
11383962|NCT02142751|Other|Ceftriaxone intravenous|1g every 24h (2-4 min)
11383963|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
11383964|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
11383965|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
11383966|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
11383967|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
11383968|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
11383972|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
11383973|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
11383974|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.
~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
11383975|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
11383976|NCT02142699|Active Comparator|Heme arginate 1mg/kg|"This is the lower of the 2 doses of Heme arginate (HA). This will be given as a single dose of 1mg/kg on the first study visit.
~This is given over 1 hour intravenously."
11383977|NCT02142699|Active Comparator|Heme arginate 3mg/kg|"This is the larger dose, Heme arginate 3mg/kg (up to a maximum dose of 250mg)
~This will be given intravenously, as a single dose on the first study visit, over one hour."
11383978|NCT02142686|Active Comparator|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm.
11383979|NCT02142686|Active Comparator|Filling pressure 50.|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg in this group
11383980|NCT02142686|Active Comparator|illing pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm Hg.
11383981|NCT02142673|Active Comparator|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
11383982|NCT02142673|Active Comparator|Filling pressure 60|The hysteroscope filling pressure will be to 50mm Hg
11383983|NCT02142673|Active Comparator|Filling pressure 40|The hysteroscope filling pressure will be to 40mm Hg
11383984|NCT02142660||Sprayshield|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie
11383985|NCT02142647|Active Comparator|meat group|Infants in this group will receive complementary foods with high protein content mainly from meat
11383986|NCT02142647|Active Comparator|dairy group|infants in this group will receive complementary foods mainly from dairy
11383987|NCT02142634|Experimental|A|Budesonide granules 9 mg
11383988|NCT02142634|Placebo Comparator|B|Placebo granules
11383989|NCT02142621|Active Comparator|transpyloric tube feeds|Continuous transpyloric tube feeds administered through an oral/nasal feeding tube.
11383990|NCT02142621|Active Comparator|gastric tube feeds|Continuous gastric tube feeds administered through an oral/nasal feeding tube.
11383991|NCT02142608|Experimental|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
11383992|NCT02142595|Experimental|dexmeditomidine group D|The sedative solution was prepared as a 10µg /ml dexmedetomidine in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
11383993|NCT02142595|Experimental|Midazolam group M|The sedative solution was prepared as a 0.375mg/ml midazolam or normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
11383994|NCT02142595|No Intervention|group control|normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
11383995|NCT02142582|Active Comparator|WHO ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
11383996|NCT02142582|Active Comparator|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
11383997|NCT02142569|Active Comparator|Chinese Red Yeast Rice (CRYR)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 Sugar Pill/Placebo capsules for 12 weeks.
11383998|NCT02142569|Active Comparator|Tocotrienol-enriched Fraction of Palm Oil (TRF)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 TRF and 2 Sugar Pill/Placebo capsules for 12 weeks.
11383999|NCT02142569|Active Comparator|CRYR + TRF|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF + CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 TRF capsules for 12 weeks.
11384000|NCT02142569|Placebo Comparator|Sugar Pill|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the placebo (sugar pill) arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 4 placebo tablets for 12 weeks. Additionally during a two-week run-in period, subjects will be asked to follow the American Heart Association Step 1 dietary regimen and to take a placebo capsule daily to determine their ability to comply with the diet and a pill regimen.
11384001|NCT02142556|Experimental|Quetiapine XR|Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
11384002|NCT02142543|Placebo Comparator|placebo|placebo powder containing zinc oxide, karaya gum, and yellow dye, which was added to imitate the color of the original powder, applied twice a day until the ulcer had resolved, an expected average of 3-5 days
11384003|NCT02142543|Experimental|2-DeNT powder|2-DeNT powder containing dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum, applied twice a day until the ulcer had resolved, applied twice a day until the ulcer had resolved, in an expected average of 3 to 5 days
11384004|NCT02142530|Experimental|Carfilzomib/ Belinostat|"Carfilzomib and Belinostat will be administered on a 28-day schedule.
~Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).
~Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.
~Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2
~A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2."
11384005|NCT02142517|Active Comparator|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
11384006|NCT02142517|Active Comparator|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
11384007|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
11384008|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
11384009|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
11384010|NCT02142478||Adapted scheme|Participants referred by their GP practices to Centre A will take part in the Adapted Exercise for Health (EFH) scheme.
11384011|NCT02142478||Standard scheme|Participants referred by their GP practices to Centre B will take part in the Standard Exercise for Health (EFH) scheme.
11384012|NCT02142452|Experimental|mobile health intervention|Behavioral intervention. Women with excessive weight gain in pregnancy will be recruited in their 3rd trimester. They will begin with a 5 week group session on weight management. After they deliver the baby, they will begin receiving text messages supporting behavior change they learned in their 3rd trimester. They will follow up at 6 weeks postpartum and 4 months postpartum.
11384013|NCT02142452|Placebo Comparator|Control Group|Women will receive usual prenatal care from their OB. Postpartum, they will receive a monthly newsletter relevant to the new mother on her nutrition and physical activity. They will be followed at 6 weeks postpartum and 4 months postpartum.
11384014|NCT02142439|Experimental|Intervention group 1|Exercise counseling 1 time/week, Strength training 3 times/week, dose: 5 RM x 3 sets.
11384015|NCT02142439|Experimental|Intervention group 2|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
11384016|NCT02142439|Experimental|Intervention group 3|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 30 RM x 3 sets
11384017|NCT02142439|No Intervention|Control group|Exercise counseling 1 time/week
11384018|NCT02142413||Acute Ischemic Stroke|Patients older than 18 years with an acute ischemic stroke (according to WHO criteria), stroke onset within 2 days, language: German, MRI compatibility, admission to the stroke unit at the Charité, Campus Benjamin Franklin.
11384019|NCT02142400|Experimental|DS-1093|Group 1 will receive 10mg, group 2 will receive 25mg of DS-1093
11384020|NCT02142400|Placebo Comparator|placebo|placebo to match DS-1093 dosage
11384021|NCT02142387|Active Comparator|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
11384022|NCT02142387|No Intervention|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000&bid=0021&tag=&act=view&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
11384023|NCT02142361|Active Comparator|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
11384024|NCT02142361|Active Comparator|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
11384025|NCT02142361|Active Comparator|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
11384026|NCT02142348||osteoprosis research|
11384027|NCT02142335|Experimental|Rituxan/Abraxane|This is a single arm study. All patients recieve treatment.
11384028|NCT02142309|Experimental|Glimepiride|up to 4 mg/day
11384029|NCT02142309|Experimental|Vildagliptin|50 mg bid
11384030|NCT02142309|Experimental|Pioglitazone|up to 30 mg/day
11384031|NCT02142309|Experimental|Canagliflozin|300 mg/day
11384032|NCT02142296|Other|Eylea|The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
11384033|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
11384034|NCT02142283|Active Comparator|Medical Management|Medical Management
11384035|NCT02142270||Victims of cardiac arrest, either SCD or aborted SCA|
11384036|NCT02142270||Premature death|"All residents of districts of interest will be surveyed during 3 years. premature deaths occurring in residents of districts of interest will be checked for past medical history, circumstances of death, and autopsy report (if possible). Investigators will also analyze the employment of resuscitation attempts during the timeframe of sudden cardiac arrest (SCA) in various patient populations throughout African countries.
~The arm group of the study is every resident of the district of interest"
11384037|NCT02142257||Gastric Bypass|Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
11384038|NCT02142257||AspireAssist Aspiration Therapy|Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
11384039|NCT02142244|Experimental|Near infra red sentinel node biopsy|Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.
11384040|NCT02142231|Placebo Comparator|Laser Acupuncture|Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
11384041|NCT02142231|Active Comparator|Acupuncture|Acupuncture at the acupoint Heart 7, on both wrists, each for 1 minute, eliciting a deqi-response, additional stimulation and total needle-in time of 20 minutes (2 minutes treatment and 18 minutes of resting time)
11384042|NCT02142205|Experimental|BG00002 (natalizumab)|300 mg IV infusion every 4 weeks
11384043|NCT02142192|Experimental|natalizumab|natalizumab 300mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)
11384044|NCT02142179|Experimental|KARE Intervention|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
11384045|NCT02142179|No Intervention|A traditional curriculum education.|The control group will receive a traditional curriculum education.
11384046|NCT02142166|Experimental|SAB analysis|"Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture
~Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
11384047|NCT02142166|Experimental|Control|"Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology
~Single analysis of Biomarker in serum and liquor"
11384048|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
11384049|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
11384050|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
11384051|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
11384052|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
11384053|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
11384054|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
11384055|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
11384056|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
11384057|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
11384058|NCT02142140|Experimental|Medication Monitoring & Case Management|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning. Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher).
11384138|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
11384059|NCT02142140|Active Comparator|Community Follow-up Group|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
11384060|NCT02142127|Experimental|14C-labelled GFT505 120 mg|
11384061|NCT02142114|Active Comparator|Eye injection by 30 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection). When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
11384062|NCT02142114|Active Comparator|Eye injection by 32 gauge needle|
11384063|NCT02142101||GFR >60|5 patients with polycystic kidney disease with eGFR > 60 ml/min.
11384064|NCT02142101||GFR 15-60|5 patients with polycystic kidney disease with eGFR between 15-60 ml/min.
11384065|NCT02142101||GFR <15|5 patients with polycystic kidney disease with eGFR <15 ml/min.
11384066|NCT02142088|Other|Glucose Monitoring|Each patient will undergo simultaneous Glucose monitoring with 2 devices. One is GlySure's intervascular continuous measurement sensor (test device) introduced through a CVC, and the other measures glucose intermittently from repeated venous blood samples drawn through an indwelling ventflon style catheter
11384067|NCT02142075|Experimental|Daptomycin, IV|"Patients with creatinine clearance ≥30 ml/min will receive 10 mg/kg of daptomycin (Cubicin®) once daily,
~Patients with creatinine clearance <30 ml/min will receive the same daptomycin dose (10 mg/kg) but less frequently, every 48h instead of every day"
11384068|NCT02142062||Venography and IVUS imaging guiding treatment|
11384069|NCT02142049|Experimental|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
11384070|NCT02142049|Experimental|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
11384071|NCT02142049|Experimental|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
11384072|NCT02142049|Experimental|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
11384073|NCT02142049|Experimental|Part 2: RP2D|Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
11384074|NCT02142036|Experimental|ATI based targeted therapy.|EMA-approved ATI based targeted therapy. Patients will receive therapy based on molecular aberrations identified in the metastatic lesion.
11384075|NCT02142010|Other|paclitaxel liposome injection plus cisplatin|
11384076|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
11384077|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
11384078|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
11384079|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
11384080|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
11384081|NCT02141971||Non-demented; Ages 30-40|Four non-demented Down syndrome patients between the ages of 30-40 years old
11384082|NCT02141971||Non-demented; Ages 40-50|Four non-demented Down syndrome patients between the ages of 40-50 years old
11384083|NCT02141971||Demented; Ages 50-60|Four demented Down syndrome patients between the ages of 50-60 years old
11384084|NCT02141958|Experimental|Fenretinide|Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
11384085|NCT02141958|Placebo Comparator|Placebo|Four (4) patients will be on Placebo.
11384086|NCT02141932|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries and the heart. All participants will then be examined by reference imaging in specific ultrasound laboratories and when appropriate computer tomography or magnetic resonance imaging.
11384087|NCT02141919|Experimental|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Radiation Therapy (SABR)
11384088|NCT02141906|Experimental|Oncozene-DEB-TACE|"Screening Visit (procedures should be done within 28 days of treatment day):
~Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw).
~Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day
~Follow up after completion of treatment every 4-6 weeks:"
11384089|NCT02141893|Active Comparator|CALMA|Participants only received a family education intervention (previously tested) known as CALMA
11384090|NCT02141893|Experimental|Calma plus|Participants in Arm 2 received the CALMA family education intervention and physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs.
11384091|NCT02141880||Treatment|All subjects will be under the same protocol which is eating and drinking on one afternoon.
11384092|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
11384093|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
11384094|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
11384095|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
11384096|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
11384097|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
11384098|NCT02141828|Experimental|EPZ-5676|EPZ-5676 Dose escalation and expansion cohorts
11384099|NCT02141815|Experimental|Arabinoxylan-oligosaccharides|Arabinoxylan-oligosaccharides 10g BID
11384100|NCT02141815|Placebo Comparator|Maltodextrine|Maltodextrine BID
11384101|NCT02141802|Active Comparator|Control|Normal standing time
11384102|NCT02141802|Experimental|Doubling standing time|Doubled standing time calculated by doubling baseline standing time
11384103|NCT02141789|Experimental|Outpatient Cognitive Behavioral Psychotherapy|Outpatient Cognitive Behavioral Therapy is a well-known and frequently applied psychotherapy approach that does not need further description.
11384104|NCT02141776|Sham Comparator|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
11384105|NCT02141776|Active Comparator|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
11384106|NCT02141763|Experimental|240/160/160 mg of UCB4940|240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
11384107|NCT02141763|Experimental|160/80/80 mg of UCB4940|160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
11384108|NCT02141763|Experimental|80/40/40 mg of UCB4940|80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
11384109|NCT02141763|Experimental|560/320/320 mg of UCB4940|560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
11384110|NCT02141763|Placebo Comparator|Placebo|0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial
11384111|NCT02141737|Placebo Comparator|Group C|Induction protocol: patients will be given 2 ml normal saline solution, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
11384112|NCT02141737|Experimental|Group L1|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 20 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
11384113|NCT02141737|Experimental|Group L2|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 30 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
11384114|NCT02141737|Experimental|group L3|Induction protocol: patients will be given 2 ml lidocaine injection in which 40 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
11384115|NCT02141724||neuromuscular patients|neuromuscular patients using wheelchair
11384116|NCT02141711|Experimental|Cohort 1: TAK-438 10 mg|TAK-438 10 mg tablets, orally, once, daily, for 7 days.
11384117|NCT02141711|Experimental|Cohort 2: TAK-438 20 mg|TAK-438 20 mg tablets, orally, once, daily, for 7 days.
11384118|NCT02141711|Experimental|Cohort 3: TAK-438 40 mg|TAK-438 40 mg tablets, orally, once, daily, for 7 days.
11384119|NCT02141711|Experimental|Cohort 4: TAK-438 30 mg|TAK-438 30 mg tablets, orally, once, daily, for 7 days.
11384120|NCT02141711|Placebo Comparator|Cohorts 1-4: Placebo|TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
11384121|NCT02141698|Experimental|Cohort 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
11384122|NCT02141698|Experimental|Cohort 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
11384123|NCT02141698|Experimental|Cohort 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
11384124|NCT02141698|Experimental|Cohort 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
11384125|NCT02141698|Experimental|Cohort 5: TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once on Day 1.
11384126|NCT02141698|Experimental|Cohort 6: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
11384127|NCT02141698|Experimental|Cohort 7: TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once on Day 1.
11384128|NCT02141698|Experimental|Cohort 8A: Food-effect|TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
11384129|NCT02141698|Experimental|Cohort 8B: Food-effect|TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.
11384130|NCT02141698|Experimental|Cohort 9: TAK-438 Multiple Dose 1|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
11384131|NCT02141698|Experimental|Cohort 10: TAK-438 Multiple Dose 2|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
11384132|NCT02141698|Experimental|Cohort 11: TAK-438 Multiple Dose 3|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
11384133|NCT02141698|Experimental|Cohort 12: Ethnic Bridging|TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.
11384134|NCT02141698|Placebo Comparator|Cohorts 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1
11384135|NCT02141698|Placebo Comparator|Cohorts 9-11: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.
11384136|NCT02141685||IVF patients undergoing aCGH Testing|Women undergoing fresh IVF treatment and array-comparative genomic hybridization testing (aCGH), as recommended based on medical need by the clinical site reproductive endocrinologist.
11384137|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
11384139|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID
~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
11384140|NCT02141659|Experimental|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
11384141|NCT02141659|Experimental|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
11384142|NCT02141659|Experimental|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
11384143|NCT02141659|Experimental|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
11384144|NCT02141659|Experimental|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
11384145|NCT02141659|Experimental|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
11384146|NCT02141646|Experimental|Motivational interviewing|
11384147|NCT02141646|Experimental|Behavioral skills training|
11384148|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
11384149|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
11384150|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
11384151|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
11384152|NCT02141607||Hemorrhagic Shock|"Hypovolemic shock characterized by:
~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.
~Rapid loss of significant amount of blood
~Lactate levels ≥ 2 mmol/L"
11384153|NCT02141607||Cardiogenic shock|"State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:
~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.
~Need for a continuous infusion of inotropic drugs
~Cardiac Index <2.2 L/min/m2 or use of inotropic drugs (dobutamine/isoprenaline/phosphodiesterase inhibitors or levosimendan)
~Signs of reduced heart function
~Cardiac overload or altered left/right ventricular function"
11384154|NCT02141607||Septic shock|"Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.
~Only community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).
~Lactate levels ≥ 2mmol/L."
11384155|NCT02141607||control group|"The control group will consist on:
~5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis
~a cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
11384156|NCT02141594||Early glaucoma|The study group consisted of consecutive unilateral glaucoma patients, categorized as early stage by Hodapp-Anderson-Parrish classification.
11384157|NCT02141594||Normal subjects|Normal control subjects had a normal ocular examination, Intraocular pressure (IOP) <22 mmHg, no past history of high IOP, no family history of glaucoma, normal optic disc morphology and visual field in both eyes. One eye of control subject was randomly selected.
11384158|NCT02141581|Experimental|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)
~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
11384159|NCT02141581|Experimental|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)
~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
11384160|NCT02141581|Experimental|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.
~FluMist was only used in the first year of study."
11384161|NCT02141568|Experimental|Intervention Group for Prospective Study|"Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis."
11384162|NCT02141568|No Intervention|No Intervention|Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur
11384163|NCT02141555|Active Comparator|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
11384164|NCT02141555|Experimental|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
11384165|NCT02141542|Experimental|Tremelimumab and MEDI3617|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
~Tremelimumab-Fixed doses of Tremelimumab are given once per cycle
~MEDI3617-MEDI3617 is administered twice per cycle"
11384166|NCT02141529|Active Comparator|Unipolar PRF|Unipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
11384167|NCT02141529|Experimental|Bipolar PRF|Bipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
11384171|NCT02141490|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
11384172|NCT02141477|Experimental|Omacetaxine + Decitabine|"Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.
~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
11384173|NCT02141451|Experimental|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
11384174|NCT02141451|Experimental|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
11384175|NCT02141451|Experimental|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
11384176|NCT02141451|Experimental|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
11384177|NCT02141438||Radium-223 dichloride (Xofigo, BAY88-8223)|Single-arm cohort observational study with CRPC patients with bone metastasis treated with Radium-223.
11384178|NCT02141425|Experimental|ASP015K low dose|
11384179|NCT02141425|Experimental|ASP015K medium dose|
11384180|NCT02141425|Experimental|ASP015K high dose|Optional, depending on safety review and regulatory authority input
11384181|NCT02141425|Placebo Comparator|Placebo|
11384182|NCT02141412|Active Comparator|Group I|Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane
11384183|NCT02141412|Active Comparator|Group II|Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane
11384184|NCT02141412|Active Comparator|Group III|Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane
11384185|NCT02141412|Placebo Comparator|Group IV|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
11384186|NCT02141399|Experimental|ALKS 5461|
11384187|NCT02141386|Experimental|Treatment A|plasticity-based, adaptive, computerized cognitive remediation (PACR)
11384188|NCT02141386|Active Comparator|Treatment B|"Ordinary Computer Games (an active control condition)"
11384189|NCT02141373|Experimental|Glubran 2|Glubran 2 will be used at end of surgery
11384190|NCT02141373|No Intervention|Standard Surgery|
11384191|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
11384192|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
11384193|NCT02141347|Other|Part A|Dose escalation of tremelimumab mono therapy for advanced solid malignancies
11384194|NCT02141347|Other|Part B|Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies
11384195|NCT02141347|Other|Part C|Fixed dose of tremelimumab for malignant mesothelioma
11384196|NCT02141321|Experimental|Misoprostol|Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
11384197|NCT02141321|Placebo Comparator|Placebo|Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
11384198|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
11384199|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
11384200|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
11384201|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
11384202|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
11384247|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
11384248|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
11384203|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
11384204|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
11384205|NCT02141282|Experimental|ABT-199 after ibrutinib therapy|Single daily doses increasing weekly as tolerated
11384206|NCT02141282|Experimental|ABT-199 after ibrutinib or idelalisib therapy|Single daily doses increasing weekly as tolerated
11384207|NCT02141282|Experimental|ABT-199 after idelalisib therapy|Single daily doses increasing weekly as tolerated
11384208|NCT02141256|Experimental|Protein enriched products|Protein enriched products will be given to elderly residents of a care home for 10 days. Does this lead to an increased protein intake or do elderly compensate for the extra amount of protein?
11384209|NCT02141243|Experimental|Group A|"All participants will receive both the lingual frenotomy and sham procedure. Group A infants will receive lingual frenotomy for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.
~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.
~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).
~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and a laser, (iLaseTM 940 ± 15 nm) or scissors, will be used to release its attachment to the level of the periosteum."
11384210|NCT02141243|Experimental|Group B|"All participating infants will receive both the lingual frenotomy and sham procedure. Group B infants will receive the sham procedure for intervention #1 and a lingual frenotomy for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.
~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).
~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.
~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and an iLaseTM 940 ± 15 nm laser used to release its attachment to the level of the periosteum."
11384211|NCT02141230|Experimental|Alli® 60 mg|Participants purchasing Alli®
11384212|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
11384213|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
11384214|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination who receive two oral doses of Liquid Human Rotavirus Vaccine according to a 0, 1 month schedule.
11384215|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who receive two oral doses of Lyophilized Human Rotavirus Vaccine according to a 0, 1 month schedule.
11384216|NCT02141191|Experimental|HS/sham|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
11384217|NCT02141191|Experimental|sham/HS|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
11384218|NCT02141178|Active Comparator|Bupivacaine|Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
11384219|NCT02141178|Experimental|Exparel|Patients will received Exparel subcutaneously for local anesthesia during surgery
11384220|NCT02141165|Experimental|Primary.|Diagnosis, autoCPAP, follow up.
11384221|NCT02141165|Active Comparator|Hospital|Diagnosis, autoCPAP, follow up
11384222|NCT02141152||gastric cancer|This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
11384223|NCT02141152||colorectal cancer|This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
11384249|NCT02140957|Experimental|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
11384250|NCT02140957|Placebo Comparator|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
11384251|NCT02140944||Pre-Transplant Cohort|HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant
11384328|NCT02140463||metastatic cancer|metastatic gastrointestinal cancer metastatic genitourinary cancer other rare cancer lung cancer
11384224|NCT02141152||biliary tract cancer/pancreatic cancer|This study will recruit a total of 78 biliary tract cancer/pancreatic cancer patients. It is expected to recruit about 100 biliary tract cancer/pancreatic cancer patients per year. About 20% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 35% for the targeted group and about 5% for the untargeted group. With N=78 biliary tract cancer/pancreatic cancer patients, about 16 patients will belong to the targeted group and about 62 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
11384225|NCT02141152||Rare cancer|Rare cancer is hepatocellular carcinoma, melanoma and neuroendocrine tumor. This study will recruit a total of 87 hepatocellular carcinoma/rare cancer patients. It is expected to recruit about 150 biliary tract cancer/pancreatic cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 30% for the targeted group and about 5% for the untargeted group. With N=87 biliary tract cancer/pancreatic cancer patients, about 22 patients will belong to the targeted group and about 65 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 86% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
11384226|NCT02141152||genitourinary cancer|
11384227|NCT02141139|No Intervention|Control arm|no medication or acetaminophen
11384228|NCT02141139|Experimental|NSAIDS (ketorolac intravenous, ibuprofen)|ketorolac IV (just before surgery) and ibuprofen for 1 weeks
11384229|NCT02141126|Experimental|Resistance training|Usual care and resistance exercises.
11384230|NCT02141126|Other|Usual care|Usual inpatient physiotherapy
11384231|NCT02141113|Active Comparator|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)"
11384232|NCT02141113|Placebo Comparator|Sugar Pill Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)
~mg Guanfacine Hydrochloride (orally, QD)"
11384233|NCT02141100|Experimental|6-thioguanine, 6-mercaptopurine and methotrexate|"This is the only treatment arm; all eligible patients will receive standard methotrexate/6-mercaptopurine (6MP/MTX) maintenance therapy supplemented with 6-thioguanine (6TG).
~Patients are enrolled when they have 12 to 3.5 months remaining of their maintenance therapy. After dose reduction in 6MP to 2/3 of the current dose 6TG therapy is initiated with a starting dose of 2.5 mg/m2/day. The 6TG dose will hereafter be increased at 2.5 mg/m2/day every 14 days until a max. of 12.5 mg/m2/day is reached or until the thiopurine metabolite profile (Ery-TGN/Ery-MeMP) has been increased by at least a factor 5."
11384234|NCT02141074|Experimental|50 EDs (exposure days)|
11384235|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation A (Treatment A)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
11384236|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation B (Treatment B)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
11384237|NCT02141048|Experimental|Positive Parenting Skills Training|Participants assigned to the intervention group will receive the Positive Parenting Skills Training.
11384238|NCT02141048|No Intervention|Wait-list control|Participants assigned to the wait-list control group will receive no intervention for the duration of this trial. Only after the one-year follow-up assessment has been completed will they receive the Positive Parenting Skills Training.
11384239|NCT02141035|Experimental|Acetyl-l-carnitine|Acetyl-l-carnitine will be administered for 2 months duration at a dosage of 3000 mg/d starting at the time of decompression surgery.
11384240|NCT02141035|Placebo Comparator|Placebo|Placebo will be given for 2 months starting at the time of decompression surgery
11384241|NCT02141022|Experimental|PACR Program: Plasticity based, Adaptive Cognitve Remediation|PACR Program Use: To use PACR, the participant navigates to the PACR study web site. The participant then logs into the PACR (using a study provided screen name and study identification number). A game-like experience begins, where the participant is presented with games in a set order. Each game consists of targeted exercises that contain the core science stimuli and tasks. The scheduling mechanism ensures that a participant progresses through the exercises in a defined order, generally moving from more simple (early sensory processing) exercises to more complex (multimodal, cognitive control) exercises over the course of the three-month experience.
11384242|NCT02141022|Active Comparator|Ordinary Computer Games|Active Control Program Use (Ordinary Computer Games): The active control program is composed of 13 ordinary computer games matched to the PACR condition overall. This condition is designed to be a face-valid approach to cognitive remediation. The control condition is also designed to account for nonspecific treatment effects, including placebo response, interactions with research personnel, and experience with computers and computer-related activities, and any halo or expectation effect on study assessments.
11384243|NCT02141009|Other|Prevnar 13|Prevnar 13, 1 administration of 1 single dose (0.5mL)
11384244|NCT02140996|Experimental|Ad-sig-hMUC-1/ecdCD40L vector vaccine|Experimental: Ad-sig-hMUC-1/ecdCD40L vector vaccine This trial has six cohorts with 3 subjects planned for each cohort. Subjects in the 1st cohort will receive 1 dose of vaccine injection at the lowest planned dose of the vector, 1 x 10^9 VP. If none of the patients in the 1st cohort experience Dose limiting toxicity (DLT), a 2nd cohort will receive 1 dose of 1x10^10 VP. If none of the patients in the 2nd cohort experience DLT, the dose escalation will continue with the 3rd cohort receiving 1 doses of 5 x 10^10 VP per injection. The patients in the 4th cohort will receive 1 injection of 1x10^11 if no DLT occurs in the preceding cohort. Additional patients will be added to cohort 5 or 6 if DLTs are encountered in the first 3 patients tested in each of these cohorts.
11384245|NCT02140983|Active Comparator|Liraglutide|90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
11384246|NCT02140983|Placebo Comparator|Placebo|90 days of placebo pen, up to 1.8mg/day.
11384252|NCT02140944||Post-Transplant Cohort|HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant
11384253|NCT02140931|Active Comparator|Angiogenic Cell Precursors|Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg
11384254|NCT02140931|Placebo Comparator|Cell culture medium|Intra-muscular injections of cell culture medium in the ischemic leg
11384255|NCT02140918|Experimental|Fludrocortisone 100 μg|"100 μg/day (25 µg four times daily) of fludrocortisone during 5 days
~Investigations the sixth day"
11384256|NCT02140918|Experimental|Fludrocortisone 200 μg|"200 μg/day (50 µg four times daily) of fludrocortisone during 5 days
~Investigations the sixth day"
11384257|NCT02140918|Experimental|Fludrocortisone 400 μg|"400 μg/day (100 µg four times daily) of fludrocortisone during 5 days
~Investigations the sixth day"
11384258|NCT02140918|Placebo Comparator|Placebo|"Placebo (four times daily) during 5 days
~Investigations the sixth day"
11384259|NCT02140905||Patients undergoing hemodialysis.|Subjects participating in the study
11384260|NCT02140892|Experimental|respiratory physical therapy manual technique|respiratory physical therapy manual technique- Autogenic Drainage
11384261|NCT02140892|Experimental|respiratory physical therapy technique- IPV|respiratory physical therapy technique- Intrapulmonary Percussive Ventilation
11384262|NCT02140892|No Intervention|standart medical care|standard medical care
11384263|NCT02140879|Placebo Comparator|Capsule 1|Placebo is a mixture of corn and soy oils.
11384264|NCT02140879|Active Comparator|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
11384265|NCT02140866|Experimental|Hand Exercise|The intervention group will receive an exercise program for the hand/arm in combination with a compensatory intervention program (CIP).
11384266|NCT02140866|Active Comparator|Compensatory Intervention Program (CIP)|The control group will receive the Compensatory Intervention Program (CIP) only.
11384267|NCT02140853||MDR group|patients of MDR pathogen infection
11384268|NCT02140853||non-MDR group|patients of non-MDR pathogen infection
11384269|NCT02140827|Experimental|IMP education|patients in this group are educated about bowel preparation by instant messaging program and meanwhile a booklet was also sent to them.
11384270|NCT02140827|No Intervention|normal education|patients in this group are educated about bowel preparation on the day of reservation by nurse for about 15 minutes and meanwhile a booklet was also sent to them.
11384271|NCT02140814|Experimental|Niacinamide|All subjects in this study will take niacinamide at a dose of 30 mg per kilogram of body weight by mouth daily, in two divided daily doses, for 12 months.
11384272|NCT02140801|Experimental|Ticagrelor|Ticagrelor 90mg tablet, twice daily
11384273|NCT02140801|Experimental|Clopidogrel|Clopidogrel 75mg tablet, daily
11384274|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
11384275|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
11384276|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
11384277|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
11384278|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
11384279|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
11384280|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
11384281|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
11384282|NCT02140749|Experimental|sc-FOS 2g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)
11384283|NCT02140749|Experimental|sc-FOS 4g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)
11384284|NCT02140749|Experimental|sc-FOS 8g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)
11384285|NCT02140736||Patients with chemo-induced symptomatic anemia|
11384286|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
11384287|NCT02140710|Active Comparator|Osteopathic treatment group|visceral osteopathic treatment algorithm
11384288|NCT02140710|No Intervention|Control group|no intervention
11384289|NCT02140697|Experimental|Hippophae rhamnoides L. Leaf Extract|Hippophae rhamnoides L. Leaf Extract 3g/day
11384290|NCT02140697|Placebo Comparator|Placebo|Placebo 3g/day
11384291|NCT02140684||eNO monitoring|Patients undergoing eNO monitoring at the index prescription date
11384292|NCT02140684||No eNO monitoring|
11384293|NCT02140671||Patients with an asthma diagnosis|
11384294|NCT02140671||Patients where there is diagnostic doubt|
11384295|NCT02140658|Active Comparator|multiple health education interventions|The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
11384884|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
11384296|NCT02140658|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
11384297|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
11384298|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
11384299|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
11384300|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
11384301|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
11384302|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
11384303|NCT02140632|Experimental|Local steroid injection|"The local injection of steroid is performed by the same investigator after the randomization. Using a sterile technique, 20mg methylprednisolone acetate premixed with lidnocaine is injected using a 25-gauge x 5/8 needle. The needle is inserted medially to the palmaris longus tendon at the distal palmar crease in the wrist at an angle of 45-degree to the forearm. The steroid is injected at approximately 1cm below the skin. The needle will be repositioned if there is any resistance to injection, or any pain or paraesthesia in the median nerve territory."
11384304|NCT02140632|Active Comparator|Wrist splinting|After randomization, the hands of the patients in the splinting group are splinted in neutral position with standard cotton-polyester splint. Patients are encouraged to use the splints during nighttime whenever possible for one month.
11384305|NCT02140619|Active Comparator|multiple health education interventions|The group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 1 year after discharge.
11384306|NCT02140619|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
11384307|NCT02140606|Experimental|Cafusertib Hydrochloride + Cytarabine|Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
11384308|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
11384309|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
11384310|NCT02140580|Active Comparator|Minimally invasive surfactant therapy|Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.
11384311|NCT02140580|Sham Comparator|Continuation on CPAP|Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.
11384312|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
11384313|NCT02140554|Experimental|Group A|"Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by bone marrow harvest transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
~*No Longer Recruiting"
11384314|NCT02140554|Experimental|Group B|"Group B1:
~Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by bone marrow harvest transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
~*No Longer Recruiting
~Group B2:
~Plerixafor mobilization and apheresis will be used for collection of rescue cells and exploratory manufacturing development. Subjects will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by bone marrow harvest transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
~*No Longer Recruiting"
11384315|NCT02140554|Experimental|Group C|Plerixafor mobilization and apheresis will be used for collection of rescue cells, and subjects will receive treatment of LentiGlobin BB305 Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis transduced with LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.
11384316|NCT02140541||Blood eosinophil count ≤ 400/µl|
11384317|NCT02140541||Blood eosinophil count > 400/µl|
11384318|NCT02140528|Experimental|Mesenchymal stem cell receipients|Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.
11384319|NCT02140528|Placebo Comparator|Placebo|Placebo injection in the site of fracture in patients with tibia fracture.
11384320|NCT02140515|Active Comparator|Luveris|Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
11384321|NCT02140515|Active Comparator|Gonal-F& Luveris|Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
11384322|NCT02140502||Men undergoing prostate biopsy|
11384323|NCT02140489|Experimental|Sequence 1|amosartan → rosuvastatin → amosartan and rosuvastatin
11384324|NCT02140489|Experimental|Sequence 2|rosuvastatin → amosartan and rosuvastatin → amosartan
11384325|NCT02140489|Experimental|Sequence 3|amosartan and rosuvastatin → amosartan → rosuvastatin
11384326|NCT02140476|Experimental|Thyroid Goiter|Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
11384327|NCT02140476|Active Comparator|Papillary Thyroid Cancer|Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.
11384885|NCT02136914|Placebo Comparator|Placebo|Placebo
11384329|NCT02140450|Active Comparator|Timolol|Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
11384330|NCT02140450|Active Comparator|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
11384331|NCT02140450|Active Comparator|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
11384332|NCT02140450|Active Comparator|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
11384333|NCT02140450|Sham Comparator|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
11384334|NCT02140437|Experimental|Fulvestrant and anastrozole|Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
11384335|NCT02140437|Active Comparator|Anastrozole|Anastrozole 1 mg PO QD
11384336|NCT02140424||youth with type 1 diabetes|
11384337|NCT02140424||healthy controls|
11384338|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
11384339|NCT02140398|Experimental|Currettage|Endometrial Currettage (endometrial scrapping) will be performed at the time of laparoscopic ovarian drilling
11384340|NCT02140398|No Intervention|Nothing|No endometrial curettage at time of Laparoscopic ovarian drilling
11384341|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia preservation|Scarpa's fascia preservation Lymphoscintigraphy 3D imaging Abdominal ultrasound
11384342|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia ablation|Scarpa's fascia ablation Lymphoscintigraphy 3D imaging Abdominal ultrasound
11384343|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
11384344|NCT02140359|No Intervention|Control Group: Usual Care|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet with case managers according to the usual procedures for new residents and will be given a standard case manager interaction.
11384345|NCT02140359|Experimental|Motivational Network Interview Recipients|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
11384346|NCT02140346|Experimental|28 day repeat dose (low dose)|
11384347|NCT02140346|Experimental|28 day repeat dose (high dose)|
11384348|NCT02140333|Experimental|Erlotinib 100mg|Erlotinib 100mg
11384349|NCT02140333|Active Comparator|Erlotinib 150mg|Erlotinib 150mg
11384350|NCT02140320|Experimental|Single dose (healthy volunteers)|
11384351|NCT02140320|Experimental|14 day repeat dose (healthy volunteers)|
11384352|NCT02140320|Experimental|14 day repeat dose (asthma patients)|
11384353|NCT02140320|Experimental|28 day repeat dose (healthy volunteers)|
11384354|NCT02140307|Experimental|Meditation training, group format|"The course Relaxation Response-based Mental Health Promotion (publicly referred to as Open and Calm) is given in group format.
~The intervention entails 9 courses (1 per week of 2.5 hrs), a course book (120 pages), audio support (6 guided meditative practices), access to a webpage with additional information, and the possibility of two personal sessions with the intervention instructor (a certified psychologist)."
11384355|NCT02140307|Active Comparator|Meditation training, individual format|"The course Relaxation Response-based Mental Health Promotion (Open and Calm) is given by the same instructor as for group formats using precisely the same material and methods, but in about 6-9 (as to each persons' individual needs and preferences) face-to-face meetings."
11384356|NCT02140307|No Intervention|Wait-list control|This arm is an inactive wait-list control.
11384357|NCT02140294|Experimental|Polymeric nutritional supplement|
11384358|NCT02140294|Active Comparator|Standard Nutritional Treatment|
11384359|NCT02140281|Experimental|Sequence 1 (Treatment A/B)|Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2
11384360|NCT02140281|Experimental|Sequence 2 (Treatment B/A)|Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2
11384361|NCT02140268|Active Comparator|Midazolam 7.5 mg|Volunteers will receive Midazolam 7.5 mg administered by mouth as a syrup
11384362|NCT02140268|Experimental|AZD1722 15 mg|Volunteers will received AZD1722 15 mg administered by mouth, as a tablet
11384363|NCT02140268|Experimental|AZD1722 15 mg and Midazolam 7.5 mg|Volunteers will receive AZD1722 15 mg tablet and Midazolam 7.5 mg syrup, by mouth
11384364|NCT02140255|Experimental|Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
11384365|NCT02140255|Experimental|Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
11384366|NCT02140255|Experimental|Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
11384367|NCT02140255|Experimental|Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
11384368|NCT02140255|Experimental|Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01|Participants will receive 2 NRTIs + NVP + RAL + VRC01.
11384369|NCT02140242|Active Comparator|daunorubicin 60 mg/m2|study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5
11384370|NCT02140242|Active Comparator|Double induction|study part 2: induction cycles double induction (only patients with good response)
11384371|NCT02140242|Experimental|Single induction|study part 2: induction cycles single induction (only patients with good response)
11384372|NCT02140229|Active Comparator|Usual care|Usual care and follow-up every 3 months
11384373|NCT02140229|Experimental|US-driven therapy|Clinical evaluation according to DAS28 + US every 3 months
11384374|NCT02140229|Active Comparator|ACR/EULAR remission criteria-driven therapy|Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months
11384375|NCT02140216||Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
11384376|NCT02140216||Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
11384377|NCT02140216||No blood transfusion|Patients undergoing elective spine surgery receiving no blood transfusion.
11384378|NCT02140203|Active Comparator|Young Yoga Group|People who are younger than 60 year-old They have received Yoga training in one-year experimental period
11384379|NCT02140203|No Intervention|Young Control Group|People who are younger than 60 year-old No Yoga training through out the one-year experimental period
11384380|NCT02140203|No Intervention|Aged Control Group|People who are equal or older than 60 year-old They have not received any yoga training during the one-year experimental period
11384381|NCT02140203|Active Comparator|Aged Yoga Group|People who are equal or older than 60 year-old They have received any yoga training during the one-year experimental period
11384382|NCT02140177||Adult Medical Inpatients|Adult medical inpatients; We will enroll adult patients, ages 18 years and older, admitted to identified inpatient medical units during designated data collections days.
11384383|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
11384384|NCT02140151|No Intervention|Sham|Sham Injection
11384385|NCT02140151|Active Comparator|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
11384386|NCT02140138|Experimental|Arm A (i.d. vaccinations with needle free injection device)|"Duration: Patients in Arm A will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.
~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).
~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.
~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
11384387|NCT02140138|Experimental|Arm B (i.d. vaccination by conventional injection)|"Duration: Patients in Arm B will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.
~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).
~Administration site: Skin of the medial part of the upper arms and thigh
~Dose: 2 x 160 μg mRNA per injection (2 x 200 μL), equals 320 μg mRNA per RNActive® drug product component"
11384388|NCT02140138|Other|Arm C (i.d. vaccination with needle free injection device)|"Duration: Patients in Arm C will receive no vaccination before radical prostatectomy. After surgery high risk or very high risk patients will be offered to receive 6 vaccinations with CV9104 at week 8, 9, 10, 12, 14 and 16 after surgery.
~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).
~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.
~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
11384389|NCT02140125|Experimental|ASP2408 low dose group|
11384390|NCT02140125|Experimental|ASP2408 middle dose group|
11384391|NCT02140125|Experimental|ASP2408 high dose group|
11384392|NCT02140125|Placebo Comparator|Placebo group|
11384393|NCT02140112|Active Comparator|Trichuris suis ova|TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
11384394|NCT02140112|Placebo Comparator|Placebo|Placebo 8 doses every 2 weeks
11384395|NCT02140099|Experimental|Healthy Relationships Education/Skills|The experimental intervention is the group-based, 15-session Healthy Relationships Plus Program (HRPP). In this study, the HRPP will be offered in a condensed 8-day format (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the program for 2 hours, and on day 8, participants will attend the program for 1 hour. The program will be facilitated by high school teachers. Eight HRPP groups will run concurrently during the study period.
11384396|NCT02140099|Other|Classroom Activities|The control condition is a group-based, 15-session program focusing on typical Classroom Activities. The primary activity is to create a school welcome packet for incoming Grade 9 students, with other activities including reading and physical exercise. The control condition will be offered on 8 consecutive weekdays (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the control program for 2 hours, and on day 8, participants will attend the control program for 1 hour. The control group will be facilitated by bachelor's level research assistants and pre-service teachers. Eight control groups will run concurrently during the study period.
11384397|NCT02140086|Experimental|Buteyko based Remedial Breathing Therapy|Buteyko based Remedial Breathing Therapy
11384398|NCT02140086|No Intervention|Waiting List|Training in the course of the study
11384399|NCT02140073|Experimental|omeprazole+domperidone SR|patients with GERD receive omeprazole 20mg + domperidone SR 30mg , 2 capsules in the morning
11384400|NCT02140073|Active Comparator|omeprazole|omeprazole 40mg in the morning
11384401|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
11384402|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
11384403|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
11384404|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
11384555|NCT02139098|Active Comparator|Amitriptyline fixed dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
11384405|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
11384406|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
11384407|NCT02140047|Experimental|MT-2301-Low|
11384408|NCT02140047|Experimental|MT-2301-High|
11384409|NCT02140047|Active Comparator|ActHib|
11384410|NCT02140034|Experimental|Study Arm: Extensive Peritoneal Lavage|The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
11384411|NCT02140034|No Intervention|Control Arm: Standard Treatment|The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
11384412|NCT02140021|Experimental|Screening (biospecimen collection)|Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
11384413|NCT02140008|Experimental|I-gel group|
11384414|NCT02140008|Active Comparator|Air-Q group|
11384415|NCT02139995|Experimental|Transfusion trigger based on WCTS-CP|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP
11384416|NCT02139995|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience
11384417|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
11384418|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
11384419|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
11384420|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
11384421|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
11384422|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
11384423|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
11384424|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
11384425|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
11384426|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
11384427|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
11384428|NCT02139956||stress urinary incontinence|group 1 women with stress urinary incontinence by ultrasonography
11384429|NCT02139956||continent group|group 2 women without stress urinary incontinence by ultrasonography
11384430|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
11384431|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
11384432|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
11384433|NCT02139930|Active Comparator|Normal Nicotine Control Group|These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
11384434|NCT02139930|Experimental|Immediate Nicotine Reduction Group|This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
11384435|NCT02139930|Experimental|Gradual Nicotine Reduction Group|This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
11384436|NCT02139917|Experimental|Transitional Palliative Care|"Transitional palliative care include:-
~telephone follow up for early identification of signs and symptoms
~home visit for spiritual support"
11384437|NCT02139917|No Intervention|Customary care|"Customary care receive care :-
~hospital based medical follow up
~general nursing assessment and advice"
11384438|NCT02139904|Placebo Comparator|Active Symptom Control|Active symptom control includes palliative care and standard care methods used to manage symptoms
11384439|NCT02139904|Active Comparator|Vinorelbine|Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
11384440|NCT02139891|Experimental|"MultiPoint Pacing On"|Patients will be randomized to the MPP-ON Arm vs MPP-OFF in in crossover fashion with 3 months in each period.
11384441|NCT02139891|Active Comparator|"MultiPoint Pacing Off"|Patients will be randomized to the MPP-OFF arm vs MPP-ON in crossover fashion with 3 months in each period.
11384442|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
11384443|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
11384444|NCT02139865|Experimental|30%|Training at 30% 1RM
11384445|NCT02139865|Experimental|80%|Training at 80% 1RM
11384446|NCT02139852|Experimental|capsaicin|Capsaicin
11384447|NCT02139852|Placebo Comparator|Placebo|
11384448|NCT02139839|Placebo Comparator|Gelatin pill first|
11384449|NCT02139839|Experimental|Lactobacillus capsules first|
11384450|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
11384451|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
11384452|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
11384453|NCT02139813|Experimental|Laparoscopic Omega Loop Bypass|Laparoscopic Mini-gastric bypass
11384454|NCT02139813|Active Comparator|Laparoscopic Roux-en-Y Gastric ByPass|Procedure of reference in bariatric surgery
11384556|NCT02139098|Active Comparator|Zolpidem fixed dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
11384455|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
11384456|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
11384457|NCT02139787|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing hypertension or obesity through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
11384458|NCT02139787|Active Comparator|Control -listened to a brochure|Participants received an audio version of a standard brochure about hypertension or obesity prevention.
11384459|NCT02139774||Active Survelliance|Men age 65 and older who are undergoing active surveillance as primary treatment for their prostate cancer.
11384460|NCT02139774||Radiation|Men age 65 and older who are undergoing radiation only as primary treatment for their prostate cancer.
11384461|NCT02139774||Endocrine Therapy|Men age 65 and older who are undergoing endocrine therapy as primary treatment for their prostate cancer.
11384462|NCT02139774||Surgery|Men age 65 and older who are undergoing surgery as primary treatment for their prostate cancer.
11384463|NCT02139761|Active Comparator|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
11384464|NCT02139761|Placebo Comparator|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
11384465|NCT02139748|Active Comparator|Dental Implant & ADM|Dental implant placement plus simultaneous grafting use one layer of ADM.
11384466|NCT02139748|Experimental|Dental Implant & ADM & bone xenograft|Dental implant placement plus simultaneous grafting use one layer of ADM with bovine xenograft.
11384467|NCT02139735|Experimental|Ultrasound|3 MHz (Mega Hertz) ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ (Temporomandibular joint) and masseter muscles bilaterally
11384468|NCT02139735|Experimental|Ultrasound associated with stretchting|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally.
~Active stretching of the masseter muscles with mouth opening and closed lips"
11384469|NCT02139735|Experimental|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
11384470|NCT02139722|No Intervention|Provider Panel Notification (PPN) Alone|The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
11384471|NCT02139722|Experimental|Video Doctor, PA + PPN|Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
11384472|NCT02139709|Experimental|Ganglioside|1.0 gram ZETA dairy lipid powder (Fonterra NZ)
11384473|NCT02139709|Placebo Comparator|Placebo|1.0 gram milk fat fraction void of ganglioside
11384474|NCT02139696||MS patients initiating fingolimod|Patients will be imaged using PET and MRI at baseline, and twice during treatment.
11384475|NCT02139683|Experimental|HIFU treatment|HIFU treatment in patient diagnosed with fibroadenoma
11384476|NCT02139670||pregnant womens|
11384477|NCT02139657|Experimental|RIG-C|Single 20 IU/kg dose of RIG-C by intramuscular injection
11384478|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11384479|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11384480|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11384481|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11384482|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
11384483|NCT02139631|Experimental|Healthy volunteers|The volunteers initially underwent a clinical examination, spirometry and echocardiography to prove the health state. Then, different levels of positive end expiratory pressure (PEEP) is applied by the noninvasive ventilation in all individuals and the hemodynamic repercussions are evaluated by the doppler echocardiography
11384484|NCT02139618|Experimental|Methyl Aminolevulinate (MAL)|1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
11384485|NCT02139618|Placebo Comparator|Placebo|1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
11384486|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
11384487|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
11384488|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
11384489|NCT02139579|Experimental|Avastin|bevacizumab 7.5mg/kg+paclitaxel 200mg/m2＋carboplatin area under curve(AUC)=6, every 3 weeks，maximum 4 cycles
11384490|NCT02139566|Experimental|Hi-tech video consent|This group will be shown a professionally animated video that presents the major components of the informed consent document. Intervention is Video Consent (high-tech) PDF informed consent document.
11384491|NCT02139566|Experimental|Low-tech video consent|"Participants in this arm will be provided with informed consent information through viewing a talking head video produced by a non-professional presenter, with widely available and inexpensive video equipment. Intervention is video consent (low-tech), PDF informed consent document."
11384492|NCT02139566|Experimental|FAQ consent|"Participants in this arm will be provided with informed consent content through an interactive frequently asked questions format, in which the participant will click on a question and be shown text that provides an answer to that question. Major informed consent topics will have one or more question and answer pairs. Intervention is FAQ format consent, PDF informed consent document"
11384493|NCT02139566|Active Comparator|Standard consent process|Participants in this arm will be provided with informed consent content by being shown a standard informed consent document in a scrolling window within the browser window, PDF informed consent document
11384494|NCT02139553|Experimental|Rhythmic rehabilitation|Patients undergo a first evaluation, and a second evaluation one month later to determine their natural evolution. The following month, patients get 12 sessions of rhythmic therapy. A third evaluation is organized straight after this month and a fourth evaluation, 3 months after to assess the after-effects of the therapy.
11384495|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
11384496|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
11384497|NCT02139514|Active Comparator|Virtual Reality Social Cognition Training|Virtual Reality Social Cognition Training
11384498|NCT02139514|No Intervention|Control|Participants in the Control condition will be offered treatment following the Control condition.
11384499|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 14 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days
11384500|NCT02139501|Experimental|rhTPO, 300Units/kg ,one times every other day for 7 times|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times.
11384501|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 7 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days.
11384502|NCT02139488||neoadjuvant or definitive chemoradiation|Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
11384503|NCT02139475||Colonoscopy|patients undergoing colonoscopy after colorectal cancer surgery
11384504|NCT02139462|Experimental|Standard training|Therapists will receive standard training in FBT.
11384505|NCT02139462|Experimental|Novel training|Therapists will receive a novel, more efficient training in FBT
11384506|NCT02139449||ICD/CRT registry|ICD / CRTregistry in Severance or Ewha Womans University Medical Center
11384507|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
11384508|NCT02139436|Other|Wait-list time control|Subjects will wait for 6 months before performing 6 months of FES-row-training.
11384509|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training followed by 6 months of FES-row-training
11384510|NCT02139423|Experimental|All newborns who fail universal newborn|CMV PCR
11384511|NCT02139410||IGF-1 1st and 2nd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
11384512|NCT02139410||IGF-1 3rd and 4rd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
11384513|NCT02139397|Experimental|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
11384514|NCT02139371|Experimental|64Cu-DOTA-AE105 PET|One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection
11384515|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
11384516|NCT02139345|Experimental|TC-A PS|Subject will be implanted with the TC-A PS Total Knee Replacement System
11384517|NCT02139345|Active Comparator|TC-PLUS Solution PS|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
11384518|NCT02139332|Active Comparator|Resource & Referral group|Individuals randomized to the control group will receive a resource & Referral service immediately after their baseline research visit.
11384519|NCT02139332|Experimental|PFR Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
11384520|NCT02139319|Experimental|Botulinum toxin|Single intra-articular injection
11384521|NCT02139319|Placebo Comparator|Placebo|Single intra-articular injection
11384522|NCT02139306|Experimental|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
11384523|NCT02139306|Placebo Comparator|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
11384557|NCT02139098|Active Comparator|Amitriptyline continuous dosing|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
11384524|NCT02139293|Experimental|auricular vagus nerve stimulation|"Study participants (healthy) are treated with auricular vagus nerve stimulation using five needle electrodes connected to an electrical stimulation device (PrimeStim). After acclimatization the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and 10 minutes paused stimulation. This intervention is repeated on four consecutive days, whereas at each intervention only one of the four stimulation points (and one fixed reference point) is stimulated. Needle electrodes are applied at each study visit.
~Stimulation points in the auricle are stimulated in random order. One stimulation pattern is tested. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.
~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
11384525|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
11384526|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
11384527|NCT02139267|Experimental|1mg of GX-188E per dose|1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
11384528|NCT02139267|Experimental|4mg of GX-188E per dose|4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
11384529|NCT02139254||Low risk|Pregnant women with a low risk for metabolic diseases
11384530|NCT02139254||High risk|Pregnant women with a high risk for metabolic diseases
11384531|NCT02139241|Experimental|Ramosetron|Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia
11384532|NCT02139241|Placebo Comparator|Control|Intravenous administration of 2ml normal saline before the induction of general anesthesia
11384533|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).
~No vaccine was administered during this trial"
11384534|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).
~No vaccine was administered during this trial"
11384535|NCT02139202|Other|Full Program|"The intervention will (1) use the GlowCaps, a remote monitoring and reminder pill bottle; (2) be assigned an engagement advisor from the study team; (3) be asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence for the first three months; and (5) will determine their preferences for Way to Health platform communication methods during the study.
~The group receiving the program intervention will also have their claims data analyzed for the 1 months post-enrollment."
11384536|NCT02139189|Experimental|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
11384537|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
11384538|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
11384539|NCT02139163||patients with pneumonia|
11384540|NCT02139150|Experimental|Serial FLT PET Imaging|"Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma)."
11384541|NCT02139137|Experimental|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
11384542|NCT02139137|Active Comparator|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
11384543|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
11384544|NCT02139124|Experimental|PRC-063 25 mg|PRC-063 25 mg
11384545|NCT02139124|Active Comparator|PRC-063 45 mg|PRC-063 45 mg
11384546|NCT02139124|Active Comparator|PRC-063 70 mg|PRC-063 70 mg
11384547|NCT02139124|Active Comparator|PRC-063 100 mg|PRC-063 100 mg
11384548|NCT02139111|Placebo Comparator|Placebo|Placebo Arm
11384549|NCT02139111|Active Comparator|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
11384550|NCT02139111|Active Comparator|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
11384551|NCT02139111|Active Comparator|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
11384552|NCT02139111|Active Comparator|PRC-063 85 mg and Placebo|PRC-063 85 mg and placebo capsule by mouth once daily
11384553|NCT02139098|Experimental|Amitriptyline flexible dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
11384554|NCT02139098|Experimental|Zolpidem flexible dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
11384558|NCT02139085|Active Comparator|GSV Electrocoagulation|GSV Electrocoagulation Source: Electrosurgical Generator(FX-Valley Lab; USA) Energy: 60 Watts x 10 seconds
11384559|NCT02139085|Active Comparator|GSV Radiofrequency|GSV Radiofrequency Source: Closure FAST(Covidien, USA) Energy: 60 Joules / cm
11384560|NCT02139072||CoaguChek XS|INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
11384561|NCT02139072||Standard Lab Draw|INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
11384562|NCT02139059|Active Comparator|initial urinary drainage|initial urinary drainage to stabilize renal functions before ureteroscopy
11384563|NCT02139059|Active Comparator|direct ureteroscopy|direct ureteroscopy without initial urinary drainage
11384564|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11384565|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11384566|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11384567|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11384568|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11384569|NCT02139033|Experimental|Arm 1|Retain 1-2 drops, bilaterally, BID
11384570|NCT02139020||No treatment|"Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples:
~Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al [11]
~Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. [10]
~Group 3 = patients treated with a molecular targeted agent as a part of a clinical study"
11384571|NCT02139007|Active Comparator|Continuation Arm|Alendronate continuation arm
11384572|NCT02139007|Active Comparator|Discontinuation Arm|Alendronate discontinuation arm
11384573|NCT02138994|Active Comparator|Triple Antibiotic Ointment Neosporin|Daily direct application to the wound, covered with conventional dressing. Dressing should be changed daily or as directed by the health care provider.
11384574|NCT02138994|Experimental|Next Science Wound Gel|Daily direct application to the wound, covered with a conventional non-alginate dressing. Dressing should be changed daily or as directed by the health care provider.
11384575|NCT02138981|Active Comparator|Immediate Resection|patients received immediate surgical hepatic resection
11384576|NCT02138981|Experimental|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
11384577|NCT02138968|Experimental|Multidimensional intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
11384578|NCT02138968|No Intervention|Usual care|Usual care
11384579|NCT02138955|Experimental|Liposomeal curcumin ascending dose phase 1b|
11384580|NCT02138942|Experimental|The study population|"See inclusion/exclusion criteria.
~Intervention: LIR"
11384581|NCT02138929|Experimental|Everolimus + LDE 225|"Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.
~Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days."
11384582|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
11384583|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
11384584|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
11384585|NCT02138903||ZEEP and tubing-spontaneous ventilation|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
11384586|NCT02138903||trans-thoracic echocardiography|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
11384587|NCT02138890|Experimental|APS injection|Autologous Protein Solution
11384588|NCT02138890|Placebo Comparator|Control|Saline
11384589|NCT02138877|Active Comparator|After coming stent|Dismembered pyeloplasty with insertion of an after coming stent
11384590|NCT02138877|Active Comparator|Stentless|Stentless dismembered pyeloplasty
11384591|NCT02138864|Experimental|18F-FP-(+)-DTBZ only|PET tracer: 18F-FP-(+)-DTBZ
11384592|NCT02138851|Experimental|Ficus Carica|Ficus Carica 300g/day
11384593|NCT02138851|Placebo Comparator|Placebo|Placebo 300g/day
11384594|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
11384775|NCT02137603|No Intervention|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
11384595|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
11384596|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
11384597|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
11384598|NCT02138812|Experimental|BAY1161909 + Paclitaxel|Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.
11384599|NCT02138799|Experimental|1: single dose of enzalutamide|
11384600|NCT02138799|Experimental|2: multiple doses of rifampin and single dose of enzalutamide|
11384601|NCT02138786|Experimental|selinexor|"oral tablets
~10 mg & 25 mg (bottled); or
~20 mg (blister pack)"
11384602|NCT02138773|Experimental|Fed, formulation-A|drug administered at 0.5h after the start of a standard breakfast
11384603|NCT02138773|Experimental|Fed, formulation-B|drug administered at 0.5h after the start of a standard breakfast
11384604|NCT02138773|Experimental|Fasted, formulation-A|drug administered under fasted condition (fasting for at least 10 hours)
11384605|NCT02138773|Experimental|Fasted, formulation-B|drug administered under fasted condition (fasting for at least 10 hours)
11384606|NCT02138760|No Intervention|MRI guided cognitive fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional cognitive (freehand) biopsies of MRI suspicious targets
11384607|NCT02138760|Experimental|UroNav fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional UroNav fusion biopsy of MRI suspicious targets
11384608|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
11384609|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
11384610|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
11384611|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
11384612|NCT02138734|Experimental|ALT-803+BCG|(Phase Ib and IIb) for BCG-naive patients
11384613|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
11384614|NCT02138721|No Intervention|No local treatment|Routine care in metastatic prostate cancer.
11384615|NCT02138721|Experimental|Local treatment|Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
11384616|NCT02138708|Experimental|Shunt closed|patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
11384617|NCT02138695||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
11384618|NCT02138682||l-123 Ioflupane|Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.
11384619|NCT02138669|Other|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
11384620|NCT02138656|Active Comparator|Best standard care only - not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.
~Parents aware that infant is not receiving chiropractic treatment"
11384621|NCT02138656|Sham Comparator|Best Standard Care and Sham - Blind|Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
11384622|NCT02138656|Experimental|BSC & Chiropractic - Not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.
~Parents aware that infant is receiving chiropractic treatment."
11384776|NCT02137590|Experimental|Spanish Black Radish|Spanish Black Radish product
11384623|NCT02138656|Experimental|BSC & Chiropractic - Blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.
~Parents not aware that infant is receiving chiropractic treatment."
11384624|NCT02138643|Active Comparator|Endoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
11384625|NCT02138643|Sham Comparator|Laparoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
11384626|NCT02138630|Placebo Comparator|Placebo|
11384627|NCT02138630|Experimental|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
11384628|NCT02138617|Experimental|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
11384629|NCT02138617|Experimental|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
11384630|NCT02138617|Experimental|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
11384631|NCT02138591|Experimental|Vitamin D3|"Vitamin D3 (cholecalciferol) 50,000 IU by mouth daily for each of the five days prior to surgery.
~Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2"
11384632|NCT02138591|Placebo Comparator|Placebo pill|Placebo pill by mouth daily for each of the five days prior to surgery. Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2
11384633|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
11384634|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
11384635|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
11384636|NCT02138565|Experimental|Bariatric surgery|
11384637|NCT02138552|Active Comparator|OCT 0.1% vs. Placebo|0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
11384638|NCT02138552|Active Comparator|OCT 0.15% vs. Placebo|0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
11384639|NCT02138552|Active Comparator|OCT 2.0% vs. Placebo|0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
11384640|NCT02138539|Active Comparator|4% Hydroquinone|4% hydroquinone applied to one side of the face.
11384641|NCT02138539|Experimental|Herbal depigmenting agent|Herbal depigmenting agent applied on the other side of the face.
11384642|NCT02138526|Active Comparator|fasted|Intake of pazopanib in agreement with drug label - fasted state
11384643|NCT02138526|Experimental|Continental breakfast|Intake of a reduced equivalent pazopanib dose with a continental breakfast
11384644|NCT02138513|Experimental|Online MBCT|
11384645|NCT02138513|Experimental|group MBCT|
11384646|NCT02138513|No Intervention|Treatment as usual|3 months waiting list, subsequent assignment to group or online MBCT
11384647|NCT02138500|Experimental|Cohort 1: PF-06372865 10 mg|
11384648|NCT02138500|Experimental|Cohort 2: PF-06372865 TBD dose|
11384649|NCT02138500|Experimental|Cohort 3: PF-06372865 TBD dose|
11384650|NCT02138487|Active Comparator|Restricted postoperative activity|"Women in the restricted postoperative activity group must abstain from exercise and heavy lifting for 3 months postoperatively"
11384651|NCT02138487|Experimental|Liberal postoperative activity|"Women in the liberal postoperative activity group will be allowed to resume their normal activities without restriction."
11384652|NCT02138474|Experimental|Lacticum acidum homaccord|Lacticum acidum homaccord 30 mL bottle of medicated sucrose pillules take 5 pillules of the medication in the morning and in the evening for 4 weeks
11384653|NCT02138474|Placebo Comparator|Placebo|Unmedicated sucrose pillules, take 5 pillules twice daily for 4 weeks
11384654|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
11384655|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
11384656|NCT02138448|Experimental|Intervention practices|Intervention practices will implement an interactive preventive health record in addition to their standard personal health record functionality.
11384657|NCT02138448|No Intervention|Control practices|Control practices will continue to field their existing personal health record
11384658|NCT02138435||VSD-patients|Patients who had VSD closure between 1990 and 1995. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
11384659|NCT02138435||Control|A group of healthy control subjects. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
11384660|NCT02138422|Placebo Comparator|Placebo|Placebo administered intravenously every 2 weeks
11384661|NCT02138422|Active Comparator|Xilonix|Xilonix administered intravenously every 2 weeks
11384662|NCT02138409|Experimental|ON FSS 100 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 100 µg
11384663|NCT02138409|Experimental|ON FSS 200 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 200 µg
11385147|NCT02135250|Experimental|Xinkeshu tablet|4 Xinkeshu tablets are given three times per day
11384664|NCT02138409|Experimental|OE FSS 400 µg|Participants classified as opioid-experienced (OE), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, at a dose of 400 µg
11384665|NCT02138409|Placebo Comparator|ON PSS|Participants classified as opioid-naïve (ON) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
11384666|NCT02138409|Placebo Comparator|OE PSS|Participants classified as opioid-experienced (OE) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
11384667|NCT02138396|Experimental|FSS first, then FCI|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit. After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit.
11384668|NCT02138396|Experimental|FCI first, then FSS|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit. After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit.
11384669|NCT02138383|Experimental|Dose Escalation and Dose Expansion|"Dose Escalation: To find the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
~Dose Expansion: To find the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel."
11384670|NCT02138370||stage II and III colorectal cancer|
11384671|NCT02138357|Placebo Comparator|Placebo Patch|"The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.
~Each subject will participate in this arm of the study for four weeks."
11384672|NCT02138357|Experimental|buprenorphine transdermal delivery system (BTDS)|"buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.
~Each subject will participate in this arm of the study for four weeks."
11384673|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
11384674|NCT02138344||Healthy control subjects|
11384675|NCT02138344||Subjects with peripheral nerve diseases|
11384676|NCT02138331|Experimental|Exosomes|The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nm. Some of these RNAs are microRNAs that are predominantly pre-microRNAs..Additionally, CB-SC displayed very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.
11384677|NCT02138318|Other|chromoendoscopy|
11384678|NCT02138318|Other|High definition (HD) endoscopy|
11384679|NCT02138305|Other|Patients referred for CABG|"Patients who after undergoing standard of care diagnostic coronary angiography will be referred for CABG
~ComboMap XT Guidewire
~'SPY' NIRF During CABG"
11384680|NCT02138292|Experimental|Trametinib (2mg)/Digoxin (0.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.
~Digoxin (0.25mg) will be administered orally on a daily basis.
~On a 8-week cycle, duration of treatment can last from 8 to 104 weeks."
11384681|NCT02138279||Male and female adults 18+ years of age|
11384682|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
11384683|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
11384684|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
11384685|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
11384686|NCT02138253|Placebo Comparator|Placebo|Placebo BID
11384687|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
11384688|NCT02138227|Active Comparator|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
11384689|NCT02138227|Active Comparator|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
11384690|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
11384691|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
11384692|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
11384693|NCT02138201||control|individuals with normal bladder function
11384694|NCT02138201||neurogenic bladder|individuals suffering from neurogenic lower urinary tract dysfunction
11384695|NCT02138188||T1D patients on CSII|Patients affected by Type 1 Diabetes on insulin pump therapy
11384696|NCT02138175||Patients at risk for bleeding|Patients at risk for bleeding
11384697|NCT02138162|Experimental|1:Single dose of enzalutamide in hepatically impaired subjects|Single dose of enzalutamide
11384698|NCT02138162|Experimental|2:Single dose of enzalutamide in healthy subjects|Single dose of enzalutamide
11384699|NCT02138149||spinal cord injury|individuals with neurogenic lower urinary tract dysfunction
11384700|NCT02138149||control group|individuals with physiologic bladder function
11384701|NCT02138136|Experimental|Lubiprostone|"Participants receive lubiprostone twice daily
~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
11385148|NCT02135237|Active Comparator|Control Group|Standard Care
11384702|NCT02138123|Experimental|IOL-shell technique|In this group, before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
11384703|NCT02138123|Active Comparator|Conventional procedure|In this group, a Sensar IOL (AMO Laboratories) was implanted in the capsular bag with the injector system after the lens material was completely removed. The nuclear fragmentation was performed using the Phaco-chop technique, which was then followed by ultrasound emulsification of the nuclear fragments piece by piece. Due to lack of cortical shell within the capsular bag, special care was taken to carry out the emulsification of the last nuclear fragment at a relatively more anterior anatomical position between the iris plan and the anterior chamber.
11384704|NCT02138110|Experimental|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
11384705|NCT02138097||Glitazones|
11384706|NCT02138097||Linagliptin|
11384707|NCT02138097||Meglitinides|
11384708|NCT02138097||Metformin|
11384709|NCT02138097||Non-insulin injectables|
11384710|NCT02138097||Saxagliptin|
11384711|NCT02138097||Sitagliptin|
11384712|NCT02138097||Sulfonylurea|
11384713|NCT02138084|Experimental|Cohort 1: BMS-663068 + Rifabutin|"Regimen A: BMS-663068 tablet by mouth as specified
~Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified"
11384714|NCT02138084|Experimental|Cohort 2: BMS-663068 + Rifabutin + Ritonavir|"Regimen A: BMS-663068 tablet by mouth as specified
~Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified"
11384715|NCT02138071||Individual|Treatment in the 'Individual group therapy' will include physiotherapy protocols usually used by physiotherapist working at Maccabi Healthcare Services (Exercises, Modalities, Maual therapy and Back Care education)
11384716|NCT02138071||group|Participants in group therapy will receive 6-8 group treatments (6-12 pateints per group) which will also include exercises and back-care education. No intervention will be done by the investigator.Therapists will use protocols commonly used in Maccabi Healthcate Services.
11384717|NCT02138058|Placebo Comparator|Placebo|a 12 week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention
11384718|NCT02138058|Experimental|topiramate|a 12 week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention
11384719|NCT02138045|Placebo Comparator|Placebo treatment|"Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:
~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
11384720|NCT02138045|Active Comparator|Liraglutide treatment|"Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:
~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
11384721|NCT02138032|Experimental|Gains Framed Message|gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
11384722|NCT02138032|Experimental|Loss Framed Message|loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
11384723|NCT02138019|Experimental|Fibrin glue|In ophthalmic field, the use of organic glues has provided good results for the repair of leaking blebs and perforated corneal ulcers, conjunctival closure in strabismus surgery, surgery for retinal detachment, cataract surgery, trabeculectomy, and mucous membrane grafting to repair lesions of the conjunctival fornix. In this study, the investigators try to evaluate the effect of Fibrin Glue assisted external eye surgery.
11384724|NCT02138006|Experimental|Intensive insulin treatment|Intensive insulin treatment
11384725|NCT02138006|Active Comparator|Standard insulin treatment|Standard insulin treatment
11384726|NCT02137993|Experimental|A-prexa|A-prexa 5, 10mg
11384727|NCT02137993|Active Comparator|Zyprexa|Zyprexa 5, 10mg
11384728|NCT02137967|Experimental|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medication
11384729|NCT02137967|Active Comparator|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament
11384730|NCT02137954|Active Comparator|lidocaine|Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day
11384731|NCT02137954|Placebo Comparator|placebo|
11384732|NCT02137941|Active Comparator|techniques to optimize potential (TOP)|
11384733|NCT02137941|Active Comparator|heart coherence (HC)|
11384734|NCT02137941|Placebo Comparator|controls|
11384735|NCT02137928|Experimental|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)
11384736|NCT02137928|Active Comparator|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months
11384737|NCT02137902|Experimental|Tobacco/Physical Activity Intervention|Includes a psychosocial component that utilizes a counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy, and self-monitoring with a pedometer-based walking program. The intervention will provide 12 weeks of nicotine replacement therapy for participants.
11384738|NCT02137902|Experimental|Diet plus BP/CHOL Intervention|Consists of a psychosocial component that includes counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing hypertension and hypercholesterolemia, and adherence with antihypertensives and statins with supportive dietary changes. The intervention provides a cookbook of heart healthy regional recipes and medication bag for storing medications.
11384739|NCT02137889|Experimental|Arm 1- relapsed/refractory CLL patients|Patients with relapsed/refractory CLL with two or three prior treatment regimens
11384740|NCT02137889|Experimental|Arm 2 - rituximab or ofatumumab refractory CLL patients|Patients with relapsed/refractory CLL with four or more prior treatment regimens
11384777|NCT02137577|Experimental|DEB catheter|use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
11384741|NCT02137863|Placebo Comparator|Control|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
~100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.
~1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
11384742|NCT02137863|Active Comparator|Dexmedetomidine|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
~Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.
~1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
11384743|NCT02137850|Experimental|50 EDs (exposure days)|
11384744|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
11384745|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
11384746|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
11384747|NCT02137824|Experimental|sinus floor elevation|
11384748|NCT02137811||Patients that received MICK assay|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
11384749|NCT02137798|Experimental|CARTOUNIVU|Radiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
11384750|NCT02137798|Active Comparator|CARTO3|Radiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
11384751|NCT02137785|Experimental|ALA|
11384752|NCT02137785|Placebo Comparator|Vehicle|
11384753|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
11384754|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
11384755|NCT02137759|Active Comparator|Std RT/TMZ (Cohort 1)|"Standard radiation therapy
~Standard temozolomide"
11384756|NCT02137759|Experimental|Std RT/TMZ + belinostat (Cohorts 2a, 2b)|"Standard radiation therapy
~Standard temozolomide
~Belinostat"
11384757|NCT02137746|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCa Experimental therapy
11384758|NCT02137733|Active Comparator|Bisoprolol group|Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
11384759|NCT02137733|Active Comparator|Carvedilol group|Daily oral administration of carvedilol 1.25 mg, 1 tablet twice a day (after breakfast and supper) should be given (Step 1). If tolerability is confirmed by an investigator after administering 2.5 mg/day of carvedilol, the dose should be increased to 5 mg (carvedilol 2.5 mg, 1 tablet twice daily) (Step 2). In the same manner, the dose should be increased to 10 mg (carvedilol 2.5 mg, 2 tablets twice daily, Step 3), to 15 mg (carvedilol 2.5 mg, 3 tablets twice daily, Step 4), and to 20 mg (carvedilol 10 mg, 1 tablet twice daily, Step 5).
11384760|NCT02137720|Experimental|Telephonic Diabetes Self-Management Support|This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support. Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
11384761|NCT02137720|Active Comparator|Educational Print Materials|Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
11384762|NCT02137707||Gilenya treatment|Gilenya oral form once a day
11384763|NCT02137694|Other|PapU-APV|No drug and no placebo will be used in this study. For the study participants, only their medical history data and vaginal auto-takings ( APV) and urinary will be collected.
11384764|NCT02137681|Experimental|2 cycles|2 cycles RTX
11384765|NCT02137681|Active Comparator|standard 4 cycles|standard 4 cycles RTX
11384766|NCT02137668|Experimental|Oral Vancomycin|Every participant with PSC or BA will received the same Arm of Oral Vancomycin
11384767|NCT02137642|Active Comparator|RM-131|
11384768|NCT02137642|Placebo Comparator|Placebo|
11384769|NCT02137629||Korean patients|All Korean patients intended to be treated with Vidaza® according to the approved package insert
11384770|NCT02137616|Active Comparator|risperidone|low dosage of antipsychotic drug
11384771|NCT02137616|Active Comparator|olanzapine|low doseage of antipsychotic
11384772|NCT02137616|Active Comparator|quetiapine|low doseage of antipsychotic
11384773|NCT02137616|Active Comparator|aripiprazole|low doseage of antipsychotic
11384774|NCT02137603|Experimental|Fast track|Patients discharged home the same day following appendectomy
11384778|NCT02137577|Active Comparator|common PTA balloon catheter|use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
11384779|NCT02137564|Experimental|Treatment (gamma secretase inhibitor PF-03084014)|Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.
11384780|NCT02137551|Experimental|ABM Intervention in FQHC|Pharmacy technicians within El Rio will implement the ABM
11384781|NCT02137551|Experimental|ABM Intervention in a Supermarket Pharmacy|Pharmacists within Fry's will implement the ABM
11384782|NCT02137551|No Intervention|Usual care|Patients will refill prescriptions at their usual pharmacy in the customary way.
11384783|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
11384784|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
11384785|NCT02137525|Active Comparator|Morphine 6 mg|Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg
11384786|NCT02137525|Experimental|Fentanyl 100 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg
11384787|NCT02137525|Experimental|Fentanyl 200 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg
11384788|NCT02137525|Experimental|Fentanyl 400 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg
11384789|NCT02137512|Experimental|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
11384790|NCT02137512|Active Comparator|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
11384791|NCT02137499|Active Comparator|Healthy subjects|Healthy subjects, free from vascular disease
11384792|NCT02137499|Experimental|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
11384793|NCT02137499|Experimental|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
11384794|NCT02137499|Experimental|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
11384795|NCT02137486||sequential ballooning|include BMS or DES
11384796|NCT02137486||final kissing ballooning|include BMS or DES
11384797|NCT02137473|Active Comparator|Bovine protein-based fortifier|
11384798|NCT02137473|Experimental|Human milk-based fortifier|
11384799|NCT02137460||Young normal controls|"age : 20 ~ 55
~without dementia, MCI, or other major neurological/psychiatric illness"
11384800|NCT02137460||Elderly normal controls|"age : 55 ~ 90
~without dementia, MCI, or other major neurological/psychiatric illness"
11384801|NCT02137460||MCI (Mild cognitive impairment)|"age : 55 ~ 90
~without major neurological/psychiatric illness
~concern regarding a change in cognition, lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
11384802|NCT02137460||AD (Alzheimer's diseases)|"age: 55 ~ 90
~National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia"
11384803|NCT02137447|Experimental|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.
~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
11384804|NCT02137434|Placebo Comparator|Low calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 40 mg of calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
11384805|NCT02137434|Experimental|High dietary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of skimmed milk containing 540 mg of dietary calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
11384806|NCT02137434|Experimental|High supplementary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 540 mg of supplementary calcium from calcium carbonate, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
11384807|NCT02137421|Experimental|CAD, Metabolic syndrome .|"Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .
~Each experiment repeats three times ."
11384808|NCT02137421|Experimental|Healthy subjects .|"Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .
~Each experiment repeats three times ."
11384809|NCT02137408|Active Comparator|200 mg docosahexaenoic acid|Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily (1-200mg capsule of DHA). This is a standard dose used in prenatal vitamins. Participants will be supplemented by mouth daily between 18-20 weeks gestation through 6 weeks post-partum.
11384810|NCT02137408|Active Comparator|1000 mg docosahexaenoic acid|Participants will be randomized to 1000 mg of docosahexaenoic acid (DHA) administered PO daily (5- 200mg capsules of DHA). Participants will be supplemented daily PO between 18-20 weeks gestation through 6 weeks post-partum.
11384811|NCT02137395|Experimental|Dexamethasone|Patients are received dexamethasone via intravenous (iv) route of 0.5 mg.kg-1 (maximum dose of 8 mg) in group D at the induction of anesthesia.
11384812|NCT02137395|Placebo Comparator|Placebo|An equal volume of saline iv in group S at the induction of anesthesia.
11384883|NCT02136927|Active Comparator|Reference1210|Intravenous administration of Reference1210
11384813|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
11384814|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
11384815|NCT02137369|Active Comparator|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
11384816|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
11384817|NCT02137356|Experimental|treatment arm|standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
11384818|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
11384819|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
11384820|NCT02137330|Experimental|Obalon Arm|Children swalowed up to 3 intragastric balloons
11384821|NCT02137330|No Intervention|Dietary and lifestyle changes Arm|
11384822|NCT02137317|Experimental|LAPPE/DP|In the LAPPE experiment the farmer will work as usual (mixing/loading/application/cleaning). wearing the LAPPE solution and carrying a new hand pressured backpack sprayer with a standardized nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the DP solution.
11384823|NCT02137317|Active Comparator|DP/LAPPE|In the DP experiment the farmer will work as usual (mixing/loading/application/cleaning) wearing the DP solution and carrying his usual backpack sprayer with his usual nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the LAPPE solution.
11384824|NCT02137304|Experimental|neuromuscular patients|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
11384825|NCT02137291||Left-sided double-lumen tube|Lung isolation with a left-sided double-lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland)
11384826|NCT02137291||Modified right-sided double-lumen tube|Right-sided double-lumen tube modified in accordance with Bussières et al. in Can J Anesth 2007
11384827|NCT02137278|Active Comparator|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment
11384828|NCT02137278|Experimental|Vasoactive drug therapy|Continue current vasoactive therapy
11384829|NCT02137265|Active Comparator|Clomiphene citrate|Clomiphene citrate 50 mg daily during 4-6 months
11384830|NCT02137265|Placebo Comparator|Placebo|Placebo (1 pill daily) during 4-6 months
11384831|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of double-blinded naltrexone vs. placebo for 5 weeks. Treatment will be initiated at 25 mg/day (or equivalent placebo) during the first week to improve tolerability. The dose will be escalated to 50 mg/day (or equivalent placebo) after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
11384832|NCT02137252|No Intervention|Monitoring Phase|Brief self-report questionnaire (Functional Assessment of Chronic Illness Therapy-Fatigue Subscale; FACIT-F)
11384833|NCT02137252|Placebo Comparator|Sugar Pill|daily dose placebo for 5 week treatment period
11384834|NCT02137239|Experimental|Belatacept + Everolimus|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
11384835|NCT02137239|Experimental|Tacrolimus + Mycophenolate mofetil|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
11384836|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
11384837|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
11384838|NCT02137213|Experimental|Arm A: Naloxone then placebo|Subjects assigned to Arm A will receive methadone with naloxone for one week and then methadone with placebo for one week
11384839|NCT02137213|Experimental|Arm B: Placebo then naloxone|Subjects assigned to Arm B will receive methadone with placebo for one week and then methadone with naloxone for one week
11384840|NCT02137200|Active Comparator|Delayed pushing|
11384841|NCT02137200|Experimental|Immediate pushing|
11384842|NCT02137187|Experimental|Drug therapy|Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)
11384843|NCT02137187|Active Comparator|Device: AV junction ablation & CRT|AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy
11384844|NCT02137174|Active Comparator|Home and school visits|
11384845|NCT02137174|No Intervention|Control|
11384846|NCT02137161|Active Comparator|Dexamethasone+Tobramycin eye drop|An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
11384847|NCT02137161|Experimental|Bromfenac|Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
11384848|NCT02137135|Experimental|follicular phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
11384849|NCT02137135|Active Comparator|luteal phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
11384850|NCT02137122|Experimental|Cognitive Training|Participants will undergo 60 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The training control will be the same tasks set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
11384851|NCT02137122|Placebo Comparator|Training Control|Participants will undergo 60 hours of training control. Training control will involve the same computerized games as in the cognitive training condition but are set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
11384852|NCT02137109||natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab per the local label specifications.
11384853|NCT02137096|Experimental|High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
11384854|NCT02137083|Experimental|Docetaxel Plus Fulvestrant|"Docetaxel:75mg/m2 D2 every 21 days
~Fulvestrant:500mg D1, D15, D29, D57, every 28 days later"
11384855|NCT02137083|Active Comparator|Docetaxel|Docetaxel:75mg/m2 D2 every 21 days
11384856|NCT02137070||Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH & Shands Hospital.
11384857|NCT02137070||Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
11384858|NCT02137057||control ( patients without diabetes)|patients without diabetes
11384859|NCT02137057||DM ( patients with diabetes)|patients with diabetes
11384860|NCT02137044|Experimental|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
11384861|NCT02137044|No Intervention|Usual Care|Subjects assigned to usual care were informed by the CCM of their depressive and pain symptoms and that they should consult with their MS or primary care provider about possible care for these conditions. Study personnel did not make any further attempts to influence usual care participants' depression or pain management unless a psychiatric emergency arose (e.g., suicidal ideation was detected at baseline or any of the outcome assessments).
11384862|NCT02137031|Experimental|Mini Link REAL-Time Transmitter|
11384863|NCT02137018|Active Comparator|laparotomy with PPL mesh implantation|control group: laparotomy with PPL mesh implantation (traditional method)
11384864|NCT02137018|Experimental|laparotomy with PPL fixation by BP|laparotomic surgery with PPL mesh fixation by BP (new fixing method)
11384865|NCT02137018|Active Comparator|laparoscopy with PPL mesh implantation|control group: laparoscopy with PPL mesh implantation (traditional method)
11384866|NCT02137018|Experimental|laparoscopy with PPL fixation by BP|laparoscopic surgery with PPL mesh fixation by BP (new fixing method)
11384867|NCT02137005||Cerebral Palsy|Patients with cerebral palsy who were seen at the Center for Gait and Movement Analysis (CGMA) at Children's Hospital Colorado as children.
11384868|NCT02136992|Placebo Comparator|Placebo (without active ingredient)|placebo will be taken two tablets 3 times a day during the whole study process.
11384869|NCT02136992|Experimental|Pirfenidone（200mg）|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
11384870|NCT02136979|Active Comparator|Propofol group|patients with propofol-based anesthesia
11384871|NCT02136979|Active Comparator|Sevoflurane group|patients with sevoflurane-based anesthesia
11384872|NCT02136966|Experimental|Programme|"Distribution of Micronutrients powders (MNP)
~Intensive counseling on Infant and Young Child Nutrition
~Cooking demonstrations"
11384873|NCT02136966|No Intervention|Controle|"Usual Infant growth monitoring and promotion activities
~No distribution of micronutrients powders
~No Intensive counseling
~No cooking demonstrations"
11384874|NCT02136953|Experimental|Exercise|12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.
11384875|NCT02136953|Active Comparator|Cognitive Behavioural Therapy (CBT)|12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.
11384876|NCT02136953|Experimental|Exercise and CBT|Combined 12-week Exercise program and CBT.
11384877|NCT02136953|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
11384878|NCT02136940|Experimental|AMA0076 0.1%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
11384879|NCT02136940|Experimental|AMA0076 0.25%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
11384880|NCT02136940|Experimental|AMA0076 0.50%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
11384881|NCT02136940|Placebo Comparator|Placebo|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
11384882|NCT02136927|Experimental|SPARC1210|Intravenous administration of SPARC1210
11384886|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
11384887|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
11384888|NCT02136888|Experimental|Group A|"Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).
~Placebo matched for ponesimod will be given on Day -1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24."
11384889|NCT02136888|Experimental|Group B|Placebo matched for ponesimod will be administered orally, once daily on Day -1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
11384890|NCT02136875|Experimental|Double dose of Advair for AECOPD|Double dose of Salmeterol + Fluticasone Propionate (Advair) Self-administered prescription Self-management education on the use of a self-administered prescription
11384891|NCT02136836||gastric adenocarcinoma|
11384892|NCT02136823|Placebo Comparator|sugar pill|sugar pill, oral administration, placebo capsule
11384893|NCT02136823|Experimental|riluzole|50mg tablet, single oral dose, one day (single dose)
11384894|NCT02136823|Experimental|isradipine|5mg capsule, single oral dose, one day (single dose)
11384895|NCT02136823|Experimental|memantine|5mg tablet, single oral dose, one day (single oral dose)
11384896|NCT02136823|Experimental|therapeutic stretching|Manual therapeutic stretching of tested muscle by licensed clinician
11384897|NCT02136797|Experimental|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
11384898|NCT02136784|Experimental|morphine sulfate|30mg, single dose,
11384899|NCT02136784|Experimental|hydrocodone|10mg single dose
11384900|NCT02136784|Experimental|hydromorphone HCI|4mg single dose
11384901|NCT02136784|Experimental|oxycodone|10 mg single dose
11384902|NCT02136784|Experimental|buprenorphine|4 mg single dose
11384903|NCT02136784|Placebo Comparator|oral tablet placebo|single dose
11384904|NCT02136784|Placebo Comparator|sublingual tablet placebo|single dose
11384905|NCT02136771|Active Comparator|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
11384906|NCT02136771|Placebo Comparator|Placebo|Oily drops as placebo
11384907|NCT02136758|Experimental|Lifestyle modification|The intervention group participated in individualized therapeutic lifestyle plans to reduce cardiovascular risk. Participants were introduced to factors contributing to cardiovascular disease and met individually with a registered dietitian, exercise physiologist, stress management instructor, and psychologist to learn effective strategies for integrating healthy changes into their current lifestyle.
11384908|NCT02136758|No Intervention|Usual care controls|Control group received standard care from their primary physicians, but did not participate in any component of the lifestyle program or receive any information, advice, or counseling regarding healthy lifestyle behaviors.
11384909|NCT02136745|Experimental|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
11384910|NCT02136732|Experimental|Active self-management intervention|Participants will receive home visits and phone calls from a registered nurse and social worker. The registered nurse and social worker will provide participants one on one coaching, education, support and referrals to community resources to help them manage their chronic conditions.
11384911|NCT02136732|Active Comparator|Attention control phone calls|Participants will receive an initial visit and then a phone call every other month from a social services aide who can provide information about community resources that might be helpful.
11384912|NCT02136719|Active Comparator|Group A|bimanual uterine compression immediately after delivery of placenta for 5 minutes in 260 women
11384913|NCT02136719|No Intervention|Group B|no intervention (260 women).
11384914|NCT02136706|No Intervention|10/30 min rest/stress|Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
11384915|NCT02136693|Placebo Comparator|Placebo|3.5 g /day of inert compound for 180 days after STARR
11384916|NCT02136693|Experimental|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
11384917|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
11384918|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
11384919|NCT02136667||Exposed|Women with a history of preeclampsia 10 years ago
11384920|NCT02136667||Unexposed|Women with a history of uncomplicated pregnancy 10 years ago
11384921|NCT02136654|Experimental|Culturally tailored diabetes program|"Culturally tailored diabetes program
~culturally tailored diabetes education
~lifestyle counselling
~medication adherence counseling
~peer supporter
~communication training
~family member involvement"
11384922|NCT02136654|No Intervention|Usual Care|Usual Care includes continuing to visit primary care physician for ongoing diabetes management Printed diabetes education materials.
11384923|NCT02136641|Active Comparator|Midazolam|1. Sedation with Midazolam 0.03 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
11384924|NCT02136641|Experimental|Midazolam+Fentanyl Combination|2. Sedation with Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
11384925|NCT02136641|Experimental|Midazolam+Ketamine Combination|3. Sedation with Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
11384926|NCT02136628|Experimental|RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.
~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
11384927|NCT02136628|No Intervention|Control|Conventional midline mass closure technique. Upon completion of the surgical procedure was the closure of abdominal wall which will be made with the number 0 monofilament PDS, starting with knot at one end of the wound, continuous with continuous súrgete, moving each point to a centimeter away from the other. Each point will be a distance of one centimeter from the edge of the fascia. At the opposite end of the wound the same procedure was initiated and found the two suture lines at the midpoint of the wound will proceed to tying the two sutures with 4 square knots.
11384928|NCT02136615||overweight and obese male volunteers|BMI between 23-40 kg/m2
11384929|NCT02136589|Experimental|Dicrofenac|
11384930|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
11384931|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
11384932|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
11384933|NCT02136563||Darbepoetin alfa|
11384934|NCT02136550|Experimental|Smoking cessation|36 smokers will participate in the study and will be evaluated at baseline, 6 months e 12 months of the smoking cessation program. If they quit the program, they will be asked to continue the study.
11384935|NCT02136537|Active Comparator|Best medical therapy|Claudicants treated according to local protocol - no added treatment
11384936|NCT02136537|Experimental|Best medical therapy plus NMES|In addition to best medical therapy, subjects will receive bilateral neuromuscular stimulation of their legs, 4 hours per day.
11384937|NCT02136524|Experimental|Capsule formulation|
11384938|NCT02136524|Experimental|Tablet formulation|
11384939|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
11384940|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
11384941|NCT02136485|Experimental|MBSR|8 weekly sessions each lasting 2.5 hours
11384942|NCT02136485|Other|Control|Control arm - waiting list control, once the intervention group has completed MBSR the control group will be invited to participate in MBSR
11384943|NCT02136472||Subfertile women|"Women who visit the fertility clinic of the Maastricht University Medical Centre who start with a basic fertility work-up. Women diagnosed with an unexplained subfertility or with (signs of) a decreased ovarian reserve are asked for further participation in the study of the cardiovascular profile.
~As a control group parous women with an uncomplicated pregnancy more than 6 months ago will be asked for participation."
11384944|NCT02136459|Experimental|Small tube size|Size 6.5 ETT for female, size 7.0 ETT for male
11384945|NCT02136459|Active Comparator|Large tube size|Normal tube size, size 7.5 for female, size 8 for male
11384946|NCT02136446|Experimental|EchoGlo™ Peripheral Nerve Block Catheter|Echogenic nerve block catheter (test)
11384947|NCT02136446|Active Comparator|Pajunk® EpiLong Catheter|Non-echogenic nerve block catheter (control)
11384948|NCT02136433|Experimental|Tablet - self exercise|"Existing tablet Apps that encourage finger movement in a fun manner while playing a game will be used. The apps will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).
~The intervention will include 15-20 sessions of 60 minutes of self-training using a tablet."
11384949|NCT02136433|Active Comparator|GRASP self exercise|"GRASP (Graded Repetitive Arm Supplementary Program)(Harris et al., 2009)is an arm and hand exercise program developed for individuals with stroke with upper extremity impairments GRASP provides a method for patients to undertake a self-directed arm and hand exercise program.
~The exercises will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).
~The intervention will include 15-20 sessions of 60 minutes of self-training"
11384950|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
11384951|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
11384952|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
11384953|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
11384954|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
11384955|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
11384956|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
11384957|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
11384958|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.
~This arm corresponds to results published in Diaz-Artiles et al 2017."
11384959|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.
~This arm corresponds to results published in Diaz-Artiles et al 2017."
11384960|NCT02136407||Blood donors|N=540
11384961|NCT02136407||Thrombocyte donors|N=75
11384962|NCT02136394||Severe/moderate acid reflux|
11384963|NCT02136394||Mild/absent acid reflux|
11384964|NCT02136381|Experimental|LEAP intervention|A newly developed internet-based lifestyle programme (Living, Eating, Activity and Planning through retirement (LEAP)) will promote three key health and social behaviours; healthy eating following a Mediterranean diet, increasing physical activity and improve social connectedness.
11384965|NCT02136381|Other|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).
~This website contains general information on improving life style and health."
11384966|NCT02136368|Experimental|Multi-Modal, Mind Motor Exercise (M4)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of mind-motor exercise.
11384967|NCT02136368|Active Comparator|Multi-Modal Exercise (M2)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of balance and range of motion exercises.
11384968|NCT02136355|Experimental|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
11384969|NCT02136342|Experimental|chlorogenic acid|
11384970|NCT02136329|Experimental|Sildenafil|All subjects in groups 1-6 will receive SIldenafil but in escalating doses.
11384971|NCT02136316|Experimental|ASP7962 low dose|
11384972|NCT02136316|Experimental|ASP7962 medium dose|
11384973|NCT02136316|Experimental|ASP7962 high dose|
11384974|NCT02136316|Placebo Comparator|Placebo|
11384975|NCT02136303|Placebo Comparator|S1-Placebo|placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
11384976|NCT02136303|Experimental|S1-1L|capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
11384977|NCT02136303|Experimental|S1-2L|capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
11384978|NCT02136303|Experimental|S1-5L|capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
11384979|NCT02136303|Experimental|S2-Kale_extract|
11384980|NCT02136303|Experimental|S2-Kale_purée|
11384981|NCT02136303|Placebo Comparator|S3-Placebo|
11384982|NCT02136303|Experimental|S3-AMD-Patients|
11384983|NCT02136303|Experimental|S3-non-AMD|
11384984|NCT02136303|Placebo Comparator|S1-Placebo-Tagetes|capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
11384985|NCT02136303|Experimental|S1-1L-Tagetes|capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
11384986|NCT02136303|Experimental|S1-2L-Tagetes|capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
11384987|NCT02136303|Experimental|S1-5L-Tagetes|capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
11384988|NCT02136303|Experimental|S1-10L-Tagetes|capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
11384989|NCT02136290|Other|Usual Care|Weight loss counseling
11384990|NCT02136290|Experimental|Prepackaged meal|Prepackaged meals
11384991|NCT02136277||Colorectal patients|Subjects undergoing colorectal surgery
11384992|NCT02136264|Active Comparator|PCFA interventional dietary counselling|personalized categorical food avoidance dietary counselling
11384993|NCT02136264|Sham Comparator|conventional DASH diet counselling|"DASH = conventional dietary approach to stop hypertension"
11384994|NCT02136251||shoulder replacement|Subjects who had shoulder replacement surgery at The University of Nebraska and The Nebraska Medical Center at least 5 or more years ago and autologous bone graft around the anchor-peg glenoid prosthesis was used.
11384995|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
11384996|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
11384997|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
11384998|NCT02136225|Experimental|Counseling|Intervention: Means restriction counseling. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun in the home where youth are present.
11384999|NCT02136225|Experimental|Counseling and locking devices|Intervention: Means restriction counseling and locking devices. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present. Parents will also receive locking devices to store their guns securely.
11385000|NCT02136225|No Intervention|Control group|Youth in the control group will receive usual care.
11385149|NCT02135237|Experimental|Experimental Group|Standard Care plus Prize Contingency Management for Alcohol Abstinence
11385001|NCT02136212|Experimental|Approach-positive AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure designed to increase automatic approach responses for positive social cues.
11385002|NCT02136212|Placebo Comparator|Control AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
11385003|NCT02136199|Other|Active Implementation of Share EBM Toolkit|Investigators led implementation of tailored activities and tactics (Shared EBM Toolkit) designed to promote the use of the decision aids in clinical encounters (i.e. journal clubs, value map streaming).
11385004|NCT02136199|Other|Passive Implementation of Share EBM Toolkit|Locally supported dissemination of Shared EBM Toolkit designed to promote the use of the decision aids in clinical encounters.
11385005|NCT02136186|No Intervention|Standard of care|patients will receive standard of care discharge instructions
11385006|NCT02136186|Active Comparator|Philips Telehealth|patients will be discharged with a telemonitoring device for 30 days
11385007|NCT02136173|Experimental|sequential balloons|effect of weight loss by applying sequential balloons
11385008|NCT02136147||Children with ADHD medication|Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
11385009|NCT02136147||Lisdexamphetamine medication|Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
11385010|NCT02136147||Atomoxetine medication|Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
11385011|NCT02136147||Methylphenidate medication|Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
11385012|NCT02136147||Guanfacine medication|Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
11385013|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
11385014|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone.
11385015|NCT02136121|Experimental|da Vinci Sp Surgical System|da Vinci Sp Surgical System - Robotic - assisted single-port surgery
11385016|NCT02136108|Experimental|OPENtext|OPENtext will target cognitive, affective, and behavioral strategies through a single, brief in-person assessment, followed by 12 weeks of theoretically-informed text messages, a core set of information organized in a 'frequently asked questions' structure, interactive peer support, static resources on key patient-identified topics, and a library of peer stories accessible throughout the study period.
11385017|NCT02136108|Active Comparator|OPENnav|Peer Navigation is currently offered to some individuals in this Medicaid population but not all. Peer navigators interact with patients by phone/text and at home visits. Efforts focus on drivers of a patient's ED use, and may include providing or identifying patient support, improving health literacy, assisting with transportation vouchers, health education, family support, accessing housing services, and orienting to other community support services.
11385018|NCT02136095|Experimental|IFC-group|The investigators included patients undergoing laparoscopic cholecystectomy by a single surgeon between September and December 2013 at a single centre university department with unrestricted referral of patients. The included patients represented all patients undergoing laparoscopic cholecystectomy by one surgeon during the study period. All patients underwent intra-operative fluorescent cholangiography (IFC) with concomitant angiography, according to a standardized protocol, during their laparoscopic cholecystectomy.
11385019|NCT02136082|Experimental|Asha Support + Training|Asha Support + Training: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
11385020|NCT02136082|Experimental|Asha Support + Food|Asha Support + Food 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; and c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
11385021|NCT02136082|Experimental|Asha Support + Training + Food|Asha Support + Training + Food: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
11385022|NCT02136082|Active Comparator|Asha Support Only|Asha Support Only 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
11385023|NCT02136069|Experimental|Etrolizumab + Placebo (IV)|Participants will receive ertolizumab (SC) Q4W until Week 52 along with placebo matched to infliximab as IV infusion until Week 46.
11385024|NCT02136069|Active Comparator|Infliximab + Placebo (Injection)|Participants will receive IV infusion of infliximab at Weeks 0,2, and 6, then every 8 weeks until Week 46 partnered with placebo matched to etrolizumab by SC injection Q4W until Week 52.
11385150|NCT02135224|Active Comparator|Fentanyl|20 microgram per hour
11385151|NCT02135224|Placebo Comparator|Normal saline|0.4 ml per hour
11385025|NCT02136056|Experimental|Self-management program (SMP)|Participants in the experimental group receive six weekly group-sessions of self-management and patient education; specifically targeting self-management of the return to work process and disease symptoms.
11385026|NCT02136056|No Intervention|Treatment as usual|Participants in the control-group receive standard rehabilitation care and follow-up in the job-center.
11385027|NCT02136043|Experimental|Group 1|Insertion of catheter into nasal cavity carried out by patient. Fixation of catheter during treatment with patient´s hand.
11385028|NCT02136043|Experimental|Group 2|Insertion of catheter into nasal cavity carried out by health professional. Fixation of catheter during treatment with helmet.
11385029|NCT02136030|Experimental|Lipo-AB|
11385030|NCT02136030|Active Comparator|Amphotericin B|
11385031|NCT02136017||Changchun biologial's vaccine|Changchun Biological's vaccine group is the population injected with this vaccine.
11385032|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
11385033|NCT02135991|Experimental|Project CHOICE + Getting To Outcomes|Boys and Girls Club sites will receive a) training and materials for Project CHOICE and b) training, ongoing technical assistance for two years, and materials for Getting To Outcomes
11385034|NCT02135991|Active Comparator|Project CHOICE only|Boys and Girls Club sites will receive a) training and materials for Project CHOICE
11385035|NCT02135978|Experimental|One-to-one training group for shoulder home exercise program|Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
11385036|NCT02135978|Active Comparator|Enhanced training group for shoulder home exercise program|Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
11385037|NCT02135978|No Intervention|Historical control group|Historical control group has received no intervention. Eligibility criteria, outcome measures and study duration for historical control group is matched for the experimental group and active comparator.
11385038|NCT02135965|Experimental|Albuterol 2mg|2 mg of Albuterol is in a pill form or placebo
11385039|NCT02135965|Experimental|Albuterol 4mg|4mg of Albuterol or placebo is given in pill form
11385040|NCT02135965|Experimental|Caffeine 100mg|100mg of Caffeine or placebo is given in a pill form.
11385041|NCT02135965|Experimental|Caffeine 200mg|200mg of Caffeine or placebo is given in a pill form
11385042|NCT02135965|Experimental|Albuterol 2mg & Caffeine 100mg|100mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
11385043|NCT02135965|Experimental|Albuterol 2mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
11385044|NCT02135965|Experimental|Albuterol 4mg and Caffeine 100mg|100mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
11385045|NCT02135965|Experimental|Albuterol 4mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
11385046|NCT02135952|Active Comparator|SRP+MTZ+AMX|Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day [TID] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)
11385047|NCT02135952|Placebo Comparator|SRP+placebo|Scaling and root planing + placebo
11385048|NCT02135939|Active Comparator|American Heart Association diet|Participants randomized into this arm will follow an American Heart Association diet plan for 8 weeks.
11385049|NCT02135939|Experimental|Whole-food plant-based vegan diet|Participants randomized into this arm will be asked to follow a whole-food plant-based vegan diet plan for 8 weeks.
11385050|NCT02135926|Active Comparator|Best medical care|Best clinical care in dedicated stroke unit
11385051|NCT02135926|Active Comparator|Thrombectomy|All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
11385052|NCT02135913|Experimental|Viatamin D|All children enrolled into the study will be prescribed standard of care vitamin D.
11385053|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
11385054|NCT02135887||MB-6+FOLFOX chemotherapy|MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
11385055|NCT02135887||Placebo+FOLFOX chemotherapy|Placebo, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
11385056|NCT02135874|Experimental|Treatment (combination chemotherapy)|See Detailed Description.
11385057|NCT02135861|Experimental|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
11385058|NCT02135861|Experimental|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
11385059|NCT02135861|Experimental|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
11385060|NCT02135848|Experimental|GSK1278863|Study Drug
11385061|NCT02135848|Placebo Comparator|Placebo|Placebo
11385062|NCT02135835|Experimental|Shenfu Zhusheye|80 ml Shenfu Zhusheye + 70 ml 5% glucose injection, ivdrip, once a day for 7 days.
11385063|NCT02135835|Placebo Comparator|5% glucose injection|150 ml 5% glucose injection, ivdrip, once a day for 7 days.
11385064|NCT02135822|Experimental|nanoparticle albumin-bound paclitaxel, gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8, in combination with gemcitabine which is given at 1000 mg/m2, on day 1 and 8, each 21-day cycle. Number of cycle: 6 cycles.
11385065|NCT02135809|Experimental|FCSEMS|Patients will receive the WallFlex Pancreatic Stent.
11385066|NCT02135796||Sepsis/Septic Shock|Individuals who are admitted to the Intensive Care Unit (ICU) with an infection called Sepsis or Septic Shock. This group will receive transthoracic echocardiography as part of the study.
11385067|NCT02135783|Experimental|Decompressive Craniectomy|Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
11385068|NCT02135783|Active Comparator|non-Decompressive Craniectomy|non-Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
11385069|NCT02135770|Experimental|Unfractionated Heparin|Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion
11385070|NCT02135770|Placebo Comparator|Placebo|Normal saline packed in same form with trial drugs.
11385071|NCT02135744|No Intervention|Control|Group of patients undergo standard care as determined by the primary inpatient team
11385072|NCT02135744|Experimental|Bundle|Group of patients that receive the screening and educational tool
11385073|NCT02135731|No Intervention|Paper|Usual care -medication review on paper
11385074|NCT02135731|Experimental|Computer|Medication review software with pictures
11385075|NCT02135718||Group 1|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the MDI inhaler twice daily for 5 to 9 days during the second period.
11385076|NCT02135718||Group 2|Subjects will use the MDI inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
11385077|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
11385078|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
11385079|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
11385080|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
11385081|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
11385082|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
11385083|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
11385084|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
11385085|NCT02135666|Experimental|2-dose Primed Group|Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084).
11385086|NCT02135666|Experimental|3-dose Primed Group|Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084).
11385087|NCT02135653||Feasibility|
11385088|NCT02135653||Phase II|
11385089|NCT02135640|Experimental|denosumab 60 mg|solution
11385090|NCT02135640|Experimental|denosumab 120 mg|solution
11385091|NCT02135640|Placebo Comparator|placebo|solution
11385092|NCT02135627|Experimental|Control group|Current standard endoscopic therapy such as epinephrine injection, sclerotherapy, mechanical (endoclip). contact electrocautery/thermal, and non-contact electrocalcautery (APC) ± radiation therapy, angioembolization, and/or surgery.
11385093|NCT02135627|Active Comparator|TC-325|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
11385094|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
11385095|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
11385096|NCT02135601|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
11385097|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
11385098|NCT02135588|Experimental|Active Treatment|Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)
11385099|NCT02135575|Experimental|Premenopausal women|The Premenopausal women are randomized to exercise by spinning (cycle)
11385100|NCT02135575|Experimental|Postmenopausal women|The Postmenopausal women are randomized to exercise by spinning (cycle)
11385101|NCT02135562|Experimental|Supportive Care (PSMF)|Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
11385102|NCT02135549|Experimental|SugarDown 4 grams|SugarDown 4 gram dose in tablet form, before meals, daily for one week
11385103|NCT02135549|Experimental|SugarDown 8 grams|SugarDown 8 gram dose in tablet form, before meals, daily for one week
11385104|NCT02135549|Placebo Comparator|Placebo|Placebo dose in tablet form, before meals, daily for one week
11385105|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
11385106|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
11385107|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
11385108|NCT02135523|Experimental|single arm: involved-field radiation therapy group|
11385109|NCT02135510|Active Comparator|metoclopramide|
11385110|NCT02135510|Active Comparator|dexamethason|
11385111|NCT02135510|Active Comparator|palonosetron|
11385112|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
11385113|NCT02135471|Experimental|acellular dermal matrix graft|
11385114|NCT02135471|Experimental|enamel matrix derivative|
11385179|NCT02135068|Experimental|CL and exercise with proactive snacking|Subject will consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
11385115|NCT02135458|Experimental|Telemonitoring|Home-based patient management using AUTONOM@DOM telemonitoring system to record and transmit heart rate, blood pressure and weight; along side conventional care (patient therapeutic education or personalised care program)
11385116|NCT02135458|Active Comparator|Conventional care|Conventional care including patient therapeutic education or personalised care program
11385117|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
11385118|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
11385119|NCT02135432|Experimental|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
11385120|NCT02135432|Placebo Comparator|Placebo|matching placebo
11385121|NCT02135419|Experimental|Arm I (treatment)|Patients are directed to receive either topical or ablative treatment at the discretion of the clinician. Patients receiving topical treatment apply imiquimod intra-anally, peri-anally or both thrice weekly for up to 16 weeks, fluorouracil twice daily for 5 days every 2 weeks for up to 16 weeks, or trichloroacetic acid every 3 weeks up to 12 weeks. Patients receiving ablative treatment using infrared photocoagulation therapy, hyfrecation/electrocautery (thermal ablation therapy), or laser therapy. Patients may undergo excision under anesthesia if the clinician believes none of the other treatment approaches will be effective. The number and timing of such treatments will be at the discretion of the investigator. Patients with persistent HSIL should continue a protocol-approved treatment or a new protocol treatment should be considered. All participants will have samples collected for laboratory biomarker analysis.
11385122|NCT02135419|Active Comparator|Arm II (active monitoring)|Patients undergo active monitoring with examinations for clinical observation every 6 months. Every 12 months, patients undergo biopsies of visible lesions. Patients have cytology sampling performed at every visit. All participants will have samples collected for laboratory biomarker analysis.
11385123|NCT02135406|Experimental|Multiple Myeloma Patients|Adult subjects (18 years or older) with multiple myeloma and with poor prognosis by virtue of having relapsed/progressive disease within one year of first autologous stem cell transplantation.
11385124|NCT02135393|Experimental|13C5-folic acid or 13C5-6S-5-FormylTHF|Physiological 500 nmol (220 µg folic acid equivalent) dose of dietary supplement 13C5-folic acid or 13C5-6S-5-FormylTHF given to subjects with in situ transjugular intrahepatic portosystemic stent at the time of routine venography patency check followed by regular portal venous sampling for 85 minutes at pre determined intervals and then physiological 500 nmol dose of 13C-6S-5-FormylTHF or 13C5-folic acid respectively at the next annual routine venography patency check followed by portal venous sampling for 85 minutes
11385125|NCT02135380|Other|Autologous Stromal Vascular Fraction|Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
11385126|NCT02135380|Other|Autologous Adipose Derived MSCs|3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
11385127|NCT02135380|Active Comparator|Control|"corticosteroids i.e. Prednisolone ≤10mg/day or ≤20 mg every alternate day
~Immunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day
~Antioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.
~Pirfenidone at dose upto 1200 to 1800 mg/day"
11385128|NCT02135367|Experimental|PRP|This group of patients will be treated by three weekly Platelet rich Plasma intra-articular injections in the knee.
11385129|NCT02135367|Active Comparator|HA|"This group of patients will be treated by three weekly hyaluronic acid (HA) intra-articular injections in the knee.
~The HA used is Hyalubrix 30 mg/2ml (Fidia Farmaceutici Spa, Padova, Italy)"
11385130|NCT02135354|Experimental|Azithromycin|"N = 250
~From day 1 up to and including day 3: 500 mg azithromycin PO once a day
~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
11385131|NCT02135354|Placebo Comparator|Placebo|"N = 250
~From day 1 up to and including day 3: 500 mg placebo PO once a day
~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
11385132|NCT02135341|Experimental|Group A: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
11385133|NCT02135341|Experimental|Group B: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
11385134|NCT02135328|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing type 2 diabetes through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
11385135|NCT02135328|Active Comparator|Audio brochure|Participants received an audio version of a standard brochure about type 2 diabetes prevention and management.
11385136|NCT02135315|Experimental|intensive controle group|the end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous Isosorbide Dinitrate (RISORDON) perfusion associated, if needed, with Labetalol (TRANDATE) continuous perfusion.
11385137|NCT02135315|Active Comparator|standard control group|the end point in these group was to maintain the systolic blood pressure between 120 and 140 mmHg using a continuous perfusion of Isosorbide Dinitrate (RISORDON) or other drugs depending on the physician choice.
11385138|NCT02135302|Experimental|Impaired hepatic function|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.
11385139|NCT02135302|Experimental|Healthy subjects|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.
11385140|NCT02135289||IMID patients|Patients with IMID
11385141|NCT02135289||Control - subjects without IBD|Patients without IBD
11385142|NCT02135276|Experimental|End stage renal disease (ESRD) subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
11385143|NCT02135276|Experimental|Normal healthy subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
11385144|NCT02135263|Experimental|Methylphenidate|
11385145|NCT02135263|Experimental|Enalapril|
11385146|NCT02135250|Experimental|placebo|the placebo is not drug
11385152|NCT02135211|Experimental|Lifestyle counseling|This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.
11385153|NCT02135198|Experimental|2 mg AZD7325|2 mg AZD7325 in orange capsule, Size 0, single oral dose
11385154|NCT02135198|Experimental|10 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, singe oral dose
11385155|NCT02135198|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose
11385156|NCT02135185|Experimental|Rehabilitation effort|custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment
11385157|NCT02135185|Active Comparator|Control|Control with dietary management adapted to the nutritional status
11385158|NCT02135172|Experimental|Sitting|During the sitting treatment condition, walking and standing will be restricted. Participants will be in a designated room with access to a computer, books/magazines throughout the day. Participants will have a cannula fitted and the first of the half-hourly blood samples will be taken (time point: -1hr). Participants will then be asked to sit quietly for 60 minutes to achieve a steady state. Following this, participants will have another blood sample taken and then be provided with a standardised mixed meal breakfast (09:00am) (time point: 0h). Blood sampling will continue at 30 minutes intervals for 3 hours following breakfast. A second, lunch meal (12:00pm), will be then be consumed over 15 minutes. Blood sampling will then continue at 30 minute intervals for 3 hours following lunch.
11385159|NCT02135172|Experimental|Standing|This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
11385160|NCT02135172|Experimental|Walking|This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
11385161|NCT02135159|Experimental|TDM1 concommitant with RT|T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
11385162|NCT02135159|Experimental|TDM1 during and after RT|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
11385163|NCT02135159|Experimental|RT before TDM1|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
11385164|NCT02135159|Experimental|TDM1 before RT|T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
11385165|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
11385166|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
11385167|NCT02135133|Experimental|Idelalisib & Ofatumumab|Idelalisib will be given orally continuously at 150 mg BID. On day 57, ofatumumab will begin with the 300 mg dose, given after idelalisib is taken. Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8). The overall induction treatment period will then be 8 months, comprised of two months of single agent idelalisib followed by 6 months of ofatumumab with idelalisib. After the completion of the induction treatment, idelalisib will continue indefinitely in arbitrarily defined 28 day cycles in all participants who have not had excessive toxicity and do not have progressive disease.
11385168|NCT02135120|Active Comparator|Morphine group|Patients will receive a combined spinal epidural anesthesia technique with intrathecal morphine
11385169|NCT02135120|Active Comparator|Morphine-femoral group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
11385170|NCT02135120|Active Comparator|Morphine-femoral-sciatic group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
11385171|NCT02135107|Experimental|Arm A|
11385172|NCT02135107|Experimental|Arm B|
11385173|NCT02135107|Experimental|Arm C|
11385174|NCT02135107|Experimental|Arm D|
11385175|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
11385176|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
11385177|NCT02135081||Single Ventricle|"Subjects will be single ventricle patients who will be prospectively recruited when they are at the first stage of Fontan reconstruction; they will be followed throughout all 3 stages with cerebral blood flow measurements and brain MRIs.
~Additional single ventricle patients who will not participate in the study for all 3 stages but who may participate for one of two. For example, patients who completed their Stage I and hemi Fontan/bidirectional Glenn operations before this study began will be recruited before Fontan stage completion. Also, patients whose Stage I and hemi Fontan/bidirectional Glenn surgeries will be completed during the study, but who will not complete all 3 surgical stages before this project ends. Cerebral blood flow measurements and brain MRIs will be completed after each surgical stage which occurs during study participation."
11385178|NCT02135081||Normal Control Group|Children likely to have a normal brain MRI will be asked to participate. After the brain MRI is obtained as part of routine clinical care, and a normal brain scan is confirmed, measurement of cerebral blood flow using velocity mapping in the jugular veins and the aorta will be performed. This will add approximately 10 minutes to the scan but no extra sedation medications will be administered to obtain this data.
11385221|NCT02134847|No Intervention|Control cohort|This group will work on a traditional schedule
11385180|NCT02135068|Active Comparator|CL and exercise without proactive snacking|Subject will not consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
11385181|NCT02135055|Experimental|Normal immune function|The value of monocyte human leukocyte antigen-DR (mHLA-DR) is equal to or more than 15000 monoclonal antibody.
11385182|NCT02135055|Experimental|Moderate immunosuppression|The value of mHLA-DR is equal to or more than 10000 and less than 15000 monoclonal antibody.
11385183|NCT02135055|Experimental|Sever immunosuppression|The value of mHLA-DR is equal to or more than 5000 and less than 10000 monoclonal antibody.
11385184|NCT02135055|Experimental|Immune paralysis|The value of mHLA-DR is less than 5000 monoclonal antibody.
11385185|NCT02135042|Active Comparator|Arm I (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11385186|NCT02135042|Experimental|Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)|Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11385187|NCT02135042|Active Comparator|Arm III (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen as in Arm I of Phase II.
11385188|NCT02135042|Experimental|Arm IV (chemoradiation, observation)|Patients undergo clinical observation.
11385189|NCT02135029|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
11385190|NCT02135029|Active Comparator|Atorvastatin|
11385191|NCT02135029|Placebo Comparator|Placebo|
11385192|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
11385193|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
11385194|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
11385195|NCT02135003|Experimental|Buddy arm, Standard of care arm|"Standard of care: Patients enrolled for pre-ART care received general health education, clinical monitoring, CD4 testing and other clinically indicated investigations, treatment of opportunistic infections, and cotrimoxazole prophylaxis.
~Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. buddies attended at least two HIV health education. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments"
11385196|NCT02134990|Experimental|Oshadi D and Oshadi R with Docetaxel|Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy
11385197|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
11385198|NCT02134964|Experimental|OLT1177 Capsules|"A total of 5 patients in each cohort will receive OLT1177 Capsules:
~Cohort 1 will receive a single 100 mg dose of OLT1177
~Cohort 2 will receive a single 300 mg dose of OLT1177
~Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart)
~Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days
~Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days
~Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days"
11385199|NCT02134964|Placebo Comparator|Placebo Capsules|"A total of 1 patient in each cohort will receive Placebo Capsules:
~Cohort 1 will receive a single placebo capsule
~Cohort 2 will receive three placebo capsules
~Cohort 3 will receive ten placebo capsules (seven days apart)
~Cohort 4 will receive a single placebo capsule QD for 8 days
~Cohort 5 will receive three placebo capsules QD for 8 days
~Cohort 6 will receive ten placebo capsules QD for 8 days"
11385200|NCT02134951|Experimental|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
11385201|NCT02134951|Placebo Comparator|Placebo|Placebo group will receive normal saline
11385202|NCT02134938|Experimental|Konjac Glucomannan|650g KJM-G
11385203|NCT02134938|Experimental|Half Control/Half Konjac Glucomannan|325g KJM-G
11385204|NCT02134938|No Intervention|Control|0g KJM-G
11385205|NCT02134925|Experimental|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
11385206|NCT02134925|Placebo Comparator|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
11385207|NCT02134912|Experimental|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
11385208|NCT02134912|Experimental|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
11385209|NCT02134899|Experimental|Everolimus|everolimus based immunosuppression
11385210|NCT02134899|Active Comparator|Calcineurin|Calcineurin inhibitors maintenance
11385211|NCT02134886|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11385212|NCT02134873|Active Comparator|0.1ml 24% sucrose concurrent opioids|0.1ml 24% sucrose concurrent opioids
11385213|NCT02134873|Active Comparator|0.5ml 24% sucrose concurrent opioids|0.5ml 24% sucrose concurrent opioids
11385214|NCT02134873|Active Comparator|1.0ml 24% sucrose concurrent opioids|1.0ml 24% sucrose concurrent opioids
11385215|NCT02134873|Active Comparator|0.1ml 24% sucrose no opioids|0.1ml 24% sucrose no opioids
11385216|NCT02134873|Active Comparator|0.5ml 24% sucrose no opioids|0.5ml 24% sucrose no opioids
11385217|NCT02134873|Active Comparator|1.0ml 24% sucrose no opioids|1.0ml 24% sucrose no opioids
11385218|NCT02134860|Active Comparator|Isocaloric diet|3 daily meals
11385219|NCT02134860|Active Comparator|Alternate daily fasting|One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
11385220|NCT02134847|Experimental|Intervention cohort|This cohort will work on the SCS intervention schedule
11385224|NCT02134821||Low pain sensitivity group|total Pain Sensitivity Questionnaire score <6.5
11385225|NCT02134821||High pain sensitivity group|total pain sensitivity questionnaire score ≥ 6.5
11385226|NCT02134808|Active Comparator|Creatine|Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
11385227|NCT02134808|Placebo Comparator|Placebo|Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
11385228|NCT02134795|Experimental|TNM (trade name), a form of brainstem stimulation|ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for ~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
11385229|NCT02134782|Experimental|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (5 days per week or 15 days in total). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
11385230|NCT02134782|Active Comparator|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily (5 days per week) for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
11385231|NCT02134769|No Intervention|Control|No use of Bionecteur; handling according to institutional guideline
11385232|NCT02134769|Active Comparator|Bionecteur|Use of Bionecteur; handling according to institutional guideline
11385233|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
11385234|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
11385235|NCT02134743|Experimental|Experimental Group|At this group the patients will receive dental implants which have a modified SLA surface. These surface have wettability, which could improve and accelerate the osseointegration.Intervention: implant placement.
11385236|NCT02134743|Active Comparator|Control Group|The patient of this group will receive implant with conventional surface, SLA (Sandblasted and Acid-Etched Surface).Intervention: implant placement.
11385237|NCT02134730|No Intervention|Wait list|Schools in waitlist condition will be offered the intervention after the 12-months follow up. Waitlist means that the schools work as usual with issues of mental health.
11385238|NCT02134730|Experimental|FRIENDS for life|The intervention is delivered for 10 consecutive weeks, 60 minutes per session.
11385239|NCT02134717|Experimental|sarcoidosis stage II|All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.
11385240|NCT02134704|Experimental|Scoliosis Group|
11385241|NCT02134704|Experimental|Healthy Volunteers Group|
11385242|NCT02134691|Experimental|Prolonged Exposure|Behavioral: Prolonged Exposure (PE) PE is a 16 week, 90 minute culturally informed treatment program.
11385243|NCT02134691|Active Comparator|Applied Relaxation|Behavioral: Applied Relaxation (AR) AR is a 16 week, 90 minute treatment program.
11385244|NCT02134678|Experimental|self-system therapy|self-system therapy for depression
11385245|NCT02134678|Active Comparator|cognitive therapy|cognitive therapy for depression
11385246|NCT02134665||severe acute pancreatitis|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.
11385247|NCT02134665||Pneumonia|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.
11385248|NCT02134652||Suspected Dengue|Children with an acute febrile illness, and two of the following: headache, retro-orbital pain, myalgias, arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath, abdominal distention/pain) will all receive a diagnostic bedside ultrasound.
11385249|NCT02134639||Patient who is suspected of endocrine tumors|According to symptomatology, biology or imaging or pathological context
11385250|NCT02134626|Experimental|Simvastatin|Arm 1: Simvastatin 40mg / pill, one pill once a day for three months
11385251|NCT02134626|Placebo Comparator|Placebo pill|Arm 2: Placebo one pill once a day for three months
11385252|NCT02134613|Experimental|anti-TNF-alpha scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
11385253|NCT02134600|Experimental|Omega-3 enriched fruit juice|Single arm study: Omega-3 enriched fruit juice in increasing dosage
11385254|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
11385255|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
11385256|NCT02134561|Other|All subjects|psychological interview, MRI, neurological tests, cognitive tests
11385257|NCT02134535||laboratory specimens|cervical biopsies vaginal biopsies blood
11385258|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
11385259|NCT02134509|Experimental|Experimental App|This is a 3-week smartphone-based training program that trains behavioral strategies for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
11385260|NCT02134509|Active Comparator|Active comparator app|This is a 3-week smartphone application for smoking cessation in which smokers self-monitor their smoking habits, mood, and experience, to quit smoking with a target quit date of 3 weeks.
11385261|NCT02134496|No Intervention|no assessment of motorfunction in PACU|no assessment of motorfunction after spinal anesthesia in PACU
11385262|NCT02134496|Active Comparator|motorfunction assessment in PACU|Assesment of motorfunction after spinal anesthesia
11385263|NCT02134483|Experimental|Parathyroid allo-transplantation|patients who have permanent hypoparatyroidism
11385264|NCT02134470|Experimental|Testosterone|Chemical testing of saliva is an objective method to quantify steroid hormones. Recent studies indicate that salivary testosterone is significantly higher than in other body fluids. Therefore, saliva may serve as pre-screening parameter to select suspicious cases for further target evaluation. The aim of the present project is to detect administered testosterone in saliva and compare these levels to those in blood and urine. Therefore, each participant represents its own control.
11385265|NCT02134457|Experimental|Ranibizumab 0.12 mg|"20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.
~A maximum number of 3 regular re-injections can be applied."
11385266|NCT02134457|Experimental|Ranibizumab 0.20 mg|"20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.
~A maximum number of 3 re-injections can be applied."
11385267|NCT02134444|Experimental|Experimental Group|Experimental group will receive the assigned intervention which is a game-based rehabilitation program delivered at home.
11385268|NCT02134444|Active Comparator|Control group|Control group will receive a vestibular rehabilitation program which will include the Herdman gaze stabilization exercises and balance training program.
11385269|NCT02134431||HIV positive|HIV-positive subjects ages 10-14 years old and 18-21 years old taking tenofovir in their antiretroviral regimen.HIV positive subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. HIV-1 levels and tenofovir levels in tissue will be measured.
11385270|NCT02134431||HIV negative|HIV-negative subjects ages 10-14 years old and 18-21 years old. HIV negative subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. These tissue samples will be pretreated with tenofovir and challenged with laboratory HIV-1.
11385271|NCT02134418|Experimental|Irony CBT training|CBT of irony comprehension
11385272|NCT02134418|No Intervention|No Intervention|No Intervention
11385273|NCT02134405|Experimental|Rebamipide and Esomeprazole|Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
11385274|NCT02134405|Active Comparator|Rebamipide and placebo|Placebo drug with Rebamipide 100mg tid
11385275|NCT02134392|Experimental|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
11385276|NCT02134379||Heart Failure|Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction
11385277|NCT02134366|Experimental|Clobazam|Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
11385278|NCT02134366|Active Comparator|Clonazepam|Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
11385279|NCT02134366|Active Comparator|Lorazepam|Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
11385280|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
11385281|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
11385282|NCT02134340|Experimental|[I-124]-CPD-1028 PET/CT|"Administration of [I-124]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.
~A pre-targeting dose of CPD-1061 may be given prior to injection of [I-124]-CPD-1028."
11385283|NCT02134327|Experimental|Premedication with Midazolam|
11385284|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
11385285|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
11385286|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
11385287|NCT02134288|Active Comparator|Belatacept|Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
11385288|NCT02134288|Active Comparator|Everolimus|Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.
11385289|NCT02134275|Experimental|Whole body vibration training|Whole body vibration training (timed stand on vibration platform) 3 20-minute sessions per week for 6 months
11385290|NCT02134275|Placebo Comparator|Control group|No significant changes to diet, exercise and lifestyle.
11385291|NCT02134262|Experimental|Dose Level -1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
11385292|NCT02134262|Experimental|Dose Level 1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
11385293|NCT02134262|Experimental|Dose Level 2|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
11385294|NCT02134262|Experimental|Dose Level 3|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
11385295|NCT02134249|Active Comparator|Group A (Diosmin group)|In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.
11385296|NCT02134249|Active Comparator|Group B(Cabergoline group)|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .
11385297|NCT02134223|Experimental|dialectical behavior therapy|Primary intervention group: receiving one year of dialectical behavior therapy
11385298|NCT02134223|Placebo Comparator|treatment as usual|Comparison group: receiving one year of treatment as usual
11385299|NCT02134223|No Intervention|Receiving no treatment at all|Healthy control group
11385300|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
11385301|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
11385302|NCT02134197|Experimental|Lupartumab Amadotin (BAY1129980)|Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980.
11385303|NCT02134184|Experimental|CMV negative group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
11385304|NCT02134184|Experimental|CMV positive group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
11385305|NCT02134184|Experimental|Recent CMV Converters|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
11385306|NCT02134171|Experimental|Biological investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
11385307|NCT02134158|Experimental|sham and then anodal|visit 2 sham stimulation (120 seconds) and visit 3 anodal stimulation (30 minutes)
11385308|NCT02134158|Experimental|anodal and then sham|visit 2 anodal stimulation (30 minutes) and visit 3 sham stimulation (120 seconds)
11385309|NCT02134145||Self Selected Investors|A self selected crowdfunding backers from teh Scanadu Scout Crowdfunding campaign.
11385310|NCT02134132|Active Comparator|platelet rich plasma|The patients with diabetic foot ulcer who receive PG treatment.
11385311|NCT02134132|Placebo Comparator|Placebo|The patients with diabetic foot ulcer who receive placebo.
11385312|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
11385313|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
11385314|NCT02134106|Active Comparator|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
11385315|NCT02134106|Experimental|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
11385316|NCT02134093|Placebo Comparator|Normal saline|Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery
11385317|NCT02134093|Experimental|High dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery
11385318|NCT02134093|Experimental|Low dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery
11385319|NCT02134080|Active Comparator|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
11385320|NCT02134080|Placebo Comparator|Placebo|Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.
11385321|NCT02134067|Experimental|TAS-119|"TAS-119 tablets, oral, dose-escalating, 28-day cycle.
~Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms."
11385322|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
11385323|NCT02134041||traumatic brain injury|mild traumatic brain injury
11385324|NCT02134041||without TBI|without TBI
11385325|NCT02134028|Experimental|dupilumab treatment|"For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1* Dose every 2 weeks added to current controller medications.
~For participants coming from other studies: dupilumab 1 * Dose SC every 2 weeks added to current controller medications."
11385326|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
11385327|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
11385328|NCT02134002|Experimental|Disulfiram|disulfiram 250 mg/day
11385329|NCT02134002|Placebo Comparator|Placebo|Placebo
11385330|NCT02133989|Experimental|Ticlopidine+Ginko biloba|Switch to ticlopidine + ginko biloba
11385331|NCT02133989|Active Comparator|Clopidogrel|Keep clopidogrel
11385332|NCT02133976|Active Comparator|cognitive therapy|Cognitive therapy will be delivered to decrease pain interference
11385333|NCT02133976|Active Comparator|mindfulness training|Mindfulness training will be delivered to decrease pain interference
11385334|NCT02133976|Active Comparator|behavior therapy|Behavior therapy will be delivered to decrease pain interference
11385335|NCT02133976|Active Comparator|treatment as usual|Subjects will engage in their usual care for low back pain.
11385336|NCT02133963||women with no history of depression|Non-Probability Sample of women with no history of depression
11385337|NCT02133963||women with a past depression history|Non-Probability Sample of women with a past history of depression
11385338|NCT02133950|Experimental|freeze all embryos following PGD|no fresh embryo transfer; elective cryopreservation of all embryos after PGD
11385339|NCT02133950|Active Comparator|elective fresh embryo transfer|
11385340|NCT02133937|Experimental|High Concentration Liquid Formulation (HCLF)|
11385341|NCT02133937|Active Comparator|Lyophilized formulation|
11385342|NCT02133924|Experimental|Natalizumab with steroids|"For subjects whose GVHD assay is Ann Arbor score 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.
~Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD."
11385343|NCT02133911|No Intervention|Controls|
11385344|NCT02133911|Experimental|Ranolazine|Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
11385345|NCT02133898|Other|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
11385346|NCT02133885|Active Comparator|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
11385347|NCT02133885|Placebo Comparator|Placebo Group|These subjects will start with placebo (this will look like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive a minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
11385348|NCT02133872|Active Comparator|Minocycline 100mg Group|Subjects will be randomized to receive Minocycline 100mg.
11385349|NCT02133872|Active Comparator|Minocycline 200mg Group|Subjects will be randomized to receive Minocycline 200mg
11385350|NCT02133859||Chronic Heart Failure patients using ASV|Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period
11385351|NCT02133846|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
11385352|NCT02133846|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions).
11385353|NCT02133846|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
11385354|NCT02133846|Placebo Comparator|Placebo|0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
11385355|NCT02133833|Experimental|Quantum Spectrum Radiation Emitter|five pieces of Quantum Spectrum Radiation Emitter will be placed on the affected shoulder daily for three weeks.
11385356|NCT02133820|Active Comparator|12 hourly capsule fasted|4 mg 12 hourly capsule - strong pain killer fasted
11385357|NCT02133820|Active Comparator|12 hourly capsule fed|4 mg 12 hourly capsule - strong pain killer fed
11385358|NCT02133820|Experimental|12 hourly capsule with antagonist fasted|4 mg 12 hourly capsule strong painkiller with antagonist fasted
11385359|NCT02133820|Experimental|12 hourly capsule with antagonist fed|4 mg 12 hourly capsule strong painkiller with antagonist fed
11385360|NCT02133807|Experimental|Specific Lp(a) apheresis & Atorvastatin|"Specific Lp(a) apheresis was performed with Lp(a) Lipopak immunosorbent columns (POCARD Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
11385361|NCT02133807|No Intervention|Atorvastatin|Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
11385362|NCT02133794|Experimental|Tomosynthesis|
11385363|NCT02133781|Experimental|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
11385364|NCT02133781|Experimental|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
11385365|NCT02133781|Experimental|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
11385366|NCT02133755|Other|Bromocriptine mesylate (Cycloset)|Cycloset 1.6 to 3.2 mg daily for 3 months
11385367|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
11385368|NCT02133729|Experimental|Gestational diabete|
11385369|NCT02133716|Experimental|expressed breast milk|"A single dose of expressed breast milk was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.
~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
11385370|NCT02133716|Active Comparator|sucrose 24% oral|"A single dose of sucrose was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.
~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
11385371|NCT02133703|Experimental|Mutation Carrier: Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
11385372|NCT02133703|Experimental|Mutation Carrier: Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
11385373|NCT02133703|Active Comparator|Mutation Carrier: Enhanced Print DA|BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
11385374|NCT02133703|Active Comparator|Mutation Carrier: Print DA|BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
11385375|NCT02133703|Experimental|Inconclusive Results: DA|Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
11385376|NCT02133703|No Intervention|Inconclusive Results: Usual care|Participants who receive inconclusive/uninformative results who are randomized to this arm will receive usual care but no additional decision support intervention
11385377|NCT02133690|Experimental|Vaccine Arm|3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
11385378|NCT02133690|Placebo Comparator|Placebo group|3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
11385379|NCT02133677|Experimental|temozolomide+WBRT|temozolomide: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks WBRT:30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week)
11385380|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
11385381|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
11385382|NCT02133638|Active Comparator|Sevoflurane|Sevoflurane Based Volatile Induction and Maintenance of Anaesthesia
11385383|NCT02133638|Active Comparator|Propofol|Propofol Based Total Intravenous Anesthesia
11385384|NCT02133625|Experimental|Pioglitazone and Carboplatin|"MTD Determination
~Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21
~Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1"
11385385|NCT02133625|Experimental|MTD Expansion Carboplatin and Pioglitazone|"MTD Expansion:
~Carboplatin alone on cycle 1, day 1.
~Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.
~On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks"
11385386|NCT02133612|Experimental|single arm paclitaxel and cisplatin|
11385387|NCT02133599|Other|Iohexol|All patients will receive two Iohexol clearance tests, 5 mL each time before cycle 1 and 4 of HDMTX
11385388|NCT02133586|Placebo Comparator|Clean Air - O3|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
11385389|NCT02133586|Experimental|NO2-O3|"Day #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise.
~Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
11385390|NCT02133586|Placebo Comparator|Clean Air - NO2|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
11385391|NCT02133586|Experimental|O3 - NO2|"Day #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.
~Day #3: Follow-up (no exposure)"
11385392|NCT02133573|Experimental|Progesterone|Vaginal gel, 90mg twice a day (BID)
11385393|NCT02133573|Placebo Comparator|Vaginal Lubricant|Vaginal twice a day (BID)
11385394|NCT02133560|Other|Medication Administration + Education|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip during months 1-3 and completing the medication administration log during months 1-6. During months 1-6 subjects will meet with study staff and receive educational materials on a monthly basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
11385395|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
11385396|NCT02133521|Placebo Comparator|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
11385397|NCT02133521|Experimental|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
11385398|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
11385399|NCT02133495|Experimental|open label|Non Cadaveric human BellaDerm Acellular dermal tissue
11385400|NCT02133482|Experimental|BI 639667|single rising doses given as oral solution
11385401|NCT02133482|Placebo Comparator|Placebo|placebo solution
11385402|NCT02133469|Experimental|PCV7 (Vaccine)|Randomized group of 1634 subjects to be administered a single dose of PCV7 (Hib vaccine offered at end of study).
11385403|NCT02133469|Active Comparator|Hib vaccine|Randomized group of 1634 subjects to be administered a single dose of Hib Vaccine(PCV7 vaccine offered at end of study).
11385404|NCT02133456||SIBP's vaccine|SIBP's vaccine group is the population injected with this vaccine.
11385405|NCT02133443|Active Comparator|Pressure Support Ventilation|Device: PSV - pressure support ventilation
11385406|NCT02133443|Active Comparator|Neurally Adjusted Ventilatory Assist|Device: Partial ventilator support with partial ventilation mode (NAVA)
11385407|NCT02133430|Experimental|Bispectral index (BIS) group|Bispectral index as measured by a BIS Processor is used to guide doses of anesthetic for maintaining the BIS values of 40-60
11385408|NCT02133430|No Intervention|Control group|Clinical signs is used to guide doses of anestheitics.
11385409|NCT02133417||Women|Women with mammographically-detected breast lesions
11385410|NCT02133404|Experimental|ASP7991 group|receiving ASP7991 and Cinacalcet-placebo
11385411|NCT02133404|Active Comparator|Cinacalcet group|receiving Cinacalcet and ASP7991-placebo
11385412|NCT02133391|Active Comparator|Practice-based reminder/recall or Usual care arm|"Practices participating in state immunization registry invited to reminder/recall (R/R) webinar trainings and provided educational materials to encourage immunization within their practices (child and adolescent trials only)
~Patients not randomized to the collaborative centralized R/R arm will receive usual care from their provider, which does not include R/R (adult trials only)"
11385413|NCT02133391|Experimental|Collaborative centralized R/R|Collaborative centralized reminder/recall (R/R) effort will be conducted by state immunization registry in collaboration with accountable care organizations and practices
11385414|NCT02133378|Experimental|Hemopatch|Use of Hemopatch on bleeding spot
11385415|NCT02133378|Sham Comparator|Control|Traditional techniques hemostasis (dry or wet gauze compression or similar)
11385416|NCT02133365|Active Comparator|Mindfulness and Interoceptive Exposure|Atrial fibrillation patients will receive 4-5 manualized, individualized sessions of Mindfulness and Interoceptive Exposure.
11385417|NCT02133365|No Intervention|Medical care as usual|Atrial fibrillation patients will receive medical and cardiac care as usual.
11385418|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
11385419|NCT02133339|Experimental|TRN-157|
11385420|NCT02133339|Placebo Comparator|Placebo|
11385421|NCT02133326|Experimental|Caldolor|800 mg of Caldolor® will be infused at the rate of 5-7 minutes as per the manufacturer's guidelines or
11385422|NCT02133326|Experimental|Ofirmev|1000 mg of Ofirmev® will be infused at the rate of 15 minutes as per the manufacturer's guidelines.
11385423|NCT02133313||Peritoneal Dialysis Patients|Patients on Peritoneal Dialysis
11385424|NCT02133300|Experimental|electrical stimulation|Compex 3 professional NMES for 60' per day
11385425|NCT02133300|No Intervention|control|
11385426|NCT02133287|Experimental|AVI® Arsenic trioxide drug eluting stent|Study group: Arsenic trioxide drug eluting stent delivery system (AVI®)
11385427|NCT02133287|Active Comparator|Firebird2® sirolimus eluting stent system|Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2®)
11385428|NCT02133274|No Intervention|Standard oncologic care|Standard oncologic care
11385429|NCT02133274|Experimental|Early Palliative Care|A first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
11385430|NCT02133274|Experimental|Psychosocial plus early Palliative Care|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy plus early palliative care. Regarding the early Palliative Care, a first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
11385431|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
11385432|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
11385433|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
11385434|NCT02133235|Active Comparator|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
11385435|NCT02133235|Experimental|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
11385436|NCT02133222|Experimental|Metastatic (stage IV) melanoma|
11385437|NCT02133209|Active Comparator|Stress Management for Headaches|This intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills for managing migraine headaches.
11385438|NCT02133209|Active Comparator|Mindfulness Based Stress Reduction|Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. The intervention also included an extended period of training in addition to the usual 8 weeks.
11385439|NCT02133196|Experimental|1/High-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus high-dose Aldesleukin
11385440|NCT02133196|Experimental|2/Low-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus low-dose Aldesleukin
11385441|NCT02133183|Experimental|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11385442|NCT02133183|Experimental|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11385443|NCT02133170|Active Comparator|Psychopharmacological + MBCT|psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT)
11385444|NCT02133170|Active Comparator|psychopharmacological + psychoeducation|psychopharmacological treatment plus structured group psychoeducation;
11385445|NCT02133170|Other|Psychopharmacological treatment.|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
11385446|NCT02133157|Experimental|Sulfatinib capsule|cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.
11385447|NCT02133144|Experimental|High fat diet|Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
11385448|NCT02133144|Experimental|High carbohydrate diet|Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
11385449|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
11385450|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
11385451|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
11385452|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
11385453|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
11385454|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
11385455|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
11385456|NCT02133118||Patients on metformin mono-therapy who receive add-on|
11385457|NCT02133105|Active Comparator|Levosimendan|Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
11385458|NCT02133105|Active Comparator|Dobutamine|Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
11385459|NCT02133092||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
11385460|NCT02133079|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
11385461|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
11385462|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
11385463|NCT02133053||Ectoin Group|Ectoin Allergy Nasal Spray (Medical Device, drug-like)
11385464|NCT02133053||Beclomethasone Group|Beclomethasone nasal spray
11385465|NCT02133040||T3 > 4 nmol/l|Acute hyperthyroidism with a T3 > 4 nmol/l
11385466|NCT02133027|Experimental|Rouviere's Sulcus|Rouviere's sulcus is a 2 to 5 cm sulcus running to the right of the liver hilum anterior to the caudate process and usually containing the right portal triad or its branches.Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
11385467|NCT02133027|Other|traditional anatomy method|Ratcheted grasper is inserted through the lateral 5-mm port to retract the gallbladder fundus in cephalad fashion. An atraumatic grasper is inserted through the middle 5-mm port to retract the gallbladder infundibulum laterally, exposing the anteromedial aspect of the triangle of Calot.
11385468|NCT02133014|Experimental|surgical operation therapy|Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.
11385469|NCT02133014|No Intervention|conventional therapy|using the method of conventional conservative therapy without surgical management.
11385470|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
11385471|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
11385472|NCT02132988|Experimental|OPT-822/OPT-821|
11385473|NCT02132975|Experimental|With motorised probe handler|The surgeon use the motorised probe handler to do the biopsy
11385474|NCT02132975|Experimental|Without motorised probe handler|The surgeon do the biopsy as he usually do.
11385475|NCT02132962|Active Comparator|Healthy controls|Amino acid infusion
11385476|NCT02132962|Active Comparator|Cirrhosis|Amino acid infusion
11385477|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|ddAC: dose dense doxorubicin and cyclophosphamide. Participants will receive doxorubicin and cyclophosphamide every 2 weeks (q2w) for 4 cycles, followed by paclitaxel for 12 weeks, with pertuzumab and trastuzumab given every 3 weeks (q3w) (8 cycles of chemotherapy in total prior to surgery) from the start of paclitaxel. Following surgery, participants will receive further adjuvant pertuzumab and trastuzumab q3w (13 cycles), such that a total of 17 cycles of pertuzumab and trastuzumab therapy are given during the study.
11385478|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|FEC: 5-fluorouracil, epirubicin and cyclophosphamide. Participants will receive 5-fluorouracil, epirubicin, and cyclophosphamide given q3w for 4 cycles, followed by docetaxel q3w for 4 cycles, with pertuzumab and trastuzumab given q3w (8 cycles of chemotherapy in total prior to surgery) from the start of docetaxel. Following surgery, participants will receive further adjuvant pertuzumab and trastuzumab q3w (13 cycles), such that a total of 17 cycles of pertuzumab and trastuzumab therapy are given during the study.
11385479|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
11385480|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
11385481|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
11385482|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
11385483|NCT02132923||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
11385484|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.
~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.
~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.
~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.
~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
11385485|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.
~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.
~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.
~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
11385486|NCT02132897|Other|TR (Test - Reference)|Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
11385487|NCT02132897|Other|RT (Reference - Test)|Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
11385488|NCT02132884|Active Comparator|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
11385489|NCT02132884|Experimental|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
11385490|NCT02132871||1|
11385491|NCT02132858||Ancillary-Correlative (genetic mutation analysis)|Patients undergo collection of blood and tissue samples for analysis via sequencing.
11385492|NCT02132845|Active Comparator|Arm A (standard of care therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Patients receive standard of care therapy based on the discretion of the treating physician.
11385493|NCT02132845|Experimental|Arm B (target-directed therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Based on the results of the next generation sequencing, patients receive target-directed therapy.
11385494|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
11385495|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
11385496|NCT02132819|Placebo Comparator|Feeding During Transfusion|The feeding process will be continued during the transfusion
11385497|NCT02132819|Active Comparator|witholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
11385498|NCT02132806|Experimental|OFD with piezosurgery|Open flap debridement with Piezosurgery
11385499|NCT02132806|Experimental|OFD with piezosurgery+biomaterial|Open flap debridement with Piezosurgery with biomaterial mp3
11385500|NCT02132806|Experimental|OFD with piezosurgery+mp3+bracket|Open flap debridement with Piezosurgery with biomaterial mp3 + bracket
11385501|NCT02132793|Active Comparator|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
11385502|NCT02132793|Experimental|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
11385503|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF
~Amiodarone and/or DC-cardioversion
~Amiodarone Initial Dose
~Oral: 400 mg po TID for 3 days is recommended
~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
~Oral: at least 200 mg/day to be continued until 60 days after randomization
~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
11385504|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF
~Beta-blocker and/or Calcium channel blockers and/or Digoxin
~Dose, frequency and duration determined by medical professional as medically needed"
11385505|NCT02132754|Experimental|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385506|NCT02132754|Experimental|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385507|NCT02132754|Experimental|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385508|NCT02132754|Experimental|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385509|NCT02132754|Experimental|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385510|NCT02132754|Experimental|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385511|NCT02132754|Experimental|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385512|NCT02132754|Experimental|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385513|NCT02132754|Experimental|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385514|NCT02132754|Experimental|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385515|NCT02132754|Experimental|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385516|NCT02132754|Experimental|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385517|NCT02132754|Experimental|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385518|NCT02132754|Experimental|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385519|NCT02132754|Experimental|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385520|NCT02132754|Experimental|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385521|NCT02132754|Experimental|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385522|NCT02132754|Experimental|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385523|NCT02132754|Experimental|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385524|NCT02132754|Experimental|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
11385525|NCT02132754|Experimental|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385526|NCT02132754|Experimental|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385527|NCT02132754|Experimental|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385528|NCT02132754|Experimental|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385529|NCT02132754|Experimental|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385530|NCT02132754|Experimental|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385531|NCT02132754|Experimental|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385532|NCT02132754|Experimental|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385533|NCT02132754|Experimental|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385534|NCT02132754|Experimental|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385535|NCT02132754|Experimental|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385536|NCT02132754|Experimental|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385537|NCT02132754|Experimental|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385538|NCT02132754|Experimental|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
11385539|NCT02132741||Treated hypertension|Patients on treatment for hypertension
11385540|NCT02132741||CKD-ESRD|Pre- & post haemodialysis
11385541|NCT02132741||Healthy individuals|Healthy volunteers
11385542|NCT02132741||CKD|Pre-dialysis CKD & those with a functional renal transplant
11385543|NCT02132741||Hypertension|Untreated
11385544|NCT02132728|No Intervention|Control group|In the group with 11 volunteers, the control group did no change in normal food intake.
11385545|NCT02132728|Experimental|Flaxseed group|In this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
11385546|NCT02132728|Experimental|Rice and low carb group|In this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
11385547|NCT02132728|Experimental|Flaxssed and low carb group|In this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
11385548|NCT02132715|Active Comparator|Resistance exercise|Traditional isotonic lower-extremity resistance training
11385549|NCT02132715|Experimental|KAATSU exercise|Lower-extremity exercise with blood flow mildly restricted
11385550|NCT02132702|Experimental|Ekso treatment|
11385551|NCT02132689|Active Comparator|Actilyse|Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).
11385552|NCT02132689|Active Comparator|UHF/LMWH|Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).
11385553|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
11385554|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
11385555|NCT02132663|Experimental|Infant formula containing an alternate source of DHA|
11385556|NCT02132663|Active Comparator|Marketed routine infant formula|
11385557|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
11385558|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
11385559|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
11385560|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
11385561|NCT02132624|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
11385562|NCT02132611|Experimental|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
11385563|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.
~Treatment cycles are 4 weeks in duration"
11385564|NCT02132585||Sjogren|Sjogren Patients evaluated with Speckle tracking echocardiography
11385565|NCT02132585||Control|Controls Speckle tracking echocardiography
11385566|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
11385567|NCT02132559||DHEA administration,no treatment|The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
11385568|NCT02132546|Experimental|Chlorhexidine 0,2%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX.
11385569|NCT02132546|Experimental|Chlorhexidine 0,2% with ADS|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX with ADS.
11385570|NCT02132546|Experimental|Chlorhexidine 0,12%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.12% CHX.
11385571|NCT02132533|Experimental|Nifedipine|Women with preterm labor will receive nifedipine.
11385572|NCT02132533|Experimental|Placebo|Women with preterm labor will receive placebo.
11385573|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
11385574|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
11385575|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
11385576|NCT02132494|Experimental|Physical activity|60 minutes of daily physical activity during one school year
11385577|NCT02132494|No Intervention|Control|
11385578|NCT02132481|Experimental|EMA Only|See intervention
11385579|NCT02132481|Experimental|EMI Only|See intervention
11385580|NCT02132481|Experimental|EMA+EMI|See intervention
11385581|NCT02132481|Active Comparator|Neither - RSAU|See intervention
11385582|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
11385583|NCT02132455|Experimental|3 minutes in the right side colon|Colonoscopy, at least 3 minutes in the right side colon from the total withdrawal time
11385584|NCT02132455|Experimental|4 minutes in the right side colon|Colonoscopy, at least 4 minutes in the right side colon from the total withdrawal time
11385585|NCT02132455|No Intervention|6 minutes whole withdrawal time|Colonoscopy, at least 6 minutes whole withdrawal time regardless of time spent in any segment
11385586|NCT02132455|Experimental|8 minutes whole withdrawal time|Colonoscopy, at least 8 minutes whole withdrawal time regardless of time spent in any segment
11385587|NCT02132442|Experimental|Vitamin D supplementation|Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
11385588|NCT02132442|Placebo Comparator|Placebo|Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
11385589|NCT02132429|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 daily for 14 days.
11385590|NCT02132429|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo daily for 14 days.
11385591|NCT02132416|Active Comparator|Surgical management|Operative fixation of unstable thoracic cage injuries and chest wall deformity. Thoracic Epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
11385592|NCT02132416|Active Comparator|Conservative management|Conservative management of unstable thoracic cage injuries and chest wall deformity. Thoracic epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
11385593|NCT02132403|Experimental|IMPRIME PGG, BTH1704, & Gemcitabine|Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.
11385594|NCT02132390|Experimental|Arm I|Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity
11385595|NCT02132390|Experimental|Arm II|Patients who had CIA receive toremifene as in arm I
11385596|NCT02132390|Experimental|Arm III|Patients without CIA receive oral toremifene and goserelin for ovarian function suppression
11385597|NCT02132390|Experimental|Arm IV|Patients with CIA receive oral toremifene and goserelin for ovarian function suppression.
11385598|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
11385599|NCT02132364|No Intervention|typical follow-up|no intervention
11385600|NCT02132351||Hepatologists|Doctors working as hepatologists
11385601|NCT02132338|Experimental|The Education Health Program|Intervention forth knowledge and attitudes necessary for self-care
11385602|NCT02132325|Experimental|Dignity Therapy|
11385603|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
11385604|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
11385672|NCT02131883|Other|Wait-List with treatment as usual|Wait-List with treatment as usual waiting in 9 months for the intervention with group-CBT
11385673|NCT02131870|Active Comparator|L plantarum DSM 9843|
11385674|NCT02131870|Placebo Comparator|Placebo|
11385675|NCT02131857|Experimental|Staff|active interventional program based on Mindfulness training
11385605|NCT02132299|Experimental|Group 1|Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
11385606|NCT02132299|Experimental|Group 2(A)|Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
11385607|NCT02132299|Placebo Comparator|Group 2(B)|Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
11385608|NCT02132299|Experimental|Group 3(A)|Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
11385609|NCT02132299|Placebo Comparator|Group 3(B)|Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
11385610|NCT02132299|Experimental|Group 4|The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
11385611|NCT02132299|Placebo Comparator|Group 5|The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
11385612|NCT02132286|Experimental|Quetiapine -XR (extended release)|Quetiapine-XR (extended release) 150-300mg- treatment in MDD patients with S/Lg alleles in MDD
11385613|NCT02132286|Active Comparator|Citalopram|Citalopram 10-20 mgm/day treatment for 8 weeks in MDD with S/Lg alleles
11385614|NCT02132273|Experimental|Educational Story|Participants receiving this intervention will have access to the educational story as they prepare for the overnight sleep study.
11385615|NCT02132273|No Intervention|Typical Preparation|Participants will receive traditional materials, directions, what to bring list, only. They will not recieve access to educational story
11385616|NCT02132260|Experimental|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)
11385617|NCT02132260|Active Comparator|Naftin® Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2%
11385618|NCT02132260|Placebo Comparator|Placebo Topical Cream|Placebo Topical Cream
11385619|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
11385620|NCT02132234|Experimental|Biological treatment|"Patients with high disease activity receiving biological treatment according to rheumatologic indication:
~etanercept 50 mg s.c. every week
~adalimumab 40 mg s.c. every 2 weeks
~certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks
~infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
11385621|NCT02132234|Placebo Comparator|control group|Patients with high disease activity receiving other than biological treatment and receiving placebo.
11385622|NCT02132221|Experimental|Cognitive Behavioral Therapy (CBT)|cognitive therapy (10 weekly sessions)
11385623|NCT02132221|No Intervention|no CBT- wait list|no cognitive therapy
11385624|NCT02132208||Trauma|Severe trauma patients admitted in the resuscitation room of our emergency department.
11385676|NCT02131857|Experimental|Parents|active interventional program based on Mindfulness training
11385851|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
11385625|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2
~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
11385626|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
11385627|NCT02132195|Active Comparator|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
11385628|NCT02132182||Patients newly diagnosed with osteosarcoma|Blood draw
11385629|NCT02132169|Experimental|AC-170 0.24%|
11385630|NCT02132169|Placebo Comparator|AC-170 0%|
11385631|NCT02132143|Experimental|Progression-free survival&Concurrent chemoradiotherapy|"The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy, 21 days as a cycle.
~Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W."
11385632|NCT02132143|Active Comparator|Progression-free survival&sequential chemoradiotherapy|Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, 21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.
11385633|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
11385634|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
11385635|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
11385636|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
11385637|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
11385638|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
11385639|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
11385640|NCT02132104|Experimental|amnion graft in severe IUA|patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
11385641|NCT02132104|Sham Comparator|non-amnion graft in severe IUA|patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
11385642|NCT02132091|Experimental|Intermittent Fasting|Intermittent Fasting
11385643|NCT02132091|Experimental|Intermittent Fasting + Antioxidants|Intermittent Fasting; 400 IU Vitamin E; 1000 mg Vitamin C
11385644|NCT02132078||Lung transplant recipients with uncomplicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
11385645|NCT02132078||Lung transplant recipients with complicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
11385646|NCT02132065|No Intervention|Standard pain keller|
11385647|NCT02132065|Experimental|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
11385648|NCT02132039|Active Comparator|12-step sitting Tai Chi Chuan|The intervention is a simplified Tai Chi Chuan exercise, which consists of 12 steps, including weight shifting in different sitting positions, trunk and upper limb movements, and alternate thigh lift in a smooth and coordinated manner.
11385649|NCT02132039|Placebo Comparator|Control|We provide participants in the control group with a level of social contact equivalent to the intervention group, which comprises structured conversations on topic other than physical activity.
11385650|NCT02132026|Active Comparator|Alendronic Acid|50 patients will receive once weekly Alendronic Acid tablets (70mg).
11385651|NCT02132026|Placebo Comparator|Alendronic Acid placebo|25 patients will receive alendronic acid placebo tablets.
11385652|NCT02132026|Active Comparator|Denosumab|50 patients will receive 6 monthly denosumab injections
11385653|NCT02132026|Placebo Comparator|Denosumab Placebo|25 patients will receive a 6 monthly placebo injection.
11385654|NCT02132013|Experimental|Intervention SUBLIME|Intervention group
11385655|NCT02132013|No Intervention|Control|Regular care
11385656|NCT02132000|Active Comparator|tamoxifen|tamoxifen,20mg/day
11385657|NCT02132000|Experimental|toremifene|toremifene,60mg/day
11385658|NCT02131987||Dislocation|Patients operated with hip hemiarthroplasty for a femoral neck fracture with a postoperative dislocation of the prosthesis
11385659|NCT02131987||Non-dislocated|Patents without dislocation of a hemiarthroplasty for a femoral neck fracture
11385660|NCT02131961|Experimental|Study arm|Collagenase ointment topical application, once daily for 14 days, modified Contact Cast System, applied at days 0,3, and 7.
11385661|NCT02131948|Experimental|Intranasal insulin|40 IU of intranasal insulin
11385662|NCT02131948|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
11385663|NCT02131935||ISR Group|Patients Group Experienced In-Stent Restenosis (ISR)
11385664|NCT02131935||Non-ISR|Patients Group Without in-stent restenosis (ISR)
11385665|NCT02131922|Placebo Comparator|Hygenization Treatment|Basic oral hygiene instructions Supragingival plaque removal
11385666|NCT02131922|Experimental|Intensive Treatment|One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
11385667|NCT02131909|Experimental|mirror therapy|5 sessions mirror therapy 15 minutes per week for 5 weeks
11385668|NCT02131909|Placebo Comparator|bimanual rehabilitation exercises|5 sessions control therapy 15 minutes per week for 5 weeks
11385669|NCT02131896|Experimental|Mediterranean Diet|Mediterranean Diet
11385670|NCT02131896|Active Comparator|Regular nutritional instructions|Regular nutritional instructions
11385671|NCT02131883|Experimental|Group-Cognitive Behavioral Therapy|Group-Cognitive Behavioral Therapy for 7 patients and 2 therapists, 3 hours sessions a week in 12 weeks and a 3 hours booster session 12 weeks after
11385677|NCT02131857|Experimental|Patients with CF|active interventional program based on Mindfulness training
11385678|NCT02131844|Experimental|Facilitated early mobilization|Early mobilization facilitated by a dedicated health professional
11385679|NCT02131844|Active Comparator|Usual care|Instructions about early mobilization covered in a preoperative education session
11385680|NCT02131831||cirrhosis|
11385681|NCT02131818|Experimental|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
11385682|NCT02131818|Placebo Comparator|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
11385683|NCT02131805|Experimental|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
11385684|NCT02131792|Experimental|Lateral Rectus Muscle Slanted Recession|Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness
11385685|NCT02131779|Experimental|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
11385686|NCT02131779|Active Comparator|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
11385687|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.
~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
11385688|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
11385689|NCT02131753|Other|Cladribine s.c. injection, HCL treatment|Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
11385690|NCT02131740|Experimental|Eye rubbing intervention|eye rubbing performed for 1 minute in horizontal direction, clockwise rest for 5 seconds eye rubbing for a further 1 minute
11385691|NCT02131740|Active Comparator|No eye rubbing|no eye rubbing - comparator
11385692|NCT02131727|Experimental|Hand Hygiene Improvement Intervention|Hand Hygiene Improvement Intervention: Participants receive a 4 minute training video about actions to take to reduce risk of respiratory and GI infections that includes hand hygiene practices, along with educational posters and hand hygiene supplies.
11385693|NCT02131727|Placebo Comparator|Ask Me 3|Participants in the control group received a 4 minute training video about the Ask Me 3 program for clearer communication with health care providers, a brochure, and a key chain containing principles for clear communication with health care providers.
11385694|NCT02131714|Active Comparator|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
11385695|NCT02131714|Placebo Comparator|lifestyle counseling|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character.
11385696|NCT02131701|Active Comparator|Training group|The training group received individualized information about moderate training and was also offered training in group twice a week during 12 months. The training included both endurance training (nordic walking, water gymnastics) and training in gym.
11385697|NCT02131701|Active Comparator|Prescription of exercise|Individualized sessions for exercise prescription aiming at moderate exercise of 30 minutes at least 5 days a week
11385698|NCT02131688|Experimental|Mitoxantrone Hydrochloride Liposome|
11385699|NCT02131675||Boost shake|children that have had type 1 diabetes for more than 1 year
11385700|NCT02131662|Experimental|VPR 4 mg|
11385701|NCT02131662|Experimental|VPR 2 mg|
11385702|NCT02131662|Experimental|VPR 1 mg|
11385703|NCT02131662|Experimental|VPR 0.5 mg|
11385704|NCT02131662|Placebo Comparator|Placebo|
11385705|NCT02131649|Experimental|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
11385706|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
11385707|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
11385708|NCT02131623||Validation Group|Subjects with ALGS or PFIC and/or their caregivers
11385709|NCT02131610||Obstructive slep apnea patients|Patients with OSA
11385710|NCT02131610||Control group|Subjects without OSA
11385747|NCT02131246|Active Comparator|NovoRapid®|Each subject will be allocated to two treatments (in random sequence).
11385852|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
11385711|NCT02131597|Experimental|Treatment (guadecitabine)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
11385712|NCT02131584|Experimental|Supportive care (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
11385713|NCT02131571||HIV patients older than 50 years|HIV infected patients older than 50 years in current follow up
11385714|NCT02131558|Experimental|ICG Dye|Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
11385715|NCT02131545|Experimental|Quetiapine|Quetiapine 25 mg
11385716|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.
~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
11385717|NCT02131519||internal jugular vein catheter|pediatric patients required internal jugular vein catheter
11385718|NCT02131506|Experimental|Lapatinib, Caelyx|"Lapatinib is given at escalating doses orally and continuously on days 1-21.
~Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1."
11385719|NCT02131493|Active Comparator|Gemcitabine|Gemcitabine：1000mg/m2，iv 30min，d1, d8,d15 q4w, 6 cycles
11385720|NCT02131493|Experimental|S-1+ Gemcitabine|S-1：40~60mg bid，d1~14; (S-1 dosage：BSA <1.25m2，40mg bid，1.25m2≤BSA≤1.5m2，50mg bid，BSA>1.5m2， 60mg bid) Gemcitabine：1000mg/m2，iv 30min，d1, d8 q3w, 8 cycles
11385721|NCT02131480|Experimental|Soft tissue|
11385722|NCT02131480|Experimental|Uterus|
11385723|NCT02131467|Experimental|Perampanel|Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.
11385724|NCT02131454|Experimental|Education and Inhalation technique training|Training in technique of drug inhalation in asthma and COPD patients and education about the role of inhalation therapy in the course of the disease.
11385725|NCT02131454|No Intervention|Education|Basic education about asthma and COPD.
11385726|NCT02131441|Other|laparoscopic hepatectomy|laparoscopic hepatectomy
11385727|NCT02131441|Other|open liver resection|open liver resection
11385728|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
11385729|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
11385730|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
11385731|NCT02131389|Other|Iconacy Hip System|Iconacy hip system prosthesis components
11385732|NCT02131376|Active Comparator|Cortical renorrhaphy|Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
11385733|NCT02131376|Experimental|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
11385734|NCT02131363|Experimental|Ingrowing Toenail Treatment Kit|"Ingrowing Toenail Treatment Kit consists of 3 components:
~Toe nail clip: one clip to be applied each week, for 6 weeks.
~Aerosol spray: to be applied up to 5 times a day, no more than one spray per hour.
~Nail adhesive: used to attach the clip to the nail."
11385735|NCT02131350|Experimental|Ranibizumab with Photocoagulation|
11385736|NCT02131337|Other|Contact force lesions|
11385737|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
11385738|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
11385739|NCT02131311|Experimental|pessary|disposable, single-use pessary
11385740|NCT02131298|Other|Fixed sequence|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B (palbociclib with itraconazole)
11385741|NCT02131285|Experimental|Sensory training|Experimental group received balance rehabilitation aimed at improving motor strategies and sensory strategies. Subjects in this group were treated to improve recovery of sensory impairment and were given exercises in the impaired sensory conditions, inhibiting the reliable sensory systems and forcing the Central Nervous System to use the impaired ones.
11385742|NCT02131285|No Intervention|No sensory strategy|Control group received usual care rehabilitation which did not include training of sensory strategies.
11385743|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
11385744|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
11385745|NCT02131259||Afatinib|
11385746|NCT02131246|Experimental|Faster-acting insulin aspart|Each subject will be allocated to two treatments (in random sequence).
11385962|NCT02129816|Placebo Comparator|Placebo|Lactose 350mg, 2-2-2
11385748|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
11385749|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
11385750|NCT02131220|Experimental|Prourokinase|Intracoronary bolus infusion of 20mg prourokinase using selective catheter
11385751|NCT02131220|Active Comparator|Tirofiban|Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)
11385752|NCT02131220|Placebo Comparator|Normal saline|Intracoronary saline bolus infusion using selective catheter (20ml)
11385753|NCT02131207||Diagnostic (MRI and biopsy)|Participants undergo pelvic magnetic resonance imaging (MRI). Within 1-2 weeks, patients undergo scheduled prostate biopsy.
11385754|NCT02131194|Experimental|Lenstatin|Lenstatin (2) capsules orally per day for (6) months
11385755|NCT02131194|Placebo Comparator|Sugar Pill|Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months
11385756|NCT02131181||Delirium|Patients with delirium and patients without delirium
11385757|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
11385758|NCT02131155|Placebo Comparator|Placebo|Once daily
11385759|NCT02131142|Experimental|BioFreedom|
11385760|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
11385761|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
11385762|NCT02131116|Experimental|IMT|Integrated Metacognitive Therapy
11385763|NCT02131116|No Intervention|TAU|No intervention group/Treatment as Usual
11385764|NCT02131103|Active Comparator|Early ( < 24hr)|Early percutaneous coronary intervention means performed coronary intervention between 3-24 hours after successful fibrinolytic therapy.
11385765|NCT02131103|Active Comparator|Delay ( > 24 hours)|Delay percutaneous coronary intervention means received coronary intervention >24 hours to 2 weeks after successfully fibrinolytic therapy.
11385766|NCT02131103|Active Comparator|Early|"We randomized the patients into two groups early (≤ 24 hours) and delay group (> 24 hours) All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.
~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
11385767|NCT02131090|Experimental|Tegaderm TM|Participants in this arm of the study will receive the Tegaderm dressing to secure the epidural catheter
11385768|NCT02131090|Experimental|Lock-it Plus|Participants in this arm of the study will receive the Lock-it Plus dressing to secure the epidural catheter
11385769|NCT02131090|Experimental|Epifix|Participants in this arm of the study will receive the Epifix dressing to secure the epidural catheter
11385770|NCT02131077|Experimental|treatment|ALLO-ASC-TI injection
11385771|NCT02131077|Placebo Comparator|Placebo|Saline injection
11385772|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
11385773|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
11385774|NCT02131051||Azelastine group|Azelastine nasal spray Azelastine eye drops
11385775|NCT02131051||Ectoin group|Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
11385776|NCT02131038||Ectoin group|Ectoin Allergy Nasal Spray
11385777|NCT02131038||Cromolyn group|Cromolyn sodium
11385778|NCT02131012|Experimental|Celecoxib|1-4 mg intravitreal injection ofCelecoxib
11385779|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1
~Single I.V. dose of tasimelteon 2 mg on Day 6"
11385780|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1
~Single oral dose of tasimelteon 20 mg on Day 6"
11385781|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
11385782|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
11385783|NCT02130973|Active Comparator|Standard Clinical Practice Regimen|Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).
11385849|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
11385850|NCT02130570|No Intervention|Usual Care|Usual Care
11385784|NCT02130973|Experimental|Experimental (cyclic) regimen|Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).
11385785|NCT02130947|Experimental|Exercise Intervention Arm|The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting ~1.5 hours.
11385786|NCT02130947|No Intervention|Non-Exercise Control Arm|Participants in the Non-Exercise Control Arm will not exercise for 12 weeks.
11385787|NCT02130934||childhood cancer survivors|Cardiac 3D MRI
11385788|NCT02130921|No Intervention|Control|Community Health Workers (CHWs) in the control group will be invited to one group lecture didactically reviewing medical ethics, and the attending CHWs will be requested to pay a home visit to participating IDUs and FMs after the lecture.
11385789|NCT02130921|Experimental|Intervention|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.
~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.
~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
11385790|NCT02130908|Experimental|Lean fish|
11385791|NCT02130908|Experimental|Fatty fish|
11385792|NCT02130908|Experimental|Lean meat|
11385793|NCT02130895|Experimental|Intervention|STOPP Criteria Decision Support Content Intervention arm will receive CDS suggestions based on the STOPP criteria.
11385794|NCT02130895|No Intervention|Control|Control arm will provide care as usual during the intervention period.
11385795|NCT02130882|Active Comparator|Drug|Benralizumab (30mg) will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
11385796|NCT02130882|Placebo Comparator|Placebo|Placebo will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
11385797|NCT02130869|Experimental|Group A: Neuroblastoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group A participants receive busulfan, melphalan, CD133+ selected autologous stem cell infusion, hu14.18K322A, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.
~Cells for infusion are prepared using the CliniMACS System."
11385798|NCT02130869|Experimental|Group B: Lymphoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group B participants receive bendamustine, etoposide (or etoposide phosphate), cytarabine, melphalan, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.
~Cells for infusion are prepared using the CliniMACS System."
11385799|NCT02130869|Experimental|Group C: High-Risk Tumors|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group C participants receive melphalan, etoposide (or etoposide phosphate), carboplatin, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.
~Cells for infusion are prepared using the CliniMACS System."
11385800|NCT02130856|Experimental|Neonatal Kit|The neonatal kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Lady Health Workers will be equipped with a hand held electric scale to identify low birth weight newborns.
11385801|NCT02130856|No Intervention|Control (Standard care)|"In the control arm, Lady Health Workers will visit the home according to the regular schedule (same as in the intervention clusters) and will deliver the standard post-natal care consisting of:
~be present at delivery (though not conduct the delivery) and thorough examination of newborn and mother post delivery
~check mother for vaginal bleeding and abnormal blood pressure and make referral to nearest health facility as appropriate
~refer any newborn with congenital anomaly or evidence of asphyxia
~if unable to attend delivery for any reason, visit within first 24 hours post delivery
~assess newborn in first month of life during visits and provide basic treatment for acute respiratory infections, pneumonia, and diarrhea in the home
~encourage breastfeeding"
11385802|NCT02130843||MALE PATIENTS BEFORE UDS|MALE PATIENTS BEFORE UDS WITH DIFFICULT CATHETERIZATION
11385803|NCT02130830|Experimental|Topical anesthesia|Application of topical 2,5% lidocaine + 2,5% prilocaine gel to the anal canal before the procedure
11385804|NCT02130830|Placebo Comparator|Placebo|Application of placebo gel into the anal canal before the procedure
11385805|NCT02130817|Experimental|Belatacept|"Belatacept (nujolix):
~Tacrolimus withdrawal
~Standard of care(SOC) treatment:
~Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy
~Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.
~Maintenance immunosuppression:
~Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
~Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30."
11385806|NCT02130804|Experimental|Salsalate|Salsalate (4 g/day)
11385807|NCT02130804|Placebo Comparator|Placebo|Placebo (4 g/day)
11385808|NCT02130791|Experimental|PSD then TSD|baseline sleep, five nights sleep restriction, four nights recovery sleep, one night total sleep deprivation, one night recovery sleep
11385809|NCT02130791|Experimental|TSD then PSD|baseline sleep, one night total sleep deprivation, four nights recovery sleep, five nights sleep restriction, one night recovery sleep
11385810|NCT02130778|Active Comparator|Saline infusion|infusion of saline
11385811|NCT02130778|Active Comparator|Saline infusion with GLP1|infusion of saline with GLP1
11385812|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
11385813|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
11385814|NCT02130752|Experimental|Ultrasonic scalpel surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
11385815|NCT02130752|Experimental|Monopolar electrocautery surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
11385816|NCT02130739||thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
11385817|NCT02130726|Experimental|Minimally-invasive Gastrectomy|Patients allocated to the 'Minimally-invasive Gastrectomy' group will undergo minimally-invasive/laparoscopic total gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
11385818|NCT02130726|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive total resection of the stomach via laparotomy. This group is considered the control group
11385819|NCT02130713|Active Comparator|Group A, antibiotics|Prulifloxacin 600 mg
11385820|NCT02130713|Active Comparator|Group B, antibiotics plus nutraceuticals|Prulifoxacin plus Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg
11385821|NCT02130700|Experimental|Chemotherapy-Naive Patients|VT-464: given orally twice daily in 28-day cycles
11385822|NCT02130700|Experimental|Previous Chemotherapy Patients|VT-464: given orally twice daily in 28-day cycles
11385823|NCT02130700|Experimental|AR Positive 1 - 9% TNBC|VT-464: given orally once daily in 28-day cycles
11385824|NCT02130700|Experimental|Male ER Positive|VT-464: given orally once daily in 28-day cycles
11385825|NCT02130700|Experimental|AR Positive >10% TNBC|VT-464: given orally once daily in 28-day cycles
11385826|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
11385827|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
11385828|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
11385829|NCT02130674|Experimental|Dipeptiven|0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion
11385830|NCT02130661|Experimental|Part A|Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)
11385831|NCT02130661|Experimental|Part B|Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)
11385832|NCT02130648||Prenatal diagnosis|Prenatal diagnosis witch A sampling of blood de 14 ml
11385833|NCT02130635|Experimental|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
11385834|NCT02130635|Placebo Comparator|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
11385835|NCT02130635|Experimental|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
11385836|NCT02130635|Experimental|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
11385837|NCT02130635|Experimental|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
11385838|NCT02130635|Experimental|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
11385839|NCT02130635|Experimental|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
11385840|NCT02130635|Experimental|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
11385841|NCT02130635|Placebo Comparator|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
11385842|NCT02130622|Experimental|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
11385843|NCT02130622|Placebo Comparator|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
11385844|NCT02130609|Experimental|Skintel|
11385845|NCT02130596|Experimental|Acceptance-Based Behavioral Intervention|
11385846|NCT02130596|Active Comparator|Nutritional Counselling|
11385847|NCT02130583|Experimental|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
11385848|NCT02130583|Active Comparator|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
11385853|NCT02130531|Experimental|Cohort 1|"Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):
~Emixustat HCl Tablet Strength B (mid dose); 1 tablet once daily & 1 placebo tablet once daily for 7 days
~Emixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
11385854|NCT02130531|Experimental|Cohort 2|"Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):
~Emixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days
~Emixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days
~Emixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
11385855|NCT02130518|Experimental|Auriclosene (AIS)|Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks
11385856|NCT02130518|Placebo Comparator|Auriclosene Vehicle Solution|Auriclosene Vehicle Solution, 8 treatments over 4 weeks
11385857|NCT02130505|Active Comparator|T2DM|Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
11385858|NCT02130505|Active Comparator|FCH|Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
11385859|NCT02130505|Active Comparator|FH|Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
11385860|NCT02130505|Active Comparator|Healthy controls|Healthy controls
11385861|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
11385862|NCT02130479|Experimental|Contingency Management-Family Engagement|The Contingency Management-Family Engagement or CM-FAM model integrates behavioral (e.g., drug testing linked with consequences) and cognitive behavioral (e.g., functional analyses of drug use, self-management and drug refusal skills training) strategies based on the Community Reinforcement Approach with effective family engagement strategies used in Multisystemic Therapy.
11385863|NCT02130479|Active Comparator|Treatment as Usual|Standard community-based substance abuse treatment services.
11385864|NCT02130466|Experimental|Pembro+D+T (Parts 1, 2 & 3)|Participants receive pembrolizumab intravenously (IV) on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose (twice per day, or BID) starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, once daily (QD) starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
11385865|NCT02130466|Placebo Comparator|Placebo+D+T (Part 3)|Participants receive placebo IV on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
11385866|NCT02130466|Experimental|Pembro+T (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
11385867|NCT02130466|Experimental|Pembro+D (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
11385868|NCT02130466|Experimental|Pembro+T Concurrent Dosing (Parts 4 & 5)|Participants receive trametinib tablets, 1.5 mg monotherapy, orally, QD for 4 weeks. Starting with Week 5, participants receive pembrolizumab IV on Day 1 of each 3-week cycle and a concurrent dosing schedule for trametinib tablets, 1.5 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
11385869|NCT02130466|Experimental|Pembro+T Intermittent Dosing (Parts 4 & 5)|Participants receive trametinib 1.5 mg monotherapy, orally QD for 2 weeks. Starting with Week 3, participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle and an intermittent dose schedule for trametinib tablets, 1.5 mg, orally, QD with 1 week OFF trametinib and 2 weeks ON trametinib through completion of 2 years of treatment or through study treatment discontinuation.
11385870|NCT02130453|Experimental|ReSTE Cardiac Imaging|Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
11385871|NCT02130453|Other|SPECT Cardiac Imaging|After resting strain measurement done, first set of nuclear images taken. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving Regadenoson, measurements repeated. These measurements take about 2 minutes to complete. At about 30 minutes after Regadenoson given, participant will have final images for the nuclear portion of the testing.
11385872|NCT02130440|Active Comparator|Resveratrol nasal spray|2 sprays per nostril 3 times a day for a period of two months
11385873|NCT02130440|Placebo Comparator|Placebo|2 sprays per nostril 3 times a day for a period of two months
11385874|NCT02130427|Experimental|NSCLC|
11385875|NCT02130427|Experimental|Head & Neck|
11385876|NCT02130427|Experimental|GI|
11385877|NCT02130427|Experimental|Gynecologic|
11385878|NCT02130414|Active Comparator|Sandimmun® IV|Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
11385879|NCT02130414|Experimental|CyCol® capsules|CyCol®: 75 mg OD & BID for 7 days
11385880|NCT02130414|Experimental|CyCol® capsules 37.5 mg|CyCol®: 37.5 mg OD or BID for 7 days
11385881|NCT02130414|Experimental|CyCol® capsules, 150 mg|CyCol®: 150 mg OD or BID for 7 days
11385882|NCT02130401|Experimental|TNM (thermoneuromodulation device)|A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
11385883|NCT02130388|Other|Renal Insufficiency|Based on creatinine clearance
11385884|NCT02130388|Other|Renal Sufficiency|Based on creatinine clearance
11385885|NCT02130375|Experimental|stress urinary incontinence|Women with stress urinary incontinence
11385886|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
11385887|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
11385963|NCT02129816|Experimental|Solifenacin|10mg in 350mg Lactose, 2-2-2
11385888|NCT02130349||Crohns Disease|IBD patients diagnosed with Crohn's disease
11385889|NCT02130349||Ulcerative colitis|IBD patients diagnosed with ulcerative colitis
11385890|NCT02130349||IBD-Undefined|IBD patients with undefined IBD
11385891|NCT02130336|Experimental|Aerobic interval training|"Frequency: Exercise 3 times a week. Twice under supervision and home exercise once a week.
~Duration: Totally 40 minutes in one session. Intensity: 10-minute warm-up and 5-minute cool-down at 40% maximal heart rate (HRmax), participants and exercise 4-minute high-intensity training at 85-90% HRmax and 4 times separated by 3-minute active recovery at 70% HRmax.
~Type: Using treadmill while under supervision."
11385892|NCT02130336|Experimental|Continuous moderate-intensity exercise|"Frequency: 5 times a week. Twice under supervision and home exercise 3 times a week.
~Duration: Totally 45 minutes per session. Intensity: 10-minute warm-up at 40% maximal heart rate (HRmax), 30-minute moderate intensity exercise at 50-70% HRmax and 5-minute cool-down at 40% HRmax Type: Using treadmill under supervision."
11385893|NCT02130336|No Intervention|Control group|Subjects in control group will receive general exercise knowledge and counseling.
11385894|NCT02130323|Active Comparator|Loop Electrosurgical Excision Procedure|Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
11385895|NCT02130323|Experimental|Imiquimod|Imiquimod 12.5mg intravaginally once weekly for 16 weeks
11385896|NCT02130310|Experimental|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first.
11385897|NCT02130310|Placebo Comparator|Placebo injection|The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed.
11385898|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
11385899|NCT02130297|Active Comparator|Group 2 - day 10|Group 2 will receive laser therapy at the time of suture removal or post-operative day 10.
11385900|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
11385901|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
11385902|NCT02130271||Healthy|"Healthy subjects with no pain.
~Radioactive dye
~PET/MRI
~Blood draw"
11385903|NCT02130271||Sciatica|"Subjects with sciatica and scheduled for an epidural steroid injection (ESI).
~Radioactive dye
~PET/MRI
~Blood draw"
11385904|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
11385905|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
11385906|NCT02130245|Active Comparator|Early cholecystectomy|Laparoscopic cholecystectomy well be done after the immediate admission
11385907|NCT02130245|Active Comparator|Delayed cholecystectomy|Laparoscopic cholecystectomy after a period of conservative treatment
11385908|NCT02130232|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
11385909|NCT02130232|Active Comparator|Usual Care|Usual Medical Care
11385910|NCT02130219|Experimental|Chronic daily headache group|"Patients with chronic daily headache with suspicion of intracranial hypertension selected. Selection based on clinical symptoms (headache description, leading symptoms)and para-clinical pathological findings (optical nerve papilla edema). Not enough evidence to diagnose any other headache type. Simultaneous CSF pressure measurements and non-invasive ICP measurement will be performed.
~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT."
11385911|NCT02130219|Experimental|Multiple sclerosis group|"Multiple sclerosis (MS) group patients selected based on clinical symptoms and brain MRI changes typical for the disease. Diagnosis based on McDonalds criteria. CSF test for oligoclonal bands required as supporting diagnostic criteria. Patients selected with disease relapse symptoms. Simultaneous noninvasive ICP and CSF pressure measured.
~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
11385912|NCT02130219|Experimental|Stroke group|"Patients selected for this group have stroke/intracranial hemorrhage that might be complicated with intracranial hypertension. Stroke/intracranial hemorrhage diagnosed based on clinical findings and changes on brain CT/MRI. Patients with stroke less than 33% of middle cerebral artery territory included. Patients with intracranial hemorrhage 20-40 ml volume included. Patients unable to cooperate or sign informed consent excluded.
~Bilateral non-invasive ICP measurements performed. Results compared with brain MRI/CT lesion volume, mid-line shift.
~Interventions: non-invasive intracranial pressure measurement; brain MRI/CT"
11385913|NCT02130219|Experimental|Normal pressure hydrocephalus group|"Patients meeting normal pressure hydrocephalus diagnosis criteria selected to compare invasive CSF pressure versus non-invasive ICP.
~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
11385914|NCT02130206|Active Comparator|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
11385915|NCT02130206|Placebo Comparator|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
11385916|NCT02130206|Active Comparator|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
11385917|NCT02130206|Placebo Comparator|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
11385918|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
11385919|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
11385920|NCT02130180||ED T1DM and hyperglycemia without criteria for DKA|
11385921|NCT02130180||Well controlled T1DM|
11385922|NCT02130180||ED DKA|
11385923|NCT02130167|Experimental|0.01% Atropine|
11385924|NCT02130167|Active Comparator|0.05% Atropine|
11385925|NCT02130154||Young males|Healthy, Lean, Caucasian, Young males
11385926|NCT02130154||Old males|Healthy, Lean, Caucasian, Older males
11385927|NCT02130141|Experimental|Dark chocolate, dietary counselling|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
11385928|NCT02130141|Active Comparator|Dietary counselling|Usual snacks are limited.
11385929|NCT02130128|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System
11385930|NCT02130102||Users of ModuLAAr|A group of volunteers (aged 60+), living in assisted living homes, will be provided with module based technical solutions to improve their independency and quality of life.
11385931|NCT02130089|Other|All patients|Intensive tailored education
11385932|NCT02130076||Stop|Patients with stable RA stopping TNF inhibition
11385933|NCT02130076||Continue|Patients with stable RA continuing TNFi therapy
11385934|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
11385935|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
11385936|NCT02130050||OSA Patient|•male patients aged 30 to 65 yr who are newly diagnosed as severe OSA (AHI >=30/hr)
11385937|NCT02130050||Control subjects:|•male control subjects are recruited from Heath Check-up Center. Subjects who are matched with OSA patients at age (+/-2 yrs), body height (+/-3cm) and body weight (<100 kg: +/-3kg, >100 kg: +/-4kg) are screened. Only subjects who are not sleepy (ESS<10) and have no OSA (AHI<5/hr PSG)
11385938|NCT02130037|Active Comparator|psychotherapy only|
11385939|NCT02130037|Experimental|application|
11385940|NCT02130024|Experimental|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
11385941|NCT02130024|Active Comparator|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
11385942|NCT02130011|No Intervention|without feeding/fluid instructicon|Ten patients treated with preoperative chemoradiotherapy without feeding/fluid instructions
11385943|NCT02130011|Experimental|with feeding/fluid instructions|Ten patients treated with preoperative chemoradiotherapy with feeding/fluid instructions
11385944|NCT02129998||Standard IVF/ICSI treatment|
11385945|NCT02129985|Experimental|Exenatide|patients were all received a short-term intensive insulin therapy,then randomised to Exenatide group(10 ug two times a day for three months)
11385946|NCT02129985|Active Comparator|Metformin|patients were all received a short-term intensive insulin therapy,then randomised to metformin group(850mg two times a day for three months)
11385947|NCT02129972|Experimental|video capsule endoscopy|
11385948|NCT02129959||laparoscopy|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
11385949|NCT02129946|Active Comparator|Resistant Starch Bagels|Bagels made from high-resistant starch flour (provides 24g resistant starch per day)
11385950|NCT02129946|Placebo Comparator|Control Bagels|Bagels made from wheat flour
11385951|NCT02129933|Experimental|Tracer bevacizumab-IRDye800CW|"Two days prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform), all patients will receive the fluorescent tracer bevacizumab-IRDye800CW intravenously.
~*amendement June 2015: topical administration of bevacizumab-800CW"
11385952|NCT02129920||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and treated with rivaroxaban
11385953|NCT02129894|Active Comparator|abdominal binder|Post cesarean section patients will get a abdominal binder placed
11385954|NCT02129894|No Intervention|No Abdominal Binder|Post cesarean section patients will not have abdominal binder
11385955|NCT02129881|Experimental|Autologous regulatory T Cell Product|"Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:
~Prednisolone Day 0: 500 mg IV (250mg pre-op, 250mg intra-op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day -7 to -2: 500 mg/day oral Day -1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day -4 to 14: 3-12 ng/ml oral Week 3 to 12: 3-10 ng/ml oral Week 13 to 36: 3-8 ng/ml oral Week 37 to End: 3-6 ng/ml oral"
11385956|NCT02129868|Experimental|Closed-loop on day 1 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 1 after CGM sensor insertion.
11385957|NCT02129868|Active Comparator|Closed-loop on day 3 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 3 or 4 after CGM sensor insertion.
11385958|NCT02129842||Atrial Fibrillation|
11385959|NCT02129829||Observational Group|Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly
11385960|NCT02129829||Treatment Group (Tenofovir disoproxil)|Patients who meet EASL treatment criteria who receive Tenofovir disoproxil
11385961|NCT02129816|Active Comparator|Bryophyllum|50% in 350mg Lactose, 2-2-2
11385964|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
11385965|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
11385966|NCT02129790|Experimental|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A will include psychoeducation and coping strategies.
11385967|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
11385968|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
11385969|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
11385970|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
11385971|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
11385972|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
11385973|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
11385974|NCT02129764|Experimental|Prednisone|Prednisone will be given 30mg/day for 2 weeks and then tapered off.
11385975|NCT02129764|Active Comparator|Allopurinol|Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.
11385976|NCT02129751|Experimental|bupropion hydrobromide|study drug
11385977|NCT02129751|Placebo Comparator|placebo|placebo
11385978|NCT02129738|Experimental|LoFric|LoFric catheters
11385979|NCT02129725|Experimental|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
11385980|NCT02129725|Placebo Comparator|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
11385981|NCT02129712|Placebo Comparator|Non-adaptive cognitive training|Non-adaptive cognitive training
11385982|NCT02129712|Experimental|Adaptive cognitive triaining|Adaptive cognitive training
11385983|NCT02129699|Other|None, standard chemotherapy only|"4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.
~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
11385984|NCT02129699|Experimental|Standard chemotherapy + Denosumab|"4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.
~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
11385985|NCT02129686|Experimental|Immediate Acupuncture Group|"Immediate acupuncture arm will receive acupuncture 3 times per week during week 1 and week 2, then 2 times per week from week 2 to week 8 for a total of 18 sessions. The crossover will take place after 8th week.
~The immediate acupuncture arm will enter a follow-up phase without acupuncture for 8 weeks from week 9 to week 16, while the standard usual care will be provided."
11385986|NCT02129686|Active Comparator|Delayed Acupuncture Group|The patients on the usual care/delayed acupuncture arm will continue their standard usual care with their physicians and care team. The crossover will take place after 8th week. After crossover, the patients initially on the usual care/delayed acupuncture arm will receive the identical acupuncture protocol but a less frequent schedule from week 9 to week 16: 2 times per week at week 9, then 1 time per week from week 10 to week 16 for a total of 9 sessions
11385987|NCT02129673|Experimental|VS101 Insert Dose A|VS101 Insert Dose A placed under the conjunctiva
11385988|NCT02129673|Experimental|VS101 Insert Dose B|VS101 Insert Dose B placed under the conjunctiva
11385989|NCT02129673|Experimental|VS101 Insert Dose C|VS101 Insert Dose C placed under the conjunctiva
11385990|NCT02129673|Active Comparator|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
11385991|NCT02129660|Experimental|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
11385992|NCT02129660|Experimental|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
11385993|NCT02129660|Active Comparator|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
11385994|NCT02129660|Active Comparator|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
11385995|NCT02129660|Placebo Comparator|Vehicle|Vehicle Topical Wipes
11385996|NCT02129647|Experimental|Axitinib|5 mg axitinib orally twice daily, with increase to 7 mg orally twice daily and 10 mg orally twice daily after 2 and 4 weeks, respectively, provided no adverse reactions (i.e., not exceeding grade 2 toxicities) and normotensive and not receiving antihypertension medications. Axitinib will be given continuously in 28-day cycles until disease progression or unacceptable toxicity.
11385997|NCT02129634|Active Comparator|CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
11386026|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
11386027|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
11386028|NCT02129413|Experimental|Delta system treatment|
11385998|NCT02129634|Experimental|DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
11385999|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
11386000|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
11386001|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
11386002|NCT02129595|Active Comparator|resveratrol|resveratrol will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
11386003|NCT02129595|Placebo Comparator|placebo|A placebo will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
11386004|NCT02129582|Experimental|Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)|"CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.
~TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11."
11386005|NCT02129569|Experimental|Arm I (psychoeducational and behavioral interventions)|Participants meet with a nurse in-person for approximately 30 minutes to receive information about strategies for cognitive self-management of distress and an individualized walking prescription to gradually increase their walking to 30 minutes per day, 5 times per week. Participants wear a pedometer for at least 3 consecutive days during weeks 1, 6, and 12. Participants are also contacted by the nurse via telephone at 1 and 3 weeks for supplemental counseling support.
11386006|NCT02129569|Active Comparator|Arm II (control)|Participants meet with a nurse in-person for approximately 20 minutes to receive NCI educational booklets and a link to the ACS website. Participants are also contacted by the nurse via telephone at 1 and 3 weeks but the calls are primarily social in nature and do not include counseling support.
11386007|NCT02129556|Experimental|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.
~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.
~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
11386008|NCT02129543||Arm A: Treatment for Malignancy/Failure Group|Participants in this group will be those who are undergoing treatment for hematologic malignancy or bone marrow failure state.
11386009|NCT02129543||Arm B: Standard-of-Care SCT Group|Participants in this group will be cancer participants being treated with standard of care stem cell therapy
11386010|NCT02129543||Arm C: Adoptive T Cell Therapy Group|Participants in this group will be participants being treated with adoptive T cell therapy.
11386011|NCT02129543||Arm D: Control Group|Participants without cancer for studies of immunophenotype and immunologic function.
11386012|NCT02129530|Experimental|Community Social Mobilization Program|A manualized intervention developed with Sonke Gender Justice Network using a workshop intervention manual and a community mobilization toolkit will be used.
11386013|NCT02129530|No Intervention|Control Arm|The Control Arm does not receive the Community Mobilization Intervention
11386014|NCT02129517|Experimental|Arm I (IMPACT Intervention)|Oncology nurses watch tailored, web-based informational video clips addressing knowledge, attitudes, subjective norms, and perceived behavioral control (barriers of discussing clinical trials with patients). They also watch role-play video clips to help improve perceived behavioral control and address attitudinal barriers.
11386015|NCT02129517|Active Comparator|Arm II (online educational materials)|Oncology nurses view online clinical trials educational materials developed based upon NCI clinical trials educational materials for health care providers. The educational materials contain text and tables as presented on the NCI Website.
11386016|NCT02129504|Experimental|coronal advanced technique|root coverage with the porcine collagen matrix using the coronal advanced technique (standard technique)
11386017|NCT02129504|Experimental|extended flap technique|root coverage with the porcine collagen matrix using the extended flap technique (new surgical technique)
11386018|NCT02129491||Pediatric Stroke and Hemiplegia|Any infant or child with acute stroke or hemiplegia
11386019|NCT02129478|Experimental|Olanzapine|
11386020|NCT02129452||CDR (Clinical dementia rating) 0|10 participants complaining subjective memory problem and acquiring CDR 0
11386021|NCT02129452||CDR 0.5|10 participants complaining subjective memory problem and acquiring CDR 0.5
11386022|NCT02129452||CDR 1|10 participants with mild cognitive impairment and acquiring CDR 1
11386023|NCT02129452||CDR 2|10 participants with moderate to severe cognitive impairment and acquiring CDR 2
11386024|NCT02129439|Experimental|SB012|"SB012 will be available in this clinical trial in a concentration of 7.5 mg/ml hgd40 in 30ml PBS. The maximum daily dose will not exceed 225mg.
~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 12 of the 18 subjects will receive verum SB012 (in a 2:1 randomization SB012:Placebo)"
11386025|NCT02129439|Placebo Comparator|Placebo|"Placebo will be administered with an identical volume of 30ml PBS.
~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 6 of the 18 subjects will receive placebo (in a 2:1 randomization SB012:Placebo)"
11387079|NCT02122471|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
11386029|NCT02129400|Experimental|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
11386030|NCT02129400|Experimental|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
11386031|NCT02129400|Experimental|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
11386032|NCT02129400|Experimental|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
11386033|NCT02129400|Experimental|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
11386034|NCT02129400|Experimental|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
11386035|NCT02129400|Experimental|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
11386036|NCT02129400|Experimental|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
11386037|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
11386038|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
11386039|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
11386040|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
11386041|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
11386042|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
11386043|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
11386044|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
11386045|NCT02129374|Experimental|Direct repair of pars defect|The pars defect was repaired with 4.5mm cortical screw.
11386046|NCT02129374|No Intervention|Conservative treatment|The pars defect of spondylolysis was not repaired with cortical screw.
11386047|NCT02129361|Experimental|Adapted Screening and Brief Intervention|Adapted Screening and Brief Intervention: Participants will be screened for substance use, receive education regarding the effects of substance misuse, participate in a motivation interview, and participate in a booster session one month later
11386048|NCT02129361|Active Comparator|Screening & Education Attention Control|Screening & Education Attention Control: Participants will be screened for substance use, receive education regarding the effects of substance misuse, and participate in a booster session one month later
11386049|NCT02129348|Active Comparator|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).
~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
11386050|NCT02129348|Placebo Comparator|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).
~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
11386051|NCT02129335||stress|patient with glioblastoma diagnosis and partners
11386052|NCT02129322|Active Comparator|Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
11386053|NCT02129322|Experimental|S-1 and Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
11386054|NCT02129309|Experimental|Systemic Apelin infusion|"Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers
~Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures"
11386055|NCT02129309|Experimental|Apelin infusion - forearm|"Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.
~Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures."
11386056|NCT02129296|Active Comparator|hemiosphere® BALLOON|Balloon filled with air according to the manufacturing company orders 600 or 720 ml air
11386057|NCT02129296|Active Comparator|Fluid filled balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
11386058|NCT02129283|Experimental|Simulation training|End-of-life simulation training of critical care physicians and nurses using standardized patients to improve communication and interpersonal skills.
11386059|NCT02129283|No Intervention|Control|No simulation training
11386060|NCT02129270|Active Comparator|Lidocaine HCl 2%|Lidocaine HCl 2% (200mg/10ml) 10 ml.
11386061|NCT02129270|Experimental|Lidocaine HCl 1%|Lidocaine HCl 1% (100mg/10ml) 15-20 ml.
11386062|NCT02129257|Experimental|FOLFIRI-AFLIBERCEPT|Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen. Treatment will be repeated every 2 weeks. FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours. FOLFIRI administration will immediately follow the aflibercept one. In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
11386093|NCT02129023|Experimental|exergame|Participants were asked to use exergame (Xbox 360) half hour for three times per week in the 12-week study period.
11386094|NCT02129023|No Intervention|control|Participants were not asked to use exergames.
11386095|NCT02129010||Subarachnoid hemorrhage with and without Terson syndrome|Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome
11386063|NCT02129244|Active Comparator|NCM Plus Intervention|The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
11386064|NCT02129244|No Intervention|Standard/Usual Care|Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
11386065|NCT02129231|Placebo Comparator|placebo|calcined magnesia 100 mg tablets once a day for 16 weeks
11386066|NCT02129231|Active Comparator|ezetimibe/simvastatin|ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
11386067|NCT02129231|Active Comparator|rosuvastatin|rosuvastatin 20 mg tablets once a day for 16 weeks
11386068|NCT02129218|Experimental|Cohort 1: Low glycemic load with standard diet|Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.
11386069|NCT02129218|Experimental|Cohort 2: Low glycemic load with intensified diet|Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.
11386070|NCT02129218|Active Comparator|Cohort 3: Medium glycemic load with standard diet|Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.
11386071|NCT02129218|Active Comparator|Cohort 4: Medium glycemic load with intensified diet|Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.
11386072|NCT02129205|Experimental|PF-06650808|
11386073|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
11386074|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
11386075|NCT02129179|Experimental|GLP-1|
11386076|NCT02129166|Placebo Comparator|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
11386077|NCT02129166|Active Comparator|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.
~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
11386078|NCT02129153|Experimental|LIFT (Parent information)|"LIFT (Parent information): during their child's 7th and 8th grade years research staff will 1. communicate with parents about their child's academic and behavioral performance in school, roughly twice-monthly 2. invite parents to participate in a 2-hour parent support session to help teach parents to communicate better with their child and support better academic and behavioral performance in school
~students take a baseline survey then 3 surveys (one/year)
~parents take a baseline survey then 2 surveys (one/year)"
11386079|NCT02129153|No Intervention|Usual care group|"Usual care control group/No Intervention consists of neither communication of academic information to parents nor invitation to parent support sessions.
~students take a baseline survey then 3 surveys (one/year)
~parents take a baseline survey then 2 surveys (one/year)"
11386080|NCT02129140||Hernia graft/mesh|Hernia repair patients implanted with biologic hernia graft during surgery
11386081|NCT02129127|Experimental|Drug Coated Chocolate|Paclitaxel Coated Chocolate Balloon Angioplasty
11386082|NCT02129114|Experimental|ReDura Onlay|The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
11386083|NCT02129114|Active Comparator|DuraGen|Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
11386084|NCT02129101|Experimental|Treatment (azacitidine, sonidegib, decitabine)|"Patients receive azacitidine SC or IV on days 1-7, sonidegib PO QD on days 1-28 or 1-7* or decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: Sonidegib PO QD is given on days 1-7 if in combination with azacitidine or on days 1-28 is given if in combination with decitabine."
11386085|NCT02129088|Experimental|Cohort 1|Participants will receive esketamine 14 milligram (mg) as intranasal spray into each nostril on Day 1.
11386086|NCT02129088|Experimental|Cohort 2|All participants will receive esketamine 14 mg as intranasal spray into each nostril on Day 1 of Period 1 as Treatment A and esketamine 14 mg as intranasal spray followed by intranasal administration of placebo solution after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Period 2 as Treatment B in a fixed sequence.
11386087|NCT02129075|Experimental|Arm I (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on days 1 and 2; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11386088|NCT02129075|Active Comparator|Arm II (CDX-1401 and poly-ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11386089|NCT02129075|Experimental|Arm III (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -3 and 22-26 of course 1 only and DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11386090|NCT02129075|Experimental|Arm IV (CDX-301, CDX-1401, and poly-ICLC)|Patients receive recombinant flt3 ligand SC on days -7 to -3 of course 1 only, and DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11386091|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11386092|NCT02129049|Experimental|Supportive care (Enhancing Connections Telephone Program)|See Detailed Description.
11386096|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
11386097|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
11386098|NCT02128984|Experimental|Vitafos Junior|Symbiotic Formula with DHA and antioxidants
11386099|NCT02128984|Active Comparator|Standard Formula|Standard isocaloric and isonitrogenous formula.
11386100|NCT02128971|Active Comparator|Ferrochel® 90 mg|Ferrochel® capsule 90 mg OD for 30 days
11386101|NCT02128971|Active Comparator|Sumalate® 90 mg|Sumalate® capsule 90 mg OD for 30 days
11386102|NCT02128971|Active Comparator|Ferrous Fumarate 90 mg|Ferrous Fumarate capsule 90 mg OD for 30 days
11386103|NCT02128971|Active Comparator|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg OD for 30 days
11386104|NCT02128971|Active Comparator|Ferric glycinate 90 mg|Ferric glycinate capsule 90 mg OD for 30 days
11386105|NCT02128971|Active Comparator|Placebo|Placebo capsule OD for 30 days
11386106|NCT02128958|Experimental|CF102|orally q12h
11386107|NCT02128958|Placebo Comparator|Placebo tablets of CF102|orally q12h
11386108|NCT02128945|Experimental|FLUDATEP|[18F] - Fludarabine PET/CT
11386109|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
11386110|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
11386111|NCT02128932|Active Comparator|Insulin glargine|
11386112|NCT02128919|Experimental|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
11386113|NCT02128919|Sham Comparator|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
11386114|NCT02128906|Active Comparator|Cisplatin-IMRT|Cisplatin 40 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
11386115|NCT02128906|Active Comparator|Docetaxel-Cetuximab-IMRT|Docetaxel 15 mg/m2 weekly x 7; Cetuximab 400 mg/m2 load, one week prior to IMRT; Cetuximab 250 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
11386116|NCT02128893|Experimental|Isavuconazole alone|Isavuconazole three times a day on Days 1 and 2 and once a day on Days 3, 4, and 5
11386117|NCT02128893|Experimental|Isavuconazole and Esomeprazole|Esomeprazole daily for 10 days starting on Day 1 and isavuconazole three times a day on Days 6 and 7 and once a day on Days 8, 9, and 10
11386118|NCT02128880|Experimental|CARRII|CARRII: This is a highly interactive Internet intervention consisting of 6 Cores of Intervention material, including Core 1, Overview, Core 2: Your Risk for AEP, Core 3: Drinking, Core 4: Contraception, Core 5: Thoughts and Decisions, and Core 6: Commit to It.
11386119|NCT02128880|Active Comparator|Patient Education|CARRII Education: This is a static website containing educational information on the following topics: What is Alcohol Exposed Pregnancy (AEP)?, Fetal Alcohol Spectrum Disorders, Impact of AEP, Prevalence of AEP, Causes and Prevention of AEP, Treatment for AEP, and Links to related information.
11386120|NCT02128867|Experimental|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
11386121|NCT02128867|Experimental|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
11386122|NCT02128867|Experimental|bouncing|bouncing . intervention to relax the infant
11386123|NCT02128854|Experimental|Tablets Intervention|Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
11386124|NCT02128854|No Intervention|Usual Care|Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician. The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care. Between scheduled office encounters, contact will be initiated by the individual.
11386125|NCT02128841|Experimental|All patients|CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
11386126|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
11386127|NCT02128815|Experimental|Coaching|diabetes health coaching + usual diabetes self-management education
11386128|NCT02128815|No Intervention|Usual Care|Usual care or self-management education
11386129|NCT02128802|Experimental|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
11386130|NCT02128802|Experimental|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
11386131|NCT02128789|No Intervention|Control Condition|Subjects receive usual care and support. No study intervention provided
11386132|NCT02128789|Experimental|Elder Tree Condition|Elder Tree website. Subjects receive usual care, support and access to the study intervention website.
11386133|NCT02128776|Active Comparator|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
11386134|NCT02128776|Active Comparator|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
11386135|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
11386136|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
11386137|NCT02128750|Experimental|revascularization group|Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.
11386138|NCT02128737|No Intervention|Control|10 hours time-in-bed all nights of study
11386139|NCT02128737|Experimental|1 Recovery Night|2 baseline nights, five nights sleep restriction, 1 recovery night, five nights sleep restriction, 4 recovery nights
11386140|NCT02128737|Experimental|3 Recovery Nights|2 baseline nights, five nights sleep restriction, 3 recovery nights, five nights sleep restriction, 2 recovery nights
11386141|NCT02128737|Experimental|5 Recovery Nights|2 baseline nights, five nights sleep restriction, 5 recovery nights, five nights sleep restriction, 1 recovery nights
11386350|NCT02127268|Active Comparator|Arm T|Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
11386142|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
11386143|NCT02128698|Experimental|Protein and computer-assisted exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
11386144|NCT02128698|Placebo Comparator|Placebo and computer-assisted exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
11386145|NCT02128698|Active Comparator|Protein and usual exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
11386146|NCT02128698|Active Comparator|Placebo and usual exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
11386147|NCT02128685|Active Comparator|Dydrogesterone|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
11386148|NCT02128685|Placebo Comparator|Placebo pill|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
11386149|NCT02128672|Active Comparator|Conventional SCS lead|Conventional Thoracic-lumbar SCS lead placement
11386150|NCT02128672|Experimental|SCS Experimental Lead Placement|Experimental SCS lead placement in a novel position
11386151|NCT02128659|Experimental|SHE Project|Receives SHE Project Intervention during Week 1 of enrollment
11386152|NCT02128659|Active Comparator|Wait-List Control|Receive SHE Project intervention during Week 2 of Enrollment
11386153|NCT02128646|Experimental|Treatment Group 1|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 1 will have an open surgery for abdominal hernia repair.
11386154|NCT02128646|Experimental|Treatment Group 2|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 2 will have a laparoscopic abdominal hernia repair.
11386155|NCT02128646|Active Comparator|Control Group 1|Patients scheduled in Control Group 1 will have an open surgery for abdominal hernia repair. The Control Group patients will receive traditional treatment.
11386156|NCT02128646|Active Comparator|Control Group 2|Patients scheduled in Control Group 2 will have laparoscopic abdominal hernia repair. The Control Group patients will receive traditional treatment.
11386157|NCT02128633|Placebo Comparator|placebo|"Individuals that were randomized for treatment  A  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  A  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Placebo gel)."
11386158|NCT02128633|Experimental|Experimental gel|"Individuals that were randomized for treatment  B  - The product was delivered in a transparent plastic syringe with 10 mls identified by the letter  B . The syringes were given to individuals in an opaque plastic envelope sealed and with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% ) ."
11386159|NCT02128633|Active Comparator|Positive control|"Individuals that were randomized for treatment  C  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  C  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Fluoride neutral NaF gel 2 %)."
11386160|NCT02128620|No Intervention|Control Group|Users randomized to the www.sjekkdeg.no A version, consisting en the educative web app, not including the Game-Based Appointment System
11386161|NCT02128620|Experimental|Intervention Group|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
11386162|NCT02128607|Active Comparator|Real SNAG|A real sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
11386163|NCT02128607|Placebo Comparator|Sham SNAG|A sham (placebo) sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
11386164|NCT02128594|Experimental|Standard of Care|Standard of care
11386165|NCT02128581|Placebo Comparator|Saline|a saline infusion will be started and maintained till the end of the study at 1300 (300 minutes).
11386166|NCT02128581|Active Comparator|Exendin-9,39 @ 300|Exendin-9,39 @ 300pmol/kg/min
11386167|NCT02128581|Active Comparator|Exendin-9,39 @ 750|Exendin-9,39 @ 750pmol/kg/min
11386168|NCT02128568|Active Comparator|Waitlist + YRI only|Participants will complete the assessment and collection of biomarkers and be placed on a waitlist. Once the trial of the first arm has been concluded, participants complete another round of assessments and are offered the YRI sessions. The epigenetic biomarkers collected will be compared with the experimental arm.
11386169|NCT02128568|Experimental|YRI only|Immediately following assessment and collection of biomarkers, participants will be offered the YRI sessions.
11386170|NCT02128555|Active Comparator|Arthrodesis|Ankle arthrodesis (fusion)
11386171|NCT02128555|Experimental|Total Ankle Replacement|Total Ankle Replacement
11386172|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
11386173|NCT02128529||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
11386174|NCT02128516|Active Comparator|whey protein|whey protein
11386175|NCT02128516|Placebo Comparator|placebo|placebo
11386176|NCT02128516|Experimental|pea protein|pea protein
11386177|NCT02128503|Other|HBV DNA level monitoring|Group with HBV DNV level being monitored regularly
11386178|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11386179|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11386180|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11386181|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11386182|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
11386183|NCT02128464|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
11386184|NCT02128464|Active Comparator|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
11386185|NCT02128451|Active Comparator|Meperdine group|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
11386186|NCT02128451|Active Comparator|Fentanyl group|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
11386187|NCT02128425|Experimental|FOLFOXIRI|FOLFOXIRI
11386188|NCT02128425|Active Comparator|FOLFOX|FOLFOX
11386189|NCT02128412|Active Comparator|Stent oversize group|"Oversized stent deployed at low pressure:
~A stent premounted on a balloon with a nominal diameter halfway between the lumen diameter and the true vessel diameter (approximated by external elastic lamina) as assessed by IVUS. This will be based on the smallest of the vessel reference diameters proximal and distal to the lesion. In addition the vessel diameter must be greater than this diameter throughout the length of the lesion. This stent will be implanted at an inflation pressure of 10 atmospheres or less for at least 15 seconds and a second IVUS will be performed to assess the end point."
11386190|NCT02128412|Active Comparator|High pressure group|"Stent deployed at high pressure:
~A stent premounted on a balloon with a nominal diameter approximately equal to the vessel segment lumen reference diameter as previously assessed by IVUS will be used. This stent will be implanted at an inflation pressure of 14 atmospheres or more for at least 15 seconds and a second IVUS will be performed to assess the end point"
11386191|NCT02128399||patients before and after intervetion|
11386192|NCT02128386||Renal sympathetic denervation|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus renal sympathetic denervation
11386193|NCT02128386||Intensified antihypertensive treatment|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus second-line antihypertensive agents (e.g. mineralocorticoid receptor antagonists or alpha-1-blockers)
11386194|NCT02128373|Active Comparator|Arm I (usual care)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
11386195|NCT02128373|Experimental|Arm II (usual care with CLOSER intervention)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention
11386260|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
11386196|NCT02128360|Active Comparator|Minimal stimulation protocol|Low dose Letrozole 2.5 mg over 5 days, starting from cycle day 2, overlapping with low dose gonadotropins, starting from day 3 of the Letrozole at 150 units per day. GnRH antagonist to avoid premature LH surge will be introduced when one or more of the growing follicles reached approximately 14 mm in size
11386197|NCT02128360|Active Comparator|High dose protocol|High dose of gonadotropins (≥300 IU/day) starting from cycle day 3. GnRH antagonist will be introduced to avoid premature LH surge when one or more of the growing follicles will reach approximately 14 mm in size
11386198|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and healthcare workers to communicate through a secure, password protected online portal with data transfer capabilities. Effectiveness of the portal in improving several health outcomes from baseline-12 months will be assessed in this study.
11386199|NCT02128334||Patients with advanced prostate carcinoma|
11386200|NCT02128321|Experimental|Isavuconazole + Repaglinide + Caffeine|Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16
11386201|NCT02128308|Experimental|Levofloxacin and Streptomycin added|Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
11386202|NCT02128308|Experimental|Moxifloxacin and Kanamycin added|Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
11386203|NCT02128295|Experimental|Primiparous mothers|Mother who are primiparous
11386204|NCT02128295|Experimental|Multiparous mothers|Mothers who are multiparous
11386205|NCT02128282|Experimental|Escalation CX-4945 plus Cis/Gem|"CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9.
~PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle."
11386206|NCT02128282|Active Comparator|Cisplatin plus Gemcitabine|Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
11386207|NCT02128282|Experimental|10-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9). PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
11386208|NCT02128282|Experimental|21-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 21-day continuous dosing PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
11386209|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
11386210|NCT02128256|Experimental|Cerament G injection|Cerament G is injected to fill a bone defect after debridement of the infected bone.
11386211|NCT02128243|Experimental|Arm A: De-escalation therapy|Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated.
11386212|NCT02128243|Experimental|Arm B: Chemotherapy by Investigator's choice|Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first.
11386213|NCT02128230|Experimental|Study Treatment|
11386214|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
11386215|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
11386216|NCT02128204|Experimental|HYADERMIS LA Facial Dermal Implant|Subjects will be randomly assigned to receive experiment treatment, lidocaine contained hyaluronate facial dermal filler, in one side of the face.
11386217|NCT02128204|Active Comparator|Hya-Dermis Facial Dermal Implant|Subjects will be randomly assigned to receive control treatment, hyaluronate facial dermal filler, in one side of the face.
11386218|NCT02128191|Active Comparator|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later
11386219|NCT02128191|Placebo Comparator|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
11386220|NCT02128178|Active Comparator|ENOXAPARIN 2 HOURS BEFORE|Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
11386221|NCT02128178|Active Comparator|Enoxaparin 40 mg 12 hours before|Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
11386222|NCT02128165|Active Comparator|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
11386223|NCT02128165|Active Comparator|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere)those BMI below 45
11386224|NCT02128152|Experimental|Ekso Training Safety and Efficacy|
11386225|NCT02128126|Experimental|ISA101/ISA101b|The maximum total treatment duration for a patient is six cycles (1 cycle is 21 days) for a total of 18 weeks. On day 15 of cycles 2, 3 and 4 patients are to receive the vaccination scheme of ISA101/ISA101b. Patients will be vaccinated with a fixed dose of ISA101/ISA101b every three weeks for a total of three rounds of vaccination. Four dose levels of ISA101 have been tested. ISA101b will be tested in bridging cohorts.
11386226|NCT02128113|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days
11386227|NCT02128113|Experimental|0.5% omaveloxolone (RTA 408) opthalmic suspension|0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
11386228|NCT02128113|Experimental|1% omaveloxolone (RTA 408) opthalmic suspension|1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
11386261|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
11386229|NCT02128100|Experimental|Folririnox with SBRT|"Folfirinox
~Oxaliplatin 85 mg/m² for over 2 hours,
~Leucovorin 400n mg/m² for over 2 hours,
~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion
~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes
~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
~SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment."
11386230|NCT02128087|No Intervention|Control group|This study arm will receive care as usual.
11386231|NCT02128087|Experimental|Two-way SMS intervention group|"Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages (We hope you are feeling well today. Reply 1 if well, 2 if unwell) to request a follow-up call from the clinic."
11386232|NCT02128087|Experimental|One-way SMS intervention group|"Clients will receive a weekly one-way SMS with the message We hope you are feeling well today. There will be no prompt for response."
11386233|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
11386234|NCT02128061|Active Comparator|R-miniCHOP|"All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² Day 1 (D1) DOXORUBICINE IV : 25 mg/m² D1 VINCRISTINE IV : 1 mg Total Dose (TD) D1 PREDNISONE PO : 40 mg/m² D1 to D5 RITUXIMAB SC* : 1400 mg TD D1
~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
11386235|NCT02128061|Experimental|R2-miniCHOP|"All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14
~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
11386236|NCT02128048||Heavy smokers|Assessment of body composition and muscle function
11386237|NCT02128035|No Intervention|Without Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.
~The LEAD SHIELD will not be used in this group.
~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
11386238|NCT02128035|Experimental|With Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.
~In this group, a LEAD SHIELD will be used. The Pelvic lead shield will be draped on patient from umbilicus to knees.
~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
11386239|NCT02128022|Experimental|GLP-1 (7-36) amide and Glibenclamide|Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
11386240|NCT02128022|Experimental|Glibenclamide alone|Glibenclamide 5 mg orally prior to PCI
11386241|NCT02128022|Active Comparator|GLP-1 (7-36) amide|GLP-1 (7-36) amide
11386242|NCT02128022|No Intervention|Saline control|0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)
11386243|NCT02128009||osteoporosis,non-osteoporosis|
11386244|NCT02127996|Placebo Comparator|Normal Saline|Infusion of Normal Saline during Percutaneous Coronary Intervention
11386245|NCT02127996|Experimental|GLP-1|Infusion of GLP-1 (7-36) amide during elective percutaneous coronary intervention
11386246|NCT02127983|Experimental|Early intervention|Early intervention arm engaging informal providers Received the intervention early in the first 12 months
11386247|NCT02127983|Active Comparator|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
11386248|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
11386249|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
11386250|NCT02127957|Other|Exercise|Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
11386251|NCT02127957|No Intervention|Control|Control group will have 4 visit and 3 phone call. They will receive standard counselling for exercise in cystic fibrosis, but no prescribed exercice will be given.
11386252|NCT02127944||FERTILE GROUP|WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD
11386253|NCT02127944||UNEXPLAINED INFERTILE GROUP|WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN
11386254|NCT02127931|Experimental|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
11386255|NCT02127931|Active Comparator|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
11386256|NCT02127918||ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
11386257|NCT02127905|Other|CD34+ selected cells|use of unrelated bone marrow or peripheral blood for hematopoietic stem cell transplantation with CD34+ selected cells
11386258|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
11386259|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
11386262|NCT02127879|Experimental|Transcranial Magnetic Stimulation|Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
11386263|NCT02127879|Sham Comparator|Transcranial Magnetic Stimulation with sham coil|Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
11386264|NCT02127866|Experimental|CHF 5259 25 µg plus Foster 100/6 µg|
11386265|NCT02127866|Experimental|CHF 5259 50 µg plus Foster 100/6 µg|
11386266|NCT02127866|Experimental|CHF 5259 100 µg plus Foster 100/6 µg|
11386267|NCT02127866|Active Comparator|Foster 100/6 µg|
11386268|NCT02127853|Experimental|Gabapentin|gabapentin pretreatment
11386269|NCT02127853|Placebo Comparator|Placebo|placebo drug pretreatment
11386270|NCT02127840|Experimental|Synacthen|Synacthen infusion during adrenal venous sampling
11386271|NCT02127840|No Intervention|Without Synacthen|Adrenal venous sampling without Synacthen
11386272|NCT02127827|Experimental|investigational device off|
11386273|NCT02127814|Experimental|L. reuteri|
11386274|NCT02127814|Placebo Comparator|Identical Placebo|
11386275|NCT02127801|Experimental|Group A|Participants in group A will receive REGN1908-1909
11386276|NCT02127801|Experimental|Group B|Participants in group B will receive placebo
11386277|NCT02127788||Micafungin|Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.
11386278|NCT02127775|Experimental|Sequence B|Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)
11386279|NCT02127775|Experimental|Sequence A|Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)
11386280|NCT02127762|Experimental|Mindfulness Based Stress Reduction|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
11386281|NCT02127762|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
11386282|NCT02127749|Experimental|Control|Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
11386283|NCT02127749|Experimental|Antibiotics|Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
11386284|NCT02127736|Experimental|Experimental group|
11386285|NCT02127736|Placebo Comparator|Control group|
11386286|NCT02127723|Experimental|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
11386287|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
11386288|NCT02127697|Experimental|NVA237|Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
11386289|NCT02127697|Placebo Comparator|Placebo|Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
11386290|NCT02127684|Active Comparator|Standard Dosing Group|Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6). After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score <83
11386291|NCT02127684|Experimental|Frequent dosing group|Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab. Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity
11386292|NCT02127671|Experimental|IDEAL intervention|Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
11386293|NCT02127671|Other|Control|All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
11386294|NCT02127658|Active Comparator|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
11386295|NCT02127658|Active Comparator|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
11386296|NCT02127645|Experimental|Early Rectal Cancer|patients with T1 - T2, N0, G1-2 rectal cancer
11386297|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
11386298|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
11386299|NCT02127606|Experimental|Vibration with tilt-table standing|Participants in this arm will undergo alternating side-to-side, whole body vibration while standing on a tilt table for multiple treatments for a total of approximately 14 minutes for 3 sessions over 3 different days
11386300|NCT02127593|Experimental|First NGM/EE (Wet Process), then NGM/EE (Dry Process)|Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
11386349|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
11386351|NCT02127268|No Intervention|Arm B|With best support according to NCCN Guideline
11386301|NCT02127593|Experimental|First NGM/EE (Dry Process), then NGM/EE (Wet Process)|Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
11386302|NCT02127580||with BAV|Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
11386303|NCT02127580||without BAV|Patients undergoing TA-TAVI WITHOUT predilation of the AV
11386304|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
11386305|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
11386306|NCT02127554||Electric coagulation|Patients with anterior epistaxis, treated with electric coagulation
11386307|NCT02127554||Chemical coagulation|Patients with anterior epistaxis, treated with chemical coagulation
11386308|NCT02127554||Outpatient tamponade|Patients with posterior epistaxis, treated with tamponade as an outpatient
11386309|NCT02127554||Inpatient tamponade|Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
11386310|NCT02127554||Surgery|Patients with posterior epistaxis, treated with surgery as inpatients
11386311|NCT02127554||Foley balloon catheter|Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
11386312|NCT02127554||Combined treatment|Patients with posterior epistaxis, treated as inpatients with a combination of methods
11386313|NCT02127541|Experimental|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.
11386314|NCT02127515|Experimental|Non Invasive Prenatal Testing|Blood sample
11386315|NCT02127515|Active Comparator|Invasive Prenatal Testing|CVS or amniocentesis
11386316|NCT02127502||Critically ill patients sepsis suspected|
11386317|NCT02127489|Active Comparator|Midazolam|1 mL/kg bupivacaine 0.25%.
11386318|NCT02127489|Placebo Comparator|saline|5mL rectal saline
11386319|NCT02127476|Experimental|KHK6640|KHK6640
11386320|NCT02127476|Placebo Comparator|Placebo|Placebo
11386321|NCT02127463|Experimental|MC-1101 active|Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
11386322|NCT02127463|Placebo Comparator|MC-1101 Vehicle Control|"Topical Drug:
~Ophthalmic Solution Topically, two times per day; morning and bedtime"
11386323|NCT02127450||Case: NS-CARB positive|Patient with a clinical sample positive for a NS-CARB Enterobacteriaceae
11386324|NCT02127450||Control 1: non-NS-CARB positive|Patient with clinical sample positive for a non-NS-CARB Enterobacteriaceae
11386325|NCT02127450||Control 2 : negative sample|Patient having had clinical sample(s) being stayed negative since the beginning of his admission and up to 3 days after the detection of the case
11386326|NCT02127437|Experimental|A - treated group|
11386327|NCT02127437|Placebo Comparator|B - control group|
11386328|NCT02127424|Experimental|Combination of the nurse-driven HIV targeted screening and the|Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
11386329|NCT02127424|Active Comparator|Current practice (no intervention)|Physician-directed HIV diagnostic testing
11386330|NCT02127411|Experimental|Mindfulness-based relapse prevention|Mindfulness-Based Relapse Prevention
11386331|NCT02127411|No Intervention|Waitlist|this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
11386332|NCT02127398|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
11386333|NCT02127385||IUGR|
11386334|NCT02127359||Lung/Colon Adenocarcinomas|Metastatic lung and colon adenocarcinomas
11386335|NCT02127346||Chronic Periodontitis|"Male patients
~Patients are suffering from chronic periodontitis
~Patients do not have any systemic diseases
~Subjects should have 20 teeth at least
~Age: 30 years or greater"
11386336|NCT02127346||Healthy Volunteers|"Males
~Healthy with no systemic diseases or periodontitis
~30 years old at least
~20 teeth are present at least"
11386337|NCT02127333||CAD patients with COPD|
11386338|NCT02127333||CAD patients without COPD|
11386339|NCT02127333||healthy volunteers|
11386340|NCT02127320|Experimental|Sequence 1|Rosuvastatin 20mg → Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg
11386341|NCT02127320|Experimental|Sequence 2|Rosuvastatin 20mg and Ezetimibe 10mg→ Rosuvastatin 20mg → Ezetimibe 10mg
11386342|NCT02127320|Experimental|Sequence 3|Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg → Rosuvastatin 20mg
11386343|NCT02127320|Experimental|Sequence 4|Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg → Rosuvastatin 20mg
11386344|NCT02127320|Experimental|Sequence 5|Ezetimibe 10mg → Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg
11386345|NCT02127320|Experimental|Sequence 6|Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg
11386346|NCT02127294|Experimental|Transcatheter closure group|Migraine patients with patent foreman ovale (PFO)，who meet the criteria and agree to conduct closure of patent foramen ovale will be selected to this group.
11386347|NCT02127294|No Intervention|Contrast group|Migraine patients with PFO，who meet the criteria but don't agree to conduct closure of patent foramen ovale will be selected to this group.
11386348|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
11386352|NCT02127255|Active Comparator|A (Acupuncturist 1)|Manual acupuncture implemented by acupuncturist 1 (clinical experience >15 years)
11386353|NCT02127255|Active Comparator|B (Acupuncturist 2)|Manual acupuncture implemented by acupuncturist 2 (clinical experience < 5 years)
11386354|NCT02127242|Experimental|air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
11386355|NCT02127242|No Intervention|hepatectomy group|Hepatic resection using an open approach is performed for all segments affected by biliary stenosis and the affected bile duct drainage area.Hepaticojejunostomy is performed in patients with common bile duct stenosis and in those considered to be at high risk for recurrence.
11386356|NCT02127229|No Intervention|Blinded observation of ERCP|Blind observation of disposable accessories use.
11386357|NCT02127229|Experimental|Endoscopist informed of cost per procedure|Endoscopists informed following each ERCP.
11386358|NCT02127216|No Intervention|Standard of Care Group - A|The control group
11386359|NCT02127216|Active Comparator|MOSES - Group B|Individual patients using application and pedometer without healthcare provider support
11386360|NCT02127216|Active Comparator|MOSES - Group C|Individual patients using application and pedometer with healthcare provider support
11386361|NCT02127216|Active Comparator|MOSES - Group D|Peer patient teams using application and pedometer without healthcare provider support
11386362|NCT02127216|Active Comparator|MOSES - Group E|Peer patient teams using application and pedometer with healthcare provider support
11386363|NCT02127203||Chronic Periodontitis group (ChP)|20 patients aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
11386364|NCT02127203||Resistant Control group (R)|20 age-sex matched patients who are > 45 years exhibit no signs of periodontal disease as determined by the absence of the evidence of interproximal (CAL ≤ 1mm), PD > 3 mm at any site, whole-mouth bleeding scores <10% and have no clinical signs of gingival inflammation .
11386365|NCT02127203||Aggressive Periodontitis group (AgP)|20 patients who are aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
11386366|NCT02127203||Young Control group (YC)|20 age- and sex matched patients who are < 35 years and exhibit no signs of periodontal disease.
11386367|NCT02127190|Placebo Comparator|CXA-10 placebo emulsion|single intravenous dose of CXA 10 placebo emulsion
11386368|NCT02127190|Experimental|CXA-10 Emulsion|single ascending intravenous doses of CXA-10 emulsion
11386369|NCT02127177|Experimental|Cpap|
11386370|NCT02127177|No Intervention|No Cpap|
11386371|NCT02127164|Experimental|"Veraflo device, Dakin's solution"|
11386372|NCT02127151|Experimental|BMN 673|BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
11386373|NCT02127138|Experimental|ATP technique|This arm plan to enroll 158 subjects，Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of unprotected distal left main bifurcation lesions.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
11386374|NCT02127138|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects.Sirolimus-eluting Drug stent implantation via Provisional T Stenting technique in the treatment of unprotected distal left main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
11386375|NCT02127125|Placebo Comparator|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
11386376|NCT02127125|Placebo Comparator|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
11386377|NCT02127125|Placebo Comparator|Lean with NGT -Placebo|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
11386378|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
11386379|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
11386380|NCT02127125|Active Comparator|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
11386381|NCT02127125|Active Comparator|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
11386382|NCT02127125|Active Comparator|Lean with NGT - Synbiotic|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
11386383|NCT02127125|Active Comparator|Lean with NGT - Sevelamer|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
11386384|NCT02127112|Active Comparator|Block Allograft plus Matrix Allograft|The positive control treatment will include a block allograft plus a demineralized bone matrix moldable allograft.
11386385|NCT02127112|Experimental|Moldable Matrix Allograft|In the test arm of the study the treatment will include a demineralized bone matrix moldable allograft.
11386386|NCT02127099||Patients with OSA|Post operative patients with OSA
11386387|NCT02127099||Post-operative Patients without OSA|All post operative patients without OSA
11386429|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
11386388|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
11386389|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
11386390|NCT02127073|Experimental|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
11386391|NCT02127060|Experimental|Vitamin C|in postoperative time, vitamin C administered orally with other pain analgesics.
11386392|NCT02127060|Placebo Comparator|Placebo drug|in postoperative time, vitamin C do not administered.
11386393|NCT02127047|Experimental|Sitagliptin|Patients receive Sitagliptin (100mg/d) without further intervention
11386394|NCT02127047|Experimental|Sitagliptin and exercise|Patients receive sitagliptin (100mg/d) and follow a physical training intervention program
11386395|NCT02127034|Experimental|Digoxin / digoxin + solifenacin and mirabegron|Digoxin alone then followed by digoxin with solifenacin and mirabegron
11386396|NCT02127034|Experimental|Digoxin + solifenacin and mirabegron / digoxin|Digoxin with solifenacin and mirabegron then followed by digoxin alone
11386397|NCT02127021|Experimental|Norzyme® 40000 IU|Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
11386398|NCT02127021|Placebo Comparator|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount
11386399|NCT02127008|Experimental|Resection of epidural fat|During surgical procedure, epidural fat was resected fully.
11386400|NCT02127008|Active Comparator|No resection of epidural fat|During surgical procedure, the epidural fat was not resected.
11386401|NCT02126995|Experimental|Metadoxine Immediate/Slow-release|Flexed and fixed-dose Metadoxine Immediate/Slow-release 700 mg and 1400 mg administered orally once daily
11386402|NCT02126995|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product. Administered orally once daily
11386403|NCT02126982||Clopidogrel hydrogen sulfate (CHS)|Clopidogrel hydrogen sulfate, 75 mg / day
11386404|NCT02126982||Clopidogrel Besylate (CB)|Clopidogrel Besylate , 75 mg / day
11386405|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
11386406|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
11386407|NCT02126956|Experimental|ACT-128800|Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)
11386408|NCT02126943||Opsumit (macitentan)|10 mg tablets
11386409|NCT02126930|Active Comparator|Routine care|"The patients in this receive routine care.
~Intervention: Routine care"
11386410|NCT02126930|Experimental|Pharma consult|"The patients in this arm will have a pharmaceutical consult upon hospital discharge.
~Intervention: Pharma consult"
11386411|NCT02126917|Experimental|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
11386412|NCT02126917|Experimental|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
11386413|NCT02126917|Experimental|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
11386414|NCT02126904||IVR group|
11386415|NCT02126891|Experimental|Canoeists|13 canoeists from a training center of the French canoeing team
11386416|NCT02126891|Experimental|Military|10 young recruits in military school of officers in ground forces of the French army
11386417|NCT02126878|Active Comparator|Kenaglog 20mg|20mg/ 2ml and local anesthetic
11386418|NCT02126878|Active Comparator|Kenalog 40mg|40mg/ 2ml with local anesthetic
11386419|NCT02126878|Active Comparator|Kenalog 80mg|80mg/ 2ml and local anesthetic
11386420|NCT02126865|Experimental|BI 1060469 Healthy|Multiple rising dose qd for 15 days
11386421|NCT02126865|Placebo Comparator|Placebo to BI 1060469|Matching placebo as tablet for 15 days
11386422|NCT02126865|Experimental|BI 1060469 asthmatics|Multiple rising dose qd for 29 days
11386423|NCT02126865|Placebo Comparator|Placebo to BI 1060469 asthmatics|Matching placebo as tablet for 29 days
11386424|NCT02126852|Experimental|AMG (one-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
11386425|NCT02126852|Experimental|AMG (three-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
11386426|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
11386427|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
11386428|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
11386430|NCT02126813|Active Comparator|500 ml.|A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
11386431|NCT02126813|Experimental|800 ml|A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
11386432|NCT02126787|Experimental|Intensive Group Analytic Psychotherapy|Intensive Group Analytic Psychotherapy in a day clinic setting
11386433|NCT02126787|Experimental|Intensive GCBT|Intensive transdiagnostic cognitive-behavioral group therapy in a day clinic setting
11386434|NCT02126787|No Intervention|Wait-list control group|
11386435|NCT02126774||focal epilepsy|observational study
11386436|NCT02126761|Active Comparator|Group 1|aTIV
11386437|NCT02126761|Experimental|Group 2|aTIV + 1X MF59
11386438|NCT02126761|Experimental|Group 3|aTIV + TIV
11386439|NCT02126761|Experimental|Group 4|aTIV + aTIV
11386440|NCT02126761|Active Comparator|Group 5|aTIV (Left deltoid) Saline (Right deltoid)
11386441|NCT02126761|Experimental|Group 6|aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)
11386442|NCT02126761|Experimental|Group 7|aTIV (Left deltoid) aTIV (Right deltoid)
11386443|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
11386444|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
11386445|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
11386446|NCT02126722||Patients with dyspepsia on PPI|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
11386447|NCT02126722||Patients with dyspepsia not on PPI|Fifty patients not on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
11386448|NCT02126709|Experimental|Treatment Arm|"Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%
~Application of study cream twice a day during the 8 week study period
~It will be applied once in the morning and once in the night
~We recommend the application to occur after the face is washed
~One Finger Tip Unit is required per application to the entire face
~The gel should be left on and not washed of for at least15 -30 minutes"
11386449|NCT02126709|Placebo Comparator|Placebo Arm|"Name: Neutrogena hydroboost gel Active ingredient: NA Strength: NA Dosage form: Water gel Administration route: Topical
~Application of placebo cream twice a day during the 8 week study period
~It will be applied once in the morning and once in the night
~We recommend the application to occur after the face is washed
~One Finger Tip Unit is required per application to the entire face
~The gel should be left on and not washed of for at least15 -30 minutes"
11386450|NCT02126696||Patients on anti-retroviral therapy|The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study.
11386451|NCT02126683|Experimental|Plaquenil first|Start Plaquenil 200mg BID orally since enrollment Duration: 6 months
11386452|NCT02126683|Experimental|Plaquenil later|Start Plaquenil 200mg BID orally since the 25th week after enrollment Duration: 6 months
11386453|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
11386454|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
11386455|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
11386456|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
11386457|NCT02126657|Other|Single Arm|Single arm study - pre and post peel assessment
11386458|NCT02126644|Other|Single Arm|Single arm of 10 patients - efficacy and safety assessed pre and post peel
11386459|NCT02126618||women with lower urinary tract symptoms|
11386460|NCT02126592||PCOS cohort|Women with PCOS
11386461|NCT02126592||Control cohort|Women without PCOS
11386462|NCT02126579|Experimental|Arm A (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386463|NCT02126579|Experimental|Arm B (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386464|NCT02126579|Experimental|Arm C (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after the vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386465|NCT02126579|Experimental|Arm D (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386466|NCT02126579|Experimental|Arm E (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386467|NCT02126579|Experimental|Arm F (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386468|NCT02126579|Experimental|Arm G(Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Resiquimod will be applied to the vaccine site immediately after vaccine administration.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386469|NCT02126579|Experimental|Arm E2|"Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.
~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
11386470|NCT02126566|Experimental|Single Arm|Administration of light therapy - measurement of results before and after therapy
11386471|NCT02126553|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
11386472|NCT02126540|Experimental|Primary Cohort|Main cohort; treatment Arm with Pantheris Atherectomy System
11386473|NCT02126527|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11386474|NCT02126514|Experimental|AZD3293|7 subjects will receive AZD3293
11386475|NCT02126501|No Intervention|Sudden wean|When ready Nasal Continuous Positive Airway Pressure (NCPAP) will be removed from the neonate
11386476|NCT02126501|Active Comparator|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
11386477|NCT02126488|Experimental|treadmill perturbation|treadmill slip perturbation
11386478|NCT02126488|Placebo Comparator|treadmill placebo|treadmill training placebo
11386479|NCT02126488|Sham Comparator|observation|observation training
11386480|NCT02126475||Healthy volunteers|
11386481|NCT02126475||Park patients|
11386482|NCT02126462|Experimental|30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)|30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
11386483|NCT02126462|Active Comparator|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
11386484|NCT02126462|Experimental|100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)|100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
11386485|NCT02126449|Experimental|Fasting mimicking diet|Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC>T)
11386486|NCT02126449|No Intervention|regular diet|Standard neoadjuvant chemotherapy (AC>T)
11386487|NCT02126436|Active Comparator|Acupuncture|"Eight treatments of acupuncture will be given to participants twice weekly over four weeks. A combination of body and auricular acupuncture will be given and treatment will be pragmatic.
~In addition the group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff)."
11386488|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
11386489|NCT02126423||1st intravitreal injection|Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection
11386490|NCT02126423||>20 intravitreal injections|Conjunctival and nasopharyngeal swabs are obtained from each patient with >20 intravitreal injection therapies.
11386491|NCT02126397|Active Comparator|polyps resection with Laser Diode|application of the laser diode by hysteroscopy to remove the endometrial polyp
11386492|NCT02126397|Active Comparator|polyps resection with bipolar electrode|application of the bipolar electrode Versapoint by hysteroscopy to remove the endometrial polyp
11386493|NCT02126384|Experimental|pneumovax|Single arm, open label pneumovax vaccination of healthy subjects
11386494|NCT02126371|Other|Active|LEO32731
11386495|NCT02126358|Placebo Comparator|Gemigliptin|only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)
11386496|NCT02126358|Placebo Comparator|Rosuvastatin|only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)
11386497|NCT02126358|Experimental|FDC|Gemigliptin & Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)
11386498|NCT02126345||MASTER SL|
11386499|NCT02126332|Other|Conventional group|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
11386500|NCT02126332|Experimental|EA group (Epidural anesthesia )|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
11386501|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
11386502|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
11386503|NCT02126306|Placebo Comparator|Placebo|Normal saline administered orally daily as a placebo
11386504|NCT02126306|Active Comparator|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
11386538|NCT02126059|Experimental|reminiscence|One reminiscence session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to reminiscence.
11386539|NCT02126059|No Intervention|Control|Control group remain regular activities
11386540|NCT02126046|Other|Hi-HSC-CBT|
11386541|NCT02126033|Experimental|celiac disease|
11386505|NCT02126293|Experimental|Zinc deficient patients|If the patient is found to be zinc deficient (serum zinc < 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
11386506|NCT02126293|Active Comparator|Zinc sufficient patients|Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.
11386507|NCT02126280||Subclinical atherosclerosis|In vitro estimation of individual reactivity of monocytes in study participants with asymptomatic atherosclerotic plaques found in carotid arteries by ultrasound examination
11386508|NCT02126280||Healthy subjects|In vitro estimation of individual reactivity of monocytes in study participants without ultrasound signs of subclinical carotid atherosclerosis
11386509|NCT02126280||Diffuse intimal thickening|In vitro estimation of individual reactivity of monocytes in study participants with diffuse intima-media thickening of carotid arteries found at ultrasound examination
11386510|NCT02126267|Experimental|Full mouth disinfection - FMD|n = 10: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
11386511|NCT02126267|Experimental|FMD + chlorhexidine (FMD-CX)|n = 15: Same as FMD with the inclusion of chlorhexidine in office (application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)). In addition, use was made of homemade CX 0.2% for 60 days after the scaling in a single phase.
11386512|NCT02126267|Experimental|FMD + azithromycin (FMD-AZ)|n = 15: Same as with the FMD include the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the scaling.
11386513|NCT02126267|Experimental|Scaling and root planing (SRP)|(n = 13): scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
11386514|NCT02126267|Experimental|SRP + azithromycin (SRP-AZ)|n = 11: Same as scaling and root planing group (SRP) with inclusion of the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the last scaling hemi-arch;
11386515|NCT02126267|Experimental|SRP + chlorhexidine (SRP-CX)|n = 13 : Same as group scaling and root planing (SRP) with the inclusion of home use of CX 0.2% for 60 consecutive days after the end of the first session of scaling
11386516|NCT02126254|No Intervention|Control group|Control group will be treated in the cardiology and internal medicine departments according to the guidelines for the management of Heart Failure
11386517|NCT02126254|Active Comparator|Hemodynamic group|Hemodynamic group patients will be examined in the cardiology and internal medicine departments and treated according to the NICaS system in addition to current guidelines. Patients in this group will be tested within 12 hours from hospitalization and thereafter on an everyday basis until discharge
11386518|NCT02126241|Experimental|NICaS guided CRT optimization|For each subject, we will determine a set of AV and VV delays values, for which the NICaS measured CO will be maximum. In each patient, the CRT device will then be programmed according to these values.
11386519|NCT02126215||Study group - MRI CO2 and O2 stress test|This is a pilot study to assess feasibility of using MRI CO2 and O2 stress testing to predict POD.
11386520|NCT02126202|No Intervention|Conservative therapy|Optimized medical therapy
11386521|NCT02126202|Experimental|Invasive therapy|Coronary angiography and revascularization if feasible
11386522|NCT02126189||Head and neck cancer|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra Hospital, Brisbane, Australia are invited to participate.
11386523|NCT02126163|Experimental|Treatment Group|The treatment group will receive three interactive Computer Tailored Intervention (CTI) sessions during the course of six months, which will include tailored feedback based on the user's responses, and two assessment only follow-up sessions at twelve and eighteen months.
11386524|NCT02126163|No Intervention|Control Group|The control group will receive four assessment only sessions during 18 months.
11386525|NCT02126150||Ethnicity|
11386526|NCT02126137|Experimental|Ezetimibe|Ezetimibe administered by mouth 10 mg BID for 12 weeks
11386527|NCT02126124|Active Comparator|Active dTMS Treatment|Brainsway Deep TMS Treatment
11386528|NCT02126124|Sham Comparator|Sham Treatment|Brainsway Sham Treatment
11386529|NCT02126111|Active Comparator|DEPIGOID phleum|The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
11386530|NCT02126111|Placebo Comparator|DEPIGOID Placebo & DEPIGOID Phleum|"This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.
~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
11386531|NCT02126098||Adults who diagosed ANCA-vasculitis|"Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had
~Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA
~manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
11386532|NCT02126085|Active Comparator|Intubation|Intubation and invasive mechanical ventilation + endovascular recanalisation
11386533|NCT02126085|Experimental|No Intubation|Conscious sedation and non-invasive ventilatory support + endovascular recanalisation
11386534|NCT02126072|Experimental|Alcohol|The study is a randomized single blinded trial in cross over design. Subjects are randomized to drink alcohol in one session and water in another session.
11386535|NCT02126072|Active Comparator|Water|Water in the same volume as the volunteer would have to drink in wine according to the protocol.
11386536|NCT02126059|Experimental|Cognitive stimulation|One cognitive stimulation session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to cognitive stimulation.
11386537|NCT02126059|Experimental|Aroma-massage|One hand and shoulder massage session per week for a continuous 10 weeks, each session contains 30 minutes, totally 10 session massage.
11386542|NCT02126020|Experimental|topical infliximab|topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months
11386543|NCT02126007|Experimental|Sleep and Rhythm Intervention|This arm receives a 4-week behavioral intervention aimed at improving sleep and circadian rhythms, and thereby reducing fatigue.
11386544|NCT02126007|Placebo Comparator|Dietary Modifications|This arm receives a 4-week placebo intervention focused on dietary modifications for reducing fatigue.
11386545|NCT02125994|Active Comparator|Ropivacaine 0.5%|Ultrasound guided Intercalene nerve block with ropivacaine 0.5 %
11386546|NCT02125994|Active Comparator|Ropivacaine 0.375 %|Ultrasound guided Intercalene nerve block with ropivacaine 0.375 %
11386547|NCT02125981|Experimental|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
11386548|NCT02125981|Placebo Comparator|Control|taking placebo drug
11386549|NCT02125968|Active Comparator|interactive video game|"Participants in interactive video game group receive six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min interactive video game intervention, for 3 times per week for a 2-week duration.
~Short- and medium-term therapeutic effects of interactive video game intervention for patients with chronic low back pain will be assessed."
11386550|NCT02125968|Sham Comparator|therapeutic exercise|"Participants received six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min supervised therapeutic exercise,for 3 times per week for a 2-week duration.
~short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain will be evaluated."
11386551|NCT02125955|Experimental|Prebiotic fiber|The intervention group will consume an 8 gram dose of prebiotic fiber one time per day approximately 30 minutes prior to their evening meal.
11386552|NCT02125955|Placebo Comparator|Placebo|The placebo group will consume an isocaloric dose of placebo (maltodextrin; 3.3 grams) one time per day approximately 30 minutes prior to their evening meal.
11386553|NCT02125942|Experimental|meditation|Central Meditation and Imagery Therapy
11386554|NCT02125942|No Intervention|wait list|waiting list
11386555|NCT02125929|Experimental|robotic arm|robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
11386556|NCT02125929|Experimental|Laparoscopic surgery|laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
11386557|NCT02125929|Experimental|Open surgery|Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100
11386558|NCT02125916|Experimental|COLD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
11386559|NCT02125916|Experimental|COLD with long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
11386560|NCT02125916|Experimental|ILD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
11386561|NCT02125916|No Intervention|Controls|Driving in the simulator one time without oxygen therapy
11386562|NCT02125903|Active Comparator|Continuous Adductor Canal Block (CACB)|"Continuous Adductor Canal block performed with:
~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h
~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
11386563|NCT02125903|Active Comparator|Continuous Femoral Nerve Block (CFNB)|"Continuous Femoral Nerve Block performed with:
~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h
~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
11386564|NCT02125890|Experimental|Tranexamic Acid|We will be administering Tranexamic Acid in patients with ruptured abdominal aortic aneurysms to determine if this has an effect on primary outcome measures as significant bleeding, blood transfusion requirements.
11386565|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
11386566|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
11386567|NCT02125864|Experimental|Aflibercept|
11386568|NCT02125851|Experimental|Xanthan Gum|"A total of 12 subject will be administered sucralose slurry and the xanthan gum slurry. Six will get sucralose first (then an hour later the xanthan gum) and 6 will receive the xanthan gum first (then an hour later the sucralose slurry).
~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.
~The xanthan gum-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 1ml of xanthan gum gel, crystallized orange flavoring agent, and 1mCi of Tc99-Sulfur colloid."
11386569|NCT02125851|Experimental|Honey|"A total of 12 subject will be administered sucralose slurry and the honey slurry. Six will get sucralose first (then an hour later the honey) and 6 will receive the honey first (then an hour later the sucralose slurry).
~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.
~The honey-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 6ml of honey and 1mCi of Tc99-Sulfur Colloid."
11386570|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
11386571|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
11386572|NCT02125825||Parkinson's disease on levodopa|Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms
11386573|NCT02125812|Placebo Comparator|scaling and root planing|scaling and root planing
11386574|NCT02125812|Experimental|scaling and systemic moxifloxacin|scaling and root planing combined with systemic moxifloxacin
11386614|NCT02125565|No Intervention|No Local Anaesthesia|Patients underwent arterial puncture directly with NO prior anaesthesia
11386575|NCT02125799|Experimental|Accelerated HF-rTMS|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
11386576|NCT02125786|Experimental|Stratum 1: Local Failure|"Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.
~Participants may receive one or both: Photon therapy or proton therapy.
~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
11386577|NCT02125786|Experimental|Stratum 2: Metastatic Failure|"Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.
~Participants may receive one or both: Photon therapy or proton therapy.
~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
11386578|NCT02125786|Experimental|Stratum 3: Local and Metastatic Failure|"Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.
~Participants may receive one or both: Photon therapy or proton therapy.
~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
11386579|NCT02125786|Experimental|Stratum 4: Local Failure|"Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is >36 months at time of enrollment to <21 years. Tumor shows presence of 1q gain. Treatment is optional craniospinal irradiation.
~Participants may receive one or both: Photon therapy or proton therapy.
~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
11386580|NCT02125773|Experimental|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator.
11386581|NCT02125773|No Intervention|Control|Subjects in the control arm will not be provided with the results of the risk calculators.
11386582|NCT02125760|Sham Comparator|Inspiratory Muscle Training (IMT)|Patients with subacute stroke in a neurorehabilitation setting.
11386583|NCT02125760|Experimental|High-intensity IMT|Patients with subacute stroke in a neurorehabilitation setting.
11386584|NCT02125747|Other|No Respiratory Therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.
11386585|NCT02125747|Experimental|Respiratory therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy
11386586|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
11386587|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
11386588|NCT02125721|Experimental|Increasing doses of CBTD|Intervention: CBTD 0-3 gm
11386589|NCT02125708|Other|OvulaRing®|Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
11386590|NCT02125695||Healthy Volunteers|Skin taping; blood sampling; optional biopsy
11386591|NCT02125695||Cutaneous lupus erythematosus|This group consists of participants affected with lupus (DLE, SCLE). Skin taping; blood sampling; optional skin biopsy (DLE participants); required skin biopsy (SCLE participants)
11386592|NCT02125695||Atopic dermatitis|Skin taping; blood sampling; optional skin biopsy
11386593|NCT02125682|Active Comparator|low dose|patients receiving 10 mg of atorvastatin daily
11386594|NCT02125682|Active Comparator|High dose|Patients receiving 80 mg of atorvastatin daily
11386595|NCT02125669|Active Comparator|Laser Treatment|Pulsed dye laser 595nm
11386596|NCT02125669|Sham Comparator|SHAM Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
11386597|NCT02125656|No Intervention|Regular Sleep|A single night of regular sleep
11386598|NCT02125656|No Intervention|Sleep Deprivation|A single night of sleep deprivation
11386599|NCT02125656|Experimental|HIIT + Regular Sleep|2 weeks of HIIT and after a single night of regular sleep.
11386600|NCT02125656|Experimental|HIIT + Sleep Deprivation|2 weeks of HIIT and after a single night of sleep deprivation
11386601|NCT02125643|Active Comparator|Caffeine Pill|The caffeine will be administered.
11386602|NCT02125643|Placebo Comparator|Placebo/Flour Pill|The flour will be administered.
11386603|NCT02125630||Systemic therapy|Standart chemotherapy
11386604|NCT02125630||Primary surgery|Standart surgery
11386605|NCT02125630||Neoadjuvant chemotherapy|Standart chemotherapy followed by surgery
11386606|NCT02125617||Castration-resistant prostate cancer, Progression after taxane|Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day
11386607|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
11386608|NCT02125591|Experimental|Active PoNS CN-NINM|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
11386609|NCT02125591|Sham Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
11386610|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a)|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks.
11386611|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a) and Placebo|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
11386612|NCT02125578|Placebo Comparator|Placebo|Placebo dose will be administered SC every other week for a total of 6 weeks.
11386613|NCT02125565|Experimental|Local Anaesthesia|These subjects received an injection of lidocaine 1% 2ml subcutaneously prior to arterial puncture
11386615|NCT02125552|Experimental|Ultrasound guided intravenous access|This group will have their IV placed by ultrasound guidance.
11386616|NCT02125552|Placebo Comparator|Traditional intravenous access|The patients randomized to traditional IV access will have their IVs placed by standard technique.
11386617|NCT02125539|Experimental|Navigating my Journey program|Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
11386618|NCT02125539|Active Comparator|Attention Control|Client participants of counselors who were randomized to the control condition will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
11386619|NCT02125526|Active Comparator|IABP group|After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia
11386620|NCT02125526|No Intervention|Control group|After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines
11386621|NCT02125513|Active Comparator|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
11386622|NCT02125513|Experimental|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
11386623|NCT02125500|Experimental|Sofosbuvir/Ledipasvir|"Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks.
~Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
11386624|NCT02125487|Active Comparator|Low-Fidelity Simulation|Teaching using traditional method
11386625|NCT02125487|Experimental|Hybrid Simulation|Teaching using Hybrid Simulation of breast examination
11386626|NCT02125474|Experimental|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
11386627|NCT02125461|Experimental|MEDI4736|MEDI4736 (intravenous infusion)
11386628|NCT02125461|Placebo Comparator|PLACEBO|Placebo (matching placebo for intravenous infusion)
11386629|NCT02125448||Resectable esophageal cancer|Neoadjuvant chemoradiotherapy. MRI and PET-CT.
11386630|NCT02125435|Experimental|ASP2408 dose escalation cohort|
11386631|NCT02125435|Placebo Comparator|Placebo dose escalation cohort|
11386632|NCT02125422|Experimental|Cefaly tDCS|"Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC.
~2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV"
11386633|NCT02125409|Experimental|Group 1|Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.
11386634|NCT02125409|Experimental|Group 2|Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.
11386635|NCT02125396|Experimental|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
11386636|NCT02125396|Active Comparator|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
11386637|NCT02125383|Experimental|Active tDCS|Receives 20 minutes of anodal tDCS three times while sleeping during the night.
11386638|NCT02125383|Sham Comparator|Sham tDCS|Receives 20 minutes of sham tDCS three times while sleeping during the night.
11386639|NCT02125370||Nicotine Replacement Therapy|
11386640|NCT02125357|Other|A - Abiraterone Acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care, or until PSA progression then cross-over to Arm B.
11386641|NCT02125357|Other|B - Enzalutamide|160mg PO OD as per standard of care, or until PSA progression then cross-over to Arm A.
11386642|NCT02125344|Experimental|PM(Cb)|"PM(Cb):
~paclitaxel 80mg/m² 18 times weekly simultaneously with NPLD (Myocet®)20mg/m² 18 times weekly simultaneously with carboplatin AUC 1.5 18 times weekly (only in patients with TNBC) Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all cycles."
11386643|NCT02125344|Active Comparator|ETC|"ETC:
~epirubicin 150mg/m² every 2 weeks for 3 cycles followed by paclitaxel 225 mg/m² every 2 weeks for 3 cycles followed cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles. Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all T and C cycles."
11386644|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
11386645|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
11386646|NCT02125318|Experimental|Anagrelide CR (GALE-401)|
11386647|NCT02125305|Experimental|Metformin|Metformin 750mg(D1), Metformin 500mg(D2)
11386648|NCT02125292|Experimental|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
11386649|NCT02125292|Experimental|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
11386650|NCT02125292|Experimental|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
11386651|NCT02125279|Experimental|Calcitriol ointment|
11386652|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
11386653|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
11386654|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
11386655|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
11386656|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
11386657|NCT02125240|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
11386658|NCT02125240|Active Comparator|Placebo|1 tablet three times daily by mouth
11386659|NCT02125227|Experimental|Group 1 of Study A|single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755
11386660|NCT02125227|Experimental|Group 2 of Study A|single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin
11386661|NCT02125227|Experimental|Group 1 of Study B|single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast
11386662|NCT02125227|Experimental|Group 2 of Study B|single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state
11386663|NCT02125214|Experimental|ASA 1-2|ASA 1-2 patients 20-40 yr
11386664|NCT02125201|Experimental|intranasal fentanyl|Intranasal Fentanyl 1.5-2 mcg/kg
11386665|NCT02125201|Active Comparator|intravenous fentanyl|Intravenous Fentanyl 1-1.5 mcg/kg
11386666|NCT02125188|Experimental|Desmopressin|Desmopressin 3ug/kg in saline 100ml ivdrip before surgery
11386667|NCT02125188|Placebo Comparator|saline|saline 100ml ivdrip before surgery
11386668|NCT02125175|Experimental|Hypofractionated IMRT boost Radiotherapy|
11386669|NCT02125162|Experimental|Treatment A|BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1
11386670|NCT02125162|Experimental|Treatment B|BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1
11386671|NCT02125162|Experimental|Treatment C|BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1
11386672|NCT02125149|No Intervention|Control|Standard of care
11386673|NCT02125149|Experimental|Intervention|Exercise intervention from 12 week gestation until delivery
11386674|NCT02125136|Experimental|Gem/nab-Pac|2 further cycles Gem/nab-Pac (duration of each cycle 28 days)
11386675|NCT02125136|Experimental|FOLFIFINOX|4 cycles combination therapy with 5-fluorouracil/folinic acid, irinotecan, oxaliplatin (FOLFIFINOX) - duration of each cycle 14 days
11386676|NCT02125123|Experimental|Nutritional Supplement and Counseling|Two servings a day; ready-to-feed nutritional supplement plus dietary counseling
11386677|NCT02125123|Active Comparator|Counseling|Dietary Counseling
11386678|NCT02125110|Experimental|study group (cohort PELAGIE)|100 children included in the cohort PELAGIE
11386679|NCT02125110|Experimental|pilot group (no cohort PELAGIE)|10 children not included in the PELAGIE cohort to optimise MRI
11386680|NCT02125097|Experimental|Intracranial Aneurysm Treatment|Barrel™ Vascular Reconstruction Device (VRD) is Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
11386681|NCT02125084|Experimental|Everolimus and Enzalutamide|"Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined.
~Everolimus: Orally (PO) once daily (dose to be determined;
~Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing.
~Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase."
11386682|NCT02125071||Hepabig|Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation
11386683|NCT02125058|Other|Transcutaneous sutures|Transcutaneous sutures
11386684|NCT02125058|Other|Intracutaneous sutures|Intracutaneous sutures
11386685|NCT02125045|Experimental|L-GSH|Glutathione 100 mg tablets twice a day
11386686|NCT02125045|Placebo Comparator|Placebo|Matching placebo will be administered for 4 weeks in a double blind fashion.
11386687|NCT02125032|Active Comparator|Transcranial pulsed electromagnetic fields (T-PEMF)|One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
11386688|NCT02125032|Placebo Comparator|Trancranial electromagnetic pulsed fields (T-PEMF)|8 weeks of T-PEMF treatment placebo.
11386689|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
11386690|NCT02125006|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
11386691|NCT02125006|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
11386692|NCT02124993||Sleeve gastrectomy surgery Participants|Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger.
11386693|NCT02124980|Experimental|Recovery Line plus Treatment-as-Usual (RL+TAU)|The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
11386694|NCT02124980|No Intervention|Treatment-as-Usual|Treatment-as Usual involves daily methadone and associated psychosocial services. Patients are required to attend 1 group session per month and are encouraged to attend open drop-in groups available daily covering a range of topics.
11386695|NCT02124967|Experimental|Exercise|A one hour exercise session which includes both aerobic activity and resistance training
11386696|NCT02124954|Experimental|Digoxin with/without TA-8995|Digoxin with/without TA-8995
11386697|NCT02124954|Experimental|Midazolam with/without TA-8995|Midazolam with/without TA-8995
11386698|NCT02124941|Experimental|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
11386699|NCT02124941|Experimental|[18F]-FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
11386700|NCT02124941|Experimental|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
11386701|NCT02124941|Active Comparator|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
11386702|NCT02124928||carotid artery stenosis|Patients with symptomatic or asymptomatic carotid artery stenosis indicated for carotid endarterectomy, who provide written informed consent, will be included in this study. The investigators will compare patients ultrasonographic data, serum laboratory analyses and histomorphological preferances to look for biomarkers for the plaque instability.
11386703|NCT02124915||Transtibial amputees|
11386704|NCT02124902|Experimental|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
11386705|NCT02124902|Experimental|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
11386706|NCT02124889|Experimental|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
11386707|NCT02124889|No Intervention|No Survey|Subjects will take the multivitamin.
11386708|NCT02124876||Transtibial amputees|
11386709|NCT02124863|Experimental|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
11386710|NCT02124850|Experimental|Motolimod plus cetuximab|Cohort 1: motolimod plus cetuximab
11386711|NCT02124850|Experimental|Motolimod, cetuximab, and nivolumab|Cohort 2: motolimod, cetuximab, and nivolumab
11386712|NCT02124837|No Intervention|Control group|Participants continue their normal lunch routine.
11386713|NCT02124837|Experimental|Relaxation exercise during lunch break|Participants perform relaxation exercises during each lunch break during work for a period of 2 working weeks.
11386714|NCT02124837|Experimental|Park walk during lunch break|Participants go for a walk in the closest park nearby each lunch break during work for a period of 2 working weeks.
11386715|NCT02124824|Experimental|Arm 1: Control|Control
11386716|NCT02124824|Experimental|Arm 2: Heart Failure|Heart Failure
11386717|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
11386718|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
11386719|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
11386720|NCT02124785|Experimental|HAV Group|Subjects who were previously vaccinated with Havrix in primary studies.
11386721|NCT02124772|Experimental|Part A|Trametinib Dose-Escalation: Trametinib is administered orally once daily (OD) under fasting conditions. The starting dose of trametinib (0.0125 milligram per kilogram per dose [mg/kg/dose]) is 50% of the recommended fixed dose in adults (2 mg OD). The second dose level (0.025 mg/kg) is equivalent to the recommended dose in adults (2 mg PO daily). The third dose level (0.040 mg/kg) is equivalent to the maximum tolerated dose [MTD] in adults (3 mg PO daily).
11386722|NCT02124772|Experimental|Part B|Tumor-Specific Expansion: Trametinib is administered orally once daily under fasting conditions in 4 disease-specific cohorts of subjects Trametinib will be continued until disease progression.
11386723|NCT02124772|Experimental|Part C|The trametinib dose administered in Part C will be the trametinib monotherapy RP2D from Part A. The monotherapy RP2D of dabrafenib in children will be established on a separate trial (BRF116013). The specifics for Part C will be determined following completion of enrollment into Part A.
11386724|NCT02124772|Experimental|Part D|The trametinib and dabrafenib doses administered in Part D will be the combination trametinib and dabrafenib RP2D from Part C.
11386725|NCT02124759|Active Comparator|High fat diet|"The high fat diet will provide 60% of energy from fat (of which 50% from saturated fat), 15% of energy as CHO and 25% from protein.
~subjects will be randomized to receive, in a double-blind fashion
~placebo, maltodextrin, 6 g three times a day
~synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]
~sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day)"
11386726|NCT02124759|Active Comparator|Low fat diet|"The low fat diet will provide 55% of energy from CHO, 20% from fat, and 25% from protein.
~subjects will be randomized to receive, in a double-blind fashion
~placebo, maltodextrin, 6 g three times a day
~synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion CFU/g)three times a day]
~sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day)"
11386727|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
11386728|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
11386729|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.
~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
11386730|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
11386731|NCT02124733|Active Comparator|Group 1: 30 minutes|The first 4 patients enrolled will be considered Group 1, and will receive 30 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated in terms of erythema immediately post-PDT (Day 1) and on Day 4 . If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 2
11386732|NCT02124733|Active Comparator|Group 2: 45 minutes|Patients in this group will receive 45 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema response immediately post-PDT and at Day 4. If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 3.
11386733|NCT02124733|Active Comparator|Group 3: 60 minutes|Patients in this group will receive 60 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema responses immediately post-PDT and at Day 4. If the post-PDT reaction on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of patients, then the protocol will terminate after 15 patients (total for all groups) have been treated.
11386734|NCT02124720|Experimental|Mobile application|Use of the iSTIM mobile application 2 to 4 times per week over approximately 8 to 16 weeks
11386735|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
11386736|NCT02124694|Experimental|HTUG and IPT|This arm includes the Historical Trauma and Unresolved Grief intervention (HUTG) combined with group Interpersonal Psychotherapy (IPT).The HTUG/IPT arm is 12 two-hour sessions delivered weekly on average, except for weather delays, over 16 weeks. HTUG/IPT includes sessions on identifying relationship issues which may trigger depressive symptoms, using group support, and connecting the impact of collective tribal trauma and losses with personal lifespan and current losses. HTUG/IPT is aimed at reducing depressive symptoms related to interpersonal conflicts and grief. HTUG is a Tribal Best Practice which may serve to engage AI in IPT, an empirically supported treatment for depression.
11386737|NCT02124694|No Intervention|IPT Only|IPT is a standard empirically supported treatment. This IPT Only group is not receiving the experimental HTUG component and is being compared to the combined HTUG with IPT.
11386738|NCT02124681|Placebo Comparator|Placebo|Placebo PO
11386739|NCT02124681|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO QD
11386740|NCT02124668|Experimental|Enzalutamide|Enzalutamide
11386741|NCT02124655|Experimental|Essential oils/0.2% chlorhexidine/Sterile water|A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
11386742|NCT02124642|Active Comparator|Folic acid, 400 mcg/day|A daily 400 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 400 mcg dose approximates the current Recommended Dietary Allowance (RDA) for pregnant women of 600 mcg Dietary Folate Equivalents (400 mcg folic acid ≈ 600 mcg DFEs; conversion factor based on higher bioavailability of folic acid is: 1 mcg folic acid = 1.7 mcg DFE).
11386743|NCT02124642|Experimental|Folic acid, 800 mcg/day|A daily 800 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 800 microgram dose, which is considerably higher than the current RDA, represents an amount commonly found in over-the-counter prenatal vitamin formulations.
11386744|NCT02124616||Neuromuscular diseases|Prospective cohort of children with inherited or acquired neuromuscular diseases.
11386745|NCT02124603||single group|Patients undergone cataract surgery
11386746|NCT02124590|Experimental|Acute Exercise|Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.
11386747|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
11386748|NCT02124525|Placebo Comparator|N-acetylcysteine|"Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.
~Duration: 12 weeks"
11386749|NCT02124525|Placebo Comparator|Placebo|Placebo will be taken for 12 weeks
11386750|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
11386751|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
11386752|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
11386753|NCT02124486|Active Comparator|Dietetic Intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers diet programme.
11387080|NCT02122471|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
11386754|NCT02124486|Experimental|Bariatric surgery|Patients randomised to the bariatric surgery arm will be referred to the bariatric surgery pathway and, if judged suitable according to the bariatric surgery clinic's screening processes, undergo bariatric surgery.
11386755|NCT02124486|No Intervention|Matched obese control group|To evaluate the baseline difference in ICP between IIH patients and a matched obese control cohort we will recruit 20 obese but otherwise healthy participants who will undergo the same baseline visit as the main trial participants and then exit the study.
11386756|NCT02124486|No Intervention|MRI Test run|5 patients will undergo double baseline MR scans to validate the novel MR sequences being used in the main trial.
11386757|NCT02124473|Experimental|Homeopathy|A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
11386758|NCT02124473|Placebo Comparator|Placebo|Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
11386759|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
11386760|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
11386761|NCT02124447|Active Comparator|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
11386762|NCT02124447|Active Comparator|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
11386763|NCT02124447|Active Comparator|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
11386764|NCT02124447|Active Comparator|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
11386765|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
11386766|NCT02124421|Active Comparator|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
11386767|NCT02124421|Experimental|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
11386768|NCT02124408|Experimental|Intervention group|Personalized Behavioral Intervention
11386769|NCT02124408|No Intervention|Control group|
11386770|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
11386771|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
11386772|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
11386773|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
11386774|NCT02124369|Other|Abraxane & gemictabine|Abraxane, IV, 125mg/m2 and gemcitabine, IV, 1000mg/m2, on days 1,8 & 15 per 28 day cycle, up to a maximum of 6 cycles.
11386775|NCT02124356||Emergency High-risk Abdominal Surgery|
11386776|NCT02124343|Experimental|Interval Exercise|"Subjects will undertake an interval exercise session (on a harnessed treadmill) (HP Cosmos Mercury 4.0, HP Cosmos Sports and Medical Gmbh, Nussdorf-Traustein,Germany) based on the average speed calculated from the 6 minute walk test (6MWT).
~Intervals are based on the work previously done by Mador et al., 2009 who used intervals of 150% (for 1 minute) followed by intervals of 75% (for 2 minutes) based on 80% average speed from the 6 minute walk test.
~This study repeated these intervals 7 times with a duration of 23 minutes in total for the exercise intervention with the 75% intervals at the start and at the end of the exercise session. No warm up was undertaken for this method as it was a walking exercise test and the risk of injury was minimised with use of the harnessed treadmill."
11386777|NCT02124330|Experimental|montmorillonite 5 g|5g Montmorillonite + 15 g protein (ratio 1:3)
11386778|NCT02124330|Experimental|Montmorillonite 3 g|3g Montmorillonite + 15 g protein (ratio 1:5)
11386779|NCT02124330|Experimental|Montmorillonite 1 g|1g Montmorillonite + 15 g protein (ratio 1:15)
11386780|NCT02124330|No Intervention|Control|A control goup will intake 15 g of protein alone
11386781|NCT02124317|Experimental|nanoparticle albumin-bound paclitaxel, S-1|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycle: 6 cycles.
11386782|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
11386783|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
11386784|NCT02124291|No Intervention|No Assisted Hatching|No Assisted Hatching
11386887|NCT02123719||Control group|Patients with an abdominal incisional hernia without a history of immunosuppresion
11386785|NCT02124291|Active Comparator|Assisted Hatching|Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.
11386786|NCT02124278|Experimental|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
11386787|NCT02124278|Placebo Comparator|Sterile water for injection|Sterile water for injection administered by nebulization
11386788|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
11386789|NCT02124252|No Intervention|Control|Women will be offered HPV testing within the health facilities in the communities randomized to this arm. Women who test HPV positive will be referred to care at the sub-district and district hospitals (current standard of care).
11386790|NCT02124252|Active Comparator|Standard Intervention|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
11386791|NCT02124252|Active Comparator|Enhanced Intervention|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
11386792|NCT02124239|Experimental|Scalp|Treatment of scalp with 0.027% ingenol mebutate once daily for 3 days
11386793|NCT02124239|Experimental|Arm|Treatment of arm with 0.06% ingenol mebutate once daily for 4 days
11386794|NCT02124239|Experimental|Face|Treatment of face with 0.027% ingenol mebutate once daily for 3 days
11386795|NCT02124226|Experimental|Methotrexate|Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks
11386796|NCT02124226|Placebo Comparator|Matched placebo|Placebo pills
11386797|NCT02124213|Experimental|Cohor 1 - 30 mg|Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
11386798|NCT02124213|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
11386799|NCT02124213|Experimental|Cohort 3 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
11386800|NCT02124200|Other|EGO/CE4, 9mg nicotine|
11386801|NCT02124187|Experimental|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
11386802|NCT02124187|Sham Comparator|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
11386803|NCT02124187|Placebo Comparator|Nicotine free inhalator|nicotine free inhalator for 12 weeks
11386804|NCT02124174|Experimental|Vidaza and Valproic Acid|Vidaza and Valproic Acid
11386805|NCT02124161|Other|13vPnC+SIIV/Placebo|
11386806|NCT02124161|Other|Placebo+SIIV/13vPnC|
11386807|NCT02124148|Experimental|Prexasertib + Cisplatin (Part A)|"Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days.
~Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days.
~Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days.
~Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose.
~Participants may remain on treatment until discontinuation criteria are met."
11386808|NCT02124148|Experimental|Prexasertib + Cetuximab (Part B)|"Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days.
~Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days.
~Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days.
~Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose.
~Participants may remain on treatment until discontinuation criteria are met."
11386809|NCT02124148|Experimental|Prexasertib + Pemetrexed (Part C)|"Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days.
~Participants may remain on treatment until discontinuation criteria are met."
11386810|NCT02124148|Experimental|Prexasertib + 5-FU (Part D)|"Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days.
~Participants may remain on treatment until discontinuation criteria are met."
11386811|NCT02124148|Experimental|Prexasertib + LY3023414 (Part E)|"Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days.
~Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion).
~Participants may remain on treatment until discontinuation criteria are met."
11386812|NCT02124135|Active Comparator|Clinic-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in the clinic setting.
11386813|NCT02124135|Experimental|Restaurant-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in a restaurant, while dining.
11386814|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
11386815|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
11386816|NCT02124109||Control|Control group
11386817|NCT02124109||rheumatic heart disease|Patients with rheumatic heart disease
11386818|NCT02124083|Experimental|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
11386819|NCT02124057||Healthy female control|Age-matched healthy control women
11386820|NCT02124057||Healthy male control|Age-matched healthy control men
11386821|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
11386822|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
11386823|NCT02124057||SMBA|SBMA carrier women
11386824|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
11386825|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
11386826|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.
~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
11386827|NCT02124005|Experimental|Femoral block, ultrasound, bupivacaine|
11386828|NCT02123992|Active Comparator|Elevate Apical and Posterior|The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
11386829|NCT02123992|Active Comparator|Native Tissue Repair|The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
11386830|NCT02123979|Placebo Comparator|placebo patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
11386831|NCT02123979|Experimental|Neupro® transdermal patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
11386832|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
11386833|NCT02123953|Experimental|TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.
11386834|NCT02123953|Experimental|TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.
11386835|NCT02123953|Experimental|TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.
11386836|NCT02123953|Experimental|TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.
11386837|NCT02123953|Experimental|TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.
11386838|NCT02123953|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.
11386839|NCT02123940|Experimental|nasal humidified high flow therapy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
11386840|NCT02123940|Other|standard strategy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
11386841|NCT02123927|Experimental|Step 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
11386842|NCT02123927|Experimental|Step 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
11386843|NCT02123927|Experimental|Step 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
11386844|NCT02123927|Experimental|Step 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
11386845|NCT02123927|Experimental|Step 5: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
11386846|NCT02123927|Experimental|Step 6: TAK-438 80 mg|TAK-438 80 mg, tablets, orally, once on Day 1.
11386847|NCT02123927|Experimental|Step 7: TAK-438 120 mg|TAK-438 120 mg, tablets, orally, once on Day 1.
11386848|NCT02123927|Placebo Comparator|Steps 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1.
11386849|NCT02123927|Experimental|Step 8A: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
11386850|NCT02123927|Experimental|Step 8 B: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
11386851|NCT02123927|Experimental|Step 9A: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
11386938|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
11386852|NCT02123927|Experimental|Step 9B: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
11386853|NCT02123927|Placebo Comparator|Steps 8 (A & B) and 9 (A & B): Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.
11386854|NCT02123914|Experimental|Aerobic exercise with Vit. C & Aerobic exercise|
11386855|NCT02123914|Active Comparator|exercise without vit. c supplement & no exercise|
11386856|NCT02123901|Experimental|Walking meditation & Walking|
11386857|NCT02123901|Active Comparator|Walking meditation & No exercise|
11386858|NCT02123888|Experimental|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
11386859|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
11386860|NCT02123875|Other|Physiotherapy intervention arm|Caregiver delivered, home based physiotherapy
11386861|NCT02123862||Prostate Cancer|
11386862|NCT02123862||Breast Cancer|
11386863|NCT02123862||Colorectal Cancer|
11386864|NCT02123862||Solid Tumor|
11386865|NCT02123862||Benign Condition|
11386866|NCT02123849|Experimental|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
11386867|NCT02123849|Experimental|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
11386868|NCT02123836|Experimental|NK cells|Peripheral blood cell will be collected by apheresis from donors. Peripheral blood mononucleated cells will be cultured with irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 for 10 days. After T-cell depletion, expanded activated NK cells will be infused. Before infusion, patients will receive immunosuppressive therapy to promote temporary engraftment of NK cells. After infusion, they will receive IL-2 to support NK cell viability and expansion in vivo. The effects of NK cell infusion will be determine by comparing MRD levels before and after treatment.
11386869|NCT02123823|Active Comparator|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
11386870|NCT02123823|Experimental|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
11386871|NCT02123823|Experimental|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
11386872|NCT02123810|Other|Control|The investigators measure quality of chest compressions before nightshift. Control group
11386873|NCT02123810|Other|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
11386874|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
11386875|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
11386876|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
11386877|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
11386878|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
11386879|NCT02123784||Rotator cuff tear|Patients which demonstrate a full-thickness tear of the rotator cuff tendon and meet the inclusion criteria.
11386880|NCT02123771||Helicobactor Pylori Infection|Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects. Rapid urease test result from the respective patients will be used as the golden standard. Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
11386881|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
11386882|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
11386883|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
11386884|NCT02123732|Experimental|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
11386885|NCT02123732|Placebo Comparator|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
11386886|NCT02123719||Patients post liver transplantation|Patients after liver transplantation
11386888|NCT02123693|Experimental|Osteopathic Manipulative Treatment|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on indirect techniques
11386889|NCT02123693|Sham Comparator|Sham therapy|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on specific parameters set out previously based on a predetermined protocol
11386890|NCT02123693|Other|No intervention|Patients in this group will not receive any type of intervention, both therapeutic than fictitious, and will not be evaluated by any operator
11386891|NCT02123667||Asthmatic patients|asthmatic patients 18 to 65
11386892|NCT02123667||Healthy volunteers|Volunteers 18 to 65
11386893|NCT02123654|Experimental|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
11386894|NCT02123654|Active Comparator|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
11386895|NCT02123654|Experimental|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
11386896|NCT02123641|Active Comparator|Heavy resistance training|Heavy resistance training of the lower and upper extremities three times weekly for 52 weeks.
11386897|NCT02123641|Experimental|Moderate intensity training|Home-based moderate intensity training of the lower and upper extremities three times weekly for 52 weeks.
11386898|NCT02123641|Experimental|Control|No training
11386899|NCT02123628|Active Comparator|antibiotic therapy|"patients are treated with a 6 week-duration of antibiotic therapy :
~Rifampin IP and PO twice daily, 10mg/kg /12H
~Levofloxacin IV and PO 500-750mg once daily
~Doxycycline PO 200mg once daily
~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily
~Fusidic acid PO 500mg twice daily
~Linezolid IV and PO 600mg twice daily
~Ciprofloxacin IV and PO 750to 1000mg/12h
~Cefotaxime IV 100mg/kg in three IV infusions daily
~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily
~Cefepime IV ou intra-muscularly 2g /8-12h"
11386900|NCT02123628|Active Comparator|12 week-duration of antibiotic therapy|"patients are treated with a 12 week-duration of antibiotic therapy :
~Rifampin IP and PO twice daily, 10mg/kg /12H
~Levofloxacin IV and PO 500-750mg once daily
~Doxycycline PO 200mg once daily
~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily
~Fusidic acid PO 500mg twice daily
~Linezolid IV and PO 600mg twice daily
~Ciprofloxacin IV and PO 750to 1000mg/12h
~Cefotaxime IV 100mg/kg in three IV infusions daily
~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily
~Cefepime IV ou intra-muscularly 2g /8-12h"
11386901|NCT02123615|Experimental|Gadolinium For abdomen|"Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
11386902|NCT02123615|Experimental|Gadolinium For lower back|"1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
~Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score."
11386903|NCT02123615|Experimental|subjects (%) of any infections|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386904|NCT02123615|Experimental|Annual rate of any infections|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386905|NCT02123615|Experimental|subjects (%) with Antibiotic use|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386906|NCT02123615|Experimental|Annual rate with Antibiotic use|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386907|NCT02123615|Experimental|subjects (%) with Days out of work|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386908|NCT02123615|Experimental|Annual rate with Days out of work|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386909|NCT02123615|Experimental|(%) with hospitalized infections|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386910|NCT02123615|Experimental|Annual rate hospitalized infections|Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
11386936|NCT02123485|Experimental|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
11386937|NCT02123485|Sham Comparator|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
11387075|NCT02122497||abdominal aortic occlusive disease (AOD)|open surgical repair
11386911|NCT02123615|Experimental|Adverse Injection Local Reactions|Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386912|NCT02123615|Experimental|Adverse Reactions Headache|Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386913|NCT02123615|Experimental|Adverse Reactions Fever|Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386914|NCT02123615|Experimental|Adverse Reactions Nausea|Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386915|NCT02123615|Experimental|Adverse Reactions Vomiting|Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386916|NCT02123615|Experimental|Adverse Reactions Fatigue|Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386917|NCT02123615|Experimental|Adverse Reactions Diarrhea|Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386918|NCT02123615|Experimental|Adverse Reactions Asthma|Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386919|NCT02123615|Experimental|Adverse Reactions Oropharyngeal|Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386920|NCT02123615|Experimental|Adverse Reactions Abdominal Pain|Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
11386921|NCT02123602|Experimental|Core stabilization|This arm will receive 3 weeks of core stabilization training followed by 3 weeks of lower extremity stretching and strengthening as appropriate to address impairments noted in the examination and to progress function.
11386922|NCT02123602|Active Comparator|Lower extremity training only|This arm with receive 6 weeks of impairment based stretching and strengthening to restore function.
11386923|NCT02123589|Experimental|Deep sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3
11386924|NCT02123589|Experimental|Deep and daily interruption of sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3.and from the second day after subject was admitted in ICU, daily interruption of sedation will be taken .
11386925|NCT02123589|Experimental|Light sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -2 and +1.
11386926|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
11386927|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
11386928|NCT02123563|Experimental|Ultrason Essential oils rinse|Ultrasonic debridement followed by twice daily home use of an essential-oils mouth rinse (20mL, 30 seconds for each rinse) for 3 months
11386929|NCT02123563|Placebo Comparator|Ultrason Placebo rinse|Ultrasonic debridement followed by twice daily home use of a placebo rinse (20mL, 30 seconds for each rinse) for 3 months
11386930|NCT02123537|Experimental|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System for walking daily during the 12 weeks of the study.
11386931|NCT02123524|Experimental|Rivaroxaban|Rivaroxaban 10mg tablet daily for 45 days
11386932|NCT02123524|Placebo Comparator|Control|Placebo tablet daily for 45 days
11386933|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
11386934|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
11386935|NCT02123498|Experimental|Single Arm|
11387076|NCT02122484|Placebo Comparator|Control group|Patients taking placebo
11386939|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
11386940|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
11386941|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
11386942|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
11386943|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
11386944|NCT02123433|Experimental|13-valent vaccine|
11386945|NCT02123420|Other|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.
~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
11386946|NCT02123420|Other|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.
~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
11386947|NCT02123407|Experimental|Carbon Nanoparticles|Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.
11386948|NCT02123407|Active Comparator|Gastrectomy with D2 dissection|Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used
11386949|NCT02123394|Placebo Comparator|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
11386950|NCT02123394|Experimental|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
11386951|NCT02123381|Experimental|Arm A|All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy，patients receive right thoracotomy with three incisions radical surgery.
11386952|NCT02123368|Active Comparator|Hialuronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
11386953|NCT02123368|Active Comparator|Hyaluronic acid and MSC 10|Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
11386954|NCT02123368|Active Comparator|Hyaluronic acid AND MSC 100|Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
11386955|NCT02123355|Experimental|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
11386956|NCT02123355|Sham Comparator|Normal saline|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
11386957|NCT02123342|No Intervention|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
11386958|NCT02123342|Experimental|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
11386959|NCT02123329|Active Comparator|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
11386960|NCT02123329|Experimental|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
11386961|NCT02123316|Active Comparator|Pangramin Plus D. pteronyssinus|Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
11386962|NCT02123316|Placebo Comparator|Placebo|Placebo for subcutaneous injection
11386963|NCT02123303||Veterans|
11386964|NCT02123290|Experimental|Plasmodium falciparum|Patients with Plasmodium falciparum malaria
11386965|NCT02123290|Experimental|Plasmodium vivax|Patients with Plasmodium vivax malaria
11386966|NCT02123277|Experimental|concept proof|Balloon catheter for the Eustachian tube
11386967|NCT02123264|Active Comparator|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
11386968|NCT02123264|No Intervention|No intervention|No intervention
11386969|NCT02123251|Experimental|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
11386970|NCT02123251|No Intervention|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
11386971|NCT02123238|Other|Control|standard of care positioning (0 degree)
11386972|NCT02123238|Other|30 degree|30 degree bed positioning
11386973|NCT02123238|Other|60 degree|60 degree bed positioning
11386974|NCT02123212|Experimental|Mt. Sinai|Cluster randomization with EHR Alert intervention
11386975|NCT02123212|Experimental|Henry Ford Health System|Simple randomization with mailer intervention
11386976|NCT02123212|Experimental|University of Alabama, Birmingham|Crossover randomization with in-person recruitment intervention
11386977|NCT02123199||Indacaterol/QAB149|Patients treated with Indacaterol for COPD prior to enrollment in study
11386978|NCT02123186||newborns testing for SMA|
11386979|NCT02123173||non-intubated|VATS, non-intubated
11386980|NCT02123173||intubated|VATS, intubated
11386981|NCT02123160|Experimental|Child Parent Psychotherapy (CPP)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads will be randomly assigned to either Child Parent Psychotherapy (CPP) treatment or control (usual treatment) group. CPP treatment will be conducted by a CPP study clinician over approximately six months (24 weekly sessions). CPP includes developmental guidance and fostering affect regulation , continuity in daily living, reciprocity between mother and child, and helping the mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma.
11386982|NCT02123160|Active Comparator|Usual Treatment|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred for usual treatment via referral to therapists in the community and at Columbia University Medical Center, for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Additionally, control patient dyads will be monitored through regular contact with the study research assistant. If the research assistant detects worsening of depressive symptoms or the presentation of new symptoms, a licensed study clinician will follow up to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
11386983|NCT02123147||Sjogren's syndrome|Patients who are diagnosed with Sjogren's syndrome. Blood will be collected once every 3-6 months for up to 3 years.
11386984|NCT02123147||Healthy Control|Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
11386985|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11386986|NCT02123134|Experimental|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11386987|NCT02123121|Placebo Comparator|Vegetable cellulose|Participants will orally consume one capsule of vegetable cellulose following each of their main meals (i.e. breakfast, lunch, and dinner) for 90 days.
11386988|NCT02123121|Active Comparator|Resveratrol 1000 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1000 mg/day for 90 days.
11386989|NCT02123121|Active Comparator|Resveratrol 1500 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1500 mg/day for 90 days.
11386990|NCT02123108|Active Comparator|Basiliximab|"Basiliximab
~Basiliximab Peri-transplant
~• 40mg IV infusion within 4 hours of transplant x1
~Basiliximab Post-transplant • 20mg IV infusion Post Operative Day #4 (POD 4) x1
~Tacrolimus (with basiliximab induction)
~• Post Operative Day #7 (POD 7) or subclinical acute rejection (SCr) < 1.8 mg/dl to one year: 0.03-0.1mg/kg q12h
~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1: 720 mg po bid will be administered once the patient is able to tolerate PO medication.
~Corticosteroids • Intraoperative: hydrocortisone 1000mg intravenous push (IVP)
~Followed by:
~• Standard steroid taper:"
11386991|NCT02123108|No Intervention|Tacrolimus Group|"Tacrolimus (without basiliximab induction); standard of care group
~Beginning Post Operative Day #1 to six months: 0.03-0.1 mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL
~Six months to one year: maintain whole blood trough concentration of 5-8ng/mL
~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1. Immediately post transplant, while subjects have nasogastric (ng) tube; this will be delivered as CellCept (mycophenolate mofetil) oral suspension 1,000 mg BID administered via the ng tube. Enteric coated mycophenolic acid (Myfortic) - 720 mg po bid will be administered once the patient is able to tolerate PO medication.
~Corticosteroids • Intraoperative: hydrocortisone IVP
~Followed by:
~• Standard steroid taper"
11386992|NCT02123082|Other|Single-Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
11386993|NCT02123082|Experimental|Dual Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
11386994|NCT02123069||Women with uterine fibroids|"Brachial artery catheter
~Acetylcholine
~Nitroprusside
~Norepinephrine
~Nitroprusside and phenylephrine"
11386995|NCT02123069||Women without uterine fibroids|"Brachial artery catheter
~Acetylcholine
~Nitroprusside
~Norepinephrine
~Nitroprusside and phenylephrine"
11386996|NCT02123056|Active Comparator|Metoprolol|Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
11386997|NCT02123056|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
11386998|NCT02123043|No Intervention|Control|The control group will not experience any wheelchair training or 'practice' with a manual wheelchair.
11386999|NCT02123043|Experimental|Motor learning-based training|The motor learning-based training, like the 'practice' condition, will consist of six visits over three weeks. Each visit will involve two 5-minute wheeling trials with 10-minutes of rest between trials. The motor learning-based training will focus on variable practice and sporadic feedback.
11387000|NCT02123043|Active Comparator|Practice wheeling|To provide a comparable amount of exposure to wheelchair propulsion, the practice group will participate in the same number of visits and wheeling time as the motor-learning based training group. This will allow us to determine whether the motor-learning based training is superior to exposure through practice. The practice group will come to the lab six times over three weeks and wheel for two 5-minute trials with a 10-minute rest break in between. Participants randomized to this group will receive no feedback.
11387001|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
11387002|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
11387003|NCT02123017|Experimental|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
11387004|NCT02123017|Experimental|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
11387005|NCT02123017|Experimental|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
11387006|NCT02123004|Experimental|Ticagrelor|"Investigational product/Dosage form and strength/Manufacturer:
~ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks"
11387007|NCT02123004|Active Comparator|Clopidogrel|"Investigational product/Dosage form and strength/Manufacturer:
~clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks"
11387008|NCT02122991||Able-Bodied Controls|Subjects must be between the ages of 30 and 64 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
11387009|NCT02122991||Spinal Cord Injury|Subjects must be between the age of 30 and 64 years old, be English-literate and able to provide informed consent. They must be at least 1 year from the date of their spinal cord injury. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
11387010|NCT02122978|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
11387011|NCT02122978|Experimental|MBSCT 8 week course|Mindfulness Based Self Compassion Therapy
11387012|NCT02122978|Active Comparator|Mindfulness Based Self-Compassion - Audio guided|MBSC - minimal contact
11387013|NCT02122965|Experimental|Pharmacist-led medication review|Pharmacist-led medication review in the ED
11387014|NCT02122965|No Intervention|Usual care|Usual care includes nurse-led medication reconciliation.
11387015|NCT02122952|Experimental|Cohort 1|6.7 X 10^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
11387016|NCT02122952|Experimental|Cohort 2|2.0 X 10^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
11387017|NCT02122939|Experimental|Escitalopram|
11387018|NCT02122926|Experimental|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:
~Inpatient protocol for adjusting the discharge diabetes regimen;
~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;
~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);
~Visiting nurse intervention after discharge;
~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;
~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and
~Follow-up with PCP or endocrinologist within 1 week of discharge."
11387019|NCT02122926|No Intervention|Usual Care|Patients in the control arm of this study receive usual care.
11387020|NCT02122913|Experimental|Tumor patients_Dose 1|Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
11387021|NCT02122913|Experimental|Tumor patients_Dose 2|Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
11387022|NCT02122913|Experimental|Tumor patients_Dose 3|Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
11387023|NCT02122913|Experimental|Tumor patients_Dose 4|Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
11387024|NCT02122913|Experimental|Tumor patients_Dose 5|Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
11387025|NCT02122913|Experimental|Tumor patients_Dose 6|Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
11387026|NCT02122913|Experimental|Tumor patients_Expansion|"Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).
~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part."
11387027|NCT02122887|No Intervention|control group|no intervention for 3 months
11387028|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
11387029|NCT02122874|Active Comparator|Diet|The patients follow only a 1200 Kcal diet
11387030|NCT02122874|Experimental|Diet +PENS dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
11387031|NCT02122861|Experimental|ID-LV305|Dose escalation and expansion cohort including treatment of melanoma
11387032|NCT02122848|Experimental|Bilevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
11387033|NCT02122835|Other|heart failure|aerobic exercise training
11387034|NCT02122835|Other|heart failure plus type 2 diabetes|aerobic exercise training
11387035|NCT02122822|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
11387077|NCT02122484|Experimental|Colchicine|Active treatment group
11387078|NCT02122471|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
11387036|NCT02122809|Experimental|Chiauranib|Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
11387037|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
11387038|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
11387039|NCT02122783|Experimental|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
11387040|NCT02122783|Experimental|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
11387041|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.
~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
11387042|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.
~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.
~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.
~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
11387043|NCT02122757|Placebo Comparator|Sham Anodal Cefaly tDCS|2 mA placebo anodal tDCS (the direct current is delivered just for 30 seconds) is applied over the visual cortex for 20 minutes, everyday for 2 months, in 15 patients
11387044|NCT02122757|Active Comparator|Anodal Cefaly tDCS|2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, everyday for 2 months, in 15 patients.
11387045|NCT02122744|Active Comparator|Super Rapid Magstim Stimulator rTMS QP|rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
11387046|NCT02122744|Placebo Comparator|Placebo|rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
11387047|NCT02122731|Experimental|Amiloride|This is a non-randomized and non-controlled study with only one treatment arm with amiloride.
11387048|NCT02122718|Experimental|Allopurinol|
11387049|NCT02122718|Placebo Comparator|Placebo|
11387050|NCT02122705||VPIA remifentanil|VPIA remifentanil labour analgesia
11387051|NCT02122692|Experimental|Lu AE58054 30 mg + itraconazole 200 mg|
11387052|NCT02122679|Active Comparator|Study group|Receive tranexamic acid in operating room.
11387053|NCT02122679|Placebo Comparator|Placebo group|Receive placebo in the operating room
11387054|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
11387055|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
11387056|NCT02122653|Experimental|Older WT|Older people with weight training
11387057|NCT02122653|Experimental|Older WT and ES|Older people with weight training combined electrical stimulation.
11387058|NCT02122653|No Intervention|Young control group|Young people with control group
11387059|NCT02122627|Experimental|Vitamin D|colecalciferol 16.800 IU per week
11387060|NCT02122627|Placebo Comparator|Placebo|placebo
11387061|NCT02122614|Experimental|Experimental group|
11387062|NCT02122614|Active Comparator|Control group|
11387063|NCT02122601|Other|LBSA0103|single arm , LBSA0103 only
11387064|NCT02122588||OVATAR study patients|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18 years and older, diagnosed 3 months before enrolment into the study or later, consented to participate in this non-interventional study, who are being treated for OC, FTC (Fallopian Tube Cancer) and PC (Peritoneal Cancer) in the oncology hospitals/departments in the Russian Federation.
11387065|NCT02122575||1|Males and females between the ages of 21 and 37
11387066|NCT02122549|Experimental|HWD1000|Subjects using HWD1000
11387067|NCT02122536|Active Comparator|Xeomin right side; Xeomin to left side of face|Patients were randomized as to which side of the face was treated with Xeomin.
11387068|NCT02122536|Active Comparator|Botox right side; Botox to left side|Patients were randomized as to which side of the face was treated with Botox.
11387069|NCT02122523|Experimental|SLN identification with NIR-dye-subserosa injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
11387070|NCT02122523|Active Comparator|SLN identification with NIR-dye-submucosal injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
11387071|NCT02122510|Active Comparator|dexmetomedine group|dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.
11387072|NCT02122510|Active Comparator|Bupivacaine group|Bupivacaine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.
11387073|NCT02122497||abdominal aortic aneurysm (AAA) endovascular|endovascular aortic repair
11387074|NCT02122497||abdominal aortic aneurysm (AAA) open|open surgical repair
11387081|NCT02122458|Active Comparator|hearing impaired vs hearing impaired + PTSD|The investigators will have two treatment groups fitted with mild-gain open-fit hearing aids and will be monitored across 6 months.
11387082|NCT02122458|Other|delayed treatment|A third group will consist of a delayed treatment group. This group will be monitored over 12 months with hearing aids fitted at 6 months.
11387083|NCT02122458|No Intervention|Diagnostic Testing|Battery of auditory and auditory related assessment tasks.
11387084|NCT02122445|Experimental|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
11387085|NCT02122432|Experimental|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association and sends them to the dermatologist using a secured email server.
~Dermatologist answer is standardized."
11387086|NCT02122432|No Intervention|Usual care|Usual care for dermatologic conditions requiring an expertise from a dermatologist involves the general practitioner 1) giving the patient a paper letter containing at least the following information: date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes) and 2) telling him to see the dermatologist of his choice (patient manages his appointments alone).
11387087|NCT02122419||lateral|spinal anesthesia performed during lateral position
11387088|NCT02122419||sitting|spinal anesthesia performed during sitting position
11387089|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
11387090|NCT02122393|Active Comparator|Sertraline|
11387091|NCT02122393|Active Comparator|Cognitive Behavioural Therapy|
11387092|NCT02122393|Active Comparator|Combined Therapy|
11387093|NCT02122380|Experimental|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
11387094|NCT02122380|Experimental|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
11387095|NCT02122367|Experimental|stroke volume variation, pleth variability index|"stroke volume variation: recorded using the FloTrac/Vigileo system (Edwards Lifesciences)
~pleth variability index: recorded using the Masimo Radical-7 monitor (Masimo Corporation, Irvine, CA, USA)"
11387096|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
11387097|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
11387098|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
11387099|NCT02122328|Active Comparator|Selective procedure|Selective laser photocoagulation of communicating vessels.
11387100|NCT02122328|Experimental|Sequential procedure|Sequential laser photocoagulation of communicating vessels
11387101|NCT02122315|Experimental|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles.
11387102|NCT02122315|Active Comparator|Physical therapy|Best-evidence physical therapy intervention
11387103|NCT02122302|Experimental|Web-based health assessment|
11387104|NCT02122289|Experimental|Application of Smartphone|Weekly questionnaire on Smartphone
11387105|NCT02122289|Placebo Comparator|No application Smartphone|No Weekly questionnaire on Smartphone
11387106|NCT02122276|Experimental|SCI|SCI participated in a 4-month robot-assisted passive ankle exercise regimen.
11387107|NCT02122263||NAFLD after sleeve gastrectomy surgery|
11387108|NCT02122250|Experimental|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
11387109|NCT02122250|Active Comparator|Static web-based materials|Static version of the interactive web-based materials
11387110|NCT02122237|Experimental|Cathodal Cefaly tDCS|Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
11387111|NCT02122224|Experimental|Group 1|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
11387112|NCT02122224|Experimental|Group 2|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
11387113|NCT02122224|Experimental|Group 3|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
11387114|NCT02122224|Experimental|Group 4|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
11387115|NCT02122211|Experimental|Betaine supplement|Will use powdered betaine (BetaPower, Dupont Nutrition) that is commercially available for food uses. This powder will be delivered as capsules containing 0.5 gram of powdered betaine which will be administered as eleven capsules twice per day (6 in the morning, 5 in the evening) for a daily total of 6 grams of betaine.
11387116|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
11387117|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.
~Weekly application of estradiol patch 0.075mg/d months 6-9.
~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
11387118|NCT02122185|Experimental|Metformin plus chemotherapy|Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
11387119|NCT02122185|Placebo Comparator|Placebo plus chemotherapy|Patients receive placebo PO BID and standard chemotherapy for 6 -8 cycles. Treatment with placebo continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
11387120|NCT02122172|Experimental|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11387121|NCT02122159|Experimental|MA09-hRPE Cellular Therapy|MA09-hRPE cells for transplantation will be provided by Ocata Therapeutics as a suspension frozen to the temperature of liquid nitrogen (approximately -196 °C). They will be processed at UCLA under GMPs according to protocol. Following vitrectomy performed under general anesthesia or waking sedation at the surgeon's discretion, hRPE cells will be introduced into a subretinal bleb formed by the injection of balanced salt solution (BSS). Direct viewing will guide the implantation of thawed and washed MA09-hRPE cells, resuspended in BSS, into the created bleb over a period of one minute. To avoid cell reflux, the cannula used to introduce the cells will be held in position for an additional minute. A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
11387122|NCT02122146|Experimental|PF-06664178|Experimental
11387123|NCT02122133||PC 400|Patients treated with the PC 400 according to the IFU
11387124|NCT02122133||Conventional Embolic Coils|These are any approved embolic coils on the market used as part of the standard of care for treating intracranial aneurysms.
11387125|NCT02122120||Before HEN|Patients with tube feeding with kitchen diet for at least twelve months
11387126|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
11387127|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
11387128|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
11387129|NCT02122094|Experimental|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
11387130|NCT02122081|Experimental|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.
~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
11387131|NCT02122068|Experimental|Central Meditation and Imagery Therapy|Meditation and mindfulness 4 week program
11387132|NCT02122068|Active Comparator|Relaxation cd|Listening to a relaxation cd
11387133|NCT02122055|Experimental|Propofol/Dexmedetomidine|"Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
11387134|NCT02122055|Experimental|Midazolam/Dexmedetomidine|"Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
11387135|NCT02122042|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
11387136|NCT02122042|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
11387137|NCT02122029|Experimental|Bariatric Surgery|
11387138|NCT02122029|Experimental|Lifestyle counselling|
11387139|NCT02122016|Experimental|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
11387140|NCT02122016|Active Comparator|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
11387141|NCT02122003|Experimental|sorafenib|Sorafenib 400 mg bid
11387142|NCT02121990|Experimental|Cisplatin, Paclitaxel, bevacizumab & olaparib|All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
11387143|NCT02121977|Active Comparator|Elevate Anterior and Apical|Prolapse repair with mesh
11387144|NCT02121977|Active Comparator|Native Tissue Repair|Prolapse repair with sutures
11387145|NCT02121964|Other|Capsulectomy|Capsulectomy in Direct Anterior Total Hip Arthroplasty
11387146|NCT02121964|Other|Capsulotomy|Capsulotomy in Direct Anterior Total Hip Arthroplasty
11387147|NCT02121951|Active Comparator|Local Anesthetic infiltration and MAC|"Local Anesthetic infiltration with 1% lignocaine
~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
11387148|NCT02121951|Experimental|Quadratus Lumborum block and MAC|"QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine
~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
11387149|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
11387150|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
11387151|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
11387152|NCT02121886|Experimental|Parietal peritoneum|
11387153|NCT02121873||Women with and without breast cancer|Nipple aspirator, ductal lavage microcatheter, blood draw
11387154|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
11387155|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
11387156|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
11387157|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
11387158|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
11387159|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
11387160|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
11387161|NCT02121821|No Intervention|Control|A control group of pregnant women receiving no intervention (i.e. no SMS reminders).
11387162|NCT02121821|Experimental|SMS reminder messages|The intervention group will be composed of pregnant women receiving SMS reminder messages via the SMS Mother Reminder system.
11387163|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
11387164|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
11387165|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
11387166|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
11387167|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
11387168|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
11387169|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
11387170|NCT02121782|Active Comparator|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
11387171|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
11387172|NCT02121756|Active Comparator|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
11387173|NCT02121743|Experimental|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
11387174|NCT02121743|Placebo Comparator|No strattice|the colostomy is not reinforced with a mesh
11387175|NCT02121730||Kidney Transplantation|Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
11387176|NCT02121717|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 52 weeks
11387177|NCT02121717|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 52 weeks
11387178|NCT02121717|Placebo Comparator|Arm 3|Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
11387179|NCT02121704|No Intervention|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
11387180|NCT02121704|Active Comparator|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
11387181|NCT02121691|Experimental|Walk by Faith|Intervention arm
11387182|NCT02121691|No Intervention|Comparison|Non-intervention arm
11387183|NCT02121678|Experimental|Run-in - Aerobic - Resistance|"Week -12 to 0: Run-in period with no training
~Week 0 to 12: Aerobic training on ergometer bicycle
~Week 12 to 24: Resistance training with dumbbells"
11387184|NCT02121678|Experimental|Run-in - Resistance - Aerobic|"Week -12 to 0: Run-in period with no training
~Week 0 to 12: Resistance training with dumbbells
~Week 12 to 24: Aerobic training on ergometer bicycle"
11387185|NCT02121665|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
11387186|NCT02121665|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
11387187|NCT02121652|Active Comparator|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
11387188|NCT02121652|Experimental|Cognitve behaviroal therapy|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
11387191|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
11387192|NCT02121613|Experimental|Permixon® 160 mg & Placebo|
11387193|NCT02121613|Placebo Comparator|Placebo|
11387194|NCT02121613|Other|Tamsulosine LP & Placebo|Active control arm
11387195|NCT02121600|Other|Docetaxel|Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan
11387196|NCT02121600|Other|Abiraterone|Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan.
11387197|NCT02121587||Pain self-management course|This is a single group observational cohort study. Participants are adults with persistent musculoskeletal pain who choose to participate in an optional, six week pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment for individual patients.
11387198|NCT02121574||Zero-flux and ingestible thermometer|Ingestion of a capsule thermometer pre-operatively Attachment of a zero flux temperature electrode intraoperatively Standard oesophageal thermometer
11387199|NCT02121561|Experimental|Self-Acceptance Group Therapy|Participants receive Self-Acceptance Group Therapy
11387200|NCT02121548|Placebo Comparator|Outreach|Gets outreach materials and info on where to get screened by CHW.
11387201|NCT02121548|Active Comparator|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
11387202|NCT02121548|Active Comparator|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
11387203|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
11387204|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
11387205|NCT02121522|Experimental|BI 144807|twice daily
11387206|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
11387207|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
11387208|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
11387209|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
11387210|NCT02121496|Experimental|Resources for Postpartum Parenting|Behavioral intervention will include techniques to help mothers get their infants to cry/fuss less and sleep more to determine if this has an effect on prevalence of postpartum depression in low SES women and if it improves the quality of mother-infant interaction and subsequent child development.
11387211|NCT02121496|No Intervention|Control Group|This group will not receive the coaching tips to help babies cry less and sleep more.
11387212|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
11387213|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
11387214|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
11387215|NCT02121457|No Intervention|Control Group|This group did not receive any intervention.
11387216|NCT02121457|Experimental|Treatment Group|This group took one Brazil nut daily during 6 months.
11387217|NCT02121444||Cohort 1|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
11387218|NCT02121431|Experimental|Online-Delivered Parenting Intervention|The Online-Delivered Parenting Intervention, which is based on the Triple P--Positive Parenting Program system of interventions, is an interactive website designed to engage and activate the participant through sequenced, personalized, interactive, and video-based content. The intervention emphasizes a self-regulatory process, parent specification of goals, practical and straightforward parenting strategies, modeling, and action activation.
11387219|NCT02121431|Active Comparator|Staff-Delivered Parenting Intervention|The Staff-Delivered Parenting Intervention is based on the Triple P--Positive Parenting Program system and involves 10 face-to-face sessions with each family. This intervention is the well-established Level 4 Standard Triple P program.
11387220|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
11387221|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
11387222|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine adjuvant chemotherapy.
11387223|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
11387224|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
11387225|NCT02121379|No Intervention|control|stretching exercise
11387226|NCT02121379|Experimental|pulmonary rehablitation|warming up exercise strengthening exercise aerobic exercise cool down
11387227|NCT02121366|Experimental|Insulinoma|Patients with Insulinomas will received EUS-guided ethanol ablation therapy
11387228|NCT02121353|Experimental|PF582|PF582 is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
11387229|NCT02121353|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
11387230|NCT02121340|Experimental|Behavioral Activation|CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
11387231|NCT02121340|No Intervention|Usual Care|Usual Care
11387232|NCT02121327|Active Comparator|usual care|usual care group receive regular outpatient treatment
11387233|NCT02121327|Experimental|disease management|desease management program include self management education by nurse on 6months.
11387234|NCT02121314|Active Comparator|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
11387235|NCT02121314|Active Comparator|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
11387236|NCT02121301|Experimental|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
11387237|NCT02121301|Experimental|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
11387238|NCT02121301|Placebo Comparator|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
11387239|NCT02121288|Experimental|Ticagrelor|oral ticagrelor 90 mg (yellow) tablet
11387240|NCT02121288|Active Comparator|Clopidogrel|oral clopidogrel 75 mg (pink) tablet
11387241|NCT02121275||Laparoscopic surgery|Patients undergoing laparoscopic surgery under general anaesthesia, patients undergo ultrasound of the lungs and electric impedance tomography at 4 times during anaesthesia
11387242|NCT02121262|Other|Laser Photocoagulation|Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
11387243|NCT02121262|Experimental|Dexamethasone|Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.
11387244|NCT02121249|Experimental|Robot assisted pedicle screw fixation|posterior lumbar interbody fusion using Robot assisted pedicle screw fixation (Renaissance, Mazor Robotics Ltd, Caesare, Israel)
11387245|NCT02121249|Active Comparator|Free hand technique|using Free hand technique, posterior lumbar interbody fusion (No specific device)
11387246|NCT02121236||Patients with benign radiolucent lesions|
11387247|NCT02121223|Active Comparator|Control|Patients in control group will receive current standard therapy for STEMI: manual thrombus aspiration + Promus Element stent implantation ( with a pressure less than 12 atm), but not post-dilatation
11387248|NCT02121223|Experimental|Post-dilatation|Patients in this group will receive high pressure post-dilatation with a Quantum Maverick balloon after manual thrombus aspiration + Promus Element stent implantation
11387249|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
11387250|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
11387251|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
11387252|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
11387253|NCT02121171|Experimental|Ologen Collagen Matrix Intervention|Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
11387254|NCT02121171|Active Comparator|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
11387255|NCT02121158|Other|1|ICD implantation in addition to Optimal Medical Therapy
11387256|NCT02121158|Active Comparator|2|Optimal Medical Therapy
11387257|NCT02121145|Experimental|Vivotif + Typherix primary immunization|Vivotif + Typherix primary immunization
11387258|NCT02121145|Experimental|Vivotif booster|Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization
11387259|NCT02121145|Experimental|Typherix booster|Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization
11387260|NCT02121145|Experimental|Vivotif + Typherix booster|Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization
11387261|NCT02121132||No treatment|
11387262|NCT02121119|Active Comparator|Lidocaine|0.5% lidocaine infusion hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
11387263|NCT02121119|Placebo Comparator|Bupivacaine|Infusion of 0.1% bupivacaine hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
11387264|NCT02121106|Experimental|Cognitive Remediation|Participants in this group will receive active cognitive remediation.
11387265|NCT02121106|Sham Comparator|Sham Cognitive Remediation|Participants in this group will receive a sham comparison, which is a computerized exposure to the same exercises as the active intervention, but with cognitively complex elements removed and no titration of the difficulty of tasks.
11387266|NCT02121093|No Intervention|alpha band of the EEG and electromyographic activity|- 20 will be in the evaluation group (EG); then review the alpha band of EEG and EMG activity.
11387267|NCT02121093|Experimental|Vibration|"• 20 vai participar no grupo de baixa freqüência de vibração estimulação (LFVS);
~20 no grupo de estimulação da vibração de média freqüência (MFVS);
~20 vai participar no grupo de alta freqüência de vibração estimulação (HFVS). then review the alpha band of EEG and EMG activity."
11387268|NCT02121080|Experimental|Cohort 1|Dosing regimen 1
11387269|NCT02121080|Experimental|Cohort 2|Dosing regimen 2
11387270|NCT02121080|Experimental|Cohort 3|Dosing regimen 3
11387271|NCT02121080|Experimental|Cohort 4|Dosing regimen 4
11387272|NCT02121080|Experimental|Cohort 5|Dosing regimen 5
11387273|NCT02121067|Experimental|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
11387274|NCT02121041|No Intervention|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
11387275|NCT02121041|Active Comparator|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
11387276|NCT02121028||Intracranial Atherosclerotic Disease, Stroke/TIA|Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
11387277|NCT02121015|Active Comparator|Self-Directed|Access to the e-health intervention (an interactive website with didactic material and interactive tools) for participants to use at their own pace for 8 weeks (Self-Directed)
11387278|NCT02121015|Experimental|Share|Access to the same e-health intervention + an internet social networking component consisting of up to 12 other pregnant women (Share).
11387279|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
11387280|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
11387281|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
11387282|NCT02120976|Experimental|Dose 1 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387283|NCT02120976|Experimental|Dose 2 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387284|NCT02120976|Experimental|Dose 3 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387285|NCT02120976|Experimental|Dose 4 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387286|NCT02120976|Experimental|Dose 5 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387287|NCT02120976|Experimental|Dose 6 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387288|NCT02120976|Experimental|Dose 7 JTT-252 or Placebo|Tablets, single dose in fasted condition
11387289|NCT02120976|Experimental|Dose 8 JTT-252|Tablets, single dose in fed condition
11387290|NCT02120976|Experimental|Dose 9 JTT-252|Tablets, single dose in fasted condition
11387291|NCT02120963|Experimental|intervention program|Person-centered physical therapy intervention program
11387292|NCT02120963|No Intervention|Control group|Health care as usual
11387293|NCT02120950|Experimental|Aflibercept + Sham PDT|Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
11387294|NCT02120950|Experimental|Aflibercept + Active PDT|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
11387295|NCT02120937|Experimental|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
11387296|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
11387297|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
11387298|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
11387299|NCT02120911|Experimental|Pertuzumab, trastuzumab|Pertuzumab, trastuzumab
11387300|NCT02120898|Experimental|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
11387301|NCT02120898|Active Comparator|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
11387302|NCT02120898|Placebo Comparator|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
11387303|NCT02120885|Experimental|Exercise group|physical activity intervention
11387304|NCT02120885|No Intervention|Control group|
11387305|NCT02120872|Active Comparator|PRF and SMV Group|sites treated with Open Flap Debridement with Platelet Rich Fibrin along with Simvastatin
11387306|NCT02120872|Sham Comparator|PRF Group|sites treated with Open Flap Debridement with autologous Platelet Rich Fibrin
11387307|NCT02120872|Other|OFD Group|sites treated with Open Flap Debridement i.e. conventional flap surgery
11387308|NCT02120859|Experimental|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
11387309|NCT02120859|Other|DEB angioplasty with provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
11387310|NCT02120846|Experimental|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
11387311|NCT02120846|No Intervention|Control|Daily routines
11387312|NCT02120833|Active Comparator|EPI|
11387313|NCT02120833|Experimental|NEE|
11387314|NCT02120820|Active Comparator|Multisensory environment|Multisensory environment (MSE): 30 minutes/session, twice a week for 10 weeks
11387315|NCT02120820|Active Comparator|Massage therapy|Massage therapy (MT): 15 minutes/session, twice a week for 10 weeks
11387316|NCT02120820|Other|Control group|Control group: usual care for 10 weeks, with attention and interactions with the caregivers only.
11387317|NCT02120820|Active Comparator|Massage in multisensory environment|Participants receive 15 minutes massage therapy in multisensory environment (MT-MSE), twice a week for 10 weeks.
11387318|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
11387319|NCT02120794|Experimental|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
11387320|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
11387321|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
11387322|NCT02120768|Experimental|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
11387323|NCT02120768|Active Comparator|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
11387324|NCT02120755|Active Comparator|AmnioClear™|AmnioClear™ Human Allograft Amniotic Membrane
11387325|NCT02120755|No Intervention|Standard of Care|Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)
11387326|NCT02120742|Experimental|Social Norming|"The first group will receive SMS message reminders framed as social norming (ie Most of your peers wear helmets)."
11387327|NCT02120742|Experimental|Fear Appeal|"The second group will receive SMS message reminders framed as fear appeals (ie Not wearing your helmet increases your chance of dying in an accident)."
11387328|NCT02120742|Placebo Comparator|Control|The third group will act as the control and receive texts that relate to general road safety, but not helmet use.
11387329|NCT02120729|No Intervention|Standard of Care|Patients assigned to standard-of-care pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription and psychotropic therapy follows the institutional norm.
11387330|NCT02120729|Active Comparator|Genotype-guided Care|Patients assigned to genetically-guided pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription as part of psychotropic therapy.
11387331|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
11387332|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
11387333|NCT02120703|Active Comparator|gabapentin|
11387334|NCT02120703|Active Comparator|Pregabalin|
11387335|NCT02120690|Experimental|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
11387336|NCT02120690|Sham Comparator|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
11388202|NCT02114840|Experimental|Pronator quadratus preservation|Pronator quadratus preservation
11387337|NCT02120677|Experimental|Itraconazole ointment|Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
11387338|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
11387339|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
11387340|NCT02120651|Active Comparator|Fibrin monomer|40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
11387341|NCT02120651|Placebo Comparator|Hemostatic sponge|40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.
11387342|NCT02120638|Active Comparator|Pyrazinamide Sensitive Comparator|"Pyrazinamide containing regimen: Regimen B1 - 6ZAmkLfxClrPto\6ZlfxClrPto
~Six months of chemotherapy with Pyrazinamide,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by
~Six months of Pyrazinamide,Levofloxacin,Clarithromycin,plus Prothionamide"
11387343|NCT02120638|Experimental|Pyrazinamide Resistant Comparator|"Regimen without Pyrazinamide: Regimen B2 - 6HAmkLfxClrPto\18HlfxClrPto
~Six months of chemotherapy with Isoniazid,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by
~Eighteen months of Isoniazid,Levofloxacin,Clarithromycin,plus Prothionamide"
11387344|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
11387345|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
11387346|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
11387347|NCT02120599|Active Comparator|corn-soy-blend|This is the control group for the study, which will receive the Malawi standard of care. The treatment provided to women randomized to this arm of the study includes daily iron (60 mg) and folic acid (400 mcg) supplementation, along with 4 kg/2 weeks corn-soy blend (~357 gm/d CSB).
11387348|NCT02120599|Experimental|corn-soy-blend + multiple micronutrients|The treatment provided to women randomized to this arm of the study includes 200gm/d CSB along with a standard maternal multiple micronutrient tablet, which together provide a comparable amount of energy, protein and micronutrients to the ready-to-use supplemental food. The micronutrient supplement known as the United Nations Children's Emergency Fund (UNICEF) / World Health Organization (WHO) / United Nations University (UNU) international multiple micronutrient preparation (UNIMMAP) is widely available and has been used in many settings worldwide in pregnant women.
11387349|NCT02120599|Experimental|ready-to-use supplementary food|RUSF-P (ready-to-use supplementary food) provides 750 kcal/d, 20 g protein/d, and 200% of RDA/d for most micronutrients during pregnancy (except for vitamins A, B3, folic acid, minerals iodine, magnesium, and calcium which will remain near 100%)
11387350|NCT02120586|No Intervention|Control group|Usual care
11387351|NCT02120586|Experimental|Respiratory training group|"Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
~Intervention: Inspiratory Muscle training (12-weeks)"
11387352|NCT02120586|Experimental|Peripheral training group|"Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
~Intervention: Peripheral muscle training (12-weeks)"
11387353|NCT02120573|Active Comparator|medical students|medical students took part in workshop
11387354|NCT02120573|Active Comparator|general population|general population took part in workshop
11387355|NCT02120573|Active Comparator|nonmedical students|all students from different subjects, non medical and paramedical
11387356|NCT02120560|Active Comparator|Interrupted Anticoagulation|Patients randomized to undergo atrial fibrillation ablation with interrupted anticoagulation with apixaban (5mg twice daily; 2.5mg twice daily >80 years old, Cr > 1.5, wt < 60kg), rivaroxaban (20mg daily; 15mg daily CrCl < 50 mL/minute), dabigatran (150mg twice daily; 75mg twice daily CrCl < 30mL/minute), or warfarin (dosed case-by-case).
11387357|NCT02120560|Active Comparator|Uninterrupted anticoagulation with warfarin|Patients randomized to undergo atrial fibrillation ablation with uninterrupted anticoagulation with warfarin (dosed case-by-case).
11387358|NCT02120547|Experimental|Cenicriviroc in mild liver impaired|Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
11387359|NCT02120547|Experimental|Cenicriviroc in moderate liver impaired|Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
11387360|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
11387446|NCT02119910|Experimental|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
11388203|NCT02114840|Active Comparator|Pronator quadratus non repair|
11387361|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
11387362|NCT02120521||Sepsis group|Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
11387363|NCT02120521||SIRS group|Sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
11387364|NCT02120508|Experimental|1 Hz rTMS, real|1 Hz rTMS over unaffected hemisphere for 15 minutes
11387365|NCT02120508|Sham Comparator|1Hz rTMS, sham|1Hz sham rTMS, over unaffected hemisphere for 15 minutes
11387366|NCT02120495|Experimental|intraoral condylectomy via coronoid process resction|This procedure has no facial nerve injury and skin scar,little injury to TMJ anatomy and function.
11387367|NCT02120482|Experimental|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
11387368|NCT02120469|Experimental|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11387369|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
11387370|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
11387371|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
11387372|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
11387373|NCT02120443|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
11387374|NCT02120430|Active Comparator|Early administration of the video|Video delivered at one month of child's life
11387375|NCT02120430|Experimental|Late administration of the video|Video delivered at seven months of child's life
11387376|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
11387377|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
11387378|NCT02120404|No Intervention|Control group (GC)|Control group: no esmolol administration
11387379|NCT02120404|Experimental|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
11387380|NCT02120404|Experimental|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
11387381|NCT02120391|Sham Comparator|Control (Arm A)|"Patients randomized to Arm A(control group) will receive an iPhone application without any of the adherence intervention turned on. The control phone application will allow patients to record their medications and how many refills they have remaining. The application will also provide patients with links about their medication.
~No adherence intervention will be done to these patients."
11387382|NCT02120391|Experimental|Cases (Arm B)|"Patients randomized to Arm B will receive an iPhone application with the adherence intervention turned on. The study coordinator will help with the installation of the iPhone application.
~Participants in this group will not need to pay for the iPhone application."
11387383|NCT02120365|Experimental|Parampanel 6mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg days prior to each test day, and then observed dosing moderate 6mg dose perampanel in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
11387384|NCT02120365|Placebo Comparator|Placebo|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with placebo 7 days prior to each test day, and then observed dosing of placebo in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
11387385|NCT02120365|Experimental|Parampanel 10 mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose parempanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
11387386|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
11387387|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
11387388|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
11387389|NCT02120339|Experimental|Carvedilol|Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day
11387390|NCT02120326|Experimental|active tDCS|
11387391|NCT02120326|Placebo Comparator|simulated tDCS|
11387392|NCT02120313|Active Comparator|inpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in a rehabilitation hospital.
11387393|NCT02120313|Experimental|outpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in an outpatient rehabilitation center.
11387394|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
11387395|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
11387396|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
11387397|NCT02120287|Experimental|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.
~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
11387398|NCT02120274|No Intervention|Control|Pegylated Interferon-Alfa plus ribavirin for 48 weeks
11387399|NCT02120274|Experimental|Vitamins|Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
11387400|NCT02120261|Experimental|TPI with Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
11387401|NCT02120261|Active Comparator|TPI with Lidocaine & Triamcinolone Acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
11387402|NCT02120248|No Intervention|Control|Participants receive standard WIC breastfeeding support but do not have contact with a breastfeeding peer counselor
11387403|NCT02120248|Other|Low Intensity|Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
11387404|NCT02120248|Active Comparator|High Intensity|Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
11387405|NCT02120222|Experimental|Treatment (selinexor)|Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
11387406|NCT02120196|Experimental|rifaximin|Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.
11387407|NCT02120196|Active Comparator|norfloxacin|Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.
11387408|NCT02120183|Experimental|Psycho-educational support group therapy|4 week psycho-educational support group focusing on topics specific to psychosocial and emotional aspects of the cancer caregiving role
11387409|NCT02120170|Active Comparator|Hemoclipping during colon polypectomy for all lesion|The enrolled patients of group 1 will be performed hemoclipping for all polypectomy lesion irrespective of the presence of immediate bleeding.
11387410|NCT02120170|No Intervention|No hemoclipping if there were no bleeding during polypectomy|The patients of group 2 will be performed hemoclipping only for the immediate bleeding during colon polypectomy
11387411|NCT02120157|Experimental|1: Acute Lymphoblastic Leukemia/Lymphoma|"Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*
~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+
~Day 0: Infuse unmanipulated bone marrow
~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg Ideal body weight (IBW)/day IV#
~Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day
~Day +30 Assess chimerism and disease status in bone marrow
~Day +35 Discontinue MMF
~Day +60 Assess chimerism and disease status in bone marrow
~Day 180 Discontinue tacrolimus"
11387447|NCT02119910|No Intervention|Waitlist|Participants will serve as the control condition.
11387491|NCT02119572|Active Comparator|usual education|Patients attend the usual self-management education and communicate with the professionals every two months, getting the information on diabetes diet, exercise, glucose monitor, etc. besides that the group members should attend three follow ups at baseline,6 and 12 months.
11387492|NCT02119559|Other|CTC assay, Cetuximab|Detection & characterization of viable CTC in the peripheral blood.
11387412|NCT02120157|Experimental|2: Acute Lymphocytic Leukemia/Lymphoma|"Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+
~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days
~Day 0: Infuse unmanipulated bone marrow
~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV
~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day
~Day +30 Assess chimerism and disease status in bone marrow
~Day +35: Discontinue MMF
~Day +60: Assess chimerism and disease status in bone marrow
~Day 180 Discontinue tacrolimus"
11387413|NCT02120144|Experimental|Intervention|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
11387414|NCT02120144|Active Comparator|Reading|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to a reading phase on a computer for 10 minutes.
11387415|NCT02120131||test envelope|envelope flap
11387416|NCT02120131||control, trapezodal|standard incision
11387417|NCT02120118|Experimental|Radiation; Hyperthermia; Chemotherapy|Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will cisplatin 30mg/m2 and taxotere 20mg/m2 per week for 6 weekly cycles.
11387418|NCT02120105||Cystinuria|
11387419|NCT02120092|Active Comparator|Clopidogrel + ASA|
11387420|NCT02120092|Placebo Comparator|Clopidogrel + Placebo|
11387421|NCT02120092|Active Comparator|Ticagrelor + ASA|
11387422|NCT02120092|Placebo Comparator|Ticagrelor + Placebo|
11387423|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
11387424|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
11387425|NCT02120066|Other|Vitrectomy|
11387426|NCT02120053|Experimental|Bone substitute material group|Immediate denture placement following extractions and alveolar sockets filling with bone substitute material
11387427|NCT02120053|Active Comparator|Conventional protocol|Immediate denture placement following the conventional protocol
11387428|NCT02120040|Other|Hemangioblastoma (HB) of the Central nervous system (CNS)|
11387429|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
11387430|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
11387431|NCT02120014|Experimental|Heart Failure Reduced EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.
~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.
~Measurements form the right heart catheterization will be recorded for analysis."
11387432|NCT02120014|Experimental|Heart Failure Preserved EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.
~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.
~Measurements form the right heart catheterization will be recorded for analysis."
11387433|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
11387434|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
11387435|NCT02119988|Experimental|TIPS combined with embolization|"The covered stents were used for TIPS
~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
11387436|NCT02119988|Active Comparator|TIPS alone|"The covered stents were used for TIPS
~No embolization of any collateral will be performed during TIPS"
11387437|NCT02119975|Placebo Comparator|Placebo working memory training|
11387438|NCT02119975|Experimental|Working memory training|
11387439|NCT02119962|Experimental|Working memory training|
11387440|NCT02119962|Placebo Comparator|Placebo training|
11387441|NCT02119949|Experimental|Working memory training|
11387442|NCT02119949|Placebo Comparator|Placebo training|
11387443|NCT02119936|Experimental|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
11387444|NCT02119923|Experimental|Working memory training|
11387445|NCT02119923|Placebo Comparator|Placebo training|
11387493|NCT02119546|Experimental|Exercise intervention|Aerobic exercise and dual-task training
11387448|NCT02119897|Experimental|Low Level Light Therapy (LLLT)|"LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck
~Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2
~Route: Extraoral
~Total Treatment Time (all sites): 6 min
~Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.
~Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment."
11387449|NCT02119884|Experimental|Terlipressin group|Patients receive terlipressin 2 mg IV bolus
11387450|NCT02119884|Active Comparator|High Dose Octreotide group|Patients receive Octreotide 50 μg/h with an initial bolus of 100 μg
11387451|NCT02119871|Experimental|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
11387452|NCT02119871|Active Comparator|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
11387453|NCT02119858|Experimental|Diagnostic (ICG, diffuse optical imaging, surgery)|Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.
11387454|NCT02119845|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
11387455|NCT02119832|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
11387456|NCT02119819|Experimental|Dose 1 LY2944876|Dose 1 of LY2944876 given subcutaneously (SC) once weekly for 24 weeks.
11387457|NCT02119819|Experimental|Dose 2 LY2944876|Dose 2 of LY2944876 given SC once weekly for 24 weeks.
11387458|NCT02119819|Experimental|Dose 3 LY2944876|Dose 3 of LY2944876 given SC once weekly for 24 weeks.
11387459|NCT02119819|Experimental|Dose 4 LY2944876|Dose 4 of LY2944876 given SC once weekly for 24 weeks.
11387460|NCT02119819|Experimental|Exenatide extended-release|2 milligrams (mg) exenatide extended-release given SC once weekly for 24 weeks.
11387461|NCT02119819|Placebo Comparator|Placebo|Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.
11387462|NCT02119806|Active Comparator|Benzodiazepine group|"Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ;
~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;
~Postoperative 10-100mcg/kg/min of propofol"
11387463|NCT02119806|Active Comparator|Non-benzodiazepine group|"Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;
~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;
~Postoperative 10-100mcg/kg/min of propofol"
11387464|NCT02119793|Experimental|YVOIRE contour|
11387465|NCT02119780|Experimental|YVOIRE® contour|
11387466|NCT02119780|Active Comparator|Restylane SubQ™|
11387467|NCT02119767||Natural gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have natural gradients sampled using the LBS
11387468|NCT02119767||Induced gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have induced gradients sampled using the LBS
11387469|NCT02119754|Experimental|Plurogel PN|Plurogel PN
11387470|NCT02119741||Affected Interdental Papillae Group|This is the only group in which the material will be used
11387471|NCT02119728|Active Comparator|Arm I (standard of care surgery)|Patients undergo standard of care surgery on day 1.
11387472|NCT02119728|Experimental|Arm II (HPPH, photodynamic therapy)|Patients receive HPPH IV over 1 hour on day 0. Approximately 24 hours later, patients undergo photodynamic therapy on day 1.
11387473|NCT02119715|Experimental|Pegylated rhG-CSF 100μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4
11387474|NCT02119715|Experimental|Pegylated rhG-CSF 150μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4
11387475|NCT02119715|Active Comparator|G-CSF 5 μg/kg/d|Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4
11387476|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment, engaged in care with ART treatment history available.
11387477|NCT02119702||Uninfected Cohort|Perinatally HIV-exposed, perinatally-uninfected participant at or beyond their 18th birthday at enrollment. Must have been previously or currently enrolled in PHACS AMP or PHACS SMARTT, and may have horizontally-acquired HIV infection.
11387478|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
11387479|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
11387480|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
11387481|NCT02119676|Active Comparator|Placebo plus regorafenib|
11387482|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
11387483|NCT02119663|Active Comparator|Placebo plus capecitabine|
11387484|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
11387485|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
11387486|NCT02119624||1|Healthy non-treatment-seeking heavy drinkers
11387487|NCT02119624||2|Healthy light drinkers
11387488|NCT02119611|Other|Single-arm|Therapy
11387489|NCT02119585||Patients undergoing OLT|insertion of nasogastric tube for measurements of chest wall mechanics
11387490|NCT02119572|Experimental|peer support|Patients are divided into small groups and assigned with peer leaders for twelve months according to their residence. Besides the same training and follow-ups as the control arm, patients from intervention groups are suggested and encouraged to take part in the group activities with the peer leaders per month. And if possible, casual activities (such as phone call, chatting, short message; physical exercise, group member family visiting，going to supermarket together, etc.)are also recommended
11387494|NCT02119546|Active Comparator|Stretch exercise|Stretch exercise & sitting balance
11387561|NCT02119078|No Intervention|Standard care (other General Medicine teams)|Admission to one of the 4 non-ACE general medicine teaching teams at OHSU.
11387495|NCT02119520|Active Comparator|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
11387496|NCT02119520|Sham Comparator|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
11387497|NCT02119520|Other|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
11387498|NCT02119507|Experimental|Curodont Repair|Single application on Day 0.
11387499|NCT02119507|Other|No treatment - control|"No treatment as control - wait and see."
11387500|NCT02119481|Experimental|Mindfulness-based stress reduction|Mindfulness-based stress reduction training
11387501|NCT02119481|Active Comparator|Expressive writing condition|Expressive writing
11387502|NCT02119481|No Intervention|Waiting-list control condition|Waiting list
11387503|NCT02119468|Experimental|Treatment (ixazomib citrate, dexamethasone, pomalidomide)|Patients receive ixazomib orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11387504|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
11387505|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
11387506|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
11387507|NCT02119429|Placebo Comparator|Wheat Germ Oil|Participants will be instructed to consume 2 wheat germ oil capsules ,2g, per day for 12 weeks.
11387508|NCT02119429|Experimental|Pumpkin Seed Oil|Participants will be instructed to consume 2 pumpkin seed oil capsules ,2g, per day for 12 weeks
11387509|NCT02119416|Experimental|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
11387510|NCT02119416|Experimental|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
11387511|NCT02119416|Experimental|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
11387512|NCT02119403|Experimental|Hand Held NitrousTM|There are no other interventions to this device
11387513|NCT02119390|Other|Standard Care|Participants in the Standard Care group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care.
11387514|NCT02119390|Experimental|Pill Trial+|Participants in the Pill Trial+ group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care plus three 25-minute individualized, behavioral, staff-delivered intervention sessions at HAART initiation, and 1-, and 3-month follow-up visits. Two brief booster sessions will also be provided following sessions 1 (in clinic) and 2 (by phone).
11387515|NCT02119377||Transgender and Transsexual People|Transgender and transsexual (trans) people aged 18 years or older living in Australia were invited to complete a questionnaire assessing a range of mental and physical health domains.
11387516|NCT02119364|Active Comparator|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
11387517|NCT02119364|No Intervention|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
11387518|NCT02119351|Active Comparator|ViaValve™ Safety IV Catheter|Insertion of the ViaValve™ Safety IV Catheter
11387519|NCT02119351|Active Comparator|ProtectIV® Plus Safety IV Catheter|Insertion of the ProtectIV® Plus Safety IV Catheter
11387520|NCT02119338|Experimental|5-ala preoperatively|A dose of 5-ala will be taken by mouth approximately 3 hours before going to surgery.
11387521|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
11387522|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
11387523|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
11387524|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
11387525|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
11387526|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
11387527|NCT02119273|Experimental|Steroid|The steroid arm will take prednisone 10mg tabs starting 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
11387528|NCT02119273|Placebo Comparator|Placebo|The placebo arm will receive placebo pills identical in appearance to prednisone 10mg pills. They will start taking them 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
11387529|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
11387556|NCT02119117|Experimental|CoQ10|Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).
11387557|NCT02119104||Prevenar (13v)|
11387558|NCT02119091|Experimental|Moxifloxacin|Single oral dose 400 mg
11387530|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
11387531|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
11387532|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
11387533|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
11387534|NCT02119247|Experimental|CHF6001 dry powder for inhalation via NEXThaler®|4 inhalations of CHF 6001 NEXThaler®
11387535|NCT02119247|Active Comparator|CHF 6001 DPI capsules for inhalation via Aerolizer|3 inhalations of CHF 6001 capsules via Aerolizer®
11387536|NCT02119234|Experimental|CHF5993 pMDI + Spacer|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer
11387537|NCT02119234|Active Comparator|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only
11387538|NCT02119234|Placebo Comparator|Placebo pMDI|Placebo pMDI x 4 inhalations
11387539|NCT02119221|Experimental|[14C]Copanlisib|
11387540|NCT02119208|Experimental|Lifestyle counseling|
11387541|NCT02119195|No Intervention|No treatment|The composite resin restorations had marginal defects, but were clinically acceptable, did not receive treatment
11387542|NCT02119195|No Intervention|Positive control|Composite resins with alpha value in marginal adaptation criteria
11387543|NCT02119195|Experimental|Intervention|For this group, defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3M ESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure
11387544|NCT02119182||Comprehensive Assessment with MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.
~Phone Outcome Assessment at 3 months.
~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.
~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
11387545|NCT02119182||Comprehensive Assessment without MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.
~Phone Outcome Assessment at 3 months.
~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
11387546|NCT02119182||Brief Assessment|• Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.
11387547|NCT02119169|Experimental|pigtail catheter|Pigtail catheter for pleural drainage of recurrent hepatic hydrothorax
11387548|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
11387549|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
11387550|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
11387551|NCT02119143|Active Comparator|Vitamines and minerals|41 middel aged subjects receive vitamin and mineral supplementation
11387552|NCT02119143|Placebo Comparator|cellulose|41 middle aged subjects get the placebo
11387553|NCT02119130|No Intervention|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
11387554|NCT02119130|Experimental|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
11387555|NCT02119117|Placebo Comparator|sugar pill|Group 2 will receive a placebo of CoQ10
11387559|NCT02119091|Placebo Comparator|Placebo|Single oral dose
11387560|NCT02119078|Active Comparator|ACE Service|Admission to the Acute Care for Elders (General Medicine Team 1) service. (See Intervention, below)
11387562|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
11387563|NCT02119052|Experimental|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
11387564|NCT02119052|Placebo Comparator|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
11387565|NCT02119039|Experimental|RGTA OTR 4120 (CACICOL20)|
11387566|NCT02119039|Active Comparator|Genteal HA|
11387567|NCT02119026|Active Comparator|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)
~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance
~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
11387568|NCT02119026|Active Comparator|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)
~Arm B:
~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance
~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
11387569|NCT02119013|Experimental|OCTEOTRIDE|Octeotride, 20 mg monthly intramuscular injection for 3 years
11387570|NCT02119013|Placebo Comparator|PLACEBO|Placebo (salin soluction), intramuscular injection monthly for 3 years
11387571|NCT02119000|Experimental|PEG electrolytes 2L/2L split dose|
11387572|NCT02119000|Active Comparator|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|
11387573|NCT02118987|Experimental|Omalizumab|300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. During this treatment period, patients will continue receiving their regularly scheduled chemotherapy desensitizations per the prescribed treatment schedule from the patient's oncologist.
11387574|NCT02118974|Experimental|Robot-assisted|Robot-assisted hysterectomy
11387575|NCT02118974|Experimental|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
11387576|NCT02118961|Experimental|BK1301|
11387577|NCT02118961|Active Comparator|DT toxoid|
11387578|NCT02118948|Experimental|Abuse-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on the psychological consequences of abuse, current sexual risk behavior, and the link between the two.
11387579|NCT02118948|Active Comparator|Sexual behavior-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on current sexual risk behavior.
11387580|NCT02118935|Active Comparator|Previously marketed cow's milk-based infant formula|
11387581|NCT02118935|Experimental|Marketed cow's milk-based infant formula with prebiotics|
11387582|NCT02118922||Healthy volunteers|Volunteers with normal corneas
11387583|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
11387584|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
11387585|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
11387586|NCT02118922||Volunteers to receive PRK surgery|This group includes patients who have been diagnosed with myopia and have been scheduled to undergo PRK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen or artificial tears will be excluded.
11387587|NCT02118922||Volunteers to receive LASIK Surgery|This group includes myopic patients who are scheduled to receive LASIK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen and artificial tears will be excluded.
11387588|NCT02118922||Patients with Fuch's Endothelial Corneal Dystrophy|This group includes subjects who are diagnosed with Fuch's corneal dystrophy, at early, mild and advanced stages. The inclusion also extends to subjects with, and without keratoconus. But this exclude patients with any other corneal disorders other than keratoconus, and/or history of ophthalmological surgeries that may affect endothelium cell status, e.g. cataract surgeries.
11387589|NCT02118909|Experimental|Part 1 (Pracinostat + Itraconazole)|Single-dose pracinostat and itraconazole dosing every day for 8 days
11387590|NCT02118909|Experimental|Part 2 (Pracinostat + Ciprofloxacin)|Single dose pracinostat and ciprofloxacin 2 times a day for 7 days
11387591|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
11387592|NCT02118883|Other|Essentia Water|Essentia Water, electrolyzed high-pH water
11387593|NCT02118883|Other|Bottled Water|Purified bottle water
11387594|NCT02118870|Active Comparator|DAPT 360 days|Treatment 360 days DAPT
11387595|NCT02118870|Active Comparator|DAPT 90 days|Treatment 90 days DAPT
11387596|NCT02118857||Omnivore, vegetarian and vegan subjects.|These subjecs followed the diet from at least two years.
11387597|NCT02118844|Active Comparator|Moderate rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain moderate neuromuscular blockade (TOF-count 2-4) during gastrojejunal anastomosis
11387598|NCT02118844|Experimental|deep rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain deep neuromuscular blockade (here defined as a Posttetanic Count 1 - 5) during gastrojejunal anastomosis
11387599|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
11387600|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
11387601|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
11387602|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
11387603|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
11387604|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
11387605|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
11387606|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
11387607|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
11387608|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
11387609|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
11387610|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
11387611|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
11387612|NCT02118779|Experimental|Behavioural change intervention|Cognitive behavioural therapy (CBT) combined with exercise
11387613|NCT02118779|No Intervention|Standard Patient Management|Standard care like usual (i.e. annual checks with neurologist, checks with cardiologist, if needed physical therapy)
11387614|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
11387615|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
11387616|NCT02118753|No Intervention|ischemic preconditioning|"After baseline recordings of contractile function, the investigators will assign 2 trabeculae of each patient to either a stimulus for (1) ischemic preconditioning (IP) or (2) no IP. Subsequently, the trabeculae will be exposed to 90 min of ischemia, followed by 120 minutes of recovery. The investigators will measure the recovery of contractile function in both trabeculae.
~This experiment serves as a positive control, to ensure that our model is still working properly."
11387617|NCT02118753|Experimental|eplerenone|In the next patients, a similar ischemia-reperfusion experiment will be performed, but now the 2 trabeculae will be randomized to pretreatment with eplerenone or DMSO. The percentage recovery (compared to baseline) of contractile force of the trabeculae at the end of reperfusion will serve as the primary endpoint.
11387618|NCT02118727|Active Comparator|Memantine|20mg taken by mouth every day BID for 32 weeks
11387619|NCT02118727|Placebo Comparator|Placebo|Placebo (for Memantine) taken by mouth everyday BID for 32 weeks
11387620|NCT02118714|Experimental|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
11387621|NCT02118701|Experimental|SDM care planning|
11387622|NCT02118688|Placebo Comparator|Placebo|"Drug: Placebo
~Placebo suspension administered PO/NG/FT q12h to mimic risperidone
~Placebo suspension administered PO/NG/FT q8h to mimic trazodone"
11387623|NCT02118688|Active Comparator|Risperidone alone|"Drug: Risperidone
~Initiate risperidone at 1 mg PO/NG/FT q12h
~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose
~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
11387624|NCT02118688|Active Comparator|Trazodone alone|"Drug: Trazodone
~Initiate trazodone dosing at 50 mg PO/NG/FT q8h
~Trazodone dose can be titrated upwards every 24 hours by 25 mg per dose
~Maximum trazodone daily dose 600 mg per day (200 mg every 8 hours)"
11387625|NCT02118688|Active Comparator|Risperidone and Trazodone combination|"Drug: Risperidone
~Initiate risperidone at 1 mg PO/NG/FT q12h
~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose
~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)
~Drug: Trazodone
~Initiate risperidone at 1 mg PO/NG/FT q12h
~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose
~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
11387626|NCT02118675||Age 5-17 years|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
11387627|NCT02118675||Age 18-80 years|Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
11387628|NCT02118662|Experimental|Male Cohort|"Eight Male participants per cohort will complete the following:
~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
11387629|NCT02118662|Experimental|Female Cohort|"Eight femalel participants per cohort will complete the following:
~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
11387630|NCT02118649|Experimental|Game|Participants will play a video game directing their gaze to on-screen targets.
11387631|NCT02118636||Aromatase inhibitor therapy|Subjects who are starting treatment with any of the three aromatase inhibitor (AI) medications
11387632|NCT02118623|Active Comparator|Level 1|Moderated discussion board only
11387633|NCT02118623|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
11387634|NCT02118623|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools.
11387635|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
11387636|NCT02118610|Placebo Comparator|Sugar Pill|
11387703|NCT02118116|No Intervention|Wait-list Control|No training, wait-listed for ASIST at a later date
11387813|NCT02117401|Experimental|group 6|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
11387637|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
11387638|NCT02118584|Experimental|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
11387639|NCT02118584|No Intervention|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
11387640|NCT02118558|Experimental|Negative Pressure Wound Therapy (NPWT)|
11387641|NCT02118558|Active Comparator|standard prophylactic therapy|
11387642|NCT02118545||vWF and postoperative Outcome|An independent prospective validation cohorts will be obtained from 4 different Institutions: 2 in Vienna , 1 in Salzburg and 1 in Bern
11387643|NCT02118532|Experimental|IN.PACT Admiral|
11387644|NCT02118519|Active Comparator|mesenchymal stem cells|Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
11387645|NCT02118519|Active Comparator|mesenchymal cells&platelet lysate|Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury
11387646|NCT02118506|Active Comparator|Physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.
~Physical practice: is the execution of the motor action."
11387647|NCT02118506|Experimental|Mental and physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.
~Mental practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.
~Physical practice: is the execution of the motor action."
11387648|NCT02118493|Experimental|Benign Biliary Stenosis, Laser|Subjects that undergo the experimental intervention, that being single use of a laser excision catheter.
11387649|NCT02118480|Experimental|cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
11387650|NCT02118480|Active Comparator|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
11387651|NCT02118467|Active Comparator|Norepinephrine and epinephrine|"Patients will receive norepinephrine infusion per standard protocol. Dose range will be 0.03-0.3 mcg/kg/minute. Norepinephrine concentration will be 16 mg/250 mL. If a second vasopressor is required, epinephrine will be added. Dose range of epinephrine will be 0.03-0.3 mcg/kg/minute. Epinephrine concentration will be 16 mg/250 mL. The drugs norepinephrine and epinephrine will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.
~If the patient's shock is not adequately treated with the highest doses of both norepinephrine and epinephrine, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
11387652|NCT02118467|Active Comparator|Phenylephrine and vasopressin|"Patients will receive phenylephrine infusion per standard protocol. Dose range will be 0.3 to 3.0 mcg/kg/minute. Phenylephrine concentration will be 160 mg/250 mL. If a second vasopressor is required, vasopressin will be added. Dose range of vasopressin will be 0.1 to 0.6 milliunits/kg/minute. Vasopressin concentration will be 40 units/250 mL. The drugs phenylephrine and vasopressin will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.
~If the patient's shock is not adequately treated with the highest doses of both phenylephrine and vasopressin, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
11387653|NCT02118454|Experimental|Daily IVR calls|"The Daily IVR Calls Intervention: consisting of two (2) automated voice calls (intervention messages) each day for six months, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months"
11387654|NCT02118454|Active Comparator|Weekly IVR Survey Only|The Weekly IVR Survey Only control condition: consisting of standard care, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months.
11387655|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
11387656|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.
~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
11387657|NCT02118428|Experimental|Mirasol|Transfusions with Mirasol-treated whole blood
11387658|NCT02118428|Active Comparator|Control|Transfusions with untreated whole blood
11387659|NCT02118415|Experimental|Interventional|Interventional group: activated autologous NK cell treatment
11387660|NCT02118415|No Intervention|Control group|Control group: BSC
11387661|NCT02118402|Active Comparator|Fortified maize porridge (MNP)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, maltodextrin carrier (added up to 11g)
11387662|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
11387663|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe+GOS)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA plus 7.5 g of galactooligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
11387664|NCT02118389|Experimental|Glucerna,Meal Replacement|Glucerna 52g instead of night meal 5weeks
11387665|NCT02118376|Experimental|exenatide|exenatide, 5ug, bid, 3months
11387666|NCT02118350|Experimental|Mat Pilates training|Mat Pilates training performed two times at week for 16 weeks.
11387667|NCT02118350|No Intervention|Control|
11387668|NCT02118337|Experimental|0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
11387669|NCT02118337|Active Comparator|Nivolumab|Nivolumab monotherapy at the selected dose
11387670|NCT02118337|Experimental|0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab combination
11387671|NCT02118337|Experimental|0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
11387672|NCT02118337|Experimental|2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
11387673|NCT02118337|Experimental|10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
11387674|NCT02118337|Experimental|20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W|MEDI0680 and Durvalumab in combination
11387675|NCT02118337|Experimental|20 mg/kg MEDI0680 Q2W; 750 mg durvalumab Q2W|MEDI0680 and Durvalumab in combination
11387676|NCT02118324|Experimental|Exercise treatment|Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.
11387677|NCT02118324|No Intervention|Control group|No intervention is provided.
11387678|NCT02118311|Experimental|TREG|T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
11387679|NCT02118311|Experimental|Non-Myeloablative Only|Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
11387680|NCT02118298||Multiple Sclerosis|Ages 18 - 66, 10 years or less of MS,
11387681|NCT02118298||Demographically matched controls|Ages 18 - 66, No known neurological disorder, no learning disorder, and no psychiatric disturbance that is actually interfering with life.
11387682|NCT02118285|Experimental|Treatment|Haploidentical donor NK cells and IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion and continues twice daily for 90 days.
11387683|NCT02118272|Other|Physica KR|
11387684|NCT02118259|Other|The study population|"See inclusion and exclusion criteria.
~Intervention: Before-after study"
11387685|NCT02118246|Experimental|Dry Needling|The taut band of trigger point in vastus lateralis muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
11387686|NCT02118246|Experimental|Kinesio Tape|Y technique with 25% tension on the tails was applied. Direction of the technique was insertion to origin of the muscle and zone of the trigger point was placed at the center of Y strip.
11387687|NCT02118233||Carotid Endarterectomy (CEA)|Surgical Revascularization- Carotid Endarterectomy (CEA)
11387688|NCT02118233||Carotid Angioplasty and Stenting (CAS)|Surgical Revascularization- Carotid Angioplasty and Stenting (CAS)
11387689|NCT02118233||Control Group- Medical Management|Control Group- Medical Management
11387690|NCT02118220|Other|Concussion Questionnaire|"The questionnaire is specifically designed to elicit occurrence and symptoms of a concussion. If the patient answers yes to question 2a, which asks At the time of the injury do you recall a blow to the head, neck, face or body that resulted in sustained symptoms of concussion (e.g., headache, dizziness, confusion, nausea, vomiting, etc.)?, the research team will administer the 22 item self-reporting symptom scale in the above mentioned SCAT3. The responses obtained from the questionnaire will be used to determine the incidence of symptomatic concussions, either known or unrecognized, in pediatric patients sustaining an orthopedic injury requiring surgical repair."
11387691|NCT02118207|Experimental|Control dives 1st|Subjects in this group complete the first 3 dives as control dives and the second 3 dives preceded by aerobic exercise
11387692|NCT02118207|Experimental|Predive exercise 1st|Subjects complete the first 3 dives preceded by the intervention of aerobic exercise and the second 3 with no exercise as control dives
11387693|NCT02118194||Paraplegia, spinal cord injury|An exoskeleton-assisted walking system for people with paralysis from spinal cord injury at thoracic level 1 and below (paraplegia) will be used.
11387694|NCT02118181|No Intervention|Control|
11387695|NCT02118181|Experimental|HMB|Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate
11387696|NCT02118168||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-002 and that received at least 3 immunizations and reached 48-weeks of follow-up."
11387697|NCT02118155|Sham Comparator|Connective tissue graft (CTG)|The gingival recession defects were treated by connective tissue graft surgical procedure and received the sham application os low-intensity laser therapy.
11387698|NCT02118155|Experimental|Connective tissue graft plus laser (CTG+L)|The gingival recession defects were treated by connective tissue graft associated with the application of a LILT protocol
11387699|NCT02118142|Active Comparator|Betaine|6 gram dose of betaine delivered in encapsulated form
11387700|NCT02118142|Placebo Comparator|Dextrose|6 gram dose of dextrose delivered in encapsulated form
11387701|NCT02118129|Experimental|Behavioural intervention|Behavioural intervention consisting of an educational video component and use of a handheld mobile app to track vitamin D intake.
11387702|NCT02118129|Placebo Comparator|Control group|Wait-list control group
11387704|NCT02118116|Experimental|ASIST|Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
11387705|NCT02118116|Experimental|ASIST uncontrolled arm|The ASIST workshop will be offered to participants who refuse to be part of the waitlist control arm. This is due to the reality in gathering data in these communities. Many times it is not possible for participants to be waitlisted, and therefore we would still want to gather data on those that refuse to participate in the RCT design and will collect uncontrolled data on these participants only.
11387706|NCT02118103|Experimental|Spinal Manipulation|bilateral lumbar spine manipulation
11387707|NCT02118103|No Intervention|No Intervention - control|no intervention
11387708|NCT02118090|Experimental|Chloroquine|Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days
11387709|NCT02118090|Active Comparator|DHA-PP|Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP
11387710|NCT02118077|Experimental|G17DT|250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.
11387711|NCT02118077|Placebo Comparator|Placebo|Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.
11387712|NCT02118064|Experimental|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
11387713|NCT02118051|Experimental|CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.|"Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.
~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
11387714|NCT02118051|Active Comparator|hMG ,Ganirelix,choriogonadotropin alfa,progesterone|"Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.
~Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.
~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
11387715|NCT02118038||HELPMOM1|corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
11387716|NCT02118038||HELPMOM2|corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring
11387717|NCT02118025||Off-pump coronary artery bypass graft|Patients operated on with off-pump coronary artery bypass graft, beating heart surgery.
11387718|NCT02118025||Mini extracorporeal circulation bypass|Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
11387719|NCT02118012|Active Comparator|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
11387720|NCT02118012|Active Comparator|Chlorcyclizine HCl only|Chlorcyclizine HCl only
11387721|NCT02117999|Experimental|Cross-linking with iontophoresis|Transepithelial cross-linking by using iontophoresis to administer riboflavin into the corneal stroma
11387722|NCT02117999|Active Comparator|Standard corneal cross-linking|Standard corneal cross-linking includes de-epithelialization and stromal soaking by applying drops of riboflavin
11387723|NCT02117986|Experimental|loading dose of colistin|Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous
11387724|NCT02117986|Active Comparator|without loading dose of colistin|Patients will receive 3 million international units of colistin every 8 hours intravenous
11387725|NCT02117973|Active Comparator|Conventional Technique using Persona prosthesis|The surgeon will realize the implantation of the Persona prosthesis according to the surgical technique. Potential variables such as methodology for determining tibial rotation, measuring of bone cuts, and any intra-operative adjustments will be captured on the operative case report form.
11387726|NCT02117973|Experimental|iAssist Technique using Persona prosthesis|iAssist is an electronic displacement sensor based instrumentation system that provides intra-operative verification at each surgical step (bone cuts alignment and resection level); in order to help reduce bone cuts errors. iAssist features simple and intuitive instrumentation that is based on conventional total knee arthroplasty instrumentation. iAssist should take less than 2-3 minutes (on average) to setup
11387727|NCT02117960|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
11387728|NCT02117960|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
11387729|NCT02117947|Experimental|Behavioral Counseling|Behavioral counseling used evidence-based smoking cessation intervention components as well as a theoretically-framed focus on behavioral shaping to promote the adoption of smoke-free homes and cars. Sessions included two, 1-hour in-home counseling and seven, 5-15 minute telephone follow-up sessions over 16 weeks. Content included health ed around the benefits of eliminating children's exposure to secondhand smoke; skills training around adoption and maintenance of smoke-free environments; goal setting, problem solving, and positive reinforcement for progress toward goals; coping skills training for smoking urge and mood management; and home support for maternal smoking behavior change achieve through family contracts and home detailing promoting pro-smoke-free home norms.
11387730|NCT02117947|Active Comparator|Self-help control|The self-help control group received a comprehensive self-help manual that outlined all of the goals and strategies covered in counseling, however, counseling was not provided to this group.
11387731|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
11387768|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
11387732|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
11387733|NCT02117921|Experimental|MBS therapy education|
11387734|NCT02117908|Experimental|CPAP +4 cm H2O|CPAP +4 cm H2O pressure using ResMedTM face mask
11387735|NCT02117908|Sham Comparator|ShamCPAP|shamCPAP using ResMedTM CPAP face mask modified for technical sham
11387736|NCT02117895|Experimental|Pancreatectomy & celiac plexus resection|Left celiac plexus resection will be performed besides standard distal pancreatectomy. Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
11387737|NCT02117895|Active Comparator|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
11387738|NCT02117882||minimally invasive approach test|minimally invasive lateral approach
11387739|NCT02117882||control lateral traditional approach|standard surgical approach
11387740|NCT02117869|Experimental|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin hybrid grapefruit juice plus midazolam 5mg orally on the third day.
11387741|NCT02117869|Active Comparator|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
11387742|NCT02117869|Other|water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
11387743|NCT02117856|Active Comparator|1 implant|"Participants receive the following:
~1 implant placed surgically in the mandibular midline; Soft reline of the existing complete lower denture; 2.25mm ball patrix placed on 1 healed implant; and Reline with 1 retentive matrix in the lower denture."
11387744|NCT02117856|Active Comparator|2 implants|"Participants receive the following:
~2 implants placed surgically in the mandibular canine sites; Soft reline of the existing complete lower denture; 2.25mm ball patrices placed on 2 healed implants; and Reline with 2 retentive matrices in the lower denture."
11387745|NCT02117843|Experimental|AVI® Arsenic trioxide drug eluting stent|The Arsenic trioxide as AVI eluting drug, biodegradable polylactic acid as drug carrier.
11387746|NCT02117830|Experimental|Androxal 25 mg|
11387747|NCT02117830|Experimental|Androxal 250 mg|supratherapeutic dose
11387748|NCT02117830|Placebo Comparator|Placebo|
11387749|NCT02117830|Other|Moxifloxacin 400 mg|positive control
11387750|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
11387751|NCT02117804||High ESDP Score|Patients with 10 or greater score on the Early Screen for Discharge Planning at the time of admission.
11387752|NCT02117804||Low ESDP Score|Patients with 9 or lower score on the Early Screen for Discharge Planning at the time of admission.
11387753|NCT02117791||Group 1|Riociguat treatment group
11387754|NCT02117778|Active Comparator|Interscalene|Continuous Interscalene Nerve Block
11387755|NCT02117778|Active Comparator|Supraclavicular|Continuous Supraclavicular Nerve Block
11387756|NCT02117778|Active Comparator|Suprascapular|Continuous Suprascapular Nerve Block
11387757|NCT02117765|Experimental|Treatment|"Four cohorts of 5 subjects will be recruited:
~Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks.
~Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks.
~Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks.
~Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks."
11387758|NCT02117752|Experimental|Dapsone Gel Subset 1|Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
11387759|NCT02117752|Experimental|Dapsone Gel Subset 2|Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
11387760|NCT02117739|Experimental|All Participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches twice a week for 21 days followed by a 10 to 17 day rest period then another application of dapsone gel and dapsone gel vehicle by patch.
11387761|NCT02117726|Experimental|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
11387762|NCT02117726|Active Comparator|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
11387763|NCT02117713|Experimental|LUM001|Participant will receive LUM001 as oral solution once daily based on participant's weight. The dose will be escalated from 14, 35, 70, 140 and 280 microgram per kilogram per day (mcg/kg/day) for 4-week dose escalation period. During 8-weeks of dose optimization period, drug will be adjusted in titrated manner and will continue dosing to complete the stable dosing and safety monitoring periods for up to 96 weeks of cumulative LUM001 exposure in this study. Dosing during, long-term optional follow-up treatment periods 1 and 2 will be maintained at the same dose levels as at weeks 96 and 144 for participants rolling over into these treatment periods respectively.
11387764|NCT02117700|Experimental|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
11387765|NCT02117700|Experimental|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
11387766|NCT02117700|Placebo Comparator|Placebo|Placebo twice/day for 16 weeks
11387767|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
11387769|NCT02117674|Active Comparator|standard forward-viewing colonoscopy|polyp detection with standard forward-viewing colonoscopy polyp detection in the right colon with scope retroflexion
11387770|NCT02117674|Active Comparator|full-spectrum colonoscopy|polyp detection with full-spectrum colonoscopy polyp detection in the right colon with scope retroflexion
11387771|NCT02117661|Experimental|L-carnitine capsules|2000 mg daily (2x 500 mg capsules twice a day - BID) for six months
11387772|NCT02117661|Placebo Comparator|Cellulose capsules|2x capsules twice a day - BID (4 total per day) for six months
11387773|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
11387774|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
11387775|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
11387776|NCT02117635|Experimental|allogeneic human neural stem cell|"CTX DP
~human neural stem cell product, single dose once only injection"
11387777|NCT02117622||Patients with diabetes mellitus requiring insulin therapy|
11387778|NCT02117609|Experimental|New DELICAL formula|New high-protein oral nutrient supplement
11387779|NCT02117609|Active Comparator|Standard DELICAL formula|Standard isoenergetic isoprotein formula
11387780|NCT02117596|Other|Sirolimus|Single arm
11387781|NCT02117583|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11387782|NCT02117583|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11387783|NCT02117583|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11387784|NCT02117583|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11387785|NCT02117570|Experimental|High dose of C. difficile vaccine|
11387786|NCT02117570|Experimental|Low dose of C. difficile vaccine|
11387787|NCT02117570|Placebo Comparator|Placebo|
11387788|NCT02117557|Experimental|Single incision laparoscopic surgery|Transumbilical single incision laparoscopic surgery will be performed for patients in this group.And addition of only one trocar through the stoma for drainage tube is allowed.
11387789|NCT02117557|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
11387790|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
11387791|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
11387792|NCT02117518||no treatment|T1D patients at ages 0-25
11387793|NCT02117505|Experimental|Group 1 (Formulation 2 Then Formulation 1)|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in first treatment period; followed by JNJ-54781532 formulation 1 as 150 mg orally (5*30 mg tablet=150 mg) in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11387794|NCT02117505|Experimental|Group 2 (Formulation 1 Then Formulation 2)|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 mg oral tablet (5*30 mg tablet=150 mg) in first treatment period; followed by JNJ-54781532 formulation 2 as 150 mg oral tablet in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
11387795|NCT02117492|Experimental|Vertical Cuff|Vaginal cuff closure will be done vertically.
11387796|NCT02117492|Experimental|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
11387797|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
11387798|NCT02117479|Active Comparator|Placebo plus capecitabine|
11387799|NCT02117466|Other|Standard dose cetuximab|Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
11387800|NCT02117466|Experimental|Dose escalation cetuximab|No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
11387801|NCT02117453|Experimental|Group I|Rosuvastatin 20 mg/day
11387802|NCT02117453|Placebo Comparator|Group II|Placebo
11387803|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
11387804|NCT02117427|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
11387805|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
11387806|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
11387807|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
11387808|NCT02117401|Experimental|group 1|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s
11387809|NCT02117401|Experimental|group 2|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s
11387810|NCT02117401|Experimental|group 3|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
11387811|NCT02117401|Experimental|group 4|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
11387812|NCT02117401|Experimental|group 5|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
11387889|NCT02116946|Placebo Comparator|Saline + exercise|Saline injection and a 12 week exercise program.
11387814|NCT02117401|Experimental|group 7|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
11387815|NCT02117401|Experimental|group 8|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
11387816|NCT02117401|Experimental|group 9|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
11387817|NCT02117401|Experimental|group 10|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
11387818|NCT02117401|Experimental|group 11|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
11387819|NCT02117401|Experimental|group 12|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
11387820|NCT02117401|Experimental|group 13|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
11387821|NCT02117401|Experimental|group 14|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
11387822|NCT02117401|Experimental|group 15|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
11387823|NCT02117401|Experimental|group 16|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
11387824|NCT02117388|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
11387825|NCT02117388|Experimental|Sleep Restriction|Sleep Restriction therapy will limit the time participants spend in bed in order to make sure they are sleepy enough to fall asleep quickly.
11387826|NCT02117388|Experimental|Combined Therapy Treatment for Insomnia|Combined Therapy involves combining Sleep Restriction and Cognitive Therapy so that the two therapies reinforce each other.
11387827|NCT02117375|Experimental|Patients with multiple sclerosis|80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60
11387828|NCT02117375|Experimental|Healthy volunteers|20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24
11387829|NCT02117362|Experimental|Cohort 1|1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
11387830|NCT02117362|Experimental|Cohort 2|2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
11387831|NCT02117362|Experimental|Cohort 3|4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
11387832|NCT02117362|Experimental|Cohort 4|8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
11387833|NCT02117349|Experimental|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:
~A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.
~A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.
~Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.
~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.
~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
11387834|NCT02117349|Other|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.
~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
11387835|NCT02117336|Experimental|P1446A-05|
11387836|NCT02117310|Experimental|ICG|Angiography with administered ICG
11387837|NCT02117297|Experimental|Gemtuzumab Ozogamicin|Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is >1000/mm3 and platelet count is >40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.
11387838|NCT02117284||Coronary artery disease|All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.
11387839|NCT02117271|Placebo Comparator|nasal dilator strip|Breathe Right ® nasal dilator strip used during sleep
11387840|NCT02117271|Experimental|continuous positive airway pressure|nasal continuous positive airway pressure used during sleep
11387841|NCT02117258|Experimental|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
11387842|NCT02117258|Experimental|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
11387843|NCT02117258|Experimental|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
11387844|NCT02117258|Placebo Comparator|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
11387845|NCT02117232|Experimental|Visualization balloon|"Colonoscopy performed with the use of Visualization balloon"
11387846|NCT02117232|Active Comparator|Traditional CO2-insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
11387847|NCT02117219|Experimental|MEDI4736 Evaluate MEDI4736 in MDS|Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS
11387848|NCT02117219|Experimental|MEDI4736 + tremelimumab|Evaluate MEDI4736 in combination with tremelimumab
11387849|NCT02117219|Experimental|MEDI4736 + tremelimumab + azacitidine|Evaluate MEDI4736 in combination with tremelimumab and azacitidine
11387850|NCT02117206|Active Comparator|L-Arginine|Femoral arterial infusion of 2 g L-Arginine for 30 min
11387851|NCT02117206|Placebo Comparator|Nacl|Femoral arterial infusion of Nacl for 30 min
11387852|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
11387853|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
11387854|NCT02117180|Other|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
11387855|NCT02117167|Experimental|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, olaparib tablet per os 300 mg bd continuous dosing savolitinib tablet per os 600 mg od continuous dosing
11387856|NCT02117167|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
11387857|NCT02117167|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with durvalumab for patient without actionable genomic alterations or non eligible to Targeted substudy 1, durvalumab Intra-venous 10 mg/kg, Q2W
11387858|NCT02117167|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
11387859|NCT02117154||HbA1c, 6-day Professional CGM|6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
11387860|NCT02117141|Experimental|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
11387861|NCT02117141|Experimental|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
11387862|NCT02117128|Experimental|Tranexamic acid, IA group|Tranexamic acid 1g, intra-articular injection, post-operationally
11387863|NCT02117128|Active Comparator|Tranexamic acid, IV group|Tranexamic acid, 1g, intravenous injection, post-operationally
11387864|NCT02117128|Experimental|Tranexamic acid, IV+IA group|Tranexamic acid, 1g, intravenous injection, post-operationally; Tranexamic acid, 1g, intra-articular injection, post-operationally
11387865|NCT02117115|Experimental|CT scan with contrast|
11387866|NCT02117102|Experimental|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
11387867|NCT02117102|No Intervention|Control group|Ordinary pediatric urine collection bag
11387868|NCT02117089|Experimental|Device-assisted rehabilitation|
11387869|NCT02117076|Active Comparator|gabapentin immediate release|Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
11387870|NCT02117076|Active Comparator|gabapentin enacarbil extended release|Horizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
11387871|NCT02117063|Experimental|Go Girls! Fitness Support Group|
11387872|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
11387873|NCT02117037|Other|study of PEC markers and chemokines/ chemokine recep|blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
11387874|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
11387875|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
11387876|NCT02117011|Other|Physical activity|An 8-week structured, moderate-intensity aerobic training exercise regimen concurrent with their radiation therapy (N=15),
11387877|NCT02117011|No Intervention|Control|Patients will continue with usual care, which includes radiation treatment.
11387878|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
11387879|NCT02116998|Placebo Comparator|Placebo|
11387880|NCT02116985|Experimental|Dual-Loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
11387881|NCT02116985|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
11387882|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
11387883|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
11387884|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
11387885|NCT02116959|Experimental|Cohort 1|"Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy.
~Bilateral retinoblastoma patients will be in Cohort 1.
~For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy."
11387886|NCT02116959|Experimental|Cohort 2|Patients will receive only intra-arterial (IA) therapy for more limited disease.
11387887|NCT02116946|Experimental|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
11387888|NCT02116946|Experimental|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
11387890|NCT02116933|Active Comparator|Level I|A small, level I study will compare autologous fat grafting alone to stromal vascular fraction SVF enriched autologous fat grafting int he same patient. One breast will be treated with AFG alone and act as the control, and the other breast will be treated with SVF enriched AFG adn act as the experimental side exploring the efficacy of adipose derived stem cells.
11387891|NCT02116933|Active Comparator|Level II|A larger, level II study comparing Autologous Fat Grafting to SVF enriched AFG in different patients. In this study, patients can choose to have AFG in both breasts or SVF enriched AFG in both breasts. The two patient groups will be compared. Here the group with the AFG in both breasts will be the control and the SVF enriched AFG in both breasts will be the experimental group exploring the efficacy of adipose derived stem cells.
11387892|NCT02116920||VIA Positive|Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid
11387893|NCT02116907|Experimental|Perampanel|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
11387894|NCT02116894|Experimental|PF-03446962 plus regorafenib|
11387895|NCT02116881||Open colorectal surgery|Patients scheduled to undergo open colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
11387896|NCT02116881||Laparoscopic colorectal surgery|Patients scheduled to undergo laparoscopic colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
11387897|NCT02116868|Experimental|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
11387898|NCT02116868|No Intervention|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
11387899|NCT02116855|Experimental|tertiary prophylaxis prophy on Hemophilia A patiets|A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.
11387900|NCT02116842|Experimental|0.075% bupivacaine|Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
11387901|NCT02116842|Experimental|0.1% bupivacaine|Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
11387902|NCT02116829|Experimental|Danish butter, dairy|
11387903|NCT02116829|Active Comparator|Olive oil, refined|
11387904|NCT02116816|Experimental|Polyphenol|Polyphenol preparations
11387905|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
11387906|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
11387907|NCT02116790|Placebo Comparator|Control Group|10 participants will be given two pills: both will be placebos
11387908|NCT02116790|Active Comparator|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
11387909|NCT02116790|Active Comparator|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
11387910|NCT02116790|Active Comparator|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
11387911|NCT02116777|Experimental|Treatment (talazoparib, temozolomide)|Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11387912|NCT02116764||Cross Sectional|3 years after Transplant
11387913|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
11387914|NCT02116764||Prospective|Prior to Transplant Conditioning
11387915|NCT02116764||Retrospective|1 year after Transplant
11387916|NCT02116738|Experimental|Flap Transposition Technique|Flap Transposition Technique
11387917|NCT02116725|Experimental|Shower gel with zinc|Zinc gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
11387918|NCT02116725|Placebo Comparator|Plain shower gel|Plain shower gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
11387919|NCT02116725|Sham Comparator|Distilled water|Distilled Water is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
11387920|NCT02116712|Experimental|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.
~More regarding dose escalation is included in intervention below."
11387921|NCT02116699|Experimental|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
11387922|NCT02116699|Placebo Comparator|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
11387923|NCT02116686||Heart failure patients with sleep apnea syndrom|For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
11387924|NCT02116673|Other|Control|The control arm receives usual care discharge instructions.
11387925|NCT02116673|Experimental|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
11387955|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 2|single oral dose of levodopa carbidopa immediate release tablets
11387926|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
11387927|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
11387928|NCT02116647|Experimental|Psychoanalytic therapy|manualized psychoanalytic psychotherapy
11387929|NCT02116647|No Intervention|Control Group|Standard care
11387930|NCT02116634|Experimental|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
11387931|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
11387932|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
11387933|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
11387934|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
11387935|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
11387936|NCT02116595|Experimental|feeding a high acid diet x 24 hrs|2 diets, one low and one high net acid loads
11387937|NCT02116595|Active Comparator|low acid diet|
11387938|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
11387939|NCT02116569|Experimental|Daratumumab 8 milligram per kilogram (mg/kg)|Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
11387940|NCT02116569|Experimental|Daratumumab 16 mg/kg|Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
11387941|NCT02116556|Active Comparator|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
11387942|NCT02116556|Experimental|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
11387943|NCT02116543|Experimental|TD-6450|TD-6450 capsules
11387944|NCT02116543|Placebo Comparator|Placebo|Placebo capsules
11387945|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:
~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus
~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus
~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
11387946|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:
~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus
~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus
~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus
~placebo"
11387947|NCT02116517|Experimental|green tea extract first|green tea extract (EGCG) 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally cellulose 500mg tid for 6 weeks total 14 weeks
11387948|NCT02116517|Placebo Comparator|Placebo first|cellulose 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally EGCG 500mg tid for 6 weeks total 14 weeks
11387949|NCT02116504|Other|Global population|"All included patients :
~Sampling of blood"
11387950|NCT02116491|No Intervention|Closed suction system|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Cloesd suction system was performed which the patient remained connected to the ventilator. The catheter was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
11387951|NCT02116491|Experimental|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
11387952|NCT02116478|Experimental|gastrocnemius recession|gastrocnemius recession
11387953|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 1|single oral dose of levodopa carbidopa immediate release tablets
11387954|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 1|single oral dose of levodopa carbidopa immediate release tablets
11387956|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 2|single oral dose of levodopa carbidopa immediate release tablets
11387957|NCT02116452|No Intervention|Breast Milk|Breast FED newborns
11387958|NCT02116452|Placebo Comparator|Standard Formula|Standard Formula FED newborns
11387959|NCT02116452|Active Comparator|Supplemented Formula|GOS/PDX Formula FED newborns
11387960|NCT02116439||Violent events|People in this group were observed to manifest violence.
11387961|NCT02116439||Victims|People in this group are the victims of the other group.
11387962|NCT02116426||The study population|"The study population includes all adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected Acute Coronary Syndrome (ACS) without ST segment elevation.
~Intervention: Blood work in the ambulance Intervention: Blood work upon arrival in the emergency room Intervention: Blood work at 3 hours post-arrival in the emergency room"
11387963|NCT02116413||The study population|"The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:
~oliguria <0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate > 2 mmol / l SvcO2 <70% or SvO2 <65% Patient on noradrenaline.
~Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate> 4 mmol / l or organ dysfunction.
~Intervention: Fluid challenge Intervention: Cardiac ultrasound"
11387964|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.
~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
11387965|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.
~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
11387966|NCT02116387|Active Comparator|Routine Physical Therapy|"Patients randomized to this arm will follow a classic, routine, physical therapy program.
~Intervention: Routine Physical Therapy"
11387967|NCT02116387|Experimental|I-Moove Physical Therapy|"Patients randomized to this arm will follow a physical therapy program using the I-Moove device.
~Intervention: I-Moove Physical Therapy"
11387968|NCT02116374||HIV-1 patients|
11387969|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
11387970|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
11387971|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
11387972|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
11387973|NCT02116348|Experimental|Cerebrolysin|Nerve growth factor Cerebrolysin will be given to the intervention group
11387974|NCT02116348|No Intervention|Conventional|These children will receive conventional treatment for cerebral palsy
11387975|NCT02116335|Experimental|Bosentan|Sub-Chronic (3 days) Bosentan 250mg/day.
11387976|NCT02116335|Placebo Comparator|Placebo|Stress response and endothelial function will be determined following a three day treatment of placebo
11387977|NCT02116322|Experimental|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
11387978|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
11387979|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
11387980|NCT02116296|Other|LIfestyle counseling|
11387981|NCT02116270|Other|Control group|Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
11387982|NCT02116270|Experimental|Severe renal failure|Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
11387983|NCT02116270|Experimental|Peritoneal dialysis|Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
11387984|NCT02116270|Experimental|Hemodialysis|Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
11387985|NCT02116257|Experimental|Propacetamol|
11387986|NCT02116257|Placebo Comparator|PCA regimen|routine PCA drug
11387987|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
11387988|NCT02116231|Experimental|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy: IMRT was given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy.
11387989|NCT02116231|Active Comparator|IMRT alone|IMRT is given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume.
11387990|NCT02116218|Experimental|acupuncture|Experimental group would receive acupuncture at specific acupoints for 15 minutes.
11387991|NCT02116218|Sham Comparator|seed|Control group would receive another intervention that we would put Vaccaria seeds near the acupoints but without acupressure for the same period.
11387992|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
11388204|NCT02114840|Active Comparator|Pronator quadratus repair after disruption|
11387993|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
11387994|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
11387995|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
11387996|NCT02116192|Active Comparator|General Healthy Diet|Control: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
11387997|NCT02116192|Experimental|Low-fructose, reduced carbohydrate diet|"Intervention: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)
~● Aim for less than 25g fructose daily."
11387998|NCT02116179|Experimental|DVD Intervention|DVD Intervention presented at one 90 minute group session
11387999|NCT02116179|No Intervention|Wait list Control Group|Group will get no intervention until after 90 day follow up
11388000|NCT02116166||Young|Young (20-35 years old)
11388001|NCT02116166||Old|Older (70-99 years old)
11388002|NCT02116140|Experimental|[C11]Acetate HED PET|"AMEND is a single centre substudy of the ADVENT-HF trial. This substudy is a clinical physiologic proposal designed to determine the effects of long-term (6 months) ASV on cardiac energetics and SN function in patients with chronic stable HF and sleep apnea extending our previous evaluation of short-term CPAP in patients with OSA and HF.
~All subjects consenting to the ADVENT primary trial will be eligible to participate in the substudy.
~Substudy consenting patients will have [11C]acetate and [11C]HED PET imaging; HR variability; plasma norepinephrine (NE) levels, urine normetanephrine levels within 2 weeks of the sleep study. Baseline measurements will be repeated after 6 months in all patients."
11388003|NCT02116127|Experimental|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
11388004|NCT02116127|Sham Comparator|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
11388005|NCT02116114|Experimental|Aquatic exercises|"3 times a week
~heating
~aerobic training
~slowdown"
11388006|NCT02116114|No Intervention|control group|The control group participated in the study only to usual care , conventional medical treatment orientation about the disease , methods of energy conservation and evaluation.
11388007|NCT02116101|Active Comparator|Bright Momchilovtsi yogurt|Bright Momchilovtsi yogurt Contains 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
11388008|NCT02116101|Placebo Comparator|Bright Dairy Beverage|Dairy beverage product without prebiotics
11388009|NCT02116088|Active Comparator|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
11388010|NCT02116088|No Intervention|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
11388011|NCT02116075|Experimental|Epidural Steroid|80mg depo-medrol 9mL 1% lidocaine
11388012|NCT02116075|Active Comparator|Epidural Prolotherapy|10ml of 5% generic dextrose
11388013|NCT02116062|Other|Amniotic membrane transplantation|
11388014|NCT02116062|Other|Pterygium surgery|
11388015|NCT02116062|Other|Penetrating keratoplasty|
11388016|NCT02116049|Active Comparator|Attention Control Case Management|"Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients. This project's case management will mimic the experimental condition with a meeting schedule reflective of the experimental arm plus a booster session at 3 months."
11388017|NCT02116049|Experimental|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
11388018|NCT02116036|Experimental|Rivaroxaban|Rivaroxaban 20mg po daily
11388019|NCT02116023|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
11388020|NCT02116023|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
11388021|NCT02116023|Placebo Comparator|Orange flavored beverage - Placebo|240ml orange beverage
11388022|NCT02116010|Active Comparator|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
11388023|NCT02116010|Experimental|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
11388024|NCT02116010|Active Comparator|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
11388025|NCT02116010|Experimental|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
11388366|NCT02113826|Experimental|Pazopanib|Pazopanib 800mg po qd until disease progression
11388026|NCT02115997|Experimental|Rituximab|Participants will receive IV infusion of rituximab once weekly from Week 1 to 4. Participants will also receive one pulse of methylprednisolone, followed by a tapering dose of oral prednisolone at the discretion of the investigator. Methylprednisolone may be repeated up to total of 3 pulses at the discretion of the investigator.
11388027|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
11388028|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
11388029|NCT02115971|Experimental|Jumping exercise|"Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.
~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme."
11388030|NCT02115971|Active Comparator|Strength exercise|"Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.
~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored."
11388031|NCT02115958|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11388032|NCT02115958|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11388033|NCT02115958|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11388034|NCT02115958|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11388035|NCT02115945|Experimental|epidural block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
11388036|NCT02115945|Active Comparator|femoral block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
11388037|NCT02115932|Experimental|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
11388038|NCT02115932|No Intervention|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
11388039|NCT02115919|Experimental|Cohort A|Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
11388040|NCT02115919|Experimental|Cohort B|Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
11388041|NCT02115906||Acromegalic patients|Acromegalic patients before and after initiation of individual therapy will be investigated by 1H/31P magnetic resonance spectroscopy, thyroid sonography and oral glucose tolerance testing
11388042|NCT02115906||Healthy control subjects|Age and Body mass index matched control subjects will be investigated by 1H/31P magnetic resonance spectroscopy and oral glucose tolerance testing
11388043|NCT02115893|Active Comparator|Sodium Nitrate|Dietary Supplement: Sodium nitrate 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
11388044|NCT02115893|Placebo Comparator|Sodium Cloride|Dietary Supplement: Sodium chloride 800 mg of sodium chloride added with water to get a 140 mL solution (Frisia Zout BV, Harlingen, The Netherlands)
11388045|NCT02115880|Experimental|Prevention programme|
11388046|NCT02115880|No Intervention|Control (treatment as usual)|
11388047|NCT02115867|Active Comparator|Probiotic|"Probiotic arm Liquid broth
~1 mL/kg every morning for 90 days"
11388048|NCT02115867|Placebo Comparator|Placebo|"Placebo arm Liquid broth
~1 mL/kg each morning for 90 days"
11388049|NCT02115854||bacteriologically confirmed tuberculosis|
11388050|NCT02115841|Experimental|E1|Experiment 1 will measure the cortical excitability change after TENS intervention.
11388051|NCT02115841|Experimental|E2|Experiment 2 will measures implicit sequential motor task performance and cortical hemodynamic response using near infrared spectroscopy (NIRS) during motor execution. Cortical excitability will also be measured contemporary
11388052|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
11388053|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
11388054|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
11388055|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
11388056|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
11388057|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
11388058|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
11388059|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
11388060|NCT02115802|Experimental|Activa PC+S|Specific features of LFP recorded from the deep brain nuclei will be examined for possible correlation with different natural behaviors, such as movement, walking, or speech.
11388061|NCT02115789||Survey Group|Adult male or female volunteers.
11388062|NCT02115776|No Intervention|Control|Receiving no prophylaxis
11388063|NCT02115776|Active Comparator|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
11388064|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
11388065|NCT02115776|Active Comparator|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
11388066|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
11388067|NCT02115763|Experimental|Caffeine|There is only one arm, it receives both caffeine and placebo.
11388068|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
11388069|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
11388070|NCT02115737|Experimental|Dialectical Behavior Therapy Skills Group|Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
11388071|NCT02115737|Experimental|Psychoeducation group treatment|The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh
11388072|NCT02115724|Experimental|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
11388073|NCT02115724|Other|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
11388074|NCT02115711|Experimental|Community health worker|Home visits by community health worker to deliver the multi-component behavioural intervention targeted at the individual's hypertension, diabetes or smoking.
11388075|NCT02115711|No Intervention|Usual care|Patients will receive usual care in the community
11388076|NCT02115698|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
11388077|NCT02115698|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
11388078|NCT02115698|Active Comparator|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
11388079|NCT02115698|Active Comparator|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
11388080|NCT02115698|Placebo Comparator|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
11388081|NCT02115685|No Intervention|One day testing|Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
11388082|NCT02115685|Experimental|Effects of long term training|Aim 3 will then look at changes in bloodflow during exercise after training. Three different eight week exercise training programs will be tested including 1) treadmill training at high intensity as defined by 70-80% of HRR or 15-17 RPE 2) treadmill training at low intensity as defined by 30-40% of HRR or <13 RPE
11388083|NCT02115672|Experimental|BL-8040|Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
11388084|NCT02115659|Placebo Comparator|Placebo|Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
11388085|NCT02115659|Experimental|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.
11388086|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
11388087|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
11388088|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
11388367|NCT02113813|Experimental|ASP8273 Dose Escalation cohort (part 1)|oral
11388089|NCT02115620|Experimental|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
11388090|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
11388091|NCT02115594|Experimental|Fulvestrant + Entinostat|Arm A: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus entinostat (5 mg PO once weekly)
11388092|NCT02115594|Active Comparator|Fulvestrant + Placebo|Arm B: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus placebo (5 mg PO once weekly)
11388093|NCT02115581|Experimental|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.
~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
11388094|NCT02115581|Placebo Comparator|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
11388095|NCT02115568||Long-term safety follow-up|To be eligible, subjects must have actively participated in a Juventas (JVS-100) sponsored trial under IND 14203.
11388096|NCT02115555|Experimental|HIT-aided approach|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the Self Monitored Blood glucose tests.
11388097|NCT02115555|Experimental|Contracted conflict management system|Adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent.
11388098|NCT02115555|Experimental|HIT plus contracted conflict management|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the tests. In addition, adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent. This arm combines arms 1 and 2.
11388099|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
11388100|NCT02115529|Active Comparator|Cesamet (nabilone)|0.5 mg capsule containing Cesamet (single dose) given preoperatively
11388101|NCT02115529|Placebo Comparator|Placebo|identical capsule containing placebo (single dose) given preoperatively
11388102|NCT02115516|Experimental|Stage A: Grp A1 - 3,200 PfSPZ Challenge|Group A1 (PfSPZ Challenge) (n=9) receives three injections of 3,200 PfSPZ Challenge intravenous (IV) at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
11388103|NCT02115516|Experimental|Stage A: Grp A2 - 12,800 PfSPZ Challenge|Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
11388104|NCT02115516|Experimental|Stage A: Grp A3 - 51,200 PfSPZ Challenge|Group A3 (PfSPZ Challenge) (n=9) starts when Group A2 receives the second immunization. Group A3 receives three injections of 51,200 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A Week on 27.
11388105|NCT02115516|Placebo Comparator|Stage A: Grp A1 - 0.9% Sodium Chloride|Group A1 (placebo) (n=5) receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
11388106|NCT02115516|Placebo Comparator|Stage A: Grp A2 - 0.9% Sodium Chloride|Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
11388129|NCT02115399||ADStaph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
11388130|NCT02115399||ADStaph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
11388131|NCT02115399||NAStaph-|Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
11388107|NCT02115516|Placebo Comparator|Stage A: Grp A3 - 0.9% Sodium Chloride|Group A3 (placebo) (n=5) starts when Group A2 receives the second immunization. Group A3 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A on Week 27.
11388108|NCT02115516|Experimental|Stage B: Grp B1 - 51,200 PfSPZ Challenge|Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
11388109|NCT02115516|Placebo Comparator|Stage B: Group B1 - 0.9% Sodium Chloride|Group B1 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28. This group will follow the the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
11388110|NCT02115516|Experimental|Stage B: Grp B2 - 51,200 PfSPZ Challenge|Group B2 (n=5) will receive 3 injections of 51,200 PfSPZ Challenge on days 0, 14 and 28, using same std chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive extended-release azithromycin (ER-AZ, 2g) on the day of 1st PfSPZ Challenge and monitored for parasitemia by quantitative real time polymerase reaction (qPCR). In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following first PfSPZ Challenge injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will continue and ER-AZ will not be administered for the 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge, 10 weeks after the last immunization.
11388111|NCT02115516|Placebo Comparator|Stage B: Group B2 - 0.9% Sodium Chloride|Group B2 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28, using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive ER-AZ, 2g on the day of 1st placebo injection and monitored for parasitemia by qPCR. In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following 1st injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to the development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will be continued and ER-AZ will not be administered for 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after last immunization.
11388112|NCT02115516|Experimental|Stage B: Grp B3 - 51,200 PfSPZ Challenge|Group B3 (n=9) volunteers will receive CQ and PfSPZ Challenge simultaneously every five days with one additional dose of CQ five days after the third PfSPZ Challenge injection. A 10 mg/kg CQ base loading dose is given at the time of first PfSPZ Challenge inoculation, followed by 5 mg/kg CQ base on the day of second and third inoculation and five days after the last PfSPZ Challenge inoculation. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
11388113|NCT02115516|Placebo Comparator|Stage B: Group B3 - 0.9% Sodium Chloride|Group B3 (placebo) (n=2) volunteers will receive CQ and 0.9% Sodium Chloride simultaneously every five days with one additional dose of CQ five days after the third placebo injection. A 10 mg/kg CQ base loading dose is given at the time of first placebo injection, followed by 5 mg/kg CQ base on the day of second and third injections and five days after the last placebo injection. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
11388114|NCT02115503||Cohort 1|Cohort 1 will consist of those having primarily Class I antibody development post-transplant
11388115|NCT02115503||Cohort 2|Cohort 2 will include those having primarily Class II antibody development post-transplant
11388116|NCT02115503||Cohort 3|Cohort 3 will consist of the remaining subjects that have a mix of Class I and II antibodies.
11388117|NCT02115490||Osteoporosis_with_Bisphosphonates|This group of patients are taking Bisphosphonates orally in their treatment
11388118|NCT02115490||Osteoporosis-without-Bisphosphonates|This group of patients has not taken Bisphosphonates in the course of treatment
11388119|NCT02115477||Group with lymphadenectomy|The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery
11388120|NCT02115477||Group without lymphadenectomy|The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery
11388121|NCT02115464|Experimental|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
11388122|NCT02115464|Active Comparator|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
11388123|NCT02115451||Surgical treatment|Patients who undergo rehabilitation and anterior cruciate ligament reconstruction, other surgical interventions may be performed
11388124|NCT02115451||Nonsurgical treatment|Patients who undergo rehabilitation without anterior cruciate ligament reconstruction, other surgical interventions may be performed
11388125|NCT02115438||Occupational Stress|
11388126|NCT02115425||Age 10-17|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
11388127|NCT02115425||Age 18-80|Age 18-80 years Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
11388128|NCT02115412||medication non-adherence|
11388199|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
11388132|NCT02115399||NAStaph+|Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
11388133|NCT02115386|Experimental|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
11388134|NCT02115373|Experimental|Phase 1b: Tepotinib 300 mg|
11388135|NCT02115373|Experimental|Phase 1b: Tepotinib 500 mg|
11388136|NCT02115373|Experimental|Phase 2: Tepotinib 500 mg|
11388137|NCT02115360|Active Comparator|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,
11388138|NCT02115360|Active Comparator|fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
11388139|NCT02115347|Experimental|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
11388140|NCT02115347|Other|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
11388141|NCT02115347|Experimental|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
11388142|NCT02115334|Experimental|professional-based group|professional therapists delivering the PHPA
11388143|NCT02115334|Experimental|parents-based group|parents executing the PHPA
11388144|NCT02115334|Active Comparator|control group|health education only
11388145|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
11388146|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
11388147|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
11388148|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
11388149|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
11388150|NCT02115295|Experimental|Treatment (cladribine, cytarabine, idarubicin)|"INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity."
11388151|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
11388152|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
11388153|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
11388154|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
11388155|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
11388156|NCT02115243|Other|Ipi/ILI|Patients will receive ipilimumab followed by ILI.
11388157|NCT02115230|Experimental|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
11388158|NCT02115230|No Intervention|Medical therapy|Standard optimized medical therapy for diastolic heart failure
11388159|NCT02115217|Experimental|Leukotape K, basketball training|Use of Leukotape K to ensure stability of the ankle in basketball players
11388160|NCT02115217|Placebo Comparator|Sham, basketball training|Use of sham tape
11388161|NCT02115204|Experimental|EC-Doc|4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
11388162|NCT02115204|Active Comparator|CMF/CEF|6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks
11388163|NCT02115191|Experimental|2-octylcyanoacrylate|Application of 2-octylcyanoacrylate
11388164|NCT02115191|Active Comparator|Surgical reintervention|Surgical reintervention for urethrocutaneous fistula repair
11388165|NCT02115178||Lithotomy or Prone position|
11388166|NCT02115165|Experimental|Cabazitaxel|
11388200|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
11388167|NCT02115152|Active Comparator|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
11388168|NCT02115152|Experimental|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
11388169|NCT02115139|Experimental|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
11388170|NCT02115126|Active Comparator|LMP2A-loaded conventional DC vaccine|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine
11388171|NCT02115126|Experimental|LMP2A-loaded DC vaccine + DUK-CPG-001|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001
11388172|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
11388173|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
11388174|NCT02115100|Active Comparator|pulmonary vein+renal artery denervation|Procedure: pulmonary vein and renal artery denervation
11388175|NCT02115100|Active Comparator|Pulmonary vein isolation|Procedure: Pulmonary vein isolation
11388176|NCT02115087|Experimental|ultrasound guided rectus sheath block|Ultrasound guided rectus sheath block
11388177|NCT02115087|Active Comparator|iv morphine|0.1 mg.kg-1 loading dose of morphine by intravenous route in intraoperative period
11388178|NCT02115074|Experimental|Fluvastatine Celebrex|dose escalation for Fluvastatine
11388179|NCT02115061|Active Comparator|Cyanoacrylate|"This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
~Treatment: cyanoacrylate"
11388180|NCT02115061|Sham Comparator|Coil + cyanocrylate|"This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
~Treatment: coil + cyanoacrylate"
11388181|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
11388182|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
11388183|NCT02115035|Experimental|Vermurafenib|Vermurafenib dosing will be given twice daily by oral administration in cycles of 28 days
11388184|NCT02115022||Potentially resectable pancreatic cancer|Patients with a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery with a curative (R0) intent.
11388185|NCT02114983||first episode of suspected DVT of the lower limbs|patients with first suspected episode of DVT of the lower limbs
11388186|NCT02114970|Other|Focus Group- paper and tablet consent|Participation in a focus group of other older adults, lasting 120 minutes. Participants will answer semi-structured questions in a group format, describing their impressions of both a prototype tablet-delivered and a paper consent.
11388187|NCT02114970|Active Comparator|Randomized- paper consent|Participants will review a mock paper consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the paper informed consent form.
11388188|NCT02114970|Active Comparator|Randomized- Tablet-delivered consent|Participants will review a mock tablet-delivered consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the tablet-delivered informed consent.
11388189|NCT02114957|Experimental|study herb|
11388190|NCT02114944||NIV|Patients with acute respiratory failure or dyspnea and DNI order treated with noninvasive ventilation
11388191|NCT02114944||CPAP|Patients with dyspnea or acute respiratory failure and DNI order treated with continuous positive airways pressure (CPAP)
11388192|NCT02114944||Standard oxygen|Patients with dyspnea and/or acute respiratory failure and DNI order, treated with standard oxygen therapy either via face mask or nasal cannula
11388193|NCT02114944||HFNC|Patients with dyspnea and/or acute respiratory failure and DNI order treated with high-flow nasal cannula (HFNC).
11388194|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
11388195|NCT02114918|Experimental|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
11388196|NCT02114918|Placebo Comparator|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
11388197|NCT02114905|Experimental|OTs Trained and Deliver CBIT|CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
11388198|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
11388205|NCT02114827|Experimental|Video|"Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience"
11388206|NCT02114827|Active Comparator|FAQ Sheet|Patients will receive HSCT FAQ sheet developed by the NCI at the NIH
11388207|NCT02114814|Experimental|Diabetes Self Management|Diabetes Self Management
11388208|NCT02114814|Active Comparator|General Health Education|General Health education
11388209|NCT02114801|Experimental|manual brushing|manual brushing; Oral-B®, Stages 4, Rio de Janeiro, Rio de Janeiro;
11388210|NCT02114801|Experimental|electric toothbrush linked|electric toothbrush linked; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
11388211|NCT02114801|Experimental|off electric toothbrush|off electric toothbrush; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
11388212|NCT02114788||group 1|No intervention
11388213|NCT02114788||Group 2|Intervention with interactive website
11388214|NCT02114775|Active Comparator|Recombinant Growth Hormone|Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
11388215|NCT02114775|Active Comparator|Sildenafil|Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
11388216|NCT02114762|Experimental|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
11388217|NCT02114749|Experimental|volunteers in daily life activities|a set of wearable respiration and cardiac monitoring devices
11388218|NCT02114736|Experimental|Rectus femoris tenotomy|Surgical release of the proximal tendon of the rectus femoris
11388219|NCT02114736|Active Comparator|Botulinum toxin in the rectus femoris muscle|Botulinum toxin (200U Botox) injection in the rectus femoris muscle
11388220|NCT02114723|Active Comparator|Medical Taping Concept|"3 band of a special and hypoallergenic tape, called Cure Tape ® (2 strips of 12 x 5 cm and 1 strip of 20 cm x 5 cm) are attached to the abdominal and lower back. One piece of 12 cm in length is applied right from below the navel and reached to where the pubic hair below, and another piece of 12 cm in length is applied to make a cross shape with the first piece (inside 11-12 dermatomes area). The piece of 20cm in length is placed horizontally to the lower back.
~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
11388221|NCT02114723|Placebo Comparator|Cross tape|Two pieces of special and squared tape of 2.5 x 2 cm called Cross Tape ® are attached to the external side of the thigh at the hip joint area (outside 11-12 dermatomes area)
11388222|NCT02114710|Experimental|Hydrocortisone|little doses of hydrocortisone
11388223|NCT02114710|No Intervention|Placebo|Placebo
11388224|NCT02114697|Active Comparator|Lifestyle modification|Lifestyle modification is tailored to each participant and includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.
11388225|NCT02114697|Experimental|Statin therapy|Participants will receive statin medication along with instruction about regular exercise.
11388226|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.
~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks
~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
11388227|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.
~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.
~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
11388228|NCT02114671|Experimental|Faldaprevir QD high dose|capsules, oral administration with 240 ml water, fed conditions
11388229|NCT02114671|Experimental|Faldaprevir QD low dose|tablets/capsules, oral administration with 240 ml water, fed conditions
11388230|NCT02114671|Placebo Comparator|Placebo|capsules, oral administration with 240 ml water, fed conditions
11388231|NCT02114671|Active Comparator|Ciprofloxacin|tablets, oral administration with 240 ml water, fed conditions
11388232|NCT02114658|Experimental|Arm 1|Sorafenib 400 mg bid continuous dose
11388233|NCT02114645|Active Comparator|LongGnRH agonist protocol(controlgroup)|Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
11388234|NCT02114645|Experimental|Long protocol-leuprolide acetate|Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
11388235|NCT02114645|Active Comparator|GnRHantagonist protocol(control group)|GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
11388236|NCT02114645|Experimental|antagonist protocol-leuprolide acetate|GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
11388237|NCT02114632|Active Comparator|Polyunsaturated fatty acids|"6 capsules of food supplement Eye q per day divided in two daily doses (558 mg EPA, 174 mg DHA, 60 mg GLA per day)"
11388238|NCT02114632|Placebo Comparator|placebo|6 capsules of olive oil per day divided in two daily doses.
11388239|NCT02114619|Active Comparator|Low dose of I-131|Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
11388240|NCT02114619|Active Comparator|Intermediate dose|Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
11388241|NCT02114619|Active Comparator|High dose|Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
11388271|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
11388242|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines, and who have active eosinophilia and active symptoms. This will include patients who are newly diagnosed with EoE, patients who have stopped treatment but have had a flare, or patients who have not responded to EoE treatment. Samples will be taken once at a single time point using the Cytosponge™ Cell Collection Device (Cytosponge). To determine the utility of Cytosponge for monitoring treatment response in patients with EoE, the investigators will enroll patients with EoE who are undergoing either topical steroid or dietary treatment. Patients will be followed and tissue will be assessed over time with both Cytosponge and endoscopy; samples will be taken at up to 6 time points.
11388243|NCT02114593|Experimental|Parent support program|Parent support program
11388244|NCT02114593|No Intervention|Standard activities|Standard activities
11388245|NCT02114580|Experimental|Aerobic exercise|
11388246|NCT02114580|Active Comparator|stretching exercise|
11388247|NCT02114567|Experimental|PSV ventilation|AECOPD Patients who were ventilated wiht PSV, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. Pressure support was set to get the tidal volume of 6ml/kg.
11388248|NCT02114567|Experimental|NAVA ventilation|AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
11388249|NCT02114528|Active Comparator|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
11388250|NCT02114528|Active Comparator|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
11388251|NCT02114515|Other|Usual Care|"Hospital usual care
~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
11388252|NCT02114515|Experimental|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)
~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.
~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team
~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
11388253|NCT02114502|Experimental|Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT|Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
11388254|NCT02114489|Experimental|Ibandronate|Unique perfusion of ibandronate 3 mg IV
11388255|NCT02114489|Placebo Comparator|Placebo|Unique perfusion of NaCl 3mg IV
11388256|NCT02114476|Placebo Comparator|nonhormonal contraception|nonhormonal intrauterine device tubal sterilization
11388257|NCT02114476|Experimental|progestin implant|Jadelle
11388258|NCT02114463|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
11388259|NCT02114463|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
11388260|NCT02114450|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with the H2 lower limb powered exoskeleton. They will perform walking and other lower limb exercises (as applicable) while wearing the H2 lower limb powered exoskeleton. Training will involve 3 sessions per week for 4 weeks, each lasting about 1.5 hours.
11388261|NCT02114450|Active Comparator|Supervised motor practice|Participants in this group will perform walking and other lower limb exercises (as applicable) under the supervision of a research physical therapist. Training will be for 3 sessions per week for 4 weeks, each session lasting about 1.5 hours.
11388262|NCT02114437|Experimental|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
11388263|NCT02114437|Placebo Comparator|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
11388264|NCT02114424|Active Comparator|Positional vibrator belt|Positional belt to avoid supine sleep.
11388265|NCT02114424|No Intervention|No Night balance|the first 2 months without Night Balance
11388266|NCT02114411||Dyspeptic patients|Patients (45 years and older, both genders) with dyspepsia referred for the GastroPanel test and gastroscopy with multiple bisopies at Homerton University Hospital (London, United Kingdom).
11388267|NCT02114398|Experimental|usual treatment|usual treatment
11388268|NCT02114398|Experimental|usual treatment + sophrology|usual treatment + sophrology
11388269|NCT02114385|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
11388270|NCT02114385|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
11388334|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
11388335|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
11388272|NCT02114372||Clinical Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
11388273|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
11388274|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
11388275|NCT02114359|Experimental|Platinum/fluoropyrimidine combination chemotherapy|
11388276|NCT02114359|Active Comparator|Fluoropyrimidine monochemotherapy|
11388277|NCT02114346|Experimental|Atorvastatin|Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material.
11388278|NCT02114346|Placebo Comparator|Placebo|Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material.
11388279|NCT02114333|Active Comparator|A - Live zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85
~First dose live vaccine, Zostavax (0.65ml, subcutaneous)
~Second dose placebo, normal saline (0.65ml. subcutaneous)"
11388280|NCT02114333|Active Comparator|B - recombinant zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85
~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
11388281|NCT02114333|Active Comparator|C - Live zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85
~First dose live vaccine, Zostavax (0.65ml, subcutaneous)
~Second dose placebo, normal saline (0.65ml. subcutaneous)"
11388282|NCT02114333|Active Comparator|D - recombinant zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85
~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
11388283|NCT02114320|Experimental|EUS-BD-1|EUS-BD-1 inserts a partially covered self-expanding metallic (hybrid) stent with a dedicated introducer for EUS-BD
11388284|NCT02114320|Experimental|EUS-BD-2|EUS-BD-2 inserts a fully covered self-expanding metallic stent
11388285|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
11388286|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
11388287|NCT02114294|Experimental|Isolated hip strengthening|Isolated hip strengthening (abduction, external rotation, extension)
11388288|NCT02114294|Active Comparator|Quadriceps based training|Quadriceps based training (mini-squat, straight leg raising, terminal extensions)
11388289|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
11388290|NCT02114281|Experimental|Care|Patient with dental care
11388291|NCT02114281|Active Comparator|Not care|Patient with not dental care
11388292|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
11388293|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
11388294|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
11388295|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
11388296|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
11388297|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
11388298|NCT02114255|Experimental|BCG vaccination|BCG vaccination
11388299|NCT02114255|Placebo Comparator|NaCl 0.9%|administration of NaCl 0.9%.
11388300|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
11388301|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age > 30"
11388302|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age > 40
11388303|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).
~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
11388336|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
11388337|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
11388338|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
11388339|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
11388368|NCT02113813|Experimental|ASP8273 Response Expansion cohort (part 1)|oral
11388304|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.
~Interventions:
~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.
~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
11388305|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.
~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.
~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
11388306|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
11388307|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
11388308|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
11388309|NCT02114203|Experimental|cohort 1 PF-04447943|
11388310|NCT02114203|Experimental|cohort 2 PF-04447943|
11388311|NCT02114203|Placebo Comparator|placebo comparator|
11388312|NCT02114203|Experimental|optional cohort of PF-04447943|
11388313|NCT02114190|Experimental|Adolescent Mindful Eating Group|Adolescents will participate in a 8 week mindful eating programs tailored for adolescents.
11388314|NCT02114190|Experimental|Parent Intergrated Group|This intervention incorporates a family systems perspective into mindful eating interventions for adolescents. This intervention will consist of 11 sessions in an 8 week period, with sessions 2,7, and 11 incorporating family sessions. The purpose of the family sessions are to increase overall family motivation for behavior change, involve family members in identifying specific targets of change and establishing agreed upon strategies.
11388315|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
11388316|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
11388317|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
11388318|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
11388319|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
11388320|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
11388321|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
11388322|NCT02114125|No Intervention|Usual Care Group:|Usual care consists of standard institutionalized services provided by physicians, nurses, and support staff (e.g., nurse assistants, social workers) in long-term care facilities.
11388323|NCT02114125|Experimental|High-intensity physical activity (5PA)|The intervention conducts the group-based physical activity, 5 days per- week for 8 weeks.
11388324|NCT02114125|Experimental|Low-intensity PA and CT(3PA+2CT)|The intervention conducts 3 days per-week physical activity and 2 days per-week cognitive training for 8 weeks.
11388325|NCT02114125|Experimental|High-intensity PA and CT (5PA+5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5days per- week and group-based physical activity, 5 days per- week and for 8 weeks.
11388326|NCT02114125|Experimental|Low-intensity cognitive training (2CT)|The intervention conducts the individual-based, multi-domains cognitive training, 2 days per- week for 8 weeks.
11388327|NCT02114125|Experimental|High-intensity cognitive training (5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5 days per- week for 8 weeks.
11388328|NCT02114112|Experimental|Group A-NCPAP Cycling group|Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
11388329|NCT02114112|Active Comparator|Group B-Continuous NCPAP|Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.
11388330|NCT02114099|Experimental|Atorvastatin|prescribe Atorvastatin to see its effect
11388331|NCT02114086||breast cancer|observation of intraoperative radiotherapy
11388332|NCT02114073|Experimental|Cyclosporine|In the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
11388333|NCT02114073|Active Comparator|Betamethasone|In the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
11388340|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
11388341|NCT02114034||Non-severe asthma|"Children Controlled without treatment or with low doses of inhaled corticosteroids (<500 mg / day beclometasone equivalent) asthma
~and Children with normal EFR
~and Children who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year
~and Children not admitted in the previous year for asthma"
11388342|NCT02114034||Severe asthma|"Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene (inhaler technique and compliance verified) presents one of the 3 criteria following:
~Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months
~exacerbations in the previous year:
~at least one care unit admission or continued resuscitation
~at least two hospitalizations for acute severe asthma requiring IV therapy
~at least 2 courses of oral corticosteroids for exacerbations
~post BD FEV <80% or UARS post BD> 150% predicted"
11388343|NCT02114021|Experimental|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
11388344|NCT02114021|Experimental|lidocaine jelly|lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
11388345|NCT02114021|Placebo Comparator|distilled water|betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
11388346|NCT02114008|Active Comparator|Abbreviated fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin).
11388347|NCT02114008|Active Comparator|Traditional fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test).
11388348|NCT02113995|Active Comparator|ACERTO|"Patients received 400 ml of a beverage containing water and 50 g of maltodextrin 6 hours before the operation. They received orally extra 200 ml of this beverage containing water and 25 g of maltodextrin 3 hours before the operation. Regarding the intravenous fluids, they received 1 to 1.5 liter of crystalloid fluids (ringer lactate) in the intraoperative. In the immediate postoperative they were programmed to receive 2 liters of crystalloid fluids (ringer lactate) and 1 to 2 liters in the first day of the postoperative period. The venous hydration was suspended as soon as they started to drink liquids.
~Prophylaxis of nausea and vomiting with dexamethasone 8 mg at the beginning of the anesthesia and ondansetron 4-8 mg after the surgery. In the postoperative period we utilized analgesics such as dipyrone and ketorolac and, if necessary, low doses of morphine and antiemetics like ondansetron."
11388349|NCT02113995|Active Comparator|Traditional care|"The analgesia in the postoperative period of the group control was performed with dipyrone, tramadol hydrochloride, and morphine. The prophylaxis of nausea and vomiting with dexamethasone 8 mg in the beginning of the anesthesia and the metoclopramide at the end of the surgery. During the anesthetic induction antibiotic prophylaxis (cefazolin 3 grams/day for 2 days) was administrated.
~The control group were submitted to the protocol of traditional fasting with at least 8 hours. Patients in this group received 1 to 2 liters of crystalloid fluid (ringer lactate) in the intraoperative, and they received 3 to 4 liters of crystalloid fluids (ringer lactate, saline 0.9% and/or dextrose 5%). In the immediate postoperative, 2 to 3 liters in the first day of postoperative and, finally, 1 to 2 liters in the second day of the postoperative."
11388350|NCT02113982|Experimental|Relapse/Refractory Acute Myeloid Leukemia|Intervention: SL-401
11388351|NCT02113982|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: SL-401
11388352|NCT02113969|Experimental|Vaginal Pessary|Pessary users for at least 12 months
11388353|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
11388354|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
11388355|NCT02113930||Idiopathic CD4 lymphocytopenia|Constitution of a biobank of frozen cells, plasma and serum samples
11388356|NCT02113930||Genetic Study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
11388357|NCT02113917||hemophagocytic syndrome|patient with hemophagocytic syndrome
11388358|NCT02113904|Experimental|Adalimumab|
11388359|NCT02113891|Experimental|Eculizumab|Eculizumab will be given in addition to standard immunosuppression regimen (tacrolimus, mycophenalte mofeti, prednisone)
11388360|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.
~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.
~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).
~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
11388361|NCT02113865||Grupo 0|Null or mild fibrosis
11388362|NCT02113865||Grupo 1|Cirrhosis
11388363|NCT02113865||Grupo 2|HCC diagnosis
11388364|NCT02113839|Active Comparator|No frequent exacerbators|"Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.
~Interventions:
~Spirometry
~Emogas analysis
~Modified Borg Dyspnea Scale
~CO Exhaled breath
~P01
~FeNO"
11388365|NCT02113839|Active Comparator|Frequent exacerbators|"Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.
~Interventions:
~Spirometry
~Emogas analysis
~Modified Borg Dyspnea Scale
~CO Exhaled breath
~P01
~FeNO"
11388369|NCT02113813|Experimental|ASP8273 and Midazolam RP2D Expansion cohort (part 2)|oral
11388370|NCT02113813|Experimental|Food Effect Fasted cohort (part 2)|oral
11388371|NCT02113813|Experimental|Food Effect Fed cohort (part 2)|oral
11388372|NCT02113813|Experimental|Exon 20 Cohort (part 2)|oral
11388373|NCT02113800|Experimental|Single Arm|"Patients receive Everolimus orally, 10 mg/day.
~The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study."
11388374|NCT02113787|Active Comparator|Pharmacokinetic study, topamed|"For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in first visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in second visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day."
11388375|NCT02113787|Active Comparator|Pharmacokinetic study, topamax|"For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in first visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in second visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day.
~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day."
11388376|NCT02113774|No Intervention|no therapy|
11388377|NCT02113774|Active Comparator|antimicrobial treatment according to in-vitro susceptibility|
11388378|NCT02113748|Experimental|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
11388379|NCT02113748|Active Comparator|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
11388380|NCT02113735|Experimental|Group 1|H.P. Acthar® Gel , 64 U, 0.8 mL daily
11388381|NCT02113735|Placebo Comparator|Group 2|Placebo, 0.8 mL, daily
11388382|NCT02113735|Experimental|Group 3|H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily
11388383|NCT02113735|Placebo Comparator|Group 4|Placebo, 0.4 mL, 2x daily
11388384|NCT02113735|Experimental|Group 5|H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily
11388385|NCT02113735|Placebo Comparator|Group 6|Placebo, 0.2 mL, 2x daily
11388386|NCT02113722|Active Comparator|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation
11388387|NCT02113722|Placebo Comparator|Standard of care|Continuing medical therapy
11388388|NCT02113709|Experimental|Visual improvement|To see how efficiently visual improvement occurs by Full-time Occlusion therapy with an eye patch in severe amblyopia.
11388389|NCT02113696|Experimental|Placebo group|Placebo Capsules
11388390|NCT02113696|Experimental|Omega 3 intake|Omega 3 intake, morbid obesity
11388391|NCT02113683||MMS test|therapy monitoring of patients with colo-rectal or stomach disease or with melanoma
11388392|NCT02113670|Experimental|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
11388393|NCT02113657|Experimental|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
11388394|NCT02113644||Overweight or obese children|Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare
11388395|NCT02113644||Lean children|Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears
11388396|NCT02113631|Active Comparator|Telaprevir|Telapravir was administer with Peg-IFN and Ribavirin as per package insert Dose Telaprevir : PO, tablet 1125 mg BID for 12 weeks
11388397|NCT02113631|Active Comparator|Boceprevir|Boceprevir was administer with Peg-IFN and Ribavirin as per package insert Dose Boceprevir PO capsule, 800mg TID for up to 44 weeks
11388398|NCT02113618|Active Comparator|Cogmed Training|Cogmed® working memory training is a computer program that will be administered online. The program consists of 7 verbal and non-verbal working memory tasks and gives immediate performance feedback to the subject undergoing training.
11388399|NCT02113618|Placebo Comparator|Standard training|Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
11388400|NCT02113605|Experimental|Cognitive behavior therapy|All included children are treated with a face-to-face exposure-based cognitive behaviour therapy for 10 weeks. There will be no comparison arm.
11388401|NCT02113592|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
11388402|NCT02113592|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
11388403|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
11388404|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
11388405|NCT02113566|Placebo Comparator|Placebo|2 capsules identical to comparator, 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
11388406|NCT02113566|Active Comparator|Ibuprofen|2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
11388407|NCT02113553|Experimental|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
11388408|NCT02113540|Placebo Comparator|placebo group|taking atorvastatin like placebo 12 hours before the procedure
11388663|NCT02111837|Placebo Comparator|Standard infant formula|Standard infant formula fed ad libitum
11388409|NCT02113540|No Intervention|long term statin group|taking atorvastatin for a long time before entering the study (their routine treatment)
11388410|NCT02113540|Experimental|preoperation statin group|taking atorvastatin 12 hours before the procedure
11388411|NCT02113527||Epigastric pain syndrome (EPS)|Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
11388412|NCT02113527||Postprandial distress syndrome (PDS)|Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
11388413|NCT02113527||Healthy subjects|Healthy subjects as control group
11388414|NCT02113514||Normal Pap smear|Women with normal pap test.
11388415|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
11388416|NCT02113501||HGT1a|HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).
11388417|NCT02113501||HGT1b|HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
11388418|NCT02113488||Control: P|Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
11388419|NCT02113488||Case: A|Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
11388420|NCT02113488||Control: C|Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
11388421|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
11388422|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
11388423|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
11388424|NCT02113423|Experimental|recurrent T1-2 NPC,no treatment|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
11388425|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
11388426|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
11388427|NCT02113397||Continuous Therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
11388428|NCT02113397||Cyclic therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.
11388429|NCT02113384||Observational study|Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
11388430|NCT02113371|Experimental|Intervention|The intervention consists of monthly scripted, peer-led social support sessions covering health and safety topics.
11388431|NCT02113371|No Intervention|Control|Usual practices with regard to health and work conditions.
11388432|NCT02113358|Experimental|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.
~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.
~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
11388433|NCT02113358|Active Comparator|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.
~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.
~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
11388434|NCT02113345|Experimental|lifestyle counseling|Metamemory Cognitive Intervention
11388435|NCT02113332|Experimental|Liraglutide|Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
11388436|NCT02113332|Placebo Comparator|Placebo|Placebo injected once per day for 24 weeks. Dose is 1,8 or highest tolerable dose.
11388437|NCT02113319|Experimental|dasatinib|
11388438|NCT02113306|Experimental|t-VNS|"electrical stimulation of the concha of the ear
~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
11388439|NCT02113306|Sham Comparator|sham t-VNS|"Sham stimulation of the earlobe will be conducted by positioning the electrode upside down
~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
11388440|NCT02113293|Experimental|CyclASol®|CyclASol®
11388441|NCT02113293|Placebo Comparator|Placebo|Placebo (vehicle)
11388442|NCT02113280|Active Comparator|Physiotherapy|Physiotherapy
11388443|NCT02113280|Experimental|Arthroscopy|Arthroscopy
11388444|NCT02113267|Experimental|Mometasone furoat|Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
11388445|NCT02113267|Placebo Comparator|Placebo spray|Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
11388446|NCT02113254|Experimental|Healthy volunteer|
11388447|NCT02113241|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
11388448|NCT02113241|Placebo Comparator|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
11388449|NCT02113228||Short Bowel Syndrome|Verify the total energy expenditure in patients with short bowel syndrome using the doubly labeled water method.
11388450|NCT02113228||Control Group|Verify the total energy expenditure in patients without short bowel syndrome using the doubly labeled water method.
11388451|NCT02113215||Young Males|Males, age 18-35 years. 9-hour Stable isotope infusion
11388452|NCT02113215||Young Females|Females, age 18-35 years. 9-hour Stable isotope infusion
11388453|NCT02113215||Older Males|Males, age 60-75. 9-hour Stable isotope infusion
11388454|NCT02113215||Older Females|Females, age 60-75. 9-hour Stable isotope infusion
11388455|NCT02113202|Experimental|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
11388456|NCT02113202|Experimental|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
11388457|NCT02113202|Experimental|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
11388458|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
11388459|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
11388460|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
11388461|NCT02113176|Experimental|Minocycline|"200 mg IV/placebo
~Followed by 100 mg IV BID x 7days
~Followed by 200 mg tablet QD x 14days"
11388462|NCT02113176|Placebo Comparator|Placebo|
11388463|NCT02113163|Active Comparator|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
11388464|NCT02113163|Active Comparator|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
11388465|NCT02113150|Active Comparator|remifentanil|remifentanil, short acting opioid
11388466|NCT02113150|Active Comparator|ketamine|ketamine, intravenous anesthetic
11388467|NCT02113137|Experimental|group 1: drug|Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
11388468|NCT02113137|Experimental|group 2: device:|group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning
11388469|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
11388470|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
11388471|NCT02113111||Fasting|Patients being admitted to an internal integrative medicine hospital and referred to therapeutic fasting therapy
11388472|NCT02113098|Experimental|Treadmill, ankle load|The experimental group will perform gait training on a treadmill with added load to the non-paretic lower limb
11388473|NCT02113098|Active Comparator|Treadmill|The control group (active comparator) will perform gait training on a treadmill
11388474|NCT02113085|Experimental|Self-determination enhancement|Self-determination enhancement through one-on-one coaching and mentoring workshops
11388475|NCT02113072|Experimental|Probiotics & Beclomethasone|"It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
~Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months."
11388476|NCT02113072|Active Comparator|Beclomethasone & Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
11388477|NCT02113059||Liver resection|Patients undergoing a hemihepatectomy.
11388478|NCT02113046|Active Comparator|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
11388479|NCT02113046|Active Comparator|traditional anastomosis|pancreatic resections with traditional stump closure
11388480|NCT02113033|Experimental|Treated with Equilia system|Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
11388481|NCT02113020|Experimental|TAK-233|Oral administration
11388482|NCT02113020|Placebo Comparator|Placebo|Oral administration
11388483|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
11388484|NCT02112994|Experimental|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
11388485|NCT02112981|Experimental|Sirolimus Eluting Coronary Stent|BioMime Sirolimus Eluting Stent of Meril Life Sciences
11388486|NCT02112981|Active Comparator|Everolimus-eluting Coronary stent|XIENCE family (V, Xpedition or Prime) of Everolimus-eluting stent system of Abbott Vascular Inc.
11388487|NCT02112968|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes.
11388488|NCT02112968|Experimental|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
11388489|NCT02112968|Experimental|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
11388490|NCT02112955|Experimental|Stroke self-management program|The program is aimed at enhancing community-dwelling stroke survivors' post-stroke recovery.
11388491|NCT02112955|Active Comparator|Usual care|Usual care provided to stroke survivors discharged to their home.
11388492|NCT02112942|Experimental|Group A|Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days
11388493|NCT02112942|Experimental|Group B|HCV subjects genotype 1, IDX21459 capsules, once for 1 day
11388494|NCT02112942|Experimental|Group C|HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days
11388495|NCT02112929|Experimental|Inhalation of hyperpolarized xenon|One litre of hyperpolarized xenon to be inhaled during MRI scan of the lungs
11388496|NCT02112916|Active Comparator|Arm A (combination chemotherapy)|Patients receive combination chemotherapy without bortezomib. See Detailed Description.
11388497|NCT02112916|Experimental|Arm B (combination chemotherapy, bortezomib)|Patients receive combination chemotherapy with bortezomib. See Detailed Description.
11388498|NCT02112903|Experimental|Encapsulated vortioxetine IR tablet, 20 mg|Single oral dose
11388499|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 5.5)|Single oral dose
11388500|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 6.0)|Single oral dose
11388501|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 7.0)|Single oral dose
11388502|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
11388503|NCT02112877|Experimental|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
11388504|NCT02112877|Experimental|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
11388505|NCT02112864|Experimental|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
11388506|NCT02112864|Placebo Comparator|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
11388507|NCT02112851|Placebo Comparator|Orange flavored beverage|240ml orange beverage
11388508|NCT02112851|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
11388509|NCT02112851|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
11388510|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
11388511|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
11388512|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
11388513|NCT02112825|Experimental|Exercise|12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes
11388514|NCT02112825|No Intervention|control|Control group asked to continue usual activities
11388515|NCT02112812|Experimental|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
11388516|NCT02112799|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
11388517|NCT02112799|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
11388518|NCT02112799|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
11388519|NCT02112799|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
11388520|NCT02112786|Active Comparator|Intermittent then Continuous|This group will be set to intermittent stimulation first, then after the wash out period they will be switched to continuous stimulation.
11388521|NCT02112786|Active Comparator|Continuous Then Intermitent|This group will be set to continuous stimulation first, then switch to intermittent after the wash out time period.
11388522|NCT02112760|Experimental|Patient|To evaluate the effect of specific stabilization intervention in recurrent low back pain participants
11388523|NCT02112747|No Intervention|Arm 1: website access only|There is no intervention with this arm. Completion of the website is part of enrollment.
11388524|NCT02112747|Experimental|Arm 2: patient navigator|"The intervention consists of participants receiving the services of a patient navigator to address individual barriers to adhering to the personal prescription for colon and rectal cancer screening."
11388525|NCT02112747|No Intervention|Arm 3: genetic counseling|There is no intervention in this arm. Patients diagnosed as positive for Lynch Syndrome use genetic counseling to discuss medical and family history and genetic risk of CRC, including genetic factors such as DNA mismatch repair genes, autosomal dominant inheritance, cancer risks associated with LS, screening recommendations, and genetic testing. There is no intervention. This is standard care.
11388526|NCT02112747|Experimental|Arm 4:Gen. counselor & patient navigator|Participants diagnosed positive for Lynch syndrome use genetic counseling as in Arm 3 and in addition receive the services of a patient navigator to address individual barriers to adhering to the CRC screening recommendations.
11388527|NCT02112734|Active Comparator|vitamin D|400 IU /daily cholecalciferol/vitamin D
11388528|NCT02112734|Placebo Comparator|placebo|carrier formulation minus vitamin D
11388529|NCT02112721|Experimental|Vitamin D Group|Each participant will be given an initial stat dose of 2500 μg (100,000 IU) of Ostelin (Reckitt Benckiser). Thereafter, participants will take 100 μg/day (4,000 IU, 4 tablets) Ostelin daily for a period of 16 weeks.
11388530|NCT02112721|Placebo Comparator|Placebo group|Each participant will be given an equivalent number of placebo tablets
11388531|NCT02112708|Experimental|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
11388532|NCT02112708|Active Comparator|Control Group|The control group (GC) will take the usual medical care for dysthimia, according with up-dated guidelines.
11388533|NCT02112695|Experimental|sportswomen|3 micrograms [11C]diprenorphine
11388534|NCT02112695|Experimental|control subjects|3 micrgrams [11C]diprenorphine
11388535|NCT02112682|Active Comparator|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
11388536|NCT02112682|No Intervention|No completion axillary treatment|
11388537|NCT02112669|Experimental|AV fistula with VasQ|Implant VasQ over AV fistula
11388538|NCT02112669|No Intervention|AV fistula|AV fistula without any adjunct device
11388539|NCT02112656|Experimental|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
11388540|NCT02112656|Placebo Comparator|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
11388541|NCT02112643|Active Comparator|Selenium|100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.
11388542|NCT02112643|Placebo Comparator|Sugar pill|A placebo pill will be taken orally twice daily for 6 months.
11388543|NCT02112630|Experimental|Group 1 - Response Guided Therapy|"Treatment naive and documented relapsers : Subjects who have never been previously treated with P-IFN +/- ribavirin therapy and those who have documented relapse after P-IFN +/- ribavirin therapy.
~Subjects in group 1 will receive P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24 treatment with be continued for a total duration of 28 to 48 weeks.Subjects will be followed through treatment and up to 24 weeks post treatment."
11388544|NCT02112630|Experimental|Group 2 - Fixed Duration Therapy|"Partial/Null Responders /Undefined Previous Response, Compensated cirrhosis: Subjects who have compensated cirrhosis, and/or were previously treated with P-IFN +/- ribavirin without SVR (including partial responders, null responders, and those previously treated without adequate documentation of response).
~Subjects in Group 2 will all be assigned to fixed duration therapy.Patients will be treated with P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir for a total of 48 weeks of therapy. Subjects will be followed through treatment and up to 24 weeks post treatment."
11388545|NCT02112617|Experimental|Proton Beam Radiation Therapy (PBRT)|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
11388546|NCT02112604||Ventilated patients|Patients who have been extubated within 24 hours and have been mechanically ventilated for at least 24 hours. Alice PDx, pulmonary function tests, muscle strength tests, grip strength measurements, ventilator, Sedatives and muscle relaxants given in the ICU
11388547|NCT02112591|Active Comparator|Transobturator suburethral tape (TOT)|transobturator approaches for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide
11388548|NCT02112591|Experimental|S-TOT|transobturator subtrigonal tape: S-TOT
11388549|NCT02112578|Experimental|Meclizine|Meclizine 25 mg, tablets
11388550|NCT02112578|Active Comparator|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
11388551|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11388552|NCT02112552|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.
~RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23)."
11388553|NCT02112539||ADP Blockers|platelet aggregation in response to antiplatelet drugs
11388554|NCT02112526|Experimental|Acalabrutinib|
11388555|NCT02112513||salivary estriol measurement|Serum Estriol measurement via different assays is complex, expensive, labor intensive, time consuming, and generally performed at specific reference labs. Salivary Estriol level is an ideal potential surrogate for serum Estriol. It is convenient, non-invasive, and expedient. It may not, however, be as sensitive as serum estriol concentrations at detecting the association with glucocorticoid response. This study will collect both samples to determine which one is better suited for clinical use in this condition.
11388556|NCT02112513||serum estriol measure|we will determine if changes in maternal serum estriol represent a biomarker of response to antenatal corticosteroids as evidenced by neonatal development of RDS
11388557|NCT02112513||Betamethasone pharmacokinetic|we will determine if pharmacokinetic parameters and neonatal outcomes after antenatal corticosteroid use are associated with genetic polymorphisms in drug metabolizing enzymes, transporters, and steroid pathway genes
11388558|NCT02112513||betamethasone concentration and genetics|we will determine if maternal betamethasone concentrations and genetics are associated with maternal estriol changes or RDS development
11388559|NCT02112500|Experimental|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
11388560|NCT02112487|Experimental|Macitentan|10 mg once daily
11388561|NCT02112474|Experimental|Spinal Cord Stimulation Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
11388562|NCT02112474|Experimental|Spinal Cord Stimulation Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
11388563|NCT02112461|Experimental|Intervention Group|SCP-Hospice Alert
11388564|NCT02112461|No Intervention|Usual Care|Caregiver calls into monitoring system to report the patient's end of life symptoms but does not receive feedback about the symptoms and the hospice nurse does not receive the information.
11388565|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
11388566|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
11388567|NCT02112435|Active Comparator|Narval ORM ® or SomnoDent ®|Mandibular advancement splint (Narval ORM ® or SomnoDent ®)
11388568|NCT02112435|Experimental|Somnyx ®|Active mandibular advancement splint (Somnyx ®)
11388664|NCT02111837|Experimental|Standard infant formula with PL1|Standard infant formula enriched with PL1 lipid fraction fed ad libitum
11388569|NCT02112422|Active Comparator|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
11388570|NCT02112422|Experimental|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
11388571|NCT02112409|Experimental|cell salvage and hemodilution technique|cell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
11388572|NCT02112409|Active Comparator|cell salvage|cell salvage technique throughout scoliosis corrective surgery
11388573|NCT02112396|Experimental|Immediate Intervention|Subjects receive 12 sessions of Community Reinforcement and Family Training (CRAFT) immediately after study inclusion
11388574|NCT02112396|Other|Waiting list group|Waiting list group members receive the Community Reinforcement and Family Training CRAFT intervention after the first follow-up (3 months post study inclusion)
11388575|NCT02112383|Experimental|Internet-based cognitive behavior therapy|
11388576|NCT02112383|Experimental|Cognitive behavior group therapy|
11388577|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
11388578|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
11388579|NCT02112357||Targeted genetic sequencing of tumour specimen|
11388580|NCT02112344|Experimental|Total mucosal irradiation|
11388581|NCT02112331|Experimental|Raw human milk / pasteurized human milk|"Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk.
~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :
~one before the meal,
~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
11388582|NCT02112331|Experimental|Pasteurized human milk / pasteurized-homogenized human milk|"Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk.
~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :
~one before the meal,
~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
11388583|NCT02112305|Experimental|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval
11388584|NCT02112305|Active Comparator|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
11388585|NCT02112292|Experimental|T-C-P|Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
11388586|NCT02112292|Experimental|T-P-C|Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
11388587|NCT02112292|Experimental|C - T - P|Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
11388588|NCT02112292|Experimental|C - P - T|Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
11388589|NCT02112292|Experimental|P - T - C|Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
11388590|NCT02112292|Experimental|P - C - T|Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
11388591|NCT02112279|Experimental|Microbiota Transplant|Close relative or purchased donor microbiota transplant will be administered via colonoscopy; Donor microbiota applied via colonoscopy
11388592|NCT02112266|Other|no mail support|no mail support during follow-up
11388593|NCT02112266|Other|mail support|
11388594|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 2 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
11388595|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 3 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
11388596|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 2 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
11388597|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 3 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
11388598|NCT02112253|Active Comparator|Deep brain stimulator empirical programming|Any of the four electrode contacts on each of the two deep brain stimulation leads can be activated in any combination with any amplitude, frequency or pulse width settings to achieve optimized clinical control of motor tics whilst minimizing side effects. Both programmer and patient may be unblinded. The assessors are blinded to stimulation settings.
11388627|NCT02112097|Experimental|Adverse Reactions with Nervous system|Nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388665|NCT02111837|Experimental|Standard infant formula with PL2|Standard infant formula enriched with PL2 lipid fraction fed ad libitum
11388599|NCT02112240|Experimental|Surgery with pre- and intra-op imaging|Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
11388600|NCT02112227|Active Comparator|Discharge planning services|Proven effective discharge-planning services will be grouped into 'patient-centered care transitions in heart failure' patients. This will be known as the PACT-HF model.
11388601|NCT02112227|No Intervention|Standard Care|Standard of care will be provided to HF patients at discharge.
11388602|NCT02112214|Active Comparator|Intervention group|10-day bismuth-based quadruple therapy for H. pylori positive subjects
11388603|NCT02112214|Placebo Comparator|Placebo group|Placebo for H. pylori positive subjects
11388604|NCT02112201|Experimental|Integrated intervention for parents and adolescent girls|Twelve session parent education and support group; twelve session one-on-one adolescent skills training intervention
11388605|NCT02112201|No Intervention|Treatment as usual|Treatment as usual
11388606|NCT02112188||Chinese patients with advanced cancer|This is a study to adapt the IMCP intervention to be culturally and linguistically tailored for Chinese cancer patients. This study will be carried out in two phases: 1) formative research and 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process and session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, and Applebaum), Drs. Leng, Gany, and Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process and content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline and Treatment Integrity Coding Manual.
11388607|NCT02112175|Experimental|Lenalidomide|Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.
11388608|NCT02112162|Experimental|Diagnostic (FDG PET/MRI, gene expression)|FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
11388609|NCT02112149|Experimental|LIVESTRONG Program|Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
11388610|NCT02112149|No Intervention|Wait-List Control|Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.
11388611|NCT02112136|Other|GeneQuest|"No drug will be administrated in this study
~Blood collection"
11388612|NCT02112123|Placebo Comparator|Placebo|Matching placebo given for 5 days (qd po)
11388613|NCT02112123|Active Comparator|Icariin - 100 mg/day|Icariin given at 100 mg/day (qd po) for 5 days
11388614|NCT02112123|Active Comparator|Icariin - 200 mg/day|Icariin given at 200 mg/day (qd po) for 5 days
11388615|NCT02112123|Active Comparator|Icariin - 400 mg/day|Icariin given at 400 mg/day (qd po) for 5 days
11388616|NCT02112123|Active Comparator|Icariin - 840 mg/day|Icariin given at 840 mg/day (qd po) for 5 days
11388617|NCT02112123|Active Comparator|Icariin - 1680 mg/day|Icariin given at 1680 mg/day (qd po) for 5 days
11388618|NCT02112110|Experimental|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days
11388619|NCT02112097|Experimental|For Left Upper Arm|"For Left Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
11388620|NCT02112097|Experimental|For Right Upper Arm|"For Right Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
11388621|NCT02112097|Experimental|sPGA 50 n(%)|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, and Efficacy of Enbrel subcutaneously at Week 36 vs. Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, and Efficacy of Enbrel subdermally at Week 36. sPGA 50 n(%) clear or minimal is the % of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and % of patients with a reduction of PASI of at least 50% from baseline."
11388622|NCT02112097|Experimental|PASI 75 n(%)|"PASI 75 n(%)
~Response to treatment defined as the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI, as PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, and PASI 75 n(%) subcutaneously at Week 36 vs. PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, and PASI 75 n(%) subdermally at Week 36."
11388623|NCT02112097|Experimental|Adverse Injection site reactions|Injection site reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388624|NCT02112097|Experimental|Adverse Reactions with Heart failure|Heart failure as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388625|NCT02112097|Experimental|Adverse Reactions Allergic Reactions|Allergic Reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388626|NCT02112097|Experimental|Adverse Reactions Blood/low blood counts|Blood problems/low blood counts as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388694|NCT02111629|Experimental|Fluconazole and Secnidazole|
11388628|NCT02112097|Experimental|Adverse Reactions with Infections|Infections (upper respiratory infection, pyelonephritis, bronchitis, septic osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388629|NCT02112097|Experimental|Adverse Reactions with Malignancies|Malignancies (lymphoma, basal & squamous skin cancer, non-cutaneous solid tumor, & Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388630|NCT02112097|Experimental|Adverse Reactions with Immunogenicity|Immunogenicity as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388631|NCT02112097|Experimental|Adverse Reactions with Autoantibodies|Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
11388632|NCT02112084|No Intervention|Usual Care|Usual care participants do not receive an intervention.
11388633|NCT02112084|Experimental|Individualized DPM|Individualized DPM
11388634|NCT02112071|Experimental|Exercise|blended supervised-hombased exercise training 3-4 times/week for 12 weeks
11388635|NCT02112071|No Intervention|control|control group asked to continue usual activities
11388636|NCT02112058|Experimental|Program|A series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program. Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula. The third component was family support services.
11388637|NCT02112058|No Intervention|Control|Business as usual
11388638|NCT02112045|Experimental|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.
~HDM intravenously (IV) on Day -2.
~Autologous stem cell transplantation on Day 0"
11388639|NCT02112045|Active Comparator|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.
~Autologous stem cell transplantation on Day 0."
11388640|NCT02112032|Experimental|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
11388641|NCT02112032|Experimental|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
11388642|NCT02112032|Experimental|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
11388643|NCT02112019|Experimental|Sialoendoscopy with saline|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and possible strictures are dilated
11388644|NCT02112019|Active Comparator|Sialoendoscopy: saline and hydrocortisone|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and hydrocortisone and possible strictures are dilated
11388645|NCT02112019|No Intervention|Control: no treatment|
11388646|NCT02112006|Experimental|distal injection|0.5% bupivacaine injected in the forearm
11388647|NCT02112006|Active Comparator|proximal injection|20-30ml of 0.5% bupivacaine
11388648|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
11388649|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
11388650|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
11388651|NCT02111967||Diabetes mellitus type 2, Metformin|The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.
11388652|NCT02111967||Diabetes mellitus type 2|The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment
11388653|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
11388654|NCT02111941|Experimental|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
11388655|NCT02111928||NovaTears®|
11388656|NCT02111915|Other|Enhanced Usual Care (EUC)|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services
11388657|NCT02111915|Experimental|THPP-P|Trial participant s who are in the THPP group will receive, in addition to EUC, 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
11388658|NCT02111889|Experimental|one|
11388659|NCT02111876||AHRF follow-up|
11388660|NCT02111863|Experimental|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
11388661|NCT02111850|Experimental|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
11388662|NCT02111850|Experimental|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
11388666|NCT02111824|Experimental|Group 2|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
11388667|NCT02111824|Experimental|Group 3|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
11388668|NCT02111824|No Intervention|Group 1|Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
11388669|NCT02111811|Experimental|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
11388670|NCT02111811|No Intervention|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
11388671|NCT02111798|Placebo Comparator|placebo|Participants will be randomized to receive active or placebo medication after being stratified according to their initial response to a contingency management intervention (i.e. whether or not they stop using cocaine when offered financial incentives to do so).
11388672|NCT02111798|Active Comparator|Bupropion XL|Participants will be randomized to receive active or placebo medication after being stratified according to their initial response to a contingency management intervention (i.e. whether or not they stop using cocaine when offered financial incentives to do so). Active medication is bupropion XL 300mg/day.
11388673|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
11388674|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
11388675|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
11388676|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
11388677|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
11388678|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
11388679|NCT02111759|Other|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
11388680|NCT02111759|Other|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
11388681|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
11388682|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
11388683|NCT02111733|Experimental|Hs-TnT|Hs-TNT dosage
11388684|NCT02111720|Experimental|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
11388685|NCT02111720|Active Comparator|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
11388686|NCT02111707|Active Comparator|Rectal Indomethacin pre-ERCP|Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
11388687|NCT02111707|Active Comparator|Rectal Indomethacin post-ERCP|Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)
11388688|NCT02111694|Experimental|Clear versus Opaque Bottle|This is a within-subject study; all infants will be exposed to both conditions. Order of presentation will be counterbalanced across infants.
11388689|NCT02111681|Experimental|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.
~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
11388690|NCT02111655|Other|Clasical Surveillance of AVF|"Classical evaluation of AVF includes:
~Vital sings and predialysis physical examination of AVF every dialysis session.
~Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session.
~Weekly ktv test using biosensors or monthly if using monocompartimental Daugirdas equation.
~Quarterly recirculation with urea method.
~Following Spanish Nephrology VA guidelines will be consider as alarm criteria:
~1.25% Increased venous pressure. 2.25% Decreased pump blood flow. 3.0,2 ktv decreased compared with previous measurement. 4.> 10% recirculation using urea method. 5.Prolonged coagulation time or cannulation difficulties in 3 consecutive dialysis sessions.
~6.Pathologic physical examination with any other criteria."
11388691|NCT02111655|Experimental|Second generation surveillance of AVF|"In addition to the classical surveillance and monitoring methods, in the experimental group Doppler ultrasound and transonic dilution method will be performed on a quarterly basis.
~In addition to the classical alarm criteria and derived from the results in Doppler ultrasound an transonic dilution method the following alarm criteria would also be considered in the experimental group:
~25% or higher decreased in QA compared with previous measurement.
~QA lower than 500 ml/min.
~Stenotic area with a higher than 50% reduction of blood vessel lumen would be considered as alarm criteria only if it comes with a haemodynamic repercussion criteria defined as Peak systolic velocity (PSV) higher than 400 cm/sc, aliasing, or PSV ratio stenosis/pre-stenosis higher than 3."
11388692|NCT02111642|Experimental|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
11388693|NCT02111642|Placebo Comparator|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
11388695|NCT02111616|Active Comparator|Standard of Care (SCP)|Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
11388696|NCT02111616|Experimental|Intervention Arm (SCP + PCP visit)|"Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
~SCP plus Coordinated PCP Visit: Care coordinators will schedule patient appointment with PCP within 4 weeks of treatment."
11388697|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
11388698|NCT02111590||IVIG to SCIG|Patients with CIDP or MMN in maintenance therapy with IVIG every 3rd to 6th week are shifted to weekly SCIG treatment in unaltered dose.
11388699|NCT02111590||SCIG to SCIG|Patients with CIDP or MMN in maintenance therapy with SCIG (Subcuvia(R) or Hizentra(R)) are shifted to treatment with Gammanorm(R) in unaltered weekly dose.
11388700|NCT02111577|Experimental|DCVAC with Standard of Care Chemotherapy|Combination therapy with Dendritic Cells DCVAC and Standard of Care Chemotherapy (Docetaxel and prednisone)
11388701|NCT02111577|Active Comparator|Standard of Care Chemo and Placebo|Blinded combination therapy of Placebo and Standard of Care Chemotherapy (Docetaxel and prednisone) as Comparator
11388702|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
11388703|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
11388704|NCT02111551|Experimental|DMXB-A 75 mg|DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level
11388705|NCT02111551|Experimental|DMXB-A 150 mg|DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level
11388706|NCT02111551|Placebo Comparator|Sugar Pill|placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind
11388707|NCT02111538||Amyloidosis|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
11388708|NCT02111512|Other|Egg allergic children|Children with a physician diagnosis of egg allergy will be recruited to receive the intranasal LAIV as part of a safety surveillance study
11388709|NCT02111499|Experimental|formulation 1|topical treatment, once daily for 4 weeks
11388710|NCT02111499|Experimental|formulation 2|topical treatment, once daily for 4 weeks
11388711|NCT02111499|Experimental|formulation 3|topical treatment, once daily for 4 weeks
11388712|NCT02111499|Experimental|formulation 4|topical treatment,once daily for 4 weeks
11388713|NCT02111499|Placebo Comparator|formulation 5|topical treatment, once daily for 4 weeks
11388714|NCT02111499|Active Comparator|formulation 6|topical treatment, once daily for 4 weeks
11388715|NCT02111486|Experimental|breakfast #1|breakfast food containing high viscosity fibre
11388716|NCT02111486|Experimental|breakfast #2|breakfast food containing low viscosity fibre
11388717|NCT02111486|Placebo Comparator|Control|breakfast food without viscous fibre
11388718|NCT02111473|Other|testosterone|testosterone 250 mg injection per 3-4 weeks for 6 months
11388719|NCT02111460|Experimental|Radiotherapy|Systemic Chemotherapy Combined with Loco-regional Radiotherapy
11388720|NCT02111460|Active Comparator|Chemotherapy|Chemotherapy alone without Loco-regional Radiotherapy
11388721|NCT02111447|Active Comparator|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
11388722|NCT02111447|Active Comparator|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
11388723|NCT02111447|Active Comparator|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
11388724|NCT02111447|Active Comparator|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
11388725|NCT02111434|Experimental|testosterone|testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
11388726|NCT02111421|Experimental|parturients|Parturients after the umbilical cord was clapped in cesarean section were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
11388727|NCT02111421|Experimental|nonpregnant women|Nonpregnant women were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
11388728|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
11388729|NCT02111382|Experimental|CV4 (4th ventricle technique) technique|Will be conduced a real cranial osteopathic medicine technique.
11388730|NCT02111382|Sham Comparator|CV4 sham|This group will received only a sham manual therapy technique.
11388731|NCT02111382|No Intervention|Control|The participants will be in supine position for 5 minutes without any visual or verbal contact.
11388767|NCT02111161|Placebo Comparator|Saline 0.9%|0.9% saline for Intravenous administration. Dosage: 250 ml for three consecutive days.
11388732|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
11388733|NCT02111356|Experimental|Pinhole glasses|All subjects perform ophthalmic examinations before and after the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
11388734|NCT02111343|Experimental|Computer-based auditory training (CBAT)|The CBAT programmes in the current study were specifically designed to improve speech-in-noise and dichotic listening skills of children diagnosed with CAPD. All the training programmes were designed to be installed on home-user's computer, and they were visually attractive and appealing to children. The development of the software (non commercial) for the speech-in-noise and dichotic listening training was done by two different teams in the United Kingdom and Singapore, respectively.
11388735|NCT02111343|No Intervention|Control|No intervention other than participants' regular school activities
11388736|NCT02111330|Experimental|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
11388737|NCT02111330|Placebo Comparator|Dose I - Placebo|one Placebo capsule
11388738|NCT02111330|Experimental|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
11388739|NCT02111330|Placebo Comparator|Dose II - Placebo|Two Placebo capsule
11388740|NCT02111330|Experimental|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
11388741|NCT02111330|Placebo Comparator|Dose III - Placebo|Three Placebo capsule
11388742|NCT02111317|Experimental|ASP015K and verapamil|Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
11388743|NCT02111304|Active Comparator|Part A (Adults)|In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
11388744|NCT02111304|Active Comparator|Part B (Pediatric)|"Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.
~Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen."
11388745|NCT02111291|Experimental|SANTYL®|
11388746|NCT02111291|Sham Comparator|Supportive Care|
11388747|NCT02111278|Experimental|lumbar Manipulation|Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
11388748|NCT02111278|Placebo Comparator|Sham Manipulation|Patients randomized to this treatment group will receive a sham manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
11388749|NCT02111265|Experimental|Propofol|Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.
11388750|NCT02111265|Experimental|Etomidate|Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.
11388751|NCT02111252|Experimental|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
11388752|NCT02111239|No Intervention|No imaging|No preoperative imaging is performed for this group
11388753|NCT02111239|Experimental|CTA|Patients randomized to this group will undergo a preoperative CTA scan.
11388754|NCT02111239|Experimental|MRA|Patients randomized to this group will undergo a preoperative MRA scan.
11388755|NCT02111226|Active Comparator|Passive SMS Group|Passive SMS messages focused on lifestyle adjustment
11388756|NCT02111226|Experimental|Active SMS Group|Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
11388757|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
11388758|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
11388759|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
11388760|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
11388761|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
11388762|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
11388763|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
11388764|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
11388765|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
11388766|NCT02111161|Active Comparator|IVIG (Privigen)|Intravenous polyspecific immunoglobulin G (Privigen). Dosage: 25 g/day (250 ml) for three consecutive days
11388768|NCT02111148|Active Comparator|urea and creatinine|urea and creatinine detected in vaginal fluid wash after injecting of 5 ml saline intavaginally
11388769|NCT02111148|Active Comparator|Nitrazine|Biochemical description of Nitrazine in the vaginal wash
11388770|NCT02111148|Active Comparator|saline|5ml saline will be injected in vagina of each patient in both groups within 24 hours of membrane rupture.
11388771|NCT02111135|Experimental|Group 1|b-OPV, m-IPV HD and m-OPV2
11388772|NCT02111135|Active Comparator|Group 2|b-OPV, t-IPV and m-OPV2
11388773|NCT02111122|Experimental|Sodium Oxybate|"Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
11388774|NCT02111122|Placebo Comparator|Placebo|"Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
11388775|NCT02111109||Traumatic injury|
11388776|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
11388777|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
11388778|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
11388779|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
11388780|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
11388781|NCT02111070|Experimental|ILYANG Inactivated split influenza vaccine|IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection
11388782|NCT02111057||Perioperative RA|Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 90.
11388783|NCT02111044|Active Comparator|Octreotide|Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks
11388784|NCT02111044|Experimental|ITF2984 500 mcg|ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks
11388785|NCT02111044|Experimental|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
11388786|NCT02111044|Experimental|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
11388787|NCT02111031||Case|Patients with documented (histologically/pathologically confirmed) mBC diagnosis, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions).
11388788|NCT02111018|Active Comparator|CVVH|
11388789|NCT02111018|Experimental|CytoSorb Device|
11388790|NCT02111005||Smoking Aggressive Periodontitis group|This group comprises 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
11388791|NCT02111005||Smoking Chronic Periodontitis group|This group comprises 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
11388792|NCT02111005||Non-smoking Aggressive Periodontitis grp|This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
11388793|NCT02111005||Non-smoking Chronic periodontitis grp|This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.
11388794|NCT02110992|Experimental|Docetaxel + Stereotactic Radiation|Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by > 48 hours.
11388795|NCT02110979|Experimental|PDA|Subjects receive an internet-based patient decision aid video. The PDA is viewed outside of the doctor's office via a personal computer in preparation for regularly scheduled face to face interaction between patients and clinicians.
11388796|NCT02110979|No Intervention|Usual care|Patients receive usual care as determined by their clinician.
11388797|NCT02110966|Experimental|Mepivacaine plus Tramadol|1.3 ml of Mepivacaine 2% epinephrine 1:100000 mixed with 0.5 ml of Tramadol (50mg/ml) will be used for the anesthetic blockade in the experimental group
11388798|NCT02110966|Active Comparator|Mepivacaine|The control group will receive the inferior alveolar nerve block using 1.8 ml of Mepivacaine 2% epinephrine 1: 100000.
11388799|NCT02110953|Experimental|Treatment (irinotecan-eluting beads)|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for a total of 2 treatments in the absence of disease progression or unacceptable toxicity. Patients with bi-lobular disease and no evidence of progression in the treated lobe may repeat treatment at the discretion of the treating physician.
11388800|NCT02110940|Active Comparator|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
11388801|NCT02110940|Experimental|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.
~Subjects will be instructed to practice everyday, each action repeat for 10 times."
11388802|NCT02110927|Experimental|Transcutaneous microcurrent|This group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 milliampere (mA). Every 20 minutes changed from 25 hertz (Hz) to 10 Hz
11388803|NCT02110927|Placebo Comparator|Control group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
11388804|NCT02110914|Experimental|Coaching|10 coaching sessions over a period of 6 - 9 months. The intervention is life coaching based on principles of the co-active coaching model.
11388805|NCT02110914|No Intervention|Control|Standard care
11388806|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
11388807|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
11388808|NCT02110888|Experimental|SCS + PNS|Mutlticolumn SCS lead + Monocolumn SCS lead
11388809|NCT02110888|Active Comparator|SCS|Mutlticolumn SCS lead
11388810|NCT02110875||CONTROLS|Age- and Gender-Matched Controls
11388811|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
11388812|NCT02110849||Prostate Cancer Patients|Prostate cancer patients who received proton radiation therapy
11388813|NCT02110836|Active Comparator|Glucose ingestion|Glucose ingestion during exercise at a rate of 1.8 g/min.
11388814|NCT02110836|Experimental|Sucrose ingestion|Sucrose ingestion during exercise at a rate of 1.8 g/min.
11388815|NCT02110810|Experimental|Indomethacin|100 mg of Indomethacin suppository immediately afterwards while still under sedation
11388816|NCT02110810|Placebo Comparator|2.6-g suppository of glycerin|suppository of 2.4 g of glycerin immediately afterwards while still under sedation
11388817|NCT02110797|Other|RETT patients|
11388818|NCT02110784|Experimental|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
11388819|NCT02110771|Experimental|GAÏA - facial affect recognition targeted|"GAÏA:20hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment cognitive remediation targeted on facial affects recognition. exercises were designed by Gaudelus and Franck (2012) and tutoractiv'company. It includes photos, computer and role games exercises.Computer based exercises have 5 difficulty levels.
~2 sessions of one hour per week with therapist.
~Tasks at home are given once a week and targeting functional outcomes associated with facial affects recognition impairment."
11388820|NCT02110771|Active Comparator|RECOS - attentional process targeted|"RECOS (Cognitive REmediation for Schizophrenia): 20 hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment.
~RECOS is a validated cognitive remediation program, developed by P. Vianin and SBT company. It includes paper and pen and computer based exercises. The original program proposes 5 modules targeting 5 cognitive functions, each patient participated in the module corresponding to his/her most altered cognitive function. In this study, all patients randomized in this arm are allocated in the attentional module.Every computer exercises have 10 difficulty levels.
~2 sessions of one hour per week with therapist.
~Tasks at home are given once a week and targeting functional outcome"
11388821|NCT02110758||Patient focus groups and observations|Patients diagnosed with cancer who are receiving care at an oncology practice implementing the Patient-Centered Oncology Care model
11388822|NCT02110758||Clinicians and staff|Clinicians and staff employed at an oncology practice implementing the Patient-Centered Oncology Care model
11388823|NCT02110758||Patient survey|Patients with any active treatment for cancer (including radiation, surgery, or drug therapy) receiving care in southeastern Pennsylvania
11388824|NCT02110745|Experimental|Sevofluorane|Sevofluorane 8% in induction
11388825|NCT02110745|Experimental|Propofol|Propofol 2.5 mg/kg intravenous in induction
11388826|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
11388827|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
11388828|NCT02110719|Active Comparator|Standard|"Patients will be given the following:
~no preoperative medications
~intraoperative medications per anesthesia
~postoperatively, patients will receive ibuprofen, tylenol and narcotics as needed"
11388829|NCT02110719|Active Comparator|Multimodal|"Patients in the multimodal arm will receive the following:
~preoperative celebrex and gabapentin
~intraoperative IV acetaminophen, dexamethasone, zofran
~postoperative scheduled IV acetaminophen, PO celebrex and gabapentin, and as needed PO narcotics
~patient will be discharged on scheduled ibuprofen and acetaminophen for 3 days followed by as needed use as well as as needed narcotics"
11388830|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
11388831|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
11388832|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
11388833|NCT02110680|Active Comparator|TENS 1|TENS at posterior tibial nerve area
11388834|NCT02110680|Sham Comparator|TENS 2|TENS at shoulder area
11388835|NCT02110667||Prostate cancer, post-prostatectomy|
11388836|NCT02110654|Active Comparator|mometasone furoate nasal spray|mometasone furoate nasal spray,200ug qd, 6 months
11388837|NCT02110654|Experimental|mometasone furoate nasal spray combined with montelukast|montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months
11388838|NCT02110641|Active Comparator|In-Person or Telephone-Based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs.
11388915|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
11388839|NCT02110641|No Intervention|Usual Care/Wait List|At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
11388840|NCT02110628|Experimental|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
11388841|NCT02110628|Experimental|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
11388842|NCT02110615|Experimental|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
11388843|NCT02110602|Experimental|Initial Diet - high in amino acid levels|"Visit 1 (Day 1): Screening Visit
~Visit 2 (14-21 days after Visit 1): Begin high amino acid diet
~Visit 3 (4 days after Visit 2): Completion of high amino acid diet
~Visit 4 (3 days after Visit 3): Begin low amino acid diet
~Visit 5 (4 days after Visit 4): Completion of low amino acid diet, completion of study"
11388844|NCT02110602|Experimental|Initial Diet - low in amino acid levels|"Visit 1 (Day 1): Screening Visit
~Visit 2 (14-21 days after Visit 1): Begin low amino acid diet
~Visit 3 (4 days after Visit 2): Completion of low amino acid diet
~Visit 4 (3 days after Visit 3): Begin high amino acid diet
~Visit 5 (4 days after Visit 4): Completion of high amino acid diet, completion of study"
11388845|NCT02110589|Experimental|Patient Group 1|"Testing of Epidetect:
~Adult Patients with difficult to control tonic-clonic (convulsant) epilepsy undergoing hospitalised video telemetry monitoring. Patients will be hospitalised as part of their normal investigation of the epilepsy and patients will be consented 1 week before hospitalisation. Epidetect will be used in conjunction with the normal EEG monotoring and video telemetry. The patient will be fitted with the topical sensors at the start of monotoring and then depending on the seizure activity will wear the sensors until enough data is gathered. Hospitalisation under these circumstances typically lasts no more than five days, so monitoring with the topical sensor will be no longer than this."
11388846|NCT02110589|Experimental|Patient Group 2|"Testing of Epidetect:
~Paediatric patients (over 7 years) where parental consent will enable the epilepsy monitor to be used at home for 1 week and brought back in for analysis along with video evidence. This will not constitute any change in normal care or treatments, and the video evidence provided represents enhanced care through accurate seizure diary reporting. Suitable families and children will be selected and consented through scheduled clinics in paediatric neurology."
11388847|NCT02110589|Experimental|Patient group 3|"Testing of Epidetect:
~Patients where the epilepsy is suspected to be psychogenic (pseudo-seizures) rather than organic epilepsy. We will test whether the epilepsy monitor will be able to differentiate between epilepsy and psychogenic seizures in the medical setting when patients are hospitlised for seizure investigation. Suitable patients will be selected and consented through scheduled clinics in paediatric neurology (under 16) and adult neurology."
11388848|NCT02110589|Experimental|Patient Group 4|"Testing of Epidetect:
~Internal negative Controls. Juveniles or adults with other forms of epilepsy that do not have a hypertonic (increased muscle stiffening) phenotype e.g. absence seizures."
11388849|NCT02110589|Other|Control Group 1|"Testing of Epidetect:
~Volunteers who do not have a history of seizures / epielsy, head trauma, migraine, neurological or muscular-skeletal disorders. This is to produce the baseline data for the Monitor."
11388850|NCT02110576||Healthy Controls|Healthy controls in general good health, without chronic disease/illness, including but not limited to: cancer, diabetes mellitus, renal disease, cardiac disease, hypertension, lung disease, liver disease, complications of morbid obesity, autoimmune/inflammatory disease, or any condition of sufficient severity that it requires daily medication to manage
11388851|NCT02110563|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
11388852|NCT02110550|No Intervention|IPS.emmax crown|
11388853|NCT02110550|Experimental|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
11388854|NCT02110537|Experimental|Active Acupuncture + flecainide|The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
11388855|NCT02110537|Sham Comparator|Sham acupuncture + flecainide|The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
11388856|NCT02110524|Experimental|CVI Drug Coated Balloon|
11388857|NCT02110511|Experimental|alpha-gal & blended lentils|3 capsules of alpha-gal taken with blended lentils
11388858|NCT02110511|Experimental|alpha-gal & whole lentils|3 calpsules of alpha-gal taken with whole lentils
11388859|NCT02110511|Experimental|alpha-gal & no lentils|3 capsules of alpha-gal taken with no lentils control
11388860|NCT02110511|Placebo Comparator|Placebo & blended lentils|3 capsules of placebo taken with blended lentils
11388861|NCT02110511|Placebo Comparator|Placebo & whole lentils|3 capsules of placebo taken with whole lentils
11388862|NCT02110511|Placebo Comparator|Placebo & no lentils|3 capsules of placebo taken with no lentils control
11388863|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
11388864|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
11388865|NCT02110472|Other|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
11388866|NCT02110459|Experimental|Mild renal impairment|3h IV POL7080 infusion
11388867|NCT02110459|Experimental|Moderate renal impairment|3h IV POL7080 infusion
11388868|NCT02110459|Experimental|Severe renal impairment|3h IV POL7080 infusion
11388869|NCT02110459|Experimental|End stage renal disease arm 1|3h IV POL7080 infusion
11388870|NCT02110459|Experimental|End stage renal disease arm 2|3h IV POL7080 infusion
11388871|NCT02110459|Experimental|Normal Renal function|3h IV POL7080 infusion
11388872|NCT02110446|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
11388873|NCT02110446|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
11388874|NCT02110433|Other|Placebo group|Patients will be managed per consensus guidelines Clinicians could see the patients as many times as necessary in order to optimize their therapy and could make BNP measurement (but not using Home BNP monitoring)
11388875|NCT02110433|Experimental|Cordiva System (R)|Patient will see their cardiologist every three months and benefit from telemonitoring of their weight and general well being through a specific communicant device.
11388876|NCT02110433|Active Comparator|BNP and Cordiva (R) monitoring system|In this group, patients and doctors have access to the platform detailed above (Cordiva (R) monitoring system) and had also access to BNP home monitoring (BNP heartcheck).
11388877|NCT02110420|Experimental|CC-90001 10mg (Single Dose)|
11388878|NCT02110420|Experimental|CC-90001 30mg (Single Dose)|
11388879|NCT02110420|Experimental|CC-90001 60mg (Single Dose)|
11388880|NCT02110420|Experimental|CC-90001 120mg (Single Dose)|
11388881|NCT02110420|Experimental|CC-90001 240mg (Single Dose)|
11388882|NCT02110420|Experimental|CC-90001 10mg (Multiple Doses)|
11388883|NCT02110420|Experimental|CC-90001 30mg (Multiple Doses)|
11388884|NCT02110420|Experimental|CC-90001 60mg (Multiple Doses)|
11388885|NCT02110420|Experimental|CC-90001 120mg (Multiple Doses)|
11388886|NCT02110420|Experimental|CC-90001 240mg (Multiple Doses)|
11388887|NCT02110420|Experimental|Placebo|
11388888|NCT02110420|Experimental|CC-90001 480mg (single dose)|CC-90001 480mg will be administered as a single oral dose
11388889|NCT02110420|Experimental|CC-90001 720mg (single dose)|CC-90001 720mg will be administered as a single oral dose
11388890|NCT02110420|Experimental|CC-90001 480mg (multiple doses)|CC-90001 480mg will be administered daily for 14 days
11388891|NCT02110407|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
11388892|NCT02110407|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
11388893|NCT02110394||bendamustine and rituximab|
11388894|NCT02110381|Active Comparator|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
11388895|NCT02110381|Active Comparator|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
11388896|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
11388897|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
11388898|NCT02110355|Experimental|AMG 232 with Trametinib and Dabrabenib|Arm 1 of Part 1 and 2 and Part 3
11388899|NCT02110355|Experimental|AMG 232 with Trametinib|Arm 2 of Part 1 and 2
11388900|NCT02110355|Active Comparator|Trametinib and Dabrafenib|Part 3
11388901|NCT02110342|Experimental|Treatment|
11388902|NCT02110329|No Intervention|stage II-III colon cancer treated with surgery|stage II-III colon cancer treated with surgery
11388903|NCT02110316|Other|Bioavailability|1 arm, different dosage form
11388904|NCT02110303|Experimental|18F-F Positive - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
11388905|NCT02110303|Placebo Comparator|18F-F Positive - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
11388906|NCT02110303|Experimental|18F-F Negative - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
11388907|NCT02110303|Placebo Comparator|18F-F Negative - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
11388908|NCT02110290||Children with Physical Disabilities|This group includes children 8-18 years old participating in an adapted ski/snowboarding program with any type of physical disability, including cerebral palsy, traumatic brain injury, spinal cord injury, and amputation.
11388909|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
11388910|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
11388911|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
11388912|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
11388913|NCT02110251|Experimental|Supervised exercise therapy|Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
11388914|NCT02110251|No Intervention|Walking advice|Standard care and a oral walking advice.
11388916|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
11388917|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
11388918|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
11388919|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
11388920|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
11388921|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
11388922|NCT02110186|Experimental|Discectomy and dynamic stabilization|Discectomy with posterior dynamic stabilization
11388923|NCT02110186|Active Comparator|Discectomy alone|Discectomy
11388924|NCT02110186|Active Comparator|Discectomy and fusion|Discectomy with internal fixation and fusion
11388925|NCT02110147|Experimental|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
11388926|NCT02110134|Experimental|Revlite Laser System with Topical|Revlite Laser System for the Treatment of Melasma and hydroquinone skin care regimen
11388927|NCT02110134|Active Comparator|Topical|Hydroquinone skin care regimen
11388928|NCT02110121|Experimental|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
11388929|NCT02110121|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
11388930|NCT02110108|Experimental|Revlite Laser System|Revlite Laser System
11388931|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
11388932|NCT02110082|Experimental|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
11388933|NCT02110082|Experimental|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
11388934|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.
~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
11388935|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.
~Sirolimus trough levels will be maintained between 10-15 ng/ml."
11388936|NCT02110056|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
11388937|NCT02110056|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
11388938|NCT02110043|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with anodal transcranial direct current stimulation (tDCS)
11388939|NCT02110043|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
11388940|NCT02110030|Experimental|Transcutaneous nerve stimulation|"The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 15 sessions at a frequency of 80 Hz and with a pulse width of 150 ns.
~The group with TENS received electrical stimulation by using an approved electrotherapy device (Endomed 182, Enraf-nonius, Germany). The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2)."
11388941|NCT02110030|Active Comparator|Interferential Currents|The group with Interferential Currents (IC) received a base frequency of 4000 Hz by using the same approved electrotherapy device than the TENS group (Endomed 182, Enraf-nonius, Germany).
11388942|NCT02110017|Other|Patients with schizophrenia|"Twenty patients suffering from schizophrenia (DSM-IV-R), with medication and medical care. No recent relapse of the psychotic disease, nor change in medications.
~No neurological comorbidity.
~After anatomic scans, each subject will go through the fMRI social cognition task."
11388943|NCT02110017|Other|Healthy subjects|"Twenty healthy subjects (no mental or neurological disease)
~After anatomic scans, each subject will go through the fMRI social cognition task."
11388944|NCT02110004|Other|Ablation procedure|Collect intra-cardiac signals
11388945|NCT02109991|Experimental|CG-100 device|
11388946|NCT02109978||Responders|Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.
11388947|NCT02109978||Progressors|Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment >10 years from diagnosis.
11388948|NCT02109965|Active Comparator|Control|Use midazolam or propofol for sedation
11388949|NCT02109965|Experimental|Dexmedetomidine|Use dexmedetomidine for sedation
11388950|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
11388951|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
11388952|NCT02109926||Cases: testicular cancer patients|
11388953|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
11388954|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
11388955|NCT02109913|Other|Everolimus plus exemestane|Biomarker study in patients receiving standard treatment
11388956|NCT02109900||Serum Progesteron Levels|
11388957|NCT02109887||PCP with true CMV co-infection|
11388960|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 5/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
11388961|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 15/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
11388962|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 50/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
11388963|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 150/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol
~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
11388964|NCT02109874|Placebo Comparator|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|Placebo: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl. This is the identical buffer solution in which IC31 is formulated.
11388965|NCT02109861|Experimental|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
11388966|NCT02109861|Experimental|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
11388967|NCT02109861|Experimental|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
11388968|NCT02109848||keratoconus|
11388969|NCT02109848||post-keratoplasty|
11388970|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
11388971|NCT02109835||Asymptomatic type 2 diabetes|Patients without previous history of coronary artery disease
11388972|NCT02109822||CF patients with pulmonary exacerbations|Patients with CF who are hospitalized with a pulmonary exacerbation treated with intravenous antibiotics.
11388973|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
11388974|NCT02109796|Experimental|hemiplegic patient|anodal transcranial direct current stimulation
11388975|NCT02109796|Sham Comparator|patient control|Sham transcranial direct current stimulation
11388976|NCT02109783|Active Comparator|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
11388977|NCT02109783|Active Comparator|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
11388978|NCT02109783|Placebo Comparator|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
11388979|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
11388980|NCT02109757|Experimental|Software intervention and education|This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.
11388981|NCT02109757|Active Comparator|Education only|This group will not receive software intervention prior to and after one-on-one education, only afterwards.
11388982|NCT02109744|Experimental|A|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
11388983|NCT02109744|Experimental|B|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
11388984|NCT02109731|Experimental|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
11388985|NCT02109718|Experimental|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
11388986|NCT02109718|Active Comparator|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.
11388987|NCT02109705||Alzheimer's Disease|
11388988|NCT02109705||other Dementia|
11388989|NCT02109705||cognitive healthy|
11388990|NCT02109692|Other|cohort|blood sample : doage of miRNA
11388991|NCT02109679|Experimental|Treatment A|multiple doses BI 187004
11388992|NCT02109679|Experimental|Treatment B|multiple doses BI 187004 + multiple doses metformin
11388993|NCT02109679|Experimental|Treatment C|multiple doses metformin
11388994|NCT02109666||RA patients treated with Abatacept|RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
11388995|NCT02109653|Experimental|LGX818|Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.
11388996|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
11388997|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
11389161|NCT02108496|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
11388998|NCT02109627|Experimental|Ficlatuzumab, Cytarabine|"Ficlatuzumab 5-20 mg/kg; intravenous; Days 0, 14, 28, 42; Number of cycles: until progression or unacceptable toxicity develops.
~Cytarabine 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops."
11388999|NCT02109614|Experimental|Extended release Niacin|Taking 1500-2000mg niacin daily
11389000|NCT02109614|Placebo Comparator|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
11389001|NCT02109601|Active Comparator|Control|Control patients receive iPad tablets during their hospital stay with only LIMITED bedside training from a research assistant on how to access and effectively use their patient portal.
11389002|NCT02109601|Experimental|Intervention|Intervention patient receive iPad tablets during their hospital stay with EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
11389003|NCT02109588|No Intervention|Control|Sedentary pregnant women
11389004|NCT02109588|Experimental|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training
~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
11389005|NCT02109575||Heart Transplant Recipients|Up to 10 cc of blood will be drawn from heart transplant recipients at various time points prior to and after transplant. Blood draw is the only research activity that study participants will undergo. In addition to blood draw, data will be collected from clinical records representing the participant's transplant course such as the medical record, imaging, and biopsy slides with pathology reports.
11389006|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
11389007|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
11389008|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
11389009|NCT02109549||Diabetes and metformin|Patients with diabetes mellitus treated with metformin only.
11389010|NCT02109549||Insulin-diabetes without metformin|Patients with insulin-dependent diabetes mellitus not treated with metformin
11389011|NCT02109549||Controlgroup|The remaining patients serve as control group.
11389012|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
11389013|NCT02109523|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
11389014|NCT02109523|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
11389015|NCT02109510|Experimental|Nonintubated sedation anesthesia|nonintubated single port thoracoscopic bullectomy using local anesthesia under sedation Drug: Dexmedetomidine IV loading dose of 1ug/kg for 10 minutes and maintain dosage of 0.3-1 ug/kg/hr, ketamine IV 2-4 mg/kg/hr and intercostal nerve block with 2% lidocaine 2cc Device: facial O2 Mask
11389016|NCT02109510|Active Comparator|Intubated general anesthesia|intubated single port thoracoscopic bullectomy under general anesthesia Drug: propofol 2mg/kg IV , rocuronium 0.6mg/kg IV,1.2-2.4% sevoflurane, N20 50% 02 at fresh gas flow of 4L/min Device: double lumen endotracheal tube intubation
11389017|NCT02109497|Other|Caffeine Dosing|Single dose of caffeine 100 mg administered
11389018|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
11389019|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
11389020|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
11389021|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
11389022|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
11389023|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
11389024|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
11389025|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
11389026|NCT02109471||corneal opacities|
11389027|NCT02109458|Experimental|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
11389028|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
11389029|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
11389030|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
11389031|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:
~Self-directed Pedal Desk
~Facilitated Pedal Desk
~Facilitated Pedal Desk with Pedometer"
11389032|NCT02109419||All participants|All participants, including control, mild cognitive impairment, and dementia.
11389033|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
11389034|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
11389035|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
11389063|NCT02109185|Active Comparator|Nasonex® Nasal Spray, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
11389162|NCT02108483|Experimental|All participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches on Day 1.
11389036|NCT02109393|Experimental|MIRT group|"This group underwent a 4-weeks MIRT exploiting the use of a treadmill-plus (treadmill associated with visual cues and auditory feedbacks).
~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
11389037|NCT02109393|Experimental|MIRT+Lokomat group|"This group underwent a 4-weeks MIRT involving the use of Lokomat® for 5 days per week in spite of treadmill-plus.
~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
11389038|NCT02109380|Experimental|Bed rest|One week of bed rest.
11389039|NCT02109367||Pelvic mass|Women who present to the Gynecologic Oncology clinic with a pelvic mass who are scheduled to undergo surgical excision.
11389040|NCT02109354|Active Comparator|HIV Regimen + Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
11389041|NCT02109354|Active Comparator|HIV Vaccine Regimen|Participants will receive a placebo for tetanus vaccine by injection (placebo tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a placebo for hepatitis B vaccine series (months 7.5, 8.5, 13)
11389042|NCT02109354|Placebo Comparator|Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of a placebo for the experimental canarypox HIV vaccine (placebo for ALVAC-HIV; months 1, 2), than 2 injection of a placebo protein HIV vaccine boost (placebo for AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
11389043|NCT02109341|Experimental|Nab-FOLFIRI|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.
~Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence."
11389044|NCT02109341|Experimental|Nab-FOLFOX|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks.
~Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.
~Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence"
11389045|NCT02109328|Experimental|Alisertib + Paclitaxel|After the first single arm phase with Alisertib monotherapy (20 patients, primary endpoint: response-rate), 110 patients will be randomized 1:1 in the second part of the trial.
11389046|NCT02109328|Placebo Comparator|Paclitaxel + Placebo|Weekly paclitaxel + oral Placebo
11389047|NCT02109315|Experimental|Liraglutide endovenous 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
11389048|NCT02109315|Experimental|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
11389049|NCT02109289|Experimental|Methotrexate and Etanercept|Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks
11389050|NCT02109276|Active Comparator|Spheric Sensar(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive a Spheric Sensar(R) 3-piece IOL
11389051|NCT02109276|Experimental|Aspheric Tecnis(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive an Aspheric Tecnis(R) 3-piece IOL
11389052|NCT02109263|Experimental|saccharose|20% saccharose
11389053|NCT02109263|Placebo Comparator|breast-feeding|breast-feeding
11389054|NCT02109250||all Belgian patients treated with Caprelsa® (vandetanib)|It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
11389055|NCT02109237|Experimental|Bronchiolitis Obliterans 2 & 3|Assessment of sleep disorders and treatment if required
11389056|NCT02109237|Active Comparator|Bronchiolitis Obliterans 0|Assessment of sleep disorders and treatment if required
11389057|NCT02109224|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11389058|NCT02109211|Other|Standard care - Magill forceps|Patients will be intubated, as per standard care, with Magill forceps.
11389059|NCT02109211|Experimental|Altered Magill forceps|Patients will be intubated with modified Magill forceps.
11389060|NCT02109198|Experimental|Active CN-NINM PoNS|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
11389061|NCT02109198|Placebo Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
11389062|NCT02109185|Active Comparator|Mometasone Furoate Monohydrate Nasal Spray,50 μg/act.|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
11389064|NCT02109185|Active Comparator|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray Suspension per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
11389065|NCT02109185|Placebo Comparator|Placebo Nasal Spray, 50 μL/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays of placebo nasal spray per nostril once daily.
11389066|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
11389067|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
11389068|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
11389069|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
11389070|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
11389071|NCT02109146|Experimental|TACE|Patients after surgery receive Transcatheter Arterial Chemoembolization (TACE)
11389072|NCT02109146|Active Comparator|Control|Patients after surgery do not receive TACE
11389073|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
11389074|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
11389075|NCT02109120||carotid endarterectomy (CEA)|CEA patients with vein blood collection
11389076|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
11389077|NCT02109094||Pregnant|
11389078|NCT02109094||Not Pregnant|
11389079|NCT02109081|Experimental|Dexamethasone|Patients will be administered dexamethasone 10 mg at induction of anesthesia
11389080|NCT02109081|Placebo Comparator|Placebo-2.5 cc of saline|Patients will be administed placebo at induction of anesthesia
11389081|NCT02109068|Active Comparator|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
11389082|NCT02109068|Active Comparator|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
11389083|NCT02109068|No Intervention|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
11389084|NCT02109055|Experimental|Pilates|Regarding upper limb exercises the limit of flexion and abduction less than 90°, with the exercises involving only the movement of flexion and extension of elbow shoulder will be respected. Along with patient data will be an exercise protocol based on the Pilates method that will be performed by a trained team of physiotherapists. Before and after the exercises the data of heart rate, blood pressure, oxygen saturation and subjective feeling of perceived exertion using the Modified Borg scale will be listed.
11389085|NCT02109055|Active Comparator|Convencional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy.
11389086|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
11389087|NCT02109029|Experimental|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
11389088|NCT02109029|Active Comparator|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute [pmol/kg/min]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
11389089|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
11389090|NCT02109003|Experimental|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Pressure easy® device for 24h, followed by discontinuous control (every 4 hours) with a manual manometer for 24 h.
11389091|NCT02109003|Active Comparator|Manual control of Pcuff followed by continuous control.|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
11389092|NCT02108990|Experimental|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
11389093|NCT02108990|Experimental|Acetaminophen 500mg|500mg Acetaminophen orally three times a day
11389094|NCT02108977|Experimental|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
11389095|NCT02108977|Active Comparator|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
11389160|NCT02108496|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
11389096|NCT02108964|Experimental|Phase I part|Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
11389097|NCT02108964|Experimental|Phase II part|Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations will be administered with EGF816 at RP2D during Phase II part of the study.
11389098|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
11389099|NCT02108938||Case|Subject's with Crohn's disease at least 18 years of age
11389100|NCT02108938||Control|"Findings from this study will be compared to controls. These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
11389101|NCT02108925|Experimental|Supplementary oxygen|Study subjects receive, in randomized order, either supplementary 30% oxygen or air (21% Oxygen) from a gas tight bag
11389102|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
11389103|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
11389104|NCT02108899|Experimental|Patients with schizophrenia|
11389105|NCT02108899|Active Comparator|Healthy subjects|
11389106|NCT02108886|Experimental|Montelukast|Intervention group
11389107|NCT02108886|Placebo Comparator|Placebo|Placebo
11389108|NCT02108873||Retrospective Cohort|Adult patients who had scheduled an appointment for outpatient primary care. Patients were divided into two groups, including those who attended their scheduled appointment and those who missed it.
11389109|NCT02108860|Experimental|Blinded abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
11389110|NCT02108860|Placebo Comparator|blinded placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
11389111|NCT02108847|Experimental|Fascia Iliaca Block - Ropivacaine|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of 0.2% ropivacaine.
11389112|NCT02108847|Sham Comparator|Fascia Iliaca Block - Saline|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of Saline.
11389113|NCT02108834|Active Comparator|nerve block|cervical plexus block with ropivacaine
11389114|NCT02108834|Placebo Comparator|Placebo|placebo saline
11389115|NCT02108821|Experimental|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
11389116|NCT02108808|Active Comparator|Prasugrel or Clopidogrel|Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated
11389117|NCT02108808|Experimental|Ticagrelor|Ticagrelor 180mg loading dose
11389118|NCT02108795|Experimental|remifentanil group|Remifentanil 0.05 ug/kg/min is infused to the patients.
11389119|NCT02108795|Placebo Comparator|control|Normal saline 0.2 ml/kg/hour is infused to the patients
11389120|NCT02108782|Experimental|Treatment (dovitinib lactate)|Patients receive dovitinib lactate PO on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11389121|NCT02108769|Experimental|Yogic Breathing|"Chanting Om
~Sharp deep inhalation through nostrils
~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.
~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.
~Yogic Breathing:
~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.
~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.
~Hold breath in this position for about 16 seconds.
~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.
~Go to step a)."
11389122|NCT02108769|Active Comparator|Attention Control|The participants will read a text of their choice for 20 minutes.
11389123|NCT02108756|Experimental|L-pantoprazole sodium|
11389124|NCT02108756|Active Comparator|Panmeilu|
11389125|NCT02108743|Active Comparator|Albuterol|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
11389126|NCT02108743|Placebo Comparator|Placebo|Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
11389127|NCT02108730||non-focal congenital hyperinsulinism|13 children and one adult with non-focal congenital hyperinsulinism
11389128|NCT02108717|Experimental|Group I|"The raters in this group one firstly reviewed the CT scans numbered from one to 60 using LCD monitor and after mandatory rests of 20 minutes, reviewed the remaining CT examinations numbered from 61 to 120 using iPhone with TeamViewer at their first visit.
~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
11389163|NCT02108470|No Intervention|Dental consultation without OHQoL assessment|Dentist performs consultation in the traditional method
11389129|NCT02108717|Experimental|Group II|"The raters in this group II firstly reviewed the CT scans numbered from one to 60 using iPhone with TeamViewer and 61 to 120 with the LCD monitor.
~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
11389130|NCT02108704|Active Comparator|Helicobacter pylori eradication therapy|Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD
11389131|NCT02108704|Placebo Comparator|Placebo|Maltodextrin
11389132|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
11389133|NCT02108691|Placebo Comparator|Placebo|
11389134|NCT02108678|Experimental|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
11389135|NCT02108678|Experimental|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
11389136|NCT02108665|Other|Radiographic hysterosalpingography|Realisation in first: radiographic hysterosalpingographyresonance then imaging hysterosalpingography
11389137|NCT02108665|Other|Magnetic resonance imaging hysterosalpingography|Realisation in first : magnetic resonance imaging hysterosalpingography then a radiographic hysterosalpingography
11389138|NCT02108652|Experimental|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
11389139|NCT02108639|Experimental|DCV 3DAA FDC + BMS-791325|"Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days
~Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
11389140|NCT02108626|Active Comparator|E-Cigarette with nicotine|Electronic cigarette with cartridge fluid containing nicotine
11389141|NCT02108626|Placebo Comparator|E-Cigarette without nicotine|Electronic cigarette with cartridge fluid containing no nicotine (placebo)
11389142|NCT02108613|Experimental|Intervention|The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.
11389143|NCT02108613|No Intervention|Control|The control group will receive sexual health counseling.
11389144|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
11389145|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
11389146|NCT02108587|Experimental|optical coherence tomography for diagnosis|Patients undergo optical coherence tomography over 10-15 minutes.
11389147|NCT02108574|Placebo Comparator|Placebo Filter|Placebo device
11389148|NCT02108574|Active Comparator|Rhinix Nasal Filter|Actual Rhinix Nasal Filter
11389149|NCT02108561||Breast Cancer|Post Surgical Her2 testing
11389150|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose|
11389151|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose - Food Effect|
11389152|NCT02108548|Placebo Comparator|Part 1: Placebo|
11389153|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose|
11389154|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose Elderly|
11389155|NCT02108548|Placebo Comparator|Part 2: Placebo|
11389156|NCT02108548|Active Comparator|Part 2: Naproxen|
11389157|NCT02108535|Experimental|Nanocrystalline silver|Flexible polyester low-grip coated nanocrystalline silver dressing. The dressing was applied to the lesion after being soaked in sterile distilled water. About this compresses to bandage movements will have been added and comes to avoid tourniquet bandage on-site maintenance, temperature of the affected area, cushioning and absorption of wound exudate when present. Is finished with the application of crepe bandages in the form of flakes containment curative and maintenance of pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, avoiding tourniquet. The exchanges were performed every three days.
11389158|NCT02108535|Active Comparator|Silver sulfadiazine|Ranges for rayon containing cream 1% silver sulfadiazine were used. Involving this layer, bandages for dressings were added in movements back and forth to avoid the tourniquet, providing maintenance of the temperature of the affected area, cushioning and absorption of wound exudate when present. This application was completed with crepe bandages to contain the dressing and maintain pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, scales, avoiding the tourniquet. Dressing changes were performed daily.
11389159|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.
~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also felt to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
11389242|NCT02107924||APPI of TKR-historical|Surgery 2.4 G Tobramycin 2.0 G Vancomycin
11389164|NCT02108470|Experimental|Dental consultation using OHIP|Dental consultation using OHIP incorporating OHRQoL issues.
11389165|NCT02108457||Proton subjects|
11389166|NCT02108457||IMRT subjects|
11389167|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
11389168|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
11389169|NCT02108431|Experimental|balloon catheter for transurethral bladder-drainage|intraoperatively placement of transurethral catheter after robot-assisted radical prostatectomy
11389170|NCT02108431|Active Comparator|balloon catheter for suprapubic bladder-drainage|intraoperatively placement of suprapubic catheter after robot-assisted radical prostatectomy
11389171|NCT02108418|Experimental|TG-2349 as the original formulation|400 mg, 2 syringes
11389172|NCT02108418|Experimental|TG-2349 as a new capsule formulation|400 mg, 4 capsules
11389173|NCT02108405||Sepsis|Sepsis Forty eight patients developed septic complication during ICU stay (sepsis group).
11389174|NCT02108405||SIRS group|SIRS group Forty seven patients were critically ill without evidence of infectious organism (SIRS group).
11389175|NCT02108379|Experimental|Rhinix Nasal Filters|All included will receive rhinix nasal filters
11389176|NCT02108366|Placebo Comparator|Placebo|Placebo + oseltamivir 75mg bid for 5 days
11389177|NCT02108366|Experimental|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
11389178|NCT02108353|Active Comparator|Melatonin 2mg|The study medication will be compared to placebo control.
11389179|NCT02108353|Placebo Comparator|Placebo|The study medication will be compared to placebo control.
11389180|NCT02108340|Experimental|Microwave radiometry|Patients diagnosed with acute appendicitis will undergo a measurement of the temperature of the appendix with the use of microwave radiometry in a room temperature of 20 -24 degrees celsius.
11389181|NCT02108327|Experimental|surgical blade|
11389182|NCT02108327|Active Comparator|Unipolar electrocautery|
11389183|NCT02108314|No Intervention|Control Group|Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
11389184|NCT02108314|Active Comparator|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
11389185|NCT02108301|Experimental|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
11389186|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
11389187|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
11389188|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
11389189|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
11389190|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
11389191|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
11389192|NCT02108249||Annex Group|Patients prospectively treated with Annex™ Adjacent Level System
11389193|NCT02108249||Retrospective Control|Patients previously treated for adjacent level disease using other systems
11389194|NCT02108236|No Intervention|Blank control group|A control group of patients is put on a waiting list for no intervention and remaining unchanged lifestyle.
11389195|NCT02108236|Active Comparator|intervention group|An intervention group of patients is put on a waiting list for acupuncture treatment.
11389196|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
11389197|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
11389198|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
11389199|NCT02108210|Experimental|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
11389243|NCT02107911||men who have sex with men|MSM who seek voluntary HIV counseling and testing service at the Anonymous Clinic, TRC-ARC, including those who describe risky sexual exposure to HIV within the preceding 72 hours and meet nPEP criteria.
11389244|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
11389309|NCT02107469|Experimental|Modern extract herbal treatment|"Phyllanthus niruri extract 2 capsules 3 times a day with warm water before meals for 8 weeks
~Sida cordifolia roots extract 2 capsules 2 times a day with warm water before meals for 8 weeks"
11389200|NCT02108210|Placebo Comparator|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.
~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
11389201|NCT02108197|Experimental|CPAP Intervention|Continuous positive airway pressure (S9, ResMed)
11389202|NCT02108197|No Intervention|Wait-list|Wait list controls
11389203|NCT02108184|Experimental|Sequential therapy 10 days|1.(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 5 days
11389204|NCT02108184|Active Comparator|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days
11389205|NCT02108184|Active Comparator|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 10 days
11389206|NCT02108184|Active Comparator|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days
11389207|NCT02108171|Active Comparator|dexmedetomidine|intranasal dexmedetomidine
11389208|NCT02108171|Placebo Comparator|placebo|intranasal saline
11389209|NCT02108158|Experimental|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
11389210|NCT02108158|Active Comparator|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
11389211|NCT02108145|Active Comparator|unilateral metal stent insertion|unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more liver volume
11389212|NCT02108145|Experimental|bilateral metal stent insertion|percutaneous transhepatic biliary drainage plus bilateral metal stent.The bare stents were used for PTBS
11389213|NCT02108132|Experimental|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
11389214|NCT02108119|Active Comparator|Probiotics|
11389215|NCT02108119|Placebo Comparator|Control placebo|
11389216|NCT02108106|Experimental|AG-348|Single oral dose of AG-348
11389217|NCT02108106|Placebo Comparator|Placebo|Single oral dose of placebo
11389218|NCT02108093|Experimental|RAP (retrograde autologous priming) group|In the RAP (retrograde autologous priming) group, the priming solution is partially replaced by the patient's own circulating blood, before initiation of CPB. After initiation of cardiopulmonary bypass the priming volume is approximately 900 ml.
11389219|NCT02108093|No Intervention|Control group|In the control group, the priming volume of the arterial and venous line will not be replaced by patient's own blood. The priming volume of cardiopulmonary bypass is 1300 ml in the control group.
11389220|NCT02108054|Experimental|1|People with alcohol use disorder
11389221|NCT02108054|Experimental|2|People without alcohol use disorder
11389222|NCT02108041||Physicians that interact with the black/High SES avatar patien|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American.
11389223|NCT02108041||Physicians that interact with the black/Low SES avatar patient|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American.
11389224|NCT02108041||Physicians that interact with the white race/high SES avatar|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian.
11389225|NCT02108041||Physicians that interact with the white race/low SES avatar p|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian.
11389226|NCT02108028||Cohort 1A / Initial Young Adults with Children|At least 25 young adults who have children and are 18 through 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at one of the participating sites.
11389227|NCT02108028||Cohort 1B / Comparison Young Adults with Children|At least 15 young adults who have children and are 18 through 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol.
11389228|NCT02108028||Cohort 2A / Initial Independent Young Adults|At least 25 young adults who live independently and are 18 through 39 years diagnosed with cancer or other chronic illness and enrolled on an NIH protocol or treated at one of the participating sites.
11389229|NCT02108028||Cohort 2B / Comparison Independent Young Adults|Up to 35 young adults who live independently and are 18 through 39 years diagnosed withcancer or other chronic illness and enrolled on an NIH protocol.
11389230|NCT02108028||Cohort 3 / Non-patient participants|Up to 100 family members, friends, or health care providers of patient participant
11389231|NCT02107989||healthy volunteers|healthy volunteers
11389232|NCT02107989||Patients|Drug resistant epilepsy patients
11389233|NCT02107976||Diabetics|Type II diabetics
11389234|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
11389235|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
11389236|NCT02107950|Experimental|DCVAC/OvCa in parallel with chemotherapy|Combination therapy with DCVAC/OvCa and Standard of Care
11389237|NCT02107950|Active Comparator|Standard of Care|Standard of Care carboplatin and gemcitabine
11389238|NCT02107937|Experimental|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
11389239|NCT02107937|Experimental|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
11389240|NCT02107937|Active Comparator|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
11389241|NCT02107924||APPI of TKR-Stimulan|Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin
11389245|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.
~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)
~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
11389246|NCT02107885|Experimental|DS-1971|single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.
11389247|NCT02107885|Placebo Comparator|placebo|placebo matching each of the DS-1971 dosages.
11389248|NCT02107872|Experimental|dosing cohort 1|Patients will receive REGN1500 or placebo in dosing cohort 1
11389249|NCT02107872|Experimental|dosing cohort 2|Patients will receive REGN1500 or placebo in dosing cohort 2
11389250|NCT02107872|Experimental|dosing cohort 3|Patients will receive REGN1500 or placebo in dosing cohort 3
11389251|NCT02107872|Experimental|dosing cohort 4|Patients will receive REGN1500 or placebo in dosing cohort 4
11389252|NCT02107872|Experimental|dosing cohort 5|Patients will receive REGN1500 or placebo in dosing cohort 5
11389253|NCT02107859|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
11389254|NCT02107846|Experimental|50 Units|PRX-112 50 Units daily for 5 days
11389255|NCT02107846|Experimental|100 Units|PRX-112 100 Units daily for 5 days
11389256|NCT02107846|Experimental|200 Units|PRX-112 200 Units daily for 5 days
11389257|NCT02107846|Experimental|400 Units|PRX-112 400 Units daily for 5 days
11389258|NCT02107833|Experimental|2 mg|OPRX-106 2 mg oral once daily for 5 days
11389259|NCT02107833|Experimental|8 mg|OPRX-106 8 mg oral once daily for 5 days
11389260|NCT02107833|Experimental|16 mg|OPRX-106 16 mg oral once daily for 5 days
11389261|NCT02107820|Active Comparator|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
11389262|NCT02107820|Experimental|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
11389263|NCT02107807|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
11389264|NCT02107807|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
11389265|NCT02107807|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
11389266|NCT02107807|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
11389267|NCT02107794|Active Comparator|Decision Aid|Observation of clinical encounter using the decision aid, via video, audio or written notes.
11389268|NCT02107794|No Intervention|Usual Care|Observations in clinical encounters, either video, audio, or observational notes.
11389269|NCT02107781||Patients with open abdomen|Patients in a critical care unit with abdomen that was not closed during initial operation & will have intra-abdominal pressure monitoring using the AbViser abdominal compartment pressure measuring device.
11389270|NCT02107768|Experimental|Exercise recommendation|Patients randomized to the control group receive general advice for physical training and activity but no specific training or other rehabilitation efforts
11389271|NCT02107768|Experimental|Aerobic exercise|"The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added. The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20, Rate of Perceived Exertion (Borg 's RPE scale)
~Two fitness goals was to be achieved during the training session:
~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.
~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) .Which corresponds to 85% of maximum heart rate."
11389272|NCT02107755|Experimental|Treatment (ipilimumab, stereotactic radiosurgery)|Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
11389273|NCT02107742|Experimental|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
11389274|NCT02107729|Experimental|Needle gauge small|injection needle 23 G
11389275|NCT02107729|Experimental|Needle gauge normal|injection needle 25 G
11389276|NCT02107729|Experimental|Needle gauge large|injection needle 27 G
11389277|NCT02107716|Experimental|Bicarbonate|Each participant will receive two lidocaine injections on the abdomen with different pH
11389278|NCT02107703|Experimental|Abemaciclib + Fulvestrant|150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
11389279|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
11389280|NCT02107703|Experimental|Abemaciclib + Fulvestrant (Endocrine Naïve Cohort)|150 milligrams mg Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
11389281|NCT02107690|Experimental|low temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
11389282|NCT02107690|Experimental|room temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
11389283|NCT02107690|Experimental|body temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
11389284|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
11389285|NCT02107651||NOAC|Patients admitted for GI bleeding while in treatment with NOAC
11389286|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
11389287|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
11389288|NCT02107625|Experimental|Diet A i.e. Low FODMAP diet|The patients are thoroughly informed verbally and in writing how to eat according to the low FODMAP diet. The diet imply restrictions in carbohydrate intake and the patients need to follow a list with yes/no-foods for 4 weeks.
11389289|NCT02107625|Experimental|Diet B, i.e. Traditional IBS diet|The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
11389290|NCT02107612|Experimental|Integrated system to insert two splinted (bar) miniimplants|Participants were randomly assigned to experimental group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
11389291|NCT02107612|Active Comparator|Denture|Participants were randomly assigned to comparator group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
11389292|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
11389293|NCT02107586|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
11389294|NCT02107586|Active Comparator|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
11389295|NCT02107573|Active Comparator|Rotator cuff repair without Suprascapular Nerve decompression|approximately 17 subjects in the study will receive traditional rotator cuff repair surgical intervention with no suprascapular nerve decompression surgical intervention
11389296|NCT02107573|Active Comparator|Rotator Cuff Repair with Suprascapular Nerve decompression|approximately 17 subjects in the study will undergo rotator cuff repair with arthroscopic suprascapular nerve decompression surgical intervention
11389297|NCT02107547|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
11389298|NCT02107547|Active Comparator|Labral repair|32 subjects in the study will receive labral repair as a surgical intervention
11389299|NCT02107534|Experimental|parent training (dyslexia)|Participants take part in parent training, five two-hour sessions held biweekly.
11389300|NCT02107534|No Intervention|wait list control group|Participants of the waiting list control group had the possibility to take part in the parent training after the follow-up was completed.
11389301|NCT02107521|Active Comparator|ICSI group|In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
11389302|NCT02107521|Experimental|IMSI group|In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
11389303|NCT02107495||CHF-confirmed subjects|Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.
11389304|NCT02107495||Subjects with potentially co-morbidities|non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).
11389305|NCT02107495||Apparently healthy subjects|Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.
11389306|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
11389307|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
11389308|NCT02107469|Experimental|Ancient herbal treatment|"Phyllanthus niruri 3g fine dry powder 3 times a day with warm water before meals for 8 weeks
~Sida cordifolia 7g coarse dry powder 2 times a day prepared as traditional decoction before meals for 8 weeks. Decoction: Take provided measurement cup full of water (112ml) and soak one portion (pe-packed) of the powder for 12 hours, then boil it until the upper level has been reduced to 1/4, filter, cool down to room temperature, drink"
11389310|NCT02107469|Placebo Comparator|Placebo|"Phyllanthus niruri placebo 2 capsules 3 times a day with warm water before meals for 3 weeks
~Sida cordifolia placebo 2 capsules 2 times a day with warm water before meals for 3 weeks"
11389311|NCT02107456|Experimental|Dry Needling|The taut band of trigger point in upper trapezius muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
11389312|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
11389313|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
11389314|NCT02107430|Experimental|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
11389315|NCT02107430|Active Comparator|Standard radiotherapy|Standard care
11389316|NCT02107417|Experimental|Experimental Group (EG) - TENS active|Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
11389317|NCT02107417|Sham Comparator|Control Group (CG)- Placebo TENS|Control Group (CG) who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, . It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted.
11389318|NCT02107404|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCA Experimental therapy
11389319|NCT02107404|No Intervention|Standard Therapy|No Intervention
11389320|NCT02107391|Experimental|DCVAC/PCA added Standard Hormone Therapy|Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy
11389321|NCT02107391|Active Comparator|Standard of Care Hormone Therapy|Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate
11389322|NCT02107378|Experimental|DCVAC/OvCa in parallel with chemo (SoC)|Combination therapy with DCVAC/OvCa and Standard of Care (SoC)
11389323|NCT02107378|Active Comparator|Standard of Care (Chemotherapy)|Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)
11389324|NCT02107365|Experimental|Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a|Quadritherapy from Day 0 to Week 24
11389325|NCT02107352||Naltrexone|50mg/day
11389326|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
11389327|NCT02107352||Baclofen|30 mg/day
11389328|NCT02107352||Placebo|
11389329|NCT02107339|Experimental|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
11389330|NCT02107339|Active Comparator|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
11389331|NCT02107326|Experimental|Webdia Software use|Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.
11389332|NCT02107326|No Intervention|Observation|No use of the software. No intervention.
11389333|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
11389334|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
11389335|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
11389336|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
11389337|NCT02107287|Experimental|IMRT Hypofractionated|Neo-adjuvant hormone therapy for three months followed by IMRT combined with a 24-month hormonal therapy.
11389338|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
11389339|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
11389340|NCT02107261|Active Comparator|Naive to botulinum toxin|Individuals with musicians dystonia who have not been treated previously with botulinum toxin.
11389341|NCT02107261|Active Comparator|Prior treatment with botulinum toxin|Individuals with musician's dystonia who have been previously treated with botulinum toxin.
11389342|NCT02107248|Active Comparator|Sleep position: supine|Subjects will be instructed to sleep in a supine position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
11389343|NCT02107248|Experimental|Sleep position: no restrictions|Patients do not have any restrictions in sleeping position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
11389344|NCT02107235|Experimental|Rigosertib + Cisplatin + Radiation|"Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.
~Cisplatin will be administered intravenously at a dose of 40 mg/m^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.
~The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week."
11389345|NCT02107222|No Intervention|mechanical ventilation (MV)|mechanical ventilation according to guidelines
11389346|NCT02107222|Experimental|MV + ECCO2-R(PALP-Device/MaquetCP)|MV according to the guidelines plus CO2-Removal with PALP
11389347|NCT02107209|Experimental|Bronchoscopic Lung volume reduction using Autologous blood.|Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope
11389348|NCT02107209|Active Comparator|Bronchoscopic Lung volume reduction using Fibrin glue|injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy
11389349|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
11389350|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
11389351|NCT02107183|Experimental|Nasal high-flow oxygen therapy|High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher & Paykel Healthcare) after extubation up to ICU discharge
11389352|NCT02107183|Active Comparator|Venturi mask oxygen therapy|Oxygen delivered through standard Venturi mask after extubation up to ICU discharge
11389353|NCT02107170|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
11389354|NCT02107170|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
11389355|NCT02107157|Experimental|755nm Alexandrite laser with cap array|
11389356|NCT02107144|Experimental|trimetazidin|Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI- Paients that are TMZ naïve and randomized to TMZ group will be given oral loading of 70mg TMZ.
11389357|NCT02107144|No Intervention|Control|Patients, who are TMZ naïve, will be randomly assigned to receive just previous cardiac medication (Control group).
11389358|NCT02107131|Active Comparator|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
11389359|NCT02107131|Active Comparator|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
11389360|NCT02107118|Active Comparator|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
11389361|NCT02107118|Placebo Comparator|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
11389362|NCT02107105||Observational (questionnaire)|Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
11389363|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
11389364|NCT02107079|Active Comparator|melatonin 1 mg immediate release tablet|
11389365|NCT02107079|Active Comparator|melatonin 2,5mg immediate release capsule|
11389366|NCT02107079|Active Comparator|melatonin 0.1 mg oromucosal tablet|
11389367|NCT02107066|Active Comparator|attention control|Women randomized to attention control will receive the same attention as women randomized to exercise intervention, i.e., weekly phone calls for 6 months. Each call is about 15 min. Women in the attention control will receive information on ovarian cancer health education topics.
11389368|NCT02107066|Experimental|exercise|Women randomized to exercise will receive telephone-counseling weekly for 6 months to increase their exercise
11389369|NCT02107053|Experimental|IV iron + PJ|Each patient will serve as a self control
11389370|NCT02107053|Experimental|No IV iron + PJ|Each patient will serve as a self control
11389371|NCT02107053|Experimental|IV iron no PJ|Each patient will serve as a self control
11389372|NCT02107027|Active Comparator|nMARQ catheter (circular catheter)|Group treated with the circular ablation catheter for atrial fibrillation ablation
11389373|NCT02107027|Active Comparator|Navistar catheter (conventional catheter)|Group treated with the conventional ablation catheter for atrial fibrillation ablation
11389374|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
11389375|NCT02107001||Patients with pleuritic chest pain|Study investigators will perform lung ultrasound in each patient with pleuritic chest pain at inclusion
11389376|NCT02106988|Experimental|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.
~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
11389377|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
11389378|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
11389379|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
11389380|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
11389381|NCT02106949|Experimental|SMS|The patients of the test group receive a first SMS 48 hours after their discharge from the hospital then a total of 10 messages distributed over six months: 48 hours, S1, S2, M1, M2, M3, M4, M5, M6 and M13.
11389382|NCT02106949|No Intervention|Without SMS|The patients of the group benefit from the usual care.
11389383|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
11389384|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
11389385|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
11389386|NCT02106910|Experimental|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
11389387|NCT02106910|Experimental|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
11389388|NCT02106897|Experimental|Part 1, Cohort 1: BIIB059 0.05 mg/kg IV|BIIB059 0.05 mg/kg IV dose, Once on Day 1
11389389|NCT02106897|Experimental|Part 1, Cohort 2: BIIB059 0.3 mg/kg IV|BIIB059 0.3 mg/kg IV dose, Once on Day 1
11389390|NCT02106897|Experimental|Part 1, Cohort 3: BIIB059 1 mg/kg IV|BIIB059 1 mg/kg IV dose, Once on Day 1
11389391|NCT02106897|Experimental|Part 1, Cohort 4: BIIB059 3 mg/kg IV|BIIB059 3 mg/kg IV dose, Once on Day 1
11389392|NCT02106897|Experimental|Part 1, Cohort 5: BIIB059 10 mg/kg IV|BIIB059 10 mg/kg IV dose, Once on Day 1
11389393|NCT02106897|Experimental|Part 1, Cohort 6: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
11389394|NCT02106897|Experimental|Part 1, Cohort 7: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Once on Day 1
11389395|NCT02106897|Placebo Comparator|Part 1, Cohort 1-6: Placebo IV|Matching placebo IV dose, Once on Day 1
11389396|NCT02106897|Placebo Comparator|Part 1, Cohort 7: Placebo SC|Matching placebo SC dose, Once on Day 1
11389397|NCT02106897|Experimental|Part 2, Cohort 8: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
11389398|NCT02106897|Placebo Comparator|Part 2, Cohort 8: Placebo IV|Matching placebo IV dose, Once on Day 1
11389399|NCT02106897|Experimental|Part 3a, Cohort 9: BIIB059 20 mg SC|BIIB059 20 mg SC dose, Every 4 weeks for 2 doses
11389400|NCT02106897|Experimental|Part 3a, Cohort 10: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
11389401|NCT02106897|Experimental|Part 3a, Cohort 11: BIIB059 150 mg SC|BIIB059 150 mg SC dose, Every 4 weeks for 2 doses
11389402|NCT02106897|Experimental|Part 3a, Cohort 12: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
11389403|NCT02106897|Placebo Comparator|Part 3a, Cohort 9-12: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
11389404|NCT02106897|Experimental|Part 3b, Cohort 13: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
11389405|NCT02106897|Experimental|Part 3b, Cohort 14: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
11389406|NCT02106897|Placebo Comparator|Part 3b, Cohort 13-14: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
11389407|NCT02106884|Experimental|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
11389408|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
11389409|NCT02106871|Placebo Comparator|Placebo|Placebo daily for 4 weeks
11389410|NCT02106871|Active Comparator|Sildenafil|50mg sildenafil daily for 4 weeks
11389411|NCT02106858||Group 1|Patients treated by Physician with Stivarga under approved local prescriptions
11389412|NCT02106845|Experimental|P-gp probe substrate(digoxin)+regorafenib|
11389413|NCT02106845|Experimental|Group B: BCRP probe substrate (rosuvastatin) + regorafenib|
11389414|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
11389415|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
11389416|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
11389417|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
11389418|NCT02106819||Cerebellar Ataxia subjects|40 individuals with either hereditary or sporadic ataxia will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
11389419|NCT02106819||Healthy Control subjects|40 age matched controls will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
11389420|NCT02106806|Experimental|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
11389421|NCT02106806|Placebo Comparator|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
11389422|NCT02106806|Other|Zinc Control|Healthy volunteers supplemented with zinc
11389423|NCT02106806|Other|Placebo Control|Volunteers received placebo
11389424|NCT02106793|Experimental|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
11389425|NCT02106793|Placebo Comparator|Placebo|Identical placebo solution
11389426|NCT02106780|Experimental|1: ASP1707|
11389427|NCT02106767|Active Comparator|Rosuvastatin|
11389428|NCT02106767|Experimental|Rifampin plus rosuvastatin|
11389429|NCT02106754|Experimental|Brief Intervention|Youth may receive brief intervention from their provider based on randomization.
11389430|NCT02106754|Active Comparator|Treatment As Usual|Youth may receive treatment as usual from their provider based on randomization.
11389431|NCT02106754|Experimental|Brief Intervention with Coaching|Youth may receive brief intervention with coaching from their provider based on randomization.
11389432|NCT02106741|Experimental|Relaxation acupressure|
11389433|NCT02106741|Active Comparator|Stimulating acupressure|
11389434|NCT02106741|No Intervention|Wait-list control|
11389435|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
11389436|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
11389437|NCT02106715|Active Comparator|Training|Two exercises for training of core stability and mobility.
11389438|NCT02106715|No Intervention|Control|Control group without training
11389439|NCT02106702|Active Comparator|FAP counseling|Control arm utilizing the standard of care: access to services provided by the Forensic AIDS Project for up to 90 days after release
11389440|NCT02106702|Experimental|Navigator enhanced case-management|Experimental arm: access to Navigator enhanced case-management services for one year after release
11389441|NCT02106689|Experimental|Needle free system|"Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle"
11389442|NCT02106689|Active Comparator|Standard needle injection system|Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections
11389443|NCT02106676||Pregnant women with PCOS and offspring|Exposures of interest: Polycystic ovary Syndrome (PCOS) according to Rotterdam
11389444|NCT02106676||Pregnant women without PCOS and offspring|Exposures of interest: Pregnant women without polycystic ovary Syndrome (PCOS) according to Rotterdam
11389445|NCT02106663|Active Comparator|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs), guided by 3D electroanatomic mapping (Carto, Biosense Webster, Inc. or ESI NavX, St. Jude, Inc.) with a 3D LA geometry created either by using the roving mapping catheter or by importing a pre-recorded 3D CT image of the left atrium. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed (entrance block at a minimum).
11389446|NCT02106663|Active Comparator|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing myocardial connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter around the PV ostium or antrum, until mapping demonstrates elimination of all PV potentials (entrance block at a minimum).
11389447|NCT02106650|Experimental|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).
~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.
~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
11389448|NCT02106637|Active Comparator|study groups|study groups will receive Varenicline
11389449|NCT02106637|Placebo Comparator|control group|Participants allocated to the control group will receive placebo
11389450|NCT02106624|Experimental|High Nitrogen|In this arm, daily nitrogen supply is as much as 2.5-3.0 g per kilogram (lean mass weight)
11389451|NCT02106624|Active Comparator|conventional nitrogen|In this arm, daily nitrogen supply is 1.2-1.5g per kilogram (lean mass weight) as recommended by ESPEN guideline
11389452|NCT02106611||Hodgkin Lymphoma Survivor|This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
11389453|NCT02106598|Experimental|Phase 1 - Breast and Colorectal Malignancies|Participants will be investigated comprising 2 different regions of the body (breast and colorectal malignancies). Each cohort will be analyzed separately to assess the feasibility of conducting pre-operative SLN mapping using real-time optical detection procedures and intradermal single- or double-dose injection/s of non-radioactive cRGDY-PEGCy5.5-C dots about the primary tumor site.
11389454|NCT02106598|Experimental|Phase 2 - Head and Neck Cancer|Patients with early oral cavity squamous cell carcinoma, and prior to standard of care wide local resection of the primary tumor and elective neck dissection, will receive a locally-administered, peritumoral injection of fluorescent cRGDY-PEG-Cy5.5-C dots (0.25 - 1 ml) around the primary lesion while under standard-of-care anesthesia for identification of optically-avid SLNs and to assess for metastatic disease. After completion of the neck dissection, nodal specimens will be examined ex vivo for fluorescence signal. Any fluorescent and non-fluorescent nodes will be compared to determine the true positive and false positive rates for cancer detection in this pilot study. No change in standard of care surgical practice will occur.
11389455|NCT02106585|Experimental|Dose 1 JTT-251 or Placebo|Tablets, single dose in fed condition
11389456|NCT02106585|Experimental|Dose 2 JTT-251 or Placebo|Tablets, single dose in fed condition
11389457|NCT02106585|Experimental|Dose 3 JTT-251 or Placebo|Tablets, single dose in fed condition
11389458|NCT02106585|Experimental|Dose 4 JTT-251 or Placebo|Tablets, single dose in fed condition
11389459|NCT02106585|Experimental|Dose 5 JTT-251 or Placebo|Tablets, single dose in fed condition
11389460|NCT02106585|Experimental|Dose 6 JTT-251 or Placebo|Tablets, single dose in fed condition
11389461|NCT02106585|Experimental|Dose 7 JTT-251 or Placebo|Tablets, single dose in fed condition
11389462|NCT02106585|Experimental|Dose 8 JTT-251 or Placebo|Tablets, single dose in fed condition
11389463|NCT02106585|Experimental|Dose 9 JTT-251 or Placebo|Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
11389464|NCT02106572|Experimental|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
11389465|NCT02106572|Active Comparator|Mitomycin C|intravesical instillation of Mitomycin C
11389537|NCT02106078|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
11389466|NCT02106559|Experimental|Treatment (surgery, porfimer sodium, PDT)|Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.
11389467|NCT02106546|Experimental|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
11389468|NCT02106546|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
11389469|NCT02106533|Experimental|Group 1 peak VO2 <17.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP.
11389470|NCT02106533|Experimental|Group 2 peak VO2 > 17.5 < 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
11389471|NCT02106533|Experimental|Group 3 peak VO2 > 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill . Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
11389472|NCT02106520|Experimental|Bevacizumab 25mg|Three administrations of 25 mg of Bevacizumab spaced of 14 days
11389473|NCT02106520|Experimental|Bevacizumab 50mg|Three administrations of 50 mg of Bevacizumab spaced of 14 days
11389474|NCT02106520|Experimental|Bevacizumab 75mg|Three administrations of 75 mg of Bevacizumab spaced of 14 days
11389475|NCT02106520|Placebo Comparator|Placebo|Three administrations of placebo spaced of 14 days
11389476|NCT02106507|Experimental|Progressive Metastatic Castration-Resistant Prostate Cancer|This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of apalutamide in combination with everolimus.
11389477|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
11389478|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
11389479|NCT02106481|Active Comparator|Femoral Nerve Catheters|Patients will receive a Single Shot Femoral Nerve Block along with a conventional continuous femoral nerve catheter
11389480|NCT02106481|Active Comparator|Single Shot Femoral Nerve Blocks|Patients will receive a Single Shot Femoral Nerve Block and a sham catheter post op.
11389481|NCT02106468|Active Comparator|prednisone 50 mg tablet|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
11389482|NCT02106468|Active Comparator|Omega-3 capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
11389483|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
11389484|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
11389485|NCT02106429||PAD and CLI patients|Subjects undergoing non emergent lower extremity revascularization
11389486|NCT02106416|Experimental|PET/MRI|Patient receives PET/MRI
11389487|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
11389488|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
11389489|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
11389490|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
11389491|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
11389492|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
11389493|NCT02106364|Experimental|LY2605541|LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator. Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician.
11389494|NCT02106364|Active Comparator|Insulin Glargine|Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician.
11389495|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
11389496|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
11389497|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).
~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
11389498|NCT02106338|Experimental|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
11389499|NCT02106338|Experimental|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
11389500|NCT02106338|Experimental|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
11389501|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
11389502|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
11389503|NCT02106312|Other|Radiation|Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.
11389504|NCT02106299|Experimental|Regen Sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen Sling (medprin).
11389505|NCT02106299|Active Comparator|tension-free vaginal tape-obturator|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
11389506|NCT02106286|Active Comparator|Bisoprolol|Patients not betablocked at baseline receive an acute 72hr dose of beta blocker therapy before CPET
11389507|NCT02106286|No Intervention|No Bisoprolol|No beta blocker given
11389508|NCT02106273||Bronchial blocker|Pilot study to enroll ASA class I-III patients age between 18-70 years who undergoes thoracic surgery which require one-lung ventilation.
11389509|NCT02106260|Experimental|CLS003|
11389510|NCT02106247|Experimental|1 BI 1181181 low dose|tablet
11389511|NCT02106247|Experimental|BI 1181181 high dose|tablet
11389512|NCT02106247|Experimental|Placebo|tablet
11389513|NCT02106234|Active Comparator|Control: NO prophylactic iv hydration|"Control group:
~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed."
11389514|NCT02106234|No Intervention|Standard care: prophylactic iv hydration|"Standard care group:
~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will receive the standard intravenous prophylactic hydration treatment with normal saline as prescribed."
11389515|NCT02106221|Experimental|Intervention|Financial incentives will be provided based on performance in areas determined to be of high-value.
11389516|NCT02106221|Active Comparator|Control|Financial incentives are a flat rate which can be reduced if an appropriate amount of effort or improvement is not met
11389517|NCT02106208|Experimental|Cheese diet|A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
11389518|NCT02106208|Experimental|Butter diet|A 4-week experimental diet with all meals and foods be provided to participants, the diet will contain 13% of SFA mostly from butter. The diet will contain 14% of MUFA, 5% of PUFA and 53% of CHO.
11389519|NCT02106208|Experimental|CHO diet|A 4-week experimental diet with all meals and foods will provided to participants. The diet will contain 60% of CHO, 6% of SFA, 14% of MUFA and 5% of PUFA.
11389520|NCT02106208|Experimental|MUFA diet|A 4-week experimental diet with all meals and foods be provided to participants. The diet will contain 21% of MUFA, 6% of SFA, 5% of PUFA and 53% of CHO.
11389521|NCT02106208|Experimental|PUFA diet|A 4-week experimental diet with all meals and foods will be provided to participants. The diet will contain 12% of PUFA, 14% of MUFA, 6% of SFA and 53% of CHO.
11389522|NCT02106195|Experimental|KD025|KD025 200 mg (two 100 mg capsules) orally once daily for 28 days
11389523|NCT02106182|Experimental|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
11389524|NCT02106169|Experimental|Therapeutic education group|"At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.
~The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours)."
11389525|NCT02106169|No Intervention|Control group|At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
11389526|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
11389527|NCT02106143|Experimental|RejuvenAir™ Radial Spray Cryotherapy|Subjects will receive Rejuvenair Radial SCT prior to lobectomy.
11389528|NCT02106130|Experimental|R - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
11389529|NCT02106130|Experimental|R+M - R|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
11389530|NCT02106130|Experimental|M - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
11389531|NCT02106130|Experimental|R+M - M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
11389532|NCT02106117||neutropenic patients|Patients receiving treatment for hematological malignancies expected to result in prolonged neutropenia (neutrophil counts <0.5 x 10 ^9/L for more than seven days).
11389533|NCT02106104|Experimental|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
11389534|NCT02106104|Active Comparator|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
11389535|NCT02106091|Experimental|AFM11|IV (intravenous) infusion, dose escalation
11389536|NCT02106078|Active Comparator|Level 1|Moderated discussion board only
11389538|NCT02106078|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools
11389539|NCT02106065|Experimental|ESBR-i|Education and Skill-Building Rehabilitation (in-clinic)
11389540|NCT02106065|Experimental|ESBR-v|Education and Skill-Building Rehabilitation (over video telehealth)
11389541|NCT02106065|Active Comparator|UC|Usual Care plus supplemental paper education materials
11389542|NCT02106052|Active Comparator|Aerobic exercise|
11389543|NCT02106052|Other|Stretching and toning exercise|
11389544|NCT02106039|Experimental|intensive monitoring|more intensive monitoring strategy of blood glucose and clinical review
11389545|NCT02106039|No Intervention|standard monitoring|glucose monitoring followed the prevailing practice at each site
11389546|NCT02106026|No Intervention|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
11389547|NCT02106026|Experimental|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
11389548|NCT02106013||Low HDL-C|Study participants with HDL-C levels below the 10th percentile (HDL-C ≤32 mg/dL)
11389549|NCT02106013||Intermediate HDL-C|Study participants with HDL-C levels between 40th and 60th percentiles (40≤HDL-C≤67 mg/dL)
11389550|NCT02106013||High HDL-C|Study participants with HDL-C levels above the 90th percentile (HDL-C ≥78mg/dL)
11389551|NCT02106000||Arm 1: Non-pregnant females|Inhalation profiles will be recorded for non-pregnant females
11389552|NCT02106000||Arm 2: Pregnant females|Inhalation profiles will be recorded for the women in the 3rd stage of labour
11389553|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
11389554|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
11389555|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
11389556|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
11389557|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
11389558|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
11389559|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
11389560|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
11389561|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
11389562|NCT02105935||Normative study|male and female athletes, ages 8-14.
11389563|NCT02105935||Baseline|male and female athletes, ages 8-18.
11389564|NCT02105922|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
11389565|NCT02105922|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
11389566|NCT02105922|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
11389567|NCT02105909|Experimental|obese subjects|DNA analysis
11389568|NCT02105909|Placebo Comparator|lean subjects|DNA analysis
11389569|NCT02105883|No Intervention|Scenario C (control)|no badge
11389570|NCT02105883|Active Comparator|Scenario B (badge)|Use of Identification badge during scenarios (roles and places)
11389571|NCT02105870|Experimental|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
11389572|NCT02105870|Placebo Comparator|Control group|Intracoronary Reopro
11389573|NCT02105857|No Intervention|Standard care|Patients receiving the standard rehabilitation protocol
11389574|NCT02105857|Experimental|grade A+ knee mobilization|Patients receiving the standard rehabilitation protocol plus grade A+ knee mobilization
11389575|NCT02105844||Atrial Fibrillation|Cohort Study on patients with atrial fibrillation in Switzerland
11389576|NCT02105831||CEU skeletal muscle perfusion imaging|Heart failure with LVAD Contrast ultrasound skeletal muscle perfusion imaging
11389577|NCT02105818||Systemic sclerosis|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).
11389578|NCT02105805|Experimental|low energy diet|low energy diet treatment
11389579|NCT02105805|Active Comparator|Nordic recommendation|Nordic recommendation, no restrictions on energy
11389580|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
11389581|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment >10 years from diagnosis.
11389582|NCT02105779|Experimental|Targeted Cognitive Training|40 hours of BFP auditory training
11389583|NCT02105779|Experimental|Social Cognitive Training|40 hours of auditory training and 10 hours social exercises
11389584|NCT02105766|Experimental|1|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody).
11389585|NCT02105766|Experimental|2|The second cohort of patients will be patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort. It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
11389586|NCT02105753|Experimental|1210nm axillary laser treatments|two laser treatments right axilla and one treatment left axilla
11389587|NCT02105753|Experimental|1210nm laser treatments to the axilla|two laser treatments left axilla and one treatment right axilla
11389588|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
11389589|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
11389590|NCT02105727|Experimental|Salt reduction|Community-based salt reduction
11389591|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
11389592|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
11389593|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
11389594|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
11389595|NCT02105688|Experimental|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
11389596|NCT02105688|Placebo Comparator|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
11389597|NCT02105675|Experimental|DCVAC/PCa add on to Standard of Care|Combination therapy with Dendritic Cells DCVAC/PCa and Standard of Care
11389598|NCT02105675|Active Comparator|Standard of Care|Docetaxel as an Active Comparator
11389599|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
11389600|NCT02105649|Experimental|calf muscle strengthenig group|"experimental group
~will receive the same selected physical therapy program in addition to manual and mechanical strengthening exercises and electrical stimulation program for calf muscles of both lower limbs."
11389601|NCT02105649|Other|No calf muscle strengthening group|"control group
~will receive only the selected physical therapy program"
11389602|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
11389603|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression
~OR
~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression
~OR
~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
11389604|NCT02105623|Active Comparator|Standard Therapy|Risk factor control Diet Exercise
11389605|NCT02105623|Experimental|Rosuvastatin therapy|Risk factor control Rosuvastatin
11389606|NCT02105610|Experimental|volatile anesthetics (desflurane, isoflurane, sevoflurane)|
11389607|NCT02105610|Active Comparator|total intravenous anesthesia|
11389608|NCT02105597|Experimental|Mobile application|
11389609|NCT02105597|No Intervention|Standard care|
11389610|NCT02105584|Experimental|LAA closure device|Implantation of LAA closure device
11389611|NCT02105571|Experimental|Intervention|Intervention activities take place over a 6-month period for each participant, and include a weight loss competition with self-monitoring and feedback; computer-based training units on healthy weight loss, healthy eating, exercise, and sleep; and up to four motivational interviews with a health coach by cell phone.
11389612|NCT02105571|No Intervention|Control|"Continued work conditions and Usual Practices in that workplace"
11389613|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
11389653|NCT02105363||Age 91-95|
11389654|NCT02105363||Age 96-100|
11389655|NCT02105363||Age 0-5|
11389656|NCT02105363||Age 6-10|
11389657|NCT02105350|Experimental|MEK 162, gemcitabine, and oxaliplatin|MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
11389658|NCT02105337||tegaderm placement|all pts will have tegaderm placed prior to goggles for VEP
11389614|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
11389615|NCT02105545|Experimental|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
11389616|NCT02105532|Active Comparator|Restrictive Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
11389617|NCT02105532|Active Comparator|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
11389618|NCT02105519|No Intervention|The group receiving no influenza vaccine|Participants in this group will not receive any influenza vaccine (negative control group).
11389619|NCT02105519|Experimental|One dose of AdimFlu-S group|Participants in this group will receive one dose of the seasonal trivalent influenza vaccine (one dose of AdimFlu-S group), formulation 2013-2014, at the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
11389620|NCT02105519|Experimental|Two dose of AdimFlu-S group|Participants in this group (Two dose of AdimFlu-S group)will receive the seasonal trivalent influenza vaccine, formulation 2013-2014, at the week 0 and 4 weeks after the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
11389621|NCT02105506|Experimental|Tachosil patch|Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
11389622|NCT02105493|Active Comparator|500 microgram of Nitroglycerin|500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure
11389623|NCT02105493|Placebo Comparator|Saline 5 mL|0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure
11389624|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
11389625|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
11389626|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
11389627|NCT02105441||cochlear implant|How well patients with cochlear implants understand speech in noise with implant on, compared to implant off.
11389628|NCT02105428|No Intervention|Sedentary Control|Participants will be randomized to an exercise training program or sedentary control group. The sedentary will not perform any structured physical activity or exercise. Participants will be encouraged to maintain their sedentary lifestyle and will be monitored by an accelerometer to track physical activity.
11389629|NCT02105428|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of aerobic exercise training
11389630|NCT02105415|Active Comparator|Etomidate|weight based dose of 0.15mg/kg
11389631|NCT02105415|Experimental|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
11389632|NCT02105402|Experimental|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
11389633|NCT02105402|No Intervention|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
11389634|NCT02105389|Experimental|Individualized Yoga Intervention|Individualized Yoga Intervention sessions will be administered by a trained yoga instructor three times weekly (or up to a maximum of five times per week) for three consecutive weeks. There will be a common structure for all sessions that will include relaxation and breathing exercises as well as a series of poses focused on strengthening, flexibility, and balance. There will be low, moderate and high intensity regimens prescribed depending on the wishes and abilities of the child and parent and the judgment of the yoga instructor.
11389635|NCT02105376|Experimental|Trigeminal Nerve Stimulation (TNS)|"TNS active group
~TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally."
11389636|NCT02105376|Placebo Comparator|Sham|"TNS sham
~The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia."
11389637|NCT02105363||Age 11-15|
11389638|NCT02105363||Age 16-20|
11389639|NCT02105363||Age 21-25|
11389640|NCT02105363||Age 26-30|
11389641|NCT02105363||Age 31-35|
11389642|NCT02105363||Age 36-40|
11389643|NCT02105363||Age 41-45|
11389644|NCT02105363||Age 46-50|
11389645|NCT02105363||Age 51-55|
11389646|NCT02105363||Age 56-60|
11389647|NCT02105363||age 61-65|
11389648|NCT02105363||Age 66-70|
11389649|NCT02105363||Age 71-75|
11389650|NCT02105363||Age 76-80|
11389651|NCT02105363||Age 81-85|
11389652|NCT02105363||Age 86-90|
11389659|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
11389660|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
11389661|NCT02105311|Experimental|Selective laser trabeculoplasty|Treating with the selective laser trabeculoplasty
11389662|NCT02105311|Active Comparator|Travoprost|Using eye drop: travoprost
11389663|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
11389664|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
11389665|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
11389666|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
11389667|NCT02105259|Experimental|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for social anxiety disorder during 10 weeks and guided by a psychologist
11389668|NCT02105259|Active Comparator|Waiting list with support|Behavioral: supportive check-ups via the Internet during 10 weeks
11389669|NCT02105246|Experimental|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
11389670|NCT02105246|Active Comparator|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
11389671|NCT02105233|Experimental|BMG|brain mimicking fluid
11389672|NCT02105220||Obese|"We will enroll patients with BMI≥40 kg/m2 to describe the impact of obesity on chest wall compliance and respiratory mechanics.
~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
11389673|NCT02105220||Intraabdominal Hypertension|"We will enroll patients with IAP≥12 mmHg to describe the impact of intraabdominal hypertension on chest wall compliance and respiratory mechanics.
~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
11389674|NCT02105207|Experimental|Lung Ultrasound|In Patients allocated to this arm Lung ultrasound for detection of interstitial syndrome will be performed before chest radiography.
11389675|NCT02105207|Experimental|Chest Radiography|In Patients allocated to this arm chest radiography will be performed for the detection of indirect signs of pulmonary congestion/ADHF without ultrasound evaluation.
11389676|NCT02105194|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
11389677|NCT02105181|Other|Fully covered metal stent (FCMS)|There is one arm in the study : the intervention consists on placing a device which is a fully covered metal stent in the biliary tract of all patients
11389678|NCT02105168|Experimental|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
11389679|NCT02105155|Experimental|Conversion at day 7 ± 3|Conversion from Prograf to Advagraf at D7 ± 3
11389680|NCT02105155|Active Comparator|Conversion at day 90±5|Conversion from Prograf to Advagraf at 90±5
11389681|NCT02105142|Active Comparator|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
11389682|NCT02105142|Active Comparator|ADHD Group visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
11389683|NCT02105142|Active Comparator|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Online discussion portal access granted to parent participants and will allow parents to communicate with each other in between in-person group visits
11389684|NCT02105129|Experimental|HMPL-523|Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A
11389685|NCT02105129|Placebo Comparator|Placebo|Placebo: oral administration
11389686|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
11389687|NCT02105103|Other|Accu-Chek® Insight Insulin Pump|
11389688|NCT02105090|Placebo Comparator|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
11389689|NCT02105090|Experimental|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
11389690|NCT02105090|Experimental|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
11389691|NCT02105077||Xenon|Patients undergoing surgery with xenon-based general anesthesia
11389692|NCT02105064|Active Comparator|Active rTMS|rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions.
11389693|NCT02105064|Sham Comparator|Sham|Sham stimulation, 20 minutes per session, total 20 sessions
11389694|NCT02105038|Experimental|Knob|Steering in a driving simulator using a steering wheel spinner knob.
11389695|NCT02105038|Active Comparator|No Knob|Steering in a driving simulator immediately following surgical treatment of hip fractures.
11389696|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
11389697|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
11389698|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
11389699|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
11389700|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
11389701|NCT02104999|Other|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
11389702|NCT02104986|Experimental|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
11389703|NCT02104986|Experimental|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
11389704|NCT02104986|Experimental|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
11389705|NCT02104986|Experimental|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
11389706|NCT02104973|Experimental|Lifestyle counseling|After obtaining the approval of schools and parents, will be established in schools, units in which individual attention is given to children, parents and teachers that request: the advice is aimed at training users on healthy diet and constant physical activity. Workshops with children, in which selected topics will be discussed based on the analysis of depth interviews with children, parents and teachers, and information on habits and resources gathered through questionnaires will be conducted. The intervention included the provision of information and feedback with the population through a website. The work will include participation in the selection of foods sold in schools.
11389707|NCT02104973|No Intervention|Control|Usual care
11389708|NCT02104960||PROOF|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date. (NCT00759304)
11389709|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
11389710|NCT02104934|No Intervention|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
11389711|NCT02104934|Active Comparator|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
11389712|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
11389713|NCT02104921||Healthy volunteers|
11389714|NCT02104908|Experimental|paravertebral nerve|Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)
11389715|NCT02104908|Other|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
11389716|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
11389717|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
11389718|NCT02104882|Experimental|Intraoperative Radiotherapy|Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.
11389719|NCT02104869|Active Comparator|Recommended dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: single 0.5 mL dose."
11389720|NCT02104869|Active Comparator|Healthy adults|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: single 0.5 mL dose."
11389721|NCT02104869|Experimental|Single double dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: single 1.0 mL dose."
11389722|NCT02104869|Experimental|Two sequential doses (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).
~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).
~Dose: two 0.5 mL doses 21 days apart."
11389723|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
11389724|NCT02104843|Experimental|Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin|"Treatment A: Rosuvastatin tablet orally on specified days
~Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days
~Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
11389725|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
11389800|NCT02104479||Immunocompromised Patients|Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population
11389726|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
11389727|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
11389728|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
11389729|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
11389730|NCT02104804|Experimental|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
11389731|NCT02104804|Placebo Comparator|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
11389732|NCT02104791||procalcitonin in blood|-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
11389733|NCT02104791||plasma of blood|-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
11389734|NCT02104791||procalcitonin,prematureruptureofmembrane in blood|"Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).
~Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.
~The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.
~They will be asked for their permission and consent."
11389735|NCT02104778|Experimental|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
11389736|NCT02104778|Placebo Comparator|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
11389737|NCT02104778|Experimental|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
11389738|NCT02104765|Experimental|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
11389739|NCT02104765|Experimental|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
11389740|NCT02104765|Experimental|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
11389741|NCT02104765|Experimental|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
11389742|NCT02104765|Experimental|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
11389743|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
11389744|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
11389745|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
11389746|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
11389747|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
11389748|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
11389749|NCT02104739|Placebo Comparator|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
11389750|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
11389751|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
11389752|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
11389753|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
11389754|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
11389755|NCT02104739|Experimental|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
11389756|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
11389757|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
11389758|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
11389759|NCT02104726|Active Comparator|Blind Steroid Injection|Blind Steroid Injection for patients with OA deemed qualified for it clinically
11389760|NCT02104726|Active Comparator|Fluoroscopy guided steroid injection|Fluoroscopy guided Steroid Injection for patients with OA deemed qualified for it clinically. We want to see which one is better.
11389801|NCT02104479||Control Group|Patients without Immunosuppression with pleural effusions
11389761|NCT02104713|Experimental|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.
~Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
11389762|NCT02104700|Active Comparator|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
11389763|NCT02104700|Active Comparator|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
11389764|NCT02104687|Active Comparator|Flow|The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value >2.5 l/m/m2 (FTc - flow time <330 ms was chosen as variable defining preload; PV, peak velocity <70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
11389765|NCT02104687|Active Comparator|Press|The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
11389766|NCT02104674|Placebo Comparator|Placebo|
11389767|NCT02104674|Active Comparator|Singulair (montelukast)|
11389768|NCT02104674|Experimental|lebrikizumab|
11389769|NCT02104661|Experimental|OxCarbazepine Treatment|Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
11389770|NCT02104661|Placebo Comparator|OxCarbazepine Placebo|Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
11389771|NCT02104648|Placebo Comparator|Part A: Placebo|
11389772|NCT02104648|Experimental|Part A: RO4602522|
11389773|NCT02104648|Experimental|Part B: RO4602522 Multiple Doses|
11389774|NCT02104648|Experimental|Part B: RO4602522 Single Dose|
11389775|NCT02104648|Experimental|Part B: moxifloxacin Single Dose|
11389776|NCT02104635|No Intervention|Control group|The control group receives standard of care from Jacaranda clinic and does not receive any additional post-partum check-in from a community health worker.
11389777|NCT02104635|Experimental|CHW-Visit|The CHW-Visit group will receive a visit at their home from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
11389778|NCT02104635|Experimental|CHW-Phone|The CHW-Visit group will receive a phone call from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
11389779|NCT02104622|Experimental|ReWalk training|
11389780|NCT02104609||Normal weight women|Levonorgestrel 1.5mg by mouth once
11389781|NCT02104609||Obese women|Levonorgestrel 1.5mg by mouth once
11389782|NCT02104609||Extremely obese women|Levonorgestrel 1.5mg by mouth once
11389783|NCT02104596|Experimental|Xylitol injection|Intraarticular injection of Xylitol
11389784|NCT02104596|Placebo Comparator|Control|
11389785|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
11389786|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
11389787|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
11389788|NCT02104570|Other|Control|In this session, participants will be evaluated before and after a muscle fatigue protocol, with no intervention.
11389789|NCT02104570|Experimental|Kinesio taping with tension|A kinesio taping technique for the deltoid muscle will be applied before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
11389790|NCT02104570|Sham Comparator|Kinesio taping without tension|A kinesio taping technique will be applied on the deltoid muscle without tension (tension is considered to be the therapeutic effect) before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
11389791|NCT02104557||prevention of pregnancy|Non intervention
11389792|NCT02104557||management of endometriosis-associated pain|Non intervention
11389793|NCT02104531||Shoulder Pain|No intervention. Subjects will have a standard static MRI taken of their shoulder, and also complete a series of shoulder motions using video fluoroscopy.
11389794|NCT02104531||Healthy Subjects|No intervention. Subjects will receive a standard shoulder MRI and perform shoulder motions while being measured with video fluoroscopy.
11389795|NCT02104518||G6PD testing|Blood samples will be tested for G6PD activity levels
11389796|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
11389797|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
11389798|NCT02104492|Experimental|Intervention group|a 12-week respiratory muscles training program (RMTP) with ORYGEN Dual® device and peripheric resistive muscle training program
11389799|NCT02104492|Active Comparator|Control Group|Peripheric resistive muscle training program and Health Education Program.
11389802|NCT02104466|No Intervention|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
11389803|NCT02104466|Experimental|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
11389804|NCT02104466|Experimental|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
11389805|NCT02104453|Experimental|E-C clamp mask holding technique|"the airway maneuver that press the mask against the patient's face (using the C of our thumb and forefinger) while pulling the jaw forward (using the E of our other fingers behind the mandible), and leaves one hand free to squeeze the bag."
11389806|NCT02104453|Experimental|two-handed ventilation with jaw thrust|the airway maneuver performed with thumbs point toward feet, palms press down and other fingers perform jaw thrust
11389807|NCT02104453|Experimental|triple airway maneuver|the airway maneuver performed with two-handed mask ventilation, jaw thrust and head-tilt chin-lift technique
11389808|NCT02104440|Experimental|Patients with cytopenia after allo-HSCT|Patients with cytopenia after allo-HSCT
11389809|NCT02104427|Experimental|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
11389810|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
11389811|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
11389812|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
11389813|NCT02104401|Experimental|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
11389814|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
11389815|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
11389816|NCT02104375|Experimental|L-citrulline|L-citrulline (6 g/day for 2 weeks)
11389817|NCT02104375|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
11389818|NCT02104362|Other|exclusive single-fraction irradiation|
11389819|NCT02104349|Experimental|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
11389820|NCT02104349|No Intervention|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
11389821|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
11389822|NCT02104323|Experimental|Endostatin，treatment effect evaluation|Patients receive continuous intravenous Endostatin drug pumping during the course of treatment. The drug dosage is 7.5mg/m2/d. Every course of treatment lasts three months. Patients are designed to receive total three courses of treatment if there is no disease progression. The interval between two courses is one month.
11389823|NCT02104310|Experimental|Fluorine-18-L-dihydroxyphenylalanine|18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure
11389824|NCT02104297|Active Comparator|Deksmedetomidine infusion|To prevent agitation deksmedetomidine infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
11389825|NCT02104297|Experimental|Remifentanil infusion|To prevent agitation remifentanil infused during operation at the end of surgery agitation scor measured by Riker sedation agitation scale.
11389826|NCT02104297|Placebo Comparator|Saline infusion|Saline infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
11389827|NCT02104284|Other|Normal controls, methacholine positive|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls
11389828|NCT02104284|Other|Normal controls, mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.
11389829|NCT02104284|Active Comparator|Asthma, Methacholine|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics
11389830|NCT02104284|Active Comparator|Asthma, Mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics
11389831|NCT02104271|Experimental|Argon Plasma Coagulation|"Argon Plasma Coagulation (APC) treatment will be delivered using a spray-painting technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
11389832|NCT02104271|Active Comparator|Historical control|"Argon Plasma Coagulation (APC) treatment was delivered using a spray-painting technique, with short applications at 40-50W power and argon gas flow of 2.0 - 2.5 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
11389873|NCT02103946|Active Comparator|Paravertebral block|Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
11390008|NCT02103023|Active Comparator|IM TIV + aq|aqueous cream followed by intramuscular influenza vaccine
11389833|NCT02104258|Active Comparator|Physiotherapy ASPETAR|"The patients will follow the ASPETAR Hamstring Rehabilitation Protocol, which is a standardised physiotherapy protocol, including range of motion exercises, progressive strengthening exercises, core stability training and agility exercises [10].
~The ASPETAR protocol consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.
~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
11389834|NCT02104258|Active Comparator|Physiotherapy ASPETAR+|"The patients will follow the ASPETAR+ Hamstring Rehabilitation Protocol. ASPETAR+ is similar to ASPETAR, but consists of additional lengthening exercises which will be initiated early in the rehabilitation phase.
~ASPETAR+ consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.
~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
11389835|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
11389836|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
11389837|NCT02104232|Experimental|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
11389838|NCT02104232|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
11389839|NCT02104193|Experimental|simvastatin|they will receive simvastatin in addition to radiation therapy
11389840|NCT02104193|Active Comparator|control|they will receive radiation therapy only
11389841|NCT02104180|Active Comparator|TulleGras M.S.|
11389842|NCT02104180|Active Comparator|Urgotul|
11389843|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
11389844|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
11389845|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
11389846|NCT02104128|Experimental|Depressed patient given bupropion|All depressed patients will be given open label bupropion
11389847|NCT02104128|No Intervention|Control pts given no intervention|Control participants will be assessed at the same time points as the depressed group, but will be given no drug
11389848|NCT02104115|Other|Gluten free white bread|Sliced loaf of gluten free white bread
11389849|NCT02104115|Other|Normal gluten content white wheat bread|Sliced loaf of normal gluten content white wheat bread
11389850|NCT02104115|Other|High gluten content white wheat bread|Sliced loaf of high gluten content white wheat bread
11389851|NCT02104102|Experimental|Mirror group|Composed of 30 volunteers who carry out the mirror therapy, whose name shall Mirror Group (MG).
11389852|NCT02104102|Experimental|Control Group - kinesiotherapy|Called by Control Group (CG), composed of 30 volunteers who will carry out the kinesiotherapy with the same sequence of movements for the Mirror Therapy that the MG, but without the view in the mirror, since it will be blocked.
11389853|NCT02104089||Endovascular treatment|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
11389854|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
11389855|NCT02104063||MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
11389856|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
11389857|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
11389858|NCT02104037|Experimental|Liraglutide treated patients|
11389859|NCT02104024||Kidney transplant recipients|CEUS in Kidney Transplant recipients
11389860|NCT02104024||Pancreas transplant recipients|CEUS in pancreas transplant recipients
11389861|NCT02104011|Experimental|Patient|
11389862|NCT02103998|Experimental|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
11389863|NCT02103998|Placebo Comparator|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
11389864|NCT02103985|Experimental|Treatment A|Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition.
11389865|NCT02103985|Experimental|Treatment B|Participants will receive 100 mg JNJ-39823277 under fasted condition.
11389866|NCT02103972|Placebo Comparator|Maltodextrin|Maltodextrin
11389867|NCT02103972|Active Comparator|GM080|GM080
11389868|NCT02103959|Experimental|CMX-2043 2.4 mg/Kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
11389869|NCT02103959|Experimental|CMX-2043 3.6 mg/kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
11389870|NCT02103959|Experimental|CMX-2043 2.4 mg/kg given twice|Bolus injection of investigational product given prior to the cardiac catheterization and again 24 hours after the first dose.
11389871|NCT02103959|Placebo Comparator|Placebo comparator|Placebo comparator (PBS) given prior to cardiac catheterization and again 24 hours after the first dose.
11389872|NCT02103946|Active Comparator|Serratus anterior muscle plane block|Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
11390009|NCT02103023|Active Comparator|ID TIV + aq|aqueous cream followed by intradermal influenza vaccine
11389874|NCT02103907|No Intervention|Wait list|Wait list control group. Participants will be placed on the wait list and asked to maintain their current routine and level of activity during the 10 week period. Control group participants will receive the dynamic balance training program in a single training session after the followup (second testing session at 10 weeks).
11389875|NCT02103907|Experimental|Treatment (balance training)|Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
11389876|NCT02103894|Experimental|[18F]T807 ([18F]MNI-777)|At the [18F]MNI-777 PET imaging visit, subjects will be injected with no more than 10 mCi (370 MBq) of [18F]MNI-777).
11389877|NCT02103881|Experimental|Ketamine|Patients enrolled in this arm will be given 500 mg of intramuscular ketamine for their severe agitation they experience in the prehospital environment.
11389878|NCT02103881|Experimental|Haloperidol|Patients enrolled in this arm will be given 10 mg of intramuscular haloperidol for their severe agitation they experience in the prehospital environment.
11389879|NCT02103868|No Intervention|Control|No active intervention will be given for tobacco cessation.
11389880|NCT02103868|Experimental|Medium Intervention|Tobacco Cessation Counseling : Medium intervention in the form of 3 contact sessions will be given for tobacco cessation.
11389881|NCT02103868|Experimental|Low intensity intervention|Tobacco Cessation Counseling: Only a single contact session will be done for tobacco cessation.
11389882|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.
~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
11389883|NCT02103842|Experimental|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
11389884|NCT02103829|Active Comparator|Condition #1|Condition #1 will consist of Brief Intervention #1, a brief online suggestion that takes less than 1 minute to complete.
11389885|NCT02103829|Experimental|Condition #2|Condition #2 will consist of Brief Intervention #1 and Brief Intervention #2 that together take less than a minute to complete.
11389886|NCT02103829|Experimental|Condition #3|Condition #3 will consist of Brief Intervention #1 and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
11389887|NCT02103829|Experimental|Condition #4|Condition #4 will consist of Brief Intervention #1, Brief Intervention #2, and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
11389888|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
11389889|NCT02103790|Experimental|Home NIV installation|
11389890|NCT02103777|Active Comparator|High dose caffeine|High dose (loading 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base)
11389891|NCT02103777|Active Comparator|Low dose caffeine|Low dose (loading 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base and maintenance of 10 mg/kg/day equivalent to 5 mg /kg/day of caffeine base) caffeine.
11389892|NCT02103764|Experimental|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
11389893|NCT02103764|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
11389894|NCT02103738||Arm 1 (Monthly)|0.5 mg intravitreal injections of Ranibizumab monthly for the duration of the study.
11389895|NCT02103738||Arm 2 (Treat and Extend)|Three consecutive months of 0.5 mg Ranibizumab intravitreal injections (Day 1, Month 1, and Month 2). Monthly injections will continue until evidence of disease stability is observed. Specifically, monthly treatment will continue until visual acuity is deemed stable as indicated by a gain in visual acuity of ≤ 3 ETDRS letters from the prior month, no clinical evidence of lesion growth, fluid or blood, and no intraretinal or subretinal fluid on OCT. When this is achieved, the intervals between each subsequent injection will be extended by 2 weeks (intervals of 6 weeks, 8 weeks, 10 weeks, to a maximum of 12 weeks) until clinical or diagnostic evidence of disease instability is observed based on OCT findings and/or BCVA ETDRS.
11389896|NCT02103725|Experimental|pimecrolimus 10 mg/g cream|Active drug
11389897|NCT02103725|Placebo Comparator|Vehicle cream|Placebo drug
11389898|NCT02103712||Hypospadias|
11389899|NCT02103699||Hepatitis C virus infected patients receiving simeprevir|
11389900|NCT02103686|Active Comparator|Immediate release capsule|Immediate release capsule treatment under fasted condition
11389901|NCT02103686|Experimental|sustained release tablet|sustained release tablet treatment under fasted condition
11389902|NCT02103686|Experimental|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
11389903|NCT02103673|Experimental|DAOIB|Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks
11389904|NCT02103673|Placebo Comparator|Placebo|Placebo by mouth per day for 6 weeks
11389905|NCT02103660|Active Comparator|Depo-Medroxyprogesterone Acetate|Half of women will be randomized to receive Depo-Medroxyprogesterone Acetate injections every 13 weeks
11389906|NCT02103660|Active Comparator|Progestin Implant (Jadelle)|Half of women will be randomized to receive progestin implant.
11389907|NCT02103647|Active Comparator|Immediate release capsule(lyrica capsule 150mg)|Immediate release capsule repeat treatment for 3days under fasted condition
11389908|NCT02103647|Experimental|sustained release tablet|sustained release tablet repeat treatment for 3days under fasted condition
11389909|NCT02103634||Lesion Imaging|Image patients with the standard of care of a FDG PET/CT and the experimental method of the NaF PET/MRI and compare the number of images found within and between patients to determine the most effective way of looking at breast cancers metastasized to bone
11389910|NCT02103621|Experimental|Unifed Protocol (UP) for Discontinuation|Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
11389911|NCT02103621|Active Comparator|Taper and Monitoring (TAP-M)|Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter. TAP-M consists of assessment and monitoring. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
11389912|NCT02103608|Experimental|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
11389913|NCT02103595|Other|Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink|
11389914|NCT02103595|Other|Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus|
11389915|NCT02103582|Placebo Comparator|control|Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
11389916|NCT02103582|Experimental|intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
11389917|NCT02103569|Experimental|Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325|"Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days
~Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
11389918|NCT02103556|Active Comparator|Mineral oil|4ml daily (adjusted as needed), for 4 weeks
11389919|NCT02103556|Active Comparator|Olive oil|4ml daily (adjusted as needed), for 4 weeks
11389920|NCT02103556|Active Comparator|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
11389921|NCT02103543|Active Comparator|Physical Therapy first|patients will undergo physical therapy 3-4 sessions followed by lumbar interlaminar epidural steroid injection
11389922|NCT02103543|Active Comparator|lumbar epidural steroid first|lumbar interlaminar epidural steroid injection followed by patients will undergo physical therapy 3-4 sessions
11389923|NCT02103530|Experimental|FLT PET/CT|Patients who had FLT PET/CT
11389924|NCT02103517|Experimental|Omega-3 fatty acid capsules|Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
11389925|NCT02103517|Placebo Comparator|corn oil|Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.
11389926|NCT02103504|Other|DePuy Attune TKA|DePuy Attune posterior stabilized fixed bearing total knee replacement
11389927|NCT02103491|Active Comparator|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol).
11389928|NCT02103491|Placebo Comparator|Placebo administration|In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose).
11389929|NCT02103478|Experimental|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
11389930|NCT02103478|Experimental|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
11389931|NCT02103478|Experimental|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
11389932|NCT02103465|Experimental|Rotigotine|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
11389933|NCT02103465|Placebo Comparator|Placebo|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
11389934|NCT02103452|Experimental|ovarian endometrioma|Ovarian and endometrial samples
11389935|NCT02103452|Experimental|normal ovary|Ovarian and endometrial samples
11389974|NCT02103257|Active Comparator|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
11389936|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
11389937|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
11389938|NCT02103426|Experimental|Part 1: ASP0113 CMV-seropositive healthy cohort|5 mg single dose IM injection
11389939|NCT02103426|Experimental|Part 1: ASP0113 CMV-seronegative healthy cohort|5 mg single dose IM injection
11389940|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seropositive healthy cohort|single dose IM injection
11389941|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seronegative healthy cohort|single dose IM injection
11389942|NCT02103426|Experimental|Part 2: ASP0113 CMV-seropositive healthy cohort|4 IM injections of ASP0113
11389943|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative healthy cohort|4 IM injections of ASP0113
11389944|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative dialysis cohort|4 IM injections of ASP0113
11389945|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seropositive healthy cohort|4 placebo IM injections
11389946|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative healthy cohort|4 placebo IM injections
11389947|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative dialysis cohort|4 placebo IM injections
11389948|NCT02103413|Experimental|EUS-BD|EUS-BD using a fully or partially covered self-expanding metallic stent will be performed by EUS guided 19 G needle puncture.
11389949|NCT02103413|Experimental|PTBD|PTBD with 8.5F catheter will be inserted under fluoroscopic and/or ultrasonography guidance by experienced interventional radiologists.
11389950|NCT02103400|Experimental|Experimental group|Patients hospitalized for community-acquired pneumonia
11389951|NCT02103400|Active Comparator|Control group|Patients hospitalized for community-acquired pneumonia
11389952|NCT02103387|Experimental|Cognitive Behavioral Training|Cognitive Behavioral Training 5 weekly 1.5-hour sessions of group-based cognitive behavioral training
11389953|NCT02103387|Experimental|Relaxation Training|Relaxation Training 5 weekly 1.5-hour sessions of group-based relaxation training
11389954|NCT02103387|Active Comparator|Health Education Control|Health Education Control 5 weekly 1.5 sessions of group-based health education training
11389955|NCT02103374|Experimental|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
11389956|NCT02103374|Placebo Comparator|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
11389957|NCT02103361||Stelara (ustekinumab) exposed|Stelara (ustekinumab)-exposed pregnant women
11389958|NCT02103361||Tremfya (guselkumab) exposed|Tremfya (guselkumab-exposed pregnant women
11389959|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
11389960|NCT02103348||Severe Asthma|"Major Criteria: (1 required)
~Treatment with oral corticosteroids for at least 6 of the previous 12 months
~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months
~Minor Criteria: (2 required)
~Daily treatment with an asthma controller medication in addition to inhaled, or
~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or
~Persistent airway obstruction with baseline FEV1 <80% predicted, or
~≥ 1 urgent visits for asthma in the previous 12 months, or
~≥ 3 systemic corticosteroid bursts in the previous 12 months, or
~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or
~A near-fatal asthma event (i.e., intubation) in the past."
11389961|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
11389962|NCT02103335|Experimental|Single Group Assignment|Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
11389963|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
11389964|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
11389965|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
11389966|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
11389967|NCT02103296|Active Comparator|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
11389968|NCT02103296|Experimental|Cord Blood|Admission labs to be drawn from the infant's cord blood
11389969|NCT02103283|Experimental|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
11389970|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
11389971|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
11389972|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
11389973|NCT02103257|Experimental|Sequential icotinib plus chemotherapy|Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
11390010|NCT02103010||HNC patients|head and neck cancer patients
11389975|NCT02103244|Experimental|carboplatin|An adjusted dosing algorithm will be applied to calculate the dose of carboplatin. in 24 patients blood will be obtained in order to determine the pharmacokinetics of carboplatin after adjusted dosing
11389976|NCT02103231||Full Term Birth|History of full term birth (>37 weeks gestation) including sub-group with diagnosis of hypertension
11389977|NCT02103231||Preterm Birth|History of preterm birth (<37 weeks gestation) including subgroup with diagnosis of hypertension
11389978|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
11389979|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
11389980|NCT02103205|Active Comparator|Low iron, with lactoferrin|Low iron, with lactoferrin
11389981|NCT02103205|Active Comparator|Low iron, no lactoferrin|Low iron, no lactoferrin
11389982|NCT02103205|Placebo Comparator|Normal iron, no lactoferrin|Normal iron, no lactoferrin
11389983|NCT02103192|Experimental|Control plus low level nutrient fortification|Control plus low level nutrient fortification
11389984|NCT02103192|Experimental|Control plus increasing level nutrient fortification|Control plus increasing level nutrient fortification
11389985|NCT02103192|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
11389986|NCT02103179||ECC patients|Extrahepatic cholangiocarcinoma patients treated by surgical treatment
11389987|NCT02103166|Experimental|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
11389988|NCT02103166|Placebo Comparator|Physiological serum|100 ml of physiological serum (0.9% NaCl).
11389989|NCT02103153|Experimental|Picosure Laser System|
11389990|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
11389991|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
11389992|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
11389993|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
11389994|NCT02103114|Experimental|Anti-thrombin III|
11389995|NCT02103114|Placebo Comparator|Placebo|
11389996|NCT02103101|Other|Study cohort|"Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp
~All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated."
11389997|NCT02103088|Experimental|Sexual and urological intervention|Standard care and the PROCAN intervention consisting of i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
11389998|NCT02103088|No Intervention|Control|Standard care consists of:systematic offer of medical treatment for erectile dysfunction, if not contra indicated. The medical treatment will consist of either daily treatment with Cialis 5 mg or phosphodiesterase type 5 inhibitor on demand before sexual activity. Alternatively use of alprostadil as either urethral pin or penile injection. Furthermore standard treatments include preoperative instruction in pelvic floor muscle training, regular outpatient visits and possible referral to rehabilitation in accordance with the rules that apply to the Danish Health legislations. In case of prolonged incontinence the patients may on request be referred to a private practicing physiotherapist.
11389999|NCT02103075|Experimental|The SCA|
11390000|NCT02103075|Experimental|The age-matched control|
11390001|NCT02103075|Experimental|The young control|
11390002|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
11390003|NCT02103049|Other|Ezetimibe, dyslipidemia, kidney transplant|
11390004|NCT02103036|Experimental|Core Stability Exercises|"Core Stability Exercises:
~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Core Stability Exercises (25-30 minutes)."
11390005|NCT02103036|Experimental|Traditional Back School|"Traditional Back School:
~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Traditional Back School (25-30 minutes)."
11390006|NCT02103023|Experimental|ID TIV + imiquimod|imiquimod ointment followed by intradermal influenza vaccine
11390007|NCT02103023|Sham Comparator|ID sham + imiquimod|imiquimod ointment followed by sham intradermal influenza vaccine
11390143|NCT02101957|Experimental|RP103|RP103 capsule, 16 capsules per day
11390011|NCT02102984|Active Comparator|covered stents|endoscopic placement of covered biliary stents
11390012|NCT02102984|Active Comparator|uncovered biliary stents|endoscopic placement of uncovered biliary stents
11390013|NCT02102971||Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
11390014|NCT02102958|Experimental|Experimental|DSME with Nonvisual Foot Examination
11390015|NCT02102958|Active Comparator|Comparison|DSME with Usual Foot Examination Instruction
11390016|NCT02102945|Other|Computed tomography perfusion|Participants will undergo CT perfusion of the head after cooling following cardiac arrest.
11390017|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
11390018|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
11390019|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
11390020|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
11390021|NCT02102919|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & virtual games) - T2
11390022|NCT02102919|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
11390023|NCT02102906|Experimental|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
11390024|NCT02102880|Other|Healthy Subjects|
11390025|NCT02102854|Active Comparator|Standard dose rATG|Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
11390026|NCT02102854|Experimental|Single dose rATG|Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration
11390027|NCT02102841|Experimental|Skin biopsy|5mm skin punch biopsy on forearm
11390028|NCT02102841|Experimental|Skin suction blister|Skin suction blister induced on forearm
11390029|NCT02102841|Experimental|Mantoux, skin biopsy, suction blister|0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
11390030|NCT02102828|Placebo Comparator|Aspirin only|Patients receive aspirin therapy
11390031|NCT02102828|Experimental|extended compression|aspirin and extended compression therapy in combination
11390032|NCT02102815|Experimental|Dexamethasone|Preoperative dexamethasone 0.15mg/Kg mixed with NSS to 50 mL IV slowly push over 5 minutes
11390033|NCT02102815|Placebo Comparator|Placebo|Preoperative intravenous normal saline 50 mL slowly push over 5 minutes
11390034|NCT02102802|Active Comparator|Low or medium dose MDMA|Participants receive 30 mg MDMA possibly followed 1.5 to 2 h later by 15 mg or participants receive 75 mg MDMA possibly followed by 37.5 mg MDMA
11390035|NCT02102802|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA possibly followed 1.5 to 2 h later by 62.5 mg MDMA
11390036|NCT02102789|Experimental|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
11390037|NCT02102789|Experimental|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
11390038|NCT02102776|Active Comparator|MMC after pterygium excision|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision. The conjunctival defect will be left bare without graft.
11390039|NCT02102776|Active Comparator|AMT after Pterygium Excision|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
11390040|NCT02102776|Active Comparator|CAG after Pterygium Excision|A conjunctival autograft will be harvested from the superior side of the operating eye's bulbar conjunctiva. Then the graft will be sutured to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
11390041|NCT02102750|Experimental|tafluprost|
11390042|NCT02102737|Experimental|6-DIG and clamp|injection of 6-DIG and hyperinsulinemic euglycemic clamp
11390043|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
11390044|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
11390045|NCT02102711|Experimental|vitaminA drops|3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
11390046|NCT02102711|No Intervention|control|Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
11390047|NCT02102698|Experimental|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
11390048|NCT02102698|Placebo Comparator|Placebo|Placebo is the inactive comparator
11390049|NCT02102685|Active Comparator|VAC Therapy|active comparator: 14 patients within the first three days the VAC therapy was placed , proceeding as follows : organize the material , bandage removal , cleaning of the wound with irrigation solution , cut the sponge and placement on the wound , use of polyvinyl alcohol and / or silver foam, insertion of the tube seal and connection to the containing recipient.
11390050|NCT02102685|Placebo Comparator|Traditional Therapy|14 patients: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
11390051|NCT02102672|Placebo Comparator|Sugar pill|Placebo 1 pill bid, 3 months
11390052|NCT02102672|Experimental|Trimetazidine|Trimetazidine 35 mg bid for 3 months
11390053|NCT02102659|Experimental|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium."
11390054|NCT02102659|Active Comparator|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
11390055|NCT02102646|Active Comparator|Triptorelin|Triptorelin 22,5mg/24th week intramuscularly
11390056|NCT02102646|Active Comparator|orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
11390057|NCT02102633|Experimental|Dabigatran|Dabigatran 150 mg orally
11390058|NCT02102633|Experimental|Dabigatran + Bosutinib|Dabigatran 150 mg co-administered with Bosutinib 500 mg orally
11390059|NCT02102620|Experimental|IAI triamcinolone hexacetonide|"Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).
~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day)."
11390060|NCT02102620|Placebo Comparator|IAI lidocaine|Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
11390061|NCT02102607||age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
11390062|NCT02102594|Experimental|Bortezomib (Velcade)|
11390063|NCT02102581||short time tourniquet|60 patients were randomly divided into 2 groups (30 cases/group): group A using the tourniquet throughout the operation, and group B using the tourniquet starting from the implantation of prosthesis to the completion of the operation(short time).
11390064|NCT02102555|Active Comparator|IV acetaminophen|Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
11390065|NCT02102555|Placebo Comparator|Placebo|Patients in the placebo arm will receive normal saline in the pre-operative area.
11390066|NCT02102542||Antisialagouge|A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
11390067|NCT02102542||Bradycardia|A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
11390068|NCT02102542||For reversal of neuromuscular blocking agents|Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
11390069|NCT02102529||bowel endometriosis|laparoscopic colonic resection
11390070|NCT02102516|Experimental|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
11390071|NCT02102503|Experimental|MI and Medication review|The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.
11390072|NCT02102503|Active Comparator|Standard treatment|Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.
11390073|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
11390074|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
11390075|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
11390076|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
11390077|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
11390078|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
11390079|NCT02102438|Experimental|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
11390080|NCT02102425||Chronic kidney disease, PD|Patients with or without bandage over exit site
11390081|NCT02102412|Experimental|single arm|single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.
11390082|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
11390083|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
11390084|NCT02102386||CerOx|Patients will be monitored using the CerOx monitor. Probes will be attached bi-laterally in the OR to the forehead.
11390085|NCT02102373|Active Comparator|low-fiber diet|Patients received low-fiber diet for 24 hours before colonoscopy
11390086|NCT02102373|Active Comparator|clear liquid diet|Patients received clear liquid diet for 24 hours before colonoscopy
11390087|NCT02102360|Experimental|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
11390088|NCT02102360|Experimental|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
11390089|NCT02102347|Experimental|exercise group|An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
11390090|NCT02102347|Experimental|phototherapy group|And, Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant.with one 905-nm diode (mean power: 1 milliwatt ; peak power: 10 megawatt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 17.5 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 15 mW; spot size: 1 cm2); frequency: 1000 Hz; 300-second irradiation time in each quadrant; total energy: 39.3 Joules per quadrant. Phototherapy will be included in the exercises group.
11390091|NCT02102347|Placebo Comparator|Phototherapy placebo|Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
11390092|NCT02102334||Unilateral osteoarthritis|Patients operated with a total hip replacement due to unilateral osteoarthritis of the hip. Radiographic measurements of the postoperative radiographs.
11390093|NCT02102321|Experimental|albendazole|albendazole 400 mg
11390094|NCT02102321|Active Comparator|placebo|placebo
11390095|NCT02102308|Experimental|Exercise|Multicomponent exercise
11390096|NCT02102308|Placebo Comparator|Education classes|Education classes
11390097|NCT02102295|Active Comparator|Experimental toothpaste|L-ascorbic acid 2-phosphate magnesium salt / fluoride
11390098|NCT02102295|Placebo Comparator|Control toothpaste|fluoride
11390099|NCT02102282||Subject study|Patients with breast cancer during pregnancy
11390100|NCT02102269|Active Comparator|actimove sling|standard orthosis: actimove sling
11390101|NCT02102269|Experimental|shoulderlift|newly developed orthosis: shoulderlift
11390102|NCT02102269|No Intervention|controle group|no orthosis
11390103|NCT02102256|Experimental|Experimental|Device Implantation
11390104|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:
~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
11390105|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:
~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
11390106|NCT02102230|Experimental|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
11390107|NCT02102230|Active Comparator|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
11390108|NCT02102230|Placebo Comparator|PC|Desensitization Treatment for Insomnia (DTI)
11390109|NCT02102217|Experimental|Precious arm|Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted.
11390110|NCT02102217|No Intervention|Control|Standard postoperative controls. Additional testing will only be conducted on demand.
11390111|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
11390112|NCT02102191|Active Comparator|cigarette|common cigarette sold in the stores
11390113|NCT02102191|Active Comparator|e-cigarette|e-cigarette (Ovale Elips)
11390144|NCT02101957|Placebo Comparator|placebo|placebo capsule, 16 capsules per day
11390254|NCT02101216|Experimental|Bioequivalence of Prurisol (350 mg)|Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
11390114|NCT02102178|Experimental|Group 1 (Intensive occupational therapy)|"All patients received pharmacological treatment for pain in accordance with the World Health Organization (WHO)'s analgesic ladder and occupational therapy follow-up, with guidance regarding activities of daily living (ADLs).
~They also carried out therapeutic activities such as embroidery onto gauze (tapestry), weaving a scarf on a nail frame and playing dominos."
11390115|NCT02102178|Active Comparator|Group 2 (Regular occupation therapy)|All patients received pharmacological treatment for pain in according to WHO's analgesic ladder and only guidance regarding ADLs from the occupational therapist.
11390116|NCT02102165|Experimental|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
11390117|NCT02102152|Active Comparator|TOBI / Placebo|TOBI / Placebo.
11390118|NCT02102152|Active Comparator|Placebo / TOBI|Placebo / TOBI
11390119|NCT02102139|Experimental|DXM + Propofol|"DXM (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During DXM loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.
~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.
~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
11390120|NCT02102139|Placebo Comparator|Saline + Propofol|"Saline (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During saline loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.
~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.
~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
11390121|NCT02102126|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
11390122|NCT02102126|No Intervention|Control group|Subjects are maintained on baseline anti-hypertensive medications.
11390123|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
11390124|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
11390125|NCT02102100|Experimental|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
11390126|NCT02102100|Experimental|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
11390127|NCT02102087|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used in conjunction with standard blood culture bottles.
11390128|NCT02102087|Active Comparator|Lab standard practice (LSP)|A standard blood culture kit will be used.
11390129|NCT02102061|Experimental|multidisciplinary intervention|
11390130|NCT02102061|No Intervention|control|
11390131|NCT02102048|Active Comparator|Atazanavir|patients that switch cART to boosted or unboosted ATV
11390132|NCT02102048|No Intervention|other Protease Inibithors|patients that continue the previous cART without changes.
11390133|NCT02102035|Other|Dorsal digital island flap|The flap is used to cover the soft-tissue defects of the fingers.
11390134|NCT02102022|Experimental|ADI-PEG 20 plus modified FOLFOX6|"Dose: 36 mg/m2 given weekly
~Route of Administration: Intramuscular (IM)
~In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus"
11390135|NCT02102009|Experimental|Vitafos|Complete enteral formula
11390136|NCT02102009|Active Comparator|Dietary Advise|Dietary advise according to the hospital routine clinical practice.
11390137|NCT02101996||Healthy|Not insulin resistant
11390138|NCT02101996||Insulin resistant|Insulin resistant by an insulin clamp
11390139|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
11390140|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
11390141|NCT02101970|Experimental|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
11390142|NCT02101970|Active Comparator|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
11390145|NCT02101944|Experimental|Treatment (dexamethasone, carfilzomib, wild-type reovirus)|Patients receive dexamethasone IV, carfilzomib IV over 30 minutes, and wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390146|NCT02101931|Experimental|Urine spectral analysis|The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking Amino levulinic Acid and the samples will be analyzed by photodynamic diagnostic procedure. Amino levulinic Acid gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).The above samples is taken in a four side polished quartz cuvette of 1cmx1cmx4cm and put into the table top spectral scan. This consists of a 5 mw, blue diode laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid.
11390147|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
11390148|NCT02101905|Experimental|Group A (lapatinib ditosylate, surgery)|Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390149|NCT02101905|Active Comparator|Reference Group (surgery, lapatinib ditosylate)|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390150|NCT02101892|Active Comparator|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
11390151|NCT02101892|Placebo Comparator|placebo|sugar pills
11390152|NCT02101879||Breast cancer Her2 positive|Trastuzumab & Pertuzumab & Taxanes
11390153|NCT02101866|Experimental|Vapendavir 300 mg tablet|Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose
11390154|NCT02101866|Experimental|Two Vapendavir 132 mg capsules|Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose
11390155|NCT02101853|Active Comparator|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT. Closed effective September 18, 2019.
11390156|NCT02101853|Experimental|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
11390157|NCT02101853|Active Comparator|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
11390158|NCT02101853|Experimental|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance.
11390159|NCT02101840|Active Comparator|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
11390160|NCT02101840|Active Comparator|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
11390161|NCT02101840|Placebo Comparator|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
11390162|NCT02101827||Hysteroscopic surgery|Women who received hysteroscopic surgeries or examinations
11390163|NCT02101814|Other|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
11390164|NCT02101801|Other|freshwater|receives vegetables from freshwater farms
11390165|NCT02101801|Active Comparator|recycled wastewater|receives vegetables from farms using recycled wastewater irrigation
11390166|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
11390167|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390168|NCT02101775|Experimental|Arm I (WEE1 inhibitor MK-1775, gemcitabine hydrochloride)|Patients receive WEE1 inhibitor MK-1775 PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390169|NCT02101775|Active Comparator|Arm II (placebo, gemcitabine hydrochloride)|Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390170|NCT02101762||Silver Coated Catheters|Subjects that had previously received silver coated Foley catheters.
11390171|NCT02101762||ERASE CAUTI Non-Silver Coated Catheters|Subjects that received non-silver catheters from an ERASE CAUTI tray.
11390172|NCT02101749|Active Comparator|trivalent inactivated influenza (INTANZA)|Intradermal injection
11390173|NCT02101749|Active Comparator|trivalent inactivated influenza (VAXIGRIP)|Intramuscle injection
11390212|NCT02101450|No Intervention|Intra-abdominal removal of the placenta|The uterus will be left in the abdominal cavity and the placenta will be manually removed with uterine massage as soon as possible. After removal of the placenta, the uterus will be dragged out of the abdominal cavity. The cesarean incision will be sutured with no. 1 Vicryl ®. Uterus will be replaced in the abdominal cavity. Intra-abdominal cavity will be cleaned by aspirator and mounted-gauze tampon. The weight of the placenta will be measured. The weight of the gauze tampons will be measured with gravimetric method before and after use.
11390255|NCT02101216|Active Comparator|Bioequivalence of Ziagen (300 mg)|Single dose of Ziagen 300 mg (1 x 300mg tablet)
11390174|NCT02101736|Experimental|Experimental Agent XL184 (Cabozantinib)|"Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.
~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose
~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort."
11390175|NCT02101723|Active Comparator|Micronutrient Powder (MNP) + Zn/Fe|Micronutrient Powder with 5 mg Zn and 12 mg Fe
11390176|NCT02101723|Active Comparator|MNP + Zn|Micronutrient Powder with 5 mg Zn
11390177|NCT02101723|Placebo Comparator|Control|Placebo sachets without micronutrients
11390178|NCT02101710|Experimental|Elantan SR 60 mg fed|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 2 and on Day 1 of treatment period 2 for Fed group 1.
11390179|NCT02101710|Experimental|Imdur SR 60 mg fed|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 1 and on Day 1 of treatment period 2 for Fed group 2.
11390180|NCT02101710|Experimental|Elantan SR 60 mg fasted|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 2 and on Day 1 of treatment period 2 for Fasted group 1.
11390181|NCT02101710|Experimental|Imdur SR 60 mg fasted|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 1 and on Day 1 of treatment period 2 for Fasted group 2.
11390182|NCT02101697|Experimental|HIV Stigma Reduction Intervention|The HIV stigma reduction arm group will participate in a promising intervention designed to reduce HIV stigma among health professionals. The intervention builds on results of our previous research, identifying prevalence and drivers of stigma and discrimination in Indian healthcare settings among PLHIV, health care providers, and uninfected patients.The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
11390183|NCT02101697|Placebo Comparator|Time Matched Control Group|The time-matched control group will also receive three sessions; two administered by computers and one in small group format to control for attention effects. However, rather than AIDS stigma, the content will be focused on diabetes management (a disease not considered to be stigmatized).
11390184|NCT02101684|Experimental|Orteronel 300mg b.i.d.|Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.
11390185|NCT02101671||trendelemburg positioning|Patients undergone laparoscopic surgery in trendelemburg position
11390186|NCT02101671||Not trendelemburg positioning|Patients undergone laparoscopic surgery not in trendelemburg position
11390187|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
11390188|NCT02101645|Experimental|LIDC treatment and bioimpedance monitoring of venous ulcers.|Lower extremity venous ulcers will be treated using periodical LIDC stimulation. Wound healing and edema reduction efforts will be monitored using bioimpedance based monitoring.
11390189|NCT02101632|Experimental|Bee Venom|Bee Venom Ointment 0,0005%
11390190|NCT02101632|Placebo Comparator|Vaseline|Vaseline ointment
11390191|NCT02101619||Moderate aortic stenosis.|
11390192|NCT02101619||Severe aortic stenosis.|
11390193|NCT02101606|Experimental|Tenecteplase|
11390194|NCT02101593|Experimental|ADI-PEG 20|
11390195|NCT02101580|Experimental|ADI-PEG 20|
11390196|NCT02101567|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
11390197|NCT02101567|Active Comparator|Oxytocin and Methergine (methyl ergometrine)|The second group of patients included in the study will be given Oxytocin 5 IU ampoule by intravenous infusion and Methergine 0.2 mg IV after delivery of fetal head.
11390198|NCT02101554|Experimental|Embeda|One arm, open label, active
11390199|NCT02101541|Experimental|FIRM ablation|"The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.
~The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme."
11390200|NCT02101528||PD Patients|"PD patients with a diagnosis of clinically probable idiopathic PD in Hoehn-Yahr stage 2-3, with the ability to walk without any assistance, with mini-mental state examination score ≥26, without any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance."
11390201|NCT02101528||Controls|age and sex matched healthy volunteers
11390202|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
11390203|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural
~Intervention: one additional hour for the second stage of labor
~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
11390204|NCT02101502|Active Comparator|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
11390205|NCT02101502|Active Comparator|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
11390206|NCT02101502|Active Comparator|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
11390207|NCT02101489|Active Comparator|Intraop Foley catheter measurement|20 women will have intraoperative Foley catheter measurement of the urethral length
11390208|NCT02101489|No Intervention|Without intraop Foley cath measurement|20 women without intraoperative Foley catheter measurement of the urethral length
11390209|NCT02101476|Active Comparator|Percocet|Oxycodone/APAP (acetaminophen)
11390210|NCT02101476|Active Comparator|Xartemis|
11390211|NCT02101463|Other|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
11390252|NCT02101216|Experimental|Pharmacokinetics medium dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
11390253|NCT02101216|Experimental|Pharmacokinetics of high dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
11390213|NCT02101450|Experimental|Extra-abdominal removal of the placenta|"No drug or device is used. The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
~The placenta will be manually removed with uterine massage as soon as possible. The cesarean section will be completed as described in No intervention group."
11390214|NCT02101437|Placebo Comparator|control|normal subjects.
11390215|NCT02101437|Active Comparator|clopidogrel|subjects received clopidogrel 75mg qd.
11390216|NCT02101437|Active Comparator|ticagrelor|subjects received ticagrelor 90mg qd.
11390217|NCT02101437|Active Comparator|cilostazol|subjects received cilostazol 100mg bid.
11390218|NCT02101424||Overdose|
11390219|NCT02101411||clopidogrel|treated with cloopidogrel
11390220|NCT02101411||ticagrelor|treated with ticagrelor
11390221|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
11390222|NCT02101398|Experimental|F7A|Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
11390223|NCT02101398|Experimental|F7C|Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
11390224|NCT02101398|Experimental|T5A|Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
11390225|NCT02101398|Experimental|T5C|Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
11390226|NCT02101398|Sham Comparator|Sham|Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
11390227|NCT02101385|Experimental|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
11390228|NCT02101385|Other|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
11390229|NCT02101372|Active Comparator|treatment as usual|
11390230|NCT02101372|Experimental|Psychoeducation Group|
11390231|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.
~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
11390232|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.
~Topical Mydriatic treatments were instilled three times before surgery."
11390233|NCT02101346|Experimental|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
11390234|NCT02101346|Experimental|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.
~Saturated fat Triolein 13C"
11390235|NCT02101333|Experimental|TOCILIZUMAB MONTHLY DURING 6|intravenous injection, 8 mg/kg, monthly during 6 months
11390236|NCT02101320|No Intervention|Group 1|Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
11390237|NCT02101320|Experimental|Group 2|Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
11390238|NCT02101307||RA Patients on RoActemra/Actemra treatment|
11390239|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
11390240|NCT02101281|Experimental|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
11390241|NCT02101281|Experimental|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
11390242|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
11390243|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
11390244|NCT02101255|Experimental|Curodont Repair|Application on Day 0 and Day 360
11390245|NCT02101255|Active Comparator|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
11390246|NCT02101242||Orthopedic surgery of the shoulder|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
11390247|NCT02101242||Gynecological, urological or general surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
11390248|NCT02101242||Cardiac surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).
11390249|NCT02101229|No Intervention|unsual treatment|The patient will have his usual treatment in this arm
11390250|NCT02101229|Experimental|The Diabeloop algorithm|In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
11390251|NCT02101216|Experimental|Pharmacokinetics of low dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
11390257|NCT02101203|Experimental|Testosterone + Buspirone|40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride
11390258|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
11390259|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
11390260|NCT02101177||Patients under Dual therapy|- 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A).
11390261|NCT02101177||Early Defaulters|- 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).
11390262|NCT02101164|Active Comparator|Treatment Group A|1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.
11390263|NCT02101164|Active Comparator|Treatment Group B|1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.
11390264|NCT02101151|Experimental|Vitamin D3 group|supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months
11390265|NCT02101151|Placebo Comparator|Placebo group|Placebo (starch) capsules identical to vitamin D capsules in appearance
11390266|NCT02101138|Experimental|Dexpramipexole|Dexpramipexole treatment
11390267|NCT02101125|Experimental|BMS-986020 + Rosuvastatin (Treatment A, B and C)|"Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days
~Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
11390268|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
11390269|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
11390270|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
11390271|NCT02101099||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
11390272|NCT02101086|Experimental|Autologous Cord Blood Transfusion|Autologous cord blood transfusion 10 mL per kg for anemia
11390273|NCT02101086|Active Comparator|Allogeneic blood transfusion|Allogeneic blood transfusion 10 mL per kg for anemia
11390274|NCT02101073|Experimental|ALX-0061 low dose i.v.|
11390275|NCT02101073|Experimental|ALX-0061 high dose i.v.|
11390276|NCT02101073|Experimental|ALX-0061 low dose s.c.|
11390277|NCT02101073|Experimental|ALX-0061 middle dose s.c.|
11390278|NCT02101073|Experimental|ALX-0061 high dose s.c.|
11390279|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
11390280|NCT02101060|No Intervention|control|usual care controls
11390281|NCT02101047|Experimental|phenylephrine 50mcg bolus|Phenylephrine 50 mcg bolus dosing with continuous placebo infusion
11390282|NCT02101047|Experimental|Phenylephrine 100 mcg bolus|Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.
11390283|NCT02101047|Experimental|Phenylephrine continuous infusion 100mcg/min|Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.
11390284|NCT02101034|Experimental|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
11390285|NCT02101034|Experimental|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
11390286|NCT02101034|Experimental|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
11390287|NCT02101034|Experimental|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
11390288|NCT02101034|Experimental|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.
~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
11390289|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
11390290|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
11390291|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
11390292|NCT02100995|Experimental|STOP Intervention|The STOP treatment includes content designed to simultaneously and explicitly target both chronic pain and obesity. Treatment components are drawn from evidence-based interventions for chronic pain and obesity, separately.
11390293|NCT02100995|Active Comparator|Standard Care Weight (SCW)|The weight loss intervention includes content focused around nutrition and eating habits, stimulus control and behavioral change, and physical activity. This content has been chosen because of its demonstrated effectiveness and importance in behavioral interventions to reduce weight.
11390368|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
11390369|NCT02100514|Placebo Comparator|placebo|
11390294|NCT02100995|Active Comparator|Standard Care Pain (SCP)|The chronic pain intervention is focused around reconceptualization of pain, decreasing catastrophizing, and increasing self-efficacy for pain. This content has been chosen because of its demonstrated effectiveness and importance in non-pharmacological interventions to improve pain management.
11390295|NCT02100982|Other|Care As Usual|Before the office visit with the PCP, patient participants in the Care As Usual arm will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
11390296|NCT02100982|Experimental|Customized Care|Before the office visit with the PCP, patient participants in the intervention group will interact with the computer based components of the customized care intervention while in the waiting room. The research staff will help the participant use an iPad in the waiting room and direct them to the Discussion Prioritization tool (DPT). After participants use the DPT, the program automatically generates a customized questions prompt list (QPL) which will be printed out in the office. Study staff will hand the QPL to intervention patients to bring to their office visit with the PCP. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
11390297|NCT02100969|Experimental|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
11390298|NCT02100956|Experimental|oxytocin|oxytocin 100 micrograms administered intrathecally (IT)
11390299|NCT02100956|Placebo Comparator|normal saline|preservative free normal saline: 3 milliliters administered intrathecally (IT)
11390300|NCT02100943||OSA in Pregnancy|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation
11390301|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
11390302|NCT02100917|Experimental|DMB-3111|6 mg/kg is once given in intravenous drip infusion taking 90 min
11390303|NCT02100917|Active Comparator|trastuzumab|6 mg/kg is once given in intravenous drip infusion taking 90 min
11390304|NCT02100904||Women undergoing radiofrequency ablation.|Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
11390305|NCT02100904||Women undergoing myomectomy|About 25% of women in the trial will be in the group who receive treatment with myomectomy.
11390306|NCT02100891|Experimental|Allogeneic HCT + Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
11390307|NCT02100878||Lean adolescents|
11390308|NCT02100878||Obese adolescents|
11390309|NCT02100865|Experimental|Solar powered oxygen|Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
11390310|NCT02100865|Active Comparator|Oxygen from cylinders|Conventional oxygen delivery from compressed gas cylinders
11390311|NCT02100852|Experimental|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days.
11390312|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL
~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
11390313|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.
~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
11390314|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
11390315|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
11390316|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
11390317|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
11390318|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
11390319|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
11390320|NCT02100800|Experimental|COPD Group|30 patients with diagnosis of COPD
11390321|NCT02100800|Sham Comparator|Control Group|10 volunteers with extrapulmonary neoplasia
11390322|NCT02100787|Experimental|TheraTears lubricating drops|TheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
11390323|NCT02100774||healthy male adults|no added micronutrient, tomato puree, lutein supplement, vitamin E supplement, vitamin D supplement
11390324|NCT02100761||invasive pulmonary aspergillosis|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole according to their physician decision in five hospital, Jinan, China
11390325|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
11390326|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
11390327|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
11390328|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
11390329|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
11390330|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
11390331|NCT02100735|Experimental|Sedation protocol|Sedation protocol is a document that will be used to guide the adjustment of sedation in the ICU.
11390332|NCT02100735|Active Comparator|Standard of care|Current practices
11390333|NCT02100722|Active Comparator|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
11390334|NCT02100722|Active Comparator|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
11390335|NCT02100709|No Intervention|Control Arm|This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
11390336|NCT02100709|Active Comparator|Intervention Arm|This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.
11390337|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-Label Induction Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
11390338|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
11390339|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
11390340|NCT02100696|Experimental|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
11390341|NCT02100696|Placebo Comparator|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
11390342|NCT02100696|Placebo Comparator|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
11390343|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA with a minimum diameter of < 4 mm.
11390344|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
11390345|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
11390346|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
11390347|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
11390348|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).
~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.
~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
11390349|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
11390350|NCT02100631|Experimental|PXVX0200|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x108 CFU in a liquid suspension
11390351|NCT02100631|Placebo Comparator|Placebo|Placebo physiological saline
11390352|NCT02100618|Experimental|HPV Group 1|Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970).
11390353|NCT02100618|Active Comparator|HPV Group 2|Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970).
11390354|NCT02100605|Active Comparator|Phytosun, decongestant, nasal spray|"Phytosun, decongestant, nasal spray
~Nasal spray 20 ml contains:
~22g/l hypertonic seawater Essential oils of Eucalyptus, Niaouli and Wild menthol
~Instructions for use:
~Shake the bottle before use
~Tilt the bottle to one side; press the nozzle firmly for at least one second, repeat until obtaining the 1st spray.
~Spray in each nostril with the head upright"
11390355|NCT02100605|Placebo Comparator|Isotonic saline, nasal spray|"Isotonic saline, nasal spray
~20 ml nasal spray contains Isotonic water solution 0.9% sodium chloride"
11390356|NCT02100592|Experimental|Erigo treated|Early rehabilitation treatment on Erigo Hocoma, a tilt table with integrated stepping device within 3 - 30 days from injury
11390357|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
11390358|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
11390359|NCT02100566|Experimental|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
11390360|NCT02100566|No Intervention|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
11390361|NCT02100553|Other|Non-Obese|BMI <30 kg/m^2
11390362|NCT02100553|Other|Obese|BMI >= 30 kg/m^2
11390363|NCT02100540|Placebo Comparator|I placebo capsule|I placebo capsule
11390364|NCT02100540|Experimental|II RDC 0.3mg capsule|II RDC 0.3mg capsule
11390365|NCT02100540|Experimental|III RDC 0.6mg capsule|III RDC 0.6mg capsule
11390370|NCT02100501||Atkins diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 53. enrolled patients are assigned to randomly in one of KD group or Atkins group.
11390371|NCT02100501||Ketogenic diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 51. enrolled patients are assigned to randomly in one of KD group or Atkins group.
11390372|NCT02100488|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
11390373|NCT02100488|Experimental|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
11390374|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
11390375|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
11390376|NCT02100462|Experimental|Chlorthalidone 12.5 mg|Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
11390377|NCT02100462|Experimental|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
11390378|NCT02100462|Active Comparator|Aspirin 81 mg|Aspirin 81 mg by mouth once daily for 2 weeks
11390379|NCT02100449|Other|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
11390380|NCT02100449|Other|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
11390381|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
11390382|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
11390383|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
11390384|NCT02100423|Experimental|Treatment (curcumin, cholecalciferol)|Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years.
11390385|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
11390386|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
11390387|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
11390388|NCT02100397|Experimental|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
11390389|NCT02100384|Active Comparator|Ultrasonics|Ultrasonic instrumentation for peri-implant maintenance
11390390|NCT02100384|Active Comparator|Scalers|Titanium Scalers instrumentation for peri-implant maintenance
11390391|NCT02100371|Experimental|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
11390392|NCT02100358||acute cholecystitis|acute cholecystitis
11390393|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
11390394|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
11390395|NCT02100306|Experimental|Patients|"Patients will receive:
~Auditory Feedback 100% Auditory Feedback 50% alternate"
11390396|NCT02100293|Active Comparator|standard dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.6 mg/kg
11390397|NCT02100293|Active Comparator|low dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.45 mg/kg
11390398|NCT02100293|Active Comparator|low dose rocuronium plus magnesium group|pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg
11390399|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
11390400|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
11390401|NCT02100267|Experimental|Asthma patients|
11390402|NCT02100267|Experimental|Healthy volunteers|
11390403|NCT02100254|Experimental|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
11390404|NCT02100254|Active Comparator|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
11390405|NCT02100241|Experimental|Active stretching with currents|Active stretching performed while currents are applied on hamstring muscles.
11390406|NCT02100241|Experimental|Active stretching|Active stretching are performed.
11390407|NCT02100241|No Intervention|Control group|Routine clinical practice
11390408|NCT02100228|Experimental|Apixaban|
11390409|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
11390410|NCT02100215|Experimental|Expert Modeling|Participants will have access to 70 minutes of expert modeling videos available over 5 weeks on an online learning management system. The investigator will be the expert model in the videos. Expert modeling videos will address content related to seven concepts: Taking report with a graphic organizer worksheet, prioritizing patient care, delegating to unlicensed assistive personnel, safety checks in patient rooms, focused physical assessments, safe medication administration, and using a standardized healthcare provider communication tool on the telephone.
11390411|NCT02100215|Active Comparator|Voice Over PowerPoint|Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
11390412|NCT02100215|Placebo Comparator|Reading|Participants will have access to articles, policies, and procedures on an online learning management system. The estimated time required for participants to review these materials is 45 minutes
11390413|NCT02100202|Placebo Comparator|Placebo|Capsules containing 250 mg of placebo, two times a day
11390414|NCT02100202|Experimental|BioTurmin|Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
11390415|NCT02100202|Experimental|BioTurmin-WD|Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
11390416|NCT02100202|Experimental|MaQxan|Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
11390417|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
11390418|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
11390419|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H&Y stages 1,5-2)
11390420|NCT02100163|Experimental|Virtual Reality Hypnosis|The patient receives VRH daily.
11390421|NCT02100163|Experimental|Audio Hypnosis|The patient receives Audio Hypnosis daily.
11390422|NCT02100163|Experimental|Standard Treatment|The patient receives the standard treatment. This is a control group and there are no interventions.
11390423|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
11390424|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
11390425|NCT02100137||Women with endometrial hyperplasia|
11390426|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
11390427|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
11390428|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
11390429|NCT02100111||Participants with advanced or metastatic BCC|Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.
11390430|NCT02100085||Observational group|Subjects in the period less than 48 weeks after the final administration of GX-188E
11390431|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
11390432|NCT02100059|Experimental|Electrical Stimulation (TENS)|The TENS (transcutaneous electrical nerve stimulation) electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
11390433|NCT02100046|Experimental|ethosuximide|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
11390434|NCT02100046|Other|control group|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
11390435|NCT02100033|Experimental|acupuncture|acupuncture manipulation
11390436|NCT02100020|Experimental|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
11390437|NCT02100020|No Intervention|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
11390438|NCT02100007|Experimental|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
11390439|NCT02099994|Experimental|A - AM|Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.
11390440|NCT02099994|Experimental|B - DDDAM|pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
11390734|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
11390441|NCT02099994|Experimental|C - DeDeDeAM|"Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.
~Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20."
11390442|NCT02099981|Experimental|Control Group|Control subjects will receive AG.
11390443|NCT02099981|Experimental|Type 1 diabetes|Type 1 diabetic subjects will receive AG.
11390444|NCT02099968|Experimental|Comprehensive Lifestyle Modification|
11390445|NCT02099968|Active Comparator|Standard Lifestyle Modification / modified DASH|
11390446|NCT02099955|No Intervention|Screening Study|To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
11390447|NCT02099955|Experimental|Pulmonary Arm|"Vitamin D3 Supplementation and Pulmonary Function:
~To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).
~To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels)."
11390448|NCT02099955|Experimental|Endocrine Arm|"Vitamin D3 Supplementation and Endocrine Function:
~To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR."
11390449|NCT02099929|Experimental|Coffee with Sugar|300mL of Coffee with 30g of Sugar
11390450|NCT02099929|Experimental|Coffee without Sugar|300mL of Coffee without Sugar
11390451|NCT02099929|Experimental|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
11390452|NCT02099929|Sham Comparator|Water with Sugar|300mL of Water with 30g of Sugar
11390453|NCT02099929|Sham Comparator|Water without Sugar|300mL of Water without Sugar
11390454|NCT02099916|Active Comparator|gonadotropins plus DHEA|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks.
11390455|NCT02099916|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
11390456|NCT02099903|No Intervention|Medical therapy for heart failure|Standard optimized medical therapy for heart failure.
11390457|NCT02099903|Experimental|Renal denervation + medical therapy.|Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.
11390458|NCT02099890|Experimental|Anti-inflammatory Supplementation|Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
11390459|NCT02099877||Nulliparous requesting epidural|"Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated course of singleton vertex pregnancy requesting epidural analgesia for pain relief will be included.
~When the patient requests analgesia, cervical dilatation will be verified by the obstetric resident/attending. Then epidural analgesia will be initiated with a test dose of 3mL of 2% lidocaine and epinephrine 15 µg and a dose of fentanyl 100 µg diluted to a total volume of 10 mL with preservative- free normal saline. Before placement of the epidural, venous blood (2 mL) will be drawn into special tubes. Genotyping of OPRM1: p.118A/G will be also performed."
11390460|NCT02099864|Experimental|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
11390461|NCT02099851|Experimental|Carotid body ablation|Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
11390462|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
11390463|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
11390464|NCT02099825|Experimental|Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
11390465|NCT02099825|Active Comparator|Non-Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
11390466|NCT02099812||Obese|Obese individuals
11390467|NCT02099812||Non-obese|Non-obese individuals
11390468|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
11390469|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
11390470|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
11390471|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
11390472|NCT02099773||support workers & AAC users|Support workers who use KeyWordSigning in the communication with their client who has an intellectual disability
11390473|NCT02099773||support workers & KWS users|Support workers who use aided AAC in the communication with their client who has an intellectual disability
11390474|NCT02099760||STD testing (GC/Ct/trich)|
11390475|NCT02099747|Active Comparator|hATG + CsA|Control Arm
11390476|NCT02099747|Experimental|hATG + CsA + Eltrombopag|Experimental
11390477|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
11390478|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
11390479|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
11391112|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
11390480|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.
~These subjects receive an ICD/CRT-D implant."
11390481|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.
~These subjects choose not to receive an ICD/CRT-D implant."
11390482|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).
~These subjects receive an ICD/CRT-D implant."
11390483|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).
~These subjects choose not to receive an ICD/CRT-D implant."
11390484|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.
~These subjects receive an ICD/CRT-D implant."
11390485|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.
~These subjects choose not to receive an ICD/CRT-D implant."
11390486|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
11390487|NCT02099695|Active Comparator|Oxybutynin Chloride|"Tablet
~Dose 5,0 or 10 mg/ day"
11390488|NCT02099695|Placebo Comparator|Placebo|- Tablet
11390489|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
11390490|NCT02099669|Experimental|Liberal transfusion strategy|"Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is < 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L.
~Transfusions administered more frequently."
11390491|NCT02099669|Active Comparator|Restrictive transfusion strategy|Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is < 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration
11390492|NCT02099656|Experimental|Lebrikizumab|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.
11390493|NCT02099656|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.
11390494|NCT02099617|Experimental|Drug Eluting Stent|Synergy II
11390495|NCT02099617|Active Comparator|Bare Metal Stent|Omega or Rebel
11390496|NCT02099604|Experimental|Vitamin D|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
11390497|NCT02099604|No Intervention|Standard of Care|Pegylated Interferon Alpha 2b + Ribavirin
11390498|NCT02099591|Experimental|Age group: > = 12y to < 18y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
11390499|NCT02099591|Experimental|Age group: > = 12y to < 18y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
11390500|NCT02099591|Experimental|Age group: > = 6y to < 12y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
11390501|NCT02099591|Experimental|Age group: > = 6y to < 12y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
11390502|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
11390503|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
11390504|NCT02099578|Placebo Comparator|Control Group|Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
11390505|NCT02099578|Active Comparator|25 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
11390506|NCT02099578|Experimental|50 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
11390507|NCT02099565||OPTIMA study patients|The study population will consist of OPTIMA study patients who have not been lost for follow-up and have given a written informed consent.
11390508|NCT02099552||XLHED|Those with the condition of XLHED
11390509|NCT02099539|Experimental|ALT-803|
11390510|NCT02099500|Experimental|Stem Cell Injection|Non-Randomized
11390511|NCT02099487|Experimental|Radiation|To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
11390512|NCT02099474|Experimental|Raltegravir|All women have been prescribed raltegravir before study participation.
11390513|NCT02099461|Other|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
11390514|NCT02099461|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
11390515|NCT02099461|Experimental|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
11390516|NCT02099448||Elective Cardiac Catheterization|
11390517|NCT02099435||Hemospray to treat lower GI bleeds|
11390518|NCT02099409|Experimental|Starting with FLORENCED2 followed by open loop|Start 2 Overnight periods with closed loop through FLORENCED2 Device , followed by 2 overnight periods with open loop.
11390519|NCT02099409|Experimental|Start open loop followed by FLORENCED2|Start with 2 overnight periods with open loop , followed by 2 overnight with closed loop FLORENCED2
11390520|NCT02099396|Experimental|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.
~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
11390521|NCT02099396|Experimental|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.
~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
11390522|NCT02099383|Active Comparator|normal saline, bolus|Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
11390523|NCT02099383|No Intervention|normal saline, control|Patients of control group will receive intravenous normal saline 60 cc per hour.
11390524|NCT02099357|Placebo Comparator|Placebo|Daily supplementation with 3g of dextrose during eight weeks and placebo ampoules each two weeks.
11390525|NCT02099357|Experimental|Creatine|Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
11390526|NCT02099357|Active Comparator|Vitamin D|Daily supplementation with 3g of dextrose during eight weeks. Vitamin D supplementation, 25000 IU each two weeks.
11390527|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
11390528|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
11390529|NCT02099331|Experimental|Melatonin|The investigators will administer melatonin at 40mg by mouth (two 20 mg tablets), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
11390530|NCT02099331|Placebo Comparator|Placebo|The investigators will administer matching Placebo by mouth (two tablets to match Melatonin), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
11390531|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
11390532|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
11390533|NCT02099305|Experimental|Intervention|Receive Adolescent Depression Awareness Program (ADAP) intervention
11390534|NCT02099305|No Intervention|Wait list control|no intervention
11390535|NCT02099292|Experimental|Rituximab and DexaBEAM|Rituximab and DexaBEAM
11390536|NCT02099279||echocardiography examination|
11390537|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
11390538|NCT02099253|Experimental|Youth Group|People in this group, aged 18~39,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
11390539|NCT02099253|Experimental|Middle-aged Group|People in this group, aged 40~64,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
11390540|NCT02099253|Experimental|Older Group|People in this group, aged 65~80,were accepted an initial dose of 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
11390541|NCT02099240|Active Comparator|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
11390542|NCT02099240|Active Comparator|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
11390543|NCT02099227||Ultrasound|those who received point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
11390544|NCT02099227||No Ultrasound|those who did not receive point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
11390545|NCT02099214|Experimental|Patients with HFE hereditary haemochromatosis|"The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.
~Then will be performed :
~An electrocardiogram
~Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank
~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)
~A 3Tesla abdominal MRI
~An echocardiography at rest."
11390735|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
11390546|NCT02099214|Experimental|Healthy volunteers|"The healthy volunteers (10 men and 10 women) will undergo :
~A urinary pregnancy test (if applicable)
~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)
~An echocardiography at rest."
11390547|NCT02099201|Experimental|Group A1|Ten subjects will receive ACT-389949 40 mg and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
11390548|NCT02099201|Experimental|Group A2|Ten subjects will receive ACT-389949 (Predicted to be 200 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
11390549|NCT02099201|Experimental|Group A3|Ten subjects will receive ACT-389949 (Predicted to be 800 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
11390550|NCT02099201|Experimental|Group B1|Ten subjects will receive ACT-389949 200 mg and 3 subjects will receive placebo, every 3 days for 13 days (a total of 5 doses), administered orally, in the morning, following an overnight fast.
11390551|NCT02099201|Experimental|Group B2|Ten subjects will receive ACT-389949 (provisionally 200 mg) and 3 subjects will receive placebo, every 2 days for 9 days (a total of 5 doses), administered orally, in the morning following an overnight fast. The actual dose will depend on the emerging data from Group B1.
11390552|NCT02099201|Experimental|Group C1|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
11390553|NCT02099201|Experimental|Group C2|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
11390554|NCT02099188|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:
~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w
~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w
~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.
~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.
~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle
~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.
~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.
~Intestinal Type Adenocarcinoma with functional p53.
~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.
~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w
~Followed by radiotherapy"
11390555|NCT02099175|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:
~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w
~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w
~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:
~First Cycle and every other cycle:
~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Second Cycle and every other cycle:
~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w
~Intestinal Type Adenocarcinoma with functional p53:
~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w
~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w
~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w
~Followed by Radiotherapy"
11390556|NCT02099149||Controls|Infants born to GBS colonized mother who do not develop GBS disease
11390557|NCT02099149||Cases|Infants with culture confirmed GBS disease
11390558|NCT02099136|Experimental|Group I (placebo)|Patients receive placebo PO BID for 14 days.
11390559|NCT02099136|Experimental|Group II (low-dose celecoxib)|Patients receive low-dose celecoxib PO BID for 14 days.
11390560|NCT02099136|Experimental|Group III (higher dose celecoxib BID)|Patients receive higher dose celecoxib PO BID for 14 days.
11390561|NCT02099136|Experimental|Group IV (higher dose celecoxib QD)|Patients receive same dose of celecoxib PO as Group III QD for 14 days.
11390562|NCT02099136|Experimental|Group V (high-dose celecoxib)|Patients receive high-dose celecoxib PO QD for 14 days.
11390563|NCT02099123|Experimental|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
11390564|NCT02099123|Placebo Comparator|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
11390565|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
11390566|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
11390567|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
11390568|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
11390569|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
11390570|NCT02099097|Active Comparator|Standard Care|"usual care, which consists of four (face-to-face or telephone) counseling sessions with a trained nurse who has expertise in helping cancer patients quit smoking. This is the same as the treatment an MSK patient who enrolls in the MSK smoking cessation program would receive.
~To collect further data to improve the game intervention, the investigators will conduct semi-structured telephone interviews with patients who were randomized to the treatment arm but did not play the game during the one month intervention period. The purpose of the interviews is to elicit qualitative feedback on any barriers that may have prevented participants from playing. At the completion of the intervention period, patients will be asked if they would like to participate in a telephone interview. Telephone interviews will take about twenty minutes and will be held at a time that is convenient for the patient."
11390600|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
11390813|NCT02097485|Placebo Comparator|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
11390571|NCT02099097|Experimental|Smoking Cues Coping Skills Game (SC+SCCS/Quit IT).|Smokers randomly assigned to SC+SCCS/Quit IT will receive all the components of Standard Care. The patient will be oriented and trained face-to-face (during their hospitalization) on use of the game by study staff using an iPad. The orientation and training session will comprise: 1) Overview of the game and its objectives; 2) discussion of the rules of the game; 3) watching a 10 minute tutorial given by the game narrator (avatar); 4) answering all patient questions; and 5) evaluation of the patient's comprehension of game play via a 17 question survey. Once patients have access to QuitIT, they will also receive a set of Coping Cards
11390572|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
11390573|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
11390574|NCT02099071|Experimental|Group 1|Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390575|NCT02099071|Experimental|Group 2|Six subjects will receive a single oral dose of ACT-389949 5 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390576|NCT02099071|Experimental|Group 3|Six subjects will receive a single oral dose of ACT-389949 20 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390577|NCT02099071|Experimental|Group 4|"Subjects will participate in two different treatment periods separated by a washout of 7-10 days between the study drug administrations.
~In the first treatment period six subjects will receive a single oral dose of ACT-389949 50 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
~In the second treatment period, subjects randomized to ACT-389949 will receive a single oral dose of ACT-389949 50 mg in fed condition, 30 minutes after the start of a high fat and high calorie breakfast."
11390578|NCT02099071|Experimental|Group 5|Six subjects will receive a single oral dose of ACT-389949 100 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390579|NCT02099071|Experimental|Group 6|Six subjects will receive a single oral dose of ACT-389949 200 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390580|NCT02099071|Experimental|Group 7|Six subjects will receive a single oral dose of ACT-389949 500 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390581|NCT02099071|Experimental|Group 8|Six subjects will receive a single oral dose of ACT-389949 1000 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
11390582|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin (21-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
11390583|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin(28-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
11390584|NCT02099058|Experimental|Arm A (Telisotuzumab vedotin plus Erlotinib)|Telisotuzumab vedotin to be evaluated with Erlotinib.
11390585|NCT02099058|Experimental|Arm D (Telisotuzumab vedotin plus Nivolumab)|Telisotuzumab vedotin to be evaluated with Nivolumab.
11390586|NCT02099058|Experimental|Arm E (Telisotuzumab vedotin plus Osimertinib)|Telisotuzumab vedotin to be evaluated with Osimertinib.
11390587|NCT02099045||Ultrasound examination|All patients over the age of 18 presenting in the emergency department.
11390588|NCT02099032|Experimental|3g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
11390589|NCT02099032|Experimental|5 g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
11390590|NCT02099032|Placebo Comparator|Unfortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks
11390591|NCT02099006|Experimental|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
11390592|NCT02099006|Placebo Comparator|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
11390593|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.
~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
11390594|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
11390595|NCT02098980|Active Comparator|Dietary Supplement: Vitamin D|Vitamin D supplement 4000 IU/day for 6 months
11390596|NCT02098980|Placebo Comparator|Placebo|Placebo for 6 months
11390597|NCT02098967|Experimental|Acute myeloid leukemia patients|
11390598|NCT02098967|Experimental|Cohort 0|
11390599|NCT02098967|Experimental|Solid tumor patients|
11390601|NCT02098941||Topiramate|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.
11391624|NCT02091947|Sham Comparator|sham group|sham FMS, 5 Hz, 20 min per day, for 10 weekdays.
11390602|NCT02098941||Levetiracetam|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.
11390603|NCT02098941||Oxcarbazepine|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.
11390604|NCT02098928|Active Comparator|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
11390605|NCT02098928|Placebo Comparator|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
11390606|NCT02098915|Experimental|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide
11390607|NCT02098915|Placebo Comparator|control arm|the control arm will receive placebo
11390608|NCT02098902|Experimental|Smart Moms Intervention|This arm will receive the Smart Moms intervention immediately following randomization.
11390609|NCT02098902|No Intervention|Waitlist control group|This arm will receive a modified version of the Smart Moms intervention after the 6-month assessment.
11390610|NCT02098889|Active Comparator|hyoscine-N-butyl bromide|A single dose intravenously(IV) 20ml hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose 20ml IV NaCl) on the active phase of labor
11390611|NCT02098889|Placebo Comparator|Saline(0,9NaCl)|Placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
11390612|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
11390613|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
11390614|NCT02098837|Active Comparator|Immediate switch|Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
11390615|NCT02098837|Active Comparator|Deferred switch|Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
11390616|NCT02098824|Active Comparator|Galantamine|Single administration of capsule containing 16 mg Galantamine
11390617|NCT02098824|Placebo Comparator|Placebo|Single oral administration of capsule containing placebo
11390618|NCT02098824|Active Comparator|Methylphenidate|Single administration of capsule containing 10 mg Methylphenidate
11390619|NCT02098811|Experimental|1064nm laser Treatment Before Abdominoplasty|Patient will be treated with 1064nm Laser prior to abdominoplasty
11390620|NCT02098811|Experimental|940nm Laser Treatment Before Abdominoplasty|Patient will be treated with 940nm Laser prior to abdominoplasty
11390621|NCT02098798||HD|High Definition Colonoscopy alone
11390622|NCT02098798||HD + iSCAN|HD colonoscopy + iSCAN
11390623|NCT02098798||HD + Dye|High definition colonoscopy + dye spraying chromoendoscopy
11390624|NCT02098785|Experimental|Caffeine citrate (Peyona) 400mg|Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)
11390625|NCT02098772|Experimental|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
11390626|NCT02098772|Active Comparator|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
11390627|NCT02098759|Experimental|epilepsy early diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
11390628|NCT02098759|Experimental|standard epilepsy diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
11390629|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
11390630|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
11390631|NCT02098720|Experimental|Conbercept|Subjects will receive Conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 3 months, the investigator will decide whether repeat injections are needed based on the monthly assessment results.
11390632|NCT02098707||30 Parkinson disease patients|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen&Yahr (mean Unified Parkinson Disease Rating Scale [UPDRS] III 18.8±10.5) will undergo a balance training using a stabilometric platform.
11390633|NCT02098694|Experimental|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
11390634|NCT02098694|No Intervention|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
11390635|NCT02098668||Normal, pathological cycle, infertility|healthy women PCOS Endometriosis hyperprolactinemia fertility treatment
11390636|NCT02098655||30 patients with PD|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) with PD in stage 3 of H&Y will undergo training of balance using a stabilometric platform
11390637|NCT02098655||12 healthy volunteers|12 healthy volunteers (3 M, 9 F, mean age 66,5 ± 6,0) served as controls will undergo training of balance using a stabilometric platform
11390638|NCT02098642||Patients with passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT), including the mobilization of the metatarsophalangeal joint of the hallux
11390639|NCT02098642||No passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT)
11390640|NCT02098629|Active Comparator|Milrinone+Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.
~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
11390641|NCT02098629|Placebo Comparator|Saline infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion.
11390642|NCT02098616|Experimental|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
11390643|NCT02098616|Experimental|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
11390644|NCT02098616|Experimental|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
11390645|NCT02098616|Experimental|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
11390646|NCT02098616|Experimental|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
11390647|NCT02098616|Experimental|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
11390648|NCT02098603|No Intervention|Testing Only|
11390649|NCT02098603|Experimental|Testing & Intervention|
11390650|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF135.C10|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
11390651|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF166.C8|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
11390652|NCT02098590|Other|NF54 CPS-immunization challenged by NF54|[Negative control group, to assess effectiveness of CPS-immunization.] Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a homologous malaria challenge infection by exposure to the bites of 5 NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
11390653|NCT02098590|Other|Control group challenged by NF135.C10|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
11390654|NCT02098590|Other|Control group challenged by NF166.C8|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
11390655|NCT02098590|Other|Control group challenged by NF54|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
11390656|NCT02098577||PD patients cross-over treatment|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent cross-over treatment with the ability to walk without any assistance with mini-mental state examination score >26.
11390657|NCT02098577||PD patients stabilometric platform|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent stabilometric platform treatment, with the ability to walk without any assistance with mini-mental state examination score >26.
11390658|NCT02098564|Active Comparator|strong sense of coherence control group|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
11390659|NCT02098564|Experimental|strong sense of coherence intervention|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
11390660|NCT02098564|Active Comparator|weak sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
11390661|NCT02098564|Experimental|weak sense of coherence intervention|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
11390662|NCT02098564|Experimental|medium sense of coherence intervention|Patients with a medium sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
11390663|NCT02098564|Active Comparator|medium sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
11391625|NCT02091934|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
11390664|NCT02098551||Four (4)|"Group 1: Birch pollen-related atopic dermatitis (AD) (n=15) Group 2: Birch pollen allergic patients without AD (n=5) Group 3: Allergic individuals without birch pollen allergy (n=5) Group 4: Non-allergic individuals (n=5)
~Patients will be tested by SPT and APT:
~SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, and equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.
~APT: birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, equimolar mix of rBet v 1 fragments (160 μg/application); negative control with vaseline"
11390665|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
11390666|NCT02098525||HIV associated CM patients|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital.
11390667|NCT02098512|Experimental|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
11390668|NCT02098499|Active Comparator|Haloperidol and Diphenhydramine|Haloperidol 5mg IV X1 and Diphenhydramine 25mg IV X1
11390669|NCT02098499|Active Comparator|Metoclopramide and Diphenhydramine|Metoclopramide 10mg IV X1 and Diphenhydramine 25mg IV X1
11390670|NCT02098486|Active Comparator|Ceftraxone|ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)
11390671|NCT02098486|Active Comparator|Moxifloxacin|Intravenous moxifloxacin (400 mg/day, infused more than 60 min)
11390672|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
11390673|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
11390674|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
11390675|NCT02098460|Placebo Comparator|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
11390676|NCT02098460|Placebo Comparator|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
11390677|NCT02098460|Active Comparator|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
11390678|NCT02098447|Experimental|auricular vagal nerve stimulation|"Study participants (healthy and diabetics) are treated with auricular vagal nerve stimulation using four needle electrodes connected to an electrical stimulation device (PrimeStim). After an acclimatization phase the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and another 10 minutes paused stimulation. This intervention is repeated on four consecutive days. Needle electrodes stay fixed over the whole study period.
~Two different stimulation schemes are tested, each being assessed twice in random order. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.
~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
11390679|NCT02098434|Experimental|Montreal Imaging Stress Task|Math task to induce stress response
11390680|NCT02098421|No Intervention|Control|No oxytocin while the Foley bulb is in place
11390681|NCT02098421|Experimental|Oxytocin|Use of oxytocin while the Foley bulb is in place
11390682|NCT02098421|Experimental|PROMS Foley and oxytocin|Subjects who are induced due to premature rupture of membranes randomized to use of Foley bulb and oxytocin once the bulb is removed.
11390683|NCT02098421|No Intervention|PROMS no Foley bulb|Subjects who are induced due to premature rupture of membranes randomized to no Foley bulb.
11390684|NCT02098408|Experimental|Standard treatment + cognitive remediation|The cognitive remediation therapy targets neurocognition as well as social cognition.
11390685|NCT02098408|Active Comparator|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling
11390686|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
11390687|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
11390688|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
11390689|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
11390690|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
11390691|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
11390692|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
11390693|NCT02098369|Other|Usual care|Written education material (basic)
11390694|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
11390695|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
11390696|NCT02098356|Experimental|Low bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
11390697|NCT02098343|Experimental|Phase Ib. APR-246 + Carboplatin/PLD.|Dose escalation of APR-246.
11390698|NCT02098343|Experimental|Phase II: Arm A. APR-246 + Carboplatin/PLD.|Experimental
11390699|NCT02098343|Active Comparator|Phase II: Arm B. Carboplatin/PLD.|Active Comparator
11390700|NCT02098330|Active Comparator|: Ginkgo biloba & methylprednisolone|Patients receive Ginkgo biloba & methylprednisolone per oral.
11390701|NCT02098330|Placebo Comparator|Ginkgo biloba|Patients receive Ginkgo biloba per oral.
11390702|NCT02098317|Experimental|TREATED GROUP|this group will treated with pearls containing DHA plus Vitamin D3 (500 mg and 800 IU, respectively) given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
11390733|NCT02098096|Placebo Comparator|Stretching|A home exercise program consisting of stretches for the major lower extremity muscles groups will be performed twice per week for 12 weeks.
11390703|NCT02098317|Placebo Comparator|PLACEBO GROUP|this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
11390704|NCT02098304|Other|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
11390705|NCT02098291|Experimental|G17DT|
11390706|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
11390707|NCT02098265|Experimental|Experimental Group - Immediate BCI Therapy|EEG - BCI training (closed loop)
11390708|NCT02098265|Experimental|Experimental Group - Delayed BCI Therapy|Scanned and tested 4 times over a 10-week period before EEG-BCI training
11390709|NCT02098265|Experimental|Experimental Group - RecoveriX|Recruited from participants who have completed the study intervention
11390710|NCT02098265|Active Comparator|Control Group 1|48 stroke patients, 48 participants with risk factors for stroke, 48 healthy controls receiving 4-6 training sessions on the EEG-BCI, pre- and post- behavioral testing, and MRI
11390711|NCT02098265|Active Comparator|Control Group 2|24 Stroke Patients with UE impairment receiving standard FES only therapy
11390712|NCT02098252|Active Comparator|Interventional therapy|"Interventional therapies include:
~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).
~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
11390713|NCT02098252|No Intervention|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
11390714|NCT02098239|Active Comparator|Group A|Jaundiced patients with bilirubin value >80 μmol/L. Received G17DT immediately prior to biliary stenting.
11390715|NCT02098239|Active Comparator|Group B|Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was <40 μmol/L.
11390716|NCT02098213|Active Comparator|Immediate Spa treatment|Three week course of spa treatment soon after randomization
11390717|NCT02098213|Sham Comparator|Late Spa treatment|Three week course of spa treatment soon after 4,5 months visit
11390718|NCT02098200|Experimental|Percutaneous treatment of TR by TriCinch|Percutaneous treatment of Tricuspid Regurgitation with TriCinch System
11390719|NCT02098187|Active Comparator|Below target dose MP-3180|0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
11390720|NCT02098187|Active Comparator|2 times above target dose MP-3180|2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
11390721|NCT02098187|Active Comparator|4 times above target dose MP-3180|4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
11390722|NCT02098187|Active Comparator|At target dose MP-3180|1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
11390723|NCT02098174|Experimental|Healthy participants|MP-3180 (1 µmol/kg or 0.372 mg/kg) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol comparator (Omnipaque 300, 5 mL) was then administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
11390724|NCT02098161|Experimental|Treatment (SMAC mimetic LCL161)|Patients receive SMAC mimetic LCL161 PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390725|NCT02098148|Experimental|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
11390726|NCT02098148|Experimental|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
11390727|NCT02098135|Experimental|ArmeoSenso|The ArmeoSenso system is an easy to set up and use upper limb rehabilitation system for the home environment. It consists of a motion capture system based on wearable sensors in combination with a personal computer as well as a therapy software that provides an ergonomic user interface, therapy games and automated assessments.
11390728|NCT02098122||Tetraplegia|
11390729|NCT02098122||Paraplegia|
11390730|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)
~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)
~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)
~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
11390731|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)
~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)
~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)
~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
11390732|NCT02098096|Experimental|Negative Work|Negative work exercise via isokinetic knee extension/flexion will be performed twice per week for 12 weeks.
11390736|NCT02098057|Placebo Comparator|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
11390737|NCT02098057|Active Comparator|Gluten|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
11390738|NCT02098044||Professional footballers|Retired professional footballers
11390739|NCT02098044||Control Population|members of the general public recruited from the east midlands region
11390740|NCT02098031|No Intervention|control|
11390741|NCT02098031|Experimental|intervention|Nutritional intervention (nutrition education)
11390742|NCT02098018|Active Comparator|Program 1|Program 1
11390743|NCT02098018|Active Comparator|Program 2|Program 2
11390744|NCT02098005|Active Comparator|Usual care|usual care evidence-based physiotherapy
11390745|NCT02098005|Experimental|modern neuroscience approach|modern neuroscience approach
11390746|NCT02097992|Experimental|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
11390747|NCT02097992|Experimental|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
11390748|NCT02097992|Experimental|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
11390749|NCT02097992|Experimental|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
11390750|NCT02097979|Experimental|Glaucoma Educational Intervention|
11390751|NCT02097979|No Intervention|Delayed Intervention|
11390752|NCT02097953|Experimental|Daptomycin and Rifampin|Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on the first study day Drug: Rifampin Rifampin 600 mg capsules will be given orally once daily for 14 days starting on study day 2 Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on study day 15
11390753|NCT02097940|Active Comparator|treatment|The treatment group performed of proprioceptive exercises with shifts and one-leg jumps.
11390754|NCT02097940|No Intervention|control|The control group remained in soccer training
11390755|NCT02097927|Experimental|High energy, low sensory|Mango-flavour beverage
11390756|NCT02097927|Experimental|Low energy, high sensory|Mango-flavour beverage
11390757|NCT02097927|Experimental|High energy, high sensory beverage|Mango-flavour beverage
11390758|NCT02097914|No Intervention|Control|Participant receives usual care.
11390759|NCT02097914|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
11390760|NCT02097901|Experimental|Microfracture|Rotator Cuff Repair AND Microfracture at rotatorcuff footprint
11390761|NCT02097901|Active Comparator|NO microfracture|Rotator cuff reinsertion without microfracture
11390762|NCT02097875|Experimental|BLZ-100|A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.
11390763|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:
~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
11390764|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:
~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
11390765|NCT02097836|Experimental|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
11390766|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.
~Olanzapine dosing:
~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses
~Aprepitant dosing:
~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
11390767|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.
~Olanzapine dosing:
~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses
~Aprepitant dosing:
~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
11390768|NCT02097810|Experimental|Entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)
11390769|NCT02097797|Experimental|Fecal Transplantation|patients receiving the fecal transplant (fecal microbiota from a healthy donor)
11390770|NCT02097797|Sham Comparator|Sham Transplantation|patients receiving the vehicle (Physiological serum)
11390771|NCT02097784|Other|cirrhosis with portal hypertension,ascite and acute kidney|
11390772|NCT02097771|Active Comparator|LMA SupremeTM|
11390773|NCT02097771|Sham Comparator|Ambu AuraOnce|
11390774|NCT02097758|Experimental|transcatheter device closure|Choosing device size using three dimensional image and the formula without sizing balloon
11390775|NCT02097745|Experimental|MabThera/Rituxan|
11390776|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
11390777|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
11390778|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
11390779|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
11390780|NCT02097706|Active Comparator|NMDA receptor antagonist|20mg/daily for 8 weeks (56 days)
11390781|NCT02097706|Placebo Comparator|Placebo tablet|1 capsule/daily for 8 weeks (56 days)
11390782|NCT02097693||dyston-dyskinetic cerebral palsy|Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi
11390783|NCT02097680|Experimental|Letrozole|
11390784|NCT02097680|Placebo Comparator|Placebo comparator|
11390785|NCT02097654|Experimental|SENATOR|Physicians attending multi-morbid older patients i.e. with 3 or more chronic medical conditions receive a SENATOR software-generated report with advice details on potentially inappropriate pharmacotherapy and/or potentially inappropriate prescribing omissions.
11390786|NCT02097654|No Intervention|Control|Standard pharmaceutical care as per local practice.
11390787|NCT02097641|Experimental|Human Mesenchymal Stromal Cells (hMSCs)|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
11390788|NCT02097641|Placebo Comparator|Plasma-Lyte A (placebo)|A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.
11390789|NCT02097628|Active Comparator|pressure-controlled ventilation|pressure-controlled ventilation: a peak airway pressure that provided a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column, respiratory rate 12-16 times per minute.
11390790|NCT02097628|Experimental|volume-controlled ventilation|volume-controlled ventilation: tidal volume 8-12ml/kg, respiratory rate 12-16 times per minute.
11390791|NCT02097615|Experimental|chlorhexidine gluconate|application every 24 hours, six weeks
11390792|NCT02097615|Other|Other: deionized water|application every 24 hours, six weeks
11390793|NCT02097589|Experimental|Pneumovax-Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
11390794|NCT02097589|Placebo Comparator|Pneumovax-Placebo|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
11390795|NCT02097576|Active Comparator|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
11390796|NCT02097576|Active Comparator|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
11390797|NCT02097563|Experimental|High Intensity Training|High intensity training: clinician attends a 6-hr live workshop in family-focused treatment techniques, and then, after taking on a case, gets weekly technical consultation sessions (by telephone) in FFT from an expert after every session;
11390798|NCT02097563|Active Comparator|Low Intensity Training|Low Intensity Training: clinician completes online workshop in FFT and then, after taking on a case, gets telephone consultation sessions after every third session.
11390799|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
11390800|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
11390801|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
11390802|NCT02097524|Experimental|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
11390803|NCT02097524|Experimental|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
11390804|NCT02097524|Active Comparator|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
11390805|NCT02097524|Active Comparator|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
11390806|NCT02097511|Experimental|Sarpogrelate pretreatment and Metoprolol|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
11390807|NCT02097511|Active Comparator|Sarpogrelate and Metoprolol|Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
11390808|NCT02097511|Active Comparator|Metoprolol only|Metoprolol Tartrate 100 mg once a day
11390809|NCT02097498|No Intervention|Simulation only|One group will be randomized to receive simulation training similar to that required for certification. Paramedics in this group will then complete a second simulation scenario
11390810|NCT02097498|Experimental|Directed feedback|One group will review their baseline simulation scenario with a member of the research staff while providing specific feedback for errors made during the first simulation. Paramedics in this group will then complete a second simulation scenario.
11390811|NCT02097498|Experimental|Basic Videolaryngoscopy|One group will review a series of instructional videos related to common airway management errors. Paramedics in this group will then complete a second simulation scenario.
11390812|NCT02097485|Active Comparator|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
11390814|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
11390815|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
11390816|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
11390817|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
11390818|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
11390819|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
11390820|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
11390821|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
11390822|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
11390823|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
11390824|NCT02097459|Experimental|Failed group|Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy.
11390825|NCT02097459|Experimental|Succeeded group|Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy.
11390826|NCT02097459|Active Comparator|No chang group|Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy.
11390827|NCT02097446|Experimental|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
11390828|NCT02097446|Active Comparator|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
11390829|NCT02097433|Experimental|Dacomitinib|
11390830|NCT02097420|Other|Single device arm|Mitral valve replacement
11390831|NCT02097407|Experimental|Group D : Dexmedetomidine + propofol group|In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
11390832|NCT02097407|Placebo Comparator|Group C : Saline + propofol group|In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.
11390833|NCT02097394|Active Comparator|Combizym-treated group|The patients who received polypectomy of colon polyps take the digestion enzyme (Combizym) regularly.
11390834|NCT02097394|Active Comparator|Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take Bifidobacteri regularly
11390835|NCT02097394|Active Comparator|Combizym + Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take drugs (Combizym + Bifidobacteri) regularly
11390836|NCT02097394|No Intervention|control|The patients who received polypectomy of colon polyps take no drugs
11390837|NCT02097381|Other|naïve for cART that met the criteria to start treatment|"patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.
~These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy."
11390838|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
11390839|NCT02097355|Experimental|TriVox Active|Provider using TriVox for clinical care
11390840|NCT02097355|No Intervention|TriVox Delayed-start|Providers not using TriVox for clinical care
11390841|NCT02097342|Experimental|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
11390842|NCT02097342|Placebo Comparator|Placebo|Tablet Placebo per oral, once daily will be given to 10 patients for 6 months
11390843|NCT02097342|Active Comparator|Voglibose|Tablet Voglibose (0.2mg) per oral, thrice daily (with meals) will be given to 10 patients for 6 months
11390844|NCT02097329|Experimental|Cohort 1: Palbociclib under fed conditions|
11390845|NCT02097329|Experimental|Cohort 2: Palbociclib under fed conditions|
11390846|NCT02097316|Experimental|JewelPump|JewelPump for the first treatment period followed by the usual pump for the second treatment period
11390847|NCT02097316|Active Comparator|Usual insulin pump|Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.
11390848|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
11390849|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
11390850|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
11390851|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
11390852|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
11390853|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
11390854|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks
~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
11390855|NCT02097264|Experimental|NNC0109-0012|
11390856|NCT02097264|Active Comparator|Adalimumab|
11390857|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11390858|NCT02097225|Experimental|Treatment (dabrafenib, trametinib, onalespib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11390859|NCT02097199||Sports group|The cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
11390860|NCT02097186|Experimental|Remote ischaemic preconditioning|Remote ischaemic preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
11390861|NCT02097186|No Intervention|Control to remote preconditioning group|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
11390862|NCT02097173|Other|SC MTX followed by IM MTX|1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week
11390863|NCT02097173|Other|IM MTX followed by SC MTX|1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL) after a wash-out phase of 1 week
11390864|NCT02097160|Active Comparator|Control Group 1|regular fortified milk + regular cheese/yogurt
11390865|NCT02097160|Experimental|Intervention Group 2|Vitamin D fortified yogurt and cheese; vitamin D dose increment of 252 IU vs grp 1
11390866|NCT02097160|Experimental|Intervention Group 3|Vitamin D fortified yogurt and cheese, vitamin D dose increment of 420 IU vs grp 1
11390867|NCT02097147|Experimental|Vilazodone 20 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.
11390868|NCT02097147|Experimental|Vilazodone 40 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days, followed by vilazodone 40 mg once daily for 21 days
11390869|NCT02097147|Active Comparator|Paroxetine 20 mg|Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days
11390870|NCT02097147|Placebo Comparator|Placebo|Placebo once daily for 35 days
11390871|NCT02097134|Experimental|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11390872|NCT02097121|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
11390873|NCT02097121|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
11390874|NCT02097121|Experimental|OnabotulinumtoxinA Dose C|OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
11390875|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
11390876|NCT02097095||Vaccine group|TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
11390877|NCT02097095||Placebo Comparator|Placebo administered on study TB-018
11390878|NCT02097082|Experimental|STANZA Drug-eluting Resorbable Scaffold|Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold
11390879|NCT02097069|Other|Subgroup A|folic acid 400 mcg/day
11390880|NCT02097069|Experimental|Subgroup B|myo-inositol 2000 mg twice a day
11390881|NCT02097069|Experimental|Subgroup C|D-chiro-inositol 250 mg twice a day
11390882|NCT02097069|Experimental|Subgroup D|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
11390883|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
11390884|NCT02097043|Experimental|[Group 1] DA-7218|200mg, By mouth or orally (PO) & intravenous(IV) administration
11390885|NCT02097043|Placebo Comparator|[Group 1] Placebo|Placebo, By mouth or orally (PO) & intravenous(IV) administration
11390886|NCT02097043|Experimental|[Group 2] DA-7218|400mg, By mouth or orally (PO) administration
11390887|NCT02097043|Placebo Comparator|[Group 2] Placebo|Placebo, By mouth or orally (PO) administration
11390888|NCT02097043|Experimental|[Group 3] DA-7218|600mg, By mouth or orally (PO) administration
11390889|NCT02097043|Placebo Comparator|[Group 3] Placebo|Placebo, By mouth or orally (PO) administration
11390890|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
11390936|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
11390891|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
11390892|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
11390893|NCT02097017|Active Comparator|lidocaine spray group|
11390894|NCT02097017|Placebo Comparator|placebo arm|
11390895|NCT02097004|Experimental|Concomitant:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks
~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
11390896|NCT02097004|Experimental|Sequential:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks
~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks
~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
11390897|NCT02097004|Active Comparator|Control Group|"Continue Entecavir(0.5mg) for 100 weeks(once daily)
~After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks"
11390898|NCT02096991|Active Comparator|Glass|consume beverage in glass first and cross over to other interventions
11390899|NCT02096991|Experimental|Can 1|consume one canned beverage and a glass bottled beverage first and cross over to other interventions
11390900|NCT02096991|Experimental|Can 2|Consume two canned beverage first and cross over to other interventions
11390901|NCT02096978|Experimental|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
11390902|NCT02096978|Active Comparator|Drill preparation|Preparing the osteotomy to accept a standard implant device
11390903|NCT02096965|Experimental|Tolvaptan first, then Placebo|Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)
11390904|NCT02096965|Experimental|Placebo first, then Tolvaptan|Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)
11390905|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
11390906|NCT02096939||Primary aldosteronism|Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists
11390907|NCT02096939||Essential hypertension|Patients with essential hypertension who will be started on antihypertensive medication
11390908|NCT02096926|Placebo Comparator|Placebo|placebo
11390909|NCT02096926|Active Comparator|Ibuprofen|400 mg PO
11390910|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 4 weeks|
11390911|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 12 weeks|
11390912|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
11390913|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
11390914|NCT02096887|Other|Patient Education|Patient Education
11390915|NCT02096874|Other|Bevacizumab|Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.
11390916|NCT02096861|Experimental|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
11390917|NCT02096861|Active Comparator|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
11390918|NCT02096861|Active Comparator|Remicade - Remicade|Remicade followed by Remicade from Week 30
11390919|NCT02096861|Experimental|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
11390920|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
11390921|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
11390922|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
11390923|NCT02096822|Active Comparator|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
11390924|NCT02096822|Experimental|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
11390925|NCT02096809|Experimental|One week loading of Bone Anchored Hearing Aid (BAHA)|Bone Anchored Hearing Aid (BAHA) loading after one week
11390926|NCT02096796||persons without arm pump|
11390927|NCT02096796||persons with arm pump|
11390928|NCT02096783|Active Comparator|Arm I (standard counseling)|Patients receive standard counseling at both the pre-operative and 2-4 week post-operative visit.
11390929|NCT02096783|Experimental|Arm II (standard counseling, scripted intervention)|Patients receive standard counseling at the pre-operative visit and the scripted sexual health intervention at the 2-4 week post-operative visit.
11390930|NCT02096783|Experimental|Arm III (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at the pre-operative visit and standard counseling at the 2-4 week post-operative visit.
11390931|NCT02096783|Experimental|Arm IV (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at both the pre-operative and 2-4 week post-operative visit.
11390932|NCT02096757|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
11390933|NCT02096757|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
11390934|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
11390935|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
11390942|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
11390943|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
11390944|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
11390945|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
11390946|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
11390947|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
11390948|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
11390949|NCT02096666|Experimental|Single arm|
11390950|NCT02096653|Experimental|X-ray guided intra-articular injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
11390951|NCT02096653|Active Comparator|Landmark-guided SI joint injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
11390952|NCT02096640|Active Comparator|Percutaneous dilatation tracheostomy: Smiths Medical|Type of surgical teqnique for tracheostomy: Percutaneous dilatation tracheostomy. The set for the tracheostomy is bought from Smiths Medical TM.
11390953|NCT02096640|Active Comparator|Open surgery tracheostomy|Type of surgical teqnique for tracheostomy: Open surgical tracheostomy
11390954|NCT02096627||conventional|Patients who undergo routine cataract surgery using conventional phacoemulsification technique
11390955|NCT02096627||FLACS|Patients who undergo femtosecond laser assisted cataract surgery
11390956|NCT02096614|Experimental|Low dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
11390957|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
11390958|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 2|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
11390959|NCT02096614|Experimental|TBI-1201 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
11390960|NCT02096601|Experimental|ND0612|Levodopa and carbidopa SC solution
11390961|NCT02096601|Active Comparator|Oral levodopa and carbidopa|Oral levodopa and carbidopa
11390962|NCT02096588|Experimental|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
11390963|NCT02096588|Active Comparator|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
11390964|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.
~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
11390965|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.
~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
11390966|NCT02096562|Placebo Comparator|B - No compression stockings|normal therapy - no compression stockings
11390967|NCT02096562|Active Comparator|A - Use of compression stockings|Patients use compression stockings for 10 days after surgery
11390968|NCT02096536|Other|Vancomycin|All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.
11390969|NCT02096523|Experimental|platelet disease|patients with inherited platelet disorders
11390970|NCT02096523|Experimental|Healthy|Healthy family members of patients with inherited platelet disorders
11390971|NCT02096510|Experimental|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
11390972|NCT02096510|Active Comparator|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
11390973|NCT02096510|Experimental|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
11390974|NCT02096497||Vascular pattern 1|
11390975|NCT02096497||Vascular pattern 2|
11390976|NCT02096497||Vascular pattern 3|
11390977|NCT02096497||Vascular pattern 4|
11390978|NCT02096497||Vascular pattern 5|
11390979|NCT02096497||Vascular pattern 6|
11390980|NCT02096497||Vascular pattern 7|
11390981|NCT02096497||Vascular pattern 8|
11390982|NCT02096497||Vascular pattern 9|
11390983|NCT02096497||Vascular pattern 10|
11390984|NCT02096497||Vascular pattern 11|
11390985|NCT02096484|Experimental|Metacognitive Therapy|Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
11390986|NCT02096484|Experimental|Mindfulness Meditation Therapy|Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
11391113|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
11390987|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
11390988|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
11390989|NCT02096445|Experimental|Robot group|"Receive robot-assisted neurocognitive therapy instead of conventional neurocognitive therapy.
~(4 x 45 min/week)"
11390990|NCT02096445|Active Comparator|Control group|Receive dose-matched conventional neurocognitive therapy
11390991|NCT02096432|Experimental|Behavioral: Behavioral Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
11390992|NCT02096432|Other|Usual Community Care|Community standard care as usual
11390993|NCT02096419|No Intervention|control group|Patients in this group will receive standard clopidogrel dose
11390994|NCT02096419|Experimental|interventional group|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).
~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.
~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
11390995|NCT02096406|Other|ACE/ARB Continuation|ACE/ARB will be continued up to and including the morning of surgery.
11390996|NCT02096406|Other|ACE/ARB withdrawal|ACE/ARB will be discontinued medication 48 hours prior to surgery
11390997|NCT02096393|Experimental|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
11390998|NCT02096393|Active Comparator|Standard instrumentation|The patient will undergo surgery using standard instrumentation
11390999|NCT02096380||one cycle induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil
~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
~Other Names:
~docetaxel, cisplatin and fluorouracil"
11391000|NCT02096380||three cycles induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil
~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
~Other Names:
~docetaxel, cisplatin and fluorouracil"
11391001|NCT02096367|Experimental|Hemiplegia after vascular stroke|"Muscle vibration stimulation
~Gait analysis with Gait Rite : quantitative and spatio-temporal gait parameters
~Kinematic gait analysis in lower limb measured by optoelectronic system (Optitrack).
~Analysis of static posture on force platform
~Evaluation of the gait on treadmill during 2 minutes"
11391002|NCT02096354|Experimental|RRx-001 followed by irinotecan|Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
11391003|NCT02096354|Active Comparator|Regorafenib followed by irinotecan|Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
11391004|NCT02096341|Experimental|RRx-001|RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses-16 and 27 mg/m2- will be tested.
11391005|NCT02096328|Experimental|POL7080, Anti-pseudomonal antibiotics|POL7080 daily co-administered with standard of care treatment
11391006|NCT02096315|Experimental|POL7080|POL7080 administered daily
11391007|NCT02096302|Experimental|Experimental Formula|Infant formula with a novel probiotic CECT7210
11391008|NCT02096302|Active Comparator|Standard Formula|Standard infant formula without probiotics
11391009|NCT02096289|Experimental|Thioridazine|Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study).
11391010|NCT02096276||Exposed cohort|A group of subjects who voluntarily report vaccine-exposed pregnancies to the registry.
11391011|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
11391012|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
11391114|NCT02095548|Experimental|SM04690, 0.03mg/2mL|Single, intra-articular injection of SM04690, 0.03mg/2mL
11391013|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
11391014|NCT02096250|Experimental|NaFeEDTA|NaFeEDTA
11391015|NCT02096250|Experimental|Ferrous fumarate|Ferrous fumarate
11391016|NCT02096250|Experimental|NaFeEDTA + ferrous fumarate|NaFeEDTA + ferrous fumarate
11391017|NCT02096237|Experimental|apheresis, IgE adsorber|9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
11391018|NCT02096237|No Intervention|Conventional drug treatment|Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
11391019|NCT02096224|Experimental|Sevoflurane|Sevoflurane will be administered as the maintenance agent of general anesthesia.
11391020|NCT02096224|Active Comparator|Desflurane|Desflurane will be administered as the maintenance agent of general anesthesia.
11391021|NCT02096211||CERAMAX COC 36mm Acetabular Cup|The CERAMAX 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic.The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
11391022|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
11391023|NCT02096185|Experimental|3 dimensional tomosynthesis imaging|Breast specimen to be x-rayed using both conditions 3 dimensional tomosynthesis imaging 2 dimensional conventional digital imaging
11391024|NCT02096185|Experimental|2 dimensional digital imaging|Breast specimens to be x-rayed under both conditions 3 dimensional tomosynthesis imaging 2 dimensional digital imaging
11391025|NCT02096159|Experimental|Antibiotics|trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days
11391026|NCT02096159|Placebo Comparator|Placebo|placebo oral suspension, 0.5 mL/kg twice daily for 10 days
11391027|NCT02096146|Other|TMT Fusion Plate|Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
11391028|NCT02096146|Other|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .
11391029|NCT02096133|Experimental|Cholecalciferol|Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
11391030|NCT02096133|Placebo Comparator|Placebo comparator|placebo drops during 16 weeks
11391031|NCT02096120||All patients|
11391032|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
11391033|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
11391034|NCT02096094|Experimental|Chlorhexidine bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes impregnated with 2% chlorhexidine and with shampoo with 0.15% chlorhexidine.
11391035|NCT02096094|Placebo Comparator|Control bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes and shampoo without chlorhexidine.
11391036|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
11391037|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
11391038|NCT02096068|Experimental|Study group|"Application of Dexmedetomidine (Dexdor®) perioperatively for a maximum of 48 hours
~Dosing Scheme:
~during operation and mechanical ventilation: 0,7μg/kgABW/h; recovery time until extubation: 0,4μg/kgABW/h; after extubation: 0,2-1,4μg/kgABW/h"
11391039|NCT02096068|Placebo Comparator|Control group|Application of placebo for a maximum of 48 hours
11391040|NCT02096068|No Intervention|POCD control group|A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
11391041|NCT02096055|Experimental|Arm I (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine as in Induction therapy. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
11391042|NCT02096055|Experimental|Arm II (CLOSED) (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-10. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 (days 1-10 of courses 1 and 2). Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
11391043|NCT02096055|Experimental|Arm III (guadecitabine, idarubicin)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on days 1-2. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on day 1. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
11391115|NCT02095548|Experimental|SM04690, 0.07mg/2mL|Single, intra-articular injection of SM04690, 0.07mg/2mL
11391116|NCT02095548|Experimental|SM04690, 0.23mg/2mL|Single, intra-articular injection of SM04690, 0.23mg/2mL
11391117|NCT02095548|Placebo Comparator|Placebo|Single, intra-articular injection of placebo
11391044|NCT02096055|Experimental|Arm IV (CLOSED) (guadecitabine, cladribine)|"INDUCTION THERPAY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.
~MAINTENANCE THERAPY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
11391045|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
11391046|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
11391047|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
11391048|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
11391049|NCT02096016||Human Papilloma Virus test|"Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.
~It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study"
11391050|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
11391051|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
11391052|NCT02095990|Experimental|Hydroquinone|"Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.
~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.
~It will be applied daily, at night, during 8 weeks."
11391053|NCT02095990|Placebo Comparator|Placebo|"Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.
~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.
~It will be applied daily, at night, during 8 weeks."
11391054|NCT02095977|Other|participants|all subjects meeting inclusion and none of exclusion criteria
11391055|NCT02095964||Cardiac Syndrome X|
11391056|NCT02095964||Control Group|
11391057|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
11391058|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
11391059|NCT02095938|Experimental|Solian|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
11391060|NCT02095925||cancer patients|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
11391061|NCT02095899|Experimental|Rufinamide|- oral Rufinamide administration as ad-on to Oxycodone
11391062|NCT02095899|Placebo Comparator|Manitol|- oral Placebo administration - as ad-on to Oxycodone
11391063|NCT02095886|Experimental|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
11391064|NCT02095886|Experimental|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
11391065|NCT02095886|Experimental|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
11391066|NCT02095886|Experimental|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
11391067|NCT02095886|Experimental|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
11391068|NCT02095886|Experimental|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
11391069|NCT02095886|Experimental|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
11391070|NCT02095886|Experimental|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
11391071|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
11391072|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
11391073|NCT02095860|Experimental|Treatment A: DCV 3DAA FDC fasted state|DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state
11391074|NCT02095860|Experimental|Treatment B: DCV 3DAA FDC with high-fat meal|DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal
11391075|NCT02095860|Experimental|Treatment C: DCV 3DAA FDC with light meal|DCV 3DAA FDC tablet by mouth once on specified days with light meal
11391118|NCT02095535||Study group|All study participants
11391119|NCT02095522|Experimental|Colchicine|Colchicine 1mg per day for one month
11391120|NCT02095522|Placebo Comparator|Placebo|Placebo 1mg per day
11391076|NCT02095847|Experimental|Hysteroscope Imaging|All patients entered in study will undergo cervical dilation after induction of general anesthesia. Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the High-Resolution Microendoscopy (HRME) camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera. The resectoscope will then be used to remove all tumor as guided through HRME images. The entire imaging and tumor resection process is estimated to take 45 minutes or less.
11391077|NCT02095834|Experimental|Treatment (dexamethasone, bendamustine, carfilzomib)|Patients receive dexamethasone PO or IV over 20 minutes on days 1, 2, 8, 9, 15, 16, 22, and 23 of courses 1-3; on days 1, 2, 15, and 16 of courses 4-12; and on days 1 and 2 of all subsequent courses. Patients also receive bendamustine hydrochloride IV over 10 minutes on days 1 and 2 of courses 1-3 and on day 1 of all subsequent courses and carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of courses 1-12 and on days 1, 2, 15, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11391078|NCT02095821||Humoral rejection, TPE|
11391079|NCT02095808|Experimental|Surgery|"The 13C-glucose solution will be given intravenously. It will be started at about the same time as the start of surgery, according to the study guidelines.
~The 13C-glucose IV solution will be stopped once the surgeon has removed the tumor tissue."
11391080|NCT02095795|Experimental|Technological Rehabilitation|Patients in the experimental group received a multimodal treatment intervention consisting of 60 minutes of conventional treatment according to the Bobath approach (Bobath B. Adult hemiplegia: evaluation and treatment. Oxford: Butterworth-Heineman, 1990) followed by 30 minutes of robotic gait training on the Lokomat robotic system with the supervision of an expert rehabilitator. Patients started the first session with 50% weight unload and 1.5 Km/h gait speed, performances increments are allowed only in the following sessions. Each patient received 20 sessions over a period of 4 weeks (5 sessions per week).
11391081|NCT02095795|Active Comparator|Control Rehabilitation|Patients in the control group received the same number of treatment sessions of a similar duration as those in the experimental group but they received activities of overground walking exercises targeted to improve walking in substitution of the robotic gait trainer.
11391082|NCT02095782|Experimental|chemotherapy and erlotinib|Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation
11391083|NCT02095756|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of melasma
11391084|NCT02095743|Experimental|PICC line|Use of a PICC line for chemo administration (PowerPICC SOLO²)
11391085|NCT02095743|Active Comparator|Implanted Port|Use of an implanted port for chemo administration
11391086|NCT02095730|Active Comparator|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
11391087|NCT02095730|Active Comparator|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
11391088|NCT02095730|Active Comparator|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
11391089|NCT02095730|Active Comparator|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
11391090|NCT02095717|Experimental|Curcumin|curcumine capsule
11391091|NCT02095717|Placebo Comparator|Placebo|placebo capsule
11391092|NCT02095704|Experimental|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
11391093|NCT02095704|Experimental|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
11391094|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
11391095|NCT02095678|Experimental|HCC or metastatic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
11391096|NCT02095678|Active Comparator|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
11391097|NCT02095665|Active Comparator|Narcotic analegesic only|"Drug:
~Tylenol #3 1 tablet every six hours as necessary"
11391098|NCT02095665|Active Comparator|Mirabegron and narcotic analgesia|"Drug :
~Mirabegron 50 mg oral daily
~Drug:
~Tylenol #3 1 tablet every six hours as necessary"
11391099|NCT02095665|Active Comparator|Tamsulosin and narcotic analgesia|"Drug:
~Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary"
11391100|NCT02095665|Experimental|Mirabegron, Tamsulosin and narcotic|"Drug:
~Mirabegron 50 mg oral daily
~Drug:
~Tamsulosin 0.4mg oral daily
~Drug:
~Tylenol #3 1 tablet every six hours as necessary"
11391101|NCT02095639||ECT and Treatment Resistant Depression|Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two [18F]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.
11391102|NCT02095626|Experimental|AP301|Treatment group
11391103|NCT02095626|Placebo Comparator|Saline solution|
11391104|NCT02095613|Active Comparator|Corn-soy-blend plus|food A type of ground meal called corn-soy-blend plus
11391105|NCT02095613|Active Comparator|Ready-to-use-supplementary food|food A nutrient dense food comprised of peanuts, oil, multivitamins.
11391106|NCT02095600|Experimental|Radiosurgical thalamotomy|
11391107|NCT02095587|Experimental|Mild Hepatic Impairment|
11391108|NCT02095587|Experimental|Moderate Hepatic Impairment|
11391109|NCT02095587|Experimental|Healthy Subjects|
11391110|NCT02095587|Experimental|Severe Hepatic Impairment|Optional arm based on results from Arms 1, 2, and 3
11391111|NCT02095574|Experimental|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
11391121|NCT02095509|Active Comparator|Subcutaneous Enoxaparin|Subcutaneous enoxaparin 40 mg every 24 hours for three days
11391122|NCT02095509|Active Comparator|Intravenous Enoxaparin|40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)
11391123|NCT02095496|Experimental|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
11391124|NCT02095496|Active Comparator|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
11391125|NCT02095470|Experimental|videolaryngoscope group|video laryngoscopy was done for them
11391126|NCT02095470|Placebo Comparator|traditional laryngoscope|comparison to active group with routine laryngoscope
11391127|NCT02095457|Active Comparator|Frequent Monitoring and Feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
11391128|NCT02095457|Sham Comparator|Infrequent monitoring without feedback|In the control arm, patients will infrequently fill short monitoring questionnaires, the results of which are not fed back to their therapists and staff. The frequency of monitoring is between about once a year
11391129|NCT02095444|Experimental|Menstrual blood stem cells|1x10*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.
11391130|NCT02095431||with AKI and without AKI|development of AKI by sCr and by novel biomarkers
11391131|NCT02095418|Experimental|Mycophenolate mofetil, Corticosteroids|"Mycophenolate mofetil: 500-1500mg/day, bid, PO
~Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
11391132|NCT02095418|Active Comparator|Corticosteroids, Mycophenolate mofetil|"Mycophenolate mofetil: 500-1000mg/day, bid, PO
~Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
11391133|NCT02095405|Active Comparator|Caffeine arm|"SVT group: Caffeine tablets, 5 mg/kg.
~AF group: Caffeinated substances and Dark Chocolate"
11391134|NCT02095405|Placebo Comparator|Placebo arm|"SVT group: Placebo
~AF group: Decaffeinated substances and White Chocolate"
11391135|NCT02095392|Experimental|P1000/Ca0|
11391136|NCT02095392|Experimental|P1000/Ca500|
11391137|NCT02095392|Experimental|P1000/Ca1000|
11391138|NCT02095392|Placebo Comparator|Placebo|
11391139|NCT02095379||oligosecretary|Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
11391140|NCT02095366|Experimental|IN Sufentanil AND IV Placebo|Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
11391141|NCT02095366|Active Comparator|IV Morphine AND IN Placebo|Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray
11391142|NCT02095340|Experimental|Positive Training|
11391143|NCT02095340|Sham Comparator|Neutral Training|
11391144|NCT02095314|Experimental|Pentavalen|Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly
11391145|NCT02095301|Experimental|Control plus herbal extract|Control plus herbal extract
11391146|NCT02095301|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
11391147|NCT02095288||Healthy volunteers|Blood draw
11391148|NCT02095275||Acute kidney injury|ICU patients with Acute kidney injury
11391149|NCT02095262|Active Comparator|STAR2|Reactive auditory training
11391150|NCT02095262|Experimental|Treasure Hunter|Interactive auditory training
11391151|NCT02095262|Experimental|Submarine|Interactive auditory training
11391152|NCT02095249|Other|Pimonidazole|
11391153|NCT02095236|Experimental|experimental|Radioopaque fiducial markers or electro-magnetic transponders will be implanted into or in close proximity of the tumor. During a radiotherapy treatment session image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors The data will help to characterize tumor and organ motion during one treatment session which may in fact have impact on dose distribution
11391154|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
11391155|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
11391156|NCT02095210|Experimental|[68Ga]ABY-025 PET imaging|Radiolabeled [68Ga]ABY-025
11391157|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
~No Catheter Delivery will be used to deliver the medication."
11391158|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
~Catheter targeted delivery will be used to deliver the medication."
11391159|NCT02095184|Active Comparator|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
11391160|NCT02095184|Active Comparator|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
11391161|NCT02095184|Active Comparator|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
11391162|NCT02095184|Active Comparator|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
11391163|NCT02095184|Active Comparator|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
11391164|NCT02095184|Active Comparator|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
11391165|NCT02095171|Experimental|PRX002|
11391166|NCT02095171|Placebo Comparator|Placebo|
11391167|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
11391168|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
11391169|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
11391170|NCT02095132|Experimental|Treatment (irinotecan hydrochloride, adavosertib)|Patients receive irinotecan hydrochloride PO and adavosertib PO on days 1-5. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
11391171|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
11391172|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
11391173|NCT02095093|Experimental|Intellijoint HIP|Patient's will have their leg length and hip offset determined intraoperatively using Intellijoint HIP.
11391174|NCT02095093|Active Comparator|Outrigger|Control patients will have their leg length and hip offset determined intra-operatively using the standard at Mount Sinai Hospital, which is a pin and outrigger system.
11391175|NCT02095080|Experimental|Leucine intake|Dietary supplement: Leucine intake
11391176|NCT02095067|Experimental|Video consultation|Patients in this arm receive video consultation from physician at the emergency medical dispatch center
11391177|NCT02095067|No Intervention|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician at the emergency medical dispatch center.
11391178|NCT02095054|Experimental|Regorafenib + Cetuximab|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle. Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.
~Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle. Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.
~Symptom questionnaire completed at each study visit."
11391179|NCT02095041||Healthy Term infants|
11391180|NCT02095028|Experimental|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
11391181|NCT02095028|No Intervention|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
11391182|NCT02095015||Analysis population|All subjects enrolled in the study who meet the eligibility criteria
11391183|NCT02094989||diagnostic|
11391184|NCT02094976|Active Comparator|Group C|Group C means active comparator group which use chest rolls intraoperatively for prone position.
11391185|NCT02094976|Active Comparator|Group W|Group W means experimental group which use Wilson frame intraoperatively for prone position.
11391186|NCT02094976|Experimental|Group J|Group J means experimental group which use Jackson surgical table intraoperatively for prone position.
11391187|NCT02094963|Experimental|Ticagrelor|
11391188|NCT02094963|Active Comparator|Clopidogrel|
11391189|NCT02094950|Experimental|Lung Cancer Patient with Dyspnea|
11391190|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
11391191|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
11391192|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
11391193|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
11391194|NCT02094924|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1 and treatment B in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
11391195|NCT02094924|Experimental|Sequence 2|Participants in this arm will receive treatment B in period 1 and treatment A in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
11391196|NCT02094911|Experimental|Combined lifestyle intervention|Lifestyle counselling (nutrition and physical activity) by dietician and physiotherapist during 10-month intervention period
11391197|NCT02094911|Other|Usual care group|Subjects receive brochures on healthy lifestyle at baseline, and during the 10-month intervention period only usual care as provided by their own general practitioner.
11391232|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
11391233|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
11391234|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
11391398|NCT02093481|Experimental|- ind. CHO + prim|Reference:ate no intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
11391198|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
11391199|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
11391200|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
11391201|NCT02094872|Experimental|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
11391202|NCT02094859||GlucoClear System|
11391203|NCT02094846|Active Comparator|Voice messages|This group receive voice messages to reinforce given information about diet, physical activity, glycemic index
11391204|NCT02094846|Placebo Comparator|Messages|This group received voice messages with fun facts.
11391205|NCT02094833|Experimental|Group A|Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age
11391206|NCT02094833|Active Comparator|Group B|Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim™) at age 2, 4, and 6 months
11391207|NCT02094820||Single Group Study|Questionnaires
11391208|NCT02094807|Other|Conservative management|Not operated. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
11391209|NCT02094807|Active Comparator|Operative management|Operative fixation of rib fractures. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
11391210|NCT02094794|Experimental|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
11391211|NCT02094781|Experimental|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
11391212|NCT02094781|Active Comparator|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
11391213|NCT02094781|Placebo Comparator|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
11391214|NCT02094768|Experimental|Reduced Fat Milk|20 oz. reduced fat (2%) milk per day
11391215|NCT02094768|Experimental|Sugar Sweetened Soda|24oz. soda per day
11391216|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
11391217|NCT02094742|Other|all-commers|All patients will undergo a biopsy of their metastatic lesion and have a blood sample taken for molecular screening purposes. No drugs are administered or other interventions are performed.
11391218|NCT02094729|Experimental|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
11391219|NCT02094729|Experimental|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
11391220|NCT02094729|Experimental|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
11391221|NCT02094729|Placebo Comparator|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
11391222|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
11391223|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
11391224|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
11391225|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
11391226|NCT02094703|Experimental|levofloxacin and solifenacin succinate|Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days
11391227|NCT02094703|Active Comparator|levofloxacin and placebo|Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days
11391228|NCT02094690|Active Comparator|Device Hyperboloid|"5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy (RT) and kept until the end of RT.
~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
11391229|NCT02094690|Active Comparator|Device Therabite|"10 repetitions holding the device Therabite for 30 seconds
~5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT.
~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
11391230|NCT02094690|No Intervention|Control|The control group (GEC) will not receive any of the protocols tested in the study, but together with the other groups, will receive the regular treatment offered by the institution, which is made up of guidance and advice given by the hospital´s nursing team about the radiotherapy treatment. Currently, patients do not receive any information as far as trismus is concerned.
11391231|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
11391235|NCT02094651|Experimental|divalproex sodium|divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks
11391236|NCT02094651|Placebo Comparator|Placebo|Blue and white capsules with equivalent amount of lactose spheres/beads inside Placebo will be formulated to look identical to the active medication
11391237|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
11391238|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.
~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
11391239|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
11391240|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
11391241|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
11391242|NCT02094599|Experimental|All Enrolled Participants|Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
11391243|NCT02094586|Experimental|PXVX0200|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x108 CFU in a liquid suspension
11391244|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
11391245|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each cycle of 28 days until disease progression or intolerable toxicity.
11391246|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days until disease progression or intolerable toxicity.
11391247|NCT02094560|Experimental|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
11391248|NCT02094560|Experimental|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
11391249|NCT02094560|Experimental|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
11391250|NCT02094547|Experimental|New infant formula|New infant formula with key ingredients.
11391251|NCT02094547|Active Comparator|Standard infant formula|Standard infant formula
11391252|NCT02094547|Other|Breastfeeding|Control
11391253|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
11391254|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
11391255|NCT02094521|Experimental|NNC0113-0987|
11391256|NCT02094495||breast cancer group|Taking tamoxifen
11391257|NCT02094482|Other|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
11391258|NCT02094469|Other|Cilostazol|Cilostazol 50mg and 100mg
11391259|NCT02094456|Experimental|Endoscopic clipping of diverticula|Endoscopic clipping of diverticula Follow-up colonoscopy
11391260|NCT02094443|Experimental|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
11391261|NCT02094443|Experimental|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
11391262|NCT02094430|Experimental|FGTW|
11391263|NCT02094417|Experimental|AMG531 (Dose 1)|
11391264|NCT02094417|Experimental|AMG531 (Dose 2)|
11391265|NCT02094417|Experimental|AMG531 (Dose 3)|
11391266|NCT02094417|Experimental|AMG531 (Dose 4)|
11391267|NCT02094404||Children at the ED<18yr|
11391268|NCT02094391|Experimental|Ipilimumab|
11391269|NCT02094391|No Intervention|No Ipilimumab|
11391270|NCT02094378|Experimental|Esketamine-Placebo|Participants assigned to treatment sequence 1 will receive 84 mg esketamine intranasally on Day 1 of Period 1 and then receive placebo intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
11391271|NCT02094378|Placebo Comparator|Placebo-Esketamine|Participants assigned to treatment sequence 2 will receive placebo intranasally on Day 1 of Period 1 and then receive 84 mg esketamine intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
11391272|NCT02094365|Experimental|ALS-008176|ALS-008176 drug substance for oral suspension
11391273|NCT02094365|Placebo Comparator|vehicle alone|Vehicle alone
11391274|NCT02094352|Experimental|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.
~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
11391275|NCT02094352|Placebo Comparator|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.
~Outpatient: Patients will receive three saline booster infusions over the course of three months."
11391441|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
11391276|NCT02094339|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
11391277|NCT02094339|Active Comparator|Nerve Block|People in this group will receive a postoperative pain management by continuous lumbar plexus block with 0.2% ropivacaine.
11391278|NCT02094339|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
11391279|NCT02094313|Experimental|atovastatin|
11391280|NCT02094300|Experimental|Endovascular|
11391281|NCT02094287|Experimental|verum, instruction, conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.
11391282|NCT02094287|Experimental|verum, instruction, no conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied
11391283|NCT02094287|Experimental|placebo, instruction, conditioning|This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.
11391284|NCT02094287|Experimental|verum, no instruction, no conditioning|Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.
11391285|NCT02094274|Experimental|LAS40468|Single dose, administered via Genuair® dry powder inhaler (DPI)
11391286|NCT02094274|Active Comparator|Salmeterol/fluticasone propionate|Single dose, Seretide® (salmeterol fluticasone propionate) administered via Accuhaler™
11391287|NCT02094274|Placebo Comparator|Placebo|Single dose administered via Genuair® or Accuhaler™ dry powder inhaler (DPI)
11391288|NCT02094261|Experimental|AZD9291|Once daily tablet 80 mg
11391289|NCT02094248|Experimental|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
11391290|NCT02094248|Placebo Comparator|control|Normal saline，1ml/day, s.c injection
11391291|NCT02094235|Experimental|1|E6005 0.2% ointment applied twice a day to eczema areas
11391292|NCT02094235|Experimental|2|E6005 0.05% ointment applied twice a day to eczema areas
11391293|NCT02094235|Placebo Comparator|3|Placebo ointment applied twice a day to eczema areas
11391294|NCT02094196||Controls, highrisk for AD|Community-based ad-hoc participants, high risk for alcohol dependence, matched to inpatients by sociodemographics
11391295|NCT02094196||Controls, low risk for AD|Community-based ad-hoc participants, low risk for alcohol dependence, matched to inpatients by sociodemographics
11391296|NCT02094196||Alcohol detoxification|Inpatients with alcohol dependence from local psychiatric hospital wards (18-65 years old)
11391297|NCT02094183|Experimental|GLP-1|GLP-1 and low calorie diet
11391298|NCT02094183|Experimental|Control|low calorie diet
11391299|NCT02094157|Active Comparator|Bridged regimen|Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
11391300|NCT02094157|Experimental|Tapered warfarin regimen|Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.
11391301|NCT02094144|Other|exercise group (brisk walking program)|The intervention is named brisk walking program. It consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
11391302|NCT02094144|Other|control group (physical activity habits)|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
11391303|NCT02094131|Experimental|Cliniflo group (CG)|Training using flow-oriented incentive spirometry Cliniflo
11391304|NCT02094131|Experimental|Voldyne group (VG)|Training using volume-oriented incentive spirometry Voldyne
11391305|NCT02094131|No Intervention|Control group (CONG)|No intervention. Assessment and reassessment after 5 weeks.
11391306|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
11391307|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
11391308|NCT02094105|Experimental|screening|endoscopy examination with iodine staining
11391309|NCT02094105|No Intervention|control|1/10 sampling questionnaire interview for control group.
11391310|NCT02094092|Placebo Comparator|ProTectis drops|Arm A.
11391311|NCT02094092|Placebo Comparator|Placebo drops|Arm B
11391312|NCT02094079||L-T4 treated hypothyroid pregnant women|L-T4 treated pregnant women
11391313|NCT02094066|Active Comparator|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
11391314|NCT02094066|Sham Comparator|serum physiologic|preoperative 100 cc serum physiologic
11391315|NCT02094053|Experimental|E2020 3 mg|3 mg of E2020 (oral) once daily, for 24 weeks
11391316|NCT02094053|Experimental|E2020 5 mg|5 mg of E2020 (oral) once daily, for 24 weeks
11391317|NCT02094053|Placebo Comparator|Placebo|placebo (oral) once daily, for 24 weeks
11391318|NCT02094040|Experimental|Follow-up visit|Receive municipality-based follow-up visit including primary physician.
11391319|NCT02094040|No Intervention|Usual care|Does not receive follow-up visit
11391320|NCT02094027|Experimental|Guided Self Help|Guided Self Help intervention to reduce binge eating
11391321|NCT02094027|Placebo Comparator|Treatment As Usual|No intervention for binge eating (treatment as usual in the form of bariatric surgery)
11391322|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).
~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
11391323|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.
~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
11391324|NCT02094001|Experimental|Riociguat therapy|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
11391325|NCT02093988|Experimental|Topical and Intravenous TXA|
11391326|NCT02093988|Active Comparator|Intravenous TXA only|
11391327|NCT02093975|Experimental|Video consultation|Patients in this arm receive video consultation from physician in doctor manned rapid response vehicle.
11391328|NCT02093975|Active Comparator|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician in rapid response vehicle.
11391329|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
11391330|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
11391331|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
11391332|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
11391333|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
11391334|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
11391335|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
11391336|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
11391337|NCT02093923|Experimental|DX-2930, Dose level 1|30 mg of DX-2930 administered twice, two weeks apart
11391338|NCT02093923|Experimental|DX-2930, Dose level 2|100 mg of DX-2930 administered twice, two weeks apart
11391339|NCT02093923|Experimental|DX-2930, Dose level 3|300 mg of DX-2930 administered twice, two weeks apart
11391340|NCT02093923|Experimental|DX-2930, Dose level 4|400 mg of DX-2930 administered twice, two weeks apart
11391341|NCT02093923|Placebo Comparator|Placebo|Placebo administered twice, two weeks apart
11391342|NCT02093910|Experimental|Monosialotetrahexosylganglioside|each patient in this arm received velcade+dexamethasone (VD) regimen（bortezomib,1.3mg/㎡，subcutaneously injection，d1,8,15,22；dexamethasone,20mg d1-2, 8-9,15-16,22-23）every 4 weeks; and monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.
11391343|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
11391344|NCT02093884|Experimental|Text Messaging Intervention|Patients in the text messaging group will receive educational and motivational text messages.
11391345|NCT02093884|Active Comparator|Standard Referral|Patients in the standard referral arm will receive paper based information about the Family Planning Clinic.
11391346|NCT02093871|Experimental|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
11391347|NCT02093858||olanzapine|15-25mg/day for 24 weeks
11391348|NCT02093845|Active Comparator|SYNERGY|Coronary implantatation of the SYNERGY everolimus-eluting stent
11391349|NCT02093845|Active Comparator|Biomatrix Neoflex|Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent
11391350|NCT02093832||Total hip arthroplasty|
11391351|NCT02093819|Experimental|BI 416970 single rising dose part|single rising dose given as tablet
11391352|NCT02093806||CT of the temporal bone|
11391353|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
11391354|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
11391355|NCT02093780|Experimental|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
11391356|NCT02093780|Active Comparator|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:
~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
11391357|NCT02093767|Active Comparator|7.5g dose Synergy1|7.5 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 3.75 g each which are consumed at breakfast and dinner
11391358|NCT02093767|Active Comparator|15g Synergy1|15 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 7.5 g each which are consumed at breakfast and dinner
11391359|NCT02093741||ADVATE - 2mL|
11391360|NCT02093728|Experimental|selumetinib; itraconazole; selumetinib + itraconazole|Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule
11391397|NCT02093481|Experimental|+ ind. CHO + prim|Test meal: ate intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
11391361|NCT02093728|Experimental|selumetinib; fluconazole; selumetinib + fluconazole|Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.
11391362|NCT02093715||RSV|Infant with acute bronchiolitis due to RSV
11391363|NCT02093715||Co- Infection|Infant with acute bronchiolitis due to RSV and other respiratory virus
11391364|NCT02093715||Other|Infant with acute bronchiolitis due to non-RSV respiratory virus
11391365|NCT02093715||Unknown|Infant with acute bronchiolitis with negative PCR results for respiratory viruses
11391366|NCT02093715||Control|Healthy infants
11391367|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
11391368|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
11391369|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
11391370|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
11391371|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
11391372|NCT02093676|Experimental|parents counseling|parents counseling guided by the experiment protocol
11391373|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
11391374|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
11391375|NCT02093650|Active Comparator|Black cohosh extract|black cohosh extract 80 mg daily
11391376|NCT02093650|Placebo Comparator|Placebo|Matching placebo
11391377|NCT02093637|Placebo Comparator|Placebo acupuncture|Placebo acupuncture up to 5 acupuncture needles* in each ear (up to 10 needles total) at points identified by point-finder to have no electrical conductance) plus usual operative and post-operative care (narcotic and non-narcotic pain medication).
11391378|NCT02093637|Experimental|Battlefield Acupuncture|Usual operative and post-operative care (narcotic and non-narcotic pain medication) plus Battlefield Acupuncture (up to 5 acupuncture needles* in each ear (up to 10 needles total), identified by a point-finder.
11391379|NCT02093637|No Intervention|standard therapy|standard therapy
11391380|NCT02093611|Placebo Comparator|Placebo|This arm will serve as the placebo supplementation.
11391381|NCT02093611|Active Comparator|ATP|This arm will serve as the treatment intervention, ATP
11391382|NCT02093598|Experimental|Temsirolimus|25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses).
11391383|NCT02093585|Experimental|Tenofovir to abacavir|Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
11391384|NCT02093585|Experimental|Abacavir to tenofovir|Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
11391385|NCT02093572|Experimental|Control|Subjects randomized to this group will consume 3 standard meals/day during the 2 week intervention period of the study.
11391386|NCT02093572|Experimental|Breakfast skipping|Subjects randomized to this group will consume 2 meals/day (omit breakfast - with caloric intake equal to consuming 3 meals/day) during the 2 week intervention period of the study.
11391387|NCT02093559|Experimental|Brief Counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
11391388|NCT02093559|No Intervention|Control Group|The control group will have access to brochures and be offered referral to services requested. SFDPH Community Behavioral Health Services (CBHS) provides immediate access to substance abuse treatment in San Francisco, including office- and clinic-based methadone and buprenorphine treatment. Given the pilot nature of this study, the control group will not be a full attention control; we will account for an attention effect due to assessment alone.
11391389|NCT02093546||Ancillary-correlative (Biospecimen collection)|Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28.
11391390|NCT02093533|Experimental|Eculizumab|Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
11391391|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
11391392|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
11391393|NCT02093507|Experimental|parents manipulation|parents manipulation
11391394|NCT02093507|No Intervention|no manipulation|no manipulation
11391395|NCT02093494|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used to collect the blood culture.
11391396|NCT02093494|Active Comparator|Lab standard practice (LSP)|The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.
11391399|NCT02093481|Experimental|+ ind. CHO - prim|Test meal: ate intrinsic indigestible carbohydrates 1 day prior to measurements of variables (no priming)
11391400|NCT02093481|Experimental|- ind. CHO - prim|Reference: ate no indigestible carbohydrates the day prior to measurements of variables (no priming).
11391401|NCT02093468|Placebo Comparator|Saline|Saline administered IV for 12 hours
11391402|NCT02093468|Experimental|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
11391403|NCT02093468|Experimental|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
11391404|NCT02093455|Active Comparator|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
11391405|NCT02093455|Placebo Comparator|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
11391406|NCT02093442|Experimental|Endometrial injury|Women allocated to this group will be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
11391407|NCT02093442|No Intervention|Control|Women allocated to this group will NOT be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
11391408|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
11391409|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
11391410|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
11391411|NCT02093416||Group 1: Control Group|BMI <30 There are 20 controls in this group
11391412|NCT02093416||Group 2|BMI 30-35 There were 12 controls in this class
11391413|NCT02093416||Group 3|BMI 35-40 There were 9 controls in this clas
11391414|NCT02093416||Group 4|BMI >40 There were 9 controls in this class
11391415|NCT02093403|Experimental|Treatment (decitabine and selinexor)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity."
11391416|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
11391417|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
11391418|NCT02093377|No Intervention|Control|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone
11391419|NCT02093377|Active Comparator|Adaptive servo-ventilation|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.
11391420|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
11391421|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
11391422|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
11391423|NCT02093338|Experimental|fermentum 3x|Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day
11391424|NCT02093338|Experimental|fermentum 6x|Lactobacillus fermentum CECT5716 at 6x10e9cfu/day
11391425|NCT02093338|Experimental|fermentum 9x|Lactobacillus fermentum CECT5716 at 9x10e9cfu/day
11391426|NCT02093338|Placebo Comparator|maltodextrin|maltodextrin
11391427|NCT02093325|Experimental|eltrombpag|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days.
11391428|NCT02093325|Placebo Comparator|Eltrombopag/placebo|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days
11391429|NCT02093312|No Intervention|Control group|The control group is not offered any home food-delivery service, but continues with their habitual diet
11391430|NCT02093312|Experimental|Intervention group|The intervention group is offered home food-delivery service
11391431|NCT02093299||Stroke|clopidogrel 75 mg
11391432|NCT02093286||Pentabio Vaccine|1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly
11391433|NCT02093273|Active Comparator|tOPV commercial batch (Bio Farma)|tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)
11391434|NCT02093273|Experimental|tOPV pilot batch|tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)
11391435|NCT02093260|Experimental|Vaccine|"Vaccine
~Flubio (Influenza HA) vaccine
~2 doses for infants and children (6 months - 8 years old)
~1 doses for children (9-11 years old)
~The vaccine will be given intramuscularly"
11391436|NCT02093234|Active Comparator|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
11391437|NCT02093234|Active Comparator|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
11391438|NCT02093234|Experimental|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
11391439|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
11391440|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
11391442|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
11391443|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
11391444|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
11391445|NCT02093195|Experimental|Bosentan|Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.
11391446|NCT02093195|Active Comparator|Control|Inhaled Symbicort turbuhaler, 320/9μg, bid.
11391447|NCT02093169|Experimental|Part A: Lu AF35700|
11391448|NCT02093169|Experimental|Part B: Lu AF35700|
11391449|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
11391450|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
11391451|NCT02093143|Experimental|Remifentanil|"The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group.
~The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient.
~Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe."
11391452|NCT02093143|Placebo Comparator|Placebo|"The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group.
~The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil."
11391453|NCT02093130|Experimental|Pomegranate Juice|Eight ounces of 100% Pomegranate Juice daily
11391454|NCT02093130|Placebo Comparator|Placebo|Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.
11391455|NCT02093117|Experimental|Recruitment maneuver|The recruitment maneuver will involve application of continuous positive airway pressure of 30 cm of water for 30 seconds.
11391456|NCT02093117|Sham Comparator|Sham recruitment maneuver|The sham recruitment maneuver will involve application of continuous positive airway pressure of 5 cm of water for 30 seconds.
11391457|NCT02093091|Sham Comparator|Vitremer|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer (n = 30). The right molars was always filled by Vitremer. A split-mouth design was used in the present clinical trial. Twenty nine children were involved in the present study and every one had one bilateral identical pair of carious molars except one child that had two identical pairs. This design was performed to enhance the accuracy of the present study.
11391458|NCT02093091|Active Comparator|Ketac Nano|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano (n=30). The left molars was always restored with Ketac Nano filling material.
11391459|NCT02093078||CARD|"Intervention: CARD
~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
11391460|NCT02093078||Control Arm|
11391461|NCT02093052|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up - 10 session intervention to enhance nurturance and following the lead
11391462|NCT02093052|Active Comparator|Developmental Education for Families|Developmental Education for Families - 10 session intervention that targets cognitive development
11391463|NCT02093052|No Intervention|Low-risk|Low-risk comparison group
11391464|NCT02093039|Experimental|Decision aid group|Women allocated to the decision aid group received an invitation to participate in the national breast cancer screening program and the specially-designed decision aid (a leaflet), by mail.
11391465|NCT02093039|No Intervention|Control group|Women in the control group received an invitation and the usual standard information by mail.
11391466|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
11391467|NCT02093013|Experimental|Integrated care program|
11391468|NCT02093013|No Intervention|Control group|This group kept receiving usual care from their health care professionals.
11391469|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
11391470|NCT02092987|Experimental|NYU Caregiver Intervention|"The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers."
11391519|NCT02092675||COPD patients - non frequent exacerbator|COPD patients with less than 2 exacerbation during one year
11391520|NCT02092675||control group - healthy smokers|healthy smokers, they do not have COPD
11391521|NCT02092662||Stroke|Stroke patients at the subacute phase
11391522|NCT02092662||Healthy controls|healthy age-matched voluntiers
11391471|NCT02092987|Active Comparator|REACH OUT|All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed.
11391472|NCT02092974|Experimental|tDCS + SSRI|
11391473|NCT02092974|Placebo Comparator|tDCS + placebo|
11391474|NCT02092974|Sham Comparator|sham-tDCS + SSRI|
11391475|NCT02092974|Placebo Comparator|sham-DCS + placebo|
11391476|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
11391477|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
11391478|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
11391479|NCT02092948|Experimental|All patients|Patients will receive one intravenous dose of 4 mg, 20mg or 40 mg of A11 minibody labeled with 5 mCi (185 MBq) of 124I, followed by [124I] PSCA-Minibody PET/CT imaging of the whole body.
11391480|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
11391481|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
11391482|NCT02092922|Experimental|Filanesib|
11391483|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
11391484|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 2|Study 2: Cognitive performance test
11391485|NCT02092896|Experimental|Liraglutide + Insulin + Study 2|Study 2: Cognitive performance test
11391486|NCT02092896|Experimental|Liraglutide + Insulin + Study 1|Study 1: Gastric emptying test
11391487|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 1|Study 1: Gastric emptying test
11391488|NCT02092883|Experimental|Infantile Spasms|
11391489|NCT02092870|Experimental|Treatment of Chronic Wound|Patients will receive a single treatment with ASCs in the form of multiple injections of cells within and immediately surrounding the wound. Cells will be delivered using a 1 cc syringe with an appropriate gauge and length needle. Each injection will have a volume less than 250 micro-liters. The number of injections will be determined by the surgeon as a function of total wound volume.
11391490|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
11391491|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
11391492|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
11391493|NCT02092844|Experimental|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
11391494|NCT02092844|Placebo Comparator|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
11391495|NCT02092831|Experimental|Crossover sequence 1|
11391496|NCT02092831|Experimental|Crossover sequence 2|
11391497|NCT02092831|Experimental|Crossover sequence 3|
11391498|NCT02092831|Experimental|Crossover sequence 4|
11391499|NCT02092818||Group 1|Patients who have been prescribed Adempas for a medically appropriate use
11391500|NCT02092805|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce some of subjective sensation of rTMS.
11391501|NCT02092805|Active Comparator|Real rTMS|The active group recieved real-rTMS over the motor cortical area corresponding to the hand of painful side. Each train consist of 2000 pulses at 20 Hz and 80% RMT (total duration 10s). The treatment was repeated every day for 5 consecutive days in week for two weeks (the total number of sessions had be given was 10 sessions).
11391502|NCT02092792|Experimental|Dose-Escalation Phase|
11391503|NCT02092792|Experimental|Dose-expansion cohort|
11391504|NCT02092779||Obese patients, no treatment|
11391505|NCT02092766|Experimental|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
11391506|NCT02092766|Active Comparator|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
11391507|NCT02092753|Placebo Comparator|Standard diet|Standard diet (SD): Nutrition following the standard recommendations of the German society for nutrition
11391508|NCT02092753|Experimental|Ketogenic diet|"Nutritional intervention: Ketogenic diet (KD).
~Intervention: Nutritional support (hospital) + self support (outpatient phase) with KD"
11391509|NCT02092753|Experimental|Logi diet|"Nutritional intervention: low glycämic and insulinemic diet (LOGI)
~Intervention: Nutritional support (hospital) + self support (outpatient phase) with LOGI"
11391510|NCT02092740||Seminoma|Seminoma
11391511|NCT02092740||Non-Seminoma|Non-Seminoma
11391512|NCT02092727|No Intervention|Control|Standard of care arm will receive no specific interventions, but will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
11391513|NCT02092727|Experimental|Behavioral Intervention|A variety of dialysis facility-level, behavioral interventions will be examined.
11391514|NCT02092714||Ancillary-correlative (molecular analysis)|Previously collected tissue samples are analyzed via mutational sequencing and immunohistochemistry.
11391515|NCT02092701|Experimental|cholecalciferol|
11391516|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
11391517|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
11391518|NCT02092675||COPD patients - frequent exacerbator|COPD patients with 2 and more exacerbation in one year
11391523|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
11391524|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
11391525|NCT02092636|Experimental|NIR/US Diagnostic Group|These patients will include women who have breast lumps/lesions visible by ultrasound and are prescribed follow up with an ultrasound-guided biopsy at the UCHC Cancer Center for evaluation and diagnosis of actual/suspected breast abnormalities.
11391526|NCT02092636|Experimental|NIR/US Neoadjuvant Chemotherapy Group|These patients will include women who have breast lumps/lesions visible by ultrasound and have been diagnosed with breast cancers and will undergo neoadjuvant chemotherapy. These patients may be identified from the diagnostic group or after initial diagnosis. Patients will only be enrolled to one of the two groups.
11391527|NCT02092636|Other|NIR/US Process Validation Group|This group will contain data from about five women who did not have ultrasound visible lumps on the day of the planned biopsy. Data from the NIR/US scan will be used to validate instrument measurements.
11391528|NCT02092623|Other|Transvaginal posterior mesh surgery|All study patients undergo transvaginal mesh operation.
11391529|NCT02092610|Active Comparator|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
11391530|NCT02092610|Experimental|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
11391531|NCT02092597|Active Comparator|GLP-1 agonist|Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months
11391532|NCT02092597|Active Comparator|DPP-4 inhibitor|Linagliptin 5 mg tbl qd for 3 months
11391533|NCT02092597|Active Comparator|Sulfonylurea derivate|Gliclazid 30 mg tbl qd for 3 months
11391534|NCT02092584|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
11391535|NCT02092584|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
11391536|NCT02092571|Experimental|Treatment A|1 ring intravaginal for 7 days, produced from the new process
11391537|NCT02092571|Experimental|Treatment B|1 ring intravaginal for 7 days, produced from the legacy process
11391538|NCT02092558||Female 1|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
11391539|NCT02092558||Male 2|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
11391540|NCT02092545|Other|Ketogenic diet|Weight management on a male population of retired NFL athletes.
11391541|NCT02092532|Other|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
11391542|NCT02092519|Active Comparator|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport (NA-220H-8022)
11391543|NCT02092519|Active Comparator|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport (NA-230H-8020)
11391544|NCT02092506|Active Comparator|triple therapy|10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
11391545|NCT02092506|Active Comparator|Concomitant therapy|10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
11391546|NCT02092506|Active Comparator|sequential therapy|10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)
11391547|NCT02092493|No Intervention|Non-ScopeGuide|This arm will have patients undertaking the procedure without ScopeGuide. All outcome measures will be recorded as usual
11391548|NCT02092493|Experimental|ScopeGuide|Patients have their colonoscopy done with ScopeGuide
11391549|NCT02092480|Experimental|Intervention|After baseline data collection, four schools will be randomly assigned to the intervention arm, those receiving the If I Were Jack programme. RSE teachers will deliver the intervention to all participating Year 11 pupils during four weekly lessons of the 'Learning for Life and Work' strand of the Key Stage 4 curriculum.
11391550|NCT02092480|No Intervention|Control|After baseline data collection, three schools will be randomly assigned to the control arm. Participating pupils will not receive the If I Were Jack intervention and will continue with normal RSE practice.
11391551|NCT02092467|Experimental|Treatment Arm 1|
11391552|NCT02092467|Experimental|Treatment Arm 2|
11391553|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
11391554|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
11391555|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
11391556|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
11391557|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
11391558|NCT02092428|Experimental|Image Quality|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to compare image quality between contrast and non-contrast scans.
11391623|NCT02091947|Experimental|experimental group|Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.
11391559|NCT02092428|Experimental|Diagnostic Accuracy|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to assess the diagnostic accuracy of coronary MRI in detecting CAD as compared to conventional x-ray angiography
11391560|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
11391561|NCT02092402|Placebo Comparator|Fecal transplantation of own stool|Autologous fecal transplantation (own stool)
11391562|NCT02092402|Experimental|Fecal transplantation (stool from donor)|Allogeneic fecal transplantation (from donor)
11391563|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
11391564|NCT02092376|Active Comparator|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
11391565|NCT02092376|Placebo Comparator|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
11391566|NCT02092363|Experimental|Drug: OMP-54F28, Paclitaxel and Carboplatin|
11391567|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
11391568|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
11391569|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
11391570|NCT02092337|Experimental|computer assisted speech training|computer assisted speech training
11391571|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
11391572|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
11391573|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
11391574|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
11391575|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
11391576|NCT02092272|Experimental|instructional exercise video source|instructional exercise video source
11391577|NCT02092272|No Intervention|Standard Therapy|Standard Therapy
11391578|NCT02092246|Active Comparator|Ultrasound Machine Guided Injection|Use of ultrasound machine guidance in needle placement into the knee joint
11391579|NCT02092246|Active Comparator|Unguided Injection|Needle placement performed without ultrasound machine guidance
11391580|NCT02092233||Blinded, Prospective Arm|The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.
11391581|NCT02092233||Blinded, Pre-selected Arm|For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.
11391582|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
11391583|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
11391584|NCT02092207|Experimental|KL7016 900mg|
11391585|NCT02092207|Placebo Comparator|Placebo|
11391586|NCT02092207|Experimental|KL7016 600mg|
11391587|NCT02092194|Active Comparator|Standard Dose online HDF|Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
11391588|NCT02092194|Experimental|High Dose online HDF|Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
11391589|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
11391590|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
11391591|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
11391592|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
11391593|NCT02092155||Indwelling tunneled pleural catheter|
11391594|NCT02092142|Experimental|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
11391595|NCT02092129||Acromegaly|Patients with acromegaly who have received surgical treatment
11391596|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.
~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
11391597|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).
~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.
~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
11391598|NCT02092103|No Intervention|Delayed Clamping|"The American Congress of Obstetricians and Gynecologists (ACOG) recommends delayed cord clamping for preterm infants. Infants randomized to this group will follow the protocol below:
~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)
~Once infant is delivered designated RN starts timer
~Infant warming bag on delivery table
~Infant placed into warming bag then wrapped in a towel
~Assistant to deliver preps cord clamps
~Registered Nurse (RN) notifies provider at 30 seconds
~Cord clamped and cut
~Infant handed off to waiting staff
~Exceptions: Placental separation, cord stops pulsating, need for immediate resuscitation, all would result in clamping prior to 30 seconds"
11391599|NCT02092103|Experimental|Cord Milking|"Infants randomized to the cord milking group will follow the protocol below:
~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)
~Infant held and the cord is milked from perineum to infant four times
~Assistant to deliver preps cord clamps
~Cord clamped and cut
~Infant handed off to waiting staff"
11391600|NCT02092090|No Intervention|Control|Dietary advice at baseline only
11391601|NCT02092090|Experimental|Dietary sodium reduction|Dietary advice and reduced-sodium added-potassium salt substitute
11391602|NCT02092077|Experimental|TV-1106 0.554 mg|
11391603|NCT02092077|Experimental|TV-1106 0.924 mg/kg|
11391604|NCT02092077|Experimental|TV-1106 1.20 mg/kg|
11391605|NCT02092077|Active Comparator|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
11391606|NCT02092051|Experimental|Continuous glucose monitoring|Continuous glucose monitoring with DexCom G4 platina during 6 months
11391607|NCT02092051|No Intervention|Conventional therapy|Conventional therapy during 6 months using only SMBG for glucose monitoring
11391608|NCT02092038|Experimental|Preoperative chemoradiation|Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide
11391609|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
11391610|NCT02092012|Active Comparator|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anesthesia induction
11391611|NCT02092012|Active Comparator|dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
11391612|NCT02091999|Experimental|Part A enfortumab vedotin Dose Escalation (Dose Levels 1-4)|All subjects will receive a single 30 minute intravenous (IV) infusion of enfortumab vedotin once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
11391613|NCT02091999|Experimental|Part B enfortumab vedotin Renal Insufficiency Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at a dose level below and escalated up to the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
11391614|NCT02091999|Experimental|Part B enfortumab vedotin NSCLC Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
11391615|NCT02091999|Experimental|Part B enfortumab vedotin Ovarian Cancer Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15) until disease progression, intolerability of the investigational product or consent withdrawal. A cycle is 4 weeks.
11391616|NCT02091999|Experimental|Part C enfortumab vedotin CPI Treated Expansion|Subjects will receive a single 30 minute IV infusion of enfortumab vedotin at the preliminary RP2D once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8 and 15). A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of enfortumab vedotin, Investigator decision or consent withdrawal.
11391617|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
11391618|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
11391619|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
11391620|NCT02091973|Experimental|Everolimus|everolimus dosing to tough level 6-10 ng/ml
11391621|NCT02091973|Experimental|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
11391622|NCT02091960|Experimental|Enzalutamide + Trastuzumab|Participants received 160 mg enzalutamide orally once daily and 6 mg/kg trastuzumab administered by intravenous infusion or subcutaneous injection every 21 days. Participants continued on treatment until disease progression, unacceptable toxicity or any other discontinuation criteria were met.
11391626|NCT02091934|Active Comparator|Wavefront-optimized PRK|Wavefront-optimized PRK
11391627|NCT02091921|Experimental|Experimental|All subjects will receive Ticagrelor.
11391628|NCT02091908|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
11391629|NCT02091908|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
11391630|NCT02091908|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
11391631|NCT02091908|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
11391632|NCT02091895|Experimental|endo group|colon polyp, early colon cancer, colorectal submucosal tumor, ileocecal ulcers
11391633|NCT02091882|Experimental|MIND1 System|
11391634|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
11391635|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
11391636|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
11391637|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
11391638|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
11391639|NCT02091843|Experimental|DBS of the Amygdala-30 days|Deep brain stimulation of the amygdala BLn starting at 30 days post-operatively.
11391640|NCT02091843|Experimental|DBS of the Amygdala-90 days|Deep brain stimulation of the amygdala BLn starting at 90 days post-operatively.
11391641|NCT02091830||Non-surgical treatment|
11391642|NCT02091817|Other|Control group|Control group will be administered oxytocin and placebo, in a double-blind randomized order.
11391643|NCT02091817|Experimental|congenital prosopagnosia|Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
11391644|NCT02091804|Active Comparator|Wait-List group|Individuals randomized to the control group will receive the intervention program immediately after their 3-month research visit.
11391645|NCT02091804|Experimental|Immediate Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
11391646|NCT02091791|Experimental|LT10|"Long duration (30 minutes) traction sessions of low force (10% of body weight) for 2 weeks (5 sessions/week)."
11391647|NCT02091791|Experimental|LT50|"Long duration (30 minutes) traction sessions of high force (50% of body weight) for 2 weeks (5 sessions/week)."
11391648|NCT02091778|Experimental|Fast Gelling Dressing|
11391649|NCT02091765|No Intervention|Minimal intervention control group|Women who are assigned to the control group will be contacted by telephone by a member of the study staff to inform them about this allocation. They will receive a booklet per mail that addresses 80 questions about sexuality and cancer. Six weeks later, they will receive an empathetic phone call from one of the sexologists, during which there is also time available to discuss further questions the participants may have concerning sexuality and cancer. The purpose of keeping in contact with the control group, as opposed to a pure waiting list control group, is creating the opportunity to provide some control for a possible attention placebo-effect. The final questionnaire will be completed twenty weeks post study entry, after which women will be given the opportunity to undergo the internet-based cognitive behavioral program.
11391650|NCT02091765|Experimental|Internet-based cognitive behavioral therapy|"Each woman who is allocated to the intervention group is assigned a personal sexologist (therapist) who guides her through the internet-based cognitive behavioral therapy (CBT) program and provides feedback on the homework assignments. The CBT program comprises a maximum of ten treatment modules that can be used in varying order. Each module contains three interventions and a personal evaluation form to report on the intervention. Each intervention comprises the following elements: 1) introduction, 2) psycho-education about symptoms, 3) homework assignments (e.g. relaxation techniques (pelvis); discuss intimacy with partner; sensate focus) and 4) reporting back to the therapist and receiving feedback on the homework assignments. Each week there are two practice sessions of 30 minutes each and one hour per week to report on/evaluate the intervention. The therapy has a mean duration of 20 weeks."
11391651|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
11391652|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.
~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.
~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
11391653|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.
~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.
~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
11391654|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.
~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.
~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
11391655|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
11391656|NCT02091713||Experimental/Functional movement screen|300 subjects from three different combat units will undergo functional movement screening
11391657|NCT02091700||Normals|Subjects with normal visual and retinal function will be enrolled
11391658|NCT02091674|Experimental|Hyaluronic acid|All subjects administered hyaluronic acid
11391693|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
11391833|NCT02090439|Experimental|standard treatment with Silodosin|Silodosin
11391659|NCT02091661|Active Comparator|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh.surgery started with dissection of the pelvic lymph nodes. If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing.The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
11391660|NCT02091661|Active Comparator|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
11391661|NCT02091648|Experimental|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
11391662|NCT02091648|Active Comparator|Standard Education Intervention|"this group will receive the standard American Lung Association Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute recommendations for asthma education."
11391663|NCT02091648|No Intervention|No treatment control|"This group will receive no treatment during the course of the study and will have the option to receive the Open Airways program after their participation in the study is complete."
11391664|NCT02091635|Active Comparator|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
11391665|NCT02091635|Placebo Comparator|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
11391666|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
11391667|NCT02091622|No Intervention|No intervention|No intervention.
11391668|NCT02091609|Experimental|group : implants and oral hygiene|dental floss
11391669|NCT02091609|Experimental|implants and oral hygiene|dental interproximal brush
11391670|NCT02091596|Placebo Comparator|PluroGel|PluroGel
11391671|NCT02091596|Experimental|PluroGel N|PluroGel N
11391672|NCT02091583|Placebo Comparator|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
11391673|NCT02091583|Active Comparator|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
11391674|NCT02091583|Active Comparator|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
11391675|NCT02091583|Active Comparator|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
11391676|NCT02091570|Placebo Comparator|Nutrition bar|50 g nutrition bar
11391677|NCT02091570|Experimental|Nutrition Bar 1|50 g nutrition bar with additional 2 g of milk-based nutrient
11391678|NCT02091570|Experimental|Nutrition bar 2|50 g nutrition bar with additional 3 g of milk-based nutrient
11391679|NCT02091557||GnRH-analogue|CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients
11391680|NCT02091544||Lifestyle intervention|lifestyle intervention
11391681|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
11391682|NCT02091518|Experimental|MRI|"Add-On Research Patients will include patients who are scheduled for a routine clinical MRI who meet the eligibility requirements for this protocol. Protocol participation will consist of an add-on research. MRI scan, which will be performed any point during of the routine clinical MRI scan.
~Volunteers will be subjects expressing interest in participation and who meet the eligibility requirements for this protocol. No contrast enhanced research MRIs including gadolinium-based or other contrast agents will be performed in volunteers."
11391683|NCT02091505|Experimental|Intravitreal injection of Ranibizumab|
11391684|NCT02091492|Active Comparator|Teriparatide|Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
11391685|NCT02091492|Placebo Comparator|Placebo-Teriparatide|Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
11391686|NCT02091479|Experimental|UFH Early group|anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
11391687|NCT02091479|Active Comparator|UFH Late group|anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage
11391688|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
11391689|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
11391690|NCT02091453|Experimental|attention training acute|20 hours of attention training, APT training, or multiprofessional rehabilitation
11391691|NCT02091453|Experimental|attention training subacute|20 hours of attention training, APT training, or multiprofessional rehabilitation
11391692|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
11391694|NCT02091401|Active Comparator|IV|Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IV maintenance regimen.
11391695|NCT02091401|Experimental|Springfusor|Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor® pump).
11391696|NCT02091388|Experimental|LY03004 25 mg|5 intramuscular injections 25 mg over 113 days
11391697|NCT02091388|Active Comparator|Risperdal® Consta® 25 mg|5 intramuscular injections 25 mg over 113 days
11391698|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
11391699|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
11391700|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
11391701|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
11391702|NCT02091349|Placebo Comparator|Group A- placebo|control- snack bar or muffin containing no fiber
11391703|NCT02091349|Experimental|Group B- polydextrose|polydextrose- randomly bonded polysaccharide of glucose which is poorly digested in small intestine
11391704|NCT02091349|Experimental|Group C- soluble corn fiber|Soluble corn fiber made from corn starch and contains oligosaccharides with random glyucosyl bonds and may contain minor amounts of monosaccharides
11391705|NCT02091336|Active Comparator|Glyburide|Glyburide 2,5 mg
11391706|NCT02091336|Active Comparator|Metformin|Metformin 500mg bid
11391707|NCT02091323|Experimental|BMI<28kg/m2|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI<28kg/m2 group.
11391708|NCT02091323|Other|control|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI>28kg/m2 group as well.
11391709|NCT02091310|Placebo Comparator|Placebo (Study Part I)|Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water
11391710|NCT02091310|Experimental|GFT505 300 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water
11391711|NCT02091310|Experimental|GFT505 360 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water
11391712|NCT02091310|Placebo Comparator|Placebo (Study Part II)|Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
11391713|NCT02091310|Experimental|GFT505 120 mg (Study Part II)|Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water
11391714|NCT02091310|Experimental|GFT505 xx mg (Study Part II)|Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
11391715|NCT02091310|Active Comparator|Moxifloxacin 400 mg (Study Part II)|On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14
11391716|NCT02091297|Active Comparator|TAP BLOCK|One unique regional technique for lower abdominal surgery, that has been shown effective for Cesarean Section in particular, is the transversus abdominis plane (TAP) block, which blocks T6-L1 sensory nerve branches and provides anesthesia to the anterior abdominal wall. The TAP block has been recommended and shown in case reports, but not clinically studied with trials, for patients on methadone or buprenorphine, to improve post-operative pain control. A long active local anesthetic, called ropivacaine, will be used to provide this anesthesia.
11391717|NCT02091297|Active Comparator|Common Care|Common care refers to the common way pain is treated after Cesarean Section: a long-acting spinal or epidural opioid such as morphine, plus oral and IV opioids and non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
11391718|NCT02091297|Active Comparator|Patient Controlled Epidural Analgesia|For post-Cesarean analgesia, another regional technique that has been employed for superior pain control is continued epidural analgesia with local anesthesia and an opioid, either in addition or instead of long acting neuraxial opioids (Cohen). One study revealed equal analgesic efficiency, higher patient satisfaction scores, and less side effects with patient controlled epidural ropivacaine compared to epidural morphine (Chen). This is an especially attractive option for opioid dependent patients, but like the TAP block, has been not studied whether or not it lessens acute or chronic postoperative cesarean section, in the setting or in the absence of neuraxial opioids.
11391719|NCT02091284|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
11391720|NCT02091284|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
11391721|NCT02091245|Experimental|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
11391722|NCT02091219|Experimental|25(OH)D3|20 micrograms/day by mouth for 16 weeks
11391723|NCT02091219|Experimental|Vitamin D3|2,400 IU/day by mouth for 16 weeks
11391754|NCT02091050|Other|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
11391724|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
11391725|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
11391726|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
11391727|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
11391728|NCT02091193||Placebo to Krill Oil|Group 2 receives supplement B for four weeks, undergoes a two week washout period, and then receives supplement A for another four weeks. Measurements are taken at baseline, after supplement B completion and after supplement A completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 2 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
11391729|NCT02091193||Krill Oil to Placebo|Group 1 receives supplement A for four weeks, undergoes a two week washout period, and then receives supplement B for another four weeks. Measurements are taken at baseline, after supplement A completion and after supplement B completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 1 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
11391730|NCT02091180|Experimental|Mannitol|Patients will receive 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
11391731|NCT02091180|Placebo Comparator|Control|Patients will receive normal saline
11391732|NCT02091167|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
11391733|NCT02091167|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
11391734|NCT02091154|Experimental|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
11391735|NCT02091154|Experimental|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
11391736|NCT02091154|Experimental|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
11391737|NCT02091154|No Intervention|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
11391738|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks. This treatment arm is now closed for screening and enrollment.
11391739|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
11391740|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
11391741|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
11391742|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
11391743|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
11391744|NCT02091128||Females with classic galactosemia and POI|
11391745|NCT02091115|Placebo Comparator|Dairy drink|Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
11391746|NCT02091115|Active Comparator|Dairy drink with probiotic culture|Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
11391747|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
11391748|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
11391749|NCT02091076|Experimental|Silk with bioactive coated dressing|Silk fibroin coated with bioactive layer, apply once only
11391750|NCT02091076|Active Comparator|Control|Bactigras wound dressing, apply once only
11391751|NCT02091063|Experimental|Phase Ib: Arm A: ACY-1215 QD|Phase Ib: ACY-1215 160mg PO QD
11391752|NCT02091063|Experimental|Phase Ib: Arm B: ACY-1215 BID|Phase Ib: ACY-1215 160mg PO BID
11391753|NCT02091063|Experimental|Phase II: ACY-1215|Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.
11391755|NCT02091024|Experimental|ECG (Ecklonia cava extract)|ECE 200mg, twice a day
11391757|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
11391758|NCT02090998|Active Comparator|SPG Nerve Block with Lidocaine 5% gel|Sphenopalatine Ganglion Nerve Block (SPG Nerve Block) will be administed weekly for 4 weeks using 5% Lidocaine gel This intervention (a nerve block) will treat the headache for the time period investigated
11391759|NCT02090998|Active Comparator|Amitriptyline / Elavil|Amitriptyline / Elavil 10 mg once a day for one week then Amitriotyline 20 mg once a day for three weeks This intervention will treat the headache for the time period investigated
11391760|NCT02090985|Experimental|Lipomodelling|Lipomodelling of peri-stomal skin contour abnormalities
11391761|NCT02090972||Patients with fracture|"fracture within the last 14 days
~no other fractures within the last 6 month
~patients >60 years"
11391762|NCT02090972||Control Patients|"patients hospitalized for an internal reason
~no other fractures within the last 6 month
~patients >60 years"
11391763|NCT02090959|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
11391764|NCT02090946||parental experiences|interviews
11391765|NCT02090933|Experimental|Treatment (celecoxib)|Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
11391766|NCT02090920||Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
11391767|NCT02090907|Experimental|Levothyroxin|In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.
11391768|NCT02090907|Placebo Comparator|Placebo|In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.
11391769|NCT02090894|Experimental|UV Light|
11391770|NCT02090881|Experimental|ultrasound scan in ages 2-16 years|Children aged 2-16 years of age with Sickle Cell Disease and under the care of consultant haematologist as part of the NHS screening programme.
11391771|NCT02090868||Pre Introduction|Pre tool introduction cohort 22 patient participants who will receive standard care (no patients were recruited)
11391772|NCT02090868||Nurses|12 nurse participants who will take part in 2 focus group interviews and a teaching session (6 nurse participants were recruited)
11391773|NCT02090868||Post Introduction|Pre tool introduction cohort 22 patient participants who's ability to eat and drink orally will be assessed using the Oral Intake Screening Tool (no patient participants were recruited)
11391774|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
11391775|NCT02090842|Experimental|Whey protein isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks.
11391776|NCT02090842|Experimental|Ca-caseinate|Subjects are asked to supplement their habitual diet with 56 g of Ca-caseinate a day for 8 weeks.
11391777|NCT02090842|Other|Maltodextrin|Subjects are asked to supplement their habitual diet with 54 g of maltodextrin a day for 8 weeks.
11391778|NCT02090829|Placebo Comparator|Placebo Group|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.
~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.
~One dose equals 6 spray puffs (3 puffs in each nostril)."
11391779|NCT02090829|Active Comparator|Experimental Group|"Intranasal oxytocin (Trade name: Syntocinon) Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.
~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.
~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril). Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
11391780|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
11391781|NCT02090803||Graft of autologous hematopoietic stem cells|
11391782|NCT02090790|Active Comparator|iv dexamethasone|perioperative 2ml 8 mg ıv dexamethasone
11391783|NCT02090790|Active Comparator|femoral dexamethasone|femoral block was performed postoperative 30 ml 0,5 % bupivacaine added 2 ml 8 mg dexamethasone
11391784|NCT02090790|Placebo Comparator|serum physiologic|
11391785|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
11391786|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
11391787|NCT02090764|Placebo Comparator|Placebo|Placebo cream
11391788|NCT02090751||No Maculopathy|Aged 50 to 80 with no macular disease
11391789|NCT02090751||Early Maculopathy|Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
11391790|NCT02090738|Experimental|Arm1|Treatment group
11391791|NCT02090738|Active Comparator|Arm2|Control group
11391792|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
11391793|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
11391794|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
11391795|NCT02090699||Myocardial Iron Overload|chronic blood transfusion related myocardial iron overload
11391796|NCT02090699||Healthy Volunteers|age matched healthy volunteers
11391797|NCT02090686|Active Comparator|Pulsatile Cupping|
11391798|NCT02090686|Active Comparator|Minimal Cupping|
11391799|NCT02090686|No Intervention|No Intervention|Waiting list
11391834|NCT02090439|No Intervention|standard treatment|
11391915|NCT02089867|Experimental|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
11391800|NCT02090673||Group1:Type 2 diabetic patients treated with Exenatide therapy|Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label
11391801|NCT02090660|Experimental|VATS wedge lung resection|
11391802|NCT02090647|Active Comparator|titanium 1|titanium abutment type 1
11391803|NCT02090647|Active Comparator|titanium 2|titanium abutment type 2
11391804|NCT02090647|Active Comparator|zirconia 1|zirconia abutment type 1
11391805|NCT02090647|Active Comparator|zirconia 2|zirconia abutment type 2
11391806|NCT02090647|Active Comparator|titanium nitrate|titanium nitrate abutment
11391807|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
11391808|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
11391809|NCT02090621|Experimental|Extracorporeal Photopheresis|Extracorporeal Photopheresis
11391810|NCT02090608|Experimental|Paricalcitol|In patients identified by the inclusion criteria, data will be collected at baseline , during administration of oral Paricalcitol (PCT) (after 1, 3 and 6 months), and three months after PCT withdrawal. PCT will administered at dosage of 1 mcg/day; this dosage was chosen as it is not associated with excessive decline of parathyroid hormone (PTH) levels in most patients
11391811|NCT02090595|Experimental|MBCT-C|Mindfulness-Based Cognitive Therapy for Anxious Children (MBCT-C) is a 12-week manualized group therapy program for children with anxiety disorders. The program involves teaching children to pay attention to anxiety-related thoughts, emotions, and physical sensations with openness and non-judgment.
11391812|NCT02090595|Other|Waitlist Control|Education and Therapy
11391813|NCT02090582|Other|Structured Palliative Care|
11391814|NCT02090582|Other|Usual Care|
11391815|NCT02090569|Experimental|Functional micro-Doppler sonography|
11391816|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
11391817|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
11391818|NCT02090543||Group 1|300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
11391819|NCT02090543||Group 2|300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
11391820|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
11391821|NCT02090517|Active Comparator|Pulsed Dye Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser.
11391822|NCT02090517|Active Comparator|Long Pulsed Alexandrite Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with long pulsed alexandrite laser.
11391823|NCT02090517|Active Comparator|Pulsed Dye Laser Plus Nd:YAG Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser plus Nd:YAG laser.
11391824|NCT02090517|Active Comparator|Electrodesiccation|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.
11391825|NCT02090517|No Intervention|No Treatment|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will receive no treatment.
11391826|NCT02090504|Experimental|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:
~SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);
~placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
11391827|NCT02090504|Active Comparator|Oxazepam|"Patients randomized to the second arm of the study will receive:
~OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;
~placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
11391828|NCT02090478|Sham Comparator|No change in dietary sugar levels|Group met with a dietician as often as the control group to discuss diet, but the dietician gave them advice geared toward no change in dietary sugar levels
11391829|NCT02090478|Experimental|Low sugar group|Subjects met with a dietician who discussed diet records. After the first month (baseline, regular diet), the dietician made suggestions geared toward reducing calories from simple sugars by 40%. This will be achieved by replacing sugar calories with complex carbohydrates and fats, while maintaining energy balance (same number of calories as the baseline month).
11391830|NCT02090465||all eligible patients|Treatment with Picato according to Summary of Product Characteristics (SmPC)
11391831|NCT02090452|Experimental|Transmission of vital signs, ecg, chat|Data from patients transported in ambulances with equipment which enables real time transmission of vital signs, ecg and chat from ambulances to the emergency department.
11391832|NCT02090452|No Intervention|No transmission of data|Patient transported with conventional ambulances without the possibility to transmit real time patient related data.
11391835|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
11391836|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
11391837|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.
~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
11391838|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.
~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
11391839|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.
~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
11391840|NCT02090400|Other|Bazedoxifene & Calcium/Vit D|Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)
11391841|NCT02090400|Other|Calcium/Vit D|Calcium 500mg and 400 IU vitamin D (OSTINE )daily.
11391842|NCT02090387|Active Comparator|Control ONS|ONS without AN777
11391843|NCT02090387|Experimental|Investigational ONS|ONS containing AN777
11391844|NCT02090374|Experimental|TLR agonist nasal challenge in non-atopic patients|
11391845|NCT02090374|Experimental|TLR agonist nasal challenge in atopic patients|
11391846|NCT02090374|Experimental|Tuberculin nasal challenge in subjects with latent TB|
11391847|NCT02090374|Experimental|Tuberculin nasal challenge healthy subjects|
11391848|NCT02090374|Experimental|Timothy grass pollen nasal challenge in hay fever subjects|
11391849|NCT02090374|Experimental|Timothy grass pollen nasal challenge in asthmatic subjects|
11391850|NCT02090374|Experimental|Timothy grass pollen nasal challenge in non-atopic subjects|
11391851|NCT02090374|Experimental|Resiquimod nasal challenge in allergic asthma|
11391852|NCT02090361|Experimental|skin graft with dermal matrix|Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
11391853|NCT02090361|Placebo Comparator|skin graft - classic procedure|Epidermization of the defect by applying a thin layer of autologous epidermis
11391854|NCT02090348|Experimental|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
11391855|NCT02090335|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
11391856|NCT02090335|Active Comparator|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
11391857|NCT02090322|Experimental|Bevacizumab|"The treatment for Retinopathy of prematurity is Intravitreal bevacizumab. We want to compare two dosages (0.500 and 0.625mg) and demonstrate that 0.500mg there isn't lower in efficacy than 0.625mg.
~When the baby have the diagnosis or Retinopathy of prematurity we are going to inyect the eye that have te problem, then we are going to explore until this illness disappear. It is only one intervention"
11391858|NCT02090309|Active Comparator|Hydrocortisone injection|I.V Hydrocortisone 100 mg single bolus.
11391859|NCT02090309|Placebo Comparator|normal saline|I.V normal saline 0.9% a single bolus of 5 ml.
11391860|NCT02090296|Placebo Comparator|Sugar water|Placebo arm
11391861|NCT02090296|Active Comparator|Hydroxyurea|Treatment Arm
11391862|NCT02090283|Experimental|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
11391863|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
11391864|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
11391865|NCT02090257|Experimental|TRANSIT, behavioral|The intervention group will receive more guidance during their transition from a pediatric center to the adult center
11391866|NCT02090257|No Intervention|Usual Care Group|The usual care group will receive a standard transfer of care from a pediatric center to an adult center.
11391867|NCT02090244|No Intervention|Control|Standard care postoperatively.
11391868|NCT02090244|Experimental|Teriparatide|One injection daily for 4 weeks
11391869|NCT02090231|Experimental|Real 5 Hz rTMS|real 5 Hz rTMS, 10 minutes per day, for 10 weekdays.
11391870|NCT02090231|Sham Comparator|sham 5 Hz rTMS|sham 5Hz rTMS, 10 minutes per day, for 10 weekdays.
11391871|NCT02090218|Active Comparator|I-Gel|I-Gel supraglottic airway device
11391872|NCT02090218|Active Comparator|LTS, ETI or other airway practice|Laryngeal tube, endotracheal tube or other current airway management practice
11391873|NCT02090205|Placebo Comparator|Non-ventilation during CPB|This group of patients will not be ventilated during the cardio-pulmonary bypass. They will be disconnected from the respirator.
11391874|NCT02090205|Experimental|Ventilation with CPAP|This group will receive a ventilation with CPAP (at least 5 cmH2O) and FiO2 50%-80%
11391875|NCT02090205|Experimental|Ventilation with 5 act/minute|This group will receive 5 respiratory acts/minute. Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
11391910|NCT02089919|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11391911|NCT02089906||Chinese Elderly|multi-center cross-sectional study
11391912|NCT02089893||Healthy subjects|Healthy subjects
11391876|NCT02090192|Experimental|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
11391877|NCT02090192|Experimental|WBV+ PRT training|
11391878|NCT02090192|Active Comparator|PRT training|
11391879|NCT02090192|Placebo Comparator|Control group|
11391880|NCT02090179||MPS IIIB|Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
11391881|NCT02090166|Other|lung cancer diagnosis|"4 arms will be included in the study:
~The groups sample size is as follows:
~Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects
~A blood test will be taken from each patient."
11391882|NCT02090153|Experimental|S-1 plus LV|All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.
11391883|NCT02090140|Experimental|ADSC Application|Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.
11391884|NCT02090140|Active Comparator|Microfracture Arm|Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.
11391885|NCT02090114|Experimental|Post-abiraterone or post-enzalutamide or post-castration only|Men with castration-resistant prostate cancer who have progressed on either abiraterone or enzalutamide or castration-only therapy will be enrolled to this arm. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with either abiraterone 1000 mg by mouth daily or enzalutamide 160 mg by mouth daily, depending on which drug they previously received or remain on LHRH agonist alone for one month to re-establish a castrate level of testosterone (<50 ng/dL).
11391886|NCT02090101|Experimental|ANAKINRA|LV5FU2 + bevacizumab + anakinra
11391887|NCT02090088||All Subjects|All Subjects
11391888|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
11391889|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
11391890|NCT02090049|Experimental|Puravita Breakfast|Puravita Breakfast is a high protein and high fiber soft bread that contains 22% fruit (figs, apricots, raisins and prunes), a selection of cereals: wheat, oat and spelt and no added sugar.
11391891|NCT02090049|Placebo Comparator|Control breakfast|White bread (85g) with jam (10g) and margarine (2g) adjusted for energy, fat, and sugar levels and for energy density.
11391892|NCT02090036|Active Comparator|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
11391893|NCT02090036|Experimental|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
11391894|NCT02090023||NHIRD obstructive sleep apnea|Secondary database from community-based National Health Insurance Research Database
11391895|NCT02090023||NTUH obstructive sleep apnea cohort|Primary database from enrollment of retrospective NTUH hospital-based cohort
11391896|NCT02090010|Active Comparator|GroupC|Group C means Control group which use Seldinger technique for subclavian catheterization. The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed. After that catheter is passed over the guidewire into the vessel.
11391897|NCT02090010|Experimental|Group MS|Group MS means experimental group which use modified Seldinger technique for subclavian catheterization. The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instatntly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
11391898|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
11391899|NCT02089984|Experimental|Internet-Based Training|On-line tutorial followed by live remote training via videoconferencing
11391900|NCT02089971||Young Chinese adults|cross-sectional, observational study of community dwelling young Chinese adults
11391901|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
11391902|NCT02089945||transcatheter aortic valve implantation|This study recruits individuals that are undergoing transcatheter aortic valve implantation.
11391903|NCT02089932|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
11391904|NCT02089932|Experimental|Group B-DEX 25 : Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
11391905|NCT02089932|Experimental|Group B-DEX 50:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
11391906|NCT02089932|Experimental|Group B-DEX 75:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
11391907|NCT02089919|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11391908|NCT02089919|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11391909|NCT02089919|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11391916|NCT02089867|Experimental|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
11391917|NCT02089867|No Intervention|Control group|No additional therapy, statin maintenance
11391918|NCT02089867|Experimental|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
11391919|NCT02089854|Experimental|endocrine therapy|toremifene 60mg PO. per day for premenopausal and perimenopausal patients; anastrozole 1mg PO. per day for postmenopausal patients
11391920|NCT02089854|No Intervention|observation|
11391921|NCT02089841|Experimental|Artemether/lumefantrine|In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
11391922|NCT02089828|Experimental|autologous purified CD34+ cell|transplantation of autologous purified CD34+ cell
11391923|NCT02089828|Active Comparator|autologous PB-MNC|transplantation of autologous peripheral blood mononuclear cells
11391924|NCT02089815|Experimental|Home based exercise|simple designed home based exercise program
11391925|NCT02089815|Active Comparator|fall prevention education and counseling|fall prevention education & counseling : home modification, vision screening, avoid sedative drugs use, proper shoes, report dizziness and fall to doctors
11391926|NCT02089802|Experimental|Normal plasma level patients and low plasma level patients.|"Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).
~Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
11391927|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
11391928|NCT02089763|Experimental|PEG-BCT-100|pegylated recombinant human arginase 1
11391929|NCT02089750|Active Comparator|Orthotics|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
11391930|NCT02089750|Active Comparator|Orthotics Plus Chiropractic Care|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period in addition to receiving Chiropractic Care 1-4 times per week during the first 6 weeks of the 12 week study period.
11391931|NCT02089750|Other|Wait List|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last six weeks they are fitted for the custom-made shoe orthotics.
11391932|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
11391933|NCT02089724||vemurafenib/other BRAF inhibitors|
11391934|NCT02089711||Japanese healthy subjects|subjects with healthy eyes
11391935|NCT02089698|Active Comparator|Reversed tip|Reversed Kelman tip
11391936|NCT02089698|Experimental|Mini-flared|Mini-flared Kelman tip
11391937|NCT02089685|Experimental|Pembrolizumab + PegIFN-2b|Participants in Part A receive pembrolizumab intravenously (IV) at assigned dose every 3 weeks + PegIFN-2b subcutaneously (SC) at assigned dose once a week in each 6-week cycle.
11391938|NCT02089685|Experimental|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 1 mg/kg every 3 weeks (Q3W) for a total of two 6-week cycles.
11391939|NCT02089685|Experimental|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 50 mg every 6 weeks (Q6W) for a maximum of four 6-week cycles.
11391940|NCT02089685|Experimental|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 100 mg every 12 weeks (Q12W) for a maximum of eight 6-week cycles.
11391941|NCT02089672||Atrial flutter patients|Atrial flutter patients undergoing catheter ablation
11391942|NCT02089659|Experimental|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
11391943|NCT02089659|Experimental|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
11391944|NCT02089659|Experimental|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
11391945|NCT02089633|Experimental|PACOX|Pegylated human arginase (PA) in combination with Capecitabine (C) and Oxaliplatin (OX)
11391946|NCT02089620|Active Comparator|Yasmin|Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
11391947|NCT02089620|Active Comparator|Calver|Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
11391948|NCT02089620|Placebo Comparator|Placebo|A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
11391949|NCT02089607|Experimental|Thoracoabdominal Aortic Aneurysm Arm|The TAAA study arm will include patients treated by endovascular aortic repair of thoracoabdominal aortic aneurysms (Extent I to IV) using either an off-the-shelf Zenith t-Branch or patient-specific stent-graft with a combination of fenestrations and/or branches. The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
11391992|NCT02089373|Experimental|Probe-based confocal laser endomicroscopy|
11391993|NCT02089373|Active Comparator|White light endoscopy|
11391994|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
11391995|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
11392023|NCT02089165|Experimental|Krill meal|The interventions are administered in the randomized order.
11391950|NCT02089607|Experimental|Aortic Arch Aneurysm Arm|Aortic Arch study arm will include patients with aortic arch aneurysms treated by Patient-specific stent-grafts with one to three inner branches or a scallop. The study will include patients with thoracoabdominal and/or aortic arch aneurysms due to degenerative aneurysms or chronic aortic dissections. The stent-graft design for this study will be individually selected based on anatomy at the discretion of the principal investigator, including an off-the-shelf stent-graft (t-Branch stent-graft) or patient-specific stent-graft with a combination of fenestrations and/or branches.
11391951|NCT02089594|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
11391952|NCT02089594|Experimental|No Hyperbaric Oxygen Treatment (HBOT)|Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
11391953|NCT02089581|Active Comparator|Drug|MR2XXX
11391954|NCT02089581|Experimental|MRXXX|MRXXX capsule 12 hourly
11391955|NCT02089581|Experimental|MR1XXX|MR1XXX capsule, 12 hourly
11391956|NCT02089581|Experimental|Experimental|Experimental Fed
11391957|NCT02089568|Experimental|Drug: co-amoxiclav|experimental
11391958|NCT02089568|Placebo Comparator|Control|comparator
11391959|NCT02089555||African Americans|This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
11391960|NCT02089555||Non-Hispanic Whites|This group consists of Non-Hispanic White (NHW) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)). African American (AA) and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
11391961|NCT02089542|Experimental|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
11391962|NCT02089529|Active Comparator|Ibuprofen/Ibumetin|Ibumetin is administrated. Intervention: No information about the effect.
11391963|NCT02089529|Placebo Comparator|Placebo|Placebo is administrated. Intervention: No information about the effect.
11391964|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+positive information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
11391965|NCT02089529|Placebo Comparator|Placebo+positive information|Placebo is administrated. Intervention:The patient receive written information that the capsule is Ibumetin.
11391966|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+neutral information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
11391967|NCT02089529|Placebo Comparator|Placebo+neutral information|Placebo is administrated. Intervention:The patients receive information that the capsule is placebo.
11391968|NCT02089529|No Intervention|Control|Control condition
11391969|NCT02089516||Frail elderly|Measuring movement activity in frail elderly (GFI score ≥ 4) of 75 years and older using DynaPort.
11391970|NCT02089503||induction phase + intravitreal inj.|Group of patients who received Lucentis ® with induction phase
11391971|NCT02089503||intravitreal inj. without induction|Group of patients who received Lucentis ® without induction phase
11391972|NCT02089503||intravitreal inj. + monthly follow-up|group of patients who were monthly monitored (+/- 1 week)
11391973|NCT02089503||intravitreal inj. + follow-up :> 1 month|group of patients with Follow up visits intervals> 1 month (+/- 1 week)
11391974|NCT02089503||intravitreal inj +induction+ month. FU|Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)
11391975|NCT02089503||date Lucentis® 1st intravitreal Inj.|Group of patients selected in accordance with the date of Lucentis® treatment start.
11391976|NCT02089490|Experimental|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
11391977|NCT02089477|Experimental|Support|"The participants in the intervention group receives the intervention and support consisting of:
~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.
~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
11391978|NCT02089477|No Intervention|Control group|Patient's in the control group receives the intervention with interval Walking and no other support.
11391979|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
11391980|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
11391981|NCT02089451|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 5 treatment periods
11391982|NCT02089438|Experimental|Saxagliptin|Ssaxagliptin is given before breakfast
11391983|NCT02089438|Experimental|´Sitagliptin|Sitagliptin is given before breakfast
11391984|NCT02089438|Experimental|Vildagliptin|Vildagliptin is given before breakfast
11391985|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
11391986|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
11391987|NCT02089412|Experimental|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
11391988|NCT02089412|Experimental|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
11391989|NCT02089399|Experimental|Treatment AB|S->S+C
11391990|NCT02089399|Experimental|Treatment C|C
11391991|NCT02089386|Experimental|Tamoxifen|Tamoxifen 20 mg daily for 12 weeks
11391996|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
11391997|NCT02089321||Patients with Low Back Pain|"n= 19
~Inclusion Criteria:
~Between the ages of 18 and 70 years Currently seeking, but not yet initiated, treatment from a health care professional (PT, MD, DO, DC) for a chief complaint of pain between the level of the twelfth thoracic vertebrae and the coccyx Able to transition between standing, sitting, supine, prone and sidelying independently
~Exclusion Criteria:
~Signs of neurological impairment including diminished myotatic reflex, sensory impairment or strength deficits in a myotomal pattern No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
11391998|NCT02089321||Healthy Controls|"n= 19
~Inclusion Criteria:
~Between the ages of 18 and 70 years No LBP episodes requiring clinical care by a health professional and/or greater than 3 days absence from work/school/recreation within the previous 5 years Able to transition between standing, sitting, supine, prone and sidelying independently
~Exclusion Criteria:
~No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
11391999|NCT02089308|Other|Treatment-Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.
~Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)
~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
11392000|NCT02089308|Other|Treatment-Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.
~Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)
~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
11392001|NCT02089295|Experimental|Treatment A|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11392002|NCT02089295|Experimental|Treatment B|Single dose of 20 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11392003|NCT02089295|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11392004|NCT02089282||Clavicle fractures|
11392005|NCT02089269||Cohort 1|1,625 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
11392006|NCT02089269||Cohort 2|100 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
11392007|NCT02089256|Experimental|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
11392008|NCT02089243|Experimental|Vagus nerve stimulation therapy|Surgical follow-up typically occurred 2 weeks postoperatively and, subsequently, on a variable schedule as indicated. The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes. Retrospective chart review was performed to collect follow-up and outcome data. At the time of last available clinical follow-up, the following data were collected: mean weekly seizure frequency (from seizure logs kept by caretakers or patient or caretaker report averaged of the last 3 months prior to ﬁnal follow-up), complications of VNS therapy, duration of VNS therapy, timing and all subsequent surgical procedures.
11392009|NCT02089243|Experimental|Resective surgery|The type of surgery performed consisted of standard anterior temporal lobectomy, electrocorticography tailored temporal lobectomy, anteromedial temporal lobectomy, transcortical or transsylvian or subtemporal selective amygdalohippocampectomy, temporal lobe disconnection and hippocampal transection.
11392010|NCT02089230|Experimental|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.
~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
11392011|NCT02089217|Active Comparator|Carotid Endarterectomy (CEA)|Carotid Endarterectomy
11392012|NCT02089217|Active Comparator|Carotid Stenting (CAS)|Carotid Stenting
11392013|NCT02089217|Experimental|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
11392014|NCT02089217|Experimental|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
11392015|NCT02089204||FMISO-PET/CT|18F-MISO PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
11392016|NCT02089204||FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
11392017|NCT02089204||contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy . GTVs were delineated based on fusing diagnostic CT images with simulation CT images.All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
11392018|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
11392019|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
11392020|NCT02089178|Experimental|intravenous|the total intravenous anesthesia group
11392021|NCT02089178|Active Comparator|inhalation|the inhalation anesthesia group
11392022|NCT02089165|Experimental|Krill oil|The interventions are administered in the randomized order.
11392024|NCT02089165|Active Comparator|Fish oil|The interventions are administered in the randomized order.
11392025|NCT02089152|Other|Cluster A|General education for prevention of diabetic complications in year 1, Melioidosis prevention education in years 2, 3 and 4.
11392026|NCT02089152|Other|Cluster B|General education for prevention of diabetic complications in year 1 and 2, Melioidosis prevention education in year 3 and 4.
11392027|NCT02089152|Other|Cluster C|General education for prevention of diabetic complications in year 1, 2 and 3, Melioidosis prevention education in year 4.
11392028|NCT02089139|Experimental|DISCOGEL|Percutaneous intradiscal injection of Discogel
11392029|NCT02089139|Active Comparator|conventional treatment|conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks
11392030|NCT02089126|Experimental|Gemigliptin/Glimepiride combination|Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination & Placebo for Glimepiride.
11392031|NCT02089126|Placebo Comparator|Placebo|The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination & Glimepiride.
11392032|NCT02089113|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
11392033|NCT02089113|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
11392034|NCT02089100|Experimental|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
11392035|NCT02089100|Active Comparator|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
11392036|NCT02089087|Experimental|CFZ533 in healthy volunteers|CFZ533 single dose in healthy volunteers
11392037|NCT02089087|Experimental|CFZ533 in rheumatoid arthritis patients|CFZ533 single dose in rheumatoid arthritis patients
11392038|NCT02089087|Placebo Comparator|Placebo|Placebo single dose
11392039|NCT02089074|Experimental|drug use counselling|Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
11392040|NCT02089074|No Intervention|Control group|The patients in the control group receive no intervention just treatment and follow up according to national standards
11392041|NCT02089061|Experimental|Cohort 1: Rosuvastatin + BMS-919373|"Rosuvastatin 10 mg tablet orally once for Day 1 and 5
~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
11392042|NCT02089061|Experimental|Cohort 2: Atorvastatin + BMS-919373|"Atorvastatin 40 mg tablet once for Days 1 and 5
~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
11392043|NCT02089048|Experimental|Cohort 1|15 subjects receive 6mg of auranofin once every 24 hours for 7 days
11392044|NCT02089035|Experimental|MUFA-rich dairy products|"Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period.
~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
11392045|NCT02089035|Experimental|Conventional dairy products|"Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks.
~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
11392046|NCT02089022|Experimental|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
11392047|NCT02089009|Other|Group 1 Standard Population|Retinal Imaging, vessel measurements, vessel changes of a population of a female health hospital
11392048|NCT02089009|Other|Group 2 Pregnant Population|Change in vessel diameter at perinatal visits with retinal imaging (Retinal Imaging, vessel measurements, vessel changes)
11392049|NCT02088996|Active Comparator|IT and LWD on high power|IT and LWD on high power
11392050|NCT02088996|Placebo Comparator|LWD on low power|LWD on low power
11392051|NCT02088983|Experimental|CDP-Choline|Single dose of 500 mg, 1000 mg, or 2000 mg given in one of 4 test sessions
11392052|NCT02088983|Placebo Comparator|Placebo (cellulose)|Given randomly in one of the 4 testing sessions as a comparison
11392053|NCT02088970|Active Comparator|antibiotic treatment alone|
11392054|NCT02088970|Experimental|Crosslinking + Antibiotic|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.
~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
11392055|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.
~Subjects should transition to oral medication as soon as they are able to swallow tablets."
11392056|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.
~Subjects should transition to oral medication as soon as they are able to swallow tablets."
11392057|NCT02088944||exposed to IFX|
11392275|NCT02087631|Experimental|Quetiapine|Extended-release quetiapine fumarate up to 300mg once daily for 4 weeks
11392058|NCT02088931|Experimental|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.
~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
11392059|NCT02088918|Active Comparator|Nateglinide+Metformin|coadministration of nateglinide and metformin
11392060|NCT02088918|Experimental|Nateglinide/Metformin|Nateglinide/Metformin tablet
11392061|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
11392062|NCT02088905|No Intervention|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
11392063|NCT02088892|Experimental|Group A|10 BCG-naïve subjects receiving intradermal BCG SSI at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
11392064|NCT02088892|Experimental|Group B|10 BCG-naïve subjects receiving BCG Tice at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
11392065|NCT02088892|Experimental|Group C|10 BCG-naïve subjects receiving intradermal BCG SSI at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
11392066|NCT02088892|Experimental|Group D|10 BCG-naïve subjects receiving intradermal BCG Tice at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
11392067|NCT02088892|Experimental|Group E|8-12 BCG-naïve subjects receiving the optimal strain and dose of intradermal BCG identified from preliminary results obtained from Group A, B, C and D, followed by a punch biopsy at the challenge site 14 days later.
11392068|NCT02088879|Experimental|Group1|"first : chest compression with kneeling position
~second : chst compression with standing position"
11392069|NCT02088879|Experimental|Group2|"first : chest compression with standing position
~second : chst compression with kneeling position"
11392070|NCT02088866|Experimental|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
11392071|NCT02088853|Experimental|high fat diet|
11392072|NCT02088853|Active Comparator|high carb diet|
11392073|NCT02088840||stem cell tranplant|All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease
11392074|NCT02088827|Other|Activity|During a 4 hour Meal Test subjects will cycle for 2 minutes every 20 minutes
11392075|NCT02088827|Other|Inactivity|During a 4 hour Meal Test study subjects will remain inactive (remain lying on a bed)
11392076|NCT02088814|Experimental|'EPICAP'|Secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
11392077|NCT02088814|No Intervention|Medical treatment as usual|Medical treatment of burn injuries as usual
11392078|NCT02088801|Experimental|Airtraq, blade without channel for tracheal tube|intubation
11392079|NCT02088801|Experimental|KingVision , blade without channel for tracheal tube|intubation
11392080|NCT02088801|Experimental|A.P. Advance, blade without channel for tracheal tube|intubation
11392081|NCT02088801|Experimental|Macintosh|intubation
11392082|NCT02088788|Experimental|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
11392083|NCT02088788|Active Comparator|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
11392084|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
11392085|NCT02088762||1 cm safety margin|1 cm safety margin
11392086|NCT02088762||2 cm safety margin|2 cm safety margin
11392087|NCT02088749|Experimental|small group treatment|lifestyle intervention for obesity delivered to small groups of approximately 12 participants/group
11392088|NCT02088749|Active Comparator|large group treatment|lifestyle intervention for obesity delivered to a large group of approximately 30 participants
11392089|NCT02088736|Active Comparator|Intravenous and Intraosseous|'IV + IO' Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If IV is unsuccessful, IO will attempt at the Primary site (proximal tibia). If IO is unsuccessful at scene, 2nd attempt can be done in the ambulance. Adrenaline will be delivered as according to protocol.
11392090|NCT02088736|Experimental|Intravenous|Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
11392091|NCT02088723|Experimental|head of bed elevation|Compare the apnea hypopnea index with the patient in standard polysomnography and in elevated polysomnography (head of bed elevation)
11392092|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
11392093|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
11392094|NCT02088684|Experimental|LEE011 + BKM120 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
11392095|NCT02088684|Experimental|LEE011 + BYL719 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
11392096|NCT02088684|Experimental|LEE011 + fulvestrant|LEE011 - 28 day cycles (3 weeks on, 1 week off) or (continuous daily dosing - dose escalating) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
11392097|NCT02088671||Anesthesia|"A single study group undergoing general anesthesia procedure to observe post-hoc the effect on the NeuroSENSE monitor readings.
~Interventions of interest:
~Drug: Propofol induction followed by randomized doses of desflurane; Emergence by stepping down the desflurane ET - See intervention descriptions.
~Device: Recording of EEG using NeuroSENSE (blinded to clinicians) - See intervention descriptions.
~Other: Data Collection - See intervention descriptions"
11392098|NCT02088658|Experimental|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes.
11392099|NCT02088658|No Intervention|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
11392100|NCT02088645|Experimental|Phase 0: One arm; Phase I: One arm|"Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)
~Phase I: expected 12 - 18 patients, intravenous application of max. 6 x 7-8 GBq 177Lu-PP-F11N (increasing number of applications by one in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study."
11392101|NCT02088632|Active Comparator|Incobotulinumtoxina|Xeomin 25-100 units injected to chosen area one time.
11392102|NCT02088632|Placebo Comparator|Placebo Comparator|Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.
11392103|NCT02088619|Experimental|Quality of Life Therapy (QOLT)|Positive emotion-focused cognitive behavioral psychotherapy
11392104|NCT02088619|Active Comparator|Heart Healthy Education (HHE)|Heart healthy education program
11392105|NCT02088593|Experimental|DAWN simulation|Simulated Dawn Light box
11392106|NCT02088593|Active Comparator|Sleep hygiene instructions read aloud|Standard sleep hygiene instructions were read aloud.
11392107|NCT02088580|Experimental|Triple Chronotherapy|Total sleep deprivation, Sleep phase advance, and Bright light therapy.
11392108|NCT02088567|Experimental|dHACM|Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
11392109|NCT02088567|Other|Control|Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
11392110|NCT02088554|Experimental|Model 400 aortic valve bioprosthesis|
11392111|NCT02088541|Experimental|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m^2 (milligrams per square meter) (60 to 120 mg based on body surface area [BSA]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
11392112|NCT02088541|Experimental|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
11392113|NCT02088541|Experimental|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
11392114|NCT02088541|Active Comparator|Physician's Choice 1 (PV <5)|Participants under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
11392115|NCT02088541|Active Comparator|Physician's Choice 2 (PV >=5)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
11392116|NCT02088528|Active Comparator|Aurolab glaucoma drainage device|
11392117|NCT02088528|Active Comparator|Trabeculectomy with mitomycin-c|
11392118|NCT02088515|Experimental|experimental group|experimental group: Nedaplatin(（80 mg/m2, i.v Day1）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total.
11392119|NCT02088515|Active Comparator|comparative group|comparative group:Cisplatin (（75 mg/m2, i.v Day1 or 25 mg/m2 Day1-3）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total
11392120|NCT02088502|Active Comparator|N-acetylcysteine|Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
11392121|NCT02088502|Active Comparator|Theophylline|Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
11392122|NCT02088502|Active Comparator|Theophylline plus N-acetylcysteine|Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.
11392123|NCT02088489|Active Comparator|Atrial flutter, irrigated catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® (Biosense Webster, Diamond Bar, CA) irrigated catheter
11392124|NCT02088489|Experimental|Atrial flutter, porous tip catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® SF(Biosense Webster, Diamond Bar, CA) irrigated catheter
11392125|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
11392126|NCT02088463|Experimental|Mobilization (manual therapy)|Mobilization (manual therapy) posterior- anterior at the L3 for 2 minutes in addition to the traditional treatment in the form of infra-red and ultrasound. The treatment duration for the three groups was 3 times/week for 4 weeks.
11392127|NCT02088463|Placebo Comparator|placebo mobilization|placebo mobilization applied without force application. The treatment duration for the three groups was 3 times/week for 4 weeks
11392128|NCT02088463|Other|Ultrasound and infrared therapy|ultrasound and infrared are a traditional treatment for low back painThe treatment duration for the three groups was 3 times/week for 4 weeks.
11392129|NCT02088450|Active Comparator|Active treatment|Active treatment with nitrendipine (10-40 mg/day). If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
11392130|NCT02088450|Placebo Comparator|Placebo|Placebo tablets were identical to the study drugs with a similar schedule.
11392131|NCT02088437|Active Comparator|Usual care|usual care physiotherapy - once daily treatment whilst inpatient in acute hospital
11392132|NCT02088437|Experimental|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention
11392133|NCT02088424||group A|cases with recurrent abortion with insulin resisance
11392134|NCT02088424||GROUP B|cases that are pregnant with no history of recurrent abortion with no insulin resistance
11392135|NCT02088411|Active Comparator|Diclofenac|Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
11392136|NCT02088411|Active Comparator|Wobenzym|Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.
11392137|NCT02088411|Placebo Comparator|Placebo|Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
11392138|NCT02088398|Experimental|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
11392139|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
11392140|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
11392141|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
11392142|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
11392143|NCT02088372||Vanguard with E1 PS Bearing|"E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty.
~Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, & Ascent."
11392144|NCT02088359||Cycled light|Approximately 12 hours of light on and 12 hours of light off.
11392145|NCT02088359||Near darkness|Continue near darkness
11392146|NCT02088346||Teleconsultation|Intravenous thrombolysis guided by telemedicine consultation system based on portable hardwares
11392147|NCT02088346||Historical control|Usual stroke care without the guidance from hub hospital
11392148|NCT02088333|Experimental|mCRC intervention|intervention arm
11392149|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
11392150|NCT02088307|No Intervention|Control|Subjects in the control arm will not receive an intervention.
11392151|NCT02088307|Experimental|CardioLife|The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.
11392152|NCT02088294|No Intervention|Non-intervention control|No intervention will be delivered.
11392153|NCT02088294|Experimental|Lifestyle Education (LS)|"The lifestyle curriculum will be taught in twice weekly after-school sessions of ~1.25 hours, one physical activity and one nutrition-related, delivered over 12-weeks during the course of a single academic semester. The lifestyle program will utilize the Shape Up curriculum of SOSMentor, a community non-profit collaborator, modified to seamlessly integrate key concepts of the non-diet philosophy of Intuitive Eating. The curriculum fully encompasses health-promoting nutrition and physical activity practices consistent with consensus recommendations ."
11392154|NCT02088294|Experimental|LS + Stress Reduction Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided Imagery (IGI) consisting of standard stress reduction imagery practices, delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures."
11392155|NCT02088294|Experimental|LS + Activity/Eating Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating."
11392156|NCT02088281|Experimental|Indigo naturalis extract in oil ointment|Indigo naturalis extract in oil ointment: each gram of ointment contains 200 μg±20 μg of indirubin.
11392157|NCT02088268|Experimental|platelet-rich plasma|wound healing
11392158|NCT02088255|Active Comparator|Static surface|The subjects will do the walking training with partial body weight support on static surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
11392159|NCT02088255|Active Comparator|dynamic surface|The subjects will do the walking training with partial body weight support on dynamic surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
11392160|NCT02088242|Placebo Comparator|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
11392161|NCT02088242|Experimental|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
11392162|NCT02088216|Active Comparator|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
11392163|NCT02088216|Other|Control group|Participants received as-needed therapy.
11392164|NCT02088203|Experimental|Single Dose Sequence 1|Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.
11392165|NCT02088203|Experimental|Single Dose Sequence 2|Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.
11392166|NCT02088203|Experimental|Single Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.
11392167|NCT02088203|Experimental|Single Dose Sequence 4|Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.
11392168|NCT02088203|Experimental|Single Dose Sequence 5|Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.
11392169|NCT02088203|Experimental|Single Dose Sequence 6|Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.
11392170|NCT02088203|Experimental|Single Dose Sequence 7|Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.
11392171|NCT02088203|Experimental|Single Dose Sequence 8|Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.
11392172|NCT02088203|Experimental|Single Dose Sequence 9|Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.
11392173|NCT02088203|Experimental|Multiple Dose Sequence 1|Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392174|NCT02088203|Experimental|Multiple Dose Sequence 2|Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392175|NCT02088203|Experimental|Multiple Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392176|NCT02088203|Experimental|Multiple Dose Sequence 4|Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392177|NCT02088203|Experimental|Multiple Dose Sequence 5|Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392178|NCT02088203|Experimental|Multiple Dose Sequence 6|Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392179|NCT02088203|Experimental|Multiple Dose Sequence 7|Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392180|NCT02088203|Experimental|Multiple Dose Sequence 8|Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392181|NCT02088203|Experimental|Multiple Dose Sequence 9|Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
11392182|NCT02088190||Age group 1|Age > 60 years old
11392183|NCT02088190||Age group 2|Age < 60 years old
11392184|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
11392185|NCT02088164||Healthy men|Healthy men who received PSA screening
11392186|NCT02088151|Experimental|Treatment|Patients receive selective retinal pigment epithelium laser treatment
11392187|NCT02088138|Experimental|Functional Electrical Stimulation|"Functional Electrical Stimulation
~In the intervention group the FES was applied in the medial and lateral vastus of both thighs targeting the movement of knee extension. The application frequency was 15 Hz, lasting 40 minutes, pulse width of 0.5 ms, time ON 5s, time OFF 10s, ramp-up of 0 or 1s, descent ramp 2s and intensity as tolerance patient."
11392188|NCT02088138|Experimental|FES placebo|"Functional Electrical Stimulation placebo
~The placebo group received functional electrical stimulation with the same parameters in the intervention group, except that the intensity of stimulation did not lead to visible or palpable contraction."
11392189|NCT02088125|Active Comparator|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
11392190|NCT02088125|Active Comparator|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
11392191|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
11392192|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
11392193|NCT02088099|Experimental|Complex clinical intervention|
11392194|NCT02088099|Active Comparator|Treatment as usual|
11392195|NCT02088086|Experimental|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
11392196|NCT02088086|Active Comparator|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
11392197|NCT02088086|No Intervention|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
11392198|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
11392199|NCT02088073|Placebo Comparator|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
11392200|NCT02088073|Experimental|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
11392201|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
11392202|NCT02088073|Experimental|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
11392203|NCT02088060|Experimental|Cannabidiol|Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks
11392204|NCT02088060|Active Comparator|Olanzapine|Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks
11392205|NCT02088060|Placebo Comparator|Placebo|Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks
11392206|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
11392207|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
11392208|NCT02088034|Experimental|Promotora-led Intervention|The PLI consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
11392209|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
11392210|NCT02088034|Experimental|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
11392211|NCT02088021|Experimental|Portico Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a ALC delivery system
11392212|NCT02088008|Experimental|cilnidipine/valsartan|cilnidipine/valsartan tablet
11392213|NCT02088008|Active Comparator|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
11392214|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
11392215|NCT02087982||Seniors|"The study will be based on a 6-months assessment period, with two consecutive monitoring visits on enrollment.
~Patient follow-up after 3 months will be conducted by telephone and monitoring after 6 months will be carried out as part of a routine consultation.
~Each subject will have a BGA (Brief Geriatric assesment)."
11392216|NCT02087969|Experimental|Dry Needling|Dry Needling to Triceps Surae
11392217|NCT02087969|Experimental|Stretching|Subjects will be given a home exercise program of stretches which are commonly prescribed to improve ankle dorsiflexion.
11392218|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
11392219|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
11392220|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
11392221|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
11392222|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
11392223|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
11392224|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
11392225|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
11392226|NCT02087930||healthy control|healthy infants
11392227|NCT02087917|Placebo Comparator|Placebo|
11392228|NCT02087917|Active Comparator|HS-25 5 MG|
11392229|NCT02087917|Active Comparator|HS-25 10 MG|
11392230|NCT02087917|Active Comparator|HS-25 20 MG|
11392231|NCT02087917|Active Comparator|HS-25 30 MG|
11392232|NCT02087904|Experimental|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
11392233|NCT02087904|Experimental|ABT-981 medium dose|100 mg ABT-981 SC E2W
11392234|NCT02087904|Experimental|ABT-981 high dose|200 mg ABT-981 SC E2W
11392235|NCT02087904|Placebo Comparator|Placebo|Placebo
11392236|NCT02087891|No Intervention|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
11392237|NCT02087891|Experimental|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
11392238|NCT02087891|Experimental|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
11392239|NCT02087891|Experimental|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
11392276|NCT02087618|Active Comparator|Kodro+|Will begin Kodro program at baseline
11392240|NCT02087878||Group 1|To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL.
11392241|NCT02087865|Active Comparator|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
11392242|NCT02087865|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks.
11392243|NCT02087865|No Intervention|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
11392244|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
11392245|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
11392246|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
11392247|NCT02087852||high risk|Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation
11392248|NCT02087826|Active Comparator|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test
~Day 3-7: 500mg metformin, twice daily
~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
11392249|NCT02087826|Placebo Comparator|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test
~Day 3-7: 500mg metformin, twice daily
~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
11392250|NCT02087813|Experimental|A1AT|Alpha1-antitrypsin 120mg/kg once weekly for a total of 4 doses, to be given intravenously. This will be given in addition to standard of care 3-5 days of 1000mg IV methylprednisolone.
11392251|NCT02087813|Active Comparator|Standard of care|Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
11392252|NCT02087800||F Phase Lab session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the F phase lab session will be first. Followed by the L phase lab session.
11392253|NCT02087800||L Phase Lab Session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the L phase lab session will be first. Followed by the F phase lab session.
11392254|NCT02087787|No Intervention|Control|The control group will be provided the standard method, which is providing the Cancer Legal Line (CALL) brochure with a short explanation of the resource.
11392255|NCT02087787|Experimental|Intervention|The intervention group will be provided with a 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
11392256|NCT02087774|No Intervention|Control School|Control School received no intervention.
11392257|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
11392258|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
11392259|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
11392260|NCT02087735|Experimental|cranberry extract 1|One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
11392261|NCT02087735|Experimental|cranberry extract 2.|Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
11392262|NCT02087735|Placebo Comparator|cranberry extract 3.|Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
11392263|NCT02087722|Experimental|KI1001|
11392264|NCT02087722|Placebo Comparator|Placebo|
11392265|NCT02087709|Experimental|Low-calorie diet|The subjects were prescribed a daily energy intake 500 kcal lower than the estimated energy requirement.
11392266|NCT02087696|Other|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.
~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
11392267|NCT02087696|Other|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.
~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
11392268|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months.
11392269|NCT02087683|Placebo Comparator|Control Group (Placebo)|Participants in this group will receive a placebo containing gelatin and corn oil per day for 12 months
11392270|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
11392271|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
11392272|NCT02087657|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
11392273|NCT02087644|Experimental|CYT003|Injections of CYT003
11392274|NCT02087644|Placebo Comparator|Placebo|Injections of placebo
11392277|NCT02087618|Placebo Comparator|Kodro+D|Will begin Kodro program 12-weeks post baseline
11392278|NCT02087592|No Intervention|Control|Usual standard of care
11392279|NCT02087592|Experimental|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
11392280|NCT02087579|Experimental|Cohort A: Aripiprazole|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
11392281|NCT02087579|Experimental|Cohort B: Olanzapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
11392282|NCT02087579|Experimental|Cohort C: Paliperidone|Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
11392283|NCT02087579|Experimental|Cohort D: Quetiapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
11392284|NCT02087579|Experimental|Cohort E: Risperidone|Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
11392285|NCT02087566|Other|Administration of linezolid to 6 healthy volunteers|Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
11392286|NCT02087566|Other|Administration of linezolid to 6 acute renal failure patients|Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
11392287|NCT02087566|Other|Administration of linezolid to 6 ESRD patients|Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of >60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).
11392288|NCT02087553||Transfused pediatric patients|Children who might receive packed red blood cell (PRBC) transfusion will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Transfusion of red blood cells will be done according to standard of care.
11392289|NCT02087553||Saline/Albumin infusion|Children who might receive albumin or saline for volume resuscitation will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Infusion will be done according to standard of care.
11392290|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
11392291|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
11392292|NCT02087540|Active Comparator|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
11392293|NCT02087540|Active Comparator|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
11392294|NCT02087540|Active Comparator|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
11392295|NCT02087540|Placebo Comparator|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
11392296|NCT02087527|Experimental|CORTICOSTEROID|In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
11392297|NCT02087527|Placebo Comparator|NORMAL SALINE|In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours
11392298|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
11392299|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
11392300|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
11392301|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
11392302|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
11392303|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
11392304|NCT02087501|Other|HORIZON AAA Stent Graft|All patients will received the HORIZON AAA Stent Graft
11392305|NCT02087488|Experimental|auricular acupuncture(AA) & Eszopiclone|The disposable Seirin Pyonex Needle will be chosen as AA material to attach every 3 days for 4 weeks, meanwhile, oral Eszopiclone 1 piece (3mg) will be applied 15 minutes before going to sleep everyday for 4 weeks. The manufacturer of disposable Seirin Pyonex Needles is Seirin Corporation, a Japanese company.
11392306|NCT02087488|Placebo Comparator|placebo AA & Eszopiclone|The disposable Pyonex Zero Needle, a non-invasive material will be chosen as placebo AA, with auricular acupoints have no certain effect on PI. Additionally, 1 piece (3mg) Eszopiclone will be administrated to participants 15 minutes before going to sleep everyday for 4 weeks.
11392307|NCT02087475|Experimental|Neoadjuvant therapy arm|FOLFIRI * 6 cycles +/- radiotherapy -> surgery -> FOLFIRI * 6 cycles
11392308|NCT02087475|Active Comparator|Adjuvant therapy arm|Surgery -> FOLFIRI * 12 cycles +/- radiotherapy
11392309|NCT02087462|Experimental|Electroacupuncture (EA)|Use Electroacupuncture only
11392310|NCT02087462|Other|EA + Traction|Use electroacupuncture and traction together
11392311|NCT02087462|Other|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
11392312|NCT02087449||E1-Hip Bearing|E1-Hip Bearing, Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population
11392313|NCT02087436|Active Comparator|Taperloc Complete Standard|Group one will receive a total hip replacement with Taperloc Complete Standard. Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
11392314|NCT02087436|Active Comparator|Taperloc Complete Microplasty|Group one will receive a total hip replacement with Taperloc Complete Microplasty.Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
11392315|NCT02087423|Experimental|MEDI4736|see below
11392320|NCT02087384|Placebo Comparator|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
11392321|NCT02087371||Included patients|Patients with end-stage liver failure and registered on transplantation list.
11392322|NCT02087358||Stress and craving|This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
11392323|NCT02087345||Dental erosions|
11392324|NCT02087332|Experimental|Prolonged release Torasemide (Britomar)|"Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose.
~Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect."
11392325|NCT02087332|Active Comparator|Torasemide (Diuver)|Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate. Dosage scheme: per os, once a day, after meals. Therapeutic dose - 5 mg a day. If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
11392326|NCT02087319|Experimental|platelet-rich plasma|hair loss, baldness
11392327|NCT02087306|Experimental|CMX001|
11392328|NCT02087293|Experimental|Intervention group, IVR call, RPh counseling|Group receives interactive voice response automated call asking about side effects of newly prescribed medications; has opportunity to speak with study pharmacist via phone about medication
11392329|NCT02087293|No Intervention|Control|Intervention patients are matched with control patients; control patients have only chart review completed.
11392330|NCT02087280||Anorexia Nervosa|
11392331|NCT02087280||Healthy controls|
11392332|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
11392333|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
11392334|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
11392335|NCT02087228|Experimental|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
11392336|NCT02087228|Active Comparator|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
11392337|NCT02087215|Active Comparator|boron gel|diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
11392338|NCT02087215|Placebo Comparator|control gel|placebo gel containing polymer of carbopol ultrex (1%)
11392339|NCT02087202|Experimental|magnesium|magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.
11392340|NCT02087202|Experimental|ketamine|ketamine is administered to those patients undergoing stated TKA and other operations.
11392341|NCT02087202|Placebo Comparator|control|normal saline (placebo) is administered to the patients.
11392342|NCT02087189||ICD/ CRT-D therapy|
11392343|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
11392344|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
11392345|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
11392346|NCT02087150|No Intervention|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
11392347|NCT02087150|Experimental|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
11392348|NCT02087137|Active Comparator|Memory and Aging Program|The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
11392349|NCT02087137|No Intervention|Wait-list Control|Participants randomized to the wait-list control group will receive no intervention following randomization. They will be offered the intervention immediately following completion of the week 14 outcome testing session.
11392350|NCT02087124|Experimental|0g whey protein|0g whey protein dissolved in 200 milliliter (mL) water.
11392351|NCT02087124|Experimental|10g whey protein|10g whey protein dissolved in 200 milliliter (mL) water.
11392352|NCT02087124|Experimental|20g whey protein|20g whey protein dissolved in 200 milliliter (mL) water.
11392353|NCT02087111|Experimental|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
11392354|NCT02087098||Patients with residual OAB symptoms|Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics
11392355|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
11392356|NCT02087085|Sham Comparator|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
11392357|NCT02087072||Recently discharged homebound patients|
11392387|NCT02086851|Experimental|Lifestyle Intervention plus Parent Motivational Interviewing|Lifestyle intervention + Parent MI
11392388|NCT02086851|Active Comparator|Lifestyle Intervention alone|lifestyle intervention alone
11392358|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
11392359|NCT02087046|Other|Stimulation|Deep Brain Stimulation with the Libra System
11392360|NCT02087033|Placebo Comparator|ritmonutra and placebo|ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks
11392361|NCT02087020||Periprosthetic joint infection|Patient treated with 'Debridement, antibiotics and implant retention' for early postoperative periprosthetic joint infection at Danderyd Hospital between 2007-01-01 and 2012-12-01
11392362|NCT02087007|Experimental|group 1|Cilostazol 50mg, Cilostzaol 100mg
11392363|NCT02087007|Placebo Comparator|group 2|placebo
11392364|NCT02086994|Active Comparator|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
11392365|NCT02086994|Active Comparator|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
11392366|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
11392367|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
11392368|NCT02086955|No Intervention|Standard care|All participants receive three specially-developed brochures with information regarding the diabetic foot condition. The brochures containes explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home.
11392369|NCT02086955|Experimental|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention go on for five weeks. During a period of five weeks, the participants are provided with weekly education, skill training, and counseling sessions on foot care.
11392370|NCT02086942|Experimental|modified VCD regimen1|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen1 for 5 cycles.
~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.
~Interventions:
~Drug: Bortezomib 1.6mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
11392371|NCT02086942|Experimental|modified VCD regimen2|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen 2 for 5 cycles.
~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.
~Interventions:
~Drug: Bortezomib 1.3mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
11392372|NCT02086929|Experimental|Trazodone|"300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.
~Dosage form: capsule."
11392373|NCT02086929|Active Comparator|Venlafaxine XR|"75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.
~Dosage form: capsule."
11392374|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
11392375|NCT02086903|Experimental|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
11392376|NCT02086903|Experimental|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
11392377|NCT02086890|Experimental|Electro-acupuncture|Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
11392378|NCT02086890|Sham Comparator|Sham Electro-acupuncture|No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
11392379|NCT02086890|Experimental|Laser acupuncture|Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
11392380|NCT02086890|Sham Comparator|Sham Laser acupuncture|An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
11392381|NCT02086890|Experimental|Transcorneal Electrical Stimulation|Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
11392382|NCT02086890|Sham Comparator|Sham Transcorneal Electrical Stimulation|Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
11392383|NCT02086877||ICU Survivors who required > 72 hrs mechanical ventilation|No intervention
11392384|NCT02086864|No Intervention|Usual care|
11392385|NCT02086864|Active Comparator|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
11392386|NCT02086864|Placebo Comparator|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
11392389|NCT02086838|Active Comparator|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
11392390|NCT02086838|Active Comparator|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
11392391|NCT02086825|Experimental|Rifaximin|
11392392|NCT02086825|Experimental|Lactulose|
11392393|NCT02086799|Experimental|IV thyroxin|IV thyroxin
11392394|NCT02086799|Placebo Comparator|control IV saline|Placebo
11392395|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
11392396|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
11392397|NCT02086773|Experimental|Low transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 7 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
11392398|NCT02086773|Active Comparator|High transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 8 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
11392399|NCT02086760|Experimental|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
11392400|NCT02086747|Active Comparator|Acetaminophen|Postoperative 72 hours acetaminophen 1 g iv 4 times a day for 72 hours iv
11392401|NCT02086747|Placebo Comparator|isotonic|1 g intravenous %0.9 NaCl four times Daily for 72 hours
11392402|NCT02086734||mRCC patients assessed with Perfusion CT|Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT
11392403|NCT02086721|Experimental|Oligometastatic cancer patients; N=18|
11392404|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
11392405|NCT02086695||Cancer Group|All subjects with cancer who will be treated with anyone of the following chemotherapy drugs; Pazopanib, Sutent or Bevacizumab
11392406|NCT02086682||General Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.
11392407|NCT02086682||Critical Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.
11392408|NCT02086669|Experimental|Pneumatic dilatation|Repetitive pneumatic dilatation as the initial treatment followed by repetitive dilatation in case of dysphagia recurrence.
11392409|NCT02086669|Active Comparator|Surgical myotomy|Laparoscopic myotomy and subsequent follow up.
11392410|NCT02086656|Experimental|open label|Single arm, open label
11392411|NCT02086643|Experimental|Retroclavicular block|Retroclavicular block
11392412|NCT02086630|Experimental|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
11392413|NCT02086630|No Intervention|Control|Treatment as usual
11392414|NCT02086617|Other|ultrasound of aorta|
11392415|NCT02086604|Experimental|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.
~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
11392416|NCT02086604|Experimental|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.
~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
11392417|NCT02086604|Experimental|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.
~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
11392418|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
11392419|NCT02086578|Experimental|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
11392420|NCT02086578|Experimental|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
11392421|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
11392422|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
11392532|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
11392423|NCT02086552|Experimental|Treatment (sonidegib, lenalidomide)|Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.
11392424|NCT02086539|No Intervention|Normal Letter|This arm will receive the recruitment letter in a business sized envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
11392425|NCT02086539|Experimental|Large Envelope|This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
11392426|NCT02086539|Experimental|Priority Mail|Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
11392427|NCT02086539|Experimental|Amazon|This arm will receive a recruitment letter with the image of an Amazon gift card and told they will receive the $25 gift card if they enroll in the study.
11392428|NCT02086526|Experimental|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
11392429|NCT02086526|Other|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
11392430|NCT02086513|Experimental|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose of 200 mg, 400 mg, 600 mg, or 800 mg depending on the specific cohort. Starting dose 200 mg daily for a 28 day cycle. The DLT period will be for the first 2 cycles of therapy. Each cycle is 28 days in length, making the DLT period of minimum of 56 days.
11392431|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
11392432|NCT02086500|Placebo Comparator|Control|Identical volume of saline during emergency medical transport
11392433|NCT02086487|Experimental|Nilotinib 300 mg|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely.
~In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones:
~BCR-ABL1 transcript level ≤ 10% at 3 months;
~CCyR at 6 months,
~BCR/ABL1 ≤ 1% at 6 months
~MMR at 12 months, or
~if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose."
11392434|NCT02086474|Experimental|Hyaluronan|Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection
11392435|NCT02086474|Placebo Comparator|Bupivacaine|one Marcain extra-capsular injection
11392436|NCT02086461|Sham Comparator|15 mm Pyloric balloon dilatation.|During fluoroscopic control the pneumatic balloon is positioned of the pyloric sphincter and maintained there during the entire dilatation.
11392437|NCT02086461|Active Comparator|Pneumatic pyloric dilatation.|Endoscopy and 15 mm balloon dilatation is completed according to the same principle as active comparator arm.
11392438|NCT02086448|No Intervention|Obese, SDB negative|No intervention, observational comparison group
11392439|NCT02086448|Active Comparator|Obese, SDB postive, CPAP|Therapeutic CPAP
11392440|NCT02086448|Sham Comparator|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
11392441|NCT02086448|Other|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
11392442|NCT02086435|Experimental|Extracorporeal morcellation|"Extracorporeal morcellation in which patients are treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
11392443|NCT02086435|Active Comparator|Intracorporeal morcellation|Intracorporeal morcellation patients treated with standard intracorporeal morcellation, using reusable electronic device
11392444|NCT02086422|Active Comparator|ivabradine|Exercise with ivabradine
11392445|NCT02086422|Placebo Comparator|Placebo|Exercise with placebo
11392446|NCT02086409|Experimental|Yogurt supplemented with vitamin D and calcium|20 participants take yogurt supplemented with vitamin D and calcium during 12 weeks
11392447|NCT02086409|Active Comparator|Yogurt not supplemented with vitamin D and calcium|20 participants take yogurt not supplemented with vitamin D and calcium during 12 weeks
11392448|NCT02086396|Experimental|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
11392449|NCT02086396|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
11392450|NCT02086383||Patients with COPD|This is an observational study of patients with chronic obstructive pulmonary disease (COPD) who attend pulmonary rehabilitation, which is the routine standard of care in Guy's and St. Thomas' Hospital, London. It lasts for 14 sessions, twice a week and primarily consists of a supervised exercise program and educational sessions.
11392451|NCT02086370|Active Comparator|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
11392452|NCT02086370|Experimental|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
11392453|NCT02086357||SWUE|
11392454|NCT02086344|Experimental|TLH_plus_PBS|TLH plus PBS
11392455|NCT02086344|Active Comparator|TLH _adnexal preservation|Standard TLH without PBS
11392456|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
11392457|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
11392458|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
11392459|NCT02086318||OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
11392460|NCT02086305|Experimental|Usual Care + Transitional Care Model|Transitional Care, Evidence-based symptom management, Protocol-driven home visit and telephone follow-up, Trained nurse case manager and volunteer partnership
11392461|NCT02086305|Active Comparator|Usual Care|Usual care
11392462|NCT02086292|Experimental|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
11392463|NCT02086292|Experimental|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
11392464|NCT02086279|No Intervention|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for surgery are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.
~Patients enrolled will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between 1 and 4 days of the menstrual cycle will be measured at study entry and at 1, 3 and 6 months after the administration of the first vial of GnRH-a"
11392465|NCT02086266|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
11392466|NCT02086266|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation associated with Pelvic Floor Muscle Training, supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
11392467|NCT02086253|Experimental|BQ-788|Effect of BQ-788 on the magnitude of sustained flow-mediated dilatation
11392468|NCT02086253|Experimental|BQ-123|Effect of BQ-123 on the magnitude of sustained flow-mediated dilatation
11392469|NCT02086253|Experimental|BQ-788 + BQ-123|Effect of BQ-788+BQ-123 on the magnitude of sustained flow-mediated dilatation
11392470|NCT02086240|Experimental|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity. In a previous study (approved by NRES Committee London-West London, REC ref No. 12/LO/0735), we administered an oral dose of XBD173 (up to 90mg) in 12 subjects. No adverse events due to XBD173 occurred and it was well tolerated.
11392471|NCT02086227|Experimental|A Glucagon for Injection, Fresenius Kabi USA|The subjects will be administered the test (A) (Glucagon for Injection, Fresenius Kabi USA)or reference (B) product (GlucaGen® for Injection, Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
11392472|NCT02086227|Active Comparator|B GlucaGen® (Bedford Laboratories)|The subjects will be administered the test (A) Glucagon for Injection, Fresenius Kabi USA; or reference (B) product, GlucaGen® (Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
11392473|NCT02086214|Experimental|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
11392474|NCT02086214|Placebo Comparator|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
11392475|NCT02086201|Active Comparator|Problem Solving Therapy|Problem solving therapy is an evidence based psychotherapy for depression, with 30 years of research supporting its efficacy. PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment.
11392476|NCT02086201|Experimental|Engage|"Engage utilizes reward exposure consisting of the reintroduction of activities that patients once found rewarding and enjoyed, but have abandoned after they developed depression. Engage uses basic problem solving through which patients learn how to form action plans for pursuing rewarding activities of their choice."
11392477|NCT02086188|Experimental|Mirabegron|Mirabegron - 25mg (one tablet) taken by mouth daily with option to up-titrate to 50mg daily (two tablets) taken by mouth daily
11392478|NCT02086188|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth daily and two tablets taken by mouth daily if subject chooses up-titration
11392479|NCT02086175|Experimental|Imprime PGG and Rituximab|The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment
11392480|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
11392481|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
11392482|NCT02086149|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
11392483|NCT02086149|Active Comparator|Health Education|12-week health education control
11392484|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
11392485|NCT02086123|Active Comparator|Epidural Analgesia|Subjects randomized to this arm will receive Bupivacaine + Fentanyl Epidural Analgesia. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
11392486|NCT02086123|Active Comparator|Parenteral Analgesia (Intravenous)|Subjects randomized to this arm will receive Analgesia with Dilaudid 0.2 -0.4 mg Intravenously (IV) every 3 hours. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
11392533|NCT02085707|Active Comparator|Total hip replacement arthroplasty|59 off 118 patients will be randomized to total hip replacement arthroplasty
11392534|NCT02085707|Active Comparator|Closed reduction and internal fixation|"59 off 118 patients will be randomized to closed reduction and internal fixation.
~2 cancellous parallel hip pins"
11392535|NCT02085694|Experimental|Lactobacillus brevis CD2 lozenges|
11392487|NCT02086110|Active Comparator|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
11392488|NCT02086110|Active Comparator|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
11392489|NCT02086097|Experimental|dexketoprofen trometamol|Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
11392490|NCT02086097|Active Comparator|IBUPROFEN|Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
11392491|NCT02086097|Placebo Comparator|PLACEBO|4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
11392492|NCT02086084|Active Comparator|NIV|Standard application of NIV in hypercapnic respiratory failure as per usual standard of care
11392493|NCT02086084|Experimental|ECCO2R|Addition of ECCO2R to NIV in AECOPD
11392494|NCT02086071|Other|Re biopsies feasibility|the Interest of the study is to evaluate the feasibility of the re biopsy; the re biopsy is done if the patient agrees to perform it.
11392495|NCT02086045|Other|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|DESolve Scaffold
11392496|NCT02086032|Experimental|micronized progesterone|1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
11392497|NCT02086032|Experimental|dydrogesterone|1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.
11392498|NCT02086019|Other|Conservative Arm- Medical therapy|Medical therapy
11392499|NCT02086019|Other|Invasive Arm-angiogram with PCI or CABG|same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate
11392500|NCT02086006|Other|DESolve scaffold|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold. test arm, intervention
11392501|NCT02085993||single arm|single arm study
11392502|NCT02085980|Experimental|Laser Treatment|Laser Treatment
11392503|NCT02085967|Experimental|E2006 Part A|E2006 10-mg tablets alone and in combination with rifampin 600 mg or itraconazole 200 mg
11392504|NCT02085967|Experimental|E2006 Part B|E2006 10-mg tablets alone and in combination with midazolam 2 mg plus bupropion 75 mg
11392505|NCT02085941|Experimental|Image-guided cryoablation +/- biopsy|"MRI/PET/CT imaging in the Advanced Multimodality Image Guided Operating (AMIGO) suite used to place cryoablation needle(s) into target lesion (Mean: 3 cryoprobes, Range: 1-10).
~MR/PET/CT imaging in the AMIGO suite will monitor two 15-minute freeze cycles separated by a 10 minute thaw period."
11392506|NCT02085928||Lateral epicondylitis|Patients with lateral epicondylitis with persistent pain for at least 3 months
11392507|NCT02085915|Other|strip Peri Screen|
11392508|NCT02085902|No Intervention|standard anesthesia|
11392509|NCT02085902|Experimental|standard anesthesia with ropivacaine|ropivacaine
11392510|NCT02085889||food intolerance|lactose intolerance fructose intolerance neither intolerance
11392511|NCT02085876||Patients requiring a liver biopsy|
11392512|NCT02085863|Experimental|Laquinimod|once daily oral doses of laquinimod (with combination oral contraceptives)
11392513|NCT02085863|Placebo Comparator|Placebo|Matching placebo (with combination oral contraceptives)
11392514|NCT02085850||Subjects identified in the Tema Eye Survey|Subjects identified in the Tema Eye Survey
11392515|NCT02085837|Experimental|Healthy Transitions Group|"Additional nursing services will be provided to this group in addition to a usual care by Nephrologist.
~Daily weight measurement and monitoring
~Medication review
~Universal dietary education
~Focused advanced directive program
~Countdown to fistula program"
11392516|NCT02085837|No Intervention|Usual Care Group|Usual care by nephrologist. No additional nursing support services will be provide to this group.
11392517|NCT02085824|Experimental|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
11392518|NCT02085824|Experimental|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
11392519|NCT02085824|Experimental|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
11392520|NCT02085811||Patients|
11392521|NCT02085798||Group 1|Low or intermediate-1 risk MDS patients according to IPSS
11392522|NCT02085798||Group 2|Intermediate-2 risk MDS patients according to IPSS
11392523|NCT02085798||Group 3|Any risk CMML patients according to CPSS
11392524|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
11392525|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
11392526|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
11392527|NCT02085772|Experimental|Patients with pre-conceptional obesity|
11392528|NCT02085759||Normal BMI|Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.
11392529|NCT02085759||Overweight BMI|Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.
11392530|NCT02085759||Obese BMI|Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.
11392531|NCT02085733||Possible Septic Arhtritis Patients|
11392536|NCT02085681|Experimental|Tele-medicine|Tele-medicine aided retinal imaging and referral to eye hospital
11392537|NCT02085681|Other|Conventional Referral|Patients will be counselled on the importance of eye examination and will be referred to the eye hospital in the conventional manner.
11392538|NCT02085668|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
11392539|NCT02085668|No Intervention|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
11392540|NCT02085655|Experimental|PEG-ASP+Gemox regimen group|PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21
11392541|NCT02085655|Active Comparator|AspaMetDex regimen group|Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD
11392542|NCT02085642|Experimental|Acupuncture|True acupuncture
11392543|NCT02085642|Sham Comparator|Sham needle|Retractable acupuncture needles will be used. No true transcutaneous needling through the skin
11392544|NCT02085629|Experimental|M reg treatment|"Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:
~Prednisolone
~D 0: 500 mg IV
~D 1: 125 mg IV
~D 2 - 14: 20.0 mg/d (oral)
~Wk 3 - 4: 15.0 mg/d
~Wk 5 - 8: 10.0 mg/d
~Wk 9 - 12: 5.0 mg/d
~Wk 13 - 14: 2.5 mg/d
~Wk 15 - End: Cessation
~MMF (or biologic equiv.)
~D -7 to -2: 500 mg/d (250mg 2x/d)
~D -1 to 14: 2000 mg/d
~Wk 3 - 36: 1000 mg/d
~Wk 37 - 40: 750 mg/d
~Wk 41 - 44: 500 mg/d
~Wk 45 - 48: 250 mg/d
~Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.
~Tacrolimus (or biologic equiv.)
~≤ 48 h pre-Tx to D 14: 3-12 ng/ml
~Wk 3 - 12: 3-10 ng/ml
~Wk 13 - 36: 3-8 ng/ml
~Wk 37 - End: 3-6 ng/ml"
11392545|NCT02085616|Experimental|Proactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
11392546|NCT02085616|Active Comparator|Reactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
11392547|NCT02085603|Active Comparator|Saracatinib|Saracatinib at a dose of 125mg orally will be administered daily for four weeks.
11392548|NCT02085603|Placebo Comparator|Placebo|Placebo tablet to be orally administered daily for four weeks.
11392549|NCT02085590|Active Comparator|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
11392550|NCT02085590|Placebo Comparator|NaCl 0.9%|injection 0.1 cc intradermal
11392551|NCT02085577|Experimental|Ketamine|"(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/h terminated at last suture to the skin.
~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.
~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.
~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed
~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.
~The patients usual daily opioids"
11392552|NCT02085577|Placebo Comparator|Placebo|"Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/h terminated at last suture to the skin.
~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.
~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.
~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed
~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.
~The patients usual daily opioids"
11392553|NCT02085564||GEJ-cancer patients consideres resectable|All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
11392554|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
11392555|NCT02085538|Experimental|Normal Renal Function|
11392556|NCT02085538|Experimental|Mild Renal Impairment|
11392557|NCT02085538|Experimental|Moderate Renal Impairment|
11392558|NCT02085538|Experimental|Severe Renal Impairment|
11392559|NCT02085525|Other|Weekly NP Visits|100 HNC (Head and Neck Cancer) patients seen weekly in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
11392560|NCT02085525|Other|Every Other Week NP Visits|100 HNC (Head and Neck Cancer) patients seen every other week in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
11392561|NCT02085512|Experimental|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
11392562|NCT02085512|Placebo Comparator|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
11392563|NCT02085499|Other|NIMV followed by S-NIMV|During the study infants assigned to this arm will undergo a 2-hour period of non-synchronized NIMV followed by a 2-hour period of Synchronized-NIMV.
11392670|NCT02084823|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11392564|NCT02085499|Other|S-NIMV followed by NIMV|During the study infants assigned to this arm will undergo a 2-hour period of synchronized NIMV followed by a 2-hour period of non-synchronized NIMV.
11392565|NCT02085486|Experimental|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
11392566|NCT02085486|Other|Standard|Classical method wtih inspection and palpation
11392567|NCT02085473|Active Comparator|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
11392568|NCT02085473|Experimental|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
11392569|NCT02085473|Experimental|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
11392570|NCT02085473|Experimental|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
11392571|NCT02085460|Placebo Comparator|Placebo|6 times daily
11392572|NCT02085460|Experimental|2% Rebamipide liquid|6 times daily
11392573|NCT02085460|Experimental|4% Rebamipide liquid|6 times daily
11392574|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
11392575|NCT02085434|Experimental|FITLINE practice-based referral program|
11392576|NCT02085434|No Intervention|Contemporaneous control|
11392577|NCT02085421|Active Comparator|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
11392578|NCT02085421|Sham Comparator|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
11392579|NCT02085408|Active Comparator|Arm I (daunorubicin hydrochloride and cytarabine)|See Detailed Description
11392580|NCT02085408|Experimental|Arm II (clofarabine)|See Detailed Description
11392581|NCT02085395|Experimental|SR-T100 ® Gel|Topical gel containing 2.3% of solamargine in Solanum undatum extract is used once daily with occlusive dressing for 16 weeks.
11392582|NCT02085382|Other|Kangaroo Mother Care Group|"Mothers in the KMC group were oriented in detail about KMC procedure. The mothers provided skin to skin contact using a specially tailored kangaroo tube made of soft flannel cloth. The mothers were encouraged to keep the baby in KMC as long as possible during the day and night for an accumulated time of at least 6 hours per day. The duration of the kangaroo care by each of the mother were recorded and tallied accordingly."
11392583|NCT02085382|Other|Conventional Mother Care|Conventional method of care was the routine care offered in the neonatal unit to low birth weight infants.
11392584|NCT02085356|Experimental|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
11392585|NCT02085356|Experimental|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
11392586|NCT02085356|No Intervention|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
11392587|NCT02085356|No Intervention|Control women alone|Women will enroll alone and will attend time-matched video sessions
11392588|NCT02085343|Experimental|EXP + SBF + AA|Exposure therapy (EXP) with safety behavior fading (SBF) and anti-phobic action (AA)
11392589|NCT02085343|Active Comparator|EXP + SBF|Exposure therapy (EXP) with safety behavior fading (SBF)
11392590|NCT02085343|Active Comparator|EXP|Standard therapist-guided in vivo exposure therapy (EXP)
11392591|NCT02085343|No Intervention|Wait-list control|Subjects assigned to this arm will undergo assessments at Weeks 0, Week 1, and Week 5, but will not receive any interventions.
11392592|NCT02085330|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
11392593|NCT02085330|No Intervention|Standard follow up|
11392594|NCT02085317|Other|Lepromatous Patients|Composed of patients with lepromatous Leprosy acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
11392595|NCT02085317|Other|Healthy Patients|Composed of patients without any disease acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
11392596|NCT02085304|Experimental|GammaKnife(R) stereotactic radiosurgery|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
11392597|NCT02085304|Active Comparator|Standard fractionated radiation therapy|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.
11392598|NCT02085291|Experimental|Resp-FL|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one. The target MAP was maintain MAP within 10% of the reference value.
11392599|NCT02085291|Experimental|Resp-NE|In Resp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
11392600|NCT02085291|Experimental|Nonresp-NE|In Nonresp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
11392601|NCT02085278|Experimental|Apollo Group|Apollo Micro catheter device
11392602|NCT02085265|Experimental|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
11392603|NCT02085265|Active Comparator|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
11393555|NCT02078908|Placebo Comparator|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
11392604|NCT02085252|Experimental|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
11392605|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
11392606|NCT02085239|Active Comparator|Lidocaine alone|Lidocaine: 8-10 ml of Lidocaine by subcutaneous injection
11392607|NCT02085239|Experimental|Lidocaine Ropivacaine|"Lidocaine Ropivacaine
~8-10 ml of Lidocaine given by subcutaneous injection
~8-10 ml of Ropivacaine given by subcutaneous injection"
11392608|NCT02085226|Experimental|Creative Engagement Intervention|Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
11392609|NCT02085226|Placebo Comparator|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
11392610|NCT02085213|Experimental|Glyceryl Trinitrate|"Nitrolingual Pump Spray [Coro-Nitro] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.
~Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.
~The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given."
11392611|NCT02085213|Placebo Comparator|Placebo|Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
11392612|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
11392613|NCT02085200|Other|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
11392614|NCT02085187|Experimental|Telemedicine training and counselling|
11392615|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
11392616|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
11392617|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
11392618|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
11392619|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
11392620|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
11392621|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
11392622|NCT02085135|Experimental|Titration Schedule 1|
11392623|NCT02085135|Experimental|Titration Schedule 2|
11392624|NCT02085122|Experimental|noninvasive ventilation|
11392625|NCT02085122|No Intervention|Control Group|
11392626|NCT02085109|Experimental|High fat meal|A high fat milkshake containing 60.6 grams of fat
11392627|NCT02085109|Placebo Comparator|Low fat meal|A Low fat milkshake containing 10.5 gram of fat
11392628|NCT02085109|Experimental|A Low fat meal containing theobromine|A low fat milkshake containing 10.5 grams of fat supplemented with 850 mg of theobromine
11392629|NCT02085096|Experimental|Problem-Solving Therapy|A problem-solving therapy training program will be provided to the spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
11392630|NCT02085096|Placebo Comparator|Standard Supportive Care|Participants who are randomized to this arm will be encouraged to use whatever supporting care is recommended to them by their health provider.
11392631|NCT02085083|Experimental|Regular telephone and email access to an IBD Nurse|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the intervention arm each month. The email will include the following: Brief Questionnaire;The Option For Direct Nurse Contact; Educational modules; MyHealth Passport and a Comprehensive Study Questionnaire.
11392632|NCT02085083|Active Comparator|Minimal Intervention|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the control arm every 3 months. The email will include the following: MyHealth Passport and Study Questionnaire. This intervention is not expected to significantly improve outcomes.
11392871|NCT02083406|Experimental|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
11392633|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
11392634|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
11392635|NCT02085057||anorexia nervosa|Diagnosis of anorexia nervosa
11392636|NCT02085057||obsessive-compulsive disorder|Diagnosis of obsessive-compulsive disorder
11392637|NCT02085057||healthy control|No psychiatric diagnoses
11392638|NCT02085057||sisters|Sisters of those enrolled with a diagnosis of anorexia nervosa
11392639|NCT02085044|Experimental|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
11392640|NCT02085044|Active Comparator|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
11392641|NCT02085031|Experimental|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed for the patients assigned to this arm.
11392642|NCT02085031|Active Comparator|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed for the patients assigned to this arm.
11392643|NCT02085018|Experimental|Omeprazole|Omeprazole 20 milligrams twice a day taken for 90 days
11392644|NCT02085018|Placebo Comparator|Matched placebo|Matched placebo twice a day taken for 90 days
11392645|NCT02085005|Experimental|Aflibercept|Intravenous (IV) infusion on Day 1 every 3 weeks, followed by CAPOX (capecitabine by oral administration on Day 1 to Day 14 and oxaliplatin intravenous (IV) infusion on Day 1 every 3 weeks) for the induction treatment period (6 cycles) after which the patient may enter the maintenance period during which the treatment is Aflibercept + Capecitabine
11392646|NCT02084992|Experimental|Expanded technology disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.
11392647|NCT02084992|Active Comparator|telephonic disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.
11392648|NCT02084979|Experimental|Asynchronous telepsychiatry|Experimental Arm: Asynchronous telepsychiatry evaluation and consultation
11392649|NCT02084979|Active Comparator|Synchronous telepsychiatry|Control Arm: Synchronous telepsychiatry evaluation and consultation
11392650|NCT02084966|Experimental|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
11392651|NCT02084953|Experimental|ARM A: BMS-791325|BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days
11392652|NCT02084953|Active Comparator|ARM B: Moxifloxacin|Moxifloxacin 400mg tablet orally once on third day
11392653|NCT02084953|Placebo Comparator|ARM C: Placebo matching BMS-791325|Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days
11392654|NCT02084940||GnRH antagonist depot, Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
11392655|NCT02084927|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
11392656|NCT02084927|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
11392657|NCT02084914|Experimental|Group A|Endometrial scraching of uterine cavity by pipelle .
11392658|NCT02084914|Active Comparator|Group B|Uterine sound intoduced into uterine cavity without scratch .
11392659|NCT02084901|Experimental|Orsiro Arm|
11392660|NCT02084901|Active Comparator|BioMatrix or BioMatrix Flex Arm|
11392661|NCT02084875|Experimental|tofacitinib MR 11 mg Fed|tofacitinib modified release (MR) 11 mg tablet administered with food.
11392662|NCT02084875|Experimental|tofacitinib MR 11 mg Fasting|tofacitinib modified release (MR) 11 mg tablet administered without food.
11392663|NCT02084862|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
11392664|NCT02084862|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
11392665|NCT02084849||Group 1|Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.
11392666|NCT02084849||Group 2|Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.
11392667|NCT02084836||Lean adolescents|
11392668|NCT02084823|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11392669|NCT02084823|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11392671|NCT02084823|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11392672|NCT02084810|Active Comparator|NovoSeven®|
11392673|NCT02084810|Experimental|Eptacog alfa A 6 mg|
11392674|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
11392675|NCT02084784|Experimental|Indocyanine green & methylene blue,|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%
11392676|NCT02084771|Experimental|Oral Salt and Water|"Oral Salt and Water Loading:
~Participants randomized to this arm of the trial will receive 0.1 g/kg of salt (NaCl) and 12 mL/kg of water. Patients weighing more than 110 kg will receive the same amount as per a 110 kg patient. One third of the oral salt and water will be given before the CT and 2/3 post-CT as in the intravenous saline arm. Specifically, 0.03 g/kg of NaCl and 4 mL/kg of water in the one hour before CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken over 2 hours post-CT. The ingestion of the oral salt and water will be directly observed by the study nurse to ensure adherence to the protocol."
11392677|NCT02084771|Active Comparator|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
11392678|NCT02084758|Active Comparator|Nitrate supplementation|Sodium nitrate solution
11392679|NCT02084758|Placebo Comparator|Placebo supplementation|Sodium chloride solution
11392680|NCT02084745|Active Comparator|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
11392681|NCT02084745|Active Comparator|Implantation at post-Kpro at 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
11392682|NCT02084732|Experimental|Sorafenib|drug
11392683|NCT02084719|Experimental|Group A|Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
11392684|NCT02084719|Active Comparator|Group B|Patients will be tested only with the standard algorithm
11392685|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
11392686|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
11392687|NCT02084693||COMPREHENSIVE|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
11392688|NCT02084680|No Intervention|Control|Control group standard care
11392689|NCT02084680|Experimental|Community Health Workers|individual prenatal education
11392690|NCT02084654|Active Comparator|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
11392691|NCT02084654|Placebo Comparator|placebo|placebo in addition to weight loss
11392692|NCT02084641|Experimental|Insulin resistant and insulin sensitive|Both groups will be given the same intervention and then outcomes compared between groups
11392693|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
11392694|NCT02084615|Experimental|81mg aspirin|This arm will include perioperative 81 mg of aspirin.
11392695|NCT02084615|Experimental|325mg aspirin|Subjects will be taking 325mg of aspirin.
11392696|NCT02084602|Experimental|Artesunate/mefloquine|Orally administration of artesunate 4mg/Kg by three days Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
11392697|NCT02084589|Active Comparator|PCEA of continuous background infusion with demand dose|PCEA with background infusion of 5 ml/h and demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
11392698|NCT02084589|Active Comparator|PCEA with demand dose only|PCEA with demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
11392699|NCT02084576|Experimental|Nepafenac|One drop in the study eye 3 times daily for 30 days
11392700|NCT02084576|Active Comparator|Ketorolac|One drop in the study eye 4 times daily for 30 days
11392701|NCT02084563|Other|AML-Intensive Chemotherapy|"Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.
~Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:
~Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation
~Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
11392702|NCT02084563|Other|AML-Non-intensive chemotherapy|"Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.
~Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
11392703|NCT02084563|No Intervention|Chronic Myeloid Disorders|"Patients with Chronic Myeloid Disorders:
~Myeloproliferative Neoplasms
~Myelodysplastic Syndromes
~Myeloproliferative/Myelodysplastic Neoplasms"
11392704|NCT02084550|Active Comparator|Vaminolac|Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
11392705|NCT02084550|Placebo Comparator|Saline|Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
11393274|NCT02080702||Monosyn|Construction of a gastrointestinal anastomoses
11392706|NCT02084537|Active Comparator|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7 French (Fr) double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
11392707|NCT02084537|Active Comparator|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic approach. This includes laparoscopic cystogastrostomy with internal debridement.
11392708|NCT02084524|No Intervention|Nutritional evaluation|
11392709|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
11392710|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
11392711|NCT02084511|Experimental|Placebo reference|Placebo reference
11392712|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
11392713|NCT02084498|Active Comparator|ACC|Training in advanced carbohydrate counting
11392714|NCT02084498|Experimental|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
11392715|NCT02084485|Experimental|Arm A|
11392716|NCT02084485|Placebo Comparator|Arm B|
11392717|NCT02084472|Active Comparator|study 1: aqueous cream and baby oil|enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute
11392718|NCT02084472|Active Comparator|study 2: emulsifying ointment and cetomacrogol|patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution
11392719|NCT02084459|No Intervention|Control|Standard of care
11392720|NCT02084459|Experimental|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
11392721|NCT02084446|Active Comparator|Mycophenolate + Low Tacrolimus|"Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.
~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
11392722|NCT02084446|Experimental|Everolimus + Very Low Tacrolimus|"Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.
~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
11392723|NCT02084433|Active Comparator|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
11392724|NCT02084433|Experimental|intraosseous anaesthesia|"intraosseous anaesthesia using a computerized system (Quicksleeper) 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
11392725|NCT02084420|Experimental|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
11392726|NCT02084420|Active Comparator|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
11392727|NCT02084407|Active Comparator|DM1 subject with cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
11392728|NCT02084407|Active Comparator|DM1 subject without cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
11392729|NCT02084407|Active Comparator|Not DM1subject|Clinical examination, Skin biopsy, Blood and urine sampling
11392730|NCT02084394||no intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the concommittent ultrasound of the temporal artery. Deemed interventional by JHUIRB but no actual intervention done to subject.
11392731|NCT02084381|Experimental|MCO-Ci 400|MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
11392732|NCT02084381|Active Comparator|Revaclear 400|the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
11392733|NCT02084368|Experimental|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block guided by PNS.
11392734|NCT02084368|Placebo Comparator|combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group.
11392735|NCT02084355|Experimental|opioid rotation|"Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).
~oral oxycodone : convert to oral hydromorphone or fentanyl patch
~oral hydromorphone : convert to oral oxycodone or fentanyl patch
~fentanyl patch : convert to oral oxycodone or oral hydromorphone"
11392736|NCT02084355|Active Comparator|opioid dose escalation|"Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.
~oral oxycodone : maintain oral oxycodone and titrate the dose
~oral hydromorphone : maintain oral hydromorphone and titrate the dose
~fentanyl patch : maintain fentanyl patch and titrate the dose"
11392737|NCT02084342|Placebo Comparator|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.
~Normal saline (NS) 100ml IV for 20min, before incision."
11392738|NCT02084342|Experimental|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.
~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
11392739|NCT02084329|Experimental|Weighted Compression Vest|Weighted Compression Vest
11392740|NCT02084329|No Intervention|Control|
11392768|NCT02084108|Other|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
11392741|NCT02084316|Experimental|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
11392742|NCT02084316|Active Comparator|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.
~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.
~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
11392743|NCT02084303|Other|Ferumoxytol MRI|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI.
11392744|NCT02084290|Experimental|Shared Decision Making Program|Patients will have access to an educational decision making program and a risk prediction model, this web based program will be sent subjects in the intervention arm upon enrollment, they can access the program as many times as they wish.
11392745|NCT02084290|No Intervention|Control|Subjects enrolled at sites participating as control arms will access the same web-based surveys as the intervention group, and receive the same contacts from the study coordinator as the subjects enrolled at intervention sites.
11392746|NCT02084277|Experimental|Self-ligating brackets|Several self-ligating brackets are currently FDA-approved but have not been rigorously studied in this malocclusion patient population or in comparison to traditional brackets methods. Unlike conventional brackets, Self-ligating brackets (SLB) are bracket systems, without the wire ligature or elastic ligature, that have a tube-like device build into the bracket to close off the edgewise slot.
11392747|NCT02084277|Placebo Comparator|Conventional brackets|"The conventional brackets (CB) (edgewise appliance) retain the basic principle design of a rectangular wire in a rectangular slot. Archwire are tied to the bracket once placed in the slot with either elastometric ligation ties (O-rings) or steel ligation."
11392748|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
11392749|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
11392750|NCT02084251|Experimental|Exenatide analogue, Injection|PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
11392751|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
11392752|NCT02084225||Course participants|Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
11392753|NCT02084212|Other|Patients about to undergo epiretinal membrane surgery|
11392754|NCT02084199|Experimental|Part 1 - Severe renal impairment|Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
11392755|NCT02084199|Experimental|Part 1: Normal renal function|Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
11392756|NCT02084199|Experimental|Part 2 - Mild renal impairment|Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
11392757|NCT02084199|Experimental|Part 2 - Moderate renal impairment|Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
11392758|NCT02084199|Experimental|Part 2 - Normal renal function|Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
11392759|NCT02084186|Experimental|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
11392760|NCT02084186|Placebo Comparator|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
11392761|NCT02084173|Other|MET|Motivational Enhancement Therapy (MET)
11392762|NCT02084173|Other|MET + CRA|Motivational Enhancement Therapy (MET) with subsequent add-on The Community Reinforcement Approach (CRA)
11392763|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
11392764|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
11392765|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
11392766|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
11392767|NCT02084108|No Intervention|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
11392769|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
11392770|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
11392771|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
11392772|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
11392773|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
11392774|NCT02084069|Placebo Comparator|Control|Placebo
11392775|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
11392776|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
11392777|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
11392778|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
11392779|NCT02084043|Experimental|Breath-actuated vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.
11392780|NCT02084043|Experimental|Conventional vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.
11392781|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
11392782|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
11392783|NCT02084017|Active Comparator|Current Standard|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing applied under sterile conditions in the operating room following skin closure. Dressing changed post-operative day two and daily thereafter with daily inspection for infection by a physician.
11392784|NCT02084017|Experimental|Negative Pressure Wound Therapy|A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
11392785|NCT02084004|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
11392786|NCT02084004|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
11392787|NCT02084004|No Intervention|lifestyle counseling|
11392788|NCT02083991|Experimental|Steroid-free low TAC-arm|"Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.
~Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
11392789|NCT02083991|Active Comparator|Standard low-TAC arm|"Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.
~Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
11392790|NCT02083978||Bipolar Diagnosis|Individuals identified as having a Bipolar Diagnosis with a manic episode
11392791|NCT02083978||Control|Individuals identified as not having a major psychiatric diagnosis
11392792|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.
~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
11392793|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.
~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
11392794|NCT02083952|Experimental|swaddle blanket|
11392795|NCT02083939||Antibiotic Prophylaxis|This cohort will receive antibiotic prophylaxis prior to the hernia repair
11392796|NCT02083939||No Antibiotic Prophylaxis|This cohort will not receive antibiotic prophylaxis prior to the surgery
11392797|NCT02083926|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of Ketamine.
11392798|NCT02083926|Placebo Comparator|Saline|Saline will be given at a dose of 0.5 mg/kg over a 40 minute period.
11392799|NCT02083913|Experimental|Supervised physical activity|
11392800|NCT02083900|Experimental|Banana Leaf Dressing Group|The Banana Leaf Dressing site will receive a single layer of banana leaf dressing
11392801|NCT02083900|Active Comparator|Hydrocolloid Dressing Arm|The donor under Hydrocolloid dressing was covered with hydrocolloid (DuoDERM CGF).
11392802|NCT02083887|Active Comparator|Group 1: ChAd63 ME-TRAP / MVA ME-TRAP at 16/24 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 infants aged 16 weeks at time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp (virus particles) intramuscular (IM) at 16 weeks and MVA ME-TRAP 1 x 10^8 pfu (plaque forming units) IM at 24 weeks.
11392803|NCT02083887|Active Comparator|Group 2: ChAd63 ME-TRAP / MVA ME-TRAP at 8/16 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 8 weeks at the time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 8 weeks and MVA ME-TRAP 1 x 10^8 pfu IM at 16 weeks
11392804|NCT02083887|Active Comparator|Group 3: ChAd63 ME-TRAP / MVA ME-TRAP at 1/8 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 1 week will be vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 1 week and MVA ME-TRAP 1 x 10^8 pfu IM at 8 weeks.
11392805|NCT02083887|No Intervention|Group 4: Control|20 healthy infants aged 16, 8 and 1 weeks will be enrolled into this group. (Five infants will be randomised to each of Groups 1 and 2 respectively while 10 infants aged 1 week will be randomised to Group 3). All twenty infants will receive EPI vaccinations only.
11392806|NCT02083874|Experimental|CBD|Open label CBD
11392807|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
11392808|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
11392809|NCT02083848|Other|7T MRI|All subjects are entered into a single arm.
11392810|NCT02083835||post-surgical patients|post-surgical patients > 18 years
11392811|NCT02083835||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
11392812|NCT02083822|Experimental|MRI assessment|
11392813|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
11392814|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
11392815|NCT02083796|Experimental|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
11392816|NCT02083796|Sham Comparator|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
11392817|NCT02083796|Active Comparator|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
11392818|NCT02083796|Sham Comparator|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
11392819|NCT02083783|Experimental|TRI102|Active, amphetamine extended-release oral suspension
11392820|NCT02083783|Placebo Comparator|Placebo|Placebo
11392821|NCT02083770|Experimental|Cancer Clinical Trials Education Program|Cancer Clinical Trials Education Program is offered to English- and Spanish-speaking Hispanics in the experimental arm. This program was designed to promote increased clinical trials literacy among Hispanic Americans. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among Hispanic Americans.
11392822|NCT02083770|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
11392823|NCT02083757||Resp|Fluid responsiveness is defined as a change of stroke volume stroke volume ≥ 10% after 250 ml rapid saline infusion in 10 minutes.
11392824|NCT02083757||Nonresp|Fluid responsiveness is defined as a change of stroke volume stroke volume < 10% after 250 ml rapid saline infusion in 10 minutes.
11392825|NCT02083744|Active Comparator|Control Group|Usual care group - patients will receive scales to take home and heart failure literature for self-monitoring of heart failure. Patients will complete final questionnaires
11392826|NCT02083744|Experimental|Psychoeducational Counseling|"1-on-1 psychoeducation session conducted by a bilingual research nurse at the clinic site or in the patient's home. Patients will receive a scale to measure weight, a diary to record weight and symptoms of heart failure, and telephone follow-up from the research nurse to reinforce the content of the education program every other week.
~Focus-groups - Perception of the intervention will be assessed with two focus groups."
11392827|NCT02083731|Experimental|MSCs|MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
11392828|NCT02083718|Experimental|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
11392829|NCT02083705|Experimental|SI+CC|"Chest compression will be superimposed by sustained inflations during CPR:
~CC+SI group Infants randomized in the SI group requiring CC, would receive CC at a rate of 90/min during an SI with a duration of 20sec (CC+SI). After 20 sec the SI will be interrupted for 1 sec and the next SI will be started for another 20sec13. Throughout this time CC is continued until ROSC. Every 45 sec (approximately 2 SIs) the clinical team would assess for changes in heart rate. CC+SI was continued until ROSC."
11392830|NCT02083705|Active Comparator|3:1 CPR|"CPR using 3:1 C:V ratio:
~3:1 C:V group Infants randomized into the 3:1 group requiring CC, would received CC using the current 3:1 C:V ratio recommend in the neonatal resuscitation guidelines16. Every 45 sec the clinical team would assess heart rate. 3:1 C:V CPR was continued until ROSC."
11392831|NCT02083692|Experimental|Metformin|
11392832|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
11392833|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
11392834|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
11392835|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
11392836|NCT02083666|Experimental|SOBI002|Single and repeated administration of different doses of test product
11392837|NCT02083666|Placebo Comparator|placebo|Single and repeated administration of placebo comparator
11392838|NCT02083653|Experimental|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
11392839|NCT02083653|Experimental|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
11392840|NCT02083653|Active Comparator|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
11392841|NCT02083640|Other|Treatment A (Reference)|
11392842|NCT02083640|Other|Treatment B (Test)|
11392843|NCT02083640|Other|Treatment C (Test)|
11392844|NCT02083627|Experimental|1:Single rosuvastatin,multiple fidaxomicin,single rosuvastatin|
11392845|NCT02083627|Experimental|2:Multiple fidaxomicin,single rosuvastatin,single rosuvastatin|
11392846|NCT02083614|Experimental|clamping|to clamp or release the catheter for 2 days before removal
11392847|NCT02083614|No Intervention|no clamping|
11392848|NCT02083601|Experimental|Psychological Support|The intervention group will participate in the 2-day, in-person Parent Forum and receive monthly phone calls from a mental health professional for 12 months.
11392849|NCT02083601|Other|No Psychological Support|This comparison group will attend the 2-day, in-person Parent Forum but will not receive long-term psychological support.
11392850|NCT02083588|Experimental|open - single arm|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
11392851|NCT02083575|Active Comparator|vitamin c|25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
11392852|NCT02083575|Other|iron chelator|Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
11392853|NCT02083549||Trauma 1 massively transfused|Trauma 1 massively transfused patients are identified as a Trauma level one patient by triage through guidelines from the Kessler Regional Trauma Center Trauma Triage Guidelines.
11392854|NCT02083536|Experimental|LDFWART + Docetaxel|"This study has 6 treatment cycles given at 3 weeks intervals ± 3 days. A cycle is defined as 1 treatment of morning Docetaxel and afternoon Low Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART). The first day of the first treatment is designated study day 1."
11392855|NCT02083523|Active Comparator|Motivational Interview|The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.
11392856|NCT02083523|Active Comparator|MI with Normative Feedback|The Motivational Interview with Normative Feedback, or MI + NF, condition/intervention included all procedures described for the MI condition. Additionally, in the MI + NF condition/intervention, the participants' days of marijuana and alcohol use were compared to two sets of norms ( age specific or level of care specific) available for treatment attending youth. Therapists used whichever norm provided a greater contrast with participants' use.
11392857|NCT02083510|Experimental|Colchicine|Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.
11392858|NCT02083497|Experimental|No banding|The volunteers who make up this group, held 18 kicks, 9 with the dominant leg and 9 with the non-dominant lower limb, without the intervention of any kind of bandage.
11392859|NCT02083497|Experimental|Group with Rigid Bandage|Volunteers carry out the same protocol described above, however, using rigid bandage. The bandage will be used for tape, Cremer brand and will be applied ankle support member of the individual, in order to limit the movement of the joint inversion.
11392860|NCT02083497|Experimental|Group with elastic bands|The protocol will be maintained, however, a brand elastic bandage Kinesio Sport applied to the lower support member of the individual, also in order to limit the movement of the joint inversion is used.
11392861|NCT02083471|Active Comparator|SOTI|Specific Oral Tolerance Induction with Egg or Cow's milk
11392862|NCT02083471|No Intervention|Food Allergy follow-up|
11392863|NCT02083458|Experimental|axillary vein catheterization|Catheterization of the axillary vein based on anatomical landmark.
11392864|NCT02083445|Placebo Comparator|Control group|Once a week there will be an attendance cognitive session (specific sessions designed to work on aspects related to body perception, movement, space) and the extraction of blood samples will be carried out to determine the progenitor cells on the same day of the active groups.
11392865|NCT02083445|Active Comparator|Exercise group|Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
11392866|NCT02083445|Active Comparator|Muscle electro-stimulation and IHH|Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.
11392867|NCT02083432|Active Comparator|5-weeks waiting list control|Half of the participants were randomly assigned to 5-weeks waiting list/Control group.The participants in the waiting list/Control Group are enrolled to the treatment Group (INtervention: 5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
11392868|NCT02083432|Experimental|5 session of CBT|Half of the participants were direct enrolled to 5 weeks(5 sessions) of cognitive behaviour therapy (CBT) performed by specially trained dentists. (Intervention: CBT)
11392869|NCT02083419||LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
11392870|NCT02083406|Experimental|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
11392872|NCT02083406|Experimental|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
11392873|NCT02083393||Patients with acute lung injury|Patients with sepsis induced acute lung injury
11392874|NCT02083393||Postsurgery patients|Postsurgery patients without acute lung injury and sepsis
11392875|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
11392876|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
11392877|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
11392878|NCT02083367||Hepatic Encephalopathy Group|Disease Group
11392879|NCT02083367||Control Group|Healthy Group
11392880|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
11392881|NCT02083341|Experimental|Muscle tension dysphonia - treatment|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
11392882|NCT02083341|Sham Comparator|Muscle tension dysphonia - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
11392883|NCT02083341|Experimental|Classically trained singers|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
11392884|NCT02083341|Sham Comparator|Classically trained singers - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
11392885|NCT02083328|Active Comparator|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
11392886|NCT02083328|Placebo Comparator|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
11392887|NCT02083315|Experimental|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
11392888|NCT02083315|Experimental|TRV130 3 mg|TRV130 3 mg IV x 1 dose
11392889|NCT02083315|Experimental|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
11392890|NCT02083315|Active Comparator|Morphine|Morphine 10 mg IV x 1 dose
11392891|NCT02083315|Placebo Comparator|Placebo|Dextrose 5% in water IV x 1 dose
11392892|NCT02083302|Experimental|Treatment1|The Treatment1 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2 and SCREAM Theater Dose 3.
11392893|NCT02083302|Experimental|Treatment2|The Treatment2 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2, SCREAM Theater Dose 3 and SCREAM Theater Dose 4.
11392894|NCT02083302|Other|Control|The control group received SCREAM Theater Dose 1.
11392895|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
11392896|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
11392897|NCT02083276|Experimental|Pivmecillinamhydrochlorid|Selexid 400 mg x 3 , 7 days
11392898|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
11392899|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
11392900|NCT02083250|Experimental|Treatment (vorinostat, chemotherapy, SCT)|"CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.
~TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0."
11392901|NCT02083237|Active Comparator|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
11392902|NCT02083237|No Intervention|Waitlist Control|Due to the heavy demand for this clinical program, there is a naturally-occurring waitlist of approximately 3 months. Control participants are assessed during this period.
11392903|NCT02083224||Cancer patients|
11392904|NCT02083211|Experimental|mAb Nimotuzumab + chemotherapy|
11392905|NCT02083211|Placebo Comparator|placebo + chemotherapy|
11392906|NCT02083198||High Chloride|Patients receiving .9% sodium choride for resuscitation
11392907|NCT02083198||Low chloride|Patients receiving Plasmalyte for resuscitation
11393448|NCT02079571|Experimental|ginger tea +water|
11392908|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
11392909|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
11392910|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
11392911|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
11392912|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
11392913|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
11392914|NCT02083159||Patients with NAFLD|
11392915|NCT02083146||Patients with CAD|Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.
11392916|NCT02083133||End Stage Renal Disease|GFR 15 ml/min or less or on Dialysis
11392917|NCT02083133||Chronic Kidney Disease Stage 4|GFR 15-30 ml/min
11392918|NCT02083133||Chronic Kidney Disease Stage -3|GFR 30-60 ml/min
11392919|NCT02083120|Experimental|nasal High Flow and Oxygen|overnight nasal High Flow (NHF) therapy+ individually titrated supplemental oxygen (2-6 L/min),total 35 L/min, 4 weeks at home
11392920|NCT02083120|Active Comparator|Long term Oxygen Therapy (LOT)|individually titrated supplemental oxygen (2-6 L/min), 4 weeks at home
11392921|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
11392922|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
11392923|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
11392924|NCT02083081|Experimental|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
11392925|NCT02083081|No Intervention|usual care|Usual care provided by health aides to pregnant women
11392926|NCT02083068|Experimental|Experimental|10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
11392927|NCT02083068|Placebo Comparator|Control|six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
11392928|NCT02083055|Experimental|dexmedetomidine|Intraoperative controlled hypotension by dexmedetomidine
11392929|NCT02083055|Active Comparator|nitroglycerin|Intraoperative controlled hypotension by nitroglycerin
11392930|NCT02083029|Experimental|Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
11392931|NCT02083029|Experimental|Non Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
11392932|NCT02083029|Experimental|Normal Volunteers|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
11392933|NCT02083016|Other|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
11392934|NCT02083016|Other|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
11392935|NCT02083003|Experimental|Polyamine low-diet|Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
11392936|NCT02083003|Active Comparator|Liberal alimentation|No specific alimentary diet
11392937|NCT02082990|Active Comparator|Face-to-Face Brief Intervention Group|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
11392938|NCT02082990|Experimental|Online Brief Intervention Group|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
11392939|NCT02082977|Experimental|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392940|NCT02082977|Experimental|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392941|NCT02082977|Experimental|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392942|NCT02082977|Experimental|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392943|NCT02082977|Experimental|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392944|NCT02082977|Experimental|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392945|NCT02082977|Experimental|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392946|NCT02082977|Experimental|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392947|NCT02082977|Experimental|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
11392948|NCT02082977|Experimental|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
11392949|NCT02082964|Experimental|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
11392950|NCT02082964|Experimental|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course.
11392951|NCT02082951|Experimental|Group 2: empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
11392952|NCT02082951|Experimental|Group 1: empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
11392953|NCT02082938|Experimental|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
11392954|NCT02082925|Experimental|COPD patient|
11392955|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
11392956|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
11392957|NCT02082899|Active Comparator|Active Comparator EBI-005 5 mg/mL|Administered 3 times per day
11392958|NCT02082899|Placebo Comparator|Placebo Comparator|Administered 3 times per day
11392959|NCT02082860|Experimental|Cohort A|rAAV2/5-PBGD vector dosage 1
11392960|NCT02082860|Experimental|Cohort B|rAAV2/5-PBGD vector dosage 2
11392961|NCT02082860|Experimental|Cohort C|rAAV2/5-PBGD vector dosage 3
11392962|NCT02082860|Experimental|Cohort D|rAAV2/5-PBGD vector dosage 4
11392963|NCT02082834|Experimental|EVAR|
11392964|NCT02082808|Experimental|Sequence 1|Participants will receive the study Treatment A for 5 days (DTG 50mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment B for 5 days (DCV 60mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
11392965|NCT02082808|Experimental|Sequence 2|Participants will receive the study Treatment B for 5 days (DCV 60mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment A for 5 days (DTG 50mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
11392966|NCT02082782|Experimental|irreversible electroporation (IRE)|Single arm study: percutaneous or open irreversible electropration of CRLM
11392967|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
11392968|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
11392969|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
11392970|NCT02082756|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
11392971|NCT02082756|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
11392972|NCT02082756|No Intervention|lifestyle counseling|
11392973|NCT02082743|Experimental|Outdoor activity|Outdoor activity in recess time
11392974|NCT02082743|No Intervention|Control|
11392975|NCT02082730|Active Comparator|Mid treatment Group|Patients who have completed 6 sessions at the Manchester CFS/ME Service for Children & Young People will be recruited. They would have had previous experience of using paper diaries.They will collect activity data using the ASARM system.
11392976|NCT02082730|Experimental|Start of Treatment Group|Newly presented patients, will collect activity data using the ASARM system.
11392977|NCT02082730|No Intervention|Audit group|"To provide comparative baseline data for general treatment response, we will audit pre-treatment and post-treatment clinical data on the regular gold standard clinical measures package, as these are the outcome measures routinely used in the clinic."
11392978|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
11392979|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
11392980|NCT02082704|Experimental|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
11392981|NCT02082704|Active Comparator|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
11392982|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
11392983|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
11392984|NCT02082665|Experimental|Arm 1|On Day 1 subjects will simultaneously receive single dose of Rosuvastatin 10 mg tablet and Midazolam 3 mg syrup administered orally in the morning.
11392985|NCT02082652|Active Comparator|Control group (No ART)|Etonogestrel implant in participants not yet receiving ART (control group)
11392986|NCT02082652|Active Comparator|Nevirapine-based ART group|Etonogestrel implant in participants receiving nevirapine (NVP)-based ART
11392987|NCT02082652|Active Comparator|Efavirenz-based ART group|Etonogestrel implant in participants receiving efavirenz (EFV)-based ART
11392988|NCT02082639|Experimental|HPV Group|Subjects will receive two doses of HPV vaccine intramuscularly
11392989|NCT02082639|Experimental|HAV Group|Subjects will receive two doses of HAV vaccine intramuscularly
11392990|NCT02082639|Experimental|HPV+HAV Group|Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
11392991|NCT02082626|Experimental|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
11392992|NCT02082613|Experimental|Lord´s procedure|Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
11392993|NCT02082613|Active Comparator|Sclerotherapy|Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
11392994|NCT02082600|Experimental|Sleep deprivation|Exercise induced-muscle damage protocol followed by 60h of sleep deprivation (two nights) and one night of normal sleep (rebound).
11392995|NCT02082600|Experimental|Normal sleep|Exercise induced-muscle damage protocol followed by 3 nights of normal sleep
11392996|NCT02082587||QOL Assessment|
11392997|NCT02082574||patients|HIV infected for more than 5 years, aged over 50, treated with ARV
11392998|NCT02082574||control|non HIV (matched for age and gender)
11392999|NCT02082561|Experimental|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
11393000|NCT02082561|No Intervention|Waitlist|The waitlist control condition was comprised of patients randomly assigned to the waitlist condition (WL). Individuals in this condition were reassessed after five weeks and were then offered treatment, but were no longer followed.
11393001|NCT02082548|Experimental|Intervention|educational intervention arm
11393002|NCT02082548|No Intervention|control|Standard of care
11393003|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
11393004|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
11393005|NCT02082509||Traumatic Brain Injury (TBI)|Patient who have sustained a TBI over 1 month prior to enrollment, and endorse at least 1 post-concussive symptom at the time of enrollment.
11393006|NCT02082509||Healthy Controls (no TBI)|Subjects who match the TBI group's demographic characteristics, except that they have not sustained a TBI and they are otherwise physically and mentally healthy.
11393007|NCT02082496|Experimental|Control Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
11393008|NCT02082496|Experimental|Case Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
11393009|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
11393010|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
11393011|NCT02082470|Active Comparator|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
11393012|NCT02082470|Experimental|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
11393013|NCT02082457|Placebo Comparator|Placebo|Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.
11393014|NCT02082457|Experimental|YKP10811 10mg|Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.
11393015|NCT02082457|Experimental|YKP10811 20mg|One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.
11393016|NCT02082457|Experimental|YKP10811 40mg|Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.
11393017|NCT02082444|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
11393018|NCT02082418|Experimental|Healthy|healthy control subjects
11393019|NCT02082418|Experimental|MCI|mild cognitive impariments
11393020|NCT02082418|Experimental|Dementia|established diagnosis of dementia
11393021|NCT02082405|Experimental|Treatment (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC or IV over 3-5 seconds on days 1, 8, and 15; cyclophosphamide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11393022|NCT02082392|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
11393023|NCT02082392|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
11393024|NCT02082392|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
11393025|NCT02082392|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
11393026|NCT02082379|Active Comparator|Term newborns 1-6 week old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
11393027|NCT02082379|Active Comparator|Infants 6-8 month old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
11393028|NCT02082366|Active Comparator|conventional irrigated ablation catheter|"TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter.
~Intervention: TCD monitoring of microembolic signal during procedure"
11393029|NCT02082366|Active Comparator|nMARQ circumferential irrigated catheter|"TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter.
~Intervention: TCD monitoring of microembolic signal during procedure"
11393030|NCT02082353||Retrospective CGD Cohort|Longitudinal analysis
11393031|NCT02082353||Prospective CGD Cohort|Longitudinal analysis
11393032|NCT02082353||HCT CGD Cohort|Cross-sectional analysis
11393033|NCT02082353||Conventional Non-Transplant CGD Cohort|Longitudinal analysis
11393034|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
11393035|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
11393036|NCT02082327|Experimental|0.3 mg/kg|IV infusion of migalastat HCl or placebo
11393037|NCT02082327|Experimental|1 mg/kg|IV infusion of migalastat HCl or placebo
11393038|NCT02082327|Experimental|10 mg/kg|IV infusion of migalastat HCl or placebo
11393039|NCT02082327|Experimental|150 mg IV|150 mg single IV infusion
11393040|NCT02082327|Experimental|150 mg oral|150 mg single oral dose
11393041|NCT02082301||Gestational diabetes|Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes
11393042|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
11393043|NCT02082275|Experimental|OB Nest|OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
11393044|NCT02082275|No Intervention|Traditional Prenatal care|Traditional prenatal visits in clinic with OB providers.
11393045|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
11393046|NCT02082249|Experimental|ABT-SLV187|up to 6 years
11393047|NCT02082236|Active Comparator|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
11393048|NCT02082236|Experimental|Treatment B|Single dose of SSM 30 mcg
11393049|NCT02082236|Experimental|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
11393050|NCT02082236|Experimental|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
11393051|NCT02082223|Experimental|Preoperative Rehabilitation|"Patient & caregiver input regarding 'single biggest concern right now' (modified BEACON buttons) will be elicited. Information gathered by the study team which includes a trained nursing coach and the patient/caregiver will together develop an individualized 'toolbox' of possible interventions to improve preoperative quality of life.
~Candidate interventions include, but not limited to: Participation in SMART program, caregiver participation in Caregivers study protocol MC1295 (IRB 13-002943), nutritional recommendations (deficiencies, immuno-nutrition), low impact resistance training/tai chi, referral to financial or counseling services, establishment of information sources & plans for concerns not frequently covered in clinical practice such as sleeplessness, spiritual assistance."
11393052|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
11393053|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
11393054|NCT02082197|Experimental|ABT-SLV176|ABT-SLV176 administered daily
11393055|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
11393056|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
11393057|NCT02082171|No Intervention|Control group|
11393058|NCT02082171|Experimental|Intervention group|Comprehensive geriatric assessment followed by multi-domain preventive intervention
11393059|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
11393060|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
11393061|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
11393062|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
11393063|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
11393064|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
11393065|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
11393066|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
11393067|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
11393068|NCT02082106||males/females|Participants should be capable of alpine skiing and cross country skiing.
11393069|NCT02082093|No Intervention|Traditional Care|
11393070|NCT02082093|Experimental|eNephro Application|"Telemedicine system which is a collaborative and expert system, consisting of:
~A dynamic shared medical record for the collection of administrative , medical, biological and clinical data for each patient. All health professionals can access the folder and fill in the support. It is the same for patients treated at home.
~A secure messaging for communication between health professionals and between patients and health professionals Expert systems analyzing data from each patient A management tool of therapeutic education
~These patients have a chronic renal failure moderate to end up being treated by ambulatory dialysis or kidney transplantation. The patients of each population will be randomly assigned in group 1 ie traditional care or in group 2 ie traditional care added by telemedicine system"
11393071|NCT02082080|Active Comparator|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
11393072|NCT02082080|No Intervention|Obese and overweight children|
11393073|NCT02082067|Experimental|Adductor canal|All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.
11393074|NCT02082067|Active Comparator|Femoral|All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.
11393075|NCT02082067|Placebo Comparator|Controls|No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.
11393076|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
11393077|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
11393078|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
11393079|NCT02082054|Active Comparator|PSE 120 mg, CM 8 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with M27 on scored side and plain on the other side"
11393080|NCT02082054|Experimental|Atropine 0.24 mg|Atropine 0.24 mg tablets dosed BID for 7.5 days
11393081|NCT02082041||Wounds on leg|
11393082|NCT02082028|Experimental|A (BGStar)|Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly.
11393083|NCT02082028|Active Comparator|B (traditional approach)|Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter.
11393084|NCT02082015|Experimental|true coil|Use the true coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
11393085|NCT02082015|Sham Comparator|sham coil|Use the sham coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: vertical to scalp
11393086|NCT02082002||MS-Group|MS-Group
11393087|NCT02082002||Healthy control|Healthy control
11393088|NCT02081989|Experimental|Denervation|Renal denervation
11393089|NCT02081989|No Intervention|No intervention|Control group - no intervention
11393090|NCT02081976|Active Comparator|Standard Care Group|Dental therapist providing standard periodontal treatment
11393091|NCT02081976|Experimental|Integrated Care Group|a combined treatment approach of Dental Therapist, Dental Hygienist, Cardiologist along with counselor
11393092|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
11393093|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
11393094|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
11393095|NCT02081937|Experimental|Anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.
11393096|NCT02081924|Active Comparator|Kisspeptin 0.1|Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
11393097|NCT02081924|Placebo Comparator|Saline|Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
11393098|NCT02081924|Active Comparator|Kisspeptin 0.3|Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
11393099|NCT02081924|Active Comparator|Kisspeptin 1.0|Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
11393449|NCT02079558|Experimental|Oxytocin|A single 100 microgram IV dose of carbetocin after operation
11393100|NCT02081911|Experimental|High volume Adductor canal block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
11393101|NCT02081911|Experimental|Low volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
11393102|NCT02081911|Experimental|Femoral nerve block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
11393103|NCT02081898|No Intervention|control group|weight maintenance diet
11393104|NCT02081898|Experimental|low calorie diet (LCD) group|approximate 100 kcal/d calorie deficit
11393105|NCT02081885|Experimental|Tricalcium Phosphate / Chitosan|
11393106|NCT02081885|Active Comparator|Autologous Graft|
11393107|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
11393108|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
11393109|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
11393110|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
11393111|NCT02081833||Reminder group|the reminder group receives every 2 weeks a reminder to fill out the symptom diary (postcard or SMS)
11393112|NCT02081820||aneurysmal subarachnoid hemorrhage|observational, no intervention
11393113|NCT02081807||Dabigatran|
11393114|NCT02081807||Warfarin|
11393115|NCT02081794|Experimental|Arm I (Tailored education intervention)|Participants receive a tailored educational intervention on the risk of falls comprising one of four two-minute videos determined by which educational group the participant is placed in: high risk/high perception, high risk/low perception, low risk/high perception, or low risk/low perception. Participants also receive tailored printed educational information concerning hospital falls based on the participants' answers given on the Perceived Risk Survey and are tailored to the participants' perception of falls risk. Participants also complete an investigator-constructed satisfaction survey at 24 and 72 hours post-intervention.
11393116|NCT02081794|Active Comparator|Arm II (standard fall care)|Participants receive standard care by nurses comprising a falls risk assessment and verbal education and receive an educational instruction sheet on falls prevention.
11393117|NCT02081781||Probing, topical anesthesia|Nasolacrimal duct obstruction (NLDO) is a quite common condition among the infants. An imperforate membrane at the distal end of the nasolacrimal duct is the main cause of occlusion. Children with the signs of NLDO presenting with epiphora and/or mucous discharge were included in this study. Intervention with probing under topical anesthesia was performed on the same surgeon. And success rate was evaluated.
11393118|NCT02081768|Experimental|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
11393119|NCT02081755|Experimental|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
11393120|NCT02081755|Active Comparator|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
11393121|NCT02081729||high VZV ELISPOT results|high spot counts in ELISPOT
11393122|NCT02081729||low VZV ELISPOT results|low spot counts in ELISPOT
11393123|NCT02081716||high CMV ELISPOT results|high spot counts in ELISPOT
11393124|NCT02081716||low CMV ELISPOT results|low spot counts in ELISPOT
11393125|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
11393126|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
11393127|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
11393128|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
11393129|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
11393130|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
11393131|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
11393132|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
11393133|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
11393134|NCT02081664|Other|Lifestyle intervention|life-style oriented group program together with an individualized treatment program using therapies out of the spectrum of Complementary and Alternative Medicine (CAM)
11393135|NCT02081651|Experimental|Parmigiano Reggiano cheese|Children treated Parmigiano Reggiano cheese for 12 months
11393136|NCT02081651|No Intervention|Control subjects|Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
11393137|NCT02081638|Active Comparator|Elite Controller|HIV infected off ART
11393138|NCT02081638|Active Comparator|Treated Progressors|HIV infected on ART
11393139|NCT02081625|Experimental|NS-065/NCNP-01|
11393140|NCT02081612|Active Comparator|Nutrition Education|Educational weight management group sessions alone
11393141|NCT02081612|Active Comparator|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
11393142|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
11393143|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
11393144|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
11393145|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
11393146|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
11393147|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
11393148|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
11393149|NCT02081560|Other|colistin pharmacokinetics|Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
11393150|NCT02081547||IPC status|presence of cancer cells.
11393151|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
11393152|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
11393153|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
11393154|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
11393155|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
11393156|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
11393157|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
11393158|NCT02081521|Experimental|Community behaviour change campaign|Participants will be exposed to the community behaviour change intervention.
11393159|NCT02081521|No Intervention|No community behaviour change campaign|No community intervention will take place in the control arm, although exposure to some intervention messaging (radio adverts) may take place.
11393160|NCT02081508|Experimental|Unfilled interference|Interference onset: delayed test at 540000 ms
11393161|NCT02081508|Experimental|Early interference|Interference onset: delayed test at 0 ms
11393162|NCT02081508|Experimental|Mid interference|Interference onset: delayed test at 360000 ms
11393163|NCT02081508|Experimental|Late interference|Interference onset: delayed test at 180000 ms
11393164|NCT02081495|Experimental|Sequence AB|Twenty-one participants will receive DOXIL/CAELYX reference product in Cycle 1 and DOXIL/CAELYX test product in Cycle 2. Each cycle will be separated by 28 days.
11393165|NCT02081495|Experimental|Sequence BA|Twenty-one participants will receive DOXIL/CAELYX test product in Cycle 1 and DOXIL/CAELYX reference product in Cycle 2. Each cycle will be separated by 28 days.
11393166|NCT02081482|Experimental|subjects with refractory chronic cluster headache|Adult subjects with refractory chronic cluster headache and ONS indication
11393167|NCT02081469|Other|Arm A:TDF for extend 24 weeks|Arm A:Continue TDF 300mg daily for extend 24 weeks after completion of chemotherapy
11393168|NCT02081469|Other|Arm B: TDF for extend 48 weeks|Arm B: Continue TDF 300mg daily for extend 48 weeks after completion of chemotherapy.
11393169|NCT02081456|Active Comparator|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
11393170|NCT02081456|Experimental|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
11393171|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
11393172|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
11393173|NCT02081430|Experimental|CT Manipulation|Prone cervicothoracic manipulation
11393174|NCT02081430|Active Comparator|Upper trapezius stretch|Passive sustained stretch to upper trapezius muscle
11393175|NCT02081430|No Intervention|Control|8 Minute wait
11393176|NCT02081417|Other|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
11393177|NCT02081417|Other|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
11393178|NCT02081404|Active Comparator|Esomeprazole|proton pump inhibitor
11393179|NCT02081404|Placebo Comparator|Placebo|placebo
11393180|NCT02081391|Experimental|Tapentadol immediate-release (IR)|"In the first 24 hours, tapentadol oral solution at a dose of 1.25 mg/kg body weight was given every 4 hours (±15 min) to participants aged 6 months to less than 18 years (maximum individual dose of tapentadol was 100 mg). Participants from 30 days to less than 6 months were dosed with 0.5 mg/kg body weight every 4 hours. Participants from birth to less than 30 days of age were dosed with 0.1 mg/kg body weight every 4 hours.
~After 24 hours and up to 72 hours, the dose could be reduced based on the investigator's judgment."
11393181|NCT02081391|Placebo Comparator|Placebo|Matching placebo oral solution was administered every 4 hours (±15 min) up to 72 hours.
11393182|NCT02081378|Experimental|ABL001 in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with CML
11393183|NCT02081378|Experimental|ABL001+Nilotinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with Nilotinib in adult CML patients
11393184|NCT02081378|Experimental|ABL001 in Ph+ ALL patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with Ph positive ALL patients
11393185|NCT02081378|Experimental|ABL001+Imatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with imatinib in adult CML patients
11393186|NCT02081378|Experimental|ABL001+dasatinib in CML patients|Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with dasatinib in adult CML patients
11393187|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
11393188|NCT02081365|No Intervention|High Anxiety Wailist Control|
11393189|NCT02081352|Active Comparator|DermaPure™|DermaPure™ in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
11393190|NCT02081352|Sham Comparator|Standard care|Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
11393191|NCT02081339||Macular diseases|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
11393192|NCT02081326|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
11393193|NCT02081326|Placebo Comparator|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
11393194|NCT02081313|Active Comparator|Netherton syndrome|Patients with Netherton syndrome
11393195|NCT02081313|Active Comparator|Healthy controls|healthy controls
11393196|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
11393197|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
11393198|NCT02081287|Active Comparator|Lamotrigine|As adjunct to lithium therapy
11393199|NCT02081287|Experimental|IP6|As adjunct to lithium therapy
11393200|NCT02081274||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease between 2009 and 2013 in Samsung Medical Center
11393201|NCT02081261||Coronary artery bypass surgery|patients who underwent coronary artery bypass surgery between 2010 and 2012 in Samsung Medical Center
11393202|NCT02081248|Active Comparator|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
11393203|NCT02081248|Experimental|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
11393204|NCT02081235||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease during 2012 in Samsung Medical Center
11393205|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
11393206|NCT02081209|Experimental|Fat Reduction|
11393207|NCT02081196|Experimental|Fat Reduction|
11393208|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.
~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
11393209|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.
~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
11393210|NCT02081170|Experimental|autologous platelet concentrate|
11393211|NCT02081157||Breast Mastopexy with or without reduction using GalaFlex Mesh|Breast mastopexy with or without reduction, using GalaFLEX mesh
11393212|NCT02081144|No Intervention|Control Condition|Control or Standard Care condition. No intervention will be provided.
11393213|NCT02081144|Experimental|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
11393214|NCT02081131|Active Comparator|Laparoscopic Surgery|patients will be randomized to laparoscopic pancreatoduodenectomy group
11393215|NCT02081131|Active Comparator|Open Surgery|Patients will be randomized to Open pancreatoduodenectomy
11393216|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
11393217|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
11393218|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
11393219|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
11393220|NCT02081105|Other|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
11393221|NCT02081105|Other|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
11393222|NCT02081092||Pulmonary Alveolar Proteinosis (PAP)|Patients diagnosis with Pulmonary Alveolar Proteinosis.
11393223|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
11393224|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
11393225|NCT02081066|Other|patients with cardiovascular risk factors|
11393226|NCT02081053|Other|RF Ablation and Vertebral Augmentation|
11393227|NCT02081040||Infratentorial dysphagia patients|Infratentorial brain lesion patients with confirmed evidence of dysphagia
11393228|NCT02081040||Supratentorial dysphagia patients|Supratentorial brain lesions\ patients with confirmed evidence of dysphagia
11393229|NCT02081040||Brain lesion patients without dysphagia|Brain lesion patients with no evidence of dysphagia
11393230|NCT02081027|Experimental|Riluzole|The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
11393231|NCT02081027|Placebo Comparator|Placebo|Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
11393232|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
11393233|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
11393234|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
11393235|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
11393236|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
11393237|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
11393238|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
11393239|NCT02080975|Experimental|Data Collection During Atrial Flutter Ablation|
11393240|NCT02080962|Experimental|30 Gy in 5 fractions of 6 Gy|tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
11393241|NCT02080962|Experimental|40 Gy in 10 fractions of 4 Gy|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
11393242|NCT02080949|Experimental|HSRT - 4fx x 5 Gy|It'll be recruited 3 patients to the initial regimen of four fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered that the study was initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with the next dose level.
11393243|NCT02080923|Experimental|Brief Motivational Interview|Health-related counseling that takes place in as little as one hour or up to a few sessions.
11393244|NCT02080923|No Intervention|Standard Care|Participant will receive information about dating abuse in a handout and referrals to a national domestic violence hotline.
11393245|NCT02080910|Experimental|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
11393246|NCT02080910|No Intervention|Usual care|
11393247|NCT02080897||Palliative Surgery Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment
11393248|NCT02080897||Non-surgical Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery
11393249|NCT02080884||CLL patients on Mabthera (rituximab)|
11393250|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
11393251|NCT02080858|Experimental|Ticagrelor + Apixaban + ASA|180 mg Ticagrelor loading dose + apixaban 2.5 mg bid + 300 mg ASA loading dose (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg + 100 mg ASA od to reach steady state conditions within 4.5 days
11393252|NCT02080858|Active Comparator|Ticagrelor + Apixaban|180mg ticagrelor loading dose + apixaban 2.5 mg bid (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg to reach steady state conditions within 4.5 days
11393253|NCT02080845|Placebo Comparator|no caffeine & no theobromine|Drink 1
11393254|NCT02080845|Experimental|no caffeine & low theobromine|Drink 2
11393255|NCT02080845|Experimental|no caffeine & high theobromine|Drink 3
11393256|NCT02080845|Experimental|high caffeine & no theobromine|Drink 4
11393257|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
11393258|NCT02080832|Placebo Comparator|Placebo|
11393259|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
11393260|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
11393261|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
11393262|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
11393263|NCT02080806|Active Comparator|Mechanical insufflation exsufflation|Application of cough assist machine as part of the regular physiotherapy
11393264|NCT02080793|Other|Patients phase pilote|
11393265|NCT02080793|Other|Patients phase réelle|
11393266|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:
~- Single Dose, Diltiazem (Day 1)
~- Multiple Dose, Clarithromycin XL (Days 4-9)
~- Single Dose, Diltiazem (Day 8)"
11393267|NCT02080754|Placebo Comparator|sham arm|sham sellick maneuver
11393268|NCT02080754|Experimental|sellick arm|effective sellick maneuver
11393269|NCT02080741|Other|Type A behaviour profile|
11393270|NCT02080741|Other|Type B behaviour profile|
11393271|NCT02080728|Experimental|TAP-Bloc|
11393272|NCT02080728|Placebo Comparator|Control|
11393273|NCT02080715|Experimental|Tolcapone|Tasmar
11393275|NCT02080689|Other|Salvage setting|The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)
11393276|NCT02080689|Other|Adjuvant setting|The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)
11393277|NCT02080663||Proximal row carpectomy|Proximal row carpectomy
11393278|NCT02080650|Other|Prostate cancer|Mesenchymal-marker based ferrofluid (c-MET)
11393279|NCT02080650|Other|Renal cell carcinoma|Mesenchymal-marker based ferrofluid (c-MET)
11393280|NCT02080650|Other|Bladder cancer|Mesenchymal-marker based ferrofluid (c-MET)
11393281|NCT02080650|Other|Gastric cancer|Mesenchymal-marker based ferrofluid (c-MET)
11393282|NCT02080650|Other|Colorectal cancer|Mesenchymal-marker based ferrofluid (c-MET)
11393283|NCT02080650|Other|Pancreatic cancer|Mesenchymal-marker based ferrofluid (c-MET)
11393284|NCT02080650|Other|Non-small cell lung cancer|Mesenchymal-marker based ferrofluid (c-MET)
11393285|NCT02080650|Other|Advanced MET amplified solid tumor|Mesenchymal-marker based ferrofluid (c-MET)
11393286|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
11393287|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
11393288|NCT02080624|Experimental|Rapamycin|Topical rapamycin applied once a day
11393289|NCT02080598|No Intervention|Controle|The volunteer do not smoke any cigarette during the study period
11393290|NCT02080598|Experimental|smoking|the volunteer smokes 2 cigarettes in 15 minutes
11393291|NCT02080585|No Intervention|Control group without advice|Control group receives no intervention or physical activity advice.
11393292|NCT02080585|Experimental|Computer-tailored physical activity advice|Subjects receive computer-tailored physical activity advice.
11393293|NCT02080572||Parkinson's Disease with DBS|Individuals with Parkinson's disease and deep brain stimulation will be recruited.
11393294|NCT02080559|Experimental|4CMenB - Test group|Administered at 2, 4 and 12 months of age
11393295|NCT02080559|Active Comparator|4CMenB - control group|Given at 5, 7 and 13 months of age
11393296|NCT02080546|Active Comparator|Cut/Coag|
11393297|NCT02080546|Experimental|V-mode|
11393298|NCT02080533|Experimental|Single|Slow-paced respiration therapy
11393299|NCT02080520|Active Comparator|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
11393300|NCT02080520|Placebo Comparator|Placebo|Oral placebo matched nattokinase daily
11393301|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
11393302|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
11393303|NCT02080494|No Intervention|Control|No tranexamic acid given
11393304|NCT02080494|Experimental|Tranexamic Acid|15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose
11393305|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
11393306|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
11393307|NCT02080468|Experimental|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide & EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
11393308|NCT02080468|Experimental|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide & EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
11393309|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)
~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
11393310|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)
~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
11393311|NCT02080442||Chronic Obstructive Pulmonary Disease|
11393312|NCT02080429|Active Comparator|Immediate Pushing|Patient's will begin to push when they are determined to be completely dilated.
11393313|NCT02080429|Experimental|Passive Descent|Patient's will wait 90 minutes prior to begin pushing
11393314|NCT02080416|Experimental|Nelfinavir|Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles
11393315|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
11393316|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
11393317|NCT02080390||Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
11393318|NCT02080377|Active Comparator|Current Standard Care|Insulin + Metformin
11393319|NCT02080377|Active Comparator|Treatment|Glibenclamide + Metformin
11393320|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
11393321|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
11393322|NCT02080351|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
11393323|NCT02080351|No Intervention|Usual care|Usual care in the emergency department
11393324|NCT02080338|Experimental|0.018 bracket slot system|Participants treated using 0.018-inch orthodontic bracket slot system
11393325|NCT02080338|Active Comparator|0.022 bracket slot system|Participants treated using 0.022-inch orthodontic bracket slot system
11393326|NCT02080325|Other|High Protein-Weight loss-Meat/High Protein-Weight loss Soy|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Meat with High Protein-Weight loss-Soy
11393327|NCT02080325|Other|High Protein-Weight loss-Soya/High Protein Weight loss-meat|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Soy with High Protein-Weight loss-Meat
11393328|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
11393329|NCT02080299|Active Comparator|Remote ischemic preconditioning (RIPC)|RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.
11393330|NCT02080299|Placebo Comparator|Placebo|Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.
11393331|NCT02080286|Active Comparator|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.
~They will undergo 5 consecutive daily sessions."
11393332|NCT02080286|Placebo Comparator|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.
~They will undergo 5 consecutive daily sessions."
11393333|NCT02080286|Placebo Comparator|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.
~They will undergo 5 consecutive daily sessions."
11393334|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
11393335|NCT02080273|Active Comparator|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
11393336|NCT02080273|Active Comparator|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
11393337|NCT02080260|Experimental|Single Arm|Oral Regorafenib
11393338|NCT02080247|Active Comparator|Intervention: Skin care regimen with Calmoseptine ointment|In this arm the patients with IAD will receive treatment with Calmoseptine Ointment for 6 days as a part of a structured skin regimen
11393339|NCT02080247|Active Comparator|Control: Skin care regimen with Destin ointment|In this arm , patient will receive treatment with Destin Maximum Strength 40% Zinc Oxide. Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
11393340|NCT02080234|Experimental|concurrent chemoradiotherapy with GELOX|"GELOX:
~gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
~IFRT
~IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
~the first cycle of chemotherapy was initiated on the same day of radiotherapy."
11393341|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
11393342|NCT02080208|Experimental|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
11393343|NCT02080208|No Intervention|Conventionnal|patients receiving oxygen via conventional way (low flow)
11393344|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
11393345|NCT02080182|Active Comparator|Acetylcysteine|Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
11393346|NCT02080182|Placebo Comparator|Placebo|Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
11393347|NCT02080169|Experimental|midazolam|Initiative dosage of midazolam is 0.05 mg/kg given intravenously, the maintenance dosage is 0.01-0.05 mg/kg/h, drug dosage is adjusted by target sedation level.
11393348|NCT02080169|Experimental|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min, the maintenance dosage is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level.
11393349|NCT02080169|Experimental|midazolam & dexmedetomidine|"Initiative dosage of midazolam is 0.05 mg/kg given intravenously, The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min(given or not according to patients' condition),.
~The maintenance dosage of midazolam is 0.01-0.05 mg/kg/h, the maintenance dosage of dexmedetomidine is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level."
11393350|NCT02080156|No Intervention|no-CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
11393351|NCT02080156|Experimental|CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
11393352|NCT02080143|Experimental|Air Activated Heat Patch|The experimental air activated heat patch will be worn by the subjects for 8 hours.
11393353|NCT02080143|Active Comparator|Marketed ThermaCare Air Activated Heat Patch|The marketed air activated heat patch will be worn by the subjects for 8 hours.
11393354|NCT02080130|Experimental|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
11393355|NCT02080130|Experimental|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
11393356|NCT02080130|Placebo Comparator|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
11393357|NCT02080117||patients who underwent kidney transplantation|patients who underwent living or deceased donor kidney transplantation between 2008 and 2013
11393358|NCT02080104|Active Comparator|intravenous 10 ıu oxytocin|group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery
11393359|NCT02080104|Experimental|intramusculer 10 ıu oxytocin|group which oxytocin administered intramusculary after vaginal delivery
11393360|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
11393361|NCT02080078|Experimental|Increasing dose of Theophylline|Patients will be put on the standard dose of 150 mg/day of erlotinib. Patients will be entered into the study on different dose levels of theophylline (100 mg/bid, 150 mg/bid, 200 mg/bid, or 200 mg/tid) for 28 days to find what is the lowest dose that effectively controls the diarrhea caused by erlotinib.
11393362|NCT02080078|Experimental|Increasing dose of erlotinib|Patients will be kept on a specified dose of theophylline while the dose of erlotinib increases in each group of patients enrolled (200 mg/qd, 225 mg/qd, or 250 mg/qd) for 28 days to determine what the maximum dose of erlotinib that can be given with theophylline and maintain a safety profile.
11393363|NCT02080065||liver transplantation|patients who underwent living donor liver transplantation during between 2007 and 2013
11393364|NCT02080052|Experimental|Robot-assisted prostate biopsy|
11393365|NCT02080039|Experimental|Electrical Stimulation|
11393366|NCT02080026|Experimental|CPS-immunization|"In this group a total of four CPS-immunizations will be performed, with bites from 15 Plasmodium infected mosquitoes per immunization, over a period of four months, during which volunteers will take chloroquine prophylaxis.
~14 weeks after the last immunization, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.
~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
11393367|NCT02080026|Other|Control|"This group will take chloroquine prophylaxis during the same period as the immunization group, but will not receive CPS-immunizations.
~10 weeks after stopping chloroquine prophylaxis, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.
~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
11393368|NCT02080013|Sham Comparator|ClosureFast group|Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux
11393369|NCT02080013|Sham Comparator|group 1|EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux
11393370|NCT02080000|Experimental|Optimised V-V timing delay|V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
11393371|NCT02080000|Active Comparator|Standard V-V timing delay|Standard settings
11393372|NCT02079987|Experimental|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
11393373|NCT02079987|Experimental|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
11393374|NCT02079974|Experimental|Pravastatin|Pravastatin sodium 20mg PO daily
11393375|NCT02079961|Experimental|Micronutrient-fortified yoghurt|"Micronutrient-fortified yoghurt + BCC
~All eligible children within the intervention arm will receive one fortified yoghurt per day, every day of the week, if the household satisfied to the contract of reliability in milk supply during the previous week, during the one year duration of the intervention."
11393376|NCT02079961|Active Comparator|Control|"BCC
~Children will not receive fortified yoghurt during the duration of the intervention"
11393377|NCT02079948|Active Comparator|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
11393378|NCT02079948|Placebo Comparator|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
11393379|NCT02079948|Experimental|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
11393380|NCT02079948|Experimental|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
11393381|NCT02079935|Experimental|Cognitive Behaviour Therapy|Treatment with small groups following a modified protocol first described by Fairburn 2008
11393382|NCT02079935|Experimental|Physical activity and dietary therapy|Treatment with guided physical activity and dietary therapy in small groups
11393383|NCT02079922|Experimental|Cohort 1|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11393384|NCT02079922|Experimental|Cohort 2|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11393385|NCT02079922|Experimental|Cohort 3|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11393386|NCT02079922|Experimental|Cohort 4|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11393602|NCT02078622||COPD, Education and Case Management|Respiratory Therapist Education and Case Management
11393387|NCT02079922|Experimental|Cohort 5|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11393388|NCT02079922|Experimental|Cohort 6|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
11393389|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
11393390|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
11393391|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
11393392|NCT02079896|Experimental|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
11393393|NCT02079896|Placebo Comparator|Control|Twice weekly doses of placebo, 9 total
11393394|NCT02079896|Experimental|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
11393395|NCT02079883||ocriplasmin|
11393396|NCT02079870|Experimental|Sema|Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
11393397|NCT02079870|Placebo Comparator|Placebo|
11393398|NCT02079857|Experimental|Standard|Fixed protocol
11393399|NCT02079857|Experimental|Individualized|Individualized protocol
11393400|NCT02079857|Sham Comparator|Control|Sham acupuncture/Placebo moxa
11393401|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
11393402|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
11393403|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
11393404|NCT02079831|Experimental|Higher protein and energy restriction|Participants in this arm will consume 30% of energy as protein with 25% energy restriction.
11393405|NCT02079831|Experimental|Lower protein and energy restriction|Participants in this arm will consume 15% of energy as protein with 25% energy restriction.
11393406|NCT02079818|Experimental|Penumbra Ruby Coil System|
11393407|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
11393408|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
11393409|NCT02079792|Active Comparator|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
11393410|NCT02079792|Experimental|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
11393411|NCT02079779|Experimental|Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of robotic-assisted therapy.
11393412|NCT02079779|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of classical rehabilitation.
11393413|NCT02079766|Experimental|High Risk of CTE|Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)
11393414|NCT02079766|Experimental|Control|Flortaucipir PET scans in former non-contact athletes
11393415|NCT02079753|Active Comparator|combined system|During the first visit, the technician installed a reservoir of liquid oxygen (Liberator 30, Caire) and a liquid Stroller oxygen pack (Caire) for patients using liquid oxygen, or a VisionAire5 (Airsep) stationary concentrator and an Inogen One G2 portable (Inogen) concentrator for patients using concentrators.
11393416|NCT02079753|Experimental|single system|Inogen One G2 portable concentrator (Inogen)
11393417|NCT02079740|Experimental|Treatment (trametinib, navitoclax)|Patients receive trametinib PO QD and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If unacceptable toxicity is observed, patients may receive trametinib PO QD on days 1-14.
11393418|NCT02079727|Experimental|Condrosulf (Chondroitin 4&6 sulfate)|1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days
11393419|NCT02079727|Placebo Comparator|Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule|1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days
11393420|NCT02079727|Active Comparator|Celebrex 200 mg capsule|1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days
11393450|NCT02079558|Experimental|Carbetocin|A standard 30 international units (IU) IV infusion of oxytocin during two hours
11393451|NCT02079545|Experimental|Group 1|18 participants will receive a single intravenous (IV) infusion of 100 mg sirukumab
11393603|NCT02078609|Experimental|LGH447 monotherapy arm|LGH447 monotherapy in patients with AML or MDS
11393421|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
11393422|NCT02079701|Experimental|23-valent pneumococcal vaccine|single dose, 23-valent pneumococcal vaccine, 0.5ml, intramuscular (IM)
11393423|NCT02079701|Placebo Comparator|placebo|0.5 ml injectible saline, IM
11393424|NCT02079688|Experimental|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.
~Comparison and random assignment of treatments to two distinct treatment areas (area 1, area 2).
~IMP SB011: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments) daily dosage: Approximately 10 mg hgd40 total dosage: Approximately 145 mg hgd40"
11393425|NCT02079688|Placebo Comparator|Multiple W/O/W formulation, active ingredient-free vehicle|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.
~Comparison and random assignment of treatments to two distinct treatment areas (Area 1, Area 2).
~Vehicle: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments)"
11393426|NCT02079675|Experimental|SKI3246 Low Dose|Intervention: Drug: SKI3246 Low Dose
11393427|NCT02079675|Experimental|SKI3246 High Dose|Intervention: Drug: SKI3246 High Dose
11393428|NCT02079675|Placebo Comparator|Placebo|Intervention: Drug: Placebo
11393429|NCT02079662|Experimental|Arm I (IO interventions)|Patients undergo up to 7 different IO intervention sessions per week during their 6-week course of radiotherapy for between 1 and 3 hours each session, in addition to, up to 6 aerobic training sessions per week and one grocery store trip during the course of the program. IO intervention programs consist of nutritional coaching, behavioral therapy, yoga and meditation practice, resistance training, and a weekly meal sharing and cooking class. Patients then have weekly meetings with the study psychologist on the computer for 6 months, followed by a monthly meeting on the computer from 6-12 months, and 2 hour meetings at all follow-up appointments during the first year after radiotherapy.
11393430|NCT02079662|Active Comparator|Arm II (standard of care)|Patients undergo standard of care.
11393431|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
11393432|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
11393433|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
11393434|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
11393435|NCT02079636|Experimental|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11393436|NCT02079636|Experimental|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11393437|NCT02079636|Experimental|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11393438|NCT02079636|Experimental|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11393439|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
11393440|NCT02079623||Pancreatic cancer|Patients with locally advanced pancreatic cancer.
11393441|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
11393442|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
11393443|NCT02079597||Healthy|Healthy individuals no infection
11393444|NCT02079597||SIRS|SIRS patients no included in an interventional study no peroperative infection
11393445|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
11393446|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
11393447|NCT02079571|Experimental|water+ Coconut water|forty subjects
11393452|NCT02079545|Experimental|Group 2|18 participants will receive a single subcutaneous (SC) injection of 50 mg sirukumab using a Pre-filled Syringe (PFS) fitted with the UltraSafe Passive™ Delivery System (PFS-U)
11393453|NCT02079545|Experimental|Group 3|18 participants will receive a single SC injection of 50 mg sirukumab using the SmartJect™ Autoinjector (PFS-AI)
11393454|NCT02079545|Experimental|Group 4|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-U
11393455|NCT02079545|Experimental|Group 5|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-AI
11393456|NCT02079532|Experimental|MabThera (Rituximab)|
11393457|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
11393458|NCT02079506|Experimental|Treatment A|
11393459|NCT02079506|Experimental|Treatment B|
11393460|NCT02079493||Total Knee Arthroplasty patients|TKA patients
11393461|NCT02079480|Experimental|Panel 1: BMS-986090 (0.5 mg) or Placebo|"BMS-986090 0.5 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
11393462|NCT02079480|Experimental|Panel 2: BMS-986090 (3 mg) or Placebo|"BMS-986090 3 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
11393463|NCT02079480|Experimental|Panel 3: BMS-986090 (10 mg) or Placebo|"BMS-986090 10 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
11393464|NCT02079480|Experimental|Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)|"BMS-986090 30 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
~And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once"
11393465|NCT02079480|Experimental|Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)|"BMS-986090 100 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
~And KLH 1 mg solution single intramuscular dose once"
11393466|NCT02079480|Experimental|Panel 6: BMS-986090 (100 mg) or Placebo|"BMS-986090 100 mg solution single dose intravenously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
11393467|NCT02079480|Experimental|Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)|"BMS-986090 300 mg solution single dose subcutaneously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
~And KLH 1 mg solution single intramuscular dose once"
11393468|NCT02079480|Experimental|Panel 8: BMS-986090 (750 mg) or Placebo|"BMS-986090 750 mg solution single dose intravenously once
~OR
~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
11393469|NCT02079480|Experimental|Panel 9: BMS-986090 (150 mg) or Placebo|"BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks
~OR
~Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks"
11393470|NCT02079467|Active Comparator|Standard rehabilitation|"Patients randomized to the control group will be managed with hip precautions immediately following surgery. They will weight bear on the operative joint as tolerated after surgery. They will be managed as per usual protocol post total hip arthroplasty. They will be transferred from the operative table with an abduction pillow between their legs and will be asked to keep this pillow between their legs while resting in bed and during sleep throughout their course in hospital. During physiotherapy treatments they will not flex the operative hip beyond 90 degrees, internally or externally rotate the operative hip more than 45 degrees, or actively adduct the operative hip past neutral."
11393471|NCT02079467|Experimental|Unrestricted rehabilitation|Patients randomized to the treatment group will have no restrictions in their post-operative rehabilitation. They will weight bear on the operative joint as tolerated after surgery. They will be asked to participate in activity as their level of comfort permits and will have no positional restrictions while in bed or completing activities of daily living.
11393472|NCT02079441||Infants, IBD mothers, anti TNF, pregnancy|Infants born to mother with IBD receiving ant- TNF medications during pregnancy
11393473|NCT02079441||infants, IBD mothers, pregnancy, medications|Infants born to mothers with IBD receiving non anti TNF medications during pregnancy
11393474|NCT02079428||Systolic heart failure, Diastolic heart failure|
11393475|NCT02079402|Active Comparator|Liberal (target-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.
~Fluid boluses may be given as long as hemodynamic variables improve (dynamic or static variable(s) of choice). A fluid bolus is to be followed by evaluation of effect 30 minutes after the intervention at the latest.
~'Variable(s) of choice' refers to the variable(s) used to assess hemodynamic improvement.
~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
11393476|NCT02079402|Experimental|Conservative (trigger-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.
~A fluid bolus of 250-500 ml may be given followed by evaluation of effect 30 minutes after the intervention at the latest if one of the following occurs:
~Plasma lactate concentration ≥ 4 mmol/l at point-of-care testing.
~Severe hypotension (MAP < 50mmHg).
~Mottling beyond edge of kneecap.
~Severe oliguria (only in the first 2 hours after randomisation). Severe oliguria defined as urine output ≤ 0.1 ml/kg/hour IBW last hour.
~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
11393477|NCT02079389|Active Comparator|Lap+Lus|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.
~In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a LUS examination of the primary tumor, liver and retroperitoneum.
~All the included patients are getting a CT scan of the abdomen after 3 months."
11393478|NCT02079389|No Intervention|laparoscopic examination (Lap)|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.
~In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection.
~All the included patients are getting a CT scan of the abdomen after 3 months."
11393479|NCT02079376|Experimental|Low blood TG patients|subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
11393480|NCT02079376|Experimental|High blood TG patients treated with blood TG lowering therapy|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
11393481|NCT02079376|Placebo Comparator|High blood TG patients|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
11393482|NCT02079363||Patients with pancreatic adenocarcinoma|"Exclusion criteria:
~No prior cancer. No anticoagulant treatment."
11393483|NCT02079363||Patients with chronic pancreatitis|"Exclusion criteria:
~No prior cancer. No anticoagulant treatment."
11393484|NCT02079363||Patients with acute pancreatitis|"Exclusion criteria:
~No prior cancer."
11393485|NCT02079363||Patients screened for but not having upper GI cancer|"Exclusion criteria:
~No prior cancer."
11393486|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
11393487|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
11393488|NCT02079337|Active Comparator|Deep NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during deep neuromuscular blockade and without neuromuscular blockade
11393489|NCT02079337|Placebo Comparator|No NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during no neuromuscular blockade and during deep neuromuscular blockade.
11393490|NCT02079324|Experimental|GX-051|GX-051 intratumoral injection
11393491|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
11393492|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
11393493|NCT02079298|Active Comparator|1|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole.
11393494|NCT02079298|Active Comparator|2|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen.
11393495|NCT02079298|Active Comparator|3|Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen.
11393496|NCT02079298|Placebo Comparator|4|Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen.
11393497|NCT02079285||EUS-FNA|Any patients who will undergo EUS-FNA for pancreas lesion during the study period
11393498|NCT02079272|Other|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.
~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
11393499|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
11393500|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
11393501|NCT02079233|Experimental|CLP 15 g QD|Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
11393502|NCT02079233|Experimental|CLP 7.5 g BID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner
11393503|NCT02079233|Experimental|CLP 5 g TID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner
11393504|NCT02079233|Experimental|CLP 3.75 g QID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
11393505|NCT02079220|Experimental|Arm A|"Arm A (every 2 week schedule) Dosage and dosage regimen for all study periods
~Capecitabine: will be administered 1,000 mg/m2 orally twice a day on Days 1 - 7 of each cycle, repeating every 14 days.
~Oxaliplatin: will be administered 85 mg/m2 IV on Day 1 of each cycle, repeating every 14 days.
~Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days."
11393506|NCT02079220|Experimental|Arm B|"Arm B (every 3 week schedule):
~Dosage and dosage regimen for all study periods
~Capecitabine: will be administered 850 mg/m2 orally twice a day on Days 1 - 14 of each cycle, repeating every 21 days.
~Oxaliplatin: will be administered 130 mg/m2 IV on Day 1 of each cycle, repeating every 21 days.
~Ziv-aflibercept: will be administered 6 mg/kg IV on Day 1 of each cycle, repeating every 21 days."
11393507|NCT02079207|Experimental|NBP606|Participants aged over 50 years are given a 0.5mL dose of 13-valent peumococcal conjugate vaccine administered on day 0.
11393508|NCT02079207|Active Comparator|Prodiax-23|Participants aged over 50 years are given a 0.5mL dose of 23-valent pneumococcal polysaccharide vaccine administered on day 0.
11393509|NCT02079194|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
11393510|NCT02079194|Experimental|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
11393511|NCT02079181|Experimental|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
11393512|NCT02079168|Experimental|Cohort 1|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.
11393513|NCT02079168|Experimental|Cohort 2|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
11393514|NCT02079155|Active Comparator|Arm I (RALP)|Patients undergo standard RALP.
11393515|NCT02079155|Experimental|Arm II (R-LESS RP)|Patients undergo R-LESS RP.
11393554|NCT02078908|Active Comparator|240 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
11393516|NCT02079142|Experimental|High Intensity Strategy: Train-the-trainer|One therapist from each counseling center randomized to this arm will be selected to become the trainer and will be trained to train their colleagues.
11393517|NCT02079142|Active Comparator|Low Intensity Strategy: Expert Consultation|The IPT expert from Washington University will travel to all counseling centers randomized to this condition and train all participating therapists on site and be available for monthly phone consultation for up to one year following training on site.
11393518|NCT02079116|Experimental|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.
~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
11393519|NCT02079116|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).
~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
11393520|NCT02079103|Experimental|Virtual reality|Virtual reality training using the YouGrabber® for patients with impaired arm motor function after stroke. The YouGrabber exercises focus on intensity, repetitions and motivating tasks and are adapted to the patient's motor abilities.
11393521|NCT02079103|Active Comparator|Conventional arm training|The patients receive supervised self-training exercises with focus on functional tasks adapted to their motor abilities.
11393522|NCT02079090|Active Comparator|Ketofol|Patient will receive 0.5 mg/kg Ketamine, and 2 minutes later receive 1 mg/kg Propofol.
11393523|NCT02079090|Experimental|Fentofol|Patient will receive 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol.
11393524|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
11393525|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
11393526|NCT02079064|Experimental|Desflurane|Desflurane at 1 MAC and
11393527|NCT02079064|Experimental|propofol|propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
11393528|NCT02079051|Experimental|High Intensity Weight Loss|High intensity medical weight loss
11393529|NCT02079051|Active Comparator|Moderate Intensity Weight Loss|Moderate intensity weight loss
11393530|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
11393531|NCT02079038|Active Comparator|Comparator Procedure|Comparator Surgical Procedure
11393532|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
11393533|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
11393534|NCT02079012|Experimental|Intervention group|"Receives:
~An information session
~A 10-week walking program (with documents, pedometer and three information sessions about motivation, a healthy diet and smoking cessation)
~A physical activity diary (which also functions as a tool to check protocol-compliance)
~Measurements"
11393535|NCT02079012|No Intervention|Control group|Only receives measurements.
11393536|NCT02078999||Control Grup|"Daily clinical data collection
~Quantitative tracheal aspirates (QTA) every 3 days
~Deep freeze serum samples for posterior analysis every day (two aliquots).
~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
11393537|NCT02078999||Patients with pulmonary infection|"Daily clinical data collection
~Quantitative tracheal aspirates (QTA) every 3 days
~Deep freeze serum samples for posterior analysis every day (two aliquots).
~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
11393538|NCT02078999||Patients with extrapulmonary infection|"Daily clinical data collection
~Quantitative tracheal aspirates (QTA) every 3 days
~Deep freeze serum samples for posterior analysis every day (two aliquots).
~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
11393539|NCT02078986|Experimental|Whole Body Electromyostimulation|
11393540|NCT02078986|Experimental|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks
11393541|NCT02078973|Active Comparator|15 mg tolvaptan|Oral administration of 15 mg tolvaptan on each examination day.
11393542|NCT02078973|Active Comparator|30 mg tolvaptan|Oral administration of 30 mg tolvaptan on each examination day.
11393543|NCT02078973|Active Comparator|45 mg tolvaptan|Oral administration of 45 mg tolvaptan on each examination day.
11393544|NCT02078973|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet
11393545|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
11393546|NCT02078947|Experimental|High Intensity Exercise|Patients perform interval- type endurance exercise at high intensity
11393547|NCT02078947|Active Comparator|Moderate Continuous Exercise|Patients perform endurance exercise at moderate intensity
11393548|NCT02078947|Sham Comparator|Usual Care|Patients receive advice on being physically active as well as usual care
11393549|NCT02078934|Experimental|Weight Loss|Patients with complex incisional/ventral hernias who are too obese to undergo hernia repair.
11393550|NCT02078921|Experimental|Treatment|Inorganic Nitrate
11393551|NCT02078921|Placebo Comparator|placebo|Placebo
11393552|NCT02078908|Active Comparator|40 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
11393553|NCT02078908|Active Comparator|120 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
11393556|NCT02078895|Experimental|Botox|The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
11393557|NCT02078895|No Intervention|Control|The control group will involve a ureteral stent placement with no injection.
11393558|NCT02078882|Experimental|Abatacept 125 mg weekly|Open label treatment with Abatacept
11393559|NCT02078869|Active Comparator|intramuscular Progesterone in oil|50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer
11393560|NCT02078869|Active Comparator|vaginal progesterone suppositories|200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer
11393561|NCT02078856|Experimental|A3384 Low dose|Administered twice daily for the duration of the study
11393562|NCT02078856|Experimental|A3384 High dose|Administered twice daily for the duration of the study
11393563|NCT02078856|Placebo Comparator|Placebo|Administered twice daily for the duration of the study
11393564|NCT02078843|Other|All patients|Subsequent performance of index test and standard test
11393565|NCT02078830|Placebo Comparator|3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
11393566|NCT02078830|Experimental|3M™ Tegaderm™ CHG Securement Dressing|- CHG activity at EVD entry site
11393567|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
11393568|NCT02078804|Experimental|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
11393569|NCT02078804|Experimental|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
11393570|NCT02078804|No Intervention|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
11393571|NCT02078791|Experimental|Botox infiltration|Botox infiltration in cervical region
11393572|NCT02078791|Experimental|Psychology therapy|Problem solving group therapy
11393573|NCT02078791|Experimental|Botox infiltration & psychology therapy|Botox infiltration in cervical region and problem solving group therapy.
11393574|NCT02078778|Experimental|Treatment|Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.
11393575|NCT02078765||hypertension|75 patients with hypertension and chronic kidney disease (CKD stage I-II)
11393576|NCT02078765||healthy subjects|75 healthy subjects
11393577|NCT02078752|Experimental|Part 1|
11393578|NCT02078739|Experimental|Yoga Program|Yoga Program twice per week for 8 weeks
11393579|NCT02078739|Active Comparator|Education|Education once per week for 8 weeks
11393580|NCT02078726|Active Comparator|Glucagon|1 mg glucagon given during colonoscopy
11393581|NCT02078726|Placebo Comparator|Placebo|1 mL normal saline
11393582|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
11393583|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
11393584|NCT02078700|Experimental|early palliative care programme|Patients will be proposed to be followed by the Palliative Care Team
11393585|NCT02078687|Active Comparator|Group 1, HM|This group received breastfeeding (human milk, HM) solely throughout the 4 month of intervention. Randomisation for group 1 or group 2. Mothers own milk.
11393586|NCT02078687|Active Comparator|Group 2, HMF|This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
11393587|NCT02078687|Active Comparator|Group 3, PF|This group received preterm formula (PF) throughout the intervention period of 4 month. This group was not randomised for ethical reasons. Enfalac Premature Formula, Mead Johnson Nutritionals
11393588|NCT02078674|Experimental|Group A|Placebo
11393589|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
11393590|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
11393591|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
11393592|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
11393593|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
11393594|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
11393595|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
11393596|NCT02078661|Active Comparator|PG101 0.25%|Topical application of drug
11393597|NCT02078661|Active Comparator|PG101 1.0%|Topical application of drug
11393598|NCT02078661|Placebo Comparator|Placebo|Topical application of placebo
11393599|NCT02078648|Experimental|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC
11393600|NCT02078635|Experimental|Portfolio Plus Diet|Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)
11393601|NCT02078635|Active Comparator|DASH-like (high fibre) diet|The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)
11393604|NCT02078609|Experimental|LGH447 + midostaurin combination arm|LGH447 + midostaurin in patients with AML
11393605|NCT02078596|Experimental|Divalproex|Divalproex at 10 mgs/lb
11393606|NCT02078596|Placebo Comparator|Sugar Pill|Equivalent 250 mg pills titrated to 10 mgs / lb over six weeks
11393607|NCT02078583|Experimental|Remifentanil，midazolam|Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
11393608|NCT02078583|Experimental|Fentanyl，midazolam|Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
11393609|NCT02078583|Placebo Comparator|Normal saline|Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
11393610|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
11393611|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
11393612|NCT02078544||Gynaecological cancer|
11393613|NCT02078531||Chemotherapy and anti-hormonal therapy|"cognitive assessment using CANTAB
~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
11393614|NCT02078531||chemotherapy only and healthy control group|"cognitive assessment using CANTAB
~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
11393615|NCT02078518||Multiple Myeloma|Questionnaires will be given to patients for completion.
11393616|NCT02078505|Experimental|PCOS after diet|Patients after 2 months of diet
11393617|NCT02078505|No Intervention|control|Ovulatory women
11393618|NCT02078492|Experimental|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
11393619|NCT02078492|Experimental|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
11393620|NCT02078492|Experimental|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
11393621|NCT02078479|Active Comparator|Real rTMS|The active group received Real rTMS over the hand area of motor cortex (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold) every day for ten consecutive days (5 days/week).
11393622|NCT02078479|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce the same of subjective sensation of rTMS
11393623|NCT02078466|No Intervention|Control group|Usual care
11393624|NCT02078466|Experimental|Assessment of functional ability|Assessment of functional ability and follow-up at home
11393625|NCT02078453|Active Comparator|Visual inspection|Dental treatment performed according to the caries diagnosis obtained with visual inspection performed alone
11393626|NCT02078453|Experimental|Radiographic examination|Dental treatment performed according to the caries diagnosis obtained with visual inspection and additional radiographic method.
11393627|NCT02078440|Other|Bromocriptine mesylate (Cycloset)|Bromocriptine mesylate (Cycloset)
11393628|NCT02078427||rAHF-PFM|Participants treated with rAHF-PFM alone
11393629|NCT02078427||rAHF-PEG|Participants treated with rAHF-PEG alone
11393630|NCT02078427||rAHF-PFM then rAHF-PEG|Participants treated with rAHF-PFM and subsequently switched to rAHF-PEG
11393631|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
11393632|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
11393633|NCT02078401||Neurofibromatosis type 1 children|
11393634|NCT02078388||Breast cancer,Doxorubicin|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had a pre-doxorubicin echocardiography done at NUHS will be enrolled. Study subjects will donate one sample of blood (20ml) for genetic and biomarker studies related to breast cancer and anthracyclines pharmacodynamics. An echocardiography will be performed to measure left ventricular ejection fraction, and compared with the subject's pre-doxorubicin echocardiography done at NUH. Correlative analysis will be performed between genetic variants and left ventricular ejection change.
11393635|NCT02078375|Placebo Comparator|Carbohydrate supplement|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a carbohydrate supplement to take twice daily (once after exercise).
11393636|NCT02078375|Experimental|Protein Supplementation|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a twice daily protein supplement (once after exercise).
11393637|NCT02078349|Experimental|Solid Tumors|"Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).
~One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities."
11393638|NCT02078336|Experimental|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
11393639|NCT02078336|Active Comparator|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment
~OR
~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment
~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment
~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment
~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
11393640|NCT02078323|Active Comparator|Linaclotide|Linaclotide 290micrograms q day 30 min before meal for a 10 week period
11393641|NCT02078323|Placebo Comparator|placebo|Placebo q day 30 min before meal for a 10 week period
11393642|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
11393643|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
11393644|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
11393645|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
11393646|NCT02078297||Scalp psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
11393647|NCT02078297||pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
11393648|NCT02078297||non-pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
11393649|NCT02078297||elbow psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
11393650|NCT02078297||leg psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
11393651|NCT02078297||Healthy subjects|
11393652|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
11393653|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
11393654|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
11393655|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
11393656|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
11393657|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
11393658|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
11393659|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
11393660|NCT02078271|Experimental|FBDG group|The group received Food Based Dietary Guidelines for feeding recommendation. Monthly-session with group of mothers involving interactive activities e.g. cooking session, cooking competition and games.
11393661|NCT02078271|Experimental|Stimulation group|The children received psychosocial stimulation from the mothers. Mothers were taught on psychosocial module which was developed using locally existing resources and was directed at improving four aspects of child development, namely gross motoric, fine motor, language and socio-emotional developments.
11393662|NCT02078271|Experimental|Combined (FBDG and Stimulation)|The group received both FBDG and psychosocial stimulation
11393663|NCT02078271|Other|Control|The group received standard health education messages from existing health care system.
11393664|NCT02078258|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a a variation of attention tasks to modify attentional biases, in which a probe always appears in the location of relatively positive stimuli after the two stimuli, one neutral and one emotional, were simultaneously presented.
~Participants complete 8 sessions (320 trials each with 20 minutes) over two weeks of neutral ABMT to shift attention toward neutral, in which a probe appeared in the location of neutral with 90% probability, and sadness-related with 10% probality. At a 9-week follow-up, participants completed 4 more sessions (480 trials each with 30 minutes)over two weeks of positive ABMT to shift attention toward positive words,in which a probe appeared in the location of 67% positive or 33% neutral."
11393665|NCT02078258|Active Comparator|Placebo control|The placebo ABMT was identical to the active ABMT, but shifted toward neutral (50%) or sad (50%) stimuli equally often (i.e., 50/50 training).
11393666|NCT02078245||Familial pancreatic cancer patients|Individual with ten fold higher risk to develop pancreatic cancer.
11393667|NCT02078232|Experimental|19G flex needle puncture|puncture of head of pancreas
11393668|NCT02078232|Active Comparator|22G needle puncture|puncture of head of pancreas
11393669|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
11393670|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
11393671|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
11393672|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
11393673|NCT02078219|Other|Allopurinol|Allopurinol 200mg
11393674|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
11393675|NCT02078206|No Intervention|Treatment as usual|
11393676|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
11393677|NCT02078180|Active Comparator|generic bupropion IR75|One oral dose of generic bupropion IR75
11393678|NCT02078180|Active Comparator|generic bupropion IR100|One oral dose of generic bupropion IR100
11393679|NCT02078180|Active Comparator|generic bupropion SR100|One oral dose of generic bupropion SR100
11393680|NCT02078180|Active Comparator|generic bupropion SR150|One oral dose of generic bupropion SR150
11393681|NCT02078180|Active Comparator|generic bupropion XL150|One oral dose of generic bupropion XL150
11393682|NCT02078180|Active Comparator|generic bupropion XL300|One oral dose of generic bupropion XL300
11393683|NCT02078154||Deep Venous Thrombosis (DVT)|DVT diagnosed by imaging technique with a low or moderate Wells score
11393684|NCT02078128|Experimental|oral beta-glucans|Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
11393685|NCT02078128|Placebo Comparator|oral sugar powder|control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
11393686|NCT02078115||chronic kidney disease, hypertension|20 <= age < 75 years 15 <= estimated glomerular filtration rate (GFR) < 90
11393687|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.
~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.
~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
11393688|NCT02078089|Other|Oxcarbazepine and Morphine|"Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.
~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days."
11393689|NCT02078076|Experimental|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
11393690|NCT02078063|Experimental|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
11393691|NCT02078063|Placebo Comparator|NaCL|10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
11393692|NCT02078050|Other|Phrenic nerves magnetic stimulations|
11393693|NCT02078037|Experimental|Arctic Sun cooling device|The Arctic Sun device pads will be placed on the patient as per manufacturer's instructions. Patients, who cannot tolerate placement of all the pads for any given reason, will still be included in the study if they can maintain normothermia (normal body temperature). The total normothermia time for the study is five days. After 5 days, the attending physician will make clinical decisions based on the patient needs.The temperature goal for this study is 36.5 degree Celsius, but normothermia for the purpose of this study will be defined as a temperature of 35.5 - 37.5 degree Celsius. A thermometer mounted urinary catheter will be used for temperature monitoring and feedback to the Arctic Sun.
11393694|NCT02078037|Active Comparator|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician) initiated at a temperature of 38.5 degrees Celsius
11393695|NCT02078024|Active Comparator|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
11393696|NCT02078024|Experimental|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
11393697|NCT02078024|Experimental|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
11393698|NCT02078024|Experimental|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
11393699|NCT02078024|Experimental|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
11393700|NCT02078011|Experimental|HIFU treatment|The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die
11393701|NCT02077998|Experimental|Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)|"PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.
~PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
11393702|NCT02077985|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
11393703|NCT02077985|Experimental|Sensory Adapted Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
11393704|NCT02077972|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
11393705|NCT02077959|Experimental|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11393706|NCT02077946||Liraglutide / Sitagliptin|
11393707|NCT02077933|Experimental|alpelisib and everolimus|alpelisib and everolimus administered once a day
11393708|NCT02077933|Experimental|alpelisib, everolimus and exemestane|alpelisib, everolimus and exemestane administered once a day
11393709|NCT02077933|Experimental|alpelisib and exemestane|alpelisib and exemestane administered once a day
11393710|NCT02077920|Experimental|Chlorhexidine before intubation|Group A: Oropharyngeal decontamination with chlorhexidine before intubation, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation, and every 6 hours after intubation.
11393711|NCT02077920|Experimental|Chlorhexidine after intubation|Group B: Oropharyngeal decontamination with chlorhexidine after intubation, n=48. Oral cleansing with chlorhexidine will be performed every 6 hours after endotracheal intubation.
11393712|NCT02077920|Experimental|Subglottic secretion drainage|"Group C: Suctioning of subglottic secretions, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation and every 6 hours after intubation, and fiberoptic bronchoscopy-guided suctioning of subglottic secretions will be performed at 10:00 a.m. every day. The procedure will be as follows:
~Routine cleaning of the bronchoscope.
~Oral or nasal insertion of the bronchoscope (according to the decision of the attending physician based on the patient's condition). Rinsing of the subglottic region with 5-20 mL of chlorhexidine solution followed by suctioning. The rinsing procedure will be repeated 3-5 times.
~Routine cleaning of the bronchoscope. The patient will be monitored during all procedures."
11393713|NCT02077920|Experimental|0.9% sodium chloride injection|Group D: 0.9% sodium chloride injection, n=48. After endotracheal intubation, oral cleansing with normal saline will be performed every 6 hours.
11393714|NCT02077907|Active Comparator|Super Cereal Plus (SC+)|"800 kcal/d, 215 g/d
~Current protocol for treating MAM is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. In Sierra Leone, their FBF standard is Super Cereal Plus."
11393715|NCT02077907|Experimental|Super Cereal (SC) and oil and sugar|"200 g SC and 20 g fortified oil and 15 g sugar, per day
~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
11393716|NCT02077907|Experimental|Corn Soy Blend 14 (CSB14) and fortified oil|"978 kcal/day - 150 g CSB14 and 45 g oil, per day
~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
11393717|NCT02077907|Experimental|Plumpy'Sup|"500 kcal/d, 92 g/d
~Ready-to-Use Supplementary Food (RUSF)"
11393718|NCT02077894||Participants with retinal disease|Participants with retinal disease
11393719|NCT02077894||Unaffected family members|Members of the participant's family that do not have eye disease
11393720|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:
~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.
~Phase 2 portion:
~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
11393721|NCT02077868|Other|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
11393722|NCT02077868|Experimental|Treatment Arm B|MGN1703 treatment as maintenance therapy
11393723|NCT02077855||Toddlers fractures|
11393724|NCT02077842|Experimental|Nasal CPAP|The experimental group will receive nasal continuous positive airway pressure at 10cmH20 for one hour in the Post Anesthetic Care Unit.
11393725|NCT02077842|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
11393726|NCT02077829|Other|IMR therapists, IMR patients|"30 voluntary therapists from 9 mental health services will be trained and coached in IMR.
~40 patients from the 9 mental health services will receive Illness Management and Recovery from the therapists in training."
11393727|NCT02077816||Central venous catheter|Inpatients with CVC for medical care.
11393728|NCT02077803|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
11393729|NCT02077803|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
11393730|NCT02077803|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
11393731|NCT02077790|No Intervention|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
11393732|NCT02077777|Experimental|5-ASA|Mesalazine 800 mg orally t.i.d for 3 months
11393733|NCT02077777|No Intervention|No treatment|no treatment
11393734|NCT02077764||Controls, healthy individuals|controls
11393735|NCT02077764||Heart transplanted patients|Patients
11393736|NCT02077751|Experimental|Biotin labelled RBCs|Subjects receive biotin labelled autologous red blood cells.
11393737|NCT02077738|Experimental|HFCWO|HFCWO for 15 min twice a day
11393738|NCT02077738|Placebo Comparator|placebo|not to receive high-frequency chest wall oscillation (HFCWO)
11393739|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
11393740|NCT02077712|Active Comparator|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
11393741|NCT02077712|Active Comparator|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
11393742|NCT02077699|Experimental|1|Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks
11393743|NCT02077686|Experimental|Education - Diabetes and Travel|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Travel"
11393744|NCT02077686|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
11393745|NCT02077673||open surgery|25 patients undergoing open gastroesophageal resection
11393746|NCT02077673||robotic-assissted surgery|25 patients under-going robotic-assisted gastroesophageal surgery
11393747|NCT02077660|Placebo Comparator|4 daily placebo tea bags for 12 weeks|"All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin tea-bags. The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period)."
11393748|NCT02077660|Experimental|Four green tea bags per day for 12 weeks|After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).
11393749|NCT02077647||Conservative|Conservative treatment of osteoarthritis of the knee
11393750|NCT02077634|Active Comparator|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
11393751|NCT02077634|Active Comparator|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
11393752|NCT02077621|Experimental|PG2|"Treatment Group:
~PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
11393753|NCT02077621|Placebo Comparator|Placebo|"Control group:
~Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
11393754|NCT02077608||Hyaluronan enriched transfer media|Embryos are incubated at least 10 minutes in hyaluronan enriched embryo transfer media before transfer
11393755|NCT02077608||Control group|Embryos are incubated in embryo transfer media containing low concentration of hyaluronan for at least 10 minutes before transfer
11393756|NCT02077595|Active Comparator|120Hz alternating current stimulation group|
11393757|NCT02077595|Active Comparator|5Hz alternating current stimulation group|
11393758|NCT02077595|Sham Comparator|sham alternating current stimulation group|
11393759|NCT02077569|Experimental|AZD5363 480mg|STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
11393760|NCT02077569|Placebo Comparator|Placebo|STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
11393761|NCT02077569|Experimental|AZD360mg|STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
11393762|NCT02077569|Experimental|AZD5363 240mg|STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
11393763|NCT02077556|Experimental|Everolimus|Everolimus/Tacrolimus/Methylprednisolone & Prednisolone
11393764|NCT02077556|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone
11393765|NCT02077543|Experimental|ProTool|Device: Brain Tissue Imprint - Medical Device (ProTool)
11393766|NCT02077517|Active Comparator|hand sewn anastomosis|Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing
11393767|NCT02077517|Active Comparator|stapled anastomosis|Patients with stapled anastomosis during Roux en Y Gastric Bypass performing
11393768|NCT02077504|Experimental|CONDUCTOME|MEG and MRI
11393769|NCT02077491|Active Comparator|Intervention|High-protein diet and resistance training
11393770|NCT02077491|No Intervention|Control|The control group recieves standard care during the study.
11393771|NCT02077478|Experimental|MCI|manually controlled infusion will be used
11393772|NCT02077478|Experimental|TCI|Target Controlled Infusion will be used
11393773|NCT02077465|Experimental|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
11393774|NCT02077465|Placebo Comparator|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
11393775|NCT02077452|Experimental|HMS5552 dose 1|HMS5552 25~400mg. Oral administration, twice per day.
11393776|NCT02077452|Experimental|HMS5552 dose 2|HMS5552 25~400mg. Oral administration, twice per day.
11393777|NCT02077452|Experimental|HMS5552 dose 3|HMS5552 25~400mg. Oral administration, twice per day.
11393778|NCT02077452|Experimental|HMS5552 dose 4|HMS5552 25~400mg. Oral administration, once per day.
11393779|NCT02077452|Experimental|HMS5552 dose 5|HMS5552 25~400mg. Oral administration, twice per day.
11393780|NCT02077439|Experimental|Hand Robotic Training|Hand Robotic Training
11393781|NCT02077439|Experimental|Hand and Arm Robotic Training|Hand and Arm Robotic Training
11393782|NCT02077439|Active Comparator|Conventional therapy|Conventional therapy
11393783|NCT02077426|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises
11393784|NCT02077413|Active Comparator|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
11393785|NCT02077413|Experimental|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
11393786|NCT02077413|Active Comparator|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
11393787|NCT02077413|Experimental|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
11393788|NCT02077400|No Intervention|no antibiotic|
11393789|NCT02077400|Active Comparator|Cephazolin|cefazoline
11393790|NCT02077387|Experimental|CHild Inhibitory Control Play (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
11393791|NCT02077387|Active Comparator|Attention control|Children will receive information regarding other healthy behaviors: brushing teeth, sunscreen use, being physically active
11393792|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
11393793|NCT02077374|Placebo Comparator|Placebo|Placebo BID
11393794|NCT02077361|Experimental|Open Label|"Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance. It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.
~It is the same vector used in the United Kingdom Phase I/II trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
11393795|NCT02077348|No Intervention|Insulin|"good glycemic control: 50 % of the subject's basal insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) and on the study-day. Basal period from 7.00 am to 12.00pm. The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.
~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
11393796|NCT02077348|Experimental|Insulin withdrawal|"10 % of the individual subject's regular insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) Basal period from 7.00 am to 12.00 pm (without insulin). The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.
~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
11393797|NCT02077348|Experimental|Norditropin (Growth Hormone)|"Same amount of insulin administered on the control day (good glycemic control) overnight and on the study day (hospitalized and fasting from 10 p.m.). On the study day, a bolus injection of 0,4 mg of growth hormone (Norditropin) will be administered at 7.05 am. Basal period from 7.00 am to 12.00 pm (good glycemic control).The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.
~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
11393798|NCT02077335|Experimental|HDR brachytherapy monotherapy|Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
11393799|NCT02077322|Experimental|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
11393800|NCT02077322|Active Comparator|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
11393801|NCT02077309|Active Comparator|Linagliptin|Patients will receive 5 mg linagliptin once daily for a period of 6 months.
11393802|NCT02077309|Placebo Comparator|Placebo|Patients will take placebo tablets once daily for a period of 6 months.
11393803|NCT02077296||Preoperative chemoradiotherapy|The group consists of patients aged ≥18 with a pathohistological diagnosis of locally advanced rectal adenocarcinoma (<15 cm from the anal verge). They are found eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery (stage 2 or 3 rectal cancer).
11393804|NCT02077283||Healthy people|This group contains healthy people only whose liver function and B ultrasound are normal.
11393805|NCT02077283||"group of liver depression and spleen deficiency pattern"|"In this group, patients are considered to be the pattern of liver depression and spleen deficiency. They mainly have the symptoms of loose stool, depression, fat tongue with white coating and teeth marks and soft or string pulse."
11393806|NCT02077283||"group of damp-heat in the interior pattern."|In this group ,NAFLD patients have symptoms with dry mouth, bitter mouth, heavy feeling in legs, yellow urine, reddish tongue with thick yellowish coating and slippery pulse.
11393807|NCT02077270|Experimental|electroacupuncture|patients in whom precolonoscopic electroacupuncture is preformed
11393808|NCT02077270|Placebo Comparator|Sham electroacupuncture|sham electroacupuncture
11393809|NCT02077270|Sham Comparator|No intervantion|no intervantion
11393810|NCT02077257|Other|Rosuvastatin 20mg|Rosuvastatin 20 mg/d
11393811|NCT02077257|Other|Rosuvastatin 10mg|Rosuvastatin 10 mg/d
11393812|NCT02077244|Experimental|Follow up talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
11393813|NCT02077244|No Intervention|No talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual
11393814|NCT02077244|No Intervention|Observation group|Patients with a score below 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual.
11393815|NCT02077231|Experimental|vitamin A palmitate eye gel|0.1% vitamin A palmitate; Sinqi, Shenyang, China
11393816|NCT02077231|Experimental|carbomer eye gel|0.2% Carbomer 940; Bausch & Lomb, Aschheim, Germany
11393817|NCT02077218|Experimental|Diagnostic (CT and blood biomarkers)|Patients undergo cardiac CT and collection of blood samples for analysis of hs-CRP via quantitative immunoturbidimetry and Lp-PLA2 via ELISA.
11393818|NCT02077205|Experimental|Manualised Cognitive Behavioral Therapy|Manualised Cognitive Behavioral Therapy in a Routine Care Setting
11393819|NCT02077192|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
11393820|NCT02077179|No Intervention|Standard of Care|Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
11393821|NCT02077179|Experimental|HIP Program|Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
11393822|NCT02077166|Experimental|Phase 1: Dose Level -1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
11393823|NCT02077166|Experimental|Phase 1: Dose Level 1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
11393824|NCT02077166|Experimental|Phase 1: Dose Level 1+|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
11393825|NCT02077166|Experimental|Phase 1: Dose Level 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
11393826|NCT02077166|Experimental|2Phase 1: Dose Level 3|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
11393827|NCT02077166|Experimental|Phase 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
11393828|NCT02077153|Experimental|Group Reminescence|In the experimental condition, everything begins ensuring the participants that all the memories shared will not be spread out of the group. Every session will deal with a theme, recalling specific autobiographic experiences; they will be suggested following a chronological order. Participants are encouraged to bring photos or objects related to past themes: at the end of each meeting the theme of the following is revealed. The researchers can also bring materials as cues for reminiscence.
11393829|NCT02077153|Active Comparator|Group discussion|In the control condition, every meeting will offer topics for discussion taken from newspaper and newscasts: personal opinions are promoted, and links with the daily life of participants are welcome (everyday activities, personal preferences). The main goal is to stimulate the social interaction and the communication, without dealing with personal events from the past nor private memories.
11393830|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
11393831|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
11393832|NCT02077114|Experimental|Ipilimumab|Patient who according to standard criteria are candidates to treatment with Ipilimumab
11394107|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
11393833|NCT02077114|Experimental|Vemurafenib|Patients who according to standard criteria are candidates to treatment with Vemurafenib
11393834|NCT02077101|Other|Quantitative study group|Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL [28, 29]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
11393835|NCT02077101|Other|Qualitative study group|"An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France.
~These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous .
~The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis."
11393836|NCT02077088|Experimental|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
11393837|NCT02077088|No Intervention|Only HA formula|only standard HA starter formula
11393838|NCT02077075|Active Comparator|Web-based weight loss program|Subjects will have access to a web-based weight loss program for an 8-week period.
11393839|NCT02077075|Experimental|On-line health coaching in addition to web-based program|Subjects will have access to the web-based wellness program and will also receive weekly personalized health coaching emails.
11393840|NCT02077062||study (hepatectomy) group|patients undergoing hepatectomy for malignant neoplasm
11393841|NCT02077062||control (non hepatectomy) group|patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
11393842|NCT02077049|Experimental|serious games self-training program|Serious games are played, using Kinect® and Fit Bit®. This program is performed during the 10 days of the intervention on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
11393843|NCT02077049|Active Comparator|Conventional self-training program|conventional physical exercises are performed during the 10 days of the intervention, on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
11393844|NCT02077036|Experimental|Active medical device|
11393845|NCT02077036|Placebo Comparator|Inactive medical device|
11393846|NCT02077023||Asymptomatic Carotid Artery Disease, AF|
11393847|NCT02077010|Experimental|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a jet nebulizer
11393848|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
11393849|NCT02076984|Other|Group A|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by titanium tacks
11393850|NCT02076984|Other|Group B|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by U shaped absorbable tacks
11393851|NCT02076958|Active Comparator|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
11393852|NCT02076958|Experimental|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
11393853|NCT02076945|Active Comparator|Healthy patients|Patients without diabetes and without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
11393854|NCT02076945|Experimental|Diabetic patients without neuropathy|Patients with diabetes but without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
11393855|NCT02076945|Experimental|Diabetic patients with neuropathy|Patients with diabetes and with peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus > 19.01 mm2)
11393856|NCT02076932|Active Comparator|Premenopausal women|The premenopausal women will be attending Spinning classes.
11393857|NCT02076932|Experimental|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
11393858|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
11393859|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
11393860|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
11393861|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
11393862|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
11393863|NCT02076893|Active Comparator|Tramadol/gabapentin/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled gabapentin 3 mg/kg [max 150 mg] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
11393864|NCT02076893|Placebo Comparator|Tramadol/placebo/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
11393865|NCT02076880|Experimental|Arm with caloric restriction|"Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.
~Intervention: caloric restriction"
11393866|NCT02076880|Experimental|Arm without caloric restriction|"Patients in this arm will not have a caloric restriction before surgery.
~Intervention: No caloric restriction"
11393867|NCT02076867|Experimental|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
11393868|NCT02076867|Active Comparator|Medical Care As Usual (MCAU)|
11393869|NCT02076854|Experimental|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
11393870|NCT02076854|No Intervention|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
11393871|NCT02076841||interferon beta-1a|30 μg intramuscularly once a week using an injection device (Avonex Pen).
11393872|NCT02076828|Experimental|Fe-OH-PM (Santafer® sp.)(Group II)|The patients in Group II were treated with Fe-OH-PM (Santafer® sp.), 6 mg/kg/day orally.
11393873|NCT02076828|Experimental|Fe-Zn (Ferro Zinc® sp.)(Group III)|The patients in Group III were treated with Fe-Zn (Ferro Zinc® sp.), 6 mg/kg/day orally
11393874|NCT02076828|Experimental|Fe-S (Ferro Sanol® sp.)(Group I)|The patients in Group I were treated with Ferro Sanol® sp., 6 mg/kg/day orally
11393875|NCT02076815|Experimental|Anagrelide retard|Anagrelide Retard prolonged-release formulation
11393876|NCT02076815|Active Comparator|Thromboreductin|Anagrelide immediate release formulation
11393877|NCT02076802||lifestyle counseling|physical exercises
11393878|NCT02076789||ICD generator replacement|Patients with standard indications to ICD generator replacement
11393879|NCT02076776|Active Comparator|Repetitive Task Practice (RTP)|This group focuses on RTP.
11393880|NCT02076776|Experimental|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
11393881|NCT02076776|Experimental|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
11393882|NCT02076763||Acute intermittent porphyria|Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).
11393883|NCT02076750|Experimental|Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
11393884|NCT02076750|Active Comparator|Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.
11393885|NCT02076737|Experimental|VEO|
11393886|NCT02076724|Experimental|Biological mesh (Strattice Firm)|Strattice Firm is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
11393887|NCT02076724|Experimental|Synthetic mesh (Prolene)|Prolene mesh is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
11393888|NCT02076711|Active Comparator|Active|Metoprololsuccinate
11393889|NCT02076711|Placebo Comparator|Placebo|Placebo
11393890|NCT02076698|Experimental|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
11393891|NCT02076698|Active Comparator|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
11393892|NCT02076685|Experimental|isoniazid rechalleng|When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
11393893|NCT02076672|Experimental|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
11393894|NCT02076659|Experimental|F8IL10 + MTX|"Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.
~An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.
~In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2."
11393895|NCT02076646|Experimental|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.
~L19-IL2 will be administered on days 1, 8 & 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
11393896|NCT02076646|Experimental|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
11393897|NCT02076646|Active Comparator|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
11393898|NCT02076633|Experimental|L19IL2 + L19TNF|One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF. Weekly administration for all combined leasions
11393899|NCT02076620|Experimental|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:
~cohort 1 --> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --> 17 μg/kg L19TNFα + doxorubicin."
11393900|NCT02076607||Conservative Treatment|Eleven patients underwent conservative treatment with Brace.
11393901|NCT02076607||Surgical Treatment|Fourteen patients who underwent surgical treatment (arthrodesis).
11393902|NCT02076594|Experimental|Docetaxel & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
11393903|NCT02076594|Experimental|Epirubicin & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)
11393904|NCT02076581||Stroke|Ten individuals with chronic stroke and limb spasticity will be recruited.
11393905|NCT02076581||Dystonia|Ten individuals with dystonic limbs and no spasticity will be recruited.
11393945|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
11393906|NCT02076581||Cerebral Palsy|Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited.
11393907|NCT02076581||Neurologically normal|Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited.
11393908|NCT02076568|Experimental|Education - Diabetes and Partnership|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Partnership"
11393909|NCT02076568|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
11393910|NCT02076555|Experimental|Education - Diabetes and Social Issues|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Social Issues"
11393911|NCT02076555|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
11393912|NCT02076542|Experimental|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
11393913|NCT02076542|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
11393914|NCT02076529|Experimental|Ramosetron 0.6mg|Ramosetron 0.6mg intravenous injection 30min before chemotherapy
11393915|NCT02076529|Experimental|Ramosetron 0.45mg|Ramosetron 0.45mg intravenous injection 30min before chemotherapy
11393916|NCT02076529|Active Comparator|Ramosetron 0.3mg|Ramosetron 0.3mg intravenous injection 30 min before chemotherapy
11393917|NCT02076516|Experimental|Drug-eluting stent: CORACTO®|Single arrm
11393918|NCT02076503|Experimental|PET-MR 18F-FACBC|
11393919|NCT02076490|Experimental|Software Supported Mirror Therapy|First experimental condition Physical/Occupational Therapy
11393920|NCT02076490|Experimental|Traditional mirror therapy|Second experimental condition Physical/Occupational Therapy
11393921|NCT02076490|Active Comparator|Sensomotor exercises without mirror|Control condition Physical/Occupational Therapy
11393922|NCT02076477|Experimental|Arm A|"Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.
~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
11393923|NCT02076477|Active Comparator|Arm B|"Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.
~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
11393924|NCT02076464|Experimental|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
11393925|NCT02076464|No Intervention|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
11393926|NCT02076451|Experimental|2 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
11393927|NCT02076451|Experimental|8 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
11393928|NCT02076451|Experimental|16 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
11393929|NCT02076451|Experimental|24 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
11393930|NCT02076438|Placebo Comparator|Placebo|Placebo capsules
11393931|NCT02076438|Experimental|Probiotics|Lactobacillus Rhamnosus GG 10 billion cfu BID
11393932|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
11393933|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
11393934|NCT02076412|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
11393935|NCT02076412|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
11393936|NCT02076399|Experimental|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
11393937|NCT02076399|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
11393938|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
11393939|NCT02076373|Experimental|recombinant human Erythropoietin (Epo)|"Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.
~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
11393940|NCT02076373|Placebo Comparator|Control|"Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.
~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
11393941|NCT02076360|Experimental|Preop Video|This arm will watch an instructional video in addition to their normal preoperative visit with the physician.
11393942|NCT02076360|No Intervention|No video|This arm will receive only the normal preoperative visit with the physician without the additional video
11393943|NCT02076347|Experimental|Office visit-based intervention|
11393944|NCT02076347|Experimental|Electronic message-based intervention|
11394108|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
11393946|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
11393947|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
11393948|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
11393949|NCT02076321|Other|Acetaminophen|control group
11393950|NCT02076321|Other|NSAID (Ibuprofen)|Study group
11393951|NCT02076308|Experimental|Electroacupuncture|Electroacupuncture and physical therapy
11393952|NCT02076308|Sham Comparator|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
11393953|NCT02076295||Parkinson's disease subjects|
11393954|NCT02076295||Normal control subjects|
11393955|NCT02076282||Healthy volunteers 1 MRI scan|"Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology.
~Healthy volunteers will receive 1 MRI scan without contrast agent."
11393956|NCT02076282||Patients with stage III NSCLC, 1 MRI scan|"Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available
~Patients will receive 1 MRI scan with contrast agent."
11393957|NCT02076269|Other|Arm 1|Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
11393958|NCT02076256|No Intervention|Control Group|
11393959|NCT02076256|Experimental|The helping relationships intervention program|The helping relationships intervention program will be implemented on the experimental group. And the control group will be provided with routine nursing care. Data will be collected at baseline, the sixth and the ninth month of the third year of study. Data will be analyzed using generalized estimating equation measures to evaluate the effect of the intervention program.
11393960|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
11393961|NCT02076230|Experimental|[14C] TH-302 (Label 1)|
11393962|NCT02076230|Experimental|[14C] TH-302 (Label 2)|
11393963|NCT02076217||unprotected intercourse 6-14 days prior to contraception|Women who initiate highly effective reversible contraception within 6-14 days of unprotected intercourse.
11393964|NCT02076204|Experimental|Home visiting|Home visiting group: Women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group. Home visiting for low-income, pregnant women - whereby individualized in-home services (including direct education, assessments, and referrals to community resources) are provided to families - has been identified by the Strong Start initiative as one promising method for reaching women who are vulnerable to poor birth outcomes.
11393965|NCT02076204|No Intervention|Non-Home Visiting|Control group: As described above, women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group.The home visiting program will provide control group families with referrals to other appropriate services in the community.
11393966|NCT02076191|Experimental|Myeloproliferative neoplasms|In phase I, increasing doses of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days. An initial dose of ruxolitinib of 10 mg orally twice daily is anticipated with planned, dose escalations of 15 mg orally twice daily, 25 mg orally twice daily and 50 mg orally twice daily. The dose can also be de-escalated to 5mg orally twice daily if dose limiting toxicities (DLTs) are observed at the initial 10mg dose. Patients will receive ruxolitinib as a single agent for the first 7 days followed by the administration of decitabine on day 8 for a total of 5 consecutive days. Patients will continue ruxolitinib at the assigned dose through the first cycle and may reduce the dose for specified toxicity beginning with the second cycle. Patients in Phase II will start at the recommended phase II dose (RPTD) of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days.
11393967|NCT02076178|Experimental|Arm 1|Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
11393968|NCT02076178|Experimental|Arm 2|Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
11393969|NCT02076165|Experimental|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
11393970|NCT02076165|Active Comparator|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
11393971|NCT02076152|Experimental|FMISO PET & MRI Group 1|"Bevacizumab:
~-- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).
~FMISO PET Scan
~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.
~The PET scan will be approximately 60-75 minutes.
~MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
11393972|NCT02076152|Experimental|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:
~Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).
~CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).
~-FMISO PET Scan
~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.
~The PET scan will be approximately 60-75 minutes.
~- MRI
~Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
11393973|NCT02076139|Experimental|Nyaditum resae® 10e4|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
11393974|NCT02076139|Experimental|Nyaditum resae® 10e5|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
11393975|NCT02076139|Placebo Comparator|Placebo|The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
11393976|NCT02076126||Gastric aspirate|L/S ratio on the gastric aspirates are retrospectively compared with the possible development of RDS
11393977|NCT02076126||Hypopharyngeal secretion|L/S ratio on the hypopharyngeal secretions are retrospectively compared with the possible development of RDS
11393978|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
11393979|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
11393980|NCT02076100|Experimental|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
11393981|NCT02076100|Experimental|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
11393982|NCT02076100|Experimental|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
11393983|NCT02076087||Normal Weight (BMI: 18.5-24.9 kg/m²)|Liposuction/lipectomy
11393984|NCT02076087||Overweight (BMI: 25.0-29.9 kg/m²)|Liposuction/lipectomy
11393985|NCT02076087||Obese (BMI: >30.0kg/m²)|Liposuction/lipectomy
11393986|NCT02076074|Experimental|Treatment (HG-PBI)|Patients undergo single fraction high gradient-partial breast irradiation within 8 weeks after partial mastectomy.
11393987|NCT02076061||GOLD stage I|
11393988|NCT02076061||GOLD Stage II|
11393989|NCT02076061||GOLD Stage III|
11393990|NCT02076061||GOLD Stage IV|
11393991|NCT02076061||Smokers/ex-smokers w/o COPD|
11393992|NCT02076061||non-Smokers w/o COPD|
11393993|NCT02076048||Previous LCPUFA Supplementation|Children between the ages of 7 and 10 that were previously enrolled in a study of supplemented LCPUFA formula.
11393994|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
11393995|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.
~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
11393996|NCT02076009|Experimental|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
11393997|NCT02076009|Active Comparator|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
11393998|NCT02075996||Pomalidomide following lenalidomide|75 patients with pomalidomide directly following lenalidomide treatment
11393999|NCT02075996||Pomalidomide following other therapy|75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
11394000|NCT02075983|Experimental|Group 3 (IM+EP)|Group 3 will receive 12.0mg of vaccine over 12 weeks administered with EP using the Trigid Ichor device. We expect to see the greatest proportion of individuals making T cell and antigen specific antibody responses responses in this group. Depending on the magnitude of the effects, the differences between group 3 and the other groups may be statistically significant.
11394001|NCT02075983|Experimental|Group 2 (IM+TC)|Group 2 will also receive 13.2mg of vaccine over 12 weeks, with 12.0mg given IM and 1.2mg TC. We are interested in the impact of TC relative to ID vaccination on the ratio between HIV-specific T-cell responses, and whether or not CD8+ Tcells are favoured by this route.
11394002|NCT02075983|Active Comparator|Group 1 (IM+ID)|"Group 1 will serve as the reference arm and this group will receive a total dose of 13.2mg vaccine over 12 weeks with 12.0mg given IM and 1.2mg ID. This is 7.2mg more than has been given previously to healthy individuals and 6.2 mg more than given to those HIV-infected but similar doses of HIV DNA vaccines have been given in other trials with no serious consequences."
11394003|NCT02075970|Experimental|Epoetin Alpha study 1|"Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.
~Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder."
11394004|NCT02075970|Placebo Comparator|Epoetin Alpha study 2|"Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.
~Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.
~Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders."
11394036|NCT02075723|Experimental|Overfeeding + sleep restriction|overfeeding condition (130 % of energy requirements ) + 6 days of sleep restriction (4 hours per night)
11394005|NCT02075970|Experimental|Biotinylated red blood cells|Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
11394006|NCT02075944|Experimental|High intensity aerobic exercise|30 minutes of high intensity aerobic exercise 3 times a weeks for 9 weeks - incorporation interval training
11394007|NCT02075944|Experimental|Low intensity aerobic exercise|30 minutes of low intensity aerobic exercise 3 times a weeks for 9 weeks
11394008|NCT02075944|No Intervention|Control|No intervention. Participants are told not to make any changes in their everyday life
11394009|NCT02075931|Experimental|Physical Activity Feedback|The physical activity feedback intervention will involve real-time physical activity monitoring using a device to provide activity feedback directly to patients in combination with patient group meetings held monthly during the 12 week intervention for the purposes of mutual support in attaining physical activity goals.
11394010|NCT02075931|Active Comparator|Control|The control represents the current standard of care post total knee arthroplasty.
11394011|NCT02075905||Barrett's Esophagus-Low Grade Dysplasia|Subjects enrolled who have Barrett's Esophagus with low grade dysplasia. No research intervention is administered.
11394012|NCT02075905||Barrett's Esophagus-no dysplasia|Subjects enrolled with Barrett's Esophagus and no dysplasia. No research intervention is administered.
11394013|NCT02075892|Active Comparator|Mushroom Blend|4 grams daily; oral; 7 and 21 days
11394014|NCT02075892|Placebo Comparator|Placebo|4 grams maltodextrin, oral, 7 and 21 days
11394015|NCT02075879|Experimental|Nurse-led interviewing|Participants in experimental arm received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. They were additionally instructed to start walking or brisk walking at low duration and gradually progress to a maximum of 30 minutes daily per week. To facilitate exercise progression, the nurse case managers discussed exercise benefits, explored exercise barriers and developed mutual goals with patients. The nurse motivated them and checked the exercise behaviors to ensure adherence to the recommended exercise regime. The nurse case managers interviewed the patients weekly for six weeks and biweekly for another six weeks.
11394016|NCT02075879|Active Comparator|Brief group exercise|Participants received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. The in-center training was conducted by the researcher with a group of four-to six participants focusing on flexibility and strengthening exercise only.
11394017|NCT02075853||Bovine Xenograft|Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
11394018|NCT02075853||Iliac Crest Allograft|Patients in this group received an iliac crest cadaver allograft (bicortical or tricortical) in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so all future patients will receive the allograft during the procedure.
11394019|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
11394020|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
11394021|NCT02075827|Active Comparator|Problem-solving video game|Playing the video game 'Little Big Planet'
11394022|NCT02075827|Experimental|Competitive video game|Playing the video game 'Call of Duty'
11394023|NCT02075801||Defective amalgam restorations|"Treatment Groups:
~A. Sealing of amalgam margin defects: Defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Sealant, 3MESPE)was applied over the defective area. The sealant was polymerized with a photo curing unit (Curing-Light 2500, 3MESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
~B. Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr, Orange, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
~C. Control Group: The defective restorations did not receive any treatment."
11394024|NCT02075788|Placebo Comparator|Commercial white bread|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
11394025|NCT02075788|Experimental|Millet based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
11394026|NCT02075788|Active Comparator|Corn based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
11394027|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
11394028|NCT02075762|Active Comparator|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
11394029|NCT02075762|Active Comparator|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
11394030|NCT02075762|Active Comparator|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
11394031|NCT02075749|Active Comparator|triamcinolone acetonide mucoadhesive|30 patients received triamcinolone acetonide mucoadhesive films
11394032|NCT02075749|Experimental|Licorice|30 patients received licorice mucoadhesive films
11394033|NCT02075749|Placebo Comparator|Mucoadhesive film|30 patients received mucoadhesive films without any drug ingredients
11394034|NCT02075736|Experimental|KTP laser|device
11394035|NCT02075736|Active Comparator|TUR-P|device
11394105|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
11394037|NCT02075723|Experimental|Overfeeding + normal sleep duration|overfeeding condition (130 % of energy requirements ) + 6 days of normal sleep duration (8 hours per night)
11394038|NCT02075710|Experimental|High sugar/meal feed|Diet high in simple sugar fed as two large meals daily
11394039|NCT02075710|Experimental|High sugar/nibble|Diet high in simple sugar fed as 8 small meals daily
11394040|NCT02075710|Experimental|High fat/meal feed|Diet high in fat fed as two large meals daily
11394041|NCT02075710|Experimental|High fat/nibble|Diet high in fat fed as 8 small meals daily
11394042|NCT02075710|Experimental|High sugar/3 meals a day|Diet high in simple sugar fed as 3 meals a day
11394043|NCT02075710|Experimental|High fat/ 3 meals a day|Diet high in fat fed as 3 meals a day
11394044|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
11394045|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
11394046|NCT02075684|Other|In-office, Percutaneous Renal Biopsy|
11394047|NCT02075671|Experimental|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
11394048|NCT02075671|Sham Comparator|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
11394049|NCT02075671|Placebo Comparator|Vehicle Only|Entire face treated with vehicle substance only
11394050|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
11394051|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
11394052|NCT02075645|Other|team training|"Intervention: team training course. A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
11394053|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
11394054|NCT02075619|Experimental|Sequence 1|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 Fixed dose combination (FDC) formulation-1 tablet in Period 2 and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
11394055|NCT02075619|Experimental|Sequence 2|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2 and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
11394056|NCT02075619|Experimental|Sequence 3|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1, one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
11394057|NCT02075619|Experimental|Sequence 4|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
11394058|NCT02075619|Experimental|Sequence 5|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
11394059|NCT02075619|Experimental|Sequence 6|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one GSK3074477 FDC formulation-1 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
11394060|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
11394061|NCT02075593|Experimental|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
11394062|NCT02075580|Experimental|psychological support|Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion
11394063|NCT02075580|No Intervention|standard care|this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning
11394064|NCT02075567|Experimental|Therapy adaption T1DM|
11394065|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
11394066|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
11394067|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
11394068|NCT02075528|Experimental|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
11394069|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
11394070|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
11394106|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
11394071|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
11394072|NCT02075502|Experimental|Exercise therapy|Claudication, no peripheral revasc
11394073|NCT02075502|Placebo Comparator|Exercise advice|Claudication, no peripheral revasc
11394074|NCT02075502|Experimental|lower extremity ET, exercise therapy|
11394075|NCT02075502|Placebo Comparator|lower extremity ET, exercise advice|
11394076|NCT02075502|Experimental|Peripheral open intervention, exercise therapy|
11394077|NCT02075502|Placebo Comparator|Peripheral open intervention, exercise advice|
11394078|NCT02075489|Experimental|Acupressure|This group of patients will serve as the experimental group and receive acupressure treatment in addition to routine clinical care. Acupressure will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
11394079|NCT02075489|Active Comparator|Reiki|This group of participants will serve as control group and receive Reiki treatment in addition to routine clinical care. Reiki will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
11394080|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
11394081|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
11394082|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
11394083|NCT02075450|No Intervention|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
11394084|NCT02075450|Experimental|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
11394085|NCT02075450|Experimental|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
11394086|NCT02075450|Experimental|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
11394087|NCT02075437|Experimental|Functional Abdominal Pain (FAP)|To access (FAP) subjects will participate in: 10 therapy sessions; and the following treatments: 1) identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis: 2) adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children; and 3) incorporate caregivers as role models and facilitators based on attachment research.
11394088|NCT02075424|Experimental|salivery sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.
~Only one sampling will occur to doctors who are assigned to a single workstation.
~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call For each participant, a serie of control-samples will be taken during a day off and during a security break."
11394089|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
11394090|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
11394091|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
11394092|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
11394093|NCT02075385|Experimental|Speech pathology therapy|Pre, during and pos-treatment swallowing exercises.
11394094|NCT02075385|No Intervention|Control group|These patients will not receive speech pathology therapy.
11394095|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
11394096|NCT02075359||Preschoolers|Preschoolers, ages 3 to 5
11394097|NCT02075333|Active Comparator|Sucrose (50g)|A 381g blackcurrant drink (cordial and water) providing 50g of sucrose
11394098|NCT02075333|Placebo Comparator|Sucralose (0.92 g sugars)|A 381g blackcurrant drink (cordial and water) providing 0.92g of natural sugars
11394099|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
11394100|NCT02075307|Experimental|Blueberry Powder|The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
11394101|NCT02075307|Placebo Comparator|Placebo Powder|The placebo group will receive placebo powder in the same amounts for the same duration.
11394102|NCT02075294||youth|"<45years
~Adefovir dipivoxil or Entecavir
~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.
~Participants who received 0.5mg ETV more than 3 years will be recruited."
11394103|NCT02075294||middle age|"≥45years and<65years
~Adefovir dipivoxil or Entecavir
~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.
~Participants who received 0.5mg ETV more than 3 years will be recruited."
11394104|NCT02075294||elderly|"≥65 years
~Adefovir dipivoxil or Entecavir
~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.
~Participants who received 0.5mg ETV more than 3 years will be recruited."
11394109|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
11394110|NCT02075268|Other|10 mg, 30 mg|To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.
11394111|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
11394112|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
11394113|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
11394114|NCT02075242|Active Comparator|tacrolimus|Control group: Tacrolimus + Corticosteroid (dual oral therapy)
11394115|NCT02075242|Experimental|Mycophenolate Mofetil|Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)
11394116|NCT02075229||Group A|45 participants with AzBio baseline sentence scores between 41 - 50%
11394117|NCT02075229||Group B|45 participants with AzBio baseline sentence scores between 51 - 60%.
11394118|NCT02075216|Experimental|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection
~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.
~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
11394119|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
11394120|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
11394121|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
11394122|NCT02075190|Experimental|Treatment Group|Participants randomized to receive remediation training intervention delivered online (60 days of online training)
11394123|NCT02075190|Active Comparator|Control Group|Participants randomized to receive online gaming intervention (60 days of online play)
11394124|NCT02075164|Experimental|Fructose|Volunteers will be challenged with oral 150g Fructose per day for 56 days.
11394125|NCT02075164|Experimental|Glucose|Volunteers will be challenged with oral 167g Fructose per day for 56 days.
11394126|NCT02075164|No Intervention|NAFLD|Patients with confirmed simple fatty liver will be compared at baseline with other arms.
11394127|NCT02075164|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
11394128|NCT02075151|Other|Bronchial Thermoplasty|Bronchial thermoplasty
11394129|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
11394130|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
11394131|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
11394132|NCT02075112|Experimental|Soy isoflavone|Study treatment: Soy isoflavone in combination with radiation therapy & cisplatin
11394133|NCT02075099|Experimental|Isotonic drink|"Predonation hydratation with 500 ml of isotonic drink, to drinking in immediate predonation.
~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
11394134|NCT02075099|Experimental|mineral water|"Predonation hydratation with 500 ml of mineral water to drinking in immediate predonation whole blood.
~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
11394135|NCT02075099|Active Comparator|Advices|"Advices of drinking water or fruit juice glass(es) in immediate predonation whole blood.
~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
11394136|NCT02075086|Experimental|Chemotherapy treatment|Chemotherapy treatment with Xelox or Xeliri and bevacizumab
11394137|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
11394138|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
11394139|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
11394140|NCT02075060|Experimental|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
11394141|NCT02075060|Active Comparator|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
11394142|NCT02075047|Placebo Comparator|1|
11394143|NCT02075047|Experimental|ziprasidone|
11394144|NCT02075034|Experimental|560 mg morning/280 mg afternoon|Two 280 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule of rigosertib will be taken in the afternoon.
11394145|NCT02075034|Experimental|420 mg morning and afternon|One 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the afternoon.
11394146|NCT02075034|Experimental|280 mg TID|One 280 mg capsule of rigosertib will be taken in the morning, one 280 mg capsule of rigosertib will be taken at mid-day, and one 280 mg capsule of rigosertib will be taken in the afternoon.
11394147|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
11394148|NCT02075008|Experimental|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
11394149|NCT02074995|Experimental|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
11394150|NCT02074995|Experimental|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
11394151|NCT02074995|Placebo Comparator|Placebo Group 1B/1C, 2, 3, 4|
11394244|NCT02074319|Experimental|Methotrexate|Methotrexate 10 mg once a week orally
11395769|NCT02064465|Experimental|Lamotrigine Compressed|lamotrigine compressed tablet 100mg
11394152|NCT02074982|Experimental|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
11394153|NCT02074982|Active Comparator|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
11394154|NCT02074969|Active Comparator|Gamma Nail 3|Gamma Nail 3 Stryker.
11394155|NCT02074969|Active Comparator|PFNA|PFNA Antirotation Synthes
11394156|NCT02074956|Experimental|Cohort 1 AERAS-404|"H4 Antigen at 5 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
11394157|NCT02074956|Experimental|Cohort 2 AERAS-404|"H4 Antigen at 15 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
11394158|NCT02074956|Experimental|Cohort 3 AERAS-404|"H4 Antigen at 50 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
11394159|NCT02074956|Experimental|Cohort 4 AERAS-404|"H4 Antigen at 150 ug IC31 Adjuvant 500 nmol
~2 doses at Study days 0 and 56"
11394160|NCT02074956|Experimental|Cohort 5 AERAS-404|"H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer
~2 doses at Study days 0 and 56"
11394161|NCT02074943|Experimental|PRP/Saline|Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
11394162|NCT02074930|Other|Single Arm|
11394163|NCT02074917|Experimental|AM anatomical ACL reconstruction|Femoral and tibial tunnels performed in anteromedial footprint of ACL reconstruction
11394164|NCT02074917|Experimental|CENTRAL anatomical ACL reconstruction|Femoral and tibial tunnels performed in the center of ACL footprint
11394165|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
11394166|NCT02074904|Placebo Comparator|Placebo|placebo
11394167|NCT02074891||Persons prescribed PrEP|adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
11394168|NCT02074878|Experimental|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200mg, twice daily and Sunitinib 25.0mg once daily
11394169|NCT02074878|Experimental|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
11394170|NCT02074878|Experimental|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
11394171|NCT02074865||newborns|
11394172|NCT02074852||Immediate catheter removal|The catheter was removed immediately after the CS
11394173|NCT02074852||Delayed catheter removal|The catheter was removed 12 hours postoperatively
11394174|NCT02074839|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
11394175|NCT02074826||Atrial fibrillation|"Genotyping of the AF associated variants
~Measurement of the amount of left atrial fibrosis"
11394176|NCT02074813|No Intervention|Standard|conventional pulmonary rehabilitation
11394177|NCT02074813|Experimental|Inspiratory muscle training|Inspiratory muscle training associated with a conventional pulmonary rehabilitation
11394178|NCT02074800|Experimental|Part 1|Participants will receive either 1.4 or 2.8 mg/kg of either Sp2/0-derived CNTO 328 or CHO-derived CNTO 328 or placebo.
11394179|NCT02074800|Experimental|Part 2|Participants will receive 1.4 mg/kg of either Sp2/0-derived or CHO-derived CNTO 328.
11394180|NCT02074787||Adult burn injuries|Adult patients with burns injuries attending the regional burns unit at Chelsea & Westminster hospital between 48 and 72 hours post burn will be invited to take part in the study at the time of presentation to the unit.
11394181|NCT02074774|Experimental|IntellO2|Automated control of FiO2
11394182|NCT02074774|Active Comparator|Manual|Manual control of FiO2
11394183|NCT02074761||SImmetry Implant|Subjects who are indicated for the SImmetry device and meet the inclusion/exclusion criteria will receive a SImmetry implant.
11394184|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
11394185|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
11394186|NCT02074735|Placebo Comparator|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
11394187|NCT02074735|Active Comparator|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
11394188|NCT02074722||Healthy Subjects|Healthy Subjects
11394189|NCT02074709|Active Comparator|TAP block|TAP block with plain bupivacaine
11394190|NCT02074709|Active Comparator|Wound infiltration|Wound infiltration with liposomal bupivacaine
11394191|NCT02074683|Active Comparator|YEAR A PATHWAY|"Operative Procedure will occur after screening visit.
~Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
~Follow-up visits:
~Post op Visit 1 (2 weeks +/- 5 days)
~Post op study visit 2 (1 month)
~Post op study visit 3 (2 month)
~Post op study visit 4 (6 month)
~Post op study visit 5 (12 month) CROSSOVER to YEAR B PathWay
~Post op study visit 6 (18 months)
~Post op study visit 7 (24 months)"
11394192|NCT02074683|Active Comparator|Year B Pathway|"Observational visits at 6 and 12 months with fat grafting procedures during year 2.
~Study visit 1 (month 6)
~Study Visit 2 (month 12)
~Collection of subject's medication profile, vital signs (Temp, HR, Resp, BP), and weight to calculate BMI,
~Limited physical exam with a foot exam completed by the PI and /or the Coinvestigator
~Adverse Event Reporting
~Ultrasound
~Pedobarograph
~2D Photographs
~Foot Pain Assessment Questionnaire
~Medical chart review including review of records from SOC podiatrists
~Operative Visit Followed by Post op study visits 2-5 as described in Year A Pathway"
11394193|NCT02074670|Experimental|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
11394194|NCT02074657|Experimental|Activated natural killer cells|
11394195|NCT02074644|Experimental|Prostatic Arterial Embolization|Selective catheterization of the prostatic arteries followed by slow injection of Bead Block 300-500 or PVA 100+200 micra particles under fluoroscopic control.
11394196|NCT02074644|Sham Comparator|Sham procedure|Selective catheterization of the prostatic arteries followed by removal of the catheter with no particles injected.
11394197|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
11394198|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
11394199|NCT02074618|Experimental|Physical Exercise|The program of physical exercise was a resistance and aerobic training, initiated at low intensity and with a slow progressing according to the patient's tolerance. In aerobic exercise, for greater effectiveness of the training, the literature recommends moderate intensity, which corresponds with 50 to 70% of the maximum heart rate. Patients were instructed to keep the most constant as possible the speed during exercise on treadmill or cycle ergometer. For muscle strengthening exercises, the number of repetitions varied from 1 to 4 sets of 10 to 15 repetitions.
11394200|NCT02074605||Observation|Patients with melanoma who qualify for interferon treatment, but choose not to receive it.
11394201|NCT02074605||Interferon alpha|Patients who receive high dose interferon alpha for 4 weeks
11394202|NCT02074592|Experimental|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
11394203|NCT02074592|Active Comparator|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
11394204|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
11394205|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
11394206|NCT02074566|Other|2 times 1|PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute
11394207|NCT02074566|Other|2 times 2|PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes
11394208|NCT02074566|Other|2 times 3|PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes
11394209|NCT02074553|Experimental|Part 1 (Fasted): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation (four 150 mg capsules) orally in Part 1 of the study according to following treatment sequences. Treatment A (Reference Treatment: formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (Test Treatment: formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (Test Treatment: formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (Test Treatment: formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394210|NCT02074553|Experimental|Part 1 (Fasted): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394211|NCT02074553|Experimental|Part 1 (Fasted): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394212|NCT02074553|Experimental|Part 1 (Fasted): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394213|NCT02074553|Experimental|Part 2 (Fed): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment A (formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394245|NCT02074306|Experimental|UROSHIELD®|Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
11394246|NCT02074306|Sham Comparator|SHAM UROSHIELD®|same as abouve but with Sham device.
11394338|NCT02074059|Experimental|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
11394214|NCT02074553|Experimental|Part 2 (Fed): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394215|NCT02074553|Experimental|Part 2 (Fed): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394216|NCT02074553|Experimental|Part 2 (Fed): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
11394217|NCT02074540||Diabetes Type II Patients|
11394218|NCT02074514|Experimental|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
11394219|NCT02074514|Experimental|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
11394220|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making."
11394221|NCT02074488|Experimental|Fall Prevention Exercises|Participant provided with Balancing Act exercise curriculum for completion at least fifteen minutes three times a week over a six month period.
11394222|NCT02074488|Other|Informational brochure|Participant receives an informational brochure and orientation to brochure contents.
11394223|NCT02074475||Control group|The control group of three sites for larger Adequacy of Anaesthesia study. Total 150 patients
11394224|NCT02074436|Experimental|Prophylactic EACA|Prophylactic EACA 1000 mg PO twice daily if platelets < 20 x 10⁹/L
11394225|NCT02074436|Active Comparator|Platelet transfusion|Platelet transfusion if platelet count is < 20 x 10⁹/L in the outpatient or < 10 x 10⁹/L in the inpatient setting
11394226|NCT02074423|Experimental|MealShape cinnamon extract|Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)
11394227|NCT02074423|Placebo Comparator|Placebo|Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)
11394228|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
11394229|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
11394230|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
11394231|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
11394232|NCT02074397|Experimental|Distant extrafascial injection|Injection away from the brachial plexus with the needle tip positioned in the middle scalene muscle
11394233|NCT02074397|Active Comparator|Subfascial injection|Injection within the brachial plexus, with the needle tip positioned between C5 and C6
11394234|NCT02074384|Other|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
11394235|NCT02074384|Other|Self Monitoring Blood Glucose|Participants will self test for two weeks.
11394236|NCT02074384|Other|Clinicians|Clinicians completing study visits.
11394237|NCT02074358|Experimental|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
11394238|NCT02074358|Experimental|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
11394239|NCT02074358|Experimental|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
11394240|NCT02074345|Experimental|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
11394241|NCT02074332|Experimental|Intervention|Physical activity guidance Health education
11394242|NCT02074332|No Intervention|Control|Receive no intervention
11394243|NCT02074319|Placebo Comparator|Placebo|Matching placebo for methotrexate
11394247|NCT02074293|Experimental|Splenius|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394248|NCT02074293|Experimental|Scalene|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394249|NCT02074293|Experimental|Sterno-cleido-mastoid|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394250|NCT02074293|Experimental|Levator Scapulae|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394251|NCT02074293|Experimental|Semispinalis|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394252|NCT02074293|Experimental|Trapezius|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394253|NCT02074293|Experimental|Longissimus|"Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394254|NCT02074293|Experimental|Change from Baseline in Pain Frequency|Change from Baseline in Pain Frequency as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
11394255|NCT02074293|Experimental|Change from Baseline in Pain Intensity|Change from Baseline in Pain Intensity as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The severity on scales of 0(no pain) to 4(constant or extremely severe intensity).
11394256|NCT02074293|Experimental|Change from Baseline in CDSS|Change from Baseline in CDSS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The CDSS or Cervical Dystonia Severity Scale quantifies the severity of abnormal head positioning and was newly devised for this study. CDSS allots 1 point for each 5 degrees (or part thereof) of head deviation in each of the three planes of head movement (range of scores up to theoretical maximum of 54).
11394257|NCT02074293|Experimental|Percent of Patients with Improved PGAS|Percent of Patients with Improved PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
11394258|NCT02074293|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394259|NCT02074293|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394260|NCT02074293|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394261|NCT02074293|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394262|NCT02074293|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394263|NCT02074293|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394264|NCT02074293|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394265|NCT02074293|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394266|NCT02074293|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394267|NCT02074293|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394268|NCT02074293|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394269|NCT02074280|Experimental|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
11394270|NCT02074280|Experimental|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
11394271|NCT02074280|No Intervention|control|conventional treatment
11394272|NCT02074267|Experimental|Carbatin|Carbatin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
11394273|NCT02074267|Active Comparator|Neurontin|Neurontin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
11394274|NCT02074241||Positive Expression|Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.
11394337|NCT02074059|Experimental|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
11394275|NCT02074241||Negative Expression|Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.
11394276|NCT02074228|Experimental|Methylphenidate|Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks
11394277|NCT02074215|Experimental|Aerobic exercises|90-minute exercise sessions per week for 12 weeks
11394278|NCT02074215|Active Comparator|Stretch exercise|90-minute exercise sessions per week for 12 weeks
11394279|NCT02074202|Experimental|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
11394280|NCT02074202|Active Comparator|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
11394281|NCT02074189|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
11394282|NCT02074189|No Intervention|Control|No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
11394283|NCT02074163|Experimental|Glabella|"Glabella
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394284|NCT02074163|Experimental|Frontal|"Frontal
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394285|NCT02074163|Experimental|Temporal|"Temporal
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394286|NCT02074163|Experimental|Occipital|"Occipital
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394287|NCT02074163|Experimental|Paraspinal|"Paraspinal
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394288|NCT02074163|Experimental|Trapezius|"Trapezius
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394289|NCT02074163|Experimental|Change in frequency of headache days|Change in frequency of headache days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
11394290|NCT02074163|Experimental|Change in hrs of HA on HA days|Change in hrs of HA on HA days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
11394291|NCT02074163|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394292|NCT02074163|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394293|NCT02074163|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394294|NCT02074163|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394295|NCT02074163|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394296|NCT02074163|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394297|NCT02074163|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394298|NCT02074163|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394299|NCT02074163|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394300|NCT02074163|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394301|NCT02074163|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394302|NCT02074150|Experimental|Biceps Brachii|"Biceps Brachii (elbow flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394303|NCT02074150|Experimental|Flexor Carpi Radialis|"Flexor Carpi Radialis (wrist flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394304|NCT02074150|Experimental|Flexor carpi ulnaris|"Flexor carpi ulnaris (wrist flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394305|NCT02074150|Experimental|Flexor digitorum profundus|"Flexor digitorum profundus (finger flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394306|NCT02074150|Experimental|Flexor digitorum sublimis|"Flexor digitorum sublimis (finger flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394307|NCT02074150|Experimental|Adductor pollicis|"Adductor pollicis (thumb flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394308|NCT02074150|Experimental|Flexor pollicis longus|"Flexor pollicis longus (thumb flexors)
~Gadolinium Magnevist® (gadopentetate dimeglumine)
~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
11394309|NCT02074150|Experimental|Change from Baseline in Elbow Ashworth|"Change from Baseline in Elbow Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
11394310|NCT02074150|Experimental|Change from Baseline in Wrist Ashworth|"Change from Baseline in Wrist Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
11394311|NCT02074150|Experimental|Change from Baseline in Finger Ashworth|"Change from Baseline in Finger Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
11394312|NCT02074150|Experimental|Change from Baseline in Thumb Ashworth|"Change from Baseline in Thumb Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):
~0 = No increase in muscle tone (none)
~= Slight increase
~= Moderate increase
~= Considerable increase
~= Limb rigid (very severe)."
11394313|NCT02074150|Experimental|Change from Baseline in PGAS|Change from Baseline in PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
11394314|NCT02074150|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30
11394315|NCT02074150|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394316|NCT02074150|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394317|NCT02074150|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394318|NCT02074150|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394319|NCT02074150|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394320|NCT02074150|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394321|NCT02074150|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394322|NCT02074150|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394323|NCT02074150|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394324|NCT02074150|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
11394325|NCT02074137|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
11394326|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
11394327|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
11394328|NCT02074111||Intracranial atherosclerotic stroke|
11394329|NCT02074111||Moyamoya disease|
11394330|NCT02074111||Healthy controls|
11394331|NCT02074098|Experimental|a 65 cm bed height|1) Bed height : approximately 65cm (Lowest)
11394332|NCT02074098|Experimental|a 95cm bed height|2) Bed height : approximately 95cm (highest)
11394333|NCT02074072|Experimental|Direct laryngoscope|Macintosh laryngoscope
11394334|NCT02074072|Experimental|Videolaryngoscope-1|Glidescope
11394335|NCT02074072|Experimental|Videolaryngoscope-2|Airwayscope
11394336|NCT02074059|Experimental|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
11394339|NCT02074059|Experimental|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
11394340|NCT02074059|Experimental|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
11394341|NCT02074059|Active Comparator|nCPAP alone|nCPAP therapy alone
11394342|NCT02074046|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11394343|NCT02074046|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11394344|NCT02074046|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11394345|NCT02074046|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
11394346|NCT02074033||antibiotics for pneumonia|We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )
11394347|NCT02074020|Experimental|Blisibimod|
11394348|NCT02074020|Placebo Comparator|Placebo|
11394349|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops
~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
11394350|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops
~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
11394351|NCT02073994|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
11394352|NCT02073981||Parkinson Disease|
11394353|NCT02073968|Experimental|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.
~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.
~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC > 1500, and platelet count > 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
11394354|NCT02073955||Pakistani adults|"Men and women aged 40 and above, residing in Ibrahim Hyderi (periurban Pakistani community)
~Consenting to Interview about stroke symptoms"
11394355|NCT02073929|Active Comparator|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
11394356|NCT02073929|Placebo Comparator|Placebo|Placebo s.c. daily for 26 weeks
11394357|NCT02073916|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 with Laptinib followed by Abraxane
11394358|NCT02073903||LEP inpatients and their providers|This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
11394359|NCT02073890||traumatic subarachnoid haemorrhage|
11394360|NCT02073877||Controls - Holgers 0 & 1|
11394361|NCT02073877||Cases - Holgers >1 (active peri-implant dermatitis)|
11394362|NCT02073851|Experimental|TriGuard™HDH|Patients undergoing TAVR will be treated wIth experimental device TriGuard™HDH
11394363|NCT02073838|Experimental|Ribavirin, vismodegib, decitabine|Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
11394364|NCT02073838|Experimental|Ribavirin, vismodegib|Ribavirin 1400mg BID, vismodegib 150mg QD
11394365|NCT02073825|Experimental|Web Brief Intervention (WBI)|4-session WBI
11394366|NCT02073825|No Intervention|Delayed-WBI|4-session WBI after follow-up
11394367|NCT02073812|Experimental|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
11394368|NCT02073799||Photoselective vaporization of the prostate|Patients who underwent photoselective vaporization of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
11394369|NCT02073799||Holmium laser enucleation of the prostate|Patients who underwent holmium laser enucleation of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
11394370|NCT02073786|Active Comparator|Lightwand|Conventional lightwand intubation will performe for intubation
11394371|NCT02073786|Experimental|Optiscope|Rigid video stylet, manufactural named Optiscope, will perform for intubation
11394372|NCT02073773|Experimental|Virtual Reality based therapy, levodopa|"The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
11394373|NCT02073773|Active Comparator|occupational therapy, levodopa|"The control group will receive and additional half an hour per working day of standard occupational therapy.
~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
11394374|NCT02073760||Infection Prevention Experts|Adult caregivers of cardiac surgery patients (e.g. surgeons, nurses, infection preventionists) and administrators
11394375|NCT02073747|Placebo Comparator|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
11394376|NCT02073747|Active Comparator|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
11394377|NCT02073734|Experimental|Dexamethasone|Dexamethasone
11394378|NCT02073734|Placebo Comparator|Placebo|Sterile normal saline solution
11394379|NCT02073721|Experimental|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.
11394380|NCT02073721|Active Comparator|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor
11394381|NCT02073695|Other|Neutral Rotation Brace|Neutral Rotation Brace
11394382|NCT02073695|Other|Standard polysling (Current practice)|Standard polysling (Current practice)
11394383|NCT02073682|Experimental|Edoxaban group|After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
11394384|NCT02073682|Active Comparator|Dalteparin group|Participants receive Dalteparin treatment daily -solution for subcutaneous injection
11394385|NCT02073669|Other|Second generation immigrants from high TB incidence countries|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
11394386|NCT02073669|Other|Native Israelis|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
11394387|NCT02073656|Experimental|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
11394388|NCT02073656|Experimental|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
11394389|NCT02073630|Other|Healthy subjects|healthy subjects will receive either sham or active cerebellar stimulation
11394390|NCT02073630|Other|Dystonia|dystonic patients will receive either sham or active cerebellar stimulation
11394391|NCT02073617|Experimental|Real-time 3-dimensional DynaCT|Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
11394392|NCT02073604|Other|Healthy volunteers|Healthy volunteers
11394393|NCT02073604|Other|Congenital mirror movements|Patients presenting with congenital mirror movements
11394394|NCT02073591||Ceradan Regimen|Ceradan Cream and Ceradan Wash
11394395|NCT02073578|Other|Treatment|Peroral Endoscopic Myotomy (POEM)
11394396|NCT02073565|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
11394397|NCT02073565|Active Comparator|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
11394398|NCT02073552|Active Comparator|High volume|"Two 5 mg bisacodyl tablets It is a stimulant laxative with local action.
~Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate."
11394399|NCT02073552|Experimental|Low volume|"Two 5 mg bisacodyl tablets, taken in the same way as for the high volume group.
~Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid."
11394400|NCT02073539|Experimental|chest compression with 5cm feedback|We will feedback by one accelerometer (U-cpr). U-cpr is android based smartphone application.
11394401|NCT02073539|Experimental|chest compression with 6cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
11394402|NCT02073539|Experimental|chest compression with 7cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
11394403|NCT02073526||Anti-TNF|Inflammatory bowel patients age 18 and over treated with anti-TNF agents
11394404|NCT02073513|Experimental|kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied which controled the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.
~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
11394405|NCT02073513|Experimental|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
11394406|NCT02073513|No Intervention|Control Group (CG)|No application.
11394407|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
11394408|NCT02073487|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
11394409|NCT02073487|Active Comparator|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
11394410|NCT02073474||Sativex® users|UK: All patients and who are prescribed Sativex®. Germany and Sweden: Patients who are prescribed Sativex® from selected specialist neurology centres.
11394411|NCT02073461|Experimental|CD1579 2.5%|Benzoyl Peroxide 2.5%
11394412|NCT02073461|Experimental|CD1579 5%|Benzoyl Peroxide 5%
11394413|NCT02073461|Placebo Comparator|Vehicle|Vehicle
11394414|NCT02073448|Experimental|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
11394415|NCT02073448|Active Comparator|CD0271|Adapalene 01% Gel
11394416|NCT02073448|Active Comparator|CD1579|Benzoyl Peroxide 2.5% Gel
11394417|NCT02073435||Post-Implementation Group|Living Donor Liver Transplant patients with evidence based donor pain management solution.
11394418|NCT02073435||Pre-Implementation Group|Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
11394419|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
11394420|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
11394421|NCT02073396||Patients|Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.
11394422|NCT02073383|Experimental|Around Artery|"Intervention Name: Axillary brachial plexus block
~Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 ."
11394423|NCT02073383|Experimental|Two injections|Group 2: 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position .
11394424|NCT02073383|Active Comparator|Perineural|Group Perineural : 10 ml of bupivacaine 0.375 % will be injected around the median, ulnar and radial nerves .
11394425|NCT02073370||health subjects; outpatients aged over 65|The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
11394426|NCT02073357|Experimental|Light general anaesthesia (BIS = 50)|Light general anaesthesia
11394427|NCT02073357|Experimental|deep general anaesthesia (BIS = 35)|deep general anaesthesia
11394428|NCT02073344|Experimental|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
11394429|NCT02073344|Experimental|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
11394430|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
11394431|NCT02073318|Experimental|Balance training|
11394432|NCT02073318|Active Comparator|Control|Control group received 4 weeks upper extremities exercise in sitting position
11394433|NCT02073305||No sleep apnea|Subjects with no or light sleep apnea (AHI < 15/h)
11394434|NCT02073305||Sleep Apnea - untreated|"Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.
~Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol."
11394435|NCT02073305||Sleep Apnea - treated|Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.
11394436|NCT02073292|Experimental|c-RFA|cooled radiofrequency ablation
11394437|NCT02073292|Active Comparator|t-RFA|thermal radiofrequency ablation
11394438|NCT02073279|Experimental|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
11394439|NCT02073279|Placebo Comparator|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
11394440|NCT02073266|Active Comparator|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
11394441|NCT02073266|Active Comparator|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
11394442|NCT02073253|No Intervention|Without performing any operation (Phase Control)|
11394443|NCT02073253|Experimental|With ventilatory support through NIV (NIV Phase)|
11394444|NCT02073240||Enhanced TB IC Package|"Facilities randomized to the intervention group will receive the following:
~Skills-based training for TB IC focal points
~Audits and Feedback of performance data
~TB IC collaborative (including mentoring)
~Checklists"
11394445|NCT02073240||Usual Care Group|Usual Care group will receive available TB IC training/education alone.
11394446|NCT02073227|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
11394447|NCT02073227|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
11394448|NCT02073227|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
11394449|NCT02073214|Experimental|Probiotic|"Single dose of probiotic, was administered enterally twice daily with food (in the morning and in the evening). The first dose of probiotic was administered within the first 48 hours after birth. The probiotic administration was continued for 6 weeks or until hospital discharge (whichever was earlier).
~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the probiotic. If the probiotic was discontinued for more than 7 days, the patient was withdrawn from the study."
11394540|NCT02072603|Active Comparator|Control Hospitals|Existing standard of EID care
11394541|NCT02072577|Experimental|Knowledge|Educational video.
11394542|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
11394543|NCT02072551||Adult with neonatal diabetes|Adult with neonatal diabetes (before 1 year ) and need for insulin
11394450|NCT02073214|Placebo Comparator|Placebo|"Single dose of placebo was administered enterally twice daily with food (in the morning and in the evening). The first dose of placebo was administered within the first 48 hours after birth. The placebo administration was continued for 6 weeks or until hospital discharge (whichever was earlier).
~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the placebo. If the placebo was discontinued for more than 7 days, the patient was withdrawn from the study."
11394451|NCT02073201||High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
11394452|NCT02073201||Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
11394453|NCT02073201||Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
11394454|NCT02073188|Experimental|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
11394455|NCT02073188|Active Comparator|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
11394456|NCT02073175|Experimental|Postpartum with crying spells-Full dose|"Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.
~Intervention: Full dose dietary supplement Motherwell"
11394457|NCT02073175|Experimental|Day-5 postpartum - Full dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.
~Intervention: Full dose dietary supplement Motherwell"
11394458|NCT02073175|Experimental|Day-5 postpartum - Half dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.
~Intervention: Half dose dietary supplement Motherwell"
11394459|NCT02073175|Experimental|Day-5 postpartum - Quarter dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.
~Intervention: Quarter dose dietary supplement Motherwell"
11394460|NCT02073175|Other|Day-5 postpartum - Control|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.
~Intervention: Control protein to compare with Motherwell"
11394461|NCT02073162|Active Comparator|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
11394462|NCT02073162|Experimental|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
11394463|NCT02073149|Active Comparator|Low-dose iron as NaFeEDTA|Daily point-of-care fortification of (complementary) foods with 3 mg iron as NaFeEDTA.
11394464|NCT02073149|Active Comparator|Conventional dose iron as ferrous salt|Daily point-of-care fortification of (complementary) foods with 12.5 mg iron as encapsulated ferrous fumarate.
11394465|NCT02073149|Placebo Comparator|Placebo|Daily point-of-care fortification of (complementary) foods with placebo.
11394466|NCT02073136|Experimental|Phosphate modified diet|
11394467|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.
~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).
~Patients will continue until they experience disease progression or limiting toxicity."
11394468|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.
~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
11394469|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.
~Nivolumab administered intravenously at 240 mg every 2 weeks."
11394470|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
11394471|NCT02073097|Experimental|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):
~Rituximab IV over at least 90 minutes on day 2
~Carfilzomib IV over 30 minutes on days 1, and 2
~Cyclophosphamide IV over 30-60 minutes on day 3
~Doxorubicin hydrochloride IV over 3-5 minutes on day 3
~Vincristine sulfate IV over 1 minute on day 3
~Prednisone PO on days 3-7 any time
~Pegfilgrastim day 4
~Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6
~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
11394472|NCT02073084|Other|Sequence A|Sequence A
11394473|NCT02073084|Other|Sequence B|Sequence B
11394474|NCT02073084|Other|Sequence C|Sequence C
11394475|NCT02073084|Other|Sequence D|Sequence D
11394476|NCT02073071||Preterm/low birth weight infants|Preterm infant formula per standard of care
11394544|NCT02072551||non diabetic adults with a relative with neonatal diabetes|
11394545|NCT02072538||Pre-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
11394477|NCT02073045|Experimental|Supportive care (lymphedema education)|In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
11394478|NCT02073032||Head -Neck cancer patients, no intervention|
11394479|NCT02073019|Experimental|Cohort A|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
11394480|NCT02073019|Experimental|Cohort B|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
11394481|NCT02073019|Experimental|Cohort C|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
11394482|NCT02073006|Active Comparator|Natural Fibre Supplement|2 doses per day for 4 weeks
11394483|NCT02073006|Placebo Comparator|Placebo|2 doses per day for 4 weeks
11394484|NCT02072993|Experimental|AZD1979|Single ascending doses of oral solution AZD1979
11394485|NCT02072993|Placebo Comparator|Placebo|Placebo to match single ascending doses of oral solution AZD1979
11394486|NCT02072980|Other|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
11394487|NCT02072980|Other|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
11394488|NCT02072967||Ribomustin and rituximab|
11394489|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
11394490|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
11394491|NCT02072941|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
11394492|NCT02072941|No Intervention|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
11394493|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
11394494|NCT02072915|Experimental|Suction|Suction will be applied to patients undergoing EUS-FNA
11394495|NCT02072915|No Intervention|Without suction|No suction will be applied to patients undergoing EUS-FNA
11394496|NCT02072902||diabetes free|No intervention
11394497|NCT02072902||Diabetes prevalent|The exposure is diabetes morbidity present at study entery
11394498|NCT02072902||Diabetes incidence|The exposure is diabetes incidence during study follow up
11394499|NCT02072889|Experimental|Neck Angle Measures|Subjects will position his/her neck in order to measure distance between the internal jugular and the carotid artery to determine if there is a maximal distance to target prior to cannulation
11394500|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
11394501|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
11394502|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.
~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
11394503|NCT02072850||Myocardial infarction|Patients presenting with acute-ST elevation myocardial infarction referred for emergency invasive management by primary or rescue percutaneous coronary intervention.
11394504|NCT02072824|Experimental|Study Drug Level 1|
11394505|NCT02072824|Experimental|Study Drug Level 2|
11394506|NCT02072824|Placebo Comparator|Placebo|
11394507|NCT02072811|Other|Induction, DAC|"The first stage of treatment.
~First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
11394508|NCT02072811|Other|II early induction, CLAG|"Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16 day.
~Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day"
11394509|NCT02072811|Other|Consolidation, I HAM cycle|"I induction cycle starts after complete remission (CR).
~- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):
~If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation
~- After I consolidation, patients from Adverse risk group (ELN prognostic system):
~If compatible donor is present - immediate qualification for allogeneic HSCT.
~- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
11394546|NCT02072538||Post-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
11395906|NCT02063529|Experimental|A (FOLFOXIRI + Cetuximab)|FOLFOXIRI + Cetuximab
11394510|NCT02072811|Other|II Consolidation HiDAraC|"Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.
~Patients form Very adverse risk receive Maintenance treatment:
~Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.
~Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
11394511|NCT02072811|Other|Consolidation, III HiDAraC cycle|"Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).
~Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
11394512|NCT02072798|Active Comparator|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
11394513|NCT02072798|Active Comparator|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
11394514|NCT02072785|Experimental|Vincristine Sulfate Liposome|"Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.
~Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
11394515|NCT02072785|Active Comparator|Vincristine Sulfate|"Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.
~Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
11394516|NCT02072772|Experimental|Positively Smoke Free group treatment|"Eight 90 minute group sessions (6-8 HIV-infected smokers per group) led by a pair of trained group leaders: a professional with psychology or social work training and a peer HIV-infected ex-smoker with tobacco treatment training.
~All subjects will be offered a 3 month supply of nicotine patches"
11394517|NCT02072772|Active Comparator|Standard care|Brief (<5 minutes) advice to quit Offer of nicotine patches Self-help brochure
11394518|NCT02072759|Experimental|Carnitine supplement|Carnitine supplement
11394519|NCT02072759|Placebo Comparator|Placebo|Placebo supplement
11394520|NCT02072759|No Intervention|Healthy control|Healthy control group
11394521|NCT02072746|Active Comparator|Zinc|zinc sulfate 220 mg daily
11394522|NCT02072746|Placebo Comparator|Placebo|Placebo study for comparison
11394523|NCT02072733|Other|geriatric assessment|"The intervention is individual and based on the Comprehensive Geriatric assessment (CGA) : collection of information on comorbidity, polypharmacy, physical, psychological and cognitive functions, nutrition as well as social status and support.
~The results of the CGA, the eventual medical changes and recommendations regarding e.g. initiation of nutritional supplementation, home-care referral or referral to e.g. physiotherapist will be forwarded to the general practitioner and to the oncologist in charge of the treatment"
11394524|NCT02072720|No Intervention|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
11394525|NCT02072720|Experimental|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
11394526|NCT02072707|Active Comparator|Epicardial VT ablation|Patients will underwent combined epicardial and endocardial mapping and ablation
11394527|NCT02072707|Active Comparator|Endocardial VT Ablation|Patients will underwent endocardial only VT mapping and ablation
11394528|NCT02072694|Experimental|75 grams of glucose plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water.
~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water."
11394529|NCT02072694|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge).
~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge)."
11394530|NCT02072681||Mild and Rapidly Improving Ischemic Stroke|"Patients 18 years or older with mild or rapidly improving acute ischemic stroke defined clinically. .Absence of non-ischemic conditions neuro-imaging (i.e. absence of hemorrhage or a mass on brain imaging that arrived to the hospital within 4.5 hours after the onset of stroke symptoms.
~All participants will have two follow up telephone calls: One at approximately 30 days after the stroke and one at approximately 90 days after the stroke to ask questions about how well participant can carry out usual duties after the stroke, how much assistance do he/she needs to perform your daily activities and how good or bad would he/she considers current health to be."
11394531|NCT02072668|Other|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
11394532|NCT02072668|Other|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
11394533|NCT02072655|No Intervention|without socio-asthetic care|
11394534|NCT02072655|Experimental|with socio-aesthetic cares|
11394535|NCT02072642|Active Comparator|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
11394536|NCT02072642|Placebo Comparator|Placebo light therapy (70 lux)|Placebo light therapy
11394537|NCT02072629|Experimental|Training of VHVs in iCCM|In these villages VHVs will be provided with iCCM training and equipped to support iCCM in their villages
11394538|NCT02072616|Experimental|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done after Pancreatic adenocarcinoma diagnosis
11394539|NCT02072603|Experimental|Intervention Hospitals|HITSystem implementation at hospital and its affiliated laboratory
11394547|NCT02072525|Experimental|Mtdap1 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
11394548|NCT02072525|Experimental|Mtdap2 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
11394549|NCT02072525|Experimental|Mtdap3 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
11394550|NCT02072525|Experimental|Pneum1 Group|Subjects will receive a dose of Pneumovax 23.
11394551|NCT02072525|Experimental|Pneum2 Group|Subjects will receive a dose of Pneumovax 23.
11394552|NCT02072525|Experimental|Pneum 3 Group|Subjects will receive a dose of Pneumovax 23.
11394553|NCT02072525|Experimental|Prev1 Group|Subjects will receive a dose of Prevnar 13.
11394554|NCT02072525|Experimental|Prev2 Group|Subjects will receive a dose of Prevnar 13.
11394555|NCT02072525|Experimental|Prev3 Group|Subjects will receive a dose of Prevnar 13.
11394556|NCT02072512|Active Comparator|Fulvestrant|Goserelin plus High Dose Fulvestrant
11394557|NCT02072512|Active Comparator|Anastrozole|Goserelin plus Anastrozole
11394558|NCT02072499|Experimental|KTP Green Light Prostatectomy|Device
11394559|NCT02072499|Active Comparator|Open prostatectomy|Surgical procedure
11394560|NCT02072486|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
11394561|NCT02072473||Unsuccessful right-sided AVNRT ablation|Patients with unsuccessful right-sided slow pathway ablation attempt, will be candidates for Coronary sinus / left-sided slow pathway ablation.
11394562|NCT02072460|Experimental|vestibular signals determination|vestibular signals determination by electromyography and electroencephalography associated to approaches from psychophysics
11394563|NCT02072447|Experimental|Microdose|
11394564|NCT02072434|Experimental|Edoxaban|Edoxaban oral tablet, 60 mg-once daily (QD), reduced to 30 mg based on protocol-defined parameters, for up to 49 days
11394565|NCT02072434|Active Comparator|Warfarin|"Participants naïve to anticoagulation, taking anticoagulants other than a Vitamin K antagonist (VKA) or taking a VKA but with a prothrombin time (PT) international normalized ratio (INR) of less than 2.0 receive enoxaparin until they reach a PT INR of at least 2.0, before taking warfarin.
~All participants in this arm receive warfarin oral tablet QD at their doctor's prescribed dose, for up to 49 days."
11394566|NCT02072421|Other|Non-SOS|
11394567|NCT02072408|Experimental|polypoidal choroidal vasculopathy without polyp|
11394568|NCT02072395|Experimental|Band/Plication|Treatment -- band/plication
11394569|NCT02072382|Experimental|Metformin|Metformin 850 mg twice a day for eight weeks versus Placebo
11394570|NCT02072369|Experimental|VAEDA Glove|Voice And EMG-Driven Actuated glove used during hand occupational therapy training
11394571|NCT02072369|Active Comparator|No-glove|hand occupational therapy sessions without assistive device
11394572|NCT02072356|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
11394573|NCT02072343|Experimental|Mainstream capnometer|
11394574|NCT02072343|Experimental|Microstream capnograph|
11394575|NCT02072330|Active Comparator|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
11394576|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
11394577|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
11394578|NCT02072330|Active Comparator|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
11394579|NCT02072330|Active Comparator|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
11394580|NCT02072317|Experimental|Paclitaxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
11394581|NCT02072317|Active Comparator|taxol|taxol 135 mg/m2, every three weeks for a cycle
11394582|NCT02072304|Experimental|web-based CBT|Web-based CBT group : The intervention is made up of 8 internet modules based on behavioral activation, cognitive behavioral therapy
11394583|NCT02072304|Active Comparator|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks
11394584|NCT02072291|Experimental|Nifedipine|Nifedipine 5mg single dose
11394585|NCT02072291|Placebo Comparator|Placebo|
11394586|NCT02072278|Experimental|Vortioxetine 10 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
11394587|NCT02072278|Experimental|Vortioxetine 20 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
11394588|NCT02072278|Active Comparator|Escitalopram 15 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
11394589|NCT02072278|Placebo Comparator|Placebo|capsules; 3 daily doses in each treatment period; orally
11394590|NCT02072265||Port-A implantation and chemotherapy|Patients scheduled for Port-A implantation and subsequent chemotherapy
11394591|NCT02072265||Port-A infection|Patients receiving Port-A removal due to infection
11394592|NCT02072252|Experimental|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
11394593|NCT02072252|No Intervention|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
11394594|NCT02072239|Experimental|Device Applied|All participants will be treated with the Angioshield
11395907|NCT02063529|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
11394595|NCT02072226|Active Comparator|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
11394596|NCT02072226|Experimental|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
11394597|NCT02072213|Experimental|GL2702 GLARS-NF1 , fasted|Tamsulsoin 0.4mg
11394598|NCT02072213|Active Comparator|Omix Ocas® , fasted|Tamsulsoin 0.4mg
11394599|NCT02072213|Experimental|GL2702 GLARS-NF1, after meal|Tamsulsoin 0.4mg
11394600|NCT02072213|Active Comparator|Omix Ocas®, after meal|Tamsulsoin 0.4mg
11394601|NCT02072200|Experimental|Modified release prednisone|Single arm / Lodotra
11394602|NCT02072187|Experimental|Active|"The vitamin D formula that will be used is Bio-D Mulsion 1000, produced by Biotics Research Corporation. This formula contains: Vitamin D (cholecalciferol), water and acacia gum and sesame oil.
~Participants will be provided with a dose of vitamin D at each visit beginning at the Baseline visit. The weekly dose of vitamin D will be 28 000IU (the equivalent of 4000IU daily) for a period of eight weeks. If baseline or week 4 serum vitamin D levels are measured as >100nmol/L, the dose will be reduced to 14 000IU (the equivalent of 2000IU daily). The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
11394603|NCT02072187|Placebo Comparator|Placebo|"The placebo formula, also produced by Biotics Research Corporation, will contain all of the non-medicinal ingredients but no vitamin D. It will be identical in appearance and taste.
~Participants will be provided with a dose of the placebo at each visit beginning at the Baseline visit. The weekly dose will be 28 drops or 14 drops if serum Vitamin D levels are >100nmol/L. The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
11394604|NCT02072174|Experimental|Anaferon for Children|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
11394605|NCT02072174|Placebo Comparator|Placebo|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
11394606|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
11394607|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
11394608|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
11394609|NCT02072148|Experimental|Low Risk Group I|"Group I:
~Complete resection (margins: tonsil >1mm, tongue >3mm, pT1-2, pN0-2B),
~No LVI, no PNI, <3 positive nodes.
~No ECS, No matted or Level >III,"
11394610|NCT02072148|Experimental|Intermediate Risk Group II|"Group II
~Complete resection (margins: tonsil <1mm, tongue <1mm, pT1-2, pN0-2B),
~+LVI, +PNI, <3 positive nodes. ≤1mm ECS."
11394611|NCT02072148|Experimental|High Risk Group IIIA|"3+ nodes, no ECS > 1mm
~Contralateral or supraclavicular nodes"
11394612|NCT02072148|Experimental|High Risk Group IIIB|"Incomplete surgical resection with + surgical margins
~≥ 1 mm ECS
~Matted nodes"
11394613|NCT02072135|Experimental|Exparel|Exparel 266mg
11394614|NCT02072122||women during fertility treatment|
11394615|NCT02072109||Bolus feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
11394616|NCT02072109||Continuous feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
11394617|NCT02072096|Experimental|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
11394618|NCT02072096|Active Comparator|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
11394619|NCT02072083|Active Comparator|dexmedetomidine|intranasal 1mcg/kg
11394620|NCT02072083|Active Comparator|ketamine|intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
11394621|NCT02072070|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
11394622|NCT02072070|Placebo Comparator|Placebo|Single intra-articular injection to the damaged knee joint
11394623|NCT02072057|Experimental|Ruxolitinib|Interventional arm
11394624|NCT02072044|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11394625|NCT02072031|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11394626|NCT02072031|Active Comparator|Sunitinib maleate|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
11394627|NCT02072018|Active Comparator|H-100|H-100, gel, daily, 6 months
11394628|NCT02072018|Placebo Comparator|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
11394629|NCT02072005||Regular cigarette smokers|
11394630|NCT02071979|Experimental|Autologous PRP Gel|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. The application of topical PRP gel may be used in chronic wounds possessing an open, moist wound bed according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical application) data.
11394667|NCT02071771|Other|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
11394909|NCT02070159|Active Comparator|Clopidogrel 600 mg|Patients administer conventional loading dose of clopidogrel 600 mg as active comparators.
11394631|NCT02071979|Experimental|Autologous PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Autologous PRP Injections may be used where chronic wounds possess a raised, hyperproliferative wound margin and/or plaque, according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare Autologous PRP for injections. For data analysis, the data from these patients will be classified as PRP Treatment Group (Direct Injection) data.
11394632|NCT02071979|Experimental|Autologous PRP Gel plus PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Some wounds may be suitable for both Autologous PRP Gel plus PRP Injections. Autologous PRP injections into, or to the periphery of, a moist wound bed in which no scarification or raised wound margin is apparent (where autologous PRP Gel can also be used) may further augment wound healing by addressing wound healing in multiple areas, following the treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical and Direct) data.
11394633|NCT02071979|No Intervention|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices. For data analysis, the data from these patients will be classified as Control (Standard of Care) Group data
11394634|NCT02071966|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
11394635|NCT02071966|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
11394636|NCT02071953|Experimental|Adhesive without acid pretreatment|Experimental adhesive w/out phosphoric acid in post. rest.
11394637|NCT02071953|Active Comparator|Adhesive with acid pretreatment|Experimental adhesive with phosphoric acid in post. rest.
11394638|NCT02071940|Experimental|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
11394639|NCT02071927|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
11394640|NCT02071927|Experimental|CB-Aza|CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity
11394641|NCT02071914|Experimental|CT-P27 10mg/kg|CT-P27 will be administrated once in IV infusion.
11394642|NCT02071914|Experimental|CT-P27 20mg/kg|CT-P27 will be administrated once in IV infusion.
11394643|NCT02071914|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
11394644|NCT02071901|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach >= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
11394645|NCT02071888|Experimental|CB-839|CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity
11394646|NCT02071888|Experimental|CB-839 and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity
11394647|NCT02071888|Experimental|CB-839, pomalidomide, and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity
11394648|NCT02071875||Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording
11394649|NCT02071862|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
11394650|NCT02071862|Experimental|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
11394651|NCT02071862|Experimental|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
11394652|NCT02071862|Experimental|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
11394653|NCT02071862|Experimental|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
11394654|NCT02071862|Experimental|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
11394655|NCT02071849|Experimental|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
11394656|NCT02071836|Experimental|Right Turns web application|Right Turns web application
11394657|NCT02071836|Active Comparator|Treatment as usual|Treatment as usual
11394658|NCT02071823|Experimental|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:
~Period 1: Fed Washout Period (7days) Period 2: Fasted"
11394659|NCT02071823|Experimental|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:
~Period 1: Fasted Washout Period (7days) Period 2: Fed"
11394660|NCT02071810|Experimental|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
11394661|NCT02071810|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
11394662|NCT02071810|Experimental|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
11394663|NCT02071810|Experimental|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
11394664|NCT02071810|Experimental|Placebo|Placebo, PLC
11394665|NCT02071797|Active Comparator|Arm A - Blanketroll lll|Cutaneous Cooling Blanket, Blanketroll lll, applied to cool patient to 32C. Standard care
11394666|NCT02071797|Active Comparator|Arm B - RhinoChill|Intra nasal cooling system, RhinoChill, to cool patient to 32C - Standard care
11394790|NCT02070939|Experimental|MAD cohorts 2-6 Experimental Arm|
11394791|NCT02070939|Placebo Comparator|MAD cohorts 2-6 Placebo Arm|
11394668|NCT02071771|Other|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
11394669|NCT02071758|Experimental|20 mcg LEISH-F3 + 5 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and low dose of SLA-SE adjuvant.
11394670|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of GLA-SE adjuvant.
11394671|NCT02071758|Experimental|5 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of GLA-SE adjuvant.
11394672|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of SLA-SE adjuvant.
11394673|NCT02071745||Navigation|
11394674|NCT02071732|Active Comparator|Real rTMS|Real rTMS is real continuous theta burst stimulation.
11394675|NCT02071732|Sham Comparator|Sham rTMS|Sham rTMS is sham continuous theta burst stimulation.
11394676|NCT02071719||Sunitinib|
11394677|NCT02071719||Sorafenib|
11394678|NCT02071719||Everolimus|
11394679|NCT02071719||Pazopanib|
11394680|NCT02071719||Axitinib|
11394681|NCT02071706|Other|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
11394682|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|123I-mIBG administration followed by nuclear imaging pre-ablation and post-ablation
11394683|NCT02071667||Subjects who require sinus surgery|
11394684|NCT02071654|Experimental|Venus P-valve transcatheter implantation|Single arm of percutaneous implantation of Venus-P valve for treating RVOT stenosis
11394685|NCT02071641|Experimental|Sunitinib|Patients will be treated in repeated 6-week cycles with 50 mg sunitinib orally daily for 4 weeks followed by 2 weeks off.
11394686|NCT02071615|Experimental|Methylphenidate and placebo|Placebo or Methylphenidate 20 mg tablet given once by mouth
11394687|NCT02071615|Experimental|modafinil and placebo|placebo or modafinil 200mg tablet given once by mouth
11394688|NCT02071615|Experimental|caffein and placebo|placebo or caffein 200mg tablet given once by mouth
11394689|NCT02071602|Placebo Comparator|Placebo|Placebo infused for up to 72 hours IV
11394690|NCT02071602|Active Comparator|CD-NP 5 ng/kg/min|CD-NP 5 ng/kg/min infused for up to 72 hours IV
11394691|NCT02071602|Placebo Comparator|CD-NP 10 ng/kg/min|CD-NP 10 ng/kg/min infused for up to 72 hours IV
11394692|NCT02071589|Experimental|Nifedipine oral solution|Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose
11394693|NCT02071589|Active Comparator|Nifedipine soft gelatine capsules|Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose
11394694|NCT02071576|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes
11394695|NCT02071563|Active Comparator|CSB14|Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).
11394696|NCT02071563|Active Comparator|RUSF1|Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product
11394697|NCT02071563|Active Comparator|SC+|Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour
11394698|NCT02071563|No Intervention|CSB+|Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.
11394699|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
11394700|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
11394701|NCT02071537|Experimental|Chloroquine with Carboplatin/Gemcitabine|Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
11394702|NCT02071524|Active Comparator|Cristalloid|group cristalloid (ringer lactate)
11394703|NCT02071524|Active Comparator|colloids|colloid: cristalloid in according to cardiac output
11394704|NCT02071511|Active Comparator|control group|Ablation of ventricular arrhythmias
11394705|NCT02071511|Sham Comparator|intervention group|Ablation of ventricular arrhythmias + renal denervation
11394706|NCT02071498|Experimental|Pillbox app named ALICE|pillbox app for elderly patients taking multiple medications. App was used during three months
11394707|NCT02071498|Active Comparator|oral and written information|oral and written information regarding the main risks related to their medications and the most common errors of patients
11394708|NCT02071485||No treatment|Subjects in this study will receive no treatment and rather will only be trained in using the motor imagination-based BCI system
11394709|NCT02071472|Experimental|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
11394710|NCT02071472|No Intervention|control|conventional anesthesiologist consultation for planned surgery patients
11394711|NCT02071459|Experimental|L-Threo DOPS|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS
11394712|NCT02071459|Placebo Comparator|placebo|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo
11394713|NCT02071433|Experimental|Saphenous nerve blockade|Experimental treatment 15 mL of levobupivacaine 0.5%
11394714|NCT02071433|Active Comparator|Femoral nerve blockade|Standard treatment 15 mL of levobupivacaine 0.5%
11394715|NCT02071420|Experimental|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
11394716|NCT02071420|Active Comparator|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
11394792|NCT02070939|Experimental|Japanese MAD cohort 7 Experimental arm|
11394793|NCT02070939|Placebo Comparator|Japanese MAD cohort 7 Placebo Arm|
11394794|NCT02070926||Perform coronary CT angiography|
11394717|NCT02071407|Placebo Comparator|N1(traditional treatment group)|Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
11394718|NCT02071407|Experimental|N2(midazolam group)|Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
11394719|NCT02071394|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
11394720|NCT02071394|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
11394721|NCT02071381|Experimental|A|only DW330SR 45mg
11394722|NCT02071381|Experimental|B|only DW1030 75mg
11394723|NCT02071381|Experimental|C|DW330SR 45mg and DW1030 75mg
11394724|NCT02071368|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
11394725|NCT02071368|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]) formulation 1, under fed conditions.
11394726|NCT02071368|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]), formulation 2, under fed conditions.
11394727|NCT02071355|Experimental|Group 1|Participants will receive 100 mg TMC435 once daily for 7 days.
11394728|NCT02071355|Experimental|Group 2|Participants will receive 150 mg TMC435 once daily for 7 days.
11394729|NCT02071342||acute coronary syndrome|patients with acute myocardial infarction who are undergoing coronary angioplasty. MACE at 30 days and 1 year will be assessed . The acute recoil after implantation of bioabsorbable stents will also be assessed
11394730|NCT02071329|Experimental|Vaccine FP-01.1|Vaccine FP-01.1
11394731|NCT02071329|Placebo Comparator|Placebo|Placebo
11394732|NCT02071316|Active Comparator|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
11394733|NCT02071316|Placebo Comparator|Standard of care group, esomeprazole|* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
11394734|NCT02071303|Active Comparator|Tramadol|Women will receive Tramadol 100mg 1 hour before the procedure.
11394735|NCT02071303|Active Comparator|Celecoxib|Women will receive Celecoxib 200mg 1 hour before the procedure.
11394736|NCT02071303|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
11394737|NCT02071290|Sham Comparator|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
11394738|NCT02071290|Experimental|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
11394739|NCT02071277|Experimental|Pressure targeted modes|
11394740|NCT02071264|Other|HIV/STI intervention|This study implements a socio-behavioral intervention in Metro Manila, the Philippines, using a community-based participatory approach with 1-2 psychosocial and health education training workshops for the establishment managers and their workers, including street sex workers, focusing on HIV/AIDS risk reduction information, condom use, and condom negotiation skill-building. Participants participate in dream-building activities to explore personal goals and goals for their organization of peers. The interventions are directed at organizational behavior change and social influence modeling through training peers and managers. The participants receive information on STIs along with standard care, held on a day convenient to the participants and at a neutral location.
11394741|NCT02071251|Experimental|Prospective intervention|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
11394742|NCT02071238|Experimental|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
11394743|NCT02071238|No Intervention|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
11394744|NCT02071238|Experimental|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
11394745|NCT02071225|Experimental|Obinutuzmab + Bendamustine|Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
11394746|NCT02071212|Active Comparator|Clopidogrel|Loading dose 600 mg .Mainatinance dose 75 mg QD
11394747|NCT02071212|Experimental|Ticagrelor|Loading dose 180 mg . Maintenance 90 mg BID
11394748|NCT02071199|Experimental|Low dose 0.3X ACCS|20 microliters of 0.3X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
11394749|NCT02071199|Experimental|High dose 1X ACCS|20 microliters of 1X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
11394750|NCT02071199|Placebo Comparator|Normal saline|20 microliters of saline placebo per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
11394795|NCT02070926||Do not perform coronary CT angiography|
11394796|NCT02070900|No Intervention|Standard of Care|Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines
11394910|NCT02070159|Experimental|Prasugrel 30 mg|Patients administer lower loading dose of prasugrel 30 mg.
11395908|NCT02063516|Experimental|Guardian|Device: Guardian Laryngeal Mask
11394751|NCT02071186|Experimental|Virtual Reality training|Subjects will be asked to walk on a treadmill while negotiating virtual obstacles. The VR system includes a camera based motion capture and a computer generated simulation. The camera is used to capture the movement of the participant's feet. These images are then transferred to the computer simulation and projected to the patient on a screen. The speed, orientation, size, frequency of appearance and shape of the targets are manipulated to increase task difficulty. The Virtual environment imposes a cognitive load requiring attention and response selection as well as processing of rich visual stimuli involving several perceptual processes. The system provides visual and auditory feedback of task performance to enhance motor learning.
11394752|NCT02071186|Experimental|Computerized Cognitive Remediation|"The AttenGo program will be used for neuro-cognitive remediation aimed at enhancing attention, concentration, working memory, and executive function. The program has shown to be effective in improving attention and executive function in children with ADHD. The training is composed of cognitive exercises that challenge subjects with problem solving, information processing, response inhibition and dividing attention. The users receive immediate feedback from the system when losing focus. The program is adaptive and progresses according to the subjects abilities."
11394753|NCT02071186|Active Comparator|Control group|Subjects in this group will be assessed based on the study protocol but will receive no treatment other than their standard of care which could include pharmacological or/ and non-pharmacological treatment.
11394754|NCT02071173|Experimental|Enrolled Patients|Subjects undergo an implant procedure to receive at least one investigational lead -- ACUITY X4 left ventricular (LV) CRT lead, RELIANCE 4-FRONT right ventricular (RV) ICD lead
11394755|NCT02071160|No Intervention|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
11394756|NCT02071160|No Intervention|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
11394757|NCT02071160|Experimental|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
11394758|NCT02071147|Other|Standard clinical intervention|Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
11394759|NCT02071147|Other|No Clinical Follow up|No routine follow-up appointment is made. Patients will be instructed to visit their optometrist between 6-8 weeks post-operative for review of the patient's glasses.
11394760|NCT02071134||Parkinson's disease|Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
11394761|NCT02071121|Placebo Comparator|Placebo|Fasted participants will receive a single oral dose of placebo to BIIB061.
11394762|NCT02071121|Experimental|BIIB061 3 mg|Fasted participants will receive a single oral dose of BIIB061 3 mg.
11394763|NCT02071121|Experimental|BIIB061 10 mg|Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
11394764|NCT02071121|Experimental|BIIB061 30 mg|Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
11394765|NCT02071121|Experimental|BIIB061 60 mg|Fasted participants will receive a single oral dose of BIIB061 60 mg.
11394766|NCT02071121|Experimental|BIIB061 100 mg|Fasted participants will receive a single oral dose of BIIB061 100 mg.
11394767|NCT02071108|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
11394768|NCT02071095|Experimental|Arm A: Poly-ICLC|Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.
11394769|NCT02071095|Placebo Comparator|Arm B: Normal Saline|Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.
11394770|NCT02071082|Experimental|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
11394771|NCT02071082|Experimental|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
11394772|NCT02071069|Experimental|maintenance therapy|"Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks) .
~After 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or fluorouracil arm( leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
11394773|NCT02071056||history of visceral cancer|
11394774|NCT02071043|Experimental|XELOX|"XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:
~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
11394775|NCT02071030|Other|CBCT|Cone Beam CT
11394776|NCT02071030|Other|Panoramic radiograph|
11394777|NCT02071004|Other|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
11394778|NCT02071004|Experimental|DS-1040b|IV of 6 mg given once over 30 minutes
11394779|NCT02070991|Experimental|Macitentan|oral tablet, 10 mg once daily.
11394780|NCT02070991|Placebo Comparator|Placebo|Matching placebo, once daily.
11394781|NCT02070978|Experimental|Atacicept 75 mg|
11394782|NCT02070978|Experimental|Atacicept 150 mg|
11394783|NCT02070978|Experimental|Placebo/Atacicept 150 mg|
11394784|NCT02070965|Experimental|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
11394785|NCT02070965|Active Comparator|Comp01 Lotion|Comp01 Lotion, bid, 14 days
11394786|NCT02070965|Experimental|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
11394787|NCT02070952|Experimental|CyberKnife|CyberKnife Stereotactic Ablative Body Radiation Therapy
11394788|NCT02070939|Experimental|SAD cohorts 1-7 Experimental Arm|
11394789|NCT02070939|Placebo Comparator|SAD Cohorts 1-7 Placebo Arm|
11394797|NCT02070900|Experimental|POC Plus|Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines
11394798|NCT02070887||Entacapone|
11394799|NCT02070887||No Entacapone|
11394800|NCT02070874|Experimental|telehealth enhanced pain management|video-case conferences for providers PainTracker for patients
11394801|NCT02070874|No Intervention|usual care|usual care
11394802|NCT02070861|Experimental|Comparing cardiac output changes|"Explore the relationship between changes in cardiac output measured with eosophagal Doppler, the volume-clamp-method and exhaled CO2 during ventricular pacing and passive leg raise.
~Measurements with the volume-clamp-method were aborted due to technological difficulties."
11394803|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
11394804|NCT02070835|Experimental|ReCell®|ReCell® with skin graft
11394805|NCT02070835|Active Comparator|skin graft|split-thickness skin graft as control group
11394806|NCT02070822||TACE patients, for HCC|unresectable HCC patients
11394807|NCT02070809|Experimental|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
11394808|NCT02070809|Active Comparator|split-thickness skin graft method|This method is traditional split-thickness skin graft
11394809|NCT02070796|Experimental|Treatment A - B|Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours.
11394810|NCT02070796|Active Comparator|Treatment B - A|Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours.
11394811|NCT02070783|Experimental|ARA290|11-amino acid, linear peptide ARA290; intravenous injection with 2 mg ARA290 (single dosage).
11394812|NCT02070783|Placebo Comparator|Placebo|saline (NaCl 0.9%)
11394813|NCT02070770|Experimental|Very low calorie diet|
11394814|NCT02070770|Active Comparator|Standard weight loss diet|
11394815|NCT02070757|Experimental|Ceftolozane/tazobactam|Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
11394816|NCT02070757|Active Comparator|Meropenem|Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.
11394817|NCT02070744|Experimental|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
11394818|NCT02070744|Placebo Comparator|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
11394819|NCT02070744|Experimental|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
11394820|NCT02070744|Placebo Comparator|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
11394821|NCT02070744|Experimental|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
11394822|NCT02070731|No Intervention|unprotected TAVI|standard unprotected Transcatheter Aortic Valve Implantation
11394823|NCT02070731|Experimental|TAVI with the TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
11394824|NCT02070718|Placebo Comparator|Placebo|Cornstarch, National Formulary
11394825|NCT02070718|Experimental|Standard Dose Kappa Agonist|Pentazocine/Naloxone 50/0.5 mg
11394826|NCT02070718|Experimental|Half Dose Kappa Agonist|Pentazocine/Naloxone 25/0.25 mg
11394827|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
11394828|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
11394829|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection
11394830|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
11394831|NCT02070692|Experimental|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
11394832|NCT02070692|Placebo Comparator|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
11394833|NCT02070679|Placebo Comparator|Placebo|
11394834|NCT02070679|Active Comparator|Vit-E|600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
11394835|NCT02070666|Experimental|Protective ventilation arm|"Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)
~Plateau pressure less than 25 centimeter of water (cmH2O)
~Minimum PEEP of 5 cmH2O."
11394836|NCT02070666|Active Comparator|Control group|"Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)
~Plateau pressure less than 25 cmH2O
~Minimum PEEP of 5 cmH2O."
11394837|NCT02070653|Active Comparator|Ticagrelor|Ticagrelor 90 mg tablets twice daily for 12 months.
11394838|NCT02070653|Placebo Comparator|Placebo|Ticagrelor-placebo tablets twice daily for 12 months.
11394875|NCT02070367|Active Comparator|Usual treatment|Treatment as usual for condition Physiotherapy sessions
11394876|NCT02070354||Group 1|New clinic visit in GI Nutrition (prior to bariatric surgery).
11394877|NCT02070354||Group 2|1 month prior to bariatric surgery
11394839|NCT02070640|Experimental|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
11394840|NCT02070627|Experimental|NIRF-C and IOC|Each enrolled subject will undergo injection with indocyanine green (ICG), intraoperative near infrared fluorescence cholangiography (NIRF-C) and standard of care intraoperative cholangiography.
11394841|NCT02070614||rs2242480 wild-type homozygote|*1/*1 Grouped by rs2242480 polymorphism genotyping
11394842|NCT02070614||rs2242480 mutant heterozygote|*1/*1G Grouped by rs2242480 polymorphism genotyping
11394843|NCT02070614||rs2242480 mutant homozygote|*1G/*1G Grouped by rs2242480 polymorphism genotyping
11394844|NCT02070588|Active Comparator|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
11394845|NCT02070588|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
11394846|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
11394847|NCT02070562||Community Group|Chinese lactating mothers from community maternal & child healthcare centre
11394848|NCT02070562||VIP Group|Chinese lactating mothers from VIP clinics (maternal care center)
11394849|NCT02070549|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11394850|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
11394851|NCT02070523|Experimental|PLD-contained VDCLD regimen|PLD 36 mg/m2 ivdrip over 60 minutes( d1、15),VCR 1.4mg/m iv(d1，8，15，22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip (d1～28).
11394852|NCT02070523|Active Comparator|DNR-contained VDCLD regimen|DNR 45 mg/m2 ivdrip over 60 minutes(d1～3),VCR 1.4mg/m2 iv(d1，d8，d15，d22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip(d1～28).
11394853|NCT02070510|Experimental|Victim and perpetrator compounds|Subjects receive two different victim compounds (lisinopril and warfarin) and two different perpetrator compounds (placebo semaglutide with carrier and oral semaglutide). Each dosing occasion is separated by a 7-day wash-out period.
11394854|NCT02070497|Experimental|case management_new|The patients with new-diagnosed lung cancer and accepting case management
11394855|NCT02070497|Experimental|case management_old|the patients with non-new-diagnosed lung cancer and with accepting case management
11394856|NCT02070497|No Intervention|control group|The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management
11394857|NCT02070484|Experimental|NuCel|Stemcell allograft
11394858|NCT02070484|Active Comparator|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
11394859|NCT02070471|Experimental|LC28-0126 Dose A|LC28-0126 Dose A
11394860|NCT02070471|Experimental|LC28-0126 Dose B|LC28-0126 Dose B
11394861|NCT02070471|Experimental|LC28-0126 Dose C|LC28-0126 Dose C
11394862|NCT02070471|Placebo Comparator|Placebo|Placebo
11394863|NCT02070458|Experimental|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
11394864|NCT02070445||Patients undergoing CABG|Patients will have no ventilation during CABG. There will be non-invasive assessments of the lung using ultrasound at different times during the perioperative period.The first assessment will be conducted before anesthesia induction (i.e. patients will be awake). A second assessment will be conducted after anesthesiology induction, but before the beginning of surgery. A third assessment will be conducted at the end of the surgery in the operating room. And two subsequent assessments will be conducted in ICU before and after extubation.
11394865|NCT02070432|Experimental|LUZ11 PDT|"Study consists of two phases, in each participant:
~Dose-finding phase with sequential periods in which single-ascending doses of LUZ11 will be titrated up to a dose that shows to be effective following photoirradiation of small spots of tumor surface.
~Final PDT session with the previously identified individual effective dose."
11394866|NCT02070419|Active Comparator|Arm I (TACE)|Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
11394867|NCT02070419|Experimental|Arm II (TACE+SBRT)|Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
11394868|NCT02070406|Experimental|Treatment (gene-modified T-cells, vaccine therapy, ipilimumab)|"CONDITIONING CHEMOTHERAPY REGIMEN: Patients receive cyclophosphamide IV on days -5 and -4 and fludarabine phosphate IV over 30 minutes daily on days -4 to -1.
~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV on day 0.
~IPILIMUMAB ADMINISTRATION: Patients receive ipilimumab IV over 90 minutes before the NY-ESO-1 TCR PBMC infusion on day 0 or after the infusion on day 1. Treatment repeats every 3 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity.
~NY-ESO-1(157-165) PEPTIDE PULSED DC ADMINISTRATION: Patients receive NY-ESO-1(157-165) peptide pulsed DC vaccine ID on days 1, 14, and 30.
~LOW DOSE IL-2 ADMINISTRATION: Patients receive aldesleukin (IL-2) SC BID on days 1-14."
11394869|NCT02070393|Experimental|Radiation Treatment using Protons|14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
11394870|NCT02070380|Experimental|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
11394871|NCT02070380|Experimental|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
11394872|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
11394873|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
11394874|NCT02070367|Experimental|Somatosensory rehabilitation|Weekly sessions with a certified (RSDC) somatosensory therapist using distal vibro-tactile counter-stimulation to anatomically related territories of the area of allodynia. Participants will also be provided with a structured home exercise program.
11394882|NCT02070341|Experimental|Split dose PEG|Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
11394883|NCT02070341|Experimental|Split dose Picosalax|Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.
11394884|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
11394885|NCT02070302|Active Comparator|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
11394886|NCT02070302|Placebo Comparator|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
11394887|NCT02070289|Experimental|Group 1: Cohort 1|
11394888|NCT02070289|Experimental|Group 1: Cohort 2|
11394889|NCT02070289|Experimental|Group 1: Cohort 3|
11394890|NCT02070289|Experimental|Group 2: Cohort 4|
11394891|NCT02070289|Experimental|Group 1 or 2: Cohort 5|
11394892|NCT02070289|Experimental|Group 1 or 2: Cohort 6|
11394893|NCT02070276|No Intervention|Standard Clinical Practice|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.
~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
11394894|NCT02070276|Experimental|Trans-thoracic echocardiography|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.
~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
11394895|NCT02070276|Experimental|Passive Leg Raising Test|"In addition to the arm A of the study, is performed a measurement of end-tidal CO2 (EtCO2) by trans-nasal canula with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver : an etCO2 increasing more than 12% from baseline was interpreted as fluid-responsive.
~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
11394896|NCT02070250|Experimental|From Cancer to Health (C2H-D)|Individuals participating in the From Cancer to Health (C2H-D) Stress Management Psychological Intervention
11394897|NCT02070237|Active Comparator|Enoxaparin Once Daily|This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
11394898|NCT02070237|Active Comparator|Enoxaparin Twice Daily|This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.
11394899|NCT02070224|Other|Knee osteoarthritis|
11394900|NCT02070211|Experimental|omega-3 PUFAs in add on to standard care|omega-3 PUFA supplementation as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
11394901|NCT02070211|Placebo Comparator|Placebo in add on to standard care|Placebo made by paraffin oil (not absorbed by the gastrointestinal tract) as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
11394902|NCT02070198|Experimental|Long acting FSH and GnrH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
11394903|NCT02070198|Experimental|daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
11394904|NCT02070198|Experimental|Triptorelin and recombinant FSH|Women in triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day until the day of HCG administration.
11394905|NCT02070185|Experimental|2 exposures|During the conditioning period, the children of this group was exposed only twice to the beverages
11394906|NCT02070185|Experimental|7 exposures|During the conditioning period, children of this group were exposed exposed 7 times to the beverages
11394907|NCT02070172||Cervicogenic Headache Group|This group of subjects is considered the symptomatic group. No intervention was provided in this study so there are no intervention groups.
11394908|NCT02070172||Healthy, Asymptomatic Group|Subjects in this group had no headache symptoms. Their neck motion was compared to subjects in the headache group. No intervention was provided to subjects in either group for this study.
11394911|NCT02070159|Active Comparator|Prasugrel 60 mg|Patients administer conventional loading dose of prasugrel 60 mg as active comparators.
11394912|NCT02070133|Experimental|Simvastatin|Patients with COPD will receive simvastatin 40 mg once a day for 12 weeks
11394913|NCT02070133|Placebo Comparator|Placebo|Patients with COPD will receive placebo once a day during 12 weeks
11394914|NCT02070120|Experimental|Chemoresection|4 once weekly outpatient intravesical instillations 40mg Mitomycin C
11394915|NCT02070120|Other|Surgical Management|Surgical management according to local practice
11394916|NCT02070107|Other|no arms|no arms, sponsor withdrew
11394917|NCT02070081|Experimental|Surgery|
11394918|NCT02070068|Experimental|Group 1|ICG administered 10 minutes prior to time of visualization
11394919|NCT02070068|Experimental|Group 2|ICG administered 45 min prior to time of visualization
11394920|NCT02070055||No treatment|No treatment
11394921|NCT02070042|Experimental|Omega- 3 Fatty Acid|The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
11394922|NCT02070042|Placebo Comparator|Placebo|Seagate® Extra Virgin Olive oil capsules
11394923|NCT02070029|Experimental|Acupuncture|"Acupuncture Therapy
~- twice weekly sessions for 5 weeks: 1st session 60 minutes with remaining 9 session approximately 45 minutes each. Physical exam at 1st session includes evaluation of peripheral pulses, head, neck, throat/tongue. No pelvic exam required."
11394924|NCT02070016|Experimental|TMS Parameter Condition 1 first|Application of Transcranial Magnetic Stimulation
11394925|NCT02070016|Experimental|TMS Parameter Condition 2 First|Application of Transcranial Magnetic Stimulation
11394926|NCT02070003|Experimental|Motivational Interviewing and Physician Guided Opioid Weaning|Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol.
11394927|NCT02070003|No Intervention|Usual Care|
11394928|NCT02069990|Active Comparator|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
11394929|NCT02069990|Experimental|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
11394930|NCT02069990|Experimental|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
11394931|NCT02069990|Active Comparator|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
11394932|NCT02069977|Experimental|Aripiprazole|"Dose level: 2, 5, 10, 15 mg/day
~Starting dose: 2 mg/day
~Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.
~Target dose: 5-15 mg/day
~Maximum dose: 15 mg/day
~Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
11394933|NCT02069964||Prospective hemi-neck RT|
11394934|NCT02069951|Experimental|Practice two procedures on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises.
~Participants randomised to the intervention group will practice two procedures on a simulator. First a procedural module A (a laparoscopic appendectomy) to a predefined proficiency level. Upon reaching proficiency for procedural module A the participants will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
11394935|NCT02069951|No Intervention|Practice one procedure on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises. Each exercise has to be passed twice within five consecutive attempts.
~Participants randomised to the control group will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
11394936|NCT02069938||Healthy Subjects|Noninvasive Brain Computer Interface Control
11394937|NCT02069925|Experimental|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
11394938|NCT02069925|Active Comparator|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
11394939|NCT02069912|Experimental|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
11394940|NCT02069899|Other|NI-0501 only in case is requested|NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.
11394941|NCT02069886|Experimental|deferasirox|single arm. all patients will receive deferasirox
11394942|NCT02069873|Experimental|16-Week Group Treatment|The 16-week treatment group will contain 3 blocks of treatment (exposure, cognitive, skills) with order randomized within the treatment. The first and last group session are considered inactive treatment sessions. The group treatment will be provided weekly.
11394943|NCT02069873|No Intervention|Wait List Control|The Wait List Control group will receive minimal attention, as they will meet bi-monthly for supportive sessions with the study psychologist. The study psychologist will not introduce any active treatment in the individual sessions.
11394944|NCT02069860|Experimental|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
11394945|NCT02069847|Experimental|Esophageal stricture, Budesonide|Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR)
11394946|NCT02069847|No Intervention|Control group|Retrospective collect data for subjects who undergo endoscopic submucosal dissection or endoscopic mucosal resection
11394947|NCT02069834|Experimental|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
11394948|NCT02069834|Active Comparator|Arm 2 (control)|Continuation of existing HAART at the time of randomization
11394949|NCT02069821|Experimental|Group A|single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)
11394950|NCT02069821|Experimental|Group B|single administration : atorvastatin 40mg, qd, 7days(oral)
11394951|NCT02069808|Experimental|Group B: Follistim and Menopur|"Group B: N=25 subjects
~Cycle day 2 start Follistim 200 U/day up to 11 days duration.
~Cycle day 2 start Menopur (menotropins) 75 U/day up to 11 days duration.
~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.
~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.
~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
11394952|NCT02069808|Active Comparator|Group A: Follistim only|"Group A: N=25 subjects
~Cycle day 2 start Follistim 250 U/day up to 11 days duration.
~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.
~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.
~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
11394953|NCT02069795|Experimental|Voice recording|Subjects voices were recorded as they spoke specific words
11394954|NCT02069782|Experimental|Home visiting|Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.
11394955|NCT02069769|Experimental|communication with oncology team|oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
11394956|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
11394957|NCT02069743|Experimental|Intervention|The intervention group will use the study's mobile application during the 8-week study.
11394958|NCT02069743|No Intervention|Control|The control group will not use the study's mobile application during the study.
11394959|NCT02069730|Experimental|Unmatched Treatment (Selinexor)|"Selinexor, 30mg/m2, by mouth, twice weekly, every 28 day cycles.
~If patients have a druggable aberration but there is no access to the relevant agent, then patients will receive selinexor"
11394960|NCT02069730|Experimental|Matched Therapy|"EGFR or HER2 Inhibitor,FGFR Inhibitor,C-KIT Inhibitor, Anti-androgen ,NOTCH Inhibitor,MEK or PI3K Inhibitor .
~If the matched therapy is given through a clinical trial, the dosing schedule will be determined by that particular trial protocol. For matched treatments administered outside of a clinical trial, the dosing schedule will be the recommended dose by the expertise of the treating investigator."
11394961|NCT02069717||Not applicable-observational study|Not applicable-observational study
11394962|NCT02069704|Experimental|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
11394963|NCT02069704|Active Comparator|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
11394964|NCT02069691|Experimental|virtual reality-cycling training system|
11394965|NCT02069665|Experimental|Injection, medications and application|"Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd;
~Medications: according to TCM syndrome differentiations;
~Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough)
~Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm)
~External application: Fuxiong San"
11394966|NCT02069665|Active Comparator|Injection and medications|"Intravenous injection: Ribavirin Injection;
~Medications: symptomatic therapies
~Guaifenesin Syrup, for removing phlegm, relieving gasp-cough;
~Ibuprofen Suspension, and salbutamol in case of different symptoms"
11394967|NCT02069639||no treatment|
11394968|NCT02069626|Active Comparator|No wait|Usage of linear stapler without waiting of compression time
11394969|NCT02069626|Active Comparator|20 second wait|Usage of linear stapler with 20 second compression time
11394970|NCT02069626|Active Comparator|60 second wait|Usage of linear stapler with 60 second compression time
11394971|NCT02069613||Mild traumatic brain injury (mTBI)|Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).
11394972|NCT02069613||Control|Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI
11394973|NCT02069600|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
11394974|NCT02069600|No Intervention|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
11394975|NCT02069587|Experimental|Pomegranate|The women in this group will drink pomegranate juice
11394976|NCT02069574|Experimental|severe periodontitis group|non-surgical periodontal therapy
11394977|NCT02069574|Experimental|Moderate periodontitis group|non-surgical periodontal therapy
11394978|NCT02069574|No Intervention|healthy control|No treatment
11394979|NCT02069561|Experimental|Eicosapentaenoic Acid|Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days
11394980|NCT02069561|No Intervention|Normal controls|Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.
11394981|NCT02069548||Cervical dystonia|
11394982|NCT02069548||matched controlled subjects|matched in age (+/- 5 years) and gender
11394983|NCT02069535|Experimental|AVANZ Cupressus|AVANZ Cupressus
11394984|NCT02069522|Active Comparator|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
11394985|NCT02069522|Experimental|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
11394986|NCT02069509||Control research participants|diagnosis of FRDA genetically excluded
11394987|NCT02069509||FRDA patients|with genetically confirmed diagnosis of FRDA
11394988|NCT02069496||Subjects who receive Arepanrix®|Subjects who receive Arepanrix® as per routine practice
11394989|NCT02069483|Active Comparator|Motivational Interviewing|Subjects will engage in motivational interviewing and come up with messages to motivate quitting during the activity.
11394990|NCT02069483|Active Comparator|Tailored Feedback|Subjects will use reasons for quitting that they provided during the phone baseline for the text messages and audio recordings.
11394991|NCT02069470|Experimental|Continuing Medical Education|Continuing Medical Education
11394992|NCT02069470|No Intervention|Usual care|Usual care
11394993|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
11394994|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
11394995|NCT02069431|Experimental|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
11394996|NCT02069431|Placebo Comparator|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
11394997|NCT02069418|Experimental|Experimental arm|All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.
11394998|NCT02069405|Experimental|Music Group plus normal standard of care|Patients will listen to music prior and during the scan
11394999|NCT02069405|No Intervention|Control Group - Normal standard of care|
11395000|NCT02069392|Active Comparator|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
11395001|NCT02069392|Placebo Comparator|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
11395002|NCT02069379|No Intervention|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
11395003|NCT02069379|Experimental|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
11395004|NCT02069379|Placebo Comparator|Placebo|Placebo comparator to metformin treatment
11395005|NCT02069366|Placebo Comparator|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).
~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:
~PTSD-dronabinol (20)
~PTSD-placebo (20)
~TEC-dronabinol (20)
~TEC-placebo (20)
~HC-dronabinol (20)
~HC-placebo (20)"
11395006|NCT02069366|Active Comparator|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).
~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:
~PTSD-dronabinol (20)
~PTSD-placebo (20)
~TEC-dronabinol (20)
~TEC-placebo (20)
~HC-dronabinol (20)
~HC-placebo (20)"
11395007|NCT02069353|Experimental|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
11395008|NCT02069340|Experimental|Arm I (zoledronic acid over 15 minutes)|Patients receive zoledronic acid IV over 15 minutes on day 1.
11395009|NCT02069340|Experimental|Arm II (zoledronic acid over 30 minutes)|Patients receive zoledronic acid IV over 30 minutes on day 1.
11395010|NCT02069314|Experimental|Whey protein supplementation|50 grams of whey blended into frozen drink
11395011|NCT02069314|Experimental|Carbohydrate supplementation|50 grams of polycose blended into frozen drink
11395012|NCT02069301|Experimental|Integrated Depression/Microfinance Group|LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
11395013|NCT02069301|Other|Treatment as Usual|Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
11395014|NCT02069288|Experimental|1|Fludrocortisone
11395015|NCT02069288|Placebo Comparator|2|Placebo
11395016|NCT02069275|Experimental|Immediate mobilization|Immediate mobilization after coronary angiography or percutaneous coronary intervention
11395017|NCT02069275|Active Comparator|Two hours bedrest|Bedrest two hours after coronary angiography or percutaneous coronary intervention
11395018|NCT02069262|Experimental|angiography combination laparoscopy|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence. Those who developed rebleeding during the observation would be crossed over to the other investigation modality. Patients with negative findings on the initial assigned investigation but who developed rebleeding would undergo further investigation to localize the site of bleeding.
11395019|NCT02069262|Placebo Comparator|angiography alone|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
11395020|NCT02069249|Experimental|Healthy Nutrition Intervention|Healthy Nutrition Intervention (HNI)
11395021|NCT02069249|Experimental|Healthy Sleep Intervention|Healthy Sleep Intervention (HSI)
11395022|NCT02069249|No Intervention|Waiting list control|Waiting list control group
11395023|NCT02069236|No Intervention|G6PD Testing|All subjects receive G6PD test
11395024|NCT02069223|Active Comparator|Gastrectomy|Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.
11395025|NCT02069223|Active Comparator|BPD-DS|Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.
11395026|NCT02069223|Active Comparator|Gastrectomy+BPD-DS|Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.
11395027|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
11395028|NCT02069197|Active Comparator|Ketogenic diet, lifestyle counseling|ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction.
11395029|NCT02069197|Active Comparator|Orlistat, Lifestyle counseling|Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.
11395030|NCT02069197|Active Comparator|Standartized diet, Lifestyle counseling|Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.
11395031|NCT02069184|Experimental|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
11395032|NCT02069184|Experimental|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
11395033|NCT02069171||early ovarian cancer group|
11395034|NCT02069171||locally advanced cervical cancer group|
11395035|NCT02069171||primary endometrial cancer group|
11395036|NCT02069158|Experimental|PF-05212384, Carboplatin, Paclitaxel|starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC every 28 days Dose of Paclitaxel: 80 mg/m2 on days 1, 8 and 15
11395037|NCT02069145|Experimental|Drug: OMP-54F28, with Sorafenib|
11395038|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
11395039|NCT02069119|Experimental|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
11395040|NCT02069119|Placebo Comparator|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
11395041|NCT02069106|Experimental|Pro-Omega LDL|3 capsules 1000 mg BID for 8 weeks
11395042|NCT02069106|Placebo Comparator|Placebo|3 capsules BID for 8 weeks
11395043|NCT02069093|Experimental|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
11395044|NCT02069080|Experimental|1|All subjects are administered the study drug
11395045|NCT02069067||Advanced cancer patients with pain|
11395046|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
11395047|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
11395048|NCT02069054||Control|Healthy subjects
11395049|NCT02069041|Experimental|Ramucirumab + FOLFOX4|"8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles:
~FOLFOX4 every 2 weeks:
~85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2
~Participants may continue to receive treatment until discontinuation criteria are met."
11395050|NCT02069028||Low intensity intervention|human oriented interventions with less consideration to the system based act including, but not limited to, education, training, sepsis profile and posters with protocol algorithms.
11395051|NCT02069028||Intermediate intensity intervention|interventions that lie in between human oriented and system oriented Including, but not limited to, sepsis protocols, daily audits, feedback and clinical pathway
11395052|NCT02069028||High intensity intervention|system based interventions with less involvement of human effect including, but not limited to, electronic alert systems and sepsis response team.
11395053|NCT02069015|Experimental|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
11395054|NCT02069015|No Intervention|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
11395055|NCT02069002|Experimental|Cognitive-Behavioral Therapy (CBT)|"There will be ten (10) manualized session, fist 90 minutes and nine (9) 45-minute individual sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after the treatment. Sessions include psychoeducation about indoor air related symptoms and personal health behavior factors integrated on patients individual symptomatology, cognitive restructuring, behavioral experiments of patients health promoting behavior, imagery rescripting and relapse prevention.
~Intervention: Behavioral: Psychotherapy (CBT)"
11395091|NCT02068742|Experimental|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
11395909|NCT02063516|Experimental|Proseal|Device:Proseal Laryngeal Mask Airway
11395056|NCT02069002|Experimental|Applied relaxation group therapy|"There will be seven (7) manualized session, first 120 minutes and six (6) 90-minute group sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after treatment. Sessions include information about indoor air related symptoms, behavioral training and experiments focusing on applied relaxation technique and relapse prevention.
~Intervention: Behavioral: group therapy (ART)
~NB: The Applied Relaxation group Therapy won´t be carried out due to slow and prolonged recruiting process (A steering group agreement 4/2015 and the Ethics Committee approval 5/2015 for the change of the study plan)."
11395057|NCT02069002|Experimental|Information session (psychoeducation)|"There will be one (1) manualized 90-minute individual session. The session includes information about indoor air related symptoms and factors affecting individual health behavior.
~Intervention: Information session (psychoeducation)"
11395058|NCT02068989||Stress Hyperglycemic Group|Repeat HbA1C in 1 year
11395059|NCT02068989||Euglycemic Group|Repeat HbA1C in 1 year
11395060|NCT02068976||Women with Primary Ovarian Insufficiency|
11395061|NCT02068963||Study Population|
11395062|NCT02068950|Other|Progressive resistance training|12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand).
11395063|NCT02068937|Active Comparator|Control Group|In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
11395064|NCT02068937|Experimental|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
11395065|NCT02068924|Experimental|slow freezing|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
11395066|NCT02068924|Other|vitrification|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
11395067|NCT02068911||Monitoring of ETCO2 and PTCO2|All neuromuscular patients
11395068|NCT02068898|Experimental|XS003 Dose-level 1|Capsule formulation
11395069|NCT02068898|Experimental|XS003 Dose-level 2|Capsule formulation
11395070|NCT02068898|Experimental|XS003 Dose-level 3|Capsule formulation
11395071|NCT02068898|Experimental|Tasigna|Marketed capsule
11395072|NCT02068885|Experimental|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
11395073|NCT02068885|Experimental|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
11395074|NCT02068885|Active Comparator|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
11395075|NCT02068872|Experimental|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
11395076|NCT02068859|Experimental|Diclofenac Cream 8%|Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.
11395077|NCT02068859|Active Comparator|Control|Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks
11395078|NCT02068846|Active Comparator|Ciprofloxacin|Active treatment twice daily for 28 days
11395079|NCT02068846|Placebo Comparator|Placebo|Placebo treatment twice daily for 28 days
11395080|NCT02068833||Gastrectomy|Subjects in this group will undergo a gastrectomy only.
11395081|NCT02068833||BPD-DS|Subjects in this group will undergo a BPD-DS surgery.
11395082|NCT02068820|Active Comparator|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
11395083|NCT02068820|Experimental|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
11395084|NCT02068807|Active Comparator|Lutein drops|oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
11395085|NCT02068807|Placebo Comparator|Glucose drops|oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
11395086|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11395087|NCT02068781|Active Comparator|Start with low-sodium diet|One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
11395088|NCT02068781|Active Comparator|Start with high-sodium diet|One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
11395089|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
11395090|NCT02068755||Cardiac surgery|Patients who have undergone cardiac surgery
11395127|NCT02068482|No Intervention|1b USDD|Patients control, no drug
11395128|NCT02068482|No Intervention|Control group|Control Group, no disease, no drug
11395092|NCT02068742|Active Comparator|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
11395093|NCT02068716||Adults with HAIs|"Adult cardiac surgery patients who develop infections in hospitals within 30 days post surgery.
~We will exclude patients presenting with endocarditis."
11395094|NCT02068703|Active Comparator|Intervention|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools (face mask, ear plugs and white noise machine) to improve sleep.
11395095|NCT02068703|Placebo Comparator|Inert Control|Same 10 min time exposure and tool delivery to subjects in this arm WITHOUT demonstration.
11395096|NCT02068690|Experimental|BI 425809 single rising dose|BI 425809 powder for oral solution (PfOS) in single rising doses
11395097|NCT02068690|Experimental|BI 425809 Crossover|Bioavailability of BI 425809 PfOS
11395098|NCT02068677|Other|sympathetic response|This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
11395099|NCT02068677|Other|no sympathetic response|This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
11395100|NCT02068664||Observational|prism adaptation treatment
11395101|NCT02068651|Experimental|Advance care planning programme|Participants in the experimental group will receive a structured advance care planning programme, namely Let Me Talk, delivered by a trained nurse facilitator. The programme will be conducted on individual basis through three one-hour home visits, once weekly. Family carers of the participants will be invited to all sessions.
11395102|NCT02068651|No Intervention|Usual care|Participants in the control group will receive three weekly home visits with basic health assessment and education provided by the trained nurse facilitator. If they request advance care planning information or assistance, an advance directive form, which is available on the Internet for public access, will be provided to them for their information.
11395103|NCT02068638|Experimental|IHE first, CONT second, CSII and MDI therapy|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
11395104|NCT02068638|Experimental|CONT first, IHE second,CSII and MDI therapy|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
11395105|NCT02068638|Experimental|GLU first, GLUFRU second, CSII and MDI therapy|GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
11395106|NCT02068638|Experimental|GLU-FRU first, GLU second, CSII therapy|GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
11395107|NCT02068625|Experimental|Treatment|Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
11395108|NCT02068625|Placebo Comparator|Control|Patients getting perioperative oral treatment with placebo for 7 days
11395109|NCT02068612|Experimental|MICT + IT|Moderate Intensity Continuous Training+Interval Training
11395110|NCT02068612|Active Comparator|LICT|Low Intensity Continuous Training
11395111|NCT02068599|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
11395112|NCT02068599|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
11395113|NCT02068599|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
11395114|NCT02068586|Experimental|Sunitinib|Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity
11395115|NCT02068586|Experimental|Valproic acid|Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity
11395116|NCT02068573|Active Comparator|Ventilation|Increased ventilation in the childs bedroom to at least 2-3 air changes pr hour.
11395117|NCT02068573|Placebo Comparator|Placebo ventilation|Ventilation system that recirculates the air in the childs bedroom
11395118|NCT02068560|Experimental|dDAVP infusion|During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).
11395119|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
11395120|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
11395121|NCT02068534||survivors from charcoal-burning suicide|survivors from charcoal-burning suicide and at least above 20 years old.
11395122|NCT02068521|Experimental|Treatment naive subjects with GHD|Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
11395123|NCT02068521|Experimental|Subjects who have completed a somavaratan study|All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.
11395124|NCT02068508||Pioglitazone|Pioglitazone 15 mg to 30 mg, orally, once daily
11395125|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
11395126|NCT02068482|Active Comparator|1a USDD|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
11395129|NCT02068456||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved Korean label.
11395130|NCT02068443|Active Comparator|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
11395131|NCT02068443|Experimental|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
11395132|NCT02068443|Active Comparator|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
11395133|NCT02068430|Experimental|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
11395134|NCT02068417|Active Comparator|Shock wave treatment|Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
11395135|NCT02068417|Placebo Comparator|Placebo Shock wave treatment|Shock waves are prohibited to enter the body by placebo stand-off.
11395136|NCT02068404|Other|Nifedipine|
11395137|NCT02068391|Experimental|Exercise|This group will perform the 'Exercise Program' for months 0 to 6, and will be unsupervised for months 7 to 12.
11395138|NCT02068391|Active Comparator|Stretching|This group will perform the 'Stretching Program' for months 0 to 6, and the 'Exercise Program' for months 7 to 12.
11395139|NCT02068378|Experimental|CMPE Optical Sensor Device|Single arm study
11395140|NCT02068365|Other|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
11395141|NCT02068352|Experimental|0.3% OPA-15406|BID 0.3% OPA-15406 Ointment, N = 40
11395142|NCT02068352|Experimental|1% OPA-15406|BID 1% OPA-15406 Ointment, N = 40
11395143|NCT02068352|Placebo Comparator|Placebo|BID 0% Vehicle Ointment, N = 40
11395144|NCT02068339|Placebo Comparator|Placebo|Placebo Comparator / Tid (total 0mg)
11395145|NCT02068339|Experimental|Oltipraz 1|Total 90mg, by mouth, tid
11395146|NCT02068339|Experimental|Oltipraz 2|Total 120mg, by mouth, tid
11395147|NCT02068326|Experimental|Mentalization Based Treatment|"the experimental intervention is a year-long manualized program that comprises four components:
~Five individual case-formulation sessions,
~MBT-I, an introductory pedagogical program for patients (three weekly sessions)
~MBT-G, MBT-program in groups (37 weekly sessions)
~MBT-P, a psychoeducation program for the patients' parents or parents substitutes (six sessions)."
11395148|NCT02068326|Active Comparator|Treatment As Usual|Participants randomized to the control group will receive Treatment As Usual (TAU). TAU is defined as comprising at least 12 monthly individual supportive sessions provided by non-MBT trained mental health professionals in the Department of Child and Adolescent Psychiatry in Region Zealand. Additional supportive sessions or other types of intervention may be offered to the patients according to the needs of the patients as evaluated by mental health professionals responsible for his/hers treatment. Hence, TAU may vary considerably in number and type of intervention across clinics and patients. All mental health services delivered during the treatment period to patients in the TAU group will be monitored and registered.
11395149|NCT02068313||Single cohort|
11395150|NCT02068287|Experimental|ESMOLOL|Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.
11395151|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
11395152|NCT02068261|Experimental|Cogmed working memory training|30-40 minutes of Cogmed computerized working memory training 3-5 days a week for 5-8 weeks. Every training session consists of a set of visual- and verbal working memory tasks that are trained on during the session.
11395153|NCT02068261|Active Comparator|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
11395154|NCT02068235|Experimental|Pilot Phase|Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).
11395155|NCT02068235|Experimental|Treatment A/Treatment B|"Subjects will receive Treatment A followed by Treatment B.
~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.
~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.
~There will be a washout period between doses of 12-15 days."
11395156|NCT02068235|Experimental|Treatment B/Treatment A|"Subjects will receive Treatment B followed by Treatment A.
~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.
~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.
~There will be a washout period between doses of 12-15 days."
11395157|NCT02068222|Experimental|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
11395158|NCT02068209|Active Comparator|Tramadol|Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
11395159|NCT02068209|Placebo Comparator|Placebo|Patients will receive a placebo 1 hour before the procedure.
11395160|NCT02068196|Experimental|Ipilimumab|Ipilimumab 3mg/kg
11395202|NCT02067858|Other|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy
~Lesion dependent"
11395203|NCT02067845|Other|Pre-post test design|
11395267|NCT02067468|Active Comparator|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
11395161|NCT02068183||World Trade Center exposed group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the World Trade Center exposed group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
11395162|NCT02068183||Unexposed comparison group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the unexposed comparison group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
11395163|NCT02068170||patients treated with a potentional QT-prolonging drug|
11395164|NCT02068157|Experimental|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
11395165|NCT02068144|Experimental|Cranberry Extract|Cranberry Extract in a 15.2oz beverage daily for 8 weeks
11395166|NCT02068144|Placebo Comparator|Placebo|Placebo 15.2oz beverage daily for 8 weeks
11395167|NCT02068131|Experimental|Novaferon+ xeloda|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).
~Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
11395168|NCT02068118|No Intervention|Standard care|Standard follow-up, with conventional monitoring involving consultations and monitoring by their general practitioners or referring cardiologists
11395169|NCT02068118|Experimental|Tele-cardiology group|Telecardiology Program
11395170|NCT02068105|Experimental|ALKS 5461-A|
11395171|NCT02068105|Experimental|ALKS 5461-B|
11395172|NCT02068105|Experimental|ALKS 5461 Dose 1|
11395173|NCT02068105|Experimental|ALKS 5461 Dose 2|
11395174|NCT02068105|Experimental|ALKS 5461 Dose 3|
11395175|NCT02068105|Placebo Comparator|Placebo|
11395176|NCT02068092|Experimental|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
11395177|NCT02068079|Other|Vemurafenib and Trientine|
11395178|NCT02068053|Experimental|Arm A - BMS-986020|600 mg (approximately 80 micro Curie) of [14C] BMS-986020 Single Dose for 1 Day (Day 1) orally
11395179|NCT02068040|Experimental|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
11395180|NCT02068027|Experimental|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
11395181|NCT02068027|Placebo Comparator|Placebo|Placebo gel of identical appearance as active treatment
11395182|NCT02068001||RYGB|Food preference assessment in 100 patients at different timepoints, in a subset of 30 participants, also brain reward response to food cues will be assessed.
11395183|NCT02067988|Experimental|Treatment arm|Holmium-166 microspheres hepatic radioembolization, adjuvant to systemic 177Lu-dotatate.
11395184|NCT02067975|Active Comparator|tryptophan|6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3
11395185|NCT02067975|Placebo Comparator|Placebo|Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3.
11395186|NCT02067962|Other|Juvenile idiopathic arthritis.|Blood sample
11395187|NCT02067949|No Intervention|broad spectrum AB +fluids|Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES
11395188|NCT02067949|Active Comparator|simvastatin|50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)
11395189|NCT02067936|Active Comparator|Group A propofol + remifentanil|Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
11395190|NCT02067936|Active Comparator|Group B propofol + remifentanil|Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
11395191|NCT02067936|Active Comparator|Group C propofol + remifentanil|propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
11395192|NCT02067936|Active Comparator|group D propofol + remifentanil|propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
11395193|NCT02067923||Anti-CD3 mAb Plus Diabetes Standard of Care Group|This group of individuals received treatment in the original AbATE study.
11395194|NCT02067923||Diabetes Standard of Care Group|During the original AbATE study these individuals received standard care.
11395195|NCT02067910|Active Comparator|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
11395196|NCT02067910|Placebo Comparator|Placebo|First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
11395197|NCT02067897||Vandenbos procedure (skinfold excision)|Participants in this cohort will undergo with Vandenbos procedure (skinfold excision) for one or more ingrown toenails. This surgery will be formed as an day procedure under general anesthetic.
11395198|NCT02067884|Experimental|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
11395199|NCT02067871|Experimental|Electrical stimulation|"18-32 min of pulsed current.
~stimulation frequency of 80Hz (hertz).
~pulse duration of 200μs (microseconds).
~stimulation intensity fixed near to maximal tolerated."
11395200|NCT02067871|Experimental|Laser Therapy|"λ = 810 nm (nanometers)
~continuous wave
~200 mW (milliwatts) output power
~low-level laser therapy dose of 4-6J (Joules) per point
~six points at the knee joint"
11395201|NCT02067871|Experimental|Combined Treatment|"Electrical Stimulation:
~18-32 min of pulsed current,
~stimulation frequency of 80Hz (hertz).
~pulse duration of 200μs (microseconds).
~stimulation intensity fixed near to maximal tolerated.
~and
~Laser Therapy:
~λ = 810 nm (nanometers)
~continuous wave
~200 mW (milliwatts) output power
~low-level laser therapy dose of 4-6J (Joules) per point.
~six points at the knee joint."
11395268|NCT02067455|Other|LVAD patients|
11395204|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
11395205|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
11395206|NCT02067793|Placebo Comparator|Placebo|Placebo
11395207|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
11395208|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
11395209|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
11395210|NCT02067780|Experimental|The intervention (CRP-guided) group|500 mg (one tablet) of oral levofloxacin daily of levofloxacin for 7 days unless the serum CRP decrease by at least 50% from baseline value. Measurements of serum CRP were done at ED admission, at day-2, day-4 and day-6 and made available to the attending physicians.
11395211|NCT02067780|Experimental|The standard care (control) group|500 mg of levofloxacin per day for the first two days. Thereafter, oral tablet of placebo was prescribed according to CRP values as in CRP guided group to keep the blindness of the study.
11395212|NCT02067767|Experimental|Abacavir/Lamivudine/Dolutegravir|Patients switched from their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG.
11395213|NCT02067754||metastatic Cancer|metastatic gastrointestinal cancer, genitourinary cancer , rare cancer with treated any anti-cancer therapy
11395214|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
11395215|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
11395216|NCT02067728|Active Comparator|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
11395217|NCT02067728|Experimental|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
11395218|NCT02067715|Experimental|Sealed bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide. However, a customized tray will be placed over the bleaching agent during entire permanence of peroxide (45 minutes).
11395219|NCT02067715|Active Comparator|Conventional Bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
11395220|NCT02067702||Limb Cooling Assessment of ET Control|Healthy, volunteers with no known dermatological lesions, sensitivity to cold, or peripheral vascular disease.
11395221|NCT02067702||Limb Cooling Assessment of ET Experimental|Patients with known essential tremor for at least a year, and +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand.
11395222|NCT02067689|Experimental|Hemisphere Stimulation|Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
11395223|NCT02067689|Experimental|Temporal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
11395224|NCT02067689|Experimental|Frontal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the frontal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left frontal structures using 4x1 stimulation (e.g., 1mA left frontal, 1mA right frontal, sham; 2mA left frontal, 2mA right frontal, sham).
11395225|NCT02067689|Experimental|Parietal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the parietal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left parietal lobes using 4x1 stimulation (e.g., 1mA left parietal lobes, 1mA right parietal lobes, sham; 2mA parietal lobes, 2mA right parietal lobes, sham).
11395226|NCT02067689|Experimental|Supplementary Motor Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the Supplementary Motor Area at 1mA vs. 2mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left Supplementary Motor Area using 4x1 stimulation (e.g., 1mA left Supplementary Motor Area, 1mA right Supplementary Motor Area, sham; 2mA left Supplementary Motor Area, 2mA right Supplementary Motor Area, sham).
11395227|NCT02067689|Experimental|Brain Structure Interactions Group|This cohort will evaluate the interaction between frontal, parietal, temporal, and SMA regions in cognitive function. To accomplish this goal will require evaluation of change in cognitive and neurocognitive performance following transcranial direct current stimulation of different brain regions within the same subjects. For example, we will evaluate the contribution of frontal, SMA, and parietal regions by asking participants to undergo stimulation sessions at each of these sites, in addition to a sham session.
11395228|NCT02067676|Experimental|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
11395229|NCT02067676|Experimental|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
11395230|NCT02067676|Experimental|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
11395269|NCT02067442|Active Comparator|oral acetaminophen|Patients in this arm of the study will receive oral acetaminophen and an IV placebo
11395231|NCT02067676|Experimental|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
11395232|NCT02067676|Experimental|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
11395233|NCT02067676|Experimental|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
11395234|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
11395235|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
11395236|NCT02067637||Exposed|Individuals with one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer.
11395237|NCT02067637||Unexposed|Healthy controls
11395238|NCT02067624|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the wrist extensor groups muscle for 9 sessions
11395239|NCT02067624|Sham Comparator|Sham Ultrasound therapy|The participants will receive a thirty minutes session of sham ultrasound therapy onto the wrist extensor groups muscle for 9 sessions
11395240|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
11395241|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
11395242|NCT02067598|Experimental|Scapular exercise|The participants will receive thirty minutes session of scapular exercise for 12 sessions
11395243|NCT02067598|No Intervention|Control|
11395244|NCT02067585|Experimental|LAGB|Standardized Lipid meals will be served to Laparoscopic adjustable gastric banding patients.
11395245|NCT02067585|Experimental|LRYGB|Standardized Lipid meals will be served to the Laparoscopic Rou-en-Y gastric bypass patients.
11395246|NCT02067585|Experimental|Non-surgical|Standardized Lipid meals will be served to the non-surgical obese patients
11395247|NCT02067572|Experimental|Salvia|Salvia mouthwash used 4 times per day for 4 days
11395248|NCT02067572|Active Comparator|Saline|Saline mouthwash used 4 times per day for 4 days.
11395249|NCT02067559|Experimental|ICU Diaries|A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Instructions will be provided to the patient's family at the time of randomization and will be available at the bedside for reference. Staff instructions will be posted at charting area for staff. During the patient's stay in ICU, the diary will never leave the unit. Under no circumstances will any part of an ICU diary be duplicated. Research staff will take a photograph of the patient after consent is obtained and the photograph will be mounted on the first page of the diary. Photographs will be taken with a Polaroid camera; therefore there will be no other record of the photograph.
11395250|NCT02067559|Experimental|Psychoeducation|The research nurse will provide a psychoeducational brochure to study participants at ICU discharge (if cognitive capacity is established) or 30 days after ICU discharge. If participants are not well enough 30 days post-discharge, they will be assessed every two weeks by research staff until the brochure is given to them. The brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions. The document will also be mailed to the participant's follow-up physician.
11395251|NCT02067559|Experimental|ICU Diary plus Psychoeducation|Participants will receive both ICU diary and psychoeducation interventions, with both documents provided at ICU-discharge, or 30 days post-discharge as above.
11395252|NCT02067559|No Intervention|Treatment as Usual|No additional intervention to usual ICU care will be given.
11395253|NCT02067546|Experimental|Experimental toilet seat|Experimental toilet seat for 1 month
11395254|NCT02067546|Sham Comparator|Standard toilet seat|Standard toilet seat for 1 month
11395255|NCT02067533|Experimental|flexion position|
11395256|NCT02067533|Experimental|extension position|
11395257|NCT02067520|Other|IT hydromorphone dose|dose response study
11395258|NCT02067507|No Intervention|Control|"LACDPH Site: CDC-developed small media in preferred language
~AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation
~Northeast Valley Health Corporation Site: Usual care"
11395259|NCT02067507|Experimental|Tailored education and referral|LACDPH Site: Tailored education and referral intervention administered at LACDPH Site
11395260|NCT02067507|Experimental|Staff training and patient reminders|Staff training and patient reminders administered at AltaMed Health Services Corporation Site
11395261|NCT02067507|Experimental|Clinic-level reminder systems|Clinic-level reminders administered at Northeast Valley Health Corporation Site
11395262|NCT02067494|Experimental|Myofascial Soft Tissue Release|"Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
~Myofascial release assisted the paravertebral fascia."
11395263|NCT02067494|Active Comparator|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
11395264|NCT02067481|Experimental|Single-arm weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (AP) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment.
11395265|NCT02067468|Experimental|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
11395266|NCT02067468|Active Comparator|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
11395910|NCT02063503|Experimental|Motor control therapy|physiotherapy
11395270|NCT02067442|Active Comparator|intravenous acetaminophen|Patients in this arm of the study will receive IV acetaminophen and an oral placebo
11395271|NCT02067429|Experimental|Toric Intraocular lens|Toric intraocular lens implantation during standard cataract surgery
11395272|NCT02067429|Experimental|Limbal Relaxing Incisions|Limbal relaxing incisions during standard cataract surgery
11395273|NCT02067416|Active Comparator|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
11395274|NCT02067416|Active Comparator|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
11395275|NCT02067403|Experimental|Eadi optimized pressure-support|
11395276|NCT02067390||Vancomycin|Vancomycin
11395277|NCT02067390||Linezolid|Linezolid
11395278|NCT02067377|Placebo Comparator|inactive powder substance|inactive powder substance by mouth twice a day for 6 months
11395279|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medical food|SBI medical food 5 gr powder substance by mouth twice a day for 6 months
11395280|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medicalfood|SBI medical food 10 gr powder substance by mouth twice a day for 6 months
11395281|NCT02067364|Other|Fit & function test|CRT ShuntCheck sensors will be applied over the shunts of asymptomatic hydrocephalus patients. The device will be activated, cooling the skin under the sensor. Patients will change positions during the one hour procedure and data will be recorded. Data will be analyzed offline to identify product performance issues due to motion.
11395282|NCT02067351|Experimental|Mindfulness Intervention|Mindfulness intervention
11395283|NCT02067338|Placebo Comparator|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
11395284|NCT02067338|Active Comparator|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
11395285|NCT02067325|Experimental|Thai massage|The participants will receive thirty minutes session of Thai massage onto the trapezius muscle for 1 sessions
11395286|NCT02067325|Sham Comparator|Sham Microwave diathermy|The participants will receive thirty minutes session of Sham Microwave diathermy onto the trapezius muscle for 1 sessions
11395287|NCT02067312|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the trapezius muscle
11395288|NCT02067312|Sham Comparator|Sham Microwave diathermy|The participants will receive a thirty minutes session of Sham microwave diathermy onto the trapezius muscle
11395289|NCT02067299|Experimental|Cohort A|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of placebo (Period 1), JNJ-42847922 10 mg (Period 2), JNJ-42847922 20 mg (Period 3), and JNJ-42847922 40 mg (Period 4). Each treatment period and each subsequent treatment period will be separated by 1 week.
11395290|NCT02067299|Experimental|Cohort B|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 10 mg (Period 1), JNJ-42847922 40 mg (Period 2), placebo (Period 3), and JNJ-42847922 20 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
11395291|NCT02067299|Experimental|Cohort C|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 20 mg (Period 1), placebo (Period 2), JNJ-42847922 40 mg (Period 3), and JNJ-42847922 10 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
11395292|NCT02067299|Experimental|Cohort D|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 40 mg (Period 1), JNJ-42847922 20 mg (Period 2), JNJ-42847922 10 mg (Period 3), and placebo (Period 4). Each subsequent treatment period will be separated by 1 week.
11395293|NCT02067273|Experimental|TMS Intervention for 5 days|Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days
11395294|NCT02067273|Experimental|TMS Intervention for 1 day|Application of Transcranial Magnetic Stimulation (TMS) for 1 day
11395295|NCT02067260|Active Comparator|X5 HairLaser|
11395296|NCT02067260|Sham Comparator|X5 HairLaser Sham Device|
11395297|NCT02067247|Experimental|SOS forearm test|BeamMed Speed-of-Sound bone strength test at forearm
11395298|NCT02067234|Active Comparator|Routine Care/Education|Patient will be assessed by MD and provided education by nurse
11395299|NCT02067234|Experimental|Psychoeducation/Coping Prevention|Patient will be assessed by MD and will meet with psychologist to obtain psychoeducation about coping, behavioral strategies, and sleep hygiene
11395300|NCT02067221|Active Comparator|RIRS (retrograde intrarenal surgery)|Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
11395301|NCT02067221|Experimental|MPCNL (mini-perc)|"A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.
~Patients will be randomized and assigned to each group at the ratio 1:1"
11395302|NCT02067208|No Intervention|Waitlist Control|A waitlist control condition, where the participant receives no insole for 3 months. During this 3 month period, the participant will continue to be monitored for outcome variables.
11395303|NCT02067208|Experimental|Experimental wedged insole|Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
11395304|NCT02067195|Active Comparator|Guideline Hydration|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
11395331|NCT02066987|Experimental|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
11395305|NCT02067195|Active Comparator|Adequate Hydration|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
11395306|NCT02067182|Experimental|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.
~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:
~Patients aged 75 years or above
~Cr-Cl 30-50 ml/min
~Patients who receive concomitant verapamil
~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:
~Patients with moderate renal impairment
~Patients with gastritis, esophagitis or gastroesophageal reflux
~Other patients at increased risk of bleeding"
11395307|NCT02067182|No Intervention|No Oral Anticoagulation|
11395308|NCT02067169||CMV infection|allograft recipient with active CMV infection
11395309|NCT02067156|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
11395310|NCT02067143|Experimental|Study population|In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.
11395311|NCT02067130|Other|Fibroscan|Subjects enrolled will undergo Fibroscan. It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Fibroscan reading will be collected at the Gastroenterologist's (Dr. Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician. Anticipated timing of this procedure will be October to December 2013
11395312|NCT02067117|Experimental|influenza split vaccine|
11395313|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
11395314|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
11395315|NCT02067091|Active Comparator|BVS|Implantation of bioresorbable vascular scaffold in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
11395316|NCT02067091|Active Comparator|DES|Implantation of drug eluting stent in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
11395317|NCT02067078|Experimental|Combined saphenous nerve and obturator nerve block|
11395318|NCT02067078|Experimental|Saphenous nerve block|
11395319|NCT02067078|Active Comparator|Local infiltration analgesia|
11395320|NCT02067065|Experimental|Non-anesthesiologist propofol sedation|Bolus propofol sedation by non-anesthesiologist
11395321|NCT02067065|Active Comparator|Anesthesiologist administered propofol|Propofol sedation administered by an anesthesiologist
11395322|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
11395323|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
11395324|NCT02067039|Experimental|HIV self-testing|The intervention group of MSM (HIV negative or unaware of HIV status) will receive 4 rapid HIV test kits - 2 oral fluid tests (OraQuick), and 2 finger-stick blood tests (Sure Check). Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period, and men in the intervention arm will be allowed to order additional test kits to replenish the ones they use or give away. At month 12, all HIV-negative or those who are unaware of their HIV status participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a dried blood spot (DBS) specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
11395325|NCT02067039|No Intervention|Information only|All comparison group of MSM (HIV negative or unaware of HIV status) will take a baseline survey. Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period. At month 12, all HIV-negative and unaware of their HIV status comparison arm participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a DBS specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
11395326|NCT02067026|Experimental|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
11395327|NCT02067026|Placebo Comparator|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
11395328|NCT02067013|Active Comparator|Ranibizumab|Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
11395329|NCT02067013|Placebo Comparator|Control|Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).
11395330|NCT02067000||Obstructive Sleep Apnea|
11395332|NCT02066987|Experimental|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).
~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
11395333|NCT02066987|Active Comparator|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
11395334|NCT02066974||Hepatoma, Circulating tumor genome|Hepatoma requiring radiotherapy
11395335|NCT02066961||Cohort 1|Subjects with biochemical failure experience after primary treatment and have high-risk disease
11395336|NCT02066961||Cohort 2|Subjects with a medical diagnosis of castration-resistant prostate cancer
11395337|NCT02066961||Cohort 3|Subjects with an initial diagnosis of metastatic prostate cancer
11395338|NCT02066948|Active Comparator|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss&exercise e
11395339|NCT02066948|Active Comparator|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss&exercise
11395340|NCT02066935||kidney transplant patient|Kidney transplanted patients for at least one year
11395341|NCT02066922|Experimental|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
11395342|NCT02066922|Active Comparator|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
11395343|NCT02066909|Experimental|Cohort 1|Dosing in healthy Western subjects.
11395344|NCT02066909|Experimental|Cohort 2|Dosing in healthy Western subjects.
11395345|NCT02066909|Experimental|Cohort 3|Dosing in healthy Western subjects.
11395346|NCT02066909|Experimental|Cohort 4|Dosing in healthy Western subjects.
11395347|NCT02066909|Experimental|Cohort 5|Dosing in healthy Western subjects.
11395348|NCT02066909|Experimental|Cohort 6|Dosing in healthy Western subjects.
11395349|NCT02066909|Experimental|Cohort 7|Dosing in healthy Western subjects.
11395350|NCT02066909|Experimental|Optional Cohort 8|Dosing in healthy Western subjects. Cohort may not be conducted.
11395351|NCT02066909|Experimental|Cohort 9|Dosing in healthy Japanese subjects.
11395352|NCT02066896|Sham Comparator|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
11395353|NCT02066896|Active Comparator|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
11395354|NCT02066870|Experimental|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.
~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.
~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
11395355|NCT02066857|Active Comparator|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
11395356|NCT02066857|Active Comparator|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
11395357|NCT02066844|Active Comparator|Standard Manual Needle Injection|2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon
11395358|NCT02066844|Experimental|Navigator Injection|2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon
11395359|NCT02066831|Experimental|Telemedical Coaching|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal, which can be monitored by the participant and the coach. Health coaches which will have close phone contact to patients, supporting them to reduce weight and increase physical activity. In the first 12 weeks, patients will follow a formula diet (Almased) to achieve an initial weight reduction.
11395360|NCT02066831|Active Comparator|Telemedicine|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal which can be monitored by the participant.
11395361|NCT02066818|Active Comparator|Lidocaine Injection|Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
11395362|NCT02066818|Experimental|Lidocaine/tetracaine patch|Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
11395363|NCT02066805||Cohort 1|
11395364|NCT02066792|Experimental|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
11395365|NCT02066792|Active Comparator|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
11395366|NCT02066792|Placebo Comparator|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
11395367|NCT02066792|Active Comparator|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
11395368|NCT02066766||Subjects with diabetes mellitus (type 2)|
11395369|NCT02066753|Active Comparator|24 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.
11395370|NCT02066753|Experimental|48 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.
11395371|NCT02066740|Experimental|EverFlex™ stent with Entrust™ delivery system|
11395911|NCT02063503|Experimental|Isometric training therapy|physiotherapy
11395372|NCT02066727|Active Comparator|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
11395373|NCT02066727|Placebo Comparator|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
11395374|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
11395375|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
11395376|NCT02066701||Endoscopy Barrett's|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
11395377|NCT02066701||Endoscopy control|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
11395378|NCT02066688|Experimental|FA|Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm).
11395379|NCT02066688|Experimental|FA+Ca|Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm).
11395380|NCT02066688|Experimental|Ca|Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm).
11395381|NCT02066688|Placebo Comparator|blank control group|Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
11395382|NCT02066675|Experimental|Trabectedin|Trabectedin administered at the dose of 1.5 mg/mq-1.3 mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
11395383|NCT02066662|Experimental|Rivaroxaban|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing
11395384|NCT02066662|Active Comparator|Marcumar|Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
11395385|NCT02066649|Active Comparator|Carvedilol|Initiating patient on carvedilol after diagnosis of varices made on endoscopy
11395386|NCT02066649|Active Comparator|Variceal Band Ligation|performing variceal band ligation during endoscopy on patient after diagnosis of esophageal varices made on endoscopy
11395387|NCT02066649|Active Comparator|Combination Group (Carvedilol + Variceal band ligation)|once patient has confirmed large esophageal varices on endoscopy, he/she will be started on carvedilol (post-procedure) in addition to having variceal band ligation performed during endoscopy
11395388|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
11395389|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year (52 weeks).
~Discontinue treatment and at progression, retreatment allowed"
11395390|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
11395391|NCT02066610|Experimental|PN selenium and formula sodium selenate|Parenteral nutrition (PN) with selenium and sodium selenate supplementation of infant formula
11395392|NCT02066610|Experimental|PN selenium and formula sodium selenite|Parenteral nutrition (PN) with selenium and sodium selenite supplementation of infant formula
11395393|NCT02066610|Experimental|PN without selenium and formula sodium selenate|Parenteral nutrition (PN) without selenium and sodium selenate supplementation of infant formula
11395394|NCT02066610|Experimental|PN without selenium and formula sodium selenite|Parenteral nutrition (PN) without selenium and sodium selenite supplementation of infant formula
11395395|NCT02066597|Experimental|Intervention|
11395396|NCT02066584||Universal IVF Medium|An oocyte culture medium containing 5.55 Mm glucose (Origio, Medi-Cult)
11395397|NCT02066584||ISM1 Medium|An oocyte culture medium containing 1mM glucose ((Origio, MediCult)
11395398|NCT02066584||P1 Medium|An oocyte culture medium containing no glucose (Irvine)
11395399|NCT02066584||ECM Medium|An oocyte culture medium containing 0.5mM glucose (Irvine)
11395400|NCT02066571|Other|droxidopa, then sugar pill|Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
11395401|NCT02066571|Other|sugar pill, then droxidopa|Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
11395402|NCT02066558|Active Comparator|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
11395403|NCT02066558|Placebo Comparator|placebo|Atmospheric air
11395404|NCT02066545|Placebo Comparator|Vehicle Gel|
11395405|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
11395406|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
11395407|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
11395408|NCT02066532|Experimental|Ruxolitinib/Trastuzumab|Jakafi (Ruxolitinib) and Trastuzumab (Herceptin) - 21 day cycle until disease progression
11395409|NCT02066519|Experimental|Physical exercise arm|Arm with physical exercise on rowing machine between M3 and M6
11395410|NCT02066519|No Intervention|Control arm|Arm with standard medical care without additional physical exercise
11395411|NCT02066506|Sham Comparator|asymptomatic group|patients with systemic right ventricle who are asymptomatic,
11395412|NCT02066506|Sham Comparator|symptomatic group|symptomatic group : patients with systemic right ventricle and heart failure signs and/or decrease exercise performance
11395413|NCT02066506|Sham Comparator|control|healthy subject matched with patients of asymptomatic group
11395414|NCT02066493||conservative management|neither surgical nor endovascular management
11395415|NCT02066493||endovascular management|endovascular management
11395416|NCT02066493||surgical management|surgical management
11395417|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
11395418|NCT02066467||Heart failure patients|"Subjects with art failure who receive stable optimal pharmacologic therapy
~Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms
~Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.
~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
11395419|NCT02066454|Experimental|Apixaban|oral direct anti-Xa anticoagulant
11395420|NCT02066441|Experimental|Bio-D-Mulsion Forte®|Bio-D-Mulsion Forte® at a dosage level of 2 drops (4,000 IU) once daily for the 6-month treatment period.
11395421|NCT02066441|Placebo Comparator|Placebo|Placebo a dosage level of 2 drops once daily for the 6-month treatment period.
11395422|NCT02066428|Experimental|AERAS-404(50mcg H4/0nmol IC31) or Placebo|1 dose
11395423|NCT02066428|Experimental|AERAS404 (50mcgH4/100nmol IC31) or Placebo|1 dose
11395424|NCT02066428|Experimental|AERAS404 (50mcgH4/0nmol IC31) or Placebo|2 dose
11395425|NCT02066428|Experimental|AERAS404 (150mcgH4/0nmol IC31) or Placebo|1 dose
11395426|NCT02066428|Experimental|AERAS404 (50mcgH4/5000nmol IC31) or Placebo|1 dose
11395427|NCT02066428|Experimental|AERAS404 (50mcgH4/500nmol IC31) or Placebo|2 dose
11395428|NCT02066428|Experimental|AERAS404|2 dose placebo
11395429|NCT02066428|Experimental|AERAS404 (50mcg H4/100nmol IC31) or Placebo|2 dose
11395430|NCT02066415|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
11395431|NCT02066415|Experimental|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
11395432|NCT02066415|Placebo Comparator|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
11395433|NCT02066402|Experimental|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
11395434|NCT02066402|Active Comparator|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
11395435|NCT02066389|Placebo Comparator|Placebo|Participants received placebo capsules twice daily for 12 weeks.
11395436|NCT02066389|Experimental|Upadacitinib 3 mg BID|Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
11395437|NCT02066389|Experimental|Upadacitinib 6 mg BID|Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
11395438|NCT02066389|Experimental|Upadacitinib 12 mg BID|Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
11395439|NCT02066389|Experimental|Upadacitinib 18 mg BID|Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
11395440|NCT02066389|Experimental|Upadacitinib 24 mg QD|Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
11395441|NCT02066363|Active Comparator|Best nutritional Care|Best supportive nutritional care and dietician advise
11395442|NCT02066363|Experimental|Parenteral nutrition|Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.
11395443|NCT02066350|Experimental|Single pancreas transplantation|This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
11395444|NCT02066337|Placebo Comparator|placebo gel|scaling and root planing with placebo gel
11395445|NCT02066337|Active Comparator|Ozonated olive oil gel|scaling and root planing with Ozonated olive oil gel
11395446|NCT02066311|Experimental|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
11395447|NCT02066298|Experimental|Mometasone then Tiotropium then Placebo|Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
11395448|NCT02066298|Experimental|Mometasone then Placebo then Tiotropium|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
11395449|NCT02066298|Experimental|Placebo then Mometasone then Tiotropium|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
11395450|NCT02066298|Experimental|Placebo then Tiotropium then Mometasone|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
11395451|NCT02066298|Experimental|Tiotropium then Placebo then Mometasone|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
11395452|NCT02066298|Experimental|Tiotropium then Mometasone then Placebo|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
11395453|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
11395454|NCT02066272||IBD patients|IBD patients who start or re-start anti-TNF therapy
11395455|NCT02066259||healthy_0|healthy, people with normal (negative) colonoscopy results.
11395456|NCT02066259||patient_1|people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ
11395457|NCT02066259||benign_2|people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia
11395458|NCT02066246|Sham Comparator|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
11395459|NCT02066246|Active Comparator|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
11395460|NCT02066233|Active Comparator|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
11395461|NCT02066233|Active Comparator|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
11395462|NCT02066220|Experimental|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
11395463|NCT02066220|Experimental|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.
~Total treatment duration is 48 weeks."
11395464|NCT02066207|Experimental|Fenofibrate|Subjects received Fenofibrate
11395465|NCT02066207|Experimental|Atorvastatin|Subjects received Atorvastatin
11395466|NCT02066207|Experimental|Fenofibrate and Atorvastatin|Subjects received Fenofibrate and Atorvastatin
11395467|NCT02066194|Active Comparator|Electroacupuncture|Patients randomized to the experimental group will receive EA at acupoints relevant to the treatment of abdominal pain and anxiety. Selection of these acupoints is based on a consensus between the acupuncturist of the study (Leung WW) and several professors of the Diploma Course of Clinical Acupuncture of the School of Professional and Continuing Education, University of Hong Kong.
11395468|NCT02066194|Placebo Comparator|Sham Acupuncture|Patients randomized to the control group will receive Sham acupuncture with sterile blunt-tip needles
11395469|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
11395470|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
11395471|NCT02066155|Experimental|Parish nurse|On-going support provided by parish nurse
11395472|NCT02066155|Experimental|Peer support|On-going support provided by a person with diabetes
11395473|NCT02066155|No Intervention|Control group|No on-going support provided
11395474|NCT02066142|Active Comparator|Tomosynthesis|Tomosynthesis will be compared to Ultrasound
11395475|NCT02066142|Other|Ultrasound|Ultrasound (sensitivity and specificity) will be compared to Tomosynthesis
11395476|NCT02066129|Active Comparator|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
11395477|NCT02066129|Active Comparator|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
11395478|NCT02066116|Experimental|Kinect-based Rehabilitation|
11395479|NCT02066116|Active Comparator|Self-exercises education|
11395480|NCT02066103|Experimental|Treatment|
11395481|NCT02066090|Experimental|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
11395482|NCT02066090|Sham Comparator|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
11395483|NCT02066077|Experimental|Bilateral temporal and propofol|During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
11395484|NCT02066077|Experimental|Bilateral temporal and etomidate|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
11395485|NCT02066077|Experimental|The right temporal and propofol|During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
11395486|NCT02066077|Experimental|The right temporal and etomidate|During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
11395487|NCT02066077|Experimental|Bilateral frontal and propofol|During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
11395488|NCT02066077|Experimental|Bilateral frontal and etomidate|During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
11395489|NCT02066077|Active Comparator|Standard-therapy Group|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
11395490|NCT02066064|Experimental|Group A|Subjects will undergo complete standard colonoscopy, followed by G-EYE(TM) Colonoscopy
11395491|NCT02066064|Active Comparator|Group B|Subject will undergo G-EYE(TM) colonoscopy followed by standard colonoscopy
11395492|NCT02066051|Experimental|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
11395493|NCT02066038|Experimental|A|Pemetrexed 500mg/m2+Carboplatin area under curve(AUC)=5, every 3 weeks, maximum 4 cycles, Erlotinib 150mg/d every cycle d2-15, and Erlotinib 150mg/d from the last cycle until disease progression
11395494|NCT02066025||group_0|Women with negative mammography (BIRADS 1-2), as negative controls.
11395495|NCT02066025||group_1|Women with positive biopsy for (ID, IL, DCIS) as patients.
11395496|NCT02066025||group_2|Women with positive mammography (BIRADS 3-4-5-6), and a negative biopsy diagnosis for breast cancer (ID, IL, DCIS) will be enrolled as benign (ADH, ALH, LCIS, fibroadenoma, fibrocystic changes (including sclerosing adenosis), Benign papillaoma, normal breast) as benigns.
11395497|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
11395498|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
11395499|NCT02066012||group T|group T composed of lean subjects
11395500|NCT02065986|Experimental|Arm A: Immediate offer of Truvada-PrEP|Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
11395501|NCT02065986|Other|Arm B: Deferred (12m) offer of Truvada-PrEP|Access to Truvada from 12 months after enrolment
11395502|NCT02065973|Active Comparator|Cohort 1 (Low Dose)|The group will receive the lowest dose of the vaccine
11395503|NCT02065973|Active Comparator|Cohort 2 (Mid Dose)|The Group will receive the middle dose of the vaccine
11395504|NCT02065973|Active Comparator|Cohort 3 (High Dose)|The Group will receive the highest dose of vaccine to be tested
11395505|NCT02065960|Experimental|Stereotactic body radiotherapy (SBRT)|Radiotherapy with SBRT to a dose of 40 Gy in 5 fractions delivered every other day over a period of 10-12 days, followed by breast conserving surgery.
11395506|NCT02065947|Active Comparator|general anesthesia|fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
11395507|NCT02065947|Experimental|paravertebral block|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
11395508|NCT02065921||COPD patients|establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.
11395509|NCT02065895|Experimental|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
11395510|NCT02065895|Experimental|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
11395511|NCT02065895|Experimental|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
11395512|NCT02065895|Experimental|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
11395513|NCT02065895|Experimental|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
11395514|NCT02065895|Experimental|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
11395515|NCT02065882|Experimental|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
11395516|NCT02065869|Experimental|BPX-501 T cells and rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).
~Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
11395517|NCT02065856|Experimental|AVANZ Salsola kali|Subcutaneous immunotherapy
11395518|NCT02065843|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
11395519|NCT02065843|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
11395520|NCT02065843|Active Comparator|Passiflora incarnata|100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.
11395521|NCT02065843|Active Comparator|midazolam|15 mg midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.
11395522|NCT02065830|Experimental|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.
~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
11395523|NCT02065817|Experimental|Tracer|
11395524|NCT02065804|Experimental|Active drug|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
11395525|NCT02065804|Placebo Comparator|Placebo|10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
11395526|NCT02065791|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
11395527|NCT02065791|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily
11395528|NCT02065778|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
11395529|NCT02065752|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
11395530|NCT02065752|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
11395531|NCT02065752|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
11395532|NCT02065739|Experimental|Period 1|Participants will receive a single 30-mg dose of JNJ-42165279 on Day 1.
11395533|NCT02065739|Experimental|Period 2|Participants will receive itraconazole 200 mg once a day from Day 4 to Day 10. A single oral 30-mg dose of JNJ-42165279 will be administered on Day 8 along with the dose of 200 mg itraconazole.
11395534|NCT02065726|Experimental|Whey protein|Nutritional counseling + 20 g (2 x 10 g) of whey proteins (Prother® - Spepharm Italy)
11395535|NCT02065726|Active Comparator|Nutritional counseling|Nutritional counseling
11395536|NCT02065713|Experimental|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.
~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
11395537|NCT02065713|Active Comparator|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
11395538|NCT02065700|Experimental|Filgotinib 200 mg once daily|Filgotinib 200 mg (2 x 100 mg) once daily (morning)
11395539|NCT02065700|Experimental|Filgotinib 100 mg twice daily|Filgotinib 100 mg twice daily (morning and evening)
11395540|NCT02065687|Experimental|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
11395541|NCT02065687|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
11395542|NCT02065648||Syngo NATIVE MRA|All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
11395543|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
11395544|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
11395545|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-SD|Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
11395546|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-HD|Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
11395547|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-SD|Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
11395548|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-HD|Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
11395549|NCT02065622|Experimental|Maintenance (Main Study): TDM Regimen|Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
11395550|NCT02065609|Experimental|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
11395551|NCT02065609|Experimental|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
11395552|NCT02065596|Experimental|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
11395553|NCT02065583||GI abdominal surgery patients|Patients recovering from gastrointestinal abdominal surgery.
11395554|NCT02065570|Other|Arm 2 - Induction|Subjects are randomized to receive a standard induction regimen of adalimumab. After the induction regimen is provided, subjects in this arm will receive blinded adalimumab until Week 12. No placebo arm is planned.
11395555|NCT02065570|Other|Arm 2 Maintenance|Subjects are re-randomized at Week 14 to the therapeutic drug monitoring regimen.
11395556|NCT02065570|Other|Arm 1 - Induction|Subjects are randomized to receive a higher induction regimen of adalimumab. After the induction regimen is provided, subjects in this arm will receive blinded adalimumab until Week 12. No placebo arm is planned.
11395557|NCT02065570|Other|Arm 1 Maintenance|Subjects are re-randomized at Week 14 to a clinically adjusted regimen.
11395558|NCT02065557|Experimental|Adalimumab Induction Standard Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
11395559|NCT02065557|Experimental|Adalimumab Induction High Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
11395560|NCT02065557|Experimental|Adalimumab Induction High Dose - Open Label|(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
11395561|NCT02065557|Placebo Comparator|Maintenance Placebo|(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
11395562|NCT02065557|Experimental|Adalimumab Maintenance Standard Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg [maximum dose of 40 mg] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
11395563|NCT02065557|Experimental|Adalimumab Maintenance High Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg [maximum dose of 40 mg] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
11395564|NCT02065544|Experimental|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
11395565|NCT02065531|Experimental|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
11395566|NCT02065531|Active Comparator|Mobilization with impulse technique|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
11395567|NCT02065518|Active Comparator|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment supervised by a physical therapist at the physical therapy clinics.
11395568|NCT02065518|Experimental|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
11395569|NCT02065518|Experimental|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a weighted vest to begin the strengthening component.
11395570|NCT02065518|Experimental|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
11395571|NCT02065505|Experimental|Pilates Group Solo|participate in this group 30 individuals who will be treated with the Pilates Method performing the exercises on the ground, using the Swiss ball and elastic bands. The exercises will aim to lengthen the musculature that are shortened due to the characteristic postural pattern of pathology (major and minor pectoral, shoulder adductors, biceps, wrist flexors, trunk side chain); strengthen the musculature that provide postural support (abdominal, middle trapezius, rhomboids, gluteus maximus, erector spinae and latissimus dorsi) and the upper limb musculature important for activities of daily living (triceps, biceps, internal rotators, external rotators and abductors of the shoulder).
11395572|NCT02065505|Experimental|Water Pilates Group|participate in this group 30 individuals who will be treated with the Pilates method, but doing the exercises in the therapy pool, with the aid of floats and weights. The protocol of stretches and exercises will work the same muscle groups than the G1, keeping the same decubitus whenever possible. The adaptations to the exercises are justified by the physical principles of water, which at one point may act for or against the activity being performed.
11395573|NCT02065492|Experimental|Standard Chelation & Amlodipine|"This arm will receive both chelation and amlodipine.
~Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day.
~Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.
~The dosage will depend on individual requirement, as determined by the treating hematologist."
11395574|NCT02065492|Active Comparator|Standard Chelation|"Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.
~The dosage will depend on individual requirement, as determined by the treating hematologist.
~This will serve as the control arm of the study without any additional intervention."
11395575|NCT02065479|Active Comparator|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
11395576|NCT02065479|Experimental|Prasugrel|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
11395577|NCT02065466|Experimental|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
11395578|NCT02065453|Other|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
11395579|NCT02065453|Other|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
11395580|NCT02065440|Active Comparator|Ebastine/Pseudoephedrine|administration of ebastine/pseudoephedrine 1cap/day for 1 week.
11395581|NCT02065440|Placebo Comparator|placebo|administration of placebo pill 1 cap/day for 1week
11395582|NCT02065427|Experimental|Social support|"Social support intervention
~Intervention is performed by the health professionals working at the primary health care team responsible for the patient, and consisits of the following components:
~a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support."
11395583|NCT02065427|No Intervention|Usual home health care|Caregivers and dependent patients: usual home health care, consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request
11395584|NCT02065414|Placebo Comparator|Neg Control Mouth Rinse W002194-0221-P|"Mouth rinse containing 5% Hydroalcohol
~Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse W002194-0221-P for 30 seconds and spit it out."
11395585|NCT02065414|Experimental|Experimental: Mouth Rinse 19668-012|Listerine Advance Gum Defense Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
11395586|NCT02065414|Active Comparator|Active Comparator Mouth Rinse 5000347078873|"Mouth rinse containing Chlorhexidine Corsodyl ®Mouthwash
~Twice each day, brush in usual manner with a fluoride-containing dentifrice, in the usual manner, rinse mouth with water, wait 5 minutes after brushing and then rinse with 10 ml of mouth rinse 5000347078873for 60 seconds and spit it out - do not swallow."
11395587|NCT02065401|Experimental|Deferitazole (disodium salt, granule)|
11395588|NCT02065401|Experimental|Deferitazole (disodium salt, tablet)|
11395589|NCT02065401|Experimental|Deferitazole (magnesium hydroxide salt)|
11395590|NCT02065388|Active Comparator|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
11395591|NCT02065388|Experimental|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
11395592|NCT02065388|Experimental|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
11395593|NCT02065375|Experimental|RTA 408 0.5% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 0.5% or Placebo) in the study eye for 14 days
11395594|NCT02065375|Experimental|RTA 408 1.0% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 1.0% or Placebo) in the study eye for 14 days
11395595|NCT02065362|Experimental|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f
11395596|NCT02065349|Placebo Comparator|Placebo|oral
11395597|NCT02065349|Active Comparator|ASP8477|oral
11395598|NCT02065336|Experimental|ARC-520 Cohort 1|a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
11395599|NCT02065336|Placebo Comparator|ARC-520 Cohort 2|a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
11395600|NCT02065336|Experimental|ARC-520 Cohort 3|a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
11395601|NCT02065336|Experimental|ARC-520 Cohort 4|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
11395602|NCT02065336|Experimental|ARC-520 Cohort 5|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection
11395603|NCT02065336|Experimental|Placebo Normal Saline Cohorts 1-5|a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection
11395604|NCT02065336|Experimental|ARC-520 Cohort 6|two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV
11395605|NCT02065336|Experimental|ARC-520 Cohort 7|a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)
11395606|NCT02065336|Experimental|ARC-520 Cohort 8|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every [Q]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4
11395607|NCT02065336|Experimental|ARC-520 Cohort 9|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6
11395608|NCT02065336|Experimental|ARC-520 Cohort 10|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7
11395609|NCT02065336|Experimental|ARC-520 Cohort 11|a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
11395610|NCT02065336|Experimental|ARC-520 Cohort 12|a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
11395611|NCT02065323|Active Comparator|ADT alone|Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
11395612|NCT02065323|Experimental|ADT plus Dovitinib|"Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
~Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons."
11395613|NCT02065310|No Intervention|Diabetes, Non-diabetes|
11395614|NCT02065297||Horton's disease|
11395615|NCT02065297||Infectious disease|
11395616|NCT02065297||Neoplasia|
11395617|NCT02065297||Control|
11395618|NCT02065284|Active Comparator|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
11395619|NCT02065284|Active Comparator|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
11395620|NCT02065284|Active Comparator|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
11395621|NCT02065271|Experimental|herbal supplements|500mg, 3 per day, 4weeks
11395622|NCT02065271|Placebo Comparator|placebo|500mg, 3 per day, 4 weeks
11395623|NCT02065258|Active Comparator|Breathing Exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions and will be part of the routine of breathing exercises the following exercises: I) Kapalabhati ; II) Uddhiyana ;III) Surya Bedhana
11395624|NCT02065258|Active Comparator|Aerobic Exercise|Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
11395625|NCT02065245|Experimental|Pilot phase - Group 1|Group 1 (5 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million cells/ml delivered via peripheral intravenous infusion.
11395626|NCT02065245|Experimental|Pilot Phase - Group 2|Group 2 (5 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
11395627|NCT02065245|Experimental|Pilot Phase - Group 3|Group 3 (5 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million cells/ml delivered via peripheral intravenous infusion.
11395628|NCT02065245|Experimental|Randomized Phase - Group A|Group A (10 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
11395629|NCT02065245|Experimental|Randomized phase - Group B|Group B (10 subjects) - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million cells/ml delivered via peripheral intravenous infusion.
11395630|NCT02065245|Placebo Comparator|Randomized Phase - Group C|Group C (10 subjects) - Placebo delivered via peripheral intravenous infusion.
11395631|NCT02065245|Experimental|Addendum A - Pilot Phase 2nd Infusion|The pilot phase subjects will be able to receive one additional Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
11395632|NCT02065245|Experimental|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
11395633|NCT02065245|Experimental|Addendum C - Optional Follow-on Phase|"up to 2 additional doses for those that participated in Addendum A and up to 3 additional doses for subjects that took part in Addendum B.
~Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion."
11395634|NCT02065245|Experimental|Addendum D - Optional for Randomized Placebo|Randomized phase subjects that received Placebo will be able to receive one additional Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million cells/ml delivered via peripheral intravenous infusion.
11395635|NCT02065232||Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
11395636|NCT02065232||Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
11395637|NCT02065219|Experimental|Bupivacaine|injection, 25 mg, once, 5 min
11395638|NCT02065219|Placebo Comparator|Placebo|injection, 10 ml 0.9% sodium chloride, once, 5 min
11395639|NCT02065193||Beijing group|
11395640|NCT02065193||Guangdong group|
11395641|NCT02065193||Shenzhen group|
11395642|NCT02065193||Shanxi group|
11395643|NCT02065193||Liaoning group|
11395644|NCT02065193||Jilin group|
11395645|NCT02065193||Heilongjiang group|
11395646|NCT02065193||Jiangsu group|
11395647|NCT02065193||Zhejiang group|
11395648|NCT02065193||Fujian group|
11395649|NCT02065193||Henan group|
11395650|NCT02065193||Hubei group|
11395651|NCT02065193||Hunan group|
11395652|NCT02065193||'Shanxi group|
11395653|NCT02065180|Experimental|commercially available nutrition supplement|this group receives a commercially available nutritional supplement for a period of 2 months
11395654|NCT02065180|Placebo Comparator|control group|this group receives a placebo for a period of 2 months
11395655|NCT02065167|Experimental|Cultured autologous Mesenchymal Cells|"Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
~20x106 cells per cc in a single administration of 7cc"
11395656|NCT02065154|Experimental|Treatment|Cyclophosphamide (Cytoxan)
11395657|NCT02065141|Other|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.
~study day: stable isotope infusions with blood draws, sip feed"
11395658|NCT02065141|Other|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.
~study day: stable isotope infusions with blood draws, sip feed"
11395659|NCT02065141|Other|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.
~study day: stable isotope infusions with blood draws, sip feed"
11395660|NCT02065128||Healthy Volunteers|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
11395693|NCT02064920|Placebo Comparator|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
11395661|NCT02065128||Irritable Larynx Syndrome Patients|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
11395662|NCT02065115|Experimental|Cryotherapy|Cryotherapy: 12 ounces of crushed ice place in a plastic bag applied to the radial artery puncture area for 3 minutes
11395663|NCT02065115|No Intervention|Control|Cryotherapy is not applied to the radial artery puncture area
11395664|NCT02065089|Experimental|playing the ipad quiz game|There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game)
11395665|NCT02065076|Active Comparator|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
11395666|NCT02065076|Placebo Comparator|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
11395667|NCT02065063|Experimental|Part 1|Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
11395668|NCT02065063|Experimental|Part 2|Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.
11395669|NCT02065063|Experimental|Part 3|Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
11395670|NCT02065050|No Intervention|Usual Care|Individuals in the usual care arm will not receive frequent contact by the study team. Individuals will be seen by a study team clinician 1 year after discharge to review diabetes management and obtain pertinent study related data.
11395671|NCT02065050|Experimental|Continued care|team-based care: Individuals in the continued care arm will be frequently contacted by the study team (consisting of endocrinologists, nurse practitioners, and health coaches) over the course of one year post-discharge. The team will monitor blood sugars and other health data, altering management as needed.
11395672|NCT02065037|Experimental|Warmed Carbon Dioxide Insufflation|warmed carbon dioxide insufflation used in colonoscopy
11395673|NCT02065037|Active Comparator|Room Temperature Air Insufflation|room temperature air insufflation used in colonoscopy
11395674|NCT02065024|Active Comparator|b-cryptoxanthin plus phytosterols|Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols
11395675|NCT02065024|Placebo Comparator|control|Fruit and milk based beverage not enriched
11395676|NCT02065011|Other|Long-term follow up|Long-term follow up of patients who received SAR421869 in a previous study TDU13600
11395677|NCT02064998|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
11395678|NCT02064998|Experimental|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
11395679|NCT02064998|No Intervention|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
11395680|NCT02064998|Experimental|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
11395681|NCT02064998|Experimental|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
11395682|NCT02064985|Experimental|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
11395683|NCT02064985|Experimental|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
11395684|NCT02064985|Experimental|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
11395685|NCT02064972||Patients undergoing allo-HSCT, who manifest GvHD.|Patients undergoing allo-HSCT, that manifest GvHD. Patients undergoing allo-HSCT will have CEC count performed at the following timepoints: T1 (baseline), T2 (pre-transplant), T3 (engraftment), T4 (GvHD onset) and T5 (post-GvHD). All patients will also be checked for CEC at day + 28.
11395686|NCT02064959|Experimental|Hypothermia|Hypothermia to 33°C
11395687|NCT02064959|Active Comparator|Normothermia|standard care - normothermia (37°C)
11395688|NCT02064946|Active Comparator|Vitamin D3|Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
11395689|NCT02064946|Placebo Comparator|Control|Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
11395690|NCT02064933||Retrospective Cohort (Longitudinal Analysis)|Participants with WAS treated at consortium centers since 1990 who have received transplant (Stratum A) or gene therapy (Stratum B)
11395691|NCT02064933||Prospective Cohort (Longitudinal Analysis)|Participants treated at consortium centers since 1990 who will receive transplant (Stratum A) or gene therapy (Stratum B)
11395692|NCT02064933||Cross-Sectional Cohort (Cross-sectional Analysis)|Living participants with WAS who have received transplant (Stratum A) or gene therapy (Stratum B) at Consortium Centers 1990-Present And >= 2 Years Post-Transplant
11395694|NCT02064920|Experimental|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
11395695|NCT02064907|Experimental|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
11395696|NCT02064907|Experimental|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
11395697|NCT02064894|Experimental|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
11395698|NCT02064894|Experimental|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
11395699|NCT02064894|Active Comparator|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
11395700|NCT02064881|Experimental|metformin glycinate|"620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.
~Total study dose: 1240mg every 12 hours."
11395701|NCT02064881|Active Comparator|metformin hydrochloride|"500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.
~Total study dose: 1000mg every 12 hours."
11395702|NCT02064868|Experimental|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
11395703|NCT02064868|Other|Standard of Care (SOC)|All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
11395704|NCT02064842|Experimental|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
11395705|NCT02064842|Experimental|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
11395706|NCT02064842|Experimental|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
11395707|NCT02064842|Experimental|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
11395708|NCT02064842|Experimental|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
11395709|NCT02064842|Experimental|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
11395710|NCT02064842|Experimental|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
11395711|NCT02064842|Experimental|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
11395712|NCT02064842|Experimental|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
11395713|NCT02064829|Active Comparator|Reference Drug - Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1
11395714|NCT02064829|Experimental|Test Drug - IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1
11395715|NCT02064816|Experimental|Rebif® Morning Administration|
11395716|NCT02064816|Experimental|Rebif® Evening Administration|
11395717|NCT02064803|Active Comparator|Control group: A|Gastro-entero anastomosis only
11395718|NCT02064803|Experimental|Experimental: B|Gastric partitioning Plus Gastro-entero anastomosis
11395912|NCT02063503|Experimental|Combination therapy|physiotherapy
11395719|NCT02064790||Group G - receiving gabapentin|Receiving gabapentin as standard of care. No intervention
11395720|NCT02064790||Group P - receiving pregabalin|Receiving pregabalin as standard of care No intervention
11395721|NCT02064790||Group Z - no neuropathic agent|Receiving only conservative treatment No drug treatment No intervention
11395722|NCT02064777|Experimental|Tacrolimus|
11395723|NCT02064764|Active Comparator|Cryoablation only|Pulmonary vein isolation
11395724|NCT02064764|Experimental|Cryoablation and renal nerve denervation|Pulmonary vein isolation plus renal nerve denervation
11395725|NCT02064751|Experimental|MultiPoint Pacing|CRT with MultiPoint Pacing
11395726|NCT02064738|No Intervention|Normal diet|Two weeks of unaltered diet
11395727|NCT02064738|Experimental|Low omega-6/high omega-3 diet|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
11395728|NCT02064725|Experimental|Sodium cridanimod|Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
11395729|NCT02064712|Active Comparator|Low CPAP Wean|NCPAP weaned to 5cm H2O for minimum of 24h, and if the neonate remains clinically stable as defined, wean in 1cm increments to 3cm H2O for minimum of 24h, at which time move to room air or 1L/min nasal cannula if supplemental O2 is required.
11395730|NCT02064712|Active Comparator|High CPAP Wean|NCPAP weaned to 5cm H2O for a minimum of 24h, and if the neonate remains clinically stable, move to room air or 1L/min nasal cannula if supplemental O2 is required.
11395731|NCT02064699||CMV infection|Renal transplant recipient immunized against the Cytomegalovirus
11395732|NCT02064686|No Intervention|TAE|
11395733|NCT02064673|Active Comparator|Curcumin|Curcumin 500 mg orally twice a day
11395734|NCT02064673|Placebo Comparator|sugar pill|placebo orally twice a day
11395735|NCT02064660|Experimental|single arm|A series of acupressure sessions within six months from the baseline
11395736|NCT02064647|Experimental|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool, uses a formula based on the patients Insulin Sensitivity Factor (ISF) to allow adjustments to meal time insulin boluses, based on CGM trend arrows.
11395737|NCT02064647|Active Comparator|10/20% bolus adjustment|10-20% increase/decrease of the total original recommended bolus dose (10% for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose calculated by the pump calculator (i.e. Bolus Wizard).
11395738|NCT02064647|No Intervention|No adjustment/ignore trend arrows|Subjects will ignore the CGM trend arrows, meal time bolus insulin as per Bolus Wizard
11395739|NCT02064634||Shinbaro (only)|
11395740|NCT02064634||Celecoxib (only)|
11395741|NCT02064634||Shinbaro + NSAIDs|
11395742|NCT02064634||Shinbaro + Celecoxib|
11395743|NCT02064621|Experimental|C(Candesartan 32mg)|Candesartan 32mg 1T, PO, QD for 9days
11395744|NCT02064621|Experimental|B(Candesartan 32mg/Amlodipine 10mg)|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
11395745|NCT02064608|Experimental|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
11395746|NCT02064595|Other|Intramedullary nail|Fractures treated with intramedullary reamed nail
11395747|NCT02064595|Active Comparator|External fixator|Tibial fractures treated with biplanar external fixation
11395748|NCT02064582|Other|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
11395749|NCT02064569|Experimental|GS010|
11395750|NCT02064556|Experimental|A(Amlodipine 10mg)|Amlodipine 10mg 1T, PO, QD for 9days
11395751|NCT02064556|Experimental|B(Amlodipine 10mg/Candesartan 32mg)|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
11395752|NCT02064543||ADPM and GAITRite|mobility assessments (ADPM, GAITRite) measuring gait parameters
11395753|NCT02064530|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
11395754|NCT02064530|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
11395755|NCT02064530|Sham Comparator|serum phsyologic|0,9% 21 ml serum physiologic
11395756|NCT02064517|Placebo Comparator|Conventional technique|Apical MTA barrier
11395757|NCT02064517|Experimental|Revascularisation pulpaire|hydroxide of calcium
11395758|NCT02064504|Experimental|Sequence 1|Participants will receive the study treatment in the following order: ABFCED in each period (one per period). Where A=GSK961081 administered from DISKUS, B=GSK961081 Single strip (SS) administered from DPI, C=GSK961081 Dual Strip (DS) administered from DPI with a filled (lactose) second strip (DS configuration), D=GSK961081/fluticasone furoate (GSK961081/FF) administered from DPI (GSK961081 higher dose), E=FF DS administered from DPI with a filled (lactose) second strip (dual strip configuration), F=GSK961081/FF administered from DPI (GSK961081 lower dose).
11395759|NCT02064504|Experimental|Sequence 2|Participants will receive the study treatment in the following order: BCADFE in each period (one per period)
11395760|NCT02064504|Experimental|Sequence 3|Participants will receive the study treatment in the following order: CDBEAF in each period (one per period)
11395761|NCT02064504|Experimental|Sequence 4|Participants will receive the study treatment in the following order: DECFBA in each period (one per period)
11395762|NCT02064504|Experimental|Sequence 5|Participants will receive the study treatment in the following order: EFDACB in each period (one per period)
11395763|NCT02064504|Experimental|Sequence 6|Participants will receive the study treatment in the following order: FAEBDC in each period (one per period)
11395764|NCT02064491|Experimental|Erlotinib and Chemotherapy|Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance
11395765|NCT02064491|Active Comparator|Chemotherapy|Chemotherapy for four to six cycles
11395766|NCT02064478||Tissue preservation|Ponto implant installed using a tissue preservation surgical technique
11395767|NCT02064478||Tissue reduction|Ponto implant installed using a classical technique with skin thinning
11395768|NCT02064465|Experimental|Lamotrigine Dispersable/Chewable|lamotrigine dispersible/chewable tablet 100mg
11395770|NCT02064452|Experimental|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
11395771|NCT02064452|Placebo Comparator|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
11395772|NCT02064439|Experimental|Arm 1|Rivaroxaban 10 mg once daily for 12 months
11395773|NCT02064439|Experimental|Arm 2|Rivaroxaban 20 mg once daily for 12 months
11395774|NCT02064439|Active Comparator|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
11395775|NCT02064426|Experimental|Molidustat (BAY85-3934)|
11395776|NCT02064426|Active Comparator|Epoetin alfa/beta|
11395777|NCT02064413|Experimental|ESS310|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
11395778|NCT02064400||Observational study group|Musculoskeletal ultrasound (all patients) and semi-structured patient interview (anticipated maximum 15 patients)
11395779|NCT02064387|Experimental|Schedule 1 Part 1|Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
11395780|NCT02064387|Experimental|Schedule 2 Part 1|Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
11395781|NCT02064387|Experimental|Schedule 1 Part 2|Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
11395782|NCT02064387|Experimental|Schedule 2 Part 2|Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
11395783|NCT02064374|Experimental|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
11395784|NCT02064374|Experimental|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
11395785|NCT02064361|Experimental|High intensity exercise|A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling
11395786|NCT02064348|Experimental|Arm 1: semaglutide + moxifloxacin placebo|Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
11395787|NCT02064348|Active Comparator|Arm 2A:|"Semaglutide placebo + moxifloxacin/moxifloxacin placebo:
~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
11395788|NCT02064348|Experimental|Arm 2B:|"Semaglutide placebo + moxifloxacin placebo/moxifloxacin:
~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
11395789|NCT02064335|Experimental|Intervention group|"Physical activity coaching: Participants will be coached by a professional physical activity coach through individual and group sessions.
~Intake: This talk (1 hour) is the start of the coaching. A physical activity plan will be set up, according to the needs and possibilities of the participant. Activities in leisure time and daily physical activity will be included.
~Group sessions: During 5 weeks and one time a week, the subjects will take part in the exercise lessons. About 5 subjects will be in one group and all sessions are supervised by a professional physical activity coach. Activities are walking, Nordic walking and conditional fitness.
~Evaluation: After the 5 weeks of group sessions, an evaluation moment will take place between each participant and the physical activity coach. The physical activity plan will be refined."
11395790|NCT02064335|No Intervention|Control group|The control group will operate as a waiting group. It means that in the first 6 months of the project, the subjects of the control group will only be measured and will not receive any intervention.
11395791|NCT02064322||SImmetry Implant|Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant.
11395792|NCT02064309|Experimental|Human islets in Beta-Air device|
11395793|NCT02064296|No Intervention|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
11395794|NCT02064296|Active Comparator|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
11395795|NCT02064296|Active Comparator|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
11395796|NCT02064283|Experimental|Diffusion MRI Assessment|Men with newly diagnosed metastatic disease initiating therapy with androgen deprivation, or men with hormone refractory prostate cancer initiating treatment with chemotherapy, will be assessed by diffusion MRI (Magnetic Resonance Imaging) at baseline, 2 weeks and again at 9-12 weeks.
11395797|NCT02064270|Active Comparator|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
11395798|NCT02064270|Active Comparator|Standard dressings|Standard postsurgical dressings
11395799|NCT02064257|Experimental|Intervention group|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
11395800|NCT02064257|No Intervention|Assessment-only group|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
11395801|NCT02064244||Acute renal failure in ICU|Ultrasound for measurement of Inferior Vena Cava size
11395802|NCT02064231|Experimental|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
11395803|NCT02064231|Experimental|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
11395804|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
11395805|NCT02064218||healthy subjects|healthy subjects
11395806|NCT02064205|Active Comparator|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
11395807|NCT02064205|Placebo Comparator|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
11395808|NCT02064192||ICD Group (n=1500)|First ICD device implantation (after baseline assessments) is not part of this observational study and is carried out in the responsibility of the treating physician, all ICD-devices will undergo unique standard programming to ensure comparability of ICD shock events between patients.
11395809|NCT02064192||Control Group (n=750)|Patients who fulfill inclusion criteria but do not receive an ICD device will be followed as part of the Control Group
11395810|NCT02064166|Experimental|Insulin|40 IU of intranasal insulin daily
11395811|NCT02064166|Placebo Comparator|Placebo|Placebo arm using intranasal normal saline
11395812|NCT02064153|Active Comparator|Cool dialysate|Recruited study subject undergoes cool dialysate (35.5ºC) session.
11395813|NCT02064153|Active Comparator|Warm dialysate|Recruited study subject undergoes warm dialysate (37ºC) session.
11395814|NCT02064140|Experimental|Neuromuscular blocking agent|
11395815|NCT02064127||Patients with abdominal pain|Adult patients admitted to the Emergency Department with a main complaint of abdominal pain
11395816|NCT02064114|Active Comparator|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
11395817|NCT02064114|Active Comparator|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
11395818|NCT02064101||Adolescent idiopathic scoliosis|Patients with adolescent idiopathic scoliosis undergoing spinal fusion
11395819|NCT02064088|Experimental|Small volume|Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine
11395820|NCT02064088|Experimental|High volume|Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine
11395821|NCT02064075|Active Comparator|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day.
11395822|NCT02064075|Active Comparator|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day.
11395823|NCT02064062|Experimental|Autologous Mesenchymal Stem Cells|
11395824|NCT02064049|Experimental|Hepatitis C treatment|All prisoners (in participating correctional centres) with hepatitis c, as identified during the hepatitis C surveillance phase of the study will be offered treatment for hepatitis C. The treatment course is sofosbuvir/velpatasvir 400/100mg for 12 weeks (1 tablet once daily).
11395825|NCT02064036|Experimental|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
11395826|NCT02064023|Experimental|insulin pump|subjects will use an insulin pump for the duration of the pregnancy. The intervention is that they will control their diabetes using an insulin pump
11395827|NCT02064023|Active Comparator|Multiple Daily Insulin injections|subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
11395828|NCT02064010|Experimental|SNC-102, low dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
11395829|NCT02064010|Experimental|SNC-102, high dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
11395830|NCT02064010|Placebo Comparator|Placebo|Placebo tablet 4 week duration dosing
11395831|NCT02063997|Experimental|Arhalofenate 600 mg|
11395832|NCT02063997|Experimental|Arhalofenate 800 mg|
11395833|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
11395834|NCT02063997|Active Comparator|Allopurinol 300 mg|
11395835|NCT02063997|Placebo Comparator|Placebo|
11395836|NCT02063984|Experimental|Behavior Therapy + Hard Working Memory Training|Intensive Outpatient Treatment + Contingency Management, Hard (Adaptive) Working Memory Training (IOP + CM + HWMT)
11395837|NCT02063984|Active Comparator|Behavior Therapy|Intensive Outpatient Treatment + Contingency Management (IOP + CM)
11395838|NCT02063971|Experimental|Skin aging|Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day
11395839|NCT02063958|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period. Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. Dose escalation will not exceed a dose of 100 mg/m2 SNX-5422 qod even if the MTD has not been identified. Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.
11395869|NCT02063802|Placebo Comparator|Placebo and healthy habits program|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.
11396606|NCT02058927||HIV-1 uninfected children|control group of HIV-1 uninfected children matched by age
11395840|NCT02063945|Active Comparator|Methylphenidate|"Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills."
11395841|NCT02063945|Active Comparator|Risperidone|Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.
11395842|NCT02063932||endomicroscopy|
11395843|NCT02063919||endomicroscopy|
11395844|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
11395845|NCT02063893||non-vaccine|
11395846|NCT02063893||giving low vaccine|
11395847|NCT02063893||giving middle vaccine|
11395848|NCT02063893||giving high vaccine|
11395849|NCT02063880|Experimental|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.
~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
11395850|NCT02063880|Active Comparator|Early ART|Initiation of HAART 7-14 days after enrollment.
11395851|NCT02063867|No Intervention|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
11395852|NCT02063867|Active Comparator|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
11395853|NCT02063854|Active Comparator|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395854|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395855|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395856|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395857|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395858|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395859|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
11395860|NCT02063841|Active Comparator|sterile identical sham drape|Sham drape and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
11395861|NCT02063841|Experimental|lead-free protective drape containing bismuth and antimony|lead-free protective drape containing bismuth and antimony (RADPAD®) hung around the fluoroscopy image intensifier to prevent scatter radiation, and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
11395862|NCT02063828|Experimental|Group A|Group A - Device Guided Breathing Low Dose
11395863|NCT02063828|Active Comparator|Group B|Group B - Device guided breathing high dose
11395864|NCT02063828|Active Comparator|Group C|Group C - Usual Breathing Control Group
11395865|NCT02063815|Active Comparator|glass ionomer based fissure sealant|fissure sealant application
11395866|NCT02063815|Active Comparator|resin based fissure sealant|fissure sealant application
11395867|NCT02063802|Active Comparator|metformin and healthy habits program|1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
11395868|NCT02063802|Experimental|Conjugated Linoleic Acid and healthy habits|Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.
11395905|NCT02063555|Placebo Comparator|Sterile saline|Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
11395870|NCT02063789|Experimental|Human immunoglobulin intravenous|Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.
11395871|NCT02063776||Children on HDF|
11395872|NCT02063776||Children on conventional HD|
11395873|NCT02063750|Experimental|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
11395874|NCT02063750|Active Comparator|Stretching group|Performed stretching exercises
11395875|NCT02063737|Sham Comparator|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
11395876|NCT02063737|Experimental|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
11395877|NCT02063724|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
11395878|NCT02063711|Experimental|Yoga Intervention|A 1-hour yoga session will take place with guided instruction provided by a registered yoga instructor. The class includes a warm up period of 5 minutes, which includes sitting with the eyes closed and slowly breathing through the nose. After which the participant will perform a series of yoga postures in coordination with her breathing for approximately 45 minutes. The last 10 minutes of class will encompass a semi-recumbent relaxation period. This is a one time intervention.
11395879|NCT02063711|No Intervention|Control group|In order to control for 1 hour worth of time, the participants in the control group will be given a 1 hour Power Point presentation on the benefits of exercise and yoga during pregnancy.
11395880|NCT02063698|Experimental|Arm I (auranofin)|Patients receive auranofin PO on day 2.
11395881|NCT02063698|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 2.
11395882|NCT02063685|Other|GROUP 1 - STANDARD|R-CHOP or R-bendamustine + Standard Maintenance
11395883|NCT02063685|Experimental|GROUP 2|FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
11395884|NCT02063685|Experimental|GROUP 1a|FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation
11395885|NCT02063685|Experimental|GROUP 1b|FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4
11395886|NCT02063672|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
11395887|NCT02063672|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
11395888|NCT02063659|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
11395889|NCT02063659|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
11395890|NCT02063659|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
11395891|NCT02063646|Placebo Comparator|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
11395892|NCT02063646|Experimental|Polyphenol-rich extract|"The test product is a food supplement named Neurophenol. It is presented as a hard-shell capsule containing polyphenol-rich extracts.
~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
11395893|NCT02063620|Active Comparator|ketamine HCL|%0.5 Lidocaine+Ketamine HCL 0.8 mg/kg, total 40ml, single dose administration, 30 minute duration, total 200mg lidocaine
11395894|NCT02063620|No Intervention|lidocaine+ serum physiologic|% 0.5 lidocaine+ serum physiologic, total 40ml, total 200 mg lidocaine, 30 minute duration, single dose administration,
11395895|NCT02063607|Active Comparator|Peginterferon alfa 2a|Peginterferon alfa 2a 180 mcg
11395896|NCT02063607|Experimental|Peginterferon Lambda|Peginterferon Lambda 60,120,180 and 240 mcg
11395897|NCT02063594|Placebo Comparator|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
11395898|NCT02063594|Experimental|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
11395899|NCT02063581|Experimental|Sequence 1: Tablet followed by Capsule|
11395900|NCT02063581|Experimental|Sequence 2: Capsule followed by Tablet|
11395901|NCT02063568|Active Comparator|Low dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
11395902|NCT02063568|Active Comparator|High dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
11395903|NCT02063555|Experimental|DAR-901|"Intradermal administration at 0, 2 and 4 months
~Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
11395904|NCT02063555|Active Comparator|BCG|Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
11395913|NCT02063490|Experimental|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)
~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
11395914|NCT02063490|No Intervention|Control arm|Standard care
11395915|NCT02063477|Placebo Comparator|Product one|150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)
11395916|NCT02063477|Active Comparator|Product two|150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)
11395917|NCT02063464||Cohort 1|Subjects w/ovarian, primary peritoneal or fallopian tube ca who are not currently on therapy and are screening for trials, being seen in consultation, or presenting for enrollment on a trial.
11395918|NCT02063451|Other|Obese, Weight Loss, Very Low Calorie Diet|Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
11395919|NCT02063451|No Intervention|Lean, baseline measure|MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
11395920|NCT02063438|Active Comparator|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
11395921|NCT02063438|Active Comparator|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
11395922|NCT02063425|Active Comparator|Fluoxetine|
11395923|NCT02063425|Placebo Comparator|Placebo|
11395924|NCT02063412||XELOX|Capecitabine (Xeloda) 1000mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
11395925|NCT02063412||XP|Cisplatin (CDDP) 80 mg/m2 iv over 3 hrs d1 Capecitabine (Xeloda) 1000 mg/m2 po bid d1-14, Q3w
11395926|NCT02063412||FOLFOX|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and d2 5-FU 400mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d1 and d2 Q2w
11395927|NCT02063412||FP|Cisplatin (CDDP) 100 mg/m2 iv d1 5-FU 1000 mg/m2/d civi d1-5, Q4w
11395928|NCT02063386|Experimental|AZD1722|Single oral dose 15 mg of [14C]AZD1722
11395929|NCT02063373|Experimental|biomechanis knee OA and HA injection|Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks
11395930|NCT02063360|Experimental|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
11395931|NCT02063360|Experimental|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
11395932|NCT02063360|Experimental|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
11395933|NCT02063347||Coronary artery disease|With coronary artery disease
11395934|NCT02063347||No coronary artery disease|Without coronary artery disease
11395935|NCT02063334|Active Comparator|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
11395936|NCT02063334|Placebo Comparator|Placebo|Placebo in two doses during one day
11395937|NCT02063308|Experimental|Oxaloacetate (OAA)|100 mg OAA to be taken twice daily over the course of a month
11395938|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
11395939|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
11395940|NCT02063282||Clostridium difficile carriers|
11395941|NCT02063282||Clostridium difficile non carriers|
11395942|NCT02063269|Experimental|Rivastigmine|Rivastigmine
11395943|NCT02063256|Active Comparator|7 NUTS a day|the patients allocated to this arm will be instructed to supplement their diet with 7 nuts a day (whole shelled weight around 75 grams)
11395944|NCT02063256|Experimental|Diet modification|the patients allocated to this arm will be instructed to modify their diet allowing more intake of PUFA rich food avoiding saturated fat rich food
11395945|NCT02063243|Other|keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
11395946|NCT02063230|Experimental|Selumetinib HV|Healthy volunteers (HV)
11395947|NCT02063230|Experimental|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
11395948|NCT02063230|Experimental|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
11395949|NCT02063230|Experimental|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
11395950|NCT02063217|Experimental|Sleep Induction|7.5 grams of sodium oxybate
11395951|NCT02063217|Experimental|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
11395952|NCT02063217|No Intervention|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
11395953|NCT02063204|Experimental|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
11395954|NCT02063204|Experimental|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
11395955|NCT02063204|Experimental|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
11395956|NCT02063191||Atrial Fibrillation|Patients with atrial fibrillation during the EP study
11395957|NCT02063191||Bundle Branch Block|Patient with bundle branch block during the course of the EP study
11396720|NCT02058199|Experimental|Obese non bypassed|A single dose of rivaroxaban will be administered
11395958|NCT02063178|Experimental|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
11395959|NCT02063178|Active Comparator|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
11395960|NCT02063152||Entire Taiwan women|
11395961|NCT02063139|Experimental|Flutiform 50/5 ug (2 puffs bid) pMDI|Flutiform 50/5 ug (2 puffs bid) pMDI
11395962|NCT02063139|Active Comparator|Fluticasone 50 ug (2puffs bid) pMDI|Fluticasone 50 ug (2puffs bid) pMDI
11395963|NCT02063139|Other|Beclometasone Autohaler 50 ug (2 puffs bid)|Active control
11395964|NCT02063126|Active Comparator|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
11395965|NCT02063126|Placebo Comparator|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
11395966|NCT02063113|No Intervention|NA/NA|
11395967|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 100mg|
11395968|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 50mg|
11395969|NCT02063100|Experimental|Losartan potassium 50mg|
11395970|NCT02063100|Experimental|Shenyankangfu tablets|
11395971|NCT02063100|Experimental|Losartan potassium 100mg|
11395972|NCT02063087|Active Comparator|Decision Aid|Head CT Decision Aid
11395973|NCT02063087|No Intervention|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
11395974|NCT02063061|Sham Comparator|Sham treatment|Subject will answer standardized questionnaires. Sham treatment arm will receive initially 5 sham series and after they answer standardized questionnaires they will receive 5 series of active treatment. Afterwards patients will answer standardized questionnaires again.
11395975|NCT02063061|Active Comparator|ESWT treatment|Subject will answer standardized questionnaires. Subjects will receive 10 treatments with ESWT. Afterwards patients will answer standardized questionnaires again.
11395976|NCT02063048|No Intervention|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
11395977|NCT02063048|Experimental|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
11395978|NCT02063035|Experimental|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
11395979|NCT02063035|Placebo Comparator|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
11395980|NCT02063022|Active Comparator|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).
~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
11395981|NCT02063022|Experimental|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
11395982|NCT02063009||patients scheduled for oncologic high-risk surgery|
11395983|NCT02062996|Experimental|ENT - full strength|Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
11395984|NCT02062996|Experimental|ENT - 1/2 strength|½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
11395985|NCT02062996|Experimental|DENTAL - Full strength 1.0 mL|Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).
11395986|NCT02062996|Experimental|DENTAL - Full strength 0.5 mL|Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).
11395987|NCT02062996|Experimental|DENTAL - ½ strength 0.5 mL|½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).
11395988|NCT02062983||Herceptin|The study will be carried in prospective manner enrolling all patients diagnosed with breast cancer and over expressed human epidermal growth factor receptor 2 (HER2) and they are requiring Trastuzumab Neu adjuvant/ adjuvant /metastatic therapy as per standard care.
11395989|NCT02062970|Experimental|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
11396721|NCT02058199|Experimental|obese bypassed|A single dose of rivaroxaban will be administered
11395990|NCT02062944|Experimental|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
11395991|NCT02062931|Experimental|Stem Cell Preparation and Injection|"Stem Cell Preparation and Injection:
~Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .
~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
11395992|NCT02062918|No Intervention|Control group|Patients in the control group did not use an abdominal belt.
11395993|NCT02062918|Experimental|Experimental group|Patients were instructed in how to use the abdominal belt for activities of physical effort that exacerbated lumbar pain as well as during moments of pain, and not to use it during rest. They should record the number of hours of belt use per day on spreadsheets distributed for this purpose.
11395994|NCT02062905|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
11395995|NCT02062905|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
11395996|NCT02062892|Experimental|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
11395997|NCT02062892|Active Comparator|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
11395998|NCT02062879|Experimental|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
11395999|NCT02062879|Active Comparator|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
11396000|NCT02062866|Active Comparator|Purse-String|Surgical wounds are healed via suturing.
11396001|NCT02062866|Active Comparator|Second Intent|Surgical wounds are allowed to heal without sutures.
11396002|NCT02062853|Experimental|Video Group|Subjects view educational video on the use of cream medication for the treatment of actinic keratoses.
11396003|NCT02062853|Active Comparator|Verbal Group|Subjects are given verbal instructions on the use of cream medication for the treatment of actinic keratoses.
11396004|NCT02062840|Experimental|High intensity whole-body infrared heating and Neuroimaging|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
11396005|NCT02062840|Sham Comparator|Low intensity whole-body infrared heating and|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH-control intervention where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
11396006|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
11396007|NCT02062801|Active Comparator|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
11396008|NCT02062801|Placebo Comparator|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
11396009|NCT02062788|Experimental|ORS group|Oral rehydration solution (ORS) treated group
11396010|NCT02062788|No Intervention|Non-ORS group|Oral rehydration solution (ORS) untreated group
11396011|NCT02062775|Active Comparator|Self-Fixating Hernia Mesh|Self-fixating polyester mesh will be used for laparoscopic inguinal hernia repair.
11396012|NCT02062775|Placebo Comparator|Non-Fixating Hernia Mesh|Non-fixating polyester mesh will be used for laparoscopic hernia repair.
11396013|NCT02062762|Experimental|Online-MBSR|8 week mindfulness based stress reduction online
11396014|NCT02062762|Active Comparator|Expressive Writing Online|Online distributed expressive writing intervention as active control
11396015|NCT02062749|Experimental|Hyperthermic Intraperitoneal Chemotherapy|After cytoreductive surgery and lysis of adhesions, two large bore catheters are placed in the peritoneal cavity through the incision. Thirty minutes before HIPEC is begun, body temperature is cooled to 35°C. ). The catheters are connected to a perfusion circuit. Heated Oxaliplatin is added to the perfusate administered over 90 minutes. The starting dose of Oxaliplatin is 175 mg/m2.
11396016|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
11396017|NCT02062723||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
11396018|NCT02062710|Experimental|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).
~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
11396019|NCT02062710|Experimental|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).
~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
11397063|NCT02056041||Hepatectomy for HCC|Patients submitted to surgery for HCC
11396020|NCT02062710|Experimental|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
11396021|NCT02062710|Experimental|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).
~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
11396022|NCT02062710|Experimental|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
11396023|NCT02062710|Experimental|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
11396024|NCT02062697|Other|Ovarian Epithelial Cancer|"Lavage of the Cavum uteri and proximal fallopian tubes
~Liquid-PAP (Papanicolaou) smear"
11396025|NCT02062684|Experimental|Blisibimod|Blisibimod administered subcutaneously
11396026|NCT02062684|Placebo Comparator|Placebo|Placebo administered subcutaneously
11396027|NCT02062671|Experimental|immediate renal denervation|immediate renal denervation
11396028|NCT02062671|Active Comparator|delayed renal denervation|delayed renal denervation
11396029|NCT02062658|Experimental|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
11396030|NCT02062645|Experimental|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
11396031|NCT02062632|Experimental|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
11396032|NCT02062632|Placebo Comparator|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
11396033|NCT02062619|Experimental|Real tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.
~2mA anodal direct current stimulation applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
11396034|NCT02062619|Sham Comparator|Sham tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.
~Sham tDCS (periodical fade-in and fade-out stimulation routine) applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
11396035|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
11396036|NCT02062593|Active Comparator|Coronary angioplasty and optimum medical therapy|Percutaneous coronary intervention and optimal medical therapy
11396037|NCT02062593|Placebo Comparator|Sham procedure and optimum medical therapy|Placebo percutaneous coronary intervention and optimal medical therapy with risk factor modification and anti-anginal therapy
11396038|NCT02062580|Active Comparator|Delayed BCG|BCG delayed to 8 weeks of age
11396039|NCT02062580|Other|Early BCG|BCG at birth; standard of care
11396040|NCT02062567||Acute Achilles tendon rupture|
11396041|NCT02062541|Experimental|Funct. assessment+fast rehabilitation|Funct. assessment+fast rehabilitation
11396042|NCT02062541|Experimental|Funct. assessment+usual rehabilitation|Funct. assessment+usual rehabilitation
11396043|NCT02062541|Experimental|usual assessment+fast rehabilitation|usual assessment+fast rehabilitation
11396044|NCT02062541|No Intervention|usual assessment+usual rehabilitation|usual assessment+usual rehabilitation
11396045|NCT02062528|Experimental|omega-3 fatty acids|3 capsules each day during 8 weeks
11396046|NCT02062528|Placebo Comparator|placebo|3 capsules each day during 8 weeks
11396047|NCT02062515|Experimental|Icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
11396048|NCT02062502|Experimental|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
11396049|NCT02062502|Active Comparator|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
11396050|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
11396051|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
11396052|NCT02062476|Experimental|Treatment with Lactobacillus GG|extensively hydrolyzed casein formula containing LGG
11396053|NCT02062476|No Intervention|Children at diagnosis|
11396054|NCT02062463|Active Comparator|SPIROMAX|"Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.
~Participants receiving 800 mcg to 1000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 640 mcg and 18 mcg, respectively."
11396094|NCT02062242|Experimental|Transvaginal electrical stimulation|Patients treated with transvaginal electrical stimulation.
11396095|NCT02062242|Experimental|Palpation|Patients treated with vaginal palpation.
11396096|NCT02062242|Experimental|Palpation with posterior pelvic tilt|Patients treated with vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles.
11396055|NCT02062463|Active Comparator|TURBOHALER|"Period 1 of this study will comprise a single visit wherein mastery of inhaler technique will be assessed. Empty training devices will be utilized for this period. Period 2 dosage will be equivalent to that received via the participants current device at baseline.
~Participants receiving 1600 mcg to 2000 mcg budesonide diphosphate (BDP)-equivalent inhaled corticosteroids at study entry will receive budesonide and formoterol at daily doses of 1280 mcg and 36 mcg, respectively."
11396056|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
11396057|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
11396058|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
11396059|NCT02062424|Active Comparator|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
11396060|NCT02062424|Active Comparator|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
11396061|NCT02062424|No Intervention|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
11396062|NCT02062411|Experimental|CBT with booster sessions|Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol.
11396063|NCT02062411|Active Comparator|CBT only|Participants will only receive 12 cognitive-behavioral therapy sessions weekly.
11396064|NCT02062411|No Intervention|waiting|Participations will not be treated with CBT and keep waiting for 12 weeks for comparison.
11396065|NCT02062398|Experimental|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
11396066|NCT02062385|Experimental|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
11396067|NCT02062385|Placebo Comparator|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
11396068|NCT02062385|Experimental|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
11396069|NCT02062385|Placebo Comparator|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
11396070|NCT02062372|Experimental|Biopsy|Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies
11396071|NCT02062359|Experimental|All Participants|Patients will receive the standard National Cancer Institute (NCI) Surgery Branch non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of the anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ engineered peripheral blood lymphocyte (PBL) and aldesleukin
11396072|NCT02062346|Placebo Comparator|Placebo|Saline placebo
11396073|NCT02062346|Experimental|BQ123|Intravenous infusion of BQ123 1000nmol/min for 15min
11396074|NCT02062346|Experimental|BQ123/788|Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min
11396075|NCT02062346|No Intervention|Assessment of forearm vascular function|Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators
11396076|NCT02062333|Active Comparator|dexmedetomidine|0,4-0,8 µg./kg./h dexmedetomidine
11396077|NCT02062333|Active Comparator|esmolol|100- 300 µg./kg./min esmolol
11396078|NCT02062320||PRE-PCAPS|Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010
11396079|NCT02062320||POST-PCAPS|Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011.
11396080|NCT02062307||control patients|BMI and age matched healthy male subjects
11396081|NCT02062307||hypogonadism patients|unconfounded group of patients with hypogonadism
11396082|NCT02062294||Cohort|
11396083|NCT02062281|Active Comparator|23-valent Pneumococcal Polysaccharide vaccine|"0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.
~lot number: 20130106-1, duration:JAN,17,2015."
11396084|NCT02062281|Active Comparator|Trivalent Influenza Vaccine|"0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.
~lot number:20130713, duration:Jul,1,2014."
11396085|NCT02062281|Experimental|23vPPV+TIV|
11396086|NCT02062268||Urban area in South Jiangsu Province|health education & law enforcement
11396087|NCT02062268||urban area in Middle Jiangsu Province|health education & law enforcement
11396088|NCT02062268||urban area in North Jiangsu Province|health education & law enforcement
11396089|NCT02062268||rural area in South Jiangsu Province|health education & law enforcement
11396090|NCT02062268||rural area in North Jiangsu Province|health education & law enforcement
11396091|NCT02062255|Active Comparator|Aspirin|Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.
11396092|NCT02062255|Active Comparator|Omega-3 Free Fatty Acids|Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
11396093|NCT02062255|Active Comparator|Aspirin & Omega-3 FFAs|Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.
11396267|NCT02061124|Active Comparator|T2DM, sevelamer|Patients with type 2 diabetes treated with sevelamer
11396097|NCT02062242|Experimental|Control group|Patients receive verbal instructions related to the pelvic floor and its contraction.
11396098|NCT02062229||Halthy controls|Subjects not affected by any disease and with normal seminal fluid characteristics
11396099|NCT02062229||Oligospermia|Infertile subjects with oligospermia
11396100|NCT02062229||Varicocele|Infertile subjects with varicocele
11396101|NCT02062229||Asthenospermia|Infertile subjects with asthenospermia
11396102|NCT02062216||STEMI|Patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (PCI)
11396103|NCT02062216||STABLE ANGINA|Patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with Class I indication to elective percutaneous coronary intervention
11396104|NCT02062203|Experimental|AKB-6548 (therapeutic dose)|
11396105|NCT02062203|Experimental|AKB-6548 (supratherapeutic dose)|
11396106|NCT02062203|Placebo Comparator|Placebo|
11396107|NCT02062203|Active Comparator|Moxifloxacin|
11396108|NCT02062190|Active Comparator|resveratrol|
11396109|NCT02062190|Placebo Comparator|corn starch|"(10 patients) 100mg 2x/day
~1 month"
11396110|NCT02062177|Experimental|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
11396111|NCT02062177|Active Comparator|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
11396112|NCT02062164||bariatric surgery group|subjects who participate in the overall project and undergo bariatric surgery
11396113|NCT02062164||conservative care group|subjects who participate in the overall project and do not undergo bariatric surgery
11396114|NCT02062151|Experimental|NAS babies|Acupuncture for NAS
11396115|NCT02062138|Active Comparator|continuous passive motion (CPM)|
11396116|NCT02062138|Experimental|controlled active motion (CAM I)|
11396117|NCT02062138|Experimental|controlled active motion (CAM II)|
11396118|NCT02062112|No Intervention|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
11396119|NCT02062112|Active Comparator|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
11396120|NCT02062112|Active Comparator|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
11396121|NCT02062099|Experimental|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
11396122|NCT02062086|Other|Population 1|"(Community-dwelling older adults) will participate in the study for approximately 65 days.
~Population 1 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.
~The estimation of muscle mass will be made on 2 separate occasions in the community-dwelling elderly population in order to assess reproducibility of the method when tested approximately 60 days apart."
11396123|NCT02062086|Other|Population 2|"(Hip-fracture patients) will participate in the study for approximately 35 days during their in-hospital period, followed by 30 during their post-discharge period, so for a total period of at least 65 days.
~Population 2 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.
~In the hip fracture population, estimation of muscle mass by the D3 creatine method will be performed on up to 3 separate occasions to assess whether the method is sensitive enough to detect decreases in muscle mass that may occur during the recovery period after hip fracture."
11396124|NCT02062073|Active Comparator|Abametapir Lotion 0.74%|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
11396125|NCT02062073|Placebo Comparator|Vehicle Lotion|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
11396126|NCT02062073|Other|0.1% sodium lauryl sulfate|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
11396127|NCT02062073|Other|Saline 0.9%|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
11396128|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
11396129|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
11396130|NCT02062047|Experimental|FMSRP+CLX|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of chlorhexidine 2% gel, rinsing chlorhexidine 0.12% solution during 60 days
11396131|NCT02062047|Placebo Comparator|FMSRP + placebo group|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of placebo, rinsing placebo solution during 60 days
11396132|NCT02062047|Active Comparator|PMSRP group|Partial-mouth scaling and root planing in 4-6 sessions in a maximum of 2 weeks
11396133|NCT02062034|Experimental|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
11396134|NCT02062034|Experimental|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
11396135|NCT02062034|Placebo Comparator|Placebo|Placebo. 100mg daily oral intake for 24 weeks
11396136|NCT02062008|Other|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
11396137|NCT02061995|Experimental|PREOB® Intravenous Infusion|
11396138|NCT02061982|Experimental|Caffeine|Instant coffee with or without caffeine will be provided
11396139|NCT02061982|Placebo Comparator|Coffee without caffeine|Coffee without caffeine
11396140|NCT02061969|Active Comparator|Insulin glargine|Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
11396141|NCT02061969|Experimental|linagliptin|Oral linagliptin 5mg once daily added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
11396142|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
11396143|NCT02061930||single crowns supported by implants|single crowns supported by implants placed in the anterior maxilla region, periodontally healthy
11396144|NCT02061917|Experimental|Tobacco-Heating Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette
11396145|NCT02061917|Experimental|Snus (Smokeless Tobacco)|A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)
11396146|NCT02061917|Experimental|Tobacco-Burning Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette
11396147|NCT02061904|Other|Bone Mineral Density|"Bone mineral density measurement with intervention DEXA at the bone impaction graft site:
~DEXA: dual energy X-ray absorptiometry"
11396148|NCT02061904|Other|Hip function|"Hip Function/mobility development:
~Harris Hip Score"
11396149|NCT02061904|Other|pain experience|Pain experiences after surgery in the hip joint VAS-pain
11396150|NCT02061904|Other|General Patients Health condition|"Patients health condition monitoring: intervention SF12:
~Short Form Health Survey 12"
11396151|NCT02061904|Other|Intervention Satisfaction|Patients satisfaction development after the intervention VAS-satisfaction
11396152|NCT02061891|Active Comparator|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
11396153|NCT02061891|Experimental|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
11396154|NCT02061878|Experimental|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
11396155|NCT02061878|Placebo Comparator|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
11396156|NCT02061865|Experimental|Cohorts 1 - 4|Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4.
11396157|NCT02061852|Active Comparator|Physiotherapy|Traditional techniques
11396158|NCT02061852|Experimental|simeox|Medical device
11396159|NCT02061839|Experimental|Teinted sunscream|UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
11396160|NCT02061839|Active Comparator|Regular sunscream|UVA and UVB protection
11396161|NCT02061813|Experimental|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
11396162|NCT02061813|Placebo Comparator|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
11396163|NCT02061813|Other|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
11396164|NCT02061813|Other|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
11396165|NCT02061800|Active Comparator|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
11396166|NCT02061800|Experimental|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
11396167|NCT02061800|Experimental|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
11396168|NCT02061787||cardiopulmonary exercise testing|cardiopulmonary exercise testing
11396169|NCT02061774|Active Comparator|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
11396170|NCT02061774|Placebo Comparator|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
11396171|NCT02061761|Experimental|BMS-986016|BMS-986016 specified dose on specified days
11396172|NCT02061761|Experimental|BMS-986016 + BMS-936558|BMS-986-016 + BMS-936558 specified dose on specified days
11396173|NCT02061748||dabigatran|
11396174|NCT02061748||warfarin|
11396268|NCT02061124|Placebo Comparator|T2DM, placebo|Patients with type 2 diabetes treated with placebo
11396269|NCT02061124|Active Comparator|Healthy subjects, sevelamer|Healthy subjects treated with sevelamer
11396175|NCT02061735||oral propranolol|Dosage of 1 mg/kg per day divided 2 times daily. Blood pressure, heart rate and oxygen saturation are monitored after propranolol initiation. Treatment is continued with a gradual increase to 2 mg/kg per day divided 2 times daily. Treatment is continued until the hemangioma no longer changes in the characteristics judged by the physicians, including, color, size, temperature and deformability.
11396176|NCT02061735||timolol maleate 0.5% gel|One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
11396177|NCT02061735||No treatment, observation only|No oral or topical treatment will be given as recommended by the treating physicians and elected by the parents. Patients will be evaluated periodically to determine what changes in treatment are warranted. If this occurs, the patients will be included in the appropriate study group.
11396178|NCT02061722|Experimental|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).
~The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.
~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
11396179|NCT02061709|Experimental|Ragweed-SPIRE 1|Ragweed SPIRE regimen 1 given 2 weeks apart
11396180|NCT02061709|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
11396181|NCT02061709|Experimental|Ragweed-SPIRE 3|Ragweed-SPIRE regimen 3 given 2 weeks apart
11396182|NCT02061709|Placebo Comparator|Placebo|Placebo given 2 weeks apart
11396183|NCT02061696|Active Comparator|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
11396184|NCT02061696|Active Comparator|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
11396185|NCT02061683|Experimental|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
11396186|NCT02061670|Experimental|Ragweed-SPIRE 1|Ragweed-SPIRE regimen 1 given 2 weeks apart
11396187|NCT02061670|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
11396188|NCT02061670|Placebo Comparator|Placebo|Placebo given 2 weeks apart
11396189|NCT02061657|Experimental|Myomectomy, rectal Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
11396190|NCT02061657|Active Comparator|Myomectomy, Placebo|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
11396191|NCT02061644|Experimental|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
11396192|NCT02061631|Experimental|Docetaxel, Cisplatin|"Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles.
~Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks.
~Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions."
11396193|NCT02061618|No Intervention|Usual Care|
11396194|NCT02061618|Experimental|Bollywood Dance Exercise|Participants in the Bollywood Dance Exercise group will take part in an 8-week dance intervention. The dance classes will take place 2 times per week, approximately 60 minutes per class, for 8 weeks total.
11396195|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
11396196|NCT02061592|Active Comparator|Etafilcon A Control Lens|etafilcon A
11396197|NCT02061592|Experimental|Etafilcon A Test Lens|etafilcon A
11396198|NCT02061579|Experimental|Once-Weekly Structured Contact|Participants in the Once Weekly Structured Contact group will take part in an 6-month exercise intervention and attend one structured group exercise session per week. They will engage in aerobic and resistance training for approximately 80 minutes per exercise session. Additionally, they will attend three exercise evaluations and six study visits.
11396199|NCT02061579|Experimental|Thrice-Weekly Structured Contact|Participants in the Thrice-Weekly Structured Contact group will take part in an 6-month exercise intervention and attend three structured group exercise sessions per week. In total, they will engage in aerobic and resistance training sessions for approximately 200 minutes per week. Additionally, they will attend three exercise evaluations and six study visits.
11396200|NCT02061579|No Intervention|Usual Care|Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
11396201|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
11396202|NCT02061566||Non acute kidney injury|Non acute kidney injury
11396203|NCT02061553|Sham Comparator|Motivation|1 in person session focused on importance of motivation followed by 8 wk SMS messages with self-selected motivational statements.
11396204|NCT02061553|Active Comparator|Intention|1 session of Behavioral Activation followed by 8 wk SMS messages in the form of BA- based implementation intentions.
11396205|NCT02061553|Experimental|BA-Tech|6 in person and 2 phone sessions of Behavioral Activation with EMA-based activity monitoring and SMS-assisted scheduling of value-based activities.
11396206|NCT02061540|Experimental|LUM001|LUM001 administered orally once each day
11397064|NCT02056028||Bile leak after hepatic resection|
11396207|NCT02061527|Experimental|Breast reconstruction with ADM|Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.
11396208|NCT02061527|Active Comparator|Breast reconstruction without ADM|Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.
11396209|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
11396210|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
11396211|NCT02061501|Active Comparator|Speech therapy|Speech therapy (30 min per week) alone for the 6 first months. Then speech therapy (30 min per week) and optometric therapy (30 min per week) for the 6 last months.
11396212|NCT02061501|Experimental|Speech therapy and optometric therapy|Speech therapy (30 min per week) and optometric therapy (30 min per week) for 12 months.
11396213|NCT02061488|Active Comparator|open-loop night|
11396214|NCT02061488|Experimental|closed-loop night|
11396215|NCT02061475|Active Comparator|Lidocaine Patches|
11396216|NCT02061475|Placebo Comparator|Placebo Patches|
11396217|NCT02061462|No Intervention|Standard Group|Recipients of lungs procured from brain dead donors.
11396218|NCT02061462|Active Comparator|EVLP-DCD Group|Recipients of lungs procured from DCD donors, reconditioned/evaluated by EVLP
11396219|NCT02061449|Experimental|Initiating therapy with Romidepsin (Arm A)|Patients who are starting therapy with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
11396220|NCT02061449|Experimental|treatment with Romidepsin with SD or PR (Arm B)|Patients with stable disease on the treatment with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
11396221|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
11396222|NCT02061410|Experimental|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
11396223|NCT02061397|Experimental|simvastatin treatment arm|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
11396224|NCT02061384|Experimental|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
11396225|NCT02061384|Experimental|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
11396226|NCT02061371|Experimental|virtual therapy|Group 1 (G1) included 20 patients who will carry out the virtual therapy.
11396227|NCT02061371|Experimental|conventional physiotherapy|Group 2 (G2) included 20 patients who hold conventional physiotherapy.
11396228|NCT02061358|Experimental|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
11396229|NCT02061358|Experimental|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
11396230|NCT02061358|Experimental|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
11396231|NCT02061358|Experimental|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
11396232|NCT02061358|Experimental|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
11396233|NCT02061358|Experimental|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
11396234|NCT02061358|Experimental|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
11396235|NCT02061358|Experimental|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
11396236|NCT02061345||MCI|Prostate cancer patients having mild cognitive impairment (MCI) attributable to ADT with LHRHa
11396237|NCT02061345||Control|Prostate cancer patients on ADT with LHRHa not having mild cognitive impairment
11396238|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
11396239|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
11396240|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
11396270|NCT02061124|Placebo Comparator|Healthy subjects, placebo|Healthy subjects treated with placebo
11396271|NCT02061111||Subclinical thyroid disease|26 pregnant women with subclinical hypothyroidism and/orTPO-antibodies, and their offspring.
11396272|NCT02061111||Healthy controls|51 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.
11396241|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
11396242|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
11396243|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
11396244|NCT02061293|Experimental|Psilocybin|Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8. Psilocybin 25-40 mg/70 kg administered at 38 weeks.
11396245|NCT02061293|Active Comparator|Diphenhydramine|Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8. Psilocybin 25 mg/70 kg administered at 38 weeks.
11396246|NCT02061280|Experimental|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.
~Randomized to one of 3 study treatments:
~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
11396247|NCT02061280|Active Comparator|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.
~Randomized to one of 3 study treatments:
~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
11396248|NCT02061267|Experimental|Niacin Control|The subjects will receive a vitamin B3 supplement (2 g)
11396249|NCT02061267|Experimental|Niacin + SAT|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
11396250|NCT02061267|Experimental|Niacin + ROO|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
11396251|NCT02061267|Experimental|Niacin + O3|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
11396252|NCT02061254|Experimental|3 groups of subjects|"3 groups:
~group of 48 healthy volunteers (matched with venous insufficiency patients)
~group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)
~group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))
~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
11396253|NCT02061241||Patients|All included patients, having CRT implant procedure Will have both Pacing in vein at site of latest mechanical activation and Pacing in other suitable vein.
11396254|NCT02061228|No Intervention|Control arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
11396255|NCT02061228|Experimental|Induced endometrial injury arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
11396256|NCT02061215||recipients aged 20-40|CMV viral load
11396257|NCT02061215||recipients older than 60|CMV viral load
11396258|NCT02061202|Experimental|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
11396259|NCT02061202|Placebo Comparator|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
11396260|NCT02061189|Experimental|Swimming pool training group|"10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18 or M18 to M24 or M24 to M36, in defined and reproducible conditions.
~M0, M6, M12 and M18 or M0, M6, M12, M18 and M24 or M0, M6, M12, M18, M24 and M30 assessments: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis.
~M12 to M18 or M18 to M24 or M24 to M30: Physical exercise in a swimming pool (3 times per week).
~M24 or M30 or M36: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis."
11396261|NCT02061189|No Intervention|Control group|"20 patients with same assessments at M0, M6, M12 and M18, but:
~without swimming pool training.
~without M24 assessment."
11396262|NCT02061176|Experimental|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
11396263|NCT02061176|Active Comparator|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
11396264|NCT02061163|Experimental|Subjects with Crohn's disease|Contrast Enhanced Ultrasound Optison
11396265|NCT02061150||Asymptomatic newborns that had sepsis workup|Evaluation of medical records of asymptomatic newborns that had sepsis workup in the first 48 hours of life.
11396266|NCT02061137|Experimental|Rett syndrome, fingolimod (FTY720)|0.5 or 0.25mg Fingolimod daily
11396273|NCT02061098|Experimental|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.
~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
11396274|NCT02061098|Placebo Comparator|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.
~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
11396275|NCT02061085|Experimental|monotherapy treatment with Eribulin|Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
11396276|NCT02061072||Population pharmacokinetic estimation|Patients with severe or moderate hemophilia A or B, providing sparse data for population PK estimation
11396277|NCT02061059|Other|group 1|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements.
~group is assigned to standard: wears shoes produced with standard procedure"
11396278|NCT02061059|Other|group 2|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
11396279|NCT02061059|Other|group 3|"group is assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
~group is assigned to standard: wears shoes produced with standard procedure"
11396280|NCT02061059|Other|group 4|"group assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
11396281|NCT02061046||On CPAP therapy|OSA patients assessed before and after 8 weeks of CPAP therapy
11396282|NCT02061020|Experimental|Sequence 1|"THC containing cigarettes 10mg
~THC containing cigarettes 30mg
~Placebo"
11396283|NCT02061020|Experimental|Sequence 2|"THC containing cigarettes 30mg
~Placebo
~THC containing cigarettes 10mg"
11396284|NCT02061020|Experimental|Sequence 3|"Placebo
~THC containing cigarettes 10mg
~THC containing cigarettes 30mg"
11396285|NCT02061007|Experimental|Scans, Surgery and Follow-up|Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
11396286|NCT02060994||37-38 weeks|"Children who were born by elective Cesarean section after 37-38 gestational weeks.
~Intervention: No intervention."
11396287|NCT02060994||39 week or more|Children who were born by elective Cesarean section after 39 gestational weeks or more Intervention: No intervention.
11396288|NCT02060981|Active Comparator|Interview only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
11396289|NCT02060981|Placebo Comparator|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
11396290|NCT02060981|Experimental|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension, and to provide feedback regarding a new tool for helping patients learn more about their medications. Interview plus patients' index date for follow-up is the date of the scheduled interview.
11396291|NCT02060968||IRIS PREMIER Cohort|Promus PREMIER
11396292|NCT02060955|Experimental|Alecsat|"The experimental product is an autologous product based on the individual patients blood. Blood donation are performed in study weeks 0, 6, 11, 23 and 43.
~The patient receives treatment as bolus injection at study weeks 4, 9, 14, 26 and 46."
11396293|NCT02060955|Active Comparator|bevacizumab/irinotecan|Patients allocated to the comparator arm will be treated in accordance with standard practice in Denmark for relapsed glioblastoma multiforme, up to 16 treatment cycles with 4 weeks duration
11396294|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
11396295|NCT02060929|Experimental|Sequence 1|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
11396339|NCT02060565||Chronic liver disease|all patients with chronic liver disease followed using non-invasive methods
11396340|NCT02060552|Placebo Comparator|Febuxostat|Febuxostat 40mg once a day
11397065|NCT02056015|Experimental|[68Ga]MLN6907|
11396296|NCT02060929|Experimental|Sequence 2|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
11396297|NCT02060916|Experimental|PAZ320|Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.
11396298|NCT02060903|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
11396299|NCT02060903|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
11396300|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
11396301|NCT02060877||patients suspected of having lung cancer|observational study, there is no study intervention, only patient questionnaires
11396302|NCT02060864|Placebo Comparator|Placebo|2 Placebo pills
11396303|NCT02060864|Experimental|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
11396304|NCT02060864|Experimental|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
11396305|NCT02060851|Experimental|Vifor and EPO|intravenous iron and EPO
11396306|NCT02060851|Placebo Comparator|control|no intravenous iron or EPO
11396307|NCT02060851|Experimental|Vifor|intravenous iton but no EPO
11396308|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
11396309|NCT02060825||Regional saturation monitor|Patients undergoing surgical repair of hypoplastic left heart syndrome.
11396310|NCT02060812|Experimental|Group I, SSNB & ANB|21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
11396311|NCT02060812|Placebo Comparator|Group II, SSNB alone|The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
11396312|NCT02060786|Active Comparator|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
11396313|NCT02060786|Experimental|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
11396314|NCT02060760||UTROPIA study cohort|At least two cTnI data points available (including baseline) with blood samples available for hs-cTnI testing. No intervention.
11396315|NCT02060747|Experimental|Coordinator-based post fracture program|The intervention arm deals with the intervention of a nurse trained in the management of osteoporosis fractures assisted by a clinical research technician who will manage the logistics and reglementary aspects of the study (patient enrollment, quality and study proceedings).
11396316|NCT02060747|No Intervention|standard care|
11396317|NCT02060734|Experimental|lidocaine|The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.
11396318|NCT02060734|Active Comparator|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
11396319|NCT02060721|Experimental|Macitentan|Macitentan 10mg, oral tablet, once daily
11396320|NCT02060708|Other|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
11396321|NCT02060708|Other|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
11396322|NCT02060682||Navvus Catheter FFR|The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.
11396323|NCT02060669|Experimental|Arm 1|xeloda maintaenance
11396324|NCT02060669|No Intervention|Arm 2|best supprotive care
11396325|NCT02060656|Active Comparator|Control: R-GEM-P|Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
11396326|NCT02060656|Experimental|Experimental: LR-GEM|Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
11396327|NCT02060643||Cross-sectional hemi-neck RT|
11396328|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
11396329|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
11396330|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
11396331|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
11396332|NCT02060617|Experimental|Impairment-Based Group|The impairment-based intervention will be a multi-modal treatment approach utilizing manual therapy of the thoracolumbosacral spine and hips as well as motor control exercises. Patient education will also be provided.
11396333|NCT02060617|Active Comparator|Classification-Based Group|Patients in this group will be categorized into subgroups according to the Treatment-Based Classification (TBC) Algorithm and treated accordingly. Patient education will also be provided.
11396334|NCT02060604|Experimental|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
11396335|NCT02060604|Active Comparator|Ranibizumab Alone|3 monthly ranibizumab, then as needed
11396336|NCT02060591|Active Comparator|Exparel|
11396337|NCT02060591|Active Comparator|Marcaine|
11396338|NCT02060578|Other|Intervention|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
11396341|NCT02060552|Experimental|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
11396342|NCT02060552|Experimental|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
11396343|NCT02060539|Experimental|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
11396344|NCT02060526|Active Comparator|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
11396345|NCT02060526|Active Comparator|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
11396346|NCT02060526|Placebo Comparator|Placebo|The comparator group will receive no treatment with rhHNS.
11396347|NCT02060500|Experimental|Cardiaplication|
11396348|NCT02060487|Experimental|Low dose|
11396349|NCT02060487|Experimental|Medium dose|
11396350|NCT02060487|Experimental|High dose|
11396351|NCT02060474|Experimental|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
11396352|NCT02060461|Experimental|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
11396353|NCT02060461|Experimental|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
11396354|NCT02060448|Experimental|2wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal self-injurious thoughts and behaviors, or SITBs, (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
11396355|NCT02060448|Experimental|2wk baseline + reappraisal (+ awareness)|"Participants will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs and behaviors (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
11396356|NCT02060448|Experimental|4wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
11396357|NCT02060448|Experimental|4wk baseline + reappraisal + (awareness)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
11396358|NCT02060435||EBER+ AMC|EBV+DLBCL patients in Asan Medical Center
11396359|NCT02060435||EBER+ SMC|EBV+DLBCL patients in Samsung Medical Center
11396360|NCT02060435||EBER- SMC|EBV-DLBCL patients in Samsung Medical Center
11396361|NCT02060422|Placebo Comparator|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
11396362|NCT02060422|Experimental|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
11396363|NCT02060409||spliceosome|patient who have available data for spliceosome mutation status
11396364|NCT02060396|Experimental|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
11396365|NCT02060383|Experimental|Incretin based therapy (randomized group)|Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
11396366|NCT02060383|Experimental|Insulin (randomized group)|Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
11396398|NCT02060175|Experimental|1 CILOTAX arm|Cilotax drug-eluting stents implantation
11396399|NCT02060175|Active Comparator|2 DESyne arm|DESyne drug-eluting stents implantation
11396400|NCT02060162||HIV/HBV co-infected|150-200 patients in Zambia and 250-300 across all sites
11396401|NCT02060162||HIV mono-infected|700-750 patients in Zambia and 1600-1700 across all sites
11396367|NCT02060383|Other|Non-Randomized Arm|"This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.
~For the purpose of analysis, this non-randomized arm is further split into 3 groups:
~Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry
~Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment
~No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial"
11396368|NCT02060370|Experimental|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
11396369|NCT02060357|Active Comparator|Resolute Integrity Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
11396370|NCT02060357|Active Comparator|Promus Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
11396371|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
11396372|NCT02060331||Pelvic Organ Prolapse with Nocturia|Pelvic Organ Prolapse with Nocturia
11396373|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
11396374|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
11396375|NCT02060305|Experimental|Bevacizumab|Bevacizumab intra-articular injection; dose 20mg~40mg every 28 days for 4 times
11396376|NCT02060292||COPD|Stable, Non hypoxaemic, without history of vascular disease
11396377|NCT02060292||Healthy smokers|Age matched, smokers without COPD
11396378|NCT02060279|Experimental|Lifestyle intervention and carotenoid supplement|
11396379|NCT02060279|Experimental|Lifestyle intervention and placebo|
11396380|NCT02060266|Experimental|Semaglutide|
11396381|NCT02060253|Experimental|ganetespib, paclitaxel, and trastuzumab with pertuzumab|Patients receive trastuzumab intravenously (IV) over 30 minutes on days 1, 8, 15, and 22, pertuzumab IV over 30 minutes every 3 weeks (only in Part II of the study, starting day 1), paclitaxel IV over 1 hour on days 1, 8, 15, and 22, and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The MTD for ganetespib in combination with paclitaxel and trastuzumab is 150 mg/m2.
11396382|NCT02060240|Experimental|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
11396383|NCT02060240|No Intervention|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
11396384|NCT02060227|Active Comparator|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
11396385|NCT02060227|Active Comparator|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
11396386|NCT02060201|Other|Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting|Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods
11396387|NCT02060201|Other|Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
11396388|NCT02060201|Other|Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
11396389|NCT02060201|Other|Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting|Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods
11396390|NCT02060201|Other|Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
11396391|NCT02060201|Other|Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
11396392|NCT02060188|Experimental|Nivolumab Monotherapy|Nivolumab administered as IV infusion at a dose of 3mg/kg every 2 weeks until disease progression
11396393|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi)|"Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3 week (wk) for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
~Dose Escalation Phase: (Complete)
~Dose Level (DL) 1: Nivo 0.3mg/Kg with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
~DL 1: Nivo 1mg/Kg IV with Ipi 1 mg/Kg IV every 3 wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
~DL 2a: Nivo 1mg/Kg IV with Ipi 3 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression
~DL 2b: Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression"
11396394|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3|Nivo IV dosed every 2wk with Ipi IV dosed every 6wk.
11396395|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4|Nivo IV dosed every 2wk, with Ipi IV dosed every 6wk, combined with Cobimetinib dosed orally once daily 21 days on/7 days off.
11396396|NCT02060188|Experimental|Nivolumab (Nivo) + BMS-986016 Cohort C5|Nivo IV dosed every 2wk with BMS-986016 dosed every 2 wk
11396397|NCT02060188|Experimental|Nivolumab (Nivo) + Daratumumab Cohort C6|Daratumumab IV dosed weekly for week 1-8; then every 2 wks from Week 9-24; then every 4 wks on week 25; with Nivo dosed every 2 wks starting at week 3 and every 4 wks starting at week 25
11396402|NCT02060149|Sham Comparator|no nebulization|Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
11396403|NCT02060149|Active Comparator|nebulization with pH 7.4 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
11396404|NCT02060149|Experimental|nebulization with pH 7.8 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
11396405|NCT02060136||Study group|Men presenting to the urology clinic with lower urinary tract symptoms
11396406|NCT02060123|Experimental|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:
~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),
~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and
~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
11396407|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
11396408|NCT02060110||MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
11396409|NCT02060110||MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study
11396410|NCT02060097|Active Comparator|Cocoa flavanol beverage|flavanol 320mg/day
11396411|NCT02060097|Placebo Comparator|Placebo beverage|no flavanol
11396412|NCT02060084|Experimental|a control group|a control group : the same dose of luke warm water
11396413|NCT02060084|Experimental|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
11396414|NCT02060071|Other|Aortic setnsosi|blood test
11396415|NCT02060071|Other|controls|blood test
11396416|NCT02060058|Experimental|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.
~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.
~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
11396417|NCT02060058|Experimental|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.
~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
11396418|NCT02060058|Experimental|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.
~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
11396419|NCT02060045|Experimental|bundle implementation|The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
11396420|NCT02060032|Active Comparator|Atorvastatin|1.2% atorvastatin local drug delivery
11396421|NCT02060032|Sham Comparator|Simvastatin|1.2% simvastatin local drug delivery
11396422|NCT02060032|Placebo Comparator|Placebo|Placebo local drug delivery
11396423|NCT02060019|Experimental|exforge 10/160mg(amlodipine 10mg, valsartan160mg)|1 tablet daily for 10days
11396424|NCT02060019|Experimental|crestor 20mg(rosuvastatin 20mg)|1 tablet daily for 7days
11396425|NCT02060006|Placebo Comparator|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
11396426|NCT02060006|Experimental|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
11396427|NCT02059993|Other|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
11396428|NCT02059993|No Intervention|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
11396429|NCT02059980|Experimental|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
11396430|NCT02059980|Placebo Comparator|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
11396431|NCT02059967|Experimental|Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)|Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
11396432|NCT02059954|Active Comparator|Vaginal hysterectomy|Vaginal hysterectomy
11396433|NCT02059954|Active Comparator|Total laparoscopic hysterectomy|Laparoscopic hysterectomy
11396434|NCT02059928|Experimental|Intraosseous device placement|Intraosseous device
11396508|NCT02059473|Active Comparator|Physiotherapy|Structured physiotherapy
11396435|NCT02059915|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11396436|NCT02059915|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11396437|NCT02059915|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11396438|NCT02059915|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11396439|NCT02059902|Placebo Comparator|Normal pain management|Normal saline (bolus followed by continuous infusion)
11396440|NCT02059902|Experimental|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
11396441|NCT02059889|Experimental|Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)|Patients undergo 15 imaging studies: 5 chest CT scans, 5 chest MRI scans, 5 PET scans. Each scan will be obtained before treatment begins, weeks 2 and 4 during radiation therapy, 3 months and 1 year following radiation therapy. THe chest CT obtained pre-treatment, at 3 months post treatment and 1 year post treatment are considered routine and would be obtained regardless of study participation. The pre-treatment PET scan is also considered routine. All other scans are being done for the purposes of this research.
11396442|NCT02059876|Experimental|carboplatin and paclitaxel ± trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer.
11396443|NCT02059863|Experimental|SPRING intervention clusters|"SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
~PLUS access to routine maternal and child health services"
11396444|NCT02059863|No Intervention|Control clusters|access to routine maternal and child health services
11396445|NCT02059850|Experimental|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
11396446|NCT02059837||Pterygium,recurrent|Consecutively recorded photographs of recurrent pterygium excision and following grafting were analyzed.
11396447|NCT02059824|Experimental|Eyelid|The selection of the laterality of the eyelid will be randomized
11396448|NCT02059811|Experimental|DASH Diet|"All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in to-go packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries."
11396449|NCT02059798||Decompression of cervical myelopathy|JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit
11396450|NCT02059785|Experimental|Pinocembrin for Injection|40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
11396451|NCT02059785|Placebo Comparator|placebo|60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
11396452|NCT02059772|Experimental|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
11396453|NCT02059772|Experimental|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
11396454|NCT02059759|Placebo Comparator|Placebo|"Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
~Intervention: Placebo"
11396455|NCT02059759|Experimental|1.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
~Intervention: 1.0 MIU IL-2 per day"
11396456|NCT02059759|Experimental|2.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
~Intervention: 2.0 MIU IL-2 per day"
11396457|NCT02059746||Vaginal birth|"Patients in the group give birth vaginally.
~Intervention: Questionnaires sent by mail"
11396458|NCT02059746||Cesaren section|"Patients in this group give birth via cesarean section.
~Intervention: Questionnaires sent by mail"
11396459|NCT02059733|Experimental|18F-DTBZ for Parkinson's Disease and parkinsonism|"This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.
~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
11396460|NCT02059720|Active Comparator|auto|patients receive autologous SCT
11396461|NCT02059720|Active Comparator|haplo|patients receive haplo-SCT
11396462|NCT02059707|Experimental|LAA exclusion procedure|LAA exclusion with the LARIAT RS Suture Delivery Device
11396463|NCT02059694|Experimental|Hyaluronidase|"Dilutions (Blocks):
~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
11396464|NCT02059694|Other|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
11396465|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
11396466|NCT02059668||Biomarker analyses head & neck cancer tissue, blood specimen|Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.
11397661|NCT02051907|Experimental|KAM1403 Gel|A group treated with KAM1403 for the study period.
11396467|NCT02059655|Placebo Comparator|Eye drop solution|Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
11396468|NCT02059655|Active Comparator|Bimatoprost|1 drop daily of Bimatoprost 0.03%. Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
11396469|NCT02059642|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
11396470|NCT02059642|Experimental|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
11396471|NCT02059629||Group A: Eluna pacemaker family|Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.
11396472|NCT02059629||Group B: Sentus BP lead|Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).
11396473|NCT02059616|Experimental|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
11396474|NCT02059616|Experimental|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
11396475|NCT02059616|Experimental|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
11396476|NCT02059616|Experimental|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
11396477|NCT02059616|Experimental|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
11396478|NCT02059616|Experimental|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
11396479|NCT02059616|Experimental|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
11396480|NCT02059616|Experimental|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
11396481|NCT02059603|Experimental|Electroacupuncture|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the acupuncture needles.
11396482|NCT02059603|Active Comparator|Fast-track program|The design of this program is based on the consensus between our surgeons, anesthetists, physiotherapists, dietitians, and nurses, who have reviewed the relevant literature and made appropriate adjustments to suit the local situation.
11396483|NCT02059590|Experimental|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|single dose
11396484|NCT02059577|Experimental|Treatment Group|This group received a combination of nutritional treatments, added sequentially, including vitamins/minerals, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets.
11396485|NCT02059577|No Intervention|Non-Treatment Group|This group did not have any significant changes in their treatments for 12 months
11396486|NCT02059564|Experimental|Cohort A|The weekly treatment of the 6 mg HM11260C or placebo will be maintained
11396487|NCT02059564|Experimental|Cohort B|The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
11396488|NCT02059564|Experimental|Cohort C|The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
11396489|NCT02059551|Experimental|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\intervention section\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
11396490|NCT02059538|Other|Group 1|Metabolic syndrome
11396491|NCT02059538|Other|Group 2|Severly obese patients
11396492|NCT02059538|Other|Group 3|Type-2 diabetics patients
11396493|NCT02059538|Other|Group 4|Patients with first recent (< 2 weeks) acute coronary syndrome (ACS)
11396494|NCT02059538|Other|Group 5|Patients with stable chronic coronary artery disease without heart failure
11396495|NCT02059538|Other|Group 6|Patients with ischemic systolic heart failure (CHF)
11396496|NCT02059538|Other|Group 7|Patients with non-ischemic chronic heart failure
11396497|NCT02059538|Other|Group 8|Healthy volunteers
11396498|NCT02059525||syphilis infected|all patients with a new diagnosis of syphilis, receiving treatment at the Institute of Tropical Medicine
11396499|NCT02059512|Active Comparator|cell Therapy 1|intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting
11396500|NCT02059512|Placebo Comparator|non cell therapy|intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml
11396501|NCT02059512|Active Comparator|cell therapy 2|intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting
11396502|NCT02059499|Experimental|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
11396503|NCT02059499|Experimental|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
11396504|NCT02059499|No Intervention|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
11396505|NCT02059486|Experimental|Teen Choice|The curriculum provides comprehensive sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress. The curriculum can be delivered in different formats that range in length from 6 to 12 weeks.
11396506|NCT02059486|No Intervention|Control|Business as usual school health curriuclum
11396507|NCT02059473|Experimental|Physiotherapy & Surgery|Mini-open rotator cuff repair
11396509|NCT02059460|Experimental|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
11396510|NCT02059460|Placebo Comparator|Control group|
11396511|NCT02059447|Experimental|Mindfulness Based Cognitive Therapy|An 8 week course of Mindfulness Based Cognitive therapy
11396512|NCT02059447|Active Comparator|Relaxation Therapy|An 8 week course of Relaxation Therapy.
11396513|NCT02059434|Experimental|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396514|NCT02059434|Experimental|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396515|NCT02059434|Experimental|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396516|NCT02059434|Experimental|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396517|NCT02059434|Experimental|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396518|NCT02059434|Experimental|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396519|NCT02059434|Placebo Comparator|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396520|NCT02059434|Experimental|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396521|NCT02059434|Experimental|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396522|NCT02059434|Active Comparator|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
11396523|NCT02059434|Active Comparator|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
11396524|NCT02059434|Placebo Comparator|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
11396525|NCT02059421|Experimental|Johrei Therapy|"3 sessions per week lasting 30 minutes.
~Daily report of bedtime and wake time.
~Baseline:
~Polysomnography
~Actigraphy
~Questionnaires
~Blood draw
~Urine collection
~2 weeks:
~Questionnaires
~Actigraphy download
~Sleep log reconciliation
~6 weeks:
~Polysomnography
~Actigraphy download
~sleep log reconciliation
~Questionnaires
~Blood draw
~Urine collection"
11396526|NCT02059421|Active Comparator|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"1 session per week for a total of 6 weeks with the option of 2 additional sessions.
~Daily report of bedtime and wake time.
~Baseline:
~Polysomnography
~Actigraphy
~Questionnaires
~Blood draw
~Urine collection
~2 weeks:
~Questionnaires
~Actigraphy download
~Sleep log reconciliation
~6 weeks:
~Polysomnography
~Actigraphy download
~sleep log reconciliation
~Questionnaires
~Blood draw
~Urine collection"
11396527|NCT02059408|No Intervention|Usual Care|The patients in this arm will receive normal primary care.
11396528|NCT02059408|Active Comparator|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm recommends using creatinine, cystatin C and albuminuria for detection and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
11396529|NCT02059408|Active Comparator|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment adds a pharmacist-led CKD management program and attempts to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
11396530|NCT02059395|Active Comparator|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
11396531|NCT02059395|Experimental|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
11396532|NCT02059382|Active Comparator|Control|ChiRunning training Weekly training log Blinded accelerometer
11396533|NCT02059382|Experimental|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
11396534|NCT02059369|Active Comparator|CFAE ablation|Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
11396535|NCT02059369|Active Comparator|CFAE + Lines|CFAE Ablation followed by linear lesions (anterior and Roof line)
11396536|NCT02059356||Non-cirrhotic patients with cognitive impairment|
11396537|NCT02059343||age less than or equal to 2 years|
11396538|NCT02059330|Experimental|Healthy Subjects of Japanese Descent|Enrolled Japanese subjects will receive four palbociclib single doses of differing dose amounts in fixed sequence over four treatment periods.
11396539|NCT02059330|Experimental|Healthy Non-Asian Subjects|Enrolled healthy non-Asian subjects will receive a single 125mg oral dose of palbociclib in a single treatment period.
11396540|NCT02059317||Group 1|"Six groups are created in order to randomized the order of interventions. In group 1, the order of interventions is as follows:
~Flexion-extension in the sagittal plane
~Rotation in a transverse plane
~Complex movement in three dimensions
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
11396541|NCT02059317||Group 2|"Six groups are created in order to randomized the order of interventions. In group 2, the order of interventions is as follows:
~Flexion-extension in the sagittal plane
~Complex movement in three dimensions
~Rotation in a transverse plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
11396542|NCT02059317||Group 3|"Six groups are created in order to randomized the order of interventions. In group 3, the order of interventions is as follows:
~Rotation in a transverse plane
~Flexion-extension in the sagittal plane
~Complex movement in three dimensions
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
11396565|NCT02059200|No Intervention|TAU|This cohort receives treatment as usual of any nature, e.g. psychotherapy, antidepressant medication etc.
11396566|NCT02059187|Experimental|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
11396567|NCT02059187|Active Comparator|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
11396543|NCT02059317||Group 4|"Six groups are created in order to randomized the order of interventions. In group 4, the order of interventions is as follows:
~Rotation in a transverse plane
~Complex movement in three dimensions
~Flexion-extension in the sagittal plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
11396544|NCT02059317||Group 5|"Six groups are created in order to randomized the order of interventions. In group 5, the order of interventions is as follows:
~Complex movement in three dimensions
~Flexion-extension in the sagittal plane
~Rotation in a transverse plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
11396545|NCT02059317||Group 6|"Six groups are created in order to randomized the order of interventions. In group 6, the order of interventions is as follows:
~Complex movement in three dimensions
~Rotation in a transverse plane
~Flexion-extension in the sagittal plane
~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
11396546|NCT02059304|Other|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
11396547|NCT02059304|Other|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
11396548|NCT02059291|Experimental|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
11396549|NCT02059291|Placebo Comparator|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.
~150mg, participants were uptitrated to open-label canakinumab 300 mg."
11396550|NCT02059291|Experimental|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
11396551|NCT02059291|Placebo Comparator|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
11396552|NCT02059291|Experimental|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
11396553|NCT02059291|Placebo Comparator|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
11396554|NCT02059278|Experimental|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
11396555|NCT02059278|Experimental|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
11396556|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11396557|NCT02059252|Experimental|SmartMatrix scaffold|SmartMatrix dermal replacement scaffold
11396558|NCT02059239|Experimental|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
11396559|NCT02059239|Experimental|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
11396560|NCT02059226|Experimental|Internet-based CBT|Internet-based cognitive behavioural therapy
11396561|NCT02059226|Active Comparator|Internet-based resource page|Static webpage
11396562|NCT02059213|Active Comparator|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
11396563|NCT02059213|Experimental|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
11396564|NCT02059200|Experimental|MBCL + TAU|This cohort receives the Mindfulness Based Compassionate Living program in addition to treatment as usual.
11396568|NCT02059174|Experimental|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
11396569|NCT02059174|Experimental|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
11396570|NCT02059161|Experimental|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
11396571|NCT02059161|Active Comparator|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
11396572|NCT02059148|Experimental|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
11396573|NCT02059148|Experimental|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
11396574|NCT02059148|Experimental|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
11396575|NCT02059135|Active Comparator|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
11396576|NCT02059135|Placebo Comparator|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
11396577|NCT02059109|Experimental|Single|Staff will work alone to assemble the Belmont Rapid Infuser
11396578|NCT02059109|Experimental|Pair|Staff will work in pairs to assemble the Belmont Rapid Infuser
11396579|NCT02059096|Experimental|Repetitive transcranial magnetic stimulation (rTMS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation
11396580|NCT02059096|Other|Theta-Burst Stimulation (pcTBS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
11396581|NCT02059096|Other|repetitive Transcranial Magnetic Stimulation (rTMS)placebo|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
11396582|NCT02059083|Active Comparator|Cognitive behavioral therapy (CBT) alone|
11396583|NCT02059083|Experimental|Cognitive behavioral therapy plus HRV biofeedback|
11396584|NCT02059070|Experimental|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
11396585|NCT02059070|Experimental|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
11396586|NCT02059057|Experimental|LVRC System|
11396587|NCT02059044|Experimental|ISTOP-ADE|Interactive Voice Response System + Pharmacist
11396588|NCT02059044|No Intervention|Routine care|Routine care
11396589|NCT02059031|Experimental|Part A|In Part A, subjects will be randomized to receive two new formulations of GSK1265744 30 mg (New formulation 1 -micronized [B], New formulation 2un-micronized [C]) and the sodium salt reference formulation 30 mg (Reference formulation [A]) in one of six sequences; ABC, BCA, CAB, BAC, ACB, CBA in three treatment periods under fasting condition.
11396590|NCT02059031|Experimental|Part B|Fifteen eligible subjects completing the Part A of the study will enter in to Part B where they will receive either formulation B or C. The selected drug (B or C) will be administered under fed (moderate fat meal) condition in the fourth treatment period.
11396591|NCT02059018|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days
11396592|NCT02059018|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days
11396593|NCT02059005|Experimental|Specialized Community Disease Management|Specialized Community Disease Management
11396594|NCT02059005|Active Comparator|Treatment As Usual|Treatment as Usual: standard post-hospital discharge with medical monitoring.
11396595|NCT02058992||Ramelteon 8 mg administered orally once daily|
11396596|NCT02058979|Active Comparator|BOLUS INFUSION|Bolus infusion of antibiotics
11396597|NCT02058979|Experimental|CONTINUOUS INFUSION|Continuous infusion of antibiotics by way of infusion pump
11396598|NCT02058966|Placebo Comparator|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
11396599|NCT02058966|Experimental|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
11396600|NCT02058966|Experimental|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
11396601|NCT02058966|Experimental|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
11396602|NCT02058953||Craniotomy scheduled|"Patients who have scheduled craniotomy with melanoma brain metastases will have the following specimens collected:
~CNS tumor specimens, specifically the remaining portion from the resected melanoma CNS metastasis
~the remaining portion from the adjacent normal CNS tissue. No additional normal brain tissue will be collected for research purposes only, however the routinely collect peritumoral tissue will be retained.
~melanoma specimens from other extracranial, clinically palpable metastatic sites.
~CSF taken at around the time of the craniotomy procedure
~peripheral blood prior to craniotomy."
11396603|NCT02058953||Collection for non-craniotomy|"For those eligible patients who are not having a craniotomy:
~collection of CSF will be performed by lumbar puncture or from the patient's Ommaya reservoir, if present.
~collection of peripheral blood.
~NOTE: Only patients who have no absolute contraindications or up to two relative contraindications will be considered for lumbar puncture"
11396604|NCT02058940|Experimental|Exenatide|
11396605|NCT02058927||HIV-1 infected children|HIV-1-infected children initiating ART
11396607|NCT02058927||HIV-1 infected children revaccinated|nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers
11396608|NCT02058914|Experimental|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
11396609|NCT02058914|Active Comparator|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
11396610|NCT02058901|Experimental|Sunitinib high dose, weekly schedule|Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
11396611|NCT02058901|Experimental|Sunitinib high dose, biweekly schedule|When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
11396612|NCT02058875|Experimental|Treatment Group|Maximization of mycophenolicacid (MPA) derivative (to a total daily dosage of 1440mg of Myfortic®) and reduction of cyclosporine dosage (as defined by C2 monitoring) in 50 stable renal transplant patients previously on immunosuppressive therapy with cyclosporine, an MPA derivative and prednisone.
11396613|NCT02058875|Active Comparator|Control Group|25 patients continued on an mycophenolicacid (MPA) derivative, cyclosporine and prednisone.
11396614|NCT02058875|No Intervention|Observation Group|25 patients continued on an mycophenolic acid (MPA) derivative, tacrolimus, and prednisone will be followed during the same recruitment period as an additional comparison, as this is the other Calcineurin Inhibitor (CNI), which is used in kidney transplantation.
11396615|NCT02058849|Experimental|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
11396616|NCT02058849|Placebo Comparator|Placebo|Placebo
11396617|NCT02058836|Experimental|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
11396618|NCT02058836|Placebo Comparator|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
11396619|NCT02058823|Placebo Comparator|Arm 1: Real hypoxia and ¨Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 2.
11396620|NCT02058823|Placebo Comparator|Arm 2: Hypoxia placebo and Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the hypoxia placebo and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 1.
11396621|NCT02058823|Active Comparator|Arm 3: Hypoxia and Valsartan|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the Valsartan during the first two weeks and, after the wash-out, receive the treatment of the arm 4.
11396622|NCT02058823|Active Comparator|Arm 4: Hypoxia and Amlodipine|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the amlodipine during the first two weeks and, after the wash-out, receive the treatment of the arm 3.
11396623|NCT02058810|Other|Conventional nasal Oxygen|Conventional nasal Oxygen as needed
11396624|NCT02058810|Other|Nasal high flow|Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
11396625|NCT02058797|Experimental|Coherence Therapy|Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
11396626|NCT02058797|Active Comparator|Cognitive Behavioral Therapy|Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
11396627|NCT02058784|Experimental|Single-dose food effect in nonsmokers|Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
11396628|NCT02058784|Experimental|Single-dose food effect in smokers|Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
11396629|NCT02058771||Ischaemic cardiomyopathy|Patients with ischaemic cardiomyopathy attending for ICD implantation
11396630|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
11396631|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
11396632|NCT02058745|Active Comparator|CAU+ (Enhanced Care as Usual)|CAU+ (Enhanced Care as Usual) is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page for the 10 month duration of the study.
11396633|NCT02058745|Experimental|CAU+ and SmartCare|CAU+ (Enhanced Care as Usual) for eight weeks, followed by eight weeks of SmartCare. SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management.
11396634|NCT02058745|Experimental|CAU+ and Beating the Blues and SmartCare|CAU+ (Enhanced Care as Usual) and Beating the Blues concurrently for eight weeks, followed by SmartCare for eight weeks. Beating the Blues is an established, web-based, self-directed, cognitive behavioral therapy for managing depressive symptoms.
11396722|NCT02058199|Experimental|pre and post bypassed subject|A single dose of rivaroxaban will be administered prior to gastric bypass. Subjects will be restudied 12 to 24 weeks following bypass
11396635|NCT02058732|Active Comparator|ALS patients receivng stem cells|Amyotrophic lateral sclerosis(ALS)subjects, who will be receiving stem cells, will undergo a brief clinical evaluation and questionnaire that will last approximately 20 to 30 min. Subjects will be asked to undergo magnetic resonance imaging(MRI)scans of the cervical spine and brain that will last approximately 60 minutes.
11396636|NCT02058732|Active Comparator|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis(ALS)patient who will not be receiving stem cells, will have an MRI that lasts approximately 60 minutes. This MRI will be repeated at three different time points. Subjects will have an initial MRI, then another at both 6 and 12 months after the initial magnetic resonance imaging(MRI)scan. Subjects will also complete a clinical examination which will take approximately 30 minutes for each MRI. The follow-up magnetic resonance imaging(MRI)scans done for ALS patients who do not receive stem cells are part of routine clinical studies and therefore subjects will not be billed.
11396637|NCT02058719||Cohort A1|HIV positive smokers
11396638|NCT02058719||Cohort A2|HIV positive non-smokers
11396639|NCT02058719||Cohort A3|HIV negative smokers
11396640|NCT02058719||Cohort A4|HIV negative non-smokers
11396641|NCT02058719||Cohort B1|HIV positive with COPD
11396642|NCT02058719||Cohort B2|HIV positive without COPD (non-COPD)
11396643|NCT02058719||Cohort B3|HIV negative with COPD
11396644|NCT02058706|Experimental|Arm A (enzalutamide and LHRH analogue therapy)|Patients receive enzalutamide orally PO QD and undergo orchiectomy or receive LHRH analogue therapy (leuprolide acetate, goserelin acetate, or any other FDA approved preparation). Treatment continues in the absence of disease progression or unacceptable toxicity.
11396645|NCT02058706|Active Comparator|Arm B (bicalutamide and LHRH analogue therapy)|Patients receive bicalutamide PO QD and undergo orchiectomy or receive LHRH analogue therapy as in Arm A. Treatment continues in the absence of disease progression or unacceptable toxicity.
11396646|NCT02058693|Placebo Comparator|Placebo Group|"Phase I (3 weeks) placebo adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).
~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
11396647|NCT02058693|Active Comparator|MSA group|"mixed salts amphetamine, adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).
~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
11396648|NCT02058680|Experimental|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.
~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
11396649|NCT02058667|Experimental|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
11396650|NCT02058654|Experimental|Creatine Group|Whey protein (30 g) and creatine supplement (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
11396651|NCT02058654|Placebo Comparator|Placebo Group|Whey protein (30 g) and bulking agent powder (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
11396652|NCT02058641|Experimental|Part A|Part A will consist of 2 sessions. In Session 1, 3 blisters will be induced by a challenging agent (cantharidin solution 0.2 %, with 5 microliter administered topically) in T2DM subjects on Day 1. Blisters will be harvested 48 (+/-2) hour (hr) post induction. In Session 2, the same subjects will be administered darapladib EC tablet 160 mg orally, once daily for 11 days. On Day 10, 3 blisters will be induced by cantharidin. Blisters will be harvested 48 (+/-2) hr post induction.
11396653|NCT02058641|Experimental|Part B|In Part B, healthy subjects will be enrolled and will follow the same dosing procedure as in Part A. The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A.
11396654|NCT02058628|Experimental|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
11396655|NCT02058628|Experimental|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
11396656|NCT02058615|Experimental|Male Spouse Transition Toolkit|All participants in this group will be given access to the Male Spouse Transition Toolkit (MaTT). MaTT is a website based application that is designed to help male spouses of women with breast cancer to increase their awareness of the transitions and experiences they have as a husband and caregiver as well as to stay organized and seek help and resources as needed. To do so it consists of six sections: about me; common changes to expect; frequently asked questions; resources; calendar; and, important health information. These sections contain activities and exercises, as well as fillable templates (i.e., resources, calendar) that users can download at their convenience, from their home computer, tablet, or smart phone. They will be asked to use the MaTT for one month.
11396657|NCT02058615|No Intervention|Usual Care|Participants in this group will not receive access to the Male Spouse Transition Toolkit, and thus will not receive an intervention. Data collection for outcome variables will be the same as the participants in the experimental arm.
11396658|NCT02058602|Experimental|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
11396659|NCT02058589|Experimental|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
11396723|NCT02058186|Active Comparator|Atopic dermatitis patients: Active|Atopic dermatitis patients: age 1-18 years old
11396660|NCT02058589|Placebo Comparator|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
11396661|NCT02058576|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination) in period 2 orally once daily under fed condition.
11396662|NCT02058576|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fed condition.
11396663|NCT02058563|Experimental|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
11396664|NCT02058563|Active Comparator|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
11396665|NCT02058550|No Intervention|Arm I (no intervention)|Patients receive no additional reminders.
11396666|NCT02058550|Experimental|Arm II (email survey)|Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
11396667|NCT02058550|Experimental|Arm III (email surveys and phone calls)|Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
11396668|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
11396669|NCT02058524|Experimental|fecal microbiota transplantation|
11396670|NCT02058511|Experimental|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:
~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
11396671|NCT02058498|Experimental|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
11396672|NCT02058485|Active Comparator|Group HD|Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
11396673|NCT02058485|Sham Comparator|Group ND|Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
11396674|NCT02058485|Active Comparator|Group HM|Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
11396675|NCT02058485|Sham Comparator|Group NM|Midazolam was administered 0.025 mg. kg-1 in normotensive patient.
11396676|NCT02058472|Experimental|G3041|Amlodipine orotate 10mg/Olmesartan medoxomil 40mg
11396677|NCT02058472|Active Comparator|SEVIKAR®|Amlodipine besylate 10mg/Olmesartan medoxomil 40mg
11396678|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
11396679|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
11396680|NCT02058446|Experimental|Study group|Amlodipine/Valsartan Single-Pill Combination
11396681|NCT02058433|Experimental|pharmacokinetics group|Based on pharmacokinetics. Observe safety and efficacy. In first cycle a fixed Paclitaxel dose depends on BSA. In subsequent cycles the dosage of Paclitaxel will be adjusted depending on pharmacokinetics follow up .
11396682|NCT02058433|Active Comparator|Body surface area(BSA) group|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
11396683|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
11396684|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
11396685|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
11396686|NCT02058407|Experimental|Cohort 1- Part A|This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
11396687|NCT02058407|Experimental|Cohort 2- Part A|This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
11396688|NCT02058407|Experimental|Cohort 3- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
11396724|NCT02058186|Placebo Comparator|Atopic dermatitis patients: Placebo|Atopic dermatitis patients: age 1-18 years old
11396725|NCT02058173|Experimental|chloroquine|150 mg chloroquine and lacebo , one tablet daily for 2 month
11396726|NCT02058173|Experimental|placebo|150 mg chloroquine and lacebo , one tablet daily for 2 month
11396689|NCT02058407|Experimental|Cohort 4- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.
11396690|NCT02058394||Cataract Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
11396691|NCT02058381|Experimental|Group 1 (alpelisib)|Alpelisib plus Tamoxifen and Goserelin (Group 1)
11396692|NCT02058381|Experimental|Group 2 (buparlisib)|Buparlisib plus Tamoxifen and Goserelin (Group 2)
11396693|NCT02058368|Experimental|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
11396694|NCT02058368|Experimental|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
11396695|NCT02058355|Experimental|Personalized Normative Feedback|This group receive the complete Personalized Normative Feedback (with normative information and a list of consequences)
11396696|NCT02058355|Experimental|Normative Feedback|This group receive a feedback only with normative informations (without a list of consequences)
11396697|NCT02058355|Experimental|Consequences List Feedback|This group receive a list of consequences without normative informations
11396698|NCT02058342|Experimental|Active Play at Home Intervention|Participant parents in the intervention arm will receive: 1) Active Play at Home curriculum and equipment, 2) Training session on Active Play at Home curriculum, 3) counseling on physical activity scheduling, identification of barriers, motivational strategies, 4) phone calls to check on compliance and issues with doing the program at home
11396699|NCT02058342|No Intervention|Wait-listed control|Participants will attend the baseline visit to do baseline measurements but will not receive any materials related to the Active Play at Home curriculum and will also not be contacted by phone during the control 24 weeks. After they serve as control group, they will be provided with the opportunity to receive the intervention.
11396700|NCT02058329|No Intervention|No intervention|Standard of care with no home visit
11396701|NCT02058329|Experimental|Home Visit|After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment
11396702|NCT02058316||Patients at risk for IPA|
11396703|NCT02058303|Experimental|Exparel forearm block|Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
11396704|NCT02058303|Active Comparator|Bupivacaine supraclavicular block|Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
11396705|NCT02058290|Active Comparator|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
11396706|NCT02058290|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
11396707|NCT02058277|Other|Healthy volunteers|Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order
11396708|NCT02058264|Experimental|Low Strength BBI-4000 and Vehicle|
11396709|NCT02058264|Experimental|High Strength BBI-4000 and Vehicle|
11396710|NCT02058251|Experimental|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
11396711|NCT02058251|Placebo Comparator|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
11396712|NCT02058238||Arm 1: Robotic-guided, Open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
11396713|NCT02058238||Arm 2: control-arm - non-robotic, open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
11396714|NCT02058238||Arm 3: robotic-guided, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
11396715|NCT02058238||Arm 4: control-arm - freehand, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
11396716|NCT02058225||Infant Group 1|This group consist of healthy, full-term babies whose mothers have no known medical conditions or complications during pregnancy.
11396717|NCT02058212|Placebo Comparator|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
11396718|NCT02058212|Active Comparator|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
11396719|NCT02058199|Experimental|normal subjects|A single dose of 10 mg of rivaroxaban will be administered
11396727|NCT02058160|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
11396728|NCT02058160|Active Comparator|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
11396729|NCT02058147|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
11396730|NCT02058147|Active Comparator|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
11396731|NCT02058147|Active Comparator|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
11396732|NCT02058134|No Intervention|Control group|
11396733|NCT02058134|Experimental|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
11396734|NCT02058121|Experimental|Acceptance and Commitment Therapy|
11396735|NCT02058121|Active Comparator|Treatment as usual|
11396736|NCT02058108|Experimental|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
11396737|NCT02058108|Placebo Comparator|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
11396738|NCT02058095|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
11396739|NCT02058095|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
11396740|NCT02058082|Active Comparator|ejaculated sperm|Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm
11396741|NCT02058082|Active Comparator|testicular extracted sperm|Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm
11396742|NCT02058069|Experimental|Robotic Assisted Total Knee Arthroplasty|
11396743|NCT02058056|Experimental|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
11396744|NCT02058030|Other|3cm head elevation|Insertion of ProSeal laryngeal mask airway
11396745|NCT02058030|Active Comparator|6cm head elevation|Insertion of ProSeal laryngeal mask airway
11396746|NCT02058017|Experimental|Part I & Part II|"Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.
~Part II - This is a single-centre, open-label non-randomised phase II study evaluating OPB-51602 in stage III-IVB NPC conducted in the window period prior to definitive chemoradiotherapy. Eligible patients will receive OPB-51602 on a weekly basis (Day 1, 8, 15) at the recommended dose determined in part I for a total of 15 days prior to definitive chemoradiotherapy."
11396747|NCT02058004|Experimental|Cricoid pressure|Patients randomized to receive cricoid pressure during endotracheal intubation.
11396748|NCT02058004|No Intervention|No cricoid pressure|Patients randomized to receive no cricoid pressure during endotracheal intubation.
11396749|NCT02057991|No Intervention|Group I (standard of care)|Patients and caregivers receive standard of care.
11396750|NCT02057991|Experimental|Group II (educational video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
11396751|NCT02057991|Experimental|Group III (educational video, mindfulness exercise video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.
11396752|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
11396753|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
11396754|NCT02057965|Active Comparator|Mesenchymal Stromal Cells + Everolimus|"Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.
~At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)"
11396755|NCT02057965|No Intervention|Everolimus + Tacrolimus|Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks).
11396756|NCT02057952|No Intervention|Usual Care Control|No intervention.
11396757|NCT02057952|Active Comparator|In Person Weight Management|Education and exercise in a community health center environment.
11396758|NCT02057952|Experimental|Video Conference Weight Management|Education and exercise delivered through video conference.
11396759|NCT02057939|Experimental|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
11396760|NCT02057926|Experimental|Tetracycline, Without Tetracycline|The study consist in two groups: test group (membrane treated with tetracycline) and control group (membrane no treated with tetracycline).
11396761|NCT02057913|Experimental|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
11396762|NCT02057900|Experimental|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
11396763|NCT02057887|Experimental|Cohort1|HM10660A SC once weekly
11396764|NCT02057887|Experimental|Cohort2|HM10660A SC once every 2 weeks
11396765|NCT02057887|Experimental|Cohort3|HM10660A SC once every 4 weeks
11396766|NCT02057887|Active Comparator|Cohort4|180 mcg Pegasys SC once weekly
11396767|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
11396768|NCT02057861||non-diabetic|non-diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded.
11396769|NCT02057861||diabetic|Diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded
11396770|NCT02057848|Active Comparator|low amount of carbohydrates|2 x 10 g carbohydrates (muesli bars)
11396771|NCT02057848|Active Comparator|high amount of carbohydrates|2 x 20 g carbohydrates (muesli bars)
11396772|NCT02057848|Other|Rapid-acting carbohydrates|30 g rapidly absorbable carboh. + 20 g muesli bar
11396773|NCT02057835|Experimental|BI 691751 low dose 1|BI 691751 low dose 1
11396774|NCT02057835|Experimental|BI 691751 low dose 2|BI 691751 low dose 2
11396775|NCT02057835|Experimental|BI 691751 middle dose|BI 691751 middle dose
11396776|NCT02057835|Experimental|BI 691751 high dose|BI 691751 high dose
11396777|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
11396778|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
11396779|NCT02057809||Parent-child dyad|Children with Developmental Disabilities and their parents
11396780|NCT02057809||Therapits|Therapists experienced in serving children with developmental disabilities
11396781|NCT02057796|Experimental|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"Arm1 Extensive TB screening:
~In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
11396782|NCT02057796|Experimental|Rifampin, isoniazid, pyrazinamide, ethambutol|"Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART
~In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
11396783|NCT02057783|Experimental|Physical activity|Obstructive sleep apnea and resistant hypertension controlled + physical activity
11396784|NCT02057783|No Intervention|Control Group|Obstructive sleep apnea and resistant hypertension controlled
11396785|NCT02057770|Experimental|Treatment (preparative regimen, transplant, cyclophosphamide)|"BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.
~OR
~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.
~AND
~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.
~AND
~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4."
11396786|NCT02057770|Experimental|CRS preventive regimen|The final ~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
11396787|NCT02057757|Experimental|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
11396788|NCT02057757|Placebo Comparator|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
11396789|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
11396790|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
11396791|NCT02057731||Ia carriers|Carriers of GSD type Ia will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
11396792|NCT02057731||Ib carriers|Carriers of GSD type Ib will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
11396793|NCT02057731||III carriers|Carriers of GSD type III will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
11396794|NCT02057731||0, VI, IX carriers|Carriers of GSD types 0, VI, and IX will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
11396795|NCT02057731||Noncarriers|Noncarriers of any type of GSD will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to ensure their noncarrier status. A questionnaire will also be filled out.
11396796|NCT02057718|Experimental|LUM001|Participants will receive LUM001 twice a day (BID).
11396797|NCT02057692|Experimental|LUM001|LUM001 for oral administration
11396798|NCT02057692|Placebo Comparator|Placebo|Placebo administered orally once each day
11396799|NCT02057679|Active Comparator|Group A (Amoxicillin Clavulanic)|Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
11396800|NCT02057679|Placebo Comparator|Placebo|Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
11396801|NCT02057666|Experimental|Tasquinimod|Main study: 1 capsule (0.25, 0.50 or 1 mg) daily, taken orally once a day with water and food (preferably the main evening meal).
11396802|NCT02057666|Placebo Comparator|Placebo|1 capsule daily, taken orally once a day with water and food (preferably the main evening meal).
11396803|NCT02057653||Before GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record prior to the start of the training curriculum.
11396804|NCT02057653||After GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record after the training program took place
11396838|NCT02057393|Experimental|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
11396805|NCT02057640|Experimental|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
11396806|NCT02057627|Experimental|Perinatal Dyadic Psychotherapy|The Perinatal Dyadic Psychotherapy intervention consists of 8 home-based, nurse-delivered mother-infant sessions consisting of (a) a supportive, relationship-based, mother-infant psychotherapeutic component, and (b) a developmentally based infant-oriented component focused on promoting positive mother-infant interactions. The 8 sessions take place over three months with weekly 4 sessions (weeks 1 through 4) followed by 4 every other week sessions (weeks 5 through 8)
11396807|NCT02057627|Placebo Comparator|Standard care plus depression monitoring|Standard care plus depression monitoring by phone on a schedule comparable to the intervention groups' home visits. Eight phone calls will take place over three months with weekly 4 calls (weeks 1 through 4) followed by 4 every other week calls (weeks 5 through 8). Phone monitoring will include administration of the Edinburgh Postnatal Depression Scale.
11396808|NCT02057601|Experimental|Infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0ml and will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
11396809|NCT02057601|No Intervention|Non infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0 ml.
11396810|NCT02057588|Other|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
11396811|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.01%|Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
11396812|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.02%|Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
11396813|NCT02057575|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
11396814|NCT02057575|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
11396815|NCT02057562||Routine colonoscopy|Patients receiving routine colonoscopy (for a multitude of indications) at the study centers are eligible for participation
11396816|NCT02057549|Experimental|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
11396817|NCT02057549|Active Comparator|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
11396818|NCT02057536|Experimental|Arm A|8 week directed exercise program
11396819|NCT02057536|Active Comparator|Arm B|No directed exercise other than patients normal level of activity
11396820|NCT02057523|Experimental|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
11396821|NCT02057510||Patients receiving head and neck RT|No intervention
11396822|NCT02057497||Healthy volunteers|Considered generally healthy based on medical history and physical examination as per discretion of the investigator
11396823|NCT02057497||Type 1 Diabetes|T1DM diagnosed clinically prior to start of trial examinations
11396824|NCT02057497||Type 2 Diabetes|T2DM diagnosis prior to the start of trial examinations
11396825|NCT02057484||Organ transplant patients treated with Advagraf|To evaluate long-term graft survival in patients treated with Advagraf
11396826|NCT02057471|Experimental|Intravenous Ferric Carboxymaltose|All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
11396827|NCT02057458|Experimental|Acute Study: Sildenafil first, then Placebo|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
11396828|NCT02057458|Experimental|Acute Study: Placebo first, then Sildenafil|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
11396829|NCT02057458|Experimental|Sub-Chronic Study Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.
11396830|NCT02057445|Experimental|Recipient|EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
11396831|NCT02057445|Other|Donor|Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
11396832|NCT02057432|Experimental|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
11396833|NCT02057419||Contraceptive Method|"Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...
~Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period."
11396834|NCT02057419||Sexual Lubricant Method|3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
11396835|NCT02057406|Active Comparator|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
11396836|NCT02057406|Active Comparator|High EPA|Almost pure EPA 2 grams
11396837|NCT02057406|Placebo Comparator|Placebo|Matched placebo corn oil capsules
11396839|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
11396840|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
11396841|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
11396842|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
11396843|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
11396844|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
11396845|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
11396846|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
11396847|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
11396848|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
11396849|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
11396850|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
11396851|NCT02057367|Experimental|Scalp block with 0.5% plain marcaine|Anterior scalp block with 0.5% plain Marcaine 20 ml.
11396852|NCT02057367|Placebo Comparator|Scalp block with 0.9% normal saline|Anterior scalp block with 0.9% normal saline 20 ml.
11396853|NCT02057354|Active Comparator|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
11396854|NCT02057354|Experimental|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
11396855|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
11396856|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
11396857|NCT02057328|Active Comparator|NEBIVOLOL|Patients of the group of nebivolol will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients still classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range 12,5 mg hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
11396858|NCT02057328|Active Comparator|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisarta daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. The same procedure will be repeated at the end of the 6th month from the beginning of the study. Patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
11396859|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
11396860|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
11396861|NCT02057302|Placebo Comparator|Group B|There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper.
11396862|NCT02057302|Experimental|Group A|There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
11396863|NCT02057289|Experimental|Micafungin|"Subjects will be administered 5 mg/kg of micafungin intravenously as a ONE TIME dose.
~For patients undergoing Hematopoietic Stem Cell Transplant (HSCT), Micafungin will be given on during rest days (i.e. days when no chemotherapy is administered) and blood for pharmacokinetic measurements will be drawn over next 96 hours.
~Following this, further anti-fungal coverage will be at the discretion of the patient's attending physician. (I.e. other antifungal agent(s) or Micafungin at a standard clinical dose; repeat doses of 5mg/kg will NOT be administered.)"
11396864|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
11396865|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
11396866|NCT02057263|Experimental|Alendronate and Hepatitis B Vaccine|Participants in the experimental arm will receive 4 alendronate doses during their Hepatitis B vaccination course.
11396867|NCT02057263|Experimental|Sugar Pill and Hepatitis B Vaccine|Participants in the experimental arm will receive placebo doses during their Hepatitis B vaccination course.
11396868|NCT02057250|Experimental|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
11396993|NCT02056431|Experimental|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
11397662|NCT02051907|Sham Comparator|Aloevera Gel|A group treated with Aloevera Gel for the study period
11396869|NCT02057250|Experimental|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
11396870|NCT02057250|Experimental|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
11396871|NCT02057250|Experimental|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
11396872|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
11396873|NCT02057224|Experimental|Single arm|15 clinical patients undergoing renal denervation
11396874|NCT02057211|Placebo Comparator|sham transplantation of mesenchymal stem cells|control arm with sham transplantation
11396875|NCT02057211|Active Comparator|autologous mesenchymal stem cell transplantation|Active arm with transplantation of cells
11396876|NCT02057198|Active Comparator|Fidaxomicin|200 mg. 2 times a day for 10 days
11396877|NCT02057198|Active Comparator|Metronidazole|500 mg.orally 3 times daily for 10 days
11396878|NCT02057198|Active Comparator|Vancomycin|125 mg. orally 4 times a day for 10 days
11396879|NCT02057185||Study population|"Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.
~The study excludes non Italian speaking patients or unable to fully understand the study's forms."
11396880|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
11396881|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
11396882|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
11396883|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
11396884|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
11396885|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
11396886|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
11396887|NCT02057159|Experimental|NeuroVax|NeuroVax
11396888|NCT02057159|Placebo Comparator|IFA Placebo|IFA Placebo
11396889|NCT02057146|Experimental|Mother-baby endoscopy|Spyglass mother-baby endoscopy in conjunction with ERCP
11396890|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
11396891|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
11396892|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
11396893|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
11396894|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
11396895|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
11396896|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
11396897|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
11396898|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
11396899|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
11396900|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
11396901|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
11396902|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
11396928|NCT02056938|Active Comparator|Basiliximab|The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).
11396929|NCT02056925|Experimental|Experimental|
11396903|NCT02057120|Active Comparator|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
11396904|NCT02057120|Placebo Comparator|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
11396905|NCT02057107|Other|SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel|Previously Treated With Cetuximab - Group A No Previous Cetuximab - Group C
11396906|NCT02057107|Other|SBRT + Cetuximab followed by Cetuximab|Previously Treated with Cetuximab - Group B No Previous Cetuximab - Group D
11396907|NCT02057094|Placebo Comparator|Control|Dining facility recovery feeding only, no supplemental protein consumed (an isoenergetic, carbohydrate supplement will be consumed by those assigned to the Control group)
11396908|NCT02057094|Active Comparator|Protein|"Consume dining facility food with:
~2, 20 g whey protein supplements daily (for ~27 days)
~1, 40 g casein protein supplement daily (for ~27 days)"
11396909|NCT02057094|Active Comparator|High-Protein|"Consume dining facility food with:
~2, 40 g whey protein supplements daily (~27 days)
~1, 50 g casein protein supplement daily (~27 days)"
11396910|NCT02057081|Experimental|Treatment|Intensive 14-session psychoeducational rehabilitation and skills-building intervention for couples.
11396911|NCT02057081|Active Comparator|Control|Didactic 14-session educational group intervention for families.
11396912|NCT02057068|Experimental|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention
~. Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.
~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.
~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).
~. SLEEP-E Dyads book
~. Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
11396913|NCT02057068|No Intervention|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
11396914|NCT02057055|Experimental|Soap 300000027003|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
11396915|NCT02057055|Experimental|Soap 300000029240|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
11396916|NCT02057042|Experimental|PS-cCBT|peer-assisted computerized CBT
11396917|NCT02057042|Active Comparator|EUC|Enhanced usual care
11396918|NCT02057029|Other|BCI Assay Results|The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER positive cancers and is provided through a CLIA certified commercial laboratory. It is an RT-PCR assay that can be performed on formalin fixed paraffin embedded sections of archived tissues. Participants will work in concert with a physician to determine future treatment options based on BCI results.
11396919|NCT02057003||DAA-based therapy against HCV|HIV/HCV-coinfected patients who start therapy against HCV including one or more DAA
11396920|NCT02056990||training advise|
11396921|NCT02056977|Experimental|Titration|Individualized PEEP titration by EIT
11396922|NCT02056977|Active Comparator|Control|PEEP stablished according to the routines at the institution (PEEP table according to the P/F ratio)
11396923|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
11396924|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
11396925|NCT02056951|Active Comparator|Multidisciplinary rehabilitation|The central objective of inpatient multidisciplinary orthopedic rehabilitation (MOR) is to improve functional health with the main focus on restoring and improving work ability. A MOR lasts on average 23 days with a total extent of therapy of 48 hours on average. MOR is provided by a multiprofessional team consisting of physicians, psychologists, sport therapists, physiotherapists, occupational therapists, masseurs, social workers, dieticians and nurses. The interventions are carried out mainly in open groups.
11396926|NCT02056951|Experimental|Interprofessional rehabilitation|The central objective of the interprofessional rehabilitation (PASTOR) is the development of active self-management of chronic non-specific low back pain. PASTOR is matched to the MOR with respect to the total duration and total extent of therapy, the included professions and the interventions dimensions (physical, psychological). The differences between PASTOR and MOR are characterized by, a) an integrative combination of profession related modules within a comprehensive and consistent treatment approach, b) an interprofessional and collaborative teamwork based on profession related modules, c) the use of standardized methods, media and materials by all professions in the therapeutic team d) a highly structured and detailed manual for the entire treatment process. The interventions are carried in fixed groups with eight to twelve participants.
11396927|NCT02056938|Experimental|ATG|"The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.
~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery)."
11396930|NCT02056912|Other|Lipodystrophie Héréditaire|
11396931|NCT02056899|Experimental|Gabapentin|
11397663|NCT02051894||HIE Group|
11396932|NCT02056886|Experimental|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.
~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.
~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
11396933|NCT02056886|Other|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:
~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.
~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.
~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
11396934|NCT02056886|Other|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.
~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.
~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
11396935|NCT02056873|Experimental|Deep Brain Stimulation (DBS)|"Subjects' DBS surgical intervention requires implantation of a DBS system: two CM thalamic leads (one in each brain hemisphere), two ECOG strip leads (one in each brain hemisphere), and two neurostimulators implanted in the chest.
~The ECOG strip lead is implanted into the brain to provide an interface through which stimulation can be delivered or activity of the brain can be monitored by the device, or observed by a clinician using a programmer.
~Neurostimulator and leads system includes a programmer, which includes a wand and telemetry interface, and a patient remote control to check battery status and whether the device is on or off. The programmer is used to set up the device, including setup of stimulation and recording, as well as to retrieve data for subsequent review."
11396936|NCT02056860||Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
11396937|NCT02056860||Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
11396938|NCT02056860||Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
11396939|NCT02056860||Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
11396940|NCT02056860||Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
11396941|NCT02056847|Active Comparator|Pitavastatin calcium 4mg|Pitavastatin calcium (LIVALO®) 4mg, once a day
11396942|NCT02056847|Active Comparator|Pitavastatin calcium 2mg|Pitavastatin calcium (LIVALO®) 2mg, once a day
11396943|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
11396944|NCT02056808|Experimental|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
11396945|NCT02056795|Experimental|Electroacupuncture|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
11396946|NCT02056795|Sham Comparator|Control|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
11396947|NCT02056782|Experimental|PGX-ODSH-2013-AML-1|See Intervention Description
11396948|NCT02056769|Experimental|CT Perfusion|All patients enrolled in the study
11396949|NCT02056756|Experimental|CBD|
11396950|NCT02056743|Experimental|Fermented-red ginseng|"At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.
~During 4~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
11397059|NCT02056054||Control Subjects|Healthy pediatric patients will be enrolled at the coordinating center (Yale).
11396951|NCT02056743|Experimental|Red ginseng|"At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.
~During 4~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
11396952|NCT02056730|Experimental|Regpara|calcium sensing receptor agonist
11396953|NCT02056717|Experimental|Dexamethasone group|
11396954|NCT02056717|Placebo Comparator|Control group|
11396955|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
11396956|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
11396957|NCT02056691|Experimental|Exercise programme|Exercise programme Muscle biopsies
11396958|NCT02056678|Active Comparator|IV acetaminophen, OSA, laparoscopic cholecystectomy|IV acetaminophen 1000mg to be administered to obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy
11396959|NCT02056678|No Intervention|OSA, laparoscopic cholecystectomy, narcotics|No IV acetaminophen in obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy; patients will receive other modalities for pain control primarily including IV narcotics
11396960|NCT02056665|Experimental|MINOCYCLINE 8 weeks|"Duration of treatment: 8 weeks
~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.
~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.
~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
11396961|NCT02056665|Placebo Comparator|PLACEBO 8 weeks|Pill manufactured to mimic Minocycline 50 mg capsule
11396962|NCT02056665|Experimental|MINOCYCLINE 16 weeks|"Duration of treatment: 16 weeks
~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.
~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.
~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
11396963|NCT02056652|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
11396964|NCT02056652|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
11396965|NCT02056639|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
11396966|NCT02056639|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
11396967|NCT02056626|Active Comparator|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
11396968|NCT02056626|Active Comparator|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
11396969|NCT02056626|Active Comparator|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
11396970|NCT02056626|Active Comparator|arm 1|standard therapy, 25 mg twice daily (15 days)
11396971|NCT02056600|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
11396972|NCT02056600|Experimental|C|Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
11396973|NCT02056587|Experimental|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
11396974|NCT02056574|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
11396975|NCT02056574|Placebo Comparator|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
11396976|NCT02056561||TIVA (group T n: 15)|Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
11396977|NCT02056561||Sevoflurane (group S n: 15)|Group S were ventilated with 2% sevoflurane, 50% air and 50% O2 mix at 6 L/min flow.
11396978|NCT02056561||Desflurane (group D n: 15)|Group D cases were given 6% desflurane 50% air and 50% O2 mix at 6 L/min flow.
11396979|NCT02056535|No Intervention|Screened Only|Screened only and met criteria for eligibility for study
11396980|NCT02056535|No Intervention|Screened and Assessed|Screened as eligible for the study and received baseline assessment
11396981|NCT02056535|Active Comparator|Intervention|Screened eligible, received baseline assessment and intervention
11396982|NCT02056522||Suspicious skin lesions.|No intervention is administered.
11396983|NCT02056509||Out of hospital cardiac arrest|Out of hospital cardiac arrest of non-traumatic cause
11396984|NCT02056509||Unexpected in-hospital cardiac arrest|Unexpected cardiac arrest during emergency department stay
11396985|NCT02056496|Experimental|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
11396986|NCT02056483|Experimental|Screening-based nurse navigation|Based on systematic screening for psychological and physical symptoms as well as health behavior a nurse navigator will refer to and monitor use of appropriate rehabilitation programs
11396987|NCT02056483|No Intervention|Usual care|Usual care
11396988|NCT02056470|Experimental|Freedom Total Knee Replacement|Freedom Total Knee
11396989|NCT02056457|Experimental|Responsible fatherhood or healthy marriage|
11396990|NCT02056457|Experimental|Control|
11396991|NCT02056444|Experimental|Topical tranexamic acid (TXA)|Single dose 1.5 grams topical TXA infiltrated into the surgical field at time of arthrotomy closure.
11396992|NCT02056444|Active Comparator|Intravenous TXA|Single 20 mg/kg dose of intravenous TXA administered prior to skin incision.
11397060|NCT02056054||Subjects with Auto-immune Hepatitis|Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
11396994|NCT02056431|No Intervention|IVR Control Group|Participants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) containing general messages regarding diabetic education.
11396995|NCT02056418|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
11396996|NCT02056418|Experimental|Corticosteroid|The patients receive treatment of corticosteroid only.
11396997|NCT02056418|No Intervention|Healthy control|healthy people applied with normal diet.
11396998|NCT02056405|Placebo Comparator|Placebo|Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
11396999|NCT02056405|Active Comparator|Mosapride|Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
11397000|NCT02056392|Experimental|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
11397001|NCT02056392|Active Comparator|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
11397002|NCT02056392|Placebo Comparator|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
11397003|NCT02056379|Active Comparator|Budesonide|2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.
11397004|NCT02056379|Active Comparator|Dexamethasone|This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.
11397005|NCT02056366|Active Comparator|α-lipoic acid|α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks
11397006|NCT02056366|No Intervention|No treatment group|No Intervention
11397007|NCT02056353|Active Comparator|Nurse-directed|Blood glucose control guided by paper protocol
11397008|NCT02056353|Experimental|LOGIC-Insulin|Blood glucose control guided by the LOGIC-Insulin algorithm
11397009|NCT02056340|Active Comparator|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
11397010|NCT02056340|Placebo Comparator|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
11397011|NCT02056327||Oral appliance with monitoring suite|Subjects will sleep with a standard oral appliance with the newly developed monitoring suite embedded within it for 1-2 nights while being monitored with standard in lab polysomnography or home sleep testing.
11397012|NCT02056314|Active Comparator|brochure|The participants will be given a brochure that describes problem gambling and recommends methods of staying in control of gambling such as coping skills.
11397013|NCT02056314|Experimental|electronic tutorial|The participants will be given an electronic tutorial that will explain how to stay in control of their gambling including information about coping skills, warning signs, and information about myths related to gambling.
11397014|NCT02056301|Active Comparator|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
11397015|NCT02056301|Active Comparator|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
11397016|NCT02056288|Active Comparator|Ultrasound Guided Supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
11397017|NCT02056288|Active Comparator|IV Opioids|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
11397018|NCT02056275|Experimental|ONS + dietary counseling|ONS/day + dietary counseling
11397019|NCT02056275|Active Comparator|Dietary counseling|Dietary counseling
11397020|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.
~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
11397021|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.
~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
11397022|NCT02056249||Healthy, lean subjects|Volunteers without anemia (hematocrit), diabetes (A1c), use of illicit drugs and antidepressants, or any other major health issues.
11397023|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1. Lorazepam 4 mg iv (initial dosage) titrated up to a maximum of 12 mg/24 hours OR midazolam 10 mg (initial dosage) up to 60 mg/24 hours (in steps of 5 mg/5 minutes) PLUS Fenytoine bolus i.v. 15-20 mg/kg in 30 minutes, followed by 150 mg 2 dd 1, adapted based on serum levels.
~Step 2. Propofol infusion with a maximum of 8 mg/kg/hour PLUS A second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.
~Step 3. Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages treatment should be guided by the EEG pattern."
11397061|NCT02056054||Subjects with Chronic Hepatitis C Virus|Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
11397062|NCT02056054||Adult Subjects with d-AIH|Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
11397024|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.
~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
11397025|NCT02056223|Experimental|paracetamol|Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.
11397026|NCT02056223|Active Comparator|Intravenous ibuprofen|Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.
11397027|NCT02056210|Experimental|Stem cell mobilization in diabetic patients|Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
11397028|NCT02056210|Experimental|Stem cell mobilization in non diabetic subjects|Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects
11397029|NCT02056197|Placebo Comparator|Placebo|Shortwave 30 minutes.
11397030|NCT02056197|Active Comparator|Stable|Stable surface exercises
11397031|NCT02056197|Experimental|Unstable|Unstable surface exercises
11397032|NCT02056184|Active Comparator|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
11397033|NCT02056184|Experimental|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
11397034|NCT02056171|Experimental|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
11397035|NCT02056171|Placebo Comparator|Placebo|A randomized group will receive placebo, and not quetiapine.
11397036|NCT02056158||HIV Negative Early COPD Smokers|HIV Negative Early COPD Smokers
11397037|NCT02056158||HIV Negative COPD Smokers|HIV Negative COPD Smokers
11397038|NCT02056158||HIV Negative Nonsmokers|HIV Negative Nonsmokers
11397039|NCT02056158||HIV Negative Smokers|HIV Negative Smokers
11397040|NCT02056158||HIV Positive Smokers|HIV Positive Smokers
11397041|NCT02056158||HIV Positive Nonsmokers|HIV Positive Nonsmokers
11397042|NCT02056158||HIV Positive COPD Smokers|HIV Positive COPD Smokers
11397043|NCT02056158||HIV Positive Early COPD Smokers|HIV Positive Early COPD Smokers
11397044|NCT02056145|Placebo Comparator|Group 1|Group 1 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.9% saline solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 30 ml saline solution 0.9%.
11397045|NCT02056145|Active Comparator|Group 2|Group 2 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 20 cc 0.25% bupivacaine solution en 10 cc saline solution 0.9%.
11397046|NCT02056145|Active Comparator|Group 3|Group 3 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.25% bupivacaine solution for lateral femoral cutaneous block, for a total of 30 cc of 0.25% bupivacaine solution.
11397047|NCT02056132||Cystic Fibrosis patients.|Patients with Cystic Fibrosis. Results of Exhaled Breath Condensate lab.
11397048|NCT02056132||Control Subjects|Individuals without Cystic Fibrosis or signs of current respiratory infection. Results of Exhaled Breath Condensate lab.
11397049|NCT02056119|Active Comparator|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:
~Physician order received for subject, randomization to jet nebulizer occurred.
~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).
~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.
~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
11397050|NCT02056119|Experimental|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.
~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.
~Aerosol treatment delivered per physician order.
~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
11397051|NCT02056106|Active Comparator|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
11397052|NCT02056106|Active Comparator|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
11397053|NCT02056093|Experimental|Intubated patients|Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.
11397054|NCT02056067|Experimental|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
11397055|NCT02056067|Active Comparator|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
11397056|NCT02056054||Subjects with d-AIH|Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
11397057|NCT02056054||Subjects with Acute Rejection|Pediatric transplant patients with acute rejection will be enrolled at an outside center.
11397058|NCT02056054||Subjects with Chronic Rejection|Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
11397066|NCT02056002|Active Comparator|Usual Care|"Standard CPAP educational training
~Educational Brochures
~Educational DVD videos mailed to participant"
11397067|NCT02056002|Experimental|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy
~Standard CPAP training
~Eight phone conversations with Peer Buddy over 3 months
~Subsequent 3 months use of phone system to contact Peer Buddy as needed
~One Month Visit:
~-Home visit to collect CPAP information
~Three Month Visit:
~Questionnaires
~Psycho Motor Vigilance Test (PVT) Video Game
~Collect CPAP information
~Measure weight
~Measure blood pressure
~Six Month Visit:
~Questionnaires
~PVT (Video game)
~Collect CPAP information
~Measure Weight
~Measure Blood Pressure
~Evaluate the program and Peer Buddy"
11397068|NCT02055989|Experimental|Dose-escalated radiotherapy level 1|
11397069|NCT02055989|Experimental|Sequential dose-escalated radiotherapy level 2|
11397070|NCT02055976|Experimental|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
11397071|NCT02055976|Experimental|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
11397072|NCT02055963|Experimental|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.
~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
11397073|NCT02055963|Placebo Comparator|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.
~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).
~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
11397074|NCT02055950||Kidney perfused by pulsatile machine|
11397075|NCT02055950||Kidney stored in refrigerated solution|
11397076|NCT02055937|Experimental|immediate implant breast reconstruction|immediate implant breast reconstruction
11397077|NCT02055924|Experimental|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
11397078|NCT02055911|Experimental|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
11397079|NCT02055898|Experimental|Placebo first, then sodium oxybate|Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights
11397080|NCT02055898|Experimental|Sodium oxybate first, then placebo|Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights
11397081|NCT02055885||Positive responders|Positive responders (R+): patients exhibiting an increase in the 6WT distance ≥ 10% and/or a decrease in dyspnea ≥ 10% (i.e., ≥ 1 point on the visual analogue scale).
11397082|NCT02055885||negative responders|Negative responders(R-): patients exhibiting a decrease in the distance ≥ 10% and/or an increase in dyspnea ≥ 10%.
11397083|NCT02055872|Experimental|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
11397084|NCT02055872|Placebo Comparator|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
11397085|NCT02055859|Other|single session radiosurgery|single session radiosurgery (gold standard)
11397086|NCT02055859|Experimental|multisession radiosurgery|multisession radiosurgery (3 fraction)
11397087|NCT02055846|Experimental|prostate cancer|Realisation of blood sample, urinary sample and tumor biopsy
11397088|NCT02055833|Experimental|Intensive nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy) + n-3 polyunsaturated fatty acids-enriched oral nutritional supplements (1-2 bottles/day)
11397089|NCT02055833|Active Comparator|Nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy)
11397090|NCT02055820|Experimental|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
11397091|NCT02055820|Experimental|Venetoclax + R-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
11397092|NCT02055807|Experimental|PEEP and recruitment maneuvers|A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
11397288|NCT02054520|Active Comparator|Arm 2A Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
11397093|NCT02055807|Active Comparator|ZEEP (Zero end-expiratory pressure)|No PEEP nor recruitment maneuvers will be used during surgery. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
11397094|NCT02055794|Active Comparator|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
11397095|NCT02055794|Active Comparator|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
11397096|NCT02055794|Active Comparator|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
11397097|NCT02055781|Experimental|Pacritinib, Once Daily|Pacritinib 400 mg taken orally, once daily
11397098|NCT02055781|Experimental|Pacritinib, Twice Daily|Pacritinib 200 mg taken orally, twice daily
11397099|NCT02055781|Active Comparator|Best Available Therapy|Best Available Therapy includes any physician-selected treatment for primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, such as approved JAK2 inhibitors, and may include any treatment received before study entry. Best Available Therapy may include ruxolitinib, other approved JAK2 inhibitors, hydroxyurea, glucocorticoids, erythropoietic agents, immunomodulatory agents, mercaptopurine, danazol, interferons, cytarabine, melphalan, or other agents and may also include no treatment and symptom-directed treatment without myelofibrosis-specific treatment.
11397100|NCT02055742||Specimen Collection|
11397101|NCT02055729||The study population|"The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.
~For a description of the study population, see the inclusion/exclusion criteria.
~Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample"
11397102|NCT02055716|Placebo Comparator|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
11397103|NCT02055716|Experimental|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
11397104|NCT02055703|Experimental|E2609|Experimental drug for Parts A, B, and C
11397105|NCT02055703|Active Comparator|itraconazole|Comparator drug for Part A1
11397106|NCT02055703|Active Comparator|rifampin|Comparator drug for Part A2
11397107|NCT02055703|Active Comparator|digoxin|Comparator drug for Part B
11397108|NCT02055703|Active Comparator|donepezil|Comparator drug for Part C
11397109|NCT02055690|Experimental|Phase Ib/II: Fosbretabulin & Pazopanib|"Phase Ib:
~Fosbretabulin and Pazopanib in combination. Fosbreatabulin dose will be in the range of 45mg/m2- 60 mg/m2 delivered by infusion every week for 3 weeks of a 4 week cycle until disease progression. Pazopanib will be either 600 mg or 800mg taken orally each day of 28 day cycle until disease progression.
~The phase II dose of both drugs will be determined by the Phase Ib component which is a dose finding exercise.
~Phase II:
~Fosbretabulin and Pazopanib in combination. Fosbretabulin 54mg/m2 delivered by infusion every week for 3 weeks of a 4 week for 28 day cycle until disease progression. Pazopanib 600mg taken orally each day for 28 day cycle until disease progression"
11397110|NCT02055690|Active Comparator|Phase II: Pazopanib|Pazopanib 800mg taken orally each day of 28 day cycle until disease progression
11397111|NCT02055664|Experimental|treatment|
11397112|NCT02055664|Placebo Comparator|control|
11397113|NCT02055651||Bayer Sao Paulo employees|Workers from Bayer in site Socorro who participate in the trial
11397114|NCT02055638|Experimental|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
11397115|NCT02055638|Placebo Comparator|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
11397116|NCT02055625|Experimental|Mesenchymal stromal cell treatment|Biological: Mesenchymal stromal cells
11397117|NCT02055586||Diagnostic (FLT-PET/MRI)|Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
11397118|NCT02055573|Experimental|Ready To Learn|1) The Ready to Learn (RTL) arm will receive a DVD in both Spanish and English and a bilingual booklet (both produced by Parents' action for Children) addressing the benefits of reading, talking and playing with young children, as well as a new children's board book.
11397119|NCT02055573|Experimental|All Babies Cry|2) The All Babies Cry (ABC) arm will receive a DVD in both, Spanish and English and a bilingual booklet (both produced by VIDA Health Communications, INC) explaining crying as part of normal infant behavior, highlighting signs of parental distress and providing strategies to sooth parents and their children
11397120|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
11397121|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
11397122|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and matching placebo (PBO) in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397123|NCT02055547|Experimental|Part 1 - Panel A - PBO > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397124|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397125|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > PBO > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, PBO in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397126|NCT02055547|Experimental|Part 1- Panel B- MK-8521 150μg > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397127|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > MK-8521 200μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397128|NCT02055547|Experimental|Part 1 - Panel B - PBO > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received PBO in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397129|NCT02055547|Experimental|Part 2 - Panel C - MK-8521 50μg > MK-8521 72μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 50μg Days 1 to 5 and MK-8521 72μg Days 6 to 10 in a single treatment period.
11397130|NCT02055547|Experimental|Part 2 - Panel D - MK-8521 100μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
11397131|NCT02055547|Experimental|Part 2 - Panel E - MK-8521 125μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
11397132|NCT02055547|Experimental|Part 2 - Panel F - MK-8521 72μg > MK-8521 125μg|Obese male participants of 45 to 65 years of age received a single dose of MK-8521 72μg Days 1 to 7 and MK-8521 125μg Days 8 to 14 in a single treatment period.
11397133|NCT02055547|Placebo Comparator|Part 2 - Panels C+D+E - Pooled Placebo|Healthy male participants of 18 to 45 years of age received PBO once daily for 10 days.
11397134|NCT02055547|Placebo Comparator|Part 2 - Panel F - Placebo|Obese male participants of 45 to 65 years of age received a single dose of PBO Days 1 to 14.
11397135|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > MK-8521 35μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, MK-8521 35μg (low dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397136|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > PBO > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, PBO MK-8521 in the second treatment period, and 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397137|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 125μg > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 125μg (high dose) in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397138|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 35μg > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 35μg (low dose) in the second treatment period, and MK-8521 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397139|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > PBO > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, PBO in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397140|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > MK-8521 125μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, MK-8521 125μg (high dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
11397141|NCT02055534|Experimental|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the Amyloidosis Center
11397142|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the Amyloidosis Center
11397143|NCT02055508|Experimental|Exercise Intervention Program (EIP)|"Inpatient periods: The combined resistance and endurance program consist of free weight and rubber band training for major upper and lower body muscle groups respectively of cycling/walking on an ergometer/treadmill 3x/week.
~Outpatient periods (3x/week at least two/one supervised training sessions): Supervised training sessions in the local outpatient training center will comprise of resistance exercise on machines and endurance training on an ergometer/treadmill. For non-supervised training session during the outpatient period participants will receive an exercise manual for individualized home-based exercising.
~In weekly phone calls, the advanced practice nurse will review adherence to the intervention and identify problems. Furthermore, the patients will also be asked the same questions as in the CMPC group."
11397144|NCT02055508|Active Comparator|Care-Management-Phone-Calls (CMPC)|"Patients in this arm will receive a weekly care-management-phone-call (CMPC), performed by an advanced practice nurse (APN). The CMPCs are based on a structured questionnaire, reflecting pain, shortness of breath, disturbed sleep, exhaustion and distress and potentially treatment related side effects (e.g. infections, polyneuropathy, etc.). In case of demanding management of symptoms or complaints (e.g. uncontrolled pain or breathlessness) the treating physician is contacted by the APN to facilitate improvement."
11397145|NCT02055482|Experimental|BAY85-3934|
11397146|NCT02055482|Active Comparator|Darbepoetin|
11397147|NCT02055456|Experimental|Nandrolone Decanoate|Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose
11397148|NCT02055443||Holter monitor group|12-lead holter monitor application
11397149|NCT02055430|Active Comparator|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
11397509|NCT02052908|Experimental|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
11397150|NCT02055430|Active Comparator|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
11397151|NCT02055417|Experimental|Personal Approaches to Treatment Choices for HIV|PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART.
11397152|NCT02055417|Active Comparator|Stress Reduction Skills Program|SRSP includes training in stress reduction skills such as relaxation, problem solving, and expressing negative feelings.
11397153|NCT02055404|Experimental|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
11397154|NCT02055404|Other|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
11397155|NCT02055391|Active Comparator|Behavioral Weight Loss|State of the art behavioral weight loss treatment
11397156|NCT02055391|Experimental|Enhanced Behavioral Weight Loss|Combines behavioral weight loss skills with skills specifically targeting emotional eating.
11397157|NCT02055378|Experimental|auricular acupoint stimulation|Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
11397158|NCT02055378|Active Comparator|Atropine|topical 0.125% atropine was given nightly during the study period.
11397159|NCT02055365|Experimental|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
11397160|NCT02055352|Experimental|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
11397161|NCT02055352|Active Comparator|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
11397162|NCT02055339|Experimental|Fisher & Paykel heated humidified high flow nasal cannula|For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization. When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm. The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
11397163|NCT02055339|Active Comparator|InfantFlow/RAM nasal continuous positive airway pressure|Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart. The nCPAP circuit will only be removed when it is time for oral feeds. The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations. The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
11397164|NCT02055326|Experimental|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
11397165|NCT02055326|Active Comparator|Health & Wellness|8 week program of health & wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
11397166|NCT02055300|Experimental|LY03005 - 20|LY03005 Dose Strength 20mg
11397167|NCT02055300|Experimental|LY03005 - 40|LY03005 Dose Strength 40mg
11397168|NCT02055300|Experimental|LY03005- 80|LY03005 Dose Strength 80mg
11397169|NCT02055300|Experimental|LY03005 - 120|LY03005 Dose Strength 120mg
11397170|NCT02055300|Experimental|LY03005 - 160|LY03005 Dose Strength 160 mg
11397171|NCT02055300|Experimental|LY03005 - 200|LY03005 Dose Strength 200mg
11397172|NCT02055300|Experimental|LY03005 - 120 - Fed|LY03005 120mg under Fed Conditions
11397173|NCT02055300|Active Comparator|Pristiq|Pristiq - 50mg
11397174|NCT02055300|Placebo Comparator|Placebo|Placebo
11397175|NCT02055287|Experimental|LY03004- 12.5|LY03004 dosage strength at 12.5mg
11397176|NCT02055287|Experimental|LY03004 - 25|LY03004 Dose Strength 25mg
11397177|NCT02055287|Experimental|LY03004- 37.5|LY03004 Dose Strength 37.5mg
11397178|NCT02055287|Experimental|LY03004 - 50|LY03004 Dose Strength 50mg
11397179|NCT02055274|Experimental|LY03003|4 Stable doses of LY03003 14, 28, 42 and 56 mg
11397180|NCT02055274|Active Comparator|Neupro|Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
11397181|NCT02055274|Active Comparator|Neupro PK|Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
11397182|NCT02055261|Other|OFF PPN DBS-ON PPN DBS|Patients randomly allocated to the order OFF Low frequency DBS of the pedunculopontine nucleus then ON Low frequency DBS of the pedunculopontine nucleus
11397183|NCT02055261|Other|ON PPN DBS - OFF PPN DBS|Patients randomly allocated to the order ON Low frequency DBS of the pedunculopontine nucleus then OFF Low frequency DBS of the pedunculopontine nucleus
11397184|NCT02055248||Subjects with Moebius or related syndromes and their family me|Subjects with Moebius or related syndromes and their family members and healthy volunteers.
11397185|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
11397186|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
11397187|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
11397188|NCT02055209||1|Adults only, all genders, US-born African American
11397189|NCT02055196|Experimental|Treatment (neuronal stem cells, irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells via intracerebral catheter on day 1 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11397321|NCT02054325|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
11397190|NCT02055183||Participants treated with BAT®|Any patient of any age [age category: pediatric-newborn infants (0 to 27 days), infants and toddlers (28 days to 23 months), children (2 to 11-years), and adolescents (12 to <17-years); adult (17-64-years); and geriatric (≥65-years)] with a confirmed or suspected exposure to botulinum toxin who were treated with BAT® deployed from the national or state stockpiles.
11397191|NCT02055170|Experimental|finasteride|finasteride 5mg po od from study entry to date of surgery
11397192|NCT02055157|Experimental|Cohort 1|Cohort 1: 2.5 ug/kg
11397193|NCT02055157|Experimental|Cohort 2|Cohort 2: 7.5 ug/kg,
11397194|NCT02055157|Experimental|Cohort 3|Cohort 3: 15 ug/Kg
11397195|NCT02055157|Experimental|Cohort 4|Cohort 4: 30 ug/kg
11397196|NCT02055144||Non squamous histology|patients with advanced, non-squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and pemetrexed. Maintenance with pemetrexed is allowed.
11397197|NCT02055144||Squamous histology|patients with advanced squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and gemcitabine
11397198|NCT02055131|Placebo Comparator|aspirn fixed dose|patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.
11397199|NCT02055131|Placebo Comparator|aspirin dose titrated with PFA-100|patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.
11397200|NCT02055131|No Intervention|placebo arm|in this group of patients we will just supervise thromboembolic events of the vascular access.
11397201|NCT02055118|Experimental|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
11397202|NCT02055118|Other|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
11397203|NCT02055105|Other|miRNA|
11397204|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 38 persons with their respective family members.
11397205|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 50 persons with their respective family members.
11397206|NCT02055092||LOD|Late onset dementia >= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
11397207|NCT02055079|Experimental|Sirolimus|Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.
11397208|NCT02055079|Placebo Comparator|Placebo|Fixed oral dose of placebo (blinded) once weekly for 24 months.
11397209|NCT02055066|Experimental|Arm 1|ARGX-111 0.3 mg/kg
11397210|NCT02055066|Experimental|Arm 2|ARGX-111 1.0 mg/kg
11397211|NCT02055066|Experimental|Arm 3|ARGX-111 3.0 mg/kg
11397212|NCT02055066|Experimental|Arm 4|ARGX-111 10 mg/kg
11397213|NCT02055053|Experimental|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
11397214|NCT02055053|Placebo Comparator|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
11397215|NCT02055027||Adherent Patients|Comparison between groups
11397216|NCT02055027||Non-adherent patients|Comparison between groups
11397217|NCT02055014|Active Comparator|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
11397218|NCT02055014|Experimental|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
11397219|NCT02055014|Experimental|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
11397220|NCT02054988|Experimental|caffeine|"three cups of coffee will be administered for 10 days (on chronic phase) and two cups of coffee will be consecutively administered for acute evaluation."
11397221|NCT02054988|Active Comparator|not caffeine|not caffeine will be administered for the duration of the study
11397222|NCT02054975|Experimental|vitamin D2 + vitamin D3|Vitamin D2 50,000 IU each week x 4 + vitamin D3 4,000 IU each day for 3 months
11397223|NCT02054975|Active Comparator|Vitamin D lower dose|800 IU vitamin D3 by mouth each day for 3 months
11397224|NCT02054962||Elderly|The investigators intend to asses the effect of fear of movement, PTSD symptoms, and physical activity on persistent pain and functional decline.
11397225|NCT02054949|Experimental|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
11397226|NCT02054936|Active Comparator|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
11397227|NCT02054936|Active Comparator|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
11397228|NCT02054923|Experimental|Routine video recording group|Intervention: Procedure: Implementation of routine videorecording of colonoscopy withdrawal
11397229|NCT02054923|Active Comparator|Control group|Intervention: Behavioral: No routine videorecording (on demand videorecording possible)
11397230|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
11397231|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
11397232|NCT02054897|Experimental|Semaglutide 1.0 mg|
11397233|NCT02054897|Experimental|Semaglutide 0.5 mg|
11397234|NCT02054897|Placebo Comparator|Semaglutide placebo 1.0 mg|
11397235|NCT02054897|Placebo Comparator|Semaglutide placebo 0.5 mg|
11397236|NCT02054884|Experimental|Arm A: F16IL2 in combination with paclitaxel|
11397237|NCT02054884|Experimental|Arm B: Paclitaxel|
11397263|NCT02054715|Experimental|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
11397725|NCT02051452|Placebo Comparator|placebo|Saline
11397238|NCT02054871|Experimental|EGFR 30-60|"Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.
~Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles."
11397239|NCT02054871|Experimental|EGFR 60-90|Experimental: RIPC Remote preconditioning. EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
11397240|NCT02054871|No Intervention|EGRF 30-60|"No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.
~Patients randomised to this group will receive routine care."
11397241|NCT02054871|No Intervention|EGRF 60-90|No Intervention: Remote preconditioning control EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Patients randomised to this group will receive routine care.
11397242|NCT02054858|Experimental|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
11397243|NCT02054858|No Intervention|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
11397244|NCT02054845|Experimental|Body awareness therapy|The experimental treatment: BEWARE
11397245|NCT02054845|Active Comparator|Treatment as Usual|The new treatment is compared to this arm: Physical therapy
11397246|NCT02054832||Glycosade|A prospective cohort design will be used to assess the impact on sleep and continue to monitor safety of Glycosade.
11397247|NCT02054819|Other|Single arm study|"Induction chemotherapy and concurrent radiation to primary tumor Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
~Consolidation Radiation: therapy to metastatic sites At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites."
11397248|NCT02054806|Experimental|Pembrolizumab|Participants receive pembrolizumab 10 mg/kg, intravenously (IV), on Day 1 of every 2-week dosing cycle for up to 24 months
11397249|NCT02054780|Active Comparator|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
11397250|NCT02054780|Experimental|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
11397251|NCT02054767|Experimental|lidocaine|injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
11397252|NCT02054767|Experimental|mepivacaine|injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
11397253|NCT02054767|Experimental|articaine|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
11397254|NCT02054754|Experimental|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
11397255|NCT02054754|Experimental|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
11397256|NCT02054754|Experimental|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
11397257|NCT02054754|Experimental|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
11397258|NCT02054754|Experimental|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
11397259|NCT02054754|Placebo Comparator|Placebo|Single oral dose of matching placebo
11397260|NCT02054741|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
11397261|NCT02054741|No Intervention|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
11397262|NCT02054728|Experimental|RHC and IMT|
11397628|NCT02052128|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
11397264|NCT02054715|Experimental|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
11397265|NCT02054702|Experimental|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
11397266|NCT02054702|Experimental|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
11397267|NCT02054689|Other|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
11397268|NCT02054676|Experimental|Classification assessment.|Random group of the partially edentulous individuals will be assessed according to prepared classification evaluation protocol during dental implant treatment period. Cone-beam computed tomography preoperative evaluation will be made during preoperative stage. Intraoperative edentulous jaw segment parameters evaluation, endosseous dental implant placement parameters assessment during intraoperative stage will be made. Dental implant position evaluation during early postoperative stage will be made. Medications will be prescribed. Late postoperative soft tissue evaluation of edentulous jaw segment will be made during final crown placement. Cone-beam computed tomography analysis results will be compared with subsequent stages assessment results to evaluate reliability of the classification.
11397269|NCT02054663|Experimental|Bolus|Patients randomized to this arm will receive a 600mg bolus dose of clopidogrel at the time of switching from ticagrelor to clopidogrel, followed by 75mg daily.
11397270|NCT02054663|Experimental|no bolus|Individuals randomized to this arm will receive 75mg of clopidogrel at the time of the transition followed by a daily dose of 75mg orally.
11397271|NCT02054650|Experimental|Osteopathic Manual Treatment (OMT)|The OMT protocol will be delivered following an examination for somatic dysfunction at each treatment session. The protocol will target the thoracic, lumbosacral, iliac, and pubic regions using the following techniques: high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue including stretching, kneading, and pressure; myofascial stretching and release; counterstrain; muscle energy; and other optional techniques as time permits and indicated. The intervention will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
11397272|NCT02054650|Sham Comparator|Sham OMT|Sham OMT will involve hand contact, active and passive range of motion, and sham techniques that simulate OMT (including optional OMT techniques), but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force. Sham OMT will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
11397273|NCT02054637|Experimental|Lanreotide|Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)
11397274|NCT02054624|Active Comparator|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
~Phase 1 will be 4 months of weight loss treatment
~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.
~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
11397275|NCT02054624|Active Comparator|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
~Phase 1 will be 4 months of weight loss treatment
~Phase 2 will be 12 months of follow-up contact by conference telephone call.
~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
11397276|NCT02054624|Active Comparator|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
~Phase 1 will be 4 months of weight loss treatment
~Phase 2 will be 12 months of follow-up contact by email.
~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
11397277|NCT02054611|Active Comparator|Educational Module First|Respondents will complete the online educational module first, followed by the evaluation
11397278|NCT02054611|Placebo Comparator|Evaluation First|Respondents will complete the the evaluation first, followed by the online educational module
11397279|NCT02054598|No Intervention|Control group|Usual care.
11397280|NCT02054598|Experimental|Intervention group|Decision aid and navigation
11397281|NCT02054585|Active Comparator|NaCl %0.9|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.
~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
11397282|NCT02054585|Experimental|NaCl 0.9% +5% dextrose|"Children will be included in each group in a randomized way using SAS program.
~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% glucose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
11397283|NCT02054572|Experimental|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
11397284|NCT02054559|Active Comparator|Total 6 cycles of R-CHOP|
11397285|NCT02054559|Experimental|Total 3 cycles of R-CHOP + RT|Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)
11397286|NCT02054533||IBD patients|patients with IBD undergoing intra-abdominal surgery
11397287|NCT02054520|Experimental|Arm 1A HyperAcute®-Melanoma (HAM) + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
11397289|NCT02054520|Experimental|Arm 1B HyperAcute®-Melanoma (HAM) + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
11397290|NCT02054520|Active Comparator|Arm 2B Nivolumab alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
11397291|NCT02054520|Experimental|Arm 1C HyperAcute®-Melanoma (HAM) + pembrolizumab|Arm 1C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
11397292|NCT02054520|Active Comparator|Arm 2C Pembrolizumab alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
11397293|NCT02054507|No Intervention|Former premature infants|Cognitive and executive evaluation by Wechsler IV tests
11397294|NCT02054494||HIV patients with high CD4+ cell counts|HIV Infection, Chronic high CD4+ cell counts (>500 /μl), No known cardiac disease
11397295|NCT02054494||HIV patients with low CD4+ cell counts|HIV Infection, Chronic low CD4+ cell counts (<200 /μl), No known cardiac disease
11397296|NCT02054494||Control Group|No known cardiac disease.
11397297|NCT02054481|Experimental|Arm 1|BI 655066 s.c.
11397298|NCT02054481|Experimental|Arm 2|BI 655066 s.c.
11397299|NCT02054481|Experimental|Arm 3|BI 655066 s.c.
11397300|NCT02054481|Active Comparator|Arm 4|Ustekinumab s.c.
11397301|NCT02054468|Active Comparator|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
11397302|NCT02054468|Experimental|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
11397303|NCT02054455|Placebo Comparator|PPI and placebo|Patients will receive PPI and placebo for 3 days/week for 6 months
11397304|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for 6 months
11397305|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 1|Patients will receive placebo 3 days/week for the first three months and Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the following three months
11397306|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 2|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months
11397307|NCT02054442|Experimental|Arm A: MTX in combination with cetuximab|"The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.
~Premedication: H1-receptor antagonist and dexamethasone.
~The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.
~Premedication: ondansetron 8 mg.
~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
11397308|NCT02054442|Active Comparator|Arm B: MTX|"The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.
~Premedication: ondansetron 8 mg.
~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
11397309|NCT02054429|Experimental|Insulin|IIT arm subjects will receive an insulin aspart infusion at a minimal rate of 2 units/hr while maintaining blood glucose between 90-120mg/dl for 48 hrs
11397310|NCT02054429|No Intervention|Standard glycemic control|standard of care if not randomized to Insulin
11397311|NCT02054416|Active Comparator|Art Assist Device|The ArtAssist© (model AA1000) device is made by ACI Medical located in San Marcos, CA (http://acimedical.com/) and is cleared per FDA under K942530.The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
11397312|NCT02054416|Sham Comparator|Sham Device|"Sham devices look identical to the actual ArtAssist© devices, but provide low-pressure and differ only in number-coded tubing. The study sham intervention will consist of one hour of IPC with the sham ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the sham device has an internal device that stores the usage data) to evaluate subject compliance."
11397313|NCT02054403||angle closure|
11397314|NCT02054377|Experimental|Group A (face to face tai chi)|"8 x 1 hour taught individual classes of Tai Chi over 3 months provided by a Tai Chi instructor at the participant's home/convenient location. These focus on 8 core postures. This is in addition to participant's usual routine care. A DVD and booklet to aid home practise will be provided.
~Daily home Tai Chi practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).
~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
11397315|NCT02054377|Active Comparator|Group 2 (online tai chi)|"3 months usual routine care.
~8 x 1 hour taught individual classes of Tai Chi over 3 months provided over the internet by a Tai Chi instructor. A DVD and booklet to aid home practise will be provided.
~Daily Tai Chi home practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).
~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
11397316|NCT02054364|Experimental|FBT and CRT|Family-Based Treatment combined with Cognitive Remediation Therapy (15 sessions of each)
11397317|NCT02054364|Experimental|FBT and art therapy|Family-Based Treatment combined with art therapy (15 sessions of each)
11397318|NCT02054351|Experimental|IMAB027 administration|Monotherapy - different dose Levels.
11397319|NCT02054338|Experimental|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
11397320|NCT02054338|Active Comparator|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
11397322|NCT02054325|Active Comparator|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
11397323|NCT02054312|Experimental|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
11397324|NCT02054312|Active Comparator|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
11397325|NCT02054299|Experimental|Drug application|6 treatment periods. On each period one of the following interventions
11397326|NCT02054286|Experimental|Group 1: THV01 (5.10E+6 TU) or Placebo|5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
11397327|NCT02054286|Experimental|Group 2: THV01 (5.10E+7 TU) or Placebo|5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
11397328|NCT02054286|Experimental|Group 3: THV01 (5.10E+8 TU) or Placebo|5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
11397329|NCT02054260|Experimental|Surgicel add therapy|
11397330|NCT02054247|Experimental|ultrasound|ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2
11397331|NCT02054247|Experimental|pulsed ultrasound|pulsed ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4
11397332|NCT02054247|Placebo Comparator|placebo ultrasound|placebo ultrasound : same ultrasound device as described above seemed to be working but without delivering any output
11397333|NCT02054221|Other|extended myectomy + MVreplacement|"Procedure: extended myoectomy, mitral valve surgery
~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy with full isscheniem subvalvular apparatus and mitral valve replacement.
~Evaluation results will be made myoectomy as TEE and direct tensiometer."
11397334|NCT02054221|Other|extended myectomy + MVrepair|"Procedure: extended myoectomy, mitral valve surgery
~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles and the mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
11397335|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
11397336|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
11397337|NCT02054208|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
11397338|NCT02054195|Experimental|IUD new technique|Training
11397339|NCT02054195|Experimental|No Training|No Training
11397340|NCT02054182|Active Comparator|Vitamin D|Vitamin D 2 500 IU daily from enrolment until hospital discharge
11397341|NCT02054182|Placebo Comparator|Placebo|Placebo
11397342|NCT02054169||pre-test group|All patients aged 65 or older presenting to the ED during the pre-test period
11397343|NCT02054169||post-test period|All patients aged 65 or older presenting to the ED in the post-test period
11397344|NCT02054156|Active Comparator|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
11397345|NCT02054156|Placebo Comparator|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
11397346|NCT02054143|Experimental|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) after the intubation occured until the patient was extubated.
11397347|NCT02054130|Placebo Comparator|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
11397348|NCT02054130|Experimental|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
11397349|NCT02054130|Experimental|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
11397350|NCT02054130|Experimental|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
11397351|NCT02054117||Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
11397352|NCT02054104|Experimental|1/Vaccine plus chemotherapy|H1299 cell lysate vaccine with metronomic chemotherapy
11397353|NCT02054104|Experimental|2/Vaccine alone|H1299 cell lysate vaccine
11397629|NCT02052128|Experimental|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
11397354|NCT02054091|No Intervention|Control group|Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
11397355|NCT02054091|Experimental|Colostrum group|Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.
11397356|NCT02054078|Experimental|Bevacizumab|Bevacizumab200mg by intrapleural administration
11397357|NCT02054078|Active Comparator|Pulvis talci|Pulvis talci 4g by intrapleural administration
11397358|NCT02054065|No Intervention|Control|Normal care conditions, no computer-based physician alert.
11397359|NCT02054065|Experimental|CAUTI Decision Support|Decision support aimed at preventing Catheter Associated Urinary Tract Infections (CAUTIs)
11397360|NCT02054052|Experimental|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
11397361|NCT02054039|Experimental|Incentive spirometry (IS)|Group I
11397362|NCT02054039|Active Comparator|Breath stacking (BS)|Group II
11397363|NCT02054026|Experimental|Reducing the Risk|An eight-lesson (approximately eight-hour) version of Reducing the Risk
11397364|NCT02054026|No Intervention|Control|
11397365|NCT02054013|Experimental|Prostatic artery embolization|Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure with rapid recovery and low morbidity
11397366|NCT02054013|Other|Conventional monopolar transurethral prostatectomy|Standard treatment
11397367|NCT02054000|Active Comparator|Tirofiban group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
11397368|NCT02054000|Placebo Comparator|Placebo group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
11397369|NCT02053987|Experimental|Stroke rehabilitation|
11397370|NCT02053987|No Intervention|Control Group|This group will undergo rehabilitation as per the current stroke rehabilitation pathway.
11397371|NCT02053974|Active Comparator|Spironolactone|patients who randomized to spironolactone administered arm
11397372|NCT02053974|Placebo Comparator|Placebo|Patients who randomized to placebo administered arm
11397373|NCT02053961|Active Comparator|1Hz dTMS Real|This group will receive dTMS real treatment of 1Hz
11397374|NCT02053961|Sham Comparator|1HZ dTMS SHAM|This group will receive 1HZ dTMS SHAM treatment
11397375|NCT02053948|Experimental|Pursestring Wound Closure group|use Pursestring Wound Closure technique to close the stoma
11397376|NCT02053948|Experimental|Gunsight Skin Incision and Closure group|use Gunsight Skin Incision and Closure Technique to close the stoma
11397377|NCT02053935|Other|Dopamine|All patients will receive the same intervention.
11397378|NCT02053922|Active Comparator|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
11397379|NCT02053922|Active Comparator|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
11397380|NCT02053922|Active Comparator|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
11397381|NCT02053909|Active Comparator|Aspirin|One aspirin 81 mg capsule 2 times per day
11397382|NCT02053909|Active Comparator|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
11397383|NCT02053896||ISU302|15~60U/kg (once every 2 weeks for 6 months)
11397384|NCT02053883|Placebo Comparator|Placebo|Fibrin sealant only.
11397385|NCT02053883|Experimental|Cethrin (BA-210) - Low Dose|Low dose of Cethrin in a fibrin sealant.
11397386|NCT02053883|Experimental|Cethrin (BA-210) - High Dose|High dose of Cethrin in a fibrin sealant.
11397387|NCT02053870|Experimental|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
11397388|NCT02053870|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
11397389|NCT02053857|Active Comparator|RUTF|Standard RUTF at a dose of 175 kcal/kg/d
11397390|NCT02053857|Experimental|RUTF-P|RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d
11397391|NCT02053844|Experimental|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
11397392|NCT02053844|No Intervention|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
11397393|NCT02053818|Active Comparator|Remifentanil|Remifentanil the basic opioid drug in anesthesia
11397394|NCT02053818|Active Comparator|Sufentanil|Sufentanil the basic opioid drug in anesthesia
11397395|NCT02053805|Other|screening tests|The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.
11397424|NCT02053545|Experimental|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)
~Stratum 2 (Myeloid in remission): Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF
~Stratum 3 (Lymphoid in remission): Fractionated total body irradiation (fTBI), Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF"
11397425|NCT02053532||Positron emission tomography/magnetic resonance imaging|
11397426|NCT02053519|Active Comparator|Vigantol Oil, (Vitamin D3)|Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D). First dose at randomisation, 7 -28 days prior to commencing standard Hepatitis C treatment for Hepatitis C Genotypes 1 or 3 . Thereafter monthly with concurrent Hepatitis C treatment.
11397396|NCT02053792|Experimental|rIX-FP|"Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.
~The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.
~For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.
~The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data."
11397397|NCT02053779|Experimental|GnRH-agonist|Experimental Arm: Triptorelin 0.1 mg
11397398|NCT02053779|No Intervention|Control Arm|Control Arm: No intervention
11397399|NCT02053766|Active Comparator|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
11397400|NCT02053766|Active Comparator|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
11397401|NCT02053766|Active Comparator|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
11397402|NCT02053753|Experimental|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
11397403|NCT02053753|Experimental|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
11397404|NCT02053740|Experimental|R-S-Y-R-T|We added R-S-Y-R-T (500 mg 3 times per day) for 6 months
11397405|NCT02053740|Other|Routine western medicine|We kept routine western medicine only (as control group)
11397406|NCT02053727|Active Comparator|Abatacept Arm|This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
11397407|NCT02053727|Placebo Comparator|Placebo Arm|This arm of study patients will receive matching placebo injections during the 24 week double blind period.
11397408|NCT02053714|Other|Self-management and education group|Self-management and education group - 8 weeks of group-based information and activities designed to improve diabetes self-management
11397409|NCT02053688|Active Comparator|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
11397410|NCT02053688|Active Comparator|Toric Soft Contact Lenses|commercial toric soft contact lenses
11397411|NCT02053675|Other|Vasopressin|
11397412|NCT02053662||Bladder Cancer Patients|Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
11397413|NCT02053649|Active Comparator|Usual Care|Usual Care will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
11397414|NCT02053649|Experimental|Triple Chronotherapy + Usual Care|triple chronotherapy (TC) will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
11397415|NCT02053636|Experimental|lucitanib|"Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.
~5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
11397416|NCT02053610|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
11397417|NCT02053610|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
11397418|NCT02053610|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
11397419|NCT02053597|Experimental|doxorubicin and paclitaxel|All patients will receive four cycles of doxorubicin (A) (50 mg/m2) and paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
11397420|NCT02053584|Experimental|Dario BGMS|
11397421|NCT02053571|Experimental|TIPS with 3D overlay|
11397422|NCT02053558|Placebo Comparator|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
11397423|NCT02053558|Active Comparator|TAP BLOCK with ropivacaine|TAP block will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
11397459|NCT02053259|Experimental|Adaptive Goals with Immediate Reinforcement|Adaptive Physical Activity Goals, Immediate Financial Reinforcement
11397427|NCT02053519|Placebo Comparator|MyGliol Oil|Matched placebo. Subjects randomised to this arm will take 5 mls of active Placebo, (Mygliol oil), 7 - 28 days prior to commencing active Hepatitis C treatment and thereafter 5 mls monthly concurrent with Hepatitis C treatment for the duration of the study
11397428|NCT02053506|Experimental|Immune-enhancing nutritional beverage|This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.
11397429|NCT02053506|Experimental|Probiotics (BB-12)|This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).
11397430|NCT02053493|Active Comparator|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
11397431|NCT02053493|Placebo Comparator|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
11397432|NCT02053480||Pyruvate Kinase Deficiency|Patients of all ages with Pyruvate Kinase Deficiency
11397433|NCT02053467|Experimental|eConsult|Physicians randomized to the intervention will have access to the Champlain BASE eConsult service right away (pending completion of an orientation session)
11397434|NCT02053467|No Intervention|Control|Physicians randomized to the control group will use their standard referral practices for one year after randomization and only then will be given the option to use eConsult.
11397435|NCT02053454|Active Comparator|patisiran (ALN-TTR02)|
11397436|NCT02053454|Active Comparator|Sterile Normal Saline (0.9% NaCl)|
11397437|NCT02053428|Active Comparator|Gastrostomy - pull technique|Percutaneous image-guided gastrostomy using large-bore mushroom-retained catheters via the pull technique
11397438|NCT02053428|Active Comparator|Gastrostomy - push technique|Percutaneous image-guided gastrostomy using small-bore cope loop catheters via the push technique
11397439|NCT02053415|Experimental|Krill oil low dose|3 capsules krill oil per day, for 28 days
11397440|NCT02053415|Experimental|Krill oil high dose|9 capsules krill oil per day, for 28 days
11397441|NCT02053402|Placebo Comparator|Placebo|Placebo to be given daily for six months
11397442|NCT02053402|Active Comparator|Vitamin D|1200 IU of vitamin D, daily for six months
11397443|NCT02053389|Experimental|DVD Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) AND the DVD decision aid (Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer), which provides instruction and recommendations on how to participate in shared decision making with one's physician."
11397444|NCT02053389|Active Comparator|Written Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) alone."
11397445|NCT02053376|Experimental|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (120 mg) (160 mg for second and subsequent treatment cycles) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
11397446|NCT02053363|Experimental|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
11397447|NCT02053363|Active Comparator|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
11397448|NCT02053350|Experimental|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
11397449|NCT02053337|Experimental|Self adhesive foam dressing|Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
11397450|NCT02053337|Active Comparator|Comparator self adhesive foam dressing|Non Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
11397451|NCT02053324|Experimental|AvidinOX/ST2210|AvidinOX/ST2210 - vial containing 22.5 mg AvidinOX + vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to 15 % of the lesion volume followed by intravenous infusion of 177Lu-ST2210 Diagnostic dose : 10 ml, 250 MBq±10%177Lu, approximately 1 mg ST2210, 100 mg/mL ascorbic acid, followed by intravenous infusion of a therapeutic dose: 25 ml, escalating 177Lu dose starting at 5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210, 100 mg/ml ascorbic acid
11397452|NCT02053311|Active Comparator|Arm A: Orteronel|300mg orteronel twice daily and best supportive care until disease progression
11397453|NCT02053311|Active Comparator|Arm B: Placebo|Placebo twice daily and best supportive care until disease progression
11397454|NCT02053298|Experimental|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
11397455|NCT02053272|Active Comparator|2 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 2 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
11397456|NCT02053272|Active Comparator|5 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 5 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
11397457|NCT02053272|Active Comparator|15 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 15 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
11397458|NCT02053272|Placebo Comparator|Placebo|Licaps® size double zero (Size 00) hard gelatin capsules containing excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
11397507|NCT02052921|Active Comparator|Rectal resection|Surgical rectal resection
11397460|NCT02053259|Experimental|Adaptive Goals with Delayed Reinforcement|Adaptive Physical Activity Goals, Delayed Financial Reinforcement
11397461|NCT02053259|Experimental|Static Goals with Immediate Reinforcement|Static Physical Activity Goals, Immediate Financial Reinforcement
11397462|NCT02053259|Active Comparator|Static Goals with Delayed Reinforcement|Static Physical Activity Goals, Delayed Financial Reinforcement
11397463|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
11397464|NCT02053233|Experimental|Walkbot group|The Walkbot group received conventional physical therapy (session I for 40 min/day) companied with Walkbot training (session II for 30 min/day) 5 days a week for 4 weeks, 40 session in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks.
11397465|NCT02053233|Placebo Comparator|control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
11397466|NCT02053220|Experimental|Intra-tumoural cohort|
11397467|NCT02053220|Experimental|Intra-venous cohort|
11397468|NCT02053207|Experimental|Cog-Train Intervention|
11397469|NCT02053194|Experimental|Pharmacist-led educational intervention|Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
11397470|NCT02053194|No Intervention|Control|Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
11397471|NCT02053181|Experimental|Cadazolid|Single oral dose of 3000 mg.
11397472|NCT02053168|Other|Resorbable Mesh|Phasix Mesh
11397473|NCT02053155|Experimental|computer based patient education|The patients will complete a pre module and post module set of questions to determine whether their knowledge about peri operative smoking cessation increase smoking has changed. According to their willingness and eligibility, pharmacotherapy will be given.
11397474|NCT02053142|Experimental|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
11397475|NCT02053142|Active Comparator|Acyclovir|400 mg Acyclovir three times daily for 5 days
11397476|NCT02053142|Placebo Comparator|Placebo|Placebo three times daily for 5 days
11397477|NCT02053129|Other|HIV negative pregnant women|Pregnant women who are HIV negative attending their first ANC visit
11397478|NCT02053129|Other|HIV positive pregnant women|Pregnant women who are HIV positive accessing antenatal care.
11397479|NCT02053116|Experimental|PF-05175157|
11397480|NCT02053116|Placebo Comparator|Placebo|
11397481|NCT02053103|Experimental|PF-05175157|
11397482|NCT02053103|Placebo Comparator|Placebo|
11397483|NCT02053090|Active Comparator|Group Education with Stretching|"Group Education with Stretching will receive 10 small group educational classes at the Oregon Health & Science University (OHSU), based on the book Fibromyalgia (Biographies of Disease). Each chapter of Fibromyalgia covers different aspects of the disease and its treatment including global, economic, and risk statistics; a timeline of key events in the study of fibromyalgia; common symptoms and diagnostic indicators; natural history of fibromyalgia; pharmacologic and non-pharmacologic treatments; associated disorders and syndromes; and impact of fibromyalgia at home, in the workplace and in society at large. Participants will be informed that they should not start additional treatments until the end of the study and complementary and alternative treatments won't be covered until the last session. Participants will also receive a digital video disk (DVD) covering stretching appropriate for fibromyalgia patients and will be asked to incorporate the DVD over the next 10 weeks."
11397484|NCT02053090|Experimental|Group Acupuncture|20 treatments in 10 weeks will include individualized acupuncture in a group setting, dietary and lifestyle recommendations each based on the Traditional Chinese Medicine diagnosis (zhang fu) at the time of the visit.
11397485|NCT02053064|Experimental|SAF-301|
11397486|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
11397487|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
11397488|NCT02053038|Experimental|iFR|Treatment guided by iFR
11397489|NCT02053038|Active Comparator|FFR|Treatment guided by FFR
11397490|NCT02053025|Active Comparator|mycoprotein|3 levels of mycoprotein will be consumed
11397491|NCT02053025|Active Comparator|control protein|3 levels of a control protein will be consumed
11397492|NCT02053012||PVT-192|
11397493|NCT02052999|Experimental|PAC-14028 cream 1%|PAC-14028 cream 1%, twice daily for 8 weeks
11397494|NCT02052999|Active Comparator|Rozex gel 0.75%|Rozex gel 0.75%, twice daily for 8 weeks
11397495|NCT02052999|Placebo Comparator|Vehicle|Vehicle, twice daily for 8 weeks
11397496|NCT02052986|Experimental|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
11397497|NCT02052973|Experimental|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
11397498|NCT02052960|Experimental|CetuGEX™ plus chemotherapy|720 mg weekly administration
11397499|NCT02052960|Active Comparator|Cetuximab plus chemotherapy|250 mg/m2 weekly administration
11397500|NCT02052947|Other|SPEC-DaTscan|SPEC-DaTscan
11397501|NCT02052934|Experimental|Cohort 1|Three sublingual (SL) doses of dMLT, 1 microgram (mcg), on Days 1, 15 and 29, 8 subjects
11397502|NCT02052934|Experimental|Cohort 2|Three SL doses of dMLT, 5 mcg, on Days 1, 15 and 29, 8 subjects
11397503|NCT02052934|Experimental|Cohort 3|Three SL doses of dMLT, 25 mcg, on Days 1, 15 and 29, 11 subjects
11397504|NCT02052934|Experimental|Cohort 4|Three SL doses of dMLT, 50 mcg, on Days 1, 15 and 29, 11 subjects
11397505|NCT02052934|Experimental|Cohort 5a|Three SL doses of dMLT,25 mcg on Days 1, 15 and 29, 13 subjects.
11397506|NCT02052934|Experimental|Cohort 5b|Three oral doses of dMLT, 25 mcg on Days 1, 15and 29, 13 subjects
11397510|NCT02052908|Experimental|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
11397511|NCT02052908|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
11397512|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
11397513|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
11397514|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
11397515|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.
~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
11397516|NCT02052869|Other|esophagus intubation|all patients will be intubated in the trachea first, with subsequent intubation in the esophagus. measurements will be performed on both tubes in a blinded manner.
11397517|NCT02052856||ACL Surgery|All English speaking patients 16 years and older having anterior cruciate ligament (ACL) surgery without any other surgery to knee or contralateral knee.
11397518|NCT02052843|Experimental|Steps to Success|Steps to Success enhanced home visits-including instruction for both young mothers and fathers on contraception, comprehensive sex education, and the importance of adequate birth spacing, and accompanied by group sessions on adulthood preparation topics.
11397519|NCT02052843|Active Comparator|Traditional Healthy Families|Traditional Healthy Families home visits which cover topics of parenting and child development
11397520|NCT02052830|Experimental|Wise Guys|A sexual health and male responsibility program for adolescent males
11397521|NCT02052830|No Intervention|Control|Business as usual sexual education in schools
11397522|NCT02052817|Active Comparator|Control|Debridement and standard of care in off-loading on control patients
11397523|NCT02052817|Experimental|Toad Brace|Debridement and fitting of Toad Brace
11397524|NCT02052791|Experimental|nusinersen|
11397525|NCT02052778|Experimental|TAS-120|"TAS-120 tablets, oral; 21-day cycle
~Dose escalation portion of the study was completed.
~Dose expansion- patients with tumors harboring specific FGFR aberrations, specifically in CCA, Brain Tumor , Urotherial carcinoma and any other tumors with FGFR fusion, activating mutation and amplification.
~Phase 2- intra-hepatic CCA patients with tumors harboring FGFR2 gene fusions"
11397526|NCT02052765|Experimental|ajmaline test|All patients underwent ajmaline test for ST shift recording
11397527|NCT02052752|Experimental|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
11397528|NCT02052752|Active Comparator|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
11397529|NCT02052752|Placebo Comparator|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
11397530|NCT02052739|Experimental|active drug|SAGE-547
11397531|NCT02052726|Experimental|Arm Label: Month 0, 1 and 3 Schedule|
11397532|NCT02052726|Experimental|Day 1, 8, and 30 Schedule|
11397533|NCT02052713|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
11397534|NCT02052713|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.
11397535|NCT02052687|Experimental|Part 1: LFX453/placebo|once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
11397536|NCT02052687|Experimental|Part 2 groupA: LFX453/placebo|once daily: LFX453 cream 1 / Placebo 1
11397537|NCT02052687|Experimental|Part 2 groupB: LFX453/placebo|once daily: LFX453 cream 2 / Placebo 2
11397538|NCT02052687|Experimental|Part 2 groupC: LFX453/LFX453|once daily: LFX453 cream 1 / LFX453 cream 2
11397539|NCT02052687|Other|Part 2 groupD: Imiquimod|once daily: imiquimod cream
11397540|NCT02052687|Experimental|Part 3: LFX453/placebo|twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
11397541|NCT02052674|Experimental|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
11397542|NCT02052674|Active Comparator|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
11397543|NCT02052661|Experimental|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
11397544|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.
~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
11397630|NCT02052115|Other|Exercise and weight loss|12 month exercise and weight loss intervention
11397545|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
11397546|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.
~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
11397547|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
11397548|NCT02052635|Experimental|Ticagrelor|90 mg oral tablet
11397549|NCT02052635|Active Comparator|Clopidogrel|300 mg oral tablet
11397550|NCT02052609|Experimental|KHK4827 140mg SC|
11397551|NCT02052609|Experimental|KHK4827 210mg SC|
11397552|NCT02052596|Experimental|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
11397553|NCT02052596|Active Comparator|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
11397554|NCT02052583|Experimental|34°C|therapeutic hypothermia at 34 ° C
11397555|NCT02052583|Experimental|32°C|therapeutic hypothermia at 32 ° C
11397556|NCT02052570||Children post-HSCT|Children post-HSCT age 10-16 yrs of age who had allogeneic transplant who are within 5 years of transplant and returned to school in past 12-24 months after previously attending school pre-transplant
11397557|NCT02052570||Parents of children post-HSCT|Parents of children post-HSCT (children in focus group) will participate in focus group with other parents to discuss the challenges and successes of their child returning to school following HSCT.
11397558|NCT02052570||Teachers of children post-HSCT|Teachers of children post- HSCT (children in focus group) will participate in focus group with other teachers to discuss the challenges and successes of children returning to school post HSCT
11397559|NCT02052570||PBMT provider of child post-HSCT|PBMT provider of child-post HSCT (child in focus group) will participate in in focus group with other PBMT providers to discuss the successes and challenges of coordinating school reentry in child post-HSCT
11397560|NCT02052557|Active Comparator|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
11397561|NCT02052557|Active Comparator|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
11397562|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
11397563|NCT02052531|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, twice daily for 28 days
11397564|NCT02052531|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, twice daily for 28days
11397565|NCT02052531|Placebo Comparator|Vehicle|Vehicle, twice daily for 28days
11397566|NCT02052518|Experimental|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
11397567|NCT02052518|Placebo Comparator|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
11397568|NCT02052505|No Intervention|Usual care|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions.
11397569|NCT02052505|Experimental|Medication review|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions. Following this (usual care) a trained nurse will perform a medication review and discuss the observations with a physician.
11397570|NCT02052492|Experimental|Cohort A: EF-022 100 ng once weekly|Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks
11397571|NCT02052492|Experimental|Cohort B: EF-022 500 ng once weekly|Intra-Muscular injections of EF-022 500 ng once weekly for a period of 8 weeks
11397572|NCT02052492|Experimental|Cohort C: EF-022 1000 ng once weekly|Intra-Muscular injections of EF-022 1000 ng once weekly for a period of 8 weeks
11397573|NCT02052492|Experimental|Expanded Cohort|the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or 1000ng weekly treatment as detailed below: The first 18 patients will be assigned to alternating doses of either 100ng or 500ng in a sequential manner (each patient will be assigned to a single dose). A decision regarding adding a 1000ng dose cohort vs. continuing with the 100ng and 500ng doses will be based on a discussion of the interim analysis results.
11397574|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, Caucasian, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
11397575|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, African-American, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
11397576|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
11397577|NCT02052440|Experimental|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
11397578|NCT02052440|Placebo Comparator|Sugar Pill given three times daily|Placebo sugar bill
11397579|NCT02052427|Experimental|ADRCs|"Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:
~0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)
~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
11397580|NCT02052427|Placebo Comparator|Placebo|"Placebo - Physiological Solution
~Inactive substance (Lactated Ringers + autologous blood)
~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
11397631|NCT02052102|Active Comparator|No prior therapy, DIBH irradiation|Cohort 1 - No prior anthracycline-based chemotherapy or herceptin, deep inspiration breath hold breast radiation therapy
11397581|NCT02052414|Experimental|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.
~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.
~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
11397582|NCT02052401|Experimental|Occupational Therapy Intervention|Post Discharge Domiciliary Intervention by Occupational Therapy (OT)
11397583|NCT02052401|No Intervention|Usual follow-up|Usual follow-up of post discharge elderly patients, including pharmacological, and non-pharmacological care.
11397584|NCT02052388|Experimental|Low Single Dose Brilacidin|0.6mg/kg Brilacidin IV (single dose)
11397585|NCT02052388|Experimental|High Single Dose Brilacidin|0.8mg/kg Brilacidin IV (single dose)
11397586|NCT02052388|Experimental|3-Day Regimen Brilacidin|0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 & 3
11397587|NCT02052388|Active Comparator|Standard dosing regimen Daptomycin|4mg/kg Daptomycin IV daily for 7 Days
11397588|NCT02052375|Experimental|ASP2408 low dosing frequency|
11397589|NCT02052375|Experimental|ASP2408 high dosing frequency|
11397590|NCT02052375|Experimental|Placebo low dosing frequency|
11397591|NCT02052375|Experimental|Placebo high dosing frequency|
11397592|NCT02052362|Experimental|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
11397593|NCT02052362|Experimental|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
11397594|NCT02052349|Experimental|Arm 1: ABT-333|A single centre, open-label, 4-treatment, 3-period, 4-sequence incomplete randomised, single dose crossover study in healthy subjects.
11397595|NCT02052336|Experimental|CJ-12420 200 mg + Clarithromycin 500mg|CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
11397596|NCT02052336|Active Comparator|CJ-12420 200mg|CJ-12420 200mg QD for 5 days
11397597|NCT02052336|Active Comparator|Clarithromycin 500mg|Clarithromycin 500mg BID for 5 days
11397598|NCT02052323|Experimental|artesunate/mefloquine (AS/MQ)|The antimalarial drug regimen being evaluated is: artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours; plus mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours; plus primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
11397599|NCT02052310|Experimental|FG-4592 (roxadustat)|
11397600|NCT02052310|Active Comparator|Epoetin alfa|
11397601|NCT02052297|Other|Part A|In Part A, up to 6 healthy subjects will be enrolled in order to determine the human radiodosimetry following administration of the PET radioligand.
11397602|NCT02052297|Other|Part B|In Part B, up to 8 healthy subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in healthy subjects.
11397603|NCT02052297|Other|Part C|In Part C, up to 20 IPF subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in IPF subjects and, if appropriate, potentially quantify the test/re-test variability.
11397604|NCT02052284|No Intervention|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
11397605|NCT02052284|Experimental|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
11397606|NCT02052271|Experimental|Essential tremor|cerebellar stimulation
11397607|NCT02052271|Placebo Comparator|Placebo arm|placebo stimulation
11397608|NCT02052258|Experimental|oxytocin|
11397609|NCT02052245||Subject delivering preterm baby|
11397610|NCT02052245||Subject delivering term baby|
11397611|NCT02052232|Active Comparator|Control|Control protein powder sachet
11397612|NCT02052232|Experimental|Experimental|Experimental protein powder sachet
11397613|NCT02052219|Experimental|Blisibimod|
11397614|NCT02052219|Placebo Comparator|Placebo|
11397615|NCT02052206|Experimental|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
11397616|NCT02052193|Experimental|Dabrafenib|Dabrafenib 150mg BID orally
11397617|NCT02052193|Active Comparator|Vemurafenib|Vemurafenib 960mg orally BID
11397618|NCT02052180|Experimental|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
11397619|NCT02052180|Active Comparator|Control|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
11397620|NCT02052167|Experimental|Methotrexate|
11397621|NCT02052154|Experimental|Prime-boost pneumococcal immunization|
11397622|NCT02052141|Experimental|500/1000|500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
11397623|NCT02052141|Experimental|1000/500|1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
11397624|NCT02052128|Experimental|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
11397625|NCT02052128|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
11397626|NCT02052128|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
11397627|NCT02052128|Experimental|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
11397632|NCT02052102|Active Comparator|No prior therapy, FB technique|Cohort II - no prior Anthracycline based chemotherapy or Herceptin and (ii) to receive FB RT (not able to hold breath for at least 20 seconds or does not have a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
11397633|NCT02052102|Active Comparator|Prior therapy, DIBH irradiation|Cohort III - Prior Anthracycline-based chemotherapy or Herceptin, and (ii) eligible to receive DIBH RT. (Patient has a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
11397634|NCT02052089|Active Comparator|Physiotherapy|patients were educated to do stretching and eccentric strengthening exercise of wrist extensor muscles
11397635|NCT02052089|Experimental|extracorporeal shockwave therapy|patients were treated with 3 sessions of high-energy shock wave therapy ESWT (Evotron, Switech medical, Kreuzlingen, CH) in 2 weeks interval. Total energy flux density ranged from 0.1 to 0.14 mJ/mm2 (1500 impulses). Shockwave was targeted over lateral epicondyle where maximum tenderness was located.
11397636|NCT02052089|Experimental|Prolotherapy|injection of 20% dextrose (3cc mixed with 0.3cc of lidocaine) to ECRB tendon was done under ultrasound guidance
11397637|NCT02052089|Experimental|Platelet-rich plasma|3 cc of PRP (Harvest SmartPReP 2 APC 30 Process Kit, Harvest Technologies, Plymouth, MA) was injected into ECRB tendon under ultrasound guidance
11397638|NCT02052076|Experimental|Irregular meal pattern|Participants will be asked to consume a standard diet, spread over a different number of meals/snacks per day, for a 2week intervention period. Number of meals will range from 3 to 9 per day.
11397639|NCT02052076|Placebo Comparator|Regular Meal Pattern|Participants will be asked to consume a standard diet, spread over 6 of meals/snacks every day, for a 2week intervention period.
11397640|NCT02052063|Experimental|Surgery|Patient who undergone stapled transanal rectal resection for rectocele. Anal compliance will be evaluated before and starting the surgery using endoflip system
11397641|NCT02052050|Experimental|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
11397642|NCT02052050|No Intervention|control group|usual care
11397643|NCT02052037|Experimental|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
11397644|NCT02052037|Experimental|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.
~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained."
11397645|NCT02052024|Active Comparator|Botox|Treatment group will receive 100 units of BOTOX and will receive 1-3 injections per muscle at each visit.
11397646|NCT02052024|Active Comparator|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and will receive 1-3 injections per muscle at each visit.
11397647|NCT02052011|Experimental|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
11397648|NCT02052011|Placebo Comparator|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
11397649|NCT02051985|Experimental|Aerobic exercise training|
11397650|NCT02051985|Active Comparator|Standard physical therapy|
11397651|NCT02051972||Indicated for a VVI(R) pacemaker|
11397652|NCT02051959|Active Comparator|Crossover 1a: anodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
11397653|NCT02051959|Active Comparator|Crossover 1b: sham + anodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
11397654|NCT02051959|Active Comparator|Crossover 2a: cathodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
11397655|NCT02051959|Active Comparator|Crossover 2b: sham + cathodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area.
~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.
~Each session will last approximately one hour which will consist of:
~EEG and pain measurements
~20 minutes of stimulation
~EEG and pain measurements after completion of stimulation"
11397656|NCT02051946|Active Comparator|Retroject device only|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid).
11397657|NCT02051946|Experimental|Retroject injection with ethacrynic acid injection|The next 3 patients, after the first 5 controls, will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein.
11397658|NCT02051946|Experimental|randomization to ethacrynic acid or balanced salt solution|The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
11397659|NCT02051933|Experimental|Botox|See Botox intervention description
11397660|NCT02051933|Placebo Comparator|Placebo|See Placebo Intervention Description
11397664|NCT02051881|Other|Biopsies|Intestinal biopsies were taken in patients who underwent endoscopy.
11397665|NCT02051868|Active Comparator|Arm A|Cisplatin and 5-Fluorouracil
11397666|NCT02051868|Experimental|Arm B|Carboplatin plus Paclitaxel
11397667|NCT02051842|Experimental|Metadoxine|Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
11397668|NCT02051842|Placebo Comparator|Placebo tablet|Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
11397669|NCT02051829||All patients|Comparison of the four screening score
11397670|NCT02051816|Active Comparator|VL and AO|Video laryngoscopy and apneic oxygenation
11397671|NCT02051816|Active Comparator|DL and AO|Direct Laryngoscopy and apneic oxygenation
11397672|NCT02051816|Active Comparator|VL and no AO|Video Laryngoscopy and no apneic oxygenation
11397673|NCT02051816|Active Comparator|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
11397674|NCT02051803|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
11397675|NCT02051803|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
11397676|NCT02051790|Experimental|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
11397677|NCT02051777|Other|ONS 1 and DA|Oral Nutritional Supplement 1 and Dietary Advice
11397678|NCT02051777|Other|ONS 2 and DA|Oral Nutritional Supplement 2 and Dietary Advice
11397679|NCT02051777|Other|DA Alone|Dietary Advice Alone
11397680|NCT02051764|Experimental|Follow-up Flortaucipir PET Scan|
11397681|NCT02051751|Experimental|BYL719 and paclitaxel|All patients enrolled in the study will receive BYL719 once daily plus weekly paclitaxel
11397682|NCT02051738|Experimental|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
11397683|NCT02051738|Experimental|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
11397684|NCT02051725|Experimental|Active life-style intervention|"The active life-style intervention is designed as 12-week structured and progressive heavy-resistance power training combined with recommended everyday physical activity."
11397685|NCT02051725|No Intervention|Control|The control group is offered to enroll in the same active life-style intervention after the end of the 12-week control period. During the control period this group is asked to maintain the habitual life style.
11397686|NCT02051712|No Intervention|Usual care|Usual car accruing to guidelines
11397687|NCT02051712|Experimental|Individualized training|Individualized exercise training program in addition to usual care
11397688|NCT02051712|Experimental|Individualized training plus adherence measures|Individualized exercise training plus measures to increase adherence
11397689|NCT02051699||One-leg standing view|
11397690|NCT02051699||both-leg standing view|
11397691|NCT02051686|Active Comparator|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
11397692|NCT02051686|Placebo Comparator|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
11397693|NCT02051660|Experimental|Manualized CALM Intervention|
11397694|NCT02051660|Active Comparator|Non-manualized supportive intervention|
11397695|NCT02051634|Active Comparator|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
11397696|NCT02051634|Placebo Comparator|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
11397697|NCT02051621|Active Comparator|Cavo-tricuspid-isthmus-ablation|Ablation of atrial flutter
11397698|NCT02051621|Active Comparator|Pulmonary vein isolation|pulmonary vein isolation
11397699|NCT02051621|Active Comparator|Antiarrhythmic drug|"Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily
~cardioversion as needed"
11397700|NCT02051608|Experimental|Gantenerumab|Participants will receive gantenerumab as subcutaneous (SC) injection every 4 weeks (Q4W)
11397701|NCT02051608|Placebo Comparator|Placebo|Participants will receive placebo as SC injection Q4W
11397702|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
11397726|NCT02051439|Other|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava before balloon assisted Valsava. The second group performed balloon assisted Valsava before conventional Valsava for venous reflux examination by duplex scan.
11397727|NCT02051426|Experimental|D-serine|single P.O. administration of D-serine (2.1g)
11397703|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.
~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
11397704|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.
~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
11397705|NCT02051569|Experimental|Tryptophan first|Tryptophan is given for the first 14 days, 6 times 500mg per day. Placebo is given 6 times per day for the second 14 days.
11397706|NCT02051569|Experimental|Tryptophan second|Placebo is given 6 times per day for the first 14 days. Tryptophan is given for the second 14 days, 6 times 500mg per day.
11397707|NCT02051556|Experimental|Best Side Improvement|Physical Therapy BSI (Best Side Improvement), aimed to potentiate the less affected body side.
11397708|NCT02051556|Experimental|Worse side improvement|Physical Therapy WSI (Worst Side Improvement), aimed to potentiate the most affected body side.
11397709|NCT02051556|Active Comparator|Standard treatment|Physical Therapy ST (Standard Treatment), aimed to potentiate both sides equally.
11397710|NCT02051543|Experimental|Brief Behavioral Treatment of Insomnia-Military Version|
11397711|NCT02051530|Experimental|tryptophan depletion first day|tryptophan depletion on the first day. on the other day participants receive placebo.
11397712|NCT02051530|Experimental|tryptophan depletion on day 2|tryptophan depletion on the second day. on the first day participants receive placebo.
11397713|NCT02051517||Vitrectomy|Subjects expected to have normal vitreous, undergoing vitrectomy surgery for medically indicated reasons.
11397714|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c <7% at the entrance in the study.
~Intervention:
~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
11397715|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c >8% at the entrance in the study.
~Intervention:
~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
11397716|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.
~Intervention:
~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
11397717|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.
~Intervention:
~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
11397718|NCT02051491|Active Comparator|BP-NCPAP|Nasal BP-NCPAP will be delivered using the Infant Flow® SiPAP™ and either nasal prongs or mask interface. A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with transcutaneous carbon dioxide (TcCO2) monitor data (if available). Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm water (H2O) and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on fraction of inspired oxygen (FiO2) requirements.
11397719|NCT02051491|Experimental|NIHFV|NIHFV will be provided using the Drager VN500, using either nasal prong or mask interfaces.A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with TcCO2 monitor data (if available). Initial settings for NIHFV arm will be MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
11397720|NCT02051478|Experimental|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied.
11397721|NCT02051478|Active Comparator|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
11397722|NCT02051465|Experimental|LumenR Retractor|Endoscopic removal of polyp using modified overtube LumenR Retractor
11397723|NCT02051465|Active Comparator|Removal without overtube|Endoscopic removal of polyp without overtube
11397724|NCT02051452|Experimental|Methylphenidate|Methylphenidate
11397728|NCT02051426|Placebo Comparator|Placebo|single P.O. administration of corn starch
11397729|NCT02051413|Other|Venlafaxine extended release|Venlafaxine extended-release, flexible dose
11397730|NCT02051400|Experimental|Intubation with the McGrath® MAC video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
11397731|NCT02051400|Experimental|Intubation with the GlidesScope® Ranger video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
11397732|NCT02051400|Experimental|Intubation with Macintosh laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
11397733|NCT02051387|Active Comparator|Cannabidiol|Cannabidiol capsule, 200 mg single dose
11397734|NCT02051387|Experimental|Cannabidiol CR|Cannabidiol tablet, various dosages
11397735|NCT02051387|Experimental|Amisulpride and Cannabidiol CR|Interaction between Amisulpride and Cannabidiol CR
11397736|NCT02051387|Experimental|Olanzapine and Cannabidiol CR|Interaction between Olanzapine and Cannabidiol CR
11397737|NCT02051387|Experimental|Quetiapine and Cannabidiol CR|Interaction between Quetiapine and Cannabidiol CR
11397738|NCT02051387|Experimental|Risperidone and Cannabidiol CR|Interaction between Risperidone and Cannabidiol CR
11397739|NCT02051387|Placebo Comparator|Cannabidiol CR and Placebo|Cannabidiol CR levels without interaction with antipsychotics
11397740|NCT02051374|Active Comparator|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
11397741|NCT02051374|Active Comparator|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
11397742|NCT02051361||Clopidogrel treated patients|Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin
11397743|NCT02051348|Placebo Comparator|Placebo|Placebo - 2 doses per day for 4 weeks
11397744|NCT02051348|Active Comparator|Pylopass|Probiotic - 2 doses per day for 4 weeks
11397745|NCT02051335|Experimental|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
11397746|NCT02051335|Experimental|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
11397747|NCT02051335|Experimental|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
11397748|NCT02051335|Experimental|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
11397749|NCT02051322|Experimental|Jet Nebulizer|Nebulization with a jet nebulizer and a classic mask
11397750|NCT02051322|Experimental|Trunk Mask Nebulizer|Nebulization with a je nebulizer and a trunk mask
11397751|NCT02051322|Experimental|Aerobika Nebulizer|Nebulization with an Aerobika
11397752|NCT02051309|Experimental|Guanfacine 6mg/day ER|Guanfacine 6mg/day extended release
11397753|NCT02051309|Placebo Comparator|Placebo|Placebo matching capsule
11397754|NCT02051296|Experimental|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
11397755|NCT02051296|Placebo Comparator|Placebo|PLacebo
11397756|NCT02051283||patients with HCC eligible for RFA|patients with HCC eligible for RFA
11397757|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
11397758|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
11397846|NCT02050555|Placebo Comparator|Koji-extracted beverage|100ml/day for 12 weeks
11397759|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
11397760|NCT02051244||Subjective memory loss|Subjects who report memory loss, that may or may not be confirmed by an informant, but have normal cognitive tests ( MMSE scores of 27 or above out of 30. SLUMS scores of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education).
11397761|NCT02051244||Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment - defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. MMSE score of 23-27 out of 30. SLUMS score of 16-19 for subjects with less than 8 years of education or 20-26 for those who have 12 or more years of education.
11397762|NCT02051244||Control|Subject who do not report memory loss and have normal cognitive tests. MMSE of 27 or above out of 30. SLUMS score of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education.
11397763|NCT02051231|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with oxytocin.
11397764|NCT02051231|Experimental|Oxytocin|Samples from each patient will be exposed to oxytocin and then allowed to rest for 30, 60 or 90 minutes.
11397765|NCT02051218|Active Comparator|Arm A (standard arm)|Denosumab 120mg (XGEVA®) sc. q4w
11397766|NCT02051218|Experimental|Arm B (reduced arm)|Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]
11397767|NCT02051192|Experimental|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
11397768|NCT02051192|Active Comparator|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
11397769|NCT02051179||Replacement amalgam|Replacement The clinicians totally removed and replaced the defective restorations. After completing the cavity preparations, the tooth was restored with a new AM (Original D). Bonding agents and/or liners underneath the amalgam restorations were not used in this trial. Rubber dam isolation was used for all restorative treatments. .
11397770|NCT02051179||Repair Amalgam|The clinicians (PV and CM) used Carbide burs (330-010 Komet, Brasseler GmbH Co. Postfach 160.32631, Lemgo, Germany) to explore the defective margin, carious lesion or anatomic form of the restorations. Part of the restorative material adjacent to the defect was removed as an exploratory proceedure thus allowing a proper evaluation and subsequent diagnosis of the extent of the defect. Provided that the defect was limited and localized, the clinician then removed any defective tooth tissue. Mechanical retention was employed inside the existing AM restoration. Rubber dam isolation was used for this procedure. Repair of the restorations was carried out with a dispersed-phased amalgam (Original D, Wyckle Research Inc, Carson City, NV, USA).
11397771|NCT02051153|Experimental|Placebo|"Placebo: study participants received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
~Other Names: Placebo."
11397772|NCT02051153|Experimental|Modafinil|"Study participants received, in a double blind fashion, either a single dose (200 mg) of modafinil or a placebo pill identical to the drug.
~Other Names:
~Provigil"
11397773|NCT02051140|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry.
11397774|NCT02051140|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo.
11397775|NCT02051127|Experimental|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
11397776|NCT02051127|No Intervention|Control|Instructed to continue with their sedentary behavior for another 6 months.
11397777|NCT02051101|Other|Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
11397778|NCT02051088|Experimental|Revascularization with drug eluting technology|Revascularization with drug eluting technology
11397779|NCT02051088|Active Comparator|Revascularization without drug elution|Revascularization without drug elution technology
11397780|NCT02051075|Active Comparator|PXN only|Sperm activation with PXN before ICSI
11397781|NCT02051075|Experimental|PXN activation and oocyte activation|Sperm activation with PXN and oocyte activation
11397782|NCT02051062|Experimental|One 5 mL blood sample will be collected|A single 5 mL blood sample will be collected from pediatric patients treated with BAT®. The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
11397783|NCT02051049||Inborn errors of liver metabolism|
11397784|NCT02051036|Experimental|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
11397785|NCT02051036|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
11397786|NCT02051023|Experimental|FML 0.1% eyedrops|FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days
11397787|NCT02051023|Active Comparator|Liquifilm artificial tears eyedrops|Topical application 4 times a day in both eyes for 22 days
11397788|NCT02051010||Metastatic Breast Cancer|
11397789|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
11397790|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
11397791|NCT02050971|Active Comparator|Autologous cord blood transfusion|Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
11397792|NCT02050971|Sham Comparator|Standard treatment for neonatal anemia|Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development
11397793|NCT02050958|Experimental|OXP001|OXP001
11397794|NCT02050958|Active Comparator|Ibuprofen|Brufen
11397795|NCT02050945|Experimental|Patients with COPD|Patients with COPD are to be trained 3 times a week for 8 weeks
11397796|NCT02050945|Active Comparator|Control patients with COPD|Control patients with COPD are to be trained 3 times a week for 8 weeks
11397797|NCT02050932|Experimental|Iron absorption assessement|"60 mg Fe as FeSO4 with stable isotopic labels participants will receive at different times of the day (total of three dosages) and follow a standardized diet scheme.
~Subjects will act as their own controls during the study"
11397798|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
11397799|NCT02050906|Experimental|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.
~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
11397800|NCT02050906|Active Comparator|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
11397801|NCT02050893|Experimental|Midazolam|Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4
11397802|NCT02050893|Experimental|Propofol|Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4
11397803|NCT02050880||Normal eyes|Eyes without pathology.
11397804|NCT02050880||Glaucoma|Eyes with Glaucoma.
11397805|NCT02050880||Retinal|Eyes with Retinal Disease.
11397806|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
11397807|NCT02050854||Observation|Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole
11397808|NCT02050841|Experimental|Octaplas|Qualified patients will receive Octaplas as per protocol.
11397809|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
11397810|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
11397811|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
11397812|NCT02050815|Experimental|MEK162|A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.
11397813|NCT02050802|Experimental|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397814|NCT02050802|Experimental|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397815|NCT02050802|Experimental|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397816|NCT02050802|Experimental|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397817|NCT02050802|Experimental|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397818|NCT02050802|Experimental|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397819|NCT02050802|Experimental|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397820|NCT02050802|Experimental|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
11397821|NCT02050789|No Intervention|Usual Care Arm|Programs will continue adhering to current ACGME requirements.
11397822|NCT02050789|Experimental|Intervention Arm|The intent of the intervention arm is to allow flexibility in surgical resident duty hours and improve continuity of care.
11397823|NCT02050776|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
11397824|NCT02050763|Experimental|Intervention arm|Intervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
11397825|NCT02050763|No Intervention|Control arm|Control arm clusters (n=7) received standard of care HIV services alone.
11397826|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
11397827|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
11397828|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
11397829|NCT02050724|Experimental|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
11397830|NCT02050724|Experimental|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
11397831|NCT02050711|Other|Usual care|Patients will receive usual care from their general practitioners/pulmonologists.
11397832|NCT02050711|Experimental|Pulmonary rehabilitation|Patients will enrol in a 12-week PR program consisting on exercise training (3 times a week) and psychoeducation (once a week).
11397833|NCT02050698|Active Comparator|short leg walking cast|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed protected weightbearing in a short leg walking cast
11397834|NCT02050698|Experimental|hard-soled shoe|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed tolerable weightbearing in a hard-soled shoe
11397835|NCT02050685||All patients for PSG at SLBO|All patients incoming in the sleep study centre for a PSG. At the arrival the screening score will be recorder. AHI will be recorded next morning after analysis of the PSG.
11397836|NCT02050672|Active Comparator|untreated|Semen was prepared with routinely used media
11397837|NCT02050672|Experimental|myo-inositol|"routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.
~in particular the stock solution was prepared in order to add 15microliters per ml of medium"
11397838|NCT02050646|Experimental|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
11397839|NCT02050646|Experimental|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
11397840|NCT02050633||Severe cranial trauma|This is a cohort of adult patients who have suffered a severe TBI between 1 July 2005 and 1 May 2007.
11397841|NCT02050607|No Intervention|Control group|Control group
11397842|NCT02050607|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation from healthy lean donors
11397843|NCT02050594||Melanoma patients on Ipilimumab|All unresectable, recurrent or metastatic melanoma patients
11397844|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
11397845|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
11397847|NCT02050555|Experimental|Koji-extracted beverage fermented with LP28|100ml/day for 12 weeks. 1x10^11 cells (LP28)/day
11397848|NCT02050542|Other|Targeted biopsies guided by a fusion of MRI and ultrasound|After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
11397849|NCT02050542|Other|Systematic biopsies|The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
11397850|NCT02050529|Experimental|Labetalol|This group (Group A; Labetalol) receiveD intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20 mg wAS administered, and if required repeated in increments of 40 mg,80 mg,80 mg,80 mg every 10 minutes till SBP became <160 and DBP <110 mm Hg, upto a maximum cululative dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure were checked every 10 minutes.
11397851|NCT02050529|Active Comparator|Hydralazine|This group (Hydralazine;Group B) received intravenous Hydralazine and served control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure were checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg was still reached after 20 minutes, then second bolus was repeated. Similarly if after 20 minutes SBP was still ≥160 or DBP ≥110 mm Hg, then third dose was given. If SBP or DBP thresholds were still exceeded after 20 minutes then similarly 4th and 5th dose of 5 mg were given. Failure to reduce SBP<160 or DBP<110 after consecutive maximum 5 boluses(total 25 mg) was labeled as severe persistent hypertension.
11397852|NCT02050516|Active Comparator|single embryo culture|single embryo culture in single drops inside micro-well group culture dish
11397853|NCT02050516|Experimental|group embryo culture|group embryo culture in a single drop inside micro-well group culture dish
11397854|NCT02050503||intranasal transmucosal fentanyl pectin|intranasal transmucosal fentanyl in pectin (100, 200, 400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain
11397855|NCT02050490||Before group, no diary|
11397856|NCT02050490||After group, with symptom diary|
11397857|NCT02050477|Experimental|Laparoscopic Vertical Gastroplasty|
11397858|NCT02050464||Healthy controls|Healthy controls
11397859|NCT02050464||Alzheimer's disease|Patients with mild Alzheimer's disease
11397860|NCT02050464||Vascular dementia|Patients with vascular dementia
11397861|NCT02050464||Fronto-temporal dementia|Patients with fronto-temporal dementia
11397862|NCT02050464||Mild cognitive impairment|Patients with mild cognitive impairment
11397863|NCT02050451|Experimental|Nutrition Intervention|Ensure Plus®, consumed orally twice daily for 2 weeks before and 4 weeks after surgery
11397864|NCT02050451|Active Comparator|Control|Over the counter daily multivitamin for 2 weeks before and 4 weeks after surgery
11397865|NCT02050438||Knee Osteoarthritis patients with prostesis treatment|Patients operated previously of Knee Osteoarthritis with different prostesis designs according the Hospital guide
11397866|NCT02050425|Active Comparator|Therapeutic CPAP|Patients continue therapeutic continuous positive airway pressure (CPAP).
11397867|NCT02050425|Placebo Comparator|Subtherapeutic CPAP|Placebo-CPAP device delivering subtherapeutic pressure for two weeks.
11397868|NCT02050412|Other|Cat fur scratch test|
11397869|NCT02050399|Active Comparator|Healthy subjects|15 men, 45 and 65 years old. After initial evaluation, clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise protocol will be performed.
11397870|NCT02050399|Experimental|Coronary disease with Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease and type 2 diabetes will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood), clinical autonomic tests and isometric exercise protocol will be performed.
11397871|NCT02050399|Experimental|Coronary disease without Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise will be performed.
11397872|NCT02050386||Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds.
11397873|NCT02050386||Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds.
11397874|NCT02050373|Active Comparator|Low-Level laser (660nm, 40mW, 0.16 J, 4 J/cm2)|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
11397875|NCT02050373|No Intervention|Allocated not to receive intervention|
11397876|NCT02050360|Experimental|Sildenafil 80 mg|Sildenafil 80 mg
11397877|NCT02050360|Experimental|Sildenafil 40 mg|Sildenafil 40 mg
11397878|NCT02050360|Placebo Comparator|Placebo|placebo
11397879|NCT02050347|Experimental|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
11397880|NCT02050347|Experimental|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
11397881|NCT02050347|Experimental|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
11397882|NCT02050347|Experimental|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
11397883|NCT02050334|Experimental|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
11397884|NCT02050334|Experimental|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
11397923|NCT02050061|Experimental|compression stocking|compression stocking (SIGVARISTM), daily for 3 months
11397924|NCT02050061|No Intervention|standard medical therapy|Usual care
11397885|NCT02050321|Experimental|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
11397886|NCT02050308|Experimental|Internet-All Nations Breath of Life (I-ANBL)|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to quitting smoking (like: preparing to quit, dealing with cravings, and support systems, etc.) and topics relevant to American Indian culture (like traditional use of tobacco).
~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
11397887|NCT02050308|Active Comparator|Honoring the Gift of Heart Health|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to heart health (like: Assessing risk for heart disease, increasing fruit and vegetable consumption, physical activity, etc.).
~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
11397888|NCT02050295|Experimental|Nerve block washout|Patients will receive a washout infusion of saline through their perineural catheter to reverse their motor block while maintaining the sensory block.
11397889|NCT02050295|Sham Comparator|Sham washout|Patients will receive an infusion of saline run just enough to maintain catheter patency.
11397890|NCT02050282|No Intervention|Business as usual|Triage and treatment based on routine clinical assessment as usual
11397891|NCT02050282|Experimental|Supplementary NT-proBNP measurement|Triage and treatment based on routine clinical assessment supplemented with measurement of NT-proBNP
11397892|NCT02050269|Experimental|Iohexol|injection of 5 ml of iohexol
11397893|NCT02050256|Other|general practioner|
11397894|NCT02050243|Experimental|5ALA|All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
11397895|NCT02050230|Active Comparator|Fresh blood transfusion|One unit of blood stored for less than 14 days
11397896|NCT02050230|Experimental|Standard issue blood transfusion|One unit of blood stored under standard conditions
11397897|NCT02050217|Experimental|Noninvasive ventilation|Neurally Adjusted Ventilatory Assist versus Pressure Support flow triggered delivered by helmet
11397898|NCT02050204|Experimental|LEEF Industry only: Intervention|"Customized to the Leef (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
11397899|NCT02050204|No Intervention|LEEF Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
11397900|NCT02050204|Experimental|TOMO Industry only: Intervention|"Customized to the Tomo (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
11397901|NCT02050204|No Intervention|TOMO Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
11397902|NCT02050191|No Intervention|program feasibility|
11397903|NCT02050178|Experimental|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
11397904|NCT02050165|Experimental|KIND Bar|Daily inclusion of KIND Bars with almonds as a primary ingredient as part of the participant's usual diet, with diet counseling to adjust for the calories from the KIND Bars. KIND Bars that we will use in the study will include: Dark Chocolate Chili Almond; Cranberry Almond; Almond Walnut Macadamia; Pomegranate Blueberry Pistachio; Nut Delight; Fruit and Nut Delight; Almond and Apricot; Blueberry Pecan and Fiber.
11397905|NCT02050165|Experimental|Typical American Snack|Daily inclusion of conventional snacks (as part of the participant's usual diet, with diet counseling to adjust for the calories from the snacks. The snacks will consist of cookies considered to be conventional snack foods that are nutrient-dilute (i.e. relatively low in nutrients) and energy-dense (i.e., relatively high in kcal). Examples of conventional snack foods will include: Nabisco Snackwell Creme Sandwich 1.7 oz pack, Nabisco Newtons Fig 2 oz pack, Nabisco Cips Ahoy! Chocolate Chip 1.4 oz pack, and Nabisco Oreo Double Stuff Chocolate 1.3 oz pack.
11397906|NCT02050152|Placebo Comparator|0% nitrous oxide|Explicit and implicit memory will be tested in 0% nitrous oxide
11397907|NCT02050152|Active Comparator|30% nitrous oxide|Explicit and Implicit memory in 30% nitrous oxide
11397908|NCT02050152|Active Comparator|60% nitrous oxide|Explicit and Implicit memory with 60% nitrous oxide
11397909|NCT02050139|Experimental|L-cysteine (Biocysan®)|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
11397910|NCT02050139|Placebo Comparator|Placebo|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
11397911|NCT02050126|Experimental|Scar Revision|Caesarean Scar Revision using Lumenis UltraPulse Encore.
11397912|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft
11397913|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
11397914|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
11397915|NCT02050087|Active Comparator|3 weeks with simple sling|Early motion after arthroscopic rotator cuff repair.
11397916|NCT02050087|Active Comparator|6 weeks with neutral brace|Delayed motion after arthroscopic rotator cuff repair.
11397917|NCT02050074|Experimental|Colesevelam|
11397918|NCT02050074|Experimental|Metformin|
11397919|NCT02050074|Experimental|Placebo|
11397920|NCT02050074|Experimental|Colesevelam + exendin (9-39)|
11397921|NCT02050074|Experimental|Metformin + exendin (9-39)|
11397922|NCT02050074|Experimental|Placebo + + exendin (9-39)|
11397925|NCT02050048|Experimental|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:
~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour
~LR fluid infusion during the procedure at 5 cc/kg/hr
~Post-procedure bolus of 20 cc/kg over 90 minutes"
11397926|NCT02050048|Active Comparator|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
11397927|NCT02050035|Experimental|CKD Aerobic Exercise Training|Chronic Kidney Disease participants randomly allocated to the CKD Exercise arm will receive 12 weeks of Aerobic Exercise Training three times per week.
11397928|NCT02050035|No Intervention|CKD Control|Chronic Kidney Disease participants allocated to the the CKD Control arm will receive their standard routine care over a 12 week period.
11397929|NCT02050035|No Intervention|Healthy Control|Healthy participants will act as comparators, they will undergo baseline testing only and will not receive an intervention.
11397930|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
11397931|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
11397932|NCT02050009|Experimental|Treatment (metformin hydrochloride, carboplatin, paclitaxel)|Patients receive metformin hydrochloride BID on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11397933|NCT02049996||Robotic-assisted prolapse repair|Subjects already scheduled for robotic-assisted prolapse repair in conjunction with vaginal hysterectomy
11397934|NCT02049996||Vaginal prolapse repair|Subjects already scheduled for vaginal prolapse repair in conjunction with vaginal hysterectomy.
11397935|NCT02049983|Experimental|Use of Levita Magnetics Grasper|
11397936|NCT02049970|Experimental|dexmedetomidine and bupivacaine|Bupivacaine 50 mg and dexmedetomidine 1 microgram/kg
11397937|NCT02049970|Experimental|Bupivacaine and placebo|Bupivacaine 100 mg and SF 10 ml
11397938|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane|Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).
11397939|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Fulvestrant|Sapanisertib 5 mg, unmilled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection, intramuscularly (IM), once on Day 1 of each cycle (Up to 57 cycles).
11397940|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Exemestane|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 8 cycles).
11397941|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Fulvestrant|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle up to 14 cycles plus fulvestrant 500 mg, injection, IM, once on Day 1 of each cycle (Up to 14 cycles).
11397942|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 4 mg + Exemestane|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 18 cycles).
11397943|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg + Exemestane (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 14 cycles) in everolimus sensitive participants.
11397944|NCT02049957|Experimental|Phase 2:Sapanisertib 4 mg+Fulvestrant (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 17 cycles) in everolimus sensitive participants.
11397945|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Exemestane (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus once daily in a 28-day cycle (Up to 12 cycles) in everolimus resistant participants.
11397946|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Fulvestrant (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 9 cycles) in everolimus resistant participants.
11397947|NCT02049944|Experimental|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
11397948|NCT02049931|Experimental|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
11397949|NCT02049931|Active Comparator|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
11397950|NCT02049931|Active Comparator|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
11397951|NCT02049905|Experimental|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
11397952|NCT02049905|Active Comparator|Investigator's Choice of Treatment|"These treatments include:
~Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;
~Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;
~Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;
~Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or
~Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
11397953|NCT02049892||Metal Ion|
11397954|NCT02049879|Experimental|Injection|Corticosteroids injection
11397955|NCT02049866|Experimental|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
11397956|NCT02049853|No Intervention|default group|"Patients with the randomization result default group receive standard diagnostics"
11397957|NCT02049853|Active Comparator|POCT group|"patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle"
11397958|NCT02049840|Experimental|Altis Single Incision Sling System|Altis Single Incision Sling System
11397959|NCT02049827|Experimental|Renal transplant|
11397960|NCT02049814|Experimental|Metformin + Voglibose 0.2 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
11397961|NCT02049814|Active Comparator|Metformin + Acarbose 50 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
11397962|NCT02049801|Experimental|Treatment (MEK inhibitor, MEK162, idarubicin, cytarabine)|"INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 PO BID on days -4 to -1 and days 5-18, cytarabine IV continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. Patients may receive a second course of induction at the discretion of the principal investigator.
~POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11397963|NCT02049788|Active Comparator|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
11397964|NCT02049788|Experimental|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
11397965|NCT02049775|Experimental|NBI|
11397966|NCT02049762|Active Comparator|P2Y12 inhibitors and aspirin|ACS patients on novel P2Y12 inhibitors and aspirin
11397967|NCT02049762|Placebo Comparator|P2Y12 inhibitors and placebo|ACS patients on novel P2Y12 inhibitors and placebo
11397968|NCT02049749|No Intervention|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
11397969|NCT02049749|Experimental|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
11397970|NCT02049736|Experimental|Telbivudine|
11397971|NCT02049723||Patients with GERD|The knowledge level on GERD among Korean patients with gastroesophageal disease was evaluated by the method of multicenter survey
11397972|NCT02049710|Active Comparator|Sexual Behavior Intervention|
11397973|NCT02049710|Active Comparator|Driving behavior intervention|
11397974|NCT02049697|Experimental|14C-JNJ-39823277|
11397975|NCT02049684||Surgery|
11397976|NCT02049684||Physiotherapy|
11397977|NCT02049671||Growth Hormone Therapy|
11397978|NCT02049671||Control Group|
11397979|NCT02049658||Healthy volunteers|Healthy volunteers measured by currently used healthy screening procedures
11397980|NCT02049658||Suspected breast cancer subjects|Suspected breast cancer subjects without pathological examination yet but will have it soon
11397981|NCT02049658||Suspected lung cancer subjects|Suspected lung cancer subjects without pathological examination yet but will have it soon
11397982|NCT02049658||Suspected neurological tumor subjects|Suspected neurological tumor subjects without pathological examination yet but will have it soon
11397983|NCT02049658||Suspected patients with gynecological tumor|Suspected subjects with gynecological tumors without pathological examination yet but will have it soon
11397984|NCT02049645||faculty staff and their adult family members|faculties and their adult family members of the Third Xiang-Ya Hospital
11397985|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
11397986|NCT02049619|No Intervention|Control|Following endotracheal intubation, no pharyngeal pack was inserted into the hypopharynx.
11397987|NCT02049619|Experimental|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
11397988|NCT02049606|Experimental|LAYLA|Drug : LAYLA tablet/bid
11397989|NCT02049606|Active Comparator|CENATONE|Drug : CENATONE tablet/qd
11397990|NCT02049593|Experimental|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11398031|NCT02049255|Active Comparator|Chloroprocaine|Rachianesthesia with marcaine or chloroprocaine
11397991|NCT02049593|Experimental|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11397992|NCT02049580|Experimental|RIC regimen|Thiotepa, Fludarabine, Cyclophosphamide pre- and post- transplantation.
11397993|NCT02049567|Experimental|FluidVision AIOL|FluidVision AIOL implanted in the capsular bag following removal of the cataractous lens
11397994|NCT02049554|No Intervention|Usual Care|
11397995|NCT02049554|Experimental|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
11397996|NCT02049541|Experimental|Treatment (PI3K inhibitor BKM120, rituximab)|Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.
11397997|NCT02049528|Experimental|3 mg CC-122 reference capsule formulation|3 mg CC-122 reference capsule given by mouth with 240 mL of room temp tap water
11397998|NCT02049528|Experimental|3 mg CC-122 test capsule formulation|3 mg CC-122 test capsule give by mouth with 240 mL of room temp tap water
11397999|NCT02049528|Experimental|3 mg CC-122 test capsule + high fat meal|3 mg CC-122 test capsule given by mouth with 240 mL of room temp tap water approximately 5 minutes after eating a high-fat meal
11398000|NCT02049515|Experimental|IPI-145|IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.
11398001|NCT02049515|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
11398002|NCT02049502|Experimental|fecal microbiota transplant|fecal microbiota transplant
11398003|NCT02049489|Experimental|ICT-121 DC vaccine|Autologous dendritic cells pulsed with peptide antigens
11398004|NCT02049476|Experimental|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
11398005|NCT02049450|Experimental|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
11398006|NCT02049437|Active Comparator|Arm A: TCZ|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
11398007|NCT02049437|Placebo Comparator|Arm B: Placebo|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
11398008|NCT02049424||transplanted patients|T-repleted haploidentical transplanted patients in Italy
11398009|NCT02049411|Experimental|Ketamine group|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
11398010|NCT02049411|Sham Comparator|physiological solution|Control group: only physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
11398011|NCT02049398||Oral microbiome cohort|a cohort of 40 adults willing to provide oral samples approximately every two months forone year
11398012|NCT02049385|Experimental|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
11398013|NCT02049385|Experimental|Placebo|Subjects received a matched placebo for three weeks
11398014|NCT02049359|No Intervention|Control group|Care as usual; no bidirectional texting
11398015|NCT02049359|Experimental|Texting|Bidirectional texting weekly for 12 weeks
11398016|NCT02049346|Active Comparator|Epoetin alpha or beta (Epoetin group)|Patients in that arm were continued on the previous same dose and route of administration of Epoetin alpha/ beta (Epoetin group).
11398017|NCT02049346|Active Comparator|Darbepoetin alpha|subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol.
11398018|NCT02049346|Experimental|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous Methoxy polyethylene glycol-epoetin beta monthly.
11398019|NCT02049333|Active Comparator|Phacoemulsification|Cataract extraction alone
11398020|NCT02049333|Experimental|Phacoemulsification with Endoscopic Cycloplasty (ECPL)|Cataract extraction combined with endoscopic cycloplasty
11398021|NCT02049320||Remifentanil|Patients sedated using Remifentanil
11398022|NCT02049307|Active Comparator|Treatment|Losartan 100mg daily
11398023|NCT02049307|Placebo Comparator|Placebo|Matching placebo
11398024|NCT02049294|Active Comparator|Omalizumab (Xolair)|Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.
11398025|NCT02049294|Placebo Comparator|Placebo (Normal Saline)|0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab
11398026|NCT02049281|Experimental|Vintafolide|Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
11398027|NCT02049268|Experimental|Nicotine + Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
11398028|NCT02049268|Experimental|Placebo Nicotine + Alcohol|A placebo nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (placebo nicotine) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
11398029|NCT02049268|Experimental|Nicotine + Placebo Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink a placebo alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
11398030|NCT02049255|Placebo Comparator|Marcaine|Rachianesthesia with marcaine or chloroprocaine
11398032|NCT02049242|Active Comparator|Triple tourniquet|
11398034|NCT02049229|Experimental|OPTIMAX stent|Patients randomised to receive titanium-nitride-oxide coated OPTIMAX-stent
11398035|NCT02049229|Active Comparator|SYNERGY stent|Patients randomised to receive everolimus-eluting, biabsorabble polymer coated stent
11398036|NCT02049216|Sham Comparator|Sham tape|"Fixomull tape only
~Single piece of 10cm wide, 32cm long applied from inferior to tibial tuberosity, over patella and onto quadriceps muscle. Corners rounded. Tape to be applied with the knee in 90 degrees flexion.
~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
11398037|NCT02049216|Experimental|Flexible tape|"Flexible tape (rocktape brand) applied as follows:
~First piece of tape 10 cm wide and 32cm long (length of a standard goniometer). Split down centre 18cm from 1 end. Second piece of tape 5cm wide and 14cm long.
~Tape applied in 90 degrees knee flexion Applied with no tension in proximal and distal ends. 30% tension to un-split portion placed over quads. 50% tension to split portion placed either side of patella and crossing over at tibial tuberosity Additional piece of 5cm wide flexible tape applied with 80% tension over patella tendon, with no tension in 3cm from ends All tape corners rounded
~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
11398038|NCT02049203|Placebo Comparator|Placebo|Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days.
11398039|NCT02049203|Active Comparator|Ataciguat|Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days
11398040|NCT02049190|Experimental|onapristone 10 mg BID|onapristone 10 mg BID extended-release tablets
11398041|NCT02049190|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
11398042|NCT02049190|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
11398043|NCT02049190|Experimental|onapristone 40 mg BID|onapristone 40 mg BID extended-release tablets
11398044|NCT02049190|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release
11398045|NCT02049190|Experimental|onapristone 30 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg
11398046|NCT02049190|Experimental|onapristone 50 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg
11398047|NCT02049190|Experimental|Expansion cohort: onapristone 50 mg BID|Expansion cohort: onapristone 50 mg BID
11398048|NCT02049177||Head and Neck Cancer Cases|Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
11398049|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
11398050|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
11398051|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
11398052|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
11398053|NCT02049151|Experimental|Tecemotide|
11398054|NCT02049151|Placebo Comparator|Placebo|
11398055|NCT02049138|Experimental|Open-label extension|All subjects will start treatment with ABT-494.
11398056|NCT02049125||No AKI|Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL.
11398057|NCT02049125||AKI and Infection|Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL.
11398058|NCT02049125||AKI with No Infection|Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection.
11398059|NCT02049112|Experimental|Salivary equivalent|Single dose stick without any active substance
11398060|NCT02049112|Sham Comparator|Aequasyal|Multidose moisturizing oral spray without any active substance
11398061|NCT02049112|Sham Comparator|Biotene|Multidose moisturizing oral spray without any active substance
11398062|NCT02049086|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
11398063|NCT02049086|Active Comparator|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
11398064|NCT02049086|No Intervention|No Additional Referral|No intervention.
11398065|NCT02049073|Experimental|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
11398066|NCT02049073|Experimental|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
11398067|NCT02049073|No Intervention|Control|no medication
11398068|NCT02049060|Experimental|Tivantinib+carboplatino+pemetrexed|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
11398069|NCT02049047|Experimental|Everolimus|oral everolimus
11398070|NCT02049034|Placebo Comparator|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
11398071|NCT02049034|Experimental|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.
~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
11398072|NCT02049021|Experimental|Electroconvulsive Therapy|Patients in use of clozapine randomized to receive ECT treatment
11398073|NCT02049021|Sham Comparator|SHAM ECT|Patients receiving clozapine randomized to sham ECT (placebo)
11398074|NCT02049008|Experimental|Photodynamic Therapy|
11398075|NCT02049008|Sham Comparator|Sham Photodynamic Therapy|
11398076|NCT02048995||Bipolar Depressed|Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
11398077|NCT02048995||Healthy Comparator|Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
11398078|NCT02048982|Experimental|Guideline and Cost|The Choosing Wisely guideline and the cost of the test at our institution: $60.35 for a basic metabolic panel.
11398079|NCT02048982|Placebo Comparator|Guideline|"The Choosing Wisely guideline: Don't perform blood chemistry panels in asymptomatic, healthy adults."
11398080|NCT02048982|Active Comparator|Guideline and Victim|The Choosing Wisely Guideline and a clinical scenario with a patient as an identifiable victim who suffered harm from having an unnecessary test done
11398081|NCT02048982|Experimental|Guideline, Cost, and Victim|The Choosing Wisely guideline and a clinical scenario with a physician as an identifiable victim who suffered harm when he ordered an unnecessary test.
11398082|NCT02048969|Experimental|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil will be administered to the patient at a rate of 0.1 mg flumazenil per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
11398083|NCT02048969|Placebo Comparator|Saline|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
11398084|NCT02048956|Experimental|Hydrotherapy intervention|30 people will be recruited in order to the inclusion criteria for the study and they will receive an hydrotherapy intervention.
11398085|NCT02048956|Active Comparator|Control group|30 people will be recruited and included in this control group. The are not going to receive hydrotherapy treatment, only the treatment they receive as usual.
11398086|NCT02048943|Experimental|Treatment (dovitinib, gemcitabine, nab-paclitaxel)|Patients receive dovitinib lactate PO QD 5 days per week, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11398087|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
11398088|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
11398089|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
11398090|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
11398091|NCT02048917|Experimental|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
11398092|NCT02048917|Experimental|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
11398093|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
11398094|NCT02048917|Experimental|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
11398095|NCT02048917|Experimental|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
11398096|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
11398097|NCT02048917|Experimental|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
11398098|NCT02048917|Experimental|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
11398099|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
11398100|NCT02048917|Experimental|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
11398101|NCT02048917|Experimental|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
11398102|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
11398103|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
11398104|NCT02048891|Active Comparator|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
11398105|NCT02048891|Experimental|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
11398106|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:
~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.
~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
11398107|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:
~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.
~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
11398108|NCT02048865|Active Comparator|Apixaban|2.5 mg BID for 6 months
11398109|NCT02048865|Placebo Comparator|Placebo drug|2.5 mg BID for 6 months
11398110|NCT02048852|Experimental|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
11398111|NCT02048852|Experimental|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
11398112|NCT02048852|Active Comparator|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
11398113|NCT02048852|Experimental|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
11398114|NCT02048839||Radiel Intervention group and their children|Participated the Radiel- intervention study (2008-2011) in the Intervention group: Lifestyle counselling during and after pregnancy (up to 1 year post partum)
11398115|NCT02048839||Radiel Control Group with their children|Control group in the Radiel- intervention study.
11398116|NCT02048826|Experimental|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
11398117|NCT02048826|Experimental|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
11398118|NCT02048826|Experimental|FINGER III|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with third setting at a minimum of 3 days per week, 1 hour per day with the exercise program
11398119|NCT02048813|Experimental|Arm A (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28. Beginning course 2, patients also receive rituximab IV over 4 hours on day 1 (days 1 and 2 of course 2 only). Treatment repeats every 28 days for 7 courses. In the absence of disease progression, patients may continue ibrutinib PO QD.
11398120|NCT02048813|Experimental|Arm B (rituximab, fludarabine phosphate, cyclophosphamide)|Patients receive rituximab as seen in Arm A and fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 30 minutes on days 1-3. Treatment repeats every 28 days for 6 courses.
11398121|NCT02048800||Treosulfan PK|Children with indication to HSCT receiving Treosulfan
11398122|NCT02048787|Experimental|Moderate renal impairment group|Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group
11398123|NCT02048787|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group
11398124|NCT02048787|Experimental|Matching healthy control group|Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
11398125|NCT02048774|Active Comparator|High Social Position|The investigators will randomly assign a participant to a higher social position.
11398126|NCT02048774|Experimental|Low Social Position|The investigators will randomly assign a participant to a lower social position.
11398127|NCT02048761|Placebo Comparator|Placebo Group|After debridement, placebo gel was applied into the periodontal pockets with a syringe and a blunt canula.
11398128|NCT02048761|Active Comparator|1% Metformin|After debridement, 1% Metformin gel was applied into the periodontal pockets with a syringe and a blunt canula.
11398129|NCT02048748|Experimental|Telemonitoring|Device: Weight and blood pressure device Device: Home telemonitoring device
11398130|NCT02048748|No Intervention|Control|Usual care
11398131|NCT02048722|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11398132|NCT02048709|Experimental|GDC-0919 Dose Escalation|GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle
11398133|NCT02048696|Experimental|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
11398134|NCT02048696|No Intervention|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
11398135|NCT02048683|Experimental|burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
11398136|NCT02048683|Other|non burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
11398137|NCT02048670|Experimental|Chronic Subjective Dizziness Syndrome Subjects|Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
11398138|NCT02048670|Active Comparator|Healthy Subjects|Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.
11398139|NCT02048657|Experimental|Foley group|The Foley Airway Stylet Tool was used to guide ProSeal LMA insertion
11398140|NCT02048657|Experimental|I-Tool group|the ProSeal LMA was inserted with a standard introducer-tool
11398141|NCT02048644|Placebo Comparator|placebo inhaler|matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
11398142|NCT02048644|Experimental|fostair|fostair 100mcg/6mcg 2pufss, twice a day.
11398143|NCT02048631||Oral Cancer Patients underwent Free Flap Reconstruction|
11398144|NCT02048618|Experimental|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
11398145|NCT02048618|Experimental|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
11398146|NCT02048618|Placebo Comparator|Placebo QD|2 placebo tablets in the morning
11398147|NCT02048605|Experimental|Psycho-social (CBT) based training|Psycho-social Training in Neurological Diseases - Parkinson's Disease ( Training according to Ellgring et al., 2006)
11398148|NCT02048605|Placebo Comparator|Unspecific group training|"Health Enhancement Program
~The validation of an active control intervention for Mindfulness Based Stress Reduction (MBSR) (MacCoon et al., 2012)"
11398149|NCT02048592|Active Comparator|Impact-Nutridrink|The first arm will be given immunonutrition -Impact- for 8 weeks, afterwards the patients will return to their previous nutrition support for another 8 weeks. We expect the improvement of oxidative stress parameters after 8 weeks of immunonutriton and return to baseline values when immunonutrition is stopped
11398150|NCT02048592|Active Comparator|Nutridrink-Impact|The second group will be given their previous nutrition support (Nutridrink) for 8 weeks, afterwards the patients will be switched to immunonutrition- Impact- for another 8 weeks. In this group of patients we do not expect any change of oxidative stress parameters after the first 8 weeks. The improvement is expected at the end of the second half of study.
11398151|NCT02048579|No Intervention|Treatment as Usual|
11398152|NCT02048579|Experimental|Behavior Therap + Motivational Interviewing|Supporting Teens' Academic Needs Daily Therapy program delivered to parents and teens
11398153|NCT02048566|Experimental|hTEEPM|Group hTEE protocolled monitoring (hTEEPM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration (see below) and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
11398154|NCT02048566|Experimental|hTEESM|Group hTEE standard monitoring (hTEESM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management in which case an hTEE assessment has to be performed. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
11398155|NCT02048566|Active Comparator|ControlPM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
11398156|NCT02048566|Active Comparator|ControlSM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
11398157|NCT02048553|Experimental|Tablet-guided|Guide-assisted ventriculostomy.
11398158|NCT02048553|Experimental|Freehand|standard ventriculostomy.
11398159|NCT02048540|Experimental|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
11398160|NCT02048540|Active Comparator|DOF|patients receive DOF pre and post surgery up to total 6 cycles
11398161|NCT02048527|Active Comparator|Global|In vitro embryo culture in single-step medium (Global)
11398162|NCT02048527|Active Comparator|Origio|In vitro embryo culture in sequential media (Origio)
11398163|NCT02048514|Experimental|Nellix Aneurysm Sealing|The Nellix® EndoVascular Aneurysm Sealing System
11398164|NCT02048501|Other|Weight Regain|The weight regain group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and regained at least 15% of the post-operative nadir weight.
11398165|NCT02048501|Other|Sustained Weight Loss (SWL)|The sustained weight loss group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and have regained less than 15% of the post-operative nadir weight.
11398166|NCT02048488|Experimental|Experimental Drug TSR-011|Experimental Drug TSR-011
11398167|NCT02048475|No Intervention|desflurane|inhalation concentration
11398168|NCT02048462||Cyclists|
11398169|NCT02048436||male female 18-45 years range of body types|18 male female subject mix that are 18-45 years of age and selected to represent a range of body types of varying physiques and body mass indexes
11398170|NCT02048423|Experimental|Ketamine|Drug
11398171|NCT02048410|Active Comparator|diet plus Lactobacillus paracasei B21060|low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
11398172|NCT02048410|Placebo Comparator|low saturated fats diet|low saturated fats diet
11398173|NCT02048397|Other|Pulmonary Rehabilitation (PRP)|Pulmonary Rehabilitation (PRP)
11398174|NCT02048397|Other|Pulmonary Rehabilitation plus oral nutritional supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
11398175|NCT02048384|Experimental|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
11398176|NCT02048384|Active Comparator|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
11398177|NCT02048371|Active Comparator|Cohort A: Regorafenib|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
11398178|NCT02048371|Placebo Comparator|Cohort A: Placebo|"21 days on and 7 days off
~Placebo"
11398179|NCT02048371|Active Comparator|Cohort B: Regorafenib|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
11398180|NCT02048371|Placebo Comparator|Cohort B: Placebo|"21 days on and 7 days off
~Placebo"
11398181|NCT02048371|Active Comparator|Cohort C: Regorafenib|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
11398182|NCT02048371|Active Comparator|Cohort D: Regorafenib|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
11398183|NCT02048371|Active Comparator|Cohort E: Regorafenib|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
~Regorafenib"
11398184|NCT02048358|Experimental|2B3-201 150mg|2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose
11398185|NCT02048358|Experimental|2B3-201 300mg|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose
11398186|NCT02048358|Experimental|2B3-201 450mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose
11398187|NCT02048358|Experimental|450mg 2B3-201|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
11398188|NCT02048358|Experimental|300mg 2B3-201|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose
11398189|NCT02048358|Experimental|2B3-201 450mg male volunteers|2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose
11398190|NCT02048358|Experimental|2B3-201 300mg or 450mg female volunteers|2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose
11398191|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 450 mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
11398192|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 dose tbd|2B3-201 (dose to be determined), once, IV infusion in 5% dextrose
11398193|NCT02048345|Experimental|Suspension, fasted state|Suspension Noxafil will be administered in the fasted state to the volunteers.
11398194|NCT02048345|Experimental|Suspension, with sugar (delay gastric emptying)|Suspension will be co-administered with glucose to delay the gastric emptying time
11398195|NCT02048345|Experimental|Solution, fasted state|A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
11398196|NCT02048345|Experimental|Solution, with sugar (delaying gastric emptying)|A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
11398197|NCT02048332|Experimental|Viral Specific VST Infusion|Viral reactivation or infection. VST Reinfusion required.
11398198|NCT02048319|Experimental|Experimental: Pasireotide LAR 60 mg|The subjects will be randomized (1:1) into two groups. Both groups will undergo aspiration sclerotherapy following the standard procedure. The intervention group will additionally receive two injections of 60 mg pasireotide long-acting release (LAR) intramuscularly: the first injection 14 days before and the second injection 14 days after the intervention.
11398199|NCT02048319|Placebo Comparator|Placebo|Patients in the placebo arm will receive two injections of saline solution corresponding to the scheme of the intervention group.
11398200|NCT02048306|Experimental|Family-based PR group|
11398201|NCT02048306|Active Comparator|Conventional PR group|
11398202|NCT02048293|Active Comparator|Group O|Remifentanyl innovative molecule = Ultiva®
11398203|NCT02048293|Active Comparator|Group A|Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.
11398204|NCT02048293|Active Comparator|Group B|Remifentanyl comparator B = Fada Remifentanilo
11398205|NCT02048280|Experimental|Intubated|NAVA level from 0.1 to 3
11398206|NCT02048267||Alcoholic|
11398207|NCT02048267||Non alcoholic|
11398208|NCT02048254|Experimental|brachytherapy|Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy
11398209|NCT02048254|Active Comparator|IMRT|IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times.
11398210|NCT02048241|Other|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
11398211|NCT02048241|Experimental|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
11398212|NCT02048228|Experimental|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for *2 carriers.CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
11398213|NCT02048228|Active Comparator|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
11398214|NCT02048215|Active Comparator|Ephedrine + Caffeine + diet|Ephedrine 20 mg + Caffeine 200 mg capsule t.i.d. for one month plus hypocaloric diet
11398215|NCT02048215|Placebo Comparator|Placebo + diet|Similarly-looking placebo capsule t.i.d. for one month plus hypocaloric diet
11398216|NCT02048202||premature neonate|premature neonate
11398217|NCT02048189|Other|Intensified multiple injections|
11398218|NCT02048189|Other|Pumps|
11398219|NCT02048176||Posterior Fossa Mutism|Patients with Posterior Fossa Mutism
11398220|NCT02048176||Non Posterior Fossa Mutism|Patients that did not develop Mutism
11398221|NCT02048163||Short infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.
11398222|NCT02048163||Prolonged infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.
11398223|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
11398224|NCT02048137|Active Comparator|Active transcranial direct current stimulation|
11398225|NCT02048137|Sham Comparator|Sham transcranial direct current stimulation|
11398226|NCT02048124|Active Comparator|25g standard needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
11398227|NCT02048124|Experimental|25d ProCor needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
11398228|NCT02048111|Experimental|IB1001|
11398229|NCT02048098|Active Comparator|Buccal misoprostol|400 µg buccal misoprostol per 3 hours
11398230|NCT02048098|Active Comparator|vaginal misoprostol|400 µg vaginal misoprostol per 3 hours
11398231|NCT02048085|Experimental|Ticagrelor|Ticagrelor Arm will be dosed with a loading dose of 180 mg followed by maintenance dose of 90 mg BID until discharge or up to 8 days.
11398232|NCT02048085|Active Comparator|Clopidogrel|Clopidogrel arm will be dose with a loading dose of 300 mg followed by maintenance dose of 75 mg everyday until discharge or up to 8 days.
11398233|NCT02048072|Experimental|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
11398669|NCT02045069|Experimental|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
11398234|NCT02048059|Experimental|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
11398235|NCT02048046||ECMO|
11398236|NCT02048033|Active Comparator|Arm with Apollo Endosurgery OverStitch technical|
11398237|NCT02048033|Placebo Comparator|Arm without Apollo Endosurgery OverStitch technical|
11398238|NCT02048020|Experimental|Treatment (paclitaxel, carboplatin, IMRT)|"INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity."
11398239|NCT02048007|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years
~Morbidity monitoring:
~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community.
~Anthropometry for all children aged 1 to 60 months per community.
~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint."
11398240|NCT02048007|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community
~Anthropometry for all children aged 1 to 60 months per community
~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint"
11398241|NCT02047994|Experimental|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
11398242|NCT02047994|No Intervention|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
11398243|NCT02047981|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.
~In Niger during year 3, all communities will be offered azithroymcin."
11398244|NCT02047981|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.
~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
~In Niger during year 3, all communities will be offered azithroymcin."
11398245|NCT02047968|Experimental|wake therapy, light therapy and sleep time stabilisation|Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between. Light therapy for 30 minutes daily in the entire study period. Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
11398246|NCT02047968|No Intervention|treatment as usual|
11398247|NCT02047942|Active Comparator|Center-based cardiac rehabilitation|Patients randomized to the center-based training group will continue their training sessions at the outpatient clinics of UZ Leuven under direct supervision of physical therapists
11398248|NCT02047942|Experimental|Home-based training with telemonitoring guidance|Patients will receive an patient-tailored exercise prescription and will be asked to perform the exercise sessions in their home environment wearing heart rate monitors. Training data will be accessed by the research group on weekly basis in order to keep a record of frequency; duration and intensity of the sessions. Feedback will be given weekly to every patient.
11398249|NCT02047942|No Intervention|Control|
11398250|NCT02047929|Active Comparator|Facilitator-Led|This approach to dissemination allows clinics some freedom to tailor the Asthma Shared Decision Making (SDM) Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
11398251|NCT02047929|Active Comparator|Traditional|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will give an overview of the Asthma Shared Decision Making (SDM) Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
11398354|NCT02047175|Experimental|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)
~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
11398670|NCT02045069|Placebo Comparator|Placebo|Placebo
11398252|NCT02047929|No Intervention|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
11398253|NCT02047916||Normal Neonates > 33 weeks gestation|"Neonates >33 weeks gestational age
~Postnatal age <72 hours;
~Parental informed consent;
~Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
11398254|NCT02047903||Afatinib|
11398255|NCT02047890|Experimental|BAY1000394|Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
11398256|NCT02047877||Respiratory Illness|Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.
11398257|NCT02047864|Experimental|Creatine monohydrate|Creatine monohydrate to be given during a resistance training program
11398258|NCT02047864|Placebo Comparator|Sugar pill|Placebo to be given during a resistance training program
11398259|NCT02047851|Active Comparator|Acupuncture in active points|Patients in this group will receive real acupuncture
11398260|NCT02047851|Sham Comparator|Acupuncture in non-active points|Patients in this group will receive acupuncture, but in non-active points
11398261|NCT02047851|No Intervention|No treatment, just observation|Patients in this group will receive no treatment and will only be observed.
11398262|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
11398263|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
11398264|NCT02047825|Experimental|Experimental group|The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
11398265|NCT02047825|Active Comparator|Control group|Patients with multiple sclerosis not included in the intensive intervention. They receive the usual treatment of occupational and physical therapy.
11398266|NCT02047812||High volume hospitals|The hospitals in the upper tertile for procedural volume
11398267|NCT02047812||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
11398268|NCT02047812||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
11398269|NCT02047799|Active Comparator|Calcitriol|A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
11398270|NCT02047799|Placebo Comparator|Control|A daily dose of placebo (administered as 1 capsule )
11398271|NCT02047786||General Hospital Patients|Those patients undergoing appendicectomy in a general (non-specialised) surgical centre.
11398272|NCT02047786||Paediatric Hospital Patients|Those patients undergoing appendicectomy in specialised paediatric centres.
11398273|NCT02047773|Placebo Comparator|14 days Duration|14 days of antibiotics regardless of bacterial load.
11398274|NCT02047773|Active Comparator|Bacterial load guided duration|Antibiotics stopped early on day 8 or day 11 if the bacterial load when checked on day 7 and day 10 is less than 10^6cfu/ml.
11398275|NCT02047760||MS patients|All MS sub-types
11398276|NCT02047760||Controls|sex- and age-matched controls
11398277|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
11398278|NCT02047734|Experimental|Ozanimod 0.5 mg|Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
11398279|NCT02047734|Experimental|Ozanimod1 mg|Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
11398280|NCT02047734|Active Comparator|Interferon β-1a|Interferon (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months
11398281|NCT02047721|Experimental|Physical Intervention|A supervised exercise program
11398282|NCT02047721|Experimental|Nutritional Intervention|A supervised diet program
11398283|NCT02047695||Migraine with aura|Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls)
11398284|NCT02047682|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
11398285|NCT02047682|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
11398286|NCT02047669|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
11398287|NCT02047669|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
11398288|NCT02047656|Placebo Comparator|Placebo to LFF269 (Part 1)|Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
11398289|NCT02047656|Experimental|LFF269 (Part 1)|LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
11398290|NCT02047656|Experimental|LFF269 (Part 2)|LFF269 twice daily (b.i.d) for 5 days in patients with hypertension
11398291|NCT02047643|Experimental|On-algorithm first, then Off-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
11398355|NCT02047175|Experimental|B(Rosuvastatin)|"B(Rosuvastatin)
~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
11398671|NCT02045056|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
11398292|NCT02047643|Experimental|Off-algorithm first, then On-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
11398293|NCT02047630|Experimental|Generic latanoprost|1 eye drop hs
11398294|NCT02047630|Active Comparator|Brand-name latanoprost|1 eye drop hs
11398295|NCT02047617|Active Comparator|the standard physiotherapy group|Physiotherapy rehabilitation techniques used in the management of this group include passive range of motion, active range of motion/bed exercises, sitting at edge of bed, sitting in armchair, active transfer from the bed to chair. Mobilization and rehabilitation program is progressively introduced after clinical stabilization with a goal of progressing to ambulation and pulmonary rehabilitation.
11398296|NCT02047617|Experimental|standing table group|The same program as standard physiotherapy group is applied, with daily sessions of standing table in supplement. Standing table was performed on a motorized tilt table (ref: table de verticalisation, Franco&fils). The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform, at 10° intervals from 30° to 80°.
11398297|NCT02047604|Experimental|Cohort A - SAN-300 0.5 mg/kg|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks or placebo.
11398298|NCT02047604|Experimental|Cohort B - SAN-300 1.0 mg/kg|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks or placebo
11398299|NCT02047604|Experimental|Cohort C - SAN-300 2.0 mg/kg|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks or placebo
11398300|NCT02047604|Experimental|Cohort D - SAN-300 2.0 mg/kg|SAN-300 2.0 mg/kg subcutaneous once weekly for six weeks or placebo
11398301|NCT02047604|Experimental|Cohort E - SAN-300 4.0 mg/kg|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks or placebo
11398302|NCT02047591||Relaxing-touch method|
11398303|NCT02047591||Usual care|
11398304|NCT02047578|Experimental|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
11398305|NCT02047565|Experimental|Part 1 - 60mg edoxaban|Treatment A: single oral dose of 60 mg edoxaban (1 × 60 mg tablet)
11398306|NCT02047565|Experimental|Part 1 - 180mg edoxaban|Treatment B: single oral dose of 180 mg edoxaban (3 × 60 mg tablet)
11398307|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 50 IU/kg Beriplex P/N|Dose cohort 1: 60 mg edoxaban + 50 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
11398308|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 20 IU/kg Beriplex P/N|Dose cohort 2: 60 mg edoxaban + 25 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
11398309|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 10 IU/kg Beriplex P/N|Dose cohort 3: 60 mg edoxaban + 10 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
11398310|NCT02047552|Active Comparator|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
11398311|NCT02047552|Active Comparator|Oxandrolone|Oxandrolone 10 mg PO q12 hours will be dosed for seven days.
11398312|NCT02047552|Experimental|Iron sucrose + oxandrolone|Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.
11398313|NCT02047552|Placebo Comparator|IV iron placebo and Oxandrolone placebo|100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo
11398314|NCT02047539|Experimental|1000 mg/day aspirin|1000 mg/day aspirin
11398315|NCT02047539|Placebo Comparator|sugar pill|sugar pill
11398316|NCT02047526||1|
11398317|NCT02047513|Experimental|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
11398318|NCT02047513|Experimental|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
11398319|NCT02047500|Experimental|TH-302 plus Nab-paclitaxel plus Gemcitabine|
11398320|NCT02047474|Experimental|Treatment (mFOLFIRINOX)|"NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.
~ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11398321|NCT02047461|Experimental|ORGN001 (formerly ALXN1101)|daily IV infusions
11398322|NCT02047448|No Intervention|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
11398356|NCT02047162|Experimental|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
11398357|NCT02047162|Placebo Comparator|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
11398358|NCT02047149|Experimental|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
11398916|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the upper arm|
11398323|NCT02047448|Experimental|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
11398324|NCT02047435|Experimental|Information, event and workshops at a cartoon museum|
11398325|NCT02047435|Active Comparator|Information and event at a cartoon museum|
11398326|NCT02047422|Experimental|Add furosemide/no spironolactone|
11398327|NCT02047422|Experimental|Add metolazone/no spironolactone|
11398328|NCT02047422|Experimental|Add furosemid/spironolactone|
11398329|NCT02047422|Experimental|Add metolazone/spironolactone|
11398330|NCT02047396||Myocardial Infarction subjects|Subjects with first Myocardial Infarction presenting to one of the Mayo Clinic Hospitals in Rochester, Minnesota.
11398331|NCT02047383||respiratory infection|Hospitalized patients with a respiratory infection
11398332|NCT02047370|Experimental|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
11398333|NCT02047370|Placebo Comparator|Placebo group|Ultrasound disconnected in same position and with the same duration.
11398334|NCT02047357|Experimental|Intervention Arm|Learning Through Play Plus
11398335|NCT02047357|No Intervention|Control|This arm will receive no intervention
11398336|NCT02047344|Experimental|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
11398337|NCT02047331|Active Comparator|group PI|group PI were performed periarticular drug injection during surgery.
11398338|NCT02047331|Active Comparator|group FI|group FI were performed fascia iliaca block before surgery
11398339|NCT02047318|Experimental|LUM001|LUM001 administered orally up to twice each day
11398340|NCT02047305|Experimental|Radiofrequency ablation|To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN
11398341|NCT02047292|Active Comparator|THA28|THA Corail PinnacleCoC28
11398342|NCT02047292|Active Comparator|THA36|THA Corail DeltaMotion36
11398343|NCT02047292|Active Comparator|THA40|THA Corail DeltaMotion40
11398344|NCT02047279|Active Comparator|MVS + maze|"Procedure: Maze procedure, mitral valve surgery
~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.
~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
11398345|NCT02047279|Experimental|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction
~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.
~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
11398346|NCT02047266|Experimental|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.
~(MICS CABG group, n=50)"
11398347|NCT02047266|Active Comparator|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.
~(OPCABG group, n=50)"
11398348|NCT02047266|Active Comparator|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
11398349|NCT02047253|Experimental|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
11398350|NCT02047227|Experimental|Pergoveris®|
11398351|NCT02047227|Active Comparator|GONAL-f®|
11398352|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
11398353|NCT02047201|Experimental|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
11398390|NCT02046928|Experimental|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
11398359|NCT02047136|Experimental|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
11398360|NCT02047136|Active Comparator|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
11398361|NCT02047123|Experimental|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
11398362|NCT02047110|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.
11398363|NCT02047110|Experimental|Risankizumab 18 mg|Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks
11398364|NCT02047110|Experimental|Risankizumab 90 mg|Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
11398365|NCT02047110|Experimental|Risankizumab 180 mg|Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
11398366|NCT02047097||dimethyl fumarate (DMF)|Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care
11398367|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
11398368|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
11398369|NCT02047071|No Intervention|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
11398370|NCT02047071|Experimental|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
11398371|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
11398372|NCT02047045|Experimental|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
11398373|NCT02047045|Active Comparator|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
11398374|NCT02047032|Experimental|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
11398375|NCT02047032|Active Comparator|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
11398376|NCT02047019|Active Comparator|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
11398377|NCT02047019|Experimental|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
11398378|NCT02047019|Experimental|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
11398379|NCT02047006|Experimental|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:
~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.
~Effect of dialysis on levels of rivaroxaban:
~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
11398380|NCT02046993|Experimental|Smart phone based telemonitoring of HBP|". Patients do HBP monitoring
~. record their BP readings into the smart phone with downloaded application."
11398381|NCT02046993|Active Comparator|Enhanced usual care|". Patients to do HBP measurement
~. Record BP readings in their diary"
11398382|NCT02046980|Experimental|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
11398383|NCT02046980|Experimental|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
11398384|NCT02046980|Sham Comparator|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
11398385|NCT02046967|Active Comparator|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
11398386|NCT02046967|Active Comparator|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
11398387|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
11398388|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
11398389|NCT02046941|Experimental|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
11398391|NCT02046915|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|"Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle
~Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
~Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
11398392|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
11398393|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
11398394|NCT02046889|Experimental|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
11398395|NCT02046889|No Intervention|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
11398396|NCT02046876|Experimental|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
11398397|NCT02046863|Experimental|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
11398398|NCT02046850|Experimental|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
11398399|NCT02046850|Other|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
11398400|NCT02046850|Experimental|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
11398401|NCT02046837|Experimental|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
11398402|NCT02046837|Experimental|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
11398403|NCT02046837|Experimental|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
11398404|NCT02046824|Experimental|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
11398405|NCT02046824|Experimental|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
11398406|NCT02046824|Experimental|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
11398407|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
11398408|NCT02046811|Experimental|Patient activation and education|Patient activation and education (PAE)
11398409|NCT02046811|Experimental|PAE plus physician activation|PAE plus physician activation (PAE + MD)
11398410|NCT02046811|Experimental|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
11398411|NCT02046798|Experimental|14C labeled ASP3652|
11398412|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
11398413|NCT02046772|Experimental|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
11398414|NCT02046772|Active Comparator|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
11398415|NCT02046759|Experimental|Pharmacist-Intervention|
11398416|NCT02046759|Active Comparator|Routine Care|
11398417|NCT02046746|Experimental|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
11398418|NCT02046733|Experimental|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles
~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
11398419|NCT02046733|No Intervention|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
11398420|NCT02046720|Experimental|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
11398421|NCT02046707|Experimental|Patients with chronic heart failure|
11398422|NCT02046707|Other|Controls|
11398423|NCT02046694|Experimental|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
11398424|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
11398425|NCT02046668|Active Comparator|spironolactone|25mg spironolactone daily
11398426|NCT02046668|Placebo Comparator|Placebo|Matched Placebo
11398427|NCT02046655|Experimental|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.
~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.
~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.
~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
11398428|NCT02046655|Active Comparator|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.
~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.
~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
11398429|NCT02046642|Active Comparator|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
11398430|NCT02046642|Active Comparator|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
11398431|NCT02046629|Experimental|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
11398432|NCT02046616|Experimental|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
11398433|NCT02046603|Experimental|Tocilizumab Monotherapy|Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
11398434|NCT02046603|Experimental|Tocilizumab in Combination With Methotrexate or Other DMARDs|Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
11398435|NCT02046590|Active Comparator|Deep Sedation|"Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.
~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure."
11398436|NCT02046590|Active Comparator|General Anaesthesia|"General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.
~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator."
11398437|NCT02046577|Experimental|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
11398438|NCT02046577|Experimental|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
11398439|NCT02046577|Placebo Comparator|Placebo|Oral placebo in liquid weekly during 6 months
11398440|NCT02046564|Experimental|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
11398441|NCT02046564|Placebo Comparator|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
11398442|NCT02046551|Placebo Comparator|Placebo|placebo
11398443|NCT02046551|Experimental|Atomoxetine|atomoxetine (40 mg/day)
11398444|NCT02046538|Experimental|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.
~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
11398445|NCT02046538|Active Comparator|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.
~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
11398446|NCT02046525|Experimental|Auto fecal microbitoa therapy|autologous fecal microbiota therapy
11398447|NCT02046525|Placebo Comparator|Saline enema|Saline enema
11398448|NCT02046512|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
11398449|NCT02046512|Placebo Comparator|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
11398450|NCT02046499|Active Comparator|Oxytocin arm|Oxytocin alone administered which is current standard of care
11398451|NCT02046499|Experimental|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
11398452|NCT02046486|Active Comparator|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
11398453|NCT02046486|Experimental|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
11398454|NCT02046473|Other|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
11398455|NCT02046460|Active Comparator|Oral Anticoagulation|Vitamin K-Antagonists, target INR 2.0-3.0
11398456|NCT02046460|Experimental|Antiplatelets|Acetylsalicylic acid, 300mg o.p.d.
11398457|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
11398458|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
11398459|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
11398460|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
11398461|NCT02046434|Experimental|Parkinson's Diesase|Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease
11398462|NCT02046434|Experimental|Control|Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate
11398463|NCT02046421|Experimental|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11398464|NCT02046408|Experimental|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
11398465|NCT02046408|No Intervention|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
11398466|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
11398467|NCT02046382|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
11398468|NCT02046382|Placebo Comparator|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
11398469|NCT02046369|Experimental|Luradisone|Luradisone 20- 80 mg administered once daily
11398470|NCT02046369|Placebo Comparator|Placebo|Placebo administered once daily
11398471|NCT02046356||Early-Stage HCC|Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA
11398672|NCT02045056|Placebo Comparator|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
11398673|NCT02045043||Cardiomyopathy patients with ICDs|
11398472|NCT02046343|Experimental|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
11398473|NCT02046343|Placebo Comparator|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
11398474|NCT02046330|Experimental|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
11398475|NCT02046317|Experimental|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
11398476|NCT02046317|Active Comparator|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
11398477|NCT02046304|Experimental|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
11398478|NCT02046291|Experimental|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
11398479|NCT02046278|No Intervention|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
11398480|NCT02046278|Experimental|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
11398481|NCT02046265|Experimental|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
11398482|NCT02046265|Experimental|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
11398483|NCT02046265|Experimental|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
11398484|NCT02046265|Active Comparator|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
11398485|NCT02046239|Other|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
11398486|NCT02046239|Experimental|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
11398487|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
11398488|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
11398489|NCT02046213|Experimental|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
11398490|NCT02046200|Experimental|Ivermectin|Ivermectin 30 mg single dose
11398491|NCT02046200|Placebo Comparator|Sugar pill|Matched placebo, single dose
11398492|NCT02046187|Experimental|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
11398493|NCT02046174|Experimental|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads, at an amount of 8 RENCA macrobeads /kg body weight
11398494|NCT02046174|No Intervention|Best Supportive Care Arm|patients who will receive, or are receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
11398495|NCT02046161|Experimental|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
11398496|NCT02046161|Placebo Comparator|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
11398497|NCT02046148|Experimental|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
11398498|NCT02046148|Active Comparator|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
11398499|NCT02046135|Experimental|Sodium bicarbonate|At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains ~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
11398674|NCT02045030|Experimental|aflibercept and FOLFIRI|aflibercept and FOLFIRI
11398500|NCT02046135|Active Comparator|Sodium Chloride|At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.
11398501|NCT02046122|Experimental|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
11398502|NCT02046109|Experimental|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
11398503|NCT02046109|Active Comparator|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
11398504|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
11398505|NCT02046096|Experimental|Cook Celect® Vena Cava Filter|Cook Celect® Vena Cava Filter
11398506|NCT02046083|Experimental|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
11398507|NCT02046083|Placebo Comparator|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
11398508|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
11398509|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 400 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
11398510|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
11398511|NCT02046057|Experimental|PNB of SLN|Percutaneous core biopsy of sentinel node prior to standard sentinel node dissection
11398512|NCT02046044|Experimental|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
11398513|NCT02046044|Experimental|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
11398514|NCT02046031|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
11398515|NCT02046018|Active Comparator|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
11398516|NCT02046018|Active Comparator|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
11398517|NCT02046018|Active Comparator|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
11398518|NCT02046005|Active Comparator|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
11398519|NCT02046005|Experimental|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
11398520|NCT02046005|Experimental|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
11398521|NCT02045992|Experimental|Caffeine|Caffeine 500mg
11398522|NCT02045992|Placebo Comparator|Placebo|Lactose 500mg
11398523|NCT02045979|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
11398524|NCT02045979|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
11398525|NCT02045979|Active Comparator|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
11398553|NCT02045836|Experimental|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
11398526|NCT02045966|Experimental|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1
~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15
~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only
~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30
~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
11398527|NCT02045953|Experimental|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
11398528|NCT02045953|Experimental|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
11398529|NCT02045953|Experimental|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
11398530|NCT02045953|Experimental|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
11398531|NCT02045940|Experimental|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
11398532|NCT02045940|Experimental|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
11398533|NCT02045940|Experimental|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
11398534|NCT02045940|Experimental|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
11398535|NCT02045940|Experimental|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
11398536|NCT02045927|Active Comparator|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
11398537|NCT02045927|Other|Control Group|sedation monitoring with RASS score
11398538|NCT02045914|No Intervention|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
11398539|NCT02045914|Experimental|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
11398540|NCT02045901|Active Comparator|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
11398541|NCT02045901|Placebo Comparator|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
11398542|NCT02045888|Experimental|Low Dose ADRC|ADRCs prepared by investigational Celution Device
11398543|NCT02045888|Experimental|High Dose ADRC|ADRCs prepared by investigational Celution Device
11398544|NCT02045888|Placebo Comparator|Placebo|Placebo
11398545|NCT02045875|Experimental|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
11398546|NCT02045875|Active Comparator|Dulera Standard of Asthma Care|Dulera standard of asthma care
11398547|NCT02045862|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
11398548|NCT02045862|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
11398549|NCT02045862|Experimental|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
11398550|NCT02045849|Experimental|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
11398551|NCT02045849|Experimental|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
11398552|NCT02045849|Experimental|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
11398554|NCT02045836|Active Comparator|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
11398555|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
11398556|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
11398557|NCT02045823||Retina|clinical exam with results consistent with retina pathology
11398558|NCT02045810|Active Comparator|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
11398559|NCT02045810|Placebo Comparator|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
11398560|NCT02045797|Experimental|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily [BID]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
11398561|NCT02045797|Experimental|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
11398562|NCT02045797|Experimental|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
11398563|NCT02045784|Experimental|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
11398564|NCT02045784|Experimental|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
11398565|NCT02045784|Experimental|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
11398566|NCT02045784|Other|Breast milk|Unrestricted consumption during 4 days
11398567|NCT02045771|Other|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
11398568|NCT02045771|Experimental|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
11398569|NCT02045758|Experimental|TAP20-C|TAP20-C
11398570|NCT02045758|Active Comparator|Fingerstick|Fingerstick
11398571|NCT02045745|Experimental|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
11398572|NCT02045732|Experimental|Cohort 1|
11398573|NCT02045732|Experimental|PF-06342674 1.5 mg/kg|
11398574|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q2 Weeks)|
11398575|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q1 Week)|
11398576|NCT02045719|Experimental|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
11398577|NCT02045706|Experimental|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
11398578|NCT02045706|No Intervention|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
11398579|NCT02045693|Experimental|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1
~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
11398580|NCT02045693|Active Comparator|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1
~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
11398581|NCT02045680||deep block|deep block
11398582|NCT02045680||non deep block (historical control)|non deep block (historical control)
11398583|NCT02045667|Placebo Comparator|Placebo|Placebo tablets three times daily orally
11398584|NCT02045667|Active Comparator|Mexiletine|Mexiletine 200mg three times daily orally
11398585|NCT02045654||MDS patients|MDS patients who were treated with decitabine
11398586|NCT02045641|No Intervention|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
11398635|NCT02045264|Experimental|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
11398636|NCT02045251|Experimental|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
11398917|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the thigh|
11398587|NCT02045641|Experimental|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion > 400ml OR b) pleural effusion< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
11398588|NCT02045628|Experimental|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
11398589|NCT02045628|No Intervention|Control|Those in the control group will receive usual care.
11398590|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
11398591|NCT02045615||New|Proposed technique for Wichita nail extraction
11398592|NCT02045602|Experimental|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
11398593|NCT02045602|Experimental|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
11398594|NCT02045602|Experimental|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
11398595|NCT02045589|Experimental|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
11398596|NCT02045576|Experimental|Sleep position trainer|Nightbalance
11398597|NCT02045576|Active Comparator|Oral Appliance Therapy|Somnodent
11398598|NCT02045563||Patients with type-1 diabetes|
11398599|NCT02045563||Patients with type-2 diabetes|
11398600|NCT02045563||Volontaires sains|
11398601|NCT02045550|Placebo Comparator|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
11398602|NCT02045550|Active Comparator|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
11398603|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
11398604|NCT02045524|Experimental|Injection location1|Single dose IM injection
11398605|NCT02045524|Experimental|Injection location 2|Single dose IM Injection
11398606|NCT02045511|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
11398607|NCT02045511|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
11398608|NCT02045498|Experimental|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
11398609|NCT02045498|No Intervention|conventional cpr|conventional cpr
11398610|NCT02045472|Experimental|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
11398611|NCT02045472|Placebo Comparator|Placebo|Placebo administered as a single infusion
11398612|NCT02045459|Experimental|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
11398613|NCT02045446|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
11398614|NCT02045446|Experimental|Stereotactic Body Radiation Therapy|consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
11398615|NCT02045433|Experimental|SABR Boost Therapy|
11398616|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
11398617|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
11398618|NCT02045394||Patients presenting with haemoptysis|
11398619|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
11398620|NCT02045368|Experimental|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
11398621|NCT02045355|Experimental|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
11398622|NCT02045355|No Intervention|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
11398623|NCT02045342|Experimental|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
11398624|NCT02045342|Placebo Comparator|Placebo|Ingest 500ml of placebo prior to metabolic measures.
11398625|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
11398626|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
11398627|NCT02045316||Normal pregnants|pregnants without obstetric complications
11398628|NCT02045303|Experimental|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
11398629|NCT02045290|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.
~The placebo product will contain the following components:
~Micosolle™, silica based excipient
~Silicified Micro Crystalline Cellulose, National Formulary
~Safflower Oil, United States Pharmacopeia
~K-30 Povidone Powder
~Magnesium Stearate, National Formulary (Vegetable source)
~Fumed Silica, National Formulary"
11398630|NCT02045290|Experimental|Metformin|Metformin 2000 mg per day
11398631|NCT02045277|Experimental|IDP-118 Lotion|halobetasol propionate [HP], tazarotene [Taz]
11398632|NCT02045277|Active Comparator|IDP-118 Monad HP Lotion|HP
11398633|NCT02045277|Active Comparator|IDP-118 Monad Taz Lotion|Taz
11398634|NCT02045277|Active Comparator|IDP-118 Vehicle Lotion|Vehicle
11398637|NCT02045238|Placebo Comparator|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
11398638|NCT02045238|Experimental|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
11398639|NCT02045225|Experimental|Cognitive behavioural therapy|Reduction of social anxiety & substance use in gay/bi men
11398640|NCT02045212|Experimental|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
11398641|NCT02045212|Placebo Comparator|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
11398642|NCT02045199|Experimental|V0111|
11398643|NCT02045199|Placebo Comparator|Placebo|
11398644|NCT02045186|Other|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
11398645|NCT02045173|Other|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
11398646|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
11398647|NCT02045147|Experimental|Grp 1 Low Cognition, Low Activation|Group 1: Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
11398648|NCT02045147|Experimental|Grp 2 Low Cognition, High Activation|Group 2: Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
11398649|NCT02045147|Experimental|Grp 3 Normal Cognition, Low Activation|Group 3: Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
11398650|NCT02045147|Experimental|Grp 4 Normal Cognition, High Activation|Group 4: Subjects will receive the least intensive intervention delivered by a RN coach.
11398651|NCT02045134|Placebo Comparator|Placebo|Soluble corn flour not rich in anthocyanins
11398652|NCT02045134|Active Comparator|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
11398653|NCT02045121|Experimental|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
11398654|NCT02045121|Active Comparator|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if >75% of visceral and parietal pleura in direct contact on chest x-ray.
11398655|NCT02045108|Experimental|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
11398656|NCT02045108|Experimental|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
11398657|NCT02045108|Experimental|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
11398658|NCT02045108|Sham Comparator|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
11398659|NCT02045095|Experimental|Schedule A: MLN7243 1 mg|MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
11398660|NCT02045095|Experimental|Schedule A: MLN7243 2 mg|MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
11398661|NCT02045095|Experimental|Schedule A: MLN7243 4 mg|MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
11398662|NCT02045095|Experimental|Schedule A: MLN7243 8 mg|MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
11398663|NCT02045095|Experimental|Schedule A: MLN7243 12 mg|MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
11398664|NCT02045095|Experimental|Schedule A: MLN7243 18 mg|MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
11398665|NCT02045095|Experimental|Schedule A: MLN7243 Homozygous Mutant 4 mg|MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
11398666|NCT02045082|Experimental|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
11398667|NCT02045082|Experimental|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
11398668|NCT02045069|Experimental|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
11398675|NCT02045017|Experimental|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (> 75 years old)
11398676|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
11398677|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
11398678|NCT02044991|Active Comparator|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
11398679|NCT02044991|Placebo Comparator|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
11398680|NCT02044978|Active Comparator|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
11398681|NCT02044978|Placebo Comparator|control|Dental implant without coating Note: Both arms in each patient (2 implants)
11398682|NCT02044965|No Intervention|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
11398683|NCT02044965|Placebo Comparator|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
11398684|NCT02044965|Active Comparator|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
11398685|NCT02044952|Experimental|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
11398686|NCT02044939|Experimental|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
11398687|NCT02044939|No Intervention|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
11398688|NCT02044913|Experimental|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
11398689|NCT02044913|No Intervention|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
11398690|NCT02044887|Experimental|INTERVENTION|Participants will receive instructions to do physical activity with an adapted physical activity program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and caregivers.
11398691|NCT02044887|No Intervention|Control|The control group will receive regular care.
11398692|NCT02044874|Experimental|APD356 10 mg b.i.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
11398693|NCT02044874|Experimental|APD356 10 mg q.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
11398694|NCT02044874|Placebo Comparator|Placebo 10 mg b.i.d|Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
11398695|NCT02044861|Experimental|ACT-PFK-158|dose escalation
11398696|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
11398697|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
11398698|NCT02044835|Placebo Comparator|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
11398699|NCT02044835|Experimental|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
11398700|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
11398701|NCT02044809|Placebo Comparator|Placebo|
11398702|NCT02044809|Experimental|Cannabidiol 200mg Oral|
11398703|NCT02044809|Experimental|Cannabidiol 400mg Oral|
11398704|NCT02044809|Experimental|Cannabidiol 800mg Oral|
11398705|NCT02044796|Experimental|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.
~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11398706|NCT02044783|Experimental|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
11398707|NCT02044783|No Intervention|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
11398708|NCT02044757|Experimental|SSB withdrawal|
11398709|NCT02044744|Experimental|Referral|Physical activity referral
11398710|NCT02044744|No Intervention|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
11398711|NCT02044731|Experimental|Family group sessions|Active and Healthy Families
11398712|NCT02044705|Experimental|Family group sessions|Active and Healthy Families
11398713|NCT02044705|No Intervention|Wait-list control|Controls may participate in Active and Healthy Families after the study
11398714|NCT02044679|Experimental|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
11398715|NCT02044679|Experimental|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
11398716|NCT02044679|Other|C = no change|No change
11398717|NCT02044666|Experimental|Treatment|
11398718|NCT02044653|Experimental|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
11398719|NCT02044653|Experimental|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
11398720|NCT02044653|Experimental|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
11398721|NCT02044653|Experimental|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
11398722|NCT02044653|Experimental|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
11398723|NCT02044653|Experimental|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
11398724|NCT02044653|Experimental|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
11398725|NCT02044653|Experimental|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
11398726|NCT02044653|Active Comparator|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
11398727|NCT02044653|Experimental|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
11398728|NCT02044653|Experimental|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
11398729|NCT02044653|Experimental|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
11398730|NCT02044653|Active Comparator|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
11398731|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
11398732|NCT02044627|Experimental|1 dose of [14C-ETC-1002]|
11398733|NCT02044614|Other|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
11398734|NCT02044601|Experimental|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.
~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
11398735|NCT02044601|Experimental|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.
~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
11398736|NCT02044588||HBsAg negative kidney allograft donor|
11398737|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
11398738|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
11398739|NCT02044562|Experimental|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
11398740|NCT02044562|Placebo Comparator|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
11398741|NCT02044549|Active Comparator|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
11398742|NCT02044549|Active Comparator|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
11398743|NCT02044536||Faculty doctors|Experienced endoscopists (> 6000 cases). no intervention
11398744|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (< 4 months of endoscopy training) no intervention
11398745|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:
~Transient Elastography (Fibroscan)
~Acoustic Radiation Force Impulse (ARFI)
~Magnetic Resonance Elastography (MRE)"
11398746|NCT02044510|Experimental|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
11398747|NCT02044510|Placebo Comparator|Placebo|Inert placebo pill, matching active treatment pill.
11398748|NCT02044497|Experimental|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
11398749|NCT02044484|Experimental|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.
~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.
~Behavioral screening of patients at HIV primary care visits.
~Dissemination of palm cards with empowering messages at HIV primary care visits."
11398750|NCT02044484|No Intervention|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
11398789|NCT02044224|Experimental|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
11398790|NCT02044211|Active Comparator|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone
~Interventions:
~Behavioral:
~Counseling for heart failure self-care Counseling for depression
~Drug:
~Pharmacotherapy for heart failure Pharmacotherapy for depression"
11398994|NCT02042729|Experimental|E2022- Tape Formulation|
11398751|NCT02044471|Experimental|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.
~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
11398752|NCT02044471|No Intervention|Control|standard care
11398753|NCT02044458|Active Comparator|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
11398754|NCT02044458|No Intervention|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
11398755|NCT02044445|Active Comparator|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
11398756|NCT02044445|Active Comparator|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
11398757|NCT02044432|Experimental|Ginger compress|
11398758|NCT02044432|No Intervention|Wait list|
11398759|NCT02044419|Experimental|lomitapide sprinkled in applesauce|Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
11398760|NCT02044419|Experimental|lomitapide sprinkled in mashed banana|Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
11398761|NCT02044419|Experimental|lomitapide (intact)|Intact capsule of 20 mg lomitapide
11398762|NCT02044406|Experimental|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
11398763|NCT02044406|Experimental|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
11398764|NCT02044393|Experimental|Reference|single dose BI 691751
11398765|NCT02044393|Experimental|Test|multiple doses of itraconazole + single dose BI 691751
11398766|NCT02044380|Experimental|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
11398767|NCT02044367|Experimental|Test 1 (Treatment A)|multiple dose of dabigatran
11398768|NCT02044367|Experimental|Test 2 (Treatment B)|multiple dose of dabigatran
11398769|NCT02044367|Experimental|Reference|multiple dose of dabigatran
11398770|NCT02044354|Other|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
11398771|NCT02044354|Other|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
11398772|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops
~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period
~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
11398773|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops
~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period
~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
11398774|NCT02044328|Experimental|Icotinib|Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
11398775|NCT02044315|Sham Comparator|Conventional|Conventional ICD programming
11398776|NCT02044315|Experimental|High-zone|High-zone ICD programming
11398777|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
11398778|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
11398779|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
11398780|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
11398781|NCT02044276|Experimental|lipegfilgrastim.|subcutaneous (SC) injection of 6 mg lipegfilgrastim
11398782|NCT02044276|Active Comparator|pegfilgrastim|SC injection of 6 mg pegfilgrastim
11398783|NCT02044263|Experimental|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
11398784|NCT02044263|Active Comparator|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
11398785|NCT02044250|Active Comparator|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
11398786|NCT02044250|Placebo Comparator|Aspirin|Antiplatelet monotherapy : Aspirin 100~200mg P.O. daily
11398787|NCT02044237|Experimental|Decoupling|specific technic to reduce hair pulling
11398788|NCT02044237|Active Comparator|progressive muscle relaxation|Progressive relaxation relaxation technic
11398791|NCT02044211|Active Comparator|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone
~Interventions:
~Behavioral:
~Counseling for heart failure self-care Usual care for depression
~Drug:
~Pharmacotherapy for heart failure
~Usual Care for depression"
11398792|NCT02044211|No Intervention|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
11398793|NCT02044211|No Intervention|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
11398794|NCT02044198|Active Comparator|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.
~Blood-stage controlled human malaria infection (CHMI) at day 70."
11398795|NCT02044198|No Intervention|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.
~Blood-stage controlled human malaria infection (CHMI) at day 70."
11398796|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
11398797|NCT02044185||control group|normal population with health screening
11398798|NCT02044172|Active Comparator|Radical prostatectomy|Radical prostatectomy
11398799|NCT02044172|Active Comparator|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
11398800|NCT02044172|Active Comparator|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
11398801|NCT02044159|Experimental|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
11398802|NCT02044159|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
11398803|NCT02044146|Experimental|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19*2 and CYP2C19*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (*2 or *3) and/or diabetes and/or (having age>65 AND BMI>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients >age 75 or wt < 60 kg, prasugrel will be reduced to 5mg daily."
11398804|NCT02044146|Active Comparator|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
11398805|NCT02044146|Other|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
11398806|NCT02044133|Other|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
11398807|NCT02044133|Other|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
11398808|NCT02044120|Experimental|niraparib and temozolomide|Niraparib (capsule) and temozolomide (capsule) will be taken together.
11398809|NCT02044120|Experimental|niraparib and irinotecan|Niraparib will be taken orally and irinotecan will be administered intravenously.
11398810|NCT02044120|Experimental|niraparib, irinotecan and temozolomide|Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.
11398811|NCT02044107|Experimental|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).
~The intervention consists of health center level co-packaging and visual counseling messages (zinc & ORS packaged at health center for diarrhea, and zinc & antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
11398812|NCT02044107|No Intervention|Control group|Current standard care at public health center (zinc & ORS for treatment of diarrhea and zinc & antibiotics for treatment of of pneumonia).
11398813|NCT02044094|Experimental|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
11398814|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
11398815|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
11398816|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
11398817|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
11398818|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
11398914|NCT02043314|Experimental|Isoniazida|coated tablet of 300mg
11398819|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:
~HDV antibodies
~if positive, HDV RNA"
11398820|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
11398821|NCT02044029||Age- and gender-matched controls|
11398822|NCT02044029||Patients with spinal muscular atrophy|
11398823|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
11398824|NCT02044003|Experimental|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
11398825|NCT02043990|Experimental|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
11398826|NCT02043977|Experimental|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
11398827|NCT02043964|Experimental|tears and cerebro-spinal fluid sampling|
11398828|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
11398829|NCT02043938|Experimental|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
11398830|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
11398831|NCT02043912||patients treated with haloperidol|
11398832|NCT02043886|Active Comparator|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
11398833|NCT02043886|Placebo Comparator|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
11398834|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
11398835|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
11398836|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
11398837|NCT02043847|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, or 9Gy) with standard high dose melphalan prior to autologous stem cell rescue.
11398838|NCT02043834|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
11398839|NCT02043834|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
11398840|NCT02043821|Other|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
11398841|NCT02043821|Experimental|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
11398842|NCT02043808||Dabigatran|
11398843|NCT02043808||Warfarin|
11398844|NCT02043795|Other|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
11398845|NCT02043782|Experimental|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
~First subjects are allocated to Coloplast Test; Secondly to either
~Own product (baseline)
~Competitor soft convex"
11398846|NCT02043782|Experimental|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
~First subjects are allocated to Competitor soft convex; Secondly to either
~Own product (baseline)
~Coloplast Test"
11398847|NCT02043782|Experimental|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
~First subjects are allocated to Own product; Secondly to either
~Coloplast Test
~Competitor soft convex"
11398848|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:
~review routinely collected information;
~conduct questionnaires with caregiver and child;
~conduct additional assessments of child;
~contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and
~conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
11398849|NCT02043756|Experimental|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
11398850|NCT02043756|Active Comparator|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
11398851|NCT02043743|Experimental|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
~Stem Cell Dose:
~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
11398852|NCT02043730|Experimental|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
11398853|NCT02043730|Active Comparator|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
11398854|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
11398855|NCT02043704|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
11398856|NCT02043704|Placebo Comparator|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
11398857|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
11398858|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
11398859|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Zenith or Cook TX2 device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
11398860|NCT02043678|Experimental|Radium-223 dichloride + Abi/Pred|Participants received 6 intravenous (IV) administrations of radium-223 dichloride 50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) body weight at intervals of 4 weeks, along with oral abiraterone acetate tablets 1000 milligrams (mg) every day plus prednisone/prednisolone 5 mg twice daily (abi/pred) for 6 cycles, followed by abi/pred until an on-study symptomatic skeletal event (SSE) occurred (or other withdrawal criteria were met)
11398861|NCT02043678|Placebo Comparator|Placebo + Abi/Pred|Participants received 6 IV administrations of placebo matched to radium-223 dichloride at intervals of 4 weeks, along with abi/pred for 6 cycles, followed by abi/pred until an on-study SSE occurred (or other withdrawal criteria were met)
11398862|NCT02043665|Experimental|CVA21/pembrolizumab|CVA21/pembrolizumab
11398863|NCT02043652|Experimental|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
11398864|NCT02043626|Experimental|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
11398865|NCT02043626|No Intervention|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
11398866|NCT02043626|Experimental|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
11398867|NCT02043626|Experimental|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
11398868|NCT02043613|Active Comparator|Exercise in standard room|"Intervention: Exercise
~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
11398869|NCT02043613|Experimental|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings
~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
11398870|NCT02043613|No Intervention|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
11398871|NCT02043600|Experimental|Yoga|
11398872|NCT02043600|Active Comparator|Self-care|
11398873|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15
~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2
~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4
~1A-C repeat x1(2A-C) then 3rd Course B (3B)
~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)
~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1
~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)
~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
11398874|NCT02043574|Other|Stretching (Control)|Six months of stretching
11398875|NCT02043574|Experimental|Treadmill Exercise|Six months of treadmill training
11398876|NCT02043561|Sham Comparator|no urge|rectal balloon deflated
11398877|NCT02043561|Experimental|moderate urge|moderate urge induced by rectal balloon
11398878|NCT02043561|Experimental|high urge|high urge induced by rectal balloon
11398879|NCT02043548|Active Comparator|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
11398880|NCT02043548|Placebo Comparator|Group B: Placebo|Placebo arm - no active drug
11398881|NCT02043535|Other|Myocardial blood flow quantification|"The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels.
~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.
~Persantine stress myocardial PET perfusion imaging: as a standard for comparison."
11398915|NCT02043301|Active Comparator|Single 150 mg PF-04950615 dose administered to the abdomen|
11398882|NCT02043522|Experimental|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
11398883|NCT02043509|Experimental|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
11398884|NCT02043509|No Intervention|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
11398885|NCT02043496|Experimental|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
11398886|NCT02043496|Experimental|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
11398887|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
11398888|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
11398889|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.
11398890|NCT02043444|Experimental|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
11398891|NCT02043444|Active Comparator|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
11398892|NCT02043444|Placebo Comparator|normospermia|20 men with secretory azoospermia will have FDG PET-CT
11398893|NCT02043418||children VIH+|children infected with HIV
11398894|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
11398895|NCT02043405|Experimental|Exercise Training and Weight Loss Intervention|Combination weight loss/exercise training, on insulin sensitivity, muscle lipid composition and localization in skeletal muscle.
11398896|NCT02043405|Active Comparator|4 Month Weight Loss Only Intervention|Use exercise training and weight loss as separate interventions in obese subjects with and without pre-diabetes.
11398897|NCT02043392|Experimental|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
11398898|NCT02043379|Experimental|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
11398899|NCT02043379|Placebo Comparator|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
11398900|NCT02043366|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
11398901|NCT02043366|Active Comparator|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
11398902|NCT02043366|Active Comparator|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
11398903|NCT02043366|Active Comparator|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
11398904|NCT02043366|Active Comparator|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
11398905|NCT02043366|Sham Comparator|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
11398906|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
11398907|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
11398908|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
11398909|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
11398910|NCT02043340|Experimental|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
11398911|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
11398912|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
11398913|NCT02043314|Active Comparator|Isoniazida-LAQFA®|3 coated tablet of 100mg
11398918|NCT02043288|Experimental|NC-6004 and Gemcitabine combination|NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
11398919|NCT02043288|Active Comparator|Gemcitabine monotherapy|Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
11398920|NCT02043275|Experimental|Leg training|Lower body resistance training only
11398921|NCT02043275|Active Comparator|Arm training|Upper body resistance training only
11398922|NCT02043262|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
11398923|NCT02043262|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
11398924|NCT02043249|No Intervention|CORD MILKING|WITHOUT MILKING
11398925|NCT02043236|Active Comparator|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
11398926|NCT02043236|Active Comparator|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
11398927|NCT02043236|No Intervention|Usual care|Control group gets usual care from their oncologist.
11398928|NCT02043223|Experimental|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
11398929|NCT02043223|Experimental|Late postpartum vitamin A suppl.|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
11398930|NCT02043223|Experimental|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
11398931|NCT02043223|Experimental|No postpartum vitamin A suppl.|Placebo supplementation, both at <3-day and 6-wk postpartum.
11398932|NCT02043210|Active Comparator|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
11398933|NCT02043210|Experimental|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
11398934|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
11398935|NCT02043184|Active Comparator|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
11398936|NCT02043184|Experimental|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
11398937|NCT02043184|Experimental|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
11398938|NCT02043184|Experimental|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
11398939|NCT02043171|Placebo Comparator|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
11398940|NCT02043171|Placebo Comparator|Placebo Non-exercise|Placebo supplementation group without exercise
11398941|NCT02043171|Active Comparator|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
11398942|NCT02043171|Active Comparator|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
11398943|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
11398944|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
11398945|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
11398946|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
11398947|NCT02043132|Active Comparator|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
11398948|NCT02043132|Placebo Comparator|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
11398949|NCT02043119|Active Comparator|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
11398950|NCT02043119|No Intervention|Standard of Care|
11398951|NCT02043106|Experimental|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
11398952|NCT02043106|Active Comparator|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
11398953|NCT02043093|No Intervention|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
11398954|NCT02043093|Experimental|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
11398955|NCT02043080|No Intervention|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
11398956|NCT02043080|Experimental|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
11398957|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
11398958|NCT02043054|Experimental|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
11398959|NCT02043054|Active Comparator|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
11398960|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
11398961|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
11398962|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
11398963|NCT02043028|Experimental|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes
~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
11398964|NCT02043028|Experimental|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes
~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
11398965|NCT02043015|Other|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
11398966|NCT02043002|Experimental|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
11398967|NCT02042989|Experimental|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.
~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
11398968|NCT02042976|Experimental|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
11398969|NCT02042976|Active Comparator|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
11398970|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
11398971|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
11398972|NCT02042937|No Intervention|Control|No intervention
11398973|NCT02042937|Experimental|Exercise|Exercise to improve gluteus maximus recruitment
11398974|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
11398975|NCT02042911|Experimental|SyB L-0501|
11398976|NCT02042898|Active Comparator|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is <75 g/L (<7.5 g/dL;<4.7mmol/L) intraoperatively and/or postoperatively
11398977|NCT02042898|Active Comparator|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is <95 g/L (<9.5 g/dL<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or <85 g/L (< 8.5 g/dL;<5.3mmol/L) on the ward.
11398978|NCT02042885|Experimental|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
11398979|NCT02042885|Experimental|2: Regimen A Extension|2: OPB-111001, orally, once weekly
11398980|NCT02042885|Experimental|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
11398981|NCT02042885|Experimental|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
11398982|NCT02042872|Experimental|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
11398983|NCT02042872|No Intervention|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
11398984|NCT02042846|Experimental|SportWelding Fiji Anchor|
11398985|NCT02042833||Cohort|
11398986|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)
~Ophthalmic Examination:
~Tear Break Up Time (TBUT)
~Ocular Surface Disease Index (OSDI)
~Schirmer's II test
~Conjunctival staining with lissamine green
~Corneal staining with fluorescein
~Conjunctival redness assessment"
11398987|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)
~Ophthalmic Examination:
~TBUT
~OSDI
~Schirmer's II test
~Conjunctival staining with lissamine green
~Corneal staining with fluorescein
~Conjunctival redness assessment"
11398988|NCT02042807|Placebo Comparator|Placebo|placebo arm
11398989|NCT02042807|Active Comparator|MCS® 15 mg/day|MCS® soft capsule
11398990|NCT02042807|Active Comparator|MCS® 30 mg/day|MCS® soft capsule
11398991|NCT02042781|Experimental|PG545|Once weekly, one hour IV infusion of PG545.
11398992|NCT02042742|Experimental|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
11398993|NCT02042742|Placebo Comparator|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
11398995|NCT02042729|Placebo Comparator|Matching Placebo E2022|Matching Placebo
11398996|NCT02042729|Active Comparator|E2022- New Formulation|
11398997|NCT02042729|Placebo Comparator|Placebo E2022- New Formulation|Matching Placebo
11398998|NCT02042716|Experimental|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
11398999|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
11399000|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
11399001|NCT02042703||cataracts|patients with cataracts
11399002|NCT02042690|Active Comparator|chemotherapy|"Drugs:
~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
11399003|NCT02042690|Experimental|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
11399004|NCT02042664|Experimental|treatment BYETTA|
11399005|NCT02042664|Active Comparator|metformine|
11399006|NCT02042651|Experimental|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
11399007|NCT02042651|Sham Comparator|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
11399008|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
11399009|NCT02042625|Other|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
11399010|NCT02042612|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
11399011|NCT02042599|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
11399012|NCT02042586||Patients|
11399013|NCT02042586||Controls|
11399014|NCT02042573|Other|Depressive patients treated with rTMS|
11399015|NCT02042573|Other|Depressive patients treated with SSRI|
11399016|NCT02042573|Other|Controls|
11399017|NCT02042560||Patients with ITP|
11399018|NCT02042560||Controls|
11399019|NCT02042547||Patients about to undergo heart surgery|
11399020|NCT02042534|Experimental|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
11399021|NCT02042534|Active Comparator|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 [2.0 - 3.0].
11399022|NCT02042521|Experimental|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day
~Interventions: Dietary Supplement, Lactose Placebo"
11399023|NCT02042521|Experimental|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day
~Interventions: Dietary Supplement, Lactose Placebo"
11399024|NCT02042508|Experimental|Paraplegic patients|
11399025|NCT02042495|Experimental|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.
~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
11399026|NCT02042482|Experimental|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
11399027|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
11399028|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
11399029|NCT02042443|Experimental|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11399030|NCT02042443|Experimental|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
11399031|NCT02042430|Experimental|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
11399032|NCT02042417|Experimental|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
11399081|NCT02042001|Experimental|Immediate Switch|Immediate switch to TDF/FTC/RPV
11399033|NCT02042404|Experimental|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
11399034|NCT02042391|Experimental|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
11399035|NCT02042391|Experimental|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
11399036|NCT02042391|Experimental|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
11399037|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
11399038|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
11399039|NCT02042352||pH test|VpH test gloves
11399040|NCT02042339|Experimental|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
11399041|NCT02042339|Placebo Comparator|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
11399042|NCT02042326|Experimental|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.
~The starting dose will be 2 mg per day, and will be adapted every week for one month.
~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
11399043|NCT02042313|Active Comparator|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
11399044|NCT02042313|Experimental|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
11399045|NCT02042300||IRIS-Xpedition/Alpine/Sierra Cohort|XIENCE Xpedition/Alpine/Sierra
11399046|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
11399047|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
11399048|NCT02042274|Experimental|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
11399049|NCT02042248|Experimental|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
11399050|NCT02042248|Experimental|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
11399051|NCT02042235|Experimental|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
11399052|NCT02042235|No Intervention|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk …).
11399082|NCT02042001|Active Comparator|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
11399083|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
11399084|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
11399053|NCT02042222|Active Comparator|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
11399054|NCT02042222|Active Comparator|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.
~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
11399055|NCT02042196|Experimental|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN
~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
11399056|NCT02042196|Experimental|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN
~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
11399057|NCT02042196|Experimental|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN
~No hormone modification."
11399058|NCT02042183|Experimental|Lubiprostone|Participants receive lubiprostone twice daily (BID) up to 12 weeks
11399059|NCT02042183|Placebo Comparator|Placebo|Participants receive placebo BID up to 12 weeks
11399060|NCT02042170|Experimental|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
11399061|NCT02042170|Experimental|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
11399062|NCT02042170|Active Comparator|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
11399063|NCT02042157|Experimental|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
11399064|NCT02042157|Placebo Comparator|Usual Toileting|This group will toilet as usual.
11399065|NCT02042157|Experimental|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
11399066|NCT02042157|Placebo Comparator|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
11399067|NCT02042144||Group 1|
11399068|NCT02042131|Active Comparator|Treatment As Usual (TAU)|"TAU includes the following intervention components:
~suicide risk assessment
~supportive listening
~provision of professional and crisis contact information
~referral to mental health treatment and community resources
~verbal contract for safety"
11399069|NCT02042131|Experimental|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:
~suicide risk assessment
~supportive listening
~identify personal warning signs
~identify self-management skills
~identify social support contacts
~provision of professional and crisis contact information
~referral to mental health treatment and community resources"
11399070|NCT02042131|Experimental|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:
~suicide risk assessment
~supportive listening
~identify personal warning signs
~identify self-management skills
~identify reasons for living
~identify social support contacts
~provision of professional and crisis contact information
~referral to mental health treatment and community resources"
11399071|NCT02042118|Experimental|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
11399072|NCT02042118|Active Comparator|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
11399073|NCT02042092|Active Comparator|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
11399074|NCT02042092|Active Comparator|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
11399075|NCT02042079|Experimental|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
11399076|NCT02042066|Experimental|Treated Group|This group will receive actual shockwave treatment
11399077|NCT02042053|Experimental|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
11399078|NCT02042027|Active Comparator|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
11399079|NCT02042027|Active Comparator|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
11399080|NCT02042014|Experimental|QTI571|Participants will receive QTI571 during 3 years.
11399087|NCT02041962|Active Comparator|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
11399088|NCT02041962|Experimental|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
11399089|NCT02041936|Experimental|NanoKnife IRE System|
11399090|NCT02041923|Placebo Comparator|Attention Control|Mothers received equal amount of attention from the team
11399091|NCT02041923|Experimental|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
11399092|NCT02041910|Experimental|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
11399093|NCT02041910|Experimental|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
11399094|NCT02041897|Other|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
11399095|NCT02041884|Experimental|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
11399096|NCT02041884|Active Comparator|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
11399097|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
11399098|NCT02041871|Experimental|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
11399099|NCT02041871|Placebo Comparator|Placebo|Placebo
11399100|NCT02041858|No Intervention|Control|Control arm with organizational-based alarm parameter settings
11399101|NCT02041858|Experimental|Altered Alarm Settings|Altered set of alarm parameter settings.
11399102|NCT02041845|Active Comparator|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
11399103|NCT02041845|Experimental|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
11399104|NCT02041832|Other|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
11399105|NCT02041832|Other|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
11399106|NCT02041819|Experimental|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
~Cisplatin: 75mg/m2,IV on days 1，22.
~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.
~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
11399107|NCT02041793|Active Comparator|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
11399108|NCT02041793|Active Comparator|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
11399109|NCT02041780|Experimental|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .
~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
11399110|NCT02041767|Experimental|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
11399111|NCT02041767|Experimental|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
11399112|NCT02041754|Active Comparator|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
11399113|NCT02041754|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
11399114|NCT02041741|Active Comparator|Weekly tips|Daily small and concrete happiness tips
11399115|NCT02041741|Active Comparator|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
11399116|NCT02041741|No Intervention|Wait-List Control|No intervention
11399117|NCT02041715|Experimental|TKM-100802 for Injection|
11399118|NCT02041715|Placebo Comparator|Placebo|
11399119|NCT02041702|Experimental|Cardiac MRI Scan Group|
11399120|NCT02041702|No Intervention|Control Group|
11399121|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.
~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
11399122|NCT02041676|Experimental|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
11399123|NCT02041676|Active Comparator|2: Usual surveillance|Usual surveillance of the non invasive ventilation
11399124|NCT02041663|Experimental|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
11399125|NCT02041650|Other|Patients with ACS treated medically|
11399126|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
11399127|NCT02041611|Other|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
11399128|NCT02041598|Experimental|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
11399129|NCT02041598|No Intervention|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
11399130|NCT02041585||Elder discharge cohort|There will be no intervention in this observational survey research.
11399131|NCT02041572|Other|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
11399132|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
11399133|NCT02041546|Active Comparator|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
11399134|NCT02041546|Active Comparator|Lung lavage with surfactant|Lung lavage with surfactant
11399135|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
11399136|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first
~Squamous subjects:
~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or
~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or
~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle
~Non-Squamous subjects:
~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle
~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle
~Optional crossover:
~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
11399137|NCT02041520|Experimental|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
11399138|NCT02041520|Placebo Comparator|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
11399139|NCT02041507|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
11399140|NCT02041507|Experimental|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
11399141|NCT02041507|Experimental|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
11399142|NCT02041494|Active Comparator|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
11399143|NCT02041494|Active Comparator|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
11399144|NCT02041481|Experimental|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11399145|NCT02041481|Experimental|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11399146|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
11399147|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
11399148|NCT02041455|Experimental|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
11399149|NCT02041455|Experimental|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
11399150|NCT02041455|Active Comparator|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
11399151|NCT02041442|Experimental|All subjects|Electrical mapping of the urinary bladder
11399152|NCT02041429|Experimental|Ruxolitinib|Ruxolitinib 10 mg bid for 21 days Paclitaxel is administered at a dose of 80 mg/m2 IV weekly (3 Weeks) Pre-medicate with dexamethasone 10 mg po or IV; diphenhydramine 12.5-50 mg po or IV; famotidine 20 mg IV all administered 30-60 min prior to paclitaxel.
11399153|NCT02041416||Group 1|REDCap and paper pencil
11399154|NCT02041416||Group 2|REDCap twice
11399155|NCT02041416||Group 3|Support Screen and paper pencil
11399156|NCT02041416||Group 4|Support Screen twice
11399157|NCT02041403||Renal resistive Index|
11399158|NCT02041390|Experimental|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
11399159|NCT02041390|Active Comparator|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
11399160|NCT02041377|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes used the Karajishi TS Investigational Blood Glucose Monitoring System with no training. The criteria for the intended use population:
~At least 60% of subjects will be younger than age 65
~At least 10% of subjects will have type 1 diabetes"
11399161|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
11399162|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
11399163|NCT02041351|Experimental|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
11399164|NCT02041338|Experimental|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
11399165|NCT02041338|Active Comparator|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
11399633|NCT02038556|Experimental|cognitive behaviorial therapy for insomnia group program|Behavioral
11399166|NCT02041338|Experimental|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
11399167|NCT02041338|Active Comparator|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
11399168|NCT02041338|Experimental|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
11399169|NCT02041338|Active Comparator|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
11399170|NCT02041325|Experimental|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
11399171|NCT02041325|Placebo Comparator|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
11399172|NCT02041312||Gastric cancer|No intervention
11399173|NCT02041299|Experimental|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication.
11399174|NCT02041299|Active Comparator|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information.
11399175|NCT02041286|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:
~At least 60% of subjects will be younger than age 65
~At least 10% of subjects will have type 1 diabetes"
11399176|NCT02041273|Experimental|Palbociclib given to healthy volunteers|
11399177|NCT02041260|Experimental|Open Label Cabozantimib|
11399178|NCT02041247|Active Comparator|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
11399179|NCT02041247|Placebo Comparator|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
11399180|NCT02041247|Active Comparator|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
11399181|NCT02041247|Active Comparator|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
11399182|NCT02041234|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
11399183|NCT02041234|Active Comparator|Best Medical Treatment|"Anti-diabetic medications provided (Mono- or Combination- therapy):
~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids & BP medications according to standard of care."
11399184|NCT02041221|Experimental|SPARC1316 Dose 1|Subjects will be administered with SPARC1316 dose 1
11399185|NCT02041221|Placebo Comparator|Placebo|The subjects will receive placebo.
11399186|NCT02041221|Experimental|SPARC1316 Dose 2|Subjects will be administered with SPARC1316 dose 2
11399187|NCT02041221|Experimental|SPARC1316 Dose 3|Subjects will be administered with SPARC1316 dose 3
11399188|NCT02041221|Experimental|SPARC1316 Dose 4|Subjects will be administered with SPARC1316 dose 4
11399189|NCT02041221|Experimental|SPARC1316 Dose 5|Subjects will be administered with SPARC1316 dose 5
11399190|NCT02041195|Active Comparator|RM-493 Once Daily|Once daily in the morning, equivalent PBO in evening.
11399191|NCT02041195|Active Comparator|RM-493 Split Dose|Split dose, one half in the morning and one half in the evening.
11399192|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
11399193|NCT02041182|Experimental|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
11399194|NCT02041182|Active Comparator|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
11399195|NCT02041169|Experimental|Subsequent walking performance|Subsequent walking performance
11399196|NCT02041156|Experimental|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
11399197|NCT02041156|Active Comparator|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
11399198|NCT02041143|Experimental|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
11399199|NCT02041143|Placebo Comparator|Placebo|Placebo (no protein)
11399200|NCT02041130|Experimental|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.
~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
11399201|NCT02041130|No Intervention|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
11399202|NCT02041117|Other|Rosuvastatin|
11399246|NCT02040779|Experimental|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
11399247|NCT02040779|Experimental|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
11399248|NCT02040779|Placebo Comparator|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
11399203|NCT02041104|Experimental|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
11399204|NCT02041104|Placebo Comparator|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
11399205|NCT02041091|Experimental|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
11399206|NCT02041091|Experimental|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
11399207|NCT02041078|Placebo Comparator|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
11399208|NCT02041078|Experimental|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
11399209|NCT02041065|Experimental|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
11399210|NCT02041065|Active Comparator|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
11399211|NCT02041052|Active Comparator|Conventional Whipple procedure|Conventional Whipple procedure
11399212|NCT02041052|Experimental|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
11399213|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
11399214|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
11399215|NCT02041026|Experimental|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
11399216|NCT02041013|No Intervention|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
11399217|NCT02041013|Experimental|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
11399218|NCT02040987|Experimental|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
11399219|NCT02040987|Experimental|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
11399220|NCT02040987|Placebo Comparator|Placebo|Placebo oral solution
11399221|NCT02040987|Active Comparator|Moxifloxacin|Moxifloxacin tablet
11399222|NCT02040961|Experimental|EtView|Use of ETVew double-lumen tube
11399223|NCT02040948|Experimental|Surgical patients|"Nexfin (Pulse Pressure Variation)
~Radical 7 (Pleth Variability Index)
~CardioQ (stroke volume)"
11399224|NCT02040935|Experimental|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
11399225|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
11399226|NCT02040909|Experimental|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
11399227|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
11399228|NCT02040883|Active Comparator|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
11399229|NCT02040883|Experimental|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
11399230|NCT02040870|Experimental|LDK378|daily dosing, 28-day cycle patients
11399231|NCT02040857|Experimental|Palbociclib, Aromatase Inhibitor|"Palbociclib 125 mg PO qd 21 days on, 7 days off
~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
11399232|NCT02040844|Other|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762].No further treatment received in CP007A
11399233|NCT02040844|Other|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762].No further treatment received in CP007A.
11399234|NCT02040844|Other|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]. No further treatment received in CP007A.
11399235|NCT02040831|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
11399236|NCT02040831|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
11399237|NCT02040818|Experimental|Antibiotic Lock Solution|
11399238|NCT02040818|Active Comparator|Guide-wire Exchange|
11399239|NCT02040805|Experimental|Group Cognitive-Behavioral Therapy|Sixteen sessions of group therapy facilitated by a psychologist.
11399240|NCT02040805|Experimental|Peer Facilitated Support Group|Fifteen sessions of peer-facilitated group support.
11399241|NCT02040792|Placebo Comparator|Placebo|Placebo
11399242|NCT02040792|Experimental|44 mcg|TD-4208
11399243|NCT02040792|Experimental|88 mcg|TD-4208
11399249|NCT02040766|Experimental|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).
~Placebo MDI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
11399250|NCT02040766|Experimental|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).
~Placebo MDI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
11399251|NCT02040766|Active Comparator|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).
~Placebo BAI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
11399252|NCT02040766|Active Comparator|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).
~Placebo BAI twice daily for blinding.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
11399253|NCT02040766|Placebo Comparator|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.
~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
11399254|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
11399255|NCT02040740||Observation|Healthy early pubertal boys
11399256|NCT02040727|Active Comparator|Non-Resistance Trained|No Participation in Resistance Training
11399257|NCT02040727|Experimental|Resistance Trained|Participation in Resistance Training
11399258|NCT02040714||Nonoperative management between ages 6-8|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
11399259|NCT02040714||Operative containment between age 6-8 in early stage|Operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the early stage of the disease process (stage I)
11399260|NCT02040714||Operative containment between age 6-8 in the late stages|This arm examines operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the later stage of the disease process (stage II)
11399261|NCT02040714||Nonoperative management between age 8-11|Patients who do not undergo some form of containment surgery because of medical, social, or other reasons will receive no surgical treatment.
11399262|NCT02040714||Operative containment with short-term non-weightbearing|"As per the current standard practice for patients between age 8-11 in developed countries, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 weeks of non-weight bearing on the operated leg."
11399263|NCT02040714||Operative containment with prolonged non-weightbearing|"As per the current standard practice for patients between age 8-11, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 months of non-weight bearing on the operated leg."
11399264|NCT02040714||Multiple epiphyseal drilling for patients over age 11|Patients will receive Multiple drilling and be non weight bearing for 6 months according to the treating physician's preference
11399265|NCT02040714||Multiple epiphyseal drilling and arthrodiastasis|Patients will undergo multiple epiphyseal drilling with application of fixator for 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal.
11399266|NCT02040714||Non-surgical management in over 11 age group|Patients will be non-weight bearing and receive physical therapy according to the physician preferences.
11399267|NCT02040714||Non-surgical management in 1-6 age group|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
11399268|NCT02040714||Surgical management in 1-6 age group|The choice of osteotomy management with containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
11399269|NCT02040714||Late Stage Bracing group|Patients presenting with <= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
11399270|NCT02040714||Late Stage Symptomatic treatment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated symptomatically. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
11399271|NCT02040714||Late Stage Surgical Containment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated with surgical containment. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
11399272|NCT02040701||SDB group|
11399273|NCT02040701||Control group|
11399274|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
11399275|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
11399276|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
11399277|NCT02040662|Experimental|Continuous Thoracic Paravertebral Block|"continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000
~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
11399278|NCT02040662|Experimental|Continuous Thoracic Epidural Analgesia|"continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000
~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
11399279|NCT02040649|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
11399280|NCT02040649|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
11399281|NCT02040636|Experimental|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
11399282|NCT02040636|Active Comparator|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
11399283|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
11399284|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
11399285|NCT02040623|Placebo Comparator|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
11399286|NCT02040610|Active Comparator|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
11399287|NCT02040610|Active Comparator|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
11399288|NCT02040597|Experimental|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations
11399289|NCT02040584|Experimental|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
11399290|NCT02040584|Active Comparator|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
11399291|NCT02040571|Experimental|Closed Loop|
11399292|NCT02040571|Active Comparator|Open Loop|
11399293|NCT02040558|Experimental|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
11399294|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
11399295|NCT02040532|Experimental|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
11399296|NCT02040519|Experimental|Evaluation by voiding diaries|
11399297|NCT02040506|Experimental|IGN523|IGN523
11399298|NCT02040493|Experimental|Intra-operative radiation therapy (IORT)|IORT
11399299|NCT02040480|Experimental|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
11399300|NCT02040480|Experimental|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
11399301|NCT02040480|Experimental|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
11399302|NCT02040480|Experimental|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
11399303|NCT02040480|Experimental|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
11399304|NCT02040480|Experimental|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
11399305|NCT02040454|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent
~Paclitaxel - single intravascular dose up to 20 mg"
11399306|NCT02040454|Sham Comparator|Standard Therapy Alone|heparin, angioplasty, stent
11399307|NCT02040441|Active Comparator|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
11399308|NCT02040441|Placebo Comparator|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
11399309|NCT02040441|Other|Observational|Low-risk pattern: Standard care
11399310|NCT02040428|Experimental|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
11399311|NCT02040428|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
11399312|NCT02040415|Experimental|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
11399313|NCT02040415|Active Comparator|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
11399314|NCT02040402|Active Comparator|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:
~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.
~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
11399315|NCT02040402|Active Comparator|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:
~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.
~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
11399509|NCT02039115|Placebo Comparator|placebo|Placebo tablets will be taken in the same manner as the prednisone arm.
11399510|NCT02039102||Non-users of hormonal contraceptives|
11399316|NCT02040389|Active Comparator|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
11399317|NCT02040389|Active Comparator|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
11399318|NCT02040376|Experimental|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
11399319|NCT02040376|Experimental|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
11399320|NCT02040363|Active Comparator|COPD Patients ~90% VO2max|COPD Patients ~90% VO2max
11399321|NCT02040363|Active Comparator|COPD patients ~60-65% VO2max|COPD patients ~60-65% VO2max
11399322|NCT02040363|Placebo Comparator|healthy volunteers|healthy volunteers
11399323|NCT02040350|Placebo Comparator|Placebo|Placebo was given to compare the effects
11399324|NCT02040350|Active Comparator|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
11399325|NCT02040324|Active Comparator|Endotracheal Intubation|Clinical routine for longer lasting procedures
11399326|NCT02040324|Experimental|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
11399327|NCT02040311|Experimental|Topiramate 96 mg daily|
11399328|NCT02040311|Experimental|Topiramate 192 mg daily|
11399329|NCT02040311|Placebo Comparator|placebo|
11399330|NCT02040298|Active Comparator|3 months Clemastine, 2 months Placebo|4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequncy of placebo for last 2 months
11399331|NCT02040298|Active Comparator|3 months Placebo , 2 months Clemastine|Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
11399332|NCT02040285|Active Comparator|Free laxative CTC|
11399333|NCT02040285|Experimental|Low-dose laxative bowel preparation for CTC|
11399334|NCT02040272|Experimental|Surgery|(Extended) pleurectomy decortication
11399335|NCT02040272|No Intervention|no surgery|no surgery
11399336|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
11399337|NCT02040246|Experimental|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
11399338|NCT02040246|Active Comparator|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
11399339|NCT02040233|Active Comparator|BAY1067197 (10 mg)|
11399340|NCT02040233|Active Comparator|BAY1067197|
11399341|NCT02040233|Placebo Comparator|Placebo (10 mg)|
11399342|NCT02040233|Placebo Comparator|Placebo|
11399343|NCT02040220||Group 1|Eylea treatment goup
11399344|NCT02040207|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
11399345|NCT02040194|Experimental|AM-101 injection|AM-101
11399346|NCT02040194|Placebo Comparator|Placebo injection|Placebo
11399347|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
11399348|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
11399349|NCT02040155|Experimental|Real time dosimetric monitoring of brachytherapy.|
11399350|NCT02040142|Experimental|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
11399351|NCT02040129|Experimental|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
11399352|NCT02040116|Other|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
11399353|NCT02040103|Experimental|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
11399354|NCT02040103|No Intervention|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
11399355|NCT02040090|Experimental|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
11399356|NCT02040090|Active Comparator|FDA approved commercially available HRIG product|Comparator product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB.
11399357|NCT02040077|Experimental|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
11399358|NCT02040077|Active Comparator|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
11399359|NCT02040077|Active Comparator|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
11399360|NCT02040064|Experimental|Treatment|"Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)
~Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)
~Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
11399361|NCT02040051|Active Comparator|GROUP A: Sound isolation / Music therapy|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit
~INTERVENTION: Second hour. Sound isolation
~INTERVENTION: Third hour. Music therapy
~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
11399511|NCT02039102||Users of hormonal contraceptives|
11399362|NCT02040051|Active Comparator|GROUP B: Music therapy / Sound isolation|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit
~INTERVENTION: Second hour. Music therapy
~INTERVENTION: Third hour. Sound isolation
~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
11399363|NCT02040038|Experimental|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
11399364|NCT02040038|Active Comparator|Website|Participation in 2D website for DSMT/S for a period of 12 months.
11399365|NCT02040012|Active Comparator|AZP-531|subcut administration once or twice daily
11399366|NCT02040012|Placebo Comparator|Mannitol|subcut administration once or twice daily
11399367|NCT02039999|Experimental|Chronic cough|"Cough challenges to be administered include:
~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
11399368|NCT02039999|Active Comparator|Normal volunteer|"Cough challenges to be administered include:
~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
11399369|NCT02039986||all subjects|all subjects enrolled in same cohort
11399370|NCT02039973|Experimental|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
11399371|NCT02039973|Active Comparator|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
11399372|NCT02039960||DAWN cases including all prescription drugs|This group will consist of all DAWN cases where prescription drugs are mentioned.
11399373|NCT02039960||All bupropion cases (including use of other drugs)|This group will consist of all DAWN cases where bupropion is mentioned and is a subset of Group 1.
11399374|NCT02039960||Burpropion Only Cases|This group will consist of all DAWN cases where burpropion is specifically the only drug mentioned within the case report, and is a subset of Group 2.
11399375|NCT02039947|Experimental|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
11399376|NCT02039947|Experimental|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
11399377|NCT02039947|Experimental|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
11399378|NCT02039947|Experimental|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
11399379|NCT02039934|Experimental|high intensity interval training|
11399380|NCT02039908|Active Comparator|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
11399381|NCT02039908|Active Comparator|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
11399382|NCT02039895|Experimental|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
11399383|NCT02039882||Controls/Normals|control subjects without known cardiac disease, age ± 5 years and sex matched
11399384|NCT02039882||Acute Coronary Syndrome requiring Percutaneous Intervention|Subjects presenting to ER with Acute chest pain requiring cardiac catheterization
11399385|NCT02039882||Acute Coronary Syndrome, no intervention|Acute Coronary Syndrome, not requiring Percutaneous intervention
11399386|NCT02039869|Experimental|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
11399387|NCT02039869|Experimental|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
11399388|NCT02039856|Experimental|EBQI-Supported WH-PACT Implementation|Evidence-based Quality Improvement (EBQI) is a structured research-clinical partnership approach to facilitating implementation of new care models, including multilevel stakeholder engagement, quality improvement (QI) education/training, technical support, formative feedback, external practice facilitation, and national policy guidance.
11399389|NCT02039856|Active Comparator|Routine WH-PACT Implementation|National policy guidance
11399390|NCT02039843|Active Comparator|1|Emotional Support Dogs
11399391|NCT02039843|Active Comparator|2|Service Dogs
11399392|NCT02039830|Experimental|Group physiotherapy|12 weekly treatment visit + daily home exercise program
11399393|NCT02039830|Active Comparator|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
11399394|NCT02039817|Experimental|Healthy Volunteers|All subjects receive a single 50 mg oral dose of IDN-6556
11399395|NCT02039817|Experimental|Severe Renal Impairment|All subjects receive a single 50 mg oral dose of IDN-6556
11399396|NCT02039804|Experimental|Hyaluronic acid|Injectable hyaluronic acid.
11399397|NCT02039804|Active Comparator|Corticosteroids|Injectable corticosteroids.
11399398|NCT02039791|Experimental|Nimotuzumab plus chemoradiotherapy|
11399399|NCT02039778|Experimental|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.
~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy [IMPT] preferred) is an acceptable treatment modality.
~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
11399400|NCT02039765|Experimental|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
11399401|NCT02039752||Multivessel|from 1995
11399402|NCT02039739||Orsiro™ Drug Eluting Stent|
11399403|NCT02039726|Experimental|Quizartinib|Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.
11399404|NCT02039726|Active Comparator|Salvage chemotherapy|Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.
11399405|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
11399406|NCT02039700|Experimental|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of [14C]lesinurad
11399407|NCT02039687|Experimental|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
11399408|NCT02039687|Experimental|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
11399409|NCT02039687|Experimental|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
11399410|NCT02039687|Placebo Comparator|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
11399411|NCT02039674|Experimental|Part1 CohortA2 (Pembro2mg/kg+Paclitaxel [Pa]+Carboplatin [C])|Cohort A participants receive pembrolizumab (2 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (Aare Under the Curve [AUC] 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
11399412|NCT02039674|Experimental|Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B])|Cohort B2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
11399413|NCT02039674|Experimental|Part 1 Cohort C2 (Pembro 2mg/kg+Pemetrexed [Pe]+C)|Cohort C2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
11399414|NCT02039674|Experimental|Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
11399415|NCT02039674|Experimental|Part 1 Cohort E (Pembro 2mg/kg+Erlotinib)|Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral tablet once a day on every day of each 3-week cycle.
11399416|NCT02039674|Experimental|Part 1 Cohort F (Pembro 2mg/kg+Gefitinib)|Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via oral tablet once a day on every day of each 3-week cycle.
11399417|NCT02039674|Experimental|Part 2 Cohort G+ (Pembro 200mg+C+Pe)|Cohort G+ participants receive pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle.
11399418|NCT02039674|Experimental|Part 2 Cohort H (Pembro+I)|Cohort H participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle (at the recommended Phase II dose determined in Cohort D).
11399419|NCT02039674|Experimental|Part 1 Cohort A10 (Pembro+Paclitaxel [Pa]+Carboplatin [C])|Cohort A10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
11399420|NCT02039674|Experimental|Part 1 Cohort B10 (Pembro+Pa+C+Bevacizumab [B])|Cohort B10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
11399421|NCT02039674|Experimental|Part 1 Cohort C10 (Pembro 10mg/kg+Pemetrexed [Pe]+C)|Cohort C10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
11399422|NCT02039674|Experimental|Part 2 Cohort G- (Placebo+C+Pe)|Cohort G- participants receive placebo (normal saline solution) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS.
11399423|NCT02039674|Experimental|Part 1 Cohort D2 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D2 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
11399424|NCT02039674|Experimental|Part 1 Cohort D4 (Pembro 2mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
11399425|NCT02039661|Active Comparator|Lidocaine Spray|
11399426|NCT02039661|Placebo Comparator|Placebo|These patients received placebo spray.
11399427|NCT02039648|Active Comparator|Rumex acetosa L. extract|Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days
11399428|NCT02039648|Placebo Comparator|Placebo|Placebo mouthrinse, 10 ml, tid, 3 min, 7 days
11399429|NCT02039635|Experimental|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.
~Intervention: Dietary Supplement: Korean Red Ginseng"
11399430|NCT02039635|Placebo Comparator|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.
~Intervention: Other: Placebo"
11399431|NCT02039622||Patient under study condition|Patient under study condition
11399432|NCT02039609||Omnivores|No intervention, habitual diet
11399433|NCT02039609||Vegetarians|No intervention, habitual diet
11399434|NCT02039609||Vegans|No intervention, habitual diet
11399435|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
11399436|NCT02039596|Experimental|vegetarian breakfast|Diet: Vegetarian food items
11399437|NCT02039596|Experimental|Swedish Breakfast|Diet: Swedish food items
11399438|NCT02039596|Experimental|English breakfast|Diet: English food items
11399439|NCT02039596|Experimental|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
11399440|NCT02039596|Experimental|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
11399441|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
11399442|NCT02039570||haemorrhoids|The cohort contains only patients with symptomatic haemorrhoids - these patients will receive a transvaginal scan to examine their ovarian and internal iliac veins to ascertain whether there is any reflux
11399443|NCT02039557||NiCord®/CordIn™ transplanted|Anyone who signed the consent for this study received a NiCord®/CordIn™ infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
11399444|NCT02039544|Experimental|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
11399445|NCT02039544|Placebo Comparator|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
11399446|NCT02039531|Experimental|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.
~Procedure for the application of the treatment:
~1. Study Group or PRGF group
~Blood sample :
~Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.
~20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.
~Spinning of the sample:
~8 minutes at 1800 rpm .
~getting the blood fraction containing the PRGF
~activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.
~the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
11399447|NCT02039531|Active Comparator|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
11399448|NCT02039518|Experimental|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
11399449|NCT02039518|Other|observation group|observation
11399450|NCT02039505|Placebo Comparator|Induction Phase: Cohort 1, Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
11399451|NCT02039505|Experimental|Induction Phase: Cohort 1, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
11399452|NCT02039505|Experimental|Induction Phase: Cohort 2, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
11399453|NCT02039505|Experimental|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
11399454|NCT02039505|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
11399455|NCT02039505|Placebo Comparator|Maintenance Phase: Placebo continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
11399456|NCT02039505|Experimental|Open-Label Cohort: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
11399457|NCT02039492|Experimental|A|Denervation
11399458|NCT02039492|Active Comparator|B|Treatment with aldactone
11399459|NCT02039479|Placebo Comparator|TAU + Placebo|Treatment as Usual + Placebo
11399460|NCT02039479|Active Comparator|TAU + Lithium|Treatment as Usual + Lithium
11399461|NCT02039466|Active Comparator|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
11399462|NCT02039466|Active Comparator|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
11399463|NCT02039453|Experimental|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
11399464|NCT02039453|Active Comparator|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
11399465|NCT02039440|Other|Single arm|1 blood draw
11399466|NCT02039427|Placebo Comparator|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
11399467|NCT02039427|Active Comparator|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
11399468|NCT02039427|Active Comparator|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
11399469|NCT02039427|Active Comparator|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
11399470|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
11399471|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising >150min/week
11399472|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
11399473|NCT02039388|Other|High risk patients for breast and/or ovarian cancer|
11399474|NCT02039375|Experimental|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
11399475|NCT02039362|Other|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
11399476|NCT02039336|Experimental|Dacomitinib + PD-0325901|Dacomitinib: oral tablets PD-0325901: oral capsules
11399477|NCT02039323|Experimental|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
11399478|NCT02039310||≥ 65 years / opts for radical cystectomy|
11399479|NCT02039297|Other|No Intervention: Baseline arm|Pre and post design (same arm)
11399480|NCT02039284|Experimental|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
11399481|NCT02039284|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
11399482|NCT02039284|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
11399483|NCT02039284|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
11399484|NCT02039271|No Intervention|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
11399485|NCT02039271|Experimental|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
11399486|NCT02039258|Experimental|Sequence AB|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
11399487|NCT02039258|Experimental|Sequence BA|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
11399488|NCT02039245|Experimental|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
11399489|NCT02039232|Experimental|CarboFix Pedicle Screw System|
11399490|NCT02039219|Placebo Comparator|Placebo|Placebo
11399491|NCT02039219|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
11399492|NCT02039206|Experimental|Treatment|Deep TMS
11399493|NCT02039193|Experimental|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger & Grosse-Holtforth, 2008).
~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
11399494|NCT02039193|Experimental|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
11399495|NCT02039193|Experimental|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
11399496|NCT02039180|Experimental|AZD3293 oral solution|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
11399497|NCT02039180|Experimental|AZD3293 tablet formulation A|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
11399498|NCT02039180|Experimental|AZD3293 tablet formulation B|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
11399499|NCT02039167|Active Comparator|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
11399500|NCT02039167|No Intervention|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
11399501|NCT02039154|Experimental|Aerobic and strength training group|
11399502|NCT02039154|Active Comparator|Balance and flexibility group|
11399503|NCT02039141|Experimental|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
11399504|NCT02039141|No Intervention|Delayed ELSC Intervention Group|Control group (delayed intervention group)
11399505|NCT02039128|Experimental|Krill oil|1 gram per day in 12 weeks
11399506|NCT02039128|Active Comparator|Fish oil|1 gram per day in 12 weeks
11399507|NCT02039128|Placebo Comparator|Placebo|1 gram per day in 12 weeks
11399508|NCT02039115|Experimental|prednisone|Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
11399512|NCT02039089|Experimental|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
11399513|NCT02039089|Experimental|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
11399514|NCT02039089|Placebo Comparator|3|E2006-matched placebo tablets
11399515|NCT02039076|Experimental|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
11399516|NCT02039063|Experimental|1|E6011 2 mg/kg
11399517|NCT02039063|Experimental|2|E6011 5 mg/kg
11399518|NCT02039063|Experimental|3|E6011 10 mg/kg
11399519|NCT02039063|Experimental|4|E6011 15 mg/kg
11399520|NCT02039050|Active Comparator|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
11399521|NCT02039050|Experimental|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
11399522|NCT02039037|Active Comparator|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
11399523|NCT02039037|Active Comparator|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
11399524|NCT02039024|Experimental|18F- DTBZ for Parkinson's Disease|"This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.
~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
11399525|NCT02039011|Active Comparator|Indacaterol|
11399526|NCT02039011|Experimental|Indacaterol & tiotropium|
11399527|NCT02038998|Sham Comparator|Static group|Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.
11399528|NCT02038998|Experimental|Single pGz intervention|In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.
11399529|NCT02038998|Experimental|Multiple pGz interventions|In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.
11399530|NCT02038985|Other|+ ICG Dye (Firefly)|Participants will receive ICG Dye
11399531|NCT02038972|Experimental|Autologous Stem Cells|A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
11399532|NCT02038959|No Intervention|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
11399533|NCT02038959|Experimental|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
11399534|NCT02038946|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
11399535|NCT02038933|Experimental|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
11399536|NCT02038920|Experimental|Induction Phase: Vedolizumab, 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
11399537|NCT02038920|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
11399538|NCT02038920|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
11399539|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
11399540|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo Continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
11399541|NCT02038920|Experimental|Open-Label: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
11399542|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
11399543|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
11399544|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
11399545|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
11399546|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
11399547|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
11399548|NCT02038907|Experimental|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
11399549|NCT02038907|Experimental|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
11399550|NCT02038907|Experimental|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
11399551|NCT02038907|Experimental|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
11399552|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
11399553|NCT02038907|Experimental|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
11399554|NCT02038907|Experimental|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
11399555|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
11399556|NCT02038894|Active Comparator|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
11399557|NCT02038894|Active Comparator|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
11399558|NCT02038894|Active Comparator|Native Airway - no intubation|Anesthetic technique during (EGD)
11399559|NCT02038881|Experimental|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
11399560|NCT02038881|Experimental|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
11399561|NCT02038881|Experimental|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
11399562|NCT02038868|Experimental|ASP4901 group|After the main enrollment, patients will receive an oral dose of ASP4901 once daily for 4 weeks (double-blind treatment period).
11399563|NCT02038868|Placebo Comparator|Placebo group|After the main enrollment, patients will receive an oral dose of placebo once daily for 4 weeks (double-blind treatment period).
11399564|NCT02038868|Active Comparator|Tamsulosin group|After the main enrollment, patients will receive an oral dose of tamsulosin once daily for 4 weeks (double-blind treatment period).
11399565|NCT02038855|Active Comparator|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
11399566|NCT02038855|No Intervention|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
11399567|NCT02038842|Experimental|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
11399568|NCT02038842|Experimental|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
11399569|NCT02038842|Experimental|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
11399570|NCT02038842|Experimental|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
11399571|NCT02038829|Placebo Comparator|Placebo|Placebo bid
11399572|NCT02038829|Experimental|SUN-101 3 mcg|SUN-101 3 mcg bid
11399573|NCT02038829|Experimental|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
11399574|NCT02038829|Experimental|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
11399575|NCT02038829|Experimental|SUN-101 50 mcg|SUN-101 50 mcg bid
11399576|NCT02038829|Active Comparator|Aclidinium 400 mcg|Aclidinium 400 mcg bid
11399577|NCT02038816|Experimental|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
11399578|NCT02038816|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
11399579|NCT02038790|Experimental|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
11399631|NCT02038582|Active Comparator|Laboratory based VL assay|HIV positive persons on ART, randomized to laboratory based viral load testing
11399580|NCT02038790|Active Comparator|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
11399581|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
11399582|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
11399583|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
11399584|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
11399585|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
11399586|NCT02038777|Experimental|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
11399587|NCT02038764|Placebo Comparator|Placebo|Placebo
11399588|NCT02038764|Experimental|PF-06342674|
11399589|NCT02038751||Index proband|moderate to severe OSA (AHI>30 or AHI>15 needing CPAP intervention) age 20-99 y/o
11399590|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age >20 y/o
11399591|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age > 20 y/o
11399592|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age >20 y/o
11399593|NCT02038738|Experimental|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
11399594|NCT02038725||TIA in last 2 weeks|
11399595|NCT02038712|Experimental|Binge eating disorder (BED)|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who meet the current criteria for binge eating disorder (BED) in the fed condition and fasted condition.
11399596|NCT02038712|Experimental|Control|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who do not meet the current criteria for BED (Controls) in the fed condition and fasted condition.
11399597|NCT02038699|Experimental|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
11399598|NCT02038686|Active Comparator|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
11399599|NCT02038686|Active Comparator|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
11399600|NCT02038673|Experimental|Dose escalation part 0.5 mg QD|Oral
11399601|NCT02038673|Experimental|Dose escalation part 1.0 mg QD|Oral
11399602|NCT02038673|Experimental|Dose escalation part 2.0 mg QD|Oral
11399603|NCT02038673|Experimental|Dose escalation part 2.0 mg BID|Oral
11399604|NCT02038673|Experimental|Dose escalation part 4.0 mg BID|Oral
11399605|NCT02038673|Experimental|Dose escalation part 6.0 mg BID|Oral
11399606|NCT02038673|Experimental|Dose escalation part 10.0 mg BID|Oral
11399607|NCT02038673|Experimental|Dose escalation part 20.0 mg BID|Oral
11399608|NCT02038673|Experimental|Dose escalation part 16.0 mg BID|Oral
11399609|NCT02038673|Experimental|Expansion part Urothelial Carcinoma|Oral
11399610|NCT02038673|Experimental|Expansion part Hepatocellular Carcinoma|Oral
11399611|NCT02038673|Experimental|Expansion part Squamous Cell Lung Carcinoma|Oral
11399612|NCT02038660||Patients with coronary artery disease|
11399613|NCT02038647|Experimental|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
11399614|NCT02038647|Placebo Comparator|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).
11399615|NCT02038634|Active Comparator|Unguided injections|Corticosteroid injection (betamethasone) without ultrasound guidance.
11399616|NCT02038634|Active Comparator|Ultrasound-guided injections|Corticosteroid injections (betamethasone) under ultrasound guidance.
11399617|NCT02038621|Experimental|A|Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance.
11399618|NCT02038621|Placebo Comparator|B|Observation until progression
11399619|NCT02038608|Experimental|PET|
11399620|NCT02038595|Experimental|Healthy subjects|Healthy subjects (male, female)
11399621|NCT02038582|Active Comparator|POC CD4 & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and follow up with clinic accompaniment
11399622|NCT02038582|Active Comparator|POC CD4 & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and lay counselor follow up
11399623|NCT02038582|Active Comparator|POC CD4 & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and referral to clinic
11399624|NCT02038582|Active Comparator|CD4 Referral & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and follow up with clinic accompaniment
11399625|NCT02038582|Active Comparator|CD4 Referral & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and lay counselor follow up
11399626|NCT02038582|Active Comparator|CD4 Referral & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and referral to clinic
11399627|NCT02038582|Active Comparator|Circumcision - SMS Reminder|HIV negative uncircumcised males, randomized to SMS reminder for male circumcision
11399628|NCT02038582|Active Comparator|Circumcision - Lay Counselor|HIV negative uncircumcised males, randomized to lay counselor follow-up for male circumcision
11399629|NCT02038582|Active Comparator|Circumcision - Promotion|HIV negative uncircumcised males, randomized to promotion of male circumcision at the time of HIV testing
11399630|NCT02038582|Active Comparator|POC VL|HIV positive persons on ART, randomized to POC viral load testing
11399632|NCT02038569|Experimental|LEO 80185 gel|
11399634|NCT02038543|Experimental|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
11399635|NCT02038530||No Ultrasound|Low Clinical Pretest Probability and D-dimer < 1000 ug/L; Moderate Clinical Pretest Probability and D-dimer < 500 ug/L
11399636|NCT02038530||Ultrasound Required|Low Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; Moderate Clinical Pretest Probability and D-dimer 500 - 3000 ug/L; High Clinical Pretest Probability
11399637|NCT02038504||gastrointestinal fistula|
11399638|NCT02038491||regional anesthesia|patients undergoing regional anesthesia procedures
11399639|NCT02038478|Experimental|Transplantation Arm|"Transplantation
~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
11399640|NCT02038465|Other|patient|Complete questionary remembering the day
11399641|NCT02038465|Other|healthy volunteers|- Complete questionary, remembering the day
11399642|NCT02038452|Active Comparator|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
11399643|NCT02038452|Active Comparator|Wrist Splint|Wrist splint to be worn at night
11399644|NCT02038439|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, clinicians will be offered all 3 online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
11399645|NCT02038439|Experimental|Interventions A + B|"See Interventions Description. In this arm, clinicians will be offered the 2 following interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention B - Online Evidence Retrieval Coach"
11399646|NCT02038439|Experimental|Interventions A + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:
~Intervention A - Online Clinical Questions Recorder
~Intervention C - Online Audit and Feedback"
11399647|NCT02038439|Experimental|Interventions B + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:
~Intervention B - Online Evidence Retrieval Coach
~Intervention C - Online Audit and Feedback"
11399648|NCT02038439|Experimental|Intervention A alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:
~* Intervention A - Online Clinical Questions Recorder"
11399649|NCT02038439|Experimental|Intervention B alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:
~* Intervention B - Online Evidence Retrieval Coach"
11399650|NCT02038439|Experimental|Intervention C alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:
~* Intervention C - Online Audit and Feedback"
11399651|NCT02038439|No Intervention|No intervention|In this arm, clinicians will be offered non of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
11399652|NCT02038426|Experimental|the patients with SpA|
11399653|NCT02038426|Experimental|sports subjects|
11399654|NCT02038426|Other|control subjects|
11399655|NCT02038413||NSCLC stage I|Consecutive patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All patients received respiratory gated CT (4DCT) scans. All were patients referred for primary radiotherapy or chemo radiation.
11399656|NCT02038400|Experimental|group A|KINETUBE medical Device
11399657|NCT02038400|Active Comparator|group B|insertion of tympanic ventilation tubes (tympanostomy)
11399658|NCT02038387|Experimental|Diet|
11399659|NCT02038374|Experimental|severe asthma atopic|
11399660|NCT02038374|Experimental|asthma non atopic|
11399661|NCT02038361|Experimental|blood sample|
11399662|NCT02038348|Other|PET with 18F-FDOPA|
11399663|NCT02038335||DMPA|Depot medroxyprogesterone acetate
11399664|NCT02038335||NET-EN|Norethisterone enantate
11399665|NCT02038335||MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
11399666|NCT02038335||LNG-I|Levonorgestrel subdermal implant
11399667|NCT02038335||ENG-I|Etonogestrel subdermal implant
11399668|NCT02038335||Cu-IUD|Copper IUD
11399669|NCT02038322|No Intervention|The Stork|Device - The Stork - complete kit (Conceptacle and Applicator)
11399670|NCT02038296|Experimental|Group 1|Group 1 received single-drug (doxorubicin)transarterial chemoembolization.
11399671|NCT02038296|Experimental|Group 2|Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization
11399672|NCT02038296|Experimental|Group 3|Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.
11399673|NCT02038283||Low-risk Colorectal Polyps|≤2 adenomas or 3-4 adenomas all of which are <1cm
11399674|NCT02038283||High-risk Colorectal Polyps|≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
11399675|NCT02038283||Stage I CRC|at least six months since diagnosis of Stage I CRC
11399676|NCT02038283||Stage II CRC|at least six months since diagnosis of Stage II CRC
11399677|NCT02038283||Stage III CRC|at least six months since diagnosis of Stage III CRC
11399678|NCT02038283||Stage IV CRC|at least six months since diagnosis of Stage IV CRC
11399679|NCT02038270||surgical patients|120 Adult patients, that are having a routine surgical procedure.
11399680|NCT02038257|Active Comparator|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
11399681|NCT02038257|Active Comparator|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
11399716|NCT02037984|Experimental|Infant V114: 2x:2x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
11399682|NCT02038257|Active Comparator|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
11399683|NCT02038257|Active Comparator|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
11399684|NCT02038244|Experimental|Integrative Medicine|
11399685|NCT02038231|Experimental|Parenting Mindfully Program|Mindfulness program for parents of adolescents provided for 2 hours once per week for 8 weeks.
11399686|NCT02038231|Active Comparator|Parent Education Program|Group for parents of adolescents providing handouts and brief education to parents on topics of adolescence, family relations, and risk behaviors. Group meets 3 times over the course of 8 weeks for about 15 minutes per meeting.
11399687|NCT02038218|Experimental|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:
~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;
~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.
~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
11399688|NCT02038192|Experimental|Living with Hope Program|"All participants in this group will receive the Living with Hope Program. It consists of viewing a 15 minute film on hope. Then for 5 minutes at the end of each day to write Stories of the Presentto work on over one month. Stories of the present is a directed journaling activity which includes writing challenges of the day, what was their hope that day and what would be their hope tomorrow."
11399689|NCT02038192|Experimental|Stories of the Present|Participants in this group will write Stories of the Present and not see the film.
11399690|NCT02038192|No Intervention|Usual Care|Participants in this group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
11399691|NCT02038179|Experimental|Allopurinol, Then Placebo|Participants will be asked to take 4 weeks of allopurinol (300 mg oral per day), then will crossover (after 2-4 week washout period) and take placebo for an additional 4 weeks.
11399692|NCT02038179|Experimental|Placebo, Then Allopurinol|Participants will be asked to take 4 weeks of placebo, then will crossover (after 2-4 week washout period) and take allopurinol (300 mg oral per day) for an additional 4 weeks.
11399693|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
11399694|NCT02038140|Other|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
11399695|NCT02038114|Experimental|Instructed to read pamphlets|This group will be instructed to read patient education pamphlets.
11399696|NCT02038101|Experimental|Education and Feedback Intervention|"This intervention includes the following components:
~Formal Rounds on AUC for TTE:
~Appropriate Use for TTE Application for Smartphone
~Individualized Feedback Reports provided by email"
11399697|NCT02038101|No Intervention|Control|Usual echocardiography ordering pratice.
11399698|NCT02038088||A|intravenous inhalational anesthesia
11399699|NCT02038088||B|intravenous anesthesia
11399700|NCT02038075|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
11399701|NCT02038075|Active Comparator|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
11399702|NCT02038062|Experimental|Sevoflurane|Sevoflurane Preconditioning
11399703|NCT02038062|No Intervention|No Sevoflurane|No Sevoflurane Preconditioning
11399704|NCT02038049|Experimental|VAY736|Intravenous infusion of VAY736
11399705|NCT02038049|Placebo Comparator|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
11399706|NCT02038036|Experimental|Ruxolitinib|Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose may be adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
11399707|NCT02038036|Active Comparator|Best Available Therapy (BAT)|Best Available Therapy as selected by the investigator from: Hydroxyurea, IFN/PEG-IFN, popobroman, anagrelide, IMIDs, or observation
11399708|NCT02038023|Other|IV iron|Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.
11399709|NCT02038010|Experimental|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11399710|NCT02037997|Experimental|combination with Erlotinib|Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2
11399711|NCT02037997|Active Comparator|sequential chemotherapy for Erlotinib|docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd
11399712|NCT02037984|Experimental|Adult V114: 1x:1x:1x|Adults receive a single vaccination on Day 1.
11399713|NCT02037984|Experimental|Adult V114: 2x:2x:2x|Adults receive a single vaccination on Day 1.
11399714|NCT02037984|Experimental|Infant V114: 1x:1x:1x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
11399715|NCT02037984|Experimental|Infant V114: 2x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
11399717|NCT02037984|Experimental|Infant V114: 0.5x:0.5x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
11399718|NCT02037984|Experimental|Infant V114: 1x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
11399719|NCT02037984|Active Comparator|Infant Prevnar 13®|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
11399720|NCT02037971|Experimental|Aerobic Exercise|Subjects will follow one defined exercise process, according their cardiopulmonary exercise test, during 16 weeks, two times per a week.
11399721|NCT02037971|Experimental|Control Group|A non-exercise group will receive regular educational information relating to their condition.
11399722|NCT02037958|Experimental|Laryngeal Mask Airway-Supreme|Patients who are randomly assigned to receive the LMA-Supreme
11399723|NCT02037958|Active Comparator|Endotracheal Tube|Patients who are randomly assigned to receive endotracheal intubation
11399724|NCT02037945|Experimental|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
11399725|NCT02037932|Experimental|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
11399726|NCT02037919|Experimental|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
11399727|NCT02037919|Active Comparator|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
11399728|NCT02037906|Experimental|Escalating Energy SWL|50 Patients
11399729|NCT02037906|Experimental|Constant Energy SWL|50 Patients
11399730|NCT02037906|Experimental|Reduction Energy SWL|50 Patients
11399731|NCT02037893|Experimental|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
11399732|NCT02037893|Active Comparator|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
11399733|NCT02037893|Active Comparator|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
11399734|NCT02037893|Placebo Comparator|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
11399735|NCT02037880||MPS IIIA/B Subjects|Cohort will be followed for one year to assess natural history of the disease.
11399736|NCT02037867||Patients|"Patients identified with one of the below chronic liver disease risk factors and undergoing community liver disease stratification using fibrosis biomarkers:
~Hazardous alcohol use (>14 units per week in females, >21 units per week in males, alcohol AUDIT score >=8 or read code relevant to alcohol abuse on GP system)
~Type 2 Diabetes
~Obesity
~Persistently raised serum ALT level, negative liver serology, and absence of above 2 risk factors"
11399737|NCT02037854|Placebo Comparator|Placebo|A nutrient formulation without the active ingredient
11399738|NCT02037854|Experimental|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
11399739|NCT02037841|Experimental|Nursing-driven Asthma protocol|Children randomized to the intervention group will have their β2-agonist medication weaned by the nurse, according to the steps outlined in the clinical pathway. The nurse will ensure that the patient's family is booked for asthma teaching, and will also remind the physicians to fill out an asthma action plan on discharge. Detailed information as to when to contact physicians in the event of an acute deterioration of the patient is included in the clinical pathway.
11399740|NCT02037841|No Intervention|Physician-driven asthma management|Patients in the control group will continue receiving the current standard of care, which consists of physicians weaning the β2-agonist medication when called to the bedside by the nurse or when deemed necessary by a physician
11399741|NCT02037828||Stable COPD in STEP1|no intervention
11399742|NCT02037828||Control in STEP 1|no intervention
11399743|NCT02037828||Case group in STEP 2|no intervention
11399744|NCT02037828||Control group in STEP2|no intervention
11399745|NCT02037815|Experimental|Mannitol|20% mannitol solution, 125 ml, IV infusion in 15 min
11399746|NCT02037815|Experimental|Hypertonic saline|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
11399747|NCT02037802|Active Comparator|caudal epidural catheterization group|30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
11399748|NCT02037802|Sham Comparator|control group|30 patients didn't receive caudal epidural analgesia
11399749|NCT02037776|Placebo Comparator|Rikkunshito Placebo|
11399750|NCT02037776|Active Comparator|Rikkunshito|
11399751|NCT02037750|Experimental|LINKS|Foster parent and child participate in 16-week intervention
11399752|NCT02037750|No Intervention|Services as Usual|Foster parent and child receive standard services through child welfare system
11399753|NCT02037737||RA patients on Abatacept IV|Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
11399754|NCT02037724|Other|supplement containing 60 mg iron sulfate|nutrient supplement containing 60 mg of iron as ferous sulfate
11399755|NCT02037724|Experimental|iron rich food supplement (60 mg iron)|contains 60 mg Iron
11399756|NCT02037724|Experimental|iron rich food supplement (10 mg iron)|contains 10 mg of iron
11399757|NCT02037724|Other|supplement containing 10 mg iron sulfate|nutrient supplement containing 10 mg of iron as ferous sulfate
11399758|NCT02037711|Active Comparator|Chirocaine group (levobupivacaine )|
11399759|NCT02037711|Sham Comparator|Control group|
11399760|NCT02037698|Experimental|Pre-PCI CT scan group|Pre-PCI CT scan
11399761|NCT02037698|No Intervention|Control group|Control
11399762|NCT02037685|Active Comparator|Usual care|Subjects randomized to usual care will receive a brochure once a year on the importance and impact of controlling cardiovascular risk factors, tips to improve statin adherence and smoking cessation strategies and public services. Subjects will also receive a letter every 6 months to remind about study participation along with educational material.
11399763|NCT02037685|Experimental|Motivational Interviewing (MINT)|"The MINT intervention will consist of 6 to 9 telephone encounters between a counselor trained in Motivational interviewing. All subjects in the MINT arm will be contacted every 3 months; however subjects who are not filling medication appropriately will receive additional calls.
~Each telephone encounter will last from 20 to 30 minutes and have a patient centered approach having the following basic structure and goals:
~Establishing a connection and reinforcing autonomy: .
~Empathizing with ambivalence and rolling with resistance.
~Coach the subject towards expressions of commitment."
11399764|NCT02037672|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
11399765|NCT02037672|Active Comparator|metformin and roflumilast|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os.
11399766|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
11399767|NCT02037646|Other|Qualitative fecal immunochemical test|"Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:
~>200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list <100 ng/dL - no colonoscopy
~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
11399768|NCT02037646|Other|Quantitative fecal immunochemical test|"Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:
~Positive - colonoscopy as per waiting list Negative - no colonoscopy
~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
11399769|NCT02037633|Active Comparator|Fascia iliaca compartment block|
11399770|NCT02037633|Active Comparator|Fentanyl|
11399771|NCT02037620|Experimental|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
11399772|NCT02037594|Experimental|Counseling + SOC Adherence|Sexual Health Counseling followed by Standard of Care Adherence Support
11399773|NCT02037594|Experimental|Counseling + Enhanced Adherence|Sexual Health Counseling followed by Enhanced Adherence Intervention
11399774|NCT02037594|Experimental|Information + SOC Adherence|PrEP Information followed by Standard of Care Adherence Support
11399775|NCT02037594|Experimental|Information + Enhanced Adherence|PrEP Information followed by Enhanced Adherence Intervention
11399776|NCT02037581|Experimental|Early detection and Integrated Care|"The intervention condition consisted of measures to improve early detection and treatment quality (Integrated Care).
~Interventions for the improvement of early detection. The measures for improved early detection aiming at reducing the duration of untreated psychosis included 4-year measures to improve mental health literacy, reduce stigma and improve service utilization.
~Measures to improve treatment quality should be achieved through extending the Hamburg model to a cross-age and interdisciplinary Integrated Care model for adolescent and young adult patients with psychotic disorders aged 12-29 years."
11399777|NCT02037581|Other|Standard Care|Historical control group with standard care parallelized regarding age, diagnosis and illness stage, which was treated in the period before the implementation of the intervention conditions. The control group consisted of n=105 patients with early psychosis between the ages of 12 and 29, who had been treated between January 2005 and December 2008. The central differences in comparison with the intervention conditions lie in the lack of measures for the improvement of early detection, the absence of the TACT team, as well as the regular referral to an established psychiatrist with in most cases regular contact frequency.
11399778|NCT02037568|No Intervention|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
11399779|NCT02037568|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
11399780|NCT02037555|Experimental|AT-III (Human)|"Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:
~AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4"
11399781|NCT02037555|Placebo Comparator|Placebo|Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
11399782|NCT02037542|Experimental|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
11399783|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11399784|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11400460|NCT02033031|Active Comparator|Lucentis|PRN intravitreal injection of Lucentis
11399785|NCT02037516|Active Comparator|Control Group|qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
11399786|NCT02037516|Active Comparator|Study Group|quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
11399787|NCT02037503|Placebo Comparator|Placebo for drug resistant depression|Patients will be treated for 21 days with daily oral placebo
11399788|NCT02037503|Experimental|Ketamine for suicidal ideation|Patients will be treated for 21 days with daily oral Ketamine
11399789|NCT02037503|Experimental|Ketamine for drug resistant depression|Patients will be treated for 21 days with daily oral Ketamine
11399790|NCT02037503|Placebo Comparator|Placebo in suicidal ideation|Patients will be treated for 21 days with daily oral placebo
11399791|NCT02037503|Experimental|Healthy Participants|Healthy participants that underwent a romantic relationship breakup will attend in tow experimental sessions, one with placebo and one with ketamine. Sessions will be separated within the range of 1 to 6 weeks
11399792|NCT02037490|Experimental|Grow2Gether Intervention|"Participants in the intervention group will:
~Participate in the Grow2Gether intervention
~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
11399793|NCT02037490|No Intervention|Control|"Participants in the control group will:
~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
11399794|NCT02037477|Experimental|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
11399795|NCT02037477|Experimental|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
11399796|NCT02037477|Experimental|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
11399797|NCT02037477|Experimental|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
11399798|NCT02037464|Experimental|Capsaicin Supplement|
11399799|NCT02037451|Experimental|intervention group|intervention group which receive auditory cueing while performing movement
11399800|NCT02037451|No Intervention|Control group|control group which performing movement after listen to required movement rhythm.
11399801|NCT02037438|Active Comparator|CONV Arm|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
11399802|NCT02037438|Experimental|PCCM ARM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
11399803|NCT02037425|Other|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
11399804|NCT02037412|Experimental|Ticagrelor Arm|Ticagrelor Arm
11399805|NCT02037412|Active Comparator|Clopidogrel Arm|Clopidogrel Arm
11399806|NCT02037399|Experimental|intravenous dexamethasone|To receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD
11399807|NCT02037399|Placebo Comparator|intravenous normal saline|To receive normal saline as placebo intravenous immediately after ESD
11399808|NCT02037386|Experimental|H-side branch stent|H-side branch stent group
11399809|NCT02037373||Octaplas™|Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
11399810|NCT02037373||Plasma|Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).
11399811|NCT02037360|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
11399812|NCT02037360|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
11399813|NCT02037347|Experimental|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
11399814|NCT02037334||Pregnancy|
11399815|NCT02037308|Placebo Comparator|Control white bread|
11399816|NCT02037308|Experimental|Beetroot bread|
11399817|NCT02037295|Experimental|OF_UF Vancomycin|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin
11399818|NCT02037295|Placebo Comparator|OF_UF Placebo|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo
11399819|NCT02037295|Experimental|UF_OF Vancomycin|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin
11399820|NCT02037295|Placebo Comparator|UF_OF Placebo|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo
11399821|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
11399857|NCT02037061|Active Comparator|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
11399858|NCT02037048|Active Comparator|Positive Pathologic Response|Patients with ≤50% viable tumor cells remaining in the surgical specimen will receive postoperative chemo-radiotherapy with the mFOLFOX6 regimen
11399859|NCT02037048|Experimental|Negative Pathologic Response|Patients with >50% viable tumor cells remaining in the surgical specimen, will receive postoperative chemo-radiotherapy with weekly carboplatin and paclitaxel.
11399860|NCT02037035|Experimental|Healthy|Healthy participants will receive ketamine in the scan
11399861|NCT02037035|Experimental|Depressed|Depressed participants will receive ketamine in the scan
11399822|NCT02037256|Experimental|Treatment (bortezomib and filgrastim)|"GROUP A: Patients receive filgrastim SC on days 1-9 and begin apheresis on day 5. Patients undergo apheresis for up to 2 days, and receive bortezomib intravenously (IV) over 3-5 seconds after target collection is obtained with filgrastim alone or on the first day of collection with the Bortezomib plus filgrastim mobilization, prior to receiving the administration of filgrastim. Second apheresis will continue until target stem cell dose is reached or for maximum 4 days. Patients undergo autologous hematopoietic stem cell transplantation after receiving high dose chemotherapy and peripheral blood stem cell (PBSC) infusion following standard of care procedures.
~GROUP B: Patients receive filgrastim SC on days 1-8 and receive bortezomib IV over 3-5 seconds on days 4 and day 7, before administration of filgrastim. Patients undergo apheresis on days 5-8. (See Detailed Description)"
11399823|NCT02037243|Experimental|Water Treatment|Chlorine dispenser promotion and provision
11399824|NCT02037243|Experimental|Hand washing|Hand washing with soapy water promotion
11399825|NCT02037243|Experimental|Standard public health intervention|Health promotion using information about germs and disease
11399826|NCT02037243|Experimental|Disgust and shame intervention|Health promotion using disgust shame
11399827|NCT02037230|Experimental|MK-1775/ Gemcitabine/ Radiation Therapy|
11399828|NCT02037217|Experimental|ExAblate Treatment|
11399829|NCT02037204|Experimental|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
11399830|NCT02037191|Placebo Comparator|ARM A : METHOTREXATE|"Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).
~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):
~methotrexate alone or
~methotrexate associated with prednisone 0.3 mg/Kg/day"
11399831|NCT02037191|Placebo Comparator|ARM B : PLACEBO|"Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).
~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):
~methotrexate alone or
~methotrexate associated with prednisone 0.3 mg/Kg/day"
11399832|NCT02037178||The study population|"See inclusion/exclusion criteria.
~Intervention: First ultrasound reading
~Intervention: Second ultrasound interpretation"
11399833|NCT02037165|Experimental|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
11399834|NCT02037165|Experimental|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
11399835|NCT02037165|Experimental|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
11399836|NCT02037165|Experimental|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
11399837|NCT02037165|Experimental|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
11399838|NCT02037152|No Intervention|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
11399839|NCT02037152|Experimental|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
11399840|NCT02037139|Active Comparator|Control (screening)|screening only (standard care control)
11399841|NCT02037139|Active Comparator|Educational brochure|Screening + illustrated educational brochure
11399842|NCT02037139|Experimental|Education|Screening + illustrated educational brochure + an in-person educational intervention
11399843|NCT02037126|Experimental|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
11399844|NCT02037126|Active Comparator|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
11399845|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
11399846|NCT02037100||T2DM|Children 6-20 years old diagnosed with T2DM
11399847|NCT02037100||Obesity|
11399848|NCT02037087|Experimental|Good household prenatal practice (GHPP)|The GHPP arm receives SMS messages regarding knowledge on nutrition, labor, non-medical pain management, breastfeeding, and depression. This arm also receives messages delivered to the control group.
11399849|NCT02037087|Experimental|Care seeking (CS)|The CS arm receives SMS messages which include danger-sign recognition and reminders for government-subsidized projects. This arm also receives messages delivered to the control group.
11399850|NCT02037087|Experimental|Full bank of SMS|This arm receives the SMS messages delivered to the GHPP, CS and control group.
11399851|NCT02037087|No Intervention|Control|"Control group receives SMS messages regarding:
~Reminders of prenatal visits and certified skilled attendance of labor (status quo);
~Fetal development in different gestational stages.
~The three experimental groups receive the control messages as well."
11399852|NCT02037074|Experimental|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
11399853|NCT02037074|Experimental|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
11399854|NCT02037074|Experimental|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
11399855|NCT02037074|Placebo Comparator|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
11399856|NCT02037061|Placebo Comparator|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
11399862|NCT02037022|Experimental|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
11399863|NCT02037022|No Intervention|Delayed Treatment Group|Delayed Treatment Group (DTG)
11399864|NCT02037009|No Intervention|Usual surveillance|surveillance performed by a qualified nurse, present in the operating room during the whole anesthesia.
11399865|NCT02037009|Experimental|centralised monitoring surveillance|1 anesthetic nurse is posted at a centralised monitoring station outside of the 3 operating rooms, while another one can intervene inside the 3 operating rooms whenever needed. Interphones allow communication between the monitoring station and the operating rooms.
11399866|NCT02036983|Active Comparator|Ultrasound guided bilateral TAP block|Ultrasound guided TAP Block with local anesthetic and dexamethasone.
11399867|NCT02036983|Active Comparator|Instillation of surgical site with local anesthestic.|Instillation of surgical site under direct visualization with local anesthetics and dexamethasone.
11399868|NCT02036983|Placebo Comparator|Control Group|Standard anesthetic technique
11399869|NCT02036970|Experimental|Dose-Ranging Phase: Dose 1|Bardoxolone methyl [Dose 1] mg capsules or placebo by mouth once daily x 16 weeks
11399870|NCT02036970|Experimental|Dose-Ranging Phase: Dose 2|Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 16 weeks
11399871|NCT02036970|Experimental|Dose-Ranging Phase: Dose 3|Bardoxolone methyl [Dose 3] mg capsules or placebo by mouth once daily x 16 weeks
11399872|NCT02036970|Experimental|Dose-Ranging Phase: Dose 4|Bardoxolone methyl [Dose 4] mg capsules or placebo by mouth once daily x 16 weeks
11399873|NCT02036970|Experimental|Dose-Titration Phase|"Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 3 weeks, escalating to [Dose 3] mg or placebo by mouth once daily at Week 4 for 13 weeks
~If a patient experiences a dose-limiting toxicity, the investigator may de-escalate the dose."
11399874|NCT02036957|Experimental|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption.
11399875|NCT02036957|Placebo Comparator|PLACEBO ARM|It be applicated in like manner that balm arm
11399876|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
11399877|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
11399878|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
11399879|NCT02036918|Active Comparator|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
11399880|NCT02036918|Experimental|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
11399881|NCT02036905|Experimental|Cervical and thoracic mobilization|Cervical and thoracic mobilization: described as a repetitive low-velocity oscillatory movement applied to a joint segment. It is graded 1-4 based on the size of the amplitude and where in range it is being applied. The mobilization technique chosen will be based on the examination and clinical reasoning process of the therapist. The cervical and thoracic mobilization will be applied to the most provocative level.
11399882|NCT02036905|Experimental|Cervical and thoracic manipulation|Cervical and thoracic manipulation: is defined as high-velocity low-amplitude thrust at end range of a particular spinal segment. The therapist performs this technique by taking up all available slack at a particular segment and applying a high-velocity thrust through the end-range restriction. The manipulation technique will be chosen based on the examination and clinical reasoning process of the therapist.
11399883|NCT02036892|Experimental|Lifestyle counseling with smartphones|Lifestyle counseling assisted by smartphones
11399884|NCT02036892|Active Comparator|Lifestyle counseling|Lifestyle counseling
11399885|NCT02036879|No Intervention|Main study|"The main study is an observational study.
~All women will be followed for one menstrual cycle (or approximately one month) observationally off of any hormone supplementation. They will have 3 study visits corresponding to their menstrual cycle phases (menses, ovulation, and luteal).
~Women participating in the main study may participate in the optional interventional sub-study.
~Men participating in this study will be followed for 1 month observationally. They will have 3 study visits that correlate with the female arm of this study."
11399886|NCT02036879|Experimental|Loestrin Optional Substudy|Women participating in the main study may participate in the optional sub-study. Following a negative urine pregnancy test, women will be started on once daily oral Loestrin (1.5 mg norethindrone + 0.03 mg ethyl estradiol). They will be followed for two months on this agent and have 2 additional study visits.
11399887|NCT02036866|Experimental|Physical Therapy Positive Expectation|The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
11399888|NCT02036866|Experimental|Physical Therapy Neutral Expectation|The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
11399889|NCT02036866|Experimental|Control- No Intervention|The patients in the control group will be reminded of their appointment in 1 week and instructed to maintain their usual activity level during that time.
11399890|NCT02036853|Experimental|Schedule A|Subjects previously treated with triheptanoin
11399891|NCT02036853|Experimental|Schedule B|Naïve to triheptanoin
11399892|NCT02036840||Penicillin allergy|
11399893|NCT02036827|Active Comparator|moderate NMB + standard pressure|Investigators will administrate rocuronium until moderate neuromuscular blockade (Train of Four >=1, Post-tetanic count>=8) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
11400098|NCT02035475|Active Comparator|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
11399894|NCT02036827|Active Comparator|deep NMB + standard pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
11399895|NCT02036827|Active Comparator|deep NMB + low pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 8 mmHg.
11399896|NCT02036814|Experimental|Group A who underwent to an inter-relational strategy|Group A who underwent to a health educational orientation program (inter-relational strategy)
11399897|NCT02036814|Experimental|Group B who underwent group orientation by the nurse|
11399898|NCT02036801||ARDS|Patients with ARDS (according to the Berlin Definition criteria) in mechanical ventilation
11399899|NCT02036801||Healthy control|Patients with healthy lung supported with mechanical ventilation for clinical purposes
11399900|NCT02036788||Postsurgical patients sedated and paralized|Patients admitted to ICU after surgery, treated with mechanical ventilation, sedated and paralized
11399901|NCT02036788||Postsurgical patients intubated and breathing spontaneously|
11399902|NCT02036775|Experimental|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
11399903|NCT02036775|Experimental|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
11399904|NCT02036775|Experimental|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
11399905|NCT02036775|Experimental|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
11399906|NCT02036775|Experimental|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
11399907|NCT02036775|Experimental|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
11399908|NCT02036762|Active Comparator|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
11399909|NCT02036762|Sham Comparator|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
11399910|NCT02036749|Active Comparator|quadratus lumborum block (nerve block)|quadratus lumborum block with ropivacaine
11399911|NCT02036749|Placebo Comparator|sham block|QL block with saline
11399912|NCT02036736|Experimental|Propofol|Intraoperative anesthetic strategy by Propofol versus Desflurane
11399913|NCT02036736|Experimental|Desflurane|Intraoperative anesthetic strategy by Desflurane versus Propofol
11399914|NCT02036723|Experimental|BCD-021|"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia.
~In this arm 72 patients will receive BCD-021 at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months."
11399915|NCT02036723|Active Comparator|Lucentis®|Lucentis® is ranibizumab drug produced by Novartis Pharmaceuticals Canada Inc. In this arm 36 patients will receive Lucentis® at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
11399916|NCT02036710||Cecum|Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
11399917|NCT02036710||Ileum|Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
11399918|NCT02036697|Experimental|Low Dose Spinal|"Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.
~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section."
11399919|NCT02036697|Active Comparator|Control Spinal Group|"Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.
~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section."
11399920|NCT02036684|No Intervention|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
11399921|NCT02036684|Experimental|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
11399922|NCT02036671|Experimental|EndoAVF|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
11399956|NCT02036463|Active Comparator|Immediate Release Prednisone|During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
11399957|NCT02036463|Experimental|Delayed Release Prednisone|During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
11399923|NCT02036658|Active Comparator|Cognitive Behavioral Group Therapy|Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg & Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, & Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg & Becker, 2002).
11399924|NCT02036658|Active Comparator|Mindfulness-Based Stress Reduction|MBSR will follow the standard curriculum outline compiled in 1993 by Jon Kabat-Zinn except that the one-day meditation retreat will be converted to four additional weekly group sessions between the standard class 6 and 7 so that there will be 12 weekly 2.5 hour sessions. This will be done to match the CBGT protocol in duration and time. The MBSR intervention will be delivered by a University of Massachusetts Center for Mindfulness certified MBSR instructor with more than 30 years of teaching experience. To support the practice, each participant will be given A Mindfulness-Based Stress Reduction Workbook (Stahl & Goldstein, 2010), which includes descriptions of mindfulness exercises together with pre-recorded audio files to support ongoing practice.
11399925|NCT02036658|No Intervention|Waitlist Control|This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
11399926|NCT02036645|Experimental|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
11399927|NCT02036645|Placebo Comparator|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
11399928|NCT02036645|Experimental|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
11399929|NCT02036645|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
11399930|NCT02036632|Other|Eye Patching|Intervention
11399931|NCT02036619||pregnant women without known diabetes|
11399932|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
11399933|NCT02036606||control|Questionary and neuropsychological tasks will be administered
11399934|NCT02036593|Experimental|Walk Your Heart to Health intervention|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.
~Walking group sessions conducted 3 times per week for 32 weeks."
11399935|NCT02036593|Other|Walk Your Heart to Health lagged|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.
~Walking group sessions conducted 3 times per week for 32 weeks."
11399936|NCT02036580|Experimental|Low Dose|Investigational product Tralokinumab
11399937|NCT02036580|Experimental|High Dose|Investigational product Tralokinumab
11399938|NCT02036580|Placebo Comparator|Placebo|Placebo
11399939|NCT02036567||surgical patients|no interventions, observational study
11399940|NCT02036567||laboring women|no interventions, observational study
11399941|NCT02036567||volunteers|pain induction by noxious heat stimulation, measurement of pain by device and documentation of pain reported by subjects
11399942|NCT02036554|Experimental|Tacrolimus plus Everolimus|Low dose Tacrolimus + Everolimus
11399943|NCT02036554|Active Comparator|Tacrolimus plus Mycophenolic acid|standard dose Tacrolimus + Mycophenolic acid
11399944|NCT02036541|Experimental|AqueSys XEN 45 Glaucoma Implant|
11399945|NCT02036528|Experimental|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
11399946|NCT02036528|Active Comparator|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
11399947|NCT02036515|Experimental|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
11399948|NCT02036515|Experimental|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
11399949|NCT02036515|Placebo Comparator|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
11399950|NCT02036502|Experimental|Dose Determination Arm|Participants receive pembrolizumab 2 mg/kg every 2 weeks (Q2W, Days 1 and 15) in combination with lenalidomide 10 mg or 25 mg (Days 1-21) and dexamethasone 40 mg weekly during each 28-day cycle.
11399951|NCT02036502|Experimental|Dose Confirmation Arm|Participants receive pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg or 25 mg (Days 1-21) and dexamethasone 40 mg weekly during each 28-day cycle.
11399952|NCT02036502|Experimental|Cohort 1: rrMM|Cohort 1 is closed. All participants must stop study treatment and move into long term safety and survival follow up. Participants previously received pembrolizumab 200 mg once every 2 weeks (Q2W; Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during each 28-day cycle.
11399953|NCT02036502|Experimental|Cohort 2: rMM|Cohort 2 is closed to enrollment. Participants who are enrolled and not deriving clinical benefit must stop study treatment and move into the long term safety and survival follow up. Participants who are already enrolled and deriving clinical benefit from study treatment may continue in the study until protocol-specific end of treatment, and then progress into long term safety and survival follow up. Participants receive pembrolizumab 200 mg once every 3 weeks (Q3W) in combination with carfilzomib 56 mg/m^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
11399954|NCT02036489|Experimental|Induction and consolidation treatment|
11399955|NCT02036476|Experimental|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
11399958|NCT02036463|Placebo Comparator|Placebo-Delayed Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
11399959|NCT02036463|Placebo Comparator|Placebo-Immediate Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
11399960|NCT02036450|Experimental|ILR group|Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
11399961|NCT02036450|No Intervention|Control group|Followed according to standard care, i.e. by their general practitioner. Study visits are scheduled at inclusion and after 3 years. Furthermore, the participants are contacted by telephone after 1 and 2 years of follow-up, and endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
11399962|NCT02036437|Experimental|Cases|A dose of 20ug is required obtained by dissolving the 200ug tablet (Misotac® Sigma Pharmaceutical Industries) in 200 ml water (1ug per ml), the solution is shaked well before each administration. The solution will be orally administrated every two hours (max. 12 hrs) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy.
11399963|NCT02036437|Active Comparator|Control|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
11399964|NCT02036424|Active Comparator|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
11399965|NCT02036424|Active Comparator|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
11399966|NCT02036398|Active Comparator|Nephrostomy tube + double J stent|Standard therapy group with nephrostomy tube and double J stent left at the end of the PCNL
11399967|NCT02036398|Experimental|Double J stent without nephrostomy|Double J stent only left at the end of the procedure
11399968|NCT02036372|Experimental|BR (bolus regimen)|"Day before surgery: half evening dose long acting insulin
~Day of surgery:
~patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets
~patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets
~Measure blood glucose every 60 minutes, start 30 min prior to surgery
~Give bolus of insulin according to treatment algorithm"
11399969|NCT02036372|Experimental|LG (Liraglutide)|"Day before surgery: half dose of long acting and mealtime insulin from start liraglutide
~Day of surgery: withhold own insulin, stop oral glucose lowering tablets
~Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.
~In case of nausea graded higher than minimal, the patient will be excluded from the study
~Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.
~Measure glucose every 60 minutes, start 30 min prior to surgery
~Adjust according to bolus algorithm of BR group"
11399970|NCT02036372|Active Comparator|GIK (glucose -insulin - potassium) infusion|"Day before surgery: half evening dose long acting insulin
~Day of surgery: stop oral glucose lowering tablets and withhold own insulin.
~GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.
~Calculate the insulin amount in the GIK infusion according to the formula:
~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg
~Measure blood glucose every 60 minutes, start 30 min prior to surgery
~Adjust glucose > 8 mmol/l according to treatment algorithm"
11399971|NCT02036359|Active Comparator|erlotinib|Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
11399972|NCT02036359|Active Comparator|Chemotherapy|"Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
~Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.
~Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.
~If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
11399973|NCT02036346|Experimental|Oral rehydration solution|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
11399974|NCT02036346|Experimental|No intervention|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
11399975|NCT02036346|Active Comparator|Colorectal resection without an ileostomy|Patients who have undergone colorectal resection surgery without an ileostomy creation
11399976|NCT02036333||Concussion Group|
11399977|NCT02036333||Control Group|
11399978|NCT02036320|Experimental|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
11399979|NCT02036320|Active Comparator|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
11399980|NCT02036307|Experimental|DHA-enriched|DHA-enriched supplement (DHA 3g + 600 mg EPA in 6 g of fish oil/day)
11399981|NCT02036307|Experimental|EPA-enriched|EPA-enriched supplement (EPA 2.4 g + DHA 600mg in 6 g of fish oil/day)
11399982|NCT02036294|Other|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
11400093|NCT02035514|Experimental|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
11399983|NCT02036294|Experimental|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
11399984|NCT02036281|Experimental|SP-SAP ARM|The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
11399985|NCT02036268|Active Comparator|Standard|Subjects will receive standard ostomy education.
11399986|NCT02036268|Experimental|Pre-Operative Education|In addition to standard ostomy education, subjects will receive additional education pre-operatively.
11399987|NCT02036268|Experimental|Two-week Post Operative Education|In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.
11399988|NCT02036255|Experimental|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
11399989|NCT02036255|Active Comparator|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
11399990|NCT02036242|Experimental|Sole local anesthetic|Epidural analgesia will be given with sole local anesthetic (0.125% ropivacaine) intermittently
11399991|NCT02036242|Active Comparator|Opioid plus local anesthetic|Epidural analgesia will be given with opioid (sufentanil) combined with local anesthetic (0.125% ropivacaine) intermittently
11399992|NCT02036229|Experimental|0.5% ivermectin cream|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
11399993|NCT02036229|Placebo Comparator|vehicle cream|Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
11399994|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
11399995|NCT02036203|Experimental|SCu300A IUB|
11399996|NCT02036203|Active Comparator|TCu380A|
11399997|NCT02036190||Control group|Former or current smokers without emphysema
11399998|NCT02036190||Emphysema|Current or former smokers with emphysema
11399999|NCT02036177|Experimental|SCu300A IUB|
11400000|NCT02036177|Active Comparator|T380A copper IUD|
11400001|NCT02036164|Active Comparator|Concurrent chemoradiation|"Radiation: Radiation Therapy
~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine
~Vaginal brachytherapy for 4-5 fractions
~Chemotherapy: Cisplatin
~- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy"
11400002|NCT02036164|Experimental|Concurretn chemoradiation plus adjuvant chemotherapy|"Radiation: Radiation Therapy
~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine
~Vaginal brachytherapy for 4-5 fractions
~Chemotherapy: Cisplatin, paclitaxel, carboplatin
~Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy
~Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT
~Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel"
11400003|NCT02036151|Experimental|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
11400004|NCT02036151|Active Comparator|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
11400005|NCT02036138|Active Comparator|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
11400006|NCT02036138|Experimental|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
11400007|NCT02036138|Experimental|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
11400008|NCT02036125|Experimental|Ultrasound guided injection|Ultrasound guided injection of 40 mg of methylprednisolone
11400009|NCT02036125|Active Comparator|Blind injection|Blind injection of 40 mg of methylprednisolone
11400010|NCT02036112|Experimental|Individual ELAPE|Patients will receive Individual ELAPE technique
11400011|NCT02036112|Experimental|Conventional ELAPE|Patients with advanced lower rectal cancer will receive conventional EALPE technique
11400012|NCT02036099|Experimental|Driving in Mild Dementia Decision Tool|Participants in this arm will be assessing patients using the Driving in Mild Dementia Decision Tool
11400013|NCT02036099|No Intervention|Control|Participants will assess patients using their usual care strategies.
11400014|NCT02036086|Experimental|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
11400015|NCT02036073|Experimental|EPO|In EPO group, the EPO was given by 500IU/kg every other day intravenously for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Center Configuration, melted configured with saline to 1ml/kg solution. For severe patients, they were started to treat with EPO when their vital signs, blood pressure were stable.
11400016|NCT02036060|Experimental|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
11400017|NCT02036060|Active Comparator|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
11400018|NCT02036047|Experimental|Exclusive cold polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using an exclusive cold polypectomy snare (Exacto cold snare). The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
11400019|NCT02036047|Active Comparator|regular polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using a regular polypectomy snare. The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
11400020|NCT02036034|Active Comparator|drape with forced air warmer|forced air warmer placed under the chin before draping, inflated after draping completed.
11400021|NCT02036034|Placebo Comparator|drape with warming blanket|warming blanket placed on torso of patient under the drape.
11400022|NCT02036021||PRE/non-PRE|children who develop or did not perioperative respiratory events between November 2012 and December 2013
11400023|NCT02036008|Other|Liver MRI with EcGd and with Gdfos|All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.
11400024|NCT02035995||Healthy volunteers|This group consisted of age matched non-pregnant healthy volunteers
11400025|NCT02035995||Healthy pregnant volunteers|This group consisted of age matched healthy pregnant volunteers
11400026|NCT02035982|Active Comparator|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
11400027|NCT02035982|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
11400028|NCT02035969|No Intervention|Conventional treatment (CT)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling and clinical follow up every three months. The caretaker of the child is responsible that the child will take the drugs and is provided with a pre-packed dosage form for easy remembering
11400029|NCT02035969|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counselling and clinical follow up every three months. In addition adherence support is provided according to the description under intervention.
11400030|NCT02035956|Experimental|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
11400031|NCT02035943|Active Comparator|Insulin separated|Seprated infusion of insulin
11400032|NCT02035943|Active Comparator|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
11400033|NCT02035930|Other|menstrual cycle,dexmedetomidine|
11400034|NCT02035917|Experimental|Locking plate|
11400035|NCT02035917|Active Comparator|Non-Locking plate|
11400036|NCT02035904|Experimental|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
11400037|NCT02035904|Placebo Comparator|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
11400038|NCT02035891|Active Comparator|colchicine|0.5mg/d colchicine
11400039|NCT02035891|Placebo Comparator|placebo|appearance is same as colchicine
11400040|NCT02035878|Active Comparator|Probiotics|400mg probiotic capsule taken once daily for ten weeks
11400041|NCT02035878|Placebo Comparator|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
11400042|NCT02035865||Participants from former study 1|Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte'
11400043|NCT02035865||Participants from former study 2|Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148)
11400044|NCT02035852||Adult Gilomas|
11400045|NCT02035839|Other|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
11400046|NCT02035839|Other|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
11400047|NCT02035839|Other|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
11400048|NCT02035826|Active Comparator|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
11400049|NCT02035826|Active Comparator|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
11400050|NCT02035826|Active Comparator|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
11400051|NCT02035826|No Intervention|Arm 4|Control Arm
11400052|NCT02035813|Experimental|Ribociclib in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
11400053|NCT02035813|Experimental|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
11400054|NCT02035800|Experimental|Adalimumab (humira)|As standard of care.
11400055|NCT02035787|Experimental|Metformin|Metformin, 850 mg. twice daily.
11400056|NCT02035774|Active Comparator|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
11400057|NCT02035774|Placebo Comparator|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
11400094|NCT02035514|Experimental|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
11400095|NCT02035501|Active Comparator|L-Tyrosine|
11400058|NCT02035761||MSA Case|The screening evaluation will take less than 1 to 2 hours, and is usually conducted over the telephone. The visit for testing will take approximately 3 days, consisting (usually) of a day for clinical examinations and questionnaires and one day each for PET and MRI brain imaging and the third day for PET imaging of the heart and autonomic testing. If some checklists and questionnaires could not be completed conveniently in the time available, they may be finished over the telephone on a later day. At the completion of the 3-day evaluation, subjects are asked to return home and keep a log of their MSA symptoms and medication responses for 2 days. This will complete the active participation of MSA subjects in all aspects of the entire research program. The average time the subjects will be followed could be up to 1 week during which time the subjects are undergoing research related procedures.
11400059|NCT02035748|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
11400060|NCT02035735|Experimental|Videoendoscopy with WL and NBI|The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).
11400061|NCT02035722|No Intervention|Control group|AMD-related information is not given to patients randomized to the control group.
11400062|NCT02035722|Active Comparator|Video materials|Educational materials are presented in through a video (audio and visual)
11400063|NCT02035722|Active Comparator|Print materials|Educational materials are presented in the format of printed brochure (visual)
11400064|NCT02035709|Active Comparator|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
11400065|NCT02035709|Active Comparator|PCA|Intravenous Patient-Controlled Analgesia
11400066|NCT02035696|Experimental|TIVc-High Dose|Subjects (6 to <48 months old) received two doses of 0.75 mL of TIVc vaccine
11400067|NCT02035696|Experimental|TIVc-Full Dose|Subjects(6 to <48 months old) received two doses of 0.50 mL of TIVc vaccine
11400068|NCT02035696|Experimental|TIVc- Half Dose|Subjects (6 to <48 months old)received two doses of 0.25 mL of TIVc vaccine
11400069|NCT02035696|Active Comparator|TIVe|Subjects (6 to <48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to <36 months and IM/ 0.5 mL -for ages 36 to <48 months)
11400070|NCT02035683|Other|Advanced NSCLC patients undergoing first-line chemotherapy|single cohort
11400071|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
11400072|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.
~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
11400073|NCT02035657|Experimental|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
11400074|NCT02035644|Experimental|Jinlida granules|Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes
11400075|NCT02035644|Placebo Comparator|placebo granules|placebo prepared in indistinguishable granules
11400076|NCT02035631|Experimental|Intervention|Lifestyle intervention combining weight control, diet and physical activity
11400077|NCT02035631|Sham Comparator|Minimal intervention|Minimal diet intervention and minimal physical activity intervention
11400078|NCT02035618|Experimental|Exercises and manual therapy|
11400079|NCT02035618|Active Comparator|Exercises|
11400080|NCT02035605|Active Comparator|ALN-AT3SC|
11400081|NCT02035605|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11400082|NCT02035592|Active Comparator|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.
~Frequency: 26g per day.
~Total duration: 6-month."
11400083|NCT02035592|Active Comparator|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.
~Frequency: 26g per day.
~Total duration: 6-month."
11400084|NCT02035592|Placebo Comparator|Control|"Matched control powder; matched for appearance, taste and sugar content.
~Frequency: 26g per day.
~Total duration: 6-month."
11400085|NCT02035579|Experimental|Aerobic Training Intervention|Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
11400086|NCT02035579|Experimental|Stretching Intervention|Children in the stretching intervention will complete a series of full body stretches of the shoulders, arms, chest, back, legs, and feet 5-6 days per week and will return weekly to review the stretching program. The minimum duration of the stretching intervention will also be 6 weeks
11400087|NCT02035566|Experimental|Telehome Care Monitoring + Usual Care|
11400088|NCT02035566|No Intervention|Usual Care|
11400089|NCT02035553|Placebo Comparator|Placebo|Placebo, two tablets, once daily by mouth
11400090|NCT02035553|Experimental|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
11400091|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
11400092|NCT02035527|Experimental|Treatment (sorafenib tosylate, docetaxel, and cisplatin)|Patients receive sorafenib tosylate PO BID on days 1-14 of course 0. Beginning in course 1, patients receive sorafenib tosylate PO BID on days 1-21, docetaxel IV over 1 hour on day 1, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.Correlative studies will be performed and a total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
11400096|NCT02035501|Placebo Comparator|Placebo|
11400099|NCT02035475|Active Comparator|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
11400100|NCT02035449||McGrath MAC|McGrath MAC is a videolaryngscope
11400101|NCT02035436|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
11400102|NCT02035436|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
11400103|NCT02035423|Active Comparator|Male Guidance School|Non-Fortified Milk 120IU Milk 200IU Milk
11400104|NCT02035423|Active Comparator|Female Guidance|Non-fortified Milk 120IU Milk 200IU Milk
11400105|NCT02035423|Active Comparator|Male Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
11400106|NCT02035423|Active Comparator|Female Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
11400107|NCT02035410|Active Comparator|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
11400108|NCT02035410|No Intervention|Control group|No intervention group
11400109|NCT02035397|Experimental|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
11400110|NCT02035397|Placebo Comparator|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
11400111|NCT02035384||All patients|
11400112|NCT02035371|Experimental|FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
11400113|NCT02035371|Active Comparator|NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
11400114|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
11400115|NCT02035345|Experimental|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:
~First hour - Administer 1 percent of total dose (5ml with tubing primed)
~Second hour - Administer 9 percent (45 mL)
~Third hour - Administer 90 percent (450 mL)"
11400116|NCT02035332|Experimental|Aurora Treatment Arm|Endometrial Ablation
11400117|NCT02035319||capillary malformation treated by laser|capillary malformation treated by laser
11400118|NCT02035306|Experimental|non-invasive Haemaglobin|Measuring haemaglobin using non-invasive co-oximetry device
11400119|NCT02035293|Other|PEP|No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
11400120|NCT02035280||Elderly suffering of spine deformity|Spinal deformity patients over the age of 60 years undergoing elective surgery and requiring fusion of at least 5 levels.
11400121|NCT02035267|Placebo Comparator|Placebo - Grade 1|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 1 (mild).
11400122|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 1|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 (mild).
11400123|NCT02035267|Placebo Comparator|Placebo - Grade 4|Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).
11400124|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 4|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants with CR SMFRS Grade 4 (extreme).
11400125|NCT02035254|Experimental|Intervention group|Web-based wellness program
11400126|NCT02035254|Other|Wait control group|Web-based wellness program after 3 month wait.
11400127|NCT02035241|Experimental|Spices 1|220 ml test drink containing spices 1, acute study / one time administration
11400128|NCT02035241|Experimental|Spices 2|220 ml test drink containing spices 2, acute study / one time administration
11400129|NCT02035241|Experimental|Spices 3|220 ml test drink containing spices 3, acute study / one time administration
11400130|NCT02035241|Experimental|Herbs 1|220 ml test drink containing herbs 1, acute study / one time administration
11400131|NCT02035241|Experimental|Herbs 2|220 ml test drink containing herbs 2, acute study / one time administration
11400132|NCT02035241|Placebo Comparator|Placebo|220 ml control drink, acute study / one time administration
11400133|NCT02035228|Experimental|Seated|"Patients breathing will be compared across a series of 9 trials in which unassisted breathing is compared to abdominal stimulation (SecondBreath) assisted breathing at various intensities. Each breathing trial will last for 2 minutes and will be conducted while the patient is seated. The following abdominal stimulation trials were included:
~Abdominal Stimulation - low / early Abdominal stimulation - low/late Abdominal Stimulation - low/full Abdominal stimulation - med/early Abdominal stimulation - med/late Abdominal Stimulation - med/full Abdominal Stimulation - high/early Abdominal Stimulation - high/late Abdominal Stimulation - high/full"
11400134|NCT02035228|Experimental|6 minute step test|"Patients will complete a 6 minute step test with and without abdominal stimulation (SecondBreath).
~Abdominal Stimulation - high/full"
11400135|NCT02035215|Experimental|Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g|Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
11400136|NCT02035215|Placebo Comparator|Atorvastatin 20mg, Placebo|Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
11400218|NCT02034630|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
11400137|NCT02035202|Experimental|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
11400138|NCT02035202|Active Comparator|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
11400139|NCT02035202|No Intervention|Standard Care|Participants assigned to this condition will only participate in the assessments.
11400140|NCT02035176||Autistic children ages 6-11|Autistic children ages 6-11
11400141|NCT02035176||ADHD children ages 6-11|ADHD children ages 6-11
11400142|NCT02035176||Typical children ages 6-11|Typical children ages 6-11
11400143|NCT02035163|Active Comparator|Two sites cryoablation group|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
11400144|NCT02035163|No Intervention|Control group|No Intervention group
11400145|NCT02035150|Experimental|Oatmeal Breakfast|Participants will consume oatmeal breakfast daily for 4 weeks
11400146|NCT02035150|Experimental|Frosted Flakes|Participants will consume a frosted flakes breakfast daily for 4-weeks
11400147|NCT02035150|Placebo Comparator|No Breakfast|Participants will consume no breakfast for a 4-week period
11400148|NCT02035137|Active Comparator|Single-Agent 131I-MIBG|Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.
11400149|NCT02035137|Active Comparator|131I-MIBG with Vincristine/Irinotecan|Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 31I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
11400150|NCT02035137|Active Comparator|131I-MIBG with Vorinostat|Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.
11400151|NCT02035124|Experimental|BKM120 and Cabazitaxel|"BKM 120 orally once daily;
~Cabazitaxel 25 mg/m2 IV every 3 weeks"
11400152|NCT02035111|Experimental|Tianshu capsule|Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
11400153|NCT02035111|Placebo Comparator|Sugar pill|Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.
11400154|NCT02035098|Experimental|The Pac-IFicO programme|The Pac-IFicO programme is a complex interventions aimed at improving the quality of pain managementi in hospitalized patients.
11400155|NCT02035085|Experimental|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
11400156|NCT02035072|Experimental|Hypofractionated RT + Gem + Oxali|Hypofractionated radiotherapy + Gemcitabine + Oxaliplatin
11400157|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
11400158|NCT02035046|Other|study's population|
11400159|NCT02035033||low calcium supplement|low calcium supplement
11400160|NCT02035033||Calcium intake 500-1000 mg per day|Calcium intake 500-1000 mg per day
11400161|NCT02035033||Calcium intake above 1000 mg per day|Calcium intake above 1000 mg per day
11400162|NCT02035020|Experimental|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
11400163|NCT02035007|Experimental|LV-EF > 50%|PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]
11400164|NCT02034994|Experimental|Intervention group|Reduction of sugar sweetened beverages. cookies, sedentary activities and increasing physical activity
11400165|NCT02034994|No Intervention|Control group|No intervention
11400166|NCT02034981|Experimental|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
11400167|NCT02034968|Experimental|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.
~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle
~Cisplatin: 75mg/m2,IV on 21 day cycle"
11400168|NCT02034955|Experimental|Post-Operative adaptive radiotherapy|All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
11400169|NCT02034942|Experimental|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.
~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
11400170|NCT02034942|Active Comparator|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:
~Open the eyes to verbal commands.
~Follow the examiner's instructions with the eyes.
~Squeeze hands on request.
~Stick out the tongue on request.
~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
11400171|NCT02034929|Active Comparator|Endocuff-assisted colonoscopy|Endocuff-assisted colonoscopy
11400172|NCT02034929|Active Comparator|Standard colonoscopy|Standard Colonoscopy
11400219|NCT02034617|No Intervention|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
11400296|NCT02034214|Active Comparator|Education and health services alone|Life skills education Reproductive health services
11400173|NCT02034916|Experimental|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum
~Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
11400174|NCT02034903|No Intervention|Standard warming|Feeding warmed in water bath
11400175|NCT02034903|Experimental|Commercial warmer|Feedings warmed with a commercial warmer
11400176|NCT02034890|Experimental|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
11400177|NCT02034890|No Intervention|retrospective control patients|retrospective control patients
11400178|NCT02034877|Experimental|1|
11400179|NCT02034864|Experimental|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
11400180|NCT02034864|Sham Comparator|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
11400181|NCT02034851||Dexamethasone|Intervention group
11400182|NCT02034851||Control|Placebo group (physiological saline)
11400183|NCT02034838|Experimental|atazanavir 300mg boosted with ritonavir 100mg|"Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.
~Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive"
11400184|NCT02034825||Practicing urologic surgeons|"US board-certified
~Practicing urologic surgeons
~Performing at least 40 radical prostate surgeries annually
~Urologists will be excluded from participating in the study if:
~They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;
~They have spent less than 3 years in practice or perform less than 40 RP's per year
~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
11400185|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:
~Practicing, board-certified radiation oncologists
~Perform consultations on at least 80 patients with prostate cancer annually
~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
11400186|NCT02034799|Other|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
11400187|NCT02034799|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
11400188|NCT02034786|Experimental|Test|Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.
11400189|NCT02034786|Active Comparator|Control|Transdermal injection of hyaluronic acid only.
11400190|NCT02034773|Experimental|CC-220 0.3mg x 14 days|
11400191|NCT02034773|Experimental|CC-220 1mg x 28 days|
11400192|NCT02034773|Experimental|CC-220 0.3mg x 28 days|
11400193|NCT02034773|Experimental|CC-220 1mg x a total of 14 days|
11400194|NCT02034773|Experimental|Placebo|
11400195|NCT02034773|Experimental|CC-220 0.3mg (once every 3 days for 14 days)|
11400196|NCT02034773|Experimental|CC-220 1mg (once every 7 days for 28 days)|
11400197|NCT02034773|Experimental|CC-220 1mg (formulated and reference capsules)|
11400198|NCT02034760|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
11400199|NCT02034760|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
11400200|NCT02034760|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
11400201|NCT02034760|Active Comparator|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
11400202|NCT02034760|Placebo Comparator|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
11400203|NCT02034747|Experimental|Corticosteroid with the 50% reduced dose|oral
11400204|NCT02034747|Active Comparator|Corticosteroid with the maintained dose|oral
11400205|NCT02034734|Experimental|1: ASP3652|Multiple doses of ASP3652
11400206|NCT02034721|Experimental|Protein supplementation|60 grams protein before, during, after eccentric exercise
11400207|NCT02034721|Placebo Comparator|Placebo|60 grams placebo before, during, after eccentric exercise
11400208|NCT02034708|Experimental|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
11400209|NCT02034708|Experimental|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
11400210|NCT02034695||RAMP and Non-RAMP|
11400211|NCT02034682|Experimental|Volulyte 6%|"- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:
~Maize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da
~Na acetate trihydrate 4.63 gr
~Sodium Chloride 6.02 gr
~Potassium Chloride 0.3 gr
~MgCl 0.3 gr
~Sodium hydroxide-hydrochloric acid & H2O"
11400212|NCT02034682|Active Comparator|Geloplasma|"In 1000 ml:
~Modified fluid gelatin 30 gr
~Sodium Chloride 5.4 gr
~Potassium Chloride 0.37 gr
~MgCl 0.14 gr
~Sodium lactate 3.36 gr"
11400213|NCT02034669|Experimental|Treatment with ADSCs transplantation|4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous
11400214|NCT02034669|No Intervention|Treatment without ADSCs transplantation|Only intervention: laminectomy
11400215|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
11400216|NCT02034643|Other|patients with single-lumen tube|Patients who required intraoperative TEE and single-lumen tube; balloon pressure adjustment before TEE probe insertion
11400217|NCT02034643|Other|patients with double-lumen tube|Patients who required intraoperative TEE and double-lumen tube; balloon pressure adjustment before TEE probe insertion
11400461|NCT02033031|Active Comparator|Avastin|PRN intravitreal injection of Lucentis
11400220|NCT02034617|Experimental|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
11400221|NCT02034604|Experimental|Naftopidil Group|Naftopidil medication patients
11400222|NCT02034604|Active Comparator|Tamsulosin Goup|Tamsulosin medication patients
11400223|NCT02034591|Experimental|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
11400224|NCT02034591|Experimental|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
11400225|NCT02034591|Experimental|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
11400226|NCT02034578|Experimental|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
11400227|NCT02034578|Experimental|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
11400228|NCT02034578|Experimental|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
11400229|NCT02034565|Experimental|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
11400230|NCT02034565|Experimental|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
11400231|NCT02034552|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|
11400232|NCT02034552|Experimental|Radium-223 with abiraterone&prednisone|
11400233|NCT02034552|Experimental|Radium-223 with enzalutamide|
11400234|NCT02034539|Experimental|VADOplex treatment|best medical treatment in combination with intermittent pneumatic foot compression by the VADOplex system for 4 - 6 hours/day until total wound closure of the target lesion is achieved with a maximum treatment of 24 weeks
11400235|NCT02034539|No Intervention|conservative treatment|best medical treatment of the target lesion alone
11400236|NCT02034526|Placebo Comparator|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
11400237|NCT02034526|Experimental|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
11400238|NCT02034513|Experimental|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
11400239|NCT02034513|Active Comparator|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
11400240|NCT02034500|Experimental|S. sonnei 1790GAHB - 0.1 mcg - ID|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 0.1 mcg intradermally (ID)
11400241|NCT02034500|Experimental|S. sonnei 1790GAHB - 1 mcg - ID|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 1 mcg intradermally (ID)
11400242|NCT02034500|Experimental|S. sonnei 1790GAHB - 10 mcg - ID|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 10 mcg intradermally (ID)
11400243|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IN|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intranasally (IN)
11400244|NCT02034500|Experimental|S. sonnei 1790GAHB - 20 mcg - IN|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 20 mcg intranasally (IN)
11400245|NCT02034500|Experimental|S. sonnei 1790GAHB - 80 mcg - IN|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 80 mcg intranasally (IN)
11400246|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IM|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intramuscularly (IM)
11400247|NCT02034500|Placebo Comparator|Placebo - ID|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intradermally (ID). These were pooled in one Placebo group in the analyses
11400248|NCT02034500|Placebo Comparator|Placebo - IN|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intranasally (IN). These were pooled in one Placebo group in the analyses
11400249|NCT02034500|Placebo Comparator|Placebo - IM|2 subjects enrolled in COHORT C receiving 3 injections of Placebo intramuscularly (IM)
11400250|NCT02034487||Boys with delayed puberty|Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.
11400251|NCT02034474|Experimental|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
11400252|NCT02034474|Placebo Comparator|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
11400253|NCT02034461|Experimental|Acute surgical implantation|
11400254|NCT02034461|Experimental|Implantation of a Utah Electrode Array|Arm which has been amputated or has peripheral nerve trauma. Interventions include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about nerve stimulation.
11400255|NCT02034448||Acute Kidney Injury|CRRT intervention with adult patients with Acute Kidney Injury
11400256|NCT02034435|Active Comparator|Aim1-Low salt diet|Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.
11400257|NCT02034435|Active Comparator|Aim 1-high salt diet|Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.
11400258|NCT02034435|Active Comparator|Aim2- low salt diet and epleronone-amlodipine|Subjects on a low salt diet will receive epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with amlodipine 5mg for 8days and assessments will be made.
11400259|NCT02034435|Active Comparator|aim2- lowsaltdiet and amlodipine-epleronone|Subjects on a low salt diet will receive amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with epleronone 50mg for 8days and assessments will be made.
11400293|NCT02034227|Experimental|SG2000 - 15 µg/m2/day|Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
11400294|NCT02034227|Experimental|SG2000 - 30 µg/m2/day|Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
11400295|NCT02034214|Experimental|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
11400260|NCT02034422|Experimental|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
11400261|NCT02034422|Experimental|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
11400262|NCT02034409|Sham Comparator|Sham|Treatment to index knee with sham device for 48 weeks
11400263|NCT02034409|Experimental|PLIUS|Treatment to index knee with PLIUS device for 48 weeks
11400264|NCT02034396|Other|Blood draw|One blood draw at enrollment
11400265|NCT02034383|Experimental|Control|Diet will consist of a controlled diet without almonds for 3 weeks.
11400266|NCT02034383|Experimental|Whole Almonds|Diet will consist of a controlled diet with whole almonds for 3 weeks.
11400267|NCT02034383|Experimental|Roasted Whole Almonds|Diet will consist of a controlled diet with roasted whole almonds for 3 weeks.
11400268|NCT02034383|Experimental|Diced Almonds|Diet will consist of a controlled diet with diced almonds for 3 weeks.
11400269|NCT02034383|Experimental|Almond Butter|Diet will consist of a controlled diet with almond butter for 3 weeks.
11400270|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
11400271|NCT02034357|Other|Neurocognitive function|Neurocognitive function assessment (verbal learning and memory) as measured by CVLT and sleep evaluations in Parkinson's disease patients at baseline, and after 4 months and 1 year of CPAP treatment
11400272|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
11400273|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
11400274|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
11400275|NCT02034331|Active Comparator|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
11400276|NCT02034331|Active Comparator|Heat Application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
11400277|NCT02034331|Experimental|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
11400278|NCT02034331|Placebo Comparator|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
11400279|NCT02034292|Experimental|10mg MD|APD791 10mg Multiple dose and
11400280|NCT02034292|Experimental|20mg MD|APD791 20mg Multiple dose
11400281|NCT02034292|Experimental|40mg MD|APD791 40mg Multiple dose
11400282|NCT02034292|Experimental|60mg MD|APD791 60mg Multiple dose
11400283|NCT02034292|Placebo Comparator|Placebo MD|Placebo for Multiple dose group
11400284|NCT02034292|Experimental|120mg SD|APD791 120mg Single dose
11400285|NCT02034292|Experimental|240mg SD|APD791 240mg Single dose
11400286|NCT02034292|Experimental|320mg SD|APD791 320mg Single dose
11400287|NCT02034292|Placebo Comparator|Placebo SD|Placebo for Single dose
11400288|NCT02034279|Experimental|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
11400289|NCT02034279|No Intervention|No albumin|Only antibiotics
11400290|NCT02034266|Experimental|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
11400291|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
11400292|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
11400297|NCT02034201|Active Comparator|Lisdexamfetamine|Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.
11400298|NCT02034201|Placebo Comparator|Placebo|Placebo will be administered orally daily through week 6 of the protocol.
11400299|NCT02034188|Experimental|Umbilical cord mesenchymal stem cells|
11400300|NCT02034175|Experimental|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
11400301|NCT02034175|Active Comparator|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
11400302|NCT02034162|Active Comparator|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
11400303|NCT02034162|Placebo Comparator|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
11400304|NCT02034149|Other|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
11400305|NCT02034149|Experimental|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
11400306|NCT02034149|Experimental|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
11400307|NCT02034136|Experimental|Ginsenoside|"Ginsenoside :
~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
11400308|NCT02034136|Placebo Comparator|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
11400309|NCT02034123|Experimental|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
11400310|NCT02034123|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
11400311|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib will be administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib will be administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects will take their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
11400312|NCT02034097|Experimental|Cohort 1|Subjects with EGFRm NSCLC who have received clinical benefit (CR, PR, SD) for at least 4 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 milligram (mg) erlotinib once daily (OD) and 45 mg foretinib OD as a combination therapy until disease progression
11400313|NCT02034097|Experimental|Cohort 2|Subjects with EGFR/WT NSCLC who have received clinical benefit (CR, PR, SD) for at least 2 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 mg erlotinib OD and 45 mg foretinib OD as a combination therapy until disease progression.
11400314|NCT02034097|Experimental|Cohort 3|Subjects with NSCLC who are predicted to be sensitive to foretinib based on biomarkers identified with preclinical or clinical data will receive 60 mg foretinib OD as a monotherapy until disease progression
11400315|NCT02034084|Experimental|Right radial approach|Coronary diagnostic procedures performed through right radial approach
11400316|NCT02034084|Experimental|Left radial approach|Coronary diagnostic procedures performed through left radial approach
11400317|NCT02034071|Experimental|DCCR Open Label - DCCR Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to continue DCCR, at the same dose as they received on Day 69, in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
11400318|NCT02034071|Experimental|DCCR Open Label - Placebo Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to receive placebo equivalent to the DCCR dose received on Day 69 in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
11400319|NCT02034058|Other|Wingspan Stent System|Placement of the Wingspan Stent
11400320|NCT02034045|Active Comparator|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
11400321|NCT02034045|Experimental|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
11400322|NCT02034032|Active Comparator|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
11400357|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
11400358|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
11400323|NCT02034032|Active Comparator|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
11400324|NCT02034019|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
11400325|NCT02034019|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
11400326|NCT02034006|Experimental|Ranibizumab|Patients treated with a single ranibizumab 0.5 mg/0.05ml intravitreal injection
11400327|NCT02033993|Active Comparator|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
11400328|NCT02033993|Active Comparator|Arm 2|Paclitaxel - 175mg/m2: q21 days
11400329|NCT02033980|Other|colorectal lesions|All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
11400330|NCT02033967|Active Comparator|CVP|Central venous pressure-guided vasodilator-induced hypovolemia
11400331|NCT02033967|Experimental|SVV|stroke volume variation-guided vasodilator-induced hypovolemia
11400332|NCT02033941|Active Comparator|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
11400333|NCT02033941|Placebo Comparator|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
11400334|NCT02033928||Arm I: Transplant patients|
11400335|NCT02033928||Arm II: Plasma cell dyscrasia patients|
11400336|NCT02033915|Experimental|Interactive Discussion Group|The interactive discussion groups were held for six times (8-10 persons for each group). During the 50-60 minutes' discussion, the facilitators guided the participants to discuss a case vignette, focusing on the key issues of hospital suicide prevention, and to enhance their abilities of suicide risk identification and evaluation. Two research team members who served as facilitators led the group in a standardized manner.
11400337|NCT02033902||Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
11400338|NCT02033889|Experimental|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
11400339|NCT02033889|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
11400340|NCT02033889|Placebo Comparator|Placebo/Glimepiride|Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
11400341|NCT02033876|Experimental|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
11400342|NCT02033876|Placebo Comparator|Placebo|matching placebo capsules to be taken twice daily
11400343|NCT02033863||Cohort A|Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
11400344|NCT02033863||Cohort B|Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
11400345|NCT02033850|Experimental|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.
~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
11400346|NCT02033850|No Intervention|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
11400347|NCT02033824|Other|Group 1 Control|Will receive only traditional craniectomy
11400348|NCT02033824|Experimental|Group 2 Treatment dHACM|Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
11400349|NCT02033798|Experimental|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
11400350|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
11400351|NCT02033759|Active Comparator|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
11400352|NCT02033759|Experimental|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
11400353|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm A|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed
11400354|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm B|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator treatment while receiving concurrent buprenorphine-naloxone as prescribed
11400355|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
11400356|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
11400360|NCT02033707|Experimental|Male volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
11400361|NCT02033707|Experimental|Female volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
11400362|NCT02033694||Participants With 2 Years Follow up|Participants with NIRS-IVUS imaging at baseline and assigned to follow up for Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) for 2 years
11400363|NCT02033681|Experimental|"One-per-mil Tumescent Solution"|
11400364|NCT02033681|Placebo Comparator|Saline Solution|
11400365|NCT02033668|Active Comparator|Arm A|Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion
11400366|NCT02033668|Experimental|Arm B|Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ
11400367|NCT02033668|Experimental|Arm C|Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg).
11400368|NCT02033668|Experimental|Arm D|Participants in this arm will receive single 200 mg dose of GSK933776 administered IM
11400369|NCT02033655|Experimental|Weight loss high protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60% of animal protein from pork.
11400370|NCT02033655|Active Comparator|Weight loss control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
11400371|NCT02033642|Experimental|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child.
11400372|NCT02033642|Experimental|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors at home.
11400373|NCT02033629|Active Comparator|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
11400374|NCT02033629|Active Comparator|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
11400375|NCT02033629|Placebo Comparator|Ce 3 ng/ml|Remifentanil Ce 3 ng/ml
11400376|NCT02033616|Experimental|AVOVA-1|Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
11400377|NCT02033616|Placebo Comparator|MC|Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.
11400378|NCT02033603|Active Comparator|Femoral Nerve Block|Femoral Nerve block performed with 0.5% Ropivacaine 30mls (150mg)
11400379|NCT02033603|Active Comparator|Adductor Canal block|Adductor Canal block performed with 0.5% Ropivacaine 30mls (150mg)
11400380|NCT02033590|Experimental|SERI® Surgical Scaffold|
11400381|NCT02033577|Experimental|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb
11400382|NCT02033577|Active Comparator|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb
11400383|NCT02033564|Active Comparator|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
11400384|NCT02033564|Active Comparator|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
11400385|NCT02033551|Experimental|Arm A - Veliparib Monotherapy|Subjects in this arm will be dosed with Veliparib continuous dosing.
11400386|NCT02033551|Experimental|Arm B - Veliparib in Combination with Carboplatin & Paclitaxel|Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.
11400387|NCT02033551|Experimental|Arm C Veliparib in Combination with Modified FOLFIRI|Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.
11400388|NCT02033538|Experimental|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
11400389|NCT02033525|Experimental|XCEL-M-ALPHA and standard rehabilitation|Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
11400390|NCT02033525|Active Comparator|standard rehabilitation|Standard rehabilitation program
11400391|NCT02033499|No Intervention|No testing|No testing
11400392|NCT02033499|Other|standard messaging|SMBG standard messaging
11400393|NCT02033499|Other|enhanced messaging|SMBG enhanced messaging
11400394|NCT02033486|Experimental|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
11400395|NCT02033473|Experimental|Apelin|An apelin clamp in which an apelin infusion will be administered prior to reference clamp
11400396|NCT02033473|Placebo Comparator|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp
11400397|NCT02033460|Experimental|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :
~In the fifth session we explained the patients to perform :
~Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.
~Five sets of isometric contraction of the neck extensors for 6-8 seconds
~Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.
~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :
~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
11400398|NCT02033460|Active Comparator|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:
~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
11400399|NCT02033460|Active Comparator|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
11400400|NCT02033447|Experimental|Magnetic Nanoparticle Injection|Patients undergoing radical cystoprostatectomy or prostatectomy
11400401|NCT02033434|Experimental|Intranasal Ketamine|All patients
11400402|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
11400403|NCT02033408|Experimental|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:
~PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)
~PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks
~PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks
~PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
11400404|NCT02033408|Active Comparator|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
11400405|NCT02033408|Other|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
11400406|NCT02033395||Participants exposed to tramautic event|
11400407|NCT02033382||Healthy Controls|Age and gender matched healthy controls
11400408|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
11400409|NCT02033369|Experimental|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
11400410|NCT02033369|No Intervention|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
11400411|NCT02033356|Experimental|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
11400412|NCT02033356|Experimental|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
11400413|NCT02033356|Experimental|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
11400414|NCT02033356|Experimental|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
11400415|NCT02033356|Experimental|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
11400416|NCT02033356|Experimental|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.
~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
11400417|NCT02033343|Experimental|Real-time tracking & beam adjustment|Prostate cancer radiotherapy using real-time tracking
11400418|NCT02033330|Active Comparator|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
11400419|NCT02033330|Active Comparator|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
11400420|NCT02033330|Experimental|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
11400421|NCT02033317|Experimental|patiromer|
11400422|NCT02033291||Cortical stroke or primary intracerebral hemorrhage patients:|patients who have a clear clinical presentation of either cortical stroke or primary intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI scans can be performed within 0-6 weeks of the vascular event and on two subsequent days as the vascular permeability may change significantly on the timescale of weeks.
11400423|NCT02033291||cSVD patients|patients who present with a transient ischemic attack (TIA) and cSVD related abnormalities on brain MRI. TIA patients are defined as patients with stroke like symptoms that last no longer than 24 hours. MRI abnormalities include extended white matter lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces. The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the first.
11400424|NCT02033278|Experimental|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
11400425|NCT02033278|Placebo Comparator|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
11400426|NCT02033265||Patients with BMI less than 30 kg/m2|Patients with BMI less than 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC.
11400427|NCT02033265||Patients with BMI 30 or above|Patients with BMI 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC
11400428|NCT02033252|Experimental|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
11400429|NCT02033252|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
11400558|NCT02032342|Active Comparator|Arndt® blocker|Arndt® blocker for selective lobar deflation
11400430|NCT02033239|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
11400431|NCT02033239|Active Comparator|NovoRapid®|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
11400432|NCT02033226|Experimental|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
11400433|NCT02033226|Placebo Comparator|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
11400434|NCT02033213|Active Comparator|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
11400435|NCT02033213|Active Comparator|Liberal group|Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
11400436|NCT02033200|Experimental|Active|Stendra 200 mg
11400437|NCT02033200|Placebo Comparator|Placebo|placebo
11400438|NCT02033187|Experimental|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
11400439|NCT02033187|Active Comparator|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
11400440|NCT02033174|Other|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
11400441|NCT02033174|Other|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
11400442|NCT02033161|Experimental|Internet-delivered CBT|
11400443|NCT02033148|Experimental|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11400444|NCT02033135|Experimental|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.
11400445|NCT02033135|Active Comparator|Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.
11400446|NCT02033122|Active Comparator|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
11400447|NCT02033122|Sham Comparator|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
11400448|NCT02033109|Experimental|PC-1005|"4.00 g dosed once daily for 3 days (safety run-in)
~4.00 g dosed once daily for 14 days (main study)"
11400449|NCT02033109|Placebo Comparator|HEC gel|4.00 g dosed once daily for 14 days (main study only)
11400450|NCT02033096||Cohort 1: Stannsoporfin 1.5 mg/kg|Cohort 1: Received one 1.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
11400451|NCT02033096||Cohort 2: Stannsoporfin 3.0 mg/kg|Cohort 2: Received one 3.0 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
11400452|NCT02033096||Cohort 3: Stannsoporfin 4.5 mg/kg|Cohort 3: Received one 4.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
11400453|NCT02033096||Cohort 4: Placebo Control|Cohort 4: Received one sterile saline injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
11400454|NCT02033083|Active Comparator|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D&E procedure.
11400455|NCT02033083|Active Comparator|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D&E procedure.
11400456|NCT02033070||Non-Dysplastic IM, LGD, HGD|
11400457|NCT02033057|Experimental|Muscular electrostimulation.|The interventions is muscular electrostimulation.
11400458|NCT02033044|Experimental|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
11400459|NCT02033044|Active Comparator|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
11400462|NCT02033018|Experimental|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
11400463|NCT02033005||Breastfed infants|>80% of feeds consisting of breast milk at both scanning points
11400464|NCT02033005||Formula-fed infants|>80% of feeds consisting of formula milk at both scanning points
11400465|NCT02033005||Mixed-fed infants|20%-80% of feeds consisting of breast milk.
11400466|NCT02032979|Experimental|FSHD patient|
11400467|NCT02032966|Experimental|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
11400468|NCT02032966|Active Comparator|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
11400469|NCT02032966|Other|syndesmotic injury|"Non-randomized / syndesmotic injury: patients who have a positive ligament stress test (signifying a syndesmotic injury) during surgery will require surgical treatment of both the tibia and the fibula and cannot be randomized to either arm (nonsurgical versus surgical). Patients in this arm will still be included in the study for the collection of clinical and functional outcomes."
11400470|NCT02032953|Experimental|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
11400471|NCT02032953|Experimental|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
11400472|NCT02032953|Placebo Comparator|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
11400473|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
11400474|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
11400475|NCT02032927|Active Comparator|Codeine/paracetamol|"The combination codeine/paracetamol,30 mg/500 mg,1 tablet every 8 hours, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
~At any stage of the study, patients treated with combination codeine/paracetamol in case of ineffectiveness (NRS> 4) despite maximal dosage (2 tablets every 8 hours) and/or side effect, will be subject to the opioid switch and will start equianalgesic therapy with oxycodone/naloxone combination."
11400476|NCT02032927|Active Comparator|Oxycodone/Naloxone|Combination oxycodone /naloxone, 5 mg/2.5 mg, 1 tablet/day, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
11400477|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
11400478|NCT02032901|Experimental|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
11400479|NCT02032901|Experimental|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
11400480|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
11400481|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
11400482|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
11400483|NCT02032875|Experimental|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
11400484|NCT02032875|Experimental|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
11400485|NCT02032862|Experimental|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
11400486|NCT02032862|Placebo Comparator|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
11400487|NCT02032849|Active Comparator|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
11400488|NCT02032849|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
11400489|NCT02032836|Experimental|I-Neb - FOX|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion.
11400553|NCT02032368|Experimental|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
11400554|NCT02032368|No Intervention|Control group|Patients in Control group receive no management.
11400555|NCT02032355||hypotension|
11400490|NCT02032836|Experimental|FOX - I-Neb|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion.
11400491|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
11400492|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
11400493|NCT02032810|Experimental|Dose Escalation|Dose Escalation of Panobinostat + Ipilimumab. Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
11400494|NCT02032797|Experimental|A: 7 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.
~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
11400495|NCT02032797|Placebo Comparator|B: 5 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.
~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
11400496|NCT02032784|Experimental|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
11400497|NCT02032784|Other|no octreotide|No Octreotide
11400498|NCT02032771|Experimental|M22 IPL and ResurFX|The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
11400499|NCT02032758|Experimental|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
11400500|NCT02032758|Other|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
11400501|NCT02032745||Chemo-insensitive|Non-responders to chemotherapy (Probability for pathological negative nodal status)
11400502|NCT02032745||Chemo-sensitive|Responders to chemotherapy (Probability for pathological negative nodal status)
11400503|NCT02032732||suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for suspected infection
11400504|NCT02032732||no suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for reason other than suspected infection
11400505|NCT02032719|Experimental|smartphone assisted lifestyle coaching|6 months of smartphone assisted lifestyle coaching
11400506|NCT02032719|Active Comparator|Lifestyle health coaching|6 months of lifestyle health coaching
11400507|NCT02032706|Experimental|Positional feedback|Deliver therapy when the supine position is detected
11400508|NCT02032693|Experimental|Everycell™|Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
11400509|NCT02032693|Placebo Comparator|Placebo|Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
11400510|NCT02032680|Experimental|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
11400511|NCT02032680|Active Comparator|In-persons Multi-Family Group Psycho-Education treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group Psycho-Education (MFG) that is the standard of care in the VA.
11400512|NCT02032680|Other|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG & DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
11400513|NCT02032667|Experimental|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
11400514|NCT02032667|No Intervention|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
11400515|NCT02032654|Active Comparator|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
11400516|NCT02032654|Experimental|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
11400556|NCT02032342|Active Comparator|Fuji Uni-blocker|Fuji Uni-blocker for selective lobar deflation
11400557|NCT02032342|Active Comparator|Cohen blocker|Cohen blocker for selective lobar deflation
11400517|NCT02032641|Experimental|Laser Treatment Side|"Each patient was randomized to have one of two scars treated with Laser Genesis. The treatment was administered by manually scanning the rapidly pulsed laser in an even, painting motion throughout the entire treatment zone. The eyebrow hairs were covered with white tape to prevent inadvertent alopecia. The laser handpiece was oriented perpendicular to the skin at all times, at a distance of 1-2 cm. Patients were instructed throughout to give verbal feedback regarding if the area was too hot as an additional safeguard against epidermal damage."
11400518|NCT02032641|No Intervention|Control side|Each patient had a scar which was randomized to not undergo treatments with Laser Genesis, and was used as a control. Patients were not allowed to undergo laser or any other scar treatments with the exception of sun protection for the control scar for the duration of the study.
11400519|NCT02032628|Experimental|High Intensity/Longer Duration|Exercise at higher intensity (~75% of VO2max) for 40 minute bouts 4 times per week
11400520|NCT02032628|Experimental|High Intensity/Lower Duration|Exercise at high intensity (~75% of VO2max) for 20 minute bouts 4 times per week
11400521|NCT02032628|Experimental|Lower Intensity/Higher Duration|Exercise at lower intensity (~55% of VO2max) for 40 minute bouts 4 times per week
11400522|NCT02032628|Experimental|Low Intensity/Low Duration|Exercise at lower intensity (~55% of VO2max) for 20 minute bouts 4 times per week
11400523|NCT02032615|Active Comparator|Education plus Gudness Nutritional Bar|Subjects will receive education about anemia and will consume Gudness Nutrition bars for 3 months
11400524|NCT02032615|Placebo Comparator|Education with no nutrition bar|Subjects will receive education about anemia but will not receive nutrition bar
11400525|NCT02032602|Active Comparator|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
11400526|NCT02032602|Experimental|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
11400527|NCT02032589|Experimental|Self-generation treatment|self-generation strategy treatment, embedded within practice of various activities
11400528|NCT02032589|Placebo Comparator|memory training|Treatment consists on traditional memory training
11400529|NCT02032576|Experimental|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
11400530|NCT02032563|Experimental|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before surgery
11400531|NCT02032550|Experimental|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
11400532|NCT02032550|No Intervention|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
11400533|NCT02032537|Active Comparator|Callmax cream|
11400534|NCT02032537|Placebo Comparator|Placebo|
11400535|NCT02032524|Experimental|Avalglucosidase alfa|administered intravenously every 2 weeks
11400536|NCT02032511||RAM Cannula Nasal Continuous Positive Airway Pressure|
11400537|NCT02032511||Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|
11400538|NCT02032498|Experimental|Indocyanine Green|superficial injections of Indocyanine Green in the breast
11400539|NCT02032485|Experimental|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery
11400540|NCT02032472|No Intervention|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
11400541|NCT02032472|Experimental|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
11400542|NCT02032459||Minority Women|Study data pulled from already collected data (N=1141 from the Camden Study of low income gravidae and minority gravidae (White, African-American and Hispanic) living in the northeastern United States (New Jersey).
11400543|NCT02032446|Experimental|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.
~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).
~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
11400544|NCT02032433|Active Comparator|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
11400545|NCT02032433|Active Comparator|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
11400546|NCT02032420|Experimental|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
11400547|NCT02032420|Active Comparator|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
11400548|NCT02032407|Experimental|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
11400549|NCT02032394|Experimental|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
11400550|NCT02032394|Experimental|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
11400551|NCT02032394|Active Comparator|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
11400552|NCT02032381|Other|allogeneic hematopoietic stem cell|The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
11400645|NCT02031692|Active Comparator|Vitamin D and calcium supplement|
11400559|NCT02032342|Placebo Comparator|Endobronchial double lumen tube|Endobronchial double lumen tube for one lung ventilation
11400560|NCT02032329|Experimental|FastFES|Single Group Study - see Intervention Description
11400561|NCT02032316|Experimental|Interventional|Placement of ureteral stent following post-ureteroscopy
11400562|NCT02032303|Active Comparator|Ticagrelor|Patient randomized to Ticagrelor
11400563|NCT02032303|Active Comparator|Prasugrel|Patient randomized to Prasugrel
11400564|NCT02032290|Active Comparator|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
11400565|NCT02032290|Active Comparator|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
11400566|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
11400567|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
11400568|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
11400569|NCT02032264|Experimental|Comprehensive Chromosome Screening|Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos
11400570|NCT02032264|Placebo Comparator|No Comprehensive Chromosome Screening|The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.
11400571|NCT02032251|Experimental|ginger|The patients with infertility that underwent oral administration of ginger.
11400572|NCT02032251|Placebo Comparator|Placebo|The patients with infertility that receive placebo.
11400573|NCT02032238|Experimental|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
11400574|NCT02032238|No Intervention|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
11400575|NCT02032225||CADASIL|patients with CADASIL
11400576|NCT02032212|Experimental|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
11400577|NCT02032212|Experimental|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
11400578|NCT02032212|Experimental|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
11400579|NCT02032212|Experimental|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
11400580|NCT02032186|Experimental|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
11400581|NCT02032186|Placebo Comparator|Placebo|Placebo pills twice per day.
11400582|NCT02032173|Experimental|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
11400583|NCT02032160|Experimental|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
11400584|NCT02032160|Experimental|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
11400585|NCT02032147||NGF group|This group will be treated with NGF 18u daily for 60 days.
11400586|NCT02032147||control group|"this group will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
11400587|NCT02032134|Other|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
11400588|NCT02032121|Experimental|Intervention procedures|All the procedures will be completed for every subject
11400589|NCT02032108|Experimental|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.
~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
11400590|NCT02032095|Experimental|GB-0998|
11400591|NCT02032082|No Intervention|Ex vivo without CO|
11400592|NCT02032082|Experimental|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
11400593|NCT02032069||NHBD|Non Heart Beating Donors
11400594|NCT02032069||BDD|Brain death donors
11400595|NCT02032056|Experimental|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
11400596|NCT02032056|Experimental|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
11400597|NCT02032056|Placebo Comparator|Placebo|provided as powder in a sachet which can be added to food or drink.
11400598|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
11400599|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
11400600|NCT02032017|Experimental|Percutaneous assisted approach|In this technique, a second small incision (1 cm) at the anterior border of the femur is made. A canulla is placed underneath the muscle and used to pass the reamers in the direction of the acetabulum. There's no need to enlarge the skin incision or to release more muscle insertion to achieve good working access to the acetabulum. Two advantages can be defined: sparing of the gluteus medius muscle and safe access to the acetabulum to obtain perfect positioning of the implants.
11400601|NCT02032017|Active Comparator|Anterolateral approach|A standard transgluteal approach is used. This means a large part of the gluteus medius muscle is released to obtain good access to the acetabulum.
11400646|NCT02031692|No Intervention|Control|
11400860|NCT02030262|Experimental|Air|The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.
11400602|NCT02032004|Experimental|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
11400603|NCT02032004|Sham Comparator|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
11400604|NCT02031991|Experimental|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
11400605|NCT02031991|Active Comparator|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
11400606|NCT02031991|Active Comparator|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
11400607|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
11400608|NCT02031965|Experimental|Treatment (oncolytic HSV-1716)|Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
11400609|NCT02031952|Experimental|hepatectomy combined lymphadenectomy|hepatectomy combined lymphadenectomy
11400610|NCT02031952|Active Comparator|hepatectomy|hepatectomy alone
11400611|NCT02031939|Active Comparator|Standard chemoradiotherapy|Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )
11400612|NCT02031939|Experimental|induction and gap chemotherapy|induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + standard chemoradiotherapy (Capecitabine 2000mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)
11400613|NCT02031926|Experimental|Positive expiratory pressure|
11400614|NCT02031913||HBV without FL|Chronic hepatitis B without steatosis
11400615|NCT02031913||HBV with FL|Chronic hepatitis B patients with steatosis
11400616|NCT02031900||Undergoing EGD|
11400617|NCT02031887|Experimental|Infant starter formula with synbiotics|Infant starter formula with synbiotics
11400618|NCT02031887|Active Comparator|Infant formula without synbiotics|Infant formula without synbiotics
11400619|NCT02031874||Miami Cohort|Measured vaccine response to H1N1 in HIV perinatally infected children
11400620|NCT02031861|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
11400621|NCT02031861|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
11400622|NCT02031848|Active Comparator|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
11400623|NCT02031848|Active Comparator|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
11400624|NCT02031835|Other|BWSTT (3 days a week for maximum of 20 minutes session)|BWSTT (20 minutes of treadmill training (velocity (≥0.1km/h) and body weight support (≤40% of patients weight) according to patients capability and comfort
11400625|NCT02031822|Active Comparator|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
11400626|NCT02031822|Active Comparator|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
11400627|NCT02031809||No additional unplanned major surgery|uneventfull intra-operative and postoperative course
11400628|NCT02031809||Additional unplanned major surgery|"Additional per-operative or post-operative unplanned major surgery such as unforeseen pneumonectomy, bilobectomy, lobectomy or additional segmentectomy, repair of major vessels or bronchi, bronchopleural fistula, unplanned surgery to other organs, within 30 days after the primary surgery.
~These do not include:
~Conversions without additional unplanned major surgery or suddne blood loss less than 500cc
~Conversions or additional resection for unforeseen oncologic reasons.
~Plasty, repair or sleeve resection of vessels after deliberate resection or transection for oncologic reasons"
11400629|NCT02031796|Experimental|CAVAREC images|CAVAREC images from x-ray angiography
11400630|NCT02031783|Experimental|mixture of glucose and fructose|mixture of glucose and fructose
11400631|NCT02031783|Active Comparator|Glucose|Single glucose
11400632|NCT02031770|Other|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
11400633|NCT02031770|Other|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
11400634|NCT02031757|Experimental|perturbation training|Standard physiotherapy augmented with perturbation training (BaMPer system).
11400635|NCT02031757|Active Comparator|balance exercise|standard physiotherapy augmented with balance exercises.
11400636|NCT02031744|Placebo Comparator|erlotinib [Tarceva] + placebo|
11400637|NCT02031744|Experimental|erlotinib [Tarceva] + onartuzumab [MetMAb]|
11400638|NCT02031731|Experimental|4 mg/kg Onartuzumab (MetMAb)|
11400639|NCT02031731|Experimental|15 mg/kg Onartuzumab (MetMAb)|
11400640|NCT02031731|Experimental|30 mg/kg Onartuzumab (MetMAb)|
11400641|NCT02031718|No Intervention|Online Education|
11400642|NCT02031718|Experimental|Online Education & Virtual Counseling|Online virtual counseling
11400643|NCT02031705|Active Comparator|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
11400644|NCT02031705|Placebo Comparator|control group|Control group was performed no additional cavotricuspid isthmus ablation.
11400647|NCT02031679|Experimental|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.
~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.
~The tablets should be swallowed whole with a glass of water."
11400648|NCT02031679|Placebo Comparator|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.
~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.
~The tablets should be swallowed whole with a glass of water."
11400649|NCT02031666|Active Comparator|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
11400650|NCT02031666|Experimental|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
11400651|NCT02031666|Experimental|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
11400652|NCT02031666|Experimental|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
11400653|NCT02031666|Experimental|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
11400654|NCT02031666|Experimental|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
11400655|NCT02031666|Experimental|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
11400656|NCT02031666|Experimental|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
11400657|NCT02031653||Study Group|
11400658|NCT02031640|Experimental|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
11400659|NCT02031640|Experimental|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
11400660|NCT02031640|Active Comparator|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
11400661|NCT02031640|Active Comparator|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
11400662|NCT02031640|Placebo Comparator|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
11400663|NCT02031627|Experimental|pneumatic compression - 1 hour per day|Pneumatic compression device - 12 consecutive days undergoing a 1 hour treatment regimen.
11400664|NCT02031627|Experimental|pneumatic compression - 2 hours per day|Pneumatic compression device - 5 consecutive days undergoing 1 hour treatment in the am and 1 hour of treatment in the pm.
11400665|NCT02031627|Experimental|pneumatic compression - 4 hours per day|Pneumatic compression device - 5 consecutive days undergoing treatment twice per day consisting of 2 consecutive 1 hour treatments in the am and the pm (4 hours total)
11400666|NCT02031614|Experimental|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
11400667|NCT02031601|Experimental|Combination therapy|"Interventions:
~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
11400668|NCT02031601|Other|TKI alone therapy|"Interventions:
~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]"
11400669|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
11400670|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
11400671|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
11400672|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
11400673|NCT02031575|Experimental|Basic Treatment|Sends messages to participants about reproductive health.
11400674|NCT02031575|Experimental|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
11400675|NCT02031575|Placebo Comparator|Control|Sends messages to students about malaria prevention and control.
11400676|NCT02031562|Active Comparator|Chiropractic|Chiropractic
11400677|NCT02031562|Active Comparator|Physical therapy|Physical therapy
11400678|NCT02031549||SpermComet Assay|All study subjects will have their surplus sperm analyzed for DNA fragmentation with the SpermComet assay.
11400679|NCT02031536|Experimental|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11400680|NCT02031536|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11400681|NCT02031523|Active Comparator|Sanjie analgesic capsule|every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
11400682|NCT02031523|Placebo Comparator|placebo|every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
11400683|NCT02031510|Active Comparator|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
11400684|NCT02031510|Active Comparator|bupivacaine|transversus abdominis plane block with bupivacaine 0.25%
11400685|NCT02031510|Placebo Comparator|placebo|Transversus abdominis block with saline 0.9%
11400686|NCT02031497|Experimental|Drink with sweeteners|
11400687|NCT02031497|Active Comparator|Drink without sweeteners|
11400723|NCT02031224|Experimental|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
11400688|NCT02031471|Experimental|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
11400689|NCT02031458|Experimental|Atezolizumab|
11400690|NCT02031445|Placebo Comparator|Placebo|BID
11400691|NCT02031445|Experimental|MRX-6|BID
11400692|NCT02031432|Experimental|Cebranopadol|"Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.
~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day."
11400693|NCT02031419|Experimental|CC-122 + CC-223 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
11400694|NCT02031419|Experimental|CC-122 + CC-292 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
11400695|NCT02031419|Experimental|CC-292 + CC-223 +/- rituximab|CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
11400696|NCT02031419|Experimental|CC-122 + rituximab|CC-122 administered orally once daily in combination with Rituximab.
11400697|NCT02031406|No Intervention|Usual care|No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
11400698|NCT02031406|Experimental|Post-discharge pharmacist counseling|Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.
11400699|NCT02031393||singelton pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
11400700|NCT02031393||twin pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
11400701|NCT02031380|Experimental|Open angle glaucoma - iDropper device|Device
11400702|NCT02031367|Active Comparator|Corticosteroid|
11400703|NCT02031367|Experimental|Platelet Rich Plasma|
11400704|NCT02031354|Experimental|Lysine Chloride|
11400705|NCT02031341||Patients with type 2 diabetes mellitus|
11400706|NCT02031341||Normoglycemic individuals|Control group
11400707|NCT02031328|Experimental|Stereotactic Ablative Radiation|Stereotactic Ablative Radiation 26 Gy in 2 fractions, once weekly to prostate
11400708|NCT02031315||Resident of health areas of interest|Residents of 4 health areas will be monitored for sudden unexpected death within 72 months of follow up. Circumstances and past medical conditions will be checked.
11400709|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
11400710|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
11400711|NCT02031289|Active Comparator|Anemia|Hb < 120 g/L in women, Hb < 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
11400712|NCT02031289|Active Comparator|Iron deficiency|ferritin < 100 µg/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
11400713|NCT02031289|No Intervention|Natural comparison group|Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed
11400714|NCT02031276|Placebo Comparator|Double-blind Placebo IV|Participants randomized to receive double-blind placebo for risankizumab by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
11400715|NCT02031276|Experimental|Double-blind Risankizumab 200 mg IV|Participants randomized to receive double-blind risankizumab 200 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
11400716|NCT02031276|Experimental|Double-blind Risankizumab 600 mg IV|Participants randomized to receive double-blind risankizumab 600 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
11400717|NCT02031263|Experimental|thermoplasty group|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
11400718|NCT02031250|Active Comparator|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
11400719|NCT02031250|Experimental|Boost Arm|Boost radiation to hypoperfused volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
11400720|NCT02031237||Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.
~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
11400721|NCT02031237||Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.
~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
11400722|NCT02031237||Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.
~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
11400754|NCT02030990|Experimental|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
11400892|NCT02030093||SMS group|SMS group
11400724|NCT02031224|Active Comparator|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).
~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
11400725|NCT02031211|Placebo Comparator|Placebo|0.4 ml/kg of normal saline will be administered subcutaneously.
11400726|NCT02031211|Experimental|Etanercept|Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.
11400727|NCT02031198|Experimental|AADvac1|"Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).
~Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above."
11400728|NCT02031185|No Intervention|Wait-list control|No intervention
11400729|NCT02031185|Experimental|FitBit only|Participants will use the FitBit device
11400730|NCT02031185|Experimental|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
11400731|NCT02031172||Subjects with Dry Eye Disease|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
11400732|NCT02031172||Subjects with Sjogren's Syndrome|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
11400733|NCT02031172||Healthy Controls|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
11400734|NCT02031146|Other|LP|Participants undergo lumbar puncture for CSF evaluation
11400735|NCT02031146|No Intervention|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
11400736|NCT02031107|Active Comparator|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
11400737|NCT02031107|Active Comparator|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
11400738|NCT02031107|Sham Comparator|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
11400739|NCT02031094||Major resection|Patients undergoing resection of >3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
11400740|NCT02031094||Minor resection|Patients undergoing resection of </= 3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
11400741|NCT02031081|Experimental|Treatment Period 1|A randomized assignment of prucalopride or placebo for a period of 28 days, crossover design
11400742|NCT02031081|Experimental|Treatment Period 2|A randomized assignment of either prucalopride or placebo for a period of 28 days, crossover design. Subjects who received active drug in Treatment Arm 1 will receive placebo and vice versa.
11400743|NCT02031068|Active Comparator|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:
~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms
~A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
11400744|NCT02031068|Experimental|Behavioral:Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:
~Sub-maximal aerobic training for up to 15 minutes
~Light coordination and sport-specific exercises for up to 10 minutes
~Visualization and imagery techniques
~Home program.
~A physiotherapist will supervise the rehabilitation."
11400745|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]FTD|
11400746|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]TPI|
11400747|NCT02031016|Active Comparator|Fentanyl|"fentanyl bolus injections on an as needed base, next to the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
11400748|NCT02031016|Active Comparator|Remifentanil|remifentanil, starting with 0.15 ug/Ideal Body Weight(IBW)(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
11400749|NCT02031003|Other|Control|Standard infant formula
11400750|NCT02031003|Experimental|Experimental 1|Standard infant formula containing a new fat blend
11400751|NCT02031003|Experimental|Experimental 2|Standard infant formula containing a new fat blend and fiber
11400752|NCT02031003|No Intervention|Human Milk (HM)|Non-randomized Human Milk group
11400753|NCT02030990|Experimental|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
11400755|NCT02030990|Active Comparator|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
11400756|NCT02030977|Active Comparator|Resveratrol|"Active Comparator: Resveratrol
~1 Resveratrol capsules for 12 weeks"
11400757|NCT02030977|Placebo Comparator|Placebo|one capsule per day
11400758|NCT02030964|Experimental|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). *Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
11400759|NCT02030938|Experimental|SERI® scaffold implanted breasts|
11400760|NCT02030925|Experimental|IW-3718|Twice a day
11400761|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
11400762|NCT02030912|Active Comparator|3 doses of amoxicillin daily for 7 days|Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
11400763|NCT02030912|Active Comparator|2 doses of minocycline daily for 5 days|Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
11400764|NCT02030912|Placebo Comparator|2 doses of placebo daily for 5 days|Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.
11400765|NCT02030899|Active Comparator|Cage|Cage filled with autologous bone
11400766|NCT02030899|Other|Plate|Plate augmentation after iliac bone graft
11400767|NCT02030886|Other|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
11400768|NCT02030873|Experimental|Virtual simulation training first|Participants in this arm receive virtual simulation training before dissection training.
11400769|NCT02030873|No Intervention|Dissection training first|Participants in this arm receive dissection training first and then virtual simulation training.
11400770|NCT02030860|Experimental|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
11400771|NCT02030860|Active Comparator|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
11400772|NCT02030847|Experimental|Arm1|"phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia."
11400773|NCT02030834|Experimental|Cohort A|murine CART19
11400774|NCT02030834|Experimental|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
11400775|NCT02030834|Experimental|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
11400776|NCT02030821|Active Comparator|Tranexamic Acid (TXA)|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.
~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
11400777|NCT02030821|Active Comparator|Epsilon-aminocaproic acid (Amicar)|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.
~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
11400778|NCT02030808|Placebo Comparator|Muscle Relaxants (MR) group|Cisatracurium will be administered
11400779|NCT02030808|Active Comparator|Non- Muscle Relaxants (NMR) group|No cisatracurium will be administered
11400780|NCT02030795|Active Comparator|Disconnection group|The single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse.
11400781|NCT02030795|Active Comparator|Bronchial Suction group|The suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
11400782|NCT02030782|Active Comparator|Usual Care|Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)
11400783|NCT02030782|Experimental|Quality Improvement for Depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
11400784|NCT02030769|Experimental|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
11400785|NCT02030769|Sham Comparator|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
11400786|NCT02030756|Active Comparator|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
11400787|NCT02030756|Sham Comparator|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
11400788|NCT02030743|Active Comparator|Visual training|Training in visual attention
11400789|NCT02030743|Placebo Comparator|Usual activity|Usual activity
11400790|NCT02030730|Experimental|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
11400893|NCT02030093||Control group|Control group
11400791|NCT02030730|No Intervention|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
11400792|NCT02030717|Experimental|Spinal anesthesia|The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( < 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
11400793|NCT02030717|Active Comparator|Epidural anesthesia|Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.
11400794|NCT02030704||Atherosclerotic Plaque|
11400795|NCT02030691|Experimental|nCPAP - nHFPV|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
11400796|NCT02030691|Experimental|nHFPV - nCPAP|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
11400797|NCT02030678|Experimental|irinotecan Hydrochloride|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
11400798|NCT02030665|Active Comparator|Standardized MET plus CB (SMET-CB)|Motivational Enhancement plus Cognitive-Behavioral treatment
11400799|NCT02030665|Experimental|SMET+ CM (SMET-CB-CM)|Motivational Enhancement plus CB treatment plus contingency management
11400800|NCT02030665|Experimental|Individualized Assessment & Treatment (IATP)|Individualized Assessment and Treatment Program; Cognitive-Behavioral Treatment based on in-depth field monitoring of patient behavior
11400801|NCT02030665|Experimental|IATP + CM (IATP-CM).|Individualized Assessment and Treatment plus Contingency Management
11400802|NCT02030652|Experimental|SNIPPV Group|Synchronized nasal intermittent positive pressure using NAVA ( Intermittent nasal positive pressure positive ventilation.)
11400803|NCT02030652|Active Comparator|CPAP Group|Nasal CPAP group without intermittent ventilation.
11400804|NCT02030639|Experimental|[14C]-rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
11400805|NCT02030626|Experimental|active rTMS or active tDCS or placebo|Active rTMS (10 Hz) of the motor cortex followed by active tDCS (2 mA) of the motor cortex or conversely
11400806|NCT02030626|Placebo Comparator|Sham rTMS followed by tDCS (or conversely)|Placebo rTMD followed by placebo tDCS or conversely
11400807|NCT02030613|Other|Single arm: etanercept|Patients treated with etanercept for JIA
11400808|NCT02030600|Experimental|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
11400809|NCT02030600|Active Comparator|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
11400810|NCT02030587|Experimental|Radiofrequency Ablation|Radiofrequency Ablation
11400811|NCT02030587|Active Comparator|Laparoscopic Adrenalectomy|Laparoscopic Adrenalectomy
11400812|NCT02030574|Experimental|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
11400813|NCT02030561|Experimental|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.
~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.
~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
11400814|NCT02030548||acute CABG|patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy
11400815|NCT02030535|Experimental|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
11400816|NCT02030535|Experimental|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
11400817|NCT02030535|Placebo Comparator|Placebo|patient will receive placebo
11400818|NCT02030522|Experimental|Prospective Treatment Cohort of ART|The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
11400819|NCT02030509||New diagnosed patients of head and neck cancer|New diagnosed patients of head and neck cancer
11400820|NCT02030509||Old diagnosed head and neck cancer patients|
11400821|NCT02030496|Active Comparator|Closed reduction and plaster|Closed reduction will be performed and after adequate reduction has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks.
11400822|NCT02030496|Active Comparator|open reduction and internal fixation|The intervention group will be treated with open reduction and internal fixation with a volar locking plate.
11400924|NCT02029885|Sham Comparator|Sham Control|Blinded Sham Control Arm
11400823|NCT02030483|Experimental|All Subjects|Palbociclib (PD 0332991) will be given at a prespecified dose by cohort orally on days 1-14 of a 28-day cycle. For cycle 1 only, PD 0332991 will start on Day 0. Lenalidomide (Revlimid®) will be given at a prespecified dose by cohort orally on days 8-21 of a 28-day cycle (or days 1-21 as defined by dose cohort level). Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 8, 15, and 22 of a 28-day cycle. For cycle 1 only, the dexamethasone will be omitted on Day 1.
11400824|NCT02030470|Other|fotosan|
11400825|NCT02030457|Experimental|Treatment A|Treatment A: beclomethasone dipropionate BAI, 160 mcg - a single administration of 4 inhalations (40 mcg/inhalation)
11400826|NCT02030457|Experimental|Treatment B|Treatment B: beclomethasone dipropionate BAI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
11400827|NCT02030457|Experimental|Treatment C|Treatment C: beclomethasone dipropionate MDI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
11400828|NCT02030444|No Intervention|Standard diagnostic work-up|All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
11400829|NCT02030444|Experimental|Extensive diagnostic work-up|All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
11400830|NCT02030431|Active Comparator|Cancellous screws|Patients in this group are having osteosynthesis with three screws
11400831|NCT02030431|Active Comparator|Dynaloc|Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)
11400832|NCT02030418|Experimental|Leadless Pacemaker|VVIR pacing
11400833|NCT02030405|Experimental|Ixazomib (MLN9708)|Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11400834|NCT02030392|Experimental|Intervention group|"IG participation in the cognitive-behavioral program Stop the pain with Happy Pingu. The program compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each)."
11400835|NCT02030392|Active Comparator|Active control group|CG participation in an information and education control group (physical well-being, health and gastrointestinal tract). The program of the control group compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each).
11400836|NCT02030379|Experimental|Online QPL-CT to Oncologist|Use the online QPL-CT to prioritize their questions and the prioritized list will be conveyed to their oncologist
11400837|NCT02030379|Experimental|Online QPL-CT|Use the online QPL-CT to prioritize their questions.
11400838|NCT02030379|Experimental|Pencil and Paper QPL-CT|Use pencil and paper QPL-CT to prioritize their questions
11400839|NCT02030366||TBI patients|
11400840|NCT02030366||Healthy Volunteers|
11400841|NCT02030353|Experimental|Self-regulation plus activity monitoring|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
11400842|NCT02030353|Experimental|Self-regulation|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
11400843|NCT02030353|No Intervention|Delayed intervention control|Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
11400844|NCT02030340||Testing Lower urinary tract dysfunction|All patients with lower urinary tract dysfunction where urodynamic diagnosis is required according to standards and (international) practice guidelines will have a synchronous double system (combination of air-charged and water filled) urodynamic test.
11400845|NCT02030327||No trauma|n=5 patients
11400846|NCT02030327||trauma without organ dysfunction|n=40 patients
11400847|NCT02030327||trauma with organ dysfunction|n=40 patients
11400848|NCT02030314|Experimental|chlorthalidone, resistant high blood pressure|if Furosemide dose is 40 mg per day, start Chlorthalidone 12.5 mg per day if Furosemide dose is 80 mg per day, start Chlorthalidone 25 mg per day
11400849|NCT02030301|Experimental|VCL-HB01, 0.25-mL dose|VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
11400850|NCT02030301|Placebo Comparator|PBS, 0.25-mL dose|PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
11400851|NCT02030301|Experimental|VCL-HB01, 0.5-mL dose|VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
11400852|NCT02030301|Placebo Comparator|PBS, 0.5-mL dose|PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
11400853|NCT02030301|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
11400854|NCT02030301|Experimental|VCL-HM01, 1-mL dose|VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
11400855|NCT02030301|Placebo Comparator|PBS, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses
11400856|NCT02030288|Experimental|Relational Agent plus Treatment as Usual|"Relational Agents are onscreen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
11400857|NCT02030288|No Intervention|Treatment as Usual|Patients are routinely screened yearly for unhealthy alcohol use. Providers are prompted to provide elements of a brief intervention if the patient scores 5 or above on the AUDIT-C. Providers are also prompted to refer patients if they meet certain criteria for specialty alcohol treatment.
11400858|NCT02030275|Experimental|RXI-109|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
11400859|NCT02030275|Placebo Comparator|Placebo|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
11400861|NCT02030262|Active Comparator|Sulfur hexafluoride (SF6)|The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.
11400862|NCT02030249|Experimental|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
11400863|NCT02030249|Active Comparator|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
11400864|NCT02030236|Experimental|Cooling|
11400865|NCT02030223|Active Comparator|Transversus abdominis plane block with 20 ml ropivacaine 0,75%|Transversus abdominis plane block with 20 ml ropivacaine 0,75%
11400866|NCT02030223|Placebo Comparator|Transversus abdominis plane block with 20 ml saline|Transversus abdominis plane block with 20 ml saline
11400867|NCT02030210||cardiologists|
11400868|NCT02030210||study coordinators|
11400869|NCT02030210||registred nurses|
11400870|NCT02030197|Active Comparator|CRISP program|educational and socialization program
11400871|NCT02030197|Placebo Comparator|Control Group|no treatment control group
11400872|NCT02030184|Experimental|Topotecan and Rhenium Re 188 P2045|In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
11400873|NCT02030171|Active Comparator|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
11400874|NCT02030171|Active Comparator|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
11400875|NCT02030171|Active Comparator|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
11400876|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
11400877|NCT02030158||Usual resuscitation|Usual resuscitation
11400878|NCT02030145|Active Comparator|Classic Thoracic Lymphatic Pump|Subjects begin with Classic Thoracic Lymphatic Pump, then crossover to Compressive Thoracic Lymphatic Pump after 4-week washout period.
11400879|NCT02030145|Experimental|Compressive Thoracic Lymphatic Pump|Subjects begin with Compressive Thoracic Lymphatic Pump, then crossover to Classic Thoracic Lymphatic Pump after 4-week washout period.
11400880|NCT02030132|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
11400881|NCT02030132|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
11400882|NCT02030132|Experimental|Feedback 50th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the average team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
11400883|NCT02030132|Experimental|Feedback 75th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
11400884|NCT02030119|Active Comparator|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
11400885|NCT02030119|Experimental|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
11400886|NCT02030119|Experimental|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
11400887|NCT02030119|Experimental|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
11400888|NCT02030106||Prior Preterm Birth Patients|All obstetrical patients eligible for the study that have had a prior preterm birth.
11400889|NCT02030106||Term Birth Patients|All obstetrical patients eligible for the study that have not had a prior preterm birth.
11400890|NCT02030093||High-frequency telephone-based continuing care|High-frequency telephone-based continuing care
11400891|NCT02030093||Low-frequency telephone-based continuing care|Low-frequency telephone-based continuing care
11400894|NCT02030080|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
11400895|NCT02030080|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
11400896|NCT02030080|Experimental|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
11400897|NCT02030080|Experimental|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
11400898|NCT02030067|Experimental|RX-3117|All subjects will receive RX-3117.
11400899|NCT02030054|Active Comparator|atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
11400900|NCT02030054|Active Comparator|rosuvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin(20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
11400901|NCT02030041|Experimental|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.
~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
11400902|NCT02030041|Active Comparator|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.
~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
11400903|NCT02030041|Active Comparator|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
11400904|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
11400905|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
11400906|NCT02030002|Experimental|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
11400907|NCT02030002|Active Comparator|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
11400908|NCT02029989|Experimental|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
11400909|NCT02029989|Active Comparator|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
11400910|NCT02029976|Active Comparator|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
11400911|NCT02029976|Experimental|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting.
11400912|NCT02029963|Experimental|Cluster rTMS|Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
11400913|NCT02029963|Experimental|Taper rTMS|Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
11400914|NCT02029963|Experimental|Treatment as Usual|Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider
11400915|NCT02029950|Experimental|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
11400916|NCT02029937|Experimental|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
11400917|NCT02029937|No Intervention|Standard of care|No invention
11400918|NCT02029924|Experimental|BioChaperone insulin lispro|BioChaperone insulin lispro
11400919|NCT02029924|Active Comparator|Humalog®|Humalog®
11400920|NCT02029911|Experimental|Aurora Treatment Arm|Endometrial Ablation
11400921|NCT02029898|Active Comparator|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
11400922|NCT02029898|Placebo Comparator|Placebo|injectable solution 0.9% for the end of surgery
11400923|NCT02029885|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
11400925|NCT02029872|Active Comparator|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
11400926|NCT02029872|Active Comparator|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
11400927|NCT02029859|Experimental|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .
~Polygraphic examination between 30 and 36 weeks of amenorhea"
11400928|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
11400929|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
11400930|NCT02029833|Experimental|Regular Canola Oil|60% oleic acid
11400931|NCT02029833|Experimental|High Oleic Canola Oil|70% oleic acid
11400932|NCT02029833|Active Comparator|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, & flax oil
11400933|NCT02029820|Active Comparator|RenalGuard|Hydration with the device renalguard
11400934|NCT02029820|No Intervention|Saline|Hydration with saline 1ml/Kg/h for 12h
11400935|NCT02029807||Blood donors|Healthy adult volunteers donating blood
11400936|NCT02029794|Experimental|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
11400937|NCT02029794|Active Comparator|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
11400938|NCT02029781|Other|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
11400939|NCT02029768||Women with burn injury|
11400940|NCT02029768||Men with burn injury|
11400941|NCT02029755|Experimental|TAP block|postoperative analgesia with sono-guided transversus abdominis plane block and intravenous patient controlled analgesia (IV-PCA). Bilateral sono-guided TAP block will be performed after the induction of general anesthesia. 20 ml of 0.25% ropivacaine will be injected to the transversus abdominis plane under ultrasound guidance at each side (total 40 ml). IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
11400942|NCT02029755|Active Comparator|Local infiltration|postoperative analgesia with local anesthetics infiltration at surgical wound and intravenous patient controlled analgesia (IV-PCA). 20 ml of 0.5% ropivacaine will be injected at the surgical wound by the surgeon before the closure of wound. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
11400943|NCT02029755|Active Comparator|PCA only|postoperative analgesia with intravenous patient controlled analgesia. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
11400944|NCT02029742|Experimental|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
11400945|NCT02029742|Active Comparator|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
11400946|NCT02029729|Experimental|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
11400947|NCT02029716|Placebo Comparator|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
11400948|NCT02029716|Experimental|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, ~100 cm2 surface area)
11400949|NCT02029716|Experimental|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (~500 cm2 surface area)
11400950|NCT02029703|Sham Comparator|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
11400951|NCT02029703|Active Comparator|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
11400952|NCT02029690|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
11400953|NCT02029664|Experimental|Visual feedback distortion|Visual distortion increment based on the gait pattern
11400954|NCT02029651|Experimental|E-glove system|E-glove rehabilitation system for upper extremity
11400955|NCT02029651|Active Comparator|Conventional occupational therapy|conventional occupational therapy
11400991|NCT02029365|Other|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
11400992|NCT02029365|Other|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
11401347|NCT02026921|Experimental|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
11400956|NCT02029638|Experimental|RICG, BMT and high dose PT/Cy+SOC|"Reduced-intensity conditioning regimen (RICG), bone marrow transplantation (BMT), high dose post-transplant cyclophosphamide (PT/Cy) and Standard of Care (SOC).
~Participants will receive: ATG (pre-transplant), pre-medicated with acetaminophen, diphenhydramine; steroid taper of methylprednisolone; fludarabine (2-6 days before transplant), and low-dose cyclophosphamide (pre- transplant); total body irradiation the day before transplant. Participants will receive a living renal transplant followed by BMT. High-dose cyclophosphamide will be given on days 3 and 4 post-transplant with MESNA. Filgrastim will be given on day 5 post-transplant and continue until absolute neutrophil recovery. Standard immunosuppression of tacrolimus, MMF, and prednisone will begin on day 5 post-transplant and be given ≥26 weeks post-transplant. Eligible participants will be gradually withdrawn from medication over a period of 24-40 weeks."
11400957|NCT02029625|Experimental|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
11400958|NCT02029625|Active Comparator|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
11400959|NCT02029612|Other|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
11400960|NCT02029612|Other|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
11400961|NCT02029599|Experimental|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
11400962|NCT02029599|Experimental|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.
~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
11400963|NCT02029599|Placebo Comparator|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
11400964|NCT02029586|Experimental|MB12066|
11400965|NCT02029586|Placebo Comparator|Placebo|
11400966|NCT02029573|Experimental|Atorvastatin in Combination With Radiotherapy and Temozolomide|
11400967|NCT02029547|Experimental|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
11400968|NCT02029534|Active Comparator|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
11400969|NCT02029534|Experimental|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
11400970|NCT02029521|Experimental|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
11400971|NCT02029521|Placebo Comparator|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
11400972|NCT02029508|Active Comparator|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
11400973|NCT02029508|Active Comparator|Semont maneuver|The group using Semont maneuver for PSCC BPPV
11400974|NCT02029508|Sham Comparator|Sham|The group using Reverse Epley maneuver for PSCC BPPV
11400975|NCT02029495|Experimental|210 mg brodalumab|Administered via subcutaneous injections
11400976|NCT02029495|Experimental|140 mg brodalumab|Administered via subcutaneous injection
11400977|NCT02029495|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
11400978|NCT02029482|Experimental|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
11400979|NCT02029482|Placebo Comparator|Placebo|Matching placebo tablets, once daily, for 18 days
11400980|NCT02029469|Experimental|HRA Device|Patients who will be treated with Ascension HRA device.
11400981|NCT02029456|Experimental|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
11400982|NCT02029443|Experimental|acalabrutinib|
11400983|NCT02029430|Experimental|aldoxorubicin|Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.
11400984|NCT02029417|Experimental|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
11400985|NCT02029404|Active Comparator|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
11400986|NCT02029404|Active Comparator|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
11400987|NCT02029391|Active Comparator|Myofascial pain syndrome patients|Manual pressure release only
11400988|NCT02029391|Experimental|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
11400989|NCT02029378|Experimental|Eculizumab|Eculizumab, 900 mg intravenously once a week
11400990|NCT02029378|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
11400993|NCT02029352|Experimental|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
11400994|NCT02029352|Placebo Comparator|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
11400995|NCT02029339|Experimental|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
11400996|NCT02029339|Active Comparator|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
11400997|NCT02029313|Experimental|MKT-N2|Montelukast
11400998|NCT02029313|Active Comparator|Singulair|Montelukast sodium
11400999|NCT02029300|Other|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
11401000|NCT02029300|Other|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
11401001|NCT02029287|Experimental|Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
11401002|NCT02029287|Active Comparator|Subjects with CHF conventional clinic visit|Subjects with standardized treatment according to latest guidelines via conventional visit.
11401003|NCT02029274|Experimental|BAF312 0.5mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
11401004|NCT02029274|Experimental|BAF312 2mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
11401005|NCT02029274|Experimental|BAF312 10 mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
11401006|NCT02029274|Placebo Comparator|Placebo|During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
11401007|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
11401008|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
11401009|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
11401010|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
11401011|NCT02029235|Active Comparator|Acetaminophen/Ibuprofen (AIBU) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
11401012|NCT02029235|Active Comparator|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
11401013|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
11401014|NCT02029209|Experimental|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11401015|NCT02029209|Placebo Comparator|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
11401016|NCT02029196|Experimental|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
11401017|NCT02029196|Active Comparator|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
11401018|NCT02029183|Experimental|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
11401019|NCT02029170|Experimental|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
11401020|NCT02029170|Active Comparator|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
11401021|NCT02029157|Experimental|ARQ 197|Daily oral dose
11401022|NCT02029157|Placebo Comparator|Placebo|Daily oral dose
11401023|NCT02029131|Experimental|Exercise|
11401024|NCT02029131|No Intervention|Controls|
11401025|NCT02029118|Experimental|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
11401026|NCT02029118|Placebo Comparator|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
11401027|NCT02029118|Placebo Comparator|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
11401028|NCT02029118|Sham Comparator|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
11401029|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
11401030|NCT02029092||Orsiro|
11401031|NCT02029079|Experimental|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
11401032|NCT02029079|No Intervention|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
11401033|NCT02029066|Experimental|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
11401034|NCT02029053|Other|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
11401035|NCT02029040|Experimental|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
11401036|NCT02029040|Placebo Comparator|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
11401037|NCT02029027|Experimental|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
11401038|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
11401039|NCT02029014|Experimental|LAmbre closure system|
11401040|NCT02029001|Experimental|Arm A: Maintenance treatment|"Patients will continue targeted treatment matching the molecular alterations identified in their tumor for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion. In case of on-treatment disease progression, the patient will permanently discontinue treatment and will be withdrawn from study.
~Targeted treatments available in the study are: nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib, durvalumab + tremelimumab"
11401041|NCT02029001|No Intervention|Arm B:Interruption of targeted treatment|Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval) and treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion. If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study.
11401042|NCT02028988|Experimental|Enzalutamide with External Beam Radiation|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingest enzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (24 weeks).
11401043|NCT02028975|Other|Patients with type 2 diabetes|
11401044|NCT02028975|Other|Obese patients without diabetes|
11401045|NCT02028975|Other|Healthy volunteers|
11401046|NCT02028962|Experimental|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
11401047|NCT02028962|No Intervention|Control|
11401048|NCT02028949|Experimental|Chemo-lipiodol|
11401049|NCT02028936|Experimental|Grape juice rich in polyphenols|
11401050|NCT02028936|Active Comparator|grape juice not enriched with polyphenols|
11401051|NCT02028923|Experimental|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
11401052|NCT02028923|Placebo Comparator|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
11401053|NCT02028910|Experimental|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.
~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
11401054|NCT02028910|Placebo Comparator|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.
~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
11401055|NCT02028897|Active Comparator|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
11401056|NCT02028897|Experimental|Alternative embryo culture|Embryo culture in system using small enclosed containers
11401124|NCT02028455|Experimental|Cohort 2A|This cohort is for patient who have a history of allo-HCT with recurrence of disease post HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1.
11401057|NCT02028884|Experimental|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
11401058|NCT02028884|Placebo Comparator|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
11401059|NCT02028871|Active Comparator|Intranasal Insulin First|Intranasal Insulin First, Placebo Second
11401060|NCT02028871|Placebo Comparator|Placebo First|Placebo First, Intranasal Insulin Second
11401061|NCT02028845|Active Comparator|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
11401062|NCT02028845|Active Comparator|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
11401063|NCT02028832|Active Comparator|Usual care|Usual care provided to pediatric inpatients
11401064|NCT02028832|Experimental|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
11401065|NCT02028806|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
11401066|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
11401067|NCT02028780|Experimental|Idarucizumab single doses|different infusion durations
11401068|NCT02028780|Experimental|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
11401069|NCT02028767|Experimental|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
11401070|NCT02028767|Active Comparator|Separate tablets|Empagliflozin and Metformin tablets
11401071|NCT02028754|Experimental|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
11401072|NCT02028754|Active Comparator|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
11401073|NCT02028741|Experimental|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
11401074|NCT02028741|Sham Comparator|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
11401075|NCT02028728||Orsiro|
11401076|NCT02028715|Placebo Comparator|Experimental (Normal Saline)|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
11401077|NCT02028715|Active Comparator|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
11401078|NCT02028702|Active Comparator|Red Clover extract|150 ml/d Red Clover extract
11401079|NCT02028702|Placebo Comparator|Placebo|150 ml/d sweetened and coloured water
11401080|NCT02028689|Experimental|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg
~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
11401081|NCT02028689|Experimental|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg
~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
11401082|NCT02028676|Experimental|Clinically Driven Monitoring (CDM)|
11401083|NCT02028676|Active Comparator|Laboratory plus Clinical Monitoring (LCM)|
11401084|NCT02028676|Active Comparator|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
11401085|NCT02028676|Experimental|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
11401086|NCT02028676|Experimental|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
11401087|NCT02028676|Experimental|Once-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO
11401088|NCT02028676|Active Comparator|Twice-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
11401089|NCT02028676|Active Comparator|Continued cotrimoxazole prophylaxis|Once-daily doses 5-<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole >=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
11401090|NCT02028676|Experimental|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
11401091|NCT02028663|Experimental|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
11401092|NCT02028663|Experimental|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
11401093|NCT02028663|Experimental|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
11401094|NCT02028663|Active Comparator|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
11401095|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
11401096|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
11401097|NCT02028637|Experimental|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
11401098|NCT02028624|Experimental|Face-to-face|Patients received face-to-face nutrition counseling.
11401099|NCT02028624|Experimental|Telephone|Patients received telephone nutrition counseling.
11401100|NCT02028624|No Intervention|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
11401101|NCT02028598|Experimental|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
11401102|NCT02028598|Experimental|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
11401103|NCT02028598|Experimental|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
11401104|NCT02028598|Experimental|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
11401105|NCT02028598|Experimental|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
11401106|NCT02028598|Experimental|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
11401107|NCT02028585|Active Comparator|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
11401108|NCT02028585|No Intervention|Control group|Control group maintained their usual diet without low-fat milk supplement.
11401109|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure > 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
11401110|NCT02028559|Experimental|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
11401111|NCT02028559|No Intervention|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
11401112|NCT02028546|Experimental|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
11401113|NCT02028546|Experimental|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
11401114|NCT02028533|Active Comparator|Patients 1|Participants will receive intranasal oxytocin 40 International Units (IU).
11401115|NCT02028533|Placebo Comparator|Patients 2|Participants will receive 40 International Units of intranasal placebo.
11401116|NCT02028507|Experimental|Palbociclib plus Exemestane or Fulvestrant|"Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with
~Cohort 1: Exemestane 25 mg orally once daily.
~Cohort 2: Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle."
11401117|NCT02028507|Active Comparator|Capecitabine|Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
11401118|NCT02028494|Experimental|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
11401119|NCT02028494|Active Comparator|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
11401120|NCT02028481|Experimental|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
11401121|NCT02028468|Active Comparator|Anterolateral Approach|Patient Operated with Watson Jones Approach
11401122|NCT02028468|Active Comparator|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
11401123|NCT02028455|Experimental|Cohort 1|This cohort will determine the maximum tolerated dose of the Patient Derived CD19 specific CAR T cells also expressing an EGFRt and is restricted to patients with a prior history of allo-HCT
11401125|NCT02028455|Experimental|Cohort 2B|This cohort is restricted to patients wtih no prior history of allo-HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1
11401126|NCT02028442|Experimental|Enadenotucirev|
11401127|NCT02028429|Experimental|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
11401128|NCT02028429|No Intervention|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
11401129|NCT02028416|Active Comparator|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
11401130|NCT02028416|Experimental|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
11401131|NCT02028403|Experimental|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
11401132|NCT02028403|Placebo Comparator|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
11401133|NCT02028403|Experimental|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
11401134|NCT02028403|Placebo Comparator|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
11401135|NCT02028403|Experimental|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
11401136|NCT02028403|Placebo Comparator|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
11401137|NCT02028403|Experimental|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
11401138|NCT02028403|Placebo Comparator|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
11401139|NCT02028390|Experimental|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
11401140|NCT02028377|Experimental|Imaging|PET/MRI
11401141|NCT02028364|Experimental|Everolimus given in conjunction with exemestane|Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.
11401142|NCT02028351||Normal|No Intervention
11401143|NCT02028351||Cataract|No intervention
11401144|NCT02028351||Maculopathy|No Intervention
11401145|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
11401146|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
11401147|NCT02028325|Experimental|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
11401148|NCT02028312|Active Comparator|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
11401149|NCT02028312|Placebo Comparator|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
11401150|NCT02028299|Experimental|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
11401151|NCT02028286|Experimental|CLS001|CLS001
11401152|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
11401153|NCT02028273||Actively using patients|Participants actively using cocaine.
11401154|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
11401155|NCT02028260|Active Comparator|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
11401156|NCT02028260|Placebo Comparator|Placebo|normal saline
11401157|NCT02028247|Experimental|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
11401158|NCT02028247|Active Comparator|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
11401159|NCT02028247|No Intervention|Waitlist condition|Participants randomized to the Waitlist condition will be asked to refrain from seeking out psychotherapy for anxiety as well as making psychiatric medication changes (if applicable) for a 16-week period.
11401160|NCT02028234|Active Comparator|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
11401212|NCT02027857|No Intervention|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
11401161|NCT02028234|Active Comparator|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
11401162|NCT02028221|Placebo Comparator|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
11401163|NCT02028221|Experimental|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
11401164|NCT02028208|Experimental|Ammoniated mercury|Subjects will be patch tested with 4 experimental doses of ammoniated mercury, 0.013 mg/cm², 0.040 mg/cm², 0.12 mg/cm², and 0.36 mg/cm², a negative control and corresponding reference allergens, 1.0% ammoniated mercury in petrolatum and 0.5% elemental mercury in petrolatum. Patch tests will be worn for 48 hours.
11401165|NCT02028208|Experimental|Aluminum chloride and aluminum lactate|Subjects will be patch tested with 4 experimental doses of aluminum chloride, 0.040 mg/cm², 0.12 mg/cm², 0.36 mg/cm² and 0.72 mg/cm², 4 experimental doses of aluminum lactate 0.047 mg/cm², 0.14 mg/cm², 0.42 mg/cm² and 0.84 mg/cm², a negative control and corresponding reference allergens, 2.0% aluminum chloride in petrolatum and 12.0% aluminum lactate in petrolatum. Patch tests will be worn for 48 hours.
11401166|NCT02028208|Experimental|Sodium tetrachloropalladaate (Palladium)|Subjects will be patch tested with 5 experimental doses of sodium tetrachloropalladate 0.011 mg/cm², 0.033 mg/cm², 0.10 mg/cm², 0.30 mg/cm² and 0.60 mg/cm², a negative control and corresponding reference allergens, 3.0% sodium tetrachloropalladate in petrolatum and 1.0% palladium chloride 1.0% in petrolatum. Patch tests will be worn for 48 hours.
11401167|NCT02028195|Experimental|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
11401168|NCT02028195|No Intervention|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
11401169|NCT02028182|Experimental|Positive reactions, Concordance with reference allergen|Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
11401170|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
11401171|NCT02028156|Experimental|Partially Hydrolyzed Infant Formula|Fed ad lib.
11401172|NCT02028143|Experimental|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
11401173|NCT02028143|Active Comparator|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
11401174|NCT02028130|Experimental|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
11401175|NCT02028117|Experimental|Enadenotucirev|
11401176|NCT02028104|Experimental|stem cells|autologous bone marrow mononuclear cell transplantation
11401177|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
11401178|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
11401179|NCT02028078|Experimental|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
11401180|NCT02028065|Experimental|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
11401181|NCT02028065|Experimental|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
11401182|NCT02028065|Placebo Comparator|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
11401183|NCT02028052|Other|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
11401184|NCT02028052|Other|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
11401185|NCT02028039|Experimental|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
11401186|NCT02028026|Experimental|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
11401187|NCT02028026|Active Comparator|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
11401188|NCT02028000|Active Comparator|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
11401189|NCT02028000|Active Comparator|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
11401190|NCT02028000|Active Comparator|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
11401213|NCT02027857|Experimental|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
11401191|NCT02027987|Experimental|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
11401192|NCT02027987|Placebo Comparator|placebo|
11401193|NCT02027974|Active Comparator|Iconacy Hip System|Iconacy hip system prosthesis components
11401194|NCT02027974|Active Comparator|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
11401195|NCT02027961|Experimental|Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib|Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
11401196|NCT02027961|Experimental|Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib|Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
11401197|NCT02027961|Experimental|Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent)|Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
11401198|NCT02027961|Experimental|Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential)|Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
11401199|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
11401200|NCT02027935|Experimental|CD8+ T Cells + Cyclophosphamide + Interleukin-2 + Ipilimumab|Leukapheresis procedure performed to collect blood cells so they can be separated and grown as CD8+T cells. Cyclophosphamide administered at 300 mg/m2 by vein 2 days prior to T cell infusion. T cells administered at a dose of 10^10 cells/m2 by vein on Day 0. IL-2 250,000 U/m2 administered subcutaneously every 12 hours begins within 6 hours of T cell infusion and continues for a total of 14 days On Day 0 to Day +14. Ipilimumab administered 24 hours after T cell infusion at a dose of 3 mg/kg by vein. Subsequent infusions administered on Days +22, +43 and +64.
11401201|NCT02027922|Experimental|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
11401202|NCT02027922|Active Comparator|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
11401203|NCT02027922|No Intervention|an oral hygiene tutorial|an oral hygiene tutorial
11401204|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
11401205|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
11401206|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
11401207|NCT02027896|Experimental|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
11401208|NCT02027896|No Intervention|Standard surgical care|Surgical hip fracture repair according to the standard timing.
11401209|NCT02027883|Active Comparator|Nominal Parameter|Nominal T shock setting
11401210|NCT02027883|Experimental|Experimental Parameter|Educated T shock setting
11401211|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
11401214|NCT02027857|Other|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
11401215|NCT02027844|Experimental|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
11401216|NCT02027844|Active Comparator|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
11401217|NCT02027844|Experimental|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
11401218|NCT02027831|Experimental|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
11401219|NCT02027818|Experimental|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
11401220|NCT02027805|Experimental|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
11401221|NCT02027792|Experimental|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
11401222|NCT02027792|Active Comparator|Diclofenac gel|daily application of diclofenac gel 4 weeks application
11401223|NCT02027792|No Intervention|Usual care|no specific intervention
11401224|NCT02027779|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
11401225|NCT02027779|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
11401226|NCT02027766|Experimental|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
11401227|NCT02027766|No Intervention|Control|
11401228|NCT02027753|Experimental|Insulin glargine and Oral anti diabetic treatment(s)|"Insulin glargine: Lantus
~Add basal insulin: starting with 0.2 U/kg/day or 10 U/day
~Adjust insulin glargine dose according to Fasting blood glucose
~Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
11401229|NCT02027740|Experimental|almond|almonds are substituted for visible fat and carbohydrates
11401230|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
11401231|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.
~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
11401232|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.
~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
11401233|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.
~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.
~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
11401234|NCT02027701|Experimental|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
11401235|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
11401236|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
11401237|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
11401238|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
~Each arm corresponds to a different intervention order."
11401239|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
11401240|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
11401241|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
11401242|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
11401243|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
11401244|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
11401245|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
11401246|NCT02027623|Experimental|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
11401247|NCT02027623|Active Comparator|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
11401248|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
11401249|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
11401250|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
11401251|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
11401252|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
11401253|NCT02027584||preterm infant|gestational age at birth < 37 weeks
11401254|NCT02027584||term infant|gestational age at birth >36 weeks
11401255|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
11401256|NCT02027558|Experimental|Behavioral treatment|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
11401257|NCT02027558|Active Comparator|Active control|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
11401258|NCT02027545|Experimental|Decision Aid|Patients of primary care providers randomly assigned to the Decision Aid intervention (DA) that includes an individualized decision aid, provider education, and modified performance measure/reminder.
11401259|NCT02027545|Other|No Decision Aid|Patients of primary care providers will be randomly assigned to the pragmatic control (PC) that includes provider education and modified performance measure/reminder, but no decision aid.
11401260|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
11401261|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
11401262|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
11401263|NCT02027493|Active Comparator|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had < 1 log decrease in HCV-RNA viremia
11401264|NCT02027493|Active Comparator|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
11401265|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.
~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
11401266|NCT02027467|Experimental|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
11401267|NCT02027467|Placebo Comparator|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
11401268|NCT02027454|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
11401269|NCT02027454|Experimental|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
11401270|NCT02027454|Experimental|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
11401299|NCT02027285|Experimental|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
11401271|NCT02027454|Experimental|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
11401272|NCT02027454|Experimental|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
11401273|NCT02027454|Experimental|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
11401274|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).
~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.
~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
11401275|NCT02027428|Experimental|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
11401276|NCT02027428|Other|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
11401277|NCT02027415|Experimental|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
11401278|NCT02027415|Experimental|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
11401279|NCT02027402|Experimental|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
11401280|NCT02027402|No Intervention|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
11401281|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
11401282|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
11401283|NCT02027376|Experimental|LDE225 (sonidegib) plus docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
11401284|NCT02027363|Experimental|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
11401285|NCT02027363|Experimental|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.
~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
11401286|NCT02027350|Experimental|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
11401287|NCT02027337|No Intervention|Control group|Healthy women that no use combined oral contraceptives
11401288|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
11401289|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
11401290|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
11401291|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
11401292|NCT02027337|Experimental|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
11401293|NCT02027337|Experimental|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
11401294|NCT02027324|Experimental|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
11401295|NCT02027324|Experimental|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
11401296|NCT02027311|Experimental|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
11401297|NCT02027311|Experimental|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
11401298|NCT02027298|Experimental|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
11401300|NCT02027285|Placebo Comparator|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
11401301|NCT02027272|Active Comparator|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
11401302|NCT02027272|Placebo Comparator|Placebo|Placebo, 2 doses, 12 hours apart
11401303|NCT02027259|Experimental|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
11401304|NCT02027259|No Intervention|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
11401305|NCT02027246|Experimental|Stem cell|Autologous bone marrow mononuclear cell transplantation
11401306|NCT02027233|Experimental|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
11401307|NCT02027220|Experimental|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
11401308|NCT02027207|Experimental|Shanchol|
11401309|NCT02027207|Placebo Comparator|Placebo|
11401310|NCT02027194|Experimental|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
11401311|NCT02027194|Active Comparator|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
11401312|NCT02027194|Placebo Comparator|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
11401313|NCT02027181|Experimental|device FreeO2|Automatic adjustment of oxygen
11401314|NCT02027181|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
11401315|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
11401316|NCT02027155|Active Comparator|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
11401317|NCT02027155|Placebo Comparator|Placebo (for AR09 solution)|Placebo; normal saline
11401318|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
11401319|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
11401320|NCT02027129|Other|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
11401321|NCT02027116|Experimental|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
11401322|NCT02027116|Experimental|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
11401323|NCT02027116|Experimental|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
11401324|NCT02027103|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
11401325|NCT02027103|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
11401326|NCT02027090|Experimental|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
11401327|NCT02027090|Active Comparator|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
11401328|NCT02027077|Active Comparator|Control group|Control group
11401329|NCT02027077|Active Comparator|Lifestyle counseling|Behavioral intervention group
11401330|NCT02027064|Experimental|interferon|
11401331|NCT02027038|Experimental|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
11401332|NCT02027038|Active Comparator|Controls|healthy controls
11401333|NCT02027025|Active Comparator|SPARC 1103 low dose|The subjects will receive SPARC 1103 low dose
11401334|NCT02027025|Active Comparator|SPARC1103 high dose|The subjects will receive SPARC1103 high dose
11401335|NCT02027025|Placebo Comparator|SPARC Placebo|The subjects will receive SPARC Placebo
11401336|NCT02027012|Experimental|Renal denervation with Vessix system|
11401337|NCT02026986|Experimental|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
11401338|NCT02026986|No Intervention|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
11401339|NCT02026973|Experimental|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
11401340|NCT02026973|Experimental|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
11401341|NCT02026973|Experimental|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
11401342|NCT02026973|Experimental|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
11401343|NCT02026960|Experimental|Renal Cell Carcinoma Tumor Tissue|
11401344|NCT02026960|Experimental|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
11401345|NCT02026947|Placebo Comparator|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
11401346|NCT02026947|Experimental|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
11401348|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
11401349|NCT02026895|Experimental|Patient with infection by Staphylococcus lugdunensis|
11401350|NCT02026882|Other|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
11401351|NCT02026869|Active Comparator|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
11401352|NCT02026869|Active Comparator|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
11401353|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
11401354|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
11401355|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
11401356|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
11401357|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
11401358|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
11401359|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
11401360|NCT02026817|Experimental|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11401361|NCT02026817|Active Comparator|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11401362|NCT02026804||Prenatal mental disorders|
11401363|NCT02026791|Experimental|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
11401364|NCT02026791|Active Comparator|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
11401365|NCT02026778|Experimental|ondansetron-betahistine|ondansetron-betahistine group
11401366|NCT02026778|Placebo Comparator|ondansetron|ondansetron group
11401367|NCT02026765|Other|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
11401368|NCT02026765|Other|traditional lens|traditional Aspheric lens
11401369|NCT02026752||Study Population|
11401370|NCT02026739|Experimental|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
11401371|NCT02026739|Active Comparator|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
11401372|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
11401373|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
11401374|NCT02026713|Active Comparator|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
11401375|NCT02026700|Experimental|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
11401376|NCT02026687|Active Comparator|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
11401377|NCT02026687|Experimental|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
11401378|NCT02026674|Experimental|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
11401379|NCT02026661||those that did not receive ICSI or LAH|
11401380|NCT02026661||those that received ICSI only|
11401381|NCT02026661||those that received LAH only|
11401382|NCT02026661||those that received both ICSI and LAH|
11401383|NCT02026648||cases with cervical cancer|
11401384|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
11401385|NCT02026622|Other|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.
~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
11401386|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
11401387|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
11401388|NCT02026583|Experimental|Simvastatin|
11401389|NCT02026570|No Intervention|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
11401390|NCT02026570|Experimental|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
11401391|NCT02026570|Experimental|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
11401392|NCT02026544|Experimental|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
11401393|NCT02026531|Experimental|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
11401394|NCT02026518|Experimental|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
11401395|NCT02026518|Experimental|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
11401396|NCT02026518|Placebo Comparator|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
11401397|NCT02026518|Experimental|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
11401398|NCT02026505||Multiple Myeloma, Bortezomib|
11401399|NCT02026492|Other|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
11401400|NCT02026492|Other|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
11401401|NCT02026479|Experimental|regular treatment comparator|Ginaton
11401402|NCT02026479|Experimental|Dexamethasone Phosphate low dose|5mg
11401403|NCT02026479|Experimental|Dexamethasone Phosphate high dose|10mg
11401404|NCT02026466||CAD with CTO|Subjects will have Coronary Artery Disease with a diagnosed Chronic Total Occlusion: a coronary artery with TIMI flow of zero(no flow) for at least three months.
11401405|NCT02026453|No Intervention|Usual care|Physicians and nurses obtain admission medication history.
11401406|NCT02026453|Experimental|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
11401407|NCT02026453|Experimental|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
11401408|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
11401409|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
11401410|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
11401411|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
11401412|NCT02026414|Experimental|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
11401413|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
11401414|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
11401415|NCT02026401|Placebo Comparator|Placebo|Placebo
11401416|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
11401417|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
11401418|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
11401419|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
11401420|NCT02026362|Other|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
11401421|NCT02026362|Experimental|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
11401422|NCT02026349|Active Comparator|favipiravir|
11401423|NCT02026349|Placebo Comparator|placebo|
11401424|NCT02026336|No Intervention|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
11401425|NCT02026323|Experimental|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
11401426|NCT02026323|Experimental|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI >23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
11401502|NCT02025738|Active Comparator|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
11401427|NCT02026310|Experimental|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
11401428|NCT02026310|Active Comparator|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
11401429|NCT02026297|Placebo Comparator|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
11401430|NCT02026297|Experimental|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
11401431|NCT02026284||Gravid women|A questionnaire was performed to gravid women
11401432|NCT02026271|Experimental|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
11401433|NCT02026258|Active Comparator|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
11401434|NCT02026258|Experimental|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
11401435|NCT02026245|Experimental|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.
~Intervention: Data gloves to perform movements"
11401436|NCT02026245|Experimental|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements
~Intervention: Data gloves to perform movements"
11401437|NCT02026232|Active Comparator|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
11401438|NCT02026232|Placebo Comparator|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
11401439|NCT02026219|Experimental|Clopidogrel|Clopidogrel 600mg loading
11401440|NCT02026219|Experimental|Ticagrelor|Ticagrelor 180mg loading
11401441|NCT02026206|Experimental|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
11401442|NCT02026206|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
11401443|NCT02026193|Experimental|oocyte vitrification|All retrieved mature oocytes will be vitrified.
11401444|NCT02026193|Active Comparator|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
11401445|NCT02026180|Active Comparator|Micropuncture Access|Vascular access using micropuncture needle kit
11401446|NCT02026180|Active Comparator|Standard 18G vascular access needle|Vascular access using standard 18G needle
11401447|NCT02026167|No Intervention|Usual Care|No intervention, usual care
11401448|NCT02026167|Experimental|Intervention|Collaborative care with Health Care Assistant
11401449|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
11401450|NCT02026141|Experimental|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.
~Once the patient's spinal is performed, patient will receive the following:
~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr
~Infusion will be stopped after the last staple or suture is performed on the incision.
~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
11401451|NCT02026141|Placebo Comparator|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,
~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.
~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
11401452|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
11401453|NCT02026115|Active Comparator|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
11401454|NCT02026115|Experimental|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
11401455|NCT02026102|No Intervention|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
11401503|NCT02025738|Active Comparator|NO ACTION|no action is performed if patient meets inclusion criteria
11401504|NCT02025725|Experimental|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
11401456|NCT02026102|Experimental|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
11401457|NCT02026089|No Intervention|Sero-positive for varicella at least 5 years prior|No treatment
11401458|NCT02026089|Active Comparator|Varicella vaccine|One dose varicella vaccine (Varivax).
11401459|NCT02026076|Experimental|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
11401460|NCT02026063|Experimental|250 mg Telotristat Etiprate|One telotristat etiprate (250 mg) tablet administered three times daily.
11401461|NCT02026063|Experimental|500 mg Telotristat Etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily.
11401462|NCT02026050|Active Comparator|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
11401463|NCT02026050|Active Comparator|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
11401464|NCT02026050|Placebo Comparator|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
11401465|NCT02026037|Experimental|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
11401466|NCT02026011|Experimental|Naltrexone|Naltrexone 50 mg/day
11401467|NCT02026011|Placebo Comparator|Sugar pill|Matched placebo
11401468|NCT02025998|Experimental|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
11401469|NCT02025998|Placebo Comparator|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
11401470|NCT02025985|Experimental|Part 1, Selinexor 50mg/m2 twice weekly|3 Cohorts of patients with ovarian, endometrial, or cervical carcinoma will receive oral Selinexor 50 mg/m2 twice weekly.
11401471|NCT02025985|Experimental|Part 2, Schedule 1, Selinexor 35 mg/m2 twice weekly|Ongoing ovarian carcinoma cohort will receive oral Selinexor 35 mg/m2 twice weekly.
11401472|NCT02025985|Experimental|Part 2, Schedule 2, Selinexor 50 mg/m2 once weekly|Ongoing ovarian carcinoma cohort will receive oral Selinexor 50 mg/m2 once weekly.
11401473|NCT02025985|Experimental|Part 3, Selinexor 60 mg twice weekly|Breast cancer cohorts will receive oral Selinexor 60 mg twice weekly.
11401474|NCT02025972|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
11401475|NCT02025959|Experimental|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
11401476|NCT02025946||Total Ankle Arthroplasty|
11401477|NCT02025946||Tibiotalar Arthrodesis|
11401478|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
11401479|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
11401480|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
11401481|NCT02025920||Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
11401482|NCT02025920||Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
11401483|NCT02025920||Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
11401484|NCT02025907|Experimental|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
11401485|NCT02025907|Placebo Comparator|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
11401486|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
11401487|NCT02025881|Experimental|Treatment|carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex
11401488|NCT02025868|Experimental|Adherence reinforcement before switch to 3rd-line ART|
11401489|NCT02025855|Experimental|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
11401490|NCT02025855|Placebo Comparator|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
11401491|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
11401492|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
11401493|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
11401494|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
11401495|NCT02025803|Experimental|TAS-114/capecitabine|See intervention description
11401496|NCT02025790|Experimental|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
11401497|NCT02025790|Active Comparator|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
11401498|NCT02025777|Experimental|capsule endoscopy and colonoscopy|
11401499|NCT02025751|Experimental|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
11401500|NCT02025751|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
11401501|NCT02025738|Active Comparator|MAGNET|magnet application over cardiac device
11401505|NCT02025725|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
11401506|NCT02025712|Experimental|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
11401507|NCT02025699||LRTI|
11401508|NCT02025699||Sepsis|
11401509|NCT02025699||Non-Infectious disease group|
11401510|NCT02025686|Experimental|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
11401511|NCT02025673||Healthy Controls|Healthy subjects as control group.
11401512|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
11401513|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
11401514|NCT02025660|Experimental|Mw|
11401515|NCT02025660|Placebo Comparator|Saline; 0.3 ml x three days sc|
11401516|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
11401517|NCT02025634|Experimental|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
11401518|NCT02025634|Placebo Comparator|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
11401519|NCT02025621|Experimental|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
11401520|NCT02025621|Placebo Comparator|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
11401521|NCT02025608|Experimental|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
11401522|NCT02025608|Placebo Comparator|Placebo|Placebo, daily for 4 weeks
11401523|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
11401524|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
11401525|NCT02025582|Experimental|Kinesio tape|
11401526|NCT02025569|Experimental|Experimental group|Strain counterstrain intervention
11401527|NCT02025569|Sham Comparator|Control Group|Sham Strain Counterstrain intervention
11401528|NCT02025556|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
11401529|NCT02025556|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
11401530|NCT02025556|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
11401531|NCT02025543||Patient Group|Subjects with known or suspected iron overload will undergo serum ferritin measurement and an MRI scan.
11401532|NCT02025543||Control Group|Subjects with no known history of iron overload or liver disease will undergo an MRI scan.
11401533|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
11401534|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
11401535|NCT02025517|No Intervention|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
11401536|NCT02025517|Experimental|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
11401537|NCT02025504|Experimental|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
11401538|NCT02025504|Sham Comparator|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
11401539|NCT02025491|Experimental|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
11401540|NCT02025478|Experimental|Enteral Donor Breastmilk|"Donor breast milk will be pasteurized prior to use.
~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.
~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.
~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
11401541|NCT02025465|Experimental|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes
~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy))
~If rate inadequate the physician has option of:
~Further doses of metoprolol IV or PO
~Intravenous amiodarone
~IV diltiazem
~Observation"
11401542|NCT02025465|Active Comparator|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).
~If after 15 minutes
~The first dose is tolerated, and
~Ventricular rate is over 100 beats a minute AND
~Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy)
~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).
~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:
~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.
~If rate inadequate the physician has an option of:
~Metoprolol PO (by mouth) or IV (intravenous)
~Digoxin PO or IV
~Intravenous amiodarone
~Observation"
11401543|NCT02025452|Active Comparator|Rapid diagnostics and probiotic|
11401544|NCT02025452|Placebo Comparator|Rapid diagnostics and placebo|
11401545|NCT02025452|Experimental|Delayed diagnostics and probiotic|
11401546|NCT02025452|Placebo Comparator|Delayed diagnostics and placebo|
11401547|NCT02025439|Experimental|rTMS Alone followed by rTMS+AMA|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
11401548|NCT02025439|Experimental|AMA Alone followed by rTMS+AMA|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
11401549|NCT02025426|Active Comparator|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
11401550|NCT02025426|Active Comparator|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
11401551|NCT02025413|Other|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
11401552|NCT02025413|Other|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
11401553|NCT02025400|Active Comparator|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
11401554|NCT02025400|Experimental|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
11401555|NCT02025387|Experimental|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
11401556|NCT02025387|Sham Comparator|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
11401557|NCT02025374|Experimental|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
11401558|NCT02025374|Active Comparator|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
11401559|NCT02025361|Experimental|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
11401560|NCT02025361|Experimental|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
11401561|NCT02025348|Experimental|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
11401562|NCT02025348|Experimental|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
11401563|NCT02025348|Experimental|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
11401564|NCT02025348|Experimental|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
11401565|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
11401566|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
11401567|NCT02025322|No Intervention|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
11401568|NCT02025322|Experimental|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
11401569|NCT02025309|Active Comparator|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
11401570|NCT02025309|Placebo Comparator|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
11401571|NCT02025296|No Intervention|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
11401572|NCT02025296|Experimental|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
11401573|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
11401604|NCT02025062|No Intervention|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
11401605|NCT02025062|Experimental|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
11401574|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
11401575|NCT02025270|Other|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
11401576|NCT02025257|Experimental|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
11401577|NCT02025257|No Intervention|Control|Patients are asked to live as usual.
11401578|NCT02025244|Active Comparator|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
11401579|NCT02025244|Active Comparator|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
11401580|NCT02025231|Experimental|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
11401581|NCT02025218|Experimental|Re-administration gefitinib|
11401582|NCT02025205|Experimental|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
11401583|NCT02025205|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
11401584|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with capecitabine|
11401585|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with trastuzumab|
11401586|NCT02025192|Experimental|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
11401587|NCT02025179|Experimental|Teriparatide and vibration|"Experimental: Teriparatide and vibration
~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
~Device: Vibration 10 min/day for 12 months"
11401588|NCT02025166|Active Comparator|Paracetamol|Pain treatment, aniline analgesics
11401589|NCT02025166|Active Comparator|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
11401590|NCT02025153|Other|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
11401591|NCT02025153|Other|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
11401592|NCT02025153|Other|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
11401593|NCT02025140|Active Comparator|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
11401594|NCT02025140|Experimental|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
11401595|NCT02025140|Experimental|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
11401596|NCT02025127|Experimental|Trophic feeding|Mechanically ventilated patients with septic shock > 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
11401597|NCT02025127|No Intervention|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
11401598|NCT02025114|Experimental|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
11401599|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
11401600|NCT02025088|Active Comparator|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
11401601|NCT02025088|Active Comparator|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
11401602|NCT02025075|Experimental|Deep Neuromuscular Block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
11401603|NCT02025075|Active Comparator|Moderate Neuromuscular block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
11401606|NCT02025049|Experimental|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
11401607|NCT02025049|Placebo Comparator|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
11401608|NCT02025036|Experimental|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.
~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
11401609|NCT02025036|Active Comparator|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.
~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
11401610|NCT02025036|Experimental|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
11401611|NCT02025023|Active Comparator|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
11401612|NCT02025023|Active Comparator|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
11401613|NCT02025023|Active Comparator|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
11401614|NCT02025023|Active Comparator|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
11401615|NCT02025010|Experimental|abiraterone acetate|"Pre-treatment and progression tumor biopsies.
~Four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) taken orally on 28 day cycles.
~For participants who experience symptoms of persistent or severe hypertension or hypokalemia, prednisone 5 mg by mouth twice daily.
~For participations who tolerate AA monotherapy without the addition of prednisone to manage symptoms of persistent or severe mineralocorticoid excess, prednisone 5 mg by mouth twice daily will be added at PSA progression.
~Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess."
11401616|NCT02024997|Experimental|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
11401617|NCT02024984|Experimental|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
11401618|NCT02024984|Active Comparator|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
11401619|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
11401620|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
11401621|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
11401622|NCT02024932|Experimental|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
11401623|NCT02024932|Experimental|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
11401624|NCT02024932|Placebo Comparator|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
11401625|NCT02024932|Experimental|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
11401626|NCT02024932|Experimental|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
11401627|NCT02024932|Placebo Comparator|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
11401628|NCT02024919|Active Comparator|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
11401629|NCT02024919|Placebo Comparator|Saline|intracoronary saline 5 mL
11401630|NCT02024906|Experimental|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
11401631|NCT02024906|Active Comparator|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
11401632|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
11401633|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
11401634|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
11401635|NCT02024880|Experimental|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
11401636|NCT02024880|Active Comparator|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
11401637|NCT02024867|Active Comparator|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
11401638|NCT02024867|Experimental|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
11401639|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
11401640|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
11401641|NCT02024841|Experimental|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:
~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2
~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks
~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
11401642|NCT02024828|Experimental|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
11401643|NCT02024828|Experimental|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
11401644|NCT02024828|Experimental|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
11401645|NCT02024828|Experimental|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
11401646|NCT02024815|Experimental|External Beam radiotherapy|Single 8 Gy fraction
11401647|NCT02024815|Active Comparator|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
11401648|NCT02024789|Placebo Comparator|Placebo|
11401649|NCT02024789|Experimental|RG1662 120 mg bid|
11401650|NCT02024789|Experimental|RG1662 240 mg bid|
11401651|NCT02024776|Active Comparator|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
11401652|NCT02024776|No Intervention|No-intervention|Standard counseling and conventional pre-surgical measures
11401653|NCT02024763|Experimental|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
11401654|NCT02024763|No Intervention|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
11401655|NCT02024750|Experimental|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
11401656|NCT02024750|No Intervention|Usual Care|Patients and families obtain routine multidisciplinary diabetes care
11401657|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.
~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
11401658|NCT02024724|Active Comparator|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
11401659|NCT02024724|Active Comparator|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
11401660|NCT02024711|Experimental|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
11401661|NCT02024711|Active Comparator|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
11401662|NCT02024698|Active Comparator|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
11401663|NCT02024698|Active Comparator|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
11401664|NCT02024685|Active Comparator|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
11401665|NCT02024685|Experimental|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
11401666|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
11401667|NCT02024659|Experimental|budesonide|
11401668|NCT02024659|Placebo Comparator|placebo|
11401669|NCT02024646|Experimental|210 mg brodalumab|Administered via subcutaneous injections.
11401670|NCT02024646|Experimental|140 mg brodalumab|Administered via subcutaneous injection.
11401671|NCT02024646|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
11401692|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
11401672|NCT02024633|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
11401673|NCT02024620|Experimental|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
11401674|NCT02024620|Active Comparator|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
11401675|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
11401676|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
11401677|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
11401678|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
11401679|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
11401680|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
11401681|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
11401682|NCT02024594|Experimental|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
11401683|NCT02024594|Experimental|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
11401684|NCT02024594|No Intervention|control|No intervention
11401685|NCT02024581|Active Comparator|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
11401686|NCT02024581|Placebo Comparator|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
11401687|NCT02024568|Active Comparator|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.
~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.
~In case of poorly tolerated side effects a reduction to 50mg doses is available.
~Access to additional analgesic interventions is open as required for patient wellbeing."
11401688|NCT02024568|Placebo Comparator|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.
~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.
~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.
~Access to additional analgesic interventions is open as required for patient wellbeing."
11401689|NCT02024555|Active Comparator|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
11401690|NCT02024555|Placebo Comparator|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.
~The pill count will be the same as the comparator regimen."
11401691|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
11401693|NCT02024529|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL Intra-articular injection of Ampion
11401694|NCT02024529|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
11401696|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
11401697|NCT02024503||Control group|Healthy Volunteers.
11401698|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
11401699|NCT02024477|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
11401700|NCT02024477|Active Comparator|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
11401701|NCT02024464|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent
11401702|NCT02024464|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
11401703|NCT02024451|Active Comparator|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.
~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
11401704|NCT02024451|No Intervention|radial shock wave& no treatment|No treatment: patients recieved no intervention.
11401705|NCT02024438|Other|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
11401706|NCT02024438|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
11401707|NCT02024425|Active Comparator|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
11401708|NCT02024425|Placebo Comparator|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
11401709|NCT02024412|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
11401710|NCT02024412|Placebo Comparator|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
11401711|NCT02024399|Other|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
11401712|NCT02024386|Experimental|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
11401713|NCT02024386|Experimental|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
11401714|NCT02024386|No Intervention|Control arm|No drug
11401715|NCT02024373|Experimental|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
11401716|NCT02024373|Placebo Comparator|placebo|placebo:20 mg (every evening orally) for 8 weeks
11401717|NCT02024360|Experimental|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
11401718|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
11401719|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
11401720|NCT02024334|Active Comparator|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
11401721|NCT02024334|Placebo Comparator|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
11401722|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
11401723|NCT02024308|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
11401724|NCT02024308|Active Comparator|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
11401725|NCT02024295|Experimental|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
11401726|NCT02024295|Active Comparator|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
11401727|NCT02024282|Other|usual care|
11401728|NCT02024282|Active Comparator|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.
~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.
~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.
~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
11401729|NCT02024282|Active Comparator|Brief intervention and parent leaflet|
11401730|NCT02024282|Active Comparator|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention & parent information leaflet intervention groups (factorial design)
11401731|NCT02024269|Experimental|Adipose Stem Cells|
11401732|NCT02024256|Active Comparator|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
11401733|NCT02024256|Sham Comparator|Water|Pads soaked with cold water
11401758|NCT02024061|Active Comparator|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.
~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
11401759|NCT02024048||Pregnant|OCT
11401734|NCT02024243||miR210 and Punch Tissue Biopsy|Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
11401735|NCT02024230||Warfarin|The dose of warfarin can be controlled so that the PT-INR value will be 2.0-3.0 in those aged under 70 years and 1.6-2.6 in those aged 70 years or more.
11401736|NCT02024230||Rivaroxaban|A dose of 15 mg of rivaroxaban is orally administered to adults once a day. The dose can be reduced to 10 mg in patients with renal insufficiency (creatinine clearance: 30-49 mL/minute), patients at a high risk of hemorrhage (HAS-BLED score), old patients aged 75 years or more, and low body weight patients.
11401737|NCT02024217|Experimental|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
11401738|NCT02024204|Active Comparator|Visit 1 Uncontrolled LRS|Patients who have uncontrolled LRS (ACT < 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
11401739|NCT02024204|Other|Visit 1 Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
11401740|NCT02024191|Experimental|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
11401741|NCT02024191|No Intervention|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
11401742|NCT02024178|Experimental|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
11401743|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
11401744|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
11401745|NCT02024152|Experimental|JDP-205 IV high dose|
11401746|NCT02024152|Experimental|JDP-205 IV low dose|
11401747|NCT02024152|Experimental|JDP-205 IM high dose|
11401748|NCT02024152|Active Comparator|Control|
11401749|NCT02024139|Experimental|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
11401750|NCT02024139|Placebo Comparator|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
11401751|NCT02024126|Experimental|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
11401752|NCT02024126|Active Comparator|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
11401753|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.
~Intervention: a fasted venous blood sample is taken before PET-scan"
11401754|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.
~Intervention: fasted venous blood sample"
11401755|NCT02024087|Experimental|Dalantercept plus sorafenib|
11401756|NCT02024074|Other|Sestamibi(Tc- MBI) scan of the breast|
11401757|NCT02024061|Experimental|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.
~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
11401760|NCT02024048||Control|OCT
11401761|NCT02024035||Tomotherapy|
11401762|NCT02024035||Arc'therapy Vmat|
11401763|NCT02024035||Arctherapy Rapid'Arc|
11401787|NCT02023892|Placebo Comparator|placebo|placebo 20mg tablet, single dose of 80mg by mouth
11401764|NCT02024022|Active Comparator|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:
~4L split polyethylene glycol solution
~split magnesium citrate/sodium picosulphate preparation regimen"
11401765|NCT02024022|Experimental|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
11401766|NCT02024009|Experimental|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
11401767|NCT02024009|Experimental|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
11401768|NCT02024009|Experimental|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then
~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
11401769|NCT02024009|Experimental|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then
~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
11401770|NCT02024009|Experimental|Arm E|"6 cycles of GEMABX*
~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
11401771|NCT02023996|Experimental|PET Imaging With 89Zr-DFO-Trastuzumab|Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg [1]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics & determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts & blood draws. Subsequent patients will receive the antibody & will only undergo imaging at a single time point (based on the first 10 patients) & will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
11401772|NCT02023983|Experimental|Early discharge|
11401773|NCT02023983|Active Comparator|Standard discharge|
11401774|NCT02023970|Other|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
11401775|NCT02023970|Other|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
11401776|NCT02023970|Other|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
11401777|NCT02023957|Experimental|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
11401778|NCT02023957|No Intervention|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
11401779|NCT02023944|Other|Intervention|12-week course on memory and aging, consists of psychoeducation and skills training
11401780|NCT02023944|No Intervention|Control, No Intervention|"No Intervention, considered treatment as usual"
11401781|NCT02023931|Experimental|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
11401782|NCT02023918|Experimental|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
11401783|NCT02023905|Experimental|Arm 1|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is present, patients will be treated in Arm 1 with single-agent everolimus at 10 mg daily continuously. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
11401784|NCT02023905|Experimental|Arm 2|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If activation is not present, patients will be treated in Arm 2 with combined everolimus and Temozolomide (TMZ). Everolimus will be given at 10 mg daily continuously, and Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression. In Arm 2, TMZ will be stopped after 12 cycles.
11401785|NCT02023905|Experimental|Arm 3|If the tumor is 1p/19q intact, then patients will be further selected by whether or not their tumor demonstrates activation of the PI3K/mTOR pathway. If 1p/19q co-deletion is present, patients will be treated in Arm 3 with single-agent everolimus at 10 mg daily continuously. In all arms, treatment with everolimus will continue for up to 24 cycles, after which patients will be followed with interval MRIs until progression.
11401786|NCT02023892|Experimental|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
11401788|NCT02023879|Placebo Comparator|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.
~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
11401789|NCT02023879|Other|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.
~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
11401790|NCT02023879|Experimental|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.
~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
11401791|NCT02023866|Experimental|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
11401792|NCT02023853|Experimental|ultrasonic, erythritol, metronidazole gel|
11401793|NCT02023840|Active Comparator|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
11401794|NCT02023840|Placebo Comparator|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
11401795|NCT02023827|Experimental|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
11401796|NCT02023827|No Intervention|Standard care|Participants receive standard care from the probation officer
11401797|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
11401798|NCT02023801|Experimental|Aurora Treatment Arm|Endometrial Ablation
11401799|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
~Intervention: Biological: Pneumostem®"
11401800|NCT02023775||Patients implanted with Medtronic Melody valve|All patients that received a valve implantation were included in the registry.
11401801|NCT02023749|Active Comparator|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
11401802|NCT02023749|No Intervention|Control group|Control group maintained their usual diet without nut supplement
11401803|NCT02023736|Active Comparator|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
11401804|NCT02023736|Experimental|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
11401805|NCT02023723|Experimental|Energy Drink|16oz original flavor energy drink consume 2 -16oz energy drinks within 60 minutes
11401806|NCT02023723|Active Comparator|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
11401807|NCT02023710|Experimental|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
11401808|NCT02023710|Active Comparator|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
11401809|NCT02023697|Experimental|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
11401810|NCT02023697|Experimental|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
11401811|NCT02023697|Experimental|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
11401812|NCT02023684|Placebo Comparator|control|Irrigation will be carried out with saline
11401813|NCT02023684|Active Comparator|Lidocaine|Irrigation will be carried out with Lidocaine
11401814|NCT02023684|Active Comparator|Ropivacaine|Irrigation will be carried out with Ropivacaine
11401815|NCT02023658|Experimental|Systems analysis and improvement|pMTCT systems analysis and improvement
11401816|NCT02023658|No Intervention|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
11401817|NCT02023645|Experimental|Active supplement|10 mg lutein + 2 mg zeaxanthin
11401818|NCT02023645|Placebo Comparator|inert placebo|placebo for comparison
11401819|NCT02023632|Experimental|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
11401820|NCT02023632|Active Comparator|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
11401856|NCT02023385|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
11401821|NCT02023632|Sham Comparator|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
11401822|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
11401823|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism >2.0 D
11401824|NCT02023606|Experimental|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.
11401825|NCT02023593|Experimental|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
11401826|NCT02023580|Experimental|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
11401827|NCT02023580|Active Comparator|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
11401828|NCT02023567|Experimental|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
11401829|NCT02023567|No Intervention|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
11401830|NCT02023554|Experimental|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
11401831|NCT02023554|Active Comparator|Theophylline alone|steady-state plasma concentration of theophylline alone
11401832|NCT02023541|Other|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
11401833|NCT02023541|Other|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
11401834|NCT02023515|Experimental|Stress Management|Approximately half of the participants will be randomized to a stress management arm. Participants will undergo Emotional Brain Training during a 90 minute session once per week for ten weeks in order to rewire the brain and improve stress management techniques.
11401835|NCT02023515|Active Comparator|standard behavioral weight loss|Half of participants will receive a standard behavioral weight loss program in 90 minute sessions once per week for 10 weeks
11401836|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
11401837|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
11401838|NCT02023489|Other|Type 2 Diabetes Mellitus|
11401839|NCT02023489|Other|Insulin sensitive volunteers|
11401840|NCT02023489|Other|prediabetic subjects|
11401841|NCT02023489|Other|familiar hypocalciuric hypercalcemic patients|
11401842|NCT02023489|Other|Type 1 diabetes mellitus|
11401843|NCT02023476|Experimental|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
11401844|NCT02023476|Active Comparator|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
11401845|NCT02023463|Experimental|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
11401846|NCT02023450|Experimental|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
11401847|NCT02023450|Experimental|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
11401848|NCT02023437|Experimental|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
11401849|NCT02023437|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
11401850|NCT02023424|Experimental|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
11401851|NCT02023411|Active Comparator|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.
11401852|NCT02023411|Placebo Comparator|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.
11401853|NCT02023398|Experimental|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
11401854|NCT02023398|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
11401855|NCT02023385|Experimental|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
11401857|NCT02023372|Other|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
11401858|NCT02023359||Treatment|Everolimus and exemestane
11401859|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
11401860|NCT02023333|Experimental|Regorafenib|This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks).
11401861|NCT02023320|Experimental|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
11401862|NCT02023320|Experimental|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
11401863|NCT02023307|Experimental|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
11401864|NCT02023294|Active Comparator|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
11401865|NCT02023294|Experimental|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
11401866|NCT02023281|No Intervention|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
11401867|NCT02023281|Experimental|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
11401868|NCT02023268|Experimental|T2762|
11401869|NCT02023268|Active Comparator|Vismed®|
11401870|NCT02023255|Experimental|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
11401871|NCT02023255|Experimental|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
11401872|NCT02023255|Experimental|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
11401873|NCT02023255|Experimental|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
11401874|NCT02023255|Experimental|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
11401875|NCT02023255|Experimental|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
11401876|NCT02023255|Experimental|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
11401877|NCT02023255|Experimental|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
11401878|NCT02023242|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
11401879|NCT02023242|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
11401880|NCT02023229|Experimental|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
11401881|NCT02023229|Active Comparator|Diet|High-fiber high-protein diet
11401882|NCT02023203|Experimental|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
11401883|NCT02023203|Active Comparator|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
11401884|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
11401885|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
11401886|NCT02023164|Experimental|Test Drug|10 mg/mL, 1 mL
11401887|NCT02023164|Active Comparator|Control|50 mg/mL, 1 mL
11401888|NCT02023151|Other|Omalizumab|Active
11401889|NCT02023138|Active Comparator|Focus group|
11401890|NCT02023138|Experimental|Wiki|
11401891|NCT02023125|Experimental|Group 1: Treatment A first, then Treatment B|Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Each period will be separated by at least 10 days.
11401892|NCT02023125|Experimental|Group 1: Treatment B first, then Treatment A|Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Each period will be separated by at least 10 days.
11401929|NCT02022761|Experimental|40 mg Laninamivir octanoate|Dry Powder Inhaler
11401930|NCT02022761|Experimental|80 mg Laninamivir octanoate|Dry Powder Inhaler
11401931|NCT02022761|Placebo Comparator|Matching placebo|Dry Powder Inhaler
11401932|NCT02022748|Experimental|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
11401893|NCT02023125|Experimental|Group 2: Alectinib Alone, Alectinib + Esomeprazole|Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
11401894|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
11401895|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
11401896|NCT02023099|Experimental|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis
11401897|NCT02023099|Placebo Comparator|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
11401898|NCT02023099|Experimental|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
11401899|NCT02023086||FABRY group|"contrast sensitivity measurement
~slit lamp assessment and intra-ocular pressure measurement
~ocular coherence tomography at the optic nerve head
~visual field testing
~OSOME (oxygen flow at the optic nerve head measurement)
~Tropicamide"
11401900|NCT02023086||CONTROL group|"contrast sensitivity measurement
~slit lamp assessment and intra-ocular pressure measurement
~ocular coherence tomography at the optic nerve head
~visual field testing
~oxygen flow at the optic nerve head measurement (OSOME)
~Under tropicamide"
11401901|NCT02023073||Healthy volunteers|
11401902|NCT02023047|Experimental|Once daily|Nifedipine 12 mg Once daily
11401903|NCT02023047|Experimental|Twice Daily|Nifedipine 12 mg twice daily
11401904|NCT02023034|Experimental|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
11401905|NCT02023034|Sham Comparator|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
11401906|NCT02023021|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
11401907|NCT02023008|Experimental|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
11401908|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
11401909|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
11401910|NCT02022982|Experimental|Palbociclib and PD-0325901|"Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.
~PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
11401911|NCT02022956|Experimental|Open-Label Lorcaserin (BELVIQ)|
11401912|NCT02022930|Experimental|Hydros|Hydros Joint Therapy
11401913|NCT02022930|Experimental|Hydros-TA|Hydros-TA Joint Therapy
11401914|NCT02022930|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide
11401915|NCT02022917|Experimental|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab
11401916|NCT02022904|Experimental|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
11401917|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
11401918|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
11401919|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
11401920|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
11401921|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
11401922|NCT02022852|Active Comparator|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
11401923|NCT02022852|Experimental|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
11401924|NCT02022826|Experimental|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
11401925|NCT02022813|No Intervention|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
11401926|NCT02022813|Experimental|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.
~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
11401927|NCT02022800|Other|PET 18FDOPA|PET 18FDOPA
11401928|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
11401969|NCT02022566||Supported self-management of osteoarthrits program|
11401933|NCT02022748|Experimental|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
11401934|NCT02022748|Experimental|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
11401935|NCT02022735|Experimental|Bilateral stimulation|Deep Brain Stimulation Bilaterally
11401936|NCT02022735|Experimental|Left stimulation|Deep Brain Stimulation Left side only
11401937|NCT02022735|Experimental|Right stimulation|Deep Brain Stimulation Right side only
11401938|NCT02022735|No Intervention|OFF stimulation|No stimulation
11401939|NCT02022722|Active Comparator|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
11401940|NCT02022722|Active Comparator|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
11401941|NCT02022709|Active Comparator|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
11401942|NCT02022709|Active Comparator|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
11401943|NCT02022683|Experimental|Endoscopic Lung Volume Reduction|Patients are implanted with Zephyr Valves
11401944|NCT02022683|No Intervention|Standard of Care|Patients are given Standard Medical Care
11401945|NCT02022670|Placebo Comparator|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
11401946|NCT02022670|Experimental|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
11401947|NCT02022670|Experimental|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
11401948|NCT02022657|Active Comparator|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
11401949|NCT02022657|Active Comparator|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
11401950|NCT02022657|Active Comparator|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
11401951|NCT02022657|Active Comparator|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
11401952|NCT02022657|Active Comparator|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
11401953|NCT02022657|Active Comparator|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
11401954|NCT02022644|Experimental|Group 1 - 20 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 20 mg/ml, Infusion time: 6-24 hours, no more than 48
11401955|NCT02022644|Experimental|Group 2 - 40 mg|Tumor diameter: 2 cm,Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401956|NCT02022644|Experimental|Group 3 - 140 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 140 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401957|NCT02022644|Experimental|Group 4 - 340 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 340 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401958|NCT02022644|Experimental|Group 5 - 40 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401959|NCT02022644|Experimental|Group 6 - 80 mg|Tumor diameter: 2 cm, Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 80 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401960|NCT02022644|Experimental|Group 7 - 280 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 280 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401961|NCT02022644|Experimental|Group 8 - 680 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 680 mg/ml, Infusion Time: 6-24 hours, no more than 48
11401962|NCT02022631|Experimental|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
11401963|NCT02022631|Active Comparator|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
11401964|NCT02022605|Experimental|Hands-on EMS training group|
11401965|NCT02022605|Active Comparator|Standard training group|
11401966|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
11401967|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
11401968|NCT02022579|Experimental|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
11401972|NCT02022540|Experimental|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
11401973|NCT02022540|Experimental|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
11401974|NCT02022540|Experimental|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
11401975|NCT02022540|Experimental|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
11401976|NCT02022540|Experimental|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
11401977|NCT02022540|Experimental|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
11401978|NCT02022527|Experimental|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
11401979|NCT02022527|Active Comparator|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
11401980|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
11401981|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
11401982|NCT02022501|Experimental|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
11401983|NCT02022501|Experimental|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
11401984|NCT02022501|Experimental|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
11401985|NCT02022488|Active Comparator|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
11401986|NCT02022488|Active Comparator|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
11401987|NCT02022488|Placebo Comparator|midazolam|Midazolam 0.5mg/kg
11401988|NCT02022475|Active Comparator|Cholecalciferol|100 000 units vitamin D3 single dose
11401989|NCT02022475|Placebo Comparator|Placebo|similar appearance
11401990|NCT02022462|Experimental|Health Navigation|Up to 151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
11401991|NCT02022462|Other|Waitlist Control|Up to 146 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (n = 73, 6 month waitlist with treatment as usual then they will receive the intervention) or immediate intervention with the Bridge (n = 73). Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
11401992|NCT02022449|No Intervention|Control|participants only complete assessments
11401993|NCT02022449|Experimental|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
11401994|NCT02022436|Active Comparator|contrast ultrasound for patients with AAA|Contrast ultrasound
11401995|NCT02022436|Active Comparator|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
11401996|NCT02022423|Active Comparator|Telephone Counseling|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs
11401997|NCT02022423|Experimental|Internet-based walking program|Weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
11401998|NCT02022423|Experimental|Telephone counseling and Internet-based walking program|Weekly telephone calls to assess compliance to exercise prescription and discuss various topics related to adoption and adherence to walking programs plus weekly automated goals are delivered via email to subject; goals are based on previous week's step count accumulation.
11401999|NCT02022423|No Intervention|Usual Care|Subjects will continue with their health care as usual
11402000|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
11402001|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
11402002|NCT02022384||study patients|Blood sample and life quality questionnaires
11402003|NCT02022371|Experimental|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
11402004|NCT02022358|Active Comparator|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue
~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
11402005|NCT02022358|Experimental|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).
~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
11402006|NCT02022345|Active Comparator|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
11402007|NCT02022345|Active Comparator|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
11402008|NCT02022319|Other|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
11402009|NCT02022306|Placebo Comparator|SAD TD-6450|Single ascending dose (Part A)
11402010|NCT02022306|Placebo Comparator|MAD TD-6450|Multiple ascending dose (Part B)
11402011|NCT02022306|Active Comparator|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
11402012|NCT02022293|Active Comparator|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
11402013|NCT02022293|Placebo Comparator|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
11402014|NCT02022280|Experimental|Proton Pump Inhibitor|Lansoprazole (Prevacid)
11402015|NCT02022280|Placebo Comparator|Vitamin pill|
11402016|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
11402017|NCT02022267||control group|healthy children of employees of our hospital
11402018|NCT02022254|Experimental|Semaglutide administrations|
11402019|NCT02022241|Experimental|Repeated GnRHa|Patients were triggered with repeated GnRHa
11402020|NCT02022228|Experimental|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
11402021|NCT02022228|Experimental|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
11402022|NCT02022215|Experimental|ME1111 Solution, Low strength|
11402023|NCT02022215|Experimental|ME1111 Solution, High strength|
11402024|NCT02022215|Placebo Comparator|Matching Vehicle Solution|
11402025|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
11402026|NCT02022176|Active Comparator|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
11402027|NCT02022176|Placebo Comparator|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
11402028|NCT02022176|Active Comparator|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
11402029|NCT02022176|Placebo Comparator|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
11402030|NCT02022163|Experimental|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
11402031|NCT02022163|Experimental|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
11402032|NCT02022163|Experimental|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
11402033|NCT02022163|Experimental|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
11402034|NCT02022163|Placebo Comparator|Placebo|Placebo, 2 doses given 21 days apart
11402035|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
11402036|NCT02022137|Experimental|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
11402037|NCT02022137|Placebo Comparator|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
11402038|NCT02022137|Active Comparator|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
11402039|NCT02022124|Experimental|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
11402040|NCT02022124|No Intervention|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
11402041|NCT02022111|Active Comparator|Intervention Program of Care|"Patient Education and Behavioral Activation by a Care Coordinator;
~Supporting Self-Care;
~Psychiatrist and Diabetologist Reviews; and
~Decision-support Electronic Health Record System"
11402042|NCT02022111|Placebo Comparator|Control Arm|Participants randomized to the control arm will receive the existing standard of care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
11402043|NCT02022098|Experimental|Debio 1143|In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
11402044|NCT02022098|Placebo Comparator|Placebo|In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
11402045|NCT02022085|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;
~One implant magnet
~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
11402046|NCT02022072|Other|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
11402047|NCT02022059|Experimental|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
11402048|NCT02022059|Placebo Comparator|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
11402049|NCT02022046||2/study, control|Study group: children aged<18 years with chronic kidney disease Control group: children aged<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
11402050|NCT02022033|Experimental|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
11402051|NCT02022020||Group 1|
11402052|NCT02022007|Active Comparator|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
11402053|NCT02022007|Active Comparator|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
11402054|NCT02022007|Experimental|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)
~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
11402055|NCT02021994||Arm Automatic Electronic BPM|
11402056|NCT02021994||mercury sphygmomanometer|
11402057|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402058|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402059|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402060|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402061|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402062|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402063|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402064|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402065|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402066|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
11402067|NCT02021968|Experimental|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
11402068|NCT02021968|Placebo Comparator|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
11402069|NCT02021955|No Intervention|usual care|Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
11402070|NCT02021955|Experimental|guideline treatment recommendations|Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
11402071|NCT02021942|Experimental|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
11402072|NCT02021929|Experimental|Sorafenib|400 mg (2 capsules) taken by mouth once a day
11402073|NCT02021929|Placebo Comparator|Placebo|2 capsules taken by mouth once a day
11402074|NCT02021903|Experimental|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
11402075|NCT02021903|Placebo Comparator|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
11402076|NCT02021890|Experimental|ballroom and Latin dance program|two-hour dancing session twice a week
11402077|NCT02021890|Active Comparator|Self-selected physical activity|self-selected program of physical activity
11402078|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
11402079|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
11402080|NCT02021864|Experimental|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
11402081|NCT02021864|Active Comparator|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
11402082|NCT02021851|Active Comparator|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
11402083|NCT02021851|Placebo Comparator|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
11402084|NCT02021838||Contra Costa County, California|Lethality Assessment Program
11402085|NCT02021838||Pitt County, North Carolina|Lethality Assessment Program
11402086|NCT02021838||Cuyahoga County, Ohio|Domestic Violence High Risk Team
11402087|NCT02021838||Winnebago County, IL|Lethality Assessment Program
11402088|NCT02021838||Miami Dade County, FL|Lethality Assessment Program
11402089|NCT02021838||Battle Creek, MI|Lethality Assessment Program
11402090|NCT02021838||Nashville, TN|Lethality Assessment Program
11402091|NCT02021825|Other|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
11402092|NCT02021812|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
11402093|NCT02021799|No Intervention|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
11402094|NCT02021799|No Intervention|Nourished Pregnant Women|Pregnant women who are classified as healthy
11402095|NCT02021799|No Intervention|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
11402096|NCT02021799|Experimental|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
11402097|NCT02021799|Experimental|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
11402098|NCT02021786|Experimental|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
11402099|NCT02021786|No Intervention|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
11402100|NCT02021773|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
11402101|NCT02021773|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
11402102|NCT02021773|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
11402103|NCT02021760|Active Comparator|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if >180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
11402104|NCT02021760|Sham Comparator|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.
~Otheriwize normal primary PCI."
11402105|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
11402106|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine >30 ng/mL and urine cotinine >50 ng/mL
~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
11402107|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study
~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
11402108|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure
~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:
~Symptoms consistent with TB
~Chest X-rays and or chest CT consistent with TB
~Positive PPD test
~Positive sputum test"
11402109|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
11402110|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
11402111|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
11402112|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
11402113|NCT02021695||Group I: Non-diabetic controls|"Group I: Non-diabetic controls Good overall health without history of Type II diabetes. Normal fasting glucose level (<100 mg/dL) and HbA1C < 5.7%
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
11402114|NCT02021695||Group II: Diabetic with HbA1C<7%|"Group II:
~HbA1C<7%
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
11402115|NCT02021695||Group III: Good controlled diabetics with 7 % <HbA1C < 10%|"Group III Good controlled diabetics with 7 % <HbA1C < 10%
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
11402116|NCT02021695||Group IV: Poorly controlled diabetics with HbA1C > 10%.|"Group IV:
~Poorly controlled diabetics with HbA1C > 10%.
~Also:
~Must provide informed consent
~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus
~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)
~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
11402117|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
11402118|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
11402119|NCT02021669|Experimental|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
11402120|NCT02021669|Placebo Comparator|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
11402121|NCT02021656|Experimental|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
11402122|NCT02021643|Experimental|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
11402123|NCT02021643|Experimental|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
11402124|NCT02021643|Experimental|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
11402125|NCT02021643|Experimental|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
11402126|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
11402127|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
11402128|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
11402129|NCT02021617|No Intervention|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
11402130|NCT02021604|Experimental|Pancreatic Imaging with Fluorodopa F 18|
11402131|NCT02021591|No Intervention|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
11402132|NCT02021591|Experimental|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
11402133|NCT02021578|Experimental|Family Cognitive Behavioral Prevention|A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.
11402134|NCT02021578|Active Comparator|Written Information|Families receive written materials about depression and the effects of parental depression on children.
11402135|NCT02021565|Experimental|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.
~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
11402136|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
11402137|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU >24 hours. All subjects will undergo blood sampling.
11402138|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).
~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
11402139|NCT02021526|Experimental|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
11402140|NCT02021526|Experimental|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
11402141|NCT02021513|Experimental|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
11402142|NCT02021513|Placebo Comparator|Placebo|Olive Oil
11402143|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
11402144|NCT02021474|Experimental|Histamine Dihydrochloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
11402145|NCT02021474|Placebo Comparator|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
11402146|NCT02021461|Experimental|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
11402147|NCT02021461|Experimental|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
11402148|NCT02021461|Experimental|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
11402149|NCT02021448|Other|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
11402150|NCT02021435|Experimental|Salt Substitute|salt substitute
11402151|NCT02021435|No Intervention|Control|Participants continue to buy salt at their own expense
11402152|NCT02021422|Other|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows
~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day
~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
11402153|NCT02021409|Experimental|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
11402154|NCT02021409|Experimental|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
11402155|NCT02021409|Experimental|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
11402156|NCT02021409|Active Comparator|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
11402157|NCT02021396|Experimental|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
11402158|NCT02021396|No Intervention|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
11402159|NCT02021383|Experimental|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
11402160|NCT02021383|No Intervention|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
11402161|NCT02021383|Experimental|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
11402162|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
11402163|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
11402164|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
11402165|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
11402166|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
11402167|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
11402168|NCT02021357|Experimental|Hyperboloid associated with the exercise of proprioceptive|The proprioceptive treatment protocol if run in the use of exercises with hyperboloid based on studies of Biasotto-Gonzalez (2005), for each exercise will be held 6 sets of 6 reps. Between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain, and after that period you will be asked to volunteer the proprioceptive exercise of ´ ´ tongue on the hard palate ´ ´ Biasotto-Gonzalez-based (2005), which consists of the language supported in the hard palate, you must open and close the mouth, having as the principle language as a physical reference.
11402169|NCT02021357|Active Comparator|Hyperboloid|"The proprioceptive treatment protocol if run in the use of the hyperboloid, based on studies of Biasotto-Gonzalez (2005), but without the proprioceptive exercise of language in ´ ´ hard palate ´ ´.
~For each exercise will be held 6 series of 6 repetitions, and between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain."
11402170|NCT02021344|No Intervention|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
11402171|NCT02021344|Experimental|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
11402172|NCT02021344|Experimental|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
11402173|NCT02021344|No Intervention|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
11402174|NCT02021331|Active Comparator|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
11402175|NCT02021331|Experimental|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
11402176|NCT02021318|Experimental|Roxadustat|Study drug Roxadustat will be dosed three times weekly (TIW) during correction period, and TIW during the maintenance period. Dose adjustments are allowed during the study
11402177|NCT02021318|Active Comparator|darbepoetin alfa|darbepoetin alfa will be dosed per European Summary of Product Characteristics (SmPC)
11402178|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
11402179|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
11402180|NCT02021292|Experimental|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
11402181|NCT02021292|Placebo Comparator|Placebo|Matching placebo oral tablet, to be taken once daily.
11402182|NCT02021279|Experimental|MatriStem Pelvic Floor Matrix|surgical mesh device
11402183|NCT02021279|Active Comparator|Native Tissue Repair|suture repair
11402184|NCT02021253|Placebo Comparator|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:
~459 mg of corn starch
~6 mg of magnesium stearate
~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.
~Methods of administration: Oral.
~Duration of treatment: 14 days"
11402185|NCT02021253|Active Comparator|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule
~Composition: One capsule of 560 mg contains Lactibiane tolerance:
~345 mg of corn starch
~114 mg premix lactic
~6 mg of magnesium stearate Excipients: magnesium stearate
~Method of administration: Oral
~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
11402186|NCT02021240|Active Comparator|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
11402187|NCT02021240|Active Comparator|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
11402188|NCT02021240|Placebo Comparator|Normal saline|Single dose of intravenous normal saline before incision
11402189|NCT02021227|No Intervention|Standard group|
11402190|NCT02021227|Other|Chair sitting group|
11402191|NCT02021214|Experimental|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose Placebo, single dose
11402192|NCT02021201|Experimental|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
11402193|NCT02021201|Experimental|2|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
11402194|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
11402195|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
11402196|NCT02021175|Experimental|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
11402197|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
11402198|NCT02021162||Gilenya|MS patients taking Gilenya
11402199|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
11402231|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
11402200|NCT02021149|Other|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
11402201|NCT02021149|Experimental|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
11402202|NCT02021149|Sham Comparator|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
11402203|NCT02021136|Experimental|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
11402204|NCT02021136|Active Comparator|Control|usual antalgic treatment + physical exercises recommendations.
11402205|NCT02021123|Experimental|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
11402206|NCT02021110|No Intervention|Control group|This group will receive standard care (no treatment)
11402207|NCT02021110|Experimental|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
11402208|NCT02021097|Experimental|LNG100 mcg/EE20 mcg|
11402209|NCT02021097|Active Comparator|LNG 150mcg/ EE 30mcg|
11402210|NCT02021084|Placebo Comparator|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
11402211|NCT02021084|Active Comparator|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
11402212|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
11402213|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
11402214|NCT02021058|Experimental|Experimental Formula|Experimental Formula
11402215|NCT02021058|Other|Standard Formula|Standard Control formula
11402216|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
11402217|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
11402218|NCT02021032|Experimental|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
11402219|NCT02021019|Experimental|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
11402220|NCT02021019|No Intervention|Usual Care|Usual care
11402221|NCT02021006|Active Comparator|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.
~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
~Physicians can chose one the following schedules:
~nitrofurantoin 1.5-2 mg/kg per day
~Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
~cefixime 2 mg/kg per day
~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
11402222|NCT02021006|Experimental|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
11402223|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
11402224|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
11402225|NCT02020980||Post-stroke lower limb spasticity patients|
11402226|NCT02020967||Acromegaly patients|
11402227|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
11402228|NCT02020941|Experimental|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.
~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
11402229|NCT02020928|Experimental|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
11402230|NCT02020928|Sham Comparator|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
11402232|NCT02020889|Experimental|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
11402233|NCT02020889|Placebo Comparator|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
11402234|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
11402235|NCT02020863|Experimental|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
11402236|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
11402237|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
11402238|NCT02020824|Active Comparator|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.
~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
11402239|NCT02020824|Experimental|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.
~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
11402240|NCT02020824|Other|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.
~Imagery with functional MRI initial. Imagery with PET-scanner initial."
11402241|NCT02020811|Experimental|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
11402242|NCT02020798|Placebo Comparator|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
11402243|NCT02020798|Experimental|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
11402244|NCT02020785|Active Comparator|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
11402245|NCT02020785|Placebo Comparator|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
11402246|NCT02020772|Experimental|coordinating primary health care 1|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
11402247|NCT02020772|Active Comparator|usual primary health care 1|usual care of musculoskeletal pain in general practice
11402248|NCT02020772|Experimental|coordinating primary health care 2|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
11402249|NCT02020772|Active Comparator|usual primary health care 2|usual care of musculoskeletal pain in general practice
11402250|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
11402251|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
11402252|NCT02020759||ICU patients|Neurological monitoring with transcranial Doppler ultrasound
11402253|NCT02020746|Active Comparator|EscharEx|Enzymatic debridement
11402254|NCT02020746|Placebo Comparator|Gel Vehicle|Control arm
11402255|NCT02020733|Other|balloon catheter|
11402256|NCT02020733|Other|metal cannula|
11402257|NCT02020720|Experimental|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
11402258|NCT02020707|Experimental|Treatment (AB-complex)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11402259|NCT02020694|Experimental|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.
~Hypocaloric diet"
11402260|NCT02020694|Placebo Comparator|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.
~Hypocaloric diet"
11402261|NCT02020681|Experimental|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
11402262|NCT02020681|Placebo Comparator|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
11402263|NCT02020668|Experimental|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
11402264|NCT02020668|Other|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
11402265|NCT02020655||10 healthy volunteers|Shear- force model
11402266|NCT02020642|Experimental|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
11402267|NCT02020642|No Intervention|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
11402268|NCT02020629|Experimental|Lixisenatide|Lixisenatide 20µg daily
11402269|NCT02020616|Experimental|LY3053102|Stage 1: Escalating dose (7 milligrams [mg] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
11402270|NCT02020616|Placebo Comparator|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
11402271|NCT02020616|Active Comparator|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
11402272|NCT02020616|Experimental|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
11402273|NCT02020603|Active Comparator|APC group|epinephrine injection plus argon plasma coagulation
11402274|NCT02020603|Active Comparator|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
11402275|NCT02020590|Experimental|ALLOB® Implantation|One arm: ALLOB® Implantation
11402276|NCT02020577|Experimental|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
11402277|NCT02020564|Experimental|Treatment Group|Computerized exercised will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11402278|NCT02020564|Placebo Comparator|Placebo control group|Computerized exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11402279|NCT02020551|Placebo Comparator|saline spray application|Placebo group
11402280|NCT02020551|Experimental|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
11402281|NCT02020538|Placebo Comparator|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
11402282|NCT02020538|Active Comparator|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
11402283|NCT02020525|Experimental|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
11402284|NCT02020525|Active Comparator|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
11402285|NCT02020512|Experimental|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
11402286|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
11402287|NCT02020486|Experimental|Group A|Experimental
11402288|NCT02020486|Experimental|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
11402289|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
11402290|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
11402291|NCT02020460|Active Comparator|Subdural trial lead|SCS trial lead in the subdural space.
11402292|NCT02020460|Active Comparator|Epidural trial lead|SCS trial lead in the epidural space.
11402293|NCT02020434|Experimental|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
11402294|NCT02020421|Experimental|rTMS|Participants will receive real rTMS and sham tDCS
11402295|NCT02020421|Experimental|tDCS|Participants will receive real tDCS and sham rTMS
11402296|NCT02020421|Sham Comparator|Sham|Participants will receive both sham rTMS and sham tDCS
11402297|NCT02020408|Experimental|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
11402298|NCT02020395|Placebo Comparator|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
11402299|NCT02020395|Active Comparator|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
11402300|NCT02020382|Other|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
11402301|NCT02020382|Other|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
11402302|NCT02020382|Other|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
11402303|NCT02020382|Other|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
11402304|NCT02020382|Other|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
11402305|NCT02020382|Other|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
11402306|NCT02020369|Experimental|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
11402307|NCT02020369|Experimental|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
11402308|NCT02020356|Experimental|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
11402309|NCT02020356|Placebo Comparator|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
11402310|NCT02020343||Healthy|Not insulin resistant
11402311|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
11402312|NCT02020343||Type 2 diabetics|Type 2 diabetics
11402313|NCT02020330|Active Comparator|AL3days|Artemether-lumefantrine 3 days
11402314|NCT02020330|Experimental|AL5days|Artemether-lumefantrine 5 days
11402315|NCT02020317|Active Comparator|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
11402316|NCT02020317|No Intervention|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
11402317|NCT02020304|Experimental|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
11402318|NCT02020304|Active Comparator|refrigerated temperature|refrigerated temperature combined spinal epidural dose (~<43 degrees F)
11402319|NCT02020291|Experimental|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
11402320|NCT02020278|Experimental|Tolvaptan|"Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment.
~Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg."
11402321|NCT02020265|Experimental|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
11402322|NCT02020265|Sham Comparator|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
11402323|NCT02020265|Active Comparator|A\T NF|This group will train modulation of A\T ratio by EEG neurofeedback
11402324|NCT02020252||Touchscreen Participants|
11402325|NCT02020239|Experimental|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
11402326|NCT02020239|Experimental|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
11402327|NCT02020239|No Intervention|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
11402328|NCT02020226|Experimental|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
11402329|NCT02020213|Other|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
11402330|NCT02020200|Experimental|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
11402331|NCT02020187|Experimental|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
11402332|NCT02020187|No Intervention|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
11402333|NCT02020161|Experimental|ATRA-Idarubicin|
11402334|NCT02020135|Experimental|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
11402335|NCT02020122|Active Comparator|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
11402336|NCT02020122|Active Comparator|Pregabalin|PGB 150mg x twice a day x 2 days
11402337|NCT02020122|Placebo Comparator|Placebo|Non active placebo x twice a day x 2 days
11402338|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
11402339|NCT02020096|Experimental|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
11402340|NCT02020096|Active Comparator|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
11402341|NCT02020070|Experimental|Ipilimumab & Degarelix With Radical Prostatectomy|"Week 1: Degarelix SQ injection (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose) and Ipilimumab at 3 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose)
~Week 11, 14, 17 or after sufficient wound healing and recovery post RP:
~Ipilimumab 3 mg/kg IV Follow-up Twelve week intervals until Week 87."
11402342|NCT02020070|Experimental|Ipilimumab & Degarelix With Prior With Radical Prostatectomy|Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
11402343|NCT02020057|Active Comparator|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
11402344|NCT02020057|Experimental|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
11402345|NCT02020044|Other|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
11402346|NCT02020031|Experimental|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
11402347|NCT02020031|Active Comparator|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
11402348|NCT02020018|Experimental|Prospective group|Negative pressure wound therapy (Prevena Incision Management System) applied immediately postoperatively.
11402349|NCT02020018|Active Comparator|Retrospective arm|Conventional sterile dry wound dressing applied immediately postoperatively.
11402377|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
11402378|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
11402471|NCT02019238|Placebo Comparator|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
11402350|NCT02020005|Experimental|non-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
11402351|NCT02020005|Experimental|non-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
11402352|NCT02020005|Experimental|mint-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
11402353|NCT02020005|Experimental|mint-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
11402354|NCT02020005|Experimental|non-flavored nicotine inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
11402355|NCT02020005|Experimental|mint-flavored inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
11402356|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
11402357|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
11402358|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
11402359|NCT02019979|Experimental|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
11402360|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone
~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
11402361|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.
~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
11402362|NCT02019953|Other|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
11402363|NCT02019953|Other|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
11402364|NCT02019953|Other|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
11402365|NCT02019953|Other|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
11402366|NCT02019953|Other|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
11402367|NCT02019940|Experimental|Riluzole|Riluzole 50 mg orally twice per day
11402368|NCT02019927|Experimental|Non-arthritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
11402369|NCT02019927|Experimental|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
11402370|NCT02019927|Experimental|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
11402371|NCT02019927|Sham Comparator|Sham - Non-arthritic ischemic optic neuropathy|Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
11402372|NCT02019927|Sham Comparator|Sham - Multiple Sclerosis|Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
11402373|NCT02019927|Sham Comparator|Sham - Ocular Trauma|Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
11402374|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
11402375|NCT02019901|No Intervention|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
11402376|NCT02019901|Experimental|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
11403081|NCT02015442|Experimental|Low sucrose diet|Low sucrose diet for 7 days
11402379|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
11402380|NCT02019875|Placebo Comparator|Water|200 mL of water once a day for 14 days
11402381|NCT02019875|Active Comparator|Rifampin|Rifampin 600 mg once a day for 14 days
11402382|NCT02019875|Active Comparator|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
11402383|NCT02019875|Active Comparator|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
11402384|NCT02019875|Active Comparator|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
11402385|NCT02019875|Active Comparator|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
11402386|NCT02019862||TRJ®|
11402387|NCT02019849||Plasmafit® Total Hip Arthroplasty|
11402388|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
11402389|NCT02019823|Active Comparator|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the *StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
11402390|NCT02019823|Experimental|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:
~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text
~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment
~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
11402391|NCT02019823|Experimental|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
11402392|NCT02019810|Active Comparator|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
11402393|NCT02019810|Experimental|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
11402394|NCT02019797|Experimental|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
11402395|NCT02019797|Active Comparator|Propofol|5-8 mg/kg/hr infusion during surgery.
11402396|NCT02019784|Active Comparator|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
11402397|NCT02019784|Placebo Comparator|Placebo|Placebo tablets - 550mg twice daily for 90 days
11402398|NCT02019758|Active Comparator|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
11402399|NCT02019758|Active Comparator|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
11402400|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
11402401|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
11402402|NCT02019719|Experimental|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
11402403|NCT02019719|Experimental|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
11402404|NCT02019719|Experimental|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
11402405|NCT02019719|Experimental|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
11402406|NCT02019719|Placebo Comparator|Placebo|Subjects will receive placebo once daily for 4 weeks
11402407|NCT02019706|Experimental|Imaging|All subjects will be imaged
11402408|NCT02019693|Experimental|1/Single arm|INC280 400 mg twice every day by mouth, continuously
11402409|NCT02019667|Experimental|Placebo|Participants with SSADH Deficiency when on placebo for six months
11402410|NCT02019667|Experimental|Study Drug|Participants with SSADH Deficiency receiving SGS-742 when on study drug for six months
11402411|NCT02019654||1|Mild or moderate TBI within the past 30 days
11402412|NCT02019641|Experimental|AET|AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
11402413|NCT02019641|Active Comparator|No AET|control will not engage in AET.No AET (education only)
11402414|NCT02019628|Experimental|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
11402415|NCT02019628|Experimental|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
11402416|NCT02019615|Active Comparator|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
11402470|NCT02019251|Experimental|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
11402417|NCT02019615|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
11402418|NCT02019602|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.
~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
11402419|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
11402420|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
11402421|NCT02019589|Placebo Comparator|Placebo|Placebo
11402422|NCT02019576|Other|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
11402423|NCT02019563|Experimental|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
11402424|NCT02019563|Active Comparator|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
11402425|NCT02019550|Experimental|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
11402426|NCT02019550|Experimental|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
11402427|NCT02019537|Active Comparator|Steroid group|Triamcinolone injection group
11402428|NCT02019537|Experimental|PRP group|Allogeneic PRP injection group
11402429|NCT02019524|Experimental|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
11402430|NCT02019524|Experimental|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
11402431|NCT02019524|Experimental|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
11402432|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age >17 years
~none of the following contraindications for Methylprednisolone:
~Allergy against Methylprednisolone.
~Currently in systemic treatment with glucocorticoid
~Current gastric ulcer
~Insulin dependent diabetes mellitus
~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
11402433|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment
~age >17 years, Danish social security number
~and none of the following at time of surgery:
~systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.
~gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery
~Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
11402434|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.
11402435|NCT02019498|Experimental|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
11402436|NCT02019498|Active Comparator|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
11402675|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
11402437|NCT02019485|Experimental|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
11402438|NCT02019485|Experimental|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
11402439|NCT02019472|Experimental|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
11402440|NCT02019472|Experimental|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
11402441|NCT02019472|Experimental|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
11402442|NCT02019459|Active Comparator|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
11402443|NCT02019459|Experimental|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
11402444|NCT02019446|Experimental|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
11402445|NCT02019446|Active Comparator|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
11402446|NCT02019433||Structan®|
11402447|NCT02019420|Experimental|Tedizolid phosphate IV|Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
11402448|NCT02019420|Active Comparator|Linezolid IV|Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
11402449|NCT02019407|Experimental|CTI group|CTI(Cavo-Tricuspid Isthmus)
11402450|NCT02019407|Placebo Comparator|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
11402451|NCT02019394|Experimental|Lu AE58054|
11402452|NCT02019381|Other|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
11402453|NCT02019381|Other|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
11402454|NCT02019368|Placebo Comparator|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
11402455|NCT02019368|Experimental|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
11402456|NCT02019368|No Intervention|Non-smoker|Oxidative status in non-smoker
11402457|NCT02019355|Experimental|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
11402458|NCT02019355|Active Comparator|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
11402459|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
11402460|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
11402461|NCT02019329|Placebo Comparator|Placebo + risperidone|
11402462|NCT02019329|Experimental|RO5545965 + risperidone|
11402463|NCT02019316|Experimental|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
11402464|NCT02019316|Placebo Comparator|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
11402465|NCT02019303|Other|Abnormal lymph nodes|There is only one arm to this study and includes all eligible and consented patients with abnormal axillary lymph node on ultrasound.
11402466|NCT02019290|Experimental|bitopertin-Midazolam|
11402467|NCT02019277|Experimental|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
11402468|NCT02019264|Experimental|Lorcaserin hydrochloride (HCL)10 mg|APD356 10 mg twice daily
11402469|NCT02019264|Placebo Comparator|Placebo|Placebo twice daily
11402472|NCT02019238|Active Comparator|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
11402473|NCT02019225|Experimental|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
11402474|NCT02019225|No Intervention|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
11402475|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
11402476|NCT02019186|Experimental|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
11402477|NCT02019173|Experimental|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
11402478|NCT02019160|Experimental|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
11402479|NCT02019160|Active Comparator|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
11402480|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
11402481|NCT02019147||Healthy Term Neonates|Controls
11402482|NCT02019134|Active Comparator|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
11402483|NCT02019134|Experimental|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
11402484|NCT02019108|Experimental|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
11402485|NCT02019108|Active Comparator|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
11402486|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
11402487|NCT02019082|Active Comparator|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
11402488|NCT02019082|Placebo Comparator|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
11402489|NCT02019069|Experimental|Liposomal cytarabine-daunorubicin CPX-351|"1st INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV at a dose of 65 units/m2/day over 90 minutes on days 1, 3, and 5.
~2nd INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.
~CONSOLIDATION: Beginning on day 28, patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3."
11402490|NCT02019056|Placebo Comparator|Placebo|enteric coated capsule
11402491|NCT02019056|Experimental|MG 500mg|Metadoxine + garlic oil
11402492|NCT02019056|Experimental|MG 1000mg|Metadoxine + garlic oil
11402493|NCT02019056|Sham Comparator|Metadoxine 500mg|enteric coated capsule
11402494|NCT02019043|Experimental|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
11402495|NCT02019043|No Intervention|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
11402496|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
11402497|NCT02019017|Experimental|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
11402498|NCT02019017|Experimental|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
11402499|NCT02019004|Active Comparator|Onabotulinum Toxin A|One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.
11402500|NCT02019004|Active Comparator|Incobotulinum Toxin A|The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.
11402501|NCT02018991|Active Comparator|Everolimus-Eluting-Stent (EES)|Patients treated with EES
11402502|NCT02018991|Active Comparator|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
11402503|NCT02018991|Active Comparator|Biolimus-Eluting-Stent (BES)|Patients treated with BES
11402542|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
11402543|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
11402544|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
11402545|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
11402504|NCT02018978|Experimental|CTHP|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.
~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.
~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.
~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
11402505|NCT02018978|No Intervention|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
11402506|NCT02018965|Other|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
11402507|NCT02018965|Other|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
11402508|NCT02018952|Other|Ultrasonography assessment|
11402509|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
11402510|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
11402511|NCT02018939|Experimental|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
11402512|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle
~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
11402513|NCT02018900|Placebo Comparator|Placebo|Placebo
11402514|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
11402515|NCT02018887|Experimental|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
11402516|NCT02018887|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
11402517|NCT02018887|Experimental|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
11402518|NCT02018887|Placebo Comparator|Placebo (Part B)|Placebo administered orally for 14 days.
11402519|NCT02018887|Experimental|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
11402520|NCT02018887|Placebo Comparator|Placebo (Part C)|Placebo administered orally for 14 days.
11402521|NCT02018874|Experimental|LY2780301|
11402522|NCT02018861|Experimental|Parsaclisib|escalating doses given every day (QD)
11402523|NCT02018861|Experimental|Parsaclisib in combination with itacitinib (INCB039110)|Starting dose of parsaclisib determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD
11402524|NCT02018861|Experimental|Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide|Starting dose of parsaclisib determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.
11402525|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.
~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.
~Thus, the placebo training sessions are identical to the bias assessment sessions."
11402526|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.
~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.
~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
11402527|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
11402528|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
11402529|NCT02018835|Other|patients of an aortic bicuspidie|
11402530|NCT02018835|Other|patients of a syndrome of Marfan|
11402531|NCT02018835|Other|Healthy volunteers|
11402532|NCT02018822|Experimental|All Participants|Participants who needed at least two tooth restorations
11402533|NCT02018809|Experimental|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
11402534|NCT02018809|Experimental|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
11402535|NCT02018809|Experimental|MAP Missed Doses|The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
11402536|NCT02018809|Other|Usual Care|Usual care with GlowCap.
11402537|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
11402538|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
11402539|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
11402540|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
11402541|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
11402546|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
11402547|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
11402548|NCT02018718|Other|Marathoners|
11402549|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
11402550|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
11402551|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
11402552|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
11402553|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
11402554|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
11402555|NCT02018666|Experimental|spontaneous NAVA mode|
11402556|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
11402557|NCT02018653|Experimental|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
11402558|NCT02018653|Placebo Comparator|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
11402559|NCT02018627|Experimental|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
11402560|NCT02018627|Active Comparator|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
11402561|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
11402562|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
11402563|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
11402564|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
11402565|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
11402566|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
11402567|NCT02018562|Experimental|Intervention|"The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.
~We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.
~i. SLP will also assess the duration of successful speech during each session
~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.
~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
11402568|NCT02018562|No Intervention|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
11402569|NCT02018549|Experimental|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
11402570|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
11402571|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
11402572|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
11402573|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
11402641|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
11402642|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
11402574|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
11402575|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
11402576|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
11402577|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
11402578|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals
~1 mg/kg, single dose IV administration of 3BNC117"
11402579|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
11402580|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
11402581|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
11402582|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
11402583|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
11402584|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART
~1 mg/kg, single dose IV administration of 3BNC117"
11402585|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
11402586|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
11402587|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
11402588|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
11402589|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
11402590|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
11402591|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
11402592|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
11402593|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.
~No interventions."
11402594|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
11402595|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
11402596|NCT02018458|Experimental|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
11402597|NCT02018458|Experimental|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
11402598|NCT02018445|Other|Accell Evo3 DBM & Local Autograft|Accell Evo3 DBM (posterolateral gutter symptomatic side) and Local Autograft (posterolateral gutter contralateral non-symptomatic side)
11402599|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
11402600|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
11402601|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;
~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;
~the activation step with an IV infusion of AlloStim on Day 28;
~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;
~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
11402602|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;
~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;
~the activation step with an IV infusion of AlloStim on Day 21;
~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.
~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
11402603|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;
~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;
~the activation step with an IV infusion of AlloStim on Day 21;
~the booster step with intravenous infusion of AlloStim on days 49 and 77.
~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
11402604|NCT02018406|Experimental|Intervention|Intervention Group
11402605|NCT02018406|Placebo Comparator|Control|Control Group
11402606|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
11402607|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
11402608|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
11402609|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
11402610|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
11402611|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
11402612|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
11402613|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
11402614|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
11402615|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
11402616|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
11402617|NCT02018315|Experimental|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
11402618|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
11402619|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
11402620|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
11402621|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
11402622|NCT02018263|Active Comparator|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
11402623|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
11402624|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
11402625|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
11402626|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
11402627|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
11402628|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
11402629|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
11402630|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
11402631|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
11402632|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
11402633|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
11402634|NCT02018224|Experimental|End-to-end suturation without augmentation|
11402635|NCT02018224|Experimental|End-to-end suturation with augmentation|
11402636|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
11402637|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
11402638|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
11402639|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
11402640|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
11402643|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
11402644|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
11402645|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
11402646|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
11402647|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
11402648|NCT02018107|Experimental|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
11402649|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
11402650|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
11402651|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
11402652|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
11402653|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
11402654|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
11402655|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
11402656|NCT02018055|Active Comparator|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
11402657|NCT02018055|Experimental|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
11402658|NCT02018042|Experimental|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
11402659|NCT02018029||cardiac resynchronisation therapy|
11402660|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
11402661|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
11402662|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
11402663|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
11402664|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
11402665|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
11402666|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
11402667|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
11402668|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
11402669|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
11402670|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
11402671|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
11402672|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
11402673|NCT02017964|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
11402674|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
11402676|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
11402677|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
11402678|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
11402679|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
11402680|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
11402681|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
11402682|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
11402683|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
11402684|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
11402685|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
11402686|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
11402687|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
11402688|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
11402689|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
11402690|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
11402691|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
11402692|NCT02017899|Experimental|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
11402693|NCT02017899|Experimental|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
11402694|NCT02017899|Experimental|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
11402695|NCT02017899|Experimental|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
11402696|NCT02017899|Experimental|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
11402697|NCT02017899|Placebo Comparator|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
11402698|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
11402699|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
11402700|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
11402701|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
11402702|NCT02017860|Experimental|Everolimus|Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.
11402703|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
11402704|NCT02017834|Experimental|harmonic scalpel|
11402705|NCT02017834|Active Comparator|standard technique|
11402706|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
11402707|NCT02017821|No Intervention|care as usual|
11402708|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
11402709|NCT02017808||OCT|Healthy controls
11402710|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
11402711|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
11402712|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
11402713|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
11402714|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
11402715|NCT02017769||Healthy controls|Healthy, gender and age matched controls
11402716|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
11402717|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
11402718|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
11402719|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
11402720|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
11402721|NCT02017717|Experimental|Arm N:Nivolumab|Cohort 1, 1c, 1d and 2: Nivolumab specified dose on specified days
11402722|NCT02017717|Experimental|Arm N + I:Nivolumab + Ipilimumab|"Cohort 1: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days
~Cohort 1b: Nivolumab specified dose on specified days + Ipilimumab specified dose on specified days, then Nivolumab specified dose on specified days"
11402723|NCT02017717|Active Comparator|Arm B: Bevacizumab|Cohort 2: Bevacizumab specified dose on specified days
11402724|NCT02017704|Active Comparator|IMRT and Capecitabine (potentially randomized to this arm)|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
~Followed by:
~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion
~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions
~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus
~Cycle length: 14 days (2 weeks)
~Duration of treatment: 12 cycles
~Then: Surgical Resection"
11402725|NCT02017704|Experimental|Endo-HDR (potentially randomized to this arm)|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
~Followed by:
~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion
~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions
~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus
~Cycle length: 14 days (2 weeks)
~Duration of treatment: 12 cycles
~Then: Surgical Resection"
11402726|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
11402727|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
11402728|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
11402729|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
11402730|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
11402731|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
11402732|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
11402733|NCT02017613|Experimental|Single arm|RP6530 administered orally
11402734|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
11402735|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
11402736|NCT02017574|Experimental|Implicit Group|Receives little feedback about task performance during learning
11402737|NCT02017574|Active Comparator|Control|Receives detailed feedback about task performance during learning
11402738|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
11402739|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
11402740|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
11402741|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
11402742|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
11402743|NCT02017535|Active Comparator|6 IPT-A Sessions|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) only.
~During the Continuation IPT-A sessions, the therapist will continue to emphasize the interpersonal strategies that were learned and practiced during the acute phase, and address any current interpersonal problems before they result in a recurrence of depressive symptoms. Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions."
11402744|NCT02017535|Active Comparator|6 IPT-A Sessions + Continue Current Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.
~Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions and will continue their acute phase fluoxetine dosing regimen and will meet with the psychiatrist on a monthly basis."
11402816|NCT02017093|Experimental|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
11402745|NCT02017535|Experimental|10 IPT-A Sessions + Begin Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.
~Adolescents who received only IPT-A during acute phase and who showed a partial response (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will begin treatment with fluoxetine during the continuation phase.The dosage schedule will be 10mg per day for the first week and 20mg per day for the following 5 weeks. If no treatment response is observed by the 6th week, the dosage can be increased to 40mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and biweekly thereafter. Pharmacotherapy sessions will include assessment of vital signs, adverse effects, safety, and symptomatic response."
11402746|NCT02017535|Experimental|10 IPT-A Sessions + Increase Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.
~Adolescents who received IPT-A and fluoxetine during the acute phase and were partial responders (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will have their fluoxetine dose increased to 60mg. Partial responders will meet with the psychiatrist biweekly for the first 2 months and monthly for the second 2 months."
11402747|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.
~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
11402748|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
11402749|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
11402750|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
11402751|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.
~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
11402752|NCT02017444|Placebo Comparator|Placebo|Matched placebo tablet B.D for 12 weeks
11402753|NCT02017444|Active Comparator|AZD4017 (11b-HSD1 inhibitor)|AZD4017 400mg tablet B.D. for 12 weeks
11402754|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
11402755|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
11402756|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
11402757|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
11402758|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
11402759|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
11402760|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.
~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
11402761|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.
~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
11402762|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.
~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
11402763|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
11402764|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
11402765|NCT02017392|No Intervention|blank control|No intervention.
11402766|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
11402767|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
11402768|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
11402769|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
11402817|NCT02017093|Experimental|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
11402818|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
11402770|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
11402771|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
11402772|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
11402773|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
11402774|NCT02017327|Experimental|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
11402775|NCT02017327|Active Comparator|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
11402776|NCT02017327|Active Comparator|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
11402777|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
11402778|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
11402779|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
11402780|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
11402781|NCT02017314|Active Comparator|Group I|Patients with BMI <30
11402782|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
11402783|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
11402784|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
11402785|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
11402786|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
11402787|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
11402788|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
11402789|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
11402790|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
11402791|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
11402792|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
11402793|NCT02017223|Experimental|Knowme Device Wear|Participants wear KNOWME devices and use mobile phone interface for three days outside of school. This is a pre-post design with no control group
11402794|NCT02017210||Lean/normal weight|Individuals with body mass index (BMI)<25 kg/m^2 in the baseline study
11402795|NCT02017210||Overweight/Obese Insulin-Sensitive|Individuals with BMI>25kg/m^2 who were deemed insulin-sensitive by the hyperinsulinemic -euglycemic clamp (with M/I value above median for men and women separately)
11402796|NCT02017210||Overweight/Obese Insulin-Resistant|Individuals with BMI>25kg/m^2 who were deemed insulin-resistant by the hyperinsulinemic -euglycemic clamp (with M/I value under median for men and women separately)
11402797|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®
~Phase 2: Marevan®
~Phase 3: generic warfarin #1
~Phase 4: generic warfarin #2"
11402798|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1
~Phase 2: generic warfarin #1
~Phase 3: Marevan®
~Phase 4: generic warfarin #2"
11402799|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1
~Phase 2: generic warfarin #1
~Phase 3: generic warfarin #2
~Phase 4: Marevan®"
11402800|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®
~Phase 2: Marevan®
~Phase 3: generic warfarin #2
~Phase 4: generic warfarin #1"
11402801|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2
~Phase 2: generic warfarin #2
~Phase 3: Marevan®
~Phase 4: generic warfarin #1"
11402802|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2
~Phase 2: generic warfarin #2
~Phase 3: generic warfarin #1
~Phase 4: Marevan®"
11402803|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
11402804|NCT02017171|Experimental|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
11402805|NCT02017171|Placebo Comparator|Placebo|Oral placebo tablets
11402806|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
11402807|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
11402808|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
11402809|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
11402810|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
11402811|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
11402812|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
11402813|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
11402814|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
11402815|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
11402819|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
11402820|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
11402821|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
11402822|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
11402823|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
11402824|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
11402825|NCT02017015|Experimental|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
11402826|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
11402827|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
11402828|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
11402829|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
11402830|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
11402831|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
11402832|NCT02016963|Experimental|Raxibacumab arm|A maximum of 25 subjects (to include 3 evaluable female subjects) will receive a second dose of raxibacumab equal to that of the previous dose >= 4 months following the first dose.
11402833|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
11402834|NCT02016937||group g|general anesthesia, n: 21
11402835|NCT02016937||group S|spinal anesthesia, n: 21
11402836|NCT02016937||group E|epidural anesthesia, n: 21
11402837|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
11402838|NCT02016924|Experimental|Part A, Cohort 1|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR. The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
11402839|NCT02016924|Experimental|Cohort 2|Participants ages 6 to <12 years old will receive cobicistat 150 mg and emtricitabine/tenofovir alafenamide 200/25 mg with either ATV or DRV.
11402840|NCT02016924|Experimental|Cohort 3|Participants ages ≥ 3 will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.
11402841|NCT02016924|Experimental|Part B, Cohort 1|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus BR. The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
11402842|NCT02016911|Experimental|Subjects with hepatic impairment|
11402843|NCT02016911|Active Comparator|Subjects with normal hepatic function|
11402844|NCT02016898|Experimental|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
11402845|NCT02016898|Experimental|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
11402846|NCT02016885|Experimental|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
11402847|NCT02016885|Experimental|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
11402848|NCT02016885|Experimental|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
11402849|NCT02016885|Experimental|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
11402850|NCT02016885|Placebo Comparator|Vehicle|Vehicle Topical Wipes
11402851|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
11402852|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
11402853|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
11402854|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
11402855|NCT02016846|Placebo Comparator|Placebo|
11402856|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
11402893|NCT02016612|Active Comparator|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
11402857|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
11402858|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
11402859|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
11402860|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
11402861|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
11402862|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
11402863|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
11402864|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
11402865|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
11402866|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
11402867|NCT02016781|Active Comparator|Transplant|Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)
11402868|NCT02016781|Active Comparator|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
11402869|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
11402870|NCT02016755|Experimental|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
11402871|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
11402872|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
11402873|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
11402874|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
11402875|NCT02016729|Experimental|AMG 232|AMG 232 is an anti-cancer agent
11402876|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
11402877|NCT02016716|Experimental|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
11402878|NCT02016716|Experimental|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
11402879|NCT02016716|Experimental|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
11402880|NCT02016716|Placebo Comparator|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
11402881|NCT02016703|Experimental|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
11402882|NCT02016703|Experimental|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
11402883|NCT02016703|Experimental|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
11402884|NCT02016703|Experimental|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
11402885|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
11402886|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
11402887|NCT02016664|Experimental|Chronic pain patients on oral ketamine|"Days 1-7:
~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.
~Days 8-14:
~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
11402888|NCT02016651|Experimental|Right side position|Premature infants on mechanical ventilation are kept on their right side
11402889|NCT02016651|No Intervention|Supine position|Premature infants on mechanical ventilation are kept on their back
11402890|NCT02016638|Experimental|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:
~Obstetrics ward, AIIMS hospital"
11402891|NCT02016625|Experimental|1 Cyclosporine + Faldaprevir|
11402892|NCT02016625|Experimental|2 Tacrolimus + Faldaprevir|
11402894|NCT02016612|Active Comparator|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
11402895|NCT02016612|Active Comparator|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
11402896|NCT02016612|Active Comparator|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
11402897|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
11402898|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
11402899|NCT02016586|No Intervention|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
11402900|NCT02016586|Experimental|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
11402901|NCT02016573|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
11402902|NCT02016573|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
11402903|NCT02016560|Experimental|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
11402904|NCT02016560|Experimental|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
11402905|NCT02016560|Experimental|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
11402906|NCT02016560|Experimental|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
11402907|NCT02016547|Experimental|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
11402908|NCT02016547|Active Comparator|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
11402909|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
11402910|NCT02016521|Experimental|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
11402911|NCT02016521|Placebo Comparator|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
11402912|NCT02016508|Experimental|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
11402913|NCT02016495|Active Comparator|Magnesium + Lipoic Acid|
11402914|NCT02016495|Placebo Comparator|Placebo|
11402915|NCT02016482|Active Comparator|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
11402916|NCT02016482|Placebo Comparator|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
11402917|NCT02016469|Experimental|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
11402918|NCT02016469|Active Comparator|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
11402919|NCT02016469|Active Comparator|give pectin 20g/d|pure give pectin 20g/d for five days
11402920|NCT02016456|Experimental|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
11402921|NCT02016456|Active Comparator|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
11402922|NCT02016443|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
11402923|NCT02016443|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
11402924|NCT02016430|Experimental|MeLT Dietary intervention|Mediterranean Low-TMAO (MeLT) diet
11402925|NCT02016430|Experimental|TLC Dietary intervention|Therapeutic Lifestyle Changes (TLC) diet
11402926|NCT02016430|Experimental|MeLT dietary intervention with TMAO|Mediterranean Low TMAO diet with TMAO levels reported
11402927|NCT02016417|Experimental|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
11402928|NCT02016417|Active Comparator|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
11402929|NCT02016404|Active Comparator|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
11402930|NCT02016404|Placebo Comparator|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
11402931|NCT02016391|Experimental|Dexmedetomidine|
11402974|NCT02016066|Placebo Comparator|Placebo|
11402932|NCT02016378|Sham Comparator|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
11402933|NCT02016378|Active Comparator|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
11402934|NCT02016365|Experimental|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
11402935|NCT02016352|Experimental|patient|patient CSF extraction with hydrocephalus
11402936|NCT02016352|Other|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
11402937|NCT02016339|Active Comparator|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
11402938|NCT02016339|Active Comparator|Intensive care|"Standard group care plus:
~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
11402939|NCT02016326|Experimental|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
11402940|NCT02016326|Experimental|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
11402941|NCT02016326|Experimental|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
11402942|NCT02016313|Experimental|Immediate therapy|Physiotherapy protocol
11402943|NCT02016313|Placebo Comparator|waiting list|Physiotherapy protocol
11402944|NCT02016300|Experimental|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
11402945|NCT02016300|Active Comparator|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
11402946|NCT02016287|Experimental|sequential treatment|paclitaxel treatment and radiotherapy
11402947|NCT02016274|Experimental|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
11402948|NCT02016261|Experimental|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
11402949|NCT02016248|Experimental|Low Risk Cohort|"The low risk cohort will receive:
~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
11402950|NCT02016248|Experimental|High Risk Cohort|"The high risk cohort will receive:
~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
11402951|NCT02016235|Experimental|Dent Disease Intervention|Dent Disease subjects will receive 2 week supplementation with phosphorus
11402952|NCT02016235|Experimental|Kidney Stone subjects|Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
11402953|NCT02016235|Placebo Comparator|Dent Disease Observation|Dent disease subjects will not get phosphorus
11402954|NCT02016222|Experimental|Tears sampling|
11402955|NCT02016209|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
11402956|NCT02016196|Experimental|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
11402957|NCT02016196|Placebo Comparator|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
11402958|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil/Hydrochlorothiazide 4 mg/6.25 mg or 8 mg/6.25 mg combination tablets, orally, once daily for up to 12 months. This drug should not be used as a first-line drug for hypertension treatment. Participants received interventions as part of routine medical care.
11402959|NCT02016170|Experimental|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
11402960|NCT02016170|Experimental|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
11402961|NCT02016170|Active Comparator|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
11402962|NCT02016157|Experimental|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
11402963|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
11402964|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
11402965|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
11402966|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
11402967|NCT02016105|Experimental|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
11402968|NCT02016105|Active Comparator|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
11402969|NCT02016092||Patients with Parkinson's disease|
11402970|NCT02016092||Healthy Controls|
11402971|NCT02016079|Experimental|Omega-3|a fruit drink containing omega-3
11402972|NCT02016079|Placebo Comparator|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
11402973|NCT02016066|Experimental|CR6261|
11402975|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
11402976|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
11402977|NCT02016040|Active Comparator|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
11402978|NCT02016027|Experimental|Carica folia Arm|
11402979|NCT02016014|Experimental|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
11402980|NCT02016014|Active Comparator|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
11402981|NCT02016001|Experimental|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
11402982|NCT02016001|Experimental|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
11402983|NCT02015988|Experimental|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
11402984|NCT02015988|Active Comparator|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
11402985|NCT02015962|Experimental|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
11402986|NCT02015962|Experimental|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
11402987|NCT02015949|Active Comparator|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
11402988|NCT02015949|Placebo Comparator|Sugar pill|2 weeks of twice daily placebo
11402989|NCT02015936|Experimental|Prescriped Physical Activity|Physical fitness evaluation followed by prescribed physical activity and progress reporting.
11402990|NCT02015923|Experimental|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
11402991|NCT02015923|Active Comparator|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
11402992|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
11402993|NCT02015910|Placebo Comparator|Placebo|Placebo
11402994|NCT02015897|Active Comparator|Physical TherapyB|Group B
11402995|NCT02015897|Placebo Comparator|Physical TherapyA|Group A
11402996|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
11402997|NCT02015871|Experimental|Degarelix|
11402998|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
11402999|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
11403000|NCT02015845|Experimental|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
11403001|NCT02015845|Active Comparator|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
11403002|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
11403003|NCT02015819|Experimental|Treatment (neural stem cells, flucytosine, leucovorin)|Patients receive CD-expressing neural stem cells intracranially on days 1 and 15. Flucytosine is taken orally every 6 hours on days 4-10 and 18-24. Depending on when a subject enters the study, s/he may also be given leucovorin orally every 6 hours on days 4-10 and 18-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11403004|NCT02015806|Experimental|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
11403005|NCT02015806|Experimental|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
11403006|NCT02015806|Experimental|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
11403007|NCT02015806|No Intervention|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
11403008|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
11403009|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
11403036|NCT02015689|Experimental|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
11403010|NCT02015806|No Intervention|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
11403011|NCT02015806|Experimental|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
11403012|NCT02015806|Experimental|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
11403013|NCT02015806|Experimental|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
11403014|NCT02015806|No Intervention|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
11403015|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
11403016|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
11403017|NCT02015806|No Intervention|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
11403018|NCT02015793|Experimental|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
11403019|NCT02015793|Experimental|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
11403020|NCT02015780|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
11403021|NCT02015780|Experimental|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
11403022|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
11403023|NCT02015754|Experimental|DEBIRI|
11403024|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
11403025|NCT02015728|Experimental|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
11403026|NCT02015728|Experimental|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
11403027|NCT02015728|Experimental|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
11403028|NCT02015728|Experimental|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:
~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
11403029|NCT02015715|Experimental|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
11403030|NCT02015715|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
11403031|NCT02015702|Experimental|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
11403032|NCT02015702|Active Comparator|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
11403033|NCT02015689|Experimental|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
11403034|NCT02015689|Active Comparator|CDC VIS|CDC Vaccine Information Statement (VIS)
11403035|NCT02015689|Experimental|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
11403037|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m^2, IV, and subsequently 80 mg/m^2, IV, and continued until disease progression.
11403038|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression.
11403039|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
11403040|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
11403041|NCT02015650|Active Comparator|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
11403042|NCT02015650|Active Comparator|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
11403043|NCT02015637|Experimental|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
11403044|NCT02015637|Active Comparator|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
11403045|NCT02015611|Placebo Comparator|Placebo|Matched bottle/pill placebo
11403046|NCT02015611|Experimental|Vitamin D|2,000 IU Vitamin D3 per day
11403047|NCT02015598|Experimental|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
11403048|NCT02015598|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
11403049|NCT02015585|Experimental|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
11403050|NCT02015585|Experimental|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
11403051|NCT02015585|Active Comparator|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
11403052|NCT02015572|Experimental|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
11403053|NCT02015572|Active Comparator|Usual care|Intervention from the patient's general physician.
11403054|NCT02015559|Experimental|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
11403055|NCT02015559|No Intervention|Arm II (no intervention)|Patients receive no intervention.
11403056|NCT02015546|Experimental|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
11403057|NCT02015546|Experimental|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
11403058|NCT02015546|Experimental|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
11403059|NCT02015533|Experimental|CR8020|
11403060|NCT02015533|Placebo Comparator|Placebo|
11403061|NCT02015520|Experimental|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
11403062|NCT02015520|Experimental|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
11403063|NCT02015520|Experimental|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
11403064|NCT02015520|Experimental|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
11403065|NCT02015520|Experimental|Arm 5: Clazakizumab (Dose# A) (Open Label)|Any subject who completes Double-Blind will receive Clazakizumab Dose # A injection by subcutaneous + background Methotrexate for 96 weeks
11403066|NCT02015507|Active Comparator|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
11403067|NCT02015507|Experimental|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
11403068|NCT02015494|Experimental|4 mcg VAX2012Q|4 mcg VAX2012Q
11403069|NCT02015494|Experimental|8 mcg VAX2012Q|8 mcg VAX2012Q
11403070|NCT02015494|Experimental|14 mcg VAX2012Q|14 mcg VAX2012Q
11403071|NCT02015494|Experimental|18 mcg VAX2012Q|18 mcg VAX2012Q
11403072|NCT02015494|Experimental|12 mcg VAX2012Q|12 mcg VAX2012Q
11403073|NCT02015494|Experimental|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
11403074|NCT02015494|Experimental|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
11403075|NCT02015481|Experimental|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
11403076|NCT02015468|Experimental|Early mobilization|
11403077|NCT02015468|Experimental|Late mobilization|
11403078|NCT02015455|Experimental|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
11403079|NCT02015455|No Intervention|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
11403080|NCT02015442|Experimental|High sucrose diet|High sucrose diet for 7 days
11403082|NCT02015429|Active Comparator|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
11403083|NCT02015429|Experimental|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
11403084|NCT02015429|Experimental|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
11403085|NCT02015429|Experimental|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
11403086|NCT02015416|Experimental|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
11403087|NCT02015403|Experimental|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
11403088|NCT02015403|Active Comparator|Standard Care|
11403089|NCT02015390|Active Comparator|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
11403090|NCT02015390|Active Comparator|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
11403091|NCT02015377|Experimental|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
11403092|NCT02015377|Experimental|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
11403093|NCT02015364|Experimental|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
11403094|NCT02015364|No Intervention|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
11403095|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.
~Immunosuppression: cyclosporine and/or azathioprine"
11403096|NCT02015338||Typically Developing Children|Children with typical development (e.g. no presence of neurological disorders or diagnoses)
11403097|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
11403098|NCT02015325|No Intervention|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
11403099|NCT02015325|Experimental|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
11403100|NCT02015312|Experimental|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
11403101|NCT02015312|Placebo Comparator|Placebo|"capsules
~Dose:
~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
11403102|NCT02015299|Experimental|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
11403103|NCT02015299|Placebo Comparator|Placebo|Matching placebo + lifestyle advise
11403104|NCT02015286||Growth Disorders|
11403105|NCT02015273||Growth Disorders|
11403106|NCT02015260|Placebo Comparator|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
11403107|NCT02015260|Active Comparator|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
11403108|NCT02015260|Active Comparator|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
11403109|NCT02015260|Active Comparator|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
11403110|NCT02015247|Other|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
11403111|NCT02015234|Experimental|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
11403112|NCT02015221|Experimental|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
11403113|NCT02015221|Active Comparator|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
11403114|NCT02015208|Experimental|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
11403115|NCT02015195|Experimental|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403116|NCT02015195|Experimental|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403117|NCT02015195|Experimental|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403118|NCT02015195|Experimental|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403119|NCT02015195|Experimental|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403120|NCT02015195|Experimental|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403121|NCT02015195|Experimental|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
11403122|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
11403123|NCT02015169|Experimental|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs
~D1-D14 Capecitabine 850mg/m2 p.o bid
~D1 ~ Lapatinib 1250 mg qd dailiy"
11403124|NCT02015156|Experimental|PF-05280014|
11403125|NCT02015156|Active Comparator|Trastuzumab-US|
11403126|NCT02015143||Bipolar Disorder|
11403127|NCT02015143||Unipolar Disorder|
11403128|NCT02015130|Experimental|individual treatment|Individualized treatment
11403129|NCT02015130|No Intervention|control group|treatment according to current national guidelines
11403130|NCT02015117|Experimental|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
11403131|NCT02015117|Experimental|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
11403132|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) + PANVAC|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 10^8 pfu subcutaneous (SQ) at week 0 only; PANVAC-F 1 x 10^9 pfu SQ at weeks 3, 7, 11, and 15
11403133|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) Alone|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
11403134|NCT02015091|Experimental|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
11403135|NCT02015091|Experimental|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
11403136|NCT02015091|Experimental|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
11403137|NCT02015091|No Intervention|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
11403138|NCT02015078||African Americans|Targets are family members attending African American family reunions.
11403139|NCT02015065|Experimental|Vandetanib in Children|Children with measurable localized or metastatic wt-GIST
11403140|NCT02015065|Experimental|Vandetanib in Adults|Adults with measurable localized or metastatic wt-GIST
11403141|NCT02015039|Active Comparator|Botulinum Toxin Therapy Only|
11403142|NCT02015039|Experimental|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
11403143|NCT02015013|Experimental|Filgrastim|ICL and healthy volunteers will be given 10 g/kg daily for 5 days administered according to a vialbased algorithm to reduce wastage and increase the G-CSF dose given to lighter- Filgrastim weight donors to improve CD34+ yields
11403144|NCT02015013|Experimental|Plerixafor|ICL and healthy volunteers will be given 0.24 mg/kg as a single dose (maximum dose: 40mg) 11 hours prior to apheresis
11403145|NCT02015000|Experimental|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
11403146|NCT02014987|Experimental|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.
~The amount of running will be increased with 10 % per week."
11403147|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
11403148|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
11403149|NCT02014961|Active Comparator|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
11403150|NCT02014961|Placebo Comparator|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
11403151|NCT02014961|Other|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
11403152|NCT02014948|Experimental|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
11403153|NCT02014935|Experimental|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.
~The phases comprise:
~Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.
~Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.
~Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
11403154|NCT02014922|No Intervention|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
11403155|NCT02014922|Experimental|Treatment|"Participants in the study treatment group will receive all four products:
~TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn
~TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn
~TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD
~TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
11403156|NCT02014909|Experimental|KTN3379|KTN3379
11403157|NCT02014909|Experimental|Part II, Arm A|Combination of KTN3379 and cetuximab
11403158|NCT02014909|Experimental|Part II, Arm B|Combination of KTN3379 and erlotinib
11403159|NCT02014909|Experimental|Part II, Arm C|Combination of KTN3379 and vemurafenib
11403160|NCT02014909|Experimental|Part II, Arm D|Combination of KTN3379 and trastuzumab
11403161|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).
~Biomarker blood draw"
11403162|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).
~Biomarker blood draw"
11403163|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.
~Biomarker blood draw"
11403164|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.
~Biomarker blood draw"
11403165|NCT02014883|Experimental|GLUT1 DS|
11403166|NCT02014870|Experimental|Cohort 1|1:1000 dilution of neat virus
11403167|NCT02014870|Experimental|Cohort 2|1:100 dilution of neat virus
11403168|NCT02014870|Experimental|Cohort 3|1:10 dilution of neat virus
11403169|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
11403170|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
11403171|NCT02014844|Experimental|aldoxorubicin|Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
11403172|NCT02014831|Active Comparator|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
11403173|NCT02014831|Experimental|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
11403174|NCT02014818|Experimental|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
11403175|NCT02014818|Experimental|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
11403176|NCT02014805|Experimental|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
11403177|NCT02014805|No Intervention|observation|no treatment after radical resection for thymoma
11403178|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
11403179|NCT02014779|Experimental|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
11403180|NCT02014779|Active Comparator|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
11403181|NCT02014766|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
11403182|NCT02014766|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
11403183|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
11403184|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
11403185|NCT02014740|Experimental|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
11403186|NCT02014740|Active Comparator|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
11403187|NCT02014727|Experimental|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
11403188|NCT02014727|Experimental|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE
~AMA1-DiCo: 50µg
~GLA-SE 2.5 µg GLA per dose
~Route : Intramuscular Vaccination schedule : Do, W4, W26"
11403189|NCT02014727|Experimental|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE
~AMA1-DiCo: 50µg
~GLA-SE 2.5 µg GLA per dose
~Route : Intramuscular Vaccination schedule : Do, W4, W26"
11403190|NCT02014727|Placebo Comparator|Placebo|"Group B2 (18) : African volunteer : Placebo
~Placebo : isotonic saline solution
~Route : Intramuscular Vaccination schedule : Do, W4, W26"
11403191|NCT02014714|Active Comparator|Morphine|Intrathecal Morphine 0.1mg
11403192|NCT02014714|Active Comparator|Fentanyl|Intrathecal Fentanyl 40mcg
11403223|NCT02014558|Experimental|Gilteritinib 80 mg in Expansion Phase|Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
11403193|NCT02014701|Other|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
11403194|NCT02014688||American Indian or Alaskan Native Descent|
11403195|NCT02014688||Black or African American Descent|
11403196|NCT02014688||Asian Descent|
11403197|NCT02014688||Hispanic Descent|
11403198|NCT02014675||SD01 ICD lead|
11403199|NCT02014662|Other|Arm 1|Healthy subjects aged 18 to 35 years
11403200|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
11403201|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
11403202|NCT02014636|Experimental|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
11403203|NCT02014636|Experimental|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:
~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
11403204|NCT02014623|Active Comparator|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
11403205|NCT02014623|Other|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
11403206|NCT02014597|Experimental|Normal - No glaucoma|HOCD
11403207|NCT02014597|Experimental|Glaucoma|HOCD
11403208|NCT02014584|Experimental|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
11403209|NCT02014584|Placebo Comparator|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
11403210|NCT02014571|Experimental|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a [GT1a] and 2 HCV genotype 1b [GT1b]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
11403211|NCT02014571|Experimental|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
11403212|NCT02014571|Experimental|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
11403213|NCT02014571|Experimental|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
11403214|NCT02014558|Experimental|Gilteritinib 20 mg in Escalation Phase|Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403215|NCT02014558|Experimental|Gilteritinib 40 mg in Escalation Phase|Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403216|NCT02014558|Experimental|Gilteritinib 80 mg in Escalation Phase|Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403217|NCT02014558|Experimental|Gilteritinib 120 mg in Escalation Phase|Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403218|NCT02014558|Experimental|Gilteritinib 200 mg in Escalation Phase|Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403219|NCT02014558|Experimental|Gilteritinib 300 mg in Escalation Phase|Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403220|NCT02014558|Experimental|Gilteritinib 450 mg in Escalation Phase|Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
11403221|NCT02014558|Experimental|Gilteritinib 20 mg in Expansion Phase|Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
11403222|NCT02014558|Experimental|Gilteritinib 40 mg in Expansion Phase|Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
11403259|NCT02014363|No Intervention|Lead-in phase|"Citalopram tablets:
~Standard dosing regime"
11403260|NCT02014350||DePuy Delta Xtend RTSA|
11403224|NCT02014558|Experimental|Gilteritinib 120 mg in Expansion Phase|Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
11403225|NCT02014558|Experimental|Gilteritinib 200 mg in Expansion Phase|Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
11403226|NCT02014558|Experimental|Gilteritinib 300 mg in Expansion Phase|Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
11403227|NCT02014545|Active Comparator|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
11403228|NCT02014545|Placebo Comparator|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
11403229|NCT02014532|Active Comparator|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
11403230|NCT02014532|Placebo Comparator|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
11403231|NCT02014519|Other|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
11403232|NCT02014506|Experimental|HAPLO|
11403233|NCT02014493|Active Comparator|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
11403234|NCT02014493|Active Comparator|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
11403235|NCT02014480|Experimental|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
11403236|NCT02014480|Experimental|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
11403237|NCT02014480|Experimental|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
11403238|NCT02014467|Experimental|Denosumab 60mg|injection
11403239|NCT02014467|Placebo Comparator|Placebo|injection
11403240|NCT02014454|Experimental|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.
~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
11403241|NCT02014441|Experimental|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.
~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
11403242|NCT02014428|Experimental|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
11403243|NCT02014428|Placebo Comparator|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
11403244|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
11403245|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
11403246|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
11403247|NCT02014402|Experimental|IG1202-A (Vascular)|
11403248|NCT02014402|Experimental|IG1202-B (Hepatic)|
11403249|NCT02014402|Experimental|IG1202-C (Soft Tissue)|
11403250|NCT02014402|Experimental|IG1202-D (Spinal)|
11403251|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
11403252|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
11403253|NCT02014376|Experimental|SD-101 Dermal Cream (6%)|SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
11403254|NCT02014376|Experimental|SD-101 Dermal Cream (3%)|SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
11403255|NCT02014376|Placebo Comparator|Vehicle (0%)|Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
11403256|NCT02014363|Experimental|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
11403257|NCT02014363|Experimental|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
11403258|NCT02014363|Active Comparator|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
11403261|NCT02014337|Experimental|Mifepristone and Eribulin in combination|Single Arm
11403262|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
11403263|NCT02014311|Experimental|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with >50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
11403264|NCT02014311|Active Comparator|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis >50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
11403265|NCT02014298|Other|Control|One area assessed as a control area, compared to the laser-treated area
11403266|NCT02014298|Active Comparator|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
11403267|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
11403268|NCT02014272|Experimental|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
11403269|NCT02014272|Active Comparator|Reference|Individual references of rifampicin and isoniazid
11403270|NCT02014259|Experimental|Subjects with renal impairment|
11403271|NCT02014259|Active Comparator|Subjects with normal renal function|
11403272|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
11403273|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
11403274|NCT02014233|Experimental|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
11403275|NCT02014233|Placebo Comparator|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
11403276|NCT02014220|Experimental|Atlantic Western chips|deep fried potato chips
11403277|NCT02014220|Experimental|Dakota Pearl chips|deep fried potato chips
11403278|NCT02014220|Experimental|Andover Ontario chips|deep fried potato chips
11403279|NCT02014220|Experimental|white bread with margarine|energy control
11403280|NCT02014220|Experimental|white bread|control
11403281|NCT02014207|Experimental|golden crinkle|
11403282|NCT02014207|Experimental|high blanch|
11403283|NCT02014207|Experimental|low blanche|
11403284|NCT02014207|Experimental|high chill|
11403285|NCT02014207|Experimental|low chill|
11403286|NCT02014194|Placebo Comparator|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
11403287|NCT02014194|Active Comparator|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
11403288|NCT02014181|Experimental|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
11403289|NCT02014168|Experimental|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
11403290|NCT02014168|Placebo Comparator|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
11403291|NCT02014155|Experimental|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
11403292|NCT02014155|Experimental|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
11403293|NCT02014155|Experimental|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
11403294|NCT02014155|Experimental|COPD group not rehabilitation|
11403295|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
11403296|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
11403297|NCT02014129|Experimental|Cohort 1 - 100 mg Abemaciclib|100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
11403298|NCT02014129|Experimental|Cohort 2 - 150 mg Abemaciclib|150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
11403299|NCT02014129|Experimental|Cohort 3 - 200 mg Abemaciclib|200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
11403300|NCT02014116|Experimental|Cohort 1 Dose Escalation|LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11403301|NCT02014116|Experimental|Cohort 2 Dose Escalation|LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11403302|NCT02014116|Experimental|Cohort 3 Dose Escalation|LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11403303|NCT02014116|Experimental|Cohort 4 Dose Escalation|LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
11403304|NCT02014116|Experimental|Cohort 5 Dose Escalation|LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
11403305|NCT02014116|Experimental|Cohort 6 Dose Escalation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
11403306|NCT02014116|Experimental|Cohort A Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11403307|NCT02014116|Experimental|Cohort B Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11403308|NCT02014116|Experimental|Cohort C Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
11403309|NCT02014103|Other|Sequence 1|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
11403310|NCT02014103|Other|Sequence 2|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
11403311|NCT02014103|Other|Sequence 3|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
11403312|NCT02014090|Active Comparator|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
11403313|NCT02014090|Active Comparator|ECP|90 minutes of ECP
11403314|NCT02014077|Active Comparator|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
11403315|NCT02014077|Active Comparator|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
11403316|NCT02014064|Experimental|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety & efficacy of Atomoxetine
11403317|NCT02014064|Placebo Comparator|Placebo|"Control Group Schedule:
~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
11403318|NCT02014051|Experimental|SyB C-1101|
11403319|NCT02014025|Experimental|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
11403320|NCT02014025|Experimental|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
11403321|NCT02013999|Experimental|Virtual reality program|mobile device for virtual reality program
11403322|NCT02013999|Active Comparator|Control|standard occupuational therapy
11403323|NCT02013986|Experimental|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
11403324|NCT02013986|Active Comparator|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
11403325|NCT02013973|Experimental|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
11403326|NCT02013973|No Intervention|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
11403327|NCT02013960|Experimental|Laminaria|cytotec and laminaria
11403328|NCT02013960|Active Comparator|Cytotec|Cytotec only
11403329|NCT02013947|Other|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
11403330|NCT02013947|Other|low altitude group|2 weeks of exercise at 400 meters sea level
11403331|NCT02013934|Active Comparator|Probiotics|Dietary supplement
11403332|NCT02013934|Placebo Comparator|Placebo|Dietary supplement
11403333|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
11403334|NCT02013908|Active Comparator|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
11403402|NCT02013427|No Intervention|Observational|Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
11403406|NCT02013388|Experimental|10 mg|single oral daily dose of 10 mg N91115 for 14 days
11403335|NCT02013908|Experimental|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
11403336|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
11403337|NCT02013869|Experimental|Flow-I|Wash in of desflurane in an anaesthesia machine without below
11403338|NCT02013869|Active Comparator|Asys|Wash in of desflurane in conventional anaesthesia machine Asys
11403339|NCT02013856|Experimental|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
11403340|NCT02013856|Experimental|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
11403341|NCT02013856|Experimental|High Procyanidin|High procyanidin only
11403342|NCT02013856|Placebo Comparator|Placebo|No epicatechin and procyanidin
11403343|NCT02013843|Other|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
11403344|NCT02013830|Experimental|Avastin + Xeloda|
11403345|NCT02013817|Experimental|MabThera/Rituxan|
11403346|NCT02013804|Experimental|Dose arms|Dose Escalation
11403347|NCT02013791|Other|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
11403348|NCT02013791|Experimental|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
11403349|NCT02013791|Experimental|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
11403350|NCT02013791|Experimental|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
11403351|NCT02013791|Experimental|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
11403352|NCT02013791|Experimental|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
11403353|NCT02013791|Experimental|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
11403354|NCT02013791|Experimental|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
11403355|NCT02013791|Experimental|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
11403356|NCT02013778|Experimental|TACE + HCQ|Subjects will receive HCQ plus standard of care TACE.
11403357|NCT02013765|Experimental|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
11403358|NCT02013752|Active Comparator|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
11403359|NCT02013752|Other|Standard care|Standard care at delivery: Manual support of the perineum
11403360|NCT02013739||Patients with chronic heart failure|other
11403361|NCT02013739||Healthy volontiers|other
11403362|NCT02013726|Experimental|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
11403363|NCT02013713||Family Hypercholesterolemia in cardiology|
11403364|NCT02013700|Experimental|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
11403365|NCT02013700|Placebo Comparator|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
11403366|NCT02013700|Experimental|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
11403367|NCT02013700|Experimental|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
11403368|NCT02013687|Experimental|2 µg + Alhydrogel|vaccine
11403369|NCT02013687|Experimental|10 µg + Alhydrogel|vaccine
11403370|NCT02013687|Experimental|30 µg + Alhydrogel|vaccine
11403371|NCT02013687|Experimental|100 µg + Alhydrogel|vaccine
11403372|NCT02013674|Experimental|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
11403373|NCT02013674|Experimental|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
11403374|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
11403403|NCT02013427|Active Comparator|Naproxen & Omeprazole|Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
11403404|NCT02013427|Placebo Comparator|Placebo Only|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
11403375|NCT02013648|Active Comparator|Standard arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day administered on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7.
~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.
~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.
~Follow-up period: There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
11403376|NCT02013648|Experimental|Investigational arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-7. Patients will receive dasatinib 100 mg QD on days 8-21. Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.
~Consolidation therapy (4 cycles). Treatment consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 iv over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21. Maintenance therapy: Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
11403377|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
11403378|NCT02013622|Experimental|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
11403379|NCT02013609|Experimental|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
11403380|NCT02013596|No Intervention|Control|Patients were given no TEAS
11403381|NCT02013596|Experimental|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
11403382|NCT02013596|Experimental|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
11403383|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
11403384|NCT02013570|Active Comparator|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
11403385|NCT02013570|Placebo Comparator|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
11403386|NCT02013557|Experimental|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
11403387|NCT02013557|No Intervention|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
11403388|NCT02013544|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
11403389|NCT02013544|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
11403390|NCT02013531|Experimental|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
11403391|NCT02013518|Experimental|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
11403392|NCT02013518|Other|Control group|Treatment as usual at the participating memory clinics
11403393|NCT02013505|No Intervention|Instructions printed on a paper.|There will be no intervention.
11403394|NCT02013505|Experimental|Paper and video instructions|.Instructions printed on paper and a educational video.
11403395|NCT02013492|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
11403396|NCT02013479|Experimental|SelenoPRECISE|SelenoPRECISE
11403397|NCT02013479|Placebo Comparator|Placebo|Placebo
11403398|NCT02013466|Other|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
11403399|NCT02013453|Active Comparator|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
11403400|NCT02013453|Active Comparator|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
11403401|NCT02013453|Experimental|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
11403405|NCT02013414|Experimental|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
11403407|NCT02013388|Placebo Comparator|Placebo|single oral daily dose of placebo for 14 days
11403408|NCT02013388|Experimental|50 mg|single oral daily dose of 50 mg N91115 for 14 days
11403409|NCT02013388|Experimental|50 mg (single dose)|single oral dose of 50 mg N91115
11403410|NCT02013388|Experimental|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
11403411|NCT02013388|Experimental|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
11403412|NCT02013388|Experimental|500 mg|single oral daily dose of 500 mg N91115 for 14 days
11403413|NCT02013388|Placebo Comparator|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
11403414|NCT02013375|Experimental|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
11403415|NCT02013362|Experimental|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
11403416|NCT02013349|Other|DESyne Novolimus Eluting CSS|approved device continued access
11403417|NCT02013336|Experimental|MM-398 + cyclophosphamide|
11403418|NCT02013323|Active Comparator|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
11403419|NCT02013323|Placebo Comparator|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
11403420|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
11403421|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
11403422|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
11403423|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
11403424|NCT02013258|Active Comparator|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
11403425|NCT02013258|Placebo Comparator|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
11403426|NCT02013245|Experimental|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
11403427|NCT02013245|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
11403428|NCT02013245|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
11403429|NCT02013245|Active Comparator|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
11403430|NCT02013232|Placebo Comparator|placebo|risperidone plus placebo
11403431|NCT02013232|Experimental|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
11403432|NCT02013232|Experimental|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
11403433|NCT02013232|Experimental|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
11403434|NCT02013219|Experimental|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
11403435|NCT02013219|Experimental|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
11403436|NCT02013219|Experimental|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
11403437|NCT02013219|Experimental|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
11403438|NCT02013206|Experimental|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity.
11403439|NCT02013206|Experimental|Current/Former Smokers|Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
11403440|NCT02013193|Experimental|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
11403441|NCT02013193|Active Comparator|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
11403442|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
11403443|NCT02013180||control|benign prostatic diseases in pathologic evaluation
11403444|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.
~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.
~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
11403445|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.
~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
11403446|NCT02013154|Experimental|Part A: DKN-01 (Dose Escalation)|Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22
11403447|NCT02013154|Experimental|Part B: DKN-01 (Dose Confirmation)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
11403448|NCT02013154|Experimental|Part C: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
11403449|NCT02013154|Experimental|Part D: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
11403450|NCT02013154|Experimental|DKN-01 Monotherapy Substudy|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15
11403451|NCT02013154|Experimental|Part E: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
11403452|NCT02013154|Experimental|Part F DKN-01 (Dose Escalation+Expansion)|Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle
11403453|NCT02013141|Experimental|Telavancin|Telavancin 10 mg/kg IV administered over one hour one time.
11403454|NCT02013128|Experimental|Ublituximab + ibrutinib|Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose
11403455|NCT02013115|No Intervention|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
11403456|NCT02013115|Experimental|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
11403457|NCT02013102|Experimental|Arm Ⅰ|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks.
11403458|NCT02013102|Experimental|Arm Ⅱ|Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
11403459|NCT02013089|Experimental|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
11403460|NCT02013089|Experimental|Everolimus|Everolimus 10 mg orally once daily every day
11403461|NCT02013089|Experimental|Imatinib|Imatinib 400 mg tablet orally per day
11403462|NCT02013089|Experimental|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
11403463|NCT02013089|Experimental|Vandetanib|Vandetanib 300 mg orally once daily
11403464|NCT02013089|No Intervention|Control|No intervention was performed for patients without any gene alternation or without any available target agents
11403465|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:
~Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)
~2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
11403466|NCT02013050|Placebo Comparator|Placebo|Control
11403467|NCT02013050|Experimental|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
11403468|NCT02013037|Experimental|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
11403469|NCT02013037|No Intervention|Historical Cohort|A historical cohort of heart transplant recipients at Cedars-Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, who have not received Eculizumab intervention.
11403470|NCT02013024|Active Comparator|cryopreservation technique|slow freezing cryopreservation technique
11403471|NCT02013024|Active Comparator|vitrification cryopreservation technique|vitrification cryopreservation technique
11403472|NCT02013011|Active Comparator|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
11403473|NCT02013011|Active Comparator|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
11403474|NCT02012998|Experimental|HBVAXPRO Challenge dose|HBVAXPRO 5µg
11403475|NCT02012985|Experimental|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
11403476|NCT02012985|Placebo Comparator|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
11403477|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
11403478|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
11403517|NCT02012686|Placebo Comparator|Control group|numerical rating scale of TENS non-applied group
11403518|NCT02012686|Active Comparator|TENS group|numerical rating scale of TENS applied group
11403519|NCT02012673|Experimental|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
11403520|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
11403479|NCT02012959|Experimental|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.
~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter [mmol/L]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.
~Discontinued tolvaptan treatment immediately after randomization.
~All participants were observed up to 14 days post randomization."
11403480|NCT02012959|Experimental|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.
~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.
~Continued treatment for 2 additional days.
~All participants were observed up to 14 days post randomization."
11403481|NCT02012946|Active Comparator|dobutamine|patient receiving dobutamine
11403482|NCT02012946|Active Comparator|Levosimendan|patient receiving levosimendan
11403483|NCT02012920|Experimental|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
11403484|NCT02012920|Experimental|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
11403485|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
11403486|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
11403487|NCT02012881|Experimental|Physical activity intervention|60 minutes of physical activity on every school day
11403488|NCT02012881|Active Comparator|Control|Usual practice
11403489|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
11403490|NCT02012855|Experimental|Exercise only|90 minutes of exercise
11403491|NCT02012855|Experimental|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
11403492|NCT02012855|Experimental|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
11403493|NCT02012855|No Intervention|No exercise and no meal|No exercise and no meal
11403494|NCT02012842|Active Comparator|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
11403495|NCT02012842|Other|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
11403496|NCT02012829|No Intervention|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
11403497|NCT02012829|Active Comparator|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
11403498|NCT02012816|Other|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
11403499|NCT02012803|Experimental|Operative treatment|
11403500|NCT02012803|Active Comparator|conservative treatment|
11403501|NCT02012790|Experimental|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
11403502|NCT02012790|Experimental|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
11403503|NCT02012790|Active Comparator|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
11403504|NCT02012777|Active Comparator|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.
~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
11403505|NCT02012777|Active Comparator|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
11403506|NCT02012777|Active Comparator|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
11403507|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
11403508|NCT02012751|Experimental|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
11403509|NCT02012738|Active Comparator|Assignment to FORNET|17 participants were randomly assigned to FORNET
11403510|NCT02012738|Active Comparator|Assignment to CBT|14 participants were randomly assigned to CBT
11403511|NCT02012738|Other|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
11403512|NCT02012738|Other|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
11403513|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
11403514|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
11403515|NCT02012712|Experimental|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
11403516|NCT02012712|No Intervention|Usual care|Subjects received usual care (no invitation or access to the study PHR)
11403633|NCT02011932||Healthy volunteers|
11403521|NCT02012647|Active Comparator|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
11403522|NCT02012647|Placebo Comparator|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
11403523|NCT02012608|Active Comparator|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
11403524|NCT02012608|Placebo Comparator|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
11403525|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
11403526|NCT02012595||Healthy Controls|Healthy participants
11403527|NCT02012582|Experimental|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
11403528|NCT02012582|Experimental|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
11403529|NCT02012582|Experimental|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
11403530|NCT02012582|Placebo Comparator|Saline|0.9 % Sodium chloride infusion
11403531|NCT02012569|Experimental|TT.173|It is applied directly to the bleeding of the donor site
11403532|NCT02012569|Placebo Comparator|placebo|It is applied directly to the bleeding of the donor site
11403533|NCT02012556|Experimental|Tesamorelin|
11403534|NCT02012543|Experimental|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
11403535|NCT02012530|Active Comparator|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
11403536|NCT02012530|Active Comparator|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
11403537|NCT02012517|Active Comparator|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
11403538|NCT02012517|Experimental|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
11403539|NCT02012504||Western medicine|venlafaxine or escitalopram
11403540|NCT02012504||Chinese medcine|Shuganjieyu capsule
11403541|NCT02012491|Active Comparator|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
11403542|NCT02012491|Active Comparator|misoprostol|800 micrograms of vaginal misoprostol alone
11403543|NCT02012478|No Intervention|No intervention|baseline session - with surveys and HbA1C only
11403544|NCT02012478|Experimental|MI-informed SMS intervention|Baseline session with surveys & HbA1C MI baseline session Technology tutorial Intervention x 3 months
11403545|NCT02012465|Experimental|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):
~Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))
~Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.
~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
11403546|NCT02012452|Experimental|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
11403547|NCT02012452|Sham Comparator|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
11403548|NCT02012439|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
11403549|NCT02012439|Active Comparator|Cognitive therapy|Cognitive Therapy
11403550|NCT02012426|Experimental|Intervention Group|Participants enrolled in commercial weight management program
11403551|NCT02012426|Active Comparator|Control group|Participants enrolled in standard care weight management provision
11403552|NCT02012413|Active Comparator|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
11403553|NCT02012413|Placebo Comparator|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
11403554|NCT02012400|Experimental|Intervention group|
11403555|NCT02012400|No Intervention|Control group|
11403556|NCT02012387|Active Comparator|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
11403557|NCT02012387|Placebo Comparator|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
11403558|NCT02012387|Active Comparator|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
11403559|NCT02012374|Experimental|"Intensive Language Action Therapy (constrained)"|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. Spoken responses are explicitly modeled and encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
11403560|NCT02012374|Experimental|Unconstrained Intensive Language Action Therapy|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. All communicative responses are encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
11403561|NCT02012361|Active Comparator|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
11403562|NCT02012361|Active Comparator|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
11403563|NCT02012348|Placebo Comparator|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
11403564|NCT02012348|Experimental|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
11403565|NCT02012348|Active Comparator|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
11403566|NCT02012335|Placebo Comparator|ECT + saline|Brief pulse ECT with saline as placebo in each session
11403567|NCT02012335|Experimental|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
11403568|NCT02012322|Other|Placebo vs. Q10 100mg vs. Q10 300mg|
11403569|NCT02012322|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
11403570|NCT02012322|Other|Q10 100mg vs. Placebo vs. Q10 300mg|
11403571|NCT02012322|Other|Q10 100mg vs. Q10 300mg vs. Placebo|
11403572|NCT02012322|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
11403573|NCT02012322|Other|Q10 300mg vs. Q10 100mg vs. Placebo|
11403574|NCT02012309|Experimental|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
11403575|NCT02012309|Experimental|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
11403576|NCT02012296|Active Comparator|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
11403577|NCT02012296|Experimental|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
11403578|NCT02012283|Experimental|Vegetable Intake with Spices Added|Subjects consuming vegetables with mixed-spices added.
11403579|NCT02012283|Active Comparator|Vegetable Intake without Spices Added|Subjects consuming vegetables without spice.
11403580|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
11403581|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
11403582|NCT02012257|Experimental|Anterior Site|AMSA nerve block injection
11403583|NCT02012257|Experimental|Common Site|AMSA nerve block injection
11403584|NCT02012257|Experimental|Posterior Site|AMSA nerve block injection
11403585|NCT02012244|Experimental|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
11403586|NCT02012244|Experimental|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
11403587|NCT02012231|Experimental|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
11403588|NCT02012218|Experimental|ADT and Brexpiprazole|ADT and Brexpiprazole
11403589|NCT02012205|Experimental|wet cupping|patient will receive wet cupping
11403590|NCT02012205|No Intervention|control|not cupping
11403591|NCT02012192|Experimental|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
11403592|NCT02012192|Active Comparator|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
11403593|NCT02012179|Experimental|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
11403594|NCT02012179|No Intervention|Usual Care|General advice to limit dietary sodium as it is provided during routine clinic practice
11403595|NCT02012166|Experimental|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403596|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403597|NCT02012166|Experimental|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403634|NCT02011932||Chronic hepatitis C|
11403598|NCT02012166|Experimental|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403599|NCT02012166|Experimental|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403600|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403601|NCT02012166|Experimental|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
11403602|NCT02012153|Experimental|Mesenchymal Stromal Cells|"A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.
~2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
11403603|NCT02012140|Experimental|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
11403604|NCT02012127||Acromegalic patients|
11403605|NCT02012114|No Intervention|Cysteamine Bitartrate|Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
11403606|NCT02012101|Experimental|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
11403607|NCT02012101|Active Comparator|oxygen therapy|oxygen therapy is given during the whole experimental process
11403608|NCT02012088|Experimental|RCOMP|"R-COMP Regimen:
~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
11403609|NCT02012088|Active Comparator|RCHOP|"R-CHOP Regimen:
~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
11403610|NCT02012075|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
11403611|NCT02012075|Active Comparator|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
11403612|NCT02012062|Active Comparator|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
11403613|NCT02012062|Experimental|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
11403614|NCT02012049|Experimental|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
11403615|NCT02012049|Experimental|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
11403616|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
11403617|NCT02012023|Experimental|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
11403618|NCT02012023|Active Comparator|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
11403619|NCT02012010|Experimental|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
11403620|NCT02012010|Active Comparator|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
11403621|NCT02011997|Experimental|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
11403622|NCT02011997|Active Comparator|Lobectomy|Patients undergo cVATS lobectomy
11403623|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
11403624|NCT02011971|Active Comparator|Low dose|Vinpocetine 10 mg Healthy subjects
11403625|NCT02011971|Active Comparator|Mid-dose 1|Vinpocetine 20mg Healthy subjects
11403626|NCT02011971|Placebo Comparator|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
11403627|NCT02011971|Active Comparator|High Dose|Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
11403628|NCT02011958|Experimental|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11
~Miltefosine: orally taken every day during 28 days
~1 x 50 mg capsule per day if patient weights less or equal to 25 kg
~2 x 50 mg capsules per day if the patient weights more than 25 kg"
11403629|NCT02011958|Experimental|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
11403630|NCT02011945|Experimental|dasatinib Only|dasatinib 100 mg QD(CP) or 140 mg QD (AP)
11403631|NCT02011945|Experimental|Dose Level 1|Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
11403632|NCT02011945|Experimental|Dose Level 2|Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
11403636|NCT02011906|Active Comparator|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
11403637|NCT02011906|Active Comparator|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
11403638|NCT02011906|Placebo Comparator|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
11403639|NCT02011893|Experimental|Burst Stimulation|Burst Stimulation using the Prodigy system
11403640|NCT02011893|Active Comparator|Tonic Stimulation|Tonic Stimulation using the Prodigy system
11403641|NCT02011867|Experimental|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
11403642|NCT02011854|Experimental|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
11403643|NCT02011854|Other|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
11403644|NCT02011841|Experimental|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
11403645|NCT02011841|Active Comparator|Control group|Ciprofloxacin 500 mg/day orally for 6 months
11403646|NCT02011828|Experimental|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
11403647|NCT02011828|Experimental|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
11403648|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
11403649|NCT02011802|Active Comparator|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
11403650|NCT02011802|Experimental|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
11403651|NCT02011789|Experimental|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
11403652|NCT02011789|Active Comparator|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
11403653|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
11403654|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
11403655|NCT02011763|Experimental|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
11403656|NCT02011750|Experimental|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
11403657|NCT02011750|Placebo Comparator|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
11403658|NCT02011737|Active Comparator|Naftopidil|Naftopidil 75mg once daily
11403659|NCT02011737|Placebo Comparator|Placebo|Placebo once daily
11403660|NCT02011724|Experimental|Apligraf|
11403661|NCT02011711||Mirena|Women interested in beginning use of Mirena
11403662|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
11403663|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
11403664|NCT02011698|Experimental|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
11403665|NCT02011698|Active Comparator|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
11403666|NCT02011698|Experimental|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
11403667|NCT02011685|Active Comparator|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
11403668|NCT02011685|Experimental|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
11403669|NCT02011672|Experimental|nutrient-enriched milk|consumption of 250 ml three times per day
11403670|NCT02011672|Placebo Comparator|regular milk|consumption of 250 ml three times per day
11403671|NCT02011659|Active Comparator|Ramosetron|
11403672|NCT02011646|Experimental|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
11403673|NCT02011646|Active Comparator|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
11403674|NCT02011633|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11403675|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11403676|NCT02011633|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11403677|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11403678|NCT02011620|Active Comparator|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
11403679|NCT02011620|No Intervention|Standard care|Standard care - no intervention with nitrates
11403680|NCT02011594|Experimental|Arm A|Nimotuzumab
11403681|NCT02011594|Placebo Comparator|Arm B|Placebo (normal saline)
11403682|NCT02011568|Other|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
11403683|NCT02011568|Active Comparator|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
11403684|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
11403685|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
11403686|NCT02011529|Active Comparator|TEAMcare treatment of diabetes|
11403687|NCT02011529|No Intervention|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
11403688|NCT02011516|Placebo Comparator|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
11403689|NCT02011516|Active Comparator|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
11403690|NCT02011503|Experimental|dHACM|Application of multi-layer compression therapy with application of dHACM.
11403691|NCT02011503|Other|Control|Application of multi-layer compression therapy without application of dHACM.
11403692|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
11403693|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
11403694|NCT02011490|Experimental|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
11403695|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
11403696|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
11403697|NCT02011490|Experimental|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
11403698|NCT02011477|Experimental|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
11403699|NCT02011477|Placebo Comparator|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
11403700|NCT02011477|Active Comparator|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
11403701|NCT02011464|Experimental|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
11403702|NCT02011464|Placebo Comparator|Control|Saline infiltrated into posterior compartment
11403954|NCT02009709|Active Comparator|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
11403703|NCT02011451|Experimental|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
11403704|NCT02011451|Placebo Comparator|Sugar pill|Matched placebo capsules
11403705|NCT02011438|Experimental|UTalk Intervention|Active preventative intervention condition.
11403706|NCT02011438|No Intervention|Control|Education/Support Condition
11403707|NCT02011425|Experimental|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
11403708|NCT02011425|No Intervention|without mandibular advancement appliance|no therapy
11403709|NCT02011412||Intermountain Risk Score known|
11403710|NCT02011412||Intermountain Risk Score Unknown|
11403711|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
11403712|NCT02011373|Experimental|IFABOND|
11403713|NCT02011360|Other|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
11403714|NCT02011360|Other|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
11403715|NCT02011347|Experimental|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
11403716|NCT02011347|Experimental|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
11403717|NCT02011334|Experimental|RoActemra/Actemra|
11403718|NCT02011321|Experimental|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
11403719|NCT02011308|Active Comparator|Green Light Laser|
11403720|NCT02011308|Active Comparator|TURP|Transurethral Resection of the Prostate
11403721|NCT02011295|Other|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
11403722|NCT02011295|Other|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
11403723|NCT02011282|Experimental|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
11403724|NCT02011282|No Intervention|Control|Patients in this arm will receive the usual standard treatment
11403725|NCT02011269|Active Comparator|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
11403726|NCT02011269|Active Comparator|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
11403727|NCT02011269|Placebo Comparator|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
11403728|NCT02011256|Experimental|Implantable loop-recorder|
11403729|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
11403730|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
11403731|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
11403732|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
11403733|NCT02011230|No Intervention|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
11403734|NCT02011230|Experimental|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
11403735|NCT02011217|Experimental|Rye crisp bread A|
11403736|NCT02011217|Experimental|Rye crisp bread B|
11403737|NCT02011217|Experimental|Wheat crisp bread C|
11403738|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)
~Intervention: Electrical Impedance Myography (EIM)."
11403739|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
11403740|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
11403741|NCT02011191|Active Comparator|Biotin|10,000 micrograms biotin daily for 8 weeks
11403742|NCT02011191|Placebo Comparator|Sugar pill|
11403743|NCT02011178|Active Comparator|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
11403744|NCT02011178|Other|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
11403745|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
11403746|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
11403747|NCT02011139|Active Comparator|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
11403748|NCT02011139|Active Comparator|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
11403749|NCT02011126|Experimental|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
11403750|NCT02011113|Experimental|Pomalidomide plus dexamethasone|
11403751|NCT02011100|Experimental|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
11403752|NCT02011100|Placebo Comparator|placebo|3 months placebo intake - taken twice a day (1-0-1)
11403753|NCT02011087|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
11403754|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
11403755|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
11403756|NCT02011022|Experimental|3g group|The dose of MTX is 3 g/m2
11403757|NCT02011022|Experimental|5g group|The dose of MTX is 5g/m2
11403758|NCT02011009|Experimental|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
11403759|NCT02010996|Experimental|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
11403760|NCT02010996|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
11403761|NCT02010983|Experimental|longstanding achalasia|
11403762|NCT02010970|Experimental|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
11403763|NCT02010970|Experimental|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
11403764|NCT02010970|Experimental|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
11403765|NCT02010957|Experimental|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
11403766|NCT02010944|Experimental|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
11403767|NCT02010944|Experimental|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
11403768|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
11403769|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
11403770|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
11403771|NCT02010918|Active Comparator|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
11403772|NCT02010905|Active Comparator|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
11403773|NCT02010905|Placebo Comparator|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
11403774|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
11403775|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
11403776|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
11403777|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
11403778|NCT02010866|Other|Counseling|in-person counseling through RFWP to distressed respondents on the ISP and patients who seek counseling without completing the ISP
11403779|NCT02010853|Experimental|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:
~During the acute phase within 24 hours
~In 72 hours
~In 3 months"
11403780|NCT02010853|Other|control|"each control will receive an evaluation in resting state IRMf during three successive visits:
~During the acute phase within 24 hours
~In 72 hours
~In 3 months"
11403781|NCT02010840|Experimental|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
11403782|NCT02010840|Active Comparator|Mother only|Only the women receives the psychoeducation program.
11403783|NCT02010840|No Intervention|Control group|Receives usual perinatal care services only
11403784|NCT02010827||Patients|Patients
11403785|NCT02010827||healthy controls|healthy controls
11403786|NCT02010814||PCOS|"Women fulfilling at least two of the three Rotterdam criteria for PCOS, including
~Irregular menstrual cycle
~Clinical/biochemical hyperandrogenemia
~Polycystic ovaries"
11403787|NCT02010801|Experimental|IRE for tumor before tumor resection|
11403788|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
11403789|NCT02010775|Active Comparator|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
11403790|NCT02010775|Active Comparator|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
11403791|NCT02010775|Active Comparator|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
11403792|NCT02010775|Active Comparator|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
11403793|NCT02010775|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
11403794|NCT02010762|Active Comparator|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
11403795|NCT02010762|Placebo Comparator|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
11403796|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
11403797|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
11403798|NCT02010736|Experimental|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
11403799|NCT02010723|Active Comparator|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
11403800|NCT02010723|Experimental|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
11403801|NCT02010710|Experimental|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
11403802|NCT02010710|No Intervention|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
11403803|NCT02010697|Experimental|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
11403804|NCT02010697|Experimental|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
11403805|NCT02010697|No Intervention|Usual care|one time mailing with a self-help quit kit
11403806|NCT02010684|No Intervention|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
11403807|NCT02010684|Experimental|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
11403808|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
11403809|NCT02010658|No Intervention|Memory|
11403810|NCT02010658|Experimental|Cognitive Aid|
11403811|NCT02010645|Experimental|Eltrombopag + Decitabine|"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
~Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle."
11403812|NCT02010632|Experimental|Generic clopidogrel product|Apolets® 75 mg tablet
11403813|NCT02010632|Active Comparator|Original clopidogrel product|Plavix® 75mg tablet
11403814|NCT02010619|Experimental|Cognitive behavior therapy|
11403815|NCT02010619|Active Comparator|Supportive therapy|
11403816|NCT02010606|Experimental|Cohort A: Patients with newly diagnosed glioblastoma|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
11403817|NCT02010606|Experimental|Cohort B: Patients with recurrent glioblastoma|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
11403818|NCT02010593|Experimental|Dapivirine vaginal ring|Safety Study of a Virginal Ring Containing Dapivitine in a postmenopausal Femal population
11403819|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a felxible, platinum-catalyzed-cured matrix ring, identical to dapivirine ring-004, containing no active-drug
11403820|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
11403821|NCT02010567|Experimental|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
11403955|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
11403822|NCT02010567|Experimental|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
11403823|NCT02010554|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
11403824|NCT02010554|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
11403825|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
11403826|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
11403827|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
11403828|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
11403829|NCT02010515||Sinus rhythm, first ICD implantation|
11403830|NCT02010502|Active Comparator|Concentrated Beet Root Juice|500ml per day for 6 days
11403831|NCT02010502|Active Comparator|Beet root powder|500ml per day for 6 days
11403832|NCT02010502|Placebo Comparator|Placebo juice|Negligible nitrate
11403833|NCT02010489|No Intervention|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
11403834|NCT02010489|Other|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
11403835|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
11403836|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
11403837|NCT02010463|Other|Exercise Intervention|9-month exercise program involving four exercise education sessions
11403838|NCT02010450|Experimental|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
11403839|NCT02010450|Active Comparator|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
11403840|NCT02010437|Active Comparator|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.
~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.
~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
11403841|NCT02010437|Active Comparator|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
11403842|NCT02010437|Active Comparator|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
11403843|NCT02010424|Experimental|Individual culture|standard IVF protocol: half of the fertilized oocytes of the patient will be cultured individually in drops of 25 µl Cook cleavage medium till day 3 after fertilization and subsequently in drops of 25 µl Cook blastocyst medium till day 5 after fertilization
11403844|NCT02010424|Experimental|WOW|Half of the fertilized oocytes of the patient will be cultured in group in a WOW dish, each in a separate microwell but covered with one drop of 30 µl of Cook cleavage medium till day 3 after fertilization and subsequently all the embryos will be transferred to a new WOW dish (in the exactly the same position) covered with 30 µl of Cook blastocyst medium till day 5 after fertilization
11403845|NCT02010411|Active Comparator|Prolastin|Prolastin 250 mg nebulized BID, 10 days
11403846|NCT02010398|Active Comparator|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
11403847|NCT02010398|Active Comparator|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
11403848|NCT02010398|Experimental|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
11403849|NCT02010398|No Intervention|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
11403850|NCT02010385|Active Comparator|Octreotide|One subcutaneous injection - 1 mL
11403851|NCT02010385|Placebo Comparator|Saline|One subcutaneous injection - 1 mL
11403852|NCT02010372|Experimental|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
11403853|NCT02010372|Experimental|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
11403854|NCT02010372|No Intervention|Control|No intervention will be administered to this group.
11403855|NCT02010359|Experimental|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
11403856|NCT02010359|Placebo Comparator|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
11403857|NCT02010346|Experimental|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
11403858|NCT02010346|No Intervention|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
11403859|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
11403860|NCT02010320|Experimental|Computer dosed|Patients for which the computer model will calculate the individual doses
11403861|NCT02010320|Active Comparator|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
11403862|NCT02010307|Experimental|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
11403863|NCT02010307|Experimental|chronic periodontitis|25 patients with chronic periodontitis blood extraction
11403864|NCT02010307|Experimental|healthy|25 healthy periodontal patients blood extraction
11403865|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
11403866|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
11403867|NCT02010281|Experimental|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
11403868|NCT02010281|Placebo Comparator|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
11403869|NCT02010281|Experimental|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
11403870|NCT02010268|Experimental|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
11403871|NCT02010255|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
11403872|NCT02010255|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
11403873|NCT02010255|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
11403874|NCT02010255|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
11403875|NCT02010255|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
11403876|NCT02010255|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
11403877|NCT02010255|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
11403878|NCT02010255|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
11403879|NCT02010255|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
11403880|NCT02010255|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
11403881|NCT02010255|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
11403882|NCT02010255|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
11403883|NCT02010255|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
11403884|NCT02010255|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
11403885|NCT02010242|Experimental|GKT137831|GKT137831 100 mg capsules twice a day
11403886|NCT02010242|Placebo Comparator|Placebo|Placebo capsule twice a day
11403887|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
11403888|NCT02010216|Experimental|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
11403889|NCT02010203|Experimental|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
11403890|NCT02010203|Experimental|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
11403891|NCT02010203|Experimental|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
11403892|NCT02010203|Placebo Comparator|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
11403893|NCT02010203|Experimental|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
11403894|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
11403895|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
11403896|NCT02010164|Experimental|Old-CoQ10|
11403897|NCT02010164|No Intervention|Old|
11403898|NCT02010164|No Intervention|Young|Young less than 33 years old participants
11403899|NCT02010151|Experimental|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
11403900|NCT02010151|No Intervention|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
11403901|NCT02010138|Active Comparator|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
11403902|NCT02010138|Active Comparator|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
11403903|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.
~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
11403904|NCT02010112|Experimental|Initial Diagnosis Cohort|Subjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy
11403905|NCT02010099|Experimental|PP110 Gel|PP110 Gel
11403906|NCT02010099|Experimental|PP110 medicated wipes|PP110 Medicated wipes
11403907|NCT02010099|Active Comparator|Preparation-H cream|Preparation-H cream
11403908|NCT02010086|Experimental|Individual Cognitive Behavioral Therapy|
11403909|NCT02010086|Active Comparator|Standard Community Treatment|
11403910|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
11403911|NCT02010060|No Intervention|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
11403912|NCT02010060|Experimental|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
11403913|NCT02010060|Experimental|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
11403914|NCT02010047|Experimental|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
11403915|NCT02010034|Other|Compassionate use|This lipid preparation is only being used for compassionate use.
11403916|NCT02010021|No Intervention|No drug treatment|Post-menopausal women with stage I-III breast cancer will have surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.
11403917|NCT02010021|Active Comparator|Letrozole-presurgical|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
11403918|NCT02010008|Experimental|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
11403919|NCT02010008|No Intervention|Comparison|Usual care
11403956|NCT02009670|Experimental|13C inulin|13C inulin combined with an inulin load are administered orally
11403920|NCT02009995|Active Comparator|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
11403921|NCT02009995|Experimental|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.
~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
11403922|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
11403923|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
11403924|NCT02009956|Other|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
11403925|NCT02009943|Experimental|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
11403926|NCT02009943|Active Comparator|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:
~TSAT < 25%
~Serum iron concentration < 150 ug/mL
~Serum ferritin concentration < 1,500 ng/mL"
11403927|NCT02009943|No Intervention|Control|No iron supplementation
11403928|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
11403929|NCT02009891||Control|Control couples who will not use predictive model
11403930|NCT02009891||Predictive model|Couples who will use predictive model
11403931|NCT02009878|Other|tolvaptan 3.75 mg|tolvaptan 3.75 mg
11403932|NCT02009878|Other|tolvaptan 7.5 mg|tolvaptan 7.5 mg
11403933|NCT02009878|Other|tolvaptan 15 mg|tolvaptan 15 mg
11403934|NCT02009865|Experimental|Epanova 2 g/day|Arm 1
11403935|NCT02009865|Placebo Comparator|Olive Oil 2 g/day|Arm 2
11403936|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
11403937|NCT02009839|Experimental|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
11403938|NCT02009839|Placebo Comparator|Computer Games|14 weeks of interactive session with the therapist while playing computer games
11403939|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
11403940|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
11403941|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
11403942|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
11403943|NCT02009787|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
11403944|NCT02009787|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
11403945|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
11403946|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
11403947|NCT02009761|Experimental|BI 655064 subcutaneous|Escalating single dose as subcutaneous injection
11403948|NCT02009748|Active Comparator|Vitamin D supplementation|Colecalciferol 2.800 IU/day
11403949|NCT02009748|Placebo Comparator|Placebo|Vehicle (coconut oil)
11403950|NCT02009735|Experimental|virosensor|virus detection
11403951|NCT02009722|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
11403952|NCT02009722|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
11403953|NCT02009709|Active Comparator|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
11403957|NCT02009670|Placebo Comparator|Placebo|A placebo is administered orally
11403958|NCT02009644|Experimental|Treovance|Subjects who receive the Treovance stent-graft
11403959|NCT02009631|Experimental|Sequence Group A|200 mg Veliparib
11403960|NCT02009631|Experimental|Sequence Group B|400 mg Veliparib
11403961|NCT02009631|Placebo Comparator|Sequence Group C|Placebo
11403962|NCT02009618|Placebo Comparator|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
11403963|NCT02009618|Experimental|Rifaximin|"Irritable bowel syndrome patients
~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
11403964|NCT02009605|Experimental|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
11403965|NCT02009592|Active Comparator|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
11403966|NCT02009592|Active Comparator|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
11403967|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
11403968|NCT02009579|Placebo Comparator|Comparator arm|Placebo
11403969|NCT02009566|Experimental|Abdominal radiographs with microfabricated tags|
11403970|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
11403971|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
11403972|NCT02009540|Placebo Comparator|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
11403973|NCT02009540|Active Comparator|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
11403974|NCT02009527|Experimental|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
11403975|NCT02009527|Placebo Comparator|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
11403976|NCT02009501|Active Comparator|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
11403977|NCT02009501|Active Comparator|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
11403978|NCT02009488|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
11403979|NCT02009488|Placebo Comparator|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
11403980|NCT02009475|Active Comparator|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
11403981|NCT02009475|Experimental|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
11403982|NCT02009462|Experimental|Artefill|Four treatment visits using Artefill dermal filler
11403983|NCT02009449|Experimental|Part A: Dose Escalation Cohort 1|Pegilodecakin (1 ug/kg) - Daily subcutaneous (SC) injections of pegilodecakin for up to 22 months
11403984|NCT02009449|Experimental|Part A: Dose Escalation Cohort 2|Pegilodecakin (2.5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
11403985|NCT02009449|Experimental|Part A: Dose Escalation Cohort 3|Pegilodecakin (5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
11403986|NCT02009449|Experimental|Part A: Dose Escalation Cohort 4|Pegilodecakin (10 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
11403987|NCT02009449|Experimental|Part A: Dose Escalation Cohort 5|Pegilodecakin (20 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
11403988|NCT02009449|Experimental|Part A: Dose Escalation Cohort 6|Pegilodecakin (40 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
11403989|NCT02009449|Experimental|Part A: Dose Expansion Cohort 1|at least 15 RCC participants will be dosed with pegilodecakin for up to 22 months
11403990|NCT02009449|Experimental|Part B: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
11403991|NCT02009449|Experimental|Part B: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
11403992|NCT02009449|Experimental|Part B: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
11403993|NCT02009449|Experimental|Part B: Dose Expansion Cohort|"Daily SC injection with pegilodecakin with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
~Day 1
~Paclitaxel 200/175 mg/m2 IV, or
~Docetaxel 75/65 mg/m2 IV And
~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
~Cisplatin 75mg/m2 IV"
11403994|NCT02009449|Experimental|Part C: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
11403995|NCT02009449|Experimental|Part C: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
11403996|NCT02009449|Experimental|Part C: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
11403997|NCT02009449|Experimental|Part C: Dose Expansion Cohort 1|"Daily SC injection with pegilodecakin with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;
~Day 1
~Oxaliplatin 85 mg/m2 IV over 2 hours
~Leucovorin 200 mg/m2 IV over 2 hours followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours
~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
~5-FU 400 mg/m2 IV bolus and
~5-FU 600 mg/m2/day IV over 22 hours"
11403998|NCT02009449|Experimental|Part D: Dose Escalation Cohort 1|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).
~Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by
~• Gemcitabine 1000 mg/m2 IV."
11403999|NCT02009449|Experimental|Part E: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).
~• Capecitabine 1000 mg/m2 po BID"
11404000|NCT02009449|Experimental|Part F: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)
~• Paclitaxel 80 mg/ m2 IV"
11404001|NCT02009449|Experimental|Part G: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)
~• Pazopanib 800 mg po QD"
11404002|NCT02009449|Experimental|Part H: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
~• Pembrolizumab 2 mg/kg IV over 30 min"
11404003|NCT02009449|Experimental|Part I: Dose Escalation Cohort 1|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).
~• Nivolumab 3 mg/kg IV over 60 min"
11404004|NCT02009449|Experimental|Part H: Dose Escalation Cohort 2|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
~• Pembrolizumab 2 mg/kg IV over 30 min"
11404005|NCT02009449|Experimental|Part H: Dose Escalation Cohort 3|"Pegilodecakin (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
~• Pembrolizumab 2 mg/kg IV over 30 min"
11404006|NCT02009449|Experimental|Part J: Dose Escalation Cohort 1|Pegilodecakin (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
11404007|NCT02009436|Experimental|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
11404008|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
11404009|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
11404010|NCT02009410|Experimental|Creon|
11404011|NCT02009410|Placebo Comparator|Placebo|
11404012|NCT02009397|Experimental|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
11404013|NCT02009384|Experimental|Ipilimumab|IV ipilimumab
11404014|NCT02009371|Experimental|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
11404015|NCT02009371|Placebo Comparator|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
11404016|NCT02009358|Experimental|Mental health promotion group|
11404017|NCT02009332|Experimental|ABI-009|
11404018|NCT02009306|Experimental|PecFent and Epistatus|Medication administered by family / carer for symptoms
11404019|NCT02009306|Active Comparator|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
11404020|NCT02009306|Experimental|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:
~Epistatus administered PRN by family / carer for symptoms"
11404021|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
11404022|NCT02009280|Experimental|Propofol group|Propofol group
11404023|NCT02009280|Active Comparator|Sevoflurane group|Sevoflurane group
11404024|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
11404025|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
11404026|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
11404027|NCT02009254|Experimental|Mashed Potatoes (as produced)|
11404028|NCT02009254|Experimental|Mashed Potatoes (with no added butter during production)|
11404029|NCT02009254|Experimental|glucose control (50 g)|
11404109|NCT02008695|Active Comparator|Youth microfinance only|Youth receive loan
11404110|NCT02008695|Active Comparator|youth and adult micro finance|youth and adult receive loan
11404030|NCT02009241|Active Comparator|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
11404031|NCT02009241|No Intervention|Control|
11404032|NCT02009228|Active Comparator|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
11404033|NCT02009228|Active Comparator|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
11404034|NCT02009215|Experimental|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
11404035|NCT02009215|No Intervention|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
11404036|NCT02009202|Active Comparator|picosulphate|Picosulphate is given orally
11404037|NCT02009202|Active Comparator|polyethylene glycol|Polyethylene glycol is given orally
11404038|NCT02009189|Placebo Comparator|Control|Saline flush
11404039|NCT02009189|Active Comparator|2% Taurolidine lock|Catheter lock with 2% Taurolidine
11404040|NCT02009189|Active Comparator|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
11404041|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
11404042|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
11404043|NCT02009163|Experimental|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
11404044|NCT02009163|Placebo Comparator|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
11404045|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
11404046|NCT02009137|Experimental|EVERA|EVERA- korean ESTES system, apply for 12 weeks
11404047|NCT02009137|Active Comparator|ESTES|ESTES apply for 12 weeks
11404048|NCT02009124|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
11404049|NCT02009124|No Intervention|Control|Stem cell therapy is not done for this group of spinal cord injury patients
11404050|NCT02009111|Experimental|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
11404051|NCT02009111|Other|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
11404052|NCT02009098|Active Comparator|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
11404053|NCT02009098|Active Comparator|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
11404054|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
11404055|NCT02009072|Experimental|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
11404056|NCT02009072|Experimental|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
11404057|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
11404058|NCT02009046|Experimental|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
11404059|NCT02009046|Active Comparator|Control Classroom Curriculum|Participants receive the control classroom curriculum.
11404060|NCT02009046|Experimental|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
11404061|NCT02009046|Active Comparator|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).
11404062|NCT02009033|Experimental|Ringer's lactate|Fluid therapy during operation
11404063|NCT02009007|Experimental|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
11404064|NCT02009007|Experimental|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
11404065|NCT02008994|Experimental|Genomic and Proteomic Profiling|"Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.
~Immunohistochemistry will look for specific markers of disease in your DNA.
~RNA sequencing will be used to help doctors and scientists understand how your genes are working.
~Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
11404066|NCT02008981|Active Comparator|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
11404067|NCT02008981|Active Comparator|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
11404068|NCT02008981|Active Comparator|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
11404069|NCT02008968|Active Comparator|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
11404070|NCT02008968|Active Comparator|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
11404071|NCT02008968|Placebo Comparator|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
11404072|NCT02008955|Experimental|lysine intake at different levels of intake|all subjects will receive all 7 of the lysine test levels, assigned in random order.
11404073|NCT02008942|Experimental|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
11404074|NCT02008942|Active Comparator|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
11404075|NCT02008929|Other|MG4101|Ex vivo expanded allogeneic NK cell
11404076|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
11404077|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
11404078|NCT02008916|Placebo Comparator|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
11404079|NCT02008903||EoE active disease|Inflammation as defined by >15 eos / HPF
11404080|NCT02008903||EoE remission|No inflammation in EoE patients after treatment
11404081|NCT02008903||normal control|No inflammation
11404082|NCT02008890|Experimental|Secukinumab 300mg|"Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.
~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.
~For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148."
11404083|NCT02008890|Experimental|Secukinumab 150mg|"Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.
~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.
~For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148."
11404084|NCT02008890|Placebo Comparator|Placebo|Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
11404085|NCT02008877|Experimental|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
11404086|NCT02008864|Placebo Comparator|Placebo|Wheat
11404087|NCT02008864|Active Comparator|Senna|Senna
11404088|NCT02008851|Experimental|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
11404089|NCT02008838|Active Comparator|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])
11404090|NCT02008838|Placebo Comparator|Placebo|250 mg Maltodexterin
11404091|NCT02008825|Experimental|ViSiGi|Utilization of ViSiGi calibration tube
11404092|NCT02008825|Active Comparator|Usual standard of care|Usual non suction Bougie
11404093|NCT02008812|Experimental|Ad sensor|virus detection
11404094|NCT02008799|Experimental|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
11404095|NCT02008786|Experimental|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
11404096|NCT02008786|Experimental|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
11404097|NCT02008773|Active Comparator|valacyclovir|3000mg daily oral 16 weeks
11404098|NCT02008773|Placebo Comparator|placebo|placebo 6 capsules daily oral 16 weeks
11404099|NCT02008760|Placebo Comparator|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
11404100|NCT02008760|Active Comparator|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
11404101|NCT02008747|Active Comparator|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.
~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
11404102|NCT02008747|No Intervention|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
11404103|NCT02008734|No Intervention|Control|
11404104|NCT02008734|Experimental|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
11404105|NCT02008721|Active Comparator|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
11404106|NCT02008721|Placebo Comparator|Placebo|Placebo
11404107|NCT02008708|Experimental|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
11404108|NCT02008708|Active Comparator|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
11404111|NCT02008695|Active Comparator|adult microfinance|adults receive loan
11404112|NCT02008682|Experimental|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
11404113|NCT02008682|Active Comparator|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
11404114|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions
~Gustatory sensitivity test using Taste strips
~Blood sampling
~Questionnaires"
11404115|NCT02008656|Experimental|INCT|Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.
11404116|NCT02008656|Experimental|CNCT|Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.
11404117|NCT02008643|Experimental|children with food allergy|Chidren aged 8-18 year with food allergy
11404118|NCT02008643|Active Comparator|children with chronic diseases|
11404119|NCT02008643|Active Comparator|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient
~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
11404120|NCT02008630|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
11404121|NCT02008630|Experimental|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
11404122|NCT02008630|No Intervention|Control|Control group with treatment as usual
11404123|NCT02008617|Active Comparator|Study Drug|Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
11404124|NCT02008617|Sham Comparator|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
11404125|NCT02008604||Stroke patients|
11404126|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
11404127|NCT02008591|Active Comparator|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
11404128|NCT02008591|Active Comparator|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
11404129|NCT02008591|Active Comparator|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
11404130|NCT02008578|Experimental|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
11404131|NCT02008578|Placebo Comparator|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
11404132|NCT02008565|Placebo Comparator|Placebo - Exercise plus Biofeedback|"Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
11404133|NCT02008565|Experimental|Loperamide - Exercise plus Biofeedback|"Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
11404134|NCT02008565|Placebo Comparator|Placebo - Education Only|"Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
11404135|NCT02008565|Experimental|Loperamide - Education Only|"Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
11404136|NCT02008552|Other|Mediagene|Sampling blood
11404137|NCT02008539|Experimental|treatment arm|
11404138|NCT02008526|Experimental|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)
~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).
~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.
~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
11404139|NCT02008526|Experimental|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)
~Participants assigned to this group receive automatic text-messages.
~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.
~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
11404140|NCT02008526|No Intervention|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
11404141|NCT02008513|Active Comparator|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
11404142|NCT02008513|Active Comparator|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
11404143|NCT02008500|Placebo Comparator|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
11404144|NCT02008500|Active Comparator|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
11404145|NCT02008500|Sham Comparator|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
11404146|NCT02008487|Other|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
11404147|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 3 months|
11404148|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 3 months|
11404149|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 12 months|
11404150|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 12 months|
11404151|NCT02008461|Active Comparator|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
11404152|NCT02008461|Active Comparator|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.
~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
11404153|NCT02008448|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
11404154|NCT02008448|Active Comparator|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
11404155|NCT02008435|Experimental|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
11404156|NCT02008435|Active Comparator|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
11404157|NCT02008422|Experimental|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
11404158|NCT02008422|Active Comparator|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
11404159|NCT02008409|Experimental|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
11404160|NCT02008396|Placebo Comparator|Inactive Placebo with Psychotherapy|Subjects will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
11404161|NCT02008396|Experimental|75 mg to 125 mg MDMA with Psychotherapy|Participants will receive 75 to 125 mg during two psychotherapy sessions lasting approximately 7 hours; first session dose lower than second session dose.
11404162|NCT02008383|Experimental|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
11404163|NCT02008383|Experimental|Cabozantinib|60 mg Cabozantinib PO daily.
11404164|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
11404165|NCT02008357|Experimental|Solanezumab|"Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks.
~Participants who enter the open-label extension will receive solanezumab IV."
11404166|NCT02008357|Placebo Comparator|Placebo|"Placebo IV every 4 weeks for 240 weeks.
~Participants who enter the open-label extension will receive solanezumab IV."
11404167|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
11404168|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
11404169|NCT02008331|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
11404170|NCT02008331|Placebo Comparator|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
11404171|NCT02008318|Experimental|Phase (ph) 2: Galunisertib + BSC|Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
11404172|NCT02008318|Placebo Comparator|Ph 3: Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
11404173|NCT02008318|Experimental|Ph 3: Galunisertib + BSC|150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
11404920|NCT02003144|Experimental|Eculizumab|Eculizumab intravenous infusion every two weeks.
11404174|NCT02008305|Experimental|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
11404175|NCT02008305|Active Comparator|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
11404176|NCT02008292|Experimental|physostigmine and amphetamine|There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
11404177|NCT02008279|Experimental|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
11404178|NCT02008279|Experimental|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
11404179|NCT02008279|Experimental|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
11404180|NCT02008279|Experimental|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
11404181|NCT02008279|Experimental|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
11404182|NCT02008279|Experimental|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
11404183|NCT02008279|Experimental|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
11404184|NCT02008266||Patients with Rheumatoid Arthritis|
11404185|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
11404186|NCT02008240|Experimental|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
11404187|NCT02008240|Active Comparator|salpingectomy|Surgical removal of hydrosalpinx
11404188|NCT02008227|Experimental|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
11404189|NCT02008227|Active Comparator|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
11404190|NCT02008214|Experimental|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
11404191|NCT02008214|Placebo Comparator|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
11404192|NCT02008201|Experimental|Vitamin D dose 1|Vitamin D dose 1
11404193|NCT02008201|Experimental|Vitamin D dose 2|Vitamin D dose 2
11404194|NCT02008201|Experimental|Vitamin D dose 3|Vitamin D dose 3
11404195|NCT02008201|No Intervention|observational|No dose
11404196|NCT02008175|Experimental|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
11404197|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.
~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
11404198|NCT02008149|No Intervention|Standard of care group|SCI individuals receiving conventional rehab
11404199|NCT02008149|Experimental|FES-rowing group|Individuals with SCI participating in an FES-rowing program
11404200|NCT02008136|Experimental|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
11404201|NCT02008123|Experimental|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
11404202|NCT02008110|Experimental|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
11404203|NCT02008110|Active Comparator|Standard treatment strategy|Therapy is based on established european current guidelines
11404204|NCT02008097|Experimental|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
11404205|NCT02008097|Experimental|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
11404206|NCT02008097|Experimental|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
11404207|NCT02008097|Experimental|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
11404208|NCT02008097|Experimental|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
11404209|NCT02008097|Experimental|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
11404210|NCT02008084|Sham Comparator|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
11404211|NCT02008084|Experimental|TRIA-662|Following successful completion of the Baseline randomized to active drug
11404212|NCT02008084|Placebo Comparator|Placebo|Following successful completion of the Baseline randomized to placebo drug
11404213|NCT02008071|Experimental|Daily step goal financial incentive|
11404214|NCT02008071|Active Comparator|Control, Standard of Care|
11404215|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
11404216|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
11404217|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
11404218|NCT02008032|Experimental|All patients|Stationary Breast Tomosynthesis
11404219|NCT02008019|No Intervention|No treatment|No Everolimus treatment before surgery
11404220|NCT02008019|Experimental|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
11404221|NCT02008019|Experimental|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
11404222|NCT02008006|Experimental|BeEAM|"High Dose Chemotherapy (HDT) containing :
~Bendamustine
~Etoposide
~Cytarabine
~Melphalan
~HDT will be followed by an Autologous Stem Cell Transplantation"
11404223|NCT02007993|Active Comparator|Group 1|Treatment with a tongue scraper
11404224|NCT02007993|Experimental|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
11404225|NCT02007993|Experimental|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
11404226|NCT02007993|Experimental|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
11404227|NCT02007993|Experimental|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
11404228|NCT02007980||Patients with indwelling ureteral stent|Patients with existing indwelling ureteral stent, no additional treatment
11404229|NCT02007954|Experimental|DEBDOX|
11404230|NCT02007941|Experimental|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.
~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
11404231|NCT02007941|Active Comparator|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.
~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
11404232|NCT02007941|Experimental|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
11404233|NCT02007928|Other|rispéridone, aripiprazole, olanzapine...|"Study:
~We propose a prospective, interventional multicenter study.
~Method:
~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.
~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
11404234|NCT02007915|Experimental|Pamidronate Disodium|
11404235|NCT02007902||Very preterm babies|Observational model: cohort
11404236|NCT02007889|Active Comparator|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
11404237|NCT02007889|No Intervention|Control|control group received just antibiotic regimens without L-carnitine
11404238|NCT02007876|Experimental|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.
~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.
~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
11404239|NCT02007876|No Intervention|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.
~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.
~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
11404240|NCT02007863|Experimental|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
11404241|NCT02007850|Placebo Comparator|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
11404242|NCT02007850|Active Comparator|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
11404243|NCT02007837|Experimental|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
11404244|NCT02007837|Placebo Comparator|Placebo|5mg folic acid, cellulose filler
11404245|NCT02007824|Experimental|ULSD-12D|ultrasound surgical device made by Ultech.
11404246|NCT02007824|Active Comparator|SONOCA-180|ultrasound surgical device made by Soering
11404247|NCT02007811|Experimental|allogeneic donor derived B-lymphocytes|
11404248|NCT02007798|Experimental|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
11404249|NCT02007798|Experimental|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
11404250|NCT02007798|Experimental|control group|P group: normal saline is infused intravenously
11404251|NCT02007785|Experimental|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
11404252|NCT02007772|Active Comparator|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
11404253|NCT02007772|Experimental|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
11404254|NCT02007759|Experimental|VitalStim|This group will be assigned to the active VitalStim unit.
11404255|NCT02007759|Sham Comparator|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
11404256|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
11404257|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
11404258|NCT02007733|Other|Single Arm|All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
11404259|NCT02007720|Placebo Comparator|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
11404260|NCT02007720|Experimental|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
11404261|NCT02007707|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
11404262|NCT02007707|Active Comparator|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
11404263|NCT02007694|Active Comparator|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
11404264|NCT02007694|Active Comparator|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
11404265|NCT02007694|Placebo Comparator|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
11404266|NCT02007681|Experimental|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
11404267|NCT02007681|No Intervention|Control|Regular free week with no changes performed
11404268|NCT02007668|Experimental|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
11404269|NCT02007668|Placebo Comparator|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
11404270|NCT02007668|No Intervention|Control|This participants will not receive intervention
11404271|NCT02007655||Eliquis on Nonvalvular Atrial Fibrilliation patients|Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study
11404272|NCT02007642||No study treatment|
11404273|NCT02007629|Experimental|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
11404274|NCT02007616|Experimental|Non-action video game training|20 1-hour sessions of non-action video game training
11404275|NCT02007616|No Intervention|Control|Participants in the control group did not receive non-action video game training
11404276|NCT02007603|Experimental|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
11404277|NCT02007603|Experimental|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
11404278|NCT02007590|Experimental|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
11404279|NCT02007590|Sham Comparator|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
11404280|NCT02007590|No Intervention|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
11404281|NCT02007577|Active Comparator|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
11404282|NCT02007577|Placebo Comparator|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
11404283|NCT02007564|Experimental|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
11404284|NCT02007564|No Intervention|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
11404285|NCT02007551|Experimental|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
11404286|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
11404287|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
11404288|NCT02007525|Experimental|Yoga intervention|
11404289|NCT02007525|No Intervention|Wait list control|
11404290|NCT02007512|Experimental|Enzalutamide & exemestane|Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
11404291|NCT02007512|Active Comparator|Placebo & exemestane|Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.
11404292|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
11404293|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
11404294|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
11404295|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
11404296|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
11404297|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
11404298|NCT02007460|Experimental|Exercise leg|
11404299|NCT02007460|No Intervention|Control leg|
11404300|NCT02007447|Active Comparator|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
11404301|NCT02007447|Placebo Comparator|Placebo|Placebo - twice per day for 8 weeks
11404302|NCT02007434|Experimental|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
11404303|NCT02007434|Placebo Comparator|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
11404304|NCT02007434|Experimental|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
11404305|NCT02007434|Placebo Comparator|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
11404306|NCT02007434|Experimental|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
11404307|NCT02007434|Placebo Comparator|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
11404308|NCT02007434|Experimental|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
11404309|NCT02007434|Placebo Comparator|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
11404336|NCT02007187|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
11404337|NCT02007187|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
11404338|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
11404310|NCT02007421|Other|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.
~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
11404311|NCT02007421|Other|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.
~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
11404312|NCT02007408|Placebo Comparator|Placebo group|
11404313|NCT02007408|Active Comparator|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
11404314|NCT02007408|Active Comparator|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
11404315|NCT02007408|Active Comparator|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
11404316|NCT02007395||colonoscopy population|
11404317|NCT02007369|Experimental|WhatsApp|Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
11404318|NCT02007369|Experimental|Facebook|Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
11404319|NCT02007369|No Intervention|Control|Telephone follow ups and received a self-help book only
11404320|NCT02007356|Experimental|allogeneic HSCT|"The present study will evaluate and validate in a single-center, open-label, single arm fashion the safety and feasibility of direct infusions of donor-derived pathogen-specific IFN-γ positive T-cells in recipients of HSCT with post-transplant viral infection according to the previously clinically certified CCS® [3-6]. The Investigator will first generate and apply IFN-γ positive selected T-cells to recipients of HSCT with CMV, EBV or adenovirus as previously published. The Investigator aim is to include 6 patients from the University Hospital of Basel.
~With confirmed safety the investigator will in the future perform an efficacy study and extend this treat-ment for other clinically relevant pathogens including human herpesvirus (HHV)-6, HHV-8, polyomaviruses JC and BK and fungi including Aspergillus fumigatus and Candida albicans, to other immunosuppressed patients such as solid organ transplant (SOT) recipients."
11404321|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:
~meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);
~a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;
~receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);
~were admitted to the hospital during (part of) the infection episode.
~Date of entry into cohort: date of index culture of infection episode"
11404322|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.
~Date of cohort entry: date of index culture of matched infected patient"
11404323|NCT02007330|Experimental|Group L|Intravenous lidocaine infusion group
11404324|NCT02007330|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
11404325|NCT02007317|Experimental|Oshadi D and Oshadi R|Anti tumor agents
11404326|NCT02007304|Experimental|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
11404327|NCT02007304|Placebo Comparator|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
11404328|NCT02007278|Active Comparator|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
11404329|NCT02007278|Active Comparator|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
11404330|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
11404331|NCT02007252|Experimental|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
11404332|NCT02007252|Placebo Comparator|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
11404333|NCT02007239|Experimental|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
11404334|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury >5 years)
11404335|NCT02007200|Experimental|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
11404339|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
11404340|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
11404341|NCT02007161|Active Comparator|Nutritional State|"Fed vs. Fasted State
~Diclofenac potassium 50 mg"
11404342|NCT02007161|Active Comparator|Use of a PPI|"Nexiam (esomeprazole) 40 mg
~Diclofenac potassium 50 mg"
11404343|NCT02007148|Experimental|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
11404344|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
11404345|NCT02007122|Experimental|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
11404346|NCT02007122|Experimental|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
11404347|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.
~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
11404348|NCT02007096|Experimental|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
11404349|NCT02007096|Placebo Comparator|Non Transabdominal Plane Block|Receiving placebo saline injection
11404350|NCT02007083|Active Comparator|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
11404351|NCT02007083|Active Comparator|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
11404352|NCT02007083|Active Comparator|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
11404353|NCT02007070|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
11404354|NCT02007057|Active Comparator|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
11404355|NCT02007057|Experimental|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
11404356|NCT02007044|Experimental|Arm I (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11404357|NCT02007044|Experimental|Arm II (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm I beginning on day 1 or 2. Patients also receive rituximab IV over 3-8 hours on days 1, 8, 15, and 22 of course 1 and day 1 of courses 2-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11404358|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
11404359|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
11404394|NCT02006771|Experimental|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
11404360|NCT02007018|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
11404361|NCT02007018|Active Comparator|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
11404362|NCT02007005|Experimental|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
11404363|NCT02006992|Active Comparator|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
11404364|NCT02006992|Experimental|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
11404365|NCT02006979|Experimental|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
11404366|NCT02006979|No Intervention|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
11404367|NCT02006966|Experimental|Group L|Intravenous lidocaine infusion group
11404368|NCT02006966|Active Comparator|Group C|Intravenous normal saline infusion - control group
11404369|NCT02006953|Active Comparator|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:
~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
11404370|NCT02006953|Active Comparator|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
11404371|NCT02006940|Experimental|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
11404372|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
11404373|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
11404374|NCT02006914||Placebo|HIV+ and insulin resistant
11404375|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
11404376|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
11404377|NCT02006888|Experimental|IBI-10090 low dose|IBI-10090 low dose
11404378|NCT02006888|Experimental|IBI-10090 med dose|IBI-10090 med dose
11404379|NCT02006888|Placebo Comparator|Placebo|Placebo
11404380|NCT02006875|Experimental|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
11404381|NCT02006875|Sham Comparator|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
11404382|NCT02006862||olanzapine, schizophrenia|
11404383|NCT02006849|Other|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
11404384|NCT02006849|Other|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
11404385|NCT02006836|Other|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
11404386|NCT02006836|Other|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
11404387|NCT02006836|Other|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
11404388|NCT02006836|Other|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
11404389|NCT02006810|Experimental|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
11404390|NCT02006810|Other|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
11404391|NCT02006797|Experimental|intervention|patients with reconciliation procedure at discharge and included in the exchange process
11404392|NCT02006797|No Intervention|control|usual care
11404393|NCT02006771|Experimental|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
11404395|NCT02006771|Experimental|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
11404396|NCT02006771|Experimental|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
11404397|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
11404398|NCT02006745|Other|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
11404399|NCT02006745|Other|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
11404400|NCT02006732|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
11404401|NCT02006732|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
11404402|NCT02006732|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
11404403|NCT02006732|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
11404404|NCT02006719|Experimental|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
11404405|NCT02006719|Placebo Comparator|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
11404406|NCT02006706|Experimental|MabThera/Rituxan|
11404407|NCT02006693|Other|XEN® Gel Stent|The XEN®45 Gel Stent (XEN45 implant) was placed in the study eye as a standalone procedure.
11404408|NCT02006693|Other|XEN® Gel Stent with Cataract Surgery|The XEN® Gel Stent (XEN45 implant) with cataract surgery, occurred if the participant was diagnosed with a cataract.
11404409|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
11404410|NCT02006667|Experimental|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
11404411|NCT02006654|Placebo Comparator|Placebo|Placebo adjunct to base treatment with an AChEI
11404412|NCT02006654|Experimental|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
11404413|NCT02006641|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
11404414|NCT02006641|Experimental|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
11404415|NCT02006641|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
11404416|NCT02006628|Active Comparator|GWP42003 1000 milligrams (mg)/day|Participants received GWP42003 (100 mg/milliliter [mL]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
11404417|NCT02006628|Placebo Comparator|Placebo|Participants received placebo (0 mL cannabidiol [CBD]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
11404418|NCT02006615|Experimental|5Hz rTMS|rTMS group
11404419|NCT02006615|Sham Comparator|Sham rTMS|Sham stimulation
11404420|NCT02006602|Experimental|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
11404421|NCT02006602|Experimental|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
11404422|NCT02006589|Experimental|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
11404423|NCT02006589|Experimental|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
11404424|NCT02006576|Placebo Comparator|COPD, Placebo|Placebo three times daily
11404425|NCT02006576|No Intervention|Control subject|Control subjects, no intervention
11404426|NCT02006576|Experimental|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
11404427|NCT02006537|Experimental|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
11404428|NCT02006537|Experimental|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
11404429|NCT02006524|Active Comparator|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
11404430|NCT02006511|Experimental|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
11404431|NCT02006511|Active Comparator|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
11404432|NCT02006498|Experimental|Sillymarin|Active component study medication
11404433|NCT02006498|Placebo Comparator|Placebo|Placebo capsules
11404434|NCT02006485|Experimental|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
11404435|NCT02006485|Experimental|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
11404436|NCT02006485|Experimental|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 & 2
11404437|NCT02006472|Experimental|Pridopidine 45 mg|Twice daily
11404438|NCT02006472|Experimental|Pridopidine 67.5 mg|Twice daily
11404439|NCT02006472|Experimental|Pridopidine 90 mg|Twice daily
11404440|NCT02006472|Experimental|Pridopidine 112.5 mg|Twice daily
11404441|NCT02006472|Placebo Comparator|Placebo|Twice daily
11404442|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
11404443|NCT02006433|Experimental|Deep Brain Stimulation|"Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).
~Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156."
11404444|NCT02006420||ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
11404445|NCT02006420||Healthy Volunteers: ARFI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
11404446|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
11404447|NCT02006394|Experimental|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
11404448|NCT02006394|Placebo Comparator|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
11404449|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
11404450|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
11404451|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
11404452|NCT02006368|Experimental|Storage Age|
11404453|NCT02006355|Active Comparator|Continuous femoral nerve bloc|Continuous femoral nerve bloc
11404454|NCT02006355|Experimental|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
11404455|NCT02006342|Experimental|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
11404456|NCT02006342|Active Comparator|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
11404457|NCT02006329|Experimental|Intervention group - dietary consultation - Medit|
11404458|NCT02006329|No Intervention|Control group - dietary consultation - Mediterranean diet|
11404459|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
11404460|NCT02006303|Active Comparator|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
11404461|NCT02006303|Active Comparator|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
11404462|NCT02006290|Experimental|1|
11404463|NCT02006290|Placebo Comparator|2|
11404464|NCT02006277|Experimental|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
11404465|NCT02006277|Experimental|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
11404466|NCT02006264|Active Comparator|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
11404498|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
11404540|NCT02005744|Experimental|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
11404467|NCT02006264|Placebo Comparator|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
11404468|NCT02006238|Experimental|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
11404469|NCT02006238|Placebo Comparator|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
11404470|NCT02006225|Experimental|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
11404471|NCT02006212|Other|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
11404472|NCT02006199|Experimental|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
11404473|NCT02006199|Experimental|meditation|8 weeks of mindfulness meditation
11404474|NCT02006186|Experimental|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
11404475|NCT02006186|No Intervention|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
11404476|NCT02006173|Placebo Comparator|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
11404477|NCT02006173|Active Comparator|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
11404478|NCT02006160|Active Comparator|treatment|dalfampridine
11404479|NCT02006160|Placebo Comparator|control|placebo
11404480|NCT02006147|Experimental|TLC399|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
11404481|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
11404482|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA & serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
11404483|NCT02006134||ADULT VASCULITIS/ COHORT 1|Adult patients in this cohort are those at or near the time of diagnosis of GPA, MPA, EGPA or unclassified vasculitis that are participants in DCVAS. Clinical data and blood (RNA, DNA) will be collected at the time-of-diagnosis only.
11404484|NCT02006134||ADULT VASCULITIS / COHORT 2|Adult patients in this cohort are those individuals that are participants in DCVAS and have any form of vasculitis. Clinical data and blood (DNA) collected at the time-of-diagnosis will be used for study.
11404485|NCT02006134||HEALTHY CHILDREN / PEDIATRIC CONTROL|Participants in this cohort are otherwise healthy children with no history of inflammatory disease. Children will provide a one time donation of blood (RNA, serum) and urine.
11404486|NCT02006134||HEALTHY ADULTS / ADULT CONTROL|Participants in this cohort are otherwise healthy adults with no history of inflammatory disease. Adults will provide a one time donation urine and will provide blood (RNA, serum) as many as 4 times.
11404487|NCT02006121|Active Comparator|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
11404488|NCT02006121|Placebo Comparator|Placebo|Placebo: saline infusion
11404489|NCT02006108|Experimental|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg
~Interventions:
~Drug: Feraheme Procedure: MR Scan"
11404490|NCT02006095||Neuroimaging Correlates|
11404491|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 < 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
11404492|NCT02006069|Experimental|MPP ON|MPP ON: feature is enabled
11404493|NCT02006069|No Intervention|MPP OFF|MPP OFF: feature not enabled
11404494|NCT02006056|Experimental|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
11404495|NCT02006056|Experimental|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
11404496|NCT02006043|Experimental|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
11404497|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
11404499|NCT02006017|Experimental|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
11404500|NCT02006017|Experimental|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
11404501|NCT02005991|Experimental|PF-05212377 70 mg|
11404502|NCT02005991|Experimental|PF-05212377 20 mg|
11404503|NCT02005991|Experimental|PF-05212377 10 mg|
11404504|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
11404505|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
11404506|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
11404507|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
11404508|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
11404509|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
11404510|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
11404511|NCT02005939|Experimental|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
11404512|NCT02005939|Placebo Comparator|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
11404513|NCT02005926|Experimental|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness >3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
11404514|NCT02005900|Experimental|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
11404515|NCT02005900|Placebo Comparator|PLACEBO|
11404516|NCT02005887|Experimental|triptorelin + letrozole|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
11404517|NCT02005887|Experimental|degarelix + letrozole|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
11404518|NCT02005874||Dry eye|
11404519|NCT02005874||Non-dry eye|
11404520|NCT02005861|Experimental|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.
~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.
~After that platelet gel will be loaded on the top of implant"
11404521|NCT02005848|Experimental|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
11404522|NCT02005848|Experimental|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
11404523|NCT02005848|Placebo Comparator|Placebo|Placebo
11404524|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic
~Routine standard clinical care based on the MoH guidelines
~Mentor mothers provide education and psychosocial support at facility
~Weekly support groups provided in clinic
~Phone call, SMS, or home visit for each missed appointment"
11404525|NCT02005835|Other|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):
~Routine standard clinical care based on the MoH guidelines
~Mentor mothers provide education and psychosocial support in community prior to each visit
~Monthly support groups in community
~Home visits for each missed appointment"
11404526|NCT02005835|No Intervention|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
11404527|NCT02005822|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
11404528|NCT02005822|No Intervention|Control|"Refusal control group:
~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.
~Historical control group:
~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
11404529|NCT02005809|Active Comparator|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
11404530|NCT02005809|No Intervention|without second look endoscopy|This group is not performed second look endoscopy after ESD
11404531|NCT02005796|Experimental|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
11404532|NCT02005796|Experimental|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
11404533|NCT02005796|Experimental|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
11404534|NCT02005783|Experimental|DBD arm|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally
11404535|NCT02005783|Other|EC/TC|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
11404536|NCT02005770|Experimental|Sevoflurane|General anesthesia using Sevoflurane
11404537|NCT02005770|Active Comparator|Propofol|General anesthesia using propofol TCI
11404538|NCT02005757|Experimental|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
11404539|NCT02005757|Active Comparator|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
11404541|NCT02005744|Experimental|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
11404542|NCT02005744|Experimental|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
11404543|NCT02005744|Experimental|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
11404544|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
11404545|NCT02005718|Experimental|Vitamin D|Cholecalciferol 300,000 twice
11404546|NCT02005705|Active Comparator|Outpatient|
11404547|NCT02005705|Active Comparator|Inpatient|
11404548|NCT02005692|Experimental|DynaSense sensor|
11404549|NCT02005679|Experimental|deaf persons with potential dementia|
11404550|NCT02005666|Experimental|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
11404551|NCT02005666|Active Comparator|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
11404552|NCT02005666|Placebo Comparator|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
11404553|NCT02005653|Experimental|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
11404554|NCT02005653|Experimental|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
11404555|NCT02005653|Experimental|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
11404556|NCT02005653|Active Comparator|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
11404557|NCT02005640||MSCT-based prothesis sizing|
11404558|NCT02005640||Echocardiographic-based prothesis sizing|
11404559|NCT02005627|Active Comparator|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
11404560|NCT02005627|Placebo Comparator|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
11404561|NCT02005614|Experimental|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).
~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.
~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
11404562|NCT02005601|Experimental|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
11404563|NCT02005601|Placebo Comparator|Control|Patients will receive 0mg of duloxetine
11404564|NCT02005588|Active Comparator|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
11404565|NCT02005588|Active Comparator|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
11404566|NCT02005575|Placebo Comparator|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
11404567|NCT02005575|Active Comparator|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
11404568|NCT02005562|Experimental|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours [q12h]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
11404569|NCT02005562|Active Comparator|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
11404570|NCT02005549|Experimental|Neoadjuvant Therapy|
11404571|NCT02005536|Experimental|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
11404574|NCT02005510|Experimental|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
11404575|NCT02005510|Placebo Comparator|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
11404576|NCT02005497|Experimental|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
11404577|NCT02005497|Active Comparator|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
11404578|NCT02005497|No Intervention|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
11404579|NCT02005484|Experimental|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
11404580|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter squared (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
11404581|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
11404582|NCT02005471|Experimental|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
11404583|NCT02005471|Experimental|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
11404584|NCT02005458|Experimental|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
11404585|NCT02005458|Experimental|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
11404586|NCT02005458|Experimental|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
11404587|NCT02005458|Active Comparator|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
11404588|NCT02005445|Experimental|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
11404589|NCT02005445|Sham Comparator|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
11404590|NCT02005432|Active Comparator|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
11404591|NCT02005432|Experimental|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
11404592|NCT02005432|Other|IVR arm|only IVR (intravitreal Ranibizumabe)
11404593|NCT02005419|Placebo Comparator|gemcitabine + placebo|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
11404594|NCT02005419|Experimental|gemcitabine + metformin|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
11404595|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
11404596|NCT02005393|Other|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
11404597|NCT02005380||Text-based Task|This group is required to do the text-based task
11404598|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
11404599|NCT02005367|No Intervention|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
11404600|NCT02005367|Experimental|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
11404601|NCT02005367|Experimental|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
11404668|NCT02004912|No Intervention|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
11404669|NCT02004899|Active Comparator|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
11404602|NCT02005354|Active Comparator|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.
~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.
~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.
~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
11404603|NCT02005354|Placebo Comparator|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).
~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.
~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
11404604|NCT02005341|Active Comparator|Autograft bone|
11404605|NCT02005341|Experimental|nanOss with bone marrow aspirate|
11404606|NCT02005328|Experimental|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
11404607|NCT02005315|Experimental|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
11404608|NCT02005315|Experimental|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
11404609|NCT02005315|Experimental|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
11404610|NCT02005302|Experimental|Vitamin D2 Treatment|
11404611|NCT02005302|Active Comparator|1,25(OH)2 Vitamin D3|
11404612|NCT02005302|Experimental|low protein diet|
11404613|NCT02005302|Active Comparator|normal protein diet|
11404614|NCT02005289|Experimental|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
11404615|NCT02005289|Experimental|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
11404616|NCT02005276|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
11404617|NCT02005276|Experimental|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:
~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
11404618|NCT02005276|Experimental|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:
~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
11404619|NCT02005276|Experimental|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:
~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
11404620|NCT02005263|Experimental|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
11404621|NCT02005250||hyperthyroidism|61 pre- and postmenopausal women with hyperthyroidism
11404622|NCT02005250||hypothyroidism|32 pre- and postmenopausal women with hypothyroidism
11404623|NCT02005237|Experimental|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
11404624|NCT02005237|No Intervention|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
11404625|NCT02005224|Other|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
11404670|NCT02004899|Experimental|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
11404671|NCT02004899|Experimental|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
11405500|NCT01999218|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
11404626|NCT02005211|Experimental|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
11404627|NCT02005211|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
11404628|NCT02005198||Survey|
11404629|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
11404630|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for < 30min before the age of 2.
11404631|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
11404632|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
11404633|NCT02005172|Other|Alivecor device and event monitor|Both the Alivecor device (experimental) and the standard of care (event monitor) will be provided to all patients for the duration of the study
11404634|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
11404635|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
11404636|NCT02005133||VEGF inhibitor naïve|
11404637|NCT02005133||VEGF inhibitor prior treated|
11404638|NCT02005120|Experimental|Arm A|Bevacizumab
11404639|NCT02005120|Experimental|Arm B|recombinant human endostatin
11404640|NCT02005107|Experimental|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
11404641|NCT02005107|Other|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
11404642|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
11404643|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
11404644|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
11404645|NCT02005081|Other|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
11404646|NCT02005081|Other|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
11404647|NCT02005068|Experimental|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
11404648|NCT02005068|Experimental|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
11404649|NCT02005068|Experimental|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
11404650|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
11404651|NCT02005042|No Intervention|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
11404652|NCT02005042|No Intervention|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
11404653|NCT02005042|Experimental|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
11404654|NCT02005029|Placebo Comparator|Placebo|One time IV dose of placebo
11404655|NCT02005029|Experimental|Erythromycin|One time IV dose of 100 mg Erythromycin
11404656|NCT02005016|Experimental|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
11404657|NCT02005003|Active Comparator|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
11404658|NCT02005003|Placebo Comparator|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
11404659|NCT02004990|Experimental|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
11404660|NCT02004977|Experimental|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
11404661|NCT02004977|No Intervention|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
11404662|NCT02004951|Other|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
11404663|NCT02004951|Other|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
11404664|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
11404665|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
11404666|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
11404667|NCT02004912|Experimental|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
11404672|NCT02004886|Experimental|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
11404673|NCT02004886|Experimental|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
11404674|NCT02004886|Active Comparator|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
11404675|NCT02004886|Placebo Comparator|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
11404676|NCT02004873|Experimental|Micra Pacemaker Implant|
11404677|NCT02004860|Experimental|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
11404678|NCT02004860|Active Comparator|Mycoster Arm|2 applications per week for 6 months
11404679|NCT02004847|Experimental|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
11404680|NCT02004847|Experimental|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
11404681|NCT02004834|Active Comparator|0,5% levobupivacaine with 2% lidocaine|7,0 ml.of mixture 0,5% levobupivacaine with 2% lidocaine are given per level Th2,Th3,Th4 for ultrasound guided paravertebral blocks in breast surgery
11404682|NCT02004834|Active Comparator|0,5% levobupivacine|7,0 ml. 0,5% levobupivacaine are given per level Th2,Th3,Th4, given for ultrasound guided paravertebral blocks in breast surgery
11404683|NCT02004821|Experimental|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
11404684|NCT02004795|Experimental|BNCT+ IG-IMRT|single arm
11404685|NCT02004782|Active Comparator|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
11404686|NCT02004782|Placebo Comparator|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
11404687|NCT02004769|Experimental|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
11404688|NCT02004756|Experimental|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
11404689|NCT02004756|No Intervention|Healthy Controls|Healthy age-matched adolescents
11404690|NCT02004743|Other|Control|Treatment as Usual
11404691|NCT02004743|Other|Intervention|Psychological management guidelines + patient education
11404692|NCT02004730|Experimental|long single vessel disease|ABSORB implantation for long single vessel disease
11404693|NCT02004730|Experimental|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
11404694|NCT02004730|Experimental|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
11404695|NCT02004717|Experimental|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.
~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
11404696|NCT02004704|Experimental|GZ402665|GZ402665 administered intravenously once every 2 weeks for up to 9 years at the dose each patient was receiving at the end of their previous olipudase alfa study.
11404697|NCT02004691|Experimental|GZ402665|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
11404698|NCT02004691|Placebo Comparator|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
11404699|NCT02004678|Other|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either
~a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or
~a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
11404700|NCT02004678|Other|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either
~a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or
~a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
11404701|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
11404702|NCT02004652|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
11404703|NCT02004652|Placebo Comparator|Placebo|Vitamin C, 50mg, tablet
11404704|NCT02004639|Active Comparator|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
11404705|NCT02004639|No Intervention|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
11404706|NCT02004639|Active Comparator|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
11404707|NCT02004639|Sham Comparator|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
11404853|NCT02003664|Placebo Comparator|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
11404708|NCT02004626|Active Comparator|Collagenase|"Each gram of ointment contains :
~Collagenase ...0.6 U
~Vehicle qs ... 1 g
~Presentation:
~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .
~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
11404709|NCT02004626|Active Comparator|Kollagenase|"Each gram of ointment contains :
~Collagenase ... 0.6 U
~Vehicle qs ... 1 g
~Presentation
~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.
~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
11404710|NCT02004613|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.
11404711|NCT02004613|Placebo Comparator|Placebo|normal saline administration matching dexmedetomidine rate of infusion.
11404712|NCT02004600|Experimental|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
11404713|NCT02004587|Experimental|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
11404714|NCT02004587|Experimental|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
11404715|NCT02004587|Active Comparator|Healthy volunteers|Gemigliptin dosing in Healthy subjects
11404716|NCT02004574|Experimental|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
11404717|NCT02004574|Experimental|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
11404718|NCT02004574|Experimental|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
11404719|NCT02004561||Gastric Banding|Patients chose Gastric banding
11404720|NCT02004561||Gastric Bypass|Patients chose gastric bypass surgical operation
11404721|NCT02004548|Experimental|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
11404722|NCT02004535|Experimental|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
11404723|NCT02004522|Experimental|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules
11404724|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
11404725|NCT02004509|Active Comparator|anticoagulant by physician criteria|
11404726|NCT02004509|No Intervention|Control|
11404727|NCT02004496|No Intervention|Group A: no app|no use of an mobile application while treatment
11404728|NCT02004496|Active Comparator|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
11404729|NCT02004496|Active Comparator|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
11404730|NCT02004483|Experimental|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
11404731|NCT02004470|No Intervention|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
11404732|NCT02004470|Experimental|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
11404733|NCT02004457|Experimental|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
11404734|NCT02004457|Placebo Comparator|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
11404735|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
11404736|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
11404737|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
11404738|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
11404739|NCT02004444||Untreated|10 untreated patients
11404740|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
11404741|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
11404742|NCT02004418|Experimental|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
11404743|NCT02004405|Experimental|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
11404851|NCT02003677|Active Comparator|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
11404744|NCT02004405|Active Comparator|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
11404745|NCT02004392|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
11404746|NCT02004392|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
11404747|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
11404748|NCT02004366|Experimental|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
11404749|NCT02004366|Active Comparator|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
11404750|NCT02004366|Experimental|Linagliptin on discharge|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
11404751|NCT02004366|Experimental|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
11404752|NCT02004366|Experimental|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
11404753|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
11404754|NCT02004340|Active Comparator|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
11404755|NCT02004340|Sham Comparator|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
11404756|NCT02004340|No Intervention|control|No transcutaneous stimulation is given
11404757|NCT02004327|Experimental|A Group|"1st administration - DW1029M300mg PO Once
~2nd administration - DW1029M600mg PO Once
~3rd administration - DW1029M1200mg PO Once"
11404758|NCT02004327|Experimental|B Group|"1st administration - DW1029M600mg PO Once
~2nd administration - DW1029M1200mg PO Once
~3rd administration - DW1029M300mg PO Once"
11404759|NCT02004327|Experimental|C Group|"1st administration - DW1029M1200mg PO Once
~2nd administration - DW1029M300mg PO Once
~3rd administration - DW1029M600mg PO Once"
11404760|NCT02004314|Other|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
11404761|NCT02004301|Experimental|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
11404762|NCT02004301|Experimental|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
11404763|NCT02004288|Experimental|Lactobacillus reuteri Protectis DSM17938|One chewable tablet per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
11404764|NCT02004288|Placebo Comparator|Placebo|One chewable tablet with placebo per day
11404765|NCT02004275|Experimental|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
11404766|NCT02004275|Experimental|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11404767|NCT02004262|Experimental|Primary Cohort: Cy/GVAX + CRS-207|"200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
11404768|NCT02004262|Experimental|Primary Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.
~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
11404769|NCT02004262|Active Comparator|Primary Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.
~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
11404770|NCT02004262|Experimental|2nd-line Cohort: Cy/GVAX + CRS-207|"200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
11404852|NCT02003664|Active Comparator|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
11404771|NCT02004262|Experimental|2nd-line Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.
~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
11404772|NCT02004262|Active Comparator|2nd-line Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.
~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
11404773|NCT02004236|Experimental|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
11404774|NCT02004236|Experimental|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
11404775|NCT02004236|Placebo Comparator|tRNS with sham|This group receive 35 sessions with sham
11404776|NCT02004223|Experimental|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
11404777|NCT02004210|Experimental|The TARE group|transarterial radioembolization group
11404778|NCT02004210|Experimental|The TACE group|Transarterial chemoembolization group
11404779|NCT02004197|Experimental|Pylorex plus|Pylorex plus consisting of medicinal plants.
11404780|NCT02004197|Active Comparator|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
11404781|NCT02004184|Experimental|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
11404782|NCT02004184|Active Comparator|pemetrexed at progression|observation and pemetrexed therapy at disease progression
11404783|NCT02004171|Experimental|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
11404784|NCT02004171|Active Comparator|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
11404785|NCT02004158|Experimental|Positive psychology|Positive psychology intervention
11404786|NCT02004145|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
~Exercises:
~Gratitude for positive events
~Gratitude letter
~Performing acts of kindness
~Using personal strengths
~Enjoyable and meaningful activities:
~Repeating one of the previous exercises."
11404787|NCT02004145|Sham Comparator|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
~Exercises:
~Daily Events
~Health Events
~Morning and Evening Events
~Interactions with Others
~Leisure Time Activities
~Repeating one of the previous exercises."
11404788|NCT02004132|Experimental|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
11404789|NCT02004119|Placebo Comparator|Placebo|
11404790|NCT02004119|Experimental|KHK4577|
11404791|NCT02004106|Experimental|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (</= 6 mg) as a single intravenous (IV) infusion.
11404792|NCT02004106|Experimental|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
11404793|NCT02004106|Experimental|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
11404794|NCT02004093|Experimental|Chemotherapy + Pertuzumab|
11404795|NCT02004093|Active Comparator|Chemotherapy|
11404796|NCT02004080||TBI admitted to ICU|Intensive Care treatment
11404797|NCT02004067|Active Comparator|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
11404798|NCT02004067|Experimental|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
11404799|NCT02004054||optic neurotis|measure of pupil diameter
11404800|NCT02004041|Experimental|VLY-686 x mg|Single dose, X mg VLY-686, administered as X 50 mg VLY-686 oral capsule(s)
11404801|NCT02004041|Placebo Comparator|Placebo|Single dose, placebo, administered as X 50 mg oral capsule(s)
11404802|NCT02004028|Experimental|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
11404803|NCT02004015|Experimental|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
11404804|NCT02004015|Experimental|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
11404805|NCT02004015|Placebo Comparator|placebo|injection of placebo Injection in Intravenous bolus use
11404806|NCT02004002|Active Comparator|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
11404807|NCT02004002|Experimental|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
11404808|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
11404809|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
11404810|NCT02003976|Experimental|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
11404811|NCT02003976|Active Comparator|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
11404812|NCT02003963|Experimental|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
11404813|NCT02003963|No Intervention|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
11404814|NCT02003950|Other|Chocolate pre-restriction|
11404815|NCT02003950|Other|Chocolate Baseline|
11404816|NCT02003950|Other|Chocolate post-restriction|
11404817|NCT02003950|Other|Salty Snacks|
11404818|NCT02003950|Other|Sweet Non-Chocolate Snacks|
11404819|NCT02003950|Other|Dried Fruit|
11404820|NCT02003937|Experimental|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
11404821|NCT02003924|Sham Comparator|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
11404822|NCT02003924|Experimental|Enzalutamide|160 mg by mouth once daily
11404823|NCT02003911|Experimental|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)
~Once daily for 3 days"
11404824|NCT02003911|Placebo Comparator|Placebo suspension|"Same volume as active drug
~Once daily for 3 days"
11404825|NCT02003898|Experimental|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
11404826|NCT02003885|Experimental|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
11404827|NCT02003872|Experimental|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
11404828|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
11404829|NCT02003833|Experimental|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
11404830|NCT02003833|Placebo Comparator|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
11404831|NCT02003820|Experimental|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
11404832|NCT02003820|Experimental|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
11404833|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
11404834|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
11404835|NCT02003794|Experimental|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
11404836|NCT02003794|No Intervention|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
11404837|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
11404838|NCT02003768|Experimental|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
11404839|NCT02003768|Active Comparator|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
11404840|NCT02003755|Experimental|Spastic CP|continuous passive motion training
11404841|NCT02003742|Experimental|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
11404842|NCT02003742|Active Comparator|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
11404843|NCT02003729|Active Comparator|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
11404844|NCT02003729|No Intervention|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
11404845|NCT02003716||No treatment|
11404846|NCT02003703|Experimental|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
11404847|NCT02003703|Active Comparator|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
11404848|NCT02003690|Experimental|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
11404849|NCT02003690|Active Comparator|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
11404850|NCT02003677|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
11404854|NCT02003651|Experimental|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
11404855|NCT02003651|Placebo Comparator|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
11404856|NCT02003638|Experimental|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
11404857|NCT02003638|Placebo Comparator|Placebo|Placebo taken orally every day for 12 weeks
11404858|NCT02003625|Placebo Comparator|A. GCSF + Placebo|GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis [days -4, -3, -2, -1] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.
11404859|NCT02003625|Experimental|B. GCSF + meloxicam|"B. GCSF + meloxicam:
~Patients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected."
11404860|NCT02003612||All subjects|All subjects
11404861|NCT02003599|Placebo Comparator|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
~Both arm will use institutional skin care protocol."
11404862|NCT02003599|Experimental|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.
~Both arm will use institutional skin care protocol."
11404863|NCT02003586|Other|Plant-based ingredient to a starchy meal|Plant-based ingredient
11404864|NCT02003586|Other|Starchy meal alone|No plant-based ingredient
11404865|NCT02003573|Experimental|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
11404866|NCT02003560|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
11404867|NCT02003547|Experimental|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
11404868|NCT02003547|Experimental|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
11404869|NCT02003547|Experimental|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
11404870|NCT02003547|Placebo Comparator|Placebo|Topical Ocular Drop BID X 1 wk
11404871|NCT02003534|Experimental|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
11404872|NCT02003521||Intervension|Lung Flute
11404873|NCT02003508||Pre-school based vaccination program (not vaccine eligible)|Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
11404874|NCT02003508||Post-school based vaccination program (vaccine eligible)|Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
11404875|NCT02003495|Experimental|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.
~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.
~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.
~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
11404876|NCT02003495|Active Comparator|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
11404877|NCT02003495|Active Comparator|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
11404878|NCT02003495|Active Comparator|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
11404879|NCT02003495|Placebo Comparator|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
11404880|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
11404881|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
11404882|NCT02003469|Experimental|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
11404883|NCT02003456|Experimental|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
11404884|NCT02003443|Placebo Comparator|Sham Acupressure|Participants assigned to sham acupressure will receive similar instruction as those assigned to pain-relief acupressure, except that they will be taught to apply pressure to 10 acupoints that are unrelated to pain. That is, they will conduct self-administered acupressure 5 days/week for 8 weeks, as the pain-relief acupressure group does, but on 'sham' acupoints.
11404885|NCT02003443|No Intervention|Usual Care|Participants assigned to the UC group will receive no intervention.
11404917|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
11404886|NCT02003443|Experimental|Pain-Relief Acupressure|Participants assigned to pain-relief acupressure will be taught to apply physical pressure, using a wooden hand-held device designed for acupressure, to 10 acupoints on their body.That is, they will conduct self-administered acupressure 5 days/week for 8 weeks,on acupoints that are relevant to pain reduction.
11404887|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
11404888|NCT02003430||<65 years old|20 patients less than 65 years of age
11404889|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration > 3 months) for definitive treatment.
11404890|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
11404891|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
11404892|NCT02003391|Experimental|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
11404893|NCT02003391|Active Comparator|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
11404894|NCT02003378|Active Comparator|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
11404895|NCT02003378|Active Comparator|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
11404896|NCT02003365|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection
11404897|NCT02003365|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection
11404898|NCT02003365|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
11404899|NCT02003352|Experimental|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
11404900|NCT02003339|Experimental|RMIs|
11404901|NCT02003326|Other|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat <30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
11404902|NCT02003313|Experimental|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
11404903|NCT02003313|Active Comparator|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
11404904|NCT02003287|Experimental|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
11404905|NCT02003287|Active Comparator|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
11404906|NCT02003274|Other|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
11404907|NCT02003274|Other|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
11404908|NCT02003261|Experimental|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
11404909|NCT02003261|Other|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
11404910|NCT02003248|Experimental|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
11404911|NCT02003235|Experimental|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
11404912|NCT02003222|Experimental|Arm I (blinatumomab, chemotherapy)|See Detailed Description
11404913|NCT02003222|Active Comparator|Arm II (chemotherapy)|See Detailed Description
11404914|NCT02003209|Active Comparator|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.
~SURGERY: Patients undergo lumpectomy or mastectomy.
~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.
~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
11404915|NCT02003209|Experimental|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.
~SURGERY: Patients undergo lumpectomy or mastectomy.
~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.
~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
11404916|NCT02003183||Suspected CTE|A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, [F-18]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).
11404918|NCT02003157|Active Comparator|hypnosis|embryo transfer procedure with hypnosis
11404921|NCT02003131|Other|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
11404922|NCT02003131|Other|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
11404923|NCT02003118|Experimental|AKR 202|
11404924|NCT02003118|Placebo Comparator|Placebo|
11404925|NCT02003092|Experimental|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
11404926|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
11404927|NCT02003066|Experimental|Standard|
11404928|NCT02003066|Active Comparator|Conservative|
11404929|NCT02003053|Experimental|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
11404930|NCT02003053|Sham Comparator|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
11404931|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
11404932|NCT02003027|Experimental|BT injection|
11404933|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
11404934|NCT02003001|Experimental|BT injection|
11404935|NCT02002988|Experimental|BT injection|
11404936|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
11404937|NCT02002962|Active Comparator|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
11404938|NCT02002962|Active Comparator|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
11404939|NCT02002949|Experimental|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
11404940|NCT02002949|Active Comparator|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
11404941|NCT02002936|Experimental|SyB C-1101|
11404942|NCT02002923|Active Comparator|PVI only|
11404943|NCT02002923|Active Comparator|PVI+BT injection|
11404944|NCT02002897|Experimental|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
11404945|NCT02002897|Active Comparator|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
11404946|NCT02002884|Experimental|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
11404947|NCT02002884|Experimental|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
11404948|NCT02002884|Experimental|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
11404949|NCT02002871|Experimental|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
11404950|NCT02002871|No Intervention|Control|contralateral untreated control plaque on the same patient.
11404951|NCT02002858|Experimental|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
11404952|NCT02002858|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
11404953|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
11404954|NCT02002832|Experimental|Lurasidone group|
11404955|NCT02002832|Active Comparator|Risperidone group|
11404956|NCT02002819|Experimental|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
11404957|NCT02002819|Experimental|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
11404958|NCT02002806|Experimental|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
11404959|NCT02002806|Placebo Comparator|Placebo Injection|Celiac plexus injection - placebo injection
11404960|NCT02002793|Other|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
11405059|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
11404961|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
11404962|NCT02002780|Experimental|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.
~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
11404963|NCT02002780|No Intervention|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
11404964|NCT02002767|Experimental|Participants with renal impairment|Participants with severe renal impairment will receive a single dose of velpatasvir.
11404965|NCT02002767|Active Comparator|Participants with normal renal function|Participants with normal renal function will receive a single dose of velpatasvir.
11404966|NCT02002754|Active Comparator|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
11404967|NCT02002754|Active Comparator|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
11404968|NCT02002741|Active Comparator|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses
~+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
11404969|NCT02002741|Placebo Comparator|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses
~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
11404970|NCT02002715|Active Comparator|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
11404971|NCT02002715|Active Comparator|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
11404972|NCT02002715|Active Comparator|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
11404973|NCT02002702|Experimental|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
11404974|NCT02002702|Experimental|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
11404975|NCT02002702|Placebo Comparator|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
11404976|NCT02002689|Experimental|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
11404977|NCT02002663|Experimental|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
11404978|NCT02002663|Placebo Comparator|saline|Continuous infusion of saline through intralesional catheter for 24 hs
11404979|NCT02002650|Experimental|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
11404980|NCT02002650|Active Comparator|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
11404981|NCT02002637|Experimental|Latella Knee Implant System|
11404982|NCT02002624|Active Comparator|Conventional|Conventional instrumentation
11404983|NCT02002624|Experimental|PSI|Patient specific instrumentation
11404984|NCT02002611|Experimental|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
11404985|NCT02002611|Experimental|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
11404986|NCT02002598|Experimental|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
11404987|NCT02002585|Experimental|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
11404988|NCT02002585|No Intervention|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
11404989|NCT02002572|Experimental|Mimic facial muscle from 3T MRI data|
11404990|NCT02002559||NBI Magnify Endoscopy|Detection of esphageal neoplasia through recognition of brownish discolored area via NBI and characterize the lesion using IPCL upon magnifying endoscopy
11404991|NCT02002559||Lugol Chromoendoscopy|Detection of esophageal neoplasia through recognition of discolored area
11404992|NCT02002546||ED chest pain presenting patients|
11404993|NCT02002533|Experimental|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
11404994|NCT02002533|Active Comparator|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
11404995|NCT02002520||case group|patients undergo third molar surgery
11404996|NCT02002520||control group|subjects do not require surgery
11404997|NCT02002507||park bench position|Comparing jugular venous flow in supine and park bench position in neurosurgical patients requiring their surgery in park bench position
11405573|NCT01998763|Placebo Comparator|Placebo|5 placebo pills per day, 20 weeks
11404998|NCT02002507||prone position|Comparing the jugular venous flow in the supine and prone position in patients requiring their surgery to be done in the prone position.
11404999|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:
~Bilateral internal jugular venous flow in supine and prone position
~Bilateral internal jugular venous flow in supine and park bench position
~Bilateral internal jugular venous flow in prone and park bench"
11405000|NCT02002481|No Intervention|Control|10 minutes ALS-CPR in a normal environment
11405001|NCT02002481|Experimental|Transport|10 minutes ALS-CPR during a transport
11405002|NCT02002468|Experimental|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
11405003|NCT02002468|Active Comparator|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
11405004|NCT02002455|Experimental|Multimodality imaging|PET/CT, PET/MRI, mpMRI
11405005|NCT02002442|Active Comparator|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
11405006|NCT02002442|Active Comparator|Essential oil|LISTERINE® ZERO™ Mouthwash
11405007|NCT02002442|Active Comparator|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
11405008|NCT02002442|Placebo Comparator|Saline|
11405009|NCT02002429|Experimental|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
11405010|NCT02002429|Active Comparator|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
11405011|NCT02002429|Sham Comparator|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
11405012|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
11405013|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
11405014|NCT02002403|Placebo Comparator|Placebo|
11405015|NCT02002403|Experimental|Optina Low Dose|Optina, 15 mg orally, twice daily
11405016|NCT02002403|Experimental|Optina - High Dose|Optina, 45 mg orally, twice daily
11405017|NCT02002390|Experimental|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
11405018|NCT02002390|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
11405019|NCT02002377|Experimental|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
11405020|NCT02002364|Active Comparator|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
11405021|NCT02002364|Active Comparator|Multiple use flexible optical scope|Multiple use flexible optical scope
11405022|NCT02002351||Pulmonary disease|
11405023|NCT02002338||Pterygium|Patients who were operated of pterygium
11405024|NCT02002325|Experimental|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
11405025|NCT02002325|Other|Standard Care|Standard treatment for acute stroke
11405026|NCT02002312|Experimental|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
11405027|NCT02002286|Experimental|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
11405028|NCT02002286|Other|cART control|Continue current cART regimen
11405029|NCT02002273|Experimental|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
11405030|NCT02002273|Experimental|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
11405031|NCT02002260|Active Comparator|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
11405032|NCT02002260|Active Comparator|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
11405033|NCT02002247|Placebo Comparator|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
11405034|NCT02002247|Active Comparator|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:
~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
11405035|NCT02002234|Other|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
11405036|NCT02002234|Other|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
11405037|NCT02002221|Experimental|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
11405038|NCT02002221|Placebo Comparator|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
11405039|NCT02002208|Experimental|OC000459 Tablets|50 mg orally once a day
11405040|NCT02002208|Placebo Comparator|Placebo Tablets|Orally once a day
11405041|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
11405042|NCT02002182|Experimental|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
11405043|NCT02002182|No Intervention|Control Group|Observational control group treated with standard of care therapy only
11405044|NCT02002169|Experimental|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
11405045|NCT02002169|Active Comparator|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
11405046|NCT02002156|Experimental|BCG at birth and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
11405047|NCT02002156|Experimental|BCG at 3 months old and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
11405048|NCT02002156|Experimental|Routine vaccines|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
11405049|NCT02002143|Active Comparator|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
11405050|NCT02002143|Experimental|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).
~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
11405051|NCT02002130|Placebo Comparator|Placebo GABA and Placebo GAD-alum|"Placebo formulation, Maltodextrin, for Gamma-Amino Butyric Acid (GABA) capsule-identical in appearance and taste, but no active medication will be taken with meals.Number of pills based on body surface area.
~Placebo GAD-alum(Glutamic Acid Decarboxylase in alum) injection- identical in appearance but no active medication will be received at baseline and 1 month."
11405052|NCT02002130|Active Comparator|GABA and placebo GAD-alum|"Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.
~Patients will receive the GAD-alum( Glutamic Acid Decarboxylase in alum) placebo at baseline and 1 month."
11405053|NCT02002130|Active Comparator|Active Oral GABA and Active GAD-alum Injection|"Patients will receive Oral GABA(Gamma-Amino Butyric Acid) 250mg capsules. Dosage (# of capsules) based on body surface area and divided between 2 meals/day.
~Patients will receive a primary (at baseline)injection of recombinant human GAD(Glutamic Acid Decarboxylase) in a standard vaccine formulation with alum, and a booster injection of the same at 1 month after baseline."
11405054|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
11405055|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
11405056|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
11405057|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
11405058|NCT02002078|No Intervention|Methylprednisolone, caustic burns|
11405060|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
11405061|NCT02002052|Active Comparator|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
11405062|NCT02002052|Experimental|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
11405063|NCT02002039|Active Comparator|erythropoietin, perinatal asphyxia,|Treatment group
11405064|NCT02002039|Placebo Comparator|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
11405065|NCT02002026|Active Comparator|Ligation group|Uterine artery ligation will be done for patients in this group
11405066|NCT02002026|Placebo Comparator|Control group|Conventional CS
11405067|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
11405068|NCT02002000|Experimental|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
11405069|NCT02002000|Experimental|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
11405070|NCT02001987|Experimental|Tocilizumab|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
11405071|NCT02001974|Experimental|Paclitaxel 80 mg/m2 i.v.+Reparixin oral 400 mg t.i.d.|Paclitaxel+reparixin three weeks on one week off (three to six patients)
11405072|NCT02001974|Experimental|Paclitaxel 80 mg/m2 i.v.+Reparixin oral 800 mg t.i.d.|Paclitaxel+reparixin three weeks on one week off (three to six patients)
11405073|NCT02001974|Experimental|Paclitaxel 80 mg/m2 i.v.+Reparixin oral 1200 mg t.i.d.|Paclitaxel+reparixin oral three weeks on one week off (three to six patients).
11405074|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
11405075|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
11405076|NCT02001948|Active Comparator|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
11405077|NCT02001948|Active Comparator|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
11405078|NCT02001935|Other|theophylline|
11405079|NCT02001922|Experimental|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
11405080|NCT02001922|No Intervention|Usual care|Usual COPD care
11405081|NCT02001909|Experimental|Regorafenib|
11405082|NCT02001909|Experimental|Neomycin|
11405083|NCT02001896|Experimental|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression
11405084|NCT02001896|Active Comparator|erlotinib along|Drug: erlotinib [Tarceva] 150mg/day po until disease progression
11405085|NCT02001883|Active Comparator|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
11405086|NCT02001883|Active Comparator|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
11405087|NCT02001870|Experimental|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
11405088|NCT02001870|Active Comparator|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
11405089|NCT02001857|Experimental|TachoSil|TachoSil
11405090|NCT02001857|No Intervention|No TachoSil|No TachoSil
11405091|NCT02001844|Placebo Comparator|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).
~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
11405092|NCT02001844|Experimental|Trial Group|"Trial Group:
~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.
~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
11405093|NCT02001831|Experimental|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):
~Carbohydrate 28.5 g
~Protein 8 g as Whey Protein Isolate
~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg
~Vitamin D3 10 μg
~Resveratrol 150 mg"
11405137|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
11405094|NCT02001831|Placebo Comparator|Control|"Placebo control
~Liquid nutrient support
~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
11405095|NCT02001818|Experimental|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).
~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
11405096|NCT02001805||Marathon runners|Very active runners that have been running > 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
11405097|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level < 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
11405098|NCT02001792|Sham Comparator|Controll group|Patients lying in a supine position during colonoscopy
11405099|NCT02001792|Active Comparator|Intervention|Patients lying in a left lateral position during colonoscopy
11405100|NCT02001779|Experimental|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
11405101|NCT02001779|Active Comparator|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
11405102|NCT02001766|Experimental|High intensity exercise|3 times per week in a total of 12 weeks
11405103|NCT02001766|Experimental|Low intensity exercise|3 times per week in a total of 12 weeks
11405104|NCT02001766|Experimental|Control|Normal lifestyle for 12 weeks
11405105|NCT02001753|Experimental|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
11405106|NCT02001753|Placebo Comparator|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
11405107|NCT02001753|No Intervention|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
11405108|NCT02001740|Placebo Comparator|lidocaine|frequency = once
11405109|NCT02001740|Experimental|Triamcinalone (steroid) and lidocaine|frequency = once
11405110|NCT02001727|Active Comparator|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
11405111|NCT02001727|Other|Control group|primarily unscreened group
11405112|NCT02001714|Experimental|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
11405113|NCT02001714|No Intervention|No Treatment|Subjects will not attend group behavioral treatment class.
11405114|NCT02001701|Experimental|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
11405115|NCT02001688|Experimental|Kamada-AAT for Inhalation, 80mg|Daily inhalation of Kamada-AAT for Inhalation, 80mg
11405116|NCT02001688|Placebo Comparator|Placebo|Placebo administered by inhalation daily
11405117|NCT02001688|Experimental|Kamada-AAT for Inhalation, 160mg|Daily inhalation of Kamada-AAT for Inhalation, 160mg
11405118|NCT02001675|Experimental|Volunteer healthy|
11405119|NCT02001662|Experimental|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is > 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.
~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
11405120|NCT02001662|Sham Comparator|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.
~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
11405121|NCT02001649|Other|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.
~Individuals will be genotyped at a total of 96 SNPs"
11405122|NCT02001649|Other|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
11405123|NCT02001636|Experimental|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.
~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
11405124|NCT02001636|Placebo Comparator|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.
~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
11405125|NCT02001623|Experimental|Tisotumab Vedotin (HuMax-TF-ADC)|All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
11405126|NCT02001610|Active Comparator|Hard shell gelatin capsules|"Comparison delivery vehicle in the form of gelatin capsule
~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
11405127|NCT02001610|Experimental|Acidophilus pearls|"Encapsulated using patented process
~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
11405128|NCT02001597||Surgery patients|
11405129|NCT02001584|Experimental|Healthy Volunteers|
11405130|NCT02001584|Experimental|Obese, Otherwise Healthy Volunteers|
11405131|NCT02001571|Experimental|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
11405132|NCT02001571|Experimental|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
11405133|NCT02001571|Experimental|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
11405134|NCT02001558|Experimental|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily.
11405135|NCT02001558|Active Comparator|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily.
11405136|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
11405139|NCT02001519|Experimental|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
11405140|NCT02001506|Active Comparator|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel
~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks
~Docetaxel 75 mg/m2, every 3 weeks"
11405141|NCT02001506|No Intervention|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel
~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks
~Docetaxel 75 mg/m2, every 3 weeks"
11405142|NCT02001480|Other|Echocardiography|"12 lead holter for 7 days
~CGM = continuous Glucose Monitoring"
11405143|NCT02001467|Active Comparator|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
11405144|NCT02001467|No Intervention|Control|No training is provided the control group participants.
11405145|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
11405146|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
11405147|NCT02001441||No treatment|
11405148|NCT02001428|Experimental|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
11405149|NCT02001428|No Intervention|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
11405150|NCT02001415|Active Comparator|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
11405151|NCT02001415|Active Comparator|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
11405152|NCT02001415|Active Comparator|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
11405153|NCT02001389|Experimental|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
11405154|NCT02001389|Experimental|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
11405155|NCT02001389|Experimental|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
11405156|NCT02001389|Experimental|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
11405157|NCT02001376|Experimental|Intensive exercise & home exercise|Intensive exercise group Home exercise group
11405158|NCT02001376|Experimental|Intensive exercise & control|Intensive exercise group Control group
11405159|NCT02001376|Experimental|Home exercise & control group|Home exercise Control group
11405160|NCT02001363|Experimental|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
11405161|NCT02001363|Placebo Comparator|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
11405162|NCT02001350||Resistant hypertension|
11405163|NCT02001324|Active Comparator|Paper-based data collection|Paper-based data collection
11405164|NCT02001324|Active Comparator|Web-based data collection|Web-based data collection
11405165|NCT02001311|Experimental|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
11405166|NCT02001298|Experimental|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
11405167|NCT02001298|Experimental|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
11405168|NCT02001285|Experimental|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
11405169|NCT02001285|Active Comparator|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
11405170|NCT02001272|Experimental|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
11405171|NCT02001272|Experimental|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
11405172|NCT02001272|Experimental|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
11405173|NCT02001259|Active Comparator|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
11405174|NCT02001259|Experimental|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
11405175|NCT02001246|Active Comparator|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
11405176|NCT02001246|Experimental|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
11405177|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
11405178|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
11405179|NCT02001220|Active Comparator|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
11405180|NCT02001220|Experimental|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
11405181|NCT02001207||MICU patients|
11405182|NCT02001194|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
11405183|NCT02001194|Experimental|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
11405184|NCT02001194|Experimental|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
11405185|NCT02001194|Experimental|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
11405186|NCT02001181|Experimental|Treatment group A|
11405187|NCT02001181|Placebo Comparator|Treatment B|
11405188|NCT02001168|Experimental|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
11405189|NCT02001168|Experimental|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
11405190|NCT02001168|Experimental|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
11405191|NCT02001168|Experimental|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
11405192|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
11405193|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
11405194|NCT02001142|Experimental|Exercise|
11405195|NCT02001142|No Intervention|Sedentary Control|
11405196|NCT02001129|Experimental|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
11405197|NCT02001129|Experimental|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
11405198|NCT02001129|Active Comparator|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
11405199|NCT02001116|Experimental|Pilot Hospitals|
11405200|NCT02001116|No Intervention|Control Hospitals|
11405201|NCT02001103|Active Comparator|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
11405202|NCT02001103|Active Comparator|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
11405203|NCT02001103|Placebo Comparator|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
11405204|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
11405205|NCT02001077|Active Comparator|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
11405206|NCT02001077|Active Comparator|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
11405207|NCT02001077|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
11405208|NCT02001064|Experimental|Application + Standard of care|Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.
11405209|NCT02001064|No Intervention|Standard of care|Participants will receive standard of care while on study.
11405210|NCT02001051|Other|Operative Arm|operative arm
11405211|NCT02001051|Other|Delayed Operative Arm|delayed operative arm
11405212|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
11405213|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
11405214|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
11405215|NCT02001012|Active Comparator|Artemether-lumefantrine|"Artemether-lumefantrine.
~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet."
11405216|NCT02001012|Active Comparator|Chloroquine|"Chloroquine.
~1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.
~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
11405217|NCT02000999||Patients with bile duct strictures|
11405218|NCT02000986|Experimental|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
11405219|NCT02000973|Placebo Comparator|Normal saline|General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
11405220|NCT02000973|Experimental|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine 8ml
11405221|NCT02000973|Experimental|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
11405222|NCT02000973|Experimental|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
11405223|NCT02000960|Experimental|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
11405224|NCT02000947|Experimental|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
11405225|NCT02000947|Experimental|Arm A|Medi4736 and tremelimumab received by intravenous infusion
11405226|NCT02000947|Experimental|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
11405227|NCT02000947|Experimental|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
11405228|NCT02000934|Experimental|TAK-659 60 mg (Dose Escalation)|TAK-659 60 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 49 cycles).
11405229|NCT02000934|Experimental|TAK-659 80 mg (Dose Escalation)|TAK-659 80 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 4 cycles).
11405230|NCT02000934|Experimental|TAK-659 100 mg (Dose Escalation)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 32 cycles).
11405231|NCT02000934|Experimental|TAK-659 120 mg (Dose Escalation)|TAK-659 120 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 41 cycles).
11405232|NCT02000934|Experimental|TAK-659 CCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with chronic lymphocytic leukemia (CCL) (up to 6 cycles).
11405233|NCT02000934|Experimental|TAK-659 DLBCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with diffuse large B-cell lymphoma (DLBCL) (up to 49 cycles).
11405234|NCT02000934|Experimental|TAK-659 iNHL (Dose Expansion)|Single dose TAK-659 100 mg, tablet, orally in pharmacokinetic (PK) Run-in prior to Cycle 1 followed by TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with indolent non-hodgkin lymphoma (iNHL) (up to 32 cycles).
11405235|NCT02000934|Experimental|TAK-659 MCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with mantle cell lymphoma (MCL) (up to 6 cycles).
11405236|NCT02000934|Experimental|TAK-659 PTLD (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with post-transplant lymphoproliferative disorder (PTLD) (up to 1 cycle).
11405237|NCT02000921|Experimental|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
11405238|NCT02000921|Experimental|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
11405239|NCT02000921|Experimental|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
11405240|NCT02000908|Experimental|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
11405241|NCT02000908|Sham Comparator|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.
~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
11405242|NCT02000895||Preterm infants|>24 weeks <37 weeks gestational age
11405243|NCT02000895||Term infants|>37 weeks' gestational age
11405244|NCT02000895||Follow-up at 6 Years|Children enrolled from the birth cohort(s) to be followed at 6 to 10 years of age.
11405245|NCT02000882|Experimental|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.
~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
11405246|NCT02000869||wait-listed kidney transplant candidates|
11405247|NCT02000856|Active Comparator|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
11405248|NCT02000856|Placebo Comparator|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
11405249|NCT02000843|Other|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
11405250|NCT02000830||Placebo|Participants received placebo during the earlier study
11405251|NCT02000830||Stannsoporfin 3.0 mg/kg|Participants received Stannsoporfin 3.0 mg/kg during the earlier study
11405252|NCT02000830||Stannsoporfin 4.5 mg/kg|Participants received Stannsoporfin 4.5 mg/kg during the earlier study
11405253|NCT02000817|Experimental|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
11405254|NCT02000817|Experimental|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
11405255|NCT02000817|Experimental|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
11405256|NCT02000817|Experimental|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
11405257|NCT02000817|Placebo Comparator|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
11405258|NCT02000804|Experimental|darapladib 160mg|drug
11405259|NCT02000791|Experimental|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
11405260|NCT02000791|Active Comparator|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
11405261|NCT02000778|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
11405262|NCT02000765|Experimental|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing [14C]-GSK2140944 of approximately 22.5 microcurie [μCi] (approximately 0.8 megabecquerel [MBq]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing [14C]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
11405263|NCT02000752|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
11405264|NCT02000752|Sham Comparator|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
11405337|NCT02000206|Active Comparator|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:
~A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.
~Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
11405265|NCT02000739|Other|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.
~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
11405266|NCT02000726|Experimental|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
11405267|NCT02000713|Experimental|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
11405268|NCT02000713|Active Comparator|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
11405269|NCT02000700|Experimental|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
11405270|NCT02000700|Experimental|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
11405271|NCT02000674|Active Comparator|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
11405272|NCT02000674|Experimental|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
11405273|NCT02000661|Experimental|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
11405274|NCT02000661|Active Comparator|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
11405275|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
11405276|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
11405277|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
11405278|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
11405279|NCT02000609|Active Comparator|CHF 1535 NEXThaler 800/48 ug|single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate
11405280|NCT02000609|Placebo Comparator|CHF 1535 NEXThaler PLACEBO|single dose administration of placebo via NEXThaler DPI
11405281|NCT02000609|Active Comparator|CHF 1535 pMDI 200/12|single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate
11405282|NCT02000609|Active Comparator|CHF 1535 100/6 pMDI 800/48|single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate
11405283|NCT02000609|Active Comparator|CHF 1535 NEXThaler 200/12|single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate
11405284|NCT02000596|Experimental|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
11405285|NCT02000596|Experimental|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
11405286|NCT02000596|Experimental|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
11405287|NCT02000583|Experimental|Aerobic Exercise Group|Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks
11405288|NCT02000583|Other|Control Group|Standard of Care exercise recommendations
11405289|NCT02000570|Experimental|sitting position|
11405290|NCT02000557||Class II Malocclusion|
11405291|NCT02000544|Other|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
11405292|NCT02000531|Experimental|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
11405293|NCT02000531|Active Comparator|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
11405294|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
11405295|NCT02000505|No Intervention|Control|5 minutes chest-compression-only CPR, without any support
11405296|NCT02000505|Experimental|PocketCPR|5 minutes chest-compression-only CPR, with support
11405297|NCT02000505|Experimental|Metronome|5 minutes chest-compression-only CPR, with support
11405298|NCT02000505|Experimental|110bpm Song|5 minutes chest-compression-only CPR, with support
11405299|NCT02000492|Experimental|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
11405300|NCT02000492|No Intervention|Control|
11405301|NCT02000479|Experimental|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
11405302|NCT02000479|No Intervention|Control|Continued usual care, habitual lifestyle
11405303|NCT02000466||Exposed cohort|
11405304|NCT02000453|Experimental|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
11405338|NCT02000206|Active Comparator|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:
~A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.
~Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
11405501|NCT01999218|Active Comparator|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
11405305|NCT02000440|Experimental|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
11405306|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.
~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
11405307|NCT02000414|Experimental|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
11405308|NCT02000401|Other|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
11405309|NCT02000388|Other|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
11405310|NCT02000388|Other|Standard of care|The intervention used will be standard of care
11405311|NCT02000375|Experimental|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
11405312|NCT02000362|Experimental|Treatment|"cohort 1. 5.0 x 10^7 stem cells after registration
~cohort 2. 1.0 x 10^8 stem cells after registration"
11405313|NCT02000349|Experimental|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*).
11405314|NCT02000349|Experimental|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
11405315|NCT02000336|Experimental|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
11405316|NCT02000336|Experimental|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
11405317|NCT02000336|Placebo Comparator|Placebo|daily oral tablet
11405318|NCT02000323|Active Comparator|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
~After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.
~Patients are targeted to receive calories for 25 kcal/kg/day."
11405319|NCT02000323|Active Comparator|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
~After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.
~Patients are targeted to receive calories for 25 kcal/kg/day."
11405320|NCT02000297|Active Comparator|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
11405321|NCT02000297|Experimental|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
11405322|NCT02000284||General ASD|150 general ASD children
11405323|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
11405324|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
11405325|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
11405326|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
11405327|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
11405328|NCT02000271|Other|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
11405329|NCT02000271|Experimental|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
11405330|NCT02000258|Other|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
11405331|NCT02000258|Other|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
11405332|NCT02000245|Active Comparator|verbal expression for compassion|verbal expression for compassion
11405333|NCT02000245|Active Comparator|verbal expression and touch|verbal expression and touch
11405334|NCT02000245|No Intervention|control|control
11405335|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
11405336|NCT02000219|Experimental|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.
~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
11405339|NCT02000193|Experimental|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.
~The treatment will continue until disease progression or intolerable adverse event"
11405340|NCT02000180|Experimental|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
11405341|NCT02000180|No Intervention|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
11405342|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
11405343|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
11405344|NCT02000154|Experimental|SyB L-1101|
11405345|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
11405346|NCT02000128|Experimental|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
11405347|NCT02000128|Other|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
11405348|NCT02000115|Experimental|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve.
~Status: ACTIVE, NOT ENROLLING."
11405349|NCT02000115|Active Comparator|Randomized IDE Cohort, CAV|"Commercially available transcatheter aortic valve (CAV).
~Status: ACTIVE, NOT ENROLLING."
11405350|NCT02000115|Experimental|Nested Valve-in-valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve into the existing bioprosthesis will be considered for eligibility in the Valve-in-Valve registry. The Valve-in-Valve registry will enroll up to 100 qualified subjects from the pivotal IDE trial or CAP. Data from the valve-in-valve registry will be analyzed and presented separately to support an expanded indication for Valve-in-Valve use (Portico-in-SAVR).
~Status: RECRUITING."
11405351|NCT02000115|Experimental|FlexNav Delivery System Study|"The primary objective of the PORTICO IDE FlexNav study is to characterize the safety of the next-generation FlexNav Delivery System. The FlexNav study will be conducted as a prospective, multicenter, open-label study arm of the PORTICO IDE trial and will include 100 high or extreme risk patients with symptomatic, severe native aortic stenosis who meet eligibility criteria for the PORTICO IDE trial via a transfemoral or alternative access approach.
~Status: ACTIVE, NOT ENROLLING"
11405352|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
11405353|NCT02000089||Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):
~> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and
~come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and
~have a first-degree relationship with at least one of the relatives with pancreatic cancer.
~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
11405354|NCT02000089||Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):
~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened.
~The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), age 40 years or older, regardless of family history of pancreas cancer."
11405355|NCT02000089||Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):
~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and
~The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
11405356|NCT02000089||Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
11405357|NCT02000089||Peutz-Jeghers Syndrome|"At least 30 years old, and
~at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,
~known STK11 gene mutation carrier"
11405358|NCT02000089||Negative control|"are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and
~have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
11405359|NCT02000089||Chronic Pancreatitis|"are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,
~have no clinical or radiologic suspicion of pancreatic cancer"
11405360|NCT02000089||Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
11405361|NCT02000089||Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
11405362|NCT02000076|Experimental|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
11405363|NCT02000076|Experimental|Full sleep|Sleep with no restriction
11405364|NCT02000050|Experimental|Single Arm|"Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles
~Surgery
~Adjuvant therapy: FOLFOX4 8 cycles
~TME (Total Mesorectal Excision)"
11405365|NCT02000037|Active Comparator|Dietary care|Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).
11405366|NCT02000037|Experimental|IR reflexotherapy + dietary care|"Treatment is composed of :
~IR reflexotherapy sessions given by a trained professional ;
~dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille)."
11405367|NCT02000037|Experimental|IR Reflexotherapy|Treatment is composed of IR reflexotherapy sessions given by a trained professional.
11405368|NCT02000024|Experimental|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
11405369|NCT02000024|Active Comparator|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
11405370|NCT02000011|Other|standard strategy|
11405371|NCT02000011|Experimental|experimental strategy|
11405372|NCT01999998|Experimental|Pilot|
11405373|NCT01999985|Experimental|Dose Escalation and Dose Expansion|"Dose escalation followed by dose expansion. Escalation cohort: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.
~Expansion cohort:: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
11405374|NCT01999972|Experimental|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
11405375|NCT01999972|Experimental|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer [RCC] with no prior systemic therapy
11405376|NCT01999972|Experimental|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
11405377|NCT01999959|Experimental|Pertubation performed|Study group had pertubation and insemination
11405378|NCT01999959|No Intervention|Pertubation not performed|Study group had insemination only
11405379|NCT01999946|Experimental|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
11405380|NCT01999946|No Intervention|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
11405381|NCT01999946|No Intervention|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
11405382|NCT01999933|Active Comparator|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
11405383|NCT01999933|Experimental|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
11405384|NCT01999933|Experimental|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
11405385|NCT01999920|Experimental|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
11405386|NCT01999920|Placebo Comparator|Placebo|Pill placebo.
11405387|NCT01999907|Placebo Comparator|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
11405388|NCT01999907|Active Comparator|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
11405389|NCT01999894|Experimental|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
11405390|NCT01999881|Experimental|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
11405391|NCT01999881|Active Comparator|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
11405495|NCT01999231|Experimental|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
11405392|NCT01999868|Experimental|UST, ABA/UST Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of abatacept (ABA) (125 mg) subcutaneous injections weekly from Week 12 to 39, in addition to ustekinumab placebo subcutaneous injections at Weeks 16 and 28.
11405393|NCT01999868|Active Comparator|UST, UST/ABA Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of ustekinumab (45 mg if <=100 kg or 90 mg if >100 kg at study entry) subcutaneous injections at Weeks 16 and 28, in addition to abatacept (ABA) placebo subcutaneous injections weekly from Week 12 to 39.
11405394|NCT01999855|Active Comparator|control group|"the Phonatory Maximum Time
~Vocal Handicap Index
~Scale GRBAS of Hirano
~Videolaryngoscopy"
11405395|NCT01999855|Experimental|Asthmatic patients|"The Phonatory Maximum Time
~Vocal Handicap Index
~Scale GRBAS of Hirano
~Videolaryngoscopy"
11405396|NCT01999842|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
11405397|NCT01999842|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
11405398|NCT01999842|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
11405399|NCT01999842|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
11405400|NCT01999842|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
11405401|NCT01999842|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
11405402|NCT01999829|Experimental|citrate of caffeine|
11405403|NCT01999829|Placebo Comparator|placebo|
11405404|NCT01999816|Experimental|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
11405405|NCT01999816|No Intervention|Control|Usual care
11405406|NCT01999803|Experimental|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
11405407|NCT01999803|Placebo Comparator|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
11405408|NCT01999790|Experimental|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
11405409|NCT01999790|Experimental|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
11405410|NCT01999777|Experimental|USL261|5 mg intranasal midazolam
11405411|NCT01999777|Placebo Comparator|Placebo|intranasal placebo
11405412|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
11405413|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
11405414|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
11405415|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
11405416|NCT01999738|Experimental|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).
~Intervention: EC1456 and EC20"
11405417|NCT01999738|Experimental|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).
~Intervention: EC1456 and EC20"
11405418|NCT01999738|Experimental|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).
~Intervention: EC1456 and EC20"
11405419|NCT01999738|Experimental|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).
~Intervention: EC1456 and EC20"
11405420|NCT01999738|Experimental|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.
~Intervention: EC1456 and EC20"
11405421|NCT01999738|Experimental|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.
~Intervention: EC1456 and EC20"
11405422|NCT01999738|Experimental|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).
~Intervention: EC1456 and EC20"
11405423|NCT01999725|Experimental|EDP-788|Single doses with dose escalation to continue in successive cohorts
11405424|NCT01999725|Placebo Comparator|Placebo|Single dose with matching placebo
11405425|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
11405426|NCT01999699|Experimental|HEPLISAV|
11405427|NCT01999686|Experimental|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
11405428|NCT01999686|Active Comparator|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
11405429|NCT01999686|Experimental|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
11405430|NCT01999673|Experimental|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
11405431|NCT01999673|Placebo Comparator|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
11405432|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
11405433|NCT01999647|Active Comparator|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
11405434|NCT01999647|Experimental|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
11405435|NCT01999634|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
11405436|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
11405437|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L
11405438|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
11405439|NCT01999595|Experimental|High frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation
~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
11405440|NCT01999595|Experimental|Low frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation
~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
11405441|NCT01999595|Experimental|High frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation
~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
11405442|NCT01999595|Experimental|Low frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation
~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm
~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
11405443|NCT01999595|Placebo Comparator|Control TENS|"TENS=transcutaneous electrical nerve stimulation
~Control TENS was the application of electrical stimulation via skin with no current"
11405444|NCT01999595|Sham Comparator|Sham TENS|"TENS=transcutaneous electrical nerve stimulation
~Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told that the TENS was turn-on whether you feel it or not"
11405445|NCT01999582|Experimental|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
11405446|NCT01999582|Experimental|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
11405447|NCT01999569|No Intervention|Control|Control cycle. No intervention.
11405448|NCT01999569|Experimental|Letrozole|5mg daily
11405449|NCT01999556||Patient|Specimen Collection
11405450|NCT01999556||Relative|Specimen Collection
11405451|NCT01999543|Other|Reference food format|reference food format with and without plant-based ingredient added
11405452|NCT01999543|Experimental|Food format one|Food format one with and without plant-based ingredient added
11405453|NCT01999543|Experimental|Food format two|Food format two with and without plant-based ingredient added
11405454|NCT01999543|Experimental|Food format three|Food format three with and without plant-based ingredient added
11405455|NCT01999530|Experimental|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
11405456|NCT01999517|Active Comparator|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
11405457|NCT01999517|Placebo Comparator|Placebo|IV Fluids
11405458|NCT01999504|Experimental|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
11405459|NCT01999504|Experimental|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
11405460|NCT01999504|Placebo Comparator|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
11405461|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
11405462|NCT01999465|Active Comparator|Standard NMES cohort|Patients who will apply standard NMES device.
11405463|NCT01999465|Sham Comparator|Sham NMES cohort|Patients who will apply sham NMES device.
11405464|NCT01999452|Experimental|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
11405465|NCT01999452|Experimental|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
11405466|NCT01999439|Experimental|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
11405467|NCT01999426|Experimental|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
11405468|NCT01999426|Active Comparator|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
11405496|NCT01999231|Experimental|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
11405497|NCT01999231|Experimental|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
11405498|NCT01999231|Experimental|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
11405469|NCT01999413|Experimental|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :
~Daunorubicin 60 mg/m²/day IV on D1, D2, and D3
~Cytarabine 200 mg/m²/day D1 to D7
~OMEGAVEN® 2 ml/kg D1 to D9,
~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours
~Induction cycle :
~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3
~- Cytarabine 200 mg/m²/day IV D1 to D7
~bone marrow aspirate at D15: If BM blasts are > 5% or if second induction course :
~Daunorubicin 35 mg/m²/day IV D17 and D18
~OMEGAVEN® 2 ml/kg
~Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19
~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).
~Consolidation will be administered at investigator's discretion"
11405470|NCT01999400|Experimental|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
11405471|NCT01999400|Experimental|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
11405472|NCT01999400|Experimental|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
11405473|NCT01999400|Experimental|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
11405474|NCT01999400|Experimental|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
11405475|NCT01999400|Experimental|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
~Washout period of 10 days.
~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
~Washout period of 10 days.
~Apriso 375 mg capsule x 3 with 240 mL water, single dose.
~Washout period of 10 days.
~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
11405476|NCT01999387||Completed OIT|Patients who completed OIT >6 months prior to enrollment
11405477|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
11405478|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
11405479|NCT01999335|Experimental|Oprozomib with Pomalidomide and Dexamethasone (OPomd)|"Phase 1b:
~Oprozomib doses will be escalated in sequential groups of at least 3 subjects. Study subjects will receive oprozomib in combination with pomalidomide and dexamethasone. Assuming no dose de-escalation is needed, pomalidomide and dexamethasone doses will remain fixed, while the dose of oprozomib for subsequent cohorts will be escalated until the MTD is reached.
~Phase 3:
~Study subjects will receive oprozomib in combination with pomalidomide and dexamethasone."
11405480|NCT01999335|Placebo Comparator|Placebo with Pomalidomide and Dexamethasone (Pomd)|"Phase 3:
~Study subjects will receive placebo in combination with pomalidomide and dexamethasone."
11405481|NCT01999322|Experimental|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
11405482|NCT01999322|Active Comparator|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
11405483|NCT01999309|Experimental|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
11405484|NCT01999309|Placebo Comparator|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
11405485|NCT01999296||Patients undergoing laparoscopic surgery|
11405486|NCT01999283|Active Comparator|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
11405487|NCT01999283|Active Comparator|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
11405488|NCT01999283|No Intervention|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
11405489|NCT01999270|Experimental|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
11405490|NCT01999257|No Intervention|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
11405491|NCT01999257|Active Comparator|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
11405492|NCT01999244|Experimental|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
11405493|NCT01999244|Experimental|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
11405494|NCT01999244|Experimental|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
11405499|NCT01999218|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
11405502|NCT01999205|Experimental|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
11405503|NCT01999192|Experimental|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
11405504|NCT01999192|Experimental|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
11405505|NCT01999192|Experimental|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
11405506|NCT01999192|Placebo Comparator|Placebo|Placebo s.c. weekly
11405507|NCT01999179|Other|low-molecular-weight heparin or direct oral anticoagulant|"Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.
~Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants."
11405508|NCT01999166||Osteoarthritis|
11405509|NCT01999153|Experimental|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
11405510|NCT01999153|Placebo Comparator|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
11405511|NCT01999140||Primary prevention|
11405512|NCT01999114|Experimental|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr
11405513|NCT01999114|Experimental|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
11405514|NCT01999114|Active Comparator|Naltrexone|Naltrexone 50 mg tablets
11405515|NCT01999114|Placebo Comparator|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
11405516|NCT01999114|Active Comparator|Moxifloxacin|Moxifloxacin 400-mg tablets
11405517|NCT01999101|Experimental|Px-104|Px-104 capsules, 5 mg
11405518|NCT01999088|Experimental|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
11405519|NCT01999088|Placebo Comparator|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
11405520|NCT01999075|Placebo Comparator|Conventional Treatment|Conventional Treatment
11405521|NCT01999075|Active Comparator|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
11405522|NCT01999062|Experimental|IMRT + CT + MR scan|
11405523|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
11405524|NCT01999023|No Intervention|Observational group|No intervention
11405525|NCT01999023|Experimental|Dietary supplement|Low protein formula formula (28.5 g) twice a day
11405526|NCT01999010|No Intervention|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
11405527|NCT01999010|Experimental|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
11405528|NCT01999010|Experimental|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
11405529|NCT01998997|Active Comparator|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
11405530|NCT01998997|Placebo Comparator|general health education|The placebo group will be given a brochure on good health habits
11405531|NCT01998984|Experimental|2 days placebo and 2 days drug|Placebo and drug
11405532|NCT01998984|Experimental|1 day placebo and 3 days drug|Placebo and drug
11405533|NCT01998984|Placebo Comparator|4 days placebo|Placebo
11405534|NCT01998984|Experimental|4 days drug|Drug
11405535|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
11405536|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
11405537|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
11405538|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
11405539|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
11405540|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
11405541|NCT01998958|Experimental|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
11405542|NCT01998958|Experimental|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
11405570|NCT01998789|Active Comparator|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.
~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
11405571|NCT01998776|Active Comparator|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
11405543|NCT01998958|Experimental|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
11405544|NCT01998958|Experimental|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
11405545|NCT01998958|Placebo Comparator|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
11405546|NCT01998945|Experimental|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
11405547|NCT01998945|Active Comparator|Relaxation Training (RT)|Participants will receive relaxation training
11405548|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
11405549|NCT01998919|Experimental|Tarceva + gemcitabine/platinum|
11405550|NCT01998919|Placebo Comparator|Placebo + gemcitabine/platinum|
11405551|NCT01998906|Experimental|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m^2), IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m^2, IV; methotrexate 40 mg/m^2, IV; and 5-fluorouracil 600 mg/m^2, IV, on Day 1 of Cycles 8 through 10.
11405552|NCT01998906|Active Comparator|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
11405553|NCT01998906|Active Comparator|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
11405554|NCT01998893|Experimental|MabThera/Rituxan|
11405555|NCT01998880|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
11405556|NCT01998880|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
11405557|NCT01998880|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
11405558|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
11405559|NCT01998841|Experimental|Mutation Carriers: Crenezumab|Participants will receive crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
11405560|NCT01998841|Placebo Comparator|Mutation Carriers: Placebo|Participants will receive placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
11405561|NCT01998841|Placebo Comparator|Non-carriers of Mutation: Placebo|Participants will receive placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
11405562|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
11405563|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
11405564|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
11405565|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
11405566|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
11405567|NCT01998802|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
11405568|NCT01998802|Placebo Comparator|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
11405569|NCT01998789|Experimental|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.
~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
11405572|NCT01998776|Placebo Comparator|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
11405574|NCT01998763|Experimental|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
11405575|NCT01998750||Early-onset severe obesity|The study will enroll children and young adults up to 21 years of age with early onset severe obesity (BMI > 99th percentile noted at an age < 6 years of age).
11405576|NCT01998737||Women under osteoporosis suspicion|
11405577|NCT01998737||Healthy women|
11405578|NCT01998724|No Intervention|Standard Care|No intervention
11405579|NCT01998724|Experimental|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
11405580|NCT01998724|Experimental|Group Walking Exercise|24 week group walking intervention
11405581|NCT01998711|Experimental|Memory group|Memory training
11405582|NCT01998711|No Intervention|Control|Standard care
11405583|NCT01998698|Active Comparator|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
11405584|NCT01998698|Active Comparator|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
11405585|NCT01998685|Experimental|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
11405586|NCT01998685|Active Comparator|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
11405587|NCT01998672|Active Comparator|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
11405588|NCT01998672|Placebo Comparator|Placebo|Oral drinking solution
11405589|NCT01998659|Active Comparator|Px-102|Px-102 drinking solution, single dose
11405590|NCT01998659|Placebo Comparator|Placebo|Placebo drinking solution, single dose
11405591|NCT01998646|Experimental|ASP4058 Tablet Dose Escalation Cohort|
11405592|NCT01998646|Experimental|ASP4058 Tablet - Fasting conditions|
11405593|NCT01998646|Experimental|ASP4058 Tablet - Fed conditions|
11405594|NCT01998646|Placebo Comparator|Placebo|
11405595|NCT01998633|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
11405596|NCT01998620|Experimental|Ademetionine 1|Ademetionine 2000mg
11405597|NCT01998620|Experimental|Ademetionine 2|Ademetionine 1000mg
11405598|NCT01998620|Active Comparator|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
11405599|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
11405600|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
11405601|NCT01998594|Active Comparator|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
11405602|NCT01998594|Experimental|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
11405603|NCT01998581|Experimental|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
11405604|NCT01998581|Active Comparator|Restylane-L®|Lips injected with Restylane-L®
11405605|NCT01998568||Corneal edema|Intraocular pressure measurement
11405606|NCT01998555|Other|CAD-CBT group therapy|CAD receive web-based CBT group therapy
11405607|NCT01998555|Other|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
11405608|NCT01998542|Experimental|AlloStim+CRCL|AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
11405609|NCT01998529|Experimental|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
11405610|NCT01998516||Schizophrenia Patients|
11405611|NCT01998516||Bipolar I Patients|
11405612|NCT01998516||Siblings of Schizophrenia Patients|
11405613|NCT01998516||Siblings of Bipolar I Patients|
11405614|NCT01998516||Healthy Controls|
11405615|NCT01998503|Active Comparator|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
11405692|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
11405902|NCT01996475|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
11405616|NCT01998503|Experimental|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
11405617|NCT01998490|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
11405618|NCT01998490|Experimental|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
11405619|NCT01998490|No Intervention|Control|Control group with treatment as usual
11405620|NCT01998477|Experimental|TIVc|flu vaccine
11405621|NCT01998477|Active Comparator|TIV|flu vaccine
11405622|NCT01998464||Retinal Vasculitis Group|Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
11405623|NCT01998451|Experimental|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
11405624|NCT01998451|Other|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
11405625|NCT01998438|Experimental|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
11405626|NCT01998438|Experimental|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
11405627|NCT01998438|Experimental|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
11405628|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
11405629|NCT01998399|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
11405630|NCT01998399|Placebo Comparator|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
11405631|NCT01998386|Placebo Comparator|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
11405632|NCT01998386|Experimental|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
11405633|NCT01998386|Experimental|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
11405634|NCT01998386|Experimental|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
11405635|NCT01998373|Experimental|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
11405636|NCT01998373|No Intervention|control without education|this group did not receive an education
11405637|NCT01998360|Experimental|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
11405638|NCT01998360|Active Comparator|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
11405639|NCT01998347|Experimental|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.
~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
11405640|NCT01998347|Active Comparator|Cisplatin plus 5-fluorouracil|"Cisplatin:
~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.
~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
11405641|NCT01998334|Experimental|CVVH 6h|CVVH 6h for first three days
11405642|NCT01998334|Experimental|CVVH 10h|CVVH 10h for first three days
11405643|NCT01998334|Experimental|CVVHDF|CVVHDF 6h for first three days
11405644|NCT01998321|Experimental|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
11405645|NCT01998321|Experimental|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
11405646|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
11405647|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
11405648|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
11405649|NCT01998308||Group 4|50 knees will have single injection of Monovisc
11405650|NCT01998295|Active Comparator|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days
~Dosage:
~tablet for body weight between 5-14.9 Kilograms.
~tablets for body weight between 15-24.9 Kilograms.
~tablets for body weight between 25-34.9 Kilograms."
11405651|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
11405652|NCT01998282||Control|Traditional water management practices and cooking stoves
11405653|NCT01998269||Adult patients with diabetes and hypertension|
11405654|NCT01998256|Sham Comparator|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
11405693|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
11405655|NCT01998256|Active Comparator|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
11405656|NCT01998243|Experimental|IGB group A|the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
11405657|NCT01998243|Placebo Comparator|control group B|the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
11405658|NCT01998230|Experimental|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
11405659|NCT01998230|No Intervention|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
11405660|NCT01998217|Active Comparator|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
11405661|NCT01998217|Experimental|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
11405662|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
11405663|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
11405664|NCT01998191|Active Comparator|Implicit Case note review (nurse)|"Notes to be reviewed using the implicit method by a nurse
~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
11405665|NCT01998191|Active Comparator|Implicit Case note review (MDT)|"Notes to be reviewed using the implicit method by an expert physician and nurse team.
~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
11405666|NCT01998191|Active Comparator|Implicit Case note review (physician)|"Notes to be reviewed using the implicit method by an expert physician
~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
11405667|NCT01998165|Experimental|Remifentanil (0.25 µg/kg/min)|
11405668|NCT01998152|Experimental|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
11405669|NCT01998152|No Intervention|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
11405670|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
11405671|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
11405672|NCT01998126|Experimental|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
11405673|NCT01998126|Experimental|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
11405674|NCT01998126|Experimental|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
11405675|NCT01998126|Experimental|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
11405676|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
11405677|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
11405678|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
11405679|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
11405680|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
11405681|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
11405682|NCT01998100|Experimental|Prolonged Exposure + Exercise|
11405683|NCT01998100|Active Comparator|Prolonged Exposure Alone|
11405684|NCT01998087|Experimental|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
11405685|NCT01998087|Active Comparator|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
11405686|NCT01998087|No Intervention|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
11405687|NCT01998074|Experimental|Study formula|
11405688|NCT01998061|Experimental|Arm A|TKI alone until rapid progression
11405689|NCT01998061|Experimental|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
11405690|NCT01998048|Active Comparator|Latarjet|60 patients treated with open Latarjet operation
11405691|NCT01998048|Active Comparator|Bankart|60 patients treated with arthroscopic Bankart operation
11405694|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
11405695|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
11405696|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
11405697|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
11405698|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
11405699|NCT01998009|Other|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
11405700|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
11405701|NCT01997983|Experimental|TC-3 Gel with Botox|open label observational study
11405702|NCT01997970|Experimental|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
11405703|NCT01997970|Experimental|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
11405704|NCT01997957|Experimental|TACE+HAIC-OXA+S-1|
11405705|NCT01997957|No Intervention|TACE+HAIC-OXA|
11405706|NCT01997944|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
11405707|NCT01997944|Active Comparator|Pegasys|Peginteferon 180 mcg multiple dose S.C.
11405708|NCT01997905|Experimental|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
11405709|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
11405710|NCT01997879|Experimental|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
11405711|NCT01997866|Other|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model
~Polysomnogram Sleep Study"
11405712|NCT01997853|Active Comparator|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
11405713|NCT01997853|Placebo Comparator|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
11405714|NCT01997840|Experimental|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
11405715|NCT01997827|Active Comparator|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
11405716|NCT01997827|Experimental|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
11405717|NCT01997814|Active Comparator|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
11405718|NCT01997814|Placebo Comparator|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
11405719|NCT01997801|Placebo Comparator|C group|In C group, NS infusion will be done intraoperatively.
11405720|NCT01997801|Experimental|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
11405721|NCT01997788|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
11405722|NCT01997788|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
11405723|NCT01997775|Experimental|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
11405724|NCT01997762|Placebo Comparator|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
11405725|NCT01997762|Experimental|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
11405726|NCT01997749|Experimental|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
11405727|NCT01997749|Active Comparator|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
11405728|NCT01997736|Experimental|Ablation|
11405729|NCT01997723|Experimental|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
11405730|NCT01997710|Experimental|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
11405731|NCT01997710|Active Comparator|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
11405732|NCT01997697|Experimental|Patients with obesity|behavior change program among patients with obesity
11405733|NCT01997684|Experimental|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.
~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.
~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.
~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
11405734|NCT01997684|Active Comparator|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
11405735|NCT01997671|Experimental|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
11405736|NCT01997671|No Intervention|Control group|Routine clinical practice
11405737|NCT01997658|Experimental|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
11405738|NCT01997658|Placebo Comparator|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
11405739|NCT01997645|Active Comparator|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.
~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
11405740|NCT01997645|Active Comparator|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.
~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
11405741|NCT01997632|Active Comparator|control vaccine: Imovax Polio®|
11405742|NCT01997632|Experimental|investigational vaccine|
11405743|NCT01997606|Experimental|Purotex|use of Purotex treated bedding covers
11405744|NCT01997606|Placebo Comparator|Placebo|no use of Purotex treated bedding covers
11405745|NCT01997593|Experimental|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
11405746|NCT01997580|Experimental|Escitalopram|depressed patients receiving escitalopram treatment
11405747|NCT01997580|No Intervention|Control|healthy controls matched for age, gender, and BMI
11405748|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
11405749|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
11405750|NCT01997554|Experimental|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
11405751|NCT01997554|Experimental|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
11405752|NCT01997554|Experimental|more than 60 years old|Group of patients more than 60 years old at recruitment.
11405753|NCT01997541||plain tube|
11405754|NCT01997541||reinforced tube|
11405755|NCT01997528|Experimental|Extracorporeal CO2 elimination by ILA Activve(R)|
11405756|NCT01997515|Active Comparator|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
11405757|NCT01997515|Placebo Comparator|Group P (Placebo)|Group P (placebo) will receive the same amount of saline.
11405758|NCT01997489|Experimental|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
11405759|NCT01997476|Experimental|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.
~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
11405760|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
11405761|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
11405762|NCT01997450||Q/LAIV|FluMist Quadrivalent
11405763|NCT01997450||Inactivated Influenza Vaccine|Inactivated Influenza Vaccine
11405764|NCT01997437|Other|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
11405765|NCT01997411|Experimental|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
11405766|NCT01997411|Active Comparator|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
11405767|NCT01997385|Active Comparator|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
11405768|NCT01997385|Experimental|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
11405769|NCT01997372|Experimental|high dose ATG,low dose ATG|
11405770|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
11405829|NCT01996982|Experimental|Device|CCS Device application
11405830|NCT01996969|Other|Regorafenib|This study is a single arm study with biomarker analysis
11405831|NCT01996956|Other|Volume loading|
11405903|NCT01996462|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
11405771|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
11405772|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
11405773|NCT01997333|Active Comparator|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
11405774|NCT01997333|Experimental|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
11405775|NCT01997320|Experimental|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
11405776|NCT01997320|Active Comparator|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
11405777|NCT01997307||Stratification by gender and age, including 4 age categories|>=55-64 years
11405778|NCT01997307||Age >=65 to 74|
11405779|NCT01997307||Age >=75 to 84|
11405780|NCT01997307||Age >=85|
11405781|NCT01997294|Active Comparator|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
11405782|NCT01997294|Placebo Comparator|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
11405783|NCT01997281|Experimental|DF-cereal|"dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
~amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)
~one serving (40g) of steamed egg is added for dinner and breakfast"
11405784|NCT01997281|Other|conventional cereal|"conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
~amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)
~one serving (40g) of steamed egg is added for dinner and breakfast"
11405785|NCT01997268|Placebo Comparator|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
11405786|NCT01997268|Experimental|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
11405787|NCT01997268|Experimental|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
11405788|NCT01997268|Experimental|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
11405789|NCT01997255|Experimental|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
11405790|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
11405791|NCT01997229|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
11405792|NCT01997229|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
11405793|NCT01997216|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
11405794|NCT01997216|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
11405795|NCT01997203|Experimental|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.
~Dose of vitamin D 15,000 IU/week"
11405796|NCT01997203|No Intervention|HCV without Vit D|
11405797|NCT01997190|Experimental|Study Arm|AdV-tk + valacyclovir
11405798|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
11405799|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
11405800|NCT01997164|Experimental|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
11405801|NCT01997164|Experimental|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
11405832|NCT01996943|Placebo Comparator|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
11405833|NCT01996943|Active Comparator|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
11405899|NCT01996514|Experimental|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
11405900|NCT01996501|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
11405802|NCT01997151|Experimental|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
11405803|NCT01997151|No Intervention|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
11405804|NCT01997138|Experimental|Anakinra|Anakinra 100 mg in 2 ml saline IA
11405805|NCT01997138|Placebo Comparator|Placebo|Saline 2 ml IA
11405806|NCT01997125|Experimental|Open Label|Neural bridge system implant and external stimulator
11405807|NCT01997112|Active Comparator|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
11405808|NCT01997112|Placebo Comparator|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
11405809|NCT01997099||Library Creation|Individuals responsible for creating the drug library
11405810|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
11405811|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
11405812|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
11405813|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
11405814|NCT01997086|Active Comparator|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
11405815|NCT01997086|Active Comparator|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
11405816|NCT01997060|Experimental|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (~-700KCal/day). Education within nutrition, exercise and healthy living in general.
11405817|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
11405818|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
11405819|NCT01997021|Experimental|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
11405820|NCT01997021|Experimental|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
11405821|NCT01997021|Experimental|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
11405822|NCT01997021|Experimental|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
11405823|NCT01997021|Experimental|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
11405824|NCT01997021|Experimental|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
11405825|NCT01997008|Experimental|Intervention|"Participants receive a five week intervention providing the following activities:
~EMA:
~Ecological Momentary Assessment (EMA) of Emotion throughout the day.
~Intervention:
~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.
~Gratitude: Participants identify one more more things that make them feel grateful.
~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.
~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.
~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.
~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
11405826|NCT01997008|No Intervention|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.
~EMA detail:
~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
11405827|NCT01996995|Experimental|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
11405828|NCT01996995|Sham Comparator|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
11405834|NCT01996930|Active Comparator|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.
~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
11405835|NCT01996930|Active Comparator|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
11405836|NCT01996917|Active Comparator|Prineo closure|One breast will have skin closure with Prineo.
11405837|NCT01996917|No Intervention|Standard Suture|One breast will be closed in the standard fashion with suture.
11405838|NCT01996904|Experimental|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
11405839|NCT01996904|Active Comparator|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
11405840|NCT01996891|Other|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
11405841|NCT01996891|Other|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
11405842|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
11405843|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
11405844|NCT01996865|Experimental|Arm A: Lenalidomide + rituximab followed by lenalidomide|Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but < 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by a Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
11405845|NCT01996865|Active Comparator|Arm B: Lenalidomide + rituximab followed by rituximab|Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but < 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
11405846|NCT01996852|Active Comparator|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
11405847|NCT01996852|Experimental|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
11405848|NCT01996852|No Intervention|Usual Care (UC)|Study participants will not receive any study intervention, but will continue with standard care.
11405849|NCT01996839|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
11405850|NCT01996839|Active Comparator|Vehicle (BID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
11405851|NCT01996839|Experimental|Loteprednol Etabonate Gel (TID)|Loteprednol Gel 0.38% administered three times daily (TID).
11405852|NCT01996839|Active Comparator|Vehicle (TID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).
11405853|NCT01996826|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.
~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
11405854|NCT01996826|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.
~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
11405855|NCT01996813|Experimental|Prospective Case|Patients with a BMI of 30 kg/m^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
11405856|NCT01996813|No Intervention|Historical Control|Patients with a BMI of 30 kg/m^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
11405857|NCT01996800|Experimental|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
11405896|NCT01996514|Experimental|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
11405897|NCT01996514|Experimental|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
11405898|NCT01996514|Experimental|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
11405901|NCT01996488|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
11405858|NCT01996800|Active Comparator|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
11405859|NCT01996787|Active Comparator|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
11405860|NCT01996787|Active Comparator|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
11405861|NCT01996774||Child, peanut/ nut allergy, no treatment|
11405862|NCT01996774||Child, peanut/nut allergy, tolerance|
11405863|NCT01996774||Non allergic child, without atopia|
11405864|NCT01996761|Experimental|Study Group 1|Study Group 1: 30ml Cerebrolysin
11405865|NCT01996761|Placebo Comparator|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
11405866|NCT01996748|Experimental|DF277|Two administrations daily for 7 days
11405867|NCT01996748|Placebo Comparator|Placebo|Two administrations daily for 7 days
11405868|NCT01996735|Active Comparator|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
11405869|NCT01996735|Placebo Comparator|Placebo|Placebo single dose
11405870|NCT01996709|Experimental|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
11405871|NCT01996709|Active Comparator|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
11405872|NCT01996696|Experimental|Metformin|Metformin 500 mg PO TID x 30-36 months
11405873|NCT01996696|Placebo Comparator|Placebo|Identical placebo TID x 30-36 months
11405874|NCT01996683|Active Comparator|iron chelation|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
11405875|NCT01996683|Placebo Comparator|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
11405876|NCT01996670||<2h group|
11405877|NCT01996670||2-4h group|
11405878|NCT01996670||>4h group|
11405879|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
11405880|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
11405881|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
11405882|NCT01996644|Experimental|Setraline|250 mg DCS (setraline) versus placebo plus exposure
11405883|NCT01996644|Placebo Comparator|placebo|Placebo group plus exposure
11405884|NCT01996618|Experimental|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
11405885|NCT01996618|Placebo Comparator|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
11405886|NCT01996605|Experimental|Oxytocin 15 mcg|Oxytocin 15 mcg injected spinally
11405887|NCT01996605|Experimental|Oxytocin 150 mcg|Oxytocin 150 mcg injected spinally
11405888|NCT01996605|Active Comparator|Placebo|Preservative free normal saline injected spinally
11405889|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
11405890|NCT01996579|Experimental|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
11405891|NCT01996579|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
11405892|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
11405893|NCT01996540|Experimental|Interventional arm|Interventional arm
11405894|NCT01996540|No Intervention|Standard arm|Standard arm
11405895|NCT01996527|Experimental|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
11405904|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
11405905|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
11405906|NCT01996436|Active Comparator|Nicardipine|Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty
11405907|NCT01996436|Active Comparator|Verapamil|Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty
11405908|NCT01996436|Active Comparator|Nicardipine + Verapamil + Nitroglycerin|Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty
11405909|NCT01996423|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
11405910|NCT01996423|Placebo Comparator|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
11405911|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
11405912|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
11405913|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
11405914|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
11405915|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
11405916|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
11405917|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
11405918|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
11405919|NCT01996397|Other|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
11405950|NCT01996189|Active Comparator|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
11405951|NCT01996176|Experimental|Intervention group|Intervention group
11405920|NCT01996384|Experimental|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
11405921|NCT01996384|Active Comparator|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
11405922|NCT01996371|Other|Group 1|Unilateral pedicle screws
11405923|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
11405924|NCT01996371|Other|Group 3|Bilateral pedicle screws
11405925|NCT01996358|Active Comparator|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
11405926|NCT01996358|Active Comparator|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
11405927|NCT01996358|Active Comparator|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
11405928|NCT01996345|Experimental|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
11405929|NCT01996345|No Intervention|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
11405930|NCT01996332|Experimental|Tarceva Arm|
11405931|NCT01996319|Active Comparator|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
11405932|NCT01996319|Active Comparator|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
11405933|NCT01996306|Active Comparator|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
11405934|NCT01996306|Experimental|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
11405935|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
11405936|NCT01996280|Placebo Comparator|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
11405937|NCT01996280|Experimental|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
11405938|NCT01996267|Active Comparator|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
11405939|NCT01996267|Active Comparator|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
11405940|NCT01996254|Experimental|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
11405941|NCT01996254|Sham Comparator|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
11405942|NCT01996241|Experimental|Intervention Village Clusters|Receive multi-level, structural and norms-based intervention
11405943|NCT01996241|No Intervention|Control Village Clusters|No multi-level, structural and norms-based intervention
11405944|NCT01996228|Experimental|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
11405945|NCT01996215||AMD controls|
11405946|NCT01996215||AMD cases|
11405947|NCT01996202|Other|Resected Melanoma|Subjects with resected melanoma.
11405948|NCT01996202|Other|Unresected Melanoma|Subjects with unresected melanoma.
11405949|NCT01996189|Experimental|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
11405952|NCT01996176|Placebo Comparator|Intervention control|Control group
11405955|NCT01996150|Experimental|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
11405956|NCT01996137|Experimental|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
11405957|NCT01996124|Experimental|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
11405958|NCT01996124|Placebo Comparator|Placebo|Placebo Breezehaler
11405959|NCT01996111|Experimental|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
11405960|NCT01996111|Experimental|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
11405961|NCT01996111|Experimental|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
11405962|NCT01996111|Placebo Comparator|• Group 1|• Injection of 1.0 cc of 0.9% Saline
11405963|NCT01996098|Experimental|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
11405964|NCT01996098|Experimental|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
11405965|NCT01996098|No Intervention|Chemotherapy alone|No intervention
11405966|NCT01996085|Experimental|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.
~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
11405967|NCT01996085|Active Comparator|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).
~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
11405968|NCT01996072|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
11405969|NCT01996059|Experimental|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
11405970|NCT01996059|Active Comparator|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
11405971|NCT01996046||Bone mets|Patients will undergo an [18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
11405972|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
11405973|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
11405974|NCT01995994||RT-CGM|
11405975|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
11405976|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
11405977|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
11405978|NCT01995955|Experimental|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
11405979|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
11405980|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
11405981|NCT01995929||neurogenic dysphagia|Patients suffering from neurogenic dysphagia due to several reasons (e.g. Parkinson´s disease).
11405982|NCT01995916|Experimental|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
11405983|NCT01995916|Active Comparator|Social Support Group|Social Support Group Intervention
11405984|NCT01995903|Experimental|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
11405985|NCT01995903|Active Comparator|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
11405986|NCT01995890|Experimental|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
11405987|NCT01995890|No Intervention|control|No intervention in the control arm
11405988|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
11405989|NCT01995864|Experimental|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
11405990|NCT01995864|No Intervention|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
11405991|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
11405992|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
11405993|NCT01995838|Experimental|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
11405994|NCT01995838|Placebo Comparator|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
11405995|NCT01995825|Active Comparator|brand tablet: initial exposure|brand name lamotrigine tablet
11405996|NCT01995825|Experimental|generic: initial exposure|generic lamotrigine tablet
11405997|NCT01995825|Active Comparator|brand tablet: second exposure|brand name lamotrigine tablet
11405998|NCT01995825|Experimental|generic: second exposure|generic lamotrigine tablet
11405999|NCT01995812|Experimental|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
11406000|NCT01995812|No Intervention|Control group|
11406001|NCT01995799|Experimental|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
11406002|NCT01995799|Experimental|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
11406003|NCT01995799|Experimental|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
11406004|NCT01995786|No Intervention|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
11406005|NCT01995786|Experimental|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) < SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
11406006|NCT01995773||Healthy Controls|Healthy control women
11406007|NCT01995721|Experimental|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
11406008|NCT01995708|Experimental|Arm 1 Vaccine|This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical & Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10^6 LCs per dose (i.e., combination of 3x10^6 CT7 mRNA-electroporated LCs + 3x10^6 MAGE-A3 mRNA-electroporated LCs + 3x10^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
11406009|NCT01995708|Active Comparator|Arm 2 control|Patients receive standard of care treatment after autologous stem cell transplant
11406010|NCT01995695|Experimental|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
11406011|NCT01995695|Experimental|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
11406012|NCT01995669|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
11406013|NCT01995656|Placebo Comparator|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
11406014|NCT01995656|Experimental|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
11406015|NCT01995656|Placebo Comparator|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
11406016|NCT01995656|Experimental|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
11406017|NCT01995656|Placebo Comparator|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
11406018|NCT01995656|Experimental|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
11406019|NCT01995643|Active Comparator|Active Capsule|Grape Seed Extract Capsule: 300 mg
11406020|NCT01995643|Placebo Comparator|Placebo Capsule|Placebo Capsule: Maltodextrin
11406021|NCT01995630|Experimental|Hypermetropic, spherical IOL|AMO Sensar AR40e
11406022|NCT01995630|Experimental|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
11406023|NCT01995630|Active Comparator|Emmetropic, spherical IOL|AMO Sensar AR40e
11406024|NCT01995630|Active Comparator|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
11406025|NCT01995617|Experimental|Low Dose (Cohort 1)|
11406026|NCT01995617|Experimental|Mid Dose (Cohort 2)|
11406027|NCT01995617|Experimental|High Dose (Cohort 3)|
11406028|NCT01995604|Experimental|dHACM|UltraPulse laser therapy with application of dHACM
11406029|NCT01995604|Placebo Comparator|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
11406030|NCT01995578|Experimental|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
11406031|NCT01995552|Other|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
11406032|NCT01995539|Experimental|iPro2 Use|All subjects wearing iPro2, having therapy regimens, and having baseline and EOS A1C tests
11406033|NCT01995526|Experimental|Insulin Peglispro|Single subcutaneous dose of 1.3 Units per kilogram (U/kg) insulin peglispro on Day 1.
11406034|NCT01995513|Experimental|Enzalutamide & Abiraterone/prednisone|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
11406035|NCT01995513|Active Comparator|Enzalutamide placebo & Abiraterone/prednisone|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
11406036|NCT01995500|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:
~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent
~Delivery System - Rapid Exchange (RX) Coronary System
~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®
~Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
11406037|NCT01995500|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:
~Endeavor Resolute Stent - a premounted cobalt alloy based stent
~Delivery system - Rapid Exchange (RX) Coronary System
~Polymer system
~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
11406038|NCT01995487|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:
~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent
~Delivery System - Rapid Exchange (RX) Coronary System
~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®
~Ridaforolimus drug - CAS Registry Number: 572924-54-0
~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
11406039|NCT01995487|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:
~Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent
~Delivery system (Rapid Exchange [RX] Coronary System)
~Polymer system
~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
11406040|NCT01995474|Experimental|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
11406041|NCT01995474|Active Comparator|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
11406042|NCT01995461|Experimental|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
11406043|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
11406044|NCT01995435|Experimental|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
11406045|NCT01995435|Experimental|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
11406046|NCT01995422|Experimental|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
11406047|NCT01995396|Active Comparator|APE with intersphincteric dissection|Abdominoperineal excision with intersphincteric dissection and a stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
11406048|NCT01995396|Active Comparator|Hartmann´s procedure|Hartmann´s operation and stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
11406049|NCT01995383|Placebo Comparator|Part 1: Placebo (PL)|
11406050|NCT01995383|Experimental|Part 1: Single Ascending Doses (SAD) of RO6836191|
11406051|NCT01995383|Placebo Comparator|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
11406052|NCT01995383|Placebo Comparator|Part 2: PL: NS followed by LS diet|
11406053|NCT01995383|Experimental|Part 2: RO6836191: LS followed by NS diet|
11406054|NCT01995383|Experimental|Part 2: RO6836191: NS followed by LS diet|
11406055|NCT01995370|Active Comparator|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.
~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
11406056|NCT01995370|Experimental|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).
~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
11406057|NCT01995357|Experimental|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
11406058|NCT01995357|Experimental|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
11406059|NCT01995357|Experimental|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
11406060|NCT01995357|Experimental|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
11406128|NCT01994980|Active Comparator|Default 4 days antibiotic therapy|Default 4 days antibiotic therapy
11406061|NCT01995357|Experimental|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
11406062|NCT01995357|Experimental|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.
~The test sequence in this arm is:
~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
11406063|NCT01995344|Active Comparator|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
11406064|NCT01995344|Active Comparator|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
11406065|NCT01995331|Other|moderate-dose cyclophosphomide|
11406066|NCT01995318|Placebo Comparator|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
11406067|NCT01995318|Other|Kinesiotaping|Application of anti-edema kinesiotaping
11406068|NCT01995292|Experimental|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
11406069|NCT01995292|Experimental|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
11406070|NCT01995279|Experimental|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
11406071|NCT01995279|Placebo Comparator|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
11406072|NCT01995266|Experimental|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and
~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
11406073|NCT01995253|Experimental|Controlled conditions|
11406074|NCT01995253|Experimental|Free-living conditions|
11406075|NCT01995240|Experimental|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.
11406076|NCT01995240|Experimental|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.
11406077|NCT01995227|Experimental|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
11406078|NCT01995214|Experimental|P|Anesthesia maintenance with propofol+remifentanil
11406079|NCT01995214|Experimental|S|Anesthesia maintenance with sevoflurane+remifentanil
11406080|NCT01995201|Experimental|Part 1: All patients|
11406081|NCT01995201|Experimental|Part 2 A: Sustained clinical remission|
11406082|NCT01995201|Experimental|Part 2 B: Low disease activity|
11406083|NCT01995188|Experimental|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
11406084|NCT01995188|Experimental|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
11406085|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
11406086|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
11406087|NCT01995175|Other|Prospective Cohort|Newborn subjects followed up for LRTI symptoms from birth until they are 2 years of age and for incidence of wheeze and asthma up to 6 years of age.
11406088|NCT01995162|Experimental|Free-living conditions|
11406089|NCT01995149|Experimental|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
11406090|NCT01995136|Experimental|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
11406129|NCT01994980|No Intervention|Default 8 days antibiotic therapy|Default 8 days antibiotic therapy
11406130|NCT01994967|Experimental|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride
~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
11406091|NCT01995123|Experimental|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
11406092|NCT01995123|Active Comparator|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
11406093|NCT01995110|Experimental|normal weight subjects|
11406094|NCT01995110|Experimental|obese subjects|
11406095|NCT01995097|Experimental|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
11406096|NCT01995097|Active Comparator|Support Messages Only|support text messages through 35th week of pregnancy
11406097|NCT01995084|Experimental|Optimization|Patients undergo a [F-18]HX4 PET/CT scan 2,3 and 4h after [F-18]HX4 injection.
11406098|NCT01995084|Experimental|Reproducibility|Patients undergo two [F-18]HX4 PET/CT scans 3.5h after [F-18]HX4 injection within a 10-day time frame.
11406099|NCT01995071|Experimental|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily [QD]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406100|NCT01995071|Experimental|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406101|NCT01995071|Experimental|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406102|NCT01995071|Experimental|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406103|NCT01995071|Experimental|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406104|NCT01995071|Experimental|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406105|NCT01995071|Experimental|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406106|NCT01995071|Experimental|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406107|NCT01995071|Experimental|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406108|NCT01995071|Experimental|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406109|NCT01995071|Experimental|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406110|NCT01995071|Experimental|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11406111|NCT01995058|Experimental|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
11406112|NCT01995058|Experimental|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
11406113|NCT01995058|Experimental|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
11406114|NCT01995058|Active Comparator|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
11406115|NCT01995045|Experimental|Bupivicaine & Triamcinolone|Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
11406116|NCT01995045|Active Comparator|Bupivicaine|Retrobulbar anesthesia with Bupivicaine Hydrochloride
11406117|NCT01995032|Experimental|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
11406118|NCT01995032|Placebo Comparator|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
11406119|NCT01995019|Placebo Comparator|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
11406120|NCT01995019|Experimental|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
11406121|NCT01995006|Experimental|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
11406122|NCT01995006|Active Comparator|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
11406123|NCT01994993|Active Comparator|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
11406124|NCT01994993|Active Comparator|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
11406125|NCT01994993|Active Comparator|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
11406126|NCT01994993|Active Comparator|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
11406127|NCT01994993|Active Comparator|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
11406131|NCT01994967|Active Comparator|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride
~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
11406132|NCT01994954|No Intervention|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
11406133|NCT01994954|Experimental|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.
~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
11406134|NCT01994941|Experimental|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.
~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
11406135|NCT01994941|Active Comparator|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).
~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
11406136|NCT01994928|Active Comparator|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
11406137|NCT01994928|Experimental|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
11406138|NCT01994915|Experimental|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
11406139|NCT01994915|No Intervention|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
11406140|NCT01994902|Experimental|First Coloplast test product|"The subjects test:
~test period 1: Coloplast test product test period 2: SenSura Convex Light"
11406141|NCT01994902|Experimental|First SenSura Convex Light|"The subjects test:
~test period 1: SenSura Convex Light test period 2: Coloplast test product"
11406142|NCT01994889|Experimental|Tafamidis - 20 mg|Active Treatment-Low dose
11406143|NCT01994889|Experimental|Tafamidis - 80 mg|Active Treatment-High Dose
11406144|NCT01994889|Placebo Comparator|Placebo|Placebo control
11406145|NCT01994876|Experimental|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement
~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
11406146|NCT01994876|Experimental|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements
~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
11406147|NCT01994863|Experimental|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.
~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.
~The three Standard Care products were tested in a 1:1:1 randomisation."
11406148|NCT01994863|Experimental|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.
~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.
~The three Standard Care products were tested in a 1:1:1 randomisation."
11406149|NCT01994850|Experimental|Phase I/II|"Total of six 21-day cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP). Cycle 1 rituximab dose divided between Days 1 and 2 to prevent severe infusion reactions in rituximab naïve patients; brentuximab vedotin and cytotoxic chemotherapy administered on Day 2. Cycles 2 through 6 brentuximab vedotin and R-CHP administered on Day 1. Prednisone (or steroid equivalent) administered Days 1-5 of each cycle (prior to rituximab infusion).
~Cycle 1:
~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 100 mg/m2 IV; Day 2: Rituximab 275 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg or 1.2 mg/kg (Phase I data established a MTD of 1.8 mg/kg brentuximab vedotin)
~Cycles 2-6:
~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 375 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg"
11406150|NCT01994837|Experimental|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
11406151|NCT01994824|Experimental|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.
~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
11406152|NCT01994785|Active Comparator|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
11406153|NCT01994785|Active Comparator|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
11406154|NCT01994785|Active Comparator|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
11406155|NCT01994785|Active Comparator|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
11406156|NCT01994772|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
11406157|NCT01994772|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
11406158|NCT01994759|Active Comparator|Training|strengthening and stretching exercises.
11406159|NCT01994759|Active Comparator|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
11406160|NCT01994759|Active Comparator|Training and Glucocorticosteroid injections|A combination treatment of the two above.
11406161|NCT01994746|Experimental|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
11406162|NCT01994746|Active Comparator|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular [IM]).
11406163|NCT01994733|Experimental|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
11406164|NCT01994733|Active Comparator|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
11406165|NCT01994720|Experimental|ticagrelor|
11406166|NCT01994720|Active Comparator|Acetylsalicylic acid (ASA)|
11406167|NCT01994707|Active Comparator|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
11406168|NCT01994707|Placebo Comparator|Placebo|Deflated cuff on arm for 30 minutes.
11406169|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
11406170|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
11406171|NCT01994681||Pancreatic Cancer|
11406172|NCT01994681||Healthy|
11406173|NCT01994668|Experimental|Lorazepam|
11406174|NCT01994668|Placebo Comparator|Placebo|
11406175|NCT01994655|Experimental|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
11406176|NCT01994642|Active Comparator|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
11406177|NCT01994642|Placebo Comparator|Placebo|Placebo Sterile Otic Suspension
11406178|NCT01994642|Experimental|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
11406179|NCT01994629|Experimental|MenACWY-CRM|MenACWY-CRM
11406180|NCT01994629|Active Comparator|MenACWY-TT|MenACWY-TT
11406181|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
11406182|NCT01994603|Experimental|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
11406183|NCT01994603|Experimental|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
11406184|NCT01994590|Experimental|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.
~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.
~Participant to take 5 mg oral prednisone, twice daily."
11406185|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
11406186|NCT01994538|Active Comparator|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
11406187|NCT01994538|Placebo Comparator|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
11406188|NCT01994525|Experimental|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.
~Challenge occurs 3 weeks after final immunization."
11406189|NCT01994525|Placebo Comparator|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.
~Challenge occurs 3 weeks after final immunization."
11406190|NCT01994525|Other|Cohort 1: Nonimmunized|"No protective intervention given.
~Challenge occurs directly after screening."
11406267|NCT01994005|Active Comparator|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
11406191|NCT01994525|Experimental|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.
~Challenge occurs 3 weeks after final immunization."
11406192|NCT01994525|Placebo Comparator|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.
~Challenge occurs 3 weeks after final immunization."
11406193|NCT01994525|Other|Cohort 2: Nonimmunized|"No protective intervention given.
~Challenge occurs directly after screening."
11406194|NCT01994525|Experimental|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort
~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.
~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
11406195|NCT01994512|Experimental|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
11406196|NCT01994512|Experimental|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
11406197|NCT01994499|Experimental|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
11406198|NCT01994499|Active Comparator|Medical pleural drainage|Medical drainage
11406199|NCT01994486|Experimental|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
11406200|NCT01994473|Experimental|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
11406201|NCT01994473|Placebo Comparator|Placebo|An oral of matched placebo
11406202|NCT01994473|Experimental|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
11406203|NCT01994460|Active Comparator|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
11406204|NCT01994460|Experimental|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
11406205|NCT01994460|Experimental|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
11406206|NCT01994447|No Intervention|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
11406207|NCT01994447|Experimental|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
11406208|NCT01994434|Other|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
11406209|NCT01994421|Sham Comparator|Kinesiotape|
11406210|NCT01994408|Experimental|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
11406211|NCT01994395|Experimental|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
11406212|NCT01994395|Active Comparator|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
11406213|NCT01994382|Experimental|cerdulatinib (PRT062070)|Intervention: Drug: cerdulatinib (PRT062070) or cerdulatinib (PRT062070) plus rituximab
11406214|NCT01994369|Experimental|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
11406215|NCT01994356|Active Comparator|Usual contraceptive counseling|subjects received usual contraceptive counseling
11406216|NCT01994356|Experimental|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
11406217|NCT01994343|Experimental|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
11406218|NCT01994343|No Intervention|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
11406219|NCT01994330|Experimental|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
11406220|NCT01994330|Placebo Comparator|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
11406221|NCT01994317|Active Comparator|Standard sedation dose|IV sedation dose calculated using current standard of care
11406222|NCT01994317|Experimental|Algorithm|IV sedation dose calculated by study algorithm
11406223|NCT01994304|No Intervention|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
11406224|NCT01994304|Active Comparator|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
11406225|NCT01994291|Active Comparator|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
11406226|NCT01994291|Experimental|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
11406227|NCT01994278|Experimental|Tooth brush|Periclean is a soft rubber gentle toothbrush
11406228|NCT01994265|Active Comparator|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
11406229|NCT01994265|Active Comparator|Dabigatran|Dabigatran 150 mg twice daily
11406230|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
11406231|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
11406232|NCT01994239|Active Comparator|Radiation|"Pelvic radiotherapy
~46 Gy in 23 fractions of 2 Gy.
~prostate only-boost up to 66 Gy"
11406233|NCT01994239|Experimental|Radiation and Degarelix|"Radiotherapy:
~46 Gy in 23 fractions of 2 Gy.
~prostate only-boost up to 66 Gy
~Associated with hormonal therapy by degarelix:
~beginning in parallel to radiotherapy for 6 months
~First dose of 240 mg
~Maintenance dose of 80 mg"
11406234|NCT01994226|Active Comparator|Low-dose colchicine|500 mcg every eight hours for four days
11406235|NCT01994226|Active Comparator|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
11406236|NCT01994213|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
11406237|NCT01994200|Experimental|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
11406238|NCT01994200|Other|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
11406239|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
11406240|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
11406241|NCT01994148|Experimental|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
11406242|NCT01994135|Active Comparator|Reference food|The reference food is white bread
11406243|NCT01994135|Experimental|Test food dose 1|Test food dose 1 response will be compared to reference test food
11406244|NCT01994135|Experimental|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
11406245|NCT01994122||People who have dropped out of school|
11406246|NCT01994122||College students (control group)|
11406247|NCT01994109|Active Comparator|MYOBLOC 2500 U|Subjects will receive specified dose of MYOBLOC
11406248|NCT01994109|Active Comparator|MYOBLOC 3500 U|Subjects will receive specified dose of MYOBLOC
11406249|NCT01994109|Placebo Comparator|Placebo|Subjects will receive volume matched Placebo
11406250|NCT01994096|Experimental|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
11406251|NCT01994083|Placebo Comparator|Placebo|Placebo
11406252|NCT01994083|Experimental|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
11406253|NCT01994070|Active Comparator|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
11406254|NCT01994070|Active Comparator|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
11406255|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.
~resistant patients were defined as patients reached PD after first month administration and first three months administration"
11406256|NCT01994044|Active Comparator|Multimodal rehabilitation|
11406257|NCT01994044|Active Comparator|Cervical fusion|
11406258|NCT01994031|Experimental|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
11406259|NCT01994031|Experimental|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
11406260|NCT01994031|Experimental|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
11406261|NCT01994031|Experimental|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
11406262|NCT01994031|Experimental|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
11406263|NCT01994031|Active Comparator|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
11406264|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
11406265|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
11406266|NCT01994005|Placebo Comparator|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
11406268|NCT01993979|Other|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
11406269|NCT01993979|Experimental|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
11406270|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
11406271|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
11406272|NCT01993966||non-tumoral|specimens come from non-tumoral patients
11406273|NCT01993953|Active Comparator|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
11406274|NCT01993953|Active Comparator|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
11406275|NCT01993953|Active Comparator|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
11406276|NCT01993953|No Intervention|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
11406277|NCT01993940|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
11406278|NCT01993940|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
11406279|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
11406280|NCT01993901|Experimental|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
11406281|NCT01993901|No Intervention|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
11406282|NCT01993888|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
11406283|NCT01993888|Other|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
11406284|NCT01993875|Experimental|Lubiprostone|
11406285|NCT01993875|Placebo Comparator|Placebo|
11406286|NCT01993862|No Intervention|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
11406287|NCT01993862|Active Comparator|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
11406288|NCT01993849|Active Comparator|N-Acetylcysteine (NAC)|Oral N-acetylcysteine 1200 mg twice daily dosing for 8 weeks
11406289|NCT01993849|Placebo Comparator|Placebo|Oral placebo (matched in appearance to active treatment) twice daily dosing for 8 weeks
11406290|NCT01993836|Active Comparator|Total Intravenous Anesthesia with Propofol|Patients in this arm will receive general anesthesia with propofol as the primary amnestic agent.
11406291|NCT01993836|Active Comparator|General anesthesia with Isoflurane|Patients in this arm will undergo general anesthesia with isoflurane as the primary amnestic agent.
11406292|NCT01993823|Experimental|G238|Five drops into the ear canal twice daily for 14 days
11406293|NCT01993823|Active Comparator|Clotrimazole|Five drops into the ear canal twice daily for 14 days
11406294|NCT01993810|Active Comparator|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* IV over 1 hour and carboplatin* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.
~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
11406342|NCT01993537|No Intervention|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
11406343|NCT01993537|Experimental|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
11406528|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
11406295|NCT01993810|Experimental|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* and carboplatin*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.
~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
11406296|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
11406297|NCT01993784|Experimental|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
11406298|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
11406299|NCT01993758|Active Comparator|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
11406300|NCT01993758|Experimental|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
11406301|NCT01993745||Study group|ECMO Patients survived
11406302|NCT01993745||Control|ECMO Patient died
11406303|NCT01993732|Experimental|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
11406304|NCT01993719|Experimental|1/ Arm 1P|Standard preparative regimen + Young TIL Cells + possible retreatment with standard preparative regimen + Young TIL Cells +pembrolizumab
11406305|NCT01993719|Experimental|1/Arm 1 (CLOSED)|Standard preparative regimen + Young TIL Cells
11406306|NCT01993719|Experimental|2/Arm 2 (CLOSED)|Lower dose preparative regimen + Young TIL Cells
11406307|NCT01993719|Experimental|3/ Arm 1N|Standard preparative regimen + Young TIL Cells
11406308|NCT01993693|Experimental|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
11406309|NCT01993693|Placebo Comparator|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
11406310|NCT01993680|Experimental|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
11406311|NCT01993680|Active Comparator|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
11406312|NCT01993667|Active Comparator|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
11406313|NCT01993667|Experimental|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
11406314|NCT01993654||Nevus|
11406315|NCT01993654||Racial Melanosis|
11406316|NCT01993654||Primary Acquired Melanosis|
11406317|NCT01993654||Malignant Melanoma|
11406318|NCT01993654||Normal|
11406319|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
11406320|NCT01993628|Experimental|Alzheimer's disease (AD)|Rey figure test and MRI
11406321|NCT01993628|Experimental|Lewy body's dementia (LBD)|Rey figure test and MRI
11406322|NCT01993615|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetabular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
11406323|NCT01993615|Active Comparator|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
11406324|NCT01993602|No Intervention|Control group|no intervention was performed in this group during postoperative period,
11406325|NCT01993602|Active Comparator|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
11406326|NCT01993602|Active Comparator|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
11406327|NCT01993602|Active Comparator|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
11406328|NCT01993602|Active Comparator|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
11406329|NCT01993589|No Intervention|Control group|Control group
11406330|NCT01993589|Active Comparator|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
11406331|NCT01993589|Active Comparator|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
11406332|NCT01993589|Active Comparator|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
11406333|NCT01993589|Active Comparator|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
11406334|NCT01993589|Active Comparator|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
11406335|NCT01993576|Experimental|indocyanine green|Indocyanine green is injected intravenously.
11406336|NCT01993563|Experimental|Graded Motor Imagery|
11406337|NCT01993563|Active Comparator|Standard treatment|
11406338|NCT01993550|Experimental|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
11406339|NCT01993550|Active Comparator|Education|Overview of resources for psychosocial support and health information
11406340|NCT01993537|No Intervention|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
11406341|NCT01993537|No Intervention|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
11406529|NCT01992276|Experimental|CR8020|Investigational monoclonal antibody against influenza A viruses
11406344|NCT01993524|Experimental|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
11406345|NCT01993524|Placebo Comparator|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
11406346|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L
11406347|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L
11406348|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L
11406349|NCT01993498|Other|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
11406350|NCT01993472|Experimental|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
11406351|NCT01993472|Active Comparator|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
11406352|NCT01993459|Experimental|Midazolam intravenous|3mg/ml midazolam given intravenously
11406353|NCT01993459|Placebo Comparator|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
11406354|NCT01993446|Experimental|DRM02|DRM02 Topical Gel, 0.25%
11406355|NCT01993446|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
11406356|NCT01993433|Experimental|DRM02|DRM02 Topical Gel, 0.25%
11406357|NCT01993433|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
11406358|NCT01993420|Experimental|DRM02|DRM02 Topical Gel, 0.25%
11406359|NCT01993420|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
11406360|NCT01993407|Experimental|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
11406361|NCT01993407|Placebo Comparator|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
11406362|NCT01993394|Experimental|ventilation|hypergravity gas mixture
11406363|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
11406364|NCT01993368|Other|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
11406365|NCT01993368|Other|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
11406366|NCT01993368|Other|controls|necessitating an extraction of wisdom teeth
11406367|NCT01993355|Active Comparator|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
11406368|NCT01993355|Experimental|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
11406369|NCT01993355|Experimental|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
11406370|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
11406371|NCT01993329|Experimental|Gefapixant 50/ Gefapixant 300/ Placebo|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
11406372|NCT01993329|Experimental|Gefapixant 50/ Placebo/ Gefapixant 300|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and 300 mg twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
11406373|NCT01993329|Experimental|Gefapixant 300/ Gefapixant 50/ Placebo|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
11406374|NCT01993329|Experimental|Gefapixant 300/ Placebo/ Gefapixant 50|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and 300 mg twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
11406375|NCT01993329|Experimental|Placebo/ Gefapixant 50/ Gefapixant 300|Placebo to match gefapixant 50 mg and 300 mg twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
11406440|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
11406376|NCT01993329|Experimental|Placebo/ Gefapixant 300/ Gefapixant 50|Placebo to match gefapixant 50 mg and 300 mg twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
11406377|NCT01993316|Experimental|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
11406378|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
11406379|NCT01993290|Active Comparator|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
11406380|NCT01993290|Active Comparator|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
11406381|NCT01993290|Active Comparator|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
11406382|NCT01993277|Active Comparator|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
11406383|NCT01993277|Active Comparator|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
11406384|NCT01993277|Active Comparator|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
11406385|NCT01993277|Active Comparator|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
11406386|NCT01993251|Active Comparator|melatonin 0.5mg|
11406387|NCT01993251|Active Comparator|melatonin 2mg|
11406388|NCT01993251|Active Comparator|melatonin 6mg|
11406389|NCT01993251|Placebo Comparator|placebo|
11406390|NCT01993238|Experimental|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
11406391|NCT01993225|Placebo Comparator|Placebo|Placebo Gel and Placebo capsules
11406392|NCT01993225|Experimental|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
11406393|NCT01993225|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
11406394|NCT01993212|Placebo Comparator|Placebo|Androxal Placebo and Gel Placebo
11406395|NCT01993212|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
11406396|NCT01993212|Experimental|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
11406397|NCT01993199|Active Comparator|deep biopsy|
11406398|NCT01993186|Experimental|UX007|"Participants randomized to receive UX007 enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.
~Following completion of the Week 8 study visit, participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
11406399|NCT01993186|Placebo Comparator|Placebo|"Participants randomized to receive placebo enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.
~Following completion of the Week 8 study visit, placebo participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
11406400|NCT01993173|Experimental|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
11406401|NCT01993173|Active Comparator|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
11406402|NCT01993160|Experimental|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
11406403|NCT01993147|Other|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
11406404|NCT01993134|Experimental|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
11406405|NCT01993134|Active Comparator|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
11406406|NCT01993121|Experimental|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
11406407|NCT01993108|Experimental|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
11406408|NCT01993108|Experimental|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
11406409|NCT01993095|Experimental|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
11406410|NCT01993095|Active Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
11406411|NCT01993082|Experimental|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.
~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
11406412|NCT01993082|No Intervention|Activity Maintenance Group|Participants randomized into the waitlist control group receive no aerobic training. Wait-list control participants will receive monthly check-in phone calls to establish that they have not significantly increased activity engagement. Participants in this group will receive a free gym membership at the end of the study, monthly phone calls with a fitness coach support provider for 6 months, and 2 coaching text messages per week.
11406413|NCT01993069|Experimental|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
11406414|NCT01993056|Experimental|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
11406415|NCT01993056|Placebo Comparator|control|the control group follows its regular training routine
11406416|NCT01993030|Experimental|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
11406417|NCT01993030|Active Comparator|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
11406418|NCT01993017|Experimental|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
11406419|NCT01993017|Active Comparator|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
11406420|NCT01993017|Placebo Comparator|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
11406421|NCT01993004||Healthy subjects|Self-explanatory
11406422|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
11406423|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
11406424|NCT01992991|Experimental|Transcranial direct current stimulation|Anodal stimulation
11406425|NCT01992991|Sham Comparator|Sham stimulation|30 sek of Transcranial direct current stimulation
11406426|NCT01992978|Experimental|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
11406427|NCT01992978|Active Comparator|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
11406428|NCT01992965|Experimental|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:
~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
11406429|NCT01992965|Active Comparator|Conventional Group|"Conventional Group：
~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
11406430|NCT01992952|Experimental|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
11406431|NCT01992952|Active Comparator|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
11406432|NCT01992939|Active Comparator|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
11406433|NCT01992939|Active Comparator|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
11406434|NCT01992926|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
11406435|NCT01992926|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
11406436|NCT01992913|Experimental|iCBT|integrated CBT with computerized cognitive remediation
11406437|NCT01992913|Other|UC|usual care
11406438|NCT01992900|Experimental|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
11406439|NCT01992900|Active Comparator|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
11406472|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
11406441|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
11406442|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
11406443|NCT01992874|Experimental|Pimasertib Capsule/Pimasertib Tablet|
11406444|NCT01992874|Experimental|Pimasertib Tablet/Pimasertib Capsule|
11406445|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
11406446|NCT01992848|Experimental|All participants|"Venous blood sampling 4-day food diary
~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
11406447|NCT01992835|Placebo Comparator|measurement of mediators in biological fluids|
11406448|NCT01992835|Experimental|Grass pollen allergen extract|
11406449|NCT01992822|Experimental|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
11406450|NCT01992809|Active Comparator|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
11406451|NCT01992809|Placebo Comparator|placebo mineral oil|placebo mineral oil 3 ml/day
11406452|NCT01992796|Experimental|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).
~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.
~Route of administration : oral by nasogastric tube.
~Medication permitted and not permitted during the trial:
~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
11406453|NCT01992796|Placebo Comparator|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
11406454|NCT01992783|Experimental|Hi-maize resistant starch|13.5 g/day
11406455|NCT01992783|Placebo Comparator|Maltodextrin|13.5 g/day
11406456|NCT01992770|Experimental|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring >90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
11406457|NCT01992770|Active Comparator|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
11406458|NCT01992757||Cardiac surgery with cardiopulmary bypass|
11406459|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
11406460|NCT01992731|Active Comparator|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).
~vs."
11406461|NCT01992731|Active Comparator|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.
~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
11406462|NCT01992718|Active Comparator|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
11406463|NCT01992718|Active Comparator|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
11406464|NCT01992705|Other|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:
~Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.
~Stereotactic Body Radiotherapy (SBRT):
~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
11406465|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
11406466|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
11406467|NCT01992679|No Intervention|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
11406468|NCT01992679|Experimental|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
11406469|NCT01992666|Experimental|Blood sampling|
11406470|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
11406471|NCT01992653|Experimental|Polatuzumab Vedotin (1.0mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
11406473|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
11406474|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
11406475|NCT01992653|Experimental|Polatuzumab Vedotin (2.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
11406476|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
11406477|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
11406478|NCT01992627|Experimental|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
11406479|NCT01992614|Experimental|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
11406480|NCT01992614|Experimental|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
11406481|NCT01992614|Experimental|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
11406482|NCT01992601|Experimental|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
11406483|NCT01992601|Experimental|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
11406484|NCT01992601|Experimental|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
11406485|NCT01992601|Experimental|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
11406486|NCT01992588|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
11406487|NCT01992588|Experimental|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
11406488|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
11406489|NCT01992562|Experimental|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
11406490|NCT01992562|Placebo Comparator|Placebo|1ml of normal saline bolus intrathecal injection
11406491|NCT01992549|Experimental|Human-cl rhFVIII|
11406492|NCT01992536|Experimental|Ia: MenABCWY+OMV|Investigational
11406493|NCT01992536|Placebo Comparator|Ib: Placebo|Saline
11406494|NCT01992536|Experimental|IIa: MenABCWY+¼OMV|Investigational
11406495|NCT01992536|Placebo Comparator|IIb: Placebo|Saline
11406496|NCT01992536|Experimental|IIIa: MenABCWY+OMV|Investigational
11406497|NCT01992536|Experimental|IIIb: MenABCWY+¼OMV|Investigational
11406498|NCT01992536|Experimental|IVa: MenABCWY+OMV|Investigational
11406499|NCT01992536|Experimental|IVb: MenABCWY+¼OMV|Investigational
11406500|NCT01992536|Placebo Comparator|IVc: Placebo|Saline
11406501|NCT01992523|Experimental|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
11406502|NCT01992523|Active Comparator|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
11406503|NCT01992510||silicone oil fiiled eye|those with a condition
11406504|NCT01992510||fellow eye|the contralateral eye in the same patient
11406505|NCT01992497|Placebo Comparator|Formula + placebo|
11406506|NCT01992497|Experimental|Formula + probiotic|Formula + probiotic
11406507|NCT01992497|Experimental|Breastfed + probiotic|Breastfed + probiotic
11406508|NCT01992497|Placebo Comparator|Breastfed + placebo|
11406509|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
11406510|NCT01992445||Suicidal|
11406511|NCT01992445||Other mental health|
11406512|NCT01992445||Control (non suicidal, non mental health)|
11406513|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
11406514|NCT01992406||Transrectal hybrid-NOTES anterior resection|
11406515|NCT01992393|Experimental|TIME|This arm will receive the TIME intervention.
11406516|NCT01992393|No Intervention|Treatment as Usual (TAU)|This arm will receive treatment as usual.
11406517|NCT01992380|Experimental|Healthy Volunteer Subjects|Healthy males or females 50 years or older with no evidence of cognitive impairment
11406518|NCT01992380|Experimental|MCI subjects|Subjects 50 years or older with mild cognitive impairment (MCI)
11406519|NCT01992380|Experimental|Probable AD Subjects|Subjects 50 years or older with probable Alzheimer's Disease (AD)
11406520|NCT01992367|Placebo Comparator|Placebo|placebo arm
11406521|NCT01992367|Other|ASLAN003|Active drug
11406522|NCT01992354|Experimental|Single Arm|Evaluation of PET MR device for image assessment and device performance
11406523|NCT01992341|Experimental|AMG 386 15mg/kg and paclitaxel 80mg/m2|
11406524|NCT01992328|Experimental|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
11406525|NCT01992315|Experimental|Adipose-Derived ECM|
11406526|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
11406527|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
11406530|NCT01992276|Experimental|CR6261|Investigational monoclonal antibody against influenza A viruses
11406531|NCT01992276|Placebo Comparator|Placebo|Dextrose: 5% in water
11406532|NCT01992263|Experimental|Vitamin D (600 IU)|
11406533|NCT01992263|Experimental|Vitamin D (2000 IU)|
11406534|NCT01992263|Experimental|Vitamin D (4000 IU)|
11406535|NCT01992263|Placebo Comparator|Placebo|
11406536|NCT01992250|Other|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
11406537|NCT01992250|Other|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
11406538|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
11406539|NCT01992224|Experimental|early mechanical ventilation|"Fulfillment of three or more criteria below:
~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation
~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
11406540|NCT01992224|Experimental|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
11406541|NCT01992211|Experimental|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
11406542|NCT01992211|Experimental|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
11406543|NCT01992211|Experimental|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
11406544|NCT01992211|Experimental|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
11406545|NCT01992211|Experimental|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
11406546|NCT01992211|Experimental|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.
~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.
~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
11406547|NCT01992198|Experimental|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
11406548|NCT01992198|Active Comparator|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
11406549|NCT01992185|Active Comparator|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
11406550|NCT01992185|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
11406551|NCT01992172|Active Comparator|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
11406552|NCT01992172|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
11406553|NCT01992159|Placebo Comparator|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
11406554|NCT01992159|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
11406555|NCT01992159|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
11406556|NCT01992159|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
11406557|NCT01992146|Placebo Comparator|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
11406558|NCT01992146|Experimental|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
11406559|NCT01992133|Experimental|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
11406560|NCT01992133|Placebo Comparator|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
11406561|NCT01992120|Experimental|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:
~Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient
~Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)
~Subjects will take a written test focusing on early recognition and management of sepsis
~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient
~In the second visit:
~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios
~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis
~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
11406638|NCT01991613|No Intervention|Control group|Study subjects will receive standard of care nutrition
11406755|NCT01990846|Placebo Comparator|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
11406562|NCT01992120|Placebo Comparator|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:
~Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient
~Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios
~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis
~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient
~In the second visit:
~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios
~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis
~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
11406563|NCT01992107|Experimental|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
11406564|NCT01992107|Active Comparator|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
11406565|NCT01992107|Active Comparator|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
11406566|NCT01992094|Experimental|QIVc|Influenza vaccine
11406567|NCT01992094|Active Comparator|TIV1c|Influenza vaccine
11406568|NCT01992094|Active Comparator|TIV2c|Influenza vaccine
11406569|NCT01992081|Experimental|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
11406570|NCT01992081|Other|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
11406571|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:
~Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment
~Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
11406572|NCT01992055|Experimental|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
11406573|NCT01992055|Active Comparator|Education & relaxation training|Education and relaxation training control group
11406574|NCT01992042|Experimental|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
11406575|NCT01992029||ALS Patients|
11406576|NCT01992029||Control patients suffering from neuropathy|
11406577|NCT01992029||Control patients suffering from myopathy|
11406578|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
11406579|NCT01992016|Experimental|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
11406580|NCT01992016|Experimental|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
11406581|NCT01992003||Patients undergoing spine surgery|
11406582|NCT01991990|Placebo Comparator|Placebo|
11406583|NCT01991990|Experimental|RoActemra/Actemra|
11406584|NCT01991977|Experimental|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
11406585|NCT01991964|Experimental|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
11406586|NCT01991964|Other|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
11406587|NCT01991951|Experimental|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
11406588|NCT01991951|Active Comparator|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
11406589|NCT01991938|Experimental|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
11406590|NCT01991925||quality of life, quality of care|
11406591|NCT01991912|Experimental|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
11406592|NCT01991899|Experimental|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
11406593|NCT01991899|Active Comparator|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
11406594|NCT01991886|Experimental|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
11406673|NCT01991392|Active Comparator|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
11406674|NCT01991392|Experimental|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
11406889|NCT01989819||non auto-immune small fiber neuropathies|
11406595|NCT01991873|Experimental|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:
~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15
~Re-induction upon progression:
~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.
~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
11406596|NCT01991873|Experimental|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:
~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15
~Re-induction upon progression:
~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.
~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
11406597|NCT01991860|Experimental|APD421|APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
11406598|NCT01991860|Placebo Comparator|Placebo|Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia
11406599|NCT01991847|Experimental|Physical activity|Physical activity
11406600|NCT01991834|Placebo Comparator|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
11406601|NCT01991834|Active Comparator|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
11406602|NCT01991821|Experimental|APD421|IV APD421 single dose
11406603|NCT01991821|Placebo Comparator|Placebo|IV placebo single dose
11406604|NCT01991808|Experimental|DCE-MRI|
11406605|NCT01991795|Experimental|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
11406606|NCT01991795|Placebo Comparator|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
11406607|NCT01991782|No Intervention|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
11406608|NCT01991782|Experimental|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
11406609|NCT01991769|Experimental|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
11406610|NCT01991769|Active Comparator|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
11406611|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
11406612|NCT01991743|Active Comparator|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
11406613|NCT01991743|Active Comparator|Group 5|Administration of 5 mg bupivacaine.
11406614|NCT01991743|Active Comparator|Group 7.5|Administration of 7.5mg bupivacaine.
11406615|NCT01991743|Active Comparator|Group 10|Administration of 10 mg bupivacaine.
11406616|NCT01991717|Experimental|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
11406617|NCT01991717|Other|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
11406618|NCT01991691|Experimental|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
11406619|NCT01991678|Experimental|normal hepatic function|12 Patients will receive a 90-minute IV infusion
11406620|NCT01991678|Experimental|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
11406621|NCT01991678|Experimental|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
11406622|NCT01991665|Other|Group A|Digital examination before instrumental delivery to determine fetal head station and position
11406623|NCT01991665|Other|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
11406624|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).
~One group of patients."
11406625|NCT01991639|No Intervention|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
11406626|NCT01991639|Experimental|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
11406627|NCT01991626|Other|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
11406628|NCT01991626|Other|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
11406629|NCT01991626|Other|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
11406630|NCT01991626|Other|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
11406631|NCT01991626|Other|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
11406632|NCT01991626|Other|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
11406633|NCT01991626|Other|phytase|Maize meal containing micronutrient powder and phytase
11406634|NCT01991626|Other|MNP-control|maize meal containing micronutrient powder (MNP)
11406635|NCT01991626|Other|FePP control|Maize meal containing FePP
11406636|NCT01991626|Other|FeSO4 control|Maize meal containing FeSO4
11406637|NCT01991613|Experimental|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
11406639|NCT01991600|Active Comparator|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
11406640|NCT01991600|Experimental|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
11406641|NCT01991587|Experimental|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
11406642|NCT01991587|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
11406643|NCT01991587|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
11406644|NCT01991587|Placebo Comparator|Placebo|A single dose of Placebo
11406645|NCT01991574|Placebo Comparator|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
11406646|NCT01991574|Active Comparator|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
11406647|NCT01991574|Experimental|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
11406648|NCT01991561|Experimental|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
11406649|NCT01991561|Experimental|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
11406650|NCT01991561|Experimental|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
11406651|NCT01991561|Experimental|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
11406652|NCT01991561|Experimental|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
11406653|NCT01991561|Placebo Comparator|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
11406654|NCT01991548|Other|Diabetic participants with study devices|
11406655|NCT01991522|Experimental|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
11406656|NCT01991522|Active Comparator|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
11406657|NCT01991509|Experimental|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
11406658|NCT01991509|Experimental|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
11406659|NCT01991509|Placebo Comparator|Placebo IV|Placebo Administered Intravenously
11406660|NCT01991509|Placebo Comparator|Placebo SC|Placebo Administered Subcutaneously
11406661|NCT01991509|Experimental|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
11406662|NCT01991509|Experimental|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
11406663|NCT01991483|Experimental|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
11406664|NCT01991483|Experimental|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
11406665|NCT01991483|Placebo Comparator|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
11406666|NCT01991483|Placebo Comparator|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
11406667|NCT01991470|Experimental|Enlite sensors|Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.
11406668|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI)
11406669|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.
~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
11406670|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
11406671|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
11406672|NCT01991405|Sham Comparator|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
11406713|NCT01991119|Active Comparator|Propafenone|Propafenone group
11406675|NCT01991379|Experimental|MEK162 in Combination With Imatinib Mesylate|Pts will be treated with the combination therapy of MEK162 & imatinib. The phase Ib portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the standard 3+3 escalation doses. Phase Ib expansion cohort, pts will receive the RP2D: imatinib 400 mg once daily (standard of care first line imatinib dose) & MEK162 at the RP2D twice daily. The phase II portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the RP2D. The MEK162 RP2D was originally determined based on the phase Ib escalation data & it was established as 45 mg BID. After the completion of the phase Ib dose expansion & initiation of phase II, the MEK162 RP2D was reduced to 30 mg BID30 for better long term tolerability. Patient's will now begin MEK162 at the revised RP2D of 30 mg BID. 1 cycle is 28 days. If no progression of the tumor is seen, pts will continue on therapy. Pts who have progression of disease will proceed directly to second line therapy as per standard of care.
11406676|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
11406677|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
11406678|NCT01991366||No Eptifibatide|Receive no eptifibatide
11406679|NCT01991353|Experimental|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
11406680|NCT01991353|Active Comparator|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
11406681|NCT01991340||Cohort|
11406682|NCT01991327|Experimental|Androxal|Androxal 25 mg capsules once a day for 7 days
11406683|NCT01991327|Active Comparator|Placebo Androxal|
11406684|NCT01991314|Experimental|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
11406685|NCT01991301|Experimental|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
11406686|NCT01991288|Experimental|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
11406687|NCT01991288|Active Comparator|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
11406688|NCT01991275|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
11406689|NCT01991275|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
11406690|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
11406691|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
11406692|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
11406693|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
11406694|NCT01991249|Experimental|blood sample|
11406695|NCT01991236|Experimental|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
11406696|NCT01991236|Other|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
11406697|NCT01991223|Placebo Comparator|Placebo group|NS infusion will be done during surgery.
11406698|NCT01991223|Experimental|Dex group|DEX infusion will be done during surgery.
11406699|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
11406700|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
11406701|NCT01991197|Experimental|Sitagliptin|"Double blind phase (week 0-16):
~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.
~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.
~Open-label phase (week 16-32):
~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
11406702|NCT01991197|Active Comparator|Gliclazide|"Double-blind phase (week 0-16):
~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.
~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.
~Open-label phase (week 16-32):
~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
11406703|NCT01991184|Experimental|Dose-escalation|
11406704|NCT01991171|Experimental|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
11406705|NCT01991171|Placebo Comparator|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
11406706|NCT01991171|No Intervention|Control Group|This participants will not receive intervention
11406707|NCT01991158|Experimental|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
11406708|NCT01991145|Experimental|UCB and EPO|UCB + EPO + Rehabilitation
11406709|NCT01991145|Active Comparator|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
11406710|NCT01991145|Active Comparator|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
11406711|NCT01991145|Placebo Comparator|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
11406712|NCT01991132|Other|MediView 2.0 software|
11406715|NCT01991106|Experimental|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
11406716|NCT01991106|Experimental|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
11406717|NCT01991106|Active Comparator|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
11406718|NCT01991106|No Intervention|non-obese children|100 healthy non-obese children aged 7-16 (controls)
11406719|NCT01991080|Active Comparator|Wheatgerm juice|patients will drink Wheatgerm juice
11406720|NCT01991080|Active Comparator|Biofeedback|The patients will undergo biofeedback relaxation therapy
11406721|NCT01991067|Active Comparator|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
11406722|NCT01991067|Active Comparator|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
11406723|NCT01991054|Experimental|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
11406724|NCT01991054|Placebo Comparator|placebo group|placebo group, 15 ml per month for 6 months
11406725|NCT01991041||Rufinamide|
11406726|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
11406727|NCT01991028|Experimental|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
11406728|NCT01991028|Active Comparator|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
11406729|NCT01991002|Other|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.
~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
11406730|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
11406731|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
11406732|NCT01990950|Experimental|Zenith® Fenestrated AAA Endovascular Graft|
11406733|NCT01990937|Active Comparator|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
11406734|NCT01990937|Placebo Comparator|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
11406735|NCT01990924|Experimental|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
11406736|NCT01990924|Active Comparator|15 FPS|Conventional rate fluoroscopy at 15 FPS
11406737|NCT01990911|Experimental|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
11406738|NCT01990911|Sham Comparator|Medical therapy|This group will not receive renal sympathetic denervation
11406739|NCT01990898|Experimental|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
11406740|NCT01990885|Experimental|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
11406741|NCT01990885|Experimental|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
11406742|NCT01990885|Experimental|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
11406743|NCT01990885|Experimental|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
11406744|NCT01990885|Experimental|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
11406745|NCT01990872|Placebo Comparator|Placebo in high calcium group|Placebo + habitual dietary calcium intake (>1000 mg/d)
11406746|NCT01990872|Active Comparator|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake <700 mg/d
11406747|NCT01990872|Placebo Comparator|Placebo in low/moderate calcium group|Placebo + habitual calcium intake <700 mg/d
11406748|NCT01990872|Active Comparator|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (>1000 mg/d)
11406749|NCT01990859|Experimental|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
11406750|NCT01990846|Experimental|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
11406751|NCT01990846|Experimental|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
11406752|NCT01990846|Placebo Comparator|Placebo|Single Dose administration Placebo for Flufirvitide-3
11406753|NCT01990846|Experimental|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
11406754|NCT01990846|Experimental|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
11406756|NCT01990820|Active Comparator|Adenoidectomy without balloon dilation|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
11406757|NCT01990820|Experimental|Adenoidectomy with balloon dilation|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
11406758|NCT01990807|Active Comparator|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
11406759|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
11406760|NCT01990781|Experimental|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
11406761|NCT01990781|Active Comparator|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
11406762|NCT01990781|Active Comparator|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
11406763|NCT01990781|Placebo Comparator|N: normal saline|N: normal saline (placebo): 2 ml
11406764|NCT01990768|Experimental|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
11406765|NCT01990768|Experimental|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
11406766|NCT01990768|Placebo Comparator|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
11406767|NCT01990755|Active Comparator|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.
~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
11406768|NCT01990755|Active Comparator|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.
~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
11406769|NCT01990755|Active Comparator|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.
~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
11406770|NCT01990742|Experimental|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
11406771|NCT01990742|No Intervention|Standard care|Usual care will be provided to residents in the control homes.
11406772|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
11406773|NCT01990716|Other|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
11406774|NCT01990716|Other|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
11406775|NCT01990703|Experimental|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
11406776|NCT01990703|Active Comparator|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
11406777|NCT01990690|Active Comparator|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
11406778|NCT01990690|Placebo Comparator|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
~Group 2 was given a placebo once daily for two weeks."
11406779|NCT01990677|Active Comparator|25mg Eplerenone- Chronic CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
11406780|NCT01990677|Placebo Comparator|Placebo- Chronic CSCR Diagnosis|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
11406781|NCT01990677|Active Comparator|25mg Eplerenone- Acute CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
11406782|NCT01990677|Active Comparator|Placebo- Acute CSCR Diagnosis.|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
11406783|NCT01990664|Experimental|senofilcon A|Contact lenses to be worn in a daily wear modality
11406784|NCT01990664|Experimental|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
11406785|NCT01990638||DM group|
11406786|NCT01990638||non-DM group|
11406787|NCT01990625|Experimental|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
11406788|NCT01990625|No Intervention|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
11406789|NCT01990612|No Intervention|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
11406934|NCT01989533|Active Comparator|B|Intranasal Randomized
11406790|NCT01990612|Other|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
11406791|NCT01990599|Other|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
11406792|NCT01990573|Experimental|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
11406793|NCT01990573|Experimental|methadone HCl 0.4 mg/kg|0.4mg/kg IV methadon HCl
11406794|NCT01990573|Active Comparator|control group|control no methadone, standard of care opioids.
11406795|NCT01990560|Experimental|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
11406796|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
11406797|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
11406798|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
11406799|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
11406800|NCT01990534|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose may be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
11406801|NCT01990521|Experimental|MS3TMRI / TRUS Guided Biopsy|
11406802|NCT01990508|Experimental|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
11406803|NCT01990508|Sham Comparator|Control|Monthly letters with generic nutrition information only
11406804|NCT01990495|Active Comparator|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
11406805|NCT01990495|Active Comparator|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
11406806|NCT01990482|Experimental|coffee|coffee
11406807|NCT01990482|Placebo Comparator|water group|water
11406808|NCT01990469|Experimental|Gemigliptin|Gemigliptin 50mg qd
11406809|NCT01990469|Placebo Comparator|Placebo|Gemigliptin placebo
11406810|NCT01990456|Experimental|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
11406811|NCT01990456|Experimental|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
11406812|NCT01990443|Experimental|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
11406813|NCT01990443|Experimental|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
11406814|NCT01990430|Experimental|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.
~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
11406815|NCT01990430|No Intervention|Control|Patients will be asked to maintain their usual life style, without special changes
11406816|NCT01990417|Experimental|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
11406817|NCT01990404|Active Comparator|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
11406818|NCT01990404|Placebo Comparator|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
11406819|NCT01990391|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
11406820|NCT01990391|Experimental|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
11406821|NCT01990352|Experimental|Pegylated liposomal doxorubicin|
11406822|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
11406823|NCT01990326|Experimental|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
11406824|NCT01990326|Placebo Comparator|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
11406825|NCT01990313|Experimental|Activa PC+S|
11406826|NCT01990300||Alogliptin/Pioglitazone combination tablets|Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
11406827|NCT01990287|Experimental|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
11406828|NCT01990287|Active Comparator|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
11406829|NCT01990274|Experimental|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
11406830|NCT01990274|Active Comparator|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
11406831|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
11406832|NCT01990248||Cohort|
11406833|NCT01990235|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
11406834|NCT01990235|No Intervention|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
11406835|NCT01990209|Experimental|Orteronel|The planned dose of orteronel is 300mg orally (PO) twice daily (BID), for a total daily dose of 600mg.
11406836|NCT01990196|Active Comparator|AR inhibition only|"AR inhibition only Group 1: degarelix + enzalutamide
~Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy."
11406837|NCT01990196|Active Comparator|AR inhibition plus MEK inhibition|"AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide
~In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks."
11406838|NCT01990196|Active Comparator|AR inhibition plus SRC inhibition|"AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide
~In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks."
11406839|NCT01990183|Experimental|CareToy|CareToy intervention
11406840|NCT01990183|Other|Standard Care|Standard Care
11406841|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (>0.5s) SVR confirmed with duplex ultrasound.
11406842|NCT01990157|Experimental|TAB08|Multiple TAB08 administrations as intravenous infusions.
11406843|NCT01990144|Experimental|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
11406844|NCT01990131|Experimental|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
11406845|NCT01990131|Placebo Comparator|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
11406846|NCT01990118|Active Comparator|Neoral|Patients who continued to be treated with the drug Neoral.
11406847|NCT01990118|Experimental|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
11406848|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
11406849|NCT01990092|Experimental|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
11406850|NCT01990092|Placebo Comparator|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
11406851|NCT01990079|Experimental|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
11406852|NCT01990079|Active Comparator|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
11406935|NCT01989533|Experimental|C|Oral Open label
11406853|NCT01990066|Experimental|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
11406854|NCT01990066|No Intervention|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
11406855|NCT01990053|Experimental|Beating the Blues|Beating the Blues plus helper support.
11406856|NCT01990053|No Intervention|Waitlist Condition|Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
11406857|NCT01990040||Teduglutide treated|SBS participants who have been treated with teduglutide.
11406858|NCT01990040||Non-teduglutide treated|SBS participants who have not been treated with teduglutide.
11406859|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.
~No intervention will be undertaken."
11406860|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.
~No intervention will be undertaken."
11406861|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
11406862|NCT01990001|Experimental|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
11406863|NCT01990001|No Intervention|Control|Members in the control group were not enrolled in the reminder system
11406864|NCT01989988|Active Comparator|LRYGB|20 subjects Randomized will undergo LRYGB surgery
11406865|NCT01989988|Active Comparator|SADJB|20 subjects will undergo SADJB surgery
11406866|NCT01989988|Active Comparator|LMGB|20 subjects will undergo LMGB surgery
11406867|NCT01989962|Experimental|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
11406868|NCT01989962|Sham Comparator|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
11406869|NCT01989949|Experimental|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
11406870|NCT01989936|Placebo Comparator|Placebo|
11406871|NCT01989936|Experimental|Eletriptan 40 mg|
11406872|NCT01989936|Experimental|Eletriptan 80 mg|
11406873|NCT01989923|Active Comparator|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
11406874|NCT01989923|Active Comparator|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
11406875|NCT01989910|Active Comparator|Raltegravir|Raltegravir 400mg oral twice daily
11406876|NCT01989910|Active Comparator|Efavirenz|Efavirenz 600mg oral at bedtime
11406877|NCT01989897|Experimental|diluents|Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base
11406878|NCT01989884|Experimental|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
11406879|NCT01989871|No Intervention|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
11406880|NCT01989871|Experimental|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
11406881|NCT01989858|Experimental|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
11406882|NCT01989858|Active Comparator|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
11406883|NCT01989858|Experimental|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
11406884|NCT01989858|Active Comparator|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
11406885|NCT01989845|Experimental|oral rivaroxaban in cancer-associated VTE|
11406886|NCT01989832||Biological and clinical Data collected|
11406887|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
11406888|NCT01989819||control group|A skin biopsy will be performed in control group
11406890|NCT01989806|Active Comparator|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
11406891|NCT01989806|Placebo Comparator|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
11406892|NCT01989793|Active Comparator|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
11406893|NCT01989793|Placebo Comparator|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
11406894|NCT01989780|Active Comparator|Arm A|weekly paclitaxel + bevacizumab
11406895|NCT01989780|Experimental|Arm B|"weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice)* + bevacizumab then back to weekly paclitaxel + bevacizumab
~* Letrozole, Anastrozole, Exemestane, Fulvestrant, Goserelin, leuprorelin or LHRH Analogs + Aromatase inhibitors."
11406896|NCT01989767|Active Comparator|control|Rehabilitation as usual
11406897|NCT01989767|Experimental|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
11406898|NCT01989754|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
11406899|NCT01989754|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) once daily.
11406900|NCT01989741|Other|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
11406901|NCT01989728|Active Comparator|care as usual|
11406902|NCT01989728|Experimental|psychiatric examination and feedback|
11406903|NCT01989715|Experimental|adult patients waiting for orthognathic surgery|
11406904|NCT01989702|Active Comparator|Fermented blueberry product|
11406905|NCT01989702|Placebo Comparator|Placebo|
11406906|NCT01989702|Active Comparator|Probiotic bacteria|
11406907|NCT01989689|Experimental|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
11406908|NCT01989689|Active Comparator|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
11406909|NCT01989676|Experimental|PF-05280014|
11406910|NCT01989676|Active Comparator|Herceptin®|
11406911|NCT01989663|Experimental|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
11406912|NCT01989663|Placebo Comparator|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
11406913|NCT01989663|Experimental|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
11406914|NCT01989663|Experimental|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
11406915|NCT01989663|Placebo Comparator|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
11406916|NCT01989650|Active Comparator|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
11406917|NCT01989650|No Intervention|No break|No break will be provided
11406918|NCT01989637|Experimental|Strawberry Meal|40 g freeze-dried strawberries included in test meal
11406919|NCT01989637|Placebo Comparator|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
11406920|NCT01989624||Pancreatic Adenocarcinoma|
11406921|NCT01989611|Other|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
11406922|NCT01989598|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
11406923|NCT01989585|Experimental|Arm I (dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11406924|NCT01989585|Experimental|Arm II (dabrafenib, trametinib, and navitoclax)|Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11406925|NCT01989572|Experimental|Arm I (sargramostim, peptide vaccine)|Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
11406926|NCT01989572|Experimental|Arm II (sargramostim placebo, peptide vaccine)|Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
11406927|NCT01989572|Experimental|Arm III (sargramostim, peptide placebo)|Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
11406928|NCT01989572|Placebo Comparator|Arm IV (placebo, peptide placebo)|Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
11406929|NCT01989572|Experimental|Arm V (sargramostim)|Patients receive sargramostim SC on days 1-14.
11406930|NCT01989572|Placebo Comparator|Arm VI (sargramostim placebo)|Patients receive sargramostim placebo SC on days 1-14.
11406931|NCT01989559|Experimental|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
11406932|NCT01989546|Experimental|1|Single agent
11406933|NCT01989533|Placebo Comparator|A|Placebo controlled (blinded)
11406941|NCT01989520|Experimental|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
11406942|NCT01989507|Experimental|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
11406943|NCT01989507|Active Comparator|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
11406944|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
11406945|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
11406946|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
11406947|NCT01989468|Experimental|Secukinumab (AIN457) 150 mg s.c.|1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
11406948|NCT01989468|Experimental|Secukinumab (AIN457) 300 mg s.c.|2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
11406949|NCT01989468|Placebo Comparator|Placebo|Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
11406950|NCT01989455|Experimental|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.
~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.
~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
11406951|NCT01989455|Experimental|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.
~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.
~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
11406952|NCT01989455|Experimental|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.
~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
11406953|NCT01989455|Experimental|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.
~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.
~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
11406954|NCT01989442|Experimental|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
11406955|NCT01989442|Active Comparator|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
11406956|NCT01989429|Active Comparator|Daivonex|topical application
11406957|NCT01989429|Placebo Comparator|vehicle|topical application
11406958|NCT01989429|Experimental|M518101|topical application
11406959|NCT01989416|Placebo Comparator|Soap bathing|ICU patients will be bathing with soap at least once daily
11406960|NCT01989416|Experimental|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
11406961|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
11406962|NCT01989351||VAS<4|
11406963|NCT01989351||VAS>4|
11406964|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
11406965|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.
~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.
~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
11406966|NCT01989325|Experimental|Carfilzomib|"Single agent arm.
~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
11406967|NCT01989312|Active Comparator|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
11406968|NCT01989312|Active Comparator|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
11406969|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
11406970|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility >50% or IVC diameter less than or equal to 12mm
11406971|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility <50% or IVC diameter >12mm
11406972|NCT01989260|Other|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
11406973|NCT01989247|Experimental|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
11406974|NCT01989247|No Intervention|Control group|
11406975|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
11406976|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
11406977|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
11406978|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
11406979|NCT01989221|Placebo Comparator|Placebo|Placebo - Control
11406980|NCT01989221|Active Comparator|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
11406981|NCT01989208|Placebo Comparator|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
11406982|NCT01989208|Experimental|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
11406983|NCT01989195|Experimental|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
11406984|NCT01989182|Experimental|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
11406985|NCT01989182|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
11406986|NCT01989169|Active Comparator|Midazolam|Administered as a single oral 6 mg dose on Day 1.
11406987|NCT01989169|Experimental|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
11406988|NCT01989156|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
11406989|NCT01989156|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
11406990|NCT01989156|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
11406991|NCT01989143|Experimental|SAD Cohorts 1-8 Experimental Arm|
11406992|NCT01989143|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
11406993|NCT01989143|Experimental|MAD Cohorts 9-11 Experimental Arm|
11406994|NCT01989143|Placebo Comparator|MAD Cohorts 9-11 Placebo Arm|
11406995|NCT01989143|Experimental|MAD Cohort 12 Experimental Arm|
11406996|NCT01989143|Placebo Comparator|MAD Cohort 12 Placebo Arm|
11406997|NCT01989130|Experimental|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
11406998|NCT01989130|Active Comparator|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
11406999|NCT01989117||Osteopathy|
11407000|NCT01989117||No osteopathy|
11407001|NCT01989104||Children|6-12 years of age
11407002|NCT01989104||Adolescents|13-17 years of age
11407003|NCT01989104||Young adults|18-20 years of age
11407004|NCT01989091|Experimental|B-Lock (IMD)|Investigational Medical Device (IMD)
11407005|NCT01989091|Active Comparator|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
11407006|NCT01989078|Experimental|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
11407007|NCT01989065|Active Comparator|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
11407008|NCT01989065|Experimental|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
11407009|NCT01989052|Experimental|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
11407010|NCT01989052|Experimental|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
11407011|NCT01989052|Experimental|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
11407012|NCT01989052|Experimental|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
11407013|NCT01989026|Active Comparator|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
11407014|NCT01989026|No Intervention|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
11407015|NCT01989013|Other|biweekly intervention|biweekly intervention
11407016|NCT01989000|Active Comparator|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
11407017|NCT01989000|Active Comparator|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
11407018|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
11407019|NCT01988974|Experimental|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
11407020|NCT01988974|Active Comparator|Attention control condition|2) participation in the healthy sleep program
11407021|NCT01988961|Experimental|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
11407022|NCT01988948|Other|student cohort|"Various biological sampling
~blood sampling,
~oral, vulvar, vaginal and anal sampling for women,
~oral and genital sampling for men"
11407023|NCT01988935|Experimental|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
11407024|NCT01988935|Active Comparator|Smoking Cessation|Smoking cessation intervention
11407025|NCT01988922|Experimental|Ketamine arm- *1/*1|1.*1/*1- oral racemic ketamine 0.4 mg/kg
11407026|NCT01988922|Experimental|Ketamine arm - *1/*6|2. *1/*6- oral racemic ketamine 0.4 mg/kg
11407027|NCT01988922|Experimental|Ketamine arm - *6/*6|3. *6/*6- oral racemic ketamine 0.4 mg/kg
11407028|NCT01988909|Experimental|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
11407029|NCT01988896|Experimental|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days [14-day run-in period + 28-day concomitant dosing period]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
11407030|NCT01988896|Experimental|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
11407031|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
11407032|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
11407033|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
11407034|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
11407035|NCT01988870|Experimental|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
11407036|NCT01988857|Experimental|dTpa Group|
11407037|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
11407038|NCT01988831|Placebo Comparator|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.
~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.
~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
11407039|NCT01988831|Experimental|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.
~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.
~One long acting pill a day until an evidence of disease progression or the end of the study."
11407040|NCT01988818|Active Comparator|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
11407041|NCT01988818|Experimental|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
11407042|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
11407043|NCT01988792|Active Comparator|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
11407044|NCT01988792|Active Comparator|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
11407045|NCT01988779|Active Comparator|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
11407046|NCT01988779|Active Comparator|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
11407047|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
11407048|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
11407049|NCT01988753||Subjects with Liver Fibrosis|"Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.
~Biomarker Analysis
~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.
~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
11407050|NCT01988714|Experimental|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
11407051|NCT01988714|Placebo Comparator|(CG) plus evidence-based SE|(CG) plus evidence-based SE
11407052|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
11407053|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
11407054|NCT01988688|Experimental|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
11407055|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
11407166|NCT01987895|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
11407056|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
11407057|NCT01988662|Experimental|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
11407058|NCT01988662|Active Comparator|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
11407059|NCT01988649|Active Comparator|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
11407060|NCT01988649|Placebo Comparator|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
11407061|NCT01988636|Experimental|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
11407062|NCT01988636|Active Comparator|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
11407063|NCT01988636|Placebo Comparator|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
11407064|NCT01988623|Experimental|Pivotal Response Treatment (PRT)|
11407065|NCT01988610|Experimental|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
11407066|NCT01988597||Dry Eyes|
11407067|NCT01988584|Active Comparator|Umbilical Cord Blood (UCB) Arm|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
11407068|NCT01988584|Active Comparator|Bone Marrow Stem Cells (BMMNC's)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
11407069|NCT01988584|Placebo Comparator|Placebo (inactive substance) Group|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
11407070|NCT01988571|Active Comparator|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
11407071|NCT01988571|Placebo Comparator|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
11407072|NCT01988558|Experimental|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
11407073|NCT01988558|Placebo Comparator|Placebo Group|
11407074|NCT01988545|Active Comparator|GLP-1|1,5 nmol/kg,GLP-1 sc injection
11407075|NCT01988545|Active Comparator|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
11407076|NCT01988545|Active Comparator|Exendin-4|Exendin-4 ;10 ug,sc injection
11407077|NCT01988545|Placebo Comparator|isotonic saline|2 ml of isotonic saline, sc injection
11407078|NCT01988532||Adult PWH|
11407079|NCT01988519|Active Comparator|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
11407080|NCT01988519|Active Comparator|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
11407081|NCT01988506|Experimental|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
11407082|NCT01988493|Experimental|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
11407083|NCT01988493|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
11407084|NCT01988493|Experimental|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
11407085|NCT01988493|Experimental|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
11407086|NCT01988493|Experimental|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
11407087|NCT01988480|Experimental|Image-guided surgery|Image-guided implant placement
11407088|NCT01988480|Sham Comparator|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
11407089|NCT01988467|Experimental|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:
~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.
~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.
~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
11407090|NCT01988467|Experimental|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:
~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.
~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.
~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
11407091|NCT01988428|No Intervention|standard care|"standard care
~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
11407092|NCT01988428|Experimental|Antibiotics|"ceftriaxone 2000 mg (after taking bloodcultures)
~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
11407167|NCT01987895|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
11407168|NCT01987882||"A. Natural History or Watchful Waiting"|
11407093|NCT01988415|Other|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).
11407094|NCT01988402|Active Comparator|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
11407095|NCT01988402|Placebo Comparator|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
11407096|NCT01988389|Experimental|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
11407097|NCT01988389|Other|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
11407098|NCT01988376|Experimental|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
11407099|NCT01988376|Active Comparator|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
11407100|NCT01988363|Other|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
11407101|NCT01988350||Non-smokers|
11407102|NCT01988350||Smokers|
11407103|NCT01988337|Experimental|Resin infiltration|"One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
11407104|NCT01988337|Sham Comparator|Mock treatment|"A second proximal caries lesion of each patient (split mouth design) will recieve a placebo treatment to mimic resin infiltration."
11407105|NCT01988324|Experimental|FES/FDHT-PET|
11407106|NCT01988311|Experimental|Drug Only|psilocybin dose manipulation as described in the protocol
11407107|NCT01988311|No Intervention|Cognitive/Behavioral Tasks Only|
11407108|NCT01988311|No Intervention|Imaging Only|
11407109|NCT01988298|Experimental|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
11407110|NCT01988298|Active Comparator|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
11407111|NCT01988285||Dysphagia and GERD controls|"The cross-sectional arm will consist of patients who are having a clinically indicated endoscopy for reflux and/or dysphagia.
~Cross-sectional participants will have specimens collected and complete a questionnaire."
11407112|NCT01988285||Prospective Longitudinal EoE Cases|"The prospective longitudinal group will be subjects who have a positive EoE diagnosis during initial endoscopy. This prospective group will be followed up at their clinically indicated endoscopy after their standard of care clinical therapy of swallowed steroids.
~Prospective longitudinal participants will have specimens collected and complete questionnaires s prior to their standard of care clinical therapy of swallowed steroids and at their clinically indicated follow up upper endoscopy."
11407113|NCT01988259|Active Comparator|Bilateral approach for laminoplasty|Open approach for laminoplasty
11407114|NCT01988259|Active Comparator|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
11407115|NCT01988259|Active Comparator|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
11407116|NCT01988259|Active Comparator|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
11407117|NCT01988246|Sham Comparator|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
11407118|NCT01988246|Active Comparator|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
11407119|NCT01988233|Experimental|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
11407120|NCT01988233|Experimental|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
11407121|NCT01988220|Experimental|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
11407122|NCT01988220|Active Comparator|repeated exposure to sensory input|
11407123|NCT01988207|Experimental|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
11407124|NCT01988207|Active Comparator|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
11407125|NCT01988194|No Intervention|Usual care|Participants will receive usual care in the hospital.
11407126|NCT01988194|Experimental|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
11407165|NCT01987908|Placebo Comparator|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
11407127|NCT01988181|Active Comparator|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
11407128|NCT01988181|Experimental|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
11407129|NCT01988168|Experimental|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
11407130|NCT01988168|Active Comparator|Staples closure|Closure of skin with stainless-steel surgical staples.
11407131|NCT01988155|Active Comparator|Eccentric Exericse|
11407132|NCT01988155|Experimental|Astym|
11407133|NCT01988142|Experimental|SCI|
11407134|NCT01988129|Experimental|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
11407135|NCT01988129|No Intervention|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.
~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
11407136|NCT01988116|Experimental|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
11407137|NCT01988116|Placebo Comparator|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
11407138|NCT01988103|Experimental|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
11407139|NCT01988103|Experimental|Apremilast 30mg|Apremilast 30 mg tablets orally BID
11407140|NCT01988103|Placebo Comparator|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
11407141|NCT01988090|Experimental|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
11407142|NCT01988090|Active Comparator|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
11407143|NCT01988077|Other|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
11407144|NCT01988064|Experimental|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
11407145|NCT01988064|Experimental|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
11407146|NCT01988038||No treatment|
11407147|NCT01988012|Experimental|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
11407148|NCT01987999|Experimental|Acetogenins|Acetogenins twice (BID) per day for 12 months
11407149|NCT01987986|Experimental|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
11407150|NCT01987986|Experimental|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
11407151|NCT01987986|Experimental|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
11407152|NCT01987986|Placebo Comparator|Placebo|"Placebo
~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
11407153|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
11407154|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
11407155|NCT01987960|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
11407156|NCT01987960|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
11407157|NCT01987947|Placebo Comparator|Placebo|
11407158|NCT01987947|Active Comparator|Quilizumab|
11407159|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
11407160|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
11407161|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
11407162|NCT01987908|Experimental|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
11407163|NCT01987908|Placebo Comparator|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
11407164|NCT01987908|Experimental|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
11407169|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
11407170|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
11407171|NCT01987882||D. Hip Reconstructive Surgery|
11407172|NCT01987882||E. Salvage Hip Surgery|
11407173|NCT01987856|Active Comparator|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
11407174|NCT01987856|Placebo Comparator|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
11407175|NCT01987843|Experimental|MT-1303-Low|MT-1303-Low Dose
11407176|NCT01987843|Experimental|MT-1303-Middle|MT-1303-Middle Dose
11407177|NCT01987843|Experimental|MT-1303-High|MT-1303-High Dose
11407178|NCT01987843|Placebo Comparator|Placebo|Placebo
11407179|NCT01987830|Other|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.
~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
11407180|NCT01987817|Experimental|AR101 powder provided in capsules|Study product provided in pull-apart peanut protein capsules
11407181|NCT01987817|Placebo Comparator|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
11407182|NCT01987804|Experimental|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
11407183|NCT01987804|Experimental|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
11407184|NCT01987804|Placebo Comparator|Placebo|N=16 patients are administrated placebo vaginally
11407185|NCT01987778|Experimental|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
11407186|NCT01987778|No Intervention|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
11407187|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
11407188|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
11407189|NCT01987739|Experimental|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
11407190|NCT01987739|Experimental|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
11407191|NCT01987739|Experimental|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
11407192|NCT01987739|Experimental|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
11407193|NCT01987739|Experimental|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
11407194|NCT01987739|Experimental|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
11407195|NCT01987726||Observational (NGS, FMI testing)|"PART I: Within 10 weeks of beginning a treatment regimen, tumor tissue samples, Blood Collection and CTCs(Circulating tumor cell)from patients are collected for NGS and FMI testing, respectively. Patients remain on current line of therapy until a change in treatment is warranted. The physician's treatment recommendation is documented prior to the release of the FMI results.
~PART II: Physicians are furnished with FMI test results when patients become eligible for a change in therapy and new treatment recommendations are documented. Treatment is dependent on preferences of the physician, patient, and/or results of the FMI test."
11407329|NCT01986855|Experimental|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
11407196|NCT01987713|Experimental|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
11407197|NCT01987700|Active Comparator|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
11407198|NCT01987700|Active Comparator|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
11407199|NCT01987700|Active Comparator|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
11407200|NCT01987700|Active Comparator|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
11407201|NCT01987687|Active Comparator|Rest|Breakfast followed by a rest period prior to OGTT.
11407202|NCT01987687|Experimental|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
11407203|NCT01987687|Experimental|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
11407204|NCT01987674|Experimental|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
11407205|NCT01987674|Placebo Comparator|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
11407206|NCT01987661|Active Comparator|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
11407207|NCT01987661|Experimental|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
11407208|NCT01987648||All study participants|Included are all patients who 18 years or older, who get an elective craniotomy (no biopsy, no awake surgery, no re-operation) and who are treated at the Department of Neurosurgery
11407209|NCT01987635|Experimental|MEMO 3D anuloplasty ring|MEMO 3D anuloplasty ring
11407210|NCT01987635|Active Comparator|rigid ring|rigid ring
11407211|NCT01987622|Experimental|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
11407212|NCT01987622|Active Comparator|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
11407213|NCT01987609|Experimental|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
11407214|NCT01987609|Placebo Comparator|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
11407215|NCT01987596|Experimental|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
11407216|NCT01987596|Experimental|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
11407217|NCT01987583|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.
~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
11407218|NCT01987583|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
11407219|NCT01987570|Experimental|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
11407220|NCT01987570|Placebo Comparator|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
11407221|NCT01987557|Experimental|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
11407222|NCT01987557|Experimental|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
11407223|NCT01987557|Placebo Comparator|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
11407224|NCT01987544|Active Comparator|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
11407225|NCT01987544|Experimental|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
11407226|NCT01987531|Experimental|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
11407227|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
11407228|NCT01987505|Experimental|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
11407229|NCT01987492|Experimental|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
11407230|NCT01987492|Experimental|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
11407330|NCT01986855|Placebo Comparator|Placebo|Matching placebo
11407231|NCT01987492|Placebo Comparator|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
11407232|NCT01987479|Experimental|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
11407233|NCT01987466||Post cardiac arrest patient|
11407234|NCT01987453|Experimental|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
11407235|NCT01987453|Experimental|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
11407236|NCT01987453|Experimental|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
11407237|NCT01987440|Experimental|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
11407238|NCT01987440|Placebo Comparator|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
11407239|NCT01987427|Experimental|A|lorcaserin + phentermine placebo
11407240|NCT01987427|Experimental|B|lorcaserin + phentermine-HCl + phentermine placebo
11407241|NCT01987427|Experimental|C|lorcaserin + phentermine-HCl
11407242|NCT01987414|Experimental|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
11407243|NCT01987414|Active Comparator|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
11407244|NCT01987401||Iraq and Afghanistan Era Veterans|Veterans who served during the Iraq and Afghanistan Era
11407245|NCT01987388|Experimental|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
11407246|NCT01987388|Experimental|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
11407247|NCT01987388|Experimental|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
11407248|NCT01987388|Experimental|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
11407249|NCT01987375|Experimental|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
11407250|NCT01987362|Experimental|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
11407251|NCT01987362|Experimental|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
11407252|NCT01987349|Other|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
11407253|NCT01987349|Other|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
11407254|NCT01987349|Other|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
11407255|NCT01987349|Other|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
11407256|NCT01987349|Other|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
11407257|NCT01987349|Other|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
11407258|NCT01987349|Other|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
11407259|NCT01987323|Experimental|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
11407260|NCT01987310|Active Comparator|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
11407261|NCT01987310|No Intervention|usual care|follow up group with no intervention
11407262|NCT01987310|Active Comparator|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
11407331|NCT01986842|Experimental|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
11407263|NCT01987297|Experimental|ATRA+Arsenic|All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation. High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
11407264|NCT01987297|Active Comparator|ATRA+chemo|All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation. High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
11407265|NCT01987284|Experimental|SER100|SER100 10 mg s.c. twice daily
11407266|NCT01987284|Placebo Comparator|Placebo|Placebo administered s.c. twice daily
11407267|NCT01987271|Experimental|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
11407268|NCT01987271|No Intervention|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
11407269|NCT01987258|No Intervention|Control|No exercise (control experiment)
11407270|NCT01987258|Experimental|Interval Walking|A one hour interval walking exercise bout
11407271|NCT01987258|Experimental|Continuous walking|A one hour continuous walking exercise bout
11407272|NCT01987232|Experimental|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
11407273|NCT01987219|Active Comparator|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
11407274|NCT01987219|Active Comparator|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
11407275|NCT01987219|Placebo Comparator|Placebo|Placebo Saline solution 3 cc NA
11407276|NCT01987206|Active Comparator|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.
~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
11407277|NCT01987206|Experimental|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.
~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
11407278|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
11407279|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
11407280|NCT01987167|Experimental|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
11407281|NCT01987154|Active Comparator|Marketed cow milk-based premature infant formula|
11407282|NCT01987154|Experimental|Marketed extensively hydrolyzed casein infant formula|
11407283|NCT01987141|Experimental|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
11407284|NCT01987141|No Intervention|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
11407285|NCT01987128|Experimental|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
11407286|NCT01987128|Active Comparator|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
11407287|NCT01987115|Experimental|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
11407288|NCT01987115|Active Comparator|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
11407438|NCT01986205|Experimental|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
11407289|NCT01987102|Experimental|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)
~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
11407290|NCT01987102|Experimental|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)
~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5mg/m2 or 30mg/m2*)
~*Dose will depend on outcome from Cohort 1"
11407291|NCT01987089|Experimental|CBT-I|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician. Session 1 serves as an orientation. No active treatment is delivered at this time. Sessions 2 & 3 are used to deliver the three main components of the intervention which are Sleep Restriction (SRT), Stimulus Control, and Sleep Hygiene. All but two of the remaining sessions are dedicated to the titration of total sleep time and to ensuring patient adherence. One session (session 5) entails the delivery of a specific form of cognitive therapy. The final session (session 8) is used to engage in a relapse-prevention didactic, i.e., to review first, how insomnia becomes chronic and second, the strategies that are likely to abort an extended episode of insomnia.
11407292|NCT01987089|Placebo Comparator|QDT|"This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate conditioned arousal, occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime."
11407293|NCT01987076|Active Comparator|Corticosteroids per os: Prednisone + Emollient|
11407294|NCT01987076|Experimental|Topical corticosteroid: Clobetasol + Emollient|
11407295|NCT01987063||pregnant woman with twins|pregnant woman with twins
11407296|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
11407297|NCT01987024|Active Comparator|group A-usual procedure|
11407298|NCT01987024|Experimental|groupB- actim partus|
11407299|NCT01987011|Experimental|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
11407300|NCT01987011|Placebo Comparator|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
11407301|NCT01986998|Active Comparator|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
11407302|NCT01986998|Active Comparator|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
11407303|NCT01986985|Other|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
11407304|NCT01986972|Active Comparator|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
11407305|NCT01986972|Experimental|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
11407306|NCT01986959|Experimental|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
11407307|NCT01986959|Other|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
11407308|NCT01986946|Experimental|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
11407309|NCT01986946|Experimental|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
11407310|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
11407311|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
11407312|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
11407313|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
11407314|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
11407315|NCT01986920|Active Comparator|A-101 25%|Low dose group
11407316|NCT01986920|Active Comparator|A-101 32.5%|Mid Dose Group
11407317|NCT01986920|Active Comparator|A-101 40%|High Dose Group
11407318|NCT01986920|Placebo Comparator|A-101 Vehicle|Placebo group
11407319|NCT01986907|Experimental|Ranibizumab|Administered as an Intravitreal injection
11407320|NCT01986894|Placebo Comparator|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
11407321|NCT01986894|Experimental|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
11407322|NCT01986894|Experimental|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
11407323|NCT01986894|Active Comparator|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
11407324|NCT01986881|Experimental|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to 6.1 years
11407325|NCT01986881|Experimental|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to 6.1 years
11407326|NCT01986881|Placebo Comparator|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to 6.1 years
11407327|NCT01986868|Other|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
11407328|NCT01986855|Experimental|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
11407332|NCT01986842|Experimental|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
11407333|NCT01986829|Experimental|Treatment (ablation)|"Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.
~Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
11407334|NCT01986803|Experimental|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
11407335|NCT01986803|Active Comparator|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
11407336|NCT01986790|Experimental|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
11407337|NCT01986790|Experimental|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
11407338|NCT01986790|Experimental|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
11407339|NCT01986777|Active Comparator|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
11407340|NCT01986777|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
11407341|NCT01986764|Active Comparator|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
11407342|NCT01986764|Active Comparator|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
11407343|NCT01986764|Placebo Comparator|Placebo|
11407344|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
11407345|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
11407346|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
11407347|NCT01986725|Active Comparator|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
11407348|NCT01986725|Active Comparator|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
11407349|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
11407350|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
11407351|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
11407352|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
11407353|NCT01986686|No Intervention|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
11407354|NCT01986686|Active Comparator|Surgery|The surgery group will be offered colon resection.
11407355|NCT01986673|Experimental|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
11407356|NCT01986673|Active Comparator|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
11407357|NCT01986660|Experimental|Ibuprofen Cream (SST-0225)|
11407358|NCT01986647|Experimental|On the Move Exercise - exercise leader|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
11407359|NCT01986647|Active Comparator|Standard program - exercise leader|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
11407360|NCT01986647|Active Comparator|On the Move - staff activity personnel|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
11407361|NCT01986647|Active Comparator|Standard - staff activity personnel|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel
11407362|NCT01986634|Other|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
11407363|NCT01986621||Patients undergoing elective PCI|
11407364|NCT01986608|Experimental|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
11407365|NCT01986608|Experimental|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
11407366|NCT01986608|Experimental|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
11407367|NCT01986582|Active Comparator|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning & evening, for 8 days.
11407368|NCT01986582|Placebo Comparator|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning & evening, for 8 days.
11407369|NCT01986569|Experimental|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
11407370|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
11407439|NCT01986205|Placebo Comparator|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
11407371|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
11407372|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
11407373|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
11407374|NCT01986543|Experimental|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
11407375|NCT01986543|Experimental|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
11407376|NCT01986543|Active Comparator|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
11407377|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
11407378|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
11407379|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
11407380|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
11407381|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
11407382|NCT01986517|Experimental|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
11407383|NCT01986517|Experimental|No feedback|Therapists assigned to this group will receive no feedback
11407384|NCT01986491|Experimental|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
11407385|NCT01986491|Experimental|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
11407386|NCT01986491|Experimental|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
11407387|NCT01986491|Experimental|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
11407388|NCT01986491|Experimental|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
11407389|NCT01986491|Experimental|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
11407390|NCT01986491|Experimental|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
11407391|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
11407392|NCT01986465|Experimental|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
11407393|NCT01986465|Placebo Comparator|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
11407394|NCT01986452|Active Comparator|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
11407395|NCT01986452|Experimental|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
11407396|NCT01986426|Experimental|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.
~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.
~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
11407397|NCT01986426|Experimental|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:
~Once daily on 2 consecutive days week 1-3."
11407398|NCT01986426|Experimental|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
11407399|NCT01986426|Experimental|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
11407400|NCT01986413|Active Comparator|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
11407401|NCT01986413|Experimental|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
11407402|NCT01986400|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
11407403|NCT01986400|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
11407404|NCT01986387|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
11407405|NCT01986387|No Intervention|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
11407406|NCT01986374|Experimental|HCG is introduced with small catheter.|phase 1 non randomized pilot
11407407|NCT01986361|Experimental|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
11407408|NCT01986361|Placebo Comparator|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
11407409|NCT01986348|Experimental|Arm A: Selinexor and surgery|Patients who require surgery will receive up to 3 doses of selinexor, undergo surgery, and resume selinexor after recovery. Selinexor will be given twice weekly.
11407410|NCT01986348|Experimental|Arm C: Selinexor only|Patients who were not eligible for surgery may be randomized to take selinexor twice weekly.
11407411|NCT01986348|Experimental|Arm D: Selinexor only|Patients who were not eligible for surgery may be randomized to take selinexor once weekly.
11407412|NCT01986335|Experimental|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
11407413|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
11407414|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
11407415|NCT01986322|Experimental|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.
~DTP/HB/Hib component:
~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
11407416|NCT01986322|Active Comparator|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age
~DTP/HB component:
~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal
~Hib component:
~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
11407417|NCT01986309|Active Comparator|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
11407418|NCT01986309|Placebo Comparator|Group P|Normal saline solution administered under the same regimen
11407419|NCT01986296|Experimental|ExAblate Treatment|
11407420|NCT01986283|Placebo Comparator|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
11407421|NCT01986283|Experimental|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
11407422|NCT01986283|Experimental|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
11407423|NCT01986283|Active Comparator|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
11407424|NCT01986270|Placebo Comparator|Placebo|
11407425|NCT01986270|Experimental|Eletriptan 40 mg|
11407426|NCT01986270|Experimental|Eletriptan 80 mg|
11407427|NCT01986270|Experimental|Sumatriptan 25 mg|
11407428|NCT01986270|Experimental|Sumatriptan 50 mg|
11407429|NCT01986257|Experimental|Emotion Regulation Group Therapy (ERGT).|
11407430|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
11407431|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
11407432|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
11407433|NCT01986231|Experimental|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
11407434|NCT01986218|Experimental|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
11407435|NCT01986218|Experimental|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
11407436|NCT01986218|Experimental|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
11407437|NCT01986218|Experimental|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
11407440|NCT01986192|Experimental|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
11407441|NCT01986192|Active Comparator|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
11407442|NCT01986179|Active Comparator|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
11407443|NCT01986179|Experimental|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
11407444|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
11407445|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
11407446|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
11407447|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
11407448|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
11407449|NCT01986140|Experimental|PAXMAN Orbis Scalp Cooler|Scalp Cooling
11407450|NCT01986140|Other|Control No treatment|Control
11407451|NCT01986127|Experimental|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
11407452|NCT01986127|Placebo Comparator|saline|5 ml of saline
11407453|NCT01986114|Experimental|SM-13496 20-120mg|once daily orally SM-13496 20-120 mg flexibly dosed
11407454|NCT01986101|Placebo Comparator|Placebo|once daily orally
11407455|NCT01986101|Experimental|SM-13496 20 - 60 mg/day|once daily orally
11407456|NCT01986101|Experimental|SM-13496 80 - 120 mg/day|once daily orally
11407457|NCT01986088|Placebo Comparator|Placebo|
11407458|NCT01986088|Experimental|Eletriptan 40 mg|
11407459|NCT01986088|Experimental|Eletriptan 80 mg|
11407460|NCT01986088|Experimental|Sumatriptan 50 mg|
11407461|NCT01986088|Experimental|Sumatriptan 100 mg|
11407462|NCT01986075|Active Comparator|Computer-assisted Therapy alone|Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week when receiving Behavioral: Computer assisted therapy alone.
11407463|NCT01986075|Experimental|Computer-assisted CBT + Adderall-XR|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
11407464|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
11407465|NCT01986062|Experimental|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
11407466|NCT01986062|Placebo Comparator|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
11407467|NCT01986049|Experimental|Bupivicaine 0.5%|Drug Bupavacaine 0.5%
11407468|NCT01986049|Experimental|Bupivicaine 0.25%|Drug Bupavacaine 0.25%
11407469|NCT01986049|Placebo Comparator|Normal Saline|Saline Normal
11407470|NCT01986036|Sham Comparator|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
11407471|NCT01986036|Active Comparator|PROTEIN|High-protein breakfast.
11407472|NCT01986036|Active Comparator|CALCIUM|High-calcium breakfast.
11407473|NCT01986036|Experimental|PRO-CAL|High-protein and calcium breakfast.
11407474|NCT01986023|Experimental|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
11407475|NCT01986023|No Intervention|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
11407476|NCT01986010|Experimental|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407477|NCT01986010|Experimental|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407478|NCT01986010|Experimental|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407479|NCT01986010|Experimental|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407480|NCT01986010|Experimental|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407481|NCT01986010|Experimental|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
11407482|NCT01986010|Experimental|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407483|NCT01986010|Experimental|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
11407484|NCT01986010|Experimental|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407485|NCT01986010|Experimental|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
11407486|NCT01986010|Experimental|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
11407487|NCT01986010|Placebo Comparator|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
11407488|NCT01986010|Placebo Comparator|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
11407489|NCT01986010|Experimental|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
11407490|NCT01986010|Experimental|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
11407491|NCT01986010|Placebo Comparator|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
11407492|NCT01986010|Placebo Comparator|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
11407493|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent
~Any tumor site
~Stage I-IV, M0
~Treated with radiotherapy alone or in combination with systemic therapy
~Definitive radiotherapy or postoperative radiotherapy
~Interventions:
~Radiation alone
~Radiation in combination with systemic therapy"
11407494|NCT01985971|Experimental|EF5|
11407495|NCT01985958|Experimental|Single arm|In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.
11407496|NCT01985945|Other|Yoga|
11407497|NCT01985945|No Intervention|Without Yoga|
11407498|NCT01985932|Other|Functional MRI|Subjects in this arm receive functional MRI during radiation therapy treatment planning.
11407499|NCT01985919||Bone marrow aspirate/biopsy and blood specimens|Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases
11407500|NCT01985906|Experimental|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone < 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.
~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
11407501|NCT01985893|Other|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
11407502|NCT01985893|Other|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
11407503|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
11407504|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
11407505|NCT01985880||Control|Control
11407506|NCT01985867|Experimental|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10^8 colony forming units (CFU), twice daily, orally for 4 weeks
11407507|NCT01985867|Placebo Comparator|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
11407508|NCT01985854|Active Comparator|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
11407509|NCT01985854|Experimental|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
11407510|NCT01985841|Experimental|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -> Bevacizumab plus Docetaxel
11407511|NCT01985828|Experimental|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy
~OR
~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
11407512|NCT01985828|Experimental|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
11407513|NCT01985815|Experimental|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
11407514|NCT01985815|Experimental|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
11407515|NCT01985802|Other|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
11407516|NCT01985789|Active Comparator|diphenhydramine|50mg dose given as two 25mg capsules
11407517|NCT01985789|Active Comparator|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
11407518|NCT01985789|Active Comparator|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
11407519|NCT01985789|Placebo Comparator|placebo|given as 2 placebo capsules
11407520|NCT01985776|Active Comparator|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
11407521|NCT01985776|Active Comparator|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
11407522|NCT01985776|No Intervention|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
11407523|NCT01985776|No Intervention|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
11407524|NCT01985763|Experimental|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.
11407525|NCT01985750|Placebo Comparator|Drug: d-cycloserine or placebo|"Other Names:
~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception
~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
11407526|NCT01985750|Active Comparator|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo
~Other Names:
~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception
~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
11407527|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
11407528|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
11407529|NCT01985724|Active Comparator|A|FEC -> TXT
11407530|NCT01985724|Experimental|B|Docetaxel/Cyclophosphamide (TC)
11407531|NCT01985711|Experimental|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
11407532|NCT01985711|Other|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
11407533|NCT01985698|Experimental|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
11407534|NCT01985698|Experimental|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
11407535|NCT01985698|Active Comparator|Open Surgery|patients with low rectal cancer receiving open abdominoperineal resection.
11407536|NCT01985685|Experimental|Thiamine|200mg intravenous thiamine in 50ml 5% dextrose, single dose
11407537|NCT01985685|Placebo Comparator|Placebo|50ml intravenous 5% dextrose, single dose
11407538|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
11407539|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
11407540|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
11407541|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
11407542|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
11407543|NCT01985646|Experimental|surgery treatment|one stage pull through left-colectomy
11407544|NCT01985646|Experimental|conservative treatment|anal dilation, colonic lavage, oral probiotic
11407545|NCT01985633|Experimental|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
11407546|NCT01985633|Active Comparator|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
11407547|NCT01985620|Active Comparator|study group|Educational intervention with the parents
11407548|NCT01985620|No Intervention|control group|
11407549|NCT01985607|Experimental|Thickened|
11407550|NCT01985607|Active Comparator|Control|
11407551|NCT01985594|Active Comparator|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
11407552|NCT01985594|Placebo Comparator|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
11407553|NCT01985581|Experimental|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
11407554|NCT01985581|Placebo Comparator|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
11407555|NCT01985568|Active Comparator|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
11407700|NCT01984632|Active Comparator|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
11407556|NCT01985568|Experimental|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
11407557|NCT01985555|Experimental|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
11407558|NCT01985542|Active Comparator|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
11407559|NCT01985542|No Intervention|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
11407560|NCT01985529|Experimental|Exercise|Enrollment in pulmonary rehabilitation
11407561|NCT01985529|No Intervention|Control|
11407562|NCT01985516|Experimental|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
11407563|NCT01985516|Active Comparator|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
11407564|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
11407565|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
11407566|NCT01985490|Experimental|epiretinal membrane|
11407567|NCT01985477|Experimental|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.
~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.
~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
11407568|NCT01985477|Experimental|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.
~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
11407569|NCT01985464|Experimental|Umbilical cord mesenchymal stem cells|
11407570|NCT01985451|Experimental|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
11407571|NCT01985438|Active Comparator|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
11407572|NCT01985438|Active Comparator|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
11407573|NCT01985425|Experimental|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
11407574|NCT01985425|Placebo Comparator|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
11407575|NCT01985412||Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
11407576|NCT01985412||Pediatric Heart Transplant Recipients|Patients <18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
11407577|NCT01985412||Adult Lung Transplant Recipients|Patients >18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
11407578|NCT01985412||Pediatric Lung Transplant Recipients|Patients <18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
11407579|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
11407580|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
11407581|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
11407582|NCT01985386|Experimental|GDS (gastric delivery system), meal|GDS capsule with meal
11407583|NCT01985386|Active Comparator|Ferrous sulfate, meal|Ferrous sulfate with meal
11407584|NCT01985373|Experimental|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
11407585|NCT01985360|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Surgery) plus optimal medical therapy.
11407586|NCT01985360|Active Comparator|Conservative Strategy (CON)|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with OMT failure.
11407701|NCT01984619||Blunt Tip Cannula|
11407587|NCT01985347|Active Comparator|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
11407588|NCT01985347|No Intervention|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression & normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
11407589|NCT01985334|Experimental|A1 (any SABA and/or SAMA)|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
11407590|NCT01985334|Experimental|A2 (glycopyrronium)|Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
11407591|NCT01985334|Experimental|B1 (any LAMA or LABA and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
11407592|NCT01985334|Experimental|B2 (glycopyrronium and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
11407593|NCT01985334|Experimental|C1 (any LABA and ICS)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
11407594|NCT01985334|Experimental|C2 (indacaterol/glycopyrronium)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
11407595|NCT01985334|Experimental|D1 (any LAMA or LABA and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
11407596|NCT01985334|Experimental|D2 (indacaterol/glycopyrronium and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
11407597|NCT01985321|Experimental|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
11407598|NCT01985321|Placebo Comparator|Placebo/Ethanol|36 applications over a 96 hour period
11407599|NCT01985308|Experimental|MRT-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
11407600|NCT01985308|Sham Comparator|MRT-SHAM|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
11407601|NCT01985295|Other|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --
~(starting) 400 mg 3
~600 mg 3
~(maximum) 800 mg 3"
11407602|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
11407603|NCT01985269|Active Comparator|Home visits|Minimal physical examination at home Drug adherence/pill counts
11407604|NCT01985269|No Intervention|Control|Normal standard of care
11407605|NCT01985256|Experimental|Single Arm|Toca 511 vector/Toca FC
11407606|NCT01985243|Experimental|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
11407607|NCT01985243|Experimental|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
11407608|NCT01985243|No Intervention|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
11407609|NCT01985243|No Intervention|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
11407610|NCT01985230|Experimental|ReActiv8 Implant|
11407611|NCT01985204|Placebo Comparator|Placebo|Placebo tablet
11407612|NCT01985204|Experimental|Intervention|Iodine tablet
11407613|NCT01985191|Experimental|Arm 1|SAR405838 and pimasertib in escalating doses
11407614|NCT01985178|Experimental|Omega-3 Fatty Acid Supplement|
11407615|NCT01985165|Experimental|Imrecoxib|0.1g,BID,po
11407616|NCT01985152|Experimental|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
11407617|NCT01985152|Experimental|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
11407618|NCT01985152|Experimental|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
11407619|NCT01985152|Experimental|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
11407620|NCT01985152|Experimental|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
11407621|NCT01985152|Experimental|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
11407622|NCT01985152|Experimental|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
11407623|NCT01985152|Placebo Comparator|Placebo|Placebo-matching tablets, orally
11407624|NCT01985139|Experimental|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
11407625|NCT01985139|Experimental|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
11407626|NCT01985126|Experimental|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
11407627|NCT01985126|Experimental|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
11407628|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
11407629|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
11407630|NCT01985100|Experimental|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
11407631|NCT01985087|Experimental|Hypofractionated radiotherapy and temozolomide|All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
11407632|NCT01985074|Experimental|Case-management intervention|Receiving nurse-managed intervention
11407633|NCT01985074|No Intervention|Control arm|Control group not receiving any intervention
11407634|NCT01985061|Active Comparator|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
11407635|NCT01985061|Experimental|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
11407636|NCT01985061|Active Comparator|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
11407637|NCT01985035|Experimental|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
11407638|NCT01985035|Experimental|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
11407639|NCT01985035|Experimental|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
11407640|NCT01985035|Experimental|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
11407641|NCT01985022|Experimental|PII with IES|The treatment condition that this group receives is PII with IES for 9 months.
11407642|NCT01985022|Experimental|IES|The treatment condition that this group receives is IES for 9 months.
11407643|NCT01985009|Other|Fibroscan®|Single arm study. See intervention item for détails..
11407644|NCT01984996|Experimental|Freedom ProFlor Inguinal Hernia Implant|
11407645|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
11407646|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
11407647|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
11407648|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
11407649|NCT01984983|Placebo Comparator|Placebo: 0.9% saline|0.9% saline
11407650|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
11407651|NCT01984957|Other|disease (ALS, SMA or SBMA)|muscle biopsy
11407652|NCT01984944|Other|Autistic Patient|"50 adults
~25 childs"
11407653|NCT01984944|Other|Controls|"50 adults
~25 childs"
11407654|NCT01984931|Experimental|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
11407655|NCT01984931|Active Comparator|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
11407656|NCT01984918|Active Comparator|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
11407657|NCT01984918|No Intervention|Non-SMS reminder|No text message reminder via Short Message Service (SMS) will be sent
11407658|NCT01984892|Experimental|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
11407659|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
11407660|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).
~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
11407661|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
11407662|NCT01984840|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
11407663|NCT01984840|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
11407702|NCT01984606|Experimental|Empagliflozin|Empagliflozin once daily
11407664|NCT01984827|Experimental|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
11407665|NCT01984827|Experimental|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
11407666|NCT01984827|Placebo Comparator|Placebo|Placebo
11407667|NCT01984814|Experimental|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
11407668|NCT01984814|No Intervention|Control|No cell transplantation was done
11407669|NCT01984801|Experimental|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
11407670|NCT01984801|Experimental|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
11407671|NCT01984801|Experimental|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
11407672|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
11407673|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
11407674|NCT01984775|Experimental|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
11407675|NCT01984775|Experimental|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
11407676|NCT01984775|Experimental|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
11407677|NCT01984775|Placebo Comparator|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
11407678|NCT01984775|Active Comparator|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
11407679|NCT01984775|Active Comparator|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
11407680|NCT01984762|Active Comparator|RYGBP|Roux-en-Y gastric bypass
11407681|NCT01984762|Active Comparator|SG|sleeve gastrectomy
11407682|NCT01984749|Experimental|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
11407683|NCT01984749|No Intervention|Non-febuxostat treatment group|No febuxostat treatment
11407684|NCT01984736|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
11407685|NCT01984723|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
11407686|NCT01984710|Experimental|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
11407687|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
11407688|NCT01984697|Experimental|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
11407689|NCT01984697|Experimental|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
11407690|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
11407691|NCT01984697|Active Comparator|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
11407692|NCT01984684|Experimental|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
11407693|NCT01984684|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
11407694|NCT01984671|Experimental|Mobile Pain Coping Skills Training|Pain coping skills training
11407695|NCT01984671|No Intervention|Standard Care Control|
11407696|NCT01984658|Experimental|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
11407697|NCT01984645|Experimental|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
11407698|NCT01984645|No Intervention|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
11407699|NCT01984632|Experimental|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
11407704|NCT01984593|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
11407705|NCT01984593|Active Comparator|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
11407706|NCT01984580|Experimental|Zinc|
11407707|NCT01984580|Placebo Comparator|sodium|
11407708|NCT01984567|Experimental|Vitamin E|
11407709|NCT01984567|Experimental|Lipoic acid|
11407710|NCT01984567|Placebo Comparator|Control|
11407711|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
11407712|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
11407713|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
11407714|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
11407715|NCT01984541|Experimental|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
11407716|NCT01984528|Experimental|Prick Test|Alternaria alternata allergen extract Positve control Negative control
11407717|NCT01984515|Experimental|Team Red Primary Care|Eligible patients will receive the Referral Management System in primary care
11407718|NCT01984502|Experimental|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
11407719|NCT01984489|Placebo Comparator|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
11407720|NCT01984489|Experimental|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
11407721|NCT01984489|Experimental|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
11407722|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
11407723|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
11407724|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
11407725|NCT01984463|Active Comparator|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
11407726|NCT01984463|Experimental|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
11407727|NCT01984450|Active Comparator|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
11407728|NCT01984450|Active Comparator|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
11407729|NCT01984424|Other|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
11407730|NCT01984424|Other|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
11407731|NCT01984424|Active Comparator|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
11407732|NCT01984424|Experimental|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
11407804|NCT01983943|Placebo Comparator|Placebo|Placebo 40mg will be taken once per day for 6 months.
11408077|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
11407733|NCT01984424|Experimental|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
11407734|NCT01984411|Experimental|Radial Technical|Radial technical is the procedure for catheterization
11407735|NCT01984411|Active Comparator|Femoral Technical|Vascular Access for cardiac catheterization
11407736|NCT01984398|Experimental|12.5 mg Androxal (formulations A and B)|12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
11407737|NCT01984398|Experimental|25 mg Androxal (formulations A and B)|25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
11407738|NCT01984385||Patients with a hip fracture|
11407739|NCT01984372||Tresiba® users|
11407740|NCT01984359|Other|Single arm|Biosamples will be obtained at multiple time-points for all participants
11407741|NCT01984346|Experimental|Convergent Procedure|Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
11407742|NCT01984346|Active Comparator|Standalone Endocardial Catheter Ablation|Endocardial Catheter Ablation Treatment
11407743|NCT01984333|Experimental|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
11407744|NCT01984333|No Intervention|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
11407745|NCT01984320|Active Comparator|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
11407746|NCT01984320|Active Comparator|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
11407747|NCT01984320|Active Comparator|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
11407748|NCT01984294|Experimental|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
11407749|NCT01984294|Experimental|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
11407750|NCT01984294|Experimental|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
11407751|NCT01984281|Experimental|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
11407752|NCT01984281|No Intervention|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
11407753|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
11407754|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
11407755|NCT01984255|Active Comparator|A- Bavituximab plus Ipilimumab|Arm A-Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
11407756|NCT01984255|Experimental|Arm B Ipilimumab|Arm B-Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
11407757|NCT01984242|Experimental|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
11407758|NCT01984242|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union [EU] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
11407759|NCT01984242|Active Comparator|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
11407760|NCT01984229|Experimental|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
11407783|NCT01984073|Placebo Comparator|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
11407805|NCT01983930|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
11407761|NCT01984229|Experimental|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
11407762|NCT01984216|Experimental|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
11407763|NCT01984216|Active Comparator|Billroth II|Billroth II for the gastrojejunostomy reconstruction
11407764|NCT01984203|Experimental|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.
~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
11407765|NCT01984203|Active Comparator|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.
~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
11407766|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
11407767|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
11407768|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
11407769|NCT01984164|Active Comparator|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
11407770|NCT01984164|Active Comparator|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
11407771|NCT01984138|Experimental|Estring|ESTRING
11407772|NCT01984138|Active Comparator|REPLENS|Replens
11407773|NCT01984125|Experimental|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
11407774|NCT01984125|No Intervention|Control|
11407775|NCT01984112|Experimental|Intramedullary Locked Nail|
11407776|NCT01984112|Active Comparator|Locked Plate|
11407777|NCT01984099|Active Comparator|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
11407778|NCT01984099|Placebo Comparator|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
11407779|NCT01984086|Experimental|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
11407780|NCT01984086|Experimental|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
11407781|NCT01984073|Active Comparator|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
11407782|NCT01984073|Active Comparator|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
11407803|NCT01983943|Experimental|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
11407784|NCT01984060|Other|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.
~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
11407785|NCT01984060|No Intervention|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
11407786|NCT01984047|Experimental|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
11407787|NCT01984047|Experimental|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
11407788|NCT01984047|Experimental|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
11407789|NCT01984047|Experimental|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
11407790|NCT01984047|Experimental|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
11407791|NCT01984047|Experimental|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
11407792|NCT01984034|Experimental|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
11407793|NCT01984034|Active Comparator|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
11407794|NCT01984021|Experimental|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
11407795|NCT01984021|Placebo Comparator|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
11407796|NCT01984008|Experimental|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
11407797|NCT01984008|Active Comparator|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
11407798|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
11407799|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
11407800|NCT01983969|Experimental|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
11407801|NCT01983956|Experimental|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
11407802|NCT01983956|No Intervention|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
11407806|NCT01983930|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 20 minute meditation
11407807|NCT01983917|Other|Use of the Diabetes Application|
11407808|NCT01983904|Experimental|Long Pulse Width|deep brain stimulation with short & long pulse width
11407809|NCT01983904|Experimental|Short Pulse Width|deep brain stimulation with short & long pulse width
11407810|NCT01983891|Experimental|Intervention|6-week nutrition education and cooking course
11407811|NCT01983878|Experimental|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
11407812|NCT01983865|Other|Exposure to birch pollen|
11407813|NCT01983852||1|Children during End of Life Care
11407814|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
11407815|NCT01983826|Experimental|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
11407816|NCT01983826|Placebo Comparator|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
11407817|NCT01983813|Experimental|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
11407818|NCT01983813|Other|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
11407819|NCT01983800|Active Comparator|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
11407820|NCT01983800|Active Comparator|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
11407821|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
11407822|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
11407823|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
11407824|NCT01983761|Experimental|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment
~Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)
~Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000
~Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000
~Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000
~Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg
~Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg
~Day6 Rest
~Day7 Rest
~Day8 Cord blood infusions"
11407825|NCT01983761|Experimental|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment
~Day0 Admit, hydration
~Day1 Fludarabine 40 mg/m2 IV
~Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg
~Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg
~Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV
~Day5 Rest Day6 Cord blood infusions"
11407826|NCT01983748|Experimental|A|Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA
11407827|NCT01983748|No Intervention|B|Control, Standard of care, which is clinical control every 3 months
11407828|NCT01983735|Experimental|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
11407829|NCT01983735|Active Comparator|S-Amlodipine 2.5, 5mg|
11407830|NCT01983709|Experimental|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.
~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
11407831|NCT01983696|Experimental|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
11407832|NCT01983696|No Intervention|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
11407833|NCT01983683|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
11407834|NCT01983683|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
11407835|NCT01983670|Experimental|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
11407836|NCT01983670|Experimental|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
11407837|NCT01983670|No Intervention|health group 2|health subjects controlled group
11407838|NCT01983670|No Intervention|SCA group 2|SCA subjects controlled group
11407839|NCT01983657|Experimental|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
11407840|NCT01983657|Experimental|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
11407841|NCT01983657|Experimental|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
11407842|NCT01983657|Active Comparator|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).
~When the treatment is ineffective, and anti-GM-CSF antibody titers level <1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
11407917|NCT01983228|No Intervention|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
11407843|NCT01983644|Experimental|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
11407844|NCT01983644|Active Comparator|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
11407845|NCT01983631|Experimental|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
11407846|NCT01983631|No Intervention|Non-WBV group|Stage 1 : Controlled group
11407847|NCT01983631|Experimental|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
11407848|NCT01983631|No Intervention|non-training group|Stage 2: Controlled group
11407849|NCT01983618|Placebo Comparator|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
11407850|NCT01983618|Experimental|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
11407851|NCT01983605|Experimental|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
11407852|NCT01983592|Active Comparator|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
11407853|NCT01983592|Placebo Comparator|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
11407854|NCT01983579|Experimental|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
11407855|NCT01983579|Experimental|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
11407856|NCT01983579|Experimental|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
11407857|NCT01983566|Active Comparator|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
11407858|NCT01983566|Experimental|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
11407859|NCT01983566|Experimental|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
11407860|NCT01983566|Experimental|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
11407861|NCT01983553||CYD Dengue Vaccine Group|Participants who received 3 injections of 0.5 milliliter (mL) CYD dengue vaccine, 1 injection each at 0, 6, and 12 months, subcutaneously in study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
11407862|NCT01983553||Control Group|Participants who received either 0.5 mL Rabies vaccine (Verorab®) or placebo control, subcutaneously as a first injection on Day 0, placebo for second and third injections at 6 and 12 months, respectively in the study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
11407863|NCT01983540|Experimental|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
11407864|NCT01983540|Experimental|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
11407865|NCT01983540|Active Comparator|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
11407866|NCT01983527|Experimental|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
11407867|NCT01983527|Active Comparator|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
11407868|NCT01983527|Active Comparator|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
11407869|NCT01983514|Active Comparator|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
11407870|NCT01983514|Placebo Comparator|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
11408033|NCT01982461|Active Comparator|Crestor®|One Crestor® tablet 10mg taken once daily.
11408034|NCT01982448|Experimental|Paclitaxel|Paclitaxel will be given as an IV infusion at a dose of 80mg/m2 weekly x 12 weeks (4 cycles).
11407871|NCT01983514|Experimental|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
11407872|NCT01983514|Experimental|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
11407873|NCT01983501|Experimental|Tucatinib (ONT-380) in combination with T-DM1|
11407874|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
11407875|NCT01983475|Placebo Comparator|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
11407876|NCT01983475|Experimental|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
11407877|NCT01983462|Experimental|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
11407878|NCT01983462|Active Comparator|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
11407879|NCT01983462|Placebo Comparator|Placebo|Placebo
11407880|NCT01983449|Experimental|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
11407881|NCT01983436|Experimental|Manual Lymphatic Drainage|"9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.
~4 more sessions (one every two days)."
11407882|NCT01983436|No Intervention|Control|No session of manual lymphatic drainage
11407883|NCT01983423|Experimental|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
11407884|NCT01983423|No Intervention|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
11407885|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
11407886|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
11407887|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
11407888|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
11407889|NCT01983397|Experimental|Resistance training|Resistance training
11407890|NCT01983397|Experimental|Multicomponent training|Multicomponent training
11407891|NCT01983397|No Intervention|Control Group|The Control Group did not realize any intervention.
11407892|NCT01983384|Placebo Comparator|Anesthetic Depth: standard care|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive routine anesthetic management not guided by the processed electroencephalogram
11407893|NCT01983384|Experimental|Anesthetic Depth: interventional|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive anesthetic management guided by the processed electroencephalogram (processed EEG-guided anesthetic depth)
11407894|NCT01983371|Experimental|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
11407895|NCT01983358|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
11407896|NCT01983358|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
11407897|NCT01983345|No Intervention|Control|No prenatal surgical repair of myelomeningocele
11407898|NCT01983345|Experimental|Case - open surgical repair|Prenatal surgical repair of fetal myelomeningocele
11407899|NCT01983332||occupational therapists|Occupational Therapists
11407900|NCT01983319|Experimental|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
11407901|NCT01983319|Sham Comparator|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
11407902|NCT01983319|No Intervention|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
11407903|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
11407904|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
11407905|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
11407906|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
11407907|NCT01983293|Experimental|QLV based implant strategy|QLV represents the pacing site with the largest amount of dyssynchrony as measured by the left ventricular electrical delay. The QLV based implant strategy finds the left ventricle vein branch and left ventricular lead cathode with the longest QLV measurement and places the lead at this location and programs the device using this lead cathode.
11407908|NCT01983293|Placebo Comparator|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach.
11407909|NCT01983280|Experimental|Healing Touch|
11407910|NCT01983267|Active Comparator|cannabis|Patient using cannabis during chemotherapy treatment
11407911|NCT01983267|No Intervention|control|Patients under chemotherapy treatment
11407912|NCT01983254|Experimental|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
11407913|NCT01983254|Active Comparator|education program|6 week access to a web-based, critical illness-specific education program
11407914|NCT01983241|Experimental|Alpha-1 MP 60 mg/kg|Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
11407915|NCT01983241|Experimental|Alpha-1 MP 120 mg/kg|Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
11407916|NCT01983241|Placebo Comparator|Placebo|0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
11407918|NCT01983228|Experimental|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
11407919|NCT01983215|Experimental|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
11407920|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
11407921|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
11407922|NCT01983189|Experimental|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
11407923|NCT01983163|Active Comparator|ketogenic diet|ketogenic diet (2.5 to 4:1)
11407924|NCT01983163|Active Comparator|Modifid Atkin's diet|Modified Atkin's Diet
11407925|NCT01983150|Experimental|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
11407926|NCT01983150|Active Comparator|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
11407927|NCT01983124|Experimental|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
11407928|NCT01983111|Experimental|buprenorphine|Patch
11407929|NCT01983111|Active Comparator|tramadol/acetaminophen|Oral tablet
11407930|NCT01983085|Other|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
11407931|NCT01983085|Other|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
11407932|NCT01983072|Active Comparator|Infant starter formula|standard infant formula
11407933|NCT01983072|Experimental|Infant starter formula + prebiotics + probiotics|infant formula
11407934|NCT01983072|Other|Breastfeeding group|reference group
11407935|NCT01983059||Patients with Liver Venous Thrombosis|
11407936|NCT01983046|Placebo Comparator|placebo|placebo
11407937|NCT01983046|Active Comparator|high acetate ratio|high acetate ratio
11407938|NCT01983046|Active Comparator|high butyrate ratio|high butyrate ratio
11407939|NCT01983046|Active Comparator|high propionate ratio|high propionate ratio
11407940|NCT01983033|Experimental|active treatment condition (ATC)|training protocol 'drop it'
11407941|NCT01983033|Other|waiting list control|no treatment other than treatment as usual
11407942|NCT01983020|Experimental|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
11407943|NCT01983020|Experimental|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
11407944|NCT01983020|Experimental|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
11407945|NCT01983020|Placebo Comparator|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
11407946|NCT01983007|Experimental|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
11407947|NCT01983007|Experimental|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
11407948|NCT01982994|Experimental|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
11407949|NCT01982994|No Intervention|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
11407950|NCT01982981|No Intervention|control|The control group only be assessed
11407951|NCT01982981|Experimental|water provision|The experimental group get water every 15 days
11407952|NCT01982968|No Intervention|Control|Subjects to receive standard anti-reflux treatment per clinical discretion
11407953|NCT01982968|Active Comparator|Surgery|Subjects will receive laparoscopic fundoplication surgery
11407954|NCT01982955|Experimental|Phase 1b: Tepotinib 300 milligram (mg)|Participants received Tepotinib 300 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
11407955|NCT01982955|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
11407956|NCT01982955|Experimental|Phase 2: Tepotinib and Gefitinib|Participants randomized to receive Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
11407957|NCT01982955|Experimental|Phase 2: Pemetrexed and Cisplatin/Carboplatin|Participants randomized to receive 500 milligram per square meter (mg/m^2) of Pemetrexed as intravenous infusion over 10 minutes in combination with Cisplatin (75 mg/m2 as an intravenous infusion over 2 hours) or Carboplatin (intravenously at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator) on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment or up to 6 cycles if or 4 cycles followed by Premetrexed maintenance monotherapy.
11407958|NCT01982955|Experimental|Phase 2: Single-arm Cohort (MET+ T790M positive)|Participants with MET+ T790M positive Non-small Cell Lung Cancer (NSCLC) received a Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
11407959|NCT01982942|Experimental|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
11407960|NCT01982942|Placebo Comparator|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
11407961|NCT01982929|Sham Comparator|Sham block & Oral Meds|Definition intervention. Sham procedure. Blocks mimicked the TAP blocks, but neither needle nor injectate was used. Patients had bilateral ultrasound scans over the lateral aspect of the abdomen. To mimic the injection of medicine, a blunt needleless syringe was firmly pressed on either side of the abdomen. An adhesive bandage was applied over the injection or sham injection sites.
11407962|NCT01982929|Experimental|TAP block & Oral Meds|Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
11407963|NCT01982916|Experimental|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
11407964|NCT01982916|Placebo Comparator|Placebo|Placebo by bid for 4 weeks
11407965|NCT01982916|Active Comparator|Active comparator|Active Comparator and Placebo by bid for 4 weeks
11407966|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
11407967|NCT01982890||Normal human controls|"Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.
~Subjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
11407968|NCT01982877|Experimental|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
11407969|NCT01982877|Experimental|Educational Control|ICU educational component
11407970|NCT01982864|Experimental|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
11407971|NCT01982851|Active Comparator|Group E|Epidural de novo technique
11407972|NCT01982851|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
11407973|NCT01982851|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
11407974|NCT01982838|Active Comparator|Group E|Epidural de novo technique
11407975|NCT01982838|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
11407976|NCT01982838|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
11407977|NCT01982825|Experimental|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
11407978|NCT01982825|Active Comparator|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
11407979|NCT01982812|Experimental|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
11407980|NCT01982812|Active Comparator|Standard AED|Standard AED regimen
11407981|NCT01982799|Experimental|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
11407982|NCT01982799|Experimental|Endodontic Tx plus local anesthetic|local anesthetic
11407983|NCT01982786|Active Comparator|Arm 1|IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
11407984|NCT01982786|Active Comparator|Arm 2|"IGRT 37.5 Gy in 15 fractions
~+ HDR brachytherapy boost 15 Gy"
11407985|NCT01982773|Experimental|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
11407986|NCT01982773|Active Comparator|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
11407987|NCT01982760|Experimental|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
11407988|NCT01982760|No Intervention|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
11407989|NCT01982747|Other|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
11407990|NCT01982747|Other|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
11407991|NCT01982734|Active Comparator|Native curcumin|80 mg curcumin as native powder
11407992|NCT01982734|Experimental|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
11407993|NCT01982734|Experimental|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
11407994|NCT01982734|Experimental|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
11407995|NCT01982721|Experimental|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
11407996|NCT01982721|No Intervention|Healthy volunteers|
11407997|NCT01982695|Active Comparator|Lisinopril|
11407998|NCT01982695|Active Comparator|Losartan|
11407999|NCT01982682|Experimental|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
11408000|NCT01982669||Different degree of spicy food intake|
11408001|NCT01982656|Experimental|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
11408002|NCT01982656|Placebo Comparator|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
11408003|NCT01982643|Experimental|naltrexone plus bupropion|extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)
11408004|NCT01982630|Experimental|Part I - MK-8521 64/120 μg/day|Participants will receive once daily subcutaneous MK-8521 (starting dose 64 μg/day Days 1 to 7 escalated to 120 μg/day for Days 8 to 14).
11408005|NCT01982630|Experimental|Part I - MK-8521 34/72 μg/day|Participants will receive once daily subcutaneous MK-8521(starting dose 34 μg/day Days 1 to 7 escalated to 72 μg/day for Days 8 to 14).
11408006|NCT01982630|Active Comparator|Part I - Liraglutide 0.6/1.2/1.8 mg/day|Participants will receive once daily subcutaneous liraglutide (starting dose 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, escalated to 1.8 mg for Days 8 to 14).
11408007|NCT01982630|Placebo Comparator|Part I - Placebo|Participants receive a dose of placebo that will match the administration volume of MK-8521.
11408008|NCT01982630|Experimental|Part II - MK-8521 300 ug/day - T2DM Participants|For T2DM participants, MK-8521 titrated to 300 ug/day. Starting at 64 ug and increasing to 120 ug on Day 8 and to 180 ug on Day 15 and increasing to 240 ug on Day 20 and to 300 ug on Day 25. The total number of dosing days will be 29.
11408009|NCT01982630|Active Comparator|Part II - Liraglutide 1.8 mg/day - T2DM Participants|Liraglutide titrated to 1.8 mg/day for 29 days. Starting at 0.6 mg and increasing to 1.2 mg on Day 8 and to 1.8 mg on Day 15.
11408010|NCT01982630|Placebo Comparator|Part II - Placebo - T2DM Participants|Participants receive a dose of placebo that will match the administration volume of MK-8521 across the 29 days.
11408011|NCT01982630|Experimental|Part II - MK-8521 120 ug/day - Non-Diabetic Participants|For non-diabetic overweight/obese participants MK-8521 titrated to 120 ug/day. The total dosing days will be 14 days, starting at 64 ug and increasing to 120 ug on Day 8.
11408012|NCT01982617|Experimental|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
11408013|NCT01982617|Experimental|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
11408014|NCT01982604|Experimental|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:
~TI-Inhalation Powder A TI-Inhalation Powder B
~*30 units (10 units + 20 units)"
11408015|NCT01982604|Experimental|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:
~TI-Inhalation Powder B TI-Inhalation Powder A
~*30 units (10 units + 20 units)"
11408016|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
11408017|NCT01982578|Experimental|Product: Genistein|60 mg of genistein BID for 360 days. Intervention: Product: Genistein
11408018|NCT01982578|Placebo Comparator|Product: Placebo|1 placebo capsule BID for 360 days. Intervention: Product: Placebo
11408019|NCT01982565|Experimental|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
11408020|NCT01982565|Active Comparator|Control Arm|Standard of Care
11408021|NCT01982539|Experimental|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
11408022|NCT01982526||Endmetrioma surgery|
11408023|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.
~These patients will be examined in 4 positions with the ultrasound."
11408024|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
11408025|NCT01982487|No Intervention|Arm A (no treatment)|Patients receive no treatment.
11408026|NCT01982487|Experimental|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
11408027|NCT01982487|Experimental|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
11408028|NCT01982487|Experimental|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
11408029|NCT01982474|Experimental|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
11408030|NCT01982474|Placebo Comparator|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
11408031|NCT01982474|No Intervention|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
11408032|NCT01982461|Experimental|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
11408035|NCT01982448|Experimental|Cisplatin|Cisplatin will be given by IV at 75 mg/m2 every 3 weeks, 4 cycles.
11408036|NCT01982435|Other|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
11408037|NCT01982435|Other|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
11408038|NCT01982422|Experimental|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
11408039|NCT01982422|Placebo Comparator|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
11408040|NCT01982409|Experimental|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11408041|NCT01982396|Active Comparator|Twice daily|
11408042|NCT01982396|Experimental|Once daily|
11408043|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
11408044|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
11408045|NCT01982357||premature infant|Laser Speckle Imaging and Diffuse Optical Spectroscopy
11408046|NCT01982344|Experimental|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
11408047|NCT01982344|No Intervention|usual care (G1)|The one group perform traditional PD procedure (G1)
11408048|NCT01982331|Experimental|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
11408049|NCT01982331|Placebo Comparator|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
11408050|NCT01982318|Active Comparator|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
11408051|NCT01982318|Placebo Comparator|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
11408052|NCT01982305|Experimental|Simulator|One training session with the simulator.
11408053|NCT01982305|Active Comparator|Cadaver|One training session with a cadaver.
11408054|NCT01982292|Experimental|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
11408055|NCT01982292|Placebo Comparator|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
11408056|NCT01982266|Experimental|GRADION™ Hip Total Cartilage Replacement (TCR)™|
11408057|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
11408058|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
11408059|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
11408060|NCT01982240|Active Comparator|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
11408061|NCT01982240|Active Comparator|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
11408062|NCT01982240|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
11408063|NCT01982240|Other|Bisacodyl|Rescue medication
11408064|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
11408065|NCT01982214|Sham Comparator|sedentary|No intervention
11408066|NCT01982214|Experimental|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
11408067|NCT01982201|Experimental|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
11408068|NCT01982201|Experimental|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
11408069|NCT01982188||Single incision sling|
11408070|NCT01982175|Experimental|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
11408071|NCT01982162||Cohort A|severe school aged asthma cohort
11408072|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
11408073|NCT01982162||Cohort C|Severe pre school wheeze cohort
11408074|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
11408075|NCT01982149||Group 1|Non-smokers (n=20)
11408076|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
11408078|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
11408079|NCT01982123|Experimental|SPECT/CT Mid-& Post-RT|Investigational 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment.
11408080|NCT01982110|Experimental|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
11408081|NCT01982110|Active Comparator|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
11408082|NCT01982097||Group 1|
11408083|NCT01982071|Experimental|Treatment group|Intravenous (IV)
11408084|NCT01982058|Experimental|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
11408085|NCT01982058|Active Comparator|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
11408086|NCT01982058|Other|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
11408087|NCT01982045|Experimental|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
11408088|NCT01982045|Active Comparator|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
11408089|NCT01982032|Active Comparator|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
11408090|NCT01982032|Active Comparator|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
11408091|NCT01982019|Other|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
11408092|NCT01982019|Other|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
11408093|NCT01982019|Other|healthy volonteers|Meal test taking and hormones measure including 26RFa
11408094|NCT01982006|Active Comparator|Phaco|Cataract surgery by phacoemulsification
11408095|NCT01982006|Experimental|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
11408096|NCT01981993||patients at ICU with sepsis|
11408097|NCT01981980|Experimental|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
11408098|NCT01981980|Experimental|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
11408099|NCT01981967|Experimental|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
11408100|NCT01981967|Active Comparator|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
11408101|NCT01981954|Experimental|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
11408102|NCT01981941|Experimental|Treatment group|Oral
11408103|NCT01981928|Experimental|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
11408104|NCT01981928|Placebo Comparator|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
11408105|NCT01981915|Experimental|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
11408106|NCT01981915|Experimental|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
11408107|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
11408108|NCT01981889|Other|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
11408109|NCT01981863|Experimental|Epsilonaminocaproic acid|One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo
11408110|NCT01981863|Placebo Comparator|Placebo, Antifibrinolytic activity|Placebo: same IV volume as experimental arm
11408111|NCT01981850|Experimental|Stage 1: Cohort 1 Weekly|Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
11408112|NCT01981850|Experimental|Stage 1: Cohort 1 Every 4 Weeks|Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
11408113|NCT01981850|Experimental|Stage 1: Cohort 2 Weekly|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
11408156|NCT01981538||Adult informal caregivers|Subjects will be eligible for this protocol if they are adult informal caregivers that are familymembers or friends of a patient enrolled in a cancer treatment study at the NIH Clinical Center
11408114|NCT01981850|Experimental|Stage 1: Cohort 2 Every 4 Weeks|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
11408115|NCT01981850|Experimental|Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
11408116|NCT01981850|Experimental|Stage 2: Cohort 2 3mg/kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
11408117|NCT01981850|Experimental|Stage 2: Cohort 3 10mg /kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
11408118|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
11408119|NCT01981811|Active Comparator|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
11408120|NCT01981798|Active Comparator|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
11408121|NCT01981798|No Intervention|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
11408122|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
11408123|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
11408124|NCT01981772|Experimental|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
11408125|NCT01981772|Active Comparator|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
11408126|NCT01981759|Placebo Comparator|Placebo|Participants receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
11408127|NCT01981759|Experimental|D-Cycloserine|Participants will receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
11408128|NCT01981746|Experimental|30 ml|30 ml ropivacaine 0.1%, single bolus
11408129|NCT01981746|Experimental|10 ml|10 ml 0.1% ropivacaine, single bolus
11408130|NCT01981733|Experimental|Device|
11408131|NCT01981720|Experimental|1.0 mg/kg|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
11408132|NCT01981707|Experimental|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
11408133|NCT01981694|Experimental|Single ascending doses|
11408134|NCT01981694|Experimental|Measurement of eye blink rate|
11408135|NCT01981681|Experimental|Cohort 1 Experimental Arm|
11408136|NCT01981681|Experimental|Cohort 2 Experimental Arm|
11408137|NCT01981681|Experimental|Cohort 3 Experimental Arm|
11408138|NCT01981681|Placebo Comparator|Cohort 3 Placebo Arm|
11408139|NCT01981681|Experimental|Cohort 4 Experimental Arm|
11408140|NCT01981681|Placebo Comparator|Cohort 4 Placebo Arm|
11408141|NCT01981668|Experimental|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
11408142|NCT01981655|Experimental|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
11408143|NCT01981655|Active Comparator|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
11408144|NCT01981642|Experimental|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
11408145|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
11408146|NCT01981616|Experimental|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
11408147|NCT01981616|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
11408148|NCT01981603|Experimental|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
11408149|NCT01981603|No Intervention|usual care|usual care
11408150|NCT01981590|Experimental|All enrolled patients|All enrolled patients that underwent a scheduled cardiac catheterization involving an atrial fibrillation (AF) ablation procedure as per clinical practice
11408151|NCT01981577||Patients with Parkinson's Disease|
11408152|NCT01981577||Healthy volunteers|
11408153|NCT01981564|Experimental|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
11408154|NCT01981564|Active Comparator|Standard Asthma Education Control group|Standard asthma education during nurse home visits
11408155|NCT01981551|Experimental|PF-03084014 in Desmoid Tumors/Aggressive Fibromatosis|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
11408764|NCT01977352|Experimental|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
11408157|NCT01981525|Experimental|Arm 1|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
11408158|NCT01981499|Experimental|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
11408159|NCT01981499|Placebo Comparator|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
11408160|NCT01981499|Experimental|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
11408161|NCT01981499|Experimental|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
11408162|NCT01981499|Experimental|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
11408163|NCT01981499|Experimental|Arm B4|Placebo control
11408164|NCT01981486|Placebo Comparator|Placebo|Placebo tablets
11408165|NCT01981486|Experimental|PF-05180999|Modified-release tablets of PF-05180999
11408166|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
11408167|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
11408168|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
11408169|NCT01981460|No Intervention|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
11408170|NCT01981460|Experimental|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
11408171|NCT01981447|Active Comparator|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
11408172|NCT01981447|Active Comparator|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
11408173|NCT01981434|Active Comparator|Video game based obesity education|This is the intervention group. They will be given the opportunity to play an interactive educational video game for teaching health and nutrition.
11408174|NCT01981434|No Intervention|No intervention|This is the control group that will receive only printed information about health and nutrition and will not be given the opportunity to play the educational video game.
11408175|NCT01981421||Liver fibrosis|patients who had chronic liver disease
11408176|NCT01981408|Experimental|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
11408177|NCT01981395|Experimental|Treatment regimn 1|150 mg Fenobam Orally - once
11408178|NCT01981395|Placebo Comparator|Treatment Regimen 2|Placebo orally - once
11408179|NCT01981382||Incident cases|Persistent nonspecific low back pain
11408180|NCT01981382||Controls|Acute low back pain that resolves in <6 months
11408181|NCT01981369|Active Comparator|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
11408182|NCT01981369|Experimental|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
11408183|NCT01981356|Experimental|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
11408184|NCT01981356|Active Comparator|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
11408185|NCT01981343|Experimental|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
11408186|NCT01981343|Placebo Comparator|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
11408187|NCT01981330|Experimental|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
11408188|NCT01981317|Experimental|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.
~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
11408189|NCT01981317|Active Comparator|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
11408190|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
11408191|NCT01981291|Active Comparator|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
11408225|NCT01980992|Active Comparator|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
11408192|NCT01981291|Experimental|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
11408193|NCT01981278|Experimental|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
11408194|NCT01981278|Experimental|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
11408195|NCT01981265||Hand osteoarthritis|
11408196|NCT01981252|Experimental|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
11408197|NCT01981239|Experimental|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
11408198|NCT01981239|Active Comparator|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
11408199|NCT01981226|Experimental|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
11408200|NCT01981200|Experimental|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
11408201|NCT01981187|Experimental|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
11408202|NCT01981174|Active Comparator|30-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
11408203|NCT01981174|Active Comparator|32-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
11408204|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
11408205|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
11408206|NCT01981148||Healthy patients|Healthy patients
11408207|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
11408208|NCT01981135|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11408209|NCT01981135|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
11408210|NCT01981122|Experimental|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
11408211|NCT01981122|Experimental|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
11408212|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
11408213|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
11408214|NCT01981083|Experimental|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
11408215|NCT01981083|Active Comparator|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
11408216|NCT01981070|Other|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
11408217|NCT01981070|Active Comparator|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
11408218|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
11408219|NCT01981057||Individual|individually prescribed parenteral receipt
11408220|NCT01981044|Experimental|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
11408221|NCT01981031|Experimental|A|Drug: BioChaperone® Combo
11408222|NCT01981031|Active Comparator|B|Drug: Humalog® Mix25
11408223|NCT01981018|Experimental|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
11408224|NCT01981005|Experimental|RO5424802|
11408226|NCT01980992|Placebo Comparator|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
11408227|NCT01980979|Experimental|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
11408228|NCT01980966|Experimental|MHAA4549A|
11408229|NCT01980966|Placebo Comparator|Placebo|
11408230|NCT01980966|Active Comparator|Tamiflu|
11408231|NCT01980953|Experimental|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
11408232|NCT01980953|Experimental|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
11408233|NCT01980953|Experimental|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
11408234|NCT01980953|Experimental|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
11408235|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
11408236|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
11408237|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
11408238|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
11408239|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
11408240|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
11408241|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
11408242|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
11408243|NCT01980927|Experimental|NUCCA atlas correction|NUCCA atlas correction for migraine patients
11408244|NCT01980914|Experimental|Type 2 diabetes group|Patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin. All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %.
11408245|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
11408246|NCT01980888|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
11408247|NCT01980888|Placebo Comparator|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
11408248|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
11408249|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
11408250|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
11408251|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
11408252|NCT01980849|Experimental|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
11408253|NCT01980849|Active Comparator|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
11408254|NCT01980836|Active Comparator|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
11408255|NCT01980836|Active Comparator|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
11408256|NCT01980823|Experimental|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
11408300|NCT01980485|Active Comparator|Feedback on lung age and exhaled carbon monoxide|
11408257|NCT01980810|Experimental|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
11408258|NCT01980797||Bicuspid aortic valve disease|"Group/Cohort Label - Bicuspid aortic valve
~Group/Cohort Description -
~Patients diagnosed with bicuspid aortic valve
~All ages ≥8 years
~Able to provide fully informed consent"
11408259|NCT01980797||Tricuspid aortic valve control patients|"Group/Cohort Label - Tricuspid aortic valve control patients
~Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched.
~Patients not diagnosed with bicuspid aortic valve
~All ages ≥8 years
~Able to provide fully informed consent"
11408260|NCT01980771|Experimental|BTWB intervention|Barbershops are assigned to either experimental or active control condition. Men recruited from experimental barbershops receive a single-session group intervention focused on HIV prevention.
11408261|NCT01980771|Active Comparator|Cancer prevention and screening|Barbershops are assigned to either experimental or control condition. Men recruited from control barbershops receive information on cancer prevention and control.
11408262|NCT01980758|Experimental|Surgery|Laparoscopic Gastric Plication
11408263|NCT01980745|Active Comparator|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
11408264|NCT01980745|Placebo Comparator|sugar pill|sugar pill
11408265|NCT01980719||Healthy, Age-Matched|
11408266|NCT01980719||Fatigued|
11408267|NCT01980719||Not Fatigued|
11408268|NCT01980706|Placebo Comparator|Placebo|Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
11408269|NCT01980706|Active Comparator|30 Mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
11408270|NCT01980706|Active Comparator|90 mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
11408271|NCT01980693|Other|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
11408272|NCT01980680|Experimental|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
11408273|NCT01980680|Active Comparator|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
11408274|NCT01980667|Experimental|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
11408275|NCT01980654|Experimental|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
11408276|NCT01980654|Experimental|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
11408277|NCT01980641|No Intervention|Control group|Assessment of each participant's home and his or her performance of ADL.
11408278|NCT01980641|Experimental|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
11408279|NCT01980641|Experimental|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
11408280|NCT01980641|No Intervention|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
11408281|NCT01980628|Experimental|ibrutinib|ibrutinib capsules: 560 mg once daily
11408282|NCT01980615|Experimental|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
11408283|NCT01980615|Experimental|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
11408284|NCT01980615|Experimental|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
11408285|NCT01980615|Active Comparator|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
11408286|NCT01980615|Active Comparator|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
11408287|NCT01980615|Active Comparator|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
11408288|NCT01980602|Experimental|Supervised Exercise Program|
11408289|NCT01980589|Experimental|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
11408290|NCT01980576||Pre-operative pain measurement|Patients with low back pain
11408291|NCT01980563|Active Comparator|ultrasound|
11408292|NCT01980563|Active Comparator|combined monitoring|
11408293|NCT01980550|Experimental|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
11408294|NCT01980537|Experimental|Stereotaxis|Magnetic wire navigation
11408295|NCT01980537|Active Comparator|Conventional|Conventional wire navigation
11408296|NCT01980524|Experimental|acipimox+|250 mg at 0 and 180 minutes (one day)
11408297|NCT01980524|Placebo Comparator|Placebo|1 Tablet at 0 and 180 minutes (one day)
11408298|NCT01980498|Experimental|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:
~Fentanyl pectin nasal spray (FPNS)
~Physician choice-Usual Care (PC-UC)"
11408299|NCT01980498|Active Comparator|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:
~Fentanyl pectin nasal spray (FPNS)
~Physician choice-Usual Care (PC-UC)"
11408301|NCT01980485|Sham Comparator|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
11408302|NCT01980472|Experimental|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
11408303|NCT01980459|Experimental|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
11408304|NCT01980446|Other|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
11408305|NCT01980433|Experimental|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
11408306|NCT01980433|Sham Comparator|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
11408307|NCT01980420|Other|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
11408308|NCT01980407|Experimental|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
11408309|NCT01980394|Other|prospective cohort study|
11408310|NCT01980381|Experimental|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
11408311|NCT01980381|No Intervention|Control group|Treatment as usual, with focus on the present everyday occupations
11408312|NCT01980368|Experimental|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
11408313|NCT01980368|Active Comparator|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
11408314|NCT01980355|Experimental|Tranexamic Acid|1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.
11408315|NCT01980355|Placebo Comparator|Placebo|Placebo given over 15 minutes into the vein once prior to surgery.
11408316|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
11408317|NCT01980329|Experimental|Maraviroc|single oral administration of 300 mg maraviroc
11408318|NCT01980316|Experimental|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
11408319|NCT01980316|Experimental|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
11408320|NCT01980303|Experimental|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
11408321|NCT01980303|Experimental|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
11408322|NCT01980303|Experimental|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
11408323|NCT01980303|Experimental|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
11408324|NCT01980303|Experimental|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
11408325|NCT01980303|Experimental|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
11408326|NCT01980277|Experimental|LY2780301 + paclitaxel|"The following dose-levels will be investigated:
~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week
~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week
~Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week
~A dose reduction could be explored:
~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
11408327|NCT01980264|Experimental|Diagnostic imaging|Harmonic Generation Microscopy
11408328|NCT01980238|Experimental|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
11408329|NCT01980238|Active Comparator|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
11408330|NCT01980225|Experimental|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
11408331|NCT01980225|No Intervention|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
11408332|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
11408333|NCT01980199|Experimental|Fexinidazole|"600mg tablets
~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
11408334|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
11408335|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
11408336|NCT01980173|Experimental|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.
~Intervention: Bakri balloon"
11408337|NCT01980173|Active Comparator|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.
~Intervention: Routine Care"
11408338|NCT01980160|Active Comparator|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
11408339|NCT01980160|Sham Comparator|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
11408424|NCT01979601|Experimental|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
11408340|NCT01980147|Experimental|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
11408341|NCT01980147|No Intervention|Comparison|Naturalistic comparison arm: No intervention offered, no intervention prohibited.
11408342|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
11408343|NCT01980108|No Intervention|empty stomach|No fluid will be given to the patient prior to scanning.
11408344|NCT01980108|Experimental|50mL|50mL of water will be given to the patient prior to scanning
11408345|NCT01980108|Experimental|100mL|100mL of water will be given to the patient prior to scanning
11408346|NCT01980108|Experimental|200mL|200mL of water will be given to the patient prior to scanning
11408347|NCT01980108|Experimental|300mL|300mL of water will be given to the patient prior to scanning
11408348|NCT01980108|Experimental|400mL|400mL of water will be given to the patient prior to scanning
11408349|NCT01980095|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
11408350|NCT01980095|Placebo Comparator|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
11408351|NCT01980082|Active Comparator|Cefazolin|"Cefazolin
~1 gram/2 gram if body mass index > 40 - one time dose, 30-60 min prior to incision."
11408352|NCT01980082|Placebo Comparator|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
11408353|NCT01980069|Experimental|Neostigmine arm|Neostigmine arm
11408354|NCT01980069|Active Comparator|Sugammadex arm|Sugammadex arm
11408355|NCT01980056|Experimental|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
11408356|NCT01980043|Other|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
11408357|NCT01980030|Experimental|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
11408358|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
11408359|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
11408360|NCT01980004|Experimental|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
11408361|NCT01980004|Experimental|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
11408362|NCT01979991|Experimental|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
11408363|NCT01979978|Experimental|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
11408364|NCT01979978|No Intervention|Control|This group received standard school curriculum.
11408365|NCT01979965|Active Comparator|Active drug|Ranolazine therapy for three months
11408366|NCT01979965|Placebo Comparator|Sugar Pill|sugar pill therapy for three months
11408367|NCT01979952|Experimental|Nintedanib|150 mg twice daily
11408368|NCT01979952|Placebo Comparator|Placebo|twice daily dosing
11408369|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
11408370|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
11408371|NCT01979926|Experimental|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
11408372|NCT01979926|Experimental|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
11408373|NCT01979926|Placebo Comparator|Placebo|Sugar pill
11408374|NCT01979913|Experimental|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
11408375|NCT01979900|Experimental|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
11408376|NCT01979900|Placebo Comparator|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
11408377|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
11408378|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
11408379|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
11408380|NCT01979874|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
11408381|NCT01979874|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
11408382|NCT01979861|Experimental|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
11408383|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
11408384|NCT01979835|Experimental|GF|Women who have a GyneFix Viz inserted
11408385|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:
~Patient aged ≥ 18 years;
~diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1
~Patient is in stable clinical condition and
~the previous specific PH medication has been retained unchanged during the past 3 weeks"
11408386|NCT01979809|Sham Comparator|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
11408387|NCT01979809|Active Comparator|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
11408388|NCT01979809|Active Comparator|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
11408389|NCT01979796|Experimental|Ecig 24 mg nicotine|Ecig 24 mg nicotine
11408390|NCT01979796|Sham Comparator|Ecig 0 mg nicotine|Ecig 0 mg nicotine
11408391|NCT01979796|Placebo Comparator|Nicotine free inhalator|Nicotine free inhalator
11408392|NCT01979783||LBP|group of subjects with low back pain
11408393|NCT01979783||nonLBP|group without low back pain
11408394|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
11408395|NCT01979757|Active Comparator|Centrifugation|Patients recieved fatgraft processed by Centrifugation
11408396|NCT01979757|Active Comparator|Puregraft|Patients recieved fatgraft processed by Puregraft
11408397|NCT01979744|Experimental|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
11408398|NCT01979744|Active Comparator|Resolute Integrity - Angio|Resolute Integrity - Angio arm
11408399|NCT01979744|Active Comparator|Promus - Angio|Promus - Angio arm
11408400|NCT01979744|Active Comparator|Promus - IVUS|Promus - IVUS arm
11408401|NCT01979731|Experimental|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
11408402|NCT01979731|Active Comparator|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
11408403|NCT01979718|Experimental|Full term intervention|"random selection
~composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
11408404|NCT01979718|Active Comparator|Half term intervention|"random selection
~composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
11408405|NCT01979692|Experimental|One arm ; CLM use in TTNB|"to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions
~to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.
~the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
11408406|NCT01979679|Active Comparator|Lurasidone 80 mg per day|Lurasidone 80 mg per day
11408407|NCT01979679|Active Comparator|Lurasidone 120 mg per day|Lurasidone 120 mg per day
11408408|NCT01979679|Active Comparator|Lurasidone 160 mg per day|Lurasidone 160 mg per day
11408409|NCT01979666|Experimental|study group|the patients that will get a nitrate patch
11408410|NCT01979666|Placebo Comparator|control group|the patients that will get the placebo patch
11408411|NCT01979653|Experimental|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
11408412|NCT01979653|Experimental|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
11408413|NCT01979640|Experimental|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
11408414|NCT01979640|Experimental|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
11408415|NCT01979640|Experimental|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
11408416|NCT01979627|Experimental|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
11408417|NCT01979627|Other|transradial approach group|patients in transradial group received interventional procedure through radial artery
11408418|NCT01979614|Experimental|Serelaxin|Serelaxin was administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
11408419|NCT01979614|Placebo Comparator|Placebo|Placebo was administered by intravenous infusion for 48 hours
11408420|NCT01979601|Experimental|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
11408421|NCT01979601|Experimental|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
11408422|NCT01979601|Experimental|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
11408423|NCT01979601|Experimental|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
11408425|NCT01979601|Experimental|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
11408426|NCT01979601|Experimental|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
11408427|NCT01979601|Experimental|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
11408428|NCT01979601|Experimental|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
11408429|NCT01979601|Experimental|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
11408430|NCT01979601|Placebo Comparator|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
11408431|NCT01979601|Placebo Comparator|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
11408432|NCT01979588|Placebo Comparator|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
11408433|NCT01979588|Active Comparator|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
11408434|NCT01979562||100 runners|Male runners between 18-60 years.
11408435|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
11408436|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
11408437|NCT01979536|Experimental|Arm BV (brentuximab vedotin, combination chemotherapy)|"COURSE A (COURSES 1, 3, AND 5): Patients receive brentuximab vedotin IV over 30 minutes on day 1, dexamethasone PO BID or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV over 1-30 minutes every 12 hours for 4 doses on days 4 and 5, and etoposide IV over 2 hours on days 4 and 5.
~COURSE B (COURSES 2, 4, AND 6): Patients receive brentuximab vedotin, dexamethasone, and methotrexate as in Arm BV, Course A. Patients also receive cyclophosphamide IV over 15-30 minutes on days 1-5 and doxorubicin hydrochloride IV over 1-15 minutes on days 4 and 5."
11408438|NCT01979536|Experimental|Arm CZ (crizotinib, combination chemotherapy)|"COURSE A (COURSES 1, 3, AND 5): Patients receive crizotinib PO BID on days 1-21 and dexamethasone, ifosfamide, methotrexate, cytarabine, and etoposide as in Arm BV, Course A.
~COURSE B (COURSES 2, 4, AND 6): Patients receive crizotinib as in Arm CZ, Course A and dexamethasone, cyclophosphamide, methotrexate, and doxorubicin hydrochloride as in Arm BV, Course B."
11408439|NCT01979523|Experimental|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
11408440|NCT01979523|Experimental|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11408441|NCT01979510|Experimental|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
11408442|NCT01979510|Experimental|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
11408443|NCT01979497|Active Comparator|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
11408444|NCT01979497|Active Comparator|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
11408445|NCT01979484|Experimental|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
11408446|NCT01979484|Experimental|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
11408447|NCT01979471|Other|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
11408448|NCT01979471|No Intervention|Usual Care|"Patients randomized to the usual care group will receive:
~Usual pharmacy care with no specific interventions for 3 months
~At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
11408449|NCT01979458|Experimental|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
11408450|NCT01979445|Experimental|Prasugrel 30 Min After Cangrelor|Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours [hrs] after initiation of cangrelor infusion).
11408451|NCT01979445|Experimental|Clopidogrel Within 5 Min After Cangrelor|Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion).
11408452|NCT01979445|Experimental|Clopidogrel 1.5 Hrs During Cangrelor|Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1.
11408453|NCT01979445|Experimental|Clopidogrel 1 Hr During Cangrelor|Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.
11408454|NCT01979432|Other|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
11408455|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
11408456|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
11408457|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
11408458|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
11408459|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
11408460|NCT01979406|Active Comparator|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
11408461|NCT01979406|Experimental|Ad4-PA-1|"Given at 10^9, 10^10 and 10^11 vp
~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
11408462|NCT01979406|Experimental|Ad4-PA-2|"Given at 10^9, 10^10 and 10^11 vp
~Ad4-PA at Days 1, 15 and 29"
11408463|NCT01979406|Experimental|Ad4-PA-3|"Ad4 given at 10^9, 10^10 and 10^11 vp
~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
11408464|NCT01979406|Experimental|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles
~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
11408465|NCT01979406|Experimental|Ad4 PA-GPI-2|"Given at 10^9, 10^10 and 10^11 viral particles
~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
11408466|NCT01979406|Experimental|Ad4-PA-GPI -3|"Given at 10^9, 10^10 and 10^11 viral particles
~Ad4-PA-GPI at Days 1, 15 and 29"
11408467|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
11408468|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
11408469|NCT01979380|Experimental|KD101|
11408470|NCT01979380|Placebo Comparator|placebo|
11408471|NCT01979367|Experimental|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
11408472|NCT01979354|Active Comparator|Spinal morphine|0.15 mg spinal morphine
11408473|NCT01979354|No Intervention|Control|No spinal morphine
11408474|NCT01979341|Active Comparator|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
11408475|NCT01979341|Active Comparator|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
11408476|NCT01979341|Active Comparator|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
11408477|NCT01979328|Experimental|Study arm|geko neuromuscular electrostimulation
11408478|NCT01979315||patients with LBP|
11408479|NCT01979315||healthy individulas|
11408480|NCT01979302|Experimental|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
11408481|NCT01979302|Other|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
11408482|NCT01979289|Experimental|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
11408483|NCT01979289|Active Comparator|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
11408484|NCT01979276|Experimental|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
11408485|NCT01979263|Active Comparator|Attention Bias Modification|Attention Bias Modification computer task
11408486|NCT01979263|Placebo Comparator|Placebo Computer Task|Placebo computer task
11408487|NCT01979250|No Intervention|Normal corneas|Normal corneas from patients that undergo cataract surgery.
11408488|NCT01979250|Other|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
11408489|NCT01979237|Experimental|SPASO method, FARES method|Reduction method: SPASO method, FARES method
11408490|NCT01979224|No Intervention|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
11408491|NCT01979211|Experimental|Cetuximab and Radiation|Cetuximab 400 mg/m2 IV over 120 minutes loading dose > 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions
11408492|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
11408493|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
11408494|NCT01979185|Active Comparator|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
11408495|NCT01979185|Experimental|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
11408496|NCT01979159|Experimental|Combined Aphasia-ApraxiaTreatment|Administration of Combined Aphasia and Apraxia of Speech Treatment )(CAAST) to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
11408497|NCT01979146|Experimental|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
11408498|NCT01979146|No Intervention|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
11408499|NCT01979133|Experimental|icariin|Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
11408500|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
11408501|NCT01979107|Experimental|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
11408502|NCT01979107|No Intervention|Control group|The participants will be treated as usual by the general practitioner.
11408503|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
11408504|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
11408505|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
11408506|NCT01979055|Experimental|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
11408507|NCT01979055|Placebo Comparator|Control group|3 telephone calls to assess any additional questions regarding asthma
11408508|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
11408509|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
11408510|NCT01979029|Experimental|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
11408511|NCT01979029|Experimental|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
11408512|NCT01979016|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
11408513|NCT01979016|Experimental|Dupilumab 200 mg qw|Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
11408514|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
11408515|NCT01978990||Diabetes Management System , blood glucose|
11408516|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
11408517|NCT01978964|Experimental|ONT-10 Vaccine|
11408518|NCT01978951|Experimental|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
11408519|NCT01978951|Active Comparator|Conventional CKD care|standard guidelines of CKD treatment
11408520|NCT01978938|Experimental|Eravacycline|Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
11408521|NCT01978938|Active Comparator|Levofloxacin|Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
11408522|NCT01978925|Experimental|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
11408523|NCT01978925|No Intervention|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
11408524|NCT01978912|Experimental|Cohort 1|one time 5 μg/disc dose of KTP-001 by intradiscal injection
11408525|NCT01978912|Experimental|Cohort 2|one time 15 μg/disc dose of KTP-001 by intradiscal injection
11408526|NCT01978912|Experimental|Cohort 3|one time 50 μg/disc dose of KTP-001 by intradiscal injection
11408527|NCT01978912|Experimental|Cohort 4|one time 150 μg/disc dose of KTP-001 by intradiscal injection
11408528|NCT01978899|Active Comparator|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group
~The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.
~Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
11408529|NCT01978899|Active Comparator|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
11408530|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
11408531|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
11408532|NCT01978873|Experimental|Arm A:|"Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)
~Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
11408533|NCT01978873|Active Comparator|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
11408534|NCT01978860|Experimental|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
11408535|NCT01978821|Experimental|stem cell|autologous bone marrow mononuclear cell transplantation
11408576|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
11408577|NCT01978561|Placebo Comparator|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
11408862|NCT01976728|Experimental|LutrePulse 15 µg/pulse|Gonadorelin acetate 15 µg/pulse
11408536|NCT01978795|Experimental|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
11408537|NCT01978795|Active Comparator|Control|
11408538|NCT01978782|Active Comparator|raltegravir alone|raltegravir 400 mg BID for 5 days
11408539|NCT01978782|Active Comparator|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
11408540|NCT01978782|Experimental|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
11408541|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
11408542|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
11408543|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
11408544|NCT01978743|Experimental|Raltegravir|Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
11408545|NCT01978730|Experimental|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
11408546|NCT01978730|Experimental|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
11408547|NCT01978730|Placebo Comparator|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
11408548|NCT01978717|Experimental|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
11408549|NCT01978717|Experimental|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
11408550|NCT01978704|Experimental|Glycaemic load|
11408551|NCT01978704|Active Comparator|Carbohydrates content|
11408552|NCT01978691|Active Comparator|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
11408553|NCT01978691|Active Comparator|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
11408554|NCT01978691|Active Comparator|Synbiotic|B. lactis 420 (10^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
11408555|NCT01978691|Placebo Comparator|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
11408556|NCT01978678||Pulmicort|ICS and LABA - based on ACQ and FeNO
11408557|NCT01978665|Placebo Comparator|prednisone and Solumedrol|placebo arm versus prednisone
11408558|NCT01978665|Placebo Comparator|solumedrol|placebo versus solu medrol
11408559|NCT01978665|Other|placebo|measurement of fitness
11408560|NCT01978652|Experimental|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
11408561|NCT01978652|Experimental|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
11408562|NCT01978626|Experimental|Smart phone Apps|"1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder
~2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others
~3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
11408563|NCT01978626|Active Comparator|Control|"1st year: traditional paper-pencil diary
~2nd year: no social persuasion is given beyond sessions
~3rd year: Tai-chi teaching by Digital Video Disc only"
11408564|NCT01978613|Experimental|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
11408565|NCT01978613|Experimental|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
11408566|NCT01978613|Experimental|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
11408567|NCT01978613|Experimental|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
11408568|NCT01978613|Experimental|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
11408569|NCT01978600|Experimental|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
11408570|NCT01978600|Active Comparator|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
11408571|NCT01978587|Experimental|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
11408572|NCT01978587|Experimental|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
11408573|NCT01978574|Active Comparator|Documentary videos|In the placebo control condition, participants watch daily videos.
11408574|NCT01978574|Experimental|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
11408575|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
11408578|NCT01978548|Experimental|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
11408579|NCT01978548|Experimental|JNJ-54861911 50 mg|
11408580|NCT01978548|Placebo Comparator|Placebo|Patients will receive matching placebo.
11408581|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
11408582|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
11408583|NCT01978522|Experimental|NICOLA Participants|All participants enrolled in the NICOLA cohort
11408584|NCT01978509|Active Comparator|Low volume prep (Prepopik)|Low volume prep for colonoscopy (Prepopik)
11408585|NCT01978509|Active Comparator|Moderate volume prep (Moviprep)|Moderate volume prep for colonoscopy (Moviprep)
11408586|NCT01978509|Active Comparator|High volume prep (Golytely)|High volume prep for colonoscopy (Golytely)
11408587|NCT01978496|Placebo Comparator|Placebo|
11408588|NCT01978496|Experimental|Eletriptan 20 mg|
11408589|NCT01978496|Experimental|Eletriptan 40 mg|
11408590|NCT01978496|Experimental|Eletriptan 80 mg|
11408591|NCT01978483|Other|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
11408592|NCT01978483|Experimental|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
11408593|NCT01978483|Placebo Comparator|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
11408594|NCT01978470|Experimental|Active|Trigeminal nerve stimulation
11408595|NCT01978457|Experimental|cocaine hydrochloride|cocaine hydrochloride
11408596|NCT01978457|Experimental|propranolol|propranolol
11408597|NCT01978457|Placebo Comparator|placebo|placebo
11408598|NCT01978444|Experimental|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
11408599|NCT01978444|Active Comparator|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11408600|NCT01978431|Experimental|Stimulant|Cocaine and Methylphenidate
11408601|NCT01978431|Placebo Comparator|Placebo|methylphenidate
11408602|NCT01978418|Placebo Comparator|Placebo|Placebo is administered once, at 30-60 minutes of age
11408603|NCT01978418|Active Comparator|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
11408604|NCT01978405|Experimental|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
11408605|NCT01978405|Placebo Comparator|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
11408606|NCT01978392|Experimental|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
11408607|NCT01978392|No Intervention|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
11408608|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
11408609|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
11408610|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
11408611|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
11408612|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
11408613|NCT01978353|Experimental|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
11408614|NCT01978353|Active Comparator|Psychoeducation|Participants receive information about memory functioning and aging
11408615|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
11408616|NCT01978327|Experimental|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
11408617|NCT01978327|Placebo Comparator|Placebo|Matching placebo
11408618|NCT01978327|Experimental|simvastatin|for drug-drug interaction
11408619|NCT01978327|Experimental|simvastatin co-dosed with GSK2647544|for drug-drug interaction
11408620|NCT01978314|Experimental|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
11408621|NCT01978314|Experimental|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
11408622|NCT01978314|Experimental|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
11408623|NCT01978314|Experimental|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
11408624|NCT01978314|Experimental|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
11408625|NCT01978301|Active Comparator|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
11408626|NCT01978301|Placebo Comparator|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
11408627|NCT01978301|No Intervention|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
11408628|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
11408629|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
11408630|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
11408631|NCT01978275|Experimental|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
11408632|NCT01978275|Active Comparator|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
11408633|NCT01978262|Other|healthy woman|All women are to receive the quadrivalent influenza vaccine
11408634|NCT01978249|Experimental|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
11408635|NCT01978249|Active Comparator|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
11408636|NCT01978236|Experimental|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
11408637|NCT01978236|Experimental|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
11408638|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
11408639|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
11408640|NCT01978210|Experimental|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
11408641|NCT01978210|Active Comparator|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
11408642|NCT01978184|Experimental|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
11408643|NCT01978184|Experimental|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
11408644|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
11408645|NCT01978158|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
11408646|NCT01978158|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
11408647|NCT01978158|Active Comparator|Normoxia|Subjects wil be breathing room air (21%)
11408648|NCT01978145|Experimental|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
11408649|NCT01978145|Experimental|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
11408650|NCT01978132|Active Comparator|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).
~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
11408651|NCT01978132|Placebo Comparator|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
11408652|NCT01978119|Experimental|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
11408653|NCT01978119|Experimental|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
11408723|NCT01977651|Experimental|Enzalutamide 160 mg|Participants will receive 160 mg of enzalutamide orally once a day, for 4 months.
11408654|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
11408655|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
11408656|NCT01978093|Experimental|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
11408657|NCT01978093|Active Comparator|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
11408658|NCT01978080|Experimental|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
11408659|NCT01978080|Active Comparator|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
11408660|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
11408661|NCT01978054|Experimental|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
11408662|NCT01978054|No Intervention|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
11408663|NCT01978041|Experimental|Meal prepared with non fluoridated water (<0.1 ppm F)|
11408664|NCT01978041|Experimental|Meal prepared with fluoridated water (1 ppm F)|
11408665|NCT01978041|Experimental|Non fluoridated water (<0.1 ppm F)|
11408666|NCT01978041|Experimental|Fluoridated water (1 ppm F)|
11408667|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
11408668|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
11408669|NCT01978028|Active Comparator|ferric carboxymaltose|ferric carboxymaltose
11408670|NCT01978028|Placebo Comparator|placebo|placebo
11408671|NCT01978015|Experimental|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
11408672|NCT01978015|Experimental|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
11408673|NCT01978015|Placebo Comparator|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
11408674|NCT01978015|Experimental|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
11408675|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
11408676|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
11408677|NCT01977989|No Intervention|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
11408678|NCT01977989|Active Comparator|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
11408679|NCT01977976|Experimental|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
11408680|NCT01977976|No Intervention|Control group|No intervention prior to scheduled IVF
11408681|NCT01977963||Agranulocytosis|
11408682|NCT01977937|Experimental|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
11408683|NCT01977937|Placebo Comparator|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
11408684|NCT01977924|Experimental|polyphenols|600 mg polyphenols (grape extract)
11408685|NCT01977924|Placebo Comparator|Placebo|microcrystalline cellulose
11408686|NCT01977911|Experimental|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:
~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
11408687|NCT01977898|Experimental|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
11408688|NCT01977898|Placebo Comparator|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
11408689|NCT01977885|Experimental|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
11408690|NCT01977872|Experimental|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
11408691|NCT01977872|No Intervention|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
11408692|NCT01977859|Placebo Comparator|Saline|Saline infusion
11408693|NCT01977859|Active Comparator|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
11408694|NCT01977859|Active Comparator|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
11408695|NCT01977859|Active Comparator|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
11408696|NCT01977859|Active Comparator|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
11408697|NCT01977833|Experimental|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
11408698|NCT01977833|Active Comparator|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
11408699|NCT01977820|Experimental|Sapropterin|
11408700|NCT01977820|Placebo Comparator|Placebo|
11408701|NCT01977807|Experimental|Myopia|Myopia Lasik treatment of virgin eyes.
11408702|NCT01977807|Experimental|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
11408703|NCT01977794|Experimental|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
11408704|NCT01977794|Experimental|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
11408705|NCT01977781|Experimental|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
11408706|NCT01977781|Active Comparator|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
11408707|NCT01977768|Experimental|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
11408708|NCT01977768|Placebo Comparator|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
11408709|NCT01977755|Active Comparator|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
11408710|NCT01977755|Active Comparator|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
11408711|NCT01977755|Placebo Comparator|Placebo|bolus injection, followed by infused over 6 hours
11408712|NCT01977742|Active Comparator|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
11408713|NCT01977742|Active Comparator|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.
~The cardiac vagal index will be measured at every 8 weeks."
11408714|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
11408715|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
11408716|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
11408717|NCT01977703|Active Comparator|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
11408718|NCT01977703|Experimental|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
11408719|NCT01977690|No Intervention|Standard Management|Patients wore no brace.
11408720|NCT01977690|Experimental|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
11408721|NCT01977677|Experimental|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
11408722|NCT01977664||oocyte maturation failure|no intervention
11408724|NCT01977638|Experimental|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
11408725|NCT01977625|Active Comparator|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
11408726|NCT01977625|Placebo Comparator|Sugar Pill|Placebo pill, capsules
11408727|NCT01977612|Active Comparator|Stainless Steel Staples|Skin closure with stainless steel staples
11408728|NCT01977612|Experimental|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
11408729|NCT01977599|No Intervention|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
11408730|NCT01977599|Experimental|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
11408731|NCT01977586|Experimental|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
11408732|NCT01977573|Experimental|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
11408733|NCT01977573|Other|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
11408734|NCT01977560|Other|Standard Care|This arm will receive standard care for Type 2 diabetes: exercise and diet counseling according to the American Diabetes Association recommendations.
11408735|NCT01977560|Experimental|Optimum Lifestyle intervention|This arm will be participate in weekly visits with a dietitian and 4 weekly supervised exercise sessions. They will be advised to follow a high-protein, low-carbohydrate diet.
11408736|NCT01977547|Active Comparator|Short storage|Red blood cells storage duration of equal to or less than 7 days.
11408737|NCT01977547|Active Comparator|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
11408738|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
11408739|NCT01977521|Experimental|Treatment|transcranial direct current stimulation (2mA)
11408740|NCT01977521|Sham Comparator|Sham|Sham stimulation
11408741|NCT01977508||haemodialysis vascular access using ePTFE grafts|
11408742|NCT01977495|Active Comparator|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
11408743|NCT01977495|Active Comparator|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
11408744|NCT01977482|Experimental|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
11408745|NCT01977482|Experimental|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
11408746|NCT01977482|Experimental|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
11408747|NCT01977482|Experimental|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
11408748|NCT01977482|Experimental|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
11408749|NCT01977482|Active Comparator|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
11408750|NCT01977469|Experimental|Low intensity resistance training|Low intensity resistance training + aerobic training
11408751|NCT01977469|Experimental|High intensity resistance training|High intensity resistance training + aerobic training
11408752|NCT01977456|Experimental|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
11408753|NCT01977443|Active Comparator|APD-209 Eye drops|APD-209 Eye drops
11408754|NCT01977443|Placebo Comparator|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
11408755|NCT01977430|Experimental|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
11408756|NCT01977430|No Intervention|Control Arm|
11408757|NCT01977417|Experimental|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
11408758|NCT01977417|Placebo Comparator|Placebo|Placebo capsule twice per day
11408759|NCT01977378|Experimental|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
11408760|NCT01977378|Active Comparator|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
11408761|NCT01977365|Experimental|Growth promotion based on child centered approach|
11408762|NCT01977365|No Intervention|Control|
11408763|NCT01977352|Active Comparator|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
11408765|NCT01977339|Experimental|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
11408766|NCT01977339|Active Comparator|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
11408767|NCT01977326|Experimental|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
11408768|NCT01977326|Active Comparator|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
11408769|NCT01977313||All study participants|All study participants
11408770|NCT01977300|Placebo Comparator|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
11408771|NCT01977300|Experimental|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
11408772|NCT01977300|Active Comparator|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
11408773|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
11408774|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
11408775|NCT01977274|Experimental|gynecological cancer|blood and tumor samples
11408776|NCT01977261|Experimental|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
11408777|NCT01977261|Active Comparator|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
11408778|NCT01977248|Experimental|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
11408779|NCT01977235|Experimental|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
11408780|NCT01977235|Active Comparator|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
11408781|NCT01977222|Experimental|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
11408782|NCT01977209|Experimental|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
11408783|NCT01977209|Placebo Comparator|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
11408784|NCT01977196|Experimental|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
11408785|NCT01977183|Experimental|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
11408786|NCT01977183|Placebo Comparator|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
11408787|NCT01977183|Experimental|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
11408788|NCT01977183|Placebo Comparator|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
11408789|NCT01977170|Experimental|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:
~PRP-T 10ug NaCl 0.85%
~Frequency: 1 injection"
11408790|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
11408791|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
11408792|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
11408793|NCT01977131|Experimental|stromal cells modified HGF|
11408794|NCT01977118|Experimental|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
11408795|NCT01977118|Placebo Comparator|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
11408796|NCT01977105|Experimental|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
11408797|NCT01977092|Experimental|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
11408863|NCT01976728|Experimental|LutrePulse 20 µg/pulse|Gonadorelin acetate 20 µg/pulse
11408798|NCT01977092|Other|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
11408799|NCT01977079|Other|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.
~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
11408800|NCT01977079|Other|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.
~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
11408801|NCT01977066|Experimental|Six months supervised exercise training|
11408802|NCT01977066|Experimental|Six months home-based exercise training|
11408803|NCT01977066|No Intervention|Control group|
11408804|NCT01977053|No Intervention|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
11408805|NCT01977053|Experimental|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
11408806|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
11408807|NCT01977027|Other|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:
~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.
~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
11408808|NCT01977027|Other|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:
~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.
~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.
~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.
~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
11408809|NCT01977014||Patient with LenusPro pump|
11408810|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
11408811|NCT01976988|Active Comparator|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
11408812|NCT01976988|Experimental|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
11408813|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
11408814|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
11408815|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
11408816|NCT01976949|Active Comparator|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
11408817|NCT01976949|Active Comparator|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
11408818|NCT01976936|Experimental|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
11408819|NCT01976936|Active Comparator|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
11408820|NCT01976936|Placebo Comparator|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
11408821|NCT01976923|Active Comparator|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
11408822|NCT01976923|Sham Comparator|Control arm|Small-gauge pars plana vitrectomy
11408823|NCT01976910|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.
~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
~The MTD will be where 2 DLTs are noted and the study is discontinued."
11408824|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.
~Intervention: Knee flexion measurement 1
~Intervention: Knee flexion measurement 2
~Intervention: Heel - interface pressure measurements"
11408825|NCT01976884||Severe sepsis|Patients with severe sepsis
11408826|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
11408827|NCT01976884||Tumor|Patients with pancreatic cancer
11408828|NCT01976884||Volunteer|
11408829|NCT01976871|Experimental|Oral Dopamine Agonist to Rotigotine|During the study, we will switch patients who are not satisfied with their current oral dopamine agonist to rotigotine. Cross-titration will allow determination of the lowest effective dose of rotigotine. We will use as initial guidance the equivalence determined from the Parkinson's Disease trials, in which 1 mg rotigotine was shown to be approximately equivalent to 1-1.5 mg ropinirole or 0.25 -0.375 mg pramipexole. Tolerability, adverse events, and RLS symptom control will be evaluated. These data will provide clinicians with practical guidance to optimize RLS treatment while minimizing adverse events.
11408830|NCT01976858|Experimental|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
11408831|NCT01976858|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
11408832|NCT01976858|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
11408833|NCT01976858|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
11408834|NCT01976858|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
11408835|NCT01976845|Experimental|Propofol|Propofol 20 mg IV (2 ml)
11408836|NCT01976845|Active Comparator|Midazolam|Midazolam 2 mg IV (2 ml)
11408837|NCT01976845|Placebo Comparator|Saline|Saline 2 ml
11408838|NCT01976832|Experimental|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
11408839|NCT01976832|Active Comparator|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.
~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
11408840|NCT01976819|Experimental|TW speaking valve/HME|Use of the TW speaking valve/HME
11408841|NCT01976806|Experimental|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
11408842|NCT01976806|Active Comparator|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
11408843|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
11408844|NCT01976780|Active Comparator|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
11408845|NCT01976780|Active Comparator|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and > 34 kg: 4 tablets) given twice a day for 3 days.
11408846|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
11408847|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
11408848|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
11408849|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 > 80% predicted
11408850|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
11408851|NCT01976741|Experimental|Rogaratinib dose escalation - 50 mg BID|Participants with any type of solid tumor received a single dose of 50 mg Rogaratinib solution on Cycle 1, Day 1, and 50 mg Rogaratinib solution BID (twice daily, in total 100 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.
11408852|NCT01976741|Experimental|Rogaratinib dose escalation - 100 mg BID|Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day -3, and then continued with a single dose of 100 mg Rogaratinib solution on Cycle 1, Day 1, and 100 mg Rogaratinib solution BID (in total 200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.
11408853|NCT01976741|Experimental|Rogaratinib dose escalation - 200 mg BID|Participants with any type of solid tumor received a single dose of 200 mg Rogaratinib tablet on Cycle 1, Day 1, and 200 mg Rogaratinib tablet BID (in total 400 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.
11408854|NCT01976741|Experimental|Rogaratinib dose escalation - 400 mg BID|Participants with any type of solid tumor received a single dose of 400 mg Rogaratinib tablet on Cycle 1, Day 1, and 400 mg Rogaratinib tablet BID (in total 800 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.
11408855|NCT01976741|Experimental|Rogaratinib dose escalation - 600 mg BID|Participants with any type of solid tumor received a single dose of 600 mg Rogaratinib tablet on Cycle 1, Day 1, and 600 mg Rogaratinib tablet BID (in total 1200 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.
11408856|NCT01976741|Experimental|Rogaratinib dose escalation - 800 mg BID|Participants with any type of solid tumor received a single dose of 800 mg Rogaratinib tablet on Cycle 1, Day 1, and 800 mg Rogaratinib tablet BID (in total 1600 mg/day) from Cycle 1, Day 3 ongoing in 21-days cycles in dose escalation phase.
11408857|NCT01976741|Experimental|Rogaratinib Dose Expansion (All Comers)|"Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.
~(1600 mg/day) in 21-days cycles."
11408858|NCT01976741|Experimental|Rogaratinib Dose Expansion (BC)|Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
11408859|NCT01976741|Experimental|Rogaratinib Dose Expansion (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
11408860|NCT01976741|Experimental|Rogaratinib Dose Expansion (sqNSCLC)|Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
11408861|NCT01976728|Experimental|LutrePulse 10 µg/pulse|Gonadorelin acetate 10 µg/pulse
11408864|NCT01976728|Placebo Comparator|Placebo|Placebo
11408865|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
11408866|NCT01976702|Experimental|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
11408867|NCT01976702|Active Comparator|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
11408868|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
11408869|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
11408870|NCT01976676|Experimental|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
11408871|NCT01976676|Active Comparator|folic acid|1 mg Folic acid per day
11408872|NCT01976663|Experimental|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
11408873|NCT01976663|Active Comparator|Control NLFs|Nasolabial folds treated with Control.
11408874|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
11408875|NCT01976637|Experimental|no compression|no compression stockings worn during a 3 weeks period
11408876|NCT01976637|Active Comparator|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
11408877|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
11408878|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
11408879|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
11408880|NCT01976585|Experimental|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
11408881|NCT01976572|Placebo Comparator|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
11408882|NCT01976572|Active Comparator|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
11408883|NCT01976572|Active Comparator|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
11408884|NCT01976572|Active Comparator|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
11408885|NCT01976559|Experimental|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
11408886|NCT01976546||airway|Patients with one or more predictors of diffucult airway
11408887|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
11408888|NCT01976520|Experimental|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
11408889|NCT01976507|Experimental|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
11408890|NCT01976494|Experimental|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
11408891|NCT01976494|Active Comparator|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
11408892|NCT01976481|Experimental|Sunbed|sunbed exposure
11408893|NCT01976481|No Intervention|Observation|only observation of subjects recruited after randomization
11408894|NCT01976468||SCC metastasis|organ transplant recipients
11408895|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
11408896|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
11408897|NCT01976429|Other|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
11408898|NCT01976429|Other|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
11408899|NCT01976416|Experimental|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
11408900|NCT01976416|Placebo Comparator|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
11408901|NCT01976403|Experimental|Pain booklet|
11408902|NCT01976403|No Intervention|standard care|
11408903|NCT01976390|Active Comparator|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
11408904|NCT01976390|Active Comparator|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
11408905|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
11408906|NCT01976364|Experimental|Tofacitinib|
11408907|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
11408908|NCT01976338|Experimental|Ranibizumab 0.5 mg|PRN Intravitreal injection
11408909|NCT01976338|Sham Comparator|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
11408910|NCT01976325|No Intervention|Standard Care|This arm will receive no intervention; only standard medical care.
11408911|NCT01976325|Experimental|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
11408912|NCT01976312|Experimental|Ranibizumab 0.5 mg|PRN intravitreal injection
11408913|NCT01976312|Sham Comparator|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
11408914|NCT01976299|Experimental|Active Treatment|Standard of Care with the AVERT system
11408915|NCT01976299|No Intervention|Standard of Care|
11408916|NCT01976286|Active Comparator|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
11408917|NCT01976286|Active Comparator|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
11408918|NCT01976273|Active Comparator|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
11408919|NCT01976273|Active Comparator|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
11408920|NCT01976260|Active Comparator|Fractional Radiofrequency|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
11408921|NCT01976260|Active Comparator|1550-nm Fractional Photothermolysis|Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit.
11408922|NCT01976247|Active Comparator|Noninvasive Cryolipolysis Device|The Zeltiq System is a noninvasive (not breaking the skin) device that reduces fat by freezing fat cells until they break apart.
11408923|NCT01976247|Active Comparator|High Intensity Focused Ultrasound Device|The LipoSonix System is a noninvasive ultrasound device, which can be used to selectively target and destroy fat tissue located deep under the skin.
11408924|NCT01976234|Active Comparator|Fresh group|Fresh group will receive RBC stored for less than 14 days
11408925|NCT01976234|Active Comparator|Old group|Old group will receive RBC stored for 14 days or more
11408926|NCT01976221|Experimental|Prioritization|Team-based multifaceted interactive training
11408927|NCT01976208|Experimental|Omalizumab|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
11408928|NCT01976208|Placebo Comparator|placebo|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
11408929|NCT01976195|Experimental|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
11408930|NCT01976195|Active Comparator|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
11408931|NCT01976182|Active Comparator|METHOTREXATE|"In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take
~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.
~Non responders at Month 4 will be randomized and treated either by:
~Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;
~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
11408981|NCT01975844|Experimental|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:
~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.
~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
11408932|NCT01976182|Active Comparator|CYCLOPHOSPHAMIDE|"In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.
~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);
~Non responders at Month 4 will be randomized and treated either by:
~Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;
~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
11408933|NCT01976169|Experimental|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.
~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
11408934|NCT01976156|Experimental|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
11408935|NCT01976156|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
11408936|NCT01976143|Experimental|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
11408937|NCT01976130|Experimental|bronchoscopy|Procedure
11408938|NCT01976117|Experimental|enose|
11408939|NCT01976104|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
11408940|NCT01976104|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
11408941|NCT01976104|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
11408942|NCT01976104|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
11408943|NCT01976091|Experimental|Cohort 1A|Two (n=2) adult LGMD2D wheelchair-dependent subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via single-limb perfusion at the low dose. Subjects will receive a dose of 1 x 10 12th vg/kg in a single limb with delivery to the whole limb.
11408944|NCT01976091|Experimental|Cohort 1B|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via bilateral whole limb perfusion at low dose of 1 x 10 12th vg/kg.
11408945|NCT01976091|Experimental|Cohort 2|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA bilateral whole limb perfusion at high dose.Subjects will receive a total dose of 3 x 10 12th vg/kg per limb delivered to both extremities
11408946|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
11408947|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
11408948|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
11408949|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
11408950|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
11408951|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
11408952|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
11408953|NCT01976039|Other|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
11408954|NCT01976039|Experimental|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
11408955|NCT01976026|Experimental|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.
~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
11408979|NCT01975857|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
11408980|NCT01975857|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
11408956|NCT01976026|Active Comparator|Best standard therapy|"May be any of the following:
~Conservative management when no surgical or endovascular treatment is considered possible or reasonable
~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques
~Parent vessel occlusion, with or without bypass
~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).
~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.
~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
11408957|NCT01976013|Other|Coaguchek|infants will receive sequential coagulation checks
11408958|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
11408959|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
11408960|NCT01975987|Experimental|Intubation with the Bonfils fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia
~Glottic visualization will be evaluated by direct laryngoscopy.
~The endotracheal tube will be loaded onto the scope
~Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position
~Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.
~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
11408961|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
11408962|NCT01975961|Experimental|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).
~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
11408963|NCT01975961|Active Comparator|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).
~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
11408964|NCT01975948|Experimental|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
11408965|NCT01975948|Active Comparator|Treatment as Usual: Physicians|Those administering treatment as usual for depression
11408966|NCT01975948|Experimental|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
11408967|NCT01975948|Active Comparator|Treatment as Usual: Patients|Those receiving treatment as usual for depression
11408968|NCT01975935|Placebo Comparator|Placebo|Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
11408969|NCT01975935|Experimental|Amlexanox|Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
11408970|NCT01975922|Experimental|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.
~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
11408971|NCT01975922|No Intervention|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
11408972|NCT01975909|Active Comparator|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
11408973|NCT01975909|Sham Comparator|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
11408974|NCT01975896|Experimental|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
11408975|NCT01975896|No Intervention|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
11408976|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
11408977|NCT01975870|Experimental|intervention group|use of application on smartphone for lifestyle counseling
11408978|NCT01975870|No Intervention|control group|no use of application on smartphone
11409014|NCT01975701|Experimental|BGJ398X|To estimate anti-tumor efficacy of BGJ398
11409342|NCT01973348|Experimental|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
11408982|NCT01975831|Experimental|Escalation: 0.3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (0.3 mg/kg every 2 weeks [Q2W] for 13 cycles) and tremelimumab (3 mg/kg every 4 weeks [Q4W] for 6 cycles, then every 12 weeks [Q12W]). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408983|NCT01975831|Experimental|Escalation: 1 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (1 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408984|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408985|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 1 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 12 or 13 cycles) and tremelimumab (1 mg/kg Q4W for 6 cycles, then Q12W or Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408986|NCT01975831|Experimental|Expansion: Ovarian Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408987|NCT01975831|Experimental|Expansion: Colorectal Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408988|NCT01975831|Experimental|Expansion: Non-triple Negative Breast Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408989|NCT01975831|Experimental|Expansion: Renal Cell Carcinoma|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408990|NCT01975831|Experimental|Expansion: Cervical Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
11408991|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
11408992|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
11408993|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
11408994|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
11408995|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
11408996|NCT01975805|Experimental|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
11408997|NCT01975805|Experimental|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
11408998|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
11408999|NCT01975779|Experimental|Cohort A1: Lu AE58054 or placebo|
11409000|NCT01975779|Experimental|Cohort A2: Lu AE58054 or placebo|
11409001|NCT01975779|Experimental|Cohort B1: Lu AE58054|
11409002|NCT01975766|Experimental|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
11409003|NCT01975753|Active Comparator|Intravenous morphine|one bolus of intravenous morphine
11409004|NCT01975753|Experimental|nebulized morphine|"one nebulized bolus of morphine"
11409005|NCT01975753|Active Comparator|fentanyl|"one nebulized bolus of fentanyl"
11409006|NCT01975740|Experimental|Manual diaphragm release technique|
11409007|NCT01975740|Other|Sham manual diaphragm release technique|
11409008|NCT01975727|Placebo Comparator|Injection of Placebo|Intravenous Saline 0.9% 10 ml
11409009|NCT01975727|Active Comparator|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
11409010|NCT01975727|Active Comparator|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
11409011|NCT01975727|Active Comparator|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
11409012|NCT01975714|Experimental|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.
~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
11409013|NCT01975714|Experimental|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.
~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
11409015|NCT01975688|Experimental|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
11409016|NCT01975688|Experimental|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
11409017|NCT01975688|Experimental|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
11409018|NCT01975688|Experimental|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
11409019|NCT01975675|Experimental|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
11409020|NCT01975675|Experimental|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
11409021|NCT01975675|Experimental|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
11409022|NCT01975675|Experimental|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
11409023|NCT01975662|Experimental|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.
~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.
~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
11409024|NCT01975662|Active Comparator|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
11409025|NCT01975649|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
11409026|NCT01975649|Placebo Comparator|Placebo|patients will use placebo for 120 days
11409027|NCT01975636|Experimental|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
11409028|NCT01975623|Experimental|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
11409029|NCT01975610|Experimental|CC-292 375mg|Treatment
11409030|NCT01975610|Placebo Comparator|Placebo|Control
11409031|NCT01975597||Bone marrow aspirates and biopsy|
11409032|NCT01975584|Experimental|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
11409033|NCT01975571|Experimental|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.
~Intervention: These patients will receive a Hybrid L24 cochlear implant."
11409034|NCT01975571|Experimental|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold >90 dB HL at 1500 Hz and profound loss at higher frequencies.
~Intervention: These patients will receive a Hybrid L24 cochlear implant."
11409035|NCT01975571|Experimental|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.
~Intervention: These patients will receive a Hybrid S12 cochlear implant."
11409036|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
11409037|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
11409038|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
11409039|NCT01975545|Active Comparator|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
11409040|NCT01975545|Experimental|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
11409041|NCT01975519|Experimental|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.
11409042|NCT01975506||head start practitioners|
11409043|NCT01975493||Amoxicillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
11409044|NCT01975493||Ampicillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
11409045|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
11409046|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
11409047|NCT01975493||Flucloxacillin|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
11409119|NCT01974986|Experimental|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
11409048|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:
~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
11409049|NCT01975480|Experimental|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
11409050|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
11409051|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
11409052|NCT01975454|Active Comparator|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
11409053|NCT01975454|Experimental|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
11409054|NCT01975441|Active Comparator|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
11409055|NCT01975441|Experimental|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
11409056|NCT01975441|Experimental|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
11409057|NCT01975428|Other|Control|Disease Management program
11409058|NCT01975428|Active Comparator|DM Pgm + glucometer|iBGStar - iPhone enabled capillary blood glucose meter plus disease management program. Subjects test blood glucose up to 4 times per day, every day.
11409059|NCT01975428|Active Comparator|DM Pgm + Blood Pressure Monitor|Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.
11409060|NCT01975428|Active Comparator|DM pgm + Alive Cor ECG|Disease management program + iphone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic
11409061|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
11409062|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
11409063|NCT01975389|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
11409064|NCT01975389|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
11409065|NCT01975376|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
11409066|NCT01975376|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
11409067|NCT01975363|Experimental|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
11409068|NCT01975363|Experimental|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
11409069|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
11409070|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
11409071|NCT01975337|Experimental|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
11409072|NCT01975337|Active Comparator|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
11409073|NCT01975324|Experimental|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
11409074|NCT01975324|Placebo Comparator|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
11409075|NCT01975311|Experimental|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
11409076|NCT01975311|Placebo Comparator|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
11409077|NCT01975298|Experimental|Laquinimod 0.6 mg|
11409078|NCT01975298|Experimental|Laquinimod 1.2 mg|
11409079|NCT01975298|Active Comparator|Avonex®|
11409080|NCT01975285|Active Comparator|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
11409081|NCT01975285|Placebo Comparator|Saline group|Saline 1 ml per 20cc
11409082|NCT01975272|Active Comparator|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
11409083|NCT01975272|Active Comparator|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
11409120|NCT01974973|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
11409084|NCT01975272|Placebo Comparator|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
11409085|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:
~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
11409086|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.
~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
11409087|NCT01975246|Experimental|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
11409088|NCT01975246|Active Comparator|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
11409089|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
11409090|NCT01975220|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
11409091|NCT01975220|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
11409092|NCT01975220|Experimental|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
11409093|NCT01975207|No Intervention|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
11409094|NCT01975207|Experimental|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.
~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
11409095|NCT01975207|Experimental|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
11409096|NCT01975207|Experimental|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
11409097|NCT01975194|Experimental|Rosuvastatin|Patients that receive rosuvastatin
11409098|NCT01975168|Experimental|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
11409099|NCT01975168|Sham Comparator|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
11409100|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
11409101|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
11409102|NCT01975142|Experimental|TDM-1|
11409103|NCT01975129|Experimental|Vagitocin (Oxytocin)|
11409104|NCT01975116|Experimental|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11409105|NCT01975103|Experimental|Topcon Endpoint management|Active laser treatment
11409106|NCT01975103|Sham Comparator|Control|Powerless (sham) laser treatment
11409107|NCT01975090|Experimental|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter
11409108|NCT01975077|Experimental|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
11409109|NCT01975077|Experimental|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
11409110|NCT01975064|Active Comparator|Propofol|Propofol for maintenance of anesthesia
11409111|NCT01975064|Active Comparator|Sevoflurane|Sevoflurane for maintenance of anesthesia
11409112|NCT01975051|Experimental|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
11409113|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
11409114|NCT01975025|Experimental|All study participants|Short daily dialysis for 2 weeks
11409115|NCT01975012|Experimental|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
11409116|NCT01975012|Experimental|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
11409117|NCT01974986|Placebo Comparator|Placebo|Water with flavoring and non-nutritive sweetener.
11409118|NCT01974986|Experimental|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
11409194|NCT01974375|Experimental|micafungin|micafungin sodium IV (Mycamine®)
11409121|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
11409122|NCT01974934|Experimental|Desvenlafaxine Succinate|
11409123|NCT01974921|Experimental|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
11409124|NCT01974908|Experimental|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
11409125|NCT01974895|Experimental|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
11409126|NCT01974895|Active Comparator|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
11409127|NCT01974882|Experimental|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
11409128|NCT01974882|No Intervention|Control|No adjunctive therapy following abdominal surgery.
11409129|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
11409130|NCT01974869||Inflammatory bowel diseases-2|Controls
11409131|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
11409132|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
11409133|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients receiving augmentation therapy in the home through Coram
11409134|NCT01974817|Experimental|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
11409135|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
11409136|NCT01974791|Experimental|GET Living Treatment|
11409137|NCT01974778|Experimental|Active|Meal
11409138|NCT01974778|Placebo Comparator|Control|Water
11409139|NCT01974765|Experimental|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.
~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
11409140|NCT01974752|Experimental|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
11409141|NCT01974752|Placebo Comparator|placebo twice daily|placebo twice daily in combination with dacarbazine.
11409142|NCT01974739|Active Comparator|hydrochloorthiazide|once a day 25 mg
11409143|NCT01974739|Placebo Comparator|placebo|once a day placebo
11409144|NCT01974726|Other|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
11409145|NCT01974726|Other|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
11409146|NCT01974726|Other|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
11409147|NCT01974726|Other|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
11409148|NCT01974700|Active Comparator|Levetiracetam|
11409149|NCT01974700|No Intervention|No anti-epileptic treatment|
11409150|NCT01974687|Experimental|Group A: Healthy|Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.
11409151|NCT01974687|Experimental|Group B: GT1 HCV-infected, treatment naive on Day 1|HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.
11409152|NCT01974687|Experimental|Group C: GT1 HCV-infected on Days 1-7|HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
11409153|NCT01974687|Experimental|Group D: GT2 through GT6 HCV-infected on Days 1-7|HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
11409154|NCT01974687|Experimental|Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment|HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
11409155|NCT01974687|Experimental|Group F: GT1 HCV-infected on Days 1-7, + Itraconazole|HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.
11409195|NCT01974375|Active Comparator|Fluconazole|Fluconazole IV (use same brand in each hospital)
11409156|NCT01974674|Experimental|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
11409157|NCT01974661|Experimental|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
11409158|NCT01974648|Active Comparator|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
11409159|NCT01974648|Experimental|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
11409160|NCT01974635|Experimental|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
11409161|NCT01974622|Experimental|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
11409162|NCT01974609|Experimental|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
11409163|NCT01974609|Active Comparator|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
11409164|NCT01974596|Experimental|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
11409165|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
11409166|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
11409167|NCT01974583||the control group C|Group C were covered with paraffin gauze
11409168|NCT01974570|Experimental|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
11409169|NCT01974570|Placebo Comparator|Placebo|Participants are provided in double blinded fashion to Placebo
11409170|NCT01974544|Experimental|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
11409171|NCT01974544|Experimental|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
11409172|NCT01974544|Experimental|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
11409173|NCT01974531||Preterm birth/ Timely birth|
11409174|NCT01974531||Women/men|
11409175|NCT01974518|Active Comparator|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
11409176|NCT01974518|Active Comparator|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
11409177|NCT01974505|Experimental|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
11409178|NCT01974492|Active Comparator|Upper leg vein|Upper leg vein harvesting
11409179|NCT01974492|Active Comparator|Lower leg vein|Lower leg vein harvesting
11409180|NCT01974479|Experimental|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10^7 CD56+ cells/kg, and up to 1 x 10^8 CD56+ cells/Kg
11409181|NCT01974466|Active Comparator|Goal A|"controled fluid therapy: 5~10ml/kg/hr fulfillment of two or more of four criteria:
~heart rate <120 beats/min,
~mean arterial blood pressure 65-85 mm Hg,
~urine output ≥1 ml/kg /h
~Hematocrit ≤35%."
11409182|NCT01974466|Other|Goal B|"controled fluid therapy: 5~10ml/kg/hr fulfillment of all of the following criteria:
~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
11409183|NCT01974453||Right transradial|Procedures performed through right transradial approach
11409184|NCT01974453||Left transradial|Procedures performed through left transradial approach
11409185|NCT01974453||Femoral|Procedures performed through transfemoral approach
11409186|NCT01974440|Placebo Comparator|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab [BR] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for 6 cycles + placebo.
11409187|NCT01974440|Experimental|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
11409188|NCT01974414|Active Comparator|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
11409189|NCT01974414|No Intervention|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
11409190|NCT01974401|Active Comparator|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
11409191|NCT01974401|No Intervention|control group|patients in this group received routine oral health care protocols.
11409192|NCT01974388|Active Comparator|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
11409193|NCT01974388|Active Comparator|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
11409196|NCT01974362||Cad/Cam Monolithic Zirconia|Patients that have a full-mouth (maxilla and mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
11409197|NCT01974362||Zirconia-Feldspathic|Patients that have a full-mouth (maxilla and mandible) implant supported rehabilitation restored with zirconia substructure and feldspathic veneered biomaterial
11409198|NCT01974349|Experimental|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
11409199|NCT01974349|Experimental|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
11409200|NCT01974336|Experimental|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
11409201|NCT01974336|Experimental|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
11409202|NCT01974323|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
11409203|NCT01974323|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
11409204|NCT01974310|Active Comparator|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
11409205|NCT01974310|Experimental|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
11409206|NCT01974297|Active Comparator|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
11409207|NCT01974297|Experimental|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
11409208|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
11409209|NCT01974271||Cohort|
11409210|NCT01974258|Experimental|Dose-expansion: onartuzumab + cobimetinib|
11409211|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib|
11409212|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
11409213|NCT01974258|Experimental|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
11409214|NCT01974245|Placebo Comparator|Placebo|100 drops/week for 12 weeks
11409215|NCT01974245|Active Comparator|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
11409216|NCT01974232||Romiplostim group|
11409217|NCT01974232||Eltrombopag group|
11409218|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
11409219|NCT01974219||Healthy smokers|Healthy smokers
11409220|NCT01974219||COPD smokers|COPD smokers
11409221|NCT01974206|Experimental|ASP0113|One (1) mL of 5 mg/mL ASP0113 will be administered to the subjects at the clinical site via injection
11409222|NCT01974206|Placebo Comparator|Placebo|One (1) mL of 5 mg/mL placebo will be administered to the subjects at the clinical site via injection
11409223|NCT01974193|Experimental|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
11409224|NCT01974193|No Intervention|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
11409225|NCT01974167|Experimental|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
11409226|NCT01974167|Active Comparator|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
11409227|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
11409228|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
11409229|NCT01974141|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
11409230|NCT01974141|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
11409231|NCT01974115|Active Comparator|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
11409232|NCT01974102|Experimental|lifestyle|Both active and control groups will receive counseling on nutrition and physical activity.
11409233|NCT01974102|Experimental|therapy|Active group will receive 8 weeks of mindfulness based stress reduction therapy
11409234|NCT01974089||Pneumonia and dysphagia|Patients with community aquired pneumonia and oropharyngea dysphagia
11409235|NCT01974089||Pneumonia|Patients with community aquired pneumonia
11409236|NCT01974076|Active Comparator|Active tDCS|
11409237|NCT01974076|Sham Comparator|Sham tDCS|
11409238|NCT01974063||A. Nonsmokers|Subjects have smoked <100 cigarettes or <10 shisha pipes per lifetime and whose urine nicotine <2 ng/mL and/or urine cotinine <5 ng/mL, at entry into the study.
11409239|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine >30 ng/mL and/or urine cotinine >50 ng/ml.
11409240|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking >4 pipes/wk and carboxyhemoglobin >2.5.
11409241|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
11409298|NCT01973647|Experimental|COPD Education (COPD-ED)|Six weekly sessions of COPD education
11409299|NCT01973647|Placebo Comparator|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
11409300|NCT01973634|Active Comparator|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
11409343|NCT01973348|Active Comparator|2-hour eye patching|2-hour eye patching for moderate amblyopia
11409242|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
11409243|NCT01974050|Other|Text message monitoring|Use of text messaging to monitor post-vaccination
11409244|NCT01974037|Active Comparator|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
11409245|NCT01974037|Experimental|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
11409246|NCT01974037|Experimental|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
11409247|NCT01974037|No Intervention|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
11409248|NCT01974037|No Intervention|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
11409249|NCT01974037|Experimental|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
11409250|NCT01974037|Experimental|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
11409251|NCT01974037|Experimental|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
11409252|NCT01974024|Experimental|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
11409253|NCT01974024|Active Comparator|Dexamethasone|Dexamethasone was re-administered in the cycle.
11409254|NCT01974011|Experimental|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
11409255|NCT01974011|Active Comparator|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:
~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
11409256|NCT01973998|Experimental|Roflumilast|500 ug tablet daily for 180 days
11409257|NCT01973998|Placebo Comparator|Placebo|Placebo 1 tablet daily x 180 days
11409258|NCT01973972|Experimental|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
11409259|NCT01973972|Active Comparator|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
11409260|NCT01973946|No Intervention|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
11409261|NCT01973946|Experimental|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.
~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
11409262|NCT01973933|Experimental|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
11409263|NCT01973920|Experimental|Oshadi Icp|Oshadi Icp oral insulin,
11409264|NCT01973907|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
11409265|NCT01973907|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
11409266|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.
~Blood and urine sampling will follow this schedule:
~24h: blood (3ml)
~48h: blood (3ml) and urine
~End of infusion: blood (3ml)
~6h after end of infusion: blood (3ml) and urine.
~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.
~Then all frozen samples will be analyzed to get Midazolam concentrations."
11409301|NCT01973634|Experimental|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
11409460|NCT01972581|Experimental|Reaction Time Training|
11409267|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
11409268|NCT01973868|Experimental|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.
~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.
~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.
~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
11409269|NCT01973855|Experimental|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
11409270|NCT01973855|Placebo Comparator|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
11409271|NCT01973842|Active Comparator|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
11409272|NCT01973842|Active Comparator|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
11409273|NCT01973842|Active Comparator|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
11409274|NCT01973829|Other|Baseline arm|baseline data (50 patients or 3 months per center)
11409275|NCT01973816|Experimental|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
11409276|NCT01973816|Active Comparator|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
11409277|NCT01973790|Experimental|Z-338|100mg TID
11409278|NCT01973777|Experimental|IUB|There is one arm of women who will have IUBs inserted
11409279|NCT01973764|Other|Ultrasound guided arm|
11409280|NCT01973764|Other|Landmark-based arm|
11409281|NCT01973751|No Intervention|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
11409282|NCT01973751|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
11409283|NCT01973751|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
11409284|NCT01973725|Experimental|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
11409285|NCT01973712|Experimental|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
11409286|NCT01973712|Experimental|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
11409287|NCT01973699|Placebo Comparator|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
11409288|NCT01973699|Experimental|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
11409289|NCT01973686|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
11409290|NCT01973686|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
11409291|NCT01973686|No Intervention|Control|Receives no intervention
11409292|NCT01973673|Active Comparator|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
11409293|NCT01973673|No Intervention|Usual care|Usual clinical care to be provided by oncologists.
11409294|NCT01973660|Experimental|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
11409295|NCT01973660|Experimental|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
11409296|NCT01973647|Experimental|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
11409297|NCT01973647|Experimental|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
11409302|NCT01973634|Active Comparator|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
11409303|NCT01973634|Experimental|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
11409304|NCT01973608|Experimental|MSB0010445 Low Dose Cohort 0.3 mg/kg|
11409305|NCT01973608|Experimental|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
11409306|NCT01973608|Experimental|MSB0010445 High Dose Cohort 1.8 mg/kg|
11409307|NCT01973608|Experimental|MSB0010445 High Dose Cohort 2.4 mg/kg|
11409308|NCT01973595|Experimental|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
11409309|NCT01973595|Other|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
11409310|NCT01973569|Experimental|Denosumab 6 months|denosumab administered subcutaneously every 6 months
11409311|NCT01973569|Experimental|Denosumab 3 months|denosumab administered subcutaneously every 3 months
11409312|NCT01973569|Placebo Comparator|placebo|placebo administered subcutaneously to match denosumab
11409313|NCT01973556|Experimental|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
11409314|NCT01973556|No Intervention|Usual Care|
11409315|NCT01973543|Experimental|VY-AADC01 Dose 1|7.5 x 10^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
11409316|NCT01973543|Experimental|VY-AADC01 Dose 2|1.5 x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
11409317|NCT01973543|Experimental|VY-AADC01 Dose 3|4.7x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
11409318|NCT01973530|Active Comparator|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
11409319|NCT01973530|Other|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
11409320|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
11409321|NCT01973504|Experimental|MP4OX 500-mL|500-mL dose of MP4OX
11409322|NCT01973504|Experimental|MP4OX 750-mL|750-mL dose of MP4OX
11409323|NCT01973504|Sham Comparator|Control|Standard crystalloid Keep Vein Open (KVO) infusion
11409324|NCT01973491|Experimental|ATX-MS-1467|
11409325|NCT01973478|Experimental|DBS|"The medical device includes:
~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)
~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.
~The target is the Accumbens nucleus.
~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.
~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
11409326|NCT01973478|Sham Comparator|SHAM|"The medical device includes:
~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)
~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.
~The target is the Accumbens nucleus.
~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.
~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
11409327|NCT01973465|Experimental|Fecal Microbiota Therapy|
11409328|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
11409329|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
11409330|NCT01973439|Other|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
11409331|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
11409332|NCT01973413|Experimental|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
11409333|NCT01973413|Placebo Comparator|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
11409334|NCT01973400|Experimental|Tocotrienol|200 mg, twice a day, 12 months
11409335|NCT01973400|Placebo Comparator|Placebo|200 mg, twice a day, 12 months
11409336|NCT01973387|Experimental|Treatment Arm A|
11409337|NCT01973387|Experimental|Treatment Arm B|
11409338|NCT01973374|No Intervention|Routine Care|
11409339|NCT01973374|Experimental|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
11409340|NCT01973361|Experimental|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
11409341|NCT01973361|Active Comparator|Best Practice wound care|Participants receiving best practice wound care alone
11409461|NCT01972581|No Intervention|Control|
11409344|NCT01973348|Experimental|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
11409345|NCT01973348|Active Comparator|6-hour eye patching|6-hour eye patching for severe amblyopia
11409346|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).
~See interventions for more details."
11409347|NCT01973335|Experimental|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.
~See interventions for more details."
11409348|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.
~See interventions for more details."
11409349|NCT01973335|Active Comparator|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.
~See interventions for more details."
11409350|NCT01973322|Experimental|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
11409351|NCT01973322|Experimental|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
11409352|NCT01973322|Experimental|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
11409353|NCT01973322|Experimental|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
11409354|NCT01973309|Experimental|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
11409355|NCT01973296|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
11409356|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
11409357|NCT01973283|Experimental|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
11409358|NCT01973270|Experimental|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
11409359|NCT01973270|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
11409360|NCT01973270|No Intervention|Treatment as Usual|Treatment as Usual
11409361|NCT01973257|Experimental|select from the option menu|select from the option menu
11409362|NCT01973244|Experimental|NNC0195-0092 (somapacitan)|
11409363|NCT01973244|Active Comparator|Norditropin®|
11409364|NCT01973231|Experimental|Metformin + liraglutide 1.8 mg|
11409365|NCT01973231|Active Comparator|Metformin + lixisenatide 20 microg|
11409366|NCT01973218|Experimental|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
11409367|NCT01973218|Active Comparator|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
11409368|NCT01973205|Placebo Comparator|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
11409369|NCT01973205|Experimental|Acetaminophen 250 mg and aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
11409370|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
11409371|NCT01973166|Experimental|Picosecond Q-switched Laser Treatment|Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
11409372|NCT01973166|Active Comparator|Nanosecond Q-switched Laser Treatment|Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
11409373|NCT01973153|Active Comparator|Brief Motivational Counseling (BMC)|
11409374|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|
11409375|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Home Visits (BMC+Home)|
11409376|NCT01973140|Other|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
11409377|NCT01973127|Experimental|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.
~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
11409378|NCT01973127|Sham Comparator|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.
~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
11409379|NCT01973114|Experimental|Group 1|One intratympanic injection of latanoprost (Day1)
11409380|NCT01973114|Placebo Comparator|Group 2|One intratympanic injection of placebo
11409381|NCT01973114|Experimental|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
11409382|NCT01973114|Placebo Comparator|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
11409383|NCT01973101|Experimental|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
11409384|NCT01973101|Active Comparator|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
11409385|NCT01973088||non-urate calculus|
11409386|NCT01973088||non-calculus|
11409387|NCT01973088||urate calculus|
11409388|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
11409389|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
11409462|NCT01972568|Experimental|Atacicept 75 mg|
11409390|NCT01973062|Experimental|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
11409391|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
11409392|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Ribavirin 200mg tablet orally twice a day for 12 weeks"
11409393|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
11409394|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks
~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
11409395|NCT01973036|Active Comparator|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
11409396|NCT01973036|Experimental|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
11409397|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
11409398|NCT01973010|Experimental|Massage|To treat low back pain with massage
11409399|NCT01973010|Active Comparator|Ibuprofen|Medicine control group
11409400|NCT01972997|Experimental|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
11409401|NCT01972984|Experimental|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
11409402|NCT01972971|Other|pharmacist care|
11409403|NCT01972958|Experimental|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
11409404|NCT01972958|No Intervention|usual care|control group with usual care
11409405|NCT01972945|Experimental|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
11409406|NCT01972945|Active Comparator|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
11409407|NCT01972932|Placebo Comparator|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
11409408|NCT01972932|Active Comparator|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
11409409|NCT01972919|Experimental|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
11409410|NCT01972906|Experimental|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
11409411|NCT01972906|Active Comparator|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
11409412|NCT01972893|Experimental|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
11409413|NCT01972893|Placebo Comparator|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
11409414|NCT01972880|Experimental|tablet-1|
11409415|NCT01972880|Active Comparator|tablet-2|
11409416|NCT01972867|Experimental|NanoKnife Procedure|The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
11409417|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
11409418|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
11409419|NCT01972841|Experimental|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
11409420|NCT01972841|Experimental|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
11409421|NCT01972841|Placebo Comparator|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
11409422|NCT01972841|Active Comparator|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
11409463|NCT01972568|Experimental|Atacicept 150 mg|
11409423|NCT01972841|Active Comparator|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
11409424|NCT01972841|Active Comparator|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
11409425|NCT01972828|Experimental|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
11409426|NCT01972828|Active Comparator|CONTROL|
11409427|NCT01972789|Experimental|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
11409428|NCT01972789|Experimental|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF >200 um on OCT.
11409429|NCT01972776|Experimental|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
11409430|NCT01972776|Experimental|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
11409431|NCT01972776|Experimental|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
11409432|NCT01972776|Placebo Comparator|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
11409433|NCT01972776|Experimental|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
11409434|NCT01972776|Placebo Comparator|Placebo Part 2|Participants received matching placebo for 8 weeks.
11409435|NCT01972763|Active Comparator|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
11409436|NCT01972763|Active Comparator|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
11409437|NCT01972750|Experimental|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
11409438|NCT01972737|Experimental|Ad5-hGCC-PADRE Vaccine|Active vaccine
11409439|NCT01972724|Experimental|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
11409440|NCT01972724|Experimental|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
11409441|NCT01972724|Experimental|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
11409442|NCT01972711|Experimental|SEP-363856|Single-dose SEP-363856 50 mg
11409443|NCT01972711|Active Comparator|Amisulpride|Single-dose Amisulpride 400 mg.
11409444|NCT01972711|Placebo Comparator|Placebo|Matched placebo
11409445|NCT01972698|Experimental|Self-directed and simulation-assisted training|
11409446|NCT01972698|Active Comparator|Traditional apprenticeship training|
11409447|NCT01972685|Other|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
11409448|NCT01972672|Experimental|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
11409449|NCT01972659|Active Comparator|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
11409450|NCT01972659|Experimental|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
11409451|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
11409452|NCT01972633|Active Comparator|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
11409453|NCT01972633|Active Comparator|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
11409454|NCT01972620|Active Comparator|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
11409455|NCT01972620|No Intervention|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
11409456|NCT01972607|No Intervention|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
11409457|NCT01972607|Experimental|EXERCISE|This group will receive the treatment with aerobic exercise training
11409458|NCT01972594|No Intervention|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
11409459|NCT01972594|Experimental|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
11409465|NCT01972555|Experimental|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
11409466|NCT01972555|Active Comparator|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
11409467|NCT01972542|Active Comparator|Type 2 DM|"Intervention : Oral fat tolerance test
~well or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
11409468|NCT01972542|Active Comparator|Prediabetes|"Intervention : Oral fat tolerance test
~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
11409469|NCT01972542|Sham Comparator|Normal glucose tolerance|"Intervention : Oral fat tolerance test
~No impaired fasting glucose and impaired glucose tolerance"
11409470|NCT01972529|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
11409471|NCT01972529|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
11409472|NCT01972529|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
11409473|NCT01972529|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
11409474|NCT01972516|Experimental|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
11409475|NCT01972516|No Intervention|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
11409476|NCT01972503|Experimental|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
11409477|NCT01972503|Active Comparator|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
11409478|NCT01972490|Experimental|ARM A|patients received avastin in combination with mFOLFOX6
11409479|NCT01972490|Active Comparator|ARM B|Patients received mFOLFOX6 alone
11409480|NCT01972477|Experimental|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
11409481|NCT01972477|Experimental|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
11409482|NCT01972477|Placebo Comparator|Placebo|Placebo once daily, taken every day along the study period
11409483|NCT01972464|Placebo Comparator|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
11409484|NCT01972464|Experimental|Progesterone|In this group women will receive oral micronized progesterone twice a day.
11409485|NCT01972451|Placebo Comparator|Colonoscopy without enhanced dye|no enhanced dye
11409486|NCT01972451|Active Comparator|Colonoscopy with enhanced dye|enhanced dye
11409487|NCT01972438|Experimental|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
11409488|NCT01972438|Placebo Comparator|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
11409489|NCT01972425|Experimental|Biomarker-based diagnostic|Analyse sample on arrival
11409490|NCT01972425|No Intervention|Routine use of antibiotics|Do not analyse the sample on arrival
11409491|NCT01972412|Other|Telephone support|Intervention type: Telephone support for four months.
11409492|NCT01972399|Experimental|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
11409493|NCT01972399|Active Comparator|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
11409494|NCT01972386||Spectrum Image Analysis|
11409495|NCT01972373|Experimental|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
11409496|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
11409497|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
11409498|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
11409499|NCT01972347|Experimental|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
11409500|NCT01972334|Experimental|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
11409501|NCT01972334|Placebo Comparator|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
11409502|NCT01972321|Experimental|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
11409545|NCT01972113|Active Comparator|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
11409503|NCT01972321|Experimental|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
11409504|NCT01972321|Active Comparator|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
11409505|NCT01972308|Experimental|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
11409506|NCT01972308|Other|usual care|Patient receives asthma care as usual from their asthma provider
11409507|NCT01972269|Active Comparator|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409508|NCT01972269|Active Comparator|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409509|NCT01972269|Active Comparator|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409510|NCT01972269|Active Comparator|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409511|NCT01972269|Active Comparator|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409512|NCT01972269|Active Comparator|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409513|NCT01972269|Active Comparator|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409514|NCT01972269|Active Comparator|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409515|NCT01972269|Active Comparator|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409516|NCT01972269|Active Comparator|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409517|NCT01972269|Active Comparator|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409518|NCT01972269|Active Comparator|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
11409519|NCT01972269|Active Comparator|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
11409520|NCT01972269|Active Comparator|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
11409521|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
11409522|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
11409523|NCT01972243||venous thromboembolism|
11409524|NCT01972230|Experimental|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.
~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
11409525|NCT01972230|Active Comparator|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
11409526|NCT01972217|Active Comparator|Olaparib|200 mg or 300 mg bid
11409527|NCT01972217|Placebo Comparator|Placebo|placebo to match olaparib bid
11409528|NCT01972204|Experimental|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
11409529|NCT01972204|Sham Comparator|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
11409530|NCT01972191||Group 1|Group 1 : Bare eye marking group
11409531|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
11409532|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
11409533|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
11409534|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
11409535|NCT01972165|Experimental|Group I|Mini-incision carpal tunnel release group
11409536|NCT01972165|Active Comparator|Group II|Endoscopic carpal tunnel release group
11409537|NCT01972152|Experimental|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
11409538|NCT01972152|Experimental|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
11409539|NCT01972152|Active Comparator|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
11409540|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
11409541|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
11409542|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
11409543|NCT01972113|Placebo Comparator|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
11409544|NCT01972113|Active Comparator|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
11409588|NCT01971827|Experimental|MOVI-KIDS Program|Intervention group
11409546|NCT01972100|Active Comparator|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
11409547|NCT01972100|Active Comparator|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
11409548|NCT01972087|No Intervention|Control|Participants randomized to the control arm receive no telephone simulation training.
11409549|NCT01972087|Experimental|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
11409550|NCT01972074|Experimental|Memantine|"Participants in the placebo arm will receive placebo (no active ingredients) in capsule form twice daily. It will be administered twice daily for 12 weeks. Participants will undergo neuroimaging before and after the 12-week treatment phase.
~Placebo: Capsule"
11409551|NCT01972074|Placebo Comparator|Placebo|"Participants in the memantine arm will receive memantine in capsule form twice daily. It will be administered twice daily for 12 weeks (including a 4-week titration phase to a maximum dose of 20 mg per day). Participants will undergo neuroimaging before and after the 12-week treatment phase.
~Memantine: Capsule"
11409552|NCT01972074|No Intervention|Control Group|Healthy controls will undergo neuroimaging twice (12 weeks apart) and will receive no intervention during the 12-week window.
11409553|NCT01972061|Experimental|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
11409554|NCT01972061|Active Comparator|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
11409555|NCT01972061|Active Comparator|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
11409556|NCT01972061|Active Comparator|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
11409557|NCT01972048|Active Comparator|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
11409558|NCT01972048|Experimental|Intervention group|Participants will receive the mMammogram intervention.
11409559|NCT01972035|Experimental|ValAcyclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValA or ValG in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
11409560|NCT01972035|Active Comparator|ValGanciclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValG or ValA in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
11409561|NCT01972022|Experimental|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
11409562|NCT01972022|Active Comparator|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
11409563|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
11409564|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
11409565|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
11409566|NCT01971983|Experimental|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
11409567|NCT01971983|Experimental|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
11409568|NCT01971983|Sham Comparator|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
11409569|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
11409570|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
11409571|NCT01971957||Sjogren-Larsson syndrome|There are no cohorts for this study.
11409572|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
11409573|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
11409574|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
11409575|NCT01971931||Patients undergoing TKR.|
11409576|NCT01971918|Experimental|early switch|"early switch of monoclonal antibodies anti-TNF
~anti drug antibodies dosage"
11409577|NCT01971918|Experimental|therapeutic intensification|"therapeutic intensification of monoclonal antibodies anti-TNF
~anti drug antibodies dosage"
11409578|NCT01971905||Oben label|There is no intervention on this descriptive study
11409579|NCT01971892|Experimental|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
11409580|NCT01971892|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
11409581|NCT01971879|Sham Comparator|Control|
11409582|NCT01971879|Active Comparator|Remote preconditioning|
11409583|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
11409584|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
11409585|NCT01971840|Experimental|MOVI-KIDS Program|Intervention group
11409586|NCT01971840|No Intervention|Control|No intervention
11409587|NCT01971827|No Intervention|Control|No intervention
11409589|NCT01971814|Experimental|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
11409590|NCT01971801|Active Comparator|Vitamin D|Vitamin D3, 50,000 IU, weekly
11409591|NCT01971801|Placebo Comparator|Placebo|Placebo comparator, weekly
11409592|NCT01971788|Experimental|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
11409593|NCT01971788|Active Comparator|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
11409594|NCT01971775|Active Comparator|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
11409595|NCT01971775|Active Comparator|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
11409596|NCT01971762||Patients diagnosed bacteremia by S. aureus|
11409597|NCT01971749||Unprotected left main coronary artery stenosis patients|
11409598|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
11409599|NCT01971723|Active Comparator|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
11409600|NCT01971723|Placebo Comparator|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
11409601|NCT01971710|Other|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
11409602|NCT01971710|Other|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
11409603|NCT01971710|Other|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
11409604|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
11409605|NCT01971671||Chinese lactating mother|no intervention.
11409606|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:
~Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12
~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
11409607|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:
~Induction therapy : 4 cycles of VCD (21 days)
~Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15
~Velcade® and Dexamethasone identical treatment to Arm A
~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
11409608|NCT01971645|Experimental|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
11409609|NCT01971645|Placebo Comparator|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
11409610|NCT01971645|Active Comparator|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
11409611|NCT01971632|Active Comparator|Oxycodone/Naloxone|
11409612|NCT01971632|Placebo Comparator|Placebo oxycodone/naloxone|
11409613|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
11409614|NCT01971606|Experimental|Rosuvastatin group|Rosuvastatin group
11409615|NCT01971606|Placebo Comparator|Placebo group|Placebo group
11409616|NCT01971593|Other|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
11409617|NCT01971593|Other|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
11409618|NCT01971580|Other|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
11409619|NCT01971580|Other|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
11409620|NCT01971567|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
11409621|NCT01971567|Placebo Comparator|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
11409622|NCT01971554|Experimental|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
11409623|NCT01971554|Experimental|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
11409624|NCT01971554|Experimental|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
11409625|NCT01971554|Placebo Comparator|Placebo|Placebo, oral, QD for Days 1 to 14
11409626|NCT01971541|Experimental|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
11409627|NCT01971541|Active Comparator|Cognitive Processing Therapy|A group-administered PTSD treatment program.
11409628|NCT01971528|No Intervention|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
11409629|NCT01971528|No Intervention|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
11409630|NCT01971528|No Intervention|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
11409631|NCT01971528|No Intervention|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
11409632|NCT01971528|Experimental|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
11409633|NCT01971528|No Intervention|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
11409634|NCT01971515|Experimental|MSC2363318A|
11409635|NCT01971515|Experimental|MSC2363318A plus Trastuzumab|
11409636|NCT01971515|Experimental|MSC2363318A plus Tamoxifen|
11409637|NCT01971502|Experimental|BI 1060469 single rising dose part|single rising doses given as tablet
11409638|NCT01971502|Experimental|BI 1060469 food effect part|given as tablet fasted and fed
11409639|NCT01971489|Experimental|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11409640|NCT01971476|Experimental|All patients|Volasertib will be administered as intravenous infusion
11409641|NCT01971463|Experimental|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
11409642|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
11409643|NCT01971437|Experimental|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
11409644|NCT01971437|Placebo Comparator|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
11409645|NCT01971424|Experimental|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
11409646|NCT01971424|No Intervention|Controls|The control group was educated by a trained dietician to follow a healthy diet.
11409647|NCT01971411||Community dwelling elderly black females|
11409648|NCT01971398|Experimental|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
11409649|NCT01971398|Experimental|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
11409650|NCT01971398|Active Comparator|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
11409651|NCT01971385|Active Comparator|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
11409652|NCT01971385|Placebo Comparator|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
11409653|NCT01971359||Retrospective|
11409654|NCT01971346|Other|Etanercept|100 mg Etanercept injections per week for 3 months.
11409655|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:
~pulse pressure variation
~stroke volume variation
~plethysmographic variation index"
11409656|NCT01971320|Experimental|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks
~Urostim I stimulation will be done during meals for 6 weeks"
11409657|NCT01971320|Placebo Comparator|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks
~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
11409658|NCT01971307|Experimental|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
11409659|NCT01971307|No Intervention|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
11409660|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
11409661|NCT01971281|Experimental|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
11409662|NCT01971281|Experimental|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
11409663|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
11409664|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
11409665|NCT01971255|Experimental|High Titer (HAI > or = 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of ≥1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
11409666|NCT01971255|Experimental|Low Titer (HAI < 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of <1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
11409667|NCT01971242|Active Comparator|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
11409668|NCT01971242|Placebo Comparator|Placebo|Placebo, 2mg administered subcutaneously once weekly
11409714|NCT01970917|Other|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
11409669|NCT01971229|Sham Comparator|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
11409670|NCT01971229|Active Comparator|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
11409671|NCT01971216|No Intervention|Control|Breastfeeding mothers who are not randomised to relaxation intervention
11409672|NCT01971216|Experimental|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
11409673|NCT01971203|Experimental|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
11409674|NCT01971203|Placebo Comparator|placebo plus CBT|treatment group receiving placebo pill plus CBT
11409675|NCT01971190|Sham Comparator|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
11409676|NCT01971190|Active Comparator|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
11409677|NCT01971177|Experimental|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
11409678|NCT01971177|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
11409679|NCT01971164|Experimental|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
11409680|NCT01971164|Experimental|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
11409681|NCT01971164|Experimental|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
11409682|NCT01971164|Experimental|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
11409683|NCT01971151|Experimental|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
11409684|NCT01971151|Experimental|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
11409685|NCT01971151|Active Comparator|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
11409686|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
11409687|NCT01971125||No treatment|"Patients with:
~diabetes mellitus type 2
~absence of heart disease previously reported
~age >45 years
~Informed Consent
~Patients without:
~presence of heart disease previously reported
~diabetes type 1
~serious systemic disease, with an expected lifetime lower than 2 years
~no willingness to participate to the screening
~inadequate compliance to study procedure
~participation to other study"
11409688|NCT01971112|Experimental|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
11409689|NCT01971112|Placebo Comparator|Placebo|
11409690|NCT01971099|Placebo Comparator|Placebo|patients will use placebo for 120 days
11409691|NCT01971099|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
11409692|NCT01971086||acute rhinitis|
11409693|NCT01971073|Experimental|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.
~Intervention: Device: transcranial direct current stimulation"
11409694|NCT01971073|Sham Comparator|Sham tDCS|Sham tDCS
11409695|NCT01971060|Experimental|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
11409696|NCT01971047|Active Comparator|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
11409697|NCT01971047|Active Comparator|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
11409698|NCT01971034|Experimental|Paclitaxel and Metformin|
11409699|NCT01971021|Active Comparator|PICC-line|PICC line insertion.
11409700|NCT01971021|Active Comparator|PORT|Subcutaneous venous port insertion
11409701|NCT01971008|Placebo Comparator|Placebo binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours"
11409702|NCT01971008|Active Comparator|Elastic abdominal binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours"
11409703|NCT01970995|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
11409704|NCT01970995|Active Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
11409705|NCT01970995|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
11409706|NCT01970982|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
11409707|NCT01970982|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
11409708|NCT01970982|Active Comparator|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
11409709|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
11409710|NCT01970943|No Intervention|No Intervention|PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
11409711|NCT01970943|Placebo Comparator|Saline Injection (Placebo)|PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
11409712|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
11409713|NCT01970917|Other|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
11409715|NCT01970904|Experimental|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
11409716|NCT01970904|Experimental|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
11409717|NCT01970904|Experimental|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
11409718|NCT01970891|Experimental|Freezing of Gait amelioration|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait amelioration
11409719|NCT01970878|Experimental|GFF MDI (PT003)|
11409720|NCT01970878|Experimental|GP MDI (PT001)|
11409721|NCT01970878|Experimental|FF MDI (PT005)|
11409722|NCT01970878|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
11409723|NCT01970865|Experimental|PF-06463922|
11409724|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
11409725|NCT01970852|Experimental|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
11409726|NCT01970852|No Intervention|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
11409727|NCT01970852|Experimental|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
11409728|NCT01970839|Other|Tourniquet, pain, nerve injury, sensory nerve function|
11409729|NCT01970826|Experimental|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
11409730|NCT01970826|Active Comparator|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.
~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.
~It will be evaluated the duration of surgery."
11409731|NCT01970826|Experimental|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.
~It will be evaluated the duration of surgery."
11409732|NCT01970826|Active Comparator|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
11409733|NCT01970826|Experimental|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
11409734|NCT01970826|Active Comparator|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.
~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.
~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.
~It will be evaluated the duration of surgery."
11409735|NCT01970813|Active Comparator|Study group|acupuncture and bee venom acupuncture point injection
11409736|NCT01970813|Sham Comparator|Control group|sham acupuncture and normal saline injections
11409737|NCT01970813|No Intervention|Waiting group|no additional intervention
11409738|NCT01970800|Experimental|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
11409739|NCT01970787|Experimental|RFA|Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
11409740|NCT01970774|Experimental|MTM and PGx|Participants attend two MTM sessions and have PGx testing
11409741|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
11409868|NCT01969968|Other|non obese|non obese patients
11409742|NCT01970748|Placebo Comparator|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
11409743|NCT01970748|Active Comparator|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
11409744|NCT01970735|Experimental|FSHD patient|
11409745|NCT01970722|Experimental|Treatment (surgery, HIPEC cisplatin)|"Patients undergo surgery and receive hyperthermic cisplatin IP over 60 minutes.
~Beginning at least 3 weeks after surgery, patients may receive carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or gemcitabine hydrochloride IP or IV at the discretion of the medical and gynecologic oncologists."
11409746|NCT01970696||Ovarian Stromal Tumors|
11409747|NCT01970696||Testicular Stromal Tumors|
11409748|NCT01970696||Ovarian Small Cell Carcinoma|
11409749|NCT01970683|Experimental|VSL #3|probiotics given orally BID
11409750|NCT01970683|Other|placebo|Near-identically appearing placebo
11409751|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
11409752|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
11409753|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have >=4 brain metastases will be treated with gamma knife radiosurgery.
11409754|NCT01970631|No Intervention|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
11409755|NCT01970631|Active Comparator|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
11409756|NCT01970631|Active Comparator|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
11409757|NCT01970631|Active Comparator|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
11409758|NCT01970618|Experimental|Part A: single dose escalation (healthy subjects)|
11409759|NCT01970618|Experimental|Part B: 7 day repeat dose (healthy subjects)|
11409760|NCT01970618|Experimental|Part C: 14 day repeat dose (COPD patients)|
11409761|NCT01970605||Patients with PAOD or aneurysms|"Patients
~in Fontaine class > IIa,
~in need of aneurysm repair,
~with defined cardiovascular risk factors or
~graft infections.
~Surgical reconstruction with defined Silver Graft vascular prosthesis."
11409762|NCT01970592|Experimental|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
11409763|NCT01970579|Experimental|Paclitaxel coated balloon|
11409764|NCT01970579|Active Comparator|uncoated PTA catheter|
11409765|NCT01970566|Experimental|IE-MCR|Intense Exercise/Moderate Calorie Restriction
11409766|NCT01970566|Active Comparator|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
11409767|NCT01970566|Active Comparator|CBT|cognitive behavioral therapy
11409768|NCT01970553|Experimental|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):
~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,
~immediately followed by:
~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
11409769|NCT01970540|Experimental|lurbinectedin (PM01183) / doxorubicin|
11409770|NCT01970527|Experimental|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11409771|NCT01970514|Experimental|ARO Spinal System|ARO Spinal System
11409772|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)
~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
11409773|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)
~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
11409774|NCT01970488|Experimental|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
11409775|NCT01970488|Active Comparator|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.
~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
11409776|NCT01970475|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
11409777|NCT01970475|Active Comparator|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
11409778|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
11409779|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
11409780|NCT01970449|Experimental|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
11409869|NCT01969955|Experimental|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
11409781|NCT01970449|Placebo Comparator|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
11409782|NCT01970449|Experimental|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
11409783|NCT01970449|Placebo Comparator|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
11409784|NCT01970449|Experimental|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
11409785|NCT01970449|Placebo Comparator|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
11409786|NCT01970436|Experimental|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
11409787|NCT01970436|No Intervention|Usual Prenatal Care|Usual, in-person prenatal care.
11409788|NCT01970423|Other|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
11409789|NCT01970423|Other|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
11409790|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
11409791|NCT01970397|Experimental|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
11409792|NCT01970397|Experimental|Belotero Balance®|Perioral Lines treated with Belotero Balance®
11409793|NCT01970384|Experimental|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
11409794|NCT01970384|Sham Comparator|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
11409795|NCT01970371|Experimental|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received 15 milligram per killogram (mg/kg) plazomicin therapy (plus meropenem or tigecycline) as a 30-minute intravenous (IV) infusion once daily for 7 to 14 days.
11409796|NCT01970371|Active Comparator|Colistin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received a 5 mg/kg IV loading dose (300 mg maximum) colistin (plus meropenem or tigecycline) followed by a 5 mg/kg/d maintenance dose divided into every 8 hours (q8h) or every 12 hours (q12h) for 7 to 14 days.
11409797|NCT01970371|Experimental|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
11409798|NCT01970358|Experimental|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)
~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162
~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
11409799|NCT01970345|Experimental|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.
~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
11409800|NCT01970345|Placebo Comparator|Placebo|Placebo
11409801|NCT01970332|No Intervention|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
11409802|NCT01970332|Experimental|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
11409803|NCT01970332|Experimental|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
11409804|NCT01970319||Diabetic with nephropathy|
11409805|NCT01970319||Diabetics without nephropathy|
11409806|NCT01970306|Experimental|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
11409807|NCT01970293|Other|Introduction to AA volunteer|
11409808|NCT01970293|No Intervention|AA materials offered|
11409809|NCT01970280|Active Comparator|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
11409810|NCT01970280|No Intervention|Observation|
11409811|NCT01970267|Active Comparator|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
11409812|NCT01970267|Sham Comparator|Not Treated|
11409870|NCT01969942|Experimental|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
11409925|NCT01969643|Experimental|SGN-LIV1A|SGN-LIV1A will be given at the recommended dose (at or below the monotherapy MTD determined in the SGN-LIV1A dose escalation arm).
11409813|NCT01970254||Screening (hepatitis B screening)|Patients with unknown HBV infection status undergo 3 HBV screening tests (HBsAg, anti-HBc, and anti-HBs) before chemotherapy. Patients with known HBV infection status undergo either HBsAg or anti-HBc screening tests if there is no evidence of HBV testing in the last 3 months. All patients complete HBV risk assessment survey.
11409814|NCT01970241|Experimental|NPH with steroid dose|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).
~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
11409815|NCT01970241|Active Comparator|Control - Background and correction insulin|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
11409816|NCT01970228|Active Comparator|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
11409817|NCT01970228|Active Comparator|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
11409818|NCT01970228|Active Comparator|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
11409819|NCT01970215|Placebo Comparator|Group 1|TA-8995 0mg (placebo) & placebo statin
11409820|NCT01970215|Experimental|Group 2|TA-8995 1mg & placebo statin
11409821|NCT01970215|Experimental|Group 3|TA-8995 2.5mg & placebo statin
11409822|NCT01970215|Experimental|Group 4|TA-8995 5mg & placebo statin
11409823|NCT01970215|Experimental|Group 5|TA-8995 10mg & placebo statin
11409824|NCT01970215|Active Comparator|Group 6|TA-8995 0mg (placebo) & atorvastatin 20mg
11409825|NCT01970215|Active Comparator|Group 7|TA-8995 10mg & atorvastatin 20mg
11409826|NCT01970215|Active Comparator|Group 8|TA-8995 0mg (placebo) & rosuvastatin 10mg
11409827|NCT01970215|Active Comparator|Group 9|TA-8995 10mg & rosuvastatin 10mg
11409828|NCT01970202|Active Comparator|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
11409829|NCT01970202|Active Comparator|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
11409830|NCT01970202|Other|Control|no treatment
11409831|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. < 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
11409832|NCT01970176|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
11409833|NCT01970176|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
11409834|NCT01970163|Experimental|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
11409835|NCT01970163|Placebo Comparator|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
11409836|NCT01970163|Active Comparator|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
11409837|NCT01970150|Experimental|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
11409838|NCT01970137|Experimental|KPS-0373|
11409839|NCT01970124|Experimental|KPS-0373|
11409840|NCT01970111|Experimental|KPS-0373|
11409841|NCT01970098|Experimental|KPS-0373|
11409842|NCT01970098|Placebo Comparator|Placebo|
11409843|NCT01970072|Experimental|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
11409844|NCT01970072|Experimental|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
11409845|NCT01970072|Experimental|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
11409846|NCT01970072|Experimental|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
11409847|NCT01970072|Experimental|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
11409848|NCT01970072|Experimental|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
11409849|NCT01970072|Experimental|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
11409850|NCT01970072|Experimental|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
11409851|NCT01970072|Experimental|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
11409852|NCT01970072|Experimental|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
11409853|NCT01970072|Active Comparator|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
11409854|NCT01970059|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
11409855|NCT01970059|Active Comparator|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
11409856|NCT01970046|Placebo Comparator|Placebo/Metformin|
11409857|NCT01970046|Experimental|SP2086 (50mg b.i.d)/Metformin|
11409858|NCT01970046|Experimental|SP2086 (50mg q.d.)/Metformin|
11409859|NCT01970033|Placebo Comparator|Placebo|
11409860|NCT01970033|Experimental|SP2086 50 mg b.i.d|
11409861|NCT01970033|Experimental|SP2086 100 mg q.d.|
11409862|NCT01970020|Experimental|JNJ-38518168|
11409863|NCT01970007|Experimental|Zilver Vena Venous Stent|
11409864|NCT01969994|Experimental|Controlled dietary background & (-)-[2-14C]epicatechin intake|
11409865|NCT01969981||PICC placement|
11409866|NCT01969968|Other|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
11409867|NCT01969968|Other|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
11409871|NCT01969942|Experimental|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
11409872|NCT01969929|Active Comparator|20G|20G vitrectomy with scleral and conjunctival sutures for closure
11409873|NCT01969929|Active Comparator|23G|23G transconjunctival sutureless vitrectomy
11409874|NCT01969916|Other|Regadenoson|
11409875|NCT01969903|Experimental|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
11409876|NCT01969903|Experimental|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
11409877|NCT01969903|Experimental|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
11409878|NCT01969890|Experimental|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
11409879|NCT01969890|No Intervention|standard therapy|Standard therapy
11409880|NCT01969877|Experimental|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
11409881|NCT01969877|Experimental|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
11409882|NCT01969877|Experimental|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
11409883|NCT01969877|Experimental|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
11409884|NCT01969864|Experimental|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
11409885|NCT01969864|Experimental|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
11409886|NCT01969864|Placebo Comparator|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
11409887|NCT01969851|Experimental|Lacosamide|
11409888|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
11409889|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
11409890|NCT01969825|Experimental|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
11409891|NCT01969825|No Intervention|No massage|Normal protocol for semen collection prior to intrauterine insemination.
11409892|NCT01969812|Experimental|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
11409893|NCT01969812|Active Comparator|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
11409894|NCT01969799|Experimental|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
11409895|NCT01969799|Placebo Comparator|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
11409896|NCT01969786|Experimental|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
11409897|NCT01969786|No Intervention|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
11409898|NCT01969773|Experimental|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
11409899|NCT01969773|Placebo Comparator|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
11409900|NCT01969760|No Intervention|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
11409901|NCT01969760|Experimental|Healthy Families DC Program|Healthy Families DC Program
11409902|NCT01969747|Experimental|Empagliflozin low|Empagliflozin low once daily
11409903|NCT01969747|Experimental|Empagliflozin medium|Empagliflozin medium once daily
11409904|NCT01969747|Experimental|Empagliflozin high|Empagliflozin high once daily
11409905|NCT01969747|Placebo Comparator|Placebo|Placebo once daily
11409906|NCT01969734|Experimental|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
11409907|NCT01969721|Experimental|T+O FDC dosage 1|Low dose
11409908|NCT01969721|Experimental|T+O FDC dosage 2|High dose
11409909|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 1|Low dose
11409910|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 2|High dose
11409911|NCT01969708|Active Comparator|aflibercept|2.0 mg aflibercept every 4 weeks
11409912|NCT01969708|Active Comparator|bevacizumab|1.25 mg bevacizumab every 4 weeks
11409913|NCT01969695|Experimental|ABT-199|ABT-199 monotherapy
11409926|NCT01969630|Active Comparator|PEB|PEB angioplasty plus provisional nitinol stent implantation
11409927|NCT01969630|Experimental|PES|Systematic PES angioplasty
11409928|NCT01969617|Experimental|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
11409929|NCT01969617|Placebo Comparator|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
11409930|NCT01969604|Experimental|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
11409931|NCT01969604|No Intervention|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
11409932|NCT01969591|Experimental|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
11409933|NCT01969591|Other|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
11409934|NCT01969578|Active Comparator|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel
~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
11409935|NCT01969578|Experimental|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin
~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
11409936|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
11409937|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
11409938|NCT01969539|Experimental|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
11409939|NCT01969539|Experimental|Combivent Respimat - ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R via ventilator adapter
11409940|NCT01969526|Experimental|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
11409941|NCT01969526|No Intervention|No intervention|Usual care
11409942|NCT01969513|Experimental|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
11409943|NCT01969513|Sham Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
11409944|NCT01969500|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
11409945|NCT01969500|Experimental|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
11409946|NCT01969487|Experimental|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
11409947|NCT01969487|No Intervention|No preoperative warm-up|
11409948|NCT01969474|Experimental|Cannabis|Treatment with a Cannabis capsule
11409949|NCT01969474|Placebo Comparator|Placebo|Placebo
11409950|NCT01969461|Experimental|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
11409951|NCT01969461|Active Comparator|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
11409952|NCT01969448|Active Comparator|Inframammary Fold Incision Cohort|"Inframammary fold incision which is in the crease under the breast.
~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)
~Intraoperatively prior to mastectomy
~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)
~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
11409953|NCT01969448|Active Comparator|Lateral Radial Incision Cohort|"Lateral radial incision
~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)
~Intraoperatively prior to mastectomy
~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)
~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
11410034|NCT01968902|Placebo Comparator|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
11410402|NCT01966614|Placebo Comparator|Placebo|Placebo (Vehicle-only injection)
11409954|NCT01969448|Other|Non-Randomized Cohort|"Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.
~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)
~Intraoperatively prior to mastectomy
~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)
~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
11409955|NCT01969435|Experimental|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"Day -7, carmustine intravenous (IV) infusion
~Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day
~Day -2, melphalan HCl (propylene glycol-free)(IV) infusion
~Day 0, stem cell transplant."
11409956|NCT01969422||observation group|observation
11409957|NCT01969409|Placebo Comparator|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
11409958|NCT01969409|Experimental|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
11409959|NCT01969396|Experimental|SonoBiopsy Catheter|
11409960|NCT01969396|Active Comparator|Endometrial biopsy catheter|
11409961|NCT01969383|Experimental|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
11409962|NCT01969370|Experimental|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
11409963|NCT01969370|No Intervention|Control|No option to request non-medically actionable incidental information
11409964|NCT01969357|Placebo Comparator|Placebo|
11409965|NCT01969357|Experimental|50 mg SP2086|
11409966|NCT01969357|Experimental|100 mg SP2086|
11409967|NCT01969357|Experimental|200 mg SP2086|
11409968|NCT01969357|Active Comparator|100 mg Sitagliptin|
11409969|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
11409970|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
11409971|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
11409972|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
11409973|NCT01969331|Placebo Comparator|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.
~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
11409974|NCT01969331|Active Comparator|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
11409975|NCT01969318|Placebo Comparator|Placebo/Metformin|
11409976|NCT01969318|Experimental|SP2086 (50mg q.d)/Metformin|
11409977|NCT01969318|Experimental|SP2086 (100mg q.d.)/Metformin|
11409978|NCT01969305|Experimental|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
11409979|NCT01969305|Experimental|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
11409980|NCT01969292|Experimental|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
11409981|NCT01969292|Sham Comparator|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
11409982|NCT01969292|No Intervention|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
11409983|NCT01969266|Experimental|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
11409984|NCT01969240|Active Comparator|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
11409985|NCT01969240|No Intervention|Usual Care|Patients randomized to the usual care arm (no decision aid used)
11409986|NCT01969227|Experimental|Cohort|Adult mechanically ventilated patients who are deemed eligible for a spontaneous breathing trial and are candidates to receive subanesthetic ketamine by the primary critical care team.
11409987|NCT01969214|Experimental|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally
~1 tablet, 3 times a day"
11409988|NCT01969201|Experimental|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
11409989|NCT01969201|Active Comparator|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
11409990|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
11409991|NCT01969175|Experimental|Intervention Diet|
11409992|NCT01969175|Placebo Comparator|Control|
11409993|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
11410035|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
11410036|NCT01968876|No Intervention|Standard Care|The control group will not use the medication adherence app
11409994|NCT01969149|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.
~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .
~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
11409995|NCT01969149|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.
~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.
~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
11409996|NCT01969136|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
11409997|NCT01969136|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
11409998|NCT01969136|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
11409999|NCT01969123|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
11410000|NCT01969123|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
11410001|NCT01969123|Placebo Comparator|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
11410002|NCT01969110|Active Comparator|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
11410003|NCT01969110|Active Comparator|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
11410004|NCT01969097|Experimental|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
11410005|NCT01969097|Active Comparator|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
11410006|NCT01969097|Sham Comparator|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
11410007|NCT01969084|Experimental|Linagliptin|Subjects given Linagliptin
11410008|NCT01969084|Placebo Comparator|Sugar pill|Subjects given sugar pill/placebo
11410009|NCT01969071|Active Comparator|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
11410010|NCT01969071|Active Comparator|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
11410011|NCT01969058|Active Comparator|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
11410012|NCT01969058|No Intervention|No study treatment Arm|No Isotretinoin treatment
11410013|NCT01969045|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
11410014|NCT01969045|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
11410015|NCT01969032|Experimental|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
11410016|NCT01969019|Active Comparator|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
11410017|NCT01969019|Active Comparator|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
11410018|NCT01969006|Experimental|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
11410019|NCT01969006|Placebo Comparator|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
11410020|NCT01968993|Experimental|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
11410021|NCT01968980|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
11410022|NCT01968980|Placebo Comparator|Placebo|
11410023|NCT01968967|Experimental|Bococizumab (PF-04950615; RN316)|
11410024|NCT01968967|Placebo Comparator|Placebo|
11410025|NCT01968954|Experimental|Bococizumab (PF-04950615;RN316)|
11410026|NCT01968954|Placebo Comparator|Placebo|
11410027|NCT01968941|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT)
11410028|NCT01968941|Active Comparator|Conventional Radiotherapy|Conventional Radiotherapy (CRT)
11410029|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
11410030|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
11410031|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
11410032|NCT01968915|Experimental|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
11410033|NCT01968902|Active Comparator|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
11410403|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
11410037|NCT01968876|Experimental|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
11410038|NCT01968850|No Intervention|no bone anti-resorptive therapy|(standard of care)
11410039|NCT01968850|Experimental|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
11410040|NCT01968850|Experimental|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
11410041|NCT01968837|No Intervention|Cervical cancer screening|
11410042|NCT01968824|No Intervention|General Anesthesia|general anesthesia only
11410043|NCT01968824|Experimental|Brachial Plexus Nerve Block|brachial plexus nerve block
11410044|NCT01968811|Experimental|Avance foam, abdominal dressing kit|
11410045|NCT01968798|Active Comparator|Aspirin|100 mg enteric-coated aspirin
11410046|NCT01968798|Placebo Comparator|Placebo|Placebo
11410047|NCT01968785|Active Comparator|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
11410048|NCT01968785|Active Comparator|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
11410049|NCT01968772|Other|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
11410050|NCT01968759|Active Comparator|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
11410051|NCT01968759|Experimental|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
11410052|NCT01968746||ED patients with suspected infection|
11410053|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
11410054|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
11410055|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
11410056|NCT01968707|Active Comparator|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
11410057|NCT01968707|Placebo Comparator|Normal Saline|0.9% normal saline with applicator
11410058|NCT01968707|Experimental|3M CHG/IPA Prep Tint 10.5-mL|Chlorhexidine gluconate 2% / Isopropyl alcohol 70% 10.5 mL
11410059|NCT01968707|Experimental|3M CHG/IPA Prep Tint 26-mL|Chlorhexidine gluconate 2% / Isopropyl alcohol 70% 26 mL
11410060|NCT01968694|Experimental|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
11410061|NCT01968694|Placebo Comparator|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
11410062|NCT01968681|Experimental|Alexandrite laser treatment|
11410063|NCT01968668|Experimental|BAY94-8862 (1.25 mg)|
11410064|NCT01968668|Experimental|BAY94-8862 (2.5 mg)|
11410065|NCT01968668|Experimental|BAY94-8862 (5 mg )|
11410066|NCT01968668|Experimental|BAY94-8862 (7.5 mg)|
11410067|NCT01968668|Experimental|BAY94-8862 (10 mg)|
11410068|NCT01968668|Placebo Comparator|Placebo|
11410069|NCT01968668|Experimental|BAY 94-8862 (15 mg)|
11410070|NCT01968668|Experimental|BAY 94-8862 (20 mg)|
11410071|NCT01968642|Experimental|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
11410072|NCT01968642|No Intervention|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
11410073|NCT01968629|Experimental|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
11410074|NCT01968616|Other|Intravitreal Lucentis 0.5mg|One arm
11410075|NCT01968590|Active Comparator|cholecalciferol 600 IU|cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
11410076|NCT01968590|Active Comparator|cholecalciferol 4,000 IU|Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
11410077|NCT01968577|Experimental|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
11410078|NCT01968577|No Intervention|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
11410079|NCT01968564|Experimental|High-dose curcumin pill|
11410080|NCT01968564|Experimental|Low-dose curcumin pill|
11410081|NCT01968564|Placebo Comparator|Placebo pill|
11410082|NCT01968551|Experimental|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.
~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
11410083|NCT01968551|Experimental|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
11410404|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
11410084|NCT01968551|Active Comparator|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
11410085|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
11410086|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
11410087|NCT01968525|Experimental|Group A|the hemoglobin is >12g/L in patients from group A.
11410088|NCT01968525|Experimental|Group B|Hb 9-12g/L
11410089|NCT01968525|Experimental|Group C|Hb<9g/L
11410090|NCT01968512|Experimental|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
11410091|NCT01968512|Sham Comparator|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
11410092|NCT01968499||All recruited patients|Patients who receive stent implantation and aged >18 years.
11410093|NCT01968486|Experimental|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
11410094|NCT01968486|Experimental|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
11410095|NCT01968486|Experimental|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
11410096|NCT01968473|Experimental|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
11410097|NCT01968460|Experimental|P2B001 Treatment A|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
11410098|NCT01968460|Experimental|P2B001 Treatment B|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
11410099|NCT01968460|Placebo Comparator|Placebo|Placebo once daily for 12 weeks.
11410100|NCT01968447|Experimental|hypocapnia|arterial pCO2 of 3.5 kPa
11410101|NCT01968447|Active Comparator|normocapnia|arterial PCO2 of 6.5-7.0 kPa
11410102|NCT01968434|Experimental|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.
~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
11410103|NCT01968434|Active Comparator|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
11410104|NCT01968421|Experimental|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
11410105|NCT01968421|Placebo Comparator|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
11410106|NCT01968408|Active Comparator|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)
~ARM I: Rotavirus vaccinated patients
~ARM II: Non-rotavirus vaccinated patients"
11410107|NCT01968408|Placebo Comparator|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded
~for the duration of hospitalization"
11410108|NCT01968395|Other|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
11410109|NCT01968382|Experimental|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
11410110|NCT01968382|Experimental|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
11410111|NCT01968382|Placebo Comparator|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
11410112|NCT01968369|Active Comparator|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
11410113|NCT01968369|Placebo Comparator|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
11410114|NCT01968356|Experimental|3M CHG/IPA Prep Colorless|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL applicator
11410115|NCT01968356|Experimental|3M CHG/IPA Prep Tint|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL applicator
11410116|NCT01968356|Active Comparator|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL applicator
11410117|NCT01968356|Placebo Comparator|Normal Saline|0.9% normal saline with applicator
11410118|NCT01968343|Experimental|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
11410119|NCT01968343|Active Comparator|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
11410120|NCT01968330|Experimental|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
11410405|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
11410121|NCT01968330|No Intervention|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
11410122|NCT01968317|Experimental|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11410123|NCT01968317|Experimental|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
11410124|NCT01968304|No Intervention|Iron status follow up|
11410125|NCT01968291|Experimental|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
11410126|NCT01968291|No Intervention|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
11410127|NCT01968278|Experimental|Baked milk group|BM (baked milk)
11410128|NCT01968278|No Intervention|Control|IgE-cow's milk allergic patients not treated with OIT
11410129|NCT01968265|Placebo Comparator|Placebo|
11410130|NCT01968265|Active Comparator|ISIS-GCCRRx|
11410131|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
11410132|NCT01968239|Experimental|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
11410133|NCT01968239|Active Comparator|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
11410134|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
11410135|NCT01968213|Experimental|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
11410136|NCT01968213|Placebo Comparator|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
11410137|NCT01968200|Experimental|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
11410138|NCT01968200|Experimental|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
11410139|NCT01968187|Experimental|FE 992097|
11410140|NCT01968187|Placebo Comparator|Placebo|
11410141|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
11410142|NCT01968161|Other|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
11410143|NCT01968135|Placebo Comparator|Sugar Pill|Placebo Sugar Pill
11410144|NCT01968135|Experimental|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
11410145|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of <140mmHg (or <130mmHg in the diabetes patients); and LDL <70mg/dl (1.81mmol/L) or drop by 50%.
11410146|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
11410147|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
11410148|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
11410149|NCT01968096|No Intervention|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
11410150|NCT01968096|No Intervention|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
11410151|NCT01968096|No Intervention|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
11410152|NCT01968096|Experimental|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
11410153|NCT01968096|Experimental|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
11410154|NCT01968096|No Intervention|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
11410155|NCT01968083|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
11410156|NCT01968083|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
11410157|NCT01968070|Experimental|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
11410158|NCT01968070|Placebo Comparator|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
11410159|NCT01968070|Experimental|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
11410160|NCT01968070|Placebo Comparator|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
11410161|NCT01968070|Active Comparator|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
11410162|NCT01968057|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
11410163|NCT01968057|Experimental|Baricitinib + Ciclosporin|Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4
11410164|NCT01968044|Experimental|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
11410165|NCT01968044|Other|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
11410166|NCT01968031|Experimental|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:
~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
11410167|NCT01968031|Experimental|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:
~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
11410168|NCT01968031|Placebo Comparator|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:
~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
11410169|NCT01968018|Experimental|Tramadol HCI + acetaminophen|
11410170|NCT01968005|Placebo Comparator|Placebo|Therapy with placebo
11410171|NCT01968005|Experimental|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
11410172|NCT01967992|Active Comparator|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
11410173|NCT01967992|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.
~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
11410174|NCT01967979|Experimental|Cohort 1 (Itraconazole DDI)|
11410175|NCT01967979|Experimental|Cohort 2 (Fluoxetine DDI)|
11410176|NCT01967966|Experimental|Bioavailability|
11410177|NCT01967966|Experimental|Elimination & PK|
11410178|NCT01967953|No Intervention|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.
~Events: lung procurement, cold storage on ice, transplantation."
11410179|NCT01967953|Experimental|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).
~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
11410180|NCT01967940|Experimental|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
11410181|NCT01967940|Experimental|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
11410182|NCT01967940|Placebo Comparator|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
11410183|NCT01967940|Experimental|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a > 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
11410184|NCT01967927|Experimental|GRID 18F-MISO|
11410185|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
11410186|NCT01967901|Active Comparator|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.
~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
11410187|NCT01967901|Active Comparator|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
11410188|NCT01967901|Active Comparator|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
11410189|NCT01967901|Active Comparator|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
11410190|NCT01967888|Experimental|Reparixin|Solution for intravenous (IV) infusion with active compound
11410191|NCT01967888|Placebo Comparator|Placebo|Physiologic solution
11410192|NCT01967875|Active Comparator|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
11410193|NCT01967875|Experimental|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
11410194|NCT01967875|Active Comparator|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
11410406|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
11410195|NCT01967862|Experimental|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
11410196|NCT01967849|Other|Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
11410197|NCT01967849|Other|Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
11410198|NCT01967836|Other|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
11410199|NCT01967823|Experimental|1/Experimental Therapy|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine TCR transduced PBL + high-dose aldesleukin
11410200|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
11410201|NCT01967810|Experimental|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
11410202|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
11410203|NCT01967797|Experimental|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
11410204|NCT01967797|No Intervention|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
11410205|NCT01967784|Experimental|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
11410206|NCT01967771|Experimental|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
11410207|NCT01967758|Experimental|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
11410208|NCT01967758|Experimental|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
11410209|NCT01967758|Experimental|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
11410210|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
11410211|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
11410212|NCT01967732|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of CC)."
11410213|NCT01967732|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of CC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
11410214|NCT01967732|Active Comparator|THS 2.2 then NNS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NNS)"
11410215|NCT01967732|Active Comparator|NNS then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NNS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
11410216|NCT01967719|Active Comparator|mTHS 2.2 then mCC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mCC)."
11410217|NCT01967719|Active Comparator|mCC then mTHS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mCC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
11410218|NCT01967719|Active Comparator|mTHS 2.2 then NNS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NNS)"
11410219|NCT01967719|Active Comparator|NNS then mTHS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NNS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
11410220|NCT01967706|Active Comparator|mTHS then mCC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mCC)."
11410221|NCT01967706|Active Comparator|mCC then mTHS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mCC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS)."
11410222|NCT01967706|Active Comparator|mTHS then NRT|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of mTHS)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NRT)"
11410223|NCT01967706|Active Comparator|NRT then mTHS|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NRT)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of mTHS)."
11410224|NCT01967680|Active Comparator|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
11410225|NCT01967680|Experimental|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.
~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.
~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
11410226|NCT01967667|Experimental|Liposomal glutathione|dose steps
11410227|NCT01967667|Placebo Comparator|Placebo|dose steps
11410228|NCT01967654|Experimental|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
11410229|NCT01967654|Experimental|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
11410230|NCT01967641|Experimental|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
11410231|NCT01967628|Experimental|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
11410232|NCT01967628|Placebo Comparator|Sugar capsule|Placebo comparator made of sugar in a capsule
11410233|NCT01967589|Experimental|DC (dosing condition)|Escalation design.
11410234|NCT01967589|Experimental|Oral A|Escalation design. Planned end-dose is 5 mg.
11410235|NCT01967589|Experimental|Oral B|Escalation design. Planned end-dose is 10 mg.
11410236|NCT01967589|Experimental|Oral C|Escalation design. Planned end-dose is 20 mg.
11410237|NCT01967576|Experimental|1/Arm 1-Axitinib|Axitinib 5 mg twice a day on a 28-day cycle
11410238|NCT01967563||overweight and class I obese adult male volunteers|Adult Male Subjects (18-50) will be recruited in order to determine the effects on energy expenditure of transitioning from an energyand macronutrient-balanced standard baseline diet (50% carbohydrate, 35% fat, 15% protein) to a eucaloric ketogenic diet (5% carbohydrate, 80% fat, 15% protein).
11410239|NCT01967550|Experimental|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
11410240|NCT01967550|Placebo Comparator|Placebo|Vehicle control
11410241|NCT01967537|Experimental|68Gallium DOTATATE imaging|68Gallium DOTATATE imaging
11410242|NCT01967524|Experimental|botulinum toxin A + ropivacaïne|
11410243|NCT01967524|Active Comparator|Ropivacaïne|
11410244|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
11410245|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
11410246|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
11410247|NCT01967511||Healthy control subjects|
11410248|NCT01967498|Experimental|montelukast|this arm will receive montelukast as the active intervention of the study
11410249|NCT01967498|Placebo Comparator|placebo|
11410250|NCT01967485|Experimental|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
11410251|NCT01967485|Active Comparator|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
11410252|NCT01967472|Active Comparator|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.
~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
11410253|NCT01967472|Active Comparator|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.
~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
11410254|NCT01967459|Active Comparator|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
11410255|NCT01967459|Active Comparator|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
11410256|NCT01967433|Experimental|Diphenhydramine|Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
11410257|NCT01967433|Placebo Comparator|Placebo|0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
11410258|NCT01967420|Experimental|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
11410259|NCT01967420|Active Comparator|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
11410260|NCT01967407|Experimental|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
11410261|NCT01967394|Experimental|Intervention County|Use of internet based social marketing intervention
11410262|NCT01967394|Placebo Comparator|Control County|No use of social media
11410263|NCT01967381|Placebo Comparator|Arm 1|Subjects will be maintained on oral placebo.
11410264|NCT01967381|Experimental|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
11410265|NCT01967381|Experimental|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
11410266|NCT01967381|Experimental|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
11410267|NCT01967368|Experimental|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
11410268|NCT01967368|Active Comparator|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
11410269|NCT01967355|Experimental|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
11410270|NCT01967342|Experimental|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
11410271|NCT01967342|Experimental|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
11410272|NCT01967342|Active Comparator|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
11410273|NCT01967329|Active Comparator|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
~One of two treatments randomly assigned to treatment naive participants in Aklavik"
11410274|NCT01967329|Active Comparator|Sequential, treatment naive|"Sequential Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
11410275|NCT01967329|Active Comparator|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:
~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson"
11410276|NCT01967329|Active Comparator|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
11410277|NCT01967329|Active Comparator|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:
~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
11410278|NCT01967329|Active Comparator|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:
~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
11410279|NCT01967329|Active Comparator|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:
~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
11410280|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
11410281|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
11410282|NCT01967290|Experimental|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
11410283|NCT01967290|Active Comparator|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
11410284|NCT01967277|Placebo Comparator|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
11410285|NCT01967277|Active Comparator|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
11410286|NCT01967264|Experimental|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
11410287|NCT01967264|Experimental|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
11410288|NCT01967264|Experimental|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
11410289|NCT01967264|Placebo Comparator|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
11410290|NCT01967251|Experimental|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
11410291|NCT01967251|Experimental|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
11410292|NCT01967251|Experimental|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
11410293|NCT01967251|Placebo Comparator|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
11410294|NCT01967238|Active Comparator|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
11410295|NCT01967238|Active Comparator|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
11410296|NCT01967238|Active Comparator|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
11410297|NCT01967225|Experimental|Tedizolid Phosphate (Sivextro, BAY1192631)|Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
11410298|NCT01967225|Active Comparator|Linezolid|Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
11410299|NCT01967212|Experimental|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
11410300|NCT01967212|Active Comparator|Swallow training without biofeedback|
11410301|NCT01967199|Active Comparator|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
11410302|NCT01967199|Experimental|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
11410303|NCT01967186|Experimental|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
11410304|NCT01967186|Experimental|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
11410305|NCT01967186|Experimental|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
11410306|NCT01967186|Active Comparator|Kidney transplantation only|Subject that only undergoes kidney transplantation
11410307|NCT01967173|Experimental|Crossover sequence 1|Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
11410308|NCT01967173|Experimental|Crossover sequence 2|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
11410309|NCT01967173|Experimental|Crossover sequence 3|Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
11410310|NCT01967173|Experimental|Crossover sequence 4|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
11410311|NCT01967173|Experimental|Crossover sequence 5|Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
11410312|NCT01967173|Experimental|Crossover sequence 6|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
11410313|NCT01967173|Experimental|Crossover sequence 7|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
11410314|NCT01967173|Experimental|Crossover sequence 8|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
11410315|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
11410316|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
11410317|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
11410318|NCT01967147|Experimental|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
11410319|NCT01967147|Active Comparator|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
11410320|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Neg|LTBI Negative 3 Doses
11410321|NCT01967134|Experimental|H56:IC31 (15 ug H56) LTBI Pos|LTBI Positive 3 Doses
11410322|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Pos|LTBI Positive 3 Doses
11410323|NCT01967121|Experimental|'Compex unit's Active Recovery® program'|The Compex electrical stimulation system utilized in this study is intended for external application with electrodes to create a muscular contraction and help enhance recovery after eccentric muscular activity.
11410324|NCT01967121|Other|Ice application|A randomized pre and post-test research design will be used to compare three interventions (control, ice, compex) to alleviate the physical symptoms of delayed-onset muscle soreness (DOMS).
11410325|NCT01967121|No Intervention|Control|This is a control group where subjects will not perform an intervention.
11410326|NCT01967108|Experimental|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
11410327|NCT01967108|No Intervention|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
11410328|NCT01967095|Experimental|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.
~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
11410329|NCT01967082|Experimental|Prevention (focus group, APPSPIRE app, survey)|Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
11410330|NCT01967069|Active Comparator|DFD01 Spray|DFD01 Spray twice daily
11410331|NCT01967069|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily
11410332|NCT01967043|Experimental|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle
~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
11410333|NCT01967043|Experimental|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel
~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
11410334|NCT01967030||Women with recent GDM pregnancy|The study cohort includes women who had gestational diabetes mellitus (GDM) in their index pregnancy for study enrollment. There are two pre-defined groups: 1) women who breastfeed intensively during the first 4 months postpartum, and 2) women who mostly fed formula during the first 4 months postpartum. The study enrolled women into these pre-defined groups, but some women transitioned into mixed feeding groups after enrollment.
11410335|NCT01967017|Experimental|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
11410336|NCT01967017|Placebo Comparator|Placebo|paracervical block using 15 mL of bacteriostatic saline
11410337|NCT01967004|Experimental|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
11410338|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
11410339|NCT01966978|Active Comparator|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
11410340|NCT01966978|Active Comparator|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
11410341|NCT01966965|Experimental|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
11410342|NCT01966965|Active Comparator|NEDAX|FOLLOWING THE LEAFLET TREATMENT
11410343|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
11410344|NCT01966939||Surgery|Craniotomy or Craniectomy
11410345|NCT01966939||Control|age, gender and teeth condition matched
11410346|NCT01966926|Experimental|Daily Weight Tracking|weighing frequency instructions and tips
11410347|NCT01966926|Experimental|Weekly Weight Tracking|weighing frequency instructions and tips
11410348|NCT01966913|Experimental|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:
~A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.
~The ICE chemotherapy regimen:
~Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,
~Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,
~Ifosfamide, 2400 mg/m²/d,
~For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
11410349|NCT01966900|Active Comparator|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF
~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
11410350|NCT01966900|Active Comparator|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF
~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
11410351|NCT01966887|Experimental|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
11410352|NCT01966887|Placebo Comparator|Placebo; single intracoronary infusion|Placebo comparator
11410353|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
11410354|NCT01966861|No Intervention|usual care|Weaning as protcolised by the units' daily practice (SBT)
11410355|NCT01966861|Experimental|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
11410356|NCT01966848|Active Comparator|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
11410357|NCT01966848|Active Comparator|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
11410399|NCT01966640|Experimental|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
11410400|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
11410401|NCT01966614|Experimental|PRX302|PRX302 injection
11410358|NCT01966835|Experimental|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
11410359|NCT01966835|No Intervention|control group|no exercise intervention
11410360|NCT01966822|Experimental|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
11410361|NCT01966822|Active Comparator|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
11410362|NCT01966809|Experimental|Photofrin photodynamic therapy.|Photofrin photodynamic therapy. Drug - 2.5 mg/kg, light - 240 mJ/cm2.
11410363|NCT01966796||PSI II|PSI less than 70 or equal to 70
11410364|NCT01966796||PSI III|PSI 70-90
11410365|NCT01966796||PSI IV|PSI 90-130
11410366|NCT01966796||PSI V|PSI more than 130
11410367|NCT01966783|Experimental|Budesonide dosage 1|Budesonide 2 mg suppository
11410368|NCT01966783|Experimental|Budesonide dosage 2|Budesonide 4 mg suppository
11410369|NCT01966783|Active Comparator|Mesalazine|Mesalazine 1g suppository
11410370|NCT01966783|Experimental|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
11410371|NCT01966770|Active Comparator|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
11410372|NCT01966770|Active Comparator|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
11410373|NCT01966770|Active Comparator|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
11410374|NCT01966770|Active Comparator|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
11410375|NCT01966770|Active Comparator|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
11410376|NCT01966770|Active Comparator|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
11410377|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
11410378|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
11410379|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
11410380|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
11410381|NCT01966731|Experimental|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
11410382|NCT01966718|Experimental|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
11410383|NCT01966705|Experimental|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
11410384|NCT01966705|Experimental|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
11410385|NCT01966705|Experimental|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
11410386|NCT01966705|No Intervention|Waiting-list condition|No intervention: 12 weeks
11410387|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 1|"Fluticasone Propionate Drug formulation 1 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.
~See Formulation Development in Detailed Description for details regarding differences in formulations"
11410388|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 2|"Fluticasone Propionate Drug formulation 2 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.
~See Formulation Development in Detailed Description for details regarding differences in formulations"
11410389|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3|"Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.
~See Formulation Development in Detailed Description for details regarding differences in formulations"
11410390|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3*|Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose. * (The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
11410391|NCT01966679|Active Comparator|Double-blind (active versus placebo)|AZD7325 versus placebo
11410392|NCT01966679|Placebo Comparator|Placebo|
11410393|NCT01966666|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
11410394|NCT01966666|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
11410395|NCT01966666|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
11410396|NCT01966666|Placebo Comparator|Placebo|
11410397|NCT01966653|Active Comparator|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
11410398|NCT01966653|Active Comparator|fosfomycin|A single 3g dose of oral fosfomycin will be given.
11410407|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
11410408|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
11410409|NCT01966575|Experimental|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
11410410|NCT01966575|No Intervention|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
11410411|NCT01966562|Experimental|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
11410412|NCT01966562|Active Comparator|MC TRAINING|MULTICOMPONENT TRAINING
11410413|NCT01966562|No Intervention|CG|Control group
11410414|NCT01966549|Experimental|CNTO 6785|
11410415|NCT01966549|Placebo Comparator|Placebo|
11410416|NCT01966536|Experimental|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
11410417|NCT01966523|Experimental|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
11410418|NCT01966523|Other|Usual Care|Residents will receive usual care for infections
11410419|NCT01966510|Experimental|Cord blood transplantation|Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
11410420|NCT01966497||Core study therapy|"idarubicin for both induction and consolidation courses
~if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
11410421|NCT01966484|Active Comparator|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
11410422|NCT01966484|Active Comparator|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
11410423|NCT01966471|Active Comparator|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
11410424|NCT01966471|Experimental|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
11410425|NCT01966458|Experimental|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
11410426|NCT01966458|Active Comparator|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
11410427|NCT01966445|Experimental|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
11410428|NCT01966445|Experimental|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
11410429|NCT01966432|Other|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:
~Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.
~Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.
~Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
11410430|NCT01966419|Active Comparator|ornithine phenylacetate|continuous intravenous infusion of ornithine phenylacetate for up to 5 days on top of standard of care
11410431|NCT01966419|Placebo Comparator|placebo intravenous infusion|continuous intravenous infusion of placebo up to 5 days on top of standard of care
11410432|NCT01966406|Experimental|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
11410433|NCT01966406|Active Comparator|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
11410434|NCT01966393|Active Comparator|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
11410435|NCT01966393|Active Comparator|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
11410436|NCT01966393|Active Comparator|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
11410437|NCT01966380|Experimental|Device, dressing|Intervention: Device, Leia dressing
11410438|NCT01966380|Active Comparator|Dressing , device|Intervention: Device: Hydroactive surgical dressing
11410439|NCT01966367|Experimental|CliniMACS PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMACS (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
11410813|NCT01963663|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
11410440|NCT01966354|Experimental|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach
~Long axis, in-plane needle:
~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
11410441|NCT01966354|Experimental|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach
~Short axis, out-of-plane needle:
~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
11410442|NCT01966354|Experimental|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach
~Oblique axis, in-plane needle:
~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
11410443|NCT01966341|Active Comparator|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
11410444|NCT01966341|Experimental|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
11410445|NCT01966328|Experimental|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
11410446|NCT01966328|Active Comparator|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
11410447|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.
~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
11410448|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.
~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
11410449|NCT01966302|Experimental|Beraprost open label|Compassionate use access to open label BPS-314d-MR
11410450|NCT01966289|Experimental|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
11410451|NCT01966289|Experimental|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
11410452|NCT01966289|Experimental|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
11410453|NCT01966289|Experimental|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
11410454|NCT01966276|Experimental|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.
~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
11410455|NCT01966276|Placebo Comparator|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
11410456|NCT01966263|Active Comparator|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
11410457|NCT01966263|Active Comparator|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.
~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
11410458|NCT01966250|Experimental|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
11410459|NCT01966250|Active Comparator|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
11410460|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
11410461|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
11410497|NCT01965938|Other|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
11410739|NCT01964170|Experimental|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
11410814|NCT01963650||No treatment|
11410462|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.
~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
11410463|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.
~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
11410464|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.
~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
11410465|NCT01966198|Experimental|all patients|tilt
11410466|NCT01966185|No Intervention|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
11410467|NCT01966185|Experimental|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
11410468|NCT01966172|Experimental|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
11410469|NCT01966172|Active Comparator|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
11410470|NCT01966159|Experimental|SYNERGY Investigational Device|SYNERGY Stent System
11410471|NCT01966159|Active Comparator|PE Plus Investigational Device|PE Plus Stent System
11410472|NCT01966146|Experimental|TAVI|Echocardiography after TAVI
11410473|NCT01966146|Experimental|MitraClip|Echocardiography after MitraClip procedure
11410474|NCT01966133|No Intervention|Control|no interventions were assigned
11410475|NCT01966133|Active Comparator|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
11410476|NCT01966120|Active Comparator|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
11410477|NCT01966120|Placebo Comparator|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
11410478|NCT01966107|Experimental|Aclidinium Bromide|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
11410479|NCT01966107|Placebo Comparator|Placebo|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
11410480|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
11410481|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
11410482|NCT01966081|Other|Cases|
11410483|NCT01966081|Other|controls|
11410484|NCT01966068|Experimental|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
11410485|NCT01966055|Experimental|Solithromycin|
11410486|NCT01966042|Experimental|Stem Cell Therapy|"All subjects enrolled in the study underwent:
~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
11410487|NCT01966029|Experimental|Treatment|All patients receive treatment with BMN 110
11410488|NCT01966016|Experimental|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
11410489|NCT01966016|Experimental|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
11410490|NCT01966003|Experimental|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
11410491|NCT01966003|Active Comparator|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
11410492|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
11410493|NCT01965977|Experimental|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
11410494|NCT01965951|Experimental|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
11410495|NCT01965951|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
11410496|NCT01965938|Active Comparator|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
11410498|NCT01965925|Experimental|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
11410499|NCT01965925|Placebo Comparator|Placebo|Subjects will take placebo upon waking once per day.
11410500|NCT01965912|Experimental|Kuvan®|
11410501|NCT01965899|Experimental|Insertable Cardiac Monitor Implant|
11410502|NCT01965886|Active Comparator|Medial approach|Medial parapatellar approach (classic approach)
11410503|NCT01965886|Experimental|Keblish approach|Lateral parapatellar approach (Keblish approach)
11410504|NCT01965873|Experimental|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
11410505|NCT01965873|No Intervention|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
11410506|NCT01965860|Experimental|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module. After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
11410507|NCT01965860|No Intervention|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
11410508|NCT01965847|Active Comparator|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
11410509|NCT01965847|Experimental|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
11410510|NCT01965834|Experimental|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
11410511|NCT01965821|Other|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
11410512|NCT01965821|Other|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
11410513|NCT01965808|Experimental|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
11410514|NCT01965808|Experimental|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
11410515|NCT01965795|Placebo Comparator|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.
~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
11410516|NCT01965795|Experimental|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.
~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
11410517|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
11410518|NCT01965769|Experimental|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
11410519|NCT01965769|No Intervention|gastric residual evaluation|Infants will receive routine gastric residual evaluation
11410520|NCT01965756|Experimental|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
11410521|NCT01965756|Experimental|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
11410522|NCT01965743|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
11410523|NCT01965730|Active Comparator|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
11410524|NCT01965730|Experimental|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
11410740|NCT01964170|Active Comparator|Goserelin|part 1 for 1 year treatment
11410525|NCT01965704|Experimental|Ondansetron|Pregnant Women: ondansetron 8mg intravenously (IV) within 4 hours of delivery. Neonates: ondansetron 0.07 mg/kg given orally every 24 hours starting 4-8 hours after delivery, for up to 5 days (if IV line available in neonate, ondansetron 0.04 mg/kg IV every 24 hours for up to 5 days).
11410526|NCT01965704|Placebo Comparator|Placebo|"Pregnant Women: placebo given intravenously prior to delivery (volume to mimic the IV volume of the ondansetron group).
~Neonates: placebo given orally every 24 hours, starting 4-8 hours after delivery, for up to 5 days with volume to mimic the oral volume of the ondansetron group (if IV line available, placebo may be given IV)."
11410527|NCT01965691|Experimental|Protein intake|Protein intake- Dietary supplement
11410528|NCT01965678|Experimental|OMT|
11410529|NCT01965665|Experimental|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
11410530|NCT01965652|Experimental|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
11410531|NCT01965652|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
11410532|NCT01965639|Experimental|High Risk group|Extension of Care
11410533|NCT01965626|Active Comparator|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days
~HD-DXM (orally at 40 mg daily for 4d )"
11410534|NCT01965626|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
11410535|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
11410536|NCT01965600|Experimental|Cohort 1|
11410537|NCT01965600|Experimental|Cohort 2|
11410538|NCT01965587|Active Comparator|novasure mirena IUS combined|novasure mirena IUS combined therapy
11410539|NCT01965587|Active Comparator|novasure alone|Sole treatment with Novasure
11410540|NCT01965574|Experimental|Single arm|
11410541|NCT01965561|Experimental|CRoC|Use of Combat Ready Clamp (CRoC)
11410542|NCT01965561|Experimental|AAJT|Use of Abdominal Aortic and Junctional Tourniquet
11410543|NCT01965561|Experimental|JETT|Junctional Emergency Treatment Tool
11410544|NCT01965561|Experimental|SJT|SAM Junctional Tourniquet
11410545|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
11410546|NCT01965535|Experimental|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
11410547|NCT01965535|Experimental|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
11410548|NCT01965522|Experimental|Melatonin and Vitamin D|
11410549|NCT01965522|Experimental|Placebo and Vitamin D|
11410550|NCT01965522|Experimental|Melatonin and Placebo|
11410551|NCT01965522|Placebo Comparator|Placebo and Placebo|
11410552|NCT01965509|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
11410553|NCT01965509|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
11410554|NCT01965509|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
11410555|NCT01965496|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
11410556|NCT01965496|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
11410557|NCT01965496|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
11410558|NCT01965483|Experimental|Weekly radiation|once-weekly breast irradiation
11410559|NCT01965470|Experimental|Combination Prevention|"Scale-up of HTC services during 2 annual HTC campaigns, with a target of >90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.
~Scale-up of universal ART for all HIV-infected adults, with a target of >93% of HIV positive adults receiving ART.
~Scale-up of retention in care and adherence interventions, with a target of ensuring that >95% of HIV-infected adults are virally suppressed with HIV-1 RNA <400 copies per ML..
~Scale-up of linkage to MC services, with a target of ensuring >60% of HIV-negative men are circumcised.
~Rapid strengthening of PMTCT services, with a target of >90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery."
11410560|NCT01965470|Active Comparator|Enhanced Care|Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
11410561|NCT01965431|Experimental|BI 207127 + Faldaprevir|Tablets/capsules
11410562|NCT01965431|Active Comparator|Moxifloxacin (Avalox®)|Tablets
11410563|NCT01965431|Experimental|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
11410564|NCT01965418|Active Comparator|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
11410565|NCT01965418|Placebo Comparator|placebo|placebo of Fufang Biejia Ruangan Tablet
11410566|NCT01965405|Experimental|Phase 1: Standard of Care (A)|Brief counseling and bupropion
11410567|NCT01965405|Experimental|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
11410568|NCT01965405|Experimental|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
11410569|NCT01965405|Experimental|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
11410570|NCT01965405|Experimental|Phase 2b: Responders (A)|Bupropion, no additional treatment.
11410571|NCT01965405|Experimental|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
11410572|NCT01965392|Experimental|healtn education|one group received an educational program
11410573|NCT01965379|Active Comparator|Intervention|Restriction on food containing phosphorus additives.
11410574|NCT01965379|Placebo Comparator|Control|Standard care.
11410575|NCT01965366|Active Comparator|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
11410576|NCT01965366|Placebo Comparator|Placebo + VRE|Placebo + virtual reality exposure therapy
11410577|NCT01965353|Experimental|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
~Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.
~Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.
~Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.
~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
11410578|NCT01965340|Experimental|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
11410579|NCT01965340|No Intervention|Patients treated as usual|
11410580|NCT01965327|Experimental|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
11410581|NCT01965314|Placebo Comparator|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
11410582|NCT01965314|Active Comparator|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
11410583|NCT01965301|Experimental|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
11410584|NCT01965301|Active Comparator|Diphenhydramine|Single oral dose of diphenhydramine 50mg
11410585|NCT01965301|Placebo Comparator|Placebo|Single oral dose
11410586|NCT01965288|Experimental|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
11410587|NCT01965288|Active Comparator|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
11410588|NCT01965275|Experimental|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
11410589|NCT01965262|Active Comparator|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
11410590|NCT01965262|Active Comparator|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
11410591|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval > 10mm; Lateral > 10mm
11410592|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval < 5 mm; Lateral 5 - 8 mm
11410593|NCT01965236|Experimental|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
11410594|NCT01965236|Experimental|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
11410595|NCT01965223|Experimental|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
11410596|NCT01965223|Experimental|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
11410597|NCT01965210|Experimental|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
11410598|NCT01965210|Experimental|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
11410599|NCT01965210|Experimental|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
11410600|NCT01965210|Experimental|Large non-supplemented rye|Large portion of rye porridge without supplements.
11410601|NCT01965210|Experimental|Small non-supplemented rye|Small portion of rye porridge without supplements.
11410602|NCT01965210|Active Comparator|Refined wheat bread|Refined wheat bread.
11410603|NCT01965184|Experimental|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
11410604|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
11410605|NCT01965158|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
11410606|NCT01965158|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
11410607|NCT01965145|Experimental|Gevokizumab|Solution for subcutaneous injection, Dose 1
11410608|NCT01965145|Placebo Comparator|Placebo|Solution for subcutaneous injection, placebo
11410671|NCT01964651|Experimental|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
11410672|NCT01964651|Experimental|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
11410609|NCT01965132||Biologic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab)
11410610|NCT01965119|Experimental|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
11410611|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
11410612|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
11410613|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
11410614|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
11410615|NCT01965080|Experimental|Exemestane|Exemestane 25 mg daily
11410616|NCT01965067|Active Comparator|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
11410617|NCT01965067|Experimental|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
11410618|NCT01965054|Experimental|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
11410619|NCT01965054|No Intervention|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
11410620|NCT01965041|Experimental|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
11410621|NCT01965028|Experimental|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
11410622|NCT01965015|Experimental|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
11410623|NCT01965002|Experimental|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
11410624|NCT01964989|Experimental|aQIV|flu vaccine
11410625|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
11410626|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
11410627|NCT01964963||Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
11410628|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
11410629|NCT01964937|Experimental|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.
~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
11410630|NCT01964937|Experimental|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.
~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
11410631|NCT01964937|Experimental|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.
~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
11410632|NCT01964937|Experimental|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.
~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
11410633|NCT01964937|Experimental|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
11410634|NCT01964924|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.
~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11410635|NCT01964911|Experimental|Ropivacaïne|
11410673|NCT01964651|Experimental|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
11410674|NCT01964651|Experimental|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
11410741|NCT01964157|Experimental|LDK378 arm|
11410636|NCT01964898|Experimental|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
11410637|NCT01964898|Active Comparator|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
11410638|NCT01964885|Active Comparator|IQP-AS-105|One tablet daily
11410639|NCT01964885|Placebo Comparator|Placebo|One tablet daily
11410640|NCT01964872|Experimental|JNJ-38877618|
11410641|NCT01964872|Placebo Comparator|Placebo|
11410642|NCT01964859|Experimental|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
11410643|NCT01964846|Experimental|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
11410644|NCT01964846|Placebo Comparator|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
11410645|NCT01964833|Sham Comparator|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
11410646|NCT01964833|Experimental|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
11410647|NCT01964820|Experimental|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
11410648|NCT01964820|No Intervention|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
11410649|NCT01964807|Experimental|Cigarette smokers|Will smoke 1 cigarette, National Institute of Drug Abuse (NIDA) test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with <0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
11410650|NCT01964807|Experimental|Nonsmokers|Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.
11410651|NCT01964807|Experimental|Smokeless tobacco users|Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.
11410652|NCT01964807|Experimental|e-cigarette users|Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
11410653|NCT01964781|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
11410654|NCT01964781|Experimental|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
11410655|NCT01964781|Experimental|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
11410656|NCT01964781|Experimental|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
11410657|NCT01964781|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
11410658|NCT01964781|Placebo Comparator|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
11410659|NCT01964755|Experimental|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:
~Chemotherapy: Up to 6 cycles, 21 days each:
~Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;
~Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;
~Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;
~Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;
~Antiviral-Based Therapy
~Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;
~Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
11410660|NCT01964742|Experimental|HIV-HCV co-infected patients|
11410661|NCT01964729|Sham Comparator|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
11410662|NCT01964729|Experimental|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
11410663|NCT01964716|Experimental|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
11410664|NCT01964716|Active Comparator|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
11410665|NCT01964703|Placebo Comparator|control|
11410666|NCT01964703|Active Comparator|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
11410667|NCT01964703|Active Comparator|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
11410668|NCT01964677|Experimental|MR-HIFU of painful bone metastases|
11410669|NCT01964664|Experimental|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
11410670|NCT01964664|Active Comparator|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
11410675|NCT01964638|Other|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
11410676|NCT01964625|Experimental|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
11410677|NCT01964599|Other|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
11410678|NCT01964599|Other|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
11410679|NCT01964599|Other|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
11410680|NCT01964586|Active Comparator|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
11410681|NCT01964586|Active Comparator|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
11410682|NCT01964573|Experimental|Rotigotine group|
11410683|NCT01964573|Placebo Comparator|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
11410684|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:
~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg
~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg
~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg
~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
11410685|NCT01964547|Active Comparator|Sativex|"Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
~Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability."
11410686|NCT01964547|Placebo Comparator|Placebo|Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
11410687|NCT01964534|Active Comparator|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
11410688|NCT01964534|Experimental|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
11410689|NCT01964521|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
11410690|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
11410691|NCT01964495|Active Comparator|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
11410692|NCT01964495|Experimental|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
11410693|NCT01964495|Experimental|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
11410694|NCT01964482|Experimental|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
11410695|NCT01964482|No Intervention|Usual care|Usual care
11410696|NCT01964469|Placebo Comparator|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
11410697|NCT01964469|Experimental|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
11410698|NCT01964469|No Intervention|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
11410699|NCT01964456|Active Comparator|Patients|Patients suffering of anorexia
11410700|NCT01964456|Placebo Comparator|Control|Subjects controls (not suffering of anorexia)
11410701|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
11410735|NCT01964196|Experimental|ASP1517 middle dose group|Oral
11410736|NCT01964196|Experimental|ASP1517 high dose group|Oral
11410737|NCT01964196|Placebo Comparator|Placebo group|Oral
11410738|NCT01964183|Experimental|treatment group|
11410702|NCT01964430|Experimental|nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2|Participants received nab-Paclitaxel 125 mg/m^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
11410703|NCT01964430|Active Comparator|Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
11410704|NCT01964417|Active Comparator|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
11410705|NCT01964417|Active Comparator|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
11410706|NCT01964404|Experimental|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
11410707|NCT01964404|Experimental|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
11410708|NCT01964404|Placebo Comparator|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
11410709|NCT01964391|Experimental|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (>) 2 centimeters (cm) in diameter.
11410710|NCT01964378|Experimental|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
11410711|NCT01964378|Active Comparator|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
11410712|NCT01964365|Experimental|Rosuvastatin|multiple dose of Rosuvastatin 20mg
11410713|NCT01964365|Experimental|Fenofibric acid|multiple dose of Fenofibric acid 135mg
11410714|NCT01964365|Experimental|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
11410715|NCT01964352|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
11410716|NCT01964352|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
11410717|NCT01964352|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
11410718|NCT01964352|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
11410719|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
11410720|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
11410721|NCT01964326|Experimental|Atorvastatin calcium 10 mg|
11410722|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
11410723|NCT01964300|Experimental|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11410724|NCT01964287|Experimental|Gembrax followed by Folfirinox|"Gembrax:
~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest
~Folfirinox:
~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
11410725|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
11410726|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
11410727|NCT01964248|Experimental|Lidocaïne/prilocaïne|"Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base
~Single dose: 2 grams (one tube of cream)
~Cream applied 2 hours before blood sample"
11410728|NCT01964248|Placebo Comparator|Placebo|"Single dose: 2 grams (one tube of cream)
~Cream applied 2 hours before blood sample"
11410729|NCT01964235|Experimental|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
11410730|NCT01964235|Placebo Comparator|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
11410731|NCT01964222|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
11410732|NCT01964222|No Intervention|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
11410733|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
11410734|NCT01964196|Experimental|ASP1517 low dose group|Oral
11410743|NCT01964131|Experimental|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
11410744|NCT01964131|Other|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
11410745|NCT01964118|Other|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
11410746|NCT01964118|Experimental|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
11410747|NCT01964105|Experimental|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
11410748|NCT01964105|No Intervention|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).
~Goal: 50 patients"
11410749|NCT01964105|Other|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.
~Goal: 50 Patients"
11410750|NCT01964092|Experimental|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
11410751|NCT01964092|Active Comparator|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
11410752|NCT01964079|Active Comparator|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
11410753|NCT01964079|Active Comparator|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
11410754|NCT01964066|Experimental|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
11410755|NCT01964066|Active Comparator|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
11410756|NCT01964053|Experimental|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
11410757|NCT01964053|Active Comparator|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
11410758|NCT01964040|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
11410759|NCT01964040|Experimental|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
11410760|NCT01964040|Active Comparator|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
11410761|NCT01964027|Experimental|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
11410762|NCT01964014|Experimental|advagraf|The same capacity advagaf + sirolimus
11410763|NCT01964001|Placebo Comparator|Placebo|starch
11410764|NCT01964001|Experimental|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
11410765|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
11410766|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
11410767|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
11410768|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
11410769|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
11410770|NCT01963936|Experimental|Supreme LMA|
11410771|NCT01963936|Active Comparator|Facial mask|
11410772|NCT01963923|Experimental|Rehabilitation Group|The rehabilitation group must complete at least 16 sessions of the Pulmonary Rehabilitation Program
11410773|NCT01963923|No Intervention|Control Group|The control group must complete only the outcome measures and continue with their clinical routine as specified by their physicians.
11410774|NCT01963910|Active Comparator|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
11410775|NCT01963910|Placebo Comparator|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
11410776|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
11410777|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
11410778|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
11410779|NCT01963871|Experimental|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
11410780|NCT01963858|Experimental|Functional relaxation|Functional relaxation
11410781|NCT01963858|Active Comparator|No relaxation|No relaxation
11410782|NCT01963845|Placebo Comparator|Placebo|Placebo
11410783|NCT01963845|Experimental|Active drug|Sitagliptin 100 mg
11410784|NCT01963832|Experimental|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
11410785|NCT01963832|Experimental|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
11410786|NCT01963832|Experimental|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
11410787|NCT01963832|Experimental|Usual care and placebo|Usual physical care combined with placebo
11410788|NCT01963819|No Intervention|Control|Standard treatment
11410789|NCT01963819|Experimental|Intervention|Endometrial biopsy before standard treatment
11410790|NCT01963806|Experimental|Smartphone-supplemented iCBT with therapist support|n = 50
11410791|NCT01963806|Experimental|Smartphone-supplemented iCBT without therapist support|n = 50
11410792|NCT01963806|Active Comparator|Active waiting list control group with delayed treatment|n = 50
11410793|NCT01963793|Other|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
11410794|NCT01963793|Other|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
11410795|NCT01963780|Experimental|OCS Lung Tx.|
11410796|NCT01963767|Experimental|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
11410797|NCT01963767|Placebo Comparator|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
11410798|NCT01963754|Experimental|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
11410799|NCT01963754|Active Comparator|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
11410800|NCT01963741|Experimental|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
11410801|NCT01963741|Experimental|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
11410802|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
11410803|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
11410804|NCT01963715|Experimental|EGFR+ Solid Tumor|EGFR+ Solid Tumor
11410805|NCT01963702|Experimental|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
11410806|NCT01963702|Active Comparator|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
11410807|NCT01963689|Placebo Comparator|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
11410808|NCT01963689|Experimental|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
11410809|NCT01963689|Experimental|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
11410810|NCT01963676|Experimental|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
11410811|NCT01963676|Sham Comparator|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
11410812|NCT01963663|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
11410815|NCT01963637|Experimental|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
11410816|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
11410817|NCT01963611|Experimental|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
11410818|NCT01963611|Experimental|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
11410819|NCT01963611|Experimental|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
11410820|NCT01963611|Experimental|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
11410821|NCT01963611|Active Comparator|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
11410822|NCT01963598|Experimental|Group 1|Dosing regimen 1
11410823|NCT01963598|Experimental|Group 2|Dosing regimen 2
11410824|NCT01963598|Experimental|Group 3|Dosing regimen 3
11410825|NCT01963598|Experimental|Group 4|Dosing regimen 4
11410826|NCT01963585||Negative metacholine|Healthy control
11410827|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
11410828|NCT01963572|Experimental|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
11410829|NCT01963572|No Intervention|general care group (CG)|CG raises any health-related question, they can be answered.
11410830|NCT01963559|Other|Diabetic patients with MPP|
11410831|NCT01963559|Other|Diabetic patients without MPP|
11410832|NCT01963546|Other|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
11410833|NCT01963546|Other|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
11410834|NCT01963546|Other|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
11410835|NCT01963546|Experimental|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.
~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
11410836|NCT01963507|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
11410837|NCT01963507|No Intervention|Control|
11410838|NCT01963494|Experimental|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
11410839|NCT01963494|Active Comparator|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
11410840|NCT01963494|Active Comparator|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
11410841|NCT01963481|Experimental|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:
~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
11410842|NCT01963468|Experimental|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.
~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
11410843|NCT01963468|No Intervention|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
11410844|NCT01963455|Experimental|MDCs transplant|The women who have stress urinary incontinency.
11410845|NCT01963442|Active Comparator|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
11410846|NCT01963442|Placebo Comparator|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
11410847|NCT01963429|Experimental|A(radiofrequency ablation )|radiofrequency ablation
11410848|NCT01963429|Experimental|B(Proton)|hypofractionated proton beam therapy
11410849|NCT01963416|Placebo Comparator|Control|macro- and micro-nutrient matched control (240 ml)
11410850|NCT01963416|Experimental|Orange juice|commercial orange juice (240 ml)
11410851|NCT01963416|Experimental|whole orange|whole orange fruit (240 ml)
11410852|NCT01963416|Experimental|processed whole orange|processed whole orange (240 ml)
11410853|NCT01963403|Active Comparator|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
11410854|NCT01963403|Placebo Comparator|Placebo|Placebo
11410855|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
11410983|NCT01962610|No Intervention|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
11410856|NCT01963377|Experimental|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
11410857|NCT01963377|Experimental|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
11410858|NCT01963364|Experimental|Intervention group|All healthy volunteers
11410859|NCT01963351||Locally advanced and metastatic nsclc|non squamous
11410860|NCT01963338|Experimental|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
11410861|NCT01963338|Experimental|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
11410862|NCT01963325|Experimental|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
11410863|NCT01963312|Experimental|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
11410864|NCT01963312|Active Comparator|Transurethral Resection|Surgery to remove part of the prostate gland
11410865|NCT01963299|Active Comparator|Ropivacaine alone group|
11410866|NCT01963299|Experimental|Ropivacaine/Clonidine group|
11410867|NCT01963286|Other|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
11410868|NCT01963273|Experimental|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
11410869|NCT01963260|Experimental|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
11410870|NCT01963260|Experimental|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
11410871|NCT01963260|Experimental|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
11410872|NCT01963260|Experimental|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
11410873|NCT01963260|Experimental|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
11410874|NCT01963260|Placebo Comparator|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
11410875|NCT01963260|Experimental|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
11410876|NCT01963260|Experimental|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
11410877|NCT01963260|Placebo Comparator|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
11410878|NCT01963260|Placebo Comparator|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
11410879|NCT01963247||Healthy Athletes|
11410880|NCT01963247||Concussed Athletes|
11410881|NCT01963234|Experimental|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
11410882|NCT01963221|Other|fluodeoxyglucose (18f)|
11410883|NCT01963208|Experimental|ganaxolone|active
11410884|NCT01963208|Placebo Comparator|Placebo|placebo, non-active
11410885|NCT01963195|Experimental|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
11410886|NCT01963182|Experimental|irinotecan dose based on genetic polymorphism of UGT1A1|
11410887|NCT01963169|Experimental|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
11410888|NCT01963169|Experimental|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
11410889|NCT01963169|No Intervention|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
11410890|NCT01963156|Experimental|Prescription synchronization|
11410891|NCT01963156|No Intervention|Control|
11410892|NCT01963143|Experimental|Treatment Sequence 1 - Adults|Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
11410893|NCT01963143|Experimental|Treatment Sequence 2 - Adults|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
11410894|NCT01963143|Experimental|Pediatrics|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
11410895|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
11410896|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
11410897|NCT01963117|Experimental|Combined hypertermia and RT|Combined hypertermia and radiothearpy
11410898|NCT01963104|Experimental|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
11410899|NCT01963104|Experimental|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
11410900|NCT01963104|Experimental|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
11410901|NCT01963104|Experimental|No screening test|This group of subjects will not receive a screening test.
11410902|NCT01963104|Experimental|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
11410903|NCT01963104|Experimental|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
11410904|NCT01963104|Experimental|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
11410905|NCT01963104|Experimental|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
11410906|NCT01963104|Experimental|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
11410907|NCT01963104|Experimental|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
11410908|NCT01963091|Experimental|oxytocin|
11410909|NCT01963091|Placebo Comparator|placebo|
11410910|NCT01963078|Placebo Comparator|PTSD placebo Day 1, Oxytocin Day 2|Participants PTSD will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
11410911|NCT01963078|Experimental|PTSD Oxytocin Day 1, Placebo Day 2|Participants with PTSD will self-administer 24 IUs of OT nasal spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
11410912|NCT01963078|Placebo Comparator|Resilient Placebo Day 1, Oxytocin Day 2|Resilient controls will self-administer matching placebo spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
11410913|NCT01963078|Experimental|Resilient Oxytocin Day 1, Placebo Day 2|Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
11410914|NCT01963065||Moderately pre-term infants and their mothers|cohort of moderately pre-term infants and their mothers
11410915|NCT01963052|Experimental|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Additional subjects may be enrolled for expansion of these dose levels to further evaluate the safety and efficacy, as recommended by a data review team (DRT).
11410916|NCT01963052|Experimental|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
11410917|NCT01963052|Experimental|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
11410918|NCT01963052|Experimental|Part A: AGS15E Dose Expansion|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
11410919|NCT01963039|Active Comparator|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
11410920|NCT01963039|Sham Comparator|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
11410921|NCT01963026|Experimental|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
11410922|NCT01963013|Experimental|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
11410923|NCT01963013|Active Comparator|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
11410924|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
11410925|NCT01962987|Experimental|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
11410926|NCT01962987|Active Comparator|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
11410927|NCT01962987|Placebo Comparator|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
11410928|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
11410929|NCT01962961|Experimental|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
11410930|NCT01962961|Experimental|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
11410931|NCT01962961|Placebo Comparator|Placebo|Matching placebo pills given twice daily for 8 weeks
11410932|NCT01962948|Experimental|Treatment (paclitaxel, ganetespib)|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11410933|NCT01962935|Experimental|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
11410934|NCT01962935|Placebo Comparator|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
11410935|NCT01962935|Active Comparator|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
11410936|NCT01962922|Active Comparator|LCP-Tacro|Envarsus XR
11410937|NCT01962922|Active Comparator|Tacrolimus - IR|Tacrolimus
11410938|NCT01962909|Experimental|PTP-01|single IV bolus dose 24 hours prior to surgery
11410939|NCT01962896|Experimental|Erlotinib + sirolimus|
11410940|NCT01962883|No Intervention|Control group|Osteopathic evaluation Cognitive and Physical Rest
11410941|NCT01962883|Experimental|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
11410942|NCT01962870|Placebo Comparator|Placebo|Placebo Nasal Spray
11410943|NCT01962870|Active Comparator|Vasopressin|Vasopressin Nasal Spray
11410944|NCT01962857|Experimental|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
11410945|NCT01962857|No Intervention|Control|No intervention - participants maintain usual lifestyle
11410946|NCT01962844|Other|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
11410947|NCT01962844|Experimental|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
11410948|NCT01962831|Experimental|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
11410949|NCT01962831|Experimental|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
11410950|NCT01962818|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
11410984|NCT01962597|Active Comparator|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
11410985|NCT01962597|Active Comparator|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
11411209|NCT01961076|Experimental|modified corn starch|Patients receive modified corn starch before bed-time
11410951|NCT01962818|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
11410952|NCT01962805|Experimental|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
11410953|NCT01962805|Experimental|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
11410954|NCT01962792|Experimental|Phase 1 - Dose Finding|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
11410955|NCT01962792|Experimental|Phase 2b - Main Study|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
11410956|NCT01962792|Experimental|Phase 2b - Sub-study|Ibrutinib PO + Carfilzomib IV + Dexamethasone PO
11410957|NCT01962779|Experimental|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
11410958|NCT01962779|No Intervention|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
11410959|NCT01962766|Active Comparator|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
11410960|NCT01962766|Experimental|instructions|instructions to modify their tongue position (1 session)
11410961|NCT01962753|Experimental|18FAV45|
11410962|NCT01962740|Active Comparator|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
11410963|NCT01962740|Active Comparator|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
11410964|NCT01962740|Active Comparator|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
11410965|NCT01962714|Experimental|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
11410966|NCT01962714|Active Comparator|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
11410967|NCT01962701||OCT-group|OCT prior to C-section
11410968|NCT01962701||None-OCT-group|No OCT prior to C-section
11410969|NCT01962688|Experimental|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
11410970|NCT01962688|Sham Comparator|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
11410971|NCT01962688|Experimental|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
11410972|NCT01962688|Sham Comparator|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
11410973|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
11410974|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
11410975|NCT01962662|Experimental|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
11410976|NCT01962662|Experimental|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
11410977|NCT01962662|Other|control group|U/E exercise
11410978|NCT01962649|Experimental|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
11410979|NCT01962636|Experimental|Umbilical Cord Blood Transplant|The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI)followed by umbilical cord blood transplant. Immunosuppressive Cyclosporine and Mycophenylate Mofetil (MMF) will be administered pre- and post UCBT.
11410980|NCT01962623|Active Comparator|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
11410981|NCT01962623|Other|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
11410982|NCT01962610|Experimental|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
11411135|NCT01961648|Sham Comparator|room air|Participant will sleep connected to a mask open to rrom air, half of the night
11410986|NCT01962597|Experimental|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
11410987|NCT01962584||SAM|patients with suspected acute myocarditis
11410988|NCT01962584||HC|Healthy controls
11410989|NCT01962571|Experimental|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
11410990|NCT01962571|Placebo Comparator|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
11410991|NCT01962558|Experimental|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
11410992|NCT01962558|Sham Comparator|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
11410993|NCT01962545|Experimental|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
11410994|NCT01962545|No Intervention|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
11410995|NCT01962532|Experimental|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which <33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
11410996|NCT01962532|Experimental|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
11410997|NCT01962532|Experimental|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
11410998|NCT01962519|Experimental|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
11410999|NCT01962519|No Intervention|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
11411000|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
11411001|NCT01962493|Active Comparator|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
11411002|NCT01962493|Other|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
11411003|NCT01962480|Active Comparator|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
11411004|NCT01962480|No Intervention|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
11411005|NCT01962467|Experimental|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
11411006|NCT01962454|Experimental|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
11411007|NCT01962454|Placebo Comparator|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
11411008|NCT01962441|Experimental|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
11411009|NCT01962441|Experimental|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
11411010|NCT01962441|Experimental|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
11411011|NCT01962441|Experimental|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
11411012|NCT01962428|Experimental|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
11411013|NCT01962428|Active Comparator|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
11411014|NCT01962415|Experimental|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
11411015|NCT01962415|Experimental|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
11411016|NCT01962402|Experimental|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
11411017|NCT01962389|Experimental|Winsor Laser Catheter|
11411018|NCT01962376|Active Comparator|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
~placebo:Physiological saline"
11411019|NCT01962376|Experimental|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
11411020|NCT01962363|Experimental|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
11411021|NCT01962350|Experimental|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation
~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
11411022|NCT01962350|Experimental|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation
~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
11411023|NCT01962337|Experimental|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
11411024|NCT01962337|Experimental|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
11411025|NCT01962337|Experimental|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
11411026|NCT01962324|Experimental|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
11411027|NCT01962311|Experimental|All patients|lumbar puncture
11411028|NCT01962298|Placebo Comparator|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
11411029|NCT01962298|Active Comparator|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
11411030|NCT01962298|Active Comparator|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
11411031|NCT01962298|Active Comparator|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
11411032|NCT01962298|Active Comparator|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
11411033|NCT01962285|Experimental|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.
~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.
~32 channel-EEg and BIS continuous monitoring"
11411034|NCT01962272|Experimental|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
11411035|NCT01962272|Active Comparator|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.
~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
11411036|NCT01962259|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
11411037|NCT01962259|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
11411038|NCT01962259|Experimental|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
11411039|NCT01962259|No Intervention|Control|Receives no intervention.
11411040|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
11411041|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
11411042|NCT01962233|Experimental|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
11411043|NCT01962220|No Intervention|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.
~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
11411044|NCT01962220|Experimental|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
11411280|NCT01960608||low income group|the income 25% below the quartile
11411045|NCT01962207|Experimental|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
11411046|NCT01962207|Experimental|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
11411047|NCT01962207|Experimental|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
11411048|NCT01962207|Experimental|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
11411049|NCT01962194|Experimental|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
11411050|NCT01962181|Active Comparator|Ritalin|Ritalin treatment at different doses
11411051|NCT01962181|Placebo Comparator|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
11411052|NCT01962168||Evolution® Biliary Stent - Uncovered|
11411053|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
11411054|NCT01962142||Exacerbated asthma patients|
11411055|NCT01962129||Patients affected by a syndrome OFD|
11411056|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
11411057|NCT01962116|Placebo Comparator|Heparin lock|
11411058|NCT01962116|Experimental|Citrate lock|
11411059|NCT01962103|Experimental|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
11411060|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 120 mg/m^2|nab-paclitaxel 120 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
11411061|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 150 mg/m^2|nab-paclitaxel 150 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
11411062|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 180 mg/m^2|nab-paclitaxel 180 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
11411063|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 210 mg/m^2|nab-paclitaxel 210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
11411064|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 240 mg/m^2|nab-paclitaxel 240 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
11411065|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 270 mg/m^2|nab-paclitaxel 270 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
11411066|NCT01962103|Experimental|Phase 2: Ewing's Sarcoma|Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
11411067|NCT01962103|Experimental|Phase 2: Neuroblastoma|Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
11411068|NCT01962103|Experimental|Phase 2: Rhabdomyosarcoma|Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
11411069|NCT01962090|Experimental|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
11411070|NCT01962090|Experimental|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
11411071|NCT01962077|Experimental|MedCem MTA pulpotomies|
11411072|NCT01962064|Experimental|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
11411073|NCT01962064|Experimental|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
11411074|NCT01962064|Experimental|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
11411075|NCT01962064|Experimental|Young|cognitive assessment and Brain imaging examination MRI of young subjects
11411076|NCT01962051||Delivery system Entry|
11411077|NCT01962038|Active Comparator|Combined Aerobic and Resistance Exercise/Cognitive Training|
11411078|NCT01962038|Active Comparator|Stretching Exercises/Cognitive Training|
11411079|NCT01962025|Active Comparator|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
11411080|NCT01962025|No Intervention|Step Ladder Group|Patients will use step ladder needling technique
11411081|NCT01962012|Experimental|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
11411082|NCT01962012|Sham Comparator|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
11411083|NCT01961999|Active Comparator|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
11411084|NCT01961999|Active Comparator|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:
~persistent and refractory oliguria (<0,5 ml/Kg/h >12h), despite therapy
~refractory extravascular fluid overload
~azotemia > 40mmol/L or 240 mg/dL
~metabolic acidosis (pH<7,2)
~hyperkaliemia (k+>6 mmol/L)"
11411085|NCT01961986|Active Comparator|TSR: traditional subscap release|"TSR - traditional subscapularis release approach
~Subscapularis tendon release technique TSR"
11411086|NCT01961986|Experimental|TSR: rotator cuff sparing|Rotator cuff sparing technique TSR
11411208|NCT01961076|Experimental|uncooked corn starch|Patients receive uncooked corn starch before bed-time
11411087|NCT01961973|Active Comparator|Cultured chondrocytes|"Cultured chondrocytes:
~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
11411088|NCT01961973|Active Comparator|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
11411089|NCT01961960|Experimental|ASP7374 group|
11411090|NCT01961947|Experimental|ASP7374 group|
11411091|NCT01961947|Active Comparator|TIV group|
11411092|NCT01961934|Experimental|Sodium Acetate C11 PET/CT Imaging|
11411093|NCT01961921|Experimental|ALN-TTR02 (patisiran)|
11411094|NCT01961908|Experimental|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
11411095|NCT01961895|Active Comparator|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
11411096|NCT01961895|Experimental|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.
~Rescue bolus 5 ml and 30 minutes lockout"
11411097|NCT01961882|Experimental|OCV-501 arm|
11411098|NCT01961882|Placebo Comparator|Placebo arm|
11411099|NCT01961869|Experimental|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
11411100|NCT01961869|Experimental|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
11411101|NCT01961869|Experimental|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
11411102|NCT01961869|Experimental|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
11411103|NCT01961869|Experimental|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
11411104|NCT01961869|Experimental|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
11411105|NCT01961856|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose
11411106|NCT01961856|Experimental|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
11411107|NCT01961843|Experimental|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
11411108|NCT01961830|Experimental|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
11411109|NCT01961817|Other|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.
~The second visualization then will be performed with the conventional method."
11411110|NCT01961817|Other|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.
~The second visualization then will be performed with the retromolar method."
11411111|NCT01961804|Other|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
11411112|NCT01961804|Experimental|Preventive reversion|Realise a preventive reversion before performing any CT scan.
11411113|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
11411114|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
11411115|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
11411116|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
11411117|NCT01961765|Experimental|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
11411118|NCT01961752|Placebo Comparator|Control group|
11411119|NCT01961752|Experimental|Bupivacaine only group|
11411120|NCT01961752|Active Comparator|Bupivacaine with triamcinolone group|
11411121|NCT01961739|Experimental|2% lidocaine|topical application, two times per day for 15 consecutive days
11411122|NCT01961739|Placebo Comparator|placebo|vaseline base applied topically, two times per day for 15 consecutive days
11411123|NCT01961726|Placebo Comparator|Placebo|
11411124|NCT01961726|Experimental|30 mg dose of JVS-100|
11411125|NCT01961726|Experimental|45 mg dose of JVS-100|
11411126|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
11411127|NCT01961700|Experimental|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
11411128|NCT01961700|No Intervention|Control group|No physiotherapy.
11411129|NCT01961687|Other|Resorbable Mesh|Phasix Mesh
11411130|NCT01961674|Experimental|Capsinoid arm|On capsinoids
11411131|NCT01961674|Placebo Comparator|Placebo arm|Placebo
11411132|NCT01961661|Experimental|probiotic|Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day
11411133|NCT01961661|Placebo Comparator|placebo|maltodextrins
11411134|NCT01961648|Active Comparator|Dead space|Participant will sleep connected to a mask with added dead space half of the night
11411136|NCT01961635|Experimental|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
11411137|NCT01961635|Experimental|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
11411138|NCT01961635|Experimental|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
11411139|NCT01961622|Experimental|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
11411140|NCT01961622|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
11411141|NCT01961609|Experimental|Secukinumab (AIN457) 300 mg|Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.
11411142|NCT01961609|Experimental|Secukinumab (AIN457) 150 mg|Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg.
11411143|NCT01961596|Experimental|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
~After 2 days the measurements will be repeated with the other application."
11411144|NCT01961596|Placebo Comparator|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
~After 2 days the measurements will be repeated with the other application."
11411145|NCT01961583|Experimental|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
11411146|NCT01961557|Experimental|Feasibility Arm|All participants will evaluate the EA-KAFO and serve as their own control for measure the change in the primary outcome measure (peak knee angle) to assess the effect of the EA-KAFO intervention.
11411147|NCT01961544|Experimental|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
11411148|NCT01961531|Experimental|Accuboost APBI|28Gy delivered in 5 daily fractions
11411149|NCT01961505|Experimental|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
11411150|NCT01961505|Placebo Comparator|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
11411151|NCT01961492|Active Comparator|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
11411152|NCT01961492|No Intervention|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
11411153|NCT01961479|Experimental|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
11411154|NCT01961479|Other|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
11411155|NCT01961466||Diabetic patients|
11411156|NCT01961453|Active Comparator|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
11411157|NCT01961453|Placebo Comparator|Placebo capsule|One capsule of placebo administered once daily at 8 AM
11411158|NCT01961427|Active Comparator|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
11411159|NCT01961427|Active Comparator|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
11411160|NCT01961427|Active Comparator|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
11411161|NCT01961427|Active Comparator|sodium nitrate (0mmol)|Ingestion of water as a placebo
11411162|NCT01961427|Active Comparator|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
11411163|NCT01961427|Active Comparator|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
11411164|NCT01961427|Active Comparator|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
11411165|NCT01961414|Experimental|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
11411166|NCT01961401|Experimental|High intensity exercise|High intensity, short duration exercise on bike
11411167|NCT01961401|Experimental|Moderate exercise|Moderate intensity exercise training on bike
11411168|NCT01961401|No Intervention|No exercise|No exercise, resting in the lab
11411169|NCT01961388||Group 1|Acarbose_BAY G5421
11411170|NCT01961388||Group 2|Metformin
11411171|NCT01961375||Group 1|BAY 86-5028; Levonorgestrel- Intra Uterine System
11411172|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
11411173|NCT01961349|Placebo Comparator|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
11411174|NCT01961349|Active Comparator|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
11411175|NCT01961349|Active Comparator|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
11411176|NCT01961336|Experimental|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
11411177|NCT01961336|No Intervention|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
11411178|NCT01961323|Experimental|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
11411179|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.
~Intervention: Plasma analysis for bacterial translocation
~Intervention: Stool analysis"
11411180|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.
~Intervention: Plasma analysis for bacterial translocation
~Intervention: Stool analysis"
11411181|NCT01961297|Experimental|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
11411182|NCT01961284|Active Comparator|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
11411183|NCT01961284|Active Comparator|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
11411184|NCT01961271|Experimental|Buprenorphine transdermal patch|Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
11411185|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
11411186|NCT01961245|Active Comparator|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
11411187|NCT01961245|No Intervention|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
11411188|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
11411189|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
11411190|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
11411191|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
11411192|NCT01961219|Active Comparator|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
11411193|NCT01961219|Active Comparator|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
11411194|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
11411195|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
11411196|NCT01961193|Experimental|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
11411197|NCT01961193|Experimental|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
11411198|NCT01961193|No Intervention|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
11411199|NCT01961180|Active Comparator|active comparator|Drug: Cipralex
11411200|NCT01961180|Placebo Comparator|placebo comparator|Drug: Placebo
11411201|NCT01961167|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
11411202|NCT01961154|Other|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
11411203|NCT01961128|Experimental|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
11411204|NCT01961115|Experimental|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
11411205|NCT01961089|Experimental|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
11411206|NCT01961089|Active Comparator|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
11411207|NCT01961089|Experimental|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
11411210|NCT01961076|Experimental|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
11411211|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
11411212|NCT01961050|Experimental|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
11411213|NCT01961050|Other|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
11411214|NCT01961037|Experimental|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
11411215|NCT01961024||Type 2 diabetic men|
11411216|NCT01961024||Age- and weight-matched controls|
11411217|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
11411218|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
11411219|NCT01960998|Experimental|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
11411220|NCT01960998|Active Comparator|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
11411221|NCT01960985|Experimental|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
11411222|NCT01960985|Experimental|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
11411223|NCT01960972|Experimental|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.
~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
11411224|NCT01960946|Active Comparator|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
11411225|NCT01960946|Placebo Comparator|Placebo|Matched placebo 5 grams by mouth three times a day
11411226|NCT01960933|Active Comparator|Culprit lesion revascularization|Only the culprit lesion is treated whereas other study lesions are left un-treated.
11411227|NCT01960933|Active Comparator|Full revascularization|Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically >50% and FFR <0.80 are treated in a separate procedure within the index hospitalization. Stenoses > 90% are treated without prior FFR.
11411228|NCT01960920|Active Comparator|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
11411229|NCT01960920|Experimental|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
11411230|NCT01960907|No Intervention|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
~They will follow their usual care path as provided by their local NHS"
11411231|NCT01960907|Experimental|Interventional|"Patients will receive a system form monitoring their health status.
~The system is composed by:
~a touch-screen pc for the administration of daily questionnaires
~RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern
~a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.
~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
11411232|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
11411233|NCT01960868|Experimental|patients|
11411234|NCT01960868|Other|control group|
11411235|NCT01960855|Placebo Comparator|Placebo BID|Placebo twice daily (BID) for 12 weeks.
11411236|NCT01960855|Experimental|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
11411237|NCT01960855|Experimental|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
11411238|NCT01960855|Experimental|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
11411239|NCT01960855|Experimental|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
11411281|NCT01960608||low mid income group|the income 25% - 50% below the quartile
11411282|NCT01960608||mid income group|the income 50% - 75% below the quartile
11411283|NCT01960608||high income group|the income 75% over the quartile
11411284|NCT01960595|Experimental|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
11412363|NCT01953510|Experimental|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
11411240|NCT01960842|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.
~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
11411241|NCT01960829|Experimental|Everolimus|
11411242|NCT01960816|Experimental|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
11411243|NCT01960803|Experimental|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
11411244|NCT01960790||Participants who received Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
11411245|NCT01960777|Experimental|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
11411246|NCT01960777|Active Comparator|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
11411247|NCT01960764|Experimental|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
11411248|NCT01960764|Placebo Comparator|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
11411249|NCT01960751|Other|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
11411250|NCT01960738|Experimental|Intervention|The intervention group received a pre-dive checklist and a post-dive log
11411251|NCT01960738|No Intervention|Control|The control group received the post-dive log only.
11411252|NCT01960725|Active Comparator|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
11411253|NCT01960725|Experimental|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
11411254|NCT01960712|No Intervention|Continued external drainage|Continued external drainage alone.
11411255|NCT01960712|Active Comparator|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
11411256|NCT01960699||CPC < 3|Good neurological outcome
11411257|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
11411258|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
11411259|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
11411260|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
11411261|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
11411262|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
11411263|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
11411264|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
11411265|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
11411266|NCT01960673|Experimental|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.
~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
11411267|NCT01960673|Experimental|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.
~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
11411268|NCT01960673|Experimental|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.
~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.
~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
11411269|NCT01960673|Experimental|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
11411270|NCT01960660|Experimental|Investigational Product|Omega-3 fatty acids in the form of triglycerides
11411271|NCT01960660|Active Comparator|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
11411272|NCT01960660|Active Comparator|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
11411273|NCT01960660|Active Comparator|Comparator Product 3|Omega-3 fatty acids from salmon oil.
11411274|NCT01960647|Other|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
11411275|NCT01960647|Active Comparator|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
11411276|NCT01960621|Experimental|2|
11411277|NCT01960608||low sodium group|24_hours_urine_sodium < 100 mEq/L
11411278|NCT01960608||mid sodium group|24_hours_urine_sodium >= 100 mEq/L and < 200 mEq/L
11411279|NCT01960608||high sodium group|24_hours_urine_sodium >= 200 mEq/L
11411285|NCT01960595|Active Comparator|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
11411286|NCT01960595|Active Comparator|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
11411287|NCT01960582|Experimental|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
11411288|NCT01960582|No Intervention|Ordinary practice|Ordinary practice, not structured
11411289|NCT01960569|Active Comparator|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
11411290|NCT01960569|Placebo Comparator|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
11411291|NCT01960556||Simulation|Simulation Training part of education
11411292|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
11411293|NCT01960543|Active Comparator|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%
~Doses:
~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
11411294|NCT01960543|Active Comparator|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:
~Doses:
~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
11411295|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
11411296|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
11411297|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
11411298|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
11411299|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
11411300|NCT01960517|Experimental|Catheter placed|
11411301|NCT01960504|Experimental|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
11411302|NCT01960491|Experimental|Device Closure of Atrial Septal Defect|
11411303|NCT01960478|Other|bood test|
11411304|NCT01960465|Experimental|African Americans|138 Self identified African American
11411305|NCT01960465|Active Comparator|non African Americans|53 Caucasians and 29 Other race (non African-Americans) Veterans.
11411306|NCT01960452||Primary insomnia|
11411307|NCT01960452||Healthy sleeping controls|
11411308|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
11411309|NCT01960426|Active Comparator|Empiric Dose Intensification|Intensify treatment with the existing drug
11411310|NCT01960426|Active Comparator|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
11411311|NCT01960413|Experimental|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
11411312|NCT01960413|Placebo Comparator|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
11411313|NCT01960400|Active Comparator|GMI + tDCS|Graded motor imagery (GMI) + tDCS
11411314|NCT01960400|Placebo Comparator|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
11411315|NCT01960387|Experimental|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
11411316|NCT01960374|Experimental|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
11411317|NCT01960374|Experimental|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
11411318|NCT01960361|Experimental|ICE dental implant|Subjects implanted with ICE implant
11411319|NCT01960348|Active Comparator|patisiran (ALN-TTR02)|
11411320|NCT01960348|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11411321|NCT01960335|Active Comparator|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
11411592|NCT01958489|Experimental|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
11411322|NCT01960335|Experimental|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
11411323|NCT01960335|Experimental|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
11411324|NCT01960322|Experimental|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
11411325|NCT01960309|Experimental|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
11411326|NCT01960309|Experimental|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
11411327|NCT01960309|Experimental|3. TnI elevation|TnI>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
11411328|NCT01960309|Experimental|4. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb<5.1. Intervention: minimal invasive cardiac imaging
11411329|NCT01960309|Experimental|5. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb>5.0. Intervention: minimal invasive cardiac imaging
11411330|NCT01960309|Active Comparator|Control|TnI <0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
11411331|NCT01960296|Experimental|Clopidogrel|Continue home dose of clopidogrel into surgery
11411332|NCT01960296|Active Comparator|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
11411333|NCT01960283|Active Comparator|Group I|"The group I will receive the intervention :
~Methotrexate + anti-H1"
11411334|NCT01960283|Placebo Comparator|Group II|The intervention in group II will include : placebo + anti-H1
11411335|NCT01960270|Experimental|Alone controlateral stimulation|"Device: INTERSTIM II
~Stimulator II activated
~Stimulator I not activated
~Measure of efficacy on bladder hyperactivity"
11411336|NCT01960270|Experimental|2 sides-stimulation|"Device: INTERSTIM II
~Stimulator I and II activated
~Measure of efficacy on bladder hyperactivity"
11411337|NCT01960257|Experimental|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
11411338|NCT01960257|Active Comparator|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
11411339|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
11411340|NCT01960231||pancreas specific MODY-2|
11411341|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
11411342|NCT01960205|Experimental|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
11411343|NCT01960205|Active Comparator|Lifestyle intervention|Lifestyle intervention for 6 months
11411344|NCT01960205|Active Comparator|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
11411345|NCT01960205|Experimental|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
11411346|NCT01960192|Experimental|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
11411347|NCT01960192|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
11411348|NCT01960179|Experimental|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
11411349|NCT01960166|Experimental|Active distraction|Child will use Ipad as active distraction
11411350|NCT01960166|Experimental|Passive Distraction|Child will watch movie as passive distraction (control)
11411351|NCT01960153|Experimental|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
11411352|NCT01960153|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
11411353|NCT01960140|Experimental|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
11411354|NCT01960140|Experimental|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
11411355|NCT01960127|Experimental|Aerobic Exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
11411356|NCT01960127|Placebo Comparator|Usual Care Group|These patients will continue with their normal daily activity ad will not be provided with supervised aerobic exercise training during the study period.
11411357|NCT01960114|Experimental|Acetaminophen ER|
11411358|NCT01960114|Placebo Comparator|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
11411359|NCT01960101|Experimental|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
11411360|NCT01960101|Other|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
11411361|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
11411362|NCT01960075|Active Comparator|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
11411363|NCT01960075|Active Comparator|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
11411364|NCT01960075|Active Comparator|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
11411365|NCT01960062|No Intervention|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
11411366|NCT01960062|Experimental|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
11411367|NCT01960049|Placebo Comparator|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
11411368|NCT01960049|Active Comparator|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
11411369|NCT01960036|No Intervention|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
11411370|NCT01960036|Experimental|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
11411371|NCT01960036|Active Comparator|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
11411372|NCT01960023|Experimental|Arm 1: Cetuximab and Neratinib|Cetuximab 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV plus neratinib per oral daily until disease progression
11411373|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
11411374|NCT01960010|Placebo Comparator|Vehicle|Vehicle
11411375|NCT01959997|Active Comparator|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
11411376|NCT01959997|Active Comparator|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.
~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
11411377|NCT01959984|Experimental|100g Standard Noodles|100g Standard Noodles
11411378|NCT01959984|Experimental|75g Oral Glucose|75g Oral Glucose
11411379|NCT01959971|Experimental|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
11411380|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
11411381|NCT01959945|Experimental|Study Group 1, Flublok|Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
11411382|NCT01959945|Active Comparator|Study Group 2, Fluarix|Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
11411383|NCT01959945|Experimental|Study Group 3, Flublok|Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
11411384|NCT01959945|Active Comparator|Study Group 4, Fluarix|Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
11411385|NCT01959932|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
11411386|NCT01959932|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
11411387|NCT01959932|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
11411388|NCT01959919||Arm 1: Device|
11411389|NCT01959906||R0|Complete resection
11411390|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
11411391|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
11411392|NCT01959880|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
11411393|NCT01959880|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.
~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
11411394|NCT01959880|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
11411395|NCT01959880|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
11411396|NCT01959867|Experimental|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
11412364|NCT01953510|Experimental|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
11411397|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
11411398|NCT01959854|Active Comparator|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
11411399|NCT01959854|Experimental|xanthan gum|1 drop in each eye four times a day for 30 days
11411400|NCT01959841|Experimental|ASP2151(200 mg)|once daily
11411401|NCT01959841|Experimental|ASP2151(400mg)|once daily
11411402|NCT01959841|Experimental|valaciclovir|1000 mg three times daily
11411403|NCT01959828|Experimental|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).
~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).
~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
11411404|NCT01959815||Scleroderma and diagnosed PAH|
11411405|NCT01959815||"Low risk scleroderma"|
11411406|NCT01959815||Healthy volunteers|
11411407|NCT01959815||"High risk scleroderma"|
11411408|NCT01959802|Other|Vitrectomy|Vitrectomy for macular pseudo hole
11411409|NCT01959789||Control|Standard treatment
11411410|NCT01959789||2 days|bleaching treatments made in 2 days
11411411|NCT01959776|Other|Vitrectomy|
11411412|NCT01959763|Experimental|weight loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits
11411413|NCT01959763|Experimental|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method
11411414|NCT01959763|Experimental|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
11411415|NCT01959750|Experimental|Intervention Group|
11411416|NCT01959750|No Intervention|Control Group|
11411417|NCT01959737|No Intervention|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
11411418|NCT01959737|Experimental|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
11411419|NCT01959724|Other|Vitrectomy|Vitreous surgery to treat macular detachment
11411420|NCT01959711|Experimental|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
11411421|NCT01959711|Active Comparator|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
11411422|NCT01959698|Experimental|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11411423|NCT01959685|Experimental|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
11411424|NCT01959672|Experimental|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.
~IMMUNOTHERAPY: Patients with CA125 level >= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.
~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
11411425|NCT01959659||Cohort|
11411426|NCT01959646|Placebo Comparator|Placebo|Placebo Group
11411427|NCT01959646|Experimental|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
11411428|NCT01959633|Experimental|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
11411429|NCT01959620|No Intervention|Assessment only|Participants will receive assessment only.
11411430|NCT01959620|Experimental|1-session exposure intervention|Participants will receive one session of exposure therapy.
11411431|NCT01959620|Experimental|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
11411432|NCT01959607|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of CC)."
11411433|NCT01959607|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of CC)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
11411434|NCT01959607|Active Comparator|THS 2.2 then NRT|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single product use of THS 2.2)
~Day 2 = wash-out
~Day 3 = 2nd intervention (single administration of NRT gum [Nicorette® 2mg])."
11411435|NCT01959607|Active Comparator|NRT then THS 2.2|"Each subject will follow the below study design:
~Day 0 = Wash-out (1 day)
~Day 1 = 1st intervention (single administration of NRT gum [Nicorette® 2mg])
~Day 2 = wash-out
~Day 3 = 2nd intervention (single product use of THS 2.2)."
11411436|NCT01959594|Experimental|Cohort 1|
11411437|NCT01959594|Experimental|Cohort 2|
11411438|NCT01959594|Experimental|Cohort 3|
11411439|NCT01959594|Experimental|Optional Cohort 4|
11411440|NCT01959594|Experimental|Optional Cohort 5|
11411441|NCT01959581|Other|Movement enhancing device|Guided play while wearing a movement assisting device
11411442|NCT01959568|Experimental|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
11411803|NCT01957033|Experimental|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
11411443|NCT01959568|Active Comparator|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
11411444|NCT01959555||Retrospective collection of data|
11411445|NCT01959542|Experimental|MRIs and PSA Blood Test|"Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI
~Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI
~Visit 3 (on last day of EBRT): PSA blood test
~Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
11411446|NCT01959529|Experimental|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
11411447|NCT01959529|Active Comparator|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
11411448|NCT01959516|Experimental|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
11411449|NCT01959516|Experimental|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
11411450|NCT01959503|Experimental|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
11411451|NCT01959503|Active Comparator|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
11411452|NCT01959490|Experimental|Cohort 1P (HER2 positive)|Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11411453|NCT01959490|Experimental|Cohort 1T (HER2 positive)|Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11411454|NCT01959490|Experimental|Cohort II (HER2 negative)|Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
11411455|NCT01959477|Experimental|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
11411456|NCT01959464|Experimental|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.
~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
11411457|NCT01959464|Placebo Comparator|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
11411458|NCT01959451|Active Comparator|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
11411459|NCT01959451|Experimental|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
11411460|NCT01959438|Experimental|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
11411461|NCT01959425|Experimental|Off OAT Group (Test)|Discontinuation of OAT Therapy
11411462|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
11411463|NCT01959412|Experimental|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
11411464|NCT01959412|Experimental|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
11411465|NCT01959412|Experimental|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
11411466|NCT01959412|Experimental|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
11411467|NCT01959412|Experimental|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
11411468|NCT01959412|Experimental|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
11411469|NCT01959399|Experimental|ASP015K + rosuvastatin|
11411470|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
11411471|NCT01959373|Experimental|patients|
11411472|NCT01959373|Experimental|healthy volunteers|
11411473|NCT01959360|Active Comparator|direct lateral|
11411474|NCT01959360|Experimental|minimal invasive|
11411475|NCT01959360|Experimental|modified minimal invasive|
11411476|NCT01959347|Sham Comparator|Miduretheral Sling (Control)|Miduretheral Sling (Control)
11411477|NCT01959347|Experimental|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
11411478|NCT01959334|Active Comparator|Glucagon IM|Glucagon dose of 1 milligram (mg) administered intramuscularly (IM).
11411479|NCT01959334|Experimental|Nasal Glucagon (NG|Nasal Glucagon (NG) doses of 3 mg administered intra-nasally.
11411480|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
11411481|NCT01959295|Experimental|ASP2151|
11411482|NCT01959295|Placebo Comparator|ASP2151 placebo|
11411483|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
11411484|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
11411485|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
11411486|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
11411487|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
11411488|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
11411489|NCT01959256|Experimental|Learning|Visual perceptual learning (VPL) group
11411490|NCT01959256|No Intervention|Control|Control group
11411491|NCT01959243|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
11411492|NCT01959243|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
11411493|NCT01959230|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
11411494|NCT01959230|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
11411495|NCT01959217|Experimental|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
11411496|NCT01959204|Other|Active|Open label pharmacokinetic study of oxycodone.
11411804|NCT01957033|Experimental|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
11411497|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
11411498|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
11411499|NCT01959178|Experimental|LD127025 MF|Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
11411500|NCT01959178|Active Comparator|Air Optix Aqua MF|Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
11411501|NCT01959165|Experimental|MEDI7183 dose 1|Double blinded
11411502|NCT01959165|Experimental|MEDI7183 dose 2|Double blinded
11411503|NCT01959165|Experimental|MEDI7183 dose 3|Double blinded
11411504|NCT01959165|Placebo Comparator|Placebo|Double blinded
11411505|NCT01959152|Experimental|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
11411506|NCT01959139|Active Comparator|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11411507|NCT01959139|Experimental|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11411508|NCT01959139|Experimental|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours
11411509|NCT01959126|Experimental|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
11411510|NCT01959113|Experimental|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
11411511|NCT01959113|Placebo Comparator|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
11411512|NCT01959100|Experimental|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
11411513|NCT01959100|Placebo Comparator|Placebo|250 mg x 3/week during a meal for a period of 2 years.
11411514|NCT01959087|Experimental|1: Single port surgery|Surgery with single port
11411515|NCT01959087|Active Comparator|2: Multiport surgery|Surgery with multiport
11411516|NCT01959074|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
11411517|NCT01959074|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics
11411518|NCT01959061|Experimental|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
11411519|NCT01959048|Experimental|fecal microbiota transplant|fecal microbiota transplantation
11411520|NCT01959035|Experimental|Aripiprazole once-monthly|
11411521|NCT01959022|Experimental|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
11411522|NCT01959009|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min
~Ti = 1s
~Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
11411523|NCT01959009|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.
~MAP=mean airway pressure.
~DURING HFOV-SIGH:
~Frequency 3 breaths/min
~Ti = 1s
~Peak inspiratory pressure (PIP) = 30 cm H2O
~For patients already on HFOV-sigh at study start:
~• MAP-set will be left unchanged at pre-trial settings.
~For patients on HFOV-only at study start:
~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)
~DURING HFOV-ONLY
~For patients on HFOV-sigh at study start:
~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.
~For patients on HFOV-only at study start:
~• MAP-set will be left unchanged at pre-trial settings."
11411524|NCT01958996|Experimental|idarubicin|
11411948|NCT01956058|Experimental|brachytherapy remedial|
11411949|NCT01956045||Decision making|
11411525|NCT01958983|Experimental|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
11411526|NCT01958983|No Intervention|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
11411527|NCT01958970|Experimental|PINTA 745|
11411528|NCT01958970|Placebo Comparator|Placebo|
11411529|NCT01958957|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
11411530|NCT01958944|Experimental|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday & Saturday) in which no treatment under this study will be provided.
11411531|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
11411532|NCT01958918|Experimental|Ranibizumab|1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
11411533|NCT01958918|Active Comparator|Aflibercept|1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
11411534|NCT01958905|Experimental|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
11411535|NCT01958892||TURP|
11411536|NCT01958892||TUERP|
11411537|NCT01958879|Experimental|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
11411538|NCT01958879|Placebo Comparator|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
11411539|NCT01958866|Active Comparator|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
11411540|NCT01958866|Experimental|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
11411541|NCT01958866|Placebo Comparator|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
11411542|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
11411543|NCT01958840|Experimental|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
11411544|NCT01958840|Active Comparator|Supportive Counseling|Supportive Counseling Condition - 10 sessions
11411545|NCT01958827|Experimental|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
11411546|NCT01958814|Experimental|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
11411547|NCT01958814|Experimental|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
11411548|NCT01958801|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
11411549|NCT01958801|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
11411550|NCT01958788|Experimental|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
11411551|NCT01958775|Experimental|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
11411552|NCT01958775|Placebo Comparator|Placebo|placebo
11411553|NCT01958762|Other|Screening for cancers in the oral cavity|
11411554|NCT01958749|No Intervention|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.
~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
11411593|NCT01958489|Experimental|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.
11411555|NCT01958749|Experimental|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -
~10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation
~Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)
~Supernatant removed and collected into syringe
~Injected onto surface of fat graft
~Rest added to piece of gelfoam
~Place gelfoam + PRP on the TM perforation"
11411556|NCT01958736|Experimental|Experimental|Ballistic Strength Training
11411557|NCT01958736|Active Comparator|Control|Usual care Physiotherapy
11411558|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
11411559|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
11411560|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
11411561|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
11411562|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
11411563|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
11411564|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
11411565|NCT01958671|Experimental|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
11411566|NCT01958671|Experimental|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
11411567|NCT01958671|Other|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
11411568|NCT01958645|Experimental|A|MEDI8111
11411569|NCT01958645|Placebo Comparator|B|Placebo for MEDI8111
11411570|NCT01958632||N|nerve suture
11411571|NCT01958632||NT|nerve transplantation
11411572|NCT01958632||VM|vein-in-muscle conduit
11411573|NCT01958619|Experimental|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
11411574|NCT01958619|Experimental|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
11411575|NCT01958619|Experimental|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
11411576|NCT01958619|Experimental|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
11411577|NCT01958606|Experimental|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
11411578|NCT01958606|Active Comparator|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
11411579|NCT01958593|Placebo Comparator|Comparator|Participants will receive placebo during each of two experimental sessions.
11411580|NCT01958593|Experimental|3,4-methylenedioxymethamphetamine|Participants will receive full-dose MDMA during each of two experimental sessions.
11411581|NCT01958580|Experimental|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
11411582|NCT01958567|Experimental|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
11411583|NCT01958567|Experimental|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
11411584|NCT01958554|Experimental|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
11411585|NCT01958554|No Intervention|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
11411586|NCT01958541|Experimental|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
11411587|NCT01958541|Active Comparator|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
11411588|NCT01958528||Cohort 1 Progressors|
11411589|NCT01958528||Cohort 2 - Non-Progressors|
11411590|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
11411591|NCT01958502|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
11411594|NCT01958476|Active Comparator|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
11411595|NCT01958476|Active Comparator|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
11411596|NCT01958463|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
11411597|NCT01958450|Experimental|Er:YAG laser|acne scar treatment using Er:YAG laser
11411598|NCT01958450|Active Comparator|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
11411599|NCT01958437|Experimental|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
11411600|NCT01958437|Active Comparator|MCI ACTIVE tDCS|Group receives active brain stimulation
11411601|NCT01958437|Sham Comparator|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
11411602|NCT01958437|Sham Comparator|MCI SHAM tDCS|Group receives sham brain stimulation
11411603|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome
11411604|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome
11411605|NCT01958411||18FDG-PET/CT|
11411606|NCT01958398|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback.
11411607|NCT01958398|Experimental|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
11411608|NCT01958398|No Intervention|Control|Untreated control group
11411609|NCT01958385|Active Comparator|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
11411610|NCT01958385|Sham Comparator|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
11411611|NCT01958372|Experimental|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
11411612|NCT01958372|Experimental|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
11411613|NCT01958359|Experimental|Short IVR|IVR-based alcohol diary with feedback
11411614|NCT01958359|Experimental|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
11411615|NCT01958359|No Intervention|Control|Untreated control group
11411616|NCT01958346|Sham Comparator|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
11411617|NCT01958346|Experimental|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
11411618|NCT01958333|Experimental|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
11411619|NCT01958333|Experimental|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
11411620|NCT01958333|Experimental|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
11411621|NCT01958320|Experimental|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.
~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
11411622|NCT01958320|Active Comparator|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)
~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
11411623|NCT01958307|Experimental|Intervention|Lifestyle intervention
11411624|NCT01958307|No Intervention|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
11411625|NCT01958294|Other|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
11411626|NCT01958281|Experimental|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
11411627|NCT01958281|Experimental|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
11411628|NCT01958281|Experimental|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
11411629|NCT01958255|Other|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
11411630|NCT01958242|No Intervention|Preoperative blood harvesting|
11411631|NCT01958229||CHB patients without cirrhosis|
11411632|NCT01958216|Other|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
11411633|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
11411634|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
11411635|NCT01958177|Other|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
11411636|NCT01958164|Experimental|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
11411637|NCT01958164|Sham Comparator|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
11411638|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.
~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
11411639|NCT01958138|Experimental|propofol with Isoflurane|Propofol with Isoflurane, Group-P is the intervention arm with combination of two drugs such as low dose propofol and with reduced MAC of Isoflurane.
11411640|NCT01958138|Active Comparator|group-D|The group-D is the control arm of study by using the only Isoflurane 1.2 MAC
11411641|NCT01958125|Active Comparator|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
11411642|NCT01958125|Placebo Comparator|inactive gammacore|same as the active treatment, but without the therapy treatment provided
11411643|NCT01958112|Experimental|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
11411644|NCT01958099|Other|Injury Prevention Specialist|
11411645|NCT01958099|Experimental|Kiosk Intervention|
11411646|NCT01958086|Experimental|Neural Communication System|The Neural Communication System consists of two Neuroport Arrays, which are descried in detail in the intervention description. Both Neuroport Arrays are inserted into Brodmann's Area 5 in the posterior parietal cortex, an area of the brain used in reach planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
11411647|NCT01958073|Experimental|Conjugated Estrogen Vaginal Cream|Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
11411648|NCT01958073|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
11411649|NCT01958073|Placebo Comparator|Placebo|Per vagina
11411650|NCT01958060|Experimental|BI 1034020 intravenous part|single rising doses
11411651|NCT01958060|Experimental|BI 1034020 subcutaneous part|single rising doses
11411652|NCT01958047|Experimental|ASP3652|One single dose
11411653|NCT01958034|Experimental|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
11411654|NCT01958034|No Intervention|Control|No dietary supplement with bilberry extract
11411655|NCT01958021|Experimental|LEE011 + letrozole|LEE011 (Ribociclib) oral (3 weeks on/ 1 week off) in combination with oral once daily letrozole. 600mg LEE011 QD + 2.5 mg letrozole QD
11411656|NCT01958021|Placebo Comparator|Placebo + letrozole|Matching ribociclib placebo was the control drug and was administered orally once daily.
11411657|NCT01958008|Experimental|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
11411658|NCT01958008|Experimental|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
11411659|NCT01958008|Experimental|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
11411660|NCT01957995|Experimental|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
11411661|NCT01957995|Experimental|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
11411662|NCT01957995|Experimental|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
11411663|NCT01957995|Experimental|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
11411664|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
11411665|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
11411666|NCT01957956|Experimental|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.
~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.
~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.
~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.
~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11411667|NCT01957943|Placebo Comparator|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
11411736|NCT01957462|Experimental|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
11411668|NCT01957943|Active Comparator|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
11411669|NCT01957943|Active Comparator|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
11411670|NCT01957930|Experimental|Intensified insulin treatment|Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
11411671|NCT01957930|Active Comparator|Standard treatment|Mixed Insulin (2-3 times a day)
11411672|NCT01957930|No Intervention|Healthy controls|These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-
11411673|NCT01957917|Experimental|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
11411674|NCT01957917|Experimental|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
11411675|NCT01957917|Active Comparator|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
11411676|NCT01957904|Other|ArterX Surgical Sealant|
11411677|NCT01957878|Experimental|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
11411678|NCT01957878|Placebo Comparator|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
11411679|NCT01957865|Experimental|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
11411680|NCT01957865|Experimental|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
11411681|NCT01957865|No Intervention|control|Real-time adherence monitoring only (no SMS)
11411682|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
11411683|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
11411684|NCT01957839|No Intervention|pretreatment group|doppler evaluation at pretreatment period
11411685|NCT01957839|Experimental|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
11411686|NCT01957826|Placebo Comparator|placebo comparator|transendocardial injection of placebo solution
11411687|NCT01957826|Experimental|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
11411688|NCT01957813|Other|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
11411689|NCT01957813|Experimental|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
11411690|NCT01957800|Experimental|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
11411691|NCT01957800|Active Comparator|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
11411692|NCT01957787|Experimental|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. Tumors in both lungs are to be treated at an appropriate interval, determined on an individual basis. Treatment of bilateral index tumors in a single treatment session will not be performed. All participants will receive cryoablation of up to 6 metastatic lung tumors. Treatment of all study index tumors are to be completed within an 8-week window.
11411693|NCT01957774|Experimental|THR-18|
11411694|NCT01957774|Placebo Comparator|Placebo|matching placebo; look-alike with no active ingredients
11411695|NCT01957761||Clostridium difficile infection|
11411696|NCT01957748|No Intervention|Standard of Care (SoC)|Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services.
11411697|NCT01957748|Active Comparator|SoC + ALERT Intervention|Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study.
11411737|NCT01957449|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
11411738|NCT01957449|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
11411739|NCT01957436|Active Comparator|Arm A|androgen deprivation therapy + docetaxel
11411740|NCT01957436|Experimental|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
11411741|NCT01957436|Experimental|Arm C|Arm A + radiotherapy
11411742|NCT01957436|Experimental|Arm D|Arm B + radiotherapy
11412017|NCT01955564|Experimental|Cohort 2|NW-3509a 2mg or placebo
11411698|NCT01957735|Experimental|BP31510 monotherapy|"Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.
~first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.
~second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
11411699|NCT01957735|Active Comparator|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:
~Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;
~5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR
~Docetaxel IV once weekly at a starting dose of 20 mg/m2.
~Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
11411700|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
11411701|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
11411702|NCT01957709|Experimental|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.
11411703|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
11411704|NCT01957683|Experimental|Single Arm|
11411705|NCT01957670|Experimental|Treatment with Lacrima medical device|
11411706|NCT01957657|Experimental|Healthy volunteers group 1|Healthy volunteers with normal renal function
11411707|NCT01957657|Experimental|Renal function group 2|Patients with mild renal impairment
11411708|NCT01957657|Experimental|Renal function group 3|Patients with moderate renal impairment
11411709|NCT01957657|Experimental|Renal function group 4|Patients with severe renal impairment
11411710|NCT01957644|Experimental|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
11411711|NCT01957644|Experimental|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
11411712|NCT01957644|Experimental|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
11411713|NCT01957631|Active Comparator|Corticosteroid injection|Corticosteroid injection
11411714|NCT01957631|Experimental|Platelet rich plasma injection|Platelet rich plasma injection
11411715|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
11411716|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
11411717|NCT01957605||prone position|Patient scheduled for surgery in the prone position
11411718|NCT01957592||Subjects with diabetes mellitus (type 2)|
11411719|NCT01957579|Experimental|MEDI-551|
11411720|NCT01957566|Experimental|APS|
11411721|NCT01957553|Experimental|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
11411722|NCT01957553|Experimental|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
11411723|NCT01957540|Experimental|Ticagrelor|Ticagrelor 90mg bid for 15 days
11411724|NCT01957540|Active Comparator|Prasugrel|Prasugrel 10mg od for 15 days
11411725|NCT01957527||Ticagrelor discontinuation|
11411726|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
11411727|NCT01957501||Major Depressive Disorder Participants|
11411728|NCT01957501||Bipolar Disorder Participants:|
11411729|NCT01957501||Healthy Control Participants|
11411730|NCT01957488|Experimental|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects are first allocated to test Coloplast Test product 1 and secondly test either:
~Coloplast Test product 1 and thereafter Coloplast SenSura
~Coloplast Sensura and thereafter Coloplast Test product 2"
11411731|NCT01957488|Experimental|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects are first allocated to test Coloplast Test product 2 and secondly test either:
~Coloplast Test product 1 and thereafter Coloplast SenSura
~Coloplast Sensura and thereafter Coloplast Test product 1"
11411732|NCT01957488|Experimental|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects are first allocated to test Coloplast SenSura and secondly test either:
~Coloplast Test product 2 and thereafter Coloplast Test product 1
~Coloplast Test product 1 and thereafter Coloplast Test product 2"
11411733|NCT01957475|Experimental|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
11411734|NCT01957475|Experimental|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
11411735|NCT01957462|Experimental|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
11411802|NCT01957033|Experimental|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
11411743|NCT01957423|Experimental|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
11411744|NCT01957423|Active Comparator|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
11411745|NCT01957410|Experimental|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
11411746|NCT01957410|Placebo Comparator|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
11411747|NCT01957397|Experimental|Coloplast Test 1|"The subjects are randomised to two arms
~In both arms the subjects start measuring the performance of own product to collect baseline data.
~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2
~Finally the all subject test Coloplast Test 3"
11411748|NCT01957397|Experimental|Coloplast Test 2|"The subjects are randomised to two arms
~In both arms the subjects start measuring the performance of own product to collect baseline data.
~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1
~Finally the all subject test Coloplast Test 3"
11411749|NCT01957384|Experimental|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:
~Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)
~Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
11411750|NCT01957384|Experimental|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:
~Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)
~Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
11411751|NCT01957384|Experimental|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.
~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:
~Coloplast Test product 1 and thereafter Coloplast Test product 2
~Coloplast Test product 2 and thereafter Coloplast Test product 1"
11411752|NCT01957371|Experimental|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
11411753|NCT01957358|Experimental|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
11411754|NCT01957345|Other|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
11411755|NCT01957345|Other|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
11411756|NCT01957345|Other|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
11411757|NCT01957332|Experimental|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
11411758|NCT01957319|Active Comparator|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
11411759|NCT01957319|Placebo Comparator|placebo|sugar pill
11411760|NCT01957306|Experimental|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
11411761|NCT01957293|Experimental|Salbutamol|
11411762|NCT01957293|Placebo Comparator|Sugar Syrup|
11411763|NCT01957280|Experimental|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
11411764|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
11411765|NCT01957267||Normal Group|Volunteers with healthy eyes
11411766|NCT01957254||Severe Sepsis|Patient with severe sepsis
11411767|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
11411768|NCT01957228|Experimental|bone biopsies|
11411769|NCT01957215|Experimental|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
11411770|NCT01957215|Placebo Comparator|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
11411771|NCT01957202|Experimental|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
11411772|NCT01957189|Experimental|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
11411773|NCT01957176|Experimental|Cohort A|Cohort A consists of subjects who had completed their treatment with eltrombopag (ELT) during their participation in a parent study for Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 50 to 300 mg once daily (OD) for subjects of non- East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e. Japanese, Chinese, Taiwanese, Thai and Korean) will be 25 to 150 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
11412018|NCT01955564|Experimental|Cohort 3|NW-3509a 5mg or placebo
11411774|NCT01957176|Experimental|Cohort B|Cohort B consists of adult subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
11411775|NCT01957176|Experimental|Cohort C|Cohort C consists of pediatric subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
11411776|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
11411777|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
11411778|NCT01957163|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
11411779|NCT01957150|Experimental|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
11411780|NCT01957150|Experimental|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
11411781|NCT01957137|Other|Continuous|The device parameter will be continuous.
11411782|NCT01957137|Other|Cycling Parameter #1|The device parameter will be cyclic program #1.
11411783|NCT01957137|Other|Cycling Parameter #2|The device parameter will be cyclic program #2.
11411784|NCT01957137|Other|Cycling Parameter #3|The device parameter will be cyclic program #3.
11411785|NCT01957137|Other|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
11411786|NCT01957124|Experimental|PRF application|
11411787|NCT01957111||Individuals with insomnia|
11411788|NCT01957111||Good sleepers|
11411789|NCT01957098|Placebo Comparator|0% pentose|Pure sucrose without pentoses added.
11411790|NCT01957098|Active Comparator|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
11411791|NCT01957098|Active Comparator|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
11411792|NCT01957098|Active Comparator|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
11411793|NCT01957085||Hospitalized Patients|Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.
11411794|NCT01957072|Experimental|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
11411795|NCT01957072|Other|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
11411796|NCT01957059|Experimental|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
11411797|NCT01957059|Experimental|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
11411798|NCT01957059|Experimental|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.
~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).
~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate)."
11411799|NCT01957059|Experimental|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
11411800|NCT01957046|Other|Oral Laxative|
11411801|NCT01957033|Experimental|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
11412019|NCT01955564|Experimental|Cohort 4|NW-3509a 10 mg or placebo
11411805|NCT01957033|Experimental|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
11411806|NCT01957033|Experimental|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
11411807|NCT01957033|Experimental|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
11411808|NCT01957033|Experimental|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
11411809|NCT01957033|Experimental|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
11411810|NCT01957007|Experimental|Docetaxel|Drug: Docetaxel - administered intravenously
11411811|NCT01957007|Experimental|vantictumab|Drug: vantictumab - administered intravenously
11411812|NCT01956994|Experimental|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
11411813|NCT01956994|Active Comparator|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
11411814|NCT01956981|Placebo Comparator|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
11411815|NCT01956981|Active Comparator|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
11411816|NCT01956955|Active Comparator|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
11411817|NCT01956955|Active Comparator|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
11411818|NCT01956942|Experimental|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
11411819|NCT01956942|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
11411820|NCT01956929|Experimental|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
11411821|NCT01956929|Placebo Comparator|Placebo|2 weeks of Placebo (lactulose pills)
11411822|NCT01956916|Experimental|Probiotics|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
11411823|NCT01956916|Placebo Comparator|Placebo|Capsules containing maltodextrin
11411824|NCT01956903|Experimental|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
11411825|NCT01956890|Other|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
11411826|NCT01956877||Healthy volunteers|
11411827|NCT01956864|Experimental|Dose VD 1|Vitamin D
11411828|NCT01956864|Experimental|Dose VD 2|Vitamin D
11411829|NCT01956864|Experimental|Dose VD 3|Vitamin D
11411830|NCT01956864|Experimental|Dose VD 4|Vitamin D
11411831|NCT01956864|Experimental|Dose VD 5|Vitamin D
11411832|NCT01956864|Experimental|VD 6 Month Treatment|Vitamin D
11411833|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
11411834|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
11411835|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
11411836|NCT01956838|Experimental|Umami|intraduodenal infusion of umami
11411837|NCT01956838|Experimental|sweet|intraduodenal infusion of sweet tastant
11411838|NCT01956838|Experimental|bitter|intraduodenal infusion of bitter tastant
11411839|NCT01956838|Experimental|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
11411840|NCT01956838|Placebo Comparator|placebo|intraduodenal infusion of placebo (tap water)
11411841|NCT01956825|Placebo Comparator|water|just water
11411842|NCT01956825|Experimental|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
11411843|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
11411844|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
11411845|NCT01956786|Active Comparator|Amlodipine|5mg amlodipine,once daily for 8 weeks
11411846|NCT01956786|Experimental|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
11411847|NCT01956786|Experimental|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
11411848|NCT01956773|Experimental|MeTree - Patient|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients as clinical decision support.
11411849|NCT01956773|Experimental|MeTree - Provider|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to providers as clinical decision support.
11411850|NCT01956760|Experimental|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
11411851|NCT01956760|Placebo Comparator|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
11411852|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
11411853|NCT01956734|Experimental|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.
~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
11411854|NCT01956721|Experimental|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
11411855|NCT01956721|Experimental|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
11411856|NCT01956721|Other|Healthy Volunteers|Healthy Volunteers with no heart failure
11411857|NCT01956708|Active Comparator|RIPC|"Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):
~after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
11411858|NCT01956708|Placebo Comparator|Placebo|"No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):
~after induction of anesthesia and before surgery: the cuff is left uninflated"
11411859|NCT01956695|Experimental|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.
~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
11411860|NCT01956682|Active Comparator|Infant formula|HA formula + starch + L. reuteri
11411861|NCT01956682|Placebo Comparator|Standard Formula|Standard Infant Formula
11411862|NCT01956669|Experimental|Pazopanib|All subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m^2/dose or as a powder in suspension at a dose of 225 mg/m^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m^2/dose was not tolerated (>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
11411863|NCT01956656|Placebo Comparator|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
11411864|NCT01956656|Placebo Comparator|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
11411865|NCT01956643|Experimental|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.
~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
11411866|NCT01956643|Placebo Comparator|Control|Routine care during NPO
11411867|NCT01956630|Experimental|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
11411868|NCT01956630|Active Comparator|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
11411869|NCT01956617|Other|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
11411870|NCT01956604|Experimental|Clonidine|"Clonidine administered orally:
~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
11411871|NCT01956604|Placebo Comparator|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):
~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
11411872|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
11411873|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
11412020|NCT01955564|Experimental|Cohort 5|NW-3509a 20 mg or placebo
11411874|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
11411875|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
11411876|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
11411877|NCT01956578|Experimental|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
11411878|NCT01956565|Experimental|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
11411879|NCT01956565|No Intervention|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
11411880|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
11411881|NCT01956526|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
11411882|NCT01956526|Experimental|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
11411883|NCT01956526|No Intervention|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
11411884|NCT01956500|Experimental|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
11411885|NCT01956500|Placebo Comparator|Placebo|Placebo (3 capsules per day for 8 weeks)
11411886|NCT01956487|Other|Propafenone|Open label comparison of 2 formulations
11411887|NCT01956474|Other|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
11411888|NCT01956448|Experimental|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
11411889|NCT01956448|Experimental|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
11411890|NCT01956435|Other|Excimer Light Treatment Right Leg, Control Left Leg|Excimer light treatment will be performed on the right leg of every subject, no treatment on the left or control leg of the subject.
11411891|NCT01956435|Other|Excimer Light Treatment Left Leg, Control Right Leg|Excimer light treatment will be performed on the left leg of every subject, no treatment on the right or control leg of the subject.
11411892|NCT01956422|Experimental|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
11411893|NCT01956422|Active Comparator|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
11411894|NCT01956409|Experimental|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
11411895|NCT01956396|Experimental|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
11411896|NCT01956383|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
11411897|NCT01956370|Experimental|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
11411898|NCT01956370|Active Comparator|Surgical|Adult male surgical circumcision
11411899|NCT01956357|Experimental|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.
~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
11411900|NCT01956357|Experimental|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.
~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
11411901|NCT01956344|Experimental|Immediate Treatment|Cognitive-behavioral therapy
11411902|NCT01956344|No Intervention|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
11412021|NCT01955564|Experimental|Cohort 6|NW-3509a 30 mg or placebo
11411903|NCT01956344|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
11411904|NCT01956318|Experimental|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
11411905|NCT01956318|No Intervention|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
11411906|NCT01956305|Experimental|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
11411907|NCT01956305|Experimental|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
11411908|NCT01956305|Experimental|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
11411909|NCT01956305|Experimental|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
11411910|NCT01956305|Experimental|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
11411911|NCT01956305|Experimental|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
11411912|NCT01956305|Placebo Comparator|Placebo|placebo to match DS-7309
11411913|NCT01956292||Intraparenchimal cerebral haemorrhage|
11411914|NCT01956279|Experimental|Pregnenolone (Arm 1)|Pregnenolone
11411915|NCT01956279|Placebo Comparator|Placebo (Arm 2)|Placebo
11411916|NCT01956266|Experimental|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
11411917|NCT01956240|Experimental|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
11411918|NCT01956240|Experimental|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
11411919|NCT01956227|Experimental|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
11411920|NCT01956227|Experimental|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
11411921|NCT01956227|Experimental|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
11411922|NCT01956227|No Intervention|Control|Participants will not receive any treatment.
11411923|NCT01956214|Experimental|FES exercise|Participants will receive FES
11411924|NCT01956214|Sham Comparator|Mock FES exercise|participant will receive Mock FES
11411925|NCT01956201|Experimental|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
11411926|NCT01956201|Active Comparator|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
11411927|NCT01956188|Experimental|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
11411928|NCT01956188|Placebo Comparator|Placebo|Soy oil (3000 mg/d)
11411929|NCT01956175|Experimental|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
11411930|NCT01956175|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
11411931|NCT01956162|Experimental|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
11411932|NCT01956162|Active Comparator|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
11411933|NCT01956149|Experimental|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
11411934|NCT01956136|Experimental|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
11411935|NCT01956136|Experimental|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
11411936|NCT01956123|Experimental|A|Follitropin Delta (FE 999049) (COS cycle 2)
11411937|NCT01956123|Active Comparator|B|Follitropin Alfa (GONAL-F) (COS cycle 2)
11411938|NCT01956123|Experimental|C|Follitropin Delta (FE 999049) (COS cycle 3)
11411939|NCT01956123|Active Comparator|D|Follitropin Alfa (GONAL-F) (COS cycle 3)
11411940|NCT01956110|Experimental|A|Follitropin Delta (FE 999049)
11411941|NCT01956110|Active Comparator|B|Follitropin Alfa (GONAL-F)
11411942|NCT01956097|Experimental|HX106 590mg|HX106 590mg/day
11411943|NCT01956097|Experimental|HX106 1180mg|HX106 1180mg/day
11411944|NCT01956097|Placebo Comparator|Placebo|Placebo
11411945|NCT01956084|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
11411946|NCT01956084|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
11411947|NCT01956071|Experimental|WAPD|Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.
11411950|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.
~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
11411951|NCT01956019|Experimental|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
11411952|NCT01956006|Experimental|MIlrinone|ER milrinone
11411953|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
11411954|NCT01955980|Experimental|Buparid; Treatment A|Buparid 1mg budesonide/2 ml nebulizer solution
11411955|NCT01955980|Active Comparator|Budes; Treatment B|Budes Nasal Spray 50 µg budesonide/pump
11411956|NCT01955967|Other|Lidocaine|
11411957|NCT01955954|Experimental|Canary Breathing System|Treatment with Canary Breathing System
11411958|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
11411959|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
11411960|NCT01955928|Experimental|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
11411961|NCT01955928|No Intervention|Waiting-list|Waiting-list
11411962|NCT01955915||Choroidal Tumor Group|15 patients diagnosed with small posterior choroidal tumors will be considered and evaluated for enrollment into this study
11411963|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
11411964|NCT01955889|Experimental|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
11411965|NCT01955889|Active Comparator|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
11411966|NCT01955876||Group 1|
11411967|NCT01955863|Active Comparator|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
11411968|NCT01955863|Experimental|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
11411969|NCT01955863|Experimental|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
11411970|NCT01955850|Experimental|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
11411971|NCT01955850|Experimental|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
11411972|NCT01955850|No Intervention|Waiting-list|Waiting-list
11411973|NCT01955837|Experimental|TAS-102|
11411974|NCT01955837|Placebo Comparator|Placebo|
11411975|NCT01955824|Experimental|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
11411976|NCT01955824|Active Comparator|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
11411977|NCT01955811|Other|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
11411978|NCT01955798|Experimental|Trocar|Pyramidal tip reusable 11mm trocar
11411979|NCT01955798|Active Comparator|Veress needle|Veress needle
11411980|NCT01955785|Active Comparator|PC ventilation|Intervention with pressure controlled ventilator
11411981|NCT01955785|Active Comparator|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
11411982|NCT01955772|Experimental|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.
~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
11411983|NCT01955772|Other|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.
~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
11412365|NCT01953510|Experimental|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
11411984|NCT01955759|Experimental|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
11411985|NCT01955759|Experimental|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
11411986|NCT01955759|Placebo Comparator|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
11411987|NCT01955746||Type 1 DM|
11411988|NCT01955733|Experimental|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
11411989|NCT01955720|Experimental|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
11411990|NCT01955720|Experimental|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
11411991|NCT01955720|Experimental|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
11411992|NCT01955720|Experimental|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
11411993|NCT01955707|Experimental|natalizumab|300 mg single intravenous (IV) injection
11411994|NCT01955707|Placebo Comparator|Placebo|A single IV dose of placebo
11411995|NCT01955694|Experimental|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
11411996|NCT01955694|Experimental|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
11411997|NCT01955694|Active Comparator|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium
11411998|NCT01955694|Experimental|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
11411999|NCT01955694|Experimental|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
11412000|NCT01955694|Experimental|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
11412001|NCT01955668|Experimental|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
11412002|NCT01955655|Active Comparator|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
11412003|NCT01955655|Placebo Comparator|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
11412004|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
11412005|NCT01955629|Experimental|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m^2 q3w and Capecitabine 850 mg/m^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
11412006|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
11412007|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
11412008|NCT01955603|Experimental|Dose level 1|
11412009|NCT01955603|Experimental|Dose level 2|
11412010|NCT01955603|Experimental|Dose level 3|
11412011|NCT01955590|Experimental|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
11412012|NCT01955590|Active Comparator|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
11412013|NCT01955590|Active Comparator|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
11412014|NCT01955577|Experimental|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
11412015|NCT01955577|Placebo Comparator|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
11412016|NCT01955564|Experimental|Cohort 1|NW-3509a - 1mg or placebo
11412022|NCT01955551|Experimental|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
11412023|NCT01955551|Active Comparator|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
11412024|NCT01955538|Active Comparator|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
11412025|NCT01955538|Experimental|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
11412026|NCT01955538|Experimental|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
11412027|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
11412028|NCT01955512|Placebo Comparator|Placebo|Arm given placebo
11412029|NCT01955512|Experimental|Clopidogrel|Group given clopidogrel
11412030|NCT01955499|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11412031|NCT01955486|Experimental|flight simulation|flight simulation in pressure chamber
11412032|NCT01955473|Experimental|Sym004|
11412033|NCT01955460|Experimental|Treatment (chemotherapy, autologous T-cell immunotherapy)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
11412034|NCT01955447|Placebo Comparator|Reference|no added plant-based ingredients
11412035|NCT01955447|Active Comparator|Low level plant-based ingredients|Low level addition of plant-based ingredients
11412036|NCT01955447|Active Comparator|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
11412037|NCT01955447|Active Comparator|High level plant-based ingredients|High level addition of plant-based ingredients
11412038|NCT01955434|Experimental|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11412039|NCT01955421|Experimental|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
11412040|NCT01955421|Experimental|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
11412041|NCT01955408||Overactive bladder after Synergo|
11412042|NCT01955395|Active Comparator|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
11412043|NCT01955395|Active Comparator|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
11412044|NCT01955382|Experimental|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
11412045|NCT01955382|Placebo Comparator|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
11412046|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
11412047|NCT01955356|Experimental|Scratching|induced endometrial injury
11412048|NCT01955356|No Intervention|No scratching|None intervention
11412049|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
11412050|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
11412051|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
11412052|NCT01955317|Experimental|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
11412053|NCT01955317|Active Comparator|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
11412054|NCT01955304|Experimental|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
11412055|NCT01955304|Experimental|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
11412146|NCT01954758|Active Comparator|Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
11412056|NCT01955291|Experimental|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
11412057|NCT01955291|Other|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
11412058|NCT01955278|Experimental|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
11412059|NCT01955265|Experimental|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
11412060|NCT01955265|Active Comparator|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
11412061|NCT01955252|Experimental|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.
~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.
~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
11412062|NCT01955239|Active Comparator|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
11412063|NCT01955239|Experimental|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
11412064|NCT01955226|Experimental|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
11412065|NCT01955226|Active Comparator|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
11412066|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
11412067|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
11412068|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
11412069|NCT01955200|Experimental|CLOP-150|clopidogrel 150mg once daily
11412070|NCT01955200|Experimental|CLOP+CILOST|clopidogrel 75mg once daily plus cilostazol 100mg twice daily
11412071|NCT01955200|Experimental|TICAG|ticagrelor 90mg twice daily
11412072|NCT01955200|Active Comparator|CON(conventional DAPT)|clopidogrel 75mg once daily
11412073|NCT01955200|Active Comparator|Non-HOPR|clopidogrel 75mg once daily
11412074|NCT01955187|Experimental|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
11412075|NCT01955187|Active Comparator|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
11412076|NCT01955174|Experimental|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
11412077|NCT01955174|Sham Comparator|No injection|No injection of botulinum toxin
11412078|NCT01955161|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
11412079|NCT01955161|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
11412080|NCT01955161|Experimental|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
11412081|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
11412082|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
11412083|NCT01955148||Twin Pregnancy|Current twin pregnancy
11412084|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
11412085|NCT01955135|Active Comparator|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
11412086|NCT01955135|Active Comparator|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
11412087|NCT01955122|Other|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:
~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
11412088|NCT01955122|Other|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:
~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
11412089|NCT01955109|Experimental|Viaskin Peanut 250 mcg|
11412352|NCT01953575|Experimental|Active Eosinophilic Esophagitis|Subjects with an eosinophil count greater than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
11412090|NCT01955096|Experimental|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
11412091|NCT01955096|Other|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
11412092|NCT01955083|Experimental|Pillar implant|"Arm 1- Pillar implant (Study group):
~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
11412093|NCT01955083|Active Comparator|Radiofrequency|"Arm 2- Radiofrequency (control group):
~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
11412094|NCT01955070|Experimental|Implementation|Multimedia Presentation for Ketamine sedation
11412095|NCT01955070|Experimental|Intervention|Multimedia Presentation for Ketamine sedation
11412096|NCT01955070|No Intervention|Control|Patients that received the standard consent with signed consent form
11412097|NCT01955057||Smokers with lung cancer|
11412098|NCT01955044|Experimental|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
11412099|NCT01955044|Experimental|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
11412100|NCT01955044|Placebo Comparator|placebo|"the placebo is a drop that will be administered to ELBW infants."
11412101|NCT01955031|Experimental|Telemonitoring|Patient with type 2 diabetes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
11412102|NCT01955031|Sham Comparator|Usual care|patient randomized in this group have a usual care
11412103|NCT01955018|Experimental|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
11412104|NCT01955018|Other|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
11412105|NCT01955005|Experimental|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
11412106|NCT01955005|Active Comparator|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
11412107|NCT01954992|Experimental|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
11412108|NCT01954992|Active Comparator|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
11412109|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
11412110|NCT01954966|Active Comparator|Progesterone 200 mg capsules|Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.
11412111|NCT01954966|Placebo Comparator|Progesterone 200 mg look-alike capsules|Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.
11412112|NCT01954953||no intervention|
11412113|NCT01954940|Experimental|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
11412114|NCT01954940|No Intervention|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
11412115|NCT01954927|Active Comparator|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
11412116|NCT01954927|Placebo Comparator|Placebo|Patients will be randomized to receive one dose of placebo.
11412117|NCT01954914|Experimental|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
11412118|NCT01954901|Experimental|Standard treatment plus Hyperbaric Oxygen|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
11412119|NCT01954901|Placebo Comparator|Standard treatment with Hyperbaric Room Air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
11412120|NCT01954888|Active Comparator|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
11412121|NCT01954888|Active Comparator|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
11412122|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
11412123|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
11412124|NCT01954875||healthy controls|healthy subjects as controls
11412125|NCT01954862|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
11412126|NCT01954862|Experimental|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
11412366|NCT01953510|Experimental|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
11412127|NCT01954862|Experimental|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
11412128|NCT01954862|Experimental|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
11412129|NCT01954862|Experimental|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
11412130|NCT01954862|Experimental|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
11412131|NCT01954849|Experimental|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
11412132|NCT01954849|Placebo Comparator|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
11412133|NCT01954836|Experimental|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
11412134|NCT01954836|Active Comparator|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
11412135|NCT01954823|Experimental|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
11412136|NCT01954823|No Intervention|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
11412137|NCT01954810|No Intervention|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
11412138|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
11412139|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
11412140|NCT01954784|Experimental|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.
~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.
~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.
~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11412141|NCT01954771|Active Comparator|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
11412142|NCT01954771|Active Comparator|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
11412143|NCT01954771|Active Comparator|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
11412144|NCT01954758|Experimental|Personalized embryo transfer (pET)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and an endometrial biopsy in a substituted cycle after 5 days (around 120 hours) of progesterone administration. The ERA test will determine the window of implantation (WOI) for each patient and will recommend the best time for embryo transfer thereby increasing the chances of a successful outcome. In some specific cases (≤ 10%) a second biopsy will be required to help the bioinformatic predictor to ensure the most appropriated moment for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, following the ERA result, a personalized embryo transfer (pET) will be carried out following the same conditions in which the ERA test was obtained, using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage)
11412145|NCT01954758|Active Comparator|Frozen embryo transfer (FET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), a frozen embryo transfer (FET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
11412353|NCT01953575|Experimental|Inactive Eosinophilic Esophagitis|Subjects with an eosinophil count less than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
11412147|NCT01954745|Experimental|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
11412148|NCT01954732|No Intervention|Group I (observation)|Patients undergo observation.
11412149|NCT01954732|Experimental|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
11412150|NCT01954732|Experimental|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
11412151|NCT01954719|Experimental|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
11412152|NCT01954719|No Intervention|control group|cervix not dilated after surgery
11412153|NCT01954706|Experimental|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
11412154|NCT01954706|Active Comparator|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
11412155|NCT01954693|Experimental|Everolimus (RAD001)|2x2.5mg daily
11412156|NCT01954693|Placebo Comparator|Placebo|2x2.5mg daily
11412157|NCT01954680|Experimental|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
11412158|NCT01954680|Experimental|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
11412159|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
11412160|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to < 25 and/or WHtR ≥0.4 to <0.5)
11412161|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to < 25 and/ or WHtR ≥0.4 to <0.5)
11412162|NCT01954654|Experimental|Accelerated treatment|
11412163|NCT01954654|Active Comparator|Standard treatment|
11412164|NCT01954641|Experimental|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
11412165|NCT01954641|Active Comparator|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
11412166|NCT01954628|Experimental|AQX-1125|1 x AQX-1125 capsule daily
11412167|NCT01954628|Placebo Comparator|Placebo|1 x Placebo capsule daily
11412168|NCT01954615|Experimental|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
11412169|NCT01954615|Experimental|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
11412170|NCT01954615|Experimental|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
11412171|NCT01954615|Experimental|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
11412172|NCT01954615|Experimental|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
11412173|NCT01954615|Experimental|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
11412174|NCT01954615|Experimental|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
11412175|NCT01954602|Active Comparator|Touch group|Sphincterotome assisted guide-wire cannulation
11412176|NCT01954602|Experimental|No touch group|Guide-wire cannulation
11412177|NCT01954589|Experimental|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
11412178|NCT01954589|Experimental|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
11412179|NCT01954589|Experimental|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
11412863|NCT01950273|Experimental|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
11412180|NCT01954589|Experimental|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.
~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant & 2 subjects received placebo"
11412181|NCT01954589|Experimental|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
11412182|NCT01954589|Experimental|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
11412183|NCT01954589|Experimental|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
11412184|NCT01954576|Experimental|NovoTTF therapy|Patients undergo NovoTFF therapy at least 18 hours daily for 6 months (bevacizumab-naive) or 4 months (bevacizumab-refractory). Treatment may continue for up to 2 years in patients experiencing CR, PR, or SD.
11412185|NCT01954563|Experimental|Group 1|Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
11412186|NCT01954563|Experimental|Group 2|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28.
11412187|NCT01954563|Experimental|Group 3|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
11412188|NCT01954550|Experimental|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
11412189|NCT01954550|Sham Comparator|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
11412190|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
11412191|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
11412192|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
11412193|NCT01954524|Experimental|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
11412194|NCT01954511|No Intervention|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
11412195|NCT01954498|Experimental|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
11412196|NCT01954498|Active Comparator|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
11412197|NCT01954485|Experimental|LaserLok abutment|Laser microtexturing dental implant abutment
11412198|NCT01954485|Active Comparator|3inOne abutment|Standard dental implant abutment
11412199|NCT01954472|Experimental|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
11412200|NCT01954472|Active Comparator|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
11412201|NCT01954459|Active Comparator|Sensor alone|Glucose sensor site will not have Insupatch
11412202|NCT01954459|Experimental|Sensor with Insupatch|Glucose sensor site with Insupatch
11412203|NCT01954446|Experimental|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
11412204|NCT01954446|Experimental|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
11412205|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
11412206|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
11412207|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
11412208|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
11412209|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
11412210|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
11412211|NCT01954420|Other|Attention Control|"Standard care + cancer education
~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
11412212|NCT01954420|Experimental|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention
~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
11412213|NCT01954407|No Intervention|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
11412214|NCT01954407|Experimental|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
11412215|NCT01954407|Experimental|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
11412216|NCT01954394|Experimental|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
11412217|NCT01954381|Other|control|
11412218|NCT01954381|Experimental|patient|
11412219|NCT01954368|Placebo Comparator|Intranasal placebo|Patients receiving intranasal placebo at ED admission
11412220|NCT01954368|Experimental|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
11412221|NCT01954355|Experimental|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)
~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
11412222|NCT01954342||Pregnant|Obese pregnant women
11412223|NCT01954329||Patients suspected of TIA by the GP|
11412224|NCT01954316|Experimental|CFI-400945 fumarate Schedule A|CFI-400945 fumarate tablets daily dosing expansion at 64mg
11412225|NCT01954316|Experimental|CFI-400945 fumarate Schedule B|CFI-400945 fumarate tablets intermittent dosing schedule, 2 days on/5 days off. Escalation at following levels: 96mg, 128mg
11412226|NCT01954316|Experimental|CFI-400945 fumarate Schedule C|CFI-400945 fumarate tablets intermittent dosing schedule, 1 day on/6 days off. Escalation will start at MTD of Schedule B
11412227|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is <14 ng/L) and troponin negative (if hsTnT on first presentation is >=14 ng/l)."
11412228|NCT01954303||Progress of CHD|
11412229|NCT01954290|Active Comparator|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.
~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.
~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
11412230|NCT01954290|Experimental|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
11412231|NCT01954277|Experimental|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
11412232|NCT01954277|Sham Comparator|Placebo Sham|All patients will receive 10 placebo sham sessions.
11412233|NCT01954264|Other|Overall Study Group|Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy.
11412234|NCT01954251|Experimental|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
11412235|NCT01954251|Active Comparator|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
11412236|NCT01954238|Active Comparator|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
11412237|NCT01954238|Placebo Comparator|Placebo|GCC-4401C matching placebo capsule
11412238|NCT01954238|Experimental|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
11412239|NCT01954225|Other|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
11412240|NCT01954212|Experimental|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
11412241|NCT01954212|No Intervention|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.
~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
11412242|NCT01954199|Experimental|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
11412243|NCT01954199|No Intervention|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living
~Upon trial completion, treatment will be offered."
11412244|NCT01954186|Experimental|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
11412245|NCT01954186|Active Comparator|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
11412354|NCT01953575|Placebo Comparator|Control group|Subjects are those undergoing clinically indicated upper endoscopy for nonesophageal symptoms in whom a normal-appearing esophagus was found at the time of endoscopy
11412246|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
11412247|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
11412248|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
11412249|NCT01954147|Experimental|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
11412250|NCT01954147|Experimental|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
11412251|NCT01954147|Experimental|GLP-1|Liraglutide
11412252|NCT01954147|Active Comparator|Control|Standard Medical Treatment
11412253|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
11412254|NCT01954121|Experimental|Levetiracetam|Levetiracetam 1000 mg/day
11412255|NCT01954121|Active Comparator|Carbamazepine|Carbamazepine 400 mg/day
11412256|NCT01954108|Other|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
11412257|NCT01954108|Active Comparator|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
11412258|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups.
11412259|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
11412260|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
11412261|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
11412262|NCT01954082|Experimental|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
11412263|NCT01954082|Placebo Comparator|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
11412264|NCT01954069|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
11412265|NCT01954056|Active Comparator|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
11412266|NCT01954056|Placebo Comparator|Placebo|Saline placebo
11412267|NCT01954043|Experimental|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
11412268|NCT01954030|Experimental|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
11412269|NCT01954030|Experimental|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
11412270|NCT01954030|Experimental|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
11412271|NCT01954017|Experimental|STP206|Biological
11412272|NCT01954017|Placebo Comparator|Control|Sterile water
11412273|NCT01953991|Active Comparator|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
11412274|NCT01953991|Active Comparator|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
11412275|NCT01953978|Active Comparator|Dexamethasone|"Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
11412276|NCT01953978|Placebo Comparator|Placebo|"Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
11412355|NCT01953562||Intubated infants|
11412356|NCT01953549|Experimental|physical fitness training|aerobic physical fitness training
11412357|NCT01953549|Active Comparator|relaxation|non-aerobic training
11412277|NCT01953952|Experimental|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
11412278|NCT01953952|Active Comparator|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
11412279|NCT01953939|Experimental|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
11412280|NCT01953926|Experimental|Neratinib monotherapy|Neratinib monotherapy in HER2 mutated cancers including cervical, salivary gland, solid tumors (NOS) and lung cancers containing EGFR exon 18 mutations. Cohorts closed to enrollment in Amendment 6: gastroesophageal, biliary, ovarian, solid tumor (NOS) HER4 mutant, and fibrolamellar carcinoma.
11412281|NCT01953926|Experimental|Neratinib and Paclitaxel|Neratinib and Paclitaxel in HER2 mutated bladder/urinary tract cancers.
11412282|NCT01953926|Experimental|Neratinib and Trastuzumab|Neratinib and Trastuzumab in HER2 mutated (TNBC, HR-negative) breast cancers. Cohorts closed to enrollment in Amendment 6: colorectal, lung cancer HER2 mutant.
11412283|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Randomized)|Neratinib, Fulvestrant and Trastuzumab or Fulvestrant and Trastuzumab or Fulvestrant alone in HER2 mutated (HR-positive with prior CDK4/6i) breast cancers.
11412284|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Non-Randomized)|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated (HR-positive with CDK4/6i naïve) breast cancers.
11412285|NCT01953913|Experimental|Afatinib|Patient will receive afatinib once daily
11412286|NCT01953900|Experimental|GD2 T cells plus VZV vaccine|In this study we will be administering from 1 x 10^6 to 1 x 10^9 transduced autologous VZV-specific CTLs, derived from VZV-specific memory T cells, so there will be no risk of alloreactivity. 6.1.1 Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m2/day followed by Fludarabine 30 mg/m2/day.
11412287|NCT01953887|Experimental|1 combination tablet EC905|
11412288|NCT01953887|Experimental|2: solifenacin|
11412289|NCT01953887|Experimental|3: tamsulosin|
11412290|NCT01953874|Experimental|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
11412291|NCT01953874|Active Comparator|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
11412292|NCT01953861|Experimental|1: fasted|EC905 + fasted
11412293|NCT01953861|Experimental|2: low-fat breakfast|EC905 + low-fat breakfast
11412294|NCT01953861|Experimental|3: high-fat breakfast|EC905 + high-fat breakfast
11412295|NCT01953848|Experimental|1: Low dose EC905|
11412296|NCT01953848|Experimental|2: High dose EC905|
11412297|NCT01953835|Experimental|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
11412298|NCT01953835|Experimental|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
11412299|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
11412300|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
11412301|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
11412302|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
11412303|NCT01953809|Experimental|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
11412304|NCT01953809|Experimental|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
11412305|NCT01953809|Experimental|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
11412306|NCT01953809|Experimental|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
11412307|NCT01953796|Experimental|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle >10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
11412358|NCT01953536|Experimental|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
11412359|NCT01953536|Experimental|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
11412308|NCT01953796|Active Comparator|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
11412309|NCT01953783|Experimental|IXAZOMIB|"Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.
~Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity."
11412310|NCT01953770|Active Comparator|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
11412311|NCT01953770|Experimental|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
11412312|NCT01953770|Experimental|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
11412313|NCT01953770|Active Comparator|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
11412314|NCT01953770|Experimental|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
11412315|NCT01953770|Active Comparator|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
11412316|NCT01953770|Active Comparator|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
11412317|NCT01953770|Experimental|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
11412318|NCT01953770|Experimental|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
11412319|NCT01953757|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
11412320|NCT01953757|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
11412321|NCT01953744|Experimental|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
11412322|NCT01953744|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
11412323|NCT01953731|Experimental|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
11412324|NCT01953705|Experimental|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
11412325|NCT01953705|Placebo Comparator|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
11412326|NCT01953692|Experimental|Cohort 1: Myelodysplastic syndrome (MDS)|(Completed) 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable adverse event(s) (AEs), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after Complete Response (CR) if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
11412327|NCT01953692|Experimental|Cohort 2: Relapse refractory/refractory multiple myeloma (MM)|(Completed) Participants receive pembrolizumab 200 mg by IV infusion every 3 weeks (Q3W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after stringent complete response (sCR) if treatment has been administered for 24 weeks and 2 doses have been administered after sCR.
11412328|NCT01953692|Experimental|Cohort 3: Relapsed/refractory (R/R) Hodgkin lymphoma (HL)|(Completed) 10 mg/kg by IV infusion Q2W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
11412329|NCT01953692|Experimental|Cohort 4A: R/R mediastinal large B cell lymphoma (MLBCL)|Participants receive pembrolizumab 200 mg by IV infusion every 3 weeks (Q3W). Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
11412360|NCT01953536|Active Comparator|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
11412361|NCT01953523|Experimental|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
11412362|NCT01953510|Active Comparator|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
11412330|NCT01953692|Experimental|Cohort 4B: R/R PD-L1-positive NHL|(Completed) Participants receive pembrolizumab 10 mg/kg by IV infusion Q2W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
11412331|NCT01953692|Experimental|Cohort 4C: Relapsed/refractory Follicular Lymphoma (FL)|Participants receive pembrolizumab 200 mg by IV infusion Q3W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
11412332|NCT01953692|Experimental|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants receive pembrolizumab 200 mg by IV infusion Q3W. Treatment with pembrolizumab will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and 2 doses have been administered after CR.
11412333|NCT01953692|Experimental|Cohort 5: R/R DLBCL combination treatment|(Discontinued) Participants receive pembrolizumab 200 mg by IV infusion Q3W + lenalidomide 25 mg capsule by mouth (PO) or recommended Phase II dose for 21 consecutive days with 7 days off. Treatment with pembrolizumab + lenalidomide will continue for up to 2 years or until documented disease progression, unacceptable AEs, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the participant, participant withdraws consent, pregnancy of the participant, noncompliance with trial treatment or procedure requirements, or administrative reasons. Can stop after CR if treatment has been administered for 24 weeks and they receive an additional 21 consecutive daily doses of lenalidomide + 2 doses of pembrolizumab after CR.
11412334|NCT01953679|Active Comparator|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
11412335|NCT01953679|Active Comparator|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
11412336|NCT01953666|Experimental|Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
11412337|NCT01953666|Active Comparator|Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
11412338|NCT01953666|No Intervention|No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
11412339|NCT01953653|Other|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
11412340|NCT01953653|Other|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
11412341|NCT01953640||Ancillary-correlative (gene expression with CYP-17 inhibition)|Laboratory Biomarker Analysis: Tissue, blood, and urine samples are collected at baseline and after 12-14 weeks of treatment and assessed for circulating tumor cells, genome-wide SNP, and exome sequencing. Subjects will also receive a Quality-of-Life Assessment.
11412342|NCT01953627|Experimental|Surgical procedure with the system Kymerax|
11412343|NCT01953614|Sham Comparator|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
11412344|NCT01953614|Active Comparator|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
11412345|NCT01953614|No Intervention|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
11412346|NCT01953601|Experimental|Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)|[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
11412347|NCT01953601|Experimental|Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)|[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
11412348|NCT01953601|Placebo Comparator|Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)|[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
11412349|NCT01953588|Active Comparator|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
11412350|NCT01953588|Active Comparator|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
11412351|NCT01953588|Active Comparator|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
11412367|NCT01953510|No Intervention|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
11412368|NCT01953510|No Intervention|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
11412369|NCT01953497|Placebo Comparator|Placebo|Placebo
11412370|NCT01953497|Active Comparator|URC102|URC102
11412371|NCT01953484|Experimental|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
11412372|NCT01953484|Experimental|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
11412373|NCT01953484|Experimental|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
11412374|NCT01953471||Allergic rhinitis|
11412375|NCT01953458||hepatitis C and/or B|
11412376|NCT01953445|Experimental|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11412377|NCT01953432|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
11412378|NCT01953432|Placebo Comparator|Placebo|Matched placebo daily dosing.
11412379|NCT01953419|Experimental|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
11412380|NCT01953406|Experimental|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
11412381|NCT01953380|Active Comparator|extended information|Extended information on specific allergy
11412382|NCT01953380|No Intervention|Information according to clin. routine|Information according to clinical routine
11412383|NCT01953367|Experimental|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
11412384|NCT01953367|Active Comparator|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
11412385|NCT01953354|Experimental|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
11412386|NCT01953354|Placebo Comparator|Placebo|Six doses of TSO placebo orally over a ten-week period
11412387|NCT01953341|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 .
11412388|NCT01953341|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo.
11412389|NCT01953328|Placebo Comparator|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
11412390|NCT01953328|Placebo Comparator|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
11412391|NCT01953328|Experimental|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11412392|NCT01953328|Experimental|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
11412393|NCT01953328|Placebo Comparator|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
11412394|NCT01953328|Other|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
11412395|NCT01953328|Experimental|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11412396|NCT01953328|Experimental|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
11412397|NCT01953315|Experimental|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
11412398|NCT01953302|Experimental|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
11412399|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
11412400|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
11412401|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
11412402|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
11412403|NCT01953237|Active Comparator|Control|Individuals randomized to the control condition will be provided with a smartphone free of charge with unlimited use of the phone's voice and internet capabilities. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period. All participants will be contacted by research staff to trouble-shoot problems with the smartphone at the end of the first week, but will receive no additional contact from research staff until the end of the trial.
11412404|NCT01953237|Experimental|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
11412486|NCT01952626|Experimental|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
11412405|NCT01953224|Experimental|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
11412406|NCT01953224|No Intervention|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
11412407|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
11412408|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
11412409|NCT01953185|Experimental|Manual diaphragm release technique|
11412410|NCT01953185|Sham Comparator|Control group|
11412411|NCT01953172|Placebo Comparator|Placebo capsules|Placebo capsules
11412412|NCT01953172|Experimental|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
11412413|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
11412414|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
11412415|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged < 38 years without endometriosis where more than > 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
11412416|NCT01953133|No Intervention|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.
~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
11412417|NCT01953133|Experimental|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
11412418|NCT01953120|Experimental|Belatacept|Survival and rejection in patients switched to belatacept.
11412419|NCT01953107|Experimental|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
11412420|NCT01953107|Placebo Comparator|Placebo + Vitamin C|300 mg of Placebo
11412421|NCT01953094|Other|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
11412422|NCT01953094|Other|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
11412423|NCT01953081|Experimental|TD-8954|TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
11412424|NCT01953081|Active Comparator|Metoclopramide|Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline
11412425|NCT01953055|Experimental|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
11412426|NCT01953042|No Intervention|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
11412427|NCT01953042|Active Comparator|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
11412428|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
11412429|NCT01953016||immunodeficiency|Individual of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
11412430|NCT01953003|Experimental|Arm A : iv vinflunine plus Capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
11412431|NCT01953003|Active Comparator|capecitabineArm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
11412432|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.
~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
11412433|NCT01952977|Active Comparator|MCT|MCT oil (20 g) was included in the test breakfast
11412434|NCT01952977|Placebo Comparator|LCT|Corn oil (20 g) was included in the test breakfast
11412435|NCT01952964|Experimental|JUC spray dressing|
11412436|NCT01952951|Experimental|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
11412437|NCT01952951|Active Comparator|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
11412438|NCT01952938||LINK SL|Patients
11412439|NCT01952938||EnduRo|Patients
11412440|NCT01952925|Experimental|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
11412441|NCT01952912|Active Comparator|PkEP|
11412442|NCT01952912|Active Comparator|OP|
11412443|NCT01952899||Albert Schweitzer Hospital|
11412444|NCT01952899||Erasmus MC Academic Hospital|
11412445|NCT01952899||Ikazia Hospital|
11412446|NCT01952899||IJsselland Hospital|
11412447|NCT01952899||Maasstad Hospital|
11412448|NCT01952899||Sint Franciscus Gasthuis Hospital|
11412449|NCT01952886|Experimental|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
11412450|NCT01952886|Active Comparator|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
11412451|NCT01952873|Active Comparator|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
11412452|NCT01952873|Experimental|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
11412453|NCT01952860|Experimental|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
11412454|NCT01952847|Placebo Comparator|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
11412455|NCT01952847|Experimental|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
11412456|NCT01952847|Placebo Comparator|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
11412457|NCT01952847|Experimental|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
11412458|NCT01952834|Experimental|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
11412459|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
11412460|NCT01952808|Experimental|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
11412461|NCT01952808|No Intervention|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
11412462|NCT01952795|Active Comparator|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
11412463|NCT01952795|No Intervention|No intervention|Usual diet and exercise
11412464|NCT01952782|Experimental|Naloxone, Kisspeptin, GnRH|"The study will involve 3 visits:
~Outpatient screening visit
~Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)
~Outpatient follow-up visit"
11412465|NCT01952769|Experimental|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
11412466|NCT01952756|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
11412467|NCT01952756|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
11412468|NCT01952743|Active Comparator|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
11412469|NCT01952743|Experimental|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
11412470|NCT01952730|Experimental|Experimental Treatment Arm|GVAX, up to 6 vaccinations, administered via injection
11412471|NCT01952704|Experimental|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
11412472|NCT01952704|Placebo Comparator|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
11412473|NCT01952691|Experimental|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
11412474|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
11412475|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
11412476|NCT01952665|Active Comparator|comfilcon A|Daily wear soft contact lens comfilcon A
11412477|NCT01952665|Active Comparator|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
11412478|NCT01952652|Active Comparator|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
11412479|NCT01952652|Active Comparator|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
11412480|NCT01952639|Experimental|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
11412481|NCT01952639|Experimental|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
11412482|NCT01952639|Active Comparator|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
11412483|NCT01952639|Active Comparator|30 g of casein|Subjects will consume 30 g of casein protein type and amount
11412484|NCT01952639|Experimental|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
11412485|NCT01952626|Active Comparator|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
11412487|NCT01952613|Experimental|Stroke - FES|Stroke population currently prescribed a FES orthotic device (< week)
11412488|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
11412489|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
11412490|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
11412491|NCT01952587|Other|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
11412492|NCT01952587|Other|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
11412493|NCT01952574|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
11412494|NCT01952574|Experimental|Erenumab 7 mg QM|Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
11412495|NCT01952574|Experimental|Erenumab 21 mg QM|Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
11412496|NCT01952574|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.
11412497|NCT01952561|Experimental|2 weeks|
11412498|NCT01952561|Experimental|1 week|
11412499|NCT01952561|Experimental|4 weeks|
11412500|NCT01952561|Experimental|8 weeks|
11412501|NCT01952561|Experimental|12 weeks|
11412502|NCT01952548|Experimental|Dose 1 Active|
11412503|NCT01952548|Experimental|Dose 2 Active|
11412504|NCT01952548|Experimental|Dose 3 Active|
11412505|NCT01952548|Experimental|Dose 4 Active|
11412506|NCT01952548|Experimental|Dose 5 Active|
11412507|NCT01952548|Experimental|Dose 6 Active|
11412508|NCT01952548|Experimental|Dose 7 Active|
11412509|NCT01952548|Placebo Comparator|Dose 1 Placebo|
11412510|NCT01952548|Placebo Comparator|Dose 2 Placebo|
11412511|NCT01952548|Placebo Comparator|Dose 3 Placebo|
11412512|NCT01952548|Placebo Comparator|Dose 4 Placebo|
11412513|NCT01952548|Placebo Comparator|Dose 5 Placebo|
11412514|NCT01952548|Placebo Comparator|Dose 6 Placebo|
11412515|NCT01952548|Placebo Comparator|Dose 7 Placebo|
11412516|NCT01952535|Experimental|HMS5552 dose 1|A single dose of HMS5552 tablets (5~50mg) taken orally.
11412517|NCT01952535|Experimental|HMS5552 dose 2|A single dose of HMS5552 tablets (5~50mg) taken orally.
11412518|NCT01952535|Experimental|HMS5552 dose 3|A single dose of HMS5552 tablets (5~50mg) taken orally.
11412519|NCT01952535|Experimental|HMS5552 dose 4|A single dose of HMS5552 tablets (5~50mg) taken orally.
11412520|NCT01952535|Experimental|HMS5552 dose 5|A single dose of HMS5552 tablets (5~50mg) taken orally.
11412521|NCT01952535|Experimental|HMS5552 dose 6|A single dose of HMS5552 tablets (5~50mg) taken orally.
11412522|NCT01952522|Experimental|Weighted brace|
11412523|NCT01952522|Placebo Comparator|non weighted brace|
11412524|NCT01952509||Cohort|
11412525|NCT01952496|Other|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months."
11412526|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level <20ng/ml)
11412527|NCT01952483||Vitamin D normal|Serum level >35 ng/ml
11412528|NCT01952470|Experimental|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa.
11412529|NCT01952470|Active Comparator|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
11412530|NCT01952457|Experimental|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
11412531|NCT01952457|Active Comparator|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
11412532|NCT01952444|Experimental|Group 1 ETI-204 and Ciprofloxacin|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1, immediately followed by an IV dose of ciprofloxacin 400 mg infused over 60 minutes, followed by oral doses of ciprofloxacin (750 mg every 12 hours) from Day 2 to Day 8 and a final dose on the morning of Day 9.
11412533|NCT01952444|Other|Group 2 ETI-204 Alone|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1.
11412534|NCT01952431|Experimental|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
11412535|NCT01952431|Active Comparator|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
11412536|NCT01952418|No Intervention|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
11412537|NCT01952418|Active Comparator|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
11412538|NCT01952405|Experimental|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
11412578|NCT01952106|Experimental|distraction|use the computer game to distract children's pain and anxiety during venepuncture
11412969|NCT01949597||Patients with symptomatic endometriosis|
11412539|NCT01952405|Placebo Comparator|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
11412540|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
11412541|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
11412542|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
11412543|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
11412544|NCT01952353|Experimental|Preoperation TACE arm|In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist
11412545|NCT01952353|Active Comparator|Resection arm|Liver resection Plus Thrombectomy
11412546|NCT01952340|Experimental|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
11412547|NCT01952340|Placebo Comparator|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
11412548|NCT01952327|Other|plueurapump|Implantation of pleurapump system
11412549|NCT01952314|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics.
11412550|NCT01952314|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
11412551|NCT01952301|Active Comparator|xenogeneic collagen matrix|Xenogeneic collagen matrix device placed on treatment wound bed site
11412552|NCT01952301|Active Comparator|Free Gingival Graft|Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed
11412553|NCT01952288|Experimental|simvastatin|simvastatin 40 mg/day
11412554|NCT01952288|Placebo Comparator|placebo|
11412555|NCT01952262||critically ill ICU patients|critically ill intensive care unit patients
11412556|NCT01952249|Experimental|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
11412557|NCT01952249|Experimental|Taxol|demcizumab combined with weekly paclitaxel
11412558|NCT01952236|Experimental|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
11412559|NCT01952236|Active Comparator|Web Only|A best-practices Web-based smoking cessation program.
11412560|NCT01952223|Experimental|ADT + pelvic RT|"ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen
~Pelvic RT (by IMRT or IGRT protocol):
~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
11412561|NCT01952223|Experimental|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles
~Prostate-only RT (IMRT or IGRT):
~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
11412562|NCT01952223|Experimental|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles
~Pelvic RT (IMRT or IGRT):
~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
11412563|NCT01952223|Active Comparator|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen
~Prostate-only RT (IMRt or IGRT):
~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
11412564|NCT01952210|Experimental|nutrition consultation and exercise program|individual nutritional consultation and exercise
11412565|NCT01952210|Active Comparator|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
11412566|NCT01952197|Experimental|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
11412567|NCT01952184|Active Comparator|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
11412568|NCT01952184|Experimental|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
11412569|NCT01952171||Congenital Heart Disease|Congenital Heart Disease
11412570|NCT01952145|Experimental|Insulin degludec/liraglutide OD plus metformin|
11412571|NCT01952145|Active Comparator|Insulin glargine OD plus metformin|
11412572|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
11412573|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
11412574|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
11412575|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
11412576|NCT01952119|No Intervention|Routine Care|Routine care, no intervention
11412577|NCT01952119|Active Comparator|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
11412579|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
11412580|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
11412581|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
11412582|NCT01952093||Term control group|Healthy term infants
11412583|NCT01952080|Experimental|teduglutide|Open label teduglutide, subcutaneously injected.
11412584|NCT01952080|No Intervention|Standard of Care|
11412585|NCT01952067|Experimental|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
11412586|NCT01952067|Active Comparator|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
11412587|NCT01952054|Experimental|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
11412588|NCT01952041|Experimental|Device: Smartphone|Participants in the smartphone intervention arm received treatment as usual in addition to receiving a smartphone with the study application. The study application identified relapse risk and prompted the clinical team to provide enhanced services.
11412589|NCT01952041|Active Comparator|Treatment as Usual|Treatment as usual included outpatient case management, linkage to services and medication monitoring.
11412590|NCT01952015|Experimental|AIN457|"All subjects were assigned to receive 150 mg secukinumab (AIN457) by subcutaneous injections. AIN457 was administered at baseline, weeks 1, 2, 3, 4. Prior to receiving the week 8 dose, all subjects were assigned to the following treatment group based on clinical components of their Clinical Global Impression (CGI) evaluation at week 8.
~No up-titration group received 1 injection of 150 mg AIN457 at weeks 8, 12, and each visit from week 16 until week 48.
~Up-titration group received 2 injections of 150 mg AIN457 at weeks 8, 9, 12 and each visit from week 16 until week 48.
~Subjects who received 150 mg AIN457 can be up-titrated to 300 mg AIN 457 at any visit starting at week 16 based on clinical components of their CGI evaluation and investigator's discretion."
11412591|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
11412592|NCT01951989|Experimental|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.
~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
11412593|NCT01951976|Experimental|Intervention Condition|"Questionnaires and yoga classes.
~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
11412594|NCT01951963|Experimental|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
11412595|NCT01951963|Active Comparator|Morphine|Morphine, single dose, 0.05 mg/kg, IV
11412596|NCT01951950|Active Comparator|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
11412597|NCT01951950|Active Comparator|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
11412598|NCT01951937|Active Comparator|Fish Meals|3 Fish meals per week for 4 months
11412599|NCT01951937|Placebo Comparator|Placebo|Habitual diet
11412600|NCT01951924|Experimental|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
11412601|NCT01951924|Experimental|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
11412602|NCT01951911|Active Comparator|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
11412603|NCT01951911|Placebo Comparator|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
11412604|NCT01951898|Active Comparator|Montelukast|
11412605|NCT01951898|Sham Comparator|Vitamin B6|
11412606|NCT01951885|Active Comparator|Group A (tacrolimus, methotrexate)|Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.
11412607|NCT01951885|Experimental|Group B (tacrolimus, methotrexate, mycophenolate mofetil)|Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).
11412608|NCT01951872|Experimental|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
11413516|NCT01945944|Experimental|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
11412609|NCT01951872|Experimental|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
11412610|NCT01951859|Experimental|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
11412611|NCT01951859|Placebo Comparator|Placebo Cream|
11412612|NCT01951846|Experimental|BIBF 1120|
11412613|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
11412614|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.
~No treatment, observational"
11412615|NCT01951820|Active Comparator|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
11412616|NCT01951820|Experimental|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
11412617|NCT01951807|Experimental|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
11412618|NCT01951807|Experimental|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
11412619|NCT01951807|No Intervention|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
11412620|NCT01951781|Other|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
11412621|NCT01951768|Experimental|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
11412622|NCT01951768|Active Comparator|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
11412623|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
11412624|NCT01951742|Experimental|Dose 1|lowest dose
11412625|NCT01951742|Experimental|Dose 2|second lowest dose
11412626|NCT01951742|Experimental|Dose 3|mid-level dose
11412627|NCT01951742|Experimental|Dose 4|second highest dose
11412628|NCT01951742|Experimental|Dose 5|highest dose
11412629|NCT01951729|Experimental|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
11412630|NCT01951716|Experimental|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
11412631|NCT01951716|Experimental|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
11412632|NCT01951703|Active Comparator|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
11412633|NCT01951703|Experimental|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
11412634|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
11412635|NCT01951677|Active Comparator|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
11412636|NCT01951677|Experimental|HBsAg + Advax-1(TM)|HBsAg + Advax-1
11412637|NCT01951677|Experimental|HBsAg + Advax-2(TM)|HBsAg + Advax-2
11412638|NCT01951677|Experimental|HBsAg + Advax-3(TM)|HBsAg + Advax-3
11412639|NCT01951677|Active Comparator|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
11412640|NCT01951677|Experimental|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
11412641|NCT01951677|Experimental|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
11412642|NCT01951677|Experimental|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
11412643|NCT01951677|Active Comparator|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
11412644|NCT01951677|Experimental|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
11412645|NCT01951677|Experimental|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
11412646|NCT01951677|Experimental|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
11412647|NCT01951664|Experimental|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
11412648|NCT01951664|Active Comparator|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
11412649|NCT01951651|Experimental|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
11412650|NCT01951651|Experimental|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
11412651|NCT01951638|Experimental|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
11412652|NCT01951638|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
11412653|NCT01951638|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
11412654|NCT01951638|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
11412655|NCT01951638|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
11412656|NCT01951625|Experimental|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
11412657|NCT01951625|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
11412658|NCT01951625|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
11412659|NCT01951625|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
11412660|NCT01951625|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
11412661|NCT01951612|Experimental|Executive Function Training Program|Participants in this group will receive the novel intervention training.
11412662|NCT01951612|Active Comparator|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
11412663|NCT01951599|Experimental|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
11412664|NCT01951599|Experimental|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
11412665|NCT01951599|Experimental|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
11412666|NCT01951599|Experimental|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
11412667|NCT01951599|Experimental|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
11412668|NCT01951586|Placebo Comparator|Placebo|Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
11412669|NCT01951586|Experimental|Denosumab|Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
11412670|NCT01951573|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
11412671|NCT01951573|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
11412672|NCT01951560|Experimental|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
11412673|NCT01951560|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
11412674|NCT01951547|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
11412675|NCT01951547|Active Comparator|Oral hygiene instructions|Oral hygiene instructions given at baseline
11412676|NCT01951534|Experimental|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
11412677|NCT01951534|Other|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
11412678|NCT01951521|Experimental|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
11412679|NCT01951521|No Intervention|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
11412680|NCT01951508|Other|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
11412681|NCT01951482|Experimental|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
11412682|NCT01951482|Active Comparator|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
11412683|NCT01951469|Experimental|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
11412684|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
11412685|NCT01951456|Experimental|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
11412686|NCT01951456|Active Comparator|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
11412687|NCT01951443|Experimental|Ginseng|Encapsulated 400mg Rg3-KRG extract
11412688|NCT01951443|Placebo Comparator|Wheat Bran|400mg Wheat Bran capsule
11412689|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
11412690|NCT01951417|Experimental|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
11412691|NCT01951404|Active Comparator|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
11412692|NCT01951404|Placebo Comparator|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
11412736|NCT01951157|Experimental|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
11413540|NCT01945788|Active Comparator|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
11412693|NCT01951391|Other|Control Soap vs. Benzalkonium Chloride Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with benzalkonium chloride soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The benzalkonium chloride forearm will be swabbed at baseline and 6 hours.
11412694|NCT01951391|Other|Control Soap vs. Triclocarban Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
11412695|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
11412696|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
11412697|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
11412698|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
11412699|NCT01951352|Experimental|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
11412700|NCT01951339|Experimental|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
11412701|NCT01951339|Active Comparator|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
11412702|NCT01951326|Active Comparator|RHB-104|5 RHB-104 capsules administered orally BID
11412703|NCT01951326|Placebo Comparator|Placebo|5 placebo capsules administered orally BID
11412704|NCT01951313|Experimental|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
11412705|NCT01951300|Other|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
11412706|NCT01951287|Experimental|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
11412707|NCT01951287|Experimental|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
11412708|NCT01951287|Experimental|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
11412709|NCT01951287|Experimental|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
11412710|NCT01951287|Experimental|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
11412711|NCT01951287|Experimental|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
11412712|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
11412713|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
11412714|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
11412715|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
11412716|NCT01951261|Active Comparator|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
11412717|NCT01951261|No Intervention|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (daily visits).
11412718|NCT01951248|Experimental|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
11412719|NCT01951235|Experimental|Imeglimin (Dose 1)|
11412720|NCT01951235|Experimental|Imeglimin (Dose 2)|
11412721|NCT01951235|Experimental|Imeglimin (Dose 3)|
11412722|NCT01951235|Experimental|Imeglimin (Dose 4)|
11412723|NCT01951235|Placebo Comparator|Placebo|
11412724|NCT01951222|Experimental|V0162 dose1|
11412725|NCT01951222|Experimental|V0162 dose2|
11412726|NCT01951222|Placebo Comparator|placebo|Placebo
11412727|NCT01951209|Experimental|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
11412728|NCT01951209|Experimental|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
11412729|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
11412730|NCT01951196||Healthy subjects|75 healthy subjects.
11412731|NCT01951183|Placebo Comparator|Placebo|
11412732|NCT01951183|Experimental|RO6811135|
11412733|NCT01951170|Experimental|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
11412734|NCT01951157|Active Comparator|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
11412735|NCT01951157|Experimental|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
11412737|NCT01951144|Experimental|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
11412738|NCT01951144|Experimental|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
11412739|NCT01951144|Experimental|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
11412740|NCT01951144|Experimental|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
11412741|NCT01951118|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
11412742|NCT01951105|No Intervention|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
11412743|NCT01951105|Active Comparator|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.
~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
11412744|NCT01951105|Placebo Comparator|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
11412745|NCT01951092|Experimental|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
11412746|NCT01951079|Experimental|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
11412747|NCT01951066|Experimental|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
11412748|NCT01951066|Experimental|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
11412749|NCT01951053|Experimental|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
11412750|NCT01951053|Experimental|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
11412751|NCT01951053|Experimental|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
11412752|NCT01951053|Experimental|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
11412753|NCT01951053|Experimental|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
11412754|NCT01951053|Experimental|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
11412755|NCT01951040||Oxytocin|Oxytocin was administered during labor
11412756|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
11412757|NCT01951027|Experimental|Cohort 1|GX-G3 12.5 μg/kg or Placebo
11412758|NCT01951027|Experimental|Cohort 2|GX-G3 25 μg/kg or Placebo
11412759|NCT01951027|Experimental|Cohort 3|GX-G3 50 μg/kg or Placebo
11412760|NCT01951027|Experimental|Cohort 4|GX-G3 100 μg/kg or Placebo
11412761|NCT01951014|Experimental|Teen Social Media Education|See description under intervention description
11412762|NCT01951014|No Intervention|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
11412763|NCT01951001|Active Comparator|group 1|Fixed-dose Prasugrel of 10 mg/d
11412764|NCT01951001|Active Comparator|group 2|Fixed-dose Prasugrel of 5 mg/d
11412765|NCT01951001|Active Comparator|group 3|"Phenotype-based prasugrel dose
~If patients show PRU < 85, prasugrel dose will be reduced by 5 mg/d.
~If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d."
11412766|NCT01950988|Other|Children|
11412767|NCT01950988|Other|Adults|
11412768|NCT01950988|Other|Elderly people|
11412769|NCT01950975|Other|Parents|2 parents of child
11412770|NCT01950975|Other|infant|
11412771|NCT01950962|Other|slight periodontal disease|
11412772|NCT01950962|Other|moderate periodontal disease|
11412773|NCT01950962|Other|severe periodontal disease|
11412774|NCT01950949|Experimental|change respiratory parameters, volume expanding|
11412775|NCT01950936|Experimental|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is <0.15 ng/ml and dis-encouraged whenever Procalcitonin is <0.25 ng/ml
11412776|NCT01950936|No Intervention|Control - Standard of Care|Antibiotics are administered according to current guidelines
11412777|NCT01950923|Experimental|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
11412778|NCT01950923|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
11412779|NCT01950910||subjects w/ non-motor neurodegenerative disease|subjects with ALS or with non-motor neurodegenerative disease
11412780|NCT01950910||subjects w/out motorneuron degenerative dis|subjects without motorneuron degenerative disease
11412781|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
11412782|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
11412783|NCT01950884|Experimental|Ezetimibe|Ezetimibe tablets plus lifestyle
11412784|NCT01950884|Active Comparator|lifestyle|lifestyle
11412785|NCT01950871|Other|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
11412786|NCT01950858|Experimental|Biological|6 weeks of HBO treatment as well as non weight bearing
11412787|NCT01950858|Active Comparator|Control|non weight bearing
11412788|NCT01950845|Experimental|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
11412789|NCT01950845|Sham Comparator|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
11412790|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
11412791|NCT01950832||Control|60 healthy volunteers
11412792|NCT01950819|Experimental|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
11412793|NCT01950819|Active Comparator|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
11412794|NCT01950806|Active Comparator|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
11412795|NCT01950806|Placebo Comparator|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
11412796|NCT01950793|Active Comparator|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
~One injection only"
11412797|NCT01950793|Experimental|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
~One injection only"
11412798|NCT01950780|Experimental|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
11412799|NCT01950754|Other|depressive patients|
11412800|NCT01950754|Other|nondepressed controls|
11412801|NCT01950741|Experimental|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
11412802|NCT01950728|No Intervention|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
11412803|NCT01950728|Active Comparator|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
11412804|NCT01950728|Active Comparator|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
11412805|NCT01950728|Active Comparator|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
11412806|NCT01950715|Other|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
11412807|NCT01950702|Active Comparator|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.
~Patient's head were fixed at neutral position during all intubation period."
11412808|NCT01950702|Experimental|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
11412809|NCT01950689|Placebo Comparator|Placebo|Placebo given in parallel with radiotherapy for 6 weeks.
11412810|NCT01950689|Experimental|Nimorazole|Nimorazole given in parallel with radiotherapy for 6 weeks
11412811|NCT01950676|No Intervention|Control|Individuals in the control group will not use the smart phone application
11412812|NCT01950676|Experimental|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
11412813|NCT01950663|Experimental|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
11412814|NCT01950650||Patients with diabetes|
11412815|NCT01950650||Physicians|
11412816|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
11412817|NCT01950637||Healthcare professionals (HCPs)|
11412818|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
11412819|NCT01950611|Experimental|Bortezomib in treatment|
11412820|NCT01950598|Active Comparator|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
11412821|NCT01950598|Experimental|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
11412822|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
11412823|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
11412824|NCT01950546|Experimental|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
11412825|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
11412826|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
11412827|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
11412828|NCT01950520|Placebo Comparator|Cohort 1, The Mechanism of Human Nonshivering Thermogenesis|Cohort 1 is a singleblind, fixed order (for drug treatment), partially randomized (for temperature), crossover study. Cohort 1 uses a pharmacologicapproach to investigate the mechanism of NST in young healthy lean males.
11412829|NCT01950520|Placebo Comparator|Cohort 2, Pharmacologic Perturbations of Resting Energy Expend|Cohort 2 is a randomized, doubleblind, placebocontrolled, 6-period cross-over study, with data analysisperformed in a blinded manner. Focus is on measuring of FDAapproved drugs (such as anti-obesitydrugs) potential effect on basal metabolic rate(BMR) under thermoneutral conditions.
11412830|NCT01950520|Placebo Comparator|Cohort 3, (SqrRoot) 3- Adrenergic Receptor Agonist (mirabegron) Studies|Cohort 3 is a randomized, singleblind, placebocontrolled study, with the quantifier of BAT activity blinded to the four different interventions.Volunteers will undergo up to four experiments tostudy the effects of mirabegron on BMR and BAT activity.
11412831|NCT01950507|Experimental|Cohort 1|subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
11412832|NCT01950507|Experimental|Cohort 2|subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
11412833|NCT01950507|Experimental|Cohort 3|subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.
11412834|NCT01950494|Experimental|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
11412835|NCT01950494|Placebo Comparator|Blinded emollient therapy|Blinded emollient therapy
11412836|NCT01950481|Experimental|Normal Hepatic Function|Subjects with normal hepatic function
11412837|NCT01950481|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment
11412838|NCT01950481|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
11412839|NCT01950481|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment
11412840|NCT01950468|Experimental|NAV5001|
11412841|NCT01950468|Active Comparator|DaTscan|
11412842|NCT01950455|Experimental|NAV5001|
11412843|NCT01950416|Experimental|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
11412844|NCT01950416|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
11412845|NCT01950403|Experimental|Arm I (linaclotide acetate)|Participants receive linaclotide acetate PO QD on days 1-7.
11412846|NCT01950403|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO QD on days 1-7.
11412847|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
11412848|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
11412849|NCT01950377||Healthy Adults|Healthy adults healthy adults - male and female
11412850|NCT01950364|Experimental|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
11412851|NCT01950364|Experimental|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
11412852|NCT01950351|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
11412853|NCT01950338|Experimental|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
11412854|NCT01950338|No Intervention|Control group|The control group will not receive any intervention.
11412855|NCT01950325|Experimental|Group 1|1mg/kg IV
11412856|NCT01950325|Experimental|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)[only portion of the study that is randomized]
11412857|NCT01950325|Experimental|Group 4|20 mg/kg IV
11412858|NCT01950325|Experimental|Group 5|40 mg/kg IV
11412859|NCT01950312|Experimental|gevokizumab|Solution for subcutaneous injection
11412860|NCT01950299|Experimental|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
11412861|NCT01950299|Experimental|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
11412862|NCT01950299|Placebo Comparator|Placebo|Placebo for 14 days
11412864|NCT01950273|Active Comparator|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
11412865|NCT01950260|Experimental|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
11412866|NCT01950260|Placebo Comparator|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
11412867|NCT01950247|Experimental|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
11412868|NCT01950247|Active Comparator|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
11412869|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
11412870|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
11412871|NCT01950221|Experimental|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
11412872|NCT01950221|Placebo Comparator|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
11412873|NCT01950208||knee pain|patients suffering from knee injury
11412874|NCT01950195|Experimental|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.
~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.
~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
11412875|NCT01950195|Experimental|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.
~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.
~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
11412876|NCT01950182|Active Comparator|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
11412877|NCT01950182|Experimental|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
11412878|NCT01950169|Active Comparator|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
11412879|NCT01950169|Active Comparator|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
11412880|NCT01950169|Active Comparator|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
11412881|NCT01950156|Experimental|Vaccine|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
11412882|NCT01950143|Active Comparator|Standard broccoli soup|26 volunteers
11412883|NCT01950143|Experimental|Beneforte broccoli soup|26 volunteers
11412884|NCT01950143|Experimental|Beneforte extra broccoli soup|26 volunteers
11412885|NCT01950130|Experimental|IABP group|Preoperative IABP insertion
11412886|NCT01950130|No Intervention|Control group|Preoperative conservative treatment
11412887|NCT01950117|Active Comparator|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
11412888|NCT01950117|Experimental|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
11412889|NCT01950104|Active Comparator|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
11412890|NCT01950104|Experimental|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
11412891|NCT01950091|Experimental|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
11412892|NCT01950091|Active Comparator|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
11412893|NCT01950091|No Intervention|Usual care control group|No contact; Control group
11412894|NCT01950078||surgical patients|grouped by receiving surgery
11412895|NCT01950078||Healthy volunteers group|grouped by healthy college students
11412896|NCT01950065|Experimental|Immediate Treatment with iovera|Immediate treatment with iovera
11412897|NCT01950065|Active Comparator|Delayed Treatment with iovera|Delayed Treatment with iovera
11412898|NCT01950052|No Intervention|Control group|No special diet, patients will continue with a normal diet
11412899|NCT01950052|Experimental|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
11412900|NCT01950039|Active Comparator|Betaine|
11412901|NCT01950039|Placebo Comparator|Placebo|
11412902|NCT01950026|Experimental|white|cryotherapy application
11412903|NCT01950026|Experimental|black|cryotherapy application
11412904|NCT01950026|Experimental|Brown|cryotherapy application
11412905|NCT01950026|Experimental|asian|cryotherapy application
11412906|NCT01950013|No Intervention|Passive Control|Hearing aid alone
11412907|NCT01950013|Experimental|Training|Auditory Training Program. Hearing aid plus auditory training
11412908|NCT01950013|Sham Comparator|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
11412909|NCT01950000|Placebo Comparator|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
11412910|NCT01950000|Experimental|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.
~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).
~Pharmaceutical form:
~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
11412911|NCT01949987|Active Comparator|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
11412912|NCT01949987|Experimental|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
11412913|NCT01949974|Experimental|Integral Attention Program (PAI)|"The key points of the PAI are:
~To assess and manage pain and other symptoms resulting from disease progression.
~To evaluate the information needs that may arise and to address them.
~To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.
~To provide guidance in decision-making while respecting patient autonomy.
~To establish a plan of care and treatment, adapted to the evolution and needs of the patient.
~To promote continuity of care."
11412914|NCT01949974|Active Comparator|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
11412915|NCT01949961|Active Comparator|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
11412916|NCT01949961|Placebo Comparator|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
11412917|NCT01949948|Active Comparator|Tenecteplase|0.4 mg/kg single bolus intravenously
11412918|NCT01949948|Active Comparator|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
11412919|NCT01949935|Placebo Comparator|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
11412920|NCT01949935|Experimental|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
11412921|NCT01949922|Experimental|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
11412922|NCT01949909|Experimental|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
11412923|NCT01949909|Experimental|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
11412924|NCT01949909|Placebo Comparator|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
11412925|NCT01949909|Experimental|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
11412926|NCT01949909|Experimental|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
11412927|NCT01949909|Experimental|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
11412928|NCT01949909|Experimental|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
11412929|NCT01949896|Other|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.
~Pro-inflammatory cytokine response will be monitored at 3 times points."
11412930|NCT01949896|Other|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.
~Pro-inflammatory cytokine response will be monitored at 3 times points."
11412931|NCT01949883|Experimental|CPI-0610|
11412932|NCT01949870|Other|Selumetinib|25mg/day, 50mg/day and 75mg/day
11412933|NCT01949857|Experimental|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-15 years \6.50 lgCCID50/ml in adults aged 16 up to 65 years old
11412934|NCT01949857|Experimental|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
11412935|NCT01949857|Experimental|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
11412936|NCT01949857|Experimental|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
11412937|NCT01949844|Other|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:
~Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,
~Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.
~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
11412938|NCT01949831|No Intervention|Control|Usual care
11412939|NCT01949831|Experimental|Functional assessment|Assessment of functional ability in combination with follow-up at home
11412940|NCT01949818|Experimental|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
11412941|NCT01949818|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
11412942|NCT01949805|Active Comparator|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
11412943|NCT01949805|Experimental|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
11412944|NCT01949792|Active Comparator|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
11412945|NCT01949792|Active Comparator|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
11412946|NCT01949779||TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
11412947|NCT01949753|Experimental|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
11412948|NCT01949753|Placebo Comparator|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
11412949|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
11412950|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.
~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
11412951|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
11412952|NCT01949714||Incidentaloma patients|Incidentaloma patients
11412953|NCT01949701|Experimental|Vaccine|HLA-A*0201restricted URLC10 peptides
11412954|NCT01949688|Experimental|HLA-A*2402 restricted peptides|HLA-A*2402 restricted peptides with adjuvant
11412955|NCT01949688|Experimental|HLA-A*0201 restricted peptides|HLA-A*0201 restricted peptides with adjuvant
11412956|NCT01949675|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
11412957|NCT01949675|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
11412958|NCT01949675|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
11412959|NCT01949662|Experimental|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
11412960|NCT01949662|Active Comparator|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
11412961|NCT01949649|Active Comparator|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
11412962|NCT01949649|Active Comparator|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
11412963|NCT01949649|Active Comparator|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
11412964|NCT01949649|Active Comparator|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
11412965|NCT01949636||lean adolescents|
11412966|NCT01949623||RP patients|Retinitis Pigmentosa patients
11412967|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
11412968|NCT01949610|Experimental|14C-JNJ26489112|
11412970|NCT01949571|Experimental|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
11412971|NCT01949558|No Intervention|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
11412972|NCT01949558|Experimental|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
11412973|NCT01949545|Experimental|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
11412974|NCT01949545|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin > 1-1.5 x ULN or AST > ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
11412975|NCT01949545|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin > 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
11412976|NCT01949545|Experimental|Severe Hepatic Impairment|(Bilirubin > 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin > 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
11412977|NCT01949532|Experimental|Normal Renal Function|Participants with normal renal function (creatinine clearance [CrCl] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
11412978|NCT01949532|Experimental|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
11412979|NCT01949519|Experimental|Docetaxel and Lycopene|
11412980|NCT01949506|Other|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with > 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for >5 fraction treatment schedules.
11412981|NCT01949493|Other|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
11412982|NCT01949493|Experimental|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
11412983|NCT01949480|Active Comparator|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
11412984|NCT01949480|Experimental|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
11412985|NCT01949467|Other|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
11412986|NCT01949467|Other|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
11412987|NCT01949467|Other|TFPD|20 patients with treated Ferroportin Disease (TFPD)
11412988|NCT01949467|Other|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
11412989|NCT01949467|Other|HV|20 Healthy volunteers (HV) patients
11412990|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
11412991|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt bid x4 weeks|
11412992|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
11412993|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x4 weeks|
11412994|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
11412995|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x8 weeks|
11412996|NCT01949441|Experimental|ToleroMune HDM|
11412997|NCT01949441|Placebo Comparator|Placebo|
11412998|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
11412999|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
11413000|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio <70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
11413001|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
11413002|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
11413003|NCT01949389|Experimental|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
11413004|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
11413005|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
11413006|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
11413007|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
11413008|NCT01949376||Controls|healthy, cognitively normal subjects
11413009|NCT01949363|Experimental|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
11413010|NCT01949363|Experimental|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
11413011|NCT01949350|Active Comparator|Carbohydrate|CHO loaded test:
11413012|NCT01949350|Active Comparator|Carbohydrate protein|CHO-P loaded test:
11413013|NCT01949350|Active Comparator|Water|Starved as for surgery
11413014|NCT01949337|Experimental|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
11413015|NCT01949337|Experimental|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
11413016|NCT01949324|Experimental|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
11413017|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
11413018|NCT01949311|Experimental|Dupilumab|Participants will receive repeat doses of dupilumab
11413019|NCT01949298|Experimental|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
11413020|NCT01949298|Active Comparator|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
11413021|NCT01949285|Sham Comparator|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.
~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
11413022|NCT01949285|Active Comparator|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.
~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
11413023|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
11413024|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
11413025|NCT01949246||CRT patients|Patients undergoing CRT device implantation
11413026|NCT01949246||Healthy patients|Healthy controls
11413027|NCT01949233|Experimental|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
11413028|NCT01949233|Experimental|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
11413029|NCT01949233|Experimental|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
11413030|NCT01949233|Placebo Comparator|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
11413031|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
11413032|NCT01949207|Experimental|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
11413033|NCT01949207|Experimental|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
11413034|NCT01949194|Experimental|Regorafenib|Single-agent regorafenib
11413035|NCT01949181|Experimental|Pulmonary cancer|
11413036|NCT01949168|Active Comparator|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
11413037|NCT01949168|Active Comparator|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
11413038|NCT01949168|Active Comparator|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
11413039|NCT01949155|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:
~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
11413040|NCT01949155|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:
~One sham injection into each ear during surgery."
11413041|NCT01949142|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:
~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
11413042|NCT01949142|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:
~One sham injection into each ear during surgery."
11413043|NCT01949129|Experimental|Flu/Thio/Treo|"Fludarabine/Thiotepa/Treosulfan is for conditioning before HSCT from MSD or MD. ATG Thymo or Grafalon is used for patients who receive stem cells from unrelated donors.
~Fludarabine/Thiotepa/Treosulfan with either ATG Thymo or Grafalon is also used for HSCT from MMD with in vitro T-Cell Depletion (TCD) or with CD34+ selection.
~Fludarabine/Thiotepa/Treosulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
11413044|NCT01949129|Active Comparator|TBI/VP16|"TBI (Total Body Irradiation) / VP16 is used for conditioning for HSCT with MSD or MD graft with patients who are older than 48 months at the time of conditioning.
~TBI/VP16 is also used with Post TX-Cyclophosphamide for MMD-graft without in vitro T-Cell Depletion.
~TBI/VP16 with either ATG Thymo or Grafalon is used for MMD-HSCT with in vitro T-Cell Depletion or with CD34+ selection."
11413045|NCT01949129|Experimental|Flu/Thio/ivBu|"Fludarabine/Thiotepa/iV Busulfan is used for conditioning before HSCT from MSD or MD.
~Fludarabine/Thiotepa/iBu with either ATG Thymo or Grafalon is also used for HSCT from MMD-HSCT with T-Cell Depletion (TCD) or haplo with CD34+ selection.
~Fludarabine/Thiotepa/iV Busulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
11413046|NCT01949116|Experimental|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
11413047|NCT01949116|Placebo Comparator|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
11413048|NCT01949103|Experimental|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
11413049|NCT01949103|Experimental|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
11413050|NCT01949103|Experimental|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
11413051|NCT01949103|Experimental|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
11413052|NCT01949103|Experimental|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
11413053|NCT01949103|Experimental|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
11413054|NCT01949090|Experimental|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11413055|NCT01949090|Experimental|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11413056|NCT01949090|Experimental|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11413057|NCT01949090|Experimental|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11413541|NCT01945788|Experimental|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
11413058|NCT01949090|Placebo Comparator|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11413059|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
11413060|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
11413061|NCT01949064|Active Comparator|Michigan-type occlusal splint|Occlusal splint, Michigan-type
11413062|NCT01949064|Active Comparator|Grindcare|Biofeedback device
11413063|NCT01949051|Experimental|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
11413064|NCT01949038|Placebo Comparator|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
11413065|NCT01949038|Placebo Comparator|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
11413066|NCT01949038|Active Comparator|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
11413067|NCT01949038|Active Comparator|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
11413068|NCT01949025|Experimental|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
11413069|NCT01949025|No Intervention|Control group|
11413070|NCT01949012|No Intervention|Control|Standard monitoring
11413071|NCT01949012|Experimental|Capnography|Standard monitoring and capnography
11413072|NCT01948999|Active Comparator|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
11413073|NCT01948999|Sham Comparator|SHAM ECT|Anesthesia and concomitant muscular paralysis
11413074|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Normal Renal Function)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
11413075|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
11413076|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
11413077|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
11413078|NCT01948986|Experimental|Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)|Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
11413079|NCT01948973|Active Comparator|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
11413080|NCT01948973|Active Comparator|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
11413081|NCT01948960|No Intervention|standard care|everolimus dose is continued independently of everolimus AUC
11413082|NCT01948960|Active Comparator|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
11413083|NCT01948947|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
11413084|NCT01948947|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
11413085|NCT01948934|Experimental|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
11413086|NCT01948921|Placebo Comparator|placebo|1 ml normal saline will be given 5 minutes before EGD
11413087|NCT01948921|Active Comparator|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
11413088|NCT01948908|Experimental|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
11413089|NCT01948908|Experimental|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
11413090|NCT01948908|Experimental|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
11413091|NCT01948895|Experimental|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
11413092|NCT01948882|Experimental|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
11413093|NCT01948869|Experimental|Phoenix II|Application over 29 days twice daily
11413094|NCT01948869|Active Comparator|Phoenix I|Application over 29 days twice daily
11413095|NCT01948869|No Intervention|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
11413096|NCT01948856|Experimental|J022X ST|
11413097|NCT01948856|Placebo Comparator|Placebo|
11413098|NCT01948843|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
11413099|NCT01948830|Active Comparator|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
11413100|NCT01948830|Active Comparator|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
11413101|NCT01948817|Experimental|Deferasirox|Deferasirox 20mg/kg taken BID
11413102|NCT01948804|Experimental|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
11413103|NCT01948791|Experimental|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
11413104|NCT01948778|Experimental|oXiris™ filter|oXiris™ filter
11413105|NCT01948778|Experimental|Toraymyxin Filter|Toraymyxin Filter
11413106|NCT01948778|Other|Standard of Care|Standard of Care CRRT if necessary
11413107|NCT01948765|Active Comparator|Xenon and propofol|
11413108|NCT01948765|Placebo Comparator|propofol|
11413109|NCT01948752|No Intervention|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
11413110|NCT01948752|Experimental|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
11413111|NCT01948752|Experimental|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
11413112|NCT01948752|Experimental|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
11413113|NCT01948739|Experimental|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
11413114|NCT01948726|Experimental|Hypofractionation with SIB|
11413115|NCT01948713|Experimental|Group 1|Strengthening of pelvic floor muscles.
11413116|NCT01948713|Experimental|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
11413117|NCT01948700|Other|Brief Intervention|Motivational Interviewing (MI)
11413118|NCT01948700|Other|Standard Intervention|Education
11413119|NCT01948687||1. the control group|healthy adult volunteers
11413120|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
11413121|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
11413122|NCT01948674|Experimental|computerized tasks- adaptive|
11413123|NCT01948674|Active Comparator|computerized tasks - nonadaptive|
11413124|NCT01948661|Experimental|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
11413125|NCT01948661|Placebo Comparator|placeboA + placeboB|placeboA + placeboB per day for four weeks
11413126|NCT01948648|Active Comparator|Colesevelam|3.75g/day for 6 weeks
11413127|NCT01948648|Active Comparator|Fish Oil|1g/day for 6 weeks
11413128|NCT01948648|Active Comparator|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
11413129|NCT01948635|Experimental|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
11413130|NCT01948635|Active Comparator|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
11413131|NCT01948622|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
11413132|NCT01948622|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
11413133|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
11413134|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
11413135|NCT01948596|Experimental|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
11413136|NCT01948583|Active Comparator|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).
~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
11413137|NCT01948583|Active Comparator|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).
~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
11413138|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
11413139|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
11413140|NCT01948557|Other|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
11413141|NCT01948544||chronic obstructive pulmonary disease|"More than 12 million adults are diagnosed with COPD
~COPD is the 4th leading cause of death in the U.S.
~Breathing difficulty is the major reason patients seek medical attention
~COPD patients requiring hospitalization were associated with higher costs
~Oximetry is an important tool for assessing need for Long-term oxygen therapy
~LTOT has been proven to improve survival and quality of life
~Patients will be provided a lightweight portable oxygen concentrator to:
~support increased activity
~improve quality of life
~increase functional capacity"
11413280|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
11413142|NCT01948531|Experimental|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
11413143|NCT01948518|Experimental|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
11413144|NCT01948505|Active Comparator|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
11413145|NCT01948505|Placebo Comparator|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
11413146|NCT01948492|Experimental|protein|varying protein intake in random order from deficient to excess
11413147|NCT01948479|Experimental|Insole optimised with inshoe analysis|
11413148|NCT01948479|Active Comparator|Routine insole provision|
11413149|NCT01948466|Experimental|Commercials|Schools Administered Commercials
11413150|NCT01948466|No Intervention|Control|Schools not Administered Commercials
11413151|NCT01948453|Active Comparator|Garlic|daily consumption of two odor controlled garlic tablets
11413152|NCT01948453|Placebo Comparator|Placebo|daily consumption of placebo
11413153|NCT01948440|Experimental|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
11413154|NCT01948440|No Intervention|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
11413155|NCT01948414|Other|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
11413156|NCT01948414|Other|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
11413157|NCT01948414|Other|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
11413158|NCT01948401|Experimental|Controlled asthma|
11413159|NCT01948401|Experimental|Uncontrolled asthma with additional OCS|
11413160|NCT01948401|Experimental|Uncontrolled asthma without additional OCS|
11413161|NCT01948388|Active Comparator|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
11413162|NCT01948388|Active Comparator|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
11413163|NCT01948375|Experimental|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
11413164|NCT01948375|Experimental|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
11413165|NCT01948362|Active Comparator|Sulforadex|Active compound
11413166|NCT01948362|Experimental|alpha Cyclodextrin|Placebo control arm
11413167|NCT01948349|No Intervention|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique [31], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
11413168|NCT01948349|Experimental|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
11413169|NCT01948349|Experimental|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
11413170|NCT01948349|Experimental|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
11413171|NCT01948336|Placebo Comparator|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
11413172|NCT01948336|Active Comparator|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
11413281|NCT01947530|Active Comparator|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
11413173|NCT01948323|Other|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info
~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
11413174|NCT01948323|No Intervention|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
11413175|NCT01948310|Active Comparator|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
11413176|NCT01948310|Placebo Comparator|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
11413177|NCT01948297|Experimental|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
11413178|NCT01948297|Experimental|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
11413179|NCT01948284|Active Comparator|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
11413180|NCT01948284|Active Comparator|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
11413181|NCT01948271|Experimental|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
11413182|NCT01948258|Other|Clearblue Advanced Fertility Monitor|Use of Clearblue Fertility Monitor
11413183|NCT01948245|Active Comparator|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.
~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
11413184|NCT01948245|Placebo Comparator|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.
~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
11413185|NCT01948232|Experimental|Perindopril|
11413186|NCT01948219|Experimental|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
11413187|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(>=150ms) QRS duration
11413188|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(<150ms) QRS duration
11413189|NCT01948193|Experimental|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
11413190|NCT01948180|Experimental|baltaleucel-T|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.
~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
11413191|NCT01948167|Experimental|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
11413192|NCT01948167|Experimental|Coping with Stress|Coping with Stress
11413193|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
11413194|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
11413195|NCT01948141|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11413196|NCT01948128|Experimental|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
11413197|NCT01948128|Placebo Comparator|Placebo|Placebo taken daily by mouth
11413198|NCT01948115|Placebo Comparator|Medical air|
11413199|NCT01948115|Experimental|equimolar mixture of oxygen and nitrous oxide|
11413200|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
11413201|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
11413202|NCT01948089|Experimental|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
11413203|NCT01948089|Experimental|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
11413204|NCT01948076|Placebo Comparator|resident without GE vscan|baseline physical exam use
11413205|NCT01948076|Active Comparator|resident with GE vscan|residents with augmentation of physical exam by ultrasound
11413206|NCT01948063|Placebo Comparator|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
11413207|NCT01948063|Experimental|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
11413208|NCT01948050|Experimental|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
11413209|NCT01948050|Sham Comparator|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
11413210|NCT01948037|Active Comparator|hydrotherapy|
11413211|NCT01948037|Other|hot spring|30-minutes/per day;4weeks
11413212|NCT01948024|Active Comparator|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
11413213|NCT01948024|Experimental|Test Arm - Asenapine|10 mg BID sublingual tablet
11413214|NCT01948011|Experimental|Racecadotril 10mg suspension|single oral dose
11413215|NCT01948011|Experimental|Racecadotril 30mg suspension|single oral dose
11413216|NCT01948011|Experimental|Racecadotril 60mg suspension|single oral dose
11413217|NCT01948011|Active Comparator|Racecadotril 60mg granules|single oral dose
11413218|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
11413219|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
11413220|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
11413221|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
11413222|NCT01947972|Other|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
11413223|NCT01947959||Rivaroxaban|Patients who have been prescribed Rivaroxaban for the first time
11413224|NCT01947959||Standard of care|Patients who have been prescribed Standard of care for the first time
11413225|NCT01947946|Experimental|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
11413226|NCT01947946|Experimental|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
11413227|NCT01947946|Placebo Comparator|Placebo|A (Dummy) injection
11413228|NCT01947933|Placebo Comparator|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
11413229|NCT01947933|Experimental|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
11413230|NCT01947933|Experimental|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
11413231|NCT01947920|Experimental|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
11413232|NCT01947920|Experimental|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
11413233|NCT01947920|Experimental|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
11413234|NCT01947907|Experimental|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
11413235|NCT01947907|Experimental|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
11413236|NCT01947907|Experimental|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
11413237|NCT01947907|Active Comparator|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
11413238|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
11413239|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
11413240|NCT01947855|Experimental|Empagliflozin low dose|Empagliflozin low dose tablet once daily
11413241|NCT01947855|Experimental|Empagliflozin high dose|Empagliflozin high dose tablet once daily
11413242|NCT01947855|Placebo Comparator|Placebo|Placebo tablet once daily
11413243|NCT01947842|Experimental|Smartphone App|The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.
11413244|NCT01947842|No Intervention|Counseling Alone|This arm will receive only counseling from the pharmacist with no other intervention.
11413245|NCT01947829||Chronic Hemodialysis|
11413246|NCT01947816||Humira|Humira 40 mg (marketed product) eow for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration, for up to 52 weeks.
11413247|NCT01947803|Experimental|Paliperidone Palmitate|
11413248|NCT01947790|Experimental|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
11413249|NCT01947790|Active Comparator|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
11413250|NCT01947764|No Intervention|Usual Care|"The Usual Care components for the control clinics will include the following:
~All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training
~Chart materials to guide and document disclosure counseling and visits
~The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.
~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
11413251|NCT01947764|Experimental|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:
~Modified materials to guide disclosure sessions
~Videotaped narratives for parental counseling
~Dedicated disclosure counselors to initiate and conduct the disclosure process
~Post-disclosure support groups for children
~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
11413252|NCT01947751|Active Comparator|CVC exchange|The CVC will be removed immediately.
11413253|NCT01947751|Experimental|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
11413254|NCT01947738|Experimental|VBY-891|VBY-891
11413255|NCT01947738|Placebo Comparator|Placebo|Capsules containing excipient but no active drug
11413256|NCT01947712|Placebo Comparator|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
11413257|NCT01947712|Active Comparator|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
11413258|NCT01947699|Experimental|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
11413259|NCT01947699|Experimental|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
11413260|NCT01947699|Experimental|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
11413261|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
11413262|NCT01947673|Experimental|Mindfulness Meditation|After individual instruction, participants in this arm will perform meditation by following a series of MM recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using the MP3 player at home on non-dialysis days, and asked to keep a log of these sessions.
11413263|NCT01947673|Placebo Comparator|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
11413264|NCT01947660|Experimental|Continuous regional anesthesia|
11413265|NCT01947660|Active Comparator|Systemic analgesia|
11413266|NCT01947647|Experimental|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
11413267|NCT01947647|Active Comparator|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
11413268|NCT01947634|Experimental|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
11413269|NCT01947595|Active Comparator|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~A+B or A+C or B+C or A+B+C"
11413270|NCT01947595|Active Comparator|hight risk non responder, normal lifestyle intervention|"high risk non-responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~A+B or A+C or B+C or A+B+C"
11413271|NCT01947595|Active Comparator|Responder, normal lifestyle intervention|"Responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~No A, only B or C"
11413272|NCT01947595|Active Comparator|Responder, single lifestyle advice (control group)|"Responder:
~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)
~B) insulin resistance (ISI-Matsuda < 9,2)
~C) elevated liver fat ( MRT > 5,56%)
~No A, only B or C"
11413273|NCT01947582|Other|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
11413274|NCT01947569|Experimental|iDC recipients|iDC cells modified by in vitro engineering.
11413275|NCT01947569|Active Comparator|Control DC recipients|DC cells which have not been modified.
11413276|NCT01947569|Placebo Comparator|Placebo recipients|Saline injections.
11413277|NCT01947556|Other|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
11413278|NCT01947556|Other|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
11413279|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
11413590|NCT01945437|Experimental|magnesium|This group receive magnesium sulfate perioperatively.
11413282|NCT01947530|Active Comparator|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
11413283|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
11413284|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
11413285|NCT01947504|Experimental|education and support intervention|education and support intervention
11413286|NCT01947504|No Intervention|waiting list|waiting list and regular medical follow-up
11413287|NCT01947491|Experimental|DFD01 Spray|DFD01 Spray twice daily for 28 days
11413288|NCT01947491|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily for 28 days
11413289|NCT01947491|Active Comparator|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
11413290|NCT01947491|Placebo Comparator|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
11413291|NCT01947478|Experimental|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
11413292|NCT01947478|Active Comparator|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
11413293|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
11413294|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
11413295|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
11413296|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
11413297|NCT01947452|Experimental|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
11413298|NCT01947452|Experimental|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
11413299|NCT01947439|Experimental|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
11413300|NCT01947439|Active Comparator|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
11413301|NCT01947426|Experimental|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
11413302|NCT01947426|Placebo Comparator|Control (milk without DHA)|Mothers comsuming placebo and their neonates
11413303|NCT01947413|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
11413304|NCT01947413|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
11413305|NCT01947413|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
11413306|NCT01947400||Hospitalists|AIDET Training
11413307|NCT01947387||Integra|
11413308|NCT01947387||Integra + NPWT (short-inpatient use only)|
11413309|NCT01947387||Integra + NPWT (long-all other durations)|
11413310|NCT01947387||Integra + STSG|
11413311|NCT01947387||Integra + Dermoinductive Agent|
11413312|NCT01947387||Free Flap|
11413313|NCT01947387||Local Tissue Flap|
11413314|NCT01947387||NPWT|
11413315|NCT01947387||NPWT then Integra (on same admission)|
11413316|NCT01947374|Experimental|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
11413317|NCT01947374|Experimental|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
11413318|NCT01947348|Experimental|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
11413319|NCT01947335|No Intervention|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
11413320|NCT01947335|Active Comparator|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
11413321|NCT01947322|Experimental|Allogenic NK cells infusion|
11413322|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
11413323|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
11413324|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
11413325|NCT01947283|Experimental|Intervention Patients & Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.
~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.
~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers.
~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
11413401|NCT01946854|Other|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
11413404|NCT01946828|Experimental|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
11413326|NCT01947283|Experimental|Intervention Patients, Control Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.
~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.
~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
11413327|NCT01947283|No Intervention|Control Patients, Intervention Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.
~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.
~Control patients will receive a pamphlet called Managing Your Mental Health Care. For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
11413328|NCT01947283|No Intervention|Control Patients & Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.
~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.
~Control patients will receive a pamphlet called Managing Your Mental Health Care."
11413329|NCT01947283|No Intervention|Non-Randomized Controlled Trial Patients|Participants in this arm are patients who did not participate in the Randomized Controlled Trial. One to two patients will be recruited for each enrolled provider (Control and Intervention). One clinical session per patient will be audio recorded. These clinical recordings will be used to provide feedback only for Intervention providers during part 1 of the DECIDE-PC intervention.
11413330|NCT01947283|No Intervention|Control Providers|Participants in this arm are providers who were randomized to the Control group. Control providers will not receive the DECIDE-PC intervention.
11413331|NCT01947283|Experimental|Intervention Providers|Participants in this arm are providers who were randomized to the Intervention group. Intervention providers will receive the DECIDE-PC intervention. The DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.
11413332|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
11413333|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
11413334|NCT01947257|Other|ventilated patients|
11413335|NCT01947244|Experimental|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
11413336|NCT01947244|Active Comparator|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
11413337|NCT01947231|Experimental|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
11413338|NCT01947231|Active Comparator|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
11413339|NCT01947218|Experimental|smoking COPD|
11413340|NCT01947218|Experimental|smoking without COPD|
11413341|NCT01947218|Other|No Smoking Control|
11413342|NCT01947218|Experimental|severe asthma|
11413343|NCT01947205|Active Comparator|paracetamol|Duration
11413344|NCT01947205|Active Comparator|without drug|Control group
11413345|NCT01947205|Active Comparator|dexketoprofen trometamol|Study group
11413346|NCT01947205|Active Comparator|two puff xylocain administration on cervical surface|Study group
11413347|NCT01947205|Active Comparator|paracervical block with ultracaine|study group
11413348|NCT01947192|Experimental|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
11413349|NCT01947192|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching.
11413350|NCT01947179|No Intervention|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
11413351|NCT01947179|Experimental|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
11413352|NCT01947153|Experimental|Fixed dose combination|Linagliptin/Metformin
11413353|NCT01947153|Experimental|Free combination|Linagliptin and Metformin
11413354|NCT01947140|Experimental|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
11413355|NCT01947140|Experimental|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
11413356|NCT01947140|Experimental|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
11413357|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
11413358|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
11413359|NCT01947114|Active Comparator|Group Propofol|
11413360|NCT01947114|Active Comparator|Group Ketamine|
11413361|NCT01947101|Experimental|Ulcerative Colitis|Fecal Microbiota Transplant
11413402|NCT01946854|Active Comparator|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
11413403|NCT01946841|Experimental|RealDiet®Renal enteral nutrition|
11413362|NCT01947088|Experimental|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
11413363|NCT01947088|Active Comparator|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
11413364|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
11413365|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
11413366|NCT01947062|Active Comparator|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
11413367|NCT01947062|Experimental|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
11413368|NCT01947049|No Intervention|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
11413369|NCT01947049|Experimental|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
11413370|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
11413371|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
11413372|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
11413373|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
11413374|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
11413375|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
11413376|NCT01947023|Experimental|Treatment (lapatinib, dabrafenib)|"Patients receive dabrafenib* PO BID on days 1-28 and lapatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib."
11413377|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
11413378|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
11413379|NCT01947010|Active Comparator|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
11413380|NCT01946997||Group 1: Non Diabetic|Normal retina
11413381|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
11413382|NCT01946984|Active Comparator|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
11413383|NCT01946984|Placebo Comparator|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
11413384|NCT01946971|Experimental|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
11413385|NCT01946971|Experimental|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
11413386|NCT01946958|Experimental|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
11413387|NCT01946958|Experimental|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
11413388|NCT01946945|No Intervention|Control - Standard ART treatment|
11413389|NCT01946945|Experimental|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
11413390|NCT01946932|Active Comparator|Cardiac Arrest 33°|survivors with temperature treatment 33°
11413391|NCT01946932|Active Comparator|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
11413392|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
11413393|NCT01946906|No Intervention|No treatment|patient receive no active treatment
11413394|NCT01946906|Experimental|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
11413395|NCT01946893|Experimental|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
11413396|NCT01946893|Active Comparator|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
11413397|NCT01946880|Experimental|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
11413398|NCT01946880|Active Comparator|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
11413399|NCT01946867|Experimental|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
11413400|NCT01946867|Experimental|NBTXR3 Intra-Arterial Injection (IA)|Single intra-arterial injection
11413405|NCT01946815|Experimental|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
11413406|NCT01946802|Experimental|Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
11413407|NCT01946789|Experimental|ALT-803|
11413408|NCT01946776|Other|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
11413409|NCT01946763|No Intervention|safety of Anesthesia|No pre operative education
11413410|NCT01946763|Experimental|Behavioral : pre operative education|Behavioral pre operative education
11413411|NCT01946750|Experimental|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
11413412|NCT01946750|Other|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
11413413|NCT01946737|Active Comparator|Invasive coronary angiography (ICA)|Routine diagnostic ICA
11413414|NCT01946737|Experimental|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
11413415|NCT01946711|Experimental|Buparid; Treatment A|Buparid 1 mg budesonide/2 ml nebuliser solution
11413416|NCT01946711|Active Comparator|Budes; Treatment B|Budes® Nasal Spray 50 µg budesonide/pump
11413417|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
11413418|NCT01946672|Experimental|isotopic intraoperative detection|Lower-limb drainage isotopic intraoperative detection
11413419|NCT01946659|Experimental|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
11413420|NCT01946659|Other|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
11413421|NCT01946646|Experimental|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
11413422|NCT01946633|Experimental|Esophagogastroduodenoscopy（ECG）|n=15
11413423|NCT01946620|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
11413424|NCT01946620|Experimental|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
11413425|NCT01946620|Active Comparator|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
11413426|NCT01946607|Active Comparator|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
11413427|NCT01946607|Placebo Comparator|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
11413428|NCT01946594|Active Comparator|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:
~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
11413429|NCT01946594|Placebo Comparator|Placebo Arm|"Placebo Suspension:
~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
11413430|NCT01946581||Cataract Surgery|
11413431|NCT01946568|Experimental|Single dose Dalbavancin|
11413432|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
11413433|NCT01946542|Placebo Comparator|placebo|placebo drink, single dose, taste and color-matched to experimental drink
11413434|NCT01946542|Experimental|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
11413435|NCT01946529|Active Comparator|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
11413436|NCT01946529|Active Comparator|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
11413437|NCT01946503||Short bowel syndrome|Patients followed in a clinic for short bowel syndrome
11413438|NCT01946503||Healthy controls|Patients seen in a general pediatric clinic without chronic or acute diseases
11413439|NCT01946490||Radiotherapy in 2001|
11413440|NCT01946490||Radiotherapy in 2004|
11413441|NCT01946490||Radiotherapy in 2006|
11413442|NCT01946490||Radiotherapy in 2010|
11413443|NCT01946477|Experimental|Pomalidomide + dexamethasone|Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
11413472|NCT01946269|Active Comparator|Standard group|
11413473|NCT01946269|Active Comparator|Goal-directed therapy (GDT) protocol|
11413474|NCT01946256|Active Comparator|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
11413475|NCT01946256|Placebo Comparator|Erythromycin|Erythromycin 500mg four times in a day for 1 week
11413444|NCT01946477|Experimental|Pomalidomide + Dexamethasone + Daratumumab|"Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/ day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:
~Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2
~Days 1 and 15 for Cycle 3 through Cycle 6
~Day 1 for Cycle 7 and each cycle thereafter until disease progression"
11413445|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
11413446|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
11413447|NCT01946451||Idiophatic ERMs|
11413448|NCT01946451||Secondary ERMs|
11413449|NCT01946438|Experimental|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
11413450|NCT01946438|Experimental|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
11413451|NCT01946438|Experimental|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
11413452|NCT01946438|Experimental|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
11413453|NCT01946425|Experimental|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to < 36 months of age at enrollment
11413454|NCT01946425|Experimental|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to < 9 years of age at enrollment
11413455|NCT01946412|No Intervention|Observational Arm|
11413456|NCT01946412|Experimental|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:
~50 mg q12h for subjects 2 to <6 years of age and <14 kg,
~75 mg q12h for subjects 2 to <6 years of age and ≥ 14 kg, or
~150 mg q12h for subjects ≥ 6 years of age."
11413457|NCT01946399|Other|Ozurdex implant|Intravitreal injection of Ozurdex implant
11413458|NCT01946386|Experimental|LEO 90100|
11413459|NCT01946373|Experimental|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
11413460|NCT01946373|Experimental|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
11413461|NCT01946360|No Intervention|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
11413462|NCT01946347|Experimental|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
11413463|NCT01946347|Active Comparator|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
11413464|NCT01946334|Experimental|patients|
11413465|NCT01946321|Other|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
11413466|NCT01946308|Experimental|conformational positioner & mattress|conformational positioner & mattress, five hours on each
11413467|NCT01946295|Experimental|Famotidine|Famotidine 100mg x 2 orally
11413468|NCT01946295|Placebo Comparator|Placebo|Placebo control
11413469|NCT01946282|Active Comparator|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.
~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.
~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
11413470|NCT01946282|Active Comparator|FIT plus $5 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.
~Intervention: FIT kits and invitation letter with a $5 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.
~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
11413471|NCT01946282|Active Comparator|FIT plus $10 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.
~Intervention: FIT kits and invitation letter with a $10 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.
~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
11413476|NCT01946243|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
11413477|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
11413478|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
11413479|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
11413480|NCT01946191|Experimental|Coaching Group|"24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts
~Online self-monitoring
~Real-time updates to primary care physicians"
11413481|NCT01946191|Active Comparator|Tracking Group|-Online self-monitoring
11413482|NCT01946178|Experimental|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
11413483|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
11413484|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
11413485|NCT01946152|Experimental|Treatment (pomalidomide, dexamethasone, filgrastim-sndz)|"INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11413486|NCT01946139|Experimental|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
11413487|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
11413488|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
11413489|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
11413490|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
11413491|NCT01946100|Other|Multifocal Lung Adenocarcinoma|
11413492|NCT01946087|Experimental|RIPC group|
11413493|NCT01946087|Placebo Comparator|Control group|
11413494|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
11413495|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
11413496|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
11413497|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
11413498|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
11413499|NCT01946061|Experimental|Treatment group|
11413500|NCT01946048|Experimental|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
11413501|NCT01946035|Placebo Comparator|Placebo|Participants will take 1 capsule placebo each evening
11413502|NCT01946035|Experimental|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
11413503|NCT01946022|Active Comparator|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
11413504|NCT01946022|Active Comparator|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
11413505|NCT01946009|Experimental|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
11413506|NCT01945996|Active Comparator|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
11413507|NCT01945996|Experimental|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
11413508|NCT01945983|Active Comparator|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
11413509|NCT01945983|Placebo Comparator|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
11413510|NCT01945970|Experimental|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
11413511|NCT01945970|Active Comparator|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
11413512|NCT01945970|Placebo Comparator|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
11413513|NCT01945957|Experimental|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
11413514|NCT01945957|Experimental|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
11413515|NCT01945944|Placebo Comparator|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
11413517|NCT01945931|Experimental|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
11413518|NCT01945931|No Intervention|Control|Health workers in the control clusters will not have access to the Safe Delivery App
11413519|NCT01945918|Active Comparator|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
11413520|NCT01945918|Active Comparator|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
11413521|NCT01945918|Experimental|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
11413522|NCT01945905|Experimental|Extramural|Extramural medication delivery and supervision
11413523|NCT01945905|Active Comparator|Intramural|Intramural medication delivery and supervision
11413524|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.
~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
11413525|NCT01945879|Experimental|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
11413526|NCT01945866|Active Comparator|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
11413527|NCT01945866|Experimental|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
11413528|NCT01945853|Experimental|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
11413529|NCT01945840|Active Comparator|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
11413530|NCT01945840|Experimental|Gut hormone infusion (high dose)|Infusion of three gut hormones - GLP-1, PYY and oxyntomodulin subcutaneously.
11413531|NCT01945840|Experimental|Gut hormone infusion (low dose)|Infusion of three gut hormones - GLP-1, PYY and oxyntomodulin subcutaneously.
11413532|NCT01945840|Placebo Comparator|Placebo infusion|Saline infusion given subcutaneously
11413533|NCT01945840|Active Comparator|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks
11413534|NCT01945827||DeltaMaxx treated Patients|
11413535|NCT01945814|Experimental|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
11413536|NCT01945814|Experimental|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
11413537|NCT01945801|Active Comparator|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
11413538|NCT01945801|Placebo Comparator|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
11413539|NCT01945801|Active Comparator|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
11413542|NCT01945775|Experimental|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
11413543|NCT01945775|Active Comparator|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
11413544|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
11413545|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
11413546|NCT01945749|Experimental|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
11413547|NCT01945749|Active Comparator|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
11413548|NCT01945736||Cohort 1|> or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.
11413549|NCT01945736||Cohort 2|2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
11413550|NCT01945736||Cohort 3|6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
11413551|NCT01945723||Healthy volunteers|Healthy volunteers
11413552|NCT01945710|Experimental|Eribulin-LF Schedule 1|"Schedule 1: Eribulin-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2.
~Schedule 1a: Eribulin-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
11413553|NCT01945710|Experimental|Eribulin-LF Schedule 2|Schedule 2: Eribulin-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
11413554|NCT01945697||normal oral mucosa|
11413555|NCT01945697||oral precancerous lesion or oral cancer|
11413556|NCT01945684|Experimental|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
11413557|NCT01945684|Active Comparator|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
11413558|NCT01945645|Experimental|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
11413559|NCT01945632|No Intervention|no treatment|Control group with no treatment.
11413560|NCT01945632|Experimental|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
11413561|NCT01945632|Experimental|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
11413562|NCT01945632|Experimental|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
11413563|NCT01945606|Experimental|Placebo and BAY1067197|Patients will get both treatment 1 and 2
11413564|NCT01945593|Experimental|Fixed BAX855 prophylaxis|45-80 IU/kg twice weekly to once per week.
11413565|NCT01945593|Experimental|Pharmacokinetic (PK)-tailored BAX 855 prophylaxis|PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level
11413566|NCT01945580|Active Comparator|Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
11413567|NCT01945580|Active Comparator|Control|Prolapse Repair with Native Tissue Only
11413568|NCT01945567|Experimental|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
11413569|NCT01945567|Experimental|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
11413570|NCT01945567|Experimental|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
11413571|NCT01945554|Experimental|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
11413572|NCT01945554|Experimental|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
11413573|NCT01945541|No Intervention|standard fluid management|postoperative BMC measurements
11413574|NCT01945541|Active Comparator|body composition monitoring preoperative|pre and postoperative BCM measurements
11413575|NCT01945528|Experimental|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
11413576|NCT01945528|Active Comparator|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
11413577|NCT01945515|Experimental|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
11413578|NCT01945515|Sham Comparator|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
11413579|NCT01945502||nasal packing with dry packs|
11413580|NCT01945502||nasal packing with wet packs|
11413581|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
11413582|NCT01945502||no nasal packing|
11413583|NCT01945489|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
11413584|NCT01945489|Other|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
11413585|NCT01945476|Experimental|midazolam|midazolam group
11413586|NCT01945476|Active Comparator|normal saline|control group
11413587|NCT01945450|Active Comparator|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
11413588|NCT01945450|No Intervention|No treatment|No antibiotics
11413589|NCT01945437|Placebo Comparator|Control|Control group receive same volume of normal saline as in the magnesium group
11413591|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
11413592|NCT01945411|Experimental|Experimental|the length between incisor and mandible angle
11413593|NCT01945411|Active Comparator|Active comparator|the length between mouth corner-mandible angle
11413594|NCT01945398|Experimental|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
11413595|NCT01945398|Placebo Comparator|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
11413596|NCT01945385|Experimental|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
11413597|NCT01945385|No Intervention|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
11413598|NCT01945372|Experimental|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
11413599|NCT01945372|Sham Comparator|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
11413600|NCT01945359||Relapsing Remitting MS (RRMS)|
11413601|NCT01945346|Experimental|PRX167700|
11413602|NCT01945346|Placebo Comparator|Placebo|
11413603|NCT01945333|Active Comparator|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
11413604|NCT01945333|Active Comparator|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
11413605|NCT01945333|Active Comparator|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
11413606|NCT01945333|Active Comparator|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
11413607|NCT01945320||HD-BCM|"Patients at National Taiwan University Hospital
~Patients who have received HD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years"
11413608|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
11413609|NCT01945294|Experimental|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
11413610|NCT01945294|Experimental|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
11413611|NCT01945294|Experimental|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
11413612|NCT01945281|Experimental|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
11413613|NCT01945281|Active Comparator|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
11413614|NCT01945268|Experimental|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
11413615|NCT01945268|Placebo Comparator|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
11413616|NCT01945255||HD-ABI|"Patients at National Taiwan University Hospital (NTUH)
~Patients who have received PD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years"
11413617|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
11413618|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
11413619|NCT01945216||Alogliptin 25mg, tablets, orally, once daily, up to 36 months|
11413620|NCT01945203||PD-ABI|"Patients at National Taiwan University Hospital (NTUH)
~Patients who have received PD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years."
11413621|NCT01945190|Experimental|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
11413622|NCT01945190|Experimental|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
11413623|NCT01945177|No Intervention|white light endoscopy|white light endoscopy
11413624|NCT01945177|Active Comparator|narrow band imaging|narrow band imaging
11413663|NCT01944865|Experimental|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
11413664|NCT01944852|Experimental|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
11413665|NCT01944852|Active Comparator|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
11413625|NCT01945151|Experimental|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
11413626|NCT01945138|No Intervention|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
11413627|NCT01945138|Experimental|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
11413628|NCT01945125|No Intervention|THW Group|Patients under THW stimulation for RIT
11413629|NCT01945125|Other|rhTSH Group|Patients under rhTSH stimulation for RIT
11413630|NCT01945112|Experimental|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
11413631|NCT01945099|Active Comparator|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
11413632|NCT01945099|Experimental|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
11413633|NCT01945099|Experimental|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
11413634|NCT01945086|Experimental|Ustekinumab 45 mg|
11413635|NCT01945086|Experimental|Ustekinumab 90 mg|
11413636|NCT01945086|Placebo Comparator|Placebo|
11413637|NCT01945073|No Intervention|Control (RC)|Routine clinical care with no intervention
11413638|NCT01945073|Experimental|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
11413639|NCT01945073|Experimental|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
11413640|NCT01945060|Experimental|heart rate Control to Range System (hrCTR) using DiAs Platform|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
11413641|NCT01945060|Placebo Comparator|DiAs Control-to-Range System not informed for heart rate|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
11413642|NCT01945047|Experimental|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
11413643|NCT01945047|Active Comparator|Midazolam|In phase 1 patients will be randomized to receive active placebo
11413644|NCT01945034|Experimental|Topical IBU twice daily|
11413645|NCT01945034|Placebo Comparator|Placebo twice daily|
11413646|NCT01945034|Experimental|Topical IBU three times daily|
11413647|NCT01945034|Placebo Comparator|Placebo three times daily|
11413648|NCT01945021|Experimental|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
11413649|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
11413650|NCT01944995|Experimental|group B|
11413651|NCT01944995|Experimental|group A|
11413652|NCT01944982|Experimental|Activated natural killer cells|Activated natural killer cells
11413653|NCT01944969|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
11413654|NCT01944943|Experimental|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
11413655|NCT01944930|Experimental|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
11413656|NCT01944930|Experimental|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
11413657|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
11413658|NCT01944904|Placebo Comparator|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
11413659|NCT01944904|Active Comparator|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
11413660|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
11413661|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
11413662|NCT01944865|Experimental|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
11413666|NCT01944839|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
11413667|NCT01944839|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
11413668|NCT01944826||Tako-Tsubo And Cancer Registry|
11413669|NCT01944813|Experimental|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
11413670|NCT01944813|No Intervention|No intervention: usual care|No intervention just usual care
11413671|NCT01944800|Experimental|Ticagrelor|
11413672|NCT01944800|Active Comparator|Prasugrel|
11413673|NCT01944787|Active Comparator|Routine|IV Hydration at 125 cc hour
11413674|NCT01944787|Experimental|Intervention|IV Hydration at 250 cc hour
11413675|NCT01944774|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
11413676|NCT01944774|Experimental|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
11413677|NCT01944774|Active Comparator|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
11413678|NCT01944761|Experimental|Immediate Group|The 15 patients in this group will be randomized to start the 12 week exercise intervention without delay (immediate condition).
11413679|NCT01944761|Experimental|Delayed Intervention|The 15 patients in this group will be randomized to start the intervention after the first group has completed the exercise intervention (delayed condition)
11413680|NCT01944748|Experimental|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
11413681|NCT01944748|No Intervention|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
11413682|NCT01944735|Experimental|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
11413683|NCT01944735|Placebo Comparator|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
11413684|NCT01944722|Experimental|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
11413685|NCT01944696|Active Comparator|continuous (uninterrupted) phototherapy|standard phototherapy
11413686|NCT01944696|Experimental|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
11413687|NCT01944683|Experimental|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.
~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
11413688|NCT01944683|Placebo Comparator|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.
~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
11413689|NCT01944670|Experimental|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
11413690|NCT01944657|Active Comparator|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
11413691|NCT01944657|Active Comparator|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
11413692|NCT01944644|Active Comparator|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
11413693|NCT01944644|Sham Comparator|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
11413694|NCT01944631|Placebo Comparator|Placebo|Nasal spray 4 times a day over 4 to 10 days
11413695|NCT01944631|Experimental|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
11413696|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
11413697|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
11413698|NCT01944592|Experimental|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination with GTA's
11413699|NCT01944592|Active Comparator|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination on manikins.
11413700|NCT01944579|Experimental|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
11413701|NCT01944579|Experimental|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
11413702|NCT01944566|Experimental|heavy armpit odour|subjects with heavy armpit odour
11413703|NCT01944553|Experimental|prospective|Single Arm
11413704|NCT01944540|Active Comparator|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
11413705|NCT01944540|Experimental|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
11413706|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
11413796|NCT01943916|Experimental|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
11413707|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
11413708|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
11413709|NCT01944501|Active Comparator|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
11413710|NCT01944501|Placebo Comparator|Sham TMS|Patients receiving sham transcranial magnetic stimulation
11413711|NCT01944501|Active Comparator|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
11413712|NCT01944501|Placebo Comparator|Sham TDCS|Patients receiving sham transcranial direct current stimulation
11413713|NCT01944488|Experimental|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
11413714|NCT01944462|Experimental|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
11413715|NCT01944449|Experimental|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
11413716|NCT01944449|Experimental|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
11413717|NCT01944449|Active Comparator|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
11413718|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:
~Must be taking a stable parkinsonian medication
~Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.
~Response to cholinesterase inhibitor over a period of six months will be monitored."
11413719|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:
~Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.
~Response to cholinesterase inhibitor over a period of six months will be monitored."
11413720|NCT01944423|Experimental|PSRT_DCS|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
11413721|NCT01944423|Placebo Comparator|PSRT_PBO|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill placebo dose one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
11413722|NCT01944410|Experimental|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
11413723|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
11413724|NCT01944384|Experimental|aldactone|aldactone 25 mg for 6 months
11413725|NCT01944384|No Intervention|without aldactone|
11413726|NCT01944371|Experimental|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
11413727|NCT01944371|Experimental|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
11413728|NCT01944371|Experimental|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
11413729|NCT01944358||Taiwan AIDS study group|
11413730|NCT01944332|Experimental|gamete treatment- oocytes and sperm|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The injected oocytes will be then exposed to the previously mentioned activating agents for the purpose of inducing embryo development. The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI.
11413731|NCT01944319|Active Comparator|Control group|The participants in control group will accept routine meropenem therapy
11413732|NCT01944319|Experimental|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
11413733|NCT01944306||Low birth-weight, obese|
11413734|NCT01944306||Low birth-weight, normal body weight|
11413735|NCT01944306||Normal birth-weight, obese|
11413736|NCT01944306||Normal birth-weight, normal body weight|
11413737|NCT01944293|Experimental|Ketamine|0.5 mg/kg, I.V. (in the vein)
11413738|NCT01944293|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
11413739|NCT01944280|Experimental|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
11413740|NCT01944280|No Intervention|control|usual care
11413741|NCT01944267|Active Comparator|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
~Prepared surgical area will be measured apico-coronally and mesio-distally."
11413797|NCT01943916|Experimental|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
11413963|NCT01942707|Active Comparator|Abdominoplasty without Scarpa´s Facia|Anchor-line abdominoplasty where the Scarpa's Fascia will be removed.
11413966|NCT01942694|Active Comparator|Vitamin D (Cholecalciferol)|One vitamin D pill daily
11413742|NCT01944267|Active Comparator|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.
~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
~No vertical incision made. Gingiva coronal to horizontal incision remains intact.
~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
11413743|NCT01944267|Active Comparator|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.
~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
11413744|NCT01944254|Active Comparator|random to respiration|Cardiac output measurement at random to respiration
11413745|NCT01944254|Experimental|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
11413746|NCT01944254|Experimental|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
11413747|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
11413748|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
11413749|NCT01944228|Experimental|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
11413750|NCT01944228|Sham Comparator|Sham stimulation|Catheter placed in the IJV without stimulation
11413751|NCT01944215|Active Comparator|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
11413752|NCT01944215|Active Comparator|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
11413753|NCT01944215|Active Comparator|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At ~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
11413754|NCT01944215|Active Comparator|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
11413755|NCT01944202|Experimental|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
11413756|NCT01944202|No Intervention|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
11413757|NCT01944189|Experimental|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.
~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
11413829|NCT01943695|Experimental|Aerobic Training During Chemotherapy|The ultimate goal is for participants to complete approximately 130-180 minutes/week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The 130-180 minutes/week will be achieved via 3 individual aerobic training sessions at approximately 10 to 50 minutes/session (± 10 minutes). All sessions are required to be supervised unless otherwise specified by EP discretion.
11413758|NCT01944189|Experimental|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.
~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
11413759|NCT01944176|Experimental|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
11413760|NCT01944176|Placebo Comparator|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
11413761|NCT01944163|No Intervention|Usual care|GP provide care as usual to their CLBP patients.
11413762|NCT01944163|Other|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
11413763|NCT01944150|Active Comparator|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
11413764|NCT01944150|Experimental|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
11413765|NCT01944137|No Intervention|Standard Care|Participant will receive standard cancer care
11413766|NCT01944137|Experimental|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
11413767|NCT01944124|Experimental|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
11413768|NCT01944124|Active Comparator|Exercise Prescription|Received a tailored exercise prescription only.
11413769|NCT01944111|Experimental|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
11413770|NCT01944098|Experimental|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
11413771|NCT01944098|Active Comparator|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
11413772|NCT01944085|Active Comparator|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
11413773|NCT01944085|Active Comparator|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
11413774|NCT01944085|Placebo Comparator|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
11413775|NCT01944072|Other|60%|aerobic exercise training intensity of 60%Wmax
11413776|NCT01944072|Other|80%|aerobic exercise training intensity of 80%Wmax
11413777|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.
~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
11413778|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.
~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
11413779|NCT01944046|Placebo Comparator|Placebo Nasal Spray|Placebo
11413780|NCT01944046|Active Comparator|Oxytocin Nasal Spray|Oxytocin
11413781|NCT01944033|Active Comparator|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
11413782|NCT01944033|Experimental|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
11413783|NCT01944020|Experimental|CPAP|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
11413784|NCT01944020|No Intervention|Control|Control will be no use of CPAP for 2 months
11413785|NCT01944007|Experimental|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
11413786|NCT01944007|Experimental|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
11413787|NCT01944007|Experimental|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
11413788|NCT01944007|Experimental|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
11413789|NCT01943994|Experimental|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
11413790|NCT01943994|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
11413791|NCT01943981||Optimal/inappropriate exercise response|
11413792|NCT01943968|Other|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
11413793|NCT01943955|Experimental|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
11413794|NCT01943942|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
11413795|NCT01943942|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
11413798|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
11413799|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
11413800|NCT01943890|Experimental|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
11413801|NCT01943877|Experimental|Propolis|
11413802|NCT01943877|Sham Comparator|scaling and root planing|
11413803|NCT01943864|Experimental|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
11413804|NCT01943864|Experimental|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
11413805|NCT01943864|Experimental|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
11413806|NCT01943851|Experimental|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
11413807|NCT01943851|Experimental|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
11413808|NCT01943851|Experimental|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
11413809|NCT01943838|Experimental|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
11413810|NCT01943825|Experimental|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
11413811|NCT01943825|Experimental|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
11413812|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
11413813|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
11413814|NCT01943812|Experimental|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
11413815|NCT01943812|Active Comparator|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
11413816|NCT01943799|Experimental|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
11413817|NCT01943799|Experimental|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
11413818|NCT01943799|Experimental|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
11413819|NCT01943799|Experimental|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
11413820|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
11413821|NCT01943773|Experimental|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
11413822|NCT01943773|Experimental|No Prehabilitation|The control group will undergo routine pre-operative management.
11413823|NCT01943760|Active Comparator|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
11413824|NCT01943760|Experimental|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
11413825|NCT01943734|Experimental|Lifestyle counseling|Information passed on anthropometric assessment
11413826|NCT01943721|Experimental|VISION5 Product|VISION5 Product in both eyes
11413827|NCT01943708|Active Comparator|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
11413828|NCT01943708|Experimental|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
11413964|NCT01942707|Experimental|abdominoplasty with Scarpa's Fascia|Anchor-line abdominoplasty where the Scarpa's Fascia will be preserved.
11413830|NCT01943695|Experimental|Aerobic Training After Chemotherapy|The ultimate goal is for participants to complete approximately 130-180 minutes/week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The 130-180 minutes/week will be achieved via 3 individual aerobic training sessions at approximately 10 to 50 minutes/session (± 10 minutes). All sessions are required to be supervisedunless otherwise specified by EP discretion.
11413831|NCT01943695|Experimental|Continuous Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The 130-180 minutes/week will be achieved via 3 individual aerobic training sessions at approximately 10 to 50 minutes/session (± 10 minutes). All sessions are required to be supervised unless otherwise specified by EP discretion.
11413832|NCT01943695|Experimental|General Physical Activity Group|Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress, and answer questions.
11413833|NCT01943682|Experimental|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
11413834|NCT01943669|Experimental|ReWalk™ device|Self-controlled group; single cohort.
11413835|NCT01943656|Experimental|Tobii™ Eyegaze System|Single arm, open label study.
11413836|NCT01943643|Experimental|CT angiography, coronary bifurcations|
11413837|NCT01943630|Active Comparator|AS101|Topical 15% AS101 gel, once a day (overnight)
11413838|NCT01943630|Placebo Comparator|Vehicle|Vehicle, Once a day topical application (Overnight)
11413839|NCT01943617|Active Comparator|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
11413840|NCT01943617|Experimental|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
11413841|NCT01943604|Experimental|Experimental|"Nutella Breakfast
~Waffle Breakfast"
11413842|NCT01943591|Experimental|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
11413843|NCT01943591|Active Comparator|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
11413844|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
11413845|NCT01943565|Active Comparator|Hydromorphone 25mcg|The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
11413846|NCT01943565|Active Comparator|Hydromorphone 50mcg|The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
11413847|NCT01943565|Active Comparator|Hydromorphone 100mcg|The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
11413848|NCT01943552|Experimental|ipratropium|500 mcg four times a day
11413849|NCT01943552|Placebo Comparator|placebo|
11413850|NCT01943539|Experimental|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
11413851|NCT01943513|Experimental|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
11413852|NCT01943513|Placebo Comparator|Placebo|Participants receive intravenous (IV) infusions of placebo
11413853|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
11413854|NCT01943487|Experimental|1: verapamil + EC905|
11413855|NCT01943474|Experimental|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
11413856|NCT01943474|Active Comparator|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
11413857|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 3 mg/kg|
11413858|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 10 mg/kg|
11413859|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 20 mg/kg|
11413860|NCT01943461|Experimental|Expansion Cohort: Avelumab 10 mg/kg|
11413861|NCT01943435|Active Comparator|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.
~NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol
~Adjunctive analgesics: acetaminophen, tramadol, or gabapentin
~Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine
~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
11413890|NCT01943253|Active Comparator|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
11413862|NCT01943435|Active Comparator|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
11413863|NCT01943435|Active Comparator|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.
~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
11413864|NCT01943422|Experimental|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)
~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)
~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
11413865|NCT01943422|Experimental|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)
~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)
~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
11413866|NCT01943422|Experimental|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)
~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)
~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
11413867|NCT01943409|Active Comparator|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
11413868|NCT01943409|Experimental|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
11413869|NCT01943396|Experimental|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
11413870|NCT01943396|No Intervention|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
11413871|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
11413872|NCT01943370|Experimental|Early saline irrigation|Initiation of early saline irrigation
11413873|NCT01943370|Active Comparator|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
11413874|NCT01943357|Experimental|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
11413875|NCT01943344|Experimental|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
11413876|NCT01943331||patients admitted to ICU|
11413877|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis
~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
11413878|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
11413879|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
11413880|NCT01943318||Autoimmune|Autoimmune Cirrhosis
11413881|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
11413882|NCT01943318||Toxic|Medication related cirrhosis
11413883|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
11413884|NCT01943305|Experimental|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
11413885|NCT01943305|Experimental|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
11413886|NCT01943292|Experimental|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
11413887|NCT01943279|Active Comparator|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
11413888|NCT01943279|Experimental|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
11413889|NCT01943266|Experimental|protein intake|protein intake randomly fed from deficient to excess
11413965|NCT01942694|Placebo Comparator|Placebo|One pill daily
11413891|NCT01943253|Active Comparator|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
11413892|NCT01943240|Experimental|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
11413893|NCT01943240|Active Comparator|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
11413894|NCT01943227||6ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 6ml/kg Tidal volume.
~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
11413895|NCT01943227||9ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 9ml/kg Tidal volume.
~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
11413896|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
11413897|NCT01943201|Experimental|new bedsheet|new bedsheet
11413898|NCT01943201|Placebo Comparator|conventional bedsheet|conventional bedsheet
11413899|NCT01943188|Experimental|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.
~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.
~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
11413900|NCT01943175||Genetic High Risk|
11413901|NCT01943175||Healthy Control|
11413902|NCT01943162|Experimental|SMART-CPT|CPT with additional elements of cognitive rehabilitation
11413903|NCT01943162|Active Comparator|CPT|Standard Cognitive Processing Therapy
11413904|NCT01943136|Experimental|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
11413905|NCT01943136|Active Comparator|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
11413906|NCT01943123|Experimental|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
11413907|NCT01943123|Placebo Comparator|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
11413908|NCT01943110|Experimental|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:
~Upper deltoid with the side-load ID adapter
~Upper deltoid with the AD ID adapter
~Suprascapular (behind the shoulder) with the side-load ID adapter
~Suprascapular with the AD ID adapter
~Forearm with the side-load ID adapter
~Forearm with the AD ID adapter"
11413909|NCT01943084|Experimental|Norditropin®|
11413910|NCT01943084|Active Comparator|Genotropin®|
11413911|NCT01943071|Experimental|Day care for patients with dementia|Day care for patients with dementia
11413912|NCT01943071|No Intervention|Care as usual|Care as usual
11413913|NCT01943058|Experimental|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
11413914|NCT01943058|Experimental|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
11413915|NCT01943045|Experimental|NGM282 Dose 1|NGM Dose 1
11413916|NCT01943045|Experimental|NGM282 Dose 2|NGM Dose 2
11413917|NCT01943045|Experimental|NGM282 Dose 3|NGM Dose 3
11413918|NCT01943045|Placebo Comparator|Placebo|Placebo
11413919|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
11413920|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
11413921|NCT01943019|Experimental|Linagliptin|Linagliptin daily
11413922|NCT01943006|Experimental|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate
~Twice daily"
11413923|NCT01943006|Placebo Comparator|Placebo|"Patients treated with placebo cream without active substance
~Twice daily"
11413924|NCT01942993|Experimental|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
11413925|NCT01942980|Other|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
11413926|NCT01942980|Other|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
11413927|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
11413928|NCT01942954|Experimental|Mobile health cognitive stimulation|Experimental group
11413929|NCT01942954|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
11413930|NCT01942941|Experimental|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
11413931|NCT01942928|Active Comparator|Usual NHS care|
11413932|NCT01942928|Active Comparator|Usual NHS Care plus Osteopathic Manipulative Therapy|
11413933|NCT01942915|Experimental|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
11413934|NCT01942902|Experimental|Continuous Glucose Monitoring System|
11413935|NCT01942889|Active Comparator|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
11413936|NCT01942889|Placebo Comparator|Placebo|Placebo
11413937|NCT01942876|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
11413938|NCT01942876|Sham Comparator|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
11413939|NCT01942863|Experimental|water exchange single balloon enteroscopy|
11413940|NCT01942863|Active Comparator|CO2 insufflation single balloon enteroscopy|
11413941|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
11413942|NCT01942837|Experimental|Enzalutamide|Participants will be treated with four 40 mg capsules (160 mg) once daily of enzalutamide taken orally. All participants without orchiectomy will be maintained on LHRH agonist/antagonist therapy. Participants will be evaluated clinically and with laboratory studies on day 1 of every 28 day cycle. Participants will maintain a drug diary from time of initiation of study treatment to time of discontinuation from the study (Appendix C).
11413943|NCT01942824|Experimental|Intervention|Text Message
11413944|NCT01942824|No Intervention|Usual Care|
11413945|NCT01942811|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
11413946|NCT01942811|No Intervention|Control|Usual care and a health education booklet and video on cancer prevention
11413947|NCT01942798|Active Comparator|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).
~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
11413948|NCT01942798|Experimental|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).
~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.
~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
11413949|NCT01942785|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
11413950|NCT01942772|Experimental|experimental test of healthy subjects|wearing experiment，motion experiment
11413951|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
11413952|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
11413953|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)
~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups"
11413954|NCT01942759||Oestrogen receptor status|Negative Positive
11413955|NCT01942759||Progesterone receptor status|Negative Positive
11413956|NCT01942759||HER-2 neu status|Negative Positive
11413957|NCT01942746|Active Comparator|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
11413958|NCT01942746|Active Comparator|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
11413959|NCT01942746|Placebo Comparator|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
11413960|NCT01942746|No Intervention|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
11413961|NCT01942733|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
11413962|NCT01942720|Other|Capsule endoscopy|
11413967|NCT01942681|Other|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
11413968|NCT01942668|Experimental|Treatment 1|Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
11413969|NCT01942668|Experimental|Treatment 2|Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
11413970|NCT01942668|Experimental|Treatment 3|Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
11413971|NCT01942668|Experimental|Treatment 4|Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
11413972|NCT01942668|Placebo Comparator|Placebo|Two Placebo softgel capsules taken orally once a day for twelve months.
11413973|NCT01942655|Experimental|Patients with recto-colic biopsies prescribed|45 patients
11413974|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.
~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
11413975|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.
~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
11413976|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.
~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
11413977|NCT01942616|Experimental|Condition 1|"Each study arm contains different scenarios presented to the participant.
~Condition 1 is a Perpetrator Positive scenario.
~The content of the Condition 1 group is as follows:
~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
11413978|NCT01942616|Experimental|Condition 2|"Each study arm contains different scenarios presented to the participant.
~Condition 2 is a Perpetrator Negative scenario.
~The content of the Condition 2 group is as follows:
~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
11413979|NCT01942616|Placebo Comparator|Condition 3|"Each study arm contains different scenarios presented to the participant.
~The content of the Condition 3 group is as follows:
~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
11413980|NCT01942603||Observation|
11413981|NCT01942603||Complete Lymfnode Dissection|
11413982|NCT01942590|Experimental|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
11413983|NCT01942590|Placebo Comparator|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
11413984|NCT01942577|No Intervention|No treatment|
11413985|NCT01942577|Active Comparator|NoSting|
11413986|NCT01942564||Case Subjects|"Age 18 years or older
~Had a head injury that occurred at least 6 months prior to entering study
~Have found lights more bothersome since injury"
11413987|NCT01942564||Control Subjects|"Age 18 years or older
~Have not had a previous head injury
~Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
11413988|NCT01942551|Experimental|tadalafil, dutasteride|
11413989|NCT01942551|Experimental|dutasteride, tadalafil|
11413990|NCT01942538|Experimental|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
11413991|NCT01942538|Sham Comparator|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
11413992|NCT01942538|Sham Comparator|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
11413993|NCT01942538|Experimental|rTMS|real rTMS for 3 weeks but without clinical improvement
11413994|NCT01942538|Sham Comparator|sham|sham treatment for 3 weeks without clinical improvement
11413995|NCT01942525||Intrauterine growth restriction|birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
11413996|NCT01942525||Appropriate for gestation age|control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
11413997|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
11413998|NCT01942499|Other|Community Exercise Group|Community-based exercise program for one year
11413999|NCT01942499|No Intervention|Usual Care|
11414000|NCT01942486|Experimental|Investigational Coating|
11414001|NCT01942473|Experimental|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
11414002|NCT01942473|Placebo Comparator|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
11414003|NCT01942460|Experimental|Ferumoxytol|
11414004|NCT01942447|Experimental|FMT|FMT
11414005|NCT01942447|Active Comparator|Standard|Vancomycin
11414006|NCT01942421|Experimental|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
11414007|NCT01942408|No Intervention|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
11414189|NCT01941225|Placebo Comparator|Placebo|Nebulized normal saline. Single administration
11414008|NCT01942408|Active Comparator|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
11414009|NCT01942395|Active Comparator|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
11414010|NCT01942395|Active Comparator|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
11414011|NCT01942395|No Intervention|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
11414012|NCT01942382|Experimental|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
11414013|NCT01942382|Experimental|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
11414014|NCT01942382|Experimental|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
11414015|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
11414016|NCT01942356|Experimental|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
11414017|NCT01942356|Active Comparator|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
11414018|NCT01942356|Active Comparator|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
11414019|NCT01942343|Active Comparator|Arm 1 : Droperidol 1,25 mg|
11414020|NCT01942343|Active Comparator|Arm 2 : Droperidol 0,625 mg|
11414021|NCT01942343|Active Comparator|Arm 3 : Odansetron 4 mg|
11414022|NCT01942330|No Intervention|Traditional Laparoscopic-Assisted Colectomy|
11414023|NCT01942330|Experimental|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
11414024|NCT01942317|Experimental|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
11414025|NCT01942317|No Intervention|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
11414026|NCT01942304|Active Comparator|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
11414027|NCT01942304|Experimental|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
11414028|NCT01942291|Experimental|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
11414029|NCT01942291|Experimental|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
11414030|NCT01942278|No Intervention|Usual Care|Care is delivered according to baseline standard practice
11414031|NCT01942278|Experimental|BHOMA|Care is delivered according to the BHOMA intervention
11414032|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
11414033|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
11414034|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
11414035|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
11414036|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
11414037|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
11414038|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
11414039|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
11414040|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
11414041|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
11414042|NCT01942239|Active Comparator|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
11414043|NCT01942239|No Intervention|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
11414044|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
11414045|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
11414046|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
11414047|NCT01942187|Active Comparator|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
11414048|NCT01942187|Active Comparator|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
11414049|NCT01942174|Other|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.
~Interventions : biological/vaccine and drug"
11414050|NCT01942174|Experimental|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.
~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination
~Interventions : biological/vaccine and drug"
11414051|NCT01942161|Experimental|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
11414052|NCT01942161|Experimental|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
11414053|NCT01942161|Experimental|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
11414054|NCT01942148|Experimental|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
11414055|NCT01942135|Experimental|Arm A|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
11414056|NCT01942135|Active Comparator|Arm B|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
11414057|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
11414058|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
11414059|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
11414060|NCT01942109|Active Comparator|Furosemide|This group will receive furosemide as a diuretic treatment
11414061|NCT01942109|Experimental|Torasemide|This group will receive torasemide as a diuretic treatment
11414062|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
11414063|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
11414064|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
11414065|NCT01942083|Experimental|OPB-111077|orally, once daily
11414066|NCT01942070|Experimental|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
11414067|NCT01942070|Active Comparator|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
11414068|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
11414069|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
11414070|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
11414071|NCT01942044|Experimental|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
11414072|NCT01942044|Active Comparator|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
11414073|NCT01942044|Active Comparator|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
11414074|NCT01942031|Experimental|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
11414075|NCT01942031|No Intervention|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
11414076|NCT01942018|Experimental|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
11414077|NCT01941992|Experimental|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
11414078|NCT01941992|Placebo Comparator|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
11414079|NCT01941979|Experimental|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)
~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
11414080|NCT01941979|No Intervention|Observation|
11414081|NCT01941966|Experimental|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
11414082|NCT01941953|Experimental|Metformin and Flourouracil|
11414115|NCT01941732|Experimental|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
11414116|NCT01941719|Experimental|enhanced foot care education|Importance of daily foot self-care was reinforced at based by viewing personal barefoot plantar pressure in gait
11414083|NCT01941940|Experimental|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
11414084|NCT01941927|Experimental|Trametinib, GSK2141795|"Trametinib (GSK1120212)
~Oral
~2 mg
~Daily
~Number of Cycles: until progression or unacceptable toxicity develops
~GSK2141795
~Oral
~25 mg
~Daily
~Number of Cycles: until progression or unacceptable toxicity develops"
11414085|NCT01941914|Experimental|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.
~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
11414086|NCT01941901|Experimental|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.
~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
11414087|NCT01941901|Active Comparator|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.
~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
11414088|NCT01941888|Experimental|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
11414089|NCT01941888|Active Comparator|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged< 70 - 0.03 mg/kg if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
11414090|NCT01941875|No Intervention|No Luteal Support|Control group: No luteal phase support or medication will be used
11414091|NCT01941875|Experimental|Luteal Vaginal Progesterone|Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
11414092|NCT01941862|Experimental|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
11414093|NCT01941862|Experimental|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
11414094|NCT01941862|Experimental|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
11414095|NCT01941862|No Intervention|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
11414096|NCT01941849|Experimental|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.
~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
11414097|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
11414098|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
11414099|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
11414100|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
11414101|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
11414102|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
11414103|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
11414104|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
11414105|NCT01941810|Experimental|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
11414106|NCT01941797|Experimental|Peri-implant mucosa|
11414107|NCT01941797|Active Comparator|periodontal mucosa|
11414108|NCT01941784|Experimental|Supportive care (health education program)|See Detailed Description.
11414109|NCT01941771|Active Comparator|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
11414110|NCT01941771|Experimental|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
11414111|NCT01941758|Experimental|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
11414112|NCT01941745|Placebo Comparator|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
11414113|NCT01941745|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
11414114|NCT01941745|Experimental|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
11414117|NCT01941719|Active Comparator|Standard Foot Care Education|
11414190|NCT01941225|Experimental|Inhaled iloprost 5.0 mcg|Single administration
11414118|NCT01941706|Experimental|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
11414119|NCT01941706|Experimental|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
11414120|NCT01941693|Experimental|Integrated care|"Integrated care:
~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
11414121|NCT01941693|Active Comparator|Usual care|Usual care
11414122|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
11414123|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
~CHOP-21 Day1 = day 21 (3 cycles)
~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.
~day 2-Day 5 Prednisone
~1mg/kg/day PO."
11414124|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
11414125|NCT01941667|Experimental|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level
~Daily messages requesting weight, intake, pulse ox and pulse are automated
~Virtual home visits occur twice weekly where the investigators see the infant and families."
11414126|NCT01941667|Placebo Comparator|Usual Care|Infants will have usual care as defined by cardiology.
11414127|NCT01941654|Experimental|preemptive local ablative therapy|
11414128|NCT01941641|Experimental|neoadjuvant FOLFOXIRI|
11414129|NCT01941628|Experimental|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
11414130|NCT01941628|Active Comparator|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
11414131|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
11414132|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
11414133|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
11414134|NCT01941589|Active Comparator|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
11414135|NCT01941589|Active Comparator|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
11414136|NCT01941589|Active Comparator|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
11414137|NCT01941589|Active Comparator|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
11414138|NCT01941576|Experimental|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
11414139|NCT01941576|Placebo Comparator|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
11414140|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
11414141|NCT01941563|Sham Comparator|Control|Sham injection
11414142|NCT01941550|Other|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.
~For max. 6 times at all."
11414143|NCT01941537|Experimental|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
11414144|NCT01941537|Placebo Comparator|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
11414145|NCT01941524|Active Comparator|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
11414146|NCT01941524|Active Comparator|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
11414147|NCT01941511|Experimental|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
11414148|NCT01941498|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
11414149|NCT01941485|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
11414184|NCT01941264|No Intervention|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
11414185|NCT01941251|Active Comparator|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
11414150|NCT01941472|Experimental|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
11414151|NCT01941459||1 Custodiol|Custodiol
11414152|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
11414153|NCT01941446|Experimental|pre-generated treatment scheme|Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet
11414154|NCT01941446|Placebo Comparator|Pre-generated tratment scheme|Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet
11414155|NCT01941446|Placebo Comparator|Moxifloxacin|Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet
11414156|NCT01941433|Experimental|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
11414157|NCT01941433|Other|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
11414158|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
11414159|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
11414160|NCT01941407|Experimental|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
11414161|NCT01941394|Experimental|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
11414162|NCT01941394|No Intervention|Without MSC|Without MSC infusion
11414163|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
11414164|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
11414165|NCT01941368|No Intervention|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
11414166|NCT01941368|Placebo Comparator|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
11414167|NCT01941368|Active Comparator|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
11414168|NCT01941355|Experimental|Exercise training, psycho-educative|
11414169|NCT01941355|Experimental|Psycho-educative component|
11414170|NCT01941355|Experimental|Exercise training component|
11414171|NCT01941355|No Intervention|Usual care|
11414172|NCT01941342|Active Comparator|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
11414173|NCT01941342|Experimental|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:
~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
11414174|NCT01941342|Experimental|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:
~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
11414175|NCT01941342|Experimental|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:
~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
11414176|NCT01941329|Experimental|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
11414177|NCT01941329|Active Comparator|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.
~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
11414178|NCT01941316|Experimental|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m2 of carfilzomib and 125 mg/m2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.
~Stratification for phase II component:
~Platinum sensitive disease: initial response to platinum-based chemotherapy with progression > 90 days after last treatment.
~Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
11414179|NCT01941303||Advanced stage non-small cell lung cancer patients|
11414180|NCT01941290||Orsiro|
11414181|NCT01941277|Experimental|Intensive Exercise Group|Behavioral
11414182|NCT01941277|Experimental|Current Recommendations Exercise Group|Behavioral
11414183|NCT01941264|Active Comparator|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
11414186|NCT01941251|Sham Comparator|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
11414191|NCT01941212|Active Comparator|Music therapy and Behavioral therapy|Music and behavioral therapy
11414192|NCT01941212|Active Comparator|Music only|Music therapy without behavioral therapy
11414193|NCT01941212|No Intervention|Control|Patients will not listen to music neither will get music therapy
11414194|NCT01941199|Experimental|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
11414195|NCT01941199|Experimental|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
11414196|NCT01941199|Experimental|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
11414197|NCT01941199|Experimental|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
11414198|NCT01941199|Experimental|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
11414199|NCT01941199|Experimental|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
11414200|NCT01941186|Experimental|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
11414201|NCT01941186|No Intervention|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
11414202|NCT01941173|Experimental|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11414203|NCT01941160|Experimental|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
11414204|NCT01941160|Placebo Comparator|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
11414205|NCT01941147|Experimental|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
11414206|NCT01941134|Experimental|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.
~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
11414207|NCT01941121|Experimental|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
11414208|NCT01941108|No Intervention|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
11414209|NCT01941108|Experimental|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
11414210|NCT01941095|Experimental|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
11414211|NCT01941082|Experimental|Part A: RO6867461|Single doses
11414212|NCT01941082|Experimental|Part B: RO6867461|Multiple doses
11414213|NCT01941069|Active Comparator|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
11414214|NCT01941069|Active Comparator|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
11414215|NCT01941056|Experimental|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
11414216|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
11414217|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
11414218|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
11414219|NCT01941030|Experimental|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
11414220|NCT01941030|Active Comparator|Balloon Angioplasty|Balloon Angioplasty (BA) alone
11414221|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
11414222|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
11414223|NCT01941004|Experimental|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
11414224|NCT01941004|Placebo Comparator|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
11414225|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
11414226|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
11414227|NCT01940978|Placebo Comparator|Control|Methylphenidate ER QD placebo BID
11414228|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
11414229|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
11414230|NCT01940965|Experimental|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
11414231|NCT01940965|Experimental|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
11414232|NCT01940965|Experimental|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
11414233|NCT01940965|Experimental|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
11414234|NCT01940952|Active Comparator|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
11414235|NCT01940952|Placebo Comparator|Placebo|Placebo + Donepezil 5mg or 10mg
11414236|NCT01940952|Active Comparator|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
11414237|NCT01940939|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an inter-train interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
11414238|NCT01940939|Sham Comparator|Sham rTMS|Sham rTMS stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.Intervention: Device: Repetitive Transcranial Magnetic Stimulation
11414239|NCT01940926|Experimental|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
11414240|NCT01940913|Active Comparator|Probiotics|
11414241|NCT01940913|Placebo Comparator|Placebo|
11414242|NCT01940900|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
11414243|NCT01940900|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
11414244|NCT01940887|Experimental|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
11414245|NCT01940887|Active Comparator|Sham + bevacizumab or aflibercept|E10030 sham injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
11414246|NCT01940874||Cerebral oximetry|
11414247|NCT01940861||Traumatic brain injury|
11414248|NCT01940848|Experimental|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
11414249|NCT01940848|Placebo Comparator|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
11414250|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
11414251|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
11414252|NCT01940822|Experimental|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
11414253|NCT01940822|Experimental|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
11414254|NCT01940809|Experimental|Arm A1 (ipilimumab, dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11414255|NCT01940809|Experimental|Arm A2 (dabrafenib, trametinib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID and trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
11414256|NCT01940809|Experimental|Arm B1 (ipilimumab, trametinib)|Patients receive trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11414257|NCT01940809|Experimental|Arm B2 (trametinib, nivolumab, ipilimumab)|Patients receive trametinib PO QD for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
11414258|NCT01940809|Experimental|Arm C1 (ipilimumab, dabrafenib)|Patients receive dabrafenib PO BID for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11414450|NCT01939431||Advanced|advanced stage podoconiosis
11414259|NCT01940809|Experimental|Arm C2 (dabrafenib, nivolumab, ipilimumab)|Patients receive dabrafenib PO BID for 25 days followed by nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses.
11414260|NCT01940809|Experimental|Arm D1 (ipilimumab)|Patients receive ipilimumab IV over 90 minutes Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11414261|NCT01940809|Experimental|Arm D2 (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 4 doses, followed by nivolumab monotherapy IV every 2 weeks continuously for up to 42 courses
11414262|NCT01940796|Experimental|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing > 100 kg. The dose for participants weighing > 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
11414263|NCT01940783|Other|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
11414264|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
11414265|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
11414266|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
11414267|NCT01940744|Experimental|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
11414268|NCT01940744|Active Comparator|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
11414269|NCT01940731|Experimental|Colistimethate sodium|
11414270|NCT01940718|Experimental|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
11414271|NCT01940705|Active Comparator|Standard of care (SoC)|standard of care hearing-aid orientation as provided by clinical audiologist
11414272|NCT01940705|Experimental|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
11414273|NCT01940705|Experimental|SoC plus hearing aid DVD|SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
11414274|NCT01940705|Experimental|Soc plus teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids
11414275|NCT01940692|Active Comparator|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
11414276|NCT01940692|Experimental|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
11414277|NCT01940679|Experimental|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
11414278|NCT01940679|Experimental|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
11414279|NCT01940679|Experimental|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
11414280|NCT01940679|Experimental|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
11414281|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
11414282|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) >=2.39
11414283|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) >=2.99
11414284|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) >=6.53
11414285|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)>=181.55
11414286|NCT01940653|Other|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
11414287|NCT01940653|Active Comparator|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
11414288|NCT01940640|Experimental|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
11414289|NCT01940640|Active Comparator|Control|follow on capsules without probiotics
11414290|NCT01940627|Experimental|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
11414291|NCT01940627|Placebo Comparator|Control|Firemen consuming placebo capsules during two weeks
11414292|NCT01940601|Experimental|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
11414451|NCT01939431||Control|non-podoconiosis controls
11414293|NCT01940601|Experimental|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
11414294|NCT01940601|Active Comparator|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
11414295|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
11414296|NCT01940575|Active Comparator|Restylane®|Inject Restylane® on right or left nasolabial fold
11414297|NCT01940575|Experimental|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
11414298|NCT01940562|Experimental|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.
~Starting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.
~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
11414299|NCT01940549|Sham Comparator|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
11414300|NCT01940549|Active Comparator|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
11414301|NCT01940536|Active Comparator|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
11414302|NCT01940536|Placebo Comparator|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
11414303|NCT01940523|Active Comparator|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
11414304|NCT01940523|Active Comparator|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
11414305|NCT01940510|Experimental|Healthy subjects|
11414306|NCT01940497|Experimental|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
11414307|NCT01940497|Experimental|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
11414308|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
11414309|NCT01940471|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
11414310|NCT01940471|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
11414311|NCT01940471|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
11414312|NCT01940445|Experimental|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
11414313|NCT01940445|Experimental|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
11414314|NCT01940432|Experimental|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
11414315|NCT01940432|Experimental|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
11414316|NCT01940419|Active Comparator|Tranexamic Acid|1g Tranexamic acid iv just before surgery
11414317|NCT01940419|Placebo Comparator|Placebo|sterile sodium chloride 9mg/ml iv
11414318|NCT01940406|Experimental|Stimulation procedure|Stimulation procedure
11414319|NCT01940393|Active Comparator|Cetirizine|Cetirizine
11414320|NCT01940393|Active Comparator|Desloratadine|desloratadine
11414321|NCT01940393|Active Comparator|Fexofenadine|Fexofenadine
11414322|NCT01940393|Active Comparator|Ebastine|ebastine
11414323|NCT01940393|Active Comparator|Bilastine|bilastine
11414324|NCT01940367|Active Comparator|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
11414452|NCT01939431||Early|early stage podoconiosis
11414325|NCT01940367|Active Comparator|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
11414326|NCT01940354|Experimental|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
11414327|NCT01940354|Active Comparator|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
11414328|NCT01940341|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
11414329|NCT01940341|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
11414330|NCT01940341|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
11414331|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
11414332|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
11414333|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
11414334|NCT01940315|Active Comparator|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
11414335|NCT01940315|Placebo Comparator|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
11414336|NCT01940302|Experimental|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
11414337|NCT01940302|No Intervention|Control|Received only oral hypoglycemic agents.
11414338|NCT01940289|Active Comparator|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
11414339|NCT01940289|Active Comparator|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
11414340|NCT01940276|Experimental|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
11414341|NCT01940263|Placebo Comparator|Placebo|placebo 320 mg daily for twelve weeks
11414342|NCT01940263|Experimental|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
11414343|NCT01940250|Placebo Comparator|Sterile water|"Sterile water will be packaged identically to the active comparator.
~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
11414344|NCT01940250|Active Comparator|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.
~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:
~If the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins
~If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated
~If the systolic BP decrease rapidly more than 25% over 15 minutes
~If the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
11414345|NCT01940237|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
11414346|NCT01940224|Active Comparator|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
11414347|NCT01940224|Placebo Comparator|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
11414348|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
11414349|NCT01940172|Experimental|Birinapant with Conatumumab|
11414350|NCT01940159|Active Comparator|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
11414351|NCT01940159|Placebo Comparator|Placebo|Matched placebo.
11414352|NCT01940146|Placebo Comparator|SPARC Placebo|
11414353|NCT01940146|Experimental|SPARC1310 I|
11414354|NCT01940146|Experimental|SPARC1310 II|
11414355|NCT01940146|Experimental|SPARC1310 III|
11414356|NCT01940133|Experimental|PQR309|Different dose evaluation
11414357|NCT01940120|Experimental|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
11415710|NCT01931020|Experimental|Glucose|1ml of 25% glucose will be administered prior to heel lance
11414358|NCT01940107|Other|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
11414359|NCT01940107|Experimental|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
11414360|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
11414361|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
11414362|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:
~documented ventricular arrhythmia or
~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
~high risk for ventricular arrhythmia (LVEF ≤ 35%) or
~intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)
~who are not admitted for cardiac surgery"
11414363|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:
~documented ventricular arrhythmia or
~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
~high risk for ventricular arrhythmia (LVEF ≤ 35%)
~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
11414364|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:
~Coronary artery bypass graft surgery and who do not have prior myocardial infarction
~Aortic valve replacement"
11414365|NCT01940068|Experimental|New Thickened Amino acid based formula|
11414366|NCT01940068|Active Comparator|Amino acid based formula|
11414367|NCT01940055|Experimental|Experimental group|Dual Task Treadmill Walking Exercise Program
11414368|NCT01940055|Active Comparator|Control group|Dual task recumbent cycling exercise program
11414369|NCT01940042|Experimental|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
11414370|NCT01940042|No Intervention|clasical group|no additional action will be taken after the operation
11414371|NCT01940016|Experimental|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
11414372|NCT01940016|Active Comparator|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
11414373|NCT01940003|No Intervention|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
11414374|NCT01940003|Experimental|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
11414375|NCT01939990|Active Comparator|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
11414376|NCT01939990|Placebo Comparator|Placebo|Group B will be given Placebo.
11414377|NCT01939977|Experimental|Paricalcitol|Paricalcitol oral capsules.
11414378|NCT01939977|Active Comparator|Calcifediol|Calcifediol oral drops.
11414379|NCT01939964|Active Comparator|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
11414380|NCT01939964|Placebo Comparator|Placebo|sugar pill
11414381|NCT01939951|Active Comparator|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
11414382|NCT01939951|Placebo Comparator|Placebo|sugar pill
11414383|NCT01939938|Experimental|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
11414384|NCT01939925|Experimental|New plain language summary format|New plain language summary format of a Cochrane systematic review
11414385|NCT01939925|Active Comparator|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
11414386|NCT01939912|Experimental|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
11414387|NCT01939899|Experimental|IXAZOMIB|Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
11414388|NCT01939886|Experimental|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
11414389|NCT01939886|Active Comparator|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
11414390|NCT01939873|Experimental|KRISTELLER|Uterine fundal pressure
11414391|NCT01939873|No Intervention|Control group|
11414392|NCT01939860|No Intervention|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
11414453|NCT01939418|Experimental|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
11414393|NCT01939860|Experimental|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
11414394|NCT01939847|Experimental|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
11414395|NCT01939847|No Intervention|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
11414396|NCT01939834|Experimental|AAA Control|"Subjects will use their home insulin pump along with a continuous glucose monitor (CGM) receiver. A CGM will be worn for 7 days prior to the study admission. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.
~Subjects will be asked to provide the study team their insulin pump data on Day 2 or 3 to ensure accuracy of data collection. Subjects will be asked to submit insulin pump, glucometer, and CGM data 1-2 days prior to their admission and again the evening prior to the study admission at a Research House.
~During the Experimental Admission, the AAA system will be tested using the DiAs platform. Subjects will participate in 45 minutes of exercise during the 40 hour admission (n=36). A subset (n=5-7) will continue with 5 nights of consecutive closed loop control (23:00-07:00)."
11414397|NCT01939834|Active Comparator|CGM + insulin pump at home|"The experimental and control admissions (40hr admissions) are exactly the same except for the study admission. During the Control Admission, subjects will use their home insulin pump along with a continuous glucose monitor receiver without running any specialized mathematical equations.
~The active comparator for subjects participating in 5 consecutive nights of closed loop control will be the sensor-augmented pump therapy at home."
11414398|NCT01939821|Experimental|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
11414399|NCT01939821|Active Comparator|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
11414400|NCT01939821|No Intervention|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
11414401|NCT01939808|Other|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
11414402|NCT01939808|Other|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
11414403|NCT01939795|No Intervention|Healthy People|Control group
11414404|NCT01939795|Experimental|Untrained CRT|Untrained CRT patients
11414405|NCT01939795|Experimental|Exercise trained + CRT|Exercise-trained CRT patients
11414406|NCT01939782|Experimental|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:
~No Breakfast (NoB): fasting until lunch at 12:00
~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
11414407|NCT01939782|Active Comparator|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:
~No Breakfast (NoB): fasting until lunch at 12:00
~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
11414408|NCT01939756|Experimental|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
11414409|NCT01939743|Experimental|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
11414410|NCT01939743|Other|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
11414411|NCT01939730|Experimental|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
11414412|NCT01939717|Other|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
11414413|NCT01939717|No Intervention|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
11414414|NCT01939704|No Intervention|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
11414415|NCT01939704|No Intervention|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
11414416|NCT01939704|Experimental|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
11414417|NCT01939704|Experimental|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
11414418|NCT01939691|Experimental|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
11414419|NCT01939691|Experimental|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
11414420|NCT01939691|Experimental|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
11414421|NCT01939665|Experimental|Irreversible electroporation|Single arm study: Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma
11414422|NCT01939652|Active Comparator|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
11414423|NCT01939652|Experimental|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
11414424|NCT01939639|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
11414425|NCT01939639|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
11414426|NCT01939626|Experimental|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
11414427|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
11414428|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
11414429|NCT01939600|Experimental|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
11414430|NCT01939587|Experimental|PBF-680 5 mg|5 mg of PBF-680
11414431|NCT01939587|Experimental|PBF-680 20 mg|20 mg of PBF-680
11414432|NCT01939587|Placebo Comparator|Placebo|Placebo
11414433|NCT01939574|Experimental|Chemoradiation & Adjuvant Therapy:|"Concurrent chemoradiation Therapy:
~Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.
~Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.
~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.
~Adjuvant Therapy:
~Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.
~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
11414434|NCT01939561|Active Comparator|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
11414435|NCT01939561|Placebo Comparator|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
11414436|NCT01939548|Experimental|PF-02545920 (5mg)|
11414437|NCT01939548|Placebo Comparator|Placebo|
11414438|NCT01939548|Experimental|PF-02545920 (15mg)|
11414439|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
11414440|NCT01939522|Experimental|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
11414441|NCT01939509|Experimental|Atenolol-Bisoprolol|
11414442|NCT01939496|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
11414443|NCT01939496|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
11414444|NCT01939496|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
11414445|NCT01939483|Experimental|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
~This arm also includes laboratory biomarker analysis as an intervention."
11414446|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
11414447|NCT01939457|Experimental|misoprostol|400 mcg misoprostol sublingually
11414448|NCT01939444|Experimental|naloxone intranasal|2.0 mg by the nasal route
11414449|NCT01939444|Active Comparator|naloxone intravenous|1.0 mg intravenous
11414455|NCT01939405|Experimental|built environment use counseling|personalized counseling on active use of the built environment
11414456|NCT01939392|Experimental|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
11414457|NCT01939392|No Intervention|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
11414458|NCT01939379|Active Comparator|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
11414459|NCT01939379|Active Comparator|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
11414460|NCT01939366|Experimental|Cebranopadol 300 µg|
11414461|NCT01939366|Experimental|Cebranopadol 600 µg|
11414462|NCT01939366|Active Comparator|Pregabalin|
11414463|NCT01939366|Placebo Comparator|Matching Placebo|
11414464|NCT01939366|Experimental|Cebranopadol 100 µg|
11414465|NCT01939353|Experimental|EB-1020 SR|100-500 mg flexible titration
11414466|NCT01939353|Placebo Comparator|Placebo|Matching Placebo
11414467|NCT01939327|Experimental|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
11414468|NCT01939314|Active Comparator|Bupivacaine|Bupivicaine .03ml to each nare
11414469|NCT01939314|Placebo Comparator|Normal Saline|normal saline .03 ml to each nare
11414470|NCT01939301|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide
11414471|NCT01939301|Placebo Comparator|Placebo|Oxygen
11414472|NCT01939288|Experimental|Group 1|Half of recruited subjects (n=5)
11414473|NCT01939288|Experimental|Group 2|Other half of recruited subjects (n=5)
11414474|NCT01939275|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)|Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
11414475|NCT01939262|Experimental|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
11414476|NCT01939262|Placebo Comparator|Control|Subjects maintained their existing diet without modification.
11414477|NCT01939249|Active Comparator|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
11414478|NCT01939249|Experimental|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
11414479|NCT01939236|Experimental|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
11414480|NCT01939236|Placebo Comparator|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
11414481|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
11414482|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
11414483|NCT01939210|Experimental|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
11414484|NCT01939210|Active Comparator|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
11414485|NCT01939197|Experimental|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
11414486|NCT01939197|Experimental|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
11414487|NCT01939197|Experimental|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
11414488|NCT01939197|Experimental|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
11414489|NCT01939197|Experimental|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
11414490|NCT01939197|Experimental|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
11414491|NCT01939197|Experimental|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
11414492|NCT01939197|Experimental|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
11414493|NCT01939197|Experimental|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
11414494|NCT01939197|Experimental|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
11414553|NCT01938859|Experimental|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
11414495|NCT01939197|Experimental|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
11414496|NCT01939197|Experimental|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
11414497|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
11414498|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
11414499|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
11414500|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
11414501|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
11414502|NCT01939171|Placebo Comparator|Non treated|Cadaver donor is cared and treated as usual protocol
11414503|NCT01939171|Experimental|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
11414504|NCT01939158|Experimental|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
11414505|NCT01939158|Experimental|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
11414506|NCT01939158|Experimental|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
11414507|NCT01939158|Active Comparator|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
11414508|NCT01939145|Active Comparator|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
11414509|NCT01939145|Active Comparator|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
11414510|NCT01939132|Experimental|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
11414511|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
11414512|NCT01939106|Other|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
11414513|NCT01939093|Experimental|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
11414514|NCT01939093|Active Comparator|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
11414515|NCT01939080|Active Comparator|Medical supervision|Exercise training with supervised sessions Classics training
11414516|NCT01939080|Active Comparator|No medical supervision|Exercise training without supervised sessions Classics training
11414517|NCT01939067|Other|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).
~Escalation of the ventilatory support per protocol and the attending physician."
11414518|NCT01939067|Other|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).
~Escalation of the ventilatory support per protocol and the attending physician."
11414519|NCT01939054|Experimental|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
11414520|NCT01939054|Active Comparator|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
11414521|NCT01939041|Experimental|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
11414522|NCT01939041|Experimental|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
11414523|NCT01939041|Active Comparator|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
11414524|NCT01939028|Experimental|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
11414525|NCT01939015|Active Comparator|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
11414526|NCT01939015|Experimental|three dimensional titanium miniplate|3D curved strut miniplate* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
11414527|NCT01939002|Experimental|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
11414528|NCT01939002|Experimental|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
11414529|NCT01938989|Other|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
11414530|NCT01938989|Other|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
11414531|NCT01938976|Experimental|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
11414532|NCT01938976|Experimental|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
11414533|NCT01938963|No Intervention|Care as usual|
11414534|NCT01938963|Experimental|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
11414535|NCT01938950|Active Comparator|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
11414536|NCT01938950|Active Comparator|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
11414537|NCT01938950|Active Comparator|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
11414538|NCT01938937|Experimental|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
11414539|NCT01938937|Sham Comparator|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
11414540|NCT01938924|No Intervention|No intervention|No intervention
11414541|NCT01938924|Active Comparator|GekoTM|geko applied to bypass limb
11414542|NCT01938911|Experimental|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414543|NCT01938911|Experimental|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414544|NCT01938911|Experimental|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414545|NCT01938911|Placebo Comparator|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414546|NCT01938911|Experimental|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414547|NCT01938911|Experimental|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414548|NCT01938911|Experimental|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414549|NCT01938911|Placebo Comparator|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
11414550|NCT01938898|Other|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
11414551|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
11414552|NCT01938859|Experimental|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
11414554|NCT01938859|Active Comparator|Lithium monotherpy|Lithium monotherapy
11414555|NCT01938846|Experimental|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
11414556|NCT01938846|Experimental|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
11414557|NCT01938846|Experimental|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
11414558|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11414559|NCT01938820|Active Comparator|Entecavir Therapy|"Entecavir monotherapy:
~entecavir, 0.5mg, qd, oral, for 2 years."
11414560|NCT01938820|Experimental|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
11414561|NCT01938807|Experimental|Intervention|The intervention group receives the CareCoach mobile application
11414562|NCT01938807|Active Comparator|Control|The control group receives standard care.
11414563|NCT01938781|Active Comparator|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
11414564|NCT01938781|Experimental|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
11414565|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
11414566|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
11414567|NCT01938755|Experimental|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
11414568|NCT01938755|Experimental|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
11414569|NCT01938755|Experimental|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
11414570|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
11414571|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
11414572|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
11414573|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
11414574|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
11414575|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
11414576|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
11414577|NCT01938729|Experimental|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.
~Level 1: Systemic gemcitabine 650mg/m^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
11414578|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
11414579|NCT01938690|Sham Comparator|Sham stimulation|Sham stimulation on the scalp of unaffected brain
11414580|NCT01938690|Experimental|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
11414581|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
11414582|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
11414583|NCT01938664|Experimental|Candesartan w Cognitive Behavior Therapy|Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
11414584|NCT01938664|Placebo Comparator|Placebo w Cognitive Behavior Therapy|Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
11414585|NCT01938651|Experimental|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
11414586|NCT01938638|Experimental|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
11414587|NCT01938638|Experimental|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
11414588|NCT01938625|Experimental|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
11414589|NCT01938625|Experimental|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
11414590|NCT01938612|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
11414591|NCT01938612|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
11414592|NCT01938612|Experimental|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
11414593|NCT01938612|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
11416350|NCT01926938||adults at risk|Latino adults with family history of type 2 diabetes
11414594|NCT01938612|Experimental|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
11414595|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
11414596|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
11414597|NCT01938586||Surgical excision|
11414598|NCT01938573|Experimental|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
11414599|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
11414600|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
11414601|NCT01938547|Experimental|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).
~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
11414602|NCT01938534|Experimental|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice
~for 10 days"
11414603|NCT01938534|Active Comparator|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
11414604|NCT01938521|Experimental|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
11414605|NCT01938521|Placebo Comparator|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
11414606|NCT01938508|Experimental|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
11414607|NCT01938508|Experimental|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
11414608|NCT01938495|Experimental|NeuRx® Diaphragm Pacing System™ (DPS)|Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
11414609|NCT01938495|No Intervention|Standard of Care|patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
11414610|NCT01938482|Experimental|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
11414611|NCT01938482|Experimental|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
11414612|NCT01938469|Other|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
11414613|NCT01938469|Other|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
11414614|NCT01938456|Experimental|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
11414615|NCT01938443|Experimental|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
11414616|NCT01938443|Experimental|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
11414617|NCT01938430|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
11414618|NCT01938430|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
11414619|NCT01938430|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
11414620|NCT01938430|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
11414621|NCT01938430|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
11414622|NCT01938430|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
11414623|NCT01938430|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
11414624|NCT01938430|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
11414625|NCT01938430|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
11414626|NCT01938430|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
11414627|NCT01938430|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
11414628|NCT01938430|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
11414629|NCT01938430|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
11414630|NCT01938430|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
11414631|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
11414632|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
11414633|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
11414634|NCT01938391|Other|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
11414635|NCT01938378|Other|Pediatric patients undergoing TPE|octaplas™
11414636|NCT01938365||Diabetes|
11414637|NCT01938365||Normal glucose regulation|
11414638|NCT01938352|Experimental|CR8020|CR8020 administered as a single 2-hour intravenous infusion
11414639|NCT01938352|Placebo Comparator|Placebo|Placebo administered as a single 2-hour intravenous infusion
11414640|NCT01938339|Experimental|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
11414641|NCT01938326|Active Comparator|TLDG|No mini-laparotomy in the epigastrium Reconstruction by the uncut Roux-en Y gastrojejunostomy
11414642|NCT01938326|Active Comparator|SIDG|SIDG : pure single incision laparoscopic distal gastrectomy Reconstruction by the uncut Roux-en Y gastrojejunostomy
11414643|NCT01938313|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
11414644|NCT01938313|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
11414645|NCT01938300|Experimental|Magnesium|"Magnesium sulfate infusion during a operation period.
~Infusion regimen:
~Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes
~Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
11414646|NCT01938300|Placebo Comparator|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
11414647|NCT01938287|Experimental|SENSIMED Triggerfish|
11414648|NCT01938274|Experimental|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
11414649|NCT01938274|No Intervention|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
11414650|NCT01938261|Experimental|Paracetamol effect on ductus|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
11414651|NCT01938261|Experimental|Paracetamol effect on pain|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
11414652|NCT01938248|Active Comparator|Control|Aspirin 81 mg once daily
11414653|NCT01938248|Experimental|Intervention|Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
11414654|NCT01938235|Experimental|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)
~*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.
~If the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.
~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
11414655|NCT01938235|Placebo Comparator|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.
11414656|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval < 0,5 cm and lateral 0,5-0,8 cm
11414657|NCT01938209|Experimental|seated general thoracic spine manipulation|seated general thoracic spine manipulation
11414658|NCT01938209|Experimental|supine specific thoracic spine manipulation|Specific supine manipulation
11414659|NCT01938196|Experimental|KWA-0711 Dose1|
11414660|NCT01938196|Experimental|KWA-0711 Dose2|
11414661|NCT01938196|Experimental|KWA-0711 Dose3|
11414662|NCT01938196|Experimental|KWA-0711 Dose4|
11414663|NCT01938196|Placebo Comparator|Placebo|
11414664|NCT01938183|Placebo Comparator|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
11414698|NCT01937910|Experimental|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
11414665|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
11414666|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
11414667|NCT01938170|Experimental|FluMist|Subjects receiving vaccine at home
11414668|NCT01938157|Experimental|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
11414669|NCT01938144|Experimental|Treatment A|IBU 200 mg/ PE 10 mg
11414670|NCT01938144|Experimental|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
11414671|NCT01938144|Active Comparator|Treatment C|Acetaminophen 500 mg
11414672|NCT01938131|Placebo Comparator|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
11414673|NCT01938131|Experimental|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
11414674|NCT01938118|Experimental|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
11414675|NCT01938118|Active Comparator|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
11414676|NCT01938105|Experimental|Nimotuzumab+chemoradiotherapy|
11414677|NCT01938092|Active Comparator|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
11414678|NCT01938092|Placebo Comparator|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
11414679|NCT01938079|Active Comparator|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
11414680|NCT01938079|Experimental|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
11414681|NCT01938066|Active Comparator|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
11414682|NCT01938066|Sham Comparator|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
11414683|NCT01938053|Other|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
11414684|NCT01938053|Other|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
11414685|NCT01938040|Active Comparator|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
11414686|NCT01938040|Placebo Comparator|Sugar water|100mL of normal saline to be administered over 5 minutes
11414687|NCT01938027|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
11414688|NCT01938001|Experimental|Rituximab and Lenalidomide|Participants received rituximab 375 mg/m^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but < 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
11414689|NCT01938001|Active Comparator|Rituximab and Placebo|Participants received riituximab 375 mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
11414690|NCT01937988|Experimental|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
11414691|NCT01937988|No Intervention|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
11414692|NCT01937975|Experimental|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
11414693|NCT01937975|Experimental|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
11414694|NCT01937975|Experimental|Healthy Participants|Healthy participants (estimated glomerular filtration rate >=80 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
11414695|NCT01937949|Other|Endovascular|"The study will include patients treated by endovascular aortic repair of juxtarenal, suprarenal and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft. The graft includes combinations of scallops, holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
~Other names:
~Endovascular stent Stent-graft"
11414696|NCT01937936|Experimental|CBT|Cognitive Behavioral Therapy (CBT)
11414697|NCT01937936|Active Comparator|Education|Health Education
11414699|NCT01937910|Active Comparator|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
11414700|NCT01937897|Experimental|Left-Sided Massage|Unilateral massage on the left side of the body.
11414701|NCT01937897|Active Comparator|Right-Sided Massage|Unilateral massage on the right side of the body.
11414702|NCT01937897|Sham Comparator|Bi-Lateral Massage|Traditional massage on the back of the body.
11414703|NCT01937884|Experimental|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
11414704|NCT01937884|Active Comparator|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
11414705|NCT01937871|Placebo Comparator|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
11414706|NCT01937871|Experimental|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
11414707|NCT01937871|Other|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
11414708|NCT01937858||Normal renal function|
11414709|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
11414710|NCT01937858||End stage renal disease on hemodialysis|
11414711|NCT01937832|Active Comparator|Ertapenem|
11414712|NCT01937832|Experimental|Faropenem|
11414713|NCT01937819|Experimental|SMART arm|Using SMARTPHONE application for self judging bowel preparation
11414714|NCT01937819|No Intervention|Conventional arm|Non-using SMARTPHONE application for bowel preparation
11414715|NCT01937806|Experimental|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
11414716|NCT01937806|Active Comparator|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
11414717|NCT01937793|Active Comparator|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
11414718|NCT01937793|Active Comparator|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
11414719|NCT01937767|Active Comparator|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
11414720|NCT01937767|Experimental|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
11414721|NCT01937767|Experimental|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
11414722|NCT01937754|Active Comparator|Nitric Oxide supplement|
11414723|NCT01937754|Placebo Comparator|Placebo|
11414724|NCT01937728|Active Comparator|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
11414725|NCT01937728|Experimental|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.
~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
11414726|NCT01937728|Experimental|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
11414727|NCT01937728|Active Comparator|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
11414728|NCT01937728|Experimental|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
11414729|NCT01937728|Experimental|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.
~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
11414730|NCT01937715|Experimental|Arm A|PF-05212384 plus FOLFIRI
11414731|NCT01937715|Active Comparator|Arm B|Bevacizumab plus FOLFIRI
11414732|NCT01937702|Experimental|Anti-diabetes medication|Insulin
11414733|NCT01937689|Experimental|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
11414734|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
11414735|NCT01937663|Experimental|KWA-0711 Dose1|
11414736|NCT01937663|Experimental|KWA-0711 Dose2|
11414737|NCT01937663|Experimental|KWA-0711 Dose3|
11414738|NCT01937663|Experimental|KWA-0711 Dose4|
11414773|NCT01937364|Placebo Comparator|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
11414774|NCT01937364|Active Comparator|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
11414775|NCT01937351|Experimental|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
11414776|NCT01937338|Experimental|AZD7624|
11414777|NCT01937338|Placebo Comparator|Placebo|
11414739|NCT01937650|Active Comparator|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
11414740|NCT01937650|Placebo Comparator|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
11414741|NCT01937637|Other|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.
~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
11414742|NCT01937624||Diagnostic ultrasound and radiographic imaging|- The diagnostic musculoskeletal ultrasound and x-rays will both be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
11414743|NCT01937611|Experimental|Dexmedetomidine|dexmedetomidine 1μg•kg-1
11414744|NCT01937611|Active Comparator|midazolam|midazolam 0.03 mg•kg-1
11414745|NCT01937598|Experimental|Sitagliptin, then Placebo|
11414746|NCT01937598|Experimental|Placebo, then Sitagliptin|
11414747|NCT01937585|Active Comparator|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
11414748|NCT01937585|Experimental|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
11414749|NCT01937572|Experimental|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
11414750|NCT01937572|Other|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
11414751|NCT01937559|Experimental|Topical Tranexamic acid (TXA)|Tranexamic acid (TXA) applied topically
11414752|NCT01937559|Placebo Comparator|Saline|Normal saline
11414753|NCT01937559|Active Comparator|Tranexamic acid (TXA)|Tranexamic acid (TXA) administered intravenously
11414754|NCT01937546|Active Comparator|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
11414755|NCT01937546|Experimental|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
11414756|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
11414757|NCT01937520|Experimental|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
11414758|NCT01937520|Placebo Comparator|device|no acupuncture will be done on this group of subjects
11414759|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
11414760|NCT01937494|Experimental|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
11414761|NCT01937481|Experimental|Nutrition and Physical Activity|The Food Friends programs
11414762|NCT01937481|No Intervention|Control|Control group
11414763|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
11414764|NCT01937455|Experimental|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
11414765|NCT01937455|Experimental|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
11414766|NCT01937455|Experimental|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
11414767|NCT01937455|Experimental|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
11414768|NCT01937442|Experimental|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
11414769|NCT01937429|Experimental|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
11414770|NCT01937429|Active Comparator|Standard colonoscopy|Standard colonoscopy with insufflation of air
11414771|NCT01937416|Experimental|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
11414772|NCT01937390||LAMA/LABA Patients|
11414780|NCT01937312|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
11414781|NCT01937312|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
11414782|NCT01937299|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
11414783|NCT01937299|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
11414784|NCT01937260|Experimental|Brodalumab 140mg SC|open label, all subjects receive brodulamab
11414785|NCT01937260|Experimental|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
11414786|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
11414787|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
11414788|NCT01937234|Active Comparator|Metoclopramide|Intravenous injection of 10mg metoclopramide
11414789|NCT01937234|Placebo Comparator|Placebo|Intravenous injection of 0.9% sodium chloride
11414790|NCT01937221||mild cognitive impairment|
11414791|NCT01937221||mild to moderate cognitive impairment|
11414792|NCT01937221||normal or control group|
11414793|NCT01937208|Experimental|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
11414794|NCT01937208|Active Comparator|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
11414795|NCT01937195|Experimental|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
11414796|NCT01937182|Active Comparator|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
11414797|NCT01937182|Placebo Comparator|Placebo|Intervention Drug: Placebo
11414798|NCT01937169|Experimental|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.
~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
11414799|NCT01937169|Placebo Comparator|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.
~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
11414800|NCT01937169|Sham Comparator|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.
~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
11414801|NCT01937156|Experimental|SP-01|
11414802|NCT01937156|Active Comparator|Granisetron Hydrochloride Tablet|
11414803|NCT01937143|Placebo Comparator|Control|General information about infant immunizations at birth of a newborn infant
11414804|NCT01937143|Active Comparator|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
11414805|NCT01937143|Active Comparator|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
11414806|NCT01937130|Experimental|IDN-6556 5 mg|Dosed twice daily
11414807|NCT01937130|Experimental|IDN-6556 25 mg|Dosed twice daily
11414808|NCT01937130|Experimental|IDN-6556 50 mg|Dosed twice daily
11414809|NCT01937130|Placebo Comparator|Placebo|Dosed twice daily
11414810|NCT01937117|Experimental|Trastuzumab and Pertuzumab|Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
11414846|NCT01936831|Experimental|Group 1: Patients with a TB strain that has an inhA mutation|"Participants who meet Step 2 entry criteria will be randomized 1:1:1 to receive the following treatments for 7 days:
~5 mg cohort: Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily
~10 mg cohort: Isoniazid 10 mg/kg daily plus vitamin B6 ≥25 mg daily
~15 mg cohort: Isoniazid 15 mg/kg daily plus vitamin B6 ≥25 mg daily"
11414811|NCT01937104|Experimental|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60
~Drug: Remifentanil Adjuvant continuous administration
~- adjust effect site concentration to maintain changes of vital sign below 20%
~Device: Ultrasonographic measurement of ONSD
~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
~Trendelenburg position - 30 degree"
11414812|NCT01937104|Experimental|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60
~Drug: Remifentanil Adjuvant continuous administration
~- adjust effect site concentration to maintain changes of vital sign below 20%
~Device: Ultrasonographic measurement of ONSD
~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
~Reverse Trendelenburg position - 30 degree"
11414813|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of > 48 weeks.
11414814|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
11414815|NCT01937078|Active Comparator|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
11414816|NCT01937065||No treatment|
11414817|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
11414818|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
11414819|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
11414820|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
11414821|NCT01937026|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
11414822|NCT01937026|Experimental|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
11414823|NCT01937013|Experimental|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
11414824|NCT01937013|Placebo Comparator|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
11414825|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:
~Carboplatin* on day 1
~*If a patient is allergic to carboplatin, then give
~Cisplatin** on day 1
~**If a patient is allergic to cisplatin and carboplatin, then give
~Oxaliplatin on day 1
~Gemcitabine on day 1 only
~Bevacizumab on day 1"
11414826|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8
~Bevacizumab on day 1"
11414827|NCT01936961|Experimental|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
11414828|NCT01936948|Active Comparator|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
11414829|NCT01936948|Active Comparator|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
11414830|NCT01936948|No Intervention|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
11414831|NCT01936948|No Intervention|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
11414832|NCT01936935|Experimental|Low-fat dairy|3 servings/d of low-fat dairy
11414833|NCT01936935|Placebo Comparator|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
11414834|NCT01936922|Experimental|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
11414835|NCT01936909|Experimental|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
11414836|NCT01936909|Experimental|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
11414837|NCT01936909|Placebo Comparator|Placebo|Placebo injections daily for 12 weeks
11414838|NCT01936896|Experimental|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
11414839|NCT01936883|Active Comparator|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
11414840|NCT01936883|Active Comparator|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
11414841|NCT01936870||Fesoterodine (Toviaz)|
11414842|NCT01936857|Experimental|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
11414843|NCT01936857|Active Comparator|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
11414844|NCT01936844|Experimental|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
11414845|NCT01936844|Placebo Comparator|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
11414847|NCT01936831|Experimental|Group 2: Patients with TB without inhA nor katG mutations|Participants who meet Step 2 entry criteria will receive Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily for 7 days
11414848|NCT01936831|No Intervention|Group 3: Patients with an MTB isolate with a katG mutation|Participants with an M. tuberculosis isolate with a katG mutation will not receive study drug.
11414849|NCT01936805|Active Comparator|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
11414850|NCT01936805|Placebo Comparator|Control|A loading dose of placebo was administrated 24 h before the PCI.
11414851|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
11414852|NCT01936792||Controls|Controls with no premorbid health conditions
11414853|NCT01936779|Active Comparator|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
11414854|NCT01936779|Placebo Comparator|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
11414855|NCT01936753|Experimental|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
11414856|NCT01936753|No Intervention|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
11414857|NCT01936740|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
11414858|NCT01936740|Other|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
11414859|NCT01936727|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
11414860|NCT01936727|Other|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
11414861|NCT01936714|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
11414862|NCT01936714|Other|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
11414863|NCT01936701|Other|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
11414864|NCT01936701|Other|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
11414865|NCT01936688|Experimental|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
11414866|NCT01936688|Experimental|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
11414867|NCT01936688|Placebo Comparator|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
11414868|NCT01936688|Active Comparator|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
11414869|NCT01936675|No Intervention|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
11414870|NCT01936675|Active Comparator|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
11414871|NCT01936662|Experimental|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
11414872|NCT01936662|Active Comparator|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
11414873|NCT01936649|Experimental|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
11414944|NCT01936181|Active Comparator|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
11414945|NCT01936181|Experimental|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
11414946|NCT01936181|Active Comparator|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
11414947|NCT01936168|Active Comparator|RFA|Radiofrequency Ablation (RFA)
11414874|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.
~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
11414875|NCT01936623|Experimental|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
11414876|NCT01936623|Other|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
11414877|NCT01936610|Experimental|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
11414878|NCT01936610|Experimental|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
11414879|NCT01936597|Active Comparator|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
11414880|NCT01936597|Experimental|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
11414881|NCT01936597|Experimental|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
11414882|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
11414883|NCT01936584||TEP repair|TEP repair for inguinal hernia
11414884|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
11414885|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
11414886|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
11414887|NCT01936545|Experimental|propofol|The anesthesia was maintained with propofol during liver transplantation.
11414888|NCT01936545|Active Comparator|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
11414889|NCT01936532|Experimental|assessment of treatment lenalidomide, dexamethasone,MLN9708|
11414890|NCT01936519|Active Comparator|Arm B|Calcineurin inhibitor immunosuppression with mycophenolic acid
11414891|NCT01936519|Experimental|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
11414892|NCT01936506|Experimental|Cognitive Training A|emotional memory training exercise
11414893|NCT01936506|Active Comparator|Cognitive Training B|memory training exercise
11414894|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
11414895|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
11414896|NCT01936480|Placebo Comparator|Placebo Group|Healthy volunteers with QT genotype score in the highest or lowest quintile
11414897|NCT01936467|Experimental|Standard suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the standard suction FNA technique: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
11414898|NCT01936467|Experimental|Capillary suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the capillary suction FNA technique: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
11414899|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
11414900|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
11414901|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
11414902|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
11414903|NCT01936441|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.
~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
11414948|NCT01936168|Experimental|MOCA|Mechanochemical Endovenous Ablation (MOCA)
11415024|NCT01935635|Experimental|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
11414904|NCT01936441|Placebo Comparator|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
11414905|NCT01936428|Other|interview|
11414906|NCT01936415|Experimental|Regenerex|One of the two prosthesis investegated
11414907|NCT01936415|Active Comparator|Vanguard|
11414908|NCT01936402|Experimental|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.
~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
11414909|NCT01936402|Experimental|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.
~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
11414910|NCT01936389|Experimental|0.5%|0.5% Rho-Kinase Inhibitor
11414911|NCT01936389|Experimental|0.7%|0.7% Rho-Kinase Inhibitor
11414912|NCT01936376||head & neck cancer patients, cisplatin treatment|
11414913|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
11414914|NCT01936363|Experimental|Pimasertib (once daily) plus SAR245409|
11414915|NCT01936363|Experimental|Pimasertib (twice daily) plus SAR245409 placebo|
11414916|NCT01936350|Experimental|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
11414917|NCT01936350|Placebo Comparator|Placebo|12 patients will be in this group, they will take placebo
11414918|NCT01936337|Active Comparator|DLX105 Hydrogel|
11414919|NCT01936337|Placebo Comparator|Placebo Hydrogel|
11414920|NCT01936324|Experimental|Phase 1|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
11414921|NCT01936324|Experimental|Phase 2a|Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
11414922|NCT01936311|No Intervention|Control Group|This group will receive usual care.
11414923|NCT01936311|Experimental|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
11414924|NCT01936298|Experimental|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
11414925|NCT01936298|Experimental|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
11414926|NCT01936285|Placebo Comparator|Control group|Patients taking placebo
11414927|NCT01936285|Experimental|Colchicine|Active treatment group
11414928|NCT01936272|Active Comparator|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
11414929|NCT01936272|Active Comparator|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
11414930|NCT01936259|Active Comparator|Comprehensive Mini Humeral Stem|"The Comprehensive® Shoulder System with mini stem component, which will be the control device for this clinical investigation and was 510(k) cleared under K060692 on May 30, 2006.
~The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments."
11414931|NCT01936259|Experimental|Comprehensive Nano Humeral Component|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
11414932|NCT01936246|Experimental|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
11414933|NCT01936246|No Intervention|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
11414934|NCT01936233|Experimental|Aspirin AND Lamivudine|
11414935|NCT01936233|Active Comparator|Lamivudine|
11414936|NCT01936220|Experimental|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
11414937|NCT01936220|Experimental|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
11414938|NCT01936220|Active Comparator|Treatment as usual|Discontinuity of care, relapse prevention as usual
11414939|NCT01936207||One Group|
11414940|NCT01936194|Experimental|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
11414941|NCT01936194|Other|High Olive Oil|infants receiving capsule without DHA and EPA.
11414942|NCT01936194|Experimental|DHA+EPA|infants receiving capsule containing DHA and EPA.
11414943|NCT01936181|Experimental|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
11414949|NCT01936155|Experimental|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
11414950|NCT01936142|No Intervention|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
11414951|NCT01936142|Experimental|RenalGuard|Use of the RenalGuard system during CRT implantation
11414952|NCT01936129|Active Comparator|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
11414953|NCT01936129|Placebo Comparator|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
11414954|NCT01936116|Experimental|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
11414955|NCT01936116|Active Comparator|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
11414956|NCT01936103|Active Comparator|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
11414957|NCT01936103|Experimental|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
11414958|NCT01936090|Experimental|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.
~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
11414959|NCT01936077|Experimental|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
11414960|NCT01936064|Active Comparator|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
11414961|NCT01936064|Active Comparator|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
11414962|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
11414963|NCT01936038|Placebo Comparator|Control Group|CPAP
11414964|NCT01936038|Experimental|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
11414965|NCT01936025|Active Comparator|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
11414966|NCT01936025|Experimental|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
11414967|NCT01936025|Experimental|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
11414968|NCT01936025|Experimental|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
11414969|NCT01936025|Experimental|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
11414970|NCT01936025|Experimental|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
11414971|NCT01936025|Experimental|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
11414972|NCT01936025|Placebo Comparator|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
11414973|NCT01936012|Experimental|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
11414974|NCT01936012|Active Comparator|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
11414975|NCT01935999|Other|One piece closed pouch|One piece closed pouch
11414976|NCT01935986|Experimental|probiotic|dietary supplement
11414977|NCT01935986|Placebo Comparator|placebo|dietary supplement without probiotic
11414978|NCT01935973|Active Comparator|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
11414979|NCT01935973|Experimental|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11414980|NCT01935960|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
11414981|NCT01935960|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
11414982|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11414983|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
11414984|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
11414985|NCT01935934|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11414986|NCT01935921|Experimental|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
11414987|NCT01935908|No Intervention|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
11414988|NCT01935908|Active Comparator|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
11414989|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
11414990|NCT01935882|Active Comparator|Artemether-Lumefantrine|Artemether-Lumefantrine combination
11414991|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
11414992|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
11414993|NCT01935869|Experimental|LEO 90100|
11414994|NCT01935869|Placebo Comparator|Vehicle|
11414995|NCT01935869|Other|Petrolatum ointment|
11414996|NCT01935856|Experimental|KHK7580|
11414997|NCT01935843|Experimental|Anti-tumor responses of CART-HER-2|
11414998|NCT01935830|Experimental|LAAM arm|"[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)
~Efavirenz, oral capsules, 600 mg
~Ritonavir, oral capsules, 100 mg"
11414999|NCT01935817|Active Comparator|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
11415000|NCT01935817|Placebo Comparator|sugar pill|one placebo pill per day for 12 months
11415001|NCT01935804|Experimental|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
11415002|NCT01935804|Active Comparator|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
11415003|NCT01935791|Placebo Comparator|Control|Saline
11415004|NCT01935791|Experimental|Hormone|Intravenous glucagon infusion up to 100nmol/kg/hr for up to 90 minutes.
11415005|NCT01935778|Active Comparator|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
11415006|NCT01935778|Experimental|Docetaxel and capecitabine and oxaliplatin|"Docetaxel 60 mg/m² will be intravenously infused over at least 1 hour on Day 1 every 3 weeks.
~Oxaliplatin 100 mg/m² will be intravenously infused over at least 2 hours on Day 1 every 3 weeks.
~Capecitabine 800 mg/m² will be orally administered twice daily from Day 1 evening to Day 15 morning every 3 weeks. (Total 1,600 mg/m² daily)"
11415007|NCT01935765|Experimental|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
11415008|NCT01935765|Experimental|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
11415009|NCT01935752|Other|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples & vascular echotracking
11415010|NCT01935752|Other|healthy volunteer|healthy volunteer:blood samples & vascular echotracking
11415011|NCT01935752|Other|hypertensive patients|hypertensive patients:blood samples & vascular echotracking
11415012|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
11415013|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
11415014|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
11415015|NCT01935713|Experimental|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
11415016|NCT01935713|Experimental|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
11415017|NCT01935713|Experimental|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
11415018|NCT01935700|Experimental|colchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
11415019|NCT01935687|Experimental|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
11415020|NCT01935674|Experimental|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
11415021|NCT01935674|Experimental|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
11415022|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
11415023|NCT01935635|Experimental|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
11415025|NCT01935635|Experimental|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
11415026|NCT01935635|No Intervention|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
11415027|NCT01935635|No Intervention|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
11415028|NCT01935635|No Intervention|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
11415029|NCT01935622|Experimental|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
11415030|NCT01935622|Experimental|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
11415031|NCT01935622|Placebo Comparator|Placebo|Placebo
11415032|NCT01935609|Experimental|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
11415033|NCT01935609|No Intervention|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
11415034|NCT01935596|Active Comparator|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
11415035|NCT01935596|Active Comparator|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
11415036|NCT01935583|Experimental|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
11415037|NCT01935583|No Intervention|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
11415038|NCT01935570|Experimental|Magnesium|
11415039|NCT01935557|Active Comparator|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
11415040|NCT01935557|Active Comparator|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
11415041|NCT01935544|Experimental|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
11415042|NCT01935544|Other|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
11415043|NCT01935531|Experimental|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
11415044|NCT01935518|Experimental|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
11415045|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
11415046|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
11415047|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
11415048|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
11415049|NCT01935492|Active Comparator|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
11415050|NCT01935492|Active Comparator|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
11415051|NCT01935479|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
11415052|NCT01935479|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
11415053|NCT01935479|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
11415054|NCT01935479|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
11415055|NCT01935479|Active Comparator|MN-10-T SD|Single administration of teriparatide acetate
11415056|NCT01935479|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
11415057|NCT01935479|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
11415058|NCT01935479|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
11415059|NCT01935479|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
11415060|NCT01935479|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
11415061|NCT01935479|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
11415062|NCT01935466||Pioglitazone|Ever users of Pioglitazone
11415063|NCT01935466||Other drugs|Never users of pioglitazone
11415064|NCT01935453|Experimental|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
11415065|NCT01935440|Active Comparator|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
11415066|NCT01935440|Experimental|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
11415067|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
11415068|NCT01935414|Experimental|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
11415069|NCT01935414|Active Comparator|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
11415070|NCT01935401||Women with Bulimia Nervosa|"fNIR
~- Functional near-infrared spectroscopy measured-brain activity"
11415071|NCT01935401||Healthy Controls|"fNIR
~- Functional near-infrared spectroscopy measured-brain activity"
11415072|NCT01935388|Experimental|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
11415073|NCT01935388|No Intervention|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
11415074|NCT01935375|Experimental|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
11415075|NCT01935375|Active Comparator|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
11415076|NCT01935362|Placebo Comparator|placebo|Placebo administered to participant
11415077|NCT01935362|Active Comparator|Citrus supplement|Citrus supplement administered to participant
11415078|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
11415079|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11415080|NCT01935323|Experimental|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
11415081|NCT01935323|Active Comparator|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
11415082|NCT01935310|Experimental|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
11415083|NCT01935297|Active Comparator|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
11415084|NCT01935297|No Intervention|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
11415085|NCT01935284||Healthy Volunteers|
11415086|NCT01935271|Experimental|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
11415087|NCT01935271|Placebo Comparator|Placebo|Sugar-based placebo drink mix
11415088|NCT01935258|Experimental|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
11415089|NCT01935258|Other|care as usual|Usual care of the general practitioner
11415090|NCT01935245|Experimental|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
11415091|NCT01935245|Active Comparator|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
11415092|NCT01935232||Men|140 Men
11415093|NCT01935232||Female|500 Female
11415094|NCT01935219|Experimental|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
11415095|NCT01935219|Active Comparator|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
11415096|NCT01935219|Placebo Comparator|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
11415097|NCT01935206|Placebo Comparator|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
11415098|NCT01935206|Experimental|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
11415099|NCT01935193|Experimental|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
11415100|NCT01935180|No Intervention|Standard colonoscopy|
11415101|NCT01935180|Active Comparator|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
11415102|NCT01935167|Experimental|A Group|DW1029M 600mg for 24 weeks
11415103|NCT01935167|Experimental|B Group|DW1029M 1200mg for 24 weeks
11415104|NCT01935167|Placebo Comparator|C Group|Placebo for 24 weeks
11415105|NCT01935154|Placebo Comparator|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
11415106|NCT01935154|Experimental|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
11415107|NCT01935141|Experimental|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
11415108|NCT01935141|Active Comparator|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
11415109|NCT01935128|Experimental|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
11415110|NCT01935115|Active Comparator|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
11415111|NCT01935115|Experimental|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
11415112|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
11415113|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
11415114|NCT01935089|Experimental|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
11415115|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
11415116|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
11415117|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
11415118|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
11415119|NCT01935063|Experimental|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
11415120|NCT01935063|Active Comparator|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, & Steege, 2003).
11415121|NCT01935050|Experimental|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
11415122|NCT01935024|No Intervention|Normal Activity level|
11415123|NCT01935024|Active Comparator|Personalized Exercise Regimen|
11415124|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
11415125|NCT01934998||SCA6 and control|SCA6 and control
11415126|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
11415127|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
11415128|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
11415129|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
11415130|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
11415131|NCT01934972|Experimental|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
11415132|NCT01934972|Active Comparator|CR + placebo|Cognitive Remediation and placebo
11415133|NCT01934959|Experimental|Probiotics|
11415134|NCT01934946|Experimental|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
11415135|NCT01934946|Placebo Comparator|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
11415136|NCT01934933|Active Comparator|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
11415137|NCT01934933|Active Comparator|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
11415138|NCT01934933|Active Comparator|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
11415139|NCT01934907|Experimental|washed RBC|Packed RBCs are Washed and then, transfused.
11415140|NCT01934907|No Intervention|pack RBC|Packed RBCs are transfused.
11416714|NCT01924533|Placebo Comparator|Placebo+paclitaxel|placebo+ paclitaxel
11415141|NCT01934894|Experimental|cabazitaxel and lapatinib combination|"Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)
~Lapatinib PO once daily (dose to be determined)
~Treatment cycles will be repeated every 3 weeks."
11415142|NCT01934881|Experimental|group I|Voltage adjustment only
11415143|NCT01934881|Experimental|group II|Combined parameters adjustment
11415144|NCT01934868|Experimental|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.
~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
11415145|NCT01934868|Active Comparator|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
11415146|NCT01934842|Experimental|TAP20-C|TAP20-C
11415147|NCT01934842|Active Comparator|SAFE-T-FILL|SAFE-T-FILL
11415148|NCT01934829|Experimental|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
11415149|NCT01934829|Placebo Comparator|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
11415150|NCT01934816|Experimental|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
11415151|NCT01934816|Placebo Comparator|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
11415152|NCT01934816|Active Comparator|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
11415153|NCT01934803|Active Comparator|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
11415154|NCT01934803|Placebo Comparator|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
11415155|NCT01934790|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
11415156|NCT01934777|Experimental|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
11415157|NCT01934777|Placebo Comparator|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
11415158|NCT01934764||autoimmune disease|
11415159|NCT01934751|Other|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
11415160|NCT01934751|Other|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
11415161|NCT01934738|Experimental|Group 1: Cohort 1|
11415162|NCT01934738|Experimental|Group 1: Cohort 2|
11415163|NCT01934738|Experimental|Group 1: Cohort 3|
11415164|NCT01934738|Experimental|Group 2: Cohort 4|
11415165|NCT01934738|Experimental|Group 1: Cohort 5|
11415166|NCT01934738|Experimental|Group 2: Cohort 6|
11415167|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
11415168|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
11415169|NCT01934712|Experimental|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
11415170|NCT01934712|Active Comparator|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
11415171|NCT01934699|Active Comparator|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
11415172|NCT01934699|Experimental|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
11415173|NCT01934686||Subjects with diabetes mellitus (type 2)|
11415174|NCT01934673||Subjects with diabetes (type 2)|
11415175|NCT01934660||Group 1|Healthy Volunteers
11415176|NCT01934660||Group 2|Subjects diagnosed with diabetes
11415177|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
11415178|NCT01934647|Experimental|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
11415179|NCT01934647|Experimental|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
11415180|NCT01934647|Experimental|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
11415181|NCT01934634|Experimental|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
11415182|NCT01934621|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
11415183|NCT01934621|Placebo Comparator|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
11415184|NCT01934608|Experimental|Refill synch|Participants in this group will have their medication refill schedule synchronized.
11415185|NCT01934608|No Intervention|Control|Participants in this arm will receive usual care
11415186|NCT01934595|Experimental|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
11415187|NCT01934595|Active Comparator|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
11415188|NCT01934582|Experimental|Open label extension|
11415189|NCT01934569|Experimental|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
11415190|NCT01934556|Active Comparator|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
11415191|NCT01934556|Active Comparator|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
11415192|NCT01934556|Active Comparator|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
11415193|NCT01934543|Experimental|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
11415194|NCT01934543|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
11415195|NCT01934530|Active Comparator|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
11415196|NCT01934530|Experimental|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
11415197|NCT01934504||Tolerant AAV|Tolerant participants with AAV
11415198|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
11415199|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
11415200|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
11415201|NCT01934491|Experimental|Cognitive Training A|emotional memory training exercise
11415202|NCT01934491|Active Comparator|Cognitive Training B|memory training exercise
11415203|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
11415204|NCT01934452||Complete Remission|Complete remission arm in mRCC patients treated with sunitinib.
11415205|NCT01934452||Non Complete Remission|Non complete remission arm in mRCC patients treated with sunitinib.
11415206|NCT01934439|Experimental|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
11415207|NCT01934426||Admission High Risk|Admission High Risk
11415491|NCT01932567|Experimental|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
11415208|NCT01934413|Active Comparator|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
11415209|NCT01934413|Other|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
11415210|NCT01934374|Experimental|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
11415211|NCT01934374|No Intervention|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
11415212|NCT01934361|Experimental|Lomustine+ buparlisib (Phase Ib)|
11415213|NCT01934361|Experimental|carboplatin+ buparlisib (Phase Ib)|
11415214|NCT01934361|Experimental|lomustine+ buparlisib (Phase II)|
11415215|NCT01934361|Placebo Comparator|lumustine + placebo (Phase II)|
11415216|NCT01934361|Experimental|carboplatin+ buparlisib (Phase II)|
11415217|NCT01934348|Experimental|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
11415218|NCT01934348|Active Comparator|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
11415219|NCT01934335|Experimental|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
11415220|NCT01934335|Placebo Comparator|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
11415221|NCT01934322|Experimental|Case Management|"Furnish specific assistance and to provide referrals for the patients:
~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.
~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.
~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.
~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
11415222|NCT01934322|No Intervention|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
11415223|NCT01934309|Experimental|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
11415224|NCT01934309|No Intervention|No TB reminders|Only receive existing reminders; no TB reminders
11415225|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
11415226|NCT01934283|No Intervention|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
11415227|NCT01934270|Experimental|Anaerobic Test|
11415228|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
11415229|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
11415230|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
11415231|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
11415232|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
11415233|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
11415234|NCT01934231|Experimental|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
11415235|NCT01934218|Active Comparator|Gel-One|3 mL, a single intra-articular injection of Gel-One
11415236|NCT01934218|Placebo Comparator|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
11415237|NCT01934205|Experimental|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
11415238|NCT01934205|Experimental|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
11415239|NCT01934205|Experimental|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
11415240|NCT01934205|Experimental|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
11415315|NCT01933776|Experimental|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
11415595|NCT01931813||Infants likely to present febrile convulsions|
11415241|NCT01934205|Experimental|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415242|NCT01934205|Experimental|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415243|NCT01934205|Experimental|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415244|NCT01934205|Experimental|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415245|NCT01934205|Experimental|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415246|NCT01934205|Experimental|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415247|NCT01934205|Experimental|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415248|NCT01934205|Experimental|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
11415249|NCT01934192|Experimental|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
11415250|NCT01934192|Placebo Comparator|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
11415251|NCT01934192|Experimental|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
11415252|NCT01934192|Active Comparator|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
11415253|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
11415254|NCT01934166|Experimental|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
11415255|NCT01934153|Experimental|Cohort A|Single dose of topical [14C]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
11415256|NCT01934153|Experimental|Cohort B|Single dose of topical [14C]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
11415257|NCT01934153|Experimental|Cohort C|Single dose of topical [14C]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
11415258|NCT01934153|Experimental|Cohort D|Single dose of topical [14C]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
11415259|NCT01934140|Experimental|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
11415260|NCT01934140|Active Comparator|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
11415261|NCT01934127|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
11415262|NCT01934127|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
11415263|NCT01934127|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
11415264|NCT01934127|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
11415265|NCT01934127|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
11415266|NCT01934127|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
11415267|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
11415268|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
11415269|NCT01934101|Experimental|CHR-5154|CHR-5154
11415270|NCT01934101|Placebo Comparator|Placebo|Placebo
11415271|NCT01934088|Experimental|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
11415272|NCT01934088|Active Comparator|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
11415316|NCT01933776|Experimental|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
11415596|NCT01931800||Presenting patients a pneumonia pneumococcique|
11415273|NCT01934075|Experimental|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
11415274|NCT01934075|No Intervention|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
11415275|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
11415276|NCT01934049|Active Comparator|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
11415277|NCT01934049|Placebo Comparator|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
11415278|NCT01934036|Experimental|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
11415279|NCT01934036|Placebo Comparator|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
11415280|NCT01934023|Active Comparator|Varenicline|FDA approved smoking cessation medication
11415281|NCT01934023|Placebo Comparator|Placebo Sugar Pill|sugar pill
11415282|NCT01934010|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
11415283|NCT01933997|Experimental|MG01CI 1400 mg|
11415284|NCT01933984|Experimental|Individualized dosing|"Ventilator support
~Determining personal target airway resistance
~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
~Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
11415285|NCT01933984|Active Comparator|Fixed dosing|"Ventilator support
~Determining personal target airway resistance
~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
~No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
11415286|NCT01933971|Other|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.
~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.
~The sites, where the injections are to be performed, are planned as follows:
~st injection: upper part of the upper arm, posterior surface
~nd injection: upper part of the thigh
~rd injection: abdomen with the exception of the umbilical area
~th injection: upper part of the contra-lateral upper arm, posterior surface
~th injection: upper part of the contra-lateral thigh
~th injection: abdomen with the exception of the umbilical area
~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
11415287|NCT01933971|Other|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.
~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.
~The sites, where the injections are to be performed, are planned as follows:
~st injection: upper part of the upper arm, posterior surface
~nd injection: upper part of the thigh
~rd injection: abdomen with the exception of the umbilical area
~th injection: upper part of the contra-lateral upper arm, posterior surface
~th injection: upper part of the contra-lateral thigh
~th injection: abdomen with the exception of the umbilical area
~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
11415288|NCT01933971|Other|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.
~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.
~The sites, where the injections are to be performed, are planned as follows:
~st injection: upper part of the upper arm, posterior surface
~nd injection: upper part of the thigh
~rd injection: abdomen with the exception of the umbilical area
~th injection: upper part of the contra-lateral upper arm, posterior surface
~th injection: upper part of the contra-lateral thigh."
11415289|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
11415290|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
11415291|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
11415292|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
11415293|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
11415317|NCT01933763|Experimental|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
11415597|NCT01931800||Patients presenting a bacteremia pneumococcique|
11415294|NCT01933919|Placebo Comparator|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.
~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
11415295|NCT01933919|Experimental|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.
~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
11415296|NCT01933906|Experimental|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.
~Maximum treatment duration will not expand 18 months."
11415297|NCT01933880|Experimental|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
11415298|NCT01933880|Active Comparator|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
11415299|NCT01933867|Experimental|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
11415300|NCT01933867|Active Comparator|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
11415301|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
11415302|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
11415303|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
11415304|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
11415305|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
11415306|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
11415307|NCT01933828|Active Comparator|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
11415308|NCT01933828|Active Comparator|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
11415309|NCT01933828|Other|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
11415310|NCT01933815|Experimental|TPI 287 + bevacizumab|"All subjects in phase 1 & subjects randomized to the TPI 287 + bevacizumab arm in phase 2 will be administered a 1-hour IV infusion of TPI 287 once every 3 weeks (Days 1 & 22 of 42-day cycle) & a 30-90 minute IV infusion of bevacizumab once every 2 weeks (Days 1, 15, & 29).
~In phase 1, the dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6, while the dose of bevacizumab remains constant (10 mg/kg). The first 5 dose levels will be 140, 150, 160, 170, & 180 mg/m2. Dose levels beyond 180 mg/m2 will be increased in increments of 20 mg/m2. Three subjects will be treated at a dose level halfway between the dose level that exceeds the MTD and the dose level immediately prior to further refine the MTD.
~In phase 2, the dose of TPI 287 will be the MTD determined in phase 1, & the dose of bevacizumab will be the same as phase 1 (10 mg/kg).
~Subjects may continue on treatment unless they meet one or more of the protocol discontinuation criteria."
11415311|NCT01933815|Active Comparator|Bevacizumab|"All subjects randomized to the bevacizumab alone arm in phase 2 will be administered bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of a 42-day cycle). The dose of bevacizumab will be 10 mg/kg.
~Subjects will be withdrawn from the study if they meet one or more of the discontinuation criteria outlined in the protocol; however, treatment with bevacizumab may continue under the FDA approved labeling for bevacizumab at the discretion of the subject's doctor.
~All subjects in phase 1 will be administered TPI 287 in combination with bevacizumab (i.e., there will be no bevacizumab alone arm during phase 1)."
11415312|NCT01933802|Experimental|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
11415313|NCT01933789|Experimental|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
11415314|NCT01933789|No Intervention|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
11415318|NCT01933763|Experimental|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
11415319|NCT01933750|No Intervention|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
11415320|NCT01933750|Experimental|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
11415321|NCT01933737|Experimental|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
11415322|NCT01933737|Experimental|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
11415323|NCT01933724|Experimental|5 mg prednisone|Subjects will be randomized to 5 mg per day of prednisone for a 6 month period.
11415324|NCT01933724|Experimental|0 mg prednisone|Subjects will be randomized to 0 mg per day of prednisone dose for a 6 month period.
11415325|NCT01933711|Experimental|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
11415326|NCT01933711|No Intervention|Observation|observational arm, no intervention
11415327|NCT01933698|Active Comparator|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
11415328|NCT01933698|Active Comparator|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
11415329|NCT01933685|Experimental|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
11415330|NCT01933685|Placebo Comparator|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
11415331|NCT01933672|Experimental|PF-04937319 once-daily|
11415332|NCT01933672|Experimental|PF-04937319 split-dose|
11415333|NCT01933672|Active Comparator|Sitagliptin once-daily|
11415334|NCT01933659|Experimental|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
11415335|NCT01933659|Placebo Comparator|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
11415336|NCT01933646||Cohort 1|
11415337|NCT01933633|Experimental|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
11415338|NCT01933633|No Intervention|Control|Standard care
11415339|NCT01933620||Patient|Patients who might become colonized or infected with a multi drug-resistant organism
11415340|NCT01933607|Other|TOPS System|Post Marketing Study
11415341|NCT01933594|Experimental|Cohort 1-Arm 1A (Romidepsin)|Participants in Cohort 1, Arm 1A received Romidepsin intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415342|NCT01933594|Placebo Comparator|Cohort 1-Arm 1B (Placebo for Romidepsin)|Participants in Cohort 1, Arm 1B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415343|NCT01933594|Experimental|Cohort 2-Arm 2A (Romidepsin)|Participants in Cohort 2, Arm 2A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415344|NCT01933594|Placebo Comparator|Cohort 2-Arm 2B (Placebo for Romidepsin)|Participants in Cohort 2, Arm 2B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415345|NCT01933594|Experimental|Cohort 3-Arm 3A (Romidepsin)|Participants in Cohort 3, Arm 3A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415346|NCT01933594|Placebo Comparator|Cohort 3-Arm 3B (Placebo for Romidepsin)|Participants in Cohort 3, Arm 3B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415347|NCT01933594|Experimental|Cohort 4-Arm 4A (Romidepsin)|Participants in Cohort 4, Arm 4A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415348|NCT01933594|Placebo Comparator|Cohort 4-Arm 4B (Placebo for Romidepsin)|Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
11415349|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
11415350|NCT01933568|Experimental|Radiation|combined CFRT and SABR with concurrent cisplatin
11415351|NCT01933555|Experimental|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
11415352|NCT01933555|No Intervention|Control group|Standard care, which was routine check ups and care provided by health care professionals.
11415353|NCT01933542|Active Comparator|Chlorzoxazone|"Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
11415598|NCT01931800||Patients affected by pneumococcique meningitis|
11416715|NCT01924520|Experimental|Group 1 (FK949E lower dose)|Oral
11415354|NCT01933542|Placebo Comparator|Placebo|"Oral administration of two placebo tablets
~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
11415355|NCT01933529|Experimental|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
11415356|NCT01933529|Placebo Comparator|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
11415357|NCT01933516|Experimental|GP2013|
11415358|NCT01933503|Experimental|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
11415359|NCT01933503|Experimental|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
11415360|NCT01933503|Experimental|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
11415361|NCT01933490|Other|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
11415362|NCT01933490|Active Comparator|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
11415363|NCT01933490|Active Comparator|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
11415364|NCT01933477|No Intervention|Local Standard of Care|Arm A: Referral of post-partum women from the antenatal clinic to general adult ART services at approximately 4-8 weeks postpartum (the local current standard of care in this setting)
11415365|NCT01933477|Active Comparator|MCH-focused ART services|Arm B: Continued receipt of MCH-focused ART services based at the antenatal clinic throughout the period of breastfeeding. Post-partum women will only be referred to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined.
11415366|NCT01933464|Experimental|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
11415367|NCT01933464|Placebo Comparator|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
11415368|NCT01933451|Experimental|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
11415369|NCT01933451|Other|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
11415370|NCT01933438|Experimental|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
11415371|NCT01933438|Active Comparator|Control|Standard treatment
11415372|NCT01933425|Active Comparator|Deep neuromuscular block followed by no neuromuscular block|"Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.
~Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade"
11415373|NCT01933425|Placebo Comparator|No neuromuscular block followed by deep neuromuscular block|"No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.
~Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade."
11415374|NCT01933412|Experimental|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
11415375|NCT01933412|Active Comparator|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
11415376|NCT01933399|Other|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
11415377|NCT01933399|Experimental|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
11415378|NCT01933399|Experimental|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
11415379|NCT01933386|Other|SoundBite|SoundBite will be used for the first 30 days
11415380|NCT01933386|Other|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
11415381|NCT01933373|Active Comparator|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
11415382|NCT01933373|Experimental|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
11415383|NCT01933360|Active Comparator|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
11415384|NCT01933360|Active Comparator|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
11415385|NCT01933360|Active Comparator|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
11415386|NCT01933360|Active Comparator|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
11415387|NCT01933347|Experimental|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
11415388|NCT01933334|Experimental|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day [mg/day]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
11415389|NCT01933334|Experimental|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
11415390|NCT01933321|Experimental|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
11415419|NCT01933100|Experimental|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
11415391|NCT01933308|Experimental|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
11415392|NCT01933308|Experimental|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
11415393|NCT01933308|Experimental|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. [33] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
11415394|NCT01933295|Active Comparator|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
11415395|NCT01933295|Experimental|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
11415396|NCT01933295|Experimental|Sleep Restriction Therapy|Brief sleep restriction therapy.
11415397|NCT01933282|Experimental|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
11415398|NCT01933269|Experimental|FACBC|
11415399|NCT01933256|Experimental|600mg HIP2B|600mg HIP2B
11415400|NCT01933256|Placebo Comparator|Placebo|Placebo
11415401|NCT01933256|Experimental|400mg HIP2B|400mg HIP2B
11415402|NCT01933243|Experimental|Fish oil|Fish oil for 12 weeks
11415403|NCT01933243|Placebo Comparator|Placebo pill|Placebo pills for 12 weeks
11415404|NCT01933230|Other|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
11415405|NCT01933217|Experimental|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
11415406|NCT01933217|Placebo Comparator|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
11415407|NCT01933204|Experimental|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
11415408|NCT01933204|Active Comparator|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
11415409|NCT01933191|Experimental|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
11415410|NCT01933191|Placebo Comparator|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
11415411|NCT01933178|Other|Cirrus AS-OCT|
11415412|NCT01933165|Other|LipiView|
11415413|NCT01933152||Group 1|
11415414|NCT01933139|Experimental|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
11415415|NCT01933139|No Intervention|Control|standard physician interaction (control arm)
11415416|NCT01933126|Experimental|HCG administration|Intrauterine HCG injection
11415417|NCT01933126|Placebo Comparator|Placebo|G2 Medium
11415418|NCT01933113|Experimental|DBS of the Lateral Hypothalamic Area|"Single Arm: Deep Brain Stimulation of LHA for maximum RMR On days 1-4, subjects stayed in the inpatient unit to have metabolic weight, temperature, and resting metabolic rate (RMR) measured at different settings.
~Metabolic testing RMR measurement: A clear plastic hood was placed over the head and chest Oxygen intake and carbon dioxide out-put were measured to determine how many calories were burned during the next 15-30 minutes. Each hour for the next seven hours, DBS settings were changed and the above process was repeated. On Day 4, a DXA scan was performed to assess body composition. Primary endpoint is the determination of optimal settings"
11415420|NCT01933100|Experimental|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
11415421|NCT01933100|Experimental|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
11415422|NCT01933087|No Intervention|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
11415423|NCT01933087|Experimental|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
11415424|NCT01933061|Experimental|Abraxane 150 mg/m² Intravenous (IV)|
11415425|NCT01933061|Experimental|CC-486 orally plus Abraxane IV|
11415426|NCT01933048|Other|Healthcare Worker Administration|FluMist administered by a Healthcare Worker
11415427|NCT01933048|Experimental|Self-Administration|FluMist self-administered by subject
11415428|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
11415429|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population.
11415430|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
11415431|NCT01933022|Other|Single Arm: Eligard|Single Arm
11415432|NCT01932996|Active Comparator|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
11415433|NCT01932996|Placebo Comparator|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
11415434|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
11415435|NCT01932970|Experimental|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
11415436|NCT01932957|Other|Laparotomy arm|Standard treatment
11415437|NCT01932957|Experimental|Laparoscopy arm|Treatment by laparoscopy
11415438|NCT01932944||No treatment|
11415439|NCT01932931|Active Comparator|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
11415440|NCT01932931|Placebo Comparator|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
11415441|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
11415442|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
11415443|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
11415444|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
11415445|NCT01932905|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
11415446|NCT01932905|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
11415447|NCT01932905|Active Comparator|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
11415448|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
11415449|NCT01932879|Experimental|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
11415450|NCT01932879|Other|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
11415451|NCT01932866|Active Comparator|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
11415452|NCT01932866|Experimental|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
11415453|NCT01932853||Hemodialysis patients|Patients > 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
11415454|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
11415455|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
11415456|NCT01932814||Aminoglycosides|have received aminoglycosides
11415457|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
11415458|NCT01932801|No Intervention|Assessment-only|Assessment-only control condition
11415459|NCT01932801|Active Comparator|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
11415490|NCT01932567|Experimental|Incentive spirometry|Use of incentive spirometry during 3 minutes
11415460|NCT01932801|Experimental|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
11415461|NCT01932801|Placebo Comparator|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
11415462|NCT01932788|Active Comparator|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
11415463|NCT01932788|Placebo Comparator|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
11415464|NCT01932775|Experimental|GlucoTab System|
11415465|NCT01932762|Experimental|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
11415466|NCT01932762|Experimental|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
11415467|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
11415468|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
11415469|NCT01932749|Active Comparator|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:
~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
11415470|NCT01932749|Active Comparator|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:
~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
11415471|NCT01932736|Experimental|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
11415472|NCT01932723|Experimental|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
11415473|NCT01932710|Experimental|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
11415474|NCT01932697|Experimental|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
11415475|NCT01932684|Experimental|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
11415476|NCT01932684|No Intervention|Control Group|
11415477|NCT01932684|Experimental|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
11415478|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
11415479|NCT01932658|Experimental|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
11415480|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
11415481|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
11415482|NCT01932632|No Intervention|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
11415483|NCT01932632|Experimental|Medication Minimization|"Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)
~Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
11415484|NCT01932606|Experimental|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
11415485|NCT01932606|Placebo Comparator|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
11415486|NCT01932593|Experimental|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
11415487|NCT01932593|Placebo Comparator|Placebo|
11415488|NCT01932580|Other|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.
~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
11415489|NCT01932567|Experimental|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
11415492|NCT01932554|Experimental|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.
~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
11415493|NCT01932554|Placebo Comparator|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.
~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
11415494|NCT01932541|Experimental|Latuda (Lurasidone)|
11415495|NCT01932528|Experimental|500 mg LX606|All subjects will receive a single oral 500 mg dose of [14C]-LX1606.
11415496|NCT01932515|No Intervention|Screening|
11415497|NCT01932502|Experimental|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
11415498|NCT01932489|Other|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
11415499|NCT01932476|Experimental|Celiac Disease Alone Gluten Challenge|
11415500|NCT01932476|Sham Comparator|Celiac Disease Alone Sham Challenge|
11415501|NCT01932476|Experimental|Celiac Disease and T1D Gluten Challenge|
11415502|NCT01932476|Sham Comparator|Celiac Disease and T1D Sham Challenge|
11415503|NCT01932463|Experimental|ExAb;ate MRgFUS|
11415504|NCT01932450|Experimental|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
11415505|NCT01932450|Active Comparator|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
11415506|NCT01932437|Experimental|Cohort 1|"3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.
~1 subject will receive an IM dose of ETI-204-placebo in an identical fashion."
11415507|NCT01932437|Experimental|Cohort 2|"6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
11415508|NCT01932437|Experimental|Cohort 3|"6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
11415509|NCT01932437|Experimental|Cohort 4|"6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
11415510|NCT01932437|Experimental|Cohort 5|"6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.
~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
11415511|NCT01932424|Experimental|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
11415512|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
11415513|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
11415514|NCT01932385|Experimental|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
11415515|NCT01932385|Active Comparator|Best Supportive Care|treatment mainly on nutrition and symptoms control
11415516|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
11415517|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
11415518|NCT01932359|Active Comparator|rapidly absorbable suture (Vicryl Rapide)|
11415519|NCT01932359|Active Comparator|non-absorbable suture (Ethilon)|
11415520|NCT01932333|Experimental|Cohort 1|
11415521|NCT01932333|Experimental|Cohort 2|
11415522|NCT01932320|Experimental|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
11415523|NCT01932320|Experimental|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
11415524|NCT01932320|Experimental|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
11415525|NCT01932307|Experimental|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
11415526|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
11415527|NCT01932281|Experimental|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
11415528|NCT01932281|Placebo Comparator|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
11415529|NCT01932268|Experimental|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
11415530|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
11415531|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
11415532|NCT01932242|Experimental|Sequence A|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 14 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 120.
11415533|NCT01932242|Experimental|Sequence B|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 120 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 14.
11415534|NCT01932229|Experimental|Afatinib treatment|
11415535|NCT01932216|Active Comparator|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
11415536|NCT01932216|Active Comparator|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
11415537|NCT01932203|Active Comparator|aspirin|aspirin 100mg by mouth once a day for 104 weeks
11415538|NCT01932203|Experimental|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
11415539|NCT01932190|Experimental|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
11415540|NCT01932190|Experimental|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
11415541|NCT01932177|Active Comparator|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
11415542|NCT01932177|Active Comparator|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
11415543|NCT01932177|Experimental|Schedule C|Everolimus and sorafenib in alternance
11415544|NCT01932177|Experimental|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
11415545|NCT01932164|Experimental|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
11415546|NCT01932151|Other|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
11415547|NCT01932138|Experimental|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
11415548|NCT01932138|Other|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
11415549|NCT01932125|Experimental|Cohort|
11415550|NCT01932112|Other|adenosine arm|single arm study
11415551|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
11415552|NCT01932086|Experimental|White rice|
11415553|NCT01932086|Experimental|Brown rice|
11415554|NCT01932086|Experimental|Black rice|
11415555|NCT01932086|Active Comparator|Bread|
11415556|NCT01932086|Active Comparator|Glucose solution|
11415557|NCT01932073|No Intervention|Control Group|Receives institutional skin care protocol
11415558|NCT01932073|Experimental|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
11415559|NCT01932060|Experimental|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
11415560|NCT01932060|Active Comparator|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
11415561|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
11415562|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
11415563|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
11415564|NCT01932021|Experimental|adipose tissue grafting|
11415565|NCT01931995|Active Comparator|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
11415566|NCT01931995|Active Comparator|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
11415567|NCT01931982|Active Comparator|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
11415568|NCT01931982|No Intervention|No treatment|
11415569|NCT01931969||IJVC intervention|
11415709|NCT01931020|Active Comparator|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
11415570|NCT01931956|Experimental|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
11415571|NCT01931956|Experimental|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
11415572|NCT01931956|Experimental|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
11415573|NCT01931956|Experimental|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
11415574|NCT01931943|Experimental|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
11415575|NCT01931930|Experimental|Perilla extract|Experimental arm: Perilla extract
11415576|NCT01931930|Placebo Comparator|Maltodextrin|Placebo arm: Maltodextrin
11415577|NCT01931917|Experimental|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
11415578|NCT01931917|Active Comparator|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
11415579|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
11415580|NCT01931891||prreclampsia|
11415581|NCT01931878|Placebo Comparator|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
11415582|NCT01931878|Active Comparator|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
11415583|NCT01931865|Experimental|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
11415584|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
11415585|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
11415586|NCT01931839|Experimental|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
11415587|NCT01931839|Experimental|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
11415588|NCT01931839|Experimental|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
11415589|NCT01931839|Experimental|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
11415590|NCT01931839|No Intervention|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
11415591|NCT01931839|Experimental|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
11415592|NCT01931839|Experimental|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
11415593|NCT01931826|Active Comparator|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
11415594|NCT01931826|Active Comparator|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
11415599|NCT01931787|Experimental|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11415600|NCT01931774||Acne Patients|
11415601|NCT01931774||Control Subjects|From General Population
11415602|NCT01931761|Experimental|[C14] selumetinib 75mg single dose|[C14] selumetinib 75mg single dose
11415603|NCT01931748|Experimental|UNCNT|6 times/ 12 days
11415604|NCT01931748|Active Comparator|MELSMON|6 times/ 12 days
11415605|NCT01931735|Experimental|Randomized Meniscectomy|This group will have a partial meniscectomy
11415606|NCT01931735|Active Comparator|Randomized Lavage|This group will have arthroscopy and lavage
11415607|NCT01931735|Other|Standard of Care Meniscectomy Pre-Amend|Pre-Amendment: surgeons determined standard of care option, meniscectomy, best benefited the patient. Therefore, the patient was not randomized.
11415608|NCT01931735|Other|Standard of Care Meniscectomy Post-Amend|Post Amendment: patients received a meniscectomy as a standard of care and were observed for 24-months post-operative.
11415609|NCT01931722|Active Comparator|Branched chain amino acid|Branched chain amino acid as food supplement
11415610|NCT01931722|Active Comparator|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
11415611|NCT01931709|Experimental|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
11415612|NCT01931696|Experimental|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
11415613|NCT01931696|Sham Comparator|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
11415614|NCT01931683|Experimental|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
11415615|NCT01931670|Placebo Comparator|Placebo|Placebo twice daily (BID) for the 6-month Treatment Period
11415616|NCT01931670|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
11415617|NCT01931670|Experimental|Elagolix 200 mg BID|Elagolix 200 mg BID for the 6-month Treatment Period
11415618|NCT01931657|Experimental|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
11415619|NCT01931657|Placebo Comparator|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
11415620|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
11415621|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
11415622|NCT01931631|Experimental|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
11415623|NCT01931631|Active Comparator|ADA diet|American Diabetes Association diet
11415624|NCT01931618|Active Comparator|Usual care|"Receives two interventions:
~Online screening and feedback.
~Online booklet."
11415625|NCT01931618|Experimental|Extended follow-up|"Receives two interventions:
~Online screening and feedback.
~Online multi session follow-up."
11415626|NCT01931605|Experimental|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
11415627|NCT01931592|Active Comparator|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
11415628|NCT01931592|Placebo Comparator|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
11415629|NCT01931579|Experimental|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
11415630|NCT01931566|Placebo Comparator|Low Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.
11415631|NCT01931566|Placebo Comparator|High Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
11415632|NCT01931566|Experimental|High Risk Pioglitazone|Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
11415633|NCT01931553|Experimental|Standardized attending morning rounds|"Pre-rounds discretion
~Pre-rounds huddle
~Bedside RN integration
~Patient-centered rounding
~Real-time order writing"
11415634|NCT01931553|No Intervention|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
11415635|NCT01931540|Experimental|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
11415636|NCT01931540|No Intervention|11 non-frail controls (9 LM)|Studied only at baseline
11415637|NCT01931540|Experimental|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
11415638|NCT01931527|No Intervention|Obese subjects with normal uric acid|Subjects with a body mass index = or > 30 kg/m² with normal uric acid (= or < 5 mg/dL)
11415639|NCT01931527|Experimental|Obese subjects with high uric acid|"Subjects with a body mass index = or > 30 kg/m² with high uric acid (>6 mg/dL)
~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
11415640|NCT01931488|Other|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
11415641|NCT01931475|Experimental|Duloxetine|"Double Blind Treatment Phase:
~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.
~Extension Treatment Phase:
~60 mg duloxetine administered by mouth QD for 13 weeks.
~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
11415642|NCT01931475|Placebo Comparator|Placebo|"Double Blind Treatment Phase:
~Placebo administered by mouth once a day (QD) for 13 weeks.
~Extension Treatment Phase:
~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.
~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
11415643|NCT01931462|Experimental|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
11415644|NCT01931449|Experimental|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
11415645|NCT01931449|Active Comparator|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
11415646|NCT01931436|Experimental|Qing'E pill|Administered twice a day, and each 9 g
11415647|NCT01931423|Placebo Comparator|Drainage Group|early placental drainage plus cord traction
11415648|NCT01931423|No Intervention|Controlled Group|spontaneous removal placenta
11415649|NCT01931410|Placebo Comparator|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
11415650|NCT01931410|Placebo Comparator|rectal|rectal 600 mgr misoprostol will be administered
11415651|NCT01931410|No Intervention|synpitan|
11415652|NCT01931384|Experimental|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
11415653|NCT01931384|Placebo Comparator|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
11415654|NCT01931371|Active Comparator|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
11415655|NCT01931371|Active Comparator|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
11415656|NCT01931358|Experimental|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
11415657|NCT01931358|Placebo Comparator|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
11415658|NCT01931358|Experimental|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
11415659|NCT01931358|Placebo Comparator|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
11415660|NCT01931358|Experimental|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
11415661|NCT01931358|Placebo Comparator|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
11415662|NCT01931358|Experimental|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
11415663|NCT01931358|Placebo Comparator|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
11415664|NCT01931345|Experimental|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
11415665|NCT01931345|Active Comparator|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
11415666|NCT01931332|Active Comparator|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
11415667|NCT01931332|Active Comparator|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
11415668|NCT01931319|Experimental|Intravenous Baclofen|Three single doses were evaluated using three cohorts (N=12 per cohort). Subjects received single doses of baclofen: 7.5, 11.5 or 15mg 10-minute intravenous infusion administered over 10 minutes by an infusion pump and 10, 15, or 20mg taken orally with a 48-hour washout phase between oral and intravenous arms of the study. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
11415669|NCT01931293|Experimental|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
11415670|NCT01931280|Experimental|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
11415671|NCT01931280|No Intervention|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
11415672|NCT01931267|Experimental|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
11415673|NCT01931267|Active Comparator|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
11415674|NCT01931241|Experimental|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
11415675|NCT01931241|Experimental|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
11415676|NCT01931241|Experimental|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
11415677|NCT01931241|Experimental|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 & 3
11415678|NCT01931241|Experimental|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
11415679|NCT01931228|Experimental|MI-E plus manually assisted coughing|
11415680|NCT01931228|Experimental|Manually assisted coughing only|
11415681|NCT01931215|Active Comparator|morphine group|spinal anesthesia with intrathecal morphine
11415682|NCT01931215|Experimental|TAP group|TAP-block with ropivacaine and clonidine
11415683|NCT01931202|Placebo Comparator|Double Blind-Placebo|Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.
11415684|NCT01931202|Active Comparator|Double Blind-Escitalopram|Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.
11415685|NCT01931202|Active Comparator|Open Treatment with Escitalopram|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
11415686|NCT01931189|Experimental|NI-071|
11415687|NCT01931189|Active Comparator|Infliximab|
11415688|NCT01931176|Experimental|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
11415689|NCT01931176|Placebo Comparator|Placebo|Participants will receive a single injection of placebo at study entry.
11415690|NCT01931163|Experimental|Everolimus|Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily
11415691|NCT01931150|Experimental|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
11415692|NCT01931150|Experimental|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
11415693|NCT01931137|Experimental|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
11415694|NCT01931137|Experimental|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
11415695|NCT01931137|Experimental|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
11415696|NCT01931124|Experimental|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
11415697|NCT01931124|Experimental|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
11415698|NCT01931111||Norwegian Elderly Population|
11415699|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
11415700|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
11415701|NCT01931072|Experimental|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
11415702|NCT01931072|Active Comparator|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
11415703|NCT01931072|No Intervention|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
11415704|NCT01931059|Experimental|Risperidone then Placebo|This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
11415705|NCT01931059|Experimental|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day
11415706|NCT01931046|Experimental|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
11415707|NCT01931046|Experimental|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
11415708|NCT01931033|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
11415711|NCT01931007|Experimental|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
11415712|NCT01931007|Placebo Comparator|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
11415713|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
11415714|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
11415715|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
11415716|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
11415717|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
11415718|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
11415719|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
11415720|NCT01930955|Active Comparator|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
11415721|NCT01930955|No Intervention|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
11415722|NCT01930942|Experimental|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
11415723|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
11415724|NCT01930916|Other|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
11415725|NCT01930890|Experimental|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
11415726|NCT01930890|Experimental|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
11415727|NCT01930877|Active Comparator|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
11415728|NCT01930877|Placebo Comparator|Placebo|Normal saline placebo infusion
11415729|NCT01930864|Experimental|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
11415730|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
11415731|NCT01930838||Controls|Matched on age, sex and body mass index
11415732|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
11415733|NCT01930812|Experimental|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
11415734|NCT01930799|Other|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
11415735|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
11415736|NCT01930773|Experimental|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
11415737|NCT01930773|Experimental|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
11415738|NCT01930773|No Intervention|Conventional Arm|Regular approach for performing elective PCI.
11415739|NCT01930760|Experimental|Educational Intervention Group|
11415740|NCT01930760|Experimental|Behavioural Intervention Group|
11415741|NCT01930747|Experimental|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
11415742|NCT01930747|Experimental|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
11415743|NCT01930747|Experimental|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
11415744|NCT01930734|Placebo Comparator|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.
~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
11415745|NCT01930734|Experimental|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
11415746|NCT01930721|Experimental|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
11415822|NCT01930240|Experimental|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
11415747|NCT01930721|Experimental|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
11415748|NCT01930708|Experimental|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
11415749|NCT01930682|Experimental|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
11415750|NCT01930682|Other|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
11415751|NCT01930669|Other|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
11415752|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
11415753|NCT01930643|Experimental|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
11415754|NCT01930643|No Intervention|Control|Patients with routine passive rehabilitation program.
11415755|NCT01930630|Experimental|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
11415756|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
11415757|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
11415758|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
11415759|NCT01930604|Active Comparator|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
11415760|NCT01930604|Placebo Comparator|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
11415761|NCT01930604|Active Comparator|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
11415762|NCT01930604|Placebo Comparator|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
11415763|NCT01930604|Active Comparator|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
11415764|NCT01930604|Placebo Comparator|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
11415765|NCT01930604|Active Comparator|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
11415766|NCT01930604|Placebo Comparator|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
11415767|NCT01930604|Active Comparator|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
11415768|NCT01930604|Placebo Comparator|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
11415769|NCT01930591|Active Comparator|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
11415770|NCT01930591|Experimental|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
11415771|NCT01930578|Experimental|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
11415772|NCT01930578|Experimental|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
11415773|NCT01930578|Experimental|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
11415774|NCT01930565|Experimental|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
11415775|NCT01930565|Active Comparator|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
11415776|NCT01930552|Experimental|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
11415777|NCT01930539|Experimental|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
11415778|NCT01930539|No Intervention|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
11415779|NCT01930526|Experimental|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
11415780|NCT01930500|Experimental|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
11415781|NCT01930500|Experimental|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
11415782|NCT01930500|No Intervention|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
11415783|NCT01930487|Experimental|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
11415784|NCT01930487|Experimental|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
11415785|NCT01930461|Experimental|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
11415786|NCT01930461|Experimental|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
11415787|NCT01930461|Experimental|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
11415788|NCT01930461|Placebo Comparator|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
11415789|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
11415790|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
11415791|NCT01930435|Experimental|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
11415792|NCT01930422|Experimental|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
11415793|NCT01930422|Sham Comparator|Placebo tDCS|Sham procedure
11415794|NCT01930409|Active Comparator|Education Only|"A 1 hour education session in the acute setting
~A toolkit with education, exercise and self management instructions for after hip fracture"
11415795|NCT01930409|Experimental|Education + Telephone Follow-up|"A 1 hour education session in the acute setting
~A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
11415796|NCT01930396|Experimental|Tinzaparin|
11415797|NCT01930396|Active Comparator|Unfractionated Heparin|
11415798|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
11415799|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
11415800|NCT01930383||Arm C|patients who receive systemic therapy
11415801|NCT01930370|Experimental|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
11415802|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
11415803|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
11415804|NCT01930344|Active Comparator|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
11415805|NCT01930344|Placebo Comparator|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
11415806|NCT01930331|Experimental|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
11415807|NCT01930331|Active Comparator|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
11415808|NCT01930318|Placebo Comparator|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
11415809|NCT01930318|Placebo Comparator|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
11415810|NCT01930318|Experimental|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
11415811|NCT01930318|Experimental|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
11415812|NCT01930292|Experimental|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
11415813|NCT01930292|Experimental|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
11415814|NCT01930292|Experimental|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
11415815|NCT01930292|Experimental|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
11415816|NCT01930279||surface markers on T cells as assessed by FACS|
11415817|NCT01930266|No Intervention|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
11415818|NCT01930266|Active Comparator|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
11415819|NCT01930266|Experimental|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
11415820|NCT01930240|Placebo Comparator|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
11415821|NCT01930240|Experimental|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
11415823|NCT01930227|Experimental|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
11415824|NCT01930227|Sham Comparator|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
11415825|NCT01930227|No Intervention|Control|No stimulation was given
11415826|NCT01930214||None/mild calcification|Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
11415827|NCT01930214||Moderate Calcification|Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
11415828|NCT01930214||Severe calcification|Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
11415829|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
11415830|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
11415831|NCT01930188|Experimental|Semaglutide 0.5 mg + sitagliptin placebo|
11415832|NCT01930188|Experimental|Semaglutide 1.0 mg + sitagliptin placebo|
11415833|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
11415834|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
11415835|NCT01930175|Placebo Comparator|Placebo|single dose iv of Placebo
11415836|NCT01930175|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
11415837|NCT01930175|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg initiated following a safety review of patients receiving VAY736 3 mg/kg or placebo.
11415838|NCT01930162|Experimental|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
11415839|NCT01930149|Experimental|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
11415840|NCT01930149|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
11415841|NCT01930136|Experimental|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
11415842|NCT01930136|Active Comparator|Ad libitum health diet|
11415843|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
11415844|NCT01930123|Placebo Comparator|Health controls|15 healthy controls for comparison with NALFD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
11415845|NCT01930110|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
11415846|NCT01930110|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
11415847|NCT01930097|Active Comparator|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.
~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
11415848|NCT01930097|Active Comparator|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
11415849|NCT01930097|Active Comparator|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
11415850|NCT01930084|Experimental|Combination intervention + incentives|"Point of care CD4+ after HIV diagnosis
~Accelerated ART initiation
~SMS appointment reminders
~Non-cash financial incentives (FI)"
11415851|NCT01930084|Experimental|Combination intervention strategy(CIS)|"Point of care (POC) CD4+ after HIV diagnosis
~Accelerated ART initiation
~SMS appointment reminders"
11415852|NCT01930084|No Intervention|Standard of care (SOC)|Standard of care, no intervention
11415853|NCT01930071|Experimental|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
11415854|NCT01930058|Experimental|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
11415855|NCT01930058|Experimental|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
11415856|NCT01930058|Experimental|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
11415857|NCT01930045|Experimental|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
11415858|NCT01930045|Experimental|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
11415925|NCT01929551|Other|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
11415926|NCT01929551|Other|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
11415927|NCT01929551|Other|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
11415859|NCT01930045|Experimental|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
11415860|NCT01930045|Experimental|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
11415861|NCT01930045|Experimental|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
11415862|NCT01930045|Experimental|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
11415863|NCT01930032||All subjects|
11415864|NCT01930019|Experimental|OE|OE - obese patients (BMI>40) in which etomidate was used,
11415865|NCT01930019|Other|NE|NE - patients with normal body mass (BMI<25), in which etomidate was used,
11415866|NCT01930019|Experimental|OT|OT - obese patients in which thiopental was used,
11415867|NCT01930019|Other|NT|NT - patients with normal body mass, in which thiopental was used
11415868|NCT01930006|Experimental|MGCD265|
11415869|NCT01929993|Experimental|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
11415870|NCT01929993|Active Comparator|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
11415871|NCT01929980|Experimental|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
11415872|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
11415873|NCT01929954|Experimental|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
11415874|NCT01929954|Active Comparator|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
11415875|NCT01929941|Experimental|Group 1 INCB047986|
11415876|NCT01929941|Experimental|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
11415877|NCT01929928||Surgical Patients|
11415878|NCT01929915|Active Comparator|Epidural patient controlled analgesia|Epidural patient controlled analgesia
11415879|NCT01929915|Sham Comparator|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
11415880|NCT01929902||Surgical Patients|
11415881|NCT01929889|Experimental|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
11415882|NCT01929876|Experimental|Cobimetinib + Itraconazole|
11415883|NCT01929863|Experimental|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
11415928|NCT01929551|Other|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
11415929|NCT01929551|Other|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
11415884|NCT01929863|Experimental|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
11415885|NCT01929850|Active Comparator|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
11415886|NCT01929850|Other|Control|Weight Watchers Program for morbidly obese patients.
11415887|NCT01929837|Experimental|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
11415888|NCT01929837|Sham Comparator|sham E-field navigated rTMS|Sham electrical field navigated rTMS
11415889|NCT01929837|Experimental|non-navigated rTMS|non-navigated rTMS
11415890|NCT01929837|Experimental|Experimental, Navigated rTMS|Navigated rTMS,
11415891|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
11415892|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
11415893|NCT01929798|Experimental|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
11415894|NCT01929798|No Intervention|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
11415895|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
11415896|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
11415897|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
11415898|NCT01929759|Other|Drug switching|Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
11415899|NCT01929746|Experimental|BIIB019, 75 mg|BIIB019 delivered via Subcutaneous Injection
11415900|NCT01929746|Experimental|BIIB019, 150 mg|BIIB019 delivered via Subcutaneous Injection
11415901|NCT01929720|Experimental|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
11415902|NCT01929720|Active Comparator|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
11415903|NCT01929707|Experimental|LY3050258|Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.
11415904|NCT01929707|Placebo Comparator|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
11415905|NCT01929694|Active Comparator|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
11415906|NCT01929694|Placebo Comparator|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
11415907|NCT01929681|Experimental|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment
~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
11415908|NCT01929681|Sham Comparator|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment
~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
11415909|NCT01929668|Active Comparator|polyethylene glycol|4L polyethylene glycol
11415910|NCT01929668|Experimental|polyethylene glycol with ascorbic acid|2L polyethylene glycol and ascorbic acid
11415911|NCT01929655|Experimental|Radium-223 dichloride|
11415912|NCT01929642|Experimental|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
11415913|NCT01929629|Placebo Comparator|Placebo fasting|Single or multiple dosing placebo
11415914|NCT01929629|Experimental|Active fed condition|AZD0914 given as single dose
11415915|NCT01929616|Experimental|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
11415916|NCT01929603|Experimental|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
11415917|NCT01929590|Active Comparator|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
11415918|NCT01929590|Active Comparator|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
11415919|NCT01929590|Experimental|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
11415920|NCT01929577|Experimental|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
11415921|NCT01929577|Experimental|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
11415922|NCT01929577|Experimental|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
11415923|NCT01929564|Active Comparator|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
11415924|NCT01929564|Placebo Comparator|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
11415930|NCT01929551|Other|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
11415931|NCT01929551|Other|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
11415932|NCT01929538|Active Comparator|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
11415933|NCT01929538|Active Comparator|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
11415934|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
11415935|NCT01929512|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11415936|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11415937|NCT01929512|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11415938|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
11415939|NCT01929499|Experimental|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.
~For CapeOx regimen:
~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.
~For mFolfox6 regimen:
~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
11415940|NCT01929499|Experimental|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
11415941|NCT01929499|No Intervention|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
11415942|NCT01929486|Experimental|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|<Phase Ia> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
11415943|NCT01929486|Experimental|<Phase Ib> Mogamulizumab of the tolerated dose|<Phase Ib> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
11415944|NCT01929486|Experimental|<Phase Ib> Mogamulizumab 0.1mg/kg|<Phase Ib> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
11415945|NCT01929460|Other|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.
~Ciprofloxacin 500mg by mouth twice a day for three days."
11415946|NCT01929460|Placebo Comparator|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration
~Oral Placebo, one cap twice a day for three days."
11415947|NCT01929434|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
11415948|NCT01929434|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
11415949|NCT01929434|Experimental|stem cell injection|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
11415950|NCT01929421|Experimental|Gemcitabine/ s-1|
11415951|NCT01929395|Active Comparator|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
11415952|NCT01929395|Active Comparator|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
11415953|NCT01929382|Active Comparator|Actimmune (interferon gamma 1b)|Subjects > 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
11415954|NCT01929382|Experimental|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
11415955|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
11415956|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
11415957|NCT01929356|Experimental|chest physiotherapy|session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
11415958|NCT01929343|Experimental|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
11415989|NCT01929161|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
11415959|NCT01929343|Active Comparator|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
11415960|NCT01929343|Placebo Comparator|saline|Saline will be administered at same volume of lidocaine in active arms.
11415961|NCT01929330|Experimental|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
11415962|NCT01929330|Experimental|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
11415963|NCT01929317|Experimental|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
11415964|NCT01929317|Experimental|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
11415965|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
11415966|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
11415967|NCT01929291||Boostrix Group|Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.
11415968|NCT01929278|Experimental|CT Gel patch|CT Gel is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1% and tretinoin 0.025%) in a modified vehicle. The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
11415969|NCT01929278|Placebo Comparator|Vehicle gel patch|The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
11415970|NCT01929278|Experimental|Blank patch|Blank patches did not contain CT Gel or vehicle gel.
11415971|NCT01929265|Experimental|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)
~1 arm for all patients"
11415972|NCT01929252|Active Comparator|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
11415973|NCT01929252|Active Comparator|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
11415974|NCT01929239|Experimental|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
11415975|NCT01929226|Experimental|ETI-204|A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
11415976|NCT01929226|Placebo Comparator|Placebo for ETI-204|A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
11415977|NCT01929213|Experimental|Udenafil|
11415978|NCT01929213|Experimental|Bosentan|
11415979|NCT01929213|Experimental|Udenafil/Bosentan|
11415980|NCT01929200|Experimental|1-year treatment with icotinib|Patients will receive 1-year treatment with icotinib after operation.
11415981|NCT01929200|Experimental|2-year treatment with icotinib|Patients will receive 2-year treatment with icotinib after operation.
11415982|NCT01929187|Active Comparator|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
11415983|NCT01929187|Active Comparator|amorolfine 5% nail lacquer|5% amorolfine
11415984|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
11415985|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
11415986|NCT01929161|Experimental|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
11415987|NCT01929161|Placebo Comparator|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
11415988|NCT01929161|Experimental|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
11415990|NCT01929148|Experimental|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
11415991|NCT01929148|Active Comparator|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
11415992|NCT01929135|Experimental|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
11415993|NCT01929135|Placebo Comparator|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
11415994|NCT01929122|Placebo Comparator|Placebo-Control|Randomized participants consume 1 meal and 1 snack per day that does not include either rice bran or navy bean powder for 28 days.
11415995|NCT01929122|Experimental|Cooked Navy Bean Powder|Randomized participants consume 1 meal and 1 snack per day containing cooked navy bean powder (35 g/day) for 28 days.
11415996|NCT01929122|Experimental|Rice Bran|Randomized participants consume 1 meal and 1 snack per day containing rice bran (30 g/day) for 28 days.
11415997|NCT01929109|Experimental|LY2409021 Control|Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
11415998|NCT01929109|Experimental|LY2409021 Mild Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
11415999|NCT01929109|Experimental|LY2409021 Moderate Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
11416000|NCT01929109|Experimental|LY2409021 Severe Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
11416001|NCT01929109|Experimental|LY2409021 End Stage Renal Disease|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.
11416002|NCT01929096|Experimental|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
11416003|NCT01929096|Experimental|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
11416004|NCT01929096|Experimental|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
11416005|NCT01929096|Active Comparator|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
11416006|NCT01929083|Experimental|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
11416007|NCT01929083|Placebo Comparator|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
11416008|NCT01929070|Experimental|Group 1|"R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state
~R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet
~T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state
~T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet
~R1 -> T2 -> R2 -> T1"
11416009|NCT01929070|Experimental|Group 2|R2 -> R1 -> T1 -> T2
11416010|NCT01929070|Experimental|Group 3|T1 -> R2 -> T2 -> R1
11416011|NCT01929070|Experimental|Group 4|T2 -> T1 -> R1 -> R2
11416012|NCT01929057||Acne patients|This group consists of patients who have at least moderate to severe acne on their back
11416013|NCT01929057||Healthy Controls|This group contains participants who do not have any active acne lesions on their back
11416014|NCT01929044|Experimental|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
11416015|NCT01929044|Active Comparator|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
11416016|NCT01929031|Other|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
11416017|NCT01929031|Other|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
11416018|NCT01929031|Other|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
11416019|NCT01929031|Other|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
11416020|NCT01929031|Other|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
11416021|NCT01929031|Other|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
11416022|NCT01929018|Experimental|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
11416023|NCT01929018|No Intervention|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
11416024|NCT01929005|No Intervention|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
11416098|NCT01928589|Experimental|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
11416099|NCT01928576|Experimental|Arm C|Nivolumab 3mg/kg every 2 weeks until progression
11416025|NCT01929005|Experimental|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
11416026|NCT01928992||3D|Subjects that undergo 3D mammography
11416027|NCT01928992||2D|Subjects that undergo 2D mammography
11416028|NCT01928979||Group 1|
11416029|NCT01928966|Active Comparator|Group I - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four weeks of study: receive 1.5 ounces of pumpkin seeds per day for consumption; Third four weeks of the study: consume their perceived normal diet.
11416030|NCT01928966|Active Comparator|Group II - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four week period: consume perceived normal diet; Third four week period: receive 1.5 ounces of pumpkin seeds per day for consumption.
11416031|NCT01928940|Experimental|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
11416032|NCT01928927|Experimental|Arm A: Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
11416033|NCT01928927|No Intervention|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
11416034|NCT01928914|Placebo Comparator|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
11416035|NCT01928914|Experimental|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
11416036|NCT01928914|Active Comparator|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
11416037|NCT01928914|Experimental|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
11416038|NCT01928914|Experimental|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
11416039|NCT01928901|Experimental|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
11416040|NCT01928901|Experimental|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
11416041|NCT01928901|Placebo Comparator|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
11416042|NCT01928901|Placebo Comparator|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
11416043|NCT01928888|Experimental|Arm HFP|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo
11416044|NCT01928888|Experimental|Arm HPF|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine
11416045|NCT01928888|Experimental|Arm FHP|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo
11416046|NCT01928888|Experimental|Arm FPH|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid
11416047|NCT01928888|Experimental|Arm PHF|1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine
11416048|NCT01928888|Experimental|Arm PFH|1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid
11416049|NCT01928875|Experimental|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
11416050|NCT01928875|Active Comparator|Routine (Standard) Anesthesia Monitoring|
11416051|NCT01928862|Experimental|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
11416052|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
11416053|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
11416054|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
11416055|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
11416056|NCT01928849|Placebo Comparator|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
11416057|NCT01928849|Experimental|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
11416058|NCT01928836||Non-suspected lung cancer group|"Aged 40 to 75 years;
~Male smoker (≥400 cig/year), female smoker or non-smoker;
~Visible lung nodule lesion in the chest (based on local CT result);
~Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
11416059|NCT01928836||Suspected lung cancer group|"Aged 40 to 75 years;
~Male smoker (≥400 cig/year), female smoker or non-smoker;
~Visible lung cancer lesion in the chest (based on local CT result);
~With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
11416060|NCT01928823|Experimental|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
11416061|NCT01928823|Placebo Comparator|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
11416062|NCT01928810|Experimental|70% VO2max|"Cognitive Behavioural Therapy (CBT)
~+ aerobic exercise (30 minutes, 70% VO2max) prior to 5 in-vivo exposure sessions"
11416063|NCT01928810|Active Comparator|30% VO2max|"Cognitive Behavioural Therapy (CBT)
~+ placebo exercise (30 minutes, 30% VO2max) prior to 5 in-vivo exposure sessions"
11416064|NCT01928797|No Intervention|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
11416351|NCT01926938||controls|Latino adults without family history of type 2 diabetes and normal glucose tolerance
11416065|NCT01928797|Experimental|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
11416066|NCT01928784|Experimental|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
11416067|NCT01928784|Experimental|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
11416068|NCT01928771|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
11416069|NCT01928771|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
11416070|NCT01928771|Placebo Comparator|Placebo|Placebo administered subcutaneously
11416071|NCT01928758|Experimental|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
11416072|NCT01928758|Placebo Comparator|Usual Nicotine Content Cigarettes|Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)
11416073|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
11416074|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
11416075|NCT01928732|Active Comparator|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
11416076|NCT01928732|Active Comparator|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
11416077|NCT01928719|Experimental|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg per cigarette) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
11416078|NCT01928719|Placebo Comparator|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes with a usual nicotine content (about 11.6 mg per cigarette)
11416079|NCT01928706|Experimental|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
11416080|NCT01928706|Active Comparator|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
11416081|NCT01928693|Active Comparator|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
11416082|NCT01928693|Active Comparator|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
11416083|NCT01928693|Active Comparator|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
11416084|NCT01928680|Experimental|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.
~This is a single arm phase II clinical trial."
11416085|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
11416086|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
11416087|NCT01928654|Experimental|Micropulse laser treatment|Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern
11416088|NCT01928654|Active Comparator|Laser modified ETDRS|Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.
11416089|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
11416090|NCT01928628|Active Comparator|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
11416091|NCT01928628|Experimental|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
11416092|NCT01928628|Experimental|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
11416093|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
11416094|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
11416095|NCT01928602|Experimental|Expressive Aphasia Group A|"Behavioral: TherAppy Language App
~Behavioral: Mind-Games"
11416096|NCT01928602|Experimental|Expressive Aphasia Group B|"Behavioral: Mind-Games
~Behavioral: TherAppy Language App"
11416097|NCT01928589|Active Comparator|PBI|270 cGy (centigray) x 15
11416352|NCT01926925||1|Overweight Hispanic children/adolescents
11416100|NCT01928576|Experimental|Arm D|"Anti-PD-1/PD-L1 treatment naïve patients only
~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15
~Followed by:
~Nivolumab 3mg/kg every 2 weeks until progression
~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
11416101|NCT01928576|Experimental|Arm E|"Patients must have had refractory (Arm E=less than 24 weeks from first dose of anti-PD-1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.
~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15
~Followed by:
~Nivolumab 3mg/kg every 2 weeks until progression
~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
11416102|NCT01928576|Experimental|Arm F|"Patients must have had recurrent (Arm F=more than 24 weeks from first dose of anti-PD1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.
~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15
~Followed by:
~Nivolumab 3mg/kg every 2 weeks until progression
~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
11416103|NCT01928563|Experimental|Dapoxetine|Dapoxetine is administered
11416104|NCT01928563|Experimental|Udenafil|Udenafil is administered
11416105|NCT01928563|Experimental|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
11416106|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
11416107|NCT01928537|Experimental|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
11416108|NCT01928524|Experimental|DOS2W|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2nd week.
11416109|NCT01928524|Experimental|DOS3W|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3rd week.
11416110|NCT01928511|Active Comparator|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
11416111|NCT01928511|Experimental|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
11416112|NCT01928511|Experimental|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
11416113|NCT01928498|Experimental|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon Angioplasty
11416114|NCT01928498|Active Comparator|Conventional uncoated balloon|Percutaneous Transluminal Angioplasty (PTA)
11416115|NCT01928485|Active Comparator|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
11416116|NCT01928485|Experimental|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
11416117|NCT01928472|Experimental|Group A|H7N9c low dose with adjuvant
11416118|NCT01928472|Experimental|Group B|H7N9c medium dose with adjuvant
11416119|NCT01928472|Experimental|Group C|H7N9c high dose with adjuvant
11416120|NCT01928472|Experimental|Group D|H7N9c high dose without adjuvant
11416121|NCT01928459|Experimental|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
11416122|NCT01928459|Experimental|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
11416123|NCT01928459|Experimental|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
11416124|NCT01928459|Experimental|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
11416125|NCT01928446|Experimental|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
11416126|NCT01928446|Placebo Comparator|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
11416127|NCT01928433|Experimental|Finafloxacin 5 days|"Intervention:
~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
11416128|NCT01928433|Experimental|Finafloxacin 10 days|"Intervention:
~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
11416129|NCT01928433|Active Comparator|Ciprofloxacin 10 days|"Intervention:
~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
11416130|NCT01928420|Experimental|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
11416131|NCT01928420|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
11416132|NCT01928407|Experimental|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
11416133|NCT01928407|Experimental|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
11416353|NCT01926925||2|Lean Hispanic children/adolescents
11416134|NCT01928394|Experimental|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11416135|NCT01928394|Experimental|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11416136|NCT01928394|Experimental|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11416137|NCT01928394|Experimental|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11416138|NCT01928394|Experimental|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11416139|NCT01928394|Experimental|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11416140|NCT01928381|Placebo Comparator|placebo capsules|Capsules to match pregabalin and AZD5213
11416141|NCT01928381|Experimental|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
11416142|NCT01928381|Active Comparator|pregabalin|pregabalin capsules
11416143|NCT01928368|Active Comparator|Experimental Arm|
11416144|NCT01928368|Placebo Comparator|Placebo Arm|
11416145|NCT01928355||metabolically healthy|
11416146|NCT01928355||Unhealthy|
11416147|NCT01928342|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
11416148|NCT01928342|Placebo Comparator|Placebo|Capsule without coenzyme A.
11416149|NCT01928329|Placebo Comparator|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
11416150|NCT01928329|Experimental|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
11416151|NCT01928316|Experimental|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
11416152|NCT01928316|Experimental|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
11416153|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
11416154|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
11416155|NCT01928290|Experimental|Arm A: FOLFIRINOX (HER2-negative)|"Irinotecan 180 mg/m2 IV on Days 1 & 15.
~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.
~Leucovorin 400 mg/m2 IV on Days 1 & 15.
~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
11416156|NCT01928290|Experimental|Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.
~Irinotecan 180 mg/m2 IV on Days 1 & 15.
~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.
~Leucovorin 400 mg/m2 IV on Days 1 & 15.
~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
11416157|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
11416158|NCT01928264|Experimental|Physical activity|Physical activity group program over 12 weeks; 1 hour sessions, 2 times a week
11416159|NCT01928264|No Intervention|Leisure time activities|Predominantly sedentary leisure time group activities, like playing board games, doing handicrafts, etc.; 12 weeks, 1 hour sessions, 2 times a week
11416160|NCT01928251|Experimental|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level < 4 ppm, saliva cotinine level < 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
11416161|NCT01928251|Experimental|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
11416162|NCT01928251|No Intervention|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
11416163|NCT01928238|Experimental|Arm 1|"Patients will have two 20-minute noninvasive periods :
~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
11416164|NCT01928238|Experimental|Arm 2|"Patients will have two 20-minute noninvasive periods :
~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
11416165|NCT01928225|Experimental|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
11416166|NCT01928225|Placebo Comparator|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
11416167|NCT01928212||healthy control|Sex- and agematched healthy subjects
11416168|NCT01928212||Parkinson group|Patients with Parkinson's disease
11416169|NCT01928199|Active Comparator|Sitagliptin|"Sitaglipitin tablets will be administered orally for 3 months from randomization
~Initial dose will be 100mg/daily, adjusted per renal function:
~Creatinine clearance > or = 50mL/min: 100mg/day Creatinine clearance > or = 30 and <50mL/min: 50mg/day Creatinine clearance <30 mL/min or on dialysis: 25mg/day"
11416170|NCT01928199|Placebo Comparator|Placebo|Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator
11416171|NCT01928186|Experimental|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
11416172|NCT01928173|Active Comparator|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
11416173|NCT01928173|Active Comparator|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
11416174|NCT01928160|Experimental|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11416175|NCT01928160|Experimental|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11416176|NCT01928147|Experimental|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
11416177|NCT01928147|Experimental|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
11416178|NCT01928147|Experimental|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
11416179|NCT01928134|Experimental|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
11416180|NCT01928134|Active Comparator|B|Vit K2+CaCO3
11416181|NCT01928121|Experimental|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
11416182|NCT01928121|No Intervention|Usual care|
11416183|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
11416184|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
11416185|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
11416186|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
11416187|NCT01928043|Experimental|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
11416188|NCT01928030|Experimental|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
11416189|NCT01928017||Hematooncology patients|No intervention
11416190|NCT01928004|Experimental|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
11416191|NCT01928004|Active Comparator|denture reline|conventional reline of mandibular complete denture
11416192|NCT01927991|Experimental|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
11416193|NCT01927991|Active Comparator|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
11416194|NCT01927978||esophageal cancer, 18F-FDG PET|
11416195|NCT01927965|Experimental|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
11416196|NCT01927952|Active Comparator|Kirschner wire|surgical fixation using a Kirschner wire
11416197|NCT01927952|Active Comparator|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
11416198|NCT01927952|Active Comparator|Stryker Smart-Toe implant|surgical fixation utilizing the Stryker Smart-Toe implant
11416199|NCT01927939||Histological proven breast cancer with bone lesion|
11416200|NCT01927926|Experimental|Whey-protein & polydextrose snack|Whey-protein & polydextrose snack bar.
11416201|NCT01927926|Placebo Comparator|Control snack|Control snack bar containing minimal protein and not polydextrose.
11416202|NCT01927913|Experimental|SPD602|
11416203|NCT01927913|Active Comparator|Deferasirox|
11416204|NCT01927900|Active Comparator|HMO1|HMO diluted in water
11416205|NCT01927900|Placebo Comparator|Glucose|Glucose diluted in water
11416206|NCT01927900|Active Comparator|HMO2|HMO diluted in water
11416207|NCT01927900|Active Comparator|HMO3|HMO diluted in water
11416208|NCT01927900|Active Comparator|HMO4|HMO diluted in water
11416209|NCT01927900|Active Comparator|HMO5|HMO diluted in water
11416210|NCT01927900|Active Comparator|HMO6|HMO diluted in water
11416211|NCT01927900|Active Comparator|HMO7|HMO diluted in water
11416212|NCT01927900|Active Comparator|HMO8|HMO diluted in water
11416213|NCT01927900|Active Comparator|HMO9|HMO diluted in water
11416214|NCT01927887|Experimental|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
11416215|NCT01927874|Active Comparator|Infiltration, analgesic effect|10ml 0.5% bupivacaine each side Block Injection of local anesthetic at pudendal nerve
11416216|NCT01927874|Active Comparator|Spinal block|10 mg of hyperbaric 0.5% bupivacaine Injection of anesthetic at subarachnoidal space
11416217|NCT01927861|Experimental|0.033 mg/kg/day|
11416218|NCT01927861|Experimental|0.066 mg/kg/day|
11416219|NCT01927848|Experimental|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
11416220|NCT01927848|Placebo Comparator|Placebo|Dosage: 3 capsules once daily with meals
11416221|NCT01927835|Experimental|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
11416222|NCT01927835|Experimental|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
11416223|NCT01927835|Experimental|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
11416224|NCT01927835|Experimental|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
11416225|NCT01927835|Placebo Comparator|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
11416226|NCT01927835|Placebo Comparator|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
11416227|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
11416228|NCT01927783||Group 1|Healthy Volunteer
11416229|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
11416230|NCT01927783||Group 3|Focus Group
11416231|NCT01927783||Group 4|Focus Group- Mobile App
11416232|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
11416233|NCT01927783||Group 6|Community Organization Survey focus Group
11416234|NCT01927770||WES/WGS|Eligible adults (or parents of eligible children) consenting to enroll in an NIH study thatincludes WES/WGS.
11416235|NCT01927757|Experimental|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
11416236|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
11416237|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
11416238|NCT01927731|Experimental|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
11416239|NCT01927731|Experimental|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
11416240|NCT01927718|Experimental|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.
~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
11416241|NCT01927705|Experimental|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10^7 stem cells after registration.
~FURESTEM-AD Inj. 2. 5.0 x 10^7 stem cells after registration."
11416242|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
11416243|NCT01927679|Other|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
11416305|NCT01927289|Active Comparator|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
11416244|NCT01927679|Other|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
11416245|NCT01927666|Experimental|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
11416246|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:
~memory complaint
~normal general cognition
~normal activities of daily living
~not demented"
11416247|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:
~relatively focal executive dysfunction
~Within reference range on tests of memory, language and visuospatial skills
~normal general cognition
~normal activities of daily living
~not demented"
11416248|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:
~Age and gender matched healthy subjects without significant neuropsychiatric disorder
~Able to understand and provide signed informed consent"
11416249|NCT01927640|Experimental|Dexmedetomidine and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion
11416250|NCT01927640|Placebo Comparator|Normal saline and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)
11416251|NCT01927627|Experimental|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
11416252|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT <0.5mm (10 patients) and those with MIT >0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
11416253|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
11416254|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
11416255|NCT01927588|Experimental|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
11416256|NCT01927588|Active Comparator|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
11416257|NCT01927575|Active Comparator|Standard X-Ray + CT|Standard X-Ray + CT arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
11416258|NCT01927575|Active Comparator|Standard X-Ray + MRI|Standard X-Ray + MRI arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
11416259|NCT01927575|Experimental|Tomo|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
11416260|NCT01927562|Experimental|Duodenal Treatment|The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
11416261|NCT01927549|Active Comparator|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter >2 mm with high grade stenoses (>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
11416262|NCT01927549|Active Comparator|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
11416263|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
11416264|NCT01927523|No Intervention|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
11416265|NCT01927523|Experimental|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
11416266|NCT01927523|Experimental|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
11416267|NCT01927523|Experimental|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
11416268|NCT01927510|Experimental|early mobilisation|intervention of early mobilisation
11416269|NCT01927510|No Intervention|Control|Standard care
11416270|NCT01927497|Experimental|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
11416271|NCT01927497|Active Comparator|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
11416272|NCT01927484|Experimental|methotrexate|25mg oral methotrexate tablets
11416273|NCT01927484|Placebo Comparator|placebo|25 mg/week placebo tablets
11416274|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
11416306|NCT01927276|Placebo Comparator|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
11416275|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
11416276|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
11416277|NCT01927458|Experimental|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
11416278|NCT01927445|No Intervention|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
11416279|NCT01927445|Experimental|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
11416280|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
11416281|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
11416282|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
11416283|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
11416284|NCT01927406|Experimental|Prostaglandin Analog vs Timolol|In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
11416285|NCT01927406|Experimental|Prostaglandin Analog|In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
11416286|NCT01927393|Experimental|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
11416287|NCT01927393|Active Comparator|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
11416288|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
11416289|NCT01927367|Other|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
11416290|NCT01927367|No Intervention|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
11416291|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
11416292|NCT01927341|Experimental|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
11416293|NCT01927341|Experimental|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
11416294|NCT01927341|Experimental|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
11416295|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
11416296|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
11416297|NCT01927328|No Intervention|Control|Standard Care as determined by the clinical team
11416298|NCT01927328|Active Comparator|Iron isomaltoside 1000|Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
11416299|NCT01927315|Experimental|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
11416300|NCT01927315|Placebo Comparator|Placebo|Placebo oral tablets daily for 12 weeks
11416301|NCT01927302|Experimental|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
11416302|NCT01927302|Experimental|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
11416303|NCT01927302|Experimental|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
11416304|NCT01927289|Active Comparator|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
11416307|NCT01927276|Active Comparator|Wheat Flour|Wheat Flour 10 grams daily
11416308|NCT01927263|Experimental|NI-071|
11416310|NCT01927250|Experimental|Okada Health and Wellness program|12,166 Japanese volunteers with/without illness, who were interested in practicing Okada Health and Wellness program for 3 consecutive months.
11416311|NCT01927237|Experimental|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
11416312|NCT01927237|Experimental|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
11416313|NCT01927224|Experimental|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
11416314|NCT01927224|Experimental|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
11416315|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
11416316|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
11416317|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
11416318|NCT01927198|Placebo Comparator|Placebo|Placebo group
11416319|NCT01927185|Active Comparator|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
11416320|NCT01927185|Active Comparator|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
11416321|NCT01927172|Other|AirSonea|Use of AirSonea to detect wheeze sounds.
11416322|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
11416323|NCT01927159|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
11416324|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
11416325|NCT01927159|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
11416326|NCT01927159|Placebo Comparator|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
11416327|NCT01927146||Resectable gastric cancer|No intervention
11416328|NCT01927133||FIBROFRANCE Project|
11416329|NCT01927120|Experimental|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
11416330|NCT01927107|Active Comparator|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
11416331|NCT01927107|Active Comparator|Control|Standard diet therapy
11416332|NCT01927094|Active Comparator|Probiotic|"Saccharomyces boulardii 1 x 250 mg per day for 5 days, PO or Lactobacillus GG 1 x 10(9) CFU per day for 5 days or
~Lactobacillus reuteri 1 x 10(8) CFU per day for 5 days"
11416333|NCT01927094|Active Comparator|Control|ORS-ad libitum
11416334|NCT01927081|Active Comparator|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
11416335|NCT01927081|Active Comparator|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
11416336|NCT01927068|Experimental|Global Cohort 1|All subjects to be treated with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTX PTA) Balloon Catheter in Cohort 1.
11416337|NCT01927068|Experimental|Global ISR Cohort 2|"For Cohort 2, the same device was commercially available, and subjects were to be treated with the CE Marked, renamed device Stellarex 0.035 OTW drug-coated angioplasty balloon (Stellarex 035 DCB)"
11416338|NCT01927055|Active Comparator|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
11416339|NCT01927055|Placebo Comparator|Placebo|Placebo
11416340|NCT01927042|Experimental|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
11416341|NCT01927042|Active Comparator|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
11416342|NCT01927029|Experimental|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
11416343|NCT01927029|Placebo Comparator|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
11416344|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
11416345|NCT01927003|Experimental|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
11416346|NCT01926977|Active Comparator|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
11416347|NCT01926977|Active Comparator|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
11416348|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
11416349|NCT01926951|Experimental|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
11416355|NCT01926899|Experimental|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
11416356|NCT01926886|Experimental|Trastuzumab|Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
11416357|NCT01926886|No Intervention|Health Care Professionals|Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
11416358|NCT01926873||Healthy volunteers|
11416359|NCT01926860|Experimental|Study group - Prevenar®13 and Hepatitis A vaccines|Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0
11416360|NCT01926860|Active Comparator|Pneumococcal conjugate vaccine -Control group - Prevenar®13|PCV -Control group (group 2) - Prevenar®13: one vaccine injection administered on Day 0
11416361|NCT01926860|Active Comparator|HepA -Control group - Hepatitis A vaccine|HepA -Control group (group 3) - Hepatitis A vaccine: one vaccine injection administered on Day 0
11416362|NCT01926847|Experimental|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
11416363|NCT01926847|Experimental|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
11416364|NCT01926834|Experimental|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
11416365|NCT01926834|Placebo Comparator|placebo|normal saline, 500ml,i.v.,qd, for 7 days
11416366|NCT01926834|No Intervention|health volunteers|health volunteers, no drug to be given.
11416367|NCT01926821|Experimental|sonifilan|Group who get sonifilan
11416368|NCT01926821|No Intervention|control|No Sonifilan administered
11416369|NCT01926808||Vitamin D supplementation|
11416370|NCT01926795|Active Comparator|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
11416371|NCT01926795|Experimental|No immobilization|No cast or splint will be applied to the injured extremity
11416372|NCT01926795|Other|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
11416373|NCT01926782|Placebo Comparator|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
11416374|NCT01926782|Experimental|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
11416375|NCT01926782|Experimental|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
11416376|NCT01926769|Experimental|FOLFOX6+Metformin/FOFIRI+Metformin|
11416377|NCT01926756|Other|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
11416378|NCT01926756|Active Comparator|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
11416379|NCT01926743|Experimental|NIR with ICG group|
11416380|NCT01926730|No Intervention|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
11416381|NCT01926730|Experimental|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
11416382|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
11416383|NCT01926717||Pancreaticoduodenectomy|
11416384|NCT01926704||healthy, young subjects|
11416385|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
11416386|NCT01926678|Experimental|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
11416387|NCT01926678|Active Comparator|Light touch therapy|Light touch therapy once per week for 6 weeks
11416388|NCT01926678|Other|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
11416389|NCT01926665|Experimental|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
11416390|NCT01926652|Experimental|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
11416391|NCT01926652|Experimental|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
11416392|NCT01926639|Experimental|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
11416490|NCT01926002|Placebo Comparator|Placebo to MK-8351|Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
11416716|NCT01924520|Experimental|Group 2 (FK949E middle dose)|Oral
11416393|NCT01926626|Experimental|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
11416394|NCT01926613|Active Comparator|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
11416395|NCT01926613|Experimental|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
11416396|NCT01926600||PO|administrated by per oral
11416397|NCT01926600||IV|Administrated by intravenous
11416398|NCT01926600||SL|administrated by sublingual
11416399|NCT01926587|Experimental|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
11416400|NCT01926574|Experimental|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
11416401|NCT01926574|Experimental|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
11416402|NCT01926574|Active Comparator|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
11416403|NCT01926574|No Intervention|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
11416404|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
11416405|NCT01926548|Experimental|CJ Imatinib 200mg|1 tablet(200mg) a day,PO,QD
11416406|NCT01926548|Active Comparator|Gleevec 100mg|2 tablet(100mg) a day,PO,QD
11416407|NCT01926535|Experimental|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
11416408|NCT01926535|Active Comparator|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
11416409|NCT01926522|Experimental|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
11416410|NCT01926522|Active Comparator|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
11416411|NCT01926509|Experimental|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
11416412|NCT01926509|Experimental|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28).
11416413|NCT01926509|Experimental|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
11416414|NCT01926509|Placebo Comparator|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
11416415|NCT01926496|Experimental|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
11416416|NCT01926496|Active Comparator|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
11416417|NCT01926483|Experimental|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
11416418|NCT01926470|Experimental|anteroposterior approach group|anteroposterior approach group
11416419|NCT01926470|Active Comparator|oblique approach group|oblique approach group
11416717|NCT01924520|Experimental|Group 3 (FK949E higher dose)|Oral
11416420|NCT01926457|Experimental|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation
~diabetes education
~blood glucose monitoring
~medications as needed per California Diabetes and Pregnancy established protocol
~growth ultrasounds
~antenatal testing"
11416421|NCT01926457|Active Comparator|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation
~diabetes education
~blood glucose monitoring
~medications as needed per California Diabetes and Pregnancy established protocol
~growth ultrasounds
~antenatal testing"
11416422|NCT01926444|Experimental|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
11416423|NCT01926444|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
11416424|NCT01926444|Experimental|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
11416425|NCT01926444|Placebo Comparator|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
11416426|NCT01926431|Experimental|Exercise|60 minutes of high intensity treadmill running
11416427|NCT01926431|Experimental|Rest|60 minutes of seated rest (control trial)
11416428|NCT01926418|No Intervention|Control|The control group receives the TPB questionnaires but receives no intervention
11416429|NCT01926418|Experimental|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
11416430|NCT01926418|Experimental|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
11416431|NCT01926405|Other|Subjects with narcolepsy or with idiopathic hypersomnia|
11416432|NCT01926405|Other|Control patients with no sleeping disorder|
11416433|NCT01926392|Experimental|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
11416434|NCT01926392|Active Comparator|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
11416435|NCT01926379|Experimental|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
11416436|NCT01926379|Other|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
11416437|NCT01926366|Experimental|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
11416438|NCT01926366|Placebo Comparator|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
11416439|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
11416440|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
11416441|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
11416442|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
11416443|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
11416444|NCT01926327|Active Comparator|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
11416445|NCT01926327|Placebo Comparator|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
11416446|NCT01926314|Experimental|device|Patients in this group will be offered pelvic floor muscle rehabilitation program using PHENIX Neuromuscular Stimulation Therapy System device. The participants will start therapy once a week 42 days after delivery, and last 8 weeks.
11416447|NCT01926314|Active Comparator|usual home care without device|Patients in this group will receive usual home care without device.
11416448|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
11416449|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
11416450|NCT01926288|Other|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
11416527|NCT01925703|Experimental|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
11416528|NCT01925690|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
11416451|NCT01926288|Other|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .
~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
11416452|NCT01926275|Experimental|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
11416453|NCT01926275|Active Comparator|NPPV|noninvasive positive pressure ventilation
11416454|NCT01926275|Active Comparator|IMT|inspiratory muscle training
11416455|NCT01926275|Placebo Comparator|LTOT|Long time oxygen therapy
11416456|NCT01926262|Experimental|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
11416457|NCT01926262|No Intervention|Reference group|No Specific Strength Training
11416458|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.
~300 participants with an isolated cognitive complaint and an age of 60 years or more."
11416459|NCT01926236|Active Comparator|Arm A: Active symptom control (ASC)|Active Symptom Control
11416460|NCT01926236|Experimental|Arm B: ASC with OxMdG chemotherapy|Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU)
11416461|NCT01926223|Experimental|Home visiting Group|
11416462|NCT01926223|No Intervention|Control Group|
11416463|NCT01926210|Experimental|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
11416464|NCT01926210|Active Comparator|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
11416465|NCT01926197|Active Comparator|mFFX|mFOLFIRINOX
11416466|NCT01926197|Experimental|mFFX+SBRT|mFOLFIRINOX + SBRT
11416467|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
11416468|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
11416469|NCT01926171|Experimental|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
11416470|NCT01926158|Experimental|Denosumab|Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery
11416471|NCT01926158|Placebo Comparator|Placebo|Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery
11416472|NCT01926132|Experimental|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
11416473|NCT01926132|Active Comparator|Normal Saline 150ml|Normal Saline 150ml, covered bottle
11416474|NCT01926119|Experimental|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
11416475|NCT01926106|Experimental|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
11416476|NCT01926106|Active Comparator|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
11416477|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
11416478|NCT01926080|No Intervention|Standard Bereavement Care|Those randomized to control group (no DVD) Standard Bereavement Care Arm receive the bereavement materials given to families as standard-practice of care in the NICU at SLCH following the death of an infant
11416479|NCT01926054|Active Comparator|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
11416480|NCT01926054|Active Comparator|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
11416481|NCT01926041|Experimental|Intervention|Varenicline + individualized counseling
11416482|NCT01926041|No Intervention|Control|Usual care
11416483|NCT01926028|Experimental|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
11416484|NCT01926028|Experimental|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
11416485|NCT01926028|Placebo Comparator|Placebo|Placebo: aluminum hydroxide adjuvant
11416486|NCT01926015|Experimental|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
11416487|NCT01926015|Active Comparator|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
11416488|NCT01926002|Experimental|Low-Dose MK-8351|Low-dose MK-8351 administered as single inhaled dose.
11416489|NCT01926002|Experimental|High-Dose MK-8351|High-dose MK-8351 administered as a single inhaled dose.
11416491|NCT01925989|Experimental|Insulin Peglispro/Insulin Glargine|Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
11416492|NCT01925989|Active Comparator|Insulin Glargine/Insulin Peglispro|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin. Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen.
11416493|NCT01925989|No Intervention|Control|Control Arm. Untreated healthy participants.
11416494|NCT01925976|Other|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
11416495|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
11416496|NCT01925950|Placebo Comparator|Placebo|Control
11416497|NCT01925950|Experimental|orBec|Investigational drug
11416498|NCT01925937|Experimental|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
11416499|NCT01925937|Active Comparator|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
11416500|NCT01925924|Experimental|Resin-modified glass ionomer cement|Resin-modified glass ionomer cement is used to attach the fixed orthodontic brackets (brace) to the teeth.
11416501|NCT01925924|Active Comparator|Composite resin|Composite resin is used to attach fixed orthodontic brackets (brace)to the teeth.
11416502|NCT01925898|Experimental|Ketamine|Oral ketamine
11416503|NCT01925898|Active Comparator|Midazolam|Oral Midazolam
11416504|NCT01925885|Active Comparator|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
11416505|NCT01925885|Experimental|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
11416506|NCT01925859|Experimental|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
11416507|NCT01925833|Experimental|Both insertion and withdrawal|
11416508|NCT01925833|Active Comparator|Only withdrawal|
11416509|NCT01925820|Experimental|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
11416510|NCT01925820|Active Comparator|Arm 2|Entecavir daily for 144 weeks.
11416511|NCT01925820|Active Comparator|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
11416512|NCT01925807|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
11416513|NCT01925794|Experimental|COBRA PzF Stent|
11416514|NCT01925781|Experimental|e-Cigarette|STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
11416515|NCT01925781|Active Comparator|Nicotine polacrilex|Nicotine Replacement gum
11416516|NCT01925768|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
11416517|NCT01925768|Placebo Comparator|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
11416518|NCT01925755||Group 1|
11416519|NCT01925742|Experimental|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
11416520|NCT01925742|Experimental|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
11416521|NCT01925729|Experimental|ragweed|ragweed -- 1000PNU intranasal spray
11416522|NCT01925729|Experimental|histamine|5 mg intranasal spray
11416523|NCT01925729|Experimental|pseudoephedrine|pseudoephedrine -- 60 mg orally
11416524|NCT01925729|Experimental|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
11416525|NCT01925716|Experimental|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
11416526|NCT01925716|Experimental|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
11416559|NCT01925482|Other|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
11416945|NCT01923116|Experimental|HPV-16 vaccine|
11416529|NCT01925690|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
11416530|NCT01925677|Experimental|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
11416531|NCT01925664|Experimental|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
11416532|NCT01925664|No Intervention|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
11416533|NCT01925651|Other|Low Risk - No bolus|No Bolus
11416534|NCT01925651|Other|Low- Risk Alternate Bolus|Alternate Bolus
11416535|NCT01925651|Other|High Risk - Alternate Bolus|Alternate Bolus
11416536|NCT01925651|Other|High Risk - Continuous bolus|Continuous bolus
11416537|NCT01925638|Experimental|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
11416538|NCT01925625|No Intervention|Control|participants monitored for 10 years for lung cancer incidence.
11416539|NCT01925625|Active Comparator|Early CDT Lung Test|Early CDT lung blood test
11416540|NCT01925612|Experimental|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
11416541|NCT01925612|Experimental|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
11416542|NCT01925612|Experimental|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone
~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
11416543|NCT01925612|Active Comparator|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
11416544|NCT01925612|Experimental|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone
~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.
~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
11416545|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:
~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.
~Part 2:
~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.
~Part 3:
~Adjuvant Bevacizumab and Optune"
11416546|NCT01925560|Experimental|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
11416547|NCT01925560|Experimental|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
11416548|NCT01925560|Experimental|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
11416549|NCT01925547|Experimental|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
11416550|NCT01925547|Placebo Comparator|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
11416551|NCT01925534|Experimental|Optiflow|High-flow humidified nasal oxygen delivery system
11416552|NCT01925534|Active Comparator|Oxygen therapy|Standard oxygen therapy
11416553|NCT01925521|Experimental|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
11416554|NCT01925521|Placebo Comparator|Part1 : Placebo of OPS-2071|Single dose, Placebo
11416555|NCT01925521|Experimental|Part2 : OPS-2071|Multiple dose
11416556|NCT01925521|Placebo Comparator|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
11416557|NCT01925495|Experimental|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
11416558|NCT01925482|Other|Group 1 -- no history of otitis media|no history of otitis media
11416560|NCT01925469|Experimental|Benzocaine|Benzocaine spray (14%), an FDA approved drug, will be used to assess whether this provides additional pain relief at time of hysterosalpingogram.
11416561|NCT01925469|Placebo Comparator|Saline spray|A saline placebo spray will be used in the placebo group.
11416562|NCT01925456|Other|Toviaz|Patients willingness to take Toviaz 4mg and 8mg
11416563|NCT01925443|Experimental|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
11416564|NCT01925443|No Intervention|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
11416565|NCT01925443|Experimental|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
11416566|NCT01925430||Comparative product|A device which monitors sleep/wake states
11416567|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
11416568|NCT01925417|Experimental|RBX2660 (microbiota suspension)|enema-based delivery of RBX2660
11416569|NCT01925404|Experimental|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
11416570|NCT01925404|Experimental|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
11416571|NCT01925404|Experimental|Combined arm|We will offer free classes and the frequent user program at the park
11416572|NCT01925404|No Intervention|Control|Business as usual, no special physical activity programs offered
11416573|NCT01925391|Active Comparator|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
11416574|NCT01925391|Active Comparator|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
11416575|NCT01925378|Experimental|Nelfinavir|This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia
11416576|NCT01925365|Experimental|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
11416577|NCT01925365|Placebo Comparator|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
11416578|NCT01925352|Experimental|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
11416579|NCT01925339|Experimental|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
11416580|NCT01925339|Experimental|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
11416581|NCT01925313|Experimental|CJ-30044|
11416582|NCT01925313|Active Comparator|TALION TAB. 10mg|
11416583|NCT01925300|Experimental|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd|Single administration : 6 days, per oral
11416584|NCT01925300|Experimental|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd|Single administration : 6 days, per oral
11416585|NCT01925300|Experimental|Concor 5mg 2T and Crestor 20 mg 1Tab, qd|Combination administration : 6 days, per oral
11416586|NCT01925287|Active Comparator|Native curcumin powder|500 mg curcumin as native powder
11416587|NCT01925287|Experimental|Micronized curcumin powder|500 mg curcumin as micronized powder
11416588|NCT01925287|Experimental|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
11416589|NCT01925274|Experimental|Arm A|PF-05212384 plus Irinotecan
11416590|NCT01925274|Active Comparator|Arm B|Cetuximab plus Irinotecan
11416591|NCT01925261|Placebo Comparator|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
11416592|NCT01925261|Placebo Comparator|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
11416593|NCT01925261|Placebo Comparator|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
11416594|NCT01925261|Placebo Comparator|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
11416595|NCT01925261|Placebo Comparator|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
11416596|NCT01925248|Active Comparator|Whey protein group|Patients will be randomized to receive whey protein
11416597|NCT01925248|Placebo Comparator|Placebo group|Patients will be randomized to receive placebo
11416598|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
11416599|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
11416600|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
11416601|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
11416602|NCT01925222||Control-vaccinated infant|
11416603|NCT01925222||PCV-vaccinated child, catch-up schedule|
11416604|NCT01925222||Control-vaccinated child, catch-up schedule|
11416605|NCT01925209|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
11416606|NCT01925209|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
11416607|NCT01925209|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
11416608|NCT01925209|Placebo Comparator|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
11416610|NCT01925183|Experimental|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
11416611|NCT01925183|Experimental|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
11416612|NCT01925170|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
11416613|NCT01925157|Experimental|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
11416614|NCT01925157|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
11416615|NCT01925157|Experimental|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
11416616|NCT01925157|Placebo Comparator|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
11416617|NCT01925144|Experimental|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
11416618|NCT01925144|Experimental|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
11416619|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin)|Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11416620|NCT01925118|Experimental|High-dose IL-2|
11416621|NCT01925105|Experimental|Optimization of treatment|Optimization of treatment of diseases and symptoms
11416622|NCT01925105|Placebo Comparator|Control|Treatment as usual
11416623|NCT01925092|Experimental|mifepristone|Daily doses of mifepristone over 84 days.
11416624|NCT01925079|Experimental|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
11416625|NCT01925079|Sham Comparator|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
11416626|NCT01925066|Experimental|Aerosolized Vancomycin|
11416627|NCT01925053|Placebo Comparator|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
11416628|NCT01925053|Active Comparator|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
11416629|NCT01925040|Experimental|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
11416630|NCT01925040|Active Comparator|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
11416631|NCT01925027|Experimental|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
11416632|NCT01925014|Experimental|Low-dose CT|Diagnostic CT with low-dose radiation
11416633|NCT01925014|Active Comparator|Standard-dose CT|Diagnostic CT with standard-dose radiation
11416634|NCT01925001|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
11416635|NCT01925001|Active Comparator|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
11416636|NCT01924988|Experimental|Prostatic Embolization|Therapeutic occlusion of the prostate arteries
11416637|NCT01924975|Active Comparator|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
11416638|NCT01924975|Active Comparator|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
11416639|NCT01924962|No Intervention|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
11416640|NCT01924962|Active Comparator|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
11416641|NCT01924949|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
11416642|NCT01924936|Placebo Comparator|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
11416710|NCT01924559|Active Comparator|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
11416643|NCT01924936|Experimental|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
11416644|NCT01924936|Experimental|Email + DBT program & Coach|"Caring Email + DBT online program & Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
11416645|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
11416646|NCT01924910|Placebo Comparator|Placebo Pill|Received identical pills that do not contain vitamin D. Blood levels of 25(OH)D determined at 10 days, 3 months, and 1 year following placebo dose.
11416647|NCT01924910|Active Comparator|Vitamin D|250,000 IU cholecalciferol as single, oral dose. Blood levels 25(OH)D measured at 10 days, 3 months, and 1 year following dose.
11416648|NCT01924897|Experimental|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.
~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
11416649|NCT01924897|No Intervention|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
11416650|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
11416651|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
11416652|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
11416653|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
11416654|NCT01924871|Active Comparator|Desflurane group|1.5 MAC desflurane until extubation
11416655|NCT01924871|Active Comparator|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
11416656|NCT01924858|Experimental|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of [18F] GSK2647544 and a dynamic PET scan. [18F]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of [18F]GSK2647544
11416657|NCT01924845|Experimental|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
11416658|NCT01924832|Experimental|BG00012 Part 1|BG00012 120 mg delivered to varying locations of the GI tract
11416659|NCT01924832|Experimental|BG00012 Part 2|BG00012 240 mg delivered to varying locations of the GI tract
11416660|NCT01924819|Experimental|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).
~OR epirubicin + oxaliplatin + capecitabine OR 3 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel
~5 weeks preoperative chemoradiotherapy.
~Gastric resection.
~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).
~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
11416661|NCT01924819|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).
~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel
~Gastric resection.
~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine) OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
11416662|NCT01924806|Active Comparator|WoundWand™ Debridement Device|Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
11416663|NCT01924806|Active Comparator|Standard of Care sharp debridement|Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
11416664|NCT01924793|Experimental|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.
~Dry Powder Inhaled Dose:
~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
11416711|NCT01924546|Experimental|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
11416712|NCT01924546|No Intervention|Control|No additional water provided during the day. Additional water provided at the end of the school day.
11416713|NCT01924533|Experimental|Olaparib+ paclitaxel|olaparib + paclitaxel
11416665|NCT01924793|Experimental|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.
~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
11416666|NCT01924780|Active Comparator|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
11416667|NCT01924780|Active Comparator|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
11416668|NCT01924780|Sham Comparator|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
11416669|NCT01924767|Experimental|BI 10773 (dose group 3)|multiple doses as tablet
11416670|NCT01924767|Experimental|BI 10773 (dose group 4)|multiple doses as tablet
11416671|NCT01924767|Experimental|BI 10773 (dose group 1)|multiple doses as tablet
11416672|NCT01924767|Experimental|BI 10773 (dose group 2)|multiple doses as tablet
11416673|NCT01924754||Group 1|HPV vaccination regime-standard 3-dose needle injection IM regimen
11416674|NCT01924754||Group II|HPV vaccination regime-3-dose needle-free (NFI) IM injection regimen
11416675|NCT01924754||Group III|HPV vaccination regime - 3-dose needle-free intradermal injection regimen
11416676|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
11416677|NCT01924728|Active Comparator|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
11416678|NCT01924728|Sham Comparator|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
11416679|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
11416680|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
11416681|NCT01924702|Active Comparator|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
11416682|NCT01924702|Sham Comparator|sham tDCS|Intensive language therapy with Sham-tDCS
11416683|NCT01924689|Experimental|Clostridium novyi-NT spores|
11416684|NCT01924676|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11416685|NCT01924676|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11416686|NCT01924676|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11416687|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM|
11416688|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
11416689|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM|
11416690|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
11416691|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM|
11416692|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
11416693|NCT01924637|Experimental|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
11416694|NCT01924637|Active Comparator|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
11416695|NCT01924624|Experimental|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
11416696|NCT01924624|Active Comparator|Control|No adjuvant Thalidomide treatment after curative hepatic resection
11416697|NCT01924611|Active Comparator|Control Group|Atraumatic Restorative Technique using cotton rolls.
11416698|NCT01924611|Experimental|Experimental Group|Atraumatic Restorative Technique using rubber dam.
11416699|NCT01924598|Experimental|DBS surgery|
11416700|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
11416701|NCT01924572|No Intervention|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
11416702|NCT01924572|Experimental|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
11416703|NCT01924572|Experimental|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
11416704|NCT01924572|Experimental|cord milking|provider milks the cord 5 times from placenta to infant
11416705|NCT01924559|Active Comparator|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
11416706|NCT01924559|Active Comparator|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
11416707|NCT01924559|Experimental|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
11416708|NCT01924559|Active Comparator|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
11416709|NCT01924559|Active Comparator|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
11416718|NCT01924507|Experimental|CPAP|Patients with apnea will be treated with CPAP during the night.
11416719|NCT01924507|No Intervention|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
11416720|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
11416721|NCT01924481|Experimental|low theobromine & low caffeine|Drink 1
11416722|NCT01924481|Experimental|low theobromine & high caffeine|Drink 2
11416723|NCT01924481|Experimental|high theobromine & low caffeine|Drink 3
11416724|NCT01924481|Active Comparator|no theobromine & high caffeine|Drink 4
11416725|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
11416726|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
11416727|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
11416728|NCT01924429|Experimental|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
11416729|NCT01924429|Experimental|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
11416730|NCT01924416|Experimental|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
11416731|NCT01924416|Active Comparator|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
11416732|NCT01924403|Experimental|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
11416733|NCT01924403|Experimental|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
11416734|NCT01924403|Experimental|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
11416735|NCT01924390|Active Comparator|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
11416736|NCT01924390|Experimental|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
11416737|NCT01924377|Other|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
11416738|NCT01924377|Experimental|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
11416739|NCT01924364|Experimental|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
11416740|NCT01924364|Sham Comparator|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
11416741|NCT01924351|Other|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
11416742|NCT01924338|Experimental|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
11416743|NCT01924338|Experimental|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
11416744|NCT01924338|Experimental|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
11416745|NCT01924338|Experimental|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale
~Procedures: dental cast creation, MRI scan, laser scan"
11416746|NCT01924325|Active Comparator|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
11416747|NCT01924325|Experimental|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
11416748|NCT01924325|Experimental|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
11416749|NCT01924312|Placebo Comparator|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
11416750|NCT01924312|Experimental|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
11416751|NCT01924299|Experimental|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.
~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
11416752|NCT01924299|Experimental|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.
~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
11416753|NCT01924286|Experimental|Prednisone|Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
11416754|NCT01924286|Placebo Comparator|Placebo|Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
11416755|NCT01924273|Other|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
11416756|NCT01924260|Experimental|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11416757|NCT01924247|Other|Interventional Arm|Interventional Arm
11416758|NCT01924247|Other|Control Arm|Control Arm: Standard treatment by family physician
11416759|NCT01924234|Active Comparator|morphine|Volunteers are given morphine injection
11416760|NCT01924234|Active Comparator|remifentanil|Volunteers are given remifentanil infusion
11416761|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
11416762|NCT01924208|Active Comparator|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
11416763|NCT01924208|Active Comparator|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
11416764|NCT01924208|Active Comparator|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
11416765|NCT01924208|No Intervention|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
11416766|NCT01924195|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11416767|NCT01924195|Placebo Comparator|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
11416768|NCT01924182|Other|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
11416769|NCT01924182|Other|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
11416770|NCT01924169|Experimental|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
11416771|NCT01924156|Experimental|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
11416772|NCT01924143|Experimental|TD-9855|
11416773|NCT01924130|Experimental|One Healthy Breakfast Program|Classroom feeding, nutrition education lessons, social marketing, and parent outreach.
11416774|NCT01924130|No Intervention|Control|Only receive assessments.
11416775|NCT01924117|No Intervention|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
11416776|NCT01924104|Active Comparator|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
11416777|NCT01924104|Active Comparator|Low dose aspirin|Low dose aspirin, 75mg/day, orally
11416778|NCT01924104|Active Comparator|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
11416779|NCT01924104|Placebo Comparator|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
11416780|NCT01924091|Experimental|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.
~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
11416781|NCT01924091|Experimental|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
11416782|NCT01924078|Experimental|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
11416783|NCT01924065|Active Comparator|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
11416784|NCT01924065|Active Comparator|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
11416785|NCT01924052|Active Comparator|Migraine patients with high genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
11416786|NCT01924052|Active Comparator|Migraine patients with low genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
11416787|NCT01924039|Experimental|Brief Motivational Enhancement Therapy|
11416788|NCT01924039|Other|treatment as usual|
11416789|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
11416790|NCT01924026||Unaffected Siblings|With normal Phe levels
11416791|NCT01924013|Placebo Comparator|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)
~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
11416946|NCT01923090|Experimental|Finasteride|Finasteride treatment 5mg for 3 weeks
11416792|NCT01924013|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
11416793|NCT01924013|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
11416794|NCT01924013|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
11416795|NCT01924013|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
11416796|NCT01924000|Experimental|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
11416797|NCT01924000|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
11416798|NCT01923987|Experimental|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
11416799|NCT01923974|Placebo Comparator|Placebo|IV formulation
11416800|NCT01923974|Active Comparator|Melatonin 10 mg|IV formulation, Melatonin 10 mg
11416801|NCT01923974|Active Comparator|Melatonin 100 mg|IV formulation, Melatonin 100 mg
11416802|NCT01923961|Experimental|HDF NaCl, Then HD, Then Standard Pre-HDF|Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
11416803|NCT01923961|Experimental|HD, Then Standard Pre-HDF, Then HDF NaCl|Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
11416804|NCT01923961|Experimental|Standard Pre-HDF, Then HDF NaCl, Then HD|Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
11416805|NCT01923948|Active Comparator|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
11416806|NCT01923948|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose
11416807|NCT01923935|Experimental|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)"
11416808|NCT01923922|Other|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
11416809|NCT01923909|Active Comparator|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
11416810|NCT01923909|Experimental|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
11416811|NCT01923896|Experimental|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
11416812|NCT01923896|Active Comparator|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
11416813|NCT01923883|Active Comparator|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
11416814|NCT01923883|Experimental|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
11416815|NCT01923870|Experimental|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m^2 with moderate hepatic impairment (Child-Pugh Class B)
11416816|NCT01923870|Experimental|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m^2
11416817|NCT01923857|Experimental|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
11416818|NCT01923857|Experimental|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
11416819|NCT01923857|Experimental|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
11416820|NCT01923857|Experimental|Severe renal impairment|
11416821|NCT01923844|Experimental|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
11416822|NCT01923844|Experimental|beractant|preterm infants who received beractant for respiratory distress syndrome
11416823|NCT01923844|No Intervention|Control|Preterm infants without respiratory distress syndrome
11416824|NCT01923831|Experimental|Magnesium group|
11416825|NCT01923831|Active Comparator|Dexamethasone group|
11416826|NCT01923818|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo rivaroxaban from day 1 to day 30
11416827|NCT01923818|Experimental|Rivaroxaban 5mg|Receiving a 5-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
11416828|NCT01923818|Experimental|rivaroxaban 10mg|Receiving a 10-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
11416829|NCT01923805|Experimental|Treatment Group|Vitagel
11416830|NCT01923805|No Intervention|Control|Standard of care for surgical hemostasis.
11416831|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
11416832|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
11416833|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
11416834|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
11416947|NCT01923090|Experimental|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
11416835|NCT01923766|Experimental|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
11416836|NCT01923753|Experimental|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):
~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
11416837|NCT01923753|Active Comparator|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):
~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
11416838|NCT01923753|Sham Comparator|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):
~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
11416839|NCT01923740|Experimental|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
11416840|NCT01923740|Active Comparator|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
11416841|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
11416842|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
11416843|NCT01923701|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
11416844|NCT01923701|No Intervention|Monitoring|This group receives standard care only.
11416845|NCT01923688|Experimental|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
11416846|NCT01923688|No Intervention|control-no intervention|
11416847|NCT01923675|Experimental|color blocking tint|Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
11416848|NCT01923675|Other|holographic diffuser|Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
11416849|NCT01923675|Other|diffuser & color blocking tint|Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
11416850|NCT01923675|Other|holographic diffuser and neutral tint|Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
11416851|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
11416852|NCT01923649|Experimental|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
11416853|NCT01923649|Placebo Comparator|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
11416854|NCT01923636|Other|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
11416855|NCT01923623|Experimental|Block|Popliteal and saphenous Block with Ropivacaine
11416856|NCT01923623|Placebo Comparator|NaCl|
11416857|NCT01923610|Experimental|Main|MVA HIV-B
11416858|NCT01923597|Active Comparator|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
11416859|NCT01923597|Placebo Comparator|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
11416860|NCT01923584|Active Comparator|EPI-743 400mg|EPI-743 at a dose of 400 mg three times daily
11416861|NCT01923584|Active Comparator|EPI-743 200mg|EPI-743 at a dose of 200 mg three times daily
11416862|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
11416863|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
11416864|NCT01923558|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
11416865|NCT01923558|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
11416866|NCT01923545|Experimental|DA-3031 3.6mg|PEG-G-CSF
11416867|NCT01923545|Experimental|DA-3031 6mg|PEG-G-CSF
11416868|NCT01923545|Active Comparator|Leucostim®|G-CSF
11416869|NCT01923519|Experimental|allergic rhinitis|
11416870|NCT01923519|Experimental|allergic rhinitis and asthma|
11416871|NCT01923519|Experimental|witnesses|
11416872|NCT01923506|Experimental|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
11416873|NCT01923493|Active Comparator|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
11416874|NCT01923493|Experimental|tuina|tuina treatment
11416875|NCT01923480|Experimental|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
11416876|NCT01923480|Experimental|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
11416877|NCT01923480|Experimental|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
11416878|NCT01923467|Experimental|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
11416879|NCT01923454|Experimental|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.
~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.
~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
11416880|NCT01923441||Highschool athletes|
11416881|NCT01923441||midschool athletes|
11416882|NCT01923428|Experimental|5 mg BID|AZD1722
11416883|NCT01923428|Experimental|20 mg BID|AZD1722
11416884|NCT01923428|Experimental|50 mg BID|AZD1722
11416885|NCT01923428|Placebo Comparator|Placebo|
11416886|NCT01923415||Group 1: SLE|>=10 participants with systemic lupus erythematosus (SLE)
11416887|NCT01923415||Group 2: DLE|>=10 participants with discoid lupus erythematosus (DLE)
11416888|NCT01923415||Group 3: SCLE|>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
11416889|NCT01923402||Exclusive cigarette smokers|
11416890|NCT01923402||Exclusive moist snuff consumers|
11416891|NCT01923402||Non-tobacco consumers|
11416892|NCT01923389|Placebo Comparator|Placebo|
11416893|NCT01923389|Experimental|100 mg PF-05231023|
11416894|NCT01923376|Other|Lactulose|per standard of care
11416895|NCT01923376|Active Comparator|polyethylene glycol 3350 (Golytely)|
11416896|NCT01923363|Experimental|Standard Dose to High Dose Piperacillin/Tazobactam|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
11416897|NCT01923350|Experimental|Weight Reduction Intervention|
11416898|NCT01923350|Active Comparator|Weight Reduction Control Arm|
11416899|NCT01923350|Active Comparator|Tested for diabetes|
11416900|NCT01923350|Active Comparator|Not tested for diabetes|
11416901|NCT01923337|Experimental|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11416902|NCT01923324|Experimental|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
11416903|NCT01923324|Active Comparator|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
11416904|NCT01923311|Experimental|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.
~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
11416905|NCT01923311|Experimental|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA > 1,000 copies/mL can continue after Week 48.
~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
11416906|NCT01923311|Experimental|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.
~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
11416907|NCT01923311|Experimental|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.
~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
11416908|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
11416948|NCT01923077|Placebo Comparator|Conventional|Conventional treatment with simvastatin
11418157|NCT01914952|Active Comparator|HMB free acid (oral not in gelcap or water)|
11416909|NCT01923285|Experimental|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
11416910|NCT01923285|Active Comparator|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
11416911|NCT01923272|Sham Comparator|Sham Device|inactive AlphaCore device
11416912|NCT01923272|Active Comparator|AlphaCore|Active AlphaCore device
11416913|NCT01923259|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
11416914|NCT01923259|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
11416915|NCT01923246|Experimental|Single WEB intervention|Web intervention recieved once.
11416916|NCT01923246|Experimental|Repeated WEB intervention|Web intervention recieved twice.
11416917|NCT01923246|Experimental|Single IVR intervention|IVR intervention recieved once
11416918|NCT01923246|Experimental|Repeated IVR intervention|IVR intervention recieved twice
11416919|NCT01923246|No Intervention|Control group|Untreated Control Group.
11416920|NCT01923233|Experimental|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
11416921|NCT01923220|Experimental|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
11416922|NCT01923220|Sham Comparator|Aloe Vera Jel|To be applied topically
11416923|NCT01923207|Experimental|DX-2930|DX-2930 administered by subcutaneous route
11416924|NCT01923207|Placebo Comparator|placebo|inactive formulation of DX-2930
11416925|NCT01923194|Experimental|Test Group|
11416926|NCT01923194|Active Comparator|Comparator Group|
11416927|NCT01923181|Experimental|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416928|NCT01923181|Experimental|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416929|NCT01923181|Experimental|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416930|NCT01923181|Experimental|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416931|NCT01923181|Experimental|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.
~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
11416932|NCT01923181|Experimental|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416933|NCT01923181|Experimental|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.
~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
11416934|NCT01923181|Placebo Comparator|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416935|NCT01923181|Active Comparator|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
11416936|NCT01923168|Experimental|Alpelisib + Letrozole|Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
11416937|NCT01923168|Experimental|Buparlisib + Letrozole|Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
11416938|NCT01923168|Placebo Comparator|Placebo + Letrozole|Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
11416939|NCT01923155|Active Comparator|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
11416940|NCT01923155|Active Comparator|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
11416941|NCT01923142|Experimental|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
11416942|NCT01923142|Placebo Comparator|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
11416943|NCT01923129|Experimental|24 hour postop catheter removal|group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
11416944|NCT01923129|No Intervention|72 hour postoperative catheter removal|catheter removed on postoperative day 3 (72 hours postoperatively)
11416949|NCT01923077|Active Comparator|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
11416950|NCT01923064|Active Comparator|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
11416951|NCT01923064|Experimental|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
11416952|NCT01923038|Active Comparator|Patients ventilated with zero end expiratory pressure (ZEEP)|patients undergoing gynecologic laparoscopic surgery ventilated at zero end expiratory pressure
11416953|NCT01923038|Active Comparator|Patients ventilated with positive end expiratory pressure|patients undergoing gynecologic laparoscopic surgery ventilated at PEEP
11416954|NCT01923038|Active Comparator|recruitment plus PEEP|patients undergoing gynecologic laparoscopic surgery undergoing recruitment plus PEEP
11416955|NCT01923025|Experimental|RO5545965|
11416956|NCT01923012|Experimental|Vitamin K2|
11416957|NCT01922999|Active Comparator|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
11416958|NCT01922999|Active Comparator|Melatonin|comparison of melatonin 1mg or melatonin 3mg
11416959|NCT01922986|Experimental|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
11416960|NCT01922986|Sham Comparator|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
11416961|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
11416962|NCT01922960|Other|micro-imaging|"Sublingual or subconjunctival micro-imaging of the microcirculation taken for 3 minute intervals at certain timepoints.
~Timepoints for burn/trauma subjects: Day0, Day1,Day2,Day6 & Day7 Timepoints for general surgery population: post-induction, prior to resection, after resection,& closing of surgical wound."
11416963|NCT01922947|Active Comparator|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
11416964|NCT01922947|Sham Comparator|Health Counseling|
11416965|NCT01922934|Experimental|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
11416966|NCT01922934|No Intervention|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
11416967|NCT01922921|Active Comparator|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
11416968|NCT01922921|Experimental|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
11416969|NCT01922908|Active Comparator|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
11416970|NCT01922908|Placebo Comparator|SHAM infusion|Infusion of normal saline placebo
11416971|NCT01922895|Placebo Comparator|Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
11416972|NCT01922895|Active Comparator|Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
11416973|NCT01922882|Experimental|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:
~family engagement, personal preparation, disclosure practice using intervention materials
~health promotion training and a mother-child visit
~play-for-communication and custody care planning"
11416974|NCT01922882|No Intervention|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.
~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.
~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
11416975|NCT01922869|Experimental|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
11416976|NCT01922856|Experimental|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.
~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
11416977|NCT01922856|Experimental|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
11416978|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
11416979|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
11417021|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
11416980|NCT01922830|Experimental|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).
~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
11416981|NCT01922830|Placebo Comparator|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).
~The placebo supplementation is identical-looking to the Bio-25 supplement."
11416982|NCT01922817|Active Comparator|Saxagliptin|5mg once daily in addition to insulin therapy
11416983|NCT01922817|Placebo Comparator|Placebo|Crossover Placebo once daily
11416984|NCT01922804|Experimental|K2 vitamin|K2 vitamin 375 microgram a day for 3 years
11416985|NCT01922804|Placebo Comparator|placebo|1 tablet a day for 3 years
11416986|NCT01922791|Active Comparator|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
11416987|NCT01922791|Active Comparator|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
11416988|NCT01922791|Active Comparator|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
11416989|NCT01922791|Placebo Comparator|Placebo|Comparison of probiotics, fish oil and their combination to placebo
11416990|NCT01922778|Experimental|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.
~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
11416991|NCT01922765|Experimental|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
11416992|NCT01922765|Experimental|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
11416993|NCT01922765|Experimental|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
11416994|NCT01922765|Experimental|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
11416995|NCT01922752|Experimental|CEP-37440|
11416996|NCT01922739|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
11416997|NCT01922713|Placebo Comparator|white maize|white maize and a corn oil capsule
11416998|NCT01922713|Experimental|orange maize|orange maize and a corn oil capsule
11416999|NCT01922713|Active Comparator|vitamin A|white maize and a vitamin A capsule
11417000|NCT01922687|Experimental|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
11417001|NCT01922687|Active Comparator|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
11417002|NCT01922674|No Intervention|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
11417003|NCT01922674|Active Comparator|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
11417004|NCT01922661|Experimental|Cohort 1|Dose 1 of REGN1908-1909 or placebo
11417005|NCT01922661|Experimental|Cohort 2|Dose 2 of REGN1908-1909 or placebo
11417006|NCT01922661|Experimental|Cohort 3|Dose 3 of REGN1908-1909 or placebo
11417007|NCT01922648||2-4 months|Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
11417008|NCT01922648||6 - 12 months|Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
11417009|NCT01922648||3 - 6 years|Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
11417010|NCT01922635|Other|1|
11417011|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
11417012|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
11417013|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
11417014|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
11417015|NCT01922596|Experimental|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
11417016|NCT01922596|Experimental|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
11417017|NCT01922583|Experimental|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
11417018|NCT01922570|Experimental|Dietary supplements:parenteral nutrition|supplemental parenteral nutrition and enteral nutrition in case of failure (intake below 60% of energy needs) of enteral nutrition by day 3 after admission in the ICU or enteral nutrition only.
11417019|NCT01922557||NICOM|
11417020|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
11417022|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
11417023|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
11417024|NCT01922518|Active Comparator|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
11417025|NCT01922518|Active Comparator|Apex pacing group|Put RV lead around the apex
11417026|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
11417027|NCT01922492|Experimental|Autologous islet transplantation|Autologous islet transplantation arm: autologous islet transplantation
11417028|NCT01922492|Active Comparator|Oral anti-diabetic drugs|Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
11417029|NCT01922479|Experimental|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
11417030|NCT01922479|Active Comparator|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
11417031|NCT01922466|Experimental|Bee Venom Acupuncture|
11417032|NCT01922466|Experimental|Loxoprofen|
11417033|NCT01922466|Experimental|EWCT : Bee Venom Acupucture and Loxoprofen|
11417034|NCT01922453|Experimental|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
11417035|NCT01922453|No Intervention|no music and sound|
11417036|NCT01922440||Chronic Hypoparathyroidism|A rare disease with a duration of longer than 6 months characterized by insufficient parathyroid hormone (PTH) secretion, which can result in hypocalcemia, hyperphosphatemia, and associated clinical findings.
11417037|NCT01922414|Active Comparator|Laser|Patients will undergo Laser lithotripsy
11417038|NCT01922414|Active Comparator|Ultrasonic|Patients will undergo ultrasonic lithotripsy
11417039|NCT01922401|Experimental|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
11417040|NCT01922388||Early Motor Complication|This group is composed of PD patients with motor complications of 3 years or less. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
11417041|NCT01922388||Late Motor Complication|This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
11417042|NCT01922375|Experimental|Naftopidil dose 2|PO administration
11417043|NCT01922375|Placebo Comparator|Placebo|PO administration
11417044|NCT01922375|Experimental|Naftopidil dose 1|PO administration
11417045|NCT01922362|Experimental|Negative pressure drainage system|Negative pressure drainage system
11417046|NCT01922362|Active Comparator|Indirect wet dressing group|Indirect wet dressing
11417047|NCT01922349|Placebo Comparator|Placebo (Multiple dose)|Placebo
11417048|NCT01922349|Experimental|Dose 1, Single dose|Low dose
11417049|NCT01922349|Experimental|Dose 2, Single dose|Medium dose
11417050|NCT01922349|Experimental|Dose 3, Single dose|High dose
11417051|NCT01922349|Experimental|Dose 4, Multiple dose|Low dose
11417052|NCT01922349|Experimental|Dose 5, Multiple dose|Medium dose
11417053|NCT01922349|Experimental|Dose 6, Multiple dose|High dose
11417054|NCT01922349|Placebo Comparator|Placebo (Single dose)|Placebo
11417055|NCT01922336|Experimental|SB2|SB2 (Study drug)
11417056|NCT01922336|Active Comparator|EU Remicade|EU sourced Remicade (Reference drug)
11417057|NCT01922336|Active Comparator|US Remicade|US sourced Remicade (Reference drug)
11417058|NCT01922310|Other|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
11417059|NCT01922297|Experimental|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
11417060|NCT01922297|Other|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
11417061|NCT01922284|Experimental|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.
~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
11417095|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
11417096|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
11417097|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
11417098|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
11417062|NCT01922284|Active Comparator|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.
~At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
11417063|NCT01922271|Experimental|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
11417064|NCT01922271|Experimental|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
11417065|NCT01922258|Placebo Comparator|Placebo|Matching Placebo Once-Daily
11417066|NCT01922258|Experimental|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
11417067|NCT01922245|Experimental|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
11417068|NCT01922219|Other|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
11417069|NCT01922206|No Intervention|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
11417070|NCT01922206|Experimental|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
11417071|NCT01922193|Experimental|Test Group|
11417072|NCT01922193|Active Comparator|Control Group|
11417073|NCT01922180||COPD Exacerbation|COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
11417074|NCT01922167|Experimental|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
11417075|NCT01922167|Placebo Comparator|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
11417076|NCT01922154|Experimental|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
11417077|NCT01922141|Experimental|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
11417078|NCT01922141|Experimental|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
11417079|NCT01922141|Active Comparator|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
11417080|NCT01922128|Active Comparator|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
11417081|NCT01922128|Placebo Comparator|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
11417082|NCT01922115|Active Comparator|TROSPIUM CHLORIDE|Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).
11417083|NCT01922115|Placebo Comparator|PLACEBO|Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).
11417084|NCT01922102|Experimental|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
11417085|NCT01922102|Experimental|Group II|0.5 mg ranibizumab driven by disease activity criteria
11417086|NCT01922102|Active Comparator|Group III|verteporfin PDT
11417087|NCT01922089|Experimental|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
11417088|NCT01922089|Experimental|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
11417089|NCT01922076|Experimental|Treatment (adavosertib, radiation therapy)|Patients undergo radiation therapy 5 days a week for 6 weeks (up to 30 fractions). Patients also receive adavosertib PO on days 1-5 of weeks 1, 3, and 5; days 1-5 of weeks 1, 3, and 5 AND days 1, 3, and 5 of weeks 2, 4, and 6; OR days 1-5 of weeks 1-6 depending on dose level assignment. Treatment continues in the absence of disease progression or unacceptable toxicity.
11417090|NCT01922063|Experimental|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
11417091|NCT01922063|Sham Comparator|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
11417092|NCT01922063|No Intervention|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
11417093|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
11417094|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
11417099|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
11417100|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
11417101|NCT01922037|Experimental|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
11417102|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
11417103|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
11417104|NCT01922011|Experimental|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to <18 years (7 mg/kg); age 7 years to < 12 years (9 mg/kg); age 24 months to <7 years (12 mg/kg); age 12 months to <24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
11417105|NCT01922011|Active Comparator|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
11417106|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
11417107|NCT01921985|Active Comparator|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
11417108|NCT01921985|Placebo Comparator|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
11417109|NCT01921972|Active Comparator|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
11417110|NCT01921972|Experimental|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
11417111|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
11417112|NCT01921959||Partners of no intervention women|Partners of women randomized to control
11417113|NCT01921946|Other|Part A|Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)
11417114|NCT01921946|Other|Part B|Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)
11417115|NCT01921933|Experimental|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
11417116|NCT01921920|Active Comparator|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
11417117|NCT01921920|Active Comparator|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
11417118|NCT01921920|Active Comparator|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
11417119|NCT01921920|Active Comparator|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
11417120|NCT01921907|Experimental|Active|topical treatment
11417121|NCT01921907|Placebo Comparator|Placebo|topical treatment
11417122|NCT01921894|Experimental|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
11417123|NCT01921894|Experimental|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
11417124|NCT01921894|Active Comparator|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
11417125|NCT01921881|Experimental|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:
~Without taking any St John's wort
~After 3 weeks pretreatment with St John's wort
~Minimum 6 weeks after last St John's wort ingestion"
11417126|NCT01921868|Experimental|Acetyl-L-Carnitine|Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
11417127|NCT01921855|Experimental|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
11417128|NCT01921855|Experimental|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
11417129|NCT01921855|Experimental|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
11417130|NCT01921855|Experimental|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
11417131|NCT01921842|Experimental|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
11417132|NCT01921842|Other|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
11417133|NCT01921829|No Intervention|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
11417134|NCT01921829|Experimental|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is < 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is > 5 L/day, diuretic regimen will be reduced.
11417135|NCT01921816|Other|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
11417136|NCT01921803|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
11417137|NCT01921803|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
11417138|NCT01921790|Experimental|Avastin+ GemAOD|Avastin+ GemAOD means Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone
11417139|NCT01921777|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
11417140|NCT01921777|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
11417141|NCT01921764|Experimental|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
11417142|NCT01921764|Active Comparator|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
11417143|NCT01921751|Experimental|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
11417144|NCT01921751|Experimental|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
11417145|NCT01921751|Active Comparator|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity [randomized to this arm after 3rd cycle and no progression]
11417146|NCT01921738|Experimental|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
11417147|NCT01921738|Experimental|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
11417148|NCT01921738|Placebo Comparator|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
11417149|NCT01921738|Placebo Comparator|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
11417150|NCT01921725|Experimental|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
11417151|NCT01921712|Experimental|PUR0200 low dose|PUR0200 low dose, single dose inhalation
11417152|NCT01921712|Experimental|PUR0200 mid dose|PUR0200 mid dose, single dose inhalation
11417153|NCT01921712|Experimental|PUR0200 high dose|PUR0200 high dose, single dose inhalation
11417154|NCT01921712|Placebo Comparator|Placebo|PUR0200 matched placebo, single dose, inhalation
11417155|NCT01921712|Active Comparator|Active Comparator|Active Comparator, single dose, inhalation
11417156|NCT01921699|Other|irrelevant|
11417157|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week
~AND, At least one of the following:
~Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)
~Abnormal pH index (pH less than 4 for greater than 6% of study)
~Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
11417158|NCT01921686||Eosinophilic Esophagitis (EoE)|"History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)
~Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy
~Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
11417159|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
11417160|NCT01921673|Experimental|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off
~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
11417161|NCT01921647|Experimental|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
11417162|NCT01921647|Experimental|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
11417163|NCT01921647|Experimental|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
11417164|NCT01921647|Active Comparator|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
11417165|NCT01921634|Other|Standard analysis|Standard pathological analysis currently used.
11417166|NCT01921634|Other|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
11417167|NCT01921621|No Intervention|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
11417168|NCT01921621|Active Comparator|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
11417240|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
11417241|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
11417169|NCT01921621|Experimental|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
11417170|NCT01921608|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
11417171|NCT01921595|Experimental|Valanced salt colloid group|
11417172|NCT01921595|Active Comparator|Valanced salt crystalloid group|
11417173|NCT01921582|Experimental|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)
~Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.
~Dosage form: tablet
~Dosage frequency: daily
~Duration: 12 weeks total"
11417174|NCT01921582|Active Comparator|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy
~12 individual 50-minute appointments over the course of up to 14 weeks
~According to Fairburn, Marcus, and Wilson (1993)"
11417175|NCT01921569|Experimental|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
11417176|NCT01921569|Placebo Comparator|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
11417177|NCT01921556|Active Comparator|QualiCCare education|"QualiCCareeducation is a training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
11417178|NCT01921556|No Intervention|usual care|The practices randomized to the control group apply care as usual
11417179|NCT01921543|Experimental|CI/BNST stimulation on|
11417180|NCT01921543|Experimental|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
11417181|NCT01921543|Experimental|ITP stimulation on|
11417182|NCT01921543|Experimental|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
11417183|NCT01921530|Active Comparator|Interbody Fusion|
11417184|NCT01921530|Active Comparator|Posterolateral Fusion|
11417185|NCT01921517|Experimental|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
11417186|NCT01921517|Placebo Comparator|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
11417187|NCT01921504|Experimental|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
11417188|NCT01921504|No Intervention|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
11417189|NCT01921491|Other|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
11417190|NCT01921491|Active Comparator|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
11417191|NCT01921491|Experimental|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
11417192|NCT01921478||Cohort|
11417193|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
11417194|NCT01921452|Experimental|POC TSH Kits + Third Generation TSH Kit|
11417195|NCT01921439|Active Comparator|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
11417196|NCT01921439|No Intervention|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
11417197|NCT01921426|Experimental|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
11417198|NCT01921400||HCV-infected mothers|in situ hybridization
11417199|NCT01921400||Uninfected mothers|in situ hybridization
11417200|NCT01921387|Experimental|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
11417201|NCT01921374|Experimental|sleep parameters|To assess the sleep parameters.
11417202|NCT01921374|Other|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
11417203|NCT01921374|Experimental|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
11417204|NCT01921374|Experimental|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
11417205|NCT01921374|Experimental|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
11417206|NCT01921361|Active Comparator|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
11417395|NCT01920048|Active Comparator|Optimal Medical Therapy alone|
11417207|NCT01921361|Active Comparator|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
11417208|NCT01921361|Placebo Comparator|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
11417209|NCT01921348|Experimental|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
11417210|NCT01921348|Sham Comparator|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
11417211|NCT01921335|Active Comparator|ARRY-380 Twice Daily Dosage|ARRY-380 will be 450mg orally twice-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg.ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
11417212|NCT01921335|Active Comparator|ARRY-380 Once Daily|ARRY-380 will be 750mg orally once-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg. ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
11417213|NCT01921322|Experimental|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
11417214|NCT01921322|Active Comparator|MDI|Multiple daily insulin injections used for treatment
11417215|NCT01921309|Experimental|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
11417216|NCT01921309|Active Comparator|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
11417217|NCT01921296|Experimental|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
11417218|NCT01921283|Experimental|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
11417219|NCT01921283|Active Comparator|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
11417220|NCT01921270|Experimental|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
11417221|NCT01921257|Experimental|Treatment|Cat-PAD and Placebo
11417222|NCT01921244|No Intervention|Usual Care|"Approximately 120 families will be asked to participate as usual care subjects and will complete surveys before and immediately after their visit, and approximately 3 months after the visit. These families will not receive the decision aid nor will their provider have been trained how to use the decision aid. All participating providers will have up to 10 usual care patients enrolled at baseline prior to allocation. During the trial, the control group [usual care providers] will have up to 10 additional patients enrolled for ongoing usual care data collection. After the trial is complete, the control group providers will cross over to the intervention arm."
11417223|NCT01921244|Experimental|Intervention|Approximately 80 families/patients with regularly scheduled clinic follow-up visits in the Division of Developmental and Behavioral Pediatrics (DDBP) at Cincinnati Childrens with providers trained on shared decision making will receive the decision aid prior to their index visit and complete surveys before and immediately after their visit, and approximately 3 months later.
11417224|NCT01921231|Experimental|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
11417225|NCT01921231|Active Comparator|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
11417226|NCT01921218|Experimental|Treatment|Belatacept (Nulojix) IV
11417227|NCT01921218|Active Comparator|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
11417228|NCT01921205|Experimental|Lacosamide|
11417229|NCT01921205|Placebo Comparator|Placebo|
11417230|NCT01921192|Active Comparator|Folic Acid, vit B6 and B12|
11417231|NCT01921192|Placebo Comparator|Sugar pill|
11417232|NCT01921179|Experimental|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
11417233|NCT01921179|Active Comparator|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
11417234|NCT01921166|Active Comparator|clomiphene plus gonadotropins|clomiphene plus gonadotropins
11417235|NCT01921166|Active Comparator|Leuprolide flare|Leuprolide flare
11417236|NCT01921153|Experimental|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
11417237|NCT01921153|Experimental|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
11417238|NCT01921140|Other|Fasted|Olaparib tablets following no breakfast
11417239|NCT01921140|Other|High-fat meal|Olaparib tablets after high-fat breakfast
11417242|NCT01921114|Active Comparator|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
11417243|NCT01921114|Active Comparator|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
11417244|NCT01921101|Other|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
11417245|NCT01921101|Other|control|participants will not receive intensive nutritional support from hospital admission to discharge
11417246|NCT01921088|Experimental|Contingent|Contingent RT-fMRI-NF of brain activity in the target region of interest
11417247|NCT01921088|Sham Comparator|Non-contingent|Sham RT-fMRI-NF of brain activity of previously recorded subject
11417248|NCT01921075||Volunteers|young (age<30), healthy, lean (BMI<25) volunteers
11417249|NCT01921062|No Intervention|Control|Patients allocated to the control group only receive standard treatment.
11417250|NCT01921062|Experimental|Motor imagery|Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.
11417251|NCT01921036|Experimental|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
11417252|NCT01921036|Active Comparator|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
11417253|NCT01921010|Active Comparator|Niaspan|Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
11417254|NCT01921010|Placebo Comparator|Control|patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
11417255|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
11417256|NCT01920984|Experimental|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
11417257|NCT01920984|No Intervention|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
11417258|NCT01920971|Active Comparator|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
11417259|NCT01920971|Placebo Comparator|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
11417260|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
11417261|NCT01920945|Experimental|OnabotulinumtoxinA|
11417262|NCT01920932|Experimental|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
11417263|NCT01920919|Experimental|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
11417264|NCT01920919|Placebo Comparator|Placebo|Placebo tablet, for 180 days
11417265|NCT01920906|Experimental|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
11417266|NCT01920893|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
11417267|NCT01920893|Experimental|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
11417268|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
11417269|NCT01920880||Healthy controls|Healthy controls
11417270|NCT01920867|Active Comparator|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
11417271|NCT01920867|Active Comparator|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
11417272|NCT01920867|Active Comparator|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
11417273|NCT01920854|Experimental|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
11417274|NCT01920854|Placebo Comparator|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
11417275|NCT01920841|Experimental|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
11417276|NCT01920841|Experimental|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
11417277|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
11417278|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
11417279|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
11417280|NCT01920802|Experimental|olanzapine|5mg BID olanzapine for up to 4 weeks
11417281|NCT01920802|Experimental|iloperidone|6mg BID iloperidone up to 4 weeks
11417282|NCT01920802|Placebo Comparator|placebo|BID placebo up to 4 weeks
11417283|NCT01920789|Experimental|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
11417284|NCT01920789|Active Comparator|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
11417285|NCT01920776|Experimental|Rutine treatment group, Ultrasound group|
11417286|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
11417287|NCT01920750|Experimental|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
11417288|NCT01920750|Experimental|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
11417289|NCT01920737|Experimental|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:
~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
11417290|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores < -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and stunting (HAZ < -2 SD).
11417291|NCT01920711|Experimental|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
11417292|NCT01920711|Active Comparator|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
11417293|NCT01920698|Experimental|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
11417294|NCT01920698|Other|Control|Patients randomized to the Control group will receive optimal therapy alone
11417295|NCT01920685|Experimental|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
11417296|NCT01920685|Other|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
11417297|NCT01920672|Experimental|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
11417298|NCT01920672|Active Comparator|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
11417299|NCT01920659|Experimental|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
11417300|NCT01920659|Experimental|REHIT|6 weeks of HIT, 3 times a week (20sec)
11417301|NCT01920659|No Intervention|control|control
11417302|NCT01920646|Experimental|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.
~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
11417303|NCT01920646|No Intervention|Control|normal school meal as daily meal (5 days/weeks) for 3 months
11417304|NCT01920633||People with Down syndrome|
11417305|NCT01920620|Experimental|Intervention Arm|Inpatient weight loss counseling Motivational interviewing and troubleshooting via phone
11417306|NCT01920620|No Intervention|Usual Care Arm|Participants in the usual care group were not provided with any specific instructions regarding weight loss, diet or exercise prior to discharge. Follow-up phone calls for usual care subject were used only to obtain weight and assess for changes in medications or health condition.
11417307|NCT01920607|Active Comparator|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
11417308|NCT01920607|Experimental|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
11417309|NCT01920594|Experimental|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
11417310|NCT01920594|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
11417311|NCT01920581||volunteers|
11417312|NCT01920568|Experimental|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
11417313|NCT01920568|Experimental|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
11417314|NCT01920555|Active Comparator|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
11417315|NCT01920555|Active Comparator|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
11417316|NCT01920555|Active Comparator|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
11417317|NCT01920555|Active Comparator|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
11417318|NCT01920555|Placebo Comparator|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
11417319|NCT01920542|Experimental|no dexmedetomidine|no administration of dexmedetomidine
11417320|NCT01920542|Active Comparator|dexmedetomidine|administration of 0.5ug/kg dexmedetomidine for 10 min and infusion of 0.5ug/kg/h of dexmedetomidine until weaning of cardiopulmonary bypass
11417321|NCT01920529|Experimental|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
11417322|NCT01920529|Placebo Comparator|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
11417323|NCT01920516||Melphalan|"Day +1:
~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg
~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).
~Day +30: The above procedure is repeated.
~Day +90: In case of response, a third administration following the above procedures will be repeated."
11417324|NCT01920503||doxorubicin|"Day +1:
~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.
~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
11417325|NCT01920490|Experimental|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
11417326|NCT01920490|Active Comparator|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
11417327|NCT01920477|Experimental|Ofatumumab|Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
11417328|NCT01920477|Placebo Comparator|Placebo|Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
11417329|NCT01920451|Experimental|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
11417330|NCT01920451|No Intervention|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
11417331|NCT01920438|Experimental|PEG|Percutaneous Endoscopic Gastrostomy
11417332|NCT01920438|Experimental|RIG|Radiologically-guided Insertion of Gastrostomy
11417333|NCT01920425|Other|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
11417334|NCT01920425|Other|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
11417335|NCT01920412|Experimental|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
11417336|NCT01920399|Placebo Comparator|Placebo|IV infusions of 0.9% normal saline
11417337|NCT01920399|Experimental|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
11417338|NCT01920386|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|1tab PO within 5hours from teeth extraction
11417339|NCT01920386|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|1tab PO within 5hours from teeth extraction and then 1tab more after 6hours
11417340|NCT01920373|Active Comparator|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
11417341|NCT01920373|Experimental|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
11417342|NCT01920360|Experimental|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
11417343|NCT01920360|Experimental|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
11417344|NCT01920360|Experimental|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
11417345|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
11417346|NCT01920334|Experimental|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
11417347|NCT01920334|Placebo Comparator|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
11417348|NCT01920321|Experimental|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
11417349|NCT01920308||5 mm Bard LifeStent Vascular Stent|"The study population will be comprised of subjects who present with moderate lifestyle-limiting claudication to mild tissue loss (Rutherford Category 2-5) that are candidates for PTA and stenting.
~Subjects with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be considered for enrollment. The reference vessel diameter will be appropriate for treatment with available stent diameter of 5.0 mm (by visual estimate)."
11417350|NCT01920295|Experimental|Cryoballoon ablation|Cryoballoon ablation
11417351|NCT01920295|Active Comparator|Cryoballoon after medical therapy|Cryoballoon ablation
11417352|NCT01920295|Experimental|Cryoballoon as first-line therapy|Cryoballoon ablation
11417353|NCT01920295|Active Comparator|Cryoballoon after failed drug therapy|Cryoballoon ablation
11417354|NCT01920282|Active Comparator|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
11417355|NCT01920282|Active Comparator|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
11417356|NCT01920282|Experimental|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
11417357|NCT01920269|Active Comparator|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra-ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
11417358|NCT01920269|Active Comparator|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
11417396|NCT01920035|Experimental|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
11417397|NCT01920035|No Intervention|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
11417398|NCT01920022|Experimental|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
11417359|NCT01920269|Active Comparator|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
11417360|NCT01920256|Experimental|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
11417361|NCT01920256|Active Comparator|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
11417362|NCT01920243|Experimental|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
11417363|NCT01920243|No Intervention|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
11417364|NCT01920243|Experimental|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
11417365|NCT01920243|No Intervention|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
11417366|NCT01920230|Experimental|Mindfulness-ACT-intervention|Group meetings face-to-face and web-based program using principles of mindfulness and ACT.
11417367|NCT01920230|Experimental|Control|Control group, no intervention.
11417368|NCT01920217||normal control|
11417369|NCT01920217||Sepsis group|
11417370|NCT01920204|Experimental|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
11417371|NCT01920191|Experimental|IMA 950 and Poly ICLC|
11417372|NCT01920178|Active Comparator|PinPointe Foot Laser|Active laser
11417373|NCT01920178|Sham Comparator|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
11417374|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
11417375|NCT01920152|Experimental|Autologous PRP Hip Injection|Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
11417376|NCT01920152|Active Comparator|Hyaluronic Acid Hip Injection|Patients (n=40) randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
11417377|NCT01920139|Other|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
11417378|NCT01920126|Experimental|Sodium bicarbonate group|Sodium bicarbonate group
11417379|NCT01920126|Placebo Comparator|Saline group|Saline group
11417380|NCT01920113|Experimental|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
11417381|NCT01920113|Active Comparator|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
11417382|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
11417383|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
11417384|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
11417385|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).
~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
11417386|NCT01920087|Experimental|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
11417387|NCT01920087|Placebo Comparator|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
11417388|NCT01920074|Experimental|Rectiv|
11417389|NCT01920061|Experimental|Arm A|
11417390|NCT01920061|Experimental|Arm B|
11417391|NCT01920061|Experimental|Arm C|
11417392|NCT01920061|Experimental|Expansion Arm 1|
11417393|NCT01920061|Experimental|Expansion Arm 2|
11417394|NCT01920048|Experimental|Percutaneous Coronary Intervention and Optimal Medical Therapy|
11417399|NCT01920022|Active Comparator|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
11417400|NCT01920009|Active Comparator|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
11417401|NCT01920009|No Intervention|Controlgroup|patients in this group will receive usual care by pharmacists
11417402|NCT01919996|Experimental|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
11417403|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
11417404|NCT01919970|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
11417405|NCT01919970|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
11417406|NCT01919957|No Intervention|memory outcome|
11417407|NCT01919944|Experimental|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
11417408|NCT01919944|Experimental|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
11417409|NCT01919944|Experimental|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
11417410|NCT01919944|Placebo Comparator|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
11417411|NCT01919931||Candida Infection|Patients infected with Candida albicans
11417412|NCT01919931||No infection|Patients with no Candida albicans infection
11417413|NCT01919918|Other|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
11417414|NCT01919918|Other|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
11417415|NCT01919905|Active Comparator|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
11417416|NCT01919905|Placebo Comparator|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
11417417|NCT01919892|Experimental|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
11417418|NCT01919879|Experimental|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
11417419|NCT01919879|Active Comparator|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
11417420|NCT01919866|Experimental|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
11417421|NCT01919853|Experimental|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
11417422|NCT01919853|Active Comparator|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
11417423|NCT01919840|Active Comparator|Group C|• conventional protocol, volume replacement with massive bleeding.
11417424|NCT01919840|Experimental|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
11417425|NCT01919827|Experimental|MSC endobronchial infusion|
11417426|NCT01919814|Active Comparator|Appethyl™, then Placebo|Participants receive Appethyl™ liquid once four hours after breakfast. After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
11417427|NCT01919814|Placebo Comparator|Placebo, then Appethyl™|Participants receive the placebo drink once four hours after breakfast. After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
11417428|NCT01919801|Experimental|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
11417429|NCT01919801|Placebo Comparator|Placebo|Placebo will be administered as a single subcutaneous injection
11417430|NCT01919788|Placebo Comparator|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.
~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
11417431|NCT01919788|Experimental|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
11417432|NCT01919788|Experimental|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.
~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
11417433|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).
~Acinetobacter baumannii
~Staphylococcus aureus
~Klebsiella pneumonia
~Pseudomonas aeruginosa
~Enterococcus faecalis
~Enterococcus faecium"
11417434|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
11417435|NCT01919749|Other|treatment|recommended treatment
11417436|NCT01919736|Active Comparator|Moderate gait retraining|a moderate 7 degree toe-in modification
11417437|NCT01919736|Active Comparator|Mild gait retraining|A 2 degree toe-in gait retraining
11417438|NCT01919723|Active Comparator|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
11417439|NCT01919723|Active Comparator|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
11417440|NCT01919710|Experimental|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
11417441|NCT01919697|Experimental|Plecanatide 3.0 mg|Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
11417442|NCT01919697|Experimental|Plecanatide 6.0 mg|Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
11417443|NCT01919684|Active Comparator|Active|LGD-6972
11417444|NCT01919684|Placebo Comparator|Placebo (Captisol®)|Vehicle Control (Captisol®)
11417445|NCT01919671|Experimental|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
11417446|NCT01919671|Placebo Comparator|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
11417447|NCT01919658|Active Comparator|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
11417448|NCT01919658|Active Comparator|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
11417449|NCT01919645|Experimental|Combined Training Group|"Combined Training - (strength + aerobics).
~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.
~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
11417450|NCT01919645|Placebo Comparator|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
11417451|NCT01919632|Experimental|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
11417452|NCT01919619|Experimental|Treatment (lenalidomide and ipilimumab)|Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11417453|NCT01919606|Experimental|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
11417454|NCT01919606|Experimental|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
11417455|NCT01919593|Experimental|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
11417456|NCT01919593|Active Comparator|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
11417457|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.
~Subjects must:
~Should have a blood exam (20ml) before the surgery.
~Site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
11417458|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
11417459|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
11417460|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.
~Subjects must:
~Should have a blood exam (20ml) before the surgery.
~Site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
11417856|NCT01917006|Experimental|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
11417461|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
11417462|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.
~Subjects must:
~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
~Before the surgery site staff must:
~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
11417463|NCT01919554|Placebo Comparator|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
11417464|NCT01919554|Experimental|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
11417465|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
11417466|NCT01919528|Experimental|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
11417467|NCT01919515|Other|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
11417468|NCT01919502|Other|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
11417469|NCT01919489|Experimental|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
11417470|NCT01919489|Active Comparator|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
11417471|NCT01919476|Active Comparator|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
11417472|NCT01919476|Experimental|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
11417473|NCT01919463|No Intervention|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
11417474|NCT01919463|Experimental|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
11417475|NCT01919463|Experimental|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
11417476|NCT01919450|Active Comparator|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
11417477|NCT01919450|Active Comparator|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
11417478|NCT01919450|Active Comparator|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
11417479|NCT01919450|Active Comparator|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
11417480|NCT01919437|Experimental|Web-Enabled Cognitive Neuropsychological Evaluation System|
11417481|NCT01919424|Active Comparator|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
11417482|NCT01919424|Active Comparator|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse*II BAN nebulizer will be used to perform a methacholine challenge
11417483|NCT01919411|Experimental|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
11417484|NCT01919411|Placebo Comparator|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
11417485|NCT01919398|Experimental|LY2940680|"Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.
~Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met."
11417486|NCT01919385|Experimental|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
11417487|NCT01919372|Active Comparator|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
11417488|NCT01919372|Experimental|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
11417489|NCT01919359|Experimental|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
11417490|NCT01919359|Placebo Comparator|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2
~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
11417554|NCT01918917|Active Comparator|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
11417491|NCT01919346|Experimental|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
11417492|NCT01919346|Placebo Comparator|Normal Saline|Administered at same volume and time as Experimental arm
11417493|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
11417494|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
11417495|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
11417496|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
11417497|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
11417498|NCT01919307|Experimental|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
11417499|NCT01919294|Experimental|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
11417500|NCT01919281|Experimental|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
11417501|NCT01919281|Experimental|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
11417502|NCT01919281|No Intervention|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
11417503|NCT01919268|Experimental|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
11417504|NCT01919268|Active Comparator|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
11417505|NCT01919255|Active Comparator|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior]
11417506|NCT01919255|Active Comparator|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior]
11417507|NCT01919255|Active Comparator|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
11417508|NCT01919255|Active Comparator|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
11417509|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
11417510|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
11417511|NCT01919229|Active Comparator|Letrozole|Letrozole 2.5 mg alone once daily
11417512|NCT01919229|Experimental|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
11417513|NCT01919229|Experimental|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
11417514|NCT01919216|Active Comparator|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
11417515|NCT01919216|Placebo Comparator|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
11417516|NCT01919203|Experimental|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
11417517|NCT01919190|Active Comparator|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
11417518|NCT01919190|Sham Comparator|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
11417519|NCT01919177|Active Comparator|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
11417520|NCT01919177|Placebo Comparator|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
11417521|NCT01919164|Placebo Comparator|Placebo|Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
11417551|NCT01918956|Experimental|rush regimen of PURETHAL Birch|"Initial treatment:
~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)
~Maintenance treatment:
~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
11417522|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles|Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
11417523|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg- 4 Cycles|Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
11417524|NCT01919164|Experimental|Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
11417525|NCT01919164|Placebo Comparator|Sprifermin (AS902330) 100 mcg- 4 Cycles|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
11417526|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
11417527|NCT01919138||severe sepsis, septic shock|
11417528|NCT01919125|Experimental|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
11417529|NCT01919125|Experimental|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
11417530|NCT01919125|Experimental|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
11417531|NCT01919112|Experimental|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
11417532|NCT01919112|Active Comparator|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
11417533|NCT01919112|Sham Comparator|Sham Stimulation|Twice daily swallowing exercises only
11417534|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
11417535|NCT01919086|Experimental|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
11417536|NCT01919073|Experimental|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
11417537|NCT01919073|Active Comparator|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
11417538|NCT01919060||lesions in colon|
11417539|NCT01919060||lesions in extra-colon|
11417540|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
11417541|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
11417542|NCT01919008|Experimental|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet
~Days 3 to 6: Three FK949E low dose tablets
~Days 7 to 10: One FK949E high dose tablet"
11417543|NCT01919008|Experimental|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet
~Days 3 to 6: One FK949E high dose tablet
~Days 7 to 10: Three FK949E low dose tablets"
11417544|NCT01918995|Experimental|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
11417545|NCT01918995|Experimental|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
11417546|NCT01918995|Experimental|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
11417547|NCT01918995|Placebo Comparator|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
11417548|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm >30mm and < 50mm
11417549|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
11417550|NCT01918956|Active Comparator|conventional regimen of PURETHAL Birch|"Initial treatment:
~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).
~Maintenance treatment:
~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
11417552|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
11417553|NCT01918930|Experimental|MGA271|MGA271 (administered in main study CP-MGA271-01)
11417555|NCT01918917|Active Comparator|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
11417556|NCT01918904|Experimental|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
11417557|NCT01918904|Placebo Comparator|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
11417558|NCT01918891|No Intervention|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
11417559|NCT01918891|Experimental|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
11417560|NCT01918891|Experimental|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
11417561|NCT01918878|Experimental|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
11417562|NCT01918865|Experimental|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
11417563|NCT01918865|Placebo Comparator|Placebo|Weekly Dosing for 26 Weeks
11417564|NCT01918852|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
11417565|NCT01918852|Experimental|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
11417566|NCT01918839|Experimental|VINCI Plus|One side has been treated with VINCI Plus
11417567|NCT01918839|Active Comparator|Restylane-L|One side has been treated with Restylane-L
11417568|NCT01918826|Active Comparator|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
11417569|NCT01918826|Placebo Comparator|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
11417570|NCT01918813|Experimental|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
11417571|NCT01918800|Experimental|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
11417572|NCT01918800|Active Comparator|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
11417573|NCT01918787|Experimental|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
11417574|NCT01918774|Other|Cognitive behavior therapy for work success|Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
11417575|NCT01918761|Experimental|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 (i.v) q21d Dacomitinib 45mg/ orally (continuous)
11417576|NCT01918748|Experimental|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.
~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
11417577|NCT01918735|Experimental|Group/dose level 1a|25 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
11417578|NCT01918735|Placebo Comparator|Group/dose level 1b|Matching placebo for Group/dose level 1a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
11417579|NCT01918735|Experimental|Group/dose level 2a|75 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
11417580|NCT01918735|Placebo Comparator|Group/dose level 2b|Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
11417581|NCT01918735|Experimental|Group/dose level 3a|200 mg GWP42006 oral solution (single dose) followed by an intravenous administration of 5 mg GWP42006 after the oral dose
11417582|NCT01918735|Placebo Comparator|Group/dose level 3b|Matching placebo for Group/dose level 3a
11417583|NCT01918735|Experimental|Group/dose level 4a|400 mg GWP42006 oral solution
11417584|NCT01918735|Placebo Comparator|Group/dose level 4b|Matching placebo for Group/dose level 4a
11417900|NCT01916746|Experimental|transvaginal resection of pregnancy tissue|
11417585|NCT01918735|Experimental|GWP42006 1, 2, or 3 times daily|Subjects will receive the selected dose of GWP42006 once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
11417586|NCT01918735|Placebo Comparator|Placebo 1, 2, or 3 times daily|Subjects will receive placebo once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
11417587|NCT01918722|Experimental|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
11417588|NCT01918722|Active Comparator|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
11417589|NCT01918722|Placebo Comparator|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
11417590|NCT01918709|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
11417591|NCT01918709|Experimental|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
11417592|NCT01918709|Experimental|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
11417593|NCT01918696|Experimental|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
11417594|NCT01918696|Active Comparator|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel [write the feeling you decided on], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
11417595|NCT01918696|Placebo Comparator|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
11417596|NCT01918683|Other|A -Tace alone|A - TACE alone (control group, current practice and treatment)
11417597|NCT01918683|Experimental|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
11417598|NCT01918670||Pasteur|
11417599|NCT01918670||Grenoble|
11417600|NCT01918670||Nantes|
11417601|NCT01918670||Parly|
11417602|NCT01918670||Rennes|
11417603|NCT01918670||Rouen|
11417604|NCT01918657|Active Comparator|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded.
11417605|NCT01918657|Placebo Comparator|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
11417606|NCT01918644|Experimental|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
11417607|NCT01918631|Active Comparator|Entecavir|Entecavir 0.5mg QD for 48 weeks
11417608|NCT01918631|Active Comparator|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
11417609|NCT01918618||Levosimendan|study group
11417610|NCT01918618||No Levosimendan|Control group
11417611|NCT01918605|Experimental|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
11417612|NCT01918605|Active Comparator|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
11417613|NCT01918592|Experimental|MRI/PET|
11417614|NCT01918579|Experimental|CRP intervention|Patients will be tested by rapid POC CRP test
11417615|NCT01918579|No Intervention|Control|Patients will not be tested by rapid POC CRP test
11417616|NCT01918566|Placebo Comparator|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
11417617|NCT01918566|Active Comparator|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
11417618|NCT01918566|Active Comparator|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
11417619|NCT01918566|Active Comparator|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
11417620|NCT01918566|Active Comparator|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
11417621|NCT01918566|Sham Comparator|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
11417622|NCT01918553|Experimental|Subject in the study ALIENOR|
11417623|NCT01918540|Active Comparator|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
11417624|NCT01918540|Active Comparator|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
11417625|NCT01918527|Other|A, Conventional treatment|Operation + 4 or 8 cycles of adjuvant chemotherapy, if indicated.
11417626|NCT01918527|Other|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
11417627|NCT01918501|Experimental|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
11417628|NCT01918488|Experimental|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
11417629|NCT01918488|Experimental|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
11417630|NCT01918475|Active Comparator|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
11417631|NCT01918475|Active Comparator|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
11417632|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
11417633|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
11417634|NCT01918449|No Intervention|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
11417635|NCT01918449|Experimental|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
11417636|NCT01918436|Experimental|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.
~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.
~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
11417637|NCT01918436|Active Comparator|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
11417638|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
11417639|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
11417640|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
11417641|NCT01918410|Active Comparator|Contact Lens with alginic acid|
11417642|NCT01918410|Placebo Comparator|Contact lens without alginic acid|
11417643|NCT01918397|Active Comparator|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
11417644|NCT01918397|Experimental|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
11417645|NCT01918397|Experimental|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
11417646|NCT01918397|Experimental|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
11417647|NCT01918384|Experimental|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
11417648|NCT01918384|Placebo Comparator|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
11417649|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
11417650|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
11417651|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
11417652|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
11417653|NCT01918358|Experimental|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
11417675|NCT01918254|Experimental|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
11418945|NCT01909505||Normal Males|Males with normal levels of serum testosterone
11417654|NCT01918345|No Intervention|Standard Care (Control)|This group will receive a one-on-one counseling session during one visit with a Certified Diabetes Educator (CDE), who will provide standard advice on diabetes prevention and healthy lifestyle. They will receive a booklet on exercise and healthy diet as per current Canadian guidelines for healthy eating. This group will also receive a check-in telephone call from the Study Coordinator, half-way through the study. This group will not receive motivational interviewing, health coaching on low GI diet and/or exercise, or additional telephone follow-up.
11417655|NCT01918345|Experimental|Diet & Physical Activity Program with Health Coach|Participants assigned to this arm will receive a combination of the home-based physical activity program with health coach and the home-based low-GI diet program with health coach, as described in the respective individual arms. The Health Coach for this group will be a CDE.
11417656|NCT01918345|Experimental|Physical Activity Program with Health Coach|Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
11417657|NCT01918345|Experimental|Diet Program with Health Coach|Participants will be counseled to follow recommendations for Canadians on healthy eating (Canada's Food Guide and Space on Your Plate. Low GI education will be layered on top of Canada's Food Guide recommendations. The goal for participants in the diet group is to lower their dietary GI by 8-10 units. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their dietary and low GI goals. The health coach for this group will be a CDE.
11417658|NCT01918332|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
11417659|NCT01918332|Active Comparator|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
11417660|NCT01918332|Active Comparator|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
11417661|NCT01918332|Placebo Comparator|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
11417662|NCT01918319|Experimental|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
11417663|NCT01918319|No Intervention|Control|
11417664|NCT01918306|Experimental|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.
~Cohort 1, 3 of 3 patients received:
~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.
~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.
~If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.
~If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II
~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
11417665|NCT01918306|Experimental|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.
~Determination of the maximally tolerated dose (MTD) of GDC-0941."
11417666|NCT01918306|Active Comparator|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.
~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.
~Arm 1 Cisplatin Only Patient received:
~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
11417667|NCT01918306|Experimental|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.
~Arm 2 Cisplatin + GDC-0941 Patients received:
~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).
~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
11417668|NCT01918306|Experimental|2PHIICO|"Arm 2: Crossover post-progression
~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.
~Patient received:
~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).
~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
11417669|NCT01918293|Experimental|SMART arm|Using smartphone application for control of asthma
11417670|NCT01918293|No Intervention|conventional arm|non-using smartphone application for control asthma
11417671|NCT01918280|Experimental|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
11417672|NCT01918280|Other|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
11417673|NCT01918267||Cohort|
11417674|NCT01918254|Experimental|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
11417706|NCT01918059|Experimental|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
11417676|NCT01918254|Experimental|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
11417677|NCT01918241|Experimental|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
11417678|NCT01918241|Experimental|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
11417679|NCT01918241|Experimental|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
11417680|NCT01918241|Experimental|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10^9/L, but at least 7 days.
11417681|NCT01918228|Experimental|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
11417682|NCT01918228|No Intervention|Control group|No intervention will be provided by the study team.
11417683|NCT01918215|Other|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
11417684|NCT01918215|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
11417685|NCT01918202|Experimental|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
11417686|NCT01918202|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
11417687|NCT01918202|Experimental|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
11417688|NCT01918189|Experimental|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
11417689|NCT01918176|Experimental|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
11417690|NCT01918163|No Intervention|No Pills|Patients in this group will not receive Pomegranate pills.
11417691|NCT01918163|Active Comparator|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
11417692|NCT01918150|Experimental|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
11417693|NCT01918150|Active Comparator|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
11417694|NCT01918137|Experimental|chocolate bar|
11417695|NCT01918137|Experimental|porridge|
11417696|NCT01918124|Experimental|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:
~Radiotherapy:
~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
~Cisplatin:
~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.
~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
11417697|NCT01918111|Experimental|RD group|Renal denervation group
11417698|NCT01918111|Active Comparator|Control group|Control group
11417699|NCT01918098|Experimental|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
11417700|NCT01918098|Active Comparator|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
11417701|NCT01918085|Other|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
11417702|NCT01918085|Other|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
11417703|NCT01918072||Stepped wedge participants|"Designated Women's Health Providers with one or more episodes of care for women patients during each period of the intervention.
~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
11417704|NCT01918072||Electronic consultation survey participants|"Designated Women's Health Providers who completed surveys about use of electronic consultations.
~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
11417705|NCT01918072||Quality assessment participants|Primary care providers delivering women's health care for one or more of the following conditions: abnormal uterine bleeding; menopausal symptoms; urinary incontinence.
11417707|NCT01918059|Experimental|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
11417708|NCT01918059|Experimental|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
11417709|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
11417710|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
11417711|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
11417712|NCT01918020|Experimental|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
11417713|NCT01918020|Other|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
11417714|NCT01918007|Active Comparator|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
11417715|NCT01918007|No Intervention|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
11417716|NCT01917994|Experimental|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
11417717|NCT01917994|Active Comparator|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
11417718|NCT01917981|Experimental|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
11417719|NCT01917968|Active Comparator|Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
11417720|NCT01917968|Active Comparator|Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
11417721|NCT01917942|Active Comparator|Standard of Care|Standard of Care
11417722|NCT01917942|Experimental|Humidification|Humidification
11417723|NCT01917929|Other|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
11417724|NCT01917916|Experimental|BI 655064 dose group 1|subject to receive BI 655064 dose group 1 single dose
11417725|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 1|subject to receive placebo
11417726|NCT01917916|Experimental|BI 655064 dose group 2|subject to receive BI 655064 dose group 2 single dose
11417727|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 2|subject to receive a placebo
11417728|NCT01917916|Experimental|BI 655064 dose group 4|Subject to receive BI 655064 dose group 4 single dose
11417729|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 4|Subject to receive placebo
11417730|NCT01917916|Experimental|BI 655064 dose group 3|Subject to receive BI 655064 dose group 3 single dose
11417731|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 3|Subject to receive placebo
11417732|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
11417733|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
11417734|NCT01917890|Experimental|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
11417735|NCT01917890|Placebo Comparator|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
11417736|NCT01917877|Experimental|study group|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
11417737|NCT01917877|Active Comparator|control|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
11417738|NCT01917864|Experimental|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
11417739|NCT01917838|Experimental|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:
~Greater quality of the Design and Do process rated by therapists, parents, and independent coders.
~Greater quantity and quality of HW assignments rated by therapists and parents.
~Greater quality of the Review process as rated by therapists, parents, and independent coders.
~Greater satisfaction with treatment as rated by the parent, target child, and therapists."
11417740|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
11417741|NCT01917812|Placebo Comparator|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
11417742|NCT01917812|Experimental|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.
~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.
~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
11417743|NCT01917812|Experimental|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.
~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.
~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
11417744|NCT01917799|Experimental|Aspirin|75mg tab of aspirin once daily
11417745|NCT01917799|Active Comparator|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
11417746|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
11417747|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
11417748|NCT01917773|Experimental|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
11417749|NCT01917747|Active Comparator|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
11417750|NCT01917747|Experimental|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
11417751|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ < - 3 and/or MUAC < 115 mm.
11417752|NCT01917721|Experimental|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
11417753|NCT01917721|Active Comparator|Placebo|The comparative arm of the study will receive standard care and placebo for Kawasaki disease, but not doxycycline
11417754|NCT01917708|Experimental|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
11417755|NCT01917695|Active Comparator|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
11417756|NCT01917695|Experimental|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
11417757|NCT01917695|Experimental|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
11417758|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
11417759|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
11417760|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
11417761|NCT01917669||Diabetic Patients|These patients will have good glucose control.
11417762|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
11417763|NCT01917656|Experimental|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
11417764|NCT01917656|Active Comparator|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
11417765|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
11417766|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
11417767|NCT01917630|Experimental|ALV003|
11417768|NCT01917630|Placebo Comparator|Placebo|
11417769|NCT01917617|Experimental|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1
~Short hydration via oral rehydration solution (OS-1)
~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
11417770|NCT01917617|Active Comparator|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin
~Other Names:
~Gemcitabine； gemzer Cisplatin； Cispulan
~Standard hydration via intravenous infusion
~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
11417771|NCT01917604|Experimental|open exposure and control|● surgically uncover the canine tooth and bone removal exposing the largest diameter of the ectopic canine crown make a window in the palatal soft tissue and bond bracket after 10 days
11417772|NCT01917604|Experimental|closed exposure and control|raising a flap in the area of impacted canine,bonding an attachment and resuturing the flap
11417773|NCT01917591|Active Comparator|MariGen Wound|Fish derived extra cellular matrix
11417774|NCT01917591|Active Comparator|Oasis Sheet|Pig intestine derived extra cellular matrix
11417775|NCT01917578|Experimental|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
11417776|NCT01917578|Experimental|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
11417777|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
11417778|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
11417779|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
11417780|NCT01917552|Experimental|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
11417781|NCT01917552|No Intervention|observation|
11417782|NCT01917539|Sham Comparator|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
11417783|NCT01917539|Experimental|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
11417784|NCT01917526|Active Comparator|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
11417785|NCT01917526|Active Comparator|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
11417786|NCT01917513|Experimental|G-EYE™ colonoscopy|G-EYE™ colonoscopy
11417787|NCT01917513|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
11417788|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
11417789|NCT01917474|Experimental|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content < 20% of the total daily energy intake with the following composition:
~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
11417790|NCT01917474|Active Comparator|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:
~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
11417791|NCT01917448|Sham Comparator|Control|The skin will be injected with local anesthetic without spinal block
11417792|NCT01917448|Active Comparator|Spinal morphine|0.15 mg spinal morphine
11417793|NCT01917435|Experimental|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
11417794|NCT01917435|Experimental|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
11417795|NCT01917409|Experimental|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
11417796|NCT01917409|Experimental|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
11417797|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
11417798|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
11417799|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
11417800|NCT01917357|Experimental|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:
~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
11417801|NCT01917357|Active Comparator|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:
~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
11417802|NCT01917344|Other|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
11417803|NCT01917331|Experimental|Beclometasone/Formoterol/Glycopyrrolate|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
11417804|NCT01917331|Active Comparator|Beclometasone/Formoterol|Foster® 100/6 mcg 2 inhalations bid
11417805|NCT01917318|Experimental|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
11417806|NCT01917318|Experimental|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
11417807|NCT01917305|Experimental|platform-switched implant|platform-switched implant
11417808|NCT01917305|Active Comparator|platform-matched implant|platform-matched implant
11417809|NCT01917292|Other|Periodontal care|
11417810|NCT01917292|Experimental|One-Stage Full-Mouth Disinfection|
11417811|NCT01917279|Active Comparator|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.
11417812|NCT01917279|Experimental|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
11417813|NCT01917266||Concordant|
11417814|NCT01917266||Discordant|
11417815|NCT01917253|Experimental|standard length catheter|Standard Device for peripheral vein cannulation
11417816|NCT01917253|Experimental|Long catheter|Standard Device for peripheral vein cannulation
11417817|NCT01917240|Experimental|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
11417818|NCT01917240|Placebo Comparator|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
11417819|NCT01917227|Experimental|Video|
11417820|NCT01917214||Non-Interventional Study|
11417855|NCT01917006|Experimental|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
11417821|NCT01917201|Other|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
11417822|NCT01917201|Other|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
11417823|NCT01917188|Active Comparator|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
11417824|NCT01917188|Other|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
11417825|NCT01917188|No Intervention|Usual care|Patients will receive usual care by bedside nurse.
11417826|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
11417827|NCT01917162|Other|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
11417828|NCT01917162|Other|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
11417829|NCT01917149|Experimental|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
11417830|NCT01917149|Experimental|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
11417831|NCT01917149|Experimental|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
11417832|NCT01917149|Experimental|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
11417833|NCT01917149|Experimental|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
11417834|NCT01917136|Experimental|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
11417835|NCT01917123|Active Comparator|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
11417836|NCT01917123|Placebo Comparator|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
11417837|NCT01917110|Experimental|omafilcon A|Contact Lens Group
11417838|NCT01917110|Active Comparator|Spectacle Group|Prescription at Baseline
11417839|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
11417840|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
11417841|NCT01917084|Experimental|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
11417842|NCT01917071|Experimental|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
11417843|NCT01917058|Active Comparator|abatacept|
11417844|NCT01917058|Placebo Comparator|abatacept Subcutaneous vehicle|
11417845|NCT01917045|Experimental|low body fat percentage|body fat percentage less than 30%
11417846|NCT01917045|Experimental|heigh body fat percentage|body fat percentage more than 30%
11417847|NCT01917032|Active Comparator|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
11417848|NCT01917032|Placebo Comparator|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
11417849|NCT01917019|Placebo Comparator|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
11417850|NCT01917019|Experimental|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
11417851|NCT01917019|Experimental|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
11417852|NCT01917019|Experimental|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
11417853|NCT01917006|Experimental|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
11417854|NCT01917006|Experimental|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1. Participants were eligible for another treatment after 12 weeks.
11418946|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
11417857|NCT01917006|Experimental|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
11417858|NCT01917006|Experimental|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
11417859|NCT01917006|Placebo Comparator|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
11417860|NCT01916993|Experimental|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
11417861|NCT01916993|Experimental|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
11417862|NCT01916993|Experimental|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
11417863|NCT01916993|Experimental|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
11417864|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
11417865|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
11417866|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
11417867|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
11417868|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
11417869|NCT01916954|Active Comparator|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
11417870|NCT01916954|Experimental|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
11417871|NCT01916941|Active Comparator|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
11417872|NCT01916941|Placebo Comparator|Placebo|Placebo X 6 weeks
11417873|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
11417874|NCT01916915|Experimental|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
11417875|NCT01916915|Experimental|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
11417876|NCT01916915|Placebo Comparator|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
11417877|NCT01916902|Active Comparator|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
11417878|NCT01916902|Active Comparator|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
11417879|NCT01916889|Experimental|RACY test|"4-question RACY delirium screening tool"
11417880|NCT01916876|No Intervention|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
11417881|NCT01916876|Other|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.
~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.
~Integrated Medical Follow-up package"
11417882|NCT01916863|Experimental|LX4211|400 mg of LX4211
11417883|NCT01916863|Active Comparator|Canagliflozin|300 mg canagliflozin
11417884|NCT01916863|Placebo Comparator|Placebo|LX4211 placebo
11417885|NCT01916850|Experimental|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
11417886|NCT01916850|Experimental|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
11417887|NCT01916850|Placebo Comparator|Placebo|Identical placebo administered once daily for 10 consecutive days
11417888|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
11417889|NCT01916824|Experimental|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
11417890|NCT01916824|No Intervention|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
11417891|NCT01916798|Active Comparator|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
11417892|NCT01916798|No Intervention|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
11417893|NCT01916785|Experimental|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
11417894|NCT01916785|Active Comparator|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
11417895|NCT01916785|Active Comparator|B|Arm B : Dasatinib standard dose with Cmin < 3nM analysed on blood after 7-10 days dasatinib 100mg intake
11417896|NCT01916772||cherubism patients|no interventions
11417897|NCT01916759|Other|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
11417898|NCT01916759|Other|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
11417899|NCT01916759|Other|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
11417901|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
11417902|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
11417903|NCT01916720|Experimental|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
11417904|NCT01916720|Experimental|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
11417905|NCT01916720|Placebo Comparator|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
11417906|NCT01916707|Active Comparator|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
11417907|NCT01916707|Experimental|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
11417908|NCT01916694|Experimental|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
11417909|NCT01916694|Active Comparator|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
11417910|NCT01916681|Experimental|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
11417911|NCT01916681|Experimental|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
11417912|NCT01916681|Experimental|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
11417913|NCT01916681|Experimental|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
11417914|NCT01916655|Placebo Comparator|Usual Care|standard and typical PAP (Positive Airway Pressure) educational and support protocol
11417915|NCT01916655|Experimental|Self-Management Care|Individualized self-management educational and support protocol
11417916|NCT01916655|Experimental|Self-Management Mobile Care|Individualized self-management educational and support protocol delivered in part by mobile health tool
11417917|NCT01916642|Placebo Comparator|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
11417918|NCT01916642|Active Comparator|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
11417919|NCT01916642|Active Comparator|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
11417920|NCT01916642|Active Comparator|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
11417921|NCT01916642|Active Comparator|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
11417922|NCT01916629|Active Comparator|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
11417923|NCT01916629|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
11417924|NCT01916603|Experimental|Normative intervention|Normative intervention on diet & physical & breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
11417925|NCT01916603|No Intervention|Routine care|Routine antenatal care according to national guidelines
11417926|NCT01916590|Active Comparator|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
11417927|NCT01916590|Placebo Comparator|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
11417928|NCT01916577|Active Comparator|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
11417929|NCT01916577|Experimental|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
11417930|NCT01916564|Active Comparator|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
11417931|NCT01916564|Active Comparator|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
11417932|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
11417933|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
11417977|NCT01916226|Placebo Comparator|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
11419133|NCT01908270|Other|Usual care|Patients continue usual care by their practitioner
11417934|NCT01916525|Experimental|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
11417935|NCT01916525|No Intervention|Control|A conventional post-acute care group treated according to finnish guidelines.
11417936|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
11417937|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
11417938|NCT01916486|Experimental|Exercise training|Twice-weekly for the 6-month duration.
11417939|NCT01916486|Experimental|Complex mental and social activities|Twice-weekly for the 6-month duration.
11417940|NCT01916486|Active Comparator|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
11417941|NCT01916473|Active Comparator|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
11417942|NCT01916473|Experimental|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
11417943|NCT01916460|Experimental|Gastroparetic patient|EUS FNA of the gastric wall prior to surgical placement of gastric neurostimulator
11417944|NCT01916447|Experimental|TAS-102 and CPT-11 with or without Bevacizumab|
11417945|NCT01916434|Experimental|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
11417946|NCT01916434|Experimental|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
11417947|NCT01916434|Placebo Comparator|No salmon|The placebo group will continue to consume their habitual diet
11417948|NCT01916421|Active Comparator|EZ Shot|
11417949|NCT01916421|Active Comparator|Expect™|
11417950|NCT01916421|Active Comparator|EchoTip® Ultra|
11417951|NCT01916408|Active Comparator|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
11417952|NCT01916408|Placebo Comparator|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
11417953|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
11417954|NCT01916382|Experimental|Nitisinone|Homogentisic acid lowering drug intervention
11417955|NCT01916382|No Intervention|No treatment|comparrator
11417956|NCT01916369|Experimental|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
11417957|NCT01916356|Experimental|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
11417958|NCT01916343|Experimental|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
11417959|NCT01916343|No Intervention|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
11417960|NCT01916317|No Intervention|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
11417961|NCT01916317|Active Comparator|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
11417962|NCT01916304|Experimental|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
11417963|NCT01916291|Experimental|Propess insertion|
11417964|NCT01916278|Experimental|Emervel Lips Lidocaine|
11417965|NCT01916278|Experimental|Juvéderm Volbella with Lidocaine|
11417966|NCT01916265|Experimental|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
11417967|NCT01916265|Experimental|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
11417968|NCT01916265|Experimental|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
11417969|NCT01916252|Active Comparator|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
11417970|NCT01916252|Active Comparator|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
11417971|NCT01916239|Experimental|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
11417972|NCT01916239|Experimental|Pomegranate extract formulation-1|New pomegranate extract formulation-1
11417973|NCT01916239|Experimental|Pomegranate extract formulation-2|New pomegranate extract formulation-2
11417974|NCT01916226|Experimental|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
11417975|NCT01916226|Placebo Comparator|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
11417976|NCT01916226|Experimental|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
11418158|NCT01914939|Experimental|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
11417978|NCT01916213|Active Comparator|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
11417979|NCT01916213|Active Comparator|ICSI|
11417980|NCT01916200|Experimental|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
11417981|NCT01916200|No Intervention|Blank group|IBS regular treatment group
11417982|NCT01916187|Experimental|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
11417983|NCT01916174|Experimental|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
11417984|NCT01916174|Experimental|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
11417985|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
11417986|NCT01916135|Experimental|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of [18F]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
11417987|NCT01916122|Experimental|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.
~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
11417988|NCT01916109|Experimental|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
11417989|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
11417990|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
11417991|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
11417992|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
11417993|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
11417994|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
11417995|NCT01916070||patients with syncope|
11417996|NCT01916070||patients with near syncope|
11417997|NCT01916057|Experimental|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
11417998|NCT01916044|Experimental|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
11417999|NCT01916044|No Intervention|control|no measure of Uterine Segment Ultrasound
11418000|NCT01916031|Experimental|Education|Upper Respiratory Infection education in Fall
11418001|NCT01916031|No Intervention|Standard Curriculum|
11418002|NCT01916018|Other|hypothyroid group|Clinical exams radiologic exams Blood sample
11418003|NCT01916005|Experimental|endocarditis|
11418004|NCT01915992|Other|Volunteer healthy|
11418005|NCT01915992|Active Comparator|leukemia patient's|
11418006|NCT01915979|Experimental|Plasma rich in growth factors (PRGF)|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
11418007|NCT01915979|Active Comparator|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
11418008|NCT01915966|Experimental|Cardamom, ginger and orange juice gelatin|Dietary Supplement
11418009|NCT01915966|Active Comparator|Camomile infusion with lemon juice|Dietary Supplement
11418010|NCT01915953||anemia|Measuring Hb valuse on anemia patients
11418011|NCT01915940|Experimental|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
11418012|NCT01915940|Active Comparator|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
11418013|NCT01915927|Other|1|Only 1 arm: treatment with MSC-AFP
11418014|NCT01915914|Experimental|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
11418015|NCT01915914|Active Comparator|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
11418016|NCT01915901|Experimental|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
11418017|NCT01915901|Experimental|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
11418018|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
11418019|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
11418020|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
11418021|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
11418022|NCT01915875|Experimental|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
11418023|NCT01915849|Experimental|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
11418024|NCT01915849|Experimental|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
11418025|NCT01915849|Experimental|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
11418026|NCT01915849|Experimental|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
11418027|NCT01915836|Experimental|Alpha game testers and questionaires|"This a video game designed to help smokers quit & remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.
~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes & will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video &/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
11418028|NCT01915823|Active Comparator|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray
~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
11418029|NCT01915823|Placebo Comparator|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
11418030|NCT01915810|Experimental|Arm I (pre-quit physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning 2 weeks before the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise activity per week for 5 weeks.
11418031|NCT01915810|Experimental|Arm II (quit day physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning on the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise per week for 5 weeks.
11418032|NCT01915810|Active Comparator|Arm III (no physical activity)|Participants quit smoking on an assigned date and receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks.
11418033|NCT01915797||Patient having a cancer and abnormal development|Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
11418034|NCT01915784|Experimental|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
11418035|NCT01915784|Experimental|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
11418036|NCT01915771|Experimental|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
11418037|NCT01915758|Experimental|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
11418038|NCT01915758|Placebo Comparator|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
11418039|NCT01915745|No Intervention|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
11418040|NCT01915745|Experimental|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
11418041|NCT01915732|Experimental|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
11419376|NCT01906671|Experimental|Xaluprine|Oral liquid formulation of 6-mercaptopurine
11418042|NCT01915732|Active Comparator|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
11418043|NCT01915719|Experimental|Early non invasive ventilation|Early non invasive ventilation
11418044|NCT01915719|Active Comparator|Oxygen therapy only|Oxygen therapy only
11418045|NCT01915706|No Intervention|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
11418046|NCT01915706|Experimental|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
11418047|NCT01915693|No Intervention|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
11418048|NCT01915693|Experimental|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
11418049|NCT01915680||Glaucoma|
11418050|NCT01915680||Control|
11418051|NCT01915667|Experimental|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
11418052|NCT01915667|Experimental|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
11418053|NCT01915667|Active Comparator|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
11418054|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
11418055|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
11418056|NCT01915641|Active Comparator|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
11418057|NCT01915641|Sham Comparator|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
11418058|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
11418059|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.
~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
11418060|NCT01915602|Experimental|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
11418061|NCT01915589|Experimental|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
11418062|NCT01915576|Experimental|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
11418063|NCT01915576|Experimental|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
11418064|NCT01915576|Experimental|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
11418065|NCT01915563|No Intervention|SBT and extubation|After a SBT patients will be extubated as usual
11418066|NCT01915563|Experimental|SBT and rest 60 min before extubation|After SBT patients will be reconnected to mechanical ventilation during 60 min before extubation
11418067|NCT01915550|Active Comparator|metformin|metformin was added without raising the insulin dose
11418068|NCT01915550|Active Comparator|Raising Insulin|insulin dose is raised
11418069|NCT01915537|Experimental|Infliximab group|Infliximab with MTX treatment
11418070|NCT01915537|Active Comparator|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
11418071|NCT01915524|Experimental|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.
~local radiation (4x5 Gy)"
11418072|NCT01915511||Subjects with a new IPF diagnosis|Subjects with a new diagnosis of IPF established at the time of enrollment in the registry
11418123|NCT01915121|Active Comparator|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
11418073|NCT01915511||Subjects with a non-IPF ILD diagnosis|Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype
11418074|NCT01915498|Experimental|enasidenib|enasidenib administered orally. Multiple doses will be administered to determine the RP2D.
11418075|NCT01915485|Experimental|Lu 177|progressive metastatic medullary thyroid cancer
11418076|NCT01915472|Experimental|IMMU 130|
11418077|NCT01915459|Experimental|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
11418078|NCT01915459|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
11418079|NCT01915433|Experimental|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
11418080|NCT01915433|Experimental|Wahls Diet|Wahls Diet (modified paleolithic diet)
11418081|NCT01915433|No Intervention|Usual Care|Control - usual care only.
11418082|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
11418083|NCT01915381|Active Comparator|Control group|follow up detraining effect of multimodal intervention
11418084|NCT01915381|Experimental|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
11418085|NCT01915368|Active Comparator|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
11418086|NCT01915368|Experimental|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
11418087|NCT01915368|Experimental|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
11418088|NCT01915355|Experimental|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
11418089|NCT01915342|Experimental|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.
~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
11418090|NCT01915329|Experimental|Verum-RSS|RSS Stimulation with high frequency electric pulses
11418091|NCT01915329|Sham Comparator|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
11418092|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
11418093|NCT01915303|Experimental|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
11418094|NCT01915290||1600 elderly participants|Norwegian elderly population
11418095|NCT01915277|Experimental|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
11418096|NCT01915277|Experimental|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
11418097|NCT01915277|Experimental|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
11418098|NCT01915277|Experimental|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
11418099|NCT01915277|Experimental|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
11418100|NCT01915277|Experimental|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
11418101|NCT01915277|Experimental|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
11418102|NCT01915277|Experimental|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
11418103|NCT01915277|Experimental|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
11418104|NCT01915277|Experimental|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
11418105|NCT01915264||Group 1|
11418106|NCT01915225||1/Cohort 1|Subjects with or without solid tumors in whom diagnostic, preventative, or therapeutic intervention is being performed
11418107|NCT01915212|Experimental|HSV529|1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
11418108|NCT01915212|Placebo Comparator|Placebo|Sodium Chloride 0.9%
11418109|NCT01915199|Experimental|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
11418110|NCT01915199|No Intervention|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
11418111|NCT01915186|Experimental|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
11418112|NCT01915186|Placebo Comparator|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
11418113|NCT01915173|Experimental|Supplement + Expanded Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
11418114|NCT01915173|Placebo Comparator|Placebo + Standard Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
11418115|NCT01915173|Experimental|Supplement + Standard Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
11418116|NCT01915173|Placebo Comparator|Placebo + Expanded Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
11418117|NCT01915160|Active Comparator|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
11418118|NCT01915160|Experimental|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
11418119|NCT01915147|Experimental|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
11418120|NCT01915147|Experimental|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
11418121|NCT01915134|Experimental|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
11418122|NCT01915134|Active Comparator|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
11418124|NCT01915121|Placebo Comparator|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
11418125|NCT01915108|No Intervention|group R0|remifentanil Ce of 0 ng/ml
11418126|NCT01915108|Active Comparator|group R0.5|remifentanil Ce of 0.5 ng/ml
11418127|NCT01915108|Active Comparator|group R1.0|remifentanil Ce of 1.0 ng/ml
11418128|NCT01915108|Active Comparator|group R1.5|remifentanil Ce of 1.5 ng/ml
11418129|NCT01915095|Active Comparator|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
11418130|NCT01915095|Active Comparator|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
11418131|NCT01915095|Active Comparator|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
11418132|NCT01915082|Experimental|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).
~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
11418133|NCT01915082|Placebo Comparator|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).
~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
11418134|NCT01915069|Experimental|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
11418135|NCT01915056|No Intervention|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
11418136|NCT01915056|Experimental|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
11418137|NCT01915043|Active Comparator|health education for lymphedema prevention|health education for lymphedema prevention
11418138|NCT01915043|Experimental|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
11418139|NCT01915030|Experimental|High protein diet|High protein diet during caloric restriction
11418140|NCT01915030|Placebo Comparator|Standard protein diet|Standard protein diet during caloric restriction
11418141|NCT01915017|Experimental|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
11418142|NCT01915017|Experimental|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
11418143|NCT01915017|Experimental|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
11418144|NCT01915017|Active Comparator|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
11418145|NCT01915004|Other|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
11418146|NCT01915004|Experimental|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
11418147|NCT01914991|Active Comparator|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
11418148|NCT01914991|Experimental|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
11418149|NCT01914978|Experimental|Handbook|Food allergy handbook for parents
11418150|NCT01914978|Placebo Comparator|Treatment as usual|Food allergy treatment as usual
11418151|NCT01914965|Active Comparator|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
11418152|NCT01914965|Placebo Comparator|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
11418153|NCT01914952|Active Comparator|CaHMB Capsule|
11418159|NCT01914939|Active Comparator|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
11418160|NCT01914939|Experimental|Oxytocin|Intranasal administration of 24 IU of oxytocin
11418161|NCT01914939|Placebo Comparator|placebo drug|Intranasal placebo drug
11418162|NCT01914926|Active Comparator|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
11418163|NCT01914926|Active Comparator|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
11418164|NCT01914913|Other|BMMNCs|BMMNCs
11418165|NCT01914900|Experimental|induction TPF chemotherapy|
11418166|NCT01914887|Experimental|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
11418167|NCT01914874|Experimental|Mindfulness Meditation|12 weekly sessions in group format
11418168|NCT01914874|No Intervention|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
11418169|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
11418170|NCT01914848|Active Comparator|Control Group|A routine care discharge planning with the social service
11418171|NCT01914848|Experimental|Advance Care Planning ACP|"Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
~--------------------------------------------------------------------------------"
11418172|NCT01914835|Experimental|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
11418173|NCT01914822|Experimental|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
11418174|NCT01914822|Placebo Comparator|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
11418175|NCT01914809|Experimental|group with a preeclampsia before 34 SA|
11418176|NCT01914809|Other|group with a normal pregnancy|
11418177|NCT01914796|Placebo Comparator|Single ascending doses|
11418178|NCT01914796|Placebo Comparator|Measurement of eye blink rate|
11418179|NCT01914783|Experimental|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
11418180|NCT01914783|Active Comparator|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
11418181|NCT01914783|Placebo Comparator|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
11418182|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
11418183|NCT01914757|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
11418184|NCT01914757|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
11418185|NCT01914757|Placebo Comparator|Placebo|Placebo administered subcutaneously
11418186|NCT01914744|Experimental|entecavir|entecavir 0.5 mg/day PO
11418187|NCT01914744|Active Comparator|lamivudine|lamivudine 100 mg/day PO
11418188|NCT01914731|Experimental|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
11418189|NCT01914718|Experimental|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
11418190|NCT01914705|Active Comparator|Landmark Procedure|Using Landmarks to guide SCVC placement
11418191|NCT01914705|Active Comparator|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
11418192|NCT01914692|Experimental|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
11418193|NCT01914692|Placebo Comparator|Blank group|Use the normal saline instead of somatostatin.
11418194|NCT01914679|Experimental|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
11418195|NCT01914666|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
11418196|NCT01914653|Experimental|Pre-radiated|
11418197|NCT01914653|Experimental|Not radiated|
11418198|NCT01914653|Experimental|Post-radiated|
11418199|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
11418200|NCT01914627|Experimental|Loion|
11418201|NCT01914627|Active Comparator|SA-Gel|
11418202|NCT01914614||Working Poor Survivors|Low Wage workers
11418203|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
11418204|NCT01914601|Active Comparator|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
11418205|NCT01914601|Active Comparator|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
11418206|NCT01914588|Experimental|Telemonitoring + Standard care|
11418207|NCT01914588|Active Comparator|Standard care|
11418208|NCT01914575|Experimental|Dipole Density Mapping|
11418209|NCT01914562|Experimental|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
11418210|NCT01914562|Experimental|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
11418211|NCT01914562|Experimental|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
11418212|NCT01914562|Experimental|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
11418213|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
11418214|NCT01914523|Placebo Comparator|Macintosh|tracheal intubation will be performed using a Macintosh
11418215|NCT01914523|Active Comparator|King Vision|tracheal intubation will be performed using a King Vision
11418216|NCT01914523|Active Comparator|Glidescope|tracheal intubation will be performed using a Glidescope
11418217|NCT01914523|Active Comparator|AirTraq|tracheal intubation will be performed using a AirTraq
11418218|NCT01914510|Experimental|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
11418219|NCT01914497|Experimental|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
11418220|NCT01914484|Experimental|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.
~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
11418221|NCT01914471|No Intervention|Control|These schools did not receive the intervention.
11418222|NCT01914471|Experimental|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
11418223|NCT01914458|Experimental|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
11418224|NCT01914445|Experimental|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
11418225|NCT01914432|Experimental|YH16410|PO, Once Daily, 8 weeks
11418226|NCT01914432|Active Comparator|Rosuvastatin|PO, Once Daily, 8 weeks
11418227|NCT01914432|Active Comparator|Telmisartan|PO, Once Daily, 8 weeks
11418228|NCT01914432|Placebo Comparator|Placebo|PO, Once Daily, 8 weeks
11418229|NCT01914419|Active Comparator|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
11418230|NCT01914419|Active Comparator|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
11418231|NCT01914419|Active Comparator|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
11418232|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
11418233|NCT01914406|Active Comparator|continuous moderate training|Continued exercise 45 min.
11418234|NCT01914393|Experimental|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
11418235|NCT01914380||Group 1|
11418236|NCT01914367|Active Comparator|Cervarix group|One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.
11418237|NCT01914367|Active Comparator|Gardasil Group|One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.
11418238|NCT01914341|Experimental|Music|pentatonic live music
11418239|NCT01914341|No Intervention|control|no intervention
11418240|NCT01914315|Experimental|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
11418309|NCT01913834|Experimental|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
11418310|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
11418241|NCT01914315|Active Comparator|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
11418242|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
11418243|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
11418244|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
11418245|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
11418246|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
11418247|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
11418248|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
11418249|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
11418250|NCT01914289|Experimental|Resection|To observe prognosis of resection of icc
11418251|NCT01914289|Active Comparator|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
11418252|NCT01914263|Experimental|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10^9 CIK cells.
11418253|NCT01914263|No Intervention|Control|The eligible patients are followed up for 30 days without any treatment.
11418254|NCT01914250|Active Comparator|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
11418255|NCT01914237|Experimental|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
11418256|NCT01914224|Experimental|Group 1|dietary education of low sodium and high potassium consumption
11418257|NCT01914224|Active Comparator|Group 2|dietary education of low sodium consumption only
11418258|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
11418259|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
11418260|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
11418261|NCT01914185|No Intervention|Comparison Schools|Regular health promotion activities
11418262|NCT01914185|Experimental|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
11418263|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
11418264|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
11418265|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
11418266|NCT01914159|Experimental|Ranibizumab|
11418267|NCT01914146|Other|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
11418268|NCT01914146|Other|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
11418269|NCT01914133|No Intervention|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
11418270|NCT01914133|Placebo Comparator|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
11418271|NCT01914133|Active Comparator|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
11418272|NCT01914107|Experimental|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
11418273|NCT01914107|Experimental|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group
~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
11418274|NCT01914094|No Intervention|Standard care|Received current standard care.
11418275|NCT01914094|Experimental|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
11418276|NCT01914081|Active Comparator|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
11418277|NCT01914081|Placebo Comparator|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
11418278|NCT01914068|No Intervention|Control|No in hospital exercise training and no exercise advice.
11418279|NCT01914068|Active Comparator|Exercise Intervention|In hospital exercise training
11418280|NCT01914055|Active Comparator|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
11418281|NCT01914055|Experimental|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
11418282|NCT01914042|Experimental|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
11418283|NCT01914042|Active Comparator|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
11418284|NCT01914016|Other|prolonged walk|
11418285|NCT01914003||CSID Mutations|Individual has one or more known CSID mutations.
11418286|NCT01914003||Control|Individual does not have any known CSID mutations.
11418287|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:
~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
11418288|NCT01913990|Experimental|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:
~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of >16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
11418289|NCT01913977|Experimental|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
11418290|NCT01913964|Experimental|Acetyl-L-carnitine|2 g daily for 12 months
11418291|NCT01913964|Placebo Comparator|placebo|
11418292|NCT01913951|Experimental|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11418293|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
11418294|NCT01913925|Active Comparator|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
11418295|NCT01913925|Placebo Comparator|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
11418296|NCT01913912|Active Comparator|Lisdexamfetamine dimesylate (LDX)|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the optimal dose of LDX will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking LDX at the DRUG unit.
11418297|NCT01913912|Placebo Comparator|Sugar pill|Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
11418298|NCT01913899|Experimental|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
11418299|NCT01913899|Active Comparator|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
11418300|NCT01913886|Experimental|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
11418301|NCT01913873|Experimental|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values > 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
11418302|NCT01913860|No Intervention|Control|Control group will receive usual care
11418303|NCT01913860|Active Comparator|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
11418304|NCT01913860|Active Comparator|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
11418305|NCT01913847|Experimental|Sildenafil|Sildenafil 20 mg
11418306|NCT01913847|Placebo Comparator|Placebo|Placebo
11418307|NCT01913834|Active Comparator|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
11418308|NCT01913834|Experimental|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
11418311|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
11418312|NCT01913808|Experimental|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit [mg] = 2.4 x patient's weight [kg] x (target Hb [13 g/dL] - current Hb [g/dL]) + 500 [mg iron stores]
11418313|NCT01913808|Active Comparator|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
11418314|NCT01913795|Active Comparator|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
11418315|NCT01913795|Placebo Comparator|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
11418316|NCT01913795|Placebo Comparator|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
11418317|NCT01913795|Sham Comparator|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
11418318|NCT01913782||patients with low back pain|"Patients with disc herniation or radiculitis who are over 18 years of age.
~Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.
~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
11418319|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
11418320|NCT01913756|Experimental|Gouda-type cheese|80 g/day Gouda-type cheese
11418321|NCT01913756|No Intervention|Low cheese intake|
11418322|NCT01913756|Experimental|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
11418323|NCT01913743||MINDSETS|overweight/obese
11418324|NCT01913730|No Intervention|No prolonged therapy is scheduled|
11418325|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
11418326|NCT01913717|Experimental|External beam radiotherapy|External beam radiotherapy
11418327|NCT01913704|Placebo Comparator|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.
~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
11418328|NCT01913704|Active Comparator|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.
~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
11418329|NCT01913678|Active Comparator|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
11418330|NCT01913678|Active Comparator|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
11418331|NCT01913678|Placebo Comparator|Complete diet|The participants will be given all dietary items in their diet.
11418332|NCT01913665|Active Comparator|B.Lactis|children with functional constipation
11418333|NCT01913665|Active Comparator|Inulin|children with functional constipation
11418334|NCT01913665|Active Comparator|B.Lactis+ınulin|children with functional constipation
11418335|NCT01913665|Placebo Comparator|plasebo|children with functional constipation
11418336|NCT01913652|Experimental|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.
~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
11418337|NCT01913639|Experimental|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
11418338|NCT01913626|Experimental|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
11418339|NCT01913613|Experimental|Treatment|Treatment with the IASD device
11418340|NCT01913600|Other|Resolute Integrity|Resolute Integrity Stent
11418341|NCT01913587|Experimental|Acupuncture & Nerve block|Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
11418342|NCT01913587|Active Comparator|Nerve block|Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
11418343|NCT01913574|Experimental|Acupuncture & NCPB|The NCPB will be administered once at the start of the trial and the acupuncture will be performed 3 times per week for 2 weeks (6 times in total).
11418344|NCT01913574|Active Comparator|NCPB|The NCPB alone will be applied to the patients in this group, once at the start of the trial.
11418720|NCT01911091|No Intervention|Group 3 - Obese No Exercise|The Obese group will not receive intervention
11418345|NCT01913561|Experimental|Master Caution Garment|"each patient will be connected simultaneously with two devices:
~ECG gel electrodes
~Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
11418346|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
11418347|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
11418348|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
11418349|NCT01913535|Active Comparator|Low Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
11418350|NCT01913535|Active Comparator|High Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
11418351|NCT01913535|Other|Placebo/Low-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
11418352|NCT01913535|Other|Placebo/High-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
11418353|NCT01913535|Placebo Comparator|Placebo/Placebo Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
11418354|NCT01913522|Experimental|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
11418355|NCT01913522|Active Comparator|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
11418356|NCT01913522|Experimental|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
11418357|NCT01913509|Experimental|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
11418358|NCT01913509|Active Comparator|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
11418359|NCT01913496|Placebo Comparator|Standard care|standard care ,without the web application ebalance
11418360|NCT01913496|Active Comparator|ebalance|using the ebalance application for 14 weeks
11418361|NCT01913483|Experimental|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram [kg]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate [eGFR] <30 milliliters/minute [mL/min]).
11418362|NCT01913483|Active Comparator|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
11418363|NCT01913470|Experimental|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
11418364|NCT01913470|Experimental|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
11418365|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
11418366|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
11418367|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
11418368|NCT01913444|Experimental|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
11418369|NCT01913431|Experimental|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
11418370|NCT01913431|Experimental|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
11418371|NCT01913418|Active Comparator|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
11418372|NCT01913418|Placebo Comparator|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
11418373|NCT01913405|Experimental|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.
~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
11418374|NCT01913392||morbidly obese, chronic renal disease|adult patients (> 18 years) who have stage 4 or 5 chronic renal disease (CrCl < 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI > 40 kg/m2, or BMI > 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
11418375|NCT01913379|Experimental|1: MDV3100|
11418376|NCT01913379|Experimental|2: MDV3100 and gemfibrozil|
11418377|NCT01913379|Experimental|3: MDV3100 and itraconazole|
11418378|NCT01913366|Experimental|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
11418379|NCT01913366|Experimental|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
11418380|NCT01913353|Experimental|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
11418381|NCT01913353|Active Comparator|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
11418382|NCT01913340|Active Comparator|Erythropoietin|1000 U/kg/dose x 5 doses
11418383|NCT01913340|Placebo Comparator|Normal saline|
11418384|NCT01913327|Experimental|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
11418385|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
11418386|NCT01913314|Experimental|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) [^14C] labeled drug
11418387|NCT01913301|Experimental|Alagebrium|
11418388|NCT01913288|Experimental|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
11418389|NCT01913288|Sham Comparator|Hospital Sounds|Exposure to standard hospital sounds; routine care.
11418390|NCT01913275|Active Comparator|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
11418391|NCT01913275|Active Comparator|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
11418392|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
11418393|NCT01913249|Experimental|Intervention|Seton through fistula 6 months prior to LIFT
11418394|NCT01913249|Active Comparator|Control|Seton through fistula 3 weeks prior to LIFT surgery
11418395|NCT01913236|Experimental|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
11418396|NCT01913236|No Intervention|Control|Treatment as usual provided by general practitioners to elderly patients with depression
11418397|NCT01913223|Experimental|submucosal dissection by dissector water jet|
11418398|NCT01913197|Experimental|Pre-implant MRI images and planning|
11418399|NCT01913184|Active Comparator|Continuous nebulization|Continuous nebulization with AKITA
11418400|NCT01913184|Experimental|Discontinuous nebulization|Discontinuous nebulization with AKITA
11418401|NCT01913171|Active Comparator|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
11418402|NCT01913171|Active Comparator|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
11418403|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
11418404|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
11418405|NCT01913145|Experimental|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
11418406|NCT01913132|No Intervention|Standard wound dressing OPEN|Standard wound dressing
11418407|NCT01913132|Experimental|PICO dressing OPEN|Negative pressure wound therapy with PICO (Smith & Nephew)
11418408|NCT01913132|No Intervention|Standard dressing EVAR|Standard wound dressing
11418409|NCT01913132|Experimental|PICO dressing EVAR|Negative pressure wound therapy with PICO (Smith & Nephew)
11418410|NCT01913119|Experimental|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.
~Dose and administration: 4-hour infusion of 14 mg/m2"
11418411|NCT01913106|Experimental|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
11418412|NCT01913093||Leukemia survivors with neurocognitive deficit|"Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as case."
11418413|NCT01913093||Leukemia survivors without neurocognitive deficit|Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.
11418414|NCT01913080|Active Comparator|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
11418415|NCT01913080|No Intervention|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
11418416|NCT01913067|Experimental|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
11418417|NCT01913054|Active Comparator|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
11418418|NCT01913054|Experimental|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
11418419|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
11418420|NCT01913028|Experimental|MEDI9929|Solution of MEDI9929, SC
11418421|NCT01913028|Placebo Comparator|Placebo|Placebo solution for MEDI9929, SC
11418422|NCT01913015|Experimental|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
11418423|NCT01913015|Experimental|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
11418424|NCT01913002|Experimental|Treatment A|LX4211 800 mg
11418425|NCT01913002|Experimental|Treatment B|LX4211 2000 mg
11418426|NCT01913002|Active Comparator|Treatment C|moxifloxacin 400 mg
11418427|NCT01913002|Placebo Comparator|Treatment D|Placebo
11418428|NCT01912989|Experimental|Lifestyle counseling|NOURISH+ plus motivational interviewing
11418429|NCT01912976|Experimental|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
11418430|NCT01912976|Active Comparator|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
11418431|NCT01912963|Experimental|Phase I: Dose Level 1 (D1)|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1
~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1
~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (D1)
~Cycle duration=21 days
~The Phase I run-in potentially evaluates 2 dose levels of eribulin in combination with pertuzumab and trastuzumab. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
11418432|NCT01912963|Experimental|Phase II Cohort A: Without Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1
~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1
~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)
~Cycle duration=21 days
~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
11418433|NCT01912963|Experimental|Phase II Cohort B: With Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1
~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1
~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)
~Cycle duration=21 days
~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
11418434|NCT01912950|Experimental|Prowave LX IPL|"Prowave LX IPL, short pulse setting and snowflake mode On"
11418435|NCT01912950|No Intervention|No Treatment|No treatment administered.
11418436|NCT01912937|Experimental|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
11418437|NCT01912898||1|
11418438|NCT01912885|Placebo Comparator|Group TENS 0-1|Electrodes will be fixated to one leg and sessions will be held once a week.
11418439|NCT01912885|Experimental|Group TENS 1-1|Electrical stimulation of the posterior tibial nerve of one leg once a week.
11418440|NCT01912885|Experimental|Group TENS 1-2|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
11418441|NCT01912885|Experimental|Group TENS 2-1|Electrical stimulation of the posterior tibial nerve of two legs once a week.
11418442|NCT01912885|Experimental|Group TENS 2-2|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
11418503|NCT01912482|No Intervention|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
11418443|NCT01912872|Experimental|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
11418444|NCT01912872|Active Comparator|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
11418445|NCT01912859|Experimental|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
11418446|NCT01912859|No Intervention|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
11418447|NCT01912846|Sham Comparator|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.
~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
11418448|NCT01912846|Experimental|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
11418449|NCT01912820|Experimental|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
11418450|NCT01912820|Placebo Comparator|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
11418451|NCT01912807|Experimental|Dextrose (D5NS)|The participants received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis and Dextrose 5% in 0.9 % Normal Saline (D5NS) was used as a second antiemetic, at an intravenous rate calculated based on their weight and determined for the purpose of the study.
11418452|NCT01912807|Active Comparator|Ondansetron (Control)|The control group received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis. Ondansetron (dose 0,05 mg/Kg) was used as a second prophylactic antiemetic.
11418453|NCT01912794|Experimental|Sensory Conditions|
11418454|NCT01912781|Experimental|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
11418455|NCT01912781|Active Comparator|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
11418456|NCT01912768|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
11418457|NCT01912768|Active Comparator|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
11418458|NCT01912755|Experimental|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
11418459|NCT01912755|Active Comparator|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
11418460|NCT01912742|Experimental|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
11418461|NCT01912742|Experimental|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
11418462|NCT01912729|Experimental|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
11418463|NCT01912729|Experimental|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
11418464|NCT01912729|No Intervention|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
11418465|NCT01912716|Experimental|high-dose indomethacin|200mg rectal indomethacin
11418466|NCT01912716|Active Comparator|standard dose indomethacin|100mg rectal indomethacin
11418467|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
11418468|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
11418469|NCT01912690|Placebo Comparator|standard of care|
11418470|NCT01912690|Active Comparator|aerobic training only|
11418471|NCT01912690|Active Comparator|Aerobic and strength training|
11418504|NCT01912469|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
11418472|NCT01912677|Active Comparator|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
11418473|NCT01912677|Experimental|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
11418474|NCT01912677|Experimental|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
11418475|NCT01912651|No Intervention|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
11418476|NCT01912651|Experimental|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
11418477|NCT01912638|Experimental|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
11418478|NCT01912638|Active Comparator|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
11418479|NCT01912625|Experimental|Treatment (trametinib, chemotherapy, radiation therapy)|"CONCURRENT CHEMOTHERAPY: Patients undergo IMRT or 3D-CRT QD 5 days a week for 6 weeks. Patients receive trametinib PO QD and carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiation proceed to consolidation chemotherapy.
~CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and 22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
11418480|NCT01912612|Experimental|Arm 1 (Patients with pain, duloxetine)|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
11418481|NCT01912612|No Intervention|Arm 2 (Patients without pain -- control)|Patient reported pain and symptoms assessment for comparison at baseline.
11418482|NCT01912599|Active Comparator|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
11418483|NCT01912599|Active Comparator|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
11418484|NCT01912586|No Intervention|Arm A|Patients receive no interventions for ED after laparoscopic surgery
11418485|NCT01912586|Experimental|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
11418486|NCT01912586|Experimental|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
11418487|NCT01912573|Experimental|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
11418488|NCT01912573|Active Comparator|Standard of Care (TAU)|Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose.
11418489|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
11418490|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
11418491|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
11418492|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
11418493|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
11418494|NCT01912534|Active Comparator|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
11418495|NCT01912534|Placebo Comparator|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
11418496|NCT01912521|Experimental|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
11418497|NCT01912521|No Intervention|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
11418498|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
11418499|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
11418500|NCT01912495|Experimental|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
11418501|NCT01912482|Experimental|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
11418502|NCT01912482|Active Comparator|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
11418539|NCT01912248||patients with ischemic heart disease|strength training
11418505|NCT01912469|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
11418506|NCT01912456|Experimental|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
11418507|NCT01912456|Experimental|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
11418508|NCT01912456|Experimental|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
11418509|NCT01912456|Experimental|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
11418510|NCT01912443||Bevacizumab Plus Chemotherapy|
11418511|NCT01912430|Experimental|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
11418512|NCT01912430|Experimental|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
11418513|NCT01912417|Experimental|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
11418514|NCT01912417|No Intervention|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
11418515|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
11418516|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
11418517|NCT01912391|Experimental|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
11418518|NCT01912391|Placebo Comparator|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
11418519|NCT01912378|Experimental|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
11418520|NCT01912378|Placebo Comparator|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
11418521|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast & collar/cuff for 3 weeks
11418522|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint & collar/cuff for 3 weeks
11418523|NCT01912352|Experimental|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
11418524|NCT01912339|Experimental|Treatment|Treatment: Rezūm System
11418525|NCT01912339|Other|Control|Control: Rigid Cystoscopy
11418526|NCT01912326|Active Comparator|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
11418527|NCT01912326|Active Comparator|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
11418528|NCT01912313|Experimental|Rectal biopsy|
11418529|NCT01912300|Experimental|Lean adolescents|
11418530|NCT01912300|Experimental|Obese adolescents|
11418531|NCT01912287|Experimental|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
11418532|NCT01912287|Active Comparator|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available [88]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
11418533|NCT01912287|Sham Comparator|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
11418534|NCT01912274|Experimental|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
11418535|NCT01912261|Active Comparator|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
11418536|NCT01912261|Placebo Comparator|Placebo|one capsule orally daily
11418537|NCT01912248||Heart failure|strength training
11418538|NCT01912248||Heart Transplant recipients|strength training
11418540|NCT01912235|Active Comparator|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
11418541|NCT01912235|Active Comparator|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine &15N proline to measure arginine and proline flux
11418542|NCT01912235|Active Comparator|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
11418543|NCT01912222|Experimental|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.
~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
11418544|NCT01912222|Experimental|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.
~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
11418545|NCT01912222|Experimental|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.
~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
11418546|NCT01912209|Experimental|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
11418547|NCT01912209|No Intervention|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
11418548|NCT01912196|Experimental|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).
~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
11418549|NCT01912196|Placebo Comparator|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).
~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
11418550|NCT01912183|Active Comparator|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
11418551|NCT01912183|Experimental|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
11418552|NCT01912170|Experimental|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
11418553|NCT01912170|Experimental|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
11418554|NCT01912170|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
11418555|NCT01912157|Placebo Comparator|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
11418556|NCT01912157|Active Comparator|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
11418557|NCT01912144|Other|coffee|Coffee beverage
11418558|NCT01912131|Experimental|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
11418559|NCT01912131|Active Comparator|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
11418560|NCT01912131|Experimental|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
11418561|NCT01912131|Experimental|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences.
11418607|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
11418721|NCT01911078|Other|Renal Denervation Group|Subjects receiving renal denervation procedure.
11418562|NCT01912118|Experimental|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
11418563|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
11418564|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
11418565|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
11418566|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
11418567|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
11418568|NCT01912118|Experimental|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
11418569|NCT01912118|Experimental|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
11418570|NCT01912105|Experimental|treatment|Airway Medix Closed Suction System
11418571|NCT01912105|Active Comparator|control|standard closed suctioning systems
11418572|NCT01912092|Experimental|Askina Calgitrol Paste|
11418573|NCT01912066|Experimental|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
11418574|NCT01912066|Active Comparator|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
11418575|NCT01912053|Experimental|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
11418576|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
11418577|NCT01912027|Experimental|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
11418578|NCT01912027|Active Comparator|Open Latarjet technique|Open Latarjet technique
11418579|NCT01912014|Experimental|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
11418580|NCT01912001|Other|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
11418581|NCT01911988||Colon&Rectal Stage II /Stage III|
11418582|NCT01911975|Placebo Comparator|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
11418583|NCT01911975|Experimental|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
11418584|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
11418585|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
11418586|NCT01911949|Experimental|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
11418587|NCT01911949|Placebo Comparator|Placebo femoral nerve block|Sterile normal saline solution
11418588|NCT01911936|Experimental|LJM716|
11418589|NCT01911923|Active Comparator|No CPAP/PEEP and 100 % oxygen|This is the control group
11418590|NCT01911923|Experimental|CPAP/PEEP and 30 % oxygen|This is the intervention group
11418591|NCT01911910|No Intervention|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
11418592|NCT01911910|Experimental|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
11418593|NCT01911897|Experimental|MobiusHD|MobiusHD
11418594|NCT01911884|Other|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
11418595|NCT01911871||thalassemia|patients affected with thalassemia
11418596|NCT01911871||sickle cell disease|patients affected with sickle cell disease
11418597|NCT01911871||myelodysplasia|patients affected with myelodysplasia
11418598|NCT01911858|Experimental|Askina Calgitrol Paste|
11418599|NCT01911845|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
11418600|NCT01911832|Experimental|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
11418601|NCT01911832|Experimental|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
11418602|NCT01911819|Experimental|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
11418603|NCT01911819|Experimental|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
11418604|NCT01911819|Experimental|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
11418605|NCT01911806|Experimental|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks & back care pillow use during the day for 2 weeks
11418606|NCT01911806|Active Comparator|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
11418942|NCT01909544|Experimental|Oxygen|
11418943|NCT01909544|Sham Comparator|Room air|
11418608|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
11418609|NCT01911780|Experimental|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
11418610|NCT01911780|Active Comparator|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
11418611|NCT01911767||Dimethyl fumarate|Exposure to dimethyl fumarate since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy
11418612|NCT01911767||Peginterferon beta-1a|Exposure to Peginterferon beta-1a since 17 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
11418613|NCT01911767||Disease Modifying Therapy (DMT) Unexposed|Never received DMT therapy; discontinued treatment with any DMT at least more than 5× half-life prior to Day 1 of her LMP and throughout the entire pregnancy.
11418614|NCT01911754|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
11418615|NCT01911741|Experimental|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
11418616|NCT01911741|Experimental|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
11418617|NCT01911741|Experimental|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
11418618|NCT01911728|Experimental|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
11418619|NCT01911715|Experimental|Single Oral MDV3100 dose|
11418620|NCT01911702|Active Comparator|Conventional Group|In this group patients receive volemic standard treatment (conventional)
11418621|NCT01911702|Active Comparator|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
11418622|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
11418623|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
11418624|NCT01911676|Experimental|PF-03463275 Active Dose #1|Active dose between 40mg
11418625|NCT01911676|Experimental|PF-03463275 Active Dose #2|Active dose between 60mg
11418626|NCT01911676|Placebo Comparator|Placebo|Placebo- no active dose of PF-03463275.
11418627|NCT01911663|Experimental|KRG|500 mg Korea red ginseng (KRG)
11418628|NCT01911663|Placebo Comparator|Placebo|500 mg placebo (corn starch)
11418629|NCT01911650|Experimental|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
11418630|NCT01911650|Other|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
11418631|NCT01911637|Experimental|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
11418632|NCT01911637|Placebo Comparator|Placebo|Placebo
11418633|NCT01911624|Experimental|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
11418634|NCT01911624|Active Comparator|enoxaparin|enoxaparin 40 mg od, sc
11418635|NCT01911611|Placebo Comparator|Placebo|
11418636|NCT01911611|Experimental|RO6870868|
11418637|NCT01911598|Experimental|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
11418638|NCT01911598|Experimental|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
11418639|NCT01911585|Active Comparator|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
11418640|NCT01911585|Experimental|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
11418641|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
11418642|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
11419452|NCT01906099|Experimental|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
11418643|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
11418644|NCT01911546|Experimental|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
11418645|NCT01911533|Experimental|extracorporeal CO2|
11418646|NCT01911520|Experimental|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
11418647|NCT01911520|Experimental|BMI < 50, TBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
11418648|NCT01911520|Experimental|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
11418649|NCT01911520|Experimental|BMI < 50, IBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
11418650|NCT01911520|Experimental|BMI > 50, TBW, 2mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
11418651|NCT01911520|Experimental|BMI > 50, TBW, 4mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
11418652|NCT01911520|Experimental|BMI >50, IBW, 2 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
11418653|NCT01911520|Experimental|BMI >50, IBW, 4 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
11418654|NCT01911507|Experimental|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11418655|NCT01911494|Experimental|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
11418656|NCT01911494|No Intervention|Control|Current standard of antenatal care
11418657|NCT01911481|Experimental|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
11418658|NCT01911481|No Intervention|control|
11418659|NCT01911468|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
11418660|NCT01911468|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
11418661|NCT01911468|Active Comparator|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
11418662|NCT01911455|Active Comparator|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
11418663|NCT01911455|Placebo Comparator|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
11418664|NCT01911442|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
11418665|NCT01911442|Experimental|Lurasidone 60 mg|Lurasidone 60 mg once daily
11418666|NCT01911442|Placebo Comparator|Placebo|Placebo once daily
11418667|NCT01911429|Experimental|Lurasidone 40 mg|Lurasidone 40 mg once daily
11418668|NCT01911429|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
11418669|NCT01911429|Placebo Comparator|Placebo|Placebo 40 or 80 mg once daily
11418670|NCT01911416|Experimental|All participants|All participants on study
11418671|NCT01911403|Active Comparator|Angio-Seal|Closure procedure by Angio-Seal
11418672|NCT01911403|Active Comparator|Manual compression|Closure procedure by manual compression
11418673|NCT01911390|Placebo Comparator|Control Arm|No bean or rice bran additive in smoothie or muffin.
11418674|NCT01911390|Active Comparator|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
11418675|NCT01911390|Active Comparator|Rice bran|15 grams rice bran/day in smoothie or muffin.
11418676|NCT01911390|Active Comparator|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
11418677|NCT01911377|Active Comparator|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.
~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
11418678|NCT01911377|Placebo Comparator|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
11418679|NCT01911364|Experimental|BDP/FF/GB|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
11418680|NCT01911364|Active Comparator|Tiotropium|Tiotropium bromide 18 mcg
11418681|NCT01911364|Active Comparator|BDP/FF + Tiotropium|"BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily
~BDP/FF/GB versus BDP/FF + Tiotropium"
11418682|NCT01911351|No Intervention|standard management|Patients randomized to this arm will receive standard management alone for their minor procedure.
11418683|NCT01911351|Experimental|Nitrous Oxide|Patients randomized to this arm will receive nitrous oxide plus standard management for their minor procedure.
11418684|NCT01911338|Experimental|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
11418685|NCT01911338|Active Comparator|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
11418686|NCT01911325|Experimental|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
11418687|NCT01911325|Experimental|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
11418688|NCT01911325|Placebo Comparator|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
11418689|NCT01911312|Experimental|Intervention|
11418690|NCT01911312|Active Comparator|Body Temperature Control|Stimulation performed with body temperature control
11418691|NCT01911299|Experimental|Choline|Liquid glycerophosphocholine (GPC) supplement
11418692|NCT01911299|Placebo Comparator|Placebo|Liquid placebo supplement
11418693|NCT01911286||Standard group|Apnea test according to the recommendation
11418694|NCT01911286||CPAP group|Apnea test with CPAP connection
11418695|NCT01911273|Experimental|PF 03446962 plus best supportive care (BSC)|
11418696|NCT01911273|Placebo Comparator|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
11418697|NCT01911260|Active Comparator|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
11418698|NCT01911260|Placebo Comparator|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
11418699|NCT01911260|Placebo Comparator|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
11418700|NCT01911260|Active Comparator|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.
~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
11418701|NCT01911247|Experimental|Arm 1|
11418702|NCT01911234|Experimental|TNF-Kinoid|TNF Kinoid + ISA51
11418703|NCT01911234|Placebo Comparator|Placebo|Placebo + ISA51
11418704|NCT01911221|Experimental|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
11418705|NCT01911208|Experimental|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
11418706|NCT01911208|Experimental|Control|Clinical sites can use which ever recruitment methods they prefer.
11418707|NCT01911195|Active Comparator|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
11418708|NCT01911195|Experimental|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
11418709|NCT01911182|Experimental|Inhalation of low concentration of CO2|
11418710|NCT01911182|Active Comparator|caffeine only|
11418711|NCT01911169|Experimental|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
11418712|NCT01911169|Active Comparator|Vitamin D 400|cholecalciferol 400 IU daily by mouth
11418713|NCT01911156|Other|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
11418714|NCT01911156|Other|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
11418715|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.
~Patients undergo cardiac surgery and are over 18 years of age.
~Patients need bypass machine for their cardiac surgery and traditional CO measurement.
~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
11418716|NCT01911104|Experimental|Exercise|10 weeks of aerobic exercise
11418717|NCT01911104|No Intervention|Active Control|Young athletes as a trained control
11418718|NCT01911091|Experimental|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
11418719|NCT01911091|No Intervention|Group 2 - Athlete exercise|Athletes are not given any intervention
11418722|NCT01911078|No Intervention|Control Group|"Subjects not receiving renal denervation procedure.
~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
11418723|NCT01911065|Experimental|Zostavax™ vaccine group|Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
11418724|NCT01911065|No Intervention|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
11418725|NCT01911052|Experimental|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
11418726|NCT01911052|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
11418727|NCT01911052|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
11418728|NCT01911039|Experimental|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
11418729|NCT01911026|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
11418730|NCT01911026|No Intervention|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
11418731|NCT01911013|Active Comparator|Cage and Plate|anterior cervical discectomy and fusion surgery at one segment is performed using cervical cage and plate system
11418732|NCT01911013|Experimental|Cage alone|anterior cervical discectomy and fusion surgery at one segment is performed using only cervical cage without plate
11418733|NCT01911000|Experimental|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
11418734|NCT01910987|Experimental|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
11418735|NCT01910987|Other|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
11418736|NCT01910974|Experimental|endoscopic sub-mucosal dissection|
11418737|NCT01910961|Experimental|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
11418738|NCT01910961|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
11418739|NCT01910948|Experimental|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
11418740|NCT01910935|Experimental|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
11418741|NCT01910935|No Intervention|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
11418742|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
11418743|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
11418744|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
11418745|NCT01910909|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
11418746|NCT01910896|Experimental|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
11418747|NCT01910896|No Intervention|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
11418748|NCT01910883|Experimental|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
11418749|NCT01910883|Experimental|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
11418750|NCT01910883|Experimental|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
11418751|NCT01910883|Experimental|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
11418752|NCT01910883|Experimental|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
11418753|NCT01910883|Experimental|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
11418754|NCT01910870|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
11418755|NCT01910857|Experimental|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
11418756|NCT01910857|No Intervention|Control|Standard care
11418757|NCT01910844|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
11418758|NCT01910831|Experimental|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
11418759|NCT01910831|Placebo Comparator|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
11418760|NCT01910818|Experimental|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
11418761|NCT01910818|Experimental|No Treatment|This is the area receiving no treatment.
11418762|NCT01910805|Experimental|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
11418763|NCT01910805|No Intervention|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
11418764|NCT01910792|Active Comparator|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
11418765|NCT01910792|Active Comparator|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
11418766|NCT01910779|Active Comparator|100 joule arm|100 joule as first biphasic shock energy
11418767|NCT01910779|Active Comparator|120 joule arm|120 joule as first biphasic shock energy
11418768|NCT01910766|Experimental|Coenzyme Q10/CC group|"Intervention:
~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
11418769|NCT01910766|Active Comparator|CC alone group|"Intervention:
~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
11418770|NCT01910753|Experimental|APA|Patient with neck cancer and accepting the physical activity program .
11418771|NCT01910740|Experimental|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
11418772|NCT01910740|Active Comparator|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
11418773|NCT01910727|Experimental|Together on Diabetes-Hopkins|
11418774|NCT01910714|Active Comparator|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
11418775|NCT01910714|Experimental|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
11418776|NCT01910701|Experimental|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
11418777|NCT01910688|Experimental|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
11418778|NCT01910675|Experimental|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
11418779|NCT01910675|Active Comparator|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
11418780|NCT01910662|Experimental|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
11418781|NCT01910662|Experimental|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
11418782|NCT01910662|Experimental|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
11419453|NCT01906099|Active Comparator|healthy dietary recommendations|no nutritional intervention
11418783|NCT01910662|Experimental|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
11418784|NCT01910662|Experimental|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
11418785|NCT01910662|Experimental|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
11418786|NCT01910649|Experimental|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
11418787|NCT01910636|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
11418788|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
11418789|NCT01910610|Experimental|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
11418790|NCT01910610|Experimental|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
11418791|NCT01910597|Experimental|SBG|
11418792|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
11418793|NCT01910571|Experimental|P7435|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.
~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
11418794|NCT01910571|Placebo Comparator|Placebo|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.
~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
11418795|NCT01910558|Active Comparator|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
11418796|NCT01910558|Experimental|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
11418797|NCT01910558|Placebo Comparator|Digestible Starch|Supplementation with six grams of digestible starch
11418798|NCT01910545|Experimental|OTS167IV|single arm
11418799|NCT01910532|Experimental|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
11418800|NCT01910519|Experimental|H5N1 vaccine plus AS03 adjuvant|"H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant
~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
11418801|NCT01910519|Experimental|H5N1 vaccine without adjuvant|"H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant
~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
11418802|NCT01910506|Experimental|RDEA3170|
11418803|NCT01910493|Active Comparator|ART no SMS reminders|control group
11418804|NCT01910493|Active Comparator|PMTCT no SMS reminders|control group
11418805|NCT01910493|Experimental|SMS reminders to PMTCT cohort|experimental group
11418806|NCT01910493|Experimental|SMS reminders to ART cohort|experimental group
11418807|NCT01910480|Experimental|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
11418808|NCT01910467|Experimental|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
11418809|NCT01910467|Other|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
11418810|NCT01910454|Experimental|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
11418811|NCT01910454|Active Comparator|Task Specific Training (TST)|
11418812|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
11418813|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
11418814|NCT01910428|Experimental|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
11418815|NCT01910415|Experimental|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.
~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
11418944|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
11418816|NCT01910415|Experimental|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.
~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
11418817|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
11418818|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
11418819|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
11418820|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
11418821|NCT01910376||Control cohort|Nursing home residents without cancer
11418822|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
11418823|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
11418824|NCT01910363|Experimental|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
11418825|NCT01910363|Active Comparator|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
11418826|NCT01910350|Experimental|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
11418827|NCT01910350|Active Comparator|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
11418828|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
11418829|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
11418830|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
11418831|NCT01910324|Experimental|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
11418832|NCT01910324|Other|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
11418833|NCT01910311|Experimental|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
11418834|NCT01910311|Experimental|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
11418835|NCT01910298|Active Comparator|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).
11418836|NCT01910298|Active Comparator|Two Stage Breast Reconstruction|Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.
11418837|NCT01910285|Experimental|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
11418838|NCT01910285|Active Comparator|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
11418839|NCT01910259|Experimental|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
11418840|NCT01910259|Experimental|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
11418841|NCT01910259|Experimental|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
11418842|NCT01910259|Placebo Comparator|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
11418843|NCT01910246|Experimental|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
11418844|NCT01910233||adult patients with acute dyspnea in ED|
11418845|NCT01910220|Placebo Comparator|Group 1|placebo
11418846|NCT01910220|Experimental|Group 2|REGN1033 (SAR391786)
11418847|NCT01910220|Placebo Comparator|Group 3|placebo + exercise regimen
11418848|NCT01910220|Experimental|Group 4|REGN1033 (SAR391786) + exercise regimen
11418849|NCT01910194|Other|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
11418850|NCT01910194|Other|Lantus|4 weeks Lantus plus another 4 weeks combination
11418851|NCT01910181|Experimental|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
11418852|NCT01910181|Experimental|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
11418853|NCT01910168||Cohort|
11418854|NCT01910155|Experimental|Test|Ciprofloxacin/Dexamethasone
11418855|NCT01910155|Active Comparator|Reference|Ciprodex (R)
11418856|NCT01910155|Placebo Comparator|Placebo|Placebo
11418857|NCT01910142|Active Comparator|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
11418858|NCT01910142|Placebo Comparator|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
11418859|NCT01910129|Active Comparator|gammaCore|Active stimulation treatment
11418860|NCT01910129|Placebo Comparator|sham gammaCore|Inactive stimulation treatment
11418861|NCT01910116|Placebo Comparator|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
11418862|NCT01910116|Active Comparator|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
11418863|NCT01910090|Experimental|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
11418864|NCT01910090|Active Comparator|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
11418865|NCT01910077|Experimental|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
11418866|NCT01910077|Active Comparator|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
11418867|NCT01910064|Experimental|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
11418868|NCT01910051||Generally healthy|Generally healthy
11418869|NCT01910051||Type 2 diabetes mellitus|Type 2 diabetes mellitus
11418870|NCT01910038|Experimental|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
11418871|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
11418872|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
11418873|NCT01909999|Experimental|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
11418874|NCT01909999|Active Comparator|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
11418875|NCT01909986|Experimental|E1|[14C]-ONO-4053
11418876|NCT01909973|Experimental|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
11418877|NCT01909973|No Intervention|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
11418878|NCT01909960|Experimental|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
11418879|NCT01909960|Experimental|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
11418880|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
11418881|NCT01909934|Experimental|Brentuximab vedotin|1.8 mg/kg IV infusion
11418882|NCT01909908|Experimental|ECM in Saline|
11418883|NCT01909908|Active Comparator|Blood Products|
11418884|NCT01909908|Experimental|ECM in Blood Products|
11418885|NCT01909895|Experimental|Anger induction|The participant will be asked to undergo a validated anger induction task.
11418886|NCT01909895|Experimental|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
11418887|NCT01909895|Experimental|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
11418888|NCT01909895|Other|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
11418889|NCT01909882|Other|Family member's massage therapy|Family member's massage therapy
11418890|NCT01909869|Experimental|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
11418891|NCT01909856|Experimental|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
11418892|NCT01909856|Experimental|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
11418893|NCT01909843|Experimental|ALX-0171 Oral inhalation|
11418894|NCT01909830|Experimental|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.
~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
11418895|NCT01909817||Routine coronary angiogram patients|
11418896|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
11418897|NCT01909804|Experimental|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
11418898|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
11418899|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
11418900|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
11418901|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
11418902|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
11418903|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
11418904|NCT01909804|Experimental|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
11418905|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
11418906|NCT01909804|Experimental|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
11418907|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
11418908|NCT01909791|Experimental|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
11418909|NCT01909791|Active Comparator|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
11418910|NCT01909791|Experimental|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
11418911|NCT01909778|Experimental|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
11418912|NCT01909765|Active Comparator|Dorsal slite|Skin and mucosa insicion made together
11418913|NCT01909765|Experimental|Double incision|Skin and mucosa incision made separately
11418914|NCT01909752|Experimental|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
11418915|NCT01909752|Experimental|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
11418916|NCT01909752|Experimental|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
11418917|NCT01909739|Experimental|Statin group|
11418918|NCT01909739|Placebo Comparator|Placebo group|
11418919|NCT01909726||Interactive media|ScreenPlay
11418920|NCT01909726||Passive media|Silent nature video
11418921|NCT01909726||No media|Standard care
11418922|NCT01909713|Experimental|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
11418923|NCT01909700|Experimental|Single Incision Mesh|intervention: single incision mesh implantation
11418924|NCT01909674|Experimental|Oronasal Mask|Initial administration of oronasal CPAP mask
11418925|NCT01909674|Experimental|Nasal Mask|Initial administration of nasal CPAP mask
11418926|NCT01909661|Experimental|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
11418927|NCT01909661|Experimental|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
11418928|NCT01909648|Other|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
11418929|NCT01909635|Experimental|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
11418930|NCT01909635|Experimental|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
11418931|NCT01909622|Experimental|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
11418932|NCT01909622|Active Comparator|Vitamin D-unfortified milk|Unfortified skim milk
11418933|NCT01909609|Sham Comparator|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
11418934|NCT01909609|Experimental|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
11418935|NCT01909596|Experimental|Knee osteoarthritis patients|Without orthoses 6° lateral wedge insoles 10° lateral wedge insoles Neutral customized foot orthoses 6° lateral customized foot orthoses 7° lateral customized foot orthoses 8° lateral customized foot orthoses 9° lateral customized foot orthoses 10° lateral customized foot orthoses Orthotist integrated lateral customized foot orthoses Orthotist lateral customized foot orthoses
11418936|NCT01909583|Active Comparator|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
11418937|NCT01909583|Placebo Comparator|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
11418938|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
11418939|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
11418940|NCT01909557|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
11418941|NCT01909557|Placebo Comparator|placebo|
11418947|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
11418948|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
11418949|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
11418950|NCT01909479|Experimental|MOD-4023|
11418951|NCT01909479|Placebo Comparator|Placebo|
11418952|NCT01909466|Other|Gluteal Injection|
11418953|NCT01909466|Other|Deltoid Injection|
11418954|NCT01909453|Experimental|LGX818 450 mg + MEK162|LGX818 450 mg QD + MEK162 45 mg BID
11418955|NCT01909453|Active Comparator|Vemurafenib|Vemurafenib 960 mg BID
11418956|NCT01909453|Experimental|LGX818 300 mg + MEK162|LGX818 300 mg QD + MEK162 45 mg BID
11418957|NCT01909453|Experimental|LGX818|LGX818 300 mg QD
11418958|NCT01909440|Experimental|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
11418959|NCT01909440|Experimental|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
11418960|NCT01909440|Experimental|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
11418961|NCT01909440|Active Comparator|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
11418962|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
11418963|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
11418964|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
11418965|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
11418966|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
11418967|NCT01909414|Experimental|Arm A: GEO-D03 DNA and MVA/HIV62B vaccines|At study entry and Week 8, participants will receive the GEO-D03 DNA vaccine administered as 1 mL intramuscularly (IM) in either deltoid. At Weeks 16 and 24, they will receive the MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
11418968|NCT01909414|Placebo Comparator|Arm B: Placebo for GEO-D03 and MVA/HIV62B|At study entry and Week 8, participants will receive the placebo for GEO-D03 DNA vaccine administered as 1 mL IM in either deltoid. At Weeks 16 and 24, they will receive the placebo for MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
11418969|NCT01909388|Experimental|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
11418970|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
11418971|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer
11418972|NCT01909349|No Intervention|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (>8 weeks after signing up)
11418973|NCT01909349|Experimental|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit & vegetable intake
11418974|NCT01909336|Active Comparator|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
11418975|NCT01909336|Active Comparator|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
11418976|NCT01909336|Active Comparator|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
11418977|NCT01909323|Placebo Comparator|sugary dessert cream|
11418978|NCT01909323|Experimental|maltitol alone|
11418979|NCT01909323|Experimental|maltitol 85% / FOS 15%|
11418980|NCT01909323|Experimental|maltitol 68% / FOS 32%|
11418981|NCT01909323|Experimental|maltitol 50% / FOS 50%|
11418982|NCT01909323|Experimental|FOS alone|
11418983|NCT01909310|Active Comparator|with head support|patients are ventilated with their heads positioned on a support
11418984|NCT01909310|Sham Comparator|without head support|patients are ventilated without head support
11418985|NCT01909297|Active Comparator|ProSeal LMA|Supraglottic airway device
11418986|NCT01909297|Active Comparator|suprema LMA|Supraglottic airway device
11418987|NCT01909297|Active Comparator|I-gel LMA|Supraglottic airway device
11418988|NCT01909284|Experimental|Acupuncture & Epidural nerve block|acupuncture plus epidural block
11418989|NCT01909284|Active Comparator|Epidural nerve block|epidural block alone
11418990|NCT01909271|Experimental|Intervention Group|Participants will receive education through a novel program called Stroke Education Film Viewing.
11418991|NCT01909271|Other|Usual Care Group|Participants will receive education through Stroke Education Pamphlet Exposure.
11418992|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.
~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
11418993|NCT01909245|Experimental|Single Arm Study|
11418994|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
11418995|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
11418996|NCT01909219|Active Comparator|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
11418997|NCT01909219|Active Comparator|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
11418998|NCT01909193|Experimental|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
11418999|NCT01909193|Experimental|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
11419000|NCT01909180|Experimental|Cardiac|Revolution CT Cardiac Imaging Scan
11419001|NCT01909180|Experimental|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
11419002|NCT01909180|Experimental|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
11419003|NCT01909167|Active Comparator|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
11419004|NCT01909167|Active Comparator|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
11419005|NCT01909154|Experimental|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
11419006|NCT01909141|Active Comparator|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
11419007|NCT01909141|Active Comparator|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
11419008|NCT01909128|Experimental|fermented milk|
11419009|NCT01909128|Experimental|fermented rice|
11419010|NCT01909128|Placebo Comparator|placebo|
11419011|NCT01909115|Active Comparator|1000 IU of Vitamin D Daily|Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
11419012|NCT01909115|Experimental|4000 IU of Vitamin D Daily|Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
11419013|NCT01909102|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
11419014|NCT01909102|Active Comparator|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
11419015|NCT01909089|Experimental|Chloroprocaine|Up-down sequential allocation.
11419016|NCT01909076|Active Comparator|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
11419017|NCT01909076|Experimental|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
11419018|NCT01909063|Experimental|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
11419019|NCT01909063|Experimental|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice
~Vitamin D, Vitamin E, and Vitamin A"
11419020|NCT01909063|Placebo Comparator|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice
~Control, 700 mg Calcium"
11419021|NCT01909050||refractory celiac disease|
11419022|NCT01909050||well-controlled celiac disease|
11419023|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
11419024|NCT01909050||gluten-sensitivity|
11419025|NCT01909050||disorders other than celiac disease.|
11419026|NCT01909037|Experimental|Flexofytol (bio-optimized curcumin)|
11419027|NCT01909024|Experimental|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
11419028|NCT01909024|Active Comparator|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
11419029|NCT01909011|Experimental|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
11419030|NCT01909011|Sham Comparator|Sham CES|The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.
11419031|NCT01908998|Active Comparator|Sandal|
11419032|NCT01908972|Active Comparator|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
11419033|NCT01908972|Experimental|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
11419058|NCT01908816|Experimental|ranibizumab|0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
11419059|NCT01908803|Experimental|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
11419454|NCT01906086|Experimental|legume consumption|legume consumption, 4 servings per week, for 6 weeks
11419034|NCT01908959|Experimental|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
11419035|NCT01908959|No Intervention|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
11419036|NCT01908946|Experimental|SMS Reminders|SMS reminders
11419037|NCT01908946|No Intervention|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
11419038|NCT01908933|Experimental|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
11419039|NCT01908920|Other|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
11419040|NCT01908920|Other|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
11419041|NCT01908920|Other|CONTROL|No intervention
11419042|NCT01908907|Active Comparator|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
11419043|NCT01908907|Placebo Comparator|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
11419044|NCT01908894|Experimental|BIOD-123|SC administration of 0.20 U/kg
11419045|NCT01908894|Experimental|BIOD-125|SC administration of 0.20 U/kg
11419046|NCT01908894|Active Comparator|Humalog|SC administration of 0.20 U/kg
11419047|NCT01908881|Active Comparator|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
11419048|NCT01908881|Experimental|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
11419049|NCT01908868|Experimental|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
11419050|NCT01908868|Active Comparator|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
11419051|NCT01908855|Experimental|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
11419052|NCT01908855|Active Comparator|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
11419053|NCT01908842|Active Comparator|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
11419054|NCT01908842|Experimental|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
11419055|NCT01908829|Experimental|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
11419056|NCT01908829|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
11419057|NCT01908829|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
11419060|NCT01908803|Active Comparator|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
11419061|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
11419062|NCT01908777|Experimental|high dose chemo w/asct + maintenance txt|High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)
11419063|NCT01908764|Experimental|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
11419064|NCT01908764|Experimental|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
11419065|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
11419066|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
11419067|NCT01908751|Experimental|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
11419068|NCT01908751|Experimental|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
11419069|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
11419070|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
11419071|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
11419072|NCT01908725|Experimental|Lamazym|1 mg Lamazym/kg body weight
11419073|NCT01908712|Experimental|Lamazym|1 mg Lamazym/kg body weight
11419074|NCT01908699|Experimental|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
11419075|NCT01908699|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
11419076|NCT01908686|Active Comparator|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
11419077|NCT01908686|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
11419078|NCT01908673|Active Comparator|HRV biofeedback|heart rate variability biofeedback
11419079|NCT01908673|Active Comparator|ASTM|Automatic Self Transcedental Meditation
11419080|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
11419081|NCT01908647|Experimental|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
11419082|NCT01908647|Experimental|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
11419083|NCT01908647|Experimental|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
11419084|NCT01908647|Sham Comparator|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
11419085|NCT01908634|Active Comparator|Milk-based Strawberry Beverage|Strawberry beverage with milk
11419086|NCT01908634|Experimental|Water-based Strawberry Beverage|Strawberry beverage with water
11419087|NCT01908634|Active Comparator|Milk-based Fruit-mixed Beverage|Fruit-Mixed beverage with milk
11419088|NCT01908634|Experimental|Water-based Fruit-Mixed Beverage|Fruit-Mixed beverage with Water
11419089|NCT01908621|Active Comparator|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
11419090|NCT01908621|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
11419091|NCT01908595|Experimental|M518101|Proper quantity twice daily
11419092|NCT01908582|Experimental|Evacetrapib|"Period 1:
~130 milligram (mg) evacetrapib administered orally, once on Day 1"
11419093|NCT01908582|Experimental|Evacetrapib + Rifampin|"Period 2:
~Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)
~Evacetrapib: 130 mg administered orally once on Day 16"
11419094|NCT01908569|Active Comparator|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
11419095|NCT01908569|Experimental|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
11419096|NCT01908556|Experimental|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
11419097|NCT01908543|Experimental|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet
~This is a single arm study. Individuals in this arm will
~have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods
~receive a single tablet of ferrous sulphate 200mg
~fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months
~have a second blood sample later that day (20 mls of blood
~Total number of participants in arm = 100"
11419098|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 1|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
11419099|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 2|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
11419100|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 3 and 4|The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
11419101|NCT01908517|Experimental|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
11419102|NCT01908504|Other|PET-CT|
11419103|NCT01908491|Active Comparator|IV PCA|hydromorphone with ketorolac
11419104|NCT01908491|Experimental|Continuous wound infusion|ON-Q Painbuster with ropivacaine
11419105|NCT01908478|Experimental|Combination: veliparib, gemcitabine, and IMRT|
11419106|NCT01908465|Active Comparator|Ebastine|Ebastine
11419107|NCT01908465|Placebo Comparator|placebo|Placebo
11419108|NCT01908452|Experimental|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
11419109|NCT01908452|Placebo Comparator|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
11419110|NCT01908439|Experimental|Whole-body vibration|A new method for muscle reflex latency measurement
11419111|NCT01908426|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
11419112|NCT01908426|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo tablet once daily
11419113|NCT01908413|Experimental|CUDC-427|
11419114|NCT01908400|Other|BMMNCs|Intravenous transfer of (BMMNCs)
11419115|NCT01908387|Experimental|Oral azacitidine|
11419116|NCT01908374|Active Comparator|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
11419117|NCT01908374|Experimental|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids [(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)]
11419118|NCT01908361|Experimental|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
11419119|NCT01908361|Experimental|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
11419120|NCT01908361|Active Comparator|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
11419121|NCT01908348|Experimental|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
11419122|NCT01908335|Experimental|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
11419123|NCT01908335|Experimental|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
11419124|NCT01908335|Experimental|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
11419125|NCT01908335|Active Comparator|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
11419126|NCT01908322||Group 1|
11419127|NCT01908309|Active Comparator|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
11419128|NCT01908309|Active Comparator|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
11419129|NCT01908296|Experimental|FK949E group|receiving FK949E with and without fluvoxamine
11419130|NCT01908283|Experimental|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
11419131|NCT01908283|Experimental|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
11419132|NCT01908270|Experimental|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
11419134|NCT01908257|Experimental|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)
~Day 5: Ranitidine 150 mg twice daily (bid)
~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.
~Day 7: Ranitidine 150 mg (bid)"
11419135|NCT01908257|Experimental|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)
~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad
~Day 3: Ranitidine 150 mg (bid)
~Day 7: Lesinurad 400 mg (qd)"
11419136|NCT01908244|No Intervention|Control|No pentatonic music
11419137|NCT01908244|Experimental|Music|
11419138|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
11419139|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
11419140|NCT01908205|Experimental|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
11419141|NCT01908205|Placebo Comparator|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
11419142|NCT01908192|Experimental|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
11419143|NCT01908192|Placebo Comparator|Placebo|The control treatment is placebo.
11419144|NCT01908166|Experimental|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
11419145|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
11419146|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
11419147|NCT01908140|Experimental|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
11419148|NCT01908140|Active Comparator|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
11419149|NCT01908127|Active Comparator|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.
~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
11419150|NCT01908127|Experimental|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
11419151|NCT01908114|No Intervention|Group A|Routine Polio Program activities will be carried out with out any active intervention
11419152|NCT01908114|Experimental|Group B|"Expanded intervention with following components
~Community support groups for both male and female at village/community level
~Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations
~Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)
~Delivery of interventions & commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
11419153|NCT01908114|Experimental|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
11419154|NCT01908101|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11419155|NCT01908088|Experimental|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
11419156|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
11419157|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
11419158|NCT01908062|Active Comparator|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
11419159|NCT01908062|Experimental|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
11419160|NCT01908049|Experimental|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
11419161|NCT01908049|Placebo Comparator|Placebo|No active substance is given.
11419162|NCT01908023|Experimental|exercise|
11419163|NCT01908010|Experimental|Group 1, low dose|ABT-354
11419164|NCT01908010|Experimental|Group 2, high dose|ABT-354
11419165|NCT01907997|Experimental|Group L|Intravenous lidocaine infusion group
11419166|NCT01907997|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
11419167|NCT01907984|Experimental|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
11419168|NCT01907984|Active Comparator|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
11419169|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
11419170|NCT01907945|Experimental|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
11419171|NCT01907945|Active Comparator|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
11419172|NCT01907932|Experimental|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents
~Each resident will complete questionaire:
~Adequacy of image quality
~What is best view obtained
~Greatest Longitudinal Measure
~Diagnosis
~Diagnostic Certainty
~Time to Complete exam"
11419173|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
11419174|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:
~Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.
~Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.
~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
11419175|NCT01907906|Experimental|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
11419176|NCT01907906|Experimental|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
11419177|NCT01907893|Experimental|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
11419178|NCT01907893|No Intervention|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
11419179|NCT01907880|Active Comparator|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
11419180|NCT01907880|Active Comparator|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
11419181|NCT01907867|Experimental|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.
~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).
~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
11419182|NCT01907867|Experimental|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.
~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).
~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.
~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
11419183|NCT01907867|Experimental|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.
~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).
~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.
~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
11419184|NCT01907854|Experimental|Liraglutide + metformin + sitagliptin placebo|
11419185|NCT01907854|Experimental|Sitagliptin + metformin + liraglutide placebo|
11419186|NCT01907841|Experimental|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
11419187|NCT01907841|Placebo Comparator|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
11419188|NCT01907828|Experimental|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
11419189|NCT01907828|Active Comparator|Cardiac ablation|Cardiac ablation
11419190|NCT01907815|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11419455|NCT01906086|Active Comparator|healthy dietary recommendations|no nutritional intervention
11419191|NCT01907802|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11419192|NCT01907789|Experimental|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
11419193|NCT01907789|Experimental|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
11419194|NCT01907789|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
11419195|NCT01907776|Experimental|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
11419196|NCT01907776|Placebo Comparator|Placebo|ME1100 placebo inhalation solution
11419197|NCT01907763|Experimental|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
11419198|NCT01907763|Experimental|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
11419199|NCT01907763|Placebo Comparator|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
11419200|NCT01907750|Active Comparator|Transanastomotic tube|use of transanastomotic tube.
11419201|NCT01907750|Active Comparator|Transcystic tube|use of transcystic tube to drain bile duct
11419202|NCT01907737|Active Comparator|Active tDCS and active PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
11419203|NCT01907737|Other|Active tDCS and sham PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
11419204|NCT01907737|Other|Sham tDCS and active PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
11419205|NCT01907737|Sham Comparator|Sham tDCS and sham PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
11419206|NCT01907724|Experimental|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
11419207|NCT01907724|Experimental|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
11419208|NCT01907711|Sham Comparator|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
11419209|NCT01907711|Active Comparator|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
11419210|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
11419211|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
11419212|NCT01907685|Experimental|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
11419213|NCT01907672|Experimental|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
11419214|NCT01907672|No Intervention|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
11419215|NCT01907659|No Intervention|Standard of care|Standard of care for respiratory infections
11419216|NCT01907659|Experimental|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
11419217|NCT01907646|Experimental|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
11419218|NCT01907646|Experimental|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
11419219|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
11419220|NCT01907620|Other|Normal pregnancy|women pregnant
11419221|NCT01907620|Other|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
11419222|NCT01907607|Experimental|PD-0332991|"Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib.
~PD-0332991 is formulated as gelatin capsules of 100 mg and 25 mg respectively."
11419662|NCT01904617|Experimental|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
11419223|NCT01907594|Active Comparator|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
11419224|NCT01907594|Placebo Comparator|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
11419225|NCT01907581|Other|Patients admitted to an ICU|
11419226|NCT01907568||Patients with schizophrenia|With and without hallucinations
11419227|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
11419228|NCT01907568||Patients with hearing impairment|With and without hallucinations
11419229|NCT01907568||Patients with visual loss|With and without hallucinations
11419230|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
11419231|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
11419232|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
11419233|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
11419234|NCT01907568||Patients with delirium|With and without hallucinations
11419235|NCT01907568||Healthy participants|With and without hallucinations
11419236|NCT01907568||Patients with mood disorder|With and without hallucinations
11419237|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
11419238|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
11419239|NCT01907555||Patients presenting neutropenia|
11419240|NCT01907542|Active Comparator|Monocryl suture skin closure|Monocryl skin suture
11419241|NCT01907542|Active Comparator|Stapled skin closure|stapled skin closure
11419242|NCT01907529|Experimental|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
11419243|NCT01907529|Active Comparator|Chemo only|docetaxel, epirubicin and cyclophosphamide
11419244|NCT01907516|Active Comparator|Cell phone-internet first|Cell phone-internet home glucose reporting system first
11419245|NCT01907516|Placebo Comparator|Voicemail first|Voicemail home blood glucose reporting first
11419246|NCT01907503|Other|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
11419247|NCT01907503|Other|Healthy volunteer|Healthy volunteer
11419248|NCT01907490|Experimental|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
11419249|NCT01907477|Other|neutropenic patients|
11419250|NCT01907464|Experimental|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
11419251|NCT01907464|Active Comparator|controls subjects|This arm is composed of healthy volunteers
11419252|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
11419253|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
11419254|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
11419255|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
11419256|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
11419257|NCT01907425|Other|Pre-natal Patient|
11419258|NCT01907412|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
11419259|NCT01907412|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
11419260|NCT01907399|Other|obese patients|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
11419261|NCT01907399|Other|obese patients with type 2 diabetes|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
11419262|NCT01907399|Other|healthy volunteers|free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L
11419263|NCT01907386|Other|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).
~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.
~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).
~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
11419264|NCT01907373|Active Comparator|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
11419265|NCT01907373|Experimental|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
11419266|NCT01907360|Experimental|Adolescents (13-17yrs)|Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)
11419267|NCT01907360|Experimental|Children (6-11 yrs)|Drug: B-HLD200 54mg capsules (Methylphenidate Modified Release B Formulation) or Drug: C-HLD200 54mg capsules (Methylphenidate Modified Release C Formulation)
11419268|NCT01907347||ICU patients|
11419328|NCT01906957|Experimental|coronary patients|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
11419329|NCT01906957|Experimental|heart failure patients|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
11419269|NCT01907334|Active Comparator|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
11419270|NCT01907334|Active Comparator|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
11419271|NCT01907321|Experimental|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
11419272|NCT01907321|Placebo Comparator|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
11419273|NCT01907308|Experimental|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
11419274|NCT01907295||Patients|Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH
11419275|NCT01907295||Relatives and controls|Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals
11419276|NCT01907282|Experimental|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
11419277|NCT01907282|Active Comparator|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
11419278|NCT01907269|Experimental|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
11419279|NCT01907269|No Intervention|Usual care|
11419280|NCT01907256|Active Comparator|group A|stair step incisions
11419281|NCT01907256|Active Comparator|Group B|inverted V incision
11419282|NCT01907243|Active Comparator|spreader flap|Usage of spreader flap of upper lateral cartilage
11419283|NCT01907243|No Intervention|Control group|performing of rhinoplasty without spreader flap
11419284|NCT01907230|Experimental|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
11419285|NCT01907230|No Intervention|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
11419286|NCT01907217|Active Comparator|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
11419287|NCT01907217|Experimental|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
11419288|NCT01907204|Active Comparator|Oral|Oral drug (methylprednisolone) administration
11419289|NCT01907204|Experimental|Metered dose inhaler|
11419290|NCT01907204|Experimental|Nebulized|
11419291|NCT01907191|Experimental|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine
11419292|NCT01907191|Active Comparator|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint)
11419293|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
11419294|NCT01907165|Experimental|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
11419295|NCT01907165|Experimental|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
11419296|NCT01907152|Experimental|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
11419297|NCT01907152|No Intervention|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
11419298|NCT01907139|Experimental|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
11419299|NCT01907139|Experimental|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
11419300|NCT01907139|Active Comparator|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
11419301|NCT01907139|Experimental|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
11419302|NCT01907126|Experimental|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
11419303|NCT01907126|Placebo Comparator|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
11419304|NCT01907113|Experimental|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
11419305|NCT01907113|Experimental|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
11419306|NCT01907113|Experimental|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
11419307|NCT01907113|Experimental|BI 10773 / Group 5|Single Dose Administration (kidney failure)
11419308|NCT01907113|Experimental|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
11419309|NCT01907100|Placebo Comparator|Placebo + pemetrexed/cisplatin|Placebo controlled arm
11419310|NCT01907100|Experimental|Nintedanib 200mg + pemetrexed/cisplatin|Experimental arm
11419311|NCT01907087|Experimental|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
11419312|NCT01907074|Experimental|Cholates Compound|
11419313|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
11419314|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
11419315|NCT01907061|Active Comparator|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
11419316|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
11419317|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
11419318|NCT01907035|Experimental|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
11419319|NCT01907035|Active Comparator|Usual care|Family practice attention without the psychologist support
11419320|NCT01907022|Experimental|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
11419321|NCT01907009|Experimental|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.
~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.
~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).
~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.
~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
11419322|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
11419323|NCT01906996||four corner fusion|patients were treated with a four corner fusion
11419324|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
11419325|NCT01906970|Experimental|ClampArt|ClampArt
11419326|NCT01906957|Experimental|Elderly healthy subjects|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
11419327|NCT01906957|Experimental|Patients with metabolic syndrome|"Randomization into :
~high intensity interval training (HIIT)(n=20)
~or
~moderate intensity intensity continuous exercise (n=20)"
11419330|NCT01906944|Active Comparator|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
11419331|NCT01906944|Active Comparator|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
11419332|NCT01906931|Experimental|Portable Oxygen Concentrator first|
11419333|NCT01906931|Active Comparator|Portable oxygen cylinder first|
11419334|NCT01906918|Experimental|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
11419335|NCT01906918|Placebo Comparator|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
11419336|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation|Active TMS (1)
11419337|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 2|Active TMS (2)
11419338|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 3|Active TMS (3)
11419339|NCT01906892|Experimental|1a|6 weeks of group drumming workshops
11419340|NCT01906892|Experimental|1b|6 weeks of group drumming workshops
11419341|NCT01906892|Experimental|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
11419342|NCT01906892|Active Comparator|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
11419343|NCT01906892|Active Comparator|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
11419344|NCT01906892|Active Comparator|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
11419345|NCT01906892|Experimental|3a|10 weeks of participatory group drumming workshops
11419346|NCT01906892|Active Comparator|3b|10 weeks of engagement with other non-musical social activities
11419347|NCT01906879|Active Comparator|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
11419348|NCT01906879|Experimental|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
11419349|NCT01906879|Experimental|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
11419350|NCT01906866|Active Comparator|Circadin 2/5/10 mg|
11419351|NCT01906866|Placebo Comparator|Placebo|Placebo arm
11419352|NCT01906853|No Intervention|No BCG|No BCG
11419353|NCT01906853|Experimental|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
11419354|NCT01906840|Experimental|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
11419355|NCT01906840|Placebo Comparator|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
11419356|NCT01906827||pregnant with ICP|pregnant with ICP
11419357|NCT01906814|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
11419358|NCT01906814|Active Comparator|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
11419359|NCT01906801|Experimental|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
11419360|NCT01906801|Active Comparator|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
11419361|NCT01906788|Active Comparator|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
11419362|NCT01906788|Experimental|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
11419363|NCT01906788|Experimental|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
11419364|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
11419365|NCT01906762|Experimental|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
11419366|NCT01906762|Experimental|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient's weight(averagely 70 kg), about 7 mg Morphine was used.
11419367|NCT01906749|Placebo Comparator|Placebo|Placebo
11419368|NCT01906749|Active Comparator|Colchicine|Colchicine 0.5mg once daily for 24 months
11419369|NCT01906710|Placebo Comparator|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
11419370|NCT01906710|Active Comparator|integrated medicines management|"integrated medicines management consists of
~patient centred medication reconciliation
~intermediate medication review
~discharge counseling
~transfer of information to primary care"
11419371|NCT01906697|Active Comparator|group B|middle turbinate resection
11419372|NCT01906697|Active Comparator|group C|middle turbinate medialization
11419373|NCT01906697|Active Comparator|group A|middle turbinate Radio Frequency (RF) turbinoplasty
11419374|NCT01906684|Experimental|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
11419375|NCT01906671|Experimental|Puri-Nethol|Tablet formulation of 6-mercaptopurine
11419377|NCT01906658|Experimental|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
11419378|NCT01906658|Experimental|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
11419379|NCT01906658|Experimental|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
11419380|NCT01906658|Experimental|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
11419381|NCT01906645|No Intervention|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
11419382|NCT01906645|Experimental|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
11419383|NCT01906632|Other|gene expression profile|
11419384|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
11419385|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
11419386|NCT01906606|Experimental|Parenting Program|12 session community-based parenting program
11419387|NCT01906606|No Intervention|Control Group|received visual aids on nutrition
11419388|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
11419389|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
11419390|NCT01906580|Experimental|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
11419391|NCT01906580|Experimental|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
11419392|NCT01906580|Experimental|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
11419393|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:
~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart
~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart
~• Pulmonary edema or cyanosis
~• Oliguria (< 400 mL in 24 h)
~• Persistent headaches
~• Epigastric pain and/or impaired liver function
~• Thrombocytopenia
~• Oligohydramnios, decreased fetal growth, or placental abruption"
11419394|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
11419395|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
11419396|NCT01906554|Experimental|Egg Dose|
11419397|NCT01906541|Experimental|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
11419398|NCT01906528|Experimental|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
11419399|NCT01906515|No Intervention|Control Group|Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
11419400|NCT01906515|Experimental|SpHb Group.|Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care
11419401|NCT01906502|Experimental|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
11419402|NCT01906489|Experimental|AKB-6548|
11419403|NCT01906489|Placebo Comparator|Placebo|
11419404|NCT01906476|Experimental|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
11419405|NCT01906476|Active Comparator|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
11419406|NCT01906450|Experimental|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
11419407|NCT01906450|Placebo Comparator|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
11419408|NCT01906450|No Intervention|baselline screening only|Dental prophylaxis is offered
11419409|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
11419410|NCT01906424|Other|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
11419553|NCT01905410|Placebo Comparator|single treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort
~4 hours IV infusion"
11419663|NCT01904617|Experimental|NS at 250mL/hr|Normal saline at 250mL/hr
11419411|NCT01906424|Active Comparator|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
11419412|NCT01906424|Active Comparator|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
11419413|NCT01906411||subjecst with different BMI|
11419414|NCT01906398|Other|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1
11419415|NCT01906385|Experimental|Rhenium Liposome Treatment|
11419416|NCT01906372|Experimental|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
11419417|NCT01906359|Experimental|Dietary fat - PO|Native palm olein (IV56)
11419418|NCT01906359|Experimental|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
11419419|NCT01906359|Experimental|Dietary fat - HOS|High oleic sunflower oil
11419420|NCT01906346|Experimental|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
11419421|NCT01906346|Experimental|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
11419422|NCT01906346|Experimental|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
11419423|NCT01906333|Experimental|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
11419424|NCT01906333|Experimental|Exercise & Fasted|2 hour exercise while staying fasted
11419425|NCT01906320|Experimental|Training group|
11419426|NCT01906320|No Intervention|Control Group|
11419427|NCT01906307|Experimental|LJPC-501|LJPC-501, continuous infusion
11419428|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
11419429|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
11419430|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
11419431|NCT01906268|Experimental|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor
~Attention Bias Modification Treatment (ABMT) - active"
11419432|NCT01906268|Sham Comparator|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor
~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
11419433|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender, pregnancy) who are participating in observational or clinical studies on FTC/TDF for PrEP
11419434|NCT01906242|Placebo Comparator|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
11419435|NCT01906242|Active Comparator|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
11419436|NCT01906242|Active Comparator|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
11419437|NCT01906242|Active Comparator|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
11419438|NCT01906229||Acute respiratory distress syndrome (ARDS)|
11419439|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
11419440|NCT01906229||ARDS+SIRS|
11419441|NCT01906216|Active Comparator|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
11419442|NCT01906216|Experimental|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
11419443|NCT01906203|Experimental|ultramarathon|
11419444|NCT01906190|Experimental|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
11419445|NCT01906164|Experimental|ALS-008176|
11419446|NCT01906164|Placebo Comparator|Placebo|
11419447|NCT01906151|Other|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
11419448|NCT01906138|Other|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
11419449|NCT01906125|Experimental|Palbociclib given to Healthy Volunteers|
11419450|NCT01906112|No Intervention|Controlled|No surgery for primary breast tumor.
11419451|NCT01906112|Experimental|Study|Surgery for primary breast tumor.
11419456|NCT01906073|Experimental|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
11419457|NCT01906073|Active Comparator|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
11419458|NCT01906060|Experimental|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
11419459|NCT01906034|Experimental|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
11419460|NCT01906034|Experimental|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
11419461|NCT01906034|No Intervention|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
11419462|NCT01906021|Experimental|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
11419463|NCT01906008|Experimental|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
11419464|NCT01906008|Placebo Comparator|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
11419465|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
11419466|NCT01905982|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
11419467|NCT01905982|Experimental|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
11419468|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
11419469|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
11419470|NCT01905956|Active Comparator|IQP-AK-102|2 capsules per dose, three times daily
11419471|NCT01905956|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily
11419472|NCT01905943|Experimental|Obinutuzumab|Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
11419473|NCT01905930|Experimental|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
11419474|NCT01905930|Active Comparator|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
11419475|NCT01905917|No Intervention|Control|Usual care
11419476|NCT01905917|Experimental|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
11419477|NCT01905904|Active Comparator|sevorane|Sevorane 4% concentration during anesthesia induction
11419478|NCT01905904|Active Comparator|sevorane %7|Sevorane 7% concentration during anesthesia induction
11419479|NCT01905891|Other|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
11419480|NCT01905891|Other|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
11419551|NCT01905423||Pekalongan (semiannual MDA)|"This group includes the villages of Kertoharjo and Pabean. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.
~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
11419481|NCT01905878|Experimental|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
11419482|NCT01905878|Experimental|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
11419483|NCT01905865||Parent|Persons aged 18 years or older who have a child with an undiagnosed medical condition, who have applied to the Undiagnosed Diseases Network, and have been assigned to the NIH.
11419484|NCT01905826||Patient Relatives|Blood relatives of enrolled patients.
11419485|NCT01905826||Patients|Patients with known mutations in GATA2 or those with clinical and laboratory characteristics strongly consistent with GATA2 deficiency.
11419486|NCT01905813|Experimental|INCB040093|
11419487|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
11419488|NCT01905800|Active Comparator|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
11419489|NCT01905800|Experimental|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
11419490|NCT01905800|Placebo Comparator|Placebo treatment|Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
11419491|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
11419492|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
11419493|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
11419494|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
11419495|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
11419496|NCT01905748|Experimental|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
11419497|NCT01905748|Experimental|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
11419498|NCT01905735|Placebo Comparator|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
11419499|NCT01905735|Active Comparator|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
11419500|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
11419501|NCT01905722|Experimental|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
11419502|NCT01905709|Experimental|All patients|150-500 ml of human fecal matter
11419503|NCT01905696|Experimental|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
11419504|NCT01905683|Experimental|16-20 Units per kg body weight incobotulinumtoxinA|
11419505|NCT01905670|Experimental|Implant|Implant of the WiCS-LV system
11419506|NCT01905657|Experimental|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
11419507|NCT01905657|Experimental|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
11419508|NCT01905657|Active Comparator|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 200 mg IV Q3W.
11419509|NCT01905644|Experimental|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.
~Intervention: Perineal ultrasound"
11419510|NCT01905644|No Intervention|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
11419511|NCT01905631|No Intervention|Untreated Control Group|Subjects will apply nothing for the entire three days of the trial. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
11419512|NCT01905631|Active Comparator|Treatment Group (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
11419513|NCT01905618|Experimental|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
11419514|NCT01905618|No Intervention|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
11419515|NCT01905605|Experimental|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
11419516|NCT01905605|Placebo Comparator|placebo supplementation|Placebo to be administered BID for 8 weeks
11419517|NCT01905592|Active Comparator|Physician's choice|Physician may select from 4 active comparators
11419518|NCT01905592|Experimental|niraparib|Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
11419519|NCT01905579|Experimental|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
11419520|NCT01905579|Experimental|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
11419521|NCT01905566|Active Comparator|Clopidogrel|clopidogrel: 75mg once a day
11419522|NCT01905566|Experimental|Ticagrelor|ticagrelor: 90mg twice a day
11419523|NCT01905553|Experimental|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
11419524|NCT01905553|Experimental|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
11419525|NCT01905540|Experimental|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
11419526|NCT01905540|Experimental|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
11419527|NCT01905540|Experimental|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
11419528|NCT01905540|Experimental|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
11419529|NCT01905527||Standard Services of Group A (Group A1)|
11419530|NCT01905527||Customized Services of Group A (Group A2)|
11419531|NCT01905527||Group B|
11419532|NCT01905514|No Intervention|control|using Medication event monitoring system
11419533|NCT01905514|Active Comparator|internet mobile application|using both mobile internet application and medication event monitoring system
11419534|NCT01905501|Active Comparator|Total intravenous anesthesia|Total intravenous anaesthesia
11419535|NCT01905501|Experimental|Balanced anesthesia|
11419536|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
11419537|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
11419538|NCT01905488||Group S|patients who showed IJVVI in supine position
11419539|NCT01905475|Experimental|POL6326|POL6326 intravenous infusion
11419540|NCT01905475|Placebo Comparator|Placebo|Placebo intravenous infusion
11419541|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
11419542|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
11419543|NCT01905449|Experimental|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
11419544|NCT01905449|Experimental|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
11419545|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
11419546|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
11419547|NCT01905423||Paga (annual MDA)|"This group includes eligible residents of the village of Paga. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
~Paga received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
11419548|NCT01905423||Lewomada (annual MDA)|"This group includes eligible residents of the village of Lewomada. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
~Lewomada received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
11419549|NCT01905423||Pruda (semiannual MDA)|"This group includes eligible residents of the village of Pruda. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.
~Pruda received a total of five rounds of MDA over a period of 24 months (once every 6 months)."
11419550|NCT01905423||Pekalongan (annual MDA)|"This group includes the villages of Banyurip Ageng and Jenggot. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.
~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
11419552|NCT01905410|Experimental|single treatment - VVZ-149 Injection|"single ascending dose escalation
~0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts
~4 hours IV infusion"
11419554|NCT01905410|Experimental|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.
~high and low dosage
~4 hours IV infusion x 2 times/day x 3 days"
11419555|NCT01905410|Placebo Comparator|multiple treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort
~4 hours IV infusion x 2 times/day x 3 days"
11419556|NCT01905397|Active Comparator|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
11419557|NCT01905397|Active Comparator|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
11419558|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
11419559|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
11419560|NCT01905371|Experimental|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:
~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
11419561|NCT01905371|Placebo Comparator|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:
~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
11419562|NCT01905345|Experimental|Endurance and Resistance Training|Endurance and resistance exercise
11419563|NCT01905345|Experimental|Resistance Training|resistance exercise (12wk)
11419564|NCT01905345|Experimental|Resistance and resistance Training|resistance exercise (24 wk)
11419565|NCT01905332|Experimental|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
11419566|NCT01905332|Active Comparator|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
11419567|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
11419568|NCT01905306|Experimental|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
11419569|NCT01905306|Experimental|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
11419570|NCT01905293|Experimental|100% portion size|100% portion size condition
11419571|NCT01905293|Experimental|150% portion size|150% portion size condition
11419572|NCT01905293|Experimental|200% portion size|200% portion size condition
11419573|NCT01905280|Experimental|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
11419574|NCT01905280|Active Comparator|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
11419575|NCT01905267|Experimental|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
11419576|NCT01905267|No Intervention|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
11419577|NCT01905254|Other|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
11419578|NCT01905228|Experimental|CBL0137|"Dose Level 9: 150 mg/m2, IV
~Dose Level 10: 180 mg/m2, IV
~Dose Level 11: 240 mg/m2, IV
~Dose Level 12: 320 mg/m2, IV
~Dose Level 13: 400 mg/m2, IV
~Dose Level 14: 540 mg/m2, IV
~Dose Level 15: 700 mg/m2, IV
~Dose Level 16: 920 mg/m2, IV
~Dose Level 17: 1200 mg/m2, IV
~Dose Level 18: 1600 mg/m2, IV
~Dose Level 19: 2100 mg/m2, IV
~Dose Level 20: 2700 mg/m2, IV"
11419579|NCT01905215|Experimental|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
11419580|NCT01905215|Experimental|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
11419581|NCT01905215|Experimental|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
11419582|NCT01905215|Experimental|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
11419583|NCT01905215|Experimental|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
11419584|NCT01905215|Experimental|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
11419585|NCT01905215|Placebo Comparator|Group Placebo 1|Subjects in this group will receive a single dose of placebo
11419586|NCT01905215|Placebo Comparator|Group Placebo 2|Subjects in this group will receive a single dose of placebo
11419587|NCT01905202|Experimental|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
11419588|NCT01905189|Experimental|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
11419589|NCT01905176|Experimental|Predischarge educational intervention|In person education on heart failure topics before discharge
11419590|NCT01905176|Experimental|Telephone educational intervention|Telephone support and education post-discharge
11419591|NCT01905176|Experimental|Combination|Pre-discharge in person education and post-discharge telephone education and support
11419592|NCT01905176|No Intervention|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
11419593|NCT01905163|Experimental|laparoscopic management|Tumor Debulking Surgery by laparoscopy
11420088|NCT01901484|Active Comparator|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
11419594|NCT01905150|Experimental|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
11419595|NCT01905150|Active Comparator|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
11419596|NCT01905137|Active Comparator|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
11419597|NCT01905137|Placebo Comparator|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
11419598|NCT01905124|Experimental|Drug: CF101|CF101 1 mg q12 hours
11419599|NCT01905124|Placebo Comparator|Placebo tablets of CF101|Placebo tablets q12 hours
11419600|NCT01905111|Experimental|BI 853520|BI 853520 once daily in a dose escalation schedule
11419601|NCT01905098|Experimental|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.
~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
11419602|NCT01905098|Active Comparator|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.
~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
11419603|NCT01905072|Experimental|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
11419604|NCT01905072|No Intervention|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
11419605|NCT01905059|Active Comparator|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)
~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
11419606|NCT01905059|Active Comparator|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
11419607|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
11419608|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
11419609|NCT01905020|Active Comparator|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
11419610|NCT01905020|Active Comparator|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
11419611|NCT01905020|Active Comparator|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
11419612|NCT01905007|Active Comparator|Defibrillation testing|Defibrillation testing at initial ICD implantation
11419613|NCT01905007|No Intervention|No defibrillation testing|No defibrillation testing at initial ICD implantation
11419614|NCT01904994|No Intervention|Standard of Care|Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
11419615|NCT01904994|Experimental|Combined Intervention Strategy|Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
11419616|NCT01904981|Experimental|Atenolol|Atenolol group
11419617|NCT01904981|Experimental|Valsartan|Valsartan group
11419618|NCT01904968||Colon cancers in patients living the Cote D'or area|
11419619|NCT01904929|Experimental|Reconditioning in the effort|
11419620|NCT01904916|Other|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
11419621|NCT01904903|Other|HER2 therapies, cardiac medications|"Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses
~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:
~Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.
~Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.
~Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks."
11419622|NCT01904890|Experimental|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
11419623|NCT01904890|Active Comparator|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
11419660|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
11419661|NCT01904617|Experimental|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
11419624|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
11419625|NCT01904877||Phase II: 367 HIV positive MSM|"Linking to care:
~Providing enhanced HIV care."
11419626|NCT01904864|Active Comparator|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
11419627|NCT01904864|Active Comparator|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
11419628|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
11419629|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
11419630|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
11419631|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
11419632|NCT01904812|Other|Lupus erythematosus|
11419633|NCT01904799|Other|Cognitive Assessment|
11419634|NCT01904786|Experimental|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
11419635|NCT01904786|Placebo Comparator|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
11419636|NCT01904773|Placebo Comparator|Placebo|
11419637|NCT01904773|Experimental|low dose AZD5213|
11419638|NCT01904773|Experimental|high dose AZD5213|
11419639|NCT01904760|Experimental|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
11419640|NCT01904760|Placebo Comparator|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
11419641|NCT01904747|Experimental|Palbociclib given to healthy volunteers|
11419642|NCT01904734|Active Comparator|No previous male hormone treatment|Clomiphene
11419643|NCT01904734|Active Comparator|Previously treated with testosterone|Clomiphene
11419644|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
11419645|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
11419646|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
11419647|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
11419648|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
11419649|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
11419650|NCT01904721|Placebo Comparator|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
11419651|NCT01904708|No Intervention|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
11419652|NCT01904708|Active Comparator|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
11419653|NCT01904695|Experimental|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker & Herbs for 8 weeks
11419654|NCT01904695|Active Comparator|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
11419655|NCT01904682|Experimental|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
11419656|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive <3 months.
11419657|NCT01904656|Experimental|Arm I|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
11419658|NCT01904656|Active Comparator|Arm II|"Participants are exposed to a Healthy Eating Peaches!- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
11419659|NCT01904643|Experimental|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.
~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.
~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.
~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
11419664|NCT01904604|Placebo Comparator|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
11419665|NCT01904604|Experimental|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
11419666|NCT01904604|Experimental|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
11419667|NCT01904591|Experimental|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
11419668|NCT01904578|Experimental|true acupressure|Massage the effective pressure points as a self-care method at home [ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
11419669|NCT01904578|Sham Comparator|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
11419670|NCT01904578|No Intervention|control|The control group only received the weekly control of blood pressure and speech communication .
11419671|NCT01904565|Experimental|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
11419672|NCT01904552|Experimental|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
11419673|NCT01904552|Experimental|normal periapex (NP)|clinical pulp vitality periapical index score of 1
11419674|NCT01904539|Experimental|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
11419675|NCT01904539|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
11419676|NCT01904539|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
11419677|NCT01904539|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
11419678|NCT01904526|Experimental|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
11419679|NCT01904513|Experimental|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at ~10^10 CFU/day
11419680|NCT01904513|Other|Milk|Daily consumption of pasteurized whole milk
11419681|NCT01904500|Other|Cefazolin 2 grams|
11419682|NCT01904500|Active Comparator|Cefazolin 3 grams|
11419683|NCT01904487|Experimental|PET scans|Both alcoholics and healthy controls will undergo two [11C]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
11419684|NCT01904474|Experimental|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).
~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
11419685|NCT01904474|Active Comparator|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
11419686|NCT01904461|Experimental|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
11419687|NCT01904461|Active Comparator|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
11419688|NCT01904448|Experimental|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
11419730|NCT01904162|Experimental|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
11419731|NCT01904162|Experimental|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
11419732|NCT01904162|Experimental|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
11419689|NCT01904422|Experimental|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
11419690|NCT01904422|Experimental|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
11419691|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
11419692|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
11419693|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
11419694|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
11419695|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
11419696|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
11419697|NCT01904396|Experimental|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
11419698|NCT01904383||Trazenta|
11419699|NCT01904357|Active Comparator|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
11419700|NCT01904357|Active Comparator|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
11419701|NCT01904344|Other|Sensor testing and validation|
11419702|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
11419703|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
11419704|NCT01904318|Experimental|IDP-73152 mesylate 40 mg|
11419705|NCT01904318|Experimental|IDP-73152 mesylate 80 mg|
11419706|NCT01904318|Experimental|IDP-73152 mesylate 160 mg|
11419707|NCT01904318|Experimental|IDP-73152 mesylate 320 mg|
11419708|NCT01904318|Experimental|IDP-73152 mesylate 640 mg|
11419709|NCT01904318|Experimental|IDP-73152 mesylate 1280 mg|
11419710|NCT01904318|Placebo Comparator|Placebo|
11419711|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
11419712|NCT01904292|Experimental|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with <30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
11419713|NCT01904279|Experimental|TCZ SC 162 mg Q3W|Participants with body weight less than (<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
11419714|NCT01904279|Experimental|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
11419715|NCT01904266|Sham Comparator|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
11419716|NCT01904266|Experimental|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
11419717|NCT01904253|Experimental|TAS-102|
11419718|NCT01904253|Active Comparator|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
11419719|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
11419720|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
11419721|NCT01904227|Experimental|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.
~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.
~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
11419722|NCT01904227|Active Comparator|Outpatient DBT|Control condition: Standard outpatient DBT
11419723|NCT01904214|Experimental|severe renal impairmnt|
11419724|NCT01904214|Experimental|moderate renal impairment|
11419725|NCT01904214|Experimental|mild renal impairment|
11419726|NCT01904214|Experimental|healthy subjects|
11419727|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
11419728|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
11419729|NCT01904162|Experimental|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
11419733|NCT01904149|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
11419734|NCT01904149|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
11419735|NCT01904149|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
11419736|NCT01904149|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
11419737|NCT01904149|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
11419738|NCT01904149|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
11419739|NCT01904136|Experimental|Treatment (NK cells, allogeneic stem cell transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine phosphate IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.
~NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine phosphate IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.
~TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.
~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90."
11419740|NCT01904123|Experimental|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11419741|NCT01904110|Experimental|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
11419742|NCT01904110|Active Comparator|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
11419743|NCT01904097|Sham Comparator|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
11419744|NCT01904097|Experimental|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
11419745|NCT01904084|Active Comparator|Volar locked plating|One group with distal radius fracture is operated with Locking plate
11419746|NCT01904084|Active Comparator|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
11419747|NCT01904071|Experimental|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
11419748|NCT01904071|Experimental|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
11419749|NCT01904071|Active Comparator|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
11419750|NCT01904058|Experimental|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
11419751|NCT01904058|Placebo Comparator|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
11419752|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
11419753|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
11419754|NCT01904006|Experimental|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
11419755|NCT01904006|Active Comparator|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
11419756|NCT01903993|Active Comparator|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
11419757|NCT01903993|Experimental|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
11419758|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
11419759|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
11419760|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
11419761|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
11419762|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
11419763|NCT01903941|Experimental|Training|Aerobic
11419764|NCT01903941|Placebo Comparator|Control|Not exercise
11419765|NCT01903928|Experimental|ASP0113 group|Participants receive 1 mL of ASP0113 intramuscularly 5 times, on days -14 to -3, 14 to 40, 60 ± 5, 90 ± 10, and 180 ± 10, counting from the transplantation (stem cell transfusion) day (day 0)
11419766|NCT01903915||Patients|Schizophrenia group
11419767|NCT01903915||Control|Healthy control group
11419768|NCT01903902|Experimental|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter > 2.25 mm and ≤ 2.75 mm)
11419769|NCT01903889|Active Comparator|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
11419770|NCT01903889|Experimental|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
11419771|NCT01903876|Placebo Comparator|General Health promotion|A 3-hour general mental health web-based program.
11419772|NCT01903876|Experimental|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
11419773|NCT01903863|Experimental|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
11419774|NCT01903863|Active Comparator|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
11419775|NCT01903850|Experimental|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
11419776|NCT01903837|Experimental|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
11419777|NCT01903837|Experimental|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
11419778|NCT01903837|Experimental|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
11419779|NCT01903837|Placebo Comparator|Placebo|Olanzapine + placebo tablets taken once daily
11419780|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
11419781|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
11419782|NCT01903824|Experimental|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
11419783|NCT01903811|Experimental|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
11419784|NCT01903811|Experimental|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11419785|NCT01903798|Active Comparator|Prednisolone (Lille <0.45)|At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.
11419786|NCT01903798|Experimental|Prednisolone, rilonacept (Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).
11419787|NCT01903798|Active Comparator|Prednisolone (Lille >0.45)|Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.
11419788|NCT01903798|Experimental|Prednisolone, mycophenolate(Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.
11419789|NCT01903785|Experimental|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
11419790|NCT01903785|Placebo Comparator|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
11419791|NCT01903772|Experimental|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
11419792|NCT01903772|Sham Comparator|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
11419793|NCT01903759|Other|Patients with spontaneous rupture of the fetal membranes|
11419794|NCT01903746||Patients in septic shock|
11419795|NCT01903720|Experimental|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
11419796|NCT01903707|Experimental|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
11419797|NCT01903707|Placebo Comparator|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
11419798|NCT01903694|Active Comparator|sorafenib|800 mg of sorafenib twice daily orally.
11419799|NCT01903694|Experimental|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
11419800|NCT01903681|Active Comparator|Circadin 10 mg|Second arm higher dose
11419802|NCT01903655|Other|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
11419803|NCT01903655|Other|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
11419804|NCT01903655|Other|control group|patient with no depressive disorder during the study period and no psychiatric history
11419805|NCT01903642|Other|Patients with inflammatory syndrome|
11419806|NCT01903629|Experimental|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
11419807|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
11419808|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
11419809|NCT01903590|Active Comparator|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
11419810|NCT01903590|Experimental|Transobturator tape surgery|Randomized 50 patients undergoing TOT
11419811|NCT01903577|Experimental|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.
~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
11419812|NCT01903577|Experimental|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.
~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
11419813|NCT01903577|Experimental|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.
~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
11419814|NCT01903564||normal|pregnant women with uncomplicated pregnancies
11419815|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
11419816|NCT01903551|Experimental|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
11419817|NCT01903551|No Intervention|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
11419818|NCT01903538|Experimental|Cathodal transcranial direct current stimulation|
11419819|NCT01903538|Sham Comparator|Sham transcranial direct current stimulation|
11419820|NCT01903525|Placebo Comparator|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
11419821|NCT01903525|Experimental|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
11419822|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
11419823|NCT01903499|Active Comparator|Bean patty|Bean Patty
11419824|NCT01903499|Active Comparator|Beef patty|Beef patty
11419825|NCT01903486|Other|Prednisone|Prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
11419826|NCT01903473|Experimental|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
11419827|NCT01903473|Active Comparator|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
11419828|NCT01903460|Experimental|LUM001|LUM001 administered orally once each day
11419829|NCT01903460|Placebo Comparator|Placebo|Placebo administered orally once each day
11419830|NCT01903447|Active Comparator|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
11419831|NCT01903447|Active Comparator|CBT|12 weeks of individual cognitive behavioral therapy
11419832|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to 2 of 3 periods
11419833|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to 2 of 3 periods
11419834|NCT01903421|Active Comparator|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
11419835|NCT01903421|Active Comparator|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
11419836|NCT01903408|Other|Arm 1: Boost to prostate|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up
11419837|NCT01903408|Other|Arm 2: Boost to prostate and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) & pelvic lymph node mets (61.2 Gy) in 34 Fx
11419838|NCT01903408|Other|Arm 3: Boost to prostate bed|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published
11419839|NCT01903408|Other|Arm 4: Boost to prostate bed and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) & lymph node metastases (61.2 Gy) in 34 Fx
11419840|NCT01903408|Other|Arm 5: Boost to lymph node metastases|Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx
11419841|NCT01903395|Experimental|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
11419842|NCT01903395|No Intervention|Usual Care|Usual print media, offered standardly by the recruiting centres.
11419843|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
11419844|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery >16 years of age.
11419845|NCT01903356||Patients with T2DM|
11419846|NCT01903343||Healthy Volunteers|Single group of healthy male medical students at Ninewells Hospital & Medical School, Dundee.
11419847|NCT01903330|Experimental|(ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab|"ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab is administered as standard of care at 10 mg/kg.
~The treatment will be repeated every 28 days until progression of disease or intolerance."
11419848|NCT01903330|Placebo Comparator|(Placebo Injection/Placebo Pill) +Bevacizumab|"The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab just as the active treatment group above.
~The treatment will be repeated every 28 days until progression of disease or intolerance."
11419849|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
11419850|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
11419851|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
11419852|NCT01903304|Experimental|olive oil|intervention with olive oil for 3 months
11419853|NCT01903304|Placebo Comparator|Placebo|Intervention with placebo for 3 months
11419854|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
11419855|NCT01903278|Experimental|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
11419856|NCT01903278|Active Comparator|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
11419857|NCT01903278|Experimental|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
11419858|NCT01903278|Active Comparator|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
11419859|NCT01903265|Experimental|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
11419860|NCT01903265|Placebo Comparator|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
11419861|NCT01903252|Experimental|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
11419862|NCT01903252|Active Comparator|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
11419863|NCT01903239|Other|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
11419864|NCT01903226|Experimental|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
11419865|NCT01903226|Experimental|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
11419866|NCT01903226|No Intervention|controll|Patients in this group will perform no (additional) training.
11419867|NCT01903213||Kiklin group|Oral
11419868|NCT01903200|Experimental|FK949E Fed Group|FK949E is administered after breakfast
11419869|NCT01903200|Experimental|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
11419870|NCT01903187|Experimental|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
11419871|NCT01903187|Active Comparator|Sham procedure|Sham procedure
11419872|NCT01903174|Experimental|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
11419873|NCT01903161|Experimental|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
11419874|NCT01903161|Placebo Comparator|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
11419875|NCT01903135|Other|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
11419876|NCT01903135|Other|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
11419877|NCT01903135|Other|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
11419878|NCT01903122|Active Comparator|Cevimeline|Single Dose 30 mg Capsule
11419879|NCT01903122|Active Comparator|Evoxac|Single dose 30 mg capsule
11419880|NCT01903109|Active Comparator|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
11419909|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
11419881|NCT01903109|Active Comparator|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
11419882|NCT01903096|Experimental|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
11419883|NCT01903096|Active Comparator|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
11419884|NCT01903083|Experimental|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
11419885|NCT01903070|Experimental|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
11419886|NCT01903070|Experimental|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
11419887|NCT01903057|Experimental|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8
~Placebo has same appearance and dosing as azithromycin."
11419888|NCT01903057|Placebo Comparator|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8
~Placebo has same appearance and dosing as azithromycin."
11419889|NCT01903044|Experimental|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
11419890|NCT01903031|Experimental|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
11419891|NCT01903031|Experimental|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
11419892|NCT01903031|Experimental|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
11419893|NCT01903018|Experimental|P276-00|
11419894|NCT01903005|Experimental|Open-label BNX sublingual tablets|Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.
11419895|NCT01902992|Experimental|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
11419896|NCT01902992|Placebo Comparator|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
11419897|NCT01902979|Experimental|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
11419898|NCT01902979|No Intervention|Usual Care|
11419899|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
11419900|NCT01902953|Experimental|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
11419901|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
11419902|NCT01902927|Experimental|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
11419903|NCT01902914|Experimental|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
11419904|NCT01902914|Active Comparator|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
11419905|NCT01902901|Active Comparator|Usual care|Requested carrier status testing.
11419906|NCT01902901|Experimental|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
11419907|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
11419908|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
11419910|NCT01902862|Experimental|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
11419911|NCT01902849||Group 1 - TIVA-TCI|"include 35 patients with colorectal cancer undergoing surgery
~anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.
~for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.
~for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).
~intervention:blood sampling for IL measurement"
11419912|NCT01902849||Group II- ISOFLURANE|"include 35 patients with colorectal cancer undergoing surgery
~anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml
~maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)
~intervention:blood sampling for IL measurement"
11419913|NCT01902836|Experimental|Conventional Treatment plus DLE|"Conventional treatment plus DLE
~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;
~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
11419914|NCT01902836|Placebo Comparator|Conventional treatment plus placebo|"Conventional treatment plus placebo:
~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
11419915|NCT01902823|No Intervention|No Nurse Navigator Services|
11419916|NCT01902823|Experimental|Services from a Nurse Navigator|
11419917|NCT01902810|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization
11419918|NCT01902810|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization
11419919|NCT01902797|Experimental|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
11419920|NCT01902784|Experimental|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).
~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
11419921|NCT01902784|No Intervention|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
11419922|NCT01902771|Experimental|DC Vaccine + Lysate|"Leukapheresis: Baseline, post-surgery;
~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;
~Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;
~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
11419923|NCT01902758|Experimental|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
11419924|NCT01902758|Placebo Comparator|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
11419925|NCT01902745|Active Comparator|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.
~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
11419926|NCT01902745|Active Comparator|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.
~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
11419927|NCT01902732|Other|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
11419928|NCT01902719|Experimental|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
11419929|NCT01902719|Experimental|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
11419930|NCT01902719|Experimental|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
11419931|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.
~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
11419932|NCT01902680|Experimental|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
11419933|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
11419934|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
11419935|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
11419936|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
11419937|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
11419938|NCT01902641|Active Comparator|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
11419939|NCT01902641|Active Comparator|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
11419940|NCT01902641|Active Comparator|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
11419941|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
11419942|NCT01902615||Cohort|
11419943|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
11419944|NCT01902550|Experimental|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
11419945|NCT01902550|Experimental|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter [ml] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
11419946|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
11419947|NCT01902524|Experimental|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
11419948|NCT01902511|Experimental|G-CSF + Erythropoietin|
11419949|NCT01902511|Active Comparator|G-CSF|
11419950|NCT01902498|Experimental|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
11419951|NCT01902498|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
11419952|NCT01902498|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
11419953|NCT01902485|Active Comparator|Quickstart|Immediate start
11419954|NCT01902485|Active Comparator|Afterstart|Delayed start
11419955|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
11419956|NCT01902459|Active Comparator|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component.
11419957|NCT01902459|Other|Standard of Care|Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat.
11419958|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
11419959|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
11419960|NCT01902433|Experimental|Astym|A form of soft tissue mobilization using instruments
11419961|NCT01902433|Active Comparator|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
11419962|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
11419963|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
11419964|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.
~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
11419965|NCT01902394|Experimental|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
11419966|NCT01902394|Placebo Comparator|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
11419967|NCT01902394|No Intervention|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
11420089|NCT01901484|Active Comparator|Praziquantel|double dose
11420090|NCT01901471|Experimental|CsA Group|
11419968|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11419969|NCT01902368|Other|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
11419970|NCT01902368|No Intervention|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
11419971|NCT01902355|Experimental|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
11419972|NCT01902355|Active Comparator|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
11419973|NCT01902342|Experimental|CES1 gene variant group|Oseltamivir 75 mg 1 cap
11419974|NCT01902342|Experimental|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
11419975|NCT01902329|Experimental|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
11419976|NCT01902329|Experimental|SGN-CD33A Monotherapy|SGN-CD33A
11419977|NCT01902303|Placebo Comparator|Matching Placebo|Matching Placebo
11419978|NCT01902303|Experimental|BTL-TML-HSV|Experimental Product
11419979|NCT01902290|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injections until week 24.
11419980|NCT01902290|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injections until week 24.
11419981|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
11419982|NCT01902264|Experimental|EE20/DRSP/L-5-MTHF|
11419983|NCT01902251|Experimental|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
11419984|NCT01902251|Active Comparator|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
11419985|NCT01902238|Experimental|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
11419986|NCT01902225|Experimental|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours
~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
11419987|NCT01902212|Experimental|Oral Nutritional Supplement|2 servings a day
11419988|NCT01902199|Active Comparator|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
11419989|NCT01902199|Placebo Comparator|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
11419990|NCT01902186|Experimental|raltegravir|raltegravir and atazanavir and ritonavir
11419991|NCT01902186|Active Comparator|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
11419992|NCT01902173|Experimental|Treatment (uprosertib, dabrafenib, trametinib)|"Dabrafenib mesylate and uprosertib: Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib: Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11419993|NCT01902160|Experimental|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
11419994|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
11419995|NCT01902134|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
11419996|NCT01902134|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
11419997|NCT01902134|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
11419998|NCT01902134|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
11419999|NCT01902134|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
11420000|NCT01902134|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
11420001|NCT01902121|Experimental|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
11420002|NCT01902121|Experimental|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
11420003|NCT01902108|Experimental|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
11420004|NCT01902108|Active Comparator|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
11420005|NCT01902095|Experimental|Tooth powder (test) arm|Experimental arm: tooth powder
11420006|NCT01902095|Active Comparator|Tooth Paste (control)|Tooth Paste
11420007|NCT01902082|Experimental|Mesenchymal stem cell arm|Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
11420008|NCT01902082|Placebo Comparator|Placebo|Patients received one dose of normal saline.
11420085|NCT01901497|Experimental|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
11420091|NCT01901471|Placebo Comparator|Placebo group|
11420009|NCT01902069|Experimental|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
11420010|NCT01902069|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
11420011|NCT01902056|Active Comparator|one layer allograft|One layer allograft as a positive control
11420012|NCT01902056|Experimental|Two layer allograft|Two layer allograft as the test group.
11420013|NCT01902030||Proven/Probable IA Patients|Case Population
11420014|NCT01902030||possible/No IA Patients|Control population
11420015|NCT01902017|Experimental|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
11420016|NCT01902017|Experimental|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
11420017|NCT01902017|Placebo Comparator|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
11420018|NCT01902017|Placebo Comparator|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
11420019|NCT01902004|Active Comparator|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
11420020|NCT01902004|Active Comparator|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
11420021|NCT01901991|Experimental|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).
~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
11420022|NCT01901991|Active Comparator|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).
~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
11420023|NCT01901978|Experimental|Weight Loss|Caloric restrictive diet
11420024|NCT01901965|Experimental|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
11420025|NCT01901965|Experimental|eccentric training|unilateral eccentric resistance exercises
11420026|NCT01901965|Sham Comparator|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
11420027|NCT01901952|Active Comparator|Standard of care|
11420028|NCT01901952|Experimental|Intensive education and support|
11420029|NCT01901939|Experimental|exercise|daily bedside tailored low intensity pedaling exercise
11420030|NCT01901926|Active Comparator|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.
~Checkup will be repeated at 3, 6 & 9 month interval along with HbA1C levels"
11420031|NCT01901926|No Intervention|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
11420032|NCT01901913|Experimental|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
11420033|NCT01901913|Active Comparator|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
11420034|NCT01901887|Experimental|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months
~Other names: none"
11420035|NCT01901887|Placebo Comparator|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months
~Other names: none"
11420036|NCT01901874|Experimental|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
11420037|NCT01901861|Active Comparator|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
11420038|NCT01901861|Placebo Comparator|Placebo|Placebo is given before meal ingestion
11420039|NCT01901848|Experimental|CPT+ICSC|This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
11420040|NCT01901848|Active Comparator|ICSC only|This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
11420041|NCT01901835|Experimental|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
11420042|NCT01901835|Experimental|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
11420043|NCT01901822|Active Comparator|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
11420044|NCT01901822|Experimental|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
11420086|NCT01901497|Experimental|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
11420087|NCT01901497|Experimental|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
11420045|NCT01901809|Active Comparator|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
11420046|NCT01901809|Active Comparator|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
11420047|NCT01901809|Active Comparator|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
11420048|NCT01901809|Active Comparator|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
11420049|NCT01901796|Experimental|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
11420050|NCT01901796|No Intervention|Usual care|Usual prenatal care
11420051|NCT01901783|Active Comparator|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
11420052|NCT01901783|Experimental|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
11420053|NCT01901770|Experimental|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
11420054|NCT01901770|Active Comparator|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
11420055|NCT01901757|Experimental|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
11420056|NCT01901757|Experimental|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
11420057|NCT01901744|Experimental|Patients undergoing cataract surgery|
11420058|NCT01901731|Experimental|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
11420059|NCT01901731|Active Comparator|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
11420060|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
11420061|NCT01901705|Active Comparator|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
11420062|NCT01901705|Placebo Comparator|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
11420063|NCT01901692|Experimental|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
11420064|NCT01901692|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
11420065|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
11420066|NCT01901666|Experimental|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
11420067|NCT01901653|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
11420068|NCT01901640|Experimental|DA-8159|Udenafil(The study had one arm.)
11420069|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
11420070|NCT01901614|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
11420071|NCT01901614|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
11420072|NCT01901601|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
11420073|NCT01901601|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
11420074|NCT01901588|Experimental|Dexmedetomidine|dexmedetomidine/precedex
11420075|NCT01901588|Placebo Comparator|Placebo|patients receive saline solution.
11420076|NCT01901575|Experimental|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
11420077|NCT01901562|Experimental|Ductoscopic papillomectomy|Ductoscopic papillomectomy to treat pathological nipple discharge
11420078|NCT01901549|Active Comparator|PCI+Renal denervation|
11420079|NCT01901549|Active Comparator|PCI alone|
11420080|NCT01901536|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
11420081|NCT01901536|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
11420082|NCT01901523|Experimental|Provision of information|Reporting of discrepancy to journal
11420083|NCT01901510|Active Comparator|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
11420084|NCT01901510|Other|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
11420130|NCT01901172|Experimental|Part 1: Drug-drug interaction|
11420092|NCT01901458|Experimental|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
11420093|NCT01901458|Active Comparator|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
11420094|NCT01901445|Experimental|Educational action group|
11420095|NCT01901445|No Intervention|Control group|
11420096|NCT01901432|Experimental|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:
~50 mg b.i.d.,
~100 mg b.i.d.;
~150 mg b.i.d.,
~200 mg b.i.d.;
~150 mg t.i.d.;
~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.
~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.
~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
11420097|NCT01901419|Experimental|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
11420098|NCT01901419|Active Comparator|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
11420099|NCT01901406||ERM|idiopathic epiretinal membrane patients
11420100|NCT01901393|Experimental|IV ibuprofen|800mg ibuprofen
11420101|NCT01901393|Active Comparator|ketorolac|30mg ketorolac
11420102|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
11420103|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
11420104|NCT01901367|Experimental|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
11420105|NCT01901367|No Intervention|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
11420106|NCT01901354|Active Comparator|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of <30 cm H2O, and a goal respiratory rate of 6-35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end-expiratory pressure is set as per the ARDSNet Positive end-expiratory pressure table
11420107|NCT01901354|Active Comparator|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.
~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5-0.8 seconds to achieve an end expiratory flow 25-50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%-70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at <5 cm H20."
11420108|NCT01901341|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
11420109|NCT01901341|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
11420110|NCT01901328|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
11420111|NCT01901328|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
11420112|NCT01901315|Experimental|Online consultation|Monthly video consultations with psychiatrist
11420113|NCT01901315|Experimental|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
11420114|NCT01901302|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
11420115|NCT01901302|Placebo Comparator|Placebo|Placebo BID for a 12-week treatment period
11420116|NCT01901289|Experimental|Drug-Eluting Stent|
11420117|NCT01901276|Experimental|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
11420118|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)
~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
11420119|NCT01901250|Experimental|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
11420120|NCT01901250|Placebo Comparator|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
11420121|NCT01901237|Other|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
11420122|NCT01901224|Experimental|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
11420123|NCT01901224|Placebo Comparator|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
11420124|NCT01901211|Experimental|Exergaming|In this arm, the participants will participate in the exergaming intervention.
11420125|NCT01901211|No Intervention|Comparison Arm|In this arm of the study, participants will engage in their typical physical activity routines for the ten week duration. Participants will receive a call from the RA each week. The RA will ask the child to report on all the physical and social activities that they engaged in for that week.
11420126|NCT01901198|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
11420127|NCT01901198|Active Comparator|Pegasys|Peginterferon 180 mcg single dose S.C.
11420128|NCT01901185|Experimental|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
11420129|NCT01901172|Experimental|Extension|
11420135|NCT01901146|Experimental|ABP 980|"Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
~After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
11420136|NCT01901146|Active Comparator|Trastuzumab|"Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.
~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.
~After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
11420137|NCT01901133|Experimental|A: Mild hepatic impairment subjects + control|
11420138|NCT01901133|Experimental|B: Moderate hepatic impairment subjects + control|
11420139|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
11420140|NCT01901107||Kiklin group|
11420141|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.
~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
11420142|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
11420143|NCT01901081|Experimental|Prosthetic Training with IMES prosthesis|
11420144|NCT01901068||MonoMax|Elective primary laparotomy
11420145|NCT01901055|Experimental|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
11420146|NCT01901055|Placebo Comparator|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
11420147|NCT01901042|Experimental|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
11420148|NCT01901042|Placebo Comparator|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
11420149|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
11420150|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
11420151|NCT01901016|Experimental|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
11420152|NCT01901016|Experimental|Schultz's autogenic training|Schultz's autogenic training
11420153|NCT01901016|No Intervention|control|
11420154|NCT01901003|Placebo Comparator|placebo group|placebo
11420155|NCT01901003|Active Comparator|no premedication group|no premedication
11420156|NCT01901003|Experimental|Lorazepam group|lorazepam
11420157|NCT01900990|Experimental|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
11420158|NCT01900990|No Intervention|Conventional weaning|Patients in this group were weaned by conventional stratiges.
11420159|NCT01900977|Active Comparator|Arm A Universal Testing w/Immediate ART|
11420160|NCT01900977|Active Comparator|Arm B ART according to National Guidelines|
11420161|NCT01900977|Other|Standard of Care|"Includes:
~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
11420162|NCT01900964|Active Comparator|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
11420163|NCT01900964|Experimental|Collagen membrane|A resorbable collagen membrane will be used in the test group.
11420164|NCT01900951|Experimental|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
11420165|NCT01900938|Active Comparator|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
11420166|NCT01900938|Active Comparator|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
11420167|NCT01900925|Active Comparator|Low back treatment only (pragmatic)|"advise to stay active,
~discourage bed rest,
~appropriate medication use,
~reassurance.
~Short term use of manipulation/medication,
~supervised exercise,
~cognitive behavioral therapy,
~multidisciplinary treatment,
~termination of use of modalities."
11420168|NCT01900925|Experimental|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
11420169|NCT01900912|Experimental|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
11420170|NCT01900912|No Intervention|Rural communities|No intervention will be delivered (n=61 communities)
11420171|NCT01900899|Experimental|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
11420172|NCT01900899|Active Comparator|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
11420173|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
11420174|NCT01900873|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
11420175|NCT01900873|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
11420176|NCT01900860|Active Comparator|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
11420177|NCT01900860|Active Comparator|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
11420178|NCT01900860|Active Comparator|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
11420179|NCT01900847|Active Comparator|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
11420180|NCT01900847|Experimental|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
11420181|NCT01900834||All participants|
11420182|NCT01900821||Women|All women having mammograms
11420183|NCT01900808||Patients with chronic liver disease|
11420184|NCT01900795|Experimental|V117957|
11420185|NCT01900795|Active Comparator|Ibuprofen|
11420186|NCT01900795|Placebo Comparator|Placebo|
11420187|NCT01900782|Experimental|Dosing Regimen 1|Subcutaneous injection
11420188|NCT01900782|Active Comparator|Active Comparator|Subcutaneous injection
11420189|NCT01900782|Placebo Comparator|Placebo|Subcutaneous injection
11420190|NCT01900782|Experimental|Dosing Regimen 2|Subcutaneous injection
11420191|NCT01900769|Experimental|Blood Volume Dilution|
11420192|NCT01900756|Active Comparator|Behavioral|"Pre-appointment phone text
~In-clinic educational video
~Patient report card
~Post-clinic phone text
~Outpatient stroke registry"
11420193|NCT01900756|No Intervention|Standard care|Routine and customary management.
11420194|NCT01900743|Experimental|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
11420195|NCT01900743|Placebo Comparator|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
11420196|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
11420197|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
11420198|NCT01900717|Active Comparator|chimiotherapy alone|"LV5FU2 simplified,
~5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,
~fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
11420199|NCT01900717|Experimental|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"LV5FU2 simplified,
~FOLFOX 4 simplified,
~FOLFIRI modified.
~Bevacizumab 5 mg/kg/ 2 weeks"
11420200|NCT01900704|Experimental|SER120 750 ng|SER120 750 ng
11420201|NCT01900704|Experimental|SER120 1500 ng|SER120 1500 ng
11420202|NCT01900704|Placebo Comparator|Placebo|Placebo
11420203|NCT01900691|Experimental|Evolution® Esophageal Stent|
11420204|NCT01900678|Experimental|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
11420205|NCT01900665|Experimental|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
11420206|NCT01900665|Placebo Comparator|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
11420207|NCT01900652|Experimental|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
11420208|NCT01900652|Experimental|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
11420209|NCT01900639|Active Comparator|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
11420210|NCT01900639|Experimental|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
11420211|NCT01900626|Active Comparator|single epidural catheter|
11420212|NCT01900626|Active Comparator|double epidural catheter|
11420213|NCT01900613|Experimental|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
11420214|NCT01900613|Active Comparator|Comparison|Comparison community of San Joaquin
11420215|NCT01900600|Placebo Comparator|Placebo|Placebo
11420216|NCT01900600|Active Comparator|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
11420217|NCT01900600|Active Comparator|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
11420218|NCT01900600|Active Comparator|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
11420219|NCT01900587|Experimental|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
11420220|NCT01900587|Experimental|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
11420221|NCT01900574|Experimental|Golimumab|
11420222|NCT01900561|Experimental|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
11420223|NCT01900561|No Intervention|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
11420224|NCT01900548|Experimental|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
11420225|NCT01900548|Experimental|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
11420226|NCT01900548|Placebo Comparator|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
11420227|NCT01900522|Experimental|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
11420228|NCT01900522|Experimental|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
11420229|NCT01900509|Experimental|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.
~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
11420230|NCT01900496|Experimental|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:
~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.
~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a ~ 1 year total course of therapy."
11420231|NCT01900483||pre bariatric surgery|
11420232|NCT01900483||post bariatric surgery|
11420233|NCT01900470|Experimental|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
11420261|NCT01900301|Experimental|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
11420262|NCT01900301|Placebo Comparator|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
11420234|NCT01900470|No Intervention|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
11420235|NCT01900457|Active Comparator|Volunteer healthy|healthy volunteers
11420236|NCT01900457|Experimental|patients|vestibular defective patients
11420237|NCT01900444|Experimental|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
11420238|NCT01900431|Placebo Comparator|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
11420239|NCT01900431|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
11420240|NCT01900418|Active Comparator|Walking|Walk with Ease
11420241|NCT01900418|No Intervention|Wait list control|Wait list control receiving the active intervention 6 weeks later.
11420242|NCT01900405||Dexmedetomidine|All children undergoing
11420243|NCT01900392|No Intervention|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, & 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
11420244|NCT01900392|Experimental|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.
~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
11420245|NCT01900392|Experimental|Lottery|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.
~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
11420246|NCT01900379|Experimental|OSA/CPAP|OSA patients intervention : CPAP treatment
11420247|NCT01900379|Sham Comparator|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
11420248|NCT01900379|No Intervention|control group|Patients without any apnea syndrome
11420249|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
11420250|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
11420251|NCT01900353|Active Comparator|horizontal brushing method|brushing methods
11420252|NCT01900353|Active Comparator|Vertical brushing method|brushing methods
11420253|NCT01900340|Placebo Comparator|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
11420254|NCT01900340|Active Comparator|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
11420255|NCT01900340|Placebo Comparator|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
11420256|NCT01900340|Active Comparator|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
11420257|NCT01900327|Experimental|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
11420258|NCT01900327|Active Comparator|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
11420259|NCT01900314|Active Comparator|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
11420260|NCT01900314|Sham Comparator|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
11420295|NCT01900106|Experimental|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
11420263|NCT01900301|Experimental|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
11420264|NCT01900301|Experimental|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
11420265|NCT01900288|Experimental|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).
~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
11420266|NCT01900288|Placebo Comparator|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.
~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
11420267|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS > 15). Septic shock is defined by sepsis with hypotension requiring >4 hours of vasopressor support over previous 24 hours.
11420268|NCT01900262|Experimental|Strengthening|Novice recreational runners from the Calgary area.
11420269|NCT01900262|Experimental|Balance Training|Novice recreational runners from the Calgary area.
11420270|NCT01900262|Experimental|Stretching|Novice recreational runners from the Calgary area.
11420271|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
11420272|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
11420273|NCT01900249|Placebo Comparator|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
11420274|NCT01900236|No Intervention|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
11420275|NCT01900236|Experimental|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
11420276|NCT01900223||Shoulder prosthesis bearer|
11420277|NCT01900210|Experimental|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
11420278|NCT01900210|No Intervention|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
11420279|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
11420280|NCT01900184|Experimental|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
11420281|NCT01900184|Experimental|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
11420282|NCT01900184|Experimental|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
11420283|NCT01900184|Placebo Comparator|Placebo|The placebo will be administered in solution with 200 mL of purified water.
11420284|NCT01900171|Experimental|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420285|NCT01900171|Experimental|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420286|NCT01900171|Experimental|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420287|NCT01900171|Experimental|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420288|NCT01900171|Experimental|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420289|NCT01900171|Experimental|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420290|NCT01900171|Experimental|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420291|NCT01900171|Experimental|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420292|NCT01900171|Placebo Comparator|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
11420293|NCT01900158|Experimental|Phase I|Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.
11420294|NCT01900132|Experimental|1/ All Subjects|Healthy Volunteers and patients
11420368|NCT01899599|Experimental|PankoMab-GEX|1700mg, i.v., q3w
11420296|NCT01900106|Active Comparator|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
11420297|NCT01900093|Experimental|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
11420298|NCT01900080|Experimental|Same-Day ART Group|"Same-Day HIV testing and ART initiation:
~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
11420299|NCT01900080|Active Comparator|Standard ART Group|"Standard ART Initiation:
~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
11420300|NCT01900080|Experimental|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count >500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
11420301|NCT01900080|Active Comparator|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
11420302|NCT01900067|Active Comparator|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
11420303|NCT01900067|No Intervention|Control|no active warming, standard of care
11420304|NCT01900054|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
11420305|NCT01900041|Experimental|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
11420306|NCT01900041|Other|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
11420307|NCT01900028|Experimental|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
11420308|NCT01900015|Active Comparator|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
11420309|NCT01900015|Active Comparator|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
11420310|NCT01900002|Experimental|Treatment (sorafenib tosylate, TheraSphere)|Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11420311|NCT01899989|Experimental|A) >5cm,Chemo eligible (closed to accrual)|Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
11420312|NCT01899989|Experimental|B) 3-5cm OR Chemo ineligible|Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in < 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in < 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
11420313|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
11420314|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
11420315|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
11420316|NCT01899924|Experimental|Event Related Potentials|
11420317|NCT01899911|Experimental|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
11420318|NCT01899898|Experimental|Simplified Modified Atkins Diet|
11420319|NCT01899898|Active Comparator|Antiepileptic drugs alone|
11420320|NCT01899885|No Intervention|historic control group|Standard treatment in the historic control group
11420321|NCT01899885|Active Comparator|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:
~Intervention before, during and after abdominal surgery.
~Focus on fast track with multimodal standardized intervention:
~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)
~GDT-LiDCO fluid management pre-, per- and postoperative
~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score
~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
11420322|NCT01899872|Experimental|Patients with type 1 diabetes|Patients with type 1 diabetes
11420323|NCT01899859|Active Comparator|Cohort 1|Patient receives dose of GR-MD-02 or placebo
11420324|NCT01899859|Active Comparator|Cohort 2|Patient receives dose of GR-MD-02 or Placebo
11420325|NCT01899859|Active Comparator|Cohort 3|Patient receives dose of GR-MD-02 or placebo
11420326|NCT01899846|Experimental|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
11420327|NCT01899846|Experimental|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
11420369|NCT01899599|Placebo Comparator|Placebo|matching placebo
11420328|NCT01899846|Experimental|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
11420329|NCT01899833|Experimental|99mTc-EC-DG, Diagnostic|99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose
11420330|NCT01899820|Active Comparator|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
11420331|NCT01899820|Experimental|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
11420332|NCT01899807|Other|Single Arm|
11420333|NCT01899794|Active Comparator|TVT-O|mid-urethral sling
11420334|NCT01899794|Active Comparator|Oxytrol|medication
11420335|NCT01899781|Experimental|with antibiotic and without antibiotic|
11420336|NCT01899768|Experimental|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
11420337|NCT01899768|Experimental|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
11420338|NCT01899768|Experimental|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
11420339|NCT01899755|Experimental|GSK2800528 Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
11420340|NCT01899755|Placebo Comparator|Placebo Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
11420341|NCT01899755|Active Comparator|Adalimumab Arm|In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection
11420342|NCT01899742|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
11420343|NCT01899742|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
11420344|NCT01899729|Experimental|IMO-8400 Regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
11420345|NCT01899729|Experimental|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
11420346|NCT01899729|Experimental|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
11420347|NCT01899729|Placebo Comparator|Placebo|Saline (placebo) q wk x 12 wks
11420348|NCT01899729|Experimental|IMO-8400 Regimen 4|IMO_8400 at 0.6 mg/kg q wk x 12 wks
11420349|NCT01899716|Experimental|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
11420350|NCT01899716|No Intervention|Control|
11420351|NCT01899703|Experimental|GSK2330672|Subject will receive GSK2330672 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either (i) GSK2330672 followed by placebo; OR (ii) placebo followed by GSK2330672.
11420352|NCT01899703|Experimental|Placebo|Subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either GSK2330672 followed by placebo; OR placebo followed by GSK2330672.
11420353|NCT01899690|Experimental|antibiotic|7 days of preventive antibiotics after surgery
11420354|NCT01899690|No Intervention|No antibiotic|No preventive postoperative antibiotics
11420355|NCT01899677|Experimental|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
11420356|NCT01899677|Placebo Comparator|distilled water|2 x 0.5 cc distilled water will be given during 30 days
11420357|NCT01899664|Other|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
11420358|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
11420359|NCT01899638|Experimental|UMEC/VI 125/25 mcg|Combination in high dose
11420360|NCT01899638|Experimental|UMEC/VI 62.5/25 mcg|Combination in low dose
11420361|NCT01899638|Experimental|UMEC 125 mcg|LAMA mono in high dose
11420362|NCT01899638|Experimental|UMEC 62.5 mcg|LAMA mono in low dose
11420363|NCT01899638|Experimental|VI 25 mcg|LABA mono
11420364|NCT01899625|Active Comparator|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
11420365|NCT01899625|Active Comparator|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
11420366|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
11420367|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
11420370|NCT01899586|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
11420371|NCT01899586|Experimental|Aerobic Exercise (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
11420372|NCT01899573|Experimental|Treatment|
11420373|NCT01899560|Other|Unique arm|Experimental and comparator
11420374|NCT01899547|Experimental|Arm I|Patients undergo laparoscopic-assisted rectal resection.
11420375|NCT01899547|Active Comparator|Arm II|Patients undergo conventional open rectal resection.
11420376|NCT01899534|No Intervention|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
11420377|NCT01899534|Experimental|E-screening|Women will complete mental health screening on a tablet
11420378|NCT01899521|Placebo Comparator|Placebo zinc and placebo SAMe|Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
11420379|NCT01899521|Active Comparator|Active zinc and placebo SAMe|Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
11420380|NCT01899521|Active Comparator|Placebo zinc and active SAMe|Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
11420381|NCT01899521|Active Comparator|Active zinc and active SAMe|Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
11420382|NCT01899508|Experimental|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
11420383|NCT01899495|Experimental|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
11420384|NCT01899482|Experimental|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
11420385|NCT01899482|Active Comparator|Control|One educational session in group.
11420386|NCT01899469|Experimental|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
11420387|NCT01899469|Experimental|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
11420388|NCT01899469|Experimental|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
11420389|NCT01899456|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
11420390|NCT01899456|Experimental|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
11420391|NCT01899443||Total hip and knee replacement patients|This study will select up to 20 high volume (>275 cases annually) public and private hospitals across Australia. A random sample of c.2200 patients with diagnosis of osteoarthritis undergoing primary total hip or knee replacement surgery will be recruited.
11420392|NCT01899430|Active Comparator|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
11420393|NCT01899430|Experimental|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
11420394|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
11420395|NCT01899417||Standard Knee Replacements|knee joint replacement
11420396|NCT01899404|Experimental|18-FDG PET/CT, DWI, DCE-MRI|
11420397|NCT01899378|Experimental|daily probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month
11420398|NCT01899378|Experimental|weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month
11420399|NCT01899378|Experimental|bi-weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month
11420400|NCT01899378|No Intervention|control|
11420401|NCT01899365||Multifaceted|"brief structured interview with the physician about pneumococcal risk and vaccination,
~information sheet delivered to patients with explanation about risk and benefit of APV,
~letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,
~3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner."
11420402|NCT01899365||Control|"information sheet delivered to patients with explanation about the aim of the study,
~brief interview with the physician about study."
11420403|NCT01899352|Other|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
11420404|NCT01899339||pulmonary embolism|patients with submassive pulmonary embolism
11420405|NCT01899326|Experimental|Treatment (desipramine, filgrastim)|Patients receive desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection begins on day 6.
11420406|NCT01899313|Experimental|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
11420407|NCT01899313|Placebo Comparator|Placebo Texts|Placebo texts will be given instead of interventional texts
11420408|NCT01899300|Experimental|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
11420409|NCT01899287|Experimental|education in skin care|"The experimental intervention consists of:
~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.
~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
11420653|NCT01897597|Experimental|BI 144807 Tab Treatment B|intermediate dose of BI 144807
11420410|NCT01899287|No Intervention|no intervention|The control group will not have access to the group education, the profession specific information and the social guidance or the telephone hotline.
11420411|NCT01899274|Experimental|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
11420412|NCT01899274|No Intervention|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
11420413|NCT01899261|Experimental|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
11420414|NCT01899248||Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
11420415|NCT01899248||Desflurane|Performing liver transplantation under general anesthesia using desflurane
11420416|NCT01899235|Active Comparator|Stent|drug eluting stent (Resolute)
11420417|NCT01899235|Experimental|drug eluting balloon|drug eluting balloon (Elutax)
11420418|NCT01899222||fundus imaging|retinal photograph obtained at visit
11420419|NCT01899209|Experimental|Group A|STARR
11420420|NCT01899209|Experimental|Group B|Laparoscopic ventral Rectopexy
11420421|NCT01899196|Other|no Arm|
11420422|NCT01899170|Sham Comparator|Sham-DBS|Only patients. Inactive deep brain stimulation for the initial three months following implantation.
11420423|NCT01899170|Active Comparator|Active DBS|Only patients. Active deep brain stimulation for the initial three months following surgery.
11420424|NCT01899170|Experimental|TMS and PET imaging|This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.
11420425|NCT01899157||Survey|"Thai naive HIV-infected patients
~Thai HIV-infected patient reciering highly active antiretroviral therapy"
11420426|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
11420427|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
11420428|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
11420429|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.
~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
11420430|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
11420431|NCT01899131|Other|platform-switch tapered internal implants|2 platform-switch tapered internal implants placed in 10 participants.clinical and radiographic assessment in 6,12,24, month post implant insertion
11420432|NCT01899118|Experimental|Nimotuzumab plus chemoradiotherapy|
11420433|NCT01899105|Experimental|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
11420434|NCT01899105|Experimental|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
11420435|NCT01899092|Experimental|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
11420436|NCT01899066|Experimental|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.
~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
11420437|NCT01899066|Active Comparator|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
11420438|NCT01899053|Experimental|Dose Escalation Treatment Arm A|TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
11420439|NCT01899053|Experimental|Dose Escalation Treatment Arm B|TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
11420440|NCT01899053|Experimental|Dose Escalation Treatment Arm C|TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
11420441|NCT01899053|Experimental|Drug-Drug Interaction (DDI) Expansion Cohort|TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
11420442|NCT01899040|Active Comparator|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
11420863|NCT01896258||Local emergency centers|
11420443|NCT01899040|Placebo Comparator|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
11420444|NCT01899027|Active Comparator|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
11420445|NCT01899027|Placebo Comparator|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
11420446|NCT01899001|Experimental|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
11420447|NCT01899001|Other|Nutrition Counseling|16 weeks of Nutrition Counseling alone
11420448|NCT01898975||500ml fluid loading|All enrolled patients
11420449|NCT01898962|Experimental|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
11420450|NCT01898949|Experimental|Cold Exposure|
11420451|NCT01898936|Experimental|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.
~The laser settings will be as follows:
~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
11420452|NCT01898936|Sham Comparator|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
11420453|NCT01898923|Experimental|ON101 Cream|ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
11420454|NCT01898923|Other|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
11420455|NCT01898910|Active Comparator|PVI+renal denervation+OMT|
11420456|NCT01898910|Active Comparator|PVI+GP ablation+OMT|
11420457|NCT01898897|Active Comparator|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.
~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
11420458|NCT01898897|Experimental|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
11420459|NCT01898884|Experimental|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
11420460|NCT01898884|Experimental|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
11420461|NCT01898871|Experimental|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
11420462|NCT01898871|Active Comparator|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
11420463|NCT01898858||HYPOXIA|
11420464|NCT01898858||HYPERCAPNIA|
11420465|NCT01898858||HYPOXIA + HYPERCAPNIA|
11420466|NCT01898845|Experimental|LEE011|LEE011
11420467|NCT01898819|Experimental|dexmedetomidine|dexmedetomidine infusion from beginning of the anesthesia to just before returning to horizontal position
11420468|NCT01898819|Placebo Comparator|saline|Saline infusion from same time period.
11420469|NCT01898806|Experimental|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
11420470|NCT01898806|Experimental|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
11420471|NCT01898806|Experimental|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
11420472|NCT01898806|Placebo Comparator|Placebo|"Intralesional Saline (Placebo):
~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
11420473|NCT01898793|Experimental|Phase I: 0.5 x 10^6/kg CIML NK cells (Dose Levels 1-3)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
11420543|NCT01898312|Placebo Comparator|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
11420474|NCT01898793|Experimental|Lead-in Cohort & Phase II (ALT-803): Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
~Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
11420475|NCT01898793|Experimental|Pediatric Cohort: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
~Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses"
11420476|NCT01898793|Experimental|Phase II (IL-2): Maximum NK cell/number kg|The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
11420477|NCT01898780|Experimental|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
11420478|NCT01898780|Experimental|interrupted suture|pancreaticojejunostomy with interrupted suture
11420479|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of >70% predicted.
11420480|NCT01898754|Experimental|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
11420481|NCT01898754|No Intervention|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
11420482|NCT01898741|Experimental|irradiation|24 Gy in 3 fractions
11420483|NCT01898728|Active Comparator|Liquid preoperative medications|Liquid preoperative medications
11420484|NCT01898728|Active Comparator|Gel preoperative medications|Gel preoperative medications
11420485|NCT01898715|Experimental|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
11420486|NCT01898702|Experimental|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
11420487|NCT01898702|Placebo Comparator|No intervention|Don't participate in a scheduled and standardized expert patients programme course
11420488|NCT01898689|Experimental|Ropivacaine 0.1%|Ropivacaine 0.1% at 8 mL/h basal for 6 hours
11420489|NCT01898689|Active Comparator|Ropivacaine 0.4%|Ropivacaine 0.4% at 2 mL/h basal for 6 hours
11420490|NCT01898676|Active Comparator|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
11420491|NCT01898676|Active Comparator|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
11420492|NCT01898663|Experimental|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DCs + CIK cells
11420493|NCT01898650|Experimental|craniofacial abnormalities|Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.
11420494|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
11420495|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
11420496|NCT01898624||Betanis group|mirabegron treated group
11420497|NCT01898611|Active Comparator|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
11420498|NCT01898611|Placebo Comparator|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
11420499|NCT01898598|Placebo Comparator|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
11420500|NCT01898598|Experimental|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
11420501|NCT01898585|Experimental|Zelboraf Arm|
11420502|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
11420503|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
11420504|NCT01898559|Experimental|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black & Mild little cigars.
~Other: Switch to smoking only little cigars"
11420505|NCT01898559|Experimental|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.
~Other: Switch to smoking only little cigars"
11420506|NCT01898546|Experimental|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
11420507|NCT01898546|Active Comparator|Primary angioplasty|Primary angioplasty alone
11420508|NCT01898520|Active Comparator|Sativex|Oromucosal spray containing delta-9-tetrahydrocannabinol (THC) (27 mg/mL):cannabidiol (CBD) (25 mg/mL). Each 100 μL spray to the sub-lingual or oral mucosa delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
11420509|NCT01898520|Placebo Comparator|Placebo|Oromucosal spray containing ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum number of daily sprays was 12.
11420610|NCT01897844|Experimental|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
11420510|NCT01898507|Experimental|Low nicotine cigarettes|"Participants will smoke their own brand cigarettes during a baseline 5 day period, followed by a 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
~Other: Low nicotine cigarettes"
11420511|NCT01898494|Experimental|Arm A (TOS)|Patients undergo transoral surgical resection of the oropharyngeal tumor.
11420512|NCT01898494|Experimental|Arm B (TOS, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose IMRT QD five days a week for 5 weeks.
11420513|NCT01898494|Experimental|Arm C (TOS, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.
11420514|NCT01898494|Experimental|Arm D (TOS, standard-dose IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
11420515|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
11420516|NCT01898468|Active Comparator|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
11420517|NCT01898468|Active Comparator|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
11420518|NCT01898455|Experimental|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
11420519|NCT01898442|Active Comparator|Ticagrelor 180|Standard ticagrelor 180mg loading dose
11420520|NCT01898442|Experimental|Ticagrelor 270mg|High ticagrelor 270mg loading dose
11420521|NCT01898442|Experimental|Ticagrelor 360mg|High ticagrelor 360mg loading dose
11420522|NCT01898429|Active Comparator|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
11420523|NCT01898429|Active Comparator|Right-sided SCC DBS|Active stimulation of the right-sided electrode
11420524|NCT01898416|Experimental|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
11420525|NCT01898403|Experimental|Sentinel Lymph Node (SLN) Detection|All patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution for detection of melanoma in lymph nodes. In addition, lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) will be conducted for all participants with the same objective.
11420526|NCT01898390|Experimental|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
11420527|NCT01898390|No Intervention|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
11420528|NCT01898377|Experimental|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd
~Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)
~Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
11420529|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
11420530|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
11420531|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
11420532|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
11420533|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
11420534|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
11420535|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.
~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.
~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
11420536|NCT01898338|Experimental|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
11420537|NCT01898338|Active Comparator|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
11420538|NCT01898325|Other|Naïve GD patients|"Naïve GD patients
~Intervention: device - Fibroscan"
11420539|NCT01898325|Other|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
11420540|NCT01898325|Other|Healthy control|Healthy control Intervention: device - Fibroscan
11420541|NCT01898325|Other|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
11420542|NCT01898312|Experimental|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
11420544|NCT01898299|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
11420545|NCT01898299|Sham Comparator|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
11420546|NCT01898286|Experimental|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
11420547|NCT01898273|Experimental|Single|I-124-CLR1404, open-label
11420548|NCT01898260|Other|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
11420549|NCT01898260|Other|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
11420550|NCT01898247|No Intervention|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
11420551|NCT01898247|Experimental|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
11420552|NCT01898234|Experimental|Revaclear|
11420553|NCT01898234|Experimental|Helixone high flux|
11420554|NCT01898234|Experimental|Xevonta|
11420555|NCT01898234|Experimental|Helixone low flux|
11420556|NCT01898221|Active Comparator|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
11420557|NCT01898221|Active Comparator|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
11420558|NCT01898208|Experimental|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
11420559|NCT01898208|Experimental|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
11420560|NCT01898208|Experimental|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
11420561|NCT01898195|Active Comparator|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
11420562|NCT01898195|Experimental|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
11420563|NCT01898195|Experimental|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
11420564|NCT01898182|Experimental|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
11420565|NCT01898169|Experimental|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
11420566|NCT01898156|Experimental|BIW-8962|"Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur
~Phase 2 - Recommended dose determined in Phase 1"
11420567|NCT01898143|Other|Whole body vibration in COPD|Patients with COPD GOLD III or IV
11420568|NCT01898143|Other|Whole body vibration in ILD|PAtients with interstitial lung disease
11420569|NCT01898130|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11420570|NCT01898117|Active Comparator|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
11420571|NCT01898117|Active Comparator|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
11420572|NCT01898117|Active Comparator|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
11420573|NCT01898117|Active Comparator|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
11420574|NCT01898104|Active Comparator|SCRT|short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.
11420575|NCT01898104|Active Comparator|V-SCRT|Valproic acid (V) + short course radiotherapy
11420576|NCT01898104|Active Comparator|C-SCRT|capecitabine (C) + short course radiotherapy
11420577|NCT01898104|Active Comparator|VC-SCRT|valproic acid + capecitabine + short course radiotherapy
11420578|NCT01898091|Experimental|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
11420579|NCT01898091|Placebo Comparator|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
11420580|NCT01898078|Experimental|Alisertib 50 mg Fed + Fasted|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
11420609|NCT01897857|Active Comparator|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
11420581|NCT01898078|Experimental|Alisertib 50 mg Fasted + Fed|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
11420582|NCT01898065|Experimental|PET imaging, 18 F-miso|Single Arm study
11420583|NCT01898052|Experimental|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
11420584|NCT01898052|Active Comparator|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
11420585|NCT01898039|Experimental|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.
~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
11420586|NCT01898026|Experimental|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
11420587|NCT01898026|Other|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
11420588|NCT01898013|Active Comparator|Pregnenolone|"Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:
~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued."
11420589|NCT01898013|Placebo Comparator|Placebo|"Placebo will be administered exactly the same as the active comparator (pregnenolone) and will consist of the following schedule:
~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): placebo PO, BID x 1 week, Visit 4 (week 2): placebo PO, BID x 1 week, Visit 5 (week 3): placebo PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered in the exact manner as active study medication and then discontinued."
11420590|NCT01897987|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
11420591|NCT01897987|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
11420592|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
11420593|NCT01897961|Other|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
11420594|NCT01897961|Other|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
11420595|NCT01897961|Other|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
11420596|NCT01897948|Experimental|Milk-based beverage with DHA at mid-level|
11420597|NCT01897948|Experimental|Milk-based beverage with DHA at high level|
11420598|NCT01897948|Active Comparator|Milk-based beverage without DHA|
11420599|NCT01897922|Active Comparator|Marketed routine infant formula|
11420600|NCT01897922|Experimental|Infant formula containing a probiotic source|
11420601|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
11420602|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
11420603|NCT01897909||HIV negative|HIV negative blood donors
11420604|NCT01897896|Experimental|Rollover Cohort: SD-809 ER|Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
11420605|NCT01897896|Experimental|Switch Cohort: SD-809 ER|Participants who were receiving an approved dosing regimen of tetrabenazine for at least 8 weeks prior to screening, will be converted overnight from their existing tetrabenazine regimen to SD-809 ER regimen to achieve targeted steady-state area under the curve (AUC) of total (alpha+beta)- Dihydrotetrabenazine (HTBZ) metabolites that is predicted to be comparable to that of participant's prior tetrabenazine regimen. Participants will remain on initial dose of SD-809 ER through Week 1. Dose adjustment will be continued through Week 4 to optimize the dose. Dose of SD-809 ER can be adjusted weekly (upward or downward) in increments of 6 mg per day (6 mg/day or 12 mg/day after a total daily dose of 48 mg is reached), based on chorea control and treatment regimen tolerability. Long-term treatment with SD-809 ER at a stable dose (although further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
11420606|NCT01897883||One Group|Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
11420607|NCT01897870|Experimental|HomeCoMe-program group|the arm receiving the pharmacist home visit
11420608|NCT01897857|Experimental|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
11420611|NCT01897844|Experimental|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
11420612|NCT01897844|Experimental|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
11420613|NCT01897831|Experimental|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
11420614|NCT01897818|Experimental|ALS patients|
11420615|NCT01897805|Experimental|Heart-protecting Musk Pill|Patients will get standard treatment for coronary artery disease plus 2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months
11420616|NCT01897805|Placebo Comparator|Placebo|Patients will get standard treatment for coronary artery disease plus 2 placebo pills each time, three times a day by mouth for 24 months
11420617|NCT01897792|Experimental|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
11420618|NCT01897792|Placebo Comparator|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
11420619|NCT01897779|Experimental|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
11420620|NCT01897779|Experimental|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
11420621|NCT01897779|Placebo Comparator|Normal Saline|Single and multiple dose of normal saline
11420622|NCT01897779|Experimental|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
11420623|NCT01897766||Somatropin|Patients administered Somatropin.
11420624|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
11420625|NCT01897727|Active Comparator|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP > 140/90 mm Hg throughout the 3 month study.
11420626|NCT01897727|Sham Comparator|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP < 140/90 mm Hg throughout the study.
11420627|NCT01897714|Experimental|Phase I: Melflufen 15 mg + Dexamethasone|Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
11420628|NCT01897714|Experimental|Phase I: Melflufen 25 mg + Dexamethasone|IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
11420629|NCT01897714|Experimental|Phase I: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
11420630|NCT01897714|Experimental|Phase I: Melflufen 55 mg + Dexamethasone|IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
11420631|NCT01897714|Experimental|Phase I + II: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
11420632|NCT01897714|Experimental|Phase II: Melflufen 40 mg (Single Agent)|IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
11420633|NCT01897701|Experimental|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
11420634|NCT01897701|Experimental|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
11420635|NCT01897701|Experimental|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & 21
11420636|NCT01897701|Experimental|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & Day 21
11420637|NCT01897701|Experimental|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
11420638|NCT01897701|Experimental|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
11420639|NCT01897701|Experimental|Group G|Placebo; IM; Day 0 & 21
11420640|NCT01897688|Experimental|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
11420641|NCT01897675|Active Comparator|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
11420642|NCT01897675|Experimental|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
11420643|NCT01897662|Experimental|NUTRIOSE|Group of volunteers fed with NUTRIOSE
11420644|NCT01897662|Active Comparator|GLUCIDEX|Group of volunteers fed with GLUCIDEX
11420645|NCT01897649|Experimental|NUTRIOSE|group of volunteers fed with NUTRIOSE
11420646|NCT01897649|Active Comparator|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
11420647|NCT01897636|Experimental|EUS-guided fine-needle injection of DCs vaccinations|
11420648|NCT01897623|Other|ultrasound of aorta|
11420649|NCT01897610|No Intervention|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
11420650|NCT01897610|Experimental|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
11420651|NCT01897597|Experimental|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
11420652|NCT01897597|Experimental|BI 144807 PfoS Treatment C|high dose of BI 144807
11420654|NCT01897597|Experimental|BI 144807 Tab Treatment D|high dose of BI 144807
11420655|NCT01897597|Experimental|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
11420656|NCT01897597|Experimental|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
11420657|NCT01897597|Experimental|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
11420658|NCT01897584|Experimental|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
11420659|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 1|This portion comprises dose escalation and dose expansion to establish the recommended Phase 2 dose (RP2D) when tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as well as the drug-drug interaction (DDI) potential of tazemetostat are evaluated. CLOSED TO ENROLLMENT
11420660|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 2|This portion is restricted to subjects with DLBCL or FL for the determination of efficacy and safety of tazemetostat monotherapy and tazemetostat in combination with prednisolone as defined by histology, cell of origin and EZH2 mutation status.
11420661|NCT01897558|Active Comparator|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
11420662|NCT01897558|Active Comparator|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
11420663|NCT01897545|Active Comparator|PV isolation|
11420664|NCT01897545|Active Comparator|PV isolation+renal denervation|
11420665|NCT01897532|Experimental|Linagliptin|
11420666|NCT01897532|Placebo Comparator|Placebo|
11420667|NCT01897519|Experimental|Arm 1 lower dose ABT-719|
11420668|NCT01897519|Experimental|Arm 2 intermediate dose ABT-719|
11420669|NCT01897519|Experimental|Arm 3 high dose ABT-719|
11420670|NCT01897519|Placebo Comparator|Arm 4 Placebo|
11420671|NCT01897493|Active Comparator|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
11420672|NCT01897493|Experimental|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
11420673|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.
~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
11420674|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.
~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
11420675|NCT01897467|Placebo Comparator|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
11420676|NCT01897467|Experimental|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.
~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
11420677|NCT01897454|Experimental|Treatment (FOLFIRINOX, IMRT, and gemcitabine hydrochloride)|"CHEMOTHERAPY REGIMEN: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on day 1, and fluorouracil IV over 46 hours on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving disease progression proceed to chemoradiotherapy.
~CHEMORADIOTHERAPY REGIMEN: Beginning 4-6 weeks after completion of chemotherapy, patients undergo IMRT on 5 consecutive days per week for a total of 28 fractions and receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity."
11420678|NCT01897441|Experimental|Stratum A (HER2-positive disease)|Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks
11420679|NCT01897441|Experimental|Stratum B (paclitaxel followed by AC)|Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.
11420680|NCT01897441|Experimental|Stratum C (AC followed by paclitaxel)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
11420681|NCT01897428|Active Comparator|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
11420682|NCT01897428|Experimental|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
11420683|NCT01897415|Experimental|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
11420684|NCT01897402|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
11420685|NCT01897402|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
11420686|NCT01897389|Experimental|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
11420687|NCT01897389|Experimental|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
11420688|NCT01897389|Experimental|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
11420689|NCT01897389|Experimental|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
11420690|NCT01897389|Experimental|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
11420691|NCT01897389|Experimental|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
11420692|NCT01897389|Experimental|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
11420693|NCT01897389|Experimental|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
11420694|NCT01897376|Other|Pfannenstiel incision|
11420695|NCT01897376|Other|vertical skin incision|
11420696|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
11420697|NCT01897350||CMR following ST segment myocardial infarction|
11420698|NCT01897337|Experimental|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
11420699|NCT01897337|Placebo Comparator|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
11420700|NCT01897324|Experimental|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
11420701|NCT01897324|Experimental|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
11420702|NCT01897324|Experimental|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
11420703|NCT01897324|Experimental|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
11420704|NCT01897311|Experimental|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
11420705|NCT01897311|Experimental|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
11420706|NCT01897311|Placebo Comparator|Placebo with TENS off|TENS application when off
11420707|NCT01897298|Experimental|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
11420708|NCT01897298|No Intervention|Usual care|Patients will continue their usual care
11420709|NCT01897285|Experimental|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
11420710|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
11420711|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
11420712|NCT01897259|Active Comparator|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
11420713|NCT01897259|Active Comparator|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
11420714|NCT01897259|Placebo Comparator|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
11420715|NCT01897259|Active Comparator|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
11420716|NCT01897246|Active Comparator|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
11420717|NCT01897246|Active Comparator|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
11420718|NCT01897233|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.
~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.
~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
11420719|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
11420720|NCT01897207|Experimental|Dendritic cell application|
11420721|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
11420722|NCT01897181|Active Comparator|Hearing aids|Patients who agree to use hearing aids
11420723|NCT01897181|No Intervention|No hearing aids|Patients who did not agree to use hearing aids
11420724|NCT01897168||No grouping|
11420725|NCT01897155|Other|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
11420726|NCT01897155|Other|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
11420727|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 1|
11420728|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 2|
11420729|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 3|
11420730|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 4|
11420731|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 5|
11420732|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 6|
11420733|NCT01897129||Early pregnancy|Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
11420734|NCT01897129||Chorionic villous sampling|Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
11420735|NCT01897129||Spontaneous abortion|Women with miscarriage at a gestational age up to 22 weeks
11420736|NCT01897129||Preterm birth|Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
11420737|NCT01897129||Vaginal delivery at term|Women with spontaneous vaginal delivery at term (week 37+0-)
11420738|NCT01897129||Elective ceaserean section at term|Women undergoing elective cesarean section at term (week 37+0-)
11420739|NCT01897090|Experimental|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
11420740|NCT01897090|Active Comparator|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
11420741|NCT01897077|Experimental|Peanut Allergic|Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
11420742|NCT01897077|Active Comparator|Healthy Volunteers|Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
11420743|NCT01897064|Experimental|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
11420744|NCT01897064|Active Comparator|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
11420745|NCT01897051|Experimental|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
11420746|NCT01897051|Placebo Comparator|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
11420747|NCT01897038|Experimental|Cohort 1 (Onartuzumab)|
11420748|NCT01897038|Experimental|Cohorts 2/3 (Onartuzumab + Sorafenib)|
11420749|NCT01897025|Active Comparator|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.
~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.
~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
11420750|NCT01897025|Sham Comparator|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:
~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.
~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
11420751|NCT01897012|Experimental|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11420752|NCT01896999|Experimental|Phase I Arm I (brentuximab vedotin, ipilimumab)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
11420753|NCT01896999|Experimental|Phase I Arm II (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.
11420754|NCT01896999|Experimental|Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.
11420755|NCT01896999|Experimental|Phase II Arm I (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.
11420756|NCT01896999|Experimental|Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)|Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.
11420757|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)
~Subgroups:
~receiving immunosuppressant therapy
~not on immunosuppressant therapy"
11420758|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.
~Subgroups:
~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
11420759|NCT01896973|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
11420760|NCT01896960|Active Comparator|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
11420761|NCT01896960|Active Comparator|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
11420762|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
11420763|NCT01896934|Experimental|Sertraline|50-200mg daily
11420764|NCT01896921|Experimental|Maraviroc + Raltegravir or Dolutegravir|Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
11420765|NCT01896908|Experimental|Intervention|Sodium restriction (1.6g sodium daily - 4g salt) combined with 800 ml of fluid intake
11420766|NCT01896908|No Intervention|Control|Normal sodium diet (4g sodium daily - 10g salt) and free fluid intake
11420767|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
11420768|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
11420769|NCT01896895|Placebo Comparator|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.
~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
11420770|NCT01896882|Experimental|Intervention|Nutritional education on sodium restriction diet.
11420771|NCT01896882|No Intervention|Control|Standard treatment.
11420772|NCT01896869|Experimental|Ipilimumab + Vaccine (Arm A)|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
11420773|NCT01896869|Experimental|FOLFIRINOX (Arm B)|Administered every 14 days (one cycle)
11420774|NCT01896856|Experimental|Phase 1: Dose Escalation|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.
~Various doses of SGI-110 are tested to determine the maximum tolerated dose in combination with irinotecan."
11420775|NCT01896856|Experimental|Phase 2: Arm A SGI-110 + irinotecan|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.
~Growth factor support (filgrastim and peg-filgrastim) is given during cycle 1 with option to give additional growth factor support at subsequent cycles per clinician judgement."
11420776|NCT01896856|Active Comparator|Phase 2: Arm B regorafenib or TAS-102|"Subjects received either regorafenib or TAS-102 based on physician and patient preference. Subjects that had received one of these standard of care drugs (regorafenib or TAS-102) prior to enrollment received the other on study.
~Regorafenib taken daily from days 1-21 of each 28-day cycle or TAS-102 taken twice daily on days 1-5 and 8-12 of each 28-day cycle.
~Subjects who had disease progression on Arm B were given the option to receive Arm A study drugs after a 14 day wash-out period."
11420777|NCT01896830|Experimental|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
11420778|NCT01896830|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
11420779|NCT01896791|Active Comparator|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
11420780|NCT01896791|Placebo Comparator|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
11420781|NCT01896778|Experimental|Arm I (B-WARM for 30 minutes)|Patients undergo B-WARM at 39 degrees C for 30 minutes.
11420782|NCT01896778|Experimental|Arm II (B-WARM for 2 hours)|Patients undergo B-WARM at 39 degrees C for 2 hours.
11420783|NCT01896765|Experimental|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
11420784|NCT01896765|Other|Usual care|Standard care with respect to medical and interventional therapy.
11420785|NCT01896739|Experimental|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
11420786|NCT01896739|Active Comparator|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
11420787|NCT01896739|Experimental|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
11420788|NCT01896739|Active Comparator|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
11420789|NCT01896726|Experimental|Baricitinib + Microgynon|Microgynon [30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
11420790|NCT01896713|Other|Diagnostic: Single Arm|Imaging (MS3TMRI)
11420791|NCT01896700|Experimental|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.
~Other name: Ritalin"
11420792|NCT01896700|Placebo Comparator|Placebo|Placebo pill, bid for 6 weeks
11420793|NCT01896687|Experimental|Scrambler therapy|Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
11420794|NCT01896687|Sham Comparator|Sham Scrambler treatment|Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days
11420795|NCT01896661|Experimental|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
11420796|NCT01896661|Active Comparator|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
11420797|NCT01896648||Type 2 diabetic women|
11420798|NCT01896635|Active Comparator|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
11420799|NCT01896635|Placebo Comparator|Placebo arm|Placebo infusions
11420800|NCT01896622|Experimental|A|Ritonavir
11420801|NCT01896622|Experimental|B|Cobicistat
11420802|NCT01896609|Experimental|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:
~Reiferon Retard® 160 µg /week subcutaneous injection.
~Ribavirin in a dose of 13 mg/kg/day orally"
11420803|NCT01896609|Experimental|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;
~Reiferon Retard® 160 µg /week subcutaneous injection
~Ribavirin in a dose of 13 mg/kg/day orally
~Xerovirinc® 500mg twice daily orally."
11420804|NCT01896609|Experimental|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:
~Bon-One ® 0.5 µg daily orally
~Reiferon Retard® 160 µg /week subcutaneous injection
~Ribavirin in a dose of 13 mg/kg/day orally
~Xerovirinc® 500mg twice daily orally."
11420805|NCT01896596|Active Comparator|Menjugate|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menjugate (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
11420806|NCT01896596|Active Comparator|Menitorix|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menitorix (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
11420807|NCT01896596|Active Comparator|NeisVac-C|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with NeisVac-C(at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
11420808|NCT01896583|Experimental|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
11420809|NCT01896583|Placebo Comparator|Placebo|oral
11420810|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
11420811|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
11420812|NCT01896557|Experimental|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
11420813|NCT01896557|Experimental|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
11420814|NCT01896544|Active Comparator|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
11420815|NCT01896544|Placebo Comparator|Placebo|Oral suspension of placebo cholecalciferol
11420816|NCT01896544|Active Comparator|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
11420817|NCT01896531|Experimental|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
11420818|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
11420819|NCT01896518|No Intervention|Counseling|
11420820|NCT01896518|Experimental|Nicotine lozenge|Participants will receive nicotine lozenge to use as needed for 12 weeks.
11420821|NCT01896518|Experimental|Tobacco lozenge|Participants will receive tobacco lozenge to use as needed for 12 weeks.
11420822|NCT01896505|Experimental|Arm 1 - Treatment A, B, C, D|"There are 4 treatment formulations of KCP-330:
~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation
~In Arm 1, the following order will be utilized:
~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C Week 4, day 1: Treatment D
~(Note that recruitment has been completed for this arm)"
11420823|NCT01896505|Experimental|Arm 2 - Treatment B, A, D, C|"There are 4 treatment formulations of KCP-330:
~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation
~In Arm 2, the following order will be utilized:
~Week 1, day 1: Treatment B Week 2, day 1: Treatment A Week 3, day 1: Treatment D Week 4, day 1: Treatment C
~(Note that recruitment has been completed for this arm)"
11420824|NCT01896505|Experimental|Arm 3|"To evaluate tumor response in sarcoma patients (RECIST v1.1 criteria) on KCP-330.
~(Note that recruitment has been completed for this arm)"
11420825|NCT01896505|Experimental|Arm 4 - Treatment A, B, C|"There are 3 treatment formulations of KCP-330:
~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg
~In Arm 4, the following order will be utilized:
~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C"
11420826|NCT01896505|Experimental|Arm 5 - Treatment C, A, B|"There are 3 treatment formulations of KCP-330:
~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg
~In Arm 5, the following order will be utilized:
~Week 1, day 1: Treatment C Week 2, day 1: Treatment A Week 3, day 1: Treatment B"
11420827|NCT01896505|Experimental|Arm 6 - Treatment B, C, A|"There are 3 treatment formulations of KCP-330:
~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg
~In Arm 6, the following order will be utilized:
~Week 1, day 1: Treatment B Week 2, day 1: Treatment C Week 3, day 1: Treatment A"
11420828|NCT01896492|Active Comparator|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
11420829|NCT01896492|Placebo Comparator|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
11420830|NCT01896492|No Intervention|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
11420831|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
11420864|NCT01896245|Active Comparator|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
11420832|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
11420833|NCT01896466|Active Comparator|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
11420834|NCT01896466|Active Comparator|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
11420835|NCT01896466|Active Comparator|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
11420836|NCT01896466|Sham Comparator|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
11420837|NCT01896466|Experimental|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
11420838|NCT01896466|Active Comparator|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
11420839|NCT01896453|Active Comparator|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
11420840|NCT01896453|Experimental|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
11420841|NCT01896453|Experimental|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
11420842|NCT01896453|Sham Comparator|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).
~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
11420843|NCT01896440|Active Comparator|Group A - standard ondansetron dose first|Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.
11420844|NCT01896440|Active Comparator|Group B - high dose ondansetron first|Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.
11420845|NCT01896427|Active Comparator|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
11420846|NCT01896427|Active Comparator|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
11420847|NCT01896414|Experimental|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
11420848|NCT01896414|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
11420849|NCT01896401|Experimental|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
11420850|NCT01896388|Active Comparator|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
11420851|NCT01896388|Placebo Comparator|Placebo|Oral Administration of Placebo (After breakfast, After supper)
11420852|NCT01896349|Experimental|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.
~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
11420853|NCT01896349|Active Comparator|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.
~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
11420854|NCT01896336|Experimental|5mg sublingual Zolpidem hemitartrate|1 QD
11420855|NCT01896336|Active Comparator|10 mg oral Zolpidem hemitartrate|1 QD.
11420856|NCT01896323|Experimental|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
11420857|NCT01896323|Active Comparator|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
11420858|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
11420859|NCT01896297|Other|dabigatran etexilate|75mg BID by oral
11420860|NCT01896284|Experimental|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
11420861|NCT01896271|Experimental|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
11420862|NCT01896258||Regional emergency centers|
11420865|NCT01896245|Active Comparator|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
11420866|NCT01896245|Active Comparator|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
11420867|NCT01896232|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
11420868|NCT01896232|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
11420869|NCT01896219|Active Comparator|Gesture performed under control tomodensitometric (CT)|Conventional
11420870|NCT01896219|Experimental|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
11420871|NCT01896206|Experimental|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
11420872|NCT01896193|Experimental|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
11420873|NCT01896193|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
11420874|NCT01896180|Experimental|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
11420875|NCT01896180|Active Comparator|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
11420876|NCT01896167|Active Comparator|Hypoxia|Inhalation of air with 8-12% oxygen content
11420877|NCT01896167|Placebo Comparator|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
11420878|NCT01896154|Experimental|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
11420879|NCT01896154|Experimental|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
11420880|NCT01896154|Experimental|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
11420881|NCT01896154|Experimental|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
11420882|NCT01896154|Experimental|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
11420883|NCT01896154|Placebo Comparator|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
11420884|NCT01896128|Experimental|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
11420885|NCT01896128|Placebo Comparator|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
11420886|NCT01896115|Experimental|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
11420887|NCT01896115|Experimental|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
11420888|NCT01896115|Experimental|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
11420889|NCT01896115|Experimental|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
11420890|NCT01896102|Experimental|Lenti-D Drug Product|
11420891|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
11420892|NCT01896063|Experimental|Electroacupuncture preconditioning|
11420893|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
11420894|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
11420895|NCT01896037|Experimental|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
11420896|NCT01896024|Active Comparator|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
11420897|NCT01896024|Experimental|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
11420898|NCT01896011|Active Comparator|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
11420899|NCT01896011|Placebo Comparator|Placebo|Placebo injection pen identical to active drug injection pen
11420900|NCT01895985|Experimental|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
11420901|NCT01895972|Experimental|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
11420902|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
11420940|NCT01895660|Experimental|Group with part-time constraint and daily therapy|
11420903|NCT01895946|Experimental|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
11420904|NCT01895946|Experimental|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
11420905|NCT01895933|Active Comparator|Active / control|One side has been treated with SurgiShield
11420906|NCT01895933|No Intervention|No intervention|One side has no intervention
11420907|NCT01895920|Experimental|HIV infection|20 HIV infected subjects
11420908|NCT01895907||Special Olympic athletes|
11420909|NCT01895894|Experimental|Mycophenolate mofetil|
11420910|NCT01895894|No Intervention|Control|
11420911|NCT01895881|Experimental|Estradiol Daily|1 mg Estradiol daily for 180 days.
11420912|NCT01895881|Placebo Comparator|Placebo|Placebo for 180 days.
11420913|NCT01895868|Active Comparator|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
11420914|NCT01895868|No Intervention|Control|Clinical training alone.
11420915|NCT01895855|Experimental|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
11420916|NCT01895855|Placebo Comparator|Placebo|Biological: Placebo physiological saline
11420917|NCT01895842|Experimental|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.
~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
11420918|NCT01895829|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.
~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
11420919|NCT01895816|Experimental|fertility coated tablet|700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
11420920|NCT01895803||smoking woman 18-60 years old|
11420921|NCT01895790|Experimental|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
11420922|NCT01895777|Experimental|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
11420923|NCT01895777|Active Comparator|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
11420924|NCT01895764|Active Comparator|Adalimumab|adalimumab 40mg every 2 weeks
11420925|NCT01895764|Experimental|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
11420926|NCT01895751|No Intervention|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:
~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.
~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
11420927|NCT01895751|Active Comparator|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
11420928|NCT01895738|Experimental|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
11420929|NCT01895738|No Intervention|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
11420930|NCT01895712||Orsiro|
11420931|NCT01895699|Experimental|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
11420932|NCT01895699|Placebo Comparator|Placebo group|
11420933|NCT01895699|Other|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
11420934|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
11420935|NCT01895686||Narrow angle|patients diagnosed with narrow angles
11420936|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
11420937|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
11420938|NCT01895660|Experimental|Group with continuous constraint and daily therapy|
11420939|NCT01895660|Experimental|Group with continuous constrainit and 3 days a week therapy|
11420941|NCT01895660|Experimental|Group with part-time constraint and 3 days a week therapy|
11420942|NCT01895660|Active Comparator|Usual and customary treatment group|
11420943|NCT01895647|Experimental|Biceps stimulation|EMS
11420944|NCT01895647|Experimental|Quadriceps stimulation|EMS
11420945|NCT01895647|No Intervention|Control|Control group without electric muscle stimulation
11420946|NCT01895634|Experimental|Treatment|Intervention Device: Rev-01
11420947|NCT01895621|Experimental|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
11420948|NCT01895621|Placebo Comparator|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
11420949|NCT01895608|Experimental|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
11420950|NCT01895608|Active Comparator|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
11420951|NCT01895608|Experimental|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
11420952|NCT01895608|Active Comparator|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
11420953|NCT01895595|Experimental|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
11420954|NCT01895595|Active Comparator|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
11420955|NCT01895582||Active TB-infected patients|TB-infected patients with bacteriological and histological evidences
11420956|NCT01895582||Non active TB-infected patients (already met TB)|some of elders have already met M tuberculosis before active antibiotherapy exists
11420957|NCT01895582||Non active TB-infected patients (other diagnosis)|same symptoms than two others groups but an other diagnosis
11420958|NCT01895569|Experimental|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
11420959|NCT01895556|Experimental|Information|Information about male circumcision and HIV risk
11420960|NCT01895556|Placebo Comparator|Control|Control
11420961|NCT01895543|Experimental|EBX10|Elobixibat 10 mg
11420962|NCT01895530|No Intervention|Control group|Conventional treatment with no probiotic supplementation
11420963|NCT01895530|Experimental|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
11420964|NCT01895517|Active Comparator|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
11420965|NCT01895517|Experimental|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
11420966|NCT01895504|Experimental|ColoAssist|Screening colonoscopy with a new colonoscope with gradual stiffness
11420967|NCT01895504|Active Comparator|MEI|Screening colonoscopy with colonoscopes compatible with and guided by MEI
11420968|NCT01895491|Experimental|CohortⅠ|VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle
11420969|NCT01895491|Experimental|CohortⅡ|VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle
11420970|NCT01895491|Experimental|CohortⅢ|VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle
11420971|NCT01895478|Experimental|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
11420972|NCT01895478|No Intervention|Control|Control attendings were not given the PACCI-ED use intervention.
11420973|NCT01895465|Experimental|A slitted diaper|An ordinary pediatric urine collection bag used in the ED that will be used together with the slitted diaper
11420974|NCT01895452|Experimental|ALKS 9072, Low Dose|
11420975|NCT01895452|Experimental|ALKS 9072, High Dose|
11420976|NCT01895439|Experimental|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
11420977|NCT01895413|Experimental|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
11420978|NCT01895400|Active Comparator|Renexin|Renexin 1T bid for 12 weeks
11420979|NCT01895400|Placebo Comparator|Placebo|Placebo 1T bid for 12 weeks
11420980|NCT01895387|Experimental|Whole grains and legumes|
11420981|NCT01895387|Placebo Comparator|Refined rice|
11420982|NCT01895374|Experimental|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
11420983|NCT01895374|Active Comparator|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
11420984|NCT01895361|Experimental|High-dose SelG1 (Selg1 5.0 mg/kg)|IV Infusion, once every 4 weeks through Week 50
11420985|NCT01895361|Experimental|Low-dose SelG1 (Selg1 2.5 mg/kg)|IV Infusion, once every 4 weeks through Week 50
11420986|NCT01895361|Placebo Comparator|Placebo|IV Infusion, once every 4 weeks through Week 50
11420990|NCT01895335|Experimental|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
11420991|NCT01895322|Experimental|OPC-41061|
11420992|NCT01895309|Experimental|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
11420993|NCT01895309|Active Comparator|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
11420994|NCT01895296|Experimental|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
11420995|NCT01895296|Placebo Comparator|Placebo|saline s.c. t.i.d.
11420996|NCT01895283|Experimental|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
11420997|NCT01895270|Experimental|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
11420998|NCT01895270|Placebo Comparator|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
11420999|NCT01895257|Active Comparator|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
11421000|NCT01895257|Active Comparator|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
11421001|NCT01895244|Experimental|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
11421002|NCT01895244|Experimental|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
11421003|NCT01895231|Experimental|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
11421004|NCT01895231|Placebo Comparator|Placebo|0.9 % saline Infusion over 15 min
11421005|NCT01895218|Experimental|Iron isomaltoside 1000 (Monofer®)|
11421006|NCT01895218|Active Comparator|Standard medical Care|
11421007|NCT01895205|Experimental|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
11421008|NCT01895205|Active Comparator|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:
~Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC
~Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
11421009|NCT01895192|Other|Fertile men|Assessment of sperm morphology by high magnification with interference contrast microscopy.
11421010|NCT01895179|Experimental|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
11421011|NCT01895179|Placebo Comparator|Grazing|Participants will eat meals spread out over the course of the day.
11421012|NCT01895166|Experimental|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
11421013|NCT01895166|Active Comparator|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
11421014|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
11421015|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
11421016|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
11421017|NCT01895140|Experimental|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
11421018|NCT01895140|Other|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
11421019|NCT01895127|Active Comparator|Standard of Care|"Plasmapheresis (PP) x 3, at 40-60 cc/kg.
~Immunoglobulin (IVIg), to be administered after each PP"
11421020|NCT01895127|Experimental|Soliris (eculizumab)|"1200 mg first dose (Time: Screening/Week 0, after Biopsy Proven AMR)
~900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)
~1200 mg week 5
~Week 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
11421021|NCT01895101|Placebo Comparator|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
11421022|NCT01895101|No Intervention|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
~In this arm the subjects receives as in standard care no pericardial lavage."
11421023|NCT01895101|Experimental|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.
~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
11421024|NCT01895088|Experimental|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
11421025|NCT01895075|Experimental|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
11421026|NCT01895075|Placebo Comparator|Normal saline|Normal saline inhalation 2ml tid
11421027|NCT01895062|Experimental|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
11421028|NCT01895062|No Intervention|no intervention|Routine care is administered without the application of cNEP.
11421029|NCT01895049|Active Comparator|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
11421030|NCT01895049|Experimental|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
11421031|NCT01895036|Experimental|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
11421032|NCT01895023|Experimental|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
11421033|NCT01895023|Active Comparator|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
11421034|NCT01895023|Placebo Comparator|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
11421035|NCT01895010|Experimental|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
11421036|NCT01895010|Active Comparator|tropisetron|treated with tropisetron 6mg before TACE
11421037|NCT01894997|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.
~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
11421038|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
11421039|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
11421040|NCT01894971|Experimental|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
11421041|NCT01894958|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
11421042|NCT01894958|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
11421043|NCT01894945||Patients with suspected lymphoma.|
11421044|NCT01894932|Experimental|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
11421045|NCT01894932|Experimental|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
11421046|NCT01894932|Experimental|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
11421047|NCT01894932|Experimental|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
11421048|NCT01894932|No Intervention|normal|normal, no intervention.
11421049|NCT01894932|No Intervention|Drug treatment remission patient|Drug treatment remission patient
11421050|NCT01894919|Experimental|2H3H511_V|In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
11421051|NCT01894919|No Intervention|2H3H511_NV|In the parent study V72_28 (NCT01894919), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
11421052|NCT01894919|Experimental|3H5_11_V|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
11421053|NCT01894919|No Intervention|3H5_11_NV|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
11421054|NCT01894919|Experimental|68_11_V|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
11421055|NCT01894919|No Intervention|68_11_NV|In the parent study V72_28 (NCT01894919), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
11421056|NCT01894919|Experimental|02_2_5_V|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
11421057|NCT01894919|No Intervention|02_2_5_NV|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
11421058|NCT01894919|Experimental|02_6_10_V|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
11421059|NCT01894919|No Intervention|02_6_10_NV|In the parent study V72_28 (NCT01894919), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
11421060|NCT01894919|Experimental|NAIVE 123|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
11421061|NCT01894919|Experimental|NAIVE_4A|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
11421062|NCT01894919|Experimental|NAIVE_4B|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
11421063|NCT01894906|Placebo Comparator|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
11421064|NCT01894906|Experimental|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
11421065|NCT01894893||Breastfeeding mothers|
11421066|NCT01894880|Active Comparator|early SSC|Early SSC: bonding straight after birth
11421067|NCT01894880|Other|late SSC|late SSC: bonding after termination of operation
11421068|NCT01894867|Experimental|magnesium|will get magnesium for 6 weeks
11421069|NCT01894867|Placebo Comparator|placebo|will get placebo for 6 weeks
11421070|NCT01894854|No Intervention|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
11421071|NCT01894854|Active Comparator|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
11421072|NCT01894841|Experimental|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
11421073|NCT01894841|Other|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
11421074|NCT01894828|Active Comparator|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
11421075|NCT01894828|No Intervention|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
11421076|NCT01894815|Experimental|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
11421077|NCT01894815|Active Comparator|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
11421078|NCT01894815|Placebo Comparator|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.
~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
11421079|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
11421080|NCT01894789|Experimental|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
11421081|NCT01894789|Active Comparator|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
11421082|NCT01894776|Experimental|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin
~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily
~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
11421083|NCT01894763|Active Comparator|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
11421084|NCT01894763|Active Comparator|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
11421085|NCT01894750|Experimental|skill bulding Intevention|group-based skill building self-care program
11421086|NCT01894750|No Intervention|usual care|
11421087|NCT01894737|Placebo Comparator|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
11421088|NCT01894737|Experimental|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
11421089|NCT01894724|Experimental|NeuroSave Device|Targeted Hypothermia with NeuroSave Device
11421090|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
11421091|NCT01894685|Experimental|Mesalazine|Mesalazine, 3 grams once daily for six months
11421092|NCT01894685|Placebo Comparator|Placebo|Placebo, 3 grams, once daily for six months
11421093|NCT01894672|Experimental|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
11421094|NCT01894659|No Intervention|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
11421095|NCT01894659|Experimental|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
11421096|NCT01894659|Experimental|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
11421097|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
11421098|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
11421099|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
11421131|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.
~Intervention: HPV screening for women Intervention: HPV screening for men"
11421100|NCT01894633|Experimental|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
11421101|NCT01894633|Placebo Comparator|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
11421102|NCT01894620|Placebo Comparator|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
11421103|NCT01894620|Active Comparator|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
11421104|NCT01894607|Experimental|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.
~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.
~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
11421105|NCT01894594|Experimental|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
11421106|NCT01894581|Experimental|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
11421107|NCT01894581|Active Comparator|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
11421108|NCT01894568|Experimental|Insulin Peglispro|Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
11421109|NCT01894568|Active Comparator|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.
11421110|NCT01894555|Experimental|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
11421111|NCT01894542|Experimental|Cod protein from presscake|
11421112|NCT01894542|Experimental|Cod protein from presscake + stickwater|
11421113|NCT01894542|Placebo Comparator|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
11421114|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
11421115|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
11421116|NCT01894516|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
11421117|NCT01894516|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
11421118|NCT01894516|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
11421119|NCT01894516|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
11421120|NCT01894503|Experimental|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
11421121|NCT01894490||Jejunostomy|Patients who received a jejunostomy
11421122|NCT01894490||Nasojejunal catheter|Patients who received a nasojejunal catheter
11421123|NCT01894477|Experimental|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate
~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
11421124|NCT01894477|Experimental|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI
~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
11421125|NCT01894464|Experimental|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
11421126|NCT01894464|No Intervention|Control Group|
11421127|NCT01894451|Experimental|89Zr-bevacizumab-PET/CT Scan|"89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.
~The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.
~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
11421128|NCT01894438|No Intervention|Control Group|This arm will receive written general advice for a healthy lifestyle.
11421129|NCT01894438|Experimental|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
11421130|NCT01894438|Experimental|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
11421132|NCT01894412|Experimental|HD 203|prefilled syringe
11421134|NCT01894399|Experimental|Cohort 1|100 mg HM61713 single dose in Korean
11421135|NCT01894399|Experimental|Cohort 2|200 mg HM61713 single dose in Korean
11421136|NCT01894399|Experimental|Cohort 3|300 mg HM61713 single dose in Korean
11421137|NCT01894399|Experimental|Cohort 4|200 mg HM61713 single dose in Japanese
11421138|NCT01894399|Experimental|Cohort 5|300 mg HM61713 single dose in Japanese
11421139|NCT01894399|Experimental|Cohort 6|200 mg HM61713 single dose in Caucasian
11421140|NCT01894399|Experimental|Cohort 7|300 mg HM61713 single dose in Caucasian
11421141|NCT01894386|Experimental|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
11421142|NCT01894386|Experimental|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
11421143|NCT01894386|Experimental|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
11421144|NCT01894386|Experimental|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
11421145|NCT01894373|Experimental|CIK, psoriasis|
11421146|NCT01894360|Experimental|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
11421147|NCT01894360|Experimental|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
11421148|NCT01894347||Colistin inhalative|"Adult ICU patients with
~invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection
~indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital
~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
11421149|NCT01894334|No Intervention|Control group|no intervention
11421150|NCT01894334|Experimental|Tranexamic acid group|tranexamic acid ，intravenous 30mg/kg/d，Preoperative
11421151|NCT01894334|Experimental|Edaravone group|edaravone, iv, 1mg/kg/d,Preoperative
11421152|NCT01894334|Experimental|Ulinastatin group|Ulinastatin ,iv，20,000 U /kg/d，Preoperative
11421153|NCT01894308|Active Comparator|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
11421154|NCT01894308|Active Comparator|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
11421155|NCT01894295|Experimental|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
11421156|NCT01894295|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram
11421157|NCT01894282|Active Comparator|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
11421158|NCT01894282|Experimental|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
11421159|NCT01894269|Experimental|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
11421160|NCT01894269|No Intervention|Control|No anti-viral therapy after TACE.
11421161|NCT01894256|Other|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
11421162|NCT01894256|Other|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
11421163|NCT01894256|Other|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
11421164|NCT01894243|Other|Normal hepatic function|"Patients with:
~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
11421165|NCT01894243|Other|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
11421166|NCT01894243|Other|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
11421167|NCT01894230|Experimental|Genotype results plus usual care|SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.
11421168|NCT01894230|Active Comparator|Usual care only|SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
11421169|NCT01894217|Experimental|Genetic testing|Genetic testing and reporting for SLCO1B1*5 allele
11421170|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
11421171|NCT01894191|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
11421172|NCT01894191|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
11421470|NCT01892241|No Intervention|Control group|Those in group C didn't accept any antiviral regiment .
11421173|NCT01894191|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
11421174|NCT01894178|Active Comparator|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
11421175|NCT01894178|Active Comparator|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
11421176|NCT01894165|Experimental|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
11421177|NCT01894165|Placebo Comparator|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
11421178|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
11421179|NCT01894139|Experimental|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
11421180|NCT01894139|Active Comparator|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI ~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
11421181|NCT01894126|Experimental|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
11421182|NCT01894126|Experimental|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
11421183|NCT01894126|No Intervention|Control|
11421184|NCT01894113|Active Comparator|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
11421185|NCT01894113|Active Comparator|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
11421186|NCT01894100|Other|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
11421187|NCT01894100|Experimental|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
11421188|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
11421189|NCT01894087|No Intervention|Enhanced usual care - Cohort 1|
11421190|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
11421191|NCT01894087|No Intervention|Enhanced usual care - Cohort 2|
11421192|NCT01894074|Placebo Comparator|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
11421193|NCT01894074|Active Comparator|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
11421194|NCT01894061|Experimental|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
11421195|NCT01894048|Experimental|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
11421196|NCT01894035||Group 1|
11421197|NCT01894022|Experimental|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
11421198|NCT01894009|Active Comparator|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
11421199|NCT01894009|Sham Comparator|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
11421200|NCT01893996|Experimental|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
11421201|NCT01893996|Placebo Comparator|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
11421202|NCT01893983|Experimental|Motivational Coaching|Telephone based Motivational Coaching sessions
11421203|NCT01893983|No Intervention|Referral alone|This is the current standard of care
11421239|NCT01893736|Experimental|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
11421589|NCT01891331|Experimental|VT-1161 300mg QD|
11421204|NCT01893970|Experimental|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
11421205|NCT01893970|Active Comparator|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
11421206|NCT01893957|Experimental|Healthy|Healthy women undergoing high voltage electrical stimulation
11421207|NCT01893957|Experimental|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
11421208|NCT01893944|Experimental|Virtual Reality|- Participate in this group 20 women to be treated by means of games Xbox 360 ®, attributed to this, custom applications using virtual and augmented reality to be developed.
11421209|NCT01893944|Experimental|Vibration therapy|- participate in this group 20 women who will undergo 15 minutes of continuous vibration by vibration of the upper mantle, with a frequency of 40 Hz, 3 function and intensity tolerable, keeping the limb supported and raised to 120 °.
11421210|NCT01893944|Active Comparator|control group|- participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises, dissociation girdle, active and active-assisted exercises for groups flexors, extensors, abductors and adductors of the upper limbs, which will be three series 10 repetitions for each exercise.
11421211|NCT01893931|Placebo Comparator|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
11421212|NCT01893931|Active Comparator|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
11421213|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history > 20 pack/years
11421214|NCT01893905|Experimental|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
11421215|NCT01893905|Placebo Comparator|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
11421216|NCT01893892|Experimental|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
11421217|NCT01893892|Placebo Comparator|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
11421218|NCT01893879|Experimental|(RS)2-(3-benzoylphenyl)-propionic acid|"Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
~Laboratory biomarker analysis will be performed."
11421219|NCT01893879|Placebo Comparator|placebo for study drug|"Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
~Laboratory biomarker analysis will be performed."
11421220|NCT01893866|Experimental|A|
11421221|NCT01893866|Experimental|B|
11421222|NCT01893853|Other|Water|Electrolyte- and mineral-free water with exercise intervention
11421223|NCT01893853|Placebo Comparator|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
11421224|NCT01893853|Experimental|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
11421225|NCT01893840|Experimental|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
11421226|NCT01893827|Active Comparator|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
11421227|NCT01893827|Active Comparator|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
11421228|NCT01893814|Active Comparator|Probiotics|
11421229|NCT01893814|Placebo Comparator|Control|
11421230|NCT01893801|Experimental|nab-paclitaxel+Cisplatin+gemcitabine|This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.
11421231|NCT01893788|Active Comparator|Aliskiren|Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.
11421232|NCT01893788|Active Comparator|Eplerenone|Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers
11421233|NCT01893775|Experimental|1|Hu-Mik-Beta-1 every 3 weeks
11421234|NCT01893762|Experimental|16 rowers|Adult rowers, aged between 18 and 25, training >6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
11421235|NCT01893749|Experimental|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.
~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
11421236|NCT01893749|No Intervention|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.
~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
11421237|NCT01893736|No Intervention|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
11421238|NCT01893736|Experimental|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
11421590|NCT01891331|Experimental|VT-1161 600mg QD|
11421591|NCT01891331|Experimental|VT-1161 600mg BID|
11421240|NCT01893723|Experimental|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
11421241|NCT01893723|Other|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
11421242|NCT01893710||Control|'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
11421243|NCT01893710||chronic kidney disease|Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
11421244|NCT01893710||Peritoneal dialysis|Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
11421245|NCT01893710||Post PD and with functioning graft|Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
11421246|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
11421247|NCT01893684|Experimental|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
11421248|NCT01893684|Experimental|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams.
11421249|NCT01893684|Experimental|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
11421250|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
11421251|NCT01893658|Active Comparator|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone
~Standard clinical therapy with prednisone.
~Day 1-14: 60 mg/day 14 days (2 weeks)
~Day 15-28: 40 mg/day (2 weeks)
~Day 29-35: 30 mg/day (1 week)
~Day 36-42: 20 mg/day (1 week)
~Day 43-49: 10 mg/day (1 week)
~Day 50-56: 5 mg/day (1 week)
~Subjects will stop taking prednisone on day 57
~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
11421252|NCT01893658|Active Comparator|Prednisone|"Standard clinical therapy with prednisone.
~Day 1-14: 60 mg/day 14 days (2 weeks)
~Day 15-28: 40 mg/day (2 weeks)
~Day 29-35: 30 mg/day (1 week)
~Day 36-42: 20 mg/day (1 week)
~Day 43-49: 10 mg/day (1 week)
~Day 50-56: 5 mg/day (1 week)
~Subjects will stop taking prednisone on day 57
~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
11421253|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
11421254|NCT01893632|Experimental|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
11421255|NCT01893632|Placebo Comparator|Placebo|Capsules filled with riboflavin.
11421256|NCT01893606|Placebo Comparator|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
11421257|NCT01893606|Experimental|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
11421258|NCT01893593|Other|Control|Usual care
11421259|NCT01893593|Active Comparator|Intervention|Multifaceted intervention to improve clinical systems
11421260|NCT01893580|Experimental|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
11421261|NCT01893580|Experimental|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
11421262|NCT01893580|Experimental|3. Experimental|Exercise in a team initiated two weeks after surgery.
11421263|NCT01893580|Other|4. Usual care|Exercise in a team initiated six weeks after surgery.
11421264|NCT01893567|Experimental|Clobex spray|
11421265|NCT01893554|Experimental|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
11421266|NCT01893554|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
11421592|NCT01891331|Active Comparator|Fluconazole 150mg|
11421267|NCT01893554|Experimental|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
11421268|NCT01893554|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
11421269|NCT01893554|Experimental|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
11421270|NCT01893554|Placebo Comparator|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
11421271|NCT01893554|Experimental|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
11421272|NCT01893554|Placebo Comparator|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
11421273|NCT01893541|Active Comparator|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
11421274|NCT01893541|Active Comparator|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
11421275|NCT01893528|Experimental|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
11421276|NCT01893528|Experimental|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
11421277|NCT01893528|Experimental|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
11421278|NCT01893515|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
11421279|NCT01893515|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
11421280|NCT01893502|Active Comparator|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
11421281|NCT01893502|Active Comparator|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
11421282|NCT01893489|Active Comparator|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
11421283|NCT01893489|Sham Comparator|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
11421284|NCT01893476|No Intervention|control|In this arm, practitioners will provide usual care for COPD patients.
11421285|NCT01893476|Other|adherence to guideline|Implementation educational programme: guideline adherences. The results of this trial will be directly applicable to primary care settings. Should the interventions delivered at the level of the GP practice be found to be effective in improving patients' quality of life then the findings would have a wider application.
11421286|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
11421287|NCT01893450|Active Comparator|methimazole|methimazole 30 mg daily during one year
11421288|NCT01893450|Active Comparator|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
11421289|NCT01893450|Active Comparator|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
11421290|NCT01893437|Experimental|Single oral dose group|
11421291|NCT01893424|Active Comparator|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
11421292|NCT01893424|Experimental|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
11421293|NCT01893411|Experimental|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
11421294|NCT01893411|Experimental|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
11421295|NCT01893411|Experimental|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
11421296|NCT01893398|Experimental|rehabilitation (MST) program|The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
11421297|NCT01893398|No Intervention|Usual care program|Usual care PWA program
11421298|NCT01893385|Experimental|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
11421299|NCT01893385|Other|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
11421300|NCT01893372|Experimental|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
11421301|NCT01893372|Experimental|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
11421302|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
11421303|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
11421304|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
11421305|NCT01893346|Experimental|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
11421306|NCT01893333|Experimental|Nerve sparing radical hysterectomy group|"sparing hypogastric nerve
~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
11421307|NCT01893333|Active Comparator|Radical hysterectomy group|Conventional radical hysterectomy
11421308|NCT01893320|Experimental|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).
~Following the phase I portion, patients in phase II receive the following induction:
~Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.
~Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
11421309|NCT01893307|Experimental|Intensity-Modulated X-Ray Therapy (IMRT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
~Treating physician evaluate each patient for possible chemotherapy.
~Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
~Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy."
11421310|NCT01893307|Experimental|Intensity-Modulated Proton Beam Therapy (IMPT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
~Treating physician evaluate each patient for possible chemotherapy.
~Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
~Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy."
11421311|NCT01893294|Experimental|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
11421312|NCT01893281|Experimental|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
11421313|NCT01893268||Cohort|
11421314|NCT01893255||Cohort|
11421315|NCT01893242|Experimental|Aleglitazar Arm|
11421316|NCT01893242|Placebo Comparator|Placebo Arm|
11421317|NCT01893229|Experimental|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
11421318|NCT01893229|Experimental|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
11421319|NCT01893229|Experimental|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
11421320|NCT01893229|Experimental|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
11421321|NCT01893229|Experimental|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg-160mmg/d; duration: 6 weeks
11421322|NCT01893229|Experimental|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg-2000mg/d;serum Li level: 0.6mmol-1.2mmol/L; duration: 6 weeks
11421323|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
11421324|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
11421325|NCT01893203|Other|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
11421326|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
11421327|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
11421328|NCT01893177|Experimental|Elderly subjects aged over 60 years|
11421329|NCT01893177|Experimental|Adults from 18 to 60 years old inclusive|
11421330|NCT01893164|Experimental|moderate cubital tunnel syndrome|Sensory,Intermittent paresthesias; vibratory perception normal or decreasedMotor,Measurable weakness in pinch or grip strengthTests,Elbow flexion test or Tinel's sign is positive; finger crossing may be abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
11421331|NCT01893164|Experimental|severe cubital tunnel syndrome|Sensory,Persistent paresthesias; vibratory perception decreased; abnormal two-point discrimination(static >6 mm, moving >4 mm)Motor,Measurable weakness in pinch and grip plus muscle atrophyTests,Positive elbow flexion test or positive Tinel's sign may be present; finger crossing usually abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
11421332|NCT01893151|Experimental|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
11421333|NCT01893151|Placebo Comparator|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
11421334|NCT01893138|Experimental|Roll-in: AMDC for USR|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
11421335|NCT01893138|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
11421336|NCT01893138|Experimental|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
11421337|NCT01893138|Placebo Comparator|Roll in: Placebo|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
11421338|NCT01893125|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
11421339|NCT01893125|Placebo Comparator|Placebo|Placebo 1 cap tid 21 days
11421340|NCT01893112|Experimental|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
11421341|NCT01893112|Other|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
11421342|NCT01893099|Experimental|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
11421343|NCT01893099|Experimental|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
11421344|NCT01893099|Experimental|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
11421345|NCT01893099|Experimental|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
11421346|NCT01893086|Active Comparator|LH alone|LH, laparoscopic hysterectomy
11421347|NCT01893086|Experimental|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
11421348|NCT01893073|Active Comparator|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
11421349|NCT01893073|No Intervention|Waiting group|
11421350|NCT01893060|Experimental|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
11421351|NCT01893060|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
11421352|NCT01893060|Experimental|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
11421353|NCT01893060|Sham Comparator|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
11421354|NCT01893047|No Intervention|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
11421355|NCT01893047|Experimental|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
11421356|NCT01893047|Experimental|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
11421357|NCT01893034|Active Comparator|Conservative treatment|Physiotherapy and activity modification
11421358|NCT01893034|Active Comparator|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
11421359|NCT01893021||Postpartum Malawian women|
11421360|NCT01893008|Experimental|Usual care + Inspiratory Muscle Training (IMT)|
11421361|NCT01893008|No Intervention|Usual care (no IMT)|
11421362|NCT01892995|Experimental|Ketamine|active arm
11421363|NCT01892995|Sham Comparator|Diphenhydramine|sham arm
11421364|NCT01892995|Placebo Comparator|Saline|placebo
11421365|NCT01892982|Experimental|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
11421467|NCT01892254|Placebo Comparator|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
11421366|NCT01892982|No Intervention|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
11421367|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
11421368|NCT01892956||Healthy volunteers|
11421369|NCT01892956||Newly diagnosed T2DM|Newly diagnosed T2DM, who have not started yet medical treatment with glucose lowering medications
11421370|NCT01892943||Patients with LHON|
11421371|NCT01892930|Experimental|Treatment (SBRT, nephrectomy)|Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.
11421372|NCT01892904|Experimental|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
11421373|NCT01892904|Active Comparator|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
11421374|NCT01892891|Experimental|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
11421375|NCT01892891|Placebo Comparator|Placebo comparator|Placebo
11421376|NCT01892878|Other|Single Arm Study|All patients will receive treatment
11421377|NCT01892865|Active Comparator|Historical means method|Operative time will be predicted using historical service means. Schedule will be constructed using this time
11421378|NCT01892865|Experimental|Predictive Modeling System (PMS)|Operative time will be predicted using a regression model. Schedule will be constructed using this time
11421379|NCT01892852|Experimental|Acupuncture|Acupuncture treatment
11421380|NCT01892852|No Intervention|Control|No other active treatment or sham acupuncture for this symptoms
11421381|NCT01892839|Experimental|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
11421382|NCT01892839|Active Comparator|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
11421383|NCT01892826|Experimental|hCG group|
11421384|NCT01892826|No Intervention|LH pic|
11421385|NCT01892813|Experimental|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
11421386|NCT01892813|Active Comparator|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
11421387|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
11421388|NCT01892787|Experimental|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
11421389|NCT01892787|Active Comparator|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
11421390|NCT01892761||TCL/MMF Group|
11421391|NCT01892761||CyA/MMF Group|
11421392|NCT01892748|Active Comparator|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
11421393|NCT01892748|Placebo Comparator|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
11421394|NCT01892722|Experimental|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
11421395|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
11421396|NCT01892722|Experimental|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2)
11421397|NCT01892709|Experimental|Hydromorphone|"All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, Do you want more pain medicine? This question will be asked 30 minutes after they answered no or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers yes. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period."
11421398|NCT01892696|Other|mechanically ventilated patients|"patients admitted to a 18-bed medical surgical intensive care unit of the military hospital of Tunisia and were mechanically ventilated fully adapted to their ventilator and in sinus rhythm.
~intervention:varying inspiratory flow waveforms"
11421399|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
11421400|NCT01892670|Experimental|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.
~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
11421401|NCT01892670|Experimental|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.
~Device: Terumo IMUFLEX WB-SP collection bag system"
11421402|NCT01892670|Experimental|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.
~Device: Terumo IMUFLEX WB-SP collection bag system"
11421403|NCT01892670|Experimental|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.
~Device: Terumo IMUFLEX WB-SP collection bag system"
11421404|NCT01892670|Experimental|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).
~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
11421468|NCT01892241|Experimental|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
11421405|NCT01892670|Experimental|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).
~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
11421406|NCT01892657|Experimental|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
11421407|NCT01892644|Active Comparator|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
11421408|NCT01892644|Active Comparator|Venesection HC|10 patients with hemochromatosis treated with venesection
11421409|NCT01892644|Active Comparator|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
11421410|NCT01892644|No Intervention|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
11421411|NCT01892631|Other|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
11421412|NCT01892631|Experimental|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
11421413|NCT01892618|Active Comparator|Pneumovax|Pneumovax, 1x 0.5 ml injection
11421414|NCT01892618|Experimental|Prevenar 13|Prevenar 13, 1x 0.5 ml injection
11421415|NCT01892605|Experimental|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
11421416|NCT01892592|No Intervention|Usual Care|No Interventions
11421417|NCT01892592|No Intervention|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
11421418|NCT01892592|Experimental|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
11421419|NCT01892579|Experimental|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
11421420|NCT01892579|Active Comparator|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
11421421|NCT01892566|No Intervention|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
11421422|NCT01892566|Experimental|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
11421423|NCT01892553|Experimental|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
11421424|NCT01892553|Experimental|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
11421425|NCT01892540|Experimental|Cohort 1: Standard positioning device|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
11421426|NCT01892540|Experimental|Cohort 2: New positioning device|
11421427|NCT01892540|Experimental|Cohort 3: Current positioning device until new is available|
11421428|NCT01892527|Experimental|Tivantinib plus Cetuximab|Single arm
11421429|NCT01892514|Experimental|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
11421430|NCT01892514|Experimental|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
11421431|NCT01892501|Other|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
11421432|NCT01892488|Placebo Comparator|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
11421433|NCT01892488|Experimental|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
11421434|NCT01892475|Experimental|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
11421469|NCT01892241|Active Comparator|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
11421435|NCT01892475|Experimental|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
11421436|NCT01892449|Experimental|prolonged I:E ratio (1:1) group|
11421437|NCT01892449|Active Comparator|conventional I:E ratio (1:2) group|
11421438|NCT01892436|Experimental|Secukinumab 75mg|Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
11421439|NCT01892436|Experimental|Secukinumab 150mg|Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
11421440|NCT01892436|Experimental|Placebo - AIN457A 75mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
11421441|NCT01892436|Experimental|Placebo - AIN457 150mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
11421442|NCT01892423|Experimental|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
11421443|NCT01892410|Experimental|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
11421444|NCT01892397|Experimental|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
11421445|NCT01892384|Experimental|BI 409306 dose 1|low dose, once daily
11421446|NCT01892384|Experimental|BI 409306 dose 2|medium dose, once daily
11421447|NCT01892384|Experimental|BI 409306 dose 3|high dose, once daily
11421448|NCT01892384|Placebo Comparator|Placebo|placebo, once daily
11421449|NCT01892371|Experimental|Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11421450|NCT01892371|Experimental|Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11421451|NCT01892358|Active Comparator|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
11421452|NCT01892358|Placebo Comparator|Assessment-Only|Participants in this arm will receive treatment-as-usual
11421453|NCT01892345|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction Period: Participants received eculizumab (900 milligrams [mg]) via intravenous (IV) infusion once a week (every 7 ± 2 days) for 4 weeks followed by eculizumab 1200 mg for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received eculizumab (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
11421454|NCT01892345|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (900 mg) via IV infusion once a week (every 7 ± 2 days) for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received matching placebo (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
11421455|NCT01892332|Other|lidocaine with fentanyl 75ug|
11421456|NCT01892319||All patients|
11421457|NCT01892306|Experimental|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
11421458|NCT01892306|Active Comparator|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
11421459|NCT01892293|Experimental|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
11421460|NCT01892280|Experimental|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
11421461|NCT01892280|Experimental|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
11421462|NCT01892280|Experimental|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
11421463|NCT01892280|No Intervention|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
11421464|NCT01892267|Experimental|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
11421465|NCT01892267|Active Comparator|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
11421466|NCT01892254|Experimental|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
11421471|NCT01892228|Experimental|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
11421472|NCT01892215|Experimental|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
11421473|NCT01892215|Experimental|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
11421474|NCT01892189|Experimental|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
11421475|NCT01892189|Experimental|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
11421476|NCT01892189|Experimental|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
11421477|NCT01892189|Experimental|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
11421478|NCT01892189|Experimental|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period"
11421479|NCT01892189|Experimental|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
11421480|NCT01892189|Experimental|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:
~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period"
11421481|NCT01892189|Experimental|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.
~Period 1 & 2 are followed by 7 day washout period."
11421482|NCT01892189|Experimental|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period
11421483|NCT01892176|Experimental|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
11421484|NCT01892163|Active Comparator|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
11421485|NCT01892163|Experimental|Ozurdex fixed dosing|
11421486|NCT01892150|Experimental|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
11421487|NCT01892137|Other|Open label active|
11421846|NCT01889862|Active Comparator|BMN165 20mg/day|BMN165 20mg/day self-administered daily
11421488|NCT01892124|Experimental|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
11421489|NCT01892124|Experimental|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
11421490|NCT01892111|Experimental|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
11421491|NCT01892111|No Intervention|no intervention|IVF/ICSI procedure.
11421492|NCT01892098|Active Comparator|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
11421493|NCT01892098|Placebo Comparator|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
11421494|NCT01892085|Experimental|Early initiation|Initiation of breast milk expression <1 hour following delivery.
11421495|NCT01892085|Experimental|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
11421496|NCT01892085|Other|Late initiation|Initiation of milk expression >3-6 hours following delivery.
11421497|NCT01892072||HCC patients|Hepatocellular carcinoma patients treated by surgical treatment
11421498|NCT01892059|Experimental|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
11421499|NCT01892059|Active Comparator|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
11421500|NCT01892046|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
11421501|NCT01892033|Experimental|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
11421502|NCT01892020|Experimental|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
11421503|NCT01892020|Experimental|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
11421504|NCT01892007|Experimental|Cogmed RM (adaptive)|Online training intervention: An adaptive version of Cogmed RM working memory training. Task difficulty (number of to-be-remembered items) increases based on individual performance, in order to maintain average daily performance levels of approximately 60% of trials correct. Participants complete 35-45 minutes of active training per day, 5 days a week for 5 weeks.
11421505|NCT01892007|Placebo Comparator|Cogmed RM (non-adaptive, placebo)|Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
11421506|NCT01891994|Experimental|Eltrombopag|Administration of eltrombopag at a dose of 150mg/day for 6 months
11421507|NCT01891981|Experimental|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.
~Phase II Starting Dose: Maximum tolerated dose from Phase I."
11421508|NCT01891968|Experimental|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
11421509|NCT01891955|Active Comparator|Diet A|Healthy diet with grains and dairy
11421510|NCT01891955|Active Comparator|Diet B|Healthy diet without grains and dairy
11421511|NCT01891942|Experimental|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
11421512|NCT01891942|Experimental|normal subjects|Fifteen healthy men with normal lung function
11421513|NCT01891929|Experimental|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
11421514|NCT01891929|Active Comparator|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
11421515|NCT01891916|No Intervention|extensively hydrolysed casein formula|extensively hydrolysed casein formula
11421516|NCT01891916|Active Comparator|Extensively hydrolyzed casein formula + LGG|Extensively hydrolized formula plus LGG
11421517|NCT01891890|Active Comparator|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
11421518|NCT01891890|Active Comparator|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
11421519|NCT01891890|Active Comparator|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
11421520|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
11421521|NCT01891864|Experimental|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
11421735|NCT01890369|Experimental|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
11421522|NCT01891864|Active Comparator|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
11421523|NCT01891851|Experimental|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
11421524|NCT01891838|Active Comparator|Volume controlled ventilation|Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
11421525|NCT01891838|Experimental|Pressure-controlled ventilation|initial pressure of 15 cm H2O, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Pressure is modified to maintain a tidal volume of 7 mL/kg of ideal body weight and frequency ventilation is modified to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg
11421526|NCT01891825|Active Comparator|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
11421527|NCT01891825|Active Comparator|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
11421528|NCT01891812|Experimental|Nitrous oxide 50%|Nitrous oxide 50% administered for 15 minutes.
11421529|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
11421530|NCT01891786|No Intervention|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
11421531|NCT01891786|Active Comparator|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
11421532|NCT01891786|Active Comparator|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
11421533|NCT01891773|Experimental|School-based therapy|Daily dose of medication to be provided in the school setting.
11421534|NCT01891773|No Intervention|Usual Care|Daily medication to be taken at home.
11421535|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
11421536|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
11421537|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
11421538|NCT01891734|Experimental|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
11421539|NCT01891734|Active Comparator|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
11421540|NCT01891721|Experimental|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
11421541|NCT01891721|Experimental|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
11421542|NCT01891721|Active Comparator|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
11421543|NCT01891695|Experimental|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
11421544|NCT01891682||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
11421545|NCT01891669|Experimental|Part 1|
11421546|NCT01891656|Experimental|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
11421547|NCT01891656|No Intervention|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
11421548|NCT01891656|Experimental|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
11421549|NCT01891643|Experimental|Arm 1: Lenalidomide + Dexamethasone|"Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug
~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
11421593|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
11421550|NCT01891643|Experimental|Arm 2: Lenalidomide + Dexamethasone + Elotuzumab|"Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)
~Dexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15(cycles 3-18); Day 1 (cycle 19 & beyond)]
~Dexamethasone 40 mg tablets by mouth once daily [Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 & beyond)]
~Dexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18); Day 1 (cycle 19 & beyond)]
~Elotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18)]
~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 & beyond)
~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
11421551|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
11421552|NCT01891617|Experimental|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
11421553|NCT01891617|Experimental|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
11421554|NCT01891617|Experimental|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
11421555|NCT01891617|Experimental|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
11421556|NCT01891591||obese female subjects|16 obese female subjects with BMI > 40 kg/m2 on a waiting list for bariatric surgery
11421557|NCT01891565|Experimental|Activity Feedback|Feedback
11421558|NCT01891565|No Intervention|No Feedback|
11421559|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
11421560|NCT01891552||DEBIRI|only DEBIRI treatment
11421561|NCT01891539||doxorubicin|"Day +1:
~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.
~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
11421562|NCT01891526||Hepatic patients|patients with hepatic insufficiency
11421563|NCT01891526||Healthy Controls|Healthy adults
11421564|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
11421565|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
11421566|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
11421567|NCT01891500|Experimental|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
11421568|NCT01891500|Placebo Comparator|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
11421569|NCT01891500|Active Comparator|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
11421570|NCT01891487|Active Comparator|Track A|Those on active study medication
11421571|NCT01891487|Placebo Comparator|Track B|Those on placebo.
11421572|NCT01891474|Experimental|U-health care|voice inception technique based U-healthcare service
11421573|NCT01891474|No Intervention|control|conventional treatment
11421574|NCT01891461|Experimental|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
11421575|NCT01891461|No Intervention|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
11421576|NCT01891448|Experimental|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
11421577|NCT01891448|Other|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
11421578|NCT01891435|Active Comparator|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
11421579|NCT01891435|Active Comparator|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
11421580|NCT01891435|Active Comparator|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
11421581|NCT01891409|Other|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
11421582|NCT01891396|Placebo Comparator|Saline|Single injection of 0.9% saline supplied as a 4 mL unit dose in a 5mL glass syringe
11421583|NCT01891396|Experimental|Hyaluronic Acid and TH|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 mL unit dose in a 5 mL glass syringe
11421584|NCT01891396|Active Comparator|Hyaluronic Acid|Single injection of sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe
11421585|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
11421586|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
11421587|NCT01891357|Experimental|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
11421588|NCT01891344|Experimental|Ovarian cancer|rucaparib
11421601|NCT01891279|Experimental|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
11421602|NCT01891279|Experimental|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
11421603|NCT01891266|Experimental|Non-tourniquet assisted TKA|
11421604|NCT01891266|Other|Tourniquet assisted TKA|
11421605|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
11421606|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
11421607|NCT01891227|Experimental|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
11421608|NCT01891214||Ulcerative Colitis and Crohn's Disease|
11421609|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
11421610|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
11421611|NCT01891175|Experimental|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
11421612|NCT01891175|Active Comparator|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
11421613|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
11421614|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
11421615|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
11421616|NCT01891136|Experimental|Peanut protein|Subjects to receive varying amounts of peanut protein as peanut oral immunotherapy.
11421617|NCT01891123|Placebo Comparator|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
11421618|NCT01891123|Active Comparator|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
11421619|NCT01891110|Experimental|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
11421620|NCT01891110|Experimental|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
11421621|NCT01891110|Experimental|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
11421622|NCT01891097|Active Comparator|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
11421623|NCT01891097|Experimental|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
11421624|NCT01891097|No Intervention|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
11421625|NCT01891084|Active Comparator|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.
~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
11421626|NCT01891084|Placebo Comparator|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.
~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
11421627|NCT01891071|Experimental|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
11421628|NCT01891071|No Intervention|Standard care|Standard care
11421666|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
11421629|NCT01891058|Active Comparator|drug-shock vs shock only|For ED patients with RAFF, Investigators will compare conversion to normal sinus rhythm between the two strategies of i) attempted pharmacological cardioversion with intravenous procainamide followed by DC cardioversion if necessary (Drug-Shock), and ii) DC cardioversion alone (Shock Only).
11421630|NCT01891058|No Intervention|pad positions|For ED RAFF patients undergoing DC cardioversion, Investigators will compare conversion to normal sinus rhythm between the i) antero-posterior and ii) antero-lateral pad positions.
11421631|NCT01891045|No Intervention|Control|Patients merely monitored on background variables to function as a baseline of comparison
11421632|NCT01891045|Active Comparator|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
11421633|NCT01891045|Experimental|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
11421634|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
11421635|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
11421636|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
11421637|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
11421638|NCT01891006|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
11421639|NCT01891006|Other|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
11421640|NCT01890993||Liraglutide|
11421641|NCT01890993||DPP-4|
11421642|NCT01890967|Experimental|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
11421643|NCT01890967|Experimental|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
11421644|NCT01890967|Experimental|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
11421645|NCT01890967|Experimental|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
11421646|NCT01890967|Experimental|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
11421647|NCT01890967|Placebo Comparator|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.
~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
11421648|NCT01890954|Active Comparator|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
11421649|NCT01890954|No Intervention|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admisssion
11421650|NCT01890941|Experimental|KCT-0809 Lower Dose|
11421651|NCT01890941|Experimental|KCT-0809 Higher Dose|
11421652|NCT01890941|Placebo Comparator|Placebo|
11421653|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
11421654|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
11421655|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
11421656|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
11421657|NCT01890902|Experimental|Impracor (Ketoprofen 10% Cream)|Topical Cream over a period of 14 days
11421658|NCT01890902|Placebo Comparator|Placebo Cream:|Topical Cream over a period of 14 days
11421659|NCT01890889|Active Comparator|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
11421660|NCT01890889|Active Comparator|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
11421661|NCT01890889|Placebo Comparator|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
11421662|NCT01890876|Active Comparator|Low altitude|Walking uphill Walking downhill
11421663|NCT01890876|Active Comparator|High altitude|Walking uphill Walking downhill
11421664|NCT01890863|Experimental|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
11421665|NCT01890863|Experimental|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
11421667|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
11421668|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
11421669|NCT01890837|Placebo Comparator|Placebo|Placebo TID
11421670|NCT01890824||Breast Cancer Patients|Breast cancer patients to be studied before and after chemotherapy
11421671|NCT01890824||Healthy Female Controls|Healthy female controls will be compared to breast cancer patients before and after chemotherapy and to healthy male controls
11421672|NCT01890824||Healthy Male Controls|Healthy male controls will be compared to healthy female controls to determine gender differences
11421673|NCT01890811|Experimental|Boost High Protein|Boost high protein with added spirulina
11421674|NCT01890798|Experimental|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
11421675|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
11421676|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
11421677|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
11421678|NCT01890772|Active Comparator|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
11421679|NCT01890772|Active Comparator|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
11421680|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
11421681|NCT01890746|Experimental|Eltrombopag arm|Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
11421682|NCT01890746|Placebo Comparator|Placebo arm|Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
11421683|NCT01890733|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
11421684|NCT01890733|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
11421685|NCT01890720|Experimental|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
11421686|NCT01890720|Active Comparator|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
11421687|NCT01890707|Active Comparator|Deep Sedation|Deep sedation
11421688|NCT01890707|Other|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
11421689|NCT01890694|Placebo Comparator|Placebo|"Subjects will receive placebo once daily.
~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
11421690|NCT01890694|Experimental|Tolvaptan|"Subjects will receive Tolvaptan once daily.
~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
11421847|NCT01889862|Placebo Comparator|20 mg/day Placebo|20 mg/day Placebo self-administered daily
11421691|NCT01890681|Active Comparator|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:
~center and family self-assessment,
~center intervention materials delivered several times over the 6-month period, and;
~parent handouts
~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
11421692|NCT01890681|Experimental|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:
~center and family self-assessment;
~targeted technical assistance by Baby NAP SACC consultant for providers and parents;
~training workshops for child care providers; and
~parent outreach and support."
11421693|NCT01890668|Experimental|Osteopathic Manipulative Treatment|Randomization and first OMT will take place at discharge (Day 3); second osteopathic therapy will be performed by the same osteopath practitioner at Day10.
11421694|NCT01890668|Placebo Comparator|Control group|Control group consists in classical medical and paramedical breastfeeding support. OMT on the newborn will be realized by osteopath dissimulated behind a screen. Placebo OMT consists to mimic, without the knowledge of parents, osteopathic techniques on a dolly.
11421695|NCT01890655|Experimental|MT-1303-Low|MT-1303-Low Dose
11421696|NCT01890655|Experimental|MT-1303-Middle|MT-1303-Middle Dose
11421697|NCT01890655|Experimental|MT-1303-High|MT-1303-High Dose
11421698|NCT01890642|Sham Comparator|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if > age 1 yr or sucrose if < 1 yr
11421699|NCT01890642|Other|Pain Ease|This group will receive Pain Ease Spray only if > 1 yr or sucrose only if child < 1 yr
11421700|NCT01890642|Experimental|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if > 1 yr and will receive sucrose is < 1 yr
11421701|NCT01890629|Experimental|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
11421702|NCT01890629|Active Comparator|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
11421703|NCT01890629|Active Comparator|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
11421704|NCT01890616||Motility|This arm will ingest the SmartPill.
11421705|NCT01890603|Experimental|Care Coordination Arm|
11421706|NCT01890603|Active Comparator|Quality Measure Improvement|
11421707|NCT01890590|Experimental|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
11421708|NCT01890577||Study population|Single cohort of dialysis patients
11421709|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
11421710|NCT01890551|Other|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
11421711|NCT01890551|Other|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
11421712|NCT01890538|Active Comparator|Piracetam|2 g intravenous piracetam
11421713|NCT01890538|Active Comparator|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
11421714|NCT01890525||PROMISE study patients|
11421715|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
11421716|NCT01890499|Experimental|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.
~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
11421717|NCT01890499|Active Comparator|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
11421718|NCT01890473|Experimental|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
11421719|NCT01890473|Experimental|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
11421720|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
11421721|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
11421722|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
11421723|NCT01890434|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
11421724|NCT01890421|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
11421725|NCT01890408|Experimental|ropivacaine|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
11421726|NCT01890408|Placebo Comparator|placebo|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
11421727|NCT01890395|Other|blood collection|procedure: Blood draws as the intervention
11421728|NCT01890382|Placebo Comparator|Control|alanine as placebo to leucine (same dosage); corn starch as placebo to protein and/or creatine (same dosage)
11421729|NCT01890382|Experimental|whey protein|
11421730|NCT01890382|Experimental|soy protein|
11421731|NCT01890382|Experimental|leucine supplementation|
11421732|NCT01890382|Experimental|whey plus creatine|
11421733|NCT01890382|Experimental|creatine|
11421734|NCT01890369|Experimental|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
11421736|NCT01890369|Experimental|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
11421737|NCT01890369|Experimental|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
11421738|NCT01890356|Experimental|Transcranial electrical stimulation|
11421739|NCT01890343|Experimental|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
11421740|NCT01890343|Experimental|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
11421741|NCT01890343|Experimental|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
11421742|NCT01890330|Experimental|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
11421743|NCT01890330|Active Comparator|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
11421744|NCT01890317|Experimental|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
11421745|NCT01890317|No Intervention|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
11421746|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
11421747|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
11421748|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
11421749|NCT01890278|Active Comparator|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
11421750|NCT01890278|Active Comparator|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
11421751|NCT01890265|Experimental|Pamrevlumab|Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.
11421752|NCT01890265|Placebo Comparator|Placebo|Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.
11421753|NCT01890265|Active Comparator|Sub-Study: Pamrevlumab+Pirfenidone or Nintedanib|"Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.
~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
11421754|NCT01890265|Placebo Comparator|Sub-Study: Placebo+Pirfenidone or Nintedanib|"Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.
~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
11421755|NCT01890252|Experimental|Hyper CL|Hyper osmotic contact lens
11421756|NCT01890252|Experimental|Hyper CL + Saline solution|combined treatment of hyper osmotic contact lens+ hypertonic solution
11421757|NCT01890252|Active Comparator|saline solution|hypertonic solution
11421758|NCT01890239|Experimental|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
11421759|NCT01890239|No Intervention|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
11421760|NCT01890226|No Intervention|Control|
11421761|NCT01890226|Experimental|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
11421762|NCT01890213|Experimental|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
11421763|NCT01890200|Experimental|TCM-700C (low dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
11421764|NCT01890200|Experimental|TCM-700C (high dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
11421765|NCT01890200|Placebo Comparator|Placebo|placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
11421766|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
11421767|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
11421768|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
11421769|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
11421770|NCT01890148|Experimental|1|oral BD administration of 45 mg AZD5069
11421771|NCT01890135|Active Comparator|endothelin receptor antogonist|10 mg of zibotentan
11421772|NCT01890135|Placebo Comparator|placebo|matched placebo
11421845|NCT01889875|Active Comparator|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
11421773|NCT01890122|Active Comparator|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
11421774|NCT01890122|Active Comparator|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
11421775|NCT01890122|Experimental|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
11421776|NCT01890122|Placebo Comparator|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
11421777|NCT01890109|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
11421778|NCT01890109|Experimental|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
11421779|NCT01890096|Experimental|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
11421780|NCT01890096|Experimental|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
11421781|NCT01890083|Active Comparator|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
11421782|NCT01890083|Experimental|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
11421783|NCT01890070|Placebo Comparator|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fiber)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421784|NCT01890070|Experimental|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
~Three weeks of washout to avoid additive effects on treatments to follow."
11421785|NCT01890070|Experimental|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.
~Three weeks of washout to avoid additive effects on treatments to follow."
11421786|NCT01890070|Experimental|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.
~Three weeks of washout to avoid additive effects on treatments to follow."
11421787|NCT01890070|Experimental|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421788|NCT01890070|Experimental|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
11421789|NCT01890070|Experimental|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :
~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100g of Italian organic Olive Oil
~Three weeks of washout to avoid additive effects on treatments to follow."
11421790|NCT01890070|Placebo Comparator|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421791|NCT01890070|Experimental|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.
~Three weeks of washout to avoid additive effects on treatments to follow."
11421792|NCT01890070|Experimental|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine
~Three weeks of washout to avoid additive effects on treatments to follow."
11421793|NCT01890070|Experimental|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.
~Three weeks of washout to avoid additive effects on treatments to follow."
11421794|NCT01890070|Experimental|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421795|NCT01890070|Experimental|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
11421796|NCT01890070|Experimental|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil
~Three weeks of washout to avoid additive effects on treatment following."
11421797|NCT01890070|Placebo Comparator|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421798|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
~Three weeks of washout to avoid additive effects on treatments to follow."
11421799|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine
~Three weeks of washout to avoid additive effects on treatments to follow."
11421800|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts
~Three weeks of washout to avoid additive effects on treatments to follow."
11421801|NCT01890070|Experimental|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421802|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
11421803|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil
~Three weeks of washout to avoid additive effects on treatments to follow."
11421804|NCT01890070|Placebo Comparator|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421805|NCT01890070|Experimental|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
11421806|NCT01890070|Experimental|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine
~Three weeks of washout to avoid additive effects on treatments to follow."
11421807|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts
~Three weeks of washout to avoid additive effects on treatments to follow."
11421808|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
~Three weeks of washout to avoid additive effects on treatments to follow."
11421809|NCT01890070|Experimental|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green
~Three weeks of washout to avoid additive effects on treatments to follow."
11421810|NCT01890070|Experimental|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:
~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil
~This is followed by a 3 week wash out period, to neutralize any additive effects."
11421811|NCT01890057|Experimental|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
11421812|NCT01890057|Experimental|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
11421813|NCT01890044||Moderate to highest risk for VTE|Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
11421814|NCT01890031|No Intervention|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
11421815|NCT01890031|Other|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
11421816|NCT01890031|Other|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
11421817|NCT01890031|Other|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
11421818|NCT01890031|Other|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
11421819|NCT01890018|Active Comparator|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:
~Arm 1. Control group no modifications
~Electronic Pill Bottle tracking"
11421820|NCT01890018|Experimental|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:
~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps
~Electronic Pill Bottle tracking; Adherence Messaging"
11421821|NCT01890018|Experimental|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:
~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient
~Electronic Pill Bottle tracking; Social Influence"
11421822|NCT01890018|Experimental|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:
~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps
~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
11421823|NCT01890005|Experimental|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
11421824|NCT01890005|Placebo Comparator|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
11421825|NCT01889992|Active Comparator|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
11421826|NCT01889992|Experimental|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
~Sirolimus dosage is based on blood levels."
11421827|NCT01889992|Active Comparator|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
11421828|NCT01889992|Active Comparator|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.
~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
11421829|NCT01889992|Active Comparator|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
11421830|NCT01889992|Experimental|MTor Immunosuppression|"Sirolimus
~Sirolimus dosage is based on blood levels.
~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
11421831|NCT01889992|Experimental|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
11421832|NCT01889979|Experimental|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
11421833|NCT01889979|Placebo Comparator|Placebo|2 mL of a sterile solution SC
11421834|NCT01889966|Experimental|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
11421835|NCT01889953|Other|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
11421836|NCT01889940|No Intervention|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.
~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.
~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
11421837|NCT01889940|Other|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
11421838|NCT01889927|No Intervention|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
11421839|NCT01889927|Active Comparator|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
11421840|NCT01889914|Experimental|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.
~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
11421841|NCT01889914|Experimental|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).
~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
11421842|NCT01889888|Experimental|ADRC injection|
11421843|NCT01889875|No Intervention|Control group|
11421844|NCT01889875|Active Comparator|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
11421848|NCT01889862|Active Comparator|BMN165 40mg/day|BMN165 40mg/day self-administered daily
11421849|NCT01889862|Placebo Comparator|40 mg/day Placebo|40 mg/day Placebo self-administered daily
11421850|NCT01889849|Experimental|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
11421851|NCT01889849|Active Comparator|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
11421852|NCT01889836|Experimental|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
11421853|NCT01889836|Active Comparator|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
11421854|NCT01889823|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
11421855|NCT01889823|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
11421856|NCT01889810|Active Comparator|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
11421857|NCT01889810|Placebo Comparator|Placebo|Placebo group
11421858|NCT01889797|Active Comparator|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
11421859|NCT01889797|Experimental|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
11421860|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
11421861|NCT01889784|Other|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
11421862|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
11421863|NCT01889784|Other|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
11421864|NCT01889771|Experimental|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
11421865|NCT01889771|Experimental|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
11421866|NCT01889758|Active Comparator|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
11421867|NCT01889758|Active Comparator|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
11421868|NCT01889758|Active Comparator|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
11421869|NCT01889732||ROTEM|
11421870|NCT01889719|Experimental|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
11421871|NCT01889719|Active Comparator|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
11421872|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
11421873|NCT01889693||chronic stable angina|patients with chronic stable angina
11421874|NCT01889693||control|control subjects without coronary artery disease
11421875|NCT01889680|Active Comparator|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
11421876|NCT01889680|Experimental|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
11421877|NCT01889667|Experimental|ORMD-0801 Dose # 1|Oral Insulin Formulation
11421878|NCT01889667|Experimental|ORMD-0801 Dose # 2|Oral Insulin Formulation
11421879|NCT01889667|Placebo Comparator|Placebo|Oil Capsules
11421880|NCT01889654||patient|
11421881|NCT01889654||healthy volunteers|
11421882|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
11421883|NCT01889641||healthy volunteers|Subjects controls
11421884|NCT01889628|Other|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
11421885|NCT01889628|Other|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
11421886|NCT01889628|Other|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
11421887|NCT01889615||Suspected ovarian cancer|dual time PET/CT
11421888|NCT01889602|Experimental|Topiramate 100mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
11421889|NCT01889602|Experimental|Topiramate 150mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 150mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
11421890|NCT01889602|Experimental|Topiramate 200mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 200mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
11421891|NCT01889589||NYC adults|
11421892|NCT01889576|Experimental|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of >= 1,9 mg/dL).
11421893|NCT01889576|No Intervention|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
11421894|NCT01889563|Experimental|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
11421895|NCT01889563|No Intervention|No Physical Exercise Training Program|No Physical Exercise Training Program
11421896|NCT01889550|Active Comparator|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
11421897|NCT01889550|Placebo Comparator|Access to the website www.ouh.dk|Access to the usual information from the hospital website
11421898|NCT01889537|Experimental|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
11421899|NCT01889537|Experimental|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
11421900|NCT01889524|Active Comparator|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
11421901|NCT01889524|Experimental|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
11421902|NCT01889511|Experimental|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
11421903|NCT01889511|No Intervention|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
11421904|NCT01889498|No Intervention|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
11421905|NCT01889498|Active Comparator|Acetazolamide|Treatment arm
11421906|NCT01889472|Active Comparator|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
11421907|NCT01889472|Experimental|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
11421908|NCT01889459||PCI for CTO|
11421909|NCT01889446|Placebo Comparator|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
11421910|NCT01889446|Placebo Comparator|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
11421911|NCT01889433|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
11421912|NCT01889433|Active Comparator|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight ≥75 kg)
11421913|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
11421914|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
11421915|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
11421916|NCT01889394|Active Comparator|limberg flap|primary wound closure using a limberg flap
11421917|NCT01889394|Active Comparator|secondary wound healing|secondary wound healing
11421918|NCT01889381|Experimental|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
11421919|NCT01889368|Active Comparator|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
11421920|NCT01889368|Placebo Comparator|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
11421921|NCT01889355|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
11421922|NCT01889342|Experimental|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
11421923|NCT01889342|Active Comparator|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark & Wells, 1995) and PTSD (Foa, 2007).
11421924|NCT01889329|Experimental|RUTF-1|Made from local food ingredients
11421925|NCT01889329|Experimental|RUTF-2|Made from local food ingredients
11421926|NCT01889329|Active Comparator|Plumpynut|Made from peanut
11421927|NCT01889316|Other|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).
~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
11421928|NCT01889303|Active Comparator|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.
~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
11421929|NCT01889303|Experimental|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles
~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
11421930|NCT01889290|Experimental|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
11421931|NCT01889277|Experimental|MT-3995-Low|MT-3995-Low Dose
11421932|NCT01889277|Experimental|MT-3995-High|MT-3995-High Dose
11421933|NCT01889277|Placebo Comparator|Placebo|Placebo
11421934|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
11421935|NCT01889251|Experimental|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
11421936|NCT01889251|Sham Comparator|Sham injection|Single sham injection to the study eye at baseline
11421937|NCT01889238|Experimental|Enzalutamide|160 mg administered as four 40 mg soft gelatin capsules orally once daily
11421938|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
11421939|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
11421940|NCT01889225||Framingham Heart study|
11421941|NCT01889225||Framingham Offspring cohort|
11421942|NCT01889225||Atherosclerosis Risk In Communities|
11421943|NCT01889225||Charleston Heart study|
11421944|NCT01889225||Cardiovascular Health study|
11421945|NCT01889225||Rancho Bernardo study|
11421946|NCT01889225||Nurses' Health I study|
11421947|NCT01889225||Panel Study Income Dynamics|
11421948|NCT01889225||MRFIT Referred Care|
11421949|NCT01889225||HDFP Referral Care|
11421950|NCT01889225||Alameda County Health and Ways of Living Study|
11421951|NCT01889225||Nurses' Health II study|
11421952|NCT01889225||Tecumseh County Health study|
11421953|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
11421954|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
11421955|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
11421956|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
11421957|NCT01889212|Experimental|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
11421958|NCT01889199|Placebo Comparator|Sugar pill|Placebo intervention
11421959|NCT01889199|Experimental|Flutamide|Flutamide 125 mg orally daily for six 28-day cycles.
11421960|NCT01889186|Experimental|Single arm|Single arm
11421961|NCT01889173|Experimental|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
11421962|NCT01889173|Experimental|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
11421963|NCT01889173|Experimental|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
11421964|NCT01889173|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
11421965|NCT01889160|Experimental|Part A Active|AZD4721 Solution
11421966|NCT01889160|Placebo Comparator|Part A Placebo|Placebo for AZD4721
11421967|NCT01889160|Experimental|Part B solution|AZD4721 Solution
11421968|NCT01889160|Active Comparator|Part B Suspension|AZD4721 Suspension
11421969|NCT01889147|Active Comparator|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
11422006|NCT01888887|Experimental|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
11421970|NCT01889147|Placebo Comparator|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
11421971|NCT01889147|Active Comparator|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
11421972|NCT01889134|Experimental|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
11421973|NCT01889134|Active Comparator|Parathyroidectomy|Selective parathyroidectomy
11421974|NCT01889134|No Intervention|Control group|No intervention
11421975|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
11421976|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
11421977|NCT01889108|No Intervention|Control|Usual care
11421978|NCT01889108|Experimental|Intervention group|Intervention with SPEEDI
11421979|NCT01889095|Experimental|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
11421980|NCT01889095|Active Comparator|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
11421981|NCT01889082|Active Comparator|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
11421982|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
11421983|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). *New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
11421984|NCT01889069|Experimental|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
11421985|NCT01889056|Experimental|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
11421986|NCT01889056|Placebo Comparator|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
11421987|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
11421988|NCT01889004|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
11421989|NCT01889004|Experimental|Propofol|Intravenous propofol using target controlled infusion
11421990|NCT01888991|No Intervention|water with resting condition|
11421991|NCT01888991|Experimental|glucose with resting condition|
11421992|NCT01888991|Experimental|water with exercise condition|
11421993|NCT01888991|Experimental|glucose with exercise condition|
11421994|NCT01888978|Experimental|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
11421995|NCT01888978|Experimental|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
11421996|NCT01888978|Experimental|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
11421997|NCT01888978|Experimental|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
11421998|NCT01888978|Experimental|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
11421999|NCT01888978|Experimental|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
11422000|NCT01888978|Experimental|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
11422001|NCT01888965|Experimental|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
11422002|NCT01888952|Experimental|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).
~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.
~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
11422003|NCT01888913||Adult Women|Adult Women aged 18-50
11422004|NCT01888900|Experimental|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
11422005|NCT01888900|Experimental|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
11422007|NCT01888874|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
11422008|NCT01888874|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
11422009|NCT01888874|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
11422010|NCT01888874|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
11422011|NCT01888874|Experimental|GLPG0634 25 mg BID|Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
11422012|NCT01888874|Experimental|GLPG0634 50 mg BID|Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
11422013|NCT01888874|Experimental|GLPG0634 100 mg BID|Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.
11422014|NCT01888861|Experimental|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
11422015|NCT01888861|Placebo Comparator|placebo|the patients in this arm were received 900mg placebo through NG tube.
11422016|NCT01888848|Experimental|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
11422017|NCT01888848|Placebo Comparator|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
11422018|NCT01888835|Active Comparator|Mirtazapine|mirtazapine 30 mg orally per day
11422019|NCT01888835|Placebo Comparator|Placebo|placebo (30 mg) orally per day
11422020|NCT01888822|Placebo Comparator|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
11422021|NCT01888822|Active Comparator|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
11422022|NCT01888822|Active Comparator|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
11422023|NCT01888809|Experimental|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
11422024|NCT01888809|Active Comparator|Screening and referral|Annual screening and referral for services as needed
11422025|NCT01888796|Active Comparator|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
11422026|NCT01888796|Placebo Comparator|Placebo|Placebo (tablets) once daily for 6 month
11422027|NCT01888783|Experimental|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
11422028|NCT01888783|Active Comparator|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
11422029|NCT01888783|Active Comparator|Healthy Controls|Healthy adult persons.
11422030|NCT01888770||Normotensive Term|Infants born at term (>37 weeks) to Normotensive pregnancies
11422031|NCT01888770||Term Preeclampsia|Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
11422032|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at <37 weeks gestation
11422033|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at <37 weeks completed gestation
11422034|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
11422035|NCT01888757|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
11422036|NCT01888757|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
11422037|NCT01888744|Active Comparator|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH ≤ 10 IU/l and progesterone < 1,5ng/ml)
11422038|NCT01888744|Active Comparator|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
11422039|NCT01888731|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
11422040|NCT01888731|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
11422041|NCT01888718|Experimental|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
11422042|NCT01888718|Active Comparator|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
11422043|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
11422044|NCT01888705||NE|Smokers wiht normal spirometry.
11422045|NCT01888705||LV|Patients with COPD level I, mild.
11422046|NCT01888705||MOD|Patients with COPD level II, moderate.
11422047|NCT01888705||GV|Patients with COPD level III, severe.
11422048|NCT01888705||MGV|Patients with COPD level IV, very severe.
11422049|NCT01888679|Experimental|head movement|head movement in extension, flexion, right and left rotation
11422050|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
11422051|NCT01888666||slow palatal expansion (SPE)|
11422052|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
11422053|NCT01888653|Active Comparator|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
11422054|NCT01888640|Active Comparator|ActiveTENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
11422055|NCT01888640|Placebo Comparator|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
11422056|NCT01888640|No Intervention|No TENS (Standard Care)|Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
11422057|NCT01888627|Experimental|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
11422058|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
11422059|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
11422060|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
11422061|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
11422062|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
11422063|NCT01888575||Drug|PPI continuous use; No PPI use
11422064|NCT01888562|Experimental|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
11422065|NCT01888549|Experimental|arm1-High dose PPI|
11422066|NCT01888549|Active Comparator|arm2-standard dose PPI|
11422067|NCT01888549|Placebo Comparator|arm3-placebo|Esomeprazole placebo
11422068|NCT01888536|Experimental|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
11422069|NCT01888536|Active Comparator|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
11422070|NCT01888536|Active Comparator|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
11422071|NCT01888523|Experimental|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
11422072|NCT01888523|Experimental|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
11422073|NCT01888510|Experimental|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
11422074|NCT01888497|Experimental|Arm A|
11422075|NCT01888497|Experimental|Arm B|
11422076|NCT01888497|Active Comparator|Arm C|
11422077|NCT01888497|Placebo Comparator|Arm D|
11422078|NCT01888484|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
11422079|NCT01888471|Other|Cases Group|"Cases Group will be defined as:
~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:
~EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.
~LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
11422080|NCT01888471|Other|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
11422081|NCT01888458|Experimental|Micafungine|
11422082|NCT01888445|Experimental|ASP1517 Low dose group|Participants received an oral dose of ASP1517 three times a week.
11422083|NCT01888445|Experimental|ASP1517 Middle dose group|Participants received an oral dose of ASP1517 three times a week.
11422084|NCT01888445|Experimental|ASP1517 High dose group|Participants received an oral dose of ASP1517 three times a week.
11422085|NCT01888445|Active Comparator|Darbepoetin group|Participants received Darbepoetin alfa intravenously once a week.
11422086|NCT01888432|Experimental|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
11422087|NCT01888432|Active Comparator|Standard tacrolimus|Standard tacrolimus ± corticosteroids
11422088|NCT01888419|No Intervention|No active treatment|Clinical follow-up, no active intervention.
11422089|NCT01888419|Experimental|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
11422090|NCT01888406|Experimental|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
11422091|NCT01888406|Other|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
11422092|NCT01888393|Experimental|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
11422093|NCT01888393|Experimental|Group B|Approximately 12 healthy subjects (male and female)
11422094|NCT01888380|Experimental|Foetuses|"still birth and termination of pregnancies
~intervention: minimally invasive, virtual autopsy"
11422095|NCT01888380|Experimental|Newborns|"who died of natural- and non-natural cause
~intervention: minimally invasive, virtual autopsy"
11422096|NCT01888380|Experimental|Children and adolescents|"who died of natural- and non-natural cause
~intervention: minimally invasive, virtual autopsy"
11422097|NCT01888367|Experimental|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
11422098|NCT01888367|Placebo Comparator|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
11422099|NCT01888367|No Intervention|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
11422100|NCT01888354|Experimental|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
11422101|NCT01888354|Experimental|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
11422102|NCT01888341|Experimental|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
11422103|NCT01888341|Active Comparator|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
11422104|NCT01888328|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
11422105|NCT01888328|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
11422106|NCT01888315|Experimental|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:
~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
11422107|NCT01888315|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
11422108|NCT01888302|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11422109|NCT01888289|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
11422110|NCT01888289|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
11422111|NCT01888276|Other|healthy volunteers|evaluation of word generation and of motivation
11422112|NCT01888276|Other|compulsive gamblers|evaluation of word generation and of motivation
11422113|NCT01888263|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
11422114|NCT01888263|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
11422115|NCT01888250|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
11422116|NCT01888250|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
11422117|NCT01888237|Active Comparator|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
11422118|NCT01888237|Experimental|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
11422119|NCT01888224|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
11422120|NCT01888224|Active Comparator|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
11422121|NCT01888211|Experimental|Omega 3 fatty acid supplementation|Omacor 2 grams daily
11422122|NCT01888211|Placebo Comparator|Olive Oil|Olive Oil capsule 2 grams daily
11422123|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
11422124|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
11422125|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
11422126|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
11422127|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
11422128|NCT01888172|Experimental|Weight Watchers Online|
11422129|NCT01888172|Experimental|Weight Watchers Online + ActiveLink|
11422130|NCT01888172|Active Comparator|Internet Delivered Eating and Activity Program|
11422131|NCT01888159|Active Comparator|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
11422132|NCT01888159|Active Comparator|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
11422133|NCT01888146|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
11422134|NCT01888146|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
11422135|NCT01888133|Experimental|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
11422136|NCT01888133|Experimental|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
11422137|NCT01888120||Severe Chronic Pain|
11422138|NCT01888107|Experimental|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
11422139|NCT01888094|Experimental|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
11422140|NCT01888094|Other|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
11422141|NCT01888081|Experimental|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
11422142|NCT01888068||No treatment|
11422143|NCT01888055|Experimental|transcranial direct current stimulation|
11422144|NCT01888055|Placebo Comparator|sham stimulation|
11422145|NCT01888042|Experimental|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
11422146|NCT01888029|Experimental|transcranial direct current stimulation|
11422147|NCT01888029|Placebo Comparator|sham stimulation|
11422148|NCT01888016|Experimental|fascial manipulation|
11422149|NCT01888016|Active Comparator|standard treatment|
11422150|NCT01888003|Active Comparator|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
11422151|NCT01888003|Other|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
11422152|NCT01888003|Other|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
11422153|NCT01887990|Active Comparator|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
11422154|NCT01887990|Placebo Comparator|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
11422155|NCT01887990|Active Comparator|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
11422156|NCT01887990|Placebo Comparator|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
11422157|NCT01887977|Experimental|Computational modeling|
11422158|NCT01887964|Other|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
11422159|NCT01887964|Other|Community-2|Received RS4 flour first and then control flour
11422160|NCT01887951|Active Comparator|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
11422161|NCT01887951|Experimental|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
11422162|NCT01887938|Experimental|Cohort 1|Participants will receive 10 milligram (mg) of HGT-1110 (Recombinant human arylsulfatase A) intrathecal (IT) injection every-other-week (EOW).
11422163|NCT01887938|Experimental|Cohort 2|Participants will receive 30 mg of HGT-1110 IT injection EOW.
11422164|NCT01887938|Experimental|Cohort 3|Participants will receive 100 mg of HGT-1110 IT injection EOW.
11422165|NCT01887938|Experimental|Cohort 4|Participants will receive 100 mg of HGT-1110 IT injection once weekly for 12 weeks followed by 150 mg EOW.
11422166|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
11422167|NCT01887912|Experimental|C. difficile Vaccine Group|Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
11422168|NCT01887912|Placebo Comparator|Placebo Group|Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
11422169|NCT01887899|Experimental|transcranial direct current stimulation|
11422170|NCT01887899|Placebo Comparator|sham stimulation|
11422171|NCT01887886|Experimental|Onartuzumab + Erlotinib|
11422172|NCT01887886|Active Comparator|Placebo + Erlotinib|
11422173|NCT01887873|Other|Hyaluronan Thiomer i.o. implantable device|active treatment
11422174|NCT01887860|Experimental|Cetaphil Daily Facial Moisturizer SPF50|All subjects receive Cetaphil Daily Facial Moisturizer SPF 50
11422175|NCT01887847|Experimental|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
11422176|NCT01887847|Active Comparator|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
11422177|NCT01887834|Placebo Comparator|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules
~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
11422178|NCT01887834|Active Comparator|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules
~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:
~Lactobacillus gasseri KS-13 1.2
~Bifidobacterium bifidum G9-1 0.15
~Bifidobacterium longum MM-2 0.15
~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
11422179|NCT01887821|Active Comparator|Chloroquine|25mg base/kg for 3 days
11422180|NCT01887821|Active Comparator|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
11422181|NCT01887808|Experimental|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
11422182|NCT01887795|Experimental|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
11422183|NCT01887795|Experimental|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
11422184|NCT01887782|Experimental|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
11422185|NCT01887782|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
11422186|NCT01887769||Lung cancer patient at diagnosis|
11422187|NCT01887756|Experimental|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
11422188|NCT01887743|Experimental|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
11422189|NCT01887730|Active Comparator|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
11422190|NCT01887730|Placebo Comparator|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
11422191|NCT01887730|Active Comparator|Arm 3|Hand cleaning with alcohol-containing hand rub
11422192|NCT01887717|Experimental|TheraSphere|Participants will receive TheraSphere at a dose consistent with the approved product label to the treated lobe of the liver. TheraSphere will be administered through the hepatic artery. The target dose will be 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% will be permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere will be permitted if a treatable progression is detected during follow-up evaluations. Any re-treatment will take place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants can receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations will be permitted.
11422193|NCT01887717|Active Comparator|Sorafenib|Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
11422194|NCT01887704|Experimental|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.
~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.
~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
11422195|NCT01887704|Active Comparator|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.
~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
11422196|NCT01887691|Experimental|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
11422197|NCT01887678|Experimental|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
11422198|NCT01887678|Placebo Comparator|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
11422199|NCT01887665|Experimental|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
11422200|NCT01887652|Active Comparator|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
11422201|NCT01887652|Active Comparator|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
11422202|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
11422203|NCT01887626|Experimental|A|Ticagrelor 90 mg as a whole tablet
11422204|NCT01887626|Experimental|B|Ticagrelor 90 mg tablet crushed and suspended in water
11422205|NCT01887626|Experimental|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
11422206|NCT01887613||Regnite group|Patients who receive Regnite
11422232|NCT01887431|Experimental|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
11422233|NCT01887431|Active Comparator|Conventional therapy|3-month routine clinic visits
11422234|NCT01887418|Experimental|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
11422235|NCT01887418|Experimental|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
11422207|NCT01887600|Experimental|Roxadustat|Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.
11422208|NCT01887600|Placebo Comparator|Placebo|Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.
11422209|NCT01887587|Experimental|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
~Dexamethasone- 10 mg/m2 orally or IV on days 1-14
~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
~MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.
~For patients without central nervous system (CNS) involvement:
~Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
~Methotrexate 12 mg administered intrathecally on day 8
~For patients with CNS involvement:
~-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
11422210|NCT01887574|Experimental|Open|
11422211|NCT01887561|No Intervention|treatment|
11422212|NCT01887548|Experimental|Active CD|Patients whose CDAI score >150 points would be enrolled in this group.
11422213|NCT01887548|Active Comparator|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
11422214|NCT01887535|Experimental|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
11422215|NCT01887535|Experimental|Cohort 2: JNJ-54861911 10 mg|
11422216|NCT01887535|Experimental|Cohort 3: JNJ-54861911 30 mg|
11422217|NCT01887535|Experimental|Cohort 4: JNJ-54861911 80 mg|
11422218|NCT01887535|Experimental|Cohort 5: JNJ-54861911 25 mg|
11422219|NCT01887535|Placebo Comparator|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
11422220|NCT01887522|Experimental|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:
~Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
11422221|NCT01887522|Active Comparator|Control Vinblastine only|"Control Vinblastine only arm:
~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
~Each 28-day cycle is repeated on Day 29/Day 1.
~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.
~Vinblastine will be temporarily stopped in case of neutropenia <1 x109/L or thrombopenia <75 x 109/L. It could be re-started at a reduced dose after complete recovery.
~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
11422222|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
11422223|NCT01887483|Active Comparator|Vetal Laban active|Vetal Laban with L. acidophilus
11422224|NCT01887483|Placebo Comparator|Placebo|Vetal Laban -like product without L. acidophilus
11422225|NCT01887470|Experimental|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
11422226|NCT01887470|Experimental|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
11422227|NCT01887470|Experimental|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
11422228|NCT01887470|Experimental|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
11422229|NCT01887457|Experimental|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
11422230|NCT01887444|Experimental|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
11422231|NCT01887444|Placebo Comparator|Placebo|Other: Placebo
11422236|NCT01887418|Active Comparator|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
11422237|NCT01887405|Active Comparator|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
11422238|NCT01887405|Active Comparator|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
11422239|NCT01887392|Experimental|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
11422240|NCT01887392|Experimental|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
11422241|NCT01887379|Experimental|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
11422242|NCT01887379|Experimental|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
11422243|NCT01887366|Experimental|TV-1380 150 mg|
11422244|NCT01887366|Experimental|TV-1380 300 mg|
11422245|NCT01887366|Placebo Comparator|Placebo|
11422246|NCT01887353|Active Comparator|Ranolazine|
11422247|NCT01887353|Placebo Comparator|Placebo|
11422248|NCT01887340|Experimental|Cohort 1|"PET-TDM
~carboplatine: Dose (mg) = AUC x (GFR + 25)
~GFR : glomérulaire filtration (ml/min)
~AUC : area under curve (mg/ml x min)"
11422249|NCT01887340|Experimental|Cohort 2|"PET-TDM
~ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)
~carboplatine: Dose (mg) = AUC x (GFR + 25)
~GFR : glomérulaire filtration (ml/min)
~AUC : area under curve (mg/ml x min)"
11422250|NCT01887327|Placebo Comparator|Placebo|Participants receive placebo and phototherapy
11422251|NCT01887327|Experimental|Stannsoporfin 3.0 mg/kg|Participants receive stannsoporfin (3.0 mg/kg) and phototherapy
11422252|NCT01887327|Experimental|Stannsoporfin 4.5 mg/kg|Participants receive stannsoporfin (4.5 mg/kg) and phototherapy
11422253|NCT01887314|Experimental|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
11422254|NCT01887314|Placebo Comparator|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
11422255|NCT01887301|Active Comparator|Group 1: mild hepatic impairment|Mild hepatic impairment: eight patients of Child-Pugh Grade A (Score 5-6). All patients received Sativex treatment.
11422256|NCT01887301|Active Comparator|Group 2: Moderate hepatic impairment|Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
11422257|NCT01887301|Experimental|Group 3: Pugh Grade B (Score 7-9).|Severe hepatic impairment: eight patients of Child-Pugh Grade C (Score 10-15). All patients received Sativex treatment.
11422258|NCT01887301|Active Comparator|Group 4: Control group|Control Group: eight healthy subjects matched with respect to age (±10 years), weight (±10% body mass index [BMI]) and sex to the severe or most severe evaluable patients. All patients received Sativex treatment.
11422259|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle
~(1 cycle - 4 weeks)"
11422260|NCT01887275|Experimental|medical ozone therapy with humares|
11422261|NCT01887275|Active Comparator|conventional interferon-α|
11422262|NCT01887262|Experimental|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
11422263|NCT01887262|Active Comparator|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
11422264|NCT01887249|Experimental|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
11422265|NCT01887249|Active Comparator|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
11422266|NCT01887249|No Intervention|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
11422267|NCT01887236|Active Comparator|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
11422268|NCT01887236|Active Comparator|Stability Ball|A physical activity program that is based on the Stability Ball
11422269|NCT01887223|Experimental|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
11422270|NCT01887223|Active Comparator|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
11422271|NCT01887210|Experimental|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
11422272|NCT01887210|Active Comparator|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
11422273|NCT01887197|Experimental|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
11422274|NCT01887197|Experimental|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
11422275|NCT01887184|Placebo Comparator|Normal Saline|Normal saline was given intranasally
11422276|NCT01887184|Active Comparator|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
11422277|NCT01887171|Experimental|Tacrolimus + HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
11422278|NCT01887171|No Intervention|HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
11422279|NCT01887158|Active Comparator|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
11422280|NCT01887158|Active Comparator|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
11422281|NCT01887145|Active Comparator|Open surgery|Open surgery is Open carpal tunnel release
11422282|NCT01887145|Experimental|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
11422283|NCT01887132|Experimental|Open-Label Donepezil|
11422284|NCT01887132|Experimental|Donepezil - Blinded|
11422285|NCT01887132|Placebo Comparator|Placebo|
11422286|NCT01887119|Active Comparator|Eplerenone|Eplerenone 50 mg 1dd during four weeks
11422287|NCT01887119|Placebo Comparator|Placebo|Eplerenone-matched placebo
11422288|NCT01887106|Experimental|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
11422289|NCT01887106|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
11422290|NCT01887106|Experimental|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
11422291|NCT01887106|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
11422292|NCT01887093|Experimental|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
11422293|NCT01887093|Experimental|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
11422294|NCT01887093|No Intervention|No walking|The control group was requested to maintain their usual level of physical activity.
11422295|NCT01887080|Experimental|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
11422296|NCT01887080|Experimental|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
11422297|NCT01887080|Other|Cardiovascular Risk Factors|Education about risk factors
11422298|NCT01887067|Experimental|Renal denervation therapy|
11422299|NCT01887054|Active Comparator|Training Group|"There are 2 study visits. Subjects in this group will complete the following:
~Visit 1
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments
~Taught how to complete a visual problem-solving task (Tower of Hanoi)
~Given a diary to record training at home.
~In-home
~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1
~Visit 2
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments"
11422300|NCT01887054|Placebo Comparator|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:
~Visit 1
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments
~Visit 2
~Gait evaluation
~Neuropsychological testing
~Questionnaires and assessments"
11422301|NCT01887041|Active Comparator|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
11422302|NCT01887041|Active Comparator|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.
~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
11422303|NCT01887028|Experimental|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
11422304|NCT01887028|Other|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
11422305|NCT01887028|Other|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
11422306|NCT01887028|Other|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
11422307|NCT01887015|Experimental|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
11422308|NCT01887015|Other|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
11422309|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
11422310|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
11422311|NCT01886989|Experimental|Cocoa|Cocoa polyphenols (960mg)
11422312|NCT01886989|Placebo Comparator|Placebo|Placebo powder (109mg polyphenols) in water
11422313|NCT01886976|Experimental|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
11422314|NCT01886963|Active Comparator|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
11422315|NCT01886963|Experimental|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
11422316|NCT01886937|Experimental|37.5 mg Phentermine daily for 7 days|"In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.
~Other names for phentermine:
~adipex ionamin"
11422317|NCT01886937|Placebo Comparator|Placebo (for phentermine 37.5mg)|In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
11422318|NCT01886924|Experimental|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
11422319|NCT01886924|Active Comparator|Nutrition Control|Computer delivered nutrition education
11422320|NCT01886911|Active Comparator|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
11422321|NCT01886911|Experimental|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
11422322|NCT01886911|Experimental|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
11422323|NCT01886911|Active Comparator|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
11422324|NCT01886898|Placebo Comparator|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
11422325|NCT01886898|Experimental|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
11422326|NCT01886898|Experimental|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
11422327|NCT01886898|Other|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
11422328|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
11422329|NCT01886872|Active Comparator|Arm I (rituximab, bendamustine hydrochloride)|Patients receive rituximab IV on day 1 (day 0 course 1) and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
11422330|NCT01886872|Experimental|Arm II (ibrutinib)|Patients receive ibrutinib PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11422331|NCT01886872|Experimental|Arm III (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm II. Patients receive rituximab IV on days 1, 8, 15, and 22 of course 2 and on day 1 of courses 3-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11422332|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
11422333|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.
~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
11422334|NCT01886820|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
11422335|NCT01886807|Other|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
11422336|NCT01886807|Other|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
11422337|NCT01886807|Experimental|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
11422523|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
11422338|NCT01886794|Experimental|Postmenopausal, topical vaginal cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to estrogen cream.
11422339|NCT01886794|No Intervention|Pre-menopausal, no topical vaginal cream|Pre-menopausal, no topical vaginal cream. These women will be examined at different stages in their menstrual cycle in order to compare characteristics of the cycle at high and lower estrogen timepoints.
11422340|NCT01886794|Placebo Comparator|Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to placebo.
11422341|NCT01886781|Experimental|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
11422342|NCT01886781|Placebo Comparator|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
11422343|NCT01886781|No Intervention|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
11422344|NCT01886781|No Intervention|Wash out period|Wash out period of two weeks, no treatment.
11422345|NCT01886768|Experimental|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
11422346|NCT01886768|Active Comparator|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
11422347|NCT01886755|Experimental|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
11422348|NCT01886755|Placebo Comparator|Placebo Comparator|Standard oral rehydration solution
11422349|NCT01886742|Active Comparator|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
11422350|NCT01886742|Experimental|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
11422351|NCT01886729|Active Comparator|tDCS simultaneously with hyperbaric oxygen therapy|
11422352|NCT01886729|Active Comparator|tDCS 3 weeks after start tinnitus|
11422353|NCT01886716|Experimental|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
11422354|NCT01886716|Experimental|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
11422355|NCT01886716|Experimental|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
11422356|NCT01886716|Placebo Comparator|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
11422357|NCT01886703|Experimental|Walking Intervention|Pedometer Walking Program
11422358|NCT01886690|Experimental|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
11422359|NCT01886690|Active Comparator|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
11422360|NCT01886677|Experimental|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
11422361|NCT01886677|Other|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
11422362|NCT01886664|Active Comparator|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
11422363|NCT01886664|Experimental|Desflurane|Performing liver transplantation under general anesthesia using desflurane
11422364|NCT01886638|Experimental|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
11422365|NCT01886625|Experimental|Sympathicotomy|unilateral single-port VATS sympathicotomy
11422366|NCT01886612|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.
~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
11422367|NCT01886599|Experimental|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
11422368|NCT01886599|Experimental|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
11422369|NCT01886599|Experimental|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
11422370|NCT01886599|Experimental|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
11422371|NCT01886599|Experimental|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
11422372|NCT01886586|Active Comparator|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
11422373|NCT01886586|Active Comparator|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
11422415|NCT01886313|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
11422374|NCT01886586|Active Comparator|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
11422375|NCT01886573|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
11422376|NCT01886560|Placebo Comparator|Placebo|Adding eatable flour into the pills
11422377|NCT01886560|Experimental|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
11422378|NCT01886547||New patient presented with prostate disease|prostate disease identified
11422379|NCT01886534|Experimental|Enhanced Caregiver Support with Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©
~Standardized education sessions
~Heart Failure Diuretic Decision Support Tool for Patient Self Management©
~Digital talking scale"
11422380|NCT01886534|Other|Usual Care with Caregiver|Usual care
11422381|NCT01886534|Experimental|Enhanced Support without Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©
~Standardized education sessions
~Heart Failure Diuretic Decision Support Tool for Patient Self Management©
~Digital talking scale"
11422382|NCT01886534|Other|Usual Care without Caregiver|Usual Care
11422383|NCT01886521|Experimental|Lumbar drain group|Lumbar drain
11422384|NCT01886521|Active Comparator|Ventricular drain|Ventricular drain
11422385|NCT01886508|Experimental|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
11422386|NCT01886508|Active Comparator|RH|patients in Arm RH undergo radical hysterectomy (RH)
11422387|NCT01886495|Active Comparator|nutrition intervention|high protein diet
11422388|NCT01886495|No Intervention|control diet|
11422389|NCT01886482|Active Comparator|nutrition intervention|high protein diet
11422390|NCT01886482|No Intervention|no intervention|control diet
11422391|NCT01886469|Experimental|Adolescents (12-17yrs)|
11422392|NCT01886469|Experimental|Children (6-11 yrs)|
11422393|NCT01886456|Experimental|PLT|patients treated with patterned laser trabeculoplasty
11422394|NCT01886456|Active Comparator|SLT|patients treated with selective laser trabeculoplasty
11422395|NCT01886443|Experimental|Combined drug approach, safety study|
11422396|NCT01886430|Experimental|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
11422397|NCT01886430|Placebo Comparator|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
11422398|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
11422399|NCT01886391|Experimental|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
11422400|NCT01886378|Experimental|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
11422401|NCT01886365|Active Comparator|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
11422402|NCT01886365|Active Comparator|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
11422403|NCT01886365|Other|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
11422404|NCT01886352|Active Comparator|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
11422405|NCT01886352|Experimental|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
11422406|NCT01886352|Experimental|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
11422407|NCT01886339||Healthy population|
11422408|NCT01886326|Experimental|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
11422409|NCT01886326|Experimental|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
11422410|NCT01886326|Experimental|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
11422411|NCT01886326|Experimental|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
11422412|NCT01886326|Experimental|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
11422413|NCT01886326|Experimental|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
11422414|NCT01886313|Active Comparator|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
11422417|NCT01886287|Experimental|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
11422418|NCT01886274|Experimental|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
11422419|NCT01886274|Sham Comparator|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
11422420|NCT01886274|No Intervention|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
11422421|NCT01886248|Experimental|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
~Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
11422422|NCT01886235|Experimental|Diagnosis (intravital microscopy)|Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma.
11422423|NCT01886222|Experimental|Long-term mild hypothermia|Focused intervention
11422424|NCT01886222|Other|Normothermia|Standard management
11422425|NCT01886209|Experimental|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
11422426|NCT01886209|Experimental|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
11422427|NCT01886196|Experimental|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
11422428|NCT01886196|Placebo Comparator|placebo|placebo after exercise training sessions(3 times per week for 9 months)
11422429|NCT01886196|Experimental|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
11422430|NCT01886196|Sham Comparator|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
11422431|NCT01886183|Experimental|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
11422432|NCT01886183|Active Comparator|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
11422433|NCT01886170|No Intervention|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
11422434|NCT01886170|Experimental|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
11422435|NCT01886170|Experimental|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
11422436|NCT01886157|Active Comparator|Corticosteroid injection|Standard corticosteroid injection.
11422437|NCT01886157|Experimental|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
11422438|NCT01886144||Knee OA|People with knee OA of one knee
11422439|NCT01886131|Experimental|Synchronised video-polysomnography|
11422440|NCT01886118|Experimental|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
11422441|NCT01886118|Active Comparator|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
11422442|NCT01886105|Experimental|SmEDTMP/Autologous Stem Cell Infusion/RT|"DAY 1 Tracer dose 153Sm-EDTMP administration (1 mCi/kg) SPECT/High-resolution CT at 4 hours. SPECT/CT (low resolution) at 24 and 48 hrs
~DAY 7 Individualized treatment dose 153Sm-EDTMP administration (max 30 mCi/kg) SPECT scans at 4, 24 and 48 hours
~DAY 21 (2 weeks following treatment dose) Auto-Stem cell infusion
~DAY 40 (approx. two weeks after stem cell rescue) Initiate EBT upon count recovery
~1 MONTH following completion of all therapy Response assessment with repeat imaging (CT/MRI, Tc-99m bone scan) 18F-MISO/FDG PET"
11422443|NCT01886092|Active Comparator|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
11422444|NCT01886092|Active Comparator|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
11422445|NCT01886092|Active Comparator|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
11422446|NCT01886092|Sham Comparator|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
11422447|NCT01886079|Experimental|Dexmedetomidine group|
11422448|NCT01886079|Placebo Comparator|Saline group|
11422449|NCT01886066|Experimental|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
11422450|NCT01886053|Active Comparator|Ertapenem|
11422451|NCT01886053|Experimental|Faropenem（low-dose group)|
11422452|NCT01886053|Experimental|Faropenem（high dose group）|
11422453|NCT01886040||cases with endometrial cancer|
11422454|NCT01886027|Experimental|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
11422455|NCT01886027|Active Comparator|Relaxation|Relaxation training will teach patients different relaxation training skills.
11422456|NCT01886027|No Intervention|Wait-list control|Standard medical care until the 3-month follow-up is completed
11422457|NCT01886014|Experimental|oxytocin|application of intranasal oxytocin 40IE
11422458|NCT01886014|Placebo Comparator|placebo|"application of intranasal saline
~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
11422459|NCT01886001|Experimental|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
11422460|NCT01886001|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
11422524|NCT01885533||Post-radiodione medication|watchful monitoring
11422461|NCT01886001|Experimental|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
11422462|NCT01886001|Sham Comparator|Control (no application)|Control arm, no product is applied, which is standard of care.
11422463|NCT01885988|Active Comparator|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
11422464|NCT01885988|Placebo Comparator|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
11422465|NCT01885962|No Intervention|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
11422466|NCT01885962|Experimental|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
11422467|NCT01885949|Experimental|Experimental Treatment Arm|Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
11422468|NCT01885936|Experimental|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
11422469|NCT01885936|Placebo Comparator|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
11422470|NCT01885923|Active Comparator|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
11422471|NCT01885923|No Intervention|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
11422472|NCT01885910|Experimental|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
11422473|NCT01885897|Experimental|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
11422474|NCT01885884|Experimental|Supportive Care Intervention|Monthly (minimum) patient & caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
11422475|NCT01885884|No Intervention|Usual Care|Participants will receive standard oncology care from their oncology providers.
11422476|NCT01885871|Experimental|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
11422477|NCT01885858|Other|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
11422478|NCT01885858|Other|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
11422479|NCT01885845|Experimental|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
11422480|NCT01885845|Experimental|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
11422481|NCT01885832|Experimental|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
11422482|NCT01885819|Experimental|Treatment|Autologous stromal vascular fraction cells
11422483|NCT01885806|Experimental|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:
~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
11422484|NCT01885806|Sham Comparator|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
11422485|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
11422486|NCT01885780|Experimental|Astigmatic keratotomy|
11422487|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
11422488|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
11422489|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
11422490|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area < 55cm2/m2 for men and < 39 cm2/m2 for women
11422491|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
11422492|NCT01885741|Experimental|IPBS|
11422643|NCT01884649||Healty control group|
11422493|NCT01885728|Active Comparator|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
11422494|NCT01885728|No Intervention|No nutritional supplement|No specific nutritional requirements have to be met in this group.
11422495|NCT01885715|Placebo Comparator|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422496|NCT01885715|Active Comparator|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
11422497|NCT01885715|Active Comparator|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422498|NCT01885715|Active Comparator|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422499|NCT01885715|Placebo Comparator|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422500|NCT01885715|Active Comparator|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422501|NCT01885715|Active Comparator|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422502|NCT01885715|Active Comparator|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.
~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
11422503|NCT01885702|Experimental|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
11422504|NCT01885702|Experimental|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
11422505|NCT01885689|Experimental|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.
~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
11422506|NCT01885676|Experimental|PRGF-Endoret|
11422507|NCT01885676|Placebo Comparator|Saline Solution|
11422508|NCT01885663|Experimental|Umbilical cord blood therapy|Umbilical cord blood therapy
11422509|NCT01885650|Experimental|Normal airway clearance|The patients usual airway clearance technique
11422510|NCT01885650|Experimental|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
11422511|NCT01885637|No Intervention|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
11422512|NCT01885637|Other|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
11422513|NCT01885624|Experimental|TAB08|Single TAB08 i.v. infusion
11422514|NCT01885611|Active Comparator|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)
~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
11422515|NCT01885611|Experimental|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)
~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
11422516|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
11422517|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
11422518|NCT01885572|Other|TiLOOP Bra|Treatment with TiLOOP Bra
11422519|NCT01885559|Placebo Comparator|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
11422520|NCT01885559|Active Comparator|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
11422521|NCT01885546|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
11422522|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
11422525|NCT01885520|Experimental|fasting condition|eperisone SR administrated under fasting condition
11422526|NCT01885520|Active Comparator|Fed condition|eperisone SR administrated under fed condition
11422527|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
11422528|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:
~the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)
~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
11422529|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
11422530|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
11422531|NCT01885494||Control group|Untreated control group
11422532|NCT01885481|Active Comparator|ESI-1|epidural steroid injection using dexamethasone
11422533|NCT01885481|Experimental|ESI-2|epidural steroid injection using betamethasone
11422534|NCT01885455|Active Comparator|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
11422535|NCT01885455|Experimental|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.
~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).
~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
11422536|NCT01885442|Experimental|In-bed leg cycle ergometry|
11422537|NCT01885429|Experimental|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
11422538|NCT01885429|Experimental|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
11422539|NCT01885429|Experimental|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
11422540|NCT01885429|Experimental|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
11422541|NCT01885429|Experimental|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
11422542|NCT01885416|Active Comparator|high fat meal without dairy products|high fat meal without dairy products
11422543|NCT01885416|Experimental|high fat meal with additional milk|high fat meal with additional milk
11422544|NCT01885416|Experimental|dairy product meal|dairy product meal
11422545|NCT01885403|Experimental|Respiratory Parameters Measurements|
11422546|NCT01885390|Experimental|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
11422547|NCT01885377|Experimental|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
11422548|NCT01885377|Active Comparator|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
11422549|NCT01885364|Placebo Comparator|Placebo & propofol|Pretreatment with normal saline before injection of propofol
11422550|NCT01885364|Experimental|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
11422551|NCT01885364|Experimental|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
11422552|NCT01885364|Active Comparator|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
11422553|NCT01885351|Experimental|Phase II: MyCRCS+Prefs|
11422554|NCT01885351|Experimental|Phase II: MyCRCS+Prefs+Barriers|
11422555|NCT01885351|No Intervention|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
11422556|NCT01885338|Experimental|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
11422557|NCT01885338|Placebo Comparator|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
11422558|NCT01885325|Experimental|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
11422559|NCT01885325|No Intervention|Control|The preschools in the control group did not receive the intervention
11422560|NCT01885312|Active Comparator|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
11422561|NCT01885312|Other|Ecological Momentary Assessment|Mobile Assessment only
11422562|NCT01885312|Experimental|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
11422563|NCT01885312|Active Comparator|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
11422564|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
11422565|NCT01885273|Experimental|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
11422566|NCT01885273|Active Comparator|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
11422567|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
11422568|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
11422569|NCT01885260|Placebo Comparator|Placebo|Placebo
11422570|NCT01885234|Experimental|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
11422571|NCT01885234|Placebo Comparator|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
11422572|NCT01885221|Experimental|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
11422573|NCT01885221|No Intervention|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
11422574|NCT01885208|Experimental|Semaglutide 1.0 mg|
11422575|NCT01885208|Active Comparator|Exenatide ER 2.0 mg|
11422576|NCT01885195|Experimental|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
11422577|NCT01885182|Experimental|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
11422578|NCT01885182|Active Comparator|Oxycodone|5mg, 10mg, 20mg or 40mg
11422579|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
11422580|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
11422581|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
11422582|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
11422583|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
11422584|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
11422585|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
11422586|NCT01885130|Experimental|Cetaphil Daily Advance Ultra Hydrating Lotion|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
11422587|NCT01885117|Experimental|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
11422588|NCT01885117|Experimental|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
11422589|NCT01885104|Experimental|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
11422590|NCT01885104|Placebo Comparator|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
11422591|NCT01885091|Experimental|Kinerase|
11422592|NCT01885078|Experimental|Baricitinib 4 mg|"Baricitinib 4 milligrams (mg) administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.
~Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
11422593|NCT01885078|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.
~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
11422594|NCT01885065|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
11422595|NCT01885052|Placebo Comparator|1|Receives weekly assessment messages ONLY
11422596|NCT01885052|Active Comparator|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
11422597|NCT01885052|Active Comparator|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
11422598|NCT01885026|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use, and Internet-based treatment for depression or anxiety
11422599|NCT01885026|Experimental|Control|Assessment only of alcohol and drug use and Internet-based treatment for depression or anxiety
11422600|NCT01885013|Experimental|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.
~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
11422601|NCT01885013|Active Comparator|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
11422602|NCT01885000|Experimental|Brimonidine tartrate 0.5% gel|once-daily brimonidine tartrate 0.5% gel
11422603|NCT01885000|Placebo Comparator|Vehicle|once-daily brimonidine tartrate vehicle gel
11422604|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
11422605|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
11422606|NCT01884961|Experimental|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.
~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.
~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
11422607|NCT01884948|Active Comparator|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
11422608|NCT01884948|Placebo Comparator|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
11422609|NCT01884935|Experimental|Natalizumab|300 mg intravenously (IV) every 4 weeks
11422610|NCT01884922|Experimental|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested
~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
11422611|NCT01884909|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
11422612|NCT01884909|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
11422613|NCT01884896|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
11422614|NCT01884896|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
11422615|NCT01884883|Other|Internal unicompartmental knee brace|
11422616|NCT01884870|Other|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
11422617|NCT01884857|Active Comparator|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
11422618|NCT01884857|Experimental|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
11422619|NCT01884844|Experimental|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
11422620|NCT01884844|Placebo Comparator|Placebo|methylcellulose po qday for 12weeks
11422621|NCT01884831|Experimental|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
11422622|NCT01884818|Experimental|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
11422623|NCT01884818|Sham Comparator|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
11422624|NCT01884805|Other|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
11422625|NCT01884792|Placebo Comparator|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
11422626|NCT01884792|Experimental|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
11422627|NCT01884792|Placebo Comparator|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
11422628|NCT01884792|Experimental|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
11422629|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
11422630|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
11422631|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
11422632|NCT01884740|Experimental|SIACI of Erbitux and Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 m/m2) and Bevacizumab (15 mg/kg)
11422633|NCT01884727|Active Comparator|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
11422634|NCT01884727|Placebo Comparator|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
11422635|NCT01884714|Experimental|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
11422636|NCT01884701|Experimental|Intervention|Intervention
11422637|NCT01884688|Experimental|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
11422638|NCT01884675|Experimental|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
11422639|NCT01884675|Placebo Comparator|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
11422640|NCT01884662|Experimental|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
11422641|NCT01884662|Active Comparator|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
11422642|NCT01884649||Group of Hashimoto thyroiditis patients|
11422644|NCT01884636|Experimental|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
11422645|NCT01884623|Experimental|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
11422646|NCT01884623|Active Comparator|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
11422647|NCT01884597|Active Comparator|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
11422648|NCT01884597|Active Comparator|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
11422649|NCT01884597|Active Comparator|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
11422650|NCT01884584|Experimental|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
11422651|NCT01884571|Experimental|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
11422652|NCT01884558|Experimental|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
11422653|NCT01884545|Active Comparator|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
11422654|NCT01884545|Experimental|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
11422655|NCT01884545|Experimental|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
11422656|NCT01884545|Experimental|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
11422657|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11422658|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11422659|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11422660|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11422661|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11422662|NCT01884519|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11422663|NCT01884519|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11422664|NCT01884506|Experimental|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
11422665|NCT01884506|Experimental|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
11422666|NCT01884493|Experimental|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
11422667|NCT01884493|Sham Comparator|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
11422668|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
11422669|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
11422670|NCT01884467|Experimental|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
11422671|NCT01884467|Placebo Comparator|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
11422672|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
11422673|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
11422674|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
11422675|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index <5/h.
11422676|NCT01884441|Experimental|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
11423329|NCT01879865|Other|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
11422677|NCT01884428|Experimental|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
11422678|NCT01884415|Experimental|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
11422679|NCT01884415|Active Comparator|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
11422680|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
11422681|NCT01884389|Experimental|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
11422682|NCT01884389|No Intervention|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
11422683|NCT01884376|Experimental|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
11422684|NCT01884363|Experimental|Walnuts|This group will receive one ounce of walnuts per day
11422685|NCT01884363|No Intervention|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
11422686|NCT01884350|Experimental|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
11422687|NCT01884350|Experimental|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
11422688|NCT01884337|Experimental|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
11422689|NCT01884324|No Intervention|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
11422690|NCT01884324|Experimental|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
11422691|NCT01884311|Experimental|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
11422692|NCT01884298|Experimental|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
11422693|NCT01884285|Experimental|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
11422694|NCT01884285|Experimental|Part C2: AZD8186/abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
11422695|NCT01884285|Experimental|Part D1: AZD8186 and AZD2014|Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
11422696|NCT01884285|Experimental|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
11422697|NCT01884285|Experimental|Part D2: AZD8186/ AZD2014|Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
11422698|NCT01884285|Experimental|Part C1: AZD8186 & abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
11422699|NCT01884272|Experimental|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
11422700|NCT01884272|Active Comparator|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
11422701|NCT01884259|Active Comparator|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).
~Active comparator is 5-fluorouracil for first three cycles."
11422702|NCT01884259|Experimental|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).
~Experimental: cetuximab for the first three cycles."
11422703|NCT01884246|Experimental|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
11422704|NCT01884246|Active Comparator|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
11422705|NCT01884233|Experimental|Text Messaging CBT|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
11422746|NCT01883947|Sham Comparator|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
11422706|NCT01884233|Active Comparator|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
11422707|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
11422708|NCT01884207||orbital tumors|
11422709|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
11422710|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
11422711|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
11422712|NCT01884181||Healthy Controls|"The healthy control subjects without a clinically significant neuropsychiatric disorders.
~Able to understand and provide signed informed consent.
~Age range and gender matched with Patients with Huntington Disease Group."
11422713|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
11422714|NCT01884155|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
11422715|NCT01884142|No Intervention|Heart Failure Untrained Group|Control Group
11422716|NCT01884142|Experimental|Heart Failure Exercise-trained Group|Aerobic Exercise Training
11422717|NCT01884116|Active Comparator|NSAID patch group|administer the NSAID patch
11422718|NCT01884116|Experimental|NSAID patch + transcutaneous electric nerve stimulation group|
11422719|NCT01884116|Experimental|NSAID patch + heating pad group|
11422720|NCT01884116|Experimental|NSAID patch + topical capsaicin group|
11422721|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
11422722|NCT01884090|Experimental|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
11422723|NCT01884090|Active Comparator|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
11422724|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
11422725|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
11422726|NCT01884064|Experimental|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
11422727|NCT01884064|Placebo Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
11422728|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
11422729|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
11422730|NCT01884038|Experimental|1|
11422731|NCT01884038|Placebo Comparator|2|
11422732|NCT01884025|Experimental|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
11422733|NCT01884025|Sham Comparator|Health and Humor Class|Equally engaging attention control condition
11422734|NCT01884012|Experimental|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
11422735|NCT01884012|Sham Comparator|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
11422736|NCT01883999|Experimental|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
11422737|NCT01883986|Experimental|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
11422738|NCT01883986|No Intervention|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
11422739|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
11422740|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
11422741|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
11422742|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
11422743|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
11422744|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
11422745|NCT01883947|Experimental|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
11422747|NCT01883934|Experimental|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
11422748|NCT01883934|Active Comparator|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
11422749|NCT01883921||Immunoglobulin Therapy|
11422750|NCT01883908|Experimental|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
11422751|NCT01883908|Active Comparator|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
11422752|NCT01883895|Other|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.
~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.
~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.
~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
11422753|NCT01883882|Experimental|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
11422754|NCT01883882|No Intervention|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
11422755|NCT01883869|Experimental|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
11422756|NCT01883869|Placebo Comparator|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
11422757|NCT01883856|Active Comparator|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
11422758|NCT01883856|Experimental|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
11422759|NCT01883843|Experimental|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.
~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
11422760|NCT01883843|Active Comparator|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
11422761|NCT01883830|Experimental|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
11422762|NCT01883830|Active Comparator|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
11422763|NCT01883817|Placebo Comparator|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
11422764|NCT01883817|Experimental|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
11422765|NCT01883804|Experimental|Study group|All participants selected to continue with Methyldopa administration.
11422766|NCT01883791|Experimental|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
11422767|NCT01883791|Other|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
11422768|NCT01883778||Emergency Department Patients|
11422769|NCT01883778||Emergency Medicine Physicians|
11422770|NCT01883765|Experimental|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
11422771|NCT01883765|Sham Comparator|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
11422772|NCT01883765|Active Comparator|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
11422773|NCT01883752|No Intervention|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
11422774|NCT01883752|Experimental|Goal-directed Therapy group|Goal-direct therapy
11422775|NCT01883739|Experimental|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
11422776|NCT01883726|Experimental|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
11422817|NCT01883466|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
11422777|NCT01883726|Experimental|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap [3]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
11422778|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
11422779|NCT01883700|Experimental|Low-GI, High-GL Meal|Boiled Pasta
11422780|NCT01883700|Experimental|Low-GI, High GL Meal|Boiled Chickpeas with Oil
11422781|NCT01883700|Experimental|High-GI, High-GL Meal|Instant Mashed Potatoes
11422782|NCT01883700|Experimental|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
11422783|NCT01883687|Experimental|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
11422784|NCT01883687|No Intervention|No septoplasty|patient will only receive Le Fort I osteotomy
11422785|NCT01883674|Experimental|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
11422786|NCT01883674|Experimental|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
11422787|NCT01883674|Placebo Comparator|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
11422788|NCT01883661|Other|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
11422789|NCT01883648|Experimental|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
11422790|NCT01883648|Placebo Comparator|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
11422791|NCT01883635|Active Comparator|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
11422792|NCT01883635|Experimental|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
11422793|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
11422794|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
11422795|NCT01883622||Healthy|Healthy pregnant women
11422796|NCT01883609|Active Comparator|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
11422797|NCT01883609|Active Comparator|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
11422798|NCT01883609|No Intervention|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
11422799|NCT01883609|No Intervention|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
11422800|NCT01883596|Experimental|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
11422801|NCT01883596|Placebo Comparator|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
11422802|NCT01883583|Experimental|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
11422803|NCT01883570|Experimental|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
11422804|NCT01883570|Active Comparator|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
11422805|NCT01883544|Experimental|ALXN1007|Infusion of ALXN1007
11422806|NCT01883544|Placebo Comparator|placebo|Infusion placebo
11422807|NCT01883531|Placebo Comparator|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
11422808|NCT01883531|Active Comparator|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
11422809|NCT01883518|Experimental|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
11422810|NCT01883505|Experimental|ND0612|levodopa and carbidopa solution
11422811|NCT01883505|Placebo Comparator|Placebo|Saline
11422812|NCT01883492|Experimental|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).
~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.
~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
11422813|NCT01883492|Active Comparator|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).
~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.
~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
11422814|NCT01883479|Experimental|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
11422815|NCT01883479|Experimental|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
11422816|NCT01883479|No Intervention|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
11422818|NCT01883466|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
11422819|NCT01883453|Placebo Comparator|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
11422820|NCT01883453|Active Comparator|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
11422821|NCT01883440|Placebo Comparator|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
11422822|NCT01883440|Active Comparator|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
11422823|NCT01883427|Placebo Comparator|Placebo: Saline+glucose nasal spray|Subjects received nasal spray containing both saline+glucose twice daily for 3 months
11422824|NCT01883427|Active Comparator|Nasal spray with glucose oxidase+glucose|Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
11422825|NCT01883414|Active Comparator|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
11422826|NCT01883414|Active Comparator|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
11422827|NCT01883401|Experimental|High dose strawberry|50g freeze-dried strawberries/day
11422828|NCT01883401|Experimental|Low-dose strawberry|25g freeze-dried strawberries/day
11422829|NCT01883401|Other|Fiber/calorie control (high dose)|Dietary fiber (8g)
11422830|NCT01883401|Other|Fiber/calorie control (low dose)|Dietary fiber (4g)
11422831|NCT01883375|Experimental|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
11422832|NCT01883375|Experimental|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
11422833|NCT01883362|Experimental|Standard of Care with Midostaurin|Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
11422834|NCT01883362|Active Comparator|Standard of Care|Patients received standard of care alone in the post SCT setting
11422835|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation
11422836|NCT01883349||Control Arm|Subjects without kidney disease
11422837|NCT01883323|Experimental|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
11422838|NCT01883310|Active Comparator|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
11422839|NCT01883310|Experimental|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
11422840|NCT01883297|Experimental|Re-Stimulated Tumor-Infiltrating Lymphocytes and interleukin-2|Cyclophosphamide will be given prior to Re-Stimulated Tumor-Infiltrating Lymphocytes, and interleukin-2.
11422841|NCT01883284|Experimental|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
11422842|NCT01883284|Other|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
11422843|NCT01883271|Experimental|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
11422844|NCT01883271|Experimental|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
11422845|NCT01883271|No Intervention|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
11422846|NCT01883271|No Intervention|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
11422847|NCT01883258|Experimental|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
11422848|NCT01883258|Experimental|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
11422849|NCT01883258|No Intervention|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
11422850|NCT01883258|No Intervention|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
11422851|NCT01883245|Active Comparator|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
11422928|NCT01882621|Active Comparator|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
11422929|NCT01882621|Placebo Comparator|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
11423101|NCT01881503|Other|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
11422852|NCT01883245|Experimental|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.
~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
11422853|NCT01883232|Active Comparator|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
11422854|NCT01883232|Experimental|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
11422855|NCT01883219|Experimental|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
11422856|NCT01883193|Experimental|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
11422857|NCT01883193|Experimental|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
11422858|NCT01883193|No Intervention|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
11422859|NCT01883180|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
11422860|NCT01883180|Experimental|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
11422861|NCT01883167|Experimental|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.
~Days 15-21: RDEA3170 10 mg or placebo qd."
11422862|NCT01883167|Experimental|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.
~Days 15-21: febuxostat 40 mg qd."
11422863|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
11422864|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
11422865|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
11422866|NCT01883154||IVF pregnancies|
11422867|NCT01883141|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure
11422868|NCT01883128|Experimental|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
11422869|NCT01883128|Experimental|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
11422870|NCT01883128|Experimental|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
11422871|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
11422872|NCT01883102|Experimental|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
11422873|NCT01883102|Placebo Comparator|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
11422874|NCT01883089|Other|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
11422875|NCT01883076|Experimental|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
11422876|NCT01883063|Experimental|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
11422877|NCT01883063|Active Comparator|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
11422878|NCT01883050|Other|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
11422879|NCT01883050|No Intervention|No Intervention|No Intervention
11422880|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
11422881|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
11422882|NCT01883024|Other|Type 1 diabetes|
11422883|NCT01883011|Experimental|Piracetam|"IV infusion 12 g piracetam in 60 ml
~IV Ampoules 3 g piracetam in 15 ml
~Oral solution 33 % piracetam (bottle of 125 ml)
~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
11422884|NCT01883011|Placebo Comparator|Placebo|"IV infusion 12 g placebo in 60 ml
~IV Ampoules 3 g placebo in 15 ml
~Oral solution 33% placebo (bottle of 125 ml)
~Oral tablets 1200 mg placebo (blisters of 10 tablets)
~All IV forms were identical in presentation, size and color to allow a double blind design.
~All oral forms were identical in shape, size, color and taste to allow a double blind design."
11422885|NCT01882998|Experimental|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
11422963|NCT01882439|Placebo Comparator|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
11422964|NCT01882439|Placebo Comparator|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
11422886|NCT01882998|Experimental|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
11422887|NCT01882985|Experimental|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
11422888|NCT01882972|Experimental|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
11422889|NCT01882972|Placebo Comparator|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
11422890|NCT01882959||Placebo|
11422891|NCT01882959||Intervention|Radiofrequncy Denervation
11422892|NCT01882946|Experimental|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
11422893|NCT01882933|Experimental|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
11422894|NCT01882933|Other|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
11422895|NCT01882920|Experimental|Goal directed therapy intravenous restricitve fluid protocol|
11422896|NCT01882920|Active Comparator|Control arm|
11422897|NCT01882907|Experimental|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
11422898|NCT01882907|Active Comparator|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
11422899|NCT01882894|Experimental|Custom PFO orthosis|This is a custom made orthosis
11422900|NCT01882894|Placebo Comparator|Faux foot orthosis|Foam insert without arch support
11422901|NCT01882881|Active Comparator|Healthy American Control Diet|
11422902|NCT01882881|Experimental|Dark Chocolate/Cocoa Diet|
11422903|NCT01882881|Experimental|Almond Diet|
11422904|NCT01882881|Experimental|Dark Chocolate/Cocoa + Almond Diet|
11422905|NCT01882868|Experimental|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m^2 (2 hours) and irinotecan 180 mg/m^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m^2.
11422906|NCT01882842|Experimental|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
11422907|NCT01882842|No Intervention|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
11422908|NCT01882829|Experimental|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
11422909|NCT01882816|Experimental|IMRT and doxorubicin|All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.
11422910|NCT01882803|Experimental|Duvelisib|
11422911|NCT01882777|No Intervention|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
11422912|NCT01882777|Active Comparator|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
11422913|NCT01882764|Experimental|HMPL-004 1800 mg/day|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of HMPL-004 (600 mg TID; total dose 1800 mg/day) daily, for 52 weeks.
~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
11422914|NCT01882764|Placebo Comparator|Placebo|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of Placebo tablets TID, daily, for 52 weeks.
~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
11422915|NCT01882751||ConforMIS|Patients with ConforMIS implants
11422916|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
11422917|NCT01882725|Experimental|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
11422918|NCT01882712|Experimental|CD07805/47 Gel 0.5%|active arm
11422919|NCT01882712|Placebo Comparator|CD07805/47 Gel Placebo|Comparator arm
11422920|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
11422921|NCT01882686|Experimental|Classification Based Cognitive Functional Therapy|
11422922|NCT01882673|Experimental|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
11422923|NCT01882673|Active Comparator|Nutrition Control|Computer delivered nutrition education
11422924|NCT01882660|Experimental|Decitabine treatment|Treatment with decitabine
11422925|NCT01882647|Experimental|Active Arm|Topical lotion, applied twice daily
11422926|NCT01882647|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
11422927|NCT01882634|Experimental|Ultrasound arm|
11422930|NCT01882608|No Intervention|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
11422931|NCT01882608|Experimental|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
11422932|NCT01882595|Experimental|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
11422933|NCT01882595|Active Comparator|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
11422934|NCT01882569||Back surgery|
11422935|NCT01882556|Experimental|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
11422936|NCT01882556|Placebo Comparator|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
11422937|NCT01882543|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
11422938|NCT01882543|Placebo Comparator|Placebo|1 x placebo capsule daily
11422939|NCT01882530|Placebo Comparator|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422940|NCT01882530|Experimental|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422941|NCT01882530|Experimental|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422942|NCT01882530|Experimental|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422943|NCT01882530|Experimental|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422944|NCT01882530|Experimental|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422945|NCT01882530|Experimental|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422946|NCT01882530|Experimental|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
11422947|NCT01882517|Active Comparator|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
11422948|NCT01882517|Placebo Comparator|Placebo yogurt|Dietary Supplement: Placebo yogurt
11422949|NCT01882504|Experimental|gevokizumab|Solution for subcutaneous injection
11422950|NCT01882491|Placebo Comparator|Placebo|
11422951|NCT01882491|Experimental|gevokizumab|
11422952|NCT01882478||failure to respond to RF ablation|patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions
11422953|NCT01882465|Other|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
11422954|NCT01882465|Other|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
11422955|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
11422956|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
11422957|NCT01882465|Other|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
11422958|NCT01882465|Other|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
11422959|NCT01882452|Experimental|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
11422960|NCT01882452|Active Comparator|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
11422961|NCT01882439|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
11422962|NCT01882439|Experimental|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
11422965|NCT01882426|Active Comparator|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
11422966|NCT01882426|Placebo Comparator|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
11422967|NCT01882413||Patients with Planned Cataract Removal|Patients with planned cataract removal surgery are evaluated for the presence of inflammatory dry eye disease. No treatment is administered.
11422968|NCT01882400|Experimental|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
11422969|NCT01882387|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
11422970|NCT01882374|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
11422971|NCT01882361|Active Comparator|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
11422972|NCT01882361|Placebo Comparator|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
11422973|NCT01882348|No Intervention|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.
~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.
~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
11422974|NCT01882348|Experimental|Intervention|The Intervention Group will receive the CEASE Intervention
11422975|NCT01882335|Experimental|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
11422976|NCT01882335|No Intervention|Control|No peer support for exclusive breastfeeding
11422977|NCT01882322|Experimental|Advagraf conversion group|Oral
11422978|NCT01882322|Active Comparator|Prograf maintenance group|Oral
11422979|NCT01882296|Experimental|AGSPT_10|tablet, 10mg, QD, 7days
11422980|NCT01882296|Experimental|AGSPT_20|tablet, 20mg, QD, 7days
11422981|NCT01882296|Experimental|AGSPT_40|tablet, 20mg x 2, QD, 7days
11422982|NCT01882296|Active Comparator|Pantoprazole_20|tablet, 20mg, QD, 7days
11422983|NCT01882296|Active Comparator|Pantoprazole_40|tablet, 40mg, QD, 7days
11422984|NCT01882283|Experimental|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
11422985|NCT01882283|Placebo Comparator|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
11422986|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
11422987|NCT01882257|No Intervention|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
11422988|NCT01882257|Experimental|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
11422989|NCT01882257|Experimental|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
11422990|NCT01882244|Experimental|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
11422991|NCT01882244|Active Comparator|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
11422992|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
11422993|NCT01882218|Active Comparator|Standard treatment|Standard liver surgery and post-operative treatment
11422994|NCT01882218|Experimental|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
11422995|NCT01882205|Active Comparator|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
11422996|NCT01882205|Experimental|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
11422997|NCT01882205|Active Comparator|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
11422998|NCT01882205|Experimental|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
11422999|NCT01882205|Active Comparator|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
11423000|NCT01882205|Experimental|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
11423001|NCT01882192|Experimental|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
11423002|NCT01882192|No Intervention|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
11423003|NCT01882179|Placebo Comparator|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
11423004|NCT01882179|Active Comparator|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible
~In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
11423005|NCT01882166|Experimental|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
11423006|NCT01882166|Experimental|puregon|subcutaneous 150 IE Puregon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
11423007|NCT01882153|Experimental|Developmentally Based Intervention|
11423008|NCT01882153|Experimental|Behaviorally Based Intervention|
11423009|NCT01882140|Experimental|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
11423010|NCT01882140|Placebo Comparator|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
11423011|NCT01882127|Active Comparator|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
11423012|NCT01882127|Experimental|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
11423013|NCT01882101|Experimental|Posterior tibial nerve stimulation|
11423014|NCT01882101|Experimental|Biofeedback|
11423015|NCT01882088|Experimental|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
11423016|NCT01882075|Active Comparator|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
11423017|NCT01882075|Experimental|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
11423018|NCT01882062|Experimental|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
11423019|NCT01882049|Experimental|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
11423020|NCT01882036|Active Comparator|Gastric Bypass w/ matched hypocaloric diet|
11423021|NCT01882036|Active Comparator|Hypocaloric Diet|
11423022|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders
11423023|NCT01882023||Healthy Controls|Age- and gender matched healthy controls
11423024|NCT01882010|Sham Comparator|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
11423025|NCT01882010|Placebo Comparator|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
11423026|NCT01882010|Experimental|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
11423027|NCT01881997|Placebo Comparator|Normal Saline|IM normal saline
11423028|NCT01881997|Experimental|Fentanyl|IM Fentanyl
11423029|NCT01881984|Experimental|Ravicti|Open Label Study
11423030|NCT01881971|Placebo Comparator|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
11423031|NCT01881971|Experimental|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
11423032|NCT01881958|Experimental|DiaPep277®|
11423033|NCT01881945|Experimental|Physiological measurments|
11423034|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
11423035|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
11423099|NCT01881516|Active Comparator|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
11423100|NCT01881516|Sham Comparator|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
11423036|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
11423037|NCT01881919|Experimental|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
11423038|NCT01881919|Placebo Comparator|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
11423039|NCT01881906|Other|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
11423040|NCT01881906|Other|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
11423041|NCT01881893|No Intervention|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
11423042|NCT01881893|Experimental|ACHD-CARE Program|"Group based psychosocial intervention.
~Educational: congenital heart disease information
~Behavioral: cognitive behavioral therapy
~Behavioral: social interactions and communication skills"
11423043|NCT01881880|Other|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
11423044|NCT01881867|No Intervention|Cohort I (no therapy)|Patients receive no treatment (observation) after completion of standard sipuleucel-T therapy.
11423045|NCT01881867|Experimental|Cohort II (glycosylated recombinant human interleukin-7)|Patients receive glycosylated recombinant human interleukin-7 SC every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
11423046|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
11423047|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
11423048|NCT01881841|No Intervention|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
11423049|NCT01881841|Experimental|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
11423050|NCT01881828|Experimental|Metformin|Metformin 2000 mg per day
11423051|NCT01881828|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.
~The placebo product will contain the following components:
~Micosolle™, silica based excipient
~Silicified Micro Crystalline Cellulose, National Formulary
~Safflower Oil, United States Pharmacopeia
~K-30 Povidone Powder
~Magnesium Stearate, National Formulary (Vegetable source)
~Fumed Silica, National Formulary"
11423052|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
11423053|NCT01881802||morphine or heroin dependence patients|
11423054|NCT01881802||normal control group|
11423055|NCT01881789|Experimental|Oprozomib, Lenalidomide and Dexamethasone (ORd)|Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15,16, 22 and 23 in combination with lenalidomide at a dose of 25 mg on Days 1-21, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles.
11423056|NCT01881789|Experimental|Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)|Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15, 16, 22 and 23 in combination with oral cyclophosphamide at a dose of 300 mg/m2 on Days 1, 8, and 15, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles
11423057|NCT01881776|Active Comparator|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
11423058|NCT01881776|Active Comparator|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
11423059|NCT01881776|No Intervention|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
11423060|NCT01881763|Experimental|Ketamine|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
11423061|NCT01881763|Active Comparator|Methohexital|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
11423062|NCT01881750|Experimental|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
11423063|NCT01881750|Placebo Comparator|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
11423064|NCT01881737|Experimental|Pregnenolone|Pregnenolone up to 500 mg per day
11423065|NCT01881724|No Intervention|Usual Care|
11423066|NCT01881724|Experimental|sleep education program|
11423067|NCT01881711|Experimental|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
11423068|NCT01881711|Active Comparator|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
11423069|NCT01881711|Experimental|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
11423070|NCT01881711|Active Comparator|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
11423071|NCT01881711|Experimental|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
11423072|NCT01881711|Active Comparator|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
11423073|NCT01881672||Coma patients in ICU under mechanical ventilation|
11423074|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
11423075|NCT01881646|Experimental|Positron emission tomography (PET)|Positron emission tomography (PET) using [11C]PBR28
11423076|NCT01881633|Experimental|ISU302|15 U/kg I.V. injection
11423077|NCT01881633|Experimental|ISU302 30 U/kg|Drug ISU302 I.V. injection
11423078|NCT01881633|Experimental|ISU302 60 U/kg|Drug ISU302 I.V. injection
11423079|NCT01881633|Placebo Comparator|Placebo|ISU302 Placebo I.V. injection
11423080|NCT01881620|Experimental|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
11423081|NCT01881607|No Intervention|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
11423082|NCT01881607|Experimental|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
11423083|NCT01881594|Active Comparator|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
11423084|NCT01881594|Experimental|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
11423085|NCT01881581|Experimental|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
11423086|NCT01881581|Experimental|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
11423087|NCT01881581|Experimental|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
11423088|NCT01881581|Experimental|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
11423089|NCT01881581|Experimental|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
11423090|NCT01881581|Experimental|High dose MVA or Placebo|300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
11423091|NCT01881581|Experimental|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
11423092|NCT01881581|Experimental|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
11423093|NCT01881568|Experimental|Experimental|"Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:
~50mL by irrigation before wound closure
~50mL by intraarticular administration (Drenofast) after wound closure.
~Intravenous administration of Normal saline (0.9% sodium chloride) as follow:
~100mL before tourniquet realised
~100mL 3 hours after surgery"
11423094|NCT01881568|Active Comparator|Comparator|"Topical administration of Normal saline (0.9% sodium chloride) as follow:
~50mL by irrigation before wound closure
~50mL by intraarticular administration (Drenofast) after wound closure
~Intravenous administration of two dosis of Tranexamic Acid as follow:
~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised
~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
11423095|NCT01881555|Other|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.
~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
11423096|NCT01881555|Other|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
11423097|NCT01881529||Limited Scleroderma|
11423098|NCT01881529||Diffuse Scleroderma|
11423229|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
11423102|NCT01881490|Active Comparator|Group 1|120 Children with Crohn's disease undergoing MRE & colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
11423103|NCT01881490|Active Comparator|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
11423104|NCT01881477|Experimental|kinetics modalities|passive movements active movements assisted movements resisted movements
11423105|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
11423106|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
11423107|NCT01881425|Experimental|InnFocus MicroShunt|InnFocus MicroShunt
11423108|NCT01881425|Active Comparator|Trabeculectomy|glaucoma surgery to reduce IOP
11423109|NCT01881412|Experimental|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
11423110|NCT01881412|Placebo Comparator|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
11423111|NCT01881399|Experimental|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:
~Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)
~Virtual cholangiography (enhanced-reality) superimposed on fluorescence images
~Conventional IOC (intraoperative cholangiography)"
11423112|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
11423113|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
11423114|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
11423115|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
11423116|NCT01881373|Experimental|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
11423117|NCT01881373|Other|Delayed Optimized CHL program|Comparison community that participated in community engagement process and received delayed optimized program.
11423118|NCT01881373|No Intervention|Temporal|Communities assessed for temporal trends in anthropometry.
11423119|NCT01881360|Experimental|Gluten-free diet|
11423120|NCT01881360|Active Comparator|Hypocaloric diet|
11423121|NCT01881347|Experimental|Active First|Active resveratrol first, placebo second
11423122|NCT01881347|Experimental|Placebo first|Placebo first, active resveratrol second
11423123|NCT01881321|Experimental|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
11423124|NCT01881321|No Intervention|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
11423125|NCT01881308|Active Comparator|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
11423126|NCT01881308|Experimental|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
11423127|NCT01881308|Active Comparator|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
11423128|NCT01881308|Experimental|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
11423129|NCT01881308|Other|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
11423130|NCT01881295|Placebo Comparator|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
11423131|NCT01881295|Experimental|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
11423132|NCT01881295|Experimental|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
11423133|NCT01881295|Experimental|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
11423134|NCT01881295|Experimental|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
11423135|NCT01881295|Experimental|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
11423136|NCT01881295|Experimental|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
11423137|NCT01881295|Experimental|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
11423138|NCT01881295|Experimental|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
11423139|NCT01881282|Experimental|Carraghenates Cream|
11423140|NCT01881282|Active Comparator|Mayinglong Musk Hemorrhoid Ointment|
11423141|NCT01881269||No treatment|No treatment, prospective observational
11423142|NCT01881243||Adult patients resuscitated from cardiac arrest|
11423143|NCT01881230|Experimental|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
11423328|NCT01879865|Other|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
11423144|NCT01881230|Experimental|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
11423145|NCT01881230|Active Comparator|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
11423146|NCT01881217|Experimental|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
11423147|NCT01881217|Experimental|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
11423148|NCT01881217|Experimental|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
11423149|NCT01881204|Experimental|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
11423150|NCT01881204|Experimental|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
11423151|NCT01881204|Placebo Comparator|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
11423152|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
11423153|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
11423154|NCT01881178|Active Comparator|Apricot|Supplement: Apricot Juice
11423155|NCT01881178|Experimental|Nopalea|Supplement: Nopalea
11423156|NCT01881165|Experimental|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
11423157|NCT01881165|Placebo Comparator|Placebo|A capsule containing control formulation
11423158|NCT01881152|Experimental|Intervention|Educational campaign
11423159|NCT01881152|Other|Control|Usual care
11423160|NCT01881139|Experimental|experimental 1|men with exercise training for 3 months
11423161|NCT01881126|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
11423162|NCT01881126|Active Comparator|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
11423163|NCT01881113|Experimental|AC-170 0.24%|
11423164|NCT01881113|Placebo Comparator|AC-170 0%|
11423165|NCT01881100|Experimental|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
11423166|NCT01881100|Active Comparator|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
11423167|NCT01881087|Experimental|Levo-7.5 mg|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 7.5 mg. Single Dose.
11423168|NCT01881087|Experimental|Levo-9.37|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 9.37 mg. Single Dose.
11423169|NCT01881087|Active Comparator|Levo-11.25|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 11.25 mg. Single Dose.
11423170|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
11423171|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
11423172|NCT01881048|No Intervention|Arm I|Patients undergo observation.
11423173|NCT01881048|Experimental|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
11423174|NCT01881048|Experimental|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
11423175|NCT01881035|Experimental|Renal nerve denervation|Renal nerve denervation
11423176|NCT01881022|Experimental|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
11423177|NCT01881009|Experimental|Inpatient overnight|Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
11423178|NCT01881009|Experimental|Summer Camp Session|Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.
11423179|NCT01880996|Experimental|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
11423180|NCT01880996|No Intervention|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
11423181|NCT01880970|Active Comparator|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
11423182|NCT01880970|Placebo Comparator|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
11423183|NCT01880970|No Intervention|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
11423184|NCT01880957|Other|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
11423185|NCT01880957|Other|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
11423186|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
11423187|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
11423188|NCT01880931|Experimental|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
11423189|NCT01880931|Experimental|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
11423190|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
11423191|NCT01880905|Experimental|female undergoing gynecological surgery|
11423192|NCT01880892|Experimental|Post cricopharyngeal myotomy|There is only one arm to the study. This is patients who have undergone cricopharyngeal myotomy for Zenker's diverticulum. Their levels of laryngopharyngeal reflux will be measured using the Restech Dx-pH device.
11423193|NCT01880879|Experimental|helios stent|the group with helios stent implanted
11423194|NCT01880866|Experimental|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
11423195|NCT01880853|Experimental|group 1|screening with mammography alone
11423196|NCT01880853|Experimental|group 2|screening with ultrasonography alone
11423197|NCT01880853|Experimental|group 3|screening with both mammography and ultrasound
11423198|NCT01880840|Active Comparator|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
11423199|NCT01880840|Active Comparator|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
11423200|NCT01880827|Experimental|Royx-en-Y surgery|Blood flow after surgery
11423201|NCT01880827|Active Comparator|Control|Healthy volunteer group, GIP, GLP-1 and MMS studies
11423202|NCT01880827|Experimental|Sleeve gastrectomy|Blood flow after surgery
11423203|NCT01880814|Experimental|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
11423204|NCT01880814|Experimental|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
11423205|NCT01880788||CNV secondary to CSC|
11423206|NCT01880788||CSC without CNV|
11423207|NCT01880788||CNV secondary to advanced AMD|
11423208|NCT01880775|Experimental|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
11423209|NCT01880775|Active Comparator|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
11423210|NCT01880749|Experimental|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
11423211|NCT01880736|Experimental|IDeg OD Flexible Dose|
11423212|NCT01880736|Experimental|IDeg OD Fixed Dose|
11423213|NCT01880736|Experimental|IDeg OD Simple|
11423214|NCT01880736|Experimental|IDeg OD Stepwise|
11423215|NCT01880723|Experimental|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
11423216|NCT01880723|Placebo Comparator|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
11423217|NCT01880710|Active Comparator|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
11423218|NCT01880710|Experimental|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
11423219|NCT01880697|Experimental|TIVc (≥18 to ≤ 60 years) + TIVc (≥ 61 years)|Subjects in each age cohort received one dose of the cell-derived trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVc) formulation 2013/2014 Northern Hemisphere
11423220|NCT01880684||Passive Leg Rising|
11423221|NCT01880671|Experimental|Migraine Medical Device|
11423222|NCT01880671|Placebo Comparator|Inactive Migraine Medical Device|
11423223|NCT01880658|Experimental|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
11423224|NCT01880645|Other|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
11423225|NCT01880632|Experimental|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
11423226|NCT01880619|Placebo Comparator|Group A|Patients in this group will receive placebo
11423227|NCT01880619|Active Comparator|Group B|Patients in this group will receive Tamsulosin
11423228|NCT01880619|Active Comparator|Group C|Patients in this group will receive Solifenacin
11423230|NCT01880593|Experimental|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
11423231|NCT01880593|Placebo Comparator|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
11423232|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
11423233|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
11423234|NCT01880567|Experimental|Treatment (ibrutinib, rituximab)|Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11423235|NCT01880554|Other|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
11423236|NCT01880541|Experimental|hypnosedation|hypnosedation
11423237|NCT01880541|Other|general anesthesia|general anesthesia
11423238|NCT01880528|Experimental|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
11423239|NCT01880528|Placebo Comparator|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
11423240|NCT01880515|Experimental|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
11423241|NCT01880515|No Intervention|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
11423242|NCT01880502|Experimental|Belviq 10mg|
11423243|NCT01880502|Experimental|Belviq 20mg|
11423244|NCT01880502|Placebo Comparator|Placebo|
11423245|NCT01880489|Experimental|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
11423246|NCT01880489|No Intervention|Wait List Control Condition|
11423247|NCT01880476|Experimental|Home visits and group program|
11423248|NCT01880463|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day
~Fish oil placebo"
11423249|NCT01880463|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
11423250|NCT01880463|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo
~fish oil placebo"
11423251|NCT01880463|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
11423252|NCT01880450|Experimental|Project Prepared|
11423253|NCT01880450|Active Comparator|TEEN-Teen Education & Employment Network|
11423254|NCT01880437|Experimental|Vismodegib|
11423255|NCT01880424|Placebo Comparator|controlled arm|
11423256|NCT01880424|Experimental|treatment arm|
11423257|NCT01880411|Experimental|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
11423258|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
11423259|NCT01880385|Experimental|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
11423260|NCT01880372|Experimental|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
11423261|NCT01880372|No Intervention|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
11423262|NCT01880359|Placebo Comparator|Radiotherapy+ Cisplatin+ Placebo|Accelerated radiotherapy (Therapeutic Planning Target Volume (PTV): 70 Gray (Gy), 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) Patients will receive placebo (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only).
11423263|NCT01880359|Experimental|Radiotherapy+ Cisplatin+ Nimorazole|"Accelerated radiotherapy (Therapeutic PTV: 70 Gy, 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) .
~Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only)."
11423326|NCT01879878|Experimental|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
11423264|NCT01880346|Active Comparator|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
11423265|NCT01880346|Active Comparator|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
11423266|NCT01880333|Experimental|Children on Modified Atkin Diet|
11423267|NCT01880320|Experimental|CD0271 0.3% /CD1579 2.5% Gel|active arm
11423268|NCT01880320|Active Comparator|CD0271 0.1% / CD1579 2.5%|Comparator arm
11423269|NCT01880320|Placebo Comparator|Topical Gel Vehicle|Placebo arm
11423270|NCT01880307|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
11423271|NCT01880307|Active Comparator|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
11423272|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
11423273|NCT01880281|Active Comparator|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.
~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
11423274|NCT01880281|Active Comparator|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.
~The investigational's day, they will receive 1g of bicarbonate."
11423275|NCT01880268|Experimental|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
11423276|NCT01880268|Experimental|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
11423277|NCT01880255|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
11423278|NCT01880255|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
11423279|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with
~Diabetes (all types)
~Small vessels (≤2.75 mm)
~Chronic total occlusion (CTO)
~Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
11423280|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
11423281|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
11423282|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
11423283|NCT01880216|Active Comparator|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
11423284|NCT01880216|Experimental|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
11423285|NCT01880203|Experimental|aspiration for Molecular Cytogenetic Analysis.|
11423286|NCT01880190|Active Comparator|Ringer's Lactate|Crystalloid solution
11423287|NCT01880190|Active Comparator|HES 130/0.4 and Ringer's Lactate|Colloid solution
11423288|NCT01880177||Current smokers|Current smokers (>10 pk yrs.)
11423289|NCT01880177||Ex-smokers|Ex-smokers with a history of >10 pk yrs
11423290|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
11423291|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
11423292|NCT01880151|Experimental|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
11423293|NCT01880151|Experimental|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
11423294|NCT01880151|Experimental|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
11423295|NCT01880138|Experimental|watching animated cartoon|
11423296|NCT01880138|Placebo Comparator|not watching animated cartoon|
11423327|NCT01879878|Placebo Comparator|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
11423297|NCT01880125|Other|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
11423298|NCT01880125|Other|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
11423299|NCT01880112|Experimental|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
11423300|NCT01880112|Active Comparator|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
11423301|NCT01880099|Placebo Comparator|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
11423302|NCT01880099|Active Comparator|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
11423303|NCT01880099|Active Comparator|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
11423304|NCT01880086|Experimental|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
11423305|NCT01880086|Placebo Comparator|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
11423306|NCT01880073|Experimental|FemVue device|FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.
11423307|NCT01880060|Experimental|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
11423308|NCT01880060|Experimental|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
11423309|NCT01880047|Active Comparator|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
11423310|NCT01880047|Placebo Comparator|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
11423311|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
11423312|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
11423313|NCT01879982||Wellness Wearable System & Smartphone|
11423314|NCT01879969|Experimental|asymmetric patients, classic procedure|random selected
11423315|NCT01879969|Experimental|asymmetric patients, computer assisted|random selected
11423316|NCT01879956|Active Comparator|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
11423317|NCT01879956|Placebo Comparator|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
11423318|NCT01879943|Experimental|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.
~Interventions:
~Device: PillCam COLON 2 on D0
~Procedure: Standard colonoscopy on D1"
11423319|NCT01879930|Active Comparator|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
11423320|NCT01879930|Placebo Comparator|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
11423321|NCT01879917|Active Comparator|Liraglutide|1.8 mg
11423322|NCT01879917|Placebo Comparator|Saline|
11423323|NCT01879904|Experimental|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
11423324|NCT01879891|Other|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.
~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
11423325|NCT01879891|Other|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
11423330|NCT01879852|Active Comparator|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
11423331|NCT01879852|Experimental|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
11423332|NCT01879839|No Intervention|Control Group|Patients who don't follow a special diet.
11423333|NCT01879839|Other|Diet Group|Patients who subsist on a special diet.
11423334|NCT01879826|Sham Comparator|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
11423335|NCT01879826|Experimental|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
11423336|NCT01879813|Active Comparator|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
11423337|NCT01879813|Placebo Comparator|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
11423338|NCT01879800|No Intervention|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
11423339|NCT01879800|Experimental|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
11423340|NCT01879787|Experimental|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
11423341|NCT01879787|Experimental|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
11423342|NCT01879787|Experimental|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
11423343|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
11423344|NCT01879787|Experimental|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
11423345|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
11423346|NCT01879787|No Intervention|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
11423347|NCT01879774|Other|Patients with hyponatremia|Neuropsychological and motoric tests are conducted in patients with hyponatremia.
11423348|NCT01879774|Other|Patients with normal serum sodium|Neuropsychological and motoric tests are conducted in patients with normal serum sodium.
11423349|NCT01879761||Immunosuppressed|"Immunosuppressed includes patients with any one of the following:
~a diagnosis of a hematological malignancy
~a diagnosis of HIV
~myelosuppressive chemotherapy in the previous 90 days
~immune-modulating medications in the previous 90 days"
11423350|NCT01879761||Non-Immunosuppressed|Subject does not fit immunosuppressed criteria
11423351|NCT01879748|Experimental|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
11423352|NCT01879748|Placebo Comparator|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
11423353|NCT01879735|Experimental|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
11423354|NCT01879735|Experimental|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
11423355|NCT01879722|Experimental|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
11423356|NCT01879722|Experimental|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
11423357|NCT01879722|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
11423358|NCT01879722|Experimental|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
11423359|NCT01879722|Experimental|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
11423360|NCT01879722|Placebo Comparator|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
11423361|NCT01879709|Experimental|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
11423362|NCT01879709|Placebo Comparator|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
11423363|NCT01879709|Active Comparator|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
11423364|NCT01879696|Experimental|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
11423365|NCT01879696|No Intervention|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
11423366|NCT01879683|Experimental|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
11423367|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
11423368|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
11423369|NCT01879657|Experimental|68Ga-DOTATATE PET scans|"Will perform 68Ga-DOTATATE PET scans on subjects. The same anatomic areas will be imaged with 68Ga-DOTATATE PET and 111In-penteoctreotide Scintigraphy to ensure relevant comparison of lesion detection.
~The images from 68Ga-DOTATATE PET/CT will be reported by an experienced nuclear medicine physician who will be unaware of the results of the previous 111Inpenteoctreotide study. Areas of abnormal focal uptake will be documented. These areas of abnormal uptake will be compared with cross-sectional imaging (CT or MRI)to confirm the presence of lesions. The images from 111In- penteoctreotide Scintigraphy will be reported independently by another experienced nuclear medicine physician."
11423370|NCT01879644|Active Comparator|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
11423371|NCT01879644|Active Comparator|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
11423372|NCT01879644|Active Comparator|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
11423373|NCT01879644|Active Comparator|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
11423374|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
11423375|NCT01879618|Experimental|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
11423376|NCT01879605|Experimental|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
11423377|NCT01879605|Active Comparator|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
11423378|NCT01879605|No Intervention|Control grup|No intervention
11423379|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
11423380|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
11423381|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
11423382|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
11423383|NCT01879579|Experimental|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
11423384|NCT01879579|No Intervention|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
11423385|NCT01879553|Experimental|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
11423386|NCT01879553|Experimental|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
11423387|NCT01879540|Experimental|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
11423388|NCT01879527|Active Comparator|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
11423389|NCT01879527|Placebo Comparator|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
11423390|NCT01879514|Experimental|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
11423391|NCT01879514|Placebo Comparator|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
11423392|NCT01879501|Experimental|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
11423393|NCT01879501|No Intervention|Usual Care|Usual care delivered at the Singapore National Eye Centre
11423394|NCT01879488|Active Comparator|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
11423395|NCT01879488|Active Comparator|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
11423396|NCT01879475|Experimental|032-11|032-11 topical haemostat.
11423397|NCT01879475|Active Comparator|Floseal (R)|Floseal(R) topical haemostat
11423398|NCT01879462|Experimental|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
11423399|NCT01879462|Experimental|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
11423400|NCT01879462|Experimental|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
11423401|NCT01879462|Experimental|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
11423402|NCT01879462|Experimental|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
11423403|NCT01879462|Experimental|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
11423404|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)
~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.
~The measure of outcome is composite and includes several changes:
~Changes in:
~cell death (% from tested cells)
~cell cycle (% cells in G1, G2 and S phases)
~cell migration (% closure in Scratch test)
~cell invasion (% cells passing through membrane in Transwell assay)
~RNA repertoire (Fold change)
~miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
11423405|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
11423406|NCT01879423|Experimental|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
11423407|NCT01879423|Experimental|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
11423408|NCT01879410|Experimental|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
11423409|NCT01879410|Active Comparator|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
11423410|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
11423411|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
11423412|NCT01879384|Experimental|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
11423413|NCT01879371|Active Comparator|Ibuprofen (Brufen®)|film-coated tablet
11423414|NCT01879371|Active Comparator|Ibuprofen (Nurofen Immedia®)|film-coated tablet
11423415|NCT01879371|Experimental|Ibuprofen+caffeine|fixed-dose-combination (FDC)
11423416|NCT01879358|Active Comparator|ORSIRO stent|ORSIRO stent group
11423417|NCT01879358|Active Comparator|NOBORI stent|NOBORI stent group
11423418|NCT01879345|Experimental|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
11423419|NCT01879345|Experimental|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
11423420|NCT01879345|Placebo Comparator|Placebo|placebo tablets
11423421|NCT01879332|Placebo Comparator|Placebo|Matching placebo tablets for oral administration
11423422|NCT01879332|Experimental|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
11423423|NCT01879332|Experimental|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
11423526|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
11423424|NCT01879319|Experimental|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
11423425|NCT01879319|Experimental|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
11423426|NCT01879293|Experimental|Metformin group|In this group, metformin 0.5 three times daily for one year.
11423427|NCT01879293|Placebo Comparator|Placebo group|In this group, placebo will be given twice daily for one year.
11423428|NCT01879280|Experimental|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
11423429|NCT01879280|Active Comparator|traditional pterional craniotomy|traditional pterional craniotomy
11423430|NCT01879267|Other|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
11423431|NCT01879267|Other|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
11423432|NCT01879254||DBS for OCD|
11423433|NCT01879241|Experimental|Rasagiline|"Rasagiline
~1 mg/day; 18 months"
11423434|NCT01879241|Placebo Comparator|Placebo|once daily, 18 months
11423435|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) will be 100 mg tablet orally each morning for 6 months.
11423436|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be orally each morning for 6 months.
11423437|NCT01879215|Active Comparator|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
11423438|NCT01879215|Active Comparator|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
11423439|NCT01879202|Active Comparator|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
11423440|NCT01879202|Placebo Comparator|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
11423441|NCT01879189|Experimental|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
11423442|NCT01879189|No Intervention|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
11423443|NCT01879176|Experimental|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
11423444|NCT01879176|No Intervention|Control|No filter will be installed on the CPB machine.
11423445|NCT01879163|Experimental|Group A|The first six volunteers will receive an intradermal injection of 1x10^7 pfu MVA85A-IMX313 (non-randomised).
11423446|NCT01879163|Active Comparator|Group B|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
11423447|NCT01879163|Active Comparator|Group C|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
11423448|NCT01879150|Experimental|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.
~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.
~Subjects will be followed-up for 50 weeks post-procedure."
11423449|NCT01879137||healthy adults|
11423450|NCT01879137||Patients with a polyuria-polydipsia syndrome|
11423451|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
11423452|NCT01879111|Experimental|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
11423453|NCT01879111|No Intervention|state-of-art depression screening|
11423454|NCT01879098|Placebo Comparator|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
11423455|NCT01879098|Experimental|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11423456|NCT01879098|Experimental|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11423457|NCT01879098|Experimental|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
11423458|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
11423459|NCT01879059|Experimental|Exercise|5 days of inactivity followed by a 1 day return to physical activity
11423460|NCT01879046|Experimental|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
11423461|NCT01879033|Active Comparator|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
11423462|NCT01879033|Placebo Comparator|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
11423463|NCT01879020|Experimental|TA-8995 1 mg|
11423464|NCT01879020|Experimental|TA-8995 2.5 mg|
11423465|NCT01879020|Experimental|TA-8995 5 mg|
11423466|NCT01879020|Experimental|TA-8995 10 mg|
11423467|NCT01879020|Experimental|TA-8995 25 mg|
11423468|NCT01879020|Placebo Comparator|Placebo (TA-8995 1mg)|
11423469|NCT01879020|Placebo Comparator|Placebo (TA-8995 2.5mg)|
11423470|NCT01879020|Placebo Comparator|Placebo (TA-8995 5mg)|
11423471|NCT01879020|Placebo Comparator|Placebo (TA-8995 10mg)|
11423472|NCT01879020|Placebo Comparator|Placebo (TA-8995 25mg)|
11423473|NCT01879007|Experimental|group 1|received one intravenous administration and one oral medication with interval of 1 week,
11423474|NCT01879007|Experimental|group 2|received one oral administration and one intravenous medication with interval of 1 week
11423475|NCT01878994|Placebo Comparator|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
11423476|NCT01878994|Experimental|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
11423477|NCT01878968|Experimental|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
11423478|NCT01878968|Experimental|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
11423479|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
11423480|NCT01878942|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
11423481|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held
~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
11423482|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up
~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
11423483|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
11423484|NCT01878890|Experimental|Efavirenz|Efavirenz
11423485|NCT01878864|Experimental|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
11423486|NCT01878864|Active Comparator|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
11423487|NCT01878851||pulpotomy|
11423488|NCT01878838|Active Comparator|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
11423489|NCT01878838|Active Comparator|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
11423490|NCT01878825|Experimental|Fluviral 18-60 Years Group|Subjects aged between 18 and 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11423491|NCT01878825|Experimental|Fluviral >60 Years Group|Subjects aged > 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm
11423492|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
11423493|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Elderly Group|Subjects >60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
11423494|NCT01878799|Experimental|HIV|Subjects with HIV and HCV
11423495|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
11423496|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
11423497|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
11423498|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
11423499|NCT01878747|Experimental|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
11423500|NCT01878747|No Intervention|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
11423501|NCT01878734|No Intervention|Control|This arm will act as a control and will not receive Micronutrient Powders
11423502|NCT01878734|Experimental|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
11423503|NCT01878721||Staphylococcus aureus bacteremia|PET/CT in patients with Staphylococcus aureus bacteremia
11423504|NCT01878721||Salmonella spp. bacteremia|PET/CT in patients with Salmonella spp. bacteremia
11423505|NCT01878721||Endocarditis|PET/CT in patients with infective endocarditis
11423506|NCT01878721||Pacemaker infection|PET/CT in patients with pacemaker infection
11423507|NCT01878721||Vasculitis|PET/CT in patients with vasculitis
11423508|NCT01878708|Experimental|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
11423509|NCT01878695|Experimental|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.
~600mg n-acetylcysteine orally twice daily except on day of infusion"
11423510|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
11423511|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
11423512|NCT01878656|Active Comparator|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
11423513|NCT01878656|Active Comparator|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
11423514|NCT01878643|Placebo Comparator|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
11423515|NCT01878643|Experimental|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
11423516|NCT01878630|Experimental|Remote Patient Management|intervention group
11423517|NCT01878630|Active Comparator|Usual Care|control group
11423518|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
11423519|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
11423520|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
11423521|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
11423522|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
11423523|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
11423524|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
11423525|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
11423527|NCT01878591||Women in active second stage of labour|Ultrasound examinations
11423531|NCT01878565|Experimental|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
11423532|NCT01878565|Other|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
11423533|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
11423534|NCT01878539|Experimental|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
11423535|NCT01878526|Experimental|Omeprazole plus alginic acid and placebo of domperidone|
11423536|NCT01878526|Experimental|Omeprazole plus domperidone and placebo of alginic acid|
11423537|NCT01878513|Experimental|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
11423538|NCT01878513|Experimental|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
11423539|NCT01878513|Experimental|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
11423540|NCT01878500|Experimental|Intraoperative stereotactic imaging|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure.
11423541|NCT01878487|Other|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
11423542|NCT01878474|Experimental|Single ascending dose in Caucasian men|
11423543|NCT01878474|Experimental|Age-effect in Caucasian men|
11423544|NCT01878474|Experimental|Gender-effect in Caucasian women|
11423545|NCT01878474|Experimental|Single ascending dose in Japanese men|
11423546|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Caucasian men|
11423547|NCT01878474|Placebo Comparator|Placebo: Age-effect in Caucasian men|
11423548|NCT01878474|Placebo Comparator|Placeo: Gender-effect in Caucasian women|
11423549|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Japanese men|
11423550|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
11423551|NCT01878461|Experimental|M518101|Proper quantity twice a day
11423552|NCT01878448|Experimental|Anlotinib|
11423553|NCT01878435|Experimental|SMS reminder|
11423554|NCT01878435|Experimental|SMS reminder and Travel subsidy|
11423555|NCT01878435|No Intervention|Control|
11423556|NCT01878435|Experimental|SMS reminder and Travel subsidy 2|
11423557|NCT01878422|Experimental|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus
~FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min
~Day 1,2:
~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours
~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours
~Day 1,2:
~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
11423558|NCT01878422|Experimental|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
11423559|NCT01878422|Experimental|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
11423560|NCT01878422|Experimental|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
11423561|NCT01878422|Experimental|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
11423562|NCT01878422|Experimental|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
11423563|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
11423564|NCT01878409||Healthy Subjects|Healthy Subjects
11423565|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
11423566|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
11423567|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
11423568|NCT01878370|Experimental|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
11423569|NCT01878370|Experimental|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
11423570|NCT01878357|Experimental|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
11423571|NCT01878357|Experimental|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
11423572|NCT01878357|No Intervention|Arm 3|Without MST
11423573|NCT01878344|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
11423574|NCT01878344|Placebo Comparator|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
11423575|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
11423576|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
11423577|NCT01878318|Experimental|RoActemra/Actemra|
11423578|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
11423579|NCT01878292|Placebo Comparator|Placebo|Dose-matched placebo tablets, once per day, oral administration
11423580|NCT01878292|Experimental|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
11423581|NCT01878292|Experimental|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
11423582|NCT01878279||HIV negative|
11423583|NCT01878279||HIV positive|HIV positive children in care
11423584|NCT01878266|Active Comparator|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
11423585|NCT01878266|Active Comparator|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
11423586|NCT01878266|Other|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
11423587|NCT01878253|Experimental|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
11423588|NCT01878240|Active Comparator|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
11423589|NCT01878240|Experimental|Coil embolization during EVAR|coil embolization during Endovascular repair
11423590|NCT01878227|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
11423591|NCT01878227|Active Comparator|Fenofibrate 200mg|Fenofibrate 200mg per day
11423592|NCT01878214|Experimental|Intervention group|Targeted messaging
11423593|NCT01878214|Active Comparator|Control group|Standard messaging
11423594|NCT01878201|Experimental|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
11423595|NCT01878201|Active Comparator|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
11423596|NCT01878188|Experimental|BC-819/PEI and BCG alternating|4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG
11423597|NCT01878188|Experimental|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG
11423598|NCT01878188|Experimental|twice-weekly treatments of BC-819 and BCG|6 twice-weekly treatments of BC-819/PEI and BCG
11423599|NCT01878175|Experimental|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
11423600|NCT01878162|Experimental|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
11423601|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
11423602|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
11423603|NCT01878136|Active Comparator|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)
~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
11423604|NCT01878136|Placebo Comparator|Placebo|"Placebo
~Dose 1 mL sterile saline"
11423605|NCT01878123|Experimental|AMP-110|Escalating doses of AMP-110
11423606|NCT01878123|Placebo Comparator|Placebo|
11423607|NCT01878110|Experimental|COMB|
11423608|NCT01878097|Experimental|Green Dot Bystander Training|Green Dot intervention
11423609|NCT01878097|Active Comparator|Control|Awareness Eduation
11423610|NCT01878084|Other|all study participants|"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)
~The extraction sockets will be allocated either to the control : Extraction socket will be left empty
~or
~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"
11423611|NCT01878071||Single group cross sectional|
11423612|NCT01878058|Other|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
11423613|NCT01878045||American Indians with type 2 diabetes|previously enrolled in OH95-DK-N037
11423614|NCT01878006|Experimental|Morphine|Morphine injection 10 mg/70kg
11423615|NCT01878006|Placebo Comparator|Placebo|Saline injection
11423616|NCT01877967|Experimental|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
11423617|NCT01877967|Placebo Comparator|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
11423618|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
11423619|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
11423620|NCT01877941|Active Comparator|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
11423621|NCT01877928|Experimental|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
11423622|NCT01877928|Active Comparator|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
11423623|NCT01877915|Experimental|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
11423624|NCT01877915|Placebo Comparator|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
11423625|NCT01877902||Pemetrexed 500 mg/m 2|
11423626|NCT01877889|Experimental|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
11423627|NCT01877889|Experimental|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
11423628|NCT01877889|Experimental|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
11423629|NCT01877876||Patient undergoing spine surgery|
11423630|NCT01877863|Experimental|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
11423631|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses
11423632|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
11423633|NCT01877837|Experimental|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.
~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.
~Day Treatment
~-22 Alemtuzumab 3mg IV (test dose)
~-21 Alemtuzumab 10mg IV
~-20 Alemtuzumab 15mg IV
~-19 Alemtuzumab 20mg IV
~-8 Fludarabine 30mg/m2 IV
~-7 Fludarabine 30mg/m2 IV
~-6 Fludarabine 30mg/m2 IV
~-5 Fludarabine 30mg/m2 IV
~-4 Fludarabine 30mg/m2 IV
~-3 Melphalan 140mg/m2 IV
~-2 Rest Day
~-1 Rest Day
~0 Stem Cell Infusion"
11423634|NCT01877824|Experimental|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
11423635|NCT01877824|No Intervention|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
11423636|NCT01877811|Experimental|RXDX-105|
11423637|NCT01877798|Experimental|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
11423638|NCT01877798|Experimental|ScvO2|ScvO2 directed group
11423639|NCT01877785|Experimental|MHAA4549A Arm|
11423640|NCT01877785|Placebo Comparator|Placebo Arm|
11423641|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
11423642|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair.
11423643|NCT01877759|Other|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
11423644|NCT01877746|Experimental|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
11423645|NCT01877746|Experimental|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
11423646|NCT01877746|Other|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
11423647|NCT01877733|Experimental|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
11423648|NCT01877733|No Intervention|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
11423649|NCT01877720|Experimental|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
11423650|NCT01877720|Experimental|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
11423651|NCT01877707|Other|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
11423652|NCT01877694|Experimental|Auriclosene Solution 0.3%|Dosed QID for 4 Days
11423653|NCT01877694|Placebo Comparator|Auriclosene Vehicle|Dosed QID for 4 days
11423654|NCT01877681|Experimental|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
11423655|NCT01877681|Active Comparator|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
11423656|NCT01877668|Experimental|Tofacitinib 5 mgBID x 12 months|
11423657|NCT01877668|Experimental|Tofacitinib 10 mg BID x 12 months|
11423658|NCT01877668|Active Comparator|Adalimumab 40 mg q2 weeks x 12 months|
11423659|NCT01877668|Placebo Comparator|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
11423660|NCT01877668|Placebo Comparator|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
11423661|NCT01877655|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
11423662|NCT01877655|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
11423663|NCT01877642|Other|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
11423664|NCT01877642|Other|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
11423665|NCT01877642|Other|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
11423666|NCT01877642|Other|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
11423667|NCT01877642|Other|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
11423668|NCT01877642|Other|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
11423669|NCT01877642|Other|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
11423670|NCT01877629|Experimental|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
11423671|NCT01877629|Experimental|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
11423672|NCT01877616|Other|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
11423673|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
11423674|NCT01877590|Placebo Comparator|placebo group|An identical placebo daily
11423675|NCT01877590|Experimental|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
11423676|NCT01877577|Active Comparator|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
11423677|NCT01877577|Active Comparator|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
11423678|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
11423679|NCT01877564|No Intervention|Group 2 - No treatment|
11423680|NCT01877551|Active Comparator|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
11423681|NCT01877551|Placebo Comparator|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
11423682|NCT01877538||[11C]donepezil PET|[11C]donepezil is a radiopharmaceutical. It is evaluated whether the binding of [11C]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
11423683|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
11423684|NCT01877512|Active Comparator|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
11423685|NCT01877512|Active Comparator|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
11423686|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
11423687|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
11423688|NCT01877473|Active Comparator|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
11423689|NCT01877473|Active Comparator|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
11423690|NCT01877460|Experimental|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
11423691|NCT01877460|Experimental|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
11423692|NCT01877460|Experimental|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
11423693|NCT01877460|Experimental|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
11423694|NCT01877447|Experimental|cathodal F4|"Transcranial Direct Current Stimulation
~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
11423695|NCT01877447|Experimental|Anodal F3|"Transcranial Direct Current Stimulation'
~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
11423696|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
11423697|NCT01877421|Experimental|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
11423698|NCT01877421|Experimental|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
11423699|NCT01877421|Experimental|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
11423700|NCT01877421|Experimental|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
11423701|NCT01877421|Experimental|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
11423702|NCT01877421|Experimental|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
11423703|NCT01877421|Experimental|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
11423704|NCT01877421|Experimental|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
11423705|NCT01877421|Experimental|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
11423706|NCT01877421|Placebo Comparator|Placebo|Placebo
11423707|NCT01877408|Active Comparator|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
11423708|NCT01877408|Experimental|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
11423709|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
11423710|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
11423711|NCT01877382|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules.
11423712|NCT01877382|Experimental|Part 2, Milademetan Alone|Participants with advanced melanoma and diffuse large B cell lymphoma (DLBCL) receive milademetan alone with different dose schedules.
11423713|NCT01877356|Experimental|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
11423714|NCT01877356|Experimental|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
11423715|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
11423716|NCT01877330|Active Comparator|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
11423717|NCT01877330|Active Comparator|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
11423718|NCT01877317|Experimental|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
11423719|NCT01877304|Experimental|AKITA with program central deposition|Nebulization for central deposition
11423720|NCT01877304|Active Comparator|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
11423721|NCT01877291||Nonsmokers|Young healthy nonsmokers
11423722|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history <2.5 pack years"
11423723|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history ≥ 2.5 pack-years"
11423724|NCT01877278|Active Comparator|active|Group wearing the active device emitting pulsed electromagnetic fileds
11423725|NCT01877278|Placebo Comparator|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
11423726|NCT01877265|Experimental|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SC) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of 1 of 3 treatment periods
11423727|NCT01877265|Experimental|LY2605541 - Source 2|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1of 3 treatment periods
11423728|NCT01877265|Experimental|LY2605541 - Source 3|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1 of 3 treatment periods
11423729|NCT01877252||Endovascular treatment|Angioplasty +/- stent
11423730|NCT01877252||Open treatment|Bypass (vein or prosthetic)
11423731|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
11423732|NCT01877252||Conservative treatment|no vascular intervention
11423733|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
11423734|NCT01877226|Experimental|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
11423735|NCT01877213|Experimental|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
11423736|NCT01877213|No Intervention|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
11423737|NCT01877200||Subjects with diabetes (type 2)|
11423738|NCT01877187|Other|Lipiodol|Lipiodol, 10cc per TACE.
11423739|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
11423740|NCT01877161|Experimental|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
11423741|NCT01877161|Sham Comparator|Control group|Repetitive magnetic stimulation (Sham)
11423742|NCT01877161|Experimental|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
11423743|NCT01877148|Experimental|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
11423744|NCT01877148|Sham Comparator|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
11423745|NCT01877135||Anal AIN3|patients > 18 years, with anal AIN3, without history of anal carcinoma
11423746|NCT01877122|Experimental|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
11423747|NCT01877122|Active Comparator|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
11423748|NCT01877109||Lymphoma|Lymphoma patients
11423749|NCT01877096|Experimental|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
11423750|NCT01877096|Active Comparator|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
11423751|NCT01877083|Experimental|Lenvatinib|
11423752|NCT01877070||early stage prostate patients & their partners/close allies|
11423753|NCT01877057|Experimental|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
11423754|NCT01877044|Placebo Comparator|Placebo|Maltodextrin
11423755|NCT01877044|Experimental|NAXUS 7.5 grams|Arabinoxylan
11423756|NCT01877044|Experimental|NAXUS 15.0 grams|Arabinoxylan
11423757|NCT01877031|Active Comparator|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
11423758|NCT01877031|Experimental|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
11423759|NCT01877018|Experimental|electronic reminder|Electronic reminder introduced into primary care medical health record.
11423760|NCT01877018|No Intervention|Usual care|Usual care control group
11423761|NCT01877005|Experimental|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.
~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
11423762|NCT01876992|Experimental|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.
~For children <50kg:
~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.
~For children ≥50kg:
~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.
~For adults:
~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
11423763|NCT01876992|No Intervention|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.
~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
11423764|NCT01876979|Active Comparator|IMF Screws|Use of IMF screws as a means to wire the jaws.
11423765|NCT01876979|Active Comparator|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
11423766|NCT01876966|Experimental|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
11423767|NCT01876966|Experimental|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
11423768|NCT01876953|Experimental|Treatment (cytarabine, idarubicin, and dasatinib)|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
11423769|NCT01876940|Active Comparator|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
11423770|NCT01876940|Experimental|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
11423771|NCT01876927|Experimental|Arm A|"DOX 4 cycles - Surgery - Follow-up
~DOX:
~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.
~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
11423772|NCT01876927|Experimental|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up
~DOX:
~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.
~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.
~Each cycle will be repeated every 3 weeks."
11423773|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
11423774|NCT01876901|Experimental|ACAD|ACAD
11423775|NCT01876901|Experimental|ACAI|ACAI
11423776|NCT01876875|Experimental|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
11423777|NCT01876875|Active Comparator|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
11423778|NCT01876862|Experimental|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.
~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
11423779|NCT01876849|Experimental|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
11423780|NCT01876836|Experimental|i-gel|i-gel placed after induction
11423781|NCT01876836|Active Comparator|C-LMA|C-LMA placed after induction
11423782|NCT01876823|Experimental|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
11423783|NCT01876810|Experimental|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
11423784|NCT01876810|Placebo Comparator|Placebo pill|One lactose pill twice a day for two weeks.
11423785|NCT01876797|Other|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
11423786|NCT01876784|Experimental|Vandetanib|Vandetanib 300 mg tablet, orally once daily until disease progression or death.
11423787|NCT01876784|Placebo Comparator|Placebo|Placebo matched to vandetanib tablet, orally once daily until disease progression or death.
11423788|NCT01876771|Experimental|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) [177]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.
~Nominal maintenance stage dose of 75 mCi (2.78 GBq) [177]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
11423789|NCT01876758|Experimental|Cognitive Intervention: Memory Training|Memory training before and after ECT
11423790|NCT01876758|Active Comparator|Comparable general mental stimulation|Puzzle games before and after ECT
11423791|NCT01876758|No Intervention|Treatment as Usual|No memory training or puzzle games, just the study evaluations
11423792|NCT01876745||NovoSeven® (activated recombinant factor VII)|
11423793|NCT01876732|Experimental|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
11423794|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
11423795|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
11423796|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
11423797|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
11423798|NCT01876706|Experimental|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
11423799|NCT01876693|No Intervention|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
11423800|NCT01876693|Experimental|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
11423801|NCT01876680|Experimental|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
11423802|NCT01876680|Experimental|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
11423803|NCT01876667|Active Comparator|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
11423804|NCT01876667|Placebo Comparator|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
11423805|NCT01876654|Experimental|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
11423806|NCT01876654|No Intervention|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
11423807|NCT01876641|Experimental|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
11423808|NCT01876628|Placebo Comparator|Flucloxacillin and placebo|Intravenous or oral Flucloxacillin with an oral placebo
11423809|NCT01876628|Active Comparator|Flucloxacillin and Clindamycin|Intravenous or oral Flucloxacillin with oral Clindamycin
11423810|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
11423811|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
11423812|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
11423813|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
11423814|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
11423815|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design
~YH4808 or Diclofenac or YH4808+Diclofenac
~3 week wash out period is between each period."
11423816|NCT01876602|Experimental|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
11423817|NCT01876602|Active Comparator|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
11423818|NCT01876589|Active Comparator|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
11423819|NCT01876589|Active Comparator|Xience Prime|Participant will receive a Xience Prime stent
11423820|NCT01876576|Active Comparator|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
11423821|NCT01876576|Active Comparator|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
11423822|NCT01876563|Active Comparator|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
11423823|NCT01876563|Placebo Comparator|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
11423824|NCT01876550|Experimental|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
11423825|NCT01876550|Active Comparator|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
11423826|NCT01876550|Placebo Comparator|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
11423827|NCT01876537|Active Comparator|Usual surgery|
11423828|NCT01876537|Active Comparator|Hardware wound healing|
11423829|NCT01876524|Experimental|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
11423830|NCT01876524|Experimental|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
11423831|NCT01876524|Sham Comparator|Sham Group|75 patients will be receive tRNS sham 35 sessions.
11423832|NCT01876511|Experimental|Cohort A: MSI Positive Colorectal Cancer|
11423833|NCT01876511|Experimental|Cohort B: MSI Negative Colorectal Cancer|
11423834|NCT01876511|Experimental|Cohort C: MSI Positive Non-Colorectal Cancer|
11423835|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
11423836|NCT01876485|Experimental|Arm 1: Empowering Patients in Chronic Care (EPIC)|Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
11423837|NCT01876485|Active Comparator|Arm 2: Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
11423838|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
11423839|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
11423840|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
11423841|NCT01876459|Other|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
11423842|NCT01876459|Other|"Lewy Body Disease arm"|Patient with Lewy Body Disease
11423843|NCT01876446|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
11423844|NCT01876433|Active Comparator|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
11423845|NCT01876433|Placebo Comparator|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
11423846|NCT01876420|Experimental|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
11423847|NCT01876407|Experimental|Low energy laser|Administration of a low energy laser for oral mucositis.
11423848|NCT01876407|Placebo Comparator|Placebo|
11423849|NCT01876394|Experimental|Coconut oil|
11423850|NCT01876394|Experimental|Canola oil|
11423851|NCT01876394|Experimental|Grapeseed oil|
11423852|NCT01876394|Experimental|Chia oil|
11423853|NCT01876394|Placebo Comparator|Butter|
11423854|NCT01876381|Experimental|OPC-41061|
11423925|NCT01875848|Active Comparator|opioid dose escalation|increase of up to 25% of current opioid dose
11423855|NCT01876368|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
11423856|NCT01876368|Active Comparator|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
11423857|NCT01876355|Experimental|Clonidine|
11423858|NCT01876355|Placebo Comparator|Sodium chloride|
11423859|NCT01876342|Experimental|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
11423860|NCT01876342|Active Comparator|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
11423861|NCT01876329||Rheumatoid Arthritis|Patients with seropositive or seronegative Rheumatoid Arthritis
11423862|NCT01876329||Autoimmune Thyroid Disease (AITD)|Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.
11423863|NCT01876329||Control|Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses
11423864|NCT01876316|Active Comparator|Moxifloxacin|single oral administration of 400mg of moxifloxacin
11423865|NCT01876316|Placebo Comparator|Placebo|single oral administration of 400mg of placebo
11423866|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
11423867|NCT01876290|Experimental|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
11423868|NCT01876290|Placebo Comparator|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
11423869|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
11423870|NCT01876264|Experimental|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
11423871|NCT01876264|Active Comparator|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
11423872|NCT01876251|Experimental|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2
11423873|NCT01876238|Experimental|T-PAT Intervention|Prognosis discussion intervention with study team.
11423874|NCT01876238|Active Comparator|Control: Standard Care|Usual care appointment
11423875|NCT01876225|No Intervention|No coughing|Cervical punch biopsy without forced coughing intervention
11423876|NCT01876225|Experimental|coughing|Forced coughing during cervical punch biopsy
11423877|NCT01876212|Experimental|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).
~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.
~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
11423878|NCT01876212|Experimental|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.
~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.
~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
11423879|NCT01876199|Experimental|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
11423880|NCT01876199|No Intervention|standard follow-up|2-week follow-up appointment with no reminders
11423881|NCT01876186|Experimental|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
11423882|NCT01876186|Active Comparator|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
11423883|NCT01876173|Experimental|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
11423884|NCT01876173|No Intervention|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
11423885|NCT01876160|Experimental|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
11423886|NCT01876160|Experimental|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
11423887|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
11423888|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
11423889|NCT01876134||Elective cardiac surgery|
11423890|NCT01876121||Celecox group|
11424150|NCT01874353|Experimental|Olaparib 300mg tablets|Taken orally twice daily
11423891|NCT01876108|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
11423892|NCT01876108|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
11423893|NCT01876095|Experimental|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:
~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
11423894|NCT01876095|No Intervention|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
11423895|NCT01876082|Experimental|PAZOPANIB|"Pazopanib
~800 mg per day
~oral administration
~at least 1 hour before or 2 hours after a meal,
~until disease progression or for 12 months maximum"
11423896|NCT01876082|Active Comparator|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
11423897|NCT01876069|Active Comparator|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
11423898|NCT01876069|Active Comparator|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
11423899|NCT01876056|Experimental|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
11423900|NCT01876056|No Intervention|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
11423901|NCT01876043|Experimental|plitidepsin|plitidepsin
11423902|NCT01876030|Experimental|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
11423903|NCT01876030|No Intervention|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
11423904|NCT01876017|Other|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
11423905|NCT01876004|Experimental|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
11423906|NCT01876004|Placebo Comparator|Placebo|Prescribed Placebo intramuscularly.
11423907|NCT01875991|Experimental|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
11423908|NCT01875991|Experimental|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
11423909|NCT01875978|Active Comparator|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
11423910|NCT01875952|Other|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
11423911|NCT01875939|Other|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
11423912|NCT01875939|Other|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
11423913|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Single Dose (SD)|
11423914|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
11423915|NCT01875926|Experimental|ALX-0171 Intravenous (IV)|
11423916|NCT01875913|Experimental|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
11423917|NCT01875913|Experimental|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
11423918|NCT01875900|Active Comparator|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
11423919|NCT01875900|Experimental|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
11423920|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
11423921|NCT01875874|Experimental|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
11423922|NCT01875861|Experimental|Intervention|Evidence-Based Quality Improvement plus external facilitation to promote uptake of quality improvement tools and improvement strategies available as part of a national initiative (the MIAMI Project) to disseminate recommendations, tools, and improvement strategies relevant to metabolic monitoring and management.
11423923|NCT01875861|No Intervention|Comparison|"Usual care, in the context of the MIAMI Project."
11423924|NCT01875848|Experimental|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
11423926|NCT01875835|Active Comparator|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
11423927|NCT01875835|Active Comparator|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
11423928|NCT01875822|Experimental|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
11423929|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
11423930|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
11423931|NCT01875796|Experimental|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
11423932|NCT01875796|Active Comparator|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
11423933|NCT01875783|Experimental|OCT imaging|All study participants will undergo optical coherence tomography imaging and will be referred to a retina specialist for further standard care evaluation and management if they are identified as having diabetic macular edema or the scan quality is not sufficient to evaluate macular status.
11423934|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
11423935|NCT01875757|Experimental|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
11423936|NCT01875757|Active Comparator|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
11423937|NCT01875744|Experimental|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
11423938|NCT01875744|Active Comparator|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
11423939|NCT01875731|Experimental|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
11423940|NCT01875731|Active Comparator|Guideline|Strategy based on enforced guideline guided antibiotic use
11423941|NCT01875718|Active Comparator|UC1010 low dose|
11423942|NCT01875718|Active Comparator|UC1010 high dose|
11423943|NCT01875718|Placebo Comparator|Vehicle|
11423944|NCT01875705|Experimental|Stage I-Dose Escalation|
11423945|NCT01875705|Experimental|Stage II-Cohort-Expansion|
11423946|NCT01875679|Active Comparator|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
11423947|NCT01875679|Experimental|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
11423948|NCT01875666|Active Comparator|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
11423949|NCT01875666|Active Comparator|pertuzumab|single dose infusion of pertuzumab (840 mg)
11423950|NCT01875666|Active Comparator|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
11423951|NCT01875666|Active Comparator|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
11423952|NCT01875653|Active Comparator|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:
~Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.
~Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.
~Mode of Administration: Subcutaneous (SC) injections."
11423953|NCT01875653|Experimental|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:
~Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.
~Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.
~Mode of Administration: Subcutaneous (SC) injections."
11423954|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
11423955|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
11423956|NCT01875627|Placebo Comparator|Carbohydrate Noodles|0g Konjac Noodles
11423957|NCT01875627|Experimental|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
11423958|NCT01875627|Experimental|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
11423959|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
11423960|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
11423961|NCT01875588||DOD|Participants that are from IDCRP
11423962|NCT01875588||HIV negative controls|Participants that do not have HIV infection
11423963|NCT01875588||HIV positive|Participants that have HIV infection
11423964|NCT01875575|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
11423965|NCT01875575|Active Comparator|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
11423966|NCT01875575|Placebo Comparator|Placebo|intragastric tap water
11423967|NCT01875562|Experimental|Qishe Pill|
11423968|NCT01875549|Active Comparator|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
11423969|NCT01875549|Active Comparator|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
11423970|NCT01875536|Experimental|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
11423971|NCT01875536|Sham Comparator|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
11423972|NCT01875523|Experimental|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
11423973|NCT01875523|Experimental|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
11423974|NCT01875523|Experimental|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
11423975|NCT01875523|Experimental|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
11423976|NCT01875510|Active Comparator|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
11423977|NCT01875510|Placebo Comparator|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
11423978|NCT01875497|Experimental|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
11423979|NCT01875484||High miR-126 group|
11423980|NCT01875484||Moderate miR-126 group|
11423981|NCT01875484||Low miR-126 group|
11423982|NCT01875471|Active Comparator|delefilcon A|Spherical daily disposable soft contact lens
11423983|NCT01875471|Experimental|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
11423984|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
11423985|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
11423986|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
11423987|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
11423988|NCT01875445|Placebo Comparator|Placebo|Matched dosage of inositol daily.
11423989|NCT01875445|Active Comparator|Inositol|Powder form, 2g TID up to 6g TID
11423990|NCT01875419|Experimental|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
11423991|NCT01875419|Sham Comparator|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
11423992|NCT01875406|Experimental|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
11423993|NCT01875393|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
11423994|NCT01875380|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
11423995|NCT01875367|Experimental|Trastuzumab subcutaneous inyection vial|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles
11423996|NCT01875367|Experimental|Trastuzumab subcutaneous device administration|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
11423997|NCT01875354|Placebo Comparator|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
11423998|NCT01875354|Experimental|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)
~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
11423999|NCT01875341|Active Comparator|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas & hypopneas are prevented during all sleep stages.
11424151|NCT01874353|Placebo Comparator|Placebo tablets|Taken orally twice daily
11424000|NCT01875341|Sham Comparator|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
11424001|NCT01875328|Experimental|Telemedicine|Telemedicine group
11424002|NCT01875328|Active Comparator|Clinic|Clinic group
11424003|NCT01875289|Experimental|Ropivacain|Local anaesthesia
11424004|NCT01875289|Placebo Comparator|NaCl 0.9%|Saline
11424005|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
11424006|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
11424007|NCT01875263|Experimental|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
11424008|NCT01875263|Active Comparator|Control|Cloxacillin 2g / 4 hrs iv 14 days
11424009|NCT01875250|Experimental|Arm A - Enzalutamide for 3 months|Enzalutamide for 3 months
11424010|NCT01875250|Experimental|Arm B - Enzalutamide for 3 months + PSA-TRICOM|Enzalutamide 3 months + PSA-TRICOM (Prostvac-V/F) on weeks 1, 3, 5, 9,13,17 and 21
11424011|NCT01875237|Experimental|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
11424012|NCT01875224|Experimental|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
11424013|NCT01875224|Active Comparator|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
11424014|NCT01875198|Experimental|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
11424015|NCT01875198|Active Comparator|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
11424016|NCT01875185|Experimental|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
11424017|NCT01875172|Experimental|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
11424018|NCT01875172|Placebo Comparator|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
11424019|NCT01875159|Experimental|Caffeine|Caffeine citrate 6 mg/kg/day
11424020|NCT01875159|No Intervention|Active Comparator: no caffeine|Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.
11424021|NCT01875146|Active Comparator|4x4 min HIT|Conventional 4x4 min high-intensity interval training
11424022|NCT01875146|Experimental|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
11424023|NCT01875146|Experimental|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
11424024|NCT01875146|Active Comparator|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
11424025|NCT01875133|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
11424026|NCT01875133|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
11424027|NCT01875133|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
11424028|NCT01875133|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
11424029|NCT01875120||Female patients with increased risk to experience PONV.|
11424030|NCT01875107|Experimental|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
11424031|NCT01875094|Experimental|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
11424032|NCT01875094|No Intervention|Usual Care|
11424033|NCT01875081|No Intervention|Control group|Best Supportive care
11424034|NCT01875081|Experimental|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
11424035|NCT01875081|Experimental|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
11424036|NCT01875068|Experimental|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
11424037|NCT01875068|Other|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
11424038|NCT01875055|Experimental|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
11424039|NCT01875055|Active Comparator|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
11424040|NCT01875042|Experimental|TENS|Transcutaneous Electrical Nerve Stimulation
11424041|NCT01875042|Sham Comparator|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
11424104|NCT01874574|Experimental|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
11424042|NCT01875029|Sham Comparator|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
11424043|NCT01875029|Experimental|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.
~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
11424044|NCT01875003|Experimental|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms [mcg] of fluticasone propionate dry powder inhaler [DPI] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
11424045|NCT01875003|Experimental|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
11424046|NCT01875003|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
11424047|NCT01874990|Experimental|women with a history of severe preeclampsia|women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago
11424048|NCT01874990|Experimental|control|women with no history of pregnancy-related hypertensive complications
11424049|NCT01874977|Experimental|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
11424050|NCT01874977|Experimental|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
11424051|NCT01874977|Other|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
11424052|NCT01874964|Experimental|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
11424053|NCT01874964|Active Comparator|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
11424054|NCT01874951|Placebo Comparator|Placebo|In this arm, patients will receive placebo for three weeks.
11424055|NCT01874951|Experimental|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
11424056|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
11424057|NCT01874899||Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
11424058|NCT01874899||Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
11424059|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
11424060|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
11424061|NCT01874873|Experimental|Anlotinib|
11424105|NCT01874574|Active Comparator|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
11424317|NCT01873248|Experimental|Diagnostics with PET|68Ga-DOTATATE PET scans will be performed on subjects
11424062|NCT01874860|Experimental|Extensive treatment group|"Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening.
~For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use.
~For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended.
~For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment."
11424063|NCT01874860|Experimental|Standard care group|Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
11424064|NCT01874847|Experimental|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
11424065|NCT01874847|Placebo Comparator|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
11424066|NCT01874847|Experimental|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
11424067|NCT01874834|Placebo Comparator|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
11424068|NCT01874834|Experimental|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
11424069|NCT01874834|Experimental|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
11424070|NCT01874834|Experimental|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
11424071|NCT01874821|Experimental|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
11424072|NCT01874821|Other|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
11424073|NCT01874808||Healthy|Healthy
11424074|NCT01874808||ALS with postural instability|ALS with postural instability
11424075|NCT01874808||ALS without postural instability|ALS without postural instability
11424076|NCT01874795|Experimental|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
11424077|NCT01874795|Sham Comparator|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
11424078|NCT01874782|Experimental|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
11424079|NCT01874769||Blood collection and skin biopsies|
11424080|NCT01874756|Experimental|LY500307 150mg|LY500307 150mg
11424081|NCT01874756|Placebo Comparator|placebo|placebo 6 pills of inactive drug
11424082|NCT01874756|Experimental|LY500307 75mg|LY500307 75mg
11424083|NCT01874756|Experimental|LY500307 25mg|LY500307 25mg
11424084|NCT01874743|Experimental|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
11424085|NCT01874730|Other|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
11424086|NCT01874730|Active Comparator|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
11424087|NCT01874717|Experimental|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
11424088|NCT01874717|Other|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
11424089|NCT01874704|Other|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
11424090|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
11424091|NCT01874678|Experimental|TS-1/Cisplatin|single arm
11424092|NCT01874665|Experimental|Cohort A|Participants with KIT exon 11-mutant GIST.
11424093|NCT01874665|Experimental|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
11424094|NCT01874652|Experimental|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
11424095|NCT01874639|Experimental|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
11424096|NCT01874639|Other|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
~- Test group: hepatectomy with Aquamantys®"
11424097|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
11424098|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
11424099|NCT01874613|Experimental|Skull bone reconstruction|Patients with skull bone defect
11424100|NCT01874613|Experimental|Orbital floor defect|Patients with orbital floor defect
11424101|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
11424102|NCT01874587|No Intervention|standard radiotherapy|single pre-treatment planning before radiotherapy
11424103|NCT01874587|Experimental|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
11424106|NCT01874561|Experimental|Group 1|"Group 1: investigational product (custirsen) will receive:
~320 mg of custirsen + 5 mg of dexamethasone on day 1
~480 mg of custirsen + 5 mg of dexamethasone on day 3
~640 mg of custirsen + 3 mg of dexamethasone on day 5
~640 mg of custirsen on day 7 under fasting conditions"
11424107|NCT01874561|Placebo Comparator|Group 2|"Group 2: placebo (normal saline) will receive:
~placebo + 5 mg of dexamethasone on day 1
~placebo + 5 mg of dexamethasone on day 3
~placebo + 3 mg of dexamethasone on day 5
~placebo on day 7 under fasting conditions"
11424108|NCT01874561|Active Comparator|Group 3|"Group 3: positive control (moxifloxacin) will receive:
~placebo + 5 mg of dexamethasone on day 1
~placebo + 5 mg of dexamethasone on day 3
~placebo + 3 mg of dexamethasone on day 5
~400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
11424109|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
11424110|NCT01874548||Cervical cancer|"1st year: 30 surgical candidates with cervical cancer tissue collected during operation.
~2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.
~3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
11424111|NCT01874535|Active Comparator|GERD Los Angeles A and B-4 week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group
11424112|NCT01874535|Active Comparator|GERD Los Angeles A and B-8-week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group
11424113|NCT01874522|Experimental|TAS-102 tablets|
11424114|NCT01874522|Experimental|TAS-102 oral solution|
11424115|NCT01874509|Active Comparator|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
11424116|NCT01874509|Experimental|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
11424117|NCT01874496|Experimental|GDS, meal|GDS, meal
11424118|NCT01874496|Experimental|GDS, no meal|GDS, no meal
11424119|NCT01874496|Active Comparator|control, no meal|control, no meal
11424120|NCT01874496|Active Comparator|control, meal|control, meal
11424121|NCT01874483|Experimental|BI 187004 dose 1|multiple dose given over 14 days
11424122|NCT01874483|Experimental|BI 187004 dose 2|multiple dose given over 14 days
11424123|NCT01874483|Experimental|BI 187004 dose 3|multiple dose given over 14 days
11424124|NCT01874483|Experimental|BI 187004 dose 4|multiple dose given over 14 days
11424125|NCT01874483|Experimental|BI 187004 dose 5|multiple dose given over 14 days
11424126|NCT01874483|Experimental|BI 187004 dose 6|multiple dose given over 14 days
11424127|NCT01874483|Placebo Comparator|Placebo|placebo
11424128|NCT01874483|Experimental|BI 187004 dose 7|multiple dose given over 14 days
11424129|NCT01874470|Placebo Comparator|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
11424130|NCT01874470|Experimental|renal denervation|Allegro Renal Denervation System (AngioCare)
11424131|NCT01874444|Experimental|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
11424132|NCT01874444|Experimental|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
11424133|NCT01874444|Experimental|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
11424134|NCT01874444|Sham Comparator|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
11424135|NCT01874431|Experimental|Finerenone (BAY 94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
11424136|NCT01874431|Experimental|Finerenone (BAY 94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
11424137|NCT01874431|Experimental|Finerenone (BAY 94-8862)(5 mg)|5 mg dose oral once daily for 90 days
11424138|NCT01874431|Experimental|Finerenone (BAY 94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
11424139|NCT01874431|Experimental|Finerenone (BAY 94-8862) (10 mg)|10 mg dose oral once daily for 90 days
11424140|NCT01874431|Experimental|Finerenone (BAY 94-8862) (15 mg)|15 mg dose oral once daily for 90 days
11424141|NCT01874431|Experimental|Finerenone (BAY 94-8862)(20 mg)|20 mg dose oral once daily for 90 days
11424142|NCT01874431|Placebo Comparator|Placebo|Placebo oral dose once daily for 90 days
11424143|NCT01874418|Other|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
11424144|NCT01874392|Experimental|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
11424145|NCT01874379|Experimental|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
11424146|NCT01874379|Active Comparator|Standard of Care|This group will serve as the control arm
11424147|NCT01874379|Experimental|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
11424148|NCT01874366|Experimental|P11187|"Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort
~Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts
~Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
11424149|NCT01874366|Placebo Comparator|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
11424152|NCT01874340|Experimental|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
11424153|NCT01874340|Placebo Comparator|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
11424154|NCT01874340|Experimental|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
11424155|NCT01874340|Experimental|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
11424156|NCT01874327|Active Comparator|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
11424157|NCT01874327|Active Comparator|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
11424158|NCT01874314|Experimental|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
11424159|NCT01874314|Active Comparator|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
11424160|NCT01874314|Placebo Comparator|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
11424161|NCT01874314|Experimental|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
11424162|NCT01874301|Experimental|High quantity probiotic food product|
11424163|NCT01874301|Experimental|Low quantity probiotic food product|
11424164|NCT01874301|Placebo Comparator|Placebo|
11424165|NCT01874288|Experimental|DI-Leu16-IL2 0.5 mg/m^2|Participants will receive DI-Leu16-IL2 0.5 mg/m^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
11424166|NCT01874288|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
11424167|NCT01874288|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
11424168|NCT01874288|Experimental|DI-Leu16-IL2 4.0 mg/m^2|Participants will receive DI-Leu16-IL2 4.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
11424169|NCT01874288|Experimental|DI-Leu16-IL2 6.0 mg/m^2|Participants will receive DI-Leu16-IL2 6.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
11424170|NCT01874275|Experimental|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
11424171|NCT01874275|Placebo Comparator|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
11424172|NCT01874262|Experimental|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
11424173|NCT01874262|Placebo Comparator|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
11424174|NCT01874249|Experimental|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
11424175|NCT01874249|Experimental|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
11424176|NCT01874249|Experimental|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
11424177|NCT01874249|Experimental|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
11424178|NCT01874249|No Intervention|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
11424179|NCT01874236|Active Comparator|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
11424180|NCT01874236|Active Comparator|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
11424181|NCT01874236|Active Comparator|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
11424182|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
11424183|NCT01874210||Hemodialysis|Hemodialysis patients
11424184|NCT01874210||Control|"Household contacts on the same diet
~Healthy unrelated controls"
11424185|NCT01874197|Other|B -TEVAR|Implantation of the B-TEVAR device
11424186|NCT01874184|Experimental|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
11424436|NCT01872533|Experimental|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
11424187|NCT01874184|No Intervention|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
11424188|NCT01874171|Active Comparator|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
11424189|NCT01874171|Experimental|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
11424190|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
11424191|NCT01874145|Active Comparator|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
11424192|NCT01874145|Experimental|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.
~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
11424193|NCT01874132|Experimental|Aerobic exercise training|Dose response
11424194|NCT01874132|Experimental|Aerobic and resistance exercise training|Dose response
11424195|NCT01874132|No Intervention|Control|Non-exercising control group
11424196|NCT01874119|Experimental|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
11424197|NCT01874119|Placebo Comparator|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
11424198|NCT01874106|Experimental|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
11424199|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
11424200|NCT01874093|Experimental|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
11424201|NCT01874093|Sham Comparator|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
11424202|NCT01874080|Experimental|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
11424203|NCT01874080|Experimental|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
11424204|NCT01874080|Experimental|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
11424205|NCT01874080|Experimental|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
11424206|NCT01874067||Arthritis glove|Early inflammatory, rheumatoid or hand osteoarthritis with hand/wrist swelling and pain
11424207|NCT01874054|Experimental|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
11424208|NCT01874041|Experimental|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
11424209|NCT01874041|Experimental|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
11424210|NCT01874041|No Intervention|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
11424211|NCT01874028|Experimental|Trientine dihydrochloride|
11424212|NCT01874015|Active Comparator|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
11424213|NCT01874015|Active Comparator|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
11424214|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
11424215|NCT01873989|Experimental|Testosterone replacement|Testosterone replacement for hypogonadism.
11424216|NCT01873989|Other|Waitlist control|This arm involves watchful waiting.
11424217|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
11424218|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
11424219|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
11424220|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
11424221|NCT01873950|Experimental|Ranolazine 1500mg|Ranolazine
11424222|NCT01873950|Experimental|Dofetilide 500mcg|Dofetilide
11424223|NCT01873950|Experimental|Verapamil HCl 120 mg|Verapamil
11424224|NCT01873950|Experimental|Quinidine sulfate 400mg|Quinidine sulfate
11424225|NCT01873950|Placebo Comparator|Placebo|Placebo
11424226|NCT01873937|Experimental|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
11424227|NCT01873937|Experimental|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
11424228|NCT01873937|Active Comparator|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
11424229|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
11424230|NCT01873898|Experimental|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
11424437|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
11424231|NCT01873885|Experimental|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
11424232|NCT01873885|Experimental|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
11424233|NCT01873885|Experimental|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
11424234|NCT01873872|Active Comparator|Theralac probiotic|
11424235|NCT01873872|Active Comparator|Culturelle probiotic|
11424236|NCT01873872|Placebo Comparator|Placebo|
11424237|NCT01873859|Active Comparator|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
11424238|NCT01873859|No Intervention|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
11424239|NCT01873846|Experimental|Silicone Hydrogel Contact Lens|Contact lenses to be worn in each eye on a daily wear basis for 2 weeks. Participants will be provided with Bausch + Lomb Biotrue® multi-purpose solution and contact lens cases for daily rinsing, cleaning, disinfecting, and storing their lenses.
11424240|NCT01873833|Experimental|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11424241|NCT01873820|Experimental|Calcium ascorbate -> ascorbic acid|
11424242|NCT01873820|Experimental|Ascorbic acid -> calcium ascorbate|
11424243|NCT01873807|Experimental|IDA-Etoposide Intensified Conditioning|
11424244|NCT01873807|Active Comparator|Non-IDA Conditioning|
11424245|NCT01873794|Active Comparator|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
11424246|NCT01873794|Active Comparator|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
11424247|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
11424248|NCT01873768|Active Comparator|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
11424249|NCT01873768|Active Comparator|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
11424250|NCT01873755|Experimental|asthma physical activity intervention|two schools will receive intervention
11424251|NCT01873742|Experimental|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
11424252|NCT01873742|Experimental|Treatment as usual|This condition will not include the use of the STIC feedback system.
11424253|NCT01873729|Experimental|Naltrexone|Naltrexone
11424254|NCT01873716|Experimental|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
11424255|NCT01873716|No Intervention|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
11424256|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.
~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
11424257|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.
~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
11424258|NCT01873690|Placebo Comparator|Placebo|Placebo
11424259|NCT01873690|Active Comparator|Ciprofloxacin|Ciprofloxacin
11424260|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
11424261|NCT01873677|Experimental|M518101|Proper quantity twice a day
11424262|NCT01873664|Experimental|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
11424263|NCT01873651|Experimental|Delta III|Implantation of a Delta III Prosthesis
11424264|NCT01873638|Other|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
11424265|NCT01873638|Other|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
11424266|NCT01873625|Placebo Comparator|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
11424267|NCT01873625|Active Comparator|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
11424268|NCT01873612|Experimental|Sedation with dexmedetomidine|Sedation with dexmedetomidine
11424269|NCT01873612|Experimental|Sedation with propofol|Sedation with propofol
11424270|NCT01873599|Experimental|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
11424271|NCT01873599|No Intervention|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
11424272|NCT01873586|Experimental|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
11424273|NCT01873586|Active Comparator|Local autograft|Local autograft (posterolateral gutter at the contralateral side)
11424316|NCT01873274|Active Comparator|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
11424274|NCT01873573|Active Comparator|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
11424275|NCT01873573|Active Comparator|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
11424276|NCT01873560||FFRpost|High FFRpost group and low FFRpost group were defined according to the optimal cut-off value for predicting clinical outcome.
11424277|NCT01873547|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
11424278|NCT01873547|Experimental|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
11424279|NCT01873547|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
11424280|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
11424281|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
11424282|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
11424283|NCT01873521|Active Comparator|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
11424284|NCT01873521|Active Comparator|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
11424285|NCT01873508|Experimental|Fast release MR capsule|
11424286|NCT01873508|Experimental|Slow release MR capsule|
11424287|NCT01873508|Experimental|Target release MR capsule|
11424288|NCT01873495|Experimental|Omacetaxine: Consolidation/Maintenance|
11424289|NCT01873482|Experimental|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
11424290|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
11424291|NCT01873456|Experimental|Multifactorial nutritional intervention|dietician, resistance type exercise, dysphagia assessment and treatment
11424292|NCT01873456|No Intervention|usual care|usual care
11424293|NCT01873443|Experimental|Rituximab, MTX, folic acid|
11424294|NCT01873430|Active Comparator|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
11424295|NCT01873430|Active Comparator|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
11424296|NCT01873430|Active Comparator|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
11424297|NCT01873430|Placebo Comparator|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
11424298|NCT01873430|No Intervention|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
11424299|NCT01873417|Experimental|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
11424300|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
11424301|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
11424302|NCT01873391|Active Comparator|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
11424303|NCT01873391|Active Comparator|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
11424304|NCT01873378|Experimental|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
11424305|NCT01873378|No Intervention|No pharmacological treatment|
11424306|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
11424307|NCT01873352|Active Comparator|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
11424308|NCT01873352|Active Comparator|CA (control)|Catheter ablation of atrial fibrillation (control group)
11424309|NCT01873339|Experimental|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
11424310|NCT01873326|Experimental|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)* Mesna** 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)*
~**Additional mesna may be given at the discretion of the investigator
~*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
11424311|NCT01873326|Active Comparator|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)
~*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
11424312|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
11424313|NCT01873300|Experimental|treatment group|Patients undergoing POEM procedure
11424314|NCT01873274|Active Comparator|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
11424315|NCT01873274|Active Comparator|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
11424318|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
11424319|NCT01873222|Experimental|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI
~Assessment by OFDI at a 8-month follow-up"
11424320|NCT01873222|Active Comparator|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI
~Assessment by OFDI at a 8-month follow-up"
11424321|NCT01873196|Experimental|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
11424322|NCT01873196|No Intervention|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
11424323|NCT01873196|Experimental|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
11424324|NCT01873196|No Intervention|Control-No repackaged CSB|
11424325|NCT01873183|Experimental|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.
~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
11424326|NCT01873183|No Intervention|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
11424327|NCT01873170||Combined Oral Contraceptive pills|Levonorgestrel/ethinyl estradiol 0.15mg/30mcg daily oral tabs x21 then 7 inert tabs
11424328|NCT01873170||depot medroxyprogesterone acetate|150mg DMPA intramuscular injection once every 3 months
11424329|NCT01873170||Levonorgestrel-intrauterine device|52mg levonorgestrel intrauterine device
11424330|NCT01873170||Copper intrauterine device|Copper T380A intrauterine device
11424331|NCT01873170||Etonogestrel contraceptive implant|68mg etonogestrel subdermal implant
11424332|NCT01873170||Control|Low risk of pregnancy due to sterilization, heterosexual abstinence, or consistent condom use
11424333|NCT01873157|Placebo Comparator|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.
~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
11424334|NCT01873157|Active Comparator|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.
~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
11424335|NCT01873144|Active Comparator|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
11424336|NCT01873144|Experimental|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
11424337|NCT01873131|Experimental|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
11424338|NCT01873131|No Intervention|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
11424339|NCT01873131|Experimental|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
11424340|NCT01873118|No Intervention|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
11424341|NCT01873118|Experimental|implementation unit|"3 implementation protocols implemented sequentially:
~RN-RHDS: implementation of discharge readiness assessment by the discharging nurse
~RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness
~RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
11424342|NCT01873105|Experimental|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
11424343|NCT01873105|No Intervention|Control pre-intervention|Usual care control before implementation of the health team communication intervention
11424344|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
11424345|NCT01873079|Active Comparator|Esomeprazole|esomeprazole 40mg bd for 10 days
11424346|NCT01873079|Sham Comparator|Standard care|No other study drug or placebo will be given
11424347|NCT01873066|Experimental|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
11424438|NCT01872507|Active Comparator|biofeedback training|usual treatment+12 treatment of biofeedback training
11424439|NCT01872507|No Intervention|control|usual treatment
11424348|NCT01873066|Active Comparator|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
11424349|NCT01873053|Experimental|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
11424350|NCT01873053|Experimental|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
11424351|NCT01873053|Placebo Comparator|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
11424352|NCT01873040|Experimental|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
11424353|NCT01873040|Experimental|Information Pages|Participants will have website access to vaccine information pages.
11424354|NCT01873040|No Intervention|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
11424355|NCT01873027|Experimental|OFDI-guided PCI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI
~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
11424356|NCT01873027|Active Comparator|IVUS-guided PCI|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI
~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
11424357|NCT01873014|Experimental|high Iodine intake|
11424358|NCT01873014|Active Comparator|low Iodine intake|
11424359|NCT01873001|Experimental|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
11424360|NCT01872988|Active Comparator|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
11424361|NCT01872988|Placebo Comparator|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
11424362|NCT01872975|Active Comparator|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
11424363|NCT01872975|No Intervention|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
11424364|NCT01872975|Experimental|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
11424365|NCT01872975|Experimental|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
11424366|NCT01872962|Experimental|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
11424367|NCT01872962|Active Comparator|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
11424368|NCT01872936|Other|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
11424369|NCT01872936|Other|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
11424370|NCT01872923|Experimental|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
11424371|NCT01872910|Placebo Comparator|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.
~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.
~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
11424372|NCT01872910|Experimental|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.
~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.
~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
11424373|NCT01872910|Active Comparator|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).
~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.
~Celecoxib was not administered in Part B.
~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
11424374|NCT01872897|Active Comparator|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
11424375|NCT01872897|Placebo Comparator|Placebo tablets|Single dose of 4 Placebo tablets
11424376|NCT01872884|Experimental|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
11424377|NCT01872884|Placebo Comparator|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
11424378|NCT01872871|Placebo Comparator|local anasthetic drops|topical anaesthetic drop with placebo
11424379|NCT01872871|Active Comparator|Paracetamol|Topical anaesthetic drop with Paracetamol
11424380|NCT01872858|Active Comparator|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
11424381|NCT01872858|Experimental|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
11424382|NCT01872845|Active Comparator|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
11424383|NCT01872845|Experimental|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
11424384|NCT01872832|Experimental|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
11424385|NCT01872832|Experimental|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
11424386|NCT01872832|Experimental|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
11424387|NCT01872832|Experimental|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
11424388|NCT01872819|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
11424389|NCT01872806|Experimental|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
11424390|NCT01872780|Active Comparator|rosiglitazone|avandia
11424391|NCT01872780|Active Comparator|genetic polymorphism|avandia CYP2C8 genotype
11424392|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
11424393|NCT01872754|Active Comparator|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
11424394|NCT01872754|Experimental|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
11424395|NCT01872741|Active Comparator|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
11424396|NCT01872741|Active Comparator|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
11424397|NCT01872728|Placebo Comparator|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
11424398|NCT01872728|Active Comparator|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
11424399|NCT01872715|Experimental|Oracea|"Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.
~Oral dose for 12 weeks"
11424400|NCT01872702|Experimental|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
11424401|NCT01872702|No Intervention|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
11424402|NCT01872689|Placebo Comparator|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
11424403|NCT01872689|Experimental|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
11424404|NCT01872689|Placebo Comparator|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
11424405|NCT01872689|Experimental|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
11424406|NCT01872676|Experimental|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
11424407|NCT01872676|Sham Comparator|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
11424408|NCT01872663|Experimental|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
11424409|NCT01872663|Experimental|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
11424410|NCT01872663|Experimental|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
11424411|NCT01872663|Experimental|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
11424412|NCT01872663|Experimental|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
11424413|NCT01872663|Experimental|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
11424414|NCT01872663|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
11424415|NCT01872650|No Intervention|Control|No placement of an adhesion barrier
11424416|NCT01872650|Experimental|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
11424417|NCT01872637|Experimental|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
11424418|NCT01872637|Active Comparator|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
11424419|NCT01872624|Active Comparator|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
11424420|NCT01872624|Placebo Comparator|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
11424421|NCT01872611|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
11424422|NCT01872611|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
11424423|NCT01872598|Experimental|Masitinib escalating dose|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
11424424|NCT01872598|Experimental|Masitinib fixed dose (4.5 mg/kg/day)|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
11424425|NCT01872598|Experimental|Masitinib fixed dose (3.0 mg/kg/day)|Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
11424426|NCT01872598|Placebo Comparator|Placebo (escalating dose)|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
11424427|NCT01872598|Placebo Comparator|Placebo (fixed dose)|Participants receive fixed dose placebo, given orally twice daily
11424428|NCT01872585|Experimental|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
11424429|NCT01872572|Other|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
11424430|NCT01872572|Other|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
11424431|NCT01872572|Other|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
11424432|NCT01872572|Other|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
11424433|NCT01872572|Other|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:
~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration
~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
11424434|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
11424435|NCT01872546|Experimental|Adalimumab|
11424440|NCT01872494|Experimental|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
11424441|NCT01872494|Active Comparator|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
11424442|NCT01872481|Placebo Comparator|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
11424443|NCT01872481|Experimental|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
11424444|NCT01872468|No Intervention|Control|There is not intervention in this group.
11424445|NCT01872468|Active Comparator|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
11424446|NCT01872455|Active Comparator|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
11424447|NCT01872455|Experimental|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
11424448|NCT01872442|Experimental|Dasatinib|Dasatinib,Bristol Myers Squibb
11424449|NCT01872442|Experimental|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
11424450|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
11424451|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
11424452|NCT01872416|Experimental|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
11424453|NCT01872403|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
11424454|NCT01872390|Experimental|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
11424455|NCT01872390|Other|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
11424456|NCT01872377|Experimental|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
11424457|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
11424458|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.
~ENT consists of:
~Daily conditioning exercise: 35-40 minutes
~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.
~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
11424459|NCT01872338|Active Comparator|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
11424460|NCT01872338|Other|Treatment As Usual|VA standard care for suicide prevention
11424461|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
11424462|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
11424463|NCT01872312|Other|treatment|Loading IBV® Valve System
11424464|NCT01872299||Control|Healthy control subjects
11424465|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
11424466|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
11424467|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
11424468|NCT01872286|Experimental|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
11424469|NCT01872286|Experimental|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
11424470|NCT01872260|Experimental|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
11424471|NCT01872260|Experimental|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
11424472|NCT01872260|Experimental|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
11424473|NCT01872260|Experimental|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
11424474|NCT01872234|Experimental|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
11424475|NCT01872234|No Intervention|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
11424476|NCT01872221|Experimental|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
11424477|NCT01872208|Experimental|HAVG graft|HAVG graft implantation to study participants.
11424478|NCT01872195|Experimental|* Before checklists|The comprehensive patient safety checklist system
11424479|NCT01872195|Experimental|* After checklists|Without the comprehensive patient safety checklist system
11424481|NCT01872182|Placebo Comparator|Comparator arm|placebo in two tablets
11424482|NCT01872169|Other|Disordered eating screening questionnaire|
11424483|NCT01872156|Experimental|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
11424484|NCT01872156|Other|Control Group|The group control will act according to usual management.
11424485|NCT01872143|Experimental|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
11424486|NCT01872117|Experimental|Applications of shortwave diathermy|
11424487|NCT01872117|Experimental|Applications of microwave diathermy|
11424488|NCT01872104|No Intervention|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
11424489|NCT01872104|Experimental|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
11424490|NCT01872091|Experimental|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
11424491|NCT01872091|Experimental|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
11424492|NCT01872078|Experimental|AZD4901 20 mg once a day|AZD4901 20 mg once a day
11424493|NCT01872078|Experimental|AZD4901 20mg twice a day|AZD4901 20mg twice a day
11424494|NCT01872078|Experimental|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
11424495|NCT01872078|Experimental|Placebo to match AZD4901|
11424496|NCT01872065|Experimental|ARC-520|Single dose, intravenous administration of ARC-520.
11424497|NCT01872065|Placebo Comparator|Normal Saline|Single dose, intravenous administration of Normal Saline
11424498|NCT01872052|Experimental|Acutus Medical System|
11424499|NCT01872039|Active Comparator|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
11424500|NCT01872039|Experimental|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
11424501|NCT01872026|Experimental|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
11424502|NCT01872026|Experimental|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
11424503|NCT01872013|Experimental|low dose ASP7991|
11424504|NCT01872013|Experimental|middle dose ASP7991|
11424505|NCT01872013|Experimental|high dose ASP7991|
11424506|NCT01872013|Placebo Comparator|Placebo|
11424507|NCT01872000|Experimental|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
11424508|NCT01872000|Active Comparator|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
11424509|NCT01871987|Experimental|fasted group|receiving FK949E in fasted condition
11424510|NCT01871987|Experimental|low fat group|receiving FK949E after low fat meal
11424511|NCT01871987|Experimental|high fat group|receiving FK949E after high fat meal
11424512|NCT01871974|Experimental|low-dose group FK949E|oral
11424513|NCT01871974|Experimental|high-dose group FK949E|oral
11424514|NCT01871961|Experimental|Methotrexate|
11424515|NCT01871948|No Intervention|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
11424516|NCT01871948|Experimental|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
11424517|NCT01871935|Active Comparator|Remifentanil|Anaesthesia with remifentanil/propofol
11424518|NCT01871935|Active Comparator|Sufentanil|Anaesthesia with sufentanil/propofol
11424519|NCT01871922|Placebo Comparator|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
11424520|NCT01871922|Active Comparator|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
11424521|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
11424522|NCT01871896|Experimental|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
11424523|NCT01871883|Experimental|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
11424524|NCT01871883|Active Comparator|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
11424525|NCT01871870|Experimental|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
11424526|NCT01871857|Active Comparator|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
11424527|NCT01871857|Experimental|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
11424528|NCT01871844|Experimental|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
11424529|NCT01871844|Experimental|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
11424530|NCT01871844|Experimental|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
11424531|NCT01871844|Active Comparator|octreotide 50 mcg tid|octreotide 50 mcg tid
11424623|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
11424532|NCT01871818|Experimental|Combined program|"Combined program with physiotherapy, endurance training and resistance training.
~120 patients will receive this combined program"
11424533|NCT01871818|Active Comparator|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
11424534|NCT01871805|Experimental|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
11424535|NCT01871805|Experimental|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
11424536|NCT01871792|Experimental|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
11424537|NCT01871792|Placebo Comparator|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
11424538|NCT01871779|Experimental|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
11424539|NCT01871779|Experimental|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
11424540|NCT01871766|Experimental|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
11424541|NCT01871766|Experimental|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
11424542|NCT01871766|Experimental|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
11424543|NCT01871766|Experimental|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.
~Participants also receive ^1^1C-methionine as described in the intervention section."
11424544|NCT01871753|Experimental|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
11424545|NCT01871753|No Intervention|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
11424546|NCT01871740|Experimental|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
11424547|NCT01871740|Active Comparator|Enalapril maleate|Enalapril maleate 10 mg per day is given
11424548|NCT01871727|Experimental|E7777|
11424549|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
11424550|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
11424551|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
11424552|NCT01871701|Experimental|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
11424553|NCT01871701|Experimental|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
11424554|NCT01871701|Experimental|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
11424555|NCT01871701|Placebo Comparator|Placebo|Water intake
11424556|NCT01871688|Other|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
11424557|NCT01871675|Experimental|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.
~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
11424617|NCT01871285|Experimental|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
11424558|NCT01871675|Experimental|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.
~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
11424559|NCT01871662|Active Comparator|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
11424560|NCT01871662|Experimental|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
11424561|NCT01871662|Experimental|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
11424562|NCT01871649|Active Comparator|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
11424563|NCT01871649|Experimental|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
11424564|NCT01871636|Active Comparator|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
11424565|NCT01871636|Active Comparator|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
11424566|NCT01871623|Experimental|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
11424567|NCT01871623|Active Comparator|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
11424568|NCT01871610|Experimental|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
11424569|NCT01871610|Experimental|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
11424570|NCT01871610|Experimental|Normal control|People aged 30 or older without mTBI or AD
11424571|NCT01871597|Experimental|Intervention Group|Intervention - Pulmonary Artery Energy Seal
11424572|NCT01871584|Experimental|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
11424573|NCT01871584|Active Comparator|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
11424574|NCT01871571|Experimental|Treatment (bevacizumab, mFOLFOX7)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.
11424575|NCT01871558|Active Comparator|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
11424576|NCT01871558|Experimental|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
11424577|NCT01871545|Experimental|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
11424578|NCT01871545|No Intervention|Healthy Controls|
11424579|NCT01871532|Experimental|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
11424580|NCT01871532|Active Comparator|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
11424581|NCT01871519|Other|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
11424582|NCT01871506|Experimental|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
11424618|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
11424619|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
11424620|NCT01871220|Active Comparator|Divergent Abutment|Divergent Transition Profile
11424621|NCT01871220|Experimental|Concave Abutment|Concave Transition Profile
11424583|NCT01871506|Experimental|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
~Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
~Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant."
11424584|NCT01871493|Experimental|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
11424585|NCT01871493|Active Comparator|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
11424586|NCT01871493|Experimental|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
11424587|NCT01871493|Experimental|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
11424588|NCT01871493|Active Comparator|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
11424589|NCT01871493|Experimental|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
11424590|NCT01871493|Experimental|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
11424591|NCT01871493|Experimental|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
11424592|NCT01871480|Experimental|Group A|Gefitinib combination with CIK cell immunotherapy
11424593|NCT01871480|Active Comparator|Group B|Gefitinib alone
11424594|NCT01871467|Experimental|Sargramostim administration|Subjects will receive sargramostim.
11424595|NCT01871454|Experimental|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
11424596|NCT01871441|Experimental|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
11424597|NCT01871428|Experimental|Aleglitazar|
11424598|NCT01871428|Placebo Comparator|Placebo|
11424599|NCT01871415|Experimental|Aleglitazar + metformin|
11424600|NCT01871415|Active Comparator|Placebo + metformin|
11424601|NCT01871402|Experimental|Active Arm|Topical lotion, applied twice daily
11424602|NCT01871402|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
11424603|NCT01871389||cholecalciferol|
11424604|NCT01871389||usual treatment|
11424605|NCT01871376|Active Comparator|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.
~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
11424606|NCT01871376|Active Comparator|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.
~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
11424607|NCT01871363|Experimental|preoperative chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
~bevacizumab: at dose 5 mg/kg on days -1, 15,31.
~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
11424608|NCT01871350|Experimental|Protein and Fish Oil|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil
~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
11424609|NCT01871350|Experimental|Protein|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil
~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
11424610|NCT01871350|Placebo Comparator|Placebo|"Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil
~High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil"
11424611|NCT01871337|Experimental|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
11424612|NCT01871324|Experimental|Lifestyle counseling|
11424613|NCT01871311|Experimental|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
11424614|NCT01871298|Other|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
11424615|NCT01871298|No Intervention|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
11424616|NCT01871285|Experimental|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
11424622|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
11424625|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
11424626|NCT01871181|Experimental|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
11424627|NCT01871181|Active Comparator|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
11424628|NCT01871168|Sham Comparator|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
11424629|NCT01871168|Experimental|TAP block|Patients receive a continuous TAP block
11424630|NCT01871155|Experimental|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
11424631|NCT01871155|No Intervention|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
11424632|NCT01871142|Experimental|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
11424633|NCT01871129|Placebo Comparator|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
11424634|NCT01871129|Active Comparator|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
11424635|NCT01871116|Experimental|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
11424636|NCT01871116|Active Comparator|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
11424637|NCT01871103|Other|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
11424638|NCT01871090|Active Comparator|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
11424639|NCT01871090|No Intervention|Interrogation with programmer|Interrogation with programmer according to usual standard of care
11424640|NCT01871077|Experimental|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
11424641|NCT01871038||Rotavirus Positive Cases|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
11424642|NCT01871038||Rotavirus Negative Controls|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
11424643|NCT01871025|Experimental|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 30 days to discharge.
11424644|NCT01871025|Other|Usual care|Usual care in COPD
11424645|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
11424646|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
11424647|NCT01870999|Experimental|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
11424648|NCT01870999|Experimental|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
11424649|NCT01870999|Experimental|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
11424650|NCT01870986|Experimental|A|PF-06410293
11424651|NCT01870986|Active Comparator|B|Adalimumab-EU
11424652|NCT01870986|Active Comparator|C|Adalimumab-US
11424653|NCT01870973|Experimental|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
11424654|NCT01870973|Active Comparator|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
11424655|NCT01870960|Other|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
11424656|NCT01870960|Other|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
11424657|NCT01870947|Experimental|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
11424658|NCT01870947|Experimental|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
11424659|NCT01870934||Telemedicine, Diabetes, foot ulcer|
11424660|NCT01870921|Experimental|Ticargrelor|90 mg/tablet, 1 tablet bid
11424664|NCT01870882|Active Comparator|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
11424665|NCT01870882|Sham Comparator|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
11424666|NCT01870869|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
11424667|NCT01870869|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
11424668|NCT01870869|Experimental|Revision-Augmentation|Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
11424669|NCT01870869|Experimental|Revision-Reconstruction|Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
11424670|NCT01870856|Experimental|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
11424671|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
11424672|NCT01870856|Experimental|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
11424673|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
11424674|NCT01870843|Experimental|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
11424675|NCT01870830|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
11424676|NCT01870830|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
11424677|NCT01870830|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
11424678|NCT01870830|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
11424679|NCT01870817|Active Comparator|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
11424680|NCT01870817|No Intervention|Control|Standard care
11424681|NCT01870804|Active Comparator|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance < 30 ml/min)
11424682|NCT01870804|Active Comparator|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
11424683|NCT01870791|Experimental|Omegaven|Omegaven in combination with EOX chemotherapy
11424684|NCT01870778|Experimental|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
11424685|NCT01870778|Placebo Comparator|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
11424686|NCT01870765|Active Comparator|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
11424687|NCT01870765|Experimental|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
11424688|NCT01870752|Other|Transplantation of previously cryopreserved ovarian tissue|Surgical transplantation of previously collected cryopreserved ovarian cortical tissue.
11424689|NCT01870739|Experimental|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.
~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
11424690|NCT01870739|Active Comparator|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.
~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
11424691|NCT01870726|Experimental|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
11424692|NCT01870726|Experimental|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
11424693|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
11424694|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
11424695|NCT01870700|Experimental|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
11424696|NCT01870700|Placebo Comparator|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
11424697|NCT01870687|Experimental|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
11424698|NCT01870687|Placebo Comparator|Placebo|2 tablets in the morning, oral, 3 months treatment
11424699|NCT01870674|Experimental|YH12852|"<SAD cohort>
~Experimental: YH12852 1mg/single dose, qd
~Experimental: YH12852 3mg/single dose, qd
~Experimental: YH12852 10mg/single dose, qd
~<FSD cohort>
~Experimental: YH12852 0.5mg/single dose, qd
~Experimental: YH12852 1mg/single dose, qd
~Experimental: YH12852 2mg/single dose, qd
~Experimental: YH12852 3mg/single dose, qd
~<MAD cohort>
~Experimental: YH12852 0.5mg/repeat dose, qd
~Experimental: YH12852 1mg/repeat dose, qd
~Experimental: YH12852 2mg/repeat dose, qd
~Experimental: YH12852 3mg/repeat dose, qd
~Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
11424700|NCT01870674|Active Comparator|Prucalopride|<each cohort> Prucalopride succinate 1.321mg
11424701|NCT01870674|Placebo Comparator|Placebo|<each cohort> Matching Placebo
11424702|NCT01870661|Experimental|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
11424703|NCT01870661|Active Comparator|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
11424704|NCT01870648|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron
~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
11424705|NCT01870648|Placebo Comparator|Placebo (sugar pill)|
11424706|NCT01870635|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron
~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
11424707|NCT01870635|Placebo Comparator|Placebo (sugar pill)|
11424708|NCT01870622|Active Comparator|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
11424709|NCT01870622|Experimental|Flow waves|Flow waves will be used to confirm correct tube placement
11424710|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
11424711|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
11424712|NCT01870596|Experimental|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
11424713|NCT01870596|Active Comparator|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
11424714|NCT01870583|Active Comparator|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
11424715|NCT01870583|Active Comparator|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
11424716|NCT01870583|Active Comparator|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
11424717|NCT01870570|Other|Reference Glucose|Glucose Standard (50g of Glucose)
11424718|NCT01870570|Experimental|Food Product A: Corn Flakes|Corn Flakes
11424719|NCT01870570|Experimental|Food Product B: Ginger Bread|Ginger Bread
11424720|NCT01870570|Experimental|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
11424721|NCT01870570|Experimental|Food Product D: Crackers Nature|Crackers Nature
11424722|NCT01870570|Experimental|Food Product E: Breakfast Biscuit|Breakfast Biscuit
11424723|NCT01870570|Experimental|Food Product F: White Bread|White Bread
11424724|NCT01870557||Diabetes Mellitus type 1|n=100
11424725|NCT01870557||Diabetes Mellitus type 2|n=100
11424726|NCT01870544|Experimental|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2*10^10 organisms. The LGG is contained in capsules (1*10^10 organisms per capsule), and two capsules will be taken per day.
11424727|NCT01870544|Placebo Comparator|Placebo|Placebo to be taken orally for 44 days.
11424728|NCT01870518|Active Comparator|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
11424729|NCT01870518|Active Comparator|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
11424730|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
11424731|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
11424732|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
11424733|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
11424734|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
11424735|NCT01870479|Experimental|Live music|Patient preferred live music during chemotherapy session.
11424736|NCT01870479|Active Comparator|Taped music|Patient preferred taped music during chemotherapy
11424737|NCT01870479|No Intervention|Control|Usual care during chemotherapy
11424738|NCT01870466|Experimental|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
11424739|NCT01870466|Experimental|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
11424740|NCT01870466|Experimental|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
11424741|NCT01870466|Experimental|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
11424742|NCT01870466|Experimental|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
11424743|NCT01870466|Experimental|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
11424744|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
11424745|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
11424746|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
11424747|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
11424748|NCT01870440|Experimental|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
11424749|NCT01870427|Experimental|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
11424750|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm.
11424751|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
11424752|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
11424753|NCT01870388|Experimental|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
11424754|NCT01870388|Experimental|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
11424755|NCT01870388|Experimental|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
11424756|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
11424757|NCT01870375||MPS II|Hunter syndrome patients
11424758|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
11424759|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
11424760|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
11424761|NCT01870362|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
11424762|NCT01870362|Placebo Comparator|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
11424763|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
11424764|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
11424765|NCT01870336|Experimental|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
11424766|NCT01870336|Experimental|Knee brace|OdrA Knee brace (alone)
11424767|NCT01870336|Experimental|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
11424768|NCT01870323|Experimental|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
11424769|NCT01870323|Active Comparator|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
11424770|NCT01870310|No Intervention|Standard medical therapy|
11424771|NCT01870310|Experimental|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
11424772|NCT01870297|Experimental|LY3025876|Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
11424773|NCT01870297|Placebo Comparator|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
11424774|NCT01870297|Experimental|LY3025876 + Liraglutide|Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
11424775|NCT01870297|Placebo Comparator|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
11424776|NCT01870284|Experimental|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
11424777|NCT01870284|Experimental|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
11424778|NCT01870284|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
11424779|NCT01870284|Active Comparator|Adalimumab|Administered by 40 mg SC injection
11424780|NCT01870271|Experimental|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
11424781|NCT01870258|Placebo Comparator|those without MI in 2 weeks|patient without MI in 2 weeks
11424782|NCT01870258|Active Comparator|patient with MI|group with MI in 2 weeks
11424783|NCT01870245|Experimental|ACHN-975|
11424784|NCT01870245|Placebo Comparator|Placebo|
11424785|NCT01870232|Experimental|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
11424786|NCT01870219|Active Comparator|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
11424787|NCT01870219|Active Comparator|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
11424788|NCT01870206|Experimental|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
11424789|NCT01870206|Active Comparator|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
11424790|NCT01870193||Young controls|Young controls will be studied before and after receiving cysteine and glycine for 2 weeks
11424791|NCT01870193||Elderly group|Elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine or alanine for 4 months, and be studied at baseline, 2 weeks and 4 months
11424792|NCT01870180|Experimental|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
11424793|NCT01870180|Placebo Comparator|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
11424794|NCT01870167|Placebo Comparator|placebo|Placebo
11424795|NCT01870167|Experimental|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
11424796|NCT01870154|Experimental|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
11424797|NCT01870154|Active Comparator|Control group|Usual care
11424798|NCT01870141|Experimental|Psychological Intervention|Cognitive Behavioural Intervention
11424799|NCT01870141|No Intervention|Current standard of care|
11424800|NCT01870128|Active Comparator|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
11424801|NCT01870128|Active Comparator|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
11424802|NCT01870128|Experimental|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
11424803|NCT01870115|Placebo Comparator|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
11424804|NCT01870115|Active Comparator|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
11424805|NCT01870102|Active Comparator|Pelubiprofen IR (Pelubiprofen 30 mg)|
11424806|NCT01870102|Experimental|Pelubiprofen SR (Pelubiprofen 45 mg)|
11424807|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
11424808|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
11424809|NCT01870089|Experimental|Study group|
11424810|NCT01870076|Experimental|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
11424811|NCT01870076|Sham Comparator|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
11424812|NCT01870076|Active Comparator|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
11424813|NCT01870076|No Intervention|Control, No Presence|No Presence in the room one hour prior to bed.
11424814|NCT01870063||open heart surgery|
11424815|NCT01870050|Active Comparator|dapsone gel - verum|dapsone gel - verum
11424816|NCT01870050|Placebo Comparator|dapsone gel - vehicle only|
11424817|NCT01870037|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.
11424818|NCT01870037|Experimental|hMaxi-K 16000 µg|Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
11424819|NCT01870037|Experimental|hMaxi-K 24000 µg|Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
11424820|NCT01870024|Active Comparator|1: Lorazepam + Placebo|[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
11424821|NCT01870024|Active Comparator|2: Clonazepam + Placebo|[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
11424822|NCT01870024|Active Comparator|3: Clonazepam + Fosphenytoin|[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
11424823|NCT01870011|Experimental|Desflurane balanced anesthesia group|
11424824|NCT01870011|Active Comparator|Propofol total intravenous anesthesia group|
11424825|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
11424826|NCT01869998||High risk group 1 (B)|(B)Vortex depth<0.45 with anticoagulation
11424827|NCT01869998||High risk group 2 (C)|(C)Vortex depth <0.45 without anticoagulation
11424828|NCT01869985|Experimental|HCP1104|HCP1104
11424829|NCT01869985|Active Comparator|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
11424830|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have >1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
11424831|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
11424832|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
11424833|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
11424834|NCT01869959|Placebo Comparator|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
11424835|NCT01869959|Experimental|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
11424836|NCT01869959|Experimental|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
11424837|NCT01869959|Experimental|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
11424838|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
11424839|NCT01869933|Experimental|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
11424840|NCT01869933|Experimental|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
11424841|NCT01869920|Experimental|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
11424842|NCT01869920|Other|Controll group|Usual care
11424843|NCT01869907|Placebo Comparator|Placebo|Placebo, once daily
11424844|NCT01869907|Active Comparator|Amitriptyline|Amitriptyline 25mg, once daily
11424845|NCT01869907|Active Comparator|Minocycline|Minocycline 100mg, once daily
11424846|NCT01869894|Active Comparator|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
11424847|NCT01869894|Active Comparator|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
11424848|NCT01869894|Active Comparator|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
11424849|NCT01869881|Active Comparator|Sarpogrelate|
11424850|NCT01869881|Placebo Comparator|Placebo|
11424851|NCT01869868||Depression, ECT|
11424852|NCT01869855|Active Comparator|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
11424853|NCT01869855|Active Comparator|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
11424854|NCT01869842|Active Comparator|DM, angio group|
11424855|NCT01869842|Experimental|DM, OCT group|
11424856|NCT01869842|Active Comparator|non DM, angio group|
11424857|NCT01869842|Experimental|non DM, OCT group|
11424858|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis
11424859|NCT01869816||Acute coronary syndrome (ACS)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
11424860|NCT01869816||Stable angina pectoris (SAP)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
11424861|NCT01869816||Control|Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
11424862|NCT01869790|Experimental|Meal challenge|Different fat types
11424863|NCT01869777|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
11424864|NCT01869764|Experimental|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
11424865|NCT01869764|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
11424866|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
11424867|NCT01869738|Experimental|MGuard Prime|MGuard Prime stent
11424868|NCT01869738|Active Comparator|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
11424869|NCT01869725|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
11424870|NCT01869712|Experimental|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
11424871|NCT01869712|Experimental|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
11424872|NCT01869712|Active Comparator|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
11424932|NCT01869309|No Intervention|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
11424873|NCT01869712|Active Comparator|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
11424874|NCT01869699|Placebo Comparator|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
11424875|NCT01869699|Experimental|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
11424876|NCT01869686|Experimental|Denosumab|single subcutaneous injection
11424877|NCT01869673|Active Comparator|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
11424878|NCT01869673|Experimental|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
11424879|NCT01869660|Experimental|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
11424880|NCT01869660|No Intervention|Usual Care|Patients with no special program about decision making.
11424881|NCT01869647|Active Comparator|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
11424882|NCT01869647|Active Comparator|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
11424883|NCT01869647|Active Comparator|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
11424884|NCT01869634|Active Comparator|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
11424885|NCT01869634|No Intervention|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
11424886|NCT01869621|Experimental|Metformin|6 days treatment with metformin
11424887|NCT01869608|Experimental|postpartum screening|Oral glucose tolerance test 2 days post-partum
11424888|NCT01869582|Experimental|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
11424889|NCT01869582|Experimental|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
11424890|NCT01869582|Experimental|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
11424891|NCT01869582|Experimental|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
11424892|NCT01869569|Active Comparator|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
11424893|NCT01869569|Placebo Comparator|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
11424894|NCT01869556|Active Comparator|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
11424895|NCT01869556|Active Comparator|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
11424896|NCT01869556|Active Comparator|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
11424897|NCT01869543|Experimental|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
11424898|NCT01869543|Experimental|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
11424899|NCT01869543|Experimental|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
11424900|NCT01869543|Experimental|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
11424901|NCT01869530||Healthy children|
11424902|NCT01869517|Active Comparator|Intrastromal corneal continuous ring (Myoring)|
11424903|NCT01869517|Active Comparator|Intrastromal corneal ring segments (Keraring)|
11424933|NCT01869309|Active Comparator|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
11424904|NCT01869504|Experimental|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
11424905|NCT01869491|Active Comparator|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
11424906|NCT01869491|Placebo Comparator|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
11424907|NCT01869478|Active Comparator|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
11424908|NCT01869478|Active Comparator|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
11424909|NCT01869465|Active Comparator|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
11424910|NCT01869465|Experimental|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
11424911|NCT01869452|Other|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
11424912|NCT01869452|Other|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
11424913|NCT01869452|Other|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
11424914|NCT01869439|Experimental|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
11424915|NCT01869426|Active Comparator|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
11424916|NCT01869426|Placebo Comparator|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
11424917|NCT01869413|Experimental|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
11424918|NCT01869413|Placebo Comparator|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
11424919|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
11424920|NCT01869387|No Intervention|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
11424921|NCT01869387|Experimental|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
11424922|NCT01869374|Experimental|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
11424923|NCT01869374|Active Comparator|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
11424924|NCT01869361|Placebo Comparator|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
11424925|NCT01869361|Active Comparator|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
11424926|NCT01869348|No Intervention|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
11424927|NCT01869348|Experimental|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
11424928|NCT01869335|Active Comparator|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
11424929|NCT01869335|Active Comparator|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
11424930|NCT01869322|Experimental|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
11424931|NCT01869322|Active Comparator|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
11424934|NCT01869296|Active Comparator|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
11424935|NCT01869296|Experimental|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
11424936|NCT01869283|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
11424937|NCT01869283|Experimental|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
11424938|NCT01869283|Experimental|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
11424939|NCT01869283|No Intervention|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
11424940|NCT01869257|Active Comparator|control|regular suture not coated with triclosan
11424941|NCT01869257|Experimental|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
11424942|NCT01869244||hand resting splint|Patients with hand resting splint treatment
11424943|NCT01869231|Experimental|major surgery|colic surgery
11424944|NCT01869231|Experimental|minor surgery|appendectomy; cholecystectomy
11424945|NCT01869231|Experimental|ileostomy and colostomy|ileostomy colostomy
11424946|NCT01869231|Experimental|other surgery|all of others abdominal surgical intervention
11424947|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
11424948|NCT01869205|Experimental|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
11424949|NCT01869192|Active Comparator|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
11424950|NCT01869192|Active Comparator|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
11424951|NCT01869179|Experimental|Community of Voices choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
11424952|NCT01869179|Experimental|Wait-list control group|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
11424953|NCT01869166|Experimental|anti-tumor response of CART-EGFR|
11424954|NCT01869153||Preterm infants|Preterm infants born at either <32 weeks gestation or < 1750g birth weight
11424955|NCT01869140|Sham Comparator|sham spinal manual therapy|activator set to zero
11424956|NCT01869140|Experimental|percussive spinal manual therapy|activator set to the maximum force
11424957|NCT01869140|Experimental|Firm thoracic spinal manual therapy|Firm thoracic manipulation
11424958|NCT01869127|No Intervention|Control|Standard care
11424959|NCT01869127|Experimental|Shoes|Shoes
11424960|NCT01869114|Experimental|High risk Myleodysplastic Syndrome (MDS)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11424961|NCT01869114|Experimental|Acute Myeloid Leukemia (AML)|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11424962|NCT01869114|Experimental|MDS or AML with prior Azacitadine therapy|Patients receive sirolimus PO on days 1-10 or 1-12 and azacitidine IV on days 4-8, 11, and 12 or days 4-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11424963|NCT01869088|Active Comparator|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
11424964|NCT01869088|Experimental|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
11424965|NCT01869075|Experimental|AMI - Knowledge Translation toolkit|AMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
11424966|NCT01869075|No Intervention|AMI - Usual Care|Usual care
11424967|NCT01869075|Experimental|MGS - Knowledge Translation Toolkit|Knowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
11424968|NCT01869075|No Intervention|MGS - Usual Care|Usual Care
11424969|NCT01869075|Experimental|HFS - Knowledge Translation Toolkit|Knowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
11424970|NCT01869075|No Intervention|HFS - Usual Care|Usual Care
11424971|NCT01869062|Other|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
11424972|NCT01869062|Other|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
11424973|NCT01869049||ITP patients accepted splenectomy|
11424974|NCT01869049||Trauma with spleen rupture underwent splenectomy|
11424975|NCT01869036|Active Comparator|caudal anesthesia|
11424976|NCT01869036|Active Comparator|caudal anesthesia supplemented with morphine|
11424977|NCT01869023|Other|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
11424978|NCT01869010||HIV Tenofovir|
11424979|NCT01869010||HIV No tenofovir|
11424980|NCT01869010||Seronegative controls|
11424981|NCT01868997|Placebo Comparator|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
11424982|NCT01868997|Experimental|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
11424983|NCT01868984|Sham Comparator|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
11424984|NCT01868984|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
11424985|NCT01868971|Other|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
11424986|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
11424987|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
11424988|NCT01868945|Experimental|5 µg/day Hy.D Calcifediol|
11424989|NCT01868945|Experimental|10 µg/day Hy.D Calcifediol|
11424990|NCT01868945|Experimental|15 µg/day Hy.D Calcifediol|
11424991|NCT01868945|Active Comparator|20 µg/day vitamin D3|
11424992|NCT01868932|Experimental|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
11424993|NCT01868932|Active Comparator|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
11424994|NCT01868919|Experimental|Positive Parenting Program|Level 3 or 4 of Triple P
11424995|NCT01868906|Other|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
11424996|NCT01868906|Other|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
11424997|NCT01868893|Experimental|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
11424998|NCT01868880|Experimental|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
11424999|NCT01868880|Active Comparator|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
11425000|NCT01868867|Experimental|Intervention|Receives on line training and text messaging for treatment
11425001|NCT01868867|No Intervention|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
11425002|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
11425003|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
11425004|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
11425005|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
11425006|NCT01868841|Active Comparator|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
11425007|NCT01868841|Active Comparator|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
11425008|NCT01868828|Experimental|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)
~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)
~Drug: Dexamethasone(40mg, orally, on days 1-4)
~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
~Not suitable for transplant patients will continue accept treatment for 8 cycles."
11425009|NCT01868828|Experimental|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)
~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)
~Drug: Dexamethasone(40mg, orally, on days 1-4)
~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
~Not suitable for transplant patients will continue accept treatment for 8 cycles."
11425010|NCT01868802|Experimental|Ketamine treated|
11425011|NCT01868802|Placebo Comparator|Control, placebo treated|
11425012|NCT01868789|Experimental|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
11425013|NCT01868789|Active Comparator|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
11425014|NCT01868776|Experimental|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
11425015|NCT01868776|Active Comparator|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
11425016|NCT01868763|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks.
11425017|NCT01868763|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
11425018|NCT01868763|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
11425019|NCT01868750|Active Comparator|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
11425020|NCT01868750|Placebo Comparator|Control|Placebo pill taken twice daily for 7 days prior to surgery
11425021|NCT01868737|Experimental|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
11425022|NCT01868737|Placebo Comparator|HIV- exposed infants|MCT oil
11425023|NCT01868737|Placebo Comparator|HIV-unexposed infants|MCT oil
11425024|NCT01868737|Experimental|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
11425025|NCT01868711|Active Comparator|*Cognitive behavior therapy|Depressed patients will receive 12 sessions of cognitive behavior therapy (CBT) for depression. CBT Includes behavior activation, correcting distorted thoughts, and other tools to reduce symptoms.
11425026|NCT01868711|Other|Supportive psychotherapy|Supportive psychotherapy aims to strengthen the patient's ability to cope effectively with various life stressors. Specifically, in our study, supportive psychotherapy will be geared towards reducing or alleviating symptoms of depression.
11425027|NCT01868698|Experimental|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
11425028|NCT01868698|Experimental|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
11425029|NCT01868698|Experimental|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
11425030|NCT01868685|Placebo Comparator|Placebo|
11425031|NCT01868685|Experimental|BYM338|
11425032|NCT01868672|No Intervention|Control|Participant receives usual care.
11425033|NCT01868672|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
11425034|NCT01868659|Experimental|Diagnostic checklist|Diagnostic checklist used before patient discharged
11425035|NCT01868659|Placebo Comparator|Usual care|No diagnostic checklist used during patient encounter
11425036|NCT01868646|Experimental|Subetta|
11425037|NCT01868646|Placebo Comparator|Placebo|
11425038|NCT01868633|Active Comparator|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
11425039|NCT01868633|Placebo Comparator|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
11425040|NCT01868620|Experimental|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
11425041|NCT01868620|Active Comparator|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
11425042|NCT01868607||Adult lung function|
11425043|NCT01868594|Experimental|Subetta group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
11425044|NCT01868594|Placebo Comparator|Placebo group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
11425045|NCT01868581|Experimental|insulin degludec|
11425046|NCT01868581|Experimental|IDegAsp|
11425047|NCT01868568|Experimental|IDegAsp 30 + placebo|
11425048|NCT01868568|Experimental|Insulin aspart + insulin degludec - low concentration 1|
11425049|NCT01868568|Experimental|IDegAsp 40 + placebo|
11425050|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration 1|
11425051|NCT01868568|Experimental|IDegAsp 45 + placebo|
11425052|NCT01868568|Experimental|Insulin aspart + insulin degludec|
11425053|NCT01868568|Experimental|IDegAsp 55 + placebo|
11425054|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration|
11425055|NCT01868568|Active Comparator|BIAsp 30 + placebo|
11425056|NCT01868555|Experimental|IDegAsp 30|
11425057|NCT01868555|Experimental|IDegAsp 45|
11425058|NCT01868555|Experimental|insulin degludec (B)|
11425059|NCT01868555|Experimental|insulin degludec (E)|
11425060|NCT01868542|Experimental|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : >6.1 mmol/L (>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, < 4.4 mmol/L (<80 mg/dL) -3U insulin detemir.
11425061|NCT01868542|Experimental|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : >10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, <3.1 mmol/L (<56 mg/dL) -4U insulin detemir.
11425062|NCT01868529|Experimental|Low dose|
11425063|NCT01868529|Experimental|Medium dose|
11425064|NCT01868529|Experimental|High dose|
11425065|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
11425066|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
11425067|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
11425068|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
11425069|NCT01868503|Experimental|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
11425070|NCT01868490|Experimental|drug|single-group studies
11425071|NCT01868477|Experimental|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
11425072|NCT01868477|Experimental|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
11425073|NCT01868464|Experimental|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10^6 cfu
11425074|NCT01868464|Experimental|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10^6 colony forming units (cfu)
11425075|NCT01868464|Experimental|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10^6 cfu
11425076|NCT01868464|Experimental|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10^6 cfu
11425077|NCT01868451|Experimental|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
11425078|NCT01868451|Experimental|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
11425079|NCT01868451|Experimental|Cohort 3|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
11425116|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
11425117|NCT01868165||Cohort of older adults taking antihypertensives|Adults aged 80 and over treated with antihypertensive drugs
11425080|NCT01868451|Experimental|Cohort 4|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin & AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 & 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin & AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin & AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck & diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
11425081|NCT01868438|Active Comparator|Pyronaridine-artesunate granules (Period 1)|"In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.
~In second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
11425082|NCT01868438|Active Comparator|Pyronaridine-artesunate tablets (Period1)|"In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.
~In second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
11425083|NCT01868425|Experimental|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
11425084|NCT01868425|Placebo Comparator|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
11425085|NCT01868412|Experimental|Resin & honey|Abilar 10% resin salve
11425086|NCT01868412|Active Comparator|Resin vs. honey|Activon Tube 25 g
11425087|NCT01868399||Suspected dengue fever subjects|No any intervention
11425088|NCT01868399||Community Healty Residents|No intervention
11425089|NCT01868386|Experimental|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
11425090|NCT01868386|Experimental|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
11425091|NCT01868386|Experimental|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
11425092|NCT01868386|Experimental|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
11425093|NCT01868373|Other|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
11425094|NCT01868360|Experimental|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.
~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
11425095|NCT01868360|Placebo Comparator|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
11425096|NCT01868347|Active Comparator|control|PEEP after pneumoperitoneum and trendelenburg
11425097|NCT01868347|Experimental|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
11425098|NCT01868334|Experimental|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation
~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
11425099|NCT01868334|No Intervention|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
11425100|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
11425101|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
11425102|NCT01868295|Experimental|Sleeping with denture|Sleeping with denture at night
11425103|NCT01868295|No Intervention|Sleeping without denture|Sleeping without denture at night
11425104|NCT01868282|Experimental|Group 1|Hamstrings block
11425105|NCT01868282|Active Comparator|Group 2|Obturator block
11425106|NCT01868282|Sham Comparator|Group 3|Control group
11425107|NCT01868269|Other|Dexamethasone Cyclophosphamide Rituximab|
11425108|NCT01868256|Experimental|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in < 72 hours
11425109|NCT01868256|Active Comparator|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
11425110|NCT01868243|Experimental|Dabigatran|Dabigatran 110 mg BID
11425111|NCT01868243|Active Comparator|Warfarin|Warfarin adjusted-dose
11425112|NCT01868230|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
11425113|NCT01868230|No Intervention|Standard of Care|
11425114|NCT01868191|Placebo Comparator|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
11425115|NCT01868191|Experimental|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
11425118|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
11425119|NCT01868126|Experimental|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
11425120|NCT01868126|Experimental|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
11425121|NCT01868126|Experimental|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
11425122|NCT01868126|Experimental|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
11425123|NCT01868126|Active Comparator|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
11425124|NCT01868126|Placebo Comparator|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
11425125|NCT01868113|Active Comparator|Inhaled fluticasone propionate|Inhaled corticosteroid
11425126|NCT01868113|Placebo Comparator|Inhaler propellant|Placebo
11425127|NCT01868100|No Intervention|self-completion questionnaire|
11425128|NCT01868087|Experimental|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
11425129|NCT01868087|Placebo Comparator|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
11425130|NCT01868074|No Intervention|Usual|Participants who are not randomized to the fitted insole intervention
11425131|NCT01868074|Experimental|Insole|Participants randomized to use of a custom-molded insole during pregnancy
11425132|NCT01868061|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
11425133|NCT01868061|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
11425134|NCT01868061|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
11425135|NCT01868048|Experimental|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.
~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
11425136|NCT01868048|Placebo Comparator|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
11425137|NCT01868035|Experimental|Single Arm|tositumomab and iodine I-131 tositumomab
11425138|NCT01868022|Experimental|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
11425139|NCT01868022|Experimental|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
11425140|NCT01868022|Experimental|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
11425141|NCT01868009|Experimental|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
11425142|NCT01868009|Experimental|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
11425143|NCT01867996|Experimental|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
11425144|NCT01867983|Active Comparator|Control|Behavioral: Smoking cessation
11425145|NCT01867983|Experimental|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
11425146|NCT01867983|Experimental|Sequential|Behavioral: Weight gain prevention and smoking cessation
11425147|NCT01867970|Experimental|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
11425148|NCT01867970|Experimental|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
11425192|NCT01867684|No Intervention|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
11425193|NCT01867684|Experimental|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
11425194|NCT01867671|Experimental|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
11425149|NCT01867970|No Intervention|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
11425150|NCT01867957|Experimental|Low-dose GC1109|
11425151|NCT01867957|Placebo Comparator|Low-dose Placebo|
11425152|NCT01867957|Experimental|High-dose GC1109|
11425153|NCT01867957|Placebo Comparator|High-dose Placebo|
11425154|NCT01867944|Experimental|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
11425155|NCT01867944|Active Comparator|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
11425156|NCT01867931||Erosive Esophagitis|
11425157|NCT01867931||Non-erosive Reflux Disease|
11425158|NCT01867931||Heatlhy volunteers|
11425159|NCT01867918|Experimental|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
11425160|NCT01867918|Placebo Comparator|Cheomotherapy|Standard chemotherapy
11425161|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
11425162|NCT01867892|Experimental|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
11425163|NCT01867892|Active Comparator|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
11425164|NCT01867879|Experimental|TAS-102|
11425165|NCT01867879|Placebo Comparator|Placebo|
11425166|NCT01867866|Experimental|TAS-102|
11425167|NCT01867866|Experimental|FTD (Trifluridine)|
11425168|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
11425169|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
11425170|NCT01867840||arthritis|
11425171|NCT01867827|Experimental|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
11425172|NCT01867827|Active Comparator|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
11425173|NCT01867814|Experimental|Pneumoperitoneum|Patients undergoing laparoscopic surgery
11425174|NCT01867788||Parkinson's disease subjects|
11425175|NCT01867788||Healthy Control subjects|
11425176|NCT01867775|Active Comparator|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
11425177|NCT01867775|Placebo Comparator|Placebo|Placebo 15 mg, once a day at night for 14 days
11425178|NCT01867762|Experimental|JNJ 49095397|
11425179|NCT01867762|Placebo Comparator|Placebo|
11425180|NCT01867749|Experimental|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
11425181|NCT01867749|Active Comparator|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
11425182|NCT01867736|Experimental|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
11425183|NCT01867736|Active Comparator|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
11425184|NCT01867723|Experimental|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
11425185|NCT01867723|No Intervention|Control group|Control group get usual care
11425186|NCT01867710|Experimental|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
11425187|NCT01867710|Experimental|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
11425188|NCT01867710|Experimental|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
11425189|NCT01867710|Experimental|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
11425190|NCT01867697|Active Comparator|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
11425191|NCT01867697|Experimental|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
11425195|NCT01867671|Placebo Comparator|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
11425196|NCT01867658|Experimental|Progel® Pleural Air Leak Sealant|
11425197|NCT01867645|Active Comparator|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
11425198|NCT01867645|Placebo Comparator|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
11425199|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
11425200|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
11425201|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.
~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
11425202|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.
~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
11425203|NCT01867593|Experimental|C-11 methionine PET|C-11 methionine PET pre and post radiation
11425204|NCT01867580|Experimental|V.A.C.Ulta with Prontosan instillation|Treatment Arm
11425205|NCT01867580|Active Comparator|V.A.C.Ulta without instillation|Control Arm
11425206|NCT01867567|Experimental|6 Hours|Removal of bandage after 6 hours
11425207|NCT01867567|Active Comparator|24 hours|removal of bandage after 24 hours
11425208|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
11425209|NCT01867528|Experimental|Laparoscopic adhesiolysis|
11425210|NCT01867528|Active Comparator|Open adhesiolysis|
11425211|NCT01867515|Active Comparator|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.
~age between 18 and 35
~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
11425212|NCT01867515|Active Comparator|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below
~age 18 to 65 Acoustic distortion of speech"
11425213|NCT01867515|Active Comparator|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.
~age between 36 and 65
~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
11425214|NCT01867502|Other|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.
~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
11425215|NCT01867502|Other|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.
~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
11425216|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
11425217|NCT01867476||Healthy Normals|
11425218|NCT01867463|Experimental|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
11425219|NCT01867463|Experimental|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
11425220|NCT01867463|Experimental|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
11425221|NCT01867450||Biomarker Cross-section|Cross-sectional biomarker study in Chinese diesel workers
11425222|NCT01867437|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
11425223|NCT01867437|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
11425224|NCT01867424|Active Comparator|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
11425225|NCT01867424|Active Comparator|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
11425226|NCT01867411||ex-smokers|former smokers who have quit
11425227|NCT01867411||never smokers|never smoked
11425228|NCT01867411||non-treatment seeking smokers|smokers not interested in quitting smoking
11425229|NCT01867411||Treatment seeking smokers|smokers interested in quitting smoking
11425230|NCT01867333|Experimental|1|Enzaluatmide alone
11425231|NCT01867333|Experimental|2|Enzaluatmide with PSA-TRICOM
11425232|NCT01867320|Experimental|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
11425233|NCT01867307|Experimental|Healthy Controls|healthy controls
11425234|NCT01867307|Experimental|Patients|patients with type 2 diabetes mellitus
11425235|NCT01867294|Experimental|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
11425236|NCT01867294|Experimental|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
11425237|NCT01867294|Placebo Comparator|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
11425238|NCT01867294|Active Comparator|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
11425239|NCT01867281|Active Comparator|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
11425240|NCT01867281|Placebo Comparator|Control: placebo|Participants will receive placebo
11425241|NCT01867268|Experimental|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
11425242|NCT01867268|No Intervention|Control|control group without any intervention
11425243|NCT01867268|Experimental|Prone positioning|Positioning the patient following surgery for 10 days
11425244|NCT01867268|Experimental|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
11425245|NCT01867255|Other|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
11425246|NCT01867242|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
11425247|NCT01867242|Experimental|Complete Substitution|Use snus in place of cigarettes
11425248|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes)|Use snus and cigarettes how ever you like
11425249|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
11425250|NCT01867216|Placebo Comparator|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
11425251|NCT01867216|Experimental|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
11425252|NCT01867203||Statin users|
11425253|NCT01867190|Other|ASCT01|ASCT01 (Autologous Stem Cell Transplantation)
11425254|NCT01867177|Other|HIV testing|Identification of HIV infection among recently infected adults
11425255|NCT01867177|Experimental|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
11425256|NCT01867177|Active Comparator|standard of care|Standard of HIV care; standard of linkage to HIV care
11425257|NCT01867164|Experimental|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
11425258|NCT01867164|Experimental|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
11425259|NCT01867151|Experimental|Gluten free diet|BMS patients following a GFD
11425260|NCT01867151|Sham Comparator|Normal Diet|Patients with BMS maintaing a normal diet
11425261|NCT01867138|Experimental|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
11425262|NCT01867138|Active Comparator|Vancomycin|Initial empirical treatment with vancomycin and amikacin
11425263|NCT01867125|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams [mg]) every 4 weeks for 104 weeks.
11425264|NCT01867125|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
11425265|NCT01867125|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
11425266|NCT01867112|Active Comparator|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
11425267|NCT01867112|Active Comparator|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
11425268|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
11425269|NCT01867086|Experimental|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
11425270|NCT01867073||Advanced solid tumours|
11425271|NCT01867060|Other|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
11425272|NCT01867047|Experimental|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
11425273|NCT01867047|Experimental|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)
11425274|NCT01867034|Active Comparator|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
11425275|NCT01867034|Active Comparator|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
11425276|NCT01867021|Experimental|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
11425277|NCT01867021|Active Comparator|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
11425278|NCT01866995|Experimental|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
11425279|NCT01866995|Active Comparator|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
11425340|NCT01866488|Experimental|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
11425280|NCT01866995|Experimental|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
11425281|NCT01866982|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
11425282|NCT01866982|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
11425283|NCT01866969|Experimental|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
11425284|NCT01866943|Placebo Comparator|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
11425285|NCT01866943|Experimental|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
11425286|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks
~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks
~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
11425287|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks
~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks
~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
11425288|NCT01866917|Experimental|TAP|Patients will receive Ropivicaine 0.5% 20cc injectate from a study labeled syringe
11425289|NCT01866917|Placebo Comparator|Saline|Patients will receive Normal saline 20cc injectate from a study labeled syringe
11425290|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
11425291|NCT01866891|Experimental|single arm|
11425292|NCT01866878|Experimental|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.
~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.
~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
11425293|NCT01866878|Experimental|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
11425294|NCT01866878|No Intervention|A control group|
11425295|NCT01866839|Experimental|CD34+ cell positively selected graft stem cell recipient|Recipients received a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg total), fludarabine (125 mg/m2 total) and total body irradiation (1200 cGy with lung shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS® system. Older subjects will receive a lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
11425296|NCT01866826|Experimental|HIV Infected Subjects|Human immunodeficiency virus (HIV) infected subjects with viral suppression on antiretroviral (ART). Double-blinded/placebo controlled trial with cross-over design. Rifaximin
11425297|NCT01866826|Placebo Comparator|HIV Infected Subjects Placebo|HIV infected subjects with viral suppression on ART. Double-blinded/placebo controlled trial with cross-over design. Placebo
11425298|NCT01866813|No Intervention|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
11425299|NCT01866813|Experimental|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
11425300|NCT01866800|Active Comparator|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
11425301|NCT01866800|Placebo Comparator|Conventional Treatment|Saline and N-Acetylcysteine
11425302|NCT01866787||Study cohort|
11425303|NCT01866774|Experimental|Fecal calprotectin level|Fecal calprotectin level
11425304|NCT01866774|No Intervention|Symptom questionnaire|
11425305|NCT01866761||Periodontitis, Lifestyle-related disease|
11425306|NCT01866748|Experimental|Part A (single dose)|
11425307|NCT01866748|Experimental|Part B (multiple dose)|
11425308|NCT01866735|No Intervention|Usual Care|
11425341|NCT01866488|Placebo Comparator|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
11425342|NCT01866475|Active Comparator|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
11425343|NCT01866475|Active Comparator|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
11425960|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
11425309|NCT01866735|Experimental|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):
~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
11425310|NCT01866722|Active Comparator|Usual Care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
11425311|NCT01866722|Active Comparator|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
11425312|NCT01866722|Active Comparator|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
11425313|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
11425314|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
11425315|NCT01866696|Experimental|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
11425316|NCT01866683|Experimental|Group 1|1 month respiratory training
11425317|NCT01866683|Experimental|Group 2|1 month waiting period
11425318|NCT01866670|Experimental|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation
~Each patient will participate individually in three sequential meetings (A1, A2 and A3).
~In the experimental group, it will be developed the support spiritual intervention in all three meetings.
~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
11425319|NCT01866670|Active Comparator|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).
~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
11425320|NCT01866657|Experimental|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
11425321|NCT01866657|No Intervention|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
11425322|NCT01866644|Experimental|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
11425323|NCT01866644|Placebo Comparator|Saline|With usual technique
11425324|NCT01866631||No treatment|
11425325|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
11425326|NCT01866605|Placebo Comparator|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
11425327|NCT01866605|Active Comparator|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
11425328|NCT01866605|Active Comparator|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
11425329|NCT01866592|Other|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
11425330|NCT01866579||ethambutol optic neuropathy|
11425331|NCT01866566|Placebo Comparator|HBV-3|one dose HBV
11425332|NCT01866566|Placebo Comparator|HBV-6|one dose HBV
11425333|NCT01866566|Experimental|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
11425334|NCT01866566|Experimental|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
11425335|NCT01866553|Experimental|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
11425336|NCT01866540|Experimental|Fluenz vaccine|LAIV vaccine
11425337|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
11425338|NCT01866514|Experimental|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
11425339|NCT01866501|Experimental|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
11426039|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - fMRI|
11425344|NCT01866475|Active Comparator|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
11425345|NCT01866475|Active Comparator|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
11425346|NCT01866462|Experimental|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
11425347|NCT01866462|Placebo Comparator|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
11425348|NCT01866449|Experimental|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
11425349|NCT01866436|Experimental|Multimedia group|The multimedia group is the interventional arm of the study
11425350|NCT01866436|Experimental|Study Day Group|The study day group are the control arm of the study
11425351|NCT01866423|Experimental|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11425352|NCT01866410|Experimental|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11425353|NCT01866397|Experimental|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
11425354|NCT01866384|Other|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
11425355|NCT01866384|Experimental|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
11425356|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
11425357|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
11425358|NCT01866358|Placebo Comparator|Umbilical vein infusion|using umbilical vein infusion for resucitation
11425359|NCT01866358|Experimental|Intraosseous infusion|using intraosseous infusion for resucitation
11425360|NCT01866345|Active Comparator|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
11425361|NCT01866345|Experimental|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
11425362|NCT01866332|Active Comparator|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
11425363|NCT01866332|Experimental|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.
~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
11425364|NCT01866319|Experimental|Ipilimumab|Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
11425365|NCT01866319|Experimental|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
11425366|NCT01866319|Active Comparator|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.
11425367|NCT01866306|Experimental|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425368|NCT01866306|Experimental|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425369|NCT01866306|Experimental|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425370|NCT01866306|Experimental|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425371|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425372|NCT01866306|Experimental|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425373|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
11425374|NCT01866293|Experimental|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
11425375|NCT01866280|Experimental|Normal sleep Normal meals|Normal sleep/Normal meal times
11425376|NCT01866280|Experimental|Normal sleep Late meals|Normal sleep/Late meal times
11425377|NCT01866280|Experimental|Late sleep Late meals|Late sleep/Late meal times
11425378|NCT01866280|Experimental|Late sleep Normal meals|Late sleep/Normal meal times
11425379|NCT01866267|Other|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
11425380|NCT01866254|Experimental|Hydromorphone|100 mg, intrathecal administration
11425381|NCT01866254|Active Comparator|Morphine|200 mg, intrathecal administration
11425382|NCT01866241|Experimental|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
11425383|NCT01866241|Placebo Comparator|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
11425384|NCT01866228|No Intervention|No Consultation Recording|Participant does not receive consultation recording
11425385|NCT01866228|Experimental|Consultation Recording|Participant receives consultation recording
11425386|NCT01866215|Experimental|Study1a|exercice performed 90 min before 13C fructose meal ingestion
11425387|NCT01866215|Experimental|study 1b|exercise performed 90 min after 13C fructose meal ingestion
11425388|NCT01866215|No Intervention|study 1c|no exercise
11425389|NCT01866215|Experimental|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
11425390|NCT01866215|Active Comparator|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
11425391|NCT01866189|Experimental|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
11425392|NCT01866176|Experimental|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren & Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
11425393|NCT01866163|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
11425394|NCT01866163|Placebo Comparator|Vehicle|Aerosol foam vehicle
11425395|NCT01866150||Cohort|
11425396|NCT01866137||no treatment|no treatment
11425397|NCT01866124|Experimental|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.
~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
11425398|NCT01866124|No Intervention|Comparison group|
11425399|NCT01866111|Placebo Comparator|Placebo|Placebo
11425400|NCT01866111|Experimental|YKP3089 Low Dose|YKP3089 Low Dose
11425401|NCT01866111|Experimental|YKP3089 Medium Dose|YKP3089 Medium Dose
11425402|NCT01866111|Experimental|YKP3089 High Dose|YKP3089 High Dose
11425403|NCT01866098|Experimental|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
11425404|NCT01866098|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 52 weeks
11425405|NCT01866098|Experimental|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
11425406|NCT01866085|Active Comparator|AdVance|sling procedure
11425407|NCT01866085|Active Comparator|ARGUS|sling procedure
11425408|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
11425409|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
11425410|NCT01866059|Experimental|Calcium silicate cement|Biodentine
11425411|NCT01866059|Active Comparator|Glass Ionomer Cement|Fuji IX
11425412|NCT01866059|Active Comparator|Resin Modified Glass Ionomer Cement|Fuji II LC
11425413|NCT01866046|Experimental|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
11425414|NCT01866033|Experimental|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
11425415|NCT01866007|Experimental|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
11425416|NCT01866007|Experimental|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
11425417|NCT01866007|Experimental|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
11425418|NCT01866007|Experimental|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
11425419|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
11425420|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
11425421|NCT01865981||Brugada|Patients suffering from Brugada syndrome
11425422|NCT01865968|Experimental|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
11425423|NCT01865968|Active Comparator|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
11425424|NCT01865968|Experimental|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
11425425|NCT01865955|No Intervention|Palpation|Palpation will be used to determine placement of the spinal needle.
11425426|NCT01865955|Experimental|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
11425427|NCT01865942|Active Comparator|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
11425544|NCT01865175|Experimental|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
11425428|NCT01865942|Active Comparator|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
11425429|NCT01865929|Active Comparator|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
11425430|NCT01865929|Active Comparator|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
11425431|NCT01865916|Active Comparator|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
11425432|NCT01865916|Experimental|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
11425433|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
11425434|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
11425435|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
11425436|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
11425437|NCT01865864||1|Compliant with CPAP
11425438|NCT01865864||2|noncompliant with CPAP
11425439|NCT01865851|Active Comparator|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
11425440|NCT01865851|Active Comparator|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
11425441|NCT01865838|Active Comparator|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
11425442|NCT01865838|No Intervention|Control|Patients in this arm does NOT receive Seprafilm during surgery.
11425443|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.
~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
11425444|NCT01865812|Experimental|OCA: 10 mg|obeticholic acid, oral administration, 10 mg, 8 weeks
11425445|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
11425446|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
11425447|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
11425448|NCT01865773|Experimental|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
11425449|NCT01865760|Experimental|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
11425450|NCT01865760|Active Comparator|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
11425451|NCT01865760|Other|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
11425452|NCT01865747|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
11425453|NCT01865747|Active Comparator|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
11425454|NCT01865734|Experimental|Early Physical Therapy|Physical therapy after initial podiatry visit
11425455|NCT01865734|Active Comparator|Usual Podiatric Care|Usual care provided by podiatry
11425456|NCT01865721|Active Comparator|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
11425457|NCT01865721|Active Comparator|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
11425458|NCT01865708|Other|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
11425459|NCT01865695|Placebo Comparator|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
11425460|NCT01865695|Active Comparator|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
11426040|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - fMRI|
11425461|NCT01865669|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
11425462|NCT01865669|Experimental|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
11425463|NCT01865656|Other|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:
~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
11425464|NCT01865656|No Intervention|Control Arm|
11425465|NCT01865643|Other|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
11425466|NCT01865643|Experimental|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
11425467|NCT01865630|Experimental|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
11425468|NCT01865617|Experimental|Treatment (anti-CD19-CAR autologous T cells)|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.
~DOSE DENSE EXPANSION COHORT: An additional cohort will receive a second anti-CD19-CAR lentiviral vector-transduced autologous T cell infusion without additional lymphodepleting chemotherapy 10-21 days after the first infusion if adequate CD19 CAR-T cells can be produced and appropriate criteria are met."
11425469|NCT01865604|Experimental|Anodal tDCS|anaodal transcranial direct current stimulation
11425470|NCT01865604|Active Comparator|Cathodal tDCS|cathodal transcranial direct current stimulation
11425471|NCT01865604|Sham Comparator|Sham tDCS|no stimulation
11425472|NCT01865591|Experimental|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
11425473|NCT01865578|Experimental|tDCS|Transcranial direct current stimulation
11425474|NCT01865578|Sham Comparator|sham stimulation|sham stimulation
11425475|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at
~EC junction requiring total gastrectomy,
~Duodenum requiring Whipple operation;
~Large GIST requiring multiviceral resection;
~Rectum: requiring APR."
11425476|NCT01865552|Experimental|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
11425477|NCT01865552|Experimental|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
11425478|NCT01865552|Experimental|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
11425479|NCT01865552|Experimental|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
11425480|NCT01865552|Other|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
11425481|NCT01865552|Other|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
11425482|NCT01865539|Active Comparator|Custom Foot Orthotic|Custom foot orthotic
11425483|NCT01865539|Sham Comparator|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
11425484|NCT01865526|Active Comparator|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
11425485|NCT01865526|Experimental|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
11425486|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 4mg|
11425487|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 8 mg|
11425488|NCT01865500|Active Comparator|Budesonide 4 mg & Budesonide 8 mg|
11425489|NCT01865487|Placebo Comparator|2-Dose Placebo|Placebo QFT Neg and Pos, 2 Doses, days 0,56
11425490|NCT01865487|Experimental|2-Dose 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56
11425491|NCT01865487|Experimental|2-Dose 15/500 H56ug/IC31nmol|15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
11425492|NCT01865487|Experimental|2-Dose 50/500 H56ug/IC31nmol|50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
11425493|NCT01865487|Placebo Comparator|3-Dose, Placebo|Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112
11425494|NCT01865487|Experimental|3-Dose, 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112
11425495|NCT01865474|Experimental|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
11425496|NCT01865474|Experimental|Treatment II|Placebo tablet of DLBS1033, thrice daily
11425497|NCT01865448|Active Comparator|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
11425498|NCT01865448|Placebo Comparator|Control|Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
11425499|NCT01865435|Experimental|new borns|
11425500|NCT01865422|Experimental|chronic cough|
11425545|NCT01865162|Experimental|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
11425546|NCT01865149||both optic nerve sheath diameter|
11425501|NCT01865409|Active Comparator|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
11425502|NCT01865396|Experimental|early palliative care|Interventional palliative care, after diagnosis and once a month.
11425503|NCT01865396|Active Comparator|Standard care|Patients will receive the standard oncologic care.
11425504|NCT01865383|Experimental|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
11425505|NCT01865383|No Intervention|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
11425506|NCT01865370|Experimental|Kochujang Pills|
11425507|NCT01865370|Placebo Comparator|Placebo|
11425508|NCT01865357|Experimental|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
11425509|NCT01865357|Experimental|Control|healthy subject
11425510|NCT01865344||Heart surgery|Pain monitoring at different time periods
11425511|NCT01865331|Experimental|Low dose, insulin degludec|
11425512|NCT01865331|Experimental|Medium dose, insulin degludec|
11425513|NCT01865331|Experimental|High dose, insulin degludec|
11425514|NCT01865331|Experimental|IDegAsp 50|
11425515|NCT01865318|Experimental|Part 1 (Once-daily dosing regimen, high concentration)|
11425516|NCT01865318|Experimental|Part 2 (Twice-daily dosing regimen, high concentration)|
11425517|NCT01865318|Experimental|Part 3 (Once-daily dosing regimen, low concentration)|
11425518|NCT01865305|Experimental|Trial part 1|
11425519|NCT01865305|Experimental|Trial part 2|
11425520|NCT01865292|Experimental|Insulin degludec|
11425521|NCT01865292|Active Comparator|Insulin glargine|
11425522|NCT01865279|Experimental|Trial part 1|
11425523|NCT01865279|Active Comparator|Trial part 2|
11425524|NCT01865266|Experimental|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):
~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
11425525|NCT01865266|Experimental|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):
~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
11425526|NCT01865266|Placebo Comparator|CG|"The compare group(CG):
~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
11425527|NCT01865253|Experimental|Renal Denervation|Renal Denervation treatment
11425528|NCT01865240|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
11425529|NCT01865240|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
11425530|NCT01865227|Active Comparator|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
11425531|NCT01865227|No Intervention|Standard treatment|
11425532|NCT01865201|Experimental|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
11425533|NCT01865201|Experimental|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
11425534|NCT01865188|Experimental|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
11425535|NCT01865188|Experimental|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
11425536|NCT01865188|Active Comparator|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
11425537|NCT01865188|Active Comparator|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
11425538|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
11425539|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
11425540|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
11425541|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
11425542|NCT01865188|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
11425543|NCT01865175|Active Comparator|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
11425547|NCT01865136|Other|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
11425548|NCT01865136|No Intervention|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
11425549|NCT01865123|Experimental|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
11425550|NCT01865123|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
11425551|NCT01865123|Placebo Comparator|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
11425552|NCT01865110|Experimental|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
11425553|NCT01865110|Active Comparator|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
11425554|NCT01865110|Experimental|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
11425555|NCT01865110|Active Comparator|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
11425556|NCT01865097|Experimental|Relaxation guided imagery|
11425557|NCT01865097|Active Comparator|Relaxing music|
11425558|NCT01865084|Experimental|Placebo|Placebo taken orally once daily.
11425559|NCT01865084|Experimental|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
11425560|NCT01865084|Experimental|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
11425561|NCT01865071|Experimental|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
11425562|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
11425563|NCT01865045||no treatment|no treatment
11425564|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
11425565|NCT01865019||volume controlled|volume ontrolled ventilation
11425566|NCT01865019||pressure controlled|pressure controlled ventilation
11425567|NCT01865006||Ligasure LF1212|
11425568|NCT01865006||Ultracision|
11425569|NCT01865006||Conventional|
11425570|NCT01864993|Experimental|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
11425571|NCT01864993|Experimental|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
11425572|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
11425573|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
11425574|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
11425575|NCT01864967||control|did not receive carbon dioxide
11425576|NCT01864954|Experimental|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
11425577|NCT01864954|Active Comparator|Basic Static Web|Static website access only, only introductory call.
11425578|NCT01864941|Active Comparator|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
11425579|NCT01864941|Sham Comparator|Catheter Venography Only|Patients will undergo catheter venography only.
11425580|NCT01864928||Stroke population|Adults with ischemic stroke.
11425581|NCT01864915|Experimental|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
11425582|NCT01864915|Experimental|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
11425583|NCT01864915|Experimental|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
11425584|NCT01864902|Experimental|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
11425585|NCT01864889|Experimental|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
11425586|NCT01864876|Experimental|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
11425587|NCT01864876|Experimental|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
11425588|NCT01864876|Experimental|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
11425589|NCT01864863|Experimental|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
11425590|NCT01864863|Experimental|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
11425591|NCT01864850|Active Comparator|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
11425592|NCT01864850|Experimental|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
11425593|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
11425594|NCT01864824|Experimental|methyl donor|"Methyl donor is made up of:
~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
11426041|NCT01861639|Experimental|ineffective rTMS - Active TBS - EEG|
11425595|NCT01864824|Placebo Comparator|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
11425596|NCT01864811|Experimental|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
11425597|NCT01864811|Experimental|baby-massage|The infants will receive baby massage
11425598|NCT01864798|Experimental|Denosumab|
11425599|NCT01864785|Other|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
11425600|NCT01864785|Other|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
11425601|NCT01864772|Experimental|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)
~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
11425602|NCT01864759|Experimental|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
11425603|NCT01864746|Experimental|Palbociclib|Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
11425604|NCT01864746|Placebo Comparator|Placebo|Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles
11425605|NCT01864733|Experimental|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:
~Physical rehabilitation including endurance and resistance exercises two to three times a week.
~Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.
~n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.
~Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
11425606|NCT01864733|Other|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
11425607|NCT01864720|Active Comparator|Professionally Administered CBT-I (Standard Care)|Patients assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
11425608|NCT01864720|Experimental|Stepped Care CBT-I|Patients having an ISI score > 7 but < 15 (approximately 100 patients), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score > 14 (approximately 100 patients) will receive six weekly sessions of CBT-I administered individually by a professional.
11425609|NCT01864707|Experimental|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
11425610|NCT01864707|Experimental|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
11425611|NCT01864707|Active Comparator|usual care|usual care without additional treatment
11425612|NCT01864694|Experimental|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
11425613|NCT01864694|Experimental|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
11425614|NCT01864694|Experimental|Control|Assessment-only control group
11425615|NCT01864681|Experimental|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
11425616|NCT01864681|Placebo Comparator|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
11425617|NCT01864655|Experimental|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
11425618|NCT01864655|Experimental|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
11425619|NCT01864655|Experimental|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
11425620|NCT01864655|Placebo Comparator|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
11425621|NCT01864642|Experimental|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
11425622|NCT01864629|Other|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
11425623|NCT01864629|No Intervention|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
11425624|NCT01864616|Experimental|Group 3|Vitamin D3, 10,000 IU daily
11425625|NCT01864616|Experimental|Group 2|Vitamin D3 2,000 IU daily
11425626|NCT01864616|Experimental|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
11425627|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery
~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
11425660|NCT01864369|Active Comparator|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
11426042|NCT01861639|Experimental|Effective rTMS - Active TBS - EEG|
11426043|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - EEG|
11425628|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: universal test & treat|"Intervention arm first phase: baseline community-based HIV and multi-disease testing
~Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery"
11425629|NCT01864590|Experimental|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
11425630|NCT01864590|Active Comparator|Double Sylo Bag - Mesh Protocol|Open Abdomen
11425631|NCT01864577|Experimental|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
11425632|NCT01864577|Active Comparator|With water seal|Patients al left on water seal only
11425633|NCT01864564|No Intervention|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.
~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
11425634|NCT01864564|Experimental|Early Screening|"Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.
~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
11425635|NCT01864551|Active Comparator|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
11425636|NCT01864551|Active Comparator|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
11425637|NCT01864538|Experimental|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
11425638|NCT01864525|Placebo Comparator|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
11425639|NCT01864525|Experimental|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
11425640|NCT01864512||ITP patients receiving eltrombopag therapy|
11425641|NCT01864499|Experimental|Tumor Resection|
11425642|NCT01864499|Active Comparator|Biopsy Brain Tumor|
11425643|NCT01864486|Experimental|Intelligent Retinal Implant System|
11425644|NCT01864473|Other|Kshar Sutra|
11425645|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
11425646|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
11425647|NCT01864447|Experimental|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of >3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.
~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
11425648|NCT01864447|No Intervention|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
11425649|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
11425650|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
11425651|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
11425652|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
11425653|NCT01864408|Other|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
11425654|NCT01864408|Experimental|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
11425655|NCT01864395|Experimental|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
11425656|NCT01864395|Experimental|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
11425657|NCT01864395|Experimental|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
11425658|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
11425659|NCT01864382|Experimental|Core stability|Core stability.5 days a week during 5 weeks
11426044|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - EEG|
11425661|NCT01864369|Experimental|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
11425662|NCT01864356|Experimental|NT100 Dose 1|NT100 Dose 1
11425663|NCT01864356|Experimental|NT100 Dose 2|NT100 Dose 2
11425664|NCT01864356|Placebo Comparator|Placebo|Placebo
11425665|NCT01864343|Experimental|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
11425666|NCT01864330|Experimental|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
11425667|NCT01864330|Active Comparator|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
11425668|NCT01864330|Active Comparator|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
11425669|NCT01864317|Experimental|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
11425670|NCT01864317|Experimental|Normal Tension Glaucoma|30 patients with normal tension glaucoma
11425671|NCT01864317|Experimental|Ocular Hypertension|30 patients with ocular hypertension
11425672|NCT01864317|Other|Healthy subjects|30 healthy control subjects
11425673|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
11425674|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
11425675|NCT01864291|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
11425676|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
11425677|NCT01864265|Active Comparator|Certolizumab Pegol|
11425678|NCT01864265|Placebo Comparator|Placebo|
11425679|NCT01864252|Sham Comparator|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
11425680|NCT01864252|Active Comparator|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
11425681|NCT01864252|Experimental|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
11425682|NCT01864252|Experimental|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
11425683|NCT01864239|Experimental|Patient-centred tailored intervention|Medicines Advice Service
11425684|NCT01864239|No Intervention|Control|Usual care
11425685|NCT01864226|Placebo Comparator|Placebo|
11425686|NCT01864226|Experimental|RO5545965|
11425687|NCT01864213|Experimental|Ametop cream|
11425688|NCT01864200|Experimental|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
11425689|NCT01864200|Placebo Comparator|Saline placebo|Saline placebo
11425690|NCT01864187|Experimental|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
11425691|NCT01864174|Active Comparator|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks
~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
11425692|NCT01864174|Active Comparator|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks
~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
11425693|NCT01864161|Experimental|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
11425694|NCT01864161|Active Comparator|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
11425695|NCT01864148|Experimental|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.
~Avonex once-weekly intramuscular (IM) injection up to Week 84."
11425696|NCT01864148|Experimental|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
11425697|NCT01864148|Experimental|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
11425698|NCT01864148|Experimental|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
11425699|NCT01864148|Placebo Comparator|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.
~Avonex once-weekly IM injection up to Week 84."
11425700|NCT01864135|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
11425701|NCT01864109|Experimental|Patients with localized disease|"Patients with localized disease will receive six cycles of the combination as maintenance therapy following standard chemotherapy.
~Cycles 4-6 will include:
~Ifosfamide 2,800 mg/m2/day on days 1-5
~Etoposide 100 mg/m2/day on days 1-5
~Cycle 7 will include :
~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day
~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day
~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)
~Cycles 8-13 will include:
~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously
~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously"
11425732|NCT01863836|Active Comparator|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
11425733|NCT01863823|Other|Amoxicillin and Tetracyclines|drug treatment
11425734|NCT01863823|Other|Mouth washing|Mouth washing
11425702|NCT01864109|Experimental|Patients with metastatic disease|"Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.
~Cycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:
~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously
~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously
~Cycles 6, 9, and 12 will include:
~Ifosfamide 2,800 mg/m2/day on days 1-5
~Etoposide 100 mg/m2/day on days 1-5
~Cycle 15 will include:
~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day
~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day
~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)"
11425703|NCT01864096|Experimental|Metformin|
11425704|NCT01864096|Placebo Comparator|Placebo|
11425705|NCT01864083|Experimental|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
11425706|NCT01864083|Experimental|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
11425707|NCT01864070|Experimental|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.
~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.
~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
11425708|NCT01864057|Active Comparator|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
11425709|NCT01864057|No Intervention|American mothers|Baseline blood and breast milk sample collection
11425710|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11425711|NCT01864005|Experimental|Ticagrelor|
11425712|NCT01864005|Active Comparator|clopidogrel|
11425713|NCT01863979||Acute Atrial Fibrillation|
11425714|NCT01863966|Experimental|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
11425715|NCT01863966|Active Comparator|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
11425716|NCT01863953|Experimental|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
11425717|NCT01863953|Active Comparator|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
11425718|NCT01863953|Active Comparator|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
11425719|NCT01863940|Experimental|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
11425720|NCT01863940|No Intervention|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
11425721|NCT01863927|Experimental|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
11425722|NCT01863914|Placebo Comparator|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
11425723|NCT01863914|Active Comparator|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
11425724|NCT01863901|Experimental|Treatment with the Cryo-Touch III Device|
11425725|NCT01863888|Experimental|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
11425726|NCT01863888|No Intervention|Reference population|Untreated healthy subjects
11425727|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
11425728|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
11425729|NCT01863862|Experimental|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
11425730|NCT01863849|Other|suspension for injection|
11425731|NCT01863836|Experimental|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
11426045|NCT01861626|Other|sequence 1 : Test drug - Reference|
11425735|NCT01863810|Experimental|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
11425736|NCT01863810|Active Comparator|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
11425737|NCT01863797|Active Comparator|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.
~When the participants reached the active phase they were monitored according to the clinical guidelines."
11425738|NCT01863797|Experimental|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
11425739|NCT01863784|Experimental|JNJ-38518168|
11425740|NCT01863771|Experimental|Golimumab|
11425741|NCT01863771|Placebo Comparator|Placebo|
11425742|NCT01863758|Experimental|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
11425743|NCT01863745|Experimental|nilotinib|16 patients who are currently enrolled in a Novartis- sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study receiving nilotinib and has fulfilled all their requirements in the parent study will be enrolled.
11425744|NCT01863732|Experimental|Secukinumab (AIN457) 75mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
11425745|NCT01863732|Experimental|Secukinumab (AIN457) 75 to 150mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
11425746|NCT01863732|Experimental|Secukinumab (AIN457) 150mg Grp2|Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
11425747|NCT01863732|Experimental|Pbo in Core then AIN457 75mg Grp1|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed.Secukinumab in PFS for s.c. self-administration Q4W
11425748|NCT01863732|Experimental|Pbo in Core then AIN457 75 to 150mg Grp1|Participants were on Placebo in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
11425749|NCT01863732|Experimental|Pbo in Core then AIN457 150mg Grp2|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
11425750|NCT01863719|Experimental|Cohort 1|9 Subjects
11425751|NCT01863719|Experimental|Cohort 2|9 Subjects
11425752|NCT01863719|Experimental|Cohort 3|9 Subjects
11425753|NCT01863719|Experimental|Cohort 4|12 Subjects
11425754|NCT01863706|Experimental|Misoprostol|400µg oral misoprostol
11425755|NCT01863706|Active Comparator|Oxytocin|20 IU oxytocin
11425756|NCT01863693||Cohort|
11425757|NCT01863680|Experimental|COL-1620|
11425758|NCT01863667|Experimental|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
11425759|NCT01863667|Active Comparator|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
11425760|NCT01863654|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11425761|NCT01863654|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11425762|NCT01863641|Experimental|treatment group|Patients will receive calcitriol at a fixed dose daily.
11425763|NCT01863641|Active Comparator|control group|Patients will receive placebo daily.
11425764|NCT01863628|Placebo Comparator|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
11425765|NCT01863628|Experimental|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
11425766|NCT01863615|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11425767|NCT01863615|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11425768|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
11425769|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
11425770|NCT01863576|Active Comparator|Omega-3|This group is receiving omega-3 supplement.
11425771|NCT01863576|Placebo Comparator|Oil Corn|This group is receiving the placebo comparator.
11425772|NCT01863563|Experimental|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
11425951|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
11425952|NCT01862211|Experimental|members of family of children with a DA1AT|
11425773|NCT01863550|Experimental|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
11425774|NCT01863550|Experimental|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
11425775|NCT01863550|Experimental|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
11425776|NCT01863550|Experimental|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11425777|NCT01863537|Experimental|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
11425778|NCT01863537|Active Comparator|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
11425779|NCT01863511|Active Comparator|usual care|IV loop diuretics
11425780|NCT01863511|Active Comparator|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
11425781|NCT01863511|Active Comparator|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
11425782|NCT01863498|Active Comparator|PCA pain control|Patients will have PCA for pain control
11425783|NCT01863498|Active Comparator|Epidural pain control|Patients will have an epidural for pain control
11425784|NCT01863485|Experimental|CM082|CM082 tablet
11425785|NCT01863472|Active Comparator|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
11425786|NCT01863472|Active Comparator|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
11425787|NCT01863459|Experimental|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.
~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
11425788|NCT01863459|Placebo Comparator|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.
~Placebo is taken once per day for 8 weeks"
11425789|NCT01863446|Experimental|Lighting1|Ocular light exposure of a red wavelength light for one or two nights
11425790|NCT01863446|Experimental|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
11425791|NCT01863446|Experimental|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
11425792|NCT01863446|Experimental|Lighting4|Ocular light exposure to a red wavelength light on day1 and to a blue-green wavelength light on day 2
11425793|NCT01863433|Experimental|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
11425794|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5<95%, V10<88%,V20<80%,V30<65%, V40<45%.
11425795|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5<90%, V10<80%,V20<70%,V30<55%, V40<35%.
11425796|NCT01863407|Experimental|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
11425797|NCT01863407|Placebo Comparator|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
11425798|NCT01863394|Active Comparator|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.
~CHWs will screen children 06-59 months in their village once a month"
11425799|NCT01863394|Experimental|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village
~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns
~Mothers will be asked to check their child's MUAC and look for pedal oedema
~whenever the child does not seem to be in 'good health' to the mother
~whenever the mother feels that the child is 'unwell' or 'sick'
~whenever it seems to the mother that her child has lost weight
~whenever the mother thinks that it is necessary to do so"
11425800|NCT01863381|Experimental|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
11425801|NCT01863368|Experimental|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
11425802|NCT01863368|Active Comparator|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
11425803|NCT01863355|Experimental|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
11425804|NCT01863355|Active Comparator|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
11425805|NCT01863355|Active Comparator|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
11425806|NCT01863342||CSI score < 40|CSI cutoff value<40
11425807|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
11425808|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
11425809|NCT01863316|Experimental|1) I gel group|using supraglottic airway I gel
11425810|NCT01863316|Active Comparator|2) LMA Supreme group|using supraglottic airway LMA Supreme
11425811|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
11425812|NCT01863277|Active Comparator|Melatonin|Melatonin 14mg/daily given over 14 days
11425813|NCT01863277|Placebo Comparator|sugar pill|sugar pill given over 14 days
11425814|NCT01863264|Experimental|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.
~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
11425815|NCT01863251|Experimental|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
11425816|NCT01863251|Placebo Comparator|Placebo|Placebo inactive medication
11425817|NCT01863238||Ivacaftor Treated|
11425818|NCT01863225|Experimental|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
11425819|NCT01863225|Experimental|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
11425820|NCT01863225|Experimental|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
11425821|NCT01863225|Experimental|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
11425822|NCT01863212|Experimental|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
11425823|NCT01863212|Experimental|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
11425824|NCT01863199|Active Comparator|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
11425825|NCT01863199|Active Comparator|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
11425826|NCT01863199|Experimental|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
11425827|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
11425828|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
11425829|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
11425830|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
11425831|NCT01863173|Active Comparator|metoprolol|patient or intervention group
11425832|NCT01863173|Active Comparator|placebo group|control group
11425833|NCT01863160|Other|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
11425834|NCT01863160|Other|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
11425835|NCT01863147|Experimental|Sitagliptin|Sitagliptin 0.1 daily for 1 year
11425836|NCT01863147|Active Comparator|acarbose|acarbose 150mg daily for 1 year
11425837|NCT01863134|Experimental|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
11425838|NCT01863134|Placebo Comparator|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
11425839|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
11425840|NCT01863108|Experimental|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
11425953|NCT01862211|Experimental|children with a DA1AT|
11425954|NCT01862198|Experimental|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
11425841|NCT01863095|Experimental|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
11425842|NCT01863095|Active Comparator|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
11425843|NCT01863082|Experimental|exercise|the patients will be submitted to an exercise protocol
11425844|NCT01863056|Experimental|Sit-Stand Desk|Cross-over trial: so one group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self in period 2) and the other group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self in period 1).
11425845|NCT01863056|No Intervention|Control|Used normal work desk which only allows working sitting down
11425846|NCT01863043|Active Comparator|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
11425847|NCT01863043|Experimental|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
11425848|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
11425849|NCT01863017|Sham Comparator|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
11425850|NCT01863017|Experimental|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
11425851|NCT01863004|Experimental|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.
~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
11425852|NCT01862991|Placebo Comparator|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
11425853|NCT01862991|Active Comparator|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
11425854|NCT01862991|Experimental|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
11425855|NCT01862978|Experimental|Heparin|Patient receiving Heparin
11425856|NCT01862978|Experimental|Nadroparin|Patient receiving nadroparin
11425857|NCT01862978|Placebo Comparator|Placebo|Patients receiving placebo
11425858|NCT01862965|Experimental|PredEver|Prednisone and Everolimus
11425859|NCT01862952|Active Comparator|antiepileptic treatment as used in daily clinical practice|Antiepileptic treatment as used in daily clinical practice.
11425860|NCT01862952|No Intervention|No medication|
11425861|NCT01862939|Experimental|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
11425862|NCT01862939|Experimental|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
11425863|NCT01862939|Placebo Comparator|part 2 placebo|placebo to match part 2 DS-7309
11425864|NCT01862926|Experimental|Rituximab|1g given at baseline and two weeks.
11425865|NCT01862926|Active Comparator|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
11425866|NCT01862913|Experimental|Computer-assisted CBT|"Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.
~Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
11425867|NCT01862913|Active Comparator|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
11425868|NCT01862900|Experimental|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
11425869|NCT01862900|Experimental|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
11425870|NCT01862900|Experimental|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
11425871|NCT01862887|Experimental|PH-797804|Subjects will receive a single 24 mg dose in the fed state
11425872|NCT01862887|Experimental|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
11425873|NCT01862887|Experimental|Placebo|Subjects will receive a single placebo dose
11425874|NCT01862874|Experimental|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
11425875|NCT01862874|Placebo Comparator|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
11425876|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
11425877|NCT01862835|Experimental|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
11425878|NCT01862835|Experimental|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
11425879|NCT01862835|Experimental|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
11425880|NCT01862835|Experimental|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
11425881|NCT01862822|Experimental|upright position|Upright position during urine bag collection
11425882|NCT01862822|No Intervention|usual position|
11425883|NCT01862809||cases|smokers
11425884|NCT01862809||controls|non-smokers
11425885|NCT01862796|Experimental|Obese underfeeding (UF)|Obese randomized to received a 35% calorie reduced diet
11425886|NCT01862796|Experimental|Obese weight maintaining (WMEN)|Randomized to receive a weight-maintaining diet
11425887|NCT01862796|Experimental|Lean weight maintaining (WMEN)|Normal weight individuals receiving a weight-maintaining energy needs diet
11425888|NCT01862731||1/Control Volunteers|Healthy controls
11425889|NCT01862731||2/Volunteers with Pain|Subjects with Chronic Idiopathic Patellofemoral Pain
11425890|NCT01862718|Experimental|1|Ablation plus radiation
11425891|NCT01862705|Experimental|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
11425892|NCT01862705|Sham Comparator|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
11425893|NCT01862692|Active Comparator|Developmental Awareness Skils|
11425894|NCT01862692|Experimental|Baby-Net condition|
11425895|NCT01862679|Experimental|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
11425896|NCT01862679|Experimental|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
11425897|NCT01862653|Experimental|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
11425898|NCT01862653|No Intervention|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
11425899|NCT01862640|Placebo Comparator|Placebo|Matching placebo once daily
11425900|NCT01862640|Experimental|Brexpiprazole 1 mg|Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
11425901|NCT01862640|Experimental|Brexpiprazole 2 mg|Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
11425902|NCT01862627||Macular retinoschisis and detachment|
11425903|NCT01862601|Experimental|JetTouch injections|
11425904|NCT01862562|Active Comparator|Open surgery|Conventional procedure
11425905|NCT01862562|Experimental|Laparoscopic surgery|Minimum invasive procedure
11425906|NCT01862549|Experimental|DBT for children|Dialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
11425907|NCT01862549|Active Comparator|Treatment as Usual|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
11425908|NCT01862536|Placebo Comparator|Placebo|Placebo tablet
11425909|NCT01862536|Experimental|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
11425910|NCT01862523|Placebo Comparator|diluent|diluent
11425911|NCT01862523|Experimental|capsaicin|capsaicin
11425912|NCT01862523|No Intervention|control healthy volunteers|control healthy volunteers
11425913|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.
~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
11425914|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.
~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
11425915|NCT01862484|Experimental|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
11425916|NCT01862484|Sham Comparator|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
11425955|NCT01862185|Experimental|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
11425956|NCT01862185|No Intervention|control|patients whom do not checked semi-quantitative procalcitonin examination
11425957|NCT01862172|Other|additional MRI|
11425958|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
11425959|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
11425917|NCT01862471|Experimental|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.
~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
11425918|NCT01862458|Active Comparator|tPA alone|tPA alone used to treat empyema
11425919|NCT01862458|Experimental|tPA plus dornase|tPA plus dornase used to treat empyema
11425920|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
11425921|NCT01862432|Experimental|immediate skin-to-skin|
11425922|NCT01862432|No Intervention|control|
11425923|NCT01862419|Experimental|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
11425924|NCT01862419|No Intervention|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
11425925|NCT01862406|Experimental|Generic Label|Purportedly generic version of the analgesic presented
11425926|NCT01862406|Active Comparator|Brand-name Label|actual brand-name analgesic presented
11425927|NCT01862393|Experimental|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
11425928|NCT01862393|Experimental|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
11425929|NCT01862393|Experimental|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
11425930|NCT01862380|Experimental|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
11425931|NCT01862380|Experimental|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
11425932|NCT01862367||rFXIII|
11425933|NCT01862354|Active Comparator|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
11425934|NCT01862354|Active Comparator|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
11425935|NCT01862341|Experimental|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
11425936|NCT01862328|Experimental|MLN4924 and Docetaxel (Arm 1)|
11425937|NCT01862328|Experimental|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
11425938|NCT01862328|Experimental|MLN4924 + Gemcitabine (Arm 3)|
11425939|NCT01862315|Experimental|No prior chemo or responded/stable with prior chemo|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day30} pump flow rate) on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
11425940|NCT01862315|Experimental|patients who have failed systemic therapy|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day 30}/ pump flow rate) on day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
11425941|NCT01862315|Experimental|pts who have had prior oxaliplatin & have existing neuropathy|All patients receive will receive gemcitabine alone with HAI FUDR/Dex Gemcitabine (800 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
11425942|NCT01862302|Active Comparator|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
11425943|NCT01862302|Placebo Comparator|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
11425944|NCT01862289|Experimental|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
11425945|NCT01862263|Experimental|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
11425946|NCT01862263|Placebo Comparator|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
11425947|NCT01862250|Experimental|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
11425948|NCT01862237|Experimental|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
11425949|NCT01862237|Experimental|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
11425950|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
11425961|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
11425962|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
11425963|NCT01862120|Experimental|interleukin-2|Dose D1 of interleukin-2
11425964|NCT01862120|Experimental|Dose D2 of interleukin-2|Dose D2 of interleukin-2
11425965|NCT01862120|Experimental|Dose D3 of interleukin-2|Dose D3 of interleukin-2
11425966|NCT01862120|Placebo Comparator|placebo|placebo
11425967|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
11425968|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
11425969|NCT01862081|Experimental|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
11425970|NCT01862081|Experimental|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
11425971|NCT01862081|Experimental|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
11425972|NCT01862081|Experimental|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
11425973|NCT01862081|Experimental|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
11425974|NCT01862081|Experimental|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
11425975|NCT01862081|Experimental|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
11425976|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
11425977|NCT01862068||MPA patients|
11425978|NCT01862068||Healthy Blood Donors|
11425979|NCT01862068||Atherosclerotic patients|
11425980|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
11425981|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
11425982|NCT01862042|Other|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
11425983|NCT01862029|Experimental|Roflumilast|
11425984|NCT01862016|Active Comparator|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
11425985|NCT01862016|Experimental|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
11425986|NCT01862003|Experimental|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
11425987|NCT01861990|Experimental|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
11425988|NCT01861977|Experimental|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
11425989|NCT01861977|Active Comparator|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
11425990|NCT01861964|Placebo Comparator|Sugar Pill|
11425991|NCT01861964|Active Comparator|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
11425992|NCT01861964|Active Comparator|Xylooligosarcharide 1.4g|
11425993|NCT01861951|Experimental|Pazopanib|"Pazopanib 800 mg, p.o., daily
~Duration of treatment:
~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
11425994|NCT01861951|Active Comparator|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.
~Duration of treatment:
~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
11425995|NCT01861938|Experimental|Melanoma vaccine|
11425996|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
11425997|NCT01861925||Large regular astigmatism|Astigmatism of > 1.5 diopters, regular astigmatism.
11425998|NCT01861925||Large irregular astigmatism|Astigmatism of > 1.5 diopters, irregular astigmatism.
11425999|NCT01861912|Active Comparator|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
11426046|NCT01861626|Other|Sequence 2 : Reference - Test drug|
11426047|NCT01861613|Experimental|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
11426000|NCT01861912|Experimental|Arsenic trioxide TACE+IV|"Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
~Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
11426001|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
11426002|NCT01861886|Experimental|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
11426003|NCT01861873|Other|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
11426004|NCT01861860|Experimental|New OPERA Criteria|TAXUS™ Element long stent
11426005|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
11426006|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
11426007|NCT01861821|Active Comparator|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
11426008|NCT01861821|Active Comparator|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
11426009|NCT01861808|Other|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
11426010|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
11426011|NCT01861782|Experimental|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
11426012|NCT01861782|Experimental|Sulfur Pool & Medicinal Mud|Sulfur Pool & Medicinal Mud
11426013|NCT01861769|Experimental|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
11426014|NCT01861769|Experimental|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
11426015|NCT01861769|No Intervention|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
11426016|NCT01861756|Experimental|Diabetes Medication Choice Decision Aid|
11426017|NCT01861756|No Intervention|Standard care|
11426018|NCT01861743|Experimental|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
11426019|NCT01861743|Active Comparator|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
11426020|NCT01861730|Experimental|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
11426021|NCT01861730|Experimental|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
11426022|NCT01861730|Experimental|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
11426023|NCT01861730|Experimental|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
11426024|NCT01861730|Experimental|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
11426025|NCT01861730|Experimental|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
11426026|NCT01861730|Experimental|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
11426027|NCT01861717|Experimental|Somatuline Depot SC|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
11426028|NCT01861704|Active Comparator|Lyric|Silver Lyric device
11426029|NCT01861704|Active Comparator|Lyric2|Lyric2 (Barracuda) device
11426030|NCT01861691|Active Comparator|Open surgery|Open colectomy
11426031|NCT01861691|Experimental|Laparoscopic surgery|Laparoscopic colectomy
11426032|NCT01861678|Active Comparator|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
11426033|NCT01861678|Experimental|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
11426034|NCT01861665|Active Comparator|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
11426035|NCT01861665|Active Comparator|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
11426036|NCT01861652|Experimental|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
11426037|NCT01861639|Experimental|ineffective rTMS - Active TBS - fMRI|
11426038|NCT01861639|Experimental|Effective rTMS - Active TBS - fMRI|
11426048|NCT01861600|Experimental|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
11426049|NCT01861600|Active Comparator|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
11426050|NCT01861600|Experimental|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
11426051|NCT01861600|Other|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
11426052|NCT01861600|Experimental|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
11426053|NCT01861587|Experimental|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
11426054|NCT01861587|Experimental|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
11426055|NCT01861574|Experimental|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
11426056|NCT01861574|Sham Comparator|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
11426057|NCT01861574|Sham Comparator|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
11426058|NCT01861574|Sham Comparator|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
11426059|NCT01861561|Experimental|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
11426060|NCT01861561|Active Comparator|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
11426061|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
11426062|NCT01861535|Experimental|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
11426063|NCT01861535|Active Comparator|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
11426064|NCT01861522|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
11426065|NCT01861522|Placebo Comparator|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
11426066|NCT01861509|Experimental|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
11426067|NCT01861496|Experimental|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
11426068|NCT01861470||Preterm infants|all <32 weeks
11426069|NCT01861457|Experimental|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
11426070|NCT01861457|Placebo Comparator|Phosphate-buffered saline|Placebo
11426071|NCT01861444||Cohort|
11426072|NCT01861431|Active Comparator|HIVSRR|4 sessions of HIV sexual risk reduction
11426073|NCT01861431|Experimental|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
11426074|NCT01861418|Placebo Comparator|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
11426075|NCT01861418|Experimental|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
11426171|NCT01860833|Active Comparator|celecoxib 400 mg/day|celecoxib 200 mg bid
11426076|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
11426077|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
11426078|NCT01861392|Active Comparator|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
11426079|NCT01861392|Active Comparator|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
11426080|NCT01861379|Experimental|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
11426081|NCT01861379|Placebo Comparator|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
11426082|NCT01861366|Experimental|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
11426083|NCT01861366|Active Comparator|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
11426084|NCT01861353|Experimental|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.
~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
11426085|NCT01861353|Placebo Comparator|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.
~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
11426086|NCT01861340|Experimental|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
11426087|NCT01861327|Experimental|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
11426088|NCT01861327|Active Comparator|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
11426089|NCT01861327|Experimental|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
11426090|NCT01861327|Active Comparator|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
11426091|NCT01861327|Experimental|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
11426092|NCT01861327|Active Comparator|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
11426093|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.
~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.
~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.
~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11426094|NCT01861301|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
11426095|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).
~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD
~Inclusion of pediatric patients, <15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
11426096|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it's compliance in sleep apnea patients with ischaemic stroke.
11426097|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
11426098|NCT01861262|Experimental|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
11426099|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
11426100|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
11426101|NCT01861223|Experimental|afatinib + nimotuzumab|
11426102|NCT01861210|Experimental|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
11426103|NCT01861210|Active Comparator|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
11426104|NCT01861197|Experimental|Dovitinib monotherapy|
11426105|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
11426106|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
11426107|NCT01861171|Placebo Comparator|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
11426108|NCT01861171|Active Comparator|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
11426109|NCT01861158|Experimental|Parenting Wisely|Immediate access to the online Parenting Wisely program
11426110|NCT01861158|Active Comparator|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
11426111|NCT01861158|No Intervention|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
11426112|NCT01861145|Active Comparator|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
11426113|NCT01861145|Experimental|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.
~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
11426114|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
11426115|NCT01861119|Experimental|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
11426116|NCT01861119|Active Comparator|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
11426117|NCT01861119|No Intervention|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
11426118|NCT01861106|Active Comparator|Arm A|10/10 HLA Matched Related Donor or Unrelated Donor or 9 /10 HLA with DQ mismatch Transplant
11426119|NCT01861106|Active Comparator|Arm B|9/10 or 8/10 HLA Match Related Donor or Unrelated Donor or Haploidentical Donor Transplant
11426120|NCT01861106|Active Comparator|Arm C (combined with Arm B per Amendment N)|Haploidentical Related Donor Transplant
11426121|NCT01861106|Active Comparator|Arm D (Deleted this arm per amendment I)|Umbilical Cord Blood Transplant
11426122|NCT01861106|No Intervention|Arm E (Deleted this arm per amendment O)|Donor
11426123|NCT01861093|Experimental|1|At least one
11426124|NCT01861080||incident hypertensives|"Inclusion Criteria:
~age≧30years
~primary incident hypertension
~signed informed consent"
11426125|NCT01861067|Experimental|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
11426126|NCT01861067|Active Comparator|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
11426127|NCT01861054|Experimental|Treated patients|Patients eligible will be treated with Reparixin as add-in monotherapy
11426128|NCT01861041|Experimental|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
11426129|NCT01861041|Active Comparator|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
11426130|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
11426131|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
11426132|NCT01861015|Experimental|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine ([1/2] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
11426133|NCT01861015|Active Comparator|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
11426134|NCT01861002|Experimental|Dose Level 1|"Azacytidine 75 mg/m2/day
~Fludarabine 30 mg/m2/dose
~Cytarabine 2000 mg/m2/dose"
11426135|NCT01861002|Experimental|Dose Level 0|"Azacytidine 50 mg/m2/day
~Fludarabine 30 mg/m2/dose
~Cytarabine 2000 mg/m2/dose"
11426136|NCT01860989|Experimental|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
11426137|NCT01860989|Experimental|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
11426138|NCT01860989|Experimental|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
11426139|NCT01860989|Experimental|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
11426140|NCT01860976|Experimental|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
11426141|NCT01860976|Placebo Comparator|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
11426142|NCT01860963|Active Comparator|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
11426143|NCT01860963|Active Comparator|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
11426144|NCT01860963|Active Comparator|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
11426145|NCT01860950|Active Comparator|anodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder (Brand Phoresor-II Auto) . BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
11426146|NCT01860950|Active Comparator|anodal tDCS plus pain-education|"Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder.
~Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing."
11426147|NCT01860950|Experimental|cathodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC. BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
11426148|NCT01860950|Experimental|cathodal tDCS plus pain-education|Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode attached to the right shoulder and the cathode electrode was placed over the left DLPFC. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
11426149|NCT01860950|Sham Comparator|sham tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session.
11426150|NCT01860950|Sham Comparator|sham tDCS plus pain-education|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
11426151|NCT01860937|Experimental|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
11426152|NCT01860937|Experimental|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion & did not experience any non-hematologic grade 4 toxicities.
11426153|NCT01860924|Active Comparator|health education|health education control
11426154|NCT01860924|Experimental|exercise|vigorous supervised exercise
11426155|NCT01860911|Experimental|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
11426156|NCT01860911|Experimental|Insulin-Resistant|One group consists of insulin resistant volunteers.
11426157|NCT01860898|Other|Skin Biopsy|
11426158|NCT01860885||Patients requiring naloxone for respiratory depression|
11426159|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
11426160|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
11426161|NCT01860872||Combined Group|MRI Quality & Image Relatedness
11426162|NCT01860859|Other|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
11426163|NCT01860859|Other|Locked single layer closure|As reported in Williams Obstetrics textbook
11426164|NCT01860859|Other|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
11426165|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
11426166|NCT01860833|Active Comparator|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
11426167|NCT01860833|Active Comparator|diclofenac 150 mg/day|diclofenac 75 mg bid
11426168|NCT01860833|Active Comparator|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
11426169|NCT01860833|Active Comparator|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
11426170|NCT01860833|Active Comparator|celecoxib 200 mg/day|celecoxib 200 mg once day
11426172|NCT01860820|No Intervention|Best Medical Therapy|Participants will follow standard post-transplant protocols with IPC
11426173|NCT01860820|Active Comparator|Geko device|Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.
11426174|NCT01860807|Experimental|Ibudilast|Ibudilast 50 mg twice daily
11426175|NCT01860807|Placebo Comparator|Placebo|matching placebo twice daily
11426176|NCT01860794|Other|Mesencephalic Neuronal Precursor Cells|
11426177|NCT01860781|Experimental|paliperidone palmitate|paliperidone palmitate
11426178|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
11426179|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
11426180|NCT01860755|Experimental|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
11426181|NCT01860755|Active Comparator|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
11426182|NCT01860742|Active Comparator|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
11426183|NCT01860742|Active Comparator|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
11426184|NCT01860729|Experimental|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
11426185|NCT01860729|Placebo Comparator|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
11426186|NCT01860716|Placebo Comparator|Solution for infusion|Solution for infusion administrated via nasogastric tube
11426187|NCT01860716|Experimental|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
11426188|NCT01860703|Experimental|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
11426189|NCT01860703|Experimental|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
11426190|NCT01860703|Experimental|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
11426191|NCT01860703|Experimental|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
11426192|NCT01860690|Experimental|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
11426193|NCT01860677|Active Comparator|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
11426194|NCT01860677|Placebo Comparator|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
11426195|NCT01860664|Experimental|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
11426196|NCT01860664|Placebo Comparator|Placebo|mineral oil and white petrolatum
11426197|NCT01860651|Active Comparator|Web-monitoring|"There is two arms for intervention:
~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
11426198|NCT01860651|No Intervention|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.
~Patients in treatment with biologicals: retrospective routine treatment algorithm"
11426199|NCT01860638|Experimental|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
11426200|NCT01860638|Placebo Comparator|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
11426201|NCT01860625|Experimental|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠
~placebo : 3 people, 12.5㎠"
11426202|NCT01860625|Experimental|2(25㎠)|"drug : 9 people, 87.5mg/25㎠
~placebo : 3 people, 25㎠"
11426203|NCT01860625|Experimental|3(50㎠)|"drug : 9 people, 175mg/50㎠
~placebo : 3 people, 50㎠"
11426204|NCT01860612|Experimental|PMA Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
11426239|NCT01860378|Active Comparator|No Video: Full price & $5 off|Participants will not view the pertussis video
11426205|NCT01860612|Experimental|Compassionate Use Cohort|Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
11426206|NCT01860612|Experimental|Continued Access Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the Continued Access cohort, after enrollment in the PMA cohort is complete.The fellow eye can be treated 1 month after the primary eye.
11426207|NCT01860599|Other|Prediabetes with exercise|150 minutes of moderate exercise per week
11426208|NCT01860599|Other|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
11426209|NCT01860586|Experimental|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
11426210|NCT01860573|Active Comparator|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
11426211|NCT01860573|Experimental|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
11426212|NCT01860560|Experimental|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
11426213|NCT01860560|Experimental|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
11426214|NCT01860547|Experimental|bilberry|
11426215|NCT01860547|Experimental|sea buckthorn berry|
11426216|NCT01860547|Experimental|sea buckthorn phenolic extract|
11426217|NCT01860547|Experimental|sea buckthorn oil|
11426218|NCT01860534|Experimental|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
11426219|NCT01860534|No Intervention|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
11426220|NCT01860521|Active Comparator|Programmed Intermittent Epidural Bolus|
11426221|NCT01860521|Active Comparator|Continuous Epidural Infusion|
11426222|NCT01860508|Experimental|pemetrexed|
11426223|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
11426224|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
11426225|NCT01860482|Experimental|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
11426226|NCT01860469|Active Comparator|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
11426227|NCT01860469|Experimental|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
11426228|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
11426229|NCT01860443|Experimental|Telepsychiatry collaborative program|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.
~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).
~Supervision of primary care professionals through an internet site run by a team of specialists.
~Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
11426230|NCT01860443|Active Comparator|Usual care|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.
~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
11426231|NCT01860417|Experimental|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
11426232|NCT01860417|Active Comparator|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
11426233|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
11426234|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
11426235|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
11426236|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
11426237|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
11426238|NCT01860391|Experimental|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.
~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
11426240|NCT01860378|Experimental|Video: Full price & $5 off|Participants will watch a brief (~ 1 minute) video about Tdap vaccination
11426241|NCT01860365|Experimental|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
11426242|NCT01860365|Active Comparator|Conventional supportive care|Patients receiving conventional supportive care
11426243|NCT01860352|Other|Fish Oil|
11426244|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
11426245|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
11426246|NCT01860326|Experimental|Alisporivir|Single 200 mg oral dose
11426247|NCT01860313|Experimental|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
11426248|NCT01860313|Experimental|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
11426249|NCT01860313|No Intervention|Waiting List group|This group was used as control group and did not receive any intervention.
11426250|NCT01860300|Experimental|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
11426251|NCT01860300|Placebo Comparator|Placebo|Placebo
11426252|NCT01860287|Placebo Comparator|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
11426253|NCT01860287|Experimental|buprenorphine (0.2 mg) group|Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
11426254|NCT01860287|Experimental|buprenorphine (0.4 mg) group|Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
11426255|NCT01860274|Experimental|External Mesh|
11426256|NCT01860261|Experimental|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
11426257|NCT01860261|No Intervention|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
11426258|NCT01860248|Experimental|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
11426259|NCT01860248|Placebo Comparator|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
11426260|NCT01860235|Experimental|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
11426261|NCT01860235|Active Comparator|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
11426262|NCT01860235|Active Comparator|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
11426263|NCT01860235|Placebo Comparator|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
11426264|NCT01860222|Active Comparator|SR|
11426265|NCT01860222|Experimental|PLAT|
11426266|NCT01860209|Experimental|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
11426267|NCT01860209|Experimental|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
11426268|NCT01860196|Active Comparator|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
11426269|NCT01860196|Active Comparator|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
11426270|NCT01860183|Experimental|MMF 3g daily|
11426271|NCT01860183|Active Comparator|MMF 2 g daily|
11426272|NCT01860170|Active Comparator|Cohort 1-Bortezomib (Velcade®)|Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
11426273|NCT01860170|Active Comparator|Cohort 2-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
11426274|NCT01860170|Active Comparator|Cohort 3-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
11426275|NCT01860157|Sham Comparator|Sham H1 Coil|deep rTMS sham treatment
11426276|NCT01860157|Active Comparator|Active H1|deep rTMS active treatment
11426277|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
11426278|NCT01860131|Active Comparator|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
11426279|NCT01860131|Active Comparator|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
11426280|NCT01860131|No Intervention|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.
~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.
~This is minimal intervention and considered the control arm."
11426281|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
11426282|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
11426283|NCT01860105|Active Comparator|75mg MDCO-157|iv
11426284|NCT01860105|Active Comparator|150mg MDCO-157|iv
11426285|NCT01860105|Active Comparator|300mg MDCO-157|iv
11426286|NCT01860105|Active Comparator|300mg PLAVIX|oral
11426287|NCT01860092||Argus II Retinal Prosthesis|Patients implanted with the Argus II Retinal Prosthesis
11426288|NCT01860079|Active Comparator|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
11426289|NCT01860079|No Intervention|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
11426290|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
11426291|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
11426292|NCT01860053|Experimental|behavioral intervention|
11426293|NCT01860053|No Intervention|no treatment control|
11426294|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
11426295|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
11426296|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
11426297|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
11426298|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
11426299|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
11426300|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
11426301|NCT01859988|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
11426302|NCT01859988|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
11426303|NCT01859988|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
11426304|NCT01859988|Experimental|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
11426305|NCT01859988|Experimental|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
11426306|NCT01859988|Experimental|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
11426307|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
11426308|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
11426309|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
11426310|NCT01859949|Experimental|Genotropin (somatropin)|
11426311|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
11426312|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
11426313|NCT01859923|Experimental|Group 1: 12 to 17 Years of Age|Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
11426314|NCT01859923|Experimental|Group 2: 6 to 11 Years of Age|Participants 6 to 11 years old (inclusive) received adult formulation delamanid 50 mg (1x50 mg tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
11426315|NCT01859923|Experimental|Group 3: 3 to 5 Years of Age|Participants 3 to 5 years old (inclusive) received 25 mg pediatric formulation of delamanid (DPF - suspension prepared using dispersible tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
11426316|NCT01859923|Experimental|Group 4: Birth to 2 Years of Age|"Participants from birth to 2 years old (inclusive) received DPF (suspension prepared using dispersible tablet) for 182 days plus OBR. Participants continued to receive OBR up to Day 365. The DPF dose was based on the participant's body weight during the baseline visit:
~Participants >10 kilograms (kg) received DPF 10 mg BID plus OBR
~Participants >8 kg and ≤10 kg received DPF 5 mg BID plus OBR
~Participants ≥5.5 kg and ≤8 kg received DPF 5 mg once per day (QD) plus OBR
~Delamanid dose was adjusted as needed for Group 4 participants based on the weight measurement at specified study visits [Visits 5 (Day 28), 7 (Day 56), 9 (Day 84), 11 (Day 126) and 12 (Day 154)]."
11426317|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
11426318|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
11426319|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
11426320|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
11426321|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
11426345|NCT01859715|Active Comparator|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
11426346|NCT01859715|Active Comparator|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
11426384|NCT01859416|No Intervention|Control|Usual nutritional care
11426800|NCT01856595|Experimental|PF-06291874|
11426322|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
11426323|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
11426324|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
11426325|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
11426326|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
11426327|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
11426328|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
11426329|NCT01859819|Experimental|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH <2 X ULN.
~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
11426330|NCT01859819|Experimental|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (> 25% Bone marrow blasts) without CNS involvement.
~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
11426331|NCT01859819|Experimental|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:
~Any L3 blasts in CSF
~Cranial nerve palsy (if not explained by extracranial tumor)
~Clinical spinal cord compression
~Isolated intracerebral mass
~Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
11426332|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
11426333|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
11426334|NCT01859793|Placebo Comparator|Matching Placebo|Matching Placebo for Sitagliptin
11426335|NCT01859793|Active Comparator|Sitagliptin|100mg pill, PO administered once daily.
11426336|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.
~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
11426337|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
11426338|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
11426339|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
11426340|NCT01859741|Experimental|OMP-59R5 Combination with Etoposide and Cisplatin|
11426341|NCT01859741|Experimental|Etoposide and Cisplatin plus Placebo|
11426342|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
11426343|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
11426344|NCT01859715|Active Comparator|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
11433783|NCT01808872||Heart Failure|
11426347|NCT01859702|Experimental|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
11426348|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
11426349|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
11426350|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
11426351|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
11426352|NCT01859650||NSCLC patients undergoing RT|
11426353|NCT01859637|Experimental|Zarzio®/Filgrastim HEXAL®|Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
11426354|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
11426355|NCT01859611|Experimental|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
11426356|NCT01859585|Experimental|Parecoxib|Parecoxib
11426357|NCT01859585|Experimental|Ketorolac|Ketorolac
11426358|NCT01859585|No Intervention|No medication|No medication
11426359|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
11426360|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
11426361|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
11426362|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
11426363|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
11426364|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
11426365|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
11426366|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
11426367|NCT01859507|Experimental|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
11426368|NCT01859494|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
11426369|NCT01859481|Placebo Comparator|Placebo|
11426370|NCT01859481|Experimental|Eletriptan HBr 40 mg|
11426371|NCT01859481|Experimental|Eletriptan HBr 80 mg|
11426372|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
11426373|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
11426374|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
11426375|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
11426376|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
11426377|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
11426378|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
11426379|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
11426380|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
11426381|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
11426382|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
11426383|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
11436481|NCT01790217||Cohort|
11426385|NCT01859403|Placebo Comparator|Usual Care|Usual care for veterans as part of the MOVE! program
11426386|NCT01859403|Active Comparator|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
11426387|NCT01859390|Experimental|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
11426388|NCT01859390|Active Comparator|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
11426389|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
11426390|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
11426391|NCT01859351|Experimental|WX-037|PI3K inhibitor
11426392|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
11426393|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
11426394|NCT01859325|Experimental|Vaccine|HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 g (1500 g of the HIV-1 gag/pol plasmid and 1500 g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500 g each) will be mixed and combined with 1000 g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000 g (500 g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.
11426395|NCT01859325|Placebo Comparator|Placebo|Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.
11426396|NCT01859312|Experimental|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
11426397|NCT01859299||Affected|Participants with various types of uveitis
11426398|NCT01859299||Healthy controls|Participants without uveitis
11426399|NCT01859286||regular sign out process|
11426400|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
11426401|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
11426402|NCT01859260|No Intervention|Control|
11426403|NCT01859260|Experimental|Intervention|CPAP/autopap
11426404|NCT01859247|Active Comparator|Dorsal Premotor rTMS|0.2 Hz rTMS for 15 minutes
11426405|NCT01859247|Active Comparator|Primary motor cortex rTMS|0.2 Hz rTMS for 15 minutes
11426406|NCT01859247|Active Comparator|Supplemental Motor Area rTMS|0.2 Hz rTMS for 15 minutes
11426407|NCT01859247|Active Comparator|Anterior Cingulate rTMS|0.2 Hz rTMS for 15 minutes
11426408|NCT01859247|Sham Comparator|Sham rTMS|0.2 Hz rTMS for 15 minutes
11426409|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
11426410|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
11426411|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
11426412|NCT01859195||Focus Group Stage|~20-24 participants, to comprise 3-6 focus groups
11426413|NCT01859195||Cognitive Interview Stage|~12-16 participants in individual cognitive interviews
11426414|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11426415|NCT01859169||Control Group|Group that be administrated biliary drainage only
11426416|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
11426417|NCT01859156||Carbon Monoxide Exposure|
11426418|NCT01859143|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
11426419|NCT01859143|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
11426420|NCT01859130|Other|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
11426460|NCT01858896|Placebo Comparator|Saline Infusion|Saline infusion during experimental period
11426421|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
11426422|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
11426423|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
11426424|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
11426425|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
11426426|NCT01859091|Experimental|Fat Reduction|
11426427|NCT01859078|Experimental|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.
~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
11426428|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
11426429|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
11426430|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
11426431|NCT01859052|Other|low-fat diet|Obese Migraineurs
11426432|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
11426433|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
11426434|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.
~Phase I will be followed by an expansion Phase Ib."
11426435|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.
~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
11426436|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.
~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
11426437|NCT01859013|Experimental|Topiramate|Four (4) weeks of meal replacement therapy, followed by 28-weeks of topiramate therapy. Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks.
11426438|NCT01859013|Placebo Comparator|Sugar Pill|Four (4) weeks of meal replacement therapy, followed by 28-weeks of placebo (sugar pill) therapy.
11426439|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
11426440|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
11426441|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
11426442|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
11426443|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
11426444|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
11426445|NCT01858948|Experimental|Quitiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) for 24 weeks
11426446|NCT01858948|Placebo Comparator|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
11426447|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
11426448|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
11426449|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
11426450|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
11426451|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
11426452|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
11426453|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
11426454|NCT01858935|Placebo Comparator|Placebo|
11426455|NCT01858922|Experimental|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
11426456|NCT01858922|Experimental|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.
~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
11426457|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
11426458|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
11426459|NCT01858896|Active Comparator|Glucagon-Like Peptide -1 (GLP-1) infusion|Infusion of GLP-1 during experimental period
11440731|NCT01760993|Experimental|SPD489|
11426461|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
11426462|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
11426463|NCT01858857||Geriatric psychiatric in patients|
11426464|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
11426465|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
11426466|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
11426467|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
11426468|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
11426469|NCT01858818||healthy 18 year old males|
11426470|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
11426471|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
11426472|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
11426473|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.
~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
11426474|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
11426475|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
11426476|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
11426477|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
11426478|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
11426479|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
11426480|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
11426481|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
11426482|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
11426483|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
11426484|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
11426485|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
11426486|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
11426487|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
11426488|NCT01858753|Experimental|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
11426489|NCT01858753|Placebo Comparator|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
11426490|NCT01858740|Experimental|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.
~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.
~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
11426491|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
11426492|NCT01858727|No Intervention|control group|do not active heating group
11426493|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy
~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:
~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
11426494|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
11426495|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
11426496|NCT01858701|Other|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
11426497|NCT01858701|Other|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
11426498|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
11426499|NCT01858675|Experimental|Biomarkers, total blood volume|
11426500|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
11426501|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
11426502|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
11426503|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
11426504|NCT01858636||Angio-Seal VIP Vascular Closure|
11426505|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
11426506|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
11426507|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
11426508|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
11426509|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
11426510|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
11426511|NCT01858597||gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
11426512|NCT01858597||control|Those healthy pregnant women
11426513|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.
~dosage:
~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional
~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
11426514|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
11426515|NCT01858584|No Intervention|control group|
11426516|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.
~Cycle A
~Daily oral Thalidomide (at 3mg/kg)
~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
~Daily oral Etoposide (50 mg/m2/d)
~Cycle B
~Daily oral Thalidomide (at 3mg/kg)
~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
11426517|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)
~Capsules of same size and color as used in metronomic therapy Best supportive care
~Management of pain as per WHO standard for pain management"
11426518|NCT01858558|Experimental|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
11426519|NCT01858558|Active Comparator|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
11426520|NCT01858545|Experimental|Experimental|MatriStem MicroMatrix and MatriStem Wound Matrix
11426521|NCT01858545|Active Comparator|Comparator|Cellular Dermal Replacement Tissue
11426522|NCT01858532|Active Comparator|Atrasentan|0.75 mg atrasentan once daily by mouth for up to 52 months
11426523|NCT01858532|Placebo Comparator|Placebo|Placebo once daily by mouth for up to 52 months
11426524|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
11426525|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
11426526|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
11426527|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
11426528|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
11426529|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
11426530|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
11426531|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
11426532|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
11426533|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
11426801|NCT01856595|Placebo Comparator|Placebo|
11426534|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
11426535|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
11426536|NCT01858441|Other|Abiraterone Acetate|
11426537|NCT01858428|Active Comparator|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
11426538|NCT01858428|Experimental|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
11426539|NCT01858415|Experimental|Single arm|
11426540|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
11426541|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
11426542|NCT01858389|Experimental|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
11426543|NCT01858389|Experimental|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
11426544|NCT01858376|Other|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
11426545|NCT01858363|Experimental|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
11426546|NCT01858363|Placebo Comparator|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
11426547|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
11426548|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
11426549|NCT01858350|No Intervention|No intervention|
11426550|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
11426551|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
11426552|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
11426553|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
11426554|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
11426555|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
11426556|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
11426557|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
11426558|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
11426559|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
11426560|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
11426561|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
11426562|NCT01858285||Epilepsy, genetics|
11426563|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
11426564|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
11426565|NCT01858259||azathioprine|Patients receiving azathioprine
11426566|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
11426567|NCT01858259||methotrexate|Patients receiving methotrexate
11426568|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
11426569|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
11426570|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
11426571|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
11426572|NCT01858233|No Intervention|Routine care|standard dietary counseling
11426573|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
11426574|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.
~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
11426575|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
11440990|NCT01759173||college athletes|
11426576|NCT01858194|Experimental|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
11426577|NCT01858194|Placebo Comparator|VT ablation alone|No further therapy in addition to VT ablation
11426578|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
11426579|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
11426580|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
11426581|NCT01858168|Experimental|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Ewing sarcoma
11426582|NCT01858168|Experimental|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
11426583|NCT01858168|Experimental|Three|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Rhabdomyosarcoma
11426584|NCT01858155|Experimental|Melatonin|
11426585|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
11426586|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
11426587|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
11426588|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
11426589|NCT01858116|Experimental|[68Ga]ABY-025|
11426590|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
11426591|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
11426592|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
11426593|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
11426594|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
11426595|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
11426596|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
11426597|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
11426598|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
11426599|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
11426600|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
11426601|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
11426602|NCT01858012||HCV infection|patients with hepatitis C infection
11426603|NCT01858012||non-HCV infection|healthy controls
11426604|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
11426605|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
11426606|NCT01857986|Experimental|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
11426607|NCT01857986|Active Comparator|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
11426608|NCT01857973|Experimental|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
11426609|NCT01857960||Adolescents|Acne survey among Mexican adolescents
11426610|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
11426611|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.
~Cells for infusion are prepared using the CliniMACS System."
11426612|NCT01857921|Active Comparator|Pravastatin group|
11426613|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
11426614|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
11426615|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
11426616|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
11426617|NCT01857882|Experimental|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
11426618|NCT01857882|No Intervention|Standard Care|Routine pre-consultation education
11426619|NCT01857869|Experimental|GSK257049-0,1,7M Group|Subjects receiving 2 doses of GSK257049 vaccine given at 0 and 1 months and followed 6 months later (At Month 7) by another dose of GSK257049 vaccine.
11426620|NCT01857869|Experimental|GSK257049-0,1,2M Group|Subjects receiving 3 doses of GSK257049 vaccine given one month apart (0,1 and 2 months).
11426621|NCT01857869|Experimental|Infectivity Control Group|Volunteers who did not receive any immunization but underwent sporozoite challenge
11426622|NCT01857856|No Intervention|No treatment|no medical treatment
11426623|NCT01857856|Active Comparator|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
11426624|NCT01857843|Experimental|ZES group|
11426625|NCT01857843|Active Comparator|EES group|
11426626|NCT01857843|Experimental|Vytorin group|
11426627|NCT01857843|Active Comparator|Mevalotin group|
11426628|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
11426629|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
11426630|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
11426631|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
11426632|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
11426633|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
11426634|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
11426635|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
11426636|NCT01857791|Experimental|multidisciplinary, behavior modification|
11426637|NCT01857778||Lactating Women|
11426638|NCT01857765|Active Comparator|Standard of Care|
11426639|NCT01857765|Experimental|Rehabilitation|
11426640|NCT01857752|Experimental|temozolomide|
11426641|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
11426642|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
11426643|NCT01857713|Active Comparator|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
11426644|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
11426645|NCT01857700|Placebo Comparator|Standard of Care|
11426646|NCT01857687||patients with coronary artery stenosis|
11426647|NCT01857661|Other|control|hearing aid without an integrated sound generator
11426648|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
11426649|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
11426650|NCT01857648|No Intervention|Control|Control group.
11426651|NCT01857622|Experimental|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
11426652|NCT01857622|Experimental|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
11426653|NCT01857622|Experimental|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
11426654|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
11426655|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
11426656|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
11426657|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
11426658|NCT01857583|Experimental|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
11426896|NCT01855945|Experimental|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
11426659|NCT01857583|Experimental|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
11426660|NCT01857583|Active Comparator|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
11426661|NCT01857583|Experimental|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
11426662|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
11426663|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
11426664|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
11426665|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
11426666|NCT01857531|Experimental|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:
~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.
~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.
~Post-Quit Period:
~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.
~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
11426667|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
11426668|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
11426669|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
11426670|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
11426671|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
11426672|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
11426673|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
11426674|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].
~The first dose will be administered under direct supervision."
11426675|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
11426676|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
11426677|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
11426678|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
11426679|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
11426680|NCT01857401||Observational study|Blood draw only, observational study
11426681|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
11426682|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
11426683|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
11426684|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
11426685|NCT01857362|Active Comparator|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
11426686|NCT01857362|Experimental|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
11426687|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
11426688|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
11426689|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
11426690|NCT01857323|Experimental|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
11426691|NCT01857310|Experimental|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
11426692|NCT01857310|Placebo Comparator|Placebo|Matching placebo, taken orally daily for 6 months.
11426693|NCT01857297|Experimental|Adults (aged 18 to 59 years)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
11426694|NCT01857297|Experimental|Older Adults (aged 60 years or older)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
11426695|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
11426696|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
11426697|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
11426698|NCT01857258|Experimental|Green Tea|Participants will be provided a confection containing green tea concentrate
11426699|NCT01857258|Active Comparator|Control|Participants will be provided a confection devoid of green tea concentrate
11426700|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
11426701|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
11426702|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
11426703|NCT01857232|Other|Control|OND + DEX + FOS followed by oral DEX
11426704|NCT01857232|Placebo Comparator|Placebo|OND + APD403 followed by oral PLACEBO
11426705|NCT01857232|Experimental|Low dose APD403|OND + APD403 followed by oral APD403 low dose
11426706|NCT01857232|Experimental|Mid dose APD403|OND + APD403 followed by oral APD403 mid dose
11426707|NCT01857232|Experimental|High dose APD403|OND + APD403 followed by oral APD403 high dose
11426708|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.
~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
11426709|NCT01857206|Experimental|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
11426710|NCT01857206|Active Comparator|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
11426711|NCT01857193|Experimental|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
11426712|NCT01857193|Experimental|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
11426713|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
11426714|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
11426715|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
11426716|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
11426717|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
11426718|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
11426719|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
11426798|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
11426720|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
11426721|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
11426722|NCT01857141|Experimental|dexmedetomidine|
11426723|NCT01857141|Placebo Comparator|normal saline|
11426724|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
11426725|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
11426726|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:
~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.
~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.
~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).
~Treatment schedule for maintenance until progression or intolerance:
~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
11426727|NCT01857102|Active Comparator|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
11426728|NCT01857102|Experimental|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
11426729|NCT01857089|Experimental|Pressure Measurement|
11426730|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
11426731|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
11426732|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
11426733|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
11426734|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
11426735|NCT01857037|Other|Single arm|Single arm
11426736|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
11426737|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
11426738|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion
~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER
~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)
~Duration: Until end of surgery"
11426739|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion
~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER
~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)
~Duration: Until end of surgery"
11426740|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.
~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
11426741|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
11426742|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
11426743|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
11426744|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
11426745|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
11426746|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
11426747|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
11426748|NCT01856933|Experimental|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
11426749|NCT01856920|Experimental|A|GI-6207 for 1 year
11426750|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
11426751|NCT01856907|Experimental|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
11426752|NCT01856907|Placebo Comparator|Placebo pill|1 pill/BID for 16 weeks
11426753|NCT01856907|Active Comparator|Metformin|1000 mg BID
11426754|NCT01856881|Active Comparator|AMG 876|
11426755|NCT01856881|Placebo Comparator|Placebo|
11426756|NCT01856868|Experimental|Treatment with Epicatechin|Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
11426757|NCT01856855|Experimental|Stereotactic Body Radiation Therapy with Integrated Boost|
11426758|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
11426759|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
11426799|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
11426760|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
11426761|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
11426762|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
11426763|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
11426764|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
11426765|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
11426766|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
11426767|NCT01856790|Experimental|Closed Loop Insulin Delivery|"Each participant recruited into the study will undergo two inpatient closed loop admissions.
~The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.
~Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
~Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy."
11426768|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
11426769|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
11426770|NCT01856764|Experimental|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
11426771|NCT01856764|Placebo Comparator|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
11426772|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
11426773|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
11426774|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
11426775|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing
~Hemodynamic measurements for CRT device programming"
11426776|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing
~CRT device programming without hemodynamics"
11426777|NCT01856712|Active Comparator|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
11426778|NCT01856712|Experimental|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
11426779|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
11426780|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
11426781|NCT01856686|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
11426782|NCT01856686|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
11426783|NCT01856673|Experimental|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
11426784|NCT01856673|Experimental|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
11426785|NCT01856673|Other|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
11426786|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
11426787|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
11426788|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
11426789|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
11426790|NCT01856647||psoriatic lean|9 psoriatic lean
11426791|NCT01856647||psoriatic obese|9 psoriatic obese
11426792|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
11426793|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
11426794|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
11426795|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:
~Patient's > 10 kg will receive DPF 10 mg BID + OBR
~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR
~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
11426796|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
11426797|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
11426802|NCT01856582|Experimental|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
11426803|NCT01856569||observational|
11426804|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
11426805|NCT01856556|Placebo Comparator|Placebo|Saline
11426806|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
11426807|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
11426808|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
11426809|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
11426810|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
11426811|NCT01856543|Placebo Comparator|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
11426812|NCT01856543|Experimental|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
11426813|NCT01856530|Experimental|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
11426814|NCT01856530|Placebo Comparator|Placebo|Matched placebo nasal spray
11426815|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
11426816|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
11426817|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;
~Suspected but without known prior history of CAD
~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)
~Glomerular filtration rate >60 ml/min
~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
11426818|NCT01856491|Other|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
11426819|NCT01856478|Experimental|afatinib|oral intake, once daily
11426820|NCT01856478|Active Comparator|methotrexate|intravenous bolus injection, once weekly
11426821|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
11426822|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
11426823|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
11426824|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
11426825|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
11426826|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
11426827|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
11426828|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
11426829|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
11426830|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
11426831|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
11426832|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
11426833|NCT01856374|Active Comparator|Cypher group|
11426834|NCT01856374|Experimental|Xience group|
11426835|NCT01856374|Active Comparator|Pravastatin group|
11426836|NCT01856374|Experimental|Atorvastatin group|
11426837|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
11426838|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
11426839|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
11426840|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
11426841|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
11426842|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
11426843|NCT01856309|Experimental|Sirukumab 100 mg|
11426844|NCT01856309|Experimental|Sirukumab 50 mg / placebo|
11426845|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
11426846|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
11426847|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
11426848|NCT01856270|Experimental|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
11426849|NCT01856270|Experimental|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
11426850|NCT01856257|Active Comparator|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
11426851|NCT01856257|Experimental|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
11426852|NCT01856257|Experimental|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.
~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
11426853|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
11426854|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
11426855|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
11426856|NCT01856218|Experimental|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.
~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
11426857|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
11426858|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
11426859|NCT01856192|Experimental|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11426860|NCT01856192|Active Comparator|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11426861|NCT01856179|Experimental|Echium oil young|"BMI<25,
~age 20-30"
11426862|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
11426863|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
11426864|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
11426865|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
11426866|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
11426867|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
11426868|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
11426869|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
11426870|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
11426871|NCT01856127|Experimental|Vilazodone|Vilazodone
11426872|NCT01856127|Active Comparator|Sertraline|Sertraline
11426897|NCT01855945|Experimental|Group C|15 µg H3N2c unadjuvanted
11426898|NCT01855932|Experimental|Technology Supported|
11426899|NCT01855919|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
11426900|NCT01855919|Placebo Comparator|Placebo|Placebo administered orally once every day for 15 weeks.
11427337|NCT01852942|Placebo Comparator|Sugar Pill|
11426873|NCT01856114|Experimental|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
11426874|NCT01856114|Placebo Comparator|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
11426875|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.
~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
11426876|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
11426877|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
11426878|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
11426879|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:
~Class 1a/1c antiarrhythmics
~Sotalol
~Amiodarone"
11426880|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
11426881|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
11426882|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
11426883|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
11426884|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
11426885|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
11426886|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
11426887|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
11426888|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
11426889|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
11426890|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
11426891|NCT01855971|Active Comparator|Fragile X syndrome experimental group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).
~Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).
~Treatment period: 3 months (from month 1 to month 4)
~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
11426892|NCT01855971|Placebo Comparator|Fragile X syndrome control group|"Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).
~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
11426893|NCT01855958|Experimental|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
11426894|NCT01855958|Sham Comparator|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
11426895|NCT01855945|Experimental|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
11451668|NCT01688830|Experimental|BI 655075|
11426901|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
11426902|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
11426903|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
11426904|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
11426905|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
11426906|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
11426907|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
11426908|NCT01855867|Other|Stribild|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
11426909|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
11426910|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
11426911|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
11426912|NCT01855828|Experimental|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
11426913|NCT01855789|Experimental|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score </=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
11426914|NCT01855789|Experimental|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
11426915|NCT01855789|Active Comparator|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
11426916|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
11426917|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
11426918|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:
~$0 SGD for less than 50,000 steps during the week
~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)
~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
11426919|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
11426920|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
11426921|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
11426922|NCT01855750|Placebo Comparator|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
11426923|NCT01855750|Experimental|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
11426924|NCT01855737||Warfarin Using Group|
11426925|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.
~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.
~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
11426926|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
11426927|NCT01855698||All patients registered|
11426928|NCT01855685|Experimental|Open label|X vivo gene therapy
11456405|NCT01656525|Experimental|3|
11426929|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
11426930|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
11426931|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
11426932|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
11426933|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
11426934|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
11426935|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
11426936|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
11426937|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
11426938|NCT01855607|Experimental|topical menthol|topical menthol cream to hands and feet
11426939|NCT01855607|Placebo Comparator|placebo cream|topical cream without menthol
11426940|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
11426941|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
11426942|NCT01855581||sedation group|Children requiring sedation for MRI/CT
11426943|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
11426944|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
11426945|NCT01855555||sedation group|Children requiring sedation for MRI/CT
11426946|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
11426947|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
11426948|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
11426949|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
11426950|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
11426951|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
11426952|NCT01855503||Metastatic Breast Cancer|
11426953|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
11426954|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
11426955|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
11426956|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
11426957|NCT01855451|Active Comparator|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
11426958|NCT01855451|Active Comparator|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
11426959|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
11426960|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
11426961|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
11426962|NCT01855425|Other|Investigational CBCT|Radiation
11426963|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
11426964|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
11426965|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
11426996|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
11456406|NCT01656525|Experimental|4|
11426966|NCT01855399|Experimental|Peer Coaching + Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
11426967|NCT01855399|Active Comparator|Peer Coaching Alone|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
11426968|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
11426969|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
11426970|NCT01855373|Other|Placebo|No active ingredient
11426971|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
11426972|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
11426973|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
11426974|NCT01855360|Experimental|TUDCA and Doxycycline|TUDCA taken orally, 250 mg three times daily. Doxycycline taken orally, 100 mg twice daily
11426975|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
11426976|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
11426977|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
11426978|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
11426979|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
11426980|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
11426981|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
11426982|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
11426983|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
11426984|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
11426985|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
11426986|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
11426987|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
11426988|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
11426989|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
11426990|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
11426991|NCT01855243|Active Comparator|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG > 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
11426992|NCT01855243|Active Comparator|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG > 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
11426993|NCT01855243|Active Comparator|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG > 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
11426994|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
11426995|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
11457584|NCT01648465|Experimental|Everolimus|
11426997|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
11426998|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
11426999|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
11427000|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
11427001|NCT01855191||Standard|
11427002|NCT01855191||Standard + saliva collection|
11427003|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
11427004|NCT01855165|No Intervention|General advice|
11427005|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
11427006|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
11427007|NCT01855139||Rivaroxaban|
11427008|NCT01855126|Experimental|Blue light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two blue Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the blue light mask was worn nightly for 8 weeks. There will be a two week washout period between each intervention
11427009|NCT01855126|Placebo Comparator|Red light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two red Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the red light mask was worn nightly for 8 weeks, with a two week washout period between each intervention
11427010|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
11427011|NCT01855113||braces|those with braces for orthodontic correction.
11427012|NCT01855100||Rivaroxaban|
11427013|NCT01855074|Experimental|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
11427014|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.
~Side studies include:
~pharmacogenetics
~pharmacokinetics of SN-38
~carboxylesterase activity in the index lesion
~midazolam clearance test (only in Rotterdam patients)"
11427015|NCT01855048|Experimental|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
11427016|NCT01855048|Placebo Comparator|INT200-Placebo|Placebo
11427017|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
11427018|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
11427019|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
11427020|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
11427021|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
11427022|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
11427023|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
11427024|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
11427025|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
11427026|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
11427027|NCT01854970|Experimental|Patient|
11427028|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
11427029|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
11427030|NCT01854944|Experimental|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:
~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
11427031|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
11427109|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
11427110|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
11427032|NCT01854918|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product [all-IP] period.
11427033|NCT01854918|Experimental|Evolocumab + Standard of Care|Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
11427034|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
11427035|NCT01854892|Experimental|Manipulation|Spinal manipulation
11427036|NCT01854892|Experimental|Mobilization|Spinal mobilization
11427037|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
11427038|NCT01854879|Experimental|Nucleus 6|
11427039|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
11427040|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
11427041|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
11427042|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
11427043|NCT01854827|Experimental|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
11427044|NCT01854814|Experimental|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
11427045|NCT01854814|Active Comparator|losartan|maximus tolerated labeled dose of losartan
11427046|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
11427047|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
11427048|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
11427049|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
11427050|NCT01854775|Experimental|Cohort 1 (12 to < 18 years of age)|Participants within the ages of 12 and <18 years old will receive E/C/F/TAF STR once daily with food.
11427051|NCT01854775|Experimental|Cohort 2 (6 to < 12 years of age)|Participants within the ages of 6 and <12 years old and weighing ≥ 25 kg will receive E/C/F/TAF STR once daily with food.
11427052|NCT01854775|Experimental|Cohort 3 (≥ 2 years of age)|Participants ≥ 2 years of age and weighing ≥ 14 to < 25 kg will receive E/C/F/TAF STR once daily with food.
11427053|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
11427054|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
11427055|NCT01854749|Experimental|S1 combined with cisplatin|
11427056|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
11427057|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
11427058|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
11427059|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
11427060|NCT01854710|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
11427061|NCT01854710|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
11427062|NCT01854710|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
11427063|NCT01854710|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
11427064|NCT01854710|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
11427065|NCT01854710|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
11427066|NCT01854697|Experimental|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals [DAAs] with RBV in GT1a)
11427067|NCT01854697|Active Comparator|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
11427068|NCT01854697|Experimental|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
11427069|NCT01854697|Experimental|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
11427111|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
11427070|NCT01854697|Active Comparator|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
11427071|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
11427072|NCT01854671|No Intervention|standard care|
11427073|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
11427074|NCT01854658|Experimental|FF MDI (PT005)|FF MDI administered as two puffs BID
11427075|NCT01854658|Experimental|GP MDI (PT001)|GP MDI administered as two puffs BID
11427076|NCT01854658|Experimental|GFF MDI (PT003)|GFF MDI administered as two puffs BID
11427077|NCT01854658|Placebo Comparator|Placebo MDI|Inhaled placebo administered as two puffs BID
11427078|NCT01854645|Experimental|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
11427079|NCT01854645|Experimental|GP MDI|Glycopyrronium (GP) MDI (PT001)
11427080|NCT01854645|Experimental|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
11427081|NCT01854645|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
11427082|NCT01854645|Placebo Comparator|Placebo|Placebo MDI
11427083|NCT01854632|Experimental|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
11427084|NCT01854632|Placebo Comparator|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
11427085|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
11427086|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
11427087|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
11427088|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
11427089|NCT01854593|Active Comparator|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
11427090|NCT01854593|Sham Comparator|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
11427091|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
11427092|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
11427093|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
11427094|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
11427095|NCT01854554|Experimental|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
11427096|NCT01854554|Experimental|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
11427097|NCT01854541||Radiotherapy|All patients receiving radiotherapy
11427098|NCT01854528|Experimental|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 [150 mg/ 100 mg/ 25 mg once daily] and ABT-333 [250 mg twice daily]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
11427099|NCT01854528|Active Comparator|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously [SC] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
11427100|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
11427101|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
11427102|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
11427103|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.
~The child was given multi-faceted counseling for good oral health habits."
11427104|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
11427105|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
11427106|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
11427107|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
11427108|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
11462206|NCT01615653|Active Comparator|EUS 2|
11427112|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
11427113|NCT01854450|Other|control|usual obstetrical care
11427114|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
11427115|NCT01854437||placebo|placebo 1 tab TDS
11427116|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
11427117|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
11427118|NCT01854398|Experimental|CPAP group|
11427119|NCT01854398|Sham Comparator|sham-CPAP group|
11427120|NCT01854385|Experimental|Sumatriptan|Open label study of sumatriptan to treat post-traumatic headache. Subjects will use sumatriptan 100 mg at the onset of headache pain and may repeat the dose if not pain-free in 2 hours. Subjects will receive a maximum of 18 pills for use over two months. Subjects will maintain a daily headache diary.
11427121|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).
~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
11427122|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
11427123|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
11427124|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
11427125|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
11427126|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
11427127|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
11427128|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
11427129|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
11427130|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
11427131|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
11427132|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
11427133|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
11427134|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
11427135|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
11427136|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
11427137|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
11427138|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
11427139|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
11427140|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
11427141|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
11427142|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
11427143|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.
~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
11427144|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
11427145|NCT01854177|Active Comparator|Aprepitant|Aprepitant 125 mg
11427146|NCT01854177|Placebo Comparator|Placebo|Inert capsule
11427147|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
11427148|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
11427188|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
11462892|NCT01610791|Experimental|Single Arm|
11427149|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
11427150|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
11427151|NCT01854138|No Intervention|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
11427152|NCT01854138|Experimental|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
11427153|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
11427154|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
11427155|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
11427156|NCT01854112||T-cell lymphoma|
11427157|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
11427158|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
11427159|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
11427160|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
11427161|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
11427162|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
11427163|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
11427164|NCT01854047|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11427165|NCT01854047|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11427166|NCT01854047|Experimental|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11427167|NCT01854047|Experimental|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11427168|NCT01854047|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
11427169|NCT01854034|Experimental|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
11427170|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
11427171|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
11427172|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
11427173|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
11427174|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
11427175|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
11427176|NCT01853995|No Intervention|Untreated Class II Control Group|control group
11427177|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
11427178|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
11427179|NCT01853969||Patients who have carpal tunnel release surgery|
11427180|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
11427181|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
11427182|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
11427183|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
11427184|NCT01853930|Other|Laboratory training|Patients will be trained in the laboratory with feedback by a rehabilitation therapist
11427185|NCT01853930|Other|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
11427186|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
11427187|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
11427189|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
11427190|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
11427191|NCT01853878|Experimental|GSK2302032A Group|The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
11427192|NCT01853878|Placebo Comparator|Placebo group|The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
11427193|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
11427194|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
11427195|NCT01853852|Experimental|50 mg|GR181413A/AT1001
11427196|NCT01853852|Experimental|150 mg|GR181413A/AT1001
11427197|NCT01853852|Experimental|450 mg|GR181413A/AT1001
11427198|NCT01853852|Placebo Comparator|Placebo|placebo
11427199|NCT01853826|Experimental|afatinib|Patients will receive afatinib once daily
11427200|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
11427201|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
11427202|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
11427203|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
11427204|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
11427205|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
11427206|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
11427207|NCT01853774|Experimental|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
11427208|NCT01853774|No Intervention|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
11427209|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
11427210|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
11427211|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
11427212|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
11427213|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
11427214|NCT01853748|Active Comparator|Study Drug|T-DM1 every three weeks by IV for 17 treatments (total of 51 weeks)
11427215|NCT01853748|Active Comparator|Standard of Care|Paclitaxel and Trastuzumab once per week by IV for 12 weeks. Beginning week 13, Trastuzumab only by IV injection every three weeks for 13 treatments
11427216|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
11427217|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
11427218|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
11427219|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
11427220|NCT01853722|Experimental|DCN01|
11427221|NCT01853722|Placebo Comparator|Unisol|
11427222|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:
~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
11427223|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:
~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
11427224|NCT01853696|Active Comparator|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
11427225|NCT01853696|Active Comparator|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
11432025|NCT01820702|Active Comparator|defined training programme|
11427226|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
11427227|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
11427228|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:
~These patients will have chemotherapy during the time of radiation treatment"
11427229|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:
~These patients will have chemotherapy prior to other radiation treatment."
11427230|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
11427231|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
11427232|NCT01853644|Experimental|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
11427233|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell ALL|"3 daily doses of cyclophosphamide together with fludarabine with be administered finishing at least 24 hours before T cell infusion.
~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
11427234|NCT01853631|Experimental|CD19 CAR T Cells for Bcell ALL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
11427235|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell NHL/CLL|"3 daily doses of cyclophosphamide together with fludarabine will be administered finishing at least 24 hours before T cell infusion.
~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
11427236|NCT01853631|Experimental|CD19 CAR T Cells for Bcell NHL/CLL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
11427237|NCT01853618|Experimental|Pilot 1/Arm A1-Tremelimumab + RFA or TACE|Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
11427238|NCT01853618|Experimental|2/Arm A2 - Tremelimumab + RFA or TACE|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
11427239|NCT01853618|Experimental|3/Arm B - Tremelimumab + TACE|Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
11427240|NCT01853618|Experimental|4/Arm C (never opened)|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
11427241|NCT01853618|Experimental|5/Arm D - Tremelimumab + Cryoablation|Tremelimumab + Cryoablation
11427242|NCT01853618|Experimental|6/Arm E - Tremelimumab + RFA|Tremelimumab + Radiofrequency Ablation (RFA)
11427243|NCT01853605|Experimental|Augmentation|Women undergoing breast augmentation.
11427244|NCT01853605|Experimental|Reconstruction|Women undergoing breast reconstruction.
11427245|NCT01853605|Experimental|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
11427246|NCT01853605|Experimental|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
11427247|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
11427248|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
11427249|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
11427250|NCT01853553|Experimental|Spironolactone|Active arm
11427251|NCT01853553|Placebo Comparator|Sugar Pill|Placebo
11427252|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
11427253|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
11427254|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
11427255|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
11427256|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
11427257|NCT01853475|Experimental|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
11427258|NCT01853475|Experimental|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
11427259|NCT01853475|Active Comparator|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
11427260|NCT01853462|Experimental|Proprioceptive Neuromuscular Facilitation (PNF)|Supervised PNF training
11427261|NCT01853462|Experimental|Balance|Supervised balance training
11427262|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
11427263|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
11427264|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
11427265|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
11427266|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
11427267|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
11427268|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
11427269|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
11427270|NCT01853397|Experimental|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
11427271|NCT01853397|Experimental|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
11427272|NCT01853397|Experimental|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
11427273|NCT01853397|Active Comparator|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
11427274|NCT01853384|Experimental|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
11427275|NCT01853384|Placebo Comparator|HP802-247 Vehicle plus compression therapy|fibrinogen solution & thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
11427276|NCT01853371|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.
~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
11427277|NCT01853371|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
11427278|NCT01853358|Experimental|NK Cell infusion|"Cell collection
~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation
~NK Cell selection
~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)
~NK Cell ex-vivo activation
~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)
~NK Cell infusion (60 to 90 days after transplantation)"
11427279|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
11427280|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
11427281|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
11427282|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
11427283|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
11427284|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
11427285|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
11427286|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
11427287|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
11427288|NCT01853280|Experimental|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
11427289|NCT01853280|Placebo Comparator|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
11427290|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
11427291|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
11427292|NCT01853254|Experimental|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
11427293|NCT01853241||Single balloon|Single Balloon Enteroscopy
11427294|NCT01853241||Spirus|Spirus Enteroscopy
11427295|NCT01853228|Experimental|Decitabine and cytarabine|
11427296|NCT01853215|Experimental|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
11427297|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
11427335|NCT01852955|Placebo Comparator|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
11427298|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
11427299|NCT01853189|Other|OMT + Usual Care|
11427300|NCT01853189|Other|Usual Care|
11427301|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
11427302|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
11427303|NCT01853163|Other|Gadolinium contrast agent|Patients who have received Gadolinium contrast agents in the past
11427304|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
11427305|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
11427306|NCT01853137|Experimental|FLMGM Treatment Group|
11427307|NCT01853137|No Intervention|Untreated Class II Control Group|
11427308|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
11427309|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
11427310|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
11427311|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
11427312|NCT01853085||Patients with POAG or OHT|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
11427313|NCT01853072|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
11427314|NCT01853072|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
11427315|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
11427316|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
11427317|NCT01853046|Experimental|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
11427318|NCT01853046|Experimental|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
11427319|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
11427320|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
11427321|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
11427322|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
11427323|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
11427324|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
11427325|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
11427326|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
11427327|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
11427328|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
11427329|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
11427330|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
11427331|NCT01852981|No Intervention|Control|Control group.
11427332|NCT01852968||Patients with type 1 diabetes|"Hippocampal neurochemistry and metabolism will examined in Patients with type 1 diabetes using magnetic resonance spectroscopy.
~Patients with type 1 diabetes will also undergo neurocognitive testing to assess hippocampal function"
11427333|NCT01852968||healthy controls|"Hippocampal neurochemistry and metabolism will be examined in healthy controls using magnetic resonance spectroscopy.
~Healthy controls will also undergo neurocognitive testing to assess hippocampal function"
11427334|NCT01852955|Active Comparator|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
11427336|NCT01852942|Experimental|Losartan|
11427338|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
11427339|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
11427340|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
11427341|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
11427342|NCT01852903|Experimental|calcium ascorbate|
11427343|NCT01852903|Active Comparator|ascorbic acid|
11427344|NCT01852903|Placebo Comparator|placebo|
11427345|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
11427346|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
11427347|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
11427348|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.
~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.
~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
11427349|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
11427350|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
11427351|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
11427352|NCT01852851|Active Comparator|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
11427353|NCT01852851|No Intervention|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
11427354|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
11427355|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
11427356|NCT01852825|Experimental|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
11427357|NCT01852825|Placebo Comparator|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
11427358|NCT01852825|Experimental|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
11427359|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
11427360|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
11427361|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
11427362|NCT01852799|Experimental|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.
~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
11427363|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
11427364|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
11427365|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
11427366|NCT01852760||UC in Remission|Patients with UC in remission
11427367|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
11432026|NCT01820702|No Intervention|Control|
11427368|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
11427369|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
11427370|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
11427371|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
11427372|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
11427373|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
11427374|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
11427375|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
11427376|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
11427377|NCT01852682|Experimental|PA21|
11427378|NCT01852669|Experimental|Inversion, Hydration, ESWL|ESWL with hydration and inversion
11427379|NCT01852669|Active Comparator|ESWL, Hydration|ESWL with hydration
11427380|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
11427381|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
11427382|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
11427383|NCT01852643|Active Comparator|Spreader graft|
11427384|NCT01852643|Active Comparator|Lateral crural overlay|
11427385|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
11427386|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
11427387|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
11427388|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
11427389|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427390|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427391|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427392|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427393|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427394|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427395|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
11427396|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
11427397|NCT01852591|Experimental|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
11427398|NCT01852578|Experimental|1|
11427399|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
11427400|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
11427401|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
11427402|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
11427403|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
11427404|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
11427405|NCT01852513|Active Comparator|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
11427406|NCT01852513|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
11427407|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
11427408|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
11427409|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
11427410|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
11427411|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
11427412|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
11427413|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
11427414|NCT01852448||Patients with Cystic Fibrosis|Blood or Saliva Sample Collection and Glucose -potentiated arginine (GPA) stimulation tests will be completed for all enrolled patients.
11427415|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
11427416|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
11427417|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
11427418|NCT01852422||Pelvic prolapse|
11427419|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
11427420|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
11427421|NCT01852383|Experimental|Duloxetine|"A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.
~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.
~Administration was as a single a.m. dose."
11427422|NCT01852370|Experimental|BOLT+BMT|All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
11427423|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
11427424|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
11427425|NCT01852344|Other|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
11427426|NCT01852344|Other|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
11427427|NCT01852344|Other|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
11427428|NCT01852344|Other|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
11427429|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
11427430|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
11427431|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
11427432|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
11427433|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
11427434|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
11427462|NCT01852110|Placebo Comparator|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
11427463|NCT01852110|Experimental|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
11463445|NCT01606735|Experimental|Dose 2|
11427435|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
11427436|NCT01852292|Experimental|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m^2 weekly.
11427437|NCT01852292|Placebo Comparator|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m^2 weekly.
11427438|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
11427439|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
11427440|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
11427441|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
11427442|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
11427443|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
11427444|NCT01852240||erectile dysfunction|"Inclusion criteria:
~male patients with ED defined by an IIEF-5 score of ≤ 21
~age between 18-45a
~Exclusion criteria:
~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)
~pure psychogenic (non-organic) ED with good spontaneous / nightly erections
~periodontal treatment within the last 3 months
~antibiotic intake within the last 3 months"
11427445|NCT01852214|Active Comparator|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
11427446|NCT01852214|Active Comparator|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
11427447|NCT01852201|No Intervention|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:
~General medical management according to AHA/ASA guidelines
~Admission to monitored or intensive care unit for at least 24 hours
~Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient
~Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician
~Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines
~Follow-up imaging study required in any patient with neurologic deterioration"
11427448|NCT01852201|Experimental|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
11427449|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
11427450|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
11427451|NCT01852175|Active Comparator|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
11427452|NCT01852175|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
11427453|NCT01852162|Experimental|Dabigatran|Dabigatran 150mg
11427454|NCT01852162|Placebo Comparator|Placebo|Placebo
11427455|NCT01852149|Experimental|MPAS Implant|MPAS Implant
11427456|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
11427457|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
11427458|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
11427459|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
11427460|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
11427461|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
11427464|NCT01852110|Experimental|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
11427465|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
11427466|NCT01852110|Placebo Comparator|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
11427467|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
11427468|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
11427469|NCT01852084|Experimental|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
11427470|NCT01852084|Experimental|enVista control lens|Spherical control lens
11427471|NCT01852071|Experimental|Gene Therapy|Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
11427472|NCT01852058|Experimental|OnabotulinumtoxinA 50 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
11427473|NCT01852058|Experimental|OnabotulinumtoxinA 100 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
11427474|NCT01852058|Experimental|OnabotulinumtoxinA 200 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
11427475|NCT01852045|Experimental|OnabotulinumtoxinA 50 U|OnabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 (NCT01852058) if qualified.
11427476|NCT01852045|Experimental|OnabotulinumtoxinA 100 U|OnabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
11427477|NCT01852045|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
11427478|NCT01852032|Experimental|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
11427479|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
11427480|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
11427481|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
11427482|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
11427483|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
11427484|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
11427485|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
11427486|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
11427487|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
11427488|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
11427489|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
11427490|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
11427491|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
11427492|NCT01851954|Experimental|clarithromycin|Population PK
11427493|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
11427494|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
11427495|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
11427496|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
11427497|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
11427498|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
11427499|NCT01851889||CF-LVAD pump speed.|
11427500|NCT01851876|Experimental|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
11427611|NCT01851122|Placebo Comparator|Placebo|
11427501|NCT01851876|No Intervention|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
11427502|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
11427503|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
11427504|NCT01851863|Active Comparator|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
11427505|NCT01851863|Active Comparator|proton pump inhibitor|Prescribe Omeprazole.
11427506|NCT01851850|Experimental|Drug|
11427507|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
11427508|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
11427509|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
11427510|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
11427511|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
11427512|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
11427513|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
11427514|NCT01851772|Experimental|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.
~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
11427515|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
11427516|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
11427517|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.
~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.
~Biomarker blood draws will be drawn at different time points.
~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
11427518|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).
~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.
~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
11427519|NCT01851720|Active Comparator|Control group / Standard of Care|"IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain
~(Bolus dose can be titrated up in 25 mcg increments if necessary)
~Maximum dose of 100 mcg/hr"
11427520|NCT01851720|Active Comparator|Low dose IV fentanyl PCA|"Initially: 10 mcg demand dose every 12 minutes
~No initial bolus and no continuous infusion
~Demand dose increased 10 mcg every 12 minutes if necessary
~Maximum dose of 100 mcg/hr"
11427521|NCT01851707|Experimental|IPI-145, low dose BID|
11427522|NCT01851707|Experimental|IPI-145, medium dose BID|
11427523|NCT01851707|Experimental|IPI-145, high dose BID|
11427524|NCT01851707|Placebo Comparator|Placebo BID|
11427525|NCT01851694|Experimental|GLP-1|The incretin, Glucagon-Like-peptide-1 (GLP-1) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins. (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
11427612|NCT01851122|Experimental|l-theanine|
11427526|NCT01851694|Experimental|GIP|The incretin, Glucose-dependent Insulinotropic Polypeptide (GIP) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
11427527|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
11427528|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
11427529|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
11427530|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
11427531|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
11427532|NCT01851655|Experimental|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
11427533|NCT01851655|Active Comparator|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
11427534|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
11427535|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
11427536|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
11427537|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
11427538|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
11427539|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
11427540|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
11427541|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
11427542|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
11427543|NCT01851603|Placebo Comparator|Sugar pill|Placebo
11427544|NCT01851590|Experimental|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
11427545|NCT01851590|Active Comparator|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
11427546|NCT01851590|Active Comparator|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
11427547|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
11427548|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
11427549|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
11427550|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
11427551|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
11427552|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
11427553|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
11427554|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
11427555|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
11427556|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
11427557|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
11427558|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
11427559|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
11427560|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
11427561|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
11427562|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
11427563|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
11427564|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
11427613|NCT01851109|No Intervention|Control|
11463446|NCT01606735|Experimental|Dose 3|
11427565|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
11427566|NCT01851447||Fragile Sarcolemmal Muscular Dystrophy|patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
11427567|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
11427568|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
11427569|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
11427570|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
11427571|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
11427572|NCT01851395||1/Thoracic malignancies|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma.
11427573|NCT01851395||2/Genitourinary malignancies|Patients with genitourinary malignancies
11427574|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
11427575|NCT01851382||Cohort 1|Healthy volunteers.
11427576|NCT01851369|Experimental|1|combination treatment with oral TRC102 and oral TMZ for days 1-5 of 28-day cycles
11427577|NCT01851343|Experimental|1|All patients will receive the same treatment
11427578|NCT01851330|Experimental|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
11427579|NCT01851330|Experimental|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
11427580|NCT01851330|Experimental|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
11427581|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
11427582|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
11427583|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
11427584|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
11427585|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
11427586|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
11427587|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
11427588|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
11427589|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
11427590|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
11427591|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
11427592|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
11427593|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
11427594|NCT01851252|Experimental|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
11427595|NCT01851239||medical ICU inpatients|
11427596|NCT01851239||surgical ICU inpatients|
11427597|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
11427598|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
11427599|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
11427600|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
11427601|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
11427602|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
11427603|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
11427604|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days
~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
11427605|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
11427606|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
11427607|NCT01851148|Other|usual care|triptans treatment only
11427608|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
11427609|NCT01851135|Experimental|Patients with NF1|
11427610|NCT01851135|Other|Healthy controls|
11427614|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
11427615|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
11427616|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
11427617|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
11427618|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
11427619|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
11427620|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
11427621|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
11427622|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
11427623|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
11427624|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
11427625|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
11427626|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
11427627|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
11427628|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
11427629|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
11427630|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
11427631|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
11427632|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
11427633|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
11427634|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
11427635|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
11427636|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
11427637|NCT01850966||Iguratimod|
11427638|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
11427639|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
11427640|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
11427641|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
11427642|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
11427643|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
11427644|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
11427645|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
11427646|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
11427647|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
11427648|NCT01850888|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
11427649|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
11427650|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
11427651|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
11427806|NCT01849731|Experimental|Intervention A|Face-to face intervention
11465094|NCT01595516|Other|Bradykinin|
11427652|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
11427653|NCT01850849|Experimental|LEO 39652 cream|Active drug
11427654|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
11427655|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
11427656|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
11427657|NCT01850823|Placebo Comparator|placebo|Placebo
11427658|NCT01850823|Active Comparator|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
11427659|NCT01850823|Experimental|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
11427660|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
11427661|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
11427662|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
11427663|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
11427664|NCT01850784|Active Comparator|Standard formula|Standard formula
11427665|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
11427666|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
11427667|NCT01850758|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
11427668|NCT01850758|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
11427669|NCT01850745||Control|Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program
11427670|NCT01850745||Validation cohort|Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
11427671|NCT01850745||Pilot cohort|Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
11427672|NCT01850732|Other|ultrasound of aorta|
11427673|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
11427674|NCT01850719|Active Comparator|Physical Therapy|
11427675|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
11427676|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
11427677|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
11427678|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
11427679|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
11427680|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
11427681|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
11427682|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
11427683|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
11427684|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
11427685|NCT01850641|Experimental|PA21|
11427686|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
11427687|NCT01850615|Experimental|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
11427688|NCT01850615|Active Comparator|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
11427689|NCT01850602|Experimental|PA21|
11427690|NCT01850602|Active Comparator|Sevelamer hydrochloride|
11427691|NCT01850589|Other|Conservative Therapy|"Conservative therapy:
~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.
~Counseling consists of:
~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.
~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
11427692|NCT01850589|Other|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:
~One hour group counseling sessions, focusing on patient education and behavior modification.
~Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.
~Counseling including information on nutrition, exercise, and chemical dependency.
~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
11427693|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
11427694|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
11427695|NCT01850563|Other|HBO feasibility|
11427807|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
11427808|NCT01849731|No Intervention|Control Group|
11428147|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
11427696|NCT01850550|No Intervention|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
11427697|NCT01850550|Experimental|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
11427698|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
11427699|NCT01850524|Active Comparator|IXAZOMIB|"IXAZOMIB 4.0 mg capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle, for the first 18 cycles or until progressive disease or unacceptable toxicity, whichever occurs first.
~After cycle 18 IXAZOMIB and Lenalidomide will be reduced and Dexamethasone will be discontinued."
11427700|NCT01850524|Placebo Comparator|Placebo|"IXAZOMIB matching-placebo capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles or until progressive disease or unacceptable toxicity, whichever occurs first.
~After cycle 18 IXAZOMIB and Lenalidomide will be reduced and Dexamethasone will be discontinued."
11427701|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
11427702|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
11427703|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
11427704|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
11427705|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
11427706|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
11427707|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
11427708|NCT01850459||IQ-Matched Control Subjects|
11427709|NCT01850459||Age-Matched Neurotypical Controls|
11427710|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
11427711|NCT01850446|Experimental|Ergoferon|The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
11427712|NCT01850446|Active Comparator|Oseltamivir (Tamiflu)|"The treatment period is 5 days.
~1 capsule (75 mg) twice a day during the meal or regardless of meal."
11427713|NCT01850433|Experimental|Internet CBT|
11427714|NCT01850420|Experimental|IMC-1|Experimental intervention
11427715|NCT01850420|Placebo Comparator|Matching placebo|
11427716|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
11427717|NCT01850394|Placebo Comparator|Control group|physiologic saline 25 ml
11427718|NCT01850394|Active Comparator|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
11427719|NCT01850394|Active Comparator|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
11427720|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
11427721|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
11427722|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
11427723|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
11427724|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
11427725|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
11427726|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
11427727|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
11427728|NCT01850303|Other|Surveillance|
11427729|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
11427730|NCT01850290||Dopamine Imaging|
11427731|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.
~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
11427847|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
11465095|NCT01595516|Other|Saline|
11427732|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.
~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
11427733|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
11427734|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
11427735|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
11427736|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
11427737|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.
~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
11427738|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.
~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
11427739|NCT01850225|Experimental|Device implantation|Implantation of device
11427740|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
11427741|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
11427742|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
11427743|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
11427744|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
11427745|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
11427746|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
11427747|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
11427748|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
11427749|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
11427750|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
11427751|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
11427752|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
11427753|NCT01850147|Experimental|Sunitinib|
11427754|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
11427755|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
11427756|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
11427757|NCT01850108|Experimental|Non-Myeloablative Conditioning and Bone Marrow Transplantation|
11427758|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
11427759|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
11427760|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
11427761|NCT01850082|Other|Endoscopic Vein Harvest (EVH)|An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
11427762|NCT01850082|Other|Open Vein Harvest (OVH)|"Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as bridging technique) along the course of the vein."
11427763|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
11427764|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
11427765|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
11427766|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
11427767|NCT01850030|Experimental|Dydrogesterone 30 mg|
11427768|NCT01850030|Experimental|Micronized Progesterone 600 mg|
11428232|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
11427769|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.
~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
11427770|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.
~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
11427771|NCT01850004|Experimental|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
11427772|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
11427773|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
11427774|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
11427775|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
11427776|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
11427777|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
11427778|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
11427779|NCT01849939|Experimental|Fludarabin|
11427780|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
11427781|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
11427782|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
11427783|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
11427784|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
11427785|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
11427786|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
11427787|NCT01849887|Placebo Comparator|Placebo|Placebo
11427788|NCT01849874|Experimental|MEK162|
11427789|NCT01849874|Active Comparator|Physician's choice chemotherapy|
11427790|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).
~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.
~Variables considered in this study:
~TSH and FT4
~Questionnaire of Quality of life for older adults (WHOQOL-OLD)
~Mini-Mental State Examination
~Geriatric Depression Scale
~Cardiopulmonary exercise testing - cardiopulmonary capacity"
11427791|NCT01849848|Experimental|SyB L-0501|
11427792|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
11427793|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
11427794|NCT01849822|Experimental|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
11427795|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
11427796|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
11427797|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
11427798|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.
~After collection, participants will receive dexamethasone x 4 days every 14 days.
~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.
~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.
~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)
~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
11427799|NCT01849770|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
11427800|NCT01849770|Active Comparator|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
11427801|NCT01849770|Placebo Comparator|Placebo|Placebo, by mouth per day for 12 weeks.
11427802|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
11427803|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
11427804|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
11427805|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
11427809|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.
~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.
~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
11427810|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.
~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.
~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.
~10 x ½ an hour of individual psychotherapy."
11427811|NCT01849705||All subjects|No intervention
11427812|NCT01849692|Experimental|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
11427813|NCT01849692|Experimental|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
11427814|NCT01849692|Experimental|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
11427815|NCT01849692|Experimental|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
11427816|NCT01849692|Active Comparator|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
11427817|NCT01849679||Post-Extubation Subjects|
11427818|NCT01849666|Active Comparator|A: phenprocoumon single dose|
11427819|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
11427820|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
11427821|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
11427822|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
11427823|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
11427824|NCT01849627|Experimental|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
11427825|NCT01849627|Experimental|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
11427826|NCT01849614||Patient group|Women with left-sided breast cancer
11427827|NCT01849601|Experimental|PTA catheter|
11427828|NCT01849588|Experimental|Treatment Arm|Sorafenib taken orally twice per day
11427829|NCT01849575|Active Comparator|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
11427830|NCT01849575|No Intervention|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
11427831|NCT01849562|Active Comparator|Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg|Sovaprevir 200 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
11427832|NCT01849562|Active Comparator|Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg|Sovaprevir 400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
11427833|NCT01849562|Placebo Comparator|Placebo|Placebo for Sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based RBV QD for 12 weeks
11427834|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
11427835|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
11427836|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
11427837|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
11427838|NCT01849523|No Intervention|Standard care|Standard care
11427839|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
11427840|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
11427841|NCT01849497|Experimental|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
11427842|NCT01849497|Experimental|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
11427843|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
11427844|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
11427845|NCT01849471||patients with prostate cancer|questionnaires
11427846|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
11427848|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
11427849|NCT01849432||Control|Healthy Controls
11427850|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
11427851|NCT01849432||Panic Disorder|Participants with Panic Disorder
11427852|NCT01849432||Specific Phobia|Participants who have specific phobias
11427853|NCT01849419|Experimental|Single group|Healthy volunteers received all drug conditions (MDMA, oxytocin, and placebo) using a within-subjects design.
11427854|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
11427855|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
11427856|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
11427857|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
11427858|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
11427859|NCT01849367|Experimental|Active tDCS (1)|
11427860|NCT01849367|Active Comparator|Active tDCS (2)|
11427861|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
11427862|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
11427863|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
11427864|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
11427865|NCT01849328||Breast Cancer|
11427866|NCT01849328||Healthy|
11427867|NCT01849315|Placebo Comparator|Control|Sedentary intervention
11427868|NCT01849315|Active Comparator|AKIDS II|Physically active group
11427869|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427870|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427871|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427872|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427873|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427874|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427875|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO
~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
11427876|NCT01849289|Experimental|Insulin Degludec|
11427877|NCT01849289|Experimental|Insulin Glargine|
11427878|NCT01849276|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
11427879|NCT01849263|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
11427880|NCT01849250|Experimental|Arm I (docosahexaenoic acid)|Patients receive docosahexaenoic acid PO BID for 12 weeks.
11427881|NCT01849250|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 weeks.
11427882|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
11427883|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
11427884|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
11427885|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
11427886|NCT01849211|Other|neuromuscular block|
11427887|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
11427888|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
11427889|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
11427890|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
11427993|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
11427891|NCT01849172|Experimental|electroacupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
11427892|NCT01849172|Sham Comparator|sham electroacupuncture|Sham electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).Specially constructed EA apparatus were used with no skin penetration, electricity output, or de qi requirement for needle manipulation One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
11427893|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
11427894|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
11427895|NCT01849146|Experimental|Arm I (adavosertib, temozolomide, radiation)|"INITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.
~MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
11427896|NCT01849146|Experimental|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11427897|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
11427898|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
11427899|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
11427900|NCT01849107|Experimental|Plasma citrulline|
11427901|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).
~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
11427902|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
11427903|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
11427904|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
11427905|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
11427906|NCT01849068|Experimental|Ezetimibe|
11427907|NCT01849068|Placebo Comparator|Placebo|
11427908|NCT01849055|Placebo Comparator|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
11427909|NCT01849055|Experimental|LY3023703|Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
11427910|NCT01849055|Active Comparator|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
11427911|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
11427912|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
11427913|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
11427914|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
11427915|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
11427916|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
11427917|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
11427918|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
11427919|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
11427920|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
11427921|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:
~Day 1: 20 mg (loading dose)
~Day 2: 40 mg (loading dose)
~Days 3-7: 6 mg (maintenance dose) once daily
~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
11427922|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:
~Day 1: 50 mg (loading dose)
~Day 2-3: 10 mg once daily
~Days 4-7: 20 mg once daily"
11427923|NCT01848990|Experimental|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
11427924|NCT01848990|Experimental|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
11427925|NCT01848990|Active Comparator|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
11432027|NCT01820689|Experimental|Tympanometry measurement|
11427926|NCT01848977|Experimental|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.
~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
11427927|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.
~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.
~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
11427928|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed.Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain UNMCs standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
11427929|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound.2.The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants ( subcostal position x2 and lateral position x2)
11427930|NCT01848938|Active Comparator|Smartphone treatment|Smartphone treatment with PFMT.
11427931|NCT01848938|No Intervention|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
11427932|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
11427933|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
11427934|NCT01848912||Bone Marrow Transplant Patients|
11427935|NCT01848899|Experimental|Ioxaglate Arm|
11427936|NCT01848899|Experimental|Iodixanol arm|
11427937|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
11427938|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
11427939|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
11427940|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
11427941|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
11427942|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
11427943|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
11427944|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
11427945|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
11427946|NCT01848847|Experimental|Full Bladder|Hysteroscopy conducted under full bladder.
11427947|NCT01848847|Experimental|Empty Bladder|Hysteroscopy conducted under empty bladder.
11427948|NCT01848834|Experimental|Cohort A: Triple negative breast cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
11427949|NCT01848834|Experimental|Cohort B: Head & neck cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
11427950|NCT01848834|Experimental|Cohort C: Urothelial cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
11427951|NCT01848834|Experimental|Cohort D: Gastric cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
11427952|NCT01848834|Experimental|Cohort B2: Head & neck cancer expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
11427953|NCT01848821|Other|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
11427954|NCT01848821|Other|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
11427994|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
11427955|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
11427956|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
11427957|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
11427958|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
11427959|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
11427960|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
11427961|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
11427962|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
11427963|NCT01848756|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
11427964|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
11427965|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
11427966|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
11427967|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
11427968|NCT01848717|Experimental|Lift thread|
11427969|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
11427970|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
11427971|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
11427972|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
11427973|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
11427974|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
11427975|NCT01848652|Experimental|MYOCET|
11427976|NCT01848639|Active Comparator|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
11427977|NCT01848639|Placebo Comparator|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
11427978|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
11427979|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
11427980|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
11427981|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
11427982|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
11427983|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
11427984|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
11427985|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.
~Deliver the following information in the orde of the items below:
~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection
~Briefly additional tests:
~Radio show
~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
11427986|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
11427987|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
11427988|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
11427989|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
11427990|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
11427991|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
11427992|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
11428233|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
11427995|NCT01848483|Experimental|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
11427996|NCT01848483|Other|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
11427997|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
11427998|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
11427999|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
11428000|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
11428001|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
11428002|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
11428003|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
11428004|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
11428005|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, PTZ+C; Cycles 3 & 4: HDMTX 12 h, C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
11428006|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, C; Cycles 3 & 4: HDMTX 12 h, PTZ + C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
11428007|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, PTZ+C; Cycles 3 & 4: HDMTX 4 h, C|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
11428008|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, C; Cycles 3 & 4: HDMTX 4 h, C + PTZ|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
11428009|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
11428010|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
11428011|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
11428012|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
11428013|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:
~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises
~FD:
~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
11428014|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:
~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
11428015|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
11428016|NCT01848366|Experimental|Biowave Treatment|Twelve weekly treatments
11428017|NCT01848353|Active Comparator|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
11428018|NCT01848353|Active Comparator|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
11428019|NCT01848353|Active Comparator|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
11428020|NCT01848353|Experimental|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
11428021|NCT01848353|Experimental|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
11428022|NCT01848353|Experimental|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
11428023|NCT01848353|No Intervention|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
11428024|NCT01848353|No Intervention|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
11428025|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
11428026|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
11428027|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
11428028|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
11428029|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
11428030|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
11428031|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
11428032|NCT01848288|Experimental|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
11428033|NCT01848288|Active Comparator|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
11428034|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
11428035|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
11428036|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
11428037|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
11428038|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
11428039|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
11428040|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
11428041|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
11428042|NCT01848223||late menopause|
11428043|NCT01848210|Experimental|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
11428044|NCT01848210|Placebo Comparator|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
11428045|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
11428046|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
11428047|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning
11428048|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
11428049|NCT01848171|No Intervention|blank|No intervention
11428050|NCT01848158|Experimental|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
11428051|NCT01848158|Sham Comparator|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
11428052|NCT01848145|Experimental|Ofatumumab|Rapid Infusion of Ofatumumab
11428053|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.
~Rituximab: intravenous, 375 mg/m2, day 1
~Cyclophosphamide: intravenous, 750 mg/m2, day 1
~Doxorubicin: intravenous, 50 mg/m2, day 1
~Vincristine: intravenous, 1,4 mg/m2, day 1
~Prednisone: oral, 100 mg, days 1-5"
11428054|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days
~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15
~Rituximab: intravenous, 375 mg/m2, day 1
~Cyclophosphamide: intravenous, 750 mg/m2, day 1
~Doxorubicin: intravenous, 50 mg/m2, day 1
~Prednisone: oral, 100 mg, days 1-5"
11428055|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
11428056|NCT01848119|Placebo Comparator|Placebo|lactose capsules
11428057|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
11428058|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
11428059|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation
~sputum collection"
11428060|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
11428108|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
11428109|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
11465096|NCT01595516|Other|Vitamin C|
11428061|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
11428062|NCT01848067|Experimental|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11428063|NCT01848054|Experimental|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets
~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
11428064|NCT01848054|Active Comparator|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets
~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
11428065|NCT01848041|Experimental|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
11428066|NCT01848041|Experimental|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
11428067|NCT01848041|Placebo Comparator|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
11428068|NCT01848028||Fumaric acid ester|Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed
11428069|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
11428070|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
11428071|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
11428072|NCT01848028||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
11428073|NCT01848028||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
11428074|NCT01848028||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
11428075|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
11428076|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
11428077|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
11428078|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
11428079|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
11428080|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
11428081|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
11428082|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
11428083|NCT01848015||CTCs positive|
11428084|NCT01848002|Experimental|rFXIII|
11428085|NCT01848002|Placebo Comparator|Placebo|
11428086|NCT01847989|Experimental|rFXIII|
11428087|NCT01847989|Placebo Comparator|Placebo|
11428088|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
11428089|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
11428090|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
11428091|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
11428092|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
11428093|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
11428094|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
11428095|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
11428096|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
11428097|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
11428098|NCT01847937||Hereditary axonal neuropathic|
11428099|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
11428100|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
11428101|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
11428102|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
11428103|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
11428104|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
11428105|NCT01847898|Experimental|Balloon Kyphoplasty|
11428106|NCT01847885|Experimental|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
11428107|NCT01847885|Sham Comparator|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
11428110|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
11428111|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
11428112|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
11428113|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
11428114|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
11428115|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
11428116|NCT01847859|Experimental|Ultrasound performed by nurses|Focused examination of the pleural and pericardial cavity. Cardiologists perform reference ultrasound examinations.
11428117|NCT01847833||Patients with brain tumors|
11428118|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
11428119|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
11428120|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
11428121|NCT01847807|No Intervention|MS control|
11428122|NCT01847794|Experimental|chemotheropy|
11428123|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
11428124|NCT01847781|Active Comparator|Healthy controls|Prevenar13
11428125|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.
~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
11428126|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.
~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
11428127|NCT01847755|Experimental|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
11428128|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
11428129|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
11428130|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
11428131|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
11428132|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
11428133|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
11428134|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
11428135|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
11428136|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
11428137|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
11428138|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)
~Carboplatin AUC 6 i.v. first day
~Paclitaxel 175 mg/m2 i.v. first day
~Surgery
~Post-Operative treatment
~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):
~Carboplatin AUC 6 i.v. first day
~Paclitaxel 175 mg/m2 i.v. first day
~Bevacizumab 15 mg/Kg i.v. first day1
~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
11428139|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.
~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.
~c) Postoperative treatment
~Both arms:
~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):
~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.
~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
11428140|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
11428141|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
11428142|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
11428143|NCT01847651|Active Comparator|LOLA|"Other Names:
~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA
~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
11428144|NCT01847651|Placebo Comparator|Placebo|
11428145|NCT01847638|Active Comparator|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
11428146|NCT01847638|Active Comparator|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
11428148|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
11428149|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
11428150|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
11428151|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
11428152|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
11428153|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
11428154|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
11428155|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1
~Multiple dose administration: Dose 1"
11428156|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2
~Multiple dose administration: Dose 2"
11428157|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3
~Multiple dose administration: Dose 3"
11428158|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4
~Multiple dose administration: Dose 4"
11428159|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
11428160|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
11428161|NCT01847560||Dabigatran|
11428162|NCT01847560||Warfarin or other New Oral Anticoagulant (NOAC)|
11428163|NCT01847547||Dabigatran|
11428164|NCT01847547||Warfarin|
11428165|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
11428166|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision
~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.
~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.
~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
11428167|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
11428168|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
11428169|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
11428170|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
11428171|NCT01847482|Experimental|Therapeutic Hypothermia|
11428172|NCT01847469|Experimental|Zonisamide|Participants in this arm will receive zonisamide for 12 weeks.
11428173|NCT01847469|Placebo Comparator|Placebo|Participants in this arm will receive placebo medication for 12 weeks.
11428174|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
11428175|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
11428176|NCT01847443|Experimental|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
11428177|NCT01847443|Experimental|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
11428178|NCT01847443|Active Comparator|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
11428179|NCT01847443|Active Comparator|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
11428180|NCT01847430|Experimental|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11428181|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.
~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
11428182|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
11428183|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
11428184|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
11428185|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
11428186|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
11428366|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
11428187|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
11428188|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
11428189|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
11428190|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
11428191|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
11428192|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
11428193|NCT01847313|Active Comparator|Liraglutide|Liraglutide 0.6 mg daily
11428194|NCT01847313|No Intervention|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
11428195|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
11428196|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
11428197|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
11428198|NCT01847274|Active Comparator|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
11428199|NCT01847274|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle.
11428200|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
11428201|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
11428202|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
11428203|NCT01847248||Severe sepsis|Patients with severe sepsis
11428204|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
11428205|NCT01847248||Control|Healthy volunteers
11428206|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
11428207|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
11428208|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
11428209|NCT01847209|Experimental|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
11428210|NCT01847196|Experimental|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
11428211|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
11428212|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
11428213|NCT01847170|Experimental|Fecal Microbial Transplantation|
11428214|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.
~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
11428215|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.
~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
11428216|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
11428217|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
11428218|NCT01847131|Active Comparator|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
11428219|NCT01847131|Placebo Comparator|placebo|placebo nasal spray 2 sprays in each nostril twice daily
11428220|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
11428221|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
11428222|NCT01847092|Active Comparator|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
11428223|NCT01847092|Placebo Comparator|Placebo|Placebo capsule BID PO for 12 Weeks
11428224|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
11428225|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
11428226|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
11428227|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
11428228|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
11428229|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
11428230|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
11428231|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
11428234|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
11428235|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
11428236|NCT01847027|Active Comparator|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
11428237|NCT01847027|Placebo Comparator|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:
~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
11428238|NCT01847014|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
11428239|NCT01847001|Experimental|Propranolol + Neoadjuvant Chemotherapy|"Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.
~Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and
~Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).
~If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.
~After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.
~DOT imaging will be done at 4 additional time points, including beo."
11428240|NCT01846988|Active Comparator|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
11428241|NCT01846988|Active Comparator|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
11428242|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
11428243|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
11428244|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
11428245|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
11428246|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
11428247|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
11428248|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.
~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
11428249|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
11428250|NCT01846923|Experimental|PCV13|
11428251|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
11428252|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
11428253|NCT01846871|Experimental|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
11428254|NCT01846858||CO2 Laser|
11428255|NCT01846858||Monopolar energy|
11428256|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
11428257|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
11428258|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
11428259|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).
~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.
~Fatigue will be assessed with the FIS and 6 Minute Walk Test.
~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
11428260|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
11428261|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
11428262|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
11428263|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
11428264|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
11428265|NCT01846754||Hemodialysis patients|
11428266|NCT01846741|Other|Model 106 VNS Therapy System|
11428267|NCT01846728|Experimental|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
11428268|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
11428269|NCT01846702|Placebo Comparator|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
11428270|NCT01846702|Experimental|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
11428271|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
11428272|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
11428273|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
11428274|NCT01846663|Experimental|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
11428275|NCT01846663|Placebo Comparator|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
11428276|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
11428277|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
11428278|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
11428279|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
11428280|NCT01846624|Experimental|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.
~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed up for up to 1 year."
11428281|NCT01846611|Experimental|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
11428282|NCT01846611|Active Comparator|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
11428283|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
11428284|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
11428285|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
~E.coli Endotoxin Day 7 - 2 ng/kg"
11428286|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication
~E.coli Endotoxin Day 7 - 2 ng/kg"
11428287|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
~E.coli Endotoxin Day 7 - 2 ng/kg"
11428288|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
11428289|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
11428290|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
11428291|NCT01846507|Experimental|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
11428292|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
11428293|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
11428294|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000
~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
11428295|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo
~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
11428296|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000
~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
11428297|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine
~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo
~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
11428298|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
11428299|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
11428367|NCT01846013|Experimental|Stand|
11428368|NCT01846013|Experimental|Move|
11428300|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
11428301|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
11428302|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh A|Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
11428303|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh B|Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
11428304|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh C|Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
11428305|NCT01846455|Experimental|HCV Without Hepatic Impairment|Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
11428306|NCT01846455|Active Comparator|No Hepatic Disease or Impairment|Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
11428307|NCT01846442|Placebo Comparator|Placebo|
11428308|NCT01846442|Experimental|0.25% DHEA|
11428309|NCT01846442|Experimental|0.5% DHEA|
11428310|NCT01846442|Experimental|1.0% DHEA|
11428311|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
11428312|NCT01846416|Experimental|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
11428313|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
11428314|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
11428315|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
11428316|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
11428317|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
11428318|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
11428319|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
11428320|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
11428321|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
11428322|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
11428323|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
11428324|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
11428325|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
11428326|NCT01846312||All participants|
11428327|NCT01846299|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
11428328|NCT01846299|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
11428329|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
11428330|NCT01846273|Experimental|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
11428331|NCT01846273|Active Comparator|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
11428332|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
11428333|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
11428334|NCT01846234||MS patients|MS patients
11428335|NCT01846221|Experimental|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
11428369|NCT01846013|Experimental|Stand and Move|
11428370|NCT01846013|No Intervention|General Wellness|
11428336|NCT01846221|Experimental|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
11428337|NCT01846208|Experimental|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
11428338|NCT01846208|Experimental|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
11428339|NCT01846208|Experimental|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
11428340|NCT01846195|Sham Comparator|no blood draw|CM 1500 with no blood draw
11428341|NCT01846195|Active Comparator|blood draw|CM 1500 with blood draw
11428342|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks
11428343|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks
11428344|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
11428345|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
11428346|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
11428347|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
11428348|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
11428349|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC
~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.
~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
11428350|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.
~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
11428351|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.
~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
11428352|NCT01846130|No Intervention|Control|Control bed rest group
11428353|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
11428354|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
11428355|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
11428356|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
11428357|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
11428358|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
11428359|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
11428360|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
11428361|NCT01846104|Experimental|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
11428362|NCT01846091|Experimental|Treatment (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.
11428363|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
11428364|NCT01846039|Experimental|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
11428365|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule
~1 capsule per week"
11467311|NCT01580735|Experimental|ARQ 197|
11428371|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
11428372|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
11428373|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
11428374|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
11428375|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
11428376|NCT01845987|Placebo Comparator|Placebo|
11428377|NCT01845987|Experimental|CNTO 1959|
11428378|NCT01845974|Experimental|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
11428379|NCT01845974|Active Comparator|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
11428380|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
11428381|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
11428382|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
11428383|NCT01845922|Experimental|Low sodium diet|Low sodium diet
11428384|NCT01845922|No Intervention|Control|Standard diet regime
11428385|NCT01845909||young adults - Central region of Portugal|
11428386|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
11428387|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
11428388|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
11428389|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
11428390|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
11428391|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
11428392|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
11428393|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
11428394|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
11428395|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
11428396|NCT01845831|Experimental|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
11428397|NCT01845831|Active Comparator|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
11428398|NCT01845831|Experimental|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
11428399|NCT01845831|Experimental|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
11428400|NCT01845831|Experimental|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
11428401|NCT01845818||Ankylosing Spondylitis and Psoriatic Arthritis|Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
11428402|NCT01845805|Experimental|Arm A: CC-486|"CC-486 (oral azacitidine), 300 mg total (three 100mg tablets), taken daily on days 1-21 (of a 28 day cycle); indefinite cycles until visible tumor recurrence, then first line chemotherapy"
11428403|NCT01845805|Active Comparator|Arm B: observation|"Observation, indefinite until visible tumor recurrence, then first line chemotherapy"
11428404|NCT01845792|Experimental|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
11428405|NCT01845792|Active Comparator|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
11428406|NCT01845779|Experimental|patients in complete response|
11428407|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
11428408|NCT01845766|No Intervention|control arm|
11428409|NCT01845753||All colorectal cancer patients|
11428410|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
11428411|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
11428412|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
11468934|NCT01570088|Experimental|L-5-MTHF|
11428413|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
11428414|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
11428415|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
11428416|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
11428417|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
11428418|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
11428419|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
11428420|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
11428421|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
11428422|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
11428423|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
11428424|NCT01845649|Active Comparator|Active|Estradiol Vaginal Gel (0.03 mg estradiol / g )
11428425|NCT01845649|Sham Comparator|Vehicle|Vehicle Vaginal Gel
11428426|NCT01845636|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
11428427|NCT01845623|Experimental|Treatment A|
11428428|NCT01845623|Experimental|Treatment B|
11428429|NCT01845623|Placebo Comparator|Treatment C|
11428430|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
11428431|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
11428432|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
11428433|NCT01845597||MAKOplasty® medial UKA|Patients who have received a MAKOplasty® robotically guided unilateral knee arthroplasty (UKA) and received a medial MCK onlay implant.
11428434|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
11428435|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
11428436|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
11428437|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
11428438|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
11428439|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
11428440|NCT01845532|Experimental|TPI group|
11428441|NCT01845532|Active Comparator|ELMA group|
11428442|NCT01845532|No Intervention|None group|
11428443|NCT01845519|Experimental|Tailored Group|
11428444|NCT01845519|Active Comparator|Targeted Group|
11428445|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
11428446|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
11428447|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
11428448|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
11428449|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
11428450|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
11428451|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
11428452|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
11428453|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
11428454|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
11428455|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
11428456|NCT01845441|Experimental|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
11428457|NCT01845441|Active Comparator|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
11428458|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
11428459|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
11428460|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
11428461|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
11428462|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
11428463|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
11428464|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
11428465|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
11428466|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
11428467|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
11428468|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis
~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.
~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.
~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
11428469|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
11428470|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
11428471|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
11428472|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
11428473|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
11428474|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
11428475|NCT01845311|Experimental|ReZolve2 Treatment Group|
11428557|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
11428476|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
11428477|NCT01845285||aortic valve disease|aortic valve replacement
11428478|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).
~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
11428479|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).
~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
11428480|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
11428481|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
11428482|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
11428483|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
11428484|NCT01845233||Non invasive ventilation|
11428485|NCT01845220|Active Comparator|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
11428486|NCT01845220|Placebo Comparator|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
11428487|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
11428488|NCT01845194|Experimental|Drug application|"Two treatment periods:
~Treatment period 1:
~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application
~Treatment period 2:
~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.
~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
11428489|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
11428490|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
11428491|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
11428492|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
11428493|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
11428494|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
11428495|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
11428496|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
11428497|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
11428498|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
11428499|NCT01845155|Experimental|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
11428500|NCT01845155|Active Comparator|Counselling|Counselling
11428501|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
11428502|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
11428503|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
11428504|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
11428505|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
11428506|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
11428507|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
11428508|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
11428509|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
11428510|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
11428511|NCT01845077|Experimental|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
11428512|NCT01845077|Active Comparator|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
11428513|NCT01845077|Experimental|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
11428514|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
11428515|NCT01845077|Experimental|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
11428516|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
11428517|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
11428518|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
11428519|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
11428520|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
11428521|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
11475645|NCT01523951||Healthy volunteers|
11428522|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
11428523|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
11428524|NCT01845051||Migraine group|Patients diagnosed with migraine
11428525|NCT01845051||Healthy group|Healthy subjects with no migraine as control
11428526|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
11428527|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
11428528|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
11428529|NCT01845025|Experimental|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
11428530|NCT01845025|Active Comparator|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
11428531|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
11428532|NCT01844999|Other|Usual patient education + standard educational websites|
11428533|NCT01844999|Experimental|Usual patient education + P3P decision support website|
11428534|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
11428535|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
11428536|NCT01844973|Placebo Comparator|Vehicle|
11428537|NCT01844973|Active Comparator|M518101|
11428538|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
11428539|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
11428540|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
11428541|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
11428542|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
11428543|NCT01844908|Experimental|Electroacupuncture|
11428544|NCT01844895|Experimental|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months
~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
11428545|NCT01844882||Chronic Kidney Disease|
11428546|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.
~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
11428547|NCT01844856|Experimental|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
11428548|NCT01844856|Active Comparator|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
11428549|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
11428550|NCT01844830|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
11428551|NCT01844830|Placebo Comparator|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
11428552|NCT01844817|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
11428553|NCT01844817|Placebo Comparator|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
11428554|NCT01844804|Experimental|A = PF-06438179|
11428555|NCT01844804|Active Comparator|B = Infliximab-EU|
11428556|NCT01844804|Active Comparator|C = Infliximab-US|
11428722|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
11428558|NCT01844778|Active Comparator|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
11428559|NCT01844778|Active Comparator|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
11428560|NCT01844778|Active Comparator|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
11428561|NCT01844765|Experimental|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
11428562|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatnib or dasatnib
11428563|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatnib or dasatnib - at the end no patients were enrolled in this arm.
11428564|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
11428565|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
11428566|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
11428567|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
11428568|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
11428569|NCT01844726|Experimental|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
11428570|NCT01844726|Placebo Comparator|Placebo|Single IV administration of placebo
11428571|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
11428572|NCT01844713|No Intervention|Control|Distribution of general skin care information
11428573|NCT01844700|Active Comparator|Ziprasidone|(20-160mg/d, bid) for 12 weeks
11428574|NCT01844700|Active Comparator|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
11428575|NCT01844687|Other|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
11428576|NCT01844687|Other|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
11428577|NCT01844687|Other|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
11428578|NCT01844687|Other|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
11428579|NCT01844687|Other|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
11428580|NCT01844687|Other|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
11428581|NCT01844687|Other|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
11428582|NCT01844687|Other|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
11428583|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
11428584|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
11428585|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
11428586|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
11428587|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
11428588|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
11428589|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
11428590|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
11428591|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
11428592|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
11428593|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
11428594|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
11428595|NCT01844583|Experimental|Esomeprazole 40 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.
~Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.
~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
11428596|NCT01844583|Experimental|Rifampin 600 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.
~Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.
~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
11428597|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
11428598|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
11479619|NCT01497080||no treatment|
11428599|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
11428600|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
11428601|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
11428602|NCT01844544||patients after femur neck fracture|
11428603|NCT01844531|Experimental|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
11428604|NCT01844531|Active Comparator|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
11428605|NCT01844531|Experimental|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
11428606|NCT01844531|Active Comparator|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
11428607|NCT01844518|Experimental|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months
~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
11428608|NCT01844505|Experimental|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11428609|NCT01844505|Experimental|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11428610|NCT01844505|Experimental|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
11428611|NCT01844492|Active Comparator|ICU Usual Care Control|described below
11428612|NCT01844492|Experimental|The PARTNER Intervention|described below
11428613|NCT01844479|Active Comparator|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.
~The industry standard diabetic innersole will be used as the active comparator"
11428614|NCT01844479|Experimental|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
11428615|NCT01844466|Experimental|stroke patients|
11428616|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
11428617|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
11428618|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
11428619|NCT01844440|Experimental|HRM|
11428620|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
11428621|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
11428622|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
11428623|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
11428624|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
11428625|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
11428626|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
11428627|NCT01844388|Experimental|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
11428628|NCT01844388|Active Comparator|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
11428629|NCT01844375|Experimental|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
11428630|NCT01844375|Active Comparator|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
11428631|NCT01844362|Experimental|Uterine transplantation|Patients undergo transplantation of the uterus from live donor.
11428632|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
11428633|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
11428634|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
11428635|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
11428636|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
11428637|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
11428638|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
11428639|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
11428640|NCT01844297|Other|TDF+3TC+EFV|
11428641|NCT01844284|Experimental|Absorb™ BVS|Subjects receiving Absorb™ BVS
11428642|NCT01844284|Active Comparator|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
11428643|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
11428644|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
11428645|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
11428646|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
11428647|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
11428648|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
11428649|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.
~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.
~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.
~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
11428650|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
11428651|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.
~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.
~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
11428652|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.
~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.
~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
11428653|NCT01844232|Experimental|Arbaclofen Extended Release (ER) Tablets|Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day
11428654|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
11428655|NCT01844206|Active Comparator|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
11428656|NCT01844206|Placebo Comparator|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
11428657|NCT01844193|No Intervention|Standard Therapy|This arm of the study will follow the standard therapy course after total knee arthroplasty.
11480236|NCT01492686|Experimental|Arm 1|
11428658|NCT01844193|Experimental|Standard Therapy + NMES|This arm will follow the standard course of therapy but also incorporate daily neuromuscular electrical stimulation into the daily therapy regimen after total knee arthroplasty through use of the Compex Rehab device.
11428659|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
11428660|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
11428661|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
11428662|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951
~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
11428663|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:
~The TENS device used: FDA K071951
~TENS is calibrated to allow for maximum range in the specifications.
~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.
~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.
~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
11428664|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
11428665|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
11428666|NCT01844128||overweight women with infertility|
11428667|NCT01844115|Placebo Comparator|Placebo|Dose-matched placebo tablets, oral administration
11428668|NCT01844115|Experimental|Vilazodone|Vilazodone tablets, oral administration
11428669|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
11428670|NCT01844076|Experimental|Phase I - Determine tolerability|Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose. Group 1: quinacrine at a dose of 100 mg every 2 days (days 1,3,5,7,9,11,13); Group 2: quinacrine at a dose of 100 mg once a day (days 1-14); Group 3: quinacrine at a dose of 100 mg twice a day (days 1-14)
11428671|NCT01844076|Experimental|Phase II - Quinacrine, Capecitabine|Quinacrine 100 mg tablets po bid q12 daily day 1-14; Capecitabine 1000 mg/m2 po bid q12 daily day 1-14 21 days for 3 weeks.
11428672|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
11428673|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
11428674|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
11428675|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
11428676|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
11428677|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
11428678|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
11428679|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
11428680|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
11428681|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
11428682|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
11428683|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
11428684|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
11428685|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
11428686|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
11428687|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
11428688|NCT01843972|Experimental|BI 691751 dose 2 (part I)|single dose given as oral solution
11428689|NCT01843972|Experimental|BI 691751 dose 3 (part I)|single dose given as oral solution
11428690|NCT01843972|Experimental|BI 691751 dose 4 (part I)|single dose given as oral solution
11428691|NCT01843972|Experimental|BI 691751 dose 5 (part I)|single dose given as oral solution
11428692|NCT01843972|Experimental|BI 691751 dose 6 (part I)|single dose given as oral solution
11428693|NCT01843972|Experimental|BI 691751 dose 7 (part I)|single dose given as oral solution
11428694|NCT01843972|Experimental|BI 691751dose 1 (part I)|single dose given as oral solution
11428695|NCT01843972|Placebo Comparator|Placebo (part I)|placebo solution
11428696|NCT01843972|Experimental|BI 691751 tablet (part II)|single dose given as 1 tablet
11428697|NCT01843972|Active Comparator|BI 691751 solution (part II)|single dose given as oral solution
11428723|NCT01843777|Active Comparator|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
11428698|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.
~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes
~Group 2:
~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes
~Group 3:
~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes
~Group 4:
~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM
~Group 5:
~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM
~Group 6:
~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM
~Group 7:
~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
11428699|NCT01843933|No Intervention|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
11428700|NCT01843933|Active Comparator|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
11428701|NCT01843920|Active Comparator|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
11428702|NCT01843920|Experimental|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
11428703|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
11428704|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
11428705|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
11428706|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
11428707|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
11428708|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
11428709|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
11428710|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.
~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:
~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.
~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.
~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.
~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
11428711|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
11428712|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
11428713|NCT01843842|Experimental|Ergoferon (5 ml 3 times a day)|
11428714|NCT01843842|Placebo Comparator|Placebo (5 ml 3 times a day)|
11428715|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)
~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions
~then surgery.
~All drugs will be sourced from local stock"
11428716|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)
~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*
~then surgery.
~All drugs will be sourced from local stock"
11428717|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
11428718|NCT01843803|Experimental|patient inventory tool|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
11428719|NCT01843803|Active Comparator|attention control|prior to the encounter, the patient will view a brief video containing general health information.
11428720|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
11428721|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
11428724|NCT01843777|Experimental|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
11428725|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
11428726|NCT01843751|Active Comparator|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
11428727|NCT01843751|Experimental|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
11428728|NCT01843738|Experimental|All participants|
11428729|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
11428730|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
11428731|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
11428732|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
11428733|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
11428734|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
11428735|NCT01843673|Experimental|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
11428736|NCT01843660|Experimental|Tramadol Hydrochloride (HCl)-Paracetamol|
11428737|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
11428738|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
11428739|NCT01843634|Experimental|ODSH|
11428740|NCT01843621|Experimental|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
11428741|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.
~They cannot change physical activity and nutritional habits."
11428742|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.
~They have to present an attendance above or equal to 80%."
11428743|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
11428744|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
11428745|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
11428746|NCT01843556|Experimental|E2022 Tape Formulation|
11428747|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
11428748|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
11428749|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
11428750|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
11428751|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
11428752|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
11428753|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
11428754|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
11428755|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
11428756|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
11428757|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
11428758|NCT01843465||Cryoablation of atrial fibrillation|
11428759|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.
~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.
~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.
~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29
~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29
~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
11429800|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
11428760|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.
~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.
~popularize and educate the asthma action plan
~run a emergency call system for acute exacerbation
~educate the proper techniques using inhalers
~correct the deficiency of magnesium (magnesium 500mg per day)"
11428761|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
11428762|NCT01843413|Experimental|Treatment (SRS)|Patients undergo SRS guided by CT and MRI.
11428763|NCT01843400||Group 1|
11428764|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
11428765|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
11428766|NCT01843374|Experimental|Tremelimumab|Tremelimumab
11428767|NCT01843374|Placebo Comparator|Placebo|Placebo
11428768|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
11428769|NCT01843348|Active Comparator|TAC+MPA|
11428770|NCT01843348|Experimental|TAC+Certican|
11428771|NCT01843348|Experimental|CycA+Certican|
11428772|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
11428773|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
11428774|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
11428775|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
11428776|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
11428777|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
11428778|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
11428779|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
11428780|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
11428781|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
11428782|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
11428783|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
11428784|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
11428785|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
11428786|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
11428787|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
11428788|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
11428789|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.
~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
11428790|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
11428791|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
11429801|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
11428792|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
11428793|NCT01843205|Placebo Comparator|Placebo|Subjects will be maintained on placebo.
11428794|NCT01843205|Experimental|Buspirone|Subjects will be maintained on buspirone.
11428795|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
11428796|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
11428797|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
11428798|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
11428799|NCT01843153|Other|intermittent|injection of ropivacaine on demand
11428800|NCT01843153|Other|continuous|continuous ropivacaine infusion
11428801|NCT01843140||Young female cancer survivors|
11428802|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
11428803|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
11428804|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
11428805|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
11428806|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
11428807|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
11428808|NCT01843101|Other|Keratoconus|5 patients with keratoconus
11428809|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
11428810|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
11428811|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
11428812|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
11428813|NCT01843062|Experimental|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
11428814|NCT01843062|Placebo Comparator|Placebo|Placebo plus Radioactive Iodine Therapy
11428815|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:
~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.
~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.
~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.
~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.
~Chemotherapy:
~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.
~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
11428816|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
11428817|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
11428818|NCT01843023|Experimental|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [Vivitrol®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
11428819|NCT01843023|Active Comparator|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
11428820|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
11428821|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
11428822|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
11428823|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
11428824|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
11428825|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
11428826|NCT01842958|Active Comparator|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
11428827|NCT01842958|Experimental|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
11428828|NCT01842945|No Intervention|Wait-list control|
11428829|NCT01842945|Experimental|Treatment with therapist contact|
11428830|NCT01842945|Experimental|Treatment without therapist contact|
11428831|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
11428832|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
11428833|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
11428834|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
11428835|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
11428836|NCT01842906|Experimental|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
11428837|NCT01842906|Sham Comparator|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
11428838|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
11428839|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
11428840|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
11428841|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
11428842|NCT01842841|Experimental|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
11428843|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
11428844|NCT01842828|Other|Standard care|Standard care for smoking cessation
11428845|NCT01842815|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos
11428846|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
11428847|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
11428848|NCT01842789|Other|Acessa Procedure w/o TAG|Acessa Procedure without the use of Targeting Animation Guidance
11428849|NCT01842789|Other|Acessa Procedure with TAG|Acessa Procedure with Targeting Animation Guidance
11428850|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
11428851|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
11428852|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
11428853|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
11428854|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
11428855|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
11428856|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
11428857|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
11428858|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
11428859|NCT01842646|Experimental|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
11428860|NCT01842633|Experimental|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
11428861|NCT01842633|Active Comparator|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
11428862|NCT01842633|Placebo Comparator|Placebo Caplets|Four placebo caplets to be administered
11428863|NCT01842620|Experimental|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
11428864|NCT01842620|Active Comparator|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
11428865|NCT01842607|Experimental|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
11428866|NCT01842594|Experimental|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
11428867|NCT01842581|Experimental|Rifaximin 550 mg BID|Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
11428868|NCT01842581|Experimental|Rifaximin 550 mg BID + Lactulose|Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
11428869|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
11428870|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.
~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
11428871|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
11428872|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
11428873|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
11428874|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
11428875|NCT01842516|Placebo Comparator|Placebo|Placebo
11428876|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
11428877|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
11428878|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
11428879|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
11428880|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
11428881|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
11428882|NCT01842438|Experimental|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
11428883|NCT01842438|No Intervention|Control|This group will not receive the intervention during the life-span of the project
11428884|NCT01842412||claudication|
11428885|NCT01842412||healthy|
11428886|NCT01842399|Placebo Comparator|Experimental 1|2x/day orally
11428887|NCT01842399|Experimental|Experimental 2|75 mg, 2x/day, orally
11428888|NCT01842399|Experimental|Experimental 3|150 mg, 2x/day, orally
11428889|NCT01842386|Experimental|Rituximab|Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
11428890|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
11428891|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
11428892|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
11428893|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
11428894|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
11428895|NCT01842334|Experimental|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
11428896|NCT01842334|Placebo Comparator|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
11428897|NCT01842321|Experimental|Abiraterone Acetate|
11428898|NCT01842308|Experimental|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.
~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
11428899|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
11428900|NCT01842282|Experimental|Amlexanox|
11428901|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
11428902|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
11428903|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
11428904|NCT01842256|Active Comparator|Atorvastatin 40mg|
11428905|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
11428906|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
11428907|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
11428908|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
11428909|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
11428910|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
11428911|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
11428912|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
11428913|NCT01842191|Experimental|Fish oil|
11428914|NCT01842191|Placebo Comparator|Placebo|
11428987|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
11428988|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
11428915|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.
~Endometrial Injury
~Done between 18-24 days prior to embryo transfer cycle.
~Using transfer catheter.
~Introduction of the same to the uterine fundus.
~Systematic scrapping of the four uterine walls, lengthwise.
~Performed by a skilled doctor.
~Subsequent ultrasound control"
11428916|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
11428917|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
11428918|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
11428919|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
11428920|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
11428921|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
11428922|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
11428923|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
11428924|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
11428925|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
11428926|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
11428927|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
11428928|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
11428929|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
11428930|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
11428931|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
11428932|NCT01842061|Experimental|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
11428933|NCT01842061|Active Comparator|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
11428934|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
11428935|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
11428936|NCT01842035|Experimental|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
~--------------------------------------------------------------------------------"
11428937|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
11428938|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
11428939|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
11428940|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
11428941|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
11428942|NCT01841996|Experimental|ME1111 solution|
11428943|NCT01841996|Placebo Comparator|Vehicle Solution|
11428944|NCT01841983|Experimental|Intervention|Be Well Work Well
11428945|NCT01841983|No Intervention|Control|No intervention
11428946|NCT01841970|Other|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
11428947|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
11428948|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
11428949|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
11428950|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
11494085|NCT01396330|Other|Stress|
11428951|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
11428952|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
11428953|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
11428954|NCT01841892|No Intervention|Usual Care Control|
11428955|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
11428956|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
11428957|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
11428958|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
11428959|NCT01841866|Placebo Comparator|awake|LMA removal
11428960|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
11428961|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
11428962|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
11428963|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
11428964|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
11428965|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
11428966|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
11428967|NCT01841814|Experimental|lymphoma|
11428968|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
11428969|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
11428970|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
11428971|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
11428972|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
11428973|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
11428974|NCT01841762|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
11428975|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
11428976|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11428977|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.
11428978|NCT01841723|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11428979|NCT01841710||Women|
11428980|NCT01841697|Experimental|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
11428981|NCT01841697|Active Comparator|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
11428982|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
11428983|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
11428984|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
11428985|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
11428986|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
11428989|NCT01841645|Other|CLA depletion-repletion|
11501695|NCT01342679|Experimental|dasatinib|
11428990|NCT01841632|Experimental|MultiStem|"Dose escalation
~Cohort 1
~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)
~Cohort 2
~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)
~Cohort 3
~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)
~Cohort 4
~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
11428991|NCT01841619|Active Comparator|IVIg as a monotherapy|IVIg will be used as a first line treatment. Topical treatment will be stopped at the beginning of IVIg therapy.
11428992|NCT01841606|Experimental|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
11428993|NCT01841606|Placebo Comparator|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
11428994|NCT01841593|Experimental|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
11428995|NCT01841593|Experimental|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
11428996|NCT01841567|Other|dressing|
11428997|NCT01841554|Experimental|Single|
11428998|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.
~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
11428999|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
11429000|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
11429001|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
11429002|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
11429003|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
11429004|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
11429005|NCT01841489|Experimental|Sequence 1|
11429006|NCT01841489|Experimental|Sequence 2|
11429007|NCT01841489|Experimental|Sequence 3|
11429008|NCT01841489|Experimental|Sequence 4|
11429009|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
11429010|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-
~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
11429011|NCT01841450|Experimental|iStent|Implantation of one iStent in conjunction with cataract surgery
11429012|NCT01841450|Active Comparator|Cataract surgery|Cataract surgery alone
11429013|NCT01841437||iStent|
11429014|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
11429015|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
11429016|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
11429017|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
11429018|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
11429019|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
11429020|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
11429021|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.
~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.
~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
11429022|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
11429023|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
11429024|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
11432028|NCT01820676||iUni G2+|iUni G2+ in all patients
11429025|NCT01841359|Other|Pramlintide (Symlin)|"Participants in this study will be asked to complete 4 study visits. Study visit 1 will be for screening. Eligible individuals who provide informed consent will be asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms. At study visit 2, a baseline mixed meal tolerance test will be performed. Glucose, hormonal responses, and satiety will be assessed. Glucose and symptom log will be reviewed. Pramlintide will be prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During treatment, the participants will keep a record of all hypoglycemic symptoms and blood glucose measurements at those times.
~Study visit 3 will occur at week 4 of treatment and focus on evaluation of symptoms and side effects. Participants will again complete a food and glucose diary for 3 days. During study visit 4 (week 8 of treatment), participants will undergo a repeat mixed meal tolerance test."
11429026|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
11429027|NCT01841333|Experimental|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11429028|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
11429029|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
11429030|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
11429031|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
11429032|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
11429033|NCT01841281|Active Comparator|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.
~All subjects will receive L-arginine and placebo in this cross-over design study."
11429034|NCT01841281|Active Comparator|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.
~All subjects will receive L-arginine and placebo in this cross-over design study."
11429035|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
11429036|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
11429037|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
11429038|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
11429039|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
11429040|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
11429041|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
11429042|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
11429043|NCT01841216|Experimental|Low Back Pain|Lower Body Exercises with and without resistance
11429044|NCT01841216|Experimental|Healthy|Lower Body Exercises with and without resistance
11429045|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
11429046|NCT01841190||PROCALCITONIN|
11429047|NCT01841190||DELTA SOFA|
11429048|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
11429049|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
11429050|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
11429051|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
11429052|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
11429053|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
11429054|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
11429055|NCT01841151|No Intervention|Waiting-list|Treatment as usual only
11429056|NCT01841125|Experimental|escitalopram|escitalopram 15mg
11429057|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
11429058|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
11429059|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
11429060|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
11429061|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
11429062|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
11429063|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
11509499|NCT01287845|Experimental|Arm 2|
11429064|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
11429065|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
11429066|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
11429067|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
11429068|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
11429069|NCT01841073|Experimental|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
11429070|NCT01841073|Placebo Comparator|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
11429071|NCT01841060|Experimental|Radiofrequency ablathermy|Radiofrequency ablathermy
11429072|NCT01841047|Other|Radiotherapy|Evaluation of the combination of radiotherapy with tomotherapy coil (54 Gy) followed by surgery in liposarcomas retroperitoneal.
11429073|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
11429074|NCT01841021|Experimental|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
11429075|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
11429076|NCT01841008|Placebo Comparator|Group Placebo|
11429077|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
11429078|NCT01840982|Experimental|Giant embryonic brown rice|
11429079|NCT01840982|Experimental|Giant embryonic rice|
11429080|NCT01840982|Active Comparator|White rice|
11429081|NCT01840982|Active Comparator|Glucose solution|
11429082|NCT01840969||CAOD group|Single arm study group
11429083|NCT01840956|Experimental|HAVG|Surgical placement of HAVG
11429084|NCT01840943|Experimental|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
11429085|NCT01840943|Active Comparator|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
11429086|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
11429087|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
11429088|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
11429089|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
11429090|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
11429091|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
11429092|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
11429093|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
11429094|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
11429095|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
11429096|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
11429097|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
11429098|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
11429099|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
11429100|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
11429101|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
11429102|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
11429103|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
11429104|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
11429105|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
11429106|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
11429107|NCT01840761|Placebo Comparator|Placebo|
11429108|NCT01840748||no vasodilator|patients receiving no vasodilator
11429109|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
11429110|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
11429111|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
11429112|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
11429113|NCT01840722|No Intervention|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
11429114|NCT01840722|Experimental|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
11429115|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
11429116|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
11429117|NCT01840696|Experimental|Regadenoson|
11429118|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
11429119|NCT01840644||all participants|Walking on treadmill, different velocities and incline
11429120|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
11429121|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
11429122|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5
~Will initiate Nasal Continuous positive airway pressure (CPAP)"
11429123|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
11429124|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
11429125|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5
~Will initiate Nasal Continuous positive airway pressure (CPAP)"
11429126|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
11429127|NCT01840605|Experimental|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
11429128|NCT01840605|Active Comparator|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
11429129|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
11429130|NCT01840579|Experimental|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days).
11429131|NCT01840579|Experimental|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days).
11429132|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429133|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin Area Under The Curve (AUC) 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429134|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429135|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429136|NCT01840579|Experimental|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
11429137|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429138|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429139|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.
11429221|NCT01840072|Experimental|Active antihypertensive treatment|Active antihypertensive treatment
11432146|NCT01819870|Active Comparator|Dilatrend IR tablet 25mg|
11429140|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
11429141|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
11429142|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
11429143|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
11429144|NCT01840527||Group 1|Advanced Melanoma
11429145|NCT01840527||Group 2|Stage II/III Melanoma
11429146|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
11429147|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
11429148|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
11429149|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
11429150|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
11429151|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
11429152|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
11429153|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
11429154|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
11429155|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
11429156|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
11429157|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
11429158|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
11429159|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
11429160|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
11429161|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
11429162|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
11429163|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
11429164|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
11429165|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
11429166|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.
~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
11429167|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
11429168|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.
~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
11429169|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
11429170|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
11429171|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
11429172|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
11429173|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
11429174|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
11429175|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
11429176|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
11429177|NCT01840410|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
11429222|NCT01840072|No Intervention|Usual care|Discontinue all home BP medications.
11429178|NCT01840410|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
11429179|NCT01840397||Spine surgery|Patients undergoing spine surgery
11429180|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
11429181|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
11429182|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
11429183|NCT01840371|Experimental|Propofol based group|
11429184|NCT01840371|Active Comparator|Fentanyl based group|
11429185|NCT01840358|Other|Patients starting pump therapy|
11429186|NCT01840345|Experimental|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
11429187|NCT01840332|Experimental|L-thyroxin|this is one arm study
11429188|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
11429189|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
11429190|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
11429191|NCT01840293||Primary Breast Cancer|
11429192|NCT01840293||Recurrent/Metastatic Breast Cancer|
11429193|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
11429194|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
11429195|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
11429196|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
11429197|NCT01840241|Experimental|BIVON group|
11429198|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
11429199|NCT01840228|Active Comparator|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
11429200|NCT01840228|Placebo Comparator|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
11429201|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
11429202|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
11429203|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
11429204|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
11429205|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
11429206|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
11429207|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
11429208|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
11429209|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
11429210|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
11429211|NCT01840163|Other|CanSORT Online Tool|Comprehensive decision tool
11429212|NCT01840163|Other|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
11429213|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
11429214|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
11429215|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
11429216|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
11429217|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
11429218|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
11429219|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
11429220|NCT01840085|Experimental|0.03% DSC127 topical gel|
11429223|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
11429224|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
11429225|NCT01840046|Experimental|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:
~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.
~The dosage is as follows:
~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
11429226|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
11429227|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
11429228|NCT01840020||Gastric bypass|patients recruited from Central Norway
11429229|NCT01840020||Gastric sleeve|patients recruited from Central Norway
11429230|NCT01840007|Experimental|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.
~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
11429231|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).
~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).
~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
11429232|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
11429233|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11429234|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
11429235|NCT01839955|Experimental|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
11429236|NCT01839955|Experimental|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
11429237|NCT01839942||no gap closure|no hernia gap closure
11429238|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure
~extracorporal suturing of gap"
11429239|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
11429240|NCT01839929|Experimental|Prograf/Advagraf|conversion from Prograf to Advagraf
11429241|NCT01839916|Experimental|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
11429242|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
11429243|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
11429244|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
11429245|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
11429246|NCT01839877|Experimental|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
11429247|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
11429248|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
11429249|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
11429250|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
11429251|NCT01839838|Experimental|APBI with protons|
11429252|NCT01839825|Experimental|QuietCare|QuieCare system installed
11429253|NCT01839825|No Intervention|control|no system installed
11429254|NCT01839812|Other|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
11429255|NCT01839799|Experimental|Arm 1|
11429256|NCT01839799|Experimental|Arm 2|
11429257|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
11429327|NCT01839331|Placebo Comparator|10 mL Placebo|10 ml Placebo
11429258|NCT01839773|Experimental|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
11429259|NCT01839773|Active Comparator|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
11429260|NCT01839760||Inpatient cohort|Patients admitted to general wards
11429261|NCT01839760||ICU cohort|Patients admitted to ICU
11429262|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
11429263|NCT01839734|Experimental|Arm A|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
11429264|NCT01839734|No Intervention|Arm B|No intervention
11429265|NCT01839721|Active Comparator|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
11429266|NCT01839721|Active Comparator|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
11429267|NCT01839721|Placebo Comparator|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
11429268|NCT01839708|Experimental|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
11429269|NCT01839708|No Intervention|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
11429270|NCT01839695|Experimental|Valiant Mona LSA Stent Graft System|TEVAR procedure using Medtronic Stent Graft
11429271|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
11429272|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
11429273|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
11429274|NCT01839656|Experimental|Nusinersen 6 mg|
11429275|NCT01839656|Experimental|Nusinersen 12 mg|
11429276|NCT01839643|Experimental|2.4 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
11429277|NCT01839643|Experimental|3.0 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
11429278|NCT01839630||Group 1|
11429279|NCT01839617|Active Comparator|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
11429280|NCT01839617|Active Comparator|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
11429281|NCT01839604|Experimental|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
11429282|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
11429283|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
11429284|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
11429285|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
11429286|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
11429287|NCT01839539|No Intervention|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
11429288|NCT01839539|Experimental|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
11429289|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
11429290|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
11429291|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
11429292|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
11429293|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
11429294|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
11429295|NCT01839487|Experimental|Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m^2) NAB and 1000 mg/m^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.
11429296|NCT01839487|Active Comparator|Run-in Phase - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
11429328|NCT01839318|Experimental|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
11429297|NCT01839487|Experimental|Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.
11429298|NCT01839487|Active Comparator|Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
11429299|NCT01839487|Experimental|Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).
11429300|NCT01839487|Active Comparator|Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.
11429301|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
11429302|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
11429303|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.
~Intervention: Post-partum oral glucose tolerance test"
11429304|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.
~Intervention: Post-partum oral glucose tolerance test"
11429305|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
11429306|NCT01839422|Experimental|Controls|Memory assessment. Brain imaging examination MRI.
11429307|NCT01839422|Experimental|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
11429308|NCT01839422|Experimental|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
11429309|NCT01839409|No Intervention|control|Control without vestibular stimulation
11429310|NCT01839409|No Intervention|Bilateral areflexia|Patient with vestibular bilateral areflexia
11429311|NCT01839409|No Intervention|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
11429312|NCT01839409|Experimental|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
11429313|NCT01839396|Active Comparator|Medium continuous dose of stimulation|Subjects in this arm will receive stimulation settings at a medium continuous dose of Deep Brain stimulation that may have been effective in previous DBS patients.
11429314|NCT01839396|Sham Comparator|Low intermittent dose of stimulation|Subjects in this arm will receive stimulation settings at a lower intermittent dose of Deep Brain stimulation which is less likely to be effective.
11429315|NCT01839383|Active Comparator|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
11429316|NCT01839383|Active Comparator|DCa1.5|using dialysate calcium concentration 1.5mmol/L
11429317|NCT01839383|Active Comparator|DCa1.75|using dialysate calcium concentration 1.75mmol/L
11429318|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
11429319|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
11429320|NCT01839357|Experimental|Rivaroxaban|
11429321|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
11429322|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
11429323|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
11429324|NCT01839331|Experimental|Low Dose Ampion|4 mL Ampion
11429325|NCT01839331|Placebo Comparator|Placebo|4 mL placebo
11429326|NCT01839331|Experimental|High Dose Ampion|10 mL Ampion
11509585|NCT01287260|Experimental|Arm1|
11429329|NCT01839318|Active Comparator|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
11429330|NCT01839318|Active Comparator|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
11429331|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
11429332|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
11429333|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
11429334|NCT01839279|Experimental|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
11429335|NCT01839279|Placebo Comparator|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
11429336|NCT01839279|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
11429337|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
11429338|NCT01839253|Experimental|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
11429339|NCT01839253|Active Comparator|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
11429340|NCT01839253|Placebo Comparator|control|none of antihypertensive agents
11429341|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.
~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.
~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
11429342|NCT01839227|Experimental|regional cerebral oxygen saturation|
11429343|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
11429344|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
11429345|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
11429346|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
11429347|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
11429348|NCT01839188|Experimental|PR5I (V1); Pediacel® (V2); PR5I (V3)|[Vaccination 1]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. [Vaccination 2]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. [Vaccination 3]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.
11429349|NCT01839175|Experimental|Group 1|
11429350|NCT01839175|Active Comparator|Group 2|
11429351|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
11429352|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
11429353|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
11429354|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
11429355|NCT01839149|Experimental|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
11429356|NCT01839149|Placebo Comparator|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
11429357|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
11429358|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
11429359|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
11429360|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
11429361|NCT01839110|Active Comparator|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
11429362|NCT01839110|Placebo Comparator|Placebo|Placebo by mouth twice per day
11429363|NCT01839110|No Intervention|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF >=45%) will undergo same procedures in the observational arm but will not receive an intervention.
11509586|NCT01287260|Active Comparator|Arm 2|
11429364|NCT01839097|Experimental|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.
~Enrollment will begin with the enrollment of patients into Cohort 3.
~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
11429365|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
11429366|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
11429367|NCT01839071|Other|biopsy of fat tissue|
11429368|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
11429369|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
11429370|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
11429371|NCT01839032|Experimental|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
11429372|NCT01839019|Placebo Comparator|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
11429373|NCT01839019|Experimental|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
11429374|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
11429375|NCT01838993|Active Comparator|Lidocaine|Inhalation of lidocaine before intubation
11429376|NCT01838993|Placebo Comparator|Control|Normal saline inhalation before intubation
11429377|NCT01838980|Experimental|Colonoscopy|
11429378|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
11429379|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
11429380|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
11429381|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
11429382|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
11429383|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
11429384|NCT01838954|Active Comparator|Short-wave diathermy|Short-wave diathermy device turned on
11429385|NCT01838954|Placebo Comparator|control|Short-wave diathermy device turned off
11429386|NCT01838941|Experimental|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
11429387|NCT01838928|Experimental|Bupivacaine|
11429388|NCT01838915|Experimental|Dietary Supplement: Prebiotics+Glutamine|
11429389|NCT01838915|Placebo Comparator|Placebo|
11429390|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
11429391|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
11429392|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
11429393|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
11429394|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
11429395|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
11429396|NCT01838876|Experimental|Cariprazine + ADT|Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
11429397|NCT01838863|Experimental|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
11429398|NCT01838863|Active Comparator|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
11429469|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
11429399|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
11429400|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
11429401|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
11429402|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
11429403|NCT01838798||Study population|"See in inclusion/exclusion criteria.
~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
11429404|NCT01838785|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
11429405|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.
~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
11429406|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
11429407|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
11429408|NCT01838746||PCI|Patients undergoing PCI
11429409|NCT01838746||CABG|Patients undergoing CABG
11429410|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
11429411|NCT01838720|Experimental|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
11429412|NCT01838720|Active Comparator|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
11429413|NCT01838707|Active Comparator|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
11429414|NCT01838707|Active Comparator|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
11429415|NCT01838707|Active Comparator|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
11429416|NCT01838694|Placebo Comparator|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
11429417|NCT01838694|Experimental|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
11429418|NCT01838681|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
11429419|NCT01838681|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
11429420|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
11429421|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
11429422|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
11429423|NCT01838655|Experimental|Nitisinone|Oral administration of nitisinone
11429424|NCT01838642|Active Comparator|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
11429425|NCT01838642|Active Comparator|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
11429426|NCT01838629||thyroid nodule|
11429427|NCT01838616|Experimental|Tapentadol Prolonged Release (PR)|
11429428|NCT01838616|Active Comparator|Oxycodone/Naloxone Prolonged Release|
11429429|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
11429430|NCT01838590|Experimental|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
11429431|NCT01838590|Experimental|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
11429432|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.
~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.
~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
11429504|NCT01838057||Control cohort|
11429802|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
11429433|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.
~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.
~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
11429434|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
11429435|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
11429436|NCT01838551|Experimental|COR-003|Male or female, ≥18 year of age, or of a minimal age as required by the local regulations with confirmed diagnosis of CS as defined according to the criteria in the guidelines for diagnosis of CS (Nieman 2008).
11429437|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
11429438|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
11429439|NCT01838525||SIRS, SEPSIS|
11429440|NCT01838525||sepsis, severe sepsis, septic shock|
11429441|NCT01838525||health, SIRS, Sepsis|
11429442|NCT01838512||IMiDs|"Diagnosed relapsed/refractory multiple myeloma patients who receive IMiD treatment
~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
11429443|NCT01838512||Proteasome inhibitors|"Diagnosed relapsed/refractory multiple myeloma patients who receive Proteasome inhibitor treatment
~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
11429444|NCT01838512||Combination novel therapies|"Diagnosed relapsed/refractory multiple myeloma patients who received combinations novel therapies (an IMiD plus a proteasome inhibitor) treatment
~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
11429445|NCT01838499|Experimental|MEDI8968|
11429446|NCT01838499|Placebo Comparator|Saline|
11429447|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
11429448|NCT01838473|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
11429449|NCT01838473|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
11429450|NCT01838473|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
11429451|NCT01838473|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
11429452|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
11429453|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
11429454|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
11429455|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
11429456|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
11429457|NCT01838447|No Intervention|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
11429458|NCT01838447|Experimental|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
11429459|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
11429460|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
11429461|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
11429462|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
11429463|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
11429464|NCT01838395|Experimental|BL-8040 + Ara-C|"Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (monotherapy period) over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (combined period) over 5 days. During the combined period, BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated."
11429465|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
11429466|NCT01838369|Experimental|BI-505|
11429467|NCT01838356||No treatment.|
11429468|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
11429803|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
11429470|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
11429471|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
11429472|NCT01838317|Experimental|Pioglitazone|
11429473|NCT01838304|Active Comparator|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
11429474|NCT01838304|Experimental|Probability ramp control|Propofol titrated to deep sedation using PRC software.
11429475|NCT01838291||Patients on Ferriprox therapy <1 month|
11429476|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
11429477|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
11429478|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
11429479|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
11429480|NCT01838252|Sham Comparator|Saline|
11429481|NCT01838239|Experimental|Fish oil|
11429482|NCT01838226|Experimental|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
11429483|NCT01838226|No Intervention|Treatment as usual control|Usual VA care
11429484|NCT01838200|Experimental|Cohort 1, Group 1 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
11429485|NCT01838200|Experimental|Cohort 1, Group 2 (BCG 0.8-3.2 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
11429486|NCT01838200|Experimental|Cohort 1, Group 3 (BCG 4.0-16.0 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
11429487|NCT01838200|Experimental|Cohort 2 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration ≥10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
11429488|NCT01838174|Experimental|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
11429489|NCT01838174|Active Comparator|IV methylprednisolone (steroids)|3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
11429490|NCT01838161|Active Comparator|Part I|Interview questions will focus on reticence to vaccinate children.
11429491|NCT01838161|Experimental|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.
~a pretest survey
~the video vignette
~and a post-test survey measuring intention to receive appropriate adolescent vaccines"
11429492|NCT01838161|Experimental|Part III|"enhanced video educational intervention (video vignettes + standard of care vaccine event)
~standard of care vaccination event"
11429493|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
11429494|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
11429495|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
11429496|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
11429497|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
11429498|NCT01838109|No Intervention|Control group|no intervention total 87 patients
11429499|NCT01838096|Experimental|THA|
11429500|NCT01838083|Experimental|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
11429501|NCT01838083|Experimental|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
11429502|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
11429503|NCT01838057||painPREMIER cohort|
11429505|NCT01838044|Experimental|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
11429506|NCT01838044|Other|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
11429507|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
11429508|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
11429509|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
11429510|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
11429511|NCT01838005|No Intervention|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
11429512|NCT01838005|Experimental|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
11429513|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
11429514|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
11429515|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
11429516|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
11429517|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
11429518|NCT01837966|Active Comparator|Lavender oil|Lavender oil aromatherapy
11429519|NCT01837966|Placebo Comparator|Placebo|Placebo -- unscented oil aromatherapy
11429520|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
11429521|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
11429522|NCT01837940|Placebo Comparator|Placebo|
11429523|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
11429524|NCT01837927|Experimental|NVA237|NVA237 inhaled via the Breezhaler® device once daily
11429525|NCT01837927|Active Comparator|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
11429526|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
11429527|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
11429528|NCT01837901|Sham Comparator|Sham|No stimulation transcorneal electrostimulation
11429529|NCT01837901|Experimental|150%|transcorneal electrostimulation with 150% of phosphene threshold
11429530|NCT01837901|Experimental|200%|transcorneal electrostimulation with 200% of phosphene threshold
11429531|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
11429532|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
11429533|NCT01837875|No Intervention|Control|Mailed informational literature
11429534|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
11429535|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
11429536|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
11429537|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.
11429538|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
11429539|NCT01837823|Experimental|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
11429540|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
11429541|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
11429542|NCT01837797|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
11429543|NCT01837797|Experimental|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
11429804|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
11429544|NCT01837797|Experimental|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
11429545|NCT01837784||Elderly patients|
11429546|NCT01837784||Patients with diabetes mellitus|
11429547|NCT01837784||Patients with heart failure|
11429548|NCT01837784||Patients with resistant hypertension|
11429549|NCT01837771|Active Comparator|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
11429550|NCT01837771|No Intervention|No intervention|
11429551|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
11429552|NCT01837745|Active Comparator|Ablation group|"Administration of 1.1 GBq of I131 is given after the second intramuscular injections of rhTSH (0.9 mg). A whole body scan (WBS) is performed 2 to 5 days after the administration or I131 with determination of the neck uptake.
~Follow-up consists in:
~10 (+/- 2 months) after randomization: neck ultrasound + a serum Tg measurement after rhTSH stimulation
~2 years (+/- 2 months) after randomization: serum Tg measurement under LT4 treatment (Tg/LT4)
~3 years (+/- 2 months) after randomization: neck ultrasound and a serum Tg/LT4
~4 years (+/- 2 months) after randomization: a serum Tg/LT4
~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
11429553|NCT01837745|Experimental|Follow up group|Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
11429554|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
11429555|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
11429556|NCT01837719|Experimental|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
11429557|NCT01837719|Experimental|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
11429558|NCT01837719|Experimental|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
11429559|NCT01837719|Experimental|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
11429560|NCT01837719|Experimental|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
11429561|NCT01837706||Emergency Room Patients|
11429562|NCT01837693|No Intervention|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
11429563|NCT01837693|Experimental|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
11429564|NCT01837680|Active Comparator|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
11429565|NCT01837680|Active Comparator|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
11429566|NCT01837667|Experimental|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
11429567|NCT01837654|Experimental|Plantarflexion - 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
11429568|NCT01837654|Experimental|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
11429569|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
11429570|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
11429571|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
11429572|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
11429573|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
11429574|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
11429575|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
11429576|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
11429577|NCT01837628|Active Comparator|Lidocaine gel|Intraurethral Lidocaine gel 2%
11429578|NCT01837628|Experimental|Paraffin Oil|Intraurethral injection
11429579|NCT01837615|Experimental|Photopill treatment|
11429580|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
11429581|NCT01837589|Other|QCT and DXA|All the patients will have both QCT and DXA
11429582|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
11429583|NCT01837550|Active Comparator|Control group|no professional support
11429584|NCT01837550|Experimental|Intervention group|Professional support via Internet
11429585|NCT01837537||no treatment|no treatment, prospective observational
11429586|NCT01837524|Experimental|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
11429587|NCT01837524|Active Comparator|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
11429588|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
11429589|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
11429590|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
11429591|NCT01837485|Experimental|Lactol|
11429592|NCT01837485|Placebo Comparator|Placebo|
11429593|NCT01837472|Experimental|Probiotic|
11429594|NCT01837472|Placebo Comparator|Placebo|
11429595|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) <1
11429596|NCT01837459||Obese-SDB|Obese and with AHI>1
11429597|NCT01837459||Lean-Normal|Non-obese with AHI<1
11429598|NCT01837459||Lean-SDB|Non-obese with AHI>1
11429599|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
11429600|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
11429601|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
11429602|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
11429603|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
11429604|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
11429605|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
11429606|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
11429607|NCT01837394|Active Comparator|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
11429608|NCT01837394|Placebo Comparator|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
11429609|NCT01837381|Other|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
11429610|NCT01837355|Placebo Comparator|Placebo|placebo once daily for 12 weeks
11429611|NCT01837355|Experimental|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
11429612|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
11429613|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
11429614|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.
~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
11429615|NCT01837316|Experimental|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
11429616|NCT01837316|Placebo Comparator|Placebo|A single dose inhalation of matching placebo in the morning
11429617|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
11429618|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
11512214|NCT01268618|Experimental|Probiotic|
11429619|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
11429620|NCT01837277|Experimental|Raltegravir|Intervention: Patients will receive ART regimen based on investigational drug Raltegravir 400 mg BID + TDF 300 mg QD+ 3TC 150 mg BID
11429621|NCT01837277|Active Comparator|Efavirenz|Intervention: Patients will receive ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year
11429622|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
11429623|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
11429624|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
11429625|NCT01837238|Experimental|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
11429626|NCT01837238|Placebo Comparator|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
11429627|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
11429628|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
11429629|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
11429630|NCT01837225||Intermediate Dose Contrast Agent|Patients in the intermediate dose arm will receive 20 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
11429631|NCT01837199|Experimental|Smoking|Metronidazole plus Amoxicillin
11429632|NCT01837199|Experimental|Non-Smoking|Metronidazole plus Amoxicillin
11429633|NCT01837186||EFP|Empyema following pneumonectomy
11429634|NCT01837186||nEFP|No empyema following pneumonectomy
11429635|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
11429636|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
11429637|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.
~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
11429638|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
11429639|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
11429640|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
11429641|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.
~They will undergo a repeat CT-PET scan 3 months after the operation.
~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
11429642|NCT01837147|Experimental|Web-based Tracking Group|Technology-Based Physical Activity Promotion
11429643|NCT01837147|Active Comparator|Pedometer Group|Participants assigned to this group will receive a pedometer.
11429644|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
11429645|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
11429646|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
11429647|NCT01837121|Other|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
11429648|NCT01837121|No Intervention|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
11429649|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
11429650|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
11429999|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
11429651|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
11429652|NCT01837082|Active Comparator|Iron|ferric carboxymaltose
11429653|NCT01837082|Placebo Comparator|Placebo|Sodium chloride 0.9%
11429654|NCT01837069|Active Comparator|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
11429655|NCT01837069|No Intervention|Control|Standard of care
11429656|NCT01837043|Experimental|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
11429657|NCT01837043|Active Comparator|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
11429658|NCT01837030|Other|Oral Iron|
11429659|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
11429660|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
11429661|NCT01837017|No Intervention|Control|Wait-list control.
11429662|NCT01837004|Experimental|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
11429663|NCT01836991|Other|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
11429664|NCT01836991|Experimental|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
11429665|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
11429666|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
11429667|NCT01836965|Experimental|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
11429668|NCT01836952||Infants|Infant born via vaginal delivery
11429669|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
11429670|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
11429671|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
11429672|NCT01836926|Active Comparator|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers
~intervention:
~Trocar Placement and Exposure
~Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels
~Taking Down the Splenic Flexure
~rectal dissection till the levator ani muscle and resection of thye lateral ligaments
~then the peranal phase as in the laparotomy approach."
11429673|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
11429674|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
11429675|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
11429676|NCT01836887|Placebo Comparator|Intervention 1|Very low polyphenol fruit based drink (control)
11429677|NCT01836887|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - low
11429678|NCT01836887|Active Comparator|Invervention 3|Polyphenol-enriched fruit-based drink - high
11429679|NCT01836874||Topiramate|
11429680|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
11429681|NCT01836848|Experimental|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
11429872|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
11429682|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
11429683|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
11429684|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
11429685|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
11429686|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
11429687|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
11429688|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
11429689|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
11429690|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
11429691|NCT01836796|Placebo Comparator|Placebo|
11429692|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
11429693|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
11429694|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
11429695|NCT01836757|Experimental|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
11429696|NCT01836757|Placebo Comparator|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
11429697|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
11429698|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
11429699|NCT01836731|Experimental|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
11429700|NCT01836731|Experimental|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
11429701|NCT01836731|No Intervention|Control|"The control group is not enrolled in the CBEHPP.
~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
11429702|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
11429703|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
11429704|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
11429705|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
11429706|NCT01836692|Experimental|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
11429707|NCT01836679|Experimental|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
11429708|NCT01836679|Placebo Comparator|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
11429709|NCT01836653|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
11429710|NCT01836653|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
11429711|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
11429712|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
11429713|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
11429714|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
11512548|NCT01266343||Experimental Group|
11429715|NCT01836601|No Intervention|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
11429716|NCT01836601|Experimental|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
11429717|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.
~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
11429718|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.
~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
11429719|NCT01836575|Experimental|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle] + Antiemetic therapy at investigator's discretion.
11429720|NCT01836575|Active Comparator|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
11429721|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
11429722|NCT01836549|Experimental|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.
~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
11429723|NCT01836536|Other|BEVACIZUMAB|BEVACIZUMAB standard of care
11429724|NCT01836523|Experimental|Liraglutide 0.6 mg + insulin|
11429725|NCT01836523|Experimental|Liraglutide 1.2 mg + insulin|
11429726|NCT01836523|Experimental|Liraglutide 1.8 mg + insulin|
11429727|NCT01836523|Placebo Comparator|Liraglutide placebo 0.6 mg + insulin|
11429728|NCT01836523|Placebo Comparator|Liraglutide placebo 1.2 mg + insulin|
11429729|NCT01836523|Placebo Comparator|Liraglutide placebo 1.8 mg + insulin|
11429730|NCT01836484||Surgically staged endometrial and cervical carcinoma|
11429731|NCT01836471|Experimental|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
11429732|NCT01836471|Placebo Comparator|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
11429733|NCT01836471|Experimental|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
11429734|NCT01836471|Active Comparator|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
11429735|NCT01836471|Placebo Comparator|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
11429736|NCT01836458|Experimental|Dose 1: 30 mg|Single dose of KAE609 30 mg
11429737|NCT01836458|Experimental|Dose 2: 20 mg|Single dose of KAE609 20 mg
11429738|NCT01836458|Experimental|Dose 3: 10 mg|Single dose of KAE609 10 mg
11429739|NCT01836458|Experimental|Dose 4: 15 mg|Single dose of KAE609 15 mg
11429740|NCT01836445|Experimental|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
11429741|NCT01836445|Active Comparator|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
11429742|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy
~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.
~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.
~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.
~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.
~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
11429873|NCT01835509|Experimental|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
11429874|NCT01835509|No Intervention|Control, Newsletters|
11429743|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57
~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest
~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy
~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine
~Ineligible for surgical resection & stable disease = continue FOLFIRINOX
~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
11429744|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy
~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.
~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.
~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.
~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.
~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
11429745|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone
~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71
~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days
~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy
~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine
~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest
~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
11429746|NCT01836419|Experimental|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
11429747|NCT01836419|Active Comparator|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
11429748|NCT01836406|Experimental|Keromin Group|
11429749|NCT01836406|Placebo Comparator|Placebo Group|
11429750|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
11429751|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
11429752|NCT01836380|Experimental|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
11429753|NCT01836367|Experimental|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
11429754|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
11429755|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
11429756|NCT01836341|Experimental|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*
~*afatinib dose levels: 20mg daily, 30mg daily & 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
11429757|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.
~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.
~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.
~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
11429798|NCT01836068|Experimental|Enfuvirtide monotherapy|Enfuvirtide 90 mg subcutaneously every 12 hours will be also be administered during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions with conditioning regimens in patients who require ritonavir-boosted PI containing ART regimens.
11429799|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
11429758|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.
~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.
~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.
~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
11429759|NCT01836315||Obese|Defined by a BMI >35 kg/M2
11429760|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
11429761|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
11429762|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
11429763|NCT01836289|Experimental|High-dose Cyclophosphamide|High-dose Cyclophosphamide
11429764|NCT01836276|Experimental|African American (AA) Smokers|AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
11429765|NCT01836276|Active Comparator|White Smokers|White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
11429766|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
11429767|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
11429768|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
11429769|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
11429770|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
11429771|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
11429772|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
11429773|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
11429774|NCT01836211|Experimental|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
11429775|NCT01836211|Active Comparator|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
11429776|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 1)|Part A, Period 1. Participants will receive a single 20-milligram (mg) oral dose of LY2409021 on Day 1.
11429777|NCT01836198|Experimental|LY2409021+Gemfibrozil (Part A, Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 mg gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20-mg oral dose of LY2409021 on Day 4.
11429778|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 2)|Part A, Period 1. Participants will receive a single 20-mg oral dose of LY2409021 on Day 1.
11429779|NCT01836198|Experimental|LY2409021+Ketoconazole (Part A, Cohort 2)|Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
11429780|NCT01836198|Experimental|LY2409021+Clarithromycin (Part B)|Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
11429781|NCT01836185|Experimental|Evacetrapib (Healthy)|Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function
11429782|NCT01836185|Experimental|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
11429783|NCT01836185|Experimental|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
11429784|NCT01836185|Experimental|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
11429785|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
11429786|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
11429787|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
11429788|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
11429789|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
11429790|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
11429791|NCT01836146|Experimental|Renal Artery Ablation|
11429792|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
11429793|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
11429794|NCT01836120|Active Comparator|Docetaxel|
11429795|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
11429796|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
11429797|NCT01836081|Experimental|fluid responsiveness|
11429805|NCT01836029|Experimental|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.
~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.
~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.
~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
11429806|NCT01836029|Active Comparator|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.
~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.
~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.
~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
11429807|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
11429808|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
11429809|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
11429810|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
11429811|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
11429812|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
11429813|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
11429814|NCT01835977|Active Comparator|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
11429815|NCT01835977|Active Comparator|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
11429816|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
11429817|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
11429818|NCT01835951|Other|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
11429819|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:
~Dose level (DL) 1 = 50 mg / day,
~Dose level (DL) 2 = 100 mg / day, and
~Dose level (DL) 3 = 150 mg / day .
~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
11429820|NCT01835938|Placebo Comparator|placebo|
11429821|NCT01835925||Tissue specmien|
11429822|NCT01835912|Placebo Comparator|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
11429823|NCT01835912|Experimental|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
11429824|NCT01835912|Placebo Comparator|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
11429825|NCT01835912|Experimental|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
11429826|NCT01835899|Experimental|Placebo to BI 1015550|placebo
11429827|NCT01835899|Experimental|BI 1015550 low dose 1|powder for oral solution
11429828|NCT01835899|Experimental|BI 1015550 low dose 2|powder for oral solution
11429829|NCT01835899|Experimental|BI 1015550 medium dose 1|powder for oral solution
11429830|NCT01835899|Experimental|BI 1015550 medium dose 2|powder for oral solution
11429831|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
11429832|NCT01835873|Active Comparator|Lactated Ringer's|Crystalloid solution - 1000 ml preload
11429833|NCT01835873|Active Comparator|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
11429834|NCT01835860|Other|Embolization|Prostate artery embolization
11429835|NCT01835847|Experimental|A single-arm study|
11429875|NCT01835496|No Intervention|Ferriprox|single 1500 mg dose of Ferriprox
11430063|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
11429836|NCT01835834|Experimental|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm** thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width [mm] / area [mm2])** of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm* wall thickness. The core is veneered with dental porcelain at the dental laboratory.
~Intended use and indications:
~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.
~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
11429837|NCT01835821|Experimental|prosthesis|"NobelProcera™ Crown shaded zirconia:
~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
11429838|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
11429839|NCT01835795|Active Comparator|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
11429840|NCT01835795|Placebo Comparator|Placebo|Swiss DolorClast® CLASSIC placebo applicator
11429841|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
11429842|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
11429843|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
11429844|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
11429845|NCT01835756|Active Comparator|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
11429846|NCT01835756|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
11429847|NCT01835743|Active Comparator|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
11429848|NCT01835743|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
11429849|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
11429850|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
11429851|NCT01835717||Cognitively normal individuals|
11429852|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
11429853|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
11429854|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
11429855|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
11429856|NCT01835678|Active Comparator|Linagliptin|Linagliptin
11429857|NCT01835678|Placebo Comparator|Placebo|Placebo
11429858|NCT01835665|Experimental|Nimodipine|
11429859|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
11429860|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
11429861|NCT01835639|Experimental|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
11429862|NCT01835626|Experimental|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
11429863|NCT01835613|Other|Tocilizumab|"Biomarkers Measures
~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
11429864|NCT01835600|Active Comparator|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
11429865|NCT01835600|Placebo Comparator|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
11429866|NCT01835587|Experimental|CC-486|Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
11429867|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
11429868|NCT01835561|Experimental|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
11429869|NCT01835561|Experimental|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
11429870|NCT01835548|Experimental|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
11429871|NCT01835548|Placebo Comparator|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
11430064|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
11429876|NCT01835470|Experimental|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
11429877|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
11429878|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
11429879|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
11429880|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
11429881|NCT01835431|Experimental|Insulin degludec/insulin aspart|
11429882|NCT01835431|Active Comparator|Insulin detemir|
11429883|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
11429884|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
11429885|NCT01835405|Active Comparator|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
11429886|NCT01835405|Active Comparator|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
11429887|NCT01835405|Active Comparator|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
11429888|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
11429889|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
11429890|NCT01835379|Experimental|Oasis|Oasis
11429891|NCT01835379|Other|Standard|Standard Care
11429892|NCT01835353|Experimental|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
11429893|NCT01835353|Active Comparator|Prasugrel 60mg loading dose|
11429894|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
11429895|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
11429896|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
11429897|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
11429898|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
11429899|NCT01835288|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11429900|NCT01835275|Experimental|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
11429901|NCT01835275|Active Comparator|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
11429902|NCT01835275|No Intervention|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
11429903|NCT01835262|Active Comparator|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
11429904|NCT01835262|Experimental|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
11429905|NCT01835249|Experimental|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP <120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP <120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
11429906|NCT01835249|Active Comparator|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP <130 mmHg @ 1 visit; <135 mmHg @ 2 consecutive visits.
11429907|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
11429908|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
11429909|NCT01835223|Experimental|Treatment (tivozanib - 1 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11429910|NCT01835223|Experimental|Treatment (tivozanib - 1.5 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11429911|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
11429912|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
11429913|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
11429914|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
11429915|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
11429916|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
11429917|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
11429918|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
11429919|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
11429920|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
11429921|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
11429954|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
11429922|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11429923|NCT01835158|Active Comparator|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11429924|NCT01835158|Active Comparator|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11429925|NCT01835145|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11429926|NCT01835145|Experimental|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11429927|NCT01835132|Experimental|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
11429928|NCT01835119|Experimental|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.
~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
11429929|NCT01835119|No Intervention|control group|no gum
11429930|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
11429931|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
11429932|NCT01835093|Experimental|A single-arm study|
11429933|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
11429934|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
11429935|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
11429936|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
11429937|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.
~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
11429938|NCT01835041|Experimental|Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
11429939|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:
~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
11429940|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:
~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
11429941|NCT01835015|Experimental|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
11429942|NCT01835015|Experimental|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
11429943|NCT01835015|Experimental|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
11429944|NCT01835015|Experimental|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
11429945|NCT01835015|Experimental|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
11429946|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
11429947|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
11429948|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
11429949|NCT01834963|Experimental|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks
~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
11429950|NCT01834963|Experimental|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks
~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
11429951|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
11429952|NCT01834924|Active Comparator|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
11429953|NCT01834924|No Intervention|Control|Standard provider medication counseling
11430337|NCT01832038|Experimental|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
11429955|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
11429956|NCT01834885|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
11429957|NCT01834885|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
11429958|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
11429959|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
11429960|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
11429961|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
11429962|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
11429963|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
11429964|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
11429965|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
11429966|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
11429967|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
11429968|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
11429969|NCT01834807||Cohort|
11429970|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT
~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
11429971|NCT01834781|Active Comparator|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
11429972|NCT01834781|Placebo Comparator|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
11429973|NCT01834768|Experimental|A|Eplerenone
11429974|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
11429975|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
11429976|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
11429977|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
11429978|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
11429979|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
11429980|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
11429981|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
11429982|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
11429983|NCT01834729|Experimental|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.
~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
11429984|NCT01834729|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
11429985|NCT01834716|Experimental|Aerobics exercise|Participants in this group will be randomized to aerobics exercise (the equivalent of walking briskly for 50 minutes three times per week).
11429986|NCT01834716|Experimental|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics (attending classes of toning and stretching a minimum of three times per week) exercise group.
11429987|NCT01834703|Active Comparator|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
11429988|NCT01834703|Active Comparator|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
11429989|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
11429990|NCT01834677||Healthy Human|
11429991|NCT01834677||Depressed Human|
11429992|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
11429993|NCT01834677||Human Diagnosed with Parkinson's Disease|
11429994|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
11429995|NCT01834651|Experimental|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
11429996|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
11429997|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
11429998|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
11432147|NCT01819857|Active Comparator|Droperidol 0.625 mg intravenously|
11430000|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
11430001|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
11430002|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
11430003|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:
~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
11430004|NCT01834586|Other|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.
~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
11430005|NCT01834573|Active Comparator|Intervention|Patients of the intervention arm receive a 10 week exercise program
11430006|NCT01834573|No Intervention|Control|Patients of the control arm do not participate in exercise
11430007|NCT01834547|Experimental|Methylphenidate|Methylphenidate
11430008|NCT01834547|Experimental|modafinil|modafinil
11430009|NCT01834547|Experimental|caffeine|caffeine
11430010|NCT01834547|Placebo Comparator|placebo|placebo
11430011|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
11430012|NCT01834534|No Intervention|Usual care|Usual medical care.
11430013|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
11430014|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
11430015|NCT01834508|Other|Treatment group|
11430016|NCT01834495|Experimental|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
11430017|NCT01834495|Active Comparator|Self expandable stent|same to Balloon expandable stent
11430018|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
11430019|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
11430020|NCT01834469|Other|ICG NIR imaging|see Summary and description iv injection of ICG
11430021|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.
~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
11430022|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.
~The control group will continue to receive usual care as they did before they enrolled in this study"
11430023|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
11430024|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
11430025|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
11430026|NCT01834430|Experimental|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
11430027|NCT01834430|No Intervention|parenteral nutrient group|
11430338|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
11430028|NCT01834404|Experimental|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
11430029|NCT01834404|Placebo Comparator|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
11430030|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
11430031|NCT01834378|No Intervention|No intervention|
11430032|NCT01834378|Experimental|Low intensity intervention|
11430033|NCT01834378|Experimental|High intensity intervention|
11430034|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
11430035|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
11430036|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
11430037|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
11430038|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
11430039|NCT01834339|Active Comparator|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
11430040|NCT01834339|Experimental|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
11430041|NCT01834326|Active Comparator|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
11430042|NCT01834326|Experimental|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
11430043|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
11430044|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
11430045|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
11430046|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
11430047|NCT01834274|Experimental|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
11430048|NCT01834274|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
11430049|NCT01834261|Active Comparator|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
11430050|NCT01834261|Placebo Comparator|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
11430051|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11430052|NCT01834235|Active Comparator|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
11430053|NCT01834235|Experimental|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
11430054|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
11430055|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
11430056|NCT01834183|Experimental|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
11430057|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
11430058|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
11430059|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
11430060|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
11430061|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
11430062|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
11430065|NCT01834144|Active Comparator|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
11430066|NCT01834144|Active Comparator|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
11430067|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
11430068|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.
~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.
~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
11430069|NCT01834105|Experimental|Liuwei Dihuang Pills|
11430070|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
11430071|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
11430072|NCT01834079|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
11430073|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
11430074|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
11430075|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
11430076|NCT01834027|Experimental|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
11430077|NCT01834027|Active Comparator|No music|The patients in this group with have headphones but no music will be played.
11430078|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
11430079|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
11430080|NCT01834001||1/Untreated prostate cancer|Patients with untreated prostate cancer
11430081|NCT01834001||2/Radiotherapy treated prostate cancer|Patients with prostate cancer who have already received definitive radiotherapy and haveexperienced biochemical failure
11430082|NCT01833988|Experimental|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
11430083|NCT01833988|Active Comparator|Usual Care|Usual Care
11430084|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
11430085|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
11430086|NCT01833949|Active Comparator|ULOD arm (N=49)|"Unilateral laparoscopic drilling
~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:
~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
11430087|NCT01833949|Active Comparator|BLOD arm (N=47)|"Bilateral laparoscopic drilling
~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).
~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
11430088|NCT01833936|Active Comparator|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
11430089|NCT01833936|Sham Comparator|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
11430090|NCT01833923|Experimental|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
11430091|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
11430092|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
11430093|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
11430094|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
11430095|NCT01833897|Experimental|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
11430096|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
11430097|NCT01833871|Experimental|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
11430098|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
11512549|NCT01266343||Control Group|
11430099|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
11430100|NCT01833845|Experimental|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
11430101|NCT01833832|Experimental|Cytoreductive surgery followed by HIPEC|Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
11430102|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
11430103|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
11430104|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
11430105|NCT01833793||Group 1|
11430106|NCT01833780||GBS carriage status|
11430107|NCT01833780||GBS status during labor|
11430108|NCT01833767|Experimental|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
11430109|NCT01833754|Experimental|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
11430110|NCT01833754|Experimental|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
11430111|NCT01833754|Experimental|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
11430112|NCT01833741|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
11430113|NCT01833728|Experimental|nefopam-propacetamol combination group|
11430114|NCT01833728|Active Comparator|propacetamol alone group|
11430115|NCT01833715|Active Comparator|Morphine|morphine group 0.08 mg / kg, to start surgery
11430116|NCT01833715|Experimental|Methadone|methadone group 0.08 mg / kg, to start surgery
11430117|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
11430118|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
11430119|NCT01833689|Placebo Comparator|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
11430120|NCT01833689|Active Comparator|food consumption: product|The test food will provide 50g of available carbohydrate
11430121|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
11430122|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
11430123|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
11430124|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
11430125|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
11430126|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
11430127|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
11430128|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
11430129|NCT01833637|No Intervention|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
11430130|NCT01833637|Active Comparator|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
11430131|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
11430132|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
11430133|NCT01833611|Experimental|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
11430134|NCT01833611|Placebo Comparator|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
11430135|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
11430136|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
11430137|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
11430138|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
11430139|NCT01833559|Other|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
11430140|NCT01833559|Other|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
11430141|NCT01833559|Other|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
11430142|NCT01833546|Experimental|Evofosfamide 240 mg|
11430143|NCT01833546|Experimental|Evofosfamide 340 mg|
11430144|NCT01833546|Experimental|Evofosfamide 480 mg|
11430145|NCT01833546|Experimental|Evofosfamide 340 mg + Gemcitabine|
11430146|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11430147|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
11430148|NCT01833520|Experimental|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.
~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
11430149|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
11430150|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
11430151|NCT01833494|Experimental|PA21|
11430152|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
11430153|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
11430154|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
11430155|NCT01833455|Placebo Comparator|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
11430156|NCT01833455|Placebo Comparator|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
11430157|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
11430158|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
11430159|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
11430160|NCT01833403|Other|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
11430161|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
11430162|NCT01833377|Experimental|caraway sample|caraway sample
11430163|NCT01833377|Active Comparator|Placebo|
11430164|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
11430165|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
11430166|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
11430167|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
11430168|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
11430169|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
11430170|NCT01833312|No Intervention|Control|Best medical treatment
11430171|NCT01833299|Active Comparator|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
11430172|NCT01833299|Experimental|TACE+sorafinib|TACE+sorafinib
11430230|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
11430231|NCT01832831||Continent Men|
11430232|NCT01832831||Incontinent Men|
11430339|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
11430173|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
11430174|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
11430175|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
11430176|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
11430177|NCT01833260|No Intervention|Without music|
11430178|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
11430179|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
11430180|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
11430181|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
11430182|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
11430183|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
11430184|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
11430185|NCT01833169|Experimental|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
11430186|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
11430187|NCT01833143|Experimental|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
11430188|NCT01833130|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
11430189|NCT01833130|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
11430190|NCT01833117|Experimental|FID 119515A|FID 119515A, 1 drop instilled in the study eye, single dose
11430191|NCT01833117|Active Comparator|Blink|Blink® Tears, 1 drop instilled in the study eye, single dose
11430192|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
11430193|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
11430194|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
11430195|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
11430196|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
11430197|NCT01833091|Experimental|intervention|creat light period 12 hours with cover on incubator
11430198|NCT01833091|No Intervention|control|
11430199|NCT01833078|Other|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
11430200|NCT01833065|Experimental|EBX 10|Elobixibat 10 mg/day
11430201|NCT01833065|Experimental|EBX 5|Elobixibat 5 mg/day
11430202|NCT01833065|Placebo Comparator|PLCBO|Placebo
11430203|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
11430204|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
11430233|NCT01832818|Experimental|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
11430234|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
11430235|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
11430340|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
11430205|NCT01833026|Experimental|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.
~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
11430206|NCT01833026|Placebo Comparator|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.
~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
11430207|NCT01833013|Other|endometriosis cohort|females suffer from endometriosis
11430208|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
11430209|NCT01832987|Experimental|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
11430210|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
11430211|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
11430212|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
11430213|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
11430214|NCT01832961|Experimental|flutter valve exercises|30 minutes of breathing exercises with flutter device
11430215|NCT01832961|Sham Comparator|flutter-sham exercises|30 minutes of breathing exercise with flutter-sham device
11430216|NCT01832948|Experimental|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
11430217|NCT01832935|Active Comparator|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
11430218|NCT01832935|Active Comparator|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
11430219|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
11430220|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
11430221|NCT01832909|Experimental|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
11430222|NCT01832909|Experimental|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
11430223|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:
~Single dose of ecallantide subcutaneous dosing:
~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.
~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
11430224|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
11430225|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.
~Amblyopia:
~VA <20/40 and 2 logMAR lines difference in normal eye
~Mild amblyopia (>20/40)
~Moderate amblyopia (20/40 and <20/100)
~Severe amblyopia (≥20/100 or worse)
~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.
~Strabismus:
~Constant: >2 PD at near and or distance.
~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.
~Amblyogenic factor categorization:
~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.
~'hypermetropia' (≥3.5 D),
~'myopia' (≥-4.0 D),
~'astigmatism' (≥1.5 D).
~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
11430226|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
11430227|NCT01832870|Experimental|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
11430228|NCT01832857|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
11430229|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
11430236|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
11430237|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
11430238|NCT01832766|Active Comparator|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
11430239|NCT01832766|Placebo Comparator|sugar pill|one capsule given by mouth at 8:00 a.m.
11430240|NCT01832753|Placebo Comparator|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.
~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
11430241|NCT01832753|No Intervention|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.
~Subjects that have TSH >10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
11430242|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
11430243|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
11430244|NCT01832727|Experimental|Cohort 180 mg 5/14 Schedule (Phase 1b)|Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430245|NCT01832727|Experimental|Cohort 210 mg 5/14 Schedule (Phase 1b)|"Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
~This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
11430246|NCT01832727|Experimental|Cohort 150/180 mg 5/14 Schedule (Phase 1b)|Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward. Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430247|NCT01832727|Experimental|Cohort 210 mg 2/7 Schedule (Phase 1b)|"Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
~This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
11430248|NCT01832727|Experimental|Cohort 240 mg 2/7 Schedule (Phase 1b)|Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430249|NCT01832727|Experimental|Cohort 270 mg 2/7 Schedule (Phase 1b)|Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430250|NCT01832727|Experimental|Cohort 300 mg 2/7 Schedule (Phase 1b)|Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430251|NCT01832727|Experimental|Cohort 330 mg 2/7 Schedule (Phase 1b)|Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430252|NCT01832727|Experimental|Phase 2 300 mg 2/7 Schedule|The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
11430253|NCT01832714||mTBI|Subjects who undergo an mTBI event
11430254|NCT01832714||Control|Subjects who do not undergo an mTBI
11430255|NCT01832701|Experimental|coffee|4 cups of soluble coffee per day (2.5g per cup)
11430256|NCT01832701|Placebo Comparator|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
11430257|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
11430258|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
11431481|NCT01824498|Experimental|Low Fat High Omega 3, High Fat, Low Fat|See Intervention Description
11430259|NCT01832675|Active Comparator|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
11430260|NCT01832675|Active Comparator|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
11430261|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
11430262|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
11430263|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
11430264|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
11430265|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
11430266|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
11430267|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
11430268|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
11430269|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
11430270|NCT01832623|Experimental|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
11430271|NCT01832610||HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
11430272|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
11430273|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
11430274|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
11430275|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
11430276|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
11430277|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
11430278|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
11430279|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
11430280|NCT01832532|Experimental|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
11430281|NCT01832532|No Intervention|Control group|Control group
11430282|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
11430283|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
11430284|NCT01832506|Experimental|MSC2156119J|
11430285|NCT01832493|Experimental|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
11430286|NCT01832480|Active Comparator|MTZ 2 g|Single dose MTZ
11430287|NCT01832480|Experimental|MTZ 500 mg twice daily x 7 days|Multi dose MTZ
11430288|NCT01832467|Experimental|cetuximab-containing chemotherapy|"Cetuximab may be given at either one of the following schedules at the investigator's discretion:
~2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.
~Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.
~Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.
~Regimens to be combined with biweekly cetuximab:
~Irinotecan at 2-weekly schedule.
~FOLFIRI (as inpatient or via ambulatory pump).
~FOLFOX (as inpatient or via ambulatory pump)."
11430289|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
11430290|NCT01832441|Other|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
11430291|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
11430292|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
11430331|NCT01832090|Experimental|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
11430332|NCT01832090|Active Comparator|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
11430333|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
11430334|NCT01832077||grader|grade fundus pictures in ZOC
11430335|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
11430336|NCT01832051|Experimental|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
11430293|NCT01832402|Experimental|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
11430294|NCT01832402|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
11430295|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
11430296|NCT01832389|No Intervention|Group C|control group
11430297|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
11430298|NCT01832363|Experimental|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
11430299|NCT01832363|Active Comparator|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
11430300|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
11430301|NCT01832337|Experimental|precondition|
11430302|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
11430303|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
11430304|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup not receiving topical ketorolac."
11430305|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.
~Subgroup not receiving topical ketorolac."
11430306|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
11430307|NCT01832285|Experimental|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
11430308|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
11430309|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
11430310|NCT01832259|Placebo Comparator|Placebo arm|Participants receiving placebo
11430311|NCT01832259|Experimental|Pazopanib arm|Participants receiving Pazopanib
11430312|NCT01832233|Experimental|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
11430313|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
11430314|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
11430315|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
11430316|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
11430317|NCT01832207|Active Comparator|MTS|Motor threshold of stimulation
11430318|NCT01832207|Active Comparator|STS|Sensorial threshold of stimulation
11430319|NCT01832207|Sham Comparator|Placebo|
11430320|NCT01832194|Experimental|Botox|"Botox:
~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
11430321|NCT01832181||Metformin|
11430322|NCT01832181||Control|
11430323|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
11430324|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
11430325|NCT01832155|Experimental|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
11430326|NCT01832155|Other|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
11430327|NCT01832129|Active Comparator|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
11430328|NCT01832129|Experimental|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
11430329|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
11430330|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
11430341|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
11430342|NCT01832012|No Intervention|No intervention|Group 2
11430343|NCT01831999|Experimental|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
11430344|NCT01831999|No Intervention|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
11430345|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
11430346|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
11430347|NCT01831973|Experimental|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
11430348|NCT01831960|Experimental|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
11430349|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
11430350|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
11430351|NCT01831934|Experimental|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
11430352|NCT01831934|Experimental|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
11430353|NCT01831921|Experimental|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
11430354|NCT01831921|Active Comparator|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
11430355|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
11430356|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
11430357|NCT01831895|Experimental|MobiusHD™|MobiusHD™
11430358|NCT01831882||Major Depressive Disorder|
11430359|NCT01831882||Healthy Control|
11430360|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
11430361|NCT01831869|No Intervention|blank|no intervention
11430362|NCT01831856|Experimental|F373280|
11430363|NCT01831856|Placebo Comparator|Placebo|
11430364|NCT01831843|Placebo Comparator|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
11430365|NCT01831843|Experimental|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
11430366|NCT01831843|Experimental|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
11430367|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
11430368|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
11430369|NCT01831817|Experimental|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
11430370|NCT01831817|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
11430371|NCT01831817|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
11430372|NCT01831817|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
11430373|NCT01831804|Experimental|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
11430374|NCT01831804|Experimental|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
11431024|NCT01827527||Healthy Adult|This is a protocol development study, with no interventions or treatments.
11430375|NCT01831804|Experimental|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
11430376|NCT01831804|Experimental|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
11430377|NCT01831804|Experimental|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
11430378|NCT01831804|Experimental|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
11430379|NCT01831804|Experimental|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
11430380|NCT01831791|Experimental|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
11430381|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
11430382|NCT01831765|Experimental|Meal time FIAsp and insulin detemir|
11430383|NCT01831765|Active Comparator|Meal time insulin aspart and insulin detemir|
11430384|NCT01831765|Experimental|Post meal FIAsp and insulin detemir|
11430385|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
11430386|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
11430387|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
11430388|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
11430389|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
11430390|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
11430391|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
11430392|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
11430393|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
11430394|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
11430395|NCT01831726|Experimental|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
11430396|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
11430397|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
11430398|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
11430399|NCT01831687|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
11430400|NCT01831687|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
11430401|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
11430402|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
11430403|NCT01831661|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
11430404|NCT01831661|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
11430405|NCT01831648|Experimental|Volonteers|Blood sample
11430406|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.
~Exclusion Criteria
~younger than 18 years old.
~where the clinician/General Practitioner (GP) does not provide consent.
~incapable of giving informed consent.
~physically or cognitively incapable of completing the questionnaire.
~too ill to participate."
11430441|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
11430442|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
11513748|NCT01258543||Non-specific back pain|
11430407|NCT01831635||General Practice Control|"For each MPN case one GP control will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.
~The following patient groups will be excluded. Those:
~younger than 18 years old.
~where the clinician/GP does not provide consent.
~incapable of giving informed consent.
~physically or cognitively incapable of completing the questionnaire.
~too ill to participate. The WHO performance evaluation scale will be used at the stage of participant identification. Only those scoring 0-3 will be considered eligible for inclusion in the study. Those scoring 3 are described as Symptomatic >50% in bed but not bedbound."
11430408|NCT01831635||Non-blood relative or family control|Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.
11430409|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.
~Day 1:
~Patient arrives having abstained medication for minimum 20 hours.*
~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*
~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment.*
~Day 2:
~Patient arrives having abstained medication for a minimum of 20 hours.*
~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*
~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment.*"
11430410|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.
~Day 1:
~Patient arrives having abstained medication for minimum 20 hours.*
~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*
~CRF 2, Adult ASRS and WAIS subtests.
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*
~Day 2 (after 14 - 40 days):
~Patient arrives having abstained medication for a minimum of 20 hours.*
~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*
~CRF 3, ASRS and EHI.
~Blood sample, if consented.*
~Computerized testing.
~Administer opposite treatment.*"
11430411|NCT01831596|Experimental|ciSNaP|
11430412|NCT01831583|Experimental|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
11430413|NCT01831583|Experimental|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
11430414|NCT01831570|Other|symptomatic and radiographic hand osteoarthritis|Patients above 35-years old with symptomatic and radiographic hand osteoarthritis
11430415|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
11430416|NCT01831544|Experimental|MVAD® Pump|Implant of HeartWare MVAD® System
11430417|NCT01831531|Experimental|S-1|"Patients will receive chemoradiation with S-1.
~Interventions:
~Drug: S-1 Radiation: Radiation therapy"
11430418|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
11430419|NCT01831505|Experimental|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
11430420|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
11430421|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
11430422|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
11430423|NCT01831466|Experimental|Treatment Group A|
11430424|NCT01831466|Experimental|Treatment Group B|
11430425|NCT01831466|Placebo Comparator|Treatment Group C|
11430426|NCT01831466|Experimental|Treatment Group D|
11430427|NCT01831466|Experimental|Treatment Group E|
11430428|NCT01831466|Placebo Comparator|Treatment Group F|
11430429|NCT01831453|Placebo Comparator|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
11430430|NCT01831453|Active Comparator|experimental|omega-3 1 gram three times daily for 6 months
11430431|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
11430432|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
11430433|NCT01831427|Experimental|GS-5745|"(IV dose at 0.3 mg/kg, 1.0 mg/kg, 2.5 mg/kg, or 5.0 mg/kg and subcutaneous dose at 150 mg)
~Participants will receive GS-5745 as follows:
~SAD cohort - single IV dose;
~MAD cohort - multiple (three) IV doses every two weeks;
~Adaptive MAD cohort - a single subcutaneous dose for 5 consecutive weeks"
11430434|NCT01831427|Experimental|Placebo to match GS-5745 + GS-5745 (Adaptive MAD)|"Participants will receive placebo to match GS-5745 as follows:
~SAD cohort - single IV dose;
~MAD cohort - multiple (three) IV doses every two weeks;
~Participants will receive GS-5745 150 mg as follows:
~Adaptive MAD cohort - a single subcutaneous dose for 5 consecutive weeks"
11430435|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
11430436|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
11430437|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
11430438|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
11430439|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
11430440|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
11430511|NCT01830985|Experimental|Single Arm VX-509|
11513881|NCT01257542|Experimental|Active|
11430443|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
11430444|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
11430445|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
11430446|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
11430447|NCT01831375|Experimental|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
11430448|NCT01831375|Other|Get Connected|Attention control group
11430449|NCT01831362|Experimental|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
11430450|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
11430451|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
11430452|NCT01831336||Orsiro DES|
11430453|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
11430454|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
11430455|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
11430456|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
11430457|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
11430458|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
11430459|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
11430460|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
11430461|NCT01831297||syncope|
11430462|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
11430463|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
11430464|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
11430465|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
11430466|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
11430467|NCT01831258|Experimental|SensAwake On|The comfort feature 'SensAwake' will be turned on
11430468|NCT01831258|Active Comparator|SensAwake Off|The comfort feature 'SensAwake' will be turned off
11430469|NCT01831232|Experimental|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11430470|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
11430471|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
11430472|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
11430473|NCT01831206|No Intervention|standard treatment|Standard treatment alone
11430474|NCT01831193|Active Comparator|Diabetic|
11430475|NCT01831193|Active Comparator|Non-diabetic|
11430476|NCT01831180||Premenopausal women 19-25 yrs|
11430477|NCT01831180||Postmenopausal 60 yrs +|
11430478|NCT01831167|Experimental|dynamic light|dynamic light
11430479|NCT01831167|No Intervention|reference|normal light
11430512|NCT01830972|Experimental|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:
~Part I: participants continued on 6 g/day SA-ER for 12 weeks
~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day [QID]) for 36 months
~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)
~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
11431084|NCT01827059|Active Comparator|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
11430480|NCT01831154|Experimental|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
11430481|NCT01831154|Experimental|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
11430482|NCT01831154|Experimental|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
11430483|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
11430484|NCT01831128||Control|No ASV treatment
11430485|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
11430486|NCT01831102||Mexican American|Mexican American ancestry
11430487|NCT01831089|Experimental|Treatment|PM01183 + paclitaxel +/- bevacizumab
11430488|NCT01831076|Active Comparator|Treatment (exemestane, surgery)|Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
11430489|NCT01831076|Experimental|treatment (exemestane, tamoxifen, surgery)|Patients receive exemestane plus tamoxifen orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
11430490|NCT01831063|No Intervention|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
11430491|NCT01831063|Experimental|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
11430492|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
11430493|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
11430494|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
11430495|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
11430496|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
11430497|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
11430498|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
11430499|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
11430500|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
11430501|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
11430502|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
11430503|NCT01831024|Experimental|Treatment Group|Dignicap System
11430504|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
11430505|NCT01831011|Experimental|mildronate|infusion of mildronate
11430506|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
11430507|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
11430508|NCT01830998||control, MCI|control and MCI group.Glycaemic control
11430509|NCT01830998||control and MCI|treatment and without treatment
11430510|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
11514004|NCT01256684|Experimental|0.25% DHEA|
11430513|NCT01830972|Experimental|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:
~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months
~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)
~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
11430514|NCT01830959|Experimental|Roflumilast|Roflumilast
11430515|NCT01830959|Placebo Comparator|Placebo|Placebo
11430516|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
11430517|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
11430518|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
11430519|NCT01830933|Experimental|BreastCARE Intervention|"Intervention Clinic Patients: The RA will welcome the patient upon arrival at the clinic and again explain study procedures and field any questions. The RA will have the patient sign the HIPAA authorization form and then demonstrate how to enter information and answer questions on the tablet-PC and the patient will indicate their consent electronically before beginning the assessment.
~Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patietns before she meets with her doctor."
11430520|NCT01830933|No Intervention|BreastCARE Comparison|"Patients will be randomized into the intervention or comparison groups at the time of recruitment. Block-randomization will be used to assign patients to intervention or comparison groups.
~Comparison Clinic Patients. Contact and baseline interview procedures will be the same for patients from the comparison clinics, however there will be no computer assessment at the time of their clinic visit. An RA will meet the patient 10 minutes prior to her appointment time to obtain written HIPAA authorization."
11430521|NCT01830920|Placebo Comparator|Placebo|An identical appearing placebo will be administered.
11430522|NCT01830920|Experimental|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
11430523|NCT01830920|Experimental|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
11430524|NCT01830920|Experimental|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
11430525|NCT01830920|Experimental|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses ~80% of the pre-surgery dose.
11430526|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
11430527|NCT01830907|Active Comparator|Parenteral|
11430528|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
11430529|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
11430530|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
11430531|NCT01830881|Placebo Comparator|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
11430532|NCT01830881|Active Comparator|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
11430533|NCT01830868||Zonisamide tablets|
11430534|NCT01830855|Experimental|rLP2086 lot 1|
11430535|NCT01830855|Experimental|rLP2086 lot 2|
11430536|NCT01830855|Experimental|rLP2086 lot 3|
11430537|NCT01830855|Active Comparator|Control|Havrix (HAV) and Saline
11430538|NCT01830842|Placebo Comparator|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
11430539|NCT01830842|Other|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
11430540|NCT01830829|Experimental|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
11430541|NCT01830829|Placebo Comparator|Placebo|Placebo
11430542|NCT01830816|Experimental|Normal Renal Function: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
11430543|NCT01830816|Experimental|Severe Renal Impairment: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
11430544|NCT01830816|Experimental|End-stage Renal Disease: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
11430545|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
11431085|NCT01827059|Placebo Comparator|Placebo|Placebo tablet
11430546|NCT01830790|Active Comparator|Healthy Controls|Healthy individuals >65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
11430547|NCT01830790|Experimental|AMD patients|Age-related macular degeneration (AMD) patients >65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
11430548|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
11430549|NCT01830764|Other|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
11430550|NCT01830764|Other|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
11430551|NCT01830751|Experimental|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
11430552|NCT01830751|Sham Comparator|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
11430553|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
~Intervention: Single-port, peri-umbilical hysterectomy"
11430554|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
~Intervention: Multi-port hysterectomy"
11430555|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of > 7.2 mg/dl) and/or gout.
11430556|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
11430557|NCT01830712||Chart review|
11430558|NCT01830699|Active Comparator|Rilonacept|160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
11430559|NCT01830699|Placebo Comparator|Corticosteroid|80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once
11430560|NCT01830686|Experimental|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
11430561|NCT01830686|Active Comparator|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
11430562|NCT01830686|Placebo Comparator|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
11430563|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
11430564|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
11430565|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
11430566|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
11430567|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
11430568|NCT01830647||Cohort|
11430569|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
11430570|NCT01830621|Active Comparator|BBI608|BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care
11430571|NCT01830621|Placebo Comparator|Placebo|Placebo two times daily + Best Supportive Care
11430572|NCT01830608||300 patients with AMD|
11430573|NCT01830595|Active Comparator|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
11430574|NCT01830595|Placebo Comparator|Placebo|Matched placebo will be administered by mouth twice daily
11430575|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
11430576|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
11430577|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
11430578|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
11430579|NCT01830569|Experimental|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
11430580|NCT01830569|Other|Control group|The regular Evidence Linker will be available in this group.
11430581|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
11430582|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
11430653|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
11431482|NCT01824498|Experimental|Low Fat High Omega 3, Low Fat, High Fat|See Intervention Description
11430583|NCT01830543|Experimental|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
11430584|NCT01830543|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
11430585|NCT01830543|Experimental|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
11430586|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
11430587|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
11430588|NCT01830517|Experimental|amlodipine camsylate|amlodipine camsylate 5mg
11430589|NCT01830517|Active Comparator|losartan potassium|losartan potassium 50mg
11430590|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
11430591|NCT01830491|Experimental|Clopidogrel napadisilate|aspirin 100mg
11430592|NCT01830491|Active Comparator|clopidogrel bisulfate|aspirin 100mg
11430593|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
11430594|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
11430595|NCT01830452|Experimental|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
11430596|NCT01830452|Active Comparator|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
11430597|NCT01830439|Experimental|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
11430598|NCT01830439|Experimental|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
11430599|NCT01830439|Experimental|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
11430600|NCT01830439|Experimental|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
11430601|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
11430602|NCT01830400||Eslicarbazepine Acetate tablets|
11430603|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
11430604|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
11430605|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
11430606|NCT01830361|Experimental|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
11430607|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
11430608|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
11430609|NCT01830335|Experimental|Drug|Indomethacin 1.2 mg kg 1 dose
11430610|NCT01830335|Placebo Comparator|Placebo|flour capsule
11430611|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
11430612|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
11430654|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
11430655|NCT01829997|Experimental|nanOss Bioactive 3D BVF|Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
11514005|NCT01256684|Experimental|0.5% DHEA|
11430613|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
11430614|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
11430615|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
11430616|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
11430617|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
11430618|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
11430619|NCT01830283|Active Comparator|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
11430620|NCT01830283|Experimental|2 dose varicella vaccine|The provider never get the varicella vaccine
11430621|NCT01830270|Experimental|PET regimen|
11430622|NCT01830257|Experimental|sending message|The investigators would send the tip to the children's guardian
11430623|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.
~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
11430624|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
11430625|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:
~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation
~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,
~250 mg/m2 in patients aged >80 years."
11430626|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
11430627|NCT01830205|Experimental|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
11430628|NCT01830205|Experimental|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
11430629|NCT01830205|Experimental|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
11430630|NCT01830205|Experimental|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
11430631|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
11430632|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
11430633|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
11430634|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
11430635|NCT01830140|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
11430636|NCT01830140|Active Comparator|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
11430637|NCT01830127|Experimental|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
11430638|NCT01830127|Experimental|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
11430639|NCT01830114|Experimental|Web app evaluation group|
11430640|NCT01830101|Experimental|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
11430641|NCT01830101|Experimental|TMZ alone|TMZ alone
11430642|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
11430643|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
11430644|NCT01830075|No Intervention|Control group|The control group receives care as usual.
11430645|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
11430646|NCT01830062|Experimental|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
11430647|NCT01830049||Group I|Older males with ED
11430648|NCT01830049||Group II|Older males with normal erectile function
11430649|NCT01830049||Gourp III|Young males with normal rectile function
11430650|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
11430651|NCT01830023||cardiac ultrasound examination|
11430652|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
11430656|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
11430657|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
11430658|NCT01829971|Experimental|MRX34|Single agent MRX34
11430659|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
11430660|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
11430661|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
11430662|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
11430663|NCT01829919|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.
11430664|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
11430665|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
11430666|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
11430667|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
11430668|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
11430669|NCT01829867|Experimental|sNN0031|
11430670|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
11430671|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
11430672|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
11430673|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
11430674|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
11430675|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
11430676|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
11430677|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
11430678|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
11430679|NCT01829776|Experimental|education|Educational intervention
11430680|NCT01829763|Experimental|botox|
11430681|NCT01829750|Sham Comparator|Control|"(Stage 1) No active intervention after standard surgical treatment
~(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1."
11430682|NCT01829750|Active Comparator|Cardiac progenitor cell infusion|(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells
11430683|NCT01829724||Healthy Volunteer|The control groups for each participant cohort will consist of up to 50 individuals spanning Objectives 1 and 2, for a total recruitment of up to 100 healthy volunteers within the same age range.
11430684|NCT01829724||Individuals with childhood-onset brain or peripheral injury|The childhood-onset brain injury group 120 individuals spanning the three objectives.
11430685|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
11430686|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
11430687|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
11430688|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
11430689|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
11430690|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
11430691|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
11430692|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
11430693|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
11430694|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
11430695|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
11430696|NCT01829607|Placebo Comparator|Placebo|
11430697|NCT01829594|Experimental|Case Management|
11430698|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
11430699|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and once weekly at weeks 13, 21, 29, and 37.
11430700|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
11430701|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
11430702|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
11430703|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
11430704|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
11430705|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
11430706|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
11430707|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
11430708|NCT01829516|Experimental|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
11430709|NCT01829516|Placebo Comparator|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.
~NOTE: This is a cross-over design and subjects will participate in both arms."
11430710|NCT01829503|Experimental|decitabine and cytarabine|
11430711|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
11430712|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
11430713|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
11430714|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
11430715|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
11430716|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
11430717|NCT01829464|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
11430718|NCT01829464|Experimental|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
11430719|NCT01829464|Experimental|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
11430720|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
11430721|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
11430722|NCT01829438|No Intervention|Without music|6MWT without music
11430723|NCT01829438|Experimental|With fast music|6MWT with a fast music
11430724|NCT01829438|Experimental|With slow music|6MWT with a slow music
11430725|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
11430726|NCT01829425|Active Comparator|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
11430727|NCT01829425|Active Comparator|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
11430755|NCT01829243|Placebo Comparator|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
11430728|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:
~Patients at first-line treatment for MM:
~Within 15 days before the start of the treatment
~Within one month after the end of the first-line treatment
~Six (6) months after the end of the first-line treatment
~Patients at relapse after disease response (CR or PR) lasting at least 6 months
~At relapse
~Within 15 days after the end of the treatment of relapse
~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
11430729|NCT01829399|Experimental|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
11430730|NCT01829399|Sham Comparator|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
11430731|NCT01829386||Non heme iron levels on MRI|"Intervention: MRI scans To develop a reliable MR based measurement of Non-heme iron in brain tissue of patients with hemorrhagic stroke : on day 3, 14 and 30 after stroke to assess the non heme iron levels on MRI.
~To evaluate the role of iron chelators following a hemorrhagic stroke/parenchymal hemorrhage."
11430732|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
11430733|NCT01829360|Experimental|Standard then Alternative: High Dose|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose (dose 9 x dose frequency 4)
11430734|NCT01829360|Experimental|Alternative: High Dose then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose (dose 9 x dose frequency 4) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
11430735|NCT01829360|Experimental|Alternative: High Dose Frequency then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
11430736|NCT01829360|Experimental|Standard then Alternative: High Dose Frequency|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9)
11430737|NCT01829347|Experimental|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
11430738|NCT01829347|Other|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
11430739|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
11430740|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
11430741|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
11430742|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
11430743|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
11430744|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
11430745|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
11430746|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
11430747|NCT01829295|Experimental|Methotrexate|oral methotrexate
11430748|NCT01829295|Experimental|Mycophenolate Mofetil|oral mycophenolate mofetil
11430749|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:
~Provide HIV and STI test results
~First Interview
~Attend 8 sessions - 1 session per week
~Second interview occurs immediately following the 8th session with HIV and STI tests
~Third interview occurs 3 months after the 8th session with HIV and STI tests"
11430750|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.
~Provide HIV and STI test results
~First Interview
~No sessions for 8 weeks
~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled
~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.
~Attend 8 sessions - 1 session per week
~Fourth interview occurs immediately after the 8th session with HIV and STI tests
~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
11430751|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
11430752|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
11430753|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
11430754|NCT01829243|Experimental|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
11430756|NCT01829230|Experimental|Test lens C|Test lens C from previous study
11430757|NCT01829230|Active Comparator|Test lens A|Test lens A from previous study
11430758|NCT01829217|Experimental|Sunitinib|42 day cycle, taken orally every day for the first 28 days followed by 14 days off
11430759|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
11430760|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
11430761|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
11430762|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
11430763|NCT01829191|Experimental|Test Lens A|Test lenses will be worn in a daily wear modality
11430764|NCT01829191|Experimental|Test Lens C|Test lenses will be worn in a daily wear modality
11430765|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
11430766|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
11430767|NCT01829165|Experimental|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
11430768|NCT01829165|Sham Comparator|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.
~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
11430769|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
11430770|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
11430771|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
11430772|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
11430773|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
11430774|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
11430775|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
11430776|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
11430777|NCT01829113|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
11430778|NCT01829113|Placebo Comparator|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
11430779|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
11430780|NCT01829100|No Intervention|waitlist|15-week waitlist
11430781|NCT01829087|Experimental|Botox injection|
11430782|NCT01829087|Placebo Comparator|Control|
11430783|NCT01829061||No Treatment|
11430784|NCT01829048|Experimental|PF-02545920|
11430785|NCT01829048|Placebo Comparator|Placebo|
11430786|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
11430787|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
11430788|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
11430789|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
11430790|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.
~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
11430791|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
11430792|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
11430793|NCT01828983|Experimental|Telephone support groups|Telephone support groups, each with participants and a trained group leader. Each hour-long telephone group will meet bi-monthly for six months for a total of 12 meetings. Groups are structured with education, skills building, and support. Participants will receive and use a Spouse Workbook with information and activities.
11432148|NCT01819857|Active Comparator|Droperidol 1.25 mg intravenously|
11430794|NCT01828983|Active Comparator|Education webinars|Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
11430795|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
11430796|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
11430797|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
11430798|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
11430799|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
11430800|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
11430801|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
11430802|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
11430803|NCT01828918|Other|early recurrence|find the postoperative early relapse out
11430804|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
11430805|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
11430806|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
11430807|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
11430808|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
11430809|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
11430810|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
11430811|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
11430812|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
11430813|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
11430814|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
11430815|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
11430816|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
11430817|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
11430818|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
11430819|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
11430820|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
11430821|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
11430822|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
11430823|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
11430824|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
11430825|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
11430826|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430827|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430828|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430829|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430830|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430967|NCT01827891|Placebo Comparator|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
11430831|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430832|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430833|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
11430834|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
11430835|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
11430836|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
11430837|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
11430838|NCT01828762|Experimental|DC-TC+GM-CSF|
11430839|NCT01828749||CT abdomen and pelvis|blunt trauma patients without suspected fractures of the pelvis, hip or lumbar spine in two age groups: ages 3-17 years and 18-60 years
11430840|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV
~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
11430841|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV
~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
11430842|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
11430843|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
11430844|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
11430845|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
11430846|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:
~Fixed low dose nadroparin, or;
~Fixed low dose enoxaparin, or;
~Fixed low dose dalteparin, or;
~Fixed low dose tinzaparin."
11430847|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.
~Intermediate dose nadroparin, or;
~Intermediate dose enoxaparin, or;
~Intermediate dose dalteparin, or;
~Intermediate dose tinzaparin."
11430848|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
11430849|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
11430850|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
11430851|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
11430852|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
11430853|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
11430854|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
11430855|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
11430992|NCT01827683|Active Comparator|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
11432149|NCT01819857|Active Comparator|Ondansetron 8 mg intravenously|
11430856|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
11430857|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
11430858|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
11430859|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
11430860|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
11430861|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
11430862|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
11430863|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment
~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
11430864|NCT01828593|Placebo Comparator|Placebo|Matching Placebo
11430865|NCT01828593|Active Comparator|SBI 2.5 g|Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
11430866|NCT01828593|Active Comparator|SBI 5.0g|Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
11430867|NCT01828580|Experimental|AutoLap|
11430868|NCT01828567|Experimental|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
11430869|NCT01828567|No Intervention|Control|Usual care
11430870|NCT01828554|Experimental|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.
~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.
~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
11430871|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
11430872|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
11430873|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
11430874|NCT01828515|Experimental|Vilazodone and Hydrocortisone, then Placebo and Hydrocortisone|Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment. After a 23 day medication washout the procedure will be repeated using placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment.
11430875|NCT01828515|Experimental|Placebo and Hydrocortisone, then Vilazodone and Hydrocortisone|Placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment. After a 23 day medication washout the procedure will be repeated using Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment.
11430876|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
11430877|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
11430878|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
11430879|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
11430880|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
11430881|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
11430882|NCT01828476|Experimental|ARM A|Abiraterone with ABT-263
11430883|NCT01828476|Experimental|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
11430884|NCT01828463|No Intervention|no treatment|comparrator
11430885|NCT01828463|Experimental|Nitisinone 1mg|interventional
11430886|NCT01828463|Experimental|Nitisinone 2mg|interventional
11430887|NCT01828463|Experimental|Nitisinone 4mg|interventional
11430888|NCT01828463|Experimental|Nitisinone 8mg|interventional
11430889|NCT01828437|Experimental|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
11430890|NCT01828437|Active Comparator|Prednisolone|allocated patients receive prednisolone alone
11430891|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
11430892|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
11430893|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
11430993|NCT01827683|Other|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
11431196|NCT01826448|Experimental|Cohort 1|Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib
11430894|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.
~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
11430895|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
11430896|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
11430897|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
11430898|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
11430899|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
11430900|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
11430901|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled
~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
11430902|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
11430903|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
11430904|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
11430905|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
11430906|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
11430907|NCT01828281|Active Comparator|Therapeutic CPAP|Therapeutic CPAP
11430908|NCT01828281|Sham Comparator|control|subtherapeutic CPAP using 4 cm water
11430909|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
11430910|NCT01828255|Experimental|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
11430911|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
11430912|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
11430913|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
11430914|NCT01828229|Experimental|inactivity|Inactivity for two weeks
11430915|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
11430916|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
11430917|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
11430918|NCT01828216|Active Comparator|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest & abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer & supplemented by oronasal airflow thermistor, & finger pulse oximetry.
11430919|NCT01828216|Active Comparator|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
11430920|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
11430921|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
11430922|NCT01828190|Experimental|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
11430923|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
11430924|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
11430925|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
11430926|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
11430994|NCT01827670|Experimental|0.454% stannous fluoride dentifrice|Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
11515344|NCT01247155||non-first day review|
11430927|NCT01828164|Experimental|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
11430928|NCT01828164|Sham Comparator|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
11430929|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
11430930|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.
~After 5 days they switch their supplement."
11430931|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.
~After 5 days they switch their supplement"
11430932|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.
~After 5 days they switch their supplement"
11430933|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
11430934|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
11430935|NCT01828112|Experimental|Ceritinib|Patients in this arm received 750 mg of ceritinib.
11430936|NCT01828112|Active Comparator|Chemotherapy|Patients in this arm received chemotherapy of either pemetrexed or docetaxel as determined by BIRC.
11430937|NCT01828099|Experimental|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
11430938|NCT01828099|Active Comparator|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
11430939|NCT01828086|Experimental|CJM112|CJM112 in different doses; single ascending and multiple ascending
11430940|NCT01828086|Placebo Comparator|Placebo|Placebo to match
11430941|NCT01828086|Active Comparator|Secukinumab|Active investigational drug.
11430942|NCT01828073||Cohort 1: Full term infants exposed in utero to maternal RAL|Infants, who were expected to be ≥2000 grams at birth (i.e. full-term) at time of enrollment, born to women with HIV-1 infection who received RAL 400 mg twice daily for at least two weeks prior to delivery and continued to receive ARVs during labor. The group also includes the mothers of these infants.
11430943|NCT01828073||Cohort 2: LBW infants exposed in utero to maternal RAL|Infants, who were expected to be ≤2500 grams at birth (i.e. LBW) at time of enrollment, born to women with HIV-1 infection who received at least one dose of RAL 400 mg within 2 to 24 hours prior to delivery. The group also includes the mothers of these infants.
11430944|NCT01828060|Experimental|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
11430945|NCT01828060|Placebo Comparator|Placebo|Placebo capsules
11430946|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
11430947|NCT01828034|Experimental|Gemcitabine, Cisplatin and MEK162|Phase I component of the study, a classic 3+3 cohort dose escalation scheme will be used to identify the MTD of MEK162 when administered with gemcitabine at dose 800 mg/m2 and cisplatin given at dose 20 mg/m2 week 2 & 3 of a 3 week cycle. The final cohort will receive gemcitabine 1000mg/m2 and cisplatin 20mg/m2 week 2 and 3 of a 3 week cycle in combination with MEK162 at the MTD as determined above. In the phase II part of the study, patients will receive MEK162 at the MTD dose plus gemcitabine and cisplatin at the dose level determined acceptable in the phase I portion. In the phase II part of the study, patients will receive MEK162 at 45mg BID plus gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) as determined by the phase I portion.
11430948|NCT01828021|Experimental|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
11430949|NCT01827995|Other|Duo test|Self assessment
11430950|NCT01827995|Other|Routine follow up|Follow up in the clinic
11430951|NCT01827982|Experimental|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
11430952|NCT01827982|Experimental|Part 1 - Cohort 2: JNJ-54861911 3 mg|
11430953|NCT01827982|Experimental|Part 1 - Cohort 3: JNJ-54861911 9 mg|
11430954|NCT01827982|Experimental|Part 2 - Cohort 4: JNJ-54861911 9 mg|
11430955|NCT01827982|Experimental|Part 2 - Cohort 5: JNJ-54861911 27 mg|
11430956|NCT01827982|Experimental|Part 2 - Cohort 6: JNJ-54861911 81 mg|
11430957|NCT01827982|Experimental|Part 2 - Cohort 7: JNJ-54861911 160 mg|
11430958|NCT01827982|Experimental|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
11430959|NCT01827982|Placebo Comparator|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
11430960|NCT01827969|Experimental|ablathermy focused ultrasound|ablathermy focused ultrasound
11430961|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
11430962|NCT01827943|Experimental|TORISEL|Torisel
11430963|NCT01827930|Experimental|Imatinib|an adaptation strategy of dosage of Imatinib Mesylate versus a standard strategy
11430964|NCT01827917|Experimental|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
11430965|NCT01827904|Experimental|Transcranial ExAblate|Transcranial ExAblate
11430966|NCT01827904|Sham Comparator|Sham Transcranial ExAblate|Sham Treatment with Transcranial ExAblate
11430968|NCT01827891|Active Comparator|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
11430969|NCT01827878|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
11430970|NCT01827878|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
11430971|NCT01827865|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
11430972|NCT01827865|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
11430973|NCT01827852||Cohort|
11430974|NCT01827839|Experimental|HZ Group|Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
11430975|NCT01827826|Active Comparator|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
11430976|NCT01827826|No Intervention|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
11430977|NCT01827813|Active Comparator|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
11430978|NCT01827813|Active Comparator|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
11430979|NCT01827800|Experimental|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
11430980|NCT01827800|No Intervention|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
11430981|NCT01827787|Experimental|Cohort 1: HR+/HER2-|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle
~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
11430982|NCT01827787|Experimental|Cohort 2: TNBC|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle
~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
11430983|NCT01827774|Experimental|Surgisis® Soft Tissue Graft|
11430984|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
11430985|NCT01827748|Experimental|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
11430986|NCT01827748|Active Comparator|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
11430987|NCT01827722|Experimental|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
11430988|NCT01827722|Experimental|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
11430989|NCT01827722|Experimental|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).
~Reinjection Parameters:
~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
11430990|NCT01827696|Experimental|Treatment|American Ginseng ingestion
11430991|NCT01827696|Placebo Comparator|Placeobo|non-active ingredient
11430995|NCT01827670|Active Comparator|0.76% sodium monofluorophosphate dentifrice|Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
11430996|NCT01827657|Experimental|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
11430997|NCT01827657|Experimental|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
11430998|NCT01827657|Experimental|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
11430999|NCT01827657|Experimental|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
11431000|NCT01827657|Experimental|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
11431001|NCT01827644|Experimental|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
11431002|NCT01827644|Experimental|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
11431003|NCT01827644|Experimental|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
11431004|NCT01827644|Experimental|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
11431005|NCT01827644|Experimental|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
11431006|NCT01827644|Experimental|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
11431007|NCT01827631|Experimental|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
11431008|NCT01827631|Experimental|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
11431009|NCT01827618|Experimental|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
11431010|NCT01827618|No Intervention|Control|
11431011|NCT01827605|Experimental|Arm A RIT|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.
11431012|NCT01827605|Experimental|ARM B ASCT|BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC>1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance
11431013|NCT01827592|Experimental|EBX 10|Elobixibat 10 mg/day
11431014|NCT01827592|Experimental|EBX 5|Elobixibat 5 mg/day
11431015|NCT01827592|Placebo Comparator|PLCBO|Placebo
11431016|NCT01827579|Experimental|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
11431017|NCT01827579|No Intervention|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
11431018|NCT01827566|Active Comparator|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
11431019|NCT01827566|Placebo Comparator|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
11431020|NCT01827553|Experimental|Induction CT, chemoradiotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;
11431021|NCT01827553|Active Comparator|Induction CT, chemotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
11431022|NCT01827540|Experimental|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9.
11431023|NCT01827540|Experimental|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
11516943|NCT01235871|Experimental|SB1578|
11431025|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
11431026|NCT01827501|Experimental|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
11431027|NCT01827501|No Intervention|Group Co|Conventional fluid management
11431028|NCT01827475|Active Comparator|Ibuprofen|Ibuprofen 800 mg
11431029|NCT01827475|Active Comparator|Acetaminophen|Acetaminophen 1 gm
11431030|NCT01827475|Experimental|Ibuprofen-acetaminophen combination|Ibuprofen 800 mg plus acetaminophen 1 gm
11431031|NCT01827462|Experimental|18-30 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):
~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.
~Beginning with 2014-2015 season, Quadrivalent, inactivated influenza vaccine (IIV4) was given."
11431032|NCT01827462|Experimental|60-80 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):
~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.
~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
11431033|NCT01827462|Experimental|80-100 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):
~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.
~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
11431034|NCT01827436|Active Comparator|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
11431035|NCT01827436|Active Comparator|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
11431036|NCT01827423|Experimental|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
11431037|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
11431038|NCT01827397|Experimental|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
11431039|NCT01827397|Placebo Comparator|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
11431040|NCT01827384|Experimental|Regimen I (veliparib, temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11431041|NCT01827384|Experimental|Regimen II (adavosertib, carboplatin)|Patients receive adavosertib PO BID for 5 doses starting on day 1 and carboplatin IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11431042|NCT01827384|Experimental|Regimen III (everolimus)|Patients receive everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11431043|NCT01827384|Experimental|Regimen IV (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11431044|NCT01827371|Experimental|Arm C|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 22.
11431045|NCT01827371|Experimental|Arm B|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 15.
11431046|NCT01827371|Experimental|Arm A|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 29.
11431047|NCT01827371|Experimental|Arm D|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via Stratis™ on Days 1 and 29.
11431048|NCT01827358|Experimental|Group 1|Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
11431049|NCT01827358|No Intervention|Group 2|No treatment
11431050|NCT01827345|Experimental|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
11431051|NCT01827332|Active Comparator|Oxytocin|intranasal administration
11431052|NCT01827332|Placebo Comparator|Saline|intranasal administration
11431053|NCT01827306|Active Comparator|Biofreeze|Apply 5 minutes before therapy by applying a small coin sized amount to the painful area. Subjects will then complete a standard shoulder therapy program.
11431054|NCT01827306|No Intervention|Control|Subjects in this arm will complete a standard shoulder therapy program as normal, with no intervention.
11431055|NCT01827293|Active Comparator|Promethazine|IV promethazine (25 mg)
11431056|NCT01827293|Active Comparator|lorazepam|IV lorazepam (2 mg)
11431057|NCT01827280|Experimental|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
11431058|NCT01827280|Experimental|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
11431059|NCT01827267|Experimental|neratinib monotherapy|240 mg once daily with food, continuously in 21 day cycles
11431060|NCT01827267|Experimental|neratinib plus temsirolimus|240 mg neratinib plus 8 mg temsirolimus IV with optional dose escalation to 15 mg temsirolimus
11431061|NCT01827254||Non-Interventional Study|
11431062|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
11431086|NCT01827046|Experimental|MIS plus rt-PA management|Subjects randomized to the Minimally Invasive Surgery (MIS) plus rt-PA management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
11431087|NCT01827046|No Intervention|Medical management|Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.
11431088|NCT01827033|Other|meditation training|
11431273|NCT01825876|Active Comparator|Warfarin|15 milligrams (mg) warfarin administered as a single oral dose
11431063|NCT01827228|Experimental|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent & acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
11431064|NCT01827228|Active Comparator|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
11431065|NCT01827228|Active Comparator|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
11431066|NCT01827215|Experimental|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on every two weeks or twice a month, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 6 and 12 months to conduct a follow-up phone call to collect outcome data. At the end of the intervention period, intervention participants will be invited to participate a focus group session.
11431067|NCT01827215|No Intervention|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
11431068|NCT01827202|Active Comparator|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
11431069|NCT01827202|Active Comparator|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
11431070|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
11431071|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
11431072|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
11431073|NCT01827163|Experimental|Paclitaxel With Trastuzumab and Lapatinib|Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.
11431074|NCT01827150|Experimental|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.
~Intervention: Drug: Redbull, energy drink"
11431075|NCT01827137|Experimental|vaccine|Galinpepimut-S (GPS) inoculations are started 12-22 d following autologous stem cell transplantation (ASCT). GPS (1.0 ml of emulsion) is given s.c. on weeks 0, 2, 4, 6, 8, & 10 (i.e., x 6). Injection sites are pre-stimulated with Sargramostim (GM-CSF; 70 μg) s.c. on d -2 (± 1 d ) & d 0 of each GPS inoculation. N.B.: during each GPS inoculation, the Sargramostim & GPS are administered to the same anatomical site. Subjects are observed for >/= 30 minutes after vaccination. Non-progressing subjects who are clinically stable (no active infection with fevers & no cardiovascular/respiratory compromise) may receive up to 6 more vaccinations q-month. The use of post-ASCT maintenance therapy with either lenalidomide or bortezomib is allowed starting >/= 3 months after ASCT.
11431076|NCT01827124|Experimental|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
11431077|NCT01827124|Experimental|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
11431078|NCT01827111|Experimental|ABI-007 + Ipilimumab|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. Ipilimumab 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses. Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
11431079|NCT01827098|Experimental|Delayed induction|The root canal is disinfected and calcium hydroxide is placed in the canal. Blood clot is induced in the canal 4 weeks later. Endodontic Regeneration is performed.
11431080|NCT01827098|Experimental|Immediate Induction|Blood clot is induced after disinfection of the canal during the same visit. Endodontic regeneration is performed.
11431081|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
11431082|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
11431083|NCT01827072|Experimental|NPB-01|Intravenous immunoglobulin
11431089|NCT01827020|Active Comparator|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
11431090|NCT01827020|Active Comparator|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
11431091|NCT01827020|Placebo Comparator|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
11431092|NCT01827007|Experimental|Study arm, elevation of PEEP|
11431093|NCT01826994|Other|patients|heart type fatty acid binding protein testing
11431094|NCT01826981|Experimental|Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)|LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
11431095|NCT01826981|Experimental|Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)|SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
11431096|NCT01826981|Experimental|Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)|LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
11431097|NCT01826981|Experimental|Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)|LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
11431098|NCT01826981|Experimental|Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)|LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
11431099|NCT01826981|Experimental|Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)|LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
11431100|NCT01826981|Experimental|Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)|LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
11431101|NCT01826981|Experimental|Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)|LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
11431102|NCT01826981|Experimental|Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)|LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
11431103|NCT01826981|Experimental|Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
11431104|NCT01826981|Experimental|Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
11431105|NCT01826981|Experimental|Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
11431106|NCT01826981|Experimental|Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
11431107|NCT01826981|Experimental|Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)|LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
11431108|NCT01826981|Experimental|Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)|LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
11431109|NCT01826968|Experimental|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
11431110|NCT01826968|No Intervention|Control Group|We did not used alveolar recruitment maneuver
11431111|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
11431112|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
11431113|NCT01826942|Experimental|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
11431114|NCT01826942|Experimental|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
11431115|NCT01826929|Experimental|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
11431116|NCT01826929|No Intervention|Usual care model|
11431117|NCT01826916|Experimental|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
11431118|NCT01826916|Experimental|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
11431119|NCT01826916|Experimental|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
11431120|NCT01826916|Experimental|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
11431121|NCT01826903||depressed mother/child dyad - intervention|
11431122|NCT01826903||depressed mother/child dyad - no intervention|
11431123|NCT01826903||non-depressed mother/child dyad|
11431124|NCT01826890|Experimental|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
11431192|NCT01826461|Placebo Comparator|Vehicle Foam|topical foam, 0% concentration, twice daily
11431193|NCT01826448|Experimental|Dose extension cohort|Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
11431194|NCT01826448|Experimental|Cohort 3|Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
11431125|NCT01826890|No Intervention|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
11431126|NCT01826877|Experimental|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
11431127|NCT01826864|Experimental|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
11431128|NCT01826864|Active Comparator|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
11431129|NCT01826851|Experimental|Exparel|266 mg Exparel, single-dose injection.
11431130|NCT01826851|Placebo Comparator|Placebo|0.9% Normal saline, single-dose injection.
11431131|NCT01826838|Experimental|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
11431132|NCT01826825||Clock in the box|Results of the Clock in the box cognitive screening test.
11431133|NCT01826825||Mini-Cog|Results of the mini-cog cognitive screen
11431134|NCT01826812||Dry Eye|"The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
11431135|NCT01826812||Controls|"The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
11431136|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
11431137|NCT01826786|Experimental|JNJ-42165279 (100 mg)|
11431138|NCT01826786|Placebo Comparator|Placebo|
11431139|NCT01826773|Experimental|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.
~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
11431140|NCT01826773|Experimental|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.
~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
11431141|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
11431142|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
11431143|NCT01826747|Experimental|experimental|Luteal Phase support
11431144|NCT01826747|No Intervention|control|No luteal Phase support
11431145|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
11431146|NCT01826721|No Intervention|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
11431147|NCT01826721|Active Comparator|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
11431148|NCT01826708|No Intervention|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
11431149|NCT01826695|Placebo Comparator|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
11431150|NCT01826695|Active Comparator|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
11431151|NCT01826682|Placebo Comparator|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
11431152|NCT01826682|Active Comparator|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
11431195|NCT01826448|Experimental|Cohort 2|Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
11518572|NCT01224860|Experimental|Losartan|
11431153|NCT01826669|Active Comparator|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:
~Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;
~Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;
~Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;
~Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;
~Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
11431154|NCT01826669|No Intervention|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
11431155|NCT01826656|Other|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
11431156|NCT01826656|Active Comparator|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
11431157|NCT01826630|Active Comparator|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
11431158|NCT01826630|Active Comparator|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
11431159|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
11431160|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
11431161|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
11431162|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
11431163|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
11431164|NCT01826604|Experimental|Alexis O C-section retractor|Alexis O C-section retractor will be used.
11431165|NCT01826604|Other|Control- Conventional retractors|Conventional retractors for C-sections will be used.
11431166|NCT01826591|Experimental|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
11431167|NCT01826591|Experimental|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
11431168|NCT01826578|Experimental|single port arm|
11431169|NCT01826578|No Intervention|Conventional arm|Using 3-4 port for laparosocpic surgery
11431170|NCT01826565|No Intervention|Control|i-gel will be inserted without rotation
11431171|NCT01826565|Experimental|Rotation|Rotational technique applied
11431172|NCT01826552|Experimental|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
11431173|NCT01826552|Active Comparator|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
11431174|NCT01826539|Other|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
11431175|NCT01826526|Active Comparator|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.
~The duration of TauroSept® administration in this trial will be 12 months."
11431176|NCT01826526|Placebo Comparator|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.
~The duration of saline administration in this trial will be 12 months."
11431177|NCT01826513|Experimental|Unblinded Investigational Arm|Participants participated in an unblinded investigational phase of the trial prior to, and separate from, the single-blind cross-over phase of the trial. Data was collected from the his phase to aid the final development of the algorithm before proceeding to algorithm validation (ie. cross-over phase).
11431178|NCT01826513|Active Comparator|Standard AutoSet algorithm|Participants first received therapy with the Standard AutoSet algorithm for one night, and then received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) the following night.
11431179|NCT01826513|Experimental|Modified AutoSet algorithm|Participants first received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) for one night, and then received therapy with the standard AutoSet algorithm the following night.
11431180|NCT01826500||Patients|"Patients having any of the following criteria:
~Patients with embryo transfer fresh or frozen
~Patients from an IVF cycle,
~Patients supported surgically for endometriosis"
11431181|NCT01826500||Controls|Controls
11431182|NCT01826487|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren orally 3 times a day (TID) at morning, midday, and evening for 48 weeks.
11431183|NCT01826487|Experimental|Ataluren|Participants will receive ataluren suspension orally TID, 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
11431184|NCT01826474|Experimental|PRO045, cohort 1|0.15 mg/kg until dose-titration
11431185|NCT01826474|Experimental|PRO045, cohort 2|1.0 mg/kg until dose-titration
11431186|NCT01826474|Experimental|PRO045, cohort 3|3.0 mg/kg until dose-titration
11431187|NCT01826474|Experimental|PRO045, cohort 4|6.0 mg/kg until dose-titration
11431188|NCT01826474|Experimental|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
11431189|NCT01826474|Experimental|PRO045, cohort 6|48 week treatment phase
11431190|NCT01826461|Experimental|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
11431191|NCT01826461|Experimental|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
11518713|NCT01223911|Placebo Comparator|B|
11431197|NCT01826435|Experimental|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
11431198|NCT01826422|Experimental|EPA and DHA|Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
11431199|NCT01826422|Placebo Comparator|Placebo Comparator|Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
11431200|NCT01826409|Experimental|Fermented red ginseng|
11431201|NCT01826409|Placebo Comparator|Placebo|
11431202|NCT01826396|Experimental|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
11431203|NCT01826383|Experimental|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
11431204|NCT01826383|Placebo Comparator|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
11431205|NCT01826370||Linagliptin|
11431206|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
11431207|NCT01826331|Experimental|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
11431208|NCT01826331|Experimental|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
11431209|NCT01826318|Experimental|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
11431210|NCT01826318|No Intervention|Control|Students in the control group did not receive any further instructions.
11431211|NCT01826305|Active Comparator|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
11431212|NCT01826305|Experimental|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
11431213|NCT01826279|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
11431214|NCT01826279|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for 1 month
11431215|NCT01826266|Placebo Comparator|PER977-Dose 1|Dose titration
11431216|NCT01826266|Placebo Comparator|PER977-Dose 2|Dose Titration
11431217|NCT01826266|Placebo Comparator|PER977-Dose 3|Dose Titration
11431218|NCT01826266|Placebo Comparator|PER977-Dose 4|Dose Titration
11431219|NCT01826266|Placebo Comparator|PER977-Dose 5|Dose Titration
11431220|NCT01826266|Placebo Comparator|PER977-Dose 6|Dose Titration
11431221|NCT01826266|Placebo Comparator|PER977-Dose 7|Dose Titration
11431222|NCT01826253||Hypovolemia|Fluid expansion
11431223|NCT01826240|Experimental|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
11431224|NCT01826227|Experimental|Positron Emission Tomography|This is a pilot study to determine the ability of intraoperative PET probe to detect and localize recurrent disease. Patients with evidence for a first recurrence of ovarian, fallopian tube or primary peritoneal carcinoma, with evidence of 18F-FDG avid disease on 18F-FDG PET/CT and who are able to undergo secondary CRS are eligible. 20 patients will be studied. All patients will undergo secondary cytoreduction guided by intraoperative PET probe survey. Intraoperative count levels as well as exvivo counts of the resected specimens will be done. Specimens detected with probe only will be labeled so and will be submitted to pathology for histopathologic confirmation.
11431225|NCT01826214|Experimental|LDE225-400|Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
11431226|NCT01826214|Experimental|LDE225-800|Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
11431227|NCT01826201|Experimental|10% MOL4239 ointment & placebo ointment|10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
11431228|NCT01826188|Active Comparator|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
11431229|NCT01826188|Placebo Comparator|Placebo|olive oil but without any active ingredients.
11431230|NCT01826175|Experimental|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
11431231|NCT01826175|Active Comparator|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
11431232|NCT01826162|Experimental|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
11431233|NCT01826162|Experimental|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
11431234|NCT01826149|Experimental|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
11431622|NCT01823510|Experimental|Ticagrelor + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
11431235|NCT01826149|Experimental|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
11431236|NCT01826149|Experimental|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
11431237|NCT01826136|Experimental|Acapella|use of the Acapella device postoperatively
11431238|NCT01826136|No Intervention|Control|
11431239|NCT01826123|Active Comparator|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
11431240|NCT01826123|Active Comparator|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
11431241|NCT01826110|Experimental|[11C]PIB|[11C]PIB
11431242|NCT01826097|Experimental|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
11431243|NCT01826071|No Intervention|Symptomatic Treatment|
11431244|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
11431245|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
11431246|NCT01826058|Experimental|Stereotactic body radiation therapy|"SBRT in one to four fractions
~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size
~1 fx: 16 to 24 Gy
~2 fx's: 20 to 26 Gy
~3 fx's: 21 to 30 Gy
~4 fx's: 24 to 36 Gy"
11431247|NCT01826045|Experimental|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
11431248|NCT01826045|Placebo Comparator|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
11431249|NCT01826032|Experimental|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.
~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
11431250|NCT01826032|Active Comparator|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
11431251|NCT01826019|Experimental|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm [precise formulations used may differ in each country]; use of treatment supporters to reinforce adherence.
11431252|NCT01826019|Other|Control - Usual Care|Participants in control communities will be referred to usual care.
11431253|NCT01826006|Active Comparator|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
11431254|NCT01826006|Active Comparator|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
11431255|NCT01825993|Experimental|PCA endovenous|1mg/10 min Morphine
11431256|NCT01825993|Active Comparator|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
11431257|NCT01825993|Active Comparator|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
11431258|NCT01825980|Experimental|BZF961|
11431259|NCT01825980|Placebo Comparator|Placebo|
11431260|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
11431261|NCT01825954|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
11431262|NCT01825954|Active Comparator|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
11431263|NCT01825954|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
11431264|NCT01825941|Active Comparator|Metoclopramide + Diphenhydramine|Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
11431265|NCT01825941|Placebo Comparator|Metoclopramide + placebo|Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
11431266|NCT01825928|Experimental|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
11431267|NCT01825928|Placebo Comparator|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
11431268|NCT01825915|Active Comparator|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
11431269|NCT01825915|Active Comparator|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
11431270|NCT01825902|Experimental|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
11431271|NCT01825889|Experimental|Evacetrapib (Participants With Renal Impairment)|Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment.
11431272|NCT01825889|Experimental|Evacetrapib (Healthy Participants)|Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function.
11431274|NCT01825876|Experimental|Evacetrapib + Warfarin|130 mg evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 10
11431275|NCT01825863|Active Comparator|Active abdominal wall block|60ml ropivacaine 0.375% single shot
11431276|NCT01825863|Placebo Comparator|Placebo abdominal wall block|60ml saline 9% single shot
11431277|NCT01825850|Experimental|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
11431278|NCT01825850|Experimental|Irbesartan|Irbesartan 300mg q.d. during 7 days
11431279|NCT01825850|Experimental|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
11431280|NCT01825837|Experimental|BIA 2-093 1800 mg (Group 1)|BIA 2-093 1800 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
11431281|NCT01825837|Experimental|BIA 2-093 900 mg (Group 2)|BIA 2-093 900 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
11431282|NCT01825837|Experimental|BIA 2-093 300 mg (Group 3)|BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
11431283|NCT01825837|Experimental|ESL (Part I)|In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
11431284|NCT01825824|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
11431285|NCT01825811|Experimental|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
11431286|NCT01825811|Experimental|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
11431287|NCT01825798|Placebo Comparator|Placebo Hydrochloride Oral Solution|
11431288|NCT01825798|Experimental|Metformin|
11431289|NCT01825785|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 2 weeks (Q2W) or once every 4 weeks (Q4W) for 3 months.
11431290|NCT01825785|Experimental|Romosozumab|Participants were randomized to receive romosozumab administered by subcutaneous injection at doses of 1 mg/kg Q2W, 2 mg/kg Q4W, 2 mg/kg Q2W, or 3 mg/kg Q4W for 3 months.
11431291|NCT01825759|Experimental|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
11431292|NCT01825746|Active Comparator|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
11431293|NCT01825746|Other|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
11431294|NCT01825733|Experimental|ramosetron|
11431295|NCT01825733|Active Comparator|palonosetron|
11431296|NCT01825720|Experimental|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
11431297|NCT01825720|Active Comparator|normal saline group|same rate of normal saline
11431298|NCT01825707|Experimental|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg
11431299|NCT01825694|No Intervention|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
11431300|NCT01825694|Experimental|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
11431301|NCT01825681|Experimental|positive affect intervention|positive affect intervention
11431302|NCT01825681|No Intervention|wait list control|wait list control
11431303|NCT01825668|Experimental|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
11431304|NCT01825668|Experimental|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
11431305|NCT01825668|Placebo Comparator|Placebo|50 mg cholesterol/day in 240 ml of milk shake
11431306|NCT01825655|Active Comparator|Cetirizine|zyrtec 10mg, oral, one time
11431307|NCT01825655|Placebo Comparator|Sugar pill|Placebo, one pill, one time
11431308|NCT01825642|Active Comparator|Control Group|nerve-sparing radical prostatectomy
11431309|NCT01825642|Active Comparator|Treatment Group|seminal vesicle-sparing radical prostatectomy
11431310|NCT01825629|Experimental|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
11431311|NCT01825629|Placebo Comparator|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
11431312|NCT01825616|Experimental|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
11431313|NCT01825616|Placebo Comparator|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
11431314|NCT01825603|Experimental|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
11431315|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
11431316|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
11431355|NCT01825252|Active Comparator|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
11431317|NCT01825577|Experimental|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
11431318|NCT01825551|Active Comparator|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
11431319|NCT01825551|Placebo Comparator|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
11431320|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
11431321|NCT01825525|Experimental|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
11431322|NCT01825512|Experimental|Deferiprone|75-100 mg/kg/day seven days per week
11431323|NCT01825512|Active Comparator|Deferasirox|20 to 40 mg/kg/day seven days per week
11431324|NCT01825499||Very low birth weight infants|Infants 401 to 1500 g or 22 to 29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
11431325|NCT01825486||accidental falls|
11431326|NCT01825473|Experimental|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
11431327|NCT01825473|Placebo Comparator|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
11431328|NCT01825460|Experimental|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
11431329|NCT01825460|Active Comparator|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
11431330|NCT01825447|Placebo Comparator|Treatment A|
11431331|NCT01825447|Experimental|Treatment B|
11431332|NCT01825447|Active Comparator|Treatment C|
11431333|NCT01825434|Active Comparator|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
11431334|NCT01825434|Placebo Comparator|Placebol group|regular yogurt, 1 time per day for 30 days.
11431335|NCT01825421|No Intervention|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
11431336|NCT01825421|Active Comparator|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
11431337|NCT01825408|Active Comparator|Doxycycline, 3 weeks|Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 3 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
11431338|NCT01825408|Active Comparator|Doxycycline, 6 weeks|Subjects with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 6 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
11431339|NCT01825408|Active Comparator|Azithromycin, 3 weeks|Subjects with Chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 3 weeks duration.
11431340|NCT01825408|Active Comparator|Azithromycin, 6 weeks|Subjects with chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 6 weeks duration.
11431341|NCT01825382|No Intervention|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
11431342|NCT01825382|Experimental|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
11431343|NCT01825369|Experimental|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
11431344|NCT01825356|Active Comparator|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
11431345|NCT01825356|Experimental|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
11431346|NCT01825330|Active Comparator|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
11431347|NCT01825330|Sham Comparator|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
11431348|NCT01825317|Active Comparator|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
11431349|NCT01825317|Sham Comparator|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
11431350|NCT01825304|Active Comparator|esophageal pressure ,titrated setting|
11431351|NCT01825304|Other|ARDSNet recommendations,peep|
11431352|NCT01825291||sleep apnea|
11431353|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
11431354|NCT01825252|Experimental|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
11431356|NCT01825239|Other|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
11431357|NCT01825226|Experimental|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
11431358|NCT01825226|No Intervention|Control|
11431359|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
11431360|NCT01825200|Active Comparator|Flublok|Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
11431361|NCT01825200|Placebo Comparator|Afluria|Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
11431362|NCT01825187|Active Comparator|Treatment Group 1|Patients in this group will be randomized to receive the ULTRAPRO mesh
11431363|NCT01825187|Active Comparator|Treatment Group 2|Patients in this group will be randomized to receive the 3DMAX Mesh
11431364|NCT01825187|Other|Evaluation of Surgical Residents|Surgical residents will be evaluated on the ease of use and the amount of time it takes for them to perform the surgery using these two different meshes.
11431365|NCT01825174|Active Comparator|Non-overweight children in ball games program|twice a week different ball games 90min
11431366|NCT01825174|Experimental|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
11431367|NCT01825174|Placebo Comparator|Control group overweight children|No intervention during six months
11431368|NCT01825174|Experimental|Overweight children in ball games program|twice a week different ball games 90min
11431369|NCT01825174|Experimental|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
11431370|NCT01825174|Placebo Comparator|Non-overweight control (no intervention)|
11431371|NCT01825148||Type 1 Diabetes|patients with long standing T1D
11431372|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
11431373|NCT01825135|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
11431374|NCT01825135|Sham Comparator|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
11431375|NCT01825122|Placebo Comparator|Placebo|placebo
11431376|NCT01825122|Experimental|Active, nadolol|Active
11431377|NCT01825109|Experimental|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
11431378|NCT01825109|Experimental|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
11431379|NCT01825109|Experimental|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
11431380|NCT01825109|Experimental|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
11431381|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
11431382|NCT01825083|Active Comparator|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
11431383|NCT01825083|Placebo Comparator|Placebo|Saline group will received the same volume in saline as the ketamine dose
11431384|NCT01825070|Experimental|low dose|Montmorency cherry concentrate, 30 mls
11431385|NCT01825070|Experimental|higher dose|Montmorency cherry concentrate, 60 mls
11431386|NCT01825057|Active Comparator|Workshop (See One)|MI workshop training (referred to as SEE ONE).
11431387|NCT01825057|Experimental|Workshop plus live supervision (Do One)|MI workshop training plus live supervision of bedside practice (DO ONE).
11431388|NCT01825057|Experimental|Workshop plus consultation-liason service (Order One)|MI workshop training plus capacity to order MI from CL (ORDER ONE).
11431389|NCT01825044|Active Comparator|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
11431390|NCT01825044|Active Comparator|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
11431391|NCT01825031|Experimental|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
11431392|NCT01825031|Experimental|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
11431393|NCT01825031|Experimental|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
11431394|NCT01825018|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
11431395|NCT01825018|Active Comparator|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
11431396|NCT01825005||group 1:surgery|treatment = surgery only
11431397|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
11431398|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
11431399|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
11431400|NCT01824992|No Intervention|Observation|subject only got observation
11431480|NCT01824498|Experimental|High Fat, Low fat High Omega 3, Low Fat|See Intervention Description
11431401|NCT01824992|Experimental|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
11431402|NCT01824979|Experimental|Pilairo mask|Pilairo nasal pillows mask during CPAP titration
11431403|NCT01824979|Active Comparator|Other CPAP mask|Other CPAP mask during CPAP titration
11431404|NCT01824966||SRC<50%|Adenocarcinoma containing < 50% of signet ring cells
11431405|NCT01824966||SRC>50%|Adenocarcinoma containing > 50% of signet ring cells
11431406|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
11431407|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
11431408|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
11431409|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
11431410|NCT01824940|Placebo Comparator|Standard of Care|The Standard of Care interventions are the blanket interventions.
11431411|NCT01824940|Active Comparator|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:
~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
11431412|NCT01824940|Active Comparator|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:
~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
11431413|NCT01824940|Active Comparator|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
11431414|NCT01824927|Active Comparator|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
11431415|NCT01824927|Active Comparator|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
11431416|NCT01824927|Experimental|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
11431417|NCT01824914|Experimental|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
11431418|NCT01824901|Experimental|Phase I|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11431419|NCT01824901|Experimental|Arm I (docetaxel; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
11431420|NCT01824901|Experimental|Arm II (docetaxel and AZD4547; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11431421|NCT01824901|Experimental|Phase II step II|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11431422|NCT01824888|Active Comparator|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
11431423|NCT01824888|Experimental|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
11431424|NCT01824875|Experimental|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11431425|NCT01824875|Experimental|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11431426|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
11431427|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
11431428|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
11431429|NCT01824849|Experimental|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
11431430|NCT01824849|Experimental|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
11431431|NCT01824836|Experimental|Supportive care (anastrozole)|Patients receive anastrozole PO QD for 12 months.
11431432|NCT01824823|Experimental|Arm A (afatinib)|Patients receive afatinib PO QD on days 1-28.
11431433|NCT01824823|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28.
11431434|NCT01824810|Experimental|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
11431435|NCT01824810|Experimental|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
11431436|NCT01824810|Experimental|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
11431437|NCT01824810|Sham Comparator|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
11432869|NCT01814826|Experimental|MLN4924 and Azacitidine|
11431438|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
11431439|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
11431440|NCT01824758|Experimental|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
11431441|NCT01824758|Active Comparator|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
11431442|NCT01824758|Placebo Comparator|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
11431443|NCT01824745|Experimental|Arm I (SCP-BCS template booklet and counseling)|Participants receive SCP-BCS template booklet and receive counseling sessions with a patient navigator for 40 minutes twice weekly for 4 sessions.
11431444|NCT01824745|Active Comparator|Arm II (SCP-BCS template booklet)|Participants receive SCP-BCS template booklet and receive standard follow-up care.
11431445|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
11431446|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
11431447|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
11431448|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
11431449|NCT01824706||craniectomy|craniectomy
11431450|NCT01824693|Experimental|Arm I (busulfan, cyclophosphamide, melphalan)|"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.
~TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.
~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
11431451|NCT01824693|Experimental|Arm II (busulfan, fludarabine phosphate)|"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.
~TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.
~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
11431452|NCT01824680|Experimental|obesity|
11431453|NCT01824667|Experimental|B-GOS|2.75g daily for 4 weeks
11431454|NCT01824667|Placebo Comparator|Maltodextrin|2.75g daily for 4 weeks
11431455|NCT01824654|Experimental|Rigid and Elastic registration softwares|
11431456|NCT01824641|Experimental|Eliminate|Eliminate aspiration catheter
11431457|NCT01824641|Active Comparator|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
11431458|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
11431459|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
11431460|NCT01824615|Experimental|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
11431461|NCT01824602|Experimental|Group 1|Eslicarbazepine acetate 1800 mg
11431462|NCT01824602|Experimental|Group 2|Eslicarbazepine acetate 1200 mg
11431463|NCT01824602|Experimental|Group 3|Eslicarbazepine acetate 600 mg
11431464|NCT01824602|Placebo Comparator|Group 4|Placebo pills
11431465|NCT01824589|Active Comparator|Group A|tidal volume setting of 6ml/kg with the -7cm H2O ITPR as first device
11431466|NCT01824589|Active Comparator|Group B|tidal volume setting of 8ml/kg with the -7cm H2O ITPR as first device
11431467|NCT01824589|Active Comparator|Group C|tidal volume setting of 6ml/kg with the -12cm H2O ITPR as first device
11431468|NCT01824589|Active Comparator|Group D|tidal volume setting of 8ml/kg with the -12cm H2O ITPR as first device
11431469|NCT01824576|Experimental|ITPR|Use of the ITPR for 120 minutes.
11431470|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
11431471|NCT01824550|Experimental|home-based exercise training condition|Home based endurance exercise training
11431472|NCT01824550|No Intervention|attention control condition|Attention control condition - home based flexibility training
11431473|NCT01824537|Active Comparator|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and 18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
11431474|NCT01824537|Placebo Comparator|Hepatitis A vaccine|"The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
11431475|NCT01824524|Experimental|OROS Hydromorphone|
11431476|NCT01824511|Experimental|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
11431477|NCT01824498|Experimental|Low Fat, High Fat, Low Fat High Omega 3|See Intervention Description
11431478|NCT01824498|Experimental|Low Fat, Low Fat High Omega 3, High Fat|See Intervention Description
11431479|NCT01824498|Experimental|High Fat, Low Fat, Low Fat High Omega 3|See Intervention Description
11431483|NCT01824485|Experimental|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
11431484|NCT01824485|Experimental|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
11431485|NCT01824472|Active Comparator|CPAP+CC|Continuous Positive Airway Pressure (CPAP) therapy for sleep apnea and contact control (CC) (placebo/sham for cognitive-behavioral therapy for insomnia)
11431486|NCT01824472|Sham Comparator|sham CPAP+CC|sham CPAP (ineffective CPAP--placebo/sham for sleep apnea) and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
11431487|NCT01824472|Active Comparator|CPAP+CBT|CPAP therapy for sleep apnea and cognitive-behavioral therapy (CBT) for insomnia
11431488|NCT01824459|Active Comparator|S-1 + cisplatin(SP)|S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
11431489|NCT01824459|Experimental|S-1+Oxaliplatin（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
11431490|NCT01824446|Experimental|Radiolabeled SPD602|
11431491|NCT01824433|Active Comparator|venlafaxine|venlafaxine 75-225mg qd
11431492|NCT01824433|Active Comparator|fluoxetine|fluoxetine 20-60mg qd
11431493|NCT01824420|Experimental|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
11431494|NCT01824420|Experimental|Control group|Tolterodine (Detrusitol) 4mg QD
11431495|NCT01824407|Active Comparator|Active device plus standard of care|Active device plus standard of care
11431496|NCT01824407|Sham Comparator|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
11431497|NCT01824394|Experimental|nMARQ Catheter|nMARQ Catheter System
11431498|NCT01824394|Active Comparator|NaviStar ThermoCool Catheters|THERMOCOOL® Navigational family of catheters
11431499|NCT01824381|Experimental|Amniotic membrane in large wounds|
11431500|NCT01824368|Experimental|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
11431501|NCT01824355|Experimental|Intended Users of the Monitoring System|"Untrained subjects with diabetes used the Ninja 3 PLUS Investigational BG Monitoring System. General enrollment criteria for the 'Intended Users' population:
~At least 60% of subjects were younger than 65 years of age.
~At least 20% had type 1 diabetes.
~At least 50% with type 2 diabetes were insulin users."
11431502|NCT01824342|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
11431503|NCT01824329|Active Comparator|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
11431504|NCT01824329|Active Comparator|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
11431505|NCT01824303|Experimental|LiRIS 400 mg|LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
11431506|NCT01824303|Placebo Comparator|LiRIS Placebo|LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
11431507|NCT01824290|Experimental|Tadalafil|"Period 1: 20 mg or 40 mg administered orally by tablets once a day.
~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.
~Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to <40 kg: administered orally by tablets once a day. Light weight cohort <25 kg: administered orally by suspension once a day.
~Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension)."
11431508|NCT01824290|Placebo Comparator|Placebo|"Period 1: Participants received placebo orally by tablets once a day.
~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.
~Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort.
~Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group."
11431509|NCT01824277|No Intervention|Group 1|Group 1 - Standard Pre-operative Diabetes Care
11431510|NCT01824277|Experimental|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
11431511|NCT01824264|Experimental|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
11431512|NCT01824264|Experimental|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
11431513|NCT01824264|Experimental|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
11431514|NCT01824264|Experimental|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
11431515|NCT01824264|Experimental|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
11431516|NCT01824264|Experimental|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
11431517|NCT01824264|Experimental|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
11431518|NCT01824264|Active Comparator|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
11431519|NCT01824264|Placebo Comparator|Placebo|Patients receive placebo for 12 weeks
11431520|NCT01824251|Experimental|NPB-01|Intravenous immunoglobulin
11431521|NCT01824238|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
11431522|NCT01824238|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
11431523|NCT01824225|Active Comparator|PRN injection of aflibercept|Intravitreal aflibercept
11431524|NCT01824225|Active Comparator|Two months injection of aflibercept|Intravitreal afilibercept
11432962|NCT01814137|Experimental|IDegAsp BID + IAsp OD|
11431525|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
11431526|NCT01824199|Experimental|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
11431527|NCT01824186|Experimental|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
11431528|NCT01824186|Active Comparator|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
11431529|NCT01824173|Experimental|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
11431530|NCT01824173|Experimental|Amino acid Infusion in Obese|Amino acid Infusion in Obese
11431531|NCT01824173|Experimental|Exercise in lean|Exercise in lean
11431532|NCT01824173|Experimental|Exercise in Obese|Exercise in Obese
11431533|NCT01824160|Other|Repair of RV-PA Conduit Disruption|Covered stenting of RV-PA conduit injury
11431534|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
11431535|NCT01824134|Active Comparator|Klean & Klear|aloe vera gel
11431536|NCT01824134|Active Comparator|The Skin Gel|aloe vera gel
11431537|NCT01824121|Active Comparator|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
11431538|NCT01824121|Sham Comparator|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
11431539|NCT01824108|Active Comparator|control group: Lumbar discectomy|Lumbar discectomy alone
11431540|NCT01824108|Experimental|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
11431541|NCT01824095|Placebo Comparator|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
11431542|NCT01824095|Experimental|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.
~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
11431543|NCT01824082|Experimental|Ropivacaine 0.5%|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: normal saline.
11431544|NCT01824082|Placebo Comparator|Normal saline (salt water) infusion|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of normal saline placebo fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: ropivacaine 0.5%.
11431545|NCT01824069|Experimental|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
11431546|NCT01824056|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
11431547|NCT01824043|Experimental|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
11431548|NCT01824030|Active Comparator|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
11431549|NCT01824030|Active Comparator|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:
~percentage area stenosis ≥75 %
~percentage area stenosis between 50 and 75% and minimal lumen area <2.5 mm2
~percentage area stenosis between 50 and 75% and major plaque ulceration"
11431550|NCT01824017|Other|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
11431623|NCT01823510|Active Comparator|Clopidogrel + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
11431624|NCT01823497|Active Comparator|Parent/Nurse Controlled Analgesia|Parent/Nurse Controlled Analgesia will be the method of morphine delivery.
11431551|NCT01824004|Experimental|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
11431552|NCT01823991|Experimental|COGNUTRIN (VITABLUE and n-3 fatty acids)|Participants will be provided with two bottles containing Lovaza and VitaBlue. Participants will be asked to take 1 tablet of Lovaza two times a day and 1 tablet of VitaBlue three times a day.
11431553|NCT01823991|Placebo Comparator|Placebo Administration|Participants will be provided with two bottles containing placebo. Participants will be asked to take 1 tablet of one placebo two times a day and 1 tablet of other placebo three times a day.
11431554|NCT01823978|Experimental|BPX-201|BPX-201 vaccine plus AP1903
11431555|NCT01823965|Experimental|ranibizumab|
11431556|NCT01823952||Males|Adult 18-65
11431557|NCT01823939|Other|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
11431558|NCT01823939|Other|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
11431559|NCT01823926|Active Comparator|Control Group|Noninvasive ventilation + jet nebulizer
11431560|NCT01823926|Experimental|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
11431561|NCT01823913|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
11431562|NCT01823900|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
11431563|NCT01823887|Experimental|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
11431564|NCT01823887|Experimental|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
11431565|NCT01823874|Experimental|ID virtual reality distraction|virtual reality distraction
11431566|NCT01823874|Experimental|HMD virtual reality distraction|virtual reality distraction
11431567|NCT01823861|Experimental|Mobile phone-based intervention|Standard care plus automated voice message to support post-abortion contraception use every two weeks for total of three months and direct follow up phone call by family planning counsellor depending on response to voice message.
11431568|NCT01823861|No Intervention|Standard care|Face-to-face post-abortion family planning (PAFP) counselling, follow-up at one or two weeks, clinic phone number, existing 'Hotline' phone number.
11431569|NCT01823848|Active Comparator|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
11431570|NCT01823848|Active Comparator|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
11431571|NCT01823848|Experimental|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
11431572|NCT01823835|Experimental|GDC-0810 + Palbociclib and/or an LHRH Agonist|The starting dose for Cohort C1 dose escalation of GDC-0810 will be 400 mg per day on Days 1 to 28 of a 28-day schedule, taken together with 125 mg palbociclib administered on Days 1 to 21 of a 28-day schedule. Dose escalation will be performed in Cohort C1. In Cohort D1, GDC-0810 600 mg will be administered orally on Days 1 to 28 of a 28-day schedule and an LHRH agonist administered monthly. Treatments will continue until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
11431573|NCT01823835|Experimental|GDC-0810 Single Agent|During dose escalation (Phase I), GDC-0810 will be administered orally once daily in ascending-dose levels with a starting dose of 100 milligrams (mg) once daily. During dose expansion (Phase IIa), GDC-0810 will be administered at the MTD or RP2D define in dose escalation part of the study. Treatments will continue until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
11431574|NCT01823822|Experimental|Oral protein supplement (Tested product)|
11431575|NCT01823822|Active Comparator|Iso-caloric supplement (Control product)|
11431576|NCT01823809|Other|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
11431577|NCT01823796||Healthy women.|35 healthy women. Control group.
11431578|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
11431579|NCT01823783|Other|DMD infant|Muscle biopsy
11431580|NCT01823783|Other|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
11431581|NCT01823770|Active Comparator|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
11431582|NCT01823770|Placebo Comparator|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
11431583|NCT01823770|No Intervention|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
11431584|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
11431585|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
11431586|NCT01823744|Experimental|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.
~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
11431587|NCT01823705|Experimental|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
11431625|NCT01823497|Active Comparator|Continuous Opioid Infusion|Continuous Opioid Infusion will be the method used to deliver morphine to group 2
11518714|NCT01223898|Experimental|Nilotinib|
11431588|NCT01823692|Other|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
11431589|NCT01823679|Experimental|Capecitabine 1000 mg/m²|"Participants will receive oral capecitabine twice-a-day (BID) as 500 mg/m² doses on days 1 to 14.
~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11431590|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
11431591|NCT01823666||Control|Normal cognition.
11431592|NCT01823653|Experimental|Treated Thigh|Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)
11431593|NCT01823640|Experimental|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
11431594|NCT01823640|Experimental|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
11431595|NCT01823627|Other|Spirometry with reversibility test|Spirometry with reversibility test
11431596|NCT01823614||Naïve patients, >500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is more than 500 cells per mm3
11431597|NCT01823614||Naïve patients, 350-500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is between 350 and 500 cells per mm3
11431598|NCT01823614||Naïve patients, <350|The group contains patients who have not any ARV therapy experience and the level of CD4 count is less than 350 cells per mm3
11431599|NCT01823614||ARVT <6 months|The group contains patients who have ARVT experience and obtain ART treatment less than 6 months
11431600|NCT01823614||ARVT from 6 months to 3 years|The group contains patients who have ARVT experience and obtain ART treatment from 6 months to 3 years
11431601|NCT01823614||ARVT >3 years|The group contains patients who have ARVT experience and obtain ART treatment more than 3 years
11431602|NCT01823601|Active Comparator|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
11431603|NCT01823601|Experimental|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
11431604|NCT01823588|No Intervention|Usual care|Educational program and usual cardiovascular prevention.
11431605|NCT01823588|Experimental|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
11431606|NCT01823575|Experimental|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
11431607|NCT01823575|Active Comparator|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
11431608|NCT01823562|Active Comparator|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
11431609|NCT01823562|Active Comparator|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
11431610|NCT01823562|Active Comparator|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
11431611|NCT01823562|Experimental|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
11431612|NCT01823562|Experimental|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
11431613|NCT01823562|Experimental|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
11431614|NCT01823562|Experimental|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
11431615|NCT01823536|Experimental|MenACWY-CRM (≥7-≤10 years of age)|Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
11431616|NCT01823536|Experimental|MenACWY-CRM_1 (≥7-≤10 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
11431617|NCT01823536|Experimental|Vaccine naive (≥7-≤10 years of age)|Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
11431618|NCT01823536|Experimental|MenACWY-CRM_1 (≥11-≤15 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.
11431619|NCT01823536|Experimental|Vaccine naive (≥11-≤15 years of age)|Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
11431620|NCT01823523|Active Comparator|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin
~Clindamycin will be used in patients with allergy"
11431621|NCT01823523|Placebo Comparator|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo
~clindamycin will be used if patient has allergy"
11431626|NCT01823484|Experimental|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
11431627|NCT01823484|Active Comparator|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
11431628|NCT01823471|Experimental|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
11431629|NCT01823471|Active Comparator|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
11431630|NCT01823458|Experimental|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
11431631|NCT01823458|Experimental|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
11431632|NCT01823445|Experimental|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
11431633|NCT01823432||BAV Cohort|Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.
11431634|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
11431635|NCT01823406|Experimental|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
11431636|NCT01823406|Experimental|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
11431637|NCT01823406|Experimental|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
11431638|NCT01823406|Experimental|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
11431639|NCT01823393|Experimental|Heparin|injection of unfractionated heparin (50 IU / kg)
11431640|NCT01823393|Placebo Comparator|NaCl|without heparin
11431641|NCT01823380|Other|Amyotrophic lateral sclerosis|Blood test
11431642|NCT01823367|Experimental|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
11431643|NCT01823367|Experimental|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
11431644|NCT01823354|Other|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
11431645|NCT01823354|Other|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
11431646|NCT01823341|Active Comparator|Pump suspension algorithm|The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
11431647|NCT01823341|No Intervention|Standard of Care|The control algorithm will run passively and not suspend the patient's pump.
11431648|NCT01823328|Active Comparator|Ketamine|Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
11431649|NCT01823328|Active Comparator|Etomidate|Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
11431650|NCT01823315|Experimental|Methotrexate Single-coure chemotherapy|Regimen: Methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5. If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen.
11431713|NCT01822899|Experimental|Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS|Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.
11431651|NCT01823315|Experimental|Methotrexate+dactinomycin Single-dose chemotherapy|"Regimen: dactinomycin d 0.6mg/m2, IV, on day1, 2; methotrexate 100mg/m2, IV, on day1 (after Act-d); methotrexate 200mg/m2, IVgtt, on day1 (after methotrexate, 500ml NS, >4h).
~If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen."
11431652|NCT01823315|Active Comparator|MTX multiple courses chemotherapy|"Regimen: methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive at least 1 additional consolidation treatment.
~After treatment, all the patients were asked for contraception with condom or oral contraception. Regular hCG surveillance, once a month for 3 consecutive months and once every 3 months for 2 years, was performed. During follow-up period, pelvic ultrasound and pulmonary X ray or CT scan were conducted if needed."
11431653|NCT01823302|Other|nutritional counseling|nutritional counseling
11431654|NCT01823302|Other|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
11431655|NCT01823289|Experimental|Itraconazole Sequential Therapy|
11431656|NCT01823276|Active Comparator|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
11431657|NCT01823276|Placebo Comparator|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
11431658|NCT01823263|Experimental|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
11431659|NCT01823263|Experimental|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
11431660|NCT01823250|Experimental|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
11431661|NCT01823250|Active Comparator|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
11431662|NCT01823237|Active Comparator|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
11431663|NCT01823237|Placebo Comparator|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
11431664|NCT01823224|Experimental|Group 1|"Group 1 will receive IV acetaminophen 1000mg plus 2 oral capsules sugar pills 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses of acetaminophen totaling or equaling 2000mg"
11431665|NCT01823224|Experimental|Group 2|"Group 2 will receive an IV salt water infusion plus 2 capsules of oral acetaminophen 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses totaling or equaling 2000mg."
11431666|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
11431667|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
11431668|NCT01823198|Experimental|Treatment (NK cells, PBSC transplant)|Patients receive fludarabine phosphate IV over 1 hour and busulfan IV over 3 hours on days -13 to -10. Patients then receive allogeneic CD56-positive CD3-negative natural killer cells IV over 1 hour on day -8. Patients also receive aldesleukin SC QD on days -8 to -4. Patients then undergo allogeneic PBSC transplant on day 0.
11431669|NCT01823185|Active Comparator|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
11431670|NCT01823185|Experimental|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
11431671|NCT01823172|Experimental|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
11431672|NCT01823159|Active Comparator|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
11431673|NCT01823159|Placebo Comparator|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
11431674|NCT01823146|Experimental|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
11431675|NCT01823146|Placebo Comparator|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
11431676|NCT01823133|Experimental|gemigliptin only|Multiple administrations of gemigliptin
11431677|NCT01823133|Experimental|rosuvastatin only|Multiple administrations of rosuvastatin
11431678|NCT01823133|Experimental|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
11431679|NCT01823120|No Intervention|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
11431711|NCT01822912|Active Comparator|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
11431712|NCT01822912|Placebo Comparator|Heart Failure Usual Care|SNF patients with HF will receive usual care
11432963|NCT01814137|Experimental|IDeg OD + IAsp TID|
11431680|NCT01823120|Experimental|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
11431681|NCT01823107|Experimental|Meso BioMatrix Device|All subjects will have the Meso BioMatrix device implanted along with a tissue expander during the first stage of breast reconstruction. During the second stage of breast reconstruction, the tissue expander is replaced with a breast implant.
11431682|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
11431683|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
11431684|NCT01823081|Active Comparator|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
11431685|NCT01823081|Active Comparator|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
11431686|NCT01823068|Experimental|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
11431687|NCT01823055|Experimental|Surgery|Transvaginal suture capturing mesh device
11431688|NCT01823042|Experimental|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
11431689|NCT01823042|Experimental|azathioprine|Patients have regular diet and receive only azathioprine treatment.
11431690|NCT01823029|Experimental|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
11431691|NCT01823029|Experimental|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
11431692|NCT01823016|Placebo Comparator|Placebo|
11431693|NCT01823016|Experimental|JNJ-38518168|
11431694|NCT01823003|Experimental|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
11431695|NCT01823003|Experimental|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
11431696|NCT01823003|Experimental|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
11431697|NCT01823003|Experimental|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
11431698|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
11431699|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
11431700|NCT01822977|No Intervention|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.
~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
11431701|NCT01822964|Active Comparator|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
11431702|NCT01822964|Placebo Comparator|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
11431703|NCT01822951|Experimental|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.
~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
11431704|NCT01822951|Active Comparator|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.
~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
11431705|NCT01822938|Experimental|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
11431706|NCT01822938|No Intervention|control group|No intervention
11431707|NCT01822925|Experimental|DA-9801 300mg|DA-9801 will be administered in tablet form, 100mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
11431708|NCT01822925|Experimental|DA-9801 600mg|DA-9801 will be administered in tablet form, 200 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
11431709|NCT01822925|Experimental|DA-9801 900mg|DA-9801 will be administered in tablet form, 300 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
11431710|NCT01822925|Placebo Comparator|Placebo|Placebo (same formulation as DA-9801 but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 12 weeks.
11431714|NCT01822899|Active Comparator|Fluticasone propionate/Salmeterol + placebo NDPI|Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.
11431715|NCT01822886|Experimental|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
11431716|NCT01822873||Normal|
11431717|NCT01822873||Age-related macular degeneration|
11431718|NCT01822860|Placebo Comparator|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
11431719|NCT01822860|Experimental|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
11431720|NCT01822860|Active Comparator|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
11431721|NCT01822847||catheterization|patients undergoing elective heart catheterization
11431722|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
11431723|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
11431724|NCT01822821|Experimental|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
11431725|NCT01822821|Placebo Comparator|Placebo|Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
11431726|NCT01822808|Active Comparator|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
11431727|NCT01822808|Active Comparator|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
11431728|NCT01822795|Experimental|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
11431729|NCT01822795|Other|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
11431730|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
11431731|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
11431732|NCT01822769|Experimental|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly ~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
11431733|NCT01822769|Other|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
11431734|NCT01822756|Experimental|Regimen A -ruxolitinib, gemcitabine|Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
11431735|NCT01822756|Experimental|Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim|"Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.
~Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored.
~nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle."
11431736|NCT01822743|Experimental|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
11431737|NCT01822743|Sham Comparator|Sham comparator|sham Osteopathic pterygopalatine node compression
11431738|NCT01822730|Experimental|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
11431739|NCT01822730|Active Comparator|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
11431740|NCT01822717|Experimental|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
11431741|NCT01822717|Active Comparator|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
11431742|NCT01822704|Active Comparator|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
11431743|NCT01822704|Experimental|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
11431744|NCT01822704|Experimental|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
11431745|NCT01822691|Experimental|INCB024360 Treatment|Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.
11431746|NCT01822678|Experimental|Group 1|Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
11431747|NCT01822678|Experimental|Group 2|Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
11431748|NCT01822678|Placebo Comparator|Group 3|Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
11431825|NCT01822210|Experimental|Botox|Injection of Botox in the tumor and surrounding stomach wall.
11431749|NCT01822665|Active Comparator|Paracetamol Tablet|Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
11431750|NCT01822665|Active Comparator|Ibuprofen Tablet|Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
11431751|NCT01822665|Placebo Comparator|Placebo Tablet|Placebo tablets, 2 tablets QID administered with water.
11431752|NCT01822665|Active Comparator|Ibuprofen Capsule|Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water
11431753|NCT01822652|Experimental|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
11431754|NCT01822652|Experimental|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
11431755|NCT01822652|Experimental|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
11431756|NCT01822639|Experimental|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
11431757|NCT01822639|Experimental|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
11431758|NCT01822626|Experimental|motivational counseling|
11431759|NCT01822626|No Intervention|Usual Care|
11431760|NCT01822613|Experimental|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
11431761|NCT01822613|Active Comparator|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
11431762|NCT01822600|Experimental|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.
~Patients in this group receive intravenous omeprazole treatment."
11431763|NCT01822600|Experimental|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L.
~Patients in this group receive both Human albumin and intravenous omeprazole."
11431764|NCT01822600|Experimental|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.
~Patients in this group receive intravenous omeprazole treatment."
11431765|NCT01822587|Placebo Comparator|Placebo|Administered once orally following cue exposure on each of the first two days of testing.
11431766|NCT01822587|Active Comparator|Propranolol 40mg|Administered once orally following cue exposure on each of the first two days of testing.
11431767|NCT01822587|Active Comparator|Propranolol, 80mg|Administered once orally following cue exposure on each of the first two days of testing.
11431768|NCT01822574|Active Comparator|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
11431769|NCT01822574|Active Comparator|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
11431770|NCT01822574|Active Comparator|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
11431771|NCT01822561|Experimental|Eplerenone|All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
11431772|NCT01822548|Experimental|Vildagliptin & metformin|Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
11431773|NCT01822548|Active Comparator|Glibenclamide & metformin|Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
11431774|NCT01822535|No Intervention|No Drug: Tetraplegia|"Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.
~Exposure of up to 2 hours in a cool room."
11431775|NCT01822535|No Intervention|No Drug: AB Controls|AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
11431776|NCT01822535|Experimental|Drug (midodrine): Tetraplegia|Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)
11431777|NCT01822522|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11431778|NCT01822509|Experimental|Treatment (ipilimumab, nivolumab)|See Detailed Description.
11431779|NCT01822496|Experimental|EGFR: Erlotinib|Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
11520959|NCT01208350|Active Comparator|3|
11431780|NCT01822496|Active Comparator|EGFR: No Erlotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
11431781|NCT01822496|Experimental|ALK: Crizotinib|Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
11431782|NCT01822496|Active Comparator|ALK: No Crizotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
11431783|NCT01822483|Experimental|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
11431784|NCT01822483|Active Comparator|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
11431785|NCT01822470||Study group|a. Study Subjects will be recruited from patients who are already undergoing upper enteroscopy and aspiration for diagnosis of SIBO.
11431786|NCT01822470||Control group|b. Control Subjects will be recruited from patients who are already undergoing a double balloon enteroscopy or upper enteroscopy for another medical reason
11431787|NCT01822457|Experimental|Nike FuelBand (NFB)|Patients will receive a Nike Fuel Band to encourage exercise.
11431788|NCT01822457|No Intervention|control|Standard follow-up
11431789|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
11431790|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
11431791|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
11431792|NCT01822418|Experimental|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
11431793|NCT01822405|Active Comparator|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
11431794|NCT01822405|Experimental|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
11431795|NCT01822392|Active Comparator|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
11431796|NCT01822392|Experimental|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
11431797|NCT01822379|Experimental|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
11431798|NCT01822366|No Intervention|Usual Care Comparison Condition|Half of the participating children/guardian dyads will receive no intervention (usual care) to serve as a control.
11431799|NCT01822366|Experimental|Trauma-focused CBT group therapy|Half of the participating children/guardian dyads will receive the 12-week Trauma-focused Cognitive Behavioral Therapy (TF-CBT) group treatment.
11431800|NCT01822353|Experimental|Milk allergy|Dietary supplement, milk in increasing dosages, delivered daily and orally.
11431801|NCT01822353|Experimental|Egg allergy|Dietary supplement, egg protein given in increasing dosages, delivered daily and orally.
11431802|NCT01822353|Experimental|Nut allergy|Dietary supplement, nut cream including nut allergens, delivered in increasing dosages, daily and orally.
11431803|NCT01822340|Experimental|Cohort 1|Once weekly HM10560A
11431804|NCT01822340|Experimental|Cohort 2|Once weekly HM10560A
11431805|NCT01822340|Experimental|Cohort 3|Once weekly HM10560A
11431806|NCT01822340|Experimental|Cohort 4|Biweekly HM10560A
11431807|NCT01822340|Active Comparator|Cohort 5|Once daily Genotropin
11431808|NCT01822327|Experimental|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
11431809|NCT01822327|Experimental|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
11431810|NCT01822327|Active Comparator|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
11431811|NCT01822314|Active Comparator|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.
~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
11431812|NCT01822314|Experimental|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.
~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
11431813|NCT01822301|Experimental|Repeat Facial fat grafting|
11431814|NCT01822288|Experimental|Tibolone group|Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
11431815|NCT01822288|Active Comparator|Conventional hormone therapy group|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
11431816|NCT01822275|Other|Low Dose WBRT|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
11431817|NCT01822262|Experimental|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
11431818|NCT01822262|Experimental|laparoscopiccholecystectomy|Patients in control group all received LC.
11431819|NCT01822249|Active Comparator|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
11431820|NCT01822249|Placebo Comparator|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
11431821|NCT01822236|Experimental|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
11431822|NCT01822236|Active Comparator|One technique of craniosacral therapy|Decompression L5-S1.
11431823|NCT01822223|Experimental|Laser-ablated dental implant-abutments|Laser-ablated dental implant abutments will be attached to surgically placed dental implants.
11431824|NCT01822223|Active Comparator|Smooth implant-abutments|Smooth dental implant-abutments will be attached to surgically placed dental implants.
11523906|NCT01187459|Experimental|50 ug/day|
11431826|NCT01822197|Experimental|Phototherapy|Bright light phototherapy will be administered for 30 minutes daily over one week in the morning (Days 0-7)
11431827|NCT01822184||No treatment|Observational non-treatment study
11431828|NCT01822171|Experimental|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:
~Discharge medication counseling from a pharmacist
~Home medication if needed
~Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
11431829|NCT01822158|Other|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
11431830|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
11431831|NCT01822132|Experimental|Extended release naltrexone|One dose of intramuscular injection of 380mg extended-release naltrexone.
11431832|NCT01822132|Placebo Comparator|Placebo|One dose of intramuscular injection of placebo.
11431833|NCT01822119|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;
~One implant magnet
~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
11431834|NCT01822106|Active Comparator|Omeprazole|Omeprazole at a rate of 20mg once per day
11431835|NCT01822106|Experimental|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
11431836|NCT01822093|Experimental|Cytovir-ADV|Adenovirus-specific T-cells
11431837|NCT01822080|Experimental|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
11431838|NCT01822080|Placebo Comparator|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
11431839|NCT01822067||Normal weight- Non Maternal obesity|Full-term neonates at 2 weeks of age born to normal weight mothers
11431840|NCT01822067||Obese- Obese Mothers|Full-term neonates at two weeks of age born of obese mothers
11431841|NCT01822054||Normal weight|
11431842|NCT01822054||Obese|
11431843|NCT01822041|Active Comparator|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
11431844|NCT01822041|Active Comparator|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
11431845|NCT01822028|Placebo Comparator|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.
~For Period 2, subjects will receive the alternate dosing regimen."
11431846|NCT01822028|Experimental|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.
~For Period 2, subjects will receive the alternate dosing regimen."
11431847|NCT01822015|Experimental|Treatment (sirolimus, idarubicin, cytarabine)|Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
11431848|NCT01822002|Active Comparator|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
11431849|NCT01822002|Active Comparator|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
11431850|NCT01821989|Active Comparator|Low Dose|Lactoferrin,dose of 100 mg/day.
11431851|NCT01821989|Experimental|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
11431852|NCT01821989|Placebo Comparator|Control|Receive placebo in form of distilled water.
11431853|NCT01821976|Active Comparator|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
11431854|NCT01821976|Active Comparator|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
11431855|NCT01821963|Experimental|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
11431856|NCT01821950|No Intervention|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
11431857|NCT01821950|Experimental|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
11431858|NCT01821937|Experimental|faldaprevir(high dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
11431859|NCT01821937|Experimental|Faldaprevir(low dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
11431860|NCT01821911|Experimental|Zagreb2-1-1|Injection on day 0、7、21
11524151|NCT01185847|Experimental|A squamous|
11431861|NCT01821911|Active Comparator|Essen|Injection on day 0、3、7、14、28
11431862|NCT01821898|Active Comparator|Positive for food allergy: Group A|Oral Budesonide
11431863|NCT01821898|Active Comparator|Positive for food allergy: Group B|Elimination diet
11431864|NCT01821885|Experimental|Spirometry and a brief advice to quit smoking|"Intervention group:
~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
11431865|NCT01821885|Active Comparator|Brief advice to quit smoking|"Control group:
~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
11431866|NCT01821872|Active Comparator|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
11431867|NCT01821872|Active Comparator|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
11431868|NCT01821872|Active Comparator|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
11431869|NCT01821859|Experimental|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
11431870|NCT01821846||Liraglutide|
11431871|NCT01821833|Experimental|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.
~The capsules may be administered either once daily or as 2 capsules two times daily."
11431872|NCT01821833|Placebo Comparator|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.
~The capsules may be administered either once daily or as 2 capsules two times daily."
11431873|NCT01821820|Experimental|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
11431874|NCT01821820|No Intervention|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
11431875|NCT01821807||26 gauge quincke|Patients (n=150) will be treated with 26 gauge quincke spinal needle for spinal anesthesia for cesarean section.
11431876|NCT01821807||26 gauge atraucan|Patients (n=110) will be treated with 26 gauge atraucan spinal needle for spinal anesthesia for cesarean section.
11431877|NCT01821781|Experimental|Preparative|
11431878|NCT01821768|No Intervention|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
11431879|NCT01821768|Active Comparator|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
11431880|NCT01821755|Experimental|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
11431881|NCT01821755|No Intervention|Control|waiting-list control group who receive care-as-usual
11431882|NCT01821742||Children requiring fluid bolus on PICU|
11431883|NCT01821729|Experimental|Experimental Arm|FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
11431884|NCT01821716|Experimental|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)
~Positive control (10 mg/ml histamine dihydrochloride)
~Negative control (glycerinated phenol saline solution)"
11431885|NCT01821703|Experimental|LY3045697|Escalating dose (0.1 milligrams [mg] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
11431886|NCT01821703|Active Comparator|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
11431887|NCT01821703|Placebo Comparator|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
11431888|NCT01821690|Experimental|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
11431889|NCT01821690|Placebo Comparator|Buspirone Placebo|placebo tablets as prescribed
11431890|NCT01821677|Experimental|Low Dose Danazol|Low Dose Danazol
11431891|NCT01821677|Placebo Comparator|Placebo|Placebo
11431892|NCT01821664||Prosthetic vascular graft implantation, follow up|
11431893|NCT01821651|Experimental|HeartNavigator|Group with HeartNavigator-Software
11431894|NCT01821651|Active Comparator|Control|Control-group without HeartNavigator-Software
11431895|NCT01821651|Experimental|EchoNav|Group with EchoNav-Software
11431896|NCT01821651|Active Comparator|Conrol|Control-group without EchoNav-Software
11431897|NCT01821638||Older adults with heart failure|Older adults with heart failure
11431898|NCT01821625|Experimental|Thrombocytopenic (Low Platelet) Patients|"All study patients will undergo intervention in this study.
~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir)."
11431899|NCT01821612|Other|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m^2 IV over 46-48 hours).
~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.
~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
11431900|NCT01821599|Active Comparator|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
11431901|NCT01821599|Experimental|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
11431902|NCT01821586|Experimental|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
11431985|NCT01821014|Active Comparator|Two physician visits|Patients who had two sequential visits with different in-person physicians.
11431903|NCT01821586|Experimental|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
11431904|NCT01821586|Experimental|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
11431905|NCT01821573|Experimental|Botox Injection|Patients treated by botulinum toxin.
11431906|NCT01821573|Placebo Comparator|Saline Solution|Patients treated with saline solution.
11431907|NCT01821560|Placebo Comparator|Sugar pill|Placebo-treated subjects will follow the identical schedule as Baclofen subjects.
11431908|NCT01821560|Active Comparator|Baclofen|Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.
11431909|NCT01821534||All Participants|Healthy volunteers. No treatment (intervention) was administered.
11431910|NCT01821521|Experimental|AGSPT_L20|tablet, q.d.
11431911|NCT01821521|Active Comparator|Pantoloc 40mg|tablet, q.d.
11431912|NCT01821508|Active Comparator|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
11431913|NCT01821508|Active Comparator|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009]."
11431914|NCT01821495|No Intervention|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
11431915|NCT01821495|Experimental|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
11431916|NCT01821482|Experimental|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
11431917|NCT01821482|No Intervention|B|After complete resection or TACE, Patient only regularly follow up
11431918|NCT01821469|Experimental|psychoeducation|psychoeducation (12 weeks)
11431919|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
11431920|NCT01821443|Experimental|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
11431921|NCT01821430|Experimental|Pregabalin|Pregabalin 400mg / Day
11431922|NCT01821430|Placebo Comparator|Placebo Control|Placebo Tablet
11431923|NCT01821417|Experimental|Microtextured dental implant|Randomized for microtextured dental implant treatment
11431924|NCT01821417|Active Comparator|Dental implant|Randomized dental implant treatment with machined-collar implants
11431925|NCT01821404|Placebo Comparator|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
11431926|NCT01821404|Experimental|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
11431927|NCT01821391|Experimental|NDL-PDT/c-PDT|Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy
11431928|NCT01821391|Experimental|NDL-PDT/placebo c-PDT|Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy
11431929|NCT01821378|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
11431930|NCT01821378|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
11431931|NCT01821378|Placebo Comparator|Placebo|Placebo Comparator 20 or 80 mg once daily
11431932|NCT01821352|Active Comparator|Erchonia Obesity Laser|The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
11431933|NCT01821352|Placebo Comparator|Placebo Laser|Laser device emitting sham green light that has no therapeutic effect.
11431934|NCT01821313|Experimental|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
11431935|NCT01821313|Active Comparator|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
11431936|NCT01821300||Down syndrome|No intervention occurred as this was a cross sectional observational study.
11431937|NCT01821300||Control|No intervention occurred as this was a cross sectional observational study.
11431938|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
11431939|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
11431940|NCT01821274|Experimental|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
11431941|NCT01821274|Placebo Comparator|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
11431942|NCT01821274|Active Comparator|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
11431943|NCT01821274|Placebo Comparator|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
11431944|NCT01821261|Experimental|Mouth Rinse 19668-012|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
11431945|NCT01821261|Active Comparator|Mouth Rinse 500347078842|"Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 10 ml of mouth rinse 500347078842 for 60 seconds and spit it out - do not swallow.
~Attention: Toothpastes can stop mouth rinse from working. Rinse your mouth thoroughly with water and wait 5 minutes after brushing your teeth before using the mouth rinse. You can also use the mouthwash at a different time of day."
11431946|NCT01821261|Other|Toothpaste 035000513007|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
11431947|NCT01821248|Experimental|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
11431948|NCT01821235|Experimental|Neurontin® (gabapentin) batch A|
11431949|NCT01821235|Experimental|Neurontin® (gabapentin) batch B|
11431950|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch A|
11431951|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch B|
11431952|NCT01821222|Experimental|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
11431953|NCT01821222|No Intervention|Control|The control group received standard care
11431954|NCT01821209|No Intervention|Control|Standard robot assisted radical prostatectomy
11431955|NCT01821209|Experimental|Sling|Placement of sling at time of robot assisted radical prostatectomy
11431956|NCT01821196|Experimental|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
11431957|NCT01821183||hip rotators muscle strength|
11431958|NCT01821183||control group|no intervention
11431959|NCT01821170|Experimental|Cognitive remediation|
11431960|NCT01821170|Active Comparator|Supportive psychotherapy|
11431961|NCT01821170|Active Comparator|Methylphenidate|
11431962|NCT01821157|Active Comparator|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
11431963|NCT01821157|Active Comparator|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
11431964|NCT01821144|Other|Control|No salt awareness education
11431965|NCT01821144|Experimental|Salt reduction|Salt reduction
11431966|NCT01821131|Experimental|30g ground flaxseed per day|consume 1 muffin containing 30g ground flaxseed every day for 4 weeks
11431967|NCT01821131|Experimental|20g ground flaxseed per day|consume 1 muffin containing 20g ground flaxseed every day for 4 weeks
11431968|NCT01821131|Placebo Comparator|0g ground flaxseed per day|consume 1 muffin containing 0g ground flaxseed every day for 4 weeks
11431969|NCT01821118|Experimental|1|
11431970|NCT01821118|Placebo Comparator|2|
11431971|NCT01821105|Experimental|Preoperative PET and CT Scans|Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
11431972|NCT01821092|Active Comparator|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
11431973|NCT01821092|Active Comparator|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
11431974|NCT01821079|Experimental|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
11431975|NCT01821079|Experimental|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
11431976|NCT01821079|Experimental|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
11431977|NCT01821079|Experimental|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
11431978|NCT01821066|Experimental|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
11431979|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
11431980|NCT01821040|Experimental|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
11431981|NCT01821040|Active Comparator|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
11431982|NCT01821027|Experimental|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
11431983|NCT01821014|Experimental|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
11431984|NCT01821014|Experimental|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
11431986|NCT01821001|Experimental|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
11431987|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
11431988|NCT01820975|Experimental|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
11431989|NCT01820975|Placebo Comparator|No protein intake|No protein in the diet the day before testing
11431990|NCT01820962|Active Comparator|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
11431991|NCT01820962|Experimental|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
11431992|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
11431993|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
11431994|NCT01820936|Experimental|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
11431995|NCT01820936|Experimental|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
11431996|NCT01820936|Experimental|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
11431997|NCT01820936|Experimental|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
11431998|NCT01820936|Experimental|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
11431999|NCT01820923|Experimental|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:
~real transcranial direct current stimulation (two weeks, five days a week)
~a week of wash-out
~Sham transcranial direct current stimulation (two weeks, five days a week)
~two weeks of wash-out
~real repetitive transcranial magnetic stimulation (two weeks, four days a week)
~a week of wash-out
~Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)
~Stimulations will be counterbalanced between patients."
11432000|NCT01820910|Experimental|Doxycycline|
11432001|NCT01820897|Experimental|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
11432002|NCT01820897|Active Comparator|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
11432003|NCT01820884|Experimental|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
11432004|NCT01820884|Active Comparator|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
11432005|NCT01820871|Experimental|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.
~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
11432006|NCT01820871|Active Comparator|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
11432007|NCT01820858|Experimental|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
11432008|NCT01820858|Active Comparator|Adjuvant Radiotherapy|"Histopathological grade G3 and <50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;
~Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;
~≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
11432009|NCT01820845||Cohort of children with scoliosis surgery|
11432010|NCT01820832|Experimental|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
11432011|NCT01820832|No Intervention|Control|General treatments.
11432012|NCT01820819||Registered or not on the transplantation national waiting list|
11432013|NCT01820806|Experimental|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
11432014|NCT01820793|Experimental|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
11432015|NCT01820780|Experimental|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
11432016|NCT01820780|Active Comparator|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
11432017|NCT01820767|Experimental|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
11432018|NCT01820767|Active Comparator|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
11432019|NCT01820767|Active Comparator|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
11432020|NCT01820754|Experimental|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery) Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
11432021|NCT01820728|Experimental|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
11432022|NCT01820728|Active Comparator|Gonal-F®|75 IU/day is injected for 14 days
11432023|NCT01820715|Experimental|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
11432024|NCT01820715|Placebo Comparator|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
11432029|NCT01820663|Experimental|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
11432030|NCT01820663|Placebo Comparator|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
11432031|NCT01820637|Experimental|Test device arm (DES SFA)|Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
11432032|NCT01820624|Experimental|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11432033|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
11432034|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
11432035|NCT01820598|Other|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
11432036|NCT01820598|Other|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
11432037|NCT01820585|Placebo Comparator|Placebo|Tablets
11432038|NCT01820585|Active Comparator|ESL 400 mg|Eslicarbazepine acetate (BIA 2-093) tablets
11432039|NCT01820585|Active Comparator|ESL 800 mg|Eslicarbazepine acetate (BIA 2-093) tablets
11432040|NCT01820585|Active Comparator|ESL 1200 mg|Eslicarbazepine acetate (BIA 2-093) tablets
11432041|NCT01820572|Experimental|Belatacept|Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
11432042|NCT01820572|Active Comparator|CNI|"Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months
~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months"
11432043|NCT01820559|Active Comparator|ESL 1200 mg|eslicarbazepine acetate 1200 mg
11432044|NCT01820559|Active Comparator|ESL 800 mg|eslicarbazepine acetate 800 mg
11432045|NCT01820559|Placebo Comparator|Placebo|Placebo tablets
11432046|NCT01820533||smokers|
11432047|NCT01820520|Experimental|Double staining with brilliant blue G during vitrectomy|
11432048|NCT01820507|Experimental|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
11432049|NCT01820507|Active Comparator|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
11432050|NCT01820494|Experimental|Experimental Infant Formula|Complete amino acid-based infant formula
11432051|NCT01820481|Experimental|Treatment 1|
11432052|NCT01820481|Experimental|Treatment 2|
11432053|NCT01820481|Experimental|Treatment 3|
11432054|NCT01820481|Placebo Comparator|Placebo|
11432055|NCT01820468|Experimental|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
11432056|NCT01820468|No Intervention|Regular inpatient care|
11432057|NCT01820455|Active Comparator|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
11432058|NCT01820455|Placebo Comparator|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
11432059|NCT01820442|Active Comparator|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
11432060|NCT01820442|Placebo Comparator|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
11432061|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
11432062|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
11432063|NCT01820416|Experimental|Low-Level Laser Therapy|Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
11432064|NCT01820416|Placebo Comparator|Disabled Laser|Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
11432065|NCT01820416|No Intervention|Control|Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.
11432066|NCT01820403|Experimental|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
11432067|NCT01820403|Experimental|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
11432068|NCT01820403|Experimental|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
11432069|NCT01820403|No Intervention|control|no box lunch provided to participants.
11432070|NCT01820377|Experimental|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
11432071|NCT01820377|No Intervention|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
11432072|NCT01820364|Experimental|LGX818 single agent|Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
11432073|NCT01820338|Experimental|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
11432074|NCT01820338|Experimental|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
11432075|NCT01820338|Active Comparator|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
11432076|NCT01820325|Experimental|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
11432077|NCT01820325|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
11432078|NCT01820299|Experimental|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
11432079|NCT01820286|Experimental|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
11432080|NCT01820286|Active Comparator|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
11432081|NCT01820260|Other|Part 1: Ingenol mebutate gel|Open-label, dose escalation, 2 or 3 days treatment
11432082|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel X dose for 3 days treatment|X dose for 3 days treatment
11432083|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel X dose for 2 days treatment|X dose for 2 days treatment
11432084|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel Y dose for 3 days treatment|Y dose for 3 days treatment
11432085|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel Y dose for 2 days treatment|Y dose for 2 days treatment
11432086|NCT01820260|Placebo Comparator|Part 2: Placebo for 3 days treatment|Placebo for 3 days treatment
11432087|NCT01820260|Placebo Comparator|Part 2: Placebo for 2 days treatment|Placebo for 2 days treatment
11432088|NCT01820247|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
11432089|NCT01820247|Experimental|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
11432090|NCT01820247|Experimental|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
11432091|NCT01820234|Other|In-person dermatology evaluation|Health care modality
11432092|NCT01820234|Other|Store-and-forward teledermatology evaluation|Health care modality
11432093|NCT01820221|Active Comparator|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
11432094|NCT01820221|Active Comparator|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
11432095|NCT01820208|Placebo Comparator|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
11432096|NCT01820208|Experimental|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
11432097|NCT01820195|Active Comparator|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
11432098|NCT01820195|Placebo Comparator|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
11432099|NCT01820195|Active Comparator|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
11432100|NCT01820182|Experimental|capsocam capsula|capsocam capsula readings
11432101|NCT01820169|Experimental|Single arm|
11432102|NCT01820156|Experimental|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
11432103|NCT01820156|Experimental|PSG-HRP|First perform laboratory PSG and following three nights of HRP
11432104|NCT01820143|Experimental|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
11432105|NCT01820143|Experimental|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
11432106|NCT01820143|Experimental|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
11432107|NCT01820143|Experimental|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
11432108|NCT01820130|Experimental|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
11432109|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.
~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
11435024|NCT01800214||Vascular Cognitive Disorders (VCD)|
11432110|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.
~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
11432111|NCT01820104|Placebo Comparator|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
11432112|NCT01820104|Experimental|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
11432113|NCT01820091|Experimental|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle
~Days 2 and 16: 4 doses/day
~Days 3 and 17: 4 doses/day
~Days 4 and 18: 2 doses/day
~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
11432114|NCT01820091|Experimental|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.
~Fusilev dose to start 24 hours after Folotyn dose.
~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
11432115|NCT01820091|Experimental|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.
~Fusilev dose to start 24 hours after Folotyn dose.
~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
11432116|NCT01820091|Experimental|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.
~Fusilev dose to start 24 hours after Folotyn dose.
~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
11432117|NCT01820091|Experimental|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle
~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
11432118|NCT01820078|Experimental|Paricalcitol, Daily treatment, CKD|Experimental Arm
11432119|NCT01820078|Other|Daily treatment for CKD|Comparator Arm
11432120|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
11432121|NCT01820052|Active Comparator|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
11432122|NCT01820052|Placebo Comparator|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
11432123|NCT01820039|Experimental|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
11432124|NCT01820026|Experimental|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.
~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
11432125|NCT01820026|Active Comparator|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
11432126|NCT01820013|Experimental|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
11432127|NCT01820013|Active Comparator|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
11432128|NCT01820000|Experimental|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
11432129|NCT01819987|Active Comparator|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
11432130|NCT01819987|Experimental|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
11432131|NCT01819974|No Intervention|Control|The normal procedure at the ward
11432132|NCT01819974|Active Comparator|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
11432133|NCT01819961|Experimental|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
11432134|NCT01819961|Experimental|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
11432135|NCT01819948|Experimental|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
11432136|NCT01819935||linezolid (Zyvox)|
11432137|NCT01819935||Vancomycin|
11432138|NCT01819922|Experimental|PF-05175157|
11432139|NCT01819922|Placebo Comparator|Placebo|
11432140|NCT01819909|Experimental|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
11432141|NCT01819909|Experimental|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
11432142|NCT01819896||pacemakers and defibrillators|
11432143|NCT01819883||Active Acromegaly|All study subjects with acromegaly will be studied twice - once during the active stage of their disease (pre-treatment) and a second time: 3 months after treatment of acromegaly. Controls will be studied at one time point.
11432144|NCT01819883||Healthy controls|
11432145|NCT01819870|Experimental|Dilatrend SR capsule 32mg|
11435025|NCT01800214||Lewy Body Disease (LBD)|
11432150|NCT01819844|Experimental|Closed-loop blood glucose control|Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is > 1 u/kg or > 2 u/kg.
11432151|NCT01819831|Experimental|Preoperative proton radiation|Patients will receive 50 Gray equivalents (GyE) in 25 fractions with proton therapy, followed by surgery 4-8 weeks after completion of radiation.
11432152|NCT01819818||Paliperidone palmitate|
11432153|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
11432154|NCT01819792|Other|patient with Acute Myeloïd Leukemia|
11432155|NCT01819779|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)
~valsartan 160mg"
11432156|NCT01819779|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)
~valsartan 160mg"
11432157|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
11432158|NCT01819753|Active Comparator|Single access|It was performed only single access standard PCNL in this group.
11432159|NCT01819753|Active Comparator|Multiple access|It was performed multiple access standard PCNL in this group
11432160|NCT01819740||patients with suspected prostate cancer|
11432161|NCT01819727|Active Comparator|BMN 165, 20mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
11432162|NCT01819727|Active Comparator|BMN 165, 40mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
11432163|NCT01819714|Experimental|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
11432164|NCT01819701|Placebo Comparator|Placebo|starch
11432165|NCT01819701|Experimental|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
11432166|NCT01819675|Experimental|High frequency (10Hz) rTMS|<high frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
11432167|NCT01819675|Experimental|Low frequency (1Hz) rTMS|<low frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
11432168|NCT01819675|Sham Comparator|Sham rTMS|<Sham rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
11432169|NCT01819662|Placebo Comparator|Standard management|No echocardiogram
11432170|NCT01819662|Active Comparator|Enhanced standard management|Echocardiogram performed, with results to GP
11432171|NCT01819662|Active Comparator|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
11432172|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
11432173|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
11432174|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
11432175|NCT01819649|Placebo Comparator|Yeast tablet|
11432176|NCT01819636|Experimental|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
11432177|NCT01819636|Placebo Comparator|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
11432178|NCT01819623|Experimental|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
11432179|NCT01819623|No Intervention|Control|This group will receive the standard treatment for mild cognitive impairment
11432180|NCT01819610|Experimental|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
11432181|NCT01819597|Other|EDAS surgery|EDAS surgery is an established form of indirect revascularization. The study arm in this study will receive EDAS surgery
11432182|NCT01819584||Patients below 15 years old|
11432183|NCT01819584||Patients above 15 years old|
11432184|NCT01819571|Experimental|Normal diastolic function group|
11432185|NCT01819571|Active Comparator|Diastolic dysfunction group|
11432186|NCT01819558|Experimental|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
11432187|NCT01819545||Alzheimer's disease|no intervention
11432188|NCT01819545||Mild cognitive impairment|no intervention
11432189|NCT01819545||Normal aging|no intervention
11432190|NCT01819532|Active Comparator|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
11432191|NCT01819532|Experimental|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
11432192|NCT01819519|No Intervention|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
11432193|NCT01819519|Experimental|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
11432194|NCT01819506|Experimental|Targeted Task Practice|"Targeted task practice is defined as a therapy program aimed at patient-specific upper extremity motor impairment levels and systematically progressed to assure an ongoing just right match between task-difficulty and patient-ability. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length."
11432195|NCT01819506|Active Comparator|Non-Targeted Task Practice|Non-targeted task practice is a standard of care treatment consisting of task practice with no guidance from the measurement framework to systematically address specific upper extremity motor impairment levels or progress rehabilitation therapy. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length.
11432196|NCT01819493|Active Comparator|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
11432197|NCT01819493|Experimental|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.
~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
11432198|NCT01819480|Experimental|Transoral robotic surgery|Transoral robotic surgery
11432199|NCT01819467|Active Comparator|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
11432200|NCT01819467|No Intervention|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
11432201|NCT01819454|Experimental|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
11432202|NCT01819454|Experimental|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
11432203|NCT01819454|Experimental|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
11432204|NCT01819441|Sham Comparator|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg~140 mmHg(with or without hydrochlorothiazide).
11432205|NCT01819441|Experimental|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
11432206|NCT01819428|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
11432207|NCT01819415|No Intervention|Naive|Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
11432208|NCT01819415|Active Comparator|Anti-VEGF plus AREDS-1 supplementation.|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
11432209|NCT01819415|Experimental|Anti-VEGF plus AREDS-2|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
11432210|NCT01819415|No Intervention|Control|Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
11432211|NCT01819402|Active Comparator|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
11432212|NCT01819402|Sham Comparator|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
11432213|NCT01819389|Experimental|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
11432214|NCT01819376|Experimental|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
11432215|NCT01819376|No Intervention|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
11432216|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
11432217|NCT01819350|Experimental|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
11432218|NCT01819350|Experimental|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
11432219|NCT01819324|Experimental|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
11432220|NCT01819324|Active Comparator|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
11432221|NCT01819324|No Intervention|Usual Care|Receiving SLM materials at the end of the 7 months
11432222|NCT01819311|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program
11432223|NCT01819311|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
11432224|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
11432225|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
11432226|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
11432227|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
11432228|NCT01819285|Active Comparator|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
11432229|NCT01819285|Experimental|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
11432230|NCT01819272|Experimental|600 mg DR|600 mg delayed-release metformin once daily in the morning
11432231|NCT01819272|Experimental|800 mg DR|800 mg delayed-release metformin once daily in the morning
11432232|NCT01819272|Experimental|1000 mg DR|1000 mg delayed-release metformin once daily in the morning
11432233|NCT01819272|Active Comparator|1000 mg XR|1000 mg extended-release metformin once daily in the evening
11432234|NCT01819272|Active Comparator|2000 mg XR|2000 mg extended-release metformin once daily in the evening
11432235|NCT01819272|Placebo Comparator|Placebo|Placebo once daily in the morning
11432236|NCT01819259|Active Comparator|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
11432237|NCT01819259|Active Comparator|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
11432238|NCT01819246|Active Comparator|Pheresis Treatment Arm|
11432239|NCT01819246|Sham Comparator|Control Arm|
11432240|NCT01819233|Experimental|Behavioral dietary intervention|Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.
11432241|NCT01819220|Active Comparator|amlodipine/valsartan|
11432242|NCT01819220|Experimental|hydrochlorothiazide/telmisartan|
11432243|NCT01819207|Experimental|TEG group|
11432244|NCT01819194|Experimental|senofilcon A|Acuvvue Oasys with Hydaclear Plus with 38% water.
11432245|NCT01819155|Experimental|adjTIV|Children randomized to receive adjTIV
11432246|NCT01819155|Experimental|TIV|Children randomized to receive TIV
11432247|NCT01819155|Placebo Comparator|Placebo|Children randomized to receive Placebo
11432248|NCT01819142|Experimental|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
11432249|NCT01819129|Experimental|Faster-acting insulin aspart (FIAsp)|Meal time faster-acting insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
11432250|NCT01819129|Active Comparator|Insulin aspart|Meal time insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
11432251|NCT01819103||Acute myocardial infarction|Drug Adherence
11432252|NCT01819090|Active Comparator|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
11432253|NCT01819090|Active Comparator|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
11432254|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
11432255|NCT01819064||Children less than 5Kg.|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 5Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
11432256|NCT01819064||Children weighing 5Kg to 15Kg|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh between 5Kg and 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
11432257|NCT01819051|Experimental|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
11432258|NCT01819038|Experimental|High NGAL and early RRT|NGAL level > 400 ng/ml and start continuous renal replacement therapy early
11432259|NCT01819038|Experimental|High NGAL and late RRT|NGAL > 400 ng/ml and start continuous renal replacement therapy late
11432260|NCT01819038|Active Comparator|Low NGAL|NGAL < 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
11432261|NCT01819025|Experimental|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
11432262|NCT01819025|Active Comparator|TAU|10 sessions of face-to-face therapy, full behavioral activation
11432263|NCT01819012|Experimental|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
11432264|NCT01819012|Experimental|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
11432265|NCT01819012|Experimental|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
11432266|NCT01818999|Experimental|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
11432267|NCT01818986|Experimental|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
11432268|NCT01818973|Experimental|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).
~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.
~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.
~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
11432269|NCT01818960|Active Comparator|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
11432270|NCT01818960|Active Comparator|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
11432271|NCT01818947||Gefitinib|
11432272|NCT01818934|Active Comparator|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
11432273|NCT01818934|Active Comparator|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
11437159|NCT01785407|Active Comparator|40 mg FeSO4|40 mg FeSO4
11432274|NCT01818934|Active Comparator|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
11432275|NCT01818921|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
11432276|NCT01818921|Experimental|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
11432277|NCT01818921|Experimental|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
11432278|NCT01818908|Experimental|DA-EPOCH|"Infused agents:
~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;
~Bolus agents:
~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;
~The details of dose adjustment are described in ref 1.
~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
11432279|NCT01818895||Withdrawal of mechanical ventilation|
11432280|NCT01818882|Active Comparator|Standard care|"Patients randomized to this arm will receive standard care.
~Intervention: Standard care."
11432281|NCT01818882|Experimental|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.
~Intervention: Standard care + ultrasound"
11432282|NCT01818869|Experimental|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
11432283|NCT01818869|Placebo Comparator|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
11432284|NCT01818856|Experimental|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.
~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
11432285|NCT01818843|Experimental|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
11432286|NCT01818830||SIRS group|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
11432287|NCT01818830||sepsis|SIRS+infection
11432288|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
11432289|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
11432290|NCT01818817||GA group|In this group of patients general anesthesia is performed.
11432291|NCT01818804|Active Comparator|n-3PUFA|n-3 polyunsaturated fattyacids from fish oil
11432292|NCT01818804|Placebo Comparator|olive oil|Olive oil
11432293|NCT01818791|Active Comparator|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
11432294|NCT01818791|Experimental|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
11432295|NCT01818778|Experimental|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
11432296|NCT01818778|Active Comparator|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
11432297|NCT01818765|Experimental|Procedure|"Pre-procedure speckle-tracking echocardiography assessment of latest activation
~Trans-ventricular-septal placement of LV pacing lead
~Acute response assessment"
11432298|NCT01818752|Experimental|Carfilzomib, Melphalan, Prednisone|Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
11432299|NCT01818752|Active Comparator|Bortezomib, Melphalan, Prednisone|Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
11432300|NCT01818739|Experimental|sentinel lymph node detection|Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.
11432301|NCT01818726|Experimental|Serum ferritin level ≥ 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
11432302|NCT01818726|Experimental|Serum ferritin level < 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin < 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product
11432303|NCT01818713|Experimental|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
11432336|NCT01818453|No Intervention|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
11432304|NCT01818700|Other|Single arm-Norspan patch (Buprenorphine)|This trial is single arm with Norspan patch. Treatment with NORSPAN Ò will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to the investigator's decision. The up-titration will be considered by investigator's judgement as follows; (1) if the rescue medication was used more than 2 times per day, on average or (2) based on the daily average NRS(Numeric Rating Scale), if the NRS was changed to worsen since the previous visit, (3) Investigator's judgement by considering any titration needed situation (e.g. dose, frequency of rescue medication).
11432305|NCT01818687|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
11432306|NCT01818674|Experimental|Group A - Microclinic Behavioral Health Enhanced Program|Group A received the Microclinic Behavioral Health Full Program (structured social interactions + fully interactive classroom education curriculum; parallel clinical screenings)
11432307|NCT01818674|Experimental|Group B - Microclinic Behavioral Health Basic Program|Group B received the Microclinic Behavioral Health Basic Program (no social structured interactions; basic classroom education; parallel clinical screenings)
11432308|NCT01818674|No Intervention|Group C - Controls with Parallel Monitoring|Group C only received standard care, and only received parallel risk factor screening measurements; not participation in classroom or any social activities.
11432309|NCT01818661|Experimental|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
11432310|NCT01818648|Experimental|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
11432311|NCT01818648|Placebo Comparator|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
11432312|NCT01818622|Experimental|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
11432313|NCT01818622|Placebo Comparator|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
11432314|NCT01818622|Experimental|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
11432315|NCT01818609|Experimental|Step Reduction|"Step reduction:
~Take less than 1500 steps/d
~No disease"
11432316|NCT01818596|Experimental|E/C/F/TAF|Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
11432317|NCT01818583|Experimental|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
11432318|NCT01818583|Placebo Comparator|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
11432319|NCT01818570|Placebo Comparator|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
11432320|NCT01818570|Active Comparator|PPC-5650|"PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
11432321|NCT01818557|No Intervention|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
11432322|NCT01818557|Experimental|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
11432323|NCT01818544|Experimental|BAY85-8501|
11432324|NCT01818544|Placebo Comparator|Placebo|
11432325|NCT01818531|Experimental|Adductor canal block|Patients in this arm will receive an adductor canal block prior to undergoing a medial compartment knee arthroplasty.
11432326|NCT01818531|Active Comparator|Lumbar plexus block|Patients in this arm will receive a lumbar plexus block prior to undergoing a medial compartment knee arthroplasty.
11432327|NCT01818518||Preterm Labor|Group who goes into labor prior to 32 weeks of gestation
11432328|NCT01818518||Prelabor rupture of membranes|Group who have prelabor rupture of membranes are those who break their bag of water prior to 32 weeks gestation in the absence of labor.
11432329|NCT01818518||Premature birth before 32 weeks gestation|Premature birth before 32 weeks gestation not including PTL or PROM
11432330|NCT01818505||Gouty arthritis|Patient with gouty arthritis
11432331|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
11432332|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
11432333|NCT01818492|Experimental|NI-0501|
11432334|NCT01818479|Experimental|All participants|
11432335|NCT01818453|Active Comparator|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
11432337|NCT01818440|Active Comparator|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
11432338|NCT01818440|Experimental|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
11432339|NCT01818427|Experimental|plasma|infusion of 2 units of plasma
11432340|NCT01818427|No Intervention|standard air medical care|control group
11432341|NCT01818414|Experimental|Misoprostol|Misoprostol 400 mcg buccal 3 hours prior to D&E as an adjunct to same-day Dilapan-S.
11432342|NCT01818414|Placebo Comparator|Folic Acid|Folic acid 4 mg buccally 3 hours prior to D&E as an adjunct to same-day Dilapan-S
11432343|NCT01818401|Other|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
11432344|NCT01818401|Other|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
11432345|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
11432346|NCT01818375|Experimental|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:
~maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;
~intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
11432347|NCT01818375|Active Comparator|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
11432348|NCT01818362|Experimental|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
11432349|NCT01818362|Experimental|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
11432350|NCT01818362|Experimental|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
11432351|NCT01818362|Experimental|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
11432352|NCT01818362|Experimental|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
11432353|NCT01818362|Experimental|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
11432354|NCT01818349|Active Comparator|isokinetic lower-limb training|3 times/week for 6 weeks
11432355|NCT01818349|Placebo Comparator|isokinetic uppe-limb training|3 times/week for 6 weeks
11432356|NCT01818336|Experimental|all subjects|"Intervention: Penicillin skin test kit
~Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions."
11432357|NCT01818323|Experimental|Intra-tumoral T4 immunotherapy|Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy
11432358|NCT01818310|Experimental|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.
~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
11432359|NCT01818310|Experimental|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
11432360|NCT01818310|Experimental|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
11432361|NCT01818310|Other|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
11432362|NCT01818297|Active Comparator|Treatment|Treatment settings of Medtronic PrimeAdvanced® neurostimulator system implant
11432363|NCT01818297|Other|Control|Control settings of Medtronic PrimeAdvanced® neurostimulator system implant
11432364|NCT01818284|Experimental|Filgrastim + Plerixafor|"Each donor receives Filgrastim 5 µg/kg subcutaneously in the morning daily for 4 days. The dose of Filgrastim based on the donor's actual body weight. Donors will continue Filgrastim until completion of apheresis. Each donor receives Plerixafor 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization. The dose-volume of Plerixafor based on the donor's actual body weight. Apheresis procedure to start the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor. The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.
~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 cluster of differentiation 34 (CD34+) cells/kg (recipient's weight) is obtained."
11432365|NCT01818271|Active Comparator|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
11432366|NCT01818271|Experimental|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:
~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.
~Treadmill walking exercise program."
11432367|NCT01818258|Active Comparator|Severe Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
11432368|NCT01818258|Active Comparator|Normal Nutrition/Mild Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
11432369|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Abdomen)|Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
11432370|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Upper Arm)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
11432371|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Thigh)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
11432372|NCT01818245|Experimental|LY2605541: Cohort B (Injection site: Abdomen)|Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.
11432373|NCT01818232|Experimental|[14C]-LX4211|400 mg LX4211 administered orally
11432374|NCT01818219|Experimental|Study|
11432375|NCT01818206|Experimental|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
11432376|NCT01818180|Experimental|Urell|
11432377|NCT01818180|Placebo Comparator|Placebo|
11432378|NCT01818167|Active Comparator|10% Benzoyl Peroxide Topical Body Wash|Subjects will use 10% benzoyl peroxide twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
11432379|NCT01818167|Active Comparator|Provodine Topical Cream|Subjects will use Provodine Topical Cream twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
11432380|NCT01818154|Experimental|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
11432381|NCT01818154|Placebo Comparator|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
11432382|NCT01818141|Active Comparator|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
11432383|NCT01818141|Active Comparator|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
11432384|NCT01818128|Active Comparator|Neutral shape of bronchial tip|
11432385|NCT01818128|Experimental|Bent shape of bronchial tip|
11432386|NCT01818115|Experimental|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
11432387|NCT01818115|Active Comparator|IOL placement only.|Cataract Extraction with IOL placement only.
11432388|NCT01818102|Experimental|Width 1000 HU/Level -450 HU|
11432389|NCT01818102|Active Comparator|Width 400 HU/Level 25 HU|
11432390|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
11432391|NCT01818076|Experimental|Dose A|Dose A: Botulinum toxin type A
11432392|NCT01818063|Experimental|Arm 1 (paclitaxel, carboplatin)|Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11432393|NCT01818063|Experimental|Arm 2 (veliparib, paclitaxel, carboplatin)|Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11432394|NCT01818050|Other|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
11432395|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
11432396|NCT01818024|Experimental|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
11432397|NCT01818024|Experimental|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
11432398|NCT01818024|Experimental|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
11432399|NCT01818024|Experimental|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
11432400|NCT01818024|Experimental|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
11432401|NCT01818024|Experimental|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
11432402|NCT01818024|Experimental|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
11432403|NCT01818024|Experimental|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
11432404|NCT01818024|Experimental|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
11432405|NCT01818024|Experimental|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
11432406|NCT01818024|Experimental|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
11432478|NCT01817556|Active Comparator|Mucosta Tab.|administered three times daily for four weeks
11524396|NCT01184092|Experimental|Sequence 5|
11432407|NCT01818011|Experimental|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
11432408|NCT01818011|Experimental|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
11432409|NCT01818011|Experimental|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
11432410|NCT01818011|Experimental|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
11432411|NCT01818011|Placebo Comparator|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
11432412|NCT01817998|Experimental|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
11432413|NCT01817998|Active Comparator|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
11432414|NCT01817985|Experimental|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
11432415|NCT01817985|Experimental|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
11432416|NCT01817972|Placebo Comparator|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
11432417|NCT01817972|Active Comparator|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
11432418|NCT01817959|Experimental|Reparixin group|Continuous iv infusion
11432419|NCT01817959|Placebo Comparator|Placebo group|Continuous iv infusion
11432420|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
11432421|NCT01817933|Experimental|Physical therapy|
11432422|NCT01817920|Experimental|integrated multidisciplinary fall prevention program|
11432423|NCT01817907|Placebo Comparator|Placebo|Subjects will receive a sugar pill during their placebo night sleep study.
11432424|NCT01817907|Active Comparator|Trazodone|Subjects will receive trazodone during their treatment night sleep study
11432425|NCT01817894|Other|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
11432426|NCT01817868||Group 1|
11432427|NCT01817855|Experimental|1|"Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.
~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
11432428|NCT01817855|Placebo Comparator|2|"Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.
~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
11432429|NCT01817842|Experimental|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
11432430|NCT01817842|Active Comparator|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
11432431|NCT01817829|Active Comparator|paracetamol|paracetamol 2 tablets1000mg PO.
11432432|NCT01817829|Placebo Comparator|placebo|placebo 2 tablets containing Starch PO
11432433|NCT01817816|Experimental|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
11432434|NCT01817816|Placebo Comparator|placebo_A|receiving placebo injection at both aLE & aUE ; receiving Botox-A at both aLE & aUE at 6-month.
11432435|NCT01817816|Experimental|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
11432436|NCT01817816|Placebo Comparator|placebo_B|receiving placebo injection at both aLE & aUE ; receiving Botox-A only at aLE at 6-month.
11432437|NCT01817803|Active Comparator|1) Add furosemide/no spironolactone|
11432438|NCT01817803|Active Comparator|2) Add metolazone/no spironolactone|
11432439|NCT01817803|Active Comparator|3) Add furosemide/spironolactone|
11432440|NCT01817803|Active Comparator|4) Add metolazone/spironolactone|
11432643|NCT01816425|Active Comparator|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
11432441|NCT01817790|Experimental|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
11432442|NCT01817790|Placebo Comparator|Placebo nasal spray|Two sprays of placebo per nostril to be administered in morning.
11432443|NCT01817777|Experimental|Metformin Small Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
11432444|NCT01817777|Experimental|Metformin Large Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
11432445|NCT01817764|Experimental|Umeclidinium/vilanterol Arm|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS
11432446|NCT01817764|Active Comparator|Fluticasone propionate/salmeterol Arm|The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI
11432447|NCT01817751|Experimental|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"Patients receive sorafenib tosylate PO, valproic acid* PO, and sildenafil citrate PO BID for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~* NOTE: Patients not receiving antiepileptic therapy begin valproic acid 1 week prior to the first day of sorafenib tosylate and sildenafil citrate."
11432448|NCT01817738|Active Comparator|CV9104|CV9104 intradermal injection
11432449|NCT01817738|Placebo Comparator|Placebo|Placebo intradermal injection
11432450|NCT01817725|Experimental|Engerix-B|Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for >20 years old and 20μg for < or =20 years old
11432451|NCT01817712|Experimental|Individual Placement and Support (IPS)|The IPS intervention must achieve a rating of >66 of a possible 75 points on the Supported Employment Fidelity Scale. The fidelity ratings are conducted by the National IPS Fidelity Monitor at biannual on-site monitoring visits.
11432452|NCT01817712|Active Comparator|VA Transitional Work Program (TWP)|TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
11432453|NCT01817699|No Intervention|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL
11432454|NCT01817699|Active Comparator|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
11432455|NCT01817699|Active Comparator|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL
11432456|NCT01817699|Experimental|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
11432457|NCT01817686|Experimental|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
11432458|NCT01817686|Experimental|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
11432459|NCT01817686|Experimental|Standard Default|ADs without pre-selected defaults.
11432460|NCT01817673|Experimental|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
11432461|NCT01817673|Placebo Comparator|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
11432462|NCT01817660|Active Comparator|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
11432463|NCT01817660|Active Comparator|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
11432464|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
11432465|NCT01817634|Experimental|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
11432466|NCT01817634|Experimental|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
11432467|NCT01817634|Experimental|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
11432468|NCT01817634|Active Comparator|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
11432469|NCT01817621|Experimental|Experimental Intervention|
11432470|NCT01817621|Active Comparator|TAU Condition|
11432471|NCT01817595|Active Comparator|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
11432472|NCT01817595|Active Comparator|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
11432473|NCT01817582|Experimental|Lotemax Gel 0.5% and Restasis 0.05%|Participants will administer lotemax gel 0.5 % BID in both eyes (OU) for 2 weeks, then administer both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administer restasis emulsion 0.05% BID OU for 8 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
11432474|NCT01817582|Experimental|Lotemax Gel 0.5%|Participants will administer lotemax gel 0.5% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
11432475|NCT01817582|Active Comparator|Restasis 0.05%|Participants will administer restasis emulsion 0.05% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
11432476|NCT01817569||Byetta|
11432477|NCT01817556|Experimental|Stillen Tab.|administered three times daily for four weeks
11432479|NCT01817543|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
11432480|NCT01817530|Placebo Comparator|Cohort 1: Placebo|Placebo for elagolix and placebo for E2/NETA twice daily (BID)
11432481|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID|Elagolix 300 mg BID alone
11432482|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD|Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
11432483|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD|Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
11432484|NCT01817530|Placebo Comparator|Cohort 2: Placebo|Placebo for elagolix and E2/NETA QD
11432485|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD|Elagolix 600 mg QD alone
11432486|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD|Elagolix 600 mg QD plus LD E2/NETA QD
11432487|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD|Elagolix 600 mg QD plus SD E2/NETA QD
11432488|NCT01817517|Experimental|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
11432489|NCT01817504|Active Comparator|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
11432490|NCT01817504|Other|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
11432491|NCT01817491|Active Comparator|Reduced Fat Vegan Diet|Plant based diet with as few added oils and fats as possible.
11432492|NCT01817491|Active Comparator|American Heart Association Diet|Diet emphasizing fruits, vegetables and whole grains but also low fat dairy, low fat meat and fish.
11432493|NCT01817478|Experimental|medical staff|
11432494|NCT01817465|Experimental|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
11432495|NCT01817465|Active Comparator|Pantoline®|40mg is administered with a tablet of Motilitone®
11432496|NCT01817465|Active Comparator|Motilitone® and Pantoline®|Both drugs are administered at once
11432497|NCT01817452|Experimental|Arm A|Trastuzumab + Pertuzumab
11432498|NCT01817452|Active Comparator|Arm B|Trastuzumab + Pertuzumab + Paclitaxel
11432499|NCT01817439|Experimental|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
11432500|NCT01817439|Experimental|IV amiodarone, Group B|"Amiodarone:
~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
11432501|NCT01817426|Active Comparator|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
11432502|NCT01817426|Placebo Comparator|Placebo|Patients in this arm are randomized to receive matching placebo.
11432503|NCT01817413|Active Comparator|Apexification with MTA|"The control group will receive:
~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.
~Treatment will be carried out over two visits, two weeks apart."
11432504|NCT01817413|Experimental|Pulp revascularisation|"The experimental group will receive:
~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
11432505|NCT01817400|Experimental|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
11432506|NCT01817400|Experimental|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
11432507|NCT01817400|Experimental|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
11432508|NCT01817387|Experimental|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
11432509|NCT01817387|Experimental|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
11432510|NCT01817374|Other|2D US grayscale plus quantitative VCEUS|"Patients with breast cancer receiving neoadjuvant chemotherapy will undergo a 2D grayscale imaging followed by quantitative VCEUS imaging:
~prior to initiation of treatment (baseline);
~at 14 (± 4 days) after initiation of neoadjuvant chemotherapy (early treatment);
~at 28 days (± 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);
~at completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment). Each patient will undergo a total of four VCEUS examinations."
11432511|NCT01817348|Experimental|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly
~Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.
~Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course
~In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
11524397|NCT01184092|Experimental|Sequence 6|
11432512|NCT01817348|Placebo Comparator|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
11432513|NCT01817335|Experimental|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
11432514|NCT01817322|Experimental|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
11432515|NCT01817322|Active Comparator|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
11432516|NCT01817309|Experimental|Study group|endotoxin assay in peritoneal dialysis effluent
11432517|NCT01817296|Experimental|Single arm|
11432518|NCT01817283|Placebo Comparator|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
11432519|NCT01817283|Experimental|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
11432520|NCT01817270|Experimental|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11432521|NCT01817257|Experimental|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
11432522|NCT01817257|No Intervention|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
11432523|NCT01817244|Experimental|care management type 1|2-month care management
11432524|NCT01817244|Active Comparator|care management type 2|6-month care management
11432525|NCT01817231||breast cancer cases|breast cancer cases versus controls
11432526|NCT01817218|Experimental|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
11432527|NCT01817218|Active Comparator|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).
~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
11432528|NCT01817205|Other|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
11432529|NCT01817192|Active Comparator|Observation|Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
11432530|NCT01817192|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
11432531|NCT01817179|Experimental|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
11432532|NCT01817166|Placebo Comparator|Placebo|"Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
~Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
11432533|NCT01817166|Experimental|Vit D|"Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
~Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
11432534|NCT01817153|Placebo Comparator|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
11432535|NCT01817153|Active Comparator|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
11432536|NCT01817140||Patient MRI|Adult patients with possible maxillofacial and/or mandibular bone invasion with oral cancer or osteoradionecrosis who are scheduled for surgery. All eligible and consented participants will have MRI scans obtained using 3T and 4T magnets prior to their surgery.
11432537|NCT01817140||Normal MRI|Healthy adult volunteers recruited to test the comfort of the coil apparatus and to determine configurations which lead to satisfactory image acquisition.
11432538|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
11432539|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
11432540|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
11432541|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
11432644|NCT01816412|Experimental|LDCB|Paclitaxel Coated Balloon
11437160|NCT01785407|Active Comparator|160 mg FeSO4|
11432542|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
11432543|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
11432544|NCT01817114|Experimental|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
11432545|NCT01817114|Sham Comparator|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
11432546|NCT01817101|Active Comparator|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
11432547|NCT01817101|Placebo Comparator|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
11432548|NCT01817088|Experimental|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
11432549|NCT01817088|Active Comparator|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
11432550|NCT01817075|Experimental|Arm I (CHG cleansing wipe)|Patients receive CHG cleansing with topical skin wipes QD for 90 days.
11432551|NCT01817075|Active Comparator|Arm II (control)|Patients receive control cleansing with topical skin wipes QD for 90 days.
11432552|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
11432553|NCT01817049|Experimental|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
11432554|NCT01817049|Placebo Comparator|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
11432555|NCT01817036|Placebo Comparator|Placebo|5 placebo pills per day, 16 weeks
11432556|NCT01817036|Experimental|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
11432557|NCT01817036|Experimental|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
11432558|NCT01817036|Experimental|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
11432559|NCT01817036|Experimental|2000 IU|5 vitamin D pills per day, 16 weeks
11432560|NCT01817023|Experimental|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
11432561|NCT01817023|Active Comparator|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
11432562|NCT01817010|Experimental|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
11432563|NCT01817010|Active Comparator|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
11432564|NCT01816997|Placebo Comparator|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
11432565|NCT01816997|Active Comparator|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
11432566|NCT01816997|Experimental|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
11432567|NCT01816984|Experimental|Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)|"Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.
~All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11432568|NCT01816971|Experimental|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..
~TRANSPLANT: Patients undergo autologous stem cell transplant.
~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
11432569|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
11432570|NCT01816945|Experimental|Access to MOMBA web-based application|Study will provide the subject with a smartphone, pay the data plan, and facilitate access to the web-based application for purposes of researching the acceptability of the application, the operating and functioning of it, and its impact on maternal mental health.
11432645|NCT01816412|Active Comparator|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
11432571|NCT01816945|No Intervention|Smartphone only|Study will provide the subject with a smartphone and pay the data plan. Weekly assessments are completed through internet survey links sent via text message.
11432572|NCT01816932|Experimental|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
11432573|NCT01816932|Placebo Comparator|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
11432574|NCT01816919|Experimental|eNose breath samples|
11432575|NCT01816906|Active Comparator|MCP Insole|"The intervention is Footwear: MCP. MCP insoles are commonly used within Diabetic sandals in India."
11432576|NCT01816906|Active Comparator|PU insole|"The intervention is Footwear: PU. Insoles made of Polyurethane(PU) are given to the participants in the intervention arm."
11432577|NCT01816893|Sham Comparator|Euglycemic hyperinsulinemic clamp|participant undergoes a euglycemic hyperinsulinemic clamp
11432578|NCT01816893|Active Comparator|Hypoglycemic hyperinsulinemic clamp|participant undergoes a hypoglycemic hyperinsulinemic clamp
11432579|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
11432580|NCT01816867||Patients with a ventral hernia|
11432581|NCT01816854||Patients with PAD|
11432582|NCT01816841|Experimental|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
11432583|NCT01816841|Experimental|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
11432584|NCT01816828|Experimental|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
11432585|NCT01816828|Active Comparator|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
11432586|NCT01816815|Experimental|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
11432587|NCT01816815|Experimental|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
11432588|NCT01816815|Experimental|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
11432589|NCT01816815|Experimental|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
11432590|NCT01816815|Experimental|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
11432591|NCT01816815|Placebo Comparator|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
11432592|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
11432593|NCT01816789|Active Comparator|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
11432594|NCT01816789|Experimental|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
11432595|NCT01816776|Experimental|Treatment Group|Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
11432596|NCT01816776|Other|Control group|Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
11432597|NCT01816763|Experimental|tablet based NRS pain one week, followed by nurse pain screen|tablet-based patient self-report of the 'NRS pain one week'
11432598|NCT01816763|Experimental|tablet based PEG, followed by nurse pain screen|tablet-based enhanced pain screening with the PEG (pain intensity, emotional, and functional pain interference)
11432599|NCT01816763|Experimental|DVPRS, followed by nurse pain screen|Defense Veterans Pain Rating Scale on tablet followed by usual nursing staff documented pain screening with NRS pain now
11432600|NCT01816750|Experimental|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
11432601|NCT01816750|Experimental|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
11432602|NCT01816750|Experimental|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
11432603|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
11432604|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
11432605|NCT01816711||No hip fractures, Frail elderly|Controls: Frail elderly, without a hip fracture in the previous ten years.
11432606|NCT01816711||Hip fracture, Frail elderly|Cases: Frail elderly with a hip fracture.
11432607|NCT01816698|Active Comparator|Taurine|Interventions Drug: Taurine granule Arms: Group 1
11432608|NCT01816698|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
11432609|NCT01816685|Experimental|CPAP|Patients in the CPAP group will be instructed to wear an autotitrating positive airway pressure (APAP) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.
11432610|NCT01816685|No Intervention|Routine Care|
11432611|NCT01816672|Active Comparator|AutoloGel|AutoloGel treatment
11432612|NCT01816672|Other|Usual and Customary Care|Standard of care
11432613|NCT01816659|Experimental|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
11432614|NCT01816659|No Intervention|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
11432615|NCT01816646|Experimental|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
11432616|NCT01816633|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
11432617|NCT01816620|Experimental|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 & dexamethasone 40mg qw d1,8,15,22
11432618|NCT01816607||Rectal cancer|
11432619|NCT01816594|Experimental|BKM120 + Trastuzumab + paclitaxel|BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.
11432620|NCT01816594|Placebo Comparator|BKM120 PBO + Trastuzumab + paclitaxel|BKM120 placebo in combination with trastuzumab and paclitaxel
11432621|NCT01816581|Active Comparator|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
11432622|NCT01816581|Active Comparator|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
11432623|NCT01816568|Active Comparator|Group 1|SILS appendectomy
11432624|NCT01816568|Active Comparator|Group 2|Three port laparoscopic appendectomy
11432625|NCT01816555|Experimental|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
11432626|NCT01816555|Experimental|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D <20ng/mL) Vitamin D levels, they will be assigned to this group.
11432627|NCT01816542|Other|patch tests on healthy skin|
11432628|NCT01816529|Experimental|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
11432629|NCT01816529|Placebo Comparator|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
11432630|NCT01816529|Active Comparator|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
11432631|NCT01816529|Placebo Comparator|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
11432632|NCT01816516|Experimental|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
11432633|NCT01816516|Active Comparator|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
11432634|NCT01816503||Fentanyl matrix|
11432635|NCT01816477|Active Comparator|Thoracic epidural|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
11432636|NCT01816477|Experimental|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
11432637|NCT01816464|Experimental|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:
~an A/California/7/2009 (H1N1)pdm09-like virus;
~an A/Victoria/361/2011 (H3N2)-like virus;
~a B/Wisconsin/1/2010-like virus.
~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
11432638|NCT01816451|Experimental|interval|The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
11432639|NCT01816451|Experimental|continuous|The running training for continuous group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine.The continuous group ran at an intensity of ~87% of maximal heart rate (HRmax)
11432640|NCT01816451|No Intervention|control|The control group did not do the running training program. Control did their normal physical activities.
11432641|NCT01816438||dysplasia or colorectal lesion|300 patients
11432642|NCT01816425|Experimental|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
11432646|NCT01816399||Routine coronary angiography patients|
11528552|NCT01154361|Experimental|Arm A|
11432647|NCT01816386|Active Comparator|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
11432648|NCT01816386|No Intervention|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.
~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:
~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.
~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.
~It is allowed to treat the subject for pain with metamizol (4*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .
~Variation of this guideline based regimen are allowed if medically indicated."
11432649|NCT01816386|Active Comparator|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
11432650|NCT01816373|Other|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
11432651|NCT01816360|Experimental|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
11432652|NCT01816360|Experimental|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
11432653|NCT01816360|Experimental|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
11432654|NCT01816360|No Intervention|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
11432655|NCT01816347||Routine PCI patients|
11432656|NCT01816334|Active Comparator|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
11432657|NCT01816334|Active Comparator|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
11432658|NCT01816334|Placebo Comparator|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
11432659|NCT01816321|Experimental|Corifollitropin alfa followed by hpHMG|
11432660|NCT01816321|Active Comparator|recombinant FSH|
11432661|NCT01816295|Placebo Comparator|Placebo Solution|Placebo Solution applied topically once daily for 12 weeks.
11432662|NCT01816295|Experimental|Testosterone Solution|Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
11432663|NCT01816282|Experimental|Evicel|
11432664|NCT01816282|No Intervention|Control|
11432665|NCT01816269||Patients with scaling and patients without scaling|No drug
11432666|NCT01816269||Helicobacter eradicated or non-eradicated|
11432667|NCT01816256|Other|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
11432668|NCT01816243|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.
11432669|NCT01816230|Experimental|NiCord®|NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
11432670|NCT01816217|Experimental|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
11432671|NCT01816204|Experimental|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
11432672|NCT01816204|Active Comparator|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
11432673|NCT01816191|Experimental|Diltiazem Hydrochloride|Topical cream and oral pill
11432674|NCT01816178|Experimental|communication training|Participants were instructed in the use of a voices output communication aid.
11432675|NCT01816165|Experimental|Acipimox|Drug: acipimox
11432676|NCT01816165|Placebo Comparator|Placebo|Drug: Placebo
11432677|NCT01816152|Active Comparator|Active Intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
11432678|NCT01816152|Placebo Comparator|Inactive intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
11432679|NCT01816139|Experimental|WC3011|Vaginal Cream, 0.015 mg estradiol/0.5 g vehicle administered daily for initial 14 days followed by twice weekly for 10 weeks
11432680|NCT01816139|Placebo Comparator|Vehicle|0.5 g Vehicle vaginal cream administered daily for initial 14 days followed by twice weekly for 10 weeks
11432681|NCT01816126||one-operator technique|
11432682|NCT01816126||two-operator technique|
11432683|NCT01816113|Experimental|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
11432684|NCT01816113|Experimental|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
11432685|NCT01816113|Experimental|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
11432686|NCT01816113|Experimental|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
11432687|NCT01816100|Experimental|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.
~The primary outcome exercise data include strength and endurance"
11432688|NCT01816087|Experimental|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
11432689|NCT01816074|Experimental|Maternal Medication then meds|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
11432690|NCT01816074|Experimental|BPT then continued beh tx|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
11432691|NCT01816074|Experimental|Maternal Medication then BPT|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
11432692|NCT01816074|Experimental|BPT then maternal medication|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
11432693|NCT01816061|Experimental|Experimental - COMPASS|Goal-setting sessions
11432694|NCT01816061|Active Comparator|Control - COMPASS|Informative phone calls
11432695|NCT01816048|Experimental|TAK-700|"TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.
~The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time."
11432696|NCT01816035|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
11432697|NCT01816009|Experimental|6 weeks|the duration of antibiotic treatment will be six weeks.
11432698|NCT01816009|Active Comparator|12 weeks|the duration of antibiotic treatment will be 12 weeks.
11432699|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant
~One time blood draw to look at patient's DNA"
11432700|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours
~One time blood draw to look at patient's DNA"
11432701|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.
~One time blood draw to look at patient's DNA"
11432702|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease
~One time blood draw to look at patient's DNA"
11432703|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).
~One time blood draw to look at patient's DNA"
11432704|NCT01815983|Experimental|Videolaryngoscopy review.|Video review.
11432705|NCT01815970|Experimental|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
11432706|NCT01815957|Experimental|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
11432707|NCT01815944|Active Comparator|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
11432708|NCT01815944|Experimental|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
11432709|NCT01815931||ED patients|
11432710|NCT01815918|Placebo Comparator|Placebo|Patients receive a saline placebo before surgery, 8 hours after the first dose and 16 hours after the first dose.
11432711|NCT01815918|Active Comparator|Treatment|Patients receive 3 100 mg of hydrocortisone: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
11432712|NCT01815905|Active Comparator|Traditional therapy|Traditional rehabilitation therapy
11432713|NCT01815905|Experimental|Mobile program|Mobile program for occupational and speech therapy
11432714|NCT01815892|Active Comparator|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
11432715|NCT01815892|Experimental|Administration of furosemide|The patient will receive furosemide 120 mgms daily
11432716|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
11432717|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
11432718|NCT01815853|Experimental|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
11432719|NCT01815853|Active Comparator|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
11432720|NCT01815840|Experimental|Vismodegib Intermittent Schedule|Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
11432721|NCT01815840|Experimental|Vismodegib Induction Followed by Intermittent Schedule|Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
11432722|NCT01815827|Active Comparator|Caucasian Healthy volunteers|
11432723|NCT01815827|Experimental|Japanese Healthy volunteers|
11432724|NCT01815814|Experimental|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
11437161|NCT01785407|Active Comparator|240 mg FeSO4|
11432725|NCT01815814|Other|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
11432726|NCT01815801|Experimental|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
11432727|NCT01815801|Active Comparator|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
11432728|NCT01815788|Experimental|Teo first|"Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)
~Patient 60 years of age and older,
~No previous hearing aid"
11432729|NCT01815775|Experimental|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
11432730|NCT01815762|Active Comparator|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS <15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
11432731|NCT01815762|No Intervention|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
11432732|NCT01815749|Experimental|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
11432733|NCT01815736|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC tablet for up to 96 weeks in the Randomized Phase, and may continue treatment with E/C/F/TAF in the open-label Extension Phase.
11432734|NCT01815736|Active Comparator|Stay on Baseline Treatment Regimen (SBR)|Participants will stay on their baseline FTC/tenofovir disoproxil fumarate (TDF)-containing regimen (either E/C/F/TDF, EFV/FTC/TDF, RTV+ATV+FTC/TDF, or COBI+ATV+FTC/TDF) for up to 96 weeks in the Randomized Phase, and may switch to E/C/F/TAF in the open-label Extension Phase.
11432735|NCT01815723|Experimental|FP187|500 mg FP187 daily (250 mg twice daily)
11432736|NCT01815723|Active Comparator|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
11432737|NCT01815723|Placebo Comparator|Placebo|Matching FP187 and Fumaderm® placebo
11432738|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting & Diarrhea Pathway
11432739|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
11432740|NCT01815697|Experimental|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
11432741|NCT01815697|No Intervention|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
11432742|NCT01815684|Experimental|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
11432743|NCT01815684|Experimental|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
11432744|NCT01815684|Experimental|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
11432745|NCT01815684|Experimental|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
11432746|NCT01815671|Other|Lateral horizontal body position|Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
11432747|NCT01815671|Other|Lateral tilt down body position|Subjects randomized to receive colonoscopy in the lateral tilt down position
11432748|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
11432749|NCT01815645|Active Comparator|Standard treatment Alone|Participants in the Standard Treatment Alone group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted
11432750|NCT01815645|Experimental|ST+CM|Participants in the Standard treatment plus Contingency Management (ST+CM) group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted plus CM.
11432751|NCT01815632|Experimental|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
11432752|NCT01815632|Experimental|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
11432753|NCT01815619|Experimental|on-site evaluation of specimens by cytopathologist|The specimen will be evaluated onsite by a cytopathologist during the procedure to render a diagnosis
11432754|NCT01815619|Active Comparator|off-site specimen evaluation|The specimen will be evaluated offsite by a cytopathologist during the procedure and render a diagnosis
11432755|NCT01815606|Active Comparator|19 Gauge needle biopsy|biopsy with 19 gauge needle
11432756|NCT01815606|Active Comparator|25 gauge needle biopsy|biopsy with 25 gauge needle
11432757|NCT01815593|Experimental|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
11432758|NCT01815593|No Intervention|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
11432865|NCT01814852|Experimental|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
11528553|NCT01154361|Active Comparator|Arm B|
11432759|NCT01815580|Active Comparator|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
11432760|NCT01815580|Placebo Comparator|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
11432761|NCT01815567||controlled hypertension|hypertension with medication controlled
11432762|NCT01815567||uncontrolled hypertension|non-controlled hypertension
11432763|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
11432764|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
11432765|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
11432766|NCT01815541|Experimental|teicoplanin|this group receive the teicoplanin
11432767|NCT01815528|Experimental|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
11432768|NCT01815515|Experimental|18F-DCFBC|Participants with hormone-naive prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC) with metastatic lesions detected on conventional imaging modalities (contrast-enhanced computed tomography [CECT] and bone scintigraphy [BS]) undergo PET imaging with 18F-DCFBC radiotracer.
11432769|NCT01815502|Experimental|Dobutamine + Sildenafil|Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
11432770|NCT01815502|Placebo Comparator|Dobutamine + placebo|Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
11432771|NCT01815476|Other|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
11432772|NCT01815476|Experimental|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
11432773|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
11432774|NCT01815450|Experimental|BLI1100|BLI1100 topical cream
11432775|NCT01815450|Experimental|BLI1100 - modified formulation|BLI1100 topical cream
11432776|NCT01815450|Placebo Comparator|Placebo|Topical cream
11432777|NCT01815437|Active Comparator|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
11432778|NCT01815437|Active Comparator|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
11432779|NCT01815437|Experimental|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
11432780|NCT01815437|Placebo Comparator|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
11432781|NCT01815424|Placebo Comparator|Placebo BID|
11432782|NCT01815424|Experimental|5mg BID CP-690,550|
11432783|NCT01815424|Experimental|10mg BID CP-690,550|
11432784|NCT01815411|Experimental|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
11432785|NCT01815411|No Intervention|Control group|The control group is selected by randomisation.
11432786|NCT01815398|Active Comparator|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
11432787|NCT01815398|Experimental|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
11432788|NCT01815372|Experimental|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
11432789|NCT01815372|Active Comparator|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
11432790|NCT01815359|Experimental|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
~Exposure to chemotherapy in the prior 6 months vs. no such exposure
~Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
11432791|NCT01815359|Experimental|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
~Exposure to chemotherapy in the prior 6 months vs. no such exposure
~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
11432792|NCT01815359|Experimental|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
~Exposure to chemotherapy in the prior 6 months vs. no such exposure
~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
11432793|NCT01815359|Experimental|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
~Exposure to chemotherapy in the prior 6 months vs. no such exposure
~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
11432866|NCT01814852|Sham Comparator|Control Group|
11432867|NCT01814839|Active Comparator|ALN-TTRSC (revusiran)|
11432794|NCT01815346|Experimental|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
11432795|NCT01815346|Experimental|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
11432796|NCT01815333|Experimental|Feraheme|Magnetic resonance imaging (MRI) acquired prior to the injection of Feraheme® and repeated at approximately 48 hours and 72 hours from the time of injection (scan time). The scan time will be adjusted, as needed. The MRI scan prior to the Feraheme injection is the routine scan. The scans at 48 and 72 hours are investigational.
11432797|NCT01815320|Experimental|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
11432798|NCT01815307|Experimental|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
11432799|NCT01815307|Experimental|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
11432800|NCT01815294|Experimental|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
11432801|NCT01815294|Experimental|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
11432802|NCT01815281|Experimental|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
11432803|NCT01815281|Sham Comparator|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
11432804|NCT01815268|Experimental|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
11432805|NCT01815268|Experimental|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
11432806|NCT01815268|Active Comparator|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
11432807|NCT01815268|Active Comparator|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
11432808|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
11432809|NCT01815242|Experimental|Arm A|nab-Paclitaxel + gemcitabine
11432810|NCT01815242|Experimental|Arm B|nab-Paclitaxel + carboplatin
11432811|NCT01815229|Experimental|tracheal lavages|"After the placement of the endotracheal tube (Hi-Lo™ Evac Mallinckrodt), tracheal lavages will be performed.
~A simultaneous blood sample of approx 5cc, will be collected by venipuncture or by sampling from intravenous or arterial line if available. The same procedure for collection of tracheal sample and blood will be repeated at the end of the surgical procedure and immediately prior to removal of the ETT. A total of approx 10cc blood will be collected for research purposes."
11432812|NCT01815229|Placebo Comparator|Healthy Control|To replicate activation, neutrophils were isolated from 30mL blood of healthy volunteers and cocultured with TLF from subjects with or without sore throat pain.
11432813|NCT01815216|Experimental|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
11432814|NCT01815216|Active Comparator|Control|"Patients in the control group will not undergo surgery during study.
~These patients will be examined twice:
~9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).
~after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
11432815|NCT01815203|Experimental|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
11432816|NCT01815203|Placebo Comparator|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
11432817|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
11432818|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
11432819|NCT01815177|Experimental|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
11432820|NCT01815177|Other|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
11432821|NCT01815164|Active Comparator|Hypnotherapy|Hypnotherapy
11432822|NCT01815164|Active Comparator|Educational intervention|Educational intervention
11432823|NCT01815138|Experimental|hCG given at time of GnRHa trigger|"Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.
~Placebo administered 35 hours after GnRH agonist trigger"
11432824|NCT01815138|Active Comparator|hCG given 35 hours after GnRHa trigger|"Placebo administered at the time of GnRH agonist trigger
~Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger."
11432825|NCT01815125|Experimental|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
11432826|NCT01815125|Placebo Comparator|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
11432827|NCT01815112|Experimental|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
11432868|NCT01814839|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11531173|NCT01135888||HED children|
11432828|NCT01815112|Experimental|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
11432829|NCT01815112|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
11432830|NCT01815112|Experimental|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
11432831|NCT01815112|Experimental|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
11432832|NCT01815099|Experimental|rTMS Treatment|Clinical participants will receive rTMS
11432833|NCT01815086|Experimental|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
11432834|NCT01815073|Experimental|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11432835|NCT01815073|Experimental|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11432836|NCT01815073|Experimental|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11432837|NCT01815047|Experimental|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
11432838|NCT01815047|Experimental|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
11432839|NCT01815021|Experimental|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
11432840|NCT01815021|Active Comparator|crystalline calcium supplements|Tablets, according to the doctor's decision
11432841|NCT01815008|Experimental|Clopidogrel|Clopidogrel 75 mg daily by mouth for 1 week then Clopidogrel 75 mg daily with aspirin 81 mg daily
11432842|NCT01814995|Experimental|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
11432843|NCT01814982|Experimental|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
11432844|NCT01814982|Experimental|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
11432845|NCT01814969|Experimental|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).
~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
11432846|NCT01814969|Active Comparator|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.
~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
11432847|NCT01814956|Experimental|1|i.v. lipid emulsion for parenteral nutrition
11432848|NCT01814956|Active Comparator|2|i.v. lipid emulsion for parenteral nutrition
11432849|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
11432850|NCT01814930|No Intervention|Routine Care|Routine postpartum contraceptive counseling
11432851|NCT01814930|Experimental|Individual counseling|Brief standardized contraceptive counseling intervention
11432852|NCT01814917|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
11432853|NCT01814917|Active Comparator|CBPB|Calcium-based P binder
11432854|NCT01814904|Experimental|MCI-196-L|MCI-196 BSA eq 3g
11432855|NCT01814904|Experimental|MCI-196-M|MCI-196 BSA eq 6g
11432856|NCT01814904|Experimental|MCI-196-H|MCI-196 BSA eq 9g
11432857|NCT01814904|Active Comparator|CBPB|Calcium-based P binder
11432858|NCT01814891|Experimental|Orange maize|"Children were fed orange maize and the intervention name was orange"
11432859|NCT01814891|Active Comparator|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
11432860|NCT01814891|Placebo Comparator|White|Received oil only at the same volume as the vitamin A group
11432861|NCT01814878|Experimental|Tramadol Hydrochloride/Acetaminophen ER|Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
11432862|NCT01814878|Active Comparator|Tramadol HCl/Acetaminophen IR|Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
11432863|NCT01814865|Experimental|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
11432864|NCT01814865|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
11432870|NCT01814813|Experimental|Arm 1, HSPPC-96 + concomitant bevacizumab|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)
~Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression."
11432871|NCT01814813|Experimental|Arm 2, HSPPC-96 with bevacizumab at progression|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)
~NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.
~Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine."
11432872|NCT01814813|Active Comparator|Arm 3, Bevacizumab|Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)
11432873|NCT01814800|Experimental|RI-002 Treatment|Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
11432874|NCT01814787|Experimental|CHICA Type 2 Diabetes Module|Children treated at the two intervention clinic sites will have be treated using the CHICA system AND will be provided access to the newly developed CHICA Type 2 Diabetes Module. The CHICA Type 2 Diabetes Module will assist pediatricians in identification of those children 10 years of age or older who are at increased risk for type 2 diabetes, it will provide pediatric physicians guidelines to screen for type 2 diabetes, and it will coordinate the diagnosis and long-term management of the condition.
11432875|NCT01814787|No Intervention|Usual Care|Those patients who are assigned to the control group will have the CHICA system but will NOT be cared for using the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will just-in-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
11432876|NCT01814774||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
11432877|NCT01814774||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
11432878|NCT01814761||Pts with POAG or OH (Previously Treatment Naive)|Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
11432879|NCT01814761||Pts with POAG or OH (Switched Monotherapy)|Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
11432880|NCT01814748|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
11432881|NCT01814748|Placebo Comparator|Placebo|Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
11432882|NCT01814735|Experimental|Brown rice|Brown Rice
11432883|NCT01814735|Active Comparator|White rice|White rice
11432884|NCT01814722||Raltegravir + 2 NRTIs|Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
11432885|NCT01814722||NNRTI + 2 NRTIs|Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
11432886|NCT01814722||PI + 2 NRTIs|Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.
11432887|NCT01814709|Experimental|Itraconazole Arm|
11432888|NCT01814709|Experimental|Rifampin Arm|
11432889|NCT01814696|No Intervention|Control|Subjects will continue to receive usual medical care from their doctor(s).
11432890|NCT01814696|Experimental|MedSentry System|Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
11432891|NCT01814683|Experimental|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
11432892|NCT01814683|Placebo Comparator|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
11432893|NCT01814683|Active Comparator|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
11432894|NCT01814670|Experimental|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
11432895|NCT01814657|Placebo Comparator|Normal Saline|Conscious sedation and sterile normal saline (placebo) paracervical block
11432896|NCT01814657|Active Comparator|Lidocaine|Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
11432897|NCT01814644|Active Comparator|Standard Care|Individual assessment Lifestyle counseling
11432898|NCT01814644|Experimental|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
11432899|NCT01814631||Aloka|image quality and resolution
11432900|NCT01814618|No Intervention|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
11432901|NCT01814618|Experimental|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).
~Drug: Budesonide Respules
~Other Names:
~Pulmicort respules
~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
11432902|NCT01814605|Experimental|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.
~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
11432903|NCT01814605|Active Comparator|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
11432904|NCT01814592|Experimental|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
11432905|NCT01814592|Active Comparator|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
11432906|NCT01814579|Experimental|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
11432907|NCT01814579|Active Comparator|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
11432908|NCT01814553|Experimental|Afatinib 40 mg + Loperamide (Cohort 1)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
11432909|NCT01814553|Experimental|Afatinib 40 mg + loperamide prophylactic (Cohort 2)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
11432910|NCT01814540|Placebo Comparator|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
11432911|NCT01814540|Experimental|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period
~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
11432912|NCT01814540|Experimental|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period
~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
11432913|NCT01814527|Active Comparator|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
11432914|NCT01814527|Placebo Comparator|Placebo|The placebo group will be given an equal amount of capsules.
11432915|NCT01814514|Active Comparator|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
11432916|NCT01814514|Placebo Comparator|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
11432917|NCT01814501|Experimental|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
11432918|NCT01814488|Experimental|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
11432919|NCT01814475|Active Comparator|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
11432920|NCT01814475|Experimental|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
11432921|NCT01814462|Experimental|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
11432922|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
11432923|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
11432924|NCT01814436|Experimental|scaffold-free SHED-derived pellet|
11432925|NCT01814423|Experimental|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
11432926|NCT01814423|Active Comparator|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
11432927|NCT01814410|Placebo Comparator|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
11432999|NCT01814072|Experimental|Condition 30|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
11531174|NCT01135888||HED adolescents|
11432928|NCT01814410|Active Comparator|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
11432929|NCT01814410|Active Comparator|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
11432930|NCT01814397||Women starting AI therapy|There is only a single cohort. Postmenopausal women with ER positive breast cancer who are starting treatment with anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily. Choice of therapy is at the discretion of the treating physician.
11432931|NCT01814384|Other|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
11432932|NCT01814384|Other|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
11432933|NCT01814371|Active Comparator|Individualized Approach|The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
11432934|NCT01814371|Active Comparator|Household Approach|All members of the household will perform the decolonization regimen.
11432935|NCT01814358|Experimental|Whey protein|Subjects on this arm will receive whey protein
11432936|NCT01814358|Active Comparator|Gelatin protein|Subjects on this arm will consume gelatin protein
11432937|NCT01814358|No Intervention|Control arm|Subjects on this arm will receive no intervention
11432938|NCT01814332|Experimental|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
11432939|NCT01814332|Placebo Comparator|Placebo|Placebo compound treatment for comparison with IP
11432940|NCT01814319|Experimental|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
11432941|NCT01814319|Placebo Comparator|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
11432942|NCT01814306|Active Comparator|Supreme|Supreme LMA
11432943|NCT01814306|Active Comparator|Proseal|Proseal LMA
11432944|NCT01814293|Active Comparator|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
11432945|NCT01814293|No Intervention|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
11432946|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
11432947|NCT01814267|Experimental|Telemedicine|care and follow-up through telemedicine.
11432948|NCT01814267|Active Comparator|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
11432949|NCT01814254||Receiving hemodialysis|
11432950|NCT01814241|Experimental|Open label peanut OIT|Open label orally ingested peanut flour with maintenance dose of 1450mg
11432951|NCT01814228|Experimental|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
11432952|NCT01814215|Experimental|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
11432953|NCT01814215|Placebo Comparator|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
11432954|NCT01814202|Experimental|PTM202|PTM202 is a medical nutrition product
11432955|NCT01814202|Placebo Comparator|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
11432956|NCT01814189|Active Comparator|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
11432957|NCT01814189|Placebo Comparator|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
11432958|NCT01814176|Active Comparator|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
11432959|NCT01814176|Active Comparator|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
11432960|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
11432961|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
11432964|NCT01814124|Active Comparator|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
11432965|NCT01814124|Experimental|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.
~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
11432966|NCT01814111|Experimental|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
11432967|NCT01814111|No Intervention|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
11432968|NCT01814098|Experimental|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
11432969|NCT01814085|Experimental|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
11432970|NCT01814072|Experimental|Condition 1|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
11432971|NCT01814072|Experimental|Condition 2|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
11432972|NCT01814072|Experimental|Condition 3|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
11432973|NCT01814072|Experimental|Condition 4|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
11432974|NCT01814072|Experimental|Condition 5|1) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
11432975|NCT01814072|Experimental|Condition 6|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
11432976|NCT01814072|Experimental|Condition 7|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
11432977|NCT01814072|Experimental|Condition 8|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
11432978|NCT01814072|Experimental|Condition 9|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
11432979|NCT01814072|Experimental|Condition 10|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
11432980|NCT01814072|Experimental|Condition 11|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
11432981|NCT01814072|Experimental|Condition 12|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
11432982|NCT01814072|Experimental|Condition 13|1) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
11432983|NCT01814072|Experimental|Condition 14|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
11432984|NCT01814072|Experimental|Condition 15|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
11432985|NCT01814072|Experimental|Condition 16|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
11432986|NCT01814072|Experimental|Condition 17|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions
11432987|NCT01814072|Experimental|Condition 18|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
11432988|NCT01814072|Experimental|Condition 19|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
11432989|NCT01814072|Experimental|Condition 20|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
11432990|NCT01814072|Experimental|Condition 21|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
11432991|NCT01814072|Experimental|Condition 22|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
11432992|NCT01814072|Experimental|Condition 23|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
11432993|NCT01814072|Experimental|Condition 24|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
11432994|NCT01814072|Experimental|Condition 25|1) Lifestyle Core; 2) 24 telephone coaching sessions
11432995|NCT01814072|Experimental|Condition 26|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
11432996|NCT01814072|Experimental|Condition 27|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
11432997|NCT01814072|Experimental|Condition 28|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
11432998|NCT01814072|Experimental|Condition 29|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
11433000|NCT01814072|Experimental|Condition 31|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
11433001|NCT01814072|Experimental|Condition 32|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
11433002|NCT01814046|Experimental|cells + high dose aldesleukin|Patients receiving cells + high dose aldesleukin
11433003|NCT01814046|Experimental|cells and no high dose aldesleukin|Patients receiving cells and no high dose aldesleukin
11433004|NCT01814033|Experimental|LRU Pillow|Experimental: LRU Pillow
11433005|NCT01814033|Active Comparator|Control Group|Other: Control Group
11433006|NCT01814007|Experimental|Fat Reduction|
11433007|NCT01813994|Placebo Comparator|Control group|Without simvastatin
11433008|NCT01813994|Experimental|Statin group|With simvastatin
11433009|NCT01813981|Placebo Comparator|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
11433010|NCT01813981|Active Comparator|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
11433011|NCT01813981|Placebo Comparator|Control|110 mg caffeine at start of study
11433012|NCT01813968|Experimental|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
11433013|NCT01813968|No Intervention|Control|Standard operating technique
11433014|NCT01813955|Experimental|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
11433015|NCT01813929|Experimental|Metformin|
11433016|NCT01813929|Placebo Comparator|Placebo|
11433017|NCT01813916|No Intervention|proteomic analysis|
11433018|NCT01813903|Experimental|Nutrition|Intensified dietary counseling and use of web application.
11433019|NCT01813903|Experimental|Flexible mind|Use of mobile applications.
11433020|NCT01813903|No Intervention|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
11433021|NCT01813890|Experimental|Tapentadol IR 50 mg|
11433022|NCT01813890|Experimental|Tapentadol IR 75 mg|
11433023|NCT01813890|Placebo Comparator|Placebo|
11433024|NCT01813877|No Intervention|Standard Diagnostics without PET|
11433025|NCT01813877|Experimental|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
11433026|NCT01813864|Experimental|CASPAR Resource Guide|Treatment Enhanced/CASPAR-- All counselors in this study will receive a training and take part in the experimental arm of the study in Phase 2.
11433027|NCT01813851|No Intervention|control group|"Patients in the control group will receive:
~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
11433028|NCT01813851|Experimental|activity group|"Patients in the group exercise will:
~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
11433029|NCT01813838|Experimental|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
11433030|NCT01813838|Experimental|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
11433031|NCT01813838|Experimental|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
11433032|NCT01813825||Female >=45 years, negative margins, DCIS|
11433033|NCT01813812|Experimental|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
11433034|NCT01813812|Experimental|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
11433035|NCT01813812|Active Comparator|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
11433036|NCT01813799|Experimental|DA-9801 300mg|
11433037|NCT01813799|Experimental|DA-9801 600mg|
11433038|NCT01813799|Experimental|DA-9801 900mg|
11433039|NCT01813799|Placebo Comparator|Placebo|
11433040|NCT01813786|Experimental|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
11433041|NCT01813786|Experimental|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
11433042|NCT01813786|Experimental|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
11433043|NCT01813773|Experimental|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
11433044|NCT01813773|Experimental|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
11433045|NCT01813760|Experimental|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
11433046|NCT01813747|Experimental|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
11433047|NCT01813734|Experimental|Ponatinib Treatment Arm|Ponatinib 30 mg PO daily
11433048|NCT01813721||Group 1|All patients enrolled
11433049|NCT01813708|Experimental|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
11433050|NCT01813708|Active Comparator|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
11433051|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
11433052|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
11433053|NCT01813682|No Intervention|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
11433054|NCT01813682|Experimental|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
11433055|NCT01813682|Experimental|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
11433056|NCT01813669|Experimental|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:
~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
11433057|NCT01813669|No Intervention|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
11433058|NCT01813656|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
11433059|NCT01813656|Placebo Comparator|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
11433060|NCT01813643|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
11433061|NCT01813643|Active Comparator|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
11433062|NCT01813630|Experimental|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
11433063|NCT01813630|Active Comparator|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
11433064|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
11433065|NCT01813604|Active Comparator|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
11433066|NCT01813604|Active Comparator|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
11433067|NCT01813604|Active Comparator|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
11433068|NCT01813604|Active Comparator|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
11433069|NCT01813604|Active Comparator|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
11433070|NCT01813591|Experimental|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
11433071|NCT01813591|Experimental|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
11433072|NCT01813578|Experimental|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
11433073|NCT01813565|Experimental|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
11433074|NCT01813565|Active Comparator|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
11433075|NCT01813552|Experimental|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
11433076|NCT01813552|Experimental|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
11433077|NCT01813539|Experimental|Dose Escalation: Cohort 1|Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.
11433250|NCT01812421|Experimental|Ischemic Stroke or TIA (ISTIA) patients|
11433078|NCT01813539|Experimental|Dose Escalation: Cohort 2|Participants will receive ARGX-110 as an IV infusion at dose level 2.
11433079|NCT01813539|Experimental|Dose Escalation: Cohort 3|Participants will receive ARGX-110 as an IV infusion at dose level 3.
11433080|NCT01813539|Experimental|Dose Escalation: Cohort 4|Participants will receive ARGX-110 as an IV infusion at dose level 4.
11433081|NCT01813539|Experimental|Dose Escalation: Cohort 5|Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.
11433082|NCT01813539|Experimental|Safety Expansion: Cohort 1|Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
11433083|NCT01813539|Experimental|Safety Expansion: Cohort 2|Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
11433084|NCT01813539|Experimental|Safety Expansion: Cohort 3|Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
11433085|NCT01813539|Experimental|Safety Expansion: Cohort 4|Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
11433086|NCT01813539|Experimental|Exploratory Efficacy: Cohort 5|Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.
11433087|NCT01813526|Experimental|Experimental Infant Formula|Experimental formula to be fed ad libitum.
11433088|NCT01813513|Experimental|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
11433089|NCT01813513|Experimental|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
11433090|NCT01813513|Experimental|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
11433091|NCT01813513|Experimental|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
11433092|NCT01813513|Experimental|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
11433093|NCT01813513|Experimental|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
11433094|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
11433095|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
11433096|NCT01813487|Other|HBsAg vaccine with Entecavir|
11433097|NCT01813474|Experimental|olaparib tablet monotherapy|olaparib tablet
11433098|NCT01813461|Experimental|14C-labeled prodrug isavuconazonium sulfate|single dose
11433099|NCT01813448|Experimental|Cohort 1: Fidaxomicin low dose in Japanese males|
11433100|NCT01813448|Experimental|Cohort 2: Fidaxomicin high dose in Japanese males|
11433101|NCT01813448|Experimental|Cohort 3: Fidaxomicin high dose in Caucasian males|
11433102|NCT01813448|Placebo Comparator|Matching Placebo in Caucasian males|
11433103|NCT01813448|Placebo Comparator|Matching Placebo in Japanese males|
11433104|NCT01813435|Experimental|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.
~Dosage and frequency:
~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
11433105|NCT01813435|Active Comparator|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.
~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.
~Dosage and frequency:
~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
11433106|NCT01813422|Placebo Comparator|Placebo|Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
11433107|NCT01813422|Experimental|Evolocumab|Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
11433108|NCT01813396|Experimental|joint mobilization/massage|"joint mobilization: End-range joint mobilization
~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
11433109|NCT01813396|Experimental|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
11433110|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
11433111|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
11433112|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
11433113|NCT01813357|Placebo Comparator|Placebo|sugar pill that is encapsulated so as to appear identical to the active agent
11433114|NCT01813357|Experimental|Rosuvastatin|Rosuvastatin 20mg daily
11433115|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
11433116|NCT01813318|Placebo Comparator|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
11433251|NCT01812395|Active Comparator|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
11433117|NCT01813318|Active Comparator|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
~Other Name: Campral"
11433118|NCT01813305|Active Comparator|CSTC1|CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
11433119|NCT01813305|Placebo Comparator|CSTC1 Matched vehicle|Matched vehicle, topical, two times daily
11433120|NCT01813279|Experimental|patients|
11433121|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
11433122|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
11433123|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
11433124|NCT01813253|Experimental|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
11433125|NCT01813253|Active Comparator|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
11433126|NCT01813240|Experimental|Minocycline, Spinal Tumor patients, quality of life|
11433127|NCT01813240|Experimental|Minocycline, Trauma patuents, quality of life|
11433128|NCT01813240|Placebo Comparator|Placebo, Trauma patients, quality of life|
11433129|NCT01813240|Placebo Comparator|Placebo, Spinal cord tumors, quality of life|
11433130|NCT01813227|Experimental|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if > 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
11433131|NCT01813214|Experimental|Vemurafenib Monotherapy|Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
11433132|NCT01813214|Experimental|Vemurafenib + Cobimetinib Combination Therapy|"Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
~Cobimetinib will be given 60mg QD for 21 days on, then 7 days off, in a 28-day treatment cycle."
11433133|NCT01813201|Active Comparator|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
11433134|NCT01813201|Placebo Comparator|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
11433135|NCT01813188|Experimental|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
11433136|NCT01813188|Active Comparator|autologous bone graft|autologous bone graft
11433137|NCT01813175|Active Comparator|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
11433138|NCT01813175|Active Comparator|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
11433139|NCT01813175|Placebo Comparator|Control Group|Regular non-hydrolysed cow's milk based infant formula
11433140|NCT01813175|No Intervention|Reference Group|Exclusively breast-fed infants
11433141|NCT01813162|Active Comparator|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
11433142|NCT01813162|Active Comparator|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:
~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.
~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.
~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
11433143|NCT01813162|Experimental|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:
~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.
~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.
~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
11433144|NCT01813149|Experimental|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at affected and unaffected sites.
11433145|NCT01813136|Active Comparator|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
11433146|NCT01813136|Experimental|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.
~This sequential scheme will be maintained until the patient experiences on-treatment progression"
11433147|NCT01813123|No Intervention|Control|
11433148|NCT01813123|Experimental|Intervention|RealTeen
11433149|NCT01813110|Placebo Comparator|Placebo|Identical olive oil capsules
11433150|NCT01813110|Experimental|Omega-3|4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)
11433151|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
11433152|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
11433153|NCT01813084|Experimental|Part A: single dose escalation|
11433154|NCT01813084|Experimental|Part B: 14 day repeat dose escalation (healthy volunteers)|
11433155|NCT01813084|Experimental|Part C: 14 day repeat dose (asthma patients)|
11433156|NCT01813071|Experimental|Part A (Adults): Cohort A1|One oral dose of ~3x10^4 cfu WRSS1(10 participants) or placebo (3 participants)
11433157|NCT01813071|Experimental|Part A (Adults): Cohort A2|Three oral doses of ~3x10^5 cfu WRSS1(10 participants) or placebo (3 participants)
11433158|NCT01813071|Experimental|Part A (Adults): Cohort A3|Three oral doses of ~3x10^6 cfu WRSS1(10 participants) or placebo (3 participants)
11433159|NCT01813071|Experimental|Part B (Children): Cohort B1|One oral dose of ~3x10^3 cfu WRSS1(12 participants) or placebo (4 participants)
11433160|NCT01813071|Experimental|Part B (Children): Cohort B2|Three oral doses of ~3x10^4 cfu WRSS1(12 participants) or placebo (4 participants)
11433161|NCT01813071|Experimental|Part B (Children): Cohort B3|Three oral doses of ~3x10^5 cfu WRSS1(12 participants) or placebo (4 participants)
11433162|NCT01813071|Experimental|Part B (Children): Cohort B4|Three oral doses of ~3x10^6 cfu WRSS1(12 participants) or placebo (4 participants)
11433163|NCT01813058|Placebo Comparator|Placebo|Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery.
11433164|NCT01813058|Active Comparator|Tranexamic acid|Tranexamic acid 100 mg/ml; 50 mg/kg loading dose = 0.5 ml/kg LD given over 15 minutes and 10 mg/kg/hr = 0.1 ml/kg/hr infusion for the duration of the surgery.
11433165|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.
~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
11433166|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.
~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.
~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
11433167|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.
~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.
~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
11433168|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
11433169|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
11433170|NCT01813019|Experimental|AFQ056|"Following baseline, approximately 60 patients who are considered eligible will be randomized to AFQ056 arm and will receive the dosing regimen of 4 weeks AFQ056 b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks AFQ056 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg AFQ056 b.i.d)
~*patients that do not tolerate 200 mg b.i.d may be down-titrated to 150 mg b.i.d."
11433171|NCT01813019|Placebo Comparator|Placebo|Following baseline, approximately 60 patients who are considered eligible will be randomized to Placebo arm and will receive the dosing regimen of 4 weeks Placebo b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks Placebo 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg Placebo b.i.d) *patients that do not tolerate 200 matching placebo AFQ056 mg b.i.d may be down-titrated to 150 mg b.i.d.
11433172|NCT01813006|Active Comparator|Omega-3|Omega-3 fatty acids
11433173|NCT01813006|Placebo Comparator|Placebo|Placebo/olive oil
11433174|NCT01812993|No Intervention|Control|No ventilatory treatment; standard stroke care
11433175|NCT01812993|Experimental|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
11433176|NCT01812980|Experimental|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe
~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:
~an A/California/7/2009 (H1N1)pdm09-like virus;
~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
11433177|NCT01812941|Other|Burn: blood collection|Procedure: Blood draws as the intervention.
11433178|NCT01812941|Other|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
11433179|NCT01812941|Other|healthy volunteers: blood collection|Blood draws as the intervention
11433180|NCT01812928|No Intervention|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
11433181|NCT01812928|Experimental|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
11433182|NCT01812915|Experimental|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
11433183|NCT01812915|Experimental|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
11433184|NCT01812902|Experimental|Extended LND|Radical Prostatectomy with extended lymphadenectomy
11433185|NCT01812902|Active Comparator|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
11433186|NCT01812889|Active Comparator|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
11433187|NCT01812889|Active Comparator|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
11433188|NCT01812863|Experimental|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
11433252|NCT01812395|Active Comparator|Classic thyroidectomy|Patients having conventional thyroidectomy
11433189|NCT01812863|Placebo Comparator|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
11433190|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
11433191|NCT01812837|Experimental|20 minutes incubation - with pretreatment|
11433192|NCT01812837|Experimental|40 minutes incubation - with pretreatment|
11433193|NCT01812837|Experimental|60 minutes incubation - with pretreatment|
11433194|NCT01812837|Sham Comparator|60 minutes incubation - no pretreatment|
11433195|NCT01812824|Experimental|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
11433196|NCT01812824|No Intervention|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
11433197|NCT01812798|Active Comparator|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge
~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.
~0.1 0.25 0.5 0.75
~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
11433198|NCT01812798|Placebo Comparator|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
11433199|NCT01812772|Experimental|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
11433200|NCT01812772|Active Comparator|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
11433201|NCT01812759|Experimental|Fentanyl Nasal Spray + Hydromorphone PCA|Fentanyl 100 mcg nasal spray administered plus hydromorphone PCA. All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
11433202|NCT01812759|Experimental|Placebo Nasal Spray + Hydromorphone PCA|Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
11433203|NCT01812746|Experimental|BIND-014|
11433204|NCT01812720|Experimental|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11433205|NCT01812707|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
11433206|NCT01812707|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
11433207|NCT01812707|Experimental|Alirocumab 75 mg Q2W|Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
11433208|NCT01812707|Placebo Comparator|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
11433209|NCT01812694|Active Comparator|Enhanced Standard Care|Standard prenatal care plus education
11433210|NCT01812694|Experimental|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
11433211|NCT01812681||Low vitamin D level|The premature infants with low cord blood vitamin D level
11433212|NCT01812681||Normal Vitamin D|The premature infants with normal vitamin D level
11433213|NCT01812668|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.
11433214|NCT01812655|Experimental|Virtual Reality|Virtual reality using a software program designed for burn patients during burn wound care
11433215|NCT01812655|Active Comparator|Passive distraction|watching a movie
11433216|NCT01812655|No Intervention|UC provided by the nurses|
11433217|NCT01812642|Experimental|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
11433218|NCT01812642|Experimental|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
11433219|NCT01812629|Experimental|Experimental Infant Formula|Complete peptide amino acid-based infant formula
11433220|NCT01812616|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
11433221|NCT01812616|Placebo Comparator|Placebo and Dose-Intense Temozolomide|Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
11433222|NCT01812603|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide and in open-label manner
11433223|NCT01812590|No Intervention|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
11433224|NCT01812590|Experimental|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
11433225|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
11433226|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
11433295|NCT01812096|Experimental|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
11433227|NCT01812564|Placebo Comparator|PPP|"Placebo: Platelet Poor Plasma
~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).
~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
11433228|NCT01812564|Active Comparator|PRP|"Biological: Platelet Rich Plasma
~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).
~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
11433229|NCT01812564|No Intervention|Physiotherapy|"These patients will not receive an injection.
~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
11433230|NCT01812551|Active Comparator|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).
~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight >25 kg."
11433231|NCT01812551|Placebo Comparator|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).
~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
11433232|NCT01812538|Placebo Comparator|Placebo|Placebo
11433233|NCT01812538|Experimental|Experimental 1|DIC075V 37.5 mg
11433234|NCT01812538|Experimental|Experimental 2|DIC075V 75 mg
11433235|NCT01812538|Active Comparator|Active control|Moxifloxacin hydrochloride 400 mg
11433236|NCT01812525|Active Comparator|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.
~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
11433237|NCT01812525|Placebo Comparator|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
11433238|NCT01812512|Other|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
11433239|NCT01812512|Other|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
11433240|NCT01812486|Active Comparator|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
11433241|NCT01812486|Experimental|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
11433242|NCT01812473||Patients admitted to the Intensive Care Unit|All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.
11433243|NCT01812460|Experimental|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
~The weight cuffs are handed over to the patients for self guided exercise during weekends"
11433244|NCT01812460|No Intervention|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
11433245|NCT01812447|Experimental|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
11433246|NCT01812447|Experimental|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
11433247|NCT01812447|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
11433248|NCT01812434|Experimental|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
11433249|NCT01812434|Experimental|Placebo|Subject randomized to either Sildenafil or placebo arm
11433253|NCT01812382|Experimental|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
11433254|NCT01812369|Experimental|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
11433255|NCT01812369|Active Comparator|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
11433256|NCT01812356|Experimental|Argon gas probe|Cryomaze procedure using Argon gas probe
11433257|NCT01812356|Active Comparator|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
11433258|NCT01812343|Other|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
11433259|NCT01812330|Experimental|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
11433260|NCT01812330|Experimental|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
11433261|NCT01812330|Experimental|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
11433262|NCT01812317|Active Comparator|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
11433263|NCT01812317|Sham Comparator|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
11433264|NCT01812304|Experimental|hands-on training|probands perform predefined maneuvers to manage a vaginal breech hands-on after one instruction
11433265|NCT01812304|Active Comparator|frontal teaching|Probands perform predefined maneuvers to resolve a vaginal breech after forntal teaching
11433266|NCT01812291|Experimental|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)
~Step 2: Depression-Specific CBT (6 single sessions)
~Step 3: Referral to Psychotherapist and/or Psychiatrist"
11433267|NCT01812291|Active Comparator|Treatment-as-usual|Standard Diabetes Education
11433268|NCT01812278|Experimental|ACT|Acceptance & Commitment Therapy
11433269|NCT01812278|Active Comparator|CBT|Cognitive Behavioral Therapy
11433270|NCT01812265|Experimental|PF-06305591 Dose 1|
11433271|NCT01812265|Experimental|PF-06305591 Dose 2|
11433272|NCT01812265|Placebo Comparator|Placebo|
11433273|NCT01812252|Other|Arm A (decitabine or azacitidine)|Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
11433274|NCT01812252|Other|Arm B (induction-like chemotherapy regimen)|Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
11433275|NCT01812239|Active Comparator|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
11433276|NCT01812239|Placebo Comparator|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
11433277|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
11433278|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
11433279|NCT01812213|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months
11433280|NCT01812200|Active Comparator|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
11433281|NCT01812200|Active Comparator|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
11433282|NCT01812200|Active Comparator|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
11433283|NCT01812187|Experimental|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
11433284|NCT01812174|Experimental|17mm On-X Aortic Heart Valve|Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
11433285|NCT01812174|Experimental|23mm On-X Mitral Heart Valve|"Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.
~Enrollment into the 23mm On-X mitral arm has been terminated."
11433286|NCT01812161|Active Comparator|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
11433287|NCT01812161|Sham Comparator|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
11433288|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
11433289|NCT01812135|Experimental|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
11433290|NCT01812135|Experimental|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
11433291|NCT01812135|Experimental|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
11433292|NCT01812122|Experimental|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
11433293|NCT01812122|Experimental|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
11433294|NCT01812109|Experimental|Hutchison Technologies Inspectra StO2 NIRS|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy (NIRS) evaluation of acute scrotum per protocol
11433296|NCT01812096|Active Comparator|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
11433297|NCT01812070|Experimental|ACT|Acceptance & Commitment Therapy
11433298|NCT01812070|Active Comparator|CBT|Cognitive Behavioral Therapy
11433299|NCT01812057|Experimental|Dexamethasone|Dexamethasone 8 mg IV given intraoperatively as a one-time dose.
11433300|NCT01812057|Placebo Comparator|Placebo|Sodium chloride 0.9% (5 ml) given IV intraoperatively as a one time dose.
11433301|NCT01812044|Other|subtenons anesthetic and topical control|Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery
11433302|NCT01812044|Other|topical anesthetic and subtenons control|Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery
11433303|NCT01812044|Other|topical control and subtenons control|Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery
11433304|NCT01812031|Experimental|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
11433305|NCT01812018|Experimental|Endostar|Endostar, Gemcitabine, Docetaxel
11433306|NCT01812005|Experimental|Cohort A (alisertib, rituximab)|Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11433307|NCT01812005|Experimental|Cohort B (alisertib, rituximab)|Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11433308|NCT01811992|Experimental|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:
~A= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^9 vp
~B= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^9 vp
~C= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^10 vp
~D= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^10 vp
~E= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^11 vp
~F= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^11 vp
~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation. Once the Maximum Tolerated Dose (MTD) is determined, or after all subjects have been evaluated and found to tolerate the highest dose, the study will end."
11433309|NCT01811979|Active Comparator|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
11433310|NCT01811979|Placebo Comparator|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
11433311|NCT01811966|Sham Comparator|Control|preoperative none substitution of i.v. fluids.
11433312|NCT01811966|Active Comparator|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
11433313|NCT01811953|Experimental|1 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
11433314|NCT01811953|Experimental|2 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
11433315|NCT01811953|Experimental|3 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fasted conditions
11433316|NCT01811953|Experimental|4 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
11433317|NCT01811953|Experimental|5 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
11433318|NCT01811953|Experimental|6 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
11433319|NCT01811940|Experimental|Adderall-ER and Topiramate|Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
11433320|NCT01811940|Placebo Comparator|Placebo|Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
11433321|NCT01811927|Experimental|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
11433322|NCT01811914|Experimental|intraoperative TTE|TTE if a hemodynamic instability occurs
11433323|NCT01811901|Active Comparator|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
11433324|NCT01811901|No Intervention|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
11433325|NCT01811888||Patients with knee osteoarthritis|
11433326|NCT01811875|Experimental|Optivate 500IU|Optivate 500IU
11433327|NCT01811862|Experimental|Acupuncture|Acupuncture treatment once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
11433328|NCT01811862|Sham Comparator|Sham acupuncture|Sham acupuncture once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
11433329|NCT01811849|Experimental|BIOD-238|Subcutaneous injection
11433330|NCT01811849|Experimental|BIOD-250|Subcutaneous injection
11433331|NCT01811849|Active Comparator|Humalog|Subcutaneous injection
11433365|NCT01811615|Experimental|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
11433366|NCT01811615|No Intervention|toothbrushing alone|negative control
11433332|NCT01811836|Experimental|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (>97% enrichment),68Zn (>99% enrichment) and 70Zn (>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of ~800 μg of 68Zn.
~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
11433333|NCT01811823|Other|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.
~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:
~A/California/7/2009 (H1N1)pdm-like virus
~A/Victoria/361/2011 (H3N2)-like virus
~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
11433334|NCT01811810|Other|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
11433335|NCT01811810|Other|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
11433336|NCT01811797|Experimental|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
11433337|NCT01811797|Sham Comparator|Control group|
11433338|NCT01811784|Experimental|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
11433339|NCT01811784|Experimental|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
11433340|NCT01811784|No Intervention|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
11433341|NCT01811784|No Intervention|Phase 2:|Raw sap consumption from skirt protected trees
11433342|NCT01811771|Active Comparator|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
11433343|NCT01811771|No Intervention|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
11433344|NCT01811758|Experimental|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
11433345|NCT01811758|Active Comparator|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
11433346|NCT01811745|Experimental|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
11433347|NCT01811745|Active Comparator|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
11433348|NCT01811732|Experimental|Delafloxacin plus placebo|Delafloxacin 300 mg IV every 12 hours for a minimum of 10 and up to a maximum of 28 doses
11433349|NCT01811732|Active Comparator|Vancomycin plus Aztreonam + placebo|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 and up to a maximum of 28 doses (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
11433350|NCT01811719|Experimental|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:
~Structured and regularly occuring assessments for intimate partner violence (IPV);
~McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and
~Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
11433351|NCT01811719|Active Comparator|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
11433352|NCT01811706|Experimental|Dalfampridine and then placebo|Participant first receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks. After a washout period of 2 weeks, they then receive Placebo tablet orally every 12 hours, for a 4 weeks period.
11433353|NCT01811706|Experimental|Placebo, Then Dalfampridine|Participant first receive Placebo tablet orally every 12 hours, for a 4 weeks period. After a washout period of 2 weeks, they then receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks.
11433354|NCT01811693|Experimental|Dose Tier 1|Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
11433355|NCT01811693|Experimental|Dose Tier 2|Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
11433356|NCT01811693|Experimental|Dose Tier 3|Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
11433357|NCT01811680|Experimental|supervised treadmill training|Supervised treadmill training on variable sensing treadmill.
11433358|NCT01811667|Experimental|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
11433359|NCT01811654|No Intervention|Standard Care|Patients in this group will receive treatment per standard care. Standard Care is defined as consisting of physical therapy, activity modification (relative rest), and/or oral analgesic therapy. A specific physical therapy (PT) protocol will be implemented.
11433360|NCT01811654|Active Comparator|Intra-Articular Hyaluronic Acid-Euflexxa|Patients assigned to this group will receive treatment per standard care AND three (3) consecutive weekly injections of intra-articular hyaluronan (Euflexxa). Oral analgesics will be used at the lowest dose and for the shortest time possible to treat PFPS symptoms.
11433361|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
11433362|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
11433363|NCT01811615|Active Comparator|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
11433364|NCT01811615|Experimental|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
11433367|NCT01811602|Other|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
11433368|NCT01811602|Other|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
11433369|NCT01811589|Experimental|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
11433370|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
11433371|NCT01811576|Active Comparator|recombinant human growth hormone|Daily subcutaneous dose
11433372|NCT01811576|Experimental|TV-1106|Titration dose levels of TV-1106
11433373|NCT01811563|Active Comparator|Stryker|Subjects will be receiving the Stryker Triathlon total knee replacement
11433374|NCT01811563|Active Comparator|Zimmer|Subjects will be receiving a Zimmer NexGen total knee replacement
11433375|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
11433376|NCT01811537|Experimental|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
11433377|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
11433378|NCT01811511|Experimental|Chungkookjang|Chungkookjang(35g/day)
11433379|NCT01811511|Placebo Comparator|Placebo|Placebo(35g/day)
11433380|NCT01811498|Experimental|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
11433381|NCT01811485|Experimental|LMF237 50/250 mg|Patients took LMF237 50/250 mg twice daily for 14 weeks
11433382|NCT01811485|Experimental|LMF237 50/500 mg|Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks
11433383|NCT01811485|Placebo Comparator|Placebo|Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks
11433384|NCT01811472|Placebo Comparator|Placebo|Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
11433385|NCT01811472|Experimental|pradigastat (LCQ908) 5mg/10mg|Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
11433386|NCT01811472|Experimental|pradigastat (LCQ908) 10mg/20mg|Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
11433387|NCT01811459|Experimental|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
11433388|NCT01811459|Experimental|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
11433389|NCT01811459|Placebo Comparator|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
11433390|NCT01811446|Experimental|Obese|Subjects with BMI > 30
11433391|NCT01811446|Experimental|COPD|Non-hospitalized COPD patients
11433392|NCT01811420|Experimental|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
11433393|NCT01811420|Active Comparator|conventional method|Dental caries removal using rotatory instrument
11433394|NCT01811407|Other|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
11433395|NCT01811407|Experimental|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
11433396|NCT01811407|Experimental|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
11433397|NCT01811394|Experimental|protons|16x4GyE protons
11433398|NCT01811394|Experimental|Carbon ions|16x4GyE carbon ions
11433399|NCT01811381|Experimental|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
11433423|NCT01811238|Experimental|Oxycodone/Naloxone|Single-arm study
11433551|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
11433400|NCT01811381|Placebo Comparator|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
11433401|NCT01811381|Active Comparator|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
11433402|NCT01811381|Active Comparator|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
11433403|NCT01811368|Experimental|Treatment (ibritumomab tiuxetan, allogeneic PBSCT)|"CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28."
11433404|NCT01811355|Active Comparator|Mexiletine|Mexiletine, capsule, 150mg, PO BID, 14 days
11433405|NCT01811355|Placebo Comparator|Placebo|Placebo, capsule, PO BID, 14 days
11433406|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
11433407|NCT01811329|Active Comparator|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
11433408|NCT01811329|Experimental|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
11433409|NCT01811329|Active Comparator|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
11433410|NCT01811329|Experimental|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
11433411|NCT01811316|Active Comparator|Probiotics Lozenge (twice a day)|Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
11433412|NCT01811316|Active Comparator|Probiotics Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
11433413|NCT01811316|Placebo Comparator|Placebo Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
11433414|NCT01811303|Experimental|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
11433415|NCT01811303|Placebo Comparator|Control|Sucrose 50 g without d-fagomine, in 200 ml water
11433416|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
11433417|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
11433418|NCT01811277|Experimental|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
11433419|NCT01811264|Experimental|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
11433420|NCT01811264|No Intervention|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
11433421|NCT01811251|Experimental|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
11433422|NCT01811251|Placebo Comparator|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
11433424|NCT01811225|Experimental|Low-Dose Contraceptive, then High-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.
~Participants in this arm will begin with the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the high dose progesterone, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM)."
11433425|NCT01811225|Experimental|High-Dose Contraceptive, then Low-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.
~Participants in this arm will begin with the high progesterone dose, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM)."
11433426|NCT01811212|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11433427|NCT01811186|Other|Group A|Start oxycodone/naloxone 10/5mg b.i.d. titration->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
11433428|NCT01811186|Other|Group B|Start oxycodone/naloxone 5/2.5mg b.i.d titration-> 10/5mg b.i.d.->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
11433429|NCT01811173|Experimental|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
11433430|NCT01811173|No Intervention|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
11433431|NCT01811173|No Intervention|Usual care blinded control group|Patients will receive usual primary care.
11433432|NCT01811160|Experimental|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
11433433|NCT01811160|Placebo Comparator|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
11433434|NCT01811147|Experimental|High Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant.
11433435|NCT01811147|Experimental|Low Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant..
11433436|NCT01811147|No Intervention|Healthy Control|There is no intervention, but rather phone follow ups conducted as check ins to determine the continued eligibility of the healthy control participant.
11433437|NCT01811147|No Intervention|Bipolar|Bipolar participants are checked in with via phone conversations every three months, and have the opportunity to be scheduled for non-study visits to manage their symptoms.
11433438|NCT01811134|Experimental|PIPELINE flow diverter stent|flow diverter stent
11433439|NCT01811134|Active Comparator|Coils, with or without expendable stent|Coils
11433440|NCT01811121|Experimental|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
11433441|NCT01811121|Placebo Comparator|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
11433442|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
11433443|NCT01811095|Experimental|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
11433444|NCT01811095|Placebo Comparator|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
11433445|NCT01811082|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
11433446|NCT01811082|Active Comparator|Pantethine 600mg|Pantethine 600mg per day.
11433447|NCT01811056|No Intervention|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
11433448|NCT01811056|Experimental|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
11433449|NCT01811043|Experimental|Guided Meditation|Guided meditation is played via headphones during biopsy
11433450|NCT01811043|Active Comparator|Music|Music is played via headphones during biopsy
11433451|NCT01811043|Placebo Comparator|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
11433452|NCT01811030|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
11433453|NCT01811017|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
11433454|NCT01811017|Experimental|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
11433455|NCT01811004|Experimental|Botox®|Botox®
11433456|NCT01811004|Experimental|miraDry®|miraDry®
11433457|NCT01811004|Experimental|Nd: YAG laser|Nd: YAG laser 1440nm
11433458|NCT01810991|Experimental|Nd:YAG Laser|Nd:YAG 1440nm Laser
11433459|NCT01810978|Active Comparator|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
11433460|NCT01810978|Placebo Comparator|maltodextrin|maltodextrin
11433461|NCT01810965|Experimental|Cohort|
11433482|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
11433586|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
11433462|NCT01810952|Experimental|Glargine/Lispro Insulin Arm|"Drug: Glargine insulin was administered per above.
~Drug: Lispro insulin 0.2 unit/kg/day was administered per above. A coverage dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent was divided between 3 meals. The maximum starting coverage dose was 0.4 units/kg per day.
~The prandial dose of lispro was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG is >200 mg/dL. The prandial dose of lispro was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.
~Drug: prednisone or equivalent dose was determined by severity of exacerbation and clinician's judgement."
11433463|NCT01810952|Experimental|Glargine/Lispro/NPH Insulin Arm|"Drugs Glargine and Lispro insulin included similar starting doses of glargine and lispro.
~Drug: A coverage dose of NPH insulin 0.1 unit/kg/day for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the glucocorticoid. Maximum starting coverage dose was 0.4 units/kg per day. NPH dose was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was greater than 200 mg/dL. It was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.
~Drug: the dose of prednisone or equivalent glucocorticoid was determined by severity of exacerbation and clinician's judgement."
11433464|NCT01810939|Active Comparator|Patiromer|Patiromer was administered twice a day as a powder mixed with water.
11433465|NCT01810939|Placebo Comparator|Placebo|Placebo was administered twice a day as a powder mixed with water.
11433466|NCT01810926|Experimental|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 & ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
11433467|NCT01810926|Sham Comparator|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
11433468|NCT01810926|Experimental|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 & Rituximab in a single infusion of 200 mg/m2 on day -1
11433469|NCT01810926|Sham Comparator|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
11433470|NCT01810913|Experimental|Arm 1 (IMRT, cisplatin)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks.
11433471|NCT01810913|Experimental|Arm 2 (IMRT, docetaxel)|Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks. (CLOSED AS OF 20-MAR-2020)
11433472|NCT01810913|Experimental|Arm 3 (IMRT, docetaxel, cetuximab)|Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks.
11433473|NCT01810913|Experimental|Arm 4 (IMRT, cisplatin, atezolizumab)|Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity.
11433474|NCT01810900|Experimental|Protescal|Protescal is applied to this arm.
11433475|NCT01810900|No Intervention|non-treatment|
11433476|NCT01810887|Experimental|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
11433477|NCT01810874|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
11433478|NCT01810874|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
11433479|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
11433480|NCT01810848|Active Comparator|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
11433481|NCT01810848|Sham Comparator|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
11438219|NCT01778244|Experimental|metformin|metformin
11433483|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
11433484|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
11433485|NCT01810809|Active Comparator|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
11433486|NCT01810809|Experimental|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
11433487|NCT01810809|Experimental|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
11433488|NCT01810809|Experimental|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
11433489|NCT01810796|Experimental|Ranolazine treatment|Ranolazine 500-1000mg bid
11433490|NCT01810796|Placebo Comparator|Placebo|Placebo
11433491|NCT01810783|Experimental|Brexpiprazole|
11433492|NCT01810770|Experimental|Radium-223 dichloride|
11433493|NCT01810757|Active Comparator|Standard planning|Standard planning radiotherapy
11433494|NCT01810757|Experimental|Adaptive planning|Adaptive planning radiotherapy
11433495|NCT01810744|Other|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
11433496|NCT01810744|Other|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
11433497|NCT01810731|Experimental|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.
~Administered as a single dose on the day of enrollment."
11433498|NCT01810731|Active Comparator|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
11433499|NCT01810731|Experimental|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.
~Administered as a single dose on the day of enrollment."
11433500|NCT01810718|Experimental|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.
~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
11433501|NCT01810705|Experimental|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
11433502|NCT01810705|No Intervention|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
11433503|NCT01810692||Group 1|
11433504|NCT01810692||Group 2|
11433505|NCT01810679|Experimental|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
11433506|NCT01810666|Experimental|Recombinant Factor VIII|
11433507|NCT01810653|Experimental|Macrogol (Transipeg)|
11433508|NCT01810653|Active Comparator|Macrogol (Forlax)|
11433509|NCT01810640|No Intervention|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
11433510|NCT01810640|Active Comparator|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
11433511|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
11433512|NCT01810614|Experimental|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
11433513|NCT01810601|Experimental|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
11433514|NCT01810601|Placebo Comparator|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
11433515|NCT01810588|Experimental|All Patients|"Haplo-cord transplantation:
~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.
~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.
~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
11433516|NCT01810575|Active Comparator|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
11433517|NCT01810575|Experimental|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
11433518|NCT01810575|Placebo Comparator|WC3036-13P/Vehicle Only 0.5%|Treatment C
11433519|NCT01810562|Experimental|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
11433520|NCT01810562|No Intervention|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
11433521|NCT01810549|Active Comparator|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
11433522|NCT01810549|Placebo Comparator|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
11433523|NCT01810536|Experimental|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
11434437|NCT01804270|Sham Comparator|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
11433524|NCT01810536|Active Comparator|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
11433525|NCT01810523|Experimental|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
11433526|NCT01810523|Placebo Comparator|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
11433527|NCT01810510|Experimental|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
11433528|NCT01810510|Experimental|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
11433529|NCT01810497|Active Comparator|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
11433530|NCT01810497|Active Comparator|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
11433531|NCT01810484|Active Comparator|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.
~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
11433532|NCT01810484|Active Comparator|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.
~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
11433533|NCT01810484|Active Comparator|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.
~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
11433534|NCT01810471|Experimental|ankle supports|
11433535|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
11433536|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
11433537|NCT01810432|Experimental|Evacetrapib (Fasted)|130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days.
11433538|NCT01810432|Experimental|Evacetrapib (Fed)|130 mg oral dose of evacetrapib once daily following a high-fat breakfast for 10 days.
11433539|NCT01810419|Experimental|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld
~Will complete questionaire for both:
~Adequacy of image quality
~What is best view obtained
~Greatest Longitudinal Measure
~Diagnosis
~Diagnostic Certainty
~Time to Complete exam"
11433540|NCT01810406|Experimental|Epidural Volume Extension|CSE with 10 ml EVE
11433541|NCT01810406|Active Comparator|No Epidural Volume Extension|CSE without EVE
11433542|NCT01810393|Experimental|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
11433543|NCT01810393|Experimental|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
11433544|NCT01810380|Placebo Comparator|Placebo|
11433545|NCT01810380|Experimental|Brexpiprazole|Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
11433546|NCT01810380|Other|Quetiapine extended release|Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
11433547|NCT01810367|Experimental|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
11433548|NCT01810367|Active Comparator|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
11433549|NCT01810354|Experimental|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
11433550|NCT01810354|Active Comparator|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
11434438|NCT01804257|Experimental|Digital Health Feedback System (DHFS)|Ingestion Sensor, Wearable Sensor
11433552|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
11433553|NCT01810328|Active Comparator|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
11433554|NCT01810328|Active Comparator|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
11433555|NCT01810315|No Intervention|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
11433556|NCT01810315|Experimental|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.
~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
11433557|NCT01810315|Experimental|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
11433558|NCT01810315|Experimental|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
11433559|NCT01810302|Experimental|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
11433560|NCT01810302|Placebo Comparator|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
11433561|NCT01810289|Experimental|MJAP Clinics Intervention|START intervention. This is a stepped wedge design so each clinic will experience both conditions.
11433562|NCT01810289|No Intervention|MJAP Clinics Pre-Intervention|Standard of care. This is a stepped wedge design so each clinic will experience both conditions.
11433563|NCT01810276|Placebo Comparator|Saline|400 mL of Saline will be given intravenously over 2 hours once.
11433564|NCT01810276|Active Comparator|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
11433565|NCT01810263|Experimental|high protein supplement|high protein supplement given
11433566|NCT01810263|No Intervention|Control|no intervention
11433567|NCT01810250||Abdominal Aortic Aneurysm (Challenging anatomy)|Endovascular aneurysm repair
11433568|NCT01810237|Experimental|Dabigtran instead of LMWH for perioperative bridging.|
11433569|NCT01810224|Active Comparator|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
11433570|NCT01810224|Experimental|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
11433571|NCT01810211|Experimental|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.
~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
11433572|NCT01810211|Experimental|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.
~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
11433573|NCT01810211|No Intervention|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
11433574|NCT01810198|Active Comparator|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
11433575|NCT01810198|Active Comparator|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
11433576|NCT01810185|Experimental|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
11433577|NCT01810185|Placebo Comparator|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
11433578|NCT01810172|Active Comparator|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
11433579|NCT01810172|Experimental|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
11433580|NCT01810159|Experimental|ICC|Integrated collaborative care
11433581|NCT01810159|Active Comparator|E&R|Education and Resources--enhanced usual care
11433582|NCT01810146|No Intervention|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
11433583|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
11433584|NCT01810120|Experimental|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
11433585|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
11433587|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
11433588|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
11433589|NCT01810068|Sham Comparator|Placebo|patients who are undergoing diagnostic cystoscopy
11433590|NCT01810068|Active Comparator|HOLEP|Holmium laser enucleation of the prostate
11433591|NCT01810068|Active Comparator|monopolar TURP|Monopolar transurethral resection of the prostate
11433592|NCT01810068|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate
11433593|NCT01810042|Experimental|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
11433594|NCT01810029|Experimental|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
11433595|NCT01810029|Active Comparator|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
11433596|NCT01810016|Experimental|Arm A|Ipilimumab (IV) followed by NY-ESO-1 recombinant protein mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
11433597|NCT01810016|Experimental|Arm B|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
11433598|NCT01810016|Experimental|Arm C|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC (SC) every 3 weeks for 4 doses.
11433599|NCT01810003|Experimental|High DHA|High DHA supplementation (3g/day)
11433600|NCT01810003|Experimental|High EPA|EPA supplementation (3g/day)
11433601|NCT01810003|Placebo Comparator|Placebo|Placebo (3g corn oil/day)
11433602|NCT01809990|Experimental|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
11433603|NCT01809977|Other|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
11433604|NCT01809977|Other|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
11433605|NCT01809964|Experimental|Dose 1|ANT-1401
11433606|NCT01809964|Experimental|Dose 2|ANT-1401
11433607|NCT01809964|Placebo Comparator|Vehicle|Placebo Vehicle
11433608|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
11433609|NCT01809938|Active Comparator|Black Tea|
11433610|NCT01809938|Active Comparator|Tea with Milk|
11433611|NCT01809925|Experimental|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
11433612|NCT01809925|Placebo Comparator|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
11433613|NCT01809912|Experimental|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.
~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V
~) on a compassionate use basis at the same dose and regimen ."
11433614|NCT01809899|Experimental|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
11433615|NCT01809899|Active Comparator|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
11433616|NCT01809886|Experimental|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
11433617|NCT01809886|Active Comparator|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
11433618|NCT01809873|Experimental|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
11433619|NCT01809873|No Intervention|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
11433620|NCT01809860|Experimental|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
11433621|NCT01809847|Experimental|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
11433622|NCT01809834|Active Comparator|Etafilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
11433623|NCT01809834|Experimental|Stenfilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
11433624|NCT01809821|Experimental|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
11433820|NCT01808612|Placebo Comparator|Placebo|Placebo (capsules) administered orally, once daily, for 6 weeks
11433625|NCT01809821|No Intervention|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
11433626|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
11433627|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
11433628|NCT01809795|Experimental|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
11433629|NCT01809795|Sham Comparator|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
11433630|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
11433631|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
11433632|NCT01809769|Experimental|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
11433633|NCT01809769|Experimental|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
11433634|NCT01809769|Experimental|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
11433635|NCT01809756|Active Comparator|Caphosol|
11433636|NCT01809756|No Intervention|No intervention|
11433637|NCT01809743|Active Comparator|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
11433638|NCT01809743|Active Comparator|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
11433639|NCT01809743|Active Comparator|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
11433640|NCT01809743|Active Comparator|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
11433641|NCT01809730||Cardiovascular risk|patients with CV disease
11433642|NCT01809717|Experimental|Weight Lifting Exercises|
11433643|NCT01809704||Normal|Normal results from clinical exam and free of ocular pathology.
11433644|NCT01809704||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
11433645|NCT01809704||Retina|Clinical exam results consistent with retina pathology
11433646|NCT01809691|Experimental|ADT + TAK-700|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.
~TAK-700, 300 mg, PO, twice daily"
11433647|NCT01809691|Active Comparator|ADT + Bicalutamide|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.
~Bicalutamide, 50 mg, PO, q daily"
11433648|NCT01809678|Experimental|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
11433649|NCT01809678|Active Comparator|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
11433650|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
11433651|NCT01809652|Experimental|Remote Implant Support|Implant supported through remote implant support capability
11433652|NCT01809639|Experimental|Progesterone|400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
11433653|NCT01809639|Placebo Comparator|Placebo|
11433654|NCT01809626|Experimental|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
11433655|NCT01809626|Placebo Comparator|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
11433656|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
11433657|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
11433658|NCT01809587|Experimental|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
11433659|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
11433660|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
11433661|NCT01809548|Experimental|Early complementary feeding group|"Early intervention group:
~Introduction of early complementary feedings between the 10th -12th week of gestation corrected for prematurity"
11433662|NCT01809548|Experimental|Late complementary feeding group:|"Late intervention group:
~Introduction of late complementary feedings between the 16th and 18th week of life corrected for prematurity"
11433663|NCT01809535|Experimental|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
11433664|NCT01809535|Active Comparator|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
11433694|NCT01809353|Experimental|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
11433695|NCT01809353|Placebo Comparator|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
11433665|NCT01809522|Experimental|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
11433666|NCT01809522|No Intervention|Standard radical prostectomy|
11433667|NCT01809496|Active Comparator|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
11433668|NCT01809496|Experimental|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
11433669|NCT01809496|Experimental|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
11433670|NCT01809496|Experimental|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
11433671|NCT01809483|Experimental|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
11433672|NCT01809483|Active Comparator|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
11433673|NCT01809470|Experimental|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
11433674|NCT01809470|Experimental|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
11433675|NCT01809470|Experimental|Call of Duty|Playing the video game 'Call of duty' for 1 hour
11433676|NCT01809457|Experimental|educational poster|poster display for 2 weeks in classrooms,
11433677|NCT01809457|No Intervention|control|no intervention, waiting for two weeks
11433678|NCT01809444|Active Comparator|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
11433679|NCT01809444|Experimental|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
11433680|NCT01809431|Experimental|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
11433681|NCT01809431|No Intervention|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
11433682|NCT01809418|Experimental|keePAP|
11433683|NCT01809392|Experimental|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
11433684|NCT01809392|No Intervention|no decitabine|
11433685|NCT01809379|Experimental|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
11433686|NCT01809366|Experimental|seminal plasma insemination|seminal plasma insemination
11433687|NCT01809366|Placebo Comparator|culture medium insemination|culture medium insemination
11433688|NCT01809353|Experimental|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
11433689|NCT01809353|Experimental|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
11433690|NCT01809353|Experimental|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
11433691|NCT01809353|Placebo Comparator|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
11433692|NCT01809353|Experimental|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
11433693|NCT01809353|Experimental|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
11433696|NCT01809340|Experimental|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
11433697|NCT01809340|Placebo Comparator|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
11433698|NCT01809340|Experimental|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
11433699|NCT01809327|Experimental|Canagliflozin 100 mg|Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
11433700|NCT01809327|Experimental|Canagliflozin 300 mg|Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
11433701|NCT01809327|Experimental|Metformin XR|Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
11433702|NCT01809327|Experimental|Canagliflozin 100 mg + Metformin XR|Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
11433703|NCT01809327|Experimental|Canagliflozin 300 mg + Metformin XR|Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
11433704|NCT01809314||NeoRecormon in Symptomatic Anemia|Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.
11433705|NCT01809301|Active Comparator|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
11433706|NCT01809301|Experimental|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
11433707|NCT01809288||1|Healthy African, African-American, and white women between 30 and 65 years of age who are federal employees or contractors.
11433708|NCT01809275|Experimental|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
11433709|NCT01809275|Placebo Comparator|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
11433710|NCT01809262|Experimental|olodaterol 2 mcg|solution for inhalation
11433711|NCT01809262|Experimental|olodaterol 5 mcg|solution for inhalation
11433712|NCT01809262|Experimental|olodaterol 10 mcg|solution for inhalation
11433713|NCT01809262|Experimental|olodaterol 20 mcg|solution for inhalation
11433714|NCT01809262|Experimental|olodaterol 40 mcg|solution for inhalation
11433715|NCT01809262|Placebo Comparator|placebo|solution for inhalation
11433716|NCT01809236|Experimental|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
11433717|NCT01809223|Experimental|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
11433718|NCT01809223|Sham Comparator|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
11433719|NCT01809210|Experimental|Selumetinib+standard chemotherapy|Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
11433720|NCT01809197|Experimental|Air Optix/OFPM|Lotrafilcon B contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with OPTI-FREE MPDS lens care system
11433721|NCT01809197|Active Comparator|Acuvue Oasys/Habitual MPS|Senofilcon A contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with habitual MPS lens care system
11433722|NCT01809184|Experimental|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433723|NCT01809184|Experimental|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433724|NCT01809184|Experimental|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433725|NCT01809184|Experimental|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433726|NCT01809184|Experimental|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433727|NCT01809184|Experimental|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433728|NCT01809184|Experimental|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
11433729|NCT01809171|Experimental|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
11433730|NCT01809171|Placebo Comparator|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
11433731|NCT01809158|Active Comparator|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
11433782|NCT01808885|Placebo Comparator|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
11433732|NCT01809158|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
11433733|NCT01809145|Other|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
11433734|NCT01809132|Experimental|Anakinra & Pentoxifylline & Zinc Sulfate|anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days
11433735|NCT01809132|Active Comparator|Methylprednisolone|methylprednisolone 32 mg orally daily for 28 days
11433736|NCT01809132|No Intervention|Observational|Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.
11433737|NCT01809119|Experimental|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
11433738|NCT01809119|Active Comparator|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
11433739|NCT01809106|Active Comparator|Morphine|
11433740|NCT01809106|Experimental|Oxycodone|
11433741|NCT01809106|Experimental|Buprenorphine|
11433742|NCT01809106|Experimental|Fentanyl|
11433743|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
11433744|NCT01809080||2020|
11433745|NCT01809080||2019|
11433746|NCT01809080||2018|
11433747|NCT01809080||2017|
11433748|NCT01809080||2016|
11433749|NCT01809080||2015|
11433750|NCT01809080||2014|
11433751|NCT01809080||2013|
11433752|NCT01809080||2012|
11433753|NCT01809080||2011|
11433754|NCT01809080||2010|
11433755|NCT01809080||2009|
11433756|NCT01809080||2008|
11433757|NCT01809080||2007|
11433758|NCT01809067|Active Comparator|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
11433759|NCT01809067|No Intervention|No aromatherapy|No aromatherapy
11433760|NCT01809054|Active Comparator|Arixtra Arm|Arixtra (2.5 mg SQ/QD) subcutaneous injection daily for 2 weeks followed by aspirin 325 mg for 5 weeks
11433761|NCT01809054|Active Comparator|Pneumatic compression stockings arm|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel) for 2 weeks with concomitant Aspirin 325 mg daily for 5 weeks.
11433762|NCT01809041|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
11433763|NCT01809041|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
11433764|NCT01809028|Active Comparator|EUS FNA with 2 passes|biopsy with 2 passes of the needle
11433765|NCT01809028|Active Comparator|EUS FNA with 4 passes|biopsy with 4 passes of the needle
11433766|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
11433767|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
11433768|NCT01809002|Experimental|Processed Nerve Allograft|Processed Nerve Allograft
11433769|NCT01809002|Active Comparator|Collagen Nerve Cuff|
11433770|NCT01808976|Active Comparator|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
11433771|NCT01808976|Experimental|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
11433772|NCT01808976|Active Comparator|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
11433773|NCT01808950|Experimental|0.06% Resiquimod Gel - A|"60 mg gel
~Once daily prior to normal sleeping hours
~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
11433774|NCT01808950|Experimental|0.06% Resiquimod Gel - B|"100 mg gel
~Once daily prior to normal sleeping hours
~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
11433775|NCT01808950|Experimental|0.06% Resiquimod Gel - C|"100 mg gel
~Once daily prior to normal sleeping hours
~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation
~The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
11433776|NCT01808937||Morphea|Those having the condition morphea or other synonymous diagnosis (such as localized scleroderma, linear scleroderma, Parry-Romberg syndrome, en coup de sabre)
11433777|NCT01808911|Active Comparator|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
11433778|NCT01808911|Experimental|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
11433779|NCT01808898|Experimental|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
11433780|NCT01808898|Placebo Comparator|Saline|2mls of Normal Saline solution in a 5ml syringe
11433781|NCT01808885|Experimental|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.
~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
11433784|NCT01808859|Experimental|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
11433785|NCT01808859|No Intervention|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet
~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
11433786|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
11433787|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI>95th% and whole body insulin sensitivity index > 3.
11433788|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI> 95th% and WBISI<1.2.
11433789|NCT01808833||Frail patients|
11433790|NCT01808833||Non-frail patients|
11433791|NCT01808820|Experimental|Safety Pilot: DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;
~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;
~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 28;
~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
11433792|NCT01808820|Experimental|Expansion Cohort: DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;
~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;
~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered every 4 weeks for a total of 4 doses;
~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
11433793|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
11433794|NCT01808794|Active Comparator|Mucograft|Placement of randomized membrane on half of subjects Mucograft
11433795|NCT01808794|Active Comparator|Dynamatrix|Placement of randomized membrane on half of subjects Dynamatrix Membrane Placement
11433796|NCT01808781|Experimental|Intervention group|Home exercise program plus walking program during 8-week period
11433797|NCT01808781|Active Comparator|Comparison group|Walking only program throughout the 8-week period.
11433798|NCT01808768|Experimental|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
11433799|NCT01808755|Experimental|D Mannose|1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
11433800|NCT01808755|Active Comparator|trimethoprim/sulfamethoxazole|intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
11433801|NCT01808742||Treatment|Treatment with CryoTouch III device
11433802|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
11433803|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
11433804|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
11433805|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
11433806|NCT01808703|Experimental|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
11433807|NCT01808703|Active Comparator|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
11433808|NCT01808690|Experimental|Metformin|Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
11433809|NCT01808690|Placebo Comparator|Placebo|Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
11433810|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
11433811|NCT01808664|Experimental|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
11433812|NCT01808664|Active Comparator|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
11433813|NCT01808651|Experimental|Fluoxetine|Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
11433814|NCT01808638|Other|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
11433815|NCT01808638|Experimental|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
11433816|NCT01808638|Experimental|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
11433817|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
11433818|NCT01808612|Experimental|20 mg Fluoxetine|20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
11433819|NCT01808612|Experimental|40 mg Fluoxetine|40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
11433821|NCT01808599|Experimental|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).
~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
11433822|NCT01808586|Experimental|Dexamethasone|Intra-articular corticosteroid number 2.
11433823|NCT01808586|Experimental|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
11433824|NCT01808586|Active Comparator|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
11433825|NCT01808586|Active Comparator|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
11433826|NCT01808573|Experimental|neratinib plus capecitabine|neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
11433827|NCT01808573|Active Comparator|lapatinib plus capecitabine|lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
11433828|NCT01808560|Experimental|LipiFlow Pre-treatment|Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
11433829|NCT01808560|No Intervention|Untreated Control|Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
11433830|NCT01808560|Experimental|LipiFlow Post-treatment|Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
11433831|NCT01808547|Experimental|ISV-303|
11433832|NCT01808547|Placebo Comparator|Durasite Vehicle|
11433833|NCT01808534|Experimental|Treatment (palifosfamide)|Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11433834|NCT01808521|Experimental|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
11433835|NCT01808508|Active Comparator|Group 1- Continuous positive airway pressure (CPAP)|Group 1 will receive therapeutic CPAP for 4 months.
11433836|NCT01808508|Placebo Comparator|Group 2-Sham Continuous positive airway pressure (CPAP)|Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
11433837|NCT01808508|No Intervention|Group 3- No Intervention|Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
11433838|NCT01808482|Experimental|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
11433839|NCT01808482|Placebo Comparator|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
11433840|NCT01808482|Experimental|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
11433841|NCT01808482|Placebo Comparator|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
11433842|NCT01808482|Experimental|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A& B)
11433843|NCT01808469|Experimental|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
11433844|NCT01808469|Placebo Comparator|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
11433845|NCT01808456|Experimental|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
11433846|NCT01808456|Active Comparator|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
11433847|NCT01808443|Active Comparator|Cryotherapy|Cryotherapy, at most 4 times
11433848|NCT01808443|Experimental|laser|laser, at most 4 times
11433849|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
11433850|NCT01808417|Experimental|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
11433851|NCT01808404|Experimental|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
11433852|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
11433853|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
11433854|NCT01808378|Experimental|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
11433855|NCT01808365||Study cohort|
11433856|NCT01808352|Other|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
11433857|NCT01808339|Experimental|FF AM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).
11433898|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
11433858|NCT01808339|Experimental|FF PM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).
11433859|NCT01808339|Placebo Comparator|Placebo|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).
11433860|NCT01808326|Experimental|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
11433861|NCT01808313|Experimental|ambrisentan|ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
11433862|NCT01808300|Experimental|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
11433863|NCT01808300|Experimental|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
11433864|NCT01808300|Experimental|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
11433865|NCT01808300|Experimental|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
11433866|NCT01808300|Experimental|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
11433867|NCT01808300|Experimental|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
11433868|NCT01808287|Experimental|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
11433869|NCT01808287|Experimental|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
11433870|NCT01808274|Experimental|TAVR|with CENTERA self-expanding valve
11433871|NCT01808261|Placebo Comparator|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
11433872|NCT01808261|Active Comparator|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
11433873|NCT01808248|Experimental|SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
11433874|NCT01808235|Experimental|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
11433875|NCT01808222|Experimental|FACBC|Participants receiving a bolus of anti-[18F]FACBC injected with PET-CT detection of cancer recurrence.
11433876|NCT01808209|Experimental|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
11433877|NCT01808209|Active Comparator|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
11433878|NCT01808196|Experimental|Losartan|Participants with eosinophilic esophagitis receive Losartan daily
11433879|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
11433880|NCT01808170|Active Comparator|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
11433881|NCT01808170|Active Comparator|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
11433882|NCT01808157|Experimental|0.05% w/w CT327 ointment|Active
11433883|NCT01808157|Experimental|0.5% w/w CT327 ointment|Active
11433884|NCT01808157|Placebo Comparator|vehicle|Placebo
11433885|NCT01808144|Experimental|lesinurad 400 mg + febuxostat 80 mg|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
11433886|NCT01808144|Experimental|lesinurad 200 mg + febuxostat 80 mg|
11433887|NCT01808131|Experimental|lesinurad 200 mg + allopurinol|
11433888|NCT01808131|Experimental|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
11433889|NCT01808118|Experimental|Double-Blind Adalimumab|40 mg every other week (eow), Weeks 28-68. Blinded adalimumab was discontinued in participants who met the criteria for flare.
11433890|NCT01808118|Experimental|Open-label (OL) Adalimumab|40 mg every other week (eow), Weeks 0-28. If participants flared during the double-blind period, they had an opportunity to receive at least 12 weeks of open-label adalimumab 40 mg eow.
11433891|NCT01808118|Placebo Comparator|Placebo|Placebo every other week (eow), Weeks 28-68. Placebo was discontinued in participants who met the criteria for flare.
11433892|NCT01808105|Other|Human Milk|Reference group, breast feeding ad libitum
11433893|NCT01808105|Active Comparator|Control Formula|Ready to feed infant formula, feed ad libitum
11433894|NCT01808105|Experimental|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
11433895|NCT01808105|Experimental|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
11433896|NCT01808092|Experimental|CAZ-AVI|Intra-Venous treatment
11433897|NCT01808092|Active Comparator|Meropenem|Intra-Venous treatment
11433899|NCT01808066|Experimental|Play Groundskeeper|This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab & Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
11433900|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
11433901|NCT01808040|Experimental|1|"Tak700 (orteronel) dose escalation schedule:
~1a 200 mg PO BID TAK700
~1b 200mg PO BID TAK + glucocorticoid
~1a 300mg PO BID TAK700 starting dose
~1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
11433902|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
11433903|NCT01808014|Experimental|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
11433904|NCT01807988|Experimental|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
11433905|NCT01807988|No Intervention|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
11433906|NCT01807975|Experimental|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
11433907|NCT01807962|Active Comparator|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :
~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
11433908|NCT01807962|Placebo Comparator|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
11433909|NCT01807949|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
11433910|NCT01807949|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
11433911|NCT01807949|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
11433912|NCT01807936|Experimental|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
11433913|NCT01807936|No Intervention|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
11433914|NCT01807923|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
11433915|NCT01807923|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
11433916|NCT01807923|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
11433917|NCT01807910|Experimental|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
11433918|NCT01807910|Active Comparator|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
11433919|NCT01807897|Experimental|CPAP|Nocturnal continuous positive airway pressure
11433920|NCT01807897|Experimental|NSO|Nocturnal supplemental oxygen
11433921|NCT01807897|Other|HLSE|Healthy lifestyle and sleep education control
11433922|NCT01807884|Experimental|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
11433923|NCT01807884|Placebo Comparator|Routine oral care|Oral suction followed by mouth care and tracheal suction
11433924|NCT01807871|Experimental|nicotine patch, experimental use|Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.
11433925|NCT01807871|Active Comparator|nicotine patch, labeled use|Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.
11433926|NCT01807858|Active Comparator|Bifidobacterium lactis|5 billion Bifidobacterium lactis
11433927|NCT01807858|Active Comparator|İnulin|900 mg İnulin per day will be given
11433928|NCT01807858|Placebo Comparator|Maltodextrin|Maltodextrin
11433929|NCT01807858|Active Comparator|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
11433930|NCT01807845|Active Comparator|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
11433931|NCT01807845|Placebo Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
11433932|NCT01807845|Active Comparator|enriched skimmilk with VD|enriched skimmilk with VD
11433933|NCT01807832|Other|chronic cough|Capsaicine challenge in chronic cough patients
11433934|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
11433935|NCT01807806|Experimental|Role-playing game|All eligible participants were invited to play the role playing game
11433936|NCT01807793|Active Comparator|Psychoeducation|Psychoeducation will include attending individual and group sessions.
11433937|NCT01807793|No Intervention|Care as usual|Receive care as usual
11433938|NCT01807780|Other|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
11433939|NCT01807767|Experimental|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).
~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.
~Myfortic 360-720 mg BID"
11433940|NCT01807767|Other|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
11531175|NCT01135888||Control children|
11433941|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.
~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
11433942|NCT01807741|Experimental|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
11433943|NCT01807741|Active Comparator|Placebo Group|Sublingual tablets similar to the asenapine tablets.
11433944|NCT01807728|Experimental|Group 1 Training Program|
11433945|NCT01807728|Experimental|Group 2 Training Program|
11433946|NCT01807715||Study group|Women seeking first trimester surgical abortion
11433947|NCT01807702|Experimental|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
11433948|NCT01807676|Active Comparator|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
11433949|NCT01807676|Active Comparator|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
11433950|NCT01807663|Experimental|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
11433951|NCT01807663|Experimental|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
11433952|NCT01807663|Experimental|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
11433953|NCT01807650|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
11433954|NCT01807650|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
11433955|NCT01807637|Experimental|transcranial direct current stim|tDCS will be applied using a Soterix constant current stimulator with 5 x 5 cm (25cm2) carbon rubber electrodes (Covidien 664 REFX 2x2) applied to the scalp with 10-20 conductive paste. The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere [established during TMS motor threshold testing (Baseline Testing) and the functional MRI assessment]. The cathodal electrode will be placed over the contralateral motor cortex.
11433956|NCT01807637|Placebo Comparator|sham tDCS|Sham stimulation will be performed by turning the stimulator off after the initial sensory experience (30 seconds).
11433957|NCT01807624|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
11433958|NCT01807611|Experimental|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.
~Cells for infusion are prepared using the CliniMACS System."
11433959|NCT01807598|Experimental|Brentuximab vedotin|Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
11433960|NCT01807585|Experimental|VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
11433961|NCT01807585|Active Comparator|RFA (ClosureFast)|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
11433962|NCT01807585|Experimental|Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
11433963|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
11433964|NCT01807546|Experimental|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
11433965|NCT01807533|Experimental|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
11433966|NCT01807533|Other|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
11433967|NCT01807520|Experimental|Secukinumab (AIN457) 150 mg|Participants assigned to secukinumab 150 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
11438220|NCT01778244|Placebo Comparator|placebo|placebo
11433968|NCT01807520|Experimental|Secukinumab (AIN457) 300 mg|Participants assigned to secukinumab 300 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
11433969|NCT01807520|Placebo Comparator|Placebo|Patients assigned to placebo were dosed weekly for five weeks, then at Week 8 and Week 12. At Week 16, placebo patients were randomized in a 1:1 ratio, to receive secukinumab either 150 mg or 300 mg and were dosed weekly for five weeks starting at Week 16, then once every four weeks up to and including Week 132. All doses of study treatment are administered by sub-cutaneous injections.
11433970|NCT01807507||Healthy Volunteers|
11433971|NCT01807494|Active Comparator|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
11433972|NCT01807494|Active Comparator|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
11433973|NCT01807481|Experimental|Mircera Arm|Once Monthly Mircera
11433974|NCT01807468|Experimental|HaploSC+NK|
11433975|NCT01807455|Experimental|Restylane Vital Lidocaine|
11433976|NCT01807442|Other|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.
~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
11433977|NCT01807442|Other|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.
~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
11433978|NCT01807429|Experimental|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
11433979|NCT01807429|Active Comparator|Morphine|0.05 to 0.1 mg/kg morphine
11433980|NCT01807416|Active Comparator|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
11433981|NCT01807416|Active Comparator|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
11433982|NCT01807416|Active Comparator|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
11433983|NCT01807416|Active Comparator|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
11433984|NCT01807403|Experimental|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
11433985|NCT01807403|Experimental|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
11433986|NCT01807403|Experimental|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
11433987|NCT01807377|Experimental|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
11433988|NCT01807377|Experimental|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
11433989|NCT01807364||Congenital adrenal hyperplasia|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
11433990|NCT01807364||controls|control patients
11433991|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
11433992|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
11433993|NCT01807312|Experimental|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
11433994|NCT01807312|Placebo Comparator|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
11433995|NCT01807299|Experimental|Physical Training|The training group will make physical exercise for three months (three times a week).
11433996|NCT01807299|Other|Sedentary|The sedentary group will be oriented not to make any type of physical training for three months.
11433997|NCT01807299|Placebo Comparator|Placebo|The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
11433998|NCT01807299|Experimental|Omega 3|The omega 3 group will receive 2g per day of fish oil during 90 days treatment
11433999|NCT01807286|Experimental|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
11434000|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
11434001|NCT01807260|Active Comparator|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
11434037|NCT01807026|Placebo Comparator|Cohort B: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).
11434038|NCT01807026|Experimental|Cohort C: 280 mg LY2886721|Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.
11434288|NCT01805349|Other|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
11434002|NCT01807260|Active Comparator|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
11434003|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
11434004|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
11434005|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
11434006|NCT01807234|Experimental|Ketorolac/Placebo|Ketorolac 31.5 mg single dose nasal spray and Placebo
11434007|NCT01807234|Experimental|Sumatriptan/Placebo|Sumatriptan 20 mg single dose nasal spray and placebo
11434008|NCT01807234|Placebo Comparator|Ketorolac Placebo/Sumatriptan placebo|single dose Ketorolac placebo, single dose Sumatriptan placebo
11434009|NCT01807221|Experimental|Finerenone(BAY94-8862)[2.5mg] + Placebo|Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
11434010|NCT01807221|Experimental|Finerenone (BAY94-8862)[5mg] + Placebo|Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
11434011|NCT01807221|Experimental|Finerenone (BAY94-8862)[7.5mg] + Placebo|Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
11434012|NCT01807221|Experimental|Finerenone (BAY94-8862)[10mg] + Placebo|Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
11434013|NCT01807221|Experimental|Finerenone (BAY94-8862)[15mg] + Placebo|Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
11434014|NCT01807221|Active Comparator|Eplerenone [25 mg] + Placebo|Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
11434015|NCT01807208|Experimental|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
11434016|NCT01807208|No Intervention|Usual care|Patients in this arm of the study will receive usual care.
11434017|NCT01807195||the medical records of those in whom a contrast medium|
11434018|NCT01807182|Experimental|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
11434019|NCT01807169|Experimental|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
11434020|NCT01807156|Experimental|Tivozanib|Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
11434021|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
11434022|NCT01807130|Placebo Comparator|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
11434023|NCT01807130|Experimental|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
11434024|NCT01807117|Experimental|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
11434025|NCT01807104|Active Comparator|Anterior Approach Total Hip|Total hip arthroplasty performed through an anterior surgical approach. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach
11434026|NCT01807104|Active Comparator|Posterior Approach Total Hip|The additional arm is the posterior approach total hip, which the Anterior Approach is being compared too. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach.
11434027|NCT01807091|Experimental|Treatment (chemotherapy)|Patients receive outpatient induction chemotherapy.
11434028|NCT01807078|Active Comparator|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
11434029|NCT01807078|Active Comparator|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
11434030|NCT01807065|Experimental|Arm A (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes days 22, 36, and 50.
11434031|NCT01807065|Experimental|Arm B (radiation therapy, sipuleucel-T)|Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
11434032|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
11434033|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
11434034|NCT01807026|Experimental|Cohort A: 70 mg LY2886721|Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.
11434035|NCT01807026|Placebo Comparator|Cohort A: Placebo|Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).
11434036|NCT01807026|Experimental|Cohort B: 70 mg LY2886721|Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.
11434463|NCT01804049|Active Comparator|Metformin|60 enrolled participants will be randomized to metformin.
11434039|NCT01807026|Placebo Comparator|Cohort C: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).
11434040|NCT01807000|Experimental|Radiolabeled Prucalopride Succinate|
11434041|NCT01806987|Experimental|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
11434042|NCT01806987|No Intervention|Services as usual|These include any services that the child and family might already be receiving in the community.
11434043|NCT01806974|Other|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
11434044|NCT01806974|Other|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
11434045|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
11434046|NCT01806948|Placebo Comparator|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
11434047|NCT01806948|Experimental|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
11434048|NCT01806935|Experimental|DC086|cream
11434049|NCT01806935|Placebo Comparator|placebo|
11434050|NCT01806922|Experimental|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
11434051|NCT01806922|No Intervention|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
11434052|NCT01806909|Other|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
11434053|NCT01806896|Experimental|20 mg Arm Cohort A|
11434054|NCT01806896|Placebo Comparator|Placebo Arm Cohort A|
11434055|NCT01806896|Experimental|5 mg Arm Cohort B|
11434056|NCT01806896|Placebo Comparator|Placebo Arm Cohort B|
11434057|NCT01806883|Experimental|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
11434058|NCT01806883|Active Comparator|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
11434059|NCT01806870|Experimental|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
11434060|NCT01806857|Other|Nuedexta then Matching Placebo|Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
11434061|NCT01806857|Other|Matching Placebo then Nuedexta|Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).
11434062|NCT01806818|Experimental|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
11434063|NCT01806818|Experimental|Epirisone 50mg TID|
11434064|NCT01806818|Placebo Comparator|Placebo comparator|
11434065|NCT01806805|Experimental|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
11434066|NCT01806805|Placebo Comparator|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
11434067|NCT01806792|Experimental|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
11434068|NCT01806792|Active Comparator|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
11434069|NCT01806779|Experimental|Chantix|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
11434070|NCT01806779|Experimental|Chantix + Zyban|For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
11434071|NCT01806766|Active Comparator|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
11434072|NCT01806766|Active Comparator|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
11434073|NCT01806753|Experimental|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
11434074|NCT01806753|Active Comparator|propofol infusion|Continuous propofol infusion with opioid administration
11434075|NCT01806740|Experimental|Gadoterate meglumine|there is one single arm of patients (no comparative arm)
11434182|NCT01805960|Experimental|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
11434076|NCT01806727|Active Comparator|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
11434077|NCT01806727|Experimental|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean >7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
11434078|NCT01806714|Experimental|Text-based reminder for HPV vaccine/WCC|Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
11434079|NCT01806714|Active Comparator|Control arm|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
11434080|NCT01806701|Experimental|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
11434081|NCT01806688|Experimental|Snack #1|gluten-free high protein snack
11434082|NCT01806688|Experimental|Snack #2|gluten-free high protein and high fibre snack
11434083|NCT01806688|Placebo Comparator|reference product #1|gluten-free snack with similar energy density, but 1/2 the protein as snack #1
11434084|NCT01806688|Placebo Comparator|reference product #2|gluten-free snack with similar energy density, but less protein and fibre than snack #2
11434085|NCT01806688|Placebo Comparator|non-caloric control #1|water
11434086|NCT01806688|Placebo Comparator|non-caloric control #2|water
11434087|NCT01806675|Experimental|Glioblastoma Multiforme (GBM)|Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)
11434088|NCT01806675|Experimental|Gynecological Cancers|Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
11434089|NCT01806675|Experimental|Renal Cell Cancer (RCC)|Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
11434090|NCT01806662|Experimental|Treatment Arm (Ustekinumab first, Then Placebo)|Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of the study.
11434091|NCT01806662|Placebo Comparator|Placebo Arm (Placebo first, Then Ustekinumab)|Since there is a crossover design, each patient will be in the placebo arm for 16 weeks of the study. If a patient begins in the placebo arm, they will switch over to the treatment arm at week 16.
11434092|NCT01806649|Experimental|BKM120|BKM120, starting at 100 mg oral once daily
11434093|NCT01806636||Treatment|Patients treated with PneumRx Coil System
11434094|NCT01806623|Experimental|Fluconazole|
11434095|NCT01806610|Experimental|BPS804|Single dose BPS804 administration.
11434096|NCT01806610|Placebo Comparator|Placebo|Single dose placebo administration.
11434097|NCT01806597|Experimental|secukinumab 150mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
11434098|NCT01806597|Experimental|secukinumab 300 mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
11434099|NCT01806597|Placebo Comparator|Placebo|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.
11434100|NCT01806584|Active Comparator|SRM003|
11434101|NCT01806584|Other|Participating Site's standard practice|
11434102|NCT01806571|Experimental|Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)|"INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.
~CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.
~MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
11434103|NCT01806558|Experimental|Women with lesion on MBI|Women with lesion on MBI
11434104|NCT01806545|Active Comparator|SRM003|One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
11434105|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
11434106|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
11434107|NCT01806506|Experimental|Laparoscopic sleeve gastrectomy|The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
11434108|NCT01806506|Experimental|Roux-en-Y Gastric Bypass|The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
11434109|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
11434110|NCT01806480|Experimental|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
11434111|NCT01806480|No Intervention|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
11434112|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
11434113|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
11434114|NCT01806454|Active Comparator|calcium A|tablets, 600mg per day,till birth
11434115|NCT01806454|Active Comparator|calcium B|tablets,1200mg per day,till birth
11434116|NCT01806441|Experimental|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
11434117|NCT01806441|Active Comparator|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
11434118|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
11434119|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
11434120|NCT01806415|Experimental|Fenobam 50 mg|Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.
11434121|NCT01806415|Experimental|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
11434122|NCT01806415|Experimental|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
11434123|NCT01806415|Placebo Comparator|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
11434124|NCT01806402||Retina|Having clinical diagnosis of retina pathology
11434125|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
11434126|NCT01806389||Buprenorphine|Buprenorphine maintained women at delivery of their infant
11434127|NCT01806376|Experimental|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
11434128|NCT01806363|Active Comparator|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
11434129|NCT01806363|Active Comparator|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
11434130|NCT01806350|Experimental|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
11434131|NCT01806350|Active Comparator|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
11434132|NCT01806337|Experimental|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
11434133|NCT01806324|Experimental|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
11434134|NCT01806324|Active Comparator|Losartan + Atorvastatin|Coadministration group
11434135|NCT01806311|Active Comparator|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
11434136|NCT01806311|Active Comparator|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
11434137|NCT01806298|Experimental|Saizen®|
11434138|NCT01806285||Patients with Respiratory Symptoms|
11434139|NCT01806272|Experimental|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
~Radiotherapy: Intensity modulated radiation therapy(IMRT)
~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
11434140|NCT01806272|Active Comparator|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
~Radiotherapy: Intensity modulated radiation therapy(IMRT)
~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
11434141|NCT01806259|Experimental|ketorolac 30 mg|Active drug to be compared with placebo
11434142|NCT01806259|Placebo Comparator|NaCl 0.9% 3mL|Placebo looking like the Active drug
11434183|NCT01805960|Placebo Comparator|Placebo|1 s.c. injection directly after cardioversion
11434431|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
11434143|NCT01806246|Experimental|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
11434144|NCT01806233|Experimental|Acupuncture|acupuncture
11434145|NCT01806233|Experimental|Rehabilitation|rehabilitation exercise
11434146|NCT01806220|Active Comparator|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.
~Intervention: biopsy of retrocrycoid laryngeal mucosa"
11434147|NCT01806220|Active Comparator|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained
~Intervention:biopsy of distal esophagus mucosa"
11434148|NCT01806207|Active Comparator|Durolane injection|Intraarticular injection of 3 ml Durolane.
11434149|NCT01806207|Placebo Comparator|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
11434150|NCT01806194|Active Comparator|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
11434151|NCT01806194|Experimental|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
11434152|NCT01806181|Other|Cancer Treatment|
11434153|NCT01806168|Active Comparator|Low-frequency (1 Hz) rTMS|Low-frequency active stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
11434154|NCT01806168|Active Comparator|High-frequency (10 Hz) rTMS|High-frequency active stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
11434155|NCT01806168|Placebo Comparator|Sham rTMS|Sham stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
11434156|NCT01806155||Craniotomy|Patient undergoing major craniotomy
11434157|NCT01806142|Experimental|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
11434158|NCT01806142|Active Comparator|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
11434159|NCT01806129|No Intervention|Arm A (no intervention)|Patients undergo usual standard practice related to reproductive health.
11434160|NCT01806129|Experimental|Arm B (reproductive health program)|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
11434161|NCT01806116|Experimental|decitabine + transplantation|
11434162|NCT01806103|Experimental|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
11434163|NCT01806103|No Intervention|Control|Control sites will be within strata to maintain balance of treatment arm within strata
11434164|NCT01806090|Active Comparator|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
11434165|NCT01806090|Placebo Comparator|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
11434166|NCT01806077|Experimental|PZ-128|
11434167|NCT01806064|Experimental|TRC105 and Axitinib|Patients randomized to receive TRC105 at 3 mg/kg on day 1, 7 mg/kg on day 4, and 10 mg/kg on day 8 and weekly thereafter in combination with axitinib 5 mg twice daily
11434168|NCT01806064|Active Comparator|Axitinib|Patients randomized to receive axitinib 5 mg twice daily
11434169|NCT01806051|Experimental|PKU Participants (Arm 1)|"Subjects will be administered Kuvan once daily.
~They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
11434170|NCT01806051|No Intervention|Control Group (Arm 2)|"Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.
~These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
11434171|NCT01806038|Experimental|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
11434172|NCT01806038|Active Comparator|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
11434173|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
11434174|NCT01806012|Experimental|Enseal|Tissue sealing with Enseal device
11434175|NCT01806012|Active Comparator|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
11434176|NCT01805999|Experimental|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
11434177|NCT01805999|Placebo Comparator|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
11434178|NCT01805999|Active Comparator|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
11434179|NCT01805986||MS patient|
11434180|NCT01805973|No Intervention|Control|Standard pre-operative care, no active intervention
11434181|NCT01805973|Experimental|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.
~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
11434184|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
11434185|NCT01805934|Active Comparator|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
11434186|NCT01805934|Active Comparator|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
11434187|NCT01805921|Experimental|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.
~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
11434188|NCT01805921|Experimental|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.
~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
11434189|NCT01805921|Experimental|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.
~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
11434190|NCT01805921|Experimental|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.
~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
11434191|NCT01805921|No Intervention|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
11434192|NCT01805921|Experimental|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
11434193|NCT01805921|Experimental|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
11434194|NCT01805921|Experimental|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
11434195|NCT01805921|Experimental|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
11434196|NCT01805908|Experimental|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
11434197|NCT01805895|Experimental|Minocycline|This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
11434198|NCT01805895|No Intervention|Control|This arm will not receive any minocycline. This arm will receive standard of care treatment.
11434199|NCT01805882|Experimental|A: HCV GT-1, tx naïve, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients
11434200|NCT01805882|Experimental|B: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9669|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
11434201|NCT01805882|Experimental|C: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
11434202|NCT01805882|Experimental|D: HCV GT-1, tx-relapsed, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin
11434203|NCT01805882|Experimental|E: HCV GT-4, tx naïve/expd, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects
11434204|NCT01805882|Experimental|F: HCV GT-1, tx naïve/expd 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease
11434205|NCT01805882|Experimental|G: HCV GT-1, tx naïve, 4 wks Sofosbuvir, Ledipasvir, GS-9451|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
11434206|NCT01805882|Experimental|H: HCV GT-1, tx naïve, 4 wks Sofos/Ledip/GS-9451/GS-9669|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
11434207|NCT01805882|Experimental|D Retx: HCV GT-1, Re-Treatment, 12 wks Sofosbuvir, Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H
11434208|NCT01805869||1|Data and surgical waste tissue for research purpose in subjects undergoing clinically indicated wisdom teeth extraction at the NIH NIDCR Dental clinic
11434209|NCT01805856|Experimental|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
11434283|NCT01805401|Sham Comparator|Sham tDCS|
11439111|NCT01772082|Active Comparator|Pedometer alone|pedometer
11434210|NCT01805856|Experimental|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
11434211|NCT01805856|No Intervention|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
11434212|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
11434213|NCT01805830|Experimental|MP513 group|
11434214|NCT01805830|Placebo Comparator|Placebo group|
11434215|NCT01805817|Experimental|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
11434216|NCT01805817|Experimental|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
11434217|NCT01805817|Experimental|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
11434218|NCT01805804|Placebo Comparator|Placebo|Placebo pills to match valsartan tablets administered once daily
11434219|NCT01805804|Experimental|valsartan 80mg daily|Valsartan 80mg tablet once daily
11434220|NCT01805804|Experimental|valsartan 160mg daily|Valsartan 160mg tablet once daily
11434221|NCT01805791|Placebo Comparator|Placebo|Placebo, oral tablets, three times a day
11434222|NCT01805791|Experimental|HMPL-004 1800 mg/day|1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
11434223|NCT01805791|Experimental|HMPL-004 2400 mg/day|2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
11434224|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
11434225|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
11434226|NCT01805765|Active Comparator|Qing'E pills|9 g pills,twice a day for 12 weeks
11434227|NCT01805765|Placebo Comparator|Placebo|9 g pills,twice a day for 12 weeks
11434228|NCT01805752|Experimental|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.
~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
11434229|NCT01805752|No Intervention|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
11434230|NCT01805726|Placebo Comparator|Xylocain (C)|(C): Local anesthesia
11434231|NCT01805726|Active Comparator|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
11434232|NCT01805726|Active Comparator|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
11434233|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
11434234|NCT01805713||CF Child/Adult Cohort|CF patients > 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
11434235|NCT01805700|Experimental|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine & 84g glucose) e.g. regular red bull cans (x3)
11434236|NCT01805700|Experimental|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
11434237|NCT01805700|Active Comparator|Glucose drink|Glucose drink (containing 84g glucose alone)
11434238|NCT01805687|Other|Zileuton extended release|Oral, 1200 mg (2 x 600 mg tablets)
11434239|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
11434240|NCT01805661|Active Comparator|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
11434241|NCT01805661|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
11434242|NCT01805648|Experimental|rhTPO|Active investigational product
11434243|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
11434244|NCT01805622|Experimental|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
11434245|NCT01805622|Experimental|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
11434246|NCT01805622|Active Comparator|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
11434247|NCT01805622|Active Comparator|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
11434284|NCT01805388|Experimental|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
11434285|NCT01805388|No Intervention|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
11434286|NCT01805362|Active Comparator|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
11434287|NCT01805362|Experimental|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
11531176|NCT01135888||Control adolescents|
11434248|NCT01805609|Experimental|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
11434249|NCT01805596|Experimental|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
11434250|NCT01805596|Experimental|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
11434251|NCT01805583|Experimental|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
11434252|NCT01805583|Experimental|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
11434253|NCT01805583|Experimental|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
11434254|NCT01805583|No Intervention|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
11434255|NCT01805570|Active Comparator|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
11434256|NCT01805570|Active Comparator|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
11434257|NCT01805557|Active Comparator|R-DHAP|R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation
11434258|NCT01805557|Experimental|BR-DHAP|Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation
11434259|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
11434260|NCT01805531||Rivaroxaban|
11434261|NCT01805518|Active Comparator|Scelectium Tortuosum|S Tortuosum
11434262|NCT01805518|Placebo Comparator|Sugar pill/placebo|Sugar pill/placebo
11434263|NCT01805505|Experimental|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
11434264|NCT01805505|Active Comparator|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
11434265|NCT01805492|Experimental|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
11434266|NCT01805492|No Intervention|Control|Non-intervention controls retrospectively matched to intervention participants
11434267|NCT01805479|Placebo Comparator|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
11434268|NCT01805479|Active Comparator|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
11434269|NCT01805466|Experimental|EVADO|"The E.V.A.D.O. system is made of the following components:
~The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.
~The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).
~Paediatric circuits with 3/8 tubing for both arterial and venous lines."
11434270|NCT01805466|Active Comparator|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
11434271|NCT01805453|Active Comparator|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason
11434272|NCT01805453|Placebo Comparator|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
11434273|NCT01805440|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 500 mg twice daily by mouth for 6 weeks.
11434274|NCT01805440|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 500 mg twice daily by mouth for 6 weeks.
11434275|NCT01805440|No Intervention|Healthy Comparison|Subjects are not randomized, and do not receive any treatment intervention.
11434276|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
11434277|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
11434278|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
11434279|NCT01805414|Experimental|Intervention Breakfast|40-45g carbs (300-350 kcal)
11434280|NCT01805414|Active Comparator|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
11434281|NCT01805401|Experimental|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
11434282|NCT01805401|Experimental|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
11434289|NCT01805336|Other|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.
~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.
~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
11434290|NCT01805336|Other|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.
~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.
~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
11434291|NCT01805323||All Participants|Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX®) according to general clinical practice.
11434292|NCT01805310|Other|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
11434293|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
11434294|NCT01805297|Active Comparator|Vitrectomy with Aflibercept Injection|Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
11434295|NCT01805297|Active Comparator|Standard Vitrectomy|Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
11434296|NCT01805284|Experimental|Linezolid|
11434297|NCT01805271|Experimental|Everolimus|1 or 2 tablets/day (i.e.5 or 10mg/day )
11434298|NCT01805271|Placebo Comparator|Placebo|1 or 2 tablets/day
11434299|NCT01805258|Experimental|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
11434300|NCT01805258|Active Comparator|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
11434301|NCT01805245|Experimental|Mindfulness Based Stress Reduction|
11434302|NCT01805245|Active Comparator|Health Education Control|
11434303|NCT01805232|Experimental|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
11434304|NCT01805232|Active Comparator|quinine|quinine infusion 80 mg/kg every 8 hours
11434305|NCT01805219||healthy subjects|
11434306|NCT01805206|Experimental|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
11434307|NCT01805193||Suspected coronary heart disease|
11434308|NCT01805180|Other|Arm 1: Spectra Optia followed by COBE Spectra|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.
11434309|NCT01805180|Other|Arm 2: COBE Spectra followed by Spectra Optia|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.
11434310|NCT01805167|Other|subjects with a cochlear implant|
11434311|NCT01805154||CRT patients|Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
11434312|NCT01805128|Experimental|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
11434313|NCT01805128|Experimental|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
11434314|NCT01805128|Experimental|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
11434315|NCT01805115|Experimental|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
11434316|NCT01805115|Experimental|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
11434317|NCT01805115|Experimental|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
11434318|NCT01805115|Experimental|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
11434319|NCT01805102||maternal serum|measurement by immunoassay
11434320|NCT01805089|Active Comparator|Melatonin 3 mg|Taken orally, once per day, at/around 9:00pm
11434321|NCT01805089|Placebo Comparator|Placebo|Taken orally, once per day, at/around 9:00pm
11434322|NCT01805076|Other|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
11434323|NCT01805076|Experimental|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
11434324|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
11434325|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
11434326|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
11434327|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
11434328|NCT01805037|Experimental|Treatment (brentuximab vedotin, rituximab)|"INDUCTION: Patients receive brentuximab vedotin IV over 30 minutes once weekly for 3 weeks and rituximab IV once weekly for 4 weeks. Patients unable to achieve CR may receive additional optional consolidation therapy identical to induction therapy.
~MAINTENANCE THERAPY: Patients receive brentuximab vedotin IV once every 3 weeks and rituximab IV once every 6 weeks. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
11434329|NCT01805024|Experimental|Omigapil|Omigapil treatment oral administration once per day after breakfast Cohort 1 Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
11434330|NCT01805011||50 healthy mothers|
11434331|NCT01804998|Experimental|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in this arm
11434432|NCT01804296|Experimental|Part 2 Acute|Open-label, active repetitive transcranial magnetic stimulation
11434332|NCT01804998|Active Comparator|Laparoscopy Assisted Gastrectomy|Conventional procedure is laparoscopy assisted gastrectomy in early gastric cancer patient.
11434333|NCT01804985|Experimental|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
11434334|NCT01804972|Active Comparator|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
11434335|NCT01804972|Experimental|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
11434336|NCT01804959|Placebo Comparator|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
11434337|NCT01804959|Active Comparator|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
11434338|NCT01804946|Experimental|Ergoferon (1 tablet 3 times a day)|1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.
11434339|NCT01804946|Active Comparator|Oseltamivir(Tamiflu): 75 mg two times a day.|Oseltamivir for 5 days (75 mg b.i.d.).
11434340|NCT01804933|No Intervention|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
11434341|NCT01804933|Active Comparator|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
11434342|NCT01804933|Experimental|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
11434343|NCT01804920|Experimental|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.
~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
11434344|NCT01804920|Placebo Comparator|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.
~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
11434345|NCT01804907|Experimental|CBT|Cognitive Behavioral Therapy
11434346|NCT01804907|Sham Comparator|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
11434347|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
11434348|NCT01804881|Experimental|Lifestyle counseling|Group program using Craving Change(tm) material was the intervention for dietary counseling, 6 group sessions
11434349|NCT01804881|Placebo Comparator|Wait list control|Wait list, offered group program using Craving Change(tm) material at end of study
11434350|NCT01804868|Experimental|case vignette tutorial|The web tutorial composed of 4 case vignettes.
11434351|NCT01804868|Active Comparator|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
11434352|NCT01804855|Active Comparator|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
11434353|NCT01804855|Experimental|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
11434354|NCT01804842|Active Comparator|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
11434355|NCT01804842|Experimental|1000 mg Met DR qAM|One dose of 1000 mg metformin delayed-release in the morning
11434356|NCT01804842|Experimental|1000 mg Met DR qPM|One dose of 1000 mg metformin delayed-release in the evening
11434357|NCT01804829|No Intervention|Observational Control|Subjects who attain HCV RNA <100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
11434358|NCT01804829|Experimental|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
11434359|NCT01804829|Experimental|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
11434360|NCT01804816|Experimental|Acupuncture|10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.
11434361|NCT01804816|Placebo Comparator|No Acupuncture|"No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of no acupuncture prior to the 5 weeks of acupuncture sessions."
11434362|NCT01804803|Experimental|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
11434363|NCT01804803|Active Comparator|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
11531465|NCT01133873|Placebo Comparator|2|
11434364|NCT01804790|Active Comparator|Arm A : Radiotherapy + capecitabine|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m² twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on the center's choice.
11434365|NCT01804790|Experimental|Arm B : Chemotherapy then radiochemotherapy|"Drug: Chemotherapy mFolfirinox
~Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):
~oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-fluorouracil (5-FU): 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles).
~Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, 5 sessions per week) + capecitabine 800 mg/m² twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on the center's choice."
11434366|NCT01804777|Experimental|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
11434367|NCT01804777|Active Comparator|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
11434368|NCT01804738|No Intervention|Glucose|Glucose anhydrous 50g dissolved in 250ml water
11434369|NCT01804738|Active Comparator|Jasmine rice|50g available carbohydrate portion
11434370|NCT01804738|Active Comparator|Parboiled basmati rice|50g available carbohydrate portion
11434371|NCT01804712|Experimental|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
11434372|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
11434373|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
11434374|NCT01804686|Experimental|PCI-32765 (Ibrutinib)|
11434375|NCT01804673|Experimental|Fentanyl-ITS|
11434376|NCT01804660||25 healthy volunteers|No study treatments administered
11434377|NCT01804647||33 RRMS patients|No study treatments administered
11434378|NCT01804647||9 PPMS patients|No study treatments administered
11434379|NCT01804647||12 SPMS patients|No study treatments administered
11434380|NCT01804647||4 CIS patients|No study treatments administered
11434381|NCT01804634|Experimental|Reduced intensity conditioning|Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).
11434382|NCT01804621|Experimental|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
11434383|NCT01804621|Experimental|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit & vegetable consumption.
11434384|NCT01804621|Experimental|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
11434385|NCT01804621|Experimental|Mammography|Participant received health newsletter with targeted articles about mammography screening.
11434386|NCT01804608|Experimental|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
11434387|NCT01804608|Active Comparator|Strength|Strength, this arm will receive only hip muscle strengthening.
11434388|NCT01804595|Experimental|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
11434389|NCT01804595|Experimental|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
11434390|NCT01804595|Experimental|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
11434391|NCT01804595|Active Comparator|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
11434433|NCT01804296|Experimental|Part 2 Maintenance|Open-label, active repetitive transcranial magnetic stimulation
11434434|NCT01804283|Sham Comparator|CON|Patients undergoing double valve replacement (aortic and mitral).
11434435|NCT01804283|Experimental|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
11434436|NCT01804270|Active Comparator|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
11531836|NCT01131117||Pregnant women|
11434392|NCT01804582|Experimental|Family Navigator Consultation|"This group of parents will be contacted by a Family Navigator to assist them in accessing psychosocial resources based on their child and family needs. Components of this intervention are the following:
~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
11434393|NCT01804582|No Intervention|Usual Care|No specific study intervention is provided to this group of parents. This control group will received the usual care that they have been receiving from their child's providers.
11434394|NCT01804569|Experimental|moxa|moxibustion treatment 3 times a week for 3 weeks
11434395|NCT01804556|Other|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
11434396|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
11434397|NCT01804530|Experimental|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
11434398|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
11434399|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
11434400|NCT01804504|No Intervention|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.
~Physical examination and biochemical examination before and after the trial."
11434401|NCT01804504|Experimental|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.
~Physical examination and biochemical examination before and after the trial.
~Do nutrition education"
11434402|NCT01804491||Control group|Healthy age matched control subjects
11434403|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
11434404|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
11434405|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
11434406|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
11434407|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
11434408|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
11434409|NCT01804478|Experimental|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
11434410|NCT01804465|Experimental|Immediate IpilimumabTreatment|Arm 1 (Immediate Treatment) Ipilimumab Q3wks x 4 started 1 day following the final dose of SipT.
11434411|NCT01804465|Experimental|Delayed IpilimumabTreatment|Arm 2 (Delayed Treatment) Ipilimumab Q3wks x 4 started 3 weeks following the final dose of SipT.
11434412|NCT01804452||Subjects with a diagnosis of PSP or CBD|
11434413|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
11434414|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
11434415|NCT01804413|Active Comparator|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
11434416|NCT01804413|Active Comparator|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
11434417|NCT01804400|Experimental|QAW039 + Montelukast|
11434418|NCT01804400|Experimental|QAW039 Once a day (q.d.)|
11434419|NCT01804400|Experimental|QAW039 Twice a day (b.i.d.)|
11434420|NCT01804400|Active Comparator|Montelukast|
11434421|NCT01804400|Placebo Comparator|Placebo|
11434422|NCT01804387|Active Comparator|Telbivudine plus adefovir|study drugs
11434423|NCT01804387|Active Comparator|Lamivudine plus adefovir|standard drugs
11434424|NCT01804374|Experimental|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
11434425|NCT01804361|Experimental|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
11434426|NCT01804361|Active Comparator|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
11434427|NCT01804348|Experimental|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
11434428|NCT01804335|Experimental|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
11434429|NCT01804322|Active Comparator|Usual care|usual care according to the practice of participating Epilepsy Centers
11434430|NCT01804322|Experimental|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:
~The cause and nature of the adverse event and/or drug interaction
~The tolerability profile of each drug present in the schedule
~The clinical manifestations associated with the current drug interactions
~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule
~The reasons for and the potential benefits of the suggested treatment change
~An encouragement to withdraw any potentially interfering or contraindicated drug"
11533784|NCT01117623|Experimental|Arm 6|
11434439|NCT01804244|Experimental|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet [27.5 mg as the hydrochloride salt]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
11434440|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
11434441|NCT01804218|Placebo Comparator|Placebo|Placebo
11434442|NCT01804218|Experimental|Active, nadolol|Active
11434443|NCT01804205|Experimental|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
11434444|NCT01804205|Placebo Comparator|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
11434445|NCT01804192|Experimental|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.
~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
11434446|NCT01804192|Active Comparator|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.
~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
11434447|NCT01804192|Placebo Comparator|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
11434448|NCT01804179|Active Comparator|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
11434449|NCT01804179|Experimental|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
11434450|NCT01804166|Other|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
11434451|NCT01804153|Experimental|Autologous expanded stem cells|Adipose-derived expanded stem cells
11434452|NCT01804140||Cohort|
11434453|NCT01804127|Experimental|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
11434454|NCT01804114|Active Comparator|Local anesthetic continuous infusion|Pain management following hernia repair
11434455|NCT01804114|Placebo Comparator|Placebo continuous infusion|Placebo pain management following hernia repair
11434456|NCT01804101|Experimental|Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)|"INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.
~CONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
11434457|NCT01804101|Experimental|Arm II (closed to accrual effective 4/21/14)|"INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.
~CONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
11434458|NCT01804088|Experimental|Stent|
11434459|NCT01804075|Active Comparator|methadone|"Methadone (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:
~NAS Score Methadone 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose
~Maximum dose of methadone will be 0.2 mg/kg/dose. (NeoFax)
~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 4 hours, until NAS scores are consistently <8 for 48 hours.
~If the maximum dose of methadone is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
11434460|NCT01804075|Active Comparator|morphine|"Morphine (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:
~NAS Score Morphine 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose
~Maximum dose of morphine will be 0.2 mg/kg/dose. (NeoFax)
~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 6 hours, until NAS scores are consistently <8 for 48 hours.
~If the maximum dose of morphine is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
11434461|NCT01804062||no treatment|no treatment, prospective observational
11434462|NCT01804049|Placebo Comparator|Placebo|60 participants will be randomized to placebo pills.
11441467|NCT01755962|Other|High Glycemic Load|12-week control diet
11434464|NCT01804036|Active Comparator|Zolpidem (Ambien) Treatment|A three week treatment of Zolpidem
11434465|NCT01804036|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
11434466|NCT01804023||Healthy women|
11434467|NCT01804010|Active Comparator|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
11434468|NCT01804010|Placebo Comparator|Placebo|Placebo administration
11434469|NCT01803997|Other|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
11434470|NCT01803997|Other|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
11434471|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
11434472|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
11434473|NCT01803971|Experimental|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
11434474|NCT01803958|Experimental|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
11434475|NCT01803958|Active Comparator|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
11434476|NCT01803945|Placebo Comparator|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
11434477|NCT01803945|Active Comparator|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
11434478|NCT01803932|Experimental|Behavioral intervention|Male-focused group violence prevention intervention
11434479|NCT01803932|No Intervention|Control communities|Communities in which male-focused group prevention activities will not be conducted
11434480|NCT01803919|Experimental|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
11434481|NCT01803919|Other|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
11434482|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
11434483|NCT01803893||Embryo culture media|measurement using immunoassay
11434484|NCT01803893||maternal serum|measurement by immunoassay
11434485|NCT01803880|Active Comparator|Mechanical Debridement|Mechanical shaver removes areas of damaged tissue
11434486|NCT01803880|Active Comparator|RF-based Debridement|Electrical energy removes areas of damaged tissue (Coblation®)
11434487|NCT01803867|Placebo Comparator|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.
~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
11434488|NCT01803854||Gulf War Era Veterans|All Veterans who served in the uniformed services during 1990-1991 who signed consent forms, completed a survey, and provided a blood sample are included in the cohort.
11434489|NCT01803841|Active Comparator|Transradial access|Coronary angiography and intervention via radial artery approach
11434490|NCT01803841|Active Comparator|Transfemoral access|Coronary angiography and intervention via femoral artery approach
11434491|NCT01803828|Active Comparator|Drug Group (Tadalafil)|Tadalafil 20 mg
11434492|NCT01803828|Placebo Comparator|Placebo Group (PLC)|Placebo 20 mg
11434493|NCT01803802|Placebo Comparator|Time management|Writing prompts oriented towards objective recounting of previous day
11434494|NCT01803802|Experimental|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
11434495|NCT01803802|Active Comparator|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
11434496|NCT01803789|Active Comparator|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
11434497|NCT01803789|Active Comparator|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
11434498|NCT01803776|Experimental|lifestyle counseling|Physical activity and dietary counseling
11434499|NCT01803776|No Intervention|Control|No active intervention
11434500|NCT01803763|Active Comparator|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
11434501|NCT01803763|Placebo Comparator|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
11434502|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
11434503|NCT01803737|Active Comparator|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
11434504|NCT01803737|Experimental|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
11434505|NCT01803711|Experimental|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
11434506|NCT01803711|Active Comparator|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period
11434507|NCT01803698|Experimental|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
11434508|NCT01803698|No Intervention|Usual care|Family physicians providing usual prenatal care.
11434509|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
11434510|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
11434511|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
11434512|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
11434513|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
11434514|NCT01803672|Experimental|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
11434515|NCT01803672|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
11434516|NCT01803659|Experimental|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
11434517|NCT01803659|Active Comparator|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
11434518|NCT01803659|Placebo Comparator|placebo (corn oil)|0 ug RAE/d as corn oil
11434519|NCT01803646|Experimental|AM-101 injection|AM-101
11434520|NCT01803646|Placebo Comparator|Placebo injection|Placebo
11434521|NCT01803633|Experimental|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
11434522|NCT01803633|Active Comparator|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
11434523|NCT01803607|Experimental|Odanacatib 50 mg|Participants will receive odanacatib 50 mg once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 international units (IU) of Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
11434524|NCT01803607|Placebo Comparator|Placebo|Participants will receive dose-matched placebo to odanacatib once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 IU Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
11434525|NCT01803594|Placebo Comparator|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
11434526|NCT01803594|Active Comparator|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.
~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
11434621|NCT01803087|Active Comparator|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
11434812|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
11434527|NCT01803594|Active Comparator|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.
~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
11434528|NCT01803581|Experimental|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
11434529|NCT01803581|Active Comparator|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
11434530|NCT01803568|Experimental|Exercise in normoglycaemic individuals|
11434531|NCT01803568|Experimental|Exercise in hyperglycaemic individuals|
11434532|NCT01803555|Experimental|Budesonide/Formoterol SPIROMAX®|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
11434533|NCT01803555|Active Comparator|SYMBICORT® TURBOHALER®|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
11434534|NCT01803542|Experimental|SBRT|High dose of radiation will be used to treat tumours.
11434535|NCT01803529|Experimental|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
11434536|NCT01803529|Active Comparator|heatpack only|standard heat-pack given a maximum of 8 treatments
11434537|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
11434538|NCT01803503|Active Comparator|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
11434539|NCT01803503|Experimental|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.
~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
11434540|NCT01803477|Active Comparator|Picato® 0.05% gel|once daily for two consecutive days
11434541|NCT01803477|Experimental|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
11434542|NCT01803477|Experimental|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
11434543|NCT01803477|Experimental|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
11434544|NCT01803464|Experimental|Botox plus low-magnitude vibration|Cerebral palsy and Botox + vibration
11434545|NCT01803464|Experimental|Botox|Cerebral palsy and Botox
11434546|NCT01803464|No Intervention|Cerebral palsy control|Cerebral palsy without treatment
11434547|NCT01803464|No Intervention|Typically developing control|Typically developing
11434548|NCT01803451|Experimental|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
11434549|NCT01803451|Experimental|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
11434550|NCT01803438|Active Comparator|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
11434551|NCT01803438|Experimental|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
11434552|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
11434553|NCT01803412|Experimental|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
11434554|NCT01803412|Experimental|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
11434555|NCT01803412|Experimental|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
11434556|NCT01803399|Experimental|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
11434557|NCT01803399|Experimental|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
11434558|NCT01803399|Placebo Comparator|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
11434559|NCT01803399|Active Comparator|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
11434560|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
11434561|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
11434562|NCT01803373|Experimental|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
11434813|NCT01801787|Experimental|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
11434563|NCT01803373|Experimental|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
11434564|NCT01803373|Experimental|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
11434565|NCT01803373|Experimental|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
11434566|NCT01803373|Experimental|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
11434567|NCT01803373|Experimental|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
11434568|NCT01803360|Experimental|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
11434569|NCT01803360|Placebo Comparator|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
11434570|NCT01803347|Experimental|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
11434571|NCT01803347|Active Comparator|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
11434572|NCT01803334|Experimental|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
11434573|NCT01803334|No Intervention|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
11434574|NCT01803321|Experimental|Cohort 1|Dose 1
11434575|NCT01803321|Experimental|Cohort 2|Dose 2
11434576|NCT01803308|Experimental|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.
~Intervention: SB9200"
11434577|NCT01803308|Experimental|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.
~Intervention: SB9200 and Placebo"
11434578|NCT01803295|Experimental|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
~Other Name: MMC Gel"
11434579|NCT01803295|Active Comparator|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
11434580|NCT01803295|Experimental|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
~Other Name: MMC Gel"
11434581|NCT01803282|Experimental|Part A: ADX 200 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434582|NCT01803282|Experimental|Part A: ADX 600 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434583|NCT01803282|Experimental|Part A: ADX 1800 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug
11434584|NCT01803282|Experimental|Part B: PAC, ADX 800 mg|Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434585|NCT01803282|Experimental|Part B: LAC, ADX 1200 mg|Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434586|NCT01803282|Experimental|Part B: LSC, ADX 1200 mg|Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11533785|NCT01117623|Experimental|Arm 7|
11434587|NCT01803282|Experimental|Part B: EGC, ADX 800 mg|Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} [mFOLFOX6], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434588|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434589|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434590|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU [FOLFIRI] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434591|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434592|NCT01803282|Experimental|Part B: BRCA, ADX 800 mg|Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
11434593|NCT01803269|Active Comparator|Arm A (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11434594|NCT01803269|Experimental|Arm B (CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX10 cyclodextr1 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11434595|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
11434596|NCT01803256||Control subjects:|15 adolescent healthy control subjects
11434597|NCT01803243|Experimental|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
11434598|NCT01803243|Experimental|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
11434599|NCT01803243|Experimental|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
11434600|NCT01803243|No Intervention|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
11434601|NCT01803230|Placebo Comparator|placebo|placebo (dextrose)
11434602|NCT01803230|Experimental|creatine|creatine supplementation
11434603|NCT01803217|Experimental|mode switch to atrial pacing|
11434604|NCT01803217|Active Comparator|atrioventricular hysteresis function|
11434605|NCT01803204|Experimental|Booklet - Preoperative Educational|This group received the booklet in the preoperative consult, they will monitoring during the postoperative phase
11434606|NCT01803204|No Intervention|Control|This group don't received booklet, they will be monitored during the postoperative period to control
11434607|NCT01803191|Experimental|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
11434608|NCT01803191|Active Comparator|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
11434609|NCT01803178|Active Comparator|Plant Sterols|Plant Sterols
11434610|NCT01803178|Placebo Comparator|Placebo Product|Placebo Product
11434611|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
11434612|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
11434613|NCT01803152|Experimental|Part 1-DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;
~Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;
~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;
~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
11434614|NCT01803152|Active Comparator|Part 2-Gemcitabine/DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;
~Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;
~Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;
~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;
~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
11434615|NCT01803139|Active Comparator|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
11434616|NCT01803139|Experimental|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
11434617|NCT01803126||atherosclerosis|No treatment.
11434618|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
11434619|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
11434620|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
11434622|NCT01803087|Active Comparator|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
11434623|NCT01803074|Experimental|Part A-Group 1: BMS-955176 (5 mg) or Placebo|"BMS-955176 5 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434624|NCT01803074|Experimental|Part A-Group 2: BMS-955176 (10 mg) or Placebo|"BMS-955176 10 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434625|NCT01803074|Experimental|Part A-Group 3: BMS-955176 (20 mg) or Placebo|"BMS-955176 20 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434626|NCT01803074|Experimental|Part A-Group 4: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434627|NCT01803074|Experimental|Part B-Group 5: BMS-955176 + Atazanavir|"BMS-955176 40 mg solution by mouth once daily for 28 days
~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
11434628|NCT01803074|Experimental|Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir|"BMS-955176 40 mg solution by mouth once daily for 28 days
~Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days
~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days"
11434629|NCT01803074|Experimental|Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine|"Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days
~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days
~Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days
~Emtricitabine 1 x 200 mg capsule once daily for 28 days"
11434630|NCT01803074|Experimental|Part C-Group 8: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434631|NCT01803074|Experimental|Part A-Group 9: BMS-955176 (80 mg) or Placebo|"BMS-955176 80 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434632|NCT01803074|Experimental|Part A-Group 10: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434633|NCT01803074|Experimental|Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo|"BMS-955176 ≤120 mg solution by mouth once daily for 14 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
11434634|NCT01803074|Experimental|Part B-Group 12: BMS-955176 (80 mg) + Atazanavir|"BMS-955176 80 mg solution by mouth once daily for 28 days
~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
11434635|NCT01803074|Experimental|Part C-Group 13: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days
~OR
~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
11434636|NCT01803061|Experimental|WebCan|Provides computerized PRO to the treating physician at the point of care
11434637|NCT01803061|No Intervention|Usual care|
11434638|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
11434639|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
11434640|NCT01803035|Experimental|1 % LTX-109|LTX-109 topical gel in 1 % strength
11434641|NCT01803035|Experimental|2 % LTX-109|LTX-109 topical gel in 2 % strength
11434642|NCT01803035|Placebo Comparator|Placebo|Placebo gel, containing all ingredients except LTX-109
11434643|NCT01803022||Low Molecular Weight Heparin|
11434644|NCT01803009|Experimental|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
11434645|NCT01802996|Experimental|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
11434646|NCT01802996|No Intervention|Arm II|Only chemotherapy
11434647|NCT01802970|Experimental|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
11434648|NCT01802957|Other|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
11434649|NCT01802944|Experimental|10 IU BID|10 IU BID Intranasal Insulin
11434650|NCT01802944|Experimental|20 IU BID|20 IU BID Intranasal Insulin
11434651|NCT01802944|Experimental|PLACEBOS|Saline nasal solution used as placebo
11434652|NCT01802931|Active Comparator|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
11434653|NCT01802931|Active Comparator|Co-dose Session|Single dose session with ketoconazole co-administration
11434654|NCT01802918|Experimental|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
11434655|NCT01802918|Experimental|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
11434656|NCT01802905|Experimental|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
11434657|NCT01802892|Experimental|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
11441863|NCT01753180|Placebo Comparator|saline|
11434658|NCT01802892|Experimental|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
11434659|NCT01802879|Experimental|Panobinostat - 10 to 40 mg/day TIW QoW|10 to 40mg/day TIW QoW (3 times/week every other week) as per parent protocol design
11434660|NCT01802866|Experimental|ACU-4429 2.5 mg|2.5 mg tablet
11434661|NCT01802866|Experimental|ACU-4429 5 mg|5 mg tablet
11434662|NCT01802866|Experimental|ACU-4429 10 mg|10 mg tablet
11434663|NCT01802866|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
11434664|NCT01802853|Experimental|A: RO6811135 s.c.|
11434665|NCT01802853|Active Comparator|B: RO6811135 i.v.|
11434666|NCT01802840|Placebo Comparator|biscuits without soy fiber|biscuits without soy fiber
11434667|NCT01802840|Experimental|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
11434668|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
11434669|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
11434670|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
11434671|NCT01802814|No Intervention|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
11434672|NCT01802814|Active Comparator|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
11434673|NCT01802814|No Intervention|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
11434674|NCT01802814|Active Comparator|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
11434675|NCT01802801||1|
11434676|NCT01802788||Cohort A|"Patients implanted with a Portico valve bearing the CE mark (implanted after St Jude Medical declared the device compliant with all applicable essential requirements within the European union and marketed the device bearing the CE mark.)"
11434677|NCT01802788||Cohort B|Patients implanted with a Portico valve as part of an Investigational Device study.
11434678|NCT01802775|Experimental|edoxaban/aspirin|Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
11434679|NCT01802775|Active Comparator|clopidogrel/aspirin|Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
11434680|NCT01802762|Other|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
11434681|NCT01802749|Active Comparator|chemotherapy|"Combination chemotherapy with ONE of the following regimens:
~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;
~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;
~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days."
11434682|NCT01802749|Experimental|Chemotherapy and bevacizumab|"Combination chemotherapy AND bevacizumab with ONE of the following regimens:
~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;
~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L
~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.
~Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn."
11434683|NCT01802736|Active Comparator|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.
~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
11434684|NCT01802736|Experimental|Alcohol Motivational intervention counselling plus SPP|
11434685|NCT01802723|Experimental|LIPO-202, Low|Drug: salmeterol xinafoate
11434686|NCT01802723|Experimental|LIPO-202, Mid|Drug: salmeterol xinafoate
11434687|NCT01802723|Experimental|LIPO-202, High|Drug: salmeterol xinafoate
11434688|NCT01802723|Experimental|LIPO-202, Placebo|Drug: Placebo
11434689|NCT01802710|Experimental|Psychological support|Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson
11434690|NCT01802710|Active Comparator|No psychological support|Patients of this group only received the conventional medical treatment, not receiving any psychological support
11434691|NCT01802697|Experimental|IdeS|Intravenous infusion
11434692|NCT01802697|Placebo Comparator|PBS Buffer|Intravenous infusion
11434693|NCT01802684|Experimental|OPTIMOX-aflibercept|"Induction therapy (sequence #1)
~Regimen : aflibercept + modified FOLFOX7
~Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)
~Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)
~Duration : 6 cycles (3 months) Second phase (sequence #2B)
~Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)
~Duration : until PD or limiting toxicity Reintroduction (sequence #3)
~Regimen : aflibercept + modified FOLFOX7
~Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)
~Regimen : aflibercept + fluoropyrimidine
~Duration : until PD or limiting toxicity"
11434694|NCT01802671|Experimental|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
11434695|NCT01802671|Active Comparator|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
11434696|NCT01802671|Experimental|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
11434697|NCT01802658|Active Comparator|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
11434698|NCT01802658|Placebo Comparator|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
11434699|NCT01802645|Active Comparator|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks
~*reduced in UGT1A1 7/7 patients"
11434700|NCT01802645|Experimental|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
~*reduced in UGT1A1 7/7 patients"
11434701|NCT01802645|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
~*reduced in UGT1A1 7/7 patients"
11434702|NCT01802645|Experimental|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
~*reduced in UGT1A1 7/7 patients"
11434703|NCT01802632|Experimental|Daily dose of AZD9291|Daily oral dose of AZD9291
11434704|NCT01802619|Placebo Comparator|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
11434705|NCT01802619|Experimental|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
11434706|NCT01802593|Experimental|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
11434707|NCT01802593|Experimental|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
11434708|NCT01802580|Experimental|Intervention - internet reminder survey|Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete.
11434709|NCT01802580|Experimental|Standard of care, no internet survey|Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed.
11434710|NCT01802567|Experimental|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
11434711|NCT01802554|Experimental|Pleasant Events Program (PEP)|The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
11434742|NCT01802333|Experimental|Arm I (standard dose cytarabine, daunorubicin hydrochloride)|"INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.
~CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.
~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
11434712|NCT01802554|Active Comparator|Information-Support (IS)|Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.
11434713|NCT01802541|Experimental|DAG oil|
11434714|NCT01802541|Placebo Comparator|TAG oil|
11434715|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
11434716|NCT01802515|Active Comparator|Atomoxetine, low dose|1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
11434717|NCT01802515|Active Comparator|Atomoxetine, high dose|One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
11434718|NCT01802515|Placebo Comparator|Placebo (sugar pill)|1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
11434719|NCT01802502|Active Comparator|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
11434720|NCT01802502|Experimental|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
11434721|NCT01802502|Experimental|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
11434722|NCT01802489|Active Comparator|Amiloride|Amiloride capsules 10mg once per day for 5 months
11434723|NCT01802489|Placebo Comparator|Placebo|Placebo capsules one per day for 5 months
11434724|NCT01802476|Other|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
11434725|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
11434726|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
11434727|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
11434728|NCT01802450|Experimental|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
11434729|NCT01802437|Experimental|Talk Therapy 4-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 4 weeks of therapy, participants with at less than a 20% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy frequency or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy
11434730|NCT01802437|Experimental|Talk Therapy 8-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 8 weeks of therapy, participants with at less than a 40% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy.
11434731|NCT01802424|Experimental|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
11434732|NCT01802411|Active Comparator|Liposome bupivacaine|Single total administration of 266 mg (approximately 88 mg to each of three nerve segments) of 6.6 mL volume each for a total of 20 mL.
11434733|NCT01802411|Placebo Comparator|Placebo|Single total administration of 266 mg (approximately 88 mg to each of three nerve segments) of 6.6 mL volume each for a total of 20 mL
11434734|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
11434735|NCT01802385|No Intervention|Placebo|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day) + placebo
11434736|NCT01802385|Experimental|Sertraline 400mg|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.
11434737|NCT01802372|Active Comparator|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
11434738|NCT01802372|Sham Comparator|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
11434739|NCT01802359||Mirodenafil|
11434740|NCT01802346|Experimental|Arm I (low-calorie diet)|Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy. Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts.
11434741|NCT01802346|Active Comparator|Arm II (normal diet)|Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.
11434811|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
11434743|NCT01802333|Experimental|Arm II (high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.
~CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.
~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
11434744|NCT01802333|Experimental|Arm III (vorinostat, high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.
~CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5.
~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat."
11434745|NCT01802320|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
11434746|NCT01802307|Experimental|Focal Therapy|
11434747|NCT01802294|Experimental|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
11434748|NCT01802294|No Intervention|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
11434749|NCT01802281|Active Comparator|Hysteropexy|Uphold® LITE
11434750|NCT01802281|Active Comparator|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
11434751|NCT01802268|Active Comparator|Sirolimus|Conversion from Tacrolimus to Sirolimus
11434752|NCT01802268|Active Comparator|Tacrolimus|Maintenance on tacrolimus
11434753|NCT01802255|Experimental|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
11434754|NCT01802255|Active Comparator|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
11434755|NCT01802242|Experimental|Active Radiation Treatment (Cohort 2)|
11434756|NCT01802242|Other|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
11434757|NCT01802229|Active Comparator|Suture|Umbilical port-site closure with simple suture of the fascia.
11434758|NCT01802229|Experimental|Prophylactic mesh|Umbilical port-site closure with mesh placement
11434759|NCT01802216|No Intervention|Control/Delayed Treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Rescue scaling and root planing only to sites of periodontal disease progression (since prior examination) of greater than 3mm. Subjects will be informed of their assignment to the delayed treatment group and provided referral list of local dentists should patient not feel comfortable waiting until end of study for full intensive periodontal disease treatment. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
11434760|NCT01802216|Active Comparator|Intensive periodontal disease treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Intensive periodontal disease treatment to include administration of local anesthetic to up to two quadrants for scaling and root planing with ultrasonic and hand instruments. Minocycline will be applied to any sites with probing depth >=5mm. Hopeless teeth in scaled quadrants will be extracted. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
11434761|NCT01802203||truFreeze spray cryotherapy|truFreeze Spray Cryotherapy administered as routine clinical care
11434762|NCT01802190||Deafness patients|Deafness patients
11434763|NCT01802177|Experimental|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
11434764|NCT01802177|No Intervention|No treatment (covered)|
11434765|NCT01802164|Experimental|1|Conventional abdominal wall closure with mesh implantation
11434766|NCT01802164|No Intervention|2|Conventional abdominal wall closure without mesh implantation
11434767|NCT01802151|Placebo Comparator|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules once daily for 4 weeks.
11434768|NCT01802151|Experimental|B. subtilis R0179 (10 billion CFU)|"B. subtilis R0179 (approximately 10 billion CFU/capsule) once daily for 4 weeks.
~* CFU (Colony Forming Unit)"
11434769|NCT01802151|Experimental|B. subtilis R0179 (1 billion CFU)|B. subtilis R0179 (approximately 1 billion CFU/capsule) once daily for 4 weeks.
11434770|NCT01802151|Experimental|B. subtilis R0179 (0.1 billion CFU)|B. subtilis R0179 (approximately 0.1 billion CFU/capsule) once daily for 4 weeks.
11434771|NCT01802138|Experimental|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.
~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
11434772|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
11434773|NCT01802112|Placebo Comparator|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
11434774|NCT01802112|Experimental|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
11434775|NCT01802099|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
11434776|NCT01802099|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
11434777|NCT01802086|Active Comparator|Emla-cream|Dose: 1 g Emla-cream, 1 hour.
11434778|NCT01802086|Placebo Comparator|Miniderm cream|Dose: 1 g Miniderm-cream, 1 hour.
11434779|NCT01802073|Experimental|Oral Vancomycin|1) For children who weight < or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh >30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
11434780|NCT01802047|Experimental|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
11434781|NCT01802034||Native, Renal Tissue Preservation Group|Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
11434782|NCT01802034||Native, Non-tissue Preservation Group|"Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or
~Subjects with diabetes and renal disease who have not had a renal biopsy."
11434783|NCT01802034||Transplant Nephropathy Group|"Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or for-cause indications."
11434784|NCT01802021|Experimental|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.
~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
11434785|NCT01802021|No Intervention|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
11434786|NCT01802008|Active Comparator|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
11434787|NCT01802008|Active Comparator|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
11434788|NCT01801969||Rehabilitation service|"Centralized or Decentralized rehabilitation
~Size of municipality"
11434789|NCT01801956|Active Comparator|Motivational interviewing|A one hour motivational interview
11434790|NCT01801956|Experimental|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
11434791|NCT01801943|Experimental|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
11434792|NCT01801943|Experimental|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
11434793|NCT01801943|Experimental|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
11434794|NCT01801943|Experimental|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
11434795|NCT01801930|Experimental|Dose level 1|
11434796|NCT01801930|Experimental|Dose level 2|
11434797|NCT01801930|Experimental|Dose level 3|
11434798|NCT01801930|Experimental|Dose level 4|
11434799|NCT01801917|Placebo Comparator|Placebo|5 placebo tablets daily during non-titration phase
11434800|NCT01801917|Experimental|BAF312 2mg|1 tablet of BAF312 2 mg + 4 tablets of Placebo daily during non-titration phase
11434801|NCT01801917|Experimental|BAF312 10 mg|5 tablets of BAF312 2 mg daily during non-titration phase
11434802|NCT01801904|Experimental|Panitumumab|
11434803|NCT01801891|Active Comparator|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
11434804|NCT01801891|Experimental|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
11434805|NCT01801878|Experimental|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
11434806|NCT01801878|Active Comparator|Normal saline|Normal saline inject to the half of irradiated breast
11434807|NCT01801865|Experimental|MRI for Neonates|All participants will receive an MRI in the NICU scanner in the GE OPTIMA 1.5T MRI at CCHMC.
11434808|NCT01801852|Experimental|NKT cells|NKT cells treatment plus regular treatment
11434809|NCT01801839||SIRS,sepsis,normal|"SIRS
~(1) temperature > 38 centigrade or < 36 centigrade; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000/μL or < 4000/μL , or > 10% immature cells.
~sepsis
~SIRS + infection.
~normal
~not SIRS and have no infection."
11434810|NCT01801826||Treatment|Treatment with CryoTouch IV device
11442294|NCT01750229|Experimental|3030 Hz|Frequency Setting - 3030 Hz
11434814|NCT01801787|Sham Comparator|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
11434815|NCT01801774|Placebo Comparator|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
11434816|NCT01801774|Active Comparator|Triamcinolone|Subtenon 20-mg Triamcinolone injection
11434817|NCT01801761||develop group|previous COPD study
11434818|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
11434819|NCT01801748|Experimental|oral wheat challenge|
11434820|NCT01801735|Experimental|Meloxicam Test Capsules|One Capsule QD
11434821|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
11434822|NCT01801709|Experimental|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
11434823|NCT01801696|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
11434824|NCT01801696|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
11434825|NCT01801683|Other|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
11434826|NCT01801683|No Intervention|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
11434827|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
11434828|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
11434829|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
11434830|NCT01801644|Experimental|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
11434831|NCT01801631|Experimental|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
11434832|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
11434833|NCT01801605|Active Comparator|on|active session
11434834|NCT01801605|Placebo Comparator|off|fictive session
11434835|NCT01801566|Active Comparator|Conventional implant loading protocol|Single implant-retained mandibular overdenture
11434836|NCT01801566|Experimental|Immediate loading implant protocol|Single implant-retained mandibular overdenture
11434837|NCT01801553|Active Comparator|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
11434838|NCT01801553|Sham Comparator|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
11434839|NCT01801540|Experimental|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
11434840|NCT01801540|Other|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
11434841|NCT01801540|Other|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
11434842|NCT01801540|Other|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
11434843|NCT01801540|Other|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
11434844|NCT01801540|Other|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
11434845|NCT01801527|Experimental|Telerehabilitation group|
11434846|NCT01801527|No Intervention|Control group|Information about usual care
11434847|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
11434848|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
11434849|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
11434850|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
11434851|NCT01801475|Active Comparator|Pregnant women|Full term pregnant women scheduled for Cesarean section and will be given Ondansetron as standard-of-care prior to surgery.
11434852|NCT01801475|Active Comparator|Non-pregnant women|Non-pregnant women scheduled for surgery at Stanford who will be given Ondansetron prior to their surgery as standard-of-care.
11434853|NCT01801475|No Intervention|Neonates|"Babies of the pregnant women enrolled in the study; no ondansetron is given to babies in this Aim 1 of the study."
11434920|NCT01800903|Experimental|Sequence 2|SpeediCath catheter then ZN-C catheter then ZN-D catheter
11434921|NCT01800903|Experimental|Sequence 3|ZN-D catheter then SpeediCath catheter then ZN-C catheter
11442295|NCT01750229|Experimental|5882 Hz|Frequency Setting - 5882 Hz
11434854|NCT01801462|Experimental|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
11434855|NCT01801462|No Intervention|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
11434856|NCT01801449|Experimental|Rilonacept Treatment|Rilonacept loading dose of 4.4 mg/kg/week followed by maintenance dose of 2.2 mg/kg/week. Total duration of the study 24 months. Maintenance dose could be escalated to 4.4 mg/kg/week or further to 6.6 mg/kg/week for 3 months only.
11434857|NCT01801436|Experimental|Bortezomib|Bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
11434858|NCT01801423|Experimental|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at ~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
11434859|NCT01801410|Active Comparator|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
11434860|NCT01801410|Active Comparator|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
11434861|NCT01801397|Other|Teriparatide|one arm study. All patients receive teriparatide
11434862|NCT01801384|Experimental|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
11434863|NCT01801384|Experimental|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
11434864|NCT01801384|Sham Comparator|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
11434865|NCT01801371|Experimental|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
11434866|NCT01801358|Experimental|Arm A|AEB071 and MEK162 combined
11434867|NCT01801358|Experimental|Arm B|MEK162 alone
11434868|NCT01801345|Other|Rested|Subjects will perform the scenario, once during a normal workday (rested)
11434869|NCT01801345|Active Comparator|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
11434870|NCT01801332|Experimental|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
11434871|NCT01801332|Active Comparator|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
11434872|NCT01801319|Active Comparator|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
11434873|NCT01801319|Sham Comparator|No Stimulation|The Libra DBS System is implanted and not activated
11434874|NCT01801306|Other|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
11434875|NCT01801293|Experimental|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
11434876|NCT01801280|Active Comparator|Mycophenolate mofetil (C)|Mycophenolate mofetil (C) b.i.d. every 12 hours for 2 weeks.
11434877|NCT01801280|Other|Mycophenolate mofetil+Pantoprazole (C+P)|Mycophenolate mofetil b.i.d and Pantoprazole o.m. for 2 weeks.
11434878|NCT01801280|Other|Mycophenolate sodium (M)|Mycophenolate sodium (M) b.i.d. every 12 hours for 2 weeks.
11434879|NCT01801280|Other|Mycophenolate sodium+Pantoprazole (M+P)|Mycophenolate mofetil b.i.d and Pantoprazole 40mg o.m. for 2 weeks.
11434880|NCT01801267|Experimental|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
11434881|NCT01801267|Active Comparator|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
11434922|NCT01800903|Experimental|Sequence 4|ZN-D catheter then ZN-C catheter then SpeediCath catheter
11434923|NCT01800903|Experimental|Sequence 5|ZN-C catheter then SpeediCath catheter then ZN-D catheter
11442296|NCT01750216||Cohort|
11434882|NCT01801254|Experimental|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
11434883|NCT01801254|Sham Comparator|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
11434884|NCT01801228|Experimental|Eplerenone|oral daily treatment with doses 100 to 400 mg
11434885|NCT01801228|Active Comparator|Spironolactone|oral daily treatment with doses 100 to 400 mg
11434886|NCT01801202|Experimental|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
11434887|NCT01801189|Experimental|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
11434888|NCT01801189|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose.
11434889|NCT01801176|Experimental|Initial monitoring group|
11434890|NCT01801163|Experimental|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
11434891|NCT01801150|No Intervention|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
11434892|NCT01801150|Experimental|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
11434893|NCT01801137|Experimental|Afinitor|Treatment by Afinitor 10 mg per day
11434894|NCT01801124|Experimental|EXPAREL|undiluted EXPAREL 266 mg
11434895|NCT01801111|Experimental|Alectinib|Participants will receive alectinib treatment continuously starting from Day 1 Cycle 1 (in 28-day cycles) until disease progression, death, or withdrawal for any other reasons, whichever occurs first. After PD, participants without EGFR mutation will continue treatment with alectinib alone and participants with EGFR mutation will receive alectinib in combination with erlotinib as per discretion of the treating physician.
11434896|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
11434897|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
11434898|NCT01801072|Active Comparator|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
11434899|NCT01801072|No Intervention|No levetiracetam|No levetiracetam
11434900|NCT01801059|Active Comparator|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
11434901|NCT01801059|Experimental|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
11434902|NCT01801046|Experimental|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
11434903|NCT01801020|Experimental|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
11434904|NCT01801007|Other|Flow Re-Direction Endoluminal Device|
11434905|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
11434906|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
11434907|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
11434908|NCT01800968|Active Comparator|Liraglutide|Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.
11434909|NCT01800968|Placebo Comparator|Placebo|Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.
11434910|NCT01800955|Experimental|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
11434911|NCT01800955|Sham Comparator|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
11434912|NCT01800942|Placebo Comparator|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.
~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
11434913|NCT01800942|Experimental|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.
~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
11434914|NCT01800929|Experimental|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
11434915|NCT01800929|Active Comparator|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
11434916|NCT01800916|Experimental|Treatment sequence 1|"The subjects randomised to Treatment sequence 1 are going to test
~Coloplast Adhesive baseplate A (A)
~Coloplast Adhesive baseplate B (B)
~SenSura 1-piece (S)
~The subjects test the three test products in a randomised order: ABS; BSA; SAB"
11434917|NCT01800916|Experimental|Treatment sequence 2|"The subjects randomised to Treatment sequence 2 are going to test
~Coloplast Adhesive baseplate B (B)
~Coloplast Adhesive baseplate C (C)
~SenSura 1-piece (S)
~The subjects test the three test products in a randomised order: CBS; BSC; SCB"
11434918|NCT01800916|Experimental|Treatment sequence 3|"The subjects randomised to Treatment sequence 3 are going to test
~Coloplast Adhesive baseplate A (A)
~Coloplast Adhesive baseplate B (C)
~SenSura 1-piece (S)
~The subjects test the three test products in a randomised order: ACS; CSA; SAC"
11434919|NCT01800903|Active Comparator|Sequence 1|SpeediCath catheter then ZN-D catheter then ZN-C catheter
11434924|NCT01800903|Experimental|Sequence 6|ZN-C catheter then ZN-D catheter then SpeediCath catheter
11434925|NCT01800890|Other|Treatment sequence 1|"Subjects randomised to Treatment sequence 1 will test three different products:
~Coloplast A
~Coloplast B
~SenSura Click
~The subjects test the three test products in a randomized order: ABS; BSA, SAB"
11434926|NCT01800890|Experimental|Treatment sequence 2|"Subjects randomised to Treatment sequence 2 will test three different products:
~Coloplast C (C)
~Coloplast B (B)
~SenSura Click (S)
~The subjects test the three test products in a randomized order: CBS; BSC, SCB"
11434927|NCT01800890|Experimental|Treatment sequence 3|"Subjects randomised to Treatment sequence 3 will test three different products:
~Coloplast A (A)
~Coloplast C (C)
~SenSura Click (S)
~The subjects test the three test products in a randomized order: ACS; CSA, SAC"
11434928|NCT01800877|Other|Liberal Approach|In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
11434929|NCT01800877|Other|Restrictive Approach|We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
11434930|NCT01800864|Other|Normal|Normal weight subjects
11434931|NCT01800864|Other|Over weight /obese subjects|Overweight and obese subjects
11434932|NCT01800851|Experimental|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
11434933|NCT01800851|Experimental|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
11434934|NCT01800851|Other|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
11434935|NCT01800838|Experimental|Treatment (silicon phthalocyanine 4 and PDT)|Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
11434936|NCT01800825|Active Comparator|Clindamycin|Clindamycin 300mg orally twice daily for five days
11434937|NCT01800825|Placebo Comparator|placebo|This will be an identical placebot
11434938|NCT01800799|Experimental|UTI (WBC>10 per high power field)|"Antimicrobial agent (Baktar 800mg h.s.)
~Anti-inflammatory agent (Celecoxib 200mg QD)"
11434939|NCT01800799|Experimental|Recurrent UTI|"Antimicrobial agent (Baktar 800mg h.s.)
~Anti-inflammatory agent (Celecoxib 200mg QD)"
11434940|NCT01800799|No Intervention|Normal control|Normal control
11434941|NCT01800786|Active Comparator|OSA-CPAP group|OSA patient will use CPAP for 3 months
11434942|NCT01800786|No Intervention|OSA -no CPAP|newly diagnosed OSA patient will not wear CPAP for 3 months
11434943|NCT01800773|Experimental|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
11434944|NCT01800773|Active Comparator|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
11434945|NCT01800760|Experimental|No groups|
11434946|NCT01800747|Active Comparator|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
11434947|NCT01800747|No Intervention|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
11434948|NCT01800747|Experimental|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
11434949|NCT01800734|Other|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
11434950|NCT01800721|Experimental|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach
~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
11434951|NCT01800721|Active Comparator|SNAP Control Condition|"SNAP Control
~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
11434952|NCT01800708|Active Comparator|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
11434953|NCT01800708|Active Comparator|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
11434954|NCT01800695|Experimental|Arm A|ABT-414 in combination with radiation and temozolomide
11434955|NCT01800695|Experimental|Arm B|ABT-414 in combination with temozolomide
11434956|NCT01800695|Experimental|Arm C|ABT-414 monotherapy
11434957|NCT01800682|Experimental|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
11434958|NCT01800682|Experimental|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
11434959|NCT01800682|Experimental|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
11434960|NCT01800669|Experimental|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
11434961|NCT01800669|Active Comparator|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
11434962|NCT01800656|Experimental|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
11434963|NCT01800656|Active Comparator|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
11434964|NCT01800643|Other|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
11434965|NCT01800643|Other|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
11434995|NCT01800409|No Intervention|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
11533786|NCT01117623|Experimental|Arm 8|
11434966|NCT01800630|Experimental|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
11434967|NCT01800617|Experimental|Liothyronine, Sodium|
11434968|NCT01800604|Experimental|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
11434969|NCT01800604|Experimental|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
11434970|NCT01800604|Experimental|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
11434971|NCT01800604|Experimental|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
11434972|NCT01800591|No Intervention|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
11434973|NCT01800591|Experimental|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
11434974|NCT01800591|Experimental|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
11434975|NCT01800591|Experimental|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
11434976|NCT01800578||Bispectral Index Group|
11434977|NCT01800565|Other|pubertal progression|A collection of first voided urine sample for the measurement of LH.
11434978|NCT01800539|Experimental|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
11434979|NCT01800539|No Intervention|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
11434980|NCT01800526|Experimental|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
11434981|NCT01800526|Experimental|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.
~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
11434982|NCT01800513|Experimental|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
11434983|NCT01800513|Sham Comparator|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
11434984|NCT01800500|Experimental|Arm I (fixed rate ST product prices)|Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
11434985|NCT01800500|Experimental|Arm II (escalating ST product prices)|Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.
11434986|NCT01800487|Active Comparator|silymarin|Silymarin 140 mg three times a day for 4 weeks
11434987|NCT01800487|Placebo Comparator|placebo|"Placeo
~1 tab three times a day for 4 weeks"
11434988|NCT01800461|Experimental|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
11434989|NCT01800461|Other|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
11434990|NCT01800435|Active Comparator|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
11434991|NCT01800435|Active Comparator|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
11434992|NCT01800422|Experimental|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
11434993|NCT01800422|Placebo Comparator|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
11434994|NCT01800409|Experimental|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
11535603|NCT01105247|Experimental|PCI-32765|
11434996|NCT01800396|Placebo Comparator|Milk protein|Milk powder, twice daily at breakfast and dinner.
11434997|NCT01800396|Experimental|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
11434998|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
11434999|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
11435000|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
11435001|NCT01800370|Experimental|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
11435002|NCT01800370|Placebo Comparator|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
11435003|NCT01800370|Experimental|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.
~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.
~Includes blood draws and fasting requirements."
11435004|NCT01800357|Experimental|mildronate|infusion of mildronate
11435005|NCT01800357|Placebo Comparator|placebo|infusion of placebo mildronate
11435006|NCT01800344|Active Comparator|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
11435007|NCT01800344|Active Comparator|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure < 50 cm H2O; green 60 cm H2O; and red >70 cm H2O
11435008|NCT01800331|Experimental|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
11435009|NCT01800331|No Intervention|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
11435010|NCT01800318|Experimental|Sham NESAP with 24% oral sucrose|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.
~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
11435011|NCT01800318|Experimental|NESAP with oral water|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. 10 minutes before the heel stick, the Empi Select TENS unit will be turned on with settings 3.5mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.
~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given"
11435012|NCT01800318|Experimental|NESAP with 24% oral sucrose|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. The Empi Select TENS unit will be turned on ten minutes before the heel stick at settings 3.5 mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.
~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
11435013|NCT01800318|Placebo Comparator|Sham NESAP with oral water|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.
~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
11435014|NCT01800305|Experimental|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
11435015|NCT01800305|Active Comparator|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
11435016|NCT01800292|Experimental|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
11435017|NCT01800279|Active Comparator|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
11435018|NCT01800279|Experimental|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
11435019|NCT01800266|Experimental|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
11435020|NCT01800266|Experimental|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
11435021|NCT01800253|Experimental|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
11435022|NCT01800253|Experimental|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
11435023|NCT01800214||Alzheimer's disease (AD)|
11435026|NCT01800214||Frontotemporal Dementia (FTD)|Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)
11435027|NCT01800214||Mild Cognitive Impairment (MCI)|
11435028|NCT01800214||Cognitively Normal (CN)|
11435029|NCT01800214||Small Vessel Disease -Neurodegenerative (SVD)|
11435030|NCT01800214||Subjective Cognitive Complaints (SCC)|
11435031|NCT01800201|No Intervention|Control|The control group will have their claims data analyzed for a 12 month period. We will be examining these data for hospital admissions, new vascular events (AMI, stroke, acute coronary syndrome admission), or repeat or new cardiovascular procedures.
11435032|NCT01800201|Experimental|Intervention|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
11435033|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
11435034|NCT01800175|Experimental|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
11435035|NCT01800175|Experimental|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
11435036|NCT01800162|Active Comparator|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
11435037|NCT01800162|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
11435038|NCT01800162|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
11435039|NCT01800149|Active Comparator|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
11435040|NCT01800149|Active Comparator|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
11435041|NCT01800136|Experimental|rTMS; tDCS|
11435042|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
11435043|NCT01800110|Experimental|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
11435044|NCT01800097|Placebo Comparator|placebo|placebo
11435045|NCT01800097|Active Comparator|Modafinil|Modafinil
11435046|NCT01800084|Experimental|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.
~Intervention: Device: Asir Image Acquisition"
11435047|NCT01800058||Circulating prostatic tumor cells in the peripheral blood|"Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
~prior to any treatment;
~following AD and prior to RT; and
~following the end of RT (1-3 months afterwards).
~six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination
~The quantification of CTC in blood samples will be done with the CellSearch® system."
11435048|NCT01800045|Experimental|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
11435049|NCT01800045|Placebo Comparator|Placebo|Capsules of placebo containing lactose
11435050|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
11435051|NCT01800032||Optic Glioma|NF1 associated optic glioma
11435052|NCT01800019|Active Comparator|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)
~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.
~Mode of Administration: Transdermal Patch
~Duration of Treatment: up to 24 Weeks
~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.
~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
11435053|NCT01800019|Active Comparator|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)
~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.
~Mode of Administration: Transdermal Patch
~Duration of Treatment: up to 24 Weeks
~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
11435054|NCT01800019|Active Comparator|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)
~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period
~Mode of Administration: Oral
~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
11435142|NCT01799434|Experimental|Exercise|All participants had to run 20min on their individual anaerobic threshold
11435143|NCT01799421||Non-haematologic cancer|
11435144|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
11435055|NCT01800019|Active Comparator|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)
~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period
~Mode of Administration: Oral
~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)
~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
11435056|NCT01800006||Group 1|
11435057|NCT01799993|Experimental|Amikacin inhale (BAY41-6551)|Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.
11435058|NCT01799993|Placebo Comparator|Placebo|Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.
11435059|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
11435060|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
11435061|NCT01799954|Other|NYVAC Prime / NYVAC + AIDSVAX® B/E Boost vs. Placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a NYVAC vaccine prime and NYVAC + AIDSVAX® B/E boost. Twenty participants will get vaccines and 4 will get only placebos.
11435062|NCT01799954|Other|NYVAC + AIDSVAX® B/E Prime / Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of priming and boosting with the vaccines NYVAC + AIDSVAX® B/E. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 1 to see if the priming makes a difference in the body's immune response.
11435063|NCT01799954|Other|DNA prime + NYVAC + AIDSVAX® B/E Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 4 to see if the priming makes a difference in the body's immune response.
11435064|NCT01799954|Other|DNA+AIDSVAX® B/E prime / NYVAC+AIDSVAX® B/E boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine + AIDSVAX® B/E priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 3 to see if the priming makes a difference in the body's immune response.
11435065|NCT01799941|Other|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
11435066|NCT01799915||REM sleep behavior disorder, RBD|Patients that have rapid eye movement sleep behavior disorder.
11435067|NCT01799915||multiple system atrophy|is a neurodegenerative disorder charaterized by abnormal alpha-synuclein deposition in the cytoplasm of oligodendroglial cells in the CNS, and typically sparing peripheral autonomic nerves.
11435068|NCT01799915||Pure Autonomic failure|A neurodegenerative disorder characterized by loss of peripheral noradrenergic fibers, with low levels of plasma norepinephine.
11435069|NCT01799915||Parkinson disease|A degenerative disorder of the central nervous system that leads to termors, difficulty walking, movement and coordination.
11435070|NCT01799915||Dementia with Lewy bodies|A neurodegenerative disorder similar to PAF and PD with the accumulation of Alpha-synuclein in the CNS however DLB patients develop dementia.
11435071|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
11435072|NCT01799889|Experimental|CLL, Entospletinib MM/SDD|Participants with CLL, receive original formulation (mono-mesylate [MM]) of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib (spray dried dispersion [SDD]) 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435073|NCT01799889|Experimental|FL, Entospletinib MM/SDD|Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435074|NCT01799889|Experimental|DLBCL, Entospletinib MM/SDD|Participants with DLBCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435075|NCT01799889|Experimental|MCL, Entospletinib MM/SDD|Participants with MCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435076|NCT01799889|Experimental|non-FL iNHL, Entospletinib MM/SDD|Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435077|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 100 mg|Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435078|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 200 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435079|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 400 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435145|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
11435080|NCT01799889|Experimental|CLL (Non-Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to Bruton tyrosine kinase (BTK) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435081|NCT01799889|Experimental|CLL (Non-Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to phosphatidylinositol 3-kinase (PI3K) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435082|NCT01799889|Experimental|CLL (Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to BTK inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435083|NCT01799889|Experimental|CLL (Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to PI3K inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
11435084|NCT01799876|Experimental|Autologous Cell|Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
11435085|NCT01799876|Sham Comparator|Control|Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
11435086|NCT01799863|Experimental|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
11435087|NCT01799863|Placebo Comparator|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
11435088|NCT01799850|Active Comparator|Actos|Actos 30 mg daily
11435089|NCT01799850|Placebo Comparator|placebo|double blind placebo controlled
11435090|NCT01799837|Other|Healthy Controls|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
11435091|NCT01799837|Other|Veterans with PTSD|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
11435092|NCT01799824|Experimental|Active|ANT-1403
11435093|NCT01799824|Placebo Comparator|Vehicle|Vehicle
11435094|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
11435095|NCT01799798|Experimental|Denosumab subcutaneously|
11435096|NCT01799785|Experimental|Aerobic exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
11435097|NCT01799785|Placebo Comparator|Usual care group|These patients will continue with their normal daily activity and will not be provided with supervised aerobic exercise training during the study period.
11435098|NCT01799772|Experimental|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.
~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
11435099|NCT01799772|Active Comparator|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
11435100|NCT01799759|Experimental|Online intervention for parent and child|Children complete 8 online modules of Project FUN Parents complete 6 modules of Project FUN for Parents
11435101|NCT01799759|Other|Instruments only|The waiting list control group only completes instruments and body composition, fitness measures
11435102|NCT01799733|Active Comparator|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
11435103|NCT01799733|Placebo Comparator|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
11435104|NCT01799720|Experimental|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet. Follow-up 30 days
11435105|NCT01799720|Experimental|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 2 took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
11435179|NCT01799161|Active Comparator|DS-1|6 week course of gp96 Vaccine: >= 4 x 10^7 cells twice monthly on Day 1. Up to 3 courses, 9 vaccinations.
11435757|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
11435106|NCT01799720|Experimental|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 3 only took diet and no capsules. Follow-up 30 days
11435107|NCT01799707|Active Comparator|vision restoration training|Vision restoration training (VRT): visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
11435108|NCT01799707|Placebo Comparator|Discrimination training|Discrimination training. Here, the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
11435109|NCT01799694|Experimental|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
11435110|NCT01799681|Experimental|EXPERIMENTAL|a 4-week indoor and 4-week outdoor balance training with stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
11435111|NCT01799681|Active Comparator|CONTROL|an eight-week training on upper limb stretching and strengthening, hand agility exercise, knot tying and Chinese calligraphy
11435112|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
11435113|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
11435114|NCT01799629|Experimental|Intervention|Intervention group will receive the glycerin suppository
11435115|NCT01799629|No Intervention|Control|Normal care
11435116|NCT01799616|Experimental|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
11435117|NCT01799616|Other|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
11435118|NCT01799603|Experimental|TMC435 in fasted then fed condition|Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
11435119|NCT01799603|Experimental|TMC435 in fed then fasted condition|Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
11435120|NCT01799590|Experimental|Topiramate|
11435121|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
11435122|NCT01799564|Experimental|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
11435123|NCT01799564|No Intervention|Control|The fellow eye does not receive any treatment
11435124|NCT01799551|Active Comparator|Ca CBT|Experimental arm will receive brief version of Culturally adapted CBT for depression. This is based on our previous work in which we adapted CBT for depression in Pakistan
11435125|NCT01799551|No Intervention|Treatment As Usual|Patients in this arm will get only Treatment As Usual, which normally includes regular follow up and medicines.
11435126|NCT01799538|Experimental|1|Nebullizer
11435127|NCT01799538|Active Comparator|2|Inhaler
11435128|NCT01799525|Experimental|Hypercapnia|Intervention: SAH patients are subjected to gradual hypercapnia by reduction of respiratory volume in one trial session every day. PaCO2 is raised from normocapnia to 50 mmHg for 10 - 15 minutes and 60 mmHg for 10 - 15 minutes.
11435129|NCT01799512|Experimental|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.
~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).
~When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
11435130|NCT01799512|Active Comparator|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.
~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
11435131|NCT01799499|Experimental|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
11435132|NCT01799499|Experimental|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
11435133|NCT01799499|Experimental|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
11435134|NCT01799486|Experimental|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
11435135|NCT01799486|Experimental|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
11435136|NCT01799486|Experimental|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
11435137|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
11435138|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
11435139|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
11435140|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
11435141|NCT01799447|Other|Early intervention|Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
11442331|NCT01749982|Experimental|Betaine|Betaine 1000 mg by mouth daily
11435146|NCT01799395||Lung Cancer|All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.
11435147|NCT01799382|Experimental|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
11435148|NCT01799382|Active Comparator|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
11435149|NCT01799369|No Intervention|Control|Routine post-operative care
11435150|NCT01799369|Experimental|Intervention|Post-operative care influenced by the Surgical Apgar Score
11435151|NCT01799356|Active Comparator|moxifloxacin Group|Treatment at uPID with moxifloxacin
11435152|NCT01799356|Placebo Comparator|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
11435153|NCT01799343|Experimental|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
11435154|NCT01799330|Experimental|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
11435155|NCT01799330|Placebo Comparator|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
11435156|NCT01799317|Active Comparator|Treatment with vitamin D2|Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
11435157|NCT01799317|No Intervention|Standard of Care|Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
11435158|NCT01799304|Experimental|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
11435159|NCT01799304|Experimental|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
11435160|NCT01799304|Experimental|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
11435161|NCT01799304|Experimental|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
11435162|NCT01799291|Other|Treatment: Decision Making Tutorial|A brief presentation on mood disorders (i.e., Control condition) combined with the intervention (i.e., Treatment condition): a 20-minute training on decision-making errors and cognitive de-biasing strategies.
11435163|NCT01799291|No Intervention|Control|A brief presentation about mood disorders.
11435164|NCT01799278|Experimental|All Patients|MLN8237 at 50 mg twice daily for 7 days repeated every 21 days. Therapy will continue until disease progression, unacceptable toxicity as a result of MLN8237, or withdrawal of patient consent.
11435165|NCT01799265|Active Comparator|Transcend followed by REMstar|The patient will receive treatment with Transcend during the first night sleep study, followed by treatment with the REMstar on the second night.
11435166|NCT01799265|Active Comparator|REMstar followed by Transcend|The patient will receive treatment with REMstar during the first night sleep study followed by treatment with Transcend on the second night.
11435167|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
11435168|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
11435169|NCT01799239|Experimental|First Test product; then SenSura|"The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.
~After cross-over the subject test SenSura which is CE-marked and commerical available."
11435170|NCT01799239|Active Comparator|First SenSura, Then Test product|"The subject in this arm first test SenSura which is CE-marked and commerical available.
~After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details."
11435171|NCT01799226|Active Comparator|Toothpaste without Triclosan|This arm will use a toothpaste that does not contain triclosan
11435172|NCT01799226|Experimental|Triclosan|This arm will use colgate total which contains triclosan
11435173|NCT01799213|Experimental|Active Treatment|Eligible subjects will be randomized to Meloxicam 15 mg po per day (QD) vs placebo
11435174|NCT01799213|Placebo Comparator|Placebo|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
11435175|NCT01799187|Experimental|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
11435176|NCT01799187|Active Comparator|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
11435177|NCT01799174|Active Comparator|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
11435178|NCT01799174|Sham Comparator|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
11435296|NCT01798433|Experimental|One stent technique + Elective FKB|One stent technique + Elective FKB for non-true LM bifurcation
11435180|NCT01799161|Active Comparator|DS-2|6 week course of gp96 Vaccine: >= 2 x 10^7 cells weekly on Day 1. Up to 3 courses, 18 vaccinations.
11435181|NCT01799161|Active Comparator|DS-3|6 week course of gp96 Vaccine: >= 1 x 10^7 cells twice weekly on Days 1 and 4. Up to 3 courses, 36 vaccinations.
11435182|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
11435183|NCT01799135|Experimental|Experimental Arm|DCE-MRI scan (4 scans total); Stereotactic Body Radiation Therapy; 4D-CT scan
11435184|NCT01799122|Active Comparator|Precise sling vs TVT-O sling|
11435185|NCT01799109|Experimental|nebulization ms and albuterol|magnesium sulfate 150mg & albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
11435186|NCT01799109|Active Comparator|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
11435187|NCT01799109|Experimental|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
11435188|NCT01799096|Experimental|Sucrose|Receives sucrose
11435189|NCT01799096|Placebo Comparator|Aspartame|Receives Aspartame sweetened drinks
11435190|NCT01799083|Experimental|Decitabine|A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients.
11435191|NCT01799070||CHS|
11435192|NCT01799057|Experimental|Metformin|Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
11435193|NCT01799057|Placebo Comparator|Placebo|Matching placebo twice daily for 16-18 weeks.
11435194|NCT01799044|Experimental|Irreversible electroporation|Single arm study: Irreversible electroporation of colorectal liver metastasis
11435195|NCT01799031|Experimental|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
11435196|NCT01799031|Active Comparator|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
11435197|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
11435198|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
11435199|NCT01799005|Active Comparator|flavanol rich intervention|Ingestion of 410mg flavanols twice a day for 30 days
11435200|NCT01799005|Placebo Comparator|flavanol free intervention|Ingestion of a macro and micro nutrients matched flavanol free drink
11435201|NCT01798992|No Intervention|Non-failing control|Patients with normal ejection fraction who underwent a single myocardial biopsy and received no β-blocker therapy
11435202|NCT01798992|Active Comparator|Metoprolol succinate|Idiopathic dilated cardiomyopathy patients randomized to metoprolol succinate titrated to a goal of 200 mg by mouth daily for 18 months
11435203|NCT01798992|Active Comparator|Metoprolol succinate + doxazosin|Idiopathic dilated cardiomyopathy patients who were randomized to receive metoprolol succinate and doxazosin titrated to a goal of 200 mg and 8 mg by mouth daily for 18 months
11435204|NCT01798992|Active Comparator|Carvedilol|Idiopathic dilated cardiomyopathy patients who were randomized to receive carvedilol titrated to a goal of 25 mg by mouth twice daily for 18 months
11435205|NCT01798979|Experimental|Midazolam and GLPG0634|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
11435206|NCT01798966|Experimental|SENSIMED Triggerfish|Sensimed Triggerfish device will be worn by each subject for 24h
11435207|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
11435208|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
11435209|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
11435210|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
11435211|NCT01798927|Other|Ankle foot orthosis fitting|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
11435212|NCT01798901|Experimental|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11435213|NCT01798875|Active Comparator|Metformin|oral metformin at a dose of 850mg twice daily
11435214|NCT01798875|Active Comparator|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
11435215|NCT01798862|Experimental|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
11435216|NCT01798862|Active Comparator|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
11435297|NCT01798433|Experimental|Provisional approach|Provisional approach for true LM bifurcation
11435298|NCT01798433|Experimental|Elective 2-stent|Elective 2-stent for true LM bifurcation
11435217|NCT01798849|Experimental|Panel A-Healthy|Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, 14 mg or 2.0 mg fed, and 2 participants received placebo. Dosing periods will alternate with Panel B.
11435218|NCT01798849|Experimental|Panel B-Healthy|Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods will alternate with Panel A.
11435219|NCT01798849|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages will be determined by the results of Panels A and B.
11435220|NCT01798836|Experimental|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
11435221|NCT01798836|Active Comparator|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
11435222|NCT01798823||EIB+A+|"children with EIB and asthma
~History, physical, LF, SPT, blood sample, FeNO, EBC"
11435223|NCT01798823||EIB+A-|"children with EIB without asthma
~History, physical, LF, SPT, blood sample, FeNO, EBC"
11435224|NCT01798823||EIB-A+|"children without EIB and asthma
~History, physical, LF, SPT, blood sample, FeNO, EBC"
11435225|NCT01798823||EIB-A-|"children without EIB without asthma
~History, physical, LF, SPT, blood sample, FeNO, EBC"
11435226|NCT01798810|Experimental|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
11435227|NCT01798810|No Intervention|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
11435228|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
11435229|NCT01798784|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
11435230|NCT01798784|Experimental|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
11435231|NCT01798784|Experimental|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
11435232|NCT01798784|Experimental|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
11435233|NCT01798771|Other|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
11435234|NCT01798771|Other|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
11435235|NCT01798745|Experimental|Cohort A: JNJ-54452840 20 mg|Each patient will receive 20 mg of JNJ-54452840 as a single dose.
11435236|NCT01798745|Experimental|Cohort A: JNJ-54452840 80 mg|Each patient will receive 80 mg of JNJ-54452840 as a single dose.
11435237|NCT01798745|Experimental|Cohort A: JNJ-54452840 160 mg|Each patient will receive 160 mg of JNJ-54452840 as a single dose.
11435238|NCT01798745|Placebo Comparator|Cohort A: Placebo|Each patient will receive matching placebo as a single dose.
11435239|NCT01798745|Experimental|Cohort B: JNJ-54452840 <= 240 mg|Each patient will receive JNJ-54452840 at a dose of less than or equal to 240 mg as a single dose (dose determined by the Data Monitoring Committee).
11435240|NCT01798745|Placebo Comparator|Cohort B: Placebo|Each patient will receive matching placebo as a single dose.
11435241|NCT01798745|Experimental|Cohort C: JNJ-54452840 for 3 days|Each patient will receive JNJ-54452840 once daily for 3 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
11435242|NCT01798745|Placebo Comparator|Cohort C: Placebo|Each patient will receive matching placebo once daily for 3 days.
11435243|NCT01798745|Experimental|Cohort D: JNJ-54452840 for 5 days|Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
11435244|NCT01798745|Placebo Comparator|Cohort D: Placebo|Each patient will receive matching placebo once daily for 5 days.
11435245|NCT01798745|Experimental|Cohort E: JNJ-54452840 weekly|Each patient will receive JNJ-54452840 once weekly on Days 1, 8, 15, and 22 at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
11435246|NCT01798745|Placebo Comparator|Cohort E: Placebo|Each patient will receive matching placebo once weekly on Days 1, 8, 15, and 22.
11435247|NCT01798745|Experimental|Cohort F: JNJ-54452840 multiple dose|Each patient will receive JNJ-54452840 once daily (for 3 or 5 days) or once weekly (up to Day 22) as determined by the Data Monitoring Committee and as explored in Cohorts C, D, and E (daily dose not exceeding 240 mg).
11435248|NCT01798745|Placebo Comparator|Cohort F: Placebo|Each patient will receive matching placebo once daily (for 3 or 5 days) or once weekly (up to Day 22).
11435249|NCT01798732|Experimental|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
11435250|NCT01798719|Placebo Comparator|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
11435299|NCT01798420||Corticosteroid|
11435300|NCT01798420||non-corticosteroid group|
11435251|NCT01798719|Experimental|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
11435252|NCT01798706|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
11435253|NCT01798706|Placebo Comparator|Placebo|Placebo (matched to lixisenatide) QD for 24 Weeks.
11435254|NCT01798693|Placebo Comparator|Placebo (maltodextrin)|Maltodextrin
11435255|NCT01798693|Active Comparator|Multi-Nutrient Blend|Blend of vitamins, minerals, and amino acids, given twice daily
11435256|NCT01798680|Experimental|Vitamin D3 (cholecalciferol)|
11435257|NCT01798680|Placebo Comparator|Placebo|
11435258|NCT01798667|Placebo Comparator|Placebo|PO administration
11435259|NCT01798667|Experimental|DA-8031 dose 1|PO administration
11435260|NCT01798667|Experimental|DA-8031 dose 2|PO administration
11435261|NCT01798667|Experimental|DA-8031 dose 3|PO administration
11435262|NCT01798654||Antithrombotic agents|
11435263|NCT01798641|Experimental|Open Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be open at this time. The adjustment is done in the out-patient clinic.
11435264|NCT01798641|Placebo Comparator|Closed Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be closed during this time. The adjustment is done in the out-patient clinic.
11435265|NCT01798628|Experimental|Sequence ABC|
11435266|NCT01798628|Experimental|Sequence ACB|
11435267|NCT01798628|Experimental|Sequence BAC|
11435268|NCT01798628|Experimental|Sequence BCA|
11435269|NCT01798628|Experimental|Sequence CAB|
11435270|NCT01798628|Experimental|Sequence CBA|
11435271|NCT01798602|Experimental|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug
~Both are crushed for administration"
11435272|NCT01798602|Placebo Comparator|Placebo|Identical drug vehicle with no active agent
11435273|NCT01798589|Experimental|Ethylenediamine dihydrochloride|Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)
11435274|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
11435275|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
11435276|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking & balance-related motor symptoms of PD.
11435277|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
11435278|NCT01798550|Experimental|Reduced Dose (0.8 mg/kg)|Enoxaparin 0.8 mg/kg (using total body weight) twice daily
11435279|NCT01798550|Active Comparator|Standard Dose (1 mg/kg)|Enoxaparin 1 mg/kg (using total body weight) twice daily
11435280|NCT01798537|Experimental|Neomycin Colistin Nystatin Vancomycin|"All participating study arm patients will receive SDD from admission to discharge according to the following plan:
~ENTERAL MEDICATION (via feeding tube) x 4 times daily:
~375 mg Neomycin 100 mg Colistin Sulphate
~1 million units Nystatin * 250 mg Vancomycin *
~Nystatin will be prescribed only if there is a positive sputum or urine culture for yeast or candida Vancomycin will be prescribed only in case of a positive screen or culture for MRSA"
11435281|NCT01798537|No Intervention|Control|No SDD given for 1 year Screening performed as in intervention arm
11435282|NCT01798524||Kidney allograft recipients|
11435283|NCT01798511|Experimental|Nasogastric Tube Feeding|Patients who are to have NTF will receive enteral nutrition within 6 hours after randomisation via a nasogastric tube placed into the stomach. A commercially available low fat semi-elemental feed (Peptisorb®, Nutricia Clinical NZ) will be used. The caloric target will be 2000 kcal per day. Enteral tube feeding will be commenced at a rate of 30 mL/h and increased gradually until 100 mL/h over 24-48 h.
11435284|NCT01798511|Active Comparator|Conventional Nutritional Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case enteral tube feeding will be introduced) or the signs of AP mitigate,in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced.
11435285|NCT01798498|Experimental|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.
~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.
~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
11435286|NCT01798485|Experimental|Ganetespib and Docetaxel|Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
11435287|NCT01798485|Active Comparator|Docetaxel|Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
11435288|NCT01798472|Experimental|uncemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an uncemented hemiarthroplasty
11435289|NCT01798472|Experimental|reverse hybrid total hip arthroplasty|Patients aged between 65 and 79 years treated with an reverse hybrid arthroplasty.
11435290|NCT01798472|Active Comparator|cemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an cemented hemiarthroplasty
11435291|NCT01798472|Active Comparator|cemented total hip arthroplasty|Patients aged between 65 and 79 years treated with an cemented total hip arthroplasty.
11435292|NCT01798459|Active Comparator|Methylphenidate|Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
11435293|NCT01798459|Placebo Comparator|Placebo|Placebo is given before performing a continuous performance test.
11435294|NCT01798446|Experimental|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
11435295|NCT01798433|Experimental|One stent technique alone|One stent technique alone for non-true LM bifurcation
11435301|NCT01798407|Experimental|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
11435302|NCT01798407|Experimental|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
11435303|NCT01798394|Active Comparator|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
11435304|NCT01798394|Placebo Comparator|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
11435305|NCT01798381|Active Comparator|Essential fatty acids|Omega-3
11435306|NCT01798381|Placebo Comparator|Placebo|Placebo tablet
11435307|NCT01798368|Experimental|PBASE system 2.0|
11435308|NCT01798355|Experimental|Cognitive Behavioral Therapy|
11435309|NCT01798355|Active Comparator|Treatment as usual|
11435310|NCT01798342|Active Comparator|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
11435311|NCT01798342|Experimental|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
11435312|NCT01798329|Active Comparator|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
11435313|NCT01798329|Placebo Comparator|Placebo|subjects treated with placebo for 15 weeks
11435314|NCT01798316|Active Comparator|IV Acetaminophen|IV Acetaminophen administered on admission to post-anesthesia care unit
11435315|NCT01798316|Active Comparator|Standard of care|Standard of care pain management regimen including opioids administered on admission to post-anesthesia care unit
11435316|NCT01798303|Experimental|LY2940094|40 mg LY2940094 oral tablet, QD for 8 weeks
11435317|NCT01798303|Placebo Comparator|Placebo|Identically matched placebo oral tablet, QD for 8 weeks
11435318|NCT01798290|Experimental|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
11435319|NCT01798290|Active Comparator|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
11435320|NCT01798277|Active Comparator|Catheter Ablation|Radiofrequency ablation procedure
11435321|NCT01798277|Active Comparator|Medical therapy|Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
11435322|NCT01798264|Experimental|10 mcg./day|ITCA 650 (exenatide in DUROS)
11435323|NCT01798264|Experimental|20 mcg/day|ITCA 650 (exenatide in DUROS)
11435324|NCT01798264|Experimental|40 mcg/day|ITCA 650 (exenatide in DUROS)
11435325|NCT01798264|Experimental|80 mcg/day|ITCA 650 (exenatide in DUROS)
11435326|NCT01798251|Experimental|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.
~X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
11435327|NCT01798251|Active Comparator|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
11435328|NCT01798238|Placebo Comparator|Placebo group|
11435329|NCT01798238|Experimental|MP-513 group|
11435330|NCT01798225|Placebo Comparator|Control|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) pills.
11435331|NCT01798225|Experimental|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Doxycycline 100mg x 14 pills)
11435332|NCT01798212|Other|full thickness gastroplication|
11435333|NCT01798199|Experimental|Alzheimer disease|
11435334|NCT01798186|Experimental|Cannabis 5% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 5% THC and in a room with no ventilation.
11435335|NCT01798186|Experimental|Cannabis 11% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC and in a room with no ventilation.
11435336|NCT01798186|Experimental|Cannabis 11% THC, Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC in a room with active ventilation.
11435337|NCT01798173|Experimental|Cases: cirrhotic patients with hepatocellular carcinoma|
11435338|NCT01798173|Active Comparator|Controls: cirrhotic patients without hepatocellular carcinoma|
11435339|NCT01798160|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
11435340|NCT01798160|Experimental|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
11435341|NCT01798147|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
11435342|NCT01798147|Experimental|SIRT|Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)
11435343|NCT01798134|Other|DEB-TACE|"Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)
~Treatment: Lobes; Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin"
11435344|NCT01798121|Experimental|Aplisol|To compare new PPD to reference standard material
11435345|NCT01798121|Placebo Comparator|Reference standard|Response of standard material
11535920|NCT01103037|Experimental|QAV680|
11435346|NCT01798108|Experimental|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
11435347|NCT01798095|Experimental|Aplisol|To confirm the response of PPD materials
11435348|NCT01798095|Active Comparator|PPD Standard|Determine equivalent specificity for new material compared to standard material.
11435349|NCT01798082|No Intervention|Standard counseling|
11435350|NCT01798082|Experimental|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
11435351|NCT01798069|Experimental|Behavioral intervention|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
11435352|NCT01798069|Active Comparator|behavoral intervention|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading medical publication workshops. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
11435353|NCT01798056|Experimental|GSK1437173A Group|Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
11435354|NCT01798056|Placebo Comparator|Placebo Group|Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
11435355|NCT01798043|Experimental|Septal RV lead with >50% pacing (B1)|Cardiac MRI with pacemaker stimulation
11435356|NCT01798043|Experimental|Septal RV lead with <50% pacing (B2)|Cardiac MRI with and without pacemaker stimulation
11435357|NCT01798043|Experimental|Apical RV lead with >50% pacing (A1)|Cardiac MRI with pacemaker stimulation
11435358|NCT01798043|Experimental|Apical RV lead with <50% pacing (A2)|Cardiac MRI with and without pacemaker stimulation
11435359|NCT01798030||Vitamin D|Specimen analysis
11435360|NCT01798017|Experimental|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
11435361|NCT01798004|Experimental|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:
~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.
~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.
~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.
~Some patients also undergo EBRT after induction and consolidation."
11435362|NCT01797991|Active Comparator|Group A (dexamethasone per os)|"Dexamethasone 20 mg per os 12 hours and 6 hours before paclitaxel (form: opaque white capsules)
~Matching placebo for dexamethasone IV (NaCl 0,9%) 30 minutes before paclitaxel"
11435363|NCT01797991|Experimental|Group B (dexamethasone IV)|"Dexamethasone 20 mg IV 30 minutes before paclitaxel
~Matching placebo for dexamethasone per os (lactose capsule) 12 hours and 6 hours before paclitaxel (form: opaque white capsules)"
11435364|NCT01797978|Experimental|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
11435365|NCT01797978|Placebo Comparator|Placebo|Normal saline administration instead of methylene blue
11435366|NCT01797965|Experimental|BIIB019|BIIB019 150 mg subcutaneous (SC) every 4 weeks
11435367|NCT01797952|Active Comparator|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
11435368|NCT01797952|Placebo Comparator|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
11435369|NCT01797939||Erosive reflux disease (ERD)|
11435370|NCT01797939||Non-erovise reflux disease (NERD)|
11435371|NCT01797939||Functional heartburn (FH)|
11435372|NCT01797926|Experimental|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
11435373|NCT01797926|Experimental|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
11435374|NCT01797913|Experimental|gemcitabine|
11435499|NCT01797042|Active Comparator|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
11435375|NCT01797900|Experimental|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
11435376|NCT01797900|Active Comparator|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
11435377|NCT01797887|Experimental|Ayurveda|Ayurveda Diet and Lifestyle Counseling
11435378|NCT01797887|Active Comparator|Conventional|Standard Conventional Diet and Lifestyle Counseling
11435379|NCT01797874|Experimental|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
11435380|NCT01797874|Placebo Comparator|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
11435381|NCT01797861|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.
~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
11435382|NCT01797861|Active Comparator|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.
~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
11435383|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Placebo|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks
~Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks
~Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
11435384|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Daclatasvir|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response
~Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response
~Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
11435385|NCT01797835|Placebo Comparator|Usual Care|Youth in usual care will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. They will also receive an informational brochure.
11435386|NCT01797835|Experimental|CHAT brief MI intervention|Youth in CHAT will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. In addition, these youth will CHAT. CHAT is a brief motivational intervention that takes places in the primary care setting. It is a 15-20 minute intervention for adolescents age 12-18 focused on discussing alcohol and drug use. They will also receive a booster call one month later to check in on how they are doing.
11435387|NCT01797822|Experimental|Artificial tears first, then Dexamethasone|Artificial tears four times a day both eyes for two weeks, then Dexamethasone 0.01% four times a day both eyes for two weeks
11435388|NCT01797809||Group 1|
11435389|NCT01797796|Experimental|PF-06305591|
11435390|NCT01797796|Placebo Comparator|Placebo|
11435391|NCT01797783|Experimental|DAILIES® AquaComfort Plus® Multifocal|Nelfilcon A multifocal contact lens with comfort additive worn for 30 days on a daily wear, daily disposable basis
11435392|NCT01797783|Active Comparator|Focus® DAILIES® Progressives|Nelfilcon A multifocal contact lens worn for 30 days on a daily wear, daily disposable basis
11435393|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
11435394|NCT01797757|Active Comparator|Fish oil enriched with EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
11435395|NCT01797757|Active Comparator|MAG-EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
11435396|NCT01797757|Active Comparator|MAG-EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
11435397|NCT01797757|Active Comparator|Fish oil enriched with EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
11435398|NCT01797744|Experimental|Vestibular rehabiliation|Vestibular rehabiliation
11435399|NCT01797744|No Intervention|Control group|Usual rehabilitation whitout additional vestibular exercises
11435400|NCT01797731|Active Comparator|Conventional System|Conventional tibial extramedullary alignment system used by surgeon during surgery.
11435401|NCT01797731|Experimental|KneeAlign System|Digital hand-held surgical navigation system for tibial component placement used by surgeon during surgery.
11435402|NCT01797718|Active Comparator|Testosterone|~1mg/kg every 4 weeks for 6 months
11435403|NCT01797718|Active Comparator|Letrozole|2.5mg daily for 6 months
11435404|NCT01797705|Experimental|All subjects|All subjects underwent a sleep study with DeVilbiss AutoAdjust CPAP with revised algorithm simultaneously with hand-scored PSG.
11435405|NCT01797692|Other|geriatric assessment|geriatric assessment
11435406|NCT01797679|Other|Strength Training|"The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
~Intervention: Other: Strength training"
11435758|NCT01795248|Experimental|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
11435407|NCT01797679|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
11435408|NCT01797679|No Intervention|Control Group|The control group will do as usual.
11435409|NCT01797653|Placebo Comparator|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
11435410|NCT01797653|Active Comparator|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
11435411|NCT01797601|Active Comparator|Human Insulin|Nasal spray
11435412|NCT01797601|Placebo Comparator|Placebo solution|Nasal spray
11435413|NCT01797588|Active Comparator|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
11435414|NCT01797588|Active Comparator|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
11435415|NCT01797588|Active Comparator|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
11435416|NCT01797575|Active Comparator|Aspirin|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
11435417|NCT01797575|Active Comparator|N-acetyl-cysteine|research subject will be taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
11435418|NCT01797575|Active Comparator|Aspirin and NAC|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations.
11435419|NCT01797575|Placebo Comparator|Sugar Pill|research subject will be taking 4 capsules of matching sugar pill( placebo) in the morning and 2 capsules of matching placebo in the evenings in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
11435420|NCT01797562|Experimental|Positive Response Rates: 7 new and 4 reformulated allergens|Subjects will be patched with TRUE Test Panels 1.3, 2,2 and 3.2. Panel 1 allergens nickel sulfate (0.60 mg/cm2), potassium dichromate (0.054 mg/cm2), fragrance mix (0.050 mg/cm2) and ethylenediamine dihydrochloride (0.050 mg/cm2), Panel 2 allergen Methyldibromoglutaronitrile (0.0053 mg/cm2) and Panel 3 allergens Gold sodium thiosulfate (0.075 mg/cm2), Hydrocortisone-17-butyrate (0.020 mg/cm2), Bacitracin (0.60 mg/cm2), Parthenolide (0.0030 mg/cm2), Disperse blue 106 (0.050 mg/cm2 in PVP), 2-Bromo-2-nitropropane-1,3-diol (Bronopol) (0.25 mg/cm2) will be evaluated
11435421|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
11435422|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
11435423|NCT01797536|Experimental|Mild Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
11435424|NCT01797536|Experimental|Moderate Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
11435425|NCT01797536|Experimental|Severe Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
11435426|NCT01797536|Experimental|Healthy Participants|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
11435427|NCT01797523|Experimental|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.
~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
11435428|NCT01797510|Experimental|Coaching|Interventional web based coaching study
11435429|NCT01797510|No Intervention|Usual Care|
11435430|NCT01797497|Experimental|Care plan and coaching group|In the intervention group, parents complete a referral care plan with their children's physicians and receive a brief coaching session about how to exchange information with specialists. Outcome data are collected from parents before and after the specialist visit.
11435431|NCT01797497|No Intervention|Preintervention group|In the preintervention group, no care plan is used and no coaching takes place. Outcome data are collected from parents before and after the specialist visit.
11435432|NCT01797484|Active Comparator|Ranolazine|Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
11435433|NCT01797484|No Intervention|No additional medication|No additional medication - control group
11435759|NCT01795248|Placebo Comparator|Placebo|Placebo, subcutaneous, once-daily for one year
11435434|NCT01797471|Experimental|LEAD RT|"Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (RT) on Day 1 at dose of 18 Gy followed by;
~Conventionally fractionated radiation therapy beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy;
~Conventional Platinum Chemotherapy Doublet at discretion of treating physician beginning on day 2."
11435435|NCT01797458|Experimental|Hall Technique|This technique uses preformed Stainless Steel Crowns (SSCs) to restore carious primary molars. Local anaesthesia, caries removal or tooth preparation are not required.
11435436|NCT01797458|Experimental|Non-Restorative Caries Treatment|This is a less operative approach, here carious lesions are opened removing the overhanging enamel and making the cavity accessible for biofilm removal. No carious dentine will be removed from the pulpal wall and no local anaesthesia will be placed. Fluoride varnish (Duraphat ®) will be applied to the cavity. Parents/children will be trained to clean the cavity by brushing using a buccolingual technique.
11435437|NCT01797458|Active Comparator|Conventional Restoration|This technique corresponds to the conventional way of treating cavitated carious lesions involving complete caries removal, use of local anaesthesia (when needed), and a compomer (Dyract ®) restoration. Cotton wool roll isolation and continuous aspiration will be used.
11435438|NCT01797445|Experimental|E/C/F/TAF (Double-Blind)|"E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
11435439|NCT01797445|Active Comparator|E/C/F/TDF (Double-Blind)|"E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
11435440|NCT01797445|Experimental|Open-Label E/C/F/TAF|After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
11435441|NCT01797432|Experimental|Combined IL Kenalog and Restylane|Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
11435442|NCT01797419|Experimental|GS-5806|Single dose, oral liquid, .5 mL/kg
11435443|NCT01797419|Placebo Comparator|Placebo|Single dose, oral liquid, .5 mL/kg
11435444|NCT01797406|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
11435445|NCT01797406|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
11435446|NCT01797393|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
11435447|NCT01797393|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
11435448|NCT01797393|Experimental|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
11435449|NCT01797380|Placebo Comparator|Sugar Pill|Placebo
11435450|NCT01797380|Active Comparator|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
11435451|NCT01797354|Experimental|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
11435452|NCT01797354|Active Comparator|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
11435453|NCT01797341|Experimental|Prograf arm|"patients will self-administer tacrolimus in the form of Prograf (twice daily administration.
~Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day."
11435454|NCT01797341|Experimental|Advagraf Arm|patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
11435455|NCT01797328|Active Comparator|cold provocation|cold arm
11435456|NCT01797328|Active Comparator|to avoid feeling cold|warm arm
11435457|NCT01797315|Active Comparator|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
11435458|NCT01797315|No Intervention|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
11435459|NCT01797302|Active Comparator|Vitamin D3 2000 IU|Vitamin D3 2000 IU tablet once daily by mouth for 6 months
11435460|NCT01797302|Active Comparator|Vitamin D3 1000 IU|Vitamin D3 1000 IU tablet by mouth once daily for 6 months
11435461|NCT01797302|Placebo Comparator|Vitamin D3 600 IU|Vitamin D3 600 IU tablet by mouth once daily for 6 months
11435462|NCT01797289|Experimental|First episode of loss of consciousness|
11435496|NCT01797068|Experimental|Patient Navigator|Patients in the experimental group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH).
11435497|NCT01797068|Active Comparator|Standard of Care|Patients in the active comparator group will experience the usual intake process in the ED setting.
11435498|NCT01797055|Experimental|human apotransferrin|intravenous apotransferrin every 4-8 weeks
11435463|NCT01797263|Experimental|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
11435464|NCT01797263|Active Comparator|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
11435465|NCT01797237|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
11435466|NCT01797237|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
11435467|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
11435468|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
11435469|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
11435470|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
11435471|NCT01797211|Experimental|diet group A|Mediterranean diet+olive oil
11435472|NCT01797211|Experimental|Diet Group B|Mediterranean diet+not-fried fish
11435473|NCT01797211|Experimental|Diet Group C|Mediterranean diet+nuts
11435474|NCT01797198|Experimental|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
11435475|NCT01797198|Experimental|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
11435476|NCT01797185|Experimental|SPARC1104 group 1|
11435477|NCT01797185|Experimental|SPARC1104 group 2|
11435478|NCT01797185|Experimental|SPARC1104 group 3|
11435479|NCT01797172|Experimental|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
11435480|NCT01797172|Active Comparator|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
11435481|NCT01797159|Experimental|Hippocampal-sparing PCI|Hippocampal-sparing PCI 25 Gy in 10 fractions
11435482|NCT01797146|Active Comparator|CARE|All patients in the intervention wards will receive the Catheter Reminder and Evaluation (CARE) intervention.
11435483|NCT01797146|No Intervention|Control|All patients in the control wards will receive usual care without the CARE intervention.
11435484|NCT01797133|Active Comparator|Fellow arm|Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention.
11435485|NCT01797133|Active Comparator|Pharmacist arm|Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention.
11435486|NCT01797120|Active Comparator|Fulvestrant & Everolimus|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
11435487|NCT01797120|Placebo Comparator|Fulvestrant & Placebo|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
11435488|NCT01797107|Experimental|Treatment eye|Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
11435489|NCT01797107|Placebo Comparator|Durasite|Vehicle of Azasite used as placebo
11435490|NCT01797094|Experimental|Botulinum toxin Type A (44U)|44 units (U) botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
11435491|NCT01797094|Experimental|Botulinum toxin Type A (32U)|32 units (U) botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
11435492|NCT01797081|Experimental|Botulinum toxin Type A (24U)|24 units (U) botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
11435493|NCT01797081|Experimental|Botulinum toxin Type A (12U)|12U botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
11435494|NCT01797081|Other|Placebo/Botulinum toxin Type A (24U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
11435495|NCT01797081|Other|Placebo/Botulinum toxin Type A (12U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
11537113|NCT01094795||General population|
11435500|NCT01797042|Active Comparator|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
11435501|NCT01797042|Active Comparator|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
11435502|NCT01797042|Active Comparator|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
11435503|NCT01797029|Experimental|Vaccine|
11435504|NCT01797029|Placebo Comparator|Placebo|
11435505|NCT01797003|Active Comparator|Opening wedge HTO|Opening wedge high tibial osteotomy using Puddu plate
11435506|NCT01797003|Active Comparator|Closing wedge HTO|Closing wedge high tibial osteotomy using cramp fixation
11435507|NCT01796990|Active Comparator|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
11435508|NCT01796990|Other|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.
~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
11435509|NCT01796977|Active Comparator|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing is a closed-cell foam wound dressing enriched with gaseous and dissolved oxygen for use in the management of wounds.
11435510|NCT01796977|Placebo Comparator|Standard Gauze Dressing|A sterile 4x4 covered by an adhesive Tegaderm will serve as the comparator for this study.
11435511|NCT01796964|Experimental|ESBA1008|ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
11435512|NCT01796964|Active Comparator|EYLEA|Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol
11435513|NCT01796951|Experimental|Celecoxib, aspirin, followed by aspirin/celecoxib|Celecoxib 200 mg twice daily x3 days, aspirin 325 mg daily x10 days, celecoxib 200 mb twice daily + aspirin 325 mg daily x 3 days
11435514|NCT01796938|Experimental|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
11435515|NCT01796938|Experimental|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
11435516|NCT01796938|Experimental|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
11435517|NCT01796938|Experimental|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
11435518|NCT01796938|Experimental|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
11435519|NCT01796925|Experimental|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
11435520|NCT01796912|Active Comparator|First Lipoprotein Apheresis, then sham apheresis|Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
11435521|NCT01796912|Sham Comparator|First Sham Apheresis, then Lipoprotein Apheresis|Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis
11435522|NCT01796899|Other|Brivaracetam 10 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.
~Strength: 10 mg
~Form: Oral tablet
~Frequency: Once daily
~Duration: 1 day"
11435523|NCT01796899|Other|Brivaracetam 50 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.
~Strength: 50 mg
~Form: Oral tablet
~Frequency: Once daily
~Duration: 1 day"
11435524|NCT01796899|Other|Brivaracetam 75 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.
~Strength: 75 mg
~Form: Oral tablet
~Frequency: Once daily
~Duration: 1 day"
11435525|NCT01796899|Other|Brivaracetam 100 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.
~Strength: 100 mg
~Form: Oral tablet
~Frequency: Once daily
~Duration: 1 day"
11435526|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.
~Strength: 100 mg (10 mg/mL)
~Form: Intravenous bolus injection
~Frequency: Once daily
~Duration: 1 day"
11435527|NCT01796886|Experimental|patient's neurological status|
11435528|NCT01796860|Other|AFO|All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).
11435529|NCT01796847||PTEN, hyperglycemia|
11435530|NCT01796834|Experimental|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
11435760|NCT01795248|No Intervention|Control|Control without previous GDM.
11542776|NCT01055483|Experimental|LBH589|
11435531|NCT01796821|Placebo Comparator|Vehicle gel|vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
11435532|NCT01796821|Active Comparator|SR-T100 gel with 1.0 % SM|SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
11435533|NCT01796821|Active Comparator|SR-T100 gel with 2.3% SM|SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
11435534|NCT01796808|Other|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:
~1 week
~Post op study visit 2 (1 month)
~Post op study visit 3 (2 month)
~Post op study visit 4 (6 month)
~Post op study visit 5 (12 month)
~Crossover to standard podiatry visits
~Study visit 6 (18 months)
~Study visit 7 (24 months)"
11435535|NCT01796808|Other|Pathway B|"Screening visit followed by:
~Study visit 1 (6months)
~Study Visit 2 (12 months)
~Crossover to Pathway A
~pedal fat grafting procedure and local anesthetic and visits at:
~1 week
~Post op study visit 2 (1 month post procedure)
~Post op study visit 3 (2 month post procedure)
~Post op study visit 4 (6 month post procedure)
~Post op study visit 5 (12 month post procedure)"
11435536|NCT01796795|Placebo Comparator|vehicle gel|The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
11435537|NCT01796795|Active Comparator|SR-T100 gel with 1.0% of SM|SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
11435538|NCT01796795|Active Comparator|SR-T100 gel with 2.3% of SM|SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
11435539|NCT01796782|Active Comparator|Xeloda|Subjects will receive Xeloda until progression
11435540|NCT01796782|Experimental|QYHJ Granules|patients will receive QYHJ Granules until progression
11435541|NCT01796769|Experimental|Conventional|
11435542|NCT01796769|Active Comparator|Telemedicine|
11435543|NCT01796756|Experimental|Handover program|Standardized handover program Dedicated place and time Template Face-to-face communication Evidence-based education session Feedback and audit
11435544|NCT01796756|No Intervention|Usual handover practice|
11435545|NCT01796743||Controls|Age and gender matched controls ('control' group) with acute MI with similar degree of troponin elevation who are managed based solely on the basis of clinical or angiographic data alone.
11435546|NCT01796743||Cardiac MRI|Hospitalized patients with acute MI with a clinically-indicated CMR ordered will be enrolled. Data for T2 mapping will be added to the clinically prescribed cardiac MRI scan.
11435547|NCT01796730|Experimental|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
11435548|NCT01796730|Experimental|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
11435549|NCT01796730|Experimental|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
11435550|NCT01796717|Active Comparator|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
11435551|NCT01796717|Experimental|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
11435552|NCT01796704||healthy and mild heart failure|diversity of patients
11435553|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
11435554|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.
~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
11435555|NCT01796678|Experimental|Arginine|100 mg/kg T.I.D 3x a day IV or PO
11435556|NCT01796678|Placebo Comparator|Placebo|Saline or sugar pill
11435557|NCT01796665|Experimental|Test product|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
11435558|NCT01796665|Active Comparator|Reference product|Acanya Gel applied to the affected areas of the face once daily.
11435559|NCT01796665|Placebo Comparator|Placebo product|Placebo of the Test product applied to the affected areas of the face once daily.
11435560|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
11435561|NCT01796639||kidney transplantation patients with living-donor grafts|
11435562|NCT01796626|Experimental|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
11435563|NCT01796626|Experimental|Striae treatment|Striae treatment with the REsurFX 1565nm module
11435564|NCT01796613|Active Comparator|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
11435799|NCT01794988|Active Comparator|No TIVR|Control - no intervention
11435565|NCT01796613|Active Comparator|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
11435566|NCT01796600|Experimental|Conventional and a cone-beam scanner 5G|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
11435567|NCT01796587||LoFric Origo|
11435568|NCT01796574|Experimental|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
11435569|NCT01796561|Active Comparator|Olive leaf extract liquid|20ml of polyphenol-rich olive leaf extract liquid to be consumed daily for 6 weeks
11435570|NCT01796561|Placebo Comparator|Placebo liquid|20ml of polyphenol-free placebo liquid (containing water, glycerin, flavours, colours and aromas) to be consumed daily for 6 weeks
11435571|NCT01796548|Experimental|Oxybutynin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
11435572|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
11435573|NCT01796522|Active Comparator|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
11435574|NCT01796522|Active Comparator|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
11435575|NCT01796509|Experimental|multidisciplinary follow-up|
11435576|NCT01796509|No Intervention|no follow-up|
11435577|NCT01796496|Experimental|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
11435578|NCT01796496|Active Comparator|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
11435579|NCT01796483|Active Comparator|healthy Volunteers|
11435580|NCT01796483|Experimental|Patients|
11435581|NCT01796470|Experimental|Entospletinib + idelalisib|"Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg).
~After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy."
11435582|NCT01796444|Active Comparator|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
11435583|NCT01796444|Experimental|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
11435584|NCT01796431|Experimental|Eviplera®|Participants will take Eviplera every day for 14 days. Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood.
11435585|NCT01796418|Experimental|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
11435586|NCT01796418|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
11435587|NCT01796405|Experimental|Low-Risk|Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
11435588|NCT01796405|Experimental|High-Risk|High-risk Multi System Clofarabine, Standard Dose, Two Cycles
11435589|NCT01796392|Experimental|EBV and Optimal Medical Management|This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
11435590|NCT01796392|Other|Optimal Medical Management|This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
11435591|NCT01796379|Experimental|High Intensity Interval Training|
11435592|NCT01796379|Other|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
11435593|NCT01796366|Experimental|Insulin 338 + placebo|
11435594|NCT01796366|Active Comparator|Insulin glargine + placebo|
11435595|NCT01796353|Experimental|sexual rehabilitation|exercise plus psycho-education
11435596|NCT01796353|Active Comparator|usual care|usual care
11435597|NCT01796340|Experimental|Food cue exposure|
11435598|NCT01796340|Active Comparator|Psycho-education|
11435599|NCT01796327|Experimental|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
11435600|NCT01796314|Experimental|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
11435601|NCT01796314|No Intervention|Group B : Control|There si no associated intervention
11435602|NCT01796301|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
11435603|NCT01796301|Active Comparator|Teriparatide|Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
11435604|NCT01796288|Experimental|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
11435605|NCT01796288|Other|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
11435606|NCT01796275|Experimental|Group A|Subjects will have a core session intervention and booster intervention; questionnaire evaluation is conducted at baseline, post-session, pre-booster and 3 month after core session.
11435607|NCT01796275|Experimental|Group B|Subjects will only have a core session intervention; Questionnaire evaluation are conducted at baseline (T1-baseline), post-session (T2), 4 weeks after core session (T3) and 3 month after core session (T4).
11435608|NCT01796275|Other|Group C|Group C is a waiting list control, only questionnaire evaluations can be conducted at T1-baseline, T3- tea gathering and T4- 3 month after baseline evaluation; when finish T4 evaluation, the core session and booster can be optionally conducted subsequently.
11435609|NCT01796262|Placebo Comparator|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
11435610|NCT01796262|Active Comparator|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
11435611|NCT01796236|Active Comparator|Minimally invasive surgery and BA400|This arm involves no soft tissue reduction around the BA400 implant.
11435612|NCT01796236|Active Comparator|Traditional surgery and BA300|This arm involves traditional soft tissue reduction around the BA300 implant
11435613|NCT01796223|Experimental|Feedback|Feedback system included in psychotherapy
11435614|NCT01796223|Active Comparator|control|Psychotherapy as usual
11435615|NCT01796197|Experimental|Treatment Arm|"Run in phase: Trastuzumab IV 4 mg/kg, Pertuzumab IV 840 mg Pre-op phase: Trastuzumab IV 2 mg/kg weekly, Paclitaxel 80 mg/m2 IV weekly x 16 doses. Starting Day 21 (week 4) continue trastuzumab and paclitaxel as above and add Pertuzumab 420 mg IV every 3 weeks during 16 doses of paclitaxel administration. After completing 16 doses of Paclitaxel, Trastuzumab (6 mg/kg IV) and Pertuzumab 420 mg IV may be continued every 3 weeks until surgery
~Modified Radical Mastectomy
~Post-Operative Treatment:
~Option 1: Adriamycin 60 mg/m2 IV and Cyclophosphamide 600 mg/m2 IV every 2-3 weeks x 4 cycles. Followed by Trastuzumab 8 mg/kg and Pertuzumab 840 IV load; followed by Trastuzumab 6 mg/kg every and Pertuzumab 420 mg IV every 3 weeks to complete 12 months of HER2-directed therapy
~Option 2: Continue Trastuzumab 6 mg/kg and Pertuzumab 420 mg every 3 weeks to complete 12 months of HER2-directed therapy
~Radiation Therapy"
11435616|NCT01796171|Experimental|Part A, Arm 1: with lilotomab pre-dosing|Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.
11435617|NCT01796171|Experimental|Part A, Arm 2: without pre-dosing|Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.
11435618|NCT01796171|Experimental|Part A, Arm 3: with rituximab pre-dosing|Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.
11435619|NCT01796171|Experimental|Part A, Arm 4: with higher dose lilotomab pre-dosing|Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.
11435620|NCT01796171|Experimental|Part A, Arm 5: with intermediate dose lilotomab pre-dosing|Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.
11435621|NCT01796171|Experimental|Part B|Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100mg/m2 lilotomab
11435622|NCT01796158|Experimental|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
11435623|NCT01796158|Active Comparator|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
11435624|NCT01796145|Experimental|TACE|
11435625|NCT01796145|Experimental|Systemic Therapy|
11435626|NCT01796145|Experimental|Surgery|
11435627|NCT01796132|No Intervention|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
11435628|NCT01796132|Experimental|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
11435629|NCT01796119|Experimental|Ridge Splitting|"Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.
~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.
~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.
~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
11435630|NCT01796119|Active Comparator|Implants placed using drilling technique|"Dental implants placed in the ridge with sufficient thickness using drilling technique.
~To measure the horizontal bone width before and after implant insertion and 6 months post-op.
~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.
~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.
~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
11435631|NCT01796106|Experimental|Icon|The study clinician will provide Icon treatment to all study participants randomized to study arm 1 after the radiograph and visual exam.
11435632|NCT01796106|Active Comparator|control|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish) to all study participants randomized to study arm 2 after the radiograph and visual exam.
11435633|NCT01796093||Digoxin cross-over ivabradine|Digoxin 0,125 mg once a day 5 days per week during 3 months. Ivabradine, 7,5 mg b.id. during 3 months.
11435634|NCT01796080|Active Comparator|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
11435635|NCT01796080|Active Comparator|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
11435636|NCT01796080|Active Comparator|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
11435637|NCT01796080|Sham Comparator|Steady state normal breathing|Steady state normal breathing for 20 seconds
11435638|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
11435639|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
11435640|NCT01796067|Experimental|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
11436515|NCT01790009|Active Comparator|Flavanol rich drink|Flavanol Intervention drink 400 mg/75 Kg BW
11435641|NCT01796067|Active Comparator|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
11435642|NCT01796054|Experimental|Stress Free Now with group support|Randomized participants have access to online stress reduction program, Stress Free Now. Participants will log in to online program, read daily lessons and practice therapeutic exercises. They will also attend weekly group support session during 6-week program
11435643|NCT01796054|Experimental|Stress Free Now|Randomized participants have access to online stress reduction program, Stress Free Now, for 6 weeks. Participants will log into online program, read daily lessons and practice therapeutic exercises.
11435644|NCT01796054|No Intervention|Control|Randomized participants do not have access to online stress reduction program, Stress Free Now, nor do they attend weekly group support sessions.
11435645|NCT01796041|Experimental|IV Injection of ICG|
11435646|NCT01796028|Placebo Comparator|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
11435647|NCT01796028|Experimental|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
11435648|NCT01796015|Other|For the 97 patients|"day 0: ultrasound of ONSD (= 4 measurements: 1 transverse and 1 sagittal for each eye) + transcranial Doppler at T-15 (15 minutes before ICP measurement), within 1h following ICP measurement, and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)
~day 1: ONSD ultrasound + transcranial Doppler in the morning and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)
~days 2 and 3 : same as day 1
~when leaving the intensive care unit: Pediatric Overall Performance Category (POPC) scale"
11435649|NCT01796015|Other|For the control group|one single ONSD in addition to their usual care (4 measurements: 1 transverse and 1 sagittal for each eye) in the morning in absence of painful sensation
11435650|NCT01796015|Other|For the learning curve|minimum 15 ONSD ultrasounds will be performed by each of the 15 intensive care doctor or interns expected. One ONSD ultrasound corresponds to 2 measurements: 1 transverse and 1 sagittal. Each volunteer will have maximum 30 ONSD ultrasound measures over a 1 month period.
11435651|NCT01796002|Experimental|Romidepsin + CHOP|"Patients in experimental arm receive romidepsin plus CHOP (Ro-CHOP) administered in 3 week cycles for 6 cycles.
~Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks."
11435652|NCT01796002|Active Comparator|CHOP|Patients in control Arm receive cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
11435653|NCT01795989||Healthy Volunteers|Research only musculoskeletal (MSK) MRI for healthy volunteers.
11435654|NCT01795989||Clinical Efficacy|Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
11435655|NCT01795976|Experimental|NY-ESO-1 T cells|"NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype A serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg.."
11435656|NCT01795963|Placebo Comparator|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
11435657|NCT01795963|Active Comparator|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress.
11435658|NCT01795950|Experimental|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
11435659|NCT01795950|Experimental|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
11435660|NCT01795950|Experimental|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
11435661|NCT01795937|Experimental|Part 1: Faldaprevir + Itraconazole|Interaction of Faldaprevir and Itraconazole
11435662|NCT01795937|Experimental|Part 2:Faldaprevir+Rosuvastatin+Atorvast|Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
11435663|NCT01795924|Experimental|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
11435664|NCT01795911|Experimental|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;
~Ribasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;
~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
11435665|NCT01795898|Experimental|Fentanyl transdermal patch|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
11435666|NCT01795885|Experimental|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the show 16 and Pregnant once a week for 4 weeks."
11435667|NCT01795872|Other|Several diagnostic procedures|
11435668|NCT01795859|Experimental|SD-809 ER Tablets|SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
11435669|NCT01795859|Experimental|SD-809 Tablets|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
11435670|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
11435671|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
11435672|NCT01795833|Experimental|Text Messages|Short text messages related to healthy lifestyle will be sent to half the subjects three times per week, in addition to one off 'one-to-one structured education' during the study period.
11435673|NCT01795833|No Intervention|Control|Half of the subjects who has received only one off 'one-to-one structured education about healthy lifestyle during the study period
11435674|NCT01795820|Other|Group 1 (no loading)|Patients allocated to this group will not receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start), while ticagrelor 90 mg bis in die will be administered from the day of the pharmacological shift on.
11435675|NCT01795820|Other|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
11435676|NCT01795794|Experimental|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
11435677|NCT01795781||Patients receiving a new anticoagulant|Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively
11435678|NCT01795768|Experimental|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
11435679|NCT01795755|Experimental|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
11435680|NCT01795755|Active Comparator|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
11435681|NCT01795742|Active Comparator|Electric Nebulizer|Pulmo-Aide Model 5650D
11435682|NCT01795742|Experimental|Human-Powered Nebulizer|Human-Powered
11435683|NCT01795729|Experimental|1: Coronary stent+optimal medical therapy|Coronary stent on top of optimal medical therapy
11435684|NCT01795729|Active Comparator|2: Optimal medical therapy|Optimal medical therapy
11435685|NCT01795716|Experimental|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
11435686|NCT01795716|Active Comparator|Glivec|Single and multiple oral Glivec 400mg qd
11435687|NCT01795703|Experimental|Abiraterone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11435688|NCT01795677|Experimental|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
11435689|NCT01795664|Active Comparator|Seretide Evohaler|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)
~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
11435690|NCT01795664|Experimental|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)
~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
11435691|NCT01795651||Take-Home message|
11435692|NCT01795638|Active Comparator|Sodium chloride|Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
11435693|NCT01795638|Placebo Comparator|sterile water|Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.
11435694|NCT01795612|Other|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
11435695|NCT01795612|Other|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
11435696|NCT01795612|Other|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
11435697|NCT01795599|Experimental|mifepristone/misoprostol|
11435698|NCT01795599|Active Comparator|misoprostol|
11435699|NCT01795599|Active Comparator|mifepristone|
11435700|NCT01795586|Experimental|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
11435701|NCT01795573|Other|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant
11435702|NCT01795547|Experimental|Aripiprazole and aripiprazole once-monthly|
11435703|NCT01795547|Active Comparator|Paliperidone and paliperidone palmitate|
11435704|NCT01795534|Experimental|Beetroot shot then placebo shot|"Intervention: Participants will first consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK).
~Following a four day wash out, participants will then consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK)"
11435831|NCT01794780|Experimental|Indacaterol +Tiotropium|Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
11435705|NCT01795534|Placebo Comparator|Placebo shot then beetroot shot|"Intervention: Participants will first consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK).
~Following a four day wash out, participants will then consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK)."
11435706|NCT01795521|Experimental|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
11435707|NCT01795508|Experimental|PMTO|Parent Management Training Oregon
11435708|NCT01795508|Active Comparator|TAU|Other kinds of family treatment
11435709|NCT01795495|Active Comparator|Remifentanil|This arm will receive remifentanil alone as is the current practice.
11435710|NCT01795495|Experimental|Remifentanil plus methadone|This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
11435711|NCT01795495|Experimental|Remifentanil plus magnesium|This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
11435712|NCT01795482|Experimental|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
11435713|NCT01795482|Experimental|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
11435714|NCT01795482|No Intervention|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
11435715|NCT01795469|Experimental|Abdominal and LE compression|Zoex compression garment during tilt testing (all straps)
11435716|NCT01795469|Experimental|abdominal compression only|Zoex compression garment use during tilt table testing (straps 4 and 5 fastened around thighs and abdomen)
11435717|NCT01795469|Experimental|Lower extremity compression only|Zoex compression garment use during tilt table testing (straps 1-4, lower extremity and thighs, fastened)
11435718|NCT01795443|Active Comparator|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
11435719|NCT01795443|Active Comparator|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
11435720|NCT01795443|Active Comparator|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
11435721|NCT01795443|Active Comparator|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
11435722|NCT01795443|Active Comparator|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
11435723|NCT01795443|Active Comparator|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
11435724|NCT01795443|Experimental|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
11435725|NCT01795443|Experimental|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
11435726|NCT01795443|Experimental|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
11435755|NCT01795274|Experimental|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
11435756|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
11435862|NCT01794585|Experimental|Virtual Reality Based Exercise|
11435727|NCT01795443|Experimental|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
11435728|NCT01795443|Experimental|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
11435729|NCT01795443|Experimental|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).
~Propioception measures will be carried out in the following order:
~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
11435730|NCT01795430|Experimental|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.
~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
11435731|NCT01795417|Experimental|XP200 device RF treatments|Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
11435732|NCT01795404|Experimental|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
11435733|NCT01795404|No Intervention|Control group|Waited-list control
11435734|NCT01795391||Tegaderm HP|Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.
11435735|NCT01795391||Advanced|Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings
11435736|NCT01795365|Active Comparator|Epstein + (group I)|"Epstein + (Group I) PSA <10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;
~% of tumor biopsy invasion <50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
11435737|NCT01795365|Experimental|Epstein - (group II)|"Epstein - (Group II) PSA <15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12
~% of tumor biopsy invasion <50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
11435738|NCT01795339|Experimental|AZD3293|Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293
11435739|NCT01795339|Placebo Comparator|Placebo|Part 1: Placebo given (2 subjects in each cohort) Part 2: Placebo given (up to 4 subjects)
11435740|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435741|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435742|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435743|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435744|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435745|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435746|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435747|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
11435748|NCT01795313|Experimental|HLA-A2 restricted tumor antigen vaccine|This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod
11435749|NCT01795300|Experimental|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
11435750|NCT01795300|Experimental|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
11435751|NCT01795300|Experimental|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
11435752|NCT01795300|Active Comparator|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
11435753|NCT01795287|Active Comparator|Spinal anesthesia|Spinal anesthesia
11435754|NCT01795287|Active Comparator|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
11545820|NCT01033526|Experimental|Arm 1|
11435761|NCT01795235|Other|Saline s.c. injection and placebo tablet|Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
11435762|NCT01795235|Other|glucagon s.c. injection and placebo tablet|1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
11435763|NCT01795235|Other|Saline s.c. injection and atenolol tablet|Saline s.c. injection and 100 mg atenolol tablet
11435764|NCT01795235|Other|glucagon s.c. injection and atenolol tablet|1 mg glucagon s.c. injection and 100 mg atenolol tablet
11435765|NCT01795222|Active Comparator|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
11435766|NCT01795222|Placebo Comparator|placebo|placebo oral syrup twenty minutes before starting the procedure
11435767|NCT01795209|Experimental|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
11435768|NCT01795209|Sham Comparator|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
11435769|NCT01795183|Experimental|Amisulpride|Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week
11435770|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
11435771|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
11435772|NCT01795157|Experimental|CCADSS|questionnaire completed using i-Pad
11435773|NCT01795157|Active Comparator|pen-paper|Questionnaire completed using pen and paper
11435774|NCT01795144|Active Comparator|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:
~OGTT
~IGI
~IGI with GLP-1 infusion
~OGTT with Exendin 9-39 infusion"
11435775|NCT01795144|Experimental|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:
~OGTT
~IGI
~IGI with GLP-1 infusion
~OGTT with Exendin 9-39 infusion"
11435776|NCT01795131|Active Comparator|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
11435777|NCT01795131|Placebo Comparator|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
11435778|NCT01795105||Aripiprazole (Abilify® Tablets/Abilify® ODT)|
11435779|NCT01795092|No Intervention|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
11435780|NCT01795092|Experimental|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
11435781|NCT01795079|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
11435782|NCT01795079|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
11435783|NCT01795066|Experimental|EUS-FNB with 25-gauge|
11435784|NCT01795053|Experimental|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
11435785|NCT01795053|Placebo Comparator|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
11435786|NCT01795040|Experimental|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
11435787|NCT01795040|Placebo Comparator|placebo without PUFAs|Placebo without PUFAs
11435788|NCT01795027|Experimental|S-1 plus Oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
11435789|NCT01795027|Active Comparator|S-1 single|S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
11435790|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
11435791|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
11435792|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
11435793|NCT01795001||late-onset FECD|tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)
11435794|NCT01795001||normal control|tissue samples from patients with normal corneas
11435795|NCT01795001||non-FECD edematous control|tissue samples from patients with corneal edema but without FECD
11435796|NCT01794988|Experimental|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
11435797|NCT01794988|Active Comparator|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
11435798|NCT01794988|Experimental|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
11435800|NCT01794975|Active Comparator|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
11435801|NCT01794975|Active Comparator|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
11435802|NCT01794975|Placebo Comparator|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with [11C]ORM-13070 will be performed for all subjects with the placebo treatment only.
11435803|NCT01794962|Experimental|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
11435804|NCT01794962|Experimental|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
11435805|NCT01794949|Experimental|Non-diabetic patients receiving the Resolute stent|Non-diabetic patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
11435806|NCT01794949|Experimental|Diabetic patients receiving the Resolute stent|Non-insulin dependent diabetes mellitus (NIDDM) patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
11435807|NCT01794936|Experimental|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
11435808|NCT01794936|No Intervention|Non-Probe|Patients randomized to not receive probe evaluation.
11435809|NCT01794923|Experimental|Ibuprofen 5% topical gel BID|IBU BID (Treatment A)
11435810|NCT01794923|Placebo Comparator|Placebo topical gel BID|Placebo BID (Treatment B)
11435811|NCT01794923|Experimental|Ibuprofen 5% topical gel TID|IBU TID (Treatment C)
11435812|NCT01794923|Placebo Comparator|Placebo topical gel TID|Placebo TID (Treatment D)
11435813|NCT01794910|Experimental|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
11435814|NCT01794910|No Intervention|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
11435815|NCT01794897|Experimental|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
11435816|NCT01794897|Placebo Comparator|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
11435817|NCT01794884|Experimental|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg)(volume ratio=1:5).Intravenous injection twice (24 hours、1 hour before operation).
11435818|NCT01794884|Placebo Comparator|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation).
11435819|NCT01794858|Experimental|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).
~Secondary
~Lab values: D-Dimer, IL-6, CRP
~APACHE II Scores Day 1 and after TH (day 4)
~Length of stay in the ICU and hospital
~Prevalence of infections
~28-day mortality
~Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
11435820|NCT01794845|Experimental|Erbitux, Taxotere, LD Fractionated RT|Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)
11435821|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
11435822|NCT01794819|Experimental|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.
~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
11435823|NCT01794806|Experimental|Tooth extraction and grafting|Tooth extraction and grafting with allograft
11435824|NCT01794806|Sham Comparator|Tooth extraction|Tooth extraction
11435825|NCT01794793|Experimental|Pasireotide subcutaneous|0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
11435826|NCT01794793|Experimental|Pasireotide Long Acting Release (LAR)|10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
11435827|NCT01794780|Experimental|Indacaterol|LABA: Indacaterol, once a day, 150μg each time
11435828|NCT01794780|Experimental|Tiotropium Bromide|LAMA: Tiotropium Bromide, once a day, 18 μg
11435829|NCT01794780|Experimental|Salmeterol/Fluticasone|LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
11435830|NCT01794780|Experimental|Budesonide/ formoterol|Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
11435863|NCT01794585|Active Comparator|Standard Exercise|
11435832|NCT01794780|Experimental|LABA/ICS (Or budesonide/ formoterol)+ Tiotropium|Salmeterol / fluticasone Or budesonide / formoterol
11435833|NCT01794780|Experimental|Oral theophylline|
11435834|NCT01794780|Experimental|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
11435835|NCT01794767|Active Comparator|0,9% NaCl flush|for children enrolled in this group, the nurse will perform the flushing of peripheral venous catheter using flush-solution as a bolus with saline 0.9% NaCl in the amount (ml) needed to fill the entire circuit of the catheter. The flushing will be performed routinely at the end of each fleboclisis
11435836|NCT01794767|Experimental|Heparin 50U/ml|for children enrolled in this group, the nurse will perform the washing of peripheral venous catheter using flush-solution as a bolus with heparin 50U/ml in the amount (ml) needed to fill the entire circuit of the catheter. The washing will be performed routinely at the end of each fleboclis
11435837|NCT01794754|Other|Control|Care as usual
11435838|NCT01794754|Experimental|Occupational therapy|Occupational therapy
11435839|NCT01794741|Active Comparator|Dymista nasal spray|azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
11435840|NCT01794741|Active Comparator|fluticasone propionate nasal spray|fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
11435841|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
11435842|NCT01794715|Experimental|Ultrasound performed by nurses|Examinations including ultrasound examinations
11435843|NCT01794715|Active Comparator|Ultrasound not performed|Examinations not including ultrasound examinations, otherwise active
11435844|NCT01794702|Experimental|Clofarabine + Cytarabine + Decitabine + Idarubicin|"Phase I - Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)
~Phase II - Clofarabine 15 mg/m2 by vein over approximately 1 hour daily (number of days selected based on Phase I portion).
~Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)"
11435845|NCT01794689|Experimental|Morphine US then Morphine FA|Participants randomized to receive Morphine and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
11435846|NCT01794689|Placebo Comparator|Placebo US then Placebo FA|Participants randomized to receive the saline placebo and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
11435847|NCT01794689|Experimental|Morphine FA then Morphine US|Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
11435848|NCT01794689|Placebo Comparator|Placebo FA then Placebo US|Participants randomized to receive the saline placebo and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
11435849|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
11435850|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
11435851|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
11435852|NCT01794663|Experimental|OPN-305|
11435853|NCT01794663|Placebo Comparator|Matching placebo|
11435854|NCT01794650|Other|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
11435855|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
11435856|NCT01794624|Active Comparator|Cognitive Therapy|Cognitive Therapy for Catastrophizing
11435857|NCT01794624|Active Comparator|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
11435858|NCT01794624|No Intervention|TMJD Education|6-sessions of TMJD disease education/support control
11435859|NCT01794611|Experimental|Laryngoscopy|Patients will be intubated by an experienced anesthesiologists. Anesthesiologist first uses Macintosh laryngoscope then KingsVision videolaryngoscope and lastly C-MAC videolaryngoscope to intubate patients. Cormack-Lehane scores, the time from the start of laryngoscopy to visualization of the vocal cords and the time from the visualization of the vocals from the successful intubation will be recorded. The success of the intubation will be assessed with bilateral chest auscultation. If visualization of the vocal cords or placing of the endotracheal tube was not successful after 60 seconds with a particular laryngoscope, it will be left out and patient will be ventilated for 1 minutes and then pass to other laryngoscopes.
11435860|NCT01794598|Experimental|Educational materials|Receiving educational materials of depression care
11435861|NCT01794598|Sham Comparator|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
11435864|NCT01794572|Experimental|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.
~For Every patients:
~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.
~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
11435865|NCT01794559|Experimental|Informed by PEER Interactive Report|"The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.
~The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.
~The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health."
11435866|NCT01794559|No Intervention|No Report|This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
11435867|NCT01794546|Experimental|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
11435868|NCT01794546|Active Comparator|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
11435869|NCT01794533|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
11435870|NCT01794533|Active Comparator|Lidocaine with Epinephrine + fentanyl|
11435871|NCT01794520|Experimental|ABT-199 Safety Expansion Cohort|
11435872|NCT01794520|Experimental|Phase 2 Cohort|Venetoclax-Dexamethasone Combination Expansion
11435873|NCT01794520|Experimental|Venetoclax-Dexamethasone Combination|
11435874|NCT01794520|Experimental|ABT-199 Dose Escalation Cohorts|
11435875|NCT01794507|Experimental|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
11435876|NCT01794507|Experimental|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
11435877|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
11435878|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
11435879|NCT01794481|No Intervention|Usual Care|Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed. As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
11435880|NCT01794481|Experimental|Resistance Exercise Training|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.
~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
11435881|NCT01794468|Experimental|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
11435882|NCT01794455|Experimental|Phase 1: Sertraline|Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
11435883|NCT01794455|Experimental|Phase 2: Candesartan|For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
11435884|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
11435885|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
11435886|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
11435887|NCT01794429|Placebo Comparator|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
11435888|NCT01794429|Active Comparator|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
11435889|NCT01794416|Active Comparator|Thoracoscopic epicardial ablation|"Patients were treated with video-assisted thoracoscopy under general anesthesia. PVI was performed from the epicardial side with a bipolar RF ablation clamp (AtriCure). At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. An additional application was made in the interatrial Waterston groove in the right side to isolate the ganglionic plexi from the atria. On the left side, the ligament of Marshal was cut, but no additional ablation of ganglionic plexi was pursued.
~The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
11436516|NCT01790009|Active Comparator|Acetaminophen|2 tabletsx500 mg
11435890|NCT01794416|Active Comparator|Endocardial catheter ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
11435891|NCT01794403|Active Comparator|Extended Hypofractionation (EHRT)|"Extended Hypofractionation Radiotherapy: A total dose of 70.2 Gy, 26 fractions, 2.7 Gy to the Planning Target Volume (PTV).
~Expanded Prostate Cancer Index Composite SF-12 (EPIC SF-12) quality of life questionnaire;
~International Prostate Symptom Score (IPSS) quality of life questionnaire;
~Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire;
~OPTIONAL: Ultrasound-guided biopsy, blood and urine samples for correlative studies."
11435892|NCT01794403|Experimental|Accelerated Hypofractionation (AHRT)|"Accelerated Hypofractionation Radiotherapy: A total dose of 36.25 Gy, 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV);
~Expanded Prostate Cancer Index Composite SF-12 (EPIC SF-12) quality of life questionnaire;
~International Prostate Symptom Score (IPSS) quality of life questionnaire;
~Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire;
~OPTIONAL: Ultrasound-guided biopsy, blood and urine samples for correlative studies."
11435893|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
11435894|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
11435895|NCT01794377|Active Comparator|40 of an endurance training|Endurance training at 50% of VO2 peak measured by indirect calorimetry. Dietary Supplement: supplementation in fruits and vegetables.
11435896|NCT01794377|Experimental|30 minutes of a high intensity training|"This arm consist of an interval strength training for 30 min on bicycle ergometer (which include strengthening exercises in an high intensity interval training).
~Dietary Supplement: supplementation in fruits and vegetables."
11435897|NCT01794364|Experimental|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
11435898|NCT01794351|Experimental|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
11435899|NCT01794351|Experimental|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
11435900|NCT01794338|Experimental|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
11435901|NCT01794338|Active Comparator|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
11435902|NCT01794325|Active Comparator|Trans-radial access|Coronary angiography performed through trans-radial access
11435903|NCT01794325|Active Comparator|Trans-femoral access|Coronary angiography performed through trans-femoral access
11435904|NCT01794312|Experimental|T4020|One drop every 2 days
11435905|NCT01794312|Placebo Comparator|Vehicle|One drop every 2 days
11435906|NCT01794299|Experimental|ATIR|
11435907|NCT01794286|Active Comparator|Control Group|Trigger alerts only
11435908|NCT01794286|Experimental|Intervention Group|Trigger alerts + provider bulletins
11435909|NCT01794273|Experimental|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
11435910|NCT01794273|Experimental|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
11435911|NCT01794260|Placebo Comparator|Placebo cream|Placebo cream
11435912|NCT01794260|Experimental|Plai cream|Cream from Zingiber cassumunar Roxb. extract
11435913|NCT01794247|Experimental|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
11435914|NCT01794247|Active Comparator|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
11435915|NCT01794234||Cohort|
11435916|NCT01794221|Active Comparator|Stitches only|Stitches only closing circumcision wound
11435917|NCT01794221|Experimental|Stitches and skin adhesive|application of 2-octyl cyanoacrylate skin adhesive.
11435918|NCT01794208|Experimental|treatment 1|FSH-GEX(TM)
11435919|NCT01794208|Experimental|treatment 2|FSH-GEX(TM)
11435920|NCT01794208|Experimental|treatment 3|FSH-GEX(TM)
11435921|NCT01794208|Experimental|treatment 4|FSH-GEX(TM)
11435922|NCT01794208|Experimental|treatment 5|FSH-GEX(TM)
11435923|NCT01794208|Active Comparator|treatment 6|Gonal-f(R)
11436597|NCT01789437|Active Comparator|Dexamethasone Intravitreal Implant|
11435924|NCT01794195|Experimental|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
11435925|NCT01794195|Experimental|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
11435926|NCT01794195|Experimental|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
11435927|NCT01794182|Placebo Comparator|Matching Placebo|Subjects will receive matching placebo.
11435928|NCT01794182|Experimental|RP-1127 (Glyburide for Injection)|Subjects will receive the active agent, RP-1127 (Glyburide for Injection)
11435929|NCT01794169|Experimental|Azacitidine|Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
11435930|NCT01794169|Active Comparator|DA|"Two courses of DA in accordance with the Swedish National treatment program (reduced doses):
~In case one induction course was given:
~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.
~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.
~In case two induction courses were given:
~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.
~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5."
11435931|NCT01794156|Active Comparator|Cognitive behavior therapy|"The cognitive-behavioral model is presented and individualized.
~Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs
~Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.
~Combined phase: continues ERP while making explicit links to the cognitive targets.
~Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
11435932|NCT01794156|Active Comparator|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
11435933|NCT01794156|Experimental|Inference-based therapy|"The inference-based therapy will be delivered in 10-step
~The client will:
~learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt
~learn why this doubt is 100% irrelevant here and now
~learn the inferential confusion process
~have to recognize that the doubt originates from him/her
~have to identify/describe the narrative leading him/her to the doubt
~have to identify the cross-over point when he/she leaves reality
~learn to be aware of the reasoning devices
~learn how personal themes dictate the idiosyncratic nature of the person's obsession
~explore and reinforced an alternative self-view
~be trained to use properly his/her senses in the face of obsessional triggers situations"
11435934|NCT01794143|Active Comparator|Sulfonylurea (glimepiride)|Sulfonylurea
11435935|NCT01794143|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor (sitagliptin)
11435936|NCT01794143|Active Comparator|GLP-1 receptor agonist|GLP-1 receptor agonist (liraglutide)
11435937|NCT01794143|Active Comparator|Insulin (glargine)|Insulin (glargine), Lantus
11435938|NCT01794117|Experimental|A|An initial dose of anakinra 100 mg/day will beadministered daily via self-administered subcutaneousinjection. If pustule formation persists at this dose,anakinra dose may be escalated up to 200 mg/dayinjected subcutaneously daily at week 4
11435939|NCT01794104|Experimental|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
11435940|NCT01794091|Experimental|Eplerenone|In a subgroup of 50 patients, 25 will be randomized to eplerenone to assess effects on fibrotic index pre- and post-6 months of therapy.
11435941|NCT01794091|Placebo Comparator|Sugar pill|
11435942|NCT01794078|Placebo Comparator|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
11435943|NCT01794078|Experimental|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
11435944|NCT01794078|Experimental|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
11435945|NCT01794078|Experimental|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
11435946|NCT01794065||Cypher|100 patients who have received a Cypher stent during their coronary intervention
11435947|NCT01794065||Taxus Express|100 patients who have received a Taxus Express stent during their coronary intervention
11435948|NCT01794065||Endeavor|100 patients who have received an Endeavor stent during their coronary intervention
11435949|NCT01794065||Promus/Xience V|100 patients who have received a Promus/Xience V stent during their coronary intervention
11435950|NCT01794065||Promus Element|100 patients who have received a Taxus Element stent during their coronary intervention
11435951|NCT01794052|Experimental|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
11435952|NCT01794039|Experimental|Arm A (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.
11435991|NCT01793818|Active Comparator|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
11435953|NCT01794039|Experimental|Arm B (pomalidomide, dexamethasone)|Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11435954|NCT01794026|Experimental|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
11435955|NCT01794013|Active Comparator|Parent trianing|The parent training group will learn about DIR/ Floortime™ model approach through one on one coaching for 1 hour at the beginning of the study, the end of 1st and 3th month and through 2 hours DVD lecture and a pocket book.
11435956|NCT01794013|Active Comparator|Routine care|The children in the control group will continue their standard routine care.
11435957|NCT01794000|Experimental|Prasugrel|Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
11435958|NCT01794000|Placebo Comparator|Placebo|Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
11435959|NCT01793987|No Intervention|control: shaver|
11435960|NCT01793987|Experimental|Coblation polypectomy|
11435961|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
11435962|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
11435963|NCT01793961|Other|"Cannabis Arm"|patient addicted to cannabis
11435964|NCT01793961|Other|"Tobacco Arm"|patient addicted to tobacco
11435965|NCT01793961|Other|"Healthy volunteers"|no smokers
11435966|NCT01793948|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11435967|NCT01793948|Placebo Comparator|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11435968|NCT01793935|Experimental|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera
11435969|NCT01793935|Placebo Comparator|Placebo|Placebo
11435970|NCT01793922|Active Comparator|PD|pneumodilation
11435971|NCT01793922|Active Comparator|POEM|peroral endoscopic myotomy
11435972|NCT01793909|Other|Single Leg Exercise|Supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
11435973|NCT01793896|Sham Comparator|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
11435974|NCT01793896|Experimental|Diet group|Mediterranean diet prescription during 3 months
11435975|NCT01793896|Experimental|Exercise group|Subjects will be trained 3 times a week during 3 months
11435976|NCT01793896|Experimental|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
11435977|NCT01793883|Active Comparator|40 mg Laninamivir Octanoate DPI|40 mg Laninamivir Octanoate and matching placebo
11435978|NCT01793883|Active Comparator|80 mg Laninamivir Octanoate DPI|80 mg Laninamivir
11435979|NCT01793883|Placebo Comparator|Placebo|Matching Placebo
11435980|NCT01793870|Experimental|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram [mg]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
11435981|NCT01793870|Experimental|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
11435982|NCT01793870|Experimental|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
11435983|NCT01793870|Experimental|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
11435984|NCT01793857||Study Group|Approximately 1300 primary caregivers of at least one child aged 6 months to less than 30 months who were interviewed during a clinic visit in Panama.
11435985|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）
~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
11435986|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
11435987|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
11435988|NCT01793831|Experimental|Fecal microbiota transplantation|Standard fecal microbiota transplantation, once.
11435989|NCT01793818|Placebo Comparator|Group 1 Phase I/II|Three injections with no active principle
11435990|NCT01793818|Active Comparator|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
11435992|NCT01793818|Active Comparator|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
11435993|NCT01793805||Metastatic Colorectal Cancer Patients|
11435994|NCT01793792|Other|Device: LVIS|"The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
~Device: LVIS™ and LVIS™ Jr. MicroVention Low-profile Visualized Intraluminal Support Device"
11435995|NCT01793779|Placebo Comparator|Control|Placebo supplement given prior to exercise and two times per day following exercise
11435996|NCT01793779|Experimental|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
11435997|NCT01793779|Experimental|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
11435998|NCT01793779|Experimental|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
11435999|NCT01793766|Experimental|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
11436000|NCT01793766|Placebo Comparator|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
11436001|NCT01793753||Propofol|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal manometry including propofol per standard of care
11436002|NCT01793740|Experimental|Cogmed|These children are enrolled in the Cogmed intervention.
11436003|NCT01793740|No Intervention|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
11436004|NCT01793727|Experimental|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
11436005|NCT01793688||Sulbactam Sodium/Ampicillin Sodium|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) by intravenous injection or intravenous drip infusion from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis.
11436006|NCT01793675||haploidentical transplant|transplant with haploidentical donor
11436007|NCT01793662|Active Comparator|Open aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
11436008|NCT01793662|Experimental|Laparoscopic aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
11436009|NCT01793649|Experimental|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
11436010|NCT01793649|Experimental|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
11436011|NCT01793636|Experimental|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
11436012|NCT01793636|Active Comparator|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
11436013|NCT01793623||nonemergent heart surgery, atrial tissue|patients undergoing non-emergent heart surgery
11436014|NCT01793610|Active Comparator|Comparator-dose (40 mg) MDMA and Psychotherapy|Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
11436015|NCT01793610|Experimental|Active Dose 2 (100 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
11436016|NCT01793610|Experimental|Active Dose 1 (125 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.
11436017|NCT01793597||clopidogrel|previous treatment with clopidogrel
11436018|NCT01793597||ticagrelor|previous treatment with ticagrelor
11436019|NCT01793584|Active Comparator|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
11436020|NCT01793584|Active Comparator|Abdominal hysterectomy|Total Abdominal Hysterectomy
11436021|NCT01793571|Experimental|TAP block|20 ml Levobupivacaine 0,5%
11436022|NCT01793571|Active Comparator|Local wound infiltration|20 ml levobupivacaine 0,5%
11436023|NCT01793558|No Intervention|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
11436024|NCT01793558|Experimental|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
11436025|NCT01793545||Endometrial Cancer Cohort|Women with abnormal bleeding or other conditions associated with increased risk ofendometrial cancer.
11436026|NCT01793519|Active Comparator|Anti-tumor necrosis factor agent|Anti-TNF agent - etanercept, infliximab, adalimumab - administered parentally at standard dosage and frequencies
11436027|NCT01793519|Placebo Comparator|Placebo|Administered appropriately to active comparator
11436028|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
11436029|NCT01793493|Experimental|Cognitive stimulation|
11436030|NCT01793493|Active Comparator|Sanitary education|
11436031|NCT01793480|Experimental|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
11436032|NCT01793480|Experimental|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
11436033|NCT01793454|Active Comparator|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
11436034|NCT01793454|Active Comparator|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
11436035|NCT01793441|Placebo Comparator|Placebo|Participants will receive placebo matching to RG7314 in each stage (Stage I, II, III and IV) for 12 weeks.
11436036|NCT01793441|Experimental|RG7314|Participants will receive RG7314 orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
11436037|NCT01793428||Injured patient admitted in vital emergency unit|
11436038|NCT01793415|Active Comparator|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
11436039|NCT01793415|Placebo Comparator|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
11436040|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
11436041|NCT01793389|Active Comparator|Subepithelial connective tissue graft|Soft tissue harvested from palatum of the subjects.
11436042|NCT01793389|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
11436043|NCT01793363|Experimental|tracheotomized patients|
11436044|NCT01793350|Active Comparator|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
11436045|NCT01793350|Placebo Comparator|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
11436046|NCT01793337|Other|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
11436047|NCT01793337|Other|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
11436048|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
11436049|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
11436050|NCT01793311|Sham Comparator|Group1: Decaffeinated coffee|contains 0.5-2 mg of caffeine
11436051|NCT01793311|Active Comparator|Group2: regular dose coffee|contains 91.8 mg of caffeine
11436052|NCT01793311|Active Comparator|Group3: high dose coffee|contains 144 mg of caffeine
11436053|NCT01793298|Experimental|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
11436054|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo|Single administration of placebo
11436055|NCT01793298|Experimental|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
11436056|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
11436057|NCT01793298|Experimental|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
11436058|NCT01793272|Other|Pentoxifylline|effect of pentoxifylline on ICSI outcome
11436059|NCT01793259|Other|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
11436060|NCT01793259|Other|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
11436061|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
11436062|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
11436063|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
11436064|NCT01793220|Experimental|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
11436065|NCT01793220|No Intervention|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
11436066|NCT01793207||Normal|Subjects who had a normal colonoscopic examination (No polyps, masses or any evidence of colorectal neoplasia)
11436067|NCT01793207||colorectal cancer|Patients with endoscopic and histopathological evidence of colorectal cancer
11436068|NCT01793207||Adenoma|Patients with colorectal adenomas only detected on colonoscopy
11436069|NCT01793207||Hyperplastic polyps|Patients with hyperplastic polyps detected on colonoscopy.
11436070|NCT01793194|No Intervention|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
11436071|NCT01793194|Experimental|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
11436072|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
11436073|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
11436074|NCT01793155|Experimental|Inspiratory muscle training|Inspiratory muscle training for two weeks following surgery
11436075|NCT01793155|Placebo Comparator|Standard physiotherapy|Breathing exercises, cough/hugh, advice on early and active mobilization
11436076|NCT01793142||Viviant treatment group|Viviant treatment group
11436077|NCT01793129|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
11436078|NCT01793129|Placebo Comparator|Normothermia|Control group (with esophageal temperature at or near 37.0°C) for 72 hours
11436141|NCT01792648|Active Comparator|Standard Reference Diet|
11436142|NCT01792648|Experimental|Almond Supplemented Diet|
11436143|NCT01792648|Active Comparator|Low Carbohydrate Reference Diet|
11436079|NCT01793090|Active Comparator|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
11436080|NCT01793090|Placebo Comparator|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
11436081|NCT01793077||Prostate Cancer patients|
11436082|NCT01793064|Experimental|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
11436083|NCT01793064|Active Comparator|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
11436084|NCT01793051|Experimental|Minocycline|"Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM.
~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
11436085|NCT01793051|Placebo Comparator|Placebo|"Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
11436086|NCT01793038|Active Comparator|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
11436087|NCT01793038|Experimental|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
11436088|NCT01793025|Experimental|ATAC Therapy|
11436089|NCT01793012||critically ill intensive care patients|Treatment with one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, colistin
11436090|NCT01792999|No Intervention|Non-contrast KBCT|About 187 subjects, who had diagnostic imaging of the breast including mammography and were categorized as Breast Imaging-Reporting and Data System(BIRADS) scores 1, 2, 3, 4, or 5, received KBCT imaging without contrast injection.
11436091|NCT01792999|Experimental|Contrast-enhanced KBCT|About 231 subjects, who had diagnostic imaging of the breast including mammography and were scheduled for biopsy or surgery, received contrast-enhanced KBCT imaging of the affected breast before biopsy or surgery.
11436092|NCT01792986|Other|water-only 24-hour fasting once per week for 6 weeks|
11436093|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
11436094|NCT01792947|Active Comparator|Diet|Diet 1200 Kcal during 3 months
11436095|NCT01792947|Experimental|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
11436096|NCT01792934|Active Comparator|XELOX or FOLFOX regimen|XELOX or FOLFOX regimen
11436097|NCT01792934|Experimental|XELOX or FOLFOX regimen and maximal tumor debulking|XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).
11436098|NCT01792921||control waitlist|
11436099|NCT01792908|Experimental|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
11436100|NCT01792908|No Intervention|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
11436101|NCT01792895|Active Comparator|Manipulation group|This Technique will be applied over four sessions, during two weeks
11436102|NCT01792895|Active Comparator|Mobilisation|This treatment will be applied on cervical spine during four sessions, over two weeks
11436103|NCT01792895|Active Comparator|Mobilization with movement|This Technique will be applied over four sessions, during two weeks
11436104|NCT01792882||Cancer Subjects|
11436105|NCT01792856|Experimental|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
11436106|NCT01792856|Experimental|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
11436107|NCT01792843||Parkinson's disease|Patients with Parkinson's disease according to international criteria
11436108|NCT01792830|No Intervention|Control HbA1c < 7%|Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c <7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.
11436109|NCT01792830|Active Comparator|Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.
11436144|NCT01792635|No Intervention|Part A (Pilot Study)|
11436145|NCT01792635|Experimental|Monotherapy (Part B)|
11436146|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
11549174|NCT01010100|Experimental|Arm 1|
11436110|NCT01792830|Active Comparator|Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.
11436111|NCT01792830|Active Comparator|No diabetes/ Metformin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.
11436112|NCT01792830|Active Comparator|Diabetic/antidiabetic regimen|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c <7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.
11436113|NCT01792830|Active Comparator|No diabetes/ Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.
11436114|NCT01792830|Active Comparator|Diabetes/Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c >9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.
11436115|NCT01792817|Sham Comparator|Sham GammaCore device|The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
11436116|NCT01792817|Experimental|GammaCore Device|Non-Invasive Vagus Nerve Stimulator
11436117|NCT01792804|Experimental|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
11436118|NCT01792804|Experimental|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
11436119|NCT01792791||Single Arm|
11436120|NCT01792778|Active Comparator|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
11436121|NCT01792778|Active Comparator|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
11436122|NCT01792765|No Intervention|Control Arm|This arm will undergo ureteroscopy using conventional fluoroscopy to guide the procedure and visualize scope position, safety wire status, etc.
11436123|NCT01792765|Experimental|Ultrasound guidance|This arm will have intraoperative ultrasound guidance to determine safety wire position and for scope guidance.
11436124|NCT01792752|Experimental|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.
11436125|NCT01792752|No Intervention|Control / Neighborhood(s) not receiving the intervention|The neighborhood(s) not receiving the intervention will act as a control while the intervention is initiated and implemented in other neighborhoods. All neighborhoods will receive the intervention but at different times throughout the study period. Once the intervention is initiated in a neighborhood, that neighborhood will continue receiving the intervention until the end of the study period.
11436126|NCT01792739|Experimental|Kadit B|Probiotic Lactobacillus casei variety rhamnosus granules
11436127|NCT01792739|Placebo Comparator|Kadit A|Placebo
11436128|NCT01792726|Experimental|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
11436129|NCT01792726|Active Comparator|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
11436130|NCT01792713|Active Comparator|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
11436131|NCT01792713|Placebo Comparator|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
11436132|NCT01792700|Active Comparator|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
11436133|NCT01792700|Active Comparator|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
11436134|NCT01792687|Experimental|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
11436135|NCT01792674|Experimental|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
11436136|NCT01792674|Active Comparator|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
11436137|NCT01792661|Active Comparator|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
11436138|NCT01792661|Active Comparator|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
11436139|NCT01792661|Active Comparator|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
11436140|NCT01792661|Active Comparator|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
11436147|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
11436148|NCT01792609|Active Comparator|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
11436149|NCT01792609|Active Comparator|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
11436150|NCT01792596|Other|pasta|1. Plain pasta
11436151|NCT01792596|Other|pasta with protein|Pasta with protein
11436152|NCT01792596|Other|pasta with fiber|Pasta with Fiber
11436153|NCT01792583||Prospective Cohort|Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).
11436154|NCT01792583||Retrospective Cohort|Retrospective is define per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal test.
11436155|NCT01792570|Experimental|RPV + DRV/r|switch to RPV + DRV/r
11436156|NCT01792570|Active Comparator|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
11436157|NCT01792557|Active Comparator|Phenol|Crystallized Phenol Group
11436158|NCT01792557|Active Comparator|Limberg|Limberg Flap Group
11436159|NCT01792557|Active Comparator|Modified Limberg|Modified Limberg Flap Group
11436160|NCT01792557|Active Comparator|Karydakis|Karydakis Flap Group
11436161|NCT01792544|Experimental|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
11436162|NCT01792544|Experimental|No Statement|No statement is added to the echocardiography report
11436163|NCT01792531|Experimental|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
11436164|NCT01792531|Experimental|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
11436165|NCT01792518|Experimental|linagliptin 5mg|linagliptin 5 mg once daily
11436166|NCT01792518|Placebo Comparator|placebo|matching placebo for linagliptin dose once daily
11436167|NCT01792505|Experimental|Biological/Vaccine|
11436168|NCT01792479|Experimental|Arm A: BIND-014 every 3 weeks|
11436169|NCT01792479|Experimental|Arm B: BIND-014 weekly|
11436170|NCT01792466|Experimental|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
11436171|NCT01792466|No Intervention|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
11436172|NCT01792453|Experimental|240 mL water drink|Volunteers will be asked to drink 240 mL water drink
11436173|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
11436174|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
11436175|NCT01792414|Active Comparator|Active TES|Active TES
11436176|NCT01792414|Sham Comparator|Sham TES|Sham TES
11436177|NCT01792401|Placebo Comparator|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
11436178|NCT01792401|Active Comparator|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
11436179|NCT01792388|Placebo Comparator|Soya Bean oil|
11436180|NCT01792388|Active Comparator|Vitamin D|
11436181|NCT01792375|Active Comparator|Concurrent membrane sweeping with Dinoprostone|
11436182|NCT01792375|Active Comparator|Dinoprostone|
11436183|NCT01792362|Experimental|AMH|obese PCOS patients who underwent weight loss diet
11436184|NCT01792349|Experimental|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
11436185|NCT01792349|No Intervention|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
11436186|NCT01792323|Experimental|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
11436187|NCT01792323|Experimental|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
11436188|NCT01792310|Experimental|Dose Cohort 1|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
11436189|NCT01792310|Experimental|Dose Cohort 2|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 500 mg twice daily
11436190|NCT01792310|Experimental|Dose Cohort 3|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 1g twice daily
11436191|NCT01792310|Experimental|2-OHOA Dose Cohort 4|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 2g twice daily
11436192|NCT01792310|Experimental|2-OHOA Dose Cohort 5|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g twice daily
11436193|NCT01792310|Experimental|2-OHOA Dose Cohort 6|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g three times daily
11436194|NCT01792310|Experimental|2-OHOA Dose Cohort 7|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 8g twice daily
11436195|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
11436196|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Non-glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.
11436197|NCT01792297|Experimental|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
11436198|NCT01792297|Active Comparator|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
11436199|NCT01792284|Experimental|LY2605541 Fixed Time Dosing|"Participant-specific dose of LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks in the Lead-in Period and in Randomization Period 1 or Randomization Period 2.
~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).
~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on self-monitored blood glucose (SMBG). Target glucose values were as follows:
~Preprandial and bedtime BG between 71 and 130 milligrams/deciliter (mg/dL) Insulin adjustment and glucose correction between 71 and 100 mg/dL."
11436200|NCT01792284|Experimental|LY2605541 Variable Time Dosing|"Participant-specific dose of LY2605541 administered SQ on a variable time schedule (8- and 40-hour dosing intervals) for 12 weeks in Randomization Period 1 or Randomization Period 2. Dosing schedules were to remain approximately the same throughout the 12 weeks.
~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).
~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on SMBG. Target glucose values were as follows:
~Preprandial and bedtime BG between 71 and 130 mg/dL Insulin adjustment and glucose correction between 71 and 100 mg/dL."
11436201|NCT01792271|Placebo Comparator|AB: 7% HS home tx, then 0.12% NaCl|"Inhaled Inhaled 7% HS (hypertonic saline) home treatment' , then 0.12% sodium chloride solution home treatment.
~The intervention consists of the subject receiving both concentrations of inhaled sodium chloride solution, each during a different home treatment periods. Subjects randomized to order AB will receive inhaled 7% NaCl (sodium chloride solution) mist during the first home treatment period, then 0.12% NaCL during the second home treatment period."
11436202|NCT01792271|Placebo Comparator|BA: 0.12% NaCl home tx, then 7% HS|Subjects randomized to order BA will receive inhaled 0.12% NaCl mist during the first home treatment period, then Inhaled 7% HS home treatment during the second home treatment period.
11436203|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
11436204|NCT01792245|Active Comparator|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
11436205|NCT01792245|Active Comparator|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
11436206|NCT01792232|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
11436207|NCT01792232|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
11436208|NCT01792232|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
11436209|NCT01792232|Active Comparator|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
11436210|NCT01792219|Experimental|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
11436211|NCT01792206|Active Comparator|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
11436212|NCT01792206|Placebo Comparator|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
11436213|NCT01792193||Parkinson's disease|Patients with Parkinson's disease
11436214|NCT01792193||Control|Healthy controls
11436215|NCT01792180|No Intervention|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
11436216|NCT01792180|Experimental|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
11436217|NCT01792167|Experimental|Second Step|Second Step Curriculum
11436218|NCT01792167|No Intervention|Stories of Us|Stories of Us was provided to schools
11436219|NCT01792115|Active Comparator|Vit E 200 IU/d|Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
11436220|NCT01792115|Active Comparator|Vitamin E 400|Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
11436221|NCT01792115|Active Comparator|Vitamin E 800|Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
11436259|NCT01791855|Experimental|Moderate renal impairment|
11436260|NCT01791855|Experimental|Severe renal impairment|
11442456|NCT01749098|Experimental|PF-04958242|PF-04958242 and ketamine
11436222|NCT01792102|Experimental|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.
~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
11436223|NCT01792089||non-obese healthy subjects|subjects with BMI<25 and no known disease
11436224|NCT01792089||post-gastric bypass|post-obese subjects 12-48 months after Roux-en-Y gastric bypass
11436225|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
11436226|NCT01792063|Active Comparator|Sevoflurane A|Generic sevoflurane
11436227|NCT01792063|Active Comparator|Sevoflurane B|Orginal sevoflurane
11436228|NCT01792050|Placebo Comparator|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
11436229|NCT01792050|Experimental|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
11436230|NCT01792050|Placebo Comparator|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
11436231|NCT01792050|Experimental|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
11436232|NCT01792037|Active Comparator|Etomidate|After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
11436233|NCT01792037|Active Comparator|etomidate, steroid|After taking of the blood samples, patients in Group II will be intubated with 0.3 mg/kg etomidate iv following a 2mg/kg methylprednisolone iv Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
11436234|NCT01792037|Active Comparator|midazolam|"After taking of the blood samples, patients in Group III will be intubated with 0.01 mg/kg midazolam iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.
~Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired."
11436235|NCT01792024|Experimental|Treatment (LITT)|Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.
11436236|NCT01792011|Experimental|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
11436237|NCT01791998|Experimental|Treatment (MR-thermal image guided LITT)|Patients undergo MR-thermal image guided LITT over 1 hour.
11436238|NCT01791985|Experimental|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).
~AZD4547 will be given on an intermittent schedule of one week on / one week off."
11436239|NCT01791972|Experimental|Albuterol Spiromax / Placebo Spiromax|Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
11436240|NCT01791972|Experimental|Placebo Spiromax / Albuterol Spiromax|Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.
11436241|NCT01791959|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
11436242|NCT01791959|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
11436243|NCT01791946|Experimental|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
11436244|NCT01791946|Experimental|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
11436245|NCT01791946|Sham Comparator|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
11436246|NCT01791933||CAM treatment|
11436247|NCT01791920|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
11436248|NCT01791920|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A
11436249|NCT01791907|Experimental|Structured education in carbohydrate counting|A structured education in carbohydrate counting, a course inspired by the DAFNE program (Dose Adjustment For Normal Eating)
11436250|NCT01791907|Experimental|Structured education in healthy food choices and low GI|"A new, structured education for heart healthy food choices and low glycemic index in type 1 diabetes. The education is called My Wellness-LADDER (Lifelong Adult Diet & Diabetes Education Resource) and it is specifically designed to provide high long-term adherence through improved empowerment and transformative life style change."
11436251|NCT01791907|No Intervention|Regular routine|
11436252|NCT01791894|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11436253|NCT01791881|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
11436254|NCT01791881|Experimental|Botulinum toxin type A(Hugeltox)|Botulinum toxin type A(Hugeltox)
11436255|NCT01791868|Experimental|Intravenous sodium valproate|"Intravenous sodium valproate:
~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
11436256|NCT01791868|Placebo Comparator|Intravenous Placebo|"Intravenous Placebo:
~NaCl 0,9 % during 15 min at first then during 12 h."
11436257|NCT01791855|Experimental|Healthy Volunteers|
11436258|NCT01791855|Experimental|Mild Renal Impairment|
11549801|NCT01005784|Experimental|flexible|
11436261|NCT01791842|Experimental|Tocilizumab first, then placebo|one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.
11436262|NCT01791842|Experimental|Placebo first, then Tocilizumab|one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.
11436263|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
11436264|NCT01791816|Experimental|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
11436265|NCT01791803|Experimental|Hypnotherapy|Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after discharge.
11436266|NCT01791803|Experimental|Nicotine Replacement Therapy|Patients recieved a free one month supply of Nicotine replacement therapy to include patches and Gum, lozenges or sprays. Patients also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after hospitalization.
11436267|NCT01791803|Experimental|Hypnotherapy and Nicotine replacement|The group received similar hypnotherapy session and tape, similar brochure and counseling protocol, as well as free nicotine replacement supplies for a month after discharge.
11436268|NCT01791803|No Intervention|Self-Quit group|Patients were given brief counseling during hospitalization and will not be contacted until 26 weeks after hospitalization.
11436269|NCT01791790|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
11436270|NCT01791790|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
11436271|NCT01791777|Experimental|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
11436272|NCT01791777|Experimental|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
11436273|NCT01791751|Experimental|Clomifene Citrate|Clomifene Citrate 50 mg
11436274|NCT01791751|No Intervention|Control|No intervention
11436275|NCT01791738|Experimental|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
11436276|NCT01791738|No Intervention|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
11436277|NCT01791725|Experimental|ELND005 BID|ELND005 250 mg BID
11436278|NCT01791725|Experimental|ELND005 QD|ELND005 250 mg QD
11436279|NCT01791725|Placebo Comparator|Placebo|Placebo BID
11436280|NCT01791712|Experimental|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
11436281|NCT01791712|Active Comparator|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
11436282|NCT01791699|Placebo Comparator|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.
~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
11436283|NCT01791699|Active Comparator|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.
~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
11436284|NCT01791686|Experimental|Dense Deposit Disease|"► Induction Period
~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.
~► Maintenance Period
~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.
~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
11436285|NCT01791673|Experimental|Ultrasound Glaucoma treatment|Cyclocoagulation using High Intensity Focused Ultrasound (HIFU)
11436286|NCT01791660|Experimental|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
11436287|NCT01791647|Active Comparator|myo-inositol|1500 mg/day myoinositol
11436288|NCT01791647|Active Comparator|metformin|1500 mg/day of metformin
11436289|NCT01791634|Experimental|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
11436290|NCT01791634|Active Comparator|proximal wedge osteotomy|Proximal wedge osteotomy procedure
11436291|NCT01791621|Experimental|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
11436292|NCT01791608|Active Comparator|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
11436293|NCT01791608|Experimental|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
11436294|NCT01791608|Placebo Comparator|Milk without fortification|Milk without zinc
11436335|NCT01791231|Experimental|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
11549922|NCT01004861|Experimental|PLX3397|
11436295|NCT01791556|No Intervention|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
11436296|NCT01791556|Experimental|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
11436297|NCT01791543|Experimental|Intramural Needle Catheter Ablation|Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter
11436298|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation > 48h.
11436299|NCT01791517|Other|Lens A (senofilcon A)|Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
11436300|NCT01791517|Other|Lens B (galyfilcon A)|Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
11436301|NCT01791517|Other|Lens C (etafilcon A)|Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
11436302|NCT01791504|Experimental|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
11436303|NCT01791504|No Intervention|Control - Standard of Care|Standard wound closure techniques with drains.
11436304|NCT01791491|Experimental|Belatacept|
11436305|NCT01791478|Experimental|Treatment (PI3K inhibitor BYL719, letrozole)|Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11436306|NCT01791465|Experimental|Bydureon treatment|Treatment for 16 weeks with extended-release Exenatide (Bydureon)
11436307|NCT01791452||NAFLD|
11436308|NCT01791439|Experimental|Lidocaine|Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.
11436309|NCT01791439|Placebo Comparator|Saline|Application of saline to the glossopharyngeal nerve.
11436310|NCT01791426|Experimental|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
11436311|NCT01791426|Active Comparator|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
11436312|NCT01791413|Active Comparator|depot medroxyprogesterone acetate|
11436313|NCT01791413|No Intervention|No depot medroxyprogesterone acetate|
11436314|NCT01791400|Other|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
11436315|NCT01791400|Other|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
11436316|NCT01791387|Experimental|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
11436317|NCT01791374|Experimental|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
11436318|NCT01791374|Experimental|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
11436319|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
11436320|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
11436321|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
11436322|NCT01791348|Other|d2 test of attention|
11436323|NCT01791335||COPD patients receiving NIV|
11436324|NCT01791309|Experimental|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
11436325|NCT01791296|Experimental|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
11436326|NCT01791296|Placebo Comparator|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
11436327|NCT01791283||Healthy volunteers|Healthy volounteers with no previous medical history, age between 20-40. Both male and female. Subjects are provided extensive information about the study and the obligations and expectations included. All subjects sign a witnessed informed consent before inclusion.
11436328|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
11436329|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
11436330|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
11436331|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
11436332|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
11436333|NCT01791244|Active Comparator|Technical support for the RebiSmart™ device|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
11436334|NCT01791244|Experimental|Subject support program (MinSupport Plus)|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
11436336|NCT01791218|Experimental|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
11436337|NCT01791218|Active Comparator|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
11436338|NCT01791205||Monotherapy|Eligible participants who received any biologic drug as a monotherapy in the 12 months prior to the study entry will be observed for Phase I. Participants who were enrolled in Phase I and received tocilizumab (TCZ) as a monotherapy will be observed for 18 months from the first infusion of TCZ in Phase II, where TCZ was prescribed according to the approved product information, local treatment guidelines and/or routine clinical practice.
11436339|NCT01791205||Combination Therapy|Eligible participants who received any biologic drug in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the 12 months prior to study entry will be observed for Phase I.
11436340|NCT01791192|Experimental|FTY720|Fingolimod
11436341|NCT01791192|Active Comparator|Oral Corticosteroid|Oral Corticosteroid
11436342|NCT01791179|Experimental|Substance Abuse Treatment Group|
11436343|NCT01791166|Experimental|Pulmonary transplant|
11436344|NCT01791153|Experimental|Part 1: Tocilizumab qw + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
11436345|NCT01791153|Experimental|Part 1: Tocilizumab q2w + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
11436346|NCT01791153|Placebo Comparator|Part 1: Placebo + 26 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
11436347|NCT01791153|Placebo Comparator|Part 1: Placebo + 52 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
11436348|NCT01791153|Experimental|Part 2: Open-Label Tocilizumab qw|Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
11436349|NCT01791140||Cohort|
11436350|NCT01791127||Pacemaker Therapy|Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.
11436351|NCT01791114|Experimental|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
11436352|NCT01791114|Experimental|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
11436353|NCT01791114|Experimental|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold ~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
11436354|NCT01791114|Experimental|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
11436355|NCT01791101|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
11436356|NCT01791088|Experimental|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11436357|NCT01791075|Active Comparator|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
11436358|NCT01791075|Active Comparator|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
11436359|NCT01791062|Experimental|HYTOP®|
11436360|NCT01791049|Experimental|Active|Single escalating doses of TD-1607, administered intravenously
11436361|NCT01791049|Placebo Comparator|Placebo|Placebo
11436362|NCT01791036|Experimental|Adductor Canal Block Group|Adductor Canal Block
11436363|NCT01791036|Active Comparator|Femoral Nerve Block Group|Femoral Nerve Block
11436364|NCT01791023|Experimental|Physical exercise|Physical exercise
11436365|NCT01791010|Experimental|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
11436366|NCT01791010|Sham Comparator|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
11436367|NCT01790997|Experimental|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
11436368|NCT01790997|Active Comparator|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
11436369|NCT01790997|Active Comparator|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
11436370|NCT01790984|Experimental|High sugar low starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
11436443|NCT01790477|No Intervention|Control|
11436444|NCT01790464|Placebo Comparator|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
11436371|NCT01790984|Experimental|Low sugar high starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
11436372|NCT01790971|Active Comparator|Intrathecal morphine|100μg of morphine will be added to the intrathecal mixture.
11436373|NCT01790971|Active Comparator|No Intrathecal morphine|Morphine will not be added to the intrathecal mixture.
11436374|NCT01790945||No treatment Study|Population of subjects will have been diagnosed with mild NPDR, Moderate NPDR, Severe NPDR, PDR and DME
11436375|NCT01790932|Experimental|BKM120|"BKM120: 100 mg capsule once daily each day of a 28 day cycle .
~Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons."
11436376|NCT01790919|Experimental|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
11436377|NCT01790919|Active Comparator|Cognitive therapy|Cognitive therapy for depression
11436378|NCT01790906|Active Comparator|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
11436379|NCT01790906|Placebo Comparator|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
11436380|NCT01790893|Experimental|intravitreal aflibercept injection|"Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.
~."
11436381|NCT01790893|Experimental|intravitreal aflibercept|Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
11436382|NCT01790880|Active Comparator|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
11436383|NCT01790880|Experimental|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
11436384|NCT01790854|Experimental|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
11436385|NCT01790854|Active Comparator|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
11436386|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
11436387|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
11436388|NCT01790828||Xyntha group|Xyntha will be administered according to physician's discretion.
11436389|NCT01790802|Experimental|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
11436390|NCT01790802|Sham Comparator|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
11436391|NCT01790789|Experimental|Stress reduction program|
11436392|NCT01790789|Other|Attention control|
11436393|NCT01790776|Active Comparator|Conventional urethrography|Current golden standard.
11436394|NCT01790776|Experimental|Sono-urethrography|Experimental urethrography, which could be followed by conventional urethrography if the results are inconclusive.
11436395|NCT01790763|Active Comparator|Keramatrix|Keramatrix
11436396|NCT01790763|Active Comparator|Mepilex|Mepilex
11436397|NCT01790750|Other|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
11436398|NCT01790737|Active Comparator|A|Cyclophosphamide plus filgrastim
11436399|NCT01790737|Active Comparator|B|Filgrastim
11436400|NCT01790724|Experimental|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
11436401|NCT01790724|Active Comparator|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
11436402|NCT01790711|Experimental|FMT by endoscopy|Once, fresh or frozen bacteria
11436403|NCT01790685|Other|CRVO|Central Retinal Vein Occlusion
11436404|NCT01790685|Other|BRVO|Branch Retinal Vein Occlusion
11436405|NCT01790672|Placebo Comparator|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
11436406|NCT01790672|Active Comparator|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.
~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
11436407|NCT01790672|Placebo Comparator|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
11436445|NCT01790464|Active Comparator|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
11436408|NCT01790672|Active Comparator|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.
~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.
~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
11436409|NCT01790659|Experimental|WR 279,396|(Paromomycin and Gentamicin Topical Cream)
11436410|NCT01790659|Experimental|Paromomycin|Paromomycin alone
11436411|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
11436412|NCT01790633|Active Comparator|Standard testing with ELISA|HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
11436413|NCT01790633|Experimental|Rapid testing|HBV, HCV, and HIV infection status determined by a rapid test
11436414|NCT01790620|Experimental|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
11436415|NCT01790620|Active Comparator|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
11436416|NCT01790607|Experimental|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
11436417|NCT01790607|Experimental|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
11436418|NCT01790607|Experimental|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
11436419|NCT01790607|Experimental|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
11436420|NCT01790607|Experimental|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
11436421|NCT01790594|Active Comparator|Immunosuppression without Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;
~Induction: Anti-thymocyte Globulin (Rabbit);
~Maintenance Immunosuppression: Tacrolimus (or generic). The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed, then adjusted to target trough levels of 8-12 ng/ml during the first 24 weeks post-transplant, then adjusted to target trough levels of 5-8 ng/ml thereafter.
~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
11436422|NCT01790594|Experimental|Immunosuppression Including Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;
~Induction: Anti-thymocyte Globulin (Rabbit);
~Maintenance Immunosuppression: Belatacept
~Maintenance Immunosuppression: Tacrolimus (or generic)- The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed. The dosage will be adjusted to achieve the following therapeutic trough levels: 5-8 ng/ml during the first 24 weeks post-transplant and then 3-5 ng/ml until day 280 (week 40). Subjects may be withdrawn if they meet all the criteria defined below.
~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
11436423|NCT01790581|Active Comparator|Balance Training|
11436424|NCT01790581|Experimental|Balance Training w/ STARS|
11436425|NCT01790568|Experimental|Vorinostat|Vorinostat, in combination with standard of care medications tacrolimus and methotrexate, for GVHD prophylaxis after unrelated donor stem cell transplant.
11436426|NCT01790555|Experimental|Namisol|The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
11436427|NCT01790555|Other|Diazepam/Placebo|"The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
~Before surgery, diazepam is used as an active comparator, to aid in blinding. After surgery, an inactive placebo is used as an inactive comparator."
11436428|NCT01790542|Other|A|Iron fortified cereal
11436429|NCT01790542|Other|B|Iron fortified cereal with fruit
11436430|NCT01790542|Other|C|Meat
11436431|NCT01790529|Experimental|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
11436432|NCT01790529|Active Comparator|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
11436433|NCT01790516|Experimental|Cisplatin|Cisplatin
11436434|NCT01790516|Experimental|Cetuximab|cetuximab
11436435|NCT01790503|Experimental|Phase 1b dose escalation - 600mg/day PLX3397 cohort|600mg/day PLX3397, Radiation Therapy, and Temozolomide
11436436|NCT01790503|Experimental|Phase 1b dose escalation - 800mg/day PLX3397|800mg/day PLX3397, Radiation Therapy, and Temozolomide
11436437|NCT01790503|Experimental|Phase 1b dose escalation - 1000 mg/day PLX3397 cohort|1000 mg/day PLX3397, Radiation Therapy, and Temozolomide
11436438|NCT01790503|Experimental|Phase 2 - Recommended phase 2 dose of PLX3397|Recommended phase 2 dose of PLX3397 (800mg/day), Radiation therapy, and Temozolomide
11436439|NCT01790490|Experimental|K1|Ketamine 0.41 mg/kg infused over 52 min (K1)
11436440|NCT01790490|Experimental|K2|Ketamine 0.71 mg/kg infused over 52 min (K2)
11436441|NCT01790490|Experimental|LZP|Lorazepam 2 mg infused over 52 minutes (LZP)
11436442|NCT01790477|Experimental|Auricular Acupuncture|Use of auricular acupuncture in bilateral ears
11436446|NCT01790451|Active Comparator|peripheral ablation|an ablation of the peripheral area of the prostate
11436447|NCT01790451|Active Comparator|More central ablation|an ablation, more centrally, in proximity of the urethra
11436448|NCT01790438|Experimental|LY2605541|Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
11436449|NCT01790438|Active Comparator|Human Insulin NPH|Administered by SC injection once daily at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on FBG. Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks. Some participants who are unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may be asked to add a second injection prior to the morning meal.
11436450|NCT01790425|Experimental|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
11436451|NCT01790425|Active Comparator|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
11436452|NCT01790412|Experimental|Exercise group|"Three sessions per week:
~Supervised exercise program"
11436453|NCT01790412|No Intervention|Control|Sedentary pregnant women
11436454|NCT01790399|Experimental|Identification of sentinel node(s)|
11436455|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
11436456|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
11436457|NCT01790373|Experimental|Suubi+Adherence|"Suubi+Adherence intervention arm provides:
~Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.
~Financial education and workshops on asset-building, future planning, and protection from risks
~Mentorship from a young adult/near-peer
~Family-based microenterprise development training
~Bolstered Standard of Care: Adherence Counseling Practices
~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.
~Medical Standard of Care:
~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda
~Psychosocial Standard of Care:
~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
11436458|NCT01790373|Active Comparator|Bolstered Standard of Care|"Bolstered Standard of Care: Adherence Counseling Practices
~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.
~Medical Standard of Care:
~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda
~Psychosocial Standard of Care:
~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
11436459|NCT01790360|Active Comparator|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
11436460|NCT01790360|Experimental|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
11436461|NCT01790347|Experimental|Exercise group|
11436462|NCT01790347|No Intervention|Control group|Sedentary pregnant women
11436463|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
11436464|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
11436465|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
11436466|NCT01790321|No Intervention|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
11436467|NCT01790321|Placebo Comparator|Filtered water|Pump water purified by the LSF-filtering device
11436468|NCT01790321|Experimental|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
11436469|NCT01790308|Active Comparator|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
11436470|NCT01790308|Active Comparator|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
11436471|NCT01790295|Experimental|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 62 days (day -67) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
11436472|NCT01790282|Experimental|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
11436473|NCT01790282|Active Comparator|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
11436474|NCT01790269||fingolimod treated patients|Indication for on-label treatment with fingolimod (Gilenya®) according to the current approval
11436475|NCT01790256|Active Comparator|Cereve Sleep System at 14-16 degrees C.|Active
11436476|NCT01790256|Active Comparator|Cereve Sleep System at 30 degrees C|Active
11436477|NCT01790243|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
11436478|NCT01790243|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
11436479|NCT01790230|No Intervention|Standard of Care|Standard of Care Arm - subjects treated by routine manner
11436480|NCT01790230|Experimental|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
11436482|NCT01790204|Experimental|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
11436483|NCT01790191|Experimental|RE group|Repeated consumption of artichoke purée. This group was exposed to basic artichoke puree from Exposure 1 to 10 (E1 to E10)
11436484|NCT01790191|Active Comparator|FFL group|Repeated consumption of artichoke purée. This group (Flavor-flavor learning group) was exposed to sweet artichoke puree from Exposure 1 to 10 (E1 to E10).
11436485|NCT01790191|Active Comparator|FNL group|Repeated consumption of artichoke purée. This group (Flavor-nutrient learning group) was exposed to fat, energy-dense artichoke puree from Exposure 1 to 10 (E1 to E10).
11436486|NCT01790178|Experimental|Ultrasound Guided Biopsy|Ultrasound guided biopsy will be used in all patients.
11436487|NCT01790178|No Intervention|Non-Ultrasound Guided Group|The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.
11436488|NCT01790165|Experimental|TDT067|Active treatment
11436489|NCT01790165|Placebo Comparator|Placebo|Placebo
11436490|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
11436491|NCT01790139|No Intervention|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
11436492|NCT01790139|Experimental|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
11436493|NCT01790126|Active Comparator|ARN-509|ARN-509 Tablets, 240 mg/day administered orally
11436494|NCT01790126|Active Comparator|LHRH agonist + ARN-509|Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
11436495|NCT01790126|Active Comparator|LHRH agonist|Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
11436496|NCT01790113|Active Comparator|Univer™ II|Univers™ II Total Shoulder Replacement
11436497|NCT01790113|Experimental|Eclipse™|Eclipse™ Total Shoulder Replacement
11436498|NCT01790100|Experimental|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
11436499|NCT01790100|Experimental|VX-135 high dose in combination with ribavirin|
11436500|NCT01790087|Experimental|ANX-188 Therapeutic dose level|IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
11436501|NCT01790087|Experimental|ANX-188 Supratherapeutic dose|IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
11436502|NCT01790087|Placebo Comparator|Saline|IV administration. Six hour infusion.
11436503|NCT01790087|Active Comparator|Moxifloxacin|Oral tablet. 400 mg.
11436504|NCT01790074|Experimental|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
11436505|NCT01790074|Placebo Comparator|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
11436506|NCT01790061|Experimental|Standardized FMT|endoscopy Tubing Once or repeat
11436507|NCT01790061|Experimental|Traditional treatments|Oral Tubing
11436508|NCT01790048|Experimental|Whey permeate RUSF|75 kcal/kg/day (314 k Joules (kJ)/kg/day) of whey RUSF. Whey RUSF contains whey permeate, Whey Permeate (WPC) 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier. Whey permeate RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
11436509|NCT01790048|Active Comparator|Soy Protein RUSF|75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources. Soy RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
11436510|NCT01790035|Experimental|LGG|LGG (containing 10^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
11436511|NCT01790035|Experimental|Placebo|Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
11436512|NCT01790035|No Intervention|No intervention|Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT. These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
11436513|NCT01790022|Experimental|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
11436514|NCT01790009|Active Comparator|Flavanol Rich drink|Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)
11549962|NCT01004445|Experimental|Arm 1|
11436517|NCT01789996|Active Comparator|Alternative six minute walk test|"Subjects will be given the following instructions
~walk as fast as they can in 6 minutes
~walk as normally as they can in 6 minutes
~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
11436518|NCT01789996|Placebo Comparator|Standard six minute walk test|"Subjects will be given the following instruction
~1. walk as far as they can in 6 minutes"
11436519|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
11436520|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
11436521|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
11436522|NCT01789970|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets twice a day that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
11436523|NCT01789970|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets twice a day at the dosage deemed successful for managing their pain during the titration period.
11436524|NCT01789957|Experimental|Open-label AC2993|
11436525|NCT01789944|Experimental|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
11436526|NCT01789944|Experimental|Treatment Only|Peers receive treatment and return for a 6-month follow-up
11436527|NCT01789931|Experimental|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
11436528|NCT01789918|Experimental|Percutaneous renal denervation|PARADISE percutaneous renal denervation
11436529|NCT01789905||Tigecycline (Tygacil)|Subjects who are treated with tigecycline
11436530|NCT01789892|Experimental|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
11436531|NCT01789879|Active Comparator|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
11436532|NCT01789879|Active Comparator|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
11436533|NCT01789879|Active Comparator|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
11436534|NCT01789853|Experimental|Intensive Walking|High intensity walking training in variable context for 8 weeks
11436535|NCT01789853|Active Comparator|Conventional Physical Therapy|Regular physical therapy for 8 weeks
11436536|NCT01789840|Experimental|Prostate artery emoblization (PAE)|Prostate artery embolization using Embosphere Microspheres
11436537|NCT01789840|Active Comparator|Transurethral resection of the prostate (TURP)|Transurethral Resection of the Prostate (TURP)
11436538|NCT01789827|Experimental|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
11436539|NCT01789827|Experimental|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
11436540|NCT01789814|Active Comparator|Prasugrel|Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
11436541|NCT01789814|Active Comparator|Clopidogrel|Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention
11436542|NCT01789801|Active Comparator|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.
~Intervention: RAP palpation only"
11436543|NCT01789801|Experimental|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.
~Intervention: RAP with ultrasound guidance"
11436544|NCT01789788|Placebo Comparator|Placebo|
11436545|NCT01789788|Experimental|RO6811135|
11436546|NCT01789775|Placebo Comparator|CD07805/47 gel Placebo|Placebo
11436547|NCT01789775|Experimental|CD07805/47 gel|Intervention: Drug: CD07805/47 gel
11436548|NCT01789762|Active Comparator|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
11436549|NCT01789762|Active Comparator|Control arm|Patients transfused with platelets prepared in additive solution
11436550|NCT01789762|Experimental|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
11436551|NCT01789749|Active Comparator|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
11436552|NCT01789749|Experimental|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
11436553|NCT01789736|Experimental|PG286|PG286 Ophthalmic Solution q.d. O.U.
11436554|NCT01789736|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
11436555|NCT01789736|Active Comparator|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
11436556|NCT01789723|Experimental|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.
~Folotyn: 30 mg/m2 once weekly for 6 weeks"
11436557|NCT01789723|Experimental|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.
~Folotyn: 30 mg/m2 once weekly for 6 weeks"
11436558|NCT01789723|Experimental|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.
~Folotyn: 30 mg/m2 once weekly for 6 weeks"
11436559|NCT01789723|Experimental|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.
~Folotyn: 30 mg/m2 once weekly for 6 weeks"
11436560|NCT01789723|Experimental|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.
~Folotyn: 30 mg/m2 once weekly for 6 weeks"
11436561|NCT01789710|Experimental|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
11436562|NCT01789697|Experimental|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
11436563|NCT01789697|No Intervention|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
11436564|NCT01789684|Experimental|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
11436565|NCT01789684|No Intervention|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
11436566|NCT01789671|Experimental|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
11436567|NCT01789671|Active Comparator|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
11436568|NCT01789658|Experimental|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
11436569|NCT01789658|No Intervention|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
11436570|NCT01789645|Experimental|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
11436571|NCT01789645|Active Comparator|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
11436572|NCT01789619||Extended release tacrolimus (Advagraf®)|
11436573|NCT01789606|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|
11436574|NCT01789593|Other|Hypoglycaemia / euglycaemia clamp|
11436575|NCT01789593|Other|Euglycaemia clamp / hypoglycaemia|
11436576|NCT01789580|No Intervention|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
11436577|NCT01789580|Experimental|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
11436578|NCT01789580|Experimental|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
11436579|NCT01789580|Experimental|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
11436580|NCT01789580|Experimental|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
11436581|NCT01789567|Other|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
11436582|NCT01789554|Experimental|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
11436583|NCT01789554|No Intervention|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
11436584|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
11436585|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
11436586|NCT01789528|Experimental|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours
~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
11436587|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
11436588|NCT01789502|Active Comparator|Plastic stents|Plastic stents are inserted by ERCP
11436589|NCT01789502|Experimental|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
11436590|NCT01789489|Active Comparator|3 dimensional sonohysterography|3 dimensional sonohysterography
11436591|NCT01789489|Active Comparator|Standard hysteroscopy|Standard hysteroscopy
11436592|NCT01789476|Experimental|CR845|Peripheral kappa opioid receptor agonist
11436593|NCT01789476|Placebo Comparator|Placebo|Matched placebo
11436594|NCT01789463|Active Comparator|Self rehabilitation|Self rehabilitation
11436595|NCT01789463|Experimental|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
11436596|NCT01789450|Experimental|Section of Periareolar Dermis|Section of Periareolar Dermis
11549963|NCT01004445|Experimental|Arm 2|
11436598|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
11436599|NCT01789398|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
11436600|NCT01789398|Placebo Comparator|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
11436601|NCT01789385|Other|dexmedetomidine|Precedex 200 mcg 2ml
11436602|NCT01789359|Other|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
11436603|NCT01789346|Other|532nm KTP laser|Cutera ExcelV 532nm KTP laser
11436604|NCT01789346|Active Comparator|595nm PDL|Cynosure Cynergy 595nm pulsed-dye laser
11436605|NCT01789333|Experimental|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
11436606|NCT01789320|Experimental|triamcinolone acetonide (Triesence®)|TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
11436607|NCT01789307|Active Comparator|corn syrup solids|corn syrup solids oral ingestion
11436608|NCT01789307|Experimental|sucrose|sucrose oral ingestion
11436609|NCT01789294|Experimental|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
11436610|NCT01789294|No Intervention|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
11436611|NCT01789294|Experimental|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
11436612|NCT01789281|Experimental|Everolimus|Patients who are receiving everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that has reached its study objectives, are not progressing on the current study treatment as defined by the parent protocol and are unable to access everolimus treatment outside of a clinical trial will be allowed to enroll. If patients are receiving treatment of everolimus in combination with other approved therapies, they can participate in the roll-over study, but it is not intended for combination with unapproved or experimental treatments. Patients who meet all inclusion and none of the exclusion criteria will be treated with the same daily everolimus dose they are receiving in the parent protocol until disease progression (as defined in the parent protocol), unacceptable toxicity develops, consent withdrawl, protocol non-compliance, the investigator feels it is no longer in the patient's best interest to continue therapy, or the patient's death.
11436613|NCT01789268||Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
11436614|NCT01789268||Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
11436615|NCT01789255|Experimental|Supportive care (vorinostat, tacrolimus, methotrexate)|Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
11436616|NCT01789242|Experimental|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
11436617|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
11436618|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
11436619|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
11436620|NCT01789216|Placebo Comparator|Placebo|Standard pain management + preoperative oral placebo + perioperative intravenous placebo & oral placebo. This group will serve as the control group. Patients will take an oral placebo pill twice daily for the first 14 days of the trial. A perioperative protocol will include an oral dose of placebo immediately prior to surgery and twice daily for 48 hours following any surgery, in addition to an intravenous dose of placebo immediately prior to surgery and every 6 hours for 48 hours following surgery. The oral protocol will be suspended while the patient is receiving medication from the perioperative protocol.
11436621|NCT01789216|Active Comparator|NSAID|Standard pain management + preoperative oral meloxicam + perioperative intravenous ketorolac & oral placebo. In addition to standard of care pain management, patients randomized to the NSAID group will receive an oral 7.5 mg dose of Meloxicam twice daily, to be initiated on enrollment and continued for 14 days or through definitive fixation, whichever comes first. The proposed dosing schedule represents the maximal safe dose of an adult population. Patients will receive intravenous (IV) ketorolac dosing surrounding all operative procedures leading up to and including the definitive fixation. The oral protocol will be suspended while the patient is receiving medication from the perioperative protocol. The proposed dosing schedule of 30 mg IV every 6 hours for the first 48 hours following procedure represents the maximal generally accepted safe dose of ketorolac currently in use for orthopedic surgery.
11436622|NCT01789216|Active Comparator|Gabapentinoid|Standard pain management + preoperative pregabalin + perioperative intravenous placebo & oral pregabalin. In addition to standard of care pain management, patients randomized to the pregabalin group will receive an oral 75mg dose of pregabalin twice daily, to be initiated on enrollment and continued for 14 days or through definitive fixation, whichever comes first.
11436623|NCT01789203|Active Comparator|Ciprofloxacin|Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
11436808|NCT01787747|Experimental|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
11436624|NCT01789203|Placebo Comparator|Placebo|Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
11436625|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
11436626|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
11436627|NCT01789177|Experimental|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
11436628|NCT01789177|Active Comparator|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
11436629|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
11436630|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
11436631|NCT01789138|Experimental|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention: see 'Interventions' for more details.
11436632|NCT01789138|No Intervention|Adherence counseling, standard of care|Standard of care: Antiretroviral therapy adherence is discussed with patient (study participant) according to usual practice in the medical institution no special protocol followed.
11436633|NCT01789125|Active Comparator|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
11436634|NCT01789125|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
11436635|NCT01789112|Experimental|CCM aggregate|Taking of 10 blood samples
11436636|NCT01789099|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
11436637|NCT01789086|Experimental|Liraglutide|
11436638|NCT01789086|Placebo Comparator|Placebo|
11436639|NCT01789073|Experimental|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
11436640|NCT01789073|No Intervention|Control|The control-arm receives no intervention but is treated according to the standard procedures
11436641|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
11436642|NCT01789047|Active Comparator|Topiramate|Topiramate as adjunct to amantadine.
11436643|NCT01789047|Placebo Comparator|Placebo (sugar pill)|Placebo
11436644|NCT01789008|Other|Transient elastography|evaluation of fibrosis stage by transient elastography
11436645|NCT01789008|Active Comparator|liver biopsie|evaluation of fibrosis stage by liver biopsie
11436646|NCT01788995||Cohort|
11436647|NCT01788982|Experimental|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
11436648|NCT01788982|Placebo Comparator|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
11436649|NCT01788969|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
11436650|NCT01788969|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
11436651|NCT01788956||ICU Patients|80 subjects (male and female)
11436652|NCT01788943||Slow metabolizers|Individuals with an NMR <0.26 will be classified as slow metabolizers.
11436653|NCT01788943||Normal metabolizers|Participants with an NMR >= 0.26 will be classified as normal metabolizers.
11436654|NCT01788930|Active Comparator|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
~Other Name: positive airway pressure"
11436655|NCT01788930|Placebo Comparator|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
11436656|NCT01788917|Active Comparator|linseed oil|
11436657|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
11436658|NCT01788891||second-line pediatric cohort|Asian HIV-positive children <18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
11436659|NCT01788878|Experimental|Questionnaires|completion of questionnaires
11436660|NCT01788865|Experimental|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
11436661|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
11436662|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
11436663|NCT01788852||HIV negative adolescents|HIV negative adolescents
11436664|NCT01788839||women with breast cancer|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
11436809|NCT01787747|Experimental|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
11436665|NCT01788839||women with lymphoma|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
11436666|NCT01788826|Experimental|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
11436667|NCT01788826|Experimental|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
11436668|NCT01788813|Experimental|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
11436669|NCT01788813|Placebo Comparator|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
11436670|NCT01788800|Experimental|Exercise training|"Cognitive Behavioural Therapy (CBT)
~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
11436671|NCT01788800|Active Comparator|Movements|"Cognitive Behavioural Therapy (CBT)
~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
11436672|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
11436673|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
11436674|NCT01788774|Other|Risperidone ISM 50mg|Three different single doses will be evaluated
11436675|NCT01788774|Other|Risperidone ISM 75mg|Three different single doses will be evaluated
11436676|NCT01788774|Other|Risperidone ISM 100mg|Three different single doses will be evaluated
11436677|NCT01788761|Experimental|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
11436678|NCT01788761|Sham Comparator|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
11436679|NCT01788748|Active Comparator|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
11436680|NCT01788748|Active Comparator|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
11436681|NCT01788748|Active Comparator|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
11436682|NCT01788722||Group 1|
11436683|NCT01788709|Active Comparator|A|Fortrans (split dose) + Mentholyptus drops
11436684|NCT01788709|Active Comparator|B|MoviPrep (split dose)
11436685|NCT01788696|Active Comparator|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
11436686|NCT01788696|Active Comparator|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
11436687|NCT01788683|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
11436688|NCT01788683|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
11436689|NCT01788670|Placebo Comparator|Water|Lemon-flavoured water (150 ml)
11436690|NCT01788670|Active Comparator|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
11436691|NCT01788670|Active Comparator|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
11436692|NCT01788657|Experimental|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
11436693|NCT01788657|Experimental|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
11436694|NCT01788644||No treatment (observational study)|
11436695|NCT01788631|Active Comparator|Regadenoson Arm|1.44 mcg/kg/hour infused over 48 hours
11436696|NCT01788631|Placebo Comparator|Placebo Arm|Placebo infused over 48 hours
11436697|NCT01788618|Other|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
11436810|NCT01787747|Experimental|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
11436698|NCT01788618|Other|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
11436699|NCT01788618|Other|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
11436700|NCT01788605|Experimental|ramosetron|
11436701|NCT01788592||Drug eluting stent|Patients who receiving drug eluting stents
11436702|NCT01788579|Experimental|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
11436703|NCT01788579|Active Comparator|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
11436704|NCT01788566|Experimental|Gemcitabine + Cisplatin + Necitumumab|"Necitumumab administered intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.
~Gemcitabine administered IV at 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.
~Cisplatin administered IV at 75 mg/m^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
11436705|NCT01788553||patients with generalized anxiety disorder|
11436706|NCT01788540|Experimental|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.
~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
11436707|NCT01788540|No Intervention|Control|No intervention
11436708|NCT01788527|Experimental|CGM|Continuous Glucose Monitoring
11436709|NCT01788527|No Intervention|HGM|Standard of care, Home Glucose Monitoring
11436710|NCT01788514|Other|Videogame|Subject will play educational videogame
11436711|NCT01788501|Experimental|Tacrolimus/Methotrexate|"Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)
~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
11436712|NCT01788501|Active Comparator|Cyclosporine/Methotrexate|"Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
11436713|NCT01788488|No Intervention|Standard Therapy|
11436714|NCT01788488|Experimental|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
11436715|NCT01788475|Active Comparator|Dexamethasone implant up to every 3 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.
~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.
~Re-implantation of Ozurdex (dexamethasone) may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:
~Increase of > 50 microns from the best previous CRT measurement
~Recurrence of intraretinal cystic edema
~Persistent intraretinal cystic edema"
11436716|NCT01788475|Active Comparator|Dexamethasone implant up to every 6 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.
~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.
~Re-implantation of Ozurdex (dexamethasone) may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:
~Increase of > 50 microns from the best previous CRT measurement
~Recurrence of intraretinal cystic edema
~Persistent intraretinal cystic edema"
11436717|NCT01788475|Sham Comparator|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.
~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.
~Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:
~Increase of > 50 microns from the best previous CRT measurement
~Recurrence of intraretinal cystic edema
~Persistent intraretinal cystic edema"
11436718|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
11436719|NCT01788436|Experimental|Group 1: Patients with schizophrenia|
11436720|NCT01788436|Active Comparator|Group 2: Young healthy volunteers|
11436721|NCT01788436|Experimental|Group 3: Elderly healthy volunteers|
11436722|NCT01788423|Experimental|Audiologist-Based|Audiologist selects hearing aid for patient
11436723|NCT01788423|Experimental|Consumer Decides|Consumer selects hearing aid
11436724|NCT01788423|Placebo Comparator|Placebo|Patient fitted with hearing aid that is acoustically transparent.
11436725|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
11436726|NCT01788397|Experimental|Physical activity|Physical activity 2-4 times pr. day
11436727|NCT01788397|No Intervention|Control group|No intervention in the control group
11436728|NCT01788384|Active Comparator|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
11436729|NCT01788384|Experimental|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
11436730|NCT01788384|Placebo Comparator|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
11436731|NCT01788371|No Intervention|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
11436732|NCT01788371|Experimental|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
11436733|NCT01788371|Experimental|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
11436734|NCT01788358|Experimental|Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)|Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) for 28 or 52 weeks. The starting dose (30/8 milligram [mg] or 30/16 mg) was determined based on local practice and clinical judgment by the investigator. Based on the experience of symptomatic and asymptomatic hypotension, peripheral edema or significant tolerability, the doses were up-titrated to the highest target dose (60/32 mg).
11436735|NCT01788345|Experimental|non-invasive ventilation|
11436736|NCT01788332|Active Comparator|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
11436737|NCT01788332|Placebo Comparator|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
11436738|NCT01788319|Experimental|lasertrabeculoplasty|
11436739|NCT01788306|Active Comparator|Intervention (OOPEN+BBCC)|Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
11436740|NCT01788306|No Intervention|Control|Standard of care, referral to local available resources.
11436741|NCT01788293|Active Comparator|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
11436742|NCT01788293|No Intervention|Control group|Control group will receive fluid at the discretion of the anesthetist
11436743|NCT01788280|Experimental|All participants|All enrolled participants
11436744|NCT01788267|Experimental|Healthy volunteers|Volunteers realize a HR-pQCT scanner
11436745|NCT01788267|Experimental|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
11436746|NCT01788254|Experimental|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
11436747|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
11436748|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine 18-64 Years Group|Subjects 18-64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
11436749|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine > 64 Years Group|Subjects >64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
11436750|NCT01788215|Active Comparator|Doxycycline|Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
11436751|NCT01788215|Placebo Comparator|Sugar Pill|The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
11436752|NCT01788189|Experimental|Lenalidomide|"The LeMLAR protocol:
~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.
~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
11436753|NCT01788176|Placebo Comparator|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
11436754|NCT01788176|Active Comparator|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
11436755|NCT01788163|Other|Locally advanced/metastatic NSCLC pats.|Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
11436756|NCT01788150|Experimental|Svelte Drug-Eluting Coronary Stent|Coronary Stenting
11436757|NCT01788150|Active Comparator|Medtronic Resolute Integrity Drug-Eluting Stent|Coronary Stenting
11436758|NCT01788137|Active Comparator|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
11436759|NCT01788137|Active Comparator|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
11436760|NCT01788124||Metal Speculum|exam with metal speculum
11436761|NCT01788124||Plastic Speculum|exam with plastic speculum
11436762|NCT01788111|Experimental|Low back exercises 1|Specific low back extensor exercises in special training bench
11436763|NCT01788111|Active Comparator|Low back exercise 2|Traditional low back exercises.
11436764|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
11436765|NCT01788098||Healthy controls|Healthy control subjects
11436766|NCT01788085|Experimental|pH monitoring procedure|Bravo pH monitoring procedure
11436767|NCT01788072|Active Comparator|Intranasal Oxytocin|
11436768|NCT01788072|Placebo Comparator|Placebo|
11436769|NCT01788059|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
11436770|NCT01788046|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
11436771|NCT01788046|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
11436772|NCT01788033|Active Comparator|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
11436773|NCT01788033|Placebo Comparator|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
11436774|NCT01788020|Experimental|DRC+Bortezomib|"Induction experimental arm (Arm B):
~Cycle 1-6:
~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15 Dexamethasone 20 mg p.o. Day 1 Rituximab 375 mg/m2 i.v. Day 1 Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5 Repeat day 29."
11436775|NCT01788020|Active Comparator|DRC|"Induction standard arm (Arm A)
~Cycle 1-6:
~Dexamethasone 20 mg p.o. Day 1 Rituximab 375 mg/m2 i.v. Day 1 Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5 Repeat day 29."
11436776|NCT01788007|Experimental|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
11436777|NCT01788007|Placebo Comparator|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
11436778|NCT01788007|Active Comparator|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
11436779|NCT01787994|Experimental|Cohort 1|"Cohort 1: HIV-1-positive women and men ≥18 years with a CD4 count > 350 cells/mm3, HIV-1-RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV-1 RNA < 400 copies/mL are also eligible; however, the HIV-1 RNA must be < 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (> 50 but <1,000 copies RNA/mL; blips) will be eligible.
~There should be at least 2 documented HIV-1 RNA assays, one drawn >3 months before study entry, one drawn <3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.
~Cohort 1 subjects will receive a single dose of MazF-T cells."
11436780|NCT01787994|Experimental|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count > 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.
~Cohort 2 subjects will receive a single dose of MazF-T cells."
11436781|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
11436782|NCT01787955|Experimental|Braun anastomosis group|
11436783|NCT01787955|Active Comparator|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
11436784|NCT01787942|Active Comparator|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
11436785|NCT01787942|Placebo Comparator|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
11436786|NCT01787929|Other|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
11436787|NCT01787929|Other|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
11436788|NCT01787916|Experimental|Liraglutide|Liraglutide, s.c., 1.8 mg, die, 24 weeks
11436789|NCT01787916|Placebo Comparator|Placebo|Liraglutide placebo (visually identical to study drug) will be given s.c. 1.8 mg for 24 weeks
11436790|NCT01787903|Active Comparator|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
11436791|NCT01787903|Placebo Comparator|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
11436792|NCT01787877||Stroke patients reporting to the ER|
11436793|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.
~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
11436794|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.
~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
11436795|NCT01787851|Active Comparator|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
11436796|NCT01787851|Placebo Comparator|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
11436797|NCT01787838|Other|health education, audit and feedback|Focused health education for staff and patients.
11436798|NCT01787825|Other|PillCam SB2 then CapsoCam SV-1|PillCam SB2 capsule then CapsoCam SV-1 capsule
11436799|NCT01787825|Other|CapsoCam SV-1 then PillCam SB2|CapsoCam SV-1 capsule then PillCam SB2 capsule
11436800|NCT01787799|Experimental|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)
11436801|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
11436802|NCT01787773|Experimental|Veniti Inferior Vena Cava Filter|
11436803|NCT01787760|Experimental|Test Soft Contact Lens B|Lenses will be worn in a daily disposable modality
11436804|NCT01787760|Experimental|Test Soft Contact Lens C|Lenses will be worn in a daily disposable modality
11436805|NCT01787760|Active Comparator|Spectacle Lenses|Control spectacle lenses worn daily.
11436806|NCT01787747|Experimental|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
11436807|NCT01787747|Experimental|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
11436811|NCT01787721|Experimental|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
11436812|NCT01787721|Sham Comparator|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
11436813|NCT01787708|Active Comparator|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).
~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
11436814|NCT01787708|Active Comparator|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).
~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
11436815|NCT01787708|No Intervention|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).
~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
11436816|NCT01787708|No Intervention|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).
~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
11436817|NCT01787695|No Intervention|No treatment (covered)|
11436818|NCT01787695|Active Comparator|UVA1|
11436819|NCT01787682|Experimental|Boost High Protein|Boost high protein with added spirulina
11436820|NCT01787669|Active Comparator|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
11436821|NCT01787669|Active Comparator|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
11436822|NCT01787643|Experimental|Standing desk|Installation of standing desk
11436823|NCT01787630|Experimental|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
11436824|NCT01787617|Placebo Comparator|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
11436825|NCT01787617|Experimental|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
11436826|NCT01787604|Active Comparator|Aortic Root Reimplantation Procedure|Aortic Root Reimplantation Procedure
11436827|NCT01787604|Active Comparator|Aortic Valve Reimplantation Procedure|Aortic Valve Reimplantation Procedure
11436828|NCT01787591|Experimental|Acute Fat-Free Milk Ingestion|Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
11436829|NCT01787591|Experimental|Acute Low-Fat Milk Ingestion|Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
11436830|NCT01787591|Experimental|Acute Full-Fat Milk Ingestion|Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
11436831|NCT01787591|Experimental|Acute Soy Milk Ingestion|Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
11436832|NCT01787578|Experimental|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
11436833|NCT01787565||painPREMIER cohort|
11436834|NCT01787565||Control cohort|
11436835|NCT01787552|Experimental|LDE225 + INC424|LDE225 and INC424 in combination
11436836|NCT01787539|Experimental|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.
~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.
~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
11436837|NCT01787539|No Intervention|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.
~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.
~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
11436838|NCT01787526|Active Comparator|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
11436839|NCT01787526|Experimental|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
11436840|NCT01787513|Experimental|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
11436841|NCT01787513|Placebo Comparator|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
11437158|NCT01785407|Active Comparator|80 mg FeSO4|
11436842|NCT01787500|Experimental|Treatment (vemurafenib, cetuximab, irinotecan hydrochloride)|Patients receive vemurafenib PO BID on days 1-14, cetuximab IV over 90 minutes, and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11436843|NCT01787487|Experimental|Arm I (MF patients)|Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
11436844|NCT01787487|Experimental|Arm II (MDS/MPN patients)|Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
11436845|NCT01787474|Experimental|Treatment (NK cells)|Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).
11436846|NCT01787461|Experimental|Imedeen|Imedeen is the study product
11436847|NCT01787461|Placebo Comparator|Placebo|
11436848|NCT01787448|Experimental|Ibuprofen 5% topical gel|
11436849|NCT01787448|Experimental|Topical gel vehicle|
11436850|NCT01787448|Active Comparator|Sodium lauryl sulfate 0.1%|
11436851|NCT01787448|Sham Comparator|Sodium chloride solution 0.9% (saline)|
11436852|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
11436853|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
11436854|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
11436855|NCT01787422|Experimental|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
11436856|NCT01787422|Active Comparator|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
11436857|NCT01787409|Experimental|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
11436858|NCT01787396|Experimental|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
11436859|NCT01787396|Experimental|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
11436860|NCT01787396|Experimental|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
11436861|NCT01787383|Active Comparator|Ingenol mebutate gel 0.05 %|
11436862|NCT01787383|Active Comparator|Ingenol mebutate gel 0.015 %|
11436863|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
11436864|NCT01787357|Experimental|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
11436865|NCT01787357|Experimental|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
11436866|NCT01787357|Experimental|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
11436867|NCT01787357|Experimental|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
11436868|NCT01787344|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
11436869|NCT01787344|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
11436870|NCT01787331|Experimental|Treatment (itraconazole)|Patients receive twice/day 300mg itraconazole (oral)
11436871|NCT01787318|Experimental|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
11436872|NCT01787318|Active Comparator|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
11436873|NCT01787292|Experimental|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
11436874|NCT01787292|Experimental|Aerobic Exercise Intervention|B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.
11436875|NCT01787292|Experimental|Self Monitoring Intervention|C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer.
11436876|NCT01787279|Experimental|Peginterferon alpha-2a, 180 mcg/48 weeks|Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.
11436877|NCT01787266||1|pregnant women
11436878|NCT01787253||Irritable bowel syndrome (IBS)|
11436879|NCT01787253||Healthy controls|
11436880|NCT01787253||Microscopic Colitis (MC)|
11436881|NCT01787253||Irritable bowel disease (IBD)|
11555056|NCT00969085|Experimental|Curcumin|
11436882|NCT01787240|Placebo Comparator|Placebo|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
11436883|NCT01787240|Experimental|Escitalopram 10mg|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
11436884|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
11436885|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
11436886|NCT01787214|Active Comparator|Full dose|full dose of walnuts (20% energy needs)
11436887|NCT01787214|Active Comparator|Half-dose|Half dose of walnuts (10% of energy needs)
11436888|NCT01787214|Other|Control|Walnut free meals
11436889|NCT01787188|Experimental|Meloxicam Test Capsules low dose QD|Meloxicam Test Capsules low dose QD
11436890|NCT01787188|Experimental|Meloxicam Test Capsules high dose QD|Meloxicam Test Capsules high dose QD
11436891|NCT01787188|Placebo Comparator|Placebo Capsule QD|Placebo Capsule QD
11436892|NCT01787175|Experimental|Integrated Medication Manager|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
11436893|NCT01787175|No Intervention|Standard EHR|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
11436894|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
11436895|NCT01787149|Placebo Comparator|Placebo|DMARDs alone
11436896|NCT01787149|Experimental|ENIA11|ENIA11 25 mg
11436897|NCT01787123|Placebo Comparator|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
11436898|NCT01787123|Active Comparator|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
11436899|NCT01787110|No Intervention|No oxygen|"For patients randomised to withholding oxygen treatment
~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)
~all patients receive standard acute coronary syndrome treatment including reperfusion strategies
~observation duration 12 hours"
11436900|NCT01787110|Active Comparator|Oxygen|"For patients randomised to oxygen therapy:
~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)
~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
11436901|NCT01787097|Active Comparator|COPD|Participants with COPD
11436902|NCT01787097|Active Comparator|Symbicort® total dose 400ug/12ug|Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)
11436903|NCT01787097|Active Comparator|Symbicort® total dose 800ug/24ug|Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose
11436904|NCT01787097|Active Comparator|BUD total dose 800ug|BUD total dose 800ug: is an intermediate dose of ICS
11436905|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
11436906|NCT01787071||one group|Patients receiving fluid challebnge
11436907|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
11436908|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
11436909|NCT01787045|Experimental|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.
~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
11436910|NCT01787045|Other|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
11436911|NCT01787032|Experimental|Period 3: BI 113608+Voriconazole|tablets with 240 ml water
11436912|NCT01787032|Experimental|Period 2: BI 113608+Ketoconazole|tablets with 240 ml water
11436913|NCT01787032|Experimental|Period 1: BI 113608|tablets with 240 ml water
11436914|NCT01787019|Experimental|30 weeks|initiation of oral feedings at 30 weeks
11436915|NCT01787019|Active Comparator|33 weeks|initiation of oral feedings at 33 weeks
11436916|NCT01787006|Experimental|Cetuximab, Cisplatin, 5-FU, Radiotherapy|"Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV
~5-fluorouracil (5-FU): 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102
~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)
~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
11436917|NCT01787006|Active Comparator|Cisplatin, 5-FU, Radiotherapy|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95
~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)
~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
11436918|NCT01786993|Experimental|Multi-point pacing arm|MultiPoint Pacing
11555057|NCT00969072|Experimental|GI198745|
11436919|NCT01786993|Active Comparator|Biventricular arm|Traditional Biventricular Pacing
11436920|NCT01786980||liver cancer, Radical hepatic resection|
11436921|NCT01786967|Experimental|Fesoterodine Fumarate|Participants will receive 4 mg of study drug for first 2 weeks, and then 8 mg of study drugs for 2 weeks.
11436922|NCT01786954|Experimental|Icare then Goldmann then Tonopen|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.
11436923|NCT01786954|Experimental|Icare then Tonopen then Goldmann|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.
11436924|NCT01786941|No Intervention|Lean Group|Healthy Controls - no intervention
11436925|NCT01786941|Other|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
11436926|NCT01786941|Other|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
11436927|NCT01786928|Experimental|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
11436928|NCT01786928|No Intervention|Control|Traditional Respiratory Therapy for bronchial hygiene
11436929|NCT01786915|Experimental|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
11436930|NCT01786915|Placebo Comparator|Placebo|Placebo (matching), once daily for 7 days
11436931|NCT01786915|Experimental|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
11436932|NCT01786902|Experimental|DA-3002 Treatment group|1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)
11436933|NCT01786902|No Intervention|Non-treatment control group|Height be measured with no treatment
11436934|NCT01786889|Experimental|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
11436935|NCT01786876|Experimental|Radiolabeled SPD557|
11436936|NCT01786863||Neuromuscular blockade|
11436937|NCT01786837|Experimental|Treatment|FMS will be administered for 5 weeks
11436938|NCT01786837|Sham Comparator|Sham|FMS at 5% intensity for 5 weeks
11436939|NCT01786824|Experimental|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.
~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
11436940|NCT01786824|Active Comparator|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.
~Intervention: Hydration strategy using saline Intervention: Coronarography"
11436941|NCT01786824|Experimental|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.
~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
11436942|NCT01786824|Experimental|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.
~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
11436943|NCT01786811|Experimental|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
11436944|NCT01786811|No Intervention|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
11436945|NCT01786811|No Intervention|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
11436946|NCT01786798|Other|Transvaginal sonography|
11436947|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
11436948|NCT01786785||Controls|Age and Gender Matched Controls
11436949|NCT01786772|Experimental|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
11436950|NCT01786772|Active Comparator|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
11436951|NCT01786759|Active Comparator|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
11436952|NCT01786759|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
11436953|NCT01786746|Experimental|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
11436954|NCT01786733|Experimental|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
11436955|NCT01786733|Active Comparator|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
11436956|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
11436957|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
11557468|NCT00951561|Experimental|Vipon|
11436958|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
11436959|NCT01786707|Experimental|Autologous SC and HOT|Autologous stem cells and hyperbaric oxygen therapy
11436960|NCT01786707|Active Comparator|Control group|Patients in a control group will continue with standard medical treatment (Insulin and Metformin)
11436961|NCT01786694|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
11436962|NCT01786681|Experimental|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
11436963|NCT01786681|Experimental|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
11436964|NCT01786681|Experimental|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
11436965|NCT01786681|No Intervention|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
11436966|NCT01786668|Experimental|Tofacitinib 2 mg|
11436967|NCT01786668|Experimental|Tofacitinib 5 mg|
11436968|NCT01786668|Experimental|Tofacitinib 10 mg|
11436969|NCT01786668|Placebo Comparator|Placebo|
11436970|NCT01786655|Experimental|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
11436971|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
11436972|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
11436973|NCT01786655|Placebo Comparator|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
11436974|NCT01786642||conscious|bronchoscopy without sedative drugs
11436975|NCT01786642||conscious sedation|bronchoscopy under midazolam
11436976|NCT01786629|Experimental|SUPREP Bowel Prep Kit|SUPREP Bowel Prep Kit
11436977|NCT01786629|Active Comparator|FDA approved bowel preparation|FDA approved bowel preparation containing electrolytes
11436978|NCT01786616||Formoterol|12 mcg BID for four weeks
11436979|NCT01786603|Experimental|Rasagiline|Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
11436980|NCT01786603|Placebo Comparator|Placebo|Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
11436981|NCT01786590|Experimental|EBUS-TBNA|
11436982|NCT01786577||Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
11436983|NCT01786577||Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
11436984|NCT01786551|Experimental|Eplerenone|Eplerenone 50 mg daily for 14 days
11436985|NCT01786538|Experimental|Regorafenib/FOLFOX|
11436986|NCT01786538|Active Comparator|Placebo/FOLFOX|
11436987|NCT01786525|Experimental|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
11436988|NCT01786525|Active Comparator|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
11436989|NCT01786525|No Intervention|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
11436990|NCT01786512|Experimental|Omecamtiv mecarbil|
11436991|NCT01786512|Placebo Comparator|Placebo|
11436992|NCT01786499|Other|Relaxation Response Training|
11436993|NCT01786486||Delivery system entry|
11436994|NCT01786473|Experimental|Testogel 1% 5g QD|
11436995|NCT01786473|Placebo Comparator|Placebo gel 5g QD|
11436996|NCT01786460||Healthy Volunteers|
11436997|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
11436998|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
11436999|NCT01786434|Experimental|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
11437000|NCT01786434|Active Comparator|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
11437001|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
11437002|NCT01786408|Experimental|TAP20-C|Single Use Integrated Capillary Blood Collection System
11437003|NCT01786408|Active Comparator|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
11437004|NCT01786395|Experimental|- UF-021|UF-021 is experimental code for isopropyl unoprostone
11437005|NCT01786395|Placebo Comparator|- Placebo|
11437006|NCT01786382|Experimental|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
11437007|NCT01786382|Experimental|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
11437008|NCT01786382|Experimental|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
11437009|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
11437010|NCT01786356|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
11437011|NCT01786356|Other|B&L MI60|eyes with implanted intraocular lens B&L MI60
11437012|NCT01786343|Experimental|Decitabine - 5 Day Regimen|Decitabine 20 mg/m2 by vein daily for 5 days.
11437013|NCT01786343|Experimental|Decitabine - 10 Day Regimen|Decitabine 20 mg/m2 by vein daily for 10 days.
11437014|NCT01786330|Experimental|Intervention|Group receives elastic abdominal binders after surgery. Binder used is Procare manufactured by DJO, LLC. Binders are to be worn for 24 hours after surgery.
11437015|NCT01786330|Active Comparator|Control|Group receives standard of care
11437016|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
11437017|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
11437018|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
11437019|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
11437020|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
11437021|NCT01786278|Experimental|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
11437022|NCT01786278|Other|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
11437023|NCT01786265|Active Comparator|Arm A (finite androgen ablation)|Participants receive either leuprolide acetate via injection every month or every 4 months, goserelin acetate via injection every month, or degarelix via injection every month for 8 months. Patients also receive bicalutamide PO QD, flutamide PO TID, or nilutamide PO QD. Patients may crossover to Arm B with disease progression after 8 months.
11437024|NCT01786265|Experimental|Arm B (finite androgen ablation, abiraterone, prednisone)|Participants receive leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide as in Arm A. Patients also receive abiraterone acetate PO daily for 8 months and prednisone daily. Patients may crossover to Arm A with disease progression after 8 months.
11437025|NCT01786252|Experimental|Drug: human chorionic gonadotropin (hCG)|"Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis."
11437026|NCT01786252|Placebo Comparator|"IVF media (Global-trademark)"|Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
11437027|NCT01786239|Experimental|Omega-3 capsules & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
11437028|NCT01786239|Other|Placebo & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
11437029|NCT01786226|Experimental|Mifepristone 2.5 mg daily for three months|Experimental: 1
11437030|NCT01786226|Experimental|Mifepristone 5 mg daily for three months|Experimental: 2
11437031|NCT01786213||Colonoscopist A|
11437032|NCT01786213||Colonoscopist B|
11437033|NCT01786213||Colonoscopist C|
11437034|NCT01786213||Colonoscopist D|
11437035|NCT01786213||Colonoscopist E|
11437036|NCT01786213||Colonoscopist F|
11437037|NCT01786213||Colonoscopist G|
11437038|NCT01786213||Colonoscopist H|
11437039|NCT01786213||Colonoscopist I|
11437040|NCT01786213||Colonoscopist J|
11437041|NCT01786200|Active Comparator|Aspirin|20 patients randomised to aspirin 75mg PO once daily
11437042|NCT01786200|Active Comparator|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
11437043|NCT01786200|No Intervention|Control|20 patients randomised to receive no treatment
11437044|NCT01786187|Active Comparator|Symptom Experience Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
11437045|NCT01786187|Experimental|Light Physical Activity Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
11437046|NCT01786174|Experimental|Gilenya (fingolimod)|0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
11437047|NCT01786174|Placebo Comparator|Placebo|0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
11437048|NCT01786161|Experimental|Vancomycin with continuous infusion|24 hours continuous infusion
11437049|NCT01786161|Active Comparator|Vancomycin with intermittent dose interval|infusion rate 1000mg/hr
11437050|NCT01786148|Active Comparator|Educational music mobile app|A prerecorded program of songs on various topics in a mobile phone application (app). It is designed to provide education about non-health related topics and will be equivalent in length to the intervention app.
11437051|NCT01786148|Experimental|Live Network mobile phone App|The LN is a prerecorded mobile phone application (app). It employs a radio talk show format in which a Disc Jockey entertains HIV medication-, adherence-, and self-management-related questions and comments from callers and poses them to expert care providers, whose responses to these questions are augmented by songs that shed additional light on these issues.
11437052|NCT01786135|Experimental|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
11437053|NCT01786122|Experimental|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
11563596|NCT00908154|Other|Cohort 3|
11437054|NCT01786122|No Intervention|control group|Pharmacological treatment and selfcare encouragement.
11437055|NCT01786109|Experimental|Dronabinol 2.5 mg|One dose of dronabinol 2.5 mg was taken orally with water.
11437056|NCT01786109|Experimental|Dronabinol 5 mg|One dose of dronabinol 5 mg was taken orally with water.
11437057|NCT01786109|Placebo Comparator|Placebo|One dose of placebo was taken orally with water.
11437058|NCT01786096|Experimental|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
11437059|NCT01786083|Experimental|Lifestyle counseling|Application of Problem Solving Technique
11437060|NCT01786083|No Intervention|No counseling|Usual care by caregiver
11437061|NCT01786070|Active Comparator|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
11437062|NCT01786070|Placebo Comparator|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
11437063|NCT01786057|Active Comparator|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
11437064|NCT01786057|Placebo Comparator|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
11437065|NCT01786044|Experimental|MasterMed|MasterMed, an online interactive educational program
11437066|NCT01786044|Placebo Comparator|Usual care|Access to an online patient portal
11437067|NCT01786031|Experimental|experimental|metastasis biopsy
11437068|NCT01786018|Experimental|1|"Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)
~Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)
~Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
11437069|NCT01786005|Sham Comparator|Sham|Imitation of stimulation.
11437070|NCT01786005|Experimental|High-frequency stimulation|High-frequency stimulation
11437071|NCT01786005|Experimental|TBS Theta burst stimulation|TBS Theta burst stimulation
11437072|NCT01786005|Experimental|Low-frequency stimulation|Low-frequency stimulation
11437073|NCT01785992|Other|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
11437074|NCT01785979|Experimental|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
11437075|NCT01785979|Active Comparator|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
11437076|NCT01785966|Experimental|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit & feedback
11437077|NCT01785966|No Intervention|Usual care|Usual care
11437078|NCT01785953||1|
11437079|NCT01785940|Experimental|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
11437080|NCT01785927|Other|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
11437081|NCT01785927|Other|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
11437082|NCT01785927|Other|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
11437083|NCT01785927|Other|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
11437084|NCT01785914||1|
11437085|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
11437086|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
11437087|NCT01785875|Experimental|Etelcalcetide|Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
11437088|NCT01785862|Experimental|Drug|V0498, Ibuprofen 25 mg
11437089|NCT01785862|Placebo Comparator|Placebo|Placebo
11437090|NCT01785849|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
11437091|NCT01785849|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
11437092|NCT01785836|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
11437093|NCT01785836|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
11437094|NCT01785836|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
11437095|NCT01785836|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
11437096|NCT01785823|Experimental|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
11437097|NCT01785823|Active Comparator|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
11437098|NCT01785823|Active Comparator|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
11437099|NCT01785810|Experimental|Single Arm|Phase II, single arm, single center trial, assessing the efficacy of the combination of tacrolimus, methotrexate and maraviroc as graft-versus-host disease (GVHD) prophylaxis after unrelated donor peripheral blood stem-cell transplantation in patients with hematologic malignancies. Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
11437100|NCT01785797|No Intervention|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
11437101|NCT01785797|Experimental|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
11437102|NCT01785784|Experimental|burn patients|
11437103|NCT01785771|Experimental|ITCA 650|
11437104|NCT01785758|Experimental|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
11437105|NCT01785758|Active Comparator|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
11437106|NCT01785745|Active Comparator|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
11437107|NCT01785745|Experimental|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
11437108|NCT01785732|Active Comparator|Renal denervation|Patients are randomized to renal denervation
11437109|NCT01785732|No Intervention|Optimization of medical therapy|Antihypertensive treatment is optimized
11437110|NCT01785719|Experimental|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
11437111|NCT01785693|Other|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
11437112|NCT01785693|Other|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
11437113|NCT01785680|Active Comparator|Current protocol|These treatment arm is the standard care for moderate malnutrition. This includes a fortified cereal supplement treatment until the child reaches MUAC of above 12.5. Currently, MAM and SAM are treated separately, overseen by different agencies. Breastfeeding is often overlooked.
11437114|NCT01785680|Experimental|Integrated Protocol|Integrated protocol for treatment of children with MAM and SAM in humanitarian emergencies has the potential to result in a more streamlined, cost-effective program, higher recovery, and higher program coverage, allowing easier access to malnourished children, thus curing more children of malnutrition and preventing its lifelong effects.
11437115|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
11437116|NCT01785654||reventilation collapse|
11437117|NCT01785641|Experimental|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
11437118|NCT01785641|Active Comparator|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
11437119|NCT01785641|Experimental|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
11437120|NCT01785641|Active Comparator|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
11437121|NCT01785628|Experimental|Sarcosine capsule|Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.
11437122|NCT01785628|Placebo Comparator|Placebo capsule|Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.
11437123|NCT01785615|Experimental|Atorvastatin|44 women randomized to 80 mg atorvastatin for 6weeks
11437124|NCT01785615|Placebo Comparator|sugar pill|44 women randomized to placebo for 6 weeks
11437125|NCT01785602|Experimental|QAW039|Participants received QAW039 450 mg daily by mouth.
11437126|NCT01785602|Placebo Comparator|Placebo|Participants received matching placebo to QAW039.
11437127|NCT01785589|Other|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
11437128|NCT01785576|Experimental|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
11437129|NCT01785576|No Intervention|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
11563597|NCT00908154|Other|Cohort 2|
11437130|NCT01785563|Experimental|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
11437131|NCT01785550||Control Group|No intervention to be performed.
11437132|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
11437133|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
11437134|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
11437135|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
11437136|NCT01785524|Experimental|BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
11437137|NCT01785524|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
11437138|NCT01785511|Sham Comparator|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
11437139|NCT01785511|Experimental|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
11437140|NCT01785498|No Intervention|Control Group|Receive standard clinical care and supports.
11437141|NCT01785498|Experimental|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
11437142|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
11437143|NCT01785472|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.
11437144|NCT01785472|Experimental|LCZ696 400 mg|Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.
11437145|NCT01785472|Active Comparator|Olmesartan 20 mg|Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.
11437146|NCT01785459|Active Comparator|standard care|intravenous Prochlorperazine
11437147|NCT01785459|Experimental|treatment|0.5% bupivacaine
11437148|NCT01785446|Active Comparator|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.
~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
11437149|NCT01785446|Active Comparator|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.
~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
11437150|NCT01785446|Active Comparator|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.
~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
11437151|NCT01785446|Active Comparator|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.
~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.
~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
11437152|NCT01785433|Experimental|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
~Treatment A: Tiotropium HFA BAI 4.5 mcg/day
~Treatment B: Tiotropium HFA BAI 9.0 mcg/day
~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
~Treatment D: Spiriva® Respimat® 5 mcg/day"
11437153|NCT01785433|Experimental|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
~Treatment B: Tiotropium HFA BAI 9.0 mcg/day
~Treatment D: Spiriva® Respimat® 5 mcg/day
~Treatment A: Tiotropium HFA BAI 4.5 mcg/day
~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
11437154|NCT01785433|Experimental|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
~Treatment A: Tiotropium HFA BAI 4.5 mcg/day
~Treatment D: Spiriva® Respimat® 5 mcg/day
~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
11437155|NCT01785433|Experimental|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:
~Treatment D: Spiriva® Respimat® 5 mcg/day
~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day
~Treatment B: Tiotropium HFA BAI 9.0 mcg/day
~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
11437156|NCT01785420|Experimental|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
11437157|NCT01785420|Placebo Comparator|Control|A 90 minute intravenous infusion of saline as placebo
11437162|NCT01785394|Active Comparator|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
11437163|NCT01785394|Placebo Comparator|Placebo|30 patients will receive placebo
11437164|NCT01785381|No Intervention|usual care|usual care
11437165|NCT01785381|Other|Added value of coordinator|Added value of coordinator
11437166|NCT01785368|Other|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.
~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]
~Intervention: Baseline observation"
11437167|NCT01785368|Other|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.
~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]
~Intervention: Implementation of guidelines"
11437168|NCT01785355||Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
11437169|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
11437170|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.
~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
11437171|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
11437172|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
11437173|NCT01785316|Experimental|IHP|Isolated Hepatic Perfusion
11437174|NCT01785316|No Intervention|BAC|Best alternative care
11437175|NCT01785303|Active Comparator|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
11437176|NCT01785303|Active Comparator|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
11437177|NCT01785303|Other|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
11437178|NCT01785290|Experimental|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
11437179|NCT01785290|Experimental|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
11437180|NCT01785290|Placebo Comparator|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
11437181|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
11437182|NCT01785264|Active Comparator|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
11437183|NCT01785264|Active Comparator|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
11437184|NCT01785264|Active Comparator|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
11437185|NCT01785251|Experimental|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
11437186|NCT01785238|Experimental|cases with neonatal acute renal failure in preterm|
11437187|NCT01785238|Other|controls without neonatal acute renal failure in preterm|
11437188|NCT01785225|Experimental|modified commercial drape Tegaderm (R)|
11437189|NCT01785212|Other|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
11437190|NCT01785212|Other|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
11437191|NCT01785199|Placebo Comparator|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
11437192|NCT01785199|Active Comparator|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
11437193|NCT01785199|Active Comparator|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
11437263|NCT01784835|Experimental|OMT|patients under usual medical care plus osteopathic treatment
11437194|NCT01785199|Active Comparator|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
11437195|NCT01785186|Experimental|Arm 1 (R35)|Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
11437196|NCT01785186|Experimental|HRZQ|Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
11437197|NCT01785186|Experimental|HR20ZQ|Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
11437198|NCT01785186|Experimental|HR20ZM|Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
11437199|NCT01785186|Active Comparator|HRZE|HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
11437200|NCT01785173|Experimental|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
11437201|NCT01785173|Active Comparator|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
11437202|NCT01785160|Active Comparator|Raltegravir|coated tablets, oral administration with 240 ml water
11437203|NCT01785160|Experimental|Raltegravir + Faldaprevir|coated tablets and soft gelatine capsule, oral administration with 240 ml water
11437204|NCT01785147|Experimental|BP1.4979 3mg|BP1.4979 3mg during 3 months
11437205|NCT01785147|Experimental|BP1.4979 10mg|BP1.4979 10mg during 3 months
11437206|NCT01785147|Experimental|BP1.4979 15mg|BP1.4979 15mg during 3 months
11437207|NCT01785147|Placebo Comparator|Placebo|Placebo during 3 months
11437208|NCT01785134|Sham Comparator|Control|Gastric bypass operation without omentectomy.
11437209|NCT01785134|Active Comparator|Omentectomy|Gastric bypass operation in conjunction with removal of greater omentum
11437210|NCT01785121|Active Comparator|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
11437211|NCT01785121|Experimental|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
11437212|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"GAD-Alum (Diamyd) 20 µg given twice with one month interval
~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450
~Ibuprofen, 400 mg/day, from Day 1 to Day 90"
11437213|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg and Vitamin D|"GAD-Alum (Diamyd) 20 µg given twice with one month interval
~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
11437214|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval
~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
11437215|NCT01785108|Placebo Comparator|Placebo|
11437216|NCT01785095|Experimental|FSH|FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
11437217|NCT01785082|Experimental|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of >150 µg/kg/h would correspond to a general ward indication.
11437218|NCT01785082|No Intervention|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
11437219|NCT01785069|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
11437220|NCT01785069|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
11437221|NCT01785069|Experimental|Revision-Augmentation|Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.
11437222|NCT01785069|Experimental|Revision-Reconstruction|Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.
11437223|NCT01785056|Experimental|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
11437224|NCT01785056|Placebo Comparator|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
11437225|NCT01785043|Experimental|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
11437261|NCT01784848|Active Comparator|Clinical treatment|Optimized clinical treatment including medical management of hypertension.
11437262|NCT01784835|Other|control|patients under standard medical care
11437226|NCT01785043|Active Comparator|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
~Sitagliptin will be used daily during the study period of 12 weeks."
11437227|NCT01785030|Experimental|50% Nitrous oxide|
11437228|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
11437229|NCT01785004|Active Comparator|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
11437230|NCT01785004|Active Comparator|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
11437231|NCT01785004|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
11437232|NCT01785004|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
11437233|NCT01784991|Active Comparator|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
11437234|NCT01784991|Active Comparator|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
11437235|NCT01784978|Experimental|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
11437236|NCT01784978|Active Comparator|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
11437237|NCT01784965|Placebo Comparator|placebo|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
11437238|NCT01784965|Active Comparator|liraglutide|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
11437239|NCT01784952|Experimental|Whole grains and lequmes|
11437240|NCT01784952|Placebo Comparator|refined rice|
11437241|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes
~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin < 50μg / L"
11437242|NCT01784926|Other|IOL repositioning|Operation method: Intraocular lens repositioning by scleral suturing
11437243|NCT01784926|Other|IOL exchange|Operation method: Intraocular lens exchange with retropupillary iris-claw lens
11437244|NCT01784913|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
11437245|NCT01784900|Experimental|Schema B (140µg)|"D0 : 20 μg of catumaxomab
~D2 : 40 μg
~D4 : 80 μg"
11437246|NCT01784900|Experimental|Schema A (100µg)|"D0 : 10 μg of catumaxomab
~D2 : 30 μg
~D4 : 60 μg"
11437247|NCT01784887|Active Comparator|Bioelectric Dressing|SOC + Bioelectric Dressing
11437248|NCT01784887|No Intervention|SOC|Standard of Care
11437249|NCT01784874|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
11437250|NCT01784874|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
11437251|NCT01784861|Experimental|Dose Level 0|"X-82 100 mg by mouth once daily
~Everolimus 10mg by mouth once daily for each cycle
~Everolimus and X-82 should be taken at the same time every day
~28 days =1 cycle"
11437252|NCT01784861|Experimental|Dose Level 1|"X-82 150 mg by mouth once daily
~Everolimus 10mg by mouth once daily for each cycle
~Everolimus and X-82 should be taken at the same time every day
~28 days =1 cycle"
11437253|NCT01784861|Experimental|Dose Level 2|"X-82 200 mg by mouth once daily
~Everolimus 10mg by mouth once daily for each cycle
~Everolimus and X-82 should be taken at the same time every day
~28 days =1 cycle"
11437254|NCT01784861|Experimental|Phase II Dose|"X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily
~Everolimus 10mg by mouth once daily for each cycle
~28 days =1 cycle"
11437255|NCT01784861|Experimental|Dose Level 3|"X-82 300 mg by mouth once daily
~Everolimus 10mg by mouth once daily for each cycle
~Everolimus and X-82 should be taken at the same time every day
~28 days =1 cycle"
11437256|NCT01784861|Experimental|Dose Level 4|"Everolimus 10mg by mouth once daily for each cycle MUST BE TAKEN FIRST
~X-82 400 mg by mouth once daily 2 HOURS AFTER everolimus dose
~28 days =1 cycle"
11437257|NCT01784861|Experimental|PK Expansion Renal Cell Carcinoma - Group A|"Everolimus 10 mg by mouth once daily for each cycle (MUST BE TAKEN FIRST)
~X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily 2 HOURS AFTER everolimus dose
~28 days =1 cycle"
11437258|NCT01784861|Experimental|PK Expansion Renal Cell Carcinoma - Group B|"Everolimus 10 mg by mouth once daily for each cycle (MUST BE TAKEN FIRST)
~X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily 4 HOURS AFTER everolimus dose
~28 days =1 cycle"
11437259|NCT01784861|Experimental|PK Expansion Renal Cell Carcinoma - Group C|"Everolimus 10 mg by mouth once daily for each cycle
~X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily
~Everolimus and X-82 MUST BE TAKEN AT THE SAME TIME
~28 days =1 cycle"
11437260|NCT01784848|Experimental|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
11442457|NCT01749098|Placebo Comparator|Placebo|Placebo and ketamine
11437264|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
11437265|NCT01784809|Experimental|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
11437266|NCT01784809|Active Comparator|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
11437267|NCT01784809|Placebo Comparator|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
11437268|NCT01784796|Experimental|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction program
11437269|NCT01784796|Active Comparator|Health education program|8 week Health Education program
11437270|NCT01784783|Experimental|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.
~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
11437271|NCT01784783|Experimental|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
11437272|NCT01784770||Azithromycin IV|Subjects who are treated with Azithromycin IV for Legionnaires' disease
11437273|NCT01784757|Experimental|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
11437274|NCT01784757|Experimental|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
11437275|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
11437276|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
11437277|NCT01784731||Patients|
11437278|NCT01784705|Experimental|Transcranial bright light therapy|
11437279|NCT01784705|Placebo Comparator|Transcranial placebo treatment|
11437280|NCT01784692|Placebo Comparator|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
11437281|NCT01784692|Experimental|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
11437282|NCT01784692|Experimental|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
11437283|NCT01784692|Experimental|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
11437284|NCT01784679||Natural History Prospective Observational Group|
11437285|NCT01784679||Online Registry Patient Reported Group|
11437286|NCT01784666|Experimental|Isradipine-Isradipine|Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
11437287|NCT01784666|Experimental|Placebo -> Isradipine|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
11437288|NCT01784666|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
11437289|NCT01784653|No Intervention|Treatment as Usual|Patients will receive the usual care from the treatment program
11437290|NCT01784653|Experimental|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
11437291|NCT01784653|Experimental|MET|Clinician-delivered Motivational Enhancement Therapy
11437292|NCT01784640|Experimental|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
11437293|NCT01784627|No Intervention|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
11437294|NCT01784627|Experimental|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
11437295|NCT01784614|Experimental|0.1 milligrams (mg) LY2624803|Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods
11437296|NCT01784614|Experimental|1.0 mg LY2624803|Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
11437297|NCT01784614|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
11437298|NCT01784614|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
11437299|NCT01784614|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods
11437300|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
11437301|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
11437302|NCT01784588|Active Comparator|Solyx Single Incision Sling System|Solyx Single Incision Sling System
11437303|NCT01784588|Active Comparator|Obtryx II Sling System|Obtryx II Sling System
11437304|NCT01784575|Experimental|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
11437305|NCT01784575|Active Comparator|Control|The control arm will receive an information pamphlet about health care quality.
11442458|NCT01749085|Experimental|Sequence 1|
11437306|NCT01784549|Active Comparator|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
11437307|NCT01784549|Experimental|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"Gefitinib day for 8 wks;
~Pemetrexed day 1 q 21 days for 3 cycles;
~Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;
~Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;
~Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;
~Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
11437308|NCT01784536|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
11437309|NCT01784523|No Intervention|Standard treatment|patients randomized to standard treatment will not receive hydroxychloroquine.
11437310|NCT01784523|Experimental|Hydroxychloroquine|Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing <60kg; and 400 mg daily (200 mg twice a day)for patients weighing >60kg.
11437311|NCT01784510|Active Comparator|2 cm|
11437312|NCT01784510|Experimental|6 cm|
11437313|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
11437314|NCT01784484||patients with abnormal liver enzymnes|
11437315|NCT01784471|Experimental|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
11437316|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
11437317|NCT01784445|Experimental|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
11437318|NCT01784445|Active Comparator|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
11437319|NCT01784432|Active Comparator|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
11437320|NCT01784432|Active Comparator|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
11437321|NCT01784419|Experimental|ivacaftor-placebo|The ivacaftor-placebo arm receives a 2 week course of ivacaftor 150 mg twice daily followed by a 2 week washout period followed by a 2 week placebo course.
11437322|NCT01784419|Experimental|placebo-ivacaftor|The placebo-ivacaftor arm receives a 2 week placebo course followed by a 2 week washout period followed by a 2 week course of ivacaftor 150 mg twice daily.
11437323|NCT01784406|Experimental|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
11437324|NCT01784406|No Intervention|Control|Standard of care.
11437325|NCT01784380||the case group|
11437326|NCT01784380||the control group|
11437327|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
11437328|NCT01784367|Experimental|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
11437329|NCT01784354|Placebo Comparator|Education|target education toward Raynaud's
11437330|NCT01784354|Active Comparator|Acupressure|acupressure- dilatation
11437331|NCT01784354|Active Comparator|Acupressure relaxation|acupressure relaxation protocol
11437332|NCT01784328|Other|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
11437333|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).
~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
11437334|NCT01784302|Active Comparator|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
11437335|NCT01784302|Active Comparator|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
11437336|NCT01784302|Active Comparator|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
11437337|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
11437338|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
11437339|NCT01784289||obese non diabetics|Patients with obesity (BMI <30kg/m2), without diabetes
11437340|NCT01784289||obese diabetics|Patients with obesity (BMI <30 kg/m2), with diabetes
11437341|NCT01784276|No Intervention|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
11437342|NCT01784276|Experimental|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
11437343|NCT01784276|Experimental|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
11437344|NCT01784276|Experimental|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
11437345|NCT01784263|Experimental|Individual Cognitive Behavioral Therapy|
11437346|NCT01784263|Active Comparator|Standard Community Treatment|
11437347|NCT01784250|Experimental|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
11437348|NCT01784250|Placebo Comparator|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
11437349|NCT01784250|Experimental|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
11437350|NCT01784237|Experimental|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
11437351|NCT01784237|Active Comparator|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
11437352|NCT01784224|Experimental|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.
~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
11437353|NCT01784211|Experimental|LY2605541 (Part A)|0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SC) once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
11437354|NCT01784211|Active Comparator|Glargine (Part A)|0.5 U/kg insulin glargine SC once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
11437355|NCT01784211|Experimental|First LY2605541 + Exercise,Then LY2605541 Alone (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20).Participants remained on their regular physician-prescribed mealtime insulin.
11437356|NCT01784211|Experimental|First LY2605541 Alone, Then LY2605541 + Exercise (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17). Participants remained on their regular physician-prescribed mealtime insulin.
11437357|NCT01784211|Active Comparator|First Glargine + Exercise, Then Glargine Alone (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20). Participants remained on their regular physician-prescribed mealtime insulin.
11437358|NCT01784211|Active Comparator|First Glargine Alone, Then Glargine + Exercise (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17).
11437359|NCT01784198|Experimental|Protein Intake|Dietary supplement:Protein intake
11437360|NCT01784185|Experimental|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
11437361|NCT01784172|Experimental|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.
~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
11437362|NCT01784172|Experimental|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.
~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
11437363|NCT01784159|Placebo Comparator|Placebo|Placebo 1tb / day/ 7days
11437364|NCT01784159|Active Comparator|Aspirin|Intervention aspirin 200 mg/day for 7 days
11437365|NCT01784146|Placebo Comparator|Oxygen|
11437366|NCT01784146|Experimental|PEEP + Heliox|
11437367|NCT01784146|Experimental|Oxygen + PEEP|
11437368|NCT01784146|Active Comparator|Heliox|
11437369|NCT01784133|Active Comparator|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
11437370|NCT01784133|Active Comparator|omiganan high dose|omiganan high dose once daily application for 12 weeks
11437371|NCT01784133|Placebo Comparator|Vehicle group|Vehicle once daily application for 12 weeks
11437372|NCT01784133|Active Comparator|omiganan low dose|omiganan low dose once daily application for 12 weeks
11437373|NCT01784120|Experimental|doxotubicin/Genexol-PM|
11437374|NCT01784107|Experimental|Belotecan and Ifosfamide|
11437375|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
11437376|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
11437377|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
11437378|NCT01784068|Experimental|Nilotinib followed by treatment-free|Patients who have received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 will enter the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase will enter the Treatment-Free Remission (TFR) phase where no treatment is given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
11437379|NCT01784042|Placebo Comparator|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
11437380|NCT01784042|Placebo Comparator|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
11437381|NCT01784042|Experimental|Lovaza|Lovaza only
11437382|NCT01784042|Experimental|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
11437383|NCT01784029|Experimental|Low Dose|"VItamin D3 1,000 IU
~1 x day, 8 weeks"
11437384|NCT01784029|Experimental|Weekly High Dose|"Vitamin D3 50,000 IU
~1x week, 8 weeks"
11437385|NCT01784029|Experimental|Daily High Dose|"Vitamin D3 5,000 IU
~1x day, 8 weeks"
11437386|NCT01784016|Experimental|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
11437387|NCT01784016|Experimental|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of <100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of < 9 ppm at screening.
11437388|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
11437389|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
11437390|NCT01783990||Active|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
11437391|NCT01783990||Passive|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), variable-diversity-joining (VDJ), urine microalbumin:creatinine ratio and a stored blood sample were collected at study entry and exit to Follow-Up Study II. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, MRI/MRA, cardiac echocardiogram, or neuropsychology testing were collected as part of clinical care.
11437392|NCT01783977|Experimental|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
11437393|NCT01783977|Experimental|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
11437394|NCT01783977|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
11437395|NCT01783977|Experimental|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
11437396|NCT01783977|Placebo Comparator|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
11437397|NCT01783977|Experimental|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
11437398|NCT01783977|Placebo Comparator|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
11437399|NCT01783964|Experimental|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
11437400|NCT01783951|Experimental|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
11437401|NCT01783951|Active Comparator|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
11437402|NCT01783938|Experimental|Cohort A: Nivolumab followed by Ipilimumab|"Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.
~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period."
11437403|NCT01783938|Experimental|Cohort B: Ipilimumab followed by Nivolumab|"Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.
~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1."
11437404|NCT01783925||Group 1|
11437405|NCT01783912|Experimental|Cognitive/Motivational Intervention Group|"This arm of the project will address the following questions:
~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?
~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?"
11437406|NCT01783912|Active Comparator|Attention Control Group|"This arm of the project will address the following question:
~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate that those who are in the experimental treatment group?
~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Cognitive/Motivational Intervention Group?"
11437466|NCT01783535|Experimental|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.
~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, carboplatin, filgrastim or PEG-filgrastim, enucleation"
11437751|NCT01781611|Active Comparator|aspirin|half a tablet of a 81mg aspirin twice daily for 24 weeks
11437407|NCT01783912|No Intervention|Motivated Smokers Comparison Group|"This arm of the project will address the following question:
~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?
~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?
~Participants will not receive any intervention but will be consented and enrolled into this group and assessed for utilization of the tobacco quit line services."
11437408|NCT01783899|Experimental|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.
~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
11437409|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
11437410|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
11437411|NCT01783886|Active Comparator|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
11437412|NCT01783873|Placebo Comparator|Placebo|
11437413|NCT01783873|Active Comparator|flour allergen extract or quaternary ammonium compound|
11437414|NCT01783860|Experimental|Oral Azithromycin|Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
11437415|NCT01783860|Active Comparator|Doxycycline|Oral doxycycline 100mg capsule every 12 hours for one month
11437416|NCT01783847|Experimental|Recombinant human erythropoietin (EPO)|Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for >13 years/ day for 3 days
11437417|NCT01783847|Active Comparator|Methylprednisolone|Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.
11437418|NCT01783847|Other|Observation|Observation
11437419|NCT01783834|Active Comparator|pemetrexed|pemetrexed
11437420|NCT01783834|Active Comparator|gefitinib|gefitinib
11437421|NCT01783821|Experimental|Budesonide and Formoterol|Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
11437422|NCT01783821|Placebo Comparator|Placebo|Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
11437423|NCT01783808|Experimental|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.
~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
11437424|NCT01783808|No Intervention|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
11437425|NCT01783795|Other|Genetic Analysis|Genetic Analysis
11437426|NCT01783782|Experimental|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
11437427|NCT01783782|Experimental|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
11437428|NCT01783782|Experimental|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
11437429|NCT01783782|Experimental|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
11437430|NCT01783782|Experimental|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
11437431|NCT01783769|No Intervention|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
11437432|NCT01783769|Active Comparator|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
11437433|NCT01783756|Experimental|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
11437434|NCT01783743|Experimental|Intervention arm|"Community treatment assistants (CTA ) will receive usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
~In addition to the usual training, these CTA's will also receive an additional modest half day training for TT case recognition which is called the TT training program and TT Screening Card to help them identify TT cases and refer them for surgery."
11437435|NCT01783743|No Intervention|Usual Assessment arm|Community treatment assistants will receive only usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
11437436|NCT01783730||Participants with high rheumatoid arthritis disease activity|Participants who received adalimumab treatment
11437437|NCT01783717|Experimental|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
11437557|NCT01782898|Placebo Comparator|.9 normal saline|.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
11437558|NCT01782885|Active Comparator|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts.
11442459|NCT01749085|Experimental|Sequence 2|
11437438|NCT01783704|Experimental|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
11437439|NCT01783704|Experimental|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
11437440|NCT01783691|Experimental|NKTT120|
11437441|NCT01783678|Experimental|Genotype 2 treatment-naive|Treatment-naive (TN) participants with HIV-1 and genotype 2 HCV coinfection will receive sofosbuvir plus RBV for 12 weeks.
11437442|NCT01783678|Experimental|Genotype 2/3 treatment-experienced|Treatment-experienced (TE) participants with HIV-1 and genotype 2 or 3 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
11437443|NCT01783678|Experimental|Genotype 1/3/4 treatment-naive|Treatment naive (TN) participants with HIV-1 and genotype 1, 3, or 4 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
11437444|NCT01783665|Experimental|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
11437445|NCT01783665|Active Comparator|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
11437446|NCT01783652|Experimental|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
11437447|NCT01783652|No Intervention|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
11437448|NCT01783639|Experimental|Arm 1|"Device: WIRION™ Embolic Protection System
~Interventions: Carotid Artery Stent"
11437449|NCT01783626|Sham Comparator|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
11437450|NCT01783626|Experimental|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
11437451|NCT01783626|Experimental|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
11437452|NCT01783626|Experimental|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
11437453|NCT01783613|Experimental|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
11437454|NCT01783613|Placebo Comparator|placebo|50 patients will receive placebo
11437455|NCT01783600|Other|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
11437456|NCT01783587|Experimental|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
11437457|NCT01783587|Experimental|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
11437458|NCT01783574|Active Comparator|Testosterone|Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
11437459|NCT01783574|Placebo Comparator|Placebo|Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
11437460|NCT01783561|Active Comparator|early caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
11437461|NCT01783561|Placebo Comparator|Routine caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. If the infant is in the routine caffeine group, the blinded drug will be placebo in the DR and IV caffeine citrate 20mg/kg at 12 hours of life.
11437462|NCT01783548|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
11437463|NCT01783548|Placebo Comparator|Placebo Nasal Aerosol|Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.
11437464|NCT01783535|Experimental|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).
~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
11437465|NCT01783535|Experimental|Stratum B|"Participants considered candidates for conservative management including those:
~Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye
~Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.
~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
11437752|NCT01781598||Patients treated with Patient specific instruments in TKA|
11437467|NCT01783535|Experimental|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).
~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
11437468|NCT01783522|Experimental|Arm I (preventative nutritional supplementation)|Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
11437469|NCT01783522|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
11437470|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
11437471|NCT01783496|Active Comparator|Framed Tip|Treatment with Thermage CPT Framed Tip
11437472|NCT01783496|Experimental|Pattern Tip|Treatment with the Thermage CPT Pattern Tip
11437473|NCT01783496|Experimental|Pattern Tip Group 2|Treatment with the Thermage CPT Pattern tip
11437474|NCT01783496|Experimental|Total Tip|Treatment with the Thermage CPT Total tip
11437475|NCT01783496|Experimental|Framed and Patterned Tip|Split face treatment with the Thermage CPT Framed and Patterned tips
11437476|NCT01783496|Experimental|Total and Patterned Tip|Split face treatment with the Thermage CPT Total and Patterned tips
11437477|NCT01783483|Active Comparator|Suture Wire|The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
11437478|NCT01783483|Experimental|SternaLock Blu closure system|"Patients will receive treatment option for sternal closure with the SternaLock Blue closure system at a minimum of 2 X plates on the sternal body and 1 L plate (or equivalent) on the manubrium. This technique is the standard configuration for this study, and is intended to ensure that at least 3 plates are used to achieve adequate fixation and stability, while allowing for variations in the plating configuration as a result of patient anatomy and surgeon preference. Various Sternal Blu plates may be used on the manubrium as described below, as can an additional plate on the sternal body."
11437479|NCT01783470|Experimental|beta3-adrenergic receptor agonist|single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.
11437480|NCT01783457|Experimental|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
11437481|NCT01783457|Active Comparator|Control|Usual treatment
11437482|NCT01783444|Experimental|Capecitabine Monotherapy|Capecitabine monotherapy arm (1250mg/m2 twice daily) orally for two weeks, followed by a one week rest period in 3-weeks cycles.
11437483|NCT01783444|Experimental|Everolimus Monotherapy|Everolimus (10mg daily).
11437484|NCT01783444|Active Comparator|Everolimus with Exemestane|Everolimus (10mg daily) with exemestane (25mg daily).
11437485|NCT01783431|Experimental|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
11437486|NCT01783418|Experimental|Mindfulness intervention|
11437487|NCT01783418|Active Comparator|Wait-list control|
11437488|NCT01783405||Cases|FH heterozygous
11437489|NCT01783405||Controls|Parents of FH heterozygotes with FH
11437490|NCT01783392|Active Comparator|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
11437491|NCT01783392|Active Comparator|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
11437492|NCT01783392|Active Comparator|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
11437493|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
11437494|NCT01783366|No Intervention|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
11437495|NCT01783366|Active Comparator|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, [cook medical, Bloomington, IN]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
11437496|NCT01783353|Placebo Comparator|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
11437497|NCT01783353|Experimental|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
11437559|NCT01782885|Experimental|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks
11437560|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|
11437561|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|
11437498|NCT01783340|Active Comparator|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
~Placebo capsules daily on three consecutive days starting on each of three immunization days.
~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
11437499|NCT01783340|Experimental|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).
~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.
~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
11437500|NCT01783340|Placebo Comparator|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.
~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
11437501|NCT01783327|Experimental|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
11437502|NCT01783327|Active Comparator|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
11437503|NCT01783314|Active Comparator|Normal liver function|Control group. Subjects will obtain MRI of liver.
11437504|NCT01783314|Experimental|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
11437505|NCT01783301|Active Comparator|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide
~AFC < 6 on both ovary: 375 IU FSH
~6<AFC <=15 on both ovary: 225 IU FSH
~AFC> 15 on both ovary: 150 IU FSH"
11437506|NCT01783301|Active Comparator|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide
~AMH < 5 pmol/L or < 0.7ng/ml: 375 IU FSH
~AMH 5 to < 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH
~AMH ≥ 15 pmol/L or > 2.1ng/ml: 150 IU FSH"
11437507|NCT01783288|Other|All participants|"All participants will be administered all procedures as described previously.
~Interventions:
~Autonomic Function Testing, Posture Study ,Measurement of Total Blood Volume ,Exercise Capacity Test"
11437508|NCT01783275|Experimental|Aerobic Exercise|12 weeks of aerobic exercise
11437509|NCT01783275|No Intervention|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
11437510|NCT01783262|Active Comparator|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
11437511|NCT01783262|Placebo Comparator|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
11437512|NCT01783249|No Intervention|Control|Usual care monitoring
11437513|NCT01783249|Other|Exercise using stationary cycling|Stationary cycling exercise program
11437514|NCT01783236|Placebo Comparator|Saline Placebo|Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
11437515|NCT01783236|Active Comparator|IV Acetaminophen|Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
11437516|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
11437517|NCT01783210|Experimental|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
11437518|NCT01783210|Other|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
11437519|NCT01783197|Experimental|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib
~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
11437520|NCT01783197|Experimental|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)
~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
11437521|NCT01783197|Experimental|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)
~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
11437522|NCT01783171|Experimental|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.
~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11437523|NCT01783171|Experimental|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.
~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11437562|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|
11437563|NCT01782872|Active Comparator|Interscalene Block (ISB) - Systemic Control|
11437564|NCT01782859|Placebo Comparator|Placebo|Control group
11437598|NCT01782625|Experimental|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
11563662|NCT00907894|Experimental|Stratum 3|
11437524|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
11437525|NCT01783145||Patients|Patients with disseminated TC who have finished their chemotherapy, if needed followed by surgery, and who are in complete remission and currently in active follow-up.
11437526|NCT01783132|Other|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
11437527|NCT01783132|No Intervention|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
11437528|NCT01783119|Experimental|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
11437529|NCT01783119|Placebo Comparator|water|Consume 200 ml of placebo per day over a period of three months
11437530|NCT01783106|Active Comparator|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
11437531|NCT01783106|Experimental|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
11437532|NCT01783093||Sickle cell and pulmonary hypertension|
11437533|NCT01783080|Experimental|Behavioral Activation for Return to Work|BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.
11437534|NCT01783067|Experimental|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
11437535|NCT01783067|Active Comparator|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
11437536|NCT01783054|Experimental|chemotherapy, surgery, genetic expression|"All patients enrolled on study will start study treatment on a chemotherapy treatment regimen of Gemcitabine and abraxane. Treatment will be given on days 1, 8 and 15 of each cycle for 2 cycles over the course of 12 weeks.
~Patients will move on to surgery, 4-8 weeks after chemotherapy treatment. Patients must be recovered from any adverse effects of the chemotherapy before proceeding with surgery.
~As part of this study, tissue samples will be collect from each patient at the time of surgery for gene expression testing"
11437537|NCT01783041|Placebo Comparator|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
11437538|NCT01783041|Experimental|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
11437539|NCT01783028|Experimental|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
11437540|NCT01783028|No Intervention|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
11437541|NCT01783015|Experimental|Group A|Subjects who are mAb ADA positive
11437542|NCT01783015|Experimental|Group B|Subjects who are mAb ADA negative
11437543|NCT01783015|Placebo Comparator|Group C|Subjects who are mAb ADA positive
11437544|NCT01783015|Placebo Comparator|Group D|Subjects who are mAb ADA negative
11437545|NCT01783002|Experimental|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
11437546|NCT01782989|Experimental|ORACEA®|40mg doxycycline
11437547|NCT01782989|Placebo Comparator|Placebo|
11437548|NCT01782976|Experimental|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
11437549|NCT01782963|Experimental|Treatment Arm|"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)
~Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15"
11437550|NCT01782950|Other|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
11437551|NCT01782937|Experimental|KHK4827|
11437552|NCT01782924|Experimental|KHK4827 140mg SC|
11437553|NCT01782924|Experimental|KHK4827 210mg SC|
11437554|NCT01782911|Experimental|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
11437555|NCT01782911|Placebo Comparator|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
11437556|NCT01782898|Active Comparator|Esmolol|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
11568358|NCT00871598|Experimental|Repeat 4.0|
11437565|NCT01782859|Active Comparator|Prednisone/hydrocortisone|"Steroid group will receive the following:
~20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital
~100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by 3. Second and last dose of 100 mg hydrocortisone IV"
11437566|NCT01782846|Active Comparator|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
11437567|NCT01782846|Active Comparator|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
11437568|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
11437569|NCT01782820||no dexamethasone|no dexamethasone during measurements
11437570|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
11437571|NCT01782807|No Intervention|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
11437572|NCT01782807|Experimental|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
11437573|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
11437574|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
11437575|NCT01782781|Placebo Comparator|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.
~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
11437576|NCT01782781|Active Comparator|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.
~Drug: ropivacaine, ketorelac and epinephrine
~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
11437577|NCT01782768|Experimental|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
11437578|NCT01782755|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
11437579|NCT01782755|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
11437580|NCT01782742|Active Comparator|Bexarotene treatment Arm|"75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.
~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
11437581|NCT01782742|Placebo Comparator|Placebo|"1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.
~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
11437582|NCT01782729|Experimental|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
11437583|NCT01782716||ASA|
11437584|NCT01782716||ASA+Euroscore|
11437585|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
11437586|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
11437587|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
11437588|NCT01782690||Erlotinib plus Gemcitabine|Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
11437589|NCT01782677|Experimental|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
11437590|NCT01782664|Experimental|100 mg GSK2586184|Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
11437591|NCT01782664|Experimental|200 mg GSK2586184|Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
11437592|NCT01782664|Experimental|400 mg GSK2586184|Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
11437593|NCT01782664|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo twice daily for up to 84 days
11437594|NCT01782664|Experimental|400 mg GSK2586184 (Cohort B)|Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
11437595|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
11437596|NCT01782638|Experimental|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
11437597|NCT01782638|Other|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
11437599|NCT01782625|Experimental|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
11437600|NCT01782625|Experimental|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
11437601|NCT01782625|Experimental|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
11437602|NCT01782612|Active Comparator|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
11437603|NCT01782612|Experimental|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
11437604|NCT01782599|Experimental|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
11437605|NCT01782573|Active Comparator|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
11437606|NCT01782573|Active Comparator|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
11437607|NCT01782560|Placebo Comparator|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
11437608|NCT01782560|Active Comparator|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
11437609|NCT01782547|Experimental|Telehealth Intervention|Telehealth intervention - 6 months
11437610|NCT01782547|Active Comparator|Usual care|Usual care control with comparable frequency of contact
11437611|NCT01782534||aortic dissection|aortic dissection
11437612|NCT01782521|No Intervention|Primer|Metal brackets bonded with primer
11437613|NCT01782521|Experimental|No primer|Metal brackets bonded without primer
11437614|NCT01782508|Experimental|imatinib|Participants will take 400mg tablets once daily for one year
11437615|NCT01782508|Active Comparator|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
11437616|NCT01782495|Experimental|Arm A|Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
11437617|NCT01782495|Experimental|Arm B|Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
11437618|NCT01782495|Experimental|Arm C|Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
11437619|NCT01782495|Experimental|Arm D|Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
11437620|NCT01782495|Experimental|Arm E|Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
11437621|NCT01782495|Experimental|Arm F|Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
11437622|NCT01782495|Experimental|Arm G|Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
11437623|NCT01782495|Experimental|Arm H|Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
11437624|NCT01782495|Experimental|Arm I|Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
11437625|NCT01782495|Experimental|Arm J|Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
11437626|NCT01782495|Experimental|Arm K|Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
11437627|NCT01782482|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
11437628|NCT01782482|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
11437629|NCT01782469||Rheumatoid Arthritis (RA) participants|Male or female participants at least 18 years of age with diagnosis of RA
11437630|NCT01782456|Experimental|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
11437631|NCT01782443|Experimental|Experimental Treatment Arm|Ziv-aflibercept IV every 2 weeks, 4 mg/kg
11437632|NCT01782430|Experimental|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
11437633|NCT01782430|Experimental|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
11437634|NCT01782430|Other|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
11437635|NCT01782417|Other|Patient and provider intervention|participants will receive a patient and provider intervention
11437636|NCT01782404|Experimental|Chlorhexidine|
11437637|NCT01782391|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
11437638|NCT01782391|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
11437639|NCT01782378|Active Comparator|Real LED Treatment Series|Participants in this group receive a series of 15 real LED treatments with the helmet and intranasal devices: Transcranial NIR, 830nm LED Helmet and two intranasal nose clips (633 nm, and 810 nm, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two NIR 870nm LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. LEDs are FDA-cleared, non-significant risk. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
11437640|NCT01782378|Sham Comparator|Sham LED Treatment Series|Participants in this group first receive a series of 15 sham LED treatments with the helmet and intranasal devices containing sham LEDs (no photons were emitted): Transcranial LED Helmet and two intranasal nose clips (sham LEDs, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two sham LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. These participants were offered an optional Second Real Series of identical 15 real LED treatments. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
11437641|NCT01782365|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
11437642|NCT01782365|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of SWS
11437643|NCT01782352|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day
~Fish oil placebo"
11437644|NCT01782352|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
11437645|NCT01782352|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo
~fish oil placebo"
11437646|NCT01782352|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
11437647|NCT01782339|Experimental|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2
~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.
~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
11437648|NCT01782326|Experimental|QVA149|QVA149 (110/50 μg) once daily
11437649|NCT01782326|Active Comparator|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone (50/500μg) b.i.d
11437650|NCT01782313|Experimental|Treatment (tivozanib)|Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11437651|NCT01782300|Experimental|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
11437652|NCT01782300|Placebo Comparator|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
11437653|NCT01782287|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
11437654|NCT01782287|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
11437687|NCT01782053|Experimental|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
11437753|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
11437655|NCT01782274|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
11437656|NCT01782274|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
11437657|NCT01782261|Experimental|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
11437658|NCT01782261|Active Comparator|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
11437659|NCT01782248|Other|Alzheimer disease|Patients with Alzheimer disease
11437660|NCT01782248|Other|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
11437661|NCT01782248|Other|Control|Control group
11437662|NCT01782235|Experimental|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
11437663|NCT01782235|Placebo Comparator|Placebo arm|Placebo arm will receive placebo.
11437664|NCT01782222|Experimental|Rotigotine, high dose|Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
11437665|NCT01782222|Experimental|Rotigotine, low dose|Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
11437666|NCT01782222|Placebo Comparator|Placebo|Placebo transdermal patches
11437667|NCT01782196|Experimental|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
11437668|NCT01782196|Experimental|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
11437669|NCT01782183|Experimental|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
11437670|NCT01782170|Active Comparator|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
11437671|NCT01782170|Placebo Comparator|Placebo Control|Once daily 30 second rinse for 24 weeks
11437672|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
11437673|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
11437674|NCT01782144|Active Comparator|NutriSystem|weekly behavior group weight loss education
11437675|NCT01782144|Placebo Comparator|Education|monthly behavior group weight loss education
11437676|NCT01782131|Experimental|Posaconazole (POS)|Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
11437677|NCT01782131|Active Comparator|Voriconazole|Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
11437678|NCT01782118|Experimental|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
11437679|NCT01782118|Placebo Comparator|Placebo|Placebo two times per day for six weeks
11437680|NCT01782105|Active Comparator|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
11437681|NCT01782105|Experimental|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.
~The intervention include:
~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
11437682|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
11437683|NCT01782079|Experimental|L. brevis|
11437684|NCT01782066|Experimental|Menveo, dose escalating|
11437685|NCT01782066|Experimental|Nimenrix, dose escalating|
11437686|NCT01782053|Experimental|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
11437688|NCT01782053|Experimental|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
11437689|NCT01782040|No Intervention|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
11437690|NCT01782040|Experimental|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
11437691|NCT01782027|Experimental|3H-cholesterol|
11437692|NCT01782014|Experimental|Water Insufflation|Colonoscopy using water insufflation
11437693|NCT01782014|Active Comparator|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
11437694|NCT01782014|Active Comparator|Air insufflation|Colonoscopy using air insufflation
11437695|NCT01782001|Experimental|Vitamin A and zinc|combination of vitamin A and zinc supplements
11437696|NCT01782001|Active Comparator|Vitamin A and placebo|vitamin A with placebo
11437697|NCT01781988|Experimental|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
11437698|NCT01781988|Experimental|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
11437699|NCT01781975|Experimental|Imatinib Mesylate|400 mg imatinib given once daily basis.
11437700|NCT01781975|Placebo Comparator|Placebo|Placebo given once daily basis.
11437701|NCT01781962||All Participants|Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
11437702|NCT01781949|Other|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
11437703|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
11437704|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
11437705|NCT01781936|Experimental|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
11437706|NCT01781923|Experimental|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.
~40 week small group social skills training sessions aimed to improve social skills and cognition."
11437707|NCT01781923|No Intervention|Control|No intervention
11437708|NCT01781910|Experimental|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
11437709|NCT01781910|Placebo Comparator|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
11437710|NCT01781897|Active Comparator|mosapride|mosapride
11437711|NCT01781897|Experimental|Electro-acupuncture|Electro-acupuncture
11437712|NCT01781897|Sham Comparator|mosapride + sham acupuncture|mosapride + sham acupuncture
11437713|NCT01781884|Active Comparator|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
11437714|NCT01781884|Active Comparator|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
11437715|NCT01781884|Placebo Comparator|placebo|placebo will be given thrice daily for 52 weeks
11437716|NCT01781871|Experimental|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
11437717|NCT01781871|Active Comparator|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
11437718|NCT01781871|Experimental|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
11437719|NCT01781871|Active Comparator|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
11437720|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
11437721|NCT01781845|Experimental|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
11437748|NCT01781637|Placebo Comparator|placebo|Patients will receive placebo.
11437749|NCT01781624|Experimental|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
11437750|NCT01781611|Experimental|extended release dipyridamole/aspirin|extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
11437722|NCT01781832|Experimental|(ARFI)-Derived Shear Wave Velocities|"This is an ultrasound-based new technique using Acoustic Radiation Force Impulse (ARFI). Shear Wave speeds are derived using ARFI.
~During ultrasound scanning a sound wave is sent towards tissue. The tissue's movement in response to the wave is measured in Shear Wave Velocity, which can estimate tissue stiffness. This technique may help detect bladder wall thickness and fibrosis (thickening) in the urinary bladder of pediatric patients."
11437723|NCT01781819|Experimental|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
11437724|NCT01781806|Active Comparator|Cohort H (PrEP)|"Participants in the H cohort will be provided with a CPP, including daily oral emtricitabine/tenofovir-based PrEP.
~High Risk Cohort Criteria (one or more of the following has to be met):
~No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last three months.
~STD diagnosis during the last 12 months.
~Previous PEP use during the last 12 months (* see exclusion criteria)
~Has at least one HIV infected sexual partner for ≥4 weeks."
11437725|NCT01781806|Active Comparator|Cohort LM (PEP)|Participants who do not meet criteria for High Risk (Cohort H) will be assigned to the LM (low moderate) cohort and will receive a customized prevention package based on baseline assessments (in the same manner as the Cohort H Participants). In addition, they will receive education on the availability and use of post-exposure prophylaxis.
11437726|NCT01781793|Placebo Comparator|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
11437727|NCT01781793|Active Comparator|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
11437728|NCT01781780|Active Comparator|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
11437729|NCT01781780|Experimental|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
11437730|NCT01781780|Experimental|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
11437731|NCT01781754||Diabetic patients|Un balanced diabetic patients
11437732|NCT01781741|Experimental|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
11437733|NCT01781728|Active Comparator|RT naive|
11437734|NCT01781728|Active Comparator|Previous RT|
11437735|NCT01781715|Experimental|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
11437736|NCT01781715|Active Comparator|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
11437737|NCT01781702|Experimental|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
11437738|NCT01781702|Active Comparator|Celebrex 200 mg|Celebrex 200 mg, tid
11437739|NCT01781689|Experimental|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
11437740|NCT01781689|Sham Comparator|traditional rehabilitation program|Receive traditional rehabilitation programs
11437741|NCT01781689|No Intervention|Health|with no motor function impairment
11437742|NCT01781663|Experimental|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
11437743|NCT01781663|Sham Comparator|petrolatum-based moisturizer|control group
11437744|NCT01781650|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
11437745|NCT01781650|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
11437746|NCT01781650|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
11437747|NCT01781637|Experimental|omalizumab group|Patients will receive omalizumab.
11437798|NCT01781286|No Intervention|No Snack|No Snack
11437754|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
11437755|NCT01781572|Experimental|Phase Ib|"The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.
~Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).
~Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).
~Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle)."
11437756|NCT01781572|Experimental|Phase II|"The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.
~Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination."
11437757|NCT01781559|Experimental|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
11437758|NCT01781559|Placebo Comparator|Maltodextrin|Maltodextrin
11437759|NCT01781559|Active Comparator|flavanol + maltodextrin|flavanol + maltodextrin
11437760|NCT01781546|Experimental|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), Includes both stable CAD and ACS patients.
11437761|NCT01781546|Active Comparator|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
11437762|NCT01781533|Experimental|algorithm|
11437763|NCT01781520|Experimental|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
11437764|NCT01781520|Active Comparator|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
11437765|NCT01781520|Active Comparator|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
11437766|NCT01781520|Active Comparator|Best supportive care|
11437767|NCT01781507|Experimental|Cetirizine|Cetirizine 10 mg orally once a day
11437768|NCT01781507|Placebo Comparator|Sugar pill|This will be the placebo arm
11437769|NCT01781494|Active Comparator|Immobilization|Immobilization followed by protected range of motion
11437770|NCT01781494|Experimental|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
11437771|NCT01781481||Children and youth with IBD|Children/youth (ages 8-17) with confirmed diagnoses of IBD.
11437772|NCT01781468|Experimental|Arm I|Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks.
11437773|NCT01781468|Placebo Comparator|Arm II|Patients receive placebo orally every day in the morning for 8 weeks.
11437774|NCT01781468|Experimental|Arm III|Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks.
11437775|NCT01781455|Experimental|BBI503|
11437776|NCT01781442||Patient Arm- temsirolimus|
11437777|NCT01781429|Experimental|BVD-523|
11437778|NCT01781416||1|
11437779|NCT01781403|Experimental|Capecitabine, Temozolomide, Radiotherapy|"The total dose of radiotherapy will be 50.4 Gy, with a daily dose of 1.8 Gy administered on 5 days of each week, comprising a total of 45 Gy to the whole pelvis, followed by a 5.4 Gy boost to the primary tumor.
~The doses and schedules for capecitabine will be fixed, with only temozolomide being prescribed using a dose-escalation schedule. Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break)."
11437780|NCT01781390|Experimental|12.5M Mesenchymal Precursor Cells (MPC)|12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion
11437781|NCT01781390|Experimental|25M Mesenchymal Precursor Cells (MPC)|25M Mesenchymal Precursor Cell (MPC) administered via IC infusion
11437782|NCT01781390|Placebo Comparator|Placebo|Placebo via IC infusion
11437783|NCT01781377|Experimental|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
11437784|NCT01781377|Experimental|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
11437785|NCT01781377|Experimental|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
11437786|NCT01781377|Placebo Comparator|PLACEBO|SALINE INFUSION
11437787|NCT01781364|Experimental|Cognitive Training|Brain Fitness Training, Posit Science SF
11437788|NCT01781351|Experimental|taping the ankle|
11437789|NCT01781338|Experimental|Induction Therapy|The kind of induction therapy is dependent on the respective sub-protocol.
11437790|NCT01781325|Active Comparator|IBEHR|IBEHR
11437791|NCT01781325|No Intervention|Standard therapy|written instructions
11437792|NCT01781312|Experimental|ProTectis|
11437793|NCT01781312|Experimental|Gastrus|
11437794|NCT01781299|Active Comparator|AlloDerm RTU|Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.
11437795|NCT01781299|Active Comparator|SurgiMend PRS|Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.
11437796|NCT01781286|Active Comparator|High Protein|Higher Protein Soy-based Snacks
11437797|NCT01781286|Active Comparator|Low Protein|Typical, Low Protein Snacks
11437799|NCT01781273|Placebo Comparator|Cranberry juice alone|500 mL of cranberry juice
11437800|NCT01781273|Experimental|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
11437801|NCT01781273|Experimental|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
11437802|NCT01781273|Experimental|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
11437803|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
11437804|NCT01781247|Experimental|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
11437805|NCT01781247|Active Comparator|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
11437806|NCT01781234|Experimental|Intranasal Insulin|Intranasal Insulin
11437807|NCT01781234|Placebo Comparator|Placebo|Placebo
11437808|NCT01781221|Active Comparator|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
11437809|NCT01781221|Active Comparator|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
11437810|NCT01781208|Experimental|Ultrasound-based Acoustic Radiation Force Imaging|The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).
11437811|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score >20) under CNI-based immunosuppression with Advagraf
11437812|NCT01781169|Experimental|Obese group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
11437813|NCT01781169|Experimental|Normal-weight group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
11437814|NCT01781143|Experimental|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
11437815|NCT01781130|Placebo Comparator|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
11437816|NCT01781130|Experimental|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
11437817|NCT01781117|Experimental|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
11437818|NCT01781104|Active Comparator|RM-131|
11437819|NCT01781104|Placebo Comparator|Placebo|
11437820|NCT01781091|Experimental|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
11437821|NCT01781091|Active Comparator|Conventional modes ventilation|Conventional modes
11437822|NCT01781078|Experimental|MRI Group|Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
11437823|NCT01781078|Experimental|Control Group|Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
11437824|NCT01781065|Experimental|transcranial direct current stimulation|Anodal stimulation on motor cortex
11437825|NCT01781065|Sham Comparator|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
11437826|NCT01781052||Group 1|
11437827|NCT01781039||low HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
11437828|NCT01781039||high HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
11437829|NCT01781039||Hearing Aid fitting: MAD|Microphone adaptive directionality (MAD) feature will be activated, the WDC set to linear, and the DNR minimized
11437830|NCT01781039||Hearing Aid fitting: WDC|Wide dynamic compression (WDC) feature will be set to target levels, the MAD feature set to omnidirectional, and the DNR minimized.
11437831|NCT01781039||Hearing Aid fitting: DNR|Digital noise reduction (DNR) set to maximum, MAD set to omnidirectional, and WDC set to linear
11437832|NCT01781039||Hearing Aid fitting: Positive control|All hearing aid features enables
11437833|NCT01781039||Hearing Aid fitting: Negative control|All hearing aid features disabled
11437834|NCT01781026|Experimental|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
11437835|NCT01781013|Experimental|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
11437836|NCT01781013|No Intervention|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
11437837|NCT01781013|No Intervention|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
11437838|NCT01781000|Experimental|Auditiory verbal discrimination training|Brain Fitness & Brain Training- Posit Science
11442858|NCT01746446|No Intervention|Usual Care|Patients receive usual care.
11437839|NCT01781000|Experimental|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
11437840|NCT01781000|Active Comparator|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
11437841|NCT01780987|Experimental|Apixaban|
11437842|NCT01780987|Active Comparator|UFH/Warfarin|
11437843|NCT01780974|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 caps morning, 1 cap evening) + 2 placebo LA capsules per day. Capsules will be taken with food or a meal.
11437844|NCT01780974|Experimental|Lipoic acid plus omega-3 fatty acids|Three 1-gram fish oil concentrate capsules per day (2 caps morning, 1 cap evening) containing a daily dose of 675 mg docosahexaenoic acid (DHA) and 975 mg eicosapentaenoic acid (EPA) plus 2 LA capsules per day with a daily dose of 600 mg. Capsules will be taken with food or a meal.
11437845|NCT01780948|Placebo Comparator|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
11437846|NCT01780948|Experimental|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
~Atorvastatin 20 mg/day (fixed dose)"
11437847|NCT01780935|Experimental|RBZ 0.5 mg: VA only (Group I)|RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
11437848|NCT01780935|Experimental|RBZ 0.5 mg: VA and/or OCT (Group II)|RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).
11437849|NCT01780922|Active Comparator|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
11437850|NCT01780922|Active Comparator|Cranberry Extract Beverage|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
11437851|NCT01780922|Placebo Comparator|Non-Cranberry Beverage|Beverage absent cranberry: one dose of 15.2 ounces consumed within 15 minutes
11437852|NCT01780909|Experimental|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
11437853|NCT01780909|Experimental|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
11437854|NCT01780909|Experimental|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
11437855|NCT01780909|Experimental|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
11437856|NCT01780896||Study Group|
11437857|NCT01780883|Placebo Comparator|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
11437858|NCT01780883|Experimental|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
11437859|NCT01780883|Experimental|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
11437860|NCT01780883|Experimental|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
11437861|NCT01780870|No Intervention|Control Group|Obese, otherwise healthy people who are not receiving any nutritional,surgical or behavioral therapy
11437862|NCT01780870|Active Comparator|Weight loss group|Full Meal replacement Protocol
11437863|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
11437864|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
11437865|NCT01780844|Active Comparator|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
11437866|NCT01780844|Experimental|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
11437867|NCT01780844|Experimental|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
11437970|NCT01780155||1|Parents and premature newborns with a birth weight less than or equal to1250 g from member institutions of the hospital network will be invited to participate in this study.
11568359|NCT00871598|Experimental|Repeat 8.0|
11437868|NCT01780831|Experimental|Cohort 1|"HIV-1-exposed full-term infants. Infants received two single doses of RAL: first dose within 48 hours of birth and second dose at 7-10 days of life:
~RAL-naive: 3 or 2 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life.
~RAL-exposed: 1.5 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life."
11437869|NCT01780831|Experimental|Cohort 2|"HIV-1-exposed full-term infants. Daily RAL through 6 weeks of life with first dosing within 48 hours of birth and between 12-60 hours of birth for in utero RAL-naive and RAL-exposed infants, respectively.
~Daily RAL through 6 weeks of life: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg twice daily during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of life."
11437870|NCT01780818|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
11437871|NCT01780818|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
11437872|NCT01780818|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
11437873|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
11437874|NCT01780792|Experimental|Dance Dance Revolution game play|Dance Dance Revolution video game play
11437875|NCT01780792|No Intervention|control|individuals continue usual care for 8 weeks
11437876|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.
~All included patients will be treated by chemotherapy (EURAMOS protocol)
~An MRI will be performed before, during and post-treatment"
11437877|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.
~All included patients will be treated by chemotherapy (EURO-EWING protocol)
~An MRI will be performed in all included patients before, during and after the chemotherapy"
11437878|NCT01780766||Indolent myeloma patient|
11437879|NCT01780766||Symptomatic Myeloma patient|
11437880|NCT01780753|Experimental|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
11437881|NCT01780740|Experimental|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
11437882|NCT01780740|Placebo Comparator|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
11437883|NCT01780727|No Intervention|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
11437884|NCT01780727|Experimental|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
11437885|NCT01780714|Active Comparator|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
11437886|NCT01780714|Experimental|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
11437887|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
11437888|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
11437889|NCT01780688|Active Comparator|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
11437890|NCT01780688|Experimental|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
11437891|NCT01780675|Active Comparator|Prophylactic Cranial Irradiation|Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)
11437892|NCT01780675|Experimental|Hippocampal Avoidance PCI|Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).
11437893|NCT01780662|Experimental|Treatment (brentuximab vedotin, gemcitabine hydrochloride)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
11437894|NCT01780649|Experimental|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
11437895|NCT01780649|Active Comparator|ICSI|Intracytoplasmic sperm injection (ICSI)
11437896|NCT01780636|Experimental|Botulinum toxin (Botox) injection|All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.
11437897|NCT01780623|Experimental|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
11437898|NCT01780623|Active Comparator|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
11437971|NCT01780142||asthmatics|Subjects with confirmed diagnosis of asthma without other lung disease followed forcollection of clinical data &amp; specimens
11443252|NCT01743846||Major Surgery|Patients undergoing major surgery
11437899|NCT01780610|Other|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
11437900|NCT01780610|Other|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
11437901|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
11437902|NCT01780584|Active Comparator|Oral T3 low dose & placebo|Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
11437903|NCT01780584|Placebo Comparator|Placebo|Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
11437904|NCT01780584|Experimental|Oral T3 high dose|Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)
11437905|NCT01780571|No Intervention|Control group|Neutral pressure breathing after 2 min preoxygenation
11437906|NCT01780571|Active Comparator|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
11437907|NCT01780558|Other|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
11437908|NCT01780558|Other|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
11437909|NCT01780545|Experimental|Experimental Arm: Arm A|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
11437910|NCT01780545|Active Comparator|Control Arm: Arm B|Docetaxel (75 mg/M2) will be administered IV on day 1 of each 21 day cycle for a maximum of 10 cycles.
11437911|NCT01780532|Experimental|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
11437912|NCT01780519|Other|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
11437913|NCT01780519|Other|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
11437914|NCT01780519|Other|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
11437915|NCT01780519|Other|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
11437916|NCT01780519|Other|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
11437917|NCT01780506|Experimental|E/C/F/TAF (Double-Blind Phase)|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
11437918|NCT01780506|Active Comparator|E/C/F/TDF (Double-Blind Phase)|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
11437919|NCT01780506|Experimental|Open-Label Extension Phase|After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
11437920|NCT01780493|Other|Direct Nipple Ureteroneocystostomy|
11437921|NCT01780480|Experimental|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
11437922|NCT01780480|Placebo Comparator|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
11437923|NCT01780467|Experimental|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
11437924|NCT01780467|Other|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
11437925|NCT01780454|Experimental|Combined Bone Marrow and Kidney Transplantation|Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
11437926|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
11437927|NCT01780428|Experimental|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
11437928|NCT01780428|Active Comparator|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
11437929|NCT01780428|Placebo Comparator|Placebo|CL-108 formulation without API
11437930|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
11437968|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
11572046|NCT00845585|Active Comparator|PTFE|
11437931|NCT01780402|Experimental|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
11437932|NCT01780389|Experimental|Milnacipran|Open-label flexibly dosed milnacipran
11437933|NCT01780376|Experimental|WBV group|whole-body vibration (WBV) group
11437934|NCT01780363||controls|frequency of mevalonate kinase gene frequency
11437935|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
11437936|NCT01780350|Experimental|ResQGARD ITD|Subjects receive a ResQGARD ITD.
11437937|NCT01780337|Active Comparator|Oxytocin|Patients will be administered an intranasal dose of the study drug, 20 IU oxytocin. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
11437938|NCT01780337|Placebo Comparator|Saline|Patients will be administered an intranasal dose of saline. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
11437939|NCT01780324|No Intervention|No lidocaine|This group will have urinary catheterization without lidocaine (per standard procedure)
11437940|NCT01780324|Experimental|Lidocaine|The Intervention is the application of intraurethral lidocaine 5 minutes prior to urethral catheterization.
11437941|NCT01780311|Active Comparator|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
11437942|NCT01780311|Experimental|ABLATION|Catheter Ablation
11437943|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
11437944|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
11437945|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
11437946|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
11437947|NCT01780285|Active Comparator|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
11437948|NCT01780285|Active Comparator|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
11437949|NCT01780272|Other|Normoglycaemia followed by hypoglycaemia|
11437950|NCT01780272|Other|Hypoglycaemia followed by normoglycaemia|
11437951|NCT01780259|Experimental|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
11437952|NCT01780259|Experimental|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
11437953|NCT01780259|Experimental|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
11437954|NCT01780259|Experimental|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
11437955|NCT01780259|Experimental|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
11437956|NCT01780259|Experimental|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
11437957|NCT01780259|Experimental|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
11437958|NCT01780246|Experimental|nusinersen|
11437959|NCT01780233|Experimental|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
11437960|NCT01780233|Active Comparator|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
11437961|NCT01780233|Active Comparator|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
11437962|NCT01780220|Experimental|abiraterone|Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
11437963|NCT01780207|No Intervention|OSA without PFO|
11437964|NCT01780207|Other|OSA with PFO|PFO closure
11437965|NCT01780194||Lumbar fusion group|
11437966|NCT01780194||Conservative treatment group|
11437967|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
11437969|NCT01780168||Inborn errors of metabolism/mitochondrial disease|Patients with inborn errors of metabolism including those with mitochondrial disease
11572736|NCT00840463|Active Comparator|1|
11437972|NCT01780142||non-asthmatic healthy volunteers|Healthy volunteers in whom asthma has been ruled out and without other lung diseasefollowed for comparison to asthmatics
11437973|NCT01780129|Experimental|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
11437974|NCT01780129|Placebo Comparator|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
11437975|NCT01780116|Experimental|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:
~Engaging patients: assessing needs and concerns in medication adherence;
~Reviewing strengths and barriers and developing coping strategies; and
~Rationalizing beliefs and concerns and preventing relapse."
11437976|NCT01780116|No Intervention|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
11437977|NCT01780090|Experimental|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
11437978|NCT01780077|Experimental|RXI-109|
11437979|NCT01780077|Placebo Comparator|Placebo|
11437980|NCT01780064|Placebo Comparator|Standard group|routine monitoring with questionnaires
11437981|NCT01780064|Active Comparator|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
11437982|NCT01780051|Experimental|Sequence A|
11437983|NCT01780051|Experimental|Sequence B|
11437984|NCT01780038|Experimental|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
11437985|NCT01780038|Active Comparator|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
11437986|NCT01780025||Mixed hearing loss|
11437987|NCT01780012|Experimental|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
11437988|NCT01780012|No Intervention|Control|Control women will receive usual post-fracture care without information
11437989|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
11437990|NCT01779973|Experimental|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
11437991|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
11437992|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
11437993|NCT01779947|Experimental|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
11437994|NCT01779947|Active Comparator|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
11437995|NCT01779947|Placebo Comparator|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
11437996|NCT01779921||FVII|
11437997|NCT01779908|Experimental|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
11437998|NCT01779908|Placebo Comparator|Placebo|Placebo pill for 6 months
11437999|NCT01779895|Active Comparator|NCC2461|probiotic blended in maltodextrin powder to be taken daily
11438000|NCT01779895|Placebo Comparator|Placebo|maltodextrin
11438001|NCT01779882|Active Comparator|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
11438002|NCT01779882|Experimental|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
11438003|NCT01779869|Experimental|Single group assignment - imaging|All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.
11438004|NCT01779856|Other|REVEAL Insertable Cardiac Monitor (ICM)|Monitoring of cardiac arrhythmic events and the relationship between such events and the characteristics.
11438005|NCT01779843|Experimental|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.
~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
11438006|NCT01779830|Experimental|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
11438007|NCT01779830|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
11438008|NCT01779830|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
11438009|NCT01779830|Active Comparator|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
11438010|NCT01779830|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
11438011|NCT01779817|Other|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
11438012|NCT01779817|Other|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
11438013|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
11438014|NCT01779791|Experimental|PCI-32765 (Ibrutinib)|
11438015|NCT01779765|Experimental|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
11438016|NCT01779765|Placebo Comparator|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
11438017|NCT01779739|No Intervention|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
11438018|NCT01779739|Active Comparator|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
11438019|NCT01779726|Experimental|CT scan before chest physician|CT scan before chest physician
11438020|NCT01779726|Active Comparator|Usual diagnostic workup|Usual diagnostic workup
11438021|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
11438022|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
11438023|NCT01779700|Active Comparator|Fingolimod|0.5mg of fingolimod, oral administration, daily, for 8 weeks.
11438024|NCT01779700|Placebo Comparator|placebo|placebo, oral administration, daily, for 8 weeks.
11438025|NCT01779687|Active Comparator|raltegravir alone|Raltegravir 400 mg BID for 7 days
11438026|NCT01779687|Active Comparator|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
11438027|NCT01779687|Experimental|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
11438028|NCT01779661|Active Comparator|Infant Aquatics|
11438029|NCT01779661|Active Comparator|Infant Massage|Infant Massage
11438030|NCT01779648|Active Comparator|Simultaneous compression+Fixed refill time|Simultaneous bilateral compression with fixed venous refill time through the whole duration of pneumatic compression
11438031|NCT01779648|Active Comparator|Alternate compression+Adjusted refill time|alternate bilateral compression with adjusted venous refill time which would change several times during pneumatic compression
11438032|NCT01779635|Active Comparator|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
11438033|NCT01779635|Other|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
11438034|NCT01779622|Experimental|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
11438035|NCT01779609|Experimental|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
11438036|NCT01779609|Placebo Comparator|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
11438037|NCT01779609|Other|Exercise|3x/week supervised exercise for 8 weeks
11438038|NCT01779596|Experimental|Bosentan|Single dose of Bosentan (125 mg)
11438039|NCT01779596|Placebo Comparator|Placebo|Single dose of placebo (125 mg)
11438040|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
11438041|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
11438042|NCT01779570|Experimental|Macrolide treatment|Azithromycin 500 mg daily for 5 days
11438043|NCT01779570|No Intervention|No macrolide treatment|No azithromycin
11438044|NCT01779557|Experimental|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
11438045|NCT01779557|Active Comparator|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
11438046|NCT01779544|Active Comparator|Brief intervention only|Brief intervention, an educational model, consists of information
11438047|NCT01779544|Active Comparator|Exercise group|Brief educational intervention combined with exercise therapy
11438048|NCT01779531||pCR，XT|
11438049|NCT01779505|Experimental|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
11438050|NCT01779505|Experimental|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
11438051|NCT01779505|Experimental|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
11438052|NCT01779492|Experimental|GL2907|Oxycodone HCl 20mg
11438053|NCT01779492|Active Comparator|Oxycontine CR 10mg|Oxycodone HCl 10mg
11438054|NCT01779479|Experimental|Cabacitaxel|
11438055|NCT01779479|Active Comparator|Paclitaxel|
11438056|NCT01779466|Experimental|Experimental A|
11438057|NCT01779466|Experimental|Experimental B|
11438058|NCT01779466|Placebo Comparator|Placebo|
11438059|NCT01779453|Experimental|ETC-1002|ETC-1002 treatment group, oral once daily
11438060|NCT01779453|Placebo Comparator|Placebo|Placebo treatment group, oral once daily
11438061|NCT01779440|Other|Electronic Decision Support System|The Electronic Decision Support System is a web-based computer program designed to motivate, educate, and engage people with severe mental illness into evidence-based smoking cessation treatment.
11438062|NCT01779440|Placebo Comparator|Control Computer Program|A computer program aimed to educate people about smoking cessation treatment.
11438063|NCT01779427|Experimental|AIM Intervention|
11438064|NCT01779427|Experimental|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
11438065|NCT01779414|No Intervention|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
11438066|NCT01779414|Experimental|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
11438067|NCT01779401|Active Comparator|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
11438068|NCT01779401|Active Comparator|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
11438069|NCT01779401|Active Comparator|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
11438070|NCT01779388|Other|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
11438071|NCT01779388|Experimental|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
11438072|NCT01779375|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
11438073|NCT01779375|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.
11438074|NCT01779362|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
11438075|NCT01779362|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
11438076|NCT01779362|Placebo Comparator|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
11438077|NCT01779362|Active Comparator|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
11438078|NCT01779349|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
11438079|NCT01779336|Experimental|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
11438080|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
11438081|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
11438082|NCT01779284|Active Comparator|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
11438083|NCT01779284|Active Comparator|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
11438084|NCT01779271|Experimental|Pelubiprofen|
11438085|NCT01779271|Active Comparator|Loxoprofen|
11438086|NCT01779258|Other|Group 2|Active control arm, Locatop@, Locapred@
11438087|NCT01779258|Other|Group 3|Absence of emollient treatment, Locatop@, Locapred@
11438088|NCT01779258|Experimental|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@
~, Locapred@"
11438089|NCT01779245|Placebo Comparator|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
11438090|NCT01779245|Experimental|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
11438091|NCT01779232|Placebo Comparator|control|patients treated with placebo for at least 4 months before IVF attempt
11438092|NCT01779232|Active Comparator|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
11438093|NCT01779219|Active Comparator|iMRI-guided|Intervention: iMRI-guided brain tumour biopsy. The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet imager will be used in all cases. After the patient's positioning, the preoperative reference examination is routinely carried out. The entry point, target and optimal biopsy trajectory are then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples are collected. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) is routinely performed to confirm and document the proper targeting and to exclude postoperative hyperacute intraparenchymal bleeding.
11438094|NCT01779219|Active Comparator|non-iMRI|Intervention: Stereotactic frameless brain tumour biopsy. A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
11438095|NCT01779206|Active Comparator|Anthracycline - Taxane|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
11438096|NCT01779206|Experimental|Taxane - Anthracycline|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
11438097|NCT01779193|Experimental|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
11438098|NCT01779193|Active Comparator|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
11438099|NCT01779193|Placebo Comparator|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
11438100|NCT01779167|Experimental|All Patients|Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
11438101|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
11438102|NCT01779141||CSII|Patients using CSII with or without CGM.
11438103|NCT01779128|Experimental|Experimental Arm|PET/CT Scan MR-PET Scan
11438104|NCT01779102|Experimental|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
11438105|NCT01779102|Active Comparator|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
11438106|NCT01779102|Experimental|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
11438107|NCT01779089|Experimental|Minocycline|Minocycline 100 mg po bid for 6 months
11438108|NCT01779089|Placebo Comparator|Placebo|Placebo one tablet po bid
11438109|NCT01779076|Experimental|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
11438110|NCT01779076|Experimental|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
11438111|NCT01779063|Experimental|web based multimedia intervention|interactive,web based multimedia intervention
11438112|NCT01779063|Active Comparator|education booklet|printed educational booklet
11438113|NCT01779050|Active Comparator|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:
~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel
~docetaxel plus cyclophosphamide
~single-agent paclitaxel
~docetaxel plus carboplatin
~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
11438114|NCT01779050|Experimental|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:
~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel
~docetaxel plus cyclophosphamide
~single-agent paclitaxel
~docetaxel plus carboplatin
~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel
~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
11438115|NCT01779037||Inpatient Rehabilitation Patients|
11438116|NCT01779024|Experimental|ASA/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first ASA visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second ASA visit.
11438117|NCT01779024|Placebo Comparator|ASA/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first ASA visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second ASA visit
11438118|NCT01779024|Experimental|fMRI/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first fMRI visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second fMRI visit.
11438119|NCT01779024|Placebo Comparator|fMRI/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first fMRI visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second fMRI visit
11438120|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
11438121|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
11438122|NCT01778998|Active Comparator|MICS-group|
11438123|NCT01778998|Active Comparator|SICS-group|
11438124|NCT01778998|Active Comparator|SICS pre-cut|
11438125|NCT01778998|Active Comparator|SICS stab-incision|
11438126|NCT01778985|Experimental|Premarin|Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
11438127|NCT01778985|Placebo Comparator|Placebo|Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
11438128|NCT01778972|Experimental|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.
~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
11438129|NCT01778972|Experimental|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
11438130|NCT01778972|No Intervention|Control grop|Participants are instructed to live their ordinary lives.
11438131|NCT01778959|Active Comparator|standard OVD|
11438132|NCT01778959|Active Comparator|Iris hooks|
11438133|NCT01778959|Active Comparator|Malyugin Ring|
11438134|NCT01778959|Active Comparator|OVD|
11438135|NCT01778946|Experimental|Nicotine|"Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)
~All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).
~Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.
~All participants will apply a new patch daily for a total of 28 days (1 month)"
11438136|NCT01778933|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
11438137|NCT01778920|Experimental|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
11438138|NCT01778907|No Intervention|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
11438139|NCT01778907|No Intervention|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
11438140|NCT01778907|Experimental|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
11438141|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
11438142|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, > Grade II (NYHA functional class) and/or > Grade II Diastolic Dysfunction as evaluated by echocardiography
11438143|NCT01778881|Experimental|Massage + Exercise|Massage and stretching exercises
11438144|NCT01778881|Experimental|Relaxation +Imagination|Relaxation and Imagination therapies
11438145|NCT01778881|Experimental|Dental treatment|Reconstruction with composite resin
11438146|NCT01778881|Experimental|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
11438147|NCT01778868||Overweight and obese individuals|
11438148|NCT01778868||Normal weight individuals|
11438149|NCT01778855|Active Comparator|Normothermia|IV t-PA and normothermia
11438150|NCT01778855|Active Comparator|Hypothermia|IV t-PA and hypothermia
11438151|NCT01778842|Experimental|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
11438152|NCT01778842|Experimental|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
11438153|NCT01778829|Active Comparator|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
11438154|NCT01778829|Experimental|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
11438155|NCT01778803|Experimental|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
11438156|NCT01778790|Sham Comparator|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
11438157|NCT01778790|Active Comparator|Stimulation for 8 weeks|Implantation of IPG and active stimulation
11438158|NCT01778777|Experimental|UniverseReverse|Cohort get an universe reverse prosthesis
11438159|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
11438160|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
11438161|NCT01778751|No Intervention|Control|Veterans will receive diabetes educational materials and management per their primary provider
11438162|NCT01778751|Experimental|Intervention|Veterans randomized to the intervention arm will be enrolled in the HT program, provided with standard telemonitoring equipment by HT nursing staff (current HT practice at DVAMC is use of the Health Buddy 3 device for patients with landline phones and the Cardiocom Interactive Voice Response System for patients with cell phones), and will receive the study intervention for 6 months. Veterans without depressive symptoms on baseline PHQ-9 assessment (PHQ-9 < 10) will not initially be entered into the depressive symptom management component of the intervention, but will be monitored for new symptoms throughout the intervention.
11438163|NCT01778738|Experimental|Sleeve gastrectomy|Sleeve gastrectomy.
11438164|NCT01778738|Experimental|Gastric bypass|Gastric bypass surgery.
11438165|NCT01778738|No Intervention|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
11438166|NCT01778712|Experimental|Intervention|Multi-level intervention
11438167|NCT01778699|Experimental|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
11438168|NCT01778699|Placebo Comparator|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
11438169|NCT01778686|Experimental|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.
~Pindolol peroral administration starting 3 days before scanning:
~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
11438170|NCT01778686|Placebo Comparator|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol
~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)
~Placebo for Seropram: NaCl infusion"
11438171|NCT01778686|Experimental|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
11438172|NCT01778673||Distal radius fractures Sundsvall Hospital|
11438173|NCT01778673||Distal radius fractures Östersund Hospital.|
11438174|NCT01778660|Active Comparator|Standard Counselling|Patients in this arm are randomised to standard counselling.
11438175|NCT01778660|Experimental|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
11438176|NCT01778647|Experimental|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
11438177|NCT01778647|Placebo Comparator|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
11438178|NCT01778634|Placebo Comparator|Placebo (5% dextrose)|Placebo
11438179|NCT01778634|Experimental|Azithromycin|Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
11438180|NCT01778621|Experimental|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
11438181|NCT01778621|No Intervention|No acupuncture|No intervention was done for this group of patients.
11438182|NCT01778569||Group 1|Patient with a diagnosis of chronic plaque psoriasis, psoriatic arthritis, or pustular psoriasis
11438183|NCT01778556|Experimental|Leptin naive|Studied for 5 days without metreleptin, then 14 days while taking metreleptin
11438184|NCT01778556|Experimental|On-leptin|Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
11438185|NCT01778543||Coloboma|Participants with Coloboma and their family members.
11438186|NCT01778530|Experimental|TRC105 for Recurrent Glioblastoma|
11438187|NCT01778504||Probands|Children, adolescents, and adults
11438188|NCT01778504||Relatives of Probands|1st, 2nd, and 3rd degree relatives
11438189|NCT01778465|Experimental|Low salicylate diet|Patients are to follow a low salicylate diet for one week.
11438190|NCT01778465|No Intervention|Normal diet|Patients are to continue with a normal diet for one week. There is then cross-over after one week for a further week into the intervention group.
11438191|NCT01778452|Active Comparator|Natural cycle|Natural cycle endometrial biopsy, lh+7
11438192|NCT01778452|Experimental|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
11438193|NCT01778452|Experimental|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
11438194|NCT01778439|Experimental|OMP-52M51|
11438195|NCT01778426||Patients with Medtronic neurostimulator|Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.
11438196|NCT01778413|Experimental|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
11438197|NCT01778413|Active Comparator|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
11438198|NCT01778400|Experimental|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
11438199|NCT01778400|Active Comparator|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
11438200|NCT01778387|Active Comparator|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
11438201|NCT01778387|Placebo Comparator|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
11438202|NCT01778374|Experimental|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
11438203|NCT01778374|Experimental|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
11438204|NCT01778361||HIV positive|
11438205|NCT01778361||HIV negative|
11438206|NCT01778348|Experimental|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
11438207|NCT01778348|Active Comparator|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
11438208|NCT01778335|No Intervention|Control|Control arm subjects will receive best medical care.
11438209|NCT01778335|Experimental|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
11438210|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
11438211|NCT01778309|Experimental|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
11438212|NCT01778296|Experimental|Surgical flap|The neurocutaneous island flap is based on the dorsal branch of the digital nerve
11438213|NCT01778283|Experimental|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
11438214|NCT01778283|Active Comparator|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
11438215|NCT01778270|Other|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
11438216|NCT01778270|Other|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.
~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
11438217|NCT01778257|Experimental|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
11438218|NCT01778257|Placebo Comparator|Placebo group|Placebo (3150 mg/day) for 12 weeks
11438221|NCT01778231|Experimental|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
11438222|NCT01778231|Placebo Comparator|Inert oil capsule|1 capsule daily for 16 weeks
11438223|NCT01778218|Experimental|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
11438224|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
11438225|NCT01778192|Active Comparator|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
11438226|NCT01778192|Active Comparator|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
11438227|NCT01778192|Active Comparator|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
11438228|NCT01778192|Active Comparator|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
11438229|NCT01778179|Active Comparator|Group 1|"Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) plus sunscreen for 2 weeks. At week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).
~Post-procedure phase (From Week 2 up to Week 13)
~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.
~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):
~The investigational drug (Tri-Luma® cream) plus sunscreen will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
11438230|NCT01778179|Placebo Comparator|Group 2|"Subjects (group 2) will be treated daily for their solar lentigines with sunscreen alone for 2 weeks. At week 2, all the subjects will have the solar lentigines will treated by cryotherapy (CRY-AC3® device).
~Post-procedure phase (Week 2 up to Week 13)
~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.
~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):
~Sunscreen alone will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
11438231|NCT01778166|Active Comparator|Standard early enteral nutrition|There would be 100 patients in this group
11438232|NCT01778166|Experimental|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
11438233|NCT01778153|Experimental|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
11438234|NCT01778153|No Intervention|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
11438235|NCT01778140|Experimental|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
11438236|NCT01778140|Active Comparator|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
11438237|NCT01778140|No Intervention|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
11438238|NCT01778127|Experimental|Group A: Minimal Rewards|Participants use an activity monitor and the interactive website. They will receive minimal rewards based on their physical activity levels.
11438239|NCT01778127|Experimental|Group B: Immediate Incentives|"Participants use an activity monitor and the interactive website.
~In addition to minimal rewards, participants will receive immediate incentives as they move from one level to the other on the website."
11438240|NCT01778127|Experimental|Group C: Control|Participants in the control group will receive an activity monitor and educational materials, but will not have access to the interactive website. No rewards will be offered for their participation.
11438241|NCT01778114|Placebo Comparator|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
11438242|NCT01778114|Experimental|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
11438243|NCT01778114|Experimental|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
11438244|NCT01778114|Active Comparator|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
11438245|NCT01778114|Active Comparator|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
11438246|NCT01778101|Experimental|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
11438247|NCT01778088|Other|Single Group|I-131-CLR1404 Injection
11438248|NCT01778075|Experimental|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
11438249|NCT01778075|Experimental|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
11438250|NCT01778062|Experimental|Indacaterol|Indacaterol 150 µg once daily
11438251|NCT01778062|Placebo Comparator|Placebo|Placebo once daily
11438252|NCT01778049|Experimental|Empagliflozin 10 mg dose|Empagliflozin open label treatment period
11438253|NCT01778049|Experimental|Placebo add on 10 mg dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
11438254|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
11438255|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose.|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
11438256|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
11572737|NCT00840463|Placebo Comparator|2|
11438257|NCT01778049|Experimental|Empagliflozin 25 mg dose|Empagliflozin open label treatment period
11438258|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose.|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
11438259|NCT01778049|Experimental|Placebo add on 25 mg dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
11438260|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
11438261|NCT01778023|Experimental|hGH:12months treatment|
11438262|NCT01778023|Active Comparator|hGH: 6 month un-treatment + 6 month treatment|
11438263|NCT01778010|Placebo Comparator|Modafinil 0mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.
11438264|NCT01778010|Experimental|Modafinil 200mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.
11438265|NCT01778010|Experimental|Modafinil 400mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.
11438266|NCT01777997|Experimental|FTC/RPV/TDF|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.
~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
11438267|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
11438268|NCT01777958||Cohort|
11438269|NCT01777945||Participants Receiving Capecitabine/Docetaxel|Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.
11438270|NCT01777932||Cohort|
11438271|NCT01777919|Experimental|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.
~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
11438272|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
11438273|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
11438274|NCT01777893|Experimental|HP-HI|High protein/ high intensity physical activity
11438275|NCT01777893|Experimental|HP-MI|High protein/ moderate intensity physical activity
11438276|NCT01777893|Experimental|MP-HI|Moderate protein/ high intensity physical activity
11438277|NCT01777893|Experimental|MP-MI|Moderate protein/ moderate intensity physical activity
11438278|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
11438279|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
11438280|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
11438281|NCT01777854|Active Comparator|Omeprazole|"Yes. Omeprazole (generic) will be used. Children >20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.
~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
11438282|NCT01777854|Placebo Comparator|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
11438283|NCT01777841|Other|Electronic Care plan delivery|
11438284|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
11438285|NCT01777815|Experimental|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
11438286|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
11438287|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
11438288|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
11438289|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
11438290|NCT01777776|Experimental|Phase Ib|Phase Ib will randomize 18 patients with BRAF mutant melanoma, who are naïve or who have progressed on prior therapy to evaluate the safety and tolerability of the combination of LEE011 and LGX818.
11438291|NCT01777776|Experimental|Phase II arm 1a|Phase II arm 1a will randomize 60 patients that are naïve to prior BRAF inhibitor therapy to LGX818+LEE011 to evaluate the effect of adding LEE011 to a BRAFi in this population.
11438292|NCT01777776|Experimental|Phase II arm 1b|Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
11438293|NCT01777776|Experimental|Phase II arm 2|Phase II arm 2 will evaluate a single arm LEE011+LGX818 in 40 patients resistant to prior BRAF inhibitor therapy. Single agent LGX818 has shown limited activity in patients with melanoma who have failed prior BRAF inhibitor treatment; the contribution of LEE011 in this combination will be evaluated.
11438442|NCT01776749|Sham Comparator|SubQ OFF|subcutaneous leads implanted, but no stimulation
11438294|NCT01777763|Experimental|Posaconazole 200 mg|Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
11438295|NCT01777763|Experimental|Posaconazole 300 mg|Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days
11438296|NCT01777750|Active Comparator|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
11438297|NCT01777750|No Intervention|Standard treatment|Standard treatment
11438298|NCT01777737|Experimental|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
11438299|NCT01777737|Placebo Comparator|Placebo|Identical capsules to cotrimoxazole
11438300|NCT01777724|Experimental|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
11438301|NCT01777724|No Intervention|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
11438302|NCT01777711|Active Comparator|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
11438303|NCT01777711|Active Comparator|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
11438304|NCT01777685|Other|sulpiride 50 mg|
11438305|NCT01777672|Active Comparator|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
11438306|NCT01777672|Experimental|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
11438307|NCT01777672|Experimental|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
11438308|NCT01777672|Experimental|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
11438309|NCT01777659|Experimental|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
11438310|NCT01777659|Placebo Comparator|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
11438311|NCT01777646|Experimental|MSC-NTF|
11438312|NCT01777633|Experimental|re-irradiation|re-irradiation for progressive DIPG in children
11438313|NCT01777620|Active Comparator|BOTOX®|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
11438314|NCT01777620|Placebo Comparator|Placebo|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
11438315|NCT01777607|Experimental|Intervention|
11438316|NCT01777594|Experimental|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
11438317|NCT01777581|Experimental|milnacipran|Milnacipran, flexibly dosed
11438318|NCT01777581|Placebo Comparator|Sugar pill (placebo)|Placebo
11438319|NCT01777568|Experimental|30% oxygen|Inspired oxygen will be maintained at 30%.
11438320|NCT01777568|Experimental|80% oxygen|Inspired oxygen will be maintained at 80%.
11438321|NCT01777555|Experimental|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
11438322|NCT01777555|Placebo Comparator|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
11438323|NCT01777542|Active Comparator|Treatment Period 1|One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) , and the other half of subjects will be randomly assigned to receive placebo.
11438324|NCT01777542|Placebo Comparator|Treatment Period 2|Subjects that initially received Recombinant Human Insulin Growth Factor 1 (rhIGF-1) will now receive placebo, and subjects that initially received placebo will now receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1).
11438325|NCT01777529|Experimental|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
11438326|NCT01777529|Active Comparator|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
11438327|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
11438328|NCT01777503|Experimental|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
11438329|NCT01777503|Active Comparator|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
11438330|NCT01777490|Active Comparator|Arm 1: Control - Caregiver|Caregivers in the control arm will be referred to the VA Caregiver Support Program (usual care), as a resource for them as they care for the patient in the home.
11438331|NCT01777490|Experimental|Arm 2: HI FIVES - Caregiver|Caregivers will take part in three phone training sessions and will attend four group training sessions at the VA. They will also be given the option of participating in 2 booster phone training sessions post-group sessions. Caregivers will be asked to provide one in-person (baseline) and three phone assessments (3, 9, and 15 months). Patients will also be enrolled and contact will be limited to assessments
11438332|NCT01777490|Active Comparator|Arm 1: Control - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
11438333|NCT01777490|Experimental|Arm 2: HI-FIVES - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
11438334|NCT01777477|Experimental|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
11438335|NCT01777464|Experimental|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
11438336|NCT01777464|Sham Comparator|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
11438337|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )
~GROUP 2:
~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
11438338|NCT01777438||control group|a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period
11438339|NCT01777438||patients having SCIT|patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.
11438340|NCT01777425||rhinosinusitis patients|patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.
11438341|NCT01777412|Experimental|Bevacizumab|Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.
11438342|NCT01777386|Active Comparator|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
11438343|NCT01777386|No Intervention|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
11438344|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
11438345|NCT01777373||Control|Control
11438346|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
11438347|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
11438348|NCT01777360|Experimental|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
11438349|NCT01777347|Experimental|3% Saline|Nebulized 3% Saline
11438350|NCT01777347|Placebo Comparator|0.9% Normal Saline|Nebulized 0.9% normal saline
11438351|NCT01777334|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
11438352|NCT01777334|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
11438353|NCT01777321|Experimental|SC HZ/su Group|Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
11438354|NCT01777321|Active Comparator|IM HZ/su Group|Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
11438355|NCT01777308|Experimental|Menitorix Group|"Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).
~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
11438356|NCT01777308|Experimental|Meningitec + Hiberix Group|"Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).
~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
11438357|NCT01777295|Experimental|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
11438358|NCT01777295|Active Comparator|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
11438359|NCT01777282|Active Comparator|Albiglutide + Sulfonylurea|Albiglutide in combination with background sulfonylurea
11438360|NCT01777282|Active Comparator|Albiglutide + Biguanide|Albiglutide in combination with background biguanide
11438361|NCT01777282|Active Comparator|Albiglutide + Glinide|Albiglutide in combination with background glinide
11438362|NCT01777282|Active Comparator|Albiglutide + Thiazolidinedione|Albiglutide in combination with background thiazolidinedione
11438363|NCT01777282|Active Comparator|Albiglutide + Alpha-glucosidase inhibitor|Albiglutide in combination with background alpha-glucosidase inhibitor
11438364|NCT01777269|Experimental|Duodart|Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
11438365|NCT01777269|Placebo Comparator|Sugar Pill|A capsule once daily during 12 months
11438366|NCT01777256|Experimental|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
11438439|NCT01776762|No Intervention|Standard Follow-home programme|Standard Follow-home programme without individual nutritional therapy
11438367|NCT01777256|Experimental|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
11438368|NCT01777256|Experimental|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
11438369|NCT01777256|Experimental|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
11438370|NCT01777256|Placebo Comparator|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
11438371|NCT01777243|Experimental|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
11438372|NCT01777243|Experimental|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
11438373|NCT01777230||All patients|Alle subjects included retain in one cohort.
11438374|NCT01777217|Active Comparator|solifenacin succinate|Solifenacin succinate, 5mg or 10 mg once daily
11438375|NCT01777217|Placebo Comparator|Placebo|Drug: Placebo oral
11438376|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
11438377|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
11438378|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
11438379|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
11438380|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
11438381|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
11438382|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
11438383|NCT01777191|Experimental|80 mg Ixekizumab Auto-Injector|Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
11438384|NCT01777191|Experimental|80 mg Ixekizumab Prefilled Syringe|Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
11438385|NCT01777178|Experimental|Low bicarbonate dialysis|
11438386|NCT01777165|Experimental|Arm 1 ABT-719 lower dose|
11438387|NCT01777165|Experimental|Arm 2 ABT-719 intermediate dose|
11438388|NCT01777165|Experimental|Arm 3 ABT-719 higher dose|
11438389|NCT01777165|Placebo Comparator|Arm 4 placebo|
11438390|NCT01777152|Active Comparator|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
11438391|NCT01777152|Experimental|A+CHP|brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
11438392|NCT01777139|Experimental|Retigabine IR|All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
11438393|NCT01777126|Active Comparator|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
11438394|NCT01777126|Experimental|Oral Nutrition Protocol (ONP) group|Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
11438395|NCT01777113|Experimental|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
11438396|NCT01777113|Experimental|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
11438397|NCT01777113|Active Comparator|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
11438398|NCT01777100|Experimental|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
11438399|NCT01777100|No Intervention|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
11438400|NCT01777087|Experimental|Healthy normal volunteers|Healthy normal volunteers
11438401|NCT01777074||Generalist physicians Cohort|
11438402|NCT01777074||Paediatricians Cohort|
11438403|NCT01777048|Experimental|Omega-3 Fatty Acids|1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
11438404|NCT01777048|Placebo Comparator|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
11438440|NCT01776749|No Intervention|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
11438441|NCT01776749|Active Comparator|SubQ ON|Subcutaneous stimulation on
11438405|NCT01777035|Experimental|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
11438406|NCT01777035|No Intervention|standard care|PT OT delivered as ordered by the primary ICU team
11438407|NCT01777022|No Intervention|Current treatment|Current education and management protocols will be followed
11438408|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
11438409|NCT01777009|Experimental|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
11438410|NCT01777009|Active Comparator|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
11438411|NCT01776970|Experimental|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
11438412|NCT01776970|Placebo Comparator|Placebo|Placebo oromucosal spray
11438413|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
11438414|NCT01776944||Obese children|
11438415|NCT01776931|Experimental|Lysine intake|Dietary supplement:lysine intake
11438416|NCT01776918||Metabolic Disease- Phenylketonuria|
11438417|NCT01776918||Mitochondrial disorder|
11438418|NCT01776905||Healthy control subjects|Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.
11438419|NCT01776905||Advanced-Stage Melanoma|To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.
11438420|NCT01776905||Early-Stage Melanoma|To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.
11438421|NCT01776892|Experimental|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.
~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.
~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
11438422|NCT01776892|Active Comparator|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
11438423|NCT01776892|Active Comparator|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
11438424|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
11438425|NCT01776879||recording speech and voice|no intervention(s) will be administered
11438426|NCT01776879||speech intelligibility|no intervention(s) will be administered
11438427|NCT01776866|Other|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).
~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
11438428|NCT01776853|Placebo Comparator|Glucose|40g glucose in 500ml water flavoured with lime juice
11438429|NCT01776853|Experimental|Fructose|40g fructose in 500ml water flavoured with lime juice
11438430|NCT01776853|Experimental|Fructans|40g fructans in 500ml water flavoured with lime juice
11438431|NCT01776840|Placebo Comparator|Treatment Arm A|
11438432|NCT01776840|Experimental|Treatment Arm B|
11438433|NCT01776801|Experimental|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
11438434|NCT01776788|Experimental|insulin lispro injection, exenatide injection|
11438435|NCT01776788|Active Comparator|insulin lispro injection|
11438436|NCT01776775|Active Comparator|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
11438437|NCT01776775|No Intervention|No abdominal binder|No intervention
11438438|NCT01776762|Experimental|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
11438443|NCT01776736|Experimental|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
11438444|NCT01776723|Experimental|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the rolling six Phase I design."
11438445|NCT01776723|Experimental|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
11438446|NCT01776710|Experimental|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
11438447|NCT01776710|No Intervention|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
11438448|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fasting|
11438449|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fed|
11438450|NCT01776697|Experimental|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
11438451|NCT01776684|Experimental|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
11438452|NCT01776671|Other|Gralise|Efficacy of Gralise
11438453|NCT01776658|Experimental|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
11438454|NCT01776658|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
11438455|NCT01776645|Experimental|Compassion cultivation training|
11438456|NCT01776632|Experimental|Physical activity|Latinas exposed to multi-level Faith in Action intervention promoting physical activity.
11438457|NCT01776632|Active Comparator|Cancer screening|Latinas exposed to Faith in Action intervention on cancer screening and prevention.
11438458|NCT01776619|Experimental|Multiple Dose: Cohort 1|
11438459|NCT01776619|Experimental|Multiple Dose: Cohort 2|
11438460|NCT01776619|Experimental|Multiple Dose: Cohort 3|
11438461|NCT01776619|Experimental|Multiple Dose: Cohort 4|
11438462|NCT01776619|Experimental|Relative Bioavilability: Cohort 1|
11438463|NCT01776606|Active Comparator|Dose A|Dose A: Botulinum toxin type A
11438464|NCT01776606|Placebo Comparator|Dose B|Dose B: Placebo
11438465|NCT01776593||Lower urinary tract symptoms|
11438466|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
11438467|NCT01776567|Active Comparator|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
11438468|NCT01776567|Active Comparator|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
11438469|NCT01776554|Experimental|aH5N1c-High dose|
11438470|NCT01776554|Experimental|aH5N1c-Low dose|
11438471|NCT01776541|Experimental|aH5N1c-High Dose|Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
11438472|NCT01776541|Experimental|aH5N1c-Low dose|Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
11438473|NCT01776528|Experimental|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
11438474|NCT01776528|Experimental|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
11438475|NCT01776528|Experimental|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
11438476|NCT01776528|Experimental|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
11438477|NCT01776528|Experimental|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
11438478|NCT01776528|Experimental|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
11438479|NCT01776528|Experimental|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
11438480|NCT01776528|Experimental|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
11438481|NCT01776528|Experimental|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
11438482|NCT01776528|Experimental|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
11438483|NCT01776528|Experimental|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
11438484|NCT01776528|Experimental|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
11438485|NCT01776515|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|
11438486|NCT01776515|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|
11438487|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
11438488|NCT01776489||food allergic|positive reaction during DBPCFC
11438489|NCT01776489||Non-food allergic|no reaction during DBPCFC
11438490|NCT01776463|Experimental|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
11438491|NCT01776463|Placebo Comparator|Placebo|1)Single dose study, 2)Multiple doses study
11438492|NCT01776437|Experimental|Treatment A|Period 1: fasted control → Period 2: fed control
11438493|NCT01776437|Experimental|Treatment B|Period 1: fed control → Period 2: fasted control
11438494|NCT01776424|Experimental|Rivaroxaban [2.5mg] + Aspirin|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily. (Long-term open-label extension was added to make rivaroxaban 2.5 mg twice daily + aspirin 100 mg once daily available to COMPASS trial subjects until the rivaroxaban treatment is commercially available for this indication or for approximately 3 years from regulatory approval of the long term open label extension in a country, whichever comes first.)
11438495|NCT01776424|Experimental|Rivaroxaban [5mg] + Placebo(1)|Rivaroxaban 5 mg twice daily and Aspirin Placebo once daily
11438496|NCT01776424|Active Comparator|Aspirin + Placebo(2)|Rivaroxaban Placebo twice daily and Aspirin 100 mg once daily
11438497|NCT01776411|Experimental|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
11574264|NCT00829842|Experimental|2|
11438498|NCT01776398||1.1 HEALTHY SUBJECTS|Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
11438499|NCT01776398||1.2 SUBJECTS WITH LUNG DISEASE|Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)
11438500|NCT01776398||2. WCMC/NYPH CLINICAL PATIENTS|"Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.
~WCMC/NYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study."
11438501|NCT01776398||3. PCNY CLINICAL PATIENTS|Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).
11438502|NCT01776385|Experimental|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
11438503|NCT01776385|Placebo Comparator|Control group|Patients with pneumothorax or of benign tumor of the thyroid
11438504|NCT01776372|Active Comparator|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
11438505|NCT01776372|Active Comparator|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
11438506|NCT01776359|Active Comparator|High Protein|High Protein
11438507|NCT01776359|Placebo Comparator|Low Protein|Low Protein
11438508|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
11438509|NCT01776346||Healthy control|
11438510|NCT01776333|No Intervention|usual care|
11438511|NCT01776333|Experimental|video arm|video decision aid intervention
11438512|NCT01776320|Experimental|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
11438513|NCT01776307|Experimental|BBI608 in combination with cetuximab|
11438514|NCT01776307|Experimental|BBI608 in combination with panitumumab|
11438515|NCT01776307|Experimental|BBI608 in combination with capecitabine|
11438516|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
11438517|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic <120 AND diastolic <80)
11438518|NCT01776281|Experimental|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
11438519|NCT01776281|Active Comparator|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
11438520|NCT01776268|Experimental|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
11438521|NCT01776268|No Intervention|No oral priming|No oral priming
11438522|NCT01776255|Experimental|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
11438523|NCT01776255|Active Comparator|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
11438524|NCT01776229|Experimental|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
11438525|NCT01776229|No Intervention|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
11438526|NCT01776216|Experimental|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
11438527|NCT01776216|Placebo Comparator|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
11438528|NCT01776203|Active Comparator|medroxyprogesterone acetate|
11438529|NCT01776203|No Intervention|control|
11438530|NCT01776190|Experimental|UVA1 treatment|Low-dose UVA1 will be applied to active cutaneous lupus lesions three times a week for 10 weeks.
11438531|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
11438532|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
11438533|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
11438534|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
11438535|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
11438536|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
11438537|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
11438538|NCT01776112|Experimental|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
11438539|NCT01776112|Placebo Comparator|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
11438612|NCT01775618|Experimental|Part 2 (Expansion group)|Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
11575209|NCT00822705|Placebo Comparator|4|
11438540|NCT01776112|Experimental|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
11438541|NCT01776099|Active Comparator|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
11438542|NCT01776099|Placebo Comparator|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
11438543|NCT01776099|Placebo Comparator|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
11438544|NCT01776099|Active Comparator|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
11438545|NCT01776086|Other|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
11438546|NCT01776073|Experimental|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
11438547|NCT01776073|No Intervention|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
11438548|NCT01776047|Active Comparator|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
11438549|NCT01776047|Experimental|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
11438550|NCT01776034|Experimental|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include up to 10 patients, and family is encouraged to attend. Intervention sessions consist of 30-min of behavior change activities and 60-min focused on healthy behaviors."
11438551|NCT01776034|Active Comparator|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
11438552|NCT01776021|Active Comparator|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
11438553|NCT01776021|Placebo Comparator|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
11438554|NCT01776008|Experimental|Treatment (MK2206, anastrozole, goserelin acetate)|Patients receive Akt inhibitor MK-2206 PO on days 2, 9, 16, and 23; anastrozole PO daily on days 1-28; and goserelin acetate SC on day 1 (premenopausal patients only). Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11438555|NCT01775995|Experimental|Meditation-CBT|Participants receiving the meditation-CBT intervention, in addition to usual care for CLBP and opioid therapy management.
11438556|NCT01775995|Other|Wait-list Control|Participants receiving usual care for CLBP and opioid therapy management.
11438557|NCT01775982||Study population|"See inclusion and exclusion criteria.
~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation
~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
11438558|NCT01775969|No Intervention|Standard of Care|Written discharge instructions only
11438559|NCT01775969|Experimental|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
11438560|NCT01775969|Experimental|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
11438561|NCT01775930|Experimental|Carfilzomib|Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
11438562|NCT01775904|Experimental|LY2886721 Capsule (water, fasting)|Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods.
11438563|NCT01775904|Experimental|LY2886721 ODT (no water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
11438564|NCT01775904|Experimental|LY2886721 ODT (water, fed)|A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods.
11438565|NCT01775904|Experimental|LY2886721 ODT (water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods.
11438566|NCT01775891|Active Comparator|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
11438567|NCT01775891|Placebo Comparator|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
11438568|NCT01775878|No Intervention|Usual Care|This arm received usual care from the diabetes care managers
11438569|NCT01775878|Experimental|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
11438570|NCT01775865|Experimental|Salsalate|Salsalate capsule 1.5 g/day twice per day by mouth for 4 weeks
11438571|NCT01775865|Placebo Comparator|Placebo|Placebo capsule twice per day by mouth for 4 weeks
11438572|NCT01775865|No Intervention|Young Control|No intervention; Baseline measurements only
11438573|NCT01775852|Active Comparator|ACT-IM|The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
11438684|NCT01775124|Experimental|Ranibizumab 0.5 mg monthly|Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
11438574|NCT01775852|No Intervention|Waitlist/Treatment as Usual|The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
11438575|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
11438576|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
11438577|NCT01775826|Other|All Purposes|All participants.
11438578|NCT01775813|Experimental|Metformin|Dosage form: Metformin 1000 mg tablets Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
11438579|NCT01775813|Placebo Comparator|Sugar pill|Dosage form: Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
11438580|NCT01775800|Experimental|Treatment modification|Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
11438581|NCT01775800|No Intervention|Usual care|Patients will receive the usual hemodialysis care with no modifications
11438582|NCT01775787|Other|Tobacco Flavor/ Tobacco & Menthol Flavor|"Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.
~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
11438583|NCT01775787|Other|Tobacco & Menthol Flavor/Tobacco Flavor|"Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.
~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
11438584|NCT01775774|Experimental|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
11438585|NCT01775761|Experimental|Period 1: 960 mg tafamidis (Vyndaqel)|
11438586|NCT01775761|Experimental|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
11438587|NCT01775761|Experimental|Period 3: Placebo|
11438588|NCT01775748|Other|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
11438589|NCT01775748|Other|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
11438590|NCT01775735|Experimental|Treatment|The treatment is continuous stimulation with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
11438591|NCT01775735|Active Comparator|Control|The control is intermittent stimulation for 20 seconds every 90 minutes with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
11438592|NCT01775722|Other|Pulsed Dye Laser|port wine stain treatment using Pulse Dye Laser
11438593|NCT01775722|Experimental|Bipolar Radiofrequency&Pulsed Dye Laser|Port wine stain using Combined Bipolar Radiofrequency&Pulsed Dye Laser
11438594|NCT01775709|Experimental|PE tube with Duckbill Valve|PE tube with Duckbill Valve
11438595|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
11438596|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
11438597|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
11438598|NCT01775696||controls|40 controls
11438599|NCT01775696||genetic FTD|5 genetic forms of FTD
11438600|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
11438601|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
11438602|NCT01775670|Experimental|Off-the-Shelf Splint|Subjects in this arm will be managed with off-the-shelf splints for TMC arthrosis.
11438603|NCT01775670|Active Comparator|OT Splint|Subjects in this arm will be managed with a custom-made splint made by the Massachusetts General Hospital Occupational Therapists.
11438604|NCT01775657|Experimental|Air leak present - Analogue|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, air leak present.
11438605|NCT01775657|Active Comparator|Air leak absent - Analogue (Pleur Evac)|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, no air leak present
11438606|NCT01775657|Experimental|Air leak present - Digital (Thopaz)|Patients with an air leak present, randomized to Thopaz (digital drainage) monitoring system.
11438607|NCT01775657|Active Comparator|Air leak absent - Digital (Thopaz)|Patients randomized to digital system, no air leak present.
11438608|NCT01775644||Metastatic Colorectal Cancer Participants|"Administration of treatment will be as used in normal daily routine under local labelling in 4 subgroups- participants with liver and/or lung metastases, potentially resectable after a response to a systemic therapy and clinically operable; participants with tumor related symptoms, risks for complications or fast progression for whom quick proliferation control is needed; asymptomatic participants (indolent tumor) without the option of a metastases resection (no pressure for remission) for whom the aim of the therapy is proliferation control and participants without classification."
11438609|NCT01775631|Experimental|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days
~Rituximab intravenous flat dose infusion on specified days"
11438610|NCT01775631|Experimental|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days
~Rituximab intravenous flat dose infusion on specified days"
11438611|NCT01775618|Experimental|Main study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
11438857|NCT01773837|Placebo Comparator|placebo|the same number of pills (p.o.) than methylphenidate for six days
11438613|NCT01775618|Experimental|Extension study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.
11438614|NCT01775605|Active Comparator|Synera|Synera Pain Patch
11438615|NCT01775605|No Intervention|No patch control|No intervention group
11438616|NCT01775605|Sham Comparator|Control|Sham
11438617|NCT01775592|Other|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5
~≥ 15 years:2.0, 2.0, 2.0, 2.0"
11438618|NCT01775579|Experimental|Crestor tablet 20 mg|Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
11438619|NCT01775579|Experimental|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single
11438620|NCT01775579|Experimental|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
11438621|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
11438622|NCT01775553|Experimental|Carfilzomib|All patients will receive Carfilzomib
11438623|NCT01775540|Experimental|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
11438624|NCT01775540|Placebo Comparator|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
11438625|NCT01775540|Active Comparator|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
11438626|NCT01775527|Other|blood test|
11438627|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
11438628|NCT01775501|Experimental|Experimental Treatment Arm|FOLFOX (Leucovorin, Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally, twice daily FOLFOX: injected via portacath once every two weeks
11438629|NCT01775488|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
11438630|NCT01775475|Active Comparator|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11438631|NCT01775475|Experimental|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11438632|NCT01775462|Experimental|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
11438633|NCT01775462|Experimental|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
11438634|NCT01775449|Experimental|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
11438635|NCT01775449|Other|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
11438636|NCT01775436|Active Comparator|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.
~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.
~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
11438637|NCT01775436|Experimental|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.
~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.
~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
11438638|NCT01775423|Experimental|BBI608|
11438639|NCT01775410|Experimental|Interventional|Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
11438640|NCT01775397|Experimental|Fidaxomicin|Fidaxomicin with alternating matching placebo
11438641|NCT01775397|Active Comparator|Vancomycin|Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period
11438642|NCT01775384|Experimental|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
11438643|NCT01775384|Placebo Comparator|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
11438644|NCT01775371|Experimental|Patient Controlled Analgesia|PCA (loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes)
11438645|NCT01775371|Active Comparator|Usual Care|Usual opioid analgesia determined by the provider
11438646|NCT01775358|Experimental|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
11438647|NCT01775358|Experimental|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
11438648|NCT01775358|Experimental|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
11438649|NCT01775358|Placebo Comparator|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
11438650|NCT01775358|Placebo Comparator|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
11438651|NCT01775358|Placebo Comparator|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
11575549|NCT00820235|Experimental|A|
11438652|NCT01775345|Experimental|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).
~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
11438653|NCT01775345|Experimental|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
11438654|NCT01775345|Experimental|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
11438655|NCT01775332|Experimental|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
11438656|NCT01775332|No Intervention|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
11438657|NCT01775319|Active Comparator|Biofortified wheat|Biofortified wheat
11438658|NCT01775319|Placebo Comparator|Control wheat|Control wheat with low level of Zn
11438659|NCT01775319|Active Comparator|Fortified wheat|Wheat fortified before consumption
11438660|NCT01775293|Experimental|Non-absorbable polypropylene mesh|"2 step procedures
~first step is insertion of Non-absorbable polypropylene mesh under the facial skin
~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
11438661|NCT01775280|Experimental|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
11438662|NCT01775267|Experimental|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
11438663|NCT01775267|Active Comparator|PVO|Patient undergo portal vein embolization or ligation
11438664|NCT01775254||Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancers followed by adjuvant chemotherapy.
11438665|NCT01775254||No Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancer and who do not receive chemotherapy.
11438666|NCT01775228|No Intervention|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
11438667|NCT01775228|Active Comparator|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
11438668|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
11438669|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction >50%, not yet requiring aortic valve replacement.
11438670|NCT01775189|Placebo Comparator|Treatment A|
11438671|NCT01775189|Experimental|Treatment B|
11438672|NCT01775189|Placebo Comparator|Treatment C|
11438673|NCT01775189|Active Comparator|Treatment D|
11438674|NCT01775176|No Intervention|Control|Control subjects recieve no intervention for diet, exercise or metformin and are asked to adhere to usual behaviors throughout the trial.
11438675|NCT01775176|Experimental|Metformin|1000mg BID
11438676|NCT01775176|Experimental|Dietary Restriction|25% dietary restriction
11438677|NCT01775176|Experimental|Exercise|10 kcal/kg/week in exercise energy expenditure. 3 x resistance training sessions per week (8 exercises)
11438678|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
11438679|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
11438680|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
11438681|NCT01775150|Experimental|health education|health education via text messaging
11438682|NCT01775150|No Intervention|no health education|no health education via text messaging
11438683|NCT01775137|Experimental|TBM100|TIP 112 mg/b.i.d
11439112|NCT01772082|Experimental|Pedometer plus website|pedometer and website
11438685|NCT01775124|Experimental|Ranibizumab 0.5 mg pro re nata (PRN)|PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
11438686|NCT01775111|Sham Comparator|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
11438687|NCT01775111|Experimental|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
11438688|NCT01775111|Experimental|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
11438689|NCT01775098|Experimental|Allopurinol|treatment with allopurinol
11438690|NCT01775098|Placebo Comparator|placebo|placebo comparator
11438691|NCT01775085|Experimental|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
11438692|NCT01775085|Active Comparator|Discussion Group (DG)|
11438693|NCT01775072||Pts with solid tumors|Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.
11438694|NCT01775059|Experimental|Integrated sensor and infusion set.|
11438695|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
11438696|NCT01775033|Experimental|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
11438697|NCT01775033|No Intervention|Control|Hospitals in the control arm will receive usual care.
11438698|NCT01775020|Experimental|L-arginine|L-arginine
11438699|NCT01775007|Experimental|Normal Healthy Subjects|Brillouin Ocular Analyser
11438700|NCT01774994|Experimental|stable isotopes|stable isotope infusion for measurement of metabolism
11438701|NCT01774981|Placebo Comparator|Placebo (Part A)|Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4.
11438702|NCT01774981|Experimental|10 mg LY3016859 (Part A)|Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
11438703|NCT01774981|Experimental|100 mg LY3016859 (Part A)|Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
11438704|NCT01774981|Experimental|750 mg LY3016859 (Part A)|Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
11438705|NCT01774981|Placebo Comparator|Placebo (Part B)|Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
11438706|NCT01774981|Experimental|50 mg LY3016859 (Part B)|Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
11438707|NCT01774981|Experimental|250 mg LY3016859 (Part B)|Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
11438708|NCT01774981|Experimental|750 mg LY3016859 (Part B)|Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
11438709|NCT01774968|Experimental|Human Regular U-500 Insulin TID|Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
11438710|NCT01774968|Experimental|Human Regular U-500 Insulin BID|U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
11438711|NCT01774942|Experimental|Procedure/Surgery (Impants/Overdentures)|One-arm clinical intervention study: All teeth out, full dentures, dental implants, blood draw. The interventions are not experimental in nature, they are standard procedures, namely extraction of all natural teeth followed by suturing to hold soft tissue in place during initial healing; surgical insertion of commercially available dental implants; and fabrication and re-lining (filling in with acrylic the base of the denture as needed during healing and shrinking of underlying tissue) of full dentures, that is full plates in upper and lower jaw to replace all teeth.
11438712|NCT01774929|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
11438713|NCT01774916|Other|patients|
11438714|NCT01774916|Other|volunter|
11438715|NCT01774903|Experimental|TTS-fentanyl|
11438716|NCT01774877|Experimental|Xinfeng capsule & placebo|"Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months
~placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
11438717|NCT01774877|Active Comparator|leflunomide & placebo|"leflunomide :10mg each time, one time a day, by mouth,for 3 months
~placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
11438718|NCT01774864|Experimental|DA-8159 dose 1|Udenafil
11438719|NCT01774864|Experimental|DA-8159 dose 2|Udenafil
11438720|NCT01774864|Placebo Comparator|Placebo|
11438721|NCT01774851|Experimental|Arm 1a|MM-111 + Paclitaxel + Trastuzumab
11438722|NCT01774851|Active Comparator|Arm 1b|Paclitaxel + Trastuzumab
11438723|NCT01774838|Experimental|Prasugrel|3 months treatment with 10 mg prasugrel
11438724|NCT01774838|Active Comparator|Clopidogrel|3 months treatment with clopidogrel 75 mg
11438725|NCT01774825|Active Comparator|IQP-CL-101|2 softgels twice a day
11438726|NCT01774825|Placebo Comparator|Placebo|2 softgels twice a day
11438858|NCT01773824|Other|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
11438727|NCT01774812|Active Comparator|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
11438728|NCT01774812|Active Comparator|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
11438729|NCT01774799|Experimental|Advance care planning intervention|At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
11438730|NCT01774799|Active Comparator|Usual care|Residents in control nursing homes with receive the usual advance care planning that occurs in their nursing home.
11438731|NCT01774786|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive pertuzumab and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.
11438732|NCT01774786|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive pertuzumab placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive pertuzumab placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.
11438733|NCT01774773|Experimental|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
11438734|NCT01774773|Experimental|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
11438735|NCT01774773|Experimental|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
11438736|NCT01774760|Experimental|Patients with stage III-IV head and neck cancer|18F-EF5 PET/CT scan
11438737|NCT01774747|Experimental|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
11438738|NCT01774747|Placebo Comparator|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
11438739|NCT01774734|Experimental|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
11438740|NCT01774734|Placebo Comparator|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
11438741|NCT01774721|Experimental|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
11438742|NCT01774721|Active Comparator|gefitinib|Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
11438743|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.
~Inclusion/Exclusion:
~Inclusion:
~Ambulatory patient able to leave the bed.
~Willingness to consent and participate in a 30-night study
~Exclusion:
~Lack of capacity to consent, without an identifiable surrogate.
~Terminal Prognosis
~Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
11438744|NCT01774695|Other|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
11438745|NCT01774682|Other|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
11438746|NCT01774669|Experimental|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
11438747|NCT01774669|Active Comparator|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
11438748|NCT01774656|Experimental|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
11438749|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
11438750|NCT01774630|Experimental|Nilotinib|300 mg/twice a day
11438751|NCT01774617||Patients with advanced liver disease|Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level >1.5 mg/dL), severe bleeding disorder (prothrombin activity test < 30% or platelets count <35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.
11438752|NCT01774604|Experimental|Indomethacin|Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
11438753|NCT01774604|Placebo Comparator|Placebo|Placebo suppositories (#2)
11438754|NCT01774591|Active Comparator|azilsartan medoximil.|Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
11438755|NCT01774591|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
11438756|NCT01774578|Active Comparator|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.
~First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity."
11438780|NCT01774396|Other|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
11438896|NCT01773551||Optical Index of Breast Density|Breast Density
11438757|NCT01774578|Experimental|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.
~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.
~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
11438758|NCT01774578|Experimental|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.
~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.
~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
11438759|NCT01774565|Experimental|Fully Automated Closed-Loop Insulin Delivery (phase 1-4)|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
11438760|NCT01774565|Active Comparator|Usual care/ fully-automated closed-loop using Iasp|"Phase 1-3: During usual care (conventional therapy), subject's s.c. insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).
~Phase 4: subjects will receive fully-automated insulin delivery using standard insulin aspart (Iasp)"
11438761|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
11438762|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
11438763|NCT01774513|Experimental|Procore Needle|
11438764|NCT01774487|Experimental|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.
~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
11438765|NCT01774474|Active Comparator|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
11438766|NCT01774474|Active Comparator|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
11438767|NCT01774474|Active Comparator|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
11438768|NCT01774474|Active Comparator|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
11438769|NCT01774474|Active Comparator|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
11438770|NCT01774474|Active Comparator|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
~& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
11438771|NCT01774474|Active Comparator|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)
~& a peroperative intravitreal injection of 1.25 mg bevacizumab"
11438772|NCT01774461|No Intervention|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
11438773|NCT01774461|Active Comparator|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
11438774|NCT01774448|No Intervention|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
11438775|NCT01774448|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
11438776|NCT01774435|Experimental|EN3342|EN3342 (risperidone) subcutaneous implant
11438777|NCT01774422|Experimental|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
~Noninvasive ventilation alone
~Noninvasive ventilation associated with the DECAP CO2 device"
11438778|NCT01774422|Other|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:
~Noninvasive ventilation alone
~Noninvasive ventilation associated with the DECAP CO2 device"
11438779|NCT01774409|Experimental|Blood and tumor samples|
11438781|NCT01774396|Experimental|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
11438782|NCT01774370||Pradaxa group|
11438783|NCT01774344|Experimental|Regorafenib|160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
11438784|NCT01774344|Placebo Comparator|Placebo|4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
11438785|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
11438786|NCT01774318|Other|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
11438787|NCT01774305|Experimental|dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
11438788|NCT01774305|Placebo Comparator|saline|We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.
11438789|NCT01774292|Active Comparator|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
11438790|NCT01774292|Placebo Comparator|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
11438791|NCT01774279||anaplastic thyroid cancer|
11438792|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
11438793|NCT01774253|Experimental|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
11438794|NCT01774240|No Intervention|before|no systematic approach
11438795|NCT01774240|Experimental|after|systematic screening and treatment of delirium
11438796|NCT01774227|Experimental|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
11438797|NCT01774227|Experimental|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
11438798|NCT01774214|Experimental|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
11438799|NCT01774214|Experimental|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
11438800|NCT01774201|Experimental|Breathing exercises|Daily deep breathing exercises during two month
11438801|NCT01774201|No Intervention|Control|Control group
11438802|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
11438803|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
11438804|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
11438805|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
11438806|NCT01774162|Active Comparator|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
11438807|NCT01774162|Experimental|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
11438808|NCT01774149|Active Comparator|Delayed Diastat|Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.
11438809|NCT01774149|Experimental|Diastat|Few Touch Application with Diastat module turned on in week 4 post-enrollment.
11438810|NCT01774136|Experimental|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
11438811|NCT01774136|No Intervention|Standard of Care|
11438812|NCT01774123||Healthy|Healthy controls
11438813|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
11438814|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
11438815|NCT01774110|Experimental|early standardized task training|Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.
11438816|NCT01774097|Experimental|ALD-301|Participants will receive ALD-301 via intramuscular injection
11438817|NCT01774097|Placebo Comparator|Placebo (vehicle)|Participants will receive placebo (vehicle)via intramuscular injection
11438818|NCT01774084|Active Comparator|PreOp, NutriciaNordica AB|PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
11438819|NCT01774084|Placebo Comparator|Water|Water: One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
11438820|NCT01774071|Experimental|89Zr DFOMSTP2109A tracer Group 1|The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
11438821|NCT01774071|Experimental|89Zr-DFO-MSTP2109A tracer Group 2|Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
11438822|NCT01774058|Experimental|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
11438823|NCT01774045|Experimental|PDC-1421|Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
11438824|NCT01774045|Placebo Comparator|Placebo control|Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
11438825|NCT01774032|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
11438826|NCT01774019|Active Comparator|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
11438827|NCT01774019|No Intervention|None (No Pre-Operative Biliary Drainage)|Patients in this group will not receive pre-operative biliary drainage with a study SEMS
11438828|NCT01774006||Group culture|Embryos cultured in groups of 2-10
11438829|NCT01774006||Individual culture|Embryos cultured individually
11438830|NCT01773993||Pregabalin|Subjects who are treated with pregabalin
11438831|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.
~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
11438832|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
11438833|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
11438834|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
11438835|NCT01773967|Experimental|LGG|LGG 10^10 cfu PO bid x 5 days
11438836|NCT01773967|Placebo Comparator|Placebo|micro-crystalline cellulose PO bid x 5 days
11438837|NCT01773954|Experimental|Intravitreal Aflibercept Injection More|Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
11438838|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
11438839|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
11438840|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
11438841|NCT01773928|Active Comparator|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
11438842|NCT01773928|Active Comparator|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
11438843|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
11438844|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
11438845|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
11438846|NCT01773928|Active Comparator|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
11438847|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
11438848|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
11438849|NCT01773902|Experimental|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
11438850|NCT01773902|Experimental|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
11438851|NCT01773902|Active Comparator|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
11438852|NCT01773889|Experimental|Denileukin Diftitox/SC Pegylated IFNα-2A|Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
11438853|NCT01773876|Active Comparator|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
11438854|NCT01773876|Placebo Comparator|PLACEBO|0.9% sodium chlorides 100ml infusion
11438855|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
11438856|NCT01773837|Experimental|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
11438859|NCT01773824|Experimental|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
11438860|NCT01773811|No Intervention|Control|Individuals will write objectively about the events of their day.
11438861|NCT01773811|Experimental|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
11438862|NCT01773811|Active Comparator|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
11438863|NCT01773798|Experimental|IDegAsp 15|
11438864|NCT01773798|Experimental|IDegAsp|
11438865|NCT01773798|Experimental|IDeg|
11438866|NCT01773798|Active Comparator|IAsp|
11438867|NCT01773798|Experimental|IDeg + IAsp|
11438868|NCT01773785|Experimental|SPI-1620 & Docetaxel|"SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
~Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620."
11438869|NCT01773772|Experimental|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
11438870|NCT01773772|Placebo Comparator|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
11438871|NCT01773759|Experimental|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
11438872|NCT01773759|No Intervention|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
11438873|NCT01773746|Active Comparator|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
11438874|NCT01773746|Active Comparator|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
11438875|NCT01773733||BMI ≥ 30|
11438876|NCT01773733||BMI ≥27 kg/m2 associated with DM2|
11438877|NCT01773707|Experimental|abatacept IV infusion|CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)
11438878|NCT01773707|Placebo Comparator|Placebo|The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.
11438879|NCT01773694|Active Comparator|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
11438880|NCT01773694|No Intervention|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
11438881|NCT01773668|Experimental|Integrated sensor and infusion set|
11438882|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
11438883|NCT01773642|Experimental|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
11438884|NCT01773642|No Intervention|Standard of Care|
11438885|NCT01773629|Experimental|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
11438886|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
11438887|NCT01773616|Experimental|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
11438888|NCT01773616|Active Comparator|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
11438889|NCT01773603|No Intervention|Conventional incubation|Five-day embryo culture in conventional incubators
11438890|NCT01773603|Active Comparator|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
11438891|NCT01773590|Other|Asthmatics|Rhinovirus Infection
11438892|NCT01773590|Other|Healthy Volunteers|Rhinovirus Infection
11438893|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
11438894|NCT01773564|Active Comparator|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith & Nephew IV3000 ™
11438895|NCT01773564|Experimental|3M™ IV Advanced Securement dressing|New generation transparent dressing
11438897|NCT01773538|Active Comparator|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
11438898|NCT01773538|Placebo Comparator|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
11438899|NCT01773512|Experimental|Rosuvastatin|All patients will be using rosuvastatin 40 mg
11438900|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
11438901|NCT01773486|Active Comparator|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
11438902|NCT01773486|Placebo Comparator|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
11438903|NCT01773473|Experimental|Insulin Lispro Mix25|Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
11438904|NCT01773473|Experimental|Insulin Lispro Mix50|Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
11438905|NCT01773460|Experimental|Everolimus|Everolimus is given beyond progress
11438906|NCT01773460|Placebo Comparator|Everolimus-placebo|Everolimus-placebo is given beyond progress
11438907|NCT01773447|Active Comparator|Set-back suture|Wound to be close by set-back suture technique.
11438908|NCT01773447|Active Comparator|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
11438909|NCT01773434|Experimental|MORAb-004|
11438910|NCT01773421|Experimental|Part A|
11438911|NCT01773421|Experimental|Part B|
11438912|NCT01773408|Experimental|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
11438913|NCT01773408|Experimental|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
11438914|NCT01773408|Experimental|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
11438915|NCT01773408|Experimental|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
11438916|NCT01773395|Active Comparator|GVAX|"GVAX vaccine
~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points."
11438917|NCT01773395|Placebo Comparator|Placebo|"Placebo vaccine
~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points."
11438918|NCT01773382|No Intervention|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)
11438919|NCT01773382|Experimental|weight reduction|target weight reduction is 3-5% from baseline
11438920|NCT01773369|Experimental|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
11438921|NCT01773369|Experimental|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of ~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
11438922|NCT01773369|No Intervention|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
11438923|NCT01773369|Experimental|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
11438924|NCT01773356|Placebo Comparator|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
11438925|NCT01773356|Active Comparator|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
11438926|NCT01773343|Active Comparator|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
11438927|NCT01773343|Active Comparator|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
11438928|NCT01773330|Experimental|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
11438929|NCT01773317|Experimental|Perturbation|Subjects complete the training protocol and peturbation training exercises
11438930|NCT01773317|Experimental|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
11438931|NCT01773304|Experimental|Meal rich in dairy protein|
11438932|NCT01773304|Experimental|Meal rich in meat protein|
11438933|NCT01773291|Experimental|acupuncture|acupuncture on GV26 and 12 Well points
11438934|NCT01773291|Experimental|laser acupuncture|laser acupuncture on GV26 and 12 Well points
11438935|NCT01773291|Sham Comparator|control group|laser acupuncture without laser output in control group.
11438936|NCT01773278|Experimental|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
11438937|NCT01773278|Experimental|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
11438938|NCT01773278|Experimental|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
11438939|NCT01773252|Experimental|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
11438940|NCT01773239|Experimental|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets ~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.
~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
11438941|NCT01773226|Experimental|"Autologous Protein Solution APS(TM)"|Patients who have been treated with a single, intra-articular injection.
11438942|NCT01773213|Other|Bladder dysfunction, ice-water-test|
11438943|NCT01773213|Other|Bladder dysfunction, warm water-test|
11438944|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
11438945|NCT01773187|Experimental|Pacritinib|Pacritinib 400 mg QD
11438946|NCT01773187|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)
11438947|NCT01773174|Experimental|dabigatran etexilate|single dose treatment with dabigatran oral solution
11438948|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
11438949|NCT01773148|Experimental|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
11438950|NCT01773135||preterm group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver preterm (before 37 weeks of gestation)
11438951|NCT01773135||full term group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver full term (after 37 weeks of gestation)
11438952|NCT01773122|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
11438953|NCT01773122|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
11438954|NCT01773122|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
11438955|NCT01773122|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
11438956|NCT01773109|Experimental|Eligible patients will receive etirinotecan pegol at a dose of|single-arm, open-label study is designed to investigate the efficacy and safety of etirinotecan pegol in patients with metastatic or recurrent NSCLC after failure of 2nd line therapy. Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Patients will be followed clinically every week for the first cycle with laboratory parameters (section 6.2.1) and physical exam. Response will be determined with RECIST version 1.1 after 2 cycles of therapy. Patients with Stable disease (SD), partial response (PR) or complete response (CR) will continue on additional therapy for up to six cycles. In the absence of disease progression in subjects completing six full cycles, further treatment beyond cycle #6 will be left to the discretion of the treating physician and his/her staff. Patients with progressive disease will be taken off study and will be followed for OS
11438957|NCT01773096|Experimental|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
11438958|NCT01773096|Active Comparator|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
11438959|NCT01773083|Experimental|unfractionated heparin|25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
11438960|NCT01773083|Placebo Comparator|placebo|Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)
11438961|NCT01773070|Other|All Participants|Participants who received ABT-450, ABT-333 or ABT-267 at any dose level in an eligible prior AbbVie Phase 2 or 3 study for the treatment of chronic HCV, followed for up to 3 years post-treatment.
11438962|NCT01773057|Experimental|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
11438963|NCT01773057|No Intervention|Passive decision support|Regular NHGDoc domains
11438964|NCT01773044|Active Comparator|alkalinized lidocaine & lidocaine|
11438965|NCT01773044|Active Comparator|alkalinized lidocaine &Placebo|
11438966|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
11439035|NCT01772576|Experimental|Reliance 4-Front|Single arm, all patients will be implanted with the Reliance 4-Front lead
11438967|NCT01773018|Experimental|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.
~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
11438968|NCT01773005|Sham Comparator|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
11438969|NCT01773005|Active Comparator|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
11438970|NCT01772992|No Intervention|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
11438971|NCT01772992|Experimental|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
11438972|NCT01772979|Experimental|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days
~Patients will receive trabectedin until disease progression or unacceptable toxicity"
11438973|NCT01772966|Experimental|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
11438974|NCT01772966|Sham Comparator|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
11438975|NCT01772953|Experimental|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.
~Fludarabine: 30 mg/m2 IV for patients > 10 kg (or 1 mg/kg IV for patients < 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).
~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
11438976|NCT01772940|Active Comparator|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
11438977|NCT01772940|Experimental|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
11438978|NCT01772940|Active Comparator|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
11438979|NCT01772940|Experimental|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
11438980|NCT01772927||Very low birth weight infants,|Parenteral nutrition
11438981|NCT01772901|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
11438982|NCT01772901|Experimental|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
11438983|NCT01772888||Patients with ALS|All subjects aged > 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
11438984|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
11438985|NCT01772875|Active Comparator|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
11438986|NCT01772875|Active Comparator|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
11438987|NCT01772875|Sham Comparator|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
11438988|NCT01772875|Active Comparator|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
11438989|NCT01772862|No Intervention|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
11438990|NCT01772862|Experimental|Intervention group|"The intervention components includes (real time sequence):
~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.
~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.
~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
11438991|NCT01772849|Experimental|Intervention group|"The intervention components includes (real time sequence):
~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.
~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
11438992|NCT01772849|No Intervention|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
11438993|NCT01772836|Placebo Comparator|Normal saline|Single and multiple dose of normal saline
11438994|NCT01772836|Experimental|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
11438995|NCT01772836|Experimental|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
11438996|NCT01772836|Experimental|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
11438997|NCT01772823|Experimental|3MV Behavioral Intervention Group|3MV Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
11438998|NCT01772823|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
11438999|NCT01772810|Experimental|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
11439000|NCT01772797|Experimental|LDK378 and AUY922|
11439001|NCT01772784|Experimental|phenolic acids|Maltodextrine + Phenolic acids
11439002|NCT01772784|Placebo Comparator|placebo|Maltodextrine
11439003|NCT01772784|Experimental|phenolic acid|Maltodextrine + Phenolic acids
11439004|NCT01772784|Active Comparator|polyphenol|
11439005|NCT01772771||Ancillary-correlative (biospecimen collection, chart review)|Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.
11439006|NCT01772758|Experimental|Protocol 1: AOC|measurements at baseline and 2 hours following the antioxidant cocktail that is comprised of over the counter vitamins (vitamin C 1000mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) that will be given in two doses, 30 minutes apart.
11439007|NCT01772758|Experimental|Protocol 2: BH4 (5mg)|measurements at baseline and 3 hours following the single dose of 5mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
11439008|NCT01772758|Experimental|Protocol 2: BH4 (20mg)|measurements at baseline and 3 hours following the single dose of 20mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
11439009|NCT01772758|No Intervention|Healthy Controls|baseline measurements were done with no intervention
11439010|NCT01772745|Active Comparator|Group 1|SILS cholecystectomy
11439011|NCT01772745|Active Comparator|Group 2|TPCL cholecystectomy
11439012|NCT01772732|Experimental|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
11439013|NCT01772719|Experimental|Study Arm|Study Arm
11439014|NCT01772706|Experimental|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
11439015|NCT01772706|Placebo Comparator|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
11439016|NCT01772693|Experimental|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR guided Focused Ultrasound
11439017|NCT01772693|Sham Comparator|Sham ExAblate Transcranial MRgFUS|Sham treatment with ExAblate MR guided Focused Ultrasound
11439018|NCT01772680|Experimental|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
11439019|NCT01772667|No Intervention|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
11439020|NCT01772667|Active Comparator|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
11439021|NCT01772654|Experimental|Left Temporal Lobe Epilepsy Subjects|Arterial Spin Labeled (ASL) MRI sequence
11439022|NCT01772654|Active Comparator|Control Subjects|Arterial Spin Labeled (ASL) MRI sequence
11439023|NCT01772641|Experimental|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
11439024|NCT01772641|Experimental|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
11439025|NCT01772641|Experimental|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
11439026|NCT01772641|Placebo Comparator|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
11439027|NCT01772628|Experimental|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
11439028|NCT01772628|No Intervention|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
11439029|NCT01772615|Experimental|ciprofloxacin-EcN|
11439030|NCT01772615|Experimental|ciprofloxacin-placebo|
11439031|NCT01772615|Experimental|placebo-EcN|
11439032|NCT01772615|Placebo Comparator|placebo-placebo|
11439033|NCT01772589|Active Comparator|New saw blade|New saw blade
11439034|NCT01772589|Active Comparator|Reprocessed saw blade|Reprocessed saw blade
11439036|NCT01772563|Experimental|volasertib + itraconazole|administration of volasertib alone and in combination with itraconazole
11439037|NCT01772550|Experimental|20 Gauge BD Nexiva Diffusics|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
11439038|NCT01772550|Active Comparator|18 Gauge Conventional Catheter|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
11439039|NCT01772550|Experimental|BD Nexiva Diffusics - Nonrandomized|Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm. During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
11439040|NCT01772537|No Intervention|Open repair of thoracoabdominal aneurysms|These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
11439041|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms isoflurane|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
11439042|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms propofol|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.
11439043|NCT01772524|Experimental|ALD403|Single IV Dose on Day 0
11439044|NCT01772524|Placebo Comparator|Saline|Single IV infusion on Day 0
11439045|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
11439046|NCT01772498|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
11439047|NCT01772485|Experimental|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
11439048|NCT01772485|Active Comparator|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
11439049|NCT01772472|Active Comparator|Trastuzumab|
11439050|NCT01772472|Experimental|Trastuzumab emtansine|
11439051|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
11439052|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
11439053|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
11439054|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
11439055|NCT01772446|No Intervention|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
11439056|NCT01772446|Experimental|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
11439057|NCT01772433|Placebo Comparator|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
11439058|NCT01772433|Experimental|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
11439059|NCT01772420|Experimental|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts >= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.
~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
11439060|NCT01772420|Experimental|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts < 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.
~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
11439061|NCT01772407||1|laparoscopic surgery in right colon cancer operations
11439062|NCT01772407||2|open surgery in right colon cancer operations
11439063|NCT01772394|Active Comparator|Cognitive Remediation Therapy (CRT)|Active : CRT
11439064|NCT01772394|Sham Comparator|Sham Therapy (ST)|Sham : ST
11439065|NCT01772381|Experimental|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
11439066|NCT01772368|Experimental|FS MDPI 100/6.25 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
11439067|NCT01772368|Experimental|FS MDPI 100/12.5mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
11439068|NCT01772368|Experimental|FS MDPI 100/25|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
11439069|NCT01772368|Experimental|FS MDPI 100/50|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
11439070|NCT01772368|Active Comparator|Fp MDPI 100 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate.
11439071|NCT01772368|Active Comparator|Advair Diskus 100/50 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
11439072|NCT01772355|Other|tissue core|semi automated core needle biopsy of the orbital tumors
11439073|NCT01772342|Experimental|Nocturnal Air Purification|"Hepa Filtration with PureNight
~SHAM with PureNight"
11439074|NCT01772329|Experimental|4 weekly CT sessions - in person|4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).
11439075|NCT01772329|Experimental|8 weekly CT sessions|"8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/Skype. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use Skype. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks."
11439076|NCT01772329|Experimental|4 weekly CT sessions - Tele-video|"4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/Skype."
11439077|NCT01772329|Placebo Comparator|Routine care|Routine care; no CT sessions
11439078|NCT01772316|Experimental|Tocilizumab Subcutaneous (SC)|Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.
11439079|NCT01772303|Experimental|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
11439080|NCT01772290|Active Comparator|A: Vismodegib|
11439081|NCT01772290|Experimental|B: Rabeprazole + Vismodegib|
11439082|NCT01772290|Experimental|C: Itraconazole + Vismodegib|
11439083|NCT01772290|Experimental|D: Fluconazole + Vismodegib|
11439084|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
11439085|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
11439086|NCT01772264|Experimental|Arm A - active treatment|
11439087|NCT01772264|Placebo Comparator|Arm B - placebo|
11439088|NCT01772251|Experimental|Oshadi Icp & placebo|
11439089|NCT01772238|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11439090|NCT01772238|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11439091|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
11439092|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
11439093|NCT01772212|Experimental|A(test)/B(reference)|Initial administration of test and crossover to reference
11439094|NCT01772212|Experimental|B(reference)/A(test)|Initial administration of reference and crossover to test
11439095|NCT01772199|Experimental|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
11439096|NCT01772199|Placebo Comparator|Placebo Arm|Placebo once daily orally
11439097|NCT01772186|No Intervention|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
11439098|NCT01772186|Experimental|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
11439099|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
11439100|NCT01772160||Herpes Zoster Group|Male or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode.
11439101|NCT01772147|Experimental|Umeclidinium bromide|Long-acting muscarinic antagonist (LAMA)
11439102|NCT01772147|Active Comparator|Fluticasone propionate/Salmeterol|Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
11439103|NCT01772134|Experimental|Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
11439104|NCT01772134|Active Comparator|Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
11439105|NCT01772134|Placebo Comparator|Placebo + Fluticasone propionate/Salmeterol|Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
11439106|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
11439107|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
11439108|NCT01772108|Experimental|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
11439109|NCT01772108|No Intervention|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
11439110|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
11439113|NCT01772056|Experimental|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
11439114|NCT01772056|Placebo Comparator|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
11439115|NCT01772043||Duchenne muscular dystrophy|
11439116|NCT01772030|Other|Recurrent Atrial Fibrillation|
11439117|NCT01772017|Experimental|Device Treatment|Tongue Advancement Retainer Device
11439118|NCT01772004|Experimental|Avelumab|
11439119|NCT01771991|Experimental|Topical Sodermix Dismutase|Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
11439120|NCT01771991|Placebo Comparator|Placebo group|Cetaphil cream
11439121|NCT01771978|Placebo Comparator|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
11439122|NCT01771978|Experimental|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
11439123|NCT01771978|Experimental|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
11439124|NCT01771978|Experimental|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :
~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
11439125|NCT01771965|No Intervention|Usual care|No intervention.
11439126|NCT01771965|Experimental|CB Intervention|Cognitive Behavioral one-on-one single session administered by phone
11439127|NCT01771952|Experimental|Synvisc-One™|Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.
11439128|NCT01771952|Sham Comparator|Sham Treatment|Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.
11439129|NCT01771939|Experimental|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
11439130|NCT01771939|Active Comparator|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
11439131|NCT01771926|Experimental|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
11439132|NCT01771926|Experimental|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
11439133|NCT01771926|Placebo Comparator|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
11439134|NCT01771913|Sham Comparator|centrifuged fat graft|female patients who underwent breast reconstruction and present with volume insufficiency will undergo centrifuged fat graft for contour and volume refinements.
11439135|NCT01771913|Active Comparator|ADSCs enriched centrifuged fat graft|female patients who underwent breast reconstruction and present volume insufficiency will undergo ADSCs enriched fat grafting for volume and irregularity contour improvement
11439136|NCT01771900|Experimental|Heart Camp Group|
11439137|NCT01771900|Experimental|Attention Control Group|
11439138|NCT01771887|Experimental|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
11439139|NCT01771874|Experimental|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
11439140|NCT01771861||Seriously injured or potentially seriously injured patients|
11439141|NCT01771848|Experimental|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:
~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
11439142|NCT01771848|Experimental|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:
~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
11439143|NCT01771848|Experimental|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:
~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
11439144|NCT01771848|Experimental|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A
~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
11439145|NCT01771848|Experimental|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A
~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).
~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
11439180|NCT01771588|Active Comparator|Currently marketed fortifier|Currently marketed fortifier
11575550|NCT00820235|Active Comparator|B|
11439146|NCT01771848|Experimental|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A
~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.
~*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
11439147|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
11439148|NCT01771822|Experimental|Ibuprofen 5% topical gel|
11439149|NCT01771822|Experimental|Topical gel vehicle|
11439150|NCT01771822|Active Comparator|Sodium lauryl sulfate 0.2%|
11439151|NCT01771822|Sham Comparator|Sodium chloride solution 0.9% (saline)|
11439152|NCT01771809|Experimental|SHP647 75 mg|Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
11439153|NCT01771809|Experimental|SHP647 225 mg|Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
11439154|NCT01771796|Experimental|Aerobic and muscle resistance training|
11439155|NCT01771796|No Intervention|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
11439156|NCT01771783|Experimental|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
11439157|NCT01771783|Experimental|ARB-RI-ACEI|ARB-RI-ACEI
11439158|NCT01771783|Experimental|RI-ACEI-ARB|RI-ACEI-ARB
11439159|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
11439160|NCT01771744||48 morbidly obese patients|with primary gastric bypass
11439161|NCT01771731|Experimental|Cannabis|Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
11439162|NCT01771731|Placebo Comparator|Placebo|Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
11439163|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
11439164|NCT01771705|Experimental|Dose adjust group (NFAT)|Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
11439165|NCT01771705|No Intervention|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
11439166|NCT01771692|Active Comparator|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
11439167|NCT01771692|Active Comparator|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
11439168|NCT01771679|Experimental|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
11439169|NCT01771666|Experimental|ISB and ICG|"The dose of Isosulfan blue (ISB) dye and Indocyanine green (ICG) solution will be started.
~(IC-GREEN) SPY Elite Imaging willbe used to capture the images of axillary cavity."
11439170|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
11439171|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
11439172|NCT01771640|Experimental|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
11439173|NCT01771627|Experimental|Arm I (varenicline)|Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.
11439174|NCT01771627|Active Comparator|Arm II (nicotine patch)|Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
11439175|NCT01771614|Experimental|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
11439176|NCT01771614|Experimental|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
11439177|NCT01771614|Experimental|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
11439178|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
11439179|NCT01771588|Experimental|New human milk fortifier|New human milk fortifier
11439181|NCT01771588|Experimental|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
11439182|NCT01771575|Experimental|Treatment Arm|PoNS™ device
11439183|NCT01771575|Placebo Comparator|Placebo Arm|placebo device
11439184|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
11439185|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
11439186|NCT01771536|Active Comparator|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
11439187|NCT01771536|No Intervention|Usual Care|
11439188|NCT01771523|Active Comparator|Group 1|thyroidectomy
11439189|NCT01771523|Active Comparator|Group 2|thyroidectomy use of drain
11439190|NCT01771497||Women undergoing neoadjuvant therapy|
11439191|NCT01771484|Experimental|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
11439192|NCT01771484|Experimental|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
11439193|NCT01771471|Experimental|NuQu treatment|single administration
11439194|NCT01771471|Other|Saline|single administration
11439195|NCT01771458|Active Comparator|Standard chemotherapy|Treatment choice is based on Investigator decision.
11439196|NCT01771458|Experimental|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)
~Elligible therapies in this trial are :
~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
11439197|NCT01771445|Active Comparator|IL-1Ra|
11439198|NCT01771445|Placebo Comparator|Placebo|
11439199|NCT01771432|Active Comparator|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
11439200|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
11439201|NCT01771419|Experimental|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
11439202|NCT01771419|Active Comparator|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
11439203|NCT01771406|Experimental|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
11439204|NCT01771406|Experimental|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
11439205|NCT01771393|Experimental|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
11439206|NCT01771393|Experimental|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
11439207|NCT01771380||Subjects with impaired glucose tolerance|
11439208|NCT01771367|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine.
11439209|NCT01771367|Active Comparator|Agrippal|Participants receive one dose of Agrippal vaccine.
11439210|NCT01771367|Placebo Comparator|Placebo|Participants receive one dose of saline placebo.
11439211|NCT01771354|Placebo Comparator|Placebo|Placebo
11439212|NCT01771354|Active Comparator|Vaccine|Engerix B vaccine
11439213|NCT01771341|Placebo Comparator|Pressure support|
11439214|NCT01771341|Experimental|NAVA|
11439215|NCT01771328|Active Comparator|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
11439216|NCT01771328|Active Comparator|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
11439217|NCT01771315|Experimental|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
11439218|NCT01771315|No Intervention|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
11439219|NCT01771302|Active Comparator|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
11439220|NCT01771302|Experimental|calcium phosphate ceramic|is a calcium phosphate biomaterial
11439221|NCT01771289|Experimental|chemoradiation|
11439222|NCT01771276|Experimental|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
11439223|NCT01771263|Other|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
11439224|NCT01771250|Experimental|Insulin Peglispro|Stable dose of insulin peglispro (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SC) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
11439225|NCT01771250|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SC once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
11439226|NCT01771237|Experimental|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
11439227|NCT01771237|Active Comparator|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
11575551|NCT00820235|Active Comparator|C|
11439228|NCT01771224|Experimental|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
11439229|NCT01771224|Placebo Comparator|Sugar pill|Sugar pill: 720 mg/day for 56 days
11439230|NCT01771211|Experimental|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
11439231|NCT01771211|Sham Comparator|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
11439232|NCT01771198|Experimental|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
11439233|NCT01771185|Active Comparator|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
11439234|NCT01771185|Active Comparator|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
11439235|NCT01771159|Experimental|Population|All subjects will undergo the implantation of the TBC.
11439236|NCT01771146|Other|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
11439237|NCT01771133|No Intervention|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
11439238|NCT01771133|Active Comparator|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
11439239|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
11439240|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
11439241|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
11439242|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
11439243|NCT01771107|Experimental|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11439244|NCT01771094|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
11439245|NCT01771094|Experimental|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
11439246|NCT01771094|Experimental|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
11439247|NCT01771081||Group1|
11439248|NCT01771068|No Intervention|Waiting list|
11439249|NCT01771068|Experimental|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
11439250|NCT01771055|Experimental|Galactose|Galactose
11439251|NCT01771055|Placebo Comparator|Standard resuscitation|Standard surgical methods of controlling bleeding
11439252|NCT01771042|Experimental|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.
~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
11439253|NCT01771042|Experimental|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.
~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
11439254|NCT01771042|Experimental|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.
~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
11439255|NCT01771042|Experimental|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.
~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
11439256|NCT01771003|Placebo Comparator|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
11439257|NCT01771003|Active Comparator|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
11439258|NCT01770990|Active Comparator|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
11439259|NCT01770990|Experimental|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
11439260|NCT01770977|Active Comparator|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
11439341|NCT01770444|Other|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
11439261|NCT01770977|Placebo Comparator|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
11439262|NCT01770964|Other|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
11439263|NCT01770964|Other|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
11439264|NCT01770964|Other|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
11439265|NCT01770964|Other|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
11439266|NCT01770938|Active Comparator|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
11439267|NCT01770938|Placebo Comparator|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
11439268|NCT01770925|Active Comparator|n-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.
~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.
~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
11439269|NCT01770925|Active Comparator|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.
~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
11439270|NCT01770925|Active Comparator|NIPPV|o The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water, peak inspiratory pressure of 15cm of water, RRof35 and Ti of 0.32
11439271|NCT01770912|Placebo Comparator|Lactated Ringers|1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
11439272|NCT01770912|Active Comparator|Triamcinolone acetonide|1 cc of triamcinolone acetonide (20 mg) injected once after the TMJ rinsing procedure.
11439273|NCT01770899|Experimental|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
11439274|NCT01770899|Placebo Comparator|Placebo|One placebo capsule given every 24h
11439275|NCT01770886|Active Comparator|UE2343|Oral capsule
11439276|NCT01770886|Placebo Comparator|Placebo|Oral capsule
11439277|NCT01770873|Experimental|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
11439278|NCT01770873|No Intervention|Control|Standard emergency room protocol followed
11439279|NCT01770860|Active Comparator|6660|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
11439280|NCT01770860|Active Comparator|4314|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
11439281|NCT01770860|Active Comparator|8336|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
11439282|NCT01770860|Placebo Comparator|4840|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
11439283|NCT01770860|No Intervention|0000|"Device: 0000
~At each daily visit, designated study personnel will cut out the center pad of the bandage and apply only the adhesive tabs around the assigned wound site.
~Other Names:
~Sheer Strips
~BAND-AID® with QuiltVent™ Pad Technology
~Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site."
11439284|NCT01770847||Healthy controls|Healthy age matched controls
11439285|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
11439286|NCT01770834||Cohort|
11439287|NCT01770821|Active Comparator|Standard physical training & standard nutrition|Standard of care
11439288|NCT01770821|Experimental|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
11439289|NCT01770821|Experimental|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
11439290|NCT01770821|Experimental|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
11439291|NCT01770808|Experimental|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
11439292|NCT01770808|Experimental|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
11439293|NCT01770808|Placebo Comparator|Placebo|Produced by Marigot Ltd
11439294|NCT01770795|Experimental|Genexol-PM/Gemcitabine|
11439405|NCT01769924||Live kidney donors|Nephrectomy
11439406|NCT01769924||Healthy controls|Who also meet criteria to donate a kidney
11439295|NCT01770782|Other|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
11439296|NCT01770782|Other|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
11439297|NCT01770769|Active Comparator|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
11439298|NCT01770769|Experimental|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
11439299|NCT01770756|Experimental|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
11439300|NCT01770756|Experimental|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
11439301|NCT01770743|Experimental|AV7909 (Day 0 and 14)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
11439302|NCT01770743|Experimental|AV7909 (Day 0 and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
11439303|NCT01770743|Experimental|AV7909 (Day 0, 14, and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
11439304|NCT01770743|Experimental|AV7909 Reduced Dose|Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
11439305|NCT01770743|Active Comparator|BioThrax|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
11439306|NCT01770730|Experimental|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
11439307|NCT01770730|No Intervention|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
11439308|NCT01770717||Pressure Ulcer Formation|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
11439309|NCT01770704||Patients diagnosed with bipolar disorder I or II|
11439310|NCT01770691|Experimental|TIPI vaginal pessary|Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
11439311|NCT01770678|Experimental|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
11439312|NCT01770678|Active Comparator|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
11439313|NCT01770665||Mesothelioma|
11439314|NCT01770665||all cancer types|
11439315|NCT01770652|Experimental|Normal renal function|Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
11439316|NCT01770652|Experimental|Mild Renal Impairment|Mild impairment, defined as having an eGFR 60-89 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
11439317|NCT01770652|Experimental|Moderate Renal Impairment|Mild impairment, defined as having an eGFR 30-59 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
11439318|NCT01770652|Experimental|Severe Renal Impairment|Severe impairment, defined as having an eGFR 15-19 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
11439319|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
11439320|NCT01770626|No Intervention|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
11439321|NCT01770613|Experimental|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
11439322|NCT01770613|Placebo Comparator|Control|Lactated Ringer's Solution
11439323|NCT01770600|Active Comparator|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
11439324|NCT01770600|Placebo Comparator|Placebo|Administer pill of placebo once a day by mouth for 5 days.
11439325|NCT01770587|Experimental|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
11439326|NCT01770574|Experimental|ReproBone|calcaneal lengthening
11439327|NCT01770574|Active Comparator|Autologous bone graft|calcaneal lengthening
11439328|NCT01770561|Experimental|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
11439329|NCT01770548|Experimental|Autism|Analysis of the glutamate synapse in autism
11439330|NCT01770548|Other|Relative|Analysis of the glutamate synapse in autism
11439331|NCT01770548|Other|Major control|DNA collection
11439332|NCT01770548|Other|Minor control|auditory evoked potentials
11439333|NCT01770509|Active Comparator|Standard of care|Standard of care: Dressings +Compression garments
11439334|NCT01770509|Experimental|Application of NMBM|Daily application of NMBM
11439335|NCT01770496|No Intervention|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
11439336|NCT01770496|Experimental|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
11439337|NCT01770483|Experimental|study group|Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
11439338|NCT01770483|Active Comparator|control group|Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
11439339|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
11439340|NCT01770444|Experimental|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
11439342|NCT01770431|Experimental|Huaier Granule group|"Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..
~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule."
11439343|NCT01770431|No Intervention|Bank-control group|"Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.
~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles."
11439344|NCT01770418|Experimental|Proton Radiotherapy with Chemotherapy|
11439345|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
11439346|NCT01770392|Active Comparator|Test|multiple doses of Rifampicin + single dose of Nintedanib
11439347|NCT01770392|Experimental|Reference|single dose of Nintedanib
11439348|NCT01770379|Experimental|Secukinumab 75 mg|Secukinumab 75 mg s.c.
11439349|NCT01770379|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c.
11439350|NCT01770379|Placebo Comparator|Placebo|Placebo patients will be re-randomized 1:1 to secukinumab 75 or 150mg s.c. (non-responders at Week 16 will be re-assigned to new treatment at Week 16; responders at Week 16 will be re-assigned to new treatment at Week 24)
11439351|NCT01770366|Placebo Comparator|Usual Care|Patients will receive usual care from the post-surgical clinic team.
11439352|NCT01770366|Experimental|Intervention Condition|Intervention participants will receive the Weight and Exercise Lifestyle Support (WELS) intervention, which involves use of a wireless activity monitor and weight scale, as well as access to a patient portal website displaying data from these devices.
11439353|NCT01770353|Experimental|Pilot Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
11439354|NCT01770353|Experimental|Expansion Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis
11439355|NCT01770340|Sham Comparator|Control group|Radical prostatectomy without implantation of allograft
11439356|NCT01770340|Experimental|Treatment group|Radical prostatectomy with implantation of allograft
11439357|NCT01770327|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
11439358|NCT01770327|Experimental|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
11439359|NCT01770327|Experimental|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
11439360|NCT01770327|Experimental|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
11439361|NCT01770314|Experimental|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
11439362|NCT01770314|No Intervention|Control|The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.
11439363|NCT01770301|Active Comparator|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
11439364|NCT01770301|Experimental|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
11439365|NCT01770288|Experimental|Anaerobic Performance|
11439366|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
11439367|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
11439368|NCT01770262||Healthy|
11439369|NCT01770249|Other|Per-oral Endoscopic Esophagomyotomy (POEM)|An endoscopic surgical procedure for achalasia; Per-oral Endoscopic Esophagomyotomy (POEM)will be performed. The POEM procedure will be performed in the operating room under general anesthesia and a scope will then be inserted into your mouth and down your throat and measurements will be taken. With the use of this lighted flexible scope the surgeon will make a small incision in the inner lining of your esophagus (throat), create a tunnel and then cut the muscle between the esophagus (throat) and the stomach. The initial little opening will be closed with a small clip. This procedure will allow easier passage of food into the stomach.
11439370|NCT01770236|Experimental|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
11439371|NCT01770236|No Intervention|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
11439372|NCT01770223|Experimental|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
11439373|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
11439776|NCT01767311|Experimental|Core Study: BAN2401 2.5 mg/kg biweekly|2.5 mg/kg biweekly
11439374|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
11439375|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
11439376|NCT01770184|Experimental|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
11439377|NCT01770184|No Intervention|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
11439378|NCT01770171|Experimental|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
11439379|NCT01770171|Active Comparator|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
11439380|NCT01770145|Experimental|APOKYN|"APOKYN (apomorphine hydrochloride injection) is used as needed to treat off-episode motor symptoms, such as muscle stiffness, slow movements, and difficulty starting movements, in people with advanced Parkinson's disease (PD).
~In the study, subjects will complete an L-Dopa Baseline Period in which they record daily time to on following their regularly scheduled L-Dopa morning dose for 7 days. At the end of the baseline period, patients will start trimethobenzamide therapy during a minimum 3-Day Anti-Emetic Pretreatment Period. Patients determined to remain eligible at the end of the required Anti-Emetic Pretreatment Period will be initiated on APOKYN therapy by an investigator. Once the appropriate dose is identified by a study investigator, patients will inject APOKYN at their regularly scheduled levodopa morning dose time (levodopa will be delayed by 40 minutes) daily during a 7-day APOKYN Treatment Period and record time to on following the APOKYN injection."
11439381|NCT01770132|Experimental|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
11439382|NCT01770119|Experimental|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
11439383|NCT01770106|Experimental|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
11439384|NCT01770106|Active Comparator|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
11439385|NCT01770093||Parents of Pediatric Inpatients|
11439386|NCT01770080|Active Comparator|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
11439387|NCT01770080|Placebo Comparator|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
11439388|NCT01770067|Experimental|Infection Prone Patients Prior to CIED|Administration of high-dose antibiotics (CIA-RNPT)
11439389|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
11439390|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
11439391|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
11439392|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
11439393|NCT01770015|Experimental|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.
~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
11439394|NCT01770002|Active Comparator|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
11439395|NCT01770002|Active Comparator|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
11439396|NCT01769989|Active Comparator|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
11439397|NCT01769989|Active Comparator|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
11439398|NCT01769976|Experimental|Daily energy restriction|25% reduction in daily energy intake
11439399|NCT01769976|Active Comparator|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
11439400|NCT01769976|Experimental|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
11439401|NCT01769976|Experimental|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
11439402|NCT01769963|Experimental|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
11439403|NCT01769950|Experimental|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
11439404|NCT01769937|Experimental|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
11439407|NCT01769911|Experimental|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.
~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.
~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving > 10% gene marking and CD4 count of >= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
11439408|NCT01769898|Placebo Comparator|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.
~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
11439409|NCT01769898|Experimental|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.
~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
11439410|NCT01769885|Experimental|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
11439411|NCT01769872|Experimental|Autologous Adipose Tissue derived MSCs|
11439412|NCT01769846|Experimental|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
11439413|NCT01769846|No Intervention|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
11439414|NCT01769833|Active Comparator|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
11439415|NCT01769833|Placebo Comparator|Nucleosides|Nucleosides
11439416|NCT01769820|Active Comparator|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
11439417|NCT01769820|Placebo Comparator|Placebo|Placebo
11439418|NCT01769807|Experimental|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
11439419|NCT01769794|Active Comparator|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
11439420|NCT01769794|Experimental|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
11439421|NCT01769781|Experimental|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
11439422|NCT01769781|Active Comparator|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
11439423|NCT01769768|Experimental|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
11439424|NCT01769768|Experimental|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
11439425|NCT01769755|Experimental|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
11439426|NCT01769755|Placebo Comparator|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
11439427|NCT01769742|Experimental|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
11439428|NCT01769742|No Intervention|Usual care|Usual physiotherapy service only
11439429|NCT01769729|Experimental|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.
~Care management will include monthly calls with a depression care manager."
11439430|NCT01769729|Active Comparator|Care management alone|Care management will include monthly calls with a depression care manager.
11439431|NCT01769716|Experimental|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
11439432|NCT01769703|Experimental|Dabigatran|
11439433|NCT01769690|Experimental|DBS stimulator setting alteration|
11439434|NCT01769677|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:
~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).
~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
11439435|NCT01769677|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:
~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).
~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
11439436|NCT01769664|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
11439437|NCT01769664|Active Comparator|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
11439438|NCT01769664|Placebo Comparator|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
11439439|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
11439440|NCT01769638|Experimental|SPO1101|
11439441|NCT01769638|Experimental|SPO1101D|
11439442|NCT01769625|Placebo Comparator|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
11439443|NCT01769625|Active Comparator|placebo & cholecalciferol 2,000 IU|Placebo & cholecalciferol 2,000 IU
11439444|NCT01769625|Experimental|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg & cholecalciferol2,000 IU
11439445|NCT01769612||CL Detect Rapid Test and Microsopy Samples|Samples taken to be evaluated in the CL Detect and Microscopy assays
11439446|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
11439447|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
11439448|NCT01769586|Active Comparator|Diphenhydramine|Increments of 25 mcg to maximum of 3 times (total 75 mcg)
11439449|NCT01769586|Active Comparator|Midazolam|1.5 mg increments up to 3 times (maximum 4.5 mg)
11439450|NCT01769573|Experimental|100 TCID50|RG-HRV16 dose of 100 TCID50 administered intranasally (0.25ml per nostril) one time.
11439451|NCT01769573|Experimental|1,000 TCID50|RG-HRV16 dose of 1,000 TCID50 administered intranasally (0.25ml per nostril) one time.
11439452|NCT01769573|Experimental|10,000 TCID50|RG-HRV16 dose of 10,000 TCID50 administered intranasally (0.25ml per nostril) one time.
11439453|NCT01769573|Placebo Comparator|Placebo|Diluent administered intranasally (0.25ml per nostril) one time.
11439454|NCT01769573|Experimental|500 TCID50|RG-HRV16 dose of 500 TCID50 administered intranasally (0.25ml per nostril) one time.
11439455|NCT01769560|No Intervention|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
11439456|NCT01769560|Experimental|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
11439457|NCT01769547|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
11439458|NCT01769521|Experimental|Triggerfish|Device: Sensimed Triggerfish
11439459|NCT01769508|Experimental|Combined Therapy|Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
11439460|NCT01769495|No Intervention|Control|Standard post ED care
11439461|NCT01769495|Experimental|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
11439462|NCT01769482|Experimental|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
11439463|NCT01769482|Placebo Comparator|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
11439464|NCT01769469||Subjects Enrolled in ATN 110 or ATN 113|A subset of 100 participants who are enrolled in the ATN 110 or ATN 113 study will be recruited for participation in this study. There is no treatment or intervention for this study; however, all subjects will be on daily coformulated tenofovir/emtricitabine (TDF/FTC (Truvada®)) as part of the ATN 110 or ATN 113 study.
11439465|NCT01769456|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
11439466|NCT01769443|No Intervention|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
11439467|NCT01769443|Experimental|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.
~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
11439468|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
11439469|NCT01769417|Placebo Comparator|Placebo|
11439470|NCT01769417|Active Comparator|MEDI4893|
11439471|NCT01769404|Experimental|LY2605541|Stable dose of LY2605541 (0.2 to 0.6 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
11439472|NCT01769404|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 to 0.6 U/kg) administered SQ once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
11439473|NCT01769391|Experimental|Necitumumab +Paclitaxel+Carboplatin|"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.
~Paclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.
~Carboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.
~The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent."
11439474|NCT01769391|Active Comparator|Paclitaxel + Carboplatin|Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.
11439475|NCT01769378|Placebo Comparator|Placebo|Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
11439476|NCT01769378|Experimental|Dulaglutide|Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
11439477|NCT01769365|Experimental|7-day quadruple therapy|"pantoprazole 40 mg twice daily for 7 days,
~clarithromycin 500 mg twice daily for 7 days,
~amoxicillin 1 g twice daily for 7 days,
~metronidazole 500 mg twice daily for 7 days"
11439777|NCT01767311|Experimental|Core Study: BAN2401 5.0 mg/kg biweekly|5.0 mg/kg biweekly
11439478|NCT01769365|Experimental|10-day sequential therapy|"pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by
~pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days."
11439479|NCT01769365|Active Comparator|7-day standard triple therapy|"pantoprazole 40 mg twice daily for 7 days,
~clarithromycin 500 mg twice daily for 7 days,
~amoxicillin 1 g twice daily for 7 days."
11439480|NCT01769352|Active Comparator|PredA q1h WA + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
11439481|NCT01769352|Active Comparator|PredA qid + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
11439482|NCT01769339|Experimental|Miconazole plus Hydrocortisone|
11439483|NCT01769326|Experimental|MusicGlove Group|Subject participates in 3 weeks of exercising with the experimental device: MusicGlove at a minimum of 3 days per week, 1 hour per day with the exercise program
11439484|NCT01769326|Active Comparator|Control Group for Music Glove|Subject participates in 3 weeks of conventional hand exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
11439485|NCT01769326|Experimental|Resonating Arm Exerciser (RAE)|Subject participates in 3 weeks of exercising with the experimental device: RAE at a minimum of 3 days per week, 1 hour per day with the exercise program
11439486|NCT01769326|Active Comparator|Control Group for RAE|Subject participates in 3 weeks of conventional arm exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
11439487|NCT01769313|Experimental|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
11439488|NCT01769313|Active Comparator|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
11439489|NCT01769300|No Intervention|Control practices|Practices that do not use the ADHD clinical decision support
11439490|NCT01769300|Experimental|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
11439491|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
11439492|NCT01769274|Experimental|PF-05089771 1600 mg|
11439493|NCT01769274|Placebo Comparator|Placebo comparator: matching placebo|Single oral dose of placebo for PF-05089771 1600 mg
11439494|NCT01769261|Experimental|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
11439495|NCT01769261|Active Comparator|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
11439496|NCT01769261|Other|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
11439497|NCT01769248|Active Comparator|Fine needle aspiration|fine needle aspiration
11439498|NCT01769248|Active Comparator|Fine needle biopsy|Fine needle biopsy
11439499|NCT01769235|Experimental|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
11439500|NCT01769235|Active Comparator|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
11439501|NCT01769235|Placebo Comparator|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
11439502|NCT01769222|Experimental|Ipilimumab 25 mg|Participants receive ipilimumab intratumorally on Day 1
11439503|NCT01769222|Experimental|Ipilimumab 25 mg and radiation therapy|Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
11439504|NCT01769209|Experimental|Bortezomib + Chemotherapy|Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
11439505|NCT01769196|Experimental|Simtuzumab|Participants will receive simtuzumab for up to 254 weeks.
11439506|NCT01769196|Placebo Comparator|Simtuzumab Placebo|Participants will receive simtuzumab placebo for up to 254 weeks.
11439507|NCT01769183|Experimental|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
11439508|NCT01769170|Placebo Comparator|CMX001|placebo BIW
11439509|NCT01769170|Active Comparator|CMX001 100mg|100 mg CMX001 BIW
11439510|NCT01769157|Active Comparator|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
11439511|NCT01769157|Placebo Comparator|Placebo|placebo drug, 3 tablet twice daily
11439512|NCT01769144|Active Comparator|Acticoat Absorbent|Acticoat Absorbent wound dressing
11439513|NCT01769144|Experimental|BCT wound dressing|wound dressing
11439514|NCT01769131||Allis|
11439515|NCT01769131||Tenaculum|
11439516|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
11439517|NCT01769105|Active Comparator|Standard Lid Hygiene Regime|Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
11439518|NCT01769105|Active Comparator|Lipiflow|Patients receive a singe Lipiflow-treatment
11439519|NCT01769092|Experimental|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
11439520|NCT01769092|Placebo Comparator|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
11439521|NCT01769079|Active Comparator|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
11439522|NCT01769079|Placebo Comparator|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
11439523|NCT01769066|Experimental|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
11439524|NCT01769066|Active Comparator|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
11439525|NCT01769053|Active Comparator|Variable Ventilation|Patients are ventilated with variable pressure support mode.
11439526|NCT01769053|No Intervention|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
11439527|NCT01769040|Experimental|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
11439528|NCT01769040|Placebo Comparator|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
11439529|NCT01769027|Active Comparator|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
11439530|NCT01769027|Placebo Comparator|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
11439531|NCT01768988|Experimental|Group I|Conventional analgesic treatment + pregabalin.
11439532|NCT01768988|Placebo Comparator|Group II|Conventional analgesic treatment + placebo.
11439533|NCT01768975|Experimental|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
11439534|NCT01768975|Placebo Comparator|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
11439535|NCT01768962|Active Comparator|Sequence A|2 weeks, 6 week washout, 2 weeks
11439536|NCT01768962|Active Comparator|Sequence B|2 weeks, 6 week washout, 2 weeks
11439537|NCT01768949|Other|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
11439538|NCT01768936||eliminated infectious abdominal focus|
11439539|NCT01768936||persisting/progressing infectious abdominal focus|
11439540|NCT01768923|Active Comparator|SDAI remission group|SDAI remission
11439541|NCT01768923|Active Comparator|Minimal disease activity group|Minimal disease activity remission
11439542|NCT01768910|Experimental|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
11439543|NCT01768910|Experimental|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
11439544|NCT01768910|Experimental|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
11439545|NCT01768910|Experimental|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
11439546|NCT01768910|Experimental|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
11439547|NCT01768897|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
11439548|NCT01768884|Experimental|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
11439549|NCT01768884|Placebo Comparator|Standard treatment|Standard treatment
11439550|NCT01768858||Participants receiving adalimumab|Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC) received 40 mg adalimumab every two weeks.
11439551|NCT01768845|Experimental|Transplant|After a preparative regimen the patient will receive an infusion of one or two umbilical cord blood unit(s) (UBC). The UBC unit(s) will be thawed according to methods of Rubinstein et al. If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis. On day +30, +60, +100, +180, and +365 the chimeric status of patients will be interpreted by VNTR analysis. Immune reconstitution (Digeorge Panel) will also be checked at these time points.
11439552|NCT01768832|Experimental|Treadmill|Individuals assigned to the Treadmill group will complete two one hour treadmill training sessions per week for 12 weeks.
11439553|NCT01768832|Experimental|Tango|Individuals assigned to the Tango group will complete two one hour dance classes twice per week for 12 weeks.
11439554|NCT01768832|Active Comparator|Stretching|Individuals assigned to Stretching will complete two one hour stretching classes per week for 12 weeks.
11439555|NCT01768819|Experimental|Intervention Group|Physical Activity
11439556|NCT01768819|No Intervention|Control Group|
11439589|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
11439778|NCT01767311|Experimental|Core Study: BAN2401 10 mg/kg biweekly|10 mg/kg biweekly
11439557|NCT01768806|Experimental|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
11439558|NCT01768806|Active Comparator|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
11439559|NCT01768793|Experimental|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
11439560|NCT01768793|Active Comparator|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
11439561|NCT01768780|Experimental|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
11439562|NCT01768767|Experimental|Ketamine/Lithium|Participant will receive ketamine/lithium
11439563|NCT01768767|Active Comparator|Ketamine|Participant will receive ketamine
11439564|NCT01768767|Placebo Comparator|Placebo|Participant will receive placebo
11439565|NCT01768754||COPD patients|Usual and Fast Walking Speeds
11439566|NCT01768741|Active Comparator|Laparoscopic liver resection group|
11439567|NCT01768741|Active Comparator|Open liver resection|
11439568|NCT01768728|Active Comparator|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
11439569|NCT01768728|Active Comparator|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
11439570|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
11439571|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
11439572|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
11439573|NCT01768702|Sham Comparator|Control|Sham, no injection
11439574|NCT01768702|Experimental|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
11439575|NCT01768689|No Intervention|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
11439576|NCT01768689|Experimental|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:
~adherence-encouraging interventions - Group meetings
~adherence-encouraging interventions - Individual meetings
~adherence-encouraging interventions - Monthly phone calls
~Patient will receive routine treatment for CML according to the physician discretion."
11439577|NCT01768676|Experimental|avanafil|100 mg
11439578|NCT01768676|Placebo Comparator|Placebo|placebo
11439579|NCT01768663|Experimental|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
11439580|NCT01768663|Experimental|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
11439581|NCT01768663|Experimental|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
11439582|NCT01768663|Experimental|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
11439583|NCT01768650|Experimental|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
11439584|NCT01768650|Experimental|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
11439585|NCT01768637|Experimental|Chronic Kidney Disease|Patients with pre-dialysis stages 4-5 Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
11439586|NCT01768637|Active Comparator|Normal controls|Patients without Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
11439587|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
11439588|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
11439590|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
11439591|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
11439592|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
11439593|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
11439594|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
11439595|NCT01768585|Active Comparator|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
11439596|NCT01768585|Placebo Comparator|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
11439597|NCT01768572|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
11439598|NCT01768572|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
11439599|NCT01768572|Active Comparator|Tocilizumab q4w|Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
11439600|NCT01768559|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.
11439601|NCT01768559|Active Comparator|Insulin Glulisine QD|Insulin glulisine QD from randomization up to Week 26 on top of Insulin glargine with or without metformin.
11439602|NCT01768559|Active Comparator|Insulin Glulisine TID|Insulin glulisine thrice daily (TID) from randomization up to Week 26 on top of Insulin glargine with or without metformin.
11439603|NCT01768546|Experimental|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
11439604|NCT01768546|Experimental|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
11439605|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
11439606|NCT01768520|Experimental|Entelon tab. 150mg|
11439607|NCT01768520|Active Comparator|Celebrex cap.|
11439608|NCT01768520|Placebo Comparator|Placebo|
11439609|NCT01768507|Placebo Comparator|Placebo|no medication
11439610|NCT01768507|Experimental|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
11439611|NCT01768481|Experimental|Statin|Atorvastatin 10 mg every day for one year
11439612|NCT01768481|Placebo Comparator|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
11439613|NCT01768468|Experimental|LAYLA|Drug : LAYLA tablet/ bid
11439614|NCT01768468|Active Comparator|JOINS|Drug : JOINS tablet/ tid
11439615|NCT01768455|Experimental|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
11439616|NCT01768455|Experimental|Glimepiride|Single administration of glimepiride
11439617|NCT01768429|Experimental|Fatty fish|Four fatty fish meals per week
11439618|NCT01768429|Experimental|Lean Fish|Four lean fish meals per week
11439619|NCT01768429|Experimental|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
11439620|NCT01768429|Experimental|Control diet|Limited fish and alpha-linolenic acid intake
11439621|NCT01768390|Experimental|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
11439622|NCT01768390|Active Comparator|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
11439623|NCT01768377|Active Comparator|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
11439624|NCT01768377|Experimental|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
11439625|NCT01768364|Active Comparator|Antibiotics|will receive antibiotics
11439626|NCT01768364|Active Comparator|No antibiotics|will not receive antibiotics
11439627|NCT01768351|Active Comparator|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
11439628|NCT01768351|Experimental|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
11439629|NCT01768338|Experimental|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
11439630|NCT01768325|Active Comparator|EUS-Guided biopsy needle (ProCore)|"Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.
~The number of needle passes requiring to acquire adequate specimen
~Length of core tissue obtained
~Diagnostic contribution of immunohistochemical staining
~Rates of complications"
11439631|NCT01768325|Active Comparator|EUS-TCB needle (Quick-Core)|"Comparison of core biopsy needles.
~The number of needle passes requiring to acquire adequate specimen
~Length of core tissue obtained
~Diagnostic contribution of immunohistochemical staining
~Rates of complications"
11439632|NCT01768312|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
11439633|NCT01768312|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
11439634|NCT01768299|Experimental|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.
~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
11439635|NCT01768299|Experimental|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.
~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
11439636|NCT01768286|Experimental|LDV/SOF 12 Weeks|Participants will receive LDV/SOF FDC for 12 weeks.
11439637|NCT01768286|Experimental|LDV/SOF+RBV 12 Weeks|Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
11439638|NCT01768286|Experimental|LDV/SOF 24 Weeks|Participants will receive LDV/SOF FDC for 24 weeks.
11439639|NCT01768286|Experimental|LDV/SOF+RBV 24 Weeks|Participants will receive LDV/SOF FDC plus RBV for 24 weeks.
11439640|NCT01768273|Experimental|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
11439641|NCT01768260|Active Comparator|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
11439642|NCT01768260|Active Comparator|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
11439643|NCT01768247|Experimental|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
11439644|NCT01768234|Experimental|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
11439645|NCT01768234|No Intervention|Control|No supplemental water provided
11439646|NCT01768221|Other|Caregiver intervention|
11439647|NCT01768208|Experimental|Saxagliptin|
11439648|NCT01768195|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
11439649|NCT01768182|Experimental|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
11439650|NCT01768182|Placebo Comparator|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
11439651|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
11439652|NCT01768156|Experimental|Study arm|
11439653|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
11439654|NCT01768143||Nurse Experts|Educated endoscopy Nurses
11439655|NCT01768117|Experimental|rLP2086|
11439656|NCT01768104|Experimental|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
11439657|NCT01768104|Active Comparator|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
11439658|NCT01768091|Experimental|POEM|POEM for patients with esophageal achalasia
11439659|NCT01768091|Active Comparator|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
11439660|NCT01768078|Experimental|with corticoids|
11439661|NCT01768078|Other|without corticoids|
11439662|NCT01768065|Experimental|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
11439663|NCT01768065|Sham Comparator|placebo sham|A sham device
11439664|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
11439665|NCT01768039|Active Comparator|Vitamin D|treatment with weekly 50000IU vitamin D
11439666|NCT01768039|Placebo Comparator|Placebo|Treatment with placebo
11439667|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
11439668|NCT01768013|Experimental|LEO 90105 Ointment|
11439669|NCT01768000|Experimental|Family Cognitive Adaptation Training|Participants in this group will receive the Family CAT manual and DVD
11439670|NCT01768000|No Intervention|Control group|Participants in this arm will support their family members as usual, and will not receive the Family CAT manual and DVD provided to those in the experimental arm of the study.
11439671|NCT01767987|Active Comparator|Ranolazine|Oral treatment Intervention: Drug: Ranolazine 1000 mg
11439672|NCT01767987|Placebo Comparator|Placebo|Oral treatment Intervention: Drug: Placebo
11439673|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
11439775|NCT01767324|Experimental|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
11439674|NCT01767961|Experimental|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
11439675|NCT01767948|Experimental|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
11439676|NCT01767948|Experimental|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
11439677|NCT01767948|Experimental|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
11439678|NCT01767948|Experimental|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
11439679|NCT01767935|Experimental|Treatment (cryosurgery and radiation therapy)|Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11439680|NCT01767922|Experimental|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
11439681|NCT01767922|Placebo Comparator|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
11439682|NCT01767909|Experimental|Insulin (Humulin® R U-100)|120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
11439683|NCT01767909|Placebo Comparator|Placebo|120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
11439684|NCT01767896|Experimental|ASP7374 group|cell-culture-derived vaccine group
11439685|NCT01767896|Active Comparator|TIV group|approved egg-derived TIV group
11439686|NCT01767883|Experimental|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:
~CKD decision support algorithms added to their Clinical Decision Support
~System Academic detailing concerning the rationale for the algorithms
~On-going mentoring and practice facilitation"
11439687|NCT01767883|Active Comparator|Clinical Decision Support Only|"The primary care practices in this arm will receive:
~CKD decision support algorithms added to their Clinical Decision Support System
~Academic detailing concerning the rationale for the algorithms"
11439688|NCT01767870|Experimental|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
11439689|NCT01767870|Experimental|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
11439690|NCT01767857|Experimental|Xilonix|MABp1 administered IV every two weeks, plus best supportive care
11439691|NCT01767857|Placebo Comparator|Placebo|Placebo administered IV every two weeks, plus best supportive care
11439692|NCT01767844|Experimental|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
11439693|NCT01767844|Placebo Comparator|Fruit powder drink|A regular fruit flavoured powder that has no benefits
11439694|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
11439695|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
11439696|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
11439697|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
11439698|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
11439699|NCT01767805|Other|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
11439700|NCT01767805|Other|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
11439701|NCT01767792|Experimental|Bevacizumab|Follow participant for 2 years and assess hearing response rates
11439702|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
11439703|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
11439704|NCT01767766|Experimental|TGR-1202|TGR-1202 Daily Oral Dose
11439705|NCT01767753|Experimental|Triggerfish|Device: Sensimed Triggerfish
11439706|NCT01767740|Experimental|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
11439707|NCT01767740|Active Comparator|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
11439708|NCT01767727|Other|Surgical flap|Surgical flap is based on the dorsal branch of the digital artery, and is used for soft tissue coverageof multiple finger defects.
11439709|NCT01767714|Experimental|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
11439710|NCT01767714|Placebo Comparator|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
11439711|NCT01767701|Experimental|Raltegravir|All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.
11439712|NCT01767688|Experimental|Moderate Hepatic Impairment Group|
11439713|NCT01767688|Experimental|Healthy Matched Control Group|
11439714|NCT01767675|Experimental|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
11439715|NCT01767675|Experimental|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
11439716|NCT01767662|Experimental|manipulation|home program for parents manipulation
11439717|NCT01767662|Placebo Comparator|observe|observation
11439718|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
11439719|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
11439720|NCT01767636|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11439721|NCT01767623|Active Comparator|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute [NCI] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
11439722|NCT01767623|Experimental|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
11439723|NCT01767610|Experimental|micronized fenofibrate|
11439724|NCT01767610|Experimental|pitavastatin Ca|
11439725|NCT01767610|Experimental|micronized fenofibrate plus pitavastatin Ca|
11439726|NCT01767597|Active Comparator|ELISA testing|HBV infection status determined by enzyme-linked immuno-assay (ELISA)
11439727|NCT01767597|Experimental|Rapid testing|HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
11439728|NCT01767584|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
11439729|NCT01767584|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
11439730|NCT01767571|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11439731|NCT01767571|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11439732|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.
~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
11439733|NCT01767545|Active Comparator|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
11439734|NCT01767545|Active Comparator|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
11439735|NCT01767532|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11439736|NCT01767532|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11439737|NCT01767519|Experimental|BOTOX®|Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.
11439738|NCT01767519|Active Comparator|solifenacin|Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
11439739|NCT01767519|Placebo Comparator|placebo|Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
11439740|NCT01767506|Experimental|Intervention|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
11439741|NCT01767506|Active Comparator|Usual Care|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
11439742|NCT01767493|Experimental|[18F]Florbetapir and PET imaging|Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan
11439743|NCT01767480|Experimental|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
11439744|NCT01767480|Experimental|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
11439745|NCT01767480|Active Comparator|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
11439746|NCT01767467|Experimental|Vaccine Group|Subjects will receive the candidate HZ vaccine (GSK 1437173A).
11439747|NCT01767467|Placebo Comparator|Placebo Group|Subjects will receive the placebo vaccine.
11439748|NCT01767454|Experimental|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
11439749|NCT01767454|Experimental|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
11439750|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
11439751|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
11439752|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
11439753|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
11439754|NCT01767428|Experimental|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.
11439755|NCT01767428|Active Comparator|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
11439756|NCT01767415|Experimental|Indigo Carmine|Intraoperative stereotactic injection of Indigo Carmine
11439757|NCT01767402|Experimental|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
11439758|NCT01767402|Experimental|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
11439759|NCT01767402|Experimental|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
11439760|NCT01767402|Experimental|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
11439761|NCT01767402|Experimental|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
11439762|NCT01767402|Active Comparator|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
11439763|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
11439764|NCT01767376|Experimental|Nimenrix+ Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
11439765|NCT01767376|Experimental|Nimenrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
11439766|NCT01767376|Experimental|Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
11439767|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
11439768|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
11439769|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
11439770|NCT01767337|Experimental|injection of 0.1 mL saline|deliver from FluGen 101.2 device
11439771|NCT01767337|Experimental|injection of 0.25 mL saline|deliver from FluGen 101.2 device
11439772|NCT01767337|Experimental|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
11439773|NCT01767324|Experimental|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
11439774|NCT01767324|Experimental|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
11439779|NCT01767311|Experimental|Core Study: BAN2401 5.0 mg/kg monthly|5.0 mg/kg monthly
11439780|NCT01767311|Experimental|Core Study: BAN2401 10 mg/kg monthly|10 mg/kg monthly
11439781|NCT01767311|Placebo Comparator|Core Study: BAN2401-matched Placebo|Matching placebo biweekly
11439782|NCT01767311|Experimental|Extension Phase: BAN2401 10 mg/kg|All participants who fulfill Extension phase inclusion and exclusion criteria will have the option to participate in the Extension phase to receive BAN2401 10 mg/kg biweekly for up to 24 months or until the drug is commercially available in the country where the subject resides, or until the benefit-to-risk ratio from treatment with BAN2401 is no longer considered favorable, whichever comes first.
11439783|NCT01767298|Other|Valsartan 320 mg alone|Valsartan alone
11439784|NCT01767298|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
11439785|NCT01767298|Other|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
11439786|NCT01767298|Other|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
11439787|NCT01767285|Experimental|Immediate Postpartum Etonogestrel Implant|Etonogestrel implant placed in the hospital after delivery, before discharge home.
11439788|NCT01767285|Active Comparator|Delayed postpartum etonogestrel implant|These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
11439789|NCT01767272|Other|fexofenadine 60 mg|First dose strength
11439790|NCT01767272|Other|fexofenadine 120 mg|Second dose strength
11439791|NCT01767272|Other|fexofenadine 180 mg|Third dose strength
11439792|NCT01767272|Other|fexofenadine 240 mg|Fourth dose strength
11439793|NCT01767272|Other|fexofenadine 360 mg|Fifth dose strength
11439794|NCT01767259|Other|Valsartan 160 mg alone|Valsartan alone
11439795|NCT01767259|Other|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
11439796|NCT01767259|Other|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
11439797|NCT01767259|Other|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
11439798|NCT01767246|Experimental|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
11439799|NCT01767246|Active Comparator|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
11439800|NCT01767233|Experimental|Pancreatic stenting|Pancreatic stenting versus observation
11439801|NCT01767220|Active Comparator|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
11439802|NCT01767220|Active Comparator|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
11439803|NCT01767207||screening for mental disorders|screening for mental disorders
11439804|NCT01767194|Experimental|Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)|CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
11439805|NCT01767194|Experimental|Arm II (temozolomide, irinotecan hydrochloride, dinutuximab)|Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.
11439806|NCT01767181|No Intervention|A|Control group without intervention
11439807|NCT01767181|Experimental|B|Intensive light therapy during the first half of the night shift
11439808|NCT01767181|Experimental|C|Exercise before the beginning of the night shift
11439809|NCT01767181|Experimental|D|Exercise after the end of the night shift
11439810|NCT01767155|Experimental|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles up to 9 cycles
11439811|NCT01767155|Active Comparator|doxorubicin/ standard chemotherapy|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
11439812|NCT01767142|Experimental|Outer Thigh CoolSculpting Treatment|Treatment with the CoolSculpting System and a modified belt applicator will be performed on one outer thigh; the remaining thigh is considered the untreated control. Subjects will receive one cooling cycle applied to the thigh area intended for treatment with a protocol-defined cooling rate and duration of 120 minutes.
11439813|NCT01767129|Experimental|AVP-923-45|AVP-923-45 twice daily for 14 days
11439814|NCT01767129|Placebo Comparator|Placebo|Placebo twice a day for 14 days
11439815|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11439816|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
11439817|NCT01767103|Experimental|Normal Hepatic Function (healthy volunteers)|Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
11439818|NCT01767103|Experimental|Mild Hepatic Failure|Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
11439819|NCT01767103|Experimental|Moderate Hepatic Failure|Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
11439859|NCT01766804|Experimental|Bovine colostrum|A daily supplement of bovine colostrum powder.
11576118|NCT00816660|Active Comparator|2|
11439820|NCT01767090|Placebo Comparator|Placebo|Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
11439821|NCT01767090|Experimental|ASP1707 lowest dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
11439822|NCT01767090|Experimental|ASP1707 low dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
11439823|NCT01767090|Experimental|ASP1707 medium dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
11439824|NCT01767090|Experimental|ASP1707 high dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
11439825|NCT01767090|Active Comparator|Leuprorelin acetate|Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks
11439826|NCT01767077|Placebo Comparator|Butter oil|Daily intake of 40 g butter oil
11439827|NCT01767077|Active Comparator|Cream|Daily intake of 100 g cream (40%)
11439828|NCT01767064|Experimental|Posted commitment letter|The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
11439829|NCT01767064|No Intervention|Control|Usual care with no posted letters.
11439830|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
11439831|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
11439832|NCT01767025|Experimental|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
11439833|NCT01767025|Placebo Comparator|Sea water|Sea water 3 puffs per nostril
11439834|NCT01767012|Active Comparator|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
11439835|NCT01767012|Active Comparator|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
11439836|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
11439837|NCT01766973||Chronic back pain|Adults, >6months duration
11439838|NCT01766973||Control|Age and sex matched controls
11439839|NCT01766960|Experimental|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
11439840|NCT01766960|Experimental|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
11439841|NCT01766947|Experimental|Triggerfish|Device : Sensimed Triggerfish
11439842|NCT01766921|Experimental|aH5N1c - High dose|
11439843|NCT01766921|Experimental|aH5N1c - Low dose|
11439844|NCT01766908|Active Comparator|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
11439845|NCT01766908|Active Comparator|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
11439846|NCT01766908|Active Comparator|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
11439847|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
11439848|NCT01766882|Experimental|Treatment|"Lower sodium intervention:
~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day
~Lower dialysate sodium at 137 mmol/L.
~Progressive Challenge to Post Dialysis Weight:
~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
11439849|NCT01766882|No Intervention|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
11439850|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
11439851|NCT01766843|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
11439852|NCT01766843|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
11439853|NCT01766843|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
11439854|NCT01766843|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
11439855|NCT01766830|Experimental|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
11439856|NCT01766817|Experimental|Arm 1: BMS 986020, 600 mg. once daily|BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
11439857|NCT01766817|Experimental|Arm 2: BMS-986020, 600 mg twice daily|BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
11439858|NCT01766817|Placebo Comparator|Arm 3: Placebo matching with BMS-986020|Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
11444456|NCT01736306||Volunteers|Volunteer milk donors
11439860|NCT01766804|Placebo Comparator|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
11439861|NCT01766791|Experimental|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1 Repetition Maximum (1RM)
11439862|NCT01766791|Experimental|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - <75% 1RM
11439863|NCT01766791|Experimental|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
11439864|NCT01766791|Placebo Comparator|Control|No physical exercise intervention
11439865|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg once daily (QD)|Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
11439866|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg twice daily (BID)|Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
11439867|NCT01766765|Experimental|Early jejunostomy nutrition|
11439868|NCT01766765|Active Comparator|Early oral nutrition|
11439869|NCT01766752|Experimental|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
11439870|NCT01766752|No Intervention|no intervention|standard care
11439871|NCT01766739|Experimental|GL-ONC1|This is an open-label, dose-escalating, non-randomized, single-center Phase I therapeutic study of GL-ONC1 originally administered intrapleurally as a single dose and now escalating to three consecutive daily doses in patients with a diagnosis (histologically or cytologically documented) of malignant pleural effusions.
11439872|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
11439873|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
11439874|NCT01766713|Experimental|Ezetimibe|10 mg/day of Ezetimibe
11439875|NCT01766713|Placebo Comparator|Placebo|one tablet per day (identical to ezetimibe)
11439876|NCT01766700|Experimental|No calorie beverages|2 no calorie beverages per day.
11439877|NCT01766700|Active Comparator|Water|2 water beverages per day.
11439878|NCT01766687|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
11439879|NCT01766687|No Intervention|Control|
11439880|NCT01766674|Experimental|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
11439881|NCT01766674|No Intervention|Control|Control group will be enrolled in the usual care waitlist group
11439882|NCT01766661|Active Comparator|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
11439883|NCT01766661|Experimental|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
11439884|NCT01766648|Experimental|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
11439885|NCT01766648|Active Comparator|Standard locking screw fixation|Standard locking screw fixation
11439886|NCT01766609|Active Comparator|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
11439887|NCT01766609|Placebo Comparator|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
11439888|NCT01766596|Other|3C cohort|
11439889|NCT01766583|Experimental|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
11439890|NCT01766570|Experimental|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
11439891|NCT01766570|Placebo Comparator|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
11439892|NCT01766557|Experimental|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
11439893|NCT01766557|Active Comparator|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
11439894|NCT01766544|Active Comparator|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
11439895|NCT01766544|Active Comparator|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
11439896|NCT01766531|Experimental|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
11439897|NCT01766518|Experimental|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
11439898|NCT01766505|Experimental|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
11576806|NCT00812045|Experimental|1|
11439899|NCT01766505|Active Comparator|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
11439900|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
11439901|NCT01766479|Experimental|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
11439902|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 0.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 0.5 h after the initiation of cangrelor infusion.
11439903|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (7 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses (12, 24, 36, 48, 60, 72, and 84 h).
~On Day 5: 12 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
11439904|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 1.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 1.5 h after the initiation of cangrelor infusion.
11439905|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (6 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 6 doses (12, 24, 36, 48, 60, and 72 h).
~On Day 5: 24 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
11439906|NCT01766453|No Intervention|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
11439907|NCT01766453|Experimental|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
11439908|NCT01766453|Experimental|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
11439909|NCT01766440|Experimental|Calcitriol 3 mcg/g ointment|Topical application every 12 hours for 14 consecutive days
11439910|NCT01766427||morning electroacupuncture with pills|
11439911|NCT01766427||afternoon EA with pills|
11439912|NCT01766427||no EA group with pills|
11439913|NCT01766414|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
11439914|NCT01766414|Placebo Comparator|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
11439915|NCT01766401|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
11439916|NCT01766401|Experimental|Vilazadone|Vilazadone tablets, oral administration
11439917|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
11439918|NCT01766375|Experimental|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.
~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
11439919|NCT01766375|Active Comparator|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.
~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
11439920|NCT01766362|Experimental|A session|
11439921|NCT01766362|Other|Four sessions|Every session are spaced out of month
11439922|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
11439923|NCT01766336|Experimental|Group 1 ELND005/ELND005|Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
11439924|NCT01766336|Experimental|Group 2 PLACEBO/ELND005|Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
11439925|NCT01766323|Placebo Comparator|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
11439926|NCT01766323|Active Comparator|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
11439927|NCT01766310|Placebo Comparator|placebo|placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
11439928|NCT01766310|Experimental|folic acid|Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
11439929|NCT01766297|Experimental|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
11439930|NCT01766284|Experimental|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
11439931|NCT01766271|Experimental|Standard Risk Assessment (SRA) Only|
11439932|NCT01766271|Experimental|SRA plus Health Coaching|
11439933|NCT01766271|Experimental|SRA plus Genetic Testing|
11439934|NCT01766271|Experimental|SRA plus Health Coaching plus Genetic Testing|
11439935|NCT01766258|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
11439936|NCT01766258|Experimental|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
11439937|NCT01766258|Experimental|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
11439938|NCT01766245|Experimental|Formulation A followed by Formulation B|
11576807|NCT00812045|Placebo Comparator|2|
11439939|NCT01766245|Active Comparator|Formulation B followed by Formulation A|
11439940|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
11439941|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
11439942|NCT01766219|Experimental|Arm 1: (6,8-bis[benzylthio]octanoic acid) 2,300 mg/m²|"Participants will not be treated with CPI-613 during pre-Cycle 1 and will only be treated with 3 weeks on/1 week off at 2,300 mg/m² as a starting dose. If none of these 3 participants develop a dose-limiting toxicity through Cycle 1, the dose for the 3-weeks-on-1-week-off treatment cycles will be 3,000 mg/m² in all subsequent participants in this trial.
~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
11439943|NCT01766219|Experimental|Arm 2: (6,8-bis[benzylthio]octanoic acid) 1,200/3,00 mg/m²|"Participants will received pre-cycle 1 week dose at 1200 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.
~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
11439944|NCT01766219|Experimental|Arm 3 (6,8-bis[benzylthio]octanoic acid) 600/3,000 mg/m²|"Participants will received pre-cycle 1 week dose at 600 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.
~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
11439945|NCT01766206|Experimental|MenACWY-CRM Group|Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.
11439946|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
11439947|NCT01766193||cesarean section|women whose first child was born by cesarean section
11439948|NCT01766193||forceps|women whose first child was born by forceps extraction
11439949|NCT01766193||vacuum|women whose first child was born by vacuum extraction
11439950|NCT01766180|No Intervention|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
11439951|NCT01766180|Active Comparator|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
11439952|NCT01766180|Active Comparator|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
11439953|NCT01766180|Active Comparator|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
11439954|NCT01766167|Experimental|MP-424|
11439955|NCT01766154|Experimental|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl >90 mL/min)
11439956|NCT01766154|Experimental|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
11439957|NCT01766154|Experimental|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl <30 mL/min).
11439958|NCT01766141|No Intervention|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
11439959|NCT01766141|Experimental|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
11439960|NCT01766141|No Intervention|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
11439961|NCT01766128|Active Comparator|Zonisamide|The patients in this arm are treated with zonisamide 50mg/d
11439962|NCT01766128|Placebo Comparator|Placebo|The patients in this arm are treated with placebo
11439963|NCT01766115|Experimental|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
11439964|NCT01766102|Active Comparator|Intra-operative Mammography|Intra-operative Specimen Mammography
11439965|NCT01766102|Active Comparator|Standard Mammography|Standard Specimen Mammography
11439966|NCT01766089|Active Comparator|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
11439967|NCT01766089|Placebo Comparator|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
11439968|NCT01766076|Experimental|atorvastatin, Lipitor®|"Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
~Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry"
11439969|NCT01766076|Placebo Comparator|Placebo|Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
11439970|NCT01766063||Group 1|
11439971|NCT01766050|Experimental|Arm: Inje Cocktail + Belatacept|"Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11
~Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4"
11439972|NCT01766037|Experimental|Aspiration Therapy|Aspiration Therapy and Lifestyle Therapy
11439973|NCT01766037|Active Comparator|Lifestyle Therapy|Lifestyle Therapy only
11439974|NCT01766024|Experimental|BCD-033 → Rebif|Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
11439975|NCT01766024|Experimental|Rebif → BCD-033|Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
11439976|NCT01766011|Experimental|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
11439977|NCT01765998|Experimental|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
11439978|NCT01765998|Placebo Comparator|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
11439979|NCT01765985|Experimental|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
11439980|NCT01765985|Active Comparator|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.
~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.
~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
11439981|NCT01765972|Other|Test 1/Spectacles/Test 2/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
11439982|NCT01765972|Other|Test 2/Test 3/ Spectacles/Test 1|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
11439983|NCT01765972|Other|Test 3/Test 1/ Test 2/ Spectacles|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
11439984|NCT01765972|Other|Spectacles/Test 2/Test 1/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
11439985|NCT01765959|Active Comparator|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
11439986|NCT01765959|Active Comparator|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:
~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
11439987|NCT01765946|Experimental|Metformin|Metformin tablets 500 mg tid for 2 months
11439988|NCT01765946|Placebo Comparator|Placebo|Placebo tables tid for 2 months
11439989|NCT01765933|Experimental|DMAA|Single oral dose 25 mg DMAA
11439990|NCT01765920|Experimental|Ergoferon (5 ml 3 times a day)|
11439991|NCT01765920|Placebo Comparator|Placebo (5 ml 3 times a day)|
11439992|NCT01765907|Experimental|HIFU|
11439993|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
11439994|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.
~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.
~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
11439995|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.
~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
11439996|NCT01765881|Experimental|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
11439997|NCT01765881|Active Comparator|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
11439998|NCT01765868|Experimental|Single Arm Oral and IV Betrixaban|
11439999|NCT01765855|Experimental|Single Arm Oral Betrixaban|
11440000|NCT01765842|Active Comparator|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):
~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
11440001|NCT01765842|Experimental|Rituximab (2 cycles)|"A second cycle of Rituximab
~First cycle of Rituximab (4 i.v. infusions):
~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2
~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
11440002|NCT01765829|Active Comparator|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice
~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
11440003|NCT01765829|Experimental|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
11440004|NCT01765816|Experimental|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
11440005|NCT01765816|Active Comparator|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
11440006|NCT01765803|Experimental|Mellaril (thioridazine)|A single 50 gm dose of thioridizine (Mellaril) will be given orally at the beginning of the study
11440066|NCT01765465|Placebo Comparator|Placebo|Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
11440067|NCT01765452|Experimental|Closone|75mg/100mg per day, 8weeks, PO
11446035|NCT01725633|Other|Progressive Stretching Group|
11440007|NCT01765790|Experimental|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.
~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
11440008|NCT01765790|Experimental|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.
~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
11440009|NCT01765777|No Intervention|Control Group|Subjects in this arm continue with standard medical care
11440010|NCT01765777|Experimental|Osteopathic Manipulative Medicine Group|Subjects in this arm will receive an OMM intervention.
11440011|NCT01765777|Experimental|Phototherapy Group|Subjects in this arm will receive a phototherapy intervention.
11440012|NCT01765777|Experimental|OMM and Phototherapy Group|Subjects in this arm will receive both the OMM and phototherapy interventions.
11440013|NCT01765764|Experimental|Bimatoprost Solution BID|Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.
11440014|NCT01765764|Experimental|Bimatoprost Solution QD|Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.
11440015|NCT01765764|Placebo Comparator|Vehicle to Bimatoprost Solution BID|Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.
11440016|NCT01765751|Active Comparator|Manual Cervical Distraction High Force|Manual Cervical Distraction forces will be limited to greater than 50N in the high force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
11440017|NCT01765751|Active Comparator|Manual Cervical Distraction Medium Force|Manual Cervical Distraction forces will be limited to between 20N-50N in the medium force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
11440018|NCT01765751|Sham Comparator|Manual Cervical Distraction Low Force|Manual Cervical Distraction forces will be limited to less than 20N in the low force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
11440019|NCT01765738|Active Comparator|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
11440020|NCT01765738|Active Comparator|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
11440021|NCT01765725|No Intervention|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
11440022|NCT01765725|Experimental|Patient education program|Patient education program
11440023|NCT01765712|Placebo Comparator|Control Group|Patients will be randomized into the treatment arm using a computer generated randomization table (simple randomization). Patients in the control arm of the study will undergo Anterior cruciate ligament reconstruction using Autologous bone patellar tendon bone autograft. At the end of the surgery, their graft donor site will have bone graft chips placed into the bony defect and the wound will be closed using sutures.
11440024|NCT01765712|Experimental|Platelet Rich Plasma|Patients randomized into the treatment arm of the study will undergo Anterior cruciate ligament reconstruction with Autologous bone patellar tendon bone autografts. At the start of the surgery,just after the administration of anesthesia, 10cc of blood will be withdrawn from the patients IV by the anesthesiologist. This sample will be spun down into 3-5cc of Platelet Rich Plasma which will be added to the patients bone graft chips and placed into the donor site at the end of the case.
11440025|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
11440026|NCT01765686|Active Comparator|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
11440027|NCT01765686|Active Comparator|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
11440028|NCT01765673||Vibrotactile Stimulation in Dysphagia|A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.
11440029|NCT01765660|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
11440030|NCT01765660|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)every two weeks, four times for a cycle
11440031|NCT01765647|Experimental|AGY|All participants will receive the same, open-label dose of AGY
11440032|NCT01765634|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)each week, four times for a cycle
11440033|NCT01765634|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
11440034|NCT01765621|Experimental|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
11440035|NCT01765621|No Intervention|Standard Care|Control
11440068|NCT01765452|Active Comparator|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
11440069|NCT01765439|Experimental|CD resected|Patients with Crohn´s disease with the history of single resection (<60 cm) of distal leum.
11581515|NCT00778609|Active Comparator|Arm 2|
11440036|NCT01765608|Experimental|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
11440037|NCT01765608|Active Comparator|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
11440038|NCT01765608|Active Comparator|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
11440039|NCT01765595|Experimental|DDI+|DDI+ Incorporated in routine ambulatory practice
11440040|NCT01765595|No Intervention|Control|Standard care
11440041|NCT01765582|Experimental|Arm A: Concurrent FOLFOXIRI + Bevacizumab|Participants will receive concurrent FOLFOXIRI along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4 month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
11440042|NCT01765582|Experimental|Arm B: Sequential FOLFOXIRI + Bevacizumab|Participants will receive alternating 4-week administrations of FOLFOX/bevacizumab and folinic acid (leucovorin), 5-FU, and irinotecan (FOLFIRI) /Bevacizumab with a treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
11440043|NCT01765582|Experimental|Arm C: FOLFOX + Bevacizumab|Participants will receive FOLFOX along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
11440044|NCT01765569|Experimental|Vemurafenib + Digoxin|Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
11440045|NCT01765556|Experimental|Ketoconazole treatment|
11440046|NCT01765556|Experimental|Vemurafenib treatment|
11440047|NCT01765543|Experimental|Vemurafenib + Rifampin|There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
11440048|NCT01765530|Experimental|ETT cleaning manuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
11440049|NCT01765530|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
11440050|NCT01765517|Experimental|Probiotics|Probitoics
11440051|NCT01765517|Placebo Comparator|Placebo|Placebo
11440052|NCT01765491|Experimental|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
11440053|NCT01765491|Active Comparator|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
11440054|NCT01765478|Experimental|Treatment A Period 2|40mg HM71224 single dose
11440055|NCT01765478|Experimental|Treatment B Period1|20mg HM71224 single dose
11440056|NCT01765478|Experimental|Treatment A Period1|10mg HM71224 single dose
11440057|NCT01765478|Experimental|Treatment B Period2|80mg HM71224 single dose
11440058|NCT01765478|Experimental|TreatmentA Period3|160mg HM71224 single dose
11440059|NCT01765478|Experimental|TreatmentB Period3|200mg HM71224 single dose
11440060|NCT01765478|Experimental|Food effect period1|active 4subjects + placebo 4subjects
11440061|NCT01765478|Experimental|Food effect period2|active 4subjects + placebo 4subjects
11440062|NCT01765478|Experimental|TreatmentC|HM71224 Xmg multiple dose for 14days
11440063|NCT01765478|Experimental|TreatmentD|HM71224 Ymg 14days multiple dose
11440064|NCT01765478|Experimental|TreatmentE|HM71224 Zmg 14days multiple dose
11440065|NCT01765465|Experimental|Rowachol|Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
11581620|NCT00778011|Active Comparator|2|
11440070|NCT01765439|Experimental|UC unoperated|Patients with ulcerative colitis without history of gut resection.
11440071|NCT01765439|Experimental|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
11440072|NCT01765439|Experimental|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
11440073|NCT01765426|Experimental|Group 1: TDV using PharmaJet® Injector|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
11440074|NCT01765426|Experimental|Group 2: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
11440075|NCT01765426|Experimental|Group 3: TDV using Needle and Syringe|TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
11440076|NCT01765426|Experimental|Group 4: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
11440077|NCT01765413|Experimental|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
11440078|NCT01765413|Experimental|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
11440079|NCT01765413|Placebo Comparator|Placebo|Participants receive one injection of placebo.
11440080|NCT01765400|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 2 weeks
11440081|NCT01765400|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily for 2 weeks
11440082|NCT01765387|Experimental|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
11440083|NCT01765387|No Intervention|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
11440084|NCT01765374|Experimental|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
11440085|NCT01765348|Experimental|Sentence combining|
11440086|NCT01765348|Active Comparator|Narrative based method|
11440087|NCT01765335|Experimental|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
11440088|NCT01765322|Experimental|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
11440089|NCT01765322|No Intervention|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
11440090|NCT01765309|Experimental|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
11440091|NCT01765296|Active Comparator|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
11440092|NCT01765296|Placebo Comparator|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
11440093|NCT01765296|Experimental|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
11440094|NCT01765283|Experimental|Hepastem Low dose|12.5x106cells/kg
11440095|NCT01765283|Experimental|Hepastem Intermediate dose|50x106cells/kg
11440096|NCT01765283|Experimental|Hepastem High dose|200x106cells/kg
11440097|NCT01765270|Active Comparator|Saxagliptin|Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
11440098|NCT01765270|Placebo Comparator|Placebo|Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
11440099|NCT01765257|Experimental|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
11440100|NCT01765257|Placebo Comparator|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
11440101|NCT01765244|Experimental|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
11440102|NCT01765244|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
11440103|NCT01765231|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
11440104|NCT01765231|Active Comparator|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
11440105|NCT01765218|Placebo Comparator|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
11440106|NCT01765218|Active Comparator|Topiramate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
11440204|NCT01764542|Other|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
11440107|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
11440108|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
11440109|NCT01765192|Experimental|Roflumilast plus montelukast, then placebo plus montelukast|Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
11440110|NCT01765192|Experimental|Placebo plus montelukast, then roflumilast plus montelukast|Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
11440111|NCT01765179|Experimental|Oral testosterone undecanoate|
11440112|NCT01765166|Experimental|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
11440113|NCT01765166|Experimental|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
11440114|NCT01765166|Experimental|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
11440115|NCT01765166|Experimental|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
11440116|NCT01765153|Experimental|Endurance first|Participants to start with Endurance Training. Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for training in the Precision Training 5x/wk for 2 months.Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. This is followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
11440117|NCT01765153|Experimental|Precision first|Participants to start with Precision Training. Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for Endurance Training 5x/wk for 2 months. Participants are trained to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
11440118|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
11440119|NCT01765114|Experimental|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
11440120|NCT01765101|Experimental|customized insoles|"customized full-length lateral wedged shoe insoles
~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
11440121|NCT01765101|Placebo Comparator|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months
~study the immediate, short-term and intermediate-term therapeutic effects"
11440122|NCT01765088|Active Comparator|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)
11440123|NCT01765088|Experimental|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles
11440124|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
11440125|NCT01765062||Before Rapid Maxillary Expansion|T0
11440126|NCT01765062||3 months After Rapid Maxillary Expansion|T1
11440127|NCT01765062||One year After Rapid Maxillary Expansion|T2
11440128|NCT01765036|Experimental|SonoVue®|"Non randomised study
~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
11440129|NCT01765023|Experimental|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
11440130|NCT01765023|Experimental|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
11440131|NCT01765010|Placebo Comparator|Placebo control|Placebo control
11440132|NCT01765010|Active Comparator|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
11440133|NCT01765010|Experimental|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
11440134|NCT01765010|Experimental|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
11440135|NCT01764997|Experimental|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
11440136|NCT01764997|Active Comparator|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
11440137|NCT01764997|Experimental|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
11440241|NCT01764269|Other|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
11440138|NCT01764997|Experimental|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
11440139|NCT01764997|Experimental|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
11440140|NCT01764984|Experimental|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
11440141|NCT01764984|Active Comparator|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
11440142|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
11440143|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
11440144|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.
~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
11440145|NCT01764945|Experimental|1 BI 201335|low dose
11440146|NCT01764945|Experimental|2 BI 201335|high dose
11440147|NCT01764932|Other|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
11440148|NCT01764919|Experimental|[124I]FIAU|Single intravenous injection of [124I]FIAU in patients with diabetic foot infection
11440149|NCT01764906|Experimental|Novosis|Bongros/rhBMP-2
11440150|NCT01764906|Active Comparator|Iliac crest bone graft|Iliac crest bone graft
11440151|NCT01764893|Active Comparator|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
11440152|NCT01764893|Placebo Comparator|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
11440153|NCT01764880|Experimental|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.
~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
11440154|NCT01764867|Active Comparator|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
11440155|NCT01764867|Active Comparator|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
11440156|NCT01764854|Experimental|AZD1722- in patient|Tenapanor administered in a clinical pharmacology unit
11440157|NCT01764854|Placebo Comparator|Placebo- in patient|Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit
11440158|NCT01764854|Experimental|AZD1722 out-patient|Tenapanor
11440159|NCT01764854|Experimental|Placebo out-patient|Placebo
11440160|NCT01764841|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
11440161|NCT01764841|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
11440162|NCT01764841|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
11440163|NCT01764841|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
11440164|NCT01764828|Experimental|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
11440165|NCT01764815|Experimental|Directional lead|
11440166|NCT01764802|Active Comparator|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
11440167|NCT01764802|Experimental|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
11440346|NCT01763710|Experimental|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
11446036|NCT01725633|Experimental|Nonlinear Aerobic Training|
11440168|NCT01764789|Experimental|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
11440169|NCT01764776|Experimental|LDE225|LDE225
11440170|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
11440171|NCT01764763||epiaortic group|epiaortic group ( n=1273)
11440172|NCT01764750|Experimental|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
11440173|NCT01764750|Experimental|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
11440174|NCT01764750|Experimental|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
11440175|NCT01764750|Active Comparator|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
11440176|NCT01764737|Experimental|VX15/2503|
11440177|NCT01764737|Experimental|Placebo|
11440178|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
11440179|NCT01764711|Experimental|Low Salt Diet|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
11440180|NCT01764698|Experimental|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
11440181|NCT01764698|Active Comparator|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
11440182|NCT01764685|Experimental|Topiramate + Medical Management|Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
11440183|NCT01764685|Placebo Comparator|Placebo Pill + Medical Management|Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
11440184|NCT01764672|Experimental|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
11440185|NCT01764672|Experimental|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
11440186|NCT01764659||All enrolled patients|Contrast-enhanced 4D computed tomography
11440187|NCT01764646|Experimental|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
11440188|NCT01764646|Experimental|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
11440189|NCT01764633|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
11440190|NCT01764633|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.
11440191|NCT01764620|Other|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
11440192|NCT01764620|Experimental|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
11440193|NCT01764620|Sham Comparator|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
11440194|NCT01764607|Experimental|Sirolimus treatment|Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
11440195|NCT01764594|Experimental|CDP7657|"CDP7657 100 mg/ ml solution
~30 mg/ kg initial dose
~15 mg/ kg every other week
~10 weeks"
11440196|NCT01764594|Placebo Comparator|Placebo|Placebo
11440197|NCT01764581|Experimental|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
11440198|NCT01764581|No Intervention|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
11440199|NCT01764568|Experimental|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
11440200|NCT01764568|Experimental|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
11440201|NCT01764568|No Intervention|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
11440202|NCT01764555|Experimental|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
11440203|NCT01764555|Experimental|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
11440205|NCT01764529||The BVMC FCCM cohort|"Aim 1: To investigate the relationship between lesion burden and outcomes in FCCM.
~Aim 2: To investigate the role of the gut microbiome in FCCM disease severity. Aim 3: To establish blood markers predictive of disease severity and progression for medical treatment of CCM."
11440206|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
11440207|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
11440208|NCT01764516||Zinc level in male (micro gram per deciliter)|
11440209|NCT01764516||Selenium level in male (micro gram per deciliter)|
11440210|NCT01764516||Zinc level in Female (micro gram per decilitre)|
11440211|NCT01764516||Selenium level in Female (micro gram per decilitre)|
11440212|NCT01764477|Experimental|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
11440213|NCT01764464|Other|Group A|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
11440214|NCT01764464|Other|Group B|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
11440215|NCT01764451|Experimental|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
11440216|NCT01764451|No Intervention|No Treatment|
11440217|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
11440218|NCT01764425|Active Comparator|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
11440219|NCT01764425|Placebo Comparator|Placebo|Placebo tablets for oral administration
11440220|NCT01764412||Healthy women|Non interventional
11440221|NCT01764399|Experimental|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
11440222|NCT01764399|No Intervention|Information group|The information group receives 6 weekly socialization sessions.
11440223|NCT01764386|Experimental|NB + CLI|Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
11440224|NCT01764386|Other|Usual Care|"Usual Care (self-directed lifestyle intervention)
~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff."
11440225|NCT01764373|Experimental|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
11440226|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
11440227|NCT01764347|Experimental|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
11440228|NCT01764334|Active Comparator|Fractional flow reserve|"Fractional flow reserve - guided group:
~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
11440229|NCT01764334|Placebo Comparator|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
11440230|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
11440231|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
11440232|NCT01764308|Experimental|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
11440233|NCT01764308|Placebo Comparator|Placebo|4 tablets twice a day for 24 weeks
11440234|NCT01764295|Experimental|DWJ1276|Once daily, administered orally, 8 week
11440235|NCT01764295|Active Comparator|Olmesartan|Once daily, administered orally, 8 week
11440236|NCT01764295|Active Comparator|Rosuvastatin|Once daily, administered orally, 8 week
11440237|NCT01764295|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
11440238|NCT01764282|Experimental|Intervention|comprehensive intervention components
11440239|NCT01764282|No Intervention|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
11440240|NCT01764269|Other|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
11446037|NCT01725620|Experimental|Group 1|Enbrel, LBEC0101
11440242|NCT01764256|Experimental|10 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 10 μg of active ingredient.
11440243|NCT01764256|Experimental|30 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 30 μg of active ingredient.
11440244|NCT01764256|Experimental|60 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 60 μg of active ingredient.
11440245|NCT01764256|Placebo Comparator|Placebo|3 doses of placebo delivered intramuscularly.
11440246|NCT01764243|Experimental|MT-4666 Low Dose|low dose
11440247|NCT01764243|Experimental|MT-4666 High Dose|high dose
11440248|NCT01764243|Placebo Comparator|Placebo|placebo
11440249|NCT01764230|Experimental|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
11440250|NCT01764230|No Intervention|control group|no intervention
11440251|NCT01764204||Qingkailing Injection|
11440252|NCT01764178|Experimental|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
11440253|NCT01764178|Active Comparator|Pitavastatin + Valsartan|Pitavastatin, Valsartan
11440254|NCT01764165|Active Comparator|oxygen|nocturnal oxygen of 2 L/min
11440255|NCT01764165|Experimental|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
11440256|NCT01764152|Experimental|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
11440257|NCT01764139||Knee pain patients with minimal knee changes|Male & no pregnant female age between 18-40 yrs.
11440258|NCT01764126|Active Comparator|Pneumococcal protein vaccine|Pneumococcal protein vaccine
11440259|NCT01764126|Placebo Comparator|Placebo|Placebo
11440260|NCT01764113|Experimental|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
11440261|NCT01764113|Active Comparator|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
11440262|NCT01764100|Experimental|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
11440263|NCT01764087|Experimental|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)
~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
11440264|NCT01764074|Experimental|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
11440265|NCT01764048|Experimental|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):
~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams
~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).
~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.
~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.
~The total amount of paracetamol is limited to 4 gr per day."
11440266|NCT01764048|Experimental|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
11440267|NCT01764035|Active Comparator|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
11440268|NCT01764035|Experimental|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
11440269|NCT01764022|Experimental|BCD-022|BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
11440270|NCT01764022|Active Comparator|Herceptin®|In this arm patients will receive 6 courses of treatment with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. Patients will receive Herceptin® at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
11440271|NCT01764009|Experimental|Plasmid AMEP electrotransfer in muscle|
11440272|NCT01763996|Experimental|Sequence 1: Febuxostat 80 mg + Placebo|Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.
11440273|NCT01763996|Experimental|Sequence 2: Placebo + Febuxostat 80 mg|Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.
11440274|NCT01763983|Experimental|Aerobic Exercise|12-week structured and monitored aerobic exercise program
11440275|NCT01763983|Experimental|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
11440276|NCT01763983|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
11440277|NCT01763970|Experimental|Hypofractionated SBRT|800 cGy delivered in 5 fractions every day to total dose of 4000 cGy
11440278|NCT01763957|Active Comparator|Pelvic Floor Muscle Training (PFMT)|
11440279|NCT01763957|Active Comparator|Paula Method|
11440347|NCT01763697|Active Comparator|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
11581621|NCT00778011|Active Comparator|3|
11440280|NCT01763944|Active Comparator|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
11440281|NCT01763944|No Intervention|Control|The control arm will receive no dietary intervention.
11440282|NCT01763931|Experimental|Digoxin|Digoxin administration for 2 weeks prior to surgery.
11440283|NCT01763931|No Intervention|No drug administration prior to surgery|Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.
11440284|NCT01763918|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
11440285|NCT01763918|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
11440286|NCT01763918|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
11440287|NCT01763918|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
11440288|NCT01763905|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440289|NCT01763905|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440290|NCT01763905|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
11440291|NCT01763905|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
11440292|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
11440293|NCT01763879|Active Comparator|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
11440294|NCT01763879|Active Comparator|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
11440295|NCT01763866|Placebo Comparator|A10 PBO Q2W|Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
11440296|NCT01763866|Placebo Comparator|A10 PBO QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
11440297|NCT01763866|Active Comparator|A10 EZE (Q2W)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
11440298|NCT01763866|Active Comparator|A10 EZE (QM)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440299|NCT01763866|Experimental|A10 EvoMab Q2W|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
11440300|NCT01763866|Experimental|A10 EvoMab QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
11440301|NCT01763866|Placebo Comparator|A80 PBO Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
11440302|NCT01763866|Placebo Comparator|A80 PBO QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
11440303|NCT01763866|Active Comparator|A80 EZE (Q2W)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440304|NCT01763866|Active Comparator|A80 EZE (QM)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440305|NCT01763866|Experimental|A80 EvoMab Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
11440306|NCT01763866|Experimental|A80 EvoMab QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
11440307|NCT01763866|Placebo Comparator|R5 PBO Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
11440308|NCT01763866|Placebo Comparator|R5 PBO QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
11440309|NCT01763866|Experimental|R5 EvoMab Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
11440310|NCT01763866|Experimental|R5 EvoMab QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
11440311|NCT01763866|Placebo Comparator|R40 PBO Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
11440312|NCT01763866|Placebo Comparator|R40 PBO QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
11440313|NCT01763866|Experimental|R40 EvoMab Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
11440314|NCT01763866|Experimental|R40 EvoMab QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
11440315|NCT01763866|Placebo Comparator|S40 PBO Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
11440316|NCT01763866|Placebo Comparator|S40 PBO QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
11440317|NCT01763866|Experimental|S40 EvoMab Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
11440318|NCT01763866|Experimental|S40 EvoMab QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
11440319|NCT01763853|Other|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
11440320|NCT01763853|Other|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
11440321|NCT01763840|Experimental|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
11440322|NCT01763827|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
11440323|NCT01763827|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
11440324|NCT01763827|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440325|NCT01763827|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
11440326|NCT01763827|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
11440327|NCT01763827|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
11440328|NCT01763814|Active Comparator|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
11440329|NCT01763814|Active Comparator|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
11440330|NCT01763814|Active Comparator|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
11440331|NCT01763801|Active Comparator|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
11440332|NCT01763801|Active Comparator|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
11440333|NCT01763788|Experimental|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.
~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
11440334|NCT01763788|Active Comparator|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
11440335|NCT01763775|Experimental|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
11440336|NCT01763775|Experimental|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
11440337|NCT01763762|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
11440338|NCT01763762|Active Comparator|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.
~Transvaginal ES: At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
11440339|NCT01763749|Experimental|Closone|75mg/100mg per day, 4weeks, PO
11440340|NCT01763749|Active Comparator|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
11440341|NCT01763736|Experimental|Music|Everyone enrolled with receive music sessions.
11440342|NCT01763723|Experimental|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
11440343|NCT01763710|Active Comparator|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
11440344|NCT01763710|Experimental|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
11440345|NCT01763710|Experimental|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
11440348|NCT01763697|Placebo Comparator|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
11440349|NCT01763697|Active Comparator|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
11440350|NCT01763684|Active Comparator|Signature Custom Guides|Oxford Partial Knee implanted using Signature Custom Guides
11440351|NCT01763684|Active Comparator|Conventional Instrumentation|Oxford Partial Knee implanted using Conventional Instrumentation
11440352|NCT01763671|Active Comparator|Docetaxel|
11440353|NCT01763671|Experimental|Paclitaxel - Bevacizumab|
11440354|NCT01763658|Experimental|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
11440355|NCT01763658|Active Comparator|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
11440356|NCT01763645|Experimental|BCD-021 (CISC BIOCAD)|BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
11440357|NCT01763645|Active Comparator|Avastin (F. Hoffmann-La Roche Ltd)|In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
11440358|NCT01763619|Experimental|Freedom Cervical Disc|
11440359|NCT01763606|Experimental|Enoxaparin|Patients assigned to enoxaparin.
11440360|NCT01763606|Experimental|Aspirin|Patients assigned to Aspirin.
11440361|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
11440362|NCT01763580|Experimental|Tacrolimus with low-dose corticosteroid|Oral
11440363|NCT01763580|Active Comparator|High-dose corticosteroid alone|Oral
11440364|NCT01763541|Other|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.
~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.
~Intervention: Leuprolide acetate and anastrozole"
11440365|NCT01763541|Other|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.
~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.
~Intervention: leuprolide acetate"
11440366|NCT01763528|Active Comparator|nutrition intervention|high protein diet
11440367|NCT01763528|No Intervention|control group|control diet
11440368|NCT01763515|Experimental|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
11440369|NCT01763502|Experimental|FOOD|Food transfer linked to preschool enrollment
11440370|NCT01763502|Experimental|CASH|Cash transfer linked to preschool enrollment
11440371|NCT01763502|No Intervention|CTRL|No transfer linked to preschool enrollment
11440372|NCT01763489|Experimental|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
11440373|NCT01763489|Active Comparator|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
11440374|NCT01763476|Active Comparator|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
11440375|NCT01763476|Active Comparator|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
11440376|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
11440377|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
11440378|NCT01763450|Experimental|Bevacizumab plus chemotherapy|"Bevacizumab:
~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;
~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;
~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:
~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
11440379|NCT01763437|No Intervention|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
11440380|NCT01763437|Experimental|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
11440381|NCT01763424|Active Comparator|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
11440382|NCT01763424|Experimental|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
11440383|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
11440384|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
11440385|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
11440991|NCT01759160|Active Comparator|Marsh|Marsh Plasma TCI with high initial target
11440386|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
11440387|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
11440388|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
11440389|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
11440390|NCT01763385|Experimental|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
11440391|NCT01763385|Other|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
11440392|NCT01763346|Active Comparator|metformin|subjects receiving metformin
11440393|NCT01763346|Experimental|gastric banding|subjects receiving LAP-BAND
11440394|NCT01763333|Experimental|1 BI 1026706 single rising dose part|single rising doses of BI 1026706
11440395|NCT01763333|Experimental|2 BI 1026706 bioavailability part|bioavailability part of BI 1026706
11440396|NCT01763320|Experimental|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
11440397|NCT01763320|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
11440398|NCT01763307|Experimental|RECONVAL CREAM|half face treated with RECONVAL CREAM
11440399|NCT01763307|Placebo Comparator|PLACEBO|half face treated with PLACEBO cream
11440400|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
11440401|NCT01763294|Active Comparator|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
11440402|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
11440403|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
11440404|NCT01763294|Placebo Comparator|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
11440405|NCT01763281|Active Comparator|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.
~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
11440406|NCT01763281|Placebo Comparator|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.
~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
11440407|NCT01763268|Experimental|Trivivac|Children who receive Trivivac vaccine
11440408|NCT01763255|Experimental|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
11440409|NCT01763255|No Intervention|Control|The patients with cerebral palsy that underwent regular observation.
11440410|NCT01763242|Active Comparator|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
11440411|NCT01763242|No Intervention|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
11440412|NCT01763229|Experimental|transthoracic echocardiography|
11440413|NCT01763216|Experimental|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
11440414|NCT01763216|Sham Comparator|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
11440415|NCT01763203|Experimental|Care Management+Community Health Worker|Care management
11440416|NCT01763203|Active Comparator|Usual Care|Written materials
11440417|NCT01763190|Experimental|SAR302503|single treatment of 300 mg oral dose of SAR302503
11440418|NCT01763177|No Intervention|No oxygen|No given oxygen at post-anesthetic care unit
11440419|NCT01763177|Active Comparator|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
11440420|NCT01763164|Experimental|MEK162|
11440421|NCT01763164|Active Comparator|Dacarbazine|
11440422|NCT01763151|Active Comparator|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
11440992|NCT01759160|Active Comparator|Schnider|Schnider Plasma TCI with high initial target
11440423|NCT01763151|Active Comparator|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
11440424|NCT01763138|Other|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
11440425|NCT01763138|Other|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
11440426|NCT01763138|No Intervention|control|no oral health education or reminder phone calls will be provided to mothers.
11440427|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
11440428|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.
~Blood samples will be taken."
11440429|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
~Blood samples will be taken."
11440430|NCT01763112|Placebo Comparator|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
11440431|NCT01763112|Active Comparator|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
11440432|NCT01763099|Experimental|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)
11440433|NCT01763099|Experimental|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10^6 cells/kg) and cord blood
11440434|NCT01763086|Experimental|Mesenchymal stem cells|Mesenchymal stem cells 1×10^6 cells/kg, intravenously
11440435|NCT01763073||Medical Students|Fourth-year students in accredited US medical schools who have applied to, but not yet been matched with, residency programs in obstetrics and gynecology.
11440436|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
11440437|NCT01763047|Active Comparator|etafilcon A/lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
11440438|NCT01763047|Active Comparator|lotrafilcon B/etafilcon A|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
11440439|NCT01763034|Sham Comparator|limb ischemia|
11440440|NCT01763021|Experimental|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
11440441|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
11440442|NCT01762995|Experimental|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
11440443|NCT01762995|Experimental|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
11440444|NCT01762982|Experimental|Test|Benzalkonium chloride (0.13%) Disinfectant Spray water
11440445|NCT01762982|Active Comparator|Positive Control|Sodium lauryl sulfate (SLS) (0.3% weight by weight [w/w]) water solution
11440446|NCT01762982|Placebo Comparator|Negative Control 1|Normal saline water (0.9% weight by volume [w/v])
11440447|NCT01762982|Placebo Comparator|Negative Control 2|Empty Finn Chamber
11440448|NCT01762969|Experimental|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
11440449|NCT01762956|Experimental|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
11440450|NCT01762956|No Intervention|Control group(CG)|The group of patients undergoing radiotherapy only.
11440451|NCT01762943|Experimental|Women with Postpartum Depression (PPD)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
11440452|NCT01762943|Experimental|Women without any psychiatric history (Control)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
11440453|NCT01762930|Active Comparator|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
11440454|NCT01762930|Experimental|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
11440455|NCT01762930|Experimental|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
11440456|NCT01762930|Experimental|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
11440457|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
11440458|NCT01762917||Restriction|Patients suffering from pulmonary restriction
11440459|NCT01762917||Controls|Pulmonary healthy controls
11440489|NCT01762735|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
11440460|NCT01762904|Experimental|Whole group of 135 units of measurement|"The arm is composed of 135 units of measurement, it means, 540 determinations to test 2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol and two controls.
~The principal unit of measurement it will be four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites, and determination as to each separately sampling for each area for each antiseptic forearm. The same subject may be assessed up to three separate occasions provided only after a minimum period of two weeks between each determination.
~Interventions:
~Biological: Bacterial culture of the prepared skin's areas with two antiseptics and two controls
~Other: Preparing skin's areas to be tested with two antiseptics and two controls"
11440461|NCT01762891|Experimental|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
11440462|NCT01762878|Experimental|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
11440463|NCT01762878|Experimental|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
11440464|NCT01762878|Experimental|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
11440465|NCT01762878|Placebo Comparator|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
11440466|NCT01762878|Experimental|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
11440467|NCT01762852|Experimental|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion [will last for 1 hour (hr)] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
11440468|NCT01762852|Placebo Comparator|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
11440469|NCT01762839|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
11440470|NCT01762839|Placebo Comparator|Placebo|IV placebo
11440471|NCT01762839|Active Comparator|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a moxifloxacin tablet and will not receive a placebo infusion.
11440472|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
11440473|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
11440474|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
11440475|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
11440476|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
11440477|NCT01762800|Experimental|fluticasone propionate/salmeterol|Randomised treatment at Visit 2
11440478|NCT01762800|Experimental|tiotropium bromide|Randomised treatment at Visit 2
11440479|NCT01762787|Active Comparator|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
11440480|NCT01762787|Experimental|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
11440481|NCT01762787|Experimental|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
11440482|NCT01762774|Experimental|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
11440483|NCT01762774|Experimental|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
11440484|NCT01762774|Experimental|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
11440485|NCT01762774|Experimental|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
11440486|NCT01762761|Experimental|Eltrombopag (ETB115)|Thrombopoietin- receptor (TPO-R) agonist
11440487|NCT01762761|Placebo Comparator|Placebo|Placebo
11440488|NCT01762748|Experimental|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).
~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
11440528|NCT01762501|Experimental|Azilsartan|Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
11440993|NCT01759147|Experimental|Surgery|Surgical repair of acromioclavicular dislocation.
11440490|NCT01762735|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
11440491|NCT01762722|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
11440492|NCT01762709|Active Comparator|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
11440493|NCT01762709|Active Comparator|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
11440494|NCT01762709|Experimental|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
11440495|NCT01762696|Active Comparator|MET only|Motivational Enhancement Therapy only
11440496|NCT01762696|Experimental|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
11440497|NCT01762683|Experimental|pre-conceptional obesity with a scheduled cesarean section|
11440498|NCT01762683|Active Comparator|non-obese women with a scheduled cesarean section|
11440499|NCT01762683|Active Comparator|women entering labour|women entering labour for vaginal delivery and for vaginal delivery
11440500|NCT01762670|Active Comparator|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
11440501|NCT01762670|Experimental|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
11440502|NCT01762657|Experimental|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
11440503|NCT01762657|Placebo Comparator|Placebos|
11440504|NCT01762644|Experimental|Arm 1|Immune Tolerance and Proton Pump Inhibitor
11440505|NCT01762644|Active Comparator|Arm 2|Proton Pump Inhibitor
11440506|NCT01762631||Cohort 1|All participants enrolled between November 2012 and March 2013 under the original protocol.
11440507|NCT01762631||Cohort 2|After Cohort 1 was completed, the study investigators changed the protocol to eliminate the photograph/weight of the powdered formula alone in each bottle to reduce burden. All other protocol procedures remained the same. Cohort 2 participants enrolled between April 2013 and May 2014.
11440508|NCT01762618|Experimental|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
11440509|NCT01762618|No Intervention|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
11440510|NCT01762605|Experimental|Supportive Care|No casting or splinting, supportive care only by parents
11440511|NCT01762605|Active Comparator|Cast|Casting for 4 weeks
11440512|NCT01762592|Experimental|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
11440513|NCT01762579|Active Comparator|wheat flour|wheat flour is administered blindly versus placebo for 15 days
11440514|NCT01762579|Placebo Comparator|Xylose|placebo will be administered blindly versus wheat flour for 15 days
11440515|NCT01762566|Active Comparator|wheat|wheat is administered blindly versus placebo in capsules once
11440516|NCT01762566|Placebo Comparator|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
11440517|NCT01762553|Experimental|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body & healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
11440518|NCT01762553|No Intervention|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
11440519|NCT01762540|Placebo Comparator|Calcium supplement|Capsule with tablet of calclium supplement
11440520|NCT01762540|Active Comparator|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
11440521|NCT01762527|Experimental|ART|Online adaptive radiotherapy
11440522|NCT01762514|No Intervention|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
11440523|NCT01762514|Experimental|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
11440524|NCT01762514|Active Comparator|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
11440525|NCT01762514|No Intervention|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
11440526|NCT01762514|Experimental|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
11440527|NCT01762514|Active Comparator|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
11440529|NCT01762501|Active Comparator|Amlodipine|Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
11440530|NCT01762488|Active Comparator|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
11440531|NCT01762488|Sham Comparator|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
11440532|NCT01762475|Experimental|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.
~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.
~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.
~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
11440533|NCT01762475|Active Comparator|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
11440534|NCT01762475|Active Comparator|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
11440535|NCT01762462|Experimental|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
11440536|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
11440537|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
11440538|NCT01762436|Experimental|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
11440539|NCT01762436|Active Comparator|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
11440540|NCT01762423|Experimental|Active Device|"Device Placement:
~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.
~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
11440541|NCT01762423|Sham Comparator|Sham Device|"Device Placement:
~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.
~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
11440542|NCT01762410|Experimental|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
11440543|NCT01762397|Experimental|PMK-S005|
11440544|NCT01762384|Active Comparator|LSC|procedure: laparoscopic sacral colpopexy.
11440545|NCT01762384|Active Comparator|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
11440546|NCT01762371|Experimental|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
11440547|NCT01762358|Active Comparator|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
11440548|NCT01762358|Experimental|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
11440549|NCT01762345|Experimental|pessary device|pessary (disposable intra-vaginal device)
11440550|NCT01762332|Active Comparator|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
11440551|NCT01762332|Active Comparator|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
11440552|NCT01762332|Other|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.
~Continue recruitment."
11440553|NCT01762319|Experimental|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
11440554|NCT01762319|Placebo Comparator|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
11446038|NCT01725620|Experimental|Group 2|LBEC0101, Enbrel
11440555|NCT01762306|Experimental|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
11440556|NCT01762306|Placebo Comparator|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
11440557|NCT01762293|Experimental|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
11440558|NCT01762293|Placebo Comparator|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
11440559|NCT01762280|Experimental|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
11440560|NCT01762267|Active Comparator|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
11440561|NCT01762267|No Intervention|not intervention, control diet|control weight loss diet
11440562|NCT01762254|Active Comparator|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
11440563|NCT01762254|Active Comparator|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
11440564|NCT01762241|Experimental|Intervention group|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
11440565|NCT01762241|No Intervention|Control group|No systematically training/standard of care
11440566|NCT01762228|Active Comparator|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
11440567|NCT01762228|Active Comparator|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
11440568|NCT01762215|Experimental|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
11440569|NCT01762202|Experimental|Study therapy|
11440570|NCT01762176|Active Comparator|Usual care group|Usual care
11440571|NCT01762176|Active Comparator|Intensive care group|Protocolized intensive treatment
11440572|NCT01762163|Experimental|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.
~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
11440573|NCT01762163|Active Comparator|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.
~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
11440574|NCT01762163|Placebo Comparator|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.
~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
11440575|NCT01762150|Experimental|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
11440576|NCT01762137|Active Comparator|Coiling|Coiling
11440577|NCT01762137|Active Comparator|Flow Diversion|Flow Diversion
11440578|NCT01762124|Experimental|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
11440579|NCT01762098||Recurrent miscarriages|
11440580|NCT01762098||Repeated embryo implantation failures|
11440581|NCT01762085|Placebo Comparator|healed DFU control arm|"clinic-specific usual best care"
11440582|NCT01762085|Experimental|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
11440583|NCT01762072|Placebo Comparator|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
11440584|NCT01762072|Experimental|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
11440585|NCT01762072|Experimental|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
11440586|NCT01762059|Experimental|Bi-homonal Bionic Pancreas|Closed-loop blood glucose control with a bi-hormonal bionic endocrine pancreas designed by Edward Damiano and Firas El-Khatib of Boston University. The device will deliver insulin lispro (Humalog) and glucagon based on blood glucose levels estimated by a continuous glucose monitoring device (Dexcom G4 Platinum) and a proprietary dosing algorithm. Blood glucose control will be automated for 5 days during which volunteers will sleep in a hotel and roam freely in downtown Boston during the day. There will be no restrictions on diet or exercise.
11440587|NCT01762059|Active Comparator|Usual Care|Usual care for 5 days (insulin pump therapy according to usual practice), volunteers will sleep at home and maintain their usual schedule during the day, there will be no restrictions on diet or exercise, they will wear a blinded CGM
11440628|NCT01761760|Experimental|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.
~Behavioral: Videogame-based smoking cessation intervention"
11440732|NCT01760980|Experimental|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
11581624|NCT00777985|Experimental|1|
11440588|NCT01762046|Other|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
11440589|NCT01762033|Experimental|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
11440590|NCT01762020|Active Comparator|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
11440591|NCT01762020|Placebo Comparator|Standard preparations|Standard treatment
11440592|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
11440593|NCT01762007||6Mo-2Yr old male patients without hypospadias|
11440594|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
11440595|NCT01762007||2Yr-5Yr old male patients without hypospadias|
11440596|NCT01761994|Active Comparator|M100|heparin free CRRT group
11440597|NCT01761994|Experimental|HF1000|CRRT with nafamostat mesilate anticoagulation group
11440598|NCT01761968|Experimental|Givinostat|"Patients will continue at their last tolerable dose and treatment schedule of Givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
~If patients previously received Givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
11440599|NCT01761955|Experimental|High Dairy|Consuming four or more servings of dairy per day.
11440600|NCT01761955|Placebo Comparator|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
11440601|NCT01761942|Placebo Comparator|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
11440602|NCT01761942|Experimental|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
11440603|NCT01761929|Experimental|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
11440604|NCT01761916|Experimental|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
11440605|NCT01761916|Active Comparator|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
11440606|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
11440607|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
11440608|NCT01761890||CML patients|
11440609|NCT01761877|Experimental|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
11440610|NCT01761877|No Intervention|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment, and will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
11440611|NCT01761864|Experimental|intervention group|academic detailing receiver
11440612|NCT01761864|No Intervention|control group|not receiving an academic detailing intervention
11440613|NCT01761851||Cases|Liver cirrhosis
11440614|NCT01761838|Experimental|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
11440615|NCT01761838|Other|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
11440616|NCT01761838|Other|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
11440617|NCT01761825|Active Comparator|Ivabradine|Ivabradine 10 mg once
11440618|NCT01761825|Placebo Comparator|placebo|
11440619|NCT01761812|Experimental|Single arm study|
11440620|NCT01761799|Experimental|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
11440621|NCT01761799|No Intervention|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
11440622|NCT01761786|No Intervention|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
11440623|NCT01761786|Active Comparator|Intervention group|CYP2C19 genotyping will be performed <48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
11440624|NCT01761773|Experimental|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
11440625|NCT01761773|Experimental|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
11440626|NCT01761773|Experimental|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
11440627|NCT01761773|Experimental|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
11440777|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age > 18 years awaiting operation due to aortic dilation
11440629|NCT01761760|Active Comparator|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.
~Behavioral: Videogame-based smoking cessation intervention"
11440630|NCT01761747|Experimental|Ponatinib Treatment Arm|Ponatinib taken by mouth daily
11440631|NCT01761734|Experimental|text message|receipt of text message
11440632|NCT01761734|No Intervention|usual care|usual care
11440633|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
11440634|NCT01761708||umbilical, epigastric and trocar-site hernia|
11440635|NCT01761695||CML CP|Diagnosed as CML with chronic phase
11440636|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
11440637|NCT01761695||CML BC|Diagnosed as CML with blast crisis
11440638|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
11440639|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
11440640|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
11440641|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
11440642|NCT01761669||healthy voulnters|
11440643|NCT01761656|Experimental|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
11440644|NCT01761656|Active Comparator|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
11440645|NCT01761643|No Intervention|Standard of Care (SoC)|"This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.
~All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey."
11440646|NCT01761643|Active Comparator|SoC + iTab|"Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
~Subjects will have visits with the study coordinator to introduce the iTAB texting system.
~Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers."
11440647|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:
~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy
~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:
~Poor symptom control evidenced by an Asthma Control Questionnaire score consistently > 1.5 or an Asthma Control Test Score < 20 or not well controlled by NAEPP or GINA asthma treatment guidelines
~Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (> 3 days each) in the previous 12 months
~Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months
~Presence of airflow limitation evidenced by FEV1 < 80% predicted (in the face of reduced FEV1/FVC)"
11440648|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
11440649|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.
~Seven healthy subjects between the ages of 18-65 will be enrolled."
11440650|NCT01761617|Active Comparator|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
11440651|NCT01761617|Active Comparator|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
11440652|NCT01761604|Other|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
11440653|NCT01761591|Experimental|Acrobat|Device: PCI with Svelte Acrobat
11440654|NCT01761591|Active Comparator|Control BMS|Device: PCI with other BMS
11440655|NCT01761578|Experimental|ART18Z Bioresorbable stent|
11440656|NCT01761565|Experimental|Single dose of SUF NT 15 mcg then 40 doses of SUF NT 15 mcg|"Period 1: Single dose of SUF NT 15 mcg
~Period 2: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes"
11440657|NCT01761552|Experimental|Sugammadex (tradename Bridion)|
11440658|NCT01761552|Active Comparator|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
11440659|NCT01761539|Experimental|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
11440660|NCT01761539|Active Comparator|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
11440661|NCT01761526|Experimental|Rotigotine in Healthy Japanese|"Rotigotine transdermal patch
~Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects
~Transdermal patch over 24 hours"
11440662|NCT01761526|Experimental|Rotigotine in Caucasian|"Rotigotine transdermal patch
~Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects
~Transdermal patch over 24 hours"
11440663|NCT01761513|Experimental|Sequence 1|
11440664|NCT01761513|Experimental|Sequence 2|
11440665|NCT01761513|Active Comparator|Sequence 3|
11440666|NCT01761513|Active Comparator|Sequence 4|
11440667|NCT01761500|Other|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
11440668|NCT01761487|Other|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
11440778|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
11440669|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
11440670|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
11440671|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
11440672|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
11440673|NCT01761461|Experimental|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
11440674|NCT01761461|Active Comparator|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
11440675|NCT01761461|Active Comparator|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
11440676|NCT01761448|Experimental|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
11440677|NCT01761435|Experimental|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
11440678|NCT01761435|Active Comparator|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
11440679|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
11440680|NCT01761396|Experimental|CBT|Cognitive behavioral therapy
11440681|NCT01761396|Active Comparator|UC|Usual care
11440682|NCT01761383|Experimental|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
11440683|NCT01761370|Active Comparator|Treatment|AHA diet plus exercise with BIB placement
11440684|NCT01761370|Sham Comparator|Sham control|AHA diet plus exercise with sham BIB placement
11440685|NCT01761344|Experimental|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
11440686|NCT01761331|Active Comparator|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
11440687|NCT01761331|Active Comparator|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
11440688|NCT01761331|No Intervention|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
11440689|NCT01761318|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.
~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.
~Duration: 26 weeks"
11440690|NCT01761318|Placebo Comparator|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.
~Dosage: same as Liraglutide
~Duration: 26 weeks"
11440691|NCT01761305|Experimental|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
11440730|NCT01761019|Other|Taclonex topical suspension|Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
11440692|NCT01761305|Experimental|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
11440693|NCT01761305|Active Comparator|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
11440694|NCT01761292|Experimental|Givinostat|Givinostat will be administered as 2 oral doses daily while the child is in fed state.
11440695|NCT01761266|Active Comparator|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11440696|NCT01761266|Active Comparator|Sorafenib|Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
11440697|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
11440698|NCT01761240|Experimental|Study Drug|
11440699|NCT01761227|Experimental|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
11440700|NCT01761227|Placebo Comparator|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
11440701|NCT01761214|Active Comparator|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
11440702|NCT01761214|Active Comparator|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
11440703|NCT01761201|Experimental|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
11440704|NCT01761201|Active Comparator|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
11440705|NCT01761188|Experimental|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
11440706|NCT01761188|Experimental|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
11440707|NCT01761175|Active Comparator|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block
11440708|NCT01761175|Active Comparator|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block
11440709|NCT01761162||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
11440710|NCT01761149|Active Comparator|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
11440711|NCT01761149|Experimental|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
11440712|NCT01761136|Active Comparator|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
11440713|NCT01761136|Experimental|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
11440714|NCT01761123|Experimental|VXA-A1.1|Intestinal Delivery
11440715|NCT01761110|No Intervention|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
11440716|NCT01761110|Experimental|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
11440717|NCT01761097|Active Comparator|Endocuff assisted colonoscopy|Endocuff attachment
11440718|NCT01761097|Placebo Comparator|Control standard colonoscopy|Standard colonoscopy
11440719|NCT01761084|Experimental|Exercise and behaviour change strategies|The exercise program will include strength training, balance training and cardiovascular exercise that is individually tailored to the participants' abilities. The physical therapist will also implement strategies to assist with behaviour change, such as documenting progress in a log, participating in action planning and coping planning, and using techniques in the spirit of motivational interviewing.
11440720|NCT01761084|No Intervention|General health or social discussion|Participants in the control group will receive equal attention, but will not be prescribed exercise, or participate in counselling about exercise. The physical therapist will discuss topics related to general health.
11440721|NCT01761071|Experimental|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
11440722|NCT01761071|Active Comparator|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
11440723|NCT01761058||Severe Asthma|Subjects with Severe Asthma (SARP protocol definition)
11440724|NCT01761058||Well controlled asthma|subjects with well controlled asthma
11440725|NCT01761045|Active Comparator|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
11440726|NCT01761045|Active Comparator|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
11440727|NCT01761045|Placebo Comparator|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
11440728|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
11440729|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
11440733|NCT01760980|Active Comparator|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
11440734|NCT01760967|Active Comparator|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
11440735|NCT01760967|Active Comparator|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
11440736|NCT01760954|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
11440737|NCT01760954|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
11440738|NCT01760941|Experimental|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
11440739|NCT01760928||Asthma patients|all
11440740|NCT01760915||Severe asthma|Subjects with severe asthma (SARP protocol definition)
11440741|NCT01760915||Well controlled asthma|Subjects with well controlled asthma
11440742|NCT01760915||Normal control|Subjects that are healthy normals
11440743|NCT01760902|Experimental|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
11440744|NCT01760889|Experimental|SPD489 Low Dose Range|
11440745|NCT01760889|Experimental|SPD489 High Dose Range|
11440746|NCT01760889|Placebo Comparator|Placebo|
11440747|NCT01760876|Experimental|Biofreedom stent|Coronary intervention
11440748|NCT01760863|Experimental|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
11440749|NCT01760863|No Intervention|No oral antibiotics|No oral antibiotics.
11440750|NCT01760850|Experimental|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
11440751|NCT01760850|Active Comparator|Arm II (control)|Participants engage in an educational information session for diabetes.
11440752|NCT01760837|Other|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
11440753|NCT01760824|Experimental|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
11440754|NCT01760824|Active Comparator|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
11440755|NCT01760811|Other|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
11440756|NCT01760798|Active Comparator|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
11440757|NCT01760798|Experimental|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
11440758|NCT01760785|Active Comparator|divalproex sodium|
11440759|NCT01760785|Placebo Comparator|sugar pill|
11440760|NCT01760772|Placebo Comparator|Saline|0.9% saline
11440761|NCT01760772|Experimental|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
11440762|NCT01760772|Experimental|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
11440763|NCT01760759|No Intervention|Usual care|Patients receive usual care from their medical providers.
11440764|NCT01760759|Experimental|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
11440765|NCT01760759|Experimental|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
11440766|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
11440767|NCT01760720|No Intervention|control|Standard care
11440768|NCT01760720|Experimental|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
11440769|NCT01760707|Experimental|Exercise Training|aerobic exercise training
11440770|NCT01760707|Active Comparator|Control|
11440771|NCT01760694|Experimental|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
11440772|NCT01760694|Experimental|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
11440773|NCT01760681|Experimental|H coil DTMS|20 daily deep TMS treatments
11440774|NCT01760681|Sham Comparator|inactive stimulation|20 daily sham deep TMS treatments
11440775|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age > 18 years awaiting operation due to aortic dilation
11440776|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age > 18 years awaiting operation due to aortic dilation
11581625|NCT00777985|Active Comparator|2|
11440779|NCT01760655|Experimental|Treatment (RIC and stem cell transplant)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, thiotepa IV over 2 hours on days -15 to -13, donor lymphocyte infusion (DLI) on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28."
11440780|NCT01760642|Experimental|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.
~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
11440781|NCT01760629|Experimental|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
11440782|NCT01760616|Experimental|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
11440783|NCT01760616|No Intervention|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
11440784|NCT01760603|Experimental|ISFF|The patients performed ischia spinous fascia fixation surgery.
11440785|NCT01760590|Experimental|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
11440786|NCT01760590|Experimental|Manual Mobilization|Patients will be randomized to receive mobilization
11440787|NCT01760577|Experimental|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
11440788|NCT01760577|Active Comparator|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
11440789|NCT01760564|Experimental|Miglustat|miglustat 200mg tid
11440790|NCT01760551||Patients assessed with AMA guide fifth edition|
11440791|NCT01760551||Patients assessed with AMA guide sixth edition|
11440792|NCT01760538|Experimental|exercise group|exercise training
11440793|NCT01760538|Active Comparator|Control|usual care
11440794|NCT01760525|Experimental|CGM097 - Dose escalation|
11440795|NCT01760525|Experimental|CGM097 - Dose Expansion at MTD or RP2D|
11440796|NCT01760512|Experimental|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
11440797|NCT01760512|Active Comparator|Conventional laparoscopy|Laparoscopic gastric bypass
11440798|NCT01760499|Experimental|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
11440799|NCT01760486|Active Comparator|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
11440800|NCT01760486|Experimental|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
11440801|NCT01760486|Experimental|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
11440802|NCT01760473|Experimental|Bup 8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
11440803|NCT01760473|Experimental|Bup 16|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
11440804|NCT01760473|Experimental|Bup/Nal 8/2|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
11440805|NCT01760473|Experimental|Bup/Nal 8/8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
11440806|NCT01760473|Experimental|Bup/Nal 8/16|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
11440807|NCT01760473|Experimental|Bup/Nal 16/4|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
11440808|NCT01760473|Active Comparator|Heroin|Intranasal challenge drug: 24 mg of heroin administered intranasally.
11440809|NCT01760473|Sham Comparator|Placebo|Intranasal challenge drug: Intranasal lactose powder.
11440810|NCT01760473|Active Comparator|Naloxone 4 mg|Intranasal challenge drug: Intranasal Naloxone 4mg.
11440811|NCT01760460|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
11440812|NCT01760460|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
11440923|NCT01759680|Experimental|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
11440924|NCT01759680|No Intervention|Control Group|The control group had a normal daily life for the whole study period
11440813|NCT01760447|Experimental|Sitagliptin/Metformin|Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
11440814|NCT01760447|Placebo Comparator|Metformin|Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
11440815|NCT01760447|Experimental|Sitagliptin/Metformin XR|Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
11440816|NCT01760447|Placebo Comparator|Metformin XR|Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
11440817|NCT01760434|Other|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
11440818|NCT01760421|Experimental|Hydroxychloroquine|Receive treatment with hydroxychloroquine
11440819|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
11440820|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
11440821|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
11440822|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
11440823|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
11440824|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.
~The number proposed is 50."
11440825|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.
~The number proposed is 12."
11440826|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.
~The number proposed is 10."
11440827|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.
~The number proposed is 20."
11440828|NCT01760343|Experimental|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
11440829|NCT01760343|Experimental|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
11440830|NCT01760330|Active Comparator|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
11440831|NCT01760330|Placebo Comparator|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
11440832|NCT01760317|Active Comparator|Midline|Midline Lumbar Epidural Steroid Injection
11440833|NCT01760317|Active Comparator|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
11440834|NCT01760304|Experimental|Budesonide / Formoterol|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
11440835|NCT01760304|Placebo Comparator|Placebo|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
11440836|NCT01760291|Experimental|WATCHMAN|WATCHMAN LAA Closure Technology
11440837|NCT01760278|Experimental|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
11440838|NCT01760278|Active Comparator|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
11440839|NCT01760252|Experimental|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
~The proposed chemotherapy regimen CAPOXIRI is:
~Capecitabine 1000mg/m2 p.o. bid on days 1-7
~Oxaliplatin 85mg/m2 intravenously (IV) on day 1
~Irinotecan 150mg/m2 IV on day 1"
11440840|NCT01760239|Experimental|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP <90% and <120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
11440841|NCT01760239|No Intervention|Control|Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.
11440925|NCT01759667|Experimental|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
11440926|NCT01759654|Experimental|AdimFlu-V|
11583122|NCT00767403|Active Comparator|3|
11440842|NCT01760226|Experimental|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.
~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
11440843|NCT01760213|Experimental|Treatment|intervention delivered via internet
11440844|NCT01760213|No Intervention|Control|
11440845|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
11440846|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
11440847|NCT01760187|Experimental|Cohort 1|12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.
11440848|NCT01760187|Experimental|Cohort 2|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.
11440849|NCT01760187|Experimental|Cohort 3|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.
11440850|NCT01760187|Experimental|Cohort 4|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.
11440851|NCT01760174|Active Comparator|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
11440852|NCT01760174|Active Comparator|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
11440853|NCT01760161|Active Comparator|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
11440854|NCT01760161|Placebo Comparator|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
11440855|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
11440856|NCT01760135|Experimental|low calory|15kcal/kg caloric supplement
11440857|NCT01760135|Active Comparator|high calory|25kcal/kg
11440858|NCT01760122|Experimental|Ypeginterferon Alfa-2b|
11440859|NCT01760122|Active Comparator|Pegasys|
11440860|NCT01760109|Experimental|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days
~serious infections 6.0-12.0g,iv,tid for 7-14 days"
11440861|NCT01760096|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
11440862|NCT01760096|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
11440863|NCT01760096|Active Comparator|Glucocorticoids|Glucocorticoids
11440864|NCT01760083|Active Comparator|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
11440865|NCT01760083|No Intervention|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
11440866|NCT01760070|Experimental|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
11440867|NCT01760070|Active Comparator|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
11440868|NCT01760057|Placebo Comparator|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
11440869|NCT01760057|Experimental|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
11440870|NCT01760044|Experimental|Tissue oxygenation monitoring|Tissue oxygenation monitoring
11440871|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
11440872|NCT01760018|Experimental|Desflurane group|
11440873|NCT01760018|Active Comparator|TIVA(total intravenous anesthesia) group|
11440874|NCT01760005|Experimental|Gantenerumab|
11440875|NCT01760005|Experimental|Solanezumab|
11440876|NCT01760005|Placebo Comparator|Matching placebo (Gantenerumab)|
11440877|NCT01760005|Placebo Comparator|Matching Placebo (Solanezumab)|
11440878|NCT01760005|No Intervention|Cognitive Run-in|
11440879|NCT01759992|No Intervention|Control group|Usual care
11440880|NCT01759992|Experimental|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
11440881|NCT01759979|Experimental|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
11440882|NCT01759979|Active Comparator|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
11440883|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
11440884|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
11440885|NCT01759953|Active Comparator|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
11440886|NCT01759953|Active Comparator|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
11440887|NCT01759940|Experimental|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
11440888|NCT01759940|Active Comparator|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
11440889|NCT01759927|No Intervention|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
11440890|NCT01759927|Experimental|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
11440891|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
11440892|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
11440893|NCT01759901|Experimental|Pringle|Intermittent vascular inflow occlusion applied during liver resection
11440894|NCT01759901|No Intervention|Non-Pringle|No vascular inflow occlusion applied during liver resection
11440895|NCT01759888|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21~27) months following the start of their participation in the study.
11440896|NCT01759875|Active Comparator|Ritonavir-boosted Atazanavir|
11440897|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole|
11440898|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
11440899|NCT01759862|Experimental|Aminophylline|"Patients will receive aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
~Theophylline drug levels will be monitored daily for 4 days."
11440900|NCT01759862|Placebo Comparator|Control|"Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
~Drug levels will be monitored daily for 4 days."
11440901|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
11440902|NCT01759836|Experimental|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
11440903|NCT01759836|Placebo Comparator|Placebo|Placebo daily for 1 year
11440904|NCT01759823|Experimental|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
11440905|NCT01759823|Sham Comparator|Control|vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
11440906|NCT01759823|Experimental|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
11440907|NCT01759810|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
11440908|NCT01759810|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
11440909|NCT01759797|Experimental|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
11440910|NCT01759784|Experimental|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
11440911|NCT01759771|Experimental|Arm 1|4,000 IU of VD3 for one year
11440912|NCT01759771|Placebo Comparator|Arm 2|placebo for one year
11440913|NCT01759758|Active Comparator|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
11440914|NCT01759758|Experimental|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
11440915|NCT01759745||Blepharospasm|Blepharospasm, patient's group
11440916|NCT01759745||Control|Healthy control subjects
11440917|NCT01759732|Experimental|HAPLO|
11440918|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
11440919|NCT01759706|Experimental|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
11440920|NCT01759706|Active Comparator|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
11440921|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
11440922|NCT01759693||Control|Healthy volunteers
11440989|NCT01759186||None interventional|
11440927|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
11440928|NCT01759628|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
11440929|NCT01759628|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
11440930|NCT01759615|Experimental|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
11440931|NCT01759615|Active Comparator|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
11440932|NCT01759602|Experimental|C1-esterase inhibitor (Cinryze)|This is a phase 1b open-label, interventional proof-of-concept study in patients with neuromyelitis optica (NMO) in which all subjects will receive 3 daily infusions of 2000 Units of intravenous CINRYZE at the onset of an NMO exacerbation in addition to standard of care high-dose steroids, plus an additional 2 infusions of 1000 Units of intravenous CINRYZE during a second treatment phase with plasma exchange, if necessary.
11440933|NCT01759589|Placebo Comparator|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
11440934|NCT01759589|Active Comparator|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
11440935|NCT01759589|Active Comparator|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
11440936|NCT01759576|Experimental|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
11440937|NCT01759576|Experimental|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
11440938|NCT01759576|Experimental|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
11440939|NCT01759576|Experimental|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
11440940|NCT01759576|Experimental|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
11440941|NCT01759563|Other|single arm study|
11440942|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
11440943|NCT01759537|Experimental|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-sub-crestal
11440944|NCT01759537|Active Comparator|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
11440945|NCT01759524|Experimental|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
11440946|NCT01759524|Active Comparator|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
11440947|NCT01759511|Experimental|Simtuzumab|Participants will receive simtuzumab.
11440948|NCT01759498|Experimental|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
11440949|NCT01759498|Active Comparator|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
11440950|NCT01759498|Experimental|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
11440951|NCT01759485|Active Comparator|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
11440952|NCT01759485|Placebo Comparator|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
11440953|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
11440954|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
11440955|NCT01759459|Experimental|Lidocaine|1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
11440956|NCT01759459|Experimental|Buffered Lidocaine|"1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
~Buffered lidocaine is compounded by the following process:
~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine"
11440957|NCT01759459|Experimental|Bacteriostatic Normal Saline|Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm
11440958|NCT01759446|Placebo Comparator|Placebo taken first|Placebo powder snorted with all other arms taken crossover therafter
11440959|NCT01759446|Active Comparator|Generic H/A taken first|Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
11440960|NCT01759446|Active Comparator|Vycavert taken first|Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
11440961|NCT01759446|Active Comparator|Generic H/A plus i taken first|Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
11440962|NCT01759446|Active Comparator|Generic H/A plus p taken first|Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter
11440963|NCT01759420||IV Ondansetron|Adult emergency department patients receiving 4mg of IV ondansetron as part of their treatment plan.
11440964|NCT01759407|Active Comparator|Femoral Nerve Block|Ropivicaine 0.2% with epinephrine 1:200,000 will be used for patients between 10kg and up to 25kg in weight; ropivicaine 0.5% with epinephrine 1:200,000 will be used for patients greater than or equal to 25kg
11440965|NCT01759407|No Intervention|Standard Anesthetic Management|
11440966|NCT01759394|Experimental|Avatrombopag maleate 40 mg|
11440967|NCT01759381|No Intervention|No Negative Pressure Wound Therapy Device|This control group will not receive the negative pressure wound therapy device. Post operative dressings will be per the surgeon's standard routine.
11440968|NCT01759381|Experimental|NPWT Arm Therapy|This group will receive NPWT as opposed to the standard incisional dressing following complex spinal surgery.
11440969|NCT01759368|Active Comparator|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring.
11440970|NCT01759368|No Intervention|Control group|Control group received usual care that includes multidisciplinary care approach in which patients receive guidance and support for self-care. In the care of heart failure (HF) patients, the cardiac team plays a central role in monitoring and interpreting patient symptoms, optimizing medication and providing education. The cardiac team consists of two physicians, one specialized heart failure nurse and a physiotherapist who helps after a hospitalization period. As part of the care process, patients capable of carrying out self-care are identified and they are encouraged to regularly measure their blood pressure, heart rate and weight at home. So far, the information exchange between heart failure patients and care personnel has taken place during patients' visits to the clinic and by telephone. Systematic collection and exploitation of the self-measurement data has been difficult, since it depends on the patient's own activity
11440971|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
11440972|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
11440973|NCT01759342|Experimental|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
11440974|NCT01759342|Active Comparator|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
11440975|NCT01759329|Experimental|test coffee|test coffee
11440976|NCT01759329|Active Comparator|control coffee|control coffee
11440977|NCT01759316|Active Comparator|heliox|Heliox is use in this group
11440978|NCT01759316|Placebo Comparator|Placebo|Oxygen is used in this group
11440979|NCT01759303|Experimental|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.
~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
11440980|NCT01759290||Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
11440981|NCT01759277|Active Comparator|Control|Femoral perineural local anesthetic infusion
11440982|NCT01759277|Experimental|Experimental|Adductor canal perineural local anesthetic infusion
11440983|NCT01759264||Moderate-to-severe Crohn's disease|Adalimumab induction therapy participants with moderate-to-severe Crohn's Disease
11440984|NCT01759251||vestibular vertigo|Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label
11440985|NCT01759238|Experimental|Chemoradiation|Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)
11440986|NCT01759225||Cardiovascular Disease Patients|
11440987|NCT01759212|Experimental|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
11440988|NCT01759199|Experimental|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
11440994|NCT01759134|Experimental|Post Discharge Formula|Babies will be given formula for first three months post discharge
11440995|NCT01759121|Active Comparator|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
11440996|NCT01759121|Experimental|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
11440997|NCT01759108|Experimental|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
11440998|NCT01759108|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
11440999|NCT01759095|No Intervention|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
11441000|NCT01759095|Experimental|Electronic Multidrug Blister Pack|
11441001|NCT01759069|Experimental|treatment with microscope|treatment with microscope
11441002|NCT01759069|Experimental|treatment without microscope|treatment without microscope
11441003|NCT01759056|Active Comparator|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
11441004|NCT01759056|Placebo Comparator|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
11441005|NCT01759043|Experimental|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
11441006|NCT01759043|Active Comparator|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
11441007|NCT01759030|Active Comparator|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).
~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).
~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
11441008|NCT01759030|Experimental|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).
~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.
~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
11441009|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
11441010|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
11441011|NCT01759004|Active Comparator|patient with lipoedema|"Lipedema group:
~diagnosed with lipedema following the criteria of Wold
~women
~age ≥ 18 years
~clinimetrics: volume, muscle strength, physical condition, BMI"
11441012|NCT01759004|Active Comparator|patients with obesity|"Obesity group:
~BMI ≥ 30
~women
~age ≥ 18 years
~clinimetrics: volume, muscle strength, physical condition, BMI"
11441013|NCT01758991|Active Comparator|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.
~tDCS will be applied during swallowing therapy, during 20 minutes"
11441014|NCT01758991|Placebo Comparator|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
11441015|NCT01758978|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:
~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)
~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
11441016|NCT01758978|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:
~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).
~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
11441017|NCT01758965|Experimental|combination therapy of H2RA and surgicel|H2RA and surgicel
11441018|NCT01758965|Experimental|Monotherapy of PPI|PPI
11441019|NCT01758952||Beijing Chaoyang Hospital|2000 cases
11441020|NCT01758952||Peking University Hospital|2000 cases
11441021|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
11441022|NCT01758952||Tongji Hospital, Wuhan|2000 cases
11441023|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
11441024|NCT01758952||The Prince Welsh Hospital|1000 cases
11441025|NCT01758939||Hepatitis C virus infected patients|
11441026|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
11441027|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
11441028|NCT01758913|Experimental|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
11441029|NCT01758900|Active Comparator|Air insufflation regulator|Room air will be used for insufflation as the Active Comparator arm
11441030|NCT01758900|Experimental|CO2 insufflation regulator|Device: CO2 insufflation regulator
11441031|NCT01758887||Controls|Healthy control
11441032|NCT01758887||patients|clinical high risk subjects for psychosis
11441064|NCT01758601|Experimental|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
11446332|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
11441033|NCT01758874|No Intervention|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.
~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.
~Non phlebotomy arm has no phlebotomy treatment."
11441034|NCT01758874|Experimental|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.
~Procedures for therapeutic phlebotomy
~Inject heparin 5000 units to prevent blood clot during phlebotomy
~Inject volume expander equivalent to 5% of blood volume
~Remove 5% of whole blood
~Monitor the vital sign of the patient during the phlebotomy
~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.
~We will compare amputation and mortality between control and study groups."
11441035|NCT01758861|Experimental|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
11441036|NCT01758861|Placebo Comparator|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
11441037|NCT01758835|Active Comparator|Splint 3 weeks|Removable ankle brace/splint
11441038|NCT01758835|Active Comparator|Cast 3 weeks|Below-the-knee cast (glass fiber)
11441039|NCT01758835|Active Comparator|Cast 6 weeks|Below-the-knee cast (glass fiber)
11441040|NCT01758822|Experimental|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
11441041|NCT01758822|No Intervention|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
11441042|NCT01758809|Active Comparator|Bupivacaine|
11441043|NCT01758809|Other|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
11441044|NCT01758796|Experimental|Non-operative|Non-operative treatment with six weeks in a below-the-knee cast. Partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bearing as tolerated for the remaining two weeks.
11441045|NCT01758796|Active Comparator|Surgery|Open reduction and internal fixation with 1/3 semitubular plate and screws. Post-operatively, surgically treated ankles are placed in a below-the-knee cast for six weeks. They are advised to carry out partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bear as tolerated for the remaining two weeks.
11441046|NCT01758783|Placebo Comparator|placebo group|
11441047|NCT01758783|Experimental|Glutamine group|
11441048|NCT01758757|Active Comparator|Proliferative diabetic retinopathy|
11441049|NCT01758744|Experimental|Treprostinil|Inhaled prostanoid therapy with Treprostinil
11441050|NCT01758731|Experimental|Olaparib with C225 and Radiation Therapy|Patients will begin taking Olaparib at the assigned dose three days prior to their first Cetuximab infusion. Patients will receive an initial dose of Cetuximab, 400 mg/m², intravenously over 120 minutes on Day 1. The initial dose of C225 will precede the start of radiation by 5-7 days. All patients will receive RT to a total dose of 69.3 Gy in 33 fractions over 6½ weeks. Weekly C225 will be administered at 250 mg/m2 in combination with daily RT. Patients will be assigned to receive Olaparib (25, 50, 100 or 200 mg bid) in combination with RT and C225. Olaparib will be taken twice daily, beginning three days prior to first scheduled C225 infusion. A further dose level of 300mg or 400mg may be considered should the 200mg Olaparib dose be well tolerated in this C225/RT combination schedule.
11441051|NCT01758718|Active Comparator|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
11441052|NCT01758705||Cohort 1|Cohort 1
11441053|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.
~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
11441054|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.
~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
11441055|NCT01758679|Experimental|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
11441056|NCT01758666|Experimental|Methotrexate and Calcium folinate|
11441057|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
11441058|NCT01758640|Active Comparator|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
11441059|NCT01758640|Active Comparator|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
11441060|NCT01758627|No Intervention|Peritoneal dialysis group|
11441061|NCT01758627|Experimental|Conventional treatment group|medical treatment such as diuretics
11441062|NCT01758614|Experimental|bypass group|all the participants in this group will be performed EC-IC bypass surgery
11441063|NCT01758614|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg per day or clopidogrel 75mg per day
11441065|NCT01758601|Active Comparator|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
11441233|NCT01757444|Active Comparator|BiPAP- ST|Patients receiving BiPAP- ST at home
11441066|NCT01758588|No Intervention|Observation arm|Subjects will be monitored closely for disease progression, however will receive no intervention.
11441067|NCT01758588|Experimental|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years.
11441068|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
11441069|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
11441070|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
11441071|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
11441072|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
11441073|NCT01758562|No Intervention|State-of-the-art mouth care|
11441074|NCT01758562|Active Comparator|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
11441075|NCT01758549|Experimental|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
11441076|NCT01758549|Active Comparator|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
11441077|NCT01758536|Placebo Comparator|Placebo Pills|"12 g each time, twice daily.
~3 months"
11441078|NCT01758536|Experimental|Huatuo Zaizao Pills|"12 g each time, twice daily.
~3 months."
11441079|NCT01758523|Experimental|dutasteride|4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
11441080|NCT01758523|Placebo Comparator|Sugar Pill|Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
11441081|NCT01758510|Experimental|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
11441082|NCT01758497|Active Comparator|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
11441083|NCT01758497|Sham Comparator|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
11441084|NCT01758484|Experimental|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
11441085|NCT01758471|Experimental|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial blood glucose)<10.0
11441086|NCT01758471|Active Comparator|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
11441087|NCT01758458|Experimental|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.
~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
11441088|NCT01758445|Experimental|Proton Radiotherapy|Proton Radiotherapy
11441089|NCT01758432|Experimental|Module 1 (90 mg bolus)|90 mg PRT064445 given as a single IV
11441090|NCT01758432|Experimental|Module 1 (210 mg bolus)|210 mg PRT064445 given as a single IV bolus
11441091|NCT01758432|Experimental|Module 1 (420 mg bolus)|420 mg PRT064445 given as a single IV bolus
11441092|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445 given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
11441093|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445 given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus
11441094|NCT01758432|Experimental|Module 1 (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
11441095|NCT01758432|Placebo Comparator|Module 1 Placebo|Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.
11441096|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
11441097|NCT01758406|Experimental|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
11441098|NCT01758406|Placebo Comparator|Placebo|The patients with heart failure that underwent placebo injection.
11441099|NCT01758393|Experimental|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
11441100|NCT01758393|Experimental|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
11441101|NCT01758380|Experimental|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
11441134|NCT01758172|Experimental|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
11441234|NCT01757431|Other|ECULIZUMAB|
11441102|NCT01758380|Active Comparator|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
11441103|NCT01758367|Experimental|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
11441104|NCT01758354|Experimental|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
11441105|NCT01758341|Experimental|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
11441106|NCT01758328|Experimental|Pts with Mutiple myeloma|Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
11441107|NCT01758315|Experimental|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
11441108|NCT01758315|No Intervention|Control|Control practices will not receive training or in-office coaching.
11441109|NCT01758302|Active Comparator|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
11441110|NCT01758302|Active Comparator|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
11441111|NCT01758302|Active Comparator|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
11441112|NCT01758302|Active Comparator|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
11441113|NCT01758289||Paricalcitol IV|Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.
11441114|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
11441115|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
11441116|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
11441117|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
11441118|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
11441119|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
11441120|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
11441121|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
11441122|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
11441123|NCT01758237|Experimental|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
11441124|NCT01758237|Experimental|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
11441125|NCT01758224|Experimental|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
11441126|NCT01758224|Active Comparator|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
11441127|NCT01758211|Experimental|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
11441128|NCT01758211|Active Comparator|conventional AVM resection|conventional resection of AVM
11441129|NCT01758198|Experimental|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months
~Methotrexate ≥6 mg/week for 12 months"
11441130|NCT01758198|Placebo Comparator|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months
~Methotrexate ≥6 mg/week for 12 months"
11441131|NCT01758185|Placebo Comparator|recombinant hepatitis b vaccine|0.5ml intramuscular
11441132|NCT01758185|Experimental|Aleph influenza vaccine|0.5ml intramuscular
11441133|NCT01758172|Active Comparator|Albumin|albumin was administered to reach CVP up to 7mmHg
11583123|NCT00767390||ACL Patch|
11441135|NCT01758159|Experimental|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
11441136|NCT01758159|Experimental|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
11441137|NCT01758159|Experimental|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
11441138|NCT01758159|Placebo Comparator|Control group|The children in this group will receive basic health services and placebo syrup.
11441139|NCT01758146|Experimental|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
11441140|NCT01758146|Active Comparator|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
11441141|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
11441142|NCT01758133||Mothers not exposed to medical clown activity|
11441143|NCT01758120|Experimental|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
11441144|NCT01758120|Experimental|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
11441145|NCT01758107|Experimental|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
11441146|NCT01758107|No Intervention|Sirolimus with Cyclosporine with Prednisolone|
11441147|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
11441148|NCT01758081|Active Comparator|vitamin D + fish oil|vitamin D3 + Omacor
11441149|NCT01758081|Active Comparator|vitamin D + fish oil placebo|vitamin D3 + fish oil placebo
11441150|NCT01758081|Active Comparator|vitamin D placebo + fish oil|vitamin D placebo + Omacor
11441151|NCT01758081|Placebo Comparator|vitamin D placebo + fish oil placebo|vitamin D placebo + fish oil placebo
11441152|NCT01758068|Experimental|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
11441153|NCT01758068|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
11441154|NCT01758055|Experimental|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
11441155|NCT01758042|Other|Haploidentical Bone Marrow/Kidney|Single Arm Study
11441156|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
11441157|NCT01757990|Experimental|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
11441158|NCT01757990|Experimental|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
11441159|NCT01757990|Sham Comparator|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
11441160|NCT01757977|Experimental|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
11441161|NCT01757977|Active Comparator|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
11441162|NCT01757964|Experimental|Bacteriotherapy|Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant.
11441163|NCT01757951|Experimental|Unimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
11441164|NCT01757951|Active Comparator|Bimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
11441165|NCT01757938|Experimental|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
11441166|NCT01757938|Active Comparator|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
11441167|NCT01757925|Experimental|Active Gaming|Participants will receivce a weight management program plus active gaming device
11441168|NCT01757925|Active Comparator|Control Group|Participants will receive a weight management program without active gaming
11441169|NCT01757912|Experimental|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
11441170|NCT01757899|Active Comparator|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:
~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
11441171|NCT01757899|Placebo Comparator|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
11441172|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
11441173|NCT01757873|Experimental|Z160|375 mg BID
11441174|NCT01757873|Placebo Comparator|Placebo|matching placebo control
11441175|NCT01757860|Experimental|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
11441176|NCT01757860|Placebo Comparator|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
11441177|NCT01757847|Active Comparator|Brief MOVE-II active control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
11441178|NCT01757847|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The ACT protocol for this study focuses on reducing binge eating and distress and improving functioning in individual who are overweight or obese. The protocol focuses on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life. The protocol will be delivered in four 2-hour weekly group sessions to patients with overweight or obesity who have completed the VA San Diego MOVE program.
11441179|NCT01757834|Experimental|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
11441180|NCT01757821|Experimental|6-Hz Priming|real 6-Hz primed low-frequency rTMS
11441181|NCT01757821|Sham Comparator|Sham 6-Hz Priming|Sham 6-Hz Primed low-frequency rTMS
11441182|NCT01757821|Active Comparator|Real 1-Hz rTMS only|real 1-Hz rTMS only
11441183|NCT01757808|Experimental|Ranolazine|
11441184|NCT01757808|Placebo Comparator|Placebo|
11441185|NCT01757795|Experimental|SP-8203|Active arm
11441186|NCT01757795|Placebo Comparator|Placebo|Matching Placebo
11441187|NCT01757782|Active Comparator|Oral Sildenafil|In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
11441188|NCT01757782|Placebo Comparator|Distilled water|In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
11441189|NCT01757769|Experimental|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
11441190|NCT01757756|Experimental|Arm Label Pf-05175157, placebo, midazolam|
11441191|NCT01757743||Interventional closure|Interventional catheterization closure
11441192|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
11441193|NCT01757730||Altered Stiffness|Tissue stiffness will be evaluated in subjects those with disease conditions where stiffness changes from normal. These studies will be repeated for reproducibility.
11441194|NCT01757730||Healthy Volunteers|Tissue stiffness will be evaluated in normal subjects to determine the normal values. These studies will be repeated for reproducibility.
11441195|NCT01757717|Experimental|Ir-192 high dose rate (HDR)|This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine and/or pelvis that have been maximally treated with external beam radiation therapy.
11441231|NCT01757457|Active Comparator|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
11583659|NCT00763425|Active Comparator|2|
11441196|NCT01757704|Experimental|Open pleurae & conventional filling of heart|In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
11441197|NCT01757704|Experimental|Intact pleurae & staged filling of heart|In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
11441198|NCT01757691|Experimental|Fingolimod 0.5mg/daily|Oral capsule dose was given once daily for 48 weeks
11441199|NCT01757691|Placebo Comparator|Placebo|Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
11441200|NCT01757678|Other|Standard of care: FFR, ICA, cCTA, FFRct|(ICA) Invasive coronary angiography with (FFR) fractional flow reserve measurement in standard of care environment, and cCTA (computed coronary tomography angiography) and FFRct Analysis (fractional flow reserve computed tomography)
11441201|NCT01757665|Experimental|Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M|Aortic/Mitral valve replacement therapy
11441202|NCT01757639|Experimental|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11441203|NCT01757626|Experimental|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in ≥2nd CR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 & 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved.
11441204|NCT01757626|Experimental|expansion phase II single arm trial|Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123^I-MIBG scan. Group 2 patients are in >2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123^I-MIBG scan. GM-CSF can be omitted if patients have a history of an allergy to GM-CSF or develop an allergic reaction to GM-CSF after initiating therapy while on the protocol.
11441205|NCT01757613|Active Comparator|AK 3012 a for topical use|
11441206|NCT01757613|Active Comparator|AK 3012 b for topical use|
11441207|NCT01757613|Active Comparator|AK 3012 c for topical use|
11441208|NCT01757600||Macular Hole|
11441209|NCT01757587|Active Comparator|Vildagliptin|
11441210|NCT01757587|Placebo Comparator|Placebo|
11441211|NCT01757574|Experimental|Alemtuzumab|Open label study of alemtuzumab
11441212|NCT01757561||Propofol-Abnormal|patients with preoperative SjvO2<55%,using the TIVA technology with propofol,
11441213|NCT01757561||Propofol-Normal|patients with preoperative SjvO2≥55%,using the TIVA technology with propofol,
11441214|NCT01757561||Sevoflurane-Abnormal|patients with preoperative SjvO2<55%,using the VIMA technology with sevoflurane,
11441215|NCT01757561||Sevoflurane-Normal|patients with preoperative SjvO2≥55%,using the VIMA technology with sevoflurane,
11441216|NCT01757548|Experimental|open operation|high ligation of spermatic vein by open operation
11441217|NCT01757548|Experimental|microsurgery|high ligation of spermatic vein by microsurgery
11441218|NCT01757535|Experimental|Oral Azacitidine|300mg Oral Azacitidine for the first 14 days of each 28 days treatment cycle
11441219|NCT01757535|Placebo Comparator|Placebo|300 mg Placebo for the first 14 days of each 28 days treatment cycle
11441220|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
11441221|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
11441222|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
11441223|NCT01757509|Other|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
11441224|NCT01757509|No Intervention|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
11441225|NCT01757496|Experimental|Cough Assist|These children will receive 2 Cough Assist sessions daily.
11441226|NCT01757496|No Intervention|Control group|These children receive standard care but no physiotherapy.
11441227|NCT01757483||Prescribers|
11441228|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
11441229|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
11441230|NCT01757457|Experimental|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
11441232|NCT01757444|Experimental|BiPAP - A40|BiPAP with AVAPS AE mode
11441235|NCT01757418|Experimental|Immune Globulin Intravenous|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
11441236|NCT01757418|Placebo Comparator|Normal saline|An equivalent volume (weight-based)of normal saline
11441237|NCT01757405|Experimental|≤ 3 doses of 90 µg/kg rFVIIa BI|
11441238|NCT01757405|Experimental|One dose of 270 µg/kg rFVIIa BI|
11441239|NCT01757392|Experimental|Candin® 0.3 mL|Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
11441240|NCT01757379|Experimental|13C-labeled acetate|
11441241|NCT01757379|Experimental|13C-labeled propionate|
11441242|NCT01757379|Experimental|13C-labeled butyrate|
11441243|NCT01757379|Experimental|Inulin|
11441244|NCT01757366|Experimental|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
11441245|NCT01757366|Active Comparator|Active Comparator|First-line Chemotherapy
11441246|NCT01757353|Active Comparator|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
11441247|NCT01757353|Active Comparator|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
11441248|NCT01757353|Experimental|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
11441249|NCT01757340|No Intervention|Weight maintenance|Weight maintenance with normal protein and leucine intake
11441250|NCT01757340|Active Comparator|Weight loss with normal protein intake|
11441251|NCT01757340|Experimental|Weight loss with leucine supplementation|
11441252|NCT01757327|Experimental|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11441253|NCT01757327|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
11441254|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
11441255|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
11441256|NCT01757301|Active Comparator|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
11441257|NCT01757301|Experimental|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
11441258|NCT01757288|Active Comparator|PACLITAXEL|PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
11441259|NCT01757288|Experimental|NAB-PACLITAXEL|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
11441260|NCT01757275|Experimental|Esomeprazole|
11441261|NCT01757275|Active Comparator|Cimetidine|
11441262|NCT01757262|Experimental|Ticagrelor|90 mg Ticagrelor
11441263|NCT01757262|Active Comparator|Clopidogrel|75mg Clopidogrel
11441264|NCT01757249|Experimental|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
11441265|NCT01757249|No Intervention|Group 2 Control|Control Group - no intervention
11441266|NCT01757236|Active Comparator|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).
~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
11441267|NCT01757236|Experimental|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).
~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).
~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
11441268|NCT01757236|Experimental|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
11441269|NCT01757223|Experimental|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
11441270|NCT01757223|Experimental|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
11441271|NCT01757223|Experimental|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
11585776|NCT00748358|Experimental|drug|drug
11441272|NCT01757223|Experimental|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
11441273|NCT01757223|Experimental|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
11441274|NCT01757197|Experimental|All Patients|Toclizumab will be administered on Day 0. The administration of tocilizumab will be every 2 weeks for a total of 8 doses.
11441275|NCT01757184|Experimental|Double-blind Sebelipase Alfa|Double-blind Period: IV infusions of sebelipase alfa at a dose of 1 mg/kg administered qow for 20 weeks.
11441276|NCT01757184|Placebo Comparator|Double-blind Placebo|Double-blind Period: IV infusions of matched placebo administered qow for 20 weeks.
11441277|NCT01757184|Experimental|Open-label Sebelipase Alfa/Sebelipase Alfa|Participants who were randomized to receive sebelipase alfa during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
11441278|NCT01757184|Experimental|Open-label Placebo/Sebelipase Alfa|Participants who were randomized to receive placebo during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
11441279|NCT01757171|Experimental|Arm A (taxane naïve)|No prior Taxane treatment. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
11441280|NCT01757171|Experimental|Arm B (prior taxane therapy)|Subject previously treated with taxane. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
11441281|NCT01757158|Experimental|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
11441282|NCT01757145|Experimental|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.
~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.
~In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.
~After 4 weeks we will re-attempt to hold the drug."
11441283|NCT01757132|Other|Implantable Miniature Telescope|Post approval study
11441284|NCT01757119|Experimental|Drug|
11441285|NCT01757106|Experimental|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
11441286|NCT01757106|Active Comparator|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
11441287|NCT01757093|Experimental|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
11441288|NCT01757093|Active Comparator|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
11441289|NCT01757080|Experimental|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
11441290|NCT01757080|Active Comparator|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
11441291|NCT01757067|Active Comparator|ablation procedure vs medical therapy|PVC ablation vs medical therapy
11441292|NCT01757067|No Intervention|Compare 2 arms for safety, symptoms|Compare control of PVC's between 2 groups.
11441293|NCT01757054|Experimental|Probiotic group|
11441294|NCT01757054|No Intervention|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
11441295|NCT01757015|Placebo Comparator|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
11441296|NCT01757015|Experimental|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
11441297|NCT01757002|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
11441298|NCT01757002|Active Comparator|Control|Teens in the control group will receive generic, web-based asthma education.
11441299|NCT01756989|Experimental|Thalidomide, etoposide, celecoxib|Single arm study,phase II
11441300|NCT01756976||Investigational Device|The 510k cleared OrthoPAT Advance will be used in this standard of care arm.
11441301|NCT01756976||Control Group|The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.
11441302|NCT01756963||IBD-SL cohort|
11441303|NCT01756950|Experimental|Cohort 1 - CR8020|2 mg/kg CR8020
11441304|NCT01756950|Placebo Comparator|Cohort 1 - Placebo|5% dextrose in water
11441305|NCT01756950|Experimental|Cohort 2 - CR8020|5 mg/kg CR8020
11441306|NCT01756950|Placebo Comparator|Cohort 2 - Placebo|5% dextrose in water
11441307|NCT01756950|Experimental|Cohort 3 - CR8020|15 mg/kg CR8020
11441308|NCT01756950|Placebo Comparator|Cohort 3 - Placebo|5% dextrose in water
11441309|NCT01756950|Experimental|Cohort 4 - CR8020|30 mg/kg CR8020
11441310|NCT01756950|Placebo Comparator|Cohort 4 - Placebo|5% dextrose in water
11441311|NCT01756950|Experimental|Cohort 5 - CR8020|50 mg/kg CR8020
11441312|NCT01756950|Placebo Comparator|Cohort 5 - Placebo|5% dextrose in water
11441313|NCT01756950|Experimental|Cohort 6 - CR8020|30 mg/kg CR8020
11441314|NCT01756950|Placebo Comparator|Cohort 6 - Placebo|5% dextrose in water
11441315|NCT01756937|Active Comparator|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
11441316|NCT01756937|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
11441317|NCT01756924|Experimental|CEM-102 plus Rifampin|
11441318|NCT01756924|Active Comparator|Standard of Care|
11441319|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
11441320|NCT01756898|Experimental|Low dose ASB17061|Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
11441321|NCT01756898|Experimental|Middle dose ASB17061|Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
11441322|NCT01756898|Experimental|High dose ASB17061|Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
11441323|NCT01756898|Placebo Comparator|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
11441324|NCT01756885|Active Comparator|Standard Varenicline Treatment|"12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
~Days 85-168: Placebo - 1.0mg twice daily orally"
11441325|NCT01756885|Experimental|Extended Varenicline Treatment|"24 weeks of active varenicline + smoking cessation counseling
~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally"
11441326|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
11441327|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
11441328|NCT01756846|Other|usual care|Daily practice of the cardiologist or attending emergency doctor, in order to diagnose a patient with chest pain. In this period attending doctors assess the risk of a patient with chest pain, based on his/hers experience and various criteria (for example described in European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, without a formal risk score).
11441329|NCT01756846|Other|use of HEART risk score|see intervention
11441330|NCT01756833|Active Comparator|Doxycycline|100 mg capsules, twice a day, for a period of two years.
11441331|NCT01756833|Placebo Comparator|Placebo|100 mg capsules, twice a day, for a period of two years.
11441332|NCT01756820|Active Comparator|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
11441333|NCT01756820|Active Comparator|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
11441334|NCT01756807|Experimental|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
11441335|NCT01756794|Other|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
11441336|NCT01756794|Other|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
11441337|NCT01756781|Experimental|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
11441338|NCT01756781|Experimental|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
11441339|NCT01756768|Experimental|Radio-labeled Dose Arm|
11441340|NCT01756755|No Intervention|Control|Treat with severe sepsis / septic shock practice guideline
11441341|NCT01756755|Experimental|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion [Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood].
11441342|NCT01756742|Experimental|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
11441343|NCT01756742|Placebo Comparator|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
11441344|NCT01756729|Active Comparator|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
11441345|NCT01756729|Experimental|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
11441346|NCT01756716|Experimental|MT-3995 Low group|
11441347|NCT01756716|Experimental|MT-3995 High group|
11441348|NCT01756716|Placebo Comparator|Placebo group|
11441349|NCT01756703|Experimental|MT-3995 Low group|
11441350|NCT01756703|Experimental|MT-3995 High group|
11441351|NCT01756703|Placebo Comparator|Placebo group|
11441352|NCT01756664|Placebo Comparator|Control|Vaseline has been used on the first day after laser treatment
11441353|NCT01756664|Active Comparator|Sunscreen|Sunscreen has been used on the first day after laser treatment
11446335|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
11441354|NCT01756651|Experimental|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
11441355|NCT01756651|Experimental|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
11441356|NCT01756638|Experimental|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
11441357|NCT01756625||First line WT KRAS mCRC|
11441358|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
11441359|NCT01756599|Experimental|leukaemia during childhood or adolescence|
11441360|NCT01756586|Active Comparator|Control|Plain bupivacaine
11441361|NCT01756586|Experimental|Experimental|Bupivacaine with Dexamethasone
11441362|NCT01756573|Active Comparator|Bupivacaine|Control
11441363|NCT01756573|Experimental|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
11441364|NCT01756573|Active Comparator|Intravenous Dexamethasone|Dexamethasone will be given intravenously
11441365|NCT01756560|Active Comparator|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
11441366|NCT01756560|Experimental|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
11441367|NCT01756547|Experimental|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
11441368|NCT01756547|Placebo Comparator|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
11441369|NCT01756534|No Intervention|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
11441370|NCT01756534|Active Comparator|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
11441371|NCT01756521|Experimental|Moxifloxacin 400mg|moxifloxacin 400mg
11441372|NCT01756521|Experimental|Moxifloxacin 800mg|moxifloxacin 800mg
11441373|NCT01756521|Placebo Comparator|Placebo(No treatment)|Only drink water
11441374|NCT01756508|Experimental|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
11441375|NCT01756508|No Intervention|control|No intervention will be applied instead eculizumab infusion
11441376|NCT01756495|Experimental|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
11441377|NCT01756495|Experimental|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
11441378|NCT01756495|Active Comparator|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
11441379|NCT01756495|Placebo Comparator|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
11441380|NCT01756482|Experimental|GS-5806|GS-5806, powder for oral solution
11441381|NCT01756482|Placebo Comparator|Sugar powder for oral solution in juice|Sugar powder for oral solution
11441382|NCT01756469|No Intervention|Control|non-alcohol related information about nutrition
11441383|NCT01756469|Active Comparator|Intervention|Behavioral Intervention for Alcohol Use
11441384|NCT01756456|Experimental|1_rhNGF10_Phase 1_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
11441385|NCT01756456|Experimental|2_rhNGF20_Phase 1_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
11441386|NCT01756456|Placebo Comparator|3_vehicle group_Phase 1_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
11441387|NCT01756456|Experimental|4_rhNGF10_Phase 2_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
11441388|NCT01756456|Experimental|5_rhNGF20_Phase 2_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
11441389|NCT01756456|Placebo Comparator|6_vehicle group_Phase 2_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
11441390|NCT01756443|Active Comparator|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
11441391|NCT01756443|Experimental|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
11441392|NCT01756430|Experimental|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
11441393|NCT01756430|Active Comparator|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
11441394|NCT01756417|Experimental|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
11441395|NCT01756404|Experimental|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
11441396|NCT01756404|Experimental|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
11441397|NCT01756404|Experimental|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
11441398|NCT01756404|Experimental|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
11441399|NCT01756404|Experimental|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
11441400|NCT01756378|Experimental|Muligan mobilization with movement|"Interventions are:
~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
11441401|NCT01756378|Active Comparator|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
11441402|NCT01756365|Experimental|CECA|
11441403|NCT01756352|Experimental|GBM Avastin receiving 18F-FET|Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
11441404|NCT01756339|Experimental|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
11441405|NCT01756339|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
11441406|NCT01756326|Experimental|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
11441407|NCT01756326|Active Comparator|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
11441408|NCT01756313|Experimental|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
11441409|NCT01756300|Experimental|Resistant Hypertension|The catheter-based (device: Celsius® ThermoCool® RD) renal denervation will serve to treat resistant hypertension.
11441410|NCT01756287|Experimental|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
11441411|NCT01756287|Sham Comparator|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
11441412|NCT01756287|No Intervention|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
11441413|NCT01756274|Experimental|Neonates 'Left-over' Blood Samples|Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. Two left-over samples could be obtained from a single neonate. Laboratory professionals tested the BG concentration using three Bayer Blood Glucose Monitoring Systems (BGMS): Contour® NEXT BGMS, Contour® PLUS BGMS, and Contour® Next EZ BGMS.
11441414|NCT01756261||Group 1|
11441415|NCT01756248||Group 1|
11441416|NCT01756235||Participants with Rheumatoid Arthritis|Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.
11441417|NCT01756222||Bicuspid Aortic Valve Disease Patients|Patients with the diagnosis of BAV disease.
11441418|NCT01756209|Active Comparator|Acetaminophen|Acetaminophen 15 mg/kg oral single dose (n=40)
11441419|NCT01756209|Active Comparator|Ibuprofen|Ibuprofen 10 mg/kg oral single dose (n=40)
11441420|NCT01756209|Experimental|Acetaminophen + magnesium 400 mg|Acetaminophen 15 mg/kg oral single dose (n=40) + magnesium 400 mg
11441421|NCT01756209|Experimental|ibuprofen + magnesium 400 mg|ibuprofen 10 mg/kg oral single dose (n=40) + magnesium 400 mg
11441422|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
11441423|NCT01756183|Experimental|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
11441424|NCT01756170|Active Comparator|Arm 2|Patients receive radiotherapy alone as in arm 1.
11441425|NCT01756170|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
11441426|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2|SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
11441427|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1|SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
11441428|NCT01756144|Active Comparator|Autologous bone grafting|autologous bone of the iliac crest
11441429|NCT01756144|Experimental|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
11441430|NCT01756131|Experimental|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
11441431|NCT01756131|Experimental|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
11441432|NCT01756131|Experimental|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
11441433|NCT01756131|Experimental|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
11441434|NCT01756131|Experimental|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
11441435|NCT01756131|Experimental|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
11441436|NCT01756131|Experimental|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
11441437|NCT01756131|Experimental|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
11441438|NCT01756131|Experimental|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
11441439|NCT01756118|Experimental|BEZ235|
11441440|NCT01756105|Experimental|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
11441464|NCT01755962|Experimental|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
11441465|NCT01755962|Experimental|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
11441441|NCT01756105|Active Comparator|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
11441442|NCT01756092|Experimental|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
11441443|NCT01756079|Experimental|PegIFN-2b + RBV+ boceprevir|Participants will receive PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day).
11441444|NCT01756066|Active Comparator|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
11441445|NCT01756066|Experimental|B|Participant has 100% subsidy, i.e. program attendance is free
11441446|NCT01756066|Experimental|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
11441447|NCT01756066|Experimental|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
11441448|NCT01756053|Active Comparator|ABT-089|"During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.
~Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules."
11441449|NCT01756053|Placebo Comparator|Placebo|"These are matched placebo capsules manufactured by the study drug supplier.
~During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.
~Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules."
11441450|NCT01756040|Other|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
11441451|NCT01756027|Active Comparator|Group A|Ulthera System providing one treatment per cheek
11441452|NCT01756027|Active Comparator|Group B|Ulthera System providing two treatments per cheek
11441453|NCT01756014||Controls|Age matched healthy subjects
11441454|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
11441455|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
11441456|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
11441457|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
11441458|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
11441459|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
11441460|NCT01755988|No Intervention|Usual care|
11441461|NCT01755988|Experimental|Educational website.|Educational website (in addition to usual care).
11441462|NCT01755988|Experimental|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
11441463|NCT01755975|Experimental|Romidepsin and Lenalidomide|This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, and all research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program. Only enough lenalidomide for one cycle of therapy will be supplied to the patient each cycle.
11441466|NCT01755962|Experimental|Low Glycemic Load|12-week intervention diet
11441468|NCT01755949|Active Comparator|Chronic atrial fibrillation, colchicine|Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.
11441469|NCT01755949|Placebo Comparator|Chronic atrial fibrillation, placebo|Matching placebo. Subjects not undergoing ablation.
11441470|NCT01755949|Active Comparator|Pre-ablation, sinus rhythm, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
11441471|NCT01755949|Placebo Comparator|Pre-ablation, sinus rhythm, placebo|Matching placebo. Subjects undergoing ablation.
11441472|NCT01755949|Active Comparator|Pre-ablation, AF, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
11441473|NCT01755949|Placebo Comparator|Pre-ablation, AF, placebo|Matching placebo. Subjects undergoing ablation.
11441474|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
11441475|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
11441476|NCT01755923|Experimental|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
11441477|NCT01755923|Active Comparator|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
11441478|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
11441479|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
11441480|NCT01755897|Experimental|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
11441481|NCT01755897|Active Comparator|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
11441482|NCT01755884|Experimental|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
11441483|NCT01755871|Experimental|Fingolimod|Gilenya 0,5mg per day, oral
11441484|NCT01755858|Experimental|Bendavia|Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
11441485|NCT01755858|Placebo Comparator|Placebo|Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
11441486|NCT01755845|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11441487|NCT01755845|Active Comparator|Arm 2|Patients receive chemoradiotherapy as in arm 1.
11441488|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
11441489|NCT01755819|Other|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
11441490|NCT01755819|Other|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
11441491|NCT01755806||aortic root dimension change|those without aortic valve calcification
11441492|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
11441493|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
11441494|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
11441495|NCT01755767|Experimental|Tivantinib 240 mg BID Cohort|The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
11441496|NCT01755767|Experimental|Tivantinib 120 mg BID Cohort|Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
11441497|NCT01755767|Placebo Comparator|Placebo Matching 240 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
11441498|NCT01755767|Placebo Comparator|Placebo Matching 120 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
11441499|NCT01755754|Experimental|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
11441500|NCT01755754|Experimental|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
11441501|NCT01755741|Experimental|Placebo Vaginal Ring|Placebo vaginal ring with condom use
11441502|NCT01755741|Other|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
11441503|NCT01755728|No Intervention|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
11441504|NCT01755728|Active Comparator|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
11441505|NCT01755728|Active Comparator|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
11441506|NCT01755728|Experimental|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
11442076|NCT01751607||genetic variants|AFib patients with or without the genetic variants
11441507|NCT01755728|No Intervention|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
11441508|NCT01755715|No Intervention|Control group|Insertion of IUD at 2-4 weeks after abortion.
11441509|NCT01755715|Experimental|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
11441510|NCT01755702|Placebo Comparator|Arm 1|Placebo
11441511|NCT01755702|Active Comparator|Arm 2|paracetamol marketed forumulation
11441512|NCT01755702|Active Comparator|Arm 3|ibuprofen marketed formulation
11441513|NCT01755702|Experimental|Arm 4|experimental paracetamol + caffeine formulation
11441514|NCT01755689|Experimental|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
11441515|NCT01755689|Experimental|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
11441516|NCT01755689|Experimental|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
11441517|NCT01755689|Experimental|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
11441518|NCT01755689|Experimental|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
11441519|NCT01755676|Experimental|Orlistat 60 mg|
11441520|NCT01755676|Placebo Comparator|Placebo|
11441521|NCT01755663|Experimental|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
11441522|NCT01755663|Active Comparator|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
11441523|NCT01755650|Experimental|D-18F FPM|
11441524|NCT01755650|Experimental|L-18F FPM|
11441525|NCT01755637|Experimental|Albendazole tablet (Aqua Based)|Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment.
11441526|NCT01755637|Active Comparator|Albendazole tablet (Alcohol Based)|Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment.
11441527|NCT01755624|Experimental|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
11441528|NCT01755624|Active Comparator|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
11441529|NCT01755611|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11441530|NCT01755611|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11441531|NCT01755598|Experimental|M72AS01 Group|Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
11441532|NCT01755598|Placebo Comparator|Control group|Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
11441533|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
11441534|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
11441535|NCT01755572|Experimental|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
11441536|NCT01755572|Placebo Comparator|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
11441537|NCT01755559|Other|Artesunate-amodiaquine|Efficacy estimates at 95%
11441538|NCT01755559|Other|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
11441539|NCT01755559|Other|Artemether-lumefantrine|Efficacy estimates at 95%
11441540|NCT01755546|Experimental|EN3409|Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
11441541|NCT01755533|Experimental|Rural curriculum|Receive rural version of curriculum
11441542|NCT01755533|Experimental|Classic curriculum|Receive classic version of curriculum
11441543|NCT01755533|No Intervention|Control|Continue normal prevention activities
11441544|NCT01755520|Experimental|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
11441545|NCT01755520|Active Comparator|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
11441546|NCT01755507|Experimental|B|norUDCA
11441547|NCT01755507|Experimental|C|norUDCA
11441548|NCT01755507|Placebo Comparator|placebo|Placebo
11441549|NCT01755507|Experimental|A|norUDCA
11441550|NCT01755494|Experimental|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
11441551|NCT01755494|Experimental|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
11441552|NCT01755481|Experimental|Probiotics F19|F19 in an infant formula
11441553|NCT01755481|Experimental|Whey protein concentrate|Whey protein concentrate in an infant formula
11441635|NCT01754896|Experimental|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
11442077|NCT01751594|Active Comparator|H4L Comparison Intervention|
11441554|NCT01755468|Active Comparator|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
11441555|NCT01755468|Experimental|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
11441556|NCT01755455|Active Comparator|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
11441557|NCT01755455|Placebo Comparator|Placebo|Identical-appearing tablet taken by mouth daily for 6 weeks
11441558|NCT01755442|Active Comparator|AMG 151|
11441559|NCT01755442|Placebo Comparator|Placebo|
11441560|NCT01755416|Placebo Comparator|Closed loop with sensor and Insulin|subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
11441561|NCT01755416|Active Comparator|Closed loop with sensor, Insulin and Liraglutide|Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
11441562|NCT01755403|Other|Benznidazole|
11441563|NCT01755390|Experimental|Cabazitaxel|"IV escalation part:
~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.
~Oral bioavailability part:
~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
11441564|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
11441565|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
11441566|NCT01755364|Experimental|AdimFlu-V|
11441567|NCT01755338|Active Comparator|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
11441568|NCT01755338|Placebo Comparator|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
11441569|NCT01755325|Experimental|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.
~imatinib,0.4g,qd"
11441570|NCT01755325|Placebo Comparator|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.
~imatinib 0.4g qd"
11441571|NCT01755312|Experimental|medication reminder|medication reminder
11441572|NCT01755312|Placebo Comparator|Placebo|Placebo
11441573|NCT01755299|Active Comparator|Active ingredient|"Regular 5-hour Energy"
11441574|NCT01755299|Active Comparator|Active ingredient-2|"5-hour Energy Decaf"
11441575|NCT01755299|Active Comparator|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
11441576|NCT01755299|Placebo Comparator|Placebo|Flavored placebo
11441577|NCT01755286|Experimental|4 mg OTO-201|
11441578|NCT01755286|Experimental|12 mg OTO-201|
11441579|NCT01755286|Placebo Comparator|Vehicle for OTO-201|
11441580|NCT01755286|Sham Comparator|Sham|
11441581|NCT01755273|No Intervention|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
11441582|NCT01755260|No Intervention|oral intake|The patients at this arm were allowed to take food through mouth
11441583|NCT01755247|Placebo Comparator|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
11441584|NCT01755247|Active Comparator|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
11441585|NCT01755247|Active Comparator|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
11441586|NCT01755234|Active Comparator|Sevoflurane|Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
11441587|NCT01755234|Active Comparator|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
11441588|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|"Restech pH probe placement at initial clinic visit; Subject returns 24 hours later for probe removal
~Proton pump inhibitor (PPI) therapy; Subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later
~Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
11441589|NCT01755208|Experimental|Diagnostic (light-scattering spectroscopy)|Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.
11441590|NCT01755195|Experimental|1|60 mg tablets orally once a day in a 28-day cycle.
11441591|NCT01755182|Active Comparator|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
11441592|NCT01755182|Experimental|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
11441593|NCT01755169|Experimental|Ketamine 0.25 mg/kg/dose|A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
11441594|NCT01755169|Experimental|Ketamine 0.5 mg/kg/dose|A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
11441595|NCT01755169|Experimental|Ketamine 1 mg/kg/dose|A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
11441596|NCT01755169|Placebo Comparator|Placebo|
11441597|NCT01755156|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
11589245|NCT00723307|Experimental|Metformin|
11441598|NCT01755156|Placebo Comparator|Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
11441599|NCT01755143|Experimental|MRI Group|Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
11441600|NCT01755143|Sham Comparator|Control Group|Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.
11441601|NCT01755130|Experimental|LOUIS-3D Imaging Procedure|"Part I Years 1-4: Years 1-4 to develop and calibrate the LOUIS-3D machine. The subject of this project is to successfully obtain diagnostic imaging of breast tumors with new imaging technology, laser Optoacoustic Tomography system.
~Part 2 Year 5: Goal of part 2 to estimate and compare the false positive rate of LOUIS-3D compared to standard of care ultrasound. Patients will have had a positive standard of care ultrasound requiring a biopsy (gold standard). The LOUIS-3D images will be obtained within 7 days of the standard of care ultrasound."
11441602|NCT01755117|Active Comparator|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
11441603|NCT01755117|Active Comparator|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
11441604|NCT01755104|Experimental|Stablor|dietary supplement Stablor
11441605|NCT01755104|Placebo Comparator|Placebo|dietary supplement Placebo
11441606|NCT01755091|Placebo Comparator|Sugar Pill|Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
11441607|NCT01755091|Experimental|2.5 mg/day|Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
11441608|NCT01755091|Experimental|10 mg/day|Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
11441609|NCT01755078|Experimental|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
11441610|NCT01755078|Active Comparator|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
11441611|NCT01755065||Teenager laparoscopic patients|
11441612|NCT01755039||Patients with invasive out-of-hospital ventilation|
11441613|NCT01755026|Active Comparator|2 gram dose of cefazolin|2 gram dose of pre-operative cefazolin
11441614|NCT01755026|Experimental|4 gram Dose|4 gram dose of pre-operative prophylaxis
11441615|NCT01755013|Experimental|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
11441616|NCT01755000|Other|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.
~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.
~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
11441617|NCT01755000|Other|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.
~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.
~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.
~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
11441618|NCT01755000|Other|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).
~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.
~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
11441619|NCT01754987|Experimental|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate
~Dosage:
~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
11441620|NCT01754987|Other|Sorafenib alone|Sorafenib: taken daily (oral)
11441621|NCT01754974|Experimental|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
11441622|NCT01754974|Active Comparator|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
11441623|NCT01754961|Placebo Comparator|Placebo|Placebo will be given on Day 1 orally
11441624|NCT01754961|Active Comparator|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
11441625|NCT01754935|Experimental|VX-509 100 mg qd Arm|
11441626|NCT01754935|Experimental|VX-509 200 mg qd Arm|
11441627|NCT01754935|Experimental|VX-509 300 mg qd Arm|
11441628|NCT01754935|Placebo Comparator|Placebo Arm|
11441629|NCT01754922||Exposed|Veterans deployed to OEF/OIF/OND and environmentally exposed to high levels of particulate matter
11441630|NCT01754922||Control|OEF/OIF/OND Veterans deployed to regions other than Southwest Asia
11441631|NCT01754909|Active Comparator|enalapril|Use of enalapril in subjects undergoing radiotherapy for lung cancer.
11441632|NCT01754909|Placebo Comparator|placebo|Use of placebo in subjects undergoing radiotherapy for lung cancer
11441633|NCT01754896|Experimental|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
11441634|NCT01754896|Experimental|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
11442078|NCT01751594|Experimental|MOVE Intervention|
11441636|NCT01754896|Experimental|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
11441637|NCT01754883|Experimental|Lithium Augmentation|Open-label trial - active treatment
11441638|NCT01754870|Experimental|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:
~Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles
~Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)
~Maintenance phase:
~Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.
~Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
11441639|NCT01754857|Experimental|Bendamustine, rituximab, lenalidomide|"INDUCTION: Bendamustine 90mg/m2 IV D1&2 and rituximab IV D1 (up to day 5 of course 1) every 28 days for 6 cycles. Patients with objective response move to maintenance therapy. Patients with objective response after 4 courses are eligible to for maintenance therapy if ongoing induction therapy is associated w/unacceptable toxicity.
~MAINTENANCE: At 6-12 wks post induction therapy, patients receive rituximab IV on day 1 of odd-numbered cycles for 24 cycles; lenalidomide 5mg PO daily on days 1-21 of each cycle (28 day cycles). Dose escalation to 10mg daily on days 1-21 allowed at start of cycle 2 or at start of subsequent cycles in subjects w/acceptable toxicities. Lenalidomide dose escalation only allowed at start of a new cycle up to a max dose of 10 mg/day on days 1- 21. Subjects entering maintenance with CrCl ≥40 & <60mL/min will begin dosing at 5mg every other day on days 1-21. Patients with excessive toxicity from lenalidomide may continue maintenance therapy with rituximab alone."
11441640|NCT01754844|Experimental|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
11441641|NCT01754844|Placebo Comparator|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
11441642|NCT01754831|Other|Fluoride varnish|Topical fluoride
11441643|NCT01754818|Placebo Comparator|Placebo|Placebo, oral capsule, no active study drug, single dose
11441644|NCT01754818|Experimental|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
11441645|NCT01754818|Experimental|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
11441646|NCT01754818|Experimental|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
11441647|NCT01754805|Experimental|ASP015K and methotrexate|Patients receive a single dose of methotrexate on day 1 and day 8 and ASP015K (twice daily) on days 3 through 8 plus the morning of day 9.
11441648|NCT01754792|Experimental|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
11441649|NCT01754792|Experimental|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
11441650|NCT01754792|Experimental|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
11441651|NCT01754779|Placebo Comparator|Calcium Phosphate stone formers without hypercalciuria|Each subject will undergo 3 phases, the order of which will be randomized by a simple randomization scheme. The 3 phases will be Placebo, Citric Acid, and Potassium Citrate. Each phase will be 1 week in duration, during which subjects will take assigned study medications. A 1-week washout period is imposed between phases.
11441652|NCT01754779|Placebo Comparator|Calcium Phosphate stone formers with hypercalciuria|Each hypercalciuric CaP stone former will undergo 3 phases, the order of which will be randomized by a simple randomization scheme.
11441653|NCT01754766|Experimental|AGN-229666 Dose A|One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
11441654|NCT01754766|Experimental|AGN-229666 Dose B|One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
11441655|NCT01754766|Placebo Comparator|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
11441656|NCT01754753|Active Comparator|Telephone friendship groups|"Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.
~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network)."
11441657|NCT01754753|No Intervention|Usual health and social care|Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.
11441658|NCT01754740|Experimental|Study Group|19 patients whom received topical medication of urea 10%
11441659|NCT01754740|Placebo Comparator|Control Group|19 patients whom received placebo
11441660|NCT01754727||Participants with Ankylosing Spondylitis (AS)|Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
11441661|NCT01754714|Experimental|1000 mg SAMe (S-adenosyl-L-methionine)|
11441662|NCT01754714|Experimental|1500 mg SAMe|
11441663|NCT01754714|Experimental|2000 mg SAMe|
11441664|NCT01754714|No Intervention|No treatment|
11441665|NCT01754701|Experimental|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
11441666|NCT01754701|Experimental|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
11441667|NCT01754688||Jaundice infants|Bilirubin Induced Neurologic Dysfunction II score
11442151|NCT01751152|Placebo Comparator|Placebo|
11441668|NCT01754675|Experimental|Soccer|Watching the soccer match at the time that the favorite team is playing
11441669|NCT01754675|Placebo Comparator|Movie|Watching a movie at the time that the favorite team is playing
11441670|NCT01754662|Experimental|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
11441671|NCT01754662|Experimental|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
11441672|NCT01754662|Experimental|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
11441673|NCT01754662|Experimental|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
11441674|NCT01754662|Placebo Comparator|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
11441675|NCT01754649|Active Comparator|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
11441676|NCT01754649|Placebo Comparator|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
11441677|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
11441678|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
11441679|NCT01754623|Experimental|Chemotherapy Followed by Radiation Treatment|"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).
~After radiation, participants will be re-evaluated for surgery."
11441680|NCT01754610||Families participating in SFCR|Families who have experienced multiple traumas and high stress related to poverty
11441681|NCT01754597|Experimental|Peptide Natriurétique de type B|Peptide Natriurétique de type B
11441682|NCT01754571|Experimental|CBT treatment|
11441683|NCT01754558|Experimental|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
11441684|NCT01754558|Experimental|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
11441685|NCT01754545|Experimental|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
11441686|NCT01754545|Experimental|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
11441687|NCT01754532||Schizophrenia patients|
11441688|NCT01754519|Experimental|Treatment (radiation therapy)|Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
11441689|NCT01754506|Experimental|EPA+DHA|EPA+DHA (fish oil)
11441690|NCT01754506|Placebo Comparator|Placebo|mineral oil
11441691|NCT01754493|Experimental|Treatment with Duloxetine|Patients will receive open treatment with Duloxetine
11441692|NCT01754480|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
11441693|NCT01754480|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
11441694|NCT01754467|Experimental|NEAT!|Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.
11441695|NCT01754454|Experimental|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:
~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
11441696|NCT01754415|No Intervention|control|Do exercise at home with video program designed by our team.
11441697|NCT01754415|Experimental|hydraulic resistance circuit training|Intervention:12 weeks resistance training
11441698|NCT01754402|Experimental|Cohort 1: benda 120mg + pom 3mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days
~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days
~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
11441699|NCT01754402|Experimental|Cohort 2: benda 120mg + pom 4mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days
~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days
~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
11441700|NCT01754402|Experimental|Expansion|"Pomalidomide 3mg: once daily oral (PO) dosing on days 1-21, every 28 days
~Bendamustine 120 mg: once intravenous (IV) dosing on day 1, every 28 days
~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
11441701|NCT01754389|Active Comparator|Arm A (Standard of Care)|Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
11441702|NCT01754389|Experimental|Arm B (Experimental)|Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
11441703|NCT01754389|Experimental|Arm C (Experimental)|Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
11441704|NCT01754376|Experimental|Treatment Arm|"Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)
~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.
~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression."
11441827|NCT01753453|Active Comparator|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
11441705|NCT01754363||Attune Primary Total Knee Replacement|"Subjects will receive one of the following Attune total knee implants:
~Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)"
11441706|NCT01754350|Experimental|ketogenic diet and transient fasting|Calorie-restricted, ketogenic diet and transient fasting during reirradiation
11441707|NCT01754350|Active Comparator|standard nutrition|nutrition according to recommendations of the German society for nutrition during reirradiation
11441708|NCT01754337|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
11441709|NCT01754337|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
11441710|NCT01754337|Active Comparator|Insulin pump therapy|Patient's conventional treatment will be implemented.
11441711|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
11441712|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
11441713|NCT01754311||control|Blood donors
11441714|NCT01754298|Active Comparator|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
11441715|NCT01754298|Active Comparator|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
11441716|NCT01754285|Experimental|LF-PB 10 mg|2 IM injections = placebo + 10 mg
11441717|NCT01754285|Experimental|LF-PB 20 mg|2 IM injections = placebo + 20 mg
11441718|NCT01754285|Experimental|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
11441719|NCT01754285|Placebo Comparator|Placebo|2 IM injections of placebo
11441720|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
11441721|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
11441722|NCT01754259|Experimental|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
11441723|NCT01754259|Placebo Comparator|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
11441724|NCT01754246|Experimental|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
11441725|NCT01754246|Experimental|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
11441726|NCT01754233|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
11441727|NCT01754220|Active Comparator|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
11441728|NCT01754207|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
11441729|NCT01754207|Experimental|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
11441730|NCT01754194||Procedure Type 1|Gastric Sleeve Resection
11441731|NCT01754194||Procedure Type 2|Roux-en-Y Gastric Bypass
11441732|NCT01754181|Experimental|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
11441733|NCT01754181|No Intervention|usual treatment|
11441734|NCT01754155|Other|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
11441735|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
11441736|NCT01754129||Participants with Parkinson's disease|Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label
11441737|NCT01754116|Experimental|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
11441738|NCT01754116|Experimental|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
11441739|NCT01754116|Experimental|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
11441740|NCT01754116|Experimental|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
11441741|NCT01754116|Experimental|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
11441742|NCT01754103|Experimental|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
11589949|NCT00718159|Experimental|LY573636|
11441743|NCT01754090|Active Comparator|Usual care|"Receives two interventions:
~Online screening and feedback.
~Online booklet."
11441744|NCT01754090|Experimental|Extended follow-up|"Receives two interventions:
~Online screening and feedback.
~Online multi session follow-up."
11441745|NCT01754077|Experimental|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
11441746|NCT01754077|Other|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
11441747|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
11441748|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
11441749|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
11441750|NCT01754025||Cancer patients with T790M|Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (>40% allelic fraction) EGFR T790M. OR another EGFR mutation previously reported as germline detected on tumor genotyping of their cancer.
11441751|NCT01754025||Relatives of Carriers|Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
11441752|NCT01754025||Individuals known to be carriers|Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)
11441753|NCT01754012|Experimental|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
11441754|NCT01754012|No Intervention|Control Group|This group will follow the habitual diet.
11441755|NCT01753999|Active Comparator|Standard CPAP|Use of a standard CPAP (continuous positive airway pressure) device with constant pressure for 4 weeks to improve breathing during sleep
11441756|NCT01753999|Active Comparator|CPAP - Flex|Use of CPAP-Flex (continuous positive airway pressure) device with decreased pressure during expiration for 4 weeks to improve breathing during sleep
11441757|NCT01753986|Experimental|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
11441758|NCT01753986|Placebo Comparator|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
11441759|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
11441760|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
11441761|NCT01753947|Experimental|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
11441762|NCT01753947|No Intervention|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
11441763|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
11441764|NCT01753921||Healthy control|Control subjects without diabetes.
11441765|NCT01753908|Experimental|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
11441766|NCT01753908|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
11441767|NCT01753882|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
11441768|NCT01753882|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
11441769|NCT01753869|Active Comparator|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
11441770|NCT01753869|Active Comparator|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
11441771|NCT01753856|Experimental|Teriparatide|"20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.
~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.
~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.
~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.
~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
11441828|NCT01753453|Experimental|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
11441999|NCT01752244|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
11590227|NCT00716053|Sham Comparator|Saline|
11441772|NCT01753856|Active Comparator|Denosumab|"60 mg denosumab administered SC once in 6 months.
~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.
~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.
~Calcium: Approximately 1000 mg/day administered orally.
~Vitamin D: Approximately 800 to 1200 IU/day administered orally."
11441773|NCT01753843|Active Comparator|early cord clamping|cord clamping within 20 sec
11441774|NCT01753843|Experimental|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
11441775|NCT01753830|Experimental|Durolane|Single intraarticular injection of Durolane
11441776|NCT01753830|Placebo Comparator|PBS|Single intraarticular injection of PBS
11441777|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
11441778|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
11441779|NCT01753791|Experimental|Cohort 1|
11441780|NCT01753791|Experimental|Cohort 2|
11441781|NCT01753791|Experimental|Cohort 3|
11441782|NCT01753791|Experimental|Cohort 4|
11441783|NCT01753778|Experimental|Treatment|Treatment with Cryo-Touch III Device at Day 0
11441784|NCT01753765|Experimental|Treatment|Study treatment with Cryo-Touch III device at Day 0.
11441785|NCT01753752|Experimental|Chitosan-N-acetylcystein|Instillation into the study eye
11441786|NCT01753752|Placebo Comparator|Placebo|Instillation into the fellow eye
11441787|NCT01753739|Experimental|Bepotastine besilate Concentration 1|Bepotastine besilate nasal spray, BID for 14 days.
11441788|NCT01753739|Active Comparator|Placebo|Placebo nasal spray BID for 14 days
11441789|NCT01753739|Experimental|Bepotastine besilate Concentration 2|Bepotastine besilate nasal spray, BID for 14 days.
11441790|NCT01753739|Experimental|Bepotastine besilate Concentration 3|Bepotastine besilate nasal spray, BID for 14 days.
11441791|NCT01753739|Experimental|Bepotastine besilate Concentration 4|Bepotastine besilate nasal spray, BID for 14 days.
11441792|NCT01753726|Experimental|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
11441793|NCT01753726|Placebo Comparator|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
11441794|NCT01753713|Experimental|Anti-angiogenic Therapy Naive Patients|Patients who have progressed without anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11441795|NCT01753713|Experimental|Anti-angiogenic Therapy Patients|Patients who have progressed on anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11441796|NCT01753700|Experimental|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
11441797|NCT01753700|Placebo Comparator|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
11441798|NCT01753687|Other|50 patients with dry eye syndrome|
11441799|NCT01753674|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
11441800|NCT01753674|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
11441801|NCT01753661|Experimental|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
11441802|NCT01753661|Active Comparator|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
11441803|NCT01753648|Experimental|hypertensive retinopathy|30 patients with hypertensive retinopathy stage 2 or 3
11441804|NCT01753648|Experimental|healthy controls|30 healthy age- and sex-matched controls
11441805|NCT01753635|Experimental|Baska mask|In this arm the Baska mask will be used as the airway management device
11441806|NCT01753635|Active Comparator|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
11441807|NCT01753622|No Intervention|Control group|Sedentary Obese and overweight pregnant women
11441808|NCT01753622|Experimental|Exercise group|Physical exercise program
11441809|NCT01753609|Experimental|Tulip capsule|swallowing Tulip capsule for up to 29 days
11441810|NCT01753596|Experimental|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
11441811|NCT01753596|Experimental|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
11441812|NCT01753583|Experimental|10 patients with corneal abrasions|
11441813|NCT01753583|Experimental|10 patients with corneal infiltrates|
11441814|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype1|
11441815|NCT01753570|Experimental|RBV+IFN beta, Genotype1|
11441816|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype2|
11441817|NCT01753557|Experimental|Treatment-Naive|
11441818|NCT01753557|Experimental|Treatment-Relapsed|
11441819|NCT01753531||Flu Symptoms|
11441820|NCT01753518|Active Comparator|Subcuticular suture|Subcuticular suture has been used for many years to close skin incisions.
11441821|NCT01753518|Active Comparator|Subcuticular staple|Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.
11441822|NCT01753505|Experimental|MDCTA|
11441823|NCT01753492|Experimental|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
11441824|NCT01753479|Experimental|Test subject|
11441825|NCT01753466|Experimental|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
11441826|NCT01753466|No Intervention|Control|
11441829|NCT01753440|Other|Stem cells implantation|Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age <75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.
11441830|NCT01753414|Other|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
11441831|NCT01753414|Experimental|Sterotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
11441832|NCT01753401|Experimental|Period 2: Placebo/Acthar|Participants receive Placebo in Part 1, but after completion of Week 8 in the double-blind phase, patients who received Placebo may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen during Part 2 may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
11441833|NCT01753401|Experimental|Period 2: Acthar/Acthar|After completion of Week 8 in the double-blind phase, patients who received Acthar may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
11441834|NCT01753401|Placebo Comparator|Period 1: Placebo|Participants receive matching placebo (in 0.5 mL daily or in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
11441835|NCT01753401|Experimental|Period 1: Acthar|Participants receive Acthar (40 units in 0.5 mL daily or 80 units in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
11441836|NCT01753388|Experimental|Treatment by the Liberty Stent|
11441837|NCT01753375|Active Comparator|Vitamin D3|Administered orally on weekly basis
11441838|NCT01753375|Placebo Comparator|Placebo|To be administered orally on weekly basis
11441839|NCT01753362|Placebo Comparator|placebo|subcutaneous daily injection
11441840|NCT01753362|Active Comparator|liraglutide|subcutaneous daily injection
11441841|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia. BoNT-A injections, 3-4 times yearly.
11441842|NCT01753336|Experimental|Dysport®|Dysport®, up to 500 units (U)/vial using 2mL dilution
11441843|NCT01753323|Experimental|Part 1 - Cohort 1: P. vivax: KAF156 400mg QD|Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
11441844|NCT01753323|Experimental|Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD|Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
11441845|NCT01753323|Experimental|Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose|Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
11441846|NCT01753310|Active Comparator|Dysport®|Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
11441847|NCT01753310|Placebo Comparator|Placebo|Placebo, up to 2mL
11441848|NCT01753297|Active Comparator|Triptorelin, 11.25 mg|Triptorelin, powder and solvent for suspension (prolonged released form)
11441849|NCT01753297|No Intervention|Active surveillance|Active surveillance after radical prostatectomy (RP)
11441850|NCT01753271|Experimental|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
11441851|NCT01753271|Active Comparator|exercise only|shoulder mobilization plus exercise alone
11441852|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
11441853|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
11441854|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
11441855|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
11441856|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
11441857|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
11441858|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
11441859|NCT01753219|Experimental|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
11441860|NCT01753219|Active Comparator|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
11441861|NCT01753193|Experimental|Anifrolumab|Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
11441862|NCT01753180|Experimental|collagenase|
11441864|NCT01753167|Experimental|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
11441865|NCT01753167|Placebo Comparator|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
11441866|NCT01753154|Experimental|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
11441867|NCT01753154|Active Comparator|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
11441868|NCT01753141|Experimental|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
11441869|NCT01753141|Active Comparator|Control|Cognitive Behavioral Therapy for smoking cessation.
11441870|NCT01753128|Active Comparator|imipramine|
11441871|NCT01753115|Experimental|BioThrax + Ciprofloxacin PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
11441872|NCT01753115|Experimental|BioThrax + Ciprofloxacin no PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
11441873|NCT01753115|Experimental|BioThrax only|BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
11441874|NCT01753102|Experimental|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
11441875|NCT01753102|Active Comparator|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
11441876|NCT01753102|Placebo Comparator|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
11441877|NCT01753089|Other|WDVAX|Treatment
11441878|NCT01753076|Experimental|Ozanezumab IV|Administered by IV route. Treatment period - 48 Weeks
11441879|NCT01753076|Placebo Comparator|Placebo|Normal saline by IV route. Treatment period - 48 weeks
11441880|NCT01753063|Experimental|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
11441881|NCT01753050|No Intervention|Standard care|No specific hemodynamic optimization measures
11441882|NCT01753050|Experimental|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
11441883|NCT01753037|Active Comparator|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
11441884|NCT01753037|Placebo Comparator|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
11441885|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
11441886|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
11441887|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
11441888|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
11441889|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
11441890|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
11441891|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
11441892|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
11441893|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
11441894|NCT01752998|Active Comparator|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
11441895|NCT01752998|Placebo Comparator|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
11441896|NCT01752985|Experimental|Arm A: BMS-813160 150 mg & Placebo matching with BMS-813160|BMS-813160 150 mg capsules by mouth in AM and Placebo matching with BMS-813160 in PM for 12 weeks
11441897|NCT01752985|Experimental|Arm B: BMS-813160 300 mg|BMS-813160 300 mg capsules by mouth twice daily for 12 weeks
11441898|NCT01752985|Placebo Comparator|Arm C: Placebo matching with BMS-813160|Placebo matching with BMS-813160 0 mg capsules by mouth twice daily for 12 weeks
11441899|NCT01752972|Experimental|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
11441900|NCT01752972|Active Comparator|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
11441901|NCT01752972|Active Comparator|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
11441902|NCT01752959|Active Comparator|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
11441903|NCT01752959|Experimental|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
11441904|NCT01752933|Experimental|SGI-110|SGI-110 administered subcutaneously (SC) daily on Days 1 - 5 every 28 days
11441905|NCT01752920|Experimental|derazantinib|"Subjects will receive derazantinib orally at dose levels specified for their respective dose cohorts on a 28-day schedule.
~Subjects will receive treatment with derazantinib until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented."
11441906|NCT01752907|Experimental|General Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side effects education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
11442002|NCT01752205|Active Comparator|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
11590268|NCT00715793|Experimental|Single Arm|
11441907|NCT01752907|Experimental|Bone Pain Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a bone pain education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
11441908|NCT01752894|Active Comparator|Angio guided PCI|
11441909|NCT01752894|Experimental|OCT-guided PCI|
11441910|NCT01752894|Active Comparator|BES|
11441911|NCT01752894|Experimental|EES|
11441912|NCT01752894|Active Comparator|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
11441913|NCT01752894|Active Comparator|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
11441914|NCT01752881|Experimental|AdimFlu-S|
11441915|NCT01752868|Experimental|supplement|
11441916|NCT01752868|No Intervention|control|
11441917|NCT01752855|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
11441918|NCT01752842|Experimental|Fenofibrate|One fenofibrate 160 mg capsule per day for 12 weeks
11441919|NCT01752842|Placebo Comparator|Placebo for fenofibrate|One inert sugar pill per day for 12 weeks
11441920|NCT01752816|Active Comparator|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
11441921|NCT01752816|Experimental|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
11441922|NCT01752803|Experimental|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
11441923|NCT01752803|Placebo Comparator|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
11441924|NCT01752790|Experimental|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
11441925|NCT01752790|Active Comparator|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
11441926|NCT01752777|Experimental|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
11441927|NCT01752777|Sham Comparator|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
11441928|NCT01752764|Experimental|Test product|Test product: Salad with high dosage fat
11441929|NCT01752764|Other|Control product|Control product: Salad with low dosage fat
11441930|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
11441931|NCT01752725|Experimental|BiCision Arm|Coagulation with BiCision
11441932|NCT01752725|Active Comparator|Ultracision Arm|Coagulation with Ultracision
11441933|NCT01752712|Experimental|CBSST + oxytocin|Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
11441934|NCT01752712|Placebo Comparator|CBSST + placebo|Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
11441935|NCT01752699|Experimental|Methadone|in this arm patients will take methadone 5mg.
11441936|NCT01752699|Experimental|Placebo|in this arm patients will take placebo pills.
11441937|NCT01752686|Experimental|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
11441938|NCT01752686|No Intervention|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
11441939|NCT01752673|Experimental|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
11441940|NCT01752673|Active Comparator|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
11441941|NCT01752660|Experimental|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
11441942|NCT01752660|Active Comparator|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
11441943|NCT01752647|Experimental|Low dose computed tomography|Patients will have one baseline LDCT scan.
11441944|NCT01752634|Experimental|Secukinumab (AIN457) 75 mg s.c.|Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
11441945|NCT01752634|Experimental|Secukinumab (AIN457) 150 mg s.c.|Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
11441946|NCT01752634|Experimental|Secukinumab (AIN457) 300 mg s.c.|Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
11442075|NCT01751620|Active Comparator|HEALTH|Participants randomized to the comparison (HEALTH) arm.
11590269|NCT00715780||A|
11441947|NCT01752634|Placebo Comparator|Placebo s.c.|Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4. Non-responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 16. Responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 24.
11441948|NCT01752621||acromegaly|patients with acromegaly
11441949|NCT01752621||comparison population|matched background population
11441950|NCT01752608|Experimental|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
11441951|NCT01752608|No Intervention|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
11441952|NCT01752595|No Intervention|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
11441953|NCT01752595|Active Comparator|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
11441954|NCT01752595|Active Comparator|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
11441955|NCT01752582|Other|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).
~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
11441956|NCT01752582|Other|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).
~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
11441957|NCT01752569|Experimental|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
11441958|NCT01752556|Active Comparator|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
11441959|NCT01752556|Experimental|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
11441960|NCT01752543|Active Comparator|Conivaptan|10 patients will be randomized to conivaptan treatment
11441961|NCT01752543|Placebo Comparator|Dextrose|10 patients will receive placebo treatment (dextrose)
11441962|NCT01752530|Experimental|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
11441963|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
11441964|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
11441965|NCT01752504|Experimental|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
11441966|NCT01752491|Experimental|15g Ascorbate|"During radiation therapy:
~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.
~Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.
~Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).
~After radiation therapy:
~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
11441967|NCT01752491|Experimental|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.
~During radiation therapy:
~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
~Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).
~After radiation therapy:
~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
11441968|NCT01752491|Experimental|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.
~During radiation therapy:
~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
~Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
~After radiation therapy:
~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
11442000|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
11442001|NCT01752218|Experimental|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
11441969|NCT01752491|Experimental|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.
~During radiation therapy:
~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
~Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
~After radiation therapy:
~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
11441970|NCT01752491|Experimental|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.
~During radiation therapy:
~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
~Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
~After radiation therapy:
~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
11441971|NCT01752491|Experimental|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.
~During radiation therapy:
~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.
~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.
~Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).
~After radiation therapy:
~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.
~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
11441972|NCT01752465|Active Comparator|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
11441973|NCT01752465|Experimental|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
11441974|NCT01752439|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
11441975|NCT01752439|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
11441976|NCT01752439|No Intervention|Control group|
11441977|NCT01752426|Experimental|Heavy Water + PCI-32765|Subjects given 50ml 70% 2H2O (Heavy Water) 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks (labeling phase). Subjects given first dose in clinic. Subjects then given individual doses of 2H2O to consume at home; after the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765. PCI-32765 administered with 8 ounces (~240mL) of water at a dose of 420 mg (3 x 140mg capsules) orally once daily and continued daily. Treatment duration is 12 cycles, with each cycle consisting of 28 days.
11441978|NCT01752413|Experimental|Ferrous gluconate 325mg|Those found iron depleted by ferritin measure will receive 325 mg Ferrous gluconate twice a day for 100 days. They will be deferred as a whole blood donor for 120 days until completion of iron therapy. They will receive standard dietary counseling.
11441979|NCT01752413|Active Comparator|Nutrition counseling|For those consenting to this study but who demonstrate adequate ferritin levels (>20 micrograms/L female, >30 micrograms/L males), they will not receive oral iron or additional deferral period but will be allowed to donate after the standard 56 days. They will receive standard counseling about iron rich foods. Rate and frequency of subsequent donations will be tracked and compared to those receiving iron supplementation.
11441980|NCT01752400|Experimental|AUY922|Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
11441981|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
11441982|NCT01752374||Granisetron group|
11441983|NCT01752374||Ramosetron group|
11441984|NCT01752361||Ulcerative Colitis|
11441985|NCT01752348|Placebo Comparator|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
11441986|NCT01752348|Experimental|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
11441987|NCT01752348|Experimental|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
11441988|NCT01752348|Experimental|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
11441989|NCT01752335|Other|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.
~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
11441990|NCT01752322|Experimental|Lidocaine plaster|Topical hydrogel plaster
11441991|NCT01752322|Placebo Comparator|Placebo plaster|Topical hydrogel plaster
11441992|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
11441993|NCT01752283|Experimental|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
11441994|NCT01752283|Active Comparator|General anesthesia|Video-assisted thyroidectomy under general anesthesia
11441995|NCT01752270|Experimental|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
11441996|NCT01752270|No Intervention|blank control|
11441997|NCT01752257|Other|EF5 Hypoxia|EF5 administered at 21mg/kg
11441998|NCT01752244|Experimental|Alfacalcidol|Alfacalcidol
11442003|NCT01752205|Experimental|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
11442004|NCT01752192|Experimental|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
11442005|NCT01752192|No Intervention|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
11442006|NCT01752179|Experimental|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
11442007|NCT01752179|No Intervention|Control group|without using Kinesio tape
11442008|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
11442009|NCT01752153|Experimental|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
11442010|NCT01752153|Experimental|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
11442011|NCT01752140|Active Comparator|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
11442012|NCT01752140|Active Comparator|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
11442013|NCT01752127|Active Comparator|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
11442014|NCT01752127|Active Comparator|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
11442015|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
11442016|NCT01752049|Active Comparator|Topical timolol maleate|"Drug: • Topical timolol maleate 0.5% drops
~Topical timolol maleate 0.5% drops
~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions
~Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient)."
11442017|NCT01752049|Placebo Comparator|Placebo|"placebo saline drops
~-Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient."
11442018|NCT01752036|Other|Treatment|Post-Operative Stereotactic Radiosurgery
11442019|NCT01752023|Experimental|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
11442020|NCT01752023|Active Comparator|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
11442021|NCT01752010|Active Comparator|Acupuncture Treatment|Traditional Chinese acupuncture.
11442022|NCT01752010|Active Comparator|Tennant™ Biomodulator Treatment|
11442023|NCT01752010|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) Treatment|
11442024|NCT01751997|Active Comparator|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
11442025|NCT01751997|Experimental|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
11442026|NCT01751984|Experimental|ETC-1002|ETC-1002 treatment, once daily oral
11442027|NCT01751984|Placebo Comparator|Placebo|Placebo treatment, once daily oral
11442028|NCT01751971|Active Comparator|Inspired Oxygen First|Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
11442029|NCT01751971|Sham Comparator|Sham First|Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).
11442030|NCT01751958|Experimental|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
11442031|NCT01751958|Experimental|Epidural Steroid Injection2|Group-injection under angiography (continuous)
11442032|NCT01751945|Experimental|EmONC package|"The EmONC package consists of:
~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.
~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.
~Community mobilisation"
11442033|NCT01751945|No Intervention|Standard of care|Standard care as per national policy
11442034|NCT01751932|Experimental|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
11442035|NCT01751919|Other|Group 1 (RT)|"Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)
~Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
11442036|NCT01751919|Other|Group 2 (TR)|"Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)
~Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
11442037|NCT01751906|Experimental|Absorb BVS|Subjects receiving Absorb BVS
11442038|NCT01751906|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
11442039|NCT01751893|Experimental|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
11442040|NCT01751893|Placebo Comparator|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.
11442041|NCT01751880|Experimental|Exercise Group|
11442042|NCT01751867|Experimental|3-Day Dose schedule|Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
11442043|NCT01751867|Experimental|5-Day Dose schedule|Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.
11442044|NCT01751854|Experimental|SSRI|SSRI alone or with training
11442045|NCT01751854|Placebo Comparator|Placebo|Placebo alone or with training
11442046|NCT01751841||Spinal fusion patients with MIS surgery|Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
11442047|NCT01751828|Experimental|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
11442048|NCT01751815|Experimental|Acu-TENS|
11442049|NCT01751815|Sham Comparator|Placebo-TENS|
11442050|NCT01751802|Experimental|Ecopipam|Active substance being tested, orally once a day at bedtime
11442051|NCT01751802|Placebo Comparator|Placebo|Inactive substance being tested, orally once a day at bedtime
11442052|NCT01751789|Active Comparator|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
11442053|NCT01751789|Placebo Comparator|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
11442054|NCT01751776|Experimental|BI 655064 Part 1|3 different doses plus placebo in healthy volunteers
11442055|NCT01751776|Experimental|BI 655064 Part 2|2 different doses plus placebo in rheumatoid arthritis patients
11442056|NCT01751763||Group 1|
11442057|NCT01751750|Other|Grape|
11442058|NCT01751737|Experimental|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.
~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.
~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
11442059|NCT01751724|Experimental|Caffeine Arm|Subjects randomized to this arm will receive blinded Caffeine citrate.
11442060|NCT01751724|Placebo Comparator|Placebo Arm|Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).
11442061|NCT01751698|Active Comparator|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
11442062|NCT01751698|Active Comparator|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
11442063|NCT01751685|Experimental|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
11442064|NCT01751685|Placebo Comparator|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
11442065|NCT01751672|Active Comparator|SBIRT|Screening, Brief Intervention, and Referral to Treatment
11442066|NCT01751672|Experimental|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment
11442067|NCT01751659||Phase I|"Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.
~The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
11442068|NCT01751659||Phase II|"Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).
~The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
11442069|NCT01751659||Phase III|"Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.
~The total duration of Phase 3 will last approximately six to nine months."
11442070|NCT01751646|Experimental|Group A: Vitamin D3 50,000 IU|Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
11442071|NCT01751646|Placebo Comparator|Group B: Vitamin D3 placebo|Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
11442072|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:
~Posterior open approach
~Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
11442073|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
11442074|NCT01751620|Experimental|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
11591256|NCT00708838||5|
11442079|NCT01751581|Active Comparator|Habitual Sleep|Women sleep 8 h/night throughout the study phase
11442080|NCT01751581|Experimental|Short Sleep|Women sleep 4 h/night throughout the study phase
11442081|NCT01751568|Experimental|4 Weeks to Less than 12 Years of Age|Participants will receive chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily, in addition to two NRTIs to treat HIV and a rifampicin-containing regimen to treat TB. Participants will be enrolled into the study into three cohorts: Cohort I: 2 years of age to less than 6 years of age, Cohort II: 6 years of age to less than 12 years of age, and Cohort III: 4 weeks of age to less than 2 years of age. After a study visit at Day 5 to 8, a fourth ARV medication will be added to the regimen.
11442082|NCT01751555|Experimental|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
11442083|NCT01751542|Experimental|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
11442084|NCT01751542|Active Comparator|Residential Treatment|Residential treatment alone
11442085|NCT01751529|Experimental|Contrast-enhanced Ultrasound|
11442086|NCT01751503|Active Comparator|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
11442087|NCT01751503|Active Comparator|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
11442088|NCT01751490|Active Comparator|physiotherapy alone|patients undergoing physiotherapy only
11442089|NCT01751490|Active Comparator|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
11442090|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
11442091|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
11442092|NCT01751464|Experimental|WrapAround Care|
11442093|NCT01751451|Experimental|Abiraterone acetate|"Group 1
~Abiraterone acetate 1000 mg daily x 8 months
~Prednisone 5 mg once daily x 8 months"
11442094|NCT01751451|Experimental|Abiraterone acetate and Degarelix|"Group 2
~Abiraterone acetate 1000 mg daily x 8 months
~Prednisone 5 mg once daily x 8 months
~Degarelix subcutaneous depot injection q 1 month x 8 months"
11442095|NCT01751451|Experimental|Degarelix|"Group 3
~• Degarelix subcutaneous depot injection q 1 month x 8 months"
11442096|NCT01751438|Experimental|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST). Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
11442097|NCT01751438|Experimental|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
11442098|NCT01751425|Experimental|Treatment (TKIs, ruxolitinib)|Participants receive commercially available TKIs (imatinib mesylate, nilotinib, or dasatinib) as they had been receiving during the last 6 months and ruxolitinib PO BID. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
11442099|NCT01751412|Experimental|Proton Radiation|Delivered daily (Monday-Friday) for two to five weeks.
11442100|NCT01751399|Experimental|LY2605541-Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541
11442101|NCT01751399|Experimental|LY2605541-Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
11442102|NCT01751399|Experimental|LY2605541-Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
11442103|NCT01751399|Experimental|LY2605541-Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
11442104|NCT01751386|Experimental|Baclofen|Baclofen 10 mg t.i.d.
11442105|NCT01751386|Placebo Comparator|Placebo|Placebo t.i.d.
11442106|NCT01751373|Active Comparator|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
11442107|NCT01751373|Experimental|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
11442108|NCT01751360|Experimental|SYR-472 100mg|SYR-472 100mg
11442109|NCT01751347|Active Comparator|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
11442110|NCT01751347|Experimental|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
11442111|NCT01751334|Experimental|Mobile Bearing|Mobile bearing total knee arthroplasty
11442112|NCT01751334|Active Comparator|Fixed Bearing|Fixed Bearing total knee arthroplasty
11442113|NCT01751321|Other|sitagliptin, metformin, placebo|"group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day
~group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
11442114|NCT01751308|Experimental|Phase 1: Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
11442115|NCT01751308|Experimental|Phase 1: Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
11442116|NCT01751308|Experimental|Phase 1: Cabazitaxel 30 mg/m^2|Cabazitaxel 30 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
11442117|NCT01751308|Experimental|Phase 1: Cabazitaxel 35 mg/m^2|Cabazitaxel 35 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
11442118|NCT01751308|Experimental|Phase 2: Cabazitaxel 30 mg/m^2|Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
11442119|NCT01751295|Active Comparator|atorvastatin|PCI with atorvastatin pre-treatment group
11442120|NCT01751295|No Intervention|control|PCI without atorvastatin pre-treatment group
11442121|NCT01751282|Placebo Comparator|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
11442122|NCT01751282|Sham Comparator|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
11442123|NCT01751282|Experimental|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
11442124|NCT01751269|Experimental|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
11442125|NCT01751269|Placebo Comparator|Normal Saline|Ascending Single and multiple dose of normal saline.
11442126|NCT01751256|Experimental|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
11442127|NCT01751256|No Intervention|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
11442128|NCT01751243|Placebo Comparator|Group 0|Haploidentical transplantation of hematopoietic progenitors
11442129|NCT01751243|Experimental|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
11442130|NCT01751243|Experimental|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
11442131|NCT01751243|Experimental|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
11442132|NCT01751243|Experimental|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
11442133|NCT01751243|Experimental|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
11442134|NCT01751230|Experimental|WIC E-Moms|If picked for this group, you will receive a personalized diet and exercise plan to help you lose the weight you gained during your pregnancy. All information will be given to you using a SmartPhone, such as an iPhone. You can use your own phone or one can be loaned to you for the study. You will also be loaned a scale so you can weigh yourself at home. You will also get advice and services from your WIC clinic.
11442135|NCT01751230|No Intervention|WIC Moms|You will get advice and services for nutrition and weight management after pregnancy from your WIC clinic.
11442136|NCT01751217|Experimental|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
11442137|NCT01751217|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
11442138|NCT01751217|Active Comparator|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
11442139|NCT01751204|Active Comparator|Calcium tablet|250 mg calcium/tablet
11442140|NCT01751204|Experimental|Calcium ion water (250mg)|250 mg calcium in 200 ml water
11442141|NCT01751204|Experimental|Calcium ion water (125mg)|125 mg calcium in 200 ml water
11442142|NCT01751191||Training set-chronic response to propranolol|
11442143|NCT01751191||Validation set-chronic response to propranolol|
11442144|NCT01751191||Acute response to propranolol|
11442145|NCT01751178|Active Comparator|Mouthwash with Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
11442146|NCT01751178|Active Comparator|Mouthwash without Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
11442147|NCT01751165|Experimental|HZ/su-0,2 Group|Subjects will receive HZ/su vaccine on a 0,2-month schedule.
11442148|NCT01751165|Experimental|HZ/su-0,6 Group|Subjects will receive HZ/su vaccine on a 0,6-month schedule.
11442149|NCT01751165|Experimental|HZ/su-0,12 Group|Subjects will receive HZ/su vaccine on a 0,12-month schedule.
11442150|NCT01751152|Experimental|NNC0114-0006|
11442152|NCT01751139|Other|Total Group|Subjects six months of age and older at the time of enrolment, recruited from randomly selected households originating from preselected mapped communities. Preferably the recruitment period occurred outside of the peak dengue transmission season, and continued until each site had reached its foreseen target. The expected period for recruiting the target sample size was approximately three months. Recruitment of replacement subjects was done during the low dengue transmission and the recruitment period depended on the number of subjects that need to be replaced. Enrolled subjects were subjects who either lived in households in study areas with support from the Family Health Physician Program (FHP) or the Larval Index Rapid Assay (LIRA) or with field research experience in the community (preferred) or where a similar system of mapped communities with potential for surveillance existed.
11442153|NCT01751126|Experimental|Ciclosporin|One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
11442154|NCT01751126|Experimental|Ciclosporin/Placebo|One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
11442155|NCT01751126|Placebo Comparator|Placebo|One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
11442156|NCT01751113|Active Comparator|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
11442157|NCT01751113|Active Comparator|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
11442158|NCT01751113|Active Comparator|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
11442159|NCT01751100|Active Comparator|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
11442160|NCT01751100|Experimental|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
11442161|NCT01751087|Other|Osmotic dilators + placebo (vit c) + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
11442162|NCT01751087|Active Comparator|Osmotic dilators + placebo (vit c) + misoprostol|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
11442163|NCT01751087|Active Comparator|Osmotic dilators + mifepristone + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
11442164|NCT01751074|Experimental|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
11442165|NCT01751074|Experimental|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
11442166|NCT01751061|Experimental|Decision aid|Web-based decision aid (decision support tool) provided to surrogate decision maker
11442167|NCT01751061|Active Comparator|Usual care|usual care in an intensive care unit setting
11442168|NCT01751048|Experimental|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
11442169|NCT01751048|Experimental|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
11442170|NCT01751048|Experimental|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
11442171|NCT01751035|Placebo Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
11442172|NCT01751035|Experimental|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
11442173|NCT01751022|Experimental|Attain Performa LV Lead (Models 4298, 4398, 4598)|N/A: single arm study, separate analysis for each lead model (total of 3).
11442174|NCT01751009|Experimental|Vitamin A supplements|Sprinkles with Vitamin A
11442175|NCT01751009|Active Comparator|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
11442176|NCT01750996|No Intervention|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
11442177|NCT01750996|Experimental|Strongest Families|Strongest Families intervention
11442178|NCT01750983|Experimental|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.
~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.
~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
11442179|NCT01750970|Experimental|Resection under blue light|
11442180|NCT01750970|Active Comparator|Resection under white light|
11442181|NCT01750957|Placebo Comparator|Placebo|
11442182|NCT01750957|Experimental|RO4917523 Dose A|
11442183|NCT01750957|Experimental|RO4917523 Dose B|
11442184|NCT01750944|Experimental|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.
~Intervention: ankle first"
11442185|NCT01750944|Experimental|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.
~Intervention: toe first"
11442186|NCT01750931|Other|Meloxicam GSK 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
11591744|NCT00705549|Experimental|6|Taxotere
11442187|NCT01750931|Other|Mobic 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
11442188|NCT01750918|Experimental|Part 1: Dabrafenib and Panitumumab|In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams [mg] twice daily) and panitumumab (6 milligrams per kilogram [mg/kg] every-2-week [Q2W]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
11442189|NCT01750918|Experimental|Part 1: Dabrafenib, Trametinib and Panitumumab|In Part 1 after the dabrafenib/panitumumab combination dose is defined, subsequent cohorts will evaluate the addition of trametinib based on a panitumumab dose that is one dose level lower than the dabrafenib/panitumumab dose defined in Cohort 1. Trametinib starting at 1.5 mg once daily will be added to the combination of dabrafenib and panitumumab. Dose escalation will follow a 3+3 dose escalation procedure until the full monotherapy doses of all agents are evaluated or the maximum tolerated dose is determined.
11442190|NCT01750918|Experimental|Part 2: Dabrafenib and panitumumab|In Part 2, subjects will be assigned to expansion cohorts at a selected dose of dabrafenib in combination with panitumumab
11442191|NCT01750918|Experimental|Part 2: Dabrafenib, Trametinib and Panitumumab|In Part 2, subjects will be assigned to expansion cohorts at selected dose of trametinib plus dabrafenib in combination with panitumumab.
11442192|NCT01750918|Experimental|Part 3a: Dabrafenib and Panitumumab|Subjects will be randomized to receive dabrafenib plus panitumumab. Dose levels for dabrafenib, and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
11442193|NCT01750918|Experimental|Part 3b: Dabrafenib, Trametinib and Panitumumab|Subjects will be randomized to receive study treatment as dabrafenib plus trametinib plus panitumumab. Dose levels for dabrafenib, trametinib and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
11442194|NCT01750918|Experimental|Part 3c: Chemotherapy comparator|Subjects will be randomized to receive chemotherapy comparator. The chemotherapy comparator will consist of a standard chemotherapy regimen with or without the addition of a biological agent, based on local practice preferences. The available chemotherapy regimens includes 5-fluorouracil-based chemotherapy
11442195|NCT01750918|Experimental|Part 4a: Trametinib and Panitumumab|Subject will be administered starting dose of Trametinib 2 mg once daily and Panitumumab 6mg/kg Q2W. If the initial combination dose of trametinib and panitumumab in Cohort 1 (starting dose) is not tolerable, the lower dose combination defined in de-escalation cohorts (Cohort -1A, -1B and/or -1C) may be evaluated. Cohort -1A: Trametinib 1.5 mg once daily and Panitumumab 6 mg/kg Q2W; Cohort -1B: Trametinib 2 mg once daily and Panitumumab 4.8 mg/kg Q2W; Cohort-1C: Trametinib 1.5 mg once daily and Panitumumab 4.8 mg/kg Q2W
11442196|NCT01750918|Experimental|Part 4b: Trametinib and Panitumumab|In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
11442197|NCT01750905|Active Comparator|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
11442198|NCT01750905|Placebo Comparator|Placebo|Placebo: Vehicle (D5W) SQ
11442199|NCT01750892|Active Comparator|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
11442200|NCT01750892|Experimental|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
11442201|NCT01750892|Experimental|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
11442202|NCT01750892|Experimental|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
11442203|NCT01750879|Active Comparator|Peanut Flour|Oral Immunotherapy with peanut flour.
11442204|NCT01750879|Placebo Comparator|Oat Flour|Oral Immunotherapy with oat flour.
11442205|NCT01750866|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
11442206|NCT01750853|Experimental|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.
~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.
~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
11442207|NCT01750853|Experimental|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.
~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.
~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
11442208|NCT01750853|Experimental|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.
~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
11442209|NCT01750840||Stimulation Group|All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.
11442210|NCT01750827|Experimental|SB-659032|Single dose open label
11442211|NCT01750814|Active Comparator|GC FLU inj.|Influneza vaccine, single-dose vial
11442212|NCT01750814|Experimental|GC3102C|Influneza vaccine, multi-dose vial
11442213|NCT01750801|Active Comparator|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
11442214|NCT01750801|Active Comparator|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
11442215|NCT01750788||Group 1|
11442293|NCT01750229|Experimental|1200 Hz|Frequency Setting - 1200 Hz
11442216|NCT01750775|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
11442217|NCT01750775|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
11442218|NCT01750762|Experimental|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
11442219|NCT01750749|Experimental|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
11442220|NCT01750736|Experimental|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
11442221|NCT01750736|Active Comparator|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
11442222|NCT01750723|Active Comparator|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
11442223|NCT01750723|Placebo Comparator|Saline|Saline, 10 ml i.v. infusion
11442224|NCT01750697|Experimental|Rituximab|
11442225|NCT01750684|Placebo Comparator|Saline|Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
11442226|NCT01750684|Active Comparator|AC105|Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
11442227|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.
~- External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.
~- Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected
~- During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
11442228|NCT01750645||Intervention Group|
11442229|NCT01750645||Control Group|
11442230|NCT01750632|Experimental|Orchiectomy|The patients undergo subcapsular orchiectomy
11442231|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
11442232|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
11442233|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
11442234|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
11442235|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
11442236|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
11442237|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
11442238|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
11442239|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
11442240|NCT01750593|Experimental|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
11442241|NCT01750580|Experimental|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
11442242|NCT01750567|Experimental|Metformin (Glucophage)|The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
11442243|NCT01750554|Experimental|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
11442244|NCT01750554|No Intervention|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
11442245|NCT01750541|Active Comparator|Haloperidol|Haloperidol 5mg intramuscular injection
11442246|NCT01750541|Active Comparator|Valproate|Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)
11442247|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
11442248|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
11442249|NCT01750515|Experimental|Intervention group - acupuncture treatment|
11442250|NCT01750515|No Intervention|Control group|
11442251|NCT01750502||coronary-artery-disease group|Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
11442252|NCT01750502||non-coronary-artery-disease group|Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
11442253|NCT01750489|No Intervention|COPD|
11442254|NCT01750489|Experimental|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
11442255|NCT01750489|No Intervention|Healthy control subjects|
11442256|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
11442257|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
11442258|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
11442259|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.
~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
11442260|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
11442261|NCT01750437|Experimental|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
11442262|NCT01750437|Experimental|YH1885L 50mg|BID, Subject takes it for 4 week.
11442263|NCT01750437|Experimental|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
11442264|NCT01750437|Experimental|YH1885L 100mg|BID, Subject takes it for 4 week.
11442265|NCT01750437|Active Comparator|Esomeprazole 20mg|QD, Subject takes it for 4 week.
11442266|NCT01750424|Experimental|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
11442267|NCT01750424|Placebo Comparator|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
11442268|NCT01750411||Asthma|Severe Asthma Not severe Asthma
11442269|NCT01750398|Experimental|ADT plus IV testosterone|"Men with castration-resistant prostate cancer will initiate androgen deprivation therapy (ADT) with an LHRH agonist (e.g. goserelin or leuprolide) for a total of 6 months. After this initial lead-in castration phase, patients will receive intermittent intramuscular testosterone cypionate or testosterone enanthate (T) at a dose of 400 mg while continuing on ADT."
11442270|NCT01750385|Active Comparator|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
11442271|NCT01750385|Active Comparator|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
11442272|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
11442273|NCT01750359|Active Comparator|curcumin|
11442274|NCT01750359|Placebo Comparator|placebo|
11442275|NCT01750346|Active Comparator|0.05% AH-8|Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
11442276|NCT01750346|Active Comparator|0.025% AH-8|Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
11442277|NCT01750346|Placebo Comparator|Placebo|Participants in the Placebo arm received the placebo.
11442278|NCT01750333||Lean children|
11442279|NCT01750333||Overweight Children (OW)|
11442280|NCT01750333||Obese children (Ob)|
11442281|NCT01750320|Experimental|Koning Breast CT - guided Biopsy|
11442282|NCT01750307|Experimental|Fatty acid supplementation|4 capsules to be taken daily
11442283|NCT01750307|Placebo Comparator|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
11442284|NCT01750281|Experimental|Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
11442285|NCT01750281|Experimental|Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle.
11442286|NCT01750281|Experimental|Placebo twice daily + Docetaxel 75 mg/m2|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
11442287|NCT01750268|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
11442288|NCT01750268|Placebo Comparator|Placebo|Placebo capsules daily - up 300 mg
11442289|NCT01750255|Placebo Comparator|Control|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
11442290|NCT01750255|Active Comparator|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
11442291|NCT01750242||Parkinson's disease Subjects|Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
11442292|NCT01750229|Sham Comparator|Sham|Frequency Setting - Sham
11592079|NCT00703131||1|Anal Fistula Plug
11442297|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
11442298|NCT01750190|Experimental|FG-4592 (Double-blind, Three times a week)|Weight-based starting doses of 70mg or 100mg; dose adjustments to hemoglobin levels are allowed during the study.
11442299|NCT01750190|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses of 70mg or 100mg; dose adjustments to hemoglobin levels are allowed during the study.
11442300|NCT01750177|Experimental|Television Viewing|Television viewing before mealtime
11442301|NCT01750177|Experimental|Video Game Playing|Video Game Playing before mealtime
11442302|NCT01750177|Experimental|Computer Use|Computer Use before mealtime
11442303|NCT01750177|Experimental|Sitting Quietly|Sitting Quietly before mealtime
11442304|NCT01750164||Invasive breast cancer with metastatic disease|
11442305|NCT01750151|Experimental|Glucose beverage|Glucose beverage
11442306|NCT01750151|Experimental|Control beverage and video game playing|Control beverage and video game playing
11442307|NCT01750151|Experimental|Glucose beverage and video game playing|Glucose beverage and video game playing
11442308|NCT01750151|Experimental|Control beverage|Control beverage
11442309|NCT01750138|Experimental|Glutamine|Glutamine powder given preoperatively for five days
11442310|NCT01750138|Active Comparator|Placebo|dextrose powder for 5 days pre-operatively
11442311|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
11442312|NCT01750112|Experimental|Macrolane VRF20|All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.
11442313|NCT01750099|Experimental|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
11442314|NCT01750099|Placebo Comparator|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
11442315|NCT01750086|Active Comparator|Denosumab 60mg subcutaneous injection|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
11442316|NCT01750086|Active Comparator|Alendronate 70mg weekly x 8 weeks|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
11442317|NCT01750073|Experimental|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
11442318|NCT01750060|Active Comparator|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
11442319|NCT01750060|Experimental|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
11442320|NCT01750060|Experimental|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
11442321|NCT01750060|Experimental|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
11442322|NCT01750060|Experimental|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
11442323|NCT01750034|Active Comparator|Closed method|Burn patients randomized to closed method of burn wound care.
11442324|NCT01750034|Experimental|Open method|Burn patients randomized to the open method of burn wound care.
11442325|NCT01750021|Experimental|High fat low carbohydrate diet|High fat low carbohydrate diet
11442326|NCT01750021|Experimental|Low fat high carbohydrate diet|Low fat high carbohydrate diet
11442327|NCT01750008|Other|Global Fibroid Ablation|Global Fibroid Ablation
11442328|NCT01750008|Other|Laparoscopic Myomectomy|Myomectomy via laparoscopy
11442329|NCT01749982|Placebo Comparator|Placebo|Placebo tablets
11442330|NCT01749982|Experimental|Choline bitartrate|Choline bitartrate 700 mg by mouth daily
11592400|NCT00700986|Placebo Comparator|2|
11442332|NCT01749982|Experimental|Choline bitartrate + Betaine|Choline bitartrate 700 mg + Betaine 1000 mg daily
11442333|NCT01749969|Experimental|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.
~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
11442334|NCT01749956|Experimental|FOLFOX6/Aflibercept/Radiation/Surgery|"Preoperative Chemoradiation: (6 weeks)
~5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;
~Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;
~Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.
~Surgery at least 6 weeks after last day of aflibercept: Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.
~Postoperative Chemotherapy and Aflibercept Treatments (four 28-day cycles):
~Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.
~Modified FOLFOX6:
~Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.
~Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.
~5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
11442335|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
11442336|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
11442337|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
11442338|NCT01749930|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
11442339|NCT01749930|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
11442340|NCT01749917|Active Comparator|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
11442341|NCT01749917|Experimental|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
11442342|NCT01749904|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
11442343|NCT01749904|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
11442344|NCT01749891|Experimental|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
11442345|NCT01749891|Experimental|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
11442346|NCT01749891|Experimental|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
11442347|NCT01749878|Experimental|Group A: Cohorts 1 through 6|"Group A:
~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
11442348|NCT01749878|Experimental|Group B|Group B will receive REGN1500 IV or placebo
11442349|NCT01749878|Experimental|Group C: Cohorts 1 and 2|"Group C:
~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
11442350|NCT01749865|Experimental|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
11442351|NCT01749865|No Intervention|B, CONTROL|Regular follow up with no intervention
11442352|NCT01749852|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
11442353|NCT01749852|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
11442354|NCT01749826|Experimental|Chronic Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
11442355|NCT01749826|Experimental|Acute Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
11442356|NCT01749800|Experimental|Cognitive test with/without GVS|Subjects with attention span deficits and no significant motor impairments undergo solely a cognitive test. The test is carried out in multiple trials. For some of the trials (randomly selected), subjects receive galvanic vestibular stimulation (GVS). For other trials, subjects received sham GVS. GVS is delivered using a device by A-M Systems.
11442357|NCT01749800|Active Comparator|Armeo Spring +GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with galvanic vestibular stimulation (GVS). Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. GVS is delivered using a device by A-M Systems.
11442358|NCT01749800|Sham Comparator|Armeo Spring + sham GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with sham GVS. Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. Sham stimulation is delivered by connecting the subject to a device by A-M Systems, but the device is not active.
11442359|NCT01749787|Experimental|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
11442360|NCT01749787|Experimental|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
11442361|NCT01749787|Experimental|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
11442362|NCT01749787|Experimental|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
11442363|NCT01749787|Experimental|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
11442364|NCT01749787|Placebo Comparator|Placebo|Placebo administered via infusion once per week for 5 weeks
11442365|NCT01749787|Experimental|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
11442366|NCT01749774|Experimental|Physical activity counseling|
11442367|NCT01749761|Placebo Comparator|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
11446606|NCT01722266|Active Comparator|Liraglutide 1.2mg|Daily injections
11442368|NCT01749761|Active Comparator|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
11442369|NCT01749748|Other|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
11442370|NCT01749735|Experimental|Armeo training with continuous tDCS|Subjects will receive 10 sessions of transcranial Direct Current Stimulation (tDCS)/Armeo training over 2 weeks. Training sessions will last for 40 minutes and will focus on repetitive tasks using the Armeo device that. To deliver the stimulation, the anode will be placed over the primary motor cortex (M1) of the affected hemisphere, while the cathode will be placed over the unaffected M1 area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2). Continuous stimulation will be delivered at an intensity of 1mA while the subject undergoes the 40-minute Armeo motor training sessions.
11442371|NCT01749735|Sham Comparator|Armeo training with sham tDCS|Subjects will receive the same number of 40-minute training sessions (i.e. 10 sessions) as the subjects in the experimental group. Training will take place over a period of two weeks as per the experimental group. Also, electrodes will be positioned on the scalp as per the experimental group. However, for sham transcranial Direct Current Stimulation (tDCS), the current will be delivered for only 30 seconds. The current intensity will be gradually increased and decreased to diminish its perception.
11442372|NCT01749722|Experimental|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
11442373|NCT01749709|Experimental|Instrumental music listening|Daily music listening
11442374|NCT01749709|Experimental|Vocal music listening|Daily music listening
11442375|NCT01749709|No Intervention|control|Standard rehabilitation
11442376|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
11442377|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
11442378|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
11442379|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
11442380|NCT01749657|Active Comparator|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
11442381|NCT01749657|Experimental|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
11442382|NCT01749657|Experimental|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
11442383|NCT01749657|Experimental|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
11442384|NCT01749644||CF patients with chronic pseudomonas infection|
11442385|NCT01749631||Difficult to Intubate (DTI) Participants|Male or non-pregnant females over 18 years of age with Mallampati score III or IV who were undergoing surgery using sevoflurane as the anesthetic agent as judged by the investigator and in compliance with the drug market authorization and approved product labeling.
11442386|NCT01749618|No Intervention|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
11442387|NCT01749618|Experimental|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
11442388|NCT01749605|Active Comparator|nitrofurantoin 100 mg|
11442389|NCT01749605|Active Comparator|Ciprofloxacin 250 mg|
11442390|NCT01749592|Experimental|Cochlear Implant|Surgical Implantation of a Cochlear Implant
11442391|NCT01749579|Experimental|Propofol|The patients will receive propofol for sedation in addition to fentanyl
11442392|NCT01749579|Active Comparator|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
11442393|NCT01749566|Active Comparator|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
11442394|NCT01749566|Active Comparator|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
11442395|NCT01749566|No Intervention|Group C (no drug)|No additional drug
11442396|NCT01749553|Experimental|sleeper stretch|
11442397|NCT01749553|No Intervention|no intervention|
11442398|NCT01749540|Experimental|ACE 536|ACE-536 - 1 of 7 possible dose levels.
11442399|NCT01749527|Other|24-hour pad test|decreased activity
11442400|NCT01749514|Experimental|ACE-536|Subjects assigned to 1 of 7 possible dosing groups.
11442401|NCT01749501|Active Comparator|Rocuronium|0.6 mg/kg once
11442402|NCT01749501|Placebo Comparator|Placebo|Placebo
11442403|NCT01749488|No Intervention|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
11442404|NCT01749488|Experimental|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
~Intervention: Designated dietitian for the ward"
11442405|NCT01749475||midazolam|
11442406|NCT01749475||hypnosis|
11442407|NCT01749462||Oxis|
11442408|NCT01749449|Experimental|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
11442409|NCT01749449|Experimental|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
11442410|NCT01749449|Experimental|High protein consumed 6 meals/day|35% protein 6 meals/day
11442411|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
11442412|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
11442413|NCT01749410||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
11442414|NCT01749397|Experimental|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11442415|NCT01749384|Experimental|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11442416|NCT01749371|Experimental|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
11442417|NCT01749371|Experimental|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
11442418|NCT01749358|Experimental|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
11442419|NCT01749358|Experimental|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
11442420|NCT01749358|Experimental|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
11442421|NCT01749358|Other|Active Monitoring|This is an observation only group.
11442422|NCT01749332|Experimental|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
11442423|NCT01749319|Active Comparator|Oral Baclofen|
11442424|NCT01749319|Experimental|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
11442425|NCT01749306|Other|ABH001|ABH001 application plus wound care dressings.
11442426|NCT01749306|Other|Control|Control wound treatment
11442427|NCT01749293|Experimental|Haploidentical Transplant|All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
11442428|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
11442429|NCT01749267|Experimental|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
11442430|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
11442431|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
11442432|NCT01749241|Experimental|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
11442433|NCT01749241|Other|Vehicle Ointment|This arm contains vehicle only.
11442434|NCT01749228|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
11442435|NCT01749228|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
11442436|NCT01749215|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
11442437|NCT01749215|Placebo Comparator|Placebo|Placebo capsules daily - up to 300 mg
11442438|NCT01749202|Placebo Comparator|Negative Control|
11442439|NCT01749202|Active Comparator|Positive Control|
11442440|NCT01749202|Experimental|Active|
11442441|NCT01749189|Placebo Comparator|Placebo|Placebo dry blended beverage (carbohydrate)
11442442|NCT01749189|Experimental|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
11442443|NCT01749189|Active Comparator|Whey|A dry blended beverage containing Whey protein
11442444|NCT01749176|Experimental|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
11442445|NCT01749176|Placebo Comparator|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
11442446|NCT01749163|Experimental|Control|Saline will be coninfused during the pancreatic clamp
11442447|NCT01749163|Experimental|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
11442448|NCT01749163|Experimental|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
11442449|NCT01749150|Experimental|with cirrhosis|
11442450|NCT01749150|Experimental|without cirrhosis|
11442451|NCT01749137|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1mg/24hrs via subcutaneous infusion for 90 days.
11442452|NCT01749137|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 90 days.
11442453|NCT01749124|Experimental|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
11442454|NCT01749111|Experimental|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
11442455|NCT01749111|Active Comparator|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
11592592|NCT00699790|Placebo Comparator|A2|
11442460|NCT01749072|Other|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
11442461|NCT01749072|Other|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
11442462|NCT01749059||Congenital Heart Defect|
11442463|NCT01749046|Experimental|Remegal|Remegal 1500 mg
11442464|NCT01749046|Placebo Comparator|Placebo|Placebo
11442465|NCT01749033|Active Comparator|Group 1 classic|Group 1 Using the classic inserting technique and completely deflated LMA (Laryngeal Mask Airway)recommended in the LMA manual.
11442466|NCT01749033|Active Comparator|Group 2 pre inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer
11442467|NCT01749033|Active Comparator|Group 3 ELL-PIC technique|Group 3 (ELL-PIC): Using the ELL-PIC technique.
11442468|NCT01749020|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
11442469|NCT01749020|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
11442470|NCT01749007||Veterans with HIV/AIDS|
11442471|NCT01748994|Placebo Comparator|Placebo|Administration of placebo to upper- and lower-body obese women
11442472|NCT01748994|Active Comparator|Drug|Administration of pioglitazone to upper- and lower-body obese women
11442473|NCT01748981|Other|Physical training|Exercise intervention.
11442474|NCT01748981|Other|As usual|Controls
11442475|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
11442476|NCT01748955|Active Comparator|Bupropion|Participants will receive bupropion XL for 8 weeks.
11442477|NCT01748955|Active Comparator|paroxetine CR|Participants will receive Paroxetine CR for 8 weeks.
11442478|NCT01748942|Experimental|Arm I (treatment)|Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.
11442479|NCT01748942|Active Comparator|Arm II (control)|Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.
11442480|NCT01748929|Experimental|Albendazole|single dose 400 mg tablet of albendazole
11442481|NCT01748929|Placebo Comparator|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
11442482|NCT01748916|Experimental|Papaya-Carrot-Tomato|Test meals were consumed in the following order: 1. Papaya 2. Carrot 3. Tomato.
11442483|NCT01748916|Experimental|Papaya-Tomato-Carrot|Test meals were consumed in the following order: 1. Papaya 2. Tomato 3. Carrot
11442484|NCT01748916|Experimental|Tomato-Papaya-Carrot|Test meals were consumed in the following order: 1. Tomato 2. Papaya 3. Carrot
11442485|NCT01748916|Experimental|Tomato-Carrot-Papaya|Test meals were consumed in the following order: 1. Tomato 2. Carrot 3. Papaya
11442486|NCT01748916|Experimental|Carrot-Papaya-Tomato|Test meals were consumed in the following order: 1. Carrot 2. Papaya 3. Tomato
11442487|NCT01748916|Experimental|Carrot-Tomato-Papaya|Test meals were consumed in the following order: 1. Carrot 2. Tomato 3. Papaya
11442488|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
11442489|NCT01748890|Experimental|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
11442490|NCT01748877|Experimental|NXN-462|capsule, 200 mg, bi.d. 28-days
11442491|NCT01748877|Placebo Comparator|Placebo|capsule, b.i.d. 28-days
11442492|NCT01748864|Experimental|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
11442493|NCT01748851|Experimental|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
11442494|NCT01748851|Active Comparator|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
11442495|NCT01748838|Experimental|Part 1: CTX-4430|
11442496|NCT01748838|Placebo Comparator|Part 1: Placebo + Mannitol|
11442497|NCT01748838|Experimental|Part 2: CTX-4430|
11442498|NCT01748838|Placebo Comparator|Part 2: Placebo + Mannitol|
11442499|NCT01748825|Experimental|A|MK-1775 (AZD1775) administered orally for 5 doses each cycle, starting at 225 mg per dose approximately 12 hours apart
11442500|NCT01748825|Experimental|B|MK-1775 (AZD1775) administered orally for 5 doses for 2 weeks each cycle, starting at 200 mg per day
11442501|NCT01748799|Other|Sequence 1|Self-titrated placebo - Self-titrated Sativex - Fixed dose Sativex - Fixed dose placebo
11442502|NCT01748799|Other|Sequence 2|Fixed dose placebo - Fixed dose Sativex - Self-titrated Sativex - Self-titrated placebo
11442503|NCT01748799|Other|Sequence 3|Fixed dose placebo - Fixed dose Sativex - Self-titrated placebo - Self-titrated Sativex
11442504|NCT01748799|Other|Sequence 4|Fixed dose Sativex - Fixed dose placebo - Self-titrated placebo - Self-titrated Sativex
11442505|NCT01748799|Other|Sequence 5|Self-titrated Sativex - Self-titrated placebo - Fixed dose Sativex - Fixed dose placebo
11442506|NCT01748799|Other|Sequence 6|Self-titrated Sativex - Self-titrated placebo - Fixed dose placebo - Fixed dose Sativex
11442507|NCT01748799|Other|Sequence 7|Self-titrated placebo - Self-titrated Sativex - Fixed dose placebo - Fixed dose Sativex
11442508|NCT01748799|Other|Sequence 8|Fixed dose Sativex - Fixed dose placebo - Self-titrated Sativex - Self-titrated placebo
11442509|NCT01748786|Experimental|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
11442510|NCT01748786|Placebo Comparator|Placebo|12 on-line modules providing information regarding health behaviors
11442511|NCT01748773|Experimental|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
11442512|NCT01748760|Experimental|CLASP-A intervention|Adolescent participants and parents will receive adjunctive psychosocial intervention.
11442513|NCT01748760|Active Comparator|Treatment as Usual|Adolescent participants and parents will not receive study intervention
11442514|NCT01748747|Experimental|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
11442515|NCT01748747|Experimental|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
11442516|NCT01748747|Experimental|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
11442517|NCT01748734|Experimental|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
11442518|NCT01748721|Experimental|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11442519|NCT01748708|Experimental|Magnetic seizure therapy|
11442520|NCT01748708|Active Comparator|Electroconvulsive therapy|
11442521|NCT01748695|Experimental|Placebo followed by V158866|Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks
11442522|NCT01748695|Experimental|V158866 followed by Placebo|V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks
11442523|NCT01748682|Experimental|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
11442524|NCT01748682|Active Comparator|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
11442525|NCT01748669|Experimental|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
11442526|NCT01748669|Active Comparator|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
11442527|NCT01748669|Active Comparator|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
11442528|NCT01748656|Active Comparator|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
11442529|NCT01748656|Active Comparator|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
11442530|NCT01748643|Experimental|Deep neuromuscular blockade, reversal with sugammadex|a continuous rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with Sugammadex 4mg/kg. Patients are extubated when the train of four ratio is > 0.9.
11442531|NCT01748643|Active Comparator|normal neuromuscular blockade, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when TOF ratio > 0.9.
11442532|NCT01748630|Active Comparator|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
11442533|NCT01748630|Active Comparator|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
11442534|NCT01748617|Experimental|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
11442535|NCT01748617|Placebo Comparator|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
11442536|NCT01748604|Active Comparator|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
11442537|NCT01748604|Experimental|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
11442538|NCT01748604|Experimental|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
11442539|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
11442540|NCT01748578|Active Comparator|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
11442541|NCT01748578|Active Comparator|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
11442542|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
11442543|NCT01748552|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
11442544|NCT01748552|Experimental|LY2922083 (Part A)|Single ascending dose of LY2922083 (starting at 0.5 milligrams [mg]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
11442545|NCT01748552|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
11442546|NCT01748552|Experimental|LY2922083 (Part B)|Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
11442547|NCT01748539|Experimental|KHK4827 70mg SC|
11442548|NCT01748539|Experimental|KHK4827 140mg SC|
11442549|NCT01748539|Experimental|KHK4827 210mg SC|
11442550|NCT01748539|Placebo Comparator|Placebo SC|
11442551|NCT01748526|Experimental|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
11442552|NCT01748526|Experimental|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
11442553|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
11442554|NCT01748500|Experimental|Pantoprazole, Docetaxel, Prednisone|
11442555|NCT01748487|Experimental|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
11442556|NCT01748474|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
11442557|NCT01748474|Placebo Comparator|Sham room air|Room air will be applied similarly to oxygen
11442558|NCT01748461|Active Comparator|Structured intervention|Supervised cycle ergometer program
11442559|NCT01748461|Active Comparator|Coach intervention|Non-supervised cycle ergometer program
11442560|NCT01748461|No Intervention|Control group|No cycle ergometer program
11442561|NCT01748448|Active Comparator|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
11442562|NCT01748448|Placebo Comparator|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
11442563|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
11442564|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
11442565|NCT01748396|Experimental|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
11442566|NCT01748396|Active Comparator|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
11442567|NCT01748383|Experimental|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
11442568|NCT01748383|Experimental|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
11442569|NCT01748383|Active Comparator|stenting of IRA|The only stenting of IRA
11442570|NCT01748370|Experimental|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
11442571|NCT01748370|Experimental|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
11442572|NCT01748370|Placebo Comparator|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
11442573|NCT01748370|Placebo Comparator|Placebo eugonadal|Vitamin D supplementation in eugonadal men
11442574|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis >1 week are excluded.
11442575|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
11442576|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
11442577|NCT01748344|Experimental|Experimental 1|High dose ONO-4053
11442578|NCT01748344|Active Comparator|Cetirizine|10mg Cetirizine
11442579|NCT01748344|Experimental|Experimental 2|Low dose ONO-4053
11442580|NCT01748344|Placebo Comparator|Placebo|Placebo
11442581|NCT01748331|Other|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction < 1 L/day
11442582|NCT01748331|Other|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction < 2.5 L/day
11442583|NCT01748318|Experimental|NM Regional Honey|15 ml of NM Honey applied directly to wound
11442584|NCT01748318|Active Comparator|Bactrim DS|Standard of Care Oral Antibiotic
11442585|NCT01748305|Experimental|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
11442586|NCT01748292|Active Comparator|Monthly IVT ranibizumab|Monthly intravitreal injections (IVT) ranibizumab for 24 months, not less than 21 days apart to not more than 35 days apart
11442587|NCT01748292|Experimental|Treat and Extend IVT ranibizumab|0.5 mg intravitreal injections (IVT) ranibizumab for 3 consecutive months followed by a treat and extend protocol in which follow-up intervals are increased when there is no clinical and SD-OCT evidence of disease activity by 2-week intervals and patients are treated at every visit. (Comparator arm)
11442588|NCT01748279|Active Comparator|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
11442589|NCT01748279|Placebo Comparator|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
11442590|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
11442591|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (morning)|
11442592|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (bedtime)|
11442593|NCT01748240|Experimental|Azacitidine and oral vorinostat|"Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.
~Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3."
11442594|NCT01748227|Other|Peer-Coached Pain Self-Management|Participants (n=20) were assigned to a peer coach, who delivered self-management instruction one-on-one over a 4-month period.
11442595|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
11442596|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
11442597|NCT01748201|Experimental|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
11442598|NCT01748188|Active Comparator|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
11442599|NCT01748188|Experimental|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
11442600|NCT01748188|Experimental|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
11442601|NCT01748175|Other|Longitudinal follow up|Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.
11592717|NCT00698906|Experimental|Group D|
11442602|NCT01748162|Experimental|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
11442603|NCT01748162|Active Comparator|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
11442604|NCT01748149|Experimental|Vemurafenib|"Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be crushed. If patients receiving crushed tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. [Patients approved to take crushed tablets should use a pill crusher and mix pill with 3-5 ml apple sauce]. If not, then only patients able to swallow whole pills will be eligible.
~The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
11442605|NCT01748136||Single Arm|CT Scan Arm
11442606|NCT01748123|Active Comparator|Chlorthalidone|25mg daily orally for 8 weeks
11442607|NCT01748123|Active Comparator|Hydrochlorothiazide|50mg daily orally for 8 weeks
11442608|NCT01748110|No Intervention|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
11442609|NCT01748110|Experimental|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
11442610|NCT01748110|Experimental|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
11442611|NCT01748110|No Intervention|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
11442612|NCT01748110|Experimental|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
11442613|NCT01748097|Experimental|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
11442614|NCT01748097|Placebo Comparator|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
11442615|NCT01748084|Placebo Comparator|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
11442616|NCT01748084|Experimental|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
11442617|NCT01748071||Sufentanil group|Grouped by intravenous injection of sufentanil at the time of anesthesia induction
11442618|NCT01748071||Fentanyl group|Grouped by intravenous injection of fentanyl at the time of anesthesia induction
11442619|NCT01748071||Saline group|Grouped by intravenous injection of saline before the time of anesthesia induction
11442620|NCT01748058|Experimental|Active video games|Exercise based on active video gaming
11442621|NCT01748058|No Intervention|Routine care|
11442622|NCT01748045|Experimental|inhaled Nitric Oxide|iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
11442623|NCT01748045|Placebo Comparator|Nitrogen Gas|Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
11442624|NCT01748032|Other|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
11442625|NCT01748032|Other|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
11442626|NCT01748019|Experimental|ST1968|"ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
~--------------------------------------------------------------------------------"
11442627|NCT01748006||Blood and urine samples|
11442628|NCT01747993|Experimental|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
11442629|NCT01747993|Placebo Comparator|placebo|1 tablet / day for 6 days
11442630|NCT01747980|Experimental|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
11442631|NCT01747967|Experimental|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
11442632|NCT01747954|Experimental|Bag Squeezing|"20% increase in FiO2
~Inflation pressure of 30 cm H2O + 10l O2/min
~0.5 ml saline 0.9%
~10 Manual Hyperinflation
~10 vibrocompression
~Aspiration Tracheal"
11442633|NCT01747954|Active Comparator|Thoracic vibrocompression|"20% increase in FiO2
~0.5 ml saline
~10 vibrocompression toracica on the right and left
~Aspiration Tracheal"
11442634|NCT01747941|Experimental|Cohort 1|Single ascending oral doses in fasted conditions
11442635|NCT01747941|Experimental|Cohort 2|Single ascending oral doses in fasted conditions
11442636|NCT01747941|Experimental|Cohort 3|Single ascending oral doses in fed conditions
11442637|NCT01747928|Experimental|Group 1|
11442638|NCT01747915|Experimental|Study Drug Level 1|
11442639|NCT01747915|Experimental|Study Drug Level 2|
11442640|NCT01747915|Placebo Comparator|Placebo|
11446607|NCT01722266|Active Comparator|Liraglutide 0.6 mg|Daily injection
11442641|NCT01747902|Other|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
11442642|NCT01747902|Other|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
11442643|NCT01747889|Experimental|Electronic system|patients managed with an electronic chest drainage system
11442644|NCT01747889|No Intervention|traditional system|patients managed with a traditional analogue chest drainage system
11442645|NCT01747876|Experimental|LEE011|
11442646|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
11442647|NCT01747850|Experimental|Sativex|Intervention consist on Sativex Spray (Δ9-tetrahydrocannabinol/cannabidiol). Study subjects will be randomized in blocks of ten to one of the two groups (Sativex vs. placebo) in a double blind manner. There will be a gradual increase of the maximal allowed dose starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays per day at the end of week 2. There will be a total of 12 weeks of drug exposure. All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement/Cognitive Behavioral Therapy.
11442648|NCT01747850|Placebo Comparator|Placebo spray|Participants will receive a combination of Placebo spray associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy
11442649|NCT01747850|Experimental|Pilot Study|The first five subjects will be treatment-seekers that fit our inclusion/exclusion criteria and that will be treated open-label. These subjects will be instructed to use the Sativex Spray according to the induction schedule provided above. These first subjects will allow us to determine if our schedule for dosing is appropriate for the subsequent phase of the study.
11442650|NCT01747837|No Intervention|standard ICD implantation alone|These subjects will undergo standard ICD implantation alone (if not already present)
11442651|NCT01747837|Experimental|Boston Scientific Vessix Renal Denervation System|"These subjects will undergo standard ICD implantation (if not already present) plus renal sympathetic denervation.
~Ablation arm"
11442652|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
11442653|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
11442654|NCT01747811|Experimental|wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
11442655|NCT01747811|Placebo Comparator|wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
11442656|NCT01747798|Experimental|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11442657|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
11442658|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
11442659|NCT01747772|Experimental|Shear Wave Sonoelastography for Fibrosis Assessment|Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
11442660|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
11442661|NCT01747759|Other|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
11442662|NCT01747746|Active Comparator|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
11442663|NCT01747746|Other|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
11442664|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
11442665|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
11442666|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
11442667|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
11442668|NCT01747720|Placebo Comparator|Placebo|daily, for 12 months
11442669|NCT01747707|Experimental|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
11442670|NCT01747694|Experimental|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
11442671|NCT01747694|No Intervention|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
11442672|NCT01747681||Microfracture|Microfracture of articular chondral defect
11442673|NCT01747668|Placebo Comparator|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
11442674|NCT01747668|Experimental|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
11442675|NCT01747668|Experimental|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
11442676|NCT01747655||Duodopa|Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
11442677|NCT01747655||Standard of Care|Participants that return to oral or transdermal anti-parkinson's disease medications
11442678|NCT01747642|Active Comparator|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
11442679|NCT01747642|Active Comparator|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
11442680|NCT01747642|No Intervention|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
11442681|NCT01747629|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
11442682|NCT01747629|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
11442683|NCT01747616|Experimental|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
11442684|NCT01747616|Experimental|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
11442685|NCT01747616|Experimental|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
11442686|NCT01747616|Experimental|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
11442687|NCT01747603|No Intervention|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
11442688|NCT01747603|Experimental|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
11442689|NCT01747590|Experimental|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
11442690|NCT01747577|Experimental|Solifenacin group|
11442691|NCT01747577|Placebo Comparator|Placebo group|
11442692|NCT01747564|Experimental|mirabegron group|
11442693|NCT01747551|Active Comparator|mFOLFOX6 + Ziv-aflibercept|Patients received mFOLFOX6 and ziv-aflibercept every 2 weeks. Ziv-aflibercept 4mg/kg was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
11442694|NCT01747551|Active Comparator|mFOLFOX6 + Placebo|Patients received mFOLFOX6 and placebo every 2 weeks. Placebo was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
11442695|NCT01747538|Placebo Comparator|Placebo|
11442696|NCT01747538|Experimental|Dose 1 gevokizumab|
11442697|NCT01747538|Experimental|Dose 2 gevokizumab|
11442698|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
11442699|NCT01747512|Active Comparator|C-PERT|45 patients with cancer
11442700|NCT01747512|Active Comparator|G-PERT|65 patients with cancer
11442701|NCT01747499|Experimental|Cohort 1|"Conditioning treatment
~Transplant on Day 0
~15 mg/m^2 azacitidine Days 7-11
~15 mg/m^2 azacitidine Days 35-39
~15 mg/m^2 azacitidine Days 63-67
~15 mg/m^2 azacitidine Days 91-95"
11442702|NCT01747499|Experimental|Cohort 2|"Conditioning treatment
~Transplant on Day 0
~30 mg/m^2 azacitidine Days 7-11
~30 mg/m^2 azacitidine Days 35-39
~30 mg/m^2 azacitidine Days 63-67
~30 mg/m^2 azacitidine Days 91-95"
11442703|NCT01747499|Experimental|Cohort 3|"Conditioning treatment
~Transplant on Day 0
~37.5 mg/m^2 azacitidine Days 7-11
~37.5 mg/m^2 azacitidine Days 35-39
~37.5 mg/m^2 azacitidine Days 63-67
~37.5 mg/m^2 azacitidine Days 91-95"
11442704|NCT01747499|Experimental|Cohort 4|"Conditioning treatment
~Transplant on Day 0
~45 mg/m^2 azacitidine Days 7-11
~45 mg/m^2 azacitidine Days 35-39
~45 mg/m^2 azacitidine Days 63-67
~45 mg/m^2 azacitidine Days 91-95"
11442705|NCT01747499|Experimental|Phase II Cohort|"Conditioning treatment
~Transplant on Day 0
~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 7-11
~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 35-39
~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 63-67
~Dose determined in Phase I - 45 mg/m^2 attitudinize Days 91-95"
11442706|NCT01747486|Experimental|Target dose of 1-5x10e8|Arm 1: Target dose of 1-5x10e8 CART-19 cells (calculated as range of 10-50% transduced cells in 1 x10e9 total cells)
11442707|NCT01747486|Experimental|Target dose of 1-5x10e7|Arm 2: Target dose of 1-5x10e7 CART-19 cells (calculated as the range of 10-50% transduced cells in 1 x10e8 total cells)
11442708|NCT01747447|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11442709|NCT01747447|Active Comparator|Vitamin D placebo + fish oil|
11442710|NCT01747447|Active Comparator|Vitamin D + fish oil placebo|
11442711|NCT01747447|Active Comparator|Vitamin D + fish oil|
11442856|NCT01746459|Active Comparator|High, High|High Intensity, High Frequency Reminder System
11442712|NCT01747408|Experimental|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
11442713|NCT01747395|No Intervention|Control Group|No exercise group (sedentary)
11442714|NCT01747395|Experimental|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
11442715|NCT01747395|Experimental|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
11442716|NCT01747395|Experimental|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
11442717|NCT01747356|Experimental|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.
~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):
~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.
~Follow-up window:
~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
11442718|NCT01747343|Experimental|Underwear/Differential Reinforcement|All subjects will wear underwear followed by wearing underwear while receiving differential reinforcement.
11442719|NCT01747330|Experimental|Creon micro, minimicrospheres|
11442720|NCT01747317|Experimental|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
11442721|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
11442722|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
11442723|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
11442724|NCT01747291||Atypical femur fracture cohort|
11442725|NCT01747278|No Intervention|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
11442726|NCT01747278|Experimental|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
11442727|NCT01747252|Experimental|RGC1|RGC containing the equivalent of 50 mg resveratrol
11442728|NCT01747252|Active Comparator|Resveratrol|The equivalent of 150 mg resveratrol
11442729|NCT01747252|Experimental|RGC2|RGC containing the equivalent of 150 mg resveratrol
11442730|NCT01747239|Experimental|Cabazitaxel|25 mg/m2 IV every three weeks
11442731|NCT01747226|Placebo Comparator|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
11442732|NCT01747226|Active Comparator|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
11442733|NCT01747226|Active Comparator|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
11442734|NCT01747226|Sham Comparator|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
11442735|NCT01747213|Experimental|BNC|Bisnorcymserine tartrate
11442736|NCT01747213|Placebo Comparator|Placebo|microcrystalline celluose
11442737|NCT01747187||Septic shock|
11442738|NCT01747174|Experimental|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
11442739|NCT01747174|Experimental|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
11442740|NCT01747174|Active Comparator|Std PCI|Standard PCI only
11442741|NCT01747161|Experimental|botulin toxin|botulin toxin
11442742|NCT01747161|Placebo Comparator|physiological water|physiological water
11442743|NCT01747135|Experimental|Open label|
11442744|NCT01747122|Experimental|Wound catheter|Wound catheter
11442745|NCT01747122|Active Comparator|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
11442746|NCT01747109|Experimental|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
11442747|NCT01747109|Active Comparator|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
11442748|NCT01747083|Experimental|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
11442749|NCT01747083|Experimental|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
11442750|NCT01747070|Active Comparator|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
11442806|NCT01746680|Experimental|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks
11442807|NCT01746667|Experimental|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993).
11442857|NCT01746446|Experimental|Care team|Patients are offered the support and services of the care team.
11442751|NCT01747070|Placebo Comparator|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
11442752|NCT01747070|Active Comparator|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
11442753|NCT01747070|Experimental|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
11442754|NCT01747057|Experimental|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
11442755|NCT01747057|Active Comparator|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
11442756|NCT01747044|Active Comparator|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
11442757|NCT01747044|Placebo Comparator|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
11442758|NCT01747031|Experimental|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
11442759|NCT01747018|Experimental|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
11442760|NCT01747005||Conventional therapy|
11442761|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
11442762|NCT01746992|Experimental|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
11442763|NCT01746992|Active Comparator|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
11442764|NCT01746979|Active Comparator|Gemcitabine plus TH-302|
11442765|NCT01746979|Placebo Comparator|Gemcitabine plus placebo|
11442766|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
11442767|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
11442768|NCT01746940|Placebo Comparator|Group 1, Placebo Topical Solution|Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination.
11442769|NCT01746940|Active Comparator|Group 2, Cocaine HCl 4% Topical Solution|Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded.
11442808|NCT01746667|Experimental|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.
~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
11442809|NCT01746667|No Intervention|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
11442770|NCT01746940|Active Comparator|Group 3, Cocaine HCl 10% Topical Solution|Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded.
11442771|NCT01746927||cricoid pressure|
11442772|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
11442773|NCT01746901|Placebo Comparator|Treatment A|
11442774|NCT01746901|Experimental|Treatment B|
11442775|NCT01746901|Experimental|Treatment C|
11442776|NCT01746901|Active Comparator|Treatment D|
11442777|NCT01746901|Experimental|Treatment E|
11442778|NCT01746901|Active Comparator|Treatment F|
11442779|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
11442780|NCT01746875|Experimental|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
11442781|NCT01746875|No Intervention|Observation|
11442782|NCT01746862|Experimental|Saizen Test Group|
11442783|NCT01746862|Active Comparator|Saizen Control Group|
11442784|NCT01746849|Experimental|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
11442785|NCT01746849|Experimental|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
11442786|NCT01746836|Experimental|Ponatinib hydrochloride|Patients receive ponatinib hydrochloride PO QD. Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
11442787|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
11442788|NCT01746810|Experimental|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
11442789|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
11442790|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
11442791|NCT01746784|Experimental|N6022|Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days
11442792|NCT01746784|Placebo Comparator|Normal saline|Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group
11442793|NCT01746771|Experimental|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
11442794|NCT01746758|Experimental|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
11442795|NCT01746758|No Intervention|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
11442796|NCT01746745|Experimental|[^14C]-LY2940680|Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680)
11442797|NCT01746732|Experimental|Ortho-Cyclen|Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods. Treatment A
11442798|NCT01746732|Experimental|Ortho-Cyclen + Evacetrapib|Ortho-Cyclen administered orally, QD, for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods. Treatment B
11442799|NCT01746719|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
11442800|NCT01746719|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
11442801|NCT01746706|Experimental|patients|
11442802|NCT01746706|Experimental|volunteers|
11442803|NCT01746693|Experimental|amblyopia ex anisometropia|20 male and female volunteers with amblyopia ex anisometropia
11442804|NCT01746693|Experimental|amblyopia ex strabismus|20 male and female volunteers with amblyopia ex strabismus
11442805|NCT01746693|Experimental|control subjects|20 healthy male and female control subjects
11442855|NCT01746459|Active Comparator|High, Low|High Intensity, Low Frequency Reminder System
11592718|NCT00698906|Experimental|Group E|
11442810|NCT01746654|Experimental|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
11442811|NCT01746654|Experimental|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
11442812|NCT01746654|Experimental|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
11442813|NCT01746654|Placebo Comparator|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
11442814|NCT01746641|Active Comparator|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.
~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
11442815|NCT01746641|Active Comparator|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.
~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
11442816|NCT01746628|Placebo Comparator|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
11442817|NCT01746628|Active Comparator|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
11442818|NCT01746615|Experimental|30 Patients with BRVO in one eye|
11442819|NCT01746615|Experimental|30 healthy age and sex matched controls|
11442820|NCT01746602|Experimental|healthy subjects I|20 healthy subjects
11442821|NCT01746602|Experimental|healthy subjects II|20 healthy subjects
11442822|NCT01746602|Experimental|healthy subjects III|20 healthy subjects
11442823|NCT01746602|Experimental|healthy subjects IV|20 healthy subjects
11442824|NCT01746602|Experimental|healthy subjects V|20 healthy subjects
11442825|NCT01746602|No Intervention|healthy subjects VI|20 healthy subjects
11442826|NCT01746589|Other|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
11442827|NCT01746576|Other|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
11442828|NCT01746563|Experimental|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
11442829|NCT01746563|Active Comparator|Laser Therapy|Laser Therapy alone
11442830|NCT01746550|Experimental|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
11442831|NCT01746524||CR FB|Subjects receiving Cruciate Retaining Fixed Bearing configuration of ATTUNE Primary Knee Implant
11442832|NCT01746524||PS FB|Subjects receiving Posterior Stabilized Fixed Bearing configuration of ATTUNE Primary Knee Implant
11442833|NCT01746524||CR RP|Subjects receiving Cruciate Retaining Rotating Platform configuration of ATTUNE Primary Knee Implant
11442834|NCT01746524||PS RP|Subjects receiving Posterior Stabilized Rotating Platform configuration of ATTUNE Primary Knee Implant
11442835|NCT01746511|Active Comparator|Glycerin Suppository|"Based on our institution's protocol, infant will receive a glycerin shave within one hour of initiation of phototherapy and then every eight hours while under phototherapy.
~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:
~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.
~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
11442836|NCT01746511|Experimental|No Glycerin Suppository|"Infants will receive no scheduled glycerin suppositories, while under phototherapy (unless otherwise directed by attending physician).
~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:
~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.
~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
11442837|NCT01746498|Active Comparator|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
11442838|NCT01746498|Active Comparator|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
11442839|NCT01746498|Sham Comparator|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
11442840|NCT01746485|Experimental|UT-15C|
11442841|NCT01746472|Experimental|2 - B-passive|
11442842|NCT01746472|Experimental|3 - B-active|
11442843|NCT01746472|Experimental|4 - B-active, B-passive|
11442844|NCT01746472|Experimental|6 - z, B-passive|
11442845|NCT01746472|Experimental|7 - z, B-active|
11442846|NCT01746472|Experimental|8 - z, B-active, B-passive|
11442847|NCT01746472|Experimental|10 - t, B-passive|
11442848|NCT01746472|Experimental|11 - t, B-active|
11442849|NCT01746472|Experimental|12 - t, B-active, B-passive|
11442850|NCT01746472|Experimental|14 - t, z|
11442851|NCT01746472|Experimental|15 - t, z, B-active|
11442852|NCT01746472|Experimental|16 - t, z, B-active, B-passive|
11442853|NCT01746459|Active Comparator|Low Low|Low Intensity, Low Frequency Reminder System
11442854|NCT01746459|Active Comparator|Low, High|Low Intensity, High Frequency Reminder System
11442859|NCT01746433|Active Comparator|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.
~No particular brand of hanging bar is targeted."
11442860|NCT01746433|Experimental|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.
~Commercial name of the device: SAM ERGONOM (TM)
~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
11442861|NCT01746420|Placebo Comparator|Placebo Control|Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
11442862|NCT01746420|Experimental|0.45 mg rhPDGF-BB|Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
11442863|NCT01746420|Experimental|0.75 mg rhPDGF-BB|Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
11442864|NCT01746420|Experimental|1.5 mg rhPDGF-BB|Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
11442865|NCT01746420|Experimental|3.0 mg rhPDGF-BB|Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
11442866|NCT01746394|Experimental|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
11442867|NCT01746394|Active Comparator|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
11442868|NCT01746381|Experimental|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
11442869|NCT01746381|Active Comparator|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
11442870|NCT01746368|Experimental|Nurse-Supported Advance Care Planning Intervention|The Nurse-Supported Advance Care Planning Intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices.
11442871|NCT01746368|Active Comparator|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices. Subjects in this arm who desired information about risks, benefits, and alternatives of specific choices before randomization were scheduled for the Care-as-Usual session after they received that information from the Primary Care Provider.
11442872|NCT01746355|Active Comparator|rTMS-active|patients undergoing of rTMS real
11442873|NCT01746355|Sham Comparator|rTMS-Sham|patients undergoing to placebo rTMS
11442874|NCT01746342|Active Comparator|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
11442875|NCT01746342|Sham Comparator|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
11442876|NCT01746329|Experimental|Tea|Oral intake of tea containing 75 grams of glucose
11442877|NCT01746329|Experimental|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
11442878|NCT01746329|Placebo Comparator|Placebo|Oral intake of 75 grams of glucose in water
11442879|NCT01746303|Experimental|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
11442880|NCT01746303|Experimental|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
11442881|NCT01746303|Experimental|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
11442882|NCT01746303|Placebo Comparator|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
11442883|NCT01746290|Experimental|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
11442884|NCT01746290|No Intervention|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
11442885|NCT01746277|Other|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
11442886|NCT01746277|Other|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
11442887|NCT01746264|Experimental|Vitamin D3|Vitamin D3 supplementation at 100,000 IU once a month for 3 months
11442888|NCT01746251|Active Comparator|Concise Afatinib|Afatinib oral daily dose for 3 months
11442889|NCT01746251|Active Comparator|Prolonged Afatinib|Afatinib oral daily dose for 2 years
11442890|NCT01746238|Experimental|Treatment Arm|Bevacizumab, metronomic doxorubicin and radiation therapy
11442891|NCT01746225|Experimental|A: nab-Paclitaxel 150 mg/m2 days 1,15|"Arm A: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.
~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
11442892|NCT01746225|Experimental|B: nab-Paclitaxel 100 mg/m2 days 1,8,15|"Arm B: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.
~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
11449743|NCT01702220|Active Comparator|Enhanced Community Care (ECC)|
11442893|NCT01746225|Experimental|C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22|"Arm C: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.
~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
11442894|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
11442895|NCT01746199|Experimental|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
11442896|NCT01746199|Active Comparator|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
11442897|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
11442898|NCT01746173|Experimental|CHOEP + High Dose Therapy + Auto SCT|Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).
11442899|NCT01746160|Experimental|C1 Implant|Patient having C1 implant installed.
11442900|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
11442901|NCT01746134||Cohort|
11442902|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
11442903|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
11442904|NCT01746108|Experimental|At-risk-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are at an increased risk of pneumococcal infection.
11442905|NCT01746108|Experimental|At-risk-Primed Group|"Subjects who have been previously vaccinated
~with at least one dose of a pneumococcal conjugate vaccine i.e. either Synflorix (10Pn-PD-DiT), Prevenar or Prevenar13.
~with plain polysaccharide pneumococcal vaccine more than 2 years and less than 5 years before enrollment.
~and are at an increased risk of pneumococcal infection."
11442906|NCT01746108|Active Comparator|Healthy-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are healthy.
11442907|NCT01746108|Active Comparator|Healthy-Primed Group|Subjects who have been previously vaccinated with at least one dose of a pneumococcal vaccine and are healthy.
11442908|NCT01746095|Experimental|Vancomycin hydrochloride inhalation powder|32 or 64 mg twice daily (BID)
11442909|NCT01746095|Placebo Comparator|Placebo inhalation powder|Matching placebo inhalation powder BID
11442910|NCT01746082|Experimental|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
11442911|NCT01746082|Experimental|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
11442912|NCT01746069|Placebo Comparator|health advice|clinical practice routine
11442913|NCT01746069|Experimental|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
11442914|NCT01746056|Active Comparator|Heat Patch Continuous|applied 2 hrs daily for 12 weeks
11442915|NCT01746056|Active Comparator|Heat Patch Noncontinuous|applied 2 hrs daily 2 weeks on and 2 weeks off for 12 weeks
11442916|NCT01746043|Experimental|Armodafinil + Placebo|Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
11442917|NCT01746043|Experimental|Minocycline + Placebo|Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
11442918|NCT01746043|Experimental|Armodafinil + Minocycline|Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
11442919|NCT01746043|Placebo Comparator|Placebos|Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
11442920|NCT01746030||Questionnaires|No treatment
11442921|NCT01746017|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A
11592720|NCT00698893|Experimental|Group A|
11442922|NCT01746017|Experimental|LY2922470 (Part A)|Single ascending dose of LY2922470 [starting at 1 milligram (mg)] administered orally to healthy participants in up to 3 of 4 study periods in Part A
11442923|NCT01746017|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
11442924|NCT01746017|Experimental|LY2922470 (Part B)|Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
11442925|NCT01746004|Experimental|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug
11442926|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
11442927|NCT01745978|Experimental|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
11442928|NCT01745978|Active Comparator|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
11442929|NCT01745965|Experimental|T-DM1|single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)
11442930|NCT01745965|Experimental|T-DM1 + endocrine therapy|Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).
11442931|NCT01745965|Active Comparator|Trastuzumab + endocrine therapy|The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).
11442932|NCT01745952|Experimental|figure-of-eight active rTMS coil|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
11442933|NCT01745952|Experimental|round active rTMS coil|rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
11442934|NCT01745952|Sham Comparator|sham rTMS coil (figure-of-eight)|rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
11442935|NCT01745939|Active Comparator|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
11442936|NCT01745939|Sham Comparator|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
11442937|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
11442938|NCT01745913|Experimental|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
11442939|NCT01745913|Active Comparator|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
11442940|NCT01745887|Active Comparator|EBI-005-2 5mg/ml|Administration: 3 times per day
11442941|NCT01745887|Active Comparator|EBI-005-2 20 mg/ml|Administration: 3 times per day
11442942|NCT01745887|Placebo Comparator|EBI-005-2 Placebo|Administration: 3 times per day
11442943|NCT01745861|Active Comparator|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
11442944|NCT01745861|Placebo Comparator|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
11442945|NCT01745848|Experimental|Study Drug|Roflumilast 500 μcg, once daily, for 30 days
11442946|NCT01745835|Active Comparator|2L Coolprep®|
11442947|NCT01745835|Experimental|1L Coolprep® and Bisacodyl|
11442948|NCT01745822|Experimental|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate, 300 mg tablets
11442949|NCT01745822|Placebo Comparator|Placebo|matching placebo (of tenofovir disoproxil fumarate)
11442950|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
11442951|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
11442952|NCT01745796||Intubated ICU patients|
11442953|NCT01745783|Experimental|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.
~Dose: 1-2x10^6 cells/Kg"
11442954|NCT01745783|Placebo Comparator|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg
11442955|NCT01745770|Experimental|A|
11442956|NCT01745770|Active Comparator|B|
11442957|NCT01745757||Cohort|first line treatment for metastatic breast cancer
11442958|NCT01745744|Experimental|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
11442959|NCT01745744|Experimental|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
11442960|NCT01745744|No Intervention|Control|Conventional treatment
11442961|NCT01745731|Experimental|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
11450163|NCT01699139|Sham Comparator|lumbar corset|
11442962|NCT01745731|No Intervention|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
11442963|NCT01745718|Other|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
11442964|NCT01745705|Experimental|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
11442965|NCT01745705|Sham Comparator|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
11442966|NCT01745692|Active Comparator|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
11442967|NCT01745692|Experimental|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
11442968|NCT01745679|Experimental|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
11442969|NCT01745666|Experimental|patients with KCNQ1 or KCNH2 mutation|
11442970|NCT01745666|Other|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
11442971|NCT01745653|Experimental|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
11442972|NCT01745653|Sham Comparator|sham procedure|Same procedure than experimental arm except that the laser is not activated.
11442973|NCT01745653|No Intervention|no intervention|no intervention : Patient received the quadhelix with nothing else
11442974|NCT01745640|Experimental|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
11442975|NCT01745627|Experimental|Laser Treatment|
11442976|NCT01745614|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
11442977|NCT01745614|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
11442978|NCT01745601|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11442979|NCT01745601|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11442980|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
11442981|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
11442982|NCT01745575|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11442983|NCT01745575|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11442984|NCT01745562|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
11442985|NCT01745562|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
11442986|NCT01745549|Experimental|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
11442987|NCT01745549|Active Comparator|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
11442988|NCT01745536|Experimental|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
11442989|NCT01745536|Active Comparator|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
11442990|NCT01745523|Experimental|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
11442991|NCT01745523|Active Comparator|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
11442992|NCT01745510|Experimental|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.
~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
11442993|NCT01745510|Placebo Comparator|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.
~They will receive one dose every 24 h during 14 days."
11442994|NCT01745497|Experimental|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
11442995|NCT01745497|Placebo Comparator|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
11442996|NCT01745484|Experimental|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
11442997|NCT01745471||PCOS group|12 women with Polycystic Ovary Syndrome (PCOS) as defined by NIH criteria
11442998|NCT01745471||Pear shapes|12 with an android pattern as defined by a waist-to-hip greater than 0.85
11442999|NCT01745471||Apple shapes|12 will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78
11443000|NCT01745458|Experimental|SB-659032|250 mg non-enteric coated SB-659032
11443001|NCT01745458|Placebo Comparator|Placebo|matched placebo QD for 14 days
11443002|NCT01745445|Experimental|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
11450396|NCT01697423|Active Comparator|durolane|
11443003|NCT01745432|Experimental|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
11443004|NCT01745432|No Intervention|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
11443005|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
11443006|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
11443007|NCT01745406||Doctor and nurse|
11443008|NCT01745406||Doctor without nurse|
11443009|NCT01745393|Experimental|Clinic Quality Improvement + Behavioral Counseling|This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
11443010|NCT01745393|Active Comparator|Clinic Quality Improvement + Attention Control|The attention control intervention parallels the format of the experimental group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
11443011|NCT01745380|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
11443012|NCT01745380|Placebo Comparator|Placebo|Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
11443013|NCT01745367|Active Comparator|Placebo in combination with paclitaxel|Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
11443014|NCT01745367|Experimental|Tivo in combination with paclitaxel|1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
11443015|NCT01745354|Experimental|SD-101 + Combined with Local Radiation|
11443016|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
11443017|NCT01745328|Active Comparator|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
11443018|NCT01745328|Active Comparator|TCM treatment|subject is treated with TCM
11443019|NCT01745315|Active Comparator|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
11443020|NCT01745315|Active Comparator|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
11443021|NCT01745315|Active Comparator|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
11443022|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
11443023|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
11443024|NCT01745276|Experimental|External pins coated by biphosfonate.|External pins coated by biphosfonate.
11443025|NCT01745276|Active Comparator|External pins coated by hydroxylapatite.|External pins coated by hydroxylapatite.
11443026|NCT01745263|Active Comparator|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
11443027|NCT01745263|Active Comparator|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
11443028|NCT01745263|Active Comparator|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
11443029|NCT01745263|Active Comparator|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
11443030|NCT01745263|Active Comparator|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
11443031|NCT01745263|Active Comparator|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
11443032|NCT01745263|Active Comparator|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
11443033|NCT01745263|Sham Comparator|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
11443034|NCT01745250|Experimental|Emervel Lips|Emervel Lips
11443035|NCT01745250|Experimental|Juvederm Ultra Smile|Juvederm Ultra Smile
11443036|NCT01745224|Experimental|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
11443037|NCT01745224|Experimental|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
11443038|NCT01745211|Experimental|755nm Alexandrite Laser|755nm Alexandrite laser (standard handpiece)
11443039|NCT01745211|Experimental|755nm Alexandrite laser with modified handpiec|Device: 755nm Alexandrite laser with modified handpiece
11443127|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
11592721|NCT00698893|Experimental|Group B|
11443040|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
11443041|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
11443042|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
11443043|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
11443044|NCT01745172|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
11443045|NCT01745159|Experimental|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
11443046|NCT01745159|No Intervention|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
11443047|NCT01745146|Experimental|Anger Self-Management Training (ASMT)|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
11443048|NCT01745146|Active Comparator|Personal Readjustment and Ed (PRE)|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment. Significant other (friend or relative) invited to participate in 3 of 8 sessions
11443049|NCT01745133|Placebo Comparator|vehicle|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
11443050|NCT01745133|Active Comparator|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
11443051|NCT01745133|Active Comparator|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
11443052|NCT01745120|Experimental|LentiGlobin BB305 Drug Product|
11443053|NCT01745107|No Intervention|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
11443054|NCT01745107|Experimental|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
11443055|NCT01745094|Experimental|Concomitant Group|concomitant administration of mirabegron to solifenacin treated patients
11443056|NCT01745081|Experimental|Mannitol|Bolus mannitol 20% at skin incision
11443057|NCT01745081|Experimental|Hypertonic saline|Hypertonic saline 3% at skin incision
11443058|NCT01745068|No Intervention|Control group|
11443059|NCT01745068|Experimental|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
11443060|NCT01745055|Experimental|CP-690,550 (tofacitinib) 30 mg q12h|Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h
11443061|NCT01745042||android postmenopausal women|Clinical exams
11443062|NCT01745042||gynoid postmenopausal women|Clinical exams
11443063|NCT01745029||Ulcerative Colitis|
11443064|NCT01745016|Placebo Comparator|Placebo|placebo
11443065|NCT01745016|Experimental|Beta-Alanine|beta-alanine
11443066|NCT01745003|Experimental|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
11443067|NCT01744990|Other|Interventional single arm|Single group of children undergoing the same investigations and follow up
11443068|NCT01744977|Experimental|Adherence Packaging Intervention Group|[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
11443069|NCT01744977|No Intervention|Education Only Group|Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
11443070|NCT01744964|Placebo Comparator|Saline|Assessment of experimental pain models before and after treatment
11443071|NCT01744964|Active Comparator|Apomorphine|Assessment of experimental pain models before and after treatment
11443072|NCT01744951|Experimental|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
11443073|NCT01744951|No Intervention|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
11443074|NCT01744938|No Intervention|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
11443075|NCT01744938|Experimental|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
11443076|NCT01744925|Active Comparator|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
11443077|NCT01744925|Experimental|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
11443128|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
11443129|NCT01744600|Experimental|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
11443130|NCT01744600|No Intervention|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
11443131|NCT01744587|Placebo Comparator|Placebo|Placebo qd (2# bid) for 3 years
11593183|NCT00696072|Active Comparator|A2|
11443078|NCT01744912|Experimental|Ublituximab + Lenalidomide|"4 cohorts, with 3 - 6 patients per cohort, as follows:
~Cohort 1: Ublituximab 450 mg + Lenalidomide 10 mg
~Cohort 2: Ublituximab 450 mg + Lenalidomide 15 mg
~Cohort 3: Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)
~Cohort 4: Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)
~Ublituximab is an IV infusion on days 1, 8, and 15 of cycles 1 & 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.
~Lenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
11443079|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
11443080|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
11443081|NCT01744886|Active Comparator|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.
~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
11443082|NCT01744886|Active Comparator|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.
~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
11443083|NCT01744873|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
11443084|NCT01744873|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
11443085|NCT01744860||"INCa molecular genetics laboratory in-house methods"|"BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using in-house methods"
11443086|NCT01744860||Cobas 4800 Mutation Test|BRAF V600 mutations were analysed using Cobas 4800 mutation test
11443087|NCT01744847|Active Comparator|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
11443088|NCT01744847|Active Comparator|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
11443089|NCT01744834||18-year-old males|18-year-old males, representative random sample of the Dresden/Berlin (Germany) area, categorized as high and as low-risk drinkers respectively
11443090|NCT01744821|Active Comparator|Arm A: Vitamin D3 Group|Patients will take Vitamin D3 by mouth in the weeks prior to and including the morning of surgery. If blood test done at the start of the study shows that patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given two 25,000 IU Vitamin D3 Tablets (for a total of 50,000 IU) to take once a week until surgery. If baseline Vitamin D level is >30ng/ml, patients will be given on 2,000 IU Vitamin D3 tablet to take once a day until day of surgery.
11443091|NCT01744821|Placebo Comparator|Arm B: Placebo Group|Patients will take a placebo by mouth prior to and including the morning of surgery. If bloods tests done at the start of study show that the patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given 2 placebo tablets to take once a week until surgery. If baseline Vitamin D level is > 30 ng/ml, patients will be given on placebo tablet to take once a day until surgery.
11443092|NCT01744808|Active Comparator|EB-1020 SR1|Sustained release formulation
11443093|NCT01744808|Active Comparator|EB-1020 SR2|Sustained Release Formulation
11443094|NCT01744808|Active Comparator|EB-1020 SR3|Sustained Release Formulation
11443095|NCT01744808|Active Comparator|EB-1020 IR|Immediate Release Formulation
11443096|NCT01744808|Placebo Comparator|Placebo|Placebo Formulation
11443097|NCT01744795|Experimental|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
11443098|NCT01744782|Experimental|RP103|From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.
11443099|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
11443100|NCT01744756|Experimental|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
11443101|NCT01744743|Active Comparator|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
11443102|NCT01744743|Active Comparator|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
11443132|NCT01744587|Experimental|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
11443991|NCT01739244|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
11443103|NCT01744743|Placebo Comparator|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
11443104|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)|Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
11443105|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)|Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
11443106|NCT01744730|Active Comparator|Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)|Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
11443107|NCT01744730|Active Comparator|Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)|Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
11443108|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
11443109|NCT01744704|Experimental|rhNGF 0.5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
11443110|NCT01744704|Experimental|rhNGF 5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
11443111|NCT01744704|Experimental|rhNGF 60 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
11443112|NCT01744704|Experimental|rhNGF 20 µg/mL Sentinel|1 x 35 µL drop 3 subjects
11443113|NCT01744704|Experimental|rhNGF 20 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
11443114|NCT01744704|Experimental|rhNGF 180 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
11443115|NCT01744704|Placebo Comparator|Placebo Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
11443116|NCT01744704|Experimental|rhNGF 20 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subjects
11443117|NCT01744704|Experimental|rhNGF 60 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
11443118|NCT01744704|Experimental|rhNGF 180 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
11443119|NCT01744704|Placebo Comparator|Placebo Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
11443120|NCT01744691|Experimental|ibrutinib|All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.
11443121|NCT01744678|Experimental|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:
~first, prior to the beginning of the work shift
~second, during an operationally feasible 20-min break during the 1st half of the work shift
~third, once during an operationally feasible 20-min break during the 2nd half of the work shift
~fourth, immediately after the end of the work shift
~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.
~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
11443122|NCT01744665|Experimental|Treatment Free Remission|Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.
11443123|NCT01744652|Experimental|Arm A - Crizotinib + Dasatinib|"Arm A: Patients receive dose of crizotinib plus an increasing dose of dasatinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.
~Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle.
~Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib Expansion Dose: MTD from dose escalation group."
11443124|NCT01744652|Experimental|Arm B - Dasatinib + Crizotinib|"Arm B: Patients receive dasatinib plus an increasing dose of crizotinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.
~Dasatinib 140 mg by mouth daily in a 28 day cycle. Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle.
~Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
11443125|NCT01744639|Experimental|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
11443126|NCT01744626|Experimental|CC-292 with Rituximab|Dose Escalation
11443133|NCT01744574|Placebo Comparator|Placebo|Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
11443134|NCT01744574|Experimental|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
11443135|NCT01744561|Experimental|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
11443136|NCT01744561|No Intervention|Control|Keep activity level constant
11443137|NCT01744548|Experimental|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
11443138|NCT01744548|No Intervention|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
11443139|NCT01744535|Active Comparator|Paper food diary|
11443140|NCT01744535|Active Comparator|Online food diary|
11443141|NCT01744535|Experimental|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
11443142|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
11443143|NCT01744509|Other|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
11443144|NCT01744496|Experimental|Rotigotine|Rotigotine Transdermal Patches
11443145|NCT01744496|Placebo Comparator|Placebo|Placebo Transdermal Patches
11443146|NCT01744483|Active Comparator|PVC ETT|Polyvinylchloride cuff endotracheal tube
11443147|NCT01744483|Experimental|PUC ETT|Polyurethane cuff endotracheal tube
11443148|NCT01744483|Experimental|PUC-CASS ETT|Polyurethane cuff with continuous aspiration of subglottic secretions endotracheal tube
11443149|NCT01744470|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.
~Drug: Tacrolimus targeted half-dose"
11443150|NCT01744470|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
11443151|NCT01744457|Other|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
11443152|NCT01744457|Other|20 healthy control subjects|age- and sex-matched controls
11443153|NCT01744444|Experimental|Memantine first|
11443154|NCT01744444|Experimental|Gabapentin first|
11443155|NCT01744431||No treatment|
11443156|NCT01744418|Experimental|HAVG graft|HAVG graft implantation to study participants.
11443157|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
11443158|NCT01744392|Experimental|education intervention|The intervention provides a personalized Meducation calendar to all patients enrolled in the study (identified in package as Example Calendar). The Meducation Calendar will include medications for diabetes (sugar), high blood pressure, cholesterol, heart medications and blood thinning medications. The medication calendars contains the following for each medication 1) the name, 2) the time of day, including a pictorial display, it should be taken 3) the number of times each day to take the medication, and 4) the indication for the medication.
11443159|NCT01744379|Experimental|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
11443160|NCT01744379|Experimental|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
11443161|NCT01744379|Experimental|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
11443162|NCT01744379|Experimental|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
11443163|NCT01744379|Experimental|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
11443164|NCT01744366|Experimental|Degarelix|Degarelix 240/80 mg
11443165|NCT01744366|Active Comparator|Goserelin|Goserelin 3.6 mg
11443166|NCT01744353|Experimental|Dose level 1|Abraxane 125 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
11443167|NCT01744353|Experimental|Dose level 2/ MTD|Abraxane 150 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
11443168|NCT01744353|Experimental|Dose level 3|Abraxane 175 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
11443169|NCT01744340|Experimental|head and neck|Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
11443170|NCT01744340|Experimental|Colon- closed as of May 2014|"Eribulin Mesylate:
~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
11443171|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
11443172|NCT01744314|Experimental|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
11444215|NCT01737866|Experimental|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)
11443173|NCT01744314|Placebo Comparator|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
11443174|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
11443175|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
11443176|NCT01744288|Experimental|1|Ticagrelor with Platelet transfusion
11443177|NCT01744288|Experimental|2|Ticagrelor without Platelet transfusion
11443178|NCT01744288|Active Comparator|3|Clopidogrel with Platelet transfusion
11443179|NCT01744288|Active Comparator|4|Clopidogrel without Platelet transfusion
11443180|NCT01744275|Placebo Comparator|Placebo|Placebo
11443181|NCT01744275|Experimental|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
11443182|NCT01744262|Active Comparator|Inhalational anesthesia group|
11443183|NCT01744262|Experimental|Total intravenous anesthesia group|
11443184|NCT01744249|Experimental|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
11443185|NCT01744249|Placebo Comparator|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
11443186|NCT01744236|Experimental|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
11443187|NCT01744236|Experimental|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
11443188|NCT01744236|Placebo Comparator|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
11443189|NCT01744236|Experimental|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
11443190|NCT01744236|Placebo Comparator|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
11443191|NCT01744236|Other|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
11443192|NCT01744236|Other|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
11443193|NCT01744223|Experimental|SCT, BPX-501 dose 1, Rimiducid if needed|"2x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.
~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
11443194|NCT01744223|Experimental|SCT, BPX-501 dose 2, Rimiducid if needed|"5x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.
~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
11443195|NCT01744223|Experimental|SCT, BPX-501 dose 3, Rimiducid if needed|"1x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.
~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
11443196|NCT01744223|Experimental|SCT, BPX-501 dose 4, Rimiducid if needed|"3x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant .
~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
11443197|NCT01744210||CHF|
11443198|NCT01744197|Experimental|Arm 1|First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
11443199|NCT01744197|Experimental|Arm 2|First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch
11443200|NCT01744184|Active Comparator|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia
~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
11443201|NCT01744184|Experimental|Entonox|"Entonox combined with pharyngeal anaesthesia.
~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.
~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
11443202|NCT01744171|Experimental|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
11443203|NCT01744158||Children with cerebral palsy|No intervention applicable
11443204|NCT01744145|Active Comparator|Interventional 40-60|Interventional group aged 40-60
11443205|NCT01744145|Placebo Comparator|Control 40-60|Control group aged 40-60
11443206|NCT01744145|Active Comparator|Interventional 60 and above|Interventional group aged 60 and above
11443207|NCT01744145|Placebo Comparator|Control 60 and above|Control group aged 60 and above
11443251|NCT01743859|Experimental|Azacitidine + Lenalidomide + Off Therapy|Patients will receive 7 days of azacitidine followed by 3 weeks of lenalidomide. They will then have 2 weeks off therapy, for a maximum of 12 cycles.
11443208|NCT01744132|Experimental|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
11443209|NCT01744132|No Intervention|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
11443210|NCT01744119||Abdominal Aortic Aneurysm|
11443211|NCT01744106|Experimental|pseudoephedrine hydrochloride 30 mg tablets|Test product
11443212|NCT01744106|Placebo Comparator|placebo tablets|Placebo
11443213|NCT01744093|Active Comparator|Doxycycline|100 mg twice daily (BID orally) x 6 months
11443214|NCT01744093|Placebo Comparator|Placebo (sugar pill)|100 mg twice daily (BID orally) x 6 months
11443215|NCT01744080|Active Comparator|Early Surgery|
11443216|NCT01744080|Experimental|Regular Wait Time|
11443217|NCT01744067|Active Comparator|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
11443218|NCT01744067|Placebo Comparator|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
11443219|NCT01744054|Other|PET/MR or PET/CT|"Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT
~Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
11443220|NCT01744041|Experimental|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
11443221|NCT01744041|Active Comparator|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
11443222|NCT01744028|Experimental|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
11443223|NCT01744028|Experimental|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
11443224|NCT01744015|Experimental|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
11443225|NCT01744015|Active Comparator|Standard of care|Control group consisting of normal care
11443226|NCT01744002|Experimental|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
11443227|NCT01744002|Active Comparator|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
11443228|NCT01743989|Active Comparator|arm 1|12 months of nilotinib consolidation (arm 1) plus 36 months of TFR phase
11443229|NCT01743989|Active Comparator|arm 2|24 months of nilotinib consolidation plus 24 months of TFR phase
11443230|NCT01743976|Experimental|Donepezil|donepezil 5 mg every day
11443231|NCT01743976|Placebo Comparator|Placebo|Placebo (sugar pill) every day
11443232|NCT01743963|Experimental|Decision Support Intervention|Clinical pharmacists mediated computerized decision support
11443233|NCT01743963|Active Comparator|Usual Care|Clinicians' typical approach for GID monitoring
11443234|NCT01743950|Active Comparator|Bevacizumab naive recurrent grade IV gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
11443235|NCT01743950|Active Comparator|Bevacuzumab exposed and refractive grade IV gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
11443236|NCT01743950|Active Comparator|Bevacizumab naive recurrent grade III gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
11443237|NCT01743950|Active Comparator|Bevacizumab exposed and refractive grade III gliomas|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
11443238|NCT01743937|Active Comparator|Ticagrelor|Coronary occlusion with balloon inflation
11443239|NCT01743937|Active Comparator|Clopidogrel|Coronary occlusion with balloon inflation
11443240|NCT01743924|Experimental|Raw|Broccoli,200 grams
11443241|NCT01743924|Experimental|cooked|Microwaved, 200 grams
11443242|NCT01743911|Placebo Comparator|sugar pill|Intervention: sugar pill
11443243|NCT01743911|Active Comparator|tadalafil|Intervention: tadalafil
11443244|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
11443245|NCT01743898||Control Group|Patient not taking any form of anticoagulation
11443246|NCT01743885|Active Comparator|propanolol|Propanolol (Syprol:oral solution)
11443247|NCT01743885|Active Comparator|Acebutolol|Acebutolol (Sectral:oral solution)
11443248|NCT01743872|Active Comparator|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
11443249|NCT01743872|Active Comparator|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
11443250|NCT01743872|Active Comparator|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
11598804|NCT00656188|Active Comparator|Arm 1|
11443253|NCT01743833|Active Comparator|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
11443254|NCT01743833|Active Comparator|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
11443255|NCT01743833|Active Comparator|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
11443256|NCT01743833|Active Comparator|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
11443257|NCT01743820|Active Comparator|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
11443258|NCT01743820|Experimental|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
11443259|NCT01743820|Experimental|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
11443260|NCT01743820|Experimental|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
11443261|NCT01743820|Experimental|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
11443262|NCT01743807|Experimental|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
11443263|NCT01743807|Experimental|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
11443264|NCT01743807|Experimental|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
11443265|NCT01743807|Experimental|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
11443266|NCT01743794|Experimental|ropivacaine 0.2%, wound infusion|
11443267|NCT01743794|Placebo Comparator|saline solution 0.9%, wound infusion|
11443268|NCT01743781|Experimental|intervention group|view a 10-minute informational video about comprehensive eye examination
11443269|NCT01743781|No Intervention|control group|No intervention
11443270|NCT01743768|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.
~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).
~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
11443271|NCT01743768|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.
~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
11443272|NCT01743755|Active Comparator|Dexamethasone|
11443273|NCT01743755|Placebo Comparator|Placebo|Placebo tablet, once daily for four consecutive days
11443274|NCT01743742|Experimental|Oral vitamin E, vitamin C|Single dose of vitamin E drops 200 IU within 6 hours of birth and vitamin C tablet 250 mg in pulverised form (2 doses at 24 hr interval) via infant feeding tube
11443275|NCT01743729|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution (5.0%)
11443276|NCT01743729|Placebo Comparator|Placebo|
11443277|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
11443278|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
11443279|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
11443280|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
11443281|NCT01743703|Other|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
11443282|NCT01743690|Active Comparator|fluocinolone, placebo|fluocinolone, placebo
11443283|NCT01743690|Experimental|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
11443284|NCT01743690|Active Comparator|Nystatin, placebo|Nystatin, placebo
11443285|NCT01743690|Experimental|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
11443286|NCT01743677|Experimental|CP-690,550 100 mg|
11443287|NCT01743677|Placebo Comparator|Placebo|
11443288|NCT01743677|Active Comparator|Moxifloxacin hydrochloride|
11443289|NCT01743664|Experimental|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
11443290|NCT01743664|Active Comparator|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
11443291|NCT01743651|Placebo Comparator|Placebo|Placebo
11443292|NCT01743651|Active Comparator|Baclofen|Baclofen
11443293|NCT01743651|Experimental|Arbaclofen|Arbaclofen
11443294|NCT01743638|Experimental|MR-Guided Laser Ablation|
11443295|NCT01743625|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
11443296|NCT01743625|Placebo Comparator|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
11443297|NCT01743612|Experimental|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
11443298|NCT01743612|Experimental|Primary Raynaud's phenomenon|without secondary disease
11443299|NCT01743612|Experimental|Healthy subjects|18 years old or more
11443300|NCT01743599||Diabetic men|
11443301|NCT01743599||Non-diabetic men|
11443302|NCT01743586|No Intervention|Control|
11443303|NCT01743573|Experimental|yoga training|Yoga training
11443304|NCT01743573|No Intervention|control|no yoga training
11443305|NCT01743560|Experimental|Everolimus and Exemestane|Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
11443306|NCT01743547|No Intervention|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
11443307|NCT01743547|Active Comparator|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
11443308|NCT01743534||Conservation of praxies and form plates|
11443309|NCT01743521|Experimental|Group A - 8 weeks total therapy|8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
11443310|NCT01743521|Experimental|Group B - 12 weeks total therapy|12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
11443311|NCT01743521|Experimental|Group C - 24 weeks total therapy|24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
11443312|NCT01743508|Active Comparator|Misoprostol by physician|Misoprostol treatment by midwife
11443313|NCT01743508|Experimental|Misoprostol by midwife|Misoprostol treatment by midwife
11443314|NCT01743495|Other|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
11443315|NCT01743482|Experimental|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
11443316|NCT01743469|Experimental|Hepatocellular Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
11443317|NCT01743469|Experimental|Ovarian Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
11443318|NCT01743469|Experimental|Renal Cell Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
11443319|NCT01743469|Experimental|Gastric Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
11443320|NCT01743456|No Intervention|Current practice (BIS and rSO2 blinded)|
11443321|NCT01743456|Experimental|Targeted intra-operative depth of anaesthesia|
11443322|NCT01743443|Experimental|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
11443323|NCT01743430|Experimental|telerehabilitation|telerehabilitation via internet
11443324|NCT01743430|No Intervention|conventional|conventional therapy
11443325|NCT01743417|Experimental|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
11443326|NCT01743417|Active Comparator|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
11443327|NCT01743417|No Intervention|Passive control|No computer training or games will be provided to this group
11443328|NCT01743404|Active Comparator|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
11443329|NCT01743404|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
11443330|NCT01743391|No Intervention|Control|Standard treatment
11443331|NCT01743391|Experimental|Intervention|Office-hysteroscopy with endometrial biopsy before standard treatment
11443332|NCT01743378|Experimental|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
11443333|NCT01743378|Placebo Comparator|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
11443334|NCT01743365|Experimental|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
11443335|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
11443336|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
11443337|NCT01743339|Active Comparator|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
11443338|NCT01743339|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
11443339|NCT01743326|Experimental|RFD-group|Radio Frequency Denervation
11443340|NCT01743326|Active Comparator|Local Anesthesia-group|Local Anesthesia-group
11443341|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
11443342|NCT01743300|Active Comparator|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
11443343|NCT01743300|Active Comparator|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
11443344|NCT01743287|Experimental|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
11443345|NCT01743287|Placebo Comparator|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
11443373|NCT01743079|Experimental|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
11443374|NCT01743079|Experimental|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
11443346|NCT01743274|No Intervention|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.
~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
11443347|NCT01743274|Experimental|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.
~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
11443348|NCT01743261|Active Comparator|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
11443349|NCT01743261|Experimental|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.
~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
11443350|NCT01743235|Experimental|Placebo|30 subjects administered a placebo
11443351|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
11443352|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
11443353|NCT01743235|Experimental|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
11443354|NCT01743235|Experimental|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
11443355|NCT01743235|Experimental|Testosterone|30 subjects are given 0.5 mg Testosterone
11443356|NCT01743235|Experimental|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
11443357|NCT01743222|Experimental|eASC|"eASC
~First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.
~Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
11443358|NCT01743222|Placebo Comparator|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node
~Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
11443359|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
11443360|NCT01743196||Obese|Women with BMI > 30 kg/m2
11443361|NCT01743183|Experimental|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
11443362|NCT01743170|No Intervention|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
11443363|NCT01743170|Experimental|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
11443364|NCT01743157|Experimental|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
11443365|NCT01743144|Active Comparator|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
11443366|NCT01743144|Placebo Comparator|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
11443367|NCT01743131|Placebo Comparator|Standard GVHD Prophylxis + Placebo|"Standard GVHD prophylaxis and placebo.
~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
11443368|NCT01743131|Experimental|Standard GVHD Prophylxis + Abatacept|"Standard GVHD prophylaxis and abatacept (investigational product).
~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
11443369|NCT01743118|Experimental|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
11443370|NCT01743105|Experimental|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.
~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
11443371|NCT01743092|Other|Tutorial Workbook|Tutorial Workbook Group only receives a Tutorial Workbook Group
11443372|NCT01743092|Experimental|Tutorial Workbook Group plus webinar|Tutorial Workbook Group plus webinar will receive in addition, a webinar as an additional resource.
11450397|NCT01697410|Experimental|terlipressin|
11443375|NCT01743079|No Intervention|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
11443376|NCT01743066|Experimental|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
11443377|NCT01743066|Active Comparator|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
11443378|NCT01743066|Active Comparator|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
11443379|NCT01743053|Other|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
11443380|NCT01743053|Experimental|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
11443381|NCT01743040||CADence plus Standard Angiogram|All patients who were indicated for angiogram due to results of SPECT nuclear stress test
11443382|NCT01743040||CADence plus CT Angiogram|All patients who were not indicated for angiogram due to results of SPECT nuclear stress test underwent CT angiogram
11443383|NCT01743027|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
11443384|NCT01743027|Active Comparator|PATADAY|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
11443385|NCT01743027|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
11443386|NCT01743027|Placebo Comparator|Vehicle|AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
11443387|NCT01743014|Active Comparator|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
11443388|NCT01743014|Active Comparator|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
11443389|NCT01743001|Experimental|Macitentan|Subjects receive macitentan 10 mg oral tablet once daily
11443390|NCT01743001|Placebo Comparator|Placebo|Subjects receive macitentan-matching placebo oral tablet once daily
11443391|NCT01742988|Experimental|Fimepinostat - Continuous Once Daily|Fimepinostat 30-60 mg/day
11443392|NCT01742988|Experimental|Fimepinostat - 2x/week|Fimepinostat 60-240 mg/day
11443393|NCT01742988|Experimental|Fimepinostat - 3x/week|Fimepinostat 60-180 mg/day
11443394|NCT01742988|Experimental|Fimepinostat - 4x/week|Fimepinosta 60-180 mg/day
11443395|NCT01742988|Experimental|Fimepinostat - 5x/week|Fimepinostat 60-180 mg/day
11443396|NCT01742988|Experimental|Fimepinostat - Expansion 5x/week|Fimepinostat 60 mg on the 5 days on/2 days off
11443397|NCT01742988|Experimental|Fimepinostat - Expansion 3x/week|Fimepinostat 120 mg 3 days on/4 days off
11443398|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ rituximab|Fimepinostat 60 mg 5 days on.2 days off plus rituximab
11443399|NCT01742988|Experimental|Fimepinostat 120 mg - Combination w/ rituximab|Fimepinostat 120 mg 3x/week plus rituximab
11443400|NCT01742988|Experimental|Fimepinostat - Biocomparability Arm|Biocomparability Arm
11443401|NCT01742988|Experimental|Fimepinostat 30 mg - Combination w/ venetoclax|Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
11443402|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ venetoclax|Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
11443403|NCT01742988|Experimental|Fimepinostat - Combination w/ venetoclax and rituximab|Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle
11443404|NCT01742975|Experimental|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
11443405|NCT01742975|No Intervention|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
11443406|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
11443407|NCT01742949|Active Comparator|Thermosmart|Subjects receive heated humidification
11443408|NCT01742949|Placebo Comparator|No humidification|Subjects use dry CPAP / APAP
11443409|NCT01742936|Experimental|Spinal fusion|Patients undergoing a posterior spinal fusion and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
11443410|NCT01742936|Experimental|Cardiac bypass|Patients undergoing surgery requiring cardiopulmonary bypass and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
11443411|NCT01742923|Placebo Comparator|Usual care|Usual care
11443412|NCT01742923|Experimental|Complex tailored intervention|"The interventions consists of 3 elements:
~Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications
~Consultation with a pharmacist using motivational interviewing techniques
~Follow-up telephone calls one month and six months after inclusion"
11443413|NCT01742910|Other|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
11443414|NCT01742910|Other|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
11443415|NCT01742897|Experimental|TTS-fentanyl|Transdermal therapeutic system (TTS) fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
11443416|NCT01742884|Experimental|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
11443417|NCT01742884|Placebo Comparator|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
11443418|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
11443419|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
11443420|NCT01742858||Adolescents|15-18 years old
11443421|NCT01742858||Young adults I|19-24 years old
11443422|NCT01742858||Young adults II|25-30 years old
11443559|NCT01742065|No Intervention|Usual Care|Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
11443423|NCT01742845|Active Comparator|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
11443424|NCT01742845|Experimental|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
11443425|NCT01742832|Active Comparator|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
11443426|NCT01742832|Placebo Comparator|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
11443427|NCT01742819||Advanced glaucoma|Patients with MD < -6 or visual field loss within the central 10 degrees of the visual field.
11443428|NCT01742806|No Intervention|control|not to use bio-absorbable felt(NEOVEIL®)
11443429|NCT01742806|Experimental|NEOVEIL®|To use bio-absorbable felt
11443430|NCT01742793|Experimental|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:
~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous
~2 10mg D1-7, D15-21 6mg D1, 8, 15
~1 10mg D1-7, D15-21 8mg D1, 8, 15
~10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15
~The first patient in arm L will be entered into the study at dosing level one."
11443431|NCT01742793|Experimental|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:
~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone
~2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22
~1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22
~15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22
~The first patient in arm M will be entered into the study at dosing level one."
11443432|NCT01742780|Active Comparator|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
11443433|NCT01742780|Active Comparator|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
11443434|NCT01742780|Active Comparator|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
11443435|NCT01742780|Active Comparator|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
11443436|NCT01742767|Active Comparator|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
11443437|NCT01742767|Experimental|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
11443438|NCT01742754|Experimental|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
11443439|NCT01742741|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
11443440|NCT01742741|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
11443441|NCT01742728||Nagasaki|Sample collection
11443442|NCT01742728||Tokushima|Oxidative stress, cytokine
11443443|NCT01742728||Kanagawa|oxidative stress
11443477|NCT01742559|Experimental|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman & Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
11443444|NCT01742715|Experimental|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.
~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
11443445|NCT01742715|Experimental|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.
~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
11443446|NCT01742715|Experimental|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
11443447|NCT01742702||DYNAMIC|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
11443448|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
11443449|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
11443450|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
11443451|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
11443452|NCT01742702||Aortic stenosis|Subjects with aortic stenosis confirmed by echocardiography
11443453|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
11443454|NCT01742689|Experimental|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray & 100 milligram indomethacin suppository
11443455|NCT01742689|Placebo Comparator|Placebo intranasal spray|Patients in this group will receive placebo nasal spray & 100 milligram indomethacin suppository
11443456|NCT01742676|Experimental|ADVAGRAF group|
11443457|NCT01742676|Active Comparator|PROGRAF group|
11443458|NCT01742663|Experimental|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
11443459|NCT01742663|Active Comparator|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
11443460|NCT01742663|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
11443461|NCT01742650|Active Comparator|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
11443462|NCT01742650|Active Comparator|TightRope|TightRope transfixation of syndesmosis
11443463|NCT01742637|Experimental|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
11443464|NCT01742637|Active Comparator|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
11443465|NCT01742637|Placebo Comparator|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
11443466|NCT01742624|Experimental|Advagraf group|
11443467|NCT01742624|Active Comparator|Prograf group|
11443468|NCT01742611|Experimental|ASP1585 group|
11443469|NCT01742598|Experimental|Portico Implant|
11443470|NCT01742585|Experimental|ASP1585 group|
11443471|NCT01742585|Placebo Comparator|placebo group|
11443472|NCT01742572|Experimental|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
11443473|NCT01742572|Experimental|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
11443474|NCT01742572|Experimental|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
11443475|NCT01742572|Experimental|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
11443476|NCT01742572|Active Comparator|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
11443558|NCT01742078|Experimental|750 mg LY2541546 - IV, OL|Single dose of 750 mg LY2541546 administered IV, OL
11450398|NCT01697410|Active Comparator|norepinephrine|
11443478|NCT01742559|Active Comparator|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
11443479|NCT01742546|Experimental|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.
~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
11443480|NCT01742546|Sham Comparator|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
11443481|NCT01742533|Experimental|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
11443482|NCT01742533|Experimental|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
11443483|NCT01742533|Experimental|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
11443484|NCT01742533|Experimental|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
11443485|NCT01742520|Active Comparator|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
11443486|NCT01742520|Active Comparator|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
11443487|NCT01742507|Active Comparator|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
11443488|NCT01742507|Active Comparator|Biomatrix stent|Biomatrix stent
11443489|NCT01742494|Active Comparator|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
11443490|NCT01742494|Active Comparator|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
11443491|NCT01742481|Experimental|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
11443492|NCT01742481|Placebo Comparator|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
11443493|NCT01742468|Experimental|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
11443494|NCT01742468|Placebo Comparator|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
11443495|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
11443496|NCT01742429|Experimental|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
11443497|NCT01742429|Active Comparator|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
11443498|NCT01742416|Experimental|Ultrasound|
11443499|NCT01742416|Active Comparator|Palpation Method|
11443500|NCT01742403|Experimental|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:
~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
11443501|NCT01742390|Experimental|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
11443502|NCT01742390|Active Comparator|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
11443503|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
11443504|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
11443505|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
11443506|NCT01742364|Experimental|Bioject Intradermal (ID) Pen|Intradermal administration of BCG vaccine via the Bioject ID Pen.
11443507|NCT01742364|Active Comparator|Needle and syringe|Intradermal administration of BCG vaccine via needle and syringe.
11443508|NCT01742351|Experimental|Guided internet-based cognitive behavior therapy (CBT)|
11443509|NCT01742338|Active Comparator|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.
~*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
11443510|NCT01742338|Experimental|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. *If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
11443511|NCT01742325|Other|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
11443512|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
11599029|NCT00654550|Experimental|1|
11443513|NCT01742299|Experimental|imatinib mesylate|The starting dose of imatinib should be the same as the last dose that was given in the parent imatinib study (400 mg/day to 600 mg/day). After this, the dose of imatinib is based on the investigator's judgment.
11443514|NCT01742286|Experimental|LDK378|All participants were administered a single-agent LDK378 (Ceritinib) orally, once daily, continuously in fasted or fed conditions.
11443515|NCT01742273|No Intervention|standard treatment (usual care)|standard treatment (usual care)
11443516|NCT01742273|Experimental|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
11443517|NCT01742260|Experimental|Repair of cranial defect|Repair of cranial defects by tissue engineering
11443518|NCT01742247|Experimental|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated & Non-treated
~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
11443519|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
11443520|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
11443521|NCT01742221|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
11443522|NCT01742221|Placebo Comparator|Placebo|Single subcutaneous dose
11443523|NCT01742208|Experimental|Sotagliflozin 400 mg - Pioneer Group|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
11443524|NCT01742208|Placebo Comparator|Placebo - Expansion Group|Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
11443525|NCT01742208|Experimental|Sotagliflozin 400 mg - Expansion Group|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.
11443526|NCT01742195|Other|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
11443527|NCT01742195|Other|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
11443528|NCT01742182|No Intervention|Control|
11443529|NCT01742182|No Intervention|PD patients without sleep problems|
11443530|NCT01742182|Active Comparator|PD patients with sleep problems|light exposure
11443531|NCT01742182|Placebo Comparator|PD patients with sleep problem|light exposure
11443532|NCT01742169|Experimental|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
11443533|NCT01742169|No Intervention|Usual Care|Patients assigned to this arm will receive usual care.
11443534|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
11443535|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
11443536|NCT01742143||ICCAN|For those randomized into the ICCAN arm, the core of the intervention will be three ICCAN Access Facilitators who will assess needs and synchronize for each patient an individualized set of transdisciplinary services.
11443537|NCT01742143||Usual and Customary Group (U&C)|Participants in this group will receive the same written materials on social and economic resources as ICCAN group.
11443538|NCT01742130|Experimental|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
11443539|NCT01742130|Active Comparator|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
11443540|NCT01742117|Active Comparator|Clopidogrel then Retrospective Genotyping|Clopidogrel 75 mg daily for 1 year after PCI. DNA samples at baseline to be frozen. At 12 months DNA will be genotyped to determine the *2 & *3 reduced function/wild type allele status.
11443541|NCT01742117|Active Comparator|Prospective Genotyping - Clopidogrel|Patients with the wild type CYP2C19 allele (based on prospective genotype testing) will be assigned to receive a clopidogrel 75mg tablet daily for 1 year following PCI.
11443542|NCT01742117|Active Comparator|Prospective Genotyping - Ticagrelor|Patients with the CYP2C19 heterozygous and homozygous *2 and *3 reduced function allele (based on prospective genotype testing) will be assigned to receive a ticagrelor 90 mg tablet twice per day for one year following PCI.
11443543|NCT01742117|Experimental|Digital Sub-Study|Patients previously enrolled in TAILOR-PCI in participating sites in U.S. and Canada will be invited to enroll in a digital sub-study through 24 months post PCI, utilizing their own smartphones.
11443544|NCT01742091|Experimental|180 mg LY2541546 SC Q4W|180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
11443545|NCT01742091|Experimental|270 mg LY2541546 SC Q2W|270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.
11443546|NCT01742091|Experimental|270 mg LY2541546 SC Q4W|270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
11443547|NCT01742091|Experimental|540 mg LY2541546 IV Q4W|540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.
11443548|NCT01742091|Experimental|750 mg LY2541546 IV Q2W|750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.
11443549|NCT01742091|Placebo Comparator|Placebo Q2W|Placebo administered IV or SC once every 2 weeks for 8 weeks.
11443550|NCT01742078|Experimental|7.5 mg LY2541546 - IV|Single dose of 7.5 mg LY2541546 administered intravenously (IV)
11443551|NCT01742078|Experimental|25 mg LY2541546 - IV|Single dose of 25 mg LY2541546 administered IV
11443552|NCT01742078|Experimental|75 mg LY2541546 - IV|Single dose of 75 mg LY2541546 administered IV
11443553|NCT01742078|Experimental|225 mg LY2541546 - IV|Single dose of 225 mg LY2541546 administered IV
11443554|NCT01742078|Experimental|750 mg LY2541546 - IV|Single dose of 750 mg LY2541546 administered IV
11443555|NCT01742078|Experimental|150 mg LY2541546 - SC|Single dose of 150 mg LY2541546 administered subcutaneous (SC)
11443556|NCT01742078|Placebo Comparator|Placebo|Single dose of placebo administered IV or SC
11443557|NCT01742078|Experimental|225 mg LY2541546 - IV, OL|Single dose of 225 mg LY2541546 administered IV, open label (OL)
11451669|NCT01688830|Placebo Comparator|Placebo|
11443560|NCT01742065|Active Comparator|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
11443561|NCT01742052|Experimental|MT-1303-Low|MT-1303-Low Dose
11443562|NCT01742052|Experimental|MT-1303-Middle|MT-1303-Middle Dose
11443563|NCT01742052|Experimental|MT-1303-High|MT-1303-High Dose
11443564|NCT01742052|Placebo Comparator|Placebo|Placebo
11443565|NCT01742039||b-blocker|
11443566|NCT01742039||amiodarone|
11443567|NCT01742039||atrial pacing|
11443568|NCT01742039||amiodarone plus atrial pacing|
11443569|NCT01742026||High Risk Oncohematological Patients|Detection Aspergillus PCR technique and Aspergillus AGA technique
11443570|NCT01742013|Placebo Comparator|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
11443571|NCT01742013|Experimental|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
11443572|NCT01742000|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
11443573|NCT01742000|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
11443574|NCT01741987|Active Comparator|optive® eye drop|
11443575|NCT01741987|Placebo Comparator|fresh tears ® eye drop|
11443576|NCT01741974|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
11443577|NCT01741974|Placebo Comparator|Sugar pill|Placebo tablet 500 mg by mouth three times a day
11443578|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
11443579|NCT01741948||First time users of hormonal contraceptive|
11443580|NCT01741922|Experimental|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
11443581|NCT01741922|Active Comparator|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
11443582|NCT01741909|Experimental|Before, After|The intervention is educational
11443583|NCT01741896|Active Comparator|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
11443584|NCT01741896|No Intervention|Control arm|Patients in the control arm will undergo no extra intervention.
11443585|NCT01741883|No Intervention|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
11443586|NCT01741883|Experimental|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
11443587|NCT01741883|Active Comparator|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
11443588|NCT01741870|Placebo Comparator|Control|No intervention was given. All subjects received routine care
11443589|NCT01741870|Active Comparator|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
11443590|NCT01741857|Experimental|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
11443591|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
11443592|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
11443593|NCT01741818||Group B|CVP less than 8cmH2o
11443594|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
11443595|NCT01741792|Experimental|Blinatumomab|By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
11443596|NCT01741779|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
11443597|NCT01741779|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
11443598|NCT01741779|Experimental|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
11443599|NCT01741779|Experimental|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
11443600|NCT01741766|Experimental|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
11443601|NCT01741766|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
11443602|NCT01741753|Experimental|Treatment Arm|BKM120+Abiraterone+Prednisone
11443603|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
11443604|NCT01741727|Experimental|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
11443605|NCT01741714|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
11443606|NCT01741714|Sham Comparator|Sham manipulation|Sham chiropractic manipulative therapy
11443607|NCT01741714|No Intervention|Control group|No intervention, follow headache diary
11443608|NCT01741701|Experimental|Oxaloacetate (OAA)|active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
11443609|NCT01741701|Placebo Comparator|Placebo|placebo capsules that contain only 100 mg ascorbate, taken daily
11443610|NCT01741688||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).
11443611|NCT01741675|Experimental|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
11443612|NCT01741675|Other|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
11443613|NCT01741662|Other|group psychopathological|
11443614|NCT01741649|Experimental|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
11443615|NCT01741649|Experimental|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
11443616|NCT01741636|Experimental|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
11443617|NCT01741623|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
11443618|NCT01741623|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
11443619|NCT01741610|Placebo Comparator|No coloading (Group E)|Placebo comparator
11443620|NCT01741610|Active Comparator|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
11443621|NCT01741610|Active Comparator|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
11443622|NCT01741597|Experimental|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
11443623|NCT01741584|Experimental|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
11443624|NCT01741584|Placebo Comparator|aerobic|6 months of exercise <30% anaerobic threshold
11443625|NCT01741571|Active Comparator|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.
~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
11443626|NCT01741571|Experimental|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.
~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
11443627|NCT01741558|Experimental|Methotrexate|Established treatment associated with methotrexate
11443628|NCT01741558|Placebo Comparator|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
11443629|NCT01741545|Experimental|Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks
~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks
~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
11443630|NCT01741545|Experimental|Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks
~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks
~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
11443631|NCT01741532|Experimental|Deferiprone|Deferiprone 80 mg/mL oral solution
11443632|NCT01741532|Placebo Comparator|Placebo|Matching placebo solution
11443633|NCT01741519|Experimental|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
11443634|NCT01741519|Active Comparator|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
11443635|NCT01741506|Experimental|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
11443636|NCT01741506|No Intervention|No treatment|No treatment
11443637|NCT01741506|Other|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
11443638|NCT01741493|Experimental|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
11443639|NCT01741493|Experimental|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
11443640|NCT01741493|Placebo Comparator|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
11443641|NCT01741493|Other|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
11443642|NCT01741480|Placebo Comparator|Routine care|General hospital ward patients will receive routine care.
11443643|NCT01741480|Experimental|Intervention arm|The intervention with early warning system monitoring is to have the rapid response team assess the patients real-time.
11443644|NCT01741467|Experimental|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
11443645|NCT01741454|Active Comparator|Tamsulosin plus placebo 7-day treatment|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
11443646|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 7-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
11443647|NCT01741454|Active Comparator|Tamsulosin plus placebo 21-day treamtnet|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
11443648|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 21-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
11443649|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
11443650|NCT01741428|Active Comparator|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
11443651|NCT01741428|No Intervention|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
11443652|NCT01741428|Active Comparator|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
11443653|NCT01741428|No Intervention|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
11443654|NCT01741415|Experimental|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
11443655|NCT01741415|Placebo Comparator|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
11443656|NCT01741402|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
11443657|NCT01741402|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
11443658|NCT01741389|Placebo Comparator|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
11443659|NCT01741389|Active Comparator|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
11443660|NCT01741376|Placebo Comparator|Placebo + Placebo|Two placebos are given for 84 days.
11443661|NCT01741376|Active Comparator|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
11443662|NCT01741363|Experimental|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
11443663|NCT01741363|Active Comparator|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
11443664|NCT01741363|Experimental|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
11443665|NCT01741363|Experimental|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
11443666|NCT01741363|Experimental|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
11443667|NCT01741350|Experimental|CHRP Group|Patients assigned to Community-friendly Health Recovery Program (CHRP) will receive a weekly HIV risk reduction group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. The CHRP intervention is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
11443668|NCT01741350|Active Comparator|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
11443669|NCT01741337|Experimental|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
11443670|NCT01741337|No Intervention|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
11443671|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
11443672|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
11443673|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
11443674|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
11443675|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
11443676|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
11443677|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
11443678|NCT01741324|Placebo Comparator|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
11443679|NCT01741324|Placebo Comparator|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
11443680|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
11443681|NCT01741311|Experimental|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
11443682|NCT01741311|Active Comparator|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
11443683|NCT01741298|Experimental|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
11443684|NCT01741285|Active Comparator|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
11443685|NCT01741285|Active Comparator|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
11443686|NCT01741285|Experimental|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
11443687|NCT01741272|Active Comparator|Group A (Usual Care)|Will be immobilized in a sling for 6 weeks. Intervention: Procedure: Sling
11443688|NCT01741272|Experimental|Group B (Early ROM)|Will use the sling for comfort only. Intervention: Procedure: No sling
11443689|NCT01741259|Experimental|Meperidine PCEA|Epidural Meperidine (5mg/ml) bolus of 20 mg, lockout of 30 min, hourly limit of 50 mg.
11443690|NCT01741259|Experimental|Meperidine PCEA with basal|Epidural meperidine (5mg/ml) basal rate of 10 mg/hr, bolus 20 mg, lockout 30 min, hourly limit 40 mg
11443691|NCT01741246||Control|Headache-free subjects.
11443692|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
11443693|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
11443694|NCT01741233|Experimental|UV-B irraditation|VitDgen
11443695|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
11443696|NCT01741207|No Intervention|control|control This group is without N-acetylcystein : just receives standard treatment
11443697|NCT01741207|Active Comparator|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
11443698|NCT01741194|Experimental|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
11443699|NCT01741194|Placebo Comparator|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
11443700|NCT01741181|Active Comparator|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
11443701|NCT01741181|Placebo Comparator|Placebo pill|Placebo pill
11443702|NCT01741168|Active Comparator|TLSO|TLSO brace 8-10 weeks
11443703|NCT01741168|Experimental|No Orthosis|No Orthosis
11443704|NCT01741155|Experimental|SPI-1620 & Docetaxel|"Single Arm and Randomized Part:
~SPI-1620: 11μg/m2 Docetaxel: 75 mg/m2"
11443705|NCT01741155|Active Comparator|Docetaxel|Randomized Part only Docetaxel: 75 mg/m2 on Day 1 in 3-week cycles
11443706|NCT01741142|Experimental|ABT-436|Subject receiving ABT-436
11443707|NCT01741142|Active Comparator|Escitalopram|Subject receiving escitalopram.
11443708|NCT01741142|Placebo Comparator|Placebo|Subject receiving placebo
11443709|NCT01741129|Active Comparator|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:
~Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of >88% to 92%.
~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
11443710|NCT01741129|Active Comparator|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:
~Infants needed invasive MV or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of > 88% to 92%.
~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
11443711|NCT01741116|Experimental|TKI258, inhibitor of RTKs|"Intervention: TKI258
~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:
~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
11443712|NCT01741103|Experimental|Sitagliptin|
11443713|NCT01741103|Placebo Comparator|Placebo|
11451670|NCT01688830|Experimental|BI 655075 with dabigatran|
11443714|NCT01741090|Experimental|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
11443715|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
11443716|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
11443717|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
11443718|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
11443719|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
11443720|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
11443721|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
11443722|NCT01741051|Experimental|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
11443723|NCT01741051|No Intervention|Control|
11443724|NCT01741038|Experimental|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
11443725|NCT01741038|Other|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
11443726|NCT01741025|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
11443727|NCT01741025|Active Comparator|conservative management|Medications, physical therapy, information
11443728|NCT01741012|Experimental|Gardasil|0.5 ml single dose Gardasil vaccine given at three separate visits
11443729|NCT01740999|Experimental|silicone arthroplasty|silicone arthroplasty
11443730|NCT01740999|Active Comparator|arthrodesis|arthrodesis
11443731|NCT01740986|Experimental|SA09012 Low dose|
11443732|NCT01740986|Experimental|SA09012 High dose|
11443733|NCT01740986|Placebo Comparator|Placebo|
11443734|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
11443735|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
11443736|NCT01740960|Active Comparator|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
11443737|NCT01740960|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
11443738|NCT01740947|No Intervention|Standard treatment|Standard treatment for colorectal cancer
11443739|NCT01740947|Experimental|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.
~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
11443740|NCT01740934|Active Comparator|Anatabloc Cream|Twice daily use of active facial cream
11443741|NCT01740934|Placebo Comparator|Placebo Cream|Twice daily use of placebo facial cream
11443742|NCT01740921|Active Comparator|Liraglutide|Liraglutide (Victoza) daily injections
11443743|NCT01740921|Placebo Comparator|diet|reduction in calorie intake
11443744|NCT01740921|Placebo Comparator|Aspirin|Aspirin 300mg once daily
11443745|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
11443746|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
11443747|NCT01740869|Experimental|Experimental: Patients|Children who will receive intrathecal autologous stem cells
11443748|NCT01740869|Other|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
11443749|NCT01740856|Experimental|Rest three hours|Rest three hours
11443750|NCT01740856|Experimental|Rest five hours|Rest five hours
11443751|NCT01740843|Active Comparator|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
11443752|NCT01740843|Experimental|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
11443753|NCT01740843|Sham Comparator|Sham tDCS|Sham will be administered for 10 min at 0 mA
11443754|NCT01740830|Active Comparator|Anodal tDCS|
11443755|NCT01740830|Sham Comparator|Sham tDCS|
11443756|NCT01740817|Experimental|Intralipid 20%, then saline|Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.
11443757|NCT01740817|Experimental|Saline, then Intralipid|Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.
11443758|NCT01740791|Experimental|Cohort 1|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
11443759|NCT01740791|Experimental|Cohort 2|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
11443760|NCT01740791|Experimental|Cohort 3|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
11443761|NCT01740791|Experimental|Cohort 4|(N = 10, genotype 1a): up to 150 mg GS-5816 or placebo QD fasted for 3 days
11599086|NCT00654186|Experimental|1|
11443762|NCT01740791|Experimental|Cohort 5|(N = 10, genotype 2): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443763|NCT01740791|Experimental|Cohort 6|(N = 10, genotype 2): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443764|NCT01740791|Experimental|Cohort 7|(N = 10, genotype 3): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443765|NCT01740791|Experimental|Cohort 8|(N = 10, genotype 4/5/6): up to 400 mg GS-5816 QD fasted for 3 days
11443766|NCT01740791|Experimental|Cohort 9|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443767|NCT01740791|Experimental|Cohort 10|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443768|NCT01740791|Experimental|Cohort 11|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443769|NCT01740791|Experimental|Cohort 12|(N = 10, genotype 1a, 1b, 2, 3 or 4/5/6): up to 400 mg GS-5816 or placebo QD fasted for 3 days
11443770|NCT01740778||Study Group 1|Aurora vs. Microlet 2
11443771|NCT01740778||Study Group 2|Aurora vs. SoftClix
11443772|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
11443773|NCT01740778||Study Group 4|Aurora vs. Multiclix
11443774|NCT01740765|Experimental|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
11443775|NCT01740765|Experimental|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
11443776|NCT01740765|Experimental|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
11443777|NCT01740752|Experimental|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
11443778|NCT01740752|Experimental|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
11443779|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
11443780|NCT01740726|Experimental|Behavioral Activation|
11443781|NCT01740726|Active Comparator|Fluoxetine|
11443782|NCT01740713|Experimental|Deferiprone, dose level 1|single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
11443783|NCT01740713|Experimental|Deferiprone, dose level 2|single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
11443784|NCT01740713|Experimental|Deferiprone, dose level 3|single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
11443785|NCT01740700|Experimental|p-Branch®|
11443786|NCT01740687||Essure+NovaSure|The group of women relying on Essure micro-inserts for permanent birth control when NovaSure is performed following a successful Essure Confirmation Test
11443787|NCT01740674|Experimental|Electronic data collection|The group of participants who will complete questionnaires via the internet
11443788|NCT01740674|No Intervention|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
11443789|NCT01740661|Experimental|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
11443790|NCT01740661|Placebo Comparator|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
11443791|NCT01740648|Experimental|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.
~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11443792|NCT01740635|Experimental|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
11443823|NCT01740427|Experimental|PD-0332991 + Letrozole|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
11443824|NCT01740427|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
11443825|NCT01740414|Active Comparator|MN-166 (formerly AV411) First|Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance.
11451671|NCT01688817|Other|Physician's counseling|
11443793|NCT01740635|No Intervention|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
11443794|NCT01740622|Experimental|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
11443795|NCT01740622|No Intervention|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
11443796|NCT01740609|Placebo Comparator|1. Placebo|Placebo
11443797|NCT01740609|Experimental|2.0|
11443798|NCT01740596|Experimental|C-Pulse® System|C-Pulse® System Counterpulsation
11443799|NCT01740596|No Intervention|Control Arm|Optimal Medical Therapy
11443800|NCT01740583|Experimental|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
11443801|NCT01740570|Experimental|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.
~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.
~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
11443802|NCT01740557|Experimental|Treatment (genetically modified T-cells, high-dose aldesleukin|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
11443803|NCT01740544|Experimental|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
11443804|NCT01740544|Experimental|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
11443805|NCT01740544|Sham Comparator|Sham tDCS in young study participants|Sham tDCS in young study participants
11443806|NCT01740544|Sham Comparator|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
11443807|NCT01740531|Experimental|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
11443808|NCT01740531|Active Comparator|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
11443809|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
11443810|NCT01740518||PEG 4L|Those who taken PEG 4L alone
11443811|NCT01740505|Experimental|Timing and Coordination|
11443812|NCT01740505|Experimental|Aerobic Walking|
11443813|NCT01740505|Active Comparator|Stretching and Relaxation|
11443814|NCT01740492|Experimental|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).
~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
11443815|NCT01740492|Experimental|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).
~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
11443816|NCT01740492|Placebo Comparator|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
11443817|NCT01740479|Active Comparator|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.
~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
11443818|NCT01740479|No Intervention|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.
~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
11443819|NCT01740466||Ocular diseases|Observational
11443820|NCT01740453|No Intervention|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
11443821|NCT01740453|Experimental|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
11443822|NCT01740440|Other|BMR Face treatment|BMR Face treatment used once a day for 12 weeks
11443826|NCT01740414|Placebo Comparator|Placebo First|Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance.
11443827|NCT01740401|Experimental|Cyclophosphamide, Ipilimumab|"Treatment:
~Cyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)
~Ipilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
11443828|NCT01740388|Experimental|Besifloxacin|besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
11443829|NCT01740388|Placebo Comparator|Vehicle|vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
11443830|NCT01740375|No Intervention|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
11443831|NCT01740375|Experimental|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
11443832|NCT01740362|Other|Healthy volunteers|Healthy volunteers
11443833|NCT01740362|Experimental|Mild renal impairment|patients with mild (>50 and ≤80 mL/min) renal impairment
11443834|NCT01740362|Experimental|Moderate renal impairment|patients with moderate (≥30 and ≤50 mL/min) renal impairment
11443835|NCT01740362|Experimental|severe renal impairment|patients with severe (<30 mL/min) renal impairment
11443836|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
11443837|NCT01740336|Experimental|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
11443838|NCT01740336|Placebo Comparator|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
11443839|NCT01740323|Placebo Comparator|Placebo|Placebo
11443840|NCT01740323|Experimental|Curcumin|500 mg BID
11443841|NCT01740310|Experimental|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
11443842|NCT01740310|Experimental|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
11443843|NCT01740310|Placebo Comparator|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
11443844|NCT01740297|Experimental|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
11443845|NCT01740297|Active Comparator|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
11443846|NCT01740297|Experimental|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
11443847|NCT01740284|Active Comparator|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
11443848|NCT01740284|Placebo Comparator|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
11443849|NCT01740271|Experimental|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
11443850|NCT01740258|Experimental|Bevaczimab, Radiation Therapy, Temozolomide|"In Part A, newly-diagnosed patients with Grade 4 malignant gliomas will receive standard radiation therapy, daily Temodar 75mg/M for 6-8 weeks. Bevacizumab will be given concurrently with radiation therapy and Temodar, 10 mg/kg every two weeks.
~If they are stable at the end of Part A, they will continue to Part B. In Part B patients will receive up to 12 cycles of bevacizumab and Temodar. Bevacizumab will be given on Days 1 and 15 of a 28-day cycle. Temodar will be 200 mg/meter squared daily for 5 days (days 1-5) of each cycle.
~If they have not progressed, patients will start Part C. In Part C, patients will receive bevacizumab 10mg/kg approximately every 2 weeks or 15 mg/kg approximately every 3 weeks.
~If patients progress during Part B or C, they will start Part D. In Part D, patients will receive bevacizumab-based therapy containing bevacizumab in combination with a chemotherapy and/or biologic agent, as determined by the Duke treating physician."
11443851|NCT01740245|Active Comparator|Chlorhexidine|
11443852|NCT01740245|Experimental|Polyhexamethylene biguanide|
11600224|NCT00646685|Other|2|
11443853|NCT01740232|Active Comparator|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
11443854|NCT01740232|Placebo Comparator|Normal meniscal repair|standard operation. Normal meniscalrepair.
11443855|NCT01740219|Experimental|Capacity Enhancement|
11443856|NCT01740219|Active Comparator|Standard Dissemination|
11443857|NCT01740206|Active Comparator|Amphetamine and/or methylphenidate|Patients who took their amphetamine and/or methylphenidate the morning of surgery.
11443858|NCT01740206|Experimental|Hold stimulant medication|Patients who did not take their stimulant medication the morning of surgery.
11443859|NCT01740193|Active Comparator|TAP Block|
11443860|NCT01740193|Active Comparator|Ilioinguinal/iliohypogastric blockade|
11443861|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).
~Intervention: Data entry"
11443862|NCT01740167|Experimental|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
11443863|NCT01740154|Experimental|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
11443864|NCT01740141|Other|Plexus before surgery|Plexus brachialis before surgery
11443865|NCT01740141|Other|Plexus after surgery|Plexus brachialis performed after surgery
11443866|NCT01740128|Experimental|Multimodal then Treadmill training|Participants will undergo harness-supported multimodal balance training exercises while simultaneously performing skilled hand exercises. Following a washout period of at least 6 weeks, Participants will undergo body weight supported treadmill training using the Lokomat apparatus.
11443867|NCT01740128|Active Comparator|Treadmill then Multimodal training|Robotic body weight supported treadmill training will be applied using the Lokomat apparatus. Following a washout period of at least 6 weeks, Participants will undergo harness-supported balance training exercises while simultaneously performing skilled hand exercises.
11443868|NCT01740102|Experimental|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
11443869|NCT01740102|No Intervention|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
11443870|NCT01740089|Experimental|Algeron 1.5 μg/kg|Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
11443871|NCT01740089|Experimental|Algeron 2.0 μg/kg|Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
11443872|NCT01740089|Active Comparator|PegIntron|PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
11443873|NCT01740076|Experimental|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
11443874|NCT01740076|Other|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
11443875|NCT01740063|Experimental|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
11443876|NCT01740063|Experimental|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
11443877|NCT01740063|Placebo Comparator|Placebo|placebo group
11443878|NCT01740050|Active Comparator|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
11443879|NCT01740050|Active Comparator|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
11443880|NCT01740050|Active Comparator|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
11443881|NCT01740037|Experimental|Specialized AF-clinic|Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
11443882|NCT01740037|Active Comparator|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
11443955|NCT01739478|Experimental|Non-packing of abscess cavity|
11443956|NCT01739478|Other|Packing of abscess cavity|Current practice
11443883|NCT01740024|Experimental|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
11443884|NCT01740011|Experimental|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
11443885|NCT01740011|Active Comparator|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
11443886|NCT01739998|Experimental|functional oil|Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour] during the day by 8 weeks.
11443887|NCT01739998|Placebo Comparator|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
11443888|NCT01739985|Active Comparator|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
11443889|NCT01739985|Experimental|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
11443890|NCT01739972|Active Comparator|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
11443891|NCT01739972|Active Comparator|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
11443892|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
11443893|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
11443894|NCT01739946||Implanted subject|Subjects with Interstim implanted
11443895|NCT01739946||Controls|Subjects without Interstim implanted
11443896|NCT01739933|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 5 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.
~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr."
11443897|NCT01739933|Active Comparator|Propofol|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 10 mg/mL propofol. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.
~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the propofol group, dose will range from 5-50 mcg/kg/min."
11443898|NCT01739920|Experimental|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
11443899|NCT01739920|Active Comparator|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
11443900|NCT01739907|Experimental|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
11443901|NCT01739907|Experimental|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
11443902|NCT01739894|Experimental|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
11443903|NCT01739855|Active Comparator|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:
~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
11443904|NCT01739855|No Intervention|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
11443905|NCT01739842|Active Comparator|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.
~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
11443906|NCT01739842|Placebo Comparator|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.
~During the medication week, participants will take 2 capsules three times a day."
11443907|NCT01739829|Experimental|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
11443908|NCT01739829|Experimental|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
11443909|NCT01739816|No Intervention|Control group|Patients get no intervention at study start, but only at study end after seven months.
11443910|NCT01739816|Active Comparator|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
11443911|NCT01739816|Other|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
11443912|NCT01739803|Experimental|Intervention Group|Behavioral contract intervention
11443913|NCT01739803|No Intervention|Control Group|No intervention
11443914|NCT01739790|Placebo Comparator|Sugar Pill|Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration.
11443915|NCT01739790|Active Comparator|N-Acetylcysteine|1800 mg twice daily for 8 weeks
11443916|NCT01739777|Experimental|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
11443917|NCT01739777|Placebo Comparator|Controls|Intravenous placebo solution are administrated to Patients.
11443918|NCT01739764|Experimental|Vemurafenib 480mg BID|Participants received oral vemurafenib at 480 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
11600408|NCT00645268|Other|Open-Label Arm|
11443919|NCT01739764|Experimental|Vemurafenib 720mg BID|Participants received oral vemurafenib at 720 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
11443920|NCT01739764|Experimental|Vemurafenib 960mg BID|Participants received oral vemurafenib at 960 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
11443921|NCT01739751|No Intervention|Control Group|Patients without feedback of a pedometers, followed for 3 months
11443922|NCT01739751|Experimental|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
11443923|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
11443924|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
11443925|NCT01739725|Experimental|Helical stent insertion|Study participants will receive the helical stent
11443926|NCT01739712|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
11443927|NCT01739712|Sham Comparator|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
11443928|NCT01739699|Experimental|Acetaminophen|Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.
11443929|NCT01739699|Other|Placebo|Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.
11443930|NCT01739686|Experimental|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:
~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.
~A social worker provides structured counseling targeting adjustment to illness and depression if present.
~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.
~Most of the nurse and social worker visits are by phone."
11443931|NCT01739686|No Intervention|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
11443932|NCT01739673|Experimental|Ultraviolet-A and riboflavin|
11443933|NCT01739660|Experimental|Pegloticase|Pegloticase 8 mg single intraveneous dose
11443934|NCT01739647|Experimental|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
11443935|NCT01739647|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
11443936|NCT01739634|Experimental|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
11443937|NCT01739621|Experimental|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
11443938|NCT01739621|Experimental|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
11443939|NCT01739608|Experimental|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
11443940|NCT01739608|Active Comparator|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
11443941|NCT01739595|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
11443942|NCT01739595|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
11443943|NCT01739595|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
11443944|NCT01739582|Experimental|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
11443945|NCT01739569|Experimental|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
11443946|NCT01739569|No Intervention|Habitual meals|Dietary treatment with habitual diet
11443947|NCT01739556|Experimental|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
11443948|NCT01739556|No Intervention|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
11443949|NCT01739543|Experimental|Investigational|Subject receives Hem-Avert Device.
11443950|NCT01739543|No Intervention|Control|Subject does not receive Hem-Avert Device.
11443951|NCT01739530|Experimental|Repaircell|allogenic differentiated adipocyte
11443952|NCT01739517|Experimental|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
11443953|NCT01739504|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
11443954|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
11601549|NCT00637273|Active Comparator|3|
11443957|NCT01739465|Active Comparator|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
11443958|NCT01739465|Experimental|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
11443959|NCT01739465|Experimental|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
11443960|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
11443961|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
11443962|NCT01739439|Experimental|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
11443963|NCT01739426|Experimental|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.
~Intervention: Repair w/LigaSure"
11443964|NCT01739413|Active Comparator|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
11443965|NCT01739413|Experimental|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
11443966|NCT01739400|Experimental|Macitentan|Macitentan 10 mg tablet, once daily.
11443967|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
11443968|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
11443969|NCT01739374|Experimental|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
11443970|NCT01739361|Experimental|Acetaminophen|Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
11443971|NCT01739361|Placebo Comparator|Placebo|Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
11443972|NCT01739348|Experimental|Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II]|[Part I] Verubecestat 12 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
11443973|NCT01739348|Experimental|Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 40 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
11443974|NCT01739348|Experimental|Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 60 mg once daily until the first IA in Study Part I (Base Study). Following IA, participants in this group were switched to Verubecestat 40 mg once daily, for the remainder of Study Part I (total dosing period: 78 weeks). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
11443975|NCT01739348|Placebo Comparator|Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II]|[Part I] Placebo once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
11443976|NCT01739335|Experimental|Mifepristone|'Mifepristone Oral Tablet [Korlym] (2 x 300mg =600 mg total, once daily, at bedtime) for 7 days
11443977|NCT01739335|Placebo Comparator|Placebo|Placebo Oral tablet (2 sugar pills, once daily, at bedtime) for 7 days
11443978|NCT01739322|Experimental|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)
~Positive control (10 mg/ml histamine dihydrochloride)
~Negative control (glycerinated phenol saline solution)"
11443979|NCT01739309|Experimental|Abemaciclib|200 milligram (mg) abemaciclib administered orally every 12 hours on days 1 through 28 of a 28-day cycle
11443980|NCT01739296|Experimental|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
11443981|NCT01739296|Sham Comparator|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
11443982|NCT01739283|Experimental|hyperglycemia|Hyperglycemic clamping
11443983|NCT01739283|Experimental|hypoglycemia|Hypoglycemic clamping
11443984|NCT01739270|Active Comparator|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
11443985|NCT01739270|Active Comparator|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
11443986|NCT01739257|Experimental|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
11443987|NCT01739257|Active Comparator|Lecture|1-hour lecture on the medical management of obese patients
11443988|NCT01739244|Experimental|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
11443989|NCT01739244|Experimental|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
11443990|NCT01739244|Experimental|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
11443992|NCT01739231|Experimental|ACE527 alone|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
11443993|NCT01739231|Experimental|ACE527 plus dmLT|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 with mucosal adjuvant (dmLT) at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
11443994|NCT01739231|Active Comparator|Control: Part A and B|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of CeraVacx placebo at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
11443995|NCT01739231|Active Comparator|Control: Part B only|Eligible participants were screened and administered H10407 challenge strain concurrently with other arms in Part B of the study. Their results for Part B are combined with that of the Control Arm in Part A, which received three oral doses of CeraVacx placebo.
11443996|NCT01739218|Experimental|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
11443997|NCT01739218|Active Comparator|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
11443998|NCT01739205|Experimental|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly
~I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress
~I Negative Thoughts and Emotions
~G Where's the Fat?/Three Ways to Eat Less Fat
~G Taking Your Medications/Stress and You Bi weekly
~G Move Those Muscles/Being Active: A Way of Life
~G Challenging and Changing Negative Thoughts
~G Healthy Eating
~G Problem Solving Monthly
~G Four Keys to Healthy Eating Out
~G Social Support/Communication
~G Take Charge of What's Around You/Tip the Calorie Balance
~G The Slippery Slope of Lifestyle Change
~G Jump Start Your Activity Plan
~G Assertiveness/Make Social Cues Work for You.
~G You Can Manage Stress
~G Life Goals
~G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
11443999|NCT01739192|Placebo Comparator|Arm 1|Placebo oral daily for approximately six (6) weeks.
11444000|NCT01739192|Experimental|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
11444001|NCT01739192|Experimental|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
11444002|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
11444003|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
11444004|NCT01739166|Experimental|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
11444005|NCT01739166|Experimental|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
11444006|NCT01739153|Experimental|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
11444007|NCT01739153|Experimental|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
11444008|NCT01739153|Experimental|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
11444009|NCT01739140|Experimental|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
11444010|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
11444011|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
11444012|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
11444013|NCT01739114|Experimental|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.
~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
11444014|NCT01739114|Active Comparator|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
11444015|NCT01739101|Experimental|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
11601550|NCT00637260|Experimental|A|
11444016|NCT01739101|No Intervention|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
11444017|NCT01739101|No Intervention|Control group 2|The control group 2 received standard care.
11444018|NCT01739088|Experimental|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
11444019|NCT01739088|Sham Comparator|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
11444020|NCT01739062|Experimental|Genetic risk assessment|At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.
11444021|NCT01739062|No Intervention|Familial disposition risk assessment|
11444022|NCT01739049|Experimental|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.
~Diet and Exercise"
11444023|NCT01739049|Active Comparator|Lifestyle counselling|Diet and Exercise
11444024|NCT01739036|Active Comparator|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
11444025|NCT01739036|Active Comparator|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
11444026|NCT01739036|Active Comparator|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
11444027|NCT01739036|Active Comparator|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
11444028|NCT01739023|Experimental|Autologous Human Schwann Cells|
11444029|NCT01738997|Experimental|Group A|Dilation 10 sec
11444030|NCT01738997|Active Comparator|Group B|Dilation 2 min
11444031|NCT01738984|Experimental|MomZing Web Program|Features include selection one to three 10-minute videos demonstrating yoga, aerobics, and strengthening, specifically designed for mothers with infants 2 to 8 months of age. Women will sequence together videos personalized to their fitness level, preference for exercise type, and a choice to actively exercise with her baby or alone. Exercises with a baby will be tailored to the infant's weight and include interactions that promote cognitive development and mother-child bonding.
11444032|NCT01738984|Experimental|Standard exercise DVD|Exercise DVD that demonstrates yoga or strengthening exercises a mother can perform with her infant.
11444033|NCT01738971|No Intervention|control (standard care)|standard verbal and written advice on contraception from pharmacy
11444034|NCT01738971|Experimental|rapid access|rapid access to family planning service
11444035|NCT01738971|Experimental|progestogen only pill|one month progestogen only pill
11444036|NCT01738958|Active Comparator|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
11444037|NCT01738958|Placebo Comparator|Placebo|Placebo tablets, two times a day for 6 weeks
11444038|NCT01738945|Other|Amlodipine|Amlodipine 10 mg/day for 12 weeks
11444039|NCT01738932||Patients|women with histologically verified endometriosis
11444040|NCT01738932||Controls|Healthy Danish blood donors
11444041|NCT01738919|Active Comparator|Non-subluxated - splinting|Conservative treatment with splinting for 6 weeks.
11444042|NCT01738919|Active Comparator|Non-subluxated - operation|Operative treatment with extension block technique
11444043|NCT01738906|Experimental|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
11444044|NCT01738906|Experimental|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
11444045|NCT01738906|Experimental|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
11444046|NCT01738906|Experimental|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
11444047|NCT01738906|Experimental|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
11444048|NCT01738906|Experimental|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
11444049|NCT01738893|Experimental|A (test)/ B (reference)|initial administration of test and cross-over to reference
11444050|NCT01738893|Experimental|B (reference/ A (test)|initial administration of reference and cross-over to test
11444051|NCT01738880|Active Comparator|group C|intraoperative fluid management based on CVP
11444052|NCT01738880|Experimental|group S|intraoperative fluid management based on SVV
11444053|NCT01738867|Placebo Comparator|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
11444054|NCT01738867|Experimental|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
11444055|NCT01738867|Experimental|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
11444056|NCT01738854|Experimental|intra-cuff pressure 40 cmH2O|
11444057|NCT01738854|Active Comparator|intra-cuff pressure 60 cmH2O|
11444058|NCT01738854|Active Comparator|intra-cuff pressure 80 cmH2O|
11444216|NCT01737866|Experimental|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)
11444059|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
11444060|NCT01738828||Subjects with CAD|
11444061|NCT01738828||Subjects without CAD|
11444062|NCT01738815|Experimental|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
11444063|NCT01738802|Experimental|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
11444064|NCT01738802|Placebo Comparator|Placebo|This group will take the placebo.
11444065|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
11444066|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
11444067|NCT01738763|Experimental|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
11444068|NCT01738763|Experimental|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
11444069|NCT01738763|Experimental|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
11444070|NCT01738750|Experimental|Cost Information Included|Group of patients that will receive cost information for both the laparoscopic and open surgical procedures prior to choice of procedure.
11444071|NCT01738750|No Intervention|No Cost Information Included|Group of patients that will not receive cost information for the laparoscopic and open surgical procedures prior to choice of procedure.
11444072|NCT01738737|Experimental|Stretching|Seven stretching exercises for lower limbs during 24 sessions
11444073|NCT01738737|Experimental|Placebo laser + Stretching|application of placebo laser therapy during nine sessions plus stretching exercises during 24 sessions
11444074|NCT01738737|Experimental|Active laser + Stretching|application of active laser therapy during nine sessions plus stretching exercises during 24 sessions
11444075|NCT01738737|Experimental|Active Laser|Application of active laser only during 24 sessions
11444076|NCT01738737|No Intervention|Control|Control group that will receive a small book with informations about knee osteoarthritis and postural orientation.
11444077|NCT01738724|Experimental|Dienogest|Dienogest 2mg pills daily during 6 months
11444078|NCT01738724|Experimental|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
11444079|NCT01738724|Active Comparator|Desogestrel|Desogestrel 75mcg pills daily during six months
11444080|NCT01738711|Active Comparator|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
11444081|NCT01738711|Placebo Comparator|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
11444082|NCT01738698|Experimental|SPD489 40mg|
11444083|NCT01738698|Experimental|SPD489 100mg|
11444084|NCT01738698|Experimental|SPD489 160mg|
11444085|NCT01738698|Placebo Comparator|Placebo|
11444086|NCT01738685|Other|Control.|Nutritional Education.
11444087|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
11444088|NCT01738672|Experimental|Nitrous Oxide|Parturients who request labor analgesia will be offered inhaled nitrous oxide for labor analgesia.
11444089|NCT01738659|Experimental|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
11444090|NCT01738646|Experimental|Vorinostat & Bevacizumab|Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.
11444091|NCT01738633|Experimental|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
11444092|NCT01738633|Experimental|nutritional counseling|patients will receive nutritional counseling alone
11444093|NCT01738633|Experimental|respirology counseling|patients will receive respirology counseling alone
11444094|NCT01738633|No Intervention|standard care|patients will receive standard care
11444095|NCT01738620|Experimental|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
11444096|NCT01738620|Experimental|psychological counseling|patients will receive psychological counseling
11444097|NCT01738620|Experimental|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
11444098|NCT01738620|No Intervention|standard care|patients will receive standard care
11444099|NCT01738607|Placebo Comparator|Placebo|"basic recipe for juice and muffin recipe
~abbreviated PLB"
11444100|NCT01738607|Experimental|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.
~abbreviated CMC"
11444101|NCT01738607|Experimental|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.
~abbreviated GA"
11444102|NCT01738607|Experimental|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.
~abbreviated as PSY"
11444103|NCT01738594|Experimental|Arm A (carfilzomib)|Patients receive carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16.
11444104|NCT01738594|Experimental|Arm B (carfilzomib, romidepsin)|Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.
11444105|NCT01738581|Experimental|rTMS + SMR, then rTMS + CTL|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) and sensorimotor retraining (SMR). Second phase of treatment: rTMS and control treatment (CTL) (CTL therapy consisted of non-specific therapy that includes stretching, massage, range of motion).
11444106|NCT01738581|Experimental|rTMS + CTL, then rTMS + SMR|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) with non-specific therapy that includes stretching, massage, range of motion. Second phase of treatment: rTMS and sensorimotor retraining (SMR).
11444107|NCT01738568|Experimental|Exercise|Aerobic exercise
11444108|NCT01738555|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
11444109|NCT01738555|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
11444110|NCT01738542|Experimental|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
11444111|NCT01738542|Active Comparator|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
11444112|NCT01738529|Active Comparator|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
11444113|NCT01738529|Sham Comparator|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
11444114|NCT01738516|Other|epileptic patients|Electroencephalography
11444115|NCT01738516|Other|Healthy Volunteers|Electroencephalography and additional experimental tasks
11444116|NCT01738503|Experimental|(8 mg) RBP-6000: 50 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals.
11444117|NCT01738503|Experimental|(12 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals
11444118|NCT01738503|Experimental|(24 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.
~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
11444119|NCT01738503|Experimental|(8 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals.
11444120|NCT01738503|Experimental|(14 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.
~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
11444121|NCT01738503|Experimental|(8-24 mg) RBP-6000: 300 mg|Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals.
11444122|NCT01738490|Other|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
11444123|NCT01738490|Other|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
11444124|NCT01738477|Experimental|Boostrix Group 2|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
11444125|NCT01738477|Active Comparator|Boostrix Group 1|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
11444126|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
11444127|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
11444128|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
11444129|NCT01738451|Experimental|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
11444130|NCT01738451|Experimental|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
11444131|NCT01738451|Experimental|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
11444132|NCT01738438|Experimental|Cabozantinib|Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
11444133|NCT01738425|Experimental|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
11444134|NCT01738425|Placebo Comparator|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
11444135|NCT01738412||Study population|Stroke patients
11444136|NCT01738399|Experimental|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
11444137|NCT01738399|Placebo Comparator|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
11444138|NCT01738360|Experimental|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
11444139|NCT01738347|Experimental|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
11444140|NCT01738334|Active Comparator|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
11444141|NCT01738334|No Intervention|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
11444142|NCT01738334|Experimental|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
11444143|NCT01738321||Cardiac patients|Patients undergoing cardiac surgery
11444144|NCT01738321||Non-cardiac patients|Patients undergoing any surgery other than cardiac surgery
11444145|NCT01738308|Experimental|Healing Touch Treatment|"Healing Touch Treatment
~When enter PACU + usual standard of care.
~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
11444146|NCT01738308|Sham Comparator|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
11444147|NCT01738308|No Intervention|Control- No treatment done|Usual standard of post operative care with no additional intervention
11444148|NCT01738295|Active Comparator|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
11444149|NCT01738295|Placebo Comparator|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
11444150|NCT01738282|Experimental|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
11444151|NCT01738282|Placebo Comparator|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
11444152|NCT01738269||Apparently healthy subjects|
11444153|NCT01738269||Non-malignant conditions subjects|
11444154|NCT01738269||Malignant conditions subjects|
11444155|NCT01738256|Experimental|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
11444156|NCT01738256|Experimental|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
11444157|NCT01738256|Experimental|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
11444158|NCT01738256|Experimental|Control|Control group, no intervention.
11444159|NCT01738243|Experimental|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).
~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
11444160|NCT01738243|Experimental|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).
~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
11444161|NCT01738217|Experimental|Fluobeam|
11444162|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
11444163|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
11444164|NCT01738191|Active Comparator|Atomoxetine|The study drug target dose is Atomoxetine (ATM) 80 milligram (mg) per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
11444165|NCT01738191|Placebo Comparator|Placebo|Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
11444166|NCT01738178|Placebo Comparator|Control - Placebo|These participants will receive placebo tablets during the first 5 years
11444167|NCT01738178|Active Comparator|Caffeine group|This group of participants will receive caffeine tablets.
11444168|NCT01738152|Experimental|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
11451672|NCT01688817|Active Comparator|Information leaflet|
11444169|NCT01738139|Experimental|Treatment (ipilimumab, imatinib mesylate)|Patients receive ipilimumab IV over 90 minutes on day 1 and imatinib mesylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11444170|NCT01738113|Experimental|open kinetic chain exercise|Open kinetic chain exercise
11444171|NCT01738113|Experimental|Closed Kinetic chain exercise|Closed kinetic chain exercise
11444172|NCT01738100|Experimental|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
11444173|NCT01738100|Experimental|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
11444174|NCT01738100|Experimental|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
11444175|NCT01738100|Active Comparator|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
11444176|NCT01738087|Experimental|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
11444177|NCT01738087|Experimental|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
11444178|NCT01738087|Placebo Comparator|NEXThaler placebo|Single dose (4 inhalations)
11444179|NCT01738087|Experimental|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
11444180|NCT01738087|Experimental|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
11444181|NCT01738087|Active Comparator|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
11444182|NCT01738074|Experimental|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
11444183|NCT01738074|Placebo Comparator|Placebo|2ml of placebo by mouth every month for three month
11444184|NCT01738061|No Intervention|reference group|They continued their daily routine.
11444185|NCT01738061|Experimental|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
11444186|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
11444187|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
11444188|NCT01738035|Experimental|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
11444189|NCT01738035|Experimental|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
11444190|NCT01738035|Placebo Comparator|Placebo|Placebo (4 placebo capsules daily) for 9 months
11444191|NCT01738022|Experimental|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
11444192|NCT01738009|Experimental|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
11444193|NCT01737996|Experimental|All patients|For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir
11444194|NCT01737983|Experimental|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10^10 colony-forming units) for 6 months
11444195|NCT01737983|Placebo Comparator|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
11444196|NCT01737957|Experimental|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
11444197|NCT01737957|Active Comparator|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
11444198|NCT01737944|Experimental|10mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
11444199|NCT01737944|Experimental|15mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
11444200|NCT01737944|Experimental|20mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
11444201|NCT01737944|Experimental|25mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
11444202|NCT01737931|Experimental|Topical Steroid|Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
11444203|NCT01737931|Experimental|Topical antihistamine|Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
11444204|NCT01737931|No Intervention|No-treatment|No treatment to the application sites after the patch removal
11444205|NCT01737918|Experimental|trans obturatorial tape (TOT)|placement of a sub-urethral tape
11444206|NCT01737918|Active Comparator|solifenacin|10 mg per day
11444207|NCT01737905|Experimental|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
11444208|NCT01737905|Placebo Comparator|Arm P|Placebo comparator arm utilizing Placebo-HFA
11444209|NCT01737892|Experimental|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
11444210|NCT01737892|Active Comparator|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
11444211|NCT01737879|Experimental|Peginesatide / Epoetin Alfa|Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
11444212|NCT01737866|Experimental|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
11444213|NCT01737866|Experimental|Group 2|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
11444214|NCT01737866|Experimental|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)
11444217|NCT01737866|Experimental|Group 6|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
11444218|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®
~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
11444219|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®
~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
11444220|NCT01737840|Experimental|pantoprazole|Intravenous pantoprazole 40 mg flacon
11444221|NCT01737840|Active Comparator|ranitidine|Intravenous ranitidine 50 mg
11444222|NCT01737827|Experimental|INC280|The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis.
11444223|NCT01737814|Experimental|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
11444224|NCT01737814|Placebo Comparator|Saline|Saline administered as a continuous infusion for up to 49 hours
11444225|NCT01737801|Experimental|Lung function test|Lung function test
11444226|NCT01737788|Experimental|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (<25mm)
11444227|NCT01737788|Experimental|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
11444228|NCT01737775|Experimental|Abdominal laparoscopic surgery (C group)|
11444229|NCT01737775|Experimental|Abdominal surgery by laparotomy (L group)|
11444230|NCT01737775|Experimental|Head and neck surgery (O group)|
11444231|NCT01737762|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
11444232|NCT01737762|Placebo Comparator|Vehicle|Vehicle Control(fibrinogen solution & thrombin solution without cells)
11444233|NCT01737749||Patients undergoing cardiac surgery|
11444234|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
11444235|NCT01737723||Study population|Stroke patients
11444236|NCT01737710|Experimental|92 Non-atopic controls vaccinated with Fluzone® Intradermal|Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
11444237|NCT01737710|Experimental|Moderate to severe AD vaccinated with Fluzone® Intradermal|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
11444238|NCT01737710|Active Comparator|Moderate to severe AD vaccinated with Fluzone® (Intramuscular)|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
11444239|NCT01737710|Active Comparator|Non-atopic controls vaccinated with Fluzone® (Intramuscular)|20 non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
11444240|NCT01737710|Experimental|Mild AD participants vaccinated with Fluzone® Intradermal|20 mild atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
11444241|NCT01737697|Experimental|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
11444242|NCT01737697|Placebo Comparator|Placebo (acute phase)|Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
11444243|NCT01737697|Experimental|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
11444244|NCT01737697|Placebo Comparator|Placebo (subacute phase)|Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.
11444245|NCT01737684|Experimental|Participants With Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
11444246|NCT01737684|Experimental|Healthy Matched Control Participants|Participants who are healthy will receive a single oral dose of vibegron 100 mg.
11444247|NCT01737684|Experimental|Participants With Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
11444248|NCT01737671|Experimental|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is > 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
11444249|NCT01737658|Other|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
11444250|NCT01737658|Other|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
11444251|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
11444252|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
11444253|NCT01737632|Experimental|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
11444363|NCT01736956|Experimental|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
11444364|NCT01736956|No Intervention|Control|Control group. Will receive standard prenatal and postnatal care.
11444254|NCT01737632|Other|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
11444255|NCT01737619|Experimental|Diagnostic (PET/CT, lymph node mapping)|Patients undergo PET/CT prior to surgery. Patients then undergo intraoperative lymph node mapping with indocyanine green solution, given via superficial and deep cervical injection during full lymphadenectomy.
11444256|NCT01737606|Experimental|echography|Fast Cerebral Pulsatility Imaging
11444257|NCT01737593|Active Comparator|Acetaminophen PR|Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
11444258|NCT01737593|Active Comparator|Acetaminophen PO-low dose|Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
11444259|NCT01737593|Active Comparator|Acetaminophen PO-high dose|Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
11444260|NCT01737580|Active Comparator|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
11444261|NCT01737580|Placebo Comparator|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
11444262|NCT01737567|Experimental|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
11444263|NCT01737567|Active Comparator|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
11444264|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.
~Intervention: Catheter resistance monitoring"
11444265|NCT01737541|Experimental|Fluoxetine|fluoxetine per os 20 mg daily
11444266|NCT01737541|Placebo Comparator|Placebo|per os daily
11444267|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
11444268|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
11444269|NCT01737502|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO on days 1-28 and sirolimus PO on days 1-28 (days 8-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11444270|NCT01737489|Active Comparator|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
11444271|NCT01737489|Active Comparator|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
11444272|NCT01737489|No Intervention|Control|
11444273|NCT01737476|Sham Comparator|control|control-sham
11444274|NCT01737476|Active Comparator|Deep TMS PFC Lt|Deep TMS PFC left
11444275|NCT01737476|Active Comparator|DEEP TMS PFC Rt|DEEP TMS PFC Rt
11444276|NCT01737476|Active Comparator|Superficial TMS PFC Lt|Superficial TMS PFC Lt
11444277|NCT01737476|Active Comparator|superficial TMS PFC Rt|superficial TMS PFC Rt
11444278|NCT01737463|Active Comparator|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).
~A pancreatic duct stent was inserted immediately after the excision."
11444279|NCT01737463|Active Comparator|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).
~A pancreatic duct stent was not inserted immediately after the excision."
11444280|NCT01737450|Experimental|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
11444281|NCT01737437|Experimental|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
11444282|NCT01737437|Placebo Comparator|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
11444283|NCT01737437|Experimental|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
11444284|NCT01737437|Experimental|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
11444285|NCT01737424|Placebo Comparator|Placebo|Placebo
11444286|NCT01737424|Experimental|LC28-0126|LC28-0126(IV)
11444287|NCT01737411|Active Comparator|solifenacin|10 mg solifenacin per day for three months
11444288|NCT01737411|Experimental|cesa/vasa|repair of USL
11444289|NCT01737398|Active Comparator|Inotersen|300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
11444290|NCT01737398|Active Comparator|Placebo|Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks
11444291|NCT01737385||Type 1|One segment fracture
11444292|NCT01737385||Type 2|Two segment fracture
11444293|NCT01737385||Type 3|Three segment fracture
11444294|NCT01737385||Type 4|Four segment fracture
11444295|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
11444296|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
11444297|NCT01737372||Healthy participants|No immunological or neurological illnesses.
11444298|NCT01737359|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
11444299|NCT01737359|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
11444300|NCT01737359|Active Comparator|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
11444301|NCT01737346|Experimental|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
11444302|NCT01737320|Experimental|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
11444303|NCT01737320|Active Comparator|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.
~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.
~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
11444304|NCT01737307|Experimental|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
11444305|NCT01737307|Experimental|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
11444306|NCT01737307|Experimental|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
11444307|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
11444308|NCT01737281|Experimental|Proactive outreach|Proactive outreach to deliver 7 sessions of telephone counseling and nicotine replacement therapy.
11444309|NCT01737281|Active Comparator|Usual care|Usual smoking cessation care from clinical staff
11444310|NCT01737268|Experimental|FK949E Elderly Participants|After 2 days of dose-titration, elderly participants received either FK949E 150 mg or FK949E 300 mg once daily at bedtime from day 3 to week 52. Dose increase and reduction was allowed following dose increase or reduction guidelines and at the investigator's discretion. After which, participants went through a follow-up period of 1 week. For participants, who completed or discontinued treatment at FK949E 300 mg, a dose-tapering period was placed before proceeding to the follow-up period, and FK949E 150 mg was administered once daily for 1 week in this period.
11444311|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
11444312|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
11444313|NCT01737229|Experimental|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
11444314|NCT01737229|Experimental|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
11444315|NCT01737229|Experimental|Repairing root canals/pulp chamber floor|"Iatrogenic perforation of the pulpal floor, with or without LEO.
~Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.
~Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
11444316|NCT01737229|Experimental|Retrograde endodontic surgery - adults|"Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.
~Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
11444317|NCT01737229|Experimental|Pulpotomy in primary molars - children (3 to 12 years )|"Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.
~Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
11444318|NCT01737229|Experimental|Apexification - children (7 to 18 years) + adults|"Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.
~Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.
~Apical Root Resorption"
11444319|NCT01737216|Experimental|Zoledronic acid plus First-line chemotherapy|
11444320|NCT01737216|Active Comparator|First-line chemotherapy|
11444321|NCT01737203|Active Comparator|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
11444322|NCT01737203|Experimental|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
11444323|NCT01737203|Experimental|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
11444324|NCT01737190|Experimental|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.
~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
11444325|NCT01737177|Experimental|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
11444326|NCT01737164|Experimental|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
11444327|NCT01737164|Experimental|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
11444328|NCT01737151|Active Comparator|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
11444329|NCT01737151|Experimental|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
11444330|NCT01737138|Active Comparator|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
11444331|NCT01737138|Placebo Comparator|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
11444332|NCT01737112|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
11444333|NCT01737099|Experimental|DHA-O|
11444334|NCT01737099|Active Comparator|Fish oil|
11444335|NCT01737099|Placebo Comparator|Placebo|
11444336|NCT01737086|Experimental|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
11444337|NCT01737086|Placebo Comparator|Standard ORS|Standard oral rehydration solution
11444338|NCT01737073|Experimental|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
11444339|NCT01737073|Experimental|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
11444340|NCT01737073|Experimental|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
11444341|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tips via IVR
11444342|NCT01737060|Active Comparator|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
11444343|NCT01737060|Experimental|Reverse Total Shoulder Artroplasty|Intervention group
11444344|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
11444345|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
11444346|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
11444347|NCT01737034|Experimental|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
11444348|NCT01737034|Experimental|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
11444349|NCT01737034|Experimental|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
11444350|NCT01737034|Experimental|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
11444351|NCT01737021|Experimental|Psycho-educational intervention|Psycho-education
11444352|NCT01737021|No Intervention|Treatment as usual|
11444353|NCT01737008|Experimental|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
11444354|NCT01737008|Experimental|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
11444355|NCT01736995|Experimental|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
11444356|NCT01736995|Experimental|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
11444357|NCT01736995|Experimental|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
11444358|NCT01736995|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
11444359|NCT01736982|Active Comparator|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)], breath sample monitoring, standard smoking cessation counseling
11444360|NCT01736982|Experimental|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
11444361|NCT01736969|Experimental|RD047-023|RD-047-023
11444362|NCT01736969|Active Comparator|Predicate Device|legally marketed predicate device
11601551|NCT00637260|Sham Comparator|B|
11444365|NCT01736943|Experimental|Bortezomib + Doxil|Bortezomib will be given subcutaneously at 1.5mg/m2 on days 1, 4, 8 and 11 of a 3 week cycle. Doxil will be administered once every three weeks as a single intravenous infusion at a dose of 40 mg/m2 (day 4 of each cycle).
11444366|NCT01736930|Active Comparator|Predictive pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
11444367|NCT01736930|No Intervention|Standard of Care|The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
11444368|NCT01736917|Experimental|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone|"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.
~Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).
~Acute emesis prophylaxis:
~Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.
~Dexamethasone 20mg PO (orally) daily, D1 and 2
~Fosaprepitant 150mg IV on day 3
~Delayed emesis prophylaxis:
~Fosaprepitant 150mg IV on D5
~Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8
~PRN antiemetics allowed at the discretion of the treating investigator
~No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods"
11444369|NCT01736904|Active Comparator|FOLFIRI|FOLFIRI regimen
11444370|NCT01736904|Experimental|wXELIRI regimen|wXELIRI
11444371|NCT01736891|Experimental|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
11444372|NCT01736891|Placebo Comparator|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
11444373|NCT01736878|Experimental|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
11444374|NCT01736878|Placebo Comparator|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
11444375|NCT01736865|Placebo Comparator|placebo|One placebo pill daily for 1 year
11444376|NCT01736865|Active Comparator|cholecalciferol|One cholecalciferol pill daily for 1 year
11444377|NCT01736852|Experimental|CRB plus Pitocin|
11444378|NCT01736852|Active Comparator|Pitocin|
11444379|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
11444380|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).
~100 patients will be included.
~Interventions to be administered: Bloodwork, baseline"
11444381|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.
~30 healthy volunteers will be included.
~Interventions to be administered: Bloodwork, baseline"
11444382|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.
~50 pregnant volunteers will be included.
~Interventions to be administered: Bloodwork, baseline"
11444383|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.
~Interventions to be administered: Blood work, Months 1 & 2"
11444384|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.
~Interventions to be administered: Bloodwork, Months -1 to -6"
11444385|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
11444386|NCT01736800|Experimental|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
11444387|NCT01736787|Experimental|Cauliflower Mushroom extract|
11444388|NCT01736787|Placebo Comparator|Placebo|
11444389|NCT01736774|Experimental|Usual care intervention|Primary care as required including medication
11444390|NCT01736774|Experimental|Physiotherapy treatment|Exercise and manipulative therapy
11444391|NCT01736761|Experimental|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
11444392|NCT01736748|Experimental|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
11444393|NCT01736748|Other|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
11444394|NCT01736735|Experimental|CLP|CLP BID
11444395|NCT01736735|Placebo Comparator|Placebo|BID powder
11444396|NCT01736722|Experimental|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
11444397|NCT01736709|Experimental|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
11444398|NCT01736696|Experimental|5 mg BID|5 mg BID for 13 days and once on Day 14
11444399|NCT01736696|Experimental|10 mg BID|10 mg BID for13 days and once on Day 14*
11444400|NCT01736696|Experimental|20 mg BID|20 mg BID for 13 days and once on Day 14
11444401|NCT01736696|Experimental|30 mg BID|30 mg BID for 13 days and once on Day 14
11444402|NCT01736696|Experimental|60 mg QD|60 mg QD for 14 days
11444403|NCT01736696|Experimental|50 mg BID|50 mg BID x 13 days and once on day 14
11444404|NCT01736683|Experimental|Sotatercept 0.1 mg/kg|Sotatercept 0.1 mg/kg
11444405|NCT01736683|Experimental|Sotatercept 0.3 mg/kg|Sotatercept 0.3 mg/kg
11444406|NCT01736683|Experimental|Sotatercept 0.5 mg/kg|Sotatercept 0.5 mg/kg
11444407|NCT01736683|Experimental|Sotatercept 1.0 mg/kg|Sotatercept 1.0 mg/kg
11444408|NCT01736683|Experimental|Sotatercept 1.5 mg/kg|Sotatercept 1.5 mg/kg
11444409|NCT01736683|Experimental|Sotatercept 2.0 mg/kg|Sotatercept 2.0 mg/kg
11444410|NCT01736670|Experimental|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
11444411|NCT01736670|Experimental|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
11444412|NCT01736670|Active Comparator|Control, Otherwise healthy|10 healthy controls
11444413|NCT01736657|Experimental|Red cell exchange in sickle cell|Open arm; Red cell blood exchange for patients with sickle cell disease
11444414|NCT01736644|Placebo Comparator|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
11444415|NCT01736644|Active Comparator|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
11444416|NCT01736631|Experimental|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
11444417|NCT01736618||S-ICD System Implant Attempt|
11444418|NCT01736605|Active Comparator|Massage|Daily massage for 20 minutes the first 3 days following surgery.
11444419|NCT01736605|Active Comparator|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
11444420|NCT01736592|Other|Long Term Follow up|Long term follow up in all patients who received SAR422459 in previous study TDU13583
11444421|NCT01736579|Experimental|IGIV, 10% at 0.2 g/kg body weight|IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
11444422|NCT01736579|Experimental|IGIV, 10% at 0.4 g/kg body weight|IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
11444423|NCT01736566|Experimental|Family History + Whole Genome Sequencing|Doctors and their patients receive a Genome Report and an Annotated Family History Report.
11444424|NCT01736566|Active Comparator|Family History Only|Doctors and their patients receive an Annotated Family History Report only.
11444425|NCT01736553||Infants with Spinal Muscular Atrophy|Infants diagnosed Spinal Muscular Atrophy
11444426|NCT01736553||Healthy controls|Healthy control infants
11444427|NCT01736540|Other|Magnetic Resonance Imaging (MRI)|All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.
11444428|NCT01736527|Experimental|LE Gel|A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
11444429|NCT01736514|Experimental|febuxostat group|oral
11444430|NCT01736514|Active Comparator|allopurinol group|oral
11444431|NCT01736501|No Intervention|Baseline1-demographics|Baseline survey- demographics only
11444432|NCT01736501|Other|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
11444433|NCT01736501|Other|Baseline2-demographics|Baseline survey- demographics only
11444434|NCT01736501|Other|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
11444435|NCT01736488|Experimental|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
11444436|NCT01736488|Active Comparator|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
11444437|NCT01736475|Experimental|Prophylaxis|
11444438|NCT01736475|Experimental|On-demand|
11444439|NCT01736462|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%
11444440|NCT01736449|Placebo Comparator|Pterygium Excision Alone|
11444441|NCT01736449|Experimental|Pterygium Excision with Bevacizumab Injection|
11444442|NCT01736436|Experimental|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
11444443|NCT01736423|Experimental|Female Patients with D-IBS|
11444444|NCT01736410|Other|IHC method|
11444445|NCT01736410|Other|FISH method|
11444446|NCT01736397|Experimental|Ferric Citrate|Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
11444447|NCT01736397|Placebo Comparator|Placebo|Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.
11444448|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
11444449|NCT01736371|Sham Comparator|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
11444450|NCT01736371|Active Comparator|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
11444451|NCT01736371|Active Comparator|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
11444452|NCT01736358|Experimental|Intranasal Ketoralac|A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
11444453|NCT01736358|Placebo Comparator|Placebo|A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
11444454|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
11444455|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
11444457|NCT01736293||Affected Patients|Participants with ABCA4-related retinopathies.
11444458|NCT01736280|Other|1|Standard of Care. Participants will be evaluated and treated for their particular digestive disorder or presenting symptoms.
11444459|NCT01736267|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
11444460|NCT01736254|Experimental|Gemfibrozil|Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
11444461|NCT01736254|Experimental|Evacetrapib|Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
11444462|NCT01736254|Experimental|Evacetrapib + Gemfibrozil|Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
11444463|NCT01736241|Experimental|LY3053102|A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level.
11444464|NCT01736241|Placebo Comparator|Placebo|A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks.
11444465|NCT01736228|Experimental|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
11444466|NCT01736215||Participants with cancer related anemia|Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
11444467|NCT01736202|Active Comparator|Palm oil orally|oral fat load
11444468|NCT01736202|Active Comparator|Canola oil orally|Oral fat load
11444469|NCT01736202|Placebo Comparator|Water orally|oral water administration as control
11444470|NCT01736189||Participants treated with adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks
11444471|NCT01736176|Experimental|Levodopa-Carbidopa Intestinal Gel|"Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.
~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment."
11444472|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
11444473|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
11444474|NCT01736150|Experimental|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
11444475|NCT01736150|Placebo Comparator|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
11444476|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
11444477|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
11444478|NCT01736124|Experimental|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
11444479|NCT01736124|Active Comparator|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
11444480|NCT01736111|Experimental|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:
~Text messages to prompt participant to reply with self-monitoring entries
~Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
11444481|NCT01736111|Active Comparator|One Way Text|"Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.
~Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.
~One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.
~Usual medical care from the PCP.
~Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
11444482|NCT01736098|Experimental|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
11444483|NCT01736098|Experimental|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
11444484|NCT01736098|No Intervention|Low Energy Flux|No Intervention: maintain normal lifestyle
11444485|NCT01736085|No Intervention|Material Group|Subjects will receive self-help materials
11444486|NCT01736085|Active Comparator|Materials plus Voucher|Subjects will receive self-help materials and a voucher for 2 week's worth of nicotine patches
11444487|NCT01736085|Active Comparator|Materials plus Patches|Subjects will receive self-help materials and a 2 week's worth of nicotine patches
11444488|NCT01736085|Active Comparator|Counseling|Subjects will receive up to 5 sessions of telephone counseling
11444489|NCT01736085|Active Comparator|Counseling plus Voucher|Subjects will receive up to 5 sessions of telephone counseling plus a voucher for 2 week's worth of nicotine patches.
11444490|NCT01736085|Active Comparator|Counseling plus Patches|Subjects will receive up to 5 sessions of telephone counseling plus 2 week's worth of nicotine patches.
11444491|NCT01736072|Active Comparator|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
11444492|NCT01736072|Active Comparator|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
11444493|NCT01736059|Experimental|Stem cell treated|
11444494|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
11444495|NCT01736033|Placebo Comparator|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
11444496|NCT01736033|Active Comparator|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
11444497|NCT01736020|Placebo Comparator|Placebo|Placebo
11444498|NCT01736020|Experimental|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
11444499|NCT01736020|Experimental|Propofol|Propofol intravenous infusion during scan.
11444500|NCT01736020|Experimental|Ketamine|Ketamine intravenous infusion during scan.
11444501|NCT01736020|Experimental|Nitrous Oxide|Nitrous Oxide inhalation during scan.
11444502|NCT01736007|Sham Comparator|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
11444503|NCT01736007|Active Comparator|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
11444504|NCT01735994|Experimental|Healthy Weight Intervention|Eating Disorder Prevention Program
11444505|NCT01735994|Other|Brochure wait list|Brochure wait list control group
11444506|NCT01735981|Experimental|video game exercise|Video game exercise using Dance Dance Revolution
11444507|NCT01735981|Other|control|hand-held video game control
11444508|NCT01735968|Experimental|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
11444509|NCT01735955|Experimental|AMN107 (nilotinib)|AMN107
11444510|NCT01735942|Experimental|Ingenol Mebutate|Ingenol Mebutate applied to one side of face with skin lesions
11444511|NCT01735942|Active Comparator|Cryotherapy|Cryotherapy applied to other side of face with skin lesions
11444512|NCT01735929|Experimental|Neck Liposuction and Ultrasound Treatment|Subject will receive neck liposuction and ultrasound treatment.
11444513|NCT01735929|Sham Comparator|Sham|Subject will receive sham treatment
11444514|NCT01735916|Active Comparator|CRT-P ON|CRT-P Implant CRT-P ON
11444515|NCT01735916|Placebo Comparator|CRT-P OFF|CRT-P Implant CRT-P OFF
11444516|NCT01735890|Experimental|CJ Amlodipine/Valsartan 10/160mg|
11444517|NCT01735890|Active Comparator|Novartis Exforge 10/160mg|
11444518|NCT01735877|Experimental|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
11444519|NCT01735877|Sham Comparator|Control group|Group 2 will be given sham mirror therapy
11444520|NCT01735864|Active Comparator|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
11444521|NCT01735864|Active Comparator|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
11444522|NCT01735864|Active Comparator|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
11444523|NCT01735864|Active Comparator|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
11444524|NCT01735851|Active Comparator|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
11444525|NCT01735851|Experimental|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
11444526|NCT01735825|Experimental|paclitaxel-coated balloon|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter (iopomide coating)
11444527|NCT01735825|Active Comparator|drug eluting stent|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
11444528|NCT01735825|Other|seal-wing paclitaxel-eluting balloon catheter|"Observational, non-randomised arm:
~Pts with ISR treated by seal-wing paclitaxel-eluting balloon catheter"
11444529|NCT01735812|Experimental|symptomatic UF|
11444530|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
11602366|NCT00631111|Experimental|1|
11444531|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
11444532|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
11444533|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
11444534|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
11444535|NCT01735773||Control group|Healthy volunteers
11444536|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
11444537|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
11444538|NCT01735747|Experimental|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
11444539|NCT01735734||Capillary malformation|
11444540|NCT01735721|Active Comparator|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
11444541|NCT01735721|Experimental|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
11444542|NCT01735708|Placebo Comparator|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
11444543|NCT01735708|Active Comparator|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
11444544|NCT01735682|Experimental|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
11444545|NCT01735682|Active Comparator|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
11444546|NCT01735682|Active Comparator|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
11444547|NCT01735669|Experimental|Remifentanil|External cephalic version at term under Remifentanil perfusion
11444548|NCT01735669|Active Comparator|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
11444549|NCT01735656|Experimental|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
11444550|NCT01735656|Active Comparator|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
11444551|NCT01735643|Experimental|interactive videogame intervention|
11444552|NCT01735643|Experimental|waiting group|
11444553|NCT01735630|Experimental|ELND005|ELND005 film coated tablets, BID for 12 weeks
11444554|NCT01735630|Placebo Comparator|Placebo|Matched placebo BID for 12 weeks
11444555|NCT01735617|Experimental|Hydrocortisone Modified Release Capsules|Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
11444556|NCT01735604|Experimental|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
11444557|NCT01735591|Experimental|Probiotic|Capsules with 3x10^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
11444558|NCT01735591|Placebo Comparator|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
11444559|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct < or = to 28 who are being fed and are stable.
11444560|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
11444561|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
11444562|NCT01735539|Experimental|Old Bolus|15g EAA bolus
11444563|NCT01735539|Experimental|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
11444564|NCT01735539|Experimental|Young Bolus|15g EAA bolus
11444565|NCT01735539|Experimental|Young Pulse|4 x 3.75g Mixed EAA Pulses
11444566|NCT01735539|Experimental|Old Pulse|4 x 3.75g Mixed EAA Pulses
11444567|NCT01735513|Experimental|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
11444568|NCT01735513|Active Comparator|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
11444569|NCT01735500||CAG without PCI|
11444570|NCT01735500||CAG with PCI|
11444571|NCT01735487|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
11444572|NCT01735487|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
11444573|NCT01735487|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
11444574|NCT01735487|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
11444575|NCT01735487|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
11444576|NCT01735474|Placebo Comparator|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
11444577|NCT01735474|Active Comparator|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
11444578|NCT01735461|Experimental|Dietary supplement|Calcium Carbonate
11444579|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
11444580|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
11444581|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
11444582|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
11444583|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
11444584|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
11444585|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
11444586|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
11444587|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
11444588|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
11444589|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
11444590|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
11444591|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
11444592|NCT01735435|No Intervention|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
11444593|NCT01735435|Experimental|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
11444594|NCT01735422|Experimental|r-hLH (825 International Units [IU])|
11444595|NCT01735422|Experimental|r-hLH (2750 IU)|
11444596|NCT01735422|Experimental|r-hLH (5500 IU)|
11444597|NCT01735422|Experimental|r-hLH (11000 IU)|
11444598|NCT01735422|Experimental|r-hLH (22000 IU)|
11444599|NCT01735422|Active Comparator|u-hCG (5000 IU)|
11444600|NCT01735409|Experimental|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
11444601|NCT01735409|Experimental|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
11444602|NCT01735409|Experimental|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
11444603|NCT01735396|Experimental|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
11444604|NCT01735383|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
11444605|NCT01735383|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
11444606|NCT01735370|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
11444607|NCT01735370|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
11444608|NCT01735357|Placebo Comparator|Olive oil (BP specification)|5g per day
11444609|NCT01735357|Experimental|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
11444610|NCT01735357|Experimental|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
11444611|NCT01735344|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
11444612|NCT01735344|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
11444613|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
11444614|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
11444615|NCT01735318|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
11444616|NCT01735318|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
11444617|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
11444618|NCT01735279|Placebo Comparator|Placebo|The placebo group will receive 3g per day of mineral oil during 90 days treatment
11444619|NCT01735279|Experimental|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
11444620|NCT01735266|Active Comparator|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
11444621|NCT01735266|Experimental|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
11444622|NCT01735266|Experimental|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
11444623|NCT01735253|Experimental|gastric bypass, duodenojejunal bypass|
11444624|NCT01735240|Experimental|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
11444625|NCT01735227|Experimental|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
11444663|NCT01735006|Placebo Comparator|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
11451869|NCT01687426|Placebo Comparator|Vehicle|
11444626|NCT01735227|Experimental|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
11444627|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
11444628|NCT01735201|Experimental|AGN-199201 Dose A Once Daily|AGN-199201 Dose A applied once daily to the face for 28 days.
11444629|NCT01735201|Experimental|AGN-199201 Dose B Once Daily|AGN-199201 Dose B applied once daily to the face for 28 days.
11444630|NCT01735201|Experimental|AGN-199201 Dose C Once Daily|AGN-199201 Dose C applied once daily to the face for 28 days.
11444631|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Once Daily|AGN-199201 Vehicle applied once daily to the face for 28 days.
11444632|NCT01735201|Experimental|AGN-199201 Dose A Twice Daily|AGN-199201 Dose A applied twice daily to the face for 28 days.
11444633|NCT01735201|Experimental|AGN-199201 Dose B Twice Daily|AGN-199201 Dose B applied twice daily to the face for 28 days.
11444634|NCT01735201|Experimental|AGN-199201 Dose C Twice Daily|AGN-199201 Dose C applied twice daily to the face for 28 days.
11444635|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Twice Daily|AGN-199201 Vehicle applied twice daily to the face for 28 days.
11444636|NCT01735188||Living|
11444637|NCT01735188||Deceased|
11444638|NCT01735175|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
11444639|NCT01735175|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
11444640|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
11444641|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
11444642|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
11444643|NCT01735149|Experimental|Kochujang Pills|
11444644|NCT01735149|Placebo Comparator|Placebo|
11444645|NCT01735136|Experimental|InSan Bamboo Salt|
11444646|NCT01735136|Placebo Comparator|Placebo|
11444647|NCT01735123|Experimental|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
11444648|NCT01735123|Experimental|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
11444649|NCT01735110|Active Comparator|Femoral approach group|PCI through Femoral approach
11444650|NCT01735110|Experimental|radial approach group|PCI through radial approach
11444651|NCT01735097|Experimental|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
11444652|NCT01735097|Active Comparator|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
11444653|NCT01735084|Experimental|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
11444654|NCT01735084|Experimental|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
11444655|NCT01735071|Experimental|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
11444656|NCT01735071|Experimental|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.
~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.
~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.
~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
11444657|NCT01735058|Active Comparator|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
11444658|NCT01735058|Placebo Comparator|Normal saline|Ultrasound guided injection of normal saline
11444659|NCT01735045|Experimental|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
11444660|NCT01735045|Active Comparator|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
11444661|NCT01735019|Experimental|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
11444662|NCT01735006|Experimental|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
11452185|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
11444664|NCT01734993|Experimental|Tocilizumab|Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of >1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
11444665|NCT01734980|Experimental|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
11444666|NCT01734967|Experimental|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
11444667|NCT01734954|Experimental|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
11444668|NCT01734954|Experimental|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
11444669|NCT01734941|Active Comparator|TSO 2500|2500 TSO every other week
11444670|NCT01734941|Active Comparator|7500 TSO|7500 TSO every other week
11444671|NCT01734941|Placebo Comparator|Placebo|placebo every other week.
11444672|NCT01734928|Experimental|Pomalidomide, Bortezomib and Low Dose Dexamethasone|4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
11444673|NCT01734928|Active Comparator|Bortezomib and Low Dose Dexamethasone|1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day [≤ 75 years old]or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
11444674|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
11444675|NCT01734902|Experimental|1 Hyoscine butylbromide|drops, oral administration with 240 mL water
11444676|NCT01734902|Experimental|2 Hyoscine butylbromide|sugar coated tablets, oral administration with 240 mL water
11444677|NCT01734889|Experimental|Orfadin suspension|Drug: nitisinone, oral suspension
11444678|NCT01734876|Experimental|Tactile Touch|Tactile Touch is given to the active arm
11444679|NCT01734876|Active Comparator|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
11444680|NCT01734863|Experimental|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :
~Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy [IMRT] is allowed.
~Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:
~Age < 18 years old.
~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.
~Negative surgical margins.
~Patients show good safety profile and acceptable performance status."
11444681|NCT01734863|No Intervention|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:
~Age < 18 years old.
~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.
~Negative surgical margins.
~Patients show good safety profile and acceptable performance status."
11444682|NCT01734850|Experimental|No busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning
11444683|NCT01734850|Experimental|1 x 4mg/kg busulfan preconditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
11444684|NCT01734850|Experimental|2 x 4mg/kg busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant
11444685|NCT01734824|Active Comparator|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
11444686|NCT01734824|Placebo Comparator|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
11444687|NCT01734824|Active Comparator|Denosumab|one subcutaneous injection of denosumab
11444688|NCT01734824|Active Comparator|Placebo Denosumab|one subcutaneous injection of denosumab placebo
11444689|NCT01734811|Placebo Comparator|Placebo|The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
11444690|NCT01734811|Experimental|Biological vaccine|The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
11444691|NCT01734798|Experimental|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
11444692|NCT01734798|Experimental|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
11444693|NCT01734798|Experimental|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
11444694|NCT01734785|Active Comparator|Linagliptin|5 mg once daily
11444695|NCT01734785|Experimental|Empaglifozin + Linagliptin low dose|1 tablet once daily
11444696|NCT01734785|Experimental|Empagliflozin + Linagliptin high dose|1 tablet once daily
11444697|NCT01734772|Experimental|Reference (Part 1/A, Part 2/C)|multiple doses of dabigatran (alone)
11444698|NCT01734772|Experimental|Test 1 (Part 1/Treatment B)|concomitant administration of dabigatran and ticagrelor
11444699|NCT01734772|Experimental|Test 2 (Part 2/Treatment D)|staggered administration of ticagrelor and dabigatran
11444700|NCT01734759|Experimental|Taste Test|
11444738|NCT01734473|Experimental|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
11602367|NCT00631111|Active Comparator|2|
11444701|NCT01734746|Experimental|Tracerinjection|The intervention concerns tracerinjection (both blue dye and the radioactive isotope beingtechnetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.
11444702|NCT01734733|Experimental|NTCELL|"NTCELL 40 microcapsules (+/- 20%)
~The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging."
11444703|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
11444704|NCT01734707|Active Comparator|Allicor|Allicor 150 mg tablet by mouth two times a day
11444705|NCT01734707|Placebo Comparator|Sugar pill|Placebo tablet 150 mg by mouth two times a day
11444706|NCT01734694|Active Comparator|Vancomycin|
11444707|NCT01734694|Active Comparator|Comparator|
11444708|NCT01734681|Experimental|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
11444709|NCT01734655||All Participants|Participants will be asked to complete the MEQ, the Eating Inventory Questionnaire, The Mindful Attention Awareness Scale (MAAS), and the Neighborhood Environment Walkability Scale (NEWS). Participants will then be asked to sequentially respond to each of the 28 items and the response choices from the MEQ and briefly discuss their reaction to the items and response choices. Finally, participants will either participate in a focus group or an individual cognitive interview, giving them the opportunity to elaborate on their responses to the MEQ. The first 11 participants completed focus groups and the remaining 29 participants completed individual cognitive interviews.
11444710|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
11444711|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
11444712|NCT01734616|No Intervention|Young|Young subjects to be controlled to older individuals with interventions
11444713|NCT01734616|No Intervention|Old|Older individuals to compare to young and other older intervention groups
11444714|NCT01734616|Experimental|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
11444715|NCT01734616|Experimental|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
11444716|NCT01734616|Experimental|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
11444717|NCT01734603|Active Comparator|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
11444718|NCT01734603|Experimental|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
11444719|NCT01734590|Experimental|Carbohydrate based food mix 1|Slowly digestible carbohydrate
11444720|NCT01734590|Experimental|Carbohydrate based food mix 2|Slowly digestible carbohydrate
11444721|NCT01734590|Active Comparator|Control carbohydrate based food|Rapidly digestible carbohydrate
11444722|NCT01734577|Active Comparator|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
11444723|NCT01734577|Sham Comparator|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
11444724|NCT01734564|Experimental|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
11444725|NCT01734564|Experimental|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
11444726|NCT01734551|Active Comparator|Morphine|Initial dose is 0.4mg/kg/day, divided every 3-4 hours, given PO with feeds. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
11444727|NCT01734551|Active Comparator|Clonidine|Dose is started at 5 mcg/kg/day, given PO with feeds, divided every 3-4 hours. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
11444728|NCT01734538|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
11444729|NCT01734538|Placebo Comparator|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
11444730|NCT01734525|Experimental|Anidulafungin|Patients at risk will receive therapy with anidulafungin
11444731|NCT01734512|Experimental|Everolimus|Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.
11444732|NCT01734499|Experimental|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
11444733|NCT01734499|Active Comparator|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
11444734|NCT01734486|Experimental|Low dose|
11444735|NCT01734486|Experimental|High dose|
11444736|NCT01734473|Experimental|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
11444737|NCT01734473|Experimental|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
11444823|NCT01733966|Active Comparator|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
11444739|NCT01734473|Experimental|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
11444740|NCT01734473|Experimental|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
11444741|NCT01734460||third trimester pregnant women|no intervention
11444742|NCT01734447|Experimental|1.2, continuous treatment|
11444743|NCT01734447|Experimental|1.2, non-continuous treatment|
11444744|NCT01734447|Experimental|2.4, non-continuous treatment|
11444745|NCT01734434||Pregnant women|24 weeks or more of gestation
11444746|NCT01734421|Other|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
11444747|NCT01734421|Active Comparator|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
11444748|NCT01734408|Experimental|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
11444749|NCT01734408|Placebo Comparator|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
11444750|NCT01734408|Experimental|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
11444751|NCT01734408|Placebo Comparator|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
11444752|NCT01734408|Experimental|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
11444753|NCT01734408|Placebo Comparator|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
11444754|NCT01734408|Experimental|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
11444755|NCT01734408|Placebo Comparator|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
11444756|NCT01734395||Galantamine|Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).
11444757|NCT01734382|Experimental|Part 1: Tocilizumab (TCZ) Q2W|Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants < 30 kg; 8 mg/kg for participants >/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
11444758|NCT01734382|Experimental|Part 2: TCZ IV 12 mg/kg Q3W/Q4W|Participants with weight < 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
11444759|NCT01734382|Experimental|Part 2: TCZ IV 8 mg/kg Q3W/Q4W|Participants with weight >/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.
11444760|NCT01734369||1|myositis subjects
11444761|NCT01734369||2|healthy volunteers
11444762|NCT01734356|Other|inherited arrhythmias|6 patient with inherited arrhythmias
11444763|NCT01734356|Other|valvulopathies|6 patient with valvulopathies
11444764|NCT01734356|Other|controle|8 healthy people for these pathologies
11444765|NCT01734343|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
11444766|NCT01734343|Other|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
11444767|NCT01734330|Experimental|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
11444768|NCT01734330|Other|Nicotine replacement|Nicotine replacement for 12 weeks
11444769|NCT01734317|Experimental|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
11444770|NCT01734304|Experimental|DC vaccination|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
11444771|NCT01734291|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
11444772|NCT01734291|Placebo Comparator|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
11444773|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
11444774|NCT01734265|Experimental|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
11444775|NCT01734265|Experimental|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
11444776|NCT01734252|No Intervention|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
11444824|NCT01733953|Experimental|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
11444825|NCT01733953|Placebo Comparator|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
11444777|NCT01734252|Experimental|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
11444778|NCT01734239|Experimental|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
11444779|NCT01734239|Experimental|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
11444780|NCT01734226|Experimental|Prunus Mume Extract|
11444781|NCT01734226|Placebo Comparator|Placebo|
11444782|NCT01734213|Experimental|Eriobotyra Japonica Lindley Extract|
11444783|NCT01734213|Placebo Comparator|Placebo|
11444784|NCT01734200|Experimental|Eriobotyra Japonica Lindley Extract|
11444785|NCT01734200|Placebo Comparator|Placebo|
11444786|NCT01734187|Experimental|Fermented Cinnamon Vine Powder|
11444787|NCT01734187|Placebo Comparator|Placebo|
11444788|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
11444789|NCT01734161|Active Comparator|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
11444790|NCT01734161|Placebo Comparator|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
11444791|NCT01734148|Experimental|Experimental group (RELAX TO SLEEP program)|
11444792|NCT01734148|No Intervention|Control group (Usual Care)|
11444793|NCT01734135|No Intervention|Usual Care|Usual care
11444794|NCT01734135|Experimental|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
11444795|NCT01734122||Essential Tremor|Patients with severe, medication-refractory Essential Tremor
11444796|NCT01734122||Parkinsonian Tremor|Patients with severe, medication-refractory, tremor-dominant Parkinsons
11444797|NCT01734109|Placebo Comparator|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
11444798|NCT01734109|Active Comparator|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
11444799|NCT01734109|Active Comparator|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
11444800|NCT01734096|Active Comparator|control group|healthy volunteer
11444801|NCT01734096|Active Comparator|obesity group|Patients with BMI >30 Kg/m2
11444802|NCT01734096|Active Comparator|white coat hypertension group|Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg
11444803|NCT01734096|Active Comparator|Resistant hypertension|Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
11444804|NCT01734083|Experimental|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
11444805|NCT01734083|Active Comparator|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
11444806|NCT01734070|Experimental|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
11444807|NCT01734057|Experimental|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
11444808|NCT01734057|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
11444809|NCT01734044|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
11444810|NCT01734044|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
11444811|NCT01734018||Cohort|
11444812|NCT01734005|Experimental|Red Ginseng|
11444813|NCT01734005|Placebo Comparator|Placebo|
11444814|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
11444815|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
11444816|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
11444817|NCT01733992|Placebo Comparator|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
11444818|NCT01733979|Experimental|Heme-Iron Polypeptide|
11444819|NCT01733979|Placebo Comparator|Placebo|
11444820|NCT01733979|Active Comparator|Heme-Iron|
11444821|NCT01733979|Active Comparator|Organic Iron|
11444822|NCT01733966|Experimental|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
11602368|NCT00631111|Active Comparator|3|
11444826|NCT01733940|Experimental|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
11444827|NCT01733940|Active Comparator|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
11444828|NCT01733927|Experimental|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
11444829|NCT01733914|Experimental|Acupuncture|Experimental group
11444830|NCT01733914|Sham Comparator|Waiting list|Control group
11444831|NCT01733901|Active Comparator|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
11444832|NCT01733901|Placebo Comparator|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
11444833|NCT01733888|Active Comparator|Office Bleaching|
11444834|NCT01733888|Experimental|Resin Infiltration|
11444835|NCT01733888|Experimental|Resin Infiltration twice|
11444836|NCT01733888|Experimental|Office Bleaching + Resin Infiltration|
11444837|NCT01733875|Experimental|CC-220 0.03 mg|
11444838|NCT01733875|Experimental|CC-220 0.1 mg|
11444839|NCT01733875|Experimental|CC-220 0.3 mg|
11444840|NCT01733875|Experimental|CC-220 1 mg|
11444841|NCT01733875|Experimental|CC-220 2 mg|
11444842|NCT01733875|Experimental|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
11444843|NCT01733875|Experimental|CC-220 4 mg|
11444844|NCT01733875|Experimental|CC-220 6 mg|
11444845|NCT01733875|Experimental|CC-220 1 mg (Part 2 only)|
11444846|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
11444847|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
11444848|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
11444849|NCT01733836|Experimental|Metformin|850mg BID
11444850|NCT01733836|Placebo Comparator|Placebo|
11444851|NCT01733823|Experimental|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
11444852|NCT01733823|Experimental|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
11444853|NCT01733823|Experimental|Group C|PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
11444854|NCT01733823|Experimental|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
11444855|NCT01733810|Experimental|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
11444856|NCT01733797|Experimental|Wooden spatula|
11444857|NCT01733797|Experimental|Therabite|
11444858|NCT01733784|Experimental|Viscoelastic properties of the airway|
11444859|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
11444860|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
11444861|NCT01733758|Experimental|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
11444862|NCT01733758|Experimental|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
11444863|NCT01733758|Placebo Comparator|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
11444864|NCT01733758|Active Comparator|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
11444865|NCT01733745|Experimental|SYSTANE® Family|SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
11444866|NCT01733745|Active Comparator|Standard of Care|Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
11444867|NCT01733732|Experimental|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
11444868|NCT01733732|Active Comparator|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
11444914|NCT01733420|Active Comparator|White Mineral trioxide Aggregate (MTA)|Pulpotomy using white MTA as pulpotomy medicine.
11444869|NCT01733719|Active Comparator|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
11444870|NCT01733719|Active Comparator|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
11444871|NCT01733706|Active Comparator|Standard counseling|a psychologist will provide standard counseling
11444872|NCT01733706|Experimental|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
11444873|NCT01733693|Experimental|Buprenorphine|Oral sublingual tablet, 8-32 mg per day, administered daily for duration of 4 months
11444874|NCT01733693|Active Comparator|Methadone|Oral sublingual tablet, 60-100 mg per day, administered daily for duration of 4 months
11444875|NCT01733680|Active Comparator|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.
~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
11444876|NCT01733680|Placebo Comparator|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
11444877|NCT01733667|Experimental|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
11444878|NCT01733667|Active Comparator|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
11444879|NCT01733654|Active Comparator|RO4995819 5mg|RO4995819 5mgX6wks
11444880|NCT01733654|Active Comparator|RO4995819 15mg|RO4995819 15mg X 6 weeks
11444881|NCT01733654|Active Comparator|RO4995819 30mg|RO4995819 30mg X 6 weeks
11444882|NCT01733654|Placebo Comparator|Placebo|Placebo X 6 weeks
11444883|NCT01733628||Bevacizumab + Chemotherapy|Patients who received the addition of Bevacizumab (BV) every 2-3 weeks to Chemotherapy (CT) with either oxaliplatin or irinotecan plus fluoropyrimidines in patients with Metastatic Colorectal Cancer (MCRC), either paclitaxel or capecitabine in patients with Metastatic Breast Cancer (MBC), as first-line therapy.
11444884|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
11444885|NCT01733602|Experimental|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
11444886|NCT01733602|Active Comparator|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
11444887|NCT01733589|Experimental|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.
11444888|NCT01733576|Sham Comparator|Sham HD-tDCS|
11444889|NCT01733576|Active Comparator|Active HD-tDCS 1|
11444890|NCT01733576|Active Comparator|Active HD-tDCS 2|
11444891|NCT01733576|Active Comparator|Active HD-tDCS 3|
11444892|NCT01733563|Experimental|fructose sweetened beverage|"Soft drink consumption:
~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
11444893|NCT01733563|Experimental|glucose sweetened beverage|"Soft drink consumption:
~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
11444894|NCT01733563|Experimental|sucrose sweetened beverage|"Soft drink consumption:
~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
11444895|NCT01733563|Experimental|No change of eating habits|"No Soft drink consumption (no soft drink diet):
~Subjects do not change their eating habits during 7 weeks"
11444896|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
11444897|NCT01733537|Experimental|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
11444898|NCT01733537|Other|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
11444899|NCT01733524|Sham Comparator|Picture of a fish|Participants will receive a picture of a betta fish.
11444900|NCT01733524|Active Comparator|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
11444901|NCT01733511||admitted to emergency department|
11444902|NCT01733511||patients admitted to surgical ward|
11444903|NCT01733485|Active Comparator|Aspirin|
11444904|NCT01733485|Active Comparator|Indomethacin|
11444905|NCT01733485|No Intervention|Control|
11444906|NCT01733472|Placebo Comparator|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
11444907|NCT01733472|Experimental|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
11444908|NCT01733459|Experimental|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
11444909|NCT01733459|Active Comparator|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
11444910|NCT01733446|No Intervention|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
11444911|NCT01733446|Experimental|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
11444912|NCT01733433|Experimental|taped ankle|Subjects will be taped in at the ankle for a series of exercises.
11444913|NCT01733420|Experimental|Biodentine|Pulpotomy using Biodentine as pulpotomy medicine.
11602369|NCT00631111|Placebo Comparator|4|
11444915|NCT01733420|Active Comparator|Tempophore|Pulpotomy using Tempophore as pulpotomy medicine in a control group.
11444916|NCT01733407|Placebo Comparator|Sugar pill|Placebo arm
11444917|NCT01733407|Active Comparator|L-serine|amino acid supplementation with L-serine
11444918|NCT01733394|Experimental|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
11444919|NCT01733394|Experimental|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
11444920|NCT01733394|Experimental|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
11444921|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
11444922|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
11444923|NCT01733355|Experimental|Tau diagnostic|[F18] T807
11444924|NCT01733342|Active Comparator|Celsite|patients received celsite chemoport implantation under local anesthesia
11444925|NCT01733342|Experimental|Humanport|patients received Humanport chemoport implantation under local anesthesia
11444926|NCT01733329|Experimental|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
11444927|NCT01733329|Placebo Comparator|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
11444928|NCT01733316|Experimental|All Participants|"Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).
~RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).
~Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H."
11444929|NCT01733303|Experimental|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
11444930|NCT01733290|Experimental|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
11444931|NCT01733290|Placebo Comparator|Control arm-Normal saline instillation|Normal saline instillation
11444932|NCT01733277||With neuropathic pain (PainDETECT ≥ 13)|Magnetic Resonance Imaging (MRI)
11444933|NCT01733277||No neuropathic pain (PainDETECT<13)|Magnetic Resonance Imaging (MRI)
11444934|NCT01733238|Experimental|PNT2258|PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
11444935|NCT01733212|Experimental|Ginger|2 gm powder of ginger filled in a capsule
11444936|NCT01733212|Placebo Comparator|Placebo|2 gm of placebo pill (A capsule)
11444937|NCT01733199|Experimental|BA-|Patient with no secondary behavioural addiction
11444938|NCT01733199|Experimental|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
11444939|NCT01733199|Experimental|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
11444940|NCT01733186|Experimental|CARTISTEM®|Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
11444941|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
11444942|NCT01733147|Placebo Comparator|Placebo|Subjects will be placed on 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal.
11444943|NCT01733147|Active Comparator|Omega-3 free fatty acids|Subjects will be placed on 3 capsules a day of Omega 3 free fatty acids taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
11444944|NCT01733134|Experimental|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
11444945|NCT01733134|Placebo Comparator|Standard therapy plus placebo|
11444946|NCT01733121|Experimental|NBI-98854|Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
11444947|NCT01733121|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
11444948|NCT01733108|Experimental|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
11444949|NCT01733095|Experimental|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
11444950|NCT01733082||Cohort|
11444951|NCT01733069||No treatment|
11444952|NCT01733056|Placebo Comparator|Healthy Volunteer|Healthy volunteers without skin disease that received administration of Fluzone
11444953|NCT01733056|Experimental|Azathioprine|Patients with skin diseases taking azathioprine that received administration of Fluzone
11602430|NCT00630643|Placebo Comparator|1|
11444954|NCT01733056|Experimental|TNF alpha blocker|Patients with skin diseases taking azathioprine that received administration of Fluzone
11444955|NCT01733043|Experimental|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
11444956|NCT01733043|Placebo Comparator|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
11444957|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
11444958|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
11444959|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
11444960|NCT01733017|Experimental|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
11444961|NCT01733017|Placebo Comparator|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
11444962|NCT01733004|Experimental|Arm A|MM-141 monotherapy
11444963|NCT01733004|Experimental|Arm B|MM-141 and Everolimus
11444964|NCT01733004|Experimental|Arm C|MM-141 and Abraxane and Gemcitabine
11444965|NCT01732991|Experimental|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
11444966|NCT01732978|Other|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
11444967|NCT01732965|Placebo Comparator|NB-UVB phototherapy|NB-UVB alone
11444968|NCT01732965|Experimental|phototherapy and photochemotherapy|NB-UVB and PUVA
11444969|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
11444970|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
11444971|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
11444972|NCT01732926|Experimental|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
11444973|NCT01732926|Experimental|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
11444974|NCT01732913|Experimental|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
11444975|NCT01732913|Placebo Comparator|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
11444976|NCT01732900|Active Comparator|Morphology|Embryos selected for transfer will be based on morphology alone.
11444977|NCT01732900|Experimental|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
11444978|NCT01732887|Other|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
11444979|NCT01732887|Other|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
11444980|NCT01732874|Other|Expecta 200 mg|Breastfeeding mothers of pre-mature infants randomly assigned to 200 mg Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
11444981|NCT01732874|Other|Expecta 1 Gram|Breastfeeding mothers of pre-mature infants randomly assigned to one Gram of Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
11444982|NCT01732861|Experimental|CC-292 + Lenalidomide|
11444983|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
11444984|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
11444985|NCT01732835|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
11444986|NCT01732822|Experimental|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
11444987|NCT01732822|Active Comparator|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
11444988|NCT01732809|Active Comparator|group A|Group A: Patients received 2units/0.02 mL of reconstituted ABO on the right side of the forehead and 2 units/0.02 mL of reconstituted ONA on the left side.
11444989|NCT01732809|Active Comparator|group B|Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.
11444990|NCT01732796|Experimental|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
11444991|NCT01732796|Experimental|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
11444992|NCT01732796|Experimental|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
11444993|NCT01732783||Metastatic Colorectal Cancer|Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.
11445062|NCT01732367|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
11444994|NCT01732770|Experimental|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
11444995|NCT01732770|Active Comparator|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
11444996|NCT01732757|Active Comparator|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
11444997|NCT01732757|Active Comparator|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
11444998|NCT01732757|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
11444999|NCT01732744|Placebo Comparator|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes
~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
11445000|NCT01732744|Active Comparator|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes
~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
11445001|NCT01732744|Active Comparator|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes
~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
11445002|NCT01732744|Experimental|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes
~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
11445003|NCT01732731|Experimental|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
11445004|NCT01732731|No Intervention|no treadmill training|children will not receive treadmill training
11445005|NCT01732718|Experimental|Atorvastatin, then Placebo|Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
11445006|NCT01732718|Placebo Comparator|Placebo, Then Atorvastatin|Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks.
11445007|NCT01732705|Experimental|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
11445008|NCT01732705|No Intervention|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
11445009|NCT01732705|Experimental|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
11445010|NCT01732705|No Intervention|Control leg, Control subject|Control leg (untrained leg)in control subject
11445011|NCT01732692|Experimental|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
11445012|NCT01732692|Other|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
11445013|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
11445014|NCT01732666|Placebo Comparator|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
11445015|NCT01732666|Placebo Comparator|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
11445016|NCT01732666|Experimental|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
11445017|NCT01732653|Experimental|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
11445018|NCT01732653|Active Comparator|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
11445019|NCT01732640|Experimental|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
11445020|NCT01732627|Experimental|Group 1: MenACYW Conjugate Vaccine|Adult participants aged greater than or equal to (≥) 56 years received a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine on Day 0.
11445021|NCT01732627|Active Comparator|Group 2: Menomune® A/C/Y/W 135 vaccine|Adult participants aged ≥56 years received a single dose of Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined (Menomune®) vaccine on Day 0.
11445022|NCT01732614|Experimental|Topcon Endpoint Management Laser|
11445023|NCT01732601|Experimental|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
11445024|NCT01732601|Active Comparator|Standard Care|Standard Treatment in the Community
11445025|NCT01732588|Active Comparator|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
11446039|NCT01725607|No Intervention|the control group (Group C)|general anesthesia
11445026|NCT01732588|Experimental|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
11445027|NCT01732588|Experimental|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
11445028|NCT01732575|Experimental|Enrichment|Enrichment with meaning-generating activities
11445029|NCT01732575|No Intervention|Rehabilitation as usual|The ongoing, normal day center program.
11445030|NCT01732562|No Intervention|Control|Patient receives the standard of care.
11445031|NCT01732562|Experimental|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
11445032|NCT01732549|Experimental|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
11445033|NCT01732549|Placebo Comparator|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
11445034|NCT01732536|Experimental|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
~Mometasone furoate nasal spray (200mcg) once daily"
11445035|NCT01732536|Sham Comparator|Control|"In-office bilateral sham procedure
~Mometasone furoate nasal spray (200mcg) once daily"
11445036|NCT01732523||No treatment|No intervention
11445037|NCT01732510|Experimental|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
11445038|NCT01732510|Experimental|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
11445039|NCT01732510|Experimental|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
11445040|NCT01732510|Experimental|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
11445041|NCT01732510|Placebo Comparator|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
11445042|NCT01732510|Experimental|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
11445043|NCT01732510|Placebo Comparator|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
11445044|NCT01732497|Experimental|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
11445045|NCT01732484|Other|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
11445046|NCT01732484|Other|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
11445047|NCT01732471|Experimental|Kuvan®|
11445048|NCT01732458|Experimental|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
11445049|NCT01732458|Experimental|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
11445050|NCT01732458|Experimental|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
11445051|NCT01732458|Active Comparator|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
11445052|NCT01732445|Experimental|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
11445053|NCT01732419|Experimental|Home-based training|"After the first three supervised training sessions in the hospitals, patients in the home-based training group are instructed to wear a heart rate monitor during exercise training at home. Prescribed exercise exists of two or three exercise sessions per week, of one hour at 70 - 85% of their maximum heart rate.
~Once a week the heart rate data is uploaded and evaluated by an exercise specialist together with the patient by telephone."
11445054|NCT01732419|Active Comparator|Centre-based training|Patients in the centre-based training group will perform all trainings sessions under direct supervision of a physical therapist specialized in CR. Training sessions will be performed on an cycle ergometer, starting with a warm up phase of 5 min, followed by 50 min of cycling at 70-85% of the maximal HR and a cooling down period of 5 min. During the training period, physical therapists will record attendance, training duration and actual training intensity. After the 12-week training period patients receive individual advice from their physical therapist on physical activities.
11445055|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
11445056|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
11445057|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
11445058|NCT01732393|Active Comparator|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
11445059|NCT01732393|Placebo Comparator|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
11445060|NCT01732380|Active Comparator|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
11445061|NCT01732380|Experimental|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
11446121|NCT01725243|Active Comparator|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
11445063|NCT01732367|Experimental|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
11445064|NCT01732341|Experimental|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
11445065|NCT01732341|Active Comparator|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
11445066|NCT01732328|Placebo Comparator|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
11445067|NCT01732328|Active Comparator|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
11445068|NCT01732315|Experimental|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
11445069|NCT01732315|No Intervention|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
11445070|NCT01732302|Experimental|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
11445071|NCT01732302|No Intervention|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
11445072|NCT01732289|Experimental|A|
11445073|NCT01732276|Experimental|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
11445074|NCT01732263|Experimental|SSP-004184 (Child-Pugh A Liver Impaired)|The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
11445075|NCT01732263|Experimental|SSP-004184 (Child-Pugh B Liver Impaired)|
11445076|NCT01732263|Experimental|SSP-004184 (Child-Pugh C Liver Impaired)|
11445077|NCT01732263|Experimental|SSP-004184 (Matched Healthy Subjects)|
11445078|NCT01732250|Experimental|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
11445079|NCT01732250|Active Comparator|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
11445080|NCT01732237|Experimental|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
11445081|NCT01732237|Experimental|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
11445082|NCT01732237|Experimental|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
11445083|NCT01732224|Experimental|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
11445084|NCT01732224|Active Comparator|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
11445085|NCT01732211|Experimental|PD 0360324|
11445086|NCT01732211|Placebo Comparator|Placebo|
11445087|NCT01732198|Experimental|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
11445088|NCT01732198|Active Comparator|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
11445089|NCT01732185|Other|Patient|congenital cystic adenomatoid malformations
11445090|NCT01732172|Experimental|Patient Group|Patient with urethritis
11445091|NCT01732172|Other|Control group|Subjects with no urethritis and no history urogenital infection
11445092|NCT01732159|Experimental|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
11445093|NCT01732159|No Intervention|No contact by phone|Patients who will not be contacted by phone
11445094|NCT01732146|Active Comparator|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
11445095|NCT01732146|Placebo Comparator|Placebo|0.2 ml saline solution X 3 given every 24 hours
11445096|NCT01732133|Experimental|Measurement of arterial pressure|
11445097|NCT01732120|Experimental|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
11445098|NCT01732120|No Intervention|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
11445099|NCT01732107|Experimental|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
11445100|NCT01732094|Experimental|Corifollitropin Alfa + hMG|
11445101|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
11445102|NCT01732068|Experimental|Corifollitropin alfa+hMG|
11445103|NCT01732055|Active Comparator|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
11445104|NCT01732055|Other|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
11445105|NCT01732029|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
11445171|NCT01731509|Active Comparator|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
11602431|NCT00630643|Experimental|2|
11445106|NCT01732016|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
11445107|NCT01732003|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
11445108|NCT01732003|Placebo Comparator|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
11445109|NCT01731990|Experimental|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
11445110|NCT01731990|Placebo Comparator|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
11445111|NCT01731977|Experimental|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
11445112|NCT01731977|No Intervention|Waiting list|Treatment as usual
11445113|NCT01731964|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
11445114|NCT01731951|Experimental|Arm A|Myelofibrosis (MF) participants will receive Imetelstat, 9.4 milligram per kilogram (mg/kg), intravenously [IV] as 2 hour infusion, on Day 1 of every 21-day cycle as long as they derive clinical benefit or until study end.
11445115|NCT01731951|Experimental|Arm B|MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15 of Cycle 1, then Day 1 of each subsequent 21-day cycle as long as they derive clinical benefit or until study end.
11445116|NCT01731951|Experimental|Arm D|Blast phase MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15, 22 of every 28-day cycle as long as they derive clinical benefit or until study end.
11445117|NCT01731951|Experimental|Arm E|MF participants with spliceosome mutations or ring sideroblasts will receive Imetelstat, 7.5mg/kg, IV as 2 hour infusion, on Day 1 of every 28-day cycle as long as they derive clinical benefit or until study end.
11445118|NCT01731951|Experimental|Arm F|MF participants without spliceosome mutations or ring sideroblasts will receive Imetelstat, 9.4mg/kg on Day1 of every 28-day cycle as long as they derive clinical benefit or until study end.
11445119|NCT01731951|Experimental|Arm G|Myelodysplastic syndromes (MDS)/ myeloproliferative neoplasm (MPN) or MDS participants with spliceosome mutations or ring sideroblasts will receive Imetelstat, 7.5mg/kg on Day 1 of every 28-day cycle as long as they derive clinical benefit or until study end.
11445120|NCT01731938|Experimental|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
11445121|NCT01731938|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
11445122|NCT01731925|Experimental|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
11445123|NCT01731925|Placebo Comparator|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
11445124|NCT01731912|Experimental|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
11445125|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
11445126|NCT01731886|Active Comparator|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
11445127|NCT01731886|Active Comparator|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
11445128|NCT01731860|Experimental|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
11445129|NCT01731847|Experimental|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
11445130|NCT01731834|Active Comparator|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
11445131|NCT01731834|Experimental|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
11445132|NCT01731821|Experimental|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
11445133|NCT01731821|Active Comparator|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
11445134|NCT01731808|No Intervention|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
11445135|NCT01731808|Experimental|Nursing counseling|
11445136|NCT01731795|No Intervention|No dexamethasone|Patients will be treated with conventional treatment
11445137|NCT01731795|Active Comparator|Dexamethasone|Conventional treatment plus dexamethasone
11445138|NCT01731782|Active Comparator|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
11445139|NCT01731782|Placebo Comparator|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
11445172|NCT01731509|Experimental|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
11445140|NCT01731769|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
11445141|NCT01731769|Experimental|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
11445142|NCT01731756|Experimental|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
11445143|NCT01731756|Placebo Comparator|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
11445144|NCT01731743|Other|implantation of a trifocal IOL (AT LISA tri 839MP)|
11445145|NCT01731730|Placebo Comparator|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
11445146|NCT01731730|Experimental|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
11445147|NCT01731730|Experimental|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
11445148|NCT01731717|Experimental|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: >4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.
~Patients with mild depression receive:
~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy
~Patients with moderate depression receive:
~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment
~Patients with severe depression receive:
~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
11445149|NCT01731717|Active Comparator|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
11445150|NCT01731704|Active Comparator|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
11445151|NCT01731704|Active Comparator|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
11445152|NCT01731691|Experimental|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
11445153|NCT01731691|Placebo Comparator|Placebo in HIV disease|Placebos weekly for 8 weeks
11445154|NCT01731691|No Intervention|Uninfected controls|Blood collection only for 8 weeks
11445155|NCT01731678|Experimental|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
11445156|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
11445157|NCT01731652|Experimental|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
11445158|NCT01731639|Experimental|MSOME|The samples will be evaluated under high magnification
11445159|NCT01731613|Active Comparator|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
11445160|NCT01731613|Experimental|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
11445161|NCT01731600|Experimental|N8-GP|
11445162|NCT01731587|Experimental|L-BLP25 plus Cyclophosphamide (CPA)|
11445163|NCT01731574|Active Comparator|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
11445164|NCT01731574|Experimental|Dapivirine Ring|Dapivirine Ring
11445165|NCT01731561|Experimental|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
11445166|NCT01731561|Active Comparator|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
11445167|NCT01731548|Experimental|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.
~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.
~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
11445168|NCT01731548|Active Comparator|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.
~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.
~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
11445169|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
11445170|NCT01731522|Experimental|EF condition|
11445303|NCT01730547|Active Comparator|Delayed treatment with mesenchymal stem cells|
11445173|NCT01731496|Experimental|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
11445174|NCT01731496|Experimental|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
11445175|NCT01731496|No Intervention|Control: Telephone|
11445176|NCT01731496|No Intervention|Control: Text Message|
11445177|NCT01731470|Experimental|Liposomes|Liposomes
11445178|NCT01731457|Experimental|Etanercept|
11445179|NCT01731457|No Intervention|Control|
11445180|NCT01731444|Experimental|Phenylephrine|20 ug/cc
11445181|NCT01731444|Active Comparator|Epinephrine|1:1000000
11445182|NCT01731431|Active Comparator|Insulin|standard protocol of insulin treatment for gestational diabetes
11445183|NCT01731431|Experimental|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
11445184|NCT01731418|Other|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
11445185|NCT01731418|Experimental|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
11445186|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
11445187|NCT01731405||There is not another group|
11445188|NCT01731392|Experimental|Milk with Bifidobacteria|duration of the treatment is 5 months
11445189|NCT01731392|Active Comparator|Milk with non replicating lactobacilli|duration of the treatment is 5 months
11445190|NCT01731392|Placebo Comparator|Semi skimmed milk|duration of the treatment is 5 months
11445191|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
11445192|NCT01731366|Placebo Comparator|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
11445193|NCT01731366|Active Comparator|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
11445194|NCT01731353||Emerging fungal infections|Web-based registry of invasive infections by emerging fungi
11445195|NCT01731340|Active Comparator|Supplemental Calcium|"750 mg Calcium Citrate per day
~800 IU Vitamin D3 per day
~Low Dietary Calcium (450 mg per day)"
11445196|NCT01731340|Active Comparator|Dietary Calcium|"400 IU Vitamin D3 per day
~High Dietary Calcium (1200 mg per day)"
11445197|NCT01731340|No Intervention|Usual Diet|"400 IU Vitamin D3 per day
~Unrestricted Dietary Calcium"
11445198|NCT01731327|Experimental|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
11445199|NCT01731327|Experimental|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
11445200|NCT01731301|Experimental|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
11445201|NCT01731288||vulvodynia|Women with vulvodynia
11445202|NCT01731288||control|Women without vulvar pain
11445203|NCT01731275|Experimental|E6011|
11445204|NCT01731275|Placebo Comparator|E6011 Matching Placebo|
11445205|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
11445206|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
11445207|NCT01731249|Placebo Comparator|Placebo|Placebo sublingual solution
11445208|NCT01731249|Experimental|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
11445209|NCT01731236|Active Comparator|Carnitine (No antibiotics, No aspirin)|L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
11445210|NCT01731236|Active Comparator|Choline (No Antibiotics, No aspirin)|Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
11445211|NCT01731236|Active Comparator|Antibiotics|"Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)
~Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)
~Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)
~Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)"
11445212|NCT01731236|Active Comparator|Choline and Aspirin|"Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)
~Other Names:
~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
11445213|NCT01731236|Active Comparator|Carnitine and Aspirin|"Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)
~Other Names:
~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
11445214|NCT01731223|Experimental|Group treatment for insomnia|Group treatment for insomnia.
11445215|NCT01731223|No Intervention|No intervention|Treatment as usual
11445216|NCT01731197|Experimental|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
11445217|NCT01731197|Experimental|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
11445218|NCT01731197|Active Comparator|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
11445219|NCT01731197|Active Comparator|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
11445220|NCT01731184|Experimental|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
11445221|NCT01731184|Placebo Comparator|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
11445222|NCT01731171|Experimental|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
11445223|NCT01731171|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
11445224|NCT01731158|Other|arm A|"sequential therapy with approved drugs
~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)"
11445225|NCT01731158|Other|arm B|"sequential therapy with approved drugs
~Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)"
11445226|NCT01731145|Experimental|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
11445227|NCT01731132||Group 1|
11445228|NCT01731119|Experimental|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
11445229|NCT01731093|Experimental|AT-001|AT-001
11445230|NCT01731093|Placebo Comparator|Placebo|Matching placebo.
11445231|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
11445232|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
11445233|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
11445234|NCT01731067|Active Comparator|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
11445235|NCT01731067|Active Comparator|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
11445236|NCT01731067|Active Comparator|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
11445237|NCT01731067|Experimental|Probe cocktail alone|"Oral intake of the cocktail probe drugs :
~bupropion 25 mg
~flurbiprofen 25 mg
~omeprazole 5 mg
~dextromethorphan 5 mg
~midazolam 1 mg
~fexofenadine 25mg
~Caffeine (a cup of coffee)"
11445238|NCT01731041|Experimental|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
11445239|NCT01731041|Active Comparator|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
11445240|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
11445241|NCT01731015|Experimental|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
11445242|NCT01731015|Experimental|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
11445243|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
11445244|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
11445245|NCT01731002|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
11445246|NCT01730989|Experimental|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.
~1 tablet oad for 12 weeks"
11445247|NCT01730989|Active Comparator|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.
~1 tablet oad for 12 weeks"
11445248|NCT01730976|Experimental|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
11445249|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
11445250|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
11445251|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
11445252|NCT01730950|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
11445253|NCT01730950|Experimental|Bevacizumab + RT|Radiation therapy with bevacizumab every 2 weeks
11445254|NCT01730937|Experimental|Arm 1 (sorafenib tosylate)|Patients receive sorafenib tosylate orally PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11445255|NCT01730937|Experimental|Arm 2 (SBRT and sorafenib tosylate)|Patients undergo SBRT every 24-72 hours for a total of 5 fractions over 5 to 15 days. Within 1-5 days post-SBRT, patients receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11445256|NCT01730924|Other|Contact force available|
11445257|NCT01730924|Other|Contact force not available|
11452536|NCT01682863|Experimental|QVA149 dose 2|QVA149 27.5/25 μg capsules
11445258|NCT01730911|No Intervention|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
11445259|NCT01730911|Active Comparator|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
11445260|NCT01730911|No Intervention|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
11445261|NCT01730911|Active Comparator|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
11445262|NCT01730898|Active Comparator|Control capsule|2 capsules
11445263|NCT01730898|Experimental|Experimental capsule|2 capsules
11445264|NCT01730885|Other|BGStar|Comparision
11445265|NCT01730872|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
11445266|NCT01730872|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
11445267|NCT01730859|Experimental|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.
~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
11445268|NCT01730846|Experimental|Doxazosin 4mg/day|doxazosin 4mg/day
11445269|NCT01730846|Placebo Comparator|Placebo|placebo control
11445270|NCT01730846|Experimental|Doxazosin 8mg/day|doxazosin 8mg/day
11445271|NCT01730833|Experimental|Treatment (pertuzumab, trastuzumab, nab-paclitaxel)|Patients receive pertuzumab IV over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11445272|NCT01730807|Experimental|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
11445273|NCT01730794|Other|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level <30 cmH2O.
11445274|NCT01730794|Other|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
11445275|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
11445276|NCT01730781||Cannabis dependence|Frequent users of cannabis
11445277|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
11445278|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
11445279|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
11445280|NCT01730781||PTSD-Post Traumatic Stress Disorder|Patients diagnosed with Post Traumatic Stress Disorder
11445281|NCT01730781||Opioid Use Disorder|Patients diagnosed with Opioid Use Disorder
11445282|NCT01730768|Experimental|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
11445283|NCT01730768|Placebo Comparator|Placebo to AQW051|Matching placebo administered orally.
11445284|NCT01730742|Experimental|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
11445285|NCT01730742|Experimental|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
11445286|NCT01730729|Experimental|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11445287|NCT01730716|Experimental|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
11445288|NCT01730703||Adults ages 65 and older|
11445289|NCT01730677|Experimental|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
11445290|NCT01730677|No Intervention|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
11445291|NCT01730664|Experimental|ertapenem|single dose ertapenem
11445292|NCT01730651|Experimental|Tomotherapy|"Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)
~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
11445293|NCT01730625|Experimental|ABMT + CBT|CBT and ABMT
11445294|NCT01730625|Other|CBT Alone|CBT alone (compare/control group)
11445295|NCT01730625|Placebo Comparator|ABMT placebo + CBT|ABMT placebo training and CBT
11445296|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
11445297|NCT01730586|Experimental|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
11445298|NCT01730573|Active Comparator|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
11445299|NCT01730573|Active Comparator|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
11445300|NCT01730560|Experimental|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
11445301|NCT01730560|Experimental|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
11445302|NCT01730547|Active Comparator|Early treatment with mesenchymal stem cells|
11445304|NCT01730534|Experimental|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
11445305|NCT01730534|Placebo Comparator|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
11445306|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
11445307|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
11445308|NCT01730495|Experimental|Etanercept|
11445309|NCT01730482|Experimental|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of [14C] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
11445310|NCT01730469|Experimental|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
11445311|NCT01730456|Experimental|RoActemra/Actemra|
11445312|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
11445313|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
11445314|NCT01730430||Collection of CSF|"Those with Alzheimer's disease
~Those with non-Alzheimer's disease dementia
~Healthy elderly volunteers"
11445315|NCT01730417|Experimental|Radiation dosimetry|no carrier added metaiodobenzylguanidine
11445316|NCT01730404|Experimental|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
11445317|NCT01730404|Active Comparator|Roflumilast|Roflumilast, tablet, once daily
11445318|NCT01730404|Placebo Comparator|placebo|Placebo
11445319|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
11445320|NCT01730378|Experimental|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
11445321|NCT01730378|Active Comparator|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
11445322|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
11445323|NCT01730352|No Intervention|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
11445324|NCT01730352|Experimental|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
11445325|NCT01730339|Active Comparator|Group 1|
11445326|NCT01730339|Active Comparator|Group 2|
11445327|NCT01730326|Experimental|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
11445328|NCT01730326|Active Comparator|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
11445329|NCT01730313|Experimental|Pyridoxine (B6)|Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks
11445330|NCT01730313|Experimental|Phenytoin|Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks
11445331|NCT01730313|Experimental|Sodium Valproate|Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks
11445332|NCT01730313|Placebo Comparator|Placebo|Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm
11445333|NCT01730287|Experimental|Control|No lining applied in group1.
11445334|NCT01730287|Experimental|CEM cement|CEM cement applied over remained caries in group4.
11445335|NCT01730287|Experimental|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
11445336|NCT01730287|Experimental|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
11445337|NCT01730274||patients|children operated on a cerebellar tumor
11445338|NCT01730274||healthy subjects|healthy volunteers
11445339|NCT01730261|Experimental|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
11445340|NCT01730248|Experimental|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) & an Expansion Phase
11445341|NCT01730248|Experimental|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID & an Expansion Phase
11445342|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
11445343|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
11445344|NCT01730222|Experimental|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
11445345|NCT01730222|Active Comparator|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
11445346|NCT01730209|Experimental|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
11445347|NCT01730209|Placebo Comparator|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
11445348|NCT01730196|Experimental|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
11445349|NCT01730196|Active Comparator|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
11445350|NCT01730183|Experimental|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
11445351|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
11445352|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
11445353|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
11445354|NCT01730157|Experimental|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11445355|NCT01730131||Control Patients at Risk for PML|Participants with impaired immune function from any cause and considered at risk for PML
11445356|NCT01730131||Healthy Volunteers|Healthy volunteers without impaired immune function
11445357|NCT01730131||PML Patients|Patients with PML
11445358|NCT01730118|Experimental|1/Part I dose escalation|AdHER DC vaccine administered at escalating doses
11445359|NCT01730118|Experimental|2/Part I dose expansion|AdHER DC vaccine administered at a next lower dose or the highest dose
11445360|NCT01730118|Experimental|3/Part II dose escalation|AdHER DC vaccine administered at Dose Level 1
11445361|NCT01730118|Experimental|4/Part II dose expansion|AdHER DC vaccine administered at Arm 1 MTD
11445362|NCT01730092||Healthy Volunteers|Enroll up to 120 healthy volunteers, in order to obtain approximately 55 evaluable healthy volunteers matched to pulmonary arterial hypertension subjects for age and gender
11445363|NCT01730092||Pulmonary Arterial Hypertension Subjects|150 subjects with pulmonary arterial hypertension; male or female, age greater than or equal to 18 99 years
11445364|NCT01730066|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
11445365|NCT01730066|No Intervention|Control|No intervention.What has been the standard procedure so far
11445366|NCT01730053|Active Comparator|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
11445367|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
11445368|NCT01730053|Experimental|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
11445369|NCT01730053|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
11445370|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
11445371|NCT01730053|Experimental|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
11445372|NCT01730040|Active Comparator|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
11445373|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
11445374|NCT01730040|Experimental|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
11445375|NCT01730040|Active Comparator|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
11445482|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
11445376|NCT01730040|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
11445377|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
11445378|NCT01730040|Experimental|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
11445379|NCT01730027|Experimental|ADC3680|ADC3680 oral once daily
11445380|NCT01730027|Placebo Comparator|Placebo|Placebo oral once daily
11445381|NCT01730027|Active Comparator|montelukast|montelukast oral once daily
11445382|NCT01730014|Experimental|Trial part 1|
11445383|NCT01730014|Experimental|Trial part 2, treatment A|
11445384|NCT01730014|Experimental|Trial part 2, treatment B|
11445385|NCT01730001|Active Comparator|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
11445386|NCT01730001|Active Comparator|Late intubation|Late intubation is defined as on-scene prehospital high-flow (> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
11445387|NCT01729988|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
11445388|NCT01729975||18-28 years old Non-pathologic|
11445389|NCT01729975||29-80 years old Non-Pathologic|
11445390|NCT01729975||29-80 years old pathologic corneal disease|
11445391|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
11445392|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
11445393|NCT01729949|Active Comparator|Active Treatment Beverage|Strawberry powder and Blackcurrent extract
11445394|NCT01729949|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
11445395|NCT01729936|Experimental|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.
~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
11445396|NCT01729936|No Intervention|Active Control|Control visits to the Primary Health Care Center
11445397|NCT01729923|Experimental|Treatment (capecitabine, celecoxib, radiation therapy)|"Patients proceed to surgery, radiation therapy with ADAPT therapy followed by maintenance ADAPT therapy, or ADAPT therapy. Eligible patients undergo surgical resection at baseline or upon achievement of resectable disease after radiation therapy.
~RADIATION + ADAPT: Patients undergo radiation therapy 5 days per week and receive capecitabine PO BID and celecoxib PO BID 5 days per week during radiation.
~ADAPT: Patients receive capecitabine PO BID on days 1-14 and celecoxib PO BID on days 1-21. Courses repeat every 21 days for up to 3 years in the absence of disease progression or unacceptable toxicity."
11445398|NCT01729910|Experimental|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
11445399|NCT01729910|Placebo Comparator|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
11445400|NCT01729897|Experimental|Etomidate & Fentanyl|"4 min before procedure: fentanyl 1 μg/kg (0.02 ml/kg), intravenous injection
~After injection of fentanyl, etomidate was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.
~Additional dose of etomidate would be administrated separately when duration of procedure was prolonged."
11445401|NCT01729897|Placebo Comparator|Propofol & Fentanyl|"4 min before procedure: fentanyl 1 g/kg (0.02 ml/kg), intravenous injection
~After injection of fentanyl, propofol was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.
~Additional dose of propofol would be administrated separately when duration of procedure was prolonged."
11445402|NCT01729884|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
11445403|NCT01729871|Experimental|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
11445404|NCT01729871|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
11445405|NCT01729858||Metal-Ceramic|Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
11446122|NCT01725243|Active Comparator|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
11445406|NCT01729858||Ceramic-Ceramic|Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
11445407|NCT01729845|Experimental|Treatment (decitabine, MEC)|"Patients receive decitabine IV on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).
~INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
11445408|NCT01729832|Experimental|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
11445409|NCT01729819|Experimental|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
11445410|NCT01729819|Active Comparator|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
11445411|NCT01729806|Experimental|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
11445412|NCT01729806|Experimental|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
11445413|NCT01729793|Active Comparator|Digestive Enzyme #2|A proprietary blend of dietary supplement enzymes in a capsule
11445414|NCT01729793|Placebo Comparator|Placebo|Capsule identical to active arm containing only microcrystalline cellulose
11445415|NCT01729780|Sham Comparator|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
11445416|NCT01729780|Active Comparator|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
11445417|NCT01729767|Experimental|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
11445418|NCT01729767|Placebo Comparator|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
11445419|NCT01729754|Experimental|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
11445420|NCT01729754|Experimental|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
11445421|NCT01729754|Placebo Comparator|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
11445422|NCT01729754|Active Comparator|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
11445423|NCT01729741|No Intervention|No drain|No drain was inserted after Thyroid surgery
11445424|NCT01729741|Experimental|Drain|A drain was inserted after thyroid surgery
11445425|NCT01729728|Experimental|Tapentadol|
11445426|NCT01729715|Experimental|Internet|Internet site that offers parents tips on promoting sleep in infants and toddlers
11445427|NCT01729715|Experimental|DVD|DVD that offers parents tips on promoting sleep in infants and toddlers
11445428|NCT01729715|No Intervention|No treatment|
11445429|NCT01729702|Other|single group - consecutive patients|
11445430|NCT01729689|Experimental|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
11445431|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
11445432|NCT01729663|Active Comparator|Interferon alpha 2 b|Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.
11445433|NCT01729663|Experimental|CSF470 vaccine, BCG, Molgramostim|"CSF470 vaccine, BCG, Molgramostim
~CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.
~Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used."
11445434|NCT01729650|Experimental|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
11445435|NCT01729650|No Intervention|Usual clinical care|
11445436|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
11445437|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
11445438|NCT01729598|Experimental|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
11445439|NCT01729598|Placebo Comparator|Placebo|Placebo capsule by mouth twice daily.
11445440|NCT01729585|No Intervention|control group|control group
11445483|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
11445563|NCT01728792|Experimental|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
11452537|NCT01682863|Active Comparator|QAB149|QAB149 75 μg capsules
11445441|NCT01729585|Active Comparator|Massage therapy|Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
11445442|NCT01729572|Experimental|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
11445443|NCT01729572|No Intervention|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
11445444|NCT01729559|Experimental|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
11445445|NCT01729559|Active Comparator|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
11445446|NCT01729533|Active Comparator|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
11445447|NCT01729533|Experimental|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
11445448|NCT01729520|Experimental|Knee extension strength training|
11445449|NCT01729507|Active Comparator|Treatment with tDCS|This group will receive 7x verum treatment with tDSC. All participants receive standardised behavioural therapy ('The smoke-free programme')
11445450|NCT01729507|Placebo Comparator|7x sham treatment|This group will receive 7x sham treatment. All participants will receive standardised behavioural therapy ('The smoke-free programme')
11445451|NCT01729494|Experimental|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
11445452|NCT01729494|Experimental|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
11445453|NCT01729494|Active Comparator|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
11445454|NCT01729481|Experimental|RASH positive|"Run-In-Phase during 4 weeks:
~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly
~Thereafter Treatment in patients with RASH-positve outcome after 4 weeks."
11445455|NCT01729481|Active Comparator|RASH-negative|"Run-In-Phase during 4 weeks:
~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly
~RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:
~Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion"
11445456|NCT01729468|Experimental|Aspirin|Aspirin 160 mg per day
11445457|NCT01729468|Placebo Comparator|Placebo|Placebo 160 mg per day
11445458|NCT01729455||BENLYSTA cohort|Participants with active, autoantibody-positive SLE treated with BENLYSTA at Baseline.
11445459|NCT01729455||Comparison cohort|Participants with active, autoantibody-positive SLE treated without BENLYSTA at Baseline.
11445460|NCT01729442|Other|Patients referred for first-line prostate HIFU ablation|10 patients
11445461|NCT01729442|Other|Patients referred for first-line HIFU hemi-ablation|10 patients
11445462|NCT01729442|Other|Patients referred for salvage HIFU after radiotherapy|10 patients
11445463|NCT01729429|Active Comparator|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
11445464|NCT01729429|Experimental|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit
~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine
~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
11445465|NCT01729416|Experimental|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
11445466|NCT01729416|Active Comparator|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
11445467|NCT01729403|Experimental|Aleglitazar|
11445468|NCT01729403|Placebo Comparator|Placebo|
11445469|NCT01729390|Experimental|Std ED Control|100% energy density and 133% portion size
11445470|NCT01729390|Experimental|Inc ED Control|133% energy density and 133% portion size
11445471|NCT01729390|Experimental|Std ED and Std PS|100% energy density and 100% portion size
11445472|NCT01729390|Experimental|Std ED and Inc PS|100% energy density and 133% portion size
11445473|NCT01729390|Experimental|Inc ED and Inc PS|133% energy density and 133% portion size
11445474|NCT01729390|Experimental|Inc ED and Std PS|133% energy density and 100% portion size
11445475|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
11445476|NCT01729364|Experimental|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
11445477|NCT01729364|Experimental|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
11445478|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
11445479|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
11445480|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
11445481|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
11445484|NCT01729338|Experimental|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):
~VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15
~Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15
~Dexamethasone 40 mg PO days 1,8 and 15
~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):
~Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21
~Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
11445485|NCT01729325|Experimental|Preventive Narrative Exposure Therapy|Treatment with Pre-NET before deployment in peace-keeping mission
11445486|NCT01729325|No Intervention|No treatment control|
11445487|NCT01729299|Placebo Comparator|saline|Saline: 0.9% saline solution
11445488|NCT01729299|Experimental|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
11445489|NCT01729299|Experimental|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
11445490|NCT01729299|Experimental|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
11445491|NCT01729286|Active Comparator|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
11445492|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
11445493|NCT01729273|Experimental|Diet and Exercise Intervention|"Tests will include EndoPAT analysis to assess endothelial function, applanation tonometry to assess arterial stiffness, carotid artery imaging to assess the wall thickness of the carotid arteries, exercise testing to assess the physical exercise capacity of these children and blood work to evaluate the lipid profile and inflammation status (CRP).
~The Home Exercise Program will be 3 days a week for 12 weeks and participants will connect with the trainer to perform 45-60 minutes of a combination of strength training and aerobic activity via Skype. The Dietary Approaches to Stop Hypertension(DASH) eating pattern will be prescribed to all participants in the treatment group and specific strategies to achieve goals will be discussed weekly by the participant over the phone."
11445494|NCT01729260|Experimental|Mebendazole|All study participants will receive study drug; Mebendazole.
11445495|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
11445496|NCT01729234|Experimental|Nitrate|150µmol /Kg bodyweight /day
11445497|NCT01729234|Placebo Comparator|PLacebo|150µmol /Kg bodyweight /day
11445498|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
11445499|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
11445500|NCT01729208|Experimental|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
11445501|NCT01729208|Placebo Comparator|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
11445502|NCT01729195|Experimental|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
11445503|NCT01729182||Nexium|
11445504|NCT01729169||Sarcoidosis patients|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
11445505|NCT01729156|Other|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
11445506|NCT01729156|Placebo Comparator|Placebo|Placebo
11445507|NCT01729156|Active Comparator|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
11445508|NCT01729143|Active Comparator|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
11445509|NCT01729143|Placebo Comparator|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
11445510|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
11445511|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
11445512|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
11445513|NCT01729117|Other|Meal Replacement|Meal Replacements will be provided to participants randomized to the MR group
11445514|NCT01729117|Other|Standard Care|Standard Care participants will receive standard care but no meal replacements
11445515|NCT01729104|Experimental|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
11445516|NCT01729104|Experimental|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.
~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.
~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
11445517|NCT01729104|Experimental|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).
~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.
~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.
~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
11445518|NCT01729091|Experimental|Treatment (chemotherapy, UCB-derived NK cells, transplant)|Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.
11445519|NCT01729078|Experimental|high fat ( MUFA) diet|intervention using high fat diet.
11445520|NCT01729078|Experimental|high carb/high fiber|diet using high carb-high fiber with dry beans
11445521|NCT01729078|Experimental|high carb/low fat|Habitual diet
11445522|NCT01729065|No Intervention|Home Program|Participants perform home program only.
11445523|NCT01729065|Experimental|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
11445524|NCT01729052|Experimental|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.
~Standard treatment: general anaesthesia"
11445525|NCT01729052|No Intervention|Standard treatment|General anaesthesia
11445526|NCT01729039|Experimental|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
11445527|NCT01729039|Placebo Comparator|control|standard balance rehabilitation plus placebo eye exercises
11445528|NCT01729026|Experimental|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
11445529|NCT01729026|Active Comparator|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
11445530|NCT01729013||subjects previously given placebo|
11445531|NCT01729013||subjects previously given vitamin D|
11445532|NCT01729000|No Intervention|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
11445533|NCT01729000|Experimental|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
11445534|NCT01728987|Active Comparator|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
11445535|NCT01728987|Placebo Comparator|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
11445536|NCT01728974|Experimental|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
11445537|NCT01728961|Active Comparator|ARM A: AL + NVP -based ARV treatment|AL given to children who test positive for malaria and are already taking NVP as prescribed by their healthcare provider
11445538|NCT01728961|Active Comparator|ARM B: AL with No ARV treatment|AL given to children who do not meet national guidelines for beginning ARV treatment
11445539|NCT01728948||Group 1|
11445540|NCT01728935|Other|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
11445541|NCT01728922|Active Comparator|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
11445542|NCT01728922|Active Comparator|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
11445543|NCT01728922|Placebo Comparator|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
11445544|NCT01728922|Active Comparator|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
11445545|NCT01728922|Active Comparator|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
11445546|NCT01728922|Placebo Comparator|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
11445547|NCT01728909|Experimental|Oxytocin|40 IU Oxytocin
11445548|NCT01728909|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
11445549|NCT01728896|Experimental|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
11445550|NCT01728896|No Intervention|Conventional management|
11445551|NCT01728883||Diagnosed DR/DME requiring treatment|Patients diagnosed as diabetic retinopathy(DR) and/or diabetic macular edema (DME) and requiring treatment at the time they are recruited into the Study. Patients will be home vision monitoring using myVisionTrack®.
11445552|NCT01728870|Experimental|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:
~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.
~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
11445553|NCT01728870|Active Comparator|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:
~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
11445554|NCT01728857|Experimental|Fat Reduction|
11445555|NCT01728844|Active Comparator|beta-tricalcium phosphate alone|beta-tricalcium phosphate alone
11445556|NCT01728844|Experimental|GFeBGS 0.1%|GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
11445557|NCT01728844|Experimental|GFeBGS 0.3%|GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
11445558|NCT01728844|Experimental|GFeGBS 0.4%|GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
11445559|NCT01728818|Experimental|Arm A|
11445560|NCT01728818|Active Comparator|Arm B|
11445561|NCT01728805|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
11445562|NCT01728805|Active Comparator|Vorinostat|vorinostat 400 mg once daily
11452924|NCT01680484|No Intervention|Control|Sit and rest
11445564|NCT01728792|Experimental|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
11445565|NCT01728792|Experimental|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
11445566|NCT01728792|Experimental|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
11445567|NCT01728792|Experimental|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
11445568|NCT01728779|Experimental|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
11445569|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
11445570|NCT01728753|Placebo Comparator|Placebo|Placebo
11445571|NCT01728753|Experimental|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
11445572|NCT01728753|Experimental|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
11445573|NCT01728753|Experimental|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
11445574|NCT01728740|Experimental|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
11445575|NCT01728740|Active Comparator|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
11445576|NCT01728740|Active Comparator|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
11445577|NCT01728740|Active Comparator|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
11445578|NCT01728727|Active Comparator|conventional|conventional treatment & antiviral treatment
11445579|NCT01728727|Experimental|UC-MSC transplantation|Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit
11445580|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
11445581|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
11445582|NCT01728701|Experimental|Grp 1: 75,000 PfSPZ Challenge, 3 immunizations|Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
11445583|NCT01728701|Placebo Comparator|Grp 2: Normal Saline (NS)|Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
11445584|NCT01728701|Experimental|Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations|Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
11445585|NCT01728701|Placebo Comparator|Grp 4: Normal Saline (NS)|Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
11445586|NCT01728688|Active Comparator|Conventional|conventional treatment & antiviral treatment
11445587|NCT01728688|Experimental|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
11445588|NCT01728675|Experimental|Young group|Participants will underwent two isokinetic eccentric exercise sessions
11445589|NCT01728675|Experimental|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
11445590|NCT01728662|Experimental|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
11445697|NCT01728064|Placebo Comparator|Placebo|Placebo capsules three times daily
11602432|NCT00630630|Experimental|1|
11445591|NCT01728649|No Intervention|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA approved devices. After which patient will be started on normothermia attempting to keep core body temp between 38 and 36.5 degrees centigrade. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
11445592|NCT01728649|Experimental|Mild Hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA cleared device. Patient will also have a Quattro catheter placed in the femoral vein and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours and then be rewarmed very slowly. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
11445593|NCT01728636|Experimental|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
11445594|NCT01728636|Placebo Comparator|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
11445595|NCT01728623|Experimental|E7080|
11445596|NCT01728610|Active Comparator|Active high|Probiotic, high dose
11445597|NCT01728610|Active Comparator|Active low|Probiotic, low dose
11445598|NCT01728610|Placebo Comparator|Placebo|Placebo
11445599|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
11445600|NCT01728584|Experimental|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four [TOF] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
11445601|NCT01728584|Experimental|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
11445602|NCT01728584|Experimental|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
11445603|NCT01728584|Experimental|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
11445604|NCT01728571|Active Comparator|Vitamin D + fish oil|Dietary Supplement: vitamin D3 Drug: omega-3 fatty acids (fish oil)
11445605|NCT01728571|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: vitamin D3 Dietary Supplement: Fish oil placebo
11445606|NCT01728571|Active Comparator|Vitamin D placebo + fish oil|Drug: omega-3 fatty acids (fish oil) Dietary Supplement: Vitamin D3 placebo
11445607|NCT01728571|Placebo Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement: Vitamin D3 placebo Dietary Supplement: Fish oil placebo
11445608|NCT01728558|Other|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:
~Early delivery of proposed intervention, shortly after initiating mechanical ventilation;
~Effective analgesia provided simultaneously and early (analgesia first).
~Regular and frequent assessment of patient wakefulness/sedative state;
~Avoidance of benzodiazepines and minimisation of use of propofol;
~Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.
~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
11445609|NCT01728558|Active Comparator|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
11445610|NCT01728532|Active Comparator|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
11445611|NCT01728532|Experimental|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
11445612|NCT01728519|Experimental|AllerT SC|AllerT subcutaneous injections
11445613|NCT01728519|Placebo Comparator|Placebo SC|placebo subcutaneous injections
11445614|NCT01728519|Experimental|AllerT ID|AllerT intra-dermal injections
11445615|NCT01728519|Placebo Comparator|Placebo ID|placebo intra-dermal injections
11445616|NCT01728506|Experimental|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
11445617|NCT01728493||Part 1|- newly diagnosed hypertensive patients in general practice
11445618|NCT01728493||Part 2:|"newly diagnosed hypertensive patients with primary aldosteronism
~newly diagnosed hypertensive patients with essential hypertension"
11445619|NCT01728493||Part 3:|"newly diagnosed hypertensive patients with normokalemic primary aldosteronism
~newly diagnosed hypertensive patients with essential hypertension"
11445620|NCT01728480|Experimental|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
11445621|NCT01728467|Experimental|RVX000222, 200 mg daily|
11445622|NCT01728467|Placebo Comparator|Placebo|
11445623|NCT01728454|Placebo Comparator|Placebo|Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
11445624|NCT01728454|Experimental|Telapristone acetate 6 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
11445625|NCT01728454|Experimental|Telapristone acetate 12 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.
11445698|NCT01728064|Active Comparator|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
11445626|NCT01728441|Experimental|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
11445627|NCT01728441|Active Comparator|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
11445628|NCT01728415|Experimental|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
11445629|NCT01728415|Active Comparator|B: Execise|Moderate continuous exercise training
11445630|NCT01728415|No Intervention|C: Controll|Usual care without exercise training
11445631|NCT01728402||Blood Draw|
11445632|NCT01728389|Experimental|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
11445633|NCT01728376|Experimental|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
11445634|NCT01728376|Active Comparator|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
11445635|NCT01728376|Experimental|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
11445636|NCT01728376|Experimental|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
11445637|NCT01728376|Active Comparator|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
11445638|NCT01728376|Active Comparator|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
11445639|NCT01728363|Experimental|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose
~<30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses
~<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses
~<30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses
~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
11445640|NCT01728363|Experimental|Rifampin generic antibiotic|"Cohort GA PNA Dose
~<32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses
~<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses
~≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses
~≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses
~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis."
11445641|NCT01728363|Experimental|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose
~<30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses
~<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses
~<30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses
~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
11445642|NCT01728350|Experimental|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
11445643|NCT01728350|No Intervention|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
11445644|NCT01728337|Active Comparator|Dysport and Xeomin|30 U of Dysport® was injected on the right side of the forehead and 12 U Xeomin® was injected on the left side of the forehead (dose-equivalence 2.5:1).
11445645|NCT01728337|Active Comparator|Xeomin and Dysport|30 U Dysport® was injected on the left side of the forehead and 12 U Xeomin® was injected on the right side of the forehead (dose-equivalence 2.5:1).
11445646|NCT01728324|Experimental|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
11445647|NCT01728324|Experimental|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
11445648|NCT01728324|Experimental|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
11445649|NCT01728311|Experimental|Arm 1|
11445650|NCT01728298|Active Comparator|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
11445651|NCT01728298|Active Comparator|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
11445652|NCT01728298|Active Comparator|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
11445653|NCT01728285|Active Comparator|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
11445699|NCT01728064|Active Comparator|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
11602433|NCT00630630|Placebo Comparator|2|
11445654|NCT01728285|No Intervention|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
11445655|NCT01728272|Experimental|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
11445656|NCT01728259|Experimental|Treatment (pomalidomide, bortezomib, and dexamethasone)|Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11445657|NCT01728246|Experimental|Tramadol/Paracetamol (APAP)|
11445658|NCT01728246|Active Comparator|Non-Tramadol/APAP|
11445659|NCT01728233|Experimental|Dacomitinib (PF-00299804)|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
11445660|NCT01728220|Active Comparator|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
11445661|NCT01728220|Active Comparator|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
11445662|NCT01728220|Active Comparator|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
11445663|NCT01728220|Placebo Comparator|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder
11445664|NCT01728220|Active Comparator|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
11445665|NCT01728220|Active Comparator|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
11445666|NCT01728220|Active Comparator|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder
11445667|NCT01728207|Experimental|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
11445668|NCT01728194|Experimental|Escitalopram|Target dose 20mg for 12 weeks
11445669|NCT01728194|Other|Control|Non-psychiatric comparison participants.
11445670|NCT01728181|Experimental|Phase I|Will receive Tivozanib and Erlotinib treatment.
11445671|NCT01728181|Other|Phase II Group 1 (Standard of Care)|"Group 1: VeriStrat® predicts the chance of no benefit from erlotinib
~• The patient will get standard-of- care"
11445672|NCT01728181|Active Comparator|Phase II Group 2 (arm 1)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib
~• Arm 1: Patient will get the study drugs Erlotinib and Tivozanib"
11445673|NCT01728181|Placebo Comparator|Phase II Group 2 (arm 2)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib
~• Arm 2: Patient will get the study drug erlotinib and placebo"
11445674|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (>10 points).
11445675|NCT01728168||Non-atopic|Subjects without atopy.
11445676|NCT01728155|No Intervention|Group1|initial observation (chemotherapy is only given if there is subsequent progression)
11445677|NCT01728155|Active Comparator|Group 1: chemotherapy|chemotherapy and surgery
11445678|NCT01728155|Experimental|Group 2|chemotherapy and surgery
11445679|NCT01728155|Experimental|Group 3|chemotherapy and surgery
11445680|NCT01728155|No Intervention|Group 4|Observation
11445681|NCT01728155|Experimental|Group 5|chemotherapy
11445682|NCT01728155|Experimental|Group 6|chemotherapy and surgery
11445683|NCT01728155|Experimental|Group 7|chemotherapy and surgery
11445684|NCT01728155|Experimental|Group 8|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
11445685|NCT01728155|Experimental|Group 9|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
11445686|NCT01728155|Experimental|Group 10|chemotherapy, surgery,
11445687|NCT01728142|Active Comparator|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
11445688|NCT01728142|Experimental|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
11445689|NCT01728129|Experimental|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
11445690|NCT01728129|Active Comparator|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
11445691|NCT01728116|Experimental|Device (EndoBarrier)|Device for glycemic control
11445692|NCT01728116|Sham Comparator|Sham Procedure|sham procedure
11445693|NCT01728103||No Treatment|
11445694|NCT01728090|Experimental|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.
~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
11445695|NCT01728090|No Intervention|Control|No hand sanitizer or educational programme were used
11445696|NCT01728077|Experimental|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
11445700|NCT01728038|Experimental|Cessation Counseling|Parental smokers will be given a brief cessation intervention consisting of counseling, nicotine replacement therapy and Quitline connection.
11445701|NCT01728025|Experimental|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
11445702|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of >=60 ml/min/1.73m2.
11445703|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate >=45 ml/min/1.73m2 and <60ml/min/1.73m2.
11445704|NCT01727999||TPO responder|Patients with therapeutic response to TPO
11445705|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
11445706|NCT01727986|Experimental|RoActemra/Actemra|
11445707|NCT01727973|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
11445708|NCT01727960||Korean Male Adolescents|students from two academic high schools
11445709|NCT01727947|Experimental|MSOME|Couples in which the sperm cells were analysed through MSOME
11445710|NCT01727934|Experimental|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
11445711|NCT01727921|Active Comparator|22 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 22 gauge ProCore biopsy needle.
11445712|NCT01727921|Active Comparator|25 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 25 gauge ProCore biopsy needle.
11445713|NCT01727908|No Intervention|Endoscopy without staining of the mucosa|
11445714|NCT01727908|Experimental|Endoscopy with staining of the mucosa.|
11445715|NCT01727895|Experimental|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
11445716|NCT01727895|No Intervention|Control group|
11445717|NCT01727882|Experimental|Daily Assessments & Brief Feedback|Daily assessments during 30 days after parole and a feedback intervention based on these daily assessments.
11445718|NCT01727882|Active Comparator|Daily assessments|Daily assessments during 30 days after parole.
11445719|NCT01727869|Experimental|Cohort 1|Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
11445720|NCT01727869|Experimental|Cohort 2|Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
11445721|NCT01727869|Experimental|Cohort 3|Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
11445722|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
11445723|NCT01727843|Experimental|tranexamic acid|3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
11445724|NCT01727843|Placebo Comparator|saline|3000mg/mL saline applied directly to the wound at the end of the surgical procedure
11445725|NCT01727817|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
11445726|NCT01727817|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
11445727|NCT01727804|Experimental|Laser|
11445728|NCT01727791|Experimental|open label|
11445729|NCT01727778|Experimental|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
11445730|NCT01727765|Experimental|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
11445731|NCT01727765|Sham Comparator|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
11445732|NCT01727752|Active Comparator|Surgical decompression|Surgical decompression
11445733|NCT01727752|Active Comparator|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
11445734|NCT01727739|Active Comparator|PLLA bioscrew|poly-L-lactic acid bioscrew
11445735|NCT01727739|Active Comparator|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
11445736|NCT01727726|Placebo Comparator|Placebo + ADT|Matching Placebo and assigned ADT
11445737|NCT01727726|Experimental|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
11445738|NCT01727726|Active Comparator|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
11445739|NCT01727713|Experimental|Aripiprazole|Aripiprazole Immediate Release Once-Daily
11445740|NCT01727700|Placebo Comparator|Placebo|Matching Placebo Once-Daily
11445741|NCT01727700|Experimental|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
11445742|NCT01727700|Experimental|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
11445743|NCT01727687|Experimental|Patients with Parkinson's disease|Using simulated traffic scene system to help patients with Parkinson's disease improve crossing road behaviors.
11445744|NCT01727661||type 1 diabetes mellitus|"exercise testing with near-infrared spectroscopy
~lung function testing
~quality of life"
11445745|NCT01727661||healthy controls|"exercise testing with near-infrared spectroscopy
~lung function testing
~quality of life"
11446292|NCT01724255||staple removal day 7, dressing removal day 7|late staple removal and late dressing removal
11445746|NCT01727648|Experimental|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
11445747|NCT01727648|Experimental|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
11445748|NCT01727648|Experimental|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
11445749|NCT01727648|Active Comparator|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
11445750|NCT01727635|Experimental|counseling|body-mind-spirit group therapy
11445751|NCT01727622||Controls|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
11445752|NCT01727622||Mild Cognitive Impairment|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
11445753|NCT01727609|Active Comparator|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
11445754|NCT01727609|Experimental|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
11445755|NCT01727596|Experimental|1|
11445756|NCT01727583|Active Comparator|Lipid 1|Meal intake
11445757|NCT01727583|Placebo Comparator|Lipid-free|Maltodextrine + proteins
11445758|NCT01727583|Active Comparator|Lipid 2|Meal intake
11445759|NCT01727583|Active Comparator|Lipid 3|Meal intake
11445760|NCT01727583|Active Comparator|Lipid 4|meal intake
11445761|NCT01727570|No Intervention|Nutrition Counselling|Patients will be asked to fill out a three day record of all food and drink consumed. Patients will be given an appointment with the nutritionist approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of their diet
11445762|NCT01727570|Active Comparator|Nutrition Supplementation|Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
11445763|NCT01727557|Active Comparator|Local anesthesia|
11445764|NCT01727557|Active Comparator|regional anesthesia|
11445765|NCT01727544|Active Comparator|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
11445766|NCT01727544|No Intervention|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
11445767|NCT01727531|Experimental|CQ Arm|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
11445768|NCT01727518||Reference Population|No Intervention
11445769|NCT01727505|Active Comparator|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
11445770|NCT01727505|Active Comparator|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
11445771|NCT01727492|Placebo Comparator|sugar pill|
11445772|NCT01727492|Active Comparator|Antioxidantia|Dosage: 600mg n-acetylcystein and 200mg magnesium intake: 1 hour before leisure noise exposure above 100dB of at least 30 minutes frequency: 4 separate events (2x placebo, 2x antioxidants)
11445773|NCT01727479|Experimental|Ribose|After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
11445774|NCT01727479|Placebo Comparator|Placebo|After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
11445775|NCT01727466|Experimental|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
11445776|NCT01727453|Active Comparator|Bemiparin|Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
11445856|NCT01726829|Experimental|MD-Logic Artificial Pancreas (MDLAP) system|four consecutive outpatients overnight sessions at home under closed loop MD-Logic Artificial Pancreas (MDLAP) system
11445777|NCT01727453|Active Comparator|Warfarin|which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
11445778|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
11445779|NCT01727414|Other|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
11445780|NCT01727414|Other|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
11445781|NCT01727401|Experimental|Fondaparinux|Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
11445782|NCT01727388|Experimental|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
11445783|NCT01727388|Active Comparator|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
11445784|NCT01727375|No Intervention|Standard light|In this arm patients receive standard lightening conditions
11445785|NCT01727375|Experimental|Ciradian light|In this arm patients receive artificial ceiling light (circadian light) at the bedside.
11445786|NCT01727362|Active Comparator|Usual care + acupuncture|
11445787|NCT01727362|Active Comparator|Usual care|
11445788|NCT01727349|Other|Type 2 diabetic subject|Subject with type 2 diabetes
11445789|NCT01727349|Other|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
11445790|NCT01727336|Experimental|Dalantercept plus axitinib|Subcutaneous (SC) injection of Dalantercept once every 3 weeks and Oral axitinib BID for continuous dosing.
11445791|NCT01727336|Active Comparator|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral BID for continuous dosing
11445792|NCT01727297|Other|REVEAL Implantable Cardiac Monitor|
11445793|NCT01727284|Other|MR-guided cryoablation (freezing of tissue and/or tumors)|
11445794|NCT01727271|Active Comparator|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
11445795|NCT01727271|Experimental|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
11445796|NCT01727271|Experimental|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
11445797|NCT01727258|Experimental|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
11445798|NCT01727258|Active Comparator|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
11445799|NCT01727258|Active Comparator|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
11445800|NCT01727245|Other|Obese|Obese patients undergoing gastric by-pass surgery
11445801|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
11445802|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
11445803|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
11445804|NCT01727206|Experimental|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
11445805|NCT01727193|Active Comparator|Azathioprine|cholinesterase inhibitors+Glucocorticoid +Azathioprine
11445806|NCT01727193|Active Comparator|Leflunomide|cholinesterase inhibitors+glucocorticoid+Leflunomide
11445807|NCT01727180||Chronic kidney disease|
11445808|NCT01727167|Placebo Comparator|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
11445809|NCT01727167|Experimental|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
11445810|NCT01727154||Sipuleucel-T|
11445811|NCT01727141|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
11445812|NCT01727141|Active Comparator|QAB149|27.5 ug b.i.d.
11445813|NCT01727141|Active Comparator|NVA237|12.5 ug b.i.d.
11445814|NCT01727141|Placebo Comparator|Placebo|b.i.d
11445815|NCT01727128|Experimental|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
11445816|NCT01727128|Experimental|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
11445817|NCT01727128|Experimental|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
11445818|NCT01727128|Experimental|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
11602706|NCT00628459|Experimental|2|
11445819|NCT01727115|Active Comparator|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).
~Subjects will receive the Nutramigen® formula for a 4 week period
~Then depending of the result of the challenge test we have the following possibilities:
~If the test is positive: The children continue the formula Nutramigen®
~If the test is negative: A Follow up formula is given
~(Nan pro2) if child > 6 months
~(Nan pro1) if child < 6 months"
11445820|NCT01727115|Experimental|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).
~Subjects will receive the Althera® formula for a 4 week period
~Then depending of the result of the challenge test we have the following possibilities:
~If the test is positive: The children continue the formula Althera®
~If the test is negative: A Follow up formula is given
~(Nan pro2) if child > 6 months
~(Nan pro1) if child < 6 months"
11445821|NCT01727089|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11445822|NCT01727089|Experimental|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11445823|NCT01727076|Experimental|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11445824|NCT01727063|Experimental|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
11445825|NCT01727063|No Intervention|Placebo|Saline injection
11445826|NCT01727050|Active Comparator|Mechanical stapling|
11445827|NCT01727050|Active Comparator|Fibrin sealant spray|
11445828|NCT01727037|Experimental|BIABI arm|Patients will undergo intrabullous autologous blood instillation
11445829|NCT01727024|Experimental|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
11445830|NCT01727024|Active Comparator|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
11445831|NCT01727011|Experimental|IPAS|Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction
11445832|NCT01726998|Experimental|Lokomat Group|
11445833|NCT01726998|Active Comparator|conventional gait training group|
11445834|NCT01726985||Patients hospitalized with CHF|Patients hospitalized with CHF Parameter Based Clinical Disposition
11445835|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
11445836|NCT01726946|Experimental|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
11445837|NCT01726946|Experimental|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
11445838|NCT01726933|Experimental|LAS41008|up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet
11445839|NCT01726933|Placebo Comparator|Placebo|up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet
11445840|NCT01726933|Active Comparator|LASW1835|double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks
11445841|NCT01726920|Experimental|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
11445842|NCT01726920|Active Comparator|naratriptan|
11445843|NCT01726920|Active Comparator|naproxen|
11445844|NCT01726907|Experimental|Robotic SMG resection|Robot-assisted SMG resection
11445845|NCT01726907|Active Comparator|Endoscopic SMG resection|Endoscope-assisted SMG resection
11445846|NCT01726894|Experimental|Irreversible Electroporation|
11445847|NCT01726881|Experimental|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
11445848|NCT01726881|Experimental|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
11445849|NCT01726881|Active Comparator|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
11445850|NCT01726868|Experimental|Liposorber LA-15 System|
11445851|NCT01726855||dorsal fascial flap|combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons.
11445852|NCT01726855||standard modified Kessler technique|
11445853|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
11445854|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.
~Amblyopia:
~VA <20/40 and 2 logMAR lines difference in normal eye
~Mild amblyopia (>20/40)
~Moderate amblyopia (20/40 and <20/100)
~Severe amblyopia (≥20/100 or worse)
~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.
~Strabismus:
~Constant: >2 PD at near and or distance.
~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.
~Amblyogenic factor categorization:
~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.
~'hypermetropia' (≥3.5 D),
~'myopia' (≥-4.0 D),
~'astigmatism' (≥1.5 D).
~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
11445855|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
11445857|NCT01726829|Active Comparator|Standard treatment with sensor augmented pump therapy|four consecutive outpatients overnight sessions at home under standard treatment with sensor augmented pump therapy
11445858|NCT01726816|Experimental|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
11445859|NCT01726816|Experimental|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
11445860|NCT01726816|Placebo Comparator|Placebo|Placebo group: placebo 2 tablets, 16 weeks
11445861|NCT01726803|Active Comparator|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
11445862|NCT01726803|Experimental|Early Physical Therapy with Usual Care|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
11445863|NCT01726777|Placebo Comparator|Control|30g normal cheddar cheese once per week
11445864|NCT01726777|Experimental|Vitamin D|30g cheddar cheese containing 28,000IU vitamin D once per week
11445865|NCT01726764|Experimental|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.
~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
11445866|NCT01726751|Other|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
11445867|NCT01726751|Other|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
11445868|NCT01726738|Experimental|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
11445869|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
11445870|NCT01726712|No Intervention|Routine Care|
11445871|NCT01726712|Active Comparator|Supportive Contact|
11445872|NCT01726699||Cancer Diagnosis|
11445873|NCT01726686|Active Comparator|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
11445874|NCT01726686|Placebo Comparator|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
11445875|NCT01726673|Experimental|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
11445876|NCT01726673|Placebo Comparator|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
11445877|NCT01726660|Experimental|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
11445878|NCT01726660|Experimental|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
11445879|NCT01726660|Experimental|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
11445880|NCT01726660|Experimental|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
11445881|NCT01726647||No product is tested|No intervention
11445882|NCT01726634|Experimental|Elastic Tapping|
11445883|NCT01726621|Other|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
11445884|NCT01726608|Active Comparator|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
11445885|NCT01726608|Placebo Comparator|Sham|Sham radiofrequency neurotomy
11445886|NCT01726595||severe sepsis|Patients with severe sepsis or septic shock
11445887|NCT01726595||non-infected critically ill|Patients with severe non-infectious systemic inflammatory response syndrome
11445888|NCT01726595||healthy|healthy volunteers
11445889|NCT01726582|Other|Pre surgery targeted chemo|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
~Arm A:
~Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging:
~see link to protocol Figures A & C at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445890|NCT01726582|Other|Pre surgery cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
~Arm B:
~Before surgery: Chemoradiotherapy (cRXT); restaging:
~see link to protocol Figure C and Figure A or B at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445891|NCT01726582|Other|Pre surgery targeted chemo, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
~Arm C1:
~Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging
~see link to protocol Figures B and C at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11446333|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
11445892|NCT01726582|Other|Pre surgery FOLFIRINOX, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.
~Arm C2:
~standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging:
~see link at protocol Figures B and C at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445893|NCT01726582|Other|After surgery targeted chemo, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
~Arm D1:
~After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging:
~see link to protocol Figures A and D at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445894|NCT01726582|Other|After surgery Gemcitabine, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
~Arm D2:
~Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging:
~see link to protocol Figures A and D at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445895|NCT01726582|Other|After surgery cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
~Arm E:
~After surgery: chemoradiotherapy (cXRT); restaging:
~see lint to protocol Figures A and D at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445896|NCT01726582|Other|After surgery targeted chemo|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
~Arm F1:
~Targeted chemotherapy after surgery: 8 weeks targeted chemotherapy; restaging; 8 weeks targeted chemotherapy; restaging:
~see link to protocol Figure E and Figure A or B at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445897|NCT01726582|Other|After surgery Gemcitabine|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
~Arm F2:
~Gemcitabine after surgery : 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging:
~see link to protocol Figure E and Figure A or B at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445898|NCT01726582|Other|After surgery no additional treatment|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.
~Arm G:
~No additional therapy after surgery:
~see link to protocol Figure E and Figure A or B at:
~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
11445899|NCT01726569|Experimental|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session and follow up counseling after operation 1 week and 6 weeks
11445900|NCT01726569|Other|traditional counseling|Subjects will be participate or not participate in pre-operative counseling and/or post-operative counseling with a rural hospital's doctor/nurse.
11445901|NCT01726556|Active Comparator|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
11445902|NCT01726556|Active Comparator|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
11445903|NCT01726543|Active Comparator|Canaloplasty and phacoemulsification|
11445904|NCT01726543|Active Comparator|Non-penetrating deep sclerectomy and phacoemulsification|
11445905|NCT01726530|Active Comparator|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
11445906|NCT01726530|Placebo Comparator|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
11445907|NCT01726517|Experimental|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
11445908|NCT01726517|Experimental|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
11445909|NCT01726517|Experimental|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
11445910|NCT01726517|Experimental|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
11445911|NCT01726517|Experimental|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
11445912|NCT01726504|Experimental|electro-acupuncture|"The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).
~Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.
~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
11445913|NCT01726504|Sham Comparator|sham electro-acupuncture|"The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).
~Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).
~Length of Treatment and the treatment sessions are the same as treatment group."
11445914|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that
~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
11446334|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
11445915|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that
~Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and
~Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
11445916|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that
~There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,
~There is altered methylation of genes involved in inflammation and cytoskeletal structure."
11445917|NCT01726478|Active Comparator|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
11445918|NCT01726478|Placebo Comparator|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
11445919|NCT01726465|Experimental|N-acetylcysteine|Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
11445920|NCT01726465|Experimental|Methylprednisolone|Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
11445921|NCT01726465|Placebo Comparator|Placebo|Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
11445922|NCT01726452|Experimental|A (Modified MAGIC) OR Arm A: FLOT|"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.
~FLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks."
11445923|NCT01726452|Experimental|B (CROSS)|Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
11445924|NCT01726439||CHB patients who are naive to NUC treatment|CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China
11445925|NCT01726426|Experimental|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
11445926|NCT01726426|Active Comparator|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
11445927|NCT01726426|Active Comparator|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
11445928|NCT01726413|Experimental|Test Arm|GRC17356 for daily administration
11445929|NCT01726413|Placebo Comparator|Placebo|Matching placebo for daily administration
11445930|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
11445931|NCT01726387|Experimental|Psychosocial Counseling|A Counseling Assistant offers a low-threshold intervention (self-management support, counseling, active guidance). This nurse practitioner collaborates extensively with the general practitioner, re-adjusting the intervention in order to meet the patient's needs.
11445932|NCT01726387|Placebo Comparator|Usual Care|Depending on the conditions, patients get usual care of their general practitioner.
11445933|NCT01726374|Experimental|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
11445934|NCT01726361|Experimental|MTFC|Out of home placement in MTFC family program
11445935|NCT01726361|Active Comparator|TAU|Other kind of out of home placement
11445936|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
11445937|NCT01726335|Experimental|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
11445938|NCT01726309||Stage IV CRC|
11445939|NCT01726309||Stage IV NSCLC|
11445940|NCT01726296|Experimental|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
11445941|NCT01726283||low risk subjects for developing post-operative ectasia|Patients undergoing vision correction surgery who are not at a higher risk for developing post-op ectasia
11445942|NCT01726283||Subjects at Risk for Ectasia|Patients undergoing vision correction surgery who are at a higher risk for developing post-operative ectasia
11445943|NCT01726270|Experimental|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
11445944|NCT01726257|Experimental|Nellix System|The Nellix EndoVascular Aneurysm Sealing System ( Nellix System ) will be implanted into patients with an infrarenal abdominal aortic aneurysm (AAA).
11445945|NCT01726244|No Intervention|Control group|Habitual Clinical Practice
11445998|NCT01725867|Experimental|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
11446293|NCT01724255||staple removal day 7, dressing removal day 4|late staple removal and day 4 dressing removal
11445946|NCT01726244|Experimental|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
11445947|NCT01726218||Stroke patients|
11445948|NCT01726218||Healthy Control|
11445949|NCT01726205|Active Comparator|pregabalin|perioperative pregabalin starting the evening before surgery, and for five days postoperatively
11445950|NCT01726205|Active Comparator|pregabalin and continuous wound infusion|Pregabalin as previous group and continuous infusion of ropivacaine 0.2% via a wound catheter
11445951|NCT01726205|Placebo Comparator|placebo|Placebo drug and normal saline infusion
11445952|NCT01726192|Active Comparator|HLOC|Placement of a femoral catheter with the hydrolocalization technique
11445953|NCT01726192|Active Comparator|NS|Placement of a femoral neurostimulating catheter
11445954|NCT01726179|Experimental|Icon infiltration|Icon infiltration regarding instructions for use
11445955|NCT01726179|Active Comparator|control|conventional non invasive treatment
11445956|NCT01726166|Active Comparator|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
11445957|NCT01726166|Active Comparator|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.
~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
11445958|NCT01726153|No Intervention|Web sites|Individuals assigned to this arm are given a list of websites where they can view additional information relating to condom use.
11445959|NCT01726153|Experimental|Condom-HIM|Individuals assigned to this arm must follow an on-line one session tailored intervention.
11445960|NCT01726140|Experimental|TREATMENT|Helmet CPAP
11445961|NCT01726140|Active Comparator|CONTROL|Venturi Mask
11445962|NCT01726127|Experimental|Broccoli and Brussels Sprouts|Subjects will consume broccoli or Brussels sprouts (40g daily) for 8 weeks.
11445963|NCT01726127|Experimental|Cruciferous Complete|Subjects will take Cruciferous CompleteTM supplements (2 capsules, 3 times daily) for 8 weeks.
11445964|NCT01726127|Placebo Comparator|Placebo|Subjects will take placebo capsules (2 capsules, 3 times daily) for 8 weeks.
11445965|NCT01726114|Experimental|Non-invasive Optical Glucose Monitor™|Test device
11445966|NCT01726088|Active Comparator|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
11445967|NCT01726088|Placebo Comparator|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
11445968|NCT01726075|Experimental|COLIRIOBCN070660|COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.
11445969|NCT01726075|Placebo Comparator|Placebo|Placebo Eye drops, solution. One drop/eye administered twice a day.
11445970|NCT01726075|Experimental|Brimonidine|Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.
11445971|NCT01726062|Experimental|Motivational Interviewing plus Incentives|
11445972|NCT01726062|Other|Conventional Care (CC)|
11445973|NCT01726049|Active Comparator|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
11445974|NCT01726049|Placebo Comparator|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
11445975|NCT01726036|Active Comparator|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
11445976|NCT01726036|Active Comparator|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
11445977|NCT01726023|Experimental|Ceftazidime-Avibactam plus metronidazole|
11445978|NCT01726023|Active Comparator|Meropenem|
11445979|NCT01726010|Experimental|22-G Procore Needle|
11445980|NCT01725997|Active Comparator|Operative treatment|Operative treatment with hook plate.
11445981|NCT01725997|Active Comparator|Conservative treatment|Physiotherapy
11445982|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
11445983|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
11445984|NCT01725971||Control group|Group of nonsmokers individuals without respiratory disease.
11445985|NCT01725971||normal exam|subjects with silicosis , but with normal spirometric data
11445986|NCT01725971||mild obstruction|subjects with silicosis with mild obstruction in spirometric data
11445987|NCT01725971||moderate to severe obstruction|subjects with silicosis with moderate to severe obstruction in spirometric data
11445988|NCT01725958|Experimental|Dietary Supplement|"Treatment Regimen
~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
11445989|NCT01725945|No Intervention|Usual Care|Usual Care
11445990|NCT01725945|Experimental|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
11445991|NCT01725932|Experimental|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
11445992|NCT01725932|No Intervention|Care As Usual|Control Group
11445993|NCT01725919|Experimental|Immediate CI therapy|
11445994|NCT01725919|Active Comparator|Delayed CI therapy|
11445995|NCT01725906|Active Comparator|Empirical therapy|selection of antibiotic according to medication history
11445996|NCT01725906|Experimental|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
11445997|NCT01725880||No treatment|Observation
11602707|NCT00628459|Experimental|3|
11445999|NCT01725867|Active Comparator|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
11446000|NCT01725854|Experimental|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
11446001|NCT01725854|No Intervention|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
11446002|NCT01725828|Experimental|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
11446003|NCT01725828|Experimental|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.
~The Intervention by using the Ultrasound to determine the CTM."
11446004|NCT01725815|Experimental|HARP Intervention|
11446005|NCT01725815|No Intervention|No Intervention: Control|Participants in usual care will continue to obtain any mental health or peer-support services that they would otherwise be receiving.
11446006|NCT01725802|Experimental|levodopa and carbidopa|levodopa and carbidopa solution
11446007|NCT01725802|Placebo Comparator|placebo to levodopa and carbidopa|saline
11446008|NCT01725789|Experimental|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
11446009|NCT01725789|Placebo Comparator|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
11446010|NCT01725776|Experimental|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
11446011|NCT01725763|Other|suspected PH|60 minute Cardiac MRI
11446012|NCT01725750|Experimental|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
11446013|NCT01725750|Active Comparator|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
11446014|NCT01725737|Placebo Comparator|Placebo|
11446015|NCT01725737|Active Comparator|GlyTI-M|GlyTI-M: 0.03gm/kg/day
11446016|NCT01725724|Active Comparator|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
11446017|NCT01725724|Experimental|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
11446018|NCT01725711|Experimental|Implant System|
11446019|NCT01725698|Experimental|Stemcell|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
11446020|NCT01725685|Experimental|Treatment A - FF 400 microgram (mcg)|Subjects will be randomized to single dose of FF 400 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
11446021|NCT01725685|Experimental|Treatment B - UMEC 500 mcg|Subjects will be randomized to single dose of UMEC 125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
11446022|NCT01725685|Experimental|Treatment C - FF/UMEC 400/500 mcg|Subjects will be randomized to single dose of FF/UMEC 100/125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
11446023|NCT01725672|Active Comparator|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
11446024|NCT01725672|Active Comparator|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
11446025|NCT01725672|Experimental|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
11446026|NCT01725672|Experimental|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
11446027|NCT01725672|Experimental|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
11446028|NCT01725672|Experimental|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
11446029|NCT01725659|Experimental|Motor Learning|subjects are provided with intensive motor learning training of the upper limb
11446030|NCT01725659|Experimental|Robotics and Motor Learning|subject are provided with intensive motor learning and robotics training of the upper limb
11446031|NCT01725659|Experimental|Motor learning and FES|subjects are provided with intensive motor learning and surface FES (Functional Electrical Stimulation) of the upper limb
11446032|NCT01725646|Active Comparator|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
11446033|NCT01725646|Active Comparator|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
11446034|NCT01725646|Placebo Comparator|Placebo|Subjects in this group will take 4 g of placebo everyday.
11446040|NCT01725607|Experimental|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
11446041|NCT01725607|Experimental|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
11446042|NCT01725594|Experimental|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
11446043|NCT01725594|Experimental|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
11446044|NCT01725594|Experimental|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
11446045|NCT01725594|Experimental|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
11446046|NCT01725594|Experimental|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
11446047|NCT01725594|Experimental|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
11446048|NCT01725594|Experimental|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
11446049|NCT01725594|Experimental|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
11446050|NCT01725594|Experimental|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
11446051|NCT01725594|Experimental|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
11446052|NCT01725594|Experimental|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
11446053|NCT01725581||Inexperienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
11446054|NCT01725581||Experienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
11446055|NCT01725581||Junior Doctors|Pre Royal College of Obstetric and Gynaecology registered junior doctors with experience in Obstetrics and Gynaecology
11446056|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
11446057|NCT01725555|Experimental|Fasted treatment|
11446058|NCT01725555|Experimental|Fed treatment|
11446059|NCT01725542|Experimental|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin
~Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
11446060|NCT01725529|Experimental|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
11446061|NCT01725529|Experimental|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
11446062|NCT01725529|Placebo Comparator|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
11446063|NCT01725516|Experimental|Myofascial release technique|
11446064|NCT01725503|Experimental|Creatine and amino acid supplement|
11446065|NCT01725490|Experimental|metformin 500mg daily (arm A)|
11446066|NCT01725490|Experimental|metformin 1500mg daily (arm B)|
11446067|NCT01725490|Placebo Comparator|an identical- appearing placebo (arm C)|
11446068|NCT01725477|Experimental|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
11446069|NCT01725477|Active Comparator|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
11446070|NCT01725464|Experimental|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
11446071|NCT01725451|Experimental|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
11446072|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
11446073|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
11446074|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
11446075|NCT01725451|Experimental|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
11446076|NCT01725451|Experimental|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
11446077|NCT01725438|Experimental|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
11446078|NCT01725425|Experimental|Control|Participants will receive equal amounts of foods.
11446079|NCT01725425|Experimental|Increase Portion Size|Participants will receive increased portion sizes.
11446080|NCT01725425|Experimental|Decrease Portion Sizes|Participants will receive decreased portion sizes.
11446081|NCT01725425|Experimental|Mixed Portion Sizes|Participants will receive mixed portion sizes.
11446082|NCT01725412|Experimental|Thiamine Supplementation|
11446083|NCT01725412|Placebo Comparator|Placebo|
11446084|NCT01725399|Placebo Comparator|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
11446085|NCT01725399|Experimental|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
11446086|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
11603836|NCT00620555|Experimental|gabapentin|
11446087|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
11446088|NCT01725373||Angioplasty of left main|"Patients with:
~stable or unstable angina and/or documented ischemia
~de novo ≥50% stenosis in the left main stem referred for angioplasty"
11446089|NCT01725360|Experimental|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
11446090|NCT01725347||African American Girls|-25% of sample is African American Girls
11446091|NCT01725347||African American Boys|-25% of sample is African American Boys
11446092|NCT01725347||Hispanic American Girls|-25% of sample is Hispanic American Girls
11446093|NCT01725347||Hispanic American Boys|-25% of sample is Hispanic American Boys
11446094|NCT01725334|Experimental|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
11446095|NCT01725334|Experimental|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
11446096|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
11446097|NCT01725308|Placebo Comparator|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
11446098|NCT01725308|Experimental|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
11446099|NCT01725308|Experimental|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
11446100|NCT01725308|Experimental|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
11446101|NCT01725308|Experimental|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
11446102|NCT01725308|Experimental|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
11446103|NCT01725295|Experimental|NST|A form of physical therapy to relieve symptoms of fibromyalgia
11446104|NCT01725295|Active Comparator|Hydrotherapy|An alternate form of physical therapy to relieve symptoms of fibromyalgia
11446105|NCT01725282|Placebo Comparator|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
11446106|NCT01725282|Experimental|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
11446107|NCT01725282|Experimental|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
11446108|NCT01725282|Experimental|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
11446109|NCT01725269|Experimental|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
11446110|NCT01725269|Experimental|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
11446111|NCT01725269|Experimental|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
11446112|NCT01725256|Experimental|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
11446113|NCT01725256|Experimental|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
11446114|NCT01725256|Experimental|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
11446115|NCT01725243|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
11446116|NCT01725243|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
11446117|NCT01725243|Active Comparator|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
11446118|NCT01725243|Active Comparator|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
11446119|NCT01725243|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
11446120|NCT01725243|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
11446123|NCT01725230|Experimental|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
11446124|NCT01725230|Experimental|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
11446125|NCT01725217|Experimental|MenACWY-CRM|MenACWY-CRM
11446126|NCT01725204|Experimental|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
11446127|NCT01725191|Experimental|Treatment (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11446128|NCT01725178|No Intervention|Standard care|No intervention besides usual care
11446129|NCT01725178|Active Comparator|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
11446130|NCT01725165|Experimental|Arm I (immediate LCT)|Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.
11446131|NCT01725165|Active Comparator|Arm II (delayed/no LCT)|Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.
11446132|NCT01725152|Experimental|Ganaxolone|3 mg/kg up to 12 mg/kg, with maximum of 1500 mg/day
11446133|NCT01725152|Placebo Comparator|Placebo|non active
11446134|NCT01725139|Experimental|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily [bid]) or placebo for approximately 8 days (7 to 10 days dosing)
11446135|NCT01725139|Placebo Comparator|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
11446136|NCT01725139|Experimental|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
11446137|NCT01725139|Placebo Comparator|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
11446138|NCT01725139|Experimental|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
11446139|NCT01725139|Placebo Comparator|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
11446140|NCT01725139|Experimental|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
11446141|NCT01725139|Placebo Comparator|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
11446142|NCT01725139|Experimental|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
11446143|NCT01725139|Placebo Comparator|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
11446144|NCT01725139|Experimental|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
11446145|NCT01725139|Placebo Comparator|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
11446146|NCT01725126|Experimental|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
11446147|NCT01725126|Experimental|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
11446148|NCT01725126|Experimental|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
11446149|NCT01725126|Placebo Comparator|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
11446150|NCT01725126|Placebo Comparator|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
11446151|NCT01725126|Placebo Comparator|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
11446152|NCT01725113|Experimental|Calcitriol|Patients will be converted from paricalcitol to calcitriol according to published package inserts which describe a 10mcg:3mcg ratio.
11446153|NCT01725113|Active Comparator|Paricalcitol|Continuation of intravenous paricalcitol that patient was originally on at the time of recruitment.
11446154|NCT01725100|Experimental|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
11446155|NCT01725100|Experimental|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
11446156|NCT01725087|Placebo Comparator|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
11446157|NCT01725087|Experimental|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
11446158|NCT01725087|Experimental|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
11446159|NCT01725087|Experimental|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
11446160|NCT01725087|Active Comparator|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
11446161|NCT01725074|Experimental|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
11446162|NCT01725074|Experimental|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
11446163|NCT01725074|No Intervention|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
11446164|NCT01725048|Active Comparator|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
11446165|NCT01725048|Active Comparator|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
11446166|NCT01725035||Fatty liver|
11446167|NCT01725035||Non Fatty liver|
11446168|NCT01725022|Experimental|Home Care|This is the arm for patients who receive their transplant care in their homes.
11446169|NCT01725022|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
11446170|NCT01725022|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
11446171|NCT01725009|Experimental|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
11446172|NCT01725009|Experimental|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
11446173|NCT01724983|Experimental|ketamine|patients will receive ketamine at induction
11446174|NCT01724983|Active Comparator|fentanyl|patients will receive fentanyl at induction
11446175|NCT01724970|Experimental|PLMA|ProSeal
11446176|NCT01724970|Experimental|SLMA|Supreme LMA
11446177|NCT01724957||Patients with coronary bifurcation lesions|Only one group will be studied. The patient will be a slef-reference.
11446178|NCT01724944|Experimental|Systematic Lymphadenectomy|
11446179|NCT01724931|Placebo Comparator|Placebo|Placebo once weekly
11446180|NCT01724931|Experimental|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
11446181|NCT01724931|Experimental|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
11446182|NCT01724918|Other|100 mg IV|100 mg IV lacosamide infused over 30 minutes
11446183|NCT01724918|Other|200 mg IV|200 mg IV lacosamide infused over 30 minutes
11446184|NCT01724918|Other|400 mg IV|400 mg IV lacosamide infused over 30 minutes
11446185|NCT01724905|Experimental|Modified Stop Light Diet|
11446186|NCT01724905|Active Comparator|Recommended Care for Weight Reduction|
11446187|NCT01724892|Active Comparator|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
11446188|NCT01724892|Active Comparator|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
11446189|NCT01724879|Experimental|Dasatinib and chemotherapy|Dasatinib, QD p.o. administration, day 1 to EOS
11446190|NCT01724866|Experimental|Single-dose HM10460A (45 μg/kg)|Single-dose HM10460A (45 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
11446191|NCT01724866|Experimental|Single-dose HM10460A (135 μg/kg)|Single-dose HM10460A (135 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
11446192|NCT01724866|Experimental|Single-dose HM10460A (270 μg/kg)|Single-dose HM10460A (270 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
11446193|NCT01724866|Active Comparator|Pegfilgrastim 6 mg|Pegfilgrastim (Neulasta®) is not to be administered between 14 days before or 24 hours after TC chemotherapy. Pegfilgrastim (Neulasta®) will be administered according to the manufacturer's Prescribing Information (6 mg subcutaneously once per chemotherapy cycle).
11446194|NCT01724853|Other|Surgery|Preferred surgery
11446195|NCT01724853|Other|Conservative|Conservative treatment
11446196|NCT01724840|Experimental|GraftJacket|GraftJAcket is used as interpositional material
11446197|NCT01724840|Active Comparator|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
11446198|NCT01724827|Active Comparator|ceramic|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
11446199|NCT01724827|Active Comparator|composite|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
11446200|NCT01724814|Experimental|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
11446201|NCT01724814|Experimental|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
11446202|NCT01724814|Experimental|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
11446203|NCT01724814|Experimental|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
11446204|NCT01724814|Experimental|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
11446205|NCT01724814|Experimental|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
11446206|NCT01724801|Experimental|icotinib|icotinib administered orally at a dose of 125 mg 3 times daily
11446207|NCT01724801|Active Comparator|Whole brain irradiation|Whole brain irradiation 30Gy/3Gy/10 fractions plus concurrent or sequential chemotherapy for 4-6 cycles
11446294|NCT01724242|Experimental|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
11446295|NCT01724242|Placebo Comparator|Placebo|
11446208|NCT01724788|Experimental|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
11446209|NCT01724788|Experimental|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
11446210|NCT01724775||CME surgery for colon cancer|
11446211|NCT01724775||non-CME surgery for colon cancer|
11446212|NCT01724762|Experimental|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
11446213|NCT01724749||Healthy control subjects|"Age: 21 - 80 years
~No prior history or symptoms of cardiovascular disease
~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80."
11446214|NCT01724749||Subjects with cardiovascular disease|"Age: 21 - 80 years
~HeartSCORE > 0%
~Symptoms of angina pectoris
~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80. Also, the investigators aim to include patients in 3 strata of HeartSCORE risk: low risk (1-4%), mild risk (5-9%) and high risk (> 9%)"
11446215|NCT01724736|Placebo Comparator|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
11446216|NCT01724736|Active Comparator|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
11446217|NCT01724723|Experimental|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
11446218|NCT01724723|No Intervention|Control group|Not receiving entecavir (BARACLUDE®)
11446219|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
11446220|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
11446221|NCT01724697|Active Comparator|conventional treatment|conventional treatment & antivrial treatment.
11446222|NCT01724697|Experimental|BMSC transplantation|conventional treatment & antiviral treatment & autologous bone marrow stem cell transplantation via hepatic artery
11446223|NCT01724684|Other|Telehealth program|Telehealth program service
11446224|NCT01724684|Other|Usual care|Usual care service
11446225|NCT01724671||Cefatroline|Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
11446226|NCT01724671||Vancomycin|Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
11446227|NCT01724658|Experimental|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
11446228|NCT01724658|Placebo Comparator|placebo|placebo twice a week with progynova 1 mg oral daily
11446229|NCT01724645|Experimental|Korean traditional diets|Korean traditional diets (calorie 2,100kcal) for 12weeks
11446230|NCT01724645|Active Comparator|Control group|"Control group : told to eat as usal diet) for 12weeks"
11446231|NCT01724632|Active Comparator|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
11446232|NCT01724632|Active Comparator|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
11446233|NCT01724632|Experimental|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
11446234|NCT01724619|Experimental|Healthy Volunteers|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
11446235|NCT01724619|Experimental|Prostate Cancer Patients|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
11446236|NCT01724606|Experimental|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
11446237|NCT01724593||Observational Cohort|No Intervention
11446238|NCT01724567|Experimental|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
11446239|NCT01724567|Experimental|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
11446240|NCT01724554|Experimental|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
11446241|NCT01724554|Experimental|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
11446242|NCT01724528|Experimental|Febuxostat|Febuxostat for 7-9 days
11446243|NCT01724528|Active Comparator|Allopurinol|Allopurinol for 7-9 days
11446244|NCT01724515|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
11446245|NCT01724515|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
11446246|NCT01724515|Experimental|Healthy Control Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
11446247|NCT01724502|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
11446248|NCT01724502|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
11446249|NCT01724502|Experimental|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
11446330|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
11446250|NCT01724489|Active Comparator|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
11446251|NCT01724489|Placebo Comparator|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
11446252|NCT01724476|Active Comparator|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
11446253|NCT01724476|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
11446254|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
11446255|NCT01724450|Active Comparator|Carvedilol|
11446256|NCT01724450|Placebo Comparator|Control|
11446257|NCT01724437|Active Comparator|Loss of pace capture|Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved
11446258|NCT01724437|Active Comparator|Conventional|Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.
11446259|NCT01724424|Experimental|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
11446260|NCT01724424|Experimental|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
11446261|NCT01724424|Experimental|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
11446262|NCT01724424|Experimental|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
11446263|NCT01724411|Experimental|Resistant Starch 3|Resistant Starch Type 3:dose of 26g/day males and 22g/day female during 11 days of the maintenance period. (C ActiStar 11700, Tapioca Maltodextrin, Cargill, Belgium)
11446264|NCT01724411|No Intervention|Control Non- RS3|Non-Resistant Starch type 3 food items during 11 days of the maintenance period.
11446265|NCT01724398|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
11446266|NCT01724398|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
11446267|NCT01724398|Experimental|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
11446268|NCT01724398|Experimental|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
11446269|NCT01724385|Experimental|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
11446270|NCT01724372|Experimental|Antidepressant|Fluoxetine
11446271|NCT01724372|Active Comparator|Antipsychotic|Aripiprazole
11446272|NCT01724359|Experimental|Paliperidone ER|
11446273|NCT01724346|Other|Arm A Post-Chlorambucil Therapy Followup|Patients randomized to Chlorambucil in the parent study(PCYC-1115-CA) who have not progressed at the time of parent study closure will be transferred to this Arm. Follow-up will continue until PD, unacceptable toxicity, or other reason for treatment discontinuation.
11446274|NCT01724346|Experimental|Arm B Ibrutinib|Patients randomized to Ibrutinib in the parent study (PCYC-1115-CA) who have not experienced PD at the time of parent study closure will be transferred to this Arm to continue on Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
11446275|NCT01724346|Experimental|Arm C Second-line Ibrutinib|Patients who received Chlorambucil in the parent study (PCYC-1115-CA) and experienced PD are transferred to this Arm for Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
11446276|NCT01724346|Other|Arm D Alternative Anticancer Therapy|At the Investigator's discretion, alternative anticancer treatment is a therapeutic option for patients who experienced PD during Ibrutinib treatment or during or after Chlorambucil treatment. This Arm can also be considered if drug is discontinued for other reasons (e.g., intolerability or adverse event [AE]) or prior to experiencing PD).
11446277|NCT01724333||Group 1- in active treatment|Questionnaires only
11446278|NCT01724333||Group 2 - 2-6 months post-treatment|Questionnaires only
11446279|NCT01724333||Group 3 - 6 mos-3yrs post-treatment|Questionnaires only
11446280|NCT01724333||Group 4 - Palliative treatment|Questionnaires only
11446281|NCT01724333||Group 5 - Referred to dentist/oral team|Questionnaires only
11446282|NCT01724320|Experimental|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
11446283|NCT01724307|Active Comparator|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
11446284|NCT01724307|Active Comparator|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
11446285|NCT01724294||Cohort|
11446286|NCT01724281||pregnant women between 19-30 weeks gestational age|No intervention, only follow up
11446287|NCT01724268|Experimental|Pred + Meth|"Prednisolone : 10 mg daily
~+ Methotrexate : 25 mg/ day
~ARM 1 Treatment Arm"
11446288|NCT01724268|Active Comparator|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg
~+ Methotrexate 25 mg per day Control Arm"
11446289|NCT01724255||staple removal day 4 dressing removal day 1|early staple removal and early dressing removal
11446290|NCT01724255||staple removal day 4 dressing removal day 4|early staple removal and day 4 dressing removal
11446291|NCT01724255||staple removal day 7, dressing removal day 1|late staple removal and early dressing removal
11446331|NCT01724060||Gastric banding|Patients due for gastric banding
11446296|NCT01724229|Other|treatment with OTC drug products|"Body Wash & Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.
~Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.
~2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.
~Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
11446297|NCT01724216|Experimental|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
11446298|NCT01724203|Active Comparator|Lactobacillus rhamnosus|Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
11446299|NCT01724203|Active Comparator|Bifidobacterium animalis subsp. lactis|Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
11446300|NCT01724203|Placebo Comparator|Placebo|Placebo formula without probiotics at least three times daily for 12 weeks.
11446301|NCT01724190|Active Comparator|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
11446302|NCT01724190|Placebo Comparator|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
11446303|NCT01724177|Experimental|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
11446304|NCT01724164|Experimental|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
11446305|NCT01724164|Experimental|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
11446306|NCT01724164|Active Comparator|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
11446307|NCT01724164|Experimental|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
11446308|NCT01724164|Placebo Comparator|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
11446309|NCT01724151||Healthy adults|Healthy adults, over 45 years old
11446310|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
11446311|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
11446312|NCT01724138|Experimental|Deferasirox|The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to <6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
11446313|NCT01724125|Experimental|Case|Assigned a Personal Electronic Health Record
11446314|NCT01724125|Active Comparator|Control: Usual Care|Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record.
11446315|NCT01724112|Experimental|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
11446316|NCT01724112|Placebo Comparator|Placebo|Administered orally as 1 capsule QD for 8 weeks.
11446317|NCT01724099|Experimental|Euiiyin-tang|powder type, 3 times per day before the meal, 12 weeks total
11446318|NCT01724099|Placebo Comparator|Placebo|powder type, 3 times per day before the meal, 12 weeks total
11446319|NCT01724086|Experimental|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
11446320|NCT01724086|Experimental|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
11446321|NCT01724086|Experimental|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
11446322|NCT01724086|Experimental|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
11446323|NCT01724086|Experimental|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
11446324|NCT01724086|Experimental|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
11446325|NCT01724086|Experimental|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
11446326|NCT01724073|Experimental|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
11446327|NCT01724073|Experimental|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
11446328|NCT01724073|Experimental|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
11446329|NCT01724073|No Intervention|no test food|control group receiving no test food
11446336|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
11446337|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
11446338|NCT01724047|Experimental|Playground Intervention|Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed 2) Waitlist treatment, where the training will begin the following school year. The initial delivery will occur for 30 minutes three times for a period of two to three weeks, then 30 minutes two times for a period of two weeks, then 30 minutes once a week for up to 16 sessions, within a period of 3 months, then a 30 minute follow up will occur 3 months later. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment, and 3-month follow-up. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
11446339|NCT01724047|Experimental|STAT Intervention|Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. The intervention will be over a period of 6 weeks, with baseline, treatment, and a follow up visit totaling 18 weeks at the school site. Each visit is approximately 30 minutes. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
11446340|NCT01724047|No Intervention|Playground Waitlist Control|Waitlist Control
11446341|NCT01724047|No Intervention|STAT Waitlist Control|Waitlist Control
11446342|NCT01724034|Experimental|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.
~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.
~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.
~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.
~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
11446343|NCT01724034|No Intervention|Control Group|
11446344|NCT01724021|Experimental|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
11446345|NCT01724021|Experimental|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
11446346|NCT01723995|Experimental|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
11446347|NCT01723995|Placebo Comparator|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
11446348|NCT01723982|Experimental|A. FE 200440|Barusiban (FE 200440) Solution for Injection for Subcutaneous use
11446349|NCT01723982|Placebo Comparator|B. Placebo|Placebo Solution for Injection for Subcutaneous use
11446350|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
11446351|NCT01723956|Active Comparator|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
11446352|NCT01723956|Experimental|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
11446353|NCT01723943|Active Comparator|Arm I (educational booklet)|"Participants receive the What's Happening to the Woman I Love? booklet, which focuses on ways to understand and deal with marital communication and relationship issues arising from breast cancer diagnosis."
11446354|NCT01723943|Experimental|Arm II (Helping Her Heal program)|"Participants undergo the Helping Her Heal educational counseling program comprising 5 1-hour sessions 2 weeks apart.
~SESSION I: Participants learn stress management skills and discover ways stress affects themselves and their partner.
~SESSION II: Participants practice attentive listening and reduce the tendency to try to distract patients from talking about sad or difficult aspects of the cancer experience.
~SESSION III: Patients learn to help their spouse talk when she is quiet or withdrawn, to add to their understanding of what she is thinking and feeling, and to add to their ways of supporting her during especially difficult times with the cancer.
~SESSION IV: Participants learn strategies for physically reconnecting with spouses.
~SESSION V: Participants review skills from prior sessions, identify strategies he or she will continue to use to manage their personal stress, and identify ways to maintain connection and support."
11446355|NCT01723917|Experimental|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
11446356|NCT01723917|Experimental|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
11446357|NCT01723917|Placebo Comparator|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
11446460|NCT01723215|Active Comparator|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
11446461|NCT01723215|Active Comparator|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
11446462|NCT01723215|No Intervention|Control|Control: will not receive any intervention
11446358|NCT01723904|Experimental|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.
~Duration of the Titration Period: Between 1 week and 5 weeks.
~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.
~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
11446359|NCT01723891|Active Comparator|Surfolase capsule & HT-002-01|
11446360|NCT01723891|Active Comparator|HT-002-01 & Surfolase capsule|
11446361|NCT01723878||Cohort|
11446362|NCT01723865||Conventional|Patients with heart failure having an ICD-CRT implanted, followed by conventional visits.
11446363|NCT01723865||Remote Monitoring|Patients with heart failure having an ICD-CRT implanted, followed by remote monitoring.
11446364|NCT01723852|Active Comparator|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
11446365|NCT01723852|Active Comparator|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
11446366|NCT01723839|Other|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
11446367|NCT01723826|Experimental|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
11446368|NCT01723813|Experimental|Group 1 : peptides + GM-CT-01 IV|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections
11446369|NCT01723813|Experimental|Group 2 : peptides + GM-CT-01 IV+PT|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections and Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
11446370|NCT01723800|Experimental|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
11446371|NCT01723787||Infantile Spasms|Participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
11446372|NCT01723787||biological parents|Biological parents of participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
11446373|NCT01723774|Experimental|Arm 1: PIK3CA Wild Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15
~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.
~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)
~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.
~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
11446374|NCT01723774|Experimental|Arm 2: PIK3CA Mutant Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15
~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.
~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)
~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.
~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
11446375|NCT01723774|Experimental|Arm 3: Endocrine Resistant Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15
~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)
~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.
~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
11446376|NCT01723748|Active Comparator|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.
~Stimulated with genotropin"
11446377|NCT01723748|Active Comparator|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
11446378|NCT01723735|Experimental|Alirocumab + Ezetimibe Placebo|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
11446379|NCT01723735|Experimental|Alirocumab + Ezetimibe|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
11446380|NCT01723735|Experimental|Alirocumab + Fenofibrate|Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate
11446463|NCT01723215|Placebo Comparator|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
11446464|NCT01723202|Experimental|Arm A: GSK2118436|Patients receive dabrafenib orally 2 twice a day on days 1-28. Patients with disease progression may cross over to arm II.
11447172|NCT01718496|Placebo Comparator|Placebo|patient with advanced COPD who will receive Placebo
11446381|NCT01723722|Active Comparator|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:
~The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.
~For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:
~NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose
~≥16 0.15 mg/kg/dose
~Maximum dose of methadone will be 0.15 mg/kg/dose.
~After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours.
~If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
11446382|NCT01723722|Active Comparator|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:
~The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.
~The starting dose will be determined using a sliding scale in response to the last NAS score before starting.
~NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day
~≥16 0.8 mg/kg/day
~The maximum dose of DTO will be 0.8 mg/kg/day.
~After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.
~If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
11446383|NCT01723696|Placebo Comparator|placebo tablet+prenatal vitamin|A daily placebo tablet
11446384|NCT01723696|Active Comparator|Vitamin C +prenatal vitamin|500 mg vitamin C /day
11446385|NCT01723683|Experimental|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
11446386|NCT01723683|Active Comparator|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
11446387|NCT01723670|Experimental|CHF 5074 1x|oral tablet, multidose
11446388|NCT01723670|Experimental|CHF 5074 2x|oral tablet, multidose
11446389|NCT01723670|Placebo Comparator|Placebo|placebo, oral tablet, multidose
11446390|NCT01723657|Other|Risk-adapted postremission treatment.|Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation.
11446391|NCT01723644|Other|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
11446392|NCT01723644|Other|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
11446393|NCT01723631|Other|Relapsing Multiple Sclerosis- group 1|Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
11446394|NCT01723631|Other|Relapsing Multiple Sclerosis- group 2|Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
11446395|NCT01723631|Other|secondary progressive multiple sclerosis- Group 3|Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
11446396|NCT01723631|Other|primary progressive multiple sclerosis- group 4|Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
11446397|NCT01723631|Other|control 1|healthy volunteers
11446398|NCT01723631|Other|Control 2|Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
11446399|NCT01723631|Other|Control 3|Patients having an autoimmune pathology
11446400|NCT01723618|Experimental|CRD007 10 mg|CRD007, 10 mg tablet, single dose
11446401|NCT01723618|Experimental|CRD007 25 mg|CRD007, 25 mg tablet, single dose
11446402|NCT01723618|Experimental|CRD007 40 mg|CRD007, 40 mg tablet, single dose
11446403|NCT01723605|Experimental|insitu repair|insitu repair of the uterine incision during caeserean section
11446404|NCT01723605|Active Comparator|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
11446405|NCT01723592|Placebo Comparator|Placebo|30 participants in this group receive a oral lactose placebo
11446406|NCT01723592|Active Comparator|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:
~L.rhamnosus/ LbV96 (DSM 22560)
~L.jensenii /LbV 116 (DSM 22567)
~L.crispatus/ Lbv88 (DSM 22566)
~L.gasseri /LbV 150N (DSM 22583)"
11446407|NCT01723579|Experimental|NOMAC-E2 2.5 mg/1.5 mg|Participants will receive combined oral contraceptive NOMAC-E2 2.5 mg/1.5 mg tablet for 13 consecutive 28-day cycles. Each 28-day cycle with consist of 24 active tablets and 4 placebo tablets taken at approximately the same time each day.
11446408|NCT01723553|Experimental|PiB positron emission tomography (PET)|All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
11446409|NCT01723540|Experimental|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
11446410|NCT01723540|Active Comparator|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
11446411|NCT01723527|Experimental|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
11446952|NCT01719965||Health Workers|"Worked in SMRU for at least 6 months
~Clinic assistants, medics or home visitors"
11446412|NCT01723527|Active Comparator|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
11446413|NCT01723514|Experimental|Erenumab|Healthy participants and participants with migraine received subcutaneous doses of erenumab on days 1, 29 and 57.
11446414|NCT01723514|Placebo Comparator|Placebo|Healthy participants and participants with migraine received subcutaneous doses of placebo on days 1, 29 and 57.
11446415|NCT01723501|Placebo Comparator|sterile water|sterile water wipes
11446416|NCT01723501|Experimental|0.25% chlorhexidine|0.44% chlorhexidine digluconate wipes which will release 0.25% free chlorhexidine
11446417|NCT01723488|Experimental|Tau diagnostic|Experimental: Tau diagnostic [F18] T808
11446418|NCT01723475|Experimental|BAY2010112 (s.c.)|
11446419|NCT01723475|Experimental|BAY2010112 (c.i.v.)|
11446420|NCT01723436|No Intervention|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
11446421|NCT01723436|Experimental|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
11446422|NCT01723436|Experimental|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
11446423|NCT01723436|Experimental|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
11446424|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
11446425|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
11446426|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
11446427|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
11446428|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
11446429|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
11446430|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
11446431|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
11446432|NCT01723410|Experimental|Writing condition|Subjects will be asked to write about other individuals in their lives.
11446433|NCT01723410|Placebo Comparator|Writing|Subjects will be asked to write about places or objects in their lives.
11446434|NCT01723397|Active Comparator|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
11446435|NCT01723397|Placebo Comparator|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
11446436|NCT01723384|Active Comparator|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
11446437|NCT01723384|Placebo Comparator|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
11446438|NCT01723371|Experimental|Carvedilol|
11446439|NCT01723358|Experimental|Neuromuscular electrical stimulation (NMES)|
11446440|NCT01723345|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
11446441|NCT01723345|No Intervention|control|just receive standard treatment
11446442|NCT01723332|Experimental|Intervention|Clinical based educational and self management intervention.
11446443|NCT01723332|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
11446444|NCT01723319|Experimental|1|deep TMS treatment
11446445|NCT01723319|Sham Comparator|2|inactive treatment
11446446|NCT01723306|Experimental|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
11446447|NCT01723293|No Intervention|Control|Sedentary pregnant women
11446448|NCT01723293|Experimental|Exercise group|
11446449|NCT01723280||80% oxygen group|
11446450|NCT01723280||30% oxygen group|
11446451|NCT01723267|Active Comparator|3D follicles assessment|During IVF treatment all ultrasound examinations will use 3D- SonoAVC technology. Timing of hCG injection and oocyte collection will be based on follicle volume and 3D-volume based diameter.
11446452|NCT01723267|Active Comparator|2D follicles assessment|During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
11446453|NCT01723254|Experimental|PF-06444753|
11446454|NCT01723254|Experimental|PF-06444752|
11446455|NCT01723254|Placebo Comparator|Placebo|Intramuscular
11446456|NCT01723241|Experimental|XAF5|
11446457|NCT01723241|Placebo Comparator|Placebo|
11446458|NCT01723228|Experimental|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
11446459|NCT01723228|Placebo Comparator|Placebo|Placebo oral tablets once daily for 24 weeks
11446953|NCT01719965||Researchers|"Worked in SMRU for at least 6 months
~Physician or scientist"
11446465|NCT01723202|Experimental|Arm B: GSK2118436 and GSK1120212|Patients receive dabrafenib orally twice a day and trametinib orally once a day on days 1-28.
11446466|NCT01723202|Other|Correlative Studies|Tumor pharmacodynamics (PD) evaluation,BRAF mutation quantification in circulating plasma DNA,Tumor mutation screening/Mechanisms of Drug Resistance,Predictive Markers of Response (Archival Tumor Block),Pharmacokinetics(PK,Pharmacogenetics (PGx)
11446467|NCT01723189||Central Apnoeas Patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of central apnoea (central apnoea index> 10 / h, or Cheyne-Stokes breathing for more than 30% of total sleep time or mixed apneas with central apnoeas> 50% of total apneas)
11446468|NCT01723189||Obstructive apnoea patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of obstructive sleep apnea (apnea-hypopnea index> 20 / h)
11446469|NCT01723189||No SDB patients|• 30 patients diagnosed with TIA / stroke within 7 days of admission and no evidence of sleep respiratory disorders at polysomnography
11446470|NCT01723189||Healthy controls|• 30 healthy controls matched for age, sex, race and BMI.
11446471|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
11446472|NCT01723163|Experimental|Intervention|Abstinence Reinforcement Therapy (ART)
11446473|NCT01723163|Other|Control|Telephone Counseling
11446474|NCT01723150|Experimental|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
11446475|NCT01723150|Active Comparator|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
11446476|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
11446477|NCT01723124|Experimental|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
11446478|NCT01723111||Peritoneal dialysis|start PD
11446479|NCT01723111||Hemodialysis|start HD
11446480|NCT01723098|No Intervention|Control|Sedentary pregnant women
11446481|NCT01723098|Experimental|Exercise group|
11446482|NCT01723085||Open myomectomy|All patients belong to the same group Description includes the surgical technique
11446483|NCT01723072|Experimental|1 Omalizumab|omalizumab once a month via subcutaneous injection.
11446484|NCT01723072|Placebo Comparator|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
11446485|NCT01723059|Other|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
11446486|NCT01723059|Active Comparator|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
11446487|NCT01723046|Experimental|Training with the device|Training with new upper limb robot assisted therapy device
11446488|NCT01723046|No Intervention|Control group|The control group is treated with conventional therapy.
11446489|NCT01723033||EEG acquisition|15 PTSD patients and 15 OCD patients who will, while wearing a net of electrodes for EEG acquisition on their heads, perform three error detection tasks.
11446490|NCT01723033||Control|Previously collected healthy student's data
11446491|NCT01723020|Experimental|AMG 232|AMG 232 is an anti-cancer agent.
11446492|NCT01723007|Experimental|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
11446493|NCT01723007|Active Comparator|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
11446494|NCT01723007|Active Comparator|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
11446495|NCT01722994|Experimental|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
11446496|NCT01722994|Experimental|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
11446497|NCT01722981|Active Comparator|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
11446498|NCT01722981|Active Comparator|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.
~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
11446499|NCT01722981|Active Comparator|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
11446500|NCT01722968|Active Comparator|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
11446501|NCT01722968|Active Comparator|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
11446502|NCT01722955|Experimental|Pre-warmed fluids|Pre-warmed fluids will be prepared for 8hous in 41℃ set hot cabinet.
11446503|NCT01722955|Experimental|Room temperature fluids|Room temperature fluids will be stored at ambient temperature.
11446504|NCT01722942|Active Comparator|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
11446954|NCT01719965||CAB members|- Member of the CAB for at least 3 months
11446505|NCT01722942|Active Comparator|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:
~Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;
~After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
11446506|NCT01722929|Experimental|Skin sensor on surgery side|Skin sensor will be placed on the side that had surgery. This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
11446507|NCT01722929|Active Comparator|Skin sensor on non-surgery side|Skin sensor will be placed on the contralateral side from surgery site.This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
11446508|NCT01722916|Experimental|Dose of Hyaluronidase|
11446509|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
11446510|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
11446511|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
11446512|NCT01722877|Experimental|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
11446513|NCT01722864|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
11446514|NCT01722851||Cohort 1|All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy
11446515|NCT01722851||Cohort 2|All breast cancer patients who present with metastatic disease, disease recurrence or progression, who are commencing up-front chemotherapy ± hormonal therapy
11446516|NCT01722851||Cohort 3|All breast cancer patient who present with metastatic disease who are commencing hormonal therapy only.
11446517|NCT01722838|Experimental|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
11446518|NCT01722838|No Intervention|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
11446519|NCT01722825|Experimental|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
11446520|NCT01722812|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left bodyside), Cromoglicate (on a lesion on right bodyside)
11446521|NCT01722812|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right bodyside), Cromoglicate (on a lesion on left bodyside)
11446522|NCT01722799|Experimental|Drug elluting Balloon (DEB)|Is a coronary dilating device with Paclitaxel ® drug delivery, for dilatation and provisional spot bare metal stenting (BMS).
11446523|NCT01722799|Active Comparator|Drug elluting coronary stent (DES)|The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.
11446524|NCT01722786||DOA|"Expected number of patients estimated by study duration
~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding
~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
11446525|NCT01722786||VKA|"Expected number of patients estimated by study duration
~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding
~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
11446526|NCT01722773|Active Comparator|Bipap|Bipap
11446527|NCT01722773|No Intervention|Standard of care|No intervention
11446528|NCT01722760||Term and preterm infants|Term and preterm infants
11446529|NCT01722747|Experimental|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
11446530|NCT01722747|No Intervention|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
11446531|NCT01722734|No Intervention|Control|Patients in the control arm only got a generic health message at the end of the study.
11446532|NCT01722734|Active Comparator|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
11446533|NCT01722734|Active Comparator|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
11446534|NCT01722708|Experimental|clindamycin|
11446535|NCT01722708|Experimental|metronidazole|
11446536|NCT01722695|Other|Revaclear followed by FX|
11446537|NCT01722695|Other|FX followed by Revaclear|
11446538|NCT01722682|Active Comparator|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
11446539|NCT01722682|Experimental|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
11446540|NCT01722669|Experimental|Quercetin|Single dose of quercetin with or without ascorbic acid
11446541|NCT01722669|Active Comparator|Isoquercetin|Single dose of isoquercetin with or without ascorbic acid
11446542|NCT01722656|Other|Aflibercept|All subjects will receive aflibercept
11447052|NCT01719302|Experimental|cohort 1|
11446543|NCT01722643|Experimental|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
11446544|NCT01722643|Active Comparator|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
11446545|NCT01722630|No Intervention|control|Patients received intravenously saline solution at 5 ml/Kg/h
11446546|NCT01722630|Experimental|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
11446547|NCT01722630|No Intervention|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
11446548|NCT01722617|No Intervention|DAS 28|Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.
11446549|NCT01722617|Active Comparator|DAS 28 + FLARE questionnaires|Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.
11446550|NCT01722617|Active Comparator|DAS 28+FLARE + information to doctor|Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.
11446551|NCT01722604|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
11446552|NCT01722604|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
11446553|NCT01722591|Experimental|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
11446554|NCT01722578|Experimental|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
11446555|NCT01722578|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
11446556|NCT01722565|Experimental|Mesh Group|Patients receiving conventional sigmoid end colostomy plus a preperitoneal lightweight mesh Physiomesh® by laparoscopic procedure
11446557|NCT01722565|No Intervention|Control Group|Patients receiving conventional sigmoid end colostomy by laparoscopic procedure, without mesh
11446558|NCT01722552|Experimental|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
11446559|NCT01722552|Active Comparator|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
11446560|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine|"Sulfadoxine-Pyrimethamine every Four months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
11446561|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine+Piperaquine|"Sulfadoxine-Pyrimethamine every 4 months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Piperaquine every four months Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
~Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
11446562|NCT01722539|Active Comparator|Control|"Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
11446563|NCT01722526|Experimental|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
11446564|NCT01722513|Experimental|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
11446565|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
11446603|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
11446604|NCT01722266|Placebo Comparator|Placebo|Daily Injection
11446566|NCT01722487|Experimental|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
11446567|NCT01722487|Active Comparator|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
11446568|NCT01722474|Experimental|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
11446569|NCT01722461|Experimental|Active treatment|Ulthera System treatment
11446570|NCT01722461|Sham Comparator|Sham treatment|Ulthera System delivering no ultrasound energy
11446571|NCT01722448|Experimental|Choline|Phosphatidyl choline
11446572|NCT01722448|Placebo Comparator|Placebo|Vegetable oil
11446573|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
11446574|NCT01722422|Placebo Comparator|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
11446575|NCT01722422|Active Comparator|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
11446576|NCT01722422|Active Comparator|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.
~Fluid resuscitation if needed with isotonic saline during 3 days."
11446577|NCT01722422|Active Comparator|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.
~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
11446578|NCT01722409|No Intervention|sevoflurane and saline infusion|After induction of general anesthesia, Group S received a placebo infusion of normal saline.
11446579|NCT01722409|Experimental|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
11446580|NCT01722409|Experimental|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
11446581|NCT01722396|Experimental|Vitamin D|
11446582|NCT01722383||Chronic kidney disease|Stages 3-5 chronic kidney disease (pre-dialysis)
11446583|NCT01722370|Placebo Comparator|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
11446584|NCT01722370|Experimental|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
11446585|NCT01722357|Experimental|Pedometer + Exercise Counseling|
11446586|NCT01722357|Experimental|Pedometer|
11446587|NCT01722357|No Intervention|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
11446588|NCT01722344|Experimental|Individual Placement and Support (IPS)|
11446589|NCT01722344|Experimental|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
11446590|NCT01722344|No Intervention|Standard intervention|
11446591|NCT01722331|Experimental|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
11446592|NCT01722331|Experimental|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
11446593|NCT01722331|Placebo Comparator|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
11446594|NCT01722318|Active Comparator|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
11446595|NCT01722318|Active Comparator|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
11446596|NCT01722318|Active Comparator|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
11446597|NCT01722318|Active Comparator|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
11446598|NCT01722318|Placebo Comparator|Placebo|Placebo, one tablet by mouth daily for 12 weeks
11446599|NCT01722305|Experimental|Treatment (pomalidomide, dexamethasone)|Patients receive pomalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11446600|NCT01722292|Experimental|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams [mg] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve [AUC] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.
~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
11446601|NCT01722292|Placebo Comparator|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.
~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
11446602|NCT01722292|Experimental|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.
~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
11446605|NCT01722266|Active Comparator|Liraglutide 1.8mg|Daily Injection
11446608|NCT01722253||placebo, electroacupuncture|"Electroacupuncture before and after surgery (40min and 60 min respectively) with frequency 2 Hz, and 'frequency scanning mode'.
~Placebo electroacupuncture, in which the needles are secured (without penetrating the skin) and connected to the electrical device, which is not functional."
11446609|NCT01722240|Active Comparator|Liraglutide 1.8mg|Daily Injection
11446610|NCT01722240|Placebo Comparator|Placebo|Daily Injection
11446611|NCT01722227|Active Comparator|Liraglutide 0.6mg|Daily Injection
11446612|NCT01722227|Placebo Comparator|Placebo|Daily Injection
11446613|NCT01722214|Experimental|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
11446614|NCT01722214|Placebo Comparator|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
11446615|NCT01722201|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
11446616|NCT01722201|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
11446617|NCT01722188||Optim Leads|
11446618|NCT01722175|Experimental|Arm I (ALPPS)|Patients undergo Associating Liver Partition with Portal Vein Ligation (ALPPS) step 1 surgery on day 0 and step 2 surgery 7-14 days later, based on patient's liver size.
11446619|NCT01722175|Active Comparator|Arm II (PVO)|Patients undergo portal vein occlusion (PVO) step 1 on day 0 and step 2 surgery 6-8 weeks later, based on patient's liver size.
11446620|NCT01722162|Experimental|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.
~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.
~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
11446621|NCT01722162|Experimental|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.
~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.
~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
11446622|NCT01722149|Experimental|Adoptive Transfer of re-directed T cells|Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion
11446623|NCT01722136|Experimental|Low Dosage|Exercise dose of 8kcal/kg/week
11446624|NCT01722136|Experimental|High Dosage|Exercise dose 14kcal/kg/week
11446625|NCT01722123|No Intervention|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
11446626|NCT01722123|Experimental|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
11446627|NCT01722123|Experimental|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
11446628|NCT01722123|Experimental|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
11446629|NCT01722110|Experimental|Indomethacin Extended-Release Capsules USP 75 mg|Indomethacin Extended-Release Capsules USP 75 mg of Ipca Laboratories Limited, India
11446630|NCT01722110|Active Comparator|Indomethacin Extended Release Capsules USP 75 mg|Indomethacin Extended Release Capsules USP 75 mg of Epic Pharma, USA.
11446631|NCT01722097|Active Comparator|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
11446632|NCT01722097|Placebo Comparator|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
11446633|NCT01722084|Experimental|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
11446634|NCT01722084|No Intervention|Community members without intervention|
11446635|NCT01722071|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
11446636|NCT01722071|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
11446637|NCT01722058|Experimental|peptide application|
11446638|NCT01722045|Experimental|Open label IAI|
11446639|NCT01722032|Experimental|Treatment|"The intervention centers' menus were modified to include more fresh fruit, fresh vegetables, low-fat (1%) or skim milk, water, less juice, and less simple carbohydrate snacks. The centers were also encouraged to incorporate fresh fruits and vegetables as often as possible for snack and meal time.
~Physical Activity. Physical activity was promoted for at least 60 minutes per day. TV viewing, watching movies and playing computer games were logged and limited to 30 minutes or less per day. Schools adopted Best-Practice Policies."
11446640|NCT01722032|No Intervention|Control|Those schools randomized to the control arm received a safety curriculum and some child care center locations received an attention control consisting of three visits from the University of Miami Safety Van which provided parents and teachers with home, car and child seat safety information. The control group received all the same pre-post measures as the intervention arms. They also received the same incentives as the intervention arms to foster involvement and ensure retention/reduce loss to follow up.
11446641|NCT01722019|Active Comparator|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
11446642|NCT01722019|Experimental|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
11446643|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
11446644|NCT01721993|Experimental|T121E01F|
11446645|NCT01721993|Active Comparator|zoledronic acid IV|
11446646|NCT01721980|Other|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
11446647|NCT01721980|Other|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
11446648|NCT01721980|Other|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
11446649|NCT01721980|Other|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
11446650|NCT01721967|Experimental|Ranolazine|Ranolazine, 500 mg for 60 days
11446651|NCT01721954|Active Comparator|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
11446652|NCT01721954|Experimental|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
11446653|NCT01721941|Experimental|Phase I dose level -1|TH-302 25mg; Doxorubicin 50mg
11446654|NCT01721941|Experimental|Phase I Dose level 1|TH-302 50mg; doxorubicin 50mg
11446655|NCT01721941|Experimental|Phase I Dose level 2|TH-302 100mg; doxorubicin 50mg
11446656|NCT01721941|Experimental|Phase 1 Dose level 3|TH-302 150mg; Doxorubicin 50mg
11446657|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
11446658|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
11446659|NCT01721915|Experimental|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
11446660|NCT01721915|Placebo Comparator|Placebo|the placebo group will receive oily drops without vitD
11446661|NCT01721902|Active Comparator|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
11446662|NCT01721902|Placebo Comparator|Carrier Solution|Intra-myocardial inception of carrier solution.
11446663|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
11446664|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
11446665|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
11446666|NCT01721876|Experimental|Volasertib + low dose cytarabine|
11446667|NCT01721876|Placebo Comparator|PLACEBO + low dose cytarabine|
11446668|NCT01721863|Experimental|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
11446669|NCT01721863|No Intervention|control group|Control group conducted the usual care
11446670|NCT01721850|Active Comparator|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
11446671|NCT01721850|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
11446672|NCT01721850|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
11446673|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
11446674|NCT01721824|Experimental|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.
~Participants will receive the IPS-MA method in addition to treatment as usual."
11446675|NCT01721824|No Intervention|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
11446676|NCT01721811|Experimental|Healthy|Healthy study participanats
11446677|NCT01721811|Experimental|Diabetes|Patients with diabetes
11446678|NCT01721798|Active Comparator|Copper T-380a IUD|Copper T-380a IUD
11446679|NCT01721798|Active Comparator|Mirena Levonorgestrel IUD|Mirena levonorgestrel IUD
11446680|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.
~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.
~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
11446681|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.
~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.
~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
11446682|NCT01721772|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
11446716|NCT01721512||Formula-fed infants|"Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.
~Mother consents to her infant receiving trial infant formula for 12 months"
11446683|NCT01721772|Active Comparator|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
11446684|NCT01721759|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.
11446685|NCT01721746|Experimental|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11446686|NCT01721746|Active Comparator|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
11446687|NCT01721733|Placebo Comparator|Placebo|Each patient will receive a volume of placebo based on weight
11446688|NCT01721733|Active Comparator|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
11446689|NCT01721733|Active Comparator|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
11446690|NCT01721720||1|children and adolescents and adults with ADHD
11446691|NCT01721707|Experimental|Latanoprost+Brinzolamide combination|Latanoprost 0.005%(50 mg/ml)+brinzolamide 1%(10mg/ml) eye drops
11446692|NCT01721707|Active Comparator|Latanoprost|Latanoprost 0.005% (50 mg / ml)
11446693|NCT01721694|Experimental|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
11446694|NCT01721694|Active Comparator|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
11446695|NCT01721681|Experimental|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).
~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
11446696|NCT01721668|Experimental|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
11446697|NCT01721668|Active Comparator|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
11446698|NCT01721655|Active Comparator|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
11446699|NCT01721655|Placebo Comparator|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
11446700|NCT01721642|Experimental|Apica Cardiovascular ASC Device|Access, stabilisation and closure with the Apica Cardiovascular ASC Device
11446701|NCT01721629|Other|Sudden wean of nasal CPAP|The CPAP is taken off at the morning ward round. If the discontinuation of the CPAP fails according to prespecified failure criteria, CPAP is recommenced and continued for at least 24 hours. Then a new evaluation takes place and if the infant again meets the inclusion criteria another attempt of sudden wean can be undertaken. Infants are considered successfully weaned if they are off CPAP for three days.
11446702|NCT01721629|Other|Gradual wean of nasal CPAP pressure|The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
11446703|NCT01721616|Active Comparator|Cefazolin|single antibiotic
11446704|NCT01721616|Active Comparator|Cefazolin + Azitrhromycin|double antibiotic
11446705|NCT01721603|Experimental|Dabrafenib + Trametinib + gamma knife radiosurgery|
11446706|NCT01721590|Placebo Comparator|Control|Placebo，3 capsules/time，3times/day for 1 year
11446707|NCT01721590|Experimental|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
11446708|NCT01721577|Experimental|AXL1717|In the first phase, 10-20 patients will be enrolled and treated with 300-520 mg BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 400 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
11446709|NCT01721564|Experimental|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
11446710|NCT01721551|Experimental|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
11446711|NCT01721551|Placebo Comparator|No exercise|HD patients will not participate in any type of systematic exercise training
11446712|NCT01721538|Experimental|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
11446713|NCT01721538|Placebo Comparator|Control arm|Lecture on healthy nutrition (1 hour)
11446714|NCT01721525|Experimental|afatinib, ribavirin, and weekly carboplatin/paclitaxel|This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
11446715|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
11447170|NCT01718509|Placebo Comparator|Placebo|
11446717|NCT01721499|Experimental|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.
~The control group receives 6 nutritional sessions only."
11446718|NCT01721499|Active Comparator|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
11446719|NCT01721486|Experimental|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
11446720|NCT01721486|Active Comparator|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
11446721|NCT01721473||cigarette smokers with heavy marijuana use|With heavy marijuana use
11446722|NCT01721473||cigarette smokers with heavy caffeine use|with heavy caffeine use
11446723|NCT01721473||cigarette smokers w/o heavy caffeine and marijuana use|cigarette smokers without the heavy use of marijuana or caffeine
11446724|NCT01721473||non-smokers|not a regular cigarette user
11446725|NCT01721473||cigarette smokers with non-menthol cigarette preference|non-menthol cigarette preference
11446726|NCT01721473||cigarette smokers with menthol cigarette preference|menthol cigarette preference
11446727|NCT01721460|Experimental|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
11446728|NCT01721447|Experimental|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
11446729|NCT01721434|Experimental|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
11446730|NCT01721434|Placebo Comparator|Placebo|Similar coloured placebo intravenous for a single 7 hours
11446731|NCT01721421|Experimental|Extended Treatment time|Extended treatment time of 6 hours
11446732|NCT01721421|Active Comparator|standard treatment time|Standard Treatment time of 4 hours
11446733|NCT01721408|Experimental|Group A|
11446734|NCT01721408|Active Comparator|Group B|
11446735|NCT01721395|Placebo Comparator|Colored, Flavored water|The placebo will be colored to approximate the reddish amber color of the agave syrup. The placebo will use the same flavoring used in the agave syrup. The placebo will be created in a GMP facility
11446736|NCT01721395|Experimental|Agave Syrup|The formulation of pasteurized agave syrup consists of pasteurized agave syrup and natural flavoring.
11446737|NCT01721395|Sham Comparator|Air-filled oral syringe|Air-filled oral syringe to match experimental and placebo arm
11446738|NCT01721382|Experimental|Sitagliptin|Treatment with sitagliptin
11446739|NCT01721369||Transient Loss of Consciousness (T-LOC)|Transient Loss of Consciousness (T-LOC). Treatment according to normal clinical practice.
11446740|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
11446741|NCT01721343|Experimental|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.
11446742|NCT01721343|Experimental|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.
11446743|NCT01721343|Experimental|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.
11446744|NCT01721330|Active Comparator|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
11446745|NCT01721330|Placebo Comparator|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
11446746|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
11446747|NCT01721317|Placebo Comparator|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
11446748|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
11446749|NCT01721317|Placebo Comparator|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
11446750|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
11446751|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
11446752|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
11446753|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
11446754|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
11446755|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
11446756|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
11446757|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
11446758|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
11446759|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
11446760|NCT01721317|Experimental|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
11446761|NCT01721317|Placebo Comparator|Maintenance Phase: Placebo|Subjects receive matching Placebo
11446762|NCT01721304|Experimental|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
11446763|NCT01721304|No Intervention|Usual care|Patients are counseled by their physician as usual
11446764|NCT01721291|Experimental|SALBUTAMOL 1.5 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
11446765|NCT01721291|Experimental|SALBUTAMOL 3 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
11446766|NCT01721291|Experimental|SALBUTAMOL 6 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
11446767|NCT01721291|Active Comparator|SALBUTAMOL 200 MICROGRAMS|DOSAGE FORM- SALBUTAMOL INHALED VIA METERED DOSE INHLAER;DOSAGE- 200 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT ONE VISIT INHALE SLOWY)
11446768|NCT01721239|No Intervention|Control group|No intervention
11446769|NCT01721239|Experimental|Standardized Followup program|Standardized written information, patient photos and three follow-up consultations.
11446770|NCT01721226|Sham Comparator|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
11446771|NCT01721226|Experimental|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
11446772|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
11446773|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
11446774|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
11446775|NCT01721200|Other|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
11446776|NCT01721200|Other|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
11446777|NCT01721187||Low disinhibition|fMRI during fed and fasted states
11446778|NCT01721187||High disinhibition|fMRI during fed and fasted states
11446779|NCT01721174|Active Comparator|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
11446780|NCT01721174|Active Comparator|EBRFA and SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.
11446781|NCT01721161|Experimental|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
11446782|NCT01721161|Placebo Comparator|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
11446783|NCT01721148|Other|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
11446784|NCT01721135|Experimental|GSK2190915 100mg|GSK2190915 100mg on days 1-5; moxifloxacin placebo on day 5
11446785|NCT01721135|Experimental|GSK2190915 1000mg|GSK2190915 1000mg on days 1-5; moxifloxacin placebo on day 5
11446786|NCT01721135|Active Comparator|moxifloxacin 400mg|placebo tablet on days 1-5; moxifloxacin 400mg on day 5
11446787|NCT01721135|Placebo Comparator|placebo|placebo tablet on days 1-5; moxifloxacin placebo on day 5
11446788|NCT01721109|Experimental|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
11446789|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
11446824|NCT01720836|Experimental|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
11446825|NCT01720836|Experimental|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
11446790|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
11446791|NCT01721083|Experimental|Z-Track immunization|Subject receives Intramuscular injection by z-track method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
11446792|NCT01721083|Active Comparator|Bunch immunization|Subject receives Intramuscular injection by bunch method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
11446793|NCT01721070|Experimental|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
11446794|NCT01721070|Experimental|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.
~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
11446795|NCT01721057|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.
~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
11446796|NCT01721057|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.
~Participants will continue to take background cDMARD therapy throughout study."
11446797|NCT01721057|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.
~Participants will continue to take background cDMARD therapy throughout study."
11446798|NCT01721044|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.
~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
11446799|NCT01721044|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.
~Participants will continue to take background cDMARD therapy throughout study."
11446800|NCT01721044|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.
~Participants will continue to take background cDMARD therapy throughout study."
11446801|NCT01721031|Experimental|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
11446802|NCT01721031|Active Comparator|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
11446803|NCT01721018|Experimental|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
11446804|NCT01721005|Other|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
11446805|NCT01720992|Experimental|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
11446806|NCT01720992|Other|Group B|Group B is a wait list control
11446807|NCT01720979||Patients with traumatic injuries|Children that were admitted to the hospital after traumatic injuries to body parts below the clavicles (traumatic control injury) and children that were admitted to the hospital after traumatic brain injury as diagnosed by a physician (TBI).
11446808|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
11446809|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
11446810|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
11446811|NCT01720940|Experimental|continuous vancomycin infusion|
11446812|NCT01720940|Active Comparator|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
11446813|NCT01720927||Acute Pharyngitis|Subjects presenting with acute pharyngitis
11446814|NCT01720914||Critically ill patient|
11446815|NCT01720901|Experimental|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
11446816|NCT01720888|No Intervention|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
11446817|NCT01720888|Experimental|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
11446818|NCT01720875|Experimental|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.
~Cycles 1-8 (21-day cycle)
~Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11
~Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12
~Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)
~Vorinostat: 400mg PO on 1-4 and 15-18"
11446819|NCT01720862||Episodic migraineurs|Those with migraines >2 and < 12 times per month.
11446820|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
11446821|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
11446822|NCT01720849||Fampyra group|
11446823|NCT01720836|Experimental|Stage IA or I/II NSCLC|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
11446826|NCT01720823|Experimental|home polysomnography and standard polysomnography|home polysomnography (GETEMED) and standard polysomnography (BRAINNETII) are both carried out in children during 1 night.
11446827|NCT01720797|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
11446828|NCT01720797|Other|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
11446829|NCT01720784|Placebo Comparator|Placebo|
11446830|NCT01720784|Experimental|Low dose (1.5 g DF)|
11446831|NCT01720784|Experimental|High dose (2.25 gDF)|
11446832|NCT01720771|Active Comparator|Probiotic tablet|a tablet with three probiotic streptococci strains (S. uberis KJ2, S. oralis KJ3 and S. rattus JH145) at a concentration of 3x108 CFU
11446833|NCT01720771|Placebo Comparator|Sugar pill|The same tablet but without active probiotic bacteria
11446834|NCT01720745||EUS FNA|Patients undergoing endoscopic ultrasound for solid mass lesions with a 22 G needle at University of Minnesota Medical center and Aurora St.Luke's Medical Center, Milwaukee, WI
11446835|NCT01720732|Experimental|Lifeline NET|Lifeline-NET (Short Version of NET)
11446836|NCT01720732|No Intervention|TAU|Treatment as Usual
11446837|NCT01720719|Active Comparator|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
11446838|NCT01720719|Experimental|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
11446839|NCT01720706|Experimental|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
11446840|NCT01720706|Experimental|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
11446841|NCT01720693|Experimental|hypoperfusion|Hypoperfusion of the renal artery
11446842|NCT01720667|Experimental|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
11446843|NCT01720667|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
11446844|NCT01720654|No Intervention|Control|Standardized partner notification counseling.
11446845|NCT01720654|Experimental|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
11446846|NCT01720641|No Intervention|Control|Standardized partner notification counseling
11446847|NCT01720641|Experimental|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
11446848|NCT01720641|Experimental|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
11446849|NCT01720641|Experimental|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
11446850|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
11446851|NCT01720615|No Intervention|Propofol or Sevoflurane|General anesthesia
11446852|NCT01720602|Experimental|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
11446853|NCT01720589|Experimental|Melt (test oil)|Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
11446854|NCT01720589|Active Comparator|Corn oil (control)|Participants will consume a muffin containing 20 g of dietary fat provided by the control oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the control oil and their food intake at an ad libitum meal will be measured 1 hour later.
11446855|NCT01720576|Experimental|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
11446856|NCT01720576|Experimental|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
11446857|NCT01720576|Experimental|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
11446858|NCT01720563|Placebo Comparator|Control|Placebo
11446859|NCT01720563|Experimental|Treatment|Astragalus polysaccharides 500 mg
11446860|NCT01720550|Experimental|PG2 High Dose|Astragalus Polysaccharides 500 mg
11446861|NCT01720550|Experimental|PG2 Low Dose|Astragalus Polysaccharides 250 mg
11446862|NCT01720537|Experimental|Cohort 1|
11446863|NCT01720537|Experimental|Cohort 2|
11446864|NCT01720537|Experimental|Cohort 3|
11446865|NCT01720537|Experimental|Cohort 4|
11446866|NCT01720537|Experimental|Cohort 5|
11446867|NCT01720537|Experimental|Cohort 6|
11446868|NCT01720524|Placebo Comparator|placebo|iv placebo of normal saline or 10% dextrose
11446869|NCT01720524|Experimental|sildenafil|Active study drug
11446870|NCT01720511|Experimental|Purple Rice|Twice a day given purple rice with 5mg of resveratrol.
11446871|NCT01720511|Active Comparator|Brown RIce|Plain Purple rice given twice a day
11447173|NCT01718483|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
11446872|NCT01720498|Experimental|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
11446873|NCT01720498|Experimental|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
11446874|NCT01720485|Experimental|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:
~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.
~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.
~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
11446875|NCT01720485|Active Comparator|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:
~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.
~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.
~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
11446876|NCT01720472||Community, Physical Performance|
11446877|NCT01720459|Active Comparator|Micronized trans-resveratrol|Micronized trans-resveratrol
11446878|NCT01720459|Placebo Comparator|Placebo|
11446879|NCT01720446|Experimental|Semaglutide 0.5 mg|
11446880|NCT01720446|Experimental|Semaglutide 1.0 mg|
11446881|NCT01720446|Placebo Comparator|Semaglutide placebo 0.5 mg|
11446882|NCT01720446|Placebo Comparator|Semaglutide placebo 1.0 mg|
11446883|NCT01720433|Experimental|intervention|In the intervention group, in addition to the above, the patient was placed in the Trendelenburg position (30°) and a pulmonary recruitment maneuver utilized, consisting of two manual inflations to a maximum pressure of 60 cm H2O. This was performed by the Anaesthetist, who held each positive pressure inflation for five seconds, with the valves on the operative ports fully open.
11446884|NCT01720433|No Intervention|control arm|In the control group residual carbon dioxide pneumo-peritoneum was evacuated at the end of the procedure by passively allowing the abdomen to decompress by opening the operative ports.
11446885|NCT01720420|Experimental|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
11446886|NCT01720420|Experimental|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
11446887|NCT01720407|Experimental|Imiquimod|
11446888|NCT01720407|Placebo Comparator|Placebo|
11446889|NCT01720394|Experimental|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
11446890|NCT01720394|Active Comparator|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
11446891|NCT01720368||1st Group of 50 patients|
11446892|NCT01720368||2nd Group of 50 patients|
11446893|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
11446894|NCT01720329|Active Comparator|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
11446895|NCT01720329|Placebo Comparator|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
11446896|NCT01720316|Active Comparator|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
11446897|NCT01720316|Placebo Comparator|Placebo|placebo, TID dosing, 6 weeks Double-blind
11446898|NCT01720316|Active Comparator|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
11446899|NCT01720303|Experimental|Rep + NPH|
11446900|NCT01720303|Active Comparator|Premixed insulin/NPH|
11446901|NCT01720290|Experimental|Rep|
11446902|NCT01720290|Active Comparator|Met|
11446903|NCT01720290|Active Comparator|Rep + met|
11446904|NCT01720277|Experimental|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
11446905|NCT01720277|Active Comparator|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
11446906|NCT01720264|Experimental|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
11446907|NCT01720251|Placebo Comparator|placebo|SC injections of placebo
11446908|NCT01720251|Experimental|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
11446909|NCT01720251|Experimental|AllerT full dose|SC injections of AllerT 50-100 micrograms
11446910|NCT01720238||Group 1|Entecavir Therapy
11446911|NCT01720238||Group 2|Lamivudine plus Adefovir Dipivoxil Therapy
11446912|NCT01720225|Experimental|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
11446913|NCT01720225|Experimental|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
11446914|NCT01720212|Experimental|Single dose group|
11446915|NCT01720212|Experimental|Multiple dose group|
11446916|NCT01720199|Experimental|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
11446917|NCT01720199|No Intervention|Control group|
11446918|NCT01720186|Experimental|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
11446919|NCT01720186|Active Comparator|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
11446920|NCT01720173|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11446951|NCT01719978|Placebo Comparator|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
11447174|NCT01718483|Placebo Comparator|Placebo|
11446921|NCT01720160|Experimental|Device|1) BAROSTIM NEO System and 2) standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
11446922|NCT01720160|Active Comparator|Medical Management|Standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
11446923|NCT01720147|Experimental|Quercetin - Dietary Supplement|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required) for subsequent patients.
~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
11446924|NCT01720134||after legislation 1st july 2003|2003-2006
11446925|NCT01720134||before legislation 1st july 2003|1999-2003
11446926|NCT01720121|No Intervention|Control group|The control group received the guidelines orientation provide by nursing team
11446927|NCT01720121|Experimental|Guidelines printed group|The patient received the informative material in details about the cardiac catheterization provide by the researchers
11446928|NCT01720121|Experimental|Guidelines digital video disc group|Guidelines digital video disc group: The patient received the informative provide by digital video disc in details about the cardiac catheterization
11446929|NCT01720108|Active Comparator|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
11446930|NCT01720108|Experimental|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
11446931|NCT01720095|Experimental|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
11446932|NCT01720095|No Intervention|healthy control|this is the group of healthy controls for cognitive outcome measures
11446933|NCT01720095|No Intervention|first episode control group|first episode psychosis patients who are randomized to no intervention
11446934|NCT01720082|Active Comparator|Single incision laparoscopic appendectomy|Acute appendicitis with surgical indication
11446935|NCT01720082|Active Comparator|Multiport Laparoscopic appendectomy|Acute appendicitis with surgical indication
11446936|NCT01720069|Active Comparator|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
11446937|NCT01720069|Active Comparator|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
11446938|NCT01720069|Active Comparator|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
11446939|NCT01720056|Active Comparator|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
11446940|NCT01720056|Active Comparator|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
11446941|NCT01720043|Experimental|All participants|All participants enrolled
11446942|NCT01720030|Placebo Comparator|Conventional therapy|Standard of care as protocolized locally
11446943|NCT01720030|Experimental|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
11446944|NCT01720017|Active Comparator|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
11446945|NCT01720017|Experimental|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
11446946|NCT01720004|Experimental|Repeated Use of Hands-and-Knees|The intervention was repeated use of hands-and-knees position during labour. Participants were asked to try it for at least 15 minutes every hour, from randomization until delivery. They were not required to use it for delivery.
11446947|NCT01720004|No Intervention|Usual care|Participants were asked to refrain from using hands-and-knees position at any time from randomization to delivery. They were free to use any other position.
11446948|NCT01719991|Experimental|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
11446949|NCT01719991|No Intervention|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
11446950|NCT01719978|Active Comparator|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
11454215|NCT01671878|Experimental|Test Food 2|Biscuit
11446955|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
11446956|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
11446957|NCT01719952|Experimental|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
11446958|NCT01719952|Active Comparator|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
11446959|NCT01719926|Experimental|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
11446960|NCT01719926|Experimental|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
11446961|NCT01719913|Active Comparator|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
11446962|NCT01719913|Placebo Comparator|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
11446963|NCT01719900|Experimental|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
11446964|NCT01719900|Placebo Comparator|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
11446965|NCT01719887|Active Comparator|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
11446966|NCT01719887|Experimental|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
11446967|NCT01719874|Experimental|TCN-032|single-dose, administered intravenously
11446968|NCT01719874|Placebo Comparator|Placebo (saline)|single-dose, administered intravenously
11446969|NCT01719861|Experimental|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
11446970|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
11446971|NCT01719835|Experimental|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
11446972|NCT01719835|Active Comparator|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
11446973|NCT01719822|No Intervention|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
11446974|NCT01719822|Experimental|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
11446975|NCT01719796|Experimental|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
11446976|NCT01719796|No Intervention|No TAP catheter|
11446977|NCT01719783|Experimental|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
11446978|NCT01719783|Placebo Comparator|Placebo|two doses of placebo solution intranasal
11446979|NCT01719770|Active Comparator|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
11446980|NCT01719770|Placebo Comparator|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
11446981|NCT01719757|Experimental|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
11446982|NCT01719744|Experimental|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
11446983|NCT01719731|Placebo Comparator|Non-Education|This group will not receive the psychosocial education.
11446984|NCT01719731|Active Comparator|Education|This group will receive the psychosocial education
11446985|NCT01719718|Active Comparator|Closure|
11446986|NCT01719718|Sham Comparator|Non-Closure|
11446987|NCT01719705|Placebo Comparator|Placebo|receive two identical placebo capsules
11446988|NCT01719705|Active Comparator|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
11446989|NCT01719705|Active Comparator|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
11446990|NCT01719692|Experimental|Rituximab A group|375mg/m2 for once
11446991|NCT01719692|Active Comparator|Rituximab B group|100mg/week for four weeks
11446992|NCT01719679|Experimental|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
11446993|NCT01719679|No Intervention|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
11446994|NCT01719666|Other|isolated MPFL reconstruction|
11446995|NCT01719666|Experimental|MPFL reconstruction and Lateral retinaculum release|
11446996|NCT01719653|Active Comparator|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
11446997|NCT01719653|Experimental|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
11446998|NCT01719653|Experimental|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
11446999|NCT01719653|Active Comparator|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
11447171|NCT01718496|Active Comparator|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
11447000|NCT01719653|Active Comparator|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
11447001|NCT01719640|Experimental|BMMSC+BMMNC|infusion of BMMSC+BMMNC and insulin injection
11447002|NCT01719640|Active Comparator|BMMNC|infusion of BMMNC and insulin injection
11447003|NCT01719640|Active Comparator|Insulin|insulin injection
11447004|NCT01719627|Experimental|MVC 300 mg|MVC 300 mg in unique dose
11447005|NCT01719627|Active Comparator|TVD 300/200 QD|TVD 300/200 QD during 7 days.
11447006|NCT01719627|Experimental|Maraviroc 600mg|MVC 600mg in unique dose
11447007|NCT01719614|Experimental|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
11447008|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
11447009|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
11447010|NCT01719575|Other|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
11447011|NCT01719575|Other|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
11447012|NCT01719562|Experimental|ADDENDUM: Physical Activity Intervention|Participants will be offered one to two training sessions per week at onsite rehab facilities and 1-2 sessions per week at home consisting of slow 15 minute aerobic warm-up followed by 20 minutes of strength training, 15 minutes of progressive intensity aerobic exercise and 10 minute cool down.
11447013|NCT01719562|Experimental|ADDENDUM: Healthy Living Instruction Group (Control Arm)|Organized various health workshops lasting for 60 minutes to match the number of visits to the rehab centers for participants in Arm 1 with 2 sessions offered per month onsite and remaining sessions offered over the phone for 6 months. .
11447014|NCT01719562|Experimental|MRI (Diagnostic)|Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
11447015|NCT01719549|Experimental|Dovitinib|
11447016|NCT01719536|Experimental|Icotinib|Icotinib 125mg is administered orally three times per day.
11447017|NCT01719536|Active Comparator|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
11447018|NCT01719523|Experimental|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
11447019|NCT01719510|Other|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.
~For all women included will be achieved in the delivery room:
~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.
~For mothers, the collection of milk when breastfeeding."
11447020|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
11447021|NCT01719497||Obese|Subjects diagnosed with obesity
11447022|NCT01719497||High Stress|Subjects diagnosed with high stress
11447023|NCT01719497||Healthy|Subjects deemed medically healthy
11447024|NCT01719484||Healthy|Subjects deemed to be medically healthy
11447025|NCT01719484||Obese|Subjects deemed to be medically obese
11447026|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
11447027|NCT01719471||Healthy|Medically healthy individuals who do not smoke
11447028|NCT01719458||Alcohol|Subjects diagnosed with alcohol dependence
11447029|NCT01719458||Obese|Subjects diagnosed with obesity
11447030|NCT01719458||Healthy|Subjects deemed to be medically healthy
11447031|NCT01719445||RFPM/Paper and Pen Method|
11447032|NCT01719432||Obese patients|
11447033|NCT01719432||Non-obese patients|
11447034|NCT01719419|Experimental|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
11447035|NCT01719419|Experimental|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
11447036|NCT01719406|Experimental|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
11447037|NCT01719406|No Intervention|Control|Standard medical care
11447038|NCT01719380|Experimental|LGX818 + cetuximab|
11447039|NCT01719380|Experimental|LGX818 + BYL719 + cetuximab|
11447040|NCT01719367|Experimental|Atenolol|Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol.
11447041|NCT01719354|Experimental|Community Health center|Aftercare in a community Health center
11447042|NCT01719354|Active Comparator|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
11447043|NCT01719328|Experimental|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
11447044|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
11447045|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
11447046|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
11447047|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
11447048|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
11447049|NCT01719315||Primary Insomnia|Patients with primary insomnia
11447050|NCT01719315||Narcolepsy|Subjects with narcolepsy
11447051|NCT01719315||Healthy Controls|healthy participants
11447053|NCT01719289|Experimental|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
11447054|NCT01719289|No Intervention|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
11447055|NCT01719276|Active Comparator|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
11447056|NCT01719276|Active Comparator|Supervised exercises|Stretching, Strengthening, Motor Control
11447057|NCT01719263|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
11447058|NCT01719263|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
11447059|NCT01719250|Experimental|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11447060|NCT01719237|Active Comparator|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
11447061|NCT01719237|Sham Comparator|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
11447062|NCT01719224|Active Comparator|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
11447063|NCT01719224|Active Comparator|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
11447064|NCT01719185|Experimental|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
11447065|NCT01719185|Active Comparator|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
11447066|NCT01719172|Experimental|Veriset™ Hemostatic Patch|Topical hemostat
11447067|NCT01719159|Experimental|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
11447068|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
11447069|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
11447070|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
11447071|NCT01719133|Other|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
11447072|NCT01719120|Experimental|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
11447073|NCT01719120|Experimental|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
11447074|NCT01719120|No Intervention|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
11447075|NCT01719107|Active Comparator|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
11447076|NCT01719107|Placebo Comparator|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
11447077|NCT01719094||Childhood Cancer Surviviors|
11447078|NCT01719094||Adolescent/young adults with no cancer history|
11447079|NCT01719094||Newly diagnosed cancer patients|
11447080|NCT01719081|Experimental|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
11447081|NCT01719081|Active Comparator|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
11447082|NCT01719068||Workers exposed to asbestos|
11447083|NCT01719055||Boston Scientific SCS Systems|Subjects permanently implanted with a Boston Scientific neurostimulation systems
11447084|NCT01719042|Active Comparator|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
11447085|NCT01719042|Active Comparator|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
11447086|NCT01719029|Experimental|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
11447087|NCT01719029|Experimental|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
11447088|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:
~Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.
~Injection of Lexiscan.
~Coronary catheterization:
~Pressure and flow readings using Combowire
~Injection of Adenosine."
11447089|NCT01719003|Experimental|Empagliflozin low dose qd|Empagliflozin low dose once daily
11447090|NCT01719003|Experimental|Empagliflozin high dose qd|Empagliflozin high dose once daily
11447091|NCT01719003|Experimental|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
11447092|NCT01719003|Experimental|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
11447093|NCT01719003|Experimental|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
11447094|NCT01719003|Experimental|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
11447095|NCT01719003|Experimental|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
11447096|NCT01719003|Experimental|Metformin 500 mg bid|Metformin 500 mg twice daily
11447097|NCT01719003|Experimental|Metformin 1000 mg bid|Metformin 1000 mg twice daily
11447098|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
11447099|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
11447100|NCT01718977|Experimental|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
11447101|NCT01718977|Active Comparator|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.
~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
11447102|NCT01718964|Other|A|Cortisol 20 mg /Placebo Mannitol
11447103|NCT01718964|Other|B|Placebo Mannitol/Cortisol 20mg
11447104|NCT01718951|Active Comparator|golimumab|golimumab 50mg subcutaneous every 4 weeks
11447105|NCT01718951|Active Comparator|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
11447106|NCT01718938|Experimental|Sequence 1|3-way crossover of velusetrag or placebo
11447107|NCT01718938|Experimental|Sequence 2|3-way crossover of velusetrag or placebo
11447108|NCT01718938|Experimental|Sequence 3|3-way crossover of velusetrag or placebo
11447109|NCT01718938|Experimental|Sequence 4|3-way crossover of velusetrag or placebo
11447110|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
11447111|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
11447112|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
11447113|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
11447114|NCT01718912|Other|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
11447115|NCT01718899|Experimental|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
11447116|NCT01718899|Experimental|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
11447117|NCT01718899|Experimental|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
11447118|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
11447119|NCT01718873|Experimental|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
11447120|NCT01718873|Active Comparator|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
11447121|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
11447122|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
11447123|NCT01718847|Experimental|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
11447124|NCT01718834|Active Comparator|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
11447125|NCT01718834|Active Comparator|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
11447126|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
11447127|NCT01718808|Active Comparator|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
11447128|NCT01718808|Active Comparator|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks
~* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
11447129|NCT01718795|Active Comparator|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?
~Intervention is Bag-valve mask ventilation during CPR"
11447130|NCT01718795|Active Comparator|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?
~Intervention is Ventilation through laryngeal tube during CPR"
11447131|NCT01718782|Active Comparator|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
11447132|NCT01718782|Active Comparator|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
11447133|NCT01718769|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
11447134|NCT01718769|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
11447135|NCT01718756|Placebo Comparator|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
11447136|NCT01718756|Active Comparator|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
11447137|NCT01718756|Active Comparator|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
11447138|NCT01718743|Experimental|Treatment (ixazomib citrate, lenalidomide)|Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11447139|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
11447140|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
11447141|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
11447142|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
11447143|NCT01718717|Active Comparator|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
11447144|NCT01718717|Active Comparator|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
11447145|NCT01718704|Experimental|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
11447146|NCT01718704|No Intervention|No Viberect|Men in this group will not be provided with the Viberect device
11447147|NCT01718691|Experimental|SyB L-0501＋rituximab|
11447148|NCT01718678|Active Comparator|Melatonin|Melatonin, Tablet, 3 mg, once, one month
11447149|NCT01718678|Placebo Comparator|Placebo|Placebo, tablet
11447150|NCT01718652|Experimental|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
11447151|NCT01718639|Active Comparator|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
11447152|NCT01718639|Active Comparator|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
11447153|NCT01718639|Placebo Comparator|Placebo|1 tablet to be swallowed with water.
11447154|NCT01718626|Active Comparator|S1+Docetaxel|
11447155|NCT01718626|Experimental|S1+Docetaxel followed by S1|
11447156|NCT01718613|Active Comparator|Norepinephrine|
11447157|NCT01718613|Active Comparator|Vasopressin|
11447158|NCT01718600||Neuroimaging Correlates|Carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. Neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. In this proposal, we hope to determine the risk factors and cognitive effect of microembolization following carotid revascularization procedures.
11447159|NCT01718587|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
11447160|NCT01718587|Active Comparator|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
11447161|NCT01718574|Experimental|Self-help book|
11447162|NCT01718574|No Intervention|Usual Care Control|
11447163|NCT01718561|No Intervention|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
11447164|NCT01718561|Experimental|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
11447165|NCT01718548|Active Comparator|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
11447166|NCT01718548|Placebo Comparator|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
11447167|NCT01718535||CYP2C19 Genotyping|
11447168|NCT01718522||Intervention Group|Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
11447169|NCT01718509|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
11447175|NCT01718470|Active Comparator|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
11447176|NCT01718470|Active Comparator|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
11447177|NCT01718457|Experimental|Endobarrier device insertion|
11447178|NCT01718444|Experimental|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.
~CC 50 mg oral for 5 days (Days 3-7)
~If no ovulation, CC 100 mg for 5 days (Days 12-16)
~If no ovulation, CC 150 mg for 5 days (Day 21-25)
~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
11447179|NCT01718444|Active Comparator|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)
~Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)
~CC 50 mg oral for 5 days (Day 3-7)
~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses
~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days
~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
11447180|NCT01718431|Experimental|indigestible carbohydrates|test meal: indigestible carbohydrates
11447181|NCT01718431|Experimental|reference|reference meal: no indigestible carbohydrates
11447182|NCT01718418|Experimental|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
11447183|NCT01718418|Experimental|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
11447184|NCT01718418|Experimental|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
11447185|NCT01718405|Experimental|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
11447186|NCT01718392|Experimental|Training|24 weeks combined exercise programme (supervised)
11447187|NCT01718392|No Intervention|Control|sedentary/habitual lifestyle
11447188|NCT01718379|Experimental|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.
~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.
~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.
~The patients will be followed every 3 months for 12 months"
11447189|NCT01718379|Experimental|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).
~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.
~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.
~The patients will be followed every 3 months for 12 months"
11447190|NCT01718366|Experimental|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.
~Patients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.
~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)
~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
11447191|NCT01718366|Experimental|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.
~Patients with the ferritin level > 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)
~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
11447192|NCT01718353|Experimental|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
11447193|NCT01718353|Experimental|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
11447194|NCT01718340|Experimental|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
11447195|NCT01718327|Experimental|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
11447196|NCT01718314|Experimental|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
11447197|NCT01718314|Experimental|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
11447198|NCT01718301|Experimental|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
11447199|NCT01718288|Experimental|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
11447233|NCT01718067|Experimental|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
11447200|NCT01718288|Active Comparator|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment
~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
11447201|NCT01718288|Experimental|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
11447202|NCT01718288|Active Comparator|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
11447203|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
11447204|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
11447205|NCT01718249|Other|deep brain stimulation|
11447206|NCT01718236|Experimental|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
11447207|NCT01718236|Experimental|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
11447208|NCT01718223|Experimental|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
11447209|NCT01718210|Experimental|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
11447210|NCT01718210|Placebo Comparator|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
11447211|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
11447212|NCT01718197||Severe Asthma|"Major Criteria: (1 required)
~Treatment with oral corticosteroids for at least 6 of the previous 12 months
~Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months
~Minor Criteria: (2 required)
~Daily treatment with an asthma controller medication in addition to ICS, or
~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or
~Persistent airway obstruction with baseline FEV1 <80% predicted, or
~≥ 1 urgent visits for asthma in the previous 12 months, or
~≥ 3 systemic corticosteroid bursts in the previous 12 months, or
~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or
~A near-fatal asthma event (i.e., intubation) in the past"
11447213|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
11447214|NCT01718184|Experimental|Sulcoflex|Sulcoflex intraocular lens implantation
11447215|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
11447216|NCT01718158|Experimental|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks
~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 weeks
~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
11447217|NCT01718158|Experimental|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response
~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 to 48 weeks depending on response
~Telaprevir 375 mg tablets [2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
11447218|NCT01718145|Experimental|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks
~- Naive cohort"
11447219|NCT01718145|Active Comparator|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly & Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks
~- Naive cohort"
11447220|NCT01718145|Experimental|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks
~- Relapser cohort"
11447221|NCT01718132||postoperative patients|
11447222|NCT01718119|Experimental|DA-3803|subjects treated with DA-3803(r-hCG)
11447223|NCT01718119|Active Comparator|Ovidrel|subjects treated with Ovidrel(r-hCG)
11447224|NCT01718106|Active Comparator|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
11447225|NCT01718106|Active Comparator|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
11447226|NCT01718093|Active Comparator|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
11447227|NCT01718093|Active Comparator|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
11447228|NCT01718093|Active Comparator|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
11447229|NCT01718080||Group A|Healthy lean children before puberty
11447230|NCT01718080||Group B|Otherwise healthy overweight children before puberty
11447231|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
11447232|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
11447430|NCT01717040|Placebo Comparator|Placebo|
11447234|NCT01718067|Active Comparator|Control|conventional manual ELTGOL technique
11447235|NCT01718054|Active Comparator|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine & L-Citrulline plus daily chloroquine
11447236|NCT01718054|Active Comparator|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
11447237|NCT01718041|Experimental|VRS-317|Active treatment arm
11447238|NCT01718028|Experimental|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
11447239|NCT01718028|Active Comparator|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
11447240|NCT01718015||Patients with diabetic polyneuropathy|
11447241|NCT01718015||Patients with diabetes without peripheral nerve disorder|
11447242|NCT01718015||Patients with polyneuropathies not due to diabetes|
11447243|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
11447244|NCT01718015||Patients with unspecified nerve disease|
11447245|NCT01718002|Other|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
11447246|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
11447247|NCT01717976|Experimental|Intervention|primary care based nurse telephone support
11447248|NCT01717976|No Intervention|Control|usual care
11447249|NCT01717963|Experimental|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
11447250|NCT01717963|Active Comparator|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
11447251|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel®|
11447252|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
11447253|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
11447254|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel®|
11447255|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
11447256|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
11447257|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
11447258|NCT01717924|Active Comparator|peri-operative chemotherapy|Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery
11447259|NCT01717924|Experimental|surgery first with adjuvant chemotherapy|Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy
11447260|NCT01717911|Active Comparator|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
11447261|NCT01717911|Experimental|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
11447262|NCT01717911|Experimental|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
11447263|NCT01717898|Experimental|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
11447264|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
11447265|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
11447266|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
11447267|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
11447268|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
11447269|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
11447270|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
11447271|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
11447272|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
11447273|NCT01717872|Active Comparator|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
11447274|NCT01717872|Active Comparator|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
11447275|NCT01717859|Other|Tocilizumab|All subjects will receive tocilizumab.
11447276|NCT01717846|Experimental|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
11447277|NCT01717846|Other|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
11447278|NCT01717833|Experimental|NEMS group|
11447279|NCT01717833|Sham Comparator|Sham group|
11447280|NCT01717820|Experimental|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
11447281|NCT01717807||lung cancer; advanced pancreatic cancer|
11447282|NCT01717794|Active Comparator|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.
~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.
~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
11447283|NCT01717794|Experimental|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.
~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
11447284|NCT01717781|Experimental|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.
~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
11447285|NCT01717781|Active Comparator|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.
~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.
~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
11447286|NCT01717768|Experimental|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
11447287|NCT01717768|Experimental|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
11447288|NCT01717768|Experimental|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
11447289|NCT01717768|Experimental|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.
~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.
~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.
~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
11447290|NCT01717768|Experimental|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.
~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.
~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.
~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
11447291|NCT01717768|Experimental|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.
~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.
~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.
~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
11447292|NCT01717768|Experimental|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
11447293|NCT01717768|Experimental|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
11447294|NCT01717768|Experimental|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
11447295|NCT01717768|Experimental|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
11447296|NCT01717755|No Intervention|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.
~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
11447297|NCT01717755|Experimental|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
11447298|NCT01717742|Active Comparator|tPA and placebo|
11447299|NCT01717742|Experimental|tPA and DNase|
11447300|NCT01717729|Experimental|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
11447301|NCT01717729|Active Comparator|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
11447302|NCT01717716|Experimental|Calorie-free control|Calorie-free control
11447303|NCT01717716|Experimental|HFCS-55 drink|HFCS-55 drink
11447304|NCT01717716|Experimental|Glucose drink|Glucose drink
11447305|NCT01717716|Experimental|Sucrose drink|Sucrose drink
11447306|NCT01717703|Experimental|Water Control|Water Control
11447307|NCT01717703|Experimental|Fruit drink|Fruit drink
11447308|NCT01717703|Experimental|Cola|Cola
11447309|NCT01717703|Experimental|1% chocolate milk|1% chocolate milk
11447310|NCT01717690|Active Comparator|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).
~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.
~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
11447311|NCT01717690|No Intervention|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).
~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
11447312|NCT01717677|Experimental|radical prostatectomy|Procedure/Surgery: radical prostatectomy
11447313|NCT01717677|Experimental|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
11447314|NCT01717677|Experimental|permanent seed implantation|Radiation: permanent seed implantation
11447315|NCT01717677|Experimental|Active Surveillance|Procedure/Surgery: Active Surveillance
11447316|NCT01717664|Experimental|RHB-104|5 RHB-104 capsules administered orally BID
11447317|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
11447318|NCT01717638|Experimental|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447319|NCT01717638|Experimental|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447320|NCT01717638|Experimental|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447321|NCT01717638|Experimental|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447322|NCT01717638|Experimental|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447323|NCT01717638|Experimental|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447324|NCT01717638|Experimental|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447325|NCT01717638|Experimental|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447326|NCT01717638|Experimental|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447327|NCT01717638|Experimental|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447328|NCT01717638|Experimental|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 & 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447329|NCT01717638|Experimental|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 & 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
11447330|NCT01717638|Experimental|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
11447331|NCT01717625|Experimental|Montelukast|"montelukast sodium
~dosage
~< 1000g : 0.5 mg/D QD
~1000g~1500g : 1.0 mg/D QD
~1500g~2000g : 1.5 mg/D QD
~> 2000g : 2mg/D QD
~medication period : to discharge or GA 36wks"
11447332|NCT01717625|No Intervention|Control|Standard treatment of BPD and preterm infants
11447333|NCT01717612|Active Comparator|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
11447334|NCT01717612|Experimental|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
11447335|NCT01717599|Experimental|Diclofenac group|
11447336|NCT01717599|Placebo Comparator|Placebo(normal saline) group|
11447337|NCT01717586|Active Comparator|Pravastatin Group|Pregnant women at high-risk for preeclampsia who are taking pravastatin during their pregnancy.
11447338|NCT01717586|Placebo Comparator|Control Group|Pregnant women who are at high-risk for developing preeclampsia who are taking a placebo during their pregnancy.
11447339|NCT01717573|Active Comparator|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
11447340|NCT01717573|Sham Comparator|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
11447341|NCT01717560|Experimental|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
11447342|NCT01717547|Experimental|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
11447343|NCT01717534|Experimental|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.
~The duration of the treatment is 5 months."
11447344|NCT01717534|Placebo Comparator|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.
~The duration of the treatment is 5 months."
11447345|NCT01717508|Other|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
11447346|NCT01717508|No Intervention|Healthy Controls|
11447347|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
11447348|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
11447349|NCT01717482|Active Comparator|Metformin|Metformin 850mg twice a day
11447350|NCT01717482|Placebo Comparator|Observation|Standard of Care Observation
11447351|NCT01717469|Active Comparator|RV Pacing|Right ventricular pacing
11447352|NCT01717469|Experimental|LV Pacing|Left ventricular pacing through coronary sinus tributaries
11447353|NCT01717456|Active Comparator|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements [Metamucil 1-4 packets (3.4-13.6 g)/day], laxatives or anti-diarrheals [Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day], pelvic floor muscle exercises [100 10-second squeezes/day], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments [as needed].
11447354|NCT01717456|Placebo Comparator|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day], daily diary, and protective pads or garments [as needed].
11447355|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
11447356|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
11447357|NCT01717417||group 1|Patient treated with Trans Palatal Arch as anchorage for canine traction
11447358|NCT01717417||Group 2|Patient treated with miniscrew as anchorage for canine traction
11447359|NCT01717404|Experimental|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
11447360|NCT01717391|Experimental|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
11447361|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
11447362|NCT01717365||OTs|Occupational therapists
11447363|NCT01717352|Active Comparator|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
11447364|NCT01717352|Active Comparator|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
11447365|NCT01717339|Other|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
11447366|NCT01717339|Other|OSA subjects|(Obstructive sleep apnea) OSA subjects
11447367|NCT01717326|Experimental|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447368|NCT01717326|Experimental|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447369|NCT01717326|Experimental|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
11447370|NCT01717326|Experimental|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447371|NCT01717326|Experimental|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447372|NCT01717326|Experimental|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
11447373|NCT01717326|Experimental|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
11447374|NCT01717326|Experimental|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
11447375|NCT01717326|Experimental|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447376|NCT01717326|Experimental|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
11447377|NCT01717326|Experimental|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447378|NCT01717326|Experimental|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
11447379|NCT01717326|Experimental|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447380|NCT01717326|Experimental|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
11447381|NCT01717326|Experimental|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447382|NCT01717326|Experimental|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
11447383|NCT01717326|Experimental|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
11447384|NCT01717326|Experimental|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
11447385|NCT01717326|Experimental|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447386|NCT01717326|Experimental|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
11447387|NCT01717313|Experimental|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
11447388|NCT01717313|Placebo Comparator|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
11447389|NCT01717300|Experimental|Anacetrapib 100 mg|
11447390|NCT01717300|Experimental|Anacetrapib 25 mg|
11447391|NCT01717300|Placebo Comparator|Placebo|
11454905|NCT01667133|Experimental|Phase 1 dose escalation|Phase 1
11447392|NCT01717287|Experimental|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
11447393|NCT01717287|Experimental|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
11447394|NCT01717274|Experimental|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
11447395|NCT01717274|No Intervention|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
11447396|NCT01717261|Experimental|Single Pre-Operative Radiation Therapy|
11447397|NCT01717248|Experimental|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
11447398|NCT01717235|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
11447399|NCT01717235|Experimental|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
11447400|NCT01717222|Active Comparator|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
11447401|NCT01717222|Active Comparator|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
11447402|NCT01717209|Experimental|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
11447403|NCT01717196|Experimental|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
11447404|NCT01717183|Experimental|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
11447405|NCT01717183|Placebo Comparator|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
11447406|NCT01717170|Experimental|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
11447407|NCT01717170|Experimental|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
11447408|NCT01717157|Experimental|Treatment sequence 1 (AEBD)|
11447409|NCT01717157|Experimental|Treatment sequence 2 (BACE)|
11447410|NCT01717157|Experimental|Treatment sequence 3 (CBDA)|
11447411|NCT01717157|Experimental|Treatment sequence 4 (EDAC)|
11447412|NCT01717157|Experimental|Treatment sequence 5 (DECA)|
11447413|NCT01717157|Experimental|Treatment sequence 6 (EADB)|
11447414|NCT01717157|Experimental|Treatment sequence 7 (ABEC)|
11447415|NCT01717157|Experimental|Treatment sequence 8 (BCAD)|
11447416|NCT01717144|No Intervention|traditional medical care|patients benefiting of a traditional medical care
11447417|NCT01717144|Experimental|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
11447418|NCT01717131|Active Comparator|Surgery for standard axillary node dissection|Standard axillary dissection
11447419|NCT01717131|Experimental|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
11447420|NCT01717118|Active Comparator|Tetravalent Vaccine|"Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.
~Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.
~Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
11447421|NCT01717118|Active Comparator|Bivalent Vaccine|"Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.
~Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.
~Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.
~Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.
~Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
11447422|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
11447423|NCT01717092||Consecutive patients with acute PE|
11447424|NCT01717079|Active Comparator|Effective arm|Effective coil
11447425|NCT01717079|Placebo Comparator|Placebo arm|Placebo coil
11447426|NCT01717066|Experimental|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
11447427|NCT01717066|Placebo Comparator|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
11447428|NCT01717053|Experimental|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
11447429|NCT01717040|Experimental|Pioglitazone|
11447431|NCT01717027|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11447432|NCT01717027|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11447433|NCT01717027|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11447434|NCT01717027|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11447435|NCT01717014|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
11447436|NCT01717001||ConforMIS|Patients with ConforMIS implants
11447437|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
11447438|NCT01716988||Micafungin|
11447439|NCT01716975|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
11447440|NCT01716975|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
11447441|NCT01716975|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
11447442|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
11447443|NCT01716949|Experimental|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
11447444|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
11447445|NCT01716923|Experimental|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
11447446|NCT01716923|Active Comparator|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
11447447|NCT01716910|Placebo Comparator|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
11447448|NCT01716910|Active Comparator|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
11447449|NCT01716897|Other|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
11447450|NCT01716897|Other|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
11447451|NCT01716897|Other|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
11447452|NCT01716871|Active Comparator|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.
~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
11447453|NCT01716871|Active Comparator|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.
~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
11447454|NCT01716858|Experimental|A single-arm study|
11447455|NCT01716845||Development group 1|
11447456|NCT01716845||Development group 2|
11447457|NCT01716845||Development group 3|
11447458|NCT01716845||Validation group|
11447459|NCT01716832|Experimental|Mindfulness walking|
11447460|NCT01716832|No Intervention|No intervention (waiting list)|
11447461|NCT01716819|Other|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :
~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
11447462|NCT01716806|Experimental|Part A: Brentuximab Vedotin in HL Patients|
11447463|NCT01716806|Experimental|Part B: Brentuximab Vedotin + Dacarbazine in HL Patients|
11447464|NCT01716806|Experimental|Part C: Brentuximab Vedotin + Bendamustine in HL Patients|
11447465|NCT01716806|Experimental|Part D: Brentuximab Vedotin + Nivolumab in HL Patients|
11447466|NCT01716806|Experimental|Part E: Brentuximab Vedotin in HL Patients|
11447467|NCT01716806|Experimental|Part F: Brentuximab Vedotin in PTCL Patients|
11447468|NCT01716793|Other|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
11447469|NCT01716780|No Intervention|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
11447470|NCT01716780|Experimental|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
11447471|NCT01716767|Experimental|Menthol|Biofreeze topical gel containing 3.5% menthol
11447472|NCT01716767|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
11447473|NCT01716754|Experimental|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
11447474|NCT01716754|Experimental|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
11447475|NCT01716754|Experimental|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
11447476|NCT01716754|Experimental|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
11447477|NCT01716754|Experimental|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
11447478|NCT01716754|Experimental|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
11448121|NCT01712607|No Intervention|No Warm-up|Surgery without warm-up exercise
11447479|NCT01716754|Active Comparator|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
11447480|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
11447481|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
11447482|NCT01716754|Placebo Comparator|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
11447483|NCT01716754|Placebo Comparator|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
11447484|NCT01716754|Placebo Comparator|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
11447485|NCT01716754|Placebo Comparator|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
11447486|NCT01716754|Placebo Comparator|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
11447487|NCT01716741|Other|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
11447488|NCT01716728|No Intervention|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
11447489|NCT01716715|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
11447490|NCT01716715|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
11447491|NCT01716702|Experimental|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.
~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
11447492|NCT01716702|No Intervention|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
11447493|NCT01716689|Experimental|Patients with advanced sarcoma|
11447494|NCT01716676|Active Comparator|Standard CPAP follow-up|
11447495|NCT01716676|Experimental|Telemedicine CPAP follow-up|
11447496|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
11447497|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
11447498|NCT01716637|Active Comparator|Etanercept|25 mg administered weekly for 6 weeks
11447499|NCT01716637|Active Comparator|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
11447500|NCT01716624|Active Comparator|Oxybutynin|
11447501|NCT01716624|Experimental|Botulinum Toxin A injection|
11447502|NCT01716611|Active Comparator|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
11447503|NCT01716611|Placebo Comparator|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
11447504|NCT01716598|Experimental|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
11447505|NCT01716585|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11447506|NCT01716585|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11447507|NCT01716572|Active Comparator|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
11447508|NCT01716572|Active Comparator|erythromycin|administration of 250mgr of erythromycin before the endoscopy
11447509|NCT01716559||Cohort|
11447510|NCT01716546|Experimental|1|Panitumumab plus DCF
11447511|NCT01716533|Other|Recurrence group|Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
11447512|NCT01716533|Other|Sustained response group|Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
11447513|NCT01716533|Other|Failure to antibiotic Group|Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
11447514|NCT01716533|Other|Unclassified Group|Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
11447515|NCT01716520|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
11447516|NCT01716520|Experimental|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
11447517|NCT01716520|Experimental|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
11447518|NCT01716507|Other|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
11447519|NCT01716507|Other|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
11447520|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
11447521|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
11447522|NCT01716494||Normal control|Subjects that are healthy normals
11447523|NCT01716481|Experimental|Mesenchymal stem cell treatment|
11447524|NCT01716481|No Intervention|Standard treatment|
11447564|NCT01716234|Experimental|POS 18 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
11448485|NCT01710046|Experimental|Cohort 2|
11447525|NCT01716468|Other|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
11447526|NCT01716455|Experimental|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
11447527|NCT01716455|Experimental|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
11447528|NCT01716455|Experimental|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
11447529|NCT01716455|Experimental|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
11447530|NCT01716455|Experimental|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
11447531|NCT01716455|Experimental|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
11447532|NCT01716442|Active Comparator|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
11447533|NCT01716442|Active Comparator|steroid-dependent-rituximab|steroid-responsive group: n=38
11447534|NCT01716442|Placebo Comparator|steroid-dependent-placebo|steroid-responsive group: n=23
11447535|NCT01716429|Active Comparator|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
11447536|NCT01716429|Experimental|Vegan diet|Participants in this arm will follow a very low fat diet (~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
11447537|NCT01716416|Experimental|Dose Level 1|"Pazopanib 200 mg PO QD
~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
11447538|NCT01716416|Experimental|Dose Level 2|"Pazopanib 400 mg PO QD
~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
11447539|NCT01716416|Experimental|Dose Level 3|"Pazopanib 600 mg PO QD
~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
11447540|NCT01716416|Experimental|Dose Level 4|"Pazopanib 800 mg PO QD
~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
11447541|NCT01716416|Experimental|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD
~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
11447542|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
11447543|NCT01716390|Active Comparator|Drink that contains plant stanols|Dietary supplement: Plant stanol
11447544|NCT01716390|Placebo Comparator|Placebo drink|Dietary supplement: Placebo
11447545|NCT01716377|Placebo Comparator|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
11447546|NCT01716377|Active Comparator|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
11447547|NCT01716364|Experimental|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
11447548|NCT01716351|Experimental|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
11447549|NCT01716351|No Intervention|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
11447550|NCT01716338|Active Comparator|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
11447551|NCT01716338|Placebo Comparator|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
11447552|NCT01716325|Experimental|Weight loss - ICT support|Weight loss - ICT support
11447553|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
11447554|NCT01716312|Placebo Comparator|1|Subjects who were randomized to the placebo arm originally will receive 600 mg omalizumab by subcutaneous injection
11447555|NCT01716312|Active Comparator|2|Subjects in the omalizumab arm will receive 300 mg omalizumab by subcutaneous injection in a doubleblinded fashion
11447556|NCT01716286|Experimental|yoghurt type|low fat yoghurt vs. essence yoghurt
11447557|NCT01716273|Experimental|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
11447558|NCT01716273|Active Comparator|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
11447559|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
11447560|NCT01716247|Experimental|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
11447561|NCT01716234|Experimental|POS 12 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
11447562|NCT01716234|Experimental|POS 12 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
11447563|NCT01716234|Experimental|POS 18 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
11447676|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
11448486|NCT01710033|Placebo Comparator|Placebo|
11447565|NCT01716234|Experimental|POS 18 TID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
11447566|NCT01716234|Experimental|POS 18 TID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
11447567|NCT01716234|Experimental|POS 12 TID 3 months to <2 Years|Participants aged 3 months to <2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
11447568|NCT01716221|Experimental|Bupropion & Citalopram|100mg Bupropion & 20mg Citalopram taken orally one time per day or 100mg Bupropion & 10mg Citalopram taken orally one time per day or 50mg Bupropion & 20mg Citalopram taken orally one time per day 0r 50mg Bupropion & 10mg Citalopram taken orally one time per day
11447569|NCT01716221|Active Comparator|Bupropion & Placebo|100mg Bupropion & Placebo taken orally one time per day or 50mg Bupropion & Placebo taken orally one time per day
11447570|NCT01716221|Active Comparator|Placebo & Citalopram|Placebo & 20mg Citalopram taken orally one time per day or Placebo & 10mg Citalopram taken orally one time per day
11447571|NCT01716221|Placebo Comparator|Placebo & Placebo|Placebo & Placebo taken orally one time per day
11447572|NCT01716208|Experimental|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
11447573|NCT01716195|Experimental|6 weeks of Radiotherapy|Paclitaxel + Carboplatin (2 cycles) IV followed by Radiation Therapy (6 weeks) + Paclitaxel IV
11447574|NCT01716195|Experimental|5 weeks of Radiotherapy|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 (2 cycles) IV followed by Radiation Therapy (5 weeks) + Paclitaxel 175 mg/m2 IV
11447575|NCT01716182||transacral lumbar interbody fusion procedure|
11447576|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
11447577|NCT01716169|Experimental|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).
~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
11447578|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
11447579|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
11447580|NCT01716143|Other|catheter ablation|
11447581|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
11447582|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
11447583|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
11447584|NCT01716117|Experimental|Surpass Flow Diverter|The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
11447585|NCT01716104|Experimental|Afalaza (2 tablets twice a day)|
11447586|NCT01716104|Placebo Comparator|Placebo (2 tablets twice a day)|
11447587|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
11447588|NCT01716052|Active Comparator|Ibuprofen|Pfizer 200 mg caplets (Advil)
11447589|NCT01716052|Placebo Comparator|Placebo|Lactulose
11447590|NCT01716039|Active Comparator|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
11447591|NCT01716039|Active Comparator|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
11447592|NCT01716039|Placebo Comparator|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
11447593|NCT01716026|Active Comparator|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
11447594|NCT01716026|Experimental|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
11447595|NCT01716013|Experimental|BondEase|Topical Skin Adhesive
11447596|NCT01716013|Active Comparator|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
11447597|NCT01716000|Experimental|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
11447598|NCT01716000|Experimental|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
11447599|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
11447600|NCT01715987||Entecavir|Patients who are taking Entecavir.
11447601|NCT01715974|Placebo Comparator|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
11447602|NCT01715974|Experimental|G-CSF group|patients with recurrent implantation failure treated with G-CSF (60 micrograms/day) from the day of embryo transfer through the day of beta hCG test
11448487|NCT01710033|Experimental|CP-690,550 5 mg BID|
11447603|NCT01715961|Other|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months
~anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)
~albuminemia, transthyretin, orosomucoid, CRP
~functional test to attest the muscular strength: hand grip test, unipodal test, up and go test
~hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2
~OS and PFS at 18 and 24 months
~GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
11447604|NCT01715948|Experimental|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
11447605|NCT01715948|Experimental|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
11447606|NCT01715935|Experimental|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
11447607|NCT01715922|Other|oral treatment|"Drug: Fluconazole and flucytosine
~Induction treatment for 2 weeks:
~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
11447608|NCT01715909|Experimental|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants <1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
11447609|NCT01715909|Experimental|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants <1 year will receive standard dose at 3 mg/kg.
11447610|NCT01715896|Experimental|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
11447611|NCT01715896|Experimental|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
11447612|NCT01715883|Experimental|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:
~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.
~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.
~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
11447613|NCT01715870||"Population of the Epidemiological study on AMD."|
11447614|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
11447615|NCT01715844|Active Comparator|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
11447616|NCT01715844|Placebo Comparator|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
11447617|NCT01715831|Experimental|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
11447618|NCT01715818|Experimental|Aleglitazar|
11447619|NCT01715818|Placebo Comparator|Placebo|
11447620|NCT01715805|Other|Placebo + ADT Lead-in|Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
11447621|NCT01715805|Placebo Comparator|Placebo + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
11447622|NCT01715805|Experimental|Cariprazine + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
11447623|NCT01715805|Other|Placebo + ADT (Continued Treatment)|Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
11447624|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
11447625|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
11447626|NCT01715753|Active Comparator|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
11447677|NCT01715415|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11447627|NCT01715753|Experimental|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
11447628|NCT01715740|Experimental|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
11447629|NCT01715740|Placebo Comparator|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
11447630|NCT01715727||Parkinson's Disease for follow-up|"Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.
~Able to tolerate the disability during the drug-off state, at least for 12 hours.
~Able to understand and provide signed informed consent.
~Early to moderate stage defined as Hohen and Yahr stage 1-3,"
11447631|NCT01715727||"Parkinsonss Disease with severity match"|"Parkinsonss Disease with severity match: 30 subjects
~Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.
~Able to tolerate the disability during the drug-off state, at least for 12 hours.
~Able to understand and provide signed informed consent.
~Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
11447632|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112
~Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.
~Able to understand and provide signed informed consent.
~Age range and gender matched with Parkinsonss Disease for follow up."
11447633|NCT01715727||Parkinson Plus Syndrome Group M|"MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA
~Able to tolerate the disability during the drug-off state, at least for 12 hours.
~Able to understand and provide signed informed consent"
11447634|NCT01715727||Parkinson Plus Syndrome Group P|"PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP
~Able to tolerate the disability during the drug-off state, at least for 12 hours.
~Able to understand and provide signed informed consent."
11447635|NCT01715714|Active Comparator|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
11447636|NCT01715714|Placebo Comparator|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
11447637|NCT01715701|Experimental|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
11447638|NCT01715701|Active Comparator|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
11447639|NCT01715701|Active Comparator|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
11447640|NCT01715688|Active Comparator|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).
~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
11447641|NCT01715688|Placebo Comparator|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).
~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
11447642|NCT01715675|Active Comparator|plant stanol|
11447643|NCT01715675|Placebo Comparator|control|
11447678|NCT01715415|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11447679|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
11447743|NCT01714960|Experimental|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
11447744|NCT01714960|Placebo Comparator|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
11448488|NCT01710033|Experimental|CP-690,550 15 mg BID|
11447644|NCT01715662|Experimental|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
11447645|NCT01715662|Placebo Comparator|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
11447646|NCT01715649|No Intervention|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
11447647|NCT01715649|Experimental|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
11447648|NCT01715636|Other|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
11447649|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
11447650|NCT01715623||healthy volunteers|healthy volunteers without allergy
11447651|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
11447652|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
11447653|NCT01715610|Active Comparator|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
11447654|NCT01715610|Placebo Comparator|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
11447655|NCT01715597|Experimental|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
11447656|NCT01715597|Placebo Comparator|Control|Normal saline 500ml IV infusion for 2hour
11447657|NCT01715584|Other|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide
~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.
~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
11447658|NCT01715584|Other|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide
~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).
~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
11447659|NCT01715584|Other|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide
~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
11447660|NCT01715571|Experimental|men with mild to moderate ED|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
11447661|NCT01715558||RYTHMIQ study group|
11447662|NCT01715558||Historical control from OPTI-MIND|
11447663|NCT01715545||day-3 poor quality embryos|
11447664|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
11447665|NCT01715532|Experimental|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
11447666|NCT01715532|Active Comparator|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
11447667|NCT01715519|Experimental|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
11447668|NCT01715519|Placebo Comparator|Placebo|will be compared to the treatment group (viibryd)
11447669|NCT01715506|Experimental|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
11447670|NCT01715493|Experimental|Lysozyme 90 mg|
11447671|NCT01715493|Placebo Comparator|Placebo|
11447672|NCT01715480|Experimental|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
11447673|NCT01715441|Active Comparator|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
11447674|NCT01715441|Active Comparator|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
11447675|NCT01715441|Experimental|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions
~Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
11447680|NCT01715389|Experimental|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.
~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
11447681|NCT01715389|No Intervention|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
11447682|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
11447683|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
11447684|NCT01715363|Experimental|FOLFOX + surgery + FOLFOX|"Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery
~resection of the colorectal tumor during surgery
~Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
11447685|NCT01715350|Placebo Comparator|Placebo group|"• Drug : Placebo 2 tablet
~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
11447686|NCT01715350|Experimental|Dose group 1|"Drug : Placebo 1 tablet + Study drug 1 tablet
~Study drug(650-mg PM012 tablet)
~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
11447687|NCT01715350|Experimental|Dose group 2|"Drug : Study drug 2 tablet
~Study drug (650-mg PM012 tablet)
~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
11447688|NCT01715337|Other|pulmonary rehabilitation|
11447689|NCT01715324|Experimental|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
11447690|NCT01715324|No Intervention|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
11447691|NCT01715311|Experimental|Indacaterol|Indacaterol once daily
11447692|NCT01715311|Placebo Comparator|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
11447693|NCT01715311|Active Comparator|Tiotropium|Tiotropium
11447694|NCT01715298|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
11447695|NCT01715298|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
11447696|NCT01715285|Experimental|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) along with 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
11447697|NCT01715285|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate and prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
11447698|NCT01715272|Active Comparator|Fleet enema|This group will receive Fleet enema as their treatment
11447699|NCT01715272|Experimental|TF037|This group will receive TF037 as their treatment
11447700|NCT01715259|Experimental|Abiraterone acetate|
11447701|NCT01715246|Placebo Comparator|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
11447702|NCT01715246|Active Comparator|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
11447703|NCT01715246|No Intervention|Breasfed reference group|
11447704|NCT01715233|Experimental|Metastatic Esophageal, Gastroesophageal & Gastric Cancer|Participants receive Modified Docetaxel 40mg/m2, Leucovorin 400mg/m2 and Fluorouracil 400mg/m2 on day 1, Fluorouracil 1000mg/m2 per day on days 1 and 2 and Cisplatin 40mg/m2 (or Carboplatin) on day 3 in Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
11447705|NCT01715220|Active Comparator|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
11447706|NCT01715220|Placebo Comparator|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
11447707|NCT01715207|Experimental|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
11447708|NCT01715207|Other|Atenolol|Atenolol tablet(Negative controls, Open-label)
11447740|NCT01714973|Experimental|ST266 inflamed|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The second cohort will receive ST266 and saline placebo applied to inflamed skin (after inflammation is first noted) beginning immediately following the radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
11447741|NCT01714960|Experimental|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
11448489|NCT01710033|Experimental|CP-690,550 30 mg BID|
11447709|NCT01715194|Active Comparator|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if
~CPAP was used <4h/ night for 2 consecutive night
~the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
11447710|NCT01715194|No Intervention|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
11447711|NCT01715181|No Intervention|Usual care|Individuals will receive usual care
11447712|NCT01715181|Experimental|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
11447713|NCT01715168|Active Comparator|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
11447714|NCT01715168|Experimental|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
11447715|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
11447716|NCT01715142|Experimental|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
11447717|NCT01715129|Experimental|11.25mg|11.25mg, SC on Day 1 and Day 92
11447718|NCT01715116|Experimental|Enhanced ICD programming|
11447719|NCT01715103|Other|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
11447720|NCT01715103|Other|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
11447721|NCT01715090|Experimental|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
11447722|NCT01715090|No Intervention|Standard care|
11447723|NCT01715077|Experimental|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
11447724|NCT01715064|No Intervention|Control|non-exercise control consisting of movie watching.
11447725|NCT01715064|Experimental|Exercise|1 hour of moderate intensity exercise.
11447726|NCT01715051|Active Comparator|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
11447727|NCT01715051|Placebo Comparator|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
11447728|NCT01715038|Experimental|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
11447729|NCT01715038|Experimental|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
11447730|NCT01715038|Experimental|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
11447731|NCT01715038|Active Comparator|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
11447732|NCT01715025|Experimental|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
11447733|NCT01715012|Experimental|ST266|ST266 sprayed to the skin graft and donor site
11447734|NCT01715012|Placebo Comparator|Saline|Saline (placebo)sprayed to the skin graft and donor site
11447735|NCT01714999|Experimental|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
11447736|NCT01714999|Experimental|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
11447737|NCT01714986|Active Comparator|Affect School|Psychological group education intervention
11447738|NCT01714986|Active Comparator|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
11447739|NCT01714973|Experimental|ST266 intact|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The first cohort will receive ST266 and saline placebo applied to intact skin beginning immediately following the first radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
11447742|NCT01714960|Experimental|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
11447745|NCT01714947|Experimental|Alisertib|"Part A: [^14C]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.
~Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles)."
11447746|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
11447747|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
11447748|NCT01714921||ICD patients|Patients with an indication for an ICD implantation according to the guidelines treated with a Protecta™, Protecta™ XT or any equivalent following product
11447749|NCT01714908|Experimental|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
11447750|NCT01714908|Active Comparator|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
11447751|NCT01714895|Other|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
11447752|NCT01714895|Other|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
11447753|NCT01714882|Experimental|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
11447754|NCT01714882|Active Comparator|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
11447755|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
11447756|NCT01714856|Experimental|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
11447757|NCT01714856|Experimental|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
11447758|NCT01714843|Experimental|ASP0456 lowest dose group|oral
11447759|NCT01714843|Experimental|ASP0456 low dose group|oral
11447760|NCT01714843|Experimental|ASP0456 middle dose group|oral
11447761|NCT01714843|Experimental|ASP0456 high dose group|oral
11447762|NCT01714843|Placebo Comparator|placebo group|oral
11447763|NCT01714830|Sham Comparator|sham group|the same protocol is applied but with the probe being turned off.
11447764|NCT01714830|Sham Comparator|treatment group|patients will be treated by ESWT once a week for 4 weeks
11447765|NCT01714817|Experimental|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
11447766|NCT01714817|Placebo Comparator|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
11447767|NCT01714804|Experimental|Prospective|Accell Evo3
11447768|NCT01714791|Active Comparator|Usual care|Patients following the outpatient cardiac rehabilitation program.
11447769|NCT01714791|Experimental|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
11447770|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
11447771|NCT01714765|Other|Dovitinib and Everolimus|No Arms
11447772|NCT01714752|Experimental|exercise|Patients perform exercise and pression measure is performed
11447773|NCT01714739|Experimental|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
11447774|NCT01714739|Experimental|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
11447775|NCT01714739|Experimental|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab (Study Part 4 Removed; No Subjects Enrolled)
11447776|NCT01714739|Experimental|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab (Study Part 6 Removed; No Subjects Enrolled)
11447777|NCT01714726|Experimental|1|MEDI2070 iv infusion
11447778|NCT01714726|Placebo Comparator|2|placebo iv infusion
11447779|NCT01714726|Experimental|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
11447780|NCT01714713|Experimental|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
11447781|NCT01714713|Experimental|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
11447782|NCT01714700|Active Comparator|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
11447783|NCT01714700|Placebo Comparator|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
11447784|NCT01714687|Active Comparator|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
11447785|NCT01714687|Active Comparator|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
11447786|NCT01714674|Placebo Comparator|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
11447787|NCT01714674|Active Comparator|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
11447788|NCT01714661|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
11447789|NCT01714661|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
11448490|NCT01710020|Experimental|CP-690,550|
11447790|NCT01714661|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
11447791|NCT01714648|Experimental|OHSS high risk patients|Triptorelin 0.2 mg
11447792|NCT01714635|Experimental|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
11447793|NCT01714635|Experimental|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
11447794|NCT01714635|Active Comparator|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
11447795|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
11447796|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
11447797|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
11447798|NCT01714609|Placebo Comparator|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
11447799|NCT01714609|Experimental|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
11447800|NCT01714596|Active Comparator|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
11447801|NCT01714596|Active Comparator|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
11447802|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
11447803|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
11447804|NCT01714570|Experimental|piperacillin/tazobactam|
11447805|NCT01714570|Active Comparator|imipenem/cilastatin|
11447806|NCT01714557|No Intervention|No prophylaxis|
11447807|NCT01714557|Active Comparator|piperacillin|
11447808|NCT01714557|Experimental|piperacillin/tazobactam|
11447809|NCT01714544|Experimental|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
11447810|NCT01714531|Experimental|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
11447811|NCT01714531|Active Comparator|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
11447812|NCT01714531|No Intervention|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
11447813|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
11447814|NCT01714505|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
11447815|NCT01714505|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
11447816|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
11447817|NCT01714479|Placebo Comparator|Load Carriage - Control|Load Carriage - with a calorie-free placebo
11447818|NCT01714479|Experimental|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
11447819|NCT01714479|Placebo Comparator|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
11447820|NCT01714479|Active Comparator|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
11447821|NCT01714466|Experimental|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
11447822|NCT01714466|Experimental|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
11447823|NCT01714466|Experimental|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
11447824|NCT01714466|Active Comparator|Part A, arm 4|MOVIPREP (Both evening and morning dose)
11447825|NCT01714466|Experimental|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
11447826|NCT01714466|Experimental|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
11447827|NCT01714466|Active Comparator|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
11447828|NCT01714466|Experimental|Part B, arm 4|MOVIPREP used in both evening and morning dose
11447829|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
11447830|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
11447956|NCT01713582|Experimental|AL 160 mg QD 14-21|Participants received 160 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447831|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
11447832|NCT01714427|Active Comparator|Dexamethasone|
11447833|NCT01714427|Placebo Comparator|Sterile isotonic saline|
11447834|NCT01714414|Experimental|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
11447835|NCT01714414|Experimental|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
11447836|NCT01714414|Experimental|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
11447837|NCT01714414|Active Comparator|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
11447838|NCT01714401|Active Comparator|Salbutamol 2,5 mg|25 mechanically ventilated patients to receive 2,5mg of nebulised salbtamol (Ventolin) duration of nebulisation - 20 minutes
11447839|NCT01714401|Active Comparator|Salbutamol 5mg|25 mechanically ventilated patients 5 mg of nebulised salbutamol (Ventolin) duration of nebulisation - 20 minutes
11447840|NCT01714388|Experimental|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
11447841|NCT01714375|Active Comparator|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
11447842|NCT01714375|No Intervention|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
11447843|NCT01714375|Active Comparator|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
11447844|NCT01714349|Experimental|Nerve Transfer|Surgical - Nerve transfers for patients with stable cervical spinal cord injuries
11447845|NCT01714336|Placebo Comparator|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
11447846|NCT01714336|Active Comparator|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
11447847|NCT01714323|Other|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
11447848|NCT01714323|Experimental|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
11447849|NCT01714310|Experimental|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
11447850|NCT01714310|Placebo Comparator|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
11447851|NCT01714310|Other|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
11447852|NCT01714297|Active Comparator|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
11447853|NCT01714297|Placebo Comparator|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
11447854|NCT01714284|Experimental|Diet and Exercise|
11447855|NCT01714284|Sham Comparator|Informative|
11447856|NCT01714271|Experimental|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
11447857|NCT01714271|Experimental|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
11447858|NCT01714258|Experimental|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
11447859|NCT01714232|Experimental|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
11447957|NCT01713582|Experimental|AML de novo 80 mg QD 14-21|Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11448491|NCT01710007|Experimental|1PC002|2 mg 1PC002 once daily for 12 weeks.
11447860|NCT01714219|Experimental|Posterior reconstruction|"New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron
~Vesicourethral anastomosis using the van Velthoven method
~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
11447861|NCT01714219|No Intervention|No posterior reconstruction|"No posterior reconstruction
~Vesicourethral anastomosis using the van Velthoven method
~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
11447862|NCT01714206|Active Comparator|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
11447863|NCT01714206|Experimental|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
11447864|NCT01714193|Experimental|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
11447865|NCT01714180||Obese Patients|
11447866|NCT01714180||Non-obese Patients|
11447867|NCT01714167|Active Comparator|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
11447868|NCT01714167|No Intervention|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
11447869|NCT01714154|Experimental|A: setrobuvir|
11447870|NCT01714154|Experimental|B: setrobuvir + DNV/r|
11447871|NCT01714141|Experimental|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
11447872|NCT01714141|Active Comparator|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
11447873|NCT01714128|Other|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
11447874|NCT01714102|Placebo Comparator|Placebo|Placebo for 30 days
11447875|NCT01714102|Active Comparator|Resveratrol|1000 mg PO BID for 30 days
11447876|NCT01714089|Experimental|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
11447877|NCT01714089|Experimental|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
11447878|NCT01714089|Active Comparator|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
11447879|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
11447880|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
11447881|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
11447882|NCT01714050|Experimental|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
11447883|NCT01714050|Experimental|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
11447884|NCT01714037|Experimental|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
11447885|NCT01714037|Experimental|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
11447886|NCT01714037|Experimental|Docetaxel, Debio 0932|Docetaxel, Debio 0932
11447887|NCT01714024|Experimental|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
11447888|NCT01714024|Experimental|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
11447889|NCT01714024|Experimental|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
11447890|NCT01714011|Active Comparator|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
11447958|NCT01713582|Experimental|AML/MDS 80 mg QD 14-21|Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11448492|NCT01710007|Active Comparator|Lipitor|10 mg atorvastatin once daily for 12 weeks.
11447891|NCT01714011|Active Comparator|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-[ 4-[ 4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
11447892|NCT01713998|Active Comparator|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
11447893|NCT01713998|Active Comparator|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
11447894|NCT01713998|Active Comparator|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
11447895|NCT01713985|Active Comparator|Group A|Ulthera System Treatment Right, Thermage Left
11447896|NCT01713985|Active Comparator|Group B|Ulthera System Treatment Left, Thermage Right
11447897|NCT01713972|Experimental|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11447898|NCT01713972|Other|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:
~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12
~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1
~Tumor genotyping: Archival tumor blocks or unstained slides
~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
11447899|NCT01713959|Experimental|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
11447900|NCT01713959|Active Comparator|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
11447901|NCT01713946|Experimental|Everolimus LT target of 3 - 7 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
11447902|NCT01713946|Experimental|Everolimus HT target of 9 -15 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
11447903|NCT01713946|Placebo Comparator|Placebo|Participants received placebo plus 1 to 3 antiepileptic drugs.
11447904|NCT01713933|Experimental|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
11447905|NCT01713920|Experimental|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
11447906|NCT01713907|Experimental|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
11447907|NCT01713894|Other|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
11447908|NCT01713894|Other|Standard|In this arm of the study, parents will be counseled using current standard methods.
11447909|NCT01713881||post-registry|"Registry Group:
~Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.
~Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
11447910|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
11447911|NCT01713868|Other|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
11447912|NCT01713868|Other|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
11447913|NCT01713868|Other|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
11447914|NCT01713868|Other|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
11447915|NCT01713842|Experimental|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
11447916|NCT01713829|Experimental|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
11447917|NCT01713829|Placebo Comparator|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
11447918|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
11447919|NCT01713803|Placebo Comparator|Sugar pill|
11447920|NCT01713803|Experimental|buprenorphine and nalaxone|
11447921|NCT01713790|Experimental|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
11447922|NCT01713777|Experimental|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
11447923|NCT01713777|Experimental|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
11447959|NCT01713582|Experimental|OHM 10 mg QD 21-21|Participants received 10 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
11447960|NCT01713582|Experimental|OHM 20 mg QD 21-21|Participants received 20 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
11447961|NCT01713582|Experimental|OHM 40 mg QD 21-21|Participants received 40 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
11447924|NCT01713764|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.
~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
11447925|NCT01713764|Active Comparator|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.
~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
11447926|NCT01713751|Active Comparator|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
11447927|NCT01713751|Active Comparator|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene [Prolene®].
11447928|NCT01713738|Experimental|rituximab|
11447929|NCT01713725|Active Comparator|Omalizumab 300 mg|"Subcutaneous route
~300 mg dose (independent from total IgE, weight or high)"
11447930|NCT01713725|Placebo Comparator|Placebo|"Saline serum
~Subcutaneous route
~0.6 ml saline serum with same volume as an active treatment"
11447931|NCT01713712|No Intervention|Routine Obstetric Care|
11447932|NCT01713712|Experimental|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
11447933|NCT01713699|Other|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
11447934|NCT01713686|Experimental|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
11447935|NCT01713673|Experimental|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
11447936|NCT01713673|Sham Comparator|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
11447937|NCT01713660|Other|FS Corneal Incisions|
11447938|NCT01713647|Experimental|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days
~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
11447939|NCT01713647|Active Comparator|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days
~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
11447940|NCT01713634|Experimental|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
11447941|NCT01713634|Experimental|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
11447942|NCT01713621|Experimental|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
11447943|NCT01713621|Experimental|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
11447944|NCT01713608|Experimental|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active [A] and 4 on Placebo [P]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
11447945|NCT01713608|Experimental|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
11447946|NCT01713608|Experimental|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
11447947|NCT01713595|Experimental|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
11447948|NCT01713582|Experimental|AL 10 mg QD 14-21|Participants received 10 mg MK-8628/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.
11447949|NCT01713582|Experimental|AL 20 mg QD 14-21|Participants received 20 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447950|NCT01713582|Experimental|AL 40 mg QD 14-21|Participants received 40 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447951|NCT01713582|Experimental|AL 20 mg BID 21-21|Participants received 20 mg MK-8628/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
11447952|NCT01713582|Experimental|AL 80 mg QD 14-21|Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447953|NCT01713582|Experimental|AL 40 mg BID 14-21|Participants received 40 mg MK-8628/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.
11447954|NCT01713582|Experimental|AL 120 mg QD 14-21|Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447955|NCT01713582|Experimental|AL 120 mg QD 21-21|Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
11448037|NCT01713114|Experimental|Low carbohydrate|
11447962|NCT01713582|Experimental|OHM 80 mg QD 21-21|Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
11447963|NCT01713582|Experimental|OHM 40 mg BID 21-21|Participants received 40 mg MK-8628/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
11447964|NCT01713582|Experimental|OHM 120 mg QD 21-21|Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
11447965|NCT01713582|Experimental|OHM 120 mg QD 14-21|Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447966|NCT01713582|Experimental|OHM 120 mg QD 5-7|Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.
11447967|NCT01713582|Experimental|OHM 120 mg QD 7-21|Participants received 120 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle
11447968|NCT01713582|Experimental|OHM/DLBCL 80 mg QD 14-21|Participants received 80 mg MK-8628/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
11447969|NCT01713569|Active Comparator|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
11447970|NCT01713569|Active Comparator|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
11447971|NCT01713569|Active Comparator|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
11447972|NCT01713569|Active Comparator|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
11447973|NCT01713569|Active Comparator|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
11447974|NCT01713569|Active Comparator|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
11447975|NCT01713556|Experimental|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
11447976|NCT01713556|Placebo Comparator|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
11447977|NCT01713543|Experimental|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
11447978|NCT01713543|No Intervention|Control Group|Usual care by physician.
11447979|NCT01713530|Experimental|IDegAsp BID+/-OADs|
11447980|NCT01713530|Experimental|IDeg OD plus IAsp +/-OADs|
11447981|NCT01713517|Active Comparator|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
11447982|NCT01713517|Experimental|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
11447983|NCT01713504|Experimental|Hypereosinophilic syndrome unexplained|
11447984|NCT01713504|Active Comparator|Hypereosinophilic syndrome explained|
11447985|NCT01713504|Sham Comparator|Normal rate of eosinophilic|
11447986|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
11447987|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
11447988|NCT01713491||Demented|IQCODE score 64 or more
11447989|NCT01713478|Experimental|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis
~Routine blood samples
~Electrocardiogram (12 leads)
~Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.
~Comprehensive Echocardiography"
11447990|NCT01713478|Active Comparator|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
11447991|NCT01713465|Experimental|1 CBMP|CBMP: Computer based Metabolic syndrome program
11447992|NCT01713452|Active Comparator|Purse string closure|Patients undergo a purse string closure of their old stoma site.
11447993|NCT01713452|Active Comparator|Primary closure|Patients have their stoma sites close primarily with staples.
11447994|NCT01713439|Experimental|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
11447995|NCT01713426|Experimental|Qutenza|Cutaneous patch
11447996|NCT01713426|Active Comparator|Pregabalin|Oral capsule
11447997|NCT01713413|Active Comparator|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
11447998|NCT01713413|Active Comparator|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
11448038|NCT01713114|Experimental|Moderate carbohydrate|
11448039|NCT01713114|Experimental|Higher Carbohydrate|
11448040|NCT01713114|Placebo Comparator|Meal Skipping|
11447999|NCT01713400|Experimental|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
11448000|NCT01713400|Placebo Comparator|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
11448001|NCT01713387|Experimental|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
11448002|NCT01713374|Active Comparator|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
11448003|NCT01713374|Active Comparator|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
11448004|NCT01713374|Active Comparator|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
11448005|NCT01713374|Active Comparator|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
11448006|NCT01713361|Experimental|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
11448007|NCT01713361|Experimental|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
11448008|NCT01713361|Active Comparator|Enoxaparin|Enoxaparin (40mg)
11448009|NCT01713348|Experimental|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
11448010|NCT01713348|Active Comparator|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
11448011|NCT01713322|Experimental|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
11448012|NCT01713322|Other|No pain management education|Control - parents receive general information about childhood immunization.
11448013|NCT01713309|Active Comparator|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
11448014|NCT01713309|Placebo Comparator|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
11448015|NCT01713296|Experimental|Pazopanib|
11448016|NCT01713283|Experimental|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
11448017|NCT01713283|Experimental|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
11448018|NCT01713270|Experimental|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
11448019|NCT01713270|Active Comparator|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
11448020|NCT01713257|Experimental|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
11448021|NCT01713257|Active Comparator|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
11448022|NCT01713244|Active Comparator|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
11448023|NCT01713244|Experimental|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
11448024|NCT01713231|Active Comparator|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
11448025|NCT01713231|Experimental|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
11448026|NCT01713218|Experimental|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
11448027|NCT01713192||Cardiac surgery|
11448028|NCT01713179|Experimental|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).
~one dose for one day"
11448029|NCT01713179|No Intervention|control|
11448030|NCT01713166|Active Comparator|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
11448031|NCT01713166|Experimental|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
11448032|NCT01713153|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
11448033|NCT01713153|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
11448034|NCT01713140|Experimental|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
11448035|NCT01713127|Placebo Comparator|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
11448036|NCT01713127|Active Comparator|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
11448041|NCT01713101|Experimental|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid
~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
11448042|NCT01713101|Placebo Comparator|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
11448043|NCT01713088|Experimental|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
11448044|NCT01713088|Active Comparator|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
11448045|NCT01713075||Symbicort|
11448046|NCT01713062||Vitelene|Plasmacup DC® with Vitelene® inlay manufactured by UHMWPE-XE (Ultra High Molecular Weight Polyethylene highly cross-linked with 0.1% Vitamin E) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
11448047|NCT01713062||XLPE|Plasmacup DC® with a standard polyethylene inlay manufactured by UHMWPE-X (Ultra High Molecular Weight Polyethylene highly cross-linked) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
11448048|NCT01713049|Other|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
11448049|NCT01713036|Experimental|Pimasertib|
11448050|NCT01713023|Experimental|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
11448051|NCT01713023|Experimental|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
11448052|NCT01712997|Experimental|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
11448053|NCT01712997|Active Comparator|monotherapy|Bosentan,125mg,po,bid.
11448054|NCT01712984|Experimental|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
11448055|NCT01712984|Active Comparator|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
11448056|NCT01712984|Active Comparator|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
11448057|NCT01712971||OPD|standard open pancreaticoduodenectomy
11448058|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
11448059|NCT01712945|Experimental|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
11448060|NCT01712945|Placebo Comparator|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
11448061|NCT01712919|Experimental|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
11448062|NCT01712906|Experimental|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
11448063|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
11448064|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
11448065|NCT01712906|Placebo Comparator|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
11448066|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
11448067|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
11448068|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
11448069|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
11448070|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
11448071|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
11448072|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
11448073|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
11448074|NCT01712906|Active Comparator|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
11448075|NCT01712906|Experimental|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
11448076|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
11448077|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
11448078|NCT01712906|Placebo Comparator|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
11448079|NCT01712906|Active Comparator|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
11448080|NCT01712893|Experimental|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
11448081|NCT01712893|Active Comparator|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
11448082|NCT01712880|Active Comparator|open debridement with modular exchange|
11448083|NCT01712880|Active Comparator|one stage exchange|
11448084|NCT01712867|Experimental|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
11448085|NCT01712867|Active Comparator|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
11448086|NCT01712854|Experimental|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
11448087|NCT01712854|Placebo Comparator|Budesonide only|Budesonide 80 mcg (Entocort EC) only
11448088|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
11448089|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (>125µ) and pigmentary changes without geographic atrophy
11448090|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
11448091|NCT01712828|Experimental|Lenalidomide plus Quinidine|
11448092|NCT01712828|Experimental|Lenalidomide plusTemsirolimus and Diphenhydramine|
11448093|NCT01712815|Experimental|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
11448094|NCT01712802|Experimental|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
11448095|NCT01712802|Experimental|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
11448096|NCT01712802|Placebo Comparator|control|Parallel arm that receive placebo.
11448097|NCT01712789|Experimental|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
11448098|NCT01712776|Active Comparator|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
11448099|NCT01712776|Placebo Comparator|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
11448100|NCT01712763|Experimental|Degarelix|50 women will be treated with degarelix 80mg in one administration
11448101|NCT01712763|Active Comparator|Goserelin|goserelin 3.6mg monthly for three months
11448102|NCT01712750||VOT on bypass|
11448103|NCT01712737|Experimental|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
11448104|NCT01712737|Experimental|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
11448105|NCT01712737|Experimental|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
11448106|NCT01712737|Experimental|Water control|children were given ad libitum access to water
11448107|NCT01712724|Active Comparator|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
11448108|NCT01712724|Experimental|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
11448109|NCT01712711|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
11448110|NCT01712711|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
11448111|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
11448112|NCT01712685|Experimental|Renal Cell Carcinoma|
11448113|NCT01712672||1|Healthy participants
11448114|NCT01712659|Experimental|1- CLOSED|Ruxolitinib 20mg orally twice daily for 28 days. Patient may continue to receive treatment until PD.
11448115|NCT01712659|Experimental|2- Dose Escalation|Ruxolitinib 30-50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Patients may continue to receive treatment until PD or unacceptable toxicity.
11448116|NCT01712659|Experimental|3- Dose Expansion|Ruxolitinib at the MTD orally twice daily for 28 days. Patients may continue to receive treatment until PD or unacceptable toxicity.
11448117|NCT01712633||Volunteers|Healthy Volunteers
11448118|NCT01712620|Experimental|Group A|Spironolactone
11448119|NCT01712620|Placebo Comparator|Group B|Placebo
11448120|NCT01712607|Experimental|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
11448122|NCT01712594|Active Comparator|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
11448123|NCT01712594|Active Comparator|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
11448124|NCT01712581|Experimental|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
11448125|NCT01712568|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
11448126|NCT01712568|Experimental|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
11448127|NCT01712555|Experimental|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
11448128|NCT01712529|Experimental|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
11448129|NCT01712529|No Intervention|No supervised physical exercise|No intervention for 16 weeks
11448130|NCT01712516|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
11448131|NCT01712516|Active Comparator|QAB149|27.5 ug b.i.d.
11448132|NCT01712516|Active Comparator|NVA237|12.5 ug b.i.d.
11448133|NCT01712516|Placebo Comparator|Placebo|b.i.d.
11448134|NCT01712503|Experimental|Toric intraocular lens|TFlex Lens (623T)
11448135|NCT01712503|Placebo Comparator|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
11448136|NCT01712490|Experimental|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
11448137|NCT01712490|Active Comparator|ABVD|ABVD consists of doxorubicin 25 mg/m^2, bleomycin 10 units per square meter (units/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
11448138|NCT01712477|Active Comparator|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
11448139|NCT01712477|Active Comparator|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
11448140|NCT01712464|Other|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
11448141|NCT01712464|Other|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
11448142|NCT01712451|Experimental|LIPO-102, Low|
11448143|NCT01712451|Experimental|LIPO-102, Mid|
11448144|NCT01712451|Experimental|LIPO-102, High|
11448145|NCT01712451|Experimental|LIPO-102; Placebo|
11448146|NCT01712451|Experimental|salmeterol xinafoate|
11448147|NCT01712438|Experimental|Human cl rhFVIII|
11448148|NCT01712425|Experimental|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
11448149|NCT01712425|Experimental|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
11448150|NCT01712425|No Intervention|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
11448151|NCT01712425|No Intervention|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
11448152|NCT01712412|Experimental|IW-9179|Oral IW-9179 taken daily for two weeks
11448153|NCT01712412|Placebo Comparator|Placebo|Oral placebo taken daily for two weeks
11448154|NCT01712399|Experimental|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
11448155|NCT01712386|Experimental|COPD|
11448156|NCT01712373|Active Comparator|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
11448157|NCT01712373|Placebo Comparator|Placebo|Placebo, tablet
11448158|NCT01712360|Experimental|NAFT500 (pediatric)|Topical once a day for two weeks
11448159|NCT01712360|Experimental|NAFT600 (pediatric)|Topical once a day for two weeks
11448160|NCT01712360|Experimental|NAFT500 (adult)|Topical once a day for two weeks
11448161|NCT01712360|Experimental|NAFT600 (adult)|Topical once a day for two weeks
11448162|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
11448163|NCT01712334|Experimental|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
11448164|NCT01712334|Active Comparator|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
11448165|NCT01712321|Experimental|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
11448166|NCT01712321|Placebo Comparator|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
11448167|NCT01712308|Experimental|Treatment (sotatercept)|Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
11448168|NCT01712295|Experimental|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
11448493|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
11448169|NCT01712295|Active Comparator|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
11448170|NCT01712282|Experimental|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
11448171|NCT01712269|Experimental|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
11448172|NCT01712256|Experimental|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
11448173|NCT01712243|Active Comparator|Dim light|15 minutes of very dim (<1 lux) light during the night
11448174|NCT01712243|Active Comparator|Room light|15 minutes of normal room light (~100 lux) during the night
11448175|NCT01712243|Experimental|Colored light|15 minutes of colored light during the night
11448176|NCT01712230|Placebo Comparator|Placebo|Monthly placebo injections for 6 months
11448177|NCT01712230|Active Comparator|GnRH agonist|Monthly GnRH agonist injections for 6 months
11448178|NCT01712230|Active Comparator|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
11448179|NCT01712217|Experimental|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
11448180|NCT01712217|Active Comparator|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
11448181|NCT01712217|Active Comparator|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
11448182|NCT01712204|Placebo Comparator|Placebo|Placebo plus Febuxostat
11448183|NCT01712204|Experimental|AC-201|AC-201 plus Febuxostat
11448184|NCT01712191|Experimental|NUsurface Meniscus Implant|
11448185|NCT01712178|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
11448186|NCT01712178|Active Comparator|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
11448187|NCT01712165|Active Comparator|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
11448188|NCT01712165|Placebo Comparator|Control|75g of milk powder in 400 ml water for 12 weeks.
11448189|NCT01712139|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
11448190|NCT01712139|Experimental|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
11448191|NCT01712126|Experimental|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
11448192|NCT01712126|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
11448193|NCT01712113|Experimental|irbesartan|300 mg tablet
11448194|NCT01712113|Active Comparator|Avapro|300 mg tablet
11448195|NCT01712100|Experimental|irbesartan|300 mg tablet
11448196|NCT01712100|Active Comparator|Avapro|300 mg tablet
11448197|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
11448198|NCT01712074|Experimental|30 mg QD of PF-05212377|
11448199|NCT01712074|Placebo Comparator|Placebo|
11448200|NCT01712061|Active Comparator|Arm 1 PF-04634817|
11448201|NCT01712061|Placebo Comparator|Arm 2 Placebo|
11448202|NCT01712048|Active Comparator|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
11448203|NCT01712048|Active Comparator|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
11448204|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
11448205|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
11448206|NCT01712022||Dry Eye|clinical diagnosis of dry eye
11448207|NCT01712022||Contact Lens|routine wear of contact lens
11448208|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
11448209|NCT01712009|Experimental|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
11448210|NCT01712009|Experimental|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
11448211|NCT01712009|Other|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
11448212|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
11448213|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
11448214|NCT01711996||Normal|0-3 year old children without hydronephrosis
11448215|NCT01711983|Experimental|Test Device|ASD closure with the GORE® CARDIOFORM Septal Occluder
11448216|NCT01711970|Experimental|VB-111|
11448494|NCT01709994|No Intervention|standard medication|the patients will continue with standard medication
11448217|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
11448218|NCT01711944|Experimental|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
11448219|NCT01711944|Active Comparator|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
11448220|NCT01711931|Active Comparator|Everolimus-eluting bioresorbable vascular scaffold stents|
11448221|NCT01711931|Active Comparator|Everolimus-eluting stent|
11448222|NCT01711931|Active Comparator|Biolimus-eluting stent|
11448223|NCT01711918|Experimental|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
11448224|NCT01711905|Experimental|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
11448225|NCT01711905|No Intervention|Placebo|Placebo for 12 weeks
11448226|NCT01711892|Active Comparator|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
11448227|NCT01711892|No Intervention|Control group|Usual care
11448228|NCT01711879|Active Comparator|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
11448229|NCT01711879|Experimental|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
11448230|NCT01711866|Experimental|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.
~Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.
~Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
11448231|NCT01711853|Experimental|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
11448232|NCT01711840||Symbicort|
11448233|NCT01711827|Experimental|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
11448234|NCT01711814|Experimental|ASP015K|Experimental
11448235|NCT01711801|Placebo Comparator|Part 1: Placebo|
11448236|NCT01711801|Experimental|Part 1: RO5545965|
11448237|NCT01711801|Experimental|Part 2: Food effect|
11448238|NCT01711788|Experimental|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
11448239|NCT01711775|Experimental|Aleglitazar|
11448240|NCT01711762|Experimental|GDC-0973 Single Arm|
11448241|NCT01711749|Active Comparator|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
11448242|NCT01711749|Active Comparator|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
11448243|NCT01711736|Experimental|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.
~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
11448244|NCT01711736|Active Comparator|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.
~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
11448245|NCT01711723|Experimental|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
11448246|NCT01711723|Experimental|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
11448247|NCT01711710|Experimental|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
11448248|NCT01711697|Experimental|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
11448249|NCT01711684|Experimental|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
11448250|NCT01711671|Experimental|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
11448251|NCT01711671|Experimental|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
11448252|NCT01711671|Active Comparator|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
11448253|NCT01711658|Placebo Comparator|Radiation therapy (IMRT) + cisplatin + placebo|Radiation therapy: Intensity Modulated Radiation Therapy (IMRT) + cisplatin + placebo
11448254|NCT01711658|Active Comparator|Radiation therapy (IMRT) + cisplatin + lapatinib|Radiation therapy: Intensity Modulated Radiation Therapy (IMRT) + cisplatin + lapatinib
11448255|NCT01711645|Experimental|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
11448256|NCT01711632|Experimental|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
11448257|NCT01711619|Experimental|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
11448258|NCT01711619|Active Comparator|OMM|optimized medical management
11448259|NCT01711606||unselected Fragile-X patients|
11448260|NCT01711593|Experimental|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
11448261|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
11448262|NCT01711567|Active Comparator|entecavir|standard drugs
11448263|NCT01711567|Active Comparator|tenofovir|study drugs
11448264|NCT01711554|Experimental|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11448265|NCT01711541|Experimental|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
11448266|NCT01711541|Experimental|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
11448267|NCT01711528|Experimental|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11448268|NCT01711528|Experimental|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11448269|NCT01711515|Experimental|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
11448270|NCT01711502||Female patients diagosed with metastatic breast cancer|
11448271|NCT01711489|Experimental|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
11448272|NCT01711476|Active Comparator|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
11448273|NCT01711476|Placebo Comparator|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
11448274|NCT01711463|Experimental|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
11448275|NCT01711463|Placebo Comparator|Placebo|matching placebo
11448276|NCT01711450|Experimental|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
11448277|NCT01711450|Placebo Comparator|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
11448278|NCT01711437|Experimental|PEG-S|polyethylene glycol 4000 solution with simethicon
11448279|NCT01711437|Experimental|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
11448280|NCT01711437|Experimental|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
11448281|NCT01711437|Experimental|picoprep|sodium picosulphate plus magnesium oxide and citric acid
11448282|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
11448283|NCT01711398|Experimental|IPP204106N|
11448284|NCT01711385|No Intervention|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
11448285|NCT01711385|Experimental|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
11448286|NCT01711372|Placebo Comparator|Controls who played Groundskeeper game|Controls played a go/no go task on Sifteo cubes to asses for attentional capabilities.
11448287|NCT01711372|Active Comparator|Probands played groundskeeper game|Patients with ADHD played a go/no go task on Sifteo cubes to asses for attentional capabilities
11448288|NCT01711359|Experimental|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
11448289|NCT01711359|Experimental|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
11448290|NCT01711359|Active Comparator|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
11448291|NCT01711346|Experimental|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
11448292|NCT01711346|Active Comparator|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
11448293|NCT01711333|Experimental|Pletaal SR capsule|
11448294|NCT01711320|Placebo Comparator|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
11448295|NCT01711320|Experimental|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
11448296|NCT01711307|Experimental|non-operative|cast applied within 48 hours
11448297|NCT01711307|Active Comparator|operative|cast applied within 48 hours and surgery within 14 days
11448298|NCT01711294|Active Comparator|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
11448299|NCT01711294|Active Comparator|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
11448300|NCT01711294|Active Comparator|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
11448301|NCT01711281|Experimental|Intracardiac Impedance Measurement|
11448302|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
11448303|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
11448304|NCT01711242|Experimental|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection
~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.
~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
11448305|NCT01711242|Active Comparator|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection
~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
11448306|NCT01711229|Active Comparator|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
11448307|NCT01711229|Active Comparator|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
11448308|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
11448309|NCT01711203|Experimental|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
11448310|NCT01711203|Active Comparator|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.
~Verbal cuing will include:
~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP
~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
11448311|NCT01711177|Sham Comparator|Normal control|Normal patient placebo
11448312|NCT01711177|Sham Comparator|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
11448313|NCT01711177|Experimental|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
11448314|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
11448315|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
11448316|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
11448317|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
11448318|NCT01711151||Sarciodosis|Questionnaire evaluation
11448319|NCT01711151||Healthy Controls|Questionnaire evaluation
11448320|NCT01711138||Intervention|Intervention group is geographically located near a built environment intervention (neighbourhood redevelopment).
11448321|NCT01711138||Comparison|Comparison group is not exposed to the built environment intervention according to their geographic location.
11448322|NCT01711125|Experimental|Arm 1|Baclofen low dose
11448323|NCT01711125|Experimental|Arm 2|Baclofen high dose
11448324|NCT01711125|Placebo Comparator|Arm 3|Placebo
11448325|NCT01711112|Experimental|docetaxel|Days 1 & 8 Docetaxel 35 mg/m2 IV
11448326|NCT01711099|Experimental|ESMR treated|
11448327|NCT01711086|Active Comparator|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
11448328|NCT01711086|Active Comparator|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
11448329|NCT01711073|Experimental|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
11448330|NCT01711060|Experimental|oxytocin|
11448331|NCT01711060|Experimental|balloon catheter|Dufour 1859H18
11448332|NCT01711047|Active Comparator|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
11448333|NCT01711047|Active Comparator|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
11448334|NCT01711034|Experimental|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.
~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
11448335|NCT01711021|Active Comparator|d-Amphetamine Transdermal System|d-Amphetamine Transdermal System
11448336|NCT01711021|Placebo Comparator|Placebo patch|Placebo patch
11448337|NCT01711008|Placebo Comparator|No Breakfast|Water only
11448338|NCT01711008|Active Comparator|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
11448339|NCT01711008|Active Comparator|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
11448340|NCT01710995|Active Comparator|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
11448341|NCT01710995|Active Comparator|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
11448342|NCT01710995|Active Comparator|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
11448343|NCT01710982|Active Comparator|TZP-101|TZP-101
11448344|NCT01710982|Placebo Comparator|Placebo|Placebo
11448345|NCT01710969|Experimental|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
11448346|NCT01710969|Experimental|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
11448347|NCT01710956|Experimental|Arm 1(with twice-daily TRT)|
11448348|NCT01710956|Experimental|Arm 2 (with once-daily TRT)|
11448349|NCT01710943|Experimental|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
11448350|NCT01710943|No Intervention|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
11448351|NCT01710930|Experimental|Study of predictive factors|
11448352|NCT01710917||Targinact® (oxycodon/naloxon)|
11448353|NCT01710891|Active Comparator|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
11448354|NCT01710891|Experimental|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
11448355|NCT01710878|Other|Intergard Synergy Graft|
11448356|NCT01710865|Experimental|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
11448357|NCT01710852|Experimental|Group A|ISIS CRP Rx followed by Placebo
11448358|NCT01710852|Experimental|Group B|Placebo followed by ISIS CRP Rx
11448359|NCT01710839|Experimental|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
11448360|NCT01710839|Active Comparator|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
11448361|NCT01710826|Experimental|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
11448362|NCT01710826|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
11448363|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
11448364|NCT01710800|Placebo Comparator|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
11448365|NCT01710800|Active Comparator|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
11448366|NCT01710787|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
11448367|NCT01710787|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
11448368|NCT01710787|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
11448369|NCT01710774|No Intervention|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
11448495|NCT01709981|Experimental|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
11448370|NCT01710774|Active Comparator|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
11448371|NCT01710761|Active Comparator|Nitrate supplement with caffeine|
11448372|NCT01710761|Placebo Comparator|Placebo|
11448373|NCT01710748|Active Comparator|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
11448374|NCT01710748|Experimental|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
11448375|NCT01710735|Experimental|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
11448376|NCT01710735|Active Comparator|Dry needling (superficial)|Insertion of dry needle less than 1cm.
11448377|NCT01710722|Experimental|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
11448378|NCT01710722|Experimental|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
11448379|NCT01710722|Experimental|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
11448380|NCT01710709|Experimental|Experimental|Aripiprazole, Intramuscular (IM) Depot
11448381|NCT01710696|Experimental|Individual dose|
11448382|NCT01710696|Experimental|Fixed dose|
11448383|NCT01710683||Control group|Median age 45 years, 18-63.
11448384|NCT01710683||Intervention group|Median age 46 years, 18-62.
11448385|NCT01710670|Experimental|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
11448386|NCT01710670|Experimental|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
11448387|NCT01710670|Experimental|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
11448388|NCT01710657|Placebo Comparator|Placebo|Matching placebo for 16 weeks.
11448389|NCT01710657|Experimental|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
11448390|NCT01710657|Experimental|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
11448391|NCT01710644|Experimental|Burlulipase|Burlulipase orally, per meal
11448392|NCT01710644|Placebo Comparator|Placebo (Caramel in sterile water)|Placebo orally, per meal
11448393|NCT01710631|Experimental|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
11448394|NCT01710631|Placebo Comparator|placebo|placebo tablet
11448395|NCT01710605|Active Comparator|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
11448396|NCT01710605|Experimental|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :
~If <5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
11448397|NCT01710592|Active Comparator|Epirubicin, Oxaliplatin, Capecitabine|"Epirubicin 50mg/m2 (day 1) bolus injection
~Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours
~Capecitabine 625mg/m2 (days 1-21) b.d. orally
~8 x 3-weekly cycle"
11448398|NCT01710592|Active Comparator|Docetaxel, Oxaliplatin|"Docetaxel 20mg/m2 (days 1, 8 & 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)
~Oxaliplatin 85mg/m2 (days 1 & 15)in 250mls of 5% dextrose. i.v. over 2 hours
~6 x 4-weekly cycle"
11448399|NCT01710579|Other|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
11448400|NCT01710579|Other|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
11448401|NCT01710579|Other|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
11448402|NCT01710566|Experimental|Group 1|600 mcg oral misoprostol
11448403|NCT01710566|Experimental|Group 2|10 IU oxytocin in Uniject
11448404|NCT01710553|Other|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
11448405|NCT01710553|Other|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
11448406|NCT01710540|Other|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
11448407|NCT01710540|Other|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
11448408|NCT01710527|Other|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
11448409|NCT01710527|Other|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
11448410|NCT01710514|Active Comparator|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
11448411|NCT01710514|Active Comparator|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
11448412|NCT01710501|Experimental|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
11448413|NCT01710501|Experimental|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
11448414|NCT01710501|Experimental|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
11448415|NCT01710488|Active Comparator|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
11448416|NCT01710488|Experimental|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
11448417|NCT01710462|Experimental|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
11448418|NCT01710462|Active Comparator|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
11448419|NCT01710449|Experimental|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
11448420|NCT01710449|Experimental|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
11448421|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
11448422|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
11448423|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
11448424|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
11448425|NCT01710423|Experimental|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
11448426|NCT01710423|No Intervention|Delayed Entry Control|
11448427|NCT01710410|Experimental|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
11448428|NCT01710410|Experimental|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
11448429|NCT01710410|Sham Comparator|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
11448430|NCT01710397|No Intervention|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
11448431|NCT01710397|No Intervention|Standard group, pregnant women|Comparison group (retrospective record review)
11448432|NCT01710397|Experimental|Rapid group, non-pregnant adults|Rapid ART initiation
11448433|NCT01710397|Experimental|Rapid group, pregnant women|Rapid ART initiation
11448434|NCT01710384|Experimental|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
11448435|NCT01710384|No Intervention|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
11448436|NCT01710371|Experimental|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
11448437|NCT01710371|Experimental|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
11448438|NCT01710358|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.
~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.
~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.
~Participants continued to take background methotrexate (MTX) therapy throughout study."
11448439|NCT01710358|Experimental|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.
~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.
~Participants continued to take background methotrexate (MTX) therapy throughout study."
11448440|NCT01710358|Active Comparator|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.
~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.
~Participants continued to take background methotrexate (MTX) therapy throughout study."
11448441|NCT01710345|Experimental|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
11448442|NCT01710345|Experimental|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
11448443|NCT01710345|Placebo Comparator|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
11448444|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
11448445|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
11448446|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
11448447|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
11448448|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
11448449|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
11448450|NCT01710306|No Intervention|Outreach|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: existing OEF/OIF/OND outreach. VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
11448496|NCT01709981|Placebo Comparator|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
11448451|NCT01710306|Experimental|Nurse Care Manager (NCM)|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: Study concierge nurse case manager (NCM). VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
11448452|NCT01710293|Experimental|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
11448453|NCT01710293|No Intervention|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
11448454|NCT01710280|Active Comparator|Native palm olein|75 g native palm olein
11448455|NCT01710280|Experimental|Interesterified palm olein|75 g interesterified palm olein
11448456|NCT01710267||Observation group|This group includes all volunteers of this observation study.
11448457|NCT01710254|Experimental|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
11448458|NCT01710228|Placebo Comparator|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:
~Methylprednisolone placebo or
~Methylprednisolone"
11448459|NCT01710228|Experimental|methylprednisolone|"subjects will be randomized 1:1 to receive either:
~Methylprednisolone placebo or
~Methylprednisolone"
11448460|NCT01710215|No Intervention|Usual Care|"No outreach mailed invitations.
~Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.
~Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
11448461|NCT01710215|Experimental|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).
~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.
~Centralized processes to promote guideline-based follow up."
11448462|NCT01710215|Experimental|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.
~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.
~Centralized processes to promote guideline-based follow up."
11448463|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
11448464|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
11448465|NCT01710189|Experimental|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
11448466|NCT01710189|Experimental|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
11448467|NCT01710176|Active Comparator|standard chemotherapy with full-dose epirubicin + ifosfamide|Standard arm foresees 3 cycles of preoperative chemotherapy, each cycle will be repeated every 21 days and includes: epirubicin 60 mg/m2/day, short infusion, days 1 and 2; ifosfamide 3 g/m2/day, days 1, 2, 3
11448468|NCT01710176|Experimental|histotype-tailored chemotherapy according to the histotype|gemcitabine+docetaxel for undifferentiated pleomorphic sarcoma, trabectedin for myxoid liposarcoma with hypercellularity, ifosfamide for synovial sarcoma, ifosfamide+etoposide for malignant peripheral nerve sheath tumor, gemcitabine+dacarbazine for leiomyosarcoma
11448469|NCT01710163|Experimental|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
11448470|NCT01710163|Experimental|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
11448471|NCT01710150|Placebo Comparator|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
11448472|NCT01710150|Active Comparator|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
11448473|NCT01710137|Active Comparator|Varenicline|"12 weeks of active varenicline + smoking cessation counseling
~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
11448474|NCT01710137|Placebo Comparator|Placebo|"12 weeks of placebo + smoking cessation counseling
~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
11448475|NCT01710124|Experimental|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
11448476|NCT01710124|No Intervention|No incentive|Subjects in this group will receive no financial incentives.
11448477|NCT01710111|Experimental|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
11448478|NCT01710111|No Intervention|Control Recipients|No face shield and no repeat hand hygiene measures
11448479|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
11448480|NCT01710085|Experimental|Diffusion weighted imaging, Recurrence|
11448481|NCT01710072|Experimental|aspirin|aspirin 81 mg po every day
11448482|NCT01710072|No Intervention|no aspirin|
11448483|NCT01710059|Experimental|Experimental: Intervention Group|"Experimental: Intervention Group
~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
11448484|NCT01710046|Experimental|Cohort 1|
11448497|NCT01709968|Experimental|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
11448498|NCT01709968|Placebo Comparator|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
11448499|NCT01709955|Experimental|Gucomannan|
11448500|NCT01709955|Placebo Comparator|Placebo pill|
11448501|NCT01709942|Experimental|degarelix group|group of patients treated with long acting GnRH antagonist
11448502|NCT01709942|Active Comparator|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
11448503|NCT01709929|Experimental|Insulin detemir|
11448504|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
11448505|NCT01709903|Experimental|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
11448506|NCT01709903|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
11448507|NCT01709890||Airway catheter during sedation|
11448508|NCT01709877|Active Comparator|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
11448509|NCT01709877|Experimental|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
11448510|NCT01709864|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
11448511|NCT01709864|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
11448512|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
11448513|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
11448514|NCT01709838|Other|Deferasirox|All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
11448515|NCT01709825|Placebo Comparator|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
11448516|NCT01709825|Experimental|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
11448517|NCT01709825|Experimental|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
11448518|NCT01709825|Experimental|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
11448519|NCT01709812|Other|1 standard care|standard care
11448520|NCT01709812|Experimental|2 individualized PSP|individualized patient support program
11448521|NCT01709799|Experimental|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)
~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
11448522|NCT01709799|Active Comparator|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.
~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
11448523|NCT01709799|Active Comparator|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
11448524|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
11448525|NCT01709773|Experimental|Focal treatment arm|
11448526|NCT01709760|Experimental|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
11448527|NCT01709760|Active Comparator|methotrexate & Placebo|Placebo, sc twice weekly
11448528|NCT01709747|Experimental|Hydromorphone Hydrochloride|Hydromorphone hydrochloride for intrathecal administration, 12 months safety evaluation
11448529|NCT01709734|Experimental|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension
~Dose B - galeterone tablets once daily PO for three months + extension
~Dose C - galeterone tablets once daily PO for three months + extension"
11448530|NCT01709734|Experimental|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
11448531|NCT01709721|Experimental|Active|Subjects on hydromorphone hydrochloride for the duration of therapy.
11448532|NCT01709721|Active Comparator|Titrated off therapy|Subjects on control
11448533|NCT01709708|Active Comparator|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
11448534|NCT01709708|Placebo Comparator|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
11448535|NCT01709695|Experimental|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
11448536|NCT01709695|Placebo Comparator|Placebo Group|Flexible dose titration of placebo
11448537|NCT01709682|Active Comparator|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
11448568|NCT01709500|Experimental|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
11454906|NCT01667133|Experimental|Phase 2 expansion|Phase 2
11448538|NCT01709682|Active Comparator|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
11448539|NCT01709669||Enrolling by invitation|
11448540|NCT01709656|Experimental|MSC plus NSAID|"human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).
~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
11448541|NCT01709656|Experimental|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
11448542|NCT01709643|Other|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
11448543|NCT01709643|Other|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
11448544|NCT01709643|Other|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
11448545|NCT01709643|Other|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
11448546|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
11448547|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
11448548|NCT01709617|Experimental|Glucose-glucose|Glucose ingestion
11448549|NCT01709617|Active Comparator|Glucose-Fructose|glucose-fructose ingestion
11448550|NCT01709617|Active Comparator|disaccharide|Disaccharide ingestion
11448551|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
11448552|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
11448553|NCT01709591|No Intervention|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
11448554|NCT01709591|Active Comparator|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
11448555|NCT01709578|Placebo Comparator|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
11448556|NCT01709578|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
11448557|NCT01709578|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
11448558|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
11448559|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
11448560|NCT01709552|Experimental|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
11448561|NCT01709552|Sham Comparator|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
11448562|NCT01709539|Experimental|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
11448563|NCT01709539|No Intervention|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
11448564|NCT01709526|Other|Improvement after psychiatric inpatient treatment|
11448565|NCT01709513|Other|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
11448566|NCT01709513|Active Comparator|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
11448567|NCT01709513|Experimental|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
11448569|NCT01709500|Placebo Comparator|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
11448570|NCT01709487|Experimental|HIPEC surgery with chemotherapy|"3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks
~Debulking surgery
~HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
~3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
11448571|NCT01709474|Experimental|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
11448572|NCT01709474|Active Comparator|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
11448573|NCT01709435|Experimental|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11448574|NCT01709422|Active Comparator|Propofol|both midazolam (1mg if aged <= 70 years or 0.5mg in age >70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
11448575|NCT01709422|Active Comparator|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
11448576|NCT01709409|Experimental|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
11448577|NCT01709409|Active Comparator|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
11448578|NCT01709396|Experimental|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
11448579|NCT01709383|Active Comparator|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
11448580|NCT01709383|Sham Comparator|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
11448581|NCT01709370|Experimental|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
11448582|NCT01709357|Experimental|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.
~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.
~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.
~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
11448583|NCT01709357|Experimental|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.
~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.
~Next, the therapist performed ischemic compression technique on the latent trigger point.
~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
11448584|NCT01709357|Experimental|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.
~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.
~Next, the therapist performed the passive stretching of the upper trapezius muscle.
~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
11448585|NCT01709357|Sham Comparator|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.
~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.
~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.
~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
11448586|NCT01709357|No Intervention|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.
~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.
~Next,the subject was lying for 30 seconds, without intervention.
~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
11448587|NCT01709344|Experimental|PS-OT|Problem-solving Occupational Therapy
11448588|NCT01709344|Other|Usual care|Access to all supportive and rehabilitative services available at DHMC
11448589|NCT01709331|Experimental|Corifollitropin alfa 150 μg + hCG|During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
11448652|NCT01709019|Experimental|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
11455178|NCT01665352|Experimental|TTP054 800 mg|
11448590|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 500/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448591|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 700/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448592|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 900/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448593|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 75/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448594|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 100/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448595|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2)125/300 μg for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448596|NCT01709318|Active Comparator|NuvaRing®|Participants will receive NuvaRing® (etonogestrel-ethinyl estradiol [ENG-EE] 120/15 μg) for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11448597|NCT01709305|Active Comparator|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
11448598|NCT01709305|Experimental|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
11448599|NCT01709305|Experimental|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
11448600|NCT01709305|Experimental|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
11448601|NCT01709292|Experimental|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
11448602|NCT01709292|Experimental|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
11448603|NCT01709292|No Intervention|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
11448604|NCT01709292|Experimental|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
11448605|NCT01709279|Other|adipose tissue derived stromal cells|
11448606|NCT01709266|Experimental|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
11448607|NCT01709266|Placebo Comparator|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
11448608|NCT01709253|Experimental|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
11448609|NCT01709253|Experimental|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
11448610|NCT01709253|Experimental|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
11448611|NCT01709253|Experimental|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
11448612|NCT01709240|Experimental|BioWeld1 System|
11448613|NCT01709227|Experimental|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
11448614|NCT01709227|Experimental|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
11448615|NCT01709214|Experimental|Cebranopadol (GRT6005) Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks
11448616|NCT01709214|Experimental|Cebranopadol (GRT6005) High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks
11448617|NCT01709214|Placebo Comparator|Placebo|Twice daily Placebo, oral administration for 15 weeks
11448618|NCT01709214|Active Comparator|Oxycodone CR|Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks
11448619|NCT01709201|No Intervention|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
11455179|NCT01665352|Placebo Comparator|Placebo|
11448620|NCT01709201|Experimental|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
11448621|NCT01709188|Experimental|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
11448622|NCT01709188|Active Comparator|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
11448623|NCT01709175|Experimental|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
11448624|NCT01709175|Experimental|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
11448625|NCT01709162|Experimental|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
11448626|NCT01709162|Active Comparator|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
11448627|NCT01709149|Experimental|CK-2017357|125 mg tablets
11448628|NCT01709149|Placebo Comparator|Placebo|Placebo tablets
11448629|NCT01709136|Experimental|Sirolimus|
11448630|NCT01709123|Placebo Comparator|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
11448631|NCT01709123|Experimental|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
11448632|NCT01709110|Experimental|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.
~Placebo given orally once weekly for 24 months.
~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
11448633|NCT01709110|Active Comparator|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.
~Placebo given by SC injection once daily for 24 months.
~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
11448634|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
11448635|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
11448636|NCT01709084|Experimental|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
11448637|NCT01709084|Active Comparator|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
11448638|NCT01709071|Experimental|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.
~Infants receive three vaccinations with an interval of 8 weeks between doses."
11448639|NCT01709071|Experimental|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.
~Infants receive three vaccinations with an interval of 8 weeks between doses."
11448640|NCT01709071|Experimental|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.
~Infants receive three vaccinations with an interval of 8 weeks between doses."
11448641|NCT01709071|Experimental|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.
~Infants receive three vaccinations with an interval of 8 weeks between doses."
11448642|NCT01709071|Experimental|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.
~Infants receive three vaccinations with an interval of 8 weeks between doses."
11448643|NCT01709071|Experimental|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.
~Infants receive three vaccinations with an interval of 8 weeks between doses."
11448644|NCT01709071|Active Comparator|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.
~Infants receive three injections with an interval of 8 weeks between doses."
11448645|NCT01709058|Experimental|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
11448646|NCT01709058|Other|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
11448647|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
11448648|NCT01709032|Experimental|Deferasirox and deferiprone|
11448649|NCT01709019|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
11448650|NCT01709019|Experimental|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
11448651|NCT01709019|Experimental|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
11448653|NCT01709019|Placebo Comparator|Group E|Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
11448654|NCT01709006|Other|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
11448655|NCT01708993|Active Comparator|Arm A: Pemetrexed and Reolysin (and safety run-in)|
11448656|NCT01708993|Active Comparator|Arm B: Pemetrexed|
11448657|NCT01708993|Active Comparator|Arm C: Docetaxel and Reolysin (and safety run-in)|
11448658|NCT01708993|Active Comparator|Arm D: Docetaxel|
11448659|NCT01708980|Experimental|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
11448660|NCT01708967|Experimental|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.
~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
11448661|NCT01708967|Experimental|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
11448662|NCT01708954|Experimental|Arm A (erlotinib)|Patients receive erlotinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11448663|NCT01708954|Experimental|Arm B (cabozantinib)|Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11448664|NCT01708954|Experimental|Arm C (erlotinib+cabozantinib)|Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11448665|NCT01708954|Experimental|Arm Z (erlotinib+cabozantinib; step II)|Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11448666|NCT01708941|Experimental|Arm A (higher dose ipilimumab, HDI)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.
~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
11448667|NCT01708941|Experimental|Arm B (higher dose ipilimumab)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.
~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
11448668|NCT01708941|Experimental|Arm C (lower dose ipilimumab + HDI)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.
~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
11448669|NCT01708941|Experimental|Arm D (lower dose ipilimumab)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.
~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
11448670|NCT01708928|Active Comparator|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
11448671|NCT01708928|Active Comparator|Group B|Subjects naïve to submentoplasty and or rhytidectomy
11448672|NCT01708915|Active Comparator|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
11448673|NCT01708915|Active Comparator|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
11448674|NCT01708915|Active Comparator|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
11448675|NCT01708915|Placebo Comparator|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
11448676|NCT01708902|Experimental|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
11448677|NCT01708902|Experimental|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
11448678|NCT01708902|Active Comparator|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
11448679|NCT01708902|Active Comparator|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
11448680|NCT01708902|Active Comparator|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
11448681|NCT01708889|Experimental|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
11448682|NCT01708889|Experimental|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
11448683|NCT01708889|Experimental|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
11448684|NCT01708889|Experimental|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
11448685|NCT01708889|Experimental|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)
11448686|NCT01708876|Active Comparator|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
11448687|NCT01708876|Active Comparator|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
11448688|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
11448776|NCT01708343|Sham Comparator|Placebo-sham|Placebo-sham twice a week during four weeks
11448689|NCT01708850|Other|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
11448690|NCT01708837|Other|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
11448691|NCT01708837|Other|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
11448692|NCT01708824|Experimental|dietary|"Dietary intervention to meet the target of
~1.<5 servings of red/processed meat weekly; <2 servings would be processed meat 2.2 servings of refined grains daily"
11448693|NCT01708824|Experimental|physical activity|"Physical activity intervention with the following targets:
~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);
~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
11448694|NCT01708824|Experimental|dietary and physical activity|Meeting both the dietary and physical activity targets
11448695|NCT01708824|No Intervention|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
11448696|NCT01708798|Placebo Comparator|Placebo|"One tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two tablets by mouth daily.
~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
11448697|NCT01708798|Experimental|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.
~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
11448698|NCT01708785|Active Comparator|Single context|Subjects will be exposed to food cues in a single context.
11448699|NCT01708785|Experimental|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
11448700|NCT01708785|Active Comparator|8 treatment sessions|Subjects receive 8 treatment sessions.
11448701|NCT01708785|Experimental|16 treatment sessions|Subjects receive 16 treatment sessions
11448702|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
11448703|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
11448704|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
11448705|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
11448706|NCT01708746||Enrolled subjects|
11448707|NCT01708746||Historic control|
11448708|NCT01708733|Placebo Comparator|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
11448709|NCT01708733|Experimental|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
11448710|NCT01708720|Experimental|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
11448711|NCT01708720|Experimental|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
11448712|NCT01708720|Active Comparator|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
11448713|NCT01708707|Active Comparator|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
11448714|NCT01708707|Experimental|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
11448715|NCT01708694|Placebo Comparator|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
11448716|NCT01708694|Experimental|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
11448717|NCT01708681|Experimental|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
11448718|NCT01708681|Active Comparator|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
11448719|NCT01708668|Active Comparator|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
11448720|NCT01708668|Active Comparator|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
11448721|NCT01708668|Active Comparator|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
11448722|NCT01708668|Active Comparator|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
11448723|NCT01708668|Active Comparator|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
11448724|NCT01708668|Active Comparator|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
11448725|NCT01708668|Active Comparator|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
11448726|NCT01708668|Active Comparator|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
11448727|NCT01708655|Other|Sweat Evaporimeter measurement|"0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg
~0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.
~0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:
~4.4 µg Isoproterenol hydrochloride, injection solution
~0.93 mg Aminophylline injection solution
~8.8 µg Atropine, injection solution"
11448728|NCT01708642|Experimental|Adrenaline|Intraoperative low-dose adrenaline infusion
11448729|NCT01708642|Placebo Comparator|Placebo|Placebo: Isotonic Saline
11449046|NCT01706679|Placebo Comparator|Placebo vehicle|placebo vehicle (PBS)
11448730|NCT01708629|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
11448731|NCT01708629|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
11448732|NCT01708629|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
11448733|NCT01708629|Placebo Comparator|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
11448734|NCT01708616|Placebo Comparator|Placebo + risperidone|
11448735|NCT01708616|Placebo Comparator|Placebo +placebo|
11448736|NCT01708616|Active Comparator|RO5285119 + placebo|
11448737|NCT01708616|Experimental|RO5285119 + risperidone|
11448738|NCT01708603|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
11448739|NCT01708603|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
11448740|NCT01708603|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
11448741|NCT01708603|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
11448742|NCT01708590|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
11448743|NCT01708590|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
11448744|NCT01708590|Placebo Comparator|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
11448745|NCT01708577|Experimental|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
11448746|NCT01708577|Experimental|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
11448747|NCT01708564|Experimental|Cohort 1|10 patients administered a single low dose of rhFVIIa
11448748|NCT01708564|Experimental|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
11448749|NCT01708564|Experimental|Cohort 3|10 patients administered a single high dose of rhFVIIa
11448750|NCT01708551|Active Comparator|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
11448751|NCT01708551|Active Comparator|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
11448752|NCT01708551|Active Comparator|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
11448753|NCT01708551|Active Comparator|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
11448754|NCT01708551|Active Comparator|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
11448755|NCT01708538|Active Comparator|Epithelium on|Epi not removed during CXL treatment
11448756|NCT01708538|Active Comparator|Epithelium off|Epi removed before CXL treatment
11448757|NCT01708525|Experimental|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
11448758|NCT01708512|Experimental|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
11448759|NCT01708499|Experimental|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
11448760|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
11448761|NCT01708473|Active Comparator|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
11448762|NCT01708473|Active Comparator|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
11448763|NCT01708460|Experimental|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
11448764|NCT01708447|Active Comparator|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
11448765|NCT01708447|Placebo Comparator|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
11448766|NCT01708434|Experimental|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
11448767|NCT01708408||community|
11448768|NCT01708395||Cohort 1|First 50 patients
11448769|NCT01708395||Cohort 2|2nd group of 50 patients
11448770|NCT01708382|Experimental|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
11448771|NCT01708369|Active Comparator|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
11448772|NCT01708369|Experimental|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
11448773|NCT01708369|Active Comparator|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
11448774|NCT01708369|Experimental|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
11448775|NCT01708356|Experimental|Normal cycling|Cycling on a residential and downtown route (crossover design)
11449100|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
11448777|NCT01708343|Active Comparator|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
11448778|NCT01708343|Experimental|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).
~Twice a week during four weeks"
11448779|NCT01708330|Placebo Comparator|Placebo gel|Placebo gel applied topically to the cervix
11448780|NCT01708330|Experimental|Lidocaine gel|2% lidocaine gel applied topically to the cervix
11448781|NCT01708317|Other|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
11448782|NCT01708304|Other|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
11448783|NCT01708291|Active Comparator|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
11448784|NCT01708291|Placebo Comparator|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
11448785|NCT01708278|Placebo Comparator|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
11448786|NCT01708278|Active Comparator|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
11448787|NCT01708278|Active Comparator|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
11448788|NCT01708278|Active Comparator|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
11448789|NCT01708278|Placebo Comparator|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
11448790|NCT01708278|Placebo Comparator|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
11448791|NCT01708265|Active Comparator|Early mitral valve repair|Early mitral valve repair
11448792|NCT01708265|Active Comparator|Watchful waiting|Watchful waiting
11448793|NCT01708252|Experimental|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
11448794|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
11448795|NCT01708226|Experimental|Attention Modification Program|Attention Modification Program
11448796|NCT01708213|Experimental|Dermal Filler - Aline HA|Single armed study
11448797|NCT01708200|Experimental|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
11448798|NCT01708187|Experimental|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
11448799|NCT01708187|No Intervention|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
11448800|NCT01708174|Experimental|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
11448801|NCT01708174|Active Comparator|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
11448802|NCT01708161|Experimental|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
11448803|NCT01708148|Active Comparator|Lactobacilli|30 Participants with verum
11448804|NCT01708148|Placebo Comparator|Placebo|30 Participants
11448805|NCT01708135|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
11448806|NCT01708122|Experimental|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
11448807|NCT01708122|Placebo Comparator|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
11448808|NCT01708109|Experimental|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
11448809|NCT01708109|Experimental|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
11448810|NCT01708096|Active Comparator|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
11448811|NCT01708096|Placebo Comparator|Normal diet|normal diet 2 weeks before gastric by-pass surgery
11448812|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
11448813|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
11448814|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
11448815|NCT01708070|Active Comparator|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
11448816|NCT01708070|Other|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
11448817|NCT01708057|Experimental|1|Single dose of AZD8683 50 µg
11448818|NCT01708057|Experimental|2|Single dose of AZD8683 150 µg
11448819|NCT01708057|Experimental|3|Single dose of AZD8683 300 µg
11448820|NCT01708057|Experimental|4|Single dose of AZD8683 900 µg
11448821|NCT01708057|Placebo Comparator|5|Single dose of placebo
11448822|NCT01708057|Active Comparator|6|Single dose of tiotropium 18 µg
11448823|NCT01708044|Experimental|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
11448824|NCT01708044|Experimental|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
11448862|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
11448825|NCT01708044|Experimental|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
11448826|NCT01708044|Placebo Comparator|Placebo|
11448827|NCT01708031|Experimental|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
11448828|NCT01708018|No Intervention|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
11448829|NCT01708018|Experimental|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
11448830|NCT01708005|Active Comparator|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
11448831|NCT01708005|Placebo Comparator|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.
~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
11448832|NCT01707992|Placebo Comparator|Placebo-Controlled Phase: Placebo|Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams [mg]) once daily orally for up to 24 months.
11448833|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 0.6 mg|Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
11448834|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 1.2 mg|Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
11448835|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 0.6 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
11448836|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 1.2 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
11448837|NCT01707992|No Intervention|Active Treatment Phase: Off Drug|Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.
11448838|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
11448839|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
11448840|NCT01707979||Non diabetic control|Male participants, control group non diabetic
11448841|NCT01707966|Experimental|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
11448842|NCT01707966|Placebo Comparator|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
11448843|NCT01707953|Experimental|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
11448844|NCT01707953|Placebo Comparator|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
11448845|NCT01707940|Experimental|BI 144807|subjects receive an oral single dose of BI 144807
11448846|NCT01707940|Experimental|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
11448847|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
11448848|NCT01707927||mosaic Ultra|Need a aortic valve replacement
11448849|NCT01707914|Experimental|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
11448850|NCT01707914|Placebo Comparator|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
11448851|NCT01707901|Experimental|ONO-8539|ONO-8539
11448852|NCT01707901|Placebo Comparator|Placebo|Placebo
11448853|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
11448854|NCT01707875||fetal ventricle brain asymmetry|
11448855|NCT01707849|Active Comparator|MMF arm|"MMF arm (n=20)
~They will receive immunosuppression as stipulated by hospital protocol:
~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
11448856|NCT01707849|Experimental|EVL arm|"EVL arm (n=20):
~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
11448857|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
11448858|NCT01707823|Experimental|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
11448859|NCT01707810|Sham Comparator|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
11448860|NCT01707810|Experimental|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
11448861|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
11449164|NCT01705938|Active Comparator|Group 3|SP-333 1 mg & Placebo, one tablet by mouth, single dose
11448863|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
11448864|NCT01707771|Active Comparator|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
11448865|NCT01707771|Active Comparator|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
11448866|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
11448867|NCT01707745|Other|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
11448868|NCT01707732|Active Comparator|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
11448869|NCT01707732|Experimental|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
11448870|NCT01707719||Alzheimer's disease|
11448871|NCT01707719||Non demented subjects|
11448872|NCT01707706|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
11448873|NCT01707706|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm [1 inch lateral to the middle point between HE3 and HE7] , Upper arm [1 inch lateral to LU 3 ], and Lower leg [0.5 inch dorsal to GB39]; for head, the non-acupoints include bilateral Head [middle point between GB8 and ST8], Forehead [middle point between ST8 and GB14], Neck [middle point between TB16 and SI17], and Ear [the point on the helix, inferior to the apex]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
11448874|NCT01707706|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
11448875|NCT01707693|Experimental|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
11448876|NCT01707693|Active Comparator|Information/Attention Comparison|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
11448877|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
11448878|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
11448879|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
11448880|NCT01707667|Experimental|Prucalopride|
11448881|NCT01707667|Active Comparator|PEG 3350|
11448882|NCT01707654|Other|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
11448883|NCT01707641|Active Comparator|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
11448884|NCT01707641|Active Comparator|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
11448885|NCT01707628|Active Comparator|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
11448886|NCT01707628|Active Comparator|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
11448887|NCT01707628|Active Comparator|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
11448888|NCT01707615|Other|control group|In the control group, all patients were enrolled in a lifestyle intervention
11448889|NCT01707615|Active Comparator|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
11448890|NCT01707602|Experimental|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
11448891|NCT01707602|Active Comparator|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
11448892|NCT01707602|Active Comparator|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
11448893|NCT01707589|Experimental|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
11448894|NCT01707576|Other|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
11448977|NCT01707056|Active Comparator|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
11448978|NCT01707056|Placebo Comparator|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
11448895|NCT01707563|Other|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
11448896|NCT01707563|Other|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
11448897|NCT01707550||Cohort|
11448898|NCT01707537|Experimental|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
11448899|NCT01707524|Experimental|Trans-radial approach|Randomized left versus right radial artery approach
11448900|NCT01707524|No Intervention|Trans-femoral approach|Observational
11448901|NCT01707498|Experimental|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
11448902|NCT01707498|Experimental|Healthy volunteers|RoBIK Brain-Computer Interface
11448903|NCT01707485|Experimental|Short course|amoxicillin. high-dose, 5 days
11448904|NCT01707485|Active Comparator|Standard therapy|amoxicillin, high-dose, 10 days
11448905|NCT01707472|Experimental|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
11448906|NCT01707472|Experimental|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
11448907|NCT01707472|Experimental|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
11448908|NCT01707446|Active Comparator|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
11448909|NCT01707446|No Intervention|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
11448910|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
11448911|NCT01707420|Active Comparator|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
11448912|NCT01707420|Placebo Comparator|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
11448913|NCT01707407|Experimental|Pomalidomide|
11448914|NCT01707407|Experimental|Pomalidomide plus Ketoconazole|
11448915|NCT01707407|Experimental|Pomalidomide plus Ketoconazole plus Fluvoxamine|
11448916|NCT01707407|Experimental|Pomalidomide plus Carbamazepine|
11448917|NCT01707394|Experimental|Group 1: Apixaban (low dose)|
11448918|NCT01707394|Experimental|Group 2A: Apixaban (low dose)|
11448919|NCT01707394|Experimental|Group 2B: Apixaban (low dose)|
11448920|NCT01707394|Experimental|Group 3: Apixaban (low dose)|
11448921|NCT01707394|Experimental|Group 4: Apixaban (low dose)|
11448922|NCT01707394|Experimental|Group 5: Apixaban (low dose)|
11448923|NCT01707394|Experimental|Group 2A (higher dose): Apixaban (low dose)|
11448924|NCT01707381|Active Comparator|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
11448925|NCT01707381|Experimental|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
11448926|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
11448927|NCT01707355|Active Comparator|invention with poster|intervention - poster
11448928|NCT01707355|No Intervention|control|control - no poster
11448929|NCT01707342|Experimental|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
11448930|NCT01707329|Active Comparator|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
11448931|NCT01707329|Experimental|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
11448932|NCT01707316|Experimental|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
11448933|NCT01707316|Experimental|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
11448934|NCT01707316|Experimental|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
11448935|NCT01707303|Other|Usual Care|Usual hospital rehabilitative services
11448936|NCT01707303|Experimental|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
11448937|NCT01707290|Experimental|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
11449043|NCT01706679|Active Comparator|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
11448938|NCT01707290|No Intervention|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
11448939|NCT01707277|Experimental|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
11448940|NCT01707277|Active Comparator|Usual care|Pharmacological treatment
11448941|NCT01707264|Experimental|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
11448942|NCT01707251|Experimental|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
11448943|NCT01707251|Placebo Comparator|Saline|IV saline every 6 hours starting preoperatively (5 doses).
11448944|NCT01707238|Experimental|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
11448945|NCT01707238|Active Comparator|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
11448946|NCT01707225|Experimental|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
11448947|NCT01707212|Experimental|Pain management education|Education about pain management during infant immunization
11448948|NCT01707212|Other|No pain management education|Control - general information about immunization only
11448949|NCT01707199|Experimental|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.
~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
11448950|NCT01707186||Group 1A|Early phase, requiring change in treatment
11448951|NCT01707186||Group 2|Established phase, stable treatment
11448952|NCT01707186||Group 2A|Established phase, requiring a change in treatment
11448953|NCT01707186||Group 1|Early phase, stable treatment
11448954|NCT01707173|Other|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
11448955|NCT01707173|Experimental|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
11448956|NCT01707160|Experimental|Treatment period 1|
11448957|NCT01707160|Active Comparator|Treatment period 2|
11448958|NCT01707147||Patients with Type 2 Diabetes Mellitus|
11448959|NCT01707134|Experimental|insulin aspart|
11448960|NCT01707134|Active Comparator|human insulin|
11448961|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
11448962|NCT01707108|Experimental|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
11448963|NCT01707095|Experimental|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
11448964|NCT01707095|Experimental|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
11448965|NCT01707082|Experimental|Part A Cohort 1|
11448966|NCT01707082|Experimental|Part A Cohort 2|
11448967|NCT01707082|Experimental|Part A Cohort 3|
11448968|NCT01707082|Experimental|Part A Cohort 4|
11448969|NCT01707082|Experimental|Part A Cohort 5|
11448970|NCT01707082|Experimental|Part B Cohort 1|
11448971|NCT01707082|Experimental|Part B Cohort 2|
11448972|NCT01707069|Experimental|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.
~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
11448973|NCT01707069|Experimental|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.
~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
11448974|NCT01707069|Experimental|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.
~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
11448975|NCT01707056|Active Comparator|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
11448976|NCT01707056|Active Comparator|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
11448979|NCT01707043|Active Comparator|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
11448980|NCT01707043|Active Comparator|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
11448981|NCT01707030|Experimental|BAI Arm|Receiving a web-based brief intervention for alcohol problems
11448982|NCT01707030|Active Comparator|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
11448983|NCT01707017|Active Comparator|High-load strength training|
11448984|NCT01707017|Active Comparator|Low-load strength training|
11448985|NCT01707017|Active Comparator|Low-load + moderate-load strength training|
11448986|NCT01707004|Experimental|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.
~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.
~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC >= 1,000/mm^3 for 3 consecutive days."
11448987|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
11448988|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.
~Amblyopia:
~VA <20/40 and 2 logMAR lines difference in normal eye
~Mild amblyopia (>20/40)
~Moderate amblyopia (20/40 and <20/100)
~Severe amblyopia (≥20/100 or worse)
~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.
~Strabismus:
~Constant: >2 PD at near and or distance.
~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.
~Amblyogenic factor categorization:
~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.
~'hypermetropia' (≥3.5 D),
~'myopia' (≥-4.0 D),
~'astigmatism' (≥1.5 D).
~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
11448989|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
11448990|NCT01706978|Experimental|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
11448991|NCT01706978|Active Comparator|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
11448992|NCT01706965|Experimental|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
11448993|NCT01706965|Active Comparator|Multivitamin|Daily multivitamin tablet
11448994|NCT01706952|Experimental|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.
~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
11448995|NCT01706952|Active Comparator|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.
~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
11448996|NCT01706939|Experimental|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
11448997|NCT01706939|Active Comparator|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
11448998|NCT01706926|Placebo Comparator|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.
11448999|NCT01706926|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
11449000|NCT01706926|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
11449001|NCT01706926|Experimental|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
11449044|NCT01706679|Active Comparator|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
11449045|NCT01706679|Active Comparator|Moxifloxacin|moxifloxacin (400mg)
11449002|NCT01706913|No Intervention|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
11449003|NCT01706913|Active Comparator|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
11449004|NCT01706900|Placebo Comparator|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
11449005|NCT01706900|Experimental|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
11449006|NCT01706887|Experimental|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
11449007|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
11449008|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
11449009|NCT01706861|Other|Celotres|Celotres following surgical removal of earlobe keloid.
11449010|NCT01706848|Active Comparator|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
11449011|NCT01706848|Active Comparator|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
11449012|NCT01706835|Experimental|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
11449013|NCT01706822|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
11449014|NCT01706809||Biomarkeres|
11449015|NCT01706796|Experimental|PF-06273340 Oral Solution Fasted|
11449016|NCT01706796|Experimental|PF-06273340 Immediate Release Tablet Fasted|
11449017|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fasted|
11449018|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fasted|
11449019|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fed|
11449020|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fed|
11449021|NCT01706783|Experimental|NNC0195-0092 (somapacitan)|
11449022|NCT01706783|Active Comparator|Norditropin NordiFlex®|
11449023|NCT01706770|Experimental|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
11449024|NCT01706770|Active Comparator|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
11449025|NCT01706757|Experimental|with go-cart|conducts exercises with the help of a go-cart
11449026|NCT01706757|No Intervention|without go-cart|conduct exercises without go-cart
11449027|NCT01706744|Experimental|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
11449028|NCT01706744|Active Comparator|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
11449029|NCT01706744|Active Comparator|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
11449030|NCT01706731|Active Comparator|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
11449031|NCT01706731|Sham Comparator|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
11449032|NCT01706718|Placebo Comparator|Control white bread|
11449033|NCT01706718|Experimental|Beetroot bread|
11449034|NCT01706705|Experimental|Brachytherapy Treatment Planning|"MRI-compatible intracavitary applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
~Computed tomography (CT) scan and a magnetic resonance imaging (MRI) scan performed after the implant is placed in the operating room. The CT scan should take about 20 minutes and the MRI about 45 minutes."
11449035|NCT01706692||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
11449036|NCT01706692||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
11449037|NCT01706692||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
11449038|NCT01706692||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
11449039|NCT01706692||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
11449040|NCT01706692||Fumaric acids|Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
11449041|NCT01706692||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
11449042|NCT01706692||Other anti-psoriatic systemic treatments|e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
11449047|NCT01706666|Experimental|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
11449048|NCT01706666|Experimental|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
11449049|NCT01706666|Experimental|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
11449050|NCT01706653|Active Comparator|Intervention 1|Polyphenol-enriched fruit-based drink - low
11449051|NCT01706653|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - medium
11449052|NCT01706653|Active Comparator|Intervention 3|Polyphenol-enriched fruit-based drink - high
11449053|NCT01706653|Placebo Comparator|Intervention 4|Very low polyphenol fruit based drink (control)
11449054|NCT01706627|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
11449055|NCT01706627|Active Comparator|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
11449056|NCT01706627|Active Comparator|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
11449057|NCT01706601||Hemorrhoids|Patient with hemorrhoids
11449058|NCT01706588|Experimental|Diclofenac sodium 5 mg/mL|
11449059|NCT01706588|Experimental|Diclofenac sodium 12.5 mg/mL|
11449060|NCT01706588|Experimental|Diclofenac sodium 25 mg/mL|
11449061|NCT01706588|Experimental|Diclofenac sodium 50 mg/mL|
11449062|NCT01706588|Placebo Comparator|Placebo 1 mL|
11449063|NCT01706575|Experimental|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than <0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
11449064|NCT01706562||Itraconazole|
11449065|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
11449066|NCT01706536|Placebo Comparator|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
11449067|NCT01706536|Experimental|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
11449068|NCT01706536|Experimental|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
11449069|NCT01706536|Experimental|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
11449070|NCT01706536|Experimental|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
11449071|NCT01706523|Experimental|STX209|Active treatment with STX209
11449072|NCT01706510|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
11449073|NCT01706510|Active Comparator|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
11449074|NCT01706484|Experimental|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
11449075|NCT01706484|Experimental|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
11449076|NCT01706484|Placebo Comparator|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
11449077|NCT01706471|Experimental|Everolimus + Low dose CsA +PD|
11449078|NCT01706471|Active Comparator|Myfortic+ Standard CsA + PD|
11449079|NCT01706458|Active Comparator|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
11449080|NCT01706458|Experimental|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
11449081|NCT01706445|No Intervention|Control|
11449082|NCT01706445|Other|intervention|Exercise training
11449083|NCT01706432|Experimental|Treatment (radiation therapy)|Patients with metastases in the lung, liver, abdomen, and extremities undergo 10 fractions or less of hypofractionated radiation therapy and patients with brain metastases undergo a single fraction of stereotactic radiosurgery.
11449084|NCT01706419|No Intervention|no school meal|control group receiving no school meal
11449085|NCT01706419|Placebo Comparator|normal school meal|school meal without fortified rice, placebo group
11449086|NCT01706419|Experimental|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
11449087|NCT01706419|Experimental|warm extrusion|school meal with fortified rice using warm extrusion kernels
11449088|NCT01706419|Experimental|hot extruded|school meal with fortified rice using hot extrusion kernels
11449089|NCT01706406|Experimental|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
11449090|NCT01706406|Other|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
11449091|NCT01706393|Experimental|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
11449092|NCT01706393|Placebo Comparator|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
11449093|NCT01706380|Experimental|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
11449094|NCT01706380|Active Comparator|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
11449095|NCT01706367|Experimental|Low dose C diff vaccine|
11449096|NCT01706367|Experimental|Low dose C diff vaccine + adjuvant|
11449097|NCT01706367|Experimental|Mid dose C diff vaccine|
11449098|NCT01706367|Experimental|Mid dose C diff vaccine + adjuvant|
11449099|NCT01706367|Experimental|High dose C diff vaccine|
11449101|NCT01706354|Active Comparator|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
11449102|NCT01706354|Experimental|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
11449103|NCT01706341|Active Comparator|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
11449104|NCT01706341|Active Comparator|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
11449105|NCT01706328|Experimental|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
11449106|NCT01706328|Active Comparator|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
11449107|NCT01706315|Experimental|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
11449108|NCT01706315|Placebo Comparator|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
11449109|NCT01706315|Experimental|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
11449110|NCT01706315|Placebo Comparator|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
11449111|NCT01706315|Experimental|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
11449112|NCT01706315|Placebo Comparator|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
11449113|NCT01706315|Experimental|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
11449114|NCT01706315|Placebo Comparator|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
11449115|NCT01706315|Experimental|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
11449116|NCT01706315|Placebo Comparator|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
11449117|NCT01706315|Experimental|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
11449118|NCT01706315|Placebo Comparator|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
11449119|NCT01706302||Cohort Group|
11449120|NCT01706289||diabetic mellitus screen|
11449121|NCT01706263|Experimental|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
11449122|NCT01706250|Experimental|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
11449123|NCT01706250|Active Comparator|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
11449124|NCT01706237|Experimental|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
11449125|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
11449126|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
11449127|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
11449128|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
11449165|NCT01705938|Active Comparator|Group 4|SP-333 3 mg & Placebo, 3 tablets by mouth,single dose
11449166|NCT01705938|Active Comparator|Group 5|SP-333 10 mg & Placebo, 1 tablet by mouth, single dose
11449167|NCT01705938|Active Comparator|Group 6|SP-333 30 mg & Placebo, 3 tablets by mouth, single dose
11455260|NCT01664741|Placebo Comparator|Placebo NRT|Matching placebo patch
11449129|NCT01706211|Experimental|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
11449130|NCT01706211|Placebo Comparator|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
11449131|NCT01706198|Experimental|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
11449132|NCT01706198|Active Comparator|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
11449133|NCT01706185||Cancer Group|
11449134|NCT01706172|Active Comparator|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
11449135|NCT01706172|Active Comparator|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
11449136|NCT01706159|Experimental|rFXIII|
11449137|NCT01706159|Active Comparator|Placebo|
11449138|NCT01706146|Other|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
11449139|NCT01706133|No Intervention|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
11449140|NCT01706120|Other|First-line chemotherapy with bevacizumab|"Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles
~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles
~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
11449141|NCT01706094|Experimental|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
11449142|NCT01706081|Experimental|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
11449143|NCT01706081|Experimental|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
11449144|NCT01706055||Group 1|
11449145|NCT01706042|Placebo Comparator|white bread|White bread (based on 35 g available carbohydrates)
11449146|NCT01706042|Active Comparator|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
11449147|NCT01706016|Experimental|Patients with breast cancer smaller than 20mm|
11449148|NCT01706003||Telemedicine Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated via telemedicine for migraine headaches
11449149|NCT01706003||In-Office Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated in the clinician's office for migraine headaches
11449150|NCT01705990|Experimental|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
11449151|NCT01705990|Experimental|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
11449152|NCT01705990|Experimental|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
11449153|NCT01705990|Experimental|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
11449154|NCT01705977|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
11449155|NCT01705977|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
11449156|NCT01705964|Experimental|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
11449157|NCT01705964|Sham Comparator|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
11449158|NCT01705951|Experimental|Group 1: Resistance Training/Nicotine Replacement|
11449159|NCT01705951|Experimental|Group 2: Resistance Training only|
11449160|NCT01705951|Experimental|Group 3: Nicotine Replacement Therapy only|
11449161|NCT01705951|No Intervention|Group 4: Control; no RT and no NRT|
11449162|NCT01705938|Active Comparator|Group 1|SP-333 0.1 mg & Placebo, one tablet by mouth, single dose
11449163|NCT01705938|Active Comparator|Group 2|SP-333 0.3 mg & Placebo, 3 tablets by mouth, single dose
11449168|NCT01705938|Active Comparator|Group 7|SP-333 60 mg & Placebo, 6 tablets by mouth, single dose
11449169|NCT01705912|Experimental|Training|Complete intervention i.e. basic intervention + individual training program.
11449170|NCT01705912|Active Comparator|Control|Basic intervention.
11449171|NCT01705899|Experimental|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
11449172|NCT01705899|Experimental|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
11449173|NCT01705886||Knee Arthroplasty|"Patients undergoing knee replacement surgery. This may be a Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty.
~The MAKO® Robot Assisted surgeries use the RESTORIS Multicompartmental Knee System.
~The total knee arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System."
11449174|NCT01705873||LPV/r|LPV/r based HAART
11449175|NCT01705873||Efavirenz|EFV first line based HAART
11449176|NCT01705860||Assessment|All subjects will receive same assessments.
11449177|NCT01705847|Experimental|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
11449178|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
11449179|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
11449180|NCT01705808|Experimental|Protein C concentrate|
11449181|NCT01705808|Placebo Comparator|Placebo|
11449182|NCT01705795|Active Comparator|Mepolizumab|Mepolizumab 750 mg four times one month apart.
11449183|NCT01705795|Placebo Comparator|Placebo|Placebo (saline) four times one month apart
11449184|NCT01705782|No Intervention|Saline|Only saline is given.
11449185|NCT01705782|Placebo Comparator|+ Saline|Endotoxin is given + Placebo (Saline)
11449186|NCT01705782|Active Comparator|+ amino acids|Endotoxin is given + amino acids (intravenously)
11449187|NCT01705769|Experimental|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
11449188|NCT01705769|Experimental|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
11449189|NCT01705769|Active Comparator|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
11449190|NCT01705756|Placebo Comparator|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
11449191|NCT01705756|Experimental|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
11449192|NCT01705743|Active Comparator|Group 1 Sevoflurane+Nitrous oxide|
11449193|NCT01705743|Active Comparator|Group 2 Sevoflurane|
11449194|NCT01705730||Tocilizumab|Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.
11449195|NCT01705717||cohort|
11449196|NCT01705704||Cohort|
11449197|NCT01705691|Active Comparator|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
11449198|NCT01705691|Experimental|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
11449199|NCT01705678|Active Comparator|Krill oil|Krill oil will be compared to fish oil as an active comparator
11449200|NCT01705678|Active Comparator|Fish oil|Fish oil 500 mg of DHA/EPA
11449201|NCT01705665||Aspirated Coronary Thrombi During AMI|
11449202|NCT01705652|Experimental|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
11449203|NCT01705652|Experimental|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
11449204|NCT01705639|Experimental|Melatonin|melatonin 4mg od for 3 months
11449205|NCT01705626||Participants diagnosed with small fiber polyneuropathy|Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer
11449206|NCT01705600|Experimental|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
11449207|NCT01705587|Experimental|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
11449208|NCT01705587|Experimental|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
11449209|NCT01705574|Experimental|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
11449210|NCT01705574|Active Comparator|ATV + RTV+ FTC/TDF|ATV + RTV + FTC/TDF + E/C/F/TDF placebo
11449211|NCT01705574|Experimental|Open-Label Extension Phase|After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
11449283|NCT01705002|Experimental|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.
~Only for mCRC patients."
11449212|NCT01705548|Experimental|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.
~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
11449213|NCT01705535|Experimental|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
11449214|NCT01705535|Active Comparator|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
11449215|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
11449216|NCT01705509|Other|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
11449217|NCT01705496|Experimental|[124I]FIAU|Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
11449218|NCT01705483|Experimental|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
11449219|NCT01705483|Experimental|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
11449220|NCT01705470|Experimental|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
11449221|NCT01705470|Experimental|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
11449222|NCT01705457|Active Comparator|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
11449223|NCT01705457|Placebo Comparator|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
11449224|NCT01705444|Other|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
11449225|NCT01705431|Experimental|Support for students with EBD|
11449226|NCT01705431|No Intervention|Control|Participants continue with services as usual
11449227|NCT01705405|Experimental|medical device|medical device to acquire ultrasound and endoscopic images during surgery
11449228|NCT01705392|Experimental|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
11449229|NCT01705392|Experimental|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
11449230|NCT01705392|Active Comparator|Dacarbazine|Dacarbazine 1000mg/m2 q3w
11449231|NCT01705379||MenACWY-CRM|2 years of age and older
11449232|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty
~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
11449233|NCT01705340|Experimental|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11449234|NCT01705327||Parkinson's Disease Subjects|
11449235|NCT01705327||Healthy Control Subjects|
11449236|NCT01705314|Experimental|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
11449237|NCT01705314|Placebo Comparator|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
11449238|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
11449239|NCT01705288|Active Comparator|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
11449240|NCT01705288|Experimental|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
11449241|NCT01705275|Experimental|ONO-8539 BID|ONO-8539
11449242|NCT01705275|Placebo Comparator|Placebo BID|0mg
11449243|NCT01705262||u-65 M|Male patients under 65
11449244|NCT01705262||u-65 K|Female patients under 65 years old
11449245|NCT01705262||o-65 -K|Female patients over 65 years
11449246|NCT01705262||O-65 M|Male patients over 65 years
11449247|NCT01705249|Experimental|estradiol / norethisterone acetate|
11449248|NCT01705236|Experimental|Fingolimod - Longitudinal Assessment|No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
11449249|NCT01705223|Experimental|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
11449250|NCT01705223|Experimental|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
11449251|NCT01705223|Experimental|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
11449252|NCT01705223|Experimental|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
11449253|NCT01705210||Diabetes mellitus type 2 (DM2)|
11449254|NCT01705210||metabolic syndrome (MetS)|
11449255|NCT01705210||healthy controls|
11449256|NCT01705197|Active Comparator|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
11449257|NCT01705197|Placebo Comparator|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
11449258|NCT01705184|Experimental|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2
~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
11449259|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
11449260|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
11449261|NCT01705158|Experimental|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
11449262|NCT01705145|Experimental|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than [<] 14 kilograms [kg]) or 75 mg (for participants weighing greater than or equal to [>=] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..
~Part B: Ivacaftor 50 mg (for participants weighing <14 kg) or 75 mg (for participants weighing >=14 kg) q12h for 24 weeks during Part B of the study."
11449263|NCT01705119|Experimental|Mechanically Ventilated|
11449264|NCT01705106|Experimental|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11449265|NCT01705093|Experimental|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
11449266|NCT01705093|Placebo Comparator|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
11449267|NCT01705080||A - EnligHTN for Severe Resistant HTN|"Office systolic Blood Pressure ≥160 mmHg
~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
~Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula"
11449268|NCT01705080||B - EnligHTN for Resistant HTN|"Office systolic Blood Pressure ≥140 mmHg
~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
~Patient has an estimated GFR ≥45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula"
11449269|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"Office systolic Blood Pressure ≥140 mmHg
~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.
~Patient has an estimated ≥15 GFR <45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula"
11449270|NCT01705067|Other|Journey II BCS TKA|Subjects having TKA with Journey II BCS Total Knee System
11449271|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
11449272|NCT01705041|Experimental|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
11449273|NCT01705015|Experimental|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
11449274|NCT01705015|Placebo Comparator|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
11449275|NCT01705002|Experimental|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449276|NCT01705002|Experimental|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449277|NCT01705002|Experimental|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449278|NCT01705002|Experimental|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449279|NCT01705002|Experimental|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449280|NCT01705002|Experimental|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449281|NCT01705002|Experimental|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449282|NCT01705002|Experimental|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
11449372|NCT01704495|Placebo Comparator|Placebo|Placebo oral capsules self-administered twice daily
11449284|NCT01705002|Experimental|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.
~Only for mCRC patients."
11449285|NCT01705002|Experimental|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.
~Only for mCRC patients."
11449286|NCT01705002|Experimental|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.
~Only for mCRC patients."
11449287|NCT01704989|Active Comparator|Laser pathway|Arm in which patients first randomised to receive SLT laser
11449288|NCT01704989|Active Comparator|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
11449289|NCT01704976|Experimental|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
11449290|NCT01704976|Sham Comparator|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
11449291|NCT01704963|Experimental|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
11449292|NCT01704937|Experimental|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
11449293|NCT01704937|Experimental|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
11449294|NCT01704924|Active Comparator|Prevena|Incision with prevena device overlying
11449295|NCT01704924|Active Comparator|Standard of Care dressing|Prevena device is not used
11449296|NCT01704911|Experimental|Transradial Coronary Intervention|Transradial Coronary Intervention
11449297|NCT01704911|Experimental|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
11449298|NCT01704898|Other|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
11449299|NCT01704898|Other|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
11449300|NCT01704885|Sham Comparator|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
11449301|NCT01704885|Experimental|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
11449302|NCT01704872|Experimental|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
11449303|NCT01704859|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11449304|NCT01704859|Active Comparator|Vitamin D placebo + fish oil|
11449305|NCT01704859|Active Comparator|Vitamin D + fish oil placebo|
11449306|NCT01704859|Active Comparator|Vitamin D + fish oil|
11449307|NCT01704846|Experimental|Treatment sequence 1|Test - Reference - Reference - Test
11449308|NCT01704846|Experimental|Treatment sequence 2|Reference - Test - Test - Reference
11449309|NCT01704833|Experimental|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
11449310|NCT01704833|No Intervention|Treatment as Usual|This group receives standard care only.
11449311|NCT01704820|Experimental|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
11449312|NCT01704820|Placebo Comparator|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
11449313|NCT01704807|Active Comparator|Intervention, Custom Orthotics|Wearing custom foot orthotics
11449314|NCT01704807|Sham Comparator|Sham Foot Orthotic|Wearing sham or flat shoe insoles
11449315|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
11449316|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
11449317|NCT01704794|Active Comparator|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
11449318|NCT01704781|Experimental|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.
~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
11449319|NCT01704781|Experimental|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
11449320|NCT01704781|Placebo Comparator|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide placebo two days prior to and at the day of immunization.
11455372|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
11449321|NCT01704768|Experimental|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
11449322|NCT01704768|Placebo Comparator|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
11449323|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
11449324|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
11449325|NCT01704742||No treatment|
11449326|NCT01704729|Other|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
11449327|NCT01704729|Other|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
11449328|NCT01704729|Other|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
11449329|NCT01704729|Other|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
11449330|NCT01704716|Experimental|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
11449331|NCT01704716|Active Comparator|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
11449332|NCT01704716|Active Comparator|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.
~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
11449333|NCT01704716|Experimental|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
11449334|NCT01704716|Active Comparator|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
11449335|NCT01704716|Experimental|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
11449336|NCT01704716|Active Comparator|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:
~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
11449337|NCT01704716|Experimental|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
11449338|NCT01704716|Active Comparator|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
11449339|NCT01704716|Experimental|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.
~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
11449340|NCT01704703|Experimental|Experimental|FOLFIRI + panitumumab
11449341|NCT01704690|Experimental|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
11449342|NCT01704690|Active Comparator|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.
~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
11449343|NCT01704690|Active Comparator|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
11449344|NCT01704677|Experimental|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
11449345|NCT01704677|Active Comparator|Multidiciplinary rehabilitation|
11449346|NCT01704664|Active Comparator|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
11449347|NCT01704664|Active Comparator|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
11449373|NCT01704482|Experimental|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
11449374|NCT01704482|Placebo Comparator|Glucose 5%|equivalent volume over the same period.
11449375|NCT01704469|Experimental|The local anesthetic injection group|
11449458|NCT01703988|Experimental|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
11449348|NCT01704664|Active Comparator|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
11449349|NCT01704664|Active Comparator|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
11449350|NCT01704651|Experimental|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
11449351|NCT01704651|Placebo Comparator|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
11449352|NCT01704638|Experimental|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
11449353|NCT01704638|Other|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
11449354|NCT01704625|Experimental|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
11449355|NCT01704625|Sham Comparator|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
11449356|NCT01704612|Active Comparator|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
11449357|NCT01704612|Sham Comparator|Control group|no diabete reveived 20 mL ropivacaine
11449358|NCT01704599|Experimental|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins
~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
11449359|NCT01704586|Active Comparator|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
11449360|NCT01704586|Active Comparator|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
11449361|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2* nAChR availability using 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine (2-[18F]FA) PET imaging.
~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.
~All participants who complete both PET scans will also complete an anatomical MRI scan."
11449362|NCT01704560|Experimental|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
11449363|NCT01704560|No Intervention|No Coversheet|Standard, full permission form, without the coversheet.
11449364|NCT01704534|Experimental|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
11449365|NCT01704521|Active Comparator|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
11449366|NCT01704521|Active Comparator|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
11449367|NCT01704508|Active Comparator|Artemether-lumefantrine|6-dose regime will be used:
11449368|NCT01704508|Active Comparator|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
11449369|NCT01704495|Experimental|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
11449370|NCT01704495|Experimental|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
11449371|NCT01704495|Experimental|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
11449453|NCT01704014||Control Group|Age and sex-matched control subjects
11449376|NCT01704456|Experimental|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
11449377|NCT01704456|Experimental|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
11449378|NCT01704443|Experimental|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
11449379|NCT01704443|Experimental|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
11449380|NCT01704430|Experimental|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
11449381|NCT01704430|Placebo Comparator|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
11449382|NCT01704417|Experimental|IDeg followed by IGlar|
11449383|NCT01704417|Experimental|IGlar followed by IDeg|
11449384|NCT01704404|Experimental|Dose 1 TD-4208|22 µg
11449385|NCT01704404|Experimental|Dose 2 TD-4208|44 µg
11449386|NCT01704404|Experimental|Dose 3 TD-4208|88 µg
11449387|NCT01704404|Experimental|Dose 4 TD-4208|175 µg
11449388|NCT01704404|Experimental|Dose 5 TD-4208|350 µg
11449389|NCT01704404|Experimental|Dose 6 TD-4208|700 µg
11449390|NCT01704404|Placebo Comparator|Placebo|Placebo
11449391|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
11449392|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
11449393|NCT01704378|Experimental|BIAsp|
11449394|NCT01704365|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
11449395|NCT01704365|Experimental|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
11449396|NCT01704365|Experimental|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
11449397|NCT01704365|Experimental|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
11449398|NCT01704365|Experimental|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
11449399|NCT01704365|Experimental|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
11449400|NCT01704365|Experimental|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
11449401|NCT01704365|Experimental|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
11449402|NCT01704365|Experimental|Group J|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
11449403|NCT01704365|Placebo Comparator|Group K|Placebo (Day 0 and Day 28)
11449404|NCT01704352|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
11449405|NCT01704352|No Intervention|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
11449406|NCT01704339|Experimental|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
11449407|NCT01704313|Experimental|Interrupted|Interrupted suturing technique used around heel of anastomosis
11449408|NCT01704313|Active Comparator|Continuous|Continuous suturing technique used for the anastomosis
11449409|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
11449410|NCT01704287|Experimental|Pembrolizumab 2 mg/kg|Participants were initially randomized to receive pembrolizumab 2 mg/kg intravenously (IV) once every 3 weeks (Q3W). With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
11449411|NCT01704287|Experimental|Pembrolizumab 10 mg/kg|Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
11449412|NCT01704287|Active Comparator|Investigator-Choice Chemotherapy (ICC)|Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
11449454|NCT01704001|Experimental|Renal impairment grade 0|
11449455|NCT01704001|Experimental|Renal impairment grade 1|
11449456|NCT01704001|Experimental|Renal impairment grade 2|
11449457|NCT01704001|Experimental|Renal impairment grade 3|
11449413|NCT01704287|Experimental|ICC→Pembrolizumab 2 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
11449414|NCT01704287|Experimental|ICC→Pembrolizumab 10 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
11449415|NCT01704274|Placebo Comparator|Placebo|Placebo patch
11449416|NCT01704274|Experimental|Low dose GTN 0.0285 mg/hr|Low dose GTN
11449417|NCT01704274|Experimental|High Dose GTN 0.057 mg/hr|High Dose GTN
11449418|NCT01704261|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
11449419|NCT01704261|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
11449420|NCT01704248|Placebo Comparator|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
11449421|NCT01704248|Experimental|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
11449422|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
11449423|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
11449424|NCT01704209|Experimental|Fibroblast Treatment|The fibroblast treatment will be randomly injected into one side of the face.
11449425|NCT01704209|Placebo Comparator|Vehicle|The vehicle will be injected randomly to the other side of the face.
11449426|NCT01704196|Active Comparator|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
11449427|NCT01704196|Placebo Comparator|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
11449428|NCT01704170|Experimental|Renal Denervation Using Externally Focused Ultrasound Therapy|
11449429|NCT01704157|Other|Open Treatment|Treatment with Cryo-Touch III Device
11449430|NCT01704131||children > 6 months|children > 6 months of age
11449431|NCT01704131||children < 6 months|children < 6 months
11449432|NCT01704118|Experimental|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
11449433|NCT01704118|Active Comparator|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
11449434|NCT01704105|Active Comparator|Water Quality|100 clusters, approximately 1,000 newborns
11449435|NCT01704105|Active Comparator|Sanitation|100 clusters, approximately 1,000 newborns
11449436|NCT01704105|Active Comparator|Handwashing|100 clusters, approximately 1,000 newborns
11449437|NCT01704105|Active Comparator|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
11449438|NCT01704105|Active Comparator|Nutrition|100 clusters, approximately 1,000 newborns
11449439|NCT01704105|Active Comparator|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
11449440|NCT01704105|No Intervention|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
11449441|NCT01704105|No Intervention|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
11449442|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
11449443|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
11449444|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
11449445|NCT01704079|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
11449446|NCT01704079|Placebo Comparator|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
11449447|NCT01704040|Experimental|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
11449448|NCT01704040|Placebo Comparator|Part 1: Healthy participants (placebo + HRV-16)|
11449449|NCT01704040|Experimental|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
11449450|NCT01704040|Placebo Comparator|Part 2: Asthmatic patients (placebo + HRV-16)|
11449451|NCT01704027|Experimental|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
11449452|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
11449459|NCT01703988|Experimental|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
11449460|NCT01703988|Experimental|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
11449461|NCT01703988|Experimental|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
11449462|NCT01703975|No Intervention|Single training|Students training alone on the simulator
11449463|NCT01703975|Experimental|Training in pairs (Dyad Training)|Students training in pairs on the simulator
11449464|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
11449465|NCT01703949|Experimental|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11449466|NCT01703949|Experimental|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11449467|NCT01703936|Experimental|agricultural training program|Three to four month residential agriculture and life skills training program.
11449468|NCT01703936|No Intervention|Control group|
11449469|NCT01703923|Experimental|FP01 6mg or Placebo|FP01 6mg Oral
11449470|NCT01703923|Experimental|FP01 12mg or Placebo|FP01 12mg Oral
11449471|NCT01703910|Active Comparator|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
11449472|NCT01703910|Experimental|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
11449473|NCT01703897||Obese patients|
11449474|NCT01703884|Experimental|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
11449475|NCT01703884|No Intervention|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
11449476|NCT01703858|Active Comparator|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
11449477|NCT01703858|Experimental|2 BI 113608|conventional tablet formulation
11449478|NCT01703858|Experimental|3 BI 113608|conventional tablet formulation, fed
11449479|NCT01703858|Experimental|4 BI 113608|conventional tablet after pantoprazole administration
11449480|NCT01703858|Experimental|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
11449481|NCT01703845|Experimental|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
11449482|NCT01703845|Experimental|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
11449483|NCT01703832|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
11449484|NCT01703832|No Intervention|No intervention|no tablet intake and subjects will undergo the natural course
11449485|NCT01703819|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
11449486|NCT01703819|Placebo Comparator|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
11449487|NCT01703806||Mitral regurgitation|Asymptomatic patients with severe degenerative mitral regurgitation
11449488|NCT01703793|Placebo Comparator|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
11449489|NCT01703793|Experimental|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
11449490|NCT01703793|Experimental|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
11449491|NCT01703780||resistant hypertension|blood pressure remaining above goal (< 140/90 mm Hg for the general population and < 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
11449492|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
11449493|NCT01703780||healthy control|"Age>50 years old
~Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)
~No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound
~No peripheral angiopathy (ABI<0.9 or lower extremity vessels Doppler ultrasound)
~No major cardiovascular risk factors:
~Dyslipidemia
~Diabetes
~Smoke within one year"
11449494|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
11449495|NCT01703754|Experimental|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
11449496|NCT01703754|Experimental|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
11449497|NCT01703741|Experimental|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
11449498|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
11449499|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
11449500|NCT01703702|Experimental|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
11449501|NCT01703702|Experimental|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
11449502|NCT01703689|Experimental|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
11449551|NCT01703468|Active Comparator|Trileptal then Oxcarbazepine|600 mg suspension
11449503|NCT01703689|Active Comparator|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
11449504|NCT01703676||Patients|Klinefelter Patients
11449505|NCT01703676||Parents|Parents of Klinefelter Patients
11449506|NCT01703676||Controls M|Healthy Male Control with normal karyotype
11449507|NCT01703676||Controls F|Healthy female controls
11449508|NCT01703663|Experimental|EPAP|Provent Sleep Apnea Therapy.
11449509|NCT01703663|No Intervention|control|
11449510|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
11449511|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
11449512|NCT01703637|Experimental|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
11449513|NCT01703637|Experimental|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
11449514|NCT01703637|Experimental|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
11449515|NCT01703624|Experimental|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
11449516|NCT01703624|Experimental|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
11449517|NCT01703624|Experimental|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
11449518|NCT01703624|Experimental|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
11449519|NCT01703624|Placebo Comparator|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
11449520|NCT01703611|Experimental|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
11449521|NCT01703611|Active Comparator|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
11449522|NCT01703598|Experimental|DBS surgery|Single arm
11449523|NCT01703585||metastatic breast cancer|
11449524|NCT01703585||metastatic colorectal cancer|
11449525|NCT01703585||metastatic gynecological cancer|
11449526|NCT01703585||metastatic melanoma|
11449527|NCT01703572|Experimental|OMP-52M51|
11449528|NCT01703559|Placebo Comparator|Placebo|Administered once daily in both eyes for 15 days
11449529|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 0.5%|Administered once daily in both eyes for 15 days
11449530|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 1.0%|Administered once daily in both eyes for 15 days
11449531|NCT01703546|Experimental|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP).
~The percent of Excess Body Weight Loss will be monitored at all post op visits."
11449532|NCT01703533|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
11449533|NCT01703533|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
11449534|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
11449535|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
11449536|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
11449537|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
11449538|NCT01703507|Experimental|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
11449539|NCT01703507|Experimental|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
11449540|NCT01703494|Active Comparator|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
11449541|NCT01703494|Sham Comparator|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
11449542|NCT01703481|Experimental|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
11449543|NCT01703481|Experimental|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
11449544|NCT01703481|Experimental|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
11449545|NCT01703481|Experimental|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
11449546|NCT01703481|Experimental|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
11449547|NCT01703481|Experimental|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme [GBM], ovarian or prostate).
11449548|NCT01703481|Experimental|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
11449549|NCT01703481|Experimental|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
11449550|NCT01703468|Active Comparator|Oxcarbazepine then Trileptal|600 mg suspension
11449552|NCT01703455|Experimental|Sorafenib 400 mg twice daily|Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
11449553|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
11449554|NCT01703429||Individuals with MS|
11449555|NCT01703416||1|
11449556|NCT01703390|Experimental|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
11449557|NCT01703390|Experimental|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
11449558|NCT01703364|Experimental|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs
~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days
~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
11449559|NCT01703351|Experimental|Drug: 0.5% ropivacaine|
11449560|NCT01703351|Active Comparator|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
11449561|NCT01703338||Lumbar spinal surgery|The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings
11449562|NCT01703325|Active Comparator|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C
~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
11449563|NCT01703325|Active Comparator|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
11449564|NCT01703325|No Intervention|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
11449565|NCT01703312|Experimental|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
11449566|NCT01703312|Active Comparator|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
11449567|NCT01703312|Placebo Comparator|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
11449568|NCT01703299||imipenem-treated patients|imipenem-treated patients
11449569|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
11449570|NCT01703286|Experimental|Linagliptin 5mg|given once daily over 28 days
11449571|NCT01703286|Active Comparator|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
11449572|NCT01703286|Placebo Comparator|Placebo|given once daily over 28 days
11449573|NCT01703273|Experimental|low key intervention|
11449574|NCT01703273|Active Comparator|routine care|
11449575|NCT01703260|Experimental|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
11449576|NCT01703260|Experimental|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
11449577|NCT01703260|Experimental|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
11449578|NCT01703247|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
11449579|NCT01703247|Active Comparator|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
11449580|NCT01703234|Experimental|Ramipril|
11449581|NCT01703221|Experimental|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
11449582|NCT01703221|Active Comparator|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
11449583|NCT01703221|Placebo Comparator|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
11449584|NCT01703208|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
11449585|NCT01703208|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
11449586|NCT01703195|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
11449705|NCT01702467|Placebo Comparator|Placebo|Matching placebo
11455541|NCT01662414|Active Comparator|HMS 90®|
11449587|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
11449588|NCT01703169|Experimental|Eltrombopag|Single arm study. Dose Escalation.
11449589|NCT01703156|Experimental|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
11449590|NCT01703156|Active Comparator|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
11449591|NCT01703143|Experimental|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
11449592|NCT01703130|Experimental|Local Anesthestic Dose|
11449593|NCT01703117|Experimental|age matched cohort 50-95 years old|20-22 subjects between the ages of 50-95 will receive riluzole
11449594|NCT01703117|Placebo Comparator|24 subjects between 50-95 years old|20-22 subjects between 50-95 will receive placebo
11449595|NCT01703104|Active Comparator|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
11449596|NCT01703104|Active Comparator|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
11449597|NCT01703091|Experimental|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
11449598|NCT01703091|Placebo Comparator|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
11449599|NCT01703078|Active Comparator|Ingenol mebutate gel 0.05%|once daily for two consecutive days
11449600|NCT01703078|Experimental|Ingenol derivative concentration 1|once daily for two consecutive days
11449601|NCT01703078|Experimental|Ingenol derivative concentration 2|once daily for two consecutive days
11449602|NCT01703078|Experimental|Ingenol derivative concentration 3|once daily for two consecutive days
11449603|NCT01703065|Experimental|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
11449604|NCT01703065|Experimental|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
11449605|NCT01703052|Experimental|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
11449606|NCT01703052|Experimental|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
11449607|NCT01703039|Experimental|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
11449608|NCT01703039|Active Comparator|sertraline + placebo|sertraline 100 mg po daily and placebo
11449609|NCT01703000|Experimental|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
11449610|NCT01702987|Placebo Comparator|Statin + placebo|9 patients taking statin medications and placebo.
11449611|NCT01702987|Active Comparator|Statin + ubiquinol|12 patients on statins and ubiquinol
11449612|NCT01702974|Active Comparator|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
11449613|NCT01702974|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
11449614|NCT01702961|Other|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
11449615|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer &amp; must have been diagnosed at least 3 months prior to enrollment on this study &amp; be currently receiving treatment
11449616|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
11449617|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
11449618|NCT01702909|Experimental|Interleukin-2|Interleukin-2
11449619|NCT01702896|Experimental|Interleukin-2|Interleukin-2 will be used in this group
11449620|NCT01702883|No Intervention|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
11449621|NCT01702883|Experimental|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
11449622|NCT01702883|Experimental|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
11449623|NCT01702883|Experimental|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
11449624|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
11449625|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
11449626|NCT01702857|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11449627|NCT01702857|Experimental|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11449628|NCT01702857|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
11449629|NCT01702857|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11449630|NCT01702857|Experimental|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11449631|NCT01702844|Experimental|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
11449632|NCT01702831|Experimental|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
11449633|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
11449634|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
11449635|NCT01702805|Active Comparator|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
11449636|NCT01702805|Active Comparator|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
11449637|NCT01702792|Experimental|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
11449638|NCT01702779|Other|optiflow|
11449639|NCT01702779|Other|O2|
11449640|NCT01702766|Active Comparator|Bifidobacterium animalis subsp. lactis|
11449641|NCT01702766|Placebo Comparator|Placebo|
11449642|NCT01702753|Active Comparator|Bifidobacterium animalis subsp. lactis|
11449643|NCT01702753|Placebo Comparator|Placebo|
11449644|NCT01702740|Experimental|Part A, 1 mg/kg CNTO 136|
11449645|NCT01702740|Experimental|Part A, 4 mg/kg CNTO 136|
11449646|NCT01702740|Experimental|Part A, 10 mg/kg CNTO 136|
11449647|NCT01702740|Experimental|Part B, 10 mg/kg CNTO 136/placebo|
11449648|NCT01702727|Experimental|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
11449649|NCT01702727|Active Comparator|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
11449650|NCT01702727|Experimental|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
11449651|NCT01702714|Experimental|RO5083945 + carboplatin + paclitaxel|
11449652|NCT01702714|Experimental|RO5083945 + cisplatin +gemcitabine|
11449653|NCT01702701|Active Comparator|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
11449654|NCT01702701|Active Comparator|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
11449655|NCT01702675|Experimental|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
11449656|NCT01702675|Experimental|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
11449657|NCT01702675|Experimental|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
11449658|NCT01702675|Experimental|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
11449659|NCT01702675|Experimental|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
11449660|NCT01702675|Experimental|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
11449661|NCT01702675|Placebo Comparator|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
11449662|NCT01702675|Placebo Comparator|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
11449663|NCT01702675|Placebo Comparator|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
11449664|NCT01702675|Placebo Comparator|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
11449665|NCT01702675|Placebo Comparator|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
11449666|NCT01702662|Experimental|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
11449667|NCT01702649|Experimental|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
11449668|NCT01702649|Placebo Comparator|Normal Saline|Single and multiple doses of normal saline.
11449669|NCT01702636|Active Comparator|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
11449670|NCT01702636|Placebo Comparator|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
11449671|NCT01702623|Active Comparator|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
11449741|NCT01702233|Placebo Comparator|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
11449742|NCT01702220|Experimental|CBT|
11449672|NCT01702623|Active Comparator|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
11449673|NCT01702610|Experimental|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
11449674|NCT01702597|Experimental|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
11449675|NCT01702597|Active Comparator|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
11449676|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
11449677|NCT01702571|Experimental|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
11449678|NCT01702571|Experimental|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
11449679|NCT01702558|Experimental|Phase 1 (mBC) Cohort 1: T-DM1 + Capecitabine|In Phase 1, Cohort 1 participants (with mBC) will receive trastuzumab emtansine (T-DM1) at a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion (on Day 1 [on Day 2 for Cycle 1] of each 21-day cycle) along with capecitabine at de-escalating dose levels (starting from 750 milligrams per meter squared [mg/m^2]) via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, disease progression (PD), death, or study end.
11449680|NCT01702558|Experimental|Phase 1 (LA/mGC) Cohort 2: T-DM1 + Capecitabine|In Phase 1, Cohort 2 participants (with LA/mGC) will receive trastuzumab emtansine at a dose of 2.4 mg/kg via IV infusion on Day 1 (on Day 2 of first week) of every week along with capecitabine at MTD (determined in Cohort 1) via tablet orally twice daily on Days 1-14 followed by a 7-day rest period, in each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
11449681|NCT01702558|Active Comparator|Phase 2 (mBC): T-DM1 + Capecitabine|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle along with capecitabine at MTD via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
11449682|NCT01702558|Experimental|Phase 2 (mBC): T-DM1|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle until investigator-assessed PD, unacceptable toxicity, withdrawal of consent, death, or study end.
11449683|NCT01702532|Experimental|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
11449684|NCT01702532|Active Comparator|Nicotine Lozenge|nicotine lozenge, buccal administration
11449685|NCT01702519|Active Comparator|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
11449686|NCT01702519|Active Comparator|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
11449687|NCT01702506|Experimental|Fasted|Dacomitinib administered under fasted conditions
11449688|NCT01702506|Experimental|Fed|Dacomitinib administered under fed conditions
11449689|NCT01702506|Experimental|Antacid|Dacomitinib administered under antacid treatment
11449690|NCT01702493|Active Comparator|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
11449691|NCT01702493|Experimental|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
11449692|NCT01702493|Experimental|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
11449693|NCT01702493|Experimental|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
11449694|NCT01702493|Experimental|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
11449695|NCT01702493|Experimental|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
11449696|NCT01702493|Experimental|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
11449697|NCT01702480|Experimental|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
11449698|NCT01702480|Experimental|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
11449699|NCT01702480|Experimental|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
11449700|NCT01702480|Experimental|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
11449701|NCT01702480|Placebo Comparator|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
11449702|NCT01702480|Experimental|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
11449703|NCT01702480|Placebo Comparator|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
11449704|NCT01702467|Experimental|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
11449706|NCT01702454|Experimental|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
11449707|NCT01702454|Experimental|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
11449708|NCT01702441|Experimental|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
11449709|NCT01702428|Experimental|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
11449710|NCT01702428|Experimental|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
11449711|NCT01702428|Experimental|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
11449712|NCT01702428|Active Comparator|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
11449713|NCT01702415|Placebo Comparator|Placebo|Placebo
11449714|NCT01702415|Experimental|Zoledronic acid|Active IMP
11449715|NCT01702402|Experimental|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
11449716|NCT01702402|Other|Comparison|A comparison area received standard government health services.
11449717|NCT01702389|Experimental|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
11449718|NCT01702376|Experimental|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
11449719|NCT01702376|Experimental|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
11449720|NCT01702376|Placebo Comparator|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
11449721|NCT01702376|Active Comparator|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
11449722|NCT01702363|Experimental|GSK573719|125mcg
11449723|NCT01702350|Experimental|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
11449724|NCT01702350|Experimental|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
11449725|NCT01702350|Experimental|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
11449726|NCT01702350|Experimental|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
11449727|NCT01702350|Experimental|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
11449728|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
11449729|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
11449730|NCT01702324|Experimental|DD-25|A concentration of 0.025% of topical DD-25 cream.
11449731|NCT01702311|Active Comparator|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
11449732|NCT01702311|No Intervention|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
11449733|NCT01702298|Experimental|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
11449734|NCT01702285|Experimental|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
11449735|NCT01702272||Dengue Virus|
11449736|NCT01702259|Experimental|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
11449737|NCT01702259|Sham Comparator|Placebo device|Inactive Erchonia GLS device
11449738|NCT01702246|Experimental|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
11449739|NCT01702233|Experimental|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
11449740|NCT01702233|Active Comparator|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
11449744|NCT01702207|Active Comparator|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
11449745|NCT01702207|Active Comparator|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
11449746|NCT01702194|Experimental|TD-1211 IV [C14]|TD-1211 IV [C14]
11449747|NCT01702194|Experimental|TD-1211 PO [C14]|TD-1211 PO [C14]
11449748|NCT01702181|Placebo Comparator|Placebo|Matching placebo.
11449749|NCT01702181|Active Comparator|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
11449750|NCT01702181|Experimental|OPA-15406|
11449751|NCT01702168||CBT Training|
11449752|NCT01702155|Experimental|DFP-10917|"7-day continuous infusion (in the vein): Starting dose 4 mg/m^2
~14-day continuous infusion (in the vein): Starting dose 10 mg/m^2
~Phase II Only: 6 mg/m^2 for the 14-day continuous infusion (in the vein)"
11449753|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
11449754|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
11449755|NCT01702129|Experimental|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
11449756|NCT01702116|Experimental|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
11449757|NCT01702116|Active Comparator|standard APR|conventional abdominoperineal resection (APR)
11449758|NCT01702103|Experimental|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
11449759|NCT01702103|Active Comparator|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
11449760|NCT01702090|Experimental|TMC114/ritonavir|
11449761|NCT01702077|Experimental|Neurofeedback first|Neurofeedback then sham feedback
11449762|NCT01702077|Experimental|Sham first|Sham feedback then neurofeedback
11449763|NCT01702064|Experimental|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.
~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.
~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.
~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
11449764|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
11449765|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
11449766|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
11449767|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
11449768|NCT01702038|Experimental|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
11449769|NCT01702025|Placebo Comparator|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.
~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
11449770|NCT01702025|Active Comparator|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.
~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
11449771|NCT01702025|Active Comparator|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.
~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
11449772|NCT01702025|Active Comparator|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)
~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
11449773|NCT01702012|Experimental|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
11449774|NCT01702012|Active Comparator|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
11449775|NCT01701999|Experimental|Vaccine|
11449776|NCT01701986|Experimental|Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)|"PREPARATIVE REGIMEN: Patients receive gemcitabine hydrochloride IV over 40-180 minutes on days -6 and -4, clofarabine IV over 1 hour on days -6 to -3, and busulfan IV over 3 hours on days -6 to -3. Patients with matched unrelated donors also receive antithymocyte globulin IV on days -3 to -1 and patients with CD20-positive disease also receive rituximab IV on days -14, -7, 1, and 8.
~TRANSPLANT: Patients undergo allogeneic BMT or PBSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO beginning on day -2 for up to 6 months and mycophenolate mofetil IV over 2 hours or PO TID beginning day 0."
11449777|NCT01701973|Other|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.
~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
11449778|NCT01701973|Other|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.
~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
11449779|NCT01701973|Other|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.
~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
11449780|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
11449781|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
11449782|NCT01701934|Experimental|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
11449783|NCT01701934|Placebo Comparator|Placebo pill|Placebo pill, once daily for 6 months
11449784|NCT01701921|Experimental|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
11449785|NCT01701921|Active Comparator|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
11449786|NCT01701921|Placebo Comparator|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
11449787|NCT01701882|Experimental|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
11449788|NCT01701869||NTHi positive|No intervention, this is an observational study
11449789|NCT01701869||NTHi negative|No intervention, this is an observational study
11449790|NCT01701869||Healthy Control|No intervention, this is an observational study
11449791|NCT01701856|Experimental|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
11449792|NCT01701843|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
11449793|NCT01701843|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
11449794|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
11449795|NCT01701830||Control group|30 healthy subject
11449796|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
11449797|NCT01701804||integrative treatment|
11449798|NCT01701791|Experimental|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
11449799|NCT01701791|No Intervention|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
11449800|NCT01701778|Experimental|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg
~Intravenous: 10 ml normal saline
~Anesthesia was induced and maintained with sevoflurane"
11449801|NCT01701778|Experimental|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg
~Intravenous: dexmedetomidine 1µg/kg
~Anesthesia was induced and maintained with sevoflurane"
11449802|NCT01701778|Placebo Comparator|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg
~Intravenous: 10 ml normal saline
~Anesthesia was induced and maintained with sevoflurane"
11449803|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
11449804|NCT01701752|Active Comparator|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
11449805|NCT01701752|Active Comparator|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
11449806|NCT01701752|Active Comparator|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
11449807|NCT01701752|Active Comparator|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
11449808|NCT01701752|Active Comparator|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
11449809|NCT01701752|Active Comparator|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
11449810|NCT01701739|Experimental|aleglitazar / digoxin|
11449811|NCT01701726|Experimental|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
11449812|NCT01701726|Sham Comparator|Sham acupuncture|"we use sham acupoints:
~The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))
~Half way between the tip of the elbow and the axilla
~On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.
~2cm superior to fu tu(LI18)"
11449813|NCT01701726|No Intervention|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
11449814|NCT01701713|Experimental|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
11449815|NCT01701713|Sham Comparator|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
11449816|NCT01701700|Experimental|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
11449817|NCT01701700|Active Comparator|optical aids|Use of existing optical aids for 2 months
11449818|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (>14 units for women, >21 units for men) at study enrollment
11449819|NCT01701674|Experimental|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
11449820|NCT01701661|Active Comparator|conservative treatment|Compression stockings class II
11449821|NCT01701661|Active Comparator|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
11449822|NCT01701648|Active Comparator|1|
11449823|NCT01701635|Experimental|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
11449824|NCT01701635|Active Comparator|Usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
11449825|NCT01701622|Experimental|Allopurinol, febuxostat|Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.
11449826|NCT01701609|Experimental|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
11449827|NCT01701596|Experimental|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
11449828|NCT01701596|Active Comparator|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
11449829|NCT01701583|Experimental|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
11449830|NCT01701570|Active Comparator|An Active Comparator exercise training intervention|The Active Comparator Groupwill participate in an exercise training intervention to distinguish the relative roles of objective factors (lactate level) and subjective factors (self-efficacy) in mediating pre-post change in RPE during low, moderate, and vigorous exercise.
11449831|NCT01701570|Placebo Comparator|A Placebo Attention Control|The placebo attention control group will receive monthly diabetes education and phone calls phone calls to monitor their blood glucose levels. Participants will receive an accelerometer to wear for one week.
11449832|NCT01701557|Active Comparator|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
11449833|NCT01701557|Active Comparator|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
11449834|NCT01701544|Sham Comparator|NBM DBS Off|NBM DBS switched off
11449835|NCT01701544|Active Comparator|NBM DBS On|NBM DBS Switched On
11449836|NCT01701531|Experimental|RBCPF|Treatment intervention arm
11449837|NCT01701518|Other|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
11449838|NCT01701505|Experimental|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
11449839|NCT01701505|Experimental|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
11449840|NCT01701505|Experimental|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
11449841|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
11449842|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
11449843|NCT01701479|Experimental|Experimental arm|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).
~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.
~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
11449844|NCT01701479|Active Comparator|Comparator arm|"A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.
~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
11449845|NCT01701466|Experimental|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
11449846|NCT01701466|Active Comparator|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
11449847|NCT01701453|Experimental|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
11449848|NCT01701453|Experimental|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
11449849|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
11449850|NCT01701414|Sham Comparator|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
11449890|NCT01701180|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
11449891|NCT01701180|Placebo Comparator|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
11449892|NCT01701154||Pompe|Adults and children with Pompe disease.
11449851|NCT01701414|Experimental|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
11449852|NCT01701401|Experimental|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
11449853|NCT01701401|Experimental|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
11449854|NCT01701401|Experimental|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
11449855|NCT01701401|Experimental|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
11449856|NCT01701388|Experimental|Ekso Safety and Efficacy|Observational study on the first time use of a robotic exoskeleton.
11449857|NCT01701375|Experimental|Arm 1|"PD 0332991 will be given orally days 1,2,3
~Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6
~Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
11449858|NCT01701362|Active Comparator|pregabalin|
11449859|NCT01701362|Placebo Comparator|placebo|
11449860|NCT01701349|Active Comparator|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:
~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
11449861|NCT01701349|Placebo Comparator|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:
~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
11449862|NCT01701336|Experimental|Unique Arm|"Ad6NSmut
~MVA-NSmut
~15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
11449863|NCT01701323|Experimental|Treatment (Ex-vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
11449864|NCT01701310|Experimental|Ferric carboxymaltose|
11449865|NCT01701310|Active Comparator|Ferrous Sulphate|
11449866|NCT01701297|Active Comparator|Co-trimoxazole|Co-trimoxazole 960mg daily po
11449867|NCT01701297|Experimental|VSL#3 active|VSL#3 active 2 sachets/daily
11449868|NCT01701297|Placebo Comparator|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
11449869|NCT01701284|Experimental|Right-Sided Low-Frequency rTMS|Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
11449870|NCT01701284|Experimental|Left-Sided High-Frequency rTMS|Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
11449871|NCT01701271|Experimental|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
11449872|NCT01701258|Active Comparator|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
11449873|NCT01701258|Placebo Comparator|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
11449874|NCT01701258|Active Comparator|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
11449875|NCT01701258|Placebo Comparator|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
11449876|NCT01701258|Active Comparator|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
11449877|NCT01701258|Placebo Comparator|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
11449878|NCT01701258|Active Comparator|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
11449879|NCT01701258|Placebo Comparator|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
11449880|NCT01701245|No Intervention|Standard of care|No intervention, standard of care
11449881|NCT01701245|Active Comparator|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
11449882|NCT01701232|Active Comparator|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
11449883|NCT01701232|Experimental|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
11449884|NCT01701219|Other|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
11449885|NCT01701219|Other|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
11449886|NCT01701206|Experimental|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
11449887|NCT01701206|No Intervention|Control arm|
11449888|NCT01701193|Placebo Comparator|Saline|1g/kg of body weight, 1 time intra-abdominal administration at time of surgery
11449889|NCT01701193|Experimental|Amino Acid|1g/kg of body weight, 1 time intra-abdominal administration at time of surgery
11449893|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
11449894|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
11449895|NCT01701128|Experimental|Speed TT|Walk on treadmill with progressive increases in speed
11449896|NCT01701128|Experimental|Mixed TT|Walk on treadmill with progressive increases in speed and incline
11449897|NCT01701128|Active Comparator|Control|Light-intensity exercise group, work flexibility and coordination
11449898|NCT01701115|Experimental|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
11449899|NCT01701115|Active Comparator|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
11449900|NCT01701102|Active Comparator|Mepivacaine 37.5 mg|
11449901|NCT01701102|Active Comparator|Mepivacaine 30 mg plus fentanyl 10 µg|
11449902|NCT01701102|Active Comparator|Mepivacaine 27 mg plus fentanyl 10 µg|
11449903|NCT01701102|Active Comparator|Mepivacaine 24 mg plus fentanyl 10 µg|
11449904|NCT01701089|Experimental|RO4602522 Group 1|
11449905|NCT01701089|Experimental|RO4602522 Group 2|
11449906|NCT01701076|Experimental|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
11449907|NCT01701063|Experimental|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
11449908|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
11449909|NCT01701037|Experimental|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
11449910|NCT01701024|Active Comparator|ACYC|ACYC active, topically applied to the face for 12 weeks
11449911|NCT01701024|Placebo Comparator|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
11449912|NCT01701011|Experimental|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
11449913|NCT01701011|No Intervention|Routine care control|Questionnaires
11449914|NCT01701011|No Intervention|Monitoring control|DRK and Questionnaires
11449915|NCT01700998|Placebo Comparator|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
11449916|NCT01700998|Experimental|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
11449917|NCT01700985|Experimental|122-0551|
11449918|NCT01700985|Placebo Comparator|Vehicle|
11449919|NCT01700972|Experimental|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
11449920|NCT01700959|Active Comparator|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
11449921|NCT01700959|Placebo Comparator|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
11449922|NCT01700946|Active Comparator|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone
~Cells for infusion are prepared using the CliniMACS System."
11449923|NCT01700946|Active Comparator|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone
~Cells for infusion are prepared using the CliniMACS System."
11449924|NCT01700933|Active Comparator|High-dosage-group|
11449925|NCT01700933|Active Comparator|Low-dosage-group|
11449926|NCT01700920|Experimental|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.
~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.
~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
11449927|NCT01700907|Active Comparator|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
11449928|NCT01700907|Active Comparator|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
11449929|NCT01700894|Experimental|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.
~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
11449976|NCT01700634||Control subjects|
11449977|NCT01700621|Experimental|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
11455542|NCT01662414|Placebo Comparator|Placebo (Soy protein)|
11449930|NCT01700894|Experimental|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.
~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
11449931|NCT01700894|Experimental|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.
~Participants in the WWP receive no telephone calls."
11449932|NCT01700881|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
11449933|NCT01700881|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
11449934|NCT01700868|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
11449935|NCT01700868|Active Comparator|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
11449936|NCT01700855|Experimental|Electroacupuncture|Patients received electroacupuncture stimulation
11449937|NCT01700855|Sham Comparator|Non-electroacupuncture|Patients received sham electroacupuncture
11449938|NCT01700829|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
11449939|NCT01700829|Active Comparator|Ketamine|0.5 mg/kg, I.V. (in the vein)
11449940|NCT01700816|Experimental|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
11449941|NCT01700816|Placebo Comparator|Sham light|<1000 Lux gaze directed every morning from 8 am until 8:30 am
11449942|NCT01700803|Experimental|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
11449943|NCT01700803|Experimental|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
11449944|NCT01700790|Experimental|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
11449945|NCT01700777|Experimental|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
11449946|NCT01700777|Active Comparator|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
11449947|NCT01700751|Experimental|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
11449948|NCT01700751|Experimental|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
11449949|NCT01700751|Experimental|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
11449950|NCT01700751|Experimental|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
11449951|NCT01700751|No Intervention|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
11449952|NCT01700738|Experimental|gastric ring surgery|in this group a gastric ring will be put by surgery.
11449953|NCT01700738|Active Comparator|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
11449954|NCT01700725|Experimental|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
11449955|NCT01700725|Experimental|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
11449956|NCT01700725|No Intervention|Control Group|Control group subjects continue to use routine care only
11449957|NCT01700712|Active Comparator|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
11449958|NCT01700712|Placebo Comparator|Sugar pill|2 tablets a day for 2 weeks
11449959|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
11449960|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
11449961|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
11449962|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
11449963|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
11449964|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
11449965|NCT01700686||Obese subjects|Meal test and dexa scan
11449966|NCT01700673|Experimental|Myeloablative BMT|Azacitidine and sargramostim after myeloablative stem cell transplant
11449967|NCT01700673|Experimental|Non-myeloablative BMT|Azacitidine and sargramostim after non-myeloablative stem cell transplant
11449968|NCT01700673|Experimental|Standard consolidation|Azacitidine and sargramostim after standard consolidation
11449969|NCT01700660||VIO|Patients operated under VIO.
11449970|NCT01700660||Control|Patients operated without VIO.
11449971|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
11449972|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
11449973|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
11449974|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
11449975|NCT01700634||OA patients with LOW central sensitization|
11449978|NCT01700621|Active Comparator|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
11449979|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
11449980|NCT01700595|Experimental|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
11449981|NCT01700582||Patients with advanced lung cancer|Patients with advanced lung cancer
11449982|NCT01700569|Experimental|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
11449983|NCT01700556|Active Comparator|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
11449984|NCT01700556|Experimental|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
11449985|NCT01700556|Experimental|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
11449986|NCT01700543||1|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.
11449987|NCT01700530|Experimental|Statin|Statins (40mg/day)for an average of 12 weeks
11449988|NCT01700530|Experimental|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
11449989|NCT01700530|Active Comparator|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
11449990|NCT01700517|Sham Comparator|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
11449991|NCT01700517|Experimental|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
11449992|NCT01700517|Experimental|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
11449993|NCT01700504|Experimental|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
11449994|NCT01700504|Active Comparator|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
11449995|NCT01700491|Active Comparator|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
11449996|NCT01700491|Active Comparator|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
11449997|NCT01700478|Experimental|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
11449998|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
11449999|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
11450000|NCT01700439|Experimental|EDWARDS INTUITY valve|All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
11450001|NCT01700426|Active Comparator|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.
~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
11450002|NCT01700426|Active Comparator|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.
~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
11450003|NCT01700413|Experimental|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
11450004|NCT01700400|Experimental|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3
~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3
~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3
~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
11450038|NCT01700140|Placebo Comparator|placebo group|
11450039|NCT01700127|Other|Breastfeeding|Breastfeeding Encouraged
11450040|NCT01700127|Active Comparator|Breastfeeding Withheld|Breastfeeding Withheld
11450041|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
11450005|NCT01700387|Experimental|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:
~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
11450006|NCT01700387|Placebo Comparator|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:
~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
11450007|NCT01700374||Women without Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:
~Adverse Childhood Events (ACE) Questionnaire;
~Perceived Stress Scale (PSS);
~A general health and demographic questionnaire.
~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.
~Women who report 0 or 1 adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
11450008|NCT01700374||Women with Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:
~Adverse Childhood Events (ACE) Questionnaire;
~Perceived Stress Scale (PSS);
~A general health and demographic questionnaire.
~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.
~Women who report 2 or more adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
11450009|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
11450010|NCT01700348|Experimental|Airflosser|Use of Airflosser
11450011|NCT01700348|Active Comparator|Manual Floss|Normal Routine
11450012|NCT01700335|Experimental|SyB L-1101|"In Cohort 1, SyB L-1101 1200 mg/day group, Participants were administered 1200 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.
~In Cohort 2, SyB L-1101 1800 mg/day group, Participants were administered 1800 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.
~For both Cohorts, the treatment period of 14 days constitutes 1 cycle, and the treatment was allowed for up to 8 cycles."
11450013|NCT01700322|Active Comparator|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
11450014|NCT01700322|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
11450015|NCT01700322|Active Comparator|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
11450016|NCT01700309|No Intervention|Control group|Treatment as usual
11450017|NCT01700309|Experimental|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
11450018|NCT01700296|No Intervention|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
11450019|NCT01700296|Experimental|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:
~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)
~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
11450020|NCT01700283|Experimental|exercise education and walking program|
11450021|NCT01700283|No Intervention|maintain their daily activity|
11450022|NCT01700270|Experimental|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
11450023|NCT01700257|Other|CT scan & Early CDT Lung test|Every study participant receives a CT scan & Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
11450024|NCT01700244|Experimental|Pacemaker|
11450025|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
11450026|NCT01700218|Other|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
11450027|NCT01700218|Other|control|patients in the control arm will not record any vital parameter
11450028|NCT01700205|Active Comparator|Type of Formula: CMF|Infants are randomized to feed standard cow milk formula during first year of life
11450029|NCT01700205|Experimental|Type of Formula: EHF|Infants are randomized to feed extensively hydrolyzed infant formula during first year of life
11450030|NCT01700192|Experimental|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
11450031|NCT01700192|Placebo Comparator|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
11450032|NCT01700179|Experimental|ACH-0143102 plus ribavirin daily|ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose on Days 2-84. Weight-based RBV(as per label) for Days 1-84.
11450033|NCT01700166|Experimental|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
11450034|NCT01700153|Experimental|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
11450035|NCT01700153|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
11450036|NCT01700140|Experimental|SyB D-0701: high dose group|
11450037|NCT01700140|Experimental|SyB D-0701: low dose group|
11450042|NCT01700075|Active Comparator|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.
~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.
~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
11450043|NCT01700075|Experimental|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
11450044|NCT01700062|Experimental|Medium calorie|
11450045|NCT01700062|Experimental|standard calorie|
11450046|NCT01700049|Experimental|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
11450047|NCT01700036|Experimental|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
11450048|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
11450049|NCT01700010|Experimental|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.
~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
11450050|NCT01699997|Experimental|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
11450051|NCT01699997|Placebo Comparator|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
11450052|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
11450053|NCT01699971|Active Comparator|Lichtenstein|Hernia repair with lichtenstein propylene mesh
11450054|NCT01699958|Experimental|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
11450055|NCT01699958|No Intervention|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
11450056|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
11450057|NCT01699932|Experimental|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
11450058|NCT01699919|Active Comparator|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
11450059|NCT01699919|Placebo Comparator|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
11450060|NCT01699906|Experimental|Dietary intervention|Diet regimen to induce weight loss
11450061|NCT01699893|Experimental|unique arm|"At V0: 1500 will be screened
~At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)
~At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
11450062|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
11450063|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
11450064|NCT01699854|Active Comparator|capsaicin patch|
11450065|NCT01699854|Placebo Comparator|placebo patch|
11450066|NCT01699841||HIV+ and HIV- mothers and their infants|
11450067|NCT01699828|Experimental|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
11450068|NCT01699828|Experimental|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
11450069|NCT01699828|Placebo Comparator|Placebo|Placebo (encapsulated)
11450070|NCT01699828|Experimental|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
11450071|NCT01699815|Active Comparator|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
11450072|NCT01699815|Active Comparator|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
11450073|NCT01699802|Experimental|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
11450074|NCT01699789|Active Comparator|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
11450075|NCT01699789|Experimental|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
11450076|NCT01699776|Active Comparator|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
11450077|NCT01699776|Active Comparator|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
11450078|NCT01699763|Experimental|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
11450079|NCT01699750|Experimental|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
11450080|NCT01699750|Active Comparator|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
11450081|NCT01699737|Experimental|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
11450082|NCT01699737|Experimental|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
11450083|NCT01699737|Experimental|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
11450084|NCT01699737|Active Comparator|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
11450085|NCT01699737|Placebo Comparator|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
11450086|NCT01699724|Active Comparator|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
11450087|NCT01699724|Experimental|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
11450088|NCT01699724|Experimental|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
11450089|NCT01699711|Active Comparator|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
11450090|NCT01699711|Placebo Comparator|Placebo|No active treatment is given.
11450091|NCT01699698|Experimental|Test subject|
11450092|NCT01699685|Placebo Comparator|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
11450093|NCT01699685|Active Comparator|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
11450094|NCT01699672|Experimental|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
11450095|NCT01699672|No Intervention|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
11450096|NCT01699646|Active Comparator|CTG + FBS|intrapartum surveillance with CTG+FBS
11450097|NCT01699646|Active Comparator|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
11450098|NCT01699620|Experimental|Dermatome|BAHA implant insertion with Dermatome technique
11450099|NCT01699620|Experimental|Linear incision|BAHA implant insertion with linear incision
11450100|NCT01699607|Experimental|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
11450101|NCT01699594|Experimental|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
11450102|NCT01699594|Active Comparator|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
11450103|NCT01699581|Experimental|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery
~1 dose of Nestle Impact Advanced Recovery orally three times a day"
11450104|NCT01699568|Experimental|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
11450105|NCT01699568|Active Comparator|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
11450106|NCT01699555|Experimental|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
11450107|NCT01699555|Placebo Comparator|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
11450108|NCT01699542|Active Comparator|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
11450109|NCT01699542|Active Comparator|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
11450110|NCT01699529|Experimental|Renal Denervation|
11450111|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
11450112|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
11450162|NCT01699139|Active Comparator|positional device|
11450113|NCT01699503|No Intervention|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
11450114|NCT01699503|Experimental|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
11450115|NCT01699490|Experimental|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.
~Add-on treatment to 40 mg per day of valsartan"
11450116|NCT01699490|Active Comparator|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.
~Add-on treatment to placebo"
11450117|NCT01699477|Other|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
11450118|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
11450119|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
11450120|NCT01699464|Active Comparator|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
11450121|NCT01699438|Experimental|Mesalazine|
11450122|NCT01699438|Placebo Comparator|Placebo|
11450123|NCT01699425|Experimental|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
11450124|NCT01699425|Active Comparator|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
11450125|NCT01699412|Experimental|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
11450126|NCT01699412|Experimental|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
11450127|NCT01699399|Experimental|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
11450128|NCT01699399|Experimental|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
11450129|NCT01699399|Active Comparator|air insufflation|standard colonoscopy using traditional air insufflation during insertion
11450130|NCT01699386|Active Comparator|Control Study Formula|protein hydrolysate formula
11450131|NCT01699386|Experimental|Experimental Study Formula|free-amino acid-based medical food
11450132|NCT01699373|Experimental|Ultrasound-assisted|Pre-procedural ultrasound scan performed
11450133|NCT01699373|No Intervention|Manual Palpation|
11450134|NCT01699360|Experimental|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.
~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.
~Sirolimus:tablet,2mg/d, once a day."
11450135|NCT01699347|Experimental|OK432|Intracystic injection of OK432 under US guiding
11450136|NCT01699334|Experimental|Psychoeducational video|
11450137|NCT01699334|Active Comparator|Relaxation video|
11450138|NCT01699321|Experimental|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
11450139|NCT01699321|Other|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
11450140|NCT01699308|Experimental|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using Genotropin (rhGH) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
11450141|NCT01699308|No Intervention|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
11450142|NCT01699295|Experimental|A+PAAC|Lessons delivered using A+PAAC
11450143|NCT01699295|Active Comparator|CON|Regular sedentary lessons
11450144|NCT01699282|Experimental|Group thorough VKA (antivitamin K)education|
11450145|NCT01699282|Active Comparator|control group|
11450146|NCT01699269|Other|brain tumor|
11450147|NCT01699256|Experimental|Enhanced strategy|Enhanced implementation strategy
11450148|NCT01699256|Active Comparator|Strategy as usual|Normal implementation strategy
11450149|NCT01699243||Epidural|subjects under epidural anesthesia
11450150|NCT01699230|Experimental|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
11450151|NCT01699230|No Intervention|Control group|
11450152|NCT01699204|Placebo Comparator|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
11450153|NCT01699204|Active Comparator|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
11450154|NCT01699204|Experimental|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
11450155|NCT01699191|Active Comparator|Probiotic Mixture|Probiotic mixture
11450156|NCT01699191|Placebo Comparator|Placebo|Placebo
11450157|NCT01699178|Experimental|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
11450158|NCT01699178|Active Comparator|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
11450159|NCT01699165|Sham Comparator|Placebo Nasal filter|Placebo treatment
11450160|NCT01699165|Active Comparator|Nasal Filter|Active treatment
11450161|NCT01699152|Experimental|TG02 citrate|TG02 citrate capsules given orally.
11450164|NCT01699126|Experimental|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
11450165|NCT01699126|Active Comparator|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
11450166|NCT01699126|Active Comparator|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
11450167|NCT01699126|No Intervention|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
11450168|NCT01699100|Experimental|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
11450169|NCT01699087|Experimental|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
11450170|NCT01699074|Experimental|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
11450171|NCT01699074|Experimental|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
11450172|NCT01699074|Experimental|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
11450173|NCT01699074|Placebo Comparator|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
11450174|NCT01699074|Active Comparator|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
11450175|NCT01699061|Placebo Comparator|Placebo|Placebo tablet administered with a meal twice a day on Day 1
11450176|NCT01699061|Experimental|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
11450177|NCT01699048|Other|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
11450178|NCT01699048|Other|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
11450179|NCT01699048|Other|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
11450180|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
11450181|NCT01699022|Experimental|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.
~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
11450182|NCT01699009|Experimental|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
11450183|NCT01699009|Placebo Comparator|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
11450184|NCT01698996|Active Comparator|No Packing|No Packing
11450185|NCT01698996|Experimental|Packing|Packing
11450186|NCT01698970|Experimental|1 = Tested product|
11450187|NCT01698970|Placebo Comparator|2 = Control product|
11450188|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
11450189|NCT01698944|Experimental|Somatropin|
11450190|NCT01698931|Experimental|Treatment period 1|
11450191|NCT01698931|Active Comparator|Treatment period 2|
11450192|NCT01698931|Placebo Comparator|Treatment period 3|
11450193|NCT01698918|Experimental|Everolimus + letrozole/exemestane|Enrolled patients will receive everolimus in combination with letrozole in the first line setting until disease progression, unacceptable toxicity or withdrawal of consent. Following disease progression in the first line setting, patients will be offered everolimus in combination with exemestane. Patients who discontinue treatment in the first line setting due to unacceptable toxicity or due to withdrawal of consent will not be offered everolimus plus exemestane. Those patients treated in the second line setting will continue treatment until disease progression, unacceptable toxicity or withdrawal of consent.
11450194|NCT01698905|Experimental|nilotinib|70 patients who maintain MR4.5 during the one year nilotinib consolidation phase will stop treatment when they enter the treatment-free remission (TFR) phase
11450195|NCT01698892|Experimental|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
11450196|NCT01698892|Active Comparator|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
11450197|NCT01698879|Experimental|Single arm, two cohorts|Idarubicin, cytarabine, Mylotarg, G-CSF.
11450198|NCT01698866|Experimental|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
11450199|NCT01698840|Experimental|Investigational Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Investigational Nutrition group will receive vitamin D drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
11450200|NCT01698840|Placebo Comparator|Routine Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Routine Nutrition group will receive placebo drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
11450201|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
11450202|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
11450203|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
11450204|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
11450205|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
11450206|NCT01698814|Experimental|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
11450207|NCT01698814|Placebo Comparator|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
11450208|NCT01698801|Experimental|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
11450209|NCT01698788|Experimental|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
11450210|NCT01698788|Experimental|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
11450211|NCT01698775|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
11450212|NCT01698775|Active Comparator|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
11450213|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.
~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.
~Questionnaires completed at baseline, 3, and at 6 months."
11450214|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.
~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.
~Questionnaires completed at baseline, 3, and at 6 months."
11450215|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.
~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.
~Questionnaires completed at baseline, 3, and at 6 months."
11450216|NCT01698749|Experimental|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
11450217|NCT01698736|Active Comparator|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
11450218|NCT01698736|Experimental|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
11450219|NCT01698723|Active Comparator|Ribavirin|1000 mg (5 capsules)
11450220|NCT01698723|Placebo Comparator|Placebo|5 capsules of placebo
11450221|NCT01698710|Experimental|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
11450222|NCT01698697|Active Comparator|U100|
11450223|NCT01698697|Experimental|U200|
11450224|NCT01698684|Placebo Comparator|Placebo|
11450225|NCT01698684|Experimental|Avanafil 100 mg|
11450226|NCT01698684|Experimental|Avanafil 200 mg|
11450227|NCT01698671|Other|InterGard Synergy Vascular Graft|
11450228|NCT01698658|Experimental|Diagnostic (SoftVue ultrasound tomography)|Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
11450229|NCT01698645||PecFent®|
11450230|NCT01698632||benign-looking adnexal masses|
11450231|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
11450232|NCT01698606|Active Comparator|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
11450233|NCT01698606|Experimental|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
11450234|NCT01698593|Active Comparator|Ring Finger Nerve Block|
11450235|NCT01698580|Active Comparator|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
11450236|NCT01698580|Experimental|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
11450237|NCT01698567|Active Comparator|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma
~ATIII will be dosed using the formula recommended by the manufacturer:
~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
~a."
11450238|NCT01698567|Placebo Comparator|Placebo|placebo (normal saline)
11450239|NCT01698554|Experimental|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
11450323|NCT01697865|Active Comparator|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
11450240|NCT01698554|Active Comparator|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
11450241|NCT01698554|Placebo Comparator|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
11450242|NCT01698554|Placebo Comparator|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
11450243|NCT01698541|Experimental|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
11450244|NCT01698541|Active Comparator|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
11450245|NCT01698528|Experimental|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
11450246|NCT01698528|No Intervention|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
11450247|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup
~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study.
~--------------------------------------------------------------------------------"
11450248|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml*min-1*kg-1>60), 20-30 year, BMI: 18,5-25kg/m2, males.
11450249|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml*min-1*kg-1<50), 20-30 year, BMI: 18,5-25kg/m2, males.
11450250|NCT01698476|Active Comparator|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
11450251|NCT01698476|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
11450252|NCT01698463|Other|Identify Patients at Risk/Exercise Prescription|The intervention was delivered in two visits and two follow-up phone calls. Physician identifies that the patient is at risk of falls or fractures Visit one: individualized exercise prescription by a physiotherapist. Visit two: motivational interviewing (behavioural counselling) by kinesiologist Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
11450253|NCT01698450|Other|Focused Ultrasound for Movement Disorders|
11450254|NCT01698437|Other|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
11450255|NCT01698398|Experimental|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
11450256|NCT01698385|Active Comparator|Lifestyle counseling|
11450257|NCT01698385|No Intervention|Control, just measurements|
11450258|NCT01698372|Experimental|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
11450259|NCT01698372|No Intervention|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
11450260|NCT01698346|No Intervention|control|50 unvaccinated pregnant women
11450261|NCT01698346|Active Comparator|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
11450262|NCT01698333|Experimental|122-0551|
11450263|NCT01698320|Placebo Comparator|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
11450264|NCT01698320|Experimental|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.
~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
11450265|NCT01698307|Active Comparator|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
11450266|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Index (HBI).
11450267|NCT01698294|Experimental|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
11450268|NCT01698294|Active Comparator|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
11450389|NCT01697462||Cohort|
11450390|NCT01697449||Cohort|
11450269|NCT01698281|Experimental|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
11450270|NCT01698281|Active Comparator|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;
~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
11450271|NCT01698268|Experimental|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
11450272|NCT01698268|Active Comparator|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
11450273|NCT01698255|Experimental|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:
~basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;
~the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
11450274|NCT01698255|Active Comparator|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
11450275|NCT01698242|Experimental|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
11450276|NCT01698242|Active Comparator|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
11450277|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
11450278|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
11450279|NCT01698203|Experimental|ropivacaine|
11450280|NCT01698203|Placebo Comparator|placebo|
11450281|NCT01698190|Active Comparator|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
11450282|NCT01698190|Active Comparator|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
11450283|NCT01698177|Active Comparator|Group A|This group will receive the influenza vaccine preoperatively.
11450284|NCT01698177|Active Comparator|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
11450285|NCT01698177|No Intervention|Group C|Group C subjects have already received the seasonal flu vaccine.
11450286|NCT01698177|Placebo Comparator|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
11450287|NCT01698164|Active Comparator|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.
~estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
11450288|NCT01698164|Experimental|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.
~estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
11450289|NCT01698164|Experimental|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.
11450290|NCT01698138|Placebo Comparator|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
11450291|NCT01698138|Active Comparator|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
11450292|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
11450293|NCT01698112|Experimental|Flaxseed High Dose|
11450294|NCT01698112|Experimental|Flaxseed Low Dose|
11450295|NCT01698112|No Intervention|Flaxseed control|
11450296|NCT01698086|Experimental|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
11450297|NCT01698086|No Intervention|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
11450298|NCT01698073|Experimental|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
11450391|NCT01697436|Experimental|Crossover Period 1|
11450392|NCT01697436|Experimental|Crossover Period 2|
11450299|NCT01698073|Active Comparator|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
11450300|NCT01698060|Experimental|Intestinal Delivery|ND1.1
11450301|NCT01698047|Experimental|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.
~The Resiliency Class manual covers the following topics:
~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
11450302|NCT01698047|Active Comparator|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
11450303|NCT01698034|Experimental|Volunteering|Weekly volunteering with elementary school children in after school programs
11450304|NCT01698034|No Intervention|Control|Wait-list control
11450305|NCT01698008|Experimental|Mobile application Diabetes Doctor|The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
11450306|NCT01698008|No Intervention|Standard of Care|The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
11450307|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
11450308|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
11450309|NCT01697982|Experimental|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
11450310|NCT01697982|Experimental|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
11450311|NCT01697982|No Intervention|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
11450312|NCT01697969|Experimental|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
11450313|NCT01697956|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
11450314|NCT01697956|Placebo Comparator|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
11450315|NCT01697943|Experimental|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
11450316|NCT01697930|Experimental|[18F] 4-L-Fluoroglutamine (2S,4R)|This pilot, first in-human microdose PET trial of the positron-emitting agent [18F] 4-L-Fluoroglutamine (2S,4R) will be an open-label study. The [18F] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection. In all study patients, the pharmacokinetics, metabolism, and biodistribution of [18F] 4-L-Fluoroglutamine (2S,4R) will be evaluated by non-invasive blood- and PET-based assays, at multiple time points (see Table 1,) during one day. Eligible patients optionally can participate in the study twice, on a separate date, receiving a second radiotracer microdose of [18F] 4-L-Fluoroglutamine (2S,4R), followed by non-invasive blood- and PET-based assays. At the discretion of the investigator, scan 3 can be waived.
11450317|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
11450318|NCT01697904|Experimental|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR < 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.
~Targeted Pre-ductal SpO2 After birth
~min 60%-65%
~min 65%-70%
~min 70%-75%
~min 75%-80%
~min 80%-85%
~10 min 85%-94%"
11450319|NCT01697904|Active Comparator|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
11450320|NCT01697891|Experimental|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
11450321|NCT01697878|Experimental|Randomization Group 1|CPAP first followed by standard of care
11450322|NCT01697878|Active Comparator|Randomization group 2|Standard of care followed by CPAP
11450324|NCT01697865|Active Comparator|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
11450325|NCT01697852|Experimental|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
11450326|NCT01697852|Active Comparator|LLIN only|LLIN by universal coverage campaign
11450327|NCT01697826|Active Comparator|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
11450328|NCT01697826|Active Comparator|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
11450329|NCT01697800|Placebo Comparator|Placebo|Patients received placebo capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
11450330|NCT01697800|Active Comparator|Tadalafil|Patients received 20 mg tadalafil capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
11450331|NCT01697787|Other|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
11450332|NCT01697787|Other|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
11450333|NCT01697761|Experimental|Treatment Group|treat by moxibustion and acupuncture
11450334|NCT01697761|Experimental|Control Group|treat by Sham acupuncture and moxibustion
11450335|NCT01697748|Placebo Comparator|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
11450336|NCT01697748|Active Comparator|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
11450337|NCT01697735|Experimental|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
11450338|NCT01697735|Active Comparator|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
11450339|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
11450340|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
11450341|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
11450342|NCT01697709|Placebo Comparator|Placebo|Placebo medication
11450343|NCT01697709|Experimental|quetiapine|Quetiapine treatment
11450344|NCT01697696|Experimental|NVA237 dose 1|NVA237 dose 1
11450345|NCT01697696|Active Comparator|Long-acting beta 2-agonist (LABA)|QAB149
11450346|NCT01697683|Active Comparator|Probiotic Rhamnosus Lactobacilli|
11450347|NCT01697683|Placebo Comparator|Sugar pill|
11450348|NCT01697670|Experimental|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
11450349|NCT01697657|Experimental|Detemir|
11450350|NCT01697657|Active Comparator|NPH|
11450351|NCT01697644|Experimental|Low dose|
11450352|NCT01697644|Experimental|High dose|
11450353|NCT01697631|Experimental|BIAsp|
11450354|NCT01697631|Experimental|Insulin aspart|
11450355|NCT01697618|Experimental|BIAsp 30|
11450356|NCT01697618|Active Comparator|BHI 30|
11450357|NCT01697605|Experimental|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
11450358|NCT01697592|Experimental|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
11450359|NCT01697592|Experimental|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
11450360|NCT01697592|Experimental|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
11450361|NCT01697592|Experimental|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
11450362|NCT01697592|Experimental|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
11450363|NCT01697592|Placebo Comparator|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
11450364|NCT01697592|Placebo Comparator|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
11450393|NCT01697436|Experimental|Crossover Period 3|
11450394|NCT01697436|Experimental|Crossover Period 4|
11450395|NCT01697423|Experimental|platelet-rich plasma|
11450365|NCT01697592|Placebo Comparator|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
11450366|NCT01697592|Placebo Comparator|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
11450367|NCT01697592|Placebo Comparator|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
11450368|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to <12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to <4 months old were administered 2.5 mg/kg; participants 0 to <1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
11450369|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
11450370|NCT01697579|Experimental|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
11450371|NCT01697579|Experimental|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
11450372|NCT01697579|Placebo Comparator|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
11450373|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
11450374|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
11450375|NCT01697566|Experimental|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:
~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day
~After week 4, participant continues to take 2 capsules of metformin 2 times each day.
~Each capsule is 425 mg."
11450376|NCT01697566|Experimental|Placebo + Lifestyle Intervention|Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
11450377|NCT01697566|Experimental|Metformin + Lifestyle Intervention|"Participants gradually increase the dose of metformin by mouth as listed below:
~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day
~After week 4, participant continues to take 2 capsules of metformin 2 times each day.
~Each capsule is 425 mg.
~Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period."
11450378|NCT01697566|Placebo Comparator|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
11450379|NCT01697553|Experimental|Home automation pack coupled to teleassistance service|
11450380|NCT01697553|Active Comparator|Home without automation pack coupled to teleassistance service|
11450381|NCT01697527|Experimental|Treatment (gene and vaccine therapy)|"CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.
~TRANSPLANT: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV on day 0. Patients also receive NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy ID on days 1, 14, and 30 and aldesleukin SC BID on days 1-14. Patients may receive 3 additional doses of NY-ESO-1 (157-165) peptide pulsed dendritic cell vaccine therapy after day 90."
11450382|NCT01697514|Experimental|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
11450383|NCT01697514|Experimental|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
11450384|NCT01697501|Experimental|Chronic hepatitis B patients|
11450385|NCT01697488||Cohort|Overall sample
11450386|NCT01697488||Subgroup|Patients aged >/= 70 years
11450387|NCT01697475|Experimental|Intervention Group|Motivational text messaging
11450388|NCT01697475|No Intervention|Control Group|Step count
11450399|NCT01697384|Experimental|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
11450400|NCT01697371|Experimental|Proton Radiation|
11450401|NCT01697358|Active Comparator|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
11450402|NCT01697358|Active Comparator|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
11450403|NCT01697345|Experimental|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
11450404|NCT01697332|Experimental|Subjects with and without COPD|All subjects will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function.
11450405|NCT01697319|Experimental|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
11450406|NCT01697306|Active Comparator|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
11450407|NCT01697306|Active Comparator|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
11450408|NCT01697293|Experimental|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I & II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
11450409|NCT01697280|Experimental|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
11450410|NCT01697280|Experimental|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
11450411|NCT01697280|Experimental|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
11450412|NCT01697280|No Intervention|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
11450413|NCT01697267|Experimental|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 & 20 months with standardised steroid taper
11450414|NCT01697267|Active Comparator|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
11450415|NCT01697241|Experimental|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
11450416|NCT01697241|Other|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
11450417|NCT01697228|Other|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
11450418|NCT01697228|Other|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
11450419|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
11450420|NCT01697202||no intervention|
11450421|NCT01697189|Experimental|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
11450422|NCT01697189|No Intervention|No fatigue management training|The control group subjects did not participate in the fatigue management training.
11450423|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
11450424|NCT01697150|Experimental|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
11450425|NCT01697137|No Intervention|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
11450426|NCT01697137|Experimental|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
11450427|NCT01697124|Experimental|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
11450428|NCT01697111|Experimental|Arm 1|
11450429|NCT01697111|Experimental|Arm 2|
11450430|NCT01697111|Active Comparator|Arm 3|
11450431|NCT01697098|Experimental|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
11450432|NCT01697098|Experimental|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
11450433|NCT01697085|Experimental|Sea buckthorn oil|3 g (6 capsules)/day for three months
11450434|NCT01697085|Placebo Comparator|Placebo oil|3 g (6 capsules)/day for three months
11450435|NCT01697072|Experimental|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
11450436|NCT01697072|Placebo Comparator|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
11450437|NCT01697059|Experimental|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
11450438|NCT01697046|Experimental|Isentress+Truvada|All participants will receive the intervention
11450439|NCT01697020|Experimental|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
11450440|NCT01697020|Active Comparator|Arm 2|Mercaptopurine 50mg tablets
11450441|NCT01697007|Experimental|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
11450442|NCT01697007|Experimental|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
11450443|NCT01697007|Experimental|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
11450444|NCT01696994|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
11450445|NCT01696994|Active Comparator|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
11450446|NCT01696981|Active Comparator|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
11450447|NCT01696981|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
11450448|NCT01696968|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
11450449|NCT01696968|Active Comparator|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
11450450|NCT01696955|Experimental|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11450451|NCT01696955|Experimental|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11450452|NCT01696942|Experimental|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
11450453|NCT01696942|Active Comparator|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
11450454|NCT01696929|Experimental|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
11450455|NCT01696916|Experimental|exercise testing|6-minute walking test with pCO2 and pO2 measurement
11450456|NCT01696903|No Intervention|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
11450457|NCT01696903|Active Comparator|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
11450458|NCT01696890|Active Comparator|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
11450459|NCT01696890|Active Comparator|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
11450460|NCT01696877|Active Comparator|Degarelix|Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg at 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require prostate-specific antigen evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
11450461|NCT01696877|Experimental|Cyclophosphamide, GVAX and Degarelix|Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg.
11450462|NCT01696864|Experimental|stroke patients - hand|stroke patients with the ability to move their hand
11450463|NCT01696864|Experimental|stroke patient - arm|stroke patients with the ability to move their arms
11450464|NCT01696851||wheelchair rugby players with tetraplegia|
11450465|NCT01696851||other routine sport participants with tetraplegia|
11450466|NCT01696838|Experimental|EA group|Electroacupuncture group
11450467|NCT01696838|Experimental|MOX group|Herbs-partitioned moxibustion group
11450468|NCT01696825|Experimental|Diazepam Tablet, 5 mg, Vaginal|
11450469|NCT01696825|Experimental|Diazepam Suppository, 5 mg, Vaginal|
11450470|NCT01696825|Experimental|Diazepam Cream, 5 mg, Vaginal|
11450471|NCT01696825|Active Comparator|Diazepam Tablet, 5 Mg, Oral|
11450472|NCT01696812|Experimental|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
11450473|NCT01696799|Experimental|Econazole Nitrate Foam|Investigational Drug Product
11450474|NCT01696799|Placebo Comparator|Vehicle Foam|Vehicle Foam Comparator
11450475|NCT01696799|Active Comparator|Econazole Nitrate Cream|Active comparator cream product
11450476|NCT01696786|Experimental|Oocyte cryopreservation|
11450477|NCT01696773|Experimental|Tangerine tomato juice|Tangerine tomato juice will be fed
11450478|NCT01696773|Experimental|Red tomato juice|Red tomato juice will be fed
11450479|NCT01696760|Experimental|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
11450480|NCT01696760|Experimental|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
11450481|NCT01696747||Diabetic|participants with a primary etiology of diabetic gastroparesis
11450482|NCT01696747||Idiopathic|participants with a primary etiology of idiopathic gastroparesis
11450483|NCT01696747||Post-Nissen|participants with a primary etiology of post-Nissen fundoplication gastroparesis
11450484|NCT01696734|Experimental|Treatment (domperidone)|Patients receive domperidone PO TID or QID. Treatment continues in the absence of disease progression or unacceptable toxicity.
11450485|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
11450486|NCT01696708|Other|Patients|31-Phosphorus RMN Spectroscopy
11450487|NCT01696708|Other|Volunteers|31-Phosphorus RMN Spectroscopy
11450488|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
11450489|NCT01696682|Experimental|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
11450490|NCT01696682|Experimental|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
11450491|NCT01696669|Experimental|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:
~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.
~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.
~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%.
~High risk patients:
~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
11450492|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
11450493|NCT01696643|Experimental|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
11450494|NCT01696643|Placebo Comparator|Placebo|Placebo, administered orally, BID for 52 weeks
11450495|NCT01696630|Active Comparator|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
11450496|NCT01696630|Experimental|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
11450497|NCT01696617|Experimental|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
11450498|NCT01696617|Active Comparator|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
11450499|NCT01696604|Experimental|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
11450500|NCT01696604|Experimental|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
11450501|NCT01696604|Experimental|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
11450605|NCT01695980|Experimental|LMA with modified retractor|LMA with modified retractor
11450502|NCT01696604|Experimental|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
11450503|NCT01696604|Experimental|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
11450504|NCT01696604|Experimental|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
11450505|NCT01696604|Experimental|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
11450506|NCT01696604|Experimental|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
11450507|NCT01696604|Experimental|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
11450508|NCT01696604|Experimental|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
11450509|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery
~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
11450510|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:
~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.
~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
11450511|NCT01696578|Experimental|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
11450512|NCT01696578|Active Comparator|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
11450513|NCT01696565|Experimental|125 mg/day Treatment Arm|125 mg/day PG2 treatment continuously for 7 days
11450514|NCT01696565|Experimental|250 mg/day Treatment Arm|250 mg/day PG2 treatment continuously for 7 days
11450515|NCT01696565|Experimental|500 mg/day Treatment Arm|500 mg/day PG2 treatment continuously for 7 days
11450516|NCT01696552|Active Comparator|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
11450517|NCT01696552|Active Comparator|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
11450518|NCT01696539|Experimental|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
11450519|NCT01696539|Active Comparator|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
11450520|NCT01696526|Experimental|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
11450521|NCT01696526|Placebo Comparator|conventional fish|consumption of conventional fish , 4 weeks
11450522|NCT01696513|Experimental|Subcision & Suction|Standard treatment for acne scars followed by suction.
11450523|NCT01696513|Active Comparator|Subcision|Standard treatment for acne scars only
11450524|NCT01696500|Experimental|NPB-01|
11450525|NCT01696487|Experimental|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
11450526|NCT01696487|No Intervention|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
11450527|NCT01696487|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
11450528|NCT01696487|No Intervention|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
11450529|NCT01696474|Experimental|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
11450530|NCT01696461|Experimental|Related donors receiving plerixafor|Collection of sufficient CD34+ cells using plerixafor as the mobilizing agent.
11450531|NCT01696448|Experimental|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
11450532|NCT01696448|Placebo Comparator|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
11450533|NCT01696435|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day
~Fish oil placebo"
11450534|NCT01696435|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
11450535|NCT01696435|Active Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo
~Fish oil placebo"
11450536|NCT01696435|Active Comparator|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day
~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
11450537|NCT01696422|Experimental|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
11450538|NCT01696422|Active Comparator|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
11450539|NCT01696422|Placebo Comparator|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
11450540|NCT01696422|Experimental|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
11450541|NCT01696422|Placebo Comparator|Step B: Placebo|Placebo comparator Single dose, SC
11450542|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
11450543|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
11450544|NCT01696396|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450545|NCT01696396|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450546|NCT01696396|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450547|NCT01696396|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M)for 108 weeks."
11450548|NCT01696383|Experimental|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
11450549|NCT01696370|Active Comparator|Trimetazidine|
11450550|NCT01696370|Placebo Comparator|Placebo capsule|
11450551|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
11450552|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
11450553|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
11450554|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
11450555|NCT01696331|Experimental|Text Message Reminder|
11450556|NCT01696318|No Intervention|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
11450557|NCT01696318|Experimental|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
11450558|NCT01696305|Experimental|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml*10ml/syringe and 5cm-cannula
11450559|NCT01696305|Active Comparator|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
11450560|NCT01696279|Experimental|Lanthanum Carbonate|Participants will receive lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided and mixed equally between in three meals.
11450561|NCT01696279|Active Comparator|Calcium Carbonate|Participants will receive calcium carbonate orally at a total daily dose adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
11450562|NCT01696266||Insulin-treated patients with diabetes|
11450563|NCT01696253||Subjects at risk for Alport sydrome|
11450564|NCT01696253||Newly identified subjects with Alport syndrome|
11450565|NCT01696240|Placebo Comparator|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
11450566|NCT01696240|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
11450567|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
11450568|NCT01696214|Placebo Comparator|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
11450569|NCT01696214|Placebo Comparator|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
11450570|NCT01696214|Placebo Comparator|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
11450571|NCT01696214|Placebo Comparator|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
11450572|NCT01696201|No Intervention|Control group|Sedentary pregnant women
11450573|NCT01696201|Experimental|Exercise group|Exercise program
11450574|NCT01696188|Experimental|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
11450575|NCT01696188|Experimental|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
11450576|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
11450604|NCT01695993|Experimental|Arm 3 - Expectancy-enhancing Arm|"Patients receive:
~Expectancy-enhancing handout
~Expectancy-enhancing MP3
~Acupressure bands"
11450577|NCT01696162|Active Comparator|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
11450578|NCT01696162|Active Comparator|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.
~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
11450579|NCT01696162|Experimental|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
11450580|NCT01696149|Experimental|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
11450581|NCT01696136|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
11450582|NCT01696136|Active Comparator|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
11450583|NCT01696123|Experimental|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
11450584|NCT01696110|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
11450585|NCT01696110|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
11450586|NCT01696110|Active Comparator|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
11450587|NCT01696097|Other|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
11450588|NCT01696084|Experimental|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
11450589|NCT01696084|Active Comparator|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
11450590|NCT01696071|Experimental|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
11450591|NCT01696071|Experimental|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
11450592|NCT01696058|Experimental|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
11450593|NCT01696058|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
11450594|NCT01696045|Experimental|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
11450595|NCT01696045|Experimental|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
11450596|NCT01696032|Experimental|SGI-110 + Carboplatin|Part 1: Patients will be dosed with SGI-110 and carboplatin
11450597|NCT01696032|Experimental|SGI-110 + carboplatin or TC|Part 2: Patients will be randomized to receive SGI-110 and carboplatin or Treatment of Choice (TC). TC is at the discretion of the investigator and can be one of three standard of care treatments (topotecan, paclitaxel or pegylated liposomal doxorubicin).
11450598|NCT01696019|Experimental|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
11450599|NCT01696019|Active Comparator|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
11450600|NCT01696019|Active Comparator|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
11450601|NCT01696019|Placebo Comparator|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
11450602|NCT01695993|No Intervention|Arm 1 - Standard Care Only|Patients will receive standard care only
11450603|NCT01695993|Other|Arm 2 - Expectancy-neutral Arm|"Patients receive:
~Expectancy-neutral handout
~Expectancy-neutral MP3
~Acupressure bands"
11450728|NCT01695109|Active Comparator|Liraglutide|
11450606|NCT01695980|Active Comparator|ETT with non modified retractor|ETT with non modified retractor
11450607|NCT01695967|Experimental|Turbinate Cauterization|Turbinate Cauterization will be completed.
11450608|NCT01695967|No Intervention|control|no turbinate cauterization
11450609|NCT01695954|Experimental|Arm A|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
11450610|NCT01695954|Experimental|Arm B|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
11450611|NCT01695941|Experimental|Treatment (alisertib, bortezomib, and rituximab)|"Patients receive alisertib PO BID on days 1-7; bortezomib SC on days 1, 8, and 15; and rituximab IV on day 1. Treatment repeats every 28 days* in the absence of disease progression or unacceptable toxicity.
~Note: *After 8 courses, treatment with rituximab repeats once every 3 courses (12 weeks) in the absence of disease progression or unacceptable toxicity."
11450612|NCT01695928|Active Comparator|Extracorporeal shockwave therapy (ESWT)|Active treatment
11450613|NCT01695928|Placebo Comparator|ESWT Placebo|No extracoporeal shockwave therapy
11450614|NCT01695915||Healthy|Transabdominal ultrasound
11450615|NCT01695915||Constipated|Transabdominal ultrasound
11450616|NCT01695902|Experimental|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
11450617|NCT01695902|Active Comparator|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
11450618|NCT01695876|Experimental|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
11450619|NCT01695876|Placebo Comparator|Placebo|Matching placebo to AMG 357 containing no active drug
11450620|NCT01695863|Experimental|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
11450621|NCT01695863|Experimental|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
11450622|NCT01695850|Experimental|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
11450623|NCT01695850|Active Comparator|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
11450624|NCT01695850|Placebo Comparator|Placebo|Placebo MZRW and Placebo Senna
11450625|NCT01695837|Experimental|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website
~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.
~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
11450626|NCT01695837|Other|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.
~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website
~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
11450627|NCT01695824|Active Comparator|LAA occluder|
11450628|NCT01695824|Active Comparator|Warfarin|
11450629|NCT01695811||FLAK|FLAK
11450630|NCT01695811||PKP|Retrospective
11450631|NCT01695798|No Intervention|Chronic malnourished bOPV|This arm will receive only bOPV
11450632|NCT01695798|Experimental|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
11450633|NCT01695798|No Intervention|Normally nourished bOPV|This arm will receive only bOPV
11450634|NCT01695798|Experimental|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
11450635|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
11450636|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
11450637|NCT01695772|Experimental|Bevacizumab|
11450638|NCT01695759|Experimental|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
11450639|NCT01695759|Active Comparator|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
11450640|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
11450641|NCT01695733|Experimental|Schedule A|Influenza vaccination on the first day of chemotherapy
11450642|NCT01695733|Experimental|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
11450643|NCT01695720|Experimental|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
11450644|NCT01695707|Placebo Comparator|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
11450645|NCT01695707|Experimental|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.
~One capsule will be taken by each day throughout the treatment period."
11450646|NCT01695694|Active Comparator|community support group|
11450647|NCT01695694|Experimental|supporting positive and healthy relationships|
11450648|NCT01695681|Other|Dietary instruction|Gluten-free diet
11450649|NCT01695668|Experimental|Lotemax|Loteprednol Etabonate 0.5%
11450650|NCT01695668|Active Comparator|Restasis|Cyclosporine
11450651|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
11450652|NCT01695642||Microkeratome|mechanical microkeratome
11450653|NCT01695642||Intralase|femtosecond laser
11450654|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
11450655|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
11450656|NCT01695616|Placebo Comparator|Placebo|Patients enrolled in this arm will take a tablet twice a day
11450657|NCT01695616|Active Comparator|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
11450658|NCT01695603|No Intervention|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
11450659|NCT01695603|Experimental|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
11450660|NCT01695590|Experimental|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
11450661|NCT01695577|Experimental|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
11450662|NCT01695577|Active Comparator|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
11450663|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
11450664|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
11450665|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
11450666|NCT01695538|Experimental|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
11450667|NCT01695525|Experimental|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
11450668|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
11450669|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
11450670|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
11450671|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
11450672|NCT01695473|Experimental|Neoadjuvant BKM120|Twenty four men will receive 2 weeks of daily BKM120 prior to having radical prostatectomy
11450673|NCT01695460|Active Comparator|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.
~D3 Vitamin ® consists of small white tablets, which are easy to swallow.
~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).
~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
11450674|NCT01695460|Placebo Comparator|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
11450675|NCT01695447|Experimental|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
11450676|NCT01695447|Active Comparator|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
11450677|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
11450678|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
11450679|NCT01695421|Experimental|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
11450680|NCT01695421|Experimental|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
11450681|NCT01695421|Experimental|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
11450682|NCT01695421|Placebo Comparator|Placebo|Training with the intensity of 5 mA.
11450683|NCT01695395||Intellectual disabled adults without a mental disorder|
11450684|NCT01695395||Intellectual disabled adults with a mental disorder|
11451487|NCT01690026|Other|Brief intervention|Motivational intervention based brief intervention
11450685|NCT01695382|Experimental|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
11450686|NCT01695382|No Intervention|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
11450687|NCT01695369|Active Comparator|Senofilcon A|Senofilcon A; Comfilcon A
11450688|NCT01695369|Experimental|Comfilcon A|Comfilcon A; Senofilcon A
11450689|NCT01695356|Active Comparator|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.
~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
11450690|NCT01695356|Experimental|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.
~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
11450691|NCT01695343|Experimental|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
11450692|NCT01695343|Placebo Comparator|Placebo Comparator|Placebo administered up to 5x intravenously
11450693|NCT01695330|Experimental|Subcutaneous bortezomib|
11450694|NCT01695317|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
11450695|NCT01695317|Placebo Comparator|Sugar pills|Glucose with lemon acid
11450696|NCT01695304|Experimental|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
11450697|NCT01695304|No Intervention|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
11450698|NCT01695291|Placebo Comparator|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
11450699|NCT01695291|Experimental|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
11450700|NCT01695278|Active Comparator|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
11450701|NCT01695278|Experimental|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
11450702|NCT01695265|Experimental|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
11450703|NCT01695265|Experimental|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
11450704|NCT01695252|No Intervention|S-Sup|Standard supervision
11450705|NCT01695252|Experimental|MEMOS|Patient informed clinical outcomes supervision
11450706|NCT01695239|Experimental|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
11450707|NCT01695239|Experimental|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
11450708|NCT01695239|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
11450709|NCT01695239|Active Comparator|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
11450710|NCT01695226|Placebo Comparator|placebo|pre-operative placebo twice daily for two to three weeks
11450711|NCT01695226|Experimental|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
11450712|NCT01695213|Active Comparator|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
11450713|NCT01695213|Active Comparator|Symax hip stem|Patients with the Symax uncemented hip stem
11450714|NCT01695200|Experimental|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
11450715|NCT01695187|Experimental|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
11450716|NCT01695187|Placebo Comparator|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
11450717|NCT01695174|Experimental|Xifaxan|Xifaxan 550 mg two times per day for three months
11450718|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
11450719|NCT01695161||Fabry disease|Fabry disease
11450720|NCT01695161||healthy controls|healthy controls
11450721|NCT01695148|Active Comparator|White Maize Flour|Children will receive 2 meals a day (~200 g of white maize flour), 6 days a week for 6 months.
11450722|NCT01695148|Experimental|β-Carotene Biofortified Maize|Children will receive 2 meals a day (~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
11450723|NCT01695148|No Intervention|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
11450724|NCT01695135|Experimental|Abiraterone acetate plus prednisone|
11450725|NCT01695135|Experimental|Placebo plus prednisone|
11450726|NCT01695122|Experimental|valproic acid|
11450727|NCT01695109|Placebo Comparator|Placebo|
11450729|NCT01695096|Experimental|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
11450730|NCT01695096|Placebo Comparator|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to > 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
11450731|NCT01695070|Experimental|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
11450732|NCT01695057|Experimental|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
11450733|NCT01695044|Experimental|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
11450734|NCT01695031|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
11450735|NCT01695031|Active Comparator|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
11450736|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
11450737|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
11450738|NCT01695005|Experimental|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
11450739|NCT01695005|Experimental|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
11450740|NCT01695005|Experimental|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
11450741|NCT01695005|Experimental|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
11450742|NCT01694992|Experimental|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
11450743|NCT01694992|No Intervention|Control|The Control Group will follow within the routines of the hospital as is usually done.
11450744|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
11450745|NCT01694966|Active Comparator|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
11450746|NCT01694966|Active Comparator|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
11450747|NCT01694966|Placebo Comparator|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
11450748|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
11450749|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
11450750|NCT01694927|Experimental|Mesenchymal Stem cells|
11450751|NCT01694914|Experimental|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
11450752|NCT01694914|Active Comparator|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
11450753|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
11450754|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
11450755|NCT01694888|Experimental|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
11450756|NCT01694875||No Treatment|
11450757|NCT01694862|Experimental|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
11450758|NCT01694862|No Intervention|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
11450759|NCT01694849|Experimental|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
11450760|NCT01694849|Experimental|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
11450761|NCT01694849|Placebo Comparator|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
11450762|NCT01694836|Experimental|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:
~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)
~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
11450799|NCT01694576|No Intervention|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
11450763|NCT01694836|Placebo Comparator|Placebo|"Suspension for s.c. injection. Treatment schedule:
~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)
~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
11450764|NCT01694823|Experimental|CS-ACI|"Group/Cohort Label： pretherapy post-treatment
~Group/Cohort Description ：The CS-ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
11450765|NCT01694810|Experimental|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
11450766|NCT01694810|Experimental|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
11450767|NCT01694810|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
11450768|NCT01694810|Experimental|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
11450769|NCT01694797|Experimental|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
11450770|NCT01694797|Active Comparator|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
11450771|NCT01694784|Experimental|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
11450772|NCT01694784|Active Comparator|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
11450773|NCT01694784|Experimental|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
11450774|NCT01694784|Experimental|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
11450775|NCT01694771|Experimental|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
11450776|NCT01694771|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
11450777|NCT01694758||Patients with diabetes type 2|
11450778|NCT01694732|Experimental|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
11450779|NCT01694732|Placebo Comparator|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
11450780|NCT01694719|Experimental|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
11450781|NCT01694719|Active Comparator|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
11450782|NCT01694706|Experimental|Reference|faldaprevir medium, fasted
11450783|NCT01694706|Active Comparator|Test 1|faldaprevir medium, fed
11450784|NCT01694706|Active Comparator|Test 2|faldaprevir medium + omeprazole medium
11450785|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
11450786|NCT01694680|Active Comparator|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
11450787|NCT01694680|Placebo Comparator|Placebo|Powder in sachet to prepare beverage
11450788|NCT01694667|Active Comparator|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
11450789|NCT01694667|Placebo Comparator|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
11450790|NCT01694641|Experimental|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
11450791|NCT01694641|No Intervention|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
11450792|NCT01694628|Experimental|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
11450793|NCT01694628|No Intervention|Control|Usual Care
11450794|NCT01694615|Active Comparator|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
11450795|NCT01694615|Active Comparator|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
11450796|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
11450797|NCT01694589|Experimental|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
11450798|NCT01694576|Experimental|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
11450800|NCT01694563|Other|Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
11450801|NCT01694550||Pacemaker mode programming|High grade AV-block
11450802|NCT01694537|Placebo Comparator|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
11450803|NCT01694537|Experimental|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
11450804|NCT01694511|Active Comparator|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
11450805|NCT01694511|Active Comparator|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
11450806|NCT01694498|Active Comparator|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
11450807|NCT01694498|Active Comparator|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
11450808|NCT01694498|Placebo Comparator|C. Placebo|1 orally disintegrating tablet every night during study period
11450809|NCT01694485|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450810|NCT01694485|Experimental|Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450811|NCT01694485|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450812|NCT01694485|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450813|NCT01694485|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.
~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
11450814|NCT01694472|Experimental|MAGE-A4 TCR Gene-Modified T Cells|
11450815|NCT01694459|Active Comparator|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure
11450816|NCT01694459|Experimental|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec.
11450817|NCT01694446|Experimental|Intraduodenal glucose or fructose|
11450818|NCT01694433|Experimental|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
11450819|NCT01694433|Placebo Comparator|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
11450820|NCT01694420|Experimental|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
11450821|NCT01694407|Active Comparator|TFV Alone Vaginal Tablet|
11450822|NCT01694407|Active Comparator|Emtricitabine (FTC) Alone Vaginal Tablet|
11450823|NCT01694407|Active Comparator|TFV Combined with FTC Vaginal Tablet|
11450824|NCT01694407|Placebo Comparator|Placebo Vaginal Tablet|
11450825|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
11450826|NCT01694381||mutant pro-urokinase (M5) alone|
11450827|NCT01694381||Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|
11450828|NCT01694355|Experimental|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
11450829|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
11450830|NCT01694316|Active Comparator|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
11450831|NCT01694316|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
11450832|NCT01694303|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
11450833|NCT01694303|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
11450834|NCT01694290|Experimental|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
11450835|NCT01694290|Experimental|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
11450836|NCT01694290|No Intervention|no chemical ice packs|
11450837|NCT01694277|Experimental|Masitinib|Participants receive masitinib (12 mg/kg/day), given orally twice daily.
11450838|NCT01694277|Active Comparator|Sunitinib|Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally
11450839|NCT01694264|Experimental|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
11450918|NCT01693692|Experimental|TD-9855 Group 1|Group 1 to be dosed with TD-9855
11450919|NCT01693692|Experimental|TD-9855 Group 2|Group 2 to be dosed with TD-9855
11450840|NCT01694264|Placebo Comparator|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
11450841|NCT01694238|Active Comparator|Cruciate incision|Cruciate incision in the abdominal wall fascia
11450842|NCT01694238|Experimental|Circular incision|Circular incision in the fascia
11450843|NCT01694238|Experimental|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
11450844|NCT01694225|Experimental|bubble package for monthly prescription|use of bubble packaging for monthly prescription
11450845|NCT01694212|Experimental|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
11450846|NCT01694212|Placebo Comparator|Placebo|Control group having placebo treatment
11450847|NCT01694199|Active Comparator|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
11450848|NCT01694199|Sham Comparator|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
11450849|NCT01694186|Sham Comparator|sham injection|sham injection
11450850|NCT01694186|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
11450851|NCT01694173|Experimental|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
11450852|NCT01694173|Active Comparator|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
11450853|NCT01694173|Active Comparator|Stem cell therapy-intravenous|Stem cells will be given intravenously.
11450854|NCT01694173|Placebo Comparator|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
11450855|NCT01694160|Experimental|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
11450856|NCT01694160|No Intervention|no intervention|
11450857|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
11450858|NCT01694134|Active Comparator|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
11450859|NCT01694134|Sham Comparator|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
11450860|NCT01694121|Experimental|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
11450861|NCT01694121|Active Comparator|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
11450862|NCT01694108|Experimental|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf).
~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
11450863|NCT01694108|No Intervention|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
11450864|NCT01694095||Patients with geographic atrophy|
11450865|NCT01694082|Experimental|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
11450866|NCT01694082|Experimental|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
11450867|NCT01694082|Experimental|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
11450868|NCT01694082|Sham Comparator|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
11450869|NCT01694069|Active Comparator|Intermittent Infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
11450870|NCT01694069|Experimental|Continuous infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
11450871|NCT01694056|Experimental|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
11450872|NCT01694056|Active Comparator|Control diet|High mixed protein diet (20 en%)
11450873|NCT01694043|Experimental|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
11450874|NCT01694043|Experimental|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
11450875|NCT01694043|Experimental|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
11450876|NCT01694030|Experimental|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
11450877|NCT01694030|Experimental|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
11450878|NCT01694017|Active Comparator|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
11450879|NCT01694017|Active Comparator|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
11450920|NCT01693692|Placebo Comparator|Placebo|Group to be dosed with Placebo
11451488|NCT01690026|Other|Standard intervention|Standard intervention condition
11450880|NCT01694004|Experimental|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
11450881|NCT01693991|Experimental|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
11450882|NCT01693991|Placebo Comparator|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
11450883|NCT01693991|No Intervention|Control Group|Patients in this group will only be receiving treatment as usual.
11450884|NCT01693978|Experimental|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
11450885|NCT01693978|Active Comparator|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
11450886|NCT01693965|Other|sputum samples|
11450887|NCT01693952|Experimental|blood samples|
11450888|NCT01693939|Other|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
11450889|NCT01693926|Experimental|Acute physical activity intervention|25 min of moderate physical activity
11450890|NCT01693926|Placebo Comparator|Placebo|25 min of reading (instead of physical activity)
11450891|NCT01693913|Experimental|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
11450892|NCT01693913|Active Comparator|Nurtition education|This arm will participate in nutrition and exercise education
11450893|NCT01693900|Experimental|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
11450894|NCT01693900|Active Comparator|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
11450895|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
11450896|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
11450897|NCT01693874|Experimental|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
11450898|NCT01693874|Active Comparator|control|All participants in this arm receive an attention control
11450899|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
11450900|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
11450901|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
11450902|NCT01693835||Patients|Patients with metastatic colorectal cancer
11450903|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
11450904|NCT01693822|Experimental|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
11450905|NCT01693809|Experimental|Caffeine|Caffeine 420mg, one time
11450906|NCT01693783|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
11450907|NCT01693770|Other|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
11450908|NCT01693757||BPTB group|Bone-patellar tendon-bone
11450909|NCT01693757||STG group|Semitendinosus and gracilis tendon
11450910|NCT01693757||Control|Healthy
11450911|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
11450912|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
11450913|NCT01693744||Control group|Patients with normal renal functions
11450914|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
11450915|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
11450916|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
11450917|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
11450921|NCT01693679|Experimental|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
11450922|NCT01693666|Experimental|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
11450923|NCT01693666|No Intervention|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
11450924|NCT01693653|Active Comparator|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
11450925|NCT01693653|Placebo Comparator|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
11450926|NCT01693640|Experimental|abatacept|
11450927|NCT01693627|Active Comparator|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
11450928|NCT01693627|Active Comparator|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
11450929|NCT01693627|Active Comparator|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
11450930|NCT01693627|Active Comparator|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
11450931|NCT01693614|Experimental|DLBCL Cohort|Diffuse large B-cell lymphoma cohort
11450932|NCT01693614|Experimental|MCL Cohort|Mantle cell lymphoma cohort
11450933|NCT01693614|Experimental|FL Cohort|Follicular lymphoma cohort
11450934|NCT01693601|Experimental|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
11450935|NCT01693588|Experimental|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
11450936|NCT01693575|Experimental|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
11450937|NCT01693562|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
11450938|NCT01693562|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
11450939|NCT01693562|Experimental|MEDI4736 Dose Expansion|At least 16 different types of solid tumors will be evaluated in the expansion phase
11450940|NCT01693562|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
11450941|NCT01693549|Experimental|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
11450942|NCT01693536|Experimental|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.
~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
11450943|NCT01693536|No Intervention|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
11450944|NCT01693523|Experimental|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
11450945|NCT01693523|Placebo Comparator|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
11450946|NCT01693510|Experimental|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
11450947|NCT01693510|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
11450948|NCT01693497|Experimental|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
11450949|NCT01693497|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
11450984|NCT01693250|Active Comparator|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
11450985|NCT01693237|Active Comparator|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
11450950|NCT01693484|Experimental|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
11450951|NCT01693471||SEARCH Study Group|
11450952|NCT01693458|Experimental|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
11450953|NCT01693458|Placebo Comparator|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
11450954|NCT01693445|Experimental|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;
~Oxaliplatin 85 mg/m²IV on day 1
~Irinotecan 120 mg/m² IV on day 1
~S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
11450955|NCT01693432|Experimental|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.
~Docetaxel 60 mg/m²IV on day 1
~S-1 80 mg/m2/day PO on day 1-14"
11450956|NCT01693419|Experimental|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.
~Gemcitabine 1000 mg/m² IV on day 1, 8
~Erlotinib 100 mg/day PO on day 1
~S-1 60 mg/m²/day PO on day 1-14"
11450957|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
11450958|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between > 25 kg/m2.
11450959|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
11450960|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI > 25 kg/m2.
11450961|NCT01693393|Other|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
11450962|NCT01693380|Experimental|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.
~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
11450963|NCT01693380|Sham Comparator|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.
~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
11450964|NCT01693367|Active Comparator|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
11450965|NCT01693367|Active Comparator|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
11450966|NCT01693354|Active Comparator|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
11450967|NCT01693354|Experimental|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
11450968|NCT01693341|Active Comparator|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
11450969|NCT01693341|No Intervention|Standard-care|Maintain the inherent standard-care
11450970|NCT01693328||PecFent®|
11450971|NCT01693315|Experimental|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
11450972|NCT01693315|Experimental|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
11450973|NCT01693315|Experimental|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
11450974|NCT01693315|Experimental|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
11450975|NCT01693302|Experimental|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
11450976|NCT01693302|Experimental|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
11450977|NCT01693302|Experimental|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
11450978|NCT01693289|Experimental|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
11450979|NCT01693289|Experimental|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
11450980|NCT01693276|Experimental|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
11450981|NCT01693263||brachiocephalic fistula placed|Subjects are being asked to participate in this study because they have end-stage renal disease and they are undergoing dialysis, and their doctor has recommended that they will have brachiocephalic fistula placed for their dialysis access.
11450982|NCT01693263||Sub-study participants|As part of this study there is an additional sub-study. The researchers would like to collect more information about the vascular access from 50 subjects. For the purposes of this sub-study the following will take place: Intravenous Ultrasound (IVUS) and Hand Held Doppler
11450983|NCT01693250|Experimental|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
11450986|NCT01693237|Experimental|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
11450987|NCT01693211|Experimental|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
11450988|NCT01693211|Active Comparator|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
11450989|NCT01693185|Experimental|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
11450990|NCT01693185|Active Comparator|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
11450991|NCT01693172|Active Comparator|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
11450992|NCT01693172|No Intervention|Standard|Standard rehabilitation care
11450993|NCT01693159|Experimental|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
11450994|NCT01693159|Active Comparator|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
11450995|NCT01693146|Active Comparator|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
11450996|NCT01693146|Active Comparator|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
11450997|NCT01693133|Other|Control|Standard of Care: Moist Wound Therapy and Offloading
11450998|NCT01693133|Experimental|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
11450999|NCT01693120|Experimental|Ablation|Phased RF ablation
11451000|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
11451001|NCT01693094|No Intervention|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
11451002|NCT01693094|Active Comparator|Decision Aid|One cohort will receive a decision aid.
11451003|NCT01693081|Active Comparator|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
11451004|NCT01693081|Placebo Comparator|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
11451005|NCT01693068|Experimental|Pimasertib|
11451006|NCT01693068|Active Comparator|Dacarbazine|
11451007|NCT01693055|Experimental|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
11451008|NCT01693042|Active Comparator|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
11451009|NCT01693042|Active Comparator|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
11451010|NCT01693029|Experimental|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
11451011|NCT01693029|Active Comparator|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
11451012|NCT01693016|Other|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
11451013|NCT01693016|Other|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
11451014|NCT01693003|Experimental|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
11451015|NCT01693003|Experimental|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
11451016|NCT01692990|Experimental|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
11451017|NCT01692990|Placebo Comparator|Soy bean oil|5 g/d in 10 capsules
11451018|NCT01692977|Experimental|Alzheimer disease patients|Alzheimer disease patients
11451019|NCT01692977|Active Comparator|control|healthy control subjects.
11451020|NCT01692964||InflammaDry|Patients suspected of having dry eye will be tested with the InflammaDry.
11451021|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
11451022|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
11451023|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
11451024|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
11451025|NCT01692938||No Retinal Disease|
11451026|NCT01692938||Retinal Disease|
11451027|NCT01692925|Experimental|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
11451028|NCT01692925|Experimental|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
11451029|NCT01692925|Experimental|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
11451030|NCT01692925|Experimental|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
11451031|NCT01692912|Active Comparator|Intensive Care (IC)|Rheumatologists treating to target of DAS28<2.6
11451489|NCT01690013||Klinefelter|Men with Klinefelter syndrome
11451032|NCT01692912|No Intervention|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)
11451033|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
11451034|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
11451035|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
11451036|NCT01692886|Active Comparator|7vPnC (3-, 4-, 5-, 12-Month)|
11451037|NCT01692886|Experimental|13vPnC (3-, 4-, 5-, 12-Month)|
11451038|NCT01692886|Experimental|13vPnC (2-, 4-, 6-, 12-Month)|
11451039|NCT01692886|Experimental|13vPnC (3-, 5-, 12-Month)|
11451040|NCT01692873|Experimental|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
11451041|NCT01692860|Experimental|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
11451042|NCT01692860|Placebo Comparator|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
11451043|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
11451044|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
11451045|NCT01692834|Active Comparator|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
11451046|NCT01692834|Active Comparator|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
11451047|NCT01692821|Experimental|100% oxygen breathing|
11451048|NCT01692821|Experimental|15% oxygen in N2 breathing|
11451049|NCT01692821|Experimental|12% oxygen in N2 breathing|
11451050|NCT01692808|No Intervention|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
11451051|NCT01692808|Experimental|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
11451052|NCT01692808|No Intervention|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
11451053|NCT01692808|Experimental|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
11451054|NCT01692808|Experimental|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
11451055|NCT01692795||MI patients|
11451056|NCT01692782|Experimental|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
11451057|NCT01692782|Experimental|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
11451058|NCT01692782|Placebo Comparator|Placebo|4 capsules of placebo
11451059|NCT01692769|Active Comparator|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
11451060|NCT01692769|Active Comparator|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
11451061|NCT01692756|Experimental|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
11451062|NCT01692756|Experimental|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
11451063|NCT01692756|Experimental|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
11451064|NCT01692756|Placebo Comparator|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
11451065|NCT01692743|No Intervention|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
11451066|NCT01692743|Experimental|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
11451067|NCT01692743|Experimental|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
11451068|NCT01692730|Experimental|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
11451069|NCT01692730|Active Comparator|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
11451070|NCT01692717|Active Comparator|Atorvastatin|Citalor (Atorvastatin) - Pfizer
11451071|NCT01692717|Active Comparator|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme
11451072|NCT01692717|Experimental|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
11451073|NCT01692704|Experimental|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
11451074|NCT01692691|Experimental|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
11451075|NCT01692678|Experimental|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
11451076|NCT01692678|Active Comparator|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
11451077|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
11451078|NCT01692652|Experimental|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress & ocular massage (a minimum of four times, once or twice a daily) for 2months
11451079|NCT01692652|Active Comparator|warm compress only group|warm compress only group
11451080|NCT01692626|Experimental|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
11451081|NCT01692626|Experimental|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
11451082|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
11451083|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
11451084|NCT01692587|No Intervention|Control|No changes in dietary group
11451085|NCT01692587|Experimental|Protein restrictive diet|reduced protein diet
11451086|NCT01692574|Experimental|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
11451087|NCT01692574|Active Comparator|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
11451088|NCT01692574|Active Comparator|DSE|Behavior modification for weight loss combined with depression support and education.
11451089|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
11451090|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
11451091|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
11451092|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
11451093|NCT01692548|Experimental|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
11451094|NCT01692548|No Intervention|Control|
11451095|NCT01692535|Experimental|GlideScope|intubation
11451096|NCT01692535|Experimental|Airtraq|intubation
11451097|NCT01692535|Experimental|McGrath MAC|intubation
11451098|NCT01692535|Experimental|King Vision|intubation
11451099|NCT01692535|Experimental|A.P. Advance|intubation
11451100|NCT01692535|Experimental|C-MAC|intubation
11451101|NCT01692522|Experimental|Ambu Aura-i|intubation
11451102|NCT01692522|Active Comparator|AirQ|intubation
11451103|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
11451104|NCT01692496|Experimental|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
11451105|NCT01692483||Abiraterone acetate plus prednisone|
11451106|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
11451107|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
11451108|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
11451109|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
11451110|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
11451111|NCT01692431|Experimental|DHA|High fat meal containing DHA rich oil.
11451112|NCT01692431|Experimental|EPA|High fat meal containing EPA.
11451113|NCT01692431|Placebo Comparator|Control|High fat meal with no/negligable omega-3 fatty acid content.
11451114|NCT01692418|Experimental|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
11451115|NCT01692418|Placebo Comparator|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
11451116|NCT01692405|No Intervention|Standard method|Standard method- shaking the biopsy needle into a formalin container.
11451117|NCT01692405|Active Comparator|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
11451118|NCT01692405|Experimental|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
11451119|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
11451120|NCT01692379|Experimental|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
11451121|NCT01692379|Active Comparator|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
11451151|NCT01692184|Experimental|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
11451122|NCT01692366|Experimental|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
11451123|NCT01692366|Experimental|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
11451124|NCT01692366|Experimental|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
11451125|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
11451126|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
11451127|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
11451128|NCT01692340|Experimental|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
11451129|NCT01692340|Experimental|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
11451130|NCT01692340|Experimental|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
11451131|NCT01692327|Other|Obese Group|Obese group with fat overload intake.
11451132|NCT01692327|Other|Control Group|Control Group + fat overload intake
11451133|NCT01692327|Other|Glucose Intolerance|glucose intolerance + fat overload intake
11451134|NCT01692314|Experimental|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
11451135|NCT01692301|Experimental|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
11451136|NCT01692301|Active Comparator|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
11451137|NCT01692288|Experimental|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
11451138|NCT01692288|No Intervention|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
11451139|NCT01692275|Active Comparator|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
11451140|NCT01692275|Active Comparator|Conventional Medical Care Only|Conventional medical care only
11451141|NCT01692262|Experimental|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
11451142|NCT01692262|Experimental|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
11451143|NCT01692262|Experimental|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
11451144|NCT01692249|Experimental|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
11451145|NCT01692249|No Intervention|control group|in group (B), spa therapy was delayed for 6 months (control group).
11451146|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
11451147|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
11451148|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
11451149|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
11451150|NCT01692197|Experimental|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age <60 years) or days 9-11 (age > 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
11456717|NCT01654510|Experimental|Cognitive Behavioral Therapy Group|
11451152|NCT01692184|Experimental|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
11451153|NCT01692184|Experimental|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
11451154|NCT01692184|Experimental|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
11451155|NCT01692184|Placebo Comparator|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
11451156|NCT01692184|Placebo Comparator|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
11451157|NCT01692171|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
11451158|NCT01692171|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
11451159|NCT01692158|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
11451160|NCT01692158|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
11451161|NCT01692145|Experimental|KCT-0809 ophtalmic solution|
11451162|NCT01692145|Placebo Comparator|Placebo|
11451163|NCT01692132||Prucalopride|
11451164|NCT01692119|Experimental|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
11451165|NCT01692119|No Intervention|usual care|usual care
11451166|NCT01692106|Experimental|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
11451167|NCT01692093|Experimental|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
11451168|NCT01692093|Placebo Comparator|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
11451169|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
11451170|NCT01692067||D0|Not deployed
11451171|NCT01692067||D1|Deployed to combat-related regions once
11451172|NCT01692067||D2|Deployed to combat related regions more than once
11451173|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
11451174|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
11451175|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
11451176|NCT01692041|Active Comparator|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
11451177|NCT01692041|Placebo Comparator|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
11451178|NCT01692015|Experimental|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
11451179|NCT01692015|Experimental|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
11451180|NCT01692002|Placebo Comparator|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
11451181|NCT01692002|Experimental|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
11451182|NCT01691989|Experimental|aleglitazar|
11451183|NCT01691989|Experimental|placebo|
11451184|NCT01691976|No Intervention|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
11451185|NCT01691976|Active Comparator|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
11451186|NCT01691976|Experimental|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
11451187|NCT01691963|No Intervention|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.
~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
11451188|NCT01691963|Experimental|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.
~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.
~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.
~The glottic view will be scored in both positions using the Cormack and Lehane classification system.
~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
11451189|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
11451190|NCT01691950||Healthy volunteers|Healthy volunteers for control
11451191|NCT01691937|Experimental|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
11451192|NCT01691937|Placebo Comparator|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
11451193|NCT01691924|Placebo Comparator|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
11451194|NCT01691924|Experimental|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
11451195|NCT01691911|Experimental|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
11451196|NCT01691911|No Intervention|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
11451197|NCT01691898|Experimental|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
11451198|NCT01691898|Experimental|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
11451199|NCT01691898|Experimental|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
11451200|NCT01691898|Experimental|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
11451201|NCT01691898|Experimental|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
11451202|NCT01691898|Experimental|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
11451203|NCT01691885|Experimental|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
11451204|NCT01691885|Placebo Comparator|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
11451205|NCT01691872|Experimental|Japanese|Retigabine 300mg single-dose
11451206|NCT01691872|Experimental|Caucasian|Retigabine 300mg single-dose
11451207|NCT01691859|Experimental|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
11451208|NCT01691846|Experimental|aleglitazar|
11451209|NCT01691846|Placebo Comparator|placebo|
11451210|NCT01691833|Experimental|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
11451211|NCT01691833|Placebo Comparator|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
11451212|NCT01691833|No Intervention|Normovitaminosis|Patients with normovitaminosis( levels greater than or equal to 30ng/ml) will receive no intervention.
11451213|NCT01691820|Experimental|Group S+|Cytomegalovirus (CMV) seropositive subjects aged between 10-17 years at enrollment in the study.
11451214|NCT01691820|Experimental|Group S-|Cytomegalovirus (CMV) seronegative subjects aged between 10-17 years at enrollment in the study.
11451215|NCT01691820|Experimental|Missing serostatus Group|Subjects with no confirmed serostatus, aged between 10-17 years at enrollment in the study.
11451216|NCT01691807|Experimental|Arm A|bendamustine and ofatumumab treatment of NHL
11451217|NCT01691807|Experimental|Arm B|ofatumumab only treatment of NHL
11451249|NCT01691625|Active Comparator|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
11451490|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
11451491|NCT01690000|Active Comparator|Melatonin1|1 mg melatonin nightly
11451218|NCT01691794|Active Comparator|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to <20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
11451219|NCT01691794|Active Comparator|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to <40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
11451220|NCT01691794|Active Comparator|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
11451221|NCT01691781|Experimental|lisinopril|Lisinopril - open-label, 2.5-40mg daily
11451222|NCT01691768|Experimental|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery
11451223|NCT01691768|Active Comparator|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
11451224|NCT01691755|Placebo Comparator|Placebo|
11451225|NCT01691755|Experimental|aleglitazar|
11451226|NCT01691742|Placebo Comparator|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
11451227|NCT01691742|Active Comparator|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
11451228|NCT01691729|Other|Ostomy 1|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy AccessoryProduct/Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2
11451229|NCT01691729|Other|Ostomy 2|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1
11451230|NCT01691729|Other|Ostomy 3|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product
11451231|NCT01691729|Other|Ostomy 4|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product
11451232|NCT01691729|Other|Ostomy 5|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2
11451233|NCT01691729|Other|Ostomy 6|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #1
11451234|NCT01691716|Experimental|Tendoactive|Tendoactive dosage: 3 capsules per day
11451235|NCT01691716|Active Comparator|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
11451236|NCT01691716|Active Comparator|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
11451237|NCT01691703|Experimental|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
11451238|NCT01691690|Experimental|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
11451239|NCT01691690|Placebo Comparator|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
11451240|NCT01691677|Experimental|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
11451241|NCT01691677|Placebo Comparator|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
11451242|NCT01691664|Active Comparator|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
11451243|NCT01691664|Experimental|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
11451244|NCT01691651|Active Comparator|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
11451245|NCT01691651|No Intervention|Control|The group that will not be subjected to any intervention.
11451246|NCT01691638||Periodontitis|
11451247|NCT01691638||Control|
11451248|NCT01691625|Experimental|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
11451250|NCT01691612|Experimental|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
11451251|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
11451252|NCT01691586|Experimental|Remote patient management|Remote patient management system + yearly in-clinic follow-up
11451253|NCT01691586|Other|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
11451254|NCT01691560|Experimental|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
11451255|NCT01691560|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
11451256|NCT01691560|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
11451257|NCT01691560|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
11451258|NCT01691547|Experimental|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
11451259|NCT01691547|Experimental|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
11451260|NCT01691547|Experimental|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
11451261|NCT01691547|Experimental|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
11451262|NCT01691534|Experimental|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
11451263|NCT01691534|Experimental|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
11451264|NCT01691534|Experimental|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
11451265|NCT01691534|Experimental|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
11451266|NCT01691534|Experimental|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
11451267|NCT01691534|Experimental|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
11451268|NCT01691534|Active Comparator|Rifafour|Rifafour e-275 mg dosed by weight
11451269|NCT01691521|Experimental|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
11451270|NCT01691521|Experimental|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
11451271|NCT01691521|Placebo Comparator|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
11451272|NCT01691508|Experimental|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
11451273|NCT01691508|Experimental|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
11451274|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
11451275|NCT01691482|Active Comparator|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
11451276|NCT01691482|Active Comparator|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
11451277|NCT01691469|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
11451278|NCT01691469|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
11451279|NCT01691456|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
11451280|NCT01691456|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
11451281|NCT01691443|Experimental|Use of the glove|The subject wear the glove for the time of the trial
11451282|NCT01691430|Active Comparator|2 cranberry capsules|Experimental: 2 cranberry capsules
11451283|NCT01691430|Placebo Comparator|2 placebo capsules|Experimental: 2 placebo capsules qd
11451284|NCT01691417|Experimental|Pneumatic Sleeves|
11451285|NCT01691417|Experimental|Congestive Heart Failure Patients|
11451286|NCT01691404|Active Comparator|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
11451287|NCT01691404|Active Comparator|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
11451288|NCT01691404|Placebo Comparator|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
11451289|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras and BRAF wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
11451290|NCT01691378|Experimental|WtoH Intervention|Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
11451492|NCT01690000|Active Comparator|Melatonin3|3 mg melatonin given nightly
11457030|NCT01652482|Active Comparator|FOLFIRI + Cetuximab|
11451291|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
11451292|NCT01691365|Active Comparator|vitamins pills|"antioxidant and B vitamins vitamins vitamin
~--------------------------------------------------------------------------------"
11451293|NCT01691365|Placebo Comparator|pills|MICROCRYSTALLINE CELLULOSE
11451294|NCT01691352|Active Comparator|Wick|Patients with wick placed in their wound at the time of ostomy reversal
11451295|NCT01691352|Sham Comparator|No wick|patients with non-wicked dressing placed on their wound
11451296|NCT01691339|Experimental|Fluzone vaccine (Group 1)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
11451297|NCT01691339|Experimental|Fluzone Intradermal vaccine (Group 2)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
11451298|NCT01691339|Experimental|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
11451299|NCT01691339|Active Comparator|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
11451300|NCT01691326|Experimental|6 months to < 36 months of age group|Participants at 6 months to < 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
11451301|NCT01691326|Experimental|3 years to < 9 years of age group|Participants at 3 years to < 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
11451302|NCT01691313|Experimental|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
11451303|NCT01691313|Placebo Comparator|placebo|placebo to match vanoxerine oral capsule
11451304|NCT01691313|Experimental|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
11451305|NCT01691313|Experimental|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
11451306|NCT01691300|Experimental|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
11451307|NCT01691287|Experimental|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
11451308|NCT01691274|Experimental|PF-04895162|
11451309|NCT01691274|Placebo Comparator|Placebo|
11451310|NCT01691261|Experimental|Treatment|PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
11451311|NCT01691248|Active Comparator|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
11451312|NCT01691248|Placebo Comparator|Placebo|Placebo tablet once daily for no longer than 40 days
11451313|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
11451314|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
11451315|NCT01691222|Other|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
11451316|NCT01691209|Experimental|Phoenix|Application over 29 days twice daily
11451317|NCT01691209|Active Comparator|Hydrocortison|Application over 29 days twice daily
11451318|NCT01691209|No Intervention|Untreated skin|Participants will be observed over 29 days without study treatment
11451319|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
11451320|NCT01691170|Active Comparator|Quadriceps Strengthening|
11451321|NCT01691170|Active Comparator|Stretching Hamstring|
11451322|NCT01691157|Active Comparator|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
11451323|NCT01691157|Experimental|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
11451324|NCT01691144||recently treated patients|
11451325|NCT01691144||2-3 years after treatment|
11451326|NCT01691131|Other|Exercise training on land|High intensity exercise training on land.
11451327|NCT01691131|Other|Exercise training on water|High intensity exercise training on water.
11451328|NCT01691118|Active Comparator|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
11451329|NCT01691118|Placebo Comparator|Placebo|Conventional antihypetensive treatment
11451330|NCT01691105|No Intervention|Academic Detailing (AD)|Standard of care for patients who are smokers and admitted to the hospital.
11451331|NCT01691105|Experimental|AD + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
11451332|NCT01691092|Experimental|Ketamine|All subjects will receive ketamine
11451333|NCT01691079|Placebo Comparator|placebo|placebo 2 puffs prior to exercise challenge
11451334|NCT01691079|Active Comparator|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
11451335|NCT01691066|Experimental|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
11451336|NCT01691066|No Intervention|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
11451337|NCT01691053|Active Comparator|Spironolactone|
11451338|NCT01691053|Placebo Comparator|Placebo|
11451339|NCT01691040|Experimental|Open-label pilot group|Twice weekly administration of NOX-H94
11451340|NCT01691027|Experimental|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
11451341|NCT01691014||adalimumab|
11451342|NCT01691014||Etanercept|
11451343|NCT01691014||infliximab|
11451344|NCT01691014||Certolizumab|
11451345|NCT01691001|Experimental|dexmedetomidine|
11451346|NCT01691001|Placebo Comparator|placebo group|normal saline
11451347|NCT01690988|Experimental|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
11451348|NCT01690988|Placebo Comparator|Normal saline (placebo)|Intravenous normal saline
11451349|NCT01690988|Experimental|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
11451350|NCT01690975|Placebo Comparator|Placebo|Placebo Control
11451351|NCT01690975|Experimental|Benzonatate|Benzonatate Active
11451352|NCT01690962|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
11451353|NCT01690962|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
11451354|NCT01690949|Experimental|PUR118 low dose|
11451355|NCT01690949|Experimental|PUR118 mid dose|
11451356|NCT01690949|Experimental|PUR118 high dose|
11451357|NCT01690936|Experimental|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
11451358|NCT01690936|Experimental|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
11451359|NCT01690936|Experimental|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
11451360|NCT01690936|Experimental|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
11451361|NCT01690936|No Intervention|Control no nuts|Avoided all nuts and seeds
11451362|NCT01690923|Experimental|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.
~[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX]"
11451363|NCT01690923|Experimental|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. [Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX]
11451364|NCT01690910|Active Comparator|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
11451365|NCT01690910|Active Comparator|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
11451366|NCT01690897|Experimental|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
11451367|NCT01690897|Active Comparator|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
11451368|NCT01690884|Placebo Comparator|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
11451369|NCT01690884|Active Comparator|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
11451370|NCT01690884|Experimental|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
11451371|NCT01690871|Experimental|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
11451372|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
11451373|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
11451374|NCT01690845|No Intervention|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean < 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation < 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS <= 8.
11451375|NCT01690845|Experimental|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels > 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
11451376|NCT01690832|Active Comparator|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
11451377|NCT01690832|Active Comparator|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
11451378|NCT01690819|Active Comparator|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
11451379|NCT01690819|Experimental|Protective Ventilatory Strategy|Protective ventilatory strategy
11451380|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp & Dohme) intravenously 90 min before skin incision
11451381|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
11451382|NCT01690780|Active Comparator|Ibuprofen|
11451383|NCT01690780|Experimental|Oral morphine|
11451418|NCT01690494|Experimental|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
11451384|NCT01690767|Experimental|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
11451385|NCT01690767|Active Comparator|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
11451386|NCT01690754|No Intervention|Control|This arm will receive the regular standard of care given by TB clinics.
11451387|NCT01690754|Experimental|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
11451388|NCT01690741|Experimental|Nerofe|Nerofe administered intravenously 3x/week
11451389|NCT01690728|Active Comparator|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
11451390|NCT01690728|No Intervention|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
11451391|NCT01690715||Hepatocellular carcinoma underwent surgery|
11451392|NCT01690702|Active Comparator|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
11451393|NCT01690702|Experimental|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
11451394|NCT01690689|Experimental|Surgery|Implant surgery
11451395|NCT01690676|Active Comparator|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
11451396|NCT01690676|Placebo Comparator|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
11451397|NCT01690663|Placebo Comparator|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
11451398|NCT01690663|Active Comparator|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
11451399|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
11451400|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
11451401|NCT01690650|Experimental|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
11451402|NCT01690637|Active Comparator|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
11451403|NCT01690637|Placebo Comparator|Placebo|
11451404|NCT01690624|Experimental|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
11451405|NCT01690611|Experimental|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
11451406|NCT01690611|Active Comparator|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
11451407|NCT01690598|Experimental|Veliparib and Topotecan|
11451408|NCT01690585|Experimental|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
11451409|NCT01690585|Placebo Comparator|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
11451410|NCT01690572|Active Comparator|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
11451411|NCT01690572|Active Comparator|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
11451412|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
11451413|NCT01690546|Experimental|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
11451414|NCT01690533||Group 1|
11451415|NCT01690520|Active Comparator|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.
~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
11451416|NCT01690520|Experimental|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.
~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.
~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
11451417|NCT01690507|Other|DCAG plus HLI|
11451419|NCT01690494|Active Comparator|TAU|TAU control condition delivered to the male participant
11451420|NCT01690468|Experimental|Triciribine & Carboplatin|"Phase I/II: 25mg/m^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m^2 if toxicities are not encountered.
~Phase II: Recommended phase II dose of triciribine and carboplatin."
11451421|NCT01690455||Cohort|
11451422|NCT01690442|Experimental|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
11451423|NCT01690442|Active Comparator|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
11451424|NCT01690429|Other|OSA Patients|
11451425|NCT01690416|Active Comparator|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
11451426|NCT01690416|Active Comparator|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
11451427|NCT01690403|Experimental|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
11451428|NCT01690403|Experimental|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
11451429|NCT01690403|Experimental|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
11451430|NCT01690390|Active Comparator|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
11451431|NCT01690390|Experimental|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
11451432|NCT01690377|Experimental|1|PDC or myDC
11451433|NCT01690364|Experimental|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
11451434|NCT01690364|Active Comparator|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
11451435|NCT01690351|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
11451436|NCT01690351|Experimental|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
11451437|NCT01690338|Active Comparator|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
11451438|NCT01690338|Active Comparator|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
11451439|NCT01690338|Active Comparator|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
11451440|NCT01690325|Experimental|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
11451441|NCT01690325|Experimental|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
11451442|NCT01690312|Experimental|1 (Dietary Supplement - Fish Oil)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.
~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
11451443|NCT01690312|Experimental|2 (Placebo)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.
~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
11451444|NCT01690299|Experimental|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
11451445|NCT01690299|Experimental|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
11451446|NCT01690299|Placebo Comparator|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
11451447|NCT01690286|Experimental|Group 1: JNJ-38518168 3 mg/ ketoconazole|
11451448|NCT01690286|Experimental|Group 2: JNJ-38518168 30 mg/ ketoconazole|
11451449|NCT01690286|Experimental|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
11451450|NCT01690273|No Intervention|ankylosing spondylitis control|control group
11451451|NCT01690273|Experimental|mobility exercise|mobility exercises
11451452|NCT01690273|Experimental|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
11451453|NCT01690260|Experimental|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
11451454|NCT01690260|Experimental|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
11451486|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
11451455|NCT01690247|Experimental|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
11451456|NCT01690247|Placebo Comparator|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
11451457|NCT01690234|Experimental|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
11451458|NCT01690234|Active Comparator|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
11451459|NCT01690221|Experimental|VEN 307|diltiazem hydrochloride 2% cream
11451460|NCT01690221|Placebo Comparator|Placebo|Placebo Cream
11451461|NCT01690208|Experimental|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
11451462|NCT01690208|Active Comparator|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.
~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
11451463|NCT01690195|Experimental|ABT-126|ABT-126 Open-label dose
11451464|NCT01690182|Experimental|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
11451465|NCT01690182|Experimental|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
11451466|NCT01690182|Experimental|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
11451467|NCT01690169|Experimental|NNC0113-0987|
11451468|NCT01690169|Placebo Comparator|Placebo|
11451469|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
11451470|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
11451471|NCT01690143|Experimental|Carfilzomib + high dose melphalan|Single arm.
11451472|NCT01690130|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
11451473|NCT01690130|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
11451474|NCT01690117|Experimental|GE-REACH-program|GE-REACH-program
11451475|NCT01690117|No Intervention|control group|usual care
11451476|NCT01690104|Active Comparator|Rifampicin|Rifampicin 600 mg daily
11451477|NCT01690104|Placebo Comparator|Placebo|Placebo daily
11451478|NCT01690091|Experimental|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
11451479|NCT01690091|Placebo Comparator|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
11451480|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects > 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
11451481|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
11451482|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
11451483|NCT01690065|Experimental|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy
~AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
~Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)
~Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
11451484|NCT01690052|Active Comparator|Cevimeline|Cevimeline vs Pilocarpine
11451485|NCT01690052|Active Comparator|Pilocarpine|Pilocarpine vs. Cevimeline
11451493|NCT01690000|Active Comparator|Placebo|Identical placebo given nightly
11451494|NCT01689987|Experimental|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11451495|NCT01689974|Other|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
11451496|NCT01689974|Other|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
11451497|NCT01689961|Experimental|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:
~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
11451498|NCT01689961|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
11451499|NCT01689948|Experimental|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
11451500|NCT01689935|No Intervention|Control|No drug, no treatment
11451501|NCT01689935|Active Comparator|ALA-PDT|Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT
11451502|NCT01689935|Experimental|i-PDT|Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy
11451503|NCT01689935|Active Comparator|Red Light only|Red light only - no drug
11451504|NCT01689935|Active Comparator|Blue light only|Blue light only - no drug
11451505|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
11451506|NCT01689922||Control group|1) Standard postoperative rehabilitation program
11451507|NCT01689909|Active Comparator|Zolpidem-CR|Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
11451508|NCT01689909|Placebo Comparator|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
11451509|NCT01689896|Active Comparator|Testosterone Gel|Testosterone Gel
11451510|NCT01689896|Placebo Comparator|Placebo Gel|Placebo Gel
11451511|NCT01689883|Other|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
11451512|NCT01689870|Experimental|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
11451513|NCT01689870|Experimental|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
11451514|NCT01689870|Experimental|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
11451515|NCT01689870|Experimental|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
11451516|NCT01689857|Experimental|Scarclinic™ Thin|Scarclinic™ Thin
11451517|NCT01689857|Active Comparator|Scarclinic™ Normal|Scarclinic™ Normal
11451518|NCT01689844|Active Comparator|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
11451519|NCT01689844|Other|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
11451520|NCT01689831|Experimental|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
11451521|NCT01689831|Active Comparator|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
11451522|NCT01689818|Experimental|exercise training|exercise training program which included aerobic exercise for 3 times per week.
11451523|NCT01689818|No Intervention|control|lifestyle counseling
11451524|NCT01689805||Patients with atopic dermatitis|
11451525|NCT01689805||Non-atopic controls|
11451526|NCT01689792|Active Comparator|CitraFleet|Administration of CitraFleet
11451527|NCT01689792|Experimental|MOVIPREP|Administration of MOVIPREP
11451528|NCT01689779|Active Comparator|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
11451529|NCT01689779|Placebo Comparator|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
11451530|NCT01689766|Other|Technetium Tc 99m EC20|
11451531|NCT01689753|Experimental|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
11451532|NCT01689753|Active Comparator|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
11451533|NCT01689740|Experimental|Lead in: 125 mg MDMA (Open Label)|Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
11451534|NCT01689740|Placebo Comparator|Active placebo dose MDMA (25 mg)|Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
11451535|NCT01689740|Experimental|Full dose MDMA (125 mg)|Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
11451536|NCT01689727|Other|Technetium Tc 99m EC20|
11451537|NCT01689714|Experimental|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
11451538|NCT01689701|Experimental|Hizikia Fusiformis extract|
11451539|NCT01689701|Placebo Comparator|Placebo|
11451540|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
11451541|NCT01689675|Experimental|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
11451542|NCT01689675|Active Comparator|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
11451543|NCT01689662|Experimental|Tc 99m EC20|"Subjects will receive two intravenous injections 1-3 minutes apart:
~1 mg of folic acid
~1-2 mL injection of 0.1 mg of EC20 labeled with 15-25 mCi of technetium-99m"
11451544|NCT01689649|Experimental|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
11451545|NCT01689636|Experimental|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.
~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
11451546|NCT01689623|Experimental|Panel I|Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
11451547|NCT01689623|Experimental|Panel II|Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
11451548|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
11451549|NCT01689597|Active Comparator|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
11451550|NCT01689597|Active Comparator|High dose epidural morphine|One dose of 2.5 mg epidural morphine
11451551|NCT01689597|Placebo Comparator|Saline|One dose of 10 ml saline administered through an epidural catheter
11451552|NCT01689584|Other|Covar|
11451553|NCT01689571|Placebo Comparator|Placebo DPI|Placebo by inhalation for 9 days
11451554|NCT01689571|Experimental|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
11451555|NCT01689571|Experimental|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
11451556|NCT01689558|Experimental|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
11451557|NCT01689545|Experimental|Individual level|
11451558|NCT01689545|Experimental|Structural level|
11451559|NCT01689545|Experimental|Combined individual & structural level|
11451560|NCT01689545|Active Comparator|Standard of Care|
11451561|NCT01689532|Experimental|Sirukumab 100 mg|
11451562|NCT01689532|Experimental|Sirukumab 50 mg and Placebo|
11451563|NCT01689519|Active Comparator|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
11451564|NCT01689519|Experimental|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
11451565|NCT01689506|Experimental|Volulyte|Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
11451566|NCT01689506|Active Comparator|Human Serum Albumin|5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
11451567|NCT01689493|No Intervention|usual care|usual care arm, without SMS reminder
11451568|NCT01689493|Active Comparator|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
11451569|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
11451570|NCT01689467|Experimental|Fermented Velvet Antler extract|
11451571|NCT01689467|Placebo Comparator|Placebo|
11451572|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
11451573|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
11451574|NCT01689441|Experimental|Calcitriol|Calcitriol 2mcg IV x 1
11451575|NCT01689441|Placebo Comparator|Placebo|Normal saline 2cc IV x 1
11451576|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
11451577|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
11451578|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
11451579|NCT01689389||Main study population|"All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.
~Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
11451580|NCT01689389||Schizophrenia SoC sample|Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
11451581|NCT01689389||Bipolar SoC sample|Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
11451582|NCT01689363|Experimental|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
11451583|NCT01689363|Active Comparator|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
11451584|NCT01689363|Placebo Comparator|Arm N|Intradermal injection of saline (0.02 mL)
11451585|NCT01689350|No Intervention|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
11451586|NCT01689350|Experimental|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
11451587|NCT01689337|Experimental|Sprifermin (AS902330), 30 mcg|
11451588|NCT01689337|Experimental|Sprifermin (AS902330), 100 mcg|
11451589|NCT01689337|Placebo Comparator|Placebo|
11451590|NCT01689324|Experimental|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
11451591|NCT01689311|Experimental|Treatment|All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.
11451592|NCT01689298|Active Comparator|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
11451593|NCT01689298|Active Comparator|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
11451594|NCT01689285|Active Comparator|valacyclovir tablet|Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
11451595|NCT01689285|Experimental|valacyclovir oral solution|Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
11451596|NCT01689272|Experimental|Kidney transplantation|Kidney transplantation from alive relative donor.
11451597|NCT01689259|Experimental|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
11451598|NCT01689259|Experimental|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
11451599|NCT01689259|Experimental|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
11451600|NCT01689259|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
11451601|NCT01689246|Experimental|TRx0237 250 mg/day|
11451602|NCT01689246|Placebo Comparator|Placebo|
11451603|NCT01689246|Experimental|TRx0237 150 mg/day|
11451604|NCT01689233|Experimental|TRx0237 200 mg/day|
11451605|NCT01689233|Placebo Comparator|Placebo|
11451606|NCT01689220|Experimental|SP-02L|
11451607|NCT01689207|Experimental|Drug: A|Avibactam (AVI)
11451608|NCT01689207|Experimental|Drug: B|Aztreonam (ATM)
11451609|NCT01689207|Experimental|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
11451610|NCT01689207|Placebo Comparator|Drug: D|Matching Placebo
11451611|NCT01689194|Experimental|genexolPM + cisplatin|
11451612|NCT01689181||chronic schizophrenic patients|
11451613|NCT01689181||healthy volunteers|
11451614|NCT01689168|Experimental|Counseling plus chiropractic adjustments|
11451615|NCT01689168|Active Comparator|Counseling alone|
11451616|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
11451617|NCT01689142|Experimental|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
11451618|NCT01689142|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of OADs
11451619|NCT01689129|Experimental|New formulation of insulin glargine|once daily in the evening on-top of mealtime insulin
11451667|NCT01688843|Experimental|INGEVITY lead|INGEVITY lead implant
11451620|NCT01689129|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of mealtime insulin
11451621|NCT01689116|Experimental|Bardoxolone Methyl 20mg|
11451622|NCT01689116|Experimental|Bardoxolone Methyl 80mg|
11451623|NCT01689116|Placebo Comparator|Bardoxolone Methyl Placebo|
11451624|NCT01689116|Active Comparator|Moxifloxacin|
11451625|NCT01689103|Experimental|Alliance Feedback to Therapist|Alliance feedback provided to therapist
11451626|NCT01689103|Placebo Comparator|No alliance feedback to therapist|No alliance feedback provided to therapist
11451627|NCT01689090|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.
11451628|NCT01689090|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.
11451629|NCT01689077|Active Comparator|24 hours hypothermia|24 hours hypothermia
11451630|NCT01689077|Experimental|48 hours hypothermoa|48 hours hypothermia
11451631|NCT01689064|Active Comparator|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
11451632|NCT01689064|Experimental|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
11451633|NCT01689051|Active Comparator|Healthy subjects|
11451634|NCT01689051|Active Comparator|Patients with type 2 diabetes|
11451635|NCT01689038|Experimental|Tested product|
11451636|NCT01689025|Experimental|NNC0114-0006|
11451637|NCT01689025|Placebo Comparator|Placebo|
11451638|NCT01689012|Experimental|Facial Exercise|
11451639|NCT01688999|Experimental|Cabozantinib|Administered orally at a dose of 60 mg once daily on each day of a 28-day cycle.
11451640|NCT01688973|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
11451641|NCT01688973|Experimental|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
11451642|NCT01688960|Experimental|Cohort 1|
11451643|NCT01688960|Experimental|Cohort 2|
11451644|NCT01688960|Experimental|Cohort 3a|
11451645|NCT01688960|Experimental|Cohort 3b|
11451646|NCT01688960|Experimental|Cohort 4|
11451647|NCT01688947|Experimental|V116517 - 50 mg|V116517 50-mg tablets
11451648|NCT01688947|Experimental|V116517 - 30 mg|V116517 30-mg tablets
11451649|NCT01688947|Active Comparator|Pregabalin|Pregabalin capsules
11451650|NCT01688947|Placebo Comparator|Placebo|Placebo
11451651|NCT01688934|Experimental|V116517 - 50 mg|V116517 50-mg tablets
11451652|NCT01688934|Experimental|V116517 - 30 mg|V116517 30-mg tablets
11451653|NCT01688934|Active Comparator|Naproxen 500 mg|Naproxen 500-mg capsules
11451654|NCT01688934|Placebo Comparator|Placebo|Placebo
11451655|NCT01688921|Experimental|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
11451656|NCT01688921|Active Comparator|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
11451657|NCT01688908|No Intervention|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
11451658|NCT01688908|Experimental|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
11451659|NCT01688895||Participants with Protoporphyrias|Individuals with a documented diagnosis of Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
11451660|NCT01688882|Experimental|QGE031|QGE031 240 mg Q2W s.c.
11451661|NCT01688882|Placebo Comparator|Placebo|Placebo to Match Q2W s.c.
11451662|NCT01688882|Experimental|Open Label QGE031|Open Label QGE031 Q2W s.c.
11451663|NCT01688869||Mild TBI|Patients who have been diagnosed with a mild brain injury.
11451664|NCT01688856|Experimental|Arm+Hand CCFES|Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
11451665|NCT01688856|Experimental|Hand CCFES|Uses an electrical stimulator that opens the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
11451666|NCT01688856|Active Comparator|Arm+Hand Cyclic NMES|Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
11451673|NCT01688804|Experimental|Behavioral intervention|Behavioral intervention to reduce sedentary time delivered via mobile smartphone
11451674|NCT01688791|Experimental|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
11451675|NCT01688791|Experimental|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
11451676|NCT01688791|Experimental|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
11451677|NCT01688778|Experimental|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
11451678|NCT01688778|No Intervention|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
11451679|NCT01688765||First Episode Psychosis Patients|
11451680|NCT01688765||Healthy Controls|
11451681|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
11451682|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
11451683|NCT01688739|Experimental|Erenumab|Participants received a single dose of erenumab by subcutaneous injection at doses of 1 mg, 7 mg, 21 mg, 70 mg, 140 mg, and 210 mg or by IV injection at a dose of 140 mg.
11451684|NCT01688739|Placebo Comparator|Placebo|Participants received a single dose of matching placebo administered by SC or IV injection.
11451685|NCT01688726|Experimental|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
11451686|NCT01688726|Active Comparator|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
11451687|NCT01688713|Experimental|Icotinib,Brain metastases|
11451688|NCT01688700|Experimental|Nimotuzumab plus chemotherapy|
11451689|NCT01688687||Superficial gastric neoplasia|Patients with superficial gastric neoplasia on diagnostic endoscopy, recieved both conventional endoscopic forcpes biopsies and pCLE. All patients were subject to endoscopic resection of the lesion.
11451690|NCT01688674|Placebo Comparator|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
11451691|NCT01688674|Experimental|infusion|10% dextrose infusion by burettes
11451692|NCT01688648|Experimental|Lidocaine group|a bolus dose of lidocaine 1.5 mg/kg after anesthetic induction with following lidocaine infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
11451693|NCT01688648|Experimental|Dexmedetomidine group|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
11451694|NCT01688648|Experimental|Combined infusion group|Combined lidocaine and dexmedetomidine infusion with the dose specified in single infusion group
11451695|NCT01688648|No Intervention|Control group|The group without infusion of lidocaine or dexmedetomidine
11451696|NCT01688635|Experimental|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
11451697|NCT01688635|Experimental|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
11451698|NCT01688622|Other|Exercise|obese women who are volunteers for the 3 months exercise programs
11451699|NCT01688609|Experimental|Treatment (lapatinib, trastuzumab, paclitaxel, surgery)|"Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
~Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy or mastectomy."
11451700|NCT01688596|No Intervention|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
11451701|NCT01688596|Active Comparator|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
11451702|NCT01688583||Fentanyl matrix|
11451703|NCT01688570|Active Comparator|Duloxetine|Neuromuscular fatigue testing with duloxetine dose
11451704|NCT01688570|Active Comparator|Cyproheptadine|Neuromuscular fatigue testing with cyproheptadine dose
11451705|NCT01688570|Placebo Comparator|Placebo|Neuromuscular fatigue testing with placebo dose
11451706|NCT01688557|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
11451707|NCT01688557|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
11451708|NCT01688544|Experimental|Ilaprazole|"Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.
~After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
11451709|NCT01688531|Experimental|CD0271 0.1%/CD1579 2.5% gel|Split-face design, one application a day for 6 months
11451710|NCT01688531|Placebo Comparator|CD0271 0.1%/CD1579 2.5% gel vehicle|Split-face design, one application a day for 6 months
11451711|NCT01688518|Active Comparator|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
11451712|NCT01688518|Active Comparator|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
11451713|NCT01688505||Visit-to-visit BP variability|The highest, intermediate, and the lowest visit-to-visit BP variability (Tertile grouping)
11451714|NCT01688492|Experimental|ipilimumab|This multi-institution open label study has a Phase 1 and Phase 2 component. The Phase 1 dose escalation stage is to establish the tolerability of ipilimumab to be used in combination with the standard clinical dose of abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic CRPC. Due to the overlapping potential hepatic toxicity between abiraterone and ipilimumab, a Lead in Therapy with abiraterone plus prednisone for 2 cycles will assess for adverse events related to the abiraterone plus prednisone. Patients, who tolerate well the Lead in therapy as defined by Grade 1 or less AEs, will pursue Combination Therapy. Patients with AEs Grade ≥ 2 after Lead in Therapy will be excluded and replaced. The Phase 2 stage will assess efficacy and confirm an acceptable safety profile of the recommended dose.
11451715|NCT01688479|Experimental|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
11451716|NCT01688479|Active Comparator|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
11451717|NCT01688466|Experimental|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
11451718|NCT01688466|Experimental|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
11451719|NCT01688453|Active Comparator|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
11451720|NCT01688453|Experimental|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
11451721|NCT01688453|Experimental|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
11451722|NCT01688440|Experimental|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
11451723|NCT01688427|Experimental|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
11451724|NCT01688427|Experimental|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
11451725|NCT01688414|Experimental|Diagnostic (fluorescence imaging, PAI)|Patients undergo fluorescence imaging and PAI during robot assisted laparoscopic surgery.
11451726|NCT01688401|Experimental|IA melphalan|IA melphalan is administered via the basilar artery.
11451727|NCT01688388|Experimental|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
11451728|NCT01688375|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
11451729|NCT01688362|Experimental|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
11451730|NCT01688362|Active Comparator|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
11451731|NCT01688349|Experimental|Cushing group|AT biopsy during partial nephrectomy
11451732|NCT01688349|Other|Controls1|normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
11451733|NCT01688349|Other|Controls2|obese individuals already included and having biopsies of VAT and SCAT stocked.
11451734|NCT01688336|Experimental|FOLFIRINOX|FOLFIRINOX given to all subjects
11451735|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
11451736|NCT01688310|Active Comparator|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
11451737|NCT01688310|Experimental|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
11451738|NCT01688297|Experimental|Low Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
11451739|NCT01688297|Placebo Comparator|VXA Placebo Tablet|Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
11451740|NCT01688297|Experimental|Medium Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet
11451741|NCT01688297|Experimental|High Dose VXA-A1.1 Oral Vaccine|One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.
11451742|NCT01688284|Active Comparator|No treatment|patients with recurrent miscarriages
11451743|NCT01688284|Active Comparator|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
11451744|NCT01688271||Anesthesiologists|
11451745|NCT01688245|No Intervention|Control|No SMS dialog
11451746|NCT01688245|Active Comparator|SMS Assessments|Weekly post-weekend drinking outcome assessments
11451747|NCT01688245|Experimental|SMS Assessments & Feedback|Weekly pre-weekend drinking intention & post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
11451748|NCT01688206|Experimental|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
11451988|NCT01686646|Active Comparator|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
11451749|NCT01688206|Experimental|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
11451750|NCT01688193||HCP 1004|
11451751|NCT01688193||Vimovo 500/20mg|
11451752|NCT01688167|Experimental|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
11451753|NCT01688167|No Intervention|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
11451754|NCT01688167|No Intervention|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
11451755|NCT01688154|Active Comparator|Product 1|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
11451756|NCT01688154|Placebo Comparator|Control product|2 empty capsules
11451757|NCT01688141|No Intervention|Control|Usual care
11451758|NCT01688141|Active Comparator|Enhanced Management|Practices randomised to the intervention group will be offered an enhanced level of CKD disease management led by clinical nurse specialists based on an intervention previously piloted in high risk patients. Here, high risk patients identified will be invited to a CKD clinic for tailored management of bp and proteinuria and referral as needed.
11451759|NCT01688128|Experimental|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
11451760|NCT01688128|Experimental|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
11451761|NCT01688115|Experimental|Procedure|
11451762|NCT01688115|Active Comparator|Standard Care|
11451763|NCT01688102|Active Comparator|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of oral vitamin D.
11451764|NCT01688102|Active Comparator|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of narrow band UVB.
11451765|NCT01688089|Experimental|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
11451766|NCT01688089|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
11451767|NCT01688089|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
11451768|NCT01688076|Experimental|Muscle contractions|Under supervision by study personnel, subjects be asked to make active muscle contractions for one hour after Botox injections. Subjects will return for follow-up visits.
11451769|NCT01688076|Active Comparator|No muscle contractions|Patients will be asked to not perform muscle contractions following Botox injections.
11451770|NCT01688063||Part A: 3 Arms|Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
11451771|NCT01688063||Part B|The study population in the second cohort will consist of 250 subjects who have a surgical scar >2 cm in length. Subjects enrolled will have three elasticity measurements performed in one study visit. Elasticity will be measured directly in the center of the scar, 3cm perpendicular to the center of the scar, and 3cm in line from one end of the scar (Appendix 2).
11451772|NCT01688050|Experimental|Endovascular Repair|
11451773|NCT01688037|Experimental|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
11451774|NCT01688037|Experimental|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
11451775|NCT01688037|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
11451776|NCT01688024|Experimental|Mitomycin C|Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given.
11451777|NCT01688024|Placebo Comparator|Normal saline|Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed.
11451778|NCT01688011||Lower-Risk Myelodysplastic Syndromes (LR MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
11451779|NCT01688011||Higher-Risk Myelodysplastic Syndromes (HR MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
11451780|NCT01688011||Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
11451781|NCT01688011||Unknown-Risk MDS|Newly diagnosed unknown-risk MDS patients as determined by International Prognostic Scoring System (IPSS); defined as not having risk assigned due to unsuccessful cytogenetics after two bone marrow attempts.
11451782|NCT01687998|Experimental|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
11451989|NCT01686646|Active Comparator|high dose paracetamol|highest dose paracetamol
11451783|NCT01687998|Placebo Comparator|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
11451784|NCT01687985|Experimental|BLI801 laxative - low dose|BLI801 laxative - oral solution
11451785|NCT01687985|Experimental|BLI801 laxative - high dose|BLI801 laxative - oral solution
11451786|NCT01687972|Active Comparator|Sutures|
11451787|NCT01687972|Active Comparator|Insorb Staples|
11451788|NCT01687959|Active Comparator|activity of peritoneal fibrinolysis|measurements of peritoneal fibrinolysis using tissue-type plasminogen activator and its specific activity, urokinase-type plasminogen activator, and plasminogen activator inhibitor type 1
11451789|NCT01687959|Active Comparator|surgical outcomes|surgical outcomes of laparoscopic cholecystectomy
11451790|NCT01687946||Pulmonary fibrosis in aged individuals|"Group A and B:
~Patients with UIP (histologically and/or radiologically proven) providing informed consent. According to functional and radiological assessment, the disease may be either limited (Group A) or advanced (Group B). The patients are usually older than 55 years."
11451791|NCT01687946||Pulmonary fibrosis and inflammation|"Groups C and D:
~Patients with HP (histologically and radiologically proven) providing informed consent. According to functional and radiological assessment, the disease will be either acute or chronic. The patients will be significantly younger (mean > 10 years) than in groups A and B."
11451792|NCT01687946||Regular wound healing in lung|Patients receiving lung biopsy or bronchoscopy for reasons other that the study and volunteers providing informed consent. The group will consist of young (18-40 years) and old individuals (older than 55 years).
11451793|NCT01687933|Experimental|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
11451794|NCT01687933|Experimental|usual care|Women in control group did not use the glasses.
11451795|NCT01687920|Experimental|BAY94-8862 (1.25mg)|single dose BAY94-8862 IR tablet 1.25mg
11451796|NCT01687920|Experimental|BAY94-8862 (2.5mg)|single dose BAY94-8862 IR tablet 2.5mg
11451797|NCT01687920|Experimental|BAY94-8862 (5mg)|single dose BAY94-8862 IR tablet 5mg
11451798|NCT01687920|Experimental|BAY94-8862 (7.5mg)|single dose BAY94-8862 IR tablet 7.5mg
11451799|NCT01687920|Experimental|BAY94-8862 (10mg)|single dose BAY94-8862 IR tablet 10mg
11451800|NCT01687907|Active Comparator|Fear of childbirth, music|Patients referred to the motherhood out-patient clinic because of fear of childbirth. Advised to active music listening. Followed up by weekly and monthly diaries and three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
11451801|NCT01687907|No Intervention|Fear of childbirth, control|Patients referred to the motherhood out-patient clinic because of fear of childbirth. No intervention. Followed up by three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
11451802|NCT01687907|Active Comparator|Nulliparous, music|300 nulliparous women recruited from the ultrasound screening. Advised to active music listening. Three questionnaires like the other arms, weekly and monthly diaries like the other music group. Screening questionnaires about fear of childbirth.
11451803|NCT01687907|No Intervention|Nulliparous, control|300 nulliparous women recruited from ultrasound screening. No intervention. 3 Questionnaires as all the other groups. Screening questionnaire about fear of childbirth.
11451804|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
11451805|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
11451806|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
11451807|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
11451808|NCT01687881|Sham Comparator|Sham Chiropractic|Sham Chiropractic manipulative therapy.
11451809|NCT01687881|No Intervention|Control group|No intervention: Control group.
11451810|NCT01687881|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
11451811|NCT01687868|Experimental|dexmedetomidine continuous infusion|
11451812|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
11451813|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
11451814|NCT01687842||Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
11451815|NCT01687829||ILM-on group|patients were scheduled to undergo macular hole surgery without internal limiting membrane (ILM) peeling
11451816|NCT01687829||ILM-off group|patients were scheduled to undergo macular hole surgery with internal limiting membrane (ILM) peeling
11451817|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
11451818|NCT01687803|Experimental|Physical Activity|Physical activity intervention will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
11451819|NCT01687803|Other|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
11451820|NCT01687790|Experimental|molecular breast imaging|
11451821|NCT01687777|Active Comparator|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
11451822|NCT01687777|Placebo Comparator|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
11451823|NCT01687764|Experimental|CBGT+ABMT(active)|
11451824|NCT01687764|Experimental|CBGT+ABMT(placebo)|
11451825|NCT01687764|Experimental|PCI+ABMT(active)|
11451826|NCT01687764|Placebo Comparator|PCI+ABMT(placebo)|
11451827|NCT01687751|Experimental|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
11451828|NCT01687751|Active Comparator|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
11451829|NCT01687738|Experimental|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
11451830|NCT01687738|Experimental|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
11451831|NCT01687725||Renal denervation|Renal denervation using Symplicity Catheter system
11451832|NCT01687712|Experimental|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
11451833|NCT01687712|Active Comparator|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
11451834|NCT01687699|Experimental|spironolactone|
11451835|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
11451836|NCT01687673|Experimental|Treatment|Combination temsirolimus plus sorafenib
11451837|NCT01687660|Experimental|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
11451838|NCT01687660|Other|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
11451839|NCT01687660|No Intervention|waiting list|No acupuncture nor other methods will be conducted in this group.
11451840|NCT01687647|Other|Screening|Paired-design: low-dose CT scan, sputum sample and blood test will be performed on all subjects.
11451841|NCT01687634|Experimental|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
11451842|NCT01687634|Experimental|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
11451843|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
11451844|NCT01687608|Experimental|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
11451845|NCT01687595|Experimental|HerpV and QS-21|HerpV and QS-21
11451846|NCT01687595|Placebo Comparator|Placebo|
11451847|NCT01687582|Experimental|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
11451848|NCT01687569|Placebo Comparator|Control Cracker|Base cracker snack
11451849|NCT01687569|Experimental|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
11451850|NCT01687569|Experimental|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
11451851|NCT01687556|Active Comparator|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
11451852|NCT01687556|Experimental|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
11451853|NCT01687543|Experimental|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
11451854|NCT01687543|Placebo Comparator|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
11451855|NCT01687530|Experimental|AMCA bone membrane|AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
11451856|NCT01687517|Experimental|Patient|90 patients suffering from sarcoidosis
11451857|NCT01687517|Active Comparator|Volunteer|100 volunteers
11451858|NCT01687491|Active Comparator|Enoxa|ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
11451859|NCT01687491|Active Comparator|Lovenox|LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
11451860|NCT01687478|Experimental|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.
~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
11451861|NCT01687478|Placebo Comparator|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.
~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
11451862|NCT01687465|Active Comparator|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
11451863|NCT01687465|Active Comparator|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
11451864|NCT01687452|Experimental|Groupe A|Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
11451865|NCT01687452|Experimental|group B|Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load > 40 copies / ml
11451866|NCT01687452|Placebo Comparator|group C|Healthy volunteers
11451867|NCT01687439|Experimental|Treatment|Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.
11451868|NCT01687426|Active Comparator|Brimonidine Tartrate 0.025%|
11451870|NCT01687413|Experimental|Radiotherapy|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).
~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
11451871|NCT01687413|Active Comparator|Radiotherapy, cisplatin|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)
~Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).
~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
11451872|NCT01687400|Experimental|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
11451873|NCT01687387|Experimental|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
11451874|NCT01687387|Experimental|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
11451875|NCT01687387|Placebo Comparator|Placebo (Normal saline solution)|Normal saline solution
11451876|NCT01687374|Placebo Comparator|Placebo|
11451877|NCT01687374|Experimental|Parathyroid hormone|
11451878|NCT01687361|Experimental|branched-chain amino acids (BCAA) supplementation|
11451879|NCT01687361|Placebo Comparator|PLACEBO|
11451880|NCT01687348|Experimental|lidocaine|lidocaine traitment
11451881|NCT01687335||cancerous patients|the patients benefiting from treatment by chemotherapy.
11451882|NCT01687322||total hip replacement, quality of life, functioning|
11451883|NCT01687309|Other|Cohort A fed session|GSK2586184 800mg single dose with food
11451884|NCT01687309|Other|Cohort A fasted session|GSK2586184 single dose without food
11451885|NCT01687309|Active Comparator|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
11451886|NCT01687309|Placebo Comparator|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
11451887|NCT01687296|Experimental|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
11451888|NCT01687296|Active Comparator|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
11451889|NCT01687283|Experimental|fluticasone propionate|1 mg BID inhalation via nebulizer
11451890|NCT01687283|Active Comparator|budesonide suspension|2 mg BID inhalation via nebulizer
11451891|NCT01687270|Experimental|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
11451892|NCT01687257|Experimental|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
11451893|NCT01687257|Experimental|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
11451894|NCT01687244|Experimental|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
11451895|NCT01687244|Experimental|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
11451896|NCT01687231|No Intervention|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
11451897|NCT01687231|Experimental|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
11451898|NCT01687218|Active Comparator|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
11451899|NCT01687218|Active Comparator|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
11451900|NCT01687218|Active Comparator|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
11451901|NCT01687218|Active Comparator|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
11451902|NCT01687218|Active Comparator|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
11451903|NCT01687218|Active Comparator|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
11451904|NCT01687205|Active Comparator|Group 1|Single Dose/BAT Cohort
11451905|NCT01687205|Active Comparator|Group 2|Multiple Dose Cohort
11451906|NCT01687192|Experimental|Girls and young womens receiving immunosuppressive treatment|
11451907|NCT01687179|Experimental|"Sirolimus and Hydroxychloroquine"|"Subjects will take Sirolimus at an initial dose of 2mg followed by dose adjustment to keep Sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to Sirolimus subjects will receive Hydroxychloroquine at 200 mg daily for 6 months. Once safety is established at the lower dose (Sirolimus and Hydroxychloroquine 200 mg), subjects enrolled henceforth will receive Sirolimus and Hydroxychloroquine 400 mg (200 mg twice a day) for 6 months."
11451908|NCT01687166|Experimental|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
11451990|NCT01686646|Active Comparator|low dose paracetamol|lowest dose paracetamol
11451909|NCT01687166|Active Comparator|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
11451910|NCT01687153||Traumatic Brain Injury (TBI)|65-100 Vietnam Veterans with Traumatic Brain Injury (TBI), but without PTSD, mild cognitive impairment (MCI)/dementia
11451911|NCT01687153||Post Traumatic Stress Disorder (PTSD)|65-100 Vietnam Veterans with PTSD, but without TBI, MCI/dementia
11451912|NCT01687153||Controls|65-100 Vietnam Veteran Controls without TBI or PTSD and comparable in age, gender, and education to the other cohorts
11451913|NCT01687153||TBI w/ MCI|65-100 Vietnam Veterans with TBI but without PTSD who meet the criteria for MCI but not dementia
11451914|NCT01687153||PTSD w/ MCI|65-100 Vietnam Veterans with PTSD but without TBI who meet the criteria for MCI but not dementia
11451915|NCT01687153||Controls w/ MCI|65-100 Vietnam Veteran Controls without TBI or PTSD who meet the criteria for MCI but not dementia, and are comparable in age, gender, and education to the other cohorts
11451916|NCT01687140|Placebo Comparator|Placebo|Participant takes one pill of placebo a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
11451917|NCT01687140|Active Comparator|DCS|Participant takes one pill of D-Cycloserine a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
11451918|NCT01687127|Experimental|Folic acid supplementation|Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
11451919|NCT01687127|Experimental|5-MTHF supplementation|"The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name Metafolin) will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism."
11451920|NCT01687114|Experimental|cranberry juice|27% cranberry juice
11451921|NCT01687101|Experimental|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
11451922|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
11451923|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
11451924|NCT01687075|Experimental|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
11451925|NCT01687062|Active Comparator|FeSO4 + high phytate|injera test meal 1 labeled with a 4 mg staple iron isotope tag
11451926|NCT01687062|Experimental|FeSO4 + medium phytate|injera test meal 2 labeled with a 4 mg staple iron isotope tag
11451927|NCT01687062|Experimental|FeSO4 + low phytate|injera test meal 3 labeled with a 4 mg staple iron isotope tag
11451928|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:1) + high phytate|injera test meal 4 labeled with a 4 mg staple iron isotope tag
11451929|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:3) + high phytate|injera test meal 5 labeled with a 4 mg staple iron isotope tag
11451930|NCT01687049|Experimental|red yeast rice (RYR)|Two RYR capsules three times daily for a minimum of 6 months
11451931|NCT01687036|Other|Cryoablation|Cryoablation
11451932|NCT01687023||Tai Chi|Healthy Tai Chi practitioners
11451933|NCT01686997|Active Comparator|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
11451934|NCT01686997|Active Comparator|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
11451935|NCT01686997|Active Comparator|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
11451936|NCT01686997|Active Comparator|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
11451937|NCT01686984|Experimental|Altered breath|The group where the investigators alter the inspiratory and expiratory aspects of a ventilated breath.
11451938|NCT01686971||questionaire|patients will receive a questionaire and speak to a nurse regarding their needs and/ or demands.
11451939|NCT01686958|Experimental|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
11451940|NCT01686945|Experimental|Healthy - 20 mg|
11451941|NCT01686945|Experimental|Healthy - 40 mg|
11451942|NCT01686945|Experimental|Healthy - 60 mg|
11451943|NCT01686945|Experimental|T2D - 20/40/60 mg|
11451944|NCT01686932|Experimental|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
11451945|NCT01686932|Experimental|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
11451946|NCT01686919|Experimental|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
11451947|NCT01686906|Experimental|Bowman layer graft implantation|
11451948|NCT01686893|Active Comparator|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
11451949|NCT01686893|Active Comparator|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
11451950|NCT01686880|Experimental|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
11451951|NCT01686867|Experimental|Commercially-made followed by locally-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. Four months later the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
11452066|NCT01686217|Experimental|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
11452768|NCT01681485||NSCL cancer patients|Surgery, chemotherapy and/or radiation therapy
11451952|NCT01686867|Experimental|Locally-made followed by commercially-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. Four months later the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
11451953|NCT01686854|Experimental|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
11451954|NCT01686854|Active Comparator|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
11451955|NCT01686841|Experimental|Fat Reduction|
11451956|NCT01686828|Experimental|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
11451957|NCT01686828|Experimental|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
11451958|NCT01686828|Experimental|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
11451959|NCT01686828|Experimental|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
11451960|NCT01686815||Olanzapine|Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
11451961|NCT01686815||Risperidone|Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
11451962|NCT01686815||Iloperidone|Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
11451963|NCT01686802|Active Comparator|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
11451964|NCT01686802|Active Comparator|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
11451965|NCT01686789|Active Comparator|Pegylated interferon alpha-2a plus standard dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100-1200 mg/day for 48 weeks
11451966|NCT01686789|Experimental|Pegylated interferon alpha-2a 180 mcgs adjusted dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks
11451967|NCT01686776|Active Comparator|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
11451968|NCT01686776|Experimental|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
11451969|NCT01686776|Experimental|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
11451970|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
11451971|NCT01686750|Experimental|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.
~HIV voluntary counseling and testing & staging
~Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy
~Substance abuse counseling
~Sexually transmitted infection screening and treatment
~Access to free antiretroviral therapy and adherence support
~Peer community outreach"
11451972|NCT01686750|No Intervention|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
11451973|NCT01686737|Experimental|Yoga|"Iyengar Yoga
~12 weeks of Iyengar yoga
~2 weekly sessions of 60 minutes"
11451974|NCT01686737|Active Comparator|Aerobic exercise|"Walking
~12 weeks of walking
~2 weekly sessions of 60 minutes"
11451975|NCT01686737|No Intervention|Usual Care|
11451976|NCT01686724|Other|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
11451977|NCT01686724|Experimental|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
11451978|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 15 mg|
11451979|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 30 mg|
11451980|NCT01686711|Placebo Comparator|SYR-322 25 mg , AD-4833 placebo|
11451981|NCT01686698|Active Comparator|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) sachets containing 450 x 109 bacteria, 1 sachet every 12 hours during 3 months (n=20).
11451982|NCT01686698|Placebo Comparator|Placebo|Placebo sachets, 1 sachet every 12 hours during 3 months (n=20).
11451983|NCT01686672|Experimental|Web Intervention|BeInCharge has two components: an electronic diet tracker and a 7 session intervention. The 7 treatment sessions are designed to be completed over a 7 to 10 week period. Each treatment module includes both a nutrition education and child behavior management component. Treatment sessions should be completed every 7 to 10 days, while the electronic diet tracker requires daily input.
11451984|NCT01686672|No Intervention|Usual Care|Participants will receive usual care and be assessed at baseline and week 10 for study outcomes.
11451985|NCT01686659|Experimental|SpHb Arm|These are the patients whose primary anesthesiologists have been allocated to treat them while having access to data from a continuous noninvasive hemoglobin monitoring device
11451986|NCT01686659|No Intervention|Control Arm|These are the patients whose primary anesthesiologists have been allocated to treat them without having access to data from a continuous noninvasive hemoglobin monitoring device
11451987|NCT01686646|Active Comparator|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
11451991|NCT01686633|Experimental|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
11451992|NCT01686633|Experimental|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
11451993|NCT01686633|Experimental|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
11451994|NCT01686620|Experimental|BIOD-123|BIOD-123 used as prandial insulin
11451995|NCT01686620|Active Comparator|Lispro (Humalog)|Lispro (Humalog) used as prandial insulin
11451996|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
11451997|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
11451998|NCT01686594|Active Comparator|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
11451999|NCT01686594|No Intervention|No maintenance treatment|observation
11452000|NCT01686581||BOTOX®|BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
11452001|NCT01686568|Experimental|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
11452002|NCT01686568|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
11452003|NCT01686555|Experimental|Single Dose|Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
11452004|NCT01686555|Experimental|Multiple Dose|Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)
11452005|NCT01686542|Experimental|CPVI+RSM group|Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
11452006|NCT01686542|Active Comparator|CPVI group|Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
11452007|NCT01686529|Experimental|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
11452008|NCT01686529|Experimental|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
11452009|NCT01686529|Active Comparator|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
11452010|NCT01686503|Experimental|2/5 dose intradermal IPV|Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
11452011|NCT01686503|Experimental|1/5 dose intradermal IPV|Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
11452012|NCT01686503|Active Comparator|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
11452013|NCT01686503|Active Comparator|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
11452014|NCT01686490|Other|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
11452015|NCT01686477|Active Comparator|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
11452016|NCT01686477|Active Comparator|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
11452017|NCT01686477|Active Comparator|Preterm Formula|Used to make up any shortfall in mother's own milk
11452018|NCT01686464|Experimental|Magnetic - Oxygen|Magnetic and Oxygen Treatment for Bell's Palsy
11452019|NCT01686464|Active Comparator|prednisone - valacyclovir|prednisone and valacyclovir treatments for bell palsy
11452020|NCT01686451|Experimental|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
11452021|NCT01686451|Active Comparator|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
11452022|NCT01686438|Experimental|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
11452023|NCT01686438|Active Comparator|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
11452024|NCT01686425|Active Comparator|Percutaneous Transhepatic cholangiography|
11452025|NCT01686425|Active Comparator|Endoscopic Ultrasound guided biliary drainage|
11452026|NCT01686412|Active Comparator|Healthy patients|
11452027|NCT01686412|Active Comparator|Oncology patients|
11452028|NCT01686399|Experimental|The study has a single arm|The study has one arm The whole population of the campus will be exposed to the intervention. the effectiveness will be assessed using a random selection twice - before and after the intervention
11452067|NCT01686204|Active Comparator|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
11452068|NCT01686204|Experimental|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
11452069|NCT01686191||Cardiac transplant recipients|
11453523|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
11452029|NCT01686386|Experimental|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.
~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
11452030|NCT01686373|Experimental|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
11452031|NCT01686373|Placebo Comparator|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
11452032|NCT01686360|No Intervention|Control group 1: pre/post-test|Group receives pre and post test questions only.
11452033|NCT01686360|Experimental|Control group 2: tool and pre/post-test|Group receives decision tool without personalized information. (Behavioral: Decision Aid)
11452034|NCT01686360|Experimental|Gail score in a percentage format|Group receives Gail score in a percentage format. (Behavioral: Decision Aid)
11452035|NCT01686360|Experimental|Gail score in a frequency format|Group receives Gail score in a frequency format. (Behavioral: Decision Aid)
11452036|NCT01686360|Experimental|Frequency + Average 50 year old|Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman. (Behavioral: Decision Aid)
11452037|NCT01686360|Experimental|Frequency + Mammography Data|Group receives Gail score in a frequency format as well as information about the risks of mammography. (Behavioral: Decision Aid)
11452038|NCT01686360|Experimental|Frequency + Mortality Data|Group receives Gail score in a frequency format as well as information about mortality benefit of mammography. (Behavioral:Decision Aid)
11452039|NCT01686360|Experimental|Frequency + Avg 50 year old + Mamm Data + Mortality Data|Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography. (Behavioral: Decision Aid)
11452040|NCT01686347|Other|fetal cardiac rhythm abnormally|patient at term, in spontanous labor with fetal cardiac rythm abnormally which occurs 30 minutes after the epidural analgesia induction
11452041|NCT01686347|Other|control group|patient at term, spontaneous labor, without any fetal cardiac rhythm abnormalies during the 30 minutes after the epidural analgesia induction
11452042|NCT01686334|Experimental|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment in combination with DC vaccination.
11452043|NCT01686334|No Intervention|Control arm|Follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment during the follow-up care
11452044|NCT01686321|Experimental|Bendamustine and subcutaneous Rituximab|single-arm non randomized
11452045|NCT01686308|Active Comparator|Conventional Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
11452046|NCT01686308|Experimental|Yellow Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
11452047|NCT01686295|Experimental|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
11452048|NCT01686295|Sham Comparator|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
11452049|NCT01686282|Placebo Comparator|Placebo|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
11452050|NCT01686282|Experimental|Blueberry|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
11452051|NCT01686256|Experimental|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
11452052|NCT01686243|Experimental|"echogenic 17G tuohy needles  Pajunk TuohySono"|Epidural will be placed with the aid of ultrasound and echogenic 17G Tuohy needles (Pajunk TuohySono).
11452053|NCT01686243|Placebo Comparator|standard epidural needles|Epidural will be placed in standard practice with standard needles.
11452054|NCT01686230|Experimental|acupoints on specific meridian|Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
11452055|NCT01686230|Active Comparator|acupoints on the other meridian|Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
11452056|NCT01686230|Sham Comparator|sham acupoints|Acupuncture plus foundation treatment。We use sham acupoints。
11452057|NCT01686230|Other|waiting-list|wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.
11452058|NCT01686217|Experimental|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
11452059|NCT01686217|Active Comparator|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
11452060|NCT01686217|Experimental|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
11452061|NCT01686217|Experimental|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
11452062|NCT01686217|Active Comparator|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
11452063|NCT01686217|Experimental|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
11452064|NCT01686217|Experimental|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
11452065|NCT01686217|Active Comparator|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
11452070|NCT01686178|Experimental|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
11452071|NCT01686178|No Intervention|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
11452072|NCT01686165|Experimental|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
11452073|NCT01686152|Experimental|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
11452074|NCT01686152|Active Comparator|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
11452075|NCT01686152|Placebo Comparator|Vehicle|Vehicle of Test Product (Teva)
11452076|NCT01686139|Experimental|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).
~Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
11452077|NCT01686126|Experimental|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
11452078|NCT01686126|Experimental|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
11452079|NCT01686126|Experimental|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
11452080|NCT01686113|Experimental|NEFA|Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days.
11452081|NCT01686113|Active Comparator|Control|Participants swish and spit 5 mL of sucrose solution everyday for 10 days.
11452082|NCT01686100|Active Comparator|No touch vein grafts|The grafts were harvested with there surrounding tissues.
11452083|NCT01686100|Active Comparator|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
11452084|NCT01686087|Active Comparator|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
11452085|NCT01686087|Placebo Comparator|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
11452086|NCT01686074||Chronic fatigue syndrome|
11452087|NCT01686074||fibromyalgia|
11452088|NCT01686074||chronic fatigue syndrome + fibromyalgia|
11452089|NCT01686074||healthy sedentary control|
11452090|NCT01686061||Blepharospasm Survey Group|
11452091|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
11452092|NCT01686009|Experimental|Intra-nasal ketamine|0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary
11452093|NCT01685996|Experimental|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
11452094|NCT01685996|Placebo Comparator|Placebo|Participants will receive placebo capsules to take once a day
11452095|NCT01685983|Experimental|Abiraterone actetate and Prednisolone|
11452096|NCT01685970|Placebo Comparator|High volume Split-dose PEG|Patients who are scheduled afternoon colonoscopy ingest high volume split-dose PEG for bowel preparation
11452097|NCT01685970|Active Comparator|2 sachets of picosulfate|Patients who are scheduled afternoon colonoscopy ingest 2 sachets of picosulfate at the day of colonoscopy.
11452098|NCT01685957|Active Comparator|Standard dietary treatment (STD)|Dietary treatment - 6 individual sessions with a registered dietitian
11452099|NCT01685957|Experimental|"Ned i vaegt (NIV)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
11452100|NCT01685957|Experimental|"Verdens bedste kur (VBK)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
11452101|NCT01685944|Placebo Comparator|Placebo|
11452102|NCT01685944|Experimental|Live Pediococcus pentosaceus LP28|
11452103|NCT01685944|Experimental|Heat-killed Pediococcus pentosaceus LP28|
11452104|NCT01685931|Experimental|Paliperidone Palmitate|
11452105|NCT01685892|Experimental|Dose-Finding: Schedule A: Relapsed/Refractory CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
11452106|NCT01685892|Experimental|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
11452107|NCT01685892|Experimental|Dose-Finding: Schedule A: Previously Untreated CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
11452182|NCT01685385|Active Comparator|Diagnostic intervention group A|Patients who will receive the BNP test
11452108|NCT01685892|Experimental|Dose-Finding: Schedule B: Previously Untreated CLL|In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
11452109|NCT01685892|Experimental|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
11452110|NCT01685892|Experimental|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
11452111|NCT01685879|Experimental|High Amylose Rice 1|Test rice with high dietary fiber content
11452112|NCT01685879|Experimental|High Amylose Rice 2|Test rice with high dietary fiber content
11452113|NCT01685879|Placebo Comparator|Control Rice|Rice portion that contains 50 g carbohydrate.
11452114|NCT01685879|Placebo Comparator|Glucose beverage|Glucose beverage with 50 g carbohydrate
11452115|NCT01685866|Other|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
11452116|NCT01685866|No Intervention|no medical device|in the second arm, we use no medical device
11452117|NCT01685853|Active Comparator|PEG 4 litres split|Polyethylene glycol with electrolytes (PEG)
11452118|NCT01685853|Experimental|Bisacodyl plus PEG-CS|Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)
11452119|NCT01685840|Experimental|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
11452120|NCT01685840|Experimental|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
11452121|NCT01685827|Active Comparator|NECT (Nifurtimox Eflornithine Combination Therapy)|"Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.
~Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
11452122|NCT01685827|Experimental|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:
~1 800 mg (3 tablets) once a day for 4 days,
~Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
11452123|NCT01685814|Active Comparator|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
11452124|NCT01685814|Experimental|tandem autologous transplant, lenalidomide maintenance|Arm B
11452125|NCT01685814|Active Comparator|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
11452126|NCT01685814|Experimental|tandem autologous transplant|Arm D
11452127|NCT01685801|Experimental|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
11452128|NCT01685801|Experimental|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
11452129|NCT01685801|Experimental|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
11452130|NCT01685801|Experimental|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
11452131|NCT01685788||study participants|
11452132|NCT01685775|Experimental|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
11452133|NCT01685775|Active Comparator|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
11452134|NCT01685762|Experimental|Metformin|Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
11452135|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
11452136|NCT01685723|Experimental|Counseling group|"Subjects in this group will receive a face-to-face individualized brief advice based on risk communication for 15-30 minutes from the nurse counselors and a booster intervention (10-15 minutes) at 1 week.
~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone.Ten subjects from the intervention group who have not quitted will be invited for a process evaluation in the form of face-to-face interviews by research assistants at 12-month follow-up."
11452183|NCT01685385|No Intervention|Group B|Patients who will not receive the BNP test.
11452137|NCT01685723|Sham Comparator|General supporting|"Subjects in this group will receive standard care without risk communication.
~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone."
11452138|NCT01685710|Experimental|GTN patch|GTN patch 5mg, in situ 24hrs
11452139|NCT01685710|Placebo Comparator|Placebo patch|Placebo patch, in situ for 24hrs
11452140|NCT01685697|Active Comparator|Laerdal Mask|Mask ventilation with a Laerdal face mask
11452141|NCT01685697|Experimental|F&P Mask|Mask ventilation with a F&P face mask
11452142|NCT01685684|Experimental|Oxycodone DETERx|
11452143|NCT01685684|Placebo Comparator|Placebo|
11452144|NCT01685671|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
11452145|NCT01685671|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
11452146|NCT01685658|Active Comparator|Ketaprofen|"Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.
~Intervention: intravenous ketaprofen"
11452147|NCT01685658|Experimental|Paracetamol|"Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.
~Intervention: intravenous paracetamol"
11452148|NCT01685645|Experimental|Study population|"The study population consists of male and female patients admitted for programmed major knee surgery (arthroplasty) with a truncal analgesic block (femoral nerve block with a sciatic block) and operated under general anesthesia.
~See inclusion and exclusion criteria.
~Intervention: AlgiScan"
11452149|NCT01685632|Active Comparator|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
11452150|NCT01685632|Sham Comparator|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
11452151|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
11452152|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
11452153|NCT01685606|Experimental|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
11452154|NCT01685593|Sham Comparator|regular bandage|no abdominal binder
11452155|NCT01685593|Experimental|abdominal binder|binder
11452156|NCT01685580|Experimental|Manufacturer VPAP ST|7 days minimum non-invasive ventilation at 2 levels of pressure (BPAP) to the intervention.
11452157|NCT01685580|No Intervention|No intervention|usual advice
11452158|NCT01685567|Experimental|MICHI NPS+f|The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.
11452159|NCT01685554|Active Comparator|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
11452160|NCT01685554|Active Comparator|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
11452161|NCT01685541|Experimental|Maximum AVS Content|AVS includes patient name, visit date, chief complaining, allergies, immunizations, vital signs, medications, problem list, lab order, physician contact information, referrals, instructions
11452162|NCT01685541|Experimental|Intermediate AVS content|AVS includes patient name, visit date, vital signs, medications, diagnosis, problem list, physician contact information, referrals, instructions
11452163|NCT01685541|Experimental|Minimum AVS content|AVS contains patient name, visit date, medications, diagnosis, physician contact information, referrals, instructions
11452164|NCT01685541|Active Comparator|Control Group (Usual AVS)|Content differed by clinic site
11452165|NCT01685528|Experimental|CBT|
11452166|NCT01685515|Experimental|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
11452167|NCT01685515|Placebo Comparator|Placebo|Placebo
11452168|NCT01685502||Group 1|Patients treated with Glucobay OD under practical manner
11452169|NCT01685489|Experimental|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
11452170|NCT01685489|Placebo Comparator|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
11452171|NCT01685476|Other|Intracranial pressure|
11452172|NCT01685463|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
11452173|NCT01685463|Placebo Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
11452174|NCT01685450|Other|Intracranial pressure|
11452175|NCT01685437|Experimental|AA4500|collagenase clostridium histolyticum
11452176|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
11452177|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
11452178|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
11452179|NCT01685411|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, Tacrolimus, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion.
11452180|NCT01685398|Placebo Comparator|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
11452181|NCT01685398|Experimental|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
11452184|NCT01685372|Experimental|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
11452186|NCT01685359|Experimental|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
11452187|NCT01685359|Active Comparator|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
11452188|NCT01685346|Experimental|Biofeedback|biofeedback-mediated stress management (BFSM)
11452189|NCT01685333|Other|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
11452190|NCT01685333|Other|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
11452191|NCT01685320|Active Comparator|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
11452192|NCT01685320|Active Comparator|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
11452193|NCT01685307|Experimental|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
11452194|NCT01685307|Experimental|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
11452195|NCT01685294|No Intervention|Treatment as Usual (TAU)|Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.
11452196|NCT01685294|Experimental|Group Interpersonal Psychotherapy (IPT) for Depression + TAU|Participants will receive Group IPT for Depression + TAU.
11452197|NCT01685281|Active Comparator|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
11452198|NCT01685281|Active Comparator|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
11452199|NCT01685281|Placebo Comparator|Placebo|Single dose of Placebo
11452200|NCT01685268|Experimental|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
11452201|NCT01685268|Experimental|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
11452202|NCT01685255|Active Comparator|Epacadostat|Subjects randomized to Arm A (epacadostat) will take epacadostat tablets at a dose of 600 mg BID, beginning on Day 1.
11452203|NCT01685255|Active Comparator|Tamoxifen|Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1.
11452204|NCT01685242|Experimental|AC-170 0.24%|
11452205|NCT01685242|Placebo Comparator|AC-170 0%|
11452206|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
11452207|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
11452208|NCT01685216|Experimental|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
11452209|NCT01685203|Experimental|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
11452210|NCT01685203|Experimental|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
11452211|NCT01685203|Experimental|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
11452212|NCT01685203|Experimental|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
11452213|NCT01685203|Experimental|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
11452214|NCT01685203|Experimental|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
11452215|NCT01685203|Experimental|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
11452216|NCT01685203|Experimental|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
11452217|NCT01685190|Active Comparator|Prostate Alone IMRT|Participants will receive standard prostate Intensity Modulated Radiotherapy (IMRT) of 74Gy in 37 fractions delivered over 7.5 weeks.
11452218|NCT01685190|Experimental|Prostate & Pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
11452219|NCT01685177||SADI|Patients submitted to a second-step operation after a failed sleeve on which a single-anastomosis duodena-ileal bypass at 250 cm from the cecum is performed.
11452220|NCT01685164||LNG-IUS|Nulliparous women
11452221|NCT01685164||Cu-IUD|Nulliparous women
11452222|NCT01685151|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
11452223|NCT01685151|Experimental|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
11452224|NCT01685151|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
11452225|NCT01685138|Experimental|LDK378 (Ceritinib)|Participants on this arm took oral LDK378 750 mg once daily.
11452226|NCT01685125|Active Comparator|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11452227|NCT01685125|Experimental|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11452228|NCT01685112||Conventional Group|Patients who developed refractory shock, but didn't received ECMO as salvage treatment
11452229|NCT01685112||ECMO group|Patient who have septic shock, and progreseed to have ECMO as salvage therapy
11452230|NCT01685099||Group with tuberculous pleurisy|
11452231|NCT01685099||Group with non-tuberculous pleurisy|
11452232|NCT01685086||Patients with severe chronic kidney disease|
11452233|NCT01685086||Patient with peritoneal dialysis|
11452234|NCT01685086||Patients with hemodialysis|
11452235|NCT01685073|Experimental|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
11452236|NCT01685073|Placebo Comparator|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
11452237|NCT01685060|Experimental|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
11452238|NCT01685034|Experimental|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
11452239|NCT01685021|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody
11452240|NCT01685008|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
11452241|NCT01684995|Active Comparator|Minimal|Brief physician advice to quit smoking plus nicotine patch
11452242|NCT01684995|Experimental|Tailored|
11452243|NCT01684982|Experimental|everolimus eluting stent|second generation drug eluting stent
11452244|NCT01684982|Active Comparator|sirolimus eluting stent|first generation drug eluting stent
11452245|NCT01684969|Active Comparator|intravenous haloperidol|intravenous haloperidol pharmacokinetics
11452246|NCT01684969|Placebo Comparator|Placebo|
11452247|NCT01684956|Experimental|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
11452248|NCT01684956|Experimental|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
11452249|NCT01684943|Experimental|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin. All subjects participated in the single study arm and received injections of each type of insulin. Blood samples were drawn at intervals for pharmacokinetic profiling.
11452250|NCT01684943|Experimental|Continuous insulin monitoring|Continuous insulin monitoring (CIM) of insulin lispro. Some subjects participated in the CIM sub-study, which is distinct from the Multiplex Pharmacokinetic Profiling study. This intervention involved administering insulin lispro and monitoring pharmacokinetic profile of the drug using blood samples and an investigational continuous insulin monitoring system.
11452251|NCT01684930|Experimental|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
11452252|NCT01684930|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
11452253|NCT01684917|Experimental|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
11452254|NCT01684917|Active Comparator|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
11452255|NCT01684917|Other|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
11452256|NCT01684904|Experimental|Proton radiation|Proton radiation
11452257|NCT01684891|Experimental|RG1662|
11452258|NCT01684878|Experimental|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
11452259|NCT01684878|Experimental|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
11452260|NCT01684878|Experimental|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
11452261|NCT01684878|Placebo Comparator|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
11452262|NCT01684865||Non-Hodgkin's Lymphoma Participants|Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will receive rituximab for maximum two years or until disease progression. Participants will be followed for one year after last dose of rituximab administered as maintenance.
11452263|NCT01684839|Other|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
11452264|NCT01684826|Experimental|ClarityIQ|Angiographic run with new algorithm and low dose (50% dose)
11452265|NCT01684826|Experimental|AlluraXper|Angiographic run with predecessor algorithm and dose (100% dose)
11452266|NCT01684813|Active Comparator|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
11452267|NCT01684813|Experimental|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
11452268|NCT01684800|Active Comparator|A. Desmopressin 10 microgram|
11452269|NCT01684800|Active Comparator|B. Desmopressin 25 microgram|
11452270|NCT01684800|Placebo Comparator|C. Placebo|
11452271|NCT01684787|Experimental|1|Peginterferon alfa-2a + ribavirin in normal ALT
11452272|NCT01684787|Active Comparator|2|peginterferon alfa-2a + ribavirin in elevated ALT
11452273|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
11452274|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
11452275|NCT01684761|Experimental|Tcelna|30-45 x 10E6 total cells in 2 ml. Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).
11452276|NCT01684761|Placebo Comparator|Placebo|Tcelna inactive ingredients (without cells) totaling 2 ml per dose. Administered subcutaneously with same two year treatment regimen as experimental treatment arm.
11452277|NCT01684748|Experimental|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
11452278|NCT01684748|Experimental|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
11452279|NCT01684735||women with breast cancer and chemotherapy|women recently diagnosed with breast cancer and selected to start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy
11452280|NCT01684722|Active Comparator|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
11452281|NCT01684722|Active Comparator|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
11452282|NCT01684722|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
11452283|NCT01684722|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
11452284|NCT01684709|Experimental|Telemonitoring + self-management support|Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.
11452285|NCT01684709|No Intervention|Usual Care|Usual Care
11452286|NCT01684696|Experimental|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
11452287|NCT01684696|Active Comparator|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
11452288|NCT01684683|Experimental|Theophylline|Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
11452289|NCT01684683|Placebo Comparator|placebo|Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
11452290|NCT01684670|Experimental|Behavioral speech treatment|
11452291|NCT01684657|Placebo Comparator|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
11452292|NCT01684657|Experimental|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
11452293|NCT01684644|Experimental|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
11452294|NCT01684644|Other|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
11452295|NCT01684631||Hip arthroplasty|Patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease or true femoral cervical fracture.
11452296|NCT01684618|Experimental|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
11452297|NCT01684605|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
11452298|NCT01684605|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
11452299|NCT01684592|Active Comparator|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
11452300|NCT01684592|Experimental|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
11452301|NCT01684579|Experimental|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
11457031|NCT01652482|Experimental|FOLFIRI + MEHD7945A|
11452302|NCT01684566|Experimental|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
11452303|NCT01684566|Other|Standard-Of-Care|Oral hygiene procedures
11452304|NCT01684553|Experimental|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
11452305|NCT01684553|Active Comparator|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
11452306|NCT01684527||Children Suffering From Bronchiolitis|Respiratory secretions obtained from children suffering from Bronchiolitis
11452307|NCT01684527||Healthy Children|Respiratory secretions obtained from children with no respiratory infection
11452308|NCT01684514|Experimental|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
11452309|NCT01684514|Sham Comparator|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
11452310|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
11452311|NCT01684488|Active Comparator|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
11452312|NCT01684488|No Intervention|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
11452313|NCT01684488|Experimental|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
11452314|NCT01684488|Experimental|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
11452315|NCT01684475|Experimental|Treatment with CJH1|
11452316|NCT01684462|Experimental|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4~8h
11452317|NCT01684462|Placebo Comparator|0.9 % Normal saline|Treatment with same volume of normal saline
11452318|NCT01684449|Experimental|Phase 2: Experimental Arm|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
11452319|NCT01684436|Experimental|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
11452320|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - <18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram [mg] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
11452321|NCT01684423|Active Comparator|Comparator, Age: 12 - <18 years|Subjects aged from 12 - <18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
11452322|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
11452323|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
11452324|NCT01684423|Active Comparator|Comparator, Age: 6 - <12 years|Subjects aged from 6 - <12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
11452325|NCT01684410|Experimental|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
11452326|NCT01684410|Experimental|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
11452327|NCT01684410|Placebo Comparator|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
11452328|NCT01684397|Experimental|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
11452329|NCT01684384|Experimental|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
11452330|NCT01684371||Blue Dotted Elmore Oil|Patients applied the above oil 3 times daily for four weeks and on the fifth week stopped the application completely for the flush out period before switching to Orange Dotted Elmore Oil
11452331|NCT01684371||Orange Dotted Elmore Oil|Patients give this oil applied it three times daily on the affected knees for four weeks and on the fifth week, stopped the application totally for the flush out period before switching to the Blue Dotted Elmore Oil.
11452332|NCT01684358|Experimental|Immediate implant|Sino-implant (II) inserted at enrollment visit
11452333|NCT01684358|Active Comparator|Delayed implant|Sino-implant (II) inserted at 3-month follow-up visit
11452334|NCT01684345|Placebo Comparator|Placebo|
11452335|NCT01684345|Experimental|Dose 1 gevokizumab|
11452336|NCT01684345|Experimental|Dose 2 gevokizumab|
11452337|NCT01684332|Experimental|High Sugar (HS)|Study of the postprandial effects after consuming 60g of strawberry jam with high sugar content
11458673|NCT01640483|Active Comparator|supportive|
11452338|NCT01684332|Experimental|Low Sugar (LS)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content
11452339|NCT01684332|Experimental|Low Sugar + Antioxidant (LSA)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content and an antioxidant extract from strawberry pulp
11452340|NCT01684319|Placebo Comparator|Infant formula milk|Infant formula milk adapted to age of infant
11452341|NCT01684319|Active Comparator|Formula milk free of milk proteins|Milk-free formula milk adapted to age of infant
11452342|NCT01684306|Experimental|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
11452343|NCT01684306|Experimental|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).
~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
11452344|NCT01684293|Experimental|Cognitive Rehabilitation|Occupational therapy-based cognitive rehabilitation
11452345|NCT01684293|Placebo Comparator|Psychoeducation/games|Psychoeducation/games
11452346|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
11452347|NCT01684267|Experimental|Healthy|Healthy individuals
11452348|NCT01684267|Experimental|Post-stroke|Chronic stroke survivors
11452349|NCT01684254||Children with Cerebral Palsy (CP)|
11452350|NCT01684241|Experimental|RBL001/RBL002 intranodal administration|"All participants will be treated with RBL001/RBL002 after allocation to one of the four escalating dose cohorts:
~Cohort-1 50 µg RBL001 and 50 µg RBL002
~Cohort-2 100 µg RBL001 and 100 µg RBL002
~Cohort-3 300 µg RBL001 and 300 µg RBL002
~Cohort-4 600 µg RBL001 and 600 µg RBL002"
11452351|NCT01684215|Experimental|Single-agent PD-0332991|Phase 1 Part 1
11452352|NCT01684215|Experimental|PD-0332991 in combination with letrozole|Phase 1 Part 2
11452353|NCT01684215|Experimental|PD-0332991 with letrozole|Phase 2
11452354|NCT01684202|Experimental|OPC-41061|
11452355|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
11452356|NCT01684176|Experimental|Complex tailored intervention|"The intervention consists of 3 elements:
~Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.
~Discharge consultation with an pharmacist using motivational interviewing techniques.
~Follow-up telephone calls one week, two months and six months after discharge."
11452357|NCT01684176|Placebo Comparator|Usual care|Usual care
11452358|NCT01684163|Placebo Comparator|Placebo injection|Normal saline
11452359|NCT01684163|Experimental|GLYX-13, 5 mg/kg|Low dose of GLYX-13
11452360|NCT01684163|Experimental|GLYX-13, 10 mg/kg|High dose of GLYX-13
11452361|NCT01684150|Experimental|EPZ-5676 Extension cohort|
11452362|NCT01684137|Active Comparator|Joalis Bambi Bronchi & Joalis Bambi Analerg|10 days, 2 times per day 2,5/5 ml
11452363|NCT01684137|Placebo Comparator|Placebo & Placebo|10 days, 2 times per day 2,5/5 ml
11452364|NCT01684124|Placebo Comparator|standard care|normal treatment
11452365|NCT01684124|Active Comparator|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
11452366|NCT01684111|Experimental|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.
~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
11452367|NCT01684098|Other|Tc 99m EC20|
11452368|NCT01684085|Placebo Comparator|Encouragement to sleep|Encouraging explanation to sleep, rest and receiving Lorazepam 1mg in the first night post trauma
11452369|NCT01684085|Experimental|Encouragement to deprived sleep|Encouraging explanation to deprived sleep in the first night post trauma
11452370|NCT01684072|Experimental|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11452371|NCT01684072|Active Comparator|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
11452372|NCT01684059||Single group|Single group: each participant receive same intervention (zinc sulfate) throughout study (non-randomized)
11452373|NCT01684046|Other|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
11452374|NCT01684046|Other|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
11452375|NCT01684033|Other|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
11452376|NCT01684033|Other|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
11452377|NCT01684020|Experimental|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
11452378|NCT01684020|No Intervention|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
11452379|NCT01684007|Experimental|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
11452380|NCT01684007|Active Comparator|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
11452381|NCT01683994|Experimental|combination of cabozantinib, docetaxel and prednisone|combination of cabozantinib, docetaxel and prednisone
11452382|NCT01683994|Active Comparator|PII/ Arm 1-docetaxel + prednisone only|docetaxel + prednisone only
11452383|NCT01683994|Active Comparator|PII/Arm 2 -docetaxel+ prednisone + cabozantinib|docetaxel+ prednisone + cabozantinib
11452384|NCT01683981|Experimental|L-Citrulline, Exercise Capacity|L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks
11452385|NCT01683968||Sickle cell|Patient who are admitted with sickle cell crises
11452386|NCT01683955|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
11452387|NCT01683955|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
11452388|NCT01683929|Active Comparator|Oral glucose tolerance test|The participants will consume a beverage containing 75 gram glucose During the meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes. Also, they will record their macronutrient\caloric consumption during the 24 hour following the test.
11452389|NCT01683929|Placebo Comparator|Artificial sweetner|"participants will consume a beverage containing 0.42 gram artificial sweetener (Aspartame) During each meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes.
~Also, they will record their macronutrient\caloric consumption during the 24 hour following the test."
11452390|NCT01683903||Non coronary patients (NC)|Patient with myocardial infarction with non-coronary (NC) etiology
11452391|NCT01683903||Coronary patients (C)|Patients with myocardial infarction due to coronary disease
11452392|NCT01683890||Simple hysterectomy group|Patients will undergo simple hysterectomy due to benign uterine disease.
11452393|NCT01683877|Experimental|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
11452394|NCT01683877|Active Comparator|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
11452395|NCT01683864|Experimental|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
11452396|NCT01683864|No Intervention|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
11452397|NCT01683864|No Intervention|negative cytology without HIPEC|gastric cancer with negative cytology
11452398|NCT01683838|Active Comparator|fampridine-SR 50mg/day|
11452399|NCT01683838|Placebo Comparator|Placebo|
11452400|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
11452401|NCT01683825|Other|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
11452402|NCT01683812|Experimental|Cranial Cup Arm|Single arm
11452403|NCT01683799|Experimental|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
11452404|NCT01683799|No Intervention|Control|
11452405|NCT01683786|Experimental|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
11452406|NCT01683786|Active Comparator|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
11452407|NCT01683773|Experimental|Group A|Two doses of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
11452408|NCT01683773|Experimental|Group B|One dose of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
11452409|NCT01683773|Experimental|Group C|Three doses of AERAS-402 (1x10^11 vp intramuscular injection)
11452410|NCT01683760|Experimental|Population PK|
11452411|NCT01683747|Experimental|Tranexamic acid|Study group receives enteral tranexamic acid in normal saline in addition to usual care.
11452412|NCT01683747|Placebo Comparator|Control group|Control group receives vehicle (normal saline) without study drug and usual care.
11452413|NCT01683734||Renal Function Observation|
11452414|NCT01683721||Winx|
11452415|NCT01683708||Symbiotic group|Jaundiced patients who have symbiotic therapy
11452416|NCT01683708||No Symbiotic therapy|Jaundiced patients who not have symbiotic therapy
11452417|NCT01683695|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
11452418|NCT01683695|Placebo Comparator|AMG 557 Matching Placebo|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
11452419|NCT01683682|Experimental|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.
~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
11452420|NCT01683669|Other|Noisy-PSV 1|different levels of variable pressure support
11452421|NCT01683669|Other|Noisy-PSV 2|different levels of variable pressure support
11452422|NCT01683656|Active Comparator|ER Niacin/laropipant|ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
11452423|NCT01683656|Placebo Comparator|ER Niacin/laropipant Placebo|ER niacin/laropiprant placebo p.m.
11452424|NCT01683643|Experimental|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
11452425|NCT01683643|Active Comparator|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
11452426|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
11452531|NCT01682876|Placebo Comparator|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
11458674|NCT01640483|Active Comparator|interpretative|
11452427|NCT01683617|Experimental|A treatment based on CBT and new technologies|Individuals will receive a treatment based on cognitive behavioral therapy and new technologies (virtual reality, virtual reality combined to biofeedback and mobile phones). Relaxation will be induced through the immersion in different virtual environments (e.g., lake) which will be customized with different pre-recorded audio narratives that describe the specific setting and that guide the execution of a series of relaxation exercises. During biofeedback exercises a wearable biosensor system will provide suggestions to the trainer based on the reactions of the participants, and the biosensor data will directly modify the virtual reality experience in real time.
11452428|NCT01683617|Active Comparator|Traditional treatment based on CBT|Participants will receive a treatment based on traditional cognitive behavioral therapy techniques for stress management, without the use of new technologies. Relaxation will be induced by guided imagery, through auditory narratives.
11452429|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
11452430|NCT01683591||High-risk aspiration group|Among the consecutive stroke patients, categorized to high-risk group in the patient (1) was not on alert mentality (from drowsy to comatose mentality), (2) was not able to sit upright or control his/her head, and (3) failed to pass indirect water swallow test.
11452431|NCT01683591||Low-risk aspiration group|Patents without oropharyngeal neurologic signs
11452432|NCT01683591||Intermediate-risk aspiration group|If any one of following was positive, categorized to intermediate-risk group; (1) dysarthria, (2) motor aphasia, (3) inability to close and open lips or (4) facial weakness, (5) tongue deviation or (6) uvula deviation, (7) loss of gag reflex, and (8) inability to cough voluntarily.
11452433|NCT01683578|Active Comparator|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
11452434|NCT01683578|No Intervention|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
11452435|NCT01683565|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
11452436|NCT01683565|Placebo Comparator|Canola Oil Placebo|
11452437|NCT01683552|Other|Aprepitant|Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
11452438|NCT01683552|Other|Aprepitant after anti-itch standard therapy|Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week
11452439|NCT01683539|Experimental|The Thinking Skills for Work Program|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
11452440|NCT01683539|Active Comparator|The Cognitive Skills for Work Program|The Cognitive Skills for Work Program includes 4 components delivered by a Cognitive Specialist who works with the consumer's Employment Specialist: a) assessing the consumer's cognitive strengths and weaknesses their relation to job history b) teaching coping strategies for cognitive challenges associated with job search or maintenance c)job search planning, in which the consumer and the Cognitive and Employment Specialists help identify job leads based on the consumer's interests, and identify cognitive coping strategies and supports the consumer may need to succeed at the workplace; and d) job support consultation, in which the Cognitive and Employment Specialists consult with the consumer on additional cognitive coping strategies to enable the consumer to meet the demands of the job.
11452441|NCT01683526|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
11452442|NCT01683526|Active Comparator|Video laryngoscopy|Intubation will be done using video laryngoscopy
11452443|NCT01683513|No Intervention|humaan chorion gonadotropine|ovulation induction with 5000E hCG
11452444|NCT01683513|Active Comparator|GnRH agonist + 1500E hCG|ovulation induction with GnRH agonist and 1500E hCG one hour after egg retrieval
11452445|NCT01683500|Experimental|shock wave therapy|intervention: shock wave therapy with Modulith SLK (Storz)
11452446|NCT01683474|Experimental|Venus A-Valve|single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis
11452447|NCT01683461|Experimental|Enhanced Counseling|Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
11452448|NCT01683461|Active Comparator|Standard of Care|Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
11452449|NCT01683435|Experimental|hylauronin binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
11452450|NCT01683422|Experimental|Proton Radiation|
11452451|NCT01683409|Placebo Comparator|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
11452452|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
11452453|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
11452454|NCT01683409|Experimental|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
11452455|NCT01683409|Experimental|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
11452456|NCT01683396|Placebo Comparator|Placebo|
11452457|NCT01683396|Experimental|gevokizumab|
11452458|NCT01683383|Active Comparator|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
11452459|NCT01683383|Experimental|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
11452460|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
11452461|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (> or = to 4), bilobar CLM
11452462|NCT01683331|Active Comparator|Insulin treatment for hyperglycemia|Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG > 240, NPH initiation: 14, dose increases by 4; For pts. with CPG > 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG > 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG > 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG <60 mg/dl, NPH initiation: 0, ½ of previous dose.
11452463|NCT01683331|No Intervention|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
11452464|NCT01683318|Experimental|Treatment|Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
11452465|NCT01683305||Subjects who have no mammographically detectable tumors|This group will be evaluated for marker presence in NAF. no drugs administered
11452466|NCT01683305||Subjects who have non-cancerous growths|This group will be evaluated to study whether marker(s) detected in NAF are also expressed in non-cancerous tumors. No drugs administered
11452467|NCT01683305||subjects who have cancerous growths|In this group, any markers detected in NAF could also be detected in tumor tissues. No drugs administered.
11452468|NCT01683292|Experimental|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
11452469|NCT01683292|Placebo Comparator|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
11452470|NCT01683279|Experimental|CAR+ T cells|Subjects will receive two days of cyclophosphamide for a total of 3g/m^2 followed several days later by a single dose of Autologous CD19 CAR+ EGFTt + T cells
11452471|NCT01683266|Experimental|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
11452472|NCT01683266|Active Comparator|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
11452473|NCT01683253|Experimental|Levodopa/Carbidopa(200mg/50mg)|
11452474|NCT01683253|Experimental|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
11452475|NCT01683253|No Intervention|Control B (no drug)|Parkinson diseased patients not treated.
11452476|NCT01683240|Experimental|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
11452477|NCT01683227|Experimental|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
11452478|NCT01683227|Placebo Comparator|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
11452479|NCT01683201|Experimental|Functional exercise class|Functional exercise class 45 mins twice weekly from week 12 to week 18
11452480|NCT01683201|Placebo Comparator|Usual Care Group|Usual Care
11452481|NCT01683188|Other|Cohort 1|Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
11452482|NCT01683188|Other|Cohort 2|Patients who have receive >7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
11452483|NCT01683175|Experimental|Arm 1|Erlotinib 150mg daily oral up to 2 years
11452484|NCT01683175|Active Comparator|Arm 2|NP Chemotherapy for 4 cycles
11452485|NCT01683162|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
11452486|NCT01683162|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin
11452487|NCT01683162|Experimental|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
11452532|NCT01682876|Active Comparator|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
11452533|NCT01682876|Placebo Comparator|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
11452534|NCT01682876|Active Comparator|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
11452535|NCT01682863|Experimental|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
11452488|NCT01683149|Experimental|Combination Chemotherapy|"Combination Chemotherapy: Topotecan and Sorafenib. Participants will receive the treatment in cycles. Every cycle is 28 days long. For the first cycle participants will get the chemotherapy drugs:
~Topotecan PO (by mouth) once daily on days 1-5 and days 8-12
~Sorafenib PO (by mouth) twice daily (BID), continuously on days 2-28 of cycle one and days 1-28 on each additional cycle.
~Level -1: Topotecan 1.0 mg/m^2: Sorafenib 100 mg/m^2 BID
~Level -2: Topotecan 0.8 mg/m^2: Sorafenib 100 mg/m^2 BID
~Level 1: Topotecan 1.0 mg/m^2: Sorafenib 150 mg/m^2 BID
~Level 2: Topotecan 1.4 mg/m^2: Sorafenib 150 mg/m^2 BID
~Level 3: Topotecan 1.4 mg/m^2: Sorafenib 200 mg/m^2 BID
~Level 4: Topotecan 1.8 mg/m^2: Sorafenib 200 mg/m^2 BID"
11452489|NCT01683136|Experimental|Deep TMS treatment|
11452490|NCT01683136|Sham Comparator|inactive stimulation|
11452491|NCT01683097|No Intervention|Control|Questionnaire
11452492|NCT01683097|Experimental|Intervention|Standardized explanation followed by questionnaire
11452493|NCT01683084|Active Comparator|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
11452494|NCT01683084|Placebo Comparator|Placebo|One 40mg placebo pill given once daily for 24 months
11452495|NCT01683071|Active Comparator|Group 1|EXPAREL 67 mg
11452496|NCT01683071|Active Comparator|Group 2|EXPAREL 133 mg
11452497|NCT01683071|Active Comparator|Group 3|EXPAREL 266 mg
11452498|NCT01683071|Placebo Comparator|Group 4|Placebo (preservative-free normal saline)
11452499|NCT01683058|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
11452500|NCT01683045|Experimental|The Estech COBRA® Surgical System|
11452501|NCT01683032|Experimental|Experimental: Healthy adults|Participants, aged 21-40 years, will be recruited through an advertisement posted at the University of Haifa (including the website of Haifa University).
11452502|NCT01683019|Active Comparator|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
11452503|NCT01683019|Active Comparator|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
11452504|NCT01683019|Sham Comparator|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
11452505|NCT01683006|Active Comparator|Neuromuscular blocker group|"Continuous application of neuromuscular blockers during therapeutic hypothermia.
~Bolus application of placebo in case of shivering."
11452506|NCT01683006|Placebo Comparator|Placebo group|"Continuous application of placebo during therapeutic hypothermia.
~Bolus application of neuromuscular blockers in case of shivering."
11452507|NCT01682993|Active Comparator|Corneal Cross Linking|Patients will receive a standard corneal cross linking treatment
11452508|NCT01682993|Experimental|Corneal Cross Linking and Topo Laser|Patients will receive a topography guided laser treatment in combination with a standard corneal cross linking treatment in the same session.
11452509|NCT01682980|Experimental|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
11452510|NCT01682980|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
11452511|NCT01682980|No Intervention|Control group|The control group will do as usual.
11452512|NCT01682967||Experimental group|Patients suffering from PDPH would form this group
11452513|NCT01682967||Control group - Epidural|Patients who received an epidural during labour but did not have symptoms of PDPH would form this reference group
11452514|NCT01682967||Control Group without Epidural analgesia|Patients in labour who did not receive an EDA would form this cohort of controls
11452515|NCT01682954|Experimental|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
11452516|NCT01682954|No Intervention|Usual Care|Usual care from primary care physician
11452517|NCT01682941|Active Comparator|Soy Bread Intervention|Arm I Soy Bread
11452518|NCT01682941|Experimental|Soy -Almond Bread Intervention|Arm II Soy-Almond Bread
11452519|NCT01682928|Active Comparator|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)
~Pulse Pressure
~Pulse
~Urine Specific Gravity BID
~Fetal Heart Rate
~Maternal Body Weight US Procedures
~AC/EFW
~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
~AFI (Baseline, day 3, 7 {or Discharge})
~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
~1 Liter Water PO over 2 hours
~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation
~Strict I/O's
~Vital signs"
11452520|NCT01682928|Active Comparator|Hydrotherapy Group|"Maternal BP (sitting)
~Pulse Pressure
~Pulse
~Urine Specific Gravity BID
~Fetal Heart Rate
~Maternal Body Weight US Procedures
~AC/EFW
~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
~o 1 hour +/- 30 minutes after submersion therapy
~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
~o 1 hour +/- 30 minutes after submersion therapy
~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy
~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
~1 Liter Water PO over 2 hours
~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation
~Strict I/O's
~Vital signs
~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
11452521|NCT01682915||Group 1: ADHD+DAT1, Probands|30 ADHD probands with DAT1 variants
11452522|NCT01682915||Group 2: ADHD+DAT1, Unaffected sibling|30 same-sex unaffected siblings of Group 1
11452523|NCT01682915||Group 3: ADHD Drug-naïve, Probands|30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1
11452524|NCT01682915||Group 4: ADHD Drug-naïve, unaffected sibling|30 same-sex unaffected siblings of Group 3
11452525|NCT01682915||Matched controls|30 age-, sex- and IQ-matched TD controls for each of 4 groups
11452526|NCT01682902|Experimental|Formulation 1|
11452527|NCT01682902|Experimental|Formulation 2|
11452528|NCT01682902|Active Comparator|Insulin aspart (NovoLog®)|
11452529|NCT01682889|Placebo Comparator|Placebo|NaCl 0.9% intravenously for 24 hours after induction of anaesthesia
11452530|NCT01682889|Active Comparator|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia
11452538|NCT01682850|Active Comparator|Intervention|The Intervention Arm will receive 10 sessions of Mindfulness Based Pulmonary Rehabilitation prior to lung surgery
11452539|NCT01682850|Placebo Comparator|Usual Care|The Usual Care Arm will receive the normal care that a patient with severe COPD having a lung surgery would receive.
11452540|NCT01682837|Experimental|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452541|NCT01682837|Experimental|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452542|NCT01682837|Experimental|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452543|NCT01682837|Experimental|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452544|NCT01682837|Experimental|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452545|NCT01682837|Experimental|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452546|NCT01682837|Experimental|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452547|NCT01682837|Experimental|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452548|NCT01682837|Experimental|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452549|NCT01682837|Experimental|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452550|NCT01682837|Experimental|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452551|NCT01682837|Experimental|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452552|NCT01682837|Experimental|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452553|NCT01682837|Experimental|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452554|NCT01682837|Experimental|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452555|NCT01682837|Experimental|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452556|NCT01682837|Experimental|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452557|NCT01682837|Experimental|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452558|NCT01682837|Experimental|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452559|NCT01682837|Experimental|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452596|NCT01682577|Experimental|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.
~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
11452560|NCT01682837|Experimental|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452561|NCT01682837|Experimental|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452562|NCT01682837|Experimental|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452563|NCT01682837|Experimental|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
11452564|NCT01682824||Group I (questionnaire, nutritional assessment)|Patients complete the TFEQ-R18v2 questionnaire, a dietary intake assessment, and the EQ-EMA questionnaire online.
11452565|NCT01682824||Group II (questionnaire, nutritional assessment)|Patients complete the EQ-EMA questionnaire, a dietary intake assessment and the TFEQ-R18v2 questionnaire.
11452566|NCT01682811|Experimental|Part 1|Levulan (5-aminolevulinic acid) uptake.
11452567|NCT01682811|Experimental|Part 2|Levulan (5-aminolevulinic acid) photodynamic therapy.
11452568|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 1) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
11452569|NCT01682798|Placebo Comparator|Placebo yoghurt|100g of placebo yoghurt (normal yoghurt) will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
11452570|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 2) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
11452571|NCT01682772|Experimental|Olaparib 400mg|Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle
11452572|NCT01682772|Experimental|Olaparib 300mg|Oral Olaparib at a dose of 300mg twice daily, continuously on a 28 day cycle
11452573|NCT01682759|Experimental|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
11452574|NCT01682759|Active Comparator|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
11452575|NCT01682746|Experimental|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
11452576|NCT01682733|Experimental|Botulinum toxin at injection site|All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
11452577|NCT01682720|Placebo Comparator|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
11452578|NCT01682720|Experimental|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
11452579|NCT01682720|Experimental|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
11452580|NCT01682707|Active Comparator|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
11452581|NCT01682707|Active Comparator|Track Light|
11452582|NCT01682694|Experimental|Glucosamine and Chondroitin|Glucosamine and Chondroitin
11452583|NCT01682694|Placebo Comparator|Placebo|Inactive ingredients
11452584|NCT01682681||Topiramate|
11452585|NCT01682668|Experimental|Frequency of subthalamic stimulation|Comparison between healthy controls and PD patients
11452586|NCT01682642|Active Comparator|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
11452587|NCT01682642|No Intervention|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
11452588|NCT01682629|No Intervention|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
11452589|NCT01682629|Experimental|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
11452590|NCT01682629|Experimental|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
11452591|NCT01682629|Experimental|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
11452592|NCT01682616|Experimental|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
11452593|NCT01682603|Experimental|Botulinum toxin A|BoNT-A (BOTOX 300U)
11452594|NCT01682590|Experimental|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
11452595|NCT01682590|Active Comparator|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
11452597|NCT01682577|Active Comparator|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.
~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
11452598|NCT01682564|Experimental|Candemore tablet|"Candemore tablet
~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
11452599|NCT01682564|Active Comparator|Atacand tablet|"Atacand tablet
~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
11452600|NCT01682551|Experimental|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
11452601|NCT01682551|Placebo Comparator|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
11452602|NCT01682538|Active Comparator|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
11452603|NCT01682538|Experimental|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
11452604|NCT01682538|Experimental|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
11452605|NCT01682525|Experimental|Ovarian tissue cryopreservation|The ovarian tissue is cryopreserved and stored at Boston IVF, which is an FDA compliant and American Association of Tissue Banks accredited long term storage facility for reproductive tissue.
11452606|NCT01682512|Experimental|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
11452607|NCT01682512|Active Comparator|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
11452608|NCT01682512|Active Comparator|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
11452609|NCT01682512|Experimental|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
11452610|NCT01682512|Active Comparator|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
11452611|NCT01682499|Experimental|Calcium and Magnesium Infusion|
11452612|NCT01682486|Experimental|BIP ETT, Bactigaurd coated endotracheal tube|
11452613|NCT01682486|Placebo Comparator|Standard ETT, un-coated endotracheal tube|
11452614|NCT01682473|Experimental|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
11452615|NCT01682473|Experimental|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
11452616|NCT01682460|Experimental|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
11452617|NCT01682447|Experimental|Extensive Pulmonary Rehabilitation (ERP)|Participants in this group are measured on primary and secondary outcome measures before and after a 12 week extensive pulmonary rehabilitation program.
11452618|NCT01682447|No Intervention|Waiting List Control group|Participants in the waiting list control group are measured on primary and secondary outcome measures before and after waiting time for the extensive pulmonary rehabilitation program and start with this program after the second moment of measurement.
11452619|NCT01682434|Active Comparator|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
11452620|NCT01682434|Active Comparator|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
11452621|NCT01682421|Experimental|Weak steroid|Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
11452622|NCT01682421|Experimental|Potent steroid|Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
11452623|NCT01682408|Active Comparator|Part A1|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
11452624|NCT01682408|Active Comparator|Part A2|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine
11452625|NCT01682408|Active Comparator|Part B1|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
11452626|NCT01682408|Active Comparator|Part B2|1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
11452627|NCT01682408|Active Comparator|Part B3|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
11452628|NCT01682395|Active Comparator|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
11452629|NCT01682395|Experimental|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
11452630|NCT01682395|Active Comparator|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
11452631|NCT01682395|Experimental|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
11452632|NCT01682382||choroidal neovascular (CNV) AMD subjects|Subjects diagnosed with CNV (AREDS Grade 4b)
11452633|NCT01682382||dry AMD subjects|Subjects diagnosed with dry AMD (AREDS Grade 3)
11452634|NCT01682382||age-matched controls|Subjects without AMD (AREDS Grade 1)
11452635|NCT01682369|Other|Group 1 a - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)
~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)
~V3-(Day V2+1)- Collect blood sample (up to 6.0 ml)
~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
11452636|NCT01682369|Other|Group 1 b - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)
~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)
~V3-(Day V2+3)- Collect blood sample (up to 6.0 ml)
~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
11452637|NCT01682369|Other|Group 1 c - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Aggripal) + Collect blood sample (up to 6.0 ml)
~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Aggripal)
~V3-(Day V2+7)- Collect blood sample (up to 6.0 ml)
~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
11452638|NCT01682369|Other|Group 2 a - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)
~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)
~V3- V3(Day V2+1)- Collect blood sample (up to 6.0 ml)
~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
11452639|NCT01682369|Other|Group 2 b - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)
~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)
~V3- V3(Day V2+3)- Collect blood sample (up to 6.0 ml)
~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
11452640|NCT01682369|Other|Group 2 c - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)
~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)
~V3- V3(Day V2+7)- Collect blood sample (up to 6.0 ml)
~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
11452641|NCT01682356|Placebo Comparator|BRJ crossover to placebo|Beetroot Juice without nitrate.s Patients will be studied before and after ingestion of beetroot juice
11452642|NCT01682356|Active Comparator|Beetroot Juice|Beetroot Juice with nitrates. Patients will be studied before and after ingestion of beetroot juice with nitrates
11452643|NCT01682343|Placebo Comparator|Placebo|Breakfast consisting of milk-based porridge with a normal calcium content.
11452644|NCT01682343|Experimental|High-Calcium|As control, but with a high-calcium content.
11452645|NCT01682330||Fitness|
11452646|NCT01682330||Whole-body vibration|
11452647|NCT01682330||Control|
11452648|NCT01682317|Experimental|Three Meal|Participants in this condition will be instructed to limit their number of eating frequency to three meals per day.
11452649|NCT01682317|Experimental|Grazing|Participants in the increased eating frequency condition will be instructed to eat > 100 kcals every 2-3 hours.
11452650|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
11452651|NCT01682291|Active Comparator|Life-style modifications|"Lifestyle modifications will include:
~Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)"
11452652|NCT01682291|Active Comparator|Dietary supplements|Life-style modifications along with a novel combination of dietary supplements that includes: Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
11452653|NCT01682278||Amalgam cohort|Patients with medically unexplained physical symptoms attributed to dental amalgam restorations which the patient wish to have removed.
11452654|NCT01682278||MUPS-cohort|Patients with medically unexplained physical symptoms without attribution to amalgam and no explicit wish to remove amalgam.
11452655|NCT01682278||Dental cohort|Healthy comparison group: Subjectively healthy without diagnosed chronic disease or prescribed medication.
11452656|NCT01682265|Experimental|Stretta procedure|"Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.
~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
11452657|NCT01682265|Sham Comparator|Sham procedure|"Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.
~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
11452658|NCT01682252||musculoskeletal tumors|all patients undergoing surgery for musculoskeletal tumors
11452659|NCT01682239|Experimental|RVAP lead|"Pacemaker lead implantation:
~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
11452660|NCT01682239|Experimental|RVSP arm|"Pacemaker lead implantation:
~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
11452661|NCT01682226|Experimental|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
11452662|NCT01682226|Experimental|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
11452663|NCT01682213|Experimental|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
11452664|NCT01682200|Experimental|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
11452665|NCT01682187|Experimental|LY2157299 (Part A)|Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
11452666|NCT01682187|Experimental|LY2157299 + Lomustine (Part B)|"LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.
~Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
11452667|NCT01682174|Placebo Comparator|Control Test Drink|control drink
11452668|NCT01682174|Experimental|Experimental Test Drink|Experimental Drink
11452669|NCT01682161|Experimental|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
11452670|NCT01682161|Experimental|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
11452671|NCT01682148|Experimental|NMJ Targeted|NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
11452672|NCT01682148|Active Comparator|Current Clinical Practice|"Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).
~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment."
11452673|NCT01682135|Experimental|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
11452674|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age > or = 35weeks and birth weight > 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
11452675|NCT01682109|Experimental|new paediatric valacyclovir formulation|Newly developed formulation
11452676|NCT01682109|Active Comparator|reference valacyclovir formulation|Formulation derived from FDA label information
11452677|NCT01682096|Active Comparator|Computed coronary angiography (CTA)|Patients will undergo a MDCT as the initial diagnostic test to rule out Acute Coronary Syndrome
11452678|NCT01682096|Active Comparator|Exercise stress echocardiography|Patients will undergo exercise stress echocardiography as the initial diagnostic test to rule out acute coronary syndrome.
11452679|NCT01682083|Experimental|Dabrafenib and trametinib|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
11452680|NCT01682083|Placebo Comparator|Dabrafenib and trametinib placebos|Subjects received matching placebos orally for 12 months
11452681|NCT01682070|Placebo Comparator|SUBLIVAC FIX Phleum prat. 0 AUN/ml|
11452682|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 3,333 AUN/ml|
11452683|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 10,000 AUN/ml|
11452684|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
11452685|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 40,000 AUN/ml|Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee
11452686|NCT01682057|Experimental|Group A|ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications
11452687|NCT01682044|Experimental|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
11452688|NCT01682031|Placebo Comparator|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
11452689|NCT01682031|Experimental|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
11452690|NCT01682018|Experimental|intervention group|Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
11452691|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
11452692|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
11452693|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
11452694|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
11452695|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
11452696|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
11452697|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
11452761|NCT01681563|Experimental|Pentostatin/Cyclophosphamide/Ofatumumab|Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days).
11452762|NCT01681550|Other|Incretin theapy combined with insulin|
11452763|NCT01681537|Experimental|Treatment Arm|Lenalidomide and re-induction chemotherapy
11452766|NCT01681511|Active Comparator|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
11452698|NCT01681992|Experimental|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
11452699|NCT01681992|Experimental|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
11452700|NCT01681992|Active Comparator|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
11452701|NCT01681979||Women with asthma during pregnancy|Women with asthma during pregnancy will be identified based on one of the following: 1) an asthma related medical code recorded anytime before the pregnancy start date and at least one prescription for an asthma medicine in the 6 months before the pregnancy start date or during pregnancy; 2) no asthma related medical code but at least 6 prescriptions for an asthma medicine in their record before the pregnancy start date, including one in the 6 months before the pregnancy start date or during pregnancy.
11452702|NCT01681966|Experimental|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
11452703|NCT01681953|Active Comparator|Lamazym|1 mg Lamazym/kg body weight
11452704|NCT01681953|Placebo Comparator|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
11452705|NCT01681940|Experimental|Lamazym|1 mg/kg body weight
11452706|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
11452707|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
11452708|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
11452709|NCT01681914||Anemia|Ambulatory, HIV-infected adult patients with hemoglobin <10 g/dL will be evaluated and managed in accordance with Mozambique's new anemia guideline for non-physician clinicians. The basic steps recommended by the guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral blood smear) and treat if indicated; evaluate for adverse drug reactions and manage per Mozambican national guidelines; consider nutritional deficiencies and intestinal parasites; evaluate response to therapy at <=1 month.
11452710|NCT01681914||Fever or History of Fever|Ambulatory, HIV-infected adult patients with measured axillary temperature >=37.5 C or history of fever within the past 24 hours will be evaluated and managed in accordance with Mozambique's new fever guideline for non-physician clinicians. The basic steps of the fever guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral smear) and treat if indicated; treat any other cause of fever identified through history and physical examination; re-evaluate at next scheduled clinical visit (sooner if worse or if not improving within 48 hours of initiating treatment). Although blood cultures are seldom performed in Mozambican health centers, venipuncture specimens will also be cultured for bacterial pathogens at the first study visit.
11452711|NCT01681914||Anemia and Fever/History of Fever|Patients who meet eligibility criteria for both the anemia and fever arms will be evaluated and managed using both the new Mozambican anemia guideline and the new Mozambican fever guideline, as above.
11452712|NCT01681901||Diagnostic (ultrasound)|Patients undergo breast ultrasound imaging.
11452713|NCT01681888|Experimental|Surface EMG Biofeedback|
11452714|NCT01681875|Experimental|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes
~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
11452715|NCT01681875|Experimental|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes
~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
11452716|NCT01681875|Experimental|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes
~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
11452717|NCT01681875|Experimental|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes
~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
11452718|NCT01681875|Experimental|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes
~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
11452719|NCT01681875|Experimental|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes
~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
11452720|NCT01681875|Other|Usual brand|"very low nicotine content cigarettes
~Usual brand cigarettes (control condition)"
11452764|NCT01681524|Experimental|Flurpiridaz F18|Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization
11452765|NCT01681511|Experimental|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
11452767|NCT01681498||Pregnancy|
11452721|NCT01681862|Experimental|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
11452722|NCT01681849|Experimental|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
11452723|NCT01681849|Placebo Comparator|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
11452724|NCT01681849|Other|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
11452725|NCT01681836|Experimental|Oral 15N-labeled sodium nitrate|Oral sodium nitrate 1,000 mg once first, then washout followed by oral sodium nitrite 20 mg once
11452726|NCT01681836|Experimental|Oral 15N-labeled sodium nitrite|Oral sodium nitrite 20 mg once first, then washout followed by oral sodium nitrate 1,000 mg once
11452727|NCT01681823|Experimental|PectaSol-C Modified Citrus Pectin (MCP)|Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.
11452728|NCT01681810|Experimental|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
11452729|NCT01681797|Experimental|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:
~CT angiography for an anterolateral thigh flap or an epigastric inferior flap
~A Doppler ultrasonography for a fibula flap.
~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
11452730|NCT01681771|Experimental|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
11452731|NCT01681771|Active Comparator|Discussion group|Internet moderated discussion group during 9 weeks
11452732|NCT01681758|Active Comparator|PPV|use PPV to guide fluid therapy
11452733|NCT01681758|Placebo Comparator|standard care|fluids according to standard care
11452734|NCT01681745|Experimental|Treatment|
11452735|NCT01681732|Experimental|Personalized Care Plan|A personalized plan based on baseline clinic visit data
11452736|NCT01681732|Active Comparator|Control|This arm will be standard care
11452737|NCT01681719|Experimental|WBV and resistance|used both interventions
11452738|NCT01681719|Experimental|WBV & resistance sham|used the vibrating platform and sham for resistance training
11452739|NCT01681719|Experimental|Resistance & sham WBV|used resistance exercises and sham for vibrating platform
11452740|NCT01681693|Experimental|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
11452741|NCT01681680|Other|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
11452742|NCT01681667|Active Comparator|ibuprofen|liquid ibuprofen 400mg compared to tablet ibuprofen 400mg
11452743|NCT01681667|Placebo Comparator|sugar pill or liquid|
11452744|NCT01681654|Experimental|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
11452745|NCT01681654|Experimental|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
11452746|NCT01681654|Experimental|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
11452747|NCT01681654|Experimental|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
11452748|NCT01681641|Experimental|Lifestyle counseling|Patients and spouses in the intervention group are offered 3 targeted meetings with the DBS nurse, focusing on goal setting for each individual, following DBS, based on patients and spouses own expectations, challenges and goals for everyday life after DBS.
11452749|NCT01681641|No Intervention|Control group|Patients and spouses enrolled in a control group
11452750|NCT01681628|Experimental|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
11452751|NCT01681628|Other|Wait list|"Delayed intervention.
~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
11452752|NCT01681615|Active Comparator|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
11452753|NCT01681615|Placebo Comparator|isotonic NaCl|Saline Eyedrops
11452754|NCT01681602|Active Comparator|Intervention group|16 weeks of aerobic exercise
11452755|NCT01681602|No Intervention|Control group|Usual care.
11452756|NCT01681589|Sham Comparator|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
11452757|NCT01681589|Experimental|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
11452758|NCT01681589|Other|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
11452759|NCT01681576|Experimental|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
11452760|NCT01681576|Experimental|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
11452769|NCT01681472|Active Comparator|Levoleucovorin 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
11452770|NCT01681472|Active Comparator|Levoleucovorin 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
11452771|NCT01681472|Experimental|6R-MTHF 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
11452772|NCT01681472|Experimental|6R-MTHF 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
11452773|NCT01681446|Active Comparator|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
11452774|NCT01681446|No Intervention|control|no anti-cancer interventions were assigned
11452775|NCT01681433|Experimental|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
11452776|NCT01681433|Active Comparator|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
11452777|NCT01681420|Experimental|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
11452778|NCT01681420|Experimental|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
11452779|NCT01681420|Experimental|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
11452780|NCT01681407||Depressed Patients|Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
11452781|NCT01681407||Non-Depressed Controls|Controls: Volunteers that had clinical screening with no depression diagnosis.
11452782|NCT01681407||Patients Relatives|Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
11452783|NCT01681394|Active Comparator|Product 1|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
11452784|NCT01681394|Placebo Comparator|Control product|250 g of chocolate cream
11452785|NCT01681381|Active Comparator|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
11452786|NCT01681381|Experimental|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
11452787|NCT01681368|Experimental|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
11452788|NCT01681355|Experimental|Intervention group|Healthy infants receiving standard cow's milk-based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition.
11452789|NCT01681329|Experimental|Cognitive-behavioral therapy with interpretation training|14 sessions of cognitive-behavioral therapy combined with computerized interpretation modification training
11452790|NCT01681329|Active Comparator|Cognitive-behavioral therapy with non-active training|14 sessions of cognitive-behavioral therapy combined with computerized non-active training
11452791|NCT01681316|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
11452792|NCT01681316|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
11452793|NCT01681303|Experimental|AST-120 group|Administration of AST-120
11452794|NCT01681303|No Intervention|2|
11452795|NCT01681290|Experimental|CBX129801 High Dose|Solution for injection, 2.4 mg, weekly for 52 weeks
11452796|NCT01681290|Experimental|CBX129801 Low Dose|Solution for injection, 0.8 mg, weekly for 52 weeks
11452797|NCT01681290|Placebo Comparator|Placebo|Solution for injection, vehicle with no active, weekly for 52 weeks
11452798|NCT01681277|Experimental|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
11452799|NCT01681277|Experimental|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
11452800|NCT01681277|Experimental|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
11452801|NCT01681277|Experimental|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
11452802|NCT01681264|Active Comparator|Morphine:Placebo|
11452803|NCT01681264|Active Comparator|Morphine:Guanfacine 1mg|
11452804|NCT01681264|Active Comparator|Morphine:Guanfacine 2mg|
11452805|NCT01681264|Active Comparator|Placebo:Guanfacine 2mg|
11452806|NCT01681264|Placebo Comparator|Placebo:Placebo|
11452807|NCT01681251|Experimental|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
11452808|NCT01681251|Active Comparator|Control|Fluid titrated at the discretion of the attending anesthesiologist.
11452809|NCT01681238|Other|Protocol group 1|Using standard hemodynamic therapy
11452810|NCT01681238|Experimental|Protocol group 2|Using goal-directed therapy
11452811|NCT01681225|Experimental|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp]. Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
11452812|NCT01681225|Active Comparator|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
11452922|NCT01680484|Active Comparator|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
11452813|NCT01681212|Experimental|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
11452814|NCT01681199|Experimental|Fluvastatin extended release tablet|Fluvastatin extended release tablet 80mg/day
11452815|NCT01681186|Experimental|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
11452816|NCT01681186|Placebo Comparator|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
11452817|NCT01681186|Experimental|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
11452818|NCT01681186|Experimental|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
11452819|NCT01681186|Experimental|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
11452820|NCT01681186|Experimental|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
11452821|NCT01681173|Experimental|Drink enriched in fibers|7,5g enriched fiber drinks, BID
11452822|NCT01681173|Experimental|Placebo drink|Placebo drink, BID
11452823|NCT01681160|Experimental|MAGGOT THERAPY & conventional therapy T|Maggot therapy,ADMINISTERED TWO TIMES AS A NEW METHODS OF DRESSING in experimental group.conventional therapy ,administered two times in control group
11452824|NCT01681147|No Intervention|Group One|Standard postpartum care after a pregnancy with gestational diabetes
11452825|NCT01681147|Experimental|Group Two|"Standard postpartum care after a pregnancy with gestational diabetes
~2 online nutrition and exercise education classes"
11452826|NCT01681147|Experimental|Group Three|"Standard postpartum care after a pregnancy with gestational diabetes
~2 online nutrition and exercise education classes
~Self monitoring of blood glucose levels"
11452827|NCT01681134|Experimental|Advagraf followed by Prograf|
11452828|NCT01681134|Experimental|Prograf followed by Advagraf|
11452829|NCT01681121|Experimental|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
11452830|NCT01681121|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
11452831|NCT01681108|Other|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
11452832|NCT01681095|Experimental|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.
~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
11452833|NCT01681095|Active Comparator|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.
~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
11452834|NCT01681082|Experimental|Tai Chi Training|"Subjects will be recruited from the University of Wisconsin-Madison course, Introduction to Martial Arts: Tai Chi."
11452835|NCT01681082|No Intervention|Control|"Subjects will be recruited from the University of Wisconsin-Madison course Introduction to Psychology."
11452836|NCT01681069|Active Comparator|IQP-VV-102|2 tablets twice a day
11452837|NCT01681069|Placebo Comparator|Placebo|2 tablets twice a day
11452838|NCT01681056|Experimental|Autosuggestion|
11452839|NCT01681056|No Intervention|Standard medical theraphy|
11452840|NCT01681043|No Intervention|24 hour PSG under ordinary conditions|24 hour PSG in 46 patients under ordinary (routine) conditions
11452841|NCT01681043|Active Comparator|24 hours PSG under protocol 'Quiet in the room'|24 hour PSG in the same 46 patients with protocol 'Quiet in the room' from 10 p.m. til 6 a.m.
11452842|NCT01681030|Experimental|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
11452843|NCT01681030|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
11452844|NCT01681030|Active Comparator|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
11452845|NCT01681017|Other|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
11452846|NCT01681017|Other|Master Trainers|Receive appropriate HBB training
11452847|NCT01681017|Other|Facilitators|Receive appropriate HBB training
11452848|NCT01681017|Other|Learners|Receive appropriate HBB training
11452849|NCT01681004|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
11452850|NCT01681004|Active Comparator|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
11452923|NCT01680484|Active Comparator|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
11452851|NCT01680991|Experimental|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
11452852|NCT01680991|Experimental|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
11452853|NCT01680991|Experimental|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
11452854|NCT01680978|Experimental|Aleglitazar|
11452855|NCT01680978|Placebo Comparator|Placebo|
11452856|NCT01680965|Experimental|Ofatumumab|"Phase I:
~Escalating dose of ofatumumab
~Phase II:
~Maximum tolerated dose (MTD) of Ofatumumab"
11452857|NCT01680952|Active Comparator|A) TEST|
11452858|NCT01680952|Experimental|B) CONTROL|
11452859|NCT01680939|Experimental|Morphine|Receives morphine for post-surgical pain
11452860|NCT01680939|Experimental|Ibuprofen|Receives ibuprofen for post-surgical pain
11452861|NCT01680926|Experimental|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
11452862|NCT01680913|Experimental|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
11452863|NCT01680913|Active Comparator|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
11452864|NCT01680900|Experimental|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
11452865|NCT01680900|Placebo Comparator|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
11452866|NCT01680887|Experimental|Varenicline|Oral 1.0 mg BID.
11452867|NCT01680887|Placebo Comparator|Placebo|Oral 1.0 mg BID.
11452868|NCT01680874|Experimental|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).
~The probiotic will be taken orally, once a week, for 4 weeks."
11452869|NCT01680874|Placebo Comparator|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
11452870|NCT01680861|Experimental|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
11452871|NCT01680861|Active Comparator|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
11452872|NCT01680835|Experimental|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
11452873|NCT01680822||NTM patient|confirmed NTM patient
11452874|NCT01680809|Experimental|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
11452875|NCT01680809|Experimental|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
11452876|NCT01680796|Experimental|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.
~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.
~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
11452877|NCT01680783|Other|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
11452878|NCT01680783|Experimental|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
11452879|NCT01680770||Hypotensive patients in shock|
11452880|NCT01680757|Experimental|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
11452881|NCT01680744|Experimental|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
11452882|NCT01680744|No Intervention|Standard Treatment|
11452883|NCT01680731||Forceps assisted vaginal delivery|Forceps assisted vaginal delivery within 1-5 years without any interval delivery
11452884|NCT01680731||Vacuum assisted vaginal delivery|Vacuum assisted vaginal delivery within 1-5 years without any interval delivery
11452885|NCT01680731||Elective cesarean delivery|Elective cesarean vaginal delivery within 1-5 years without any interval delivery done prior to labor
11452886|NCT01680731||Spontaneous vaginal delivery|Spontaneous vaginal delivery within 1-5 years without any interval delivery
11452887|NCT01680718|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
11452888|NCT01680718|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
11452889|NCT01680718|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
11452890|NCT01680705|Active Comparator|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
11452891|NCT01680705|Active Comparator|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
11452892|NCT01680705|Active Comparator|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
11452893|NCT01680692|Active Comparator|Continuous femoral and single shot sciatic nerve block|Will receive pre-operative continuous femoral catheter & post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine & 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
11452894|NCT01680692|Experimental|Continuous femoral and tibial peripheral nerve catheters|Patients will receive pre-operative continuous femoral catheter & post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) & 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
11452895|NCT01680679|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
11452896|NCT01680679|Placebo Comparator|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
11452897|NCT01680679|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
11452898|NCT01680666|Active Comparator|landmark guided|central line placement
11452899|NCT01680666|Active Comparator|ultrasound guided|central line placement
11452900|NCT01680653|Experimental|Mini-Glucagon and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.
~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
11452901|NCT01680653|Other|Carbohydrates and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.
~Administration of carbohydrate per camp protocol to treat nocturnal hypoglycemia. Expected treatment is 15-45g."
11452902|NCT01680653|Other|Carbohydrates No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.
~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with standard camp protocol administration of carbohydrates. Expected treatment is 15g-45g."
11452903|NCT01680653|Other|Mini-Glucagon and No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.
~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with mini-glucagon.
~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
11452904|NCT01680640|Active Comparator|Synbiotic|Fructo-oligosachharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
11452905|NCT01680640|Placebo Comparator|Maltodextrin|4 grams of maltodextrin daily.
11452906|NCT01680627||ADOLESCENT|
11452907|NCT01680614||At Risk Adult Drinkers|CASI
11452908|NCT01680601|Experimental|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
11452909|NCT01680601|Placebo Comparator|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
11452910|NCT01680588|Experimental|[18F]NAV4694|Single intravenous injection of 8.1 millicuries of [18F]NAV4694
11452911|NCT01680575||Training cohort|This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
11452912|NCT01680575||Validation cohort|"This is a retrospective cohort for validation of a risk prediction model developed using training cohort.
~This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation."
11452913|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
11452914|NCT01680549|Active Comparator|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
11452915|NCT01680549|Placebo Comparator|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
11452916|NCT01680536|Experimental|Maraviroc, darunavir, ritonavir|Single-arm,assessing cerebrospinal fluid inflammatory markers after addition of maraviroc to patients stable on monotherapy darunavir/ritonavir
11452917|NCT01680523|Experimental|RH group|Radical hysterectomy followed by tailored adjuvant therapy
11452918|NCT01680523|Active Comparator|CCRT group|Primary concurrent chemoradiation therapy
11452919|NCT01680510|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
11452920|NCT01680510|Placebo Comparator|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
11452921|NCT01680497|Experimental|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
11452925|NCT01680471|Experimental|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
11452926|NCT01680471|Experimental|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
11452927|NCT01680471|Placebo Comparator|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
11452928|NCT01680458||fluconazole|Infant Subjects who are treated with fluconazole
11452929|NCT01680432|Experimental|Probiotic cheese|The group received, for 30 days, was instructed to eat 30 g/day of probiotic fresh cheese enriched with Bifidobacterium lactis Bi-07.
11452930|NCT01680432|Placebo Comparator|Regular Cheese|The group placebo received, for 30 days, was instructed to consume 30g/day of regular fresh cheese.
11452931|NCT01680419|Experimental|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
11452932|NCT01680419|Active Comparator|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
11452933|NCT01680419|Active Comparator|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
11452934|NCT01680419|No Intervention|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
11452935|NCT01680406|Active Comparator|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
11452936|NCT01680406|Experimental|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.
~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
11452937|NCT01680406|Active Comparator|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
11452938|NCT01680406|Experimental|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.
~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
11452939|NCT01680393|Experimental|Sequential compression device|During arthroscopic shoulder surgery, an SCD device will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
11452940|NCT01680393|Experimental|TED stockings|During arthroscopic shoulder surgery, TED stockings will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
11452941|NCT01680393|No Intervention|Control|no stockings will be applied to the patients legs
11452942|NCT01680380||At-Home|Overnight sleep at home
11452943|NCT01680367|Experimental|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
11452944|NCT01680367|Experimental|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
11452945|NCT01680354|Active Comparator|ReLEx|One eye is treated with ReLEx the other with LASIK
11452946|NCT01680354|Active Comparator|LASIK|One eye is treated with ReLEx the other with LASIK
11452947|NCT01680341|Experimental|IDegAsp Simple|
11452948|NCT01680341|Experimental|IDegAsp Step wise|
11452949|NCT01680328|Other|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
11452950|NCT01680315|Experimental|Calorie information|"Low calorie yogurt
~High calorie yogurt
~with low calorie information sheet"
11452951|NCT01680315|Experimental|Calorie information (high)|"Low calorie yogurt
~High calorie yogurt
~High calorie information sheet"
11452952|NCT01680302|Experimental|High intensity exercise|High intensity exercise(Borg 16) in intervals.
11452953|NCT01680302|Experimental|Moderate intensity exercise|Moderate intensity exercise 3 times a week.
11452954|NCT01680302|Experimental|Control group|Exercise on their own. Follow current guidelines.
11452955|NCT01680289|Experimental|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
11452956|NCT01680289|Active Comparator|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
11452957|NCT01680276|Experimental|PBS based staff training|"The training, which will be supported by a treatment manual will comprise the following sections:
~Functional Behavioural Assessment and formulation skills
~• Brief Behavioural Assessment Tool for brief functional analyses
~Primary Prevention
~Secondary Prevention and Reactive Strategies
~Periodic Service Review and Problem Solving
~Developing individualised periodic service reviews
~Trouble shooting"
11452958|NCT01680276|Other|Treatment as usual|Most community intellectual disability services provide a range of health interventions that include but are not limited to psychiatric assessment and management, nursing support, psychology, speech and language therapy, occupational therapy and counselling. There may be some variation in resources but service users with challenging behaviour are likely to receive a range of broadly defined behavioural management and pharmacological interventions. Staff is routinely supervised by their clinical managers weekly.
11452959|NCT01680263|Experimental|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1 week interval"
11452960|NCT01680263|Active Comparator|NSAIDs/Physical therapy|treatment was done with NSAIDs and 10 sessions of daily physical therapy.
11452961|NCT01680250|Experimental|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
11452962|NCT01680237|Active Comparator|Cognitive behavior therapy|"Identification of bodily sensations, cognitions and safety behaviors characteristic of the individual patient
~Modification of dysfunctional beliefs and assumptions using socratic questioning and behavioral experiments
~Exposure in-vivo
~Relapse prevention"
11458675|NCT01640483|Active Comparator|mixed supportive/interpretative|
11452963|NCT01680237|Active Comparator|Exposure in-vivo|"Preparation of a brief behavior analysis of the individual case and construction of a hierarchy of relevant (internal and external) phobic situations
~Exposure with internal stimuli
~Exposure with external stimuli
~Relapse prevention
~Remark: In this condition there is no active work with the patient's catastrophic cognitions"
11452964|NCT01680224|Active Comparator|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
11452965|NCT01680224|Experimental|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
11452966|NCT01680224|Placebo Comparator|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
11452967|NCT01680211|Experimental|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
11452968|NCT01680211|Experimental|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
11452969|NCT01680211|Experimental|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
11452970|NCT01680211|Placebo Comparator|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
11452971|NCT01680198|Placebo Comparator|Placebo|Placebo capsules daily for 12 weeks.
11452972|NCT01680198|Experimental|Paracalcitol|"see Intervention description for details."
11452973|NCT01680185|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
11452974|NCT01680185|Active Comparator|Basal insulin|NPH insulin titration regimen, as specified in the IPT-NODAT study
11452975|NCT01680185|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
11452976|NCT01680172|Experimental|Ketamine|Single dose of ketamine (0.5 mg/kg)
11452977|NCT01680172|Placebo Comparator|Placebo|Single dose of placebo
11452978|NCT01680159|Experimental|TA-650|
11452979|NCT01680146|Active Comparator|PRO|Subjects will ingest 20 g of intrinsically labeled casein dissolved in water
11452980|NCT01680146|Experimental|PRO+FAT|Subjects will ingest 20 g of intrinsically labeled casein plus 26.7 g of anhydrous milk fat dissolved in water
11452981|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
11452982|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed >5yrs and Hba1c 7-9%
11452983|NCT01680120|Experimental|Continuous spinal anaesthesia|
11452984|NCT01680107|Experimental|d-cycloserine|oral, capsule, 250 mg, once
11452985|NCT01680107|Placebo Comparator|sugar pill|oral, capsule, once
11452986|NCT01680094|Experimental|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
11452987|NCT01680081|Experimental|CT perfusion group|
11452988|NCT01680068|Experimental|Pars plana vitrectomy and postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
11452989|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
11452990|NCT01680042|Active Comparator|phenytoin paste|this group receives phenytoin paste after oral biopsy
11452991|NCT01680042|Placebo Comparator|usual mucoadhesive paste|this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
11452992|NCT01680029|Experimental|PBASE-system 2.0|
11452993|NCT01680016|Experimental|Zagreb(≥6 to ≤17 Years)|
11452994|NCT01680016|Experimental|Zagreb(≥51 Years)|
11452995|NCT01680016|Active Comparator|Essen(≥6 to ≤17 Years)|
11452996|NCT01680016|Active Comparator|Essen(≥51 Years)|
11452997|NCT01680003|Experimental|Hepar-P|Hepar-P: Two capsules (250mg x 2), three times daily, orally
11452998|NCT01680003|Placebo Comparator|Placebo for Hepar-P|Placebo: Two capsules, three times daily, orally
11452999|NCT01679990|Experimental|PLX-PAD Low dose|PLX-PAD double low doses
11453000|NCT01679990|Active Comparator|PLX-PAD high doses|PLX-PAD double high dose
11453001|NCT01679990|Placebo Comparator|Placebo|Double Placebo doses
11453002|NCT01679990|Experimental|PLX-PAD high dose +Placebo|High dose+Placebo
11453003|NCT01679977|Active Comparator|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
11453041|NCT01679691|Active Comparator|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
11453042|NCT01679678|Experimental|PolyHeal 2|Negatively charged 5-micron polystyrene microspheres in Water For Injection
11453043|NCT01679678|Active Comparator|PolyHeal|Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)
11453044|NCT01679665|Experimental|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
11453004|NCT01679977|Active Comparator|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
11453005|NCT01679977|No Intervention|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
11453006|NCT01679964|Other|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
11453007|NCT01679951|Placebo Comparator|Placebo|
11453008|NCT01679951|Experimental|JNJ-38518168 (3 mg/d)|
11453009|NCT01679951|Experimental|JNJ-38518168 (10 mg/d)|
11453010|NCT01679951|Experimental|JNJ-38518168 (30 mg/d)|
11453011|NCT01679938|Experimental|primary obesity prevention|"The intervention will involve four main components:
~Training of child care providers.
~Curriculum sessions for children.
~Family outreach activities.
~Maintenance activities."
11453012|NCT01679938|No Intervention|Control group|For the control group, usual care will be provided
11453013|NCT01679912|Experimental|1: phone to call center|recommendations to phone to the call center for all the patients who have an acute attack
11453014|NCT01679912|No Intervention|2: usual strategy|usual strategy. No intervention (patients does not change their practice)
11453015|NCT01679899|Experimental|Vildagliptin|Vildagliptin 50 mg bid for 12 months
11453016|NCT01679899|Active Comparator|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
11453017|NCT01679886|Experimental|Rubidium PET|Rubidium PET
11453018|NCT01679873|Placebo Comparator|Control group|Assess abstract not reporting funding sources or conflicts of interest
11453019|NCT01679873|Experimental|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
11453020|NCT01679873|Experimental|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
11453021|NCT01679860|Experimental|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
11453022|NCT01679860|Experimental|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 ≤ 75 years
11453023|NCT01679834||Cohort|
11453024|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
11453025|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
11453026|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
11453027|NCT01679795|Experimental|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
11453028|NCT01679795|Placebo Comparator|Placebo use|Patients will use placebo for 30 days
11453029|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 < 90%.
11453030|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 < 90%
11453031|NCT01679782||control group|healthy sedentary subjects
11453032|NCT01679756|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy for cancer. .For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge. Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples. The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910. The mesenteric defects will be left open. The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
11453033|NCT01679756|Active Comparator|Extracorporeal anastomosis|"Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910.
~In both groups, a drain will not routinely inserted."
11453034|NCT01679743|Experimental|A|Breast Cancer Cohort
11453035|NCT01679743|Experimental|B|Non-Small Cell Lung Cancer Cohort
11453036|NCT01679730||irritable bowel syndrome patients|
11453037|NCT01679717|Active Comparator|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
11453038|NCT01679717|Other|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
11453039|NCT01679704|Other|Food products|Ten food products will be given to all subjects
11453040|NCT01679691|No Intervention|Control group|Control group in whom no epidural anesthesia will be applied
11453191|NCT01678677|Placebo Comparator|Group Placebo 2|Subjects in this group will receive placebo.
11453045|NCT01679665|Placebo Comparator|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
11453046|NCT01679652|Experimental|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
11453047|NCT01679652|Placebo Comparator|Placebo|Inactive placebo given as tablet for 5 days
11453048|NCT01679639|Experimental|Aleglitazar|
11453049|NCT01679613|Experimental|1 Nintedanib (Reference)|single dose, oral with 240 ml water
11453050|NCT01679613|Experimental|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
11453051|NCT01679613|Experimental|3 Nintedanib (Reference)|single dose, oral with 240 ml water
11453052|NCT01679613|Experimental|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
11453053|NCT01679600|Experimental|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
11453054|NCT01679600|Active Comparator|RATE|Robotics-assisted treadmill exercise
11453055|NCT01679587|Experimental|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
11453056|NCT01679587|Experimental|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
11453057|NCT01679587|Experimental|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
11453058|NCT01679587|Experimental|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
11453059|NCT01679574|Experimental|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
11453060|NCT01679574|Active Comparator|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months
~Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
11453061|NCT01679561|Experimental|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
11453062|NCT01679548|Experimental|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
11453063|NCT01679548|Active Comparator|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
11453064|NCT01679535|Experimental|Intervention|nutrition and hygiene education by community health workers
11453065|NCT01679522|Experimental|Single-port surgery group|Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
11453066|NCT01679522|Active Comparator|Four-port surgery group|Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
11453067|NCT01679509|Experimental|Single-port surgery group|Single-port laparoscopic adnexal surgery
11453068|NCT01679509|Active Comparator|Three-port surgery group|Three-port laparoscopic adnexal surgery
11453069|NCT01679496|Experimental|Food items|Food items low in saturated fat and high in polyunsaturated fat
11453070|NCT01679496|Placebo Comparator|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
11453071|NCT01679483|Experimental|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
11453072|NCT01679483|No Intervention|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
11453073|NCT01679457|Experimental|ACT-Focused ERP|One Session.
11453074|NCT01679457|Active Comparator|TAU-ERP|One Session.
11453075|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.
~Computed tomography and magnetic resonance imaging are performed every 2 years."
11453076|NCT01679418|Active Comparator|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
11453077|NCT01679418|Sham Comparator|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
11453078|NCT01679405|Experimental|Dose level 1 (Part A)|30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
11453079|NCT01679405|Experimental|Dose level -1 (Part A)|30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
11453080|NCT01679392|Experimental|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
11453081|NCT01679379|Active Comparator|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture].
11453082|NCT01679379|Active Comparator|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polypropylene non absorbable monofilament suture].
11453083|NCT01679366|No Intervention|Penicillin G|hospitalization of 30 patients given penicilline intraveniously for 72 hours
11453084|NCT01679366|Placebo Comparator|Placebo|30 hospitalized patients will be given placebo with a regular penicillin treatment
11453085|NCT01679366|Experimental|Probiotic|Probiotics will be given to 30 hospitalized patients with regular penicillin treatment
11453086|NCT01679353|Placebo Comparator|placebo group|normal saline 0.5ml
11453226|NCT01678391|Experimental|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
11453087|NCT01679353|Experimental|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
11453088|NCT01679340|Experimental|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
11453089|NCT01679340|Active Comparator|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
11453090|NCT01679327|Experimental|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
11453091|NCT01679314|Active Comparator|Active AlphaCore device|AlphaCore active stimulation treatment
11453092|NCT01679314|Sham Comparator|Sham AlphaCore device|AlphaCore sham device
11453093|NCT01679301|Active Comparator|Continuous dose|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator.
11453094|NCT01679301|Experimental|Pulse dose ('sleep mode')|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator
11453095|NCT01679288|Experimental|ultrasound arm|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
11453096|NCT01679275|Other|measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
11453097|NCT01679262|Other|Optimal size of OPAs|
11453098|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
11453099|NCT01679236|Active Comparator|Mindfulness Training for Smokers|Mindfulness Training for Smokers (MTS) is a 7-week intervention that provides instruction in mindfulness very similar to the way it is taught in Mindfulnes-Based Stress Reduction. In addition MTS provides mindfulness training targeted to specific smoking relapse challenges. The MTS intervention was designed around a weekly curriculum that provides instruction to help participants learn practices including mindfulness meditation, mindful walking and mindful eating. MTS participants are instructed to practice meditation 30 minutes per day with a guided meditation CD.
11453100|NCT01679236|Active Comparator|Interactive Learning for Smokers|Interactive Learning for Smokers (ILS) is a 7-week intervention that provides a closely matched active control group for MTS, but with substantive education and skills training for smoking cessation. To this end, ILS combines elements of two smoking cessation programs, the American Lung Association, Freedom from Smoking program and The Mayo Clinic Nicotine Dependence Center program. ILS participants were asked to practice 30 minutes of silent non-directed walking per day throughout the intervention and were instructed to use non-directed walking for relaxation, stress reduction and as a strategy for managing urges and withdrawal symptoms.
11453101|NCT01679223||<40 years|subjects aged less than 40 years
11453102|NCT01679223||40-60 years|subjects aged 40-60years
11453103|NCT01679223||> 60 years|subjects aged greater than 60 years
11453104|NCT01679210|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
11453105|NCT01679210|No Intervention|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
11453106|NCT01679197|Experimental|Treatment|Metreleptin
11453107|NCT01679158|Experimental|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
11453108|NCT01679158|Experimental|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
11453109|NCT01679158|Experimental|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
11453110|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
11453111|NCT01679145||Control group|Age- and gender matched healthy controls
11453112|NCT01679132|Experimental|BAROSTIM NEO System|Subjects implanted with the BAROSTIM NEO System.
11453113|NCT01679119|Experimental|IO-R-CVP|Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine & prednisolone).
11453114|NCT01679119|Active Comparator|Gem-R-CVP|Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).
11453115|NCT01679106|Placebo Comparator|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
11453116|NCT01679106|Active Comparator|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
11453117|NCT01679093|Active Comparator|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
11453118|NCT01679093|Active Comparator|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
11453119|NCT01679093|Active Comparator|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
11453120|NCT01679080|Experimental|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
11453513|NCT01676571|Experimental|Lu AA21004|
11459239|NCT01636401|Active Comparator|aclidinium bromide|
11453121|NCT01679080|Experimental|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
11453122|NCT01679080|Placebo Comparator|No active treatment|Observation in three years, no treatment
11453123|NCT01679067||HIV-GALT|
11453124|NCT01679054||EOX|Epirubicin + Oxaliplatin + Capecitabine (EOX) Epirubicin 50 mg/m2 iv bolus d1 q3w x 8 cycles Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles Capecitabine (Xeloda) 625 mg/m2 po bid x 6 months
11453125|NCT01679054||FOLFOX4|FOLFOX4 Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
11453126|NCT01679041|Experimental|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
11453127|NCT01679028|Placebo Comparator|Placebo Group A|150mg Placebo Single dose
11453128|NCT01679028|Experimental|T89 Group A|150mg T89 single dose
11453129|NCT01679028|Placebo Comparator|Placebo Group B|300mg placebo single dose
11453130|NCT01679028|Experimental|T89 Group B|300mg T89 single dose
11453131|NCT01679028|Placebo Comparator|Placebo Group C|225mg Placebo bid for 14 days
11453132|NCT01679028|Experimental|T89 Group C|225mg T89 bid for 14 days
11453133|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
11453134|NCT01679002|Experimental|Group A|"BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period
~BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid"
11453135|NCT01679002|Experimental|Group B|"BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period
~BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od"
11453136|NCT01679002|Experimental|Group C|"oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period
~OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid"
11453137|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
11453138|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
11453139|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
11453140|NCT01678976|Experimental|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
11453141|NCT01678976|Active Comparator|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
11453142|NCT01678963|Experimental|Squalamine|Squalamine eye drop 0.2%
11453143|NCT01678963|Placebo Comparator|Vehicle Control|Eye drop vehicle control
11453144|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:
~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and
~HLA microchimerism & HLA G."
11453145|NCT01678937||Monotherapy Group|"Monotherapy patients [cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:
~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and
~HLA microchimerism & HLA G."
11453146|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
11453147|NCT01678924|Experimental|AGN-214868 Dose 1|AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
11453148|NCT01678924|Experimental|AGN-214868 Dose 2|AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
11453149|NCT01678924|Placebo Comparator|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
11453150|NCT01678924|Experimental|AGN-214868 Dose 3|AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
11453151|NCT01678911|Placebo Comparator|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
11453152|NCT01678911|Active Comparator|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
11453153|NCT01678898|Experimental|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
11453154|NCT01678898|Experimental|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
11453155|NCT01678898|Experimental|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
11453192|NCT01678664|Experimental|embolization or chemoembolization plus everolimus|After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).
11453193|NCT01678651|Active Comparator|Human FSH|Human FSH
11453194|NCT01678651|Active Comparator|Recombinant FSH|Recombinant FSH
11453195|NCT01678638|Active Comparator|Early inguinal hernia (IH) repair|IH repair before NICU discharge
11453156|NCT01678885|Experimental|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
11453157|NCT01678885|Experimental|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
11453158|NCT01678872|Other|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
11453159|NCT01678846|Experimental|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
11453160|NCT01678846|No Intervention|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
11453161|NCT01678820|Experimental|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
11453162|NCT01678820|Active Comparator|Sitagliptin|Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
11453163|NCT01678820|Active Comparator|Simvastatin|Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
11453164|NCT01678807|Experimental|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
11453165|NCT01678807|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
11453166|NCT01678807|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
11453167|NCT01678794|Experimental|Candesartan|
11453168|NCT01678794|Placebo Comparator|Placebo|
11453169|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
11453170|NCT01678755|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
11453171|NCT01678755|Experimental|ABT-126 High Dose|ABT-126 High Dose
11453172|NCT01678755|Placebo Comparator|Placebo|Placebo
11453173|NCT01678742|Experimental|High-protein diet|
11453174|NCT01678742|Active Comparator|Standard diet|
11453175|NCT01678716|Active Comparator|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
11453176|NCT01678716|Experimental|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
11453177|NCT01678716|Experimental|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
11453178|NCT01678716|Experimental|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
11453179|NCT01678703|Active Comparator|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
11453180|NCT01678703|Active Comparator|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
11453181|NCT01678690|Experimental|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
11453182|NCT01678677|Experimental|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
11453183|NCT01678677|Experimental|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
11453184|NCT01678677|Experimental|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
11453185|NCT01678677|Experimental|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
11453186|NCT01678677|Experimental|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
11453187|NCT01678677|Experimental|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
11453188|NCT01678677|Experimental|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
11453189|NCT01678677|Experimental|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
11453190|NCT01678677|Placebo Comparator|Group Placebo 1|Subjects in this group will receive placebo.
11453196|NCT01678638|Active Comparator|Late inguinal hernia (IH) repair|IH repair as outpatient at approximately 55-60 weeks post-menstrual age
11453197|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
11453198|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
11453199|NCT01678612|No Intervention|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
11453200|NCT01678612|Experimental|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
11453201|NCT01678599|Other|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
11453202|NCT01678586|Active Comparator|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
11453203|NCT01678586|Sham Comparator|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
11453204|NCT01678586|Active Comparator|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
11453205|NCT01678586|Sham Comparator|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
11453206|NCT01678573|Experimental|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
11453207|NCT01678573|Experimental|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
11453208|NCT01678573|Experimental|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
11453209|NCT01678560|Active Comparator|Usual Care|Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
11453210|NCT01678560|Active Comparator|Wireless Care|Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
11453211|NCT01678547|Experimental|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
11453212|NCT01678547|Active Comparator|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
11453213|NCT01678547|Active Comparator|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
11453214|NCT01678534|Placebo Comparator|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
11453215|NCT01678534|Experimental|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
11453216|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
11453217|NCT01678495|Experimental|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection
~1 pre-filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection
~1 Mini-Spike Plus 6/8 (CE 0123) transfer system.
~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
11453218|NCT01678495|Active Comparator|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
11453219|NCT01678482|Experimental|lession count reduction post treatment|"A total of 50 subjects were included.
~The majority are female (62 %)
~At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.
~All subjects demonstrated a reduction in lesion count.
~The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.
~The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months
~The Percent of responders is similar for males & females and similar for cheeks & front."
11453220|NCT01678469|Other|blood sample|
11453221|NCT01678443|Experimental|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
11453222|NCT01678430|Active Comparator|Ofatumumab-Chlorambucil|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
11453223|NCT01678430|Experimental|Ofatumumab-Bendamustine|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
11453224|NCT01678417|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
11453225|NCT01678404|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
11453227|NCT01678378|Experimental|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
11453228|NCT01678378|No Intervention|Control|School health centers randomized to Control will provide standard of care.
11453229|NCT01678365|Experimental|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
11453230|NCT01678365|Active Comparator|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
11453231|NCT01678352|Experimental|Cohort 1|Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy).
11453232|NCT01678352|Experimental|Cohort 2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥ 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression.
11453233|NCT01678352|Experimental|Cohort 3|Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy. Patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of Temozolomide or PCV-based chemotherapy). With regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease. The intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses). If the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse.
11453234|NCT01678339||1|
11453235|NCT01678326|Active Comparator|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
11453236|NCT01678326|Active Comparator|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
11453237|NCT01678313|Experimental|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
11453238|NCT01678313|Experimental|Control group|Doxazosin 4 mg every day (QD)
11453239|NCT01678287|Experimental|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
11453240|NCT01678287|Experimental|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
11453241|NCT01678287|Experimental|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
11453242|NCT01678287|Experimental|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
11453243|NCT01678274||Turner syndrome|Females with Turner syndrome
11453244|NCT01678274||Control group|age matched females acting as controls
11453245|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
11453246|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
11453247|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
11453248|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
11453249|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
11453250|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
11453251|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
11453252|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
11453253|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
11453254|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
11453255|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
11453256|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
11453257|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
11453258|NCT01678235|Experimental|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.
~First day: insulin glulisine
~Second day: insulin aspart"
11453259|NCT01678235|Experimental|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.
~First day: insulin aspart
~Second day: insulin glulisine"
11453260|NCT01678222||SNP|individuals who are homozygous for either the major or minor variant of both SNPs
11453261|NCT01678209|Active Comparator|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
11453262|NCT01678209|Experimental|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
11453263|NCT01678209|Experimental|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
11453264|NCT01678196|Experimental|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
11453265|NCT01678196|Placebo Comparator|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
11453266|NCT01678183|Experimental|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
11453267|NCT01678183|Experimental|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
11453268|NCT01678183|No Intervention|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
11453269|NCT01678157||Documented symptomatic paraesophageal hernia|"Documented symptomatic paraesophageal hernia.
~Greater than 5 cm hiatal hernia on upper gastrointestinal study.
~Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.
~Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.
~Consenting adult 19 years of age or older
~Must be able to participate in follow-up evaluation.
~Free of cognitive impairment"
11453270|NCT01678144|Experimental|Medtentia Annuloplasty Ring (MAR)|All eligible patients underwent surgical mitral valve repair using annuloplasty device - Medtentia Annuloplasty Ring (MAR)
11453271|NCT01678131|Experimental|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
11453272|NCT01678131|Experimental|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
11453273|NCT01678131|Experimental|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
11453274|NCT01678118||minority smokers|A single arm ABA design will be used to pilot a tobacco-focused patient navigation (TPN) intervention for low income, minority smokers.
11453275|NCT01678105|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
11453276|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
11453277|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
11453278|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
11453279|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
11453280|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
11453281|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
11453282|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
11453283|NCT01678053|Experimental|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
11453284|NCT01678053|Other|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
11453285|NCT01678040||Cardiac Magnetic Resonance|"The CMR examinations will be performed in the cardiac MRI scanner (Siemens Avanto, 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children. A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration."
11453286|NCT01678027|Placebo Comparator|Placebo|Placebo for LAC triple therapy
11453287|NCT01678027|Active Comparator|LAC triple therapy|PPI (Lansoprazole), Clarithromycin, Amoxicilline
11453288|NCT01678014|Experimental|Anorexia|Anorexia patients
11453289|NCT01678001|Active Comparator|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
11453290|NCT01678001|Placebo Comparator|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
11453291|NCT01677988|Experimental|Chemotherapy, Chemoradiation, Surgery|Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection
11453292|NCT01677975|Experimental|ultrasound, dynamic lymphscintigraphy|
11453293|NCT01677962|Experimental|dendritic cell and Poly-ICLC vaccination|Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
11453294|NCT01677949|Experimental|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
11453295|NCT01677949|Experimental|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
11453296|NCT01677936|Experimental|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
11453297|NCT01677936|Active Comparator|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
11453298|NCT01677923|No Intervention|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
11453299|NCT01677923|Experimental|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
11453300|NCT01677923|Experimental|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
11453301|NCT01677923|No Intervention|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
11453302|NCT01677910|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
11453303|NCT01677910|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
11453304|NCT01677910|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
11453305|NCT01677910|Experimental|Telotristat Etiprate Open-Label Extension|Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.
11453306|NCT01677897|Experimental|Metformin|Metformin 2x1000mg orally per day
11453307|NCT01677884|Experimental|Patients with metastatic CRC|
11453308|NCT01677871|Experimental|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
11453309|NCT01677871|Active Comparator|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
11453310|NCT01677871|Experimental|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
11453311|NCT01677871|Active Comparator|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
11453312|NCT01677858|Experimental|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.
~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.
~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
11453313|NCT01677845|Experimental|Radiation Therapy|Radiation Therapy
11453314|NCT01677832||ADHD/Taiwan|
11453315|NCT01677832||Control/Taiwan|
11453316|NCT01677832||ADHD/Germany|
11453317|NCT01677832||Control/Germany|
11453318|NCT01677806|Experimental|Percutaneous vertebroplasty|
11453319|NCT01677806|Active Comparator|Conservative therapy|
11453320|NCT01677793||Child and adolescent population|
11453321|NCT01677780|Experimental|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
11453322|NCT01677767||Cohort|
11453323|NCT01677754|Placebo Comparator|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
11453324|NCT01677754|Experimental|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
11453325|NCT01677754|Experimental|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
11453326|NCT01677741|Experimental|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg [+1] and may be further to 4.5 mg/kg [+2] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg [-1] and may be further to 1.5 mg/kg [-2]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
11453327|NCT01677741|Experimental|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
11453328|NCT01677741|Experimental|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
11453329|NCT01677741|Experimental|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
11453330|NCT01677741|Experimental|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
11453331|NCT01677728||arm A|patients received chemotherapy alone
11453332|NCT01677728||arm B|patients received target therapy combined with chemotherapy
11453333|NCT01677715|Active Comparator|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
11453334|NCT01677715|Placebo Comparator|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
11453335|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
11453336|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
11453337|NCT01677702|Placebo Comparator|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
11453338|NCT01677689|Placebo Comparator|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
11453339|NCT01677689|Experimental|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
11453340|NCT01677676|Active Comparator|Group 2|FP-01.1 (250µg/peptide)
11453341|NCT01677676|Active Comparator|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
11453342|NCT01677676|Active Comparator|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
11453343|NCT01677676|Active Comparator|Group 1|FP-01.1 (150µg/peptide)
11453344|NCT01677650|Active Comparator|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
11453345|NCT01677650|Experimental|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
11453346|NCT01677650|Active Comparator|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
11453347|NCT01677650|Active Comparator|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
11453348|NCT01677650|Active Comparator|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
11453349|NCT01677637||All measurements|Total measured population
11453350|NCT01677624|Experimental|E7040|
11453351|NCT01677611|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
11453352|NCT01677611|Placebo Comparator|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
11453353|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
11453354|NCT01677572|Experimental|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
11453355|NCT01677572|Experimental|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
11453356|NCT01677572|Placebo Comparator|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
11453357|NCT01677572|Experimental|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
11453358|NCT01677572|Placebo Comparator|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
11453359|NCT01677572|Experimental|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
11453360|NCT01677572|Placebo Comparator|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
11453361|NCT01677572|Experimental|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
11453514|NCT01676558|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
11453362|NCT01677572|Placebo Comparator|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
11453363|NCT01677559|Experimental|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.
~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
11453364|NCT01677559|Experimental|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.
~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
11453365|NCT01677559|Experimental|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.
~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
11453366|NCT01677559|Experimental|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.
~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
11453367|NCT01677559|Experimental|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.
~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
11453368|NCT01677546|Experimental|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
11453369|NCT01677546|Experimental|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
11453370|NCT01677546|No Intervention|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
11453371|NCT01677533|Active Comparator|PM-Data|Team will receive data only.
11453372|NCT01677533|Experimental|PM-Support|Team will receive data and panel management support
11453373|NCT01677533|Experimental|PM-Education|Team will receive data, panel management support, and educational interventions.
11453374|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
11453375|NCT01677507|Experimental|timolol|To compare the variation in response to timolol between individuals
11453376|NCT01677507|Active Comparator|latanoprost|To compare the variation in response to latanoprost between individuals
11453377|NCT01677494||heart failure with preserved ejection fraction|- Inclusion Elevated BNP EF > 50%
11453378|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
11453379|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
11453380|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
11453381|NCT01677468|Experimental|Intermediate embolization|TACE with substatsis using gelfoam
11453382|NCT01677468|Active Comparator|Complete embolization|TACE with complete embolization using gelfoam
11453383|NCT01677455|Experimental|HER2+ breast cancer|
11453384|NCT01677455|Experimental|Triple negative breast cancer|Closed to enrollment
11453385|NCT01677455|Experimental|ER/PR+ Refractory to Prior Hormonal Treatment|
11453386|NCT01677442|Experimental|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
11453387|NCT01677442|Active Comparator|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
11453388|NCT01677429|Experimental|VR movie + balance challenge|VR-based balance training
11453389|NCT01677429|Sham Comparator|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
11453390|NCT01677429|Active Comparator|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
11453391|NCT01677416||Rheumatoid Arthritis Group|RA with at least one year since diagnosis, asymptomatic feet, and age between 18 and 65 years
11453392|NCT01677416||Control group|Absence of known osteoarticular disease
11453393|NCT01677403|Active Comparator|Nebulised Tobramycin|Nebulised Tobramycin
11453394|NCT01677403|Placebo Comparator|Nebulised 0.9% Saline|Nebulised 0.9% Saline
11453395|NCT01677390|Experimental|Arm 1|SGN-75, everolimus
11453396|NCT01677377|Experimental|Cohort 1, RBP-7000 60 mg|Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87.
11453397|NCT01677377|Experimental|Cohort 2, RBP-7000 90 mg|Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87.
11453398|NCT01677377|Experimental|Cohort 3, RBP-7000 120 mg|Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87.
11453399|NCT01677364|Active Comparator|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
11453400|NCT01677364|No Intervention|Spontaneous Labour|patients were allowed to go into spontaneous labour
11453401|NCT01677351|Active Comparator|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
11453402|NCT01677351|Placebo Comparator|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
11453403|NCT01677338|Experimental|13C-uracil and 99mTc sulfur colloid|Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.
11453404|NCT01677338|Experimental|99mTc sulfur colloid|Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.
11453405|NCT01677325|Experimental|Chinese herb|Chinese herb
11453406|NCT01677312|Active Comparator|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
11453515|NCT01676545||Chronic Periodontitis|
11453516|NCT01676545||Control|
11459240|NCT01636401|Placebo Comparator|Placebo|
11453407|NCT01677312|Active Comparator|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
11453408|NCT01677299|Active Comparator|1000 mg EFB0026 (metformin immediate-release)|BID
11453409|NCT01677299|Experimental|1000 mg EFB0027 (metformin delayed-release)|BID
11453410|NCT01677299|Experimental|500 mg EFB0027 (metformin delayed-release)|BID
11453411|NCT01677299|Experimental|500 mg EFB0026 + 1000 mg EFB0027|BID
11453412|NCT01677286|Experimental|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
11453413|NCT01677273|Active Comparator|Hydrolyzed casein|Hydrolyzed casein
11453414|NCT01677273|Active Comparator|Intact casein|Intact casein
11453415|NCT01677273|Active Comparator|Intact whey protein|Intact whey protein
11453416|NCT01677260|Experimental|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
11453417|NCT01677260|Active Comparator|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
11453418|NCT01677247|Experimental|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
11453419|NCT01677247|Active Comparator|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
11453420|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
11453421|NCT01677208|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
11453422|NCT01677208|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
11453423|NCT01677195|Active Comparator|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
11453424|NCT01677195|Active Comparator|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
11453425|NCT01677195|Placebo Comparator|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
11453426|NCT01677182|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
11453427|NCT01677182|Experimental|Ramelteon (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
11453428|NCT01677182|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 6 weeks.
11453429|NCT01677169|Experimental|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
11453430|NCT01677169|Placebo Comparator|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
11453431|NCT01677169|Experimental|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
11453432|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
11453433|NCT01677143|Active Comparator|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
11453434|NCT01677143|Placebo Comparator|Placebo|Injection of 5 ml saline in each port site.
11453435|NCT01677104|Active Comparator|DPP-IV inhibitor|Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
11453436|NCT01677104|Placebo Comparator|Placebo pill|One placebo tablet before microinjection
11453437|NCT01677091|Active Comparator|Control group|This group will benefit from conventional rehabilitation
11453438|NCT01677091|Experimental|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
11453439|NCT01677091|Experimental|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
11453440|NCT01677091|Experimental|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
11453441|NCT01677078|Experimental|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system
~Description of 1 session of the rTMS protocol :
~Frequency: 20Hz
~Intensity: 110% of motor threshold
~80 train of 2 seconds duration
~10 seconds between two trains
~3200 pulses
~Devices :
~rTMS: System Mag Pro (Magventure, Denmark)
~Neuronavigation system: Syneika One (Syneika, France)"
11453442|NCT01677078|Sham Comparator|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
~Description of 1 session of the rTMS protocol :
~Frequency: 20Hz
~Intensity: 110% of motor threshold
~80 train of 2 seconds duration
~10 seconds between two trains
~3200 pulses
~Devices :
~- rTMS: System Mag Pro (Magventure, Denmark)"
11453443|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
11453444|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
11453445|NCT01677039|Active Comparator|Treatment A|
11453446|NCT01677039|Experimental|Treatment B|
11453447|NCT01677039|Experimental|Treatment C|
11453448|NCT01677013|No Intervention|Oral medication treatment|type 2 diabetics with only oral medications
11453449|NCT01677013|Experimental|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
11453450|NCT01677013|No Intervention|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
11453451|NCT01677013|Experimental|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
11453452|NCT01676987|Experimental|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
11453453|NCT01676987|Active Comparator|Budesonide|Group 2 (comparator): Budesonide
11453454|NCT01676974||Travelers|Travelers and their family members
11453517|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
11453455|NCT01676961|Experimental|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count > 50 x 10^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
11453456|NCT01676948|Experimental|Canakinumab - Cohort 1, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
11453457|NCT01676948|Experimental|Canakinumab - Cohort 1, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
11453458|NCT01676948|Experimental|Canakinumab - Cohort 2, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
11453459|NCT01676948|Experimental|Canakinumab - Cohort 2, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
11453460|NCT01676948|Experimental|Cohort 2 - canakinumab dose reduction|
11453461|NCT01676948|Experimental|Cohort 1 - canakinumab dose reduction|
11453462|NCT01676935|Experimental|ABT-126|ABT-126 Open-label dose
11453463|NCT01676922||Cohort|
11453464|NCT01676909|Experimental|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
11453465|NCT01676909|Active Comparator|Medical Illness Education & Support Group|We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.
11453466|NCT01676896|Experimental|Asthma in-school class|Provided in 16 15-minute sessions (4 hours total didactic time); scheduled 3 sessions/week. The content is provided by trained asthma educators. The Asthma Plan for Kids (AP-K) is a 7-step curriculum for children to use when responding to asthma symptoms. Skills practice with placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters with PEF score interpretation. Topics include (a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner.
11453467|NCT01676896|Experimental|Asthma Day Camp|The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics [a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner] are covered as those in the asthma in-school classes.
11453468|NCT01676896|Sham Comparator|Health Promotion in-school class|The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
11453469|NCT01676883|Experimental|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
11453470|NCT01676870|Experimental|1x4 aerobic interval training|1x4min aerobic interval training (1-AIT), 3 times a week
11453471|NCT01676870|Experimental|4x4 aerobic interval training|4x4min aerobic interval training (4-AIT), vigorously exercise according to today's guidelines, 3 times a week
11453472|NCT01676870|Active Comparator|traditional moderate training|traditional moderate training (CME), moderate exercise at least 30 min, 5 days a week or more, according to today's guidelines
11453473|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
11453474|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
11453475|NCT01676844|Experimental|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
11453476|NCT01676844|Active Comparator|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
11453518|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
11453519|NCT01676493|Experimental|Codeine|Codeine Sulfate Oral Solution and Tablet
11453520|NCT01676480|Experimental|ADT group|
11453521|NCT01676480|Experimental|Control group|
11453522|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
11459332|NCT01635751|Active Comparator|Lyrica Capsule 75mg(fasted)|
11453477|NCT01676831|Experimental|topical resiquimod 0.06%|Topical resiquimod 0.06% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will be 3 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
11453478|NCT01676831|Experimental|topical resiquimod 0.03%|Topical resiquimod 0.03% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will begin 5 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
11453479|NCT01676818|Experimental|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 IV bolus over 2-5 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
11453480|NCT01676805||1|Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy
11453481|NCT01676805||2|Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy
11453482|NCT01676792|Experimental|Lesion reduction|
11453483|NCT01676779|Experimental|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
11453484|NCT01676779|Experimental|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
11453485|NCT01676753|Experimental|Dinaciclib & Pembrolizumab Treatment|Dinaciclib is administered on days 1 and 8 of a 21-day cycle in combination with pembrolizumab administered on day 1 of each 21-day cycle.
11453486|NCT01676740|Placebo Comparator|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
11453487|NCT01676740|Experimental|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
11453488|NCT01676740|Other|Deficeicnt hematinics|Iron supplement will be provided
11453489|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
11453490|NCT01676714|Experimental|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
11453491|NCT01676701|Experimental|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
11453492|NCT01676701|Experimental|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
11453493|NCT01676675|Experimental|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
11453494|NCT01676675|Experimental|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
11453495|NCT01676675|Experimental|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
11453496|NCT01676675|Experimental|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
11453497|NCT01676675|Experimental|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
11453498|NCT01676675|Experimental|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
11453499|NCT01676675|Placebo Comparator|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
11453500|NCT01676675|Placebo Comparator|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
11453501|NCT01676662|Experimental|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
11453502|NCT01676662|Sham Comparator|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
11453503|NCT01676649|Experimental|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
11453504|NCT01676649|Experimental|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
11453505|NCT01676636||Pregnant Women|Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.
11453506|NCT01676623|Active Comparator|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
11453507|NCT01676623|Experimental|A&T Franchise|In this arm, the 20 CHCs will offer Alive & Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
11453508|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
11453509|NCT01676597|Experimental|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
11453510|NCT01676597|Active Comparator|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
11453511|NCT01676584|Placebo Comparator|Placebo|
11453512|NCT01676584|Experimental|RO6811135|
11453524|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
11453525|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
11453526|NCT01676467||Healthy smoking|Healthy smoking control subjects
11453527|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
11453528|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:
~no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;
~no blood transfusion requirement;
~base deficit < 5 mEq/L;
~no requirement for mechanical ventilation other than transiently during orthopedic surgery."
11453529|NCT01676441|Experimental|cellgram-spine|posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively
11453530|NCT01676428|Experimental|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.
~For lesions <5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
11453531|NCT01676415|Active Comparator|Prednisone|Oral steroid medication
11453532|NCT01676415|Active Comparator|Topical Mometasone|Topical steroid medication
11453533|NCT01676402|Experimental|Group 1: HA DNA + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV ID at Week 14±2 wks
11453534|NCT01676402|Experimental|Group 2: HA DNA + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV IM at Week 14±2 wks
11453535|NCT01676402|Experimental|Group 3: TIV ID + TIV ID|licensed 2012/13 TIV ID at Day 0 and licensed 2013/14 TIV ID at Week 44±2 weeks
11453536|NCT01676402|Experimental|Group 4: TIV IM + TIV IM|2012/13 licensed TIV IM at Day 0 and licensed 2013/14 TIV IM at Week 44±2 weeks
11453537|NCT01676402|Experimental|Group 5: (HA DNA and TIV ID) + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV ID at Day 0 followed by licensed 2013/14 TIV ID at Week 44±2 weeks
11453538|NCT01676402|Experimental|Group 6: (HA DNA and TIV IM) + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV IM at Day 0 followed by licensed 2013/14 TIV IM at Week 44±2 weeks
11453539|NCT01676389|Experimental|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
11453540|NCT01676389|Placebo Comparator|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
11453541|NCT01676376|Active Comparator|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
11453542|NCT01676376|Sham Comparator|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
11453543|NCT01676376|Active Comparator|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
11453544|NCT01676363|Experimental|Diflunisal|
11453545|NCT01676350|No Intervention|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
11453546|NCT01676350|Experimental|'IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
11453547|NCT01676337|No Intervention|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
11453548|NCT01676337|Experimental|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
11453549|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
11453550|NCT01676311|Experimental|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
11453551|NCT01676311|Placebo Comparator|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
11453552|NCT01676285|Active Comparator|Metoprolol succinate|Metoprolol succinate
11453553|NCT01676285|Placebo Comparator|Placebo|Placebo
11453554|NCT01676285|No Intervention|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
11453555|NCT01676259|Active Comparator|Chemotherapy|Gemcitabine+nab-Paclitaxel
11453556|NCT01676259|Experimental|siG12D-LODER + chemotherapy|Eight siG12D-LODER+(Gemcitabine+nab-Paclitaxel)
11453557|NCT01676246|Active Comparator|flupirtine per os single dose|100 mg flupirtine per os, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
11453558|NCT01676246|Active Comparator|flupirtine intravenous|100 mg flupirtine intravenous, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
11453559|NCT01676246|Active Comparator|flupirtine per os steady state|400 mg flupirtine per os, pharmacokinetics of flupirtine, electric pain measurement
11453560|NCT01676233|Experimental|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
11453561|NCT01676233|Experimental|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
11453562|NCT01676220|Experimental|HOE901-U300|
11453563|NCT01676220|Active Comparator|Lantus|
11453564|NCT01676207||1|CAD
11453565|NCT01676207||2|no CAD
11453603|NCT01675960|Experimental|Gabapentin, then placebo|Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
11453566|NCT01676194|Experimental|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
11453567|NCT01676194|No Intervention|Control|Usual care
11453568|NCT01676181|Active Comparator|Adenotonsillectomy|Total removal of tonsils and adenoids with cold steel
11453569|NCT01676181|Active Comparator|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
11453570|NCT01676168||hypertrophic scar|1x1cm2 hypertrophic scar of post-burn patients are taked by visiting staff when they accept scar-reconstructive surgery.
11453571|NCT01676168||normal skin|When the patient accept skin grafting surgery, visiting staff will take 1x1cm2 normal skin.
11453572|NCT01676155||Patient with active tuberculosis|
11453573|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
11453574|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
11453575|NCT01676142||Patients with NTM pulmonary infection|
11453576|NCT01676142||Patients with other pathogen related lung infection|
11453577|NCT01676142||Patient with NTM pulmonary colonization|
11453578|NCT01676129|Experimental|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:
~The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)
~The intensity is set to induce C-fiber response during the stimulation
~The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)
~Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.
~Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
11453579|NCT01676129|Active Comparator|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.
~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.
~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
11453580|NCT01676116|Experimental|Insulin degludec/liraglutide + OADs|
11453581|NCT01676116|Active Comparator|Liraglutide or exenatide + OADs|
11453582|NCT01676103|Experimental|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
11453583|NCT01676103|Placebo Comparator|Sugar pill|Placebo sugar pills (2x daily) for 7 days
11453584|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
11453585|NCT01676064|Active Comparator|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
11453586|NCT01676064|Active Comparator|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.
~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
11453587|NCT01676051||Chloraprep|
11453588|NCT01676051||Duraprep|
11453589|NCT01676051||Betadine only|
11453590|NCT01676038|Active Comparator|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
11453591|NCT01676038|Active Comparator|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
11453592|NCT01676025|Experimental|PRA|Persons who get PRA surgery.
11453593|NCT01676025|Experimental|LA|Persons who get LA surgery.
11453594|NCT01676012||five types of bronchoscopy|"Bronchoscopy will be performed in a standardized order using five different imaging modes.
~Standard white light videobronchoscopy (WLB)
~High Definition -Bronchoscopy
~HD-bronchoscopy + surface enhancement (iScan-surface)
~HD-bronchoscopy + tone enhancement (iScan-tone)
~Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode"
11453595|NCT01675999|Experimental|1|"Perioperative simplified FOLFOX-4 chemotherapy
~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
11453596|NCT01675999|Experimental|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
11453597|NCT01675999|Other|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
11453598|NCT01675986|Experimental|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
11453599|NCT01675986|Experimental|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
11453600|NCT01675986|Placebo Comparator|Lactose|Groups placebo : 4 g de lactose
11453601|NCT01675973|Experimental|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
11453602|NCT01675973|Experimental|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
11453604|NCT01675960|Experimental|Placebo, then Gabapentin|Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.
11453605|NCT01675947|Experimental|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
11453606|NCT01675947|Sham Comparator|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
11453607|NCT01675934|Active Comparator|Adult colonoscope|Use of the adult colonoscope.
11453608|NCT01675934|Active Comparator|Pediatric colonoscope|Use of the pediatric colonoscope.
11453609|NCT01675921|No Intervention|Control|"Participants will continue to receive medical care from their doctor as usual.
~Participants will have access to this study website at the start and at the end of the study."
11453610|NCT01675921|Experimental|Facebook group|"Participants will continue to receive medical care from their doctor as usual.
~Participants will have access to the study website at all times throughout the study.
~Participants will have access to the secret study group on Facebook for 12 months.
~Participants will take the ACT survey once a month for 12 months."
11453611|NCT01675908|Active Comparator|Metal stent|Patients randomized to one cohort will undergo placement of fully covered self expandable metal stents. The rates (%) of stent dysfunction and complications will be evaluated.
11453612|NCT01675908|Active Comparator|Plastic Stent|At ERCP, a 10Fr plastic stent will be placed in the bile duct. The rates (%) of stent dysfunction and complications will be evaluated.
11453613|NCT01675895|Experimental|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
11453614|NCT01675895|Active Comparator|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
11453615|NCT01675882|Experimental|Viaskin Peanut 50 mcg|
11453616|NCT01675882|Experimental|Viaskin Peanut 100 mcg|
11453617|NCT01675882|Experimental|Viaskin Peanut 250 mcg|
11453618|NCT01675882|Placebo Comparator|Viaskin Placebo|
11453619|NCT01675869|Experimental|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
11453620|NCT01675869|Active Comparator|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
11453621|NCT01675856|Active Comparator|Urgent endoscopy|Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
11453622|NCT01675856|Placebo Comparator|Early endoscopy|Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
11453623|NCT01675843|Experimental|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
11453624|NCT01675843|No Intervention|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
11453625|NCT01675830|Experimental|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
11453626|NCT01675804|Experimental|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
11453627|NCT01675804|Placebo Comparator|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
11453628|NCT01675804|Experimental|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
11453629|NCT01675791|Placebo Comparator|ALK tree AIT Placebo|1 AIT administered sublingually every day
11453630|NCT01675791|Experimental|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
11453631|NCT01675791|Experimental|ALK tree AIT 1 DU|1 AIT administered sublingually every day
11453632|NCT01675791|Experimental|ALK tree AIT 2 DU|1 AIT administered sublingually every day
11453633|NCT01675791|Experimental|ALK tree AIT 4 DU|1 AIT administered sublingually every day
11453634|NCT01675791|Experimental|ALK tree AIT 7 DU|1 AIT administered sublingually every day
11453635|NCT01675791|Experimental|ALK tree AIT 12 DU|1 AIT administered sublingually every day
11453636|NCT01675778|Other|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
11453637|NCT01675765|Experimental|Immunotherapy plus chemotherapy|"Weeks 1 and 3: CRS-207 (1 × 10^9 CFU)
~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)
~Weeks 23 and 26: CRS-207
~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
11453638|NCT01675765|Experimental|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU)
~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)
~Weeks 23 and 26: cyclophosphamide one day before CRS-207
~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
11453639|NCT01675739|Active Comparator|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
11453640|NCT01675739|Experimental|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
11453641|NCT01675726|Other|quality of life|
11453642|NCT01675713|Experimental|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
11453643|NCT01675713|No Intervention|Controls|No treatment, waiting list
11453644|NCT01675700|Experimental|Myofascial trigger point|Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.
11453688|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
11453689|NCT01675440||2 or More Conditions|2 or more of the listed conditions
11453645|NCT01675687|Experimental|Internet|"Participants of this intervention group get follow up support via Internet.
~They have access to new inputs biweekly consisting of
~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)
~assignments promoting self-awareness and introspection
~spreadsheets promoting self-monitoring
~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.
~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
11453646|NCT01675687|Experimental|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.
~The manual consist of all the same inputs as are available to the Internet follow up group.
~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)
~assignments promoting self-awareness and introspection
~spreadsheets promoting self-monitoring
~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.
~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
11453647|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).
~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
11453648|NCT01675661|Active Comparator|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
11453649|NCT01675661|Placebo Comparator|Placebo plus CM|Placebo plus Contingency Management (CM)
11453650|NCT01675648|Experimental|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.
~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
11453651|NCT01675648|Active Comparator|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1&2, the dosage will be increased to 15 mg per day on Day 3&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6&7, 2mg per day on Day 8&9&10.
~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
11453652|NCT01675635|Experimental|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
11453653|NCT01675635|Active Comparator|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
11453654|NCT01675622|Experimental|Oxycodone Capsules for cancer pain|
11453655|NCT01675622|Active Comparator|Morphine tablets for cancer pain|
11453656|NCT01675609|Placebo Comparator|Placebo|
11453657|NCT01675609|Experimental|Brimonidine Tartrate 0.025%|
11453658|NCT01675596|Experimental|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
11453659|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
11453660|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
11453661|NCT01675570|Experimental|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
11453662|NCT01675570|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
11453663|NCT01675557|Active Comparator|Vitamin D2|a single oral dose of vitamin D2
11453664|NCT01675557|Placebo Comparator|Placebo|a single oral dose of a placebo
11453665|NCT01675557|Experimental|Vitamin D3|A single oral dose of vitamin D3
11453666|NCT01675544||Heart Failure Admission|Patients admitted for acute decompensated heart failure
11453667|NCT01675531|Experimental|Targin|Targin
11453668|NCT01675518|Experimental|Part-1 dose 1|
11453669|NCT01675518|Experimental|Part-1 dose 2|
11453670|NCT01675518|Experimental|Part-1 dose 3|
11453671|NCT01675518|Experimental|Part-1 dose 4|
11453672|NCT01675518|Experimental|Part-1 dose 5|
11453673|NCT01675518|Experimental|Part-1 dose 6|
11453674|NCT01675518|Placebo Comparator|Part-1 placebo|
11453675|NCT01675518|Experimental|Part-2 fed|
11453676|NCT01675518|Experimental|Part-2 fasted|
11453677|NCT01675505||Patients|"Inclusion criteria:
~Patients with first-diagnosed colon cancer. Age 18-60 y.o.
~Exclusion criteria:
~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
11453678|NCT01675492|Experimental|wave-front guided LASIK|
11453679|NCT01675479|Experimental|wavefront-guided LASIK|
11453680|NCT01675466|Active Comparator|early laparoscopy|early laparoscopy, aiming to achieve this within 12 hours
11453681|NCT01675466|Placebo Comparator|active observation|"standard management - the wait and see approach with serial examinations and investigations as deemed necessary"
11453682|NCT01675453|Active Comparator|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
11453683|NCT01675453|Placebo Comparator|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
11453684|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
11453685|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
11453686|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) <20 cc/min, but not on dialysis
11453687|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
11453690|NCT01675427|Experimental|Chronic hepatitis C patients|
11453691|NCT01675401|Experimental|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
11453692|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
11453693|NCT01675388|Experimental|Hypothermia|Hypothermia to 33.5 deg Centigrade
11453694|NCT01675375|Experimental|Eye shield|Eye shield place on post Laser Vision Correction eye
11453695|NCT01675362|Placebo Comparator|Control group|They will receive placebo
11453696|NCT01675362|Active Comparator|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
11453697|NCT01675362|Active Comparator|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
11453698|NCT01675362|Active Comparator|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
11453699|NCT01675349|Experimental|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
11453700|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
11453701|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
11453702|NCT01675310|Experimental|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
11453703|NCT01675310|Active Comparator|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
11453704|NCT01675297|Experimental|Risendronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
11453705|NCT01675297|Active Comparator|Risedronate|Sedron tablet: one tablet once a week for 12months
11453706|NCT01675284|Experimental|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
11453707|NCT01675284|Experimental|Middle Dosage AT-301|15 µg hemagglutinin (HA)
11453708|NCT01675284|Experimental|High Dosage AT-301|30 µg hemagglutinin (HA)
11453709|NCT01675271|Active Comparator|individual exercise|individualized exercise program
11453710|NCT01675271|Active Comparator|general exercise|general exercise program
11453711|NCT01675271|No Intervention|control|No exercise and dietary counselling
11453712|NCT01675258||Control|Healthy adults above the age of 18 years
11453713|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
11453714|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
11453715|NCT01675232|Active Comparator|Soak and smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
11453716|NCT01675232|Active Comparator|Dry smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
11453717|NCT01675219|Experimental|Group B|Blue light TUR-BT with no adjuvant instillations
11453718|NCT01675219|Active Comparator|Group A|White light TUR-BT with no adjuvant instillations
11453719|NCT01675219|Experimental|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
11453720|NCT01675219|Experimental|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
11453721|NCT01675206|Active Comparator|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
11453722|NCT01675206|Active Comparator|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
11453723|NCT01675206|Active Comparator|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
11453724|NCT01675193|No Intervention|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
11453725|NCT01675193|Other|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
11453726|NCT01675180|Other|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
11453727|NCT01675180|No Intervention|Control|
11453728|NCT01675167|Placebo Comparator|Placebo Buccal Film|Twice Daily Dosing
11453729|NCT01675167|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
11453730|NCT01675154|Placebo Comparator|SLx-4090 placebo/Orlistat Placebo|"Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.
~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals."
11453731|NCT01675154|Active Comparator|Orlistat/placebo|Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals.
11453732|NCT01675154|Active Comparator|Orlistat placebo /Slx-4090|Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals.
11453733|NCT01675154|Active Comparator|Orlistat/SLx-4090|Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals.
11453734|NCT01675141|Experimental|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
11453735|NCT01675128|Experimental|Phase I Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
11453736|NCT01675128|Experimental|Phase I Dose Level II|Irinotecan 180 mg/m^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
11453737|NCT01675128|Experimental|Phase II Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
11453738|NCT01675115|Active Comparator|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
11453739|NCT01675115|Sham Comparator|Aspirin|Aspirin 100mg QD for 4 weeks
11453740|NCT01675089|Experimental|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
11453741|NCT01675089|No Intervention|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
11453742|NCT01675076|Experimental|Continued NOAC|- Patients continue on their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout
11453743|NCT01675076|Active Comparator|Interrupted NOAC|"Interrupted Dabigatran:
~Discontinue Dabigatran 1 day before surgery if GFR > 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min
~Resume Dabigatran at next regular dose timing >or = 24 hours after the end of surgery
~Interrupted Rivaroxaban:
~Discontinue Rivaroxaban 1 full day before surgery
~Resume Rivaroxaban at next regular dose timing >or = 24 hours after the end of surgery
~Interrupted Apixaban:
~Discontinue Apixaban 1 full day before surgery
~Resume Apixaban at next regular dose timing >or = 24 hours after the end of surgery"
11453744|NCT01675063|Other|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
11453745|NCT01675050|Experimental|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
11453746|NCT01675050|Experimental|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
11453747|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
11453748|NCT01675024|Experimental|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
11453749|NCT01675024|Experimental|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
11453750|NCT01675011|Experimental|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
11453751|NCT01675011|Active Comparator|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
11453752|NCT01674985|Experimental|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
11453753|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
11453754|NCT01674972||Control|Matched healthy control subjects
11453755|NCT01674959|Experimental|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
11453756|NCT01674946|Placebo Comparator|ID saline|ID saline by feeding tube
11453757|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
11453758|NCT01674946|Active Comparator|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
11453759|NCT01674946|Active Comparator|ID saline + oleanolic acid (1 mmol/L)|
11453760|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L) + oleic acid|
11453761|NCT01674946|Placebo Comparator|ID saline + oleic acid (20 mmol/L)|
11453762|NCT01674933|Active Comparator|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
11453763|NCT01674933|Experimental|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
11453764|NCT01674920|Experimental|Choices|"The 3-month twelve-session intervention, Choices, included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience normal growth on study prior to intervention."
11453765|NCT01674907||Cohort|
11453766|NCT01674894||Group 1|Women treated with Menopur
11453767|NCT01674894||Group 2|Women treated with Menopur and Bravelle
11453768|NCT01674881|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
11453769|NCT01674881|Other|Waitlist control group|This group is a waitlist control group.
11453770|NCT01674868|Experimental|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
11453771|NCT01674868|Placebo Comparator|placebo|Subjects will take one pill daily for 90 days after stroke.
11453772|NCT01674855|Experimental|DA-3031|PEG-G-CSF
11453773|NCT01674855|Active Comparator|Leucostim®|G-CSF
11453774|NCT01674842|Experimental|Cisplatin + Radiation Therapy|Cisplatin concurrently with radiation therapy
11453775|NCT01674829|Experimental|Biological: MA09-hRPE Cellular therapy|"Biological: MA09-hRPE Cellular therapy
~Cohort 1 50,000 cells
~Cohort 2 100,000 cells
~Cohort 3 150,000 cells
~Cohort 4 200,000 cells"
11453776|NCT01674816|Active Comparator|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
11453777|NCT01674816|Active Comparator|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
11453778|NCT01674803|Active Comparator|Orsiro|
11453779|NCT01674803|Active Comparator|Synergy|
11453780|NCT01674803|Active Comparator|Resolute Integrity|
11453781|NCT01674790|Experimental|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
11453782|NCT01674790|Experimental|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
11453783|NCT01674790|Experimental|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
11453784|NCT01674790|Experimental|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
11453785|NCT01674777|Experimental|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
11453786|NCT01674777|Experimental|before meal group|Subjects will receive a single dose of ASP1941 before meal
11453787|NCT01674777|Experimental|after meal condition|Subjects will receive a single dose of ASP1941 after meal
11453788|NCT01674764||Early surgical intervention = Cohort 1|≤ 12 hours after the tSCI
11453789|NCT01674764||Late surgical intervention = Cohort 2|> 12 hours and < 14 days after the tSCI
11453790|NCT01674751|Experimental|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
11453791|NCT01674751|Other|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
11453792|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
11453793|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
11453794|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
11453795|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
11453796|NCT01674712|Experimental|Fenofibrate/simvastatin 145/20 mg|
11453797|NCT01674712|Active Comparator|Simvastatin 20 mg|
11453798|NCT01674712|Active Comparator|Fenofibrate 145 mg|
11453799|NCT01674712|Experimental|Fenofibrate/simvastatin 145/40 mg|
11453800|NCT01674712|Active Comparator|Simvastatin 40 mg|
11453801|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
11453802|NCT01674686|Experimental|A|Sarpogrelate versus placebo
11453803|NCT01674686|Experimental|B|Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL > 130 mg/dl
11453804|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
11453805|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
11453806|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 >5% dry weight,group2 <5% dry weight
11453807|NCT01674647|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
11453808|NCT01674647|Active Comparator|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
11453809|NCT01674634|Experimental|XIAFLEX / XIAPEX|AA4500 (collagenase clostridium histolyticum)
11453810|NCT01674621|Experimental|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
11453811|NCT01674621|Experimental|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
11453812|NCT01674621|Experimental|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
11453813|NCT01674621|Active Comparator|Abaloparatide Injection (80 mcg)|Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
11453814|NCT01674621|Placebo Comparator|Abaloparatide Transdermal Placebo (0 mcg)|Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months
11453815|NCT01674595|Experimental|Immunotherapy|AVANZ
11453816|NCT01674582|Other|MRI, Neuropsychological testing|
11453817|NCT01674569|Experimental|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
11453818|NCT01674569|Experimental|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
11453897|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
11453819|NCT01674569|Experimental|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
11453820|NCT01674569|Experimental|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
11453821|NCT01674569|Experimental|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
11453822|NCT01674569|Experimental|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
11453823|NCT01674556|Experimental|Contrast-enhanced ultrasound (CEUS)|
11453824|NCT01674543|Experimental|Resistance training|
11453825|NCT01674543|Experimental|Concurrent training|
11453826|NCT01674543|Sham Comparator|Control Group|
11453827|NCT01674530|Experimental|Lubiprostone|Manufactured by Dr Reddy's Laboratories Ltd( 24 mcg administered for 7 days )
11453828|NCT01674530|Active Comparator|AMITIZA®|Manufactured by Sucampo Pharmaceuticals(24 mcg administered for 7 days)
11453829|NCT01674530|Placebo Comparator|Placebo|Manufactured by Dr Reddy's Laboratories Ltd ( 24 mcg adminstered for 7 days )
11453830|NCT01674517|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
11453831|NCT01674517|Active Comparator|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp & Dohme Ltd., USA
11453832|NCT01674504|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
11453833|NCT01674504|Active Comparator|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp & Dohme Ltd., USA
11453834|NCT01674491|Experimental|4.5g/day black soy peptide|4.5 g/day, 8weeks
11453835|NCT01674491|Placebo Comparator|placebo|similar appearance to the black soy peptide tablet, 8 weeks
11453836|NCT01674478|Experimental|Microlipid with fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
11453837|NCT01674478|Active Comparator|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
11453838|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
11453839|NCT01674452|Experimental|home-based group|
11453840|NCT01674452|Active Comparator|supervised exercise group|
11453841|NCT01674452|No Intervention|control|Control group:no intervention
11453842|NCT01674439|Experimental|With supplementation of ADRC|Fat graft with supplementation of ADRC
11453843|NCT01674439|Active Comparator|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
11453844|NCT01674426|Experimental|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
11453845|NCT01674426|Placebo Comparator|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
11453846|NCT01674413|Placebo Comparator|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
11453847|NCT01674413|Active Comparator|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
11453848|NCT01674413|Active Comparator|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
11453849|NCT01674387|Experimental|acupuncture|30 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
11453850|NCT01674387|Other|comprehensive treatment|Other 30 patients (the matched group) receive the comprehensive treatment, including traction and low-frequency therapy. Each treatment 15 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
11453851|NCT01674374|Experimental|Arm I (SAMITAL)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
11453852|NCT01674374|Placebo Comparator|Arm II (placebo)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
11453853|NCT01674361|Experimental|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.
~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
11453854|NCT01674361|Experimental|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.
~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
11453855|NCT01674361|Placebo Comparator|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
11453856|NCT01674348|Active Comparator|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo
~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
11453857|NCT01674348|Placebo Comparator|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo
~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
11453898|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
11453933|NCT01673828|Placebo Comparator|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
11453934|NCT01673815|Experimental|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
11453858|NCT01674335|No Intervention|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
11453859|NCT01674335|Active Comparator|Operant Learning|
11453860|NCT01674335|Active Comparator|Energy Conservation|
11453861|NCT01674322|Experimental|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
11453862|NCT01674309|Other|single arm study/ non randomized trial|FOLFORINOX
11453863|NCT01674296||Group 1 (2012-2013)|Monitoring of Dietary Intake, Physical Activity and Stress
11453864|NCT01674296||Group 2 (2013-2014)|Monitoring of Dietary Intake, Physical Activity and Stress
11453865|NCT01674283|Experimental|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.
~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
11453866|NCT01674283|Placebo Comparator|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.
~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
11453867|NCT01674270|Experimental|Degarelix|Degarelix Alone
11453868|NCT01674270|Experimental|Degarelix + Casodex|Degarelix and Casodex
11453869|NCT01674270|Active Comparator|LHRH Agonist + Casodex|LHRH Agonist and Casodex
11453870|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
11453871|NCT01674244|Experimental|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
11453872|NCT01674244|Active Comparator|Monitor Only Waitlist|Monitor Only Waitlist
11453873|NCT01674231|Active Comparator|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
11453874|NCT01674231|Placebo Comparator|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
11453875|NCT01674218|Experimental|Treatment E|PA-824 400 mg plus moxifloxacin 400 mg
11453876|NCT01674218|Active Comparator|Treatment D|PA-824 placebo plus moxifloxacin 400 mg
11453877|NCT01674218|Experimental|Treatment C|PA-824 1000 mg plus moxifloxacin placebo
11453878|NCT01674218|Experimental|Treatment B|PA-824 400 mg plus moxifloxacin placebo
11453879|NCT01674218|Placebo Comparator|Treatment A|PA-824 placebo and moxifloxacin placebo
11453880|NCT01674205|Experimental|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
11453881|NCT01674205|Experimental|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
11453882|NCT01674205|Experimental|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
11453883|NCT01674205|Placebo Comparator|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
11453884|NCT01674192|Experimental|prucalopride|single dose of 2 mg prucalopride
11453885|NCT01674179||ACR diagnosis of Fibromyalgia|
11453886|NCT01674179||Patients without Fibromyalgia|
11453887|NCT01674166|Experimental|prucalopride|single dose 0.03 mg/kg prucalopride open label
11453888|NCT01674153|Experimental|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
11453889|NCT01674140|Placebo Comparator|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate*, goserelin acetate** or leuprolide acetate**, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
11453890|NCT01674140|Experimental|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
11453891|NCT01674127|Experimental|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
11453892|NCT01674127|Placebo Comparator|placebo|
11453893|NCT01674114|Experimental|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
11453894|NCT01674114|Active Comparator|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
11453895|NCT01674101|Experimental|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.
~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).
~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
11453896|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
11453899|NCT01674062|Experimental|Pertuzumab + Trastuzumab (Cohorts 1 and 2)|Females with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer will receive dual-agent treatment with pertuzumab and trastuzumab. Trastuzumab will be administered IV as 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, beginning on Day 2 of Cycle 1. Thereafter, both medications will be administered on Day 1 of each 3-week cycle. Treatment will continue for a minimum of 8 cycles and may be extended until disease progression, intolerable toxicity, or death.
11453900|NCT01674062|Experimental|Pertuzumab +/- Trastuzumab (Cohort 3)|Females with HER2-positive metastatic breast cancer will receive single-agent treatment with pertuzumab. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, administered on Day 1 of each 3-week cycle. Participants with documented disease progression may have trastuzumab added to the regimen, per the dosing schedule described for Cohorts 1 and 2, to receive dual-agent treatment until disease progression, intolerable toxicity, or death.
11453901|NCT01674049|Experimental|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
11453902|NCT01674049|Active Comparator|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
11453903|NCT01674036|Experimental|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
11453904|NCT01674036|Placebo Comparator|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
11453905|NCT01674036|Experimental|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
11453906|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR
~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
11453907|NCT01674010|Experimental|Lamotrigine or Valproic acid + ELND005|Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
11453908|NCT01674010|Placebo Comparator|Lamotrigine or Valproic acid + placebo|Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
11453909|NCT01673997|Experimental|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
11453910|NCT01673997|Active Comparator|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
11453911|NCT01673984|Experimental|Decapeptyl® SR 22.5mg (Triptorelin)|
11453912|NCT01673984|Active Comparator|Current 3-monthly LHRH agonist|One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
11453913|NCT01673971||Natural History|
11453914|NCT01673971||Treatment|
11453915|NCT01673958|Experimental|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
11453916|NCT01673958|Experimental|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
11453917|NCT01673945|Active Comparator|EUS-FNA with the CLA-EUS|patients examined with the CLA-EUS
11453918|NCT01673945|Experimental|EUS-FNA With the FV-EUS|patients examined with the FV-EUS
11453919|NCT01673932|Experimental|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
11453920|NCT01673932|Experimental|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
11453921|NCT01673919|Experimental|RoActemra/Actemra|
11453922|NCT01673906|Experimental|Diagnostic work up|The patients enrolled in the study (see below), with a consistent clinical suspicion of a primary duodenal-pancreatic NET.
11453923|NCT01673893||ST elevation myocardial infarction|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.
~1st Group/Cohort - ST elevation myocardial infarction"
11453924|NCT01673893||Non-ST elevation myocardial infarction/ACS/UNSTABLE ANGINA|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.
~2nd Group/Cohort - Non-ST elevation myocardial infarction/ACS/Unstable Angina"
11453925|NCT01673880|Other|E2006 2.5 mg|
11453926|NCT01673880|Other|E2006 10mg|
11453927|NCT01673880|Other|E2006 25 mg|
11453928|NCT01673867|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
11453929|NCT01673867|Active Comparator|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
11453930|NCT01673854|Experimental|Vemurafenib, 960 mg + Ipilimumab, 10 mg/kg|Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
11453931|NCT01673841||Relative + absolute cerebral oxygen saturation.|
11453932|NCT01673828|Experimental|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
11459484|NCT01634672||Peritoneal dialysis patients|
11453935|NCT01673815|Experimental|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
11453936|NCT01673815|Experimental|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
11453937|NCT01673815|Experimental|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
11453938|NCT01673802|Experimental|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
11453939|NCT01673789|Experimental|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
11453940|NCT01673776|No Intervention|K group|commonly used therapy
11453941|NCT01673776|Experimental|M group|multimodal intervention
11453942|NCT01673763|Active Comparator|Stent|Stent insertion into the main pancreatic duct
11453943|NCT01673763|No Intervention|No stent|No stent insertion into the main pancreatic duct
11453944|NCT01673750||Participants|Participants will have documented HIV infection and are aware of their diagnosis. They will complete a one-time questionnaire.
11453945|NCT01673737|Experimental|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
11453946|NCT01673737|Experimental|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
11453947|NCT01673724|Experimental|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
11453948|NCT01673724|Active Comparator|Bromocriptine|bromocriptine dosage form: white round tablet
11453949|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
11453950|NCT01673698|Active Comparator|ReShape Duo Balloon|ReShape Duo Balloon
11453951|NCT01673698|Sham Comparator|Sham Comparator|Sham Comparator
11453952|NCT01673685|Placebo Comparator|Portable Oxygen Cylinder|Portable Oxygen Cylinder
11453953|NCT01673685|Active Comparator|Portable Oxygen Concentrator|Portable Oxygen Concentrator
11453954|NCT01673672|Placebo Comparator|Placebo|7 weekly/biweekly injections of a placebo buffer
11453955|NCT01673672|Experimental|CYT003 low dose|7 weekly/biweekly injections of CYT003 low dose
11453956|NCT01673672|Experimental|CYT003 medium dose|7 weekly/biweekly injections of CYT003 medium dose
11453957|NCT01673672|Experimental|CYT003 high dose|7 weekly/biweekly injections of CYT003 high dose
11453958|NCT01673659|Experimental|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
11453959|NCT01673659|Active Comparator|Reference product|Nasonex Nasal Spray
11453960|NCT01673659|Placebo Comparator|Placebo Nasal Spray|vehicle of the test product
11453961|NCT01673646|Experimental|Pasireotide LAR 20mg|Enrolled patients were randomized to 20mg pasireotide LAR.
11453962|NCT01673646|Experimental|Pasireotide LAR 40mg|Enrolled patients were randomized to 40mg pasireotide LAR.
11453963|NCT01673646|Experimental|Pasireotide LAR 60mg|Enrolled patients were randomized to 60mg pasireotide LAR.
11453964|NCT01673633||SSc|Sacroiliitis
11453965|NCT01673633||Rheumatoid arthritis|Sacroiliitis
11453966|NCT01673633||Healthy controls|Sacroiliitis
11453967|NCT01673620|Experimental|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg combination tablet administered orally once daily for 2 weeks
11453968|NCT01673620|Placebo Comparator|Placebo|Matching placebo tablet administered orally once daily for 2 weeks
11453969|NCT01673594|Experimental|Naltrexone|Arm 1: Naltrexone + SODAS MPH
11453970|NCT01673594|Placebo Comparator|Placebo|Arm 2: Placebo + SODAS MPH
11453971|NCT01673581||Low risk prostate cancer|
11453972|NCT01673568|Active Comparator|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
11453973|NCT01673568|No Intervention|no abdominal binder|no abdominal binder
11453974|NCT01673555|Experimental|GSK1278863 5mg|GSK1278863 5mg
11453975|NCT01673555|Experimental|GSK1278863 100mg|GSK1278863 100mg
11453976|NCT01673555|Placebo Comparator|Placebo|Placebo
11453977|NCT01673542|Experimental|Lidocaine-Prilocaine 5%|
11453978|NCT01673542|Placebo Comparator|Dexeryl|
11453979|NCT01673529|Experimental|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
11453980|NCT01673516|Active Comparator|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
11453981|NCT01673516|Active Comparator|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
11454099|NCT01672710|Experimental|regimen of niacin, exercise, sauna,|4-5 week daily sauna, exercise and niacin with other supplements
11453982|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx flex|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
11453983|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx smile|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
11453984|NCT01673490|Experimental|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
11453985|NCT01673464||High School Athletes|
11453986|NCT01673451|Placebo Comparator|Placebo comparator|
11453987|NCT01673451|Experimental|E2006|
11453988|NCT01673438|Experimental|Aldoxorubicin plus doxorubicin|Aldoxorubicin dosages of 175, 240, and 320 (doxorubicin equivalents of 130, 180, and 240 mg/m2) will be administered as a 30 minutes IVI on Day 1 of each cycle. In addition 35 mg/m2 of doxorubicin HCl will be administered as an IVI over > 3 minutes no later than 3 hours, but no more than 6 hours before the start of aldoxorubicin infusion.
11453989|NCT01673425|Experimental|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
11453990|NCT01673412|Experimental|interventional arm|Psychological tests
11453991|NCT01673399|Active Comparator|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
11453992|NCT01673399|Placebo Comparator|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
11453993|NCT01673386|Experimental|Tivozanib Hydrochloride|1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
11453994|NCT01673386|Active Comparator|Sunitinib|50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
11453995|NCT01673373|Experimental|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
11453996|NCT01673360||Elevate PC|Subjects implanted with Elevate PC
11453997|NCT01673360||Mini Arc Pro|Subjects implanted with Mini Arc Pro
11453998|NCT01673360||RetroArc|Subjects implanted with RetroArc
11453999|NCT01673347|Experimental|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
11454000|NCT01673334|Experimental|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
11454001|NCT01673321|Experimental|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
11454002|NCT01673321|Experimental|Skim milk|Protein to carbohydrate ratio: 0.69
11454003|NCT01673321|Experimental|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
11454004|NCT01673321|Experimental|Orange juice|Protein to carbohydrate ratio: 0.07
11454005|NCT01673321|Experimental|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
11454006|NCT01673308|Experimental|Treatment arm|Lenalidomide treatment arm
11454007|NCT01673295|Experimental|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
11454008|NCT01673295|Active Comparator|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
11454009|NCT01673282||Vimpat + Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
11454010|NCT01673282||Vimpat + Non-Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
11454011|NCT01673269|Experimental|ERCP with direct examination of the CBD|
11454012|NCT01673256||SJM Confirm ICM Observational Group|
11454013|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
11454014|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
11454015|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
11454016|NCT01673230|Other|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
11454017|NCT01673217|Experimental|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11454018|NCT01673204|Experimental|Calcitriol|Calcitriol
11454019|NCT01673204|Placebo Comparator|Placebo|Placebo
11454020|NCT01673191|Experimental|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
11454021|NCT01673191|Active Comparator|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
11454022|NCT01673178|Placebo Comparator|Placebo Arm|
11454023|NCT01673178|Experimental|25 mg|
11454024|NCT01673178|Experimental|50 mg|
11454025|NCT01673178|Experimental|100 mg|
11454026|NCT01673178|Experimental|150 mg|
11454027|NCT01673165|Active Comparator|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
11454028|NCT01673165|Experimental|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
11454029|NCT01673152|Placebo Comparator|Maltodextrin|
11454030|NCT01673152|Experimental|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
11454031|NCT01673139|Experimental|Moderate exercise|Moderate exercise
11454032|NCT01673139|Experimental|Control|Control group
11454033|NCT01673139|Experimental|Interval exercise|interval exercise
11454034|NCT01673126|Active Comparator|Anodal tDCS|Patients received anodal tDCS (on DLPF cortex) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised)
11454035|NCT01673126|Sham Comparator|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
11454036|NCT01673113|Experimental|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
11454037|NCT01673113|No Intervention|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
11454038|NCT01673100|Experimental|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
11454039|NCT01673100|No Intervention|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
11454040|NCT01673087|Experimental|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:
~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
11454041|NCT01673061|Active Comparator|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
11454042|NCT01673061|Active Comparator|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
11454043|NCT01673048|Active Comparator|Femoral fracture, ESIN|"Prospectively all patients treated with the 3-nail-configuration for dislocated femoral shaft fractures were enrolled; 25 patients are planned, 18 could be enrolled Comparison will be with own previous data of patients treated with the classical 2-C-shaped ESIN-osteosynthesis"
11454044|NCT01673035|Experimental|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
11454045|NCT01673035|Active Comparator|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
11454046|NCT01673022|Experimental|IC Green Arm|One arm only: Receives IC Green for testing of study objective
11454047|NCT01673009|Experimental|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
11454048|NCT01672996|Experimental|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
11454049|NCT01672996|Experimental|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
11454050|NCT01672996|Active Comparator|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
11454051|NCT01672983|Experimental|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
11454052|NCT01672983|Experimental|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
11454053|NCT01672983|Experimental|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
11454054|NCT01672983|Experimental|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
11454055|NCT01672983|Experimental|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
11454056|NCT01672983|Experimental|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
11454057|NCT01672970||Cohort|
11454058|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
11454059|NCT01672944|Experimental|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
11454060|NCT01672944|Other|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
11454061|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
11454062|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
11454063|NCT01672892|Experimental|Intensity-Modulated Radiation Therapy|intensity-modulated radiation therapy (IMRT) to the pelvis of either 45 Gy or 50.4 Gy
11454064|NCT01672892|Active Comparator|Standard Radiation Therapy|Standard radiation therapy (4-field) to the pelvis of either 45 Gy or 50.4 Gy
11454065|NCT01672879|Experimental|SIM 200 mg|During the Randomized Double-Blind Phase, participants will receive SIM 200 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
11454100|NCT01672710|Other|waitlist|4 week waitlist with treatment as usual
11454212|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
11454066|NCT01672879|Experimental|SIM 700 mg|During the Randomized Double-Blind Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
11454067|NCT01672879|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM administered via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg administered via intravenous infusion every 2 weeks for up to an additional 240 weeks.
11454068|NCT01672866|Experimental|SIM 75 mg|During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
11454069|NCT01672866|Experimental|SIM 125 mg|During the Randomized Double-Blind Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
11454070|NCT01672866|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
11454071|NCT01672853|Experimental|Treatment Arm A|Simtuzumab 75 mg for 96 weeks
11454072|NCT01672853|Experimental|Treatment Arm B|Simtuzumab 125 mg for 96 weeks
11454073|NCT01672853|Placebo Comparator|Treatment Arm C|Placebo for 96 weeks
11454074|NCT01672840|Experimental|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
11454075|NCT01672840|Experimental|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
11454076|NCT01672827|Experimental|[18F]Flutemetamol|
11454077|NCT01672814|Active Comparator|Keraflex combined with Crosslinking|Vedera KXS microwave system used in conjunction with corneal collagen crosslinking performed with VibeX (Riboflavin ophthalmic solution)and the KXL UV System
11454078|NCT01672814|Active Comparator|Corneal collagen crosslinking alone|Corneal collagen crosslinking alone performed with VibeX (Riboflavin Ophthalmic Solution)and the KXL UV system
11454079|NCT01672801|Placebo Comparator|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
11454080|NCT01672801|Active Comparator|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
11454081|NCT01672788|Experimental|Test 1|fixed dose combination tablet
11454082|NCT01672788|Active Comparator|Reference 1|empagliflozin tablets and metformin tablet
11454083|NCT01672788|Experimental|Test 2|fixed dose combination tablet
11454084|NCT01672788|Active Comparator|Reference 2|empagliflozin tablet and metformin tablet
11454085|NCT01672775|Experimental|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
11454086|NCT01672775|Experimental|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
11454087|NCT01672775|Experimental|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
11454088|NCT01672775|Experimental|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
11454089|NCT01672775|Experimental|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
11454090|NCT01672775|Experimental|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
11454091|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
11454092|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
11454093|NCT01672762|Experimental|ASP1941 group|oral
11454094|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
11454095|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
11454096|NCT01672736|Experimental|ASP7487, Velcade, Dexamethasone|ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg
11454097|NCT01672723|Experimental|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.
~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
11454098|NCT01672723|Placebo Comparator|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.
~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
11454101|NCT01672697|Experimental|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)
~2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained
~Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered
~Follow-up Evaluation-8-week visit PT session #2
~Follow-up Evaluation-10-week visit PT session #3
~Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam
~Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
11454102|NCT01672697|No Intervention|Control Group|"Control Group:
~Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)
~Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail
~Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings
~Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
11454103|NCT01672684|Experimental|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
11454104|NCT01672684|Active Comparator|Arm II (control arm)|Participants receive an educational workbook journal.
11454105|NCT01672671|Experimental|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
11454106|NCT01672658|Experimental|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
11454107|NCT01672658|Active Comparator|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
11454108|NCT01672645|Experimental|PF-05402536|
11454109|NCT01672645|Experimental|PF-06413367|Intramuscular, multiple dose
11454110|NCT01672645|Placebo Comparator|Placebo|Intramuscular
11454111|NCT01672632|Experimental|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
11454112|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
11454113|NCT01672606|Experimental|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
11454114|NCT01672593|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
11454115|NCT01672593|Active Comparator|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
11454116|NCT01672580|Active Comparator|Random-Cloro|exposure to water chlorination
11454117|NCT01672580|Active Comparator|Random-Vitamin|exposure to vitamin use
11454118|NCT01672580|Experimental|Indegree-Cloro|high in-degree, exposure to water chlorination
11454119|NCT01672580|Experimental|Indegree-Vitamin|high in-degree, exposure to vitamin use
11454120|NCT01672580|Experimental|Nominated-Cloro|nominated by random, exposure to water chlorination
11454121|NCT01672580|Experimental|Nominated-Vitamin|nominated by random, exposure to vitamin use
11454122|NCT01672567|Experimental|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
11454123|NCT01672567|Experimental|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
11454124|NCT01672567|Experimental|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
11454125|NCT01672554|Other|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
11454126|NCT01672541|Experimental|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
11454127|NCT01672541|Active Comparator|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
11454128|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
11454129|NCT01672515|Experimental|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
11454130|NCT01672515|Sham Comparator|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
11454213|NCT01671878|Other|Reference Glucose|Glucose standard
11454214|NCT01671878|Experimental|Test Food 1|Cereal
11454131|NCT01672502|Experimental|Intervention|Firefighters in this group will receive at the beginning of the study an introduction to the study, sleep education, sleep disorder screening survey, health survey, increased sleep opportunities at their fire department, followed later by physiological monitoring of a portion of the firefighters, and then finally an 'end of year' survey at the end of the study.
11454132|NCT01672502|Active Comparator|Control|Firefighters in this group will only receive an introduction to the study and a health survey, followed later by physiological monitoring of a portion of the firefighters, and then at the end of the study will receive the sleep disorders screening survey, sleep education (Intervention group received screening survey and education much earlier at the beginning of the study), and an 'end of year' survey. None of these firefighters will receive the increased sleep opportunities as the Intervention group will.
11454133|NCT01672476|Placebo Comparator|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
11454134|NCT01672476|Active Comparator|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
11454135|NCT01672476|Experimental|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
11454136|NCT01672463|Experimental|All patients|All participants enrolled in this study
11454137|NCT01672450|Experimental|All patients|All participants in this study will receive the same treatment.
11454138|NCT01672437|Experimental|Birth and parent preparation|"The following subjects will be covered in the sessions:
~Session 1 (25 weeks gestation):
~Common challenges in the transition to parenthood and in the relationship
~Couple communication
~Session 2 (33 weeks gestation):
~Expectations in relation to birth
~The normal course of labour
~Obstetric intervention
~Pain relief,coping strategies
~Partner support
~Session 3 (35 weeks gestation):
~Feeding a newborn
~Interpreting the newborn's signs, symptoms and behaviour
~Taking care of a newborn
~Mood swings, postnatal depressive symptomatology
~Session 4 (5 weeks post-partum):
~Birth experiences
~Mood swings, postnatal depressive symptomatology
~The first time at home with a newborn
~Couplehood - partner support, communication, division of household tasks"
11454139|NCT01672437|No Intervention|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
11454140|NCT01672424||Group P: High Protein Drink|Patients receiving the high protein drink with 30 grams of protein in 11 fluid ounces.
11454141|NCT01672424||Group C: Ice Chips|The control group consisting patient receiving 11 ounces of ice chips
11454142|NCT01672398|Experimental|Intervention Group|Telemonitoring plus self-management support
11454143|NCT01672398|No Intervention|Usual Care Group|Usual Care
11454144|NCT01672385|Experimental|Intervention Group|Telemonitoring plus self-management support
11454145|NCT01672385|No Intervention|Usual Care Group|Usual Care
11454146|NCT01672372|Placebo Comparator|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
11454147|NCT01672372|Experimental|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
11454148|NCT01672359|Experimental|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
11454149|NCT01672359|Experimental|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
11454150|NCT01672359|Placebo Comparator|Placebo|cellulose pills to simulate actual products
11454151|NCT01672346|Active Comparator|Arm I|PVAI with ablation of posterior wall contained within pulmonary veins using energy up to 30 watts and post-ablation adenosine challenge
11454152|NCT01672346|Active Comparator|Arm II|AF ablationPVAI with ablation of posterior wall contained within pulmonary veins using energy up to 40 watts and post-ablation adenosine challenge
11454153|NCT01672333|Experimental|Pathological Response|
11454154|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
11454155|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
11454156|NCT01672307|Experimental|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
11454157|NCT01672307|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
11454158|NCT01672294|Experimental|treatment|three facilitator-led end-of-life preparation and completion sessions with a facilitator with both patient and caregiver
11454159|NCT01672294|Active Comparator|attention control|three facilitator led sessions of listening to a relaxation CD.
11454160|NCT01672281|Experimental|vibrox training|
11454161|NCT01672281|Experimental|resistance training|
11454162|NCT01672268|Active Comparator|Standard TAVI procedure|Patients without Cardiac CT measures before TAVI
11454163|NCT01672268|Experimental|Cardiac CT scan before TAVI procedure|patients with cardiac CT measures before TAVI
11454164|NCT01672255|Active Comparator|Trial 1-SSRI|90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.
11454165|NCT01672255|Placebo Comparator|Trial 2-Placebo|90 minute exercise at baseline with 6 weeks treatment with placebo. Repeat 90 minute exercise after 6 weeks treatment of placebo.
11454166|NCT01672242|Experimental|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
11454167|NCT01672242|Experimental|CPAP|Continuous Positive Airway Pressure (CPAP)
11454168|NCT01672229|Experimental|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
11454211|NCT01671904|Experimental|R/R CLL BR+V|Participants with relapsed/refractory (R/R) CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with R/R CLL continued single-agent venetoclax until disease progression, death, or unacceptable toxicity.
11454169|NCT01672216|Experimental|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
11454170|NCT01672216|Active Comparator|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
11454171|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
11454172|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
11454173|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
11454174|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
11454175|NCT01672190|Experimental|Yoga Therapy|Women in the Yoga Therapy Group will receive twice weekly yoga classes for 6 weeks.
11454176|NCT01672190|No Intervention|Control|Women in the Control Group will wait 6 weeks before receiving a gift certificate for yoga classes at an external yoga studio in the San Francisco Bay Area
11454177|NCT01672177|No Intervention|Control|Individuals in the control group will not receive any training.
11454178|NCT01672177|Experimental|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
11454179|NCT01672164||Liver Transplant Recipients|
11454180|NCT01672138|Active Comparator|Control|Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall
11454181|NCT01672138|Active Comparator|Study I|PVAI+ scar homogenization
11454182|NCT01672138|Active Comparator|Study II|PVAI + isolation of left atrial posterior wall + non-PV triggers ablation
11454183|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
11454184|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
11454185|NCT01672125||healthy women|healthy women adjusted in age and BMI
11454186|NCT01672112|Other|Codeine|Oral Codeine 60mg 6hrly/prn
11454187|NCT01672112|Active Comparator|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
11454188|NCT01672099|Active Comparator|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
11454189|NCT01672099|Placebo Comparator|Basic dairy|2 basic yoghurt products
11454190|NCT01672086||Stelkast Surpass Patients|
11454191|NCT01672060|Experimental|Nurse-Family Partnership (NFP)|
11454192|NCT01672060|Active Comparator|Existing services|
11454193|NCT01672047|Experimental|Treament|Intervention Vitamin D2
11454194|NCT01672047|No Intervention|Control|Not take Vitamin D2
11454195|NCT01672034||Obese, BMI > 35|
11454196|NCT01672021|Other|PET/MRI|PET/MRI
11454197|NCT01672008|Experimental|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.
~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
11454198|NCT01672008|Experimental|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.
~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
11454199|NCT01671995|Experimental|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
11454200|NCT01671995|Active Comparator|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
11454201|NCT01671982|Experimental|Tenofovir-containing HAART|
11454202|NCT01671969|Experimental|very low calorie diet|
11454203|NCT01671956|Experimental|Bertilimumab|Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes
11454204|NCT01671956|Placebo Comparator|Placebo|Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.
11454205|NCT01671943|Experimental|Breast carcinoma up to 2.0 cm|
11454206|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
11454207|NCT01671917|Experimental|Educational and exercise program|
11454208|NCT01671917|Active Comparator|Usual care|
11454209|NCT01671904|Experimental|1L CLL BR+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
11454210|NCT01671904|Experimental|1L CLL BG+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
11454216|NCT01671852|Active Comparator|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
11454217|NCT01671852|Placebo Comparator|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
11454218|NCT01671839|Experimental|Subcutaneous tissue release|Device: Subcutaneous tissue release with the Cabochon System
11454219|NCT01671826||above 65 years old|
11454220|NCT01671813|Experimental|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
11454221|NCT01671800|Experimental|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
11454222|NCT01671800|Placebo Comparator|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
11454223|NCT01671787|Experimental|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
11454224|NCT01671787|Experimental|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
11454225|NCT01671787|Experimental|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
11454226|NCT01671787|Experimental|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
11454227|NCT01671787|Experimental|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
11454228|NCT01671774|Experimental|IMAB362 + ZA|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
11454229|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (1 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
11454230|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (3 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
11454231|NCT01671774|Active Comparator|IMAB362|Participants received IMAB362 only on Day 1 of each cycle every 3 weeks.
11454232|NCT01671761||young adults|19-24 years old
11454233|NCT01671761||adolescents|15-18 years old
11454234|NCT01671748|Active Comparator|Standard Care|Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
11454235|NCT01671748|Experimental|MIST and Standard Care|MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
11454236|NCT01671735|Experimental|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
11454237|NCT01671735|No Intervention|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
11454238|NCT01671722|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
11454239|NCT01671722|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
11454240|NCT01671709|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
11454241|NCT01671709|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
11454242|NCT01671670|Experimental|acupuncture group|use traditional acupuncture to treat functional dyspepsia
11454243|NCT01671670|Sham Comparator|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
11454244|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
11454245|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
11454246|NCT01671644||Eeva Test Group|Day 3 embryo transfers that used Eeva predictions with morphology grading.
11454247|NCT01671644||Matched case control group|Day 3 embryo transfers using morphology grading only (from a matched concurrent control group).
11454248|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
11454249|NCT01671605||CKD not on dialysis|Patients with CKD not on dialysis (CKD III-IV)
11454250|NCT01671605||Controls|Controls with normal kidney function (Control)
11454251|NCT01671592|Experimental|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
11454252|NCT01671592|Experimental|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
11454253|NCT01671592|Experimental|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
11454324|NCT01671072|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells
11454254|NCT01671592|Experimental|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
11454255|NCT01671579|Other|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
11454256|NCT01671566|Experimental|Home based interval training|12 weeks home based interval training
11454257|NCT01671566|No Intervention|Control group|No structured exercise training.
11454258|NCT01671553|Experimental|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
11454259|NCT01671553|No Intervention|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
11454260|NCT01671540|Experimental|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
11454261|NCT01671540|Active Comparator|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
11454262|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
11454263|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
11454264|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
11454265|NCT01671514|Experimental|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
11454266|NCT01671514|Experimental|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
11454267|NCT01671501|Experimental|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
11454268|NCT01671501|Experimental|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
11454269|NCT01671501|Other|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
11454270|NCT01671488|Experimental|Treatment|"The first dose will be given 10-14 days prior to the initiation of chemoradiation.
~Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days and Mitomycin: 10 mg/m2, day 1 and 29 with IMRT radiation: 54 Gy in 30 fractions at 1.8 Gy per fraction.
~The 2-4th dosages of ADXS11-001 will not be until after completion of all chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of 10 days after completion of chemoradiation. The subsequent third and fourth treatment with of ADXS11 will be administered at 28 day intervals."
11454271|NCT01671475|Experimental|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
11454272|NCT01671475|No Intervention|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
11454273|NCT01671449|Active Comparator|S-1 plus Cisplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)
~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.
~Cisplatin: 60 mg/ m2/day, i.v., day 1
~Every 3 weeks"
11454274|NCT01671449|Experimental|S-1 plus Oxaliplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)
~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.
~Oxaliplatin: 130 mg/ m2/day, i.v., day 1
~Every 3 weeks"
11454275|NCT01671436|Experimental|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
11454276|NCT01671423|Active Comparator|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
11454277|NCT01671423|Placebo Comparator|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
11454322|NCT01671085|Experimental|1.0 milligrams per kilogram (mg/kg) of LY3015014|1.0 mg/kg of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
11454278|NCT01671410|Experimental|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
11454279|NCT01671410|Active Comparator|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
11454280|NCT01671397|Experimental|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
11454281|NCT01671397|Active Comparator|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
11454282|NCT01671384|Active Comparator|Valproate, levocarnitine|"The patients will be randomized into two groups:
~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
11454283|NCT01671384|Placebo Comparator|Placebo|"All patients will be randomized into two groups:
~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
11454284|NCT01671371|Other|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
11454285|NCT01671371|Other|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
11454286|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
11454287|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
11454288|NCT01671345|Active Comparator|Intervention|Patients randomized to the intervention will view the intervention video
11454289|NCT01671345|Placebo Comparator|Control|Patients randomized to control will view an informative video about nutrition and exercise of similar length
11454290|NCT01671332|Active Comparator|Docetaxel|
11454291|NCT01671332|Experimental|Docetaxel plus Suramin|
11454292|NCT01671319|Experimental|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
11454293|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
11454294|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
11454295|NCT01671293|Experimental|Multicomponent remote care model|A remote intervention based on counseling (telephone-based).
11454296|NCT01671293|Active Comparator|Usual care|Usual care.
11454297|NCT01671280||Azithromycin IV|Subjects who are treated with Azithromycin IV
11454298|NCT01671267|Experimental|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
11454299|NCT01671267|Active Comparator|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
11454300|NCT01671254|Active Comparator|FishOil + placebo|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule
11454301|NCT01671254|Experimental|FishOil + CBE75|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)
11454302|NCT01671254|Experimental|FishOil + CBE150|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)
11454303|NCT01671241|Experimental|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
11454304|NCT01671241|Active Comparator|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
11454305|NCT01671228|Experimental|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
11454306|NCT01671228|Experimental|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
11454307|NCT01671228|Experimental|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
11454308|NCT01671228|No Intervention|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
11454309|NCT01671189|Experimental|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
11454310|NCT01671189|No Intervention|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
11454311|NCT01671176|Other|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
11454312|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
11454313|NCT01671150|Placebo Comparator|Placebo control|half of the participants will receive a placebo control
11454314|NCT01671150|Active Comparator|Endotoxin (Inflammatory challenge)|
11454315|NCT01671137|Active Comparator|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
11454316|NCT01671137|Placebo Comparator|Placebo|Placebo
11454317|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
11454318|NCT01671111|Experimental|SSP-004814AQ|
11454319|NCT01671098||Control|Healthy adults
11454320|NCT01671098||Balloon Sinuplasty|Patients who had balloon sinuplasty
11454321|NCT01671098||FESS-Uncinectomy|Patients who had FESS-Uncinectomy
11454323|NCT01671085|Placebo Comparator|Placebo|0.9% sodium chloride injection given SQ (to match LY3015014) on 2 dosing occasions Q4W (Days 1 and 29).
11454325|NCT01671072|Placebo Comparator|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
11454326|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
11454327|NCT01671046||Cohort|
11454328|NCT01671033|Experimental|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
11454329|NCT01671033|Experimental|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
11454330|NCT01671033|No Intervention|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
11454331|NCT01671020|Active Comparator|(R)(T)|Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg
11454332|NCT01671020|Active Comparator|(T)(R)|Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg
11454333|NCT01670994|Experimental|ALT-801|
11454334|NCT01670981|Experimental|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
11454335|NCT01670981|Placebo Comparator|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
11454336|NCT01670955|Active Comparator|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
11454337|NCT01670955|Active Comparator|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
11454338|NCT01670942||Traumatic Pneumothorax1|hypobaric chamber
11454339|NCT01670929|Active Comparator|Progesterone group|progesterone (400 mg pessary, once daily)
11454340|NCT01670929|Placebo Comparator|Placebo group|Placebo (pessary, once daily)
11454341|NCT01670916||Probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
11454342|NCT01670916||Control|Probiotics never given
11454343|NCT01670903||ARBs|Hypertensive patients treated with ARBs
11454344|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
11454345|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
11454346|NCT01670890|Active Comparator|TMZ group|patients were treated with TMZ alone
11454347|NCT01670890|Experimental|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
11454348|NCT01670877|Experimental|Part I: met HER2- BC w/HER2 mutations|"Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
11454349|NCT01670877|Experimental|Part II: met HER2- ER- BC w/HER2 mutations|"Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
11454350|NCT01670877|Experimental|Part II: met HER2- ER+ BC w/HER2 mutations, fulvestrant-naive|"Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
11454351|NCT01670877|Experimental|Part II: met HER2- ER+ BC w/HER2 mutations, fulvestrant-tx|"Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
11454352|NCT01670864|Experimental|Counseling group|Study participants in the counseling group will receive a brief on-site face-to-face smoking cessation counseling from our trained smoking cessation counselor on the study site after signing the consent form. They will receive advice on quitting smoking and specific warning about the hazardous effects of smoking on health. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
11454353|NCT01670864|Experimental|SMS intervention group|Study participants in the SMS group will receive SMS text messages on smoking cessation advice and warning on the hazardous effects of smoking on health. The participants will receive a total of 16 tailored SMS messages after recruitment.
11454354|NCT01670864|No Intervention|Control group|Study participants in the control group will not receive any quitting assistance other than the self-help materials from the recruitment sites.
11454355|NCT01670851||Strattice|eLAPE
11454356|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
11454357|NCT01670825|Experimental|Pulsed radiofrequency + local anesthetic injection|Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
11454358|NCT01670825|Active Comparator|Corticosteroid injection + sham pulsed radiofrequency|"Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency"
11454359|NCT01670812|Experimental|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
11454360|NCT01670799|Experimental|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.
~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
11454361|NCT01670786|Experimental|Iodopovidone 1%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
11454362|NCT01670786|Experimental|Iodopovidone 2%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
11454363|NCT01670773|Experimental|CAT-1004 Dose #1|Single dose #1
11454364|NCT01670773|Active Comparator|Salsalate + DHA|Single dose #2
11454365|NCT01670773|Placebo Comparator|Placebo|Single Dose #3
11454366|NCT01670760|Experimental|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
11454367|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
11454368|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
11454369|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
11454370|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
11454371|NCT01670721|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
11454372|NCT01670708|Experimental|HOPE|Participation in HOPE program
11454373|NCT01670708|Active Comparator|Probation as Usual|Participation in probation as usual
11454374|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
11454375|NCT01670682|Active Comparator|fascia fixation group|procedure: ischia spinous fascia fixation
11454376|NCT01670682|Active Comparator|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
11454377|NCT01670669|Active Comparator|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
11454378|NCT01670656|Experimental|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11454379|NCT01670656|Experimental|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11454380|NCT01670656|Experimental|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11454381|NCT01670656|Experimental|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11454382|NCT01670656|Placebo Comparator|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
11454383|NCT01670643||Video camera magnifier|
11454384|NCT01670630|Active Comparator|Sheathed speculum|"Investigators will perform a vaginal speculum examination with either a sheathed or a standard (non sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception."
11454385|NCT01670630|Active Comparator|Standard speculum examination|Investigators will perform a vaginal speculum examination with either a standard or a sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception.
11454386|NCT01670617|Other|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
11454387|NCT01670604|Experimental|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
11454388|NCT01670604|Experimental|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
11454389|NCT01670591|Experimental|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
11454390|NCT01670591|No Intervention|Business as usual|
11454391|NCT01670578|Experimental|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
11454392|NCT01670578|Active Comparator|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
11454664|NCT01668797|Placebo Comparator|Placebo|Placebo comparator for 52 weeks
11454393|NCT01670565|Experimental|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
11454394|NCT01670565|Placebo Comparator|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
11454395|NCT01670552|Experimental|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
11454396|NCT01670552|Active Comparator|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
11454397|NCT01670539|Experimental|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
11454398|NCT01670539|No Intervention|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
11454399|NCT01670526|Experimental|Rivastigmine|Rivastigmine transdermal patch
11454400|NCT01670526|Placebo Comparator|Placebo|Placebo
11454401|NCT01670513|Experimental|IDP-118 Low Strength|IDP-118 Low Strength
11454402|NCT01670513|Experimental|IDP-118 High Strength|IDP-118 High Strength
11454403|NCT01670500|Active Comparator|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
11454404|NCT01670500|Active Comparator|Cisplatin|Cisplatin q 3 wk x 4
11454405|NCT01670487|Active Comparator|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
11454406|NCT01670487|Placebo Comparator|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
11454407|NCT01670474|Experimental|fmDLC and rt-PA (2mg/2mL actilysis)|"Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.
~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
11454408|NCT01670474|Active Comparator|polyDLC and rt-PA (2mg/2mL actilysis)|"The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.
~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
11454409|NCT01670474|Active Comparator|siDLC and rt-PA (2mg/2mL actilysis)|"Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.
~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
11454410|NCT01670461|Experimental|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
11454411|NCT01670461|Other|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
11454412|NCT01670448|Active Comparator|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
11454413|NCT01670448|Placebo Comparator|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
11454414|NCT01670435||Group 1|
11454415|NCT01670409|Experimental|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
11454416|NCT01670396||in-stent restenosis|
11454417|NCT01670396||non-in-stent restenosis|
11454418|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
11454419|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
11454420|NCT01670370|Experimental|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
11454421|NCT01670357|Experimental|DA-6034 Low dose|DA-6034 3%
11454422|NCT01670357|Experimental|DA-6034 High dose|DA-6034 5%
11454423|NCT01670357|Placebo Comparator|Placebo|DA-6034 Placebo
11454424|NCT01670344|Other|A|Treatment with investigational method (virtual implant positioning system)
11454425|NCT01670344|Other|B|Treatment with surgical standard of care
11454426|NCT01670331|Active Comparator|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
11454665|NCT01668797|Experimental|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
11454427|NCT01670331|No Intervention|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
11454428|NCT01670318|Experimental|platinum chromium everolimus-eluting stent|
11454429|NCT01670305|Experimental|Residual pocket - PDT|Photosensitizer plus diiodo laser
11454430|NCT01670305|Placebo Comparator|Residual pocket - Photosensitizer|Photosensitizer alone
11454431|NCT01670305|Active Comparator|Residual pocket - SRP|scaling and root planing alone
11454432|NCT01670305|Experimental|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
11454433|NCT01670305|Active Comparator|Furcation - SRP|Photosensitizer associated with scaling and root planing
11454434|NCT01670292|Other|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
11454435|NCT01670279|Experimental|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
11454436|NCT01670279|Experimental|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
11454437|NCT01670279|Experimental|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
11454438|NCT01670279|Placebo Comparator|Placebo|Placebo
11454439|NCT01670266|Experimental|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
11454440|NCT01670266|Experimental|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
11454441|NCT01670266|Experimental|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
11454442|NCT01670266|Experimental|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 µg/mL]to be determined and placebo
11454443|NCT01670266|Placebo Comparator|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
11454444|NCT01670253|No Intervention|Group 2|6 hours of total fast for all solid and liquid food / drinks
11454445|NCT01670253|Experimental|Group 1|"6 hour fast from all solid foods and milk beverages
~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)
~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
11454446|NCT01670240|Active Comparator|Adalimumab|Every second week, mg: 160-80-40-40-40-40 12 weeks in all
11454447|NCT01670240|Placebo Comparator|Placebo|Given as the active comparator, every second week
11454448|NCT01670227|Experimental|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
11454449|NCT01670227|Other|Control Condition|No intervention
11454450|NCT01670214|Active Comparator|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
11454451|NCT01670214|Placebo Comparator|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
11454452|NCT01670201|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
11454453|NCT01670188|Active Comparator|Pneumatic SCD|Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
11454454|NCT01670188|No Intervention|Non-SCD group|Standard care
11454455|NCT01670175|Experimental|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
11454456|NCT01670162|Experimental|3 loading doses, then every 2 months|All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
11454457|NCT01670149|Placebo Comparator|Placebo|Identical looking tablet
11454458|NCT01670149|Active Comparator|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
11454459|NCT01670136|No Intervention|sildenafil, standard of care|Infants receiving sildenafil as standard of care
11454460|NCT01670136|Other|sildenafil administered for study|1 dose of sildenafil administered for study
11454461|NCT01670123|Experimental|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
11454462|NCT01670123|Placebo Comparator|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
11454463|NCT01670110|Active Comparator|Pasireotide LAR (SOM230)|Active Pasireotide LAR
11454464|NCT01670110|Placebo Comparator|placebo injection|
11454465|NCT01670097|Experimental|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
11454510|NCT01669785|Experimental|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride
~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.
~Leave in contact for 60 seconds, rinse with water and expectorate."
11454511|NCT01669772|Other|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
11454466|NCT01670097|Placebo Comparator|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
11454467|NCT01670084|Experimental|Treatment (nilotinib, combination chemotherapy)|See Detailed Description
11454468|NCT01670071|Experimental|Paliperidone extended-release|
11454469|NCT01670071|Active Comparator|Risperidone immediate-release|
11454470|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
11454471|NCT01670058||CNIs at transplantation|
11454472|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
11454473|NCT01670032|Experimental|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
11454474|NCT01670032|Experimental|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
11454475|NCT01670032|Placebo Comparator|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
11454476|NCT01670032|Placebo Comparator|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
11454477|NCT01670019|Experimental|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
11454478|NCT01670019|Placebo Comparator|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
11454479|NCT01669980|Experimental|Ceftaroline fosamil|
11454480|NCT01669980|Active Comparator|IV Ceftriaxone and Vancomycin|
11454481|NCT01669967|Placebo Comparator|Diphenhydramine(Benadryl)|
11454482|NCT01669967|Active Comparator|Lidocaine|
11454483|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
11454484|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
11454485|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
11454486|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
11454487|NCT01669941|Experimental|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
11454488|NCT01669941|Experimental|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
11454489|NCT01669941|Active Comparator|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
11454490|NCT01669928|Active Comparator|Group B|Anti hypertensive medication in the evening (between 18.00 and 23.00)
11454491|NCT01669928|Active Comparator|Group A|Antihypertensive medication in the morning(between 06.00 and 11.00)
11454492|NCT01669915|Active Comparator|Vitamin D + fish oil|
11454493|NCT01669915|Active Comparator|Vitamin D + fish oil placebo|
11454494|NCT01669915|Active Comparator|Vitamin D placebo + fish oil|
11454495|NCT01669915|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11454496|NCT01669902||Cohort|
11454497|NCT01669889||Cohort|
11454498|NCT01669876|Active Comparator|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
11454499|NCT01669876|Placebo Comparator|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
11454500|NCT01669863|Experimental|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
11454501|NCT01669850|Experimental|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
11454502|NCT01669850|Active Comparator|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
11454503|NCT01669837||Patient group|Administration of surgical tissue glue.
11454504|NCT01669824||Group 1|
11454505|NCT01669811|Experimental|D961H 20mg twice daily|Double-blinded
11454506|NCT01669811|Active Comparator|D961H 20mg once daily|Double-blinded
11454507|NCT01669798|Experimental|BIBF 1120|BIBF 1120 will be administered at a daily oral dose of 200 mg BID until disease progression or adverse effects prohibit further therapy.
11454508|NCT01669785|Active Comparator|Group C|"NUPRO Classic Prophy Paste
~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..
~Leave in contact for 60 seconds, rinse with water and expectorate."
11454509|NCT01669785|Experimental|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin
~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.
~Leave in contact for 60 seconds, rinse with water and expectorate"
11454512|NCT01669772|Other|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
11454513|NCT01669759||fatigue|
11454514|NCT01669746|Experimental|Treatment|
11454515|NCT01669733|Experimental|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
11454516|NCT01669733|Experimental|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
11454517|NCT01669733|Active Comparator|No Music (Standard of care)|The control group will receive standard of care and no music.
11454518|NCT01669720|Experimental|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
11454519|NCT01669720|No Intervention|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
11454520|NCT01669707|Experimental|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
11454521|NCT01669707|Active Comparator|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
11454522|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
11454523|NCT01669681||Included in the cohort COBRA|
11454524|NCT01669668|Experimental|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
11454525|NCT01669642|Experimental|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
11454526|NCT01669629|Experimental|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
11454527|NCT01669629|Experimental|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
11454528|NCT01669603|Experimental|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
11454529|NCT01669603|Placebo Comparator|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
11454530|NCT01669590||old (60-75yr)|
11454531|NCT01669590||young (18-35y)|
11454532|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
11454533|NCT01669564|Active Comparator|Activated Patients|Will use HIT patient feedback to activate patients.
11454534|NCT01669564|Other|Control patients|Patients will not receive HIT patient feedback.
11454535|NCT01669564|Other|Intervention Physicians|Will use HIT patient feedback to activate patients.
11454536|NCT01669564|Other|Control Physicians|Patients will not receive HIT patient feedback.
11454537|NCT01669551||Structural or Valvular Heart Disease|
11454538|NCT01669538|Experimental|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.
~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
11454539|NCT01669538|Placebo Comparator|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.
~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
11454540|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
11454541|NCT01669512|Active Comparator|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
11454542|NCT01669512|Experimental|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
11454543|NCT01669512|Experimental|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
11454544|NCT01669499|Placebo Comparator|Placebo|Placebo on day 0-3
11454545|NCT01669499|Active Comparator|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
11454546|NCT01669499|Active Comparator|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
11454547|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
11454548|NCT01669473|Experimental|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use
~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
11454549|NCT01669473|No Intervention|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
11454550|NCT01669460|Experimental|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
11454588|NCT01669200|Placebo Comparator|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
11454589|NCT01669200|Experimental|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
11454590|NCT01669187|Active Comparator|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
11454551|NCT01669447|Experimental|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.
~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.
~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
11454552|NCT01669434|Experimental|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
11454553|NCT01669434|Experimental|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
11454554|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose baseline|Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
11454555|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) Double dose|Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
11454556|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose|4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
11454557|NCT01669408|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
11454558|NCT01669408|No Intervention|Control group|Best medical treatment following international stroke guidelines
11454559|NCT01669395|Experimental|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
11454560|NCT01669395|Experimental|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
11454561|NCT01669382|Active Comparator|Exo Seal system|Percutaneous coronary intervention
11454562|NCT01669382|Active Comparator|AngioSeal system|percutaneous coronary intervention
11454563|NCT01669369|Placebo Comparator|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
11454564|NCT01669369|Experimental|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
11454565|NCT01669356|Experimental|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
11454566|NCT01669356|Active Comparator|EN alone|Enteral nutrition alone for patients after esophagectomy
11454567|NCT01669343|Active Comparator|Part A letrozole 2.5 mg|letrozole 2.5 mg tablet,once daily for 28 days
11454568|NCT01669343|Experimental|Part B letrozole 5.0 mg|letrozole 2.5 mg tablet, two tablets,once daily for 28 days
11454569|NCT01669330|Active Comparator|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
11454570|NCT01669330|Active Comparator|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
11454571|NCT01669317|Experimental|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
11454572|NCT01669317|Placebo Comparator|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
11454573|NCT01669304|Experimental|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
11454574|NCT01669304|Experimental|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
11454575|NCT01669291|Active Comparator|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
11454576|NCT01669291|Active Comparator|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
11454577|NCT01669278|No Intervention|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
11454578|NCT01669278|Active Comparator|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
11454579|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
11454580|NCT01669252|Experimental|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
11454581|NCT01669239|Experimental|Liposomal Doxorubicin|"Six cycles of:
~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks
~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks
~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks
~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
11454582|NCT01669226|Experimental|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
11454583|NCT01669226|Active Comparator|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
11454584|NCT01669213|Active Comparator|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
11454585|NCT01669213|Active Comparator|ondansetron 8 mg|preparation of ondansetron 8mg
11454586|NCT01669213|Active Comparator|ondansetron 4 mg|preparation of ondansetron 4mg
11454587|NCT01669213|Placebo Comparator|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
11454626|NCT01668966|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
11454591|NCT01669187|Experimental|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
11454592|NCT01669174|Experimental|BYM338|
11454593|NCT01669174|Placebo Comparator|Placebo|
11454594|NCT01669161|Experimental|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
11454595|NCT01669161|Active Comparator|Rehab Only|Rehabilitation only (no implant, no VNS)
11454596|NCT01669148|Active Comparator|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
11454597|NCT01669148|Active Comparator|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
11454598|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
11454599|NCT01669122|Experimental|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
11454600|NCT01669122|Experimental|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
11454601|NCT01669122|Experimental|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
11454602|NCT01669122|Active Comparator|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
11454603|NCT01669109|Experimental|Hatha yoga|"10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention
~1 weekly class (90 minutes)"
11454604|NCT01669109|No Intervention|Usual care|Patients continue their self-directed usual care
11454605|NCT01669096|Experimental|GSK 692342 Group|Healthy male and female subjects, between and including 18 to 50 years of age, who received 2 doses of GSK 692342 vaccine administered intramuscularly in the deltoid region of the arm, at Days 0 and 30.
11454606|NCT01669083|Experimental|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
11454607|NCT01669083|Experimental|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
11454608|NCT01669083|Experimental|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
11454609|NCT01669083|Experimental|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
11454610|NCT01669070|Experimental|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
11454611|NCT01669070|Experimental|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
11454612|NCT01669070|Experimental|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
11454613|NCT01669070|Experimental|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
11454614|NCT01669057||Congenital heart defect（CHD） group|
11454615|NCT01669057||Normal control group|
11454616|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
11454617|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
11454618|NCT01669031|No Intervention|Control Group|No practice tests are performed in this arm
11454619|NCT01669031|Experimental|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).
~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
11454620|NCT01669018|Active Comparator|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
11454621|NCT01669018|Experimental|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
11454622|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
11454623|NCT01668992|Experimental|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
11454624|NCT01668992|No Intervention|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
11454625|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
11454627|NCT01668953|Experimental|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
11454628|NCT01668953|Active Comparator|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
11454629|NCT01668953|Active Comparator|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
11454630|NCT01668953|Placebo Comparator|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
11454631|NCT01668940|Experimental|Lillipops Iced Soothies (4 flavours)|"Initially, women will be given 1 multiflavour box of Lillipop samples minus the ginger flavour (4 flavours). Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.
~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
11454632|NCT01668940|Experimental|Lillipop Iced Soothies (Ginger flavour)|Initially, women will be given 1 Ginger flavor box of Lillipop samples. Each box contains 24 freezies (20 mL each). Each 20ml contains 80mg of dried ginger root. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 a day and to not have any other popsicles, freezies or other ginger products throughout the duration of the study (7 days). Due ginger's antiemetic property, a maximum daily dose is up to 1000mg/day of dried ginger root powder in pregnancy.They can request an additional box of freezies at each follow-up, as needed.All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol.
11454633|NCT01668940|Active Comparator|Mr. Freeze Freezies (4 flavours)|"Initially, women will be given 1 multiflavour box of Mr. Freeze samples. Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.
~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
11454634|NCT01668940|No Intervention|Natural Course Group|"Women will not receive any freezies and will be asked to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days).
~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
11454635|NCT01668927|Experimental|tetracycline/furazolidone|one of the four empirical rescue therapies
11454636|NCT01668927|Experimental|amoxicillin/tetracycline|one of the four empirical rescue therapies
11454637|NCT01668927|Experimental|amoxicillin/furazolidone|one of the four empirical rescue therapies
11454638|NCT01668927|Active Comparator|tetracycline /metronidazole|Classical rescue therapy
11454639|NCT01668914|Experimental|clinically positive axillary nodes|3~18 hours before surgery, under ultrasonographic guidance, 0.5~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
11454640|NCT01668901|Experimental|warfarin|medication
11454641|NCT01668901|Active Comparator|aspirin|medication
11454642|NCT01668888||Apparently Helathy Subjects|
11454643|NCT01668875|Experimental|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
11454644|NCT01668875|Experimental|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
11454645|NCT01668862|Other|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
11454646|NCT01668862|Other|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
11454647|NCT01668849|Experimental|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
11454648|NCT01668849|Active Comparator|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
11454649|NCT01668836|Experimental|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
11454650|NCT01668836|Experimental|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
11454651|NCT01668836|Active Comparator|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
11454652|NCT01668836|Active Comparator|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
11454653|NCT01668823|Experimental|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
11454654|NCT01668810||Beijing region|include six hospitals
11454655|NCT01668810||Guangdong Province|include 3 hospitals
11454656|NCT01668810||Jiangsu province|include 3 hospitals
11454657|NCT01668810||Hebei province|include 6 hospitals
11454658|NCT01668810||Hubei Province|include 7 hospitals
11454659|NCT01668810||Shanxi province|include 3 hospitals
11454660|NCT01668810||Jiangxi province|include 3 hospitals
11454661|NCT01668810||Jilin province|include 6 hospitals
11454662|NCT01668810||Sichuan province|include 3 hospitals
11454663|NCT01668810||Shaanxi province|include 3 hospitals
11454666|NCT01668784|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11454667|NCT01668784|Active Comparator|Arm 2: Everolimus|Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
11454668|NCT01668745|Experimental|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
11454669|NCT01668745|No Intervention|Control|
11454670|NCT01668732||community heroin addicts|
11454671|NCT01668719|Active Comparator|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).
~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11454672|NCT01668719|Experimental|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11454673|NCT01668706||Methadone maintenance treatment (MMT)|
11454674|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
11454675|NCT01668706||Medication-free ex-addicts(MF)|
11454676|NCT01668706||Normal control (NC)|
11454677|NCT01668693|Active Comparator|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
11454678|NCT01668693|Experimental|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
11454679|NCT01668680|Experimental|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
11454680|NCT01668680|No Intervention|observation|observation only
11454681|NCT01668667|Active Comparator|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
11454682|NCT01668667|Active Comparator|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
11454683|NCT01668667|Active Comparator|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
11454684|NCT01668667|Placebo Comparator|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
11454685|NCT01668654|Experimental|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
11454686|NCT01668641|Experimental|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
11454687|NCT01668641|Experimental|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
11454688|NCT01668641|Experimental|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
11454689|NCT01668641|Experimental|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
11454690|NCT01668641|Placebo Comparator|capsules, placebo once a day|3 capsules placebo once a day
11454691|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
11454692|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
11454693|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
11454694|NCT01668602|Experimental|Cohort 1 - FastFES Training|Participants in Cohort 1 will receive 18 training sessions of FastFES (fast treadmill walking with electrical stimulation).
11454695|NCT01668602|Experimental|Cohort 2 - Crossover of FastFES then Fast Walking|Participants in Cohort 2 who complete 3 sessions of FastFES followed by a washout period, then they complete 3 sessions of fast walking.
11454696|NCT01668602|Experimental|Cohort 2 - Crossover of Fast Walking then Fast FES|Participants in Cohort 2 who complete 3 sessions of fast walking followed by a washout period, then they complete 3 sessions of FastFES.
11454697|NCT01668563|Active Comparator|Endovascular management|Endovascular treatment will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
11454698|NCT01668563|Active Comparator|Surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
11454699|NCT01668537|Experimental|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
11454700|NCT01668537|Experimental|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
11454701|NCT01668524|Experimental|Single Arm: ATS907|Single-cohort, dose-escalation
11454702|NCT01668511|Experimental|Group 1|Randomized 7 drug/2 placebo by group
11454703|NCT01668511|Experimental|Group 2|Randomized 7 drug/2 placebo by group
11454704|NCT01668511|Experimental|Group 3|Randomized 7 drug/2 placebo by group
11454705|NCT01668511|Experimental|Group 4|Randomized 7 drug/2 placebo by group
11454706|NCT01668498|Experimental|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
11454707|NCT01668498|Active Comparator|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
11454708|NCT01668485|Experimental|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
11454709|NCT01668485|Placebo Comparator|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
11454710|NCT01668485|Active Comparator|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
11454711|NCT01668459|Experimental|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m^2 IV infusion
11454712|NCT01668459|Other|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
11454713|NCT01668446|Experimental|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.
~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
11454714|NCT01668446|Experimental|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.
~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
11454715|NCT01668433|Active Comparator|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
11454716|NCT01668433|Experimental|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
11454717|NCT01668420|Experimental|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
11454718|NCT01668420|Active Comparator|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
11454719|NCT01668407|Experimental|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
11454720|NCT01668407|Active Comparator|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
11454721|NCT01668394|Active Comparator|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
11454722|NCT01668394|Placebo Comparator|Control arm|Usual care. Teaching style: deductive.
11454723|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
11454724|NCT01668368|Other|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.
~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
11454725|NCT01668355|Experimental|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs of individuals with serious mental illness
11454726|NCT01668355|No Intervention|Usual Care|Usual Primary Care
11454727|NCT01668342|Experimental|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
11454728|NCT01668342|No Intervention|Control|Standard of care
11454729|NCT01668316|Experimental|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
11454730|NCT01668316|No Intervention|Control|Participants asked to not change dietary and physical activity habits.
11454731|NCT01668303|Experimental|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent[s] but not peer-group sessions.
11454732|NCT01668303|Other|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
11454733|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
11454734|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
11454735|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
11454736|NCT01668277|Experimental|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
11454737|NCT01668277|Active Comparator|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
11454738|NCT01668277|Active Comparator|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
11454739|NCT01668264|Experimental|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
11454740|NCT01668264|Experimental|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
11454741|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
11454742|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
11454743|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
11454744|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
11454745|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
11454746|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
11454747|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
11454748|NCT01668199|Experimental|14C TZP-101|
11454749|NCT01668186||Patients diagnosed with PBD|Collection of medical records and images (ultrasounds, X-rays, MRIs, CT scans, ophthalmic images), Next-generation panel, Drug screening, and Consultation
11454750|NCT01668173|Experimental|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
11454751|NCT01668160|Experimental|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
11454752|NCT01668147|Experimental|Control|Session 1: Control (no pretreatment) - IV 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
11454753|NCT01668147|Active Comparator|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
11454754|NCT01668147|Active Comparator|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
11454755|NCT01668134|Experimental|Stereotactic radiation|
11454756|NCT01668121|Experimental|Symbicort Turbohaler|Symbicort Turbohaler
11454757|NCT01668121|Active Comparator|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
11454758|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
11454759|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
11454760|NCT01668082|Experimental|surgical resection of a brain tumor|"The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
~--------------------------------------------------------------------------------"
11454761|NCT01668069|Experimental|Ondansetron|study drug
11454762|NCT01668069|No Intervention|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
11454763|NCT01668056|Active Comparator|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
11454764|NCT01668056|Experimental|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
11454765|NCT01668056|Experimental|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
11454766|NCT01668043|Experimental|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
11454767|NCT01668043|Experimental|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
11454768|NCT01668030|Experimental|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
11454769|NCT01668030|Experimental|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
11454770|NCT01668017|Experimental|Part 1: Pimasertib 30mg in Solid Tumor|
11454771|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in Solid Tumor|
11454772|NCT01668017|Experimental|Part 1: Pimasertib 60 mg in Solid Tumor|
11454773|NCT01668017|Experimental|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
11454774|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in HCC|
11454775|NCT01668004|Experimental|GLM 50 mg|GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months
11454776|NCT01667978|Experimental|PI|Study group with PI: atazanavir ritonavir
11454777|NCT01667978|Placebo Comparator|Control|o PI therapy, control group
11454778|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
11454779|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
11454780|NCT01667939|Experimental|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
11454781|NCT01667939|No Intervention|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
11454782|NCT01667926|Experimental|Ketamine|Subject will receive 6 infusions of ketamine over three weeks.
11454783|NCT01667926|Placebo Comparator|Placebo|Subjects will receive 6 infusions of normal saline over 3 weeks.
11454784|NCT01667913|No Intervention|6 minutes walking test|
11454785|NCT01667900|Experimental|0.5 mg Dulaglutide (Part A-Healthy)|0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
11454786|NCT01667900|Experimental|0.75 mg Dulaglutide (Part A-Healthy)|0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
11454787|NCT01667900|Experimental|1.5 mg Dulaglutide (Part A-Healthy)|1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
11454788|NCT01667900|Placebo Comparator|Placebo (Part A-Healthy)|Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
11454789|NCT01667900|Experimental|0.5 mg Dulaglutide (Part B-T2DM)|0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
11454790|NCT01667900|Experimental|0.75 mg Dulaglutide (Part B-T2DM)|0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
11454791|NCT01667900|Experimental|1.5 mg Dulaglutide (Part B-T2DM)|1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
11454792|NCT01667900|Placebo Comparator|Placebo (Part B-T2DM)|Placebo administered to participants with T2DM once weekly SQ for 4 weeks
11454793|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
11454794|NCT01667874|No Intervention|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
11454795|NCT01667874|Experimental|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
11454796|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
11454797|NCT01667848|Experimental|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
11454798|NCT01667848|Experimental|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
11454799|NCT01667835|Experimental|Yoga Intervention|
11454800|NCT01667835|No Intervention|Control|
11454801|NCT01667822|Active Comparator|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
11454802|NCT01667822|Experimental|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
11454803|NCT01667809|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
11454804|NCT01667809|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
11454805|NCT01667796|Experimental|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
11454806|NCT01667783|Active Comparator|Gastric Banding|Laparoscopic Adjustable Gastric Banding
11454807|NCT01667783|Active Comparator|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
11454808|NCT01667783|Active Comparator|Gastric Bypass|Roux-en-Y Gastric Bypass
11454809|NCT01667770|Active Comparator|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
11454810|NCT01667770|Active Comparator|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
11454811|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
11454812|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
11454813|NCT01667744|Placebo Comparator|Placebo|Placebo pill
11454814|NCT01667731|Experimental|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
11454815|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
11454816|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
11454817|NCT01667718|Active Comparator|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
11454818|NCT01667718|Experimental|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
11454819|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
11454820|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
11454821|NCT01667692|Experimental|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
11454822|NCT01667692|Experimental|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
11454823|NCT01667679|Experimental|OPTINOSE SUMATRIPTAN and Placebo|20 mg OPTINOSE SUMATRIPTAN Powder Delivered Intranasally With the Bi-directional Device nasally and Placebo Tablet
11454824|NCT01667679|Active Comparator|100mg Sumatriptan and OPTINOSE Placebo|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
11454825|NCT01667666|Experimental|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
11454826|NCT01667653|Experimental|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
11454827|NCT01667653|Experimental|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
11454828|NCT01667640|Active Comparator|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
11454829|NCT01667640|Experimental|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
11454830|NCT01667627|Active Comparator|BIO-25, Probiotic-mixture|Two capsules a day.
11454831|NCT01667627|Placebo Comparator|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
11454832|NCT01667614|No Intervention|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
11454833|NCT01667614|Active Comparator|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
11454834|NCT01667601|Experimental|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
11454835|NCT01667601|Other|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
11454836|NCT01667601|Active Comparator|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
~References:
~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.
~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
11454837|NCT01667588||Pre-Dialysis|
11454838|NCT01667588||Dialysis|
11454839|NCT01667575|Experimental|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
11454840|NCT01667575|Active Comparator|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
11454841|NCT01667575|Active Comparator|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
11454842|NCT01667562|Experimental|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
11454843|NCT01667562|No Intervention|Diagnostic Phase|Participants with advanced or metastatic NSCLC were tested for EGFR mutations. Participants who did not have an EGFR mutation were excluded from the study.
11454844|NCT01667549|Experimental|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.
~Intervention: Timing of Diet and Flavor Experience"
11454845|NCT01667549|Experimental|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.
~Intervention: Timing of Diet and Flavor Experience"
11454846|NCT01667549|Experimental|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.
~Intervention: Timing of Diet and Flavor Experience"
11454847|NCT01667549|No Intervention|Control|Mothers will not receive the intervention.
11454848|NCT01667536|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
11454849|NCT01667523|Experimental|Capsaicin|
11454850|NCT01667523|Experimental|Cinnamaldehyde|
11454851|NCT01667523|Placebo Comparator|Placebo|Physiological saline
11454852|NCT01667510|Experimental|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
11454853|NCT01667510|Placebo Comparator|Placebo|Soft gel capsule without test material, for oral use
11454854|NCT01667497|Experimental|Fampridine SR|Fampridine SR 10mg BID
11454855|NCT01667497|Placebo Comparator|Placebo|non-drug
11454856|NCT01667484|Placebo Comparator|Placebo|treatment group #1
11454857|NCT01667484|Active Comparator|Adderall XR 5mg|treatment group #2
11454858|NCT01667484|Active Comparator|Adderal XR 10mg|treatment group #3
11454859|NCT01667471|Experimental|RoActemra/Actemra|
11454860|NCT01667458||Cohort|
11454861|NCT01667445|Experimental|epimorph|single dose administration of 150mcg epimorph
11454862|NCT01667445|Active Comparator|spinal analgesia|spinal alone
11454863|NCT01667432||Peginterferon alfa-2a|Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
11454864|NCT01667419|Experimental|Cohort 1 Vemurafenib|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
11454865|NCT01667419|Placebo Comparator|Cohort 1 Placebo|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
11454866|NCT01667419|Experimental|Cohort 2 Vemurafenib|Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
11454867|NCT01667419|Placebo Comparator|Cohort 2 Placebo|Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
11454868|NCT01667406|Experimental|kisspeptin|kisspeptin
11454869|NCT01667393|Experimental|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
11454870|NCT01667393|Active Comparator|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
11454871|NCT01667380||Cohort|
11454872|NCT01667367|Placebo Comparator|Placebo|
11454873|NCT01667367|Experimental|RG1662|
11454874|NCT01667354|Experimental|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
11454875|NCT01667354|No Intervention|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
11454876|NCT01667341|Experimental|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
11454877|NCT01667341|Experimental|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
11454878|NCT01667341|Experimental|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
11454879|NCT01667341|Experimental|Low Dose GEN-003 Only|10µg GEN-003
11454880|NCT01667341|Experimental|Mid Dose GEN-003 Only|30µg GEN-003
11454881|NCT01667341|Experimental|High Dose GEN-003 Only|100µg GEN-003
11454882|NCT01667341|Placebo Comparator|Placebo|0.5 mL phosphate buffered saline
11454883|NCT01667328|Experimental|Massage therapy|This group will received presurgical massage
11454884|NCT01667328|Placebo Comparator|Control|Standard of care with no massage
11454885|NCT01667315|Experimental|Bupivacaine|Bupivacaine 0,375%
11454886|NCT01667302|Experimental|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
11454887|NCT01667289|Active Comparator|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
11454888|NCT01667289|Experimental|Concurrent chemoradiation|"Concurrent chemoradiation
~Chemotherapy:
~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
11454889|NCT01667263|Experimental|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
11454890|NCT01667263|Active Comparator|Danazol|Danazol 400mg po
11454891|NCT01667250|Active Comparator|GammaCore Active Device|Subjects will use an Active GammaCore Device
11454892|NCT01667250|Sham Comparator|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
11454893|NCT01667237|Experimental|Pulmonary rehabilitation|
11454894|NCT01667224|Experimental|Actiponin|Actiponin(extract of Gynostema pentaphyllum, 450mg/day) for 12weeks
11454895|NCT01667224|Placebo Comparator|Placebo|Placebo(450mg/day) for 12weeks
11454896|NCT01667211|Experimental|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
11454897|NCT01667198|Experimental|Train the leaders course|
11454898|NCT01667198|Active Comparator|Audit and feedback|
11454899|NCT01667185||Pediatric subjects with diabetes mellitus|
11454900|NCT01667172|Other|point-of-care test for CRP|
11454901|NCT01667159|Experimental|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
11454902|NCT01667159|Active Comparator|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
11454903|NCT01667146|Experimental|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
11454904|NCT01667146|Active Comparator|Control group ventilation|Control group mechanical ventilation strategy
11454907|NCT01667120|Placebo Comparator|Placebo|Postoperative surgical neonates will receive an equivalent volume of 0.9% normal saline as placebo.
11454908|NCT01667120|Experimental|Ketorolac|Postoperative ketorolac 0.5mg/kg intravenously every 8 hrs for 72hrs will be administered.
11454909|NCT01667107|Experimental|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
11454910|NCT01667107|Experimental|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
11454911|NCT01667094|Active Comparator|Intermittent, short infusion|"Infusion over 30 minutes of either:
~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24
~Antibiotic chosen by treating physician"
11454912|NCT01667094|Experimental|Continuous infusion|"Continuous infusion of either:
~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g
~Antibiotic chosen by treating physician"
11454913|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
11454914|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
11454915|NCT01667055||Patients with suspected drug allergy|Patients with a history of hypersensitivity reaction to beta-lactam antibiotics
11454916|NCT01667042||Without Interstitial lung disease (ILD)|
11454917|NCT01667042||With Interstitial lung disease (ILD)|
11454918|NCT01667029|Experimental|sulfasalazine|1 g oral twice daily for 2 weeks
11454919|NCT01667029|Placebo Comparator|placebo|oral placebo pill twice daily for two weeks.
11454920|NCT01667016||Orsiro DES|
11454921|NCT01667003||Orsiro DES|
11454922|NCT01666990|Experimental|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
11454923|NCT01666990|Placebo Comparator|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
11454924|NCT01666977|Experimental|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
11454925|NCT01666977|Experimental|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
11454926|NCT01666977|Experimental|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
11454927|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
11454928|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
11454929|NCT01666951|Experimental|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
11454930|NCT01666951|Active Comparator|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
11454931|NCT01666938|Experimental|Diabetes Education Group & Telephone counseling|This step was done for four months.
11454932|NCT01666938|Active Comparator|Telephone counseling about physical activity|This step was done for four months.
11454933|NCT01666925|Experimental|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
11454934|NCT01666925|Active Comparator|Rabies vaccine|2 x 2.5IU Verorab
11454935|NCT01666912|Active Comparator|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
11454936|NCT01666912|Experimental|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
11454937|NCT01666899|Experimental|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
11454938|NCT01666886|Experimental|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
11454939|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
11454940|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
11454941|NCT01666847|Experimental|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
11454942|NCT01666847|No Intervention|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
11454943|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
11454944|NCT01666808|Experimental|FACBC PET scan|A trial group in which anti-3-[18F]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
11454945|NCT01666808|Active Comparator|Radiation therapy|A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.
11454946|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
11454947|NCT01666782|Experimental|High-Dose Influenza Vaccine|
11454948|NCT01666782|Active Comparator|Standard Trivalent Influenza Vaccine|
11454949|NCT01666769|Other|Treatment Dosing|Age group: 0 - <2y, Micafungin 8 mg/kg/day IV
11454950|NCT01666769|Other|Prophylaxis dosing|Age group: 0-<2y, Micafungin 4 mg/kg/day IV
11454951|NCT01666769|Other|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
11454952|NCT01666756|Experimental|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11454953|NCT01666743|Experimental|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
11454954|NCT01666730|Experimental|Treatment (metformin hydrochloride, FOLFOX)|Patients receive metformin hydrochloride PO BID on days 1-14 and FOLFOX therapy comprising leucovorin calcium IV over 120 minutes, fluorouracil IV continuously over 46 hours, and oxaliplatin IV over 120 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11454955|NCT01666717||Healthy controls (HC)|HC
11454956|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
11454957|NCT01666704|Experimental|Treatment A: BMS-823778 (2mg)|
11454958|NCT01666704|Experimental|Treatment B: BMS-823778 (15mg)|
11454959|NCT01666704|Placebo Comparator|Treatment C: Placebo|
11454960|NCT01666691|Placebo Comparator|Placebo|ZGN-440 sterile diluent
11454961|NCT01666691|Experimental|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
11454962|NCT01666691|Experimental|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
11454963|NCT01666691|Experimental|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
11454964|NCT01666691|Experimental|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
11454965|NCT01666691|Experimental|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
11454966|NCT01666678|Experimental|Arm 1|
11454967|NCT01666678|Active Comparator|Arm 2|
11454968|NCT01666678|Active Comparator|Arm 3|
11454969|NCT01666678|Experimental|Arm 4|
11454970|NCT01666665|Active Comparator|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
11454971|NCT01666665|Placebo Comparator|Sugar pill|sugar pill up to 3 times per day for 12 months
11454972|NCT01666652|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11454973|NCT01666652|Experimental|TDENV-PIV AS01E1|1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11454974|NCT01666652|Experimental|TDENV-PIV AS03B1|1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11454975|NCT01666652|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
11454976|NCT01666652|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
11454977|NCT01666639|Active Comparator|Control Group|
11454978|NCT01666639|Experimental|Intervention Group|
11454979|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
11454980|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
11454981|NCT01666613|Experimental|1|AZD8683 iv
11454982|NCT01666613|Experimental|2|AZD8683 oral
11454983|NCT01666613|Experimental|3|AZD8683 inhalation New Dry Powder Inhaler
11454984|NCT01666613|Experimental|4|AZD8683 inhalation Turbuhaler™
11454985|NCT01666600|Experimental|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
11454986|NCT01666600|Active Comparator|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
11454987|NCT01666587|No Intervention|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
11454988|NCT01666587|Experimental|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
11454989|NCT01666587|Experimental|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
11454990|NCT01666587|Experimental|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
11454991|NCT01666574|Experimental|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
11454992|NCT01666574|Experimental|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
11454993|NCT01666561|Experimental|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:
~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
11454994|NCT01666561|Experimental|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:
~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
11454995|NCT01666561|Experimental|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:
~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
11454996|NCT01666535|Other|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
11455659|NCT01661673|Experimental|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
11454997|NCT01666535|Other|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
11454998|NCT01666522|Experimental|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
11454999|NCT01666522|Active Comparator|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
11455000|NCT01666522|Experimental|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
11455001|NCT01666522|Placebo Comparator|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
11455002|NCT01666509|Experimental|Rossoseq™|Gel, topically applied twice daily
11455003|NCT01666509|Placebo Comparator|Vehicle|Gel, topically applied twice
11455004|NCT01666496|Experimental|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
11455005|NCT01666496|Other|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
11455006|NCT01666483|Active Comparator|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
11455007|NCT01666483|Active Comparator|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
11455008|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
11455009|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
11455010|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
11455011|NCT01666444|Experimental|PLD 40 mg/m2 plus VTX-2337|The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
11455012|NCT01666444|Active Comparator|PLD 40 mg/m2 plus placebo|The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
11455013|NCT01666431|Other|Lapatinib|
11455014|NCT01666418|Other|Pazopanib/Paclitaxel|
11455015|NCT01666405|Experimental|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
11455016|NCT01666392|Experimental|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
11455017|NCT01666392|Placebo Comparator|Soybean oil|2 capsules/day
11455018|NCT01666379|Experimental|Fentanyl|
11455019|NCT01666379|Placebo Comparator|placebo|
11455020|NCT01666366|Active Comparator|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
11455021|NCT01666366|Active Comparator|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
11455022|NCT01666353|Experimental|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
11455023|NCT01666340|Experimental|high intensity aerobic training|Exercise intervention: High intensity group performing high intensity training where they are required to raise their heart rate several times during the workout and reach perceived exhaustion of 16 on a Borg scale
11455024|NCT01666340|Other|Moderate intensity training|Exercise intervention: Moderate intensity Group of people asked to perform moderate training where they exercise at a given intensity (moderate as per Borg scale) for a certain amount of time
11455025|NCT01666327|Experimental|MT-1303|
11455026|NCT01666314|Other|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455027|NCT01666314|Experimental|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455028|NCT01666314|Other|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455029|NCT01666314|Experimental|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455071|NCT01666015|Active Comparator|Standard Care|This group will follow the standard care without any EX prescription.
11455660|NCT01661673|Experimental|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
11455030|NCT01666314|Other|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.
~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
11455031|NCT01666314|Experimental|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455032|NCT01666314|Other|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455033|NCT01666314|Experimental|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
11455034|NCT01666301|Active Comparator|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
11455035|NCT01666301|Active Comparator|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
11455036|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
11455037|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
11455038|NCT01666262|Experimental|A/17/CA/2009/38 (H1N1)|
11455039|NCT01666262|Placebo Comparator|Stabilizer|
11455040|NCT01666249|Experimental|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
11455041|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.
~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
11455042|NCT01666223|Experimental|Colesevelam|
11455043|NCT01666223|Experimental|Chenodeoxycholic acid|
11455044|NCT01666223|Experimental|Colesevelam + chenodeoxycholic acid|
11455045|NCT01666223|Experimental|Placebo|
11455046|NCT01666210|Active Comparator|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
11455047|NCT01666210|Placebo Comparator|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
11455048|NCT01666197|Experimental|diclofenac potassium 25 mg tablet|
11455049|NCT01666197|Placebo Comparator|placebo|
11455050|NCT01666158|Active Comparator|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
11455051|NCT01666158|No Intervention|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
11455052|NCT01666145|Experimental|Intraoperative Imaging|Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.
11455053|NCT01666132|Experimental|Intramyocardial injection of BM cells|
11455054|NCT01666132|Experimental|Intramyocardial / intracoronary injection of BM cells|
11455055|NCT01666132|Other|control|
11455056|NCT01666119|Experimental|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
11455057|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
11455058|NCT01666093|Other|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
11455059|NCT01666080|Other|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
11455060|NCT01666067|Active Comparator|placebo|placebo
11455061|NCT01666067|Active Comparator|vytorin|vytorin
11455062|NCT01666067|Active Comparator|simvastatin|simvastatin
11455063|NCT01666054|Active Comparator|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
11455064|NCT01666054|Active Comparator|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
11455065|NCT01666041|Placebo Comparator|placebo|placebo
11455066|NCT01666041|Active Comparator|fenofibrate/omega|fenofibrate/omega
11455067|NCT01666041|Active Comparator|fenofibrate|fenofibrate
11455068|NCT01666028|Experimental|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
11455069|NCT01666028|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
11455070|NCT01666015|Experimental|Exercise (EX)|This group will perform two phases of an EX program.
11455072|NCT01666002|Experimental|Treatment|"st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.
~nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
11455073|NCT01666002|No Intervention|Placebo|"st visit: For the control group, no treatment will be given.
~nd visit: 2 weeks after initial visit, patient will be seen for second visit"
11455074|NCT01665989|Experimental|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
11455075|NCT01665989|Active Comparator|Usual Care|A research assistant will provide the usual care group participants with brief (~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
11455076|NCT01665976|Experimental|A: film coated tablets, fasted condition|
11455077|NCT01665976|Experimental|B: film coated tablets, fed condition|
11455078|NCT01665976|Experimental|C: hard gelatin capsules|
11455079|NCT01665976|Experimental|D: oral suspension|
11455080|NCT01665963|Active Comparator|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
11455081|NCT01665963|Active Comparator|Traditional Wound Closure Treatment|Pressure Bandage
11455082|NCT01665950|Experimental|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
11455083|NCT01665950|Experimental|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
11455084|NCT01665950|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
11455085|NCT01665937|Experimental|STA-9090|Patients receiving STA-9090
11455086|NCT01665924|Experimental|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
11455087|NCT01665924|Experimental|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
11455088|NCT01665924|Experimental|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
11455089|NCT01665911|Other|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
11455090|NCT01665911|Other|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
11455091|NCT01665911|Other|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
11455092|NCT01665911|Other|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
11455093|NCT01665911|Active Comparator|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
11455094|NCT01665898|Active Comparator|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
11455095|NCT01665898|Active Comparator|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
11455096|NCT01665885|Active Comparator|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
11455097|NCT01665885|Active Comparator|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
11455098|NCT01665885|No Intervention|Control group|Best medical treatment following international stroke guidelines
11455099|NCT01665872|Experimental|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
11455100|NCT01665872|Active Comparator|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
11455101|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
11455102|NCT01665846|Experimental|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
11455103|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist & Medical Resident auscultate using mechanical stethoscope
11455104|NCT01665820||Auscultate with electronic stethoscope|Cardiologist & Medical Resident auscultate using electronic stethoscope
11455105|NCT01665807|Experimental|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
11455106|NCT01665807|Experimental|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
11455107|NCT01665807|Active Comparator|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
11455108|NCT01665794|Experimental|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
11455176|NCT01665352|Experimental|TTP054 400 mg|
11455177|NCT01665352|Experimental|TTP054 200 mg|
11455109|NCT01665794|Experimental|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
11455110|NCT01665781|Experimental|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
11455111|NCT01665781|No Intervention|Control|No erythropoietin
11455112|NCT01665768|Experimental|Everolimus and Rituximab|Everolimus daily for one year and IV rituximab four times during that year.
11455113|NCT01665755|Experimental|Precompression|Control arm
11455114|NCT01665755|Active Comparator|Upstroke Compression|Intervention arm
11455115|NCT01665742|Active Comparator|Anti-inflammatory supplement|"8-weeks of daily supplementation with:
~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene
~in conjunction with a weight management programme"
11455116|NCT01665742|Placebo Comparator|Placebo supplement|"8 weeks of daily supplementation with:
~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets
~in conjunction with a weight management programme"
11455117|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
11455118|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
11455119|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
11455120|NCT01665703|Experimental|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
11455121|NCT01665690|Experimental|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
11455122|NCT01665690|No Intervention|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
11455123|NCT01665677|Experimental|Atorvastatin calcium (Lipitor)|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.
~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
11455124|NCT01665677|Experimental|Unrelated Donor|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.
~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
11455125|NCT01665664|Other|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
11455126|NCT01665664|No Intervention|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
11455127|NCT01665651|Placebo Comparator|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
11455128|NCT01665651|Placebo Comparator|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
11455129|NCT01665651|Experimental|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
11455130|NCT01665651|Experimental|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
11455131|NCT01665638|Experimental|Treatment Sequence Group AB|
11455132|NCT01665638|Experimental|Treatment Sequence Group BA|
11455133|NCT01665625|Experimental|regional interventional chemotherapy group|
11455134|NCT01665625|No Intervention|systemic chemotherapy|
11455135|NCT01665612|Experimental|MPDS1|Contact lens care solution
11455136|NCT01665612|Active Comparator|MPDS2|Contact lens care solution
11455137|NCT01665612|Active Comparator|MPDS3|Contact lens care solution
11455138|NCT01665599|Experimental|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.
~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
11455139|NCT01665586|Placebo Comparator|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
11455140|NCT01665586|Active Comparator|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
11455141|NCT01665573|Active Comparator|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
11455142|NCT01665573|Placebo Comparator|Placebo|Placebo
11455143|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO >10 ppm.
11455144|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
11455145|NCT01665547|Active Comparator|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
11455146|NCT01665534|Experimental|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
11455147|NCT01665521|Experimental|HEART Pathway|The HEART Pathway will be used for real time clinical decision making. Physicians will receive care recommendations according to the HEART Pathway, based on HEART score and serial cardiac biomarkers. This will help physicians identify low-risk patients for early discharge with no objective cardiac testing.
11455148|NCT01665521|No Intervention|Usual Care|Conventional Care cardiac testing. Patients will undergo cardiac testing as determined by their treating physicians.
11455149|NCT01665508|Experimental|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
11455150|NCT01665495|No Intervention|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
11455151|NCT01665495|Active Comparator|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml
11455152|NCT01665482|Active Comparator|Saturated fat rich diet|
11455153|NCT01665482|Active Comparator|Monounsaturated fat rich diet|
11455154|NCT01665482|Active Comparator|Carbohydrate/ Low fat diet|
11455155|NCT01665469|Placebo Comparator|Placebo|Soft gel capsule without test material
11455156|NCT01665469|Experimental|Tomato extracted lycopene|Soft gel cups for oral use
11455157|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
11455158|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
11455159|NCT01665430|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.
11455160|NCT01665417|Experimental|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
11455161|NCT01665417|Active Comparator|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
11455162|NCT01665417|Active Comparator|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
11455163|NCT01665404|Experimental|Dosing Period 1|
11455164|NCT01665404|Experimental|Dosing Period 2|
11455165|NCT01665391|Experimental|fresolimumab 1 mg/kg total body weight|
11455166|NCT01665391|Experimental|fresolimumab 4 mg/kg total body weight|
11455167|NCT01665391|Placebo Comparator|Placebo|
11455168|NCT01665378|Experimental|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:
~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
11455169|NCT01665378|Active Comparator|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
11455170|NCT01665378|Placebo Comparator|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
11455171|NCT01665378|Experimental|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:
~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
11455172|NCT01665378|Active Comparator|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
11455173|NCT01665378|Placebo Comparator|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
11455174|NCT01665365|Experimental|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
11455175|NCT01665365|No Intervention|2.|Primary percutaneous coronary intervention (control group).
11455180|NCT01665339|Experimental|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
11455181|NCT01665339|Experimental|control|subjects in control group consumed salad and yogurt with meal.
11455182|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
11455183|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
11455184|NCT01665274|Active Comparator|XELOX adjuvant group|"D2 resection
~XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles"
11455185|NCT01665274|Experimental|XELOX neoadjuvant|"XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.
~D2 resection
~After operation:
~CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
11455186|NCT01665248|Other|stable angina pectoris or acute coronary syndrome|
11455187|NCT01665235|Active Comparator|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
11455188|NCT01665235|Experimental|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
11455189|NCT01665222|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
11455190|NCT01665222|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
11455191|NCT01665209|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
11455192|NCT01665209|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
11455193|NCT01665196|Experimental|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
11455194|NCT01665183|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
11455195|NCT01665170|Placebo Comparator|Placebo|Placebo arm
11455196|NCT01665170|Active Comparator|Verum|Verum arm - Pascoflair 425mg
11455197|NCT01665157|Experimental|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
11455198|NCT01665157|Placebo Comparator|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
11455199|NCT01665157|Experimental|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
11455200|NCT01665144|Experimental|Siponimod (BAF312)|Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
11455201|NCT01665144|Placebo Comparator|Placebo|Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.
11455202|NCT01665131|Experimental|Subcutaneous ICD group|
11455203|NCT01665118|Experimental|Treated Thigh|Trusculpt (Radio Frequency) Device
11455204|NCT01665118|No Intervention|Untreated Contra-lateral Thigh|To be used as the self control in this split body study.
11455205|NCT01665105|Experimental|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
11455206|NCT01665105|Active Comparator|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
11455207|NCT01665105|Sham Comparator|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
11455208|NCT01665092|Placebo Comparator|Control|Normal saline
11455209|NCT01665092|Experimental|Carnitine Low|Levo-Carnitine 6g
11455210|NCT01665092|Experimental|Carnitine Medium|Levo-Carnitine 12 g
11455211|NCT01665092|Experimental|Carnitine High|Levo-Carnitine 18 g
11455212|NCT01665079|Experimental|Propofol|14 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery
11455213|NCT01665066|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
11455214|NCT01665066|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
11455215|NCT01665066|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
11455216|NCT01665066|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
11455217|NCT01665066|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
11455218|NCT01665053|Active Comparator|Promus Element Plus|PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
11455219|NCT01665053|Experimental|SYNERGY|SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
11455220|NCT01665040|Experimental|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
11455261|NCT01664741|No Intervention|Healthy non-smoker comparison|Demographically-matched women and men who have never smoked
11455262|NCT01664728|Experimental|Abiraterone acetate|
11455221|NCT01665027|Experimental|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
11455222|NCT01665027|Experimental|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:
~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
11455223|NCT01665014|Experimental|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
11455224|NCT01665001|Experimental|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
11455225|NCT01664988|Experimental|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
11455226|NCT01664988|Experimental|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
11455227|NCT01664988|Other|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
11455228|NCT01664975|Experimental|GDPT regimen|GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
11455229|NCT01664975|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
11455230|NCT01664962||Patients|Women with severe Vulvodynia
11455231|NCT01664962||Healthy controls|Women without vulvodynia
11455232|NCT01664949|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
11455233|NCT01664949|Active Comparator|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
11455234|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
11455235|NCT01664923|Experimental|Enzalutamide|Enzalutamide 160 mg/day orally
11455236|NCT01664923|Active Comparator|Bicalutamide|50 mg/day orally
11455237|NCT01664910|Experimental|Treatment (transplant)|Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
11455238|NCT01664897|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11455239|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
11455240|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
11455241|NCT01664871|Experimental|Levels of SIlver and Fluoride in Plasma|
11455242|NCT01664858|Active Comparator|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
11455243|NCT01664858|Active Comparator|SPECT-guided management|Patients to be managed according to the results of SPECT
11455244|NCT01664858|Active Comparator|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.
~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
11455245|NCT01664845|Active Comparator|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
11455246|NCT01664845|Placebo Comparator|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
11455247|NCT01664832|Experimental|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
11455248|NCT01664832|Placebo Comparator|nIMV|non-synchronized nasal intermittent mandatory ventilation group
11455249|NCT01664819|Active Comparator|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
11455250|NCT01664819|Placebo Comparator|Placebo|Randomized to receive placebo three times per week for five years
11455251|NCT01664806|No Intervention|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
11455252|NCT01664806|Experimental|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
11455253|NCT01664793|Experimental|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
11455254|NCT01664793|No Intervention|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
11455255|NCT01664780||Patients after liver transplantation|
11455256|NCT01664767|Experimental|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
11455257|NCT01664767|Placebo Comparator|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
11455258|NCT01664754|Experimental|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11455259|NCT01664741|Active Comparator|Nicotine patch - transdermal|21 mg nicotine patch
11455263|NCT01664715|Active Comparator|150 Minutes per Week|Performs 150 minutes of physical activity per week.
11455264|NCT01664715|Active Comparator|225 Minutes per Week|Performs 225 minutes of physical activity per week.
11455265|NCT01664715|Active Comparator|300 Minutes per Week|Performs 300 minutes of physical activity per week.
11455266|NCT01664702|Experimental|Recommended dairy diet|Recommended servings of dairy products per day
11455267|NCT01664702|Experimental|Low dairy diet|One or fewer dairy servings per day
11455268|NCT01664689|Active Comparator|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
11455269|NCT01664689|Active Comparator|Healon 5|microcoaxial phacoemulsification using healon 5
11455270|NCT01664689|Active Comparator|Celoftal|microcoaxial phacoemulsification using celoftal
11455271|NCT01664676|Experimental|Liraglutide|1.2 mg liraglutide sc. (single-dose)
11455272|NCT01664676|Placebo Comparator|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
11455273|NCT01664663|Active Comparator|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
11455274|NCT01664663|Experimental|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
11455275|NCT01664650|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
11455276|NCT01664650|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
11455277|NCT01664637|Experimental|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
11455278|NCT01664637|Placebo Comparator|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
11455279|NCT01664624|Experimental|Roflumilast + alogliptin|Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
11455280|NCT01664624|Experimental|Alogliptin alone|Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
11455281|NCT01664624|Experimental|Roflumilast alone|Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
11455282|NCT01664624|Active Comparator|Exenatide|Exenatide 5 μg subcutaneous injection twice a day for 11 days.
11455283|NCT01664611|Experimental|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
11455284|NCT01664611|Sham Comparator|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
11455285|NCT01664598|Experimental|RoActemra/Actemra|
11455286|NCT01664585|Experimental|Training group|"The rationale and means for the exercise program are to
~Motivate and teach participants for postural and motor control and strengthening exercises
~Monitor and motivate to continue exercise training, and to increase their physical activity
~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
11455287|NCT01664585|Sham Comparator|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
11455288|NCT01664572||Healthy subjects|
11455289|NCT01664559|Placebo Comparator|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
11455290|NCT01664559|Experimental|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
11455291|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
11455292|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
11455293|NCT01664520|Experimental|Dexmedetomine infusion|
11455294|NCT01664507|Active Comparator|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
11455295|NCT01664507|Experimental|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
11455296|NCT01664494||Capecitabine|Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
11455297|NCT01664260|Experimental|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
11455298|NCT01664260|Placebo Comparator|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
11455299|NCT01664247|Experimental|IDeg + Lira|
11455300|NCT01664247|Experimental|Placebo + Lira|
11455330|NCT01663987|Active Comparator|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
11459631|NCT01633762|Experimental|meropenem, gentamicin, vancomycin|
11455301|NCT01664234|Experimental|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
11455302|NCT01664234|Placebo Comparator|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
11455303|NCT01664221|Experimental|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
11455304|NCT01664221|Active Comparator|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
11455305|NCT01664195|Other|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
11455306|NCT01664195|Other|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
11455307|NCT01664182|Experimental|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11455308|NCT01664182|Experimental|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29, pazopanib hydrochloride PO QD on days 1-42, sorafenib tosylate PO BID on days 1-42, or sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11455309|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.
~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
11455310|NCT01664156|Experimental|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
11455311|NCT01664156|Placebo Comparator|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
11455312|NCT01664143|Placebo Comparator|Placebo|
11455313|NCT01664143|Experimental|RO5508887|
11455314|NCT01664130|Experimental|Treatment (SBRT)|Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
11455315|NCT01664117||bDMARD Monotherapy|Patients with moderate to severe rheumatoid arthritis (RA) will be treated with bDMARD (biologic disease-modifying antirheumatic drug) monotherapy under routine clinical practice conditions at rheumatology clinics
11455316|NCT01664104||RA Participants|Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.
11455317|NCT01664091|Experimental|TE-ADM with PMRT|Participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling placed during the same surgery. This was followed by post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months, if adjuvant chemotherapy was required. The prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. Permanent reconstruction was performed at least 5 months after completion of PMRT.
11455318|NCT01664078|Experimental|InCraft® - AAA stent graft system|Intervention: Endovascular AAA repair using the InCraft device
11455319|NCT01664065|Experimental|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
11455320|NCT01664065|Experimental|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
11455321|NCT01664052|Experimental|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
11455322|NCT01664052|Experimental|ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
11455323|NCT01664039|Experimental|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
11455324|NCT01664039|Active Comparator|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
11455325|NCT01664026|No Intervention|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
11455326|NCT01664026|Experimental|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
11455327|NCT01664026|Experimental|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
11455328|NCT01664013|Experimental|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
11455329|NCT01664000|Experimental|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
11455331|NCT01663987|Placebo Comparator|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
11455332|NCT01663974||Bipolar disorder patients|
11455333|NCT01663961|Experimental|YM178 OCAS + digoxin|
11455334|NCT01663948||Patients with Plastic bronchitis|
11455335|NCT01663935|Other|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
11455336|NCT01663922|Experimental|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
11455337|NCT01663922|Experimental|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
11455338|NCT01663909|No Intervention|Standard care|
11455339|NCT01663909|Experimental|Guided imagery|
11455340|NCT01663896||Single or multi vessel disease|Pre- and post-PCI fractional flow reserve (FFR) and OCT were performed in participants.
11455341|NCT01663883|Experimental|Healthy subjects|
11455342|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
11455343|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
11455344|NCT01663857|Experimental|Phase 1b (Cohort 1) LY2228820 200 milligrams (mg)|"Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..
~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
11455345|NCT01663857|Experimental|Phase 1b (Cohort 2) LY2228820 300 mg|"Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.
~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
11455346|NCT01663857|Experimental|Phase 2 (Arm A) LY2228820 200 mg|"Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.
~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
11455347|NCT01663857|Placebo Comparator|Phase 2 (Arm B) Placebo|"Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.
~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
11455348|NCT01663844|Experimental|(Study 1) ICBT for insomnia and depression|
11455349|NCT01663844|Active Comparator|(Study 1) ICBT for depr. plus placebo insomnia intervention|
11455350|NCT01663844|Experimental|(Study 2) ICBT for insomnia with added support|
11455351|NCT01663844|Active Comparator|(Study 2) ICBT for insomnia with regular level of support|
11455352|NCT01663831|Experimental|Topical Repellent & LLIN|
11455353|NCT01663831|No Intervention|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net
~Active ingredient: permethrin"
11455354|NCT01663818|Experimental|Treatment group|Treatment with Tack-IT Endovascular Staple
11455355|NCT01663805|Active Comparator|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
11455356|NCT01663805|No Intervention|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
11455357|NCT01663792|Placebo Comparator|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
11455358|NCT01663792|Experimental|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
11455359|NCT01663792|Placebo Comparator|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
11455360|NCT01663779|Experimental|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
11455361|NCT01663779|Active Comparator|Palpation based artery catheterization|Blind insertion of radial artery catheterization
11455362|NCT01663766|Experimental|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
11455363|NCT01663753|Experimental|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
11455364|NCT01663740|Experimental|Cohort A: Partcipants who Received Valganciclovir|Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
11455365|NCT01663740|No Intervention|Cohort B: Untreated Participants|Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.
11455366|NCT01663727|Experimental|A|Paclitaxel + Bevacizumab [Avastin]
11455367|NCT01663727|Experimental|B|Paclitaxel + Placebo
11455368|NCT01663714|Experimental|open-label, single arm|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
11455369|NCT01663701|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
11455370|NCT01663701|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
11455371|NCT01663688||Normative Data Collection|
11455373|NCT01663662|Active Comparator|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:
~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
11455374|NCT01663662|Placebo Comparator|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
11455375|NCT01663649|Experimental|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
11455376|NCT01663649|Active Comparator|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
11455377|NCT01663636||SMS Vaccine|Mothers will be sent an SMS message reminding them to come for their scheduled vaccines 1 week prior to the date of 2nd and 3rd doses
11455378|NCT01663636||Usual care|Mothers under usual care will serve as a control
11455379|NCT01663623|Placebo Comparator|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
11455380|NCT01663623|Experimental|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
11455381|NCT01663610|Experimental|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
11455382|NCT01663610|No Intervention|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
11455383|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
11455384|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
11455385|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
11455386|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
11455387|NCT01663558|Active Comparator|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.
~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).
~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.
~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.
~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
11455388|NCT01663558|Active Comparator|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.
~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.
~iii. After therapy, subject will enter 12 month observation period."
11455389|NCT01663558|No Intervention|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.
~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
11455390|NCT01663532|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
11455391|NCT01663532|Placebo Comparator|Placebo|Matching placebo
11455392|NCT01663519|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
11455393|NCT01663519|Experimental|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
11455394|NCT01663519|Experimental|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
11455395|NCT01663506||Cohort|
11455396|NCT01663493|Other|Fine needle aspiration needle|standard Beacon FNA needle
11455397|NCT01663493|Other|fine needle biopsy needle|SharkCore fine needle biopsy needle
11455398|NCT01663467|Active Comparator|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
11455399|NCT01663467|Experimental|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.
~Ginexin-F 80mg tablet will be given twice a day for 6 months."
11455400|NCT01663454|Experimental|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
11455401|NCT01663441|Experimental|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).
~Only for Dose-finding in Phase Ⅲa."
11455402|NCT01663441|Experimental|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).
~Only for Dose-finding in Phase Ⅲa."
11455403|NCT01663441|Active Comparator|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).
~Only in Phase Ⅲb."
11455439|NCT01663168|Experimental|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
11455404|NCT01663441|Active Comparator|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.
~Only in Phase Ⅲb."
11455405|NCT01663428|Experimental|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
11455406|NCT01663428|Active Comparator|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
11455407|NCT01663415|Experimental|Enzalutamide|
11455408|NCT01663402|Placebo Comparator|Placebo|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
11455409|NCT01663402|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels >=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were <25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were <15 mg/dL (0.39 mmol/L).
11455410|NCT01663389|Experimental|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
11455411|NCT01663389|Experimental|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
11455412|NCT01663363|Experimental|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
11455413|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
11455414|NCT01663337|Active Comparator|Cognitive Processing Therapy (CPT)|
11455415|NCT01663337|Active Comparator|Relapse Prevention Therapy (RP)|
11455416|NCT01663337|No Intervention|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
11455417|NCT01663324|Experimental|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation
~Intervention: Device: rTMS intervention 1"
11455418|NCT01663324|Experimental|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation
~Intervention: Device: rTMS Intervention 2"
11455419|NCT01663311|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
11455420|NCT01663311|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
11455421|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
11455422|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
11455423|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
11455424|NCT01663285|Experimental|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
11455425|NCT01663272|Experimental|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
11455426|NCT01663259|Experimental|Cetuximab|
11455427|NCT01663246|Active Comparator|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
11455428|NCT01663246|Active Comparator|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
11455429|NCT01663233|Experimental|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
11455430|NCT01663233|Active Comparator|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
11455431|NCT01663220||obese individuals with type 2 diabetes mellitus|
11455432|NCT01663207||obese individuals with prediabetes|
11455433|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
11455434|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
11455435|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
11455436|NCT01663181||urogynecologic patients undergoing outpatient cystoscopy|
11455437|NCT01663181||urogynecologic patients undergoing outpatient-urodynamics|
11455438|NCT01663168|Active Comparator|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
11455440|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
11455441|NCT01663142||Patients who receive surgical resection for intestinal in CD|
11455442|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
11455443|NCT01663129||Rheumatic Disease Patient Group|"Juvenile Idiopathic Arthritis (JIA)
~Systemic Lupus Erythematosis
~Juvenile Dermatomyositis
~Scleroderma
~Overlap Syndromes
~Sjogren's syndrome
~Sarcoidosis
~Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)
~Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis
~Other rheumatic disease"
11455444|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:
~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
11455445|NCT01663116|Experimental|Treatment|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15
~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15
~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
11455446|NCT01663116|Placebo Comparator|Placebo|Lactate Ringer´s solution
11455447|NCT01663103|Experimental|Rilonacept|12 weeks of treatment with rilonacept
11455448|NCT01663103|Placebo Comparator|Placebo|Twelve weeks of treatment with placebo
11455449|NCT01663090|Experimental|Nanoparticle enhanced MRI|
11455450|NCT01663077|Experimental|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
11455451|NCT01663064|Experimental|Endovascular|Endovascular treatment
11455452|NCT01663051||Stent|Stent
11455453|NCT01663038|Active Comparator|Clopidogrel and Aspirin|
11455454|NCT01663038|Experimental|Copidogrel|
11455455|NCT01663025|Experimental|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
11455456|NCT01663025|No Intervention|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
11455457|NCT01663012|Experimental|Drug: Etirinotecan pegol|145 mg/m2 dose
11455458|NCT01662999|Experimental|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
11455459|NCT01662999|Experimental|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
11455460|NCT01662999|Experimental|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
11455461|NCT01662999|Experimental|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
11455462|NCT01662999|Experimental|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
11455463|NCT01662999|Experimental|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
11455464|NCT01662986|Active Comparator|18 mcg tiotropium bromide|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
11455465|NCT01662986|Placebo Comparator|placebo|Patient to receive one placebo inhalation powder capsule daily (in the morning) via HandiHaler
11455466|NCT01662973|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.
~Participants will then be followed until the week 48 study visit."
11455467|NCT01662973|Placebo Comparator|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
11455468|NCT01662960|Experimental|Mirror therapy|4 weeks of home-based mirror therapy. Participants practiced making movements with mirrored visual feedback of the low-functioning arm.
11455469|NCT01662960|Active Comparator|Divider therapy|4 weeks of home-based divider therapy (control therapy to mirror therapy; mirror replaced by a divider). Participants practiced making movements with no visual feedback of the low-functioning arm.
11455470|NCT01662947|Experimental|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117
~Measurement: Blood Pressure
~Groups/Cohorts: DUT"
11455471|NCT01662947|Experimental|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
~Measurement: Blood Pressure
~Groups/Cohorts: Reference"
11455472|NCT01662934|Sham Comparator|Sham|Using not functioning device
11455473|NCT01662934|Experimental|Experimental|Using functioning device
11455474|NCT01662921|Active Comparator|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
11455475|NCT01662921|Active Comparator|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
11455476|NCT01662908|Experimental|edoxaban tosylate|
11455477|NCT01662908|Active Comparator|heparin/warfarin|
11455478|NCT01662895|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
11455479|NCT01662895|Placebo Comparator|Normal Saline|0.9% sodium chloride
11455480|NCT01662882|Experimental|AD Subjects|
11455481|NCT01662882|Experimental|MCI|MCI (mild cognitive impairment)
11455482|NCT01662882|Experimental|Healthy Controls|
11455483|NCT01662869|Experimental|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
11455484|NCT01662869|Placebo Comparator|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
11455485|NCT01662856|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
11455486|NCT01662856|Active Comparator|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
11455487|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
11455488|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
11455489|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
11455490|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
11455491|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
11455492|NCT01662804|Experimental|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10^6 U rIL-2/m^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
11455493|NCT01662791|Experimental|Case Group|All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
11455494|NCT01662791|No Intervention|Control Group|This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
11455495|NCT01662778|Active Comparator|Monodisperse FP 1.5um|50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test
11455496|NCT01662778|Active Comparator|Monodisperse FP 6.0um|50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test
11455497|NCT01662778|Placebo Comparator|Placebo STAG|No active drug, just solvent delivered from STAG followed by AMP PC20 challenge test
11455498|NCT01662778|Active Comparator|MDI FP|Fluticasone Propionate , Metered dose inhaler, 250 mg dose followed by AMP PC20 challenge test
11455499|NCT01662765|Experimental|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.
~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
11455500|NCT01662765|Active Comparator|Conservative|"Conservative treatment described as follow:
~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.
~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
11455501|NCT01662752|Other|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
11455502|NCT01662726|Experimental|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
11455503|NCT01662713|Experimental|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
11455504|NCT01662700|Experimental|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with
~Primaquine 15 mg is given daily for 14 days.
~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
11455505|NCT01662700|Active Comparator|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).
~Combine with
~Primaquine 15 mg is given daily for 14 days.
~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
11455506|NCT01662687|Experimental|Sancuso patch|
11455507|NCT01662687|Active Comparator|Kytril|
11455508|NCT01662674|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
11455509|NCT01662674|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
11455510|NCT01662661|Experimental|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
11455511|NCT01662661|Experimental|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
11455512|NCT01662648|Experimental|Paliperidone ER: Lack of efficacy|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
11455513|NCT01662648|Experimental|Paliperidone ER: Lack of tolerability, compliance or other|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
11455514|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.
~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
11455515|NCT01662622|Experimental|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
11455516|NCT01662609||Endoscopic Ultrasound (EUS) Participants|High-risk for Pancreatic Cancer: Patients with 2 or more relatives with pancreatic cancer and a first degree relationship with at least one of the relatives with pancreatic cancer.
11455517|NCT01662583|Experimental|Educational Text Message|Educational text message reminder
11455518|NCT01662583|Experimental|Plain Text Message|plain text message reminder
11455519|NCT01662583|Other|Written reminder only|written reminder at time of vaccination
11455520|NCT01662570|Active Comparator|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
11455521|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
11455522|NCT01662557|Active Comparator|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
11455523|NCT01662557|Other|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
11455524|NCT01662544|Experimental|HHFNC|Heated High Flow arm
11455525|NCT01662544|Active Comparator|Standard Nasal Cannula|Standard treatment
11455526|NCT01662531|Experimental|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
11455527|NCT01662518|Experimental|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
11455528|NCT01662505|Experimental|Volasertib|Patient to receive escalating dose of volasertib
11455529|NCT01662492|Experimental|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
11455530|NCT01662492|Experimental|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
11455531|NCT01662492|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
11455532|NCT01662466|Active Comparator|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
11455533|NCT01662466|Placebo Comparator|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
11455534|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
11455535|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
11455536|NCT01662440|Active Comparator|R/JE - Conv|Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
11455537|NCT01662440|Experimental|R/JE - Acc|Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
11455538|NCT01662440|Active Comparator|R - Conv|Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
11455539|NCT01662440|Active Comparator|JE - Conv|Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.
11455540|NCT01662427||Questionniare|
11455543|NCT01662401|Experimental|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
11455544|NCT01662401|Experimental|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
11455545|NCT01662388|Experimental|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
11455546|NCT01662388|Active Comparator|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
11455547|NCT01662375||MIII|
11455548|NCT01662362|Other|Testing Donor Specimens with ESA Chagas|Test blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
11455549|NCT01662349|Experimental|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
11455550|NCT01662336||Lopinavir/Ritonavir + KASA|Patients were treated according to the standard of care provided by their respective study sites. Treatments with LPV/r and participation in the KASA program were according to the decision of the treating physician and the participant, and were not affected in any way by their decision to participate in the study.
11455551|NCT01662323|Active Comparator|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
11455552|NCT01662323|Active Comparator|Controle|General practitioners giving care as usual to their heart failure patients.
11455553|NCT01662310|Experimental|Paliperidone: Run-in or Stabilization phase|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
11455554|NCT01662310|Experimental|Paliperidone: Double blind (DB) phase|Participants who transitioned from run-in or stabilization phase received 3 to 12 mg fixed dose of paliperidone ER oral tablet once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
11455555|NCT01662310|Active Comparator|Placebo: DB phase|Participants who transitioned from run-in or stabilization phase received matching placebo to paliperidone ER once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
11455556|NCT01662297|Active Comparator|Quetiapine|Veterans remaining on quetiapine for insomnia.
11455557|NCT01662297|Active Comparator|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
11455558|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
11455559|NCT01662284||Prostate|124I-NM404 in prostate cancer
11455560|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
11455561|NCT01662284||Gastric|124I-NM404 in gastric cancer
11455562|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
11455563|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
11455564|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
11455565|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
11455566|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
11455567|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
11455568|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
11455569|NCT01662258|Experimental|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
11455570|NCT01662258|No Intervention|Empiric therapy|Option of no application of POC laboratory tests
11455571|NCT01662232|Active Comparator|Green tea beverage|200 mg EGCG as green tea beverage.
11455572|NCT01662232|Active Comparator|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
11455573|NCT01662232|Active Comparator|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
11455574|NCT01662232|Placebo Comparator|Placebo (Water)|Same volume water as for all intervention arms.
11455575|NCT01662219|Experimental|superficial cervical plexus block|superficial cervical plexus block for experimental group
11455576|NCT01662219|No Intervention|No Block|no superficial cervical plexus block for the no intervention group
11455577|NCT01662206|Experimental|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
11455578|NCT01662206|Placebo Comparator|Placebo|Capsules containing placebo
11455579|NCT01662193|Experimental|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
11455580|NCT01662193|Experimental|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
11455581|NCT01662193|Experimental|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
11455582|NCT01662193|Placebo Comparator|placebo|placebo
11455583|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles
~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
11455584|NCT01662167|Experimental|Multiple dose mtx|mtx
11455661|NCT01661673|Experimental|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
11455585|NCT01662167|Experimental|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
11455586|NCT01662154|Experimental|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
11455587|NCT01662154|Active Comparator|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
11455588|NCT01662128|Experimental|Xeloda|Xeloda
11455589|NCT01662115|Active Comparator|Nicotine gum|100 subjects who will actually get the intervention medication
11455590|NCT01662115|Sham Comparator|regular chewing gum|100 subjects who will be part of a control group
11455591|NCT01662115|No Intervention|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
11455592|NCT01662102|Experimental|Zevalin and Rituximab|90Y-Ibritumomab tiuxetan will be administered 8 to 12 weeks after the last chemotherapy infusion. Each patient randomized to this treatment group will receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Patients with a pre-treatment platelet count between 100 and 149 x109/L will receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan.The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m^2); Day 7,8, or 9 rituximab (250 mg/m^2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion.
11455593|NCT01662102|Active Comparator|Rituximab|375 mg/m^2 of rituximab, administered by IV infusion every 8 weeks
11455594|NCT01662089|Experimental|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
11455595|NCT01662089|Placebo Comparator|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
11455596|NCT01662076|Experimental|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
11455597|NCT01662063|Experimental|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
11455598|NCT01662063|Experimental|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
11455599|NCT01662050|Experimental|One arm for all patients.|Rituximab, Bendamustine, Cytarabine
11455600|NCT01662037|Experimental|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
11455601|NCT01662037|No Intervention|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
11455602|NCT01662024|Experimental|Endoscopic gastric restrictive procedure|Restrict gastric size by approximating tissue endolumenally via an incisionless/per-oral approach.
11455603|NCT01662011|Experimental|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
11455604|NCT01662011|Active Comparator|PSV group|Patients ventilated with the mode of pressure support ventilation.
11455605|NCT01661998||Harms Study Group|
11455606|NCT01661985|Active Comparator|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
11455607|NCT01661985|Active Comparator|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
11455608|NCT01661985|Active Comparator|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
11455609|NCT01661972|Experimental|Phase 1: Capecitabine and Aflibercept|A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
11455610|NCT01661972|Experimental|Phase 2: Capecitabine and Aflibercept|Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single, Phase 2 arm
11455611|NCT01661959||Non-Operative|
11455612|NCT01661959||Operative|
11455613|NCT01661946|Active Comparator|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
11455614|NCT01661946|Active Comparator|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
11455615|NCT01661933|Experimental|Necator americanus, gluten challenge|Single arm, vertical.
11455616|NCT01661920|Experimental|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
11455617|NCT01661920|Active Comparator|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
11455618|NCT01661907|Experimental|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA).
~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.375%-0.5% ropivacaine given through the epidural catheter for analgesia maintenance. Patient-controlled epidural analgesia will be provided for postoperative analgesia (established with 0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
11455662|NCT01661673|Placebo Comparator|Arm 5|Placebo orally administered for 14 days
11455663|NCT01661660|Active Comparator|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
11459806|NCT01632449|Experimental|1|Test product
11455619|NCT01661907|Active Comparator|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA).
~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of sevoflurane with or without nitrous oxide, and/or continuous intravenous infusion of propofol. Sufentanil and rocuronium will be given when needed. Patient-controlled intravenous analgesia will be provided for postoperative analgesia (established with 50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
11455620|NCT01661894|Active Comparator|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
11455621|NCT01661894|No Intervention|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
11455622|NCT01661881|Experimental|RB/RC|"Patients received 3 cycles of outpatient RB (rituximab 375 mg/m2 day 1, bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle), followed by interim CT restaging. Patients with progressive disease (PD) went off study. Those with stable disease (SD) or better went on to receive three cycles of inpatient RC (rituximab 375 mg/m2 day 1, cytarabine 3 g/m2 every 12 h for 4 doses). The cytarabine was dose reduced to:
~2 g/m2 for age >60 years old, creatinine 114.9-176.8 lmol/l (for patients ≤60 years old), and pre-existing neurotoxicity;
~1.5 g/m2 for age >60 years old AND creatinine 114.9-176.8 lmol/l, or for age >60 years old AND pre-existing neurotoxicity;
~1 g/m2 for age > 60 years old AND creatinine 114.9-176.8 lmol/l AND pre-existing neurotoxicity.
~Stem cell mobilization and collection, ASCT and post-transplantation supportive care were performed per institutional standard and not as part of this study."
11455623|NCT01661868|Active Comparator|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
11455624|NCT01661868|Active Comparator|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
11455625|NCT01661855|Active Comparator|Riluzole|
11455626|NCT01661855|Placebo Comparator|Placebo|
11455627|NCT01661842|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.
~Participants will then be followed until the week 96 study visit."
11455628|NCT01661842|Experimental|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
11455629|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
11455630|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
11455631|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
11455632|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
11455633|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
11455634|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
11455635|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
11455636|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
11455637|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
11455638|NCT01661790|Experimental|Bevacizumab & Cisplatin|Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
11455639|NCT01661790|Active Comparator|Cisplatin|Cisplatin 30mg by intrapleural given every two weeks
11455640|NCT01661777|Other|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
11455641|NCT01661777|Active Comparator|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
11455642|NCT01661777|Active Comparator|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
11455643|NCT01661764|Active Comparator|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
11455644|NCT01661764|Placebo Comparator|rs174535 (GG), placebo|Oleic Acid
11455645|NCT01661764|Active Comparator|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
11455646|NCT01661764|Placebo Comparator|rs174535 (GT), placebo|Oleic Acid
11455647|NCT01661764|Active Comparator|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
11455648|NCT01661764|Placebo Comparator|rs174535 (TT), placebo|Oleic Acid
11455649|NCT01661751|Experimental|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
11455650|NCT01661751|Active Comparator|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
11455651|NCT01661738|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
11455652|NCT01661725|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
11455653|NCT01661712|Active Comparator|Transcutaneous electrical stimulation|One night of transcutaneous electrical stimulation (electrical current titrated according to skin sensation)
11455654|NCT01661712|Sham Comparator|Sham stimulation|One night of sham stimulation (no electrical current)
11455655|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
11455656|NCT01661686|Active Comparator|Insertion of a partially covered SEMS|
11455657|NCT01661686|Active Comparator|Insertion of a Fully covered SEMS|
11455658|NCT01661673|Experimental|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
11455664|NCT01661660|Experimental|Predementia / MCI patients|Subjects at predementia stage or MCI stage
11455665|NCT01661660|Experimental|Dementia patient|Subjects at demential stage
11455666|NCT01661647|Experimental|3D knee kinematic assessment|3D knee kinematic assessment under local anesthesia
11455667|NCT01661634|Experimental|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
11455668|NCT01661634|Placebo Comparator|Placebo|Placebo lyophilizate for i.v. infusion
11455669|NCT01661621|Experimental|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
11455670|NCT01661621|Experimental|Group 2|α-blockers (Doxazosin 4 mg QD)
11455671|NCT01661608|Experimental|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
11455672|NCT01661595|Active Comparator|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
11455673|NCT01661595|Active Comparator|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
11455674|NCT01661595|Active Comparator|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
11455675|NCT01661595|Active Comparator|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
11455676|NCT01661582|Placebo Comparator|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
11455677|NCT01661582|Experimental|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
11455678|NCT01661569|Experimental|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
11455679|NCT01661569|No Intervention|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
11455680|NCT01661556|Experimental|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
11455681|NCT01661556|Active Comparator|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
11455682|NCT01661556|Placebo Comparator|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
11455683|NCT01661543|Experimental|Bean consumption to lower cholesterol|This arm will consume 90 grams of beans per day for 5 out of 7 days for 6 weeks.
11455684|NCT01661543|Placebo Comparator|Control (rice) consumed to show results|The control group will consume 90 grams of rice per day for 5 out of 7 days for 6 weeks.
11455685|NCT01661543|Experimental|Peas consumed to lower cholesterol|This arm will consume 90g of peas per day for 5 days out of each week for 6 weeks.
11455686|NCT01661530|Experimental|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
11455687|NCT01661530|Placebo Comparator|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (<3mg) vitamin E content. Three portions per week
11455688|NCT01661517|Experimental|Lifestyle Counseling|motivational interviewer
11455689|NCT01661504|No Intervention|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
11455690|NCT01661504|Experimental|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
11455691|NCT01661491||Cystic Fibrosis|Infants and toddlers with Cystic Fibrosis
11455692|NCT01661491||Non-cystic fibrosis controls|Infants and toddlers without Cystic Fibrosis
11455693|NCT01661478||Emergency Department personnel|survey
11455694|NCT01661478||Department of Psychiatry personnel|survey
11455695|NCT01661452||patients in UAB ER,|
11455696|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
11455697|NCT01661426|Active Comparator|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
11455698|NCT01661426|Active Comparator|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
11455699|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
11455700|NCT01661400|No Intervention|Control|No intervention
11455701|NCT01661400|Experimental|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
11455702|NCT01661400|Experimental|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
11455703|NCT01661387||Plenadren|Modified release hydrocortisone
11455704|NCT01661387||Other Glucocorticoid Replacement Therapy|
11455705|NCT01661374||Mechanically Ventilated|
11455706|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
11455707|NCT01661361||vancomycin cohort|
11455708|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
11455709|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
11455739|NCT01661101|Placebo Comparator|Placebo (omeprazole)|Omeprazole placebo taken once daily
11456063|NCT01658852|Placebo Comparator|Placebo|Placebo three times per day for 10days
11455710|NCT01661335|Experimental|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
11455711|NCT01661335|Placebo Comparator|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
11455712|NCT01661322|Active Comparator|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
11455713|NCT01661322|No Intervention|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
11455714|NCT01661309|Placebo Comparator|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
11455715|NCT01661309|Experimental|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
11455716|NCT01661296|Active Comparator|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
11455717|NCT01661296|Active Comparator|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
11455718|NCT01661283|Experimental|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
11455719|NCT01661270|Placebo Comparator|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
11455720|NCT01661270|Experimental|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
11455721|NCT01661257|Experimental|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
11455722|NCT01661244|Experimental|Part A - Single dose escalation|
11455723|NCT01661244|Experimental|Part B - 14 day repeat dose escalation|
11455724|NCT01661231|Experimental|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
11455725|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
11455726|NCT01661205|Experimental|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
11455727|NCT01661192|Experimental|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.
11455728|NCT01661192|No Intervention|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
11455729|NCT01661179|Experimental|Vandetanib 300mg|300 mg/day vandetanib
11455730|NCT01661166|Experimental|Fesoterodine 4mg|Fesoterodine 4mg, Oral once daily for three months
11455731|NCT01661166|Placebo Comparator|Placebo|Placebo Oral once daily for three months
11455732|NCT01661153||Cohort|
11455733|NCT01661140|Experimental|Methotrexate (MTX) Tapering Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
11455734|NCT01661140|Active Comparator|Methotrexate (MTX) Maintenance Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
11455735|NCT01661114|Experimental|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
11455736|NCT01661101|Experimental|Dabigatran|Dabigatran 110 mg capsule taken twice daily
11455737|NCT01661101|Experimental|Omeprazole|Omeprazole 20 mg capsule taken once daily
11455738|NCT01661101|Placebo Comparator|Placebo (dabigatran)|Dabigatran placebo taken twice daily
11455740|NCT01661088|Experimental|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m^2) on days 1, 8, 22, 29.
~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.
~Patients without metastatic disease will be offered surgical exploration."
11455741|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
11455742|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
11455743|NCT01661062|Experimental|Cone Beam CT|All patients will be included in the treatment arm of this study. For the purposes of this study patients will get CT scans every day for the length of their radiation therapy (in order to assess if CT every day provides additional information compared with CT scans performed less frequently). Although the exact amount of radiation patients get will be determined by their doctor, it is expected that they will get approximately 7 weeks, approximately 35 total cone beam CT scans.
11455744|NCT01661010||Control|Family members can serve as control group
11455745|NCT01661010||Sex-linked genes|Patients previously identified through outside research or diagnostic labs as having sex- chromosome variants causing deletion/duplication of sex-linked genes or entire sex chromosomes.
11455746|NCT01660984||Parents/caregivers|Parents or caregivers of study patients to assess their psychosocial experiences and needs.
11455747|NCT01660984||Patients|Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
11455748|NCT01660971|Experimental|Treatment (gemcitabine, dasatinib, erlotinib)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11455749|NCT01660958|Experimental|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
11455750|NCT01660958|Experimental|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
11455751|NCT01660958|No Intervention|Infants: No intervention|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).
~Infant phase. Routine care - no early learning intervention"
11455752|NCT01660958|Experimental|Infants: MNP/Early Learning|"Infants receive the MNP plus early learning intervention by receiving MNP sachets
~Caregivers receive early learning messaged delivered at home biweekly for one year"
11455753|NCT01660958|Experimental|Preschoolers:MNP/High qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.
~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.
~Preschools that are classified as high quality preschools."
11455754|NCT01660958|No Intervention|Preschoolers:Placebo/High qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).
~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.
~Preschools that are classified as high quality preschools."
11455755|NCT01660958|Experimental|Preschoolers:MNP/Low qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.
~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.
~Preschools that are classified as low quality preschools."
11455756|NCT01660958|No Intervention|Preschoolers:Placebo/Low qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).
~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.
~Preschools that are classified as low quality preschools."
11455757|NCT01660945|Placebo Comparator|placebo|placebo
11455758|NCT01660945|Active Comparator|vytorin 10|vytorin 10 mg
11455759|NCT01660945|Active Comparator|vytorin 20|vytorin 20 mg
11455760|NCT01660932|Placebo Comparator|placebo|placebo
11455761|NCT01660932|Active Comparator|omega 1|omega 1 gm
11455762|NCT01660932|Active Comparator|omega 2|omega 2 gm
11455763|NCT01660932|Active Comparator|omega 4|omega 4 gm
11455764|NCT01660919|Placebo Comparator|placebo|placebo
11455765|NCT01660919|Active Comparator|rosuvastatin 5|rosuvastatin 5 mg
11455766|NCT01660919|Active Comparator|rosuvastatin 10|rosuvastatin 10 mg
11455767|NCT01660919|Active Comparator|rosuvastatin 20|rosuvastatin 20 mg
11455768|NCT01660906|Experimental|Dasatinib (100 mg)|
11455769|NCT01660893|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
11455770|NCT01660893|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
11455771|NCT01660893|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
11455772|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
11455773|NCT01660867|Placebo Comparator|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo => epinephrine + 0.9% saline
11455774|NCT01660867|Experimental|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
11455775|NCT01660867|Active Comparator|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
11455776|NCT01660854|Experimental|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.
~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.
~Other Name: atovaquone/proguanil"
11455826|NCT01660464|Experimental|ADHD-Team|Intervention
11459807|NCT01632449|Experimental|2|Reference product
11455777|NCT01660854|Active Comparator|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).
~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.
~Other Name: atovaquone/proguanil"
11455778|NCT01660841|Experimental|Arm 1|
11455779|NCT01660828|Active Comparator|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
11455780|NCT01660828|No Intervention|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
11455781|NCT01660815|Experimental|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
11455782|NCT01660802|Experimental|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
11455783|NCT01660802|Sham Comparator|Sham|Sham administered in the study eye on Day 1.
11455784|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
11455785|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
11455786|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
11455787|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
11455788|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
11455789|NCT01660776||healthy volunteers|healthy volunteers
11455790|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
11455791|NCT01660763|Experimental|Sufentanil NanoTab PCA System/15 mcg|
11455792|NCT01660763|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
11455793|NCT01660750|Experimental|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
11455794|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
11455795|NCT01660724|Experimental|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
11455796|NCT01660724|Active Comparator|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
11455797|NCT01660711|Experimental|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1
~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
11455798|NCT01660698|Placebo Comparator|Placebo|maltodextrin powder
11455799|NCT01660698|Active Comparator|Probiotic|probiotic blended in maltodextrin
11455800|NCT01660685|Experimental|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
11455801|NCT01660685|Active Comparator|Enhanced Usual Care|Participants receive standard care
11455802|NCT01660672|Other|LEVETIRACETAM|Open label, dose escalation to optimal dose.
11455803|NCT01660659|Experimental|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
11455804|NCT01660659|No Intervention|standard cooking|standard way of cooking
11455805|NCT01660646|Other|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
11455806|NCT01660646|No Intervention|control|
11455807|NCT01660633|Other|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
11455808|NCT01660620|Experimental|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
11455809|NCT01660620|Placebo Comparator|placebo|masked labeling also 2 per day administration
11455810|NCT01660607|Experimental|Dose escalation|For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
11455811|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
11455812|NCT01660581|Experimental|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
11455813|NCT01660581|Placebo Comparator|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
11455814|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
11455815|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale <3
11455816|NCT01660542|Experimental|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
11455817|NCT01660529|Experimental|hTERT/Survivin Multi-Peptide Vaccination|single-arm Phase I study for patients with metastatic breast cancer who have failed at least one regimen for metastatic disease
11455818|NCT01660516||Tea|Black tea ingestion
11455819|NCT01660503|Placebo Comparator|No SCF|Twice daily consumption of snack foods containing no SCF.
11455820|NCT01660503|Experimental|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
11455821|NCT01660503|Experimental|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
11455822|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
11455823|NCT01660477|Experimental|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
11455824|NCT01660477|Experimental|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
11455825|NCT01660477|Experimental|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
11455827|NCT01660451|Experimental|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
11455828|NCT01660451|Experimental|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
11455829|NCT01660451|Experimental|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
11455830|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
11455831|NCT01660425|No Intervention|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
11455832|NCT01660425|Active Comparator|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
11455833|NCT01660412|Active Comparator|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
11455834|NCT01660412|Active Comparator|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
11455835|NCT01660399|Experimental|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
11455836|NCT01660399|Placebo Comparator|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
11455837|NCT01660386|Experimental|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
11455838|NCT01660386|Experimental|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
11455839|NCT01660386|Experimental|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
11455840|NCT01660386|Other|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
11455841|NCT01660373|Experimental|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
11455842|NCT01660373|Active Comparator|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
11455843|NCT01660360|Experimental|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
11455844|NCT01660347|Experimental|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
11455845|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
11455846|NCT01660321|Experimental|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
11455847|NCT01660308||Tumor induced osteomalcia|
11455848|NCT01660295|Experimental|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
11455849|NCT01660295|Experimental|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:
~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
11455850|NCT01660256|Experimental|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
11455851|NCT01660256|Placebo Comparator|Placebo|OPC-12759 ophthalmic solution 0%
11455852|NCT01660256|Active Comparator|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
11455853|NCT01660243|Active Comparator|MT-9938 2.5μg|
11455854|NCT01660243|Active Comparator|MT-9938 5μg|
11455855|NCT01660243|Active Comparator|MT-9938 10μg|
11455856|NCT01660243|Placebo Comparator|Placebo|
11455857|NCT01660230|Active Comparator|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
11455858|NCT01660230|Active Comparator|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
11455859|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
11455860|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
11455861|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
11455862|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
11455863|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
11455864|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
11455941|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
11455942|NCT01659697||Intensive Lifestyle counseling|
11455865|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
11455866|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
11455867|NCT01660230|Placebo Comparator|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
11455868|NCT01660217|Experimental|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
11455869|NCT01660217|Experimental|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
11455870|NCT01660204|Active Comparator|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
11455871|NCT01660204|Active Comparator|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
11455872|NCT01660204|Active Comparator|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
11455873|NCT01660191|Active Comparator|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
11455874|NCT01660191|Active Comparator|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
11455875|NCT01660191|Active Comparator|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
11455876|NCT01660165||Observational|Pregnant women
11455877|NCT01660152|Experimental|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
11455878|NCT01660152|Experimental|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
11455879|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
11455880|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
11455881|NCT01660126|Active Comparator|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
11455882|NCT01660126|Placebo Comparator|Placebo|Matched placebo
11455883|NCT01660100|Active Comparator|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
11455884|NCT01660100|Active Comparator|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
11455885|NCT01660074|Experimental|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
11455886|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
11455887|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
11455888|NCT01660048|Experimental|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
11455889|NCT01660048|Active Comparator|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
11455890|NCT01660022|Experimental|OZ439 100mg|100mg OZ439 single oral dose
11455891|NCT01660022|Experimental|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
11455892|NCT01660022|Experimental|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
11455893|NCT01660022|Experimental|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
11455894|NCT01660022|Experimental|OZ439 300mg|300mg OZ439 single oral dose
11455895|NCT01660022|Experimental|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
11455896|NCT01660022|Experimental|OZ439 800mg|800mg OZ439 single oral dose
11455897|NCT01660022|Experimental|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
11455898|NCT01660022|Placebo Comparator|Placebo|Placebo
11455899|NCT01660009|Experimental|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
11455900|NCT01660009|Experimental|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
11455901|NCT01659996|Experimental|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
11455902|NCT01659996|Experimental|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
11455903|NCT01659996|Active Comparator|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
11455904|NCT01659983|Experimental|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
11455943|NCT01659697||usual lifestyle counseling|
11456062|NCT01658852|Active Comparator|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
11455905|NCT01659983|Active Comparator|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
11455906|NCT01659970||Cohort|
11455907|NCT01659957|Experimental|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
11455908|NCT01659957|Experimental|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
11455909|NCT01659944|Experimental|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
11455910|NCT01659931|Active Comparator|Montelukast|10 mg Tablet
11455911|NCT01659931|Active Comparator|Singulair|10 mg Tablet
11455912|NCT01659918|Active Comparator|Montelukast|10 mg Tablet
11455913|NCT01659918|Active Comparator|Singulair|10 mg Tablet
11455914|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
11455915|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
11455916|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
11455917|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
11455918|NCT01659879|Experimental|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
11455919|NCT01659879|Active Comparator|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
11455920|NCT01659866|Other|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
11455921|NCT01659866|Active Comparator|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:
~trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later
~cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later
~ceftriaxone 500 mg intramuscularly 2 hours before the procedure
~gentamicin 2mg/kg intramuscularly 2 hours before the procedure
~amikacin 5 mg/kg intramuscularly 2 hours before the procedure
~aztreonam 500 mg intramuscularly 2 hours before the procedure
~imipenem 500 mg intramuscularly 2 hours before the procedure
~ceftriaxone 2000 mg intravenously 1 hour before the procedure
~gentamicin 2 mg/kg intravenously 1 hour before the procedure
~amikacin 5mg/kg intravenously 1 hour before the procedure
~aztreonam 2000 mg intravenously 1 hour before the procedure
~imipenem 1000 mg intravenously 1 hour before the procedure"
11455922|NCT01659853|Experimental|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.
~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
11455923|NCT01659840|Other|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
11455924|NCT01659840|Other|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
11455925|NCT01659827|Sham Comparator|Control|Initial injections of Marcaine and Saline (one each)
11455926|NCT01659827|Experimental|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
11455927|NCT01659827|Experimental|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
11455928|NCT01659814||Individuals with Major Depressive Disorder|
11455929|NCT01659814||Healthy Control Individuals|
11455930|NCT01659788|Experimental|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.
~Other name: Ubiquinone"
11455931|NCT01659788|Placebo Comparator|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
11455932|NCT01659775|Experimental|Sancuso patch|
11455933|NCT01659775|Active Comparator|Zofran|
11455934|NCT01659762|Experimental|autologous mesenchymal stromal cells|
11455935|NCT01659749|Other|Metabolic Camp|Metabolic Camp is an educational and social support program for females age 11 through adult with phenylketonuria (PKU) and maple syrup urine disease (MSUD), two inherited metabolic disorders (IMD). Camp provides a supportive environment for adolescent girls and women to learn about the importance of nutrition and diet self-management, with the intention of arresting the disease process and minimizing the instances of miscarriages and severe birth defects, which are high in this population. After 20+ years, Metabolic Camp is established as a unique, national program allowing up to 35 campers to live and learn during a week of nutritional support and productive activities, while simultaneously providing researchers an opportunity to gather important data.
11455936|NCT01659736|Experimental|TMS Therapy|TMS treatment
11455937|NCT01659736|Sham Comparator|TMS-Sham|This is a sham TMS condition
11455938|NCT01659723|Active Comparator|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
11455939|NCT01659723|No Intervention|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
11455940|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
11460018|NCT01631071|Experimental|Adults from 18 to 60 years old inclusive|
11455944|NCT01659684|Experimental|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
11455945|NCT01659671|Active Comparator|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
11455946|NCT01659671|Active Comparator|Control|After six months the controls have delayed surgery then are followed for 2 year
11455947|NCT01659658|Experimental|IXAZOMIB 4 mg + Dexamethasone 20 mg/day|IXAZOMIB 4 mg, capsules, orally, once on Days 1, 8, and 15; plus dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Participants may continue to receive treatment until Progressive Disease (PD) or unacceptable toxicity, whichever comes first.
11455948|NCT01659658|Active Comparator|Physician's Choice|"Participants will receive one of the following treatment options as selected by the physician:
~Dexamethasone 20 mg/day: dexamethasone 20 mg/day, orally, on Days 1-4, 9-12 and 17- 20 of each 28-day cycle.
~Dexamethasone 20 mg/day + Melphalan 0.22 mg/kg: dexamethasone 20 mg/day, orally, on Days 1-4 of each 28-day cycle; plus melphalan 0.22 mg/kg, orally, on Days 1-4 every 28 days.
~Dexamethasone 20 mg/day + Cyclophosphamide 500 mg: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 every 28 days.
~Dexamethasone 20 mg/day + Thalidomide 200 mg/day: dexamethasone 20 mg/day, orally, weekly Days 1, 8, 15 and 22 of each 28-day cycle; plus thalidomide total dose up to 200 mg/day, orally.
~Dexamethasone 20 mg/day+ Lenalidomide 15 mg/day: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus lenalidomide 15 mg/day, orally, for 21 days every 28 days."
11455949|NCT01659645|Experimental|FACBC|
11455950|NCT01659619|Experimental|erythromycin|
11455951|NCT01659619|No Intervention|saline|
11455952|NCT01659606|Experimental|alemtuzumab/fludarabine conditioning|alemtuzumab/fludarabine conditioning; cyclosporins/mycophenolate mofetil GVHD prophylaxis
11455953|NCT01659593|Experimental|procog|cognitive remedial program 13 sessions over a 6-month period
11455954|NCT01659593|Placebo Comparator|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
11455955|NCT01659580|Experimental|T89 high dose|T89 225mg bid
11455956|NCT01659580|Experimental|T89 low dose|T89 150mg bid
11455957|NCT01659580|Experimental|Sanqi+Bingpian|225mg bid
11455958|NCT01659580|Placebo Comparator|Placebo|225mg bid
11455959|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
11455960|NCT01659554|Experimental|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
11455961|NCT01659541|Experimental|Procedure & Device|Procedure/Surgery: Implantation of device; Device: Expiratory Muscle Stimulator
11455962|NCT01659502|Experimental|TL-118 alone or with pancreas cancer chemotherapy|
11455963|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
11455964|NCT01659476|Experimental|Asthma|Individuals diagnosed with asthma.
11455965|NCT01659476|Experimental|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
11455966|NCT01659476|Experimental|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.
11455967|NCT01659476|Experimental|Normal|Individuals with no history of asthma or chronic cough
11455968|NCT01659463|Experimental|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
11455969|NCT01659463|Active Comparator|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
11455970|NCT01659450|Experimental|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
11455971|NCT01659450|Experimental|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
11455972|NCT01659437|Active Comparator|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
11455973|NCT01659437|Experimental|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
11455974|NCT01659424|Other|Single Arm|This is a single arm study.
11455975|NCT01659411||Adult CHD Patients|observational
11455976|NCT01659398|Experimental|Enhanced external counterpulsation (EECP)|
11455977|NCT01659398|No Intervention|Subjects not receiving EECP|Control group to measure data from experimental group against.
11455978|NCT01659372|Experimental|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
11455979|NCT01659372|Experimental|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
11455980|NCT01659359|Experimental|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
11455981|NCT01659359|Experimental|Lidocaine|5 cc Lidocaine2%
11455982|NCT01659346|Experimental|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
11455983|NCT01659346|Active Comparator|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
11455984|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
11460763|NCT01625585||Consecutive patients undergoing SBE for OGIB|
11455985|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
11455986|NCT01659320|Experimental|Minocycline|Open label treatment using minocycline.
11455987|NCT01659307|Active Comparator|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
11455988|NCT01659307|Active Comparator|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
11455989|NCT01659307|Placebo Comparator|Lactose powder|Placebo for 7 days. Administered by mouth.
11455990|NCT01659294|Experimental|nurse case management|nurse case management of diabetic variables
11455991|NCT01659294|Active Comparator|standard diabetologist care|standard diabetologist care
11455992|NCT01659281|Active Comparator|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
11455993|NCT01659281|Active Comparator|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
11455994|NCT01659268|Experimental|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.
~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
11455995|NCT01659268|Other|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
11455996|NCT01659255|Experimental|ONO/GS-4059|
11455997|NCT01659242|Active Comparator|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))
~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.
~MTX:Kept at the highest optimal dose."
11455998|NCT01659242|Active Comparator|Leflunomide|"ARM 2:Leflunomide(LEF)
~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.
~Methotrexate:Off"
11455999|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
11456000|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
11456001|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
11456002|NCT01659203|Experimental|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
11456003|NCT01659203|Experimental|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
11456004|NCT01659190|Experimental|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
11456005|NCT01659190|No Intervention|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
11456006|NCT01659177|Experimental|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
11456007|NCT01659177|Experimental|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
11456008|NCT01659164|Experimental|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
11456009|NCT01659151|Experimental|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
11456010|NCT01659138|Experimental|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
11456011|NCT01659138|Placebo Comparator|Placebo|Placebo at Weeks 0, 2, 4, and 6
11456012|NCT01659125|Experimental|OCFighter|OCFighter
11456013|NCT01659112|Experimental|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
11456014|NCT01659112|Active Comparator|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
11456015|NCT01659099|Experimental|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
11456016|NCT01659099|Active Comparator|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
11456017|NCT01659086|Experimental|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
11456018|NCT01659086|Experimental|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
11456019|NCT01659086|Experimental|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
11456020|NCT01659086|Experimental|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
11456021|NCT01659086|Experimental|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
11456022|NCT01659086|Experimental|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
11456023|NCT01659086|Experimental|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
11456024|NCT01659086|Experimental|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
11456025|NCT01659086|Experimental|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
11456026|NCT01659086|Experimental|Group J|Subjects will receive the investigational vaccine GSK2654909A
11456027|NCT01659086|Placebo Comparator|Placebo Group|Subjects will receive Placebo
11456028|NCT01659073|Experimental|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
11456029|NCT01659060|Experimental|Dark chocolate|
11456030|NCT01659060|Placebo Comparator|Placebo chocolate|
11456031|NCT01659047|Experimental|GS-1101|GS-1101 (oral; 150 mg BID)
11456032|NCT01659034|Experimental|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
11456033|NCT01659021|Experimental|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)
~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.
~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
11456034|NCT01659021|Active Comparator|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)
~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.
~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
11456035|NCT01659008|Experimental|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
11456036|NCT01659008|Experimental|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
11456037|NCT01658995|Active Comparator|Doxycycline|Doxycycline 100 mg oral capsules, twice daily for 10 days
11456038|NCT01658995|Placebo Comparator|Placebo|Placebo capsules, identical to oral Doxycycline 100 mg, twice daily for 10 days.
11456039|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
11456040|NCT01658956|Experimental|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
11456041|NCT01658956|No Intervention|No intervention|
11456042|NCT01658943|Experimental|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
11456043|NCT01658943|Experimental|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
11456044|NCT01658930|Active Comparator|Radical Hysterectomy|
11456045|NCT01658930|Experimental|Simple Hysterectomy|
11456046|NCT01658917||Primary|Patients greater than or equal to 18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
11456047|NCT01658904|Experimental|Cohort 1- CFZ 20 mg/m^2 (Day 1,2)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
11456048|NCT01658904|Experimental|Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
11456049|NCT01658904|Experimental|Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)
~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2
~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9
~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
11456050|NCT01658891|Experimental|CHF 1535 50/6 µg|
11456051|NCT01658891|Active Comparator|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
11456052|NCT01658878|Experimental|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
11456053|NCT01658878|Experimental|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
11456054|NCT01658878|Experimental|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
11456055|NCT01658878|Experimental|Nivolumab|Nivolumab intravenous solution on specific days
11456056|NCT01658878|Active Comparator|Sorafenib|Sorafenib tablets on specific days
11456057|NCT01658878|Experimental|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
11456058|NCT01658878|Experimental|Child-Pugh B|Nivolumab intravenous solution on specific days
11456059|NCT01658878|Experimental|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
11456060|NCT01658878|Experimental|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
11456061|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
11461207|NCT01622374|Experimental|Iranian traditional music|
11456064|NCT01658839|Experimental|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
11456065|NCT01658826|Experimental|AIC316|100 mg once daily for 28 days
11456066|NCT01658826|Active Comparator|Valacyclovir|500 mg once daily for 28 days
11456067|NCT01658813|Experimental|5-Fluorouracil and Interferon|"5-Fluorouracil
~Interferon-alfa-2b"
11456068|NCT01658800|Experimental|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
11456069|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
11456070|NCT01658774|Active Comparator|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
11456071|NCT01658774|Experimental|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
11456072|NCT01658761|Experimental|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
11456073|NCT01658748|Active Comparator|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
11456074|NCT01658748|Sham Comparator|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
11456075|NCT01658735|Active Comparator|H-Wave Device|H-Wave Device with Usual Care
11456076|NCT01658735|Active Comparator|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
11456077|NCT01658735|Sham Comparator|Sham Electrotherapy|Sham Device plus Usual Care.
11456078|NCT01658722||Observational|Long term follow-up
11456079|NCT01658709||Ankle Injured|Volunteers with an ankle injury
11456080|NCT01658709||Healthy|Healthy Volunteers
11456081|NCT01658696|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
11456082|NCT01658696|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
11456083|NCT01658683|Experimental|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
11456084|NCT01658683|No Intervention|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention & Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
11456085|NCT01658670|Active Comparator|Enhanced Usual Care (EUC) exercise group|The EUC group is provided paid access to the exercise facility and has access to regular facility staff for the 18 month study period.
11456086|NCT01658670|Experimental|HEART Camp (HC) Intervention group|The HC intervention group will be provided paid access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
11456087|NCT01658657|Experimental|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
11456088|NCT01658657|Active Comparator|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
11456089|NCT01658644|No Intervention|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
11456090|NCT01658644|Experimental|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
11456091|NCT01658644|Experimental|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
11456092|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
11456093|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
11456094|NCT01658605|Experimental|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
11456095|NCT01658605|Placebo Comparator|Placebo|Administered orally for 16 weeks in a 2:1 ratio
11456096|NCT01658592|Experimental|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
11456097|NCT01658592|Sham Comparator|Placebo A|Stimulator setting is OFF
11456098|NCT01658592|Experimental|Placebo B|The contractor located in NAc is on
11456099|NCT01658592|Experimental|Placebo C|The contactor located in VC is on
11456142|NCT01658254|Experimental|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
11456143|NCT01658254|No Intervention|Non interventional arm|This arm will receive no intervention (no email with the survey)
11456100|NCT01658579|Experimental|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
11456101|NCT01658579|Experimental|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
11456102|NCT01658579|Active Comparator|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
11456103|NCT01658579|Active Comparator|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
11456104|NCT01658553|Experimental|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
11456105|NCT01658527|Experimental|Orteronel, 300 mg twice daily|
11456106|NCT01658527|Active Comparator|Bicalutamide 50 mg per day|
11456107|NCT01658514|Experimental|Met DR|One dose of 1000 mg metformin delayed-release
11456108|NCT01658514|Active Comparator|Met XR|One dose of 1000 mg metformin extended-release
11456109|NCT01658514|Placebo Comparator|Placebo|One dose of Placebo
11456110|NCT01658501|Experimental|Diet and Exercise|Diet and exercise only.
11456111|NCT01658501|Experimental|Metformin|Metformin only
11456112|NCT01658501|Experimental|Sulfonylurea|Sulfonylurea only
11456113|NCT01658501|Experimental|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
11456114|NCT01658501|Experimental|PB1023|PB1023 weekly SC injection
11456115|NCT01658501|Placebo Comparator|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
11456116|NCT01658501|Active Comparator|Active Comparator|Active Comparator (Victoza) daily SC injection
11456117|NCT01658488|Other|Regular Rice|2 servings per day of non-fortified rice
11456118|NCT01658488|Other|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
11456119|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
11456120|NCT01658462|Experimental|Arm A|Docetaxel + Nintedanib
11456121|NCT01658462|Active Comparator|Arm B|Docetaxel + increase of the dose
11456122|NCT01658449|Experimental|group A|
11456123|NCT01658449|Experimental|group B|
11456124|NCT01658436|Experimental|BEZ235 300 mg/400 mg bid (Stage 1)|Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
11456125|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
11456126|NCT01658410|Active Comparator|BQ-123|
11456127|NCT01658410|Placebo Comparator|NaCl|
11456128|NCT01658397|Experimental|Fasting|Ten day fast
11456129|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
11456130|NCT01658371||efavirenz|HIV patients on efavirenz
11456131|NCT01658358|Experimental|Phase I part :Systemic Therapy|"Drug: Lapatinib
~Drug: Lipo-Dox"
11456132|NCT01658358|Experimental|Phase II part|"Drug: Lapatinib
~Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
11456133|NCT01658332|Experimental|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
11456134|NCT01658319|Experimental|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11456135|NCT01658306|Experimental|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
11456136|NCT01658306|Sham Comparator|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
11456137|NCT01658293|Experimental|thermal stimulation|The experimental group receiving heat and cold-water stimulation, 30 minutes a session, five sessions a week for six weeks.
11456138|NCT01658293|Active Comparator|control group|The control group receiving the similar intensity of ergometer exercise as the experimental group.
11456139|NCT01658280|Active Comparator|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.
~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
11456140|NCT01658280|Experimental|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
11456141|NCT01658267|Experimental|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
11456144|NCT01658241|Experimental|Single Arm Main population|
11456145|NCT01658228|Other|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
11456146|NCT01658228|Other|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
11456147|NCT01658228|Other|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
11456148|NCT01658228|Other|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
11456149|NCT01658215|Other|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.
~Each patch will be applied for 24 hours."
11456150|NCT01658215|Other|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.
~Each patch will be applied for 24 hours."
11456151|NCT01658202|Other|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.
~Each patch will be applied for 24h."
11456152|NCT01658202|Other|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.
~Each patch will be applied for 24h."
11456153|NCT01658176|Experimental|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
11456154|NCT01658176|Active Comparator|Exemestane|Exemestane alone
11456155|NCT01658150|Experimental|isradipine|open label
11456156|NCT01658137|Active Comparator|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is ~0.5 (low)."
11456157|NCT01658137|Experimental|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of ~1.0 (high), and low in high glycemic index carbohydrates."
11456158|NCT01658124|Experimental|Tranexamic acid|(total dose 8 grams)
11456159|NCT01658124|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
11456160|NCT01658111|Active Comparator|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
11456161|NCT01658111|Experimental|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
11456162|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
11456163|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
11456164|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
11456165|NCT01658072|Experimental|Peri-Articular Injection|
11456166|NCT01658072|Active Comparator|Epidural Patient Controlled Analgesia (Epidural PCA)|
11456167|NCT01658059|Experimental|group 1|homeopathic remedy first , placebo second
11456168|NCT01658059|Experimental|group 2|placebo first, homeopathic remedy second
11456169|NCT01658046|Experimental|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
11456170|NCT01658046|Sham Comparator|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
11456171|NCT01658033|Experimental|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
11456172|NCT01658020|Experimental|DW224|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
11456173|NCT01658020|Active Comparator|Avelox|Moxifloxacin 400mg tablet P.O. once daily for 7days
11456174|NCT01658007|Experimental|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
11456175|NCT01657994|Experimental|therapy plus fes|robotic gait training plus functional electrical stimulation
11456176|NCT01657981|Experimental|Treatment arm 1|
11456177|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
11456178|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
11456179|NCT01657955|Experimental|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
11456180|NCT01657955|Active Comparator|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC<4×109 /L at d12-d14 );
11456181|NCT01657942|Experimental|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
11456182|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
11456183|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
11456184|NCT01657929|Active Comparator|20 µg H5-VLP alone given ID|
11456185|NCT01657929|Active Comparator|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
11456186|NCT01657929|Active Comparator|90 µg licensed H5N1 vaccine|
11456187|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
11456188|NCT01657903|Experimental|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
11456189|NCT01657903|Experimental|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
11456190|NCT01657903|Active Comparator|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
11456191|NCT01657903|Placebo Comparator|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
11456192|NCT01657890|Experimental|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
11456193|NCT01657890|Experimental|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
11456194|NCT01657890|Experimental|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
11456195|NCT01657890|Experimental|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
11456196|NCT01657877|Experimental|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
11456197|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
11456198|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
11456199|NCT01657877|Active Comparator|CSP Dentifrice|Dentifrice containing CSP but no fluoride
11456200|NCT01657877|Placebo Comparator|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
11456201|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
11456202|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
11456203|NCT01657851|Experimental|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
11456204|NCT01657851|Active Comparator|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
11456205|NCT01657851|Active Comparator|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
11456206|NCT01657838|Experimental|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
11456207|NCT01657838|Experimental|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
11456208|NCT01657825|Experimental|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
11456209|NCT01657812|Experimental|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
11456210|NCT01657812|Active Comparator|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
11456211|NCT01657812|Placebo Comparator|control|Drug: normalsaline
11456212|NCT01657799|Experimental|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
11456213|NCT01657799|Experimental|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
11456214|NCT01657799|Placebo Comparator|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
11456215|NCT01657786|Experimental|Ondansetron administration group|
11456216|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
11456217|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
11456218|NCT01657760|Placebo Comparator|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
11456407|NCT01656512|Active Comparator|Arm ( A)|Arm ( A) : patients will receive calcium & vitamin D
11456219|NCT01657760|Active Comparator|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
11456220|NCT01657747|No Intervention|Not applicable (imaging study)|
11456221|NCT01657734||HGG2003|"**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial
~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
11456222|NCT01657734||HGG2010|"**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial
~prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
11456223|NCT01657721|No Intervention|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.
~After a 5-week period, participants in this arm will have access to the working memory training."
11456224|NCT01657721|Experimental|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
11456225|NCT01657721|Experimental|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
11456226|NCT01657708|Other|Shared Desicion Making Model|
11456227|NCT01657682|Experimental|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
11456228|NCT01657682|Experimental|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
11456229|NCT01657669|Other|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
11456230|NCT01657656|Experimental|Vitamin D group|Vitamin D supplement by Tishcon
11456231|NCT01657656|Placebo Comparator|Control group|Identically appearing capsules
11456232|NCT01657643|Placebo Comparator|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
11456233|NCT01657643|Experimental|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
11456234|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
11456235|NCT01657617|Experimental|Radiation Therapy|Boost Stereotactic Body Radiation Therapy (SBRT)
11456236|NCT01657604|Experimental|Nilotinib+IFN|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
11456237|NCT01657604|Active Comparator|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.
11456238|NCT01657591|Experimental|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
11456239|NCT01657578|Experimental|neonates of less than 32 weeks gestational age|omeprazole
11456240|NCT01657578|Experimental|neonates born between 32 and 35 weeks of GA|omeprazole
11456241|NCT01657578|Experimental|neonates of more than 36 weeks of GA|omeprazole
11456242|NCT01657565||open appendectomy|
11456243|NCT01657565||laparscopic appendectomy|
11456244|NCT01657552|Experimental|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
11456245|NCT01657552|Experimental|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
11456246|NCT01657552|Experimental|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
11456247|NCT01657552|Experimental|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
11456248|NCT01657552|Experimental|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
11456249|NCT01657539|Experimental|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
11456250|NCT01657539|Placebo Comparator|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
11456251|NCT01657526|Experimental|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
11456252|NCT01657526|Placebo Comparator|Group B|Subjects in this group will receive placebo in Step 1 of the study
11456253|NCT01657526|Experimental|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
11456254|NCT01657526|Placebo Comparator|Group D|Subjects in this group will receive placebo in Step 2 of the study
11456255|NCT01657513|Experimental|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
11456256|NCT01657500|Active Comparator|Life 4°C media for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
11456257|NCT01657500|Active Comparator|Optisol GS|Donor cornea is stored in the Optisol GS media prior to implantation.
11456258|NCT01657487|Experimental|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
11456259|NCT01657487|Active Comparator|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
11456260|NCT01657474|Experimental|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
11456261|NCT01657474|Experimental|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
11456262|NCT01657461|Experimental|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
11456263|NCT01657461|Active Comparator|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
11456264|NCT01657448|Experimental|Methenamine, Methylthioninium|
11456265|NCT01657448|Active Comparator|Phenazopyridine|
11456266|NCT01657435||Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
11456267|NCT01657422|Experimental|PACE+ Intervention|Intervention Group
11456268|NCT01657422|No Intervention|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
11456269|NCT01657409|Experimental|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
11456270|NCT01657409|Experimental|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
11456271|NCT01657409|Experimental|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
11456272|NCT01657396|Active Comparator|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
11456273|NCT01657396|Active Comparator|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
11456274|NCT01657396|Active Comparator|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
11456275|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
11456276|NCT01657370|Placebo Comparator|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
11456277|NCT01657370|Experimental|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
11456278|NCT01657370|Experimental|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
11456279|NCT01657370|Experimental|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
11456280|NCT01657370|Experimental|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
11456281|NCT01657370|Experimental|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
11456282|NCT01657357||PAO, osteoarhritis, THA|
11456283|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED.
11456284|NCT01657331|Experimental|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
11456285|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
11456328|NCT01657045|Experimental|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
11456286|NCT01657305|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
11456287|NCT01657305|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
11456288|NCT01657292|Experimental|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
11456289|NCT01657292|Other|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
11456290|NCT01657279|Experimental|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
11456291|NCT01657266|Experimental|PRO-155|"Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
~Maintenance therapy: 1 drop 3 times a day for 30 days"
11456292|NCT01657266|Active Comparator|Nevanac|"Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension
~Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye
~Maintenance therapy: 1 drop 3 times a day for 30 days"
11456293|NCT01657253|Experimental|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution
~doses: 1 drop in each eye, quarter in day"
11456294|NCT01657253|Active Comparator|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar
~doses: 1 drop in each eye, quarter in day"
11456295|NCT01657240|Experimental|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
11456296|NCT01657240|Active Comparator|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
11456297|NCT01657227|Experimental|Intervention to Patients|Only patients receive intervention
11456298|NCT01657227|Experimental|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
11456299|NCT01657227|Experimental|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
11456300|NCT01657227|Other|Control|Patients receive usual care
11456301|NCT01657214|Experimental|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
11456302|NCT01657201|Experimental|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
11456303|NCT01657201|Experimental|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
11456304|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
11456305|NCT01657175|Experimental|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
11456306|NCT01657175|No Intervention|Control|"The patients randomized to the control group get care as usual"
11456307|NCT01657162|Experimental|Alendronate|Alendronate
11456308|NCT01657149|Experimental|Research Group|receive lymphatic massage and individual physiotherapy
11456309|NCT01657149|Active Comparator|Control group|receive individual physiotherapy only
11456310|NCT01657136|Active Comparator|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
11456311|NCT01657136|Active Comparator|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
11456312|NCT01657123|Placebo Comparator|placebo|
11456313|NCT01657123|Experimental|hydrocortisone stress dosage|
11456314|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
11456315|NCT01657097|Experimental|INCS|Fluticasone propionate 400 microgram daily
11456316|NCT01657097|Placebo Comparator|Placebo|Placebo
11456317|NCT01657084|Experimental|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
11456318|NCT01657084|Experimental|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
11456319|NCT01657084|Experimental|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
11456320|NCT01657071|Experimental|Group A|
11456321|NCT01657071|Active Comparator|Group B|
11456322|NCT01657058|Experimental|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
11456323|NCT01657058|Experimental|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
11456324|NCT01657058|Placebo Comparator|Control # 1|No soluble viscous fibre blend
11456325|NCT01657058|Experimental|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
11456326|NCT01657058|Placebo Comparator|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
11456327|NCT01657045|Experimental|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
11456329|NCT01657045|Experimental|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
11456330|NCT01657032|Experimental|Lactobacillus GG and Smectite|"Children received:
~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and
~smectite, dose 3 g, once daily orally until diarrhea stopped"
11456331|NCT01657032|Placebo Comparator|Lactobacillus GG and Placebo|"Children received:
~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and
~placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
11456332|NCT01657019|Experimental|Lisdexamfetamine dimesylate|
11456333|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
11456334|NCT01656980|Experimental|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
11456335|NCT01656980|Sham Comparator|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
11456336|NCT01656967|Experimental|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
11456337|NCT01656967|Experimental|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
11456338|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
11456339|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
11456340|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
11456341|NCT01656928|Other|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
11456342|NCT01656928|Active Comparator|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
11456343|NCT01656915||Healthy men|Healthy male subjects with normal weight
11456344|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
11456345|NCT01656902|Experimental|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
11456346|NCT01656902|Active Comparator|Microfracture|Microfracture is the standard care surgery.
11456347|NCT01656889|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
11456348|NCT01656889|Placebo Comparator|Vehicle|Vehicle Control (fibrinogen solution & thrombin solution without cells)
11456349|NCT01656876|Experimental|Mirror therapy|mirror box training with or without sham mesh glove stimulation
11456350|NCT01656876|Experimental|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
11456351|NCT01656876|Active Comparator|Controlled intervention|conventional interventions
11456352|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
11456353|NCT01656850|Experimental|Almond diet first, then NCEP Diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
11456354|NCT01656850|Experimental|NCEP diet first, then Almond diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
11456355|NCT01656837|Experimental|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, & Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, & Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
11456356|NCT01656837|Experimental|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
11456357|NCT01656811|Experimental|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
11456358|NCT01656811|Experimental|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
11456359|NCT01656811|Active Comparator|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
11456360|NCT01656811|Placebo Comparator|Placebo|Placebo delivered via MDI
11456361|NCT01656798|Experimental|fasted condition|
11456362|NCT01656798|Experimental|fec condition|
11456363|NCT01656785|Experimental|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
11456364|NCT01656772|Active Comparator|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
11456365|NCT01656772|Experimental|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
11456366|NCT01656759|No Intervention|Control Group|Control group. Will not receive the fibrin spray.
11456402|NCT01656538|Active Comparator|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
11456403|NCT01656525|Experimental|1|
11456404|NCT01656525|Experimental|2|
11456367|NCT01656759|Active Comparator|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.
~Patients will be randomized to receive spray or not and postop parameters measured."
11456368|NCT01656746|Experimental|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
11456369|NCT01656733|Experimental|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
11456370|NCT01656733|Placebo Comparator|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
11456371|NCT01656720|Placebo Comparator|Placebo|Placebo 2g Suppository
11456372|NCT01656720|Active Comparator|NRL001 5mg|5mg NRL001 in a 2g suppository
11456373|NCT01656720|Active Comparator|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
11456374|NCT01656720|Active Comparator|NRL001 10mg|10mg NRL001 in a 2g suppository
11456375|NCT01656707|Experimental|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
11456376|NCT01656707|Experimental|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
11456377|NCT01656681|Experimental|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.
~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
11456378|NCT01656681|Active Comparator|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.
~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
11456379|NCT01656668|Experimental|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
11456380|NCT01656668|Placebo Comparator|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
11456381|NCT01656655||PTSD group|Patients with PTSD
11456382|NCT01656655||Control Group|non PTSD group
11456383|NCT01656642|Experimental|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
11456384|NCT01656642|Experimental|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
11456385|NCT01656642|Experimental|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
11456386|NCT01656642|Experimental|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
11456387|NCT01656642|Experimental|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
11456388|NCT01656642|Experimental|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
11456389|NCT01656642|Experimental|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
11456390|NCT01656629|Active Comparator|teriparatide|teriparatide 20 mcg sq for 3 months
11456391|NCT01656629|Active Comparator|Alendronate|70 mg po weekly for 3 months
11456392|NCT01656629|Active Comparator|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
11456393|NCT01656616||EMS cyanide exposure patients|
11456394|NCT01656603|Experimental|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
11456395|NCT01656590|Other|High Protein and Exercise therapy along-with Nocturnal Enteral|
11456396|NCT01656564||HIV|Individuals who acquired HIV in early life
11456397|NCT01656551|Active Comparator|A: Gemcitabine|Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks
11456398|NCT01656551|Experimental|B: Gemcitabine + Cisplatin|Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks
11456399|NCT01656551|Active Comparator|C: Pemetrexed|
11456400|NCT01656551|Experimental|D: Pemetrexed + Cisplatin|
11456401|NCT01656538|Experimental|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
11456408|NCT01656512|Experimental|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
11456409|NCT01656499|Active Comparator|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
11456410|NCT01656499|Placebo Comparator|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
11456411|NCT01656486|Experimental|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
11456412|NCT01656473|Experimental|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
11456413|NCT01656460|Experimental|Stereotactic radiation Arm 1|"Dose Levels/total Dose
~1 16 Gy"
11456414|NCT01656460|Experimental|Stereotactic radiation Arm 2|2 20 Gy
11456415|NCT01656460|Experimental|Stereotactic radiation Arm 3|3 24 Gy
11456416|NCT01656460|Experimental|Stereotactic radiation Arm 4|4 28 Gy
11456417|NCT01656447||Patients with Scleroderma|Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort.
11456418|NCT01656434|Experimental|NOMAC-E2|Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
11456419|NCT01656434|Active Comparator|NETA-EE|Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
11456420|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
11456421|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
11456422|NCT01656408|Experimental|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
11456423|NCT01656408|Experimental|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
11456424|NCT01656408|Experimental|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
11456425|NCT01656408|Experimental|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
11456426|NCT01656408|Experimental|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
11456427|NCT01656408|Experimental|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
11456428|NCT01656408|Experimental|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
11456429|NCT01656408|Experimental|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
11456430|NCT01656408|Experimental|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
11456431|NCT01656408|Experimental|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
11456432|NCT01656395|Experimental|MK-1029 10 mg|Participants receive MK-1029 10 mg tablets once daily (QD) for 12 weeks
11456433|NCT01656395|Experimental|MK-1029 30 mg|Participants receive MK-1029 30 mg tablets QD for 12 weeks
11456434|NCT01656395|Experimental|MK-1029 60 mg|Participants will receive MK-1029 two 30 mg tablets QD for 12 weeks
11456435|NCT01656395|Experimental|MK-1029 150 mg|Participants will receive MK-1029 150 mg tablets QD for 12 weeks
11456436|NCT01656395|Active Comparator|Montelukast 10 mg|Participants will receive Montelukast 10 mg tablets QD for 12 weeks
11456437|NCT01656395|Placebo Comparator|Placebo|Participants will receive Placebo tablets QD for 12 weeks
11456438|NCT01656395|Experimental|MK-1029 1 mg or 3 mg|Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
11456439|NCT01656395|Experimental|Montelukast 10 mg + MK-1029|Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
11456440|NCT01656382|Active Comparator|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
11456441|NCT01656382|Experimental|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
11456442|NCT01656369|Active Comparator|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
11456443|NCT01656369|Active Comparator|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
11456444|NCT01656356|Active Comparator|A/17/turkey/Turkey/05/133 (H5N2)|
11456445|NCT01656356|Placebo Comparator|Placebo|
11456446|NCT01656343||Belatacept treated kidney-only transplant recipients|
11456447|NCT01656343||CNI treated kidney-only transplant recipients|
11456448|NCT01656330|Experimental|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
11456530|NCT01655823|Experimental|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
11456449|NCT01656330|Experimental|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
11456450|NCT01656330|Experimental|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
11456451|NCT01656317|Active Comparator|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.
~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
11456452|NCT01656317|No Intervention|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
11456453|NCT01656304|Experimental|Treatment (monoclonal antibody, antiangiogenesis)|Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
11456454|NCT01656278|Active Comparator|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
11456455|NCT01656278|Experimental|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
11456456|NCT01656265|Experimental|ARQ 197|
11456457|NCT01656252|Experimental|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
11456458|NCT01656252|Experimental|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
11456459|NCT01656252|Experimental|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
11456460|NCT01656239|Experimental|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
11456461|NCT01656239|Experimental|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
11456462|NCT01656239|Experimental|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
11456463|NCT01656239|Placebo Comparator|sugar pill|Once daily oral dose of placebo for 12 weeks
11456464|NCT01656226|Experimental|Eryfotona AK-NMSC® cream|
11456465|NCT01656226|Other|Sunscreen SPF 50+|
11456466|NCT01656213|Experimental|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
11456467|NCT01656213|No Intervention|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).
~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
11456468|NCT01656200|Experimental|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
11456469|NCT01656187|Experimental|Memantine, Then Placebo|Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
11456470|NCT01656187|Experimental|Placebo, Then Memantine|Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.
11456471|NCT01656174||No Treatment|
11456472|NCT01656161|Experimental|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
11456473|NCT01656148|Experimental|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
11456474|NCT01656148|Placebo Comparator|Placebo|In the intervention phase 50% will receive placebo BID
11456475|NCT01656135|Other|Reference Group|"Basiliximab (Simulect®):
~Day 0: 20mg IV ≤2h prior to surgery
~Day 4: 20mg IV
~Prednisolone:
~Day 0: 500mg IV (250mg pre-op, 250mg intra-op)
~Day 1: 125mg IV
~Day 2 - 14: 20mg/day oral
~Week 3 - 4: 15mg/day oral
~Week 5 - 8: 10mg/day oral
~Week 9 - 12: 5mg/day oral
~Week 13 - 14: 2.5mg/day oral
~Week 15 - Study End: Cessation
~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.
~Mycophenolate Mofetil (MMF, or biologic equivalent):
~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:
~Day -1 - 14: 2g/day oral
~Day 15 - Study End 1.5g/day oral (750mg twice daily)
~Tacrolimus (or biologic equivalent):
~Day -4 - 14: 3-12ng/ml
~Week 3 - 12: 3-10ng/ml
~Week 13 - 36: 3-8ng/ml
~Week 37 - Study End: 3-6ng/ml"
11456476|NCT01656122|Experimental|PK|PK of abacavir and lamivudine
11456477|NCT01656109|Experimental|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load < 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
11456478|NCT01656109|Experimental|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
11456479|NCT01656096|Experimental|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
11456480|NCT01656096|Sham Comparator|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
11456481|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
11456482|NCT01656083||Non-SM intervention group: varenicline|varenicline only
11456483|NCT01656070|Experimental|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).
~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
11456484|NCT01656070|Placebo Comparator|placebo|"placebo
~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
11456485|NCT01656057|Experimental|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
11456486|NCT01656057|Experimental|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
11456487|NCT01656057|Experimental|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
11456488|NCT01656057|Experimental|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
11456489|NCT01656057|Experimental|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
11456490|NCT01656057|Experimental|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
11456491|NCT01656044|Active Comparator|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
11456492|NCT01656044|Experimental|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
11456493|NCT01656031|Experimental|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
11456494|NCT01656018|Experimental|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
11456495|NCT01656018|Experimental|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
11456496|NCT01656018|Experimental|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
11456497|NCT01656018|Experimental|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
11456498|NCT01656018|Experimental|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
11456499|NCT01656018|Experimental|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
11456500|NCT01656018|Experimental|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
11456501|NCT01656018|Experimental|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
11456502|NCT01656018|Experimental|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
11456503|NCT01656018|Experimental|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
11456504|NCT01656005|Experimental|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
11456505|NCT01656005|Active Comparator|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
11456506|NCT01655992|Experimental|S1 generic|40mg／m2 bid four weeks on two weeks off
11456507|NCT01655992|Active Comparator|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
11456508|NCT01655979|Experimental|MEP-1|
11456509|NCT01655979|Experimental|MEP-2|
11456510|NCT01655966|Active Comparator|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
11456511|NCT01655966|Experimental|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
11456512|NCT01655953|Experimental|Campaign 1|
11456513|NCT01655953|Experimental|Campaign 2|
11456514|NCT01655940||Cardiac bypass patients|
11456515|NCT01655927|Experimental|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
11456516|NCT01655927|Placebo Comparator|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
11456517|NCT01655914|Active Comparator|Arm A|"Sequence of Exposure:
~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
11456518|NCT01655914|Active Comparator|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
11456519|NCT01655901|Experimental|Active video gaming|Playing Kinect
11456520|NCT01655901|Experimental|Passive video gaming|Playing Xbox 360
11456521|NCT01655901|Experimental|Resting|Stay seated on a comfortable chair
11456522|NCT01655888|Experimental|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
11456523|NCT01655875|Experimental|bone marrow transplant|
11456524|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
11456525|NCT01655849|Experimental|Z160|375mg BID
11456526|NCT01655849|Placebo Comparator|placebo|matching placebo control
11456527|NCT01655836|Experimental|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
11456528|NCT01655823|Placebo Comparator|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
11456529|NCT01655823|Experimental|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
11456714|NCT01654536|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg
11456531|NCT01655823|Experimental|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
11456532|NCT01655823|Experimental|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
11456533|NCT01655810|Active Comparator|Vitamin D 4000 IU|PO daily
11456534|NCT01655810|Active Comparator|Vitamin D 600 IU|PO daily
11456535|NCT01655797|Experimental|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
11456536|NCT01655797|No Intervention|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
11456537|NCT01655784|Active Comparator|Eighteen Coils (0.014-0.0155 inch)|Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
11456538|NCT01655784|Active Comparator|Standard Coils (0.014 inch)|Subjects who randomize to this arm will receive the standard diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target 360 Standard, Target 360 Soft, Target 360 Ultra, Target 360 NANO, Target 360 Helical Ultra, GDC-10 360 Standard SR, GDC-10 360 Soft SR, GDC-10 UltraSoft, GDC-10 3D, GDC-10 2D, GDC-10 Soft 2D SR, GDC-10 Soft SR, GDC-10 Soft, and/or any additional 0.014 inch or less diameter bare platinum intracranial coils.
11456539|NCT01655771|Experimental|Elderly|TD-1211 Dose 1
11456540|NCT01655771|Experimental|Younger|TD-1211 Dose 2
11456541|NCT01655758|Active Comparator|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
11456542|NCT01655758|Active Comparator|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
11456543|NCT01655758|Active Comparator|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
11456544|NCT01655758|Active Comparator|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
11456545|NCT01655758|Active Comparator|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
11456546|NCT01655745|Experimental|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
11456547|NCT01655745|Experimental|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
11456548|NCT01655732|Experimental|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
11456549|NCT01655719|Experimental|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:
~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.
~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
11456550|NCT01655706|Active Comparator|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
11456551|NCT01655706|Active Comparator|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
11456552|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 20mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
11456553|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
11456554|NCT01655693|Active Comparator|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
11456555|NCT01655680|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
11456556|NCT01655680|Experimental|ABT-126 Middle Dose|ABT-126 Middle Dose
11456557|NCT01655680|Experimental|ABT-126 High Dose|ABT-126 High Dose
11456558|NCT01655680|Placebo Comparator|Placebo|Placebo
11456559|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
11456560|NCT01655654|No Intervention|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
11456561|NCT01655654|Active Comparator|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
11456562|NCT01655641|Experimental|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid
~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.
~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
11456563|NCT01655641|Active Comparator|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
11456564|NCT01655628|Experimental|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
11456565|NCT01655628|Active Comparator|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
11456566|NCT01655615|Experimental|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
11456567|NCT01655602|Experimental|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
11456568|NCT01655602|Experimental|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
11456569|NCT01655602|Experimental|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
11456570|NCT01655576|No Intervention|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
11456571|NCT01655576|Experimental|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
11456572|NCT01655563|Active Comparator|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
11456573|NCT01655563|Experimental|Pharmacogenetic Arm|"Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.
~CYP3A5 non-expressor starting dose:
~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours
~CYP3A5 expressor starting dose:
~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours"
11456574|NCT01655550|Other|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
11456575|NCT01655550|Experimental|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
11456576|NCT01655524|Experimental|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
11456577|NCT01655511|Experimental|Period 1|240 mg tafamidis arm
11456578|NCT01655511|Experimental|Period 2|480 mg arm
11456579|NCT01655511|Experimental|Period 3|TBD dose
11456580|NCT01655498|Experimental|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
11456581|NCT01655485|Experimental|Patient teaching|ipad application for social script book
11456582|NCT01655472|Active Comparator|healthy parents|
11456583|NCT01655472|Active Comparator|schizophrenic parents|
11456584|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
11456585|NCT01655446|Experimental|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
11456586|NCT01655446|Experimental|Mirror Therapy|Mirror Therapy (MT)
11456587|NCT01655446|Active Comparator|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
11456588|NCT01655446|Experimental|Robotic Rehabilitation|Robotic Rehabilitation (RR)
11456589|NCT01655446|Placebo Comparator|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
11456590|NCT01655433|Experimental|Therapeutic Hypothermia Treatment|
11456591|NCT01655433|Active Comparator|No Hypothermia Treatment|control group is no hypothermia treatment
11456592|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
11456593|NCT01655407|Experimental|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
11456594|NCT01655407|Active Comparator|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
11456595|NCT01655381|Experimental|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
11456596|NCT01655368|Experimental|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
11456597|NCT01655368|Other|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
11456598|NCT01655355||Revison of the hip joint|
11456599|NCT01655342||formocresol|
11456600|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
11456601|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
11456602|NCT01655316|Experimental|Verapamil|40 mg Verapamil Per Oral
11456603|NCT01655303|Experimental|Metoprolol Per Oral|50 mg Metoprolol
11456604|NCT01655303|Experimental|Verapamil|40 mg Verapamil Per Oral
11456605|NCT01655303|Experimental|Propranolol|40 mg Propranolol Per Oral
11456606|NCT01655303|Experimental|Diltiazem|60 mg Diltiazem Per Oral
11456607|NCT01655290|Experimental|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
11456608|NCT01655290|Experimental|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
11456609|NCT01655277|Experimental|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
11456610|NCT01655277|Experimental|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
11456611|NCT01655264|Active Comparator|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
11456612|NCT01655264|Experimental|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
11456613|NCT01655251|Experimental|Intervention|Video (DVD) discharge instructions
11456614|NCT01655251|No Intervention|Control|
11456615|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
11456616|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
11456617|NCT01655238||>99% BMI NCH main OR|Patients having a BMI >99% who are seen in the main operating rooms.
11456618|NCT01655225|Experimental|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
11456619|NCT01655225|Experimental|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
11456620|NCT01655225|Experimental|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
11456621|NCT01655225|Experimental|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
11456622|NCT01655225|Experimental|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
11456623|NCT01655225|Experimental|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
11456624|NCT01655225|Experimental|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
11456625|NCT01655225|Experimental|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
11456626|NCT01655225|Experimental|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
11456627|NCT01655212|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
11456628|NCT01655212|No Intervention|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
11456629|NCT01655199|Experimental|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
11456630|NCT01655186|Placebo Comparator|Placebo|Oral, once daily
11456631|NCT01655186|Experimental|Bardoxolone Methyl|Oral, once daily
11456632|NCT01655173|Experimental|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
11456633|NCT01655173|Active Comparator|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
11461479|NCT01620463|Placebo Comparator|Placebo|
11456634|NCT01655160|Experimental|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
11456635|NCT01655160|Active Comparator|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
11456636|NCT01655147|Experimental|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
11456637|NCT01655121|Experimental|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
11456638|NCT01655121|Experimental|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
11456639|NCT01655108|Placebo Comparator|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
11456640|NCT01655108|Active Comparator|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
11456641|NCT01655095|Experimental|PEG and Prucalopride|
11456642|NCT01655095|Experimental|Picosalax and Prucalopride|
11456643|NCT01655082|Experimental|V0116|One patch per day (during 24 hours) for 21 days
11456644|NCT01655082|Active Comparator|Reference|One patch per day (during 24 hours) for 21 days
11456645|NCT01655069|Experimental|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
11456646|NCT01655069|Experimental|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
11456647|NCT01655069|Experimental|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
11456648|NCT01655069|Experimental|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
11456649|NCT01655056|Experimental|low male dose|Japanese and Caucasian males
11456650|NCT01655056|Experimental|medium male dose|Japanese and Caucasian males
11456651|NCT01655056|Experimental|high male dose|Japanese and Caucasian males
11456652|NCT01655056|Experimental|high female dose|Japanese and Caucasian females
11456653|NCT01655056|Experimental|highest male dose|Japanese and Caucasian males
11456654|NCT01655043|Experimental|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
11456655|NCT01655030|Experimental|creatine monohydrate|6g qd for 6 weeks
11456656|NCT01655030|Placebo Comparator|placebo|6g qd for 6 weeks
11456657|NCT01655017|Experimental|biopsy|Obesity with BMI> 40 kg/m² or obesity with BMI between >35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
11456658|NCT01655017|No Intervention|healthy volunteers|biopsy during a surgery
11456659|NCT01655004|Experimental|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
11456660|NCT01654991|Active Comparator|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
11456661|NCT01654991|Experimental|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
11456662|NCT01654965|Experimental|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11456663|NCT01654939|Experimental|rifaximin|All patients will be taking rifaximin 550 mg twice daily
11456664|NCT01654926||Heart Failure patients|
11456665|NCT01654913|Experimental|surgical patients|patients studied just before induction of anesthesia
11456666|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
11456667|NCT01654887|Experimental|Lung Ultrasound|LUS first with the option of obtaining CXR second
11456668|NCT01654887|Active Comparator|Chest X-Ray|CXR first followed by LUS second
11456669|NCT01654874|Experimental|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
11456670|NCT01654874|Experimental|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
11456671|NCT01654861|Experimental|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
11456672|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
11456715|NCT01654536|Active Comparator|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg
11456716|NCT01654523|Other|Treatment arm|Open trial with no randomization
11456673|NCT01654835|Active Comparator|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
11456674|NCT01654835|Placebo Comparator|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
11456675|NCT01654822|Placebo Comparator|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
11456676|NCT01654822|Experimental|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
11456677|NCT01654809|Experimental|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
11456678|NCT01654809|Active Comparator|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
11456679|NCT01654809|Active Comparator|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
11456680|NCT01654796|Active Comparator|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
11456681|NCT01654796|Placebo Comparator|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
11456682|NCT01654796|Other|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
11456683|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
11456684|NCT01654770|Active Comparator|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
11456685|NCT01654770|Active Comparator|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
11456686|NCT01654731|Experimental|Bezafibrate|400 mg/Day
11456687|NCT01654731|Placebo Comparator|Placebo|1 tablet/ day
11456688|NCT01654718|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
11456689|NCT01654718|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
11456690|NCT01654705|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
11456691|NCT01654705|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
11456692|NCT01654692|Experimental|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
11456693|NCT01654679|Active Comparator|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
11456694|NCT01654679|Sham Comparator|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
11456695|NCT01654666|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.
~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least two weeks before carotid artery stenting.
~Procedure: Carotid Artery Stenting"
11456696|NCT01654666|Active Comparator|Control group|Treatment:Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
11456697|NCT01654666|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.
~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in RIPC group do it twice a day for at least two weeks before carotid artery stenting.
~Procedure: Carotid Artery Stenting"
11456698|NCT01654653|Experimental|HSL(Totilac)|Hypertonic Sodium Lactate
11456699|NCT01654653|Active Comparator|6% HES (Voluven)|6% Hydroxyethyl Starch
11456700|NCT01654640|Experimental|Metformin group|Metformin 500mg 1 tablet p.o. bid
11456701|NCT01654640|Placebo Comparator|Placebo group|1 tablet p.o. bid
11456702|NCT01654627|Experimental|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
11456703|NCT01654627|Active Comparator|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
11456704|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
11456705|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
11456706|NCT01654601|Experimental|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose
~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
11456707|NCT01654601|Experimental|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose
~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
11456708|NCT01654575|Experimental|Methotrexate|25mg/week orally
11456709|NCT01654575|Active Comparator|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
11456710|NCT01654562|Experimental|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
11456711|NCT01654562|Active Comparator|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
11456712|NCT01654549|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
11456713|NCT01654549|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
11461480|NCT01620450|Experimental|NN2000|
11456718|NCT01654510|Active Comparator|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
11456719|NCT01654497|Experimental|Dexanabinol|
11456720|NCT01654484|Experimental|Low Dose DE-117|Monotherapy
11456721|NCT01654484|Experimental|Medium Dose DE-117|Monotherapy
11456722|NCT01654484|Experimental|High Dose DE-117|Monotherapy
11456723|NCT01654484|Experimental|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
11456724|NCT01654484|Experimental|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
11456725|NCT01654484|Experimental|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
11456726|NCT01654484|Active Comparator|0.0015% tafluprost|Monotherapy
11456727|NCT01654484|Placebo Comparator|Placebo|Monotherapy
11456728|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
11456729|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
11456730|NCT01654458|Experimental|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
11456731|NCT01654458|No Intervention|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
11456732|NCT01654445|Experimental|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
11456733|NCT01654432|Placebo Comparator|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
11456734|NCT01654432|Active Comparator|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
11456735|NCT01654419|Active Comparator|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
11456736|NCT01654419|Experimental|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
11456737|NCT01654406|Active Comparator|Control|Pulsed dye laser (V-beam)
11456738|NCT01654406|Experimental|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
11456739|NCT01654393|Experimental|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
11456740|NCT01654393|No Intervention|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
11456741|NCT01654380|Experimental|Part A, Cohort A; LY2605541|Healthy participants received 5.1 milliunits/minute (mU/min) in Period 1, 10.2 mU/min in Period 2, and 15.3 mU/min in Period 3, administered intravenously (IV) over 8 hours. All periods were separated by a minimum 6-day washout period
11456742|NCT01654380|Active Comparator|Part A, Cohort A; Insulin Glargine|Healthy participants received insulin glargine (30 milliunits/meter squared/minute [mU/m^2/min]) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period
11456743|NCT01654380|Experimental|Part A, Cohort B; LY2605541|Healthy participants received 15.3 mU/min in Period 1, 37.0 mU/min in Period 2, and 74.1 mU/min in Period 3, administered IV over 8 hours. All periods were separated by a minimum 6-day washout period.
11456744|NCT01654380|Active Comparator|Part A, Cohort B; Insulin Glargine|Healthy participants received insulin glargine (60 mU/m^2/min) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period.
11456745|NCT01654380|Experimental|Part B; LY2605541|Participants with T1DM received 15.3 mU/min in 1 of 4 study periods, administered IV up to 8 hours and received 74.1 mU/min in 1 of 4 Periods, administered IV up to 10 hours. Each dose was separated by a minimum 6-day washout period.
11456746|NCT01654380|Active Comparator|Part B; Insulin Glargine|Participants with T1DM received 1 insulin glargine dose per study period (10 and 20 mU/m^2/min) administered IV over 8 hours in 2 of 4 study periods. Each dose was separated by a minimum 6-day washout period.
11456747|NCT01654367|Experimental|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
11456748|NCT01654341|No Intervention|Usual Care Group|Subjects undergo usual standard of care
11456749|NCT01654341|Experimental|Intervention Group|Intervention with exercise, dietary and educational programs
11456750|NCT01654328|Experimental|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
11456751|NCT01654328|Active Comparator|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
11456752|NCT01654315|Experimental|Experimental: Myomo Only Group|"Experimental: Myomo Only Group Patients are administered rehabilitative therapy known as repetitive task specific practice (RTP) using only the Myomo robotic device targeting their affected arms on 3 days/week, in 1/2 hour increments, during an 8-week period."
11456753|NCT01654315|Experimental|Experimental: Myomo + RTP Group|Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.
11456754|NCT01654315|Active Comparator|Active Comparator: RTP Group|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
11456755|NCT01654302|Active Comparator|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
11456756|NCT01654302|Placebo Comparator|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
11456986|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
11456757|NCT01654289|Experimental|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
11456758|NCT01654289|Experimental|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
11456759|NCT01654289|No Intervention|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
11456760|NCT01654276|Experimental|Febuxostat|Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.
11456761|NCT01654263|Experimental|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
11456762|NCT01654263|Experimental|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
11456763|NCT01654263|Experimental|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
11456764|NCT01654263|Experimental|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
11456765|NCT01654263|Experimental|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
11456766|NCT01654263|Experimental|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
11456767|NCT01654250|Experimental|Active|NWP09
11456768|NCT01654250|Placebo Comparator|Placebo|Placebo
11456769|NCT01654237|No Intervention|Muskind|three questionnaires to be completed by the subjects
11456770|NCT01654224|Active Comparator|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
11456771|NCT01654224|Active Comparator|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
11456772|NCT01654211|Experimental|Part 1: iv danoprevir|
11456773|NCT01654211|Placebo Comparator|Part 1: placebo|
11456774|NCT01654211|Experimental|Part 2 A: iv danoprevir|
11456775|NCT01654211|Active Comparator|Part 2 B: oral danoprevir|
11456776|NCT01654211|Active Comparator|Part 2 C: ritonavir|
11456777|NCT01654211|Experimental|Part 3 D: iv danoprevir|
11456778|NCT01654211|Experimental|Part 3 E: iv danoprevir + cyclosporine|
11456779|NCT01654198||Psoriatic arthritis|
11456780|NCT01654185|Experimental|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
11456781|NCT01654185|Active Comparator|Aromatase Inhibitor|AI monotherapy
11456782|NCT01654172|Experimental|High Flavanol Cocoa|"Cocoa drink containing ~450mg cocoa flavanols and 10g carbohydrate per serving.
~Subject consumes 2 servings per day, for 7 days."
11456783|NCT01654172|Placebo Comparator|Low Flavanol Cocoa|"Cocoa drink containing ~25mg cocoa flavanols and 10g carbohydrate per serving.
~Subject consumes 2 servings per day, for 7 days."
11456784|NCT01654159|Placebo Comparator|Monofocal|"Monofocal IOL Implant
~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
11456785|NCT01654159|Experimental|Multifocal|"Multifocal IOL
~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
11456786|NCT01654159|Experimental|Toric|"Toric IOL
~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
11456787|NCT01654146|Active Comparator|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
11456788|NCT01654146|Experimental|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
11456789|NCT01654146|Experimental|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
11456790|NCT01654133|Experimental|endovascular repair TAAA|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
11456791|NCT01654120|Experimental|liraglutide plus insulin|
11456792|NCT01654120|Active Comparator|Insulin titration only|
11456793|NCT01654107|Experimental|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
11456794|NCT01654107|Active Comparator|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
11456795|NCT01654094|Experimental|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
11456796|NCT01654094|Active Comparator|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
11456797|NCT01654081|Experimental|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
11456798|NCT01654068|Experimental|Radiation Therapy to Local Spine Metastasis|Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
11456799|NCT01654042|No Intervention|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
11456987|NCT01652755||non-AKI group|patients without AKI during study period
11456800|NCT01654042|Experimental|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
11456801|NCT01654029|No Intervention|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
11456802|NCT01654029|Experimental|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
11456803|NCT01654016|Active Comparator|Detralex|Detralex 500 mg twice daily for three month prior to surgery
11456804|NCT01654016|No Intervention|Not taking Detralex|Not taking Detralex for three months prior to surgery
11456805|NCT01654003|Active Comparator|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
11456806|NCT01654003|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).
~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
11456807|NCT01653990|Experimental|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
11456808|NCT01653990|Placebo Comparator|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
11456809|NCT01653977|Active Comparator|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
11456810|NCT01653977|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).
~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
11456811|NCT01653964|Experimental|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
11456812|NCT01653951|Experimental|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
11456813|NCT01653951|Experimental|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
11456814|NCT01653938|No Intervention|control group|
11456815|NCT01653938|Experimental|Video Arm|Use of video decision aid in the experimental arm.
11456816|NCT01653925|Experimental|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
11456817|NCT01653925|Experimental|Drug intervention first|Intake of 5α-Reductase Inhibitor
11456818|NCT01653912|Experimental|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
11456819|NCT01653899|Experimental|IDN-6556|Drug
11456820|NCT01653886|Experimental|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
11456821|NCT01653886|Experimental|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
11456822|NCT01653886|Experimental|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
11456823|NCT01653886|Experimental|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
11456824|NCT01653860|Experimental|The Brøset anger management model|Group treatment
11456825|NCT01653860|Active Comparator|ordinary group treatment|Group treatment
11456826|NCT01653847|Active Comparator|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
11456827|NCT01653847|Active Comparator|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
11456828|NCT01653847|No Intervention|Donors|One time blood samples will be collected from kidney donors to recipients in this study
11456829|NCT01653834|Experimental|Lymphocyte harvesting & reinfusion|Patients with a newly diagnosed high grade glioma (Grade III or IV), have a post-operative treatment plan that includes standard radiation and temozolomide, and have normal bone marrow function with Hematocrit ≥ 30%, platelet ≥ 100K, ANC ≥ 1000, and absolute lymphocyte count ≥ 1000 prior entry to this study are eligible for enrollment.
11456830|NCT01653821|Experimental|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
11456831|NCT01653808|Experimental|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
11456832|NCT01653808|Active Comparator|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
11456833|NCT01653795|Active Comparator|LMA Unique|
11456834|NCT01653795|Active Comparator|LMA Supreme|
11456835|NCT01653782|Experimental|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
11456836|NCT01653782|Active Comparator|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
11456837|NCT01653782|Active Comparator|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
11456838|NCT01653756|Active Comparator|IPI-145|Capsules
11456839|NCT01653756|Placebo Comparator|Placebo|Capsules
11456840|NCT01653743|Experimental|MSJ-0011|
11456841|NCT01653743|Active Comparator|urinary hCG|
11456842|NCT01653730|Experimental|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
11456843|NCT01653730|Experimental|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
11456844|NCT01653730|Experimental|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
11456845|NCT01653730|No Intervention|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
11456846|NCT01653717|Experimental|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
11456847|NCT01653704|Experimental|active management of crises scenario|participants assigned to actively manage a crisis scenario
11456848|NCT01653704|Active Comparator|Observer role in crisis scenario|Observational role in management of crises scenario
11456849|NCT01653691|Active Comparator|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
11456850|NCT01653691|Sham Comparator|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
11456851|NCT01653678|Active Comparator|Vitamin D + fish oil|
11456852|NCT01653678|Active Comparator|Vitamin D + fish oil placebo|
11456853|NCT01653678|Active Comparator|Vitamin D placebo + fish oil|
11456854|NCT01653678|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11456855|NCT01653665|Active Comparator|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
11456856|NCT01653665|Placebo Comparator|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
11456857|NCT01653652|Placebo Comparator|Placebo|maltodextrin powder to be taken daily
11456858|NCT01653652|Active Comparator|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
11456859|NCT01653639|Experimental|Arm 1|
11456860|NCT01653639|Experimental|Arm 2|
11456861|NCT01653626|Experimental|package|
11456862|NCT01653600|Experimental|LifeStent|same to SMART CONTROL Stent
11456863|NCT01653600|Active Comparator|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
11456864|NCT01653587|Active Comparator|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
11456865|NCT01653587|Active Comparator|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
11456866|NCT01653574|Experimental|Famitinib Malate|Famitinib 25mg/d
11456867|NCT01653561|Experimental|Apatinib|Apatinib 500mg/d
11456868|NCT01653548|Experimental|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
11456869|NCT01653548|Experimental|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
11456870|NCT01653548|Experimental|No HR training|50 subjects who do not receive HR training.
11456871|NCT01653535|Experimental|Fast Track Eligible|"Participants in the Experimental group received the Fast Track intervention. Intervention included school-based curriculum attended by high-risk children, parents, program staff, and occasionally teachers, home visiting, the the in-class PATHS prevention program."
11456872|NCT01653535|No Intervention|Control Group|Participants in the Control group were not eligible to receive the Fast Track intervention. These children received other services as usual, and served as the randomized comparison group for examining Fast Track program impacts
11456873|NCT01653522|Experimental|Triptan|
11456874|NCT01653522|Experimental|Doxycycline|
11456875|NCT01653522|Experimental|Triptan + Doxycycline|
11456876|NCT01653522|No Intervention|Control|
11456877|NCT01653509|Experimental|Test patch|Patch containing acyclovir applied to cold sore
11456878|NCT01653509|Placebo Comparator|Placebo patch|Patch without acyclovir applied to cold sore
11456879|NCT01653496|Experimental|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
11456880|NCT01653483|Experimental|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
11456881|NCT01653483|Placebo Comparator|GSK573719 matched-placebo|Placebo
11456882|NCT01653470|Experimental|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
11456883|NCT01653470|Experimental|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
11456884|NCT01653470|Experimental|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
11456885|NCT01653470|Experimental|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
11456886|NCT01653470|Experimental|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
11456887|NCT01653457|Placebo Comparator|Placebo|
11456888|NCT01653457|Active Comparator|Memantine|
11456889|NCT01653444|Experimental|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
11456890|NCT01653444|Experimental|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
11456891|NCT01653431|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
11456892|NCT01653431|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
11456893|NCT01653418|Experimental|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
11456894|NCT01653405|Experimental|Intervention Group|VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
11456895|NCT01653405|No Intervention|Control Group|VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.
11456896|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
11456897|NCT01653379|Experimental|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
11456898|NCT01653366|Experimental|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting
~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
11456899|NCT01653366|No Intervention|ARM B|Patients receive standard physical activity recommendations and follow up.
11456900|NCT01653353|Experimental|Entire group|A peer-applied guideline will be applied to the physicians.
11456901|NCT01653340|Experimental|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.
~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.
~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.
~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.
~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
11456902|NCT01653327|Active Comparator|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
11456903|NCT01653327|Placebo Comparator|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
11456904|NCT01653314|Experimental|Megavec|
11456905|NCT01653314|Active Comparator|Glivec|
11456906|NCT01653301|Experimental|XELOX-RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;
~Oxaliplatin: 130mg/m2, days 1, 19, 38
~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
11456937|NCT01653106|Active Comparator|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
11456988|NCT01652742|Experimental|BI 135585 XX|one single dose
11456989|NCT01652729|Experimental|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
11456907|NCT01653301|Active Comparator|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.
~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.
~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
11456908|NCT01653288|Experimental|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
11456909|NCT01653288|Experimental|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
11456910|NCT01653275|Experimental|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
11456911|NCT01653262|Experimental|Brivaracetam|"The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.
~Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.
~At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
11456912|NCT01653249|Experimental|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
11456913|NCT01653236|Experimental|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
11456914|NCT01653236|Active Comparator|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
11456915|NCT01653223|No Intervention|control|untreated
11456916|NCT01653223|Experimental|short statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.
11456917|NCT01653223|Experimental|long statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.
11456918|NCT01653197|Experimental|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
11456919|NCT01653197|Experimental|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
11456920|NCT01653197|Experimental|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your [colonoscopy/mammogram/etc.] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
11456921|NCT01653184|Experimental|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
11456922|NCT01653184|Experimental|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
11456923|NCT01653171|No Intervention|Control|Standard upper endoscopy withouth premedication
11456924|NCT01653171|Placebo Comparator|Water|100 mL of water, 20 minutes before upper endoscopy
11456925|NCT01653171|Experimental|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
11456926|NCT01653171|Experimental|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
11456927|NCT01653171|Experimental|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
11456928|NCT01653158|Experimental|CP-751,871 combined with docetaxel|
11456929|NCT01653145|Active Comparator|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
11456930|NCT01653145|Active Comparator|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
11456931|NCT01653145|Active Comparator|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
11456932|NCT01653132|Experimental|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
11456933|NCT01653132|Placebo Comparator|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
11456934|NCT01653119|Active Comparator|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
11456935|NCT01653119|Active Comparator|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
11456936|NCT01653106|Experimental|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
11456990|NCT01652729|Active Comparator|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
11456938|NCT01653093|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
11456939|NCT01653080|Experimental|Dynamic contrast-enhanced MRI|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
11456940|NCT01653067|Experimental|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.
~Treatment regimen part I:
~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4
~...repeat day 22, up to a maximum of 4 cycles
~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
11456941|NCT01653054|Experimental|IBD patients ON Immunosuppression|
11456942|NCT01653054|Experimental|IBD Patients OFF Immunosuppression|
11456943|NCT01653041|Experimental|Everolimus|Single arm
11456944|NCT01653028|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11456945|NCT01653015|Experimental|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
11456946|NCT01653015|Active Comparator|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
11456947|NCT01653002||Lung cancer with lymph node involvement|
11456948|NCT01652989|Experimental|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
11456949|NCT01652989|Experimental|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
11456950|NCT01652976|Experimental|Treatment Arm|Dasatinib and mFOLFOX6
11456951|NCT01652963|No Intervention|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
11456952|NCT01652963|Experimental|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
11456953|NCT01652950|Experimental|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
11456954|NCT01652950|Experimental|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
11456955|NCT01652950|Experimental|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
11456956|NCT01652950|Experimental|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
11456985|NCT01652768|Experimental|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
11456957|NCT01652950|Other|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
11456958|NCT01652950|Active Comparator|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
11456959|NCT01652937|Placebo Comparator|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
11456960|NCT01652937|Experimental|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
11456961|NCT01652937|Experimental|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
11456962|NCT01652937|Experimental|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
11456963|NCT01652924|Experimental|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
11456964|NCT01652924|Active Comparator|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
11456965|NCT01652911|Experimental|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
11456966|NCT01652898|Active Comparator|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
11456967|NCT01652898|Active Comparator|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
11456968|NCT01652898|Experimental|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
11456969|NCT01652885|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
11456970|NCT01652872|Active Comparator|Hb-Based Titration Group|Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.
11456971|NCT01652872|Experimental|Fixed Dose Group|Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was > 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to < 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.
11456972|NCT01652859|Experimental|Liposomal Amphotericin B|Generic drug
11456973|NCT01652859|Active Comparator|AmBisome|RLD
11456974|NCT01652833||Round 1|survey of 150 oncologists
11456975|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
11456976|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
11456977|NCT01652820|Experimental|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
11456978|NCT01652820|Experimental|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
11456979|NCT01652807|Experimental|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
11456980|NCT01652807|No Intervention|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
11456981|NCT01652794|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
11456982|NCT01652781|Experimental|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
11456983|NCT01652781|Active Comparator|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
11456984|NCT01652768|Active Comparator|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
11456991|NCT01652729|Placebo Comparator|Placebo|Placebo oral capsule once daily
11456992|NCT01652716|Experimental|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
11456993|NCT01652716|Active Comparator|Exenatide twice daily (BID)|Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks
11456994|NCT01652703|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
11456995|NCT01652703|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
11456996|NCT01652703|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11456997|NCT01652703|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11456998|NCT01652703|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11456999|NCT01652703|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11457000|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
11457001|NCT01652677|Experimental|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
11457002|NCT01652677|Experimental|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
11457003|NCT01652677|Sham Comparator|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
11457004|NCT01652677|Experimental|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
11457005|NCT01652664|Experimental|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
11457006|NCT01652664|Active Comparator|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
11457007|NCT01652651|Experimental|Psychological Intervention|
11457008|NCT01652638|Experimental|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)
~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
11457009|NCT01652638|Experimental|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)
~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
11457010|NCT01652625|Experimental|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
11457011|NCT01652625|Active Comparator|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
11457012|NCT01652612|No Intervention|Control|zero PEEP
11457013|NCT01652612|Experimental|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
11457014|NCT01652612|Experimental|OLV strategy: PEEP followed by AR|"alveolar recruitment strategy before one lung ventilation
~8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
11457015|NCT01652599|Experimental|Eltrombopag and dexamethasone|
11457016|NCT01652586|Experimental|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
11457017|NCT01652586|Active Comparator|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
11457018|NCT01652573|Experimental|Nasal calictonin|Subjects will received nasal calcitonin once daily
11457019|NCT01652573|Placebo Comparator|Saline Nasal spray|Patients will receive saline nasal spray once daily
11457020|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
11457021|NCT01652547|Experimental|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
11457022|NCT01652547|Experimental|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
11457023|NCT01652534|Active Comparator|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
11457024|NCT01652534|Placebo Comparator|placebo|Sugar Pill
11457025|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
11457026|NCT01652508|Placebo Comparator|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
11457027|NCT01652508|Experimental|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
11457028|NCT01652495|Active Comparator|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
11457029|NCT01652495|Active Comparator|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
11457032|NCT01652469|Experimental|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
11457033|NCT01652469|Experimental|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
11457034|NCT01652456|Experimental|Group A|
11457035|NCT01652456|No Intervention|Group B|
11457036|NCT01652430||PTSD cohort|
11457037|NCT01652430||No PTSD cohort|
11457038|NCT01652417|No Intervention|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
11457039|NCT01652417|Experimental|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
11457040|NCT01652404|Experimental|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
11457041|NCT01652404|Active Comparator|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
11457042|NCT01652391|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
11457043|NCT01652391|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
11457044|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
11457045|NCT01652378||Control Participants|healthy control volunteers
11457046|NCT01652365|Experimental|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
11457047|NCT01652365|Experimental|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
11457048|NCT01652365|Experimental|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
11457049|NCT01652365|No Intervention|Control|
11457050|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
11457051|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
11457052|NCT01652339|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)
~valsartan 160mg"
11457053|NCT01652339|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)
~valsartan 160mg"
11457054|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
11457055|NCT01652313|Experimental|Rasagiline|
11457056|NCT01652300|Experimental|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
11457057|NCT01652300|Other|control|received no education
11457058|NCT01652287|Active Comparator|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
11457059|NCT01652287|Placebo Comparator|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
11457060|NCT01652274||Mother|study objectives to Mother only
11457061|NCT01652274||Father|study objectives to Father only
11457062|NCT01652261|Experimental|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.
~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
11457063|NCT01652261|Active Comparator|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.
~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
11457064|NCT01652248|Placebo Comparator|Standard generator replacement|Standard generator replacement
11457065|NCT01652248|Active Comparator|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
11457066|NCT01652235|Experimental|Endovascular|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
11457067|NCT01652222|Experimental|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.
~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
11457068|NCT01652222|Active Comparator|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
11457069|NCT01652222|No Intervention|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
11457136|NCT01651793|Active Comparator|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
11457382|NCT01650155|Placebo Comparator|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
11457070|NCT01652209|No Intervention|Control|"After implementing PCI, contemporary drug treatment is conducted.
~*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
11457071|NCT01652209|Experimental|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
11457072|NCT01652196|Experimental|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
11457073|NCT01652183|Placebo Comparator|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
11457074|NCT01652183|Active Comparator|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
11457075|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
11457076|NCT01652144|Experimental|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
11457077|NCT01652131|Other|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
11457078|NCT01652118|Active Comparator|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
11457079|NCT01652118|Placebo Comparator|placebo|Second group treated with salin as same as amount of clarithromycine volume
11457080|NCT01652105|Experimental|Diet|New developed diet
11457081|NCT01652105|Active Comparator|Prodimed|Standard VLCD
11457082|NCT01652092|Other|Arm A: Fully Myeloablative regimen|For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0.
11457083|NCT01652092|Other|Arm B: Reduced Toxicity Ablative Regimen|For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m^2 IV on days -5 through -2 and stem cell infusion on day 0.
11457084|NCT01652092|Other|Arm C: Reduced Intensity Conditioning|For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -14 through -10, fludarabine phosphate 30 mg/m^2 IV on days -8 through -4, melphalan 140 mg/m^2 IV on day -3 and stem cell infusion on day 0.
11457085|NCT01652092|Other|Arm D: No Preparative Regimen|For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor.
11457086|NCT01652079|Experimental|Treatment Arm|CRLX101
11457087|NCT01652066|Placebo Comparator|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
11457088|NCT01652066|Experimental|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics
~oral consumption, once per day in the morning, fasting, with a glass of water"
11457089|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
11457090|NCT01652040|Experimental|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
11457091|NCT01652040|Experimental|Tp|Applying Testosterone patches
11457092|NCT01652027||Previously Untreated Patients with Hemophilia A|
11457093|NCT01652014|Experimental|Arm I|"Double UCB transplantation
~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
11457094|NCT01652014|Experimental|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation
~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
11457137|NCT01651793|Placebo Comparator|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
11457383|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
11457095|NCT01652001|Experimental|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).
~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
11457096|NCT01652001|Placebo Comparator|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
11457097|NCT01651988|Active Comparator|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
11457098|NCT01651988|Experimental|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
11457099|NCT01651975|Other|Thickenup|
11457100|NCT01651962|Experimental|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
11457101|NCT01651962|Active Comparator|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
11457102|NCT01651962|Placebo Comparator|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
11457103|NCT01651949|Active Comparator|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
11457104|NCT01651949|Experimental|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
11457105|NCT01651949|Experimental|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
11457106|NCT01651936|Experimental|Base Study: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
11457107|NCT01651936|Placebo Comparator|Base Study: Placebo|Participants received placebo BID orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
11457108|NCT01651936|Experimental|Safety Extension: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
11457109|NCT01651923|Other|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)
~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
11457110|NCT01651923|Other|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)
~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
11457111|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
11457112|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
11457113|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
11457114|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
11457115|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
11457116|NCT01651884|Experimental|High-Definition tDCS|
11457117|NCT01651884|Experimental|Sponge tDCS|
11457118|NCT01651871|Experimental|Treatment Group 1|
11457119|NCT01651871|Experimental|Treatment Group 2|
11457120|NCT01651871|Experimental|Treatment Group 3|
11457121|NCT01651871|Active Comparator|Treatment Group 4|
11457122|NCT01651871|Placebo Comparator|Treatment Group 5|
11457123|NCT01651858|Experimental|Nurigra Chewable tablet|
11457124|NCT01651858|Active Comparator|Viagra|
11457125|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
11457126|NCT01651832|No Intervention|usual care|routine care and case management
11457127|NCT01651832|Experimental|SCAN-Intervention|
11457128|NCT01651819|Experimental|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
11457129|NCT01651806|Active Comparator|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
11457130|NCT01651806|Active Comparator|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
11457131|NCT01651806|Active Comparator|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
11457132|NCT01651806|Active Comparator|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
11457133|NCT01651806|No Intervention|Historical Cohort|"25 patients with no TA use in their surgical history.
~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
11457134|NCT01651793|Active Comparator|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
11457135|NCT01651793|Active Comparator|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
11457138|NCT01651780|Experimental|Bivalirudin|Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.
11457139|NCT01651780|Active Comparator|Unfractionated heparin (UFH)|The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.
11457140|NCT01651767|Experimental|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
11457141|NCT01651767|Experimental|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
11457142|NCT01651767|Experimental|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
11457143|NCT01651767|Experimental|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
11457144|NCT01651754|Other|Seasonal influenza vaccination|
11457145|NCT01651741|Experimental|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
11457146|NCT01651741|Placebo Comparator|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
11457147|NCT01651728|Experimental|Simvastatin|Tablet 20 mg once daily for 30 days
11457148|NCT01651728|Placebo Comparator|Placebo|Placebo tablet once daily for 30 days
11457149|NCT01651715|Experimental|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
11457150|NCT01651715|Placebo Comparator|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
11457151|NCT01651702|Active Comparator|Carto|Patients in whom Carto system will be used
11457152|NCT01651702|Active Comparator|Ensite|Patients in whom Ensite system will be used
11457153|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
11457154|NCT01651676|Experimental|COPD arm|"VQ11 validation:
~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
11457155|NCT01651663|Experimental|Arbidol (Umifenovir)|
11457156|NCT01651663|Placebo Comparator|placebo|
11457157|NCT01651663|Experimental|Arbidol (Umifenovir) prophylaxis|
11457158|NCT01651663|Placebo Comparator|placebo prophylaxis|
11457159|NCT01651650|Other|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
11457160|NCT01651637|Experimental|Synthetic Surfactant|Cohort Design
11457161|NCT01651624|Experimental|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
11457162|NCT01651624|Experimental|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
11457163|NCT01651624|Active Comparator|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
11457164|NCT01651624|Experimental|Colonoscopy|Subjects invited to undergo colonoscopy
11457165|NCT01651611|Experimental|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
11457166|NCT01651611|Active Comparator|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
11457167|NCT01651598|Experimental|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
11457168|NCT01651598|Placebo Comparator|Placebo|Subjects receive multiple BID doses of Placebo solution
11457169|NCT01651585|Experimental|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
11457170|NCT01651572|Experimental|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.
~Cisatracurium (Nimbex):
~initial dose: 0.2 mg/kg
~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)
~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.
~Patients will be extubated with a TOF-Ratio of at least 0.90."
11457171|NCT01651572|Experimental|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl
~Rocuronium (Esmeron):
~initial dose: 0.6 mg/kg
~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)
~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.
~Patients will be extubated with a TOF-Ratio of at least 0.90."
11457172|NCT01651546|Other|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
11457173|NCT01651533|Experimental|Experimental: Mental Practice Group|
11457174|NCT01651533|Active Comparator|Active Comparator: Active Control Group|
11457175|NCT01651520|Experimental|Relapsing patients < 5 years|Relapsing patients < 5 years
11457176|NCT01651520|Experimental|relapsing patients < 10 years|relapsing patients < 10 years
11457177|NCT01651520|Experimental|primary progressive patients < 10 years|primary progressive patients < 10 years
11457178|NCT01651520|Other|healthy volunteers|healthy volunteers
11457267|NCT01650974|Experimental|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
11457179|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
11457180|NCT01651494|Active Comparator|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
11457181|NCT01651494|Placebo Comparator|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
11457182|NCT01651481|Experimental|TR|HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal
11457183|NCT01651481|Experimental|RT|coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)
11457184|NCT01651468|Experimental|HEMOFIX|3 grams a day
11457185|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
11457186|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
11457187|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1|
11457188|NCT01651442|Active Comparator|Sleep Medication 1|
11457189|NCT01651442|Active Comparator|Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1|
11457190|NCT01651442|Active Comparator|Sleep Medication 2 Following Sleep Medication 1|
11457191|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1 Following Sleep Medication 1|
11457192|NCT01651442|Active Comparator|Sleep Medication 1 Following Non-drug Sleep Therapy 1|
11457193|NCT01651429|Experimental|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
11457194|NCT01651416|Active Comparator|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
11457195|NCT01651416|Experimental|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
11457196|NCT01651416|Experimental|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
11457197|NCT01651403|Experimental|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 48 weeks.
11457198|NCT01651403|Placebo Comparator|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 48 weeks.
11457199|NCT01651403|Experimental|Tenofovir DF (Open-label Treatment)|Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
11457200|NCT01651403|Experimental|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in patients of their age and weight.
11457201|NCT01651390|Experimental|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
11457202|NCT01651390|Active Comparator|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
11457203|NCT01651377|Placebo Comparator|Placebo|
11457204|NCT01651377|Active Comparator|Pramipexole|
11457205|NCT01651364|Placebo Comparator|Placebo|
11457206|NCT01651364|Active Comparator|Cabergoline|
11457207|NCT01651351|Experimental|Cohort 1|"Day 1:
~GLASSIA at 0.04 mL/kg/min
~Placebo at 0.2 mL/kg/min
~Day 15:
~GLASSIA at 0.2 mL/kg/min
~Placebo at 0.04 mL/kg/min"
11457208|NCT01651351|Experimental|Cohort 2|"Day 1:
~GLASSIA at 0.2 mL/kg/min
~Placebo at 0.04 mL/kg/min
~Day 15:
~GLASSIA at 0.04 mL/kg/min
~Placebo at 0.2 mL/kg/min"
11457209|NCT01651338|Experimental|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
11457210|NCT01651325|Experimental|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
11457211|NCT01651312|Experimental|14C-labeled YM178|Single oral administration of 14C-labeled YM178
11457212|NCT01651286|Experimental|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
11457213|NCT01651286|Active Comparator|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
11457214|NCT01651273|Experimental|Arm 1: BMS-852927 (0.25 mg)|
11457215|NCT01651273|Experimental|Arm 2: BMS-852927 (1.0 mg)|
11457216|NCT01651273|Experimental|Arm 3: BMS-852927 (2.5 mg)|
11457217|NCT01651273|Placebo Comparator|Arm 4: Placebo|
11457218|NCT01651260|Other|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
11457219|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
11457220|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
11457221|NCT01651234|Experimental|Active|
11457222|NCT01651234|Placebo Comparator|Placebo|
11457223|NCT01651221|Experimental|Olfactory|Habituation of olfactory response
11457224|NCT01651221|Experimental|gustatory|Habituation of gustatory response.
11457225|NCT01651221|Experimental|olfactory and gustatory|Habituation of olfactory and gustatory response
11457268|NCT01650974|Sham Comparator|sham-HFNOT|same device with FiO2 ~0.4, NO high flow
11457384|NCT01650129|Experimental|BIAsp|
11457385|NCT01650129|Experimental|BHI|
11457226|NCT01651208|Experimental|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
11457227|NCT01651208|Active Comparator|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
11457228|NCT01651195|Active Comparator|Probiotic tablet|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
11457229|NCT01651195|Placebo Comparator|Placebo tablet|Chrystalline celluloce 2 x 2, 3 weeks
11457230|NCT01651182|Placebo Comparator|Standard Care|No tranexamic acid
11457231|NCT01651182|Experimental|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
11457232|NCT01651182|Experimental|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
11457233|NCT01651169|Experimental|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
11457234|NCT01651169|Experimental|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
11457235|NCT01651156|Placebo Comparator|placebo|Frequency: once per day Duration: 7days
11457236|NCT01651156|Experimental|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
11457237|NCT01651143|Experimental|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks
~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
11457238|NCT01651143|Placebo Comparator|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks
~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
11457239|NCT01651130|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
11457240|NCT01651130|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
11457241|NCT01651130|Active Comparator|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
11457242|NCT01651130|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
11457243|NCT01651130|Active Comparator|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
11457244|NCT01651130|Active Comparator|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
11457245|NCT01651117|No Intervention|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
11457246|NCT01651117|Experimental|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
11457247|NCT01651117|Experimental|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
11457248|NCT01651104|Experimental|Adjuvanted Trivalent Influenza Virus Vaccine|
11457249|NCT01651091|Experimental|Meditation Awareness Training|
11457250|NCT01651091|Active Comparator|Treatment as Usual|
11457251|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
11457252|NCT01651065|Experimental|Microclinics Group A|Subjects will be receiving a 10/9-month Microclinic Diabetes Education Program (Team Up 4 Health) and 6 months of follow up. In the intervention these subjects will engage in the Microclinic Program support groups. The intervention program consists of 25 event sessions. Sessions are offered weekly the first month, and biweekly thereafter.
11457253|NCT01651065|Placebo Comparator|Group C Controls|Individuals will receive screening by clinical staff. Control group subjects will receive clinic screenings only; they will not participate in program activities.
11457254|NCT01651052|Experimental|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
11457255|NCT01651039|Experimental|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
11457256|NCT01651026||rectal cancer|
11457257|NCT01651013||metastatic colorectal cancer|
11457258|NCT01651000|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
11457259|NCT01651000|Placebo Comparator|Sugar pill to CTAP101 30 μg capsule|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
11457260|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
11457261|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
11457262|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
11457263|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
11457264|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
11457265|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
11457266|NCT01650974|No Intervention|conventional oxygen therapy|conventional nasal prong with FiO2 ~0.4
11457380|NCT01650155|Placebo Comparator|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
11457269|NCT01650961|Experimental|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
11457270|NCT01650961|Placebo Comparator|Control|Intravenous administration of normal saline before the induction of general anesthesia
11457271|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
11457272|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
11457273|NCT01650935|Active Comparator|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
11457274|NCT01650935|Active Comparator|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
11457275|NCT01650896|No Intervention|General Medicine|
11457276|NCT01650896|Active Comparator|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
11457277|NCT01650883|Experimental|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
11457278|NCT01650883|Experimental|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
11457279|NCT01650870|Active Comparator|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
11457280|NCT01650870|Experimental|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
11457281|NCT01650844|Experimental|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
11457282|NCT01650844|Active Comparator|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
11457283|NCT01650831|Active Comparator|Clinical Suspicion of Hpylori|All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
11457284|NCT01650818|Experimental|Aerobic exercise training|
11457285|NCT01650818|Active Comparator|Standard physical therapy|
11457286|NCT01650805|Experimental|ponatinib|
11457287|NCT01650805|Active Comparator|imatinib|
11457288|NCT01650792|Active Comparator|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
11457289|NCT01650792|No Intervention|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
11457290|NCT01650779|Experimental|Agalsidase beta|
11457291|NCT01650753|Experimental|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
11457292|NCT01650753|Placebo Comparator|Placebo Powder|Equivalent amount (same volume) of maltodextrin
11457293|NCT01650740|Experimental|Open-label duloxetine|12 week treatment with duloxetine
11457294|NCT01650740|Experimental|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
11457295|NCT01650740|Experimental|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
11457296|NCT01650727|Experimental|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.
~Dinaciclib will be administered in Cycles 2-13."
11457297|NCT01650714|Experimental|Full thickness gastric biopsy|Full thickness gastric biopsy
11457298|NCT01650701|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
11457299|NCT01650701|Active Comparator|Control|• ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
11457300|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
11457301|NCT01650675|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
11457302|NCT01650675|Experimental|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
11457303|NCT01650662|Experimental|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.
~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.
~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
11457304|NCT01650662|Experimental|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
11457305|NCT01650649|Active Comparator|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
11457306|NCT01650649|Placebo Comparator|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
11457307|NCT01650636|Experimental|Cognitive Behavioral Stress Management|
11457308|NCT01650636|Active Comparator|Health Information|
11457309|NCT01650623|Experimental|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
11457310|NCT01650623|Active Comparator|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
11457311|NCT01650610|Experimental|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
11457312|NCT01650597|Experimental|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
11457313|NCT01650597|Experimental|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
11457314|NCT01650597|Experimental|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
11457315|NCT01650584|Experimental|ISTA Tears|Sterile ophthalmic solution
11457316|NCT01650584|Active Comparator|Systane|Sterile ophthalmic solution
11457317|NCT01650558|Active Comparator|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
11457318|NCT01650558|Experimental|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
11457319|NCT01650558|No Intervention|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
11457320|NCT01650545|Experimental|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
11457321|NCT01650545|Active Comparator|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.
~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
11457322|NCT01650532|Experimental|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
11457323|NCT01650532|Active Comparator|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
11457324|NCT01650519|Active Comparator|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
11457325|NCT01650519|Active Comparator|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
11457326|NCT01650506|Experimental|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
11457327|NCT01650493||Group A|Clinpro 5000
11457328|NCT01650493||Group B|MI Paste Plus
11457329|NCT01650493||Group C|Toms of Maine
11457330|NCT01650480|Experimental|Intervention group|
11457331|NCT01650480|No Intervention|Control group|
11457332|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
11457333|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
11457334|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
11457335|NCT01650454|Experimental|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.
~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
11457336|NCT01650454|Experimental|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
11457381|NCT01650155|Experimental|BI 1005273 s.c.|single dose s.c. injection
11457337|NCT01650454|Active Comparator|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
11457338|NCT01650454|Active Comparator|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
11457339|NCT01650441|Experimental|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
11457340|NCT01650428|Experimental|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.
~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
11457341|NCT01650428|Experimental|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.
~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
11457342|NCT01650415|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
11457343|NCT01650415|Placebo Comparator|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
11457344|NCT01650402|Experimental|Intensive|Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg
11457345|NCT01650402|Active Comparator|Standard|Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg
11457346|NCT01650389|Experimental|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
11457347|NCT01650389|Active Comparator|Candin|Equal volume intradermal administration within 96 hours of birth
11457348|NCT01650376|Experimental|Olaparib plus carboplatin and paclitaxel|
11457349|NCT01650363|Active Comparator|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
11457350|NCT01650363|Placebo Comparator|homeopathic placebo medication|
11457351|NCT01650350|Experimental|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
11457352|NCT01650337|Experimental|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
11457353|NCT01650337|No Intervention|Usual primary care|
11457354|NCT01650324|Experimental|DBPR108|
11457355|NCT01650324|Placebo Comparator|matching placebo|
11457356|NCT01650311||Healthy controls|Healthy control group will include participants consenting prior to colorectal cancer screening.
11457357|NCT01650311||CD patient groups|The patient groups will include patients with clinical diagnosis of CD.
11457358|NCT01650311||UC patient group|The patient groups will include patients with clinical diagnosis of UC.
11457359|NCT01650298|No Intervention|Control|Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
11457360|NCT01650298|Experimental|Tailored Anticoagulation (TAC)|"Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.
~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed"
11457361|NCT01650285|Experimental|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
11457362|NCT01650272|Experimental|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.
~Record efficacy and safety as described."
11457363|NCT01650272|Experimental|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
11457364|NCT01650259||Oral antidiabetic drug (OAD)|
11457365|NCT01650259||Trazenta|
11457366|NCT01650246|Experimental|lesinurad 400 mg|
11457367|NCT01650233|Experimental|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
11457368|NCT01650233|Placebo Comparator|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
11457369|NCT01650220||Veterans with a history of PTSD|
11457370|NCT01650220||Veterans without a history of PTSD|
11457371|NCT01650207|Experimental|EA group|To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
11457372|NCT01650207|Experimental|TENS group|The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
11457373|NCT01650207|Sham Comparator|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16).
11457374|NCT01650194|Experimental|Enzalutamide + Abiraterone + Prednisone|Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
11457375|NCT01650181|Active Comparator|Metformin|Patients treated with diet, exercise and metformin
11457376|NCT01650181|Active Comparator|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
11457377|NCT01650168||NOMAC-E2|New users of NOMAC-E2
11457378|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
11457379|NCT01650155|Experimental|BI 1005273 i.v.|single dose i.v. infusion
11457386|NCT01650090|Experimental|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
11457387|NCT01650051|Placebo Comparator|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
11457388|NCT01650051|Experimental|Phenazopyridine Hydrochloride Tables, USP 200 mg|
11457389|NCT01650038|Active Comparator|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
11457390|NCT01650038|Placebo Comparator|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
11457391|NCT01650025|Placebo Comparator|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
11457392|NCT01650025|Active Comparator|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
11457393|NCT01650012|Experimental|Eplerenone|Target of 50 mg/day
11457394|NCT01650012|Placebo Comparator|Placebo|Matching placebo
11457395|NCT01649999|Experimental|ASP015K lowest dose|Oral
11457396|NCT01649999|Experimental|ASP015K low dose|Oral
11457397|NCT01649999|Experimental|ASP015K medium dose|Oral
11457398|NCT01649999|Experimental|ASP015K high dose|Oral
11457399|NCT01649999|Placebo Comparator|Placebo|Oral
11457400|NCT01649986|Active Comparator|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
11457401|NCT01649986|Active Comparator|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
11457402|NCT01649960|Other|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
11457403|NCT01649947|Experimental|Cohort 2: Bevacizumab ineligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
11457404|NCT01649947|Experimental|Cohort 1: Bevacizumab eligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
11457405|NCT01649934|No Intervention|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
11457406|NCT01649934|Experimental|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
11457407|NCT01649934|Experimental|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
11457408|NCT01649921|Active Comparator|Interferon-gamma|
11457409|NCT01649921|Placebo Comparator|Saline 0.9%|
11457410|NCT01649908||sectional cross clamping|
11457411|NCT01649908||simultaniously cross clamping|
11457412|NCT01649908||EVAR|
11457413|NCT01649895|Experimental|D-Cycloserine|D-Cycloserine, 5 pills (50mg), once per week in 5 weeks.
11457414|NCT01649895|Placebo Comparator|Placebo|Placebo: 5 pills for 5 weeks, once per week.
11457415|NCT01649882|Experimental|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
11457416|NCT01649869|Active Comparator|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
11457417|NCT01649869|Placebo Comparator|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
11457418|NCT01649856|Experimental|A: Rituximab SC|
11457419|NCT01649856|Active Comparator|B: Rituximab IV|
11457420|NCT01649843|Experimental|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
11457421|NCT01649830|Experimental|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
11457422|NCT01649830|Active Comparator|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
11457423|NCT01649817||Cohort|
11457424|NCT01649804|Experimental|RoActemra/Actemra single arm|
11457425|NCT01649791|Experimental|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11457426|NCT01649778||Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
11457427|NCT01649765|Experimental|Arm 1|belimumab 10mg/kg IV monthly
11457428|NCT01649765|Placebo Comparator|Arm 2|Normal Saline IV monthly
11457429|NCT01649752|Experimental|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
11457430|NCT01649752|Experimental|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
11457431|NCT01649752|No Intervention|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
11457432|NCT01649739|Experimental|Levitra|
11457433|NCT01649726|Other|Standard strategy|Apnea test according to recommendations
11457434|NCT01649726|Experimental|CPAP strategy|Apnea test with CPAP connection
11457435|NCT01649713|Experimental|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
11457436|NCT01649700|Experimental|Mesenchymal stem cells treatment|All subjects will receive autologous adipose-derived mesenchymal stem cells
11457437|NCT01649687|Experimental|Mesenchymal stem cells(MSC) treatment|All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
11457438|NCT01649674|Active Comparator|PEG|polyethylene glycol solution 2 liters
11457439|NCT01649674|Active Comparator|NapP|Sodium picosulphate and magnesium citrate solution 300 ml
11457440|NCT01649661||premenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
11457441|NCT01649661||postmenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
11457442|NCT01649648|Experimental|Intervention|Autologous cord blood cells arm
11457443|NCT01649635|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
11457444|NCT01649622|Experimental|Bendamustine|"Patients receive Bendamustine at dose of 75 mg/m2 by vein over 30 minutes twice daily for four days (Days 1-4). Bendamustine dose based on actual body weight.
~Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses."
11457445|NCT01649609|Active Comparator|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
11457446|NCT01649609|Active Comparator|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
11457447|NCT01649596|Active Comparator|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
11457448|NCT01649596|Other|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
11457449|NCT01649583|Experimental|Jaw Dynasplint System|
11457450|NCT01649583|No Intervention|Control Arm|
11457451|NCT01649570|Experimental|Insulin aspart|
11457452|NCT01649557|Experimental|Open-label OPDC-34712|
11457453|NCT01649544|Experimental|EPICOR|"Cardiac ablation system EPICOR (CE n°0344).
~ablation device EpicorTM UltraCinchTM LP (Class III device)
~Positioning system and calibration EpicorTM LP (LP PASTM; device Class IIa)
~Cable connection EpicorTM LP (unsterile)
~Ablation Control System EpicorTM LP (Class IIb)"
11457454|NCT01649544|Active Comparator|Amiodarone|"Cordarone :
~400 mg/d during the 2 first months 200 mg/d from 3th to 18th month"
11457455|NCT01649531|Active Comparator|Test group|1 Implant, to be placed in the position with greater vertical bone height with a mesial or distal cantilever.
11457456|NCT01649531|Active Comparator|Control group|2 Implants
11457457|NCT01649505|Experimental|Arm I (fibrin sealant)|Patients undergo sharp dissection technique with fibrin sealant closure.
11457458|NCT01649505|Active Comparator|Arm II (standard electrocoagulation)|Patients undergo standard electrocoagulation dissection technique.
11457459|NCT01649492|No Intervention|diclofenac without pineapple juice|single dose of diclofenac 25 mg without pre-exposure to pineapple juice
11457460|NCT01649492|Active Comparator|diclofenac with pineapple juice|single dose of diclofenac 25 mg with pre-exposure to pineapple juice
11457461|NCT01649479|Other|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.
~Bloodwork later confirms that these patients have APS.
~All patients included in this study will have the following interventions:
~antiphospholipid antibody tests
~thrombophilia bloodwork
~psychiatric evaluation"
11457462|NCT01649479|Other|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.
~Bloodwork later confirms that these patients are thrombophilic.
~All patients included in this study will have the following interventions:
~antiphospholipid antibody tests
~thrombophilia bloodwork
~psychiatric evaluation"
11457463|NCT01649479|Other|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.
~Bloodwork cannot confirm APS, nor thrombophilia.
~All patients included in this study will have the following interventions:
~antiphospholipid antibody tests
~thrombophilia bloodwork
~psychiatric evaluation"
11457464|NCT01649466|Experimental|Vildagliptin|Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
11457465|NCT01649466|Active Comparator|Protaphane|Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.
11457466|NCT01649453||Cancer of uncertain primary|
11457467|NCT01649440||Normal control|Healthy volunteers
11457468|NCT01649440||SIRS|"temperature >38 ℃ or <36℃;
~pulse rate>90 beats/min;
~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;
~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
11457469|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
11457470|NCT01649440||severe sepsis|"sepsis associated with organ dysfunction, hypoperfusion, or hypotension.
~sepsis with arterial hypotension, despite adequate fluid resuscitation."
11457471|NCT01649440||death|sepsis patients within 48 hours before death.
11457901|NCT01645852|No Intervention|Control|No specified diet for one week prior to hepatic resection.
11457472|NCT01649427|Experimental|Prograf|Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
11457473|NCT01649427|Experimental|Tacroliums Hexal|Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
11457474|NCT01649401|Active Comparator|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
11457475|NCT01649401|Experimental|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.
~Manufacturer: PARI GmbH Germany"
11457476|NCT01649388|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow several months after the renal transplant
11457477|NCT01649375|Experimental|Secukinumab 75 mg|Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
11457478|NCT01649375|Experimental|Secukinumab 150 mg|Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
11457479|NCT01649375|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
11457480|NCT01649362|No Intervention|Control group|"No prefeeding oral stimulation
~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
11457481|NCT01649362|Experimental|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.
~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.
~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
11457482|NCT01649336|Experimental|MEK162 + paclitaxel|
11457483|NCT01649310|Experimental|WVB Training|
11457484|NCT01649297|Experimental|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
11457485|NCT01649297|Experimental|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
11457486|NCT01649297|Experimental|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
11457487|NCT01649297|Experimental|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
11457488|NCT01649297|Placebo Comparator|Placebo|Patients receive placebo matching Empagliflozin
11457489|NCT01649271|Experimental|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
11457490|NCT01649271|Experimental|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
11457491|NCT01649271|Experimental|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
11457492|NCT01649258|Experimental|Supportive care (antiemetics)|Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
11457493|NCT01649245|Experimental|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
11457494|NCT01649232|Experimental|active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
11457495|NCT01649232|No Intervention|controls|Healthy people that not receive tDCS
11457496|NCT01649219|Experimental|Exercise intervention|3-month supervised exercise intervention 3 times per week; 60min per time.
11457497|NCT01649219|No Intervention|No intervention|Standard couselling at baseline
11457498|NCT01649206|Experimental|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
11457499|NCT01649206|No Intervention|Group B: untreated|No treatment, only follow-up
11457500|NCT01649193||Chronic Respiratory Disease|Any patient with a chronic respiratory disease referred for pulmonary rehabilitation
11457501|NCT01649180|Experimental|Axitinib|Axitinib will be given orally and will continue until progression of disease.
11457502|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
11457503|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
11457504|NCT01649167||normal weight|Pregnant women with normal weight
11457505|NCT01649154|Active Comparator|Ligasure Small-JAW|
11457506|NCT01649154|Active Comparator|Harmonic Focus|
11457507|NCT01649154|Active Comparator|Clamp-and-Tie technique|
11457508|NCT01649141|Experimental|Treatment Group|Trauma-Focused Cognitive Behavioral Therapy
11457550|NCT01648764|Experimental|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug then repeated (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
11457551|NCT01648751|Experimental|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
11461481|NCT01620450|Active Comparator|NN-X14|
11457509|NCT01649115|No Intervention|Usual Care|The Usual Care arm, will not be receiving the interactive nutrition education. They will be meeting with the Registered Dietitian twice in person after the participants are randomized in each arm, and once on the phone. The first meeting, they will be receiving pamphlets and handouts, which are typically given as part of usual care. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool. The second meeting and the follow-up phone call are both the same for usual care and the Healthy Lifestyles Passport arm.
11457510|NCT01649115|Experimental|Healthy Lifestyles Passport|The Healthy Lifestyles Passport arm will be receiving the intervention. They will be meeting with the Registered Dietitian twice in person after the participants are randomized into each arm, and once on the phone. The first meeting, they will be receiving the Healthy Lifestyles Passport, including the interactive nutrition education. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool.
11457511|NCT01649102|Experimental|Palindroom catheter|Insertion of Palindroom catheter
11457512|NCT01649102|Experimental|Hemoglide Bard Catheter|Insertion of Hemoglide Bard Catheter
11457513|NCT01649089|Experimental|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
11457514|NCT01649063||the shape and frequency of uterine contractions in delivery|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
11457515|NCT01649063||the shape and frequency of uterine contractions in cesarean|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
11457516|NCT01649050|Experimental|BGG492|BGG492 tablets administered orally
11457517|NCT01649050|Placebo Comparator|Placebo|Matching placebo administered orally
11457518|NCT01649037|Experimental|nor adrenaline and terlipressin|
11457519|NCT01649037|Active Comparator|step up terlipressin|
11457520|NCT01649024|Experimental|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
11457521|NCT01649011||Scores of the ODI and RMQ for low back pain|
11457522|NCT01648998|Experimental|Fludrocortisone|Fludrocortisone 500 mg in capsule
11457523|NCT01648998|Placebo Comparator|Placebo|Placebo capsule, single dose, main ingredient lactose
11457524|NCT01648985||Acute stroke and TIA patients|Cohort of acute stroke patients, admitted to the Stroke Unit Danderyd hospital 2010 - 2012
11457525|NCT01648972|Experimental|Gastrografin|
11457526|NCT01648972|Placebo Comparator|Placebo|
11457527|NCT01648946|Active Comparator|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
11457528|NCT01648946|Active Comparator|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
11457529|NCT01648933|Experimental|Sarcoidosis|"Rubidium PET:
~Myocardial Perfusion Imaging"
11457530|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
11457531|NCT01648907||SPONDYLARTHRITIS COHORT|
11457532|NCT01648894|Experimental|11 weeks|The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
11457533|NCT01648894|Other|7 weeks|The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
11457534|NCT01648868|Experimental|Excitatory effects of rTMS|Study excitatory effects of rTMS applied to the STS in patients with autism
11457535|NCT01648868|Active Comparator|Inhibitory effects of rTMS|Study inhibitory effects of rTMS applied to the STS in healthy controls
11457536|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
11457537|NCT01648842||Pregnant women|
11457538|NCT01648829|Active Comparator|Atorvastatin|os, 20 mg, once per day, for 30 days
11457539|NCT01648829|Active Comparator|Pitavastatin|os, 4 mg, once per day, for 30 days
11457540|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
11457541|NCT01648816||control|caucasian mothers without depression
11457542|NCT01648790|Experimental|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
11457543|NCT01648790|Experimental|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
11457544|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
11457545|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
11457546|NCT01648790|Experimental|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
11457547|NCT01648777|Experimental|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
11457548|NCT01648777|Placebo Comparator|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
11457549|NCT01648764|Experimental|LY2334737 - Arm A|LY2334737 administered orally at escalating doses [40 milligrams (mg) - 200 mg] every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
11457583|NCT01648478|Experimental|Single Arm|
11457552|NCT01648751|Placebo Comparator|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
11457553|NCT01648738|Experimental|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
11457554|NCT01648738|Active Comparator|Usual care and counselling (Back book)|Usual care and counselling (Back book)
11457555|NCT01648725|Experimental|Hypnosis|standard care plus hypnosis followed by closed-loop administration of propofol for anesthesia induction
11457556|NCT01648725|Active Comparator|Control|standard care without hypnosis followed by closed-loop administration of propofol for anesthesia induction
11457557|NCT01648712|Other|Balance Circuit, Carmeda Circuit|"Prospective, randomized double-blind, double center, phase IV clinical trial comparing heparin (Carmeda TM) and non-heparin (BalanceTM Bio-Passive surface) extracorporeal pediatric circuit for congenital heart disease repair .
~74 infants/children will be divided in two groups, 37 patients will be assigned to the Balance group and 37 patients to the Carmeda group."
11457558|NCT01648712|Active Comparator|Bypass Circuit|"Prospective, randomized double-blind, double center, phase IV clinical trial comparing heparin (Carmeda TM) and non-heparin (BalanceTM Bio-Passive surface) extracorporeal pediatric circuit for congenital heart disease repair .
~74 infants/children will be divided in two groups, 37 patients will be assigned to the Balance group and 37 patients to the Carmeda group."
11457559|NCT01648699|Experimental|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
11457560|NCT01648686|Active Comparator|Women treated by bisphosphonate|Postmenopausal osteoporotic women treated by alendronate 70 mg weekly per os
11457561|NCT01648686|Sham Comparator|Women didn't treat by bisphosphonate|Postmenopausal osteoporotic women untreated by bisphosphonates
11457562|NCT01648660|Active Comparator|D2x - D1x|"Cross Over from double dosage to single dosage:
~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
11457563|NCT01648660|Active Comparator|D1x - D2x|"Cross Over from double dosage to single dosage:
~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
11457564|NCT01648660|Active Comparator|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
11457565|NCT01648634|Experimental|Nebivolol|
11457566|NCT01648634|Placebo Comparator|Placebo|
11457567|NCT01648621|Experimental|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
11457568|NCT01648621|Active Comparator|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
11457569|NCT01648608|Experimental|Exemestane|Exemestane for neoadjuvant chemotherapy
11457570|NCT01648595|Experimental|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention.
11457571|NCT01648595|No Intervention|Without Fentanyl|The control group did not receive Fentanyl.
11457572|NCT01648582|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
11457573|NCT01648582|Experimental|0.75 mg Dulaglutide|0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
11457574|NCT01648582|Active Comparator|Insulin Glargine|Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
11457575|NCT01648556|Other|patients with a thrombopenia isolated|Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet < 100 G/l Blood tests and bone marrow biopsy repeated
11457576|NCT01648543|Active Comparator|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
11457577|NCT01648543|Active Comparator|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7~7.5cm from midline of spinous process of lumbar spine.
11457578|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
11457579|NCT01648517|Experimental|Arm A|Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
11457580|NCT01648517|Active Comparator|Arm B|standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
11457581|NCT01648504|Experimental|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
11457582|NCT01648491|Experimental|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
11457585|NCT01648452|Experimental|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
11457586|NCT01648348|Experimental|Arm I (bevacizumab and TRC105)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11457587|NCT01648348|Active Comparator|Arm II (bevacizumab)|Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11457588|NCT01648335|Active Comparator|immobilization of the shoulder in internal rotation|
11457589|NCT01648335|Experimental|Immobilization of the shoulder in external rotation|
11457590|NCT01648322|Experimental|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
11457591|NCT01648322|Experimental|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
11457592|NCT01648322|Experimental|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
11457593|NCT01648322|Active Comparator|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
11457594|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
11457595|NCT01648296|Experimental|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of[18F]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
11457596|NCT01648296|Experimental|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of [18F]FluorbetaOx, [11C]Palmitate, and [15O]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
11457597|NCT01648283|Experimental|Methadone arm|"Intravenous racemic methadone HCl, 6.0 mg bolus
~Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
11457598|NCT01648270|Experimental|Study Arm|"Subjects will be studied on four occasions. Sessions and drugs are:
~Intravenous buprenorphine
~Sublingual buprenorphine
~Cyclosporine plus intravenous buprenorphine
~Cyclosporine plus sublingual buprenorphine"
11457599|NCT01648257|Experimental|GSK1265744 Na Salt Tablets|Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
11457600|NCT01648257|Experimental|GSK1265744 Free Acid Nanomilled Capsules|Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
11457601|NCT01648257|Experimental|GSK1265744 Free Acid Micronized Capsules|Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
11457602|NCT01648244|Experimental|Computer-Assisted Decision Support|These providers will use the CADS program to treat their enrolled patients.
11457603|NCT01648231|Other|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
11457604|NCT01648231|Other|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
11457605|NCT01648231|Other|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
11457606|NCT01648218|Active Comparator|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin
~Other Names:
~Humulin N, Novolin N
~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
11457607|NCT01648218|Experimental|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart
~Other Names:
~Humulin R, Novolin R, Novolog, NovoRapid
~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
11457608|NCT01648218|Experimental|Insulin glargine|"Drug: Insulin glargine
~Other Names:
~Lantus
~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
11457609|NCT01648205|Active Comparator|Ranolazine|Ranolazine 1000 mg bid
11457610|NCT01648205|Placebo Comparator|Placebo|Matching Placebo
11457611|NCT01648192|Experimental|2.5 mg|Losmapimod for single dose
11457612|NCT01648192|Experimental|7.5 mg|Losmapimod for single dose
11457613|NCT01648192|Experimental|20 mg|Losmapimod for single dose
11457614|NCT01648192|Placebo Comparator|Placebo|Placebo
11457615|NCT01648192|Experimental|7.5 mg BID|Losmapimod for repeat dose (14 days)
11457616|NCT01648192|Placebo Comparator|Placebo BID|Placebo
11457617|NCT01648179|Experimental|GSK1322322 IV formulation|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via IV formulation
11457618|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fasted)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fasted)
11457619|NCT01648179|Experimental|GSK1322322 Oral mesylate salt solution|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Oral mesylate salt solution
11457620|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fed)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fed)
11457621|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
11457622|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
11457623|NCT01648153|Active Comparator|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
11457624|NCT01648153|Active Comparator|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
11457625|NCT01648153|Placebo Comparator|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
11461482|NCT01620437|Experimental|Formulation A|
11457626|NCT01648140|Experimental|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
11457627|NCT01648140|Experimental|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
11457628|NCT01648140|Active Comparator|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
11457629|NCT01648140|Experimental|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
11457630|NCT01648127|Experimental|Ceftaroline|Ceftaroline intravenous 600 mg single dose
11457631|NCT01648114|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
11457632|NCT01648114|Experimental|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
11457633|NCT01648101|Experimental|Retigabine 900mg|900mg total daily dose
11457634|NCT01648101|Experimental|Retigabine 600mg|600mg total daily dose
11457635|NCT01648101|Placebo Comparator|Placebo|Placebo
11457636|NCT01648088||Pre-op THA and TKA patients|Patients who are scheduled for total joint arthroplasty
11457637|NCT01648075|Experimental|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
11457638|NCT01648075|Placebo Comparator|Skimmed Milk|150 ml of skimmed milk once a day
11457639|NCT01648062|Active Comparator|Arousal reduction using guided imagery|Sleep Self-Regulation Using Mental Imagery: Participants in the arousal reduction condition were instructed to imagine wearing a backpack loaded with their worries, then putting the heavy backpack down, and then experiencing the relief and freedom from tension.
11457640|NCT01648062|Active Comparator|Mental simulation of sleep behavior|Sleep Self-Regulation Using Mental Imagery: Participants in this condition received instructions to visualize a specific behavioral plan designed to meet the goal of obtaining quality sleep each night through the practice of certain behaviors. To form the behavioral plan, participants visualised changing into comfortable clothes and taking time to relax prior to going to bed, the time they planned to go to sleep, where they planned to sleep, and the bedtime routine they follow to help them to get to sleep. At bedtime, they were instructed to mentally run through a checklist of these behaviors and then do any behaviors that they had not yet completed.
11457641|NCT01648062|Active Comparator|Combination|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to practice a combination of the guided imagery (for relaxation) and mental simulation imagery for sleep-related behaviour
11457642|NCT01648062|Sham Comparator|Control|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to imagine a typical post work activity
11457643|NCT01648049|Experimental|CBT|Cognitive behavior therapy for both insomnia and depression featuring stimulus control and cognitive therapy.
11457644|NCT01648049|Active Comparator|Treatment as Usual|No additional treatment besides regular care.
11457645|NCT01648036|Experimental|Unfractionated Heparin|
11457646|NCT01648036|Active Comparator|Dalteparin|Standard of care
11457647|NCT01648023|Experimental|Randomization to LC OR ONCOZENE Bead with Gem-Cis or Gem-Carbo|Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo
11457648|NCT01648023|Active Comparator|Randomization to Gem-Cis or Gem-Carbo|Gem-Cis or Gem-Carbo alone
11457649|NCT01648010|Experimental|TC-3 gel|TC-3 gel group undergo intravesical instillation of the investigatory device
11457650|NCT01648010|Experimental|MMC- gel|MMC gel group undergo intravesical instillation of the reverse thermal gelation device mixed with MMC
11457651|NCT01647997|Experimental|study 1a|whole body lactate production after bacterial endotoxin challenge
11457652|NCT01647997|No Intervention|study 1b|basal whole body lactate production
11457653|NCT01647997|Experimental|study 2a|muscle lactate concentration after bacterial endotoxin challenge
11457654|NCT01647997|No Intervention|study 2b|basal muscle lactate concentrations
11457655|NCT01647984|Placebo Comparator|Placebo|Inert Placebo - Vitamin B complex + diet
11457656|NCT01647984|Active Comparator|Ritmonutra|Omega-3 polyunsaturated fatty acids, Hawthorn, Astaxanthin, Vitamin E, Vitamin B complex + diet
11457657|NCT01647971|Experimental|ublituximab|"Phase I:
~4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with CLL or SLL will have infusions on Days 1, 8 and 15 of cycle 1 & 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply."
11457658|NCT01647958|Experimental|Treatment Arm|Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
11457659|NCT01647958|Active Comparator|Control|Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.
11457660|NCT01647945|Placebo Comparator|Placebo|
11457661|NCT01647945|Experimental|FK506 level < 2|
11457662|NCT01647945|Experimental|FK506 level 2-3|
11457663|NCT01647945|Experimental|FK506 level 3-5|
11457664|NCT01647932|Active Comparator|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
11457665|NCT01647932|Placebo Comparator|Loop diuretic plus placebo|Loop diuretic plus placebo
11457666|NCT01647919|Experimental|cogniVida™ 100 mg/day|
11457667|NCT01647919|Placebo Comparator|Placebo|
11457668|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose|
11457669|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose|
11457670|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose|
11457671|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation|
11457672|NCT01647880|Experimental|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
11457673|NCT01647880|Active Comparator|Interferon beta-1b (Extavia®)|every second day, s.c.
11457674|NCT01647867|Experimental|Met analysis|Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
11457675|NCT01647854|Experimental|Device: Teleconsultation|"If patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The safety and efficacy of the introduction and operation of this system should be evaluated."
11457676|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
11457677|NCT01647828|Experimental|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
11457678|NCT01647828|Experimental|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
11457679|NCT01647815|Experimental|50 healthy volunteers|The study population consists of healthy volunteers aged 18 to 50 years and without previous surgery, trauma, or thrombosis of the axilla or the shoulder girdle.
11457680|NCT01647802|Experimental|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
11457681|NCT01647802|Experimental|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
11457682|NCT01647802|Experimental|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
11457683|NCT01647802|Experimental|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
11457684|NCT01647802|Experimental|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
11457685|NCT01647802|Experimental|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
11457686|NCT01647789|Experimental|CFG920|
11457687|NCT01647776||Individuals without colon polyps|
11457688|NCT01647776||Individuals with colon polyps|
11457689|NCT01647763|Experimental|HAL/RAR|hemorrhoidal artery ligation with rectoanal repair
11457690|NCT01647763|Active Comparator|Stapled hemorrhoidopexy|"procedure for prolapse and hemorrhoids (PPH)
~Resection using a circular stapler"
11457691|NCT01647750|Other|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
11457692|NCT01647750|Other|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
11457693|NCT01647737|Active Comparator|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
11457694|NCT01647737|Active Comparator|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
11457695|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
11457696|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
11457697|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
11457698|NCT01647711|Experimental|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
11457699|NCT01647698|Experimental|Early training group|The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).
11457700|NCT01647698|Experimental|Late training group|The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.
11457701|NCT01647698|Placebo Comparator|No training group|The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
11457702|NCT01647685|Active Comparator|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
11457703|NCT01647685|Active Comparator|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
11457704|NCT01647685|Placebo Comparator|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
11457705|NCT01647672|Experimental|Abraxane|Abraxane for neoadjuvant chemotherapy
11457706|NCT01647659|Experimental|GSK1120212 tablet|GSK1120212 tablet
11457707|NCT01647659|Experimental|GSK1120212 powder for oral solution|GSK1120212 powder for oral solution
11457708|NCT01647646|Active Comparator|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.
~Intervention drug: Seretide fixed doses therapy"
11457709|NCT01647646|Experimental|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
11457710|NCT01647633|Experimental|Calcium Glycerophosphate Nasal Wash|Nasal spray wash twice daily and up to four additional times per day as needed for nasal allergy symptoms
11457711|NCT01647620|Active Comparator|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily
11461483|NCT01620437|Experimental|Formulation B|
11457712|NCT01647620|Placebo Comparator|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
11457713|NCT01647607|Experimental|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
11457714|NCT01647607|Active Comparator|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
11457715|NCT01647594|Active Comparator|Young Women's Intervention (YWI)|
11457716|NCT01647594|Active Comparator|Physical Activity Intervention (PAI)|
11457717|NCT01647581|Experimental|Clip|A clip is been placed at the polypectomy site.
11457718|NCT01647581|Placebo Comparator|No Clip|A hemoclip is not placed at the site of the polypectomy.
11457719|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
11457720|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
11457721|NCT01647555||patient with epidermoid cancer|receiving Cetuximab and radiotherapy
11457722|NCT01647542|Experimental|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
11457723|NCT01647542|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
11457724|NCT01647542|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
11457725|NCT01647529|Experimental|Ganciclovir|Treatment with topical ganciclovir ointment
11457726|NCT01647516|Experimental|Ozanimod 0.5 mg|Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
11457727|NCT01647516|Experimental|Ozanimod 1 mg|Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
11457728|NCT01647516|Placebo Comparator|Placebo|Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
11457729|NCT01647503||Tumor group|Parathyroid adenoma, hyperplasia and carcinoma
11457730|NCT01647503||Normal|Normal parathyroid samples
11457731|NCT01647490|Active Comparator|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
11457732|NCT01647490|Experimental|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
11457733|NCT01647477|Active Comparator|questionnaires|4 questionnaires to answer at baseline 45 minutes approx.
11457734|NCT01647477|Experimental|interview|semi directive interview 105 patients
11457735|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
11457736|NCT01647451|Experimental|Active|
11457737|NCT01647451|Placebo Comparator|Placebo|
11457738|NCT01647438|Other|Print Health Education|Participants receive print health education materials
11457739|NCT01647438|Experimental|Lifestyle Intervention|Six weekly health education classes and phone counseling.
11457740|NCT01647425||head and neck or lung cancer|patient with a first head and neck cancer or first lung cancer
11457741|NCT01647412|Active Comparator|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
11457742|NCT01647412|Placebo Comparator|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
11457743|NCT01647399||Phenotypic Clusters|500 urban youth
11457744|NCT01647386||MBT Revision Component|
11457745|NCT01647360||Women with Heavy Menstrual Bleeding (HMB)|
11457746|NCT01647347|Experimental|test treatment|"Test treatment:
~1 min mouthwash with 10% PVP-iodine
~1 min subgingival rinsing with 10% PVP-iodine
~1 min ultrasonic debridement with 10% PVP-iodine as cooling liquid
~blood sampling from the V.mediana cupidi"
11457747|NCT01647347|Placebo Comparator|Control group|"Control:
~1 min mouthwash with water
~1 min subgingival rinsing with water
~1 min ultrasonic debridement with water as cooling liquid
~blood sampling from the V.mediana cupidi"
11457748|NCT01647334|Experimental|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
11457749|NCT01647321|Active Comparator|Active cycling|Individuals will receive functional electrical stimulation while on the stationary bike and instructed to actively pedal.
11457750|NCT01647321|Sham Comparator|Passive cycling|Individuals will receive active functional electrical stimulation (FES) while on the stationary bike and instructed to relax their legs, allowing the FES to move their legs on the stationary bike.
11457751|NCT01647308|Active Comparator|ISIS-APOCIIIRX|
11457752|NCT01647308|Placebo Comparator|Placebo|
11457753|NCT01647282|Experimental|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
11457754|NCT01647282|Active Comparator|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
11457755|NCT01647269|Experimental|DBS Off first|
11457756|NCT01647269|Experimental|DBS On First|
11457757|NCT01647256|Experimental|Nikkomycin Z fed - fasting|"Period 1:
~Day 1: Nikkomycin Z 500 mg with high fat breakfast
~Period 2:
~Day 1: Nikkomycin Z 500 mg under fasted conditions"
11457758|NCT01647256|Experimental|Nikkomycin Z fasting - fed|"Period 1:
~Day 1: Nikkomycin Z 500 mg under fasted conditions
~Period 2:
~Day 1: Nikkomycin Z 500 mg with high fat breakfast"
11457759|NCT01647243|Experimental|Preoperative strength training|Progressive strength training on group basis four weeks before the operation and progressive strength training on group basis four weeks after the operation
11457760|NCT01647243|No Intervention|Living as usual|The patients are living as usual the last 4 weeks before operation
11457761|NCT01647217|Experimental|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
11457762|NCT01647217|Placebo Comparator|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
11457763|NCT01647204|No Intervention|usual mealtime care|patients admitted to the control ward receiving no intervention but usual mealtime help from ward staff
11457764|NCT01647204|Experimental|mealtime assistance|Additional lunchtime help from trained volunteer mealtime assistants to supplement help from the ward staff
11457765|NCT01647191|Experimental|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
11457766|NCT01647191|Active Comparator|control group|The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
11457767|NCT01647178|Active Comparator|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
11457768|NCT01647178|Active Comparator|TORQ closure|Patients are undergo a TORQ assisted sternal closure
11457769|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
11457770|NCT01646853|Experimental|Concurrent radiochemotherapy|
11457771|NCT01646840|Experimental|PF-04958242 capsule|
11457772|NCT01646840|Active Comparator|PF-04958242 oral solution|
11457773|NCT01646827|Experimental|Deltoid|Deltoid injection site
11457774|NCT01646827|Experimental|Gluteal|Gluteal injection site
11457775|NCT01646814|Experimental|PL2200|Investigational product, PL2200
11457776|NCT01646814|Active Comparator|Aspirin tablets|Active comparator, 325 mg aspirin tablets
11457777|NCT01646801|Experimental|Experimental|NMB's Paclitaxel Drug ejecting balloon catheter
11457778|NCT01646788|Experimental|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
11457779|NCT01646775|Experimental|Epidural bupivacaine|
11457780|NCT01646775|Active Comparator|Epidural bupivacaine and fentanyl|
11457781|NCT01646762|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11457782|NCT01646749|Experimental|Protein intake of 5 energy percent (En%)|
11457783|NCT01646749|Experimental|Protein intake of 15 En%|
11457784|NCT01646749|Experimental|Protein intake of 30 En%|
11457785|NCT01646736|Placebo Comparator|GC+CYC|Patients were treated with Glucocorticosteroid and Cyclophosphamide.
11457786|NCT01646736|Experimental|GC+T2|Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
11457787|NCT01646723|Experimental|VALID Intervention|Volunteers Adding Life in Dementia (VALID) Program
11457788|NCT01646710|Experimental|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
11457789|NCT01646697|Experimental|Diagnostic (cytopathologic evaluation)|Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
11457790|NCT01646684|Experimental|SOM230|
11457791|NCT01646671|Experimental|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
11457792|NCT01646671|Experimental|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
11457828|NCT01646372|Active Comparator|2nd Control Group|This group receives a standard Simulation based ACLS refresher as the intervention, like the control group. No mention is made of Cognitive Aids in the teaching, but they are available during the post-test and retention post-test.
11457793|NCT01646671|Experimental|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
11457794|NCT01646645|Experimental|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
11457795|NCT01646632|Experimental|Physical exercise intervention|Progressive resistance training, balance training, functional training
11457796|NCT01646632|Placebo Comparator|Lifestyle counseling|Recreational sessions
11457797|NCT01646619|Active Comparator|Hypothermia + Magnesium Sulphate|
11457798|NCT01646619|Placebo Comparator|Hypothermia+ Placebo|
11457799|NCT01646606|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be measured at a frequency determined by the responsible physician (as is current practice). The reading will be displayed on the bedside monitor in the participants' room.
11457800|NCT01646606|Experimental|Intermittent oxygen monitoring|
11457801|NCT01646580|Experimental|ciclopirox|
11457802|NCT01646567|Experimental|SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate|A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.
11457803|NCT01646554|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:
~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion
~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion
~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes
~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
~On day 1 of a 14 day cycle"
11457804|NCT01646554|Experimental|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:
~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h
~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion
~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion
~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes
~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
~Day 1 of a 14 day cycle
~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
11457805|NCT01646541||Asymptomatic|No dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class I]
11457806|NCT01646541||Symptomatic|Dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class II, III, or IV]
11457807|NCT01646528||Consecutive patients for CLE examination|
11457808|NCT01646515|Placebo Comparator|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
11457809|NCT01646515|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
11457810|NCT01646502|Experimental|Esp-supplemented standard wound care|500 pmol Esp protein will be added to the standard wound care protocol.
11457811|NCT01646502|Active Comparator|Standard wound care|"The standard treatment protocol established at the Vancouver Wound Healing Clinic is based on the Best Clinical Practice Guidelines for Venous Leg Ulcers from the Canadian Association of Wound Care."
11457812|NCT01646489|Experimental|Miravirsen sodium|
11457813|NCT01646489|Active Comparator|Telaprevir|
11457814|NCT01646476|Active Comparator|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
11457815|NCT01646476|Active Comparator|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
11457816|NCT01646463|Experimental|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills is the standard CenteringPregnancy prenatal healthcare intervention combined with mindfulness meditation and mindful movement/yoga applied to pregnancy, childbirth, and parenting.
11457817|NCT01646463|Active Comparator|CenteringPregnancy|CenteringPregnancy is group-based prenatal healthcare delivered according to the guidelines of the American College of Obstetrics and Gynecology. It includes assessment, support, and health education delivered in a healthcare empowerment framework.
11457818|NCT01646450|Experimental|Icotinib|Icotinib: 125mg, oral administration, three times per day.
11457819|NCT01646437|Experimental|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
11457820|NCT01646437|Experimental|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
11457821|NCT01646437|Experimental|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
11457822|NCT01646411||assorted acute infection|300 patients diagnosed with assorted acute infection.
11457823|NCT01646398|Experimental|>= 65-year age group-13vPnC|
11457824|NCT01646398|Active Comparator|>= 65-year age group-23vPS|
11457825|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
11457826|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 >4.2 treated with non-biologic anti-rheumatic drugs(s).
11457827|NCT01646372|Active Comparator|Control Group|This group gets a simulation based ACLS refresher as treatment, but no access to cognitive aids for any of the tests.
11461484|NCT01620424|Experimental|Dosing visit 1|
11457829|NCT01646372|Experimental|Cognitive Aid Group|This group receives Cognitive Aid based teaching as the intervention. They also have access to cognitive aids for post-test and retention post-test
11457830|NCT01646359|Experimental|corrected flow time|
11457831|NCT01646346|Experimental|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
11457832|NCT01646333|Active Comparator|Supportive Therapy|The supportive therapy offers patients and support persons the opportunity to discuss and reflect upon both Parkinson's Disease and non-Parkinson's Disease related problems.
11457833|NCT01646333|Experimental|Memory and Problem-Solving Intervention|The memory and problem solving training consists of a day calendar manual and note taking system and problem solving techniques. The neurocognitive memory intervention was adapted from a 6-week manualized day calendar and note taking system previously evaluated in an amnestic MCI sample and a brain tumor sample. The problem solving intervention was adapted from an originally 12-week intervention, which was later adapted into a 6-week brain tumor sample.
11457834|NCT01646320|Experimental|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
11457835|NCT01646320|Experimental|Arm 2: Placebo + Saxagliptin + Metformin IR|
11457836|NCT01646307|Placebo Comparator|standard care group|patients receive atorvastatin 20 mg/d
11457837|NCT01646307|Active Comparator|intensive rosuvastatin|administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI
11457838|NCT01646307|Active Comparator|intensive atorvastatin|patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;
11457839|NCT01646294|Experimental|OCAS-F|YM178 OCAS tablet (OCAS-Fast) taken orally under fasted and fed condition
11457840|NCT01646294|Experimental|OCAS-S|YM178 OCAS tablet (OCAS-Slow) taken orally under fasted and fed condition
11457841|NCT01646294|Experimental|OCAS-M|YM178 OCAS tablet (OCAS-Medium) taken orally under fasted and fed condition
11457842|NCT01646281|Active Comparator|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
11457843|NCT01646281|Active Comparator|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
11457844|NCT01646268|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
11457845|NCT01646268|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
11457846|NCT01646255|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
11457847|NCT01646255|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
11457848|NCT01646242|Experimental|Cold snare polypectomy|
11457849|NCT01646242|Experimental|Double biopsy polypectomy|
11457850|NCT01646229|Active Comparator|Polymyxin-B hemoperfusion|In the HEMOPERFUSION group, a veno-venous dialysis catheter type GamCath 12 F, 3 lumen will be inserted instead of a regular double or triple-lumen central venous catheter, and connected to the Toraymyxin® (PMX-20-R) device for endotoxin adsorption by hemoperfusion with the DECAPSMART pump. The length of the hemoperfusion will be a minimum of 120 min and started just before the beginning of the surgical intervention in the OR and stopped at the end of surgery.
11457851|NCT01646229|Active Comparator|Control|"In the CONTROL group, the administration of fluids (250 to 500ml crystalloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP between > 8 and 12 < mmHg, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mMol/L, normalisation of the BE.
~At the discretion of the attending anaesthesiologist with the FMH level, a PiCCO monitoring, a transoesophageal echography, or a pulmonary artery catheter, will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
11457852|NCT01646216|Experimental|Split-belt treadmill training|Split-belt treadmill exercise
11457853|NCT01646203|Experimental|IMC-TR1|"Part A - Dose Escalation:
~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle
~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles
~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles
~Part B - Disease Specific Cohort Expansion:
~Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose."
11457854|NCT01646190|Active Comparator|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume <50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
11457855|NCT01646190|Experimental|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: >4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: >6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
11457856|NCT01646177|Placebo Comparator|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
11457857|NCT01646177|Active Comparator|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
11457858|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
11457859|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
11457860|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
11457861|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
11457862|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
11457863|NCT01646138|Experimental|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
11457864|NCT01646125|Experimental|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.
~AUY922 was to be administered weekly."
11457865|NCT01646125|Active Comparator|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.
~Pemetrexed or docetaxel was to be was to be given once every three weeks."
11457866|NCT01646099|Experimental|Sun Protection Education|Distribution of the internet-based sun protection educational program.
11457867|NCT01646099|No Intervention|Control|Distribution of general skin care information.
11457868|NCT01646086|Experimental|weekly weight tracking|12 month behavioral weight loss intervention
11457869|NCT01646086|Active Comparator|daily weight tracking|12 month behavioral weight loss intervention
11457870|NCT01646086|Active Comparator|no weight tracking|12 month behavioral weight loss intervention
11457871|NCT01646073|Experimental|Adalimumab|Adalimumab 40 mg every other week (eow)
11457872|NCT01646073|Placebo Comparator|Placebo|placebo
11457873|NCT01646060|Experimental|Blood Draw|
11457874|NCT01646047|Experimental|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
11457875|NCT01646047|Placebo Comparator|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
11457876|NCT01646047|Experimental|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
11457877|NCT01646047|Placebo Comparator|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
11457878|NCT01646034|Experimental|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
11457879|NCT01646034|Active Comparator|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents
~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
11457880|NCT01646021|Experimental|Ibrutinib|
11457881|NCT01646021|Experimental|Temsirolimus|
11457882|NCT01646008||respiratory|
11457883|NCT01645995|Experimental|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
11457884|NCT01645995|Experimental|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
11457885|NCT01645969||Cohort|
11457886|NCT01645956||Single group|
11457887|NCT01645943|No Intervention|Conservative|Coronary angiogram only if recurrent ischemia or peristent heart failure or inducible ischemia in predischarge stress test if perfomed
11457888|NCT01645943|Active Comparator|Invasive|Routine coronary angiogram
11457889|NCT01645930|Experimental|Ixazomib+Lenalidomide+Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)
11457890|NCT01645917|Experimental|Ablation|Ablation with Arctic Front Advance Cardiac CryoAblation system
11457891|NCT01645904||Group 1|Patients participate in audiotaped focus group regarding web-based program, and fill out demographics questionnaire.
11457892|NCT01645904||Group 2|Patients come to Behavioral Research and Treatment Center (BRTC) at MD Anderson to use initial version of My Family Garden website. Completion of Website Analysis and MeasureMent Inventory (WAMMI), and demographics questionnaires.
11457893|NCT01645904||Group 3|Patients use final version of My Family Garden website, and are interviewed which will be audiotaped. Completion of Website Analysis and MeasureMent Inventory (WAMMI), questionnaire and demographics questionnaire.
11457894|NCT01645891|Active Comparator|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
11457895|NCT01645891|Sham Comparator|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
11457896|NCT01645878|Experimental|Hands on|breast feeding instructed by direct help of instructor
11457897|NCT01645878|Experimental|hands off|
11457898|NCT01645878|Other|Control|Routin breast feeding education
11457899|NCT01645865||Control|
11457900|NCT01645865||Intervention|
11461485|NCT01620424|Experimental|Dosing visit 2|
11457902|NCT01645852|Active Comparator|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
11457903|NCT01645839|Experimental|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
11457904|NCT01645839|No Intervention|Systemic treatment without Depocyte|No intrathecal injection.
11457905|NCT01645826|Experimental|Diltiazem|The study agent will be Diltiazem and will start at 60 mg po BID then titrated up every two weeks until at a maximum dose of 180mg po BID.
11457906|NCT01645826|Placebo Comparator|Sugar Pill|The placebo group of patients will be treated with Drug A (sugar pill) PO bid and titrated up every two weeks for next titration dose (actually will be an unchanged concentration).
11457907|NCT01645800|Experimental|Lysozyme hydrochloride|
11457908|NCT01645800|Placebo Comparator|Placebo|
11457909|NCT01645787|Active Comparator|4-aminopyridine (Ampyra)|10 mg tab/ 1 tab twice daily
11457910|NCT01645787|Placebo Comparator|Sugar pill|Placebo 1 tab /twice daily
11457911|NCT01645774|Experimental|10s injections duration|10s injections duration
11457912|NCT01645774|Experimental|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
11457913|NCT01645774|Experimental|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
11457914|NCT01645774|Experimental|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
11457915|NCT01645761|Experimental|PPI-based triple therapy with endonase|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
11457916|NCT01645761|No Intervention|PPI-based triple therapy|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)
11457917|NCT01645748|Experimental|S-1, induction chemotherapy|Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy
11457918|NCT01645735|Experimental|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
11457919|NCT01645735|Active Comparator|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
11457920|NCT01645722|Other|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
11457921|NCT01645709|Experimental|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
11457922|NCT01645709|Placebo Comparator|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
11457923|NCT01645696|Experimental|BD Continuous Glucose Monitor (CGM) with outer layer|A subcutaneous glucose binding protein sensing device to continuously monitor glucose in diabetics.
11457924|NCT01645696|Experimental|BD CGM without outer layer|A continuous glucose binding protein sensing device used to monitor glucose in Diabetics
11457925|NCT01645696|Active Comparator|Medtronic iPro 2 Professional CGM|Commercial glucose oxidase continuous glucose monitor
11457926|NCT01645566|Experimental|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
11457927|NCT01645566|No Intervention|Control|No instructions
11457928|NCT01645475|Experimental|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
11457929|NCT01645449|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
11457930|NCT01645449|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
11457931|NCT01645436|Experimental|treatment (exercise)|combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
11457932|NCT01645436|No Intervention|control (usual care)|Usual hospital care with no exercise
11457933|NCT01645423|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
11457934|NCT01645423|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
11457935|NCT01645410|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
11457936|NCT01645410|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
11457937|NCT01645397||Asthma, elevated exhaled NO|Children with asthma with elevated exhaled NO at initial evaluation (>25ppb)
11457938|NCT01645384|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
11457939|NCT01645384|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
11457940|NCT01645371||Subjects with opioid induced constipation|
11457941|NCT01645358|Experimental|Helmet to deliver NIV|
11457942|NCT01645358|Active Comparator|Total Face to deliver NIV|
11458031|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
11457943|NCT01645345|Other|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
11457944|NCT01645332|Placebo Comparator|Treatment I (control)|Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification
11457945|NCT01645332|Experimental|Treatment II|100 mg DLBS3233 once daily for 12 weeks + lifestyle modification
11457946|NCT01645319||White, non-hispanic - Medication Treatment Pathway|
11457947|NCT01645319||White, non-Hispanic - Laser Surgery Treatment Pathway|
11457948|NCT01645319||White, non-Hispanic - Incisional/Other Treatment Pathway|
11457949|NCT01645319||Hispanic - Medication Treatment Pathway|
11457950|NCT01645319||Hispanic - Laser Surgery Treatment Pathway|
11457951|NCT01645319||Hispanic - Incisional/Other Surgery Treatment Pathway|
11457952|NCT01645319||Asian - Medication Treatment Pathway|
11457953|NCT01645319||Asian - Laser Surgery Treatment Pathway|
11457954|NCT01645319||Asian - Incisional/Other Surgery Treatment Pathway|
11457955|NCT01645319||Black - Medication Treatment Pathway|
11457956|NCT01645319||Black - Laser Surgery Treatment Pathway|
11457957|NCT01645319||Black - Incisional/Other Surgery Treatment Pathway|
11457958|NCT01645306|Placebo Comparator|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|
11457959|NCT01645306|Active Comparator|40 mg Revacept|in phosphate buffered saline (PBS), 1% sucrose, 4% mannitol
11457960|NCT01645306|Active Comparator|120 mg Revacept|in phosphate buffered saline (PBS), 1% sucrose, 4% mannitol
11457961|NCT01645293|Experimental|Genetically modified T cells #1138|
11457962|NCT01645280|Placebo Comparator|Group 1|
11457963|NCT01645280|Experimental|Group 2|
11457964|NCT01645280|Experimental|Group 3|
11457965|NCT01645280|Experimental|Group 4|
11457966|NCT01645280|Experimental|Group 5|
11457967|NCT01645267|Experimental|Osteotomy|Using hydroxyapatite bone graft material
11457968|NCT01645254|Experimental|Argemone mexicana|"Argemone mexicana is traditional medicinal plant known as having an antimalarial activity.
~The aerial part of this plant is used. The decoction of the powder of the plant will be used."
11457969|NCT01645241|Experimental|Lutheal phase ovarian stimulation|Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
11457970|NCT01645228||significant coronary artery stenosis|anyone coronary segment > 50% diameter stenosis
11457971|NCT01645215|Experimental|Fruquintinib capsule|cohort 1: fruquintinb continuous oral dosing (1mg once a day) cohort 2: fruquintinb continuous oral dosing (2mg once a day) cohort 3: fruquintinb continuous oral dosing (4mg once a day) cohort 4: fruquintinb continuous oral dosing (6mg once a day) cohort 5: fruquintinb continuous oral dosing (5mg once a day) cohort 6: fruquintinb oral dosing, 3 weeks on/1 week off (5mg once a day) cohort 7: fruquintinb oral dosing, 3 weeks on/1 week off (6mg once a day)
11457972|NCT01645202|Active Comparator|TAVI with Edwards Sapien XT valve|
11457973|NCT01645202|Active Comparator|TAVI with Medtronic CoreValve|
11457974|NCT01645189|Experimental|Test drug|Idursulfase-beta
11457975|NCT01645176|Experimental|Hydroxychloroquine/Atorvastatin open label|
11457976|NCT01645163|Experimental|Mobile phone counselling|
11457977|NCT01645150|Experimental|Strength training group|12 weeks of progressive strength training
11457978|NCT01645150|No Intervention|Control group|No intervention
11457979|NCT01645137|Experimental|OMT|patients under usual medical care plus osteopathic treatment
11457980|NCT01645137|Other|control|patients under usual medical care
11457981|NCT01645124|Active Comparator|Cytoreduction for HCT < 45%|Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
11457982|NCT01645124|Experimental|Cytoreduction for HCT between 45 and 50%|Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
11457983|NCT01645111|Active Comparator|Clevidipine|
11457984|NCT01645098|Experimental|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
11457985|NCT01645098|Experimental|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
11457986|NCT01645085|Experimental|Treatment A|100mg MCC-based 13% drug-loaded tablets
11457987|NCT01645085|Experimental|Treatment B|100mg mannitol-based 38% drug-loaded tablets
11457988|NCT01645085|Experimental|Treatment C|150mg MCC-based 13% drug-loaded tablets
11457989|NCT01645085|Experimental|Treatment D|150mg mannitol-based 38% drug-loaded tablets
11457990|NCT01645072|Experimental|Low glycemic index diet|The patients will be started on low glycemic index diet.
11458110|NCT01644240|Experimental|TD-8954 Dose 1|
11458111|NCT01644240|Placebo Comparator|Placebo|
11458112|NCT01644240|Experimental|TD-8954 Dose 2|
11457991|NCT01645072|Other|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
11457992|NCT01645046|Active Comparator|Coenzyme A 200mg|Coenzyme A 200mg per day.
11457993|NCT01645046|Placebo Comparator|Placebo|Capsule without coenzyme A.
11457994|NCT01645046|Active Comparator|Coenzyme A 400mg|Coenzyme A 400mg per day.
11457995|NCT01645033|Experimental|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
11457996|NCT01645033|Active Comparator|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:
~Teaching about the treatment program
~Teaching important ideas about sexual behaviors risks
~Increasing knowledge about specific sexually transmitted diseases
~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
11457997|NCT01644994|Experimental|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
11457998|NCT01644981||VLBW infants|
11457999|NCT01644968|Experimental|KLH + anti-OX40|Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
11458000|NCT01644968|Experimental|Tetanus vaccine + anti-OX40|Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
11458001|NCT01644955|Experimental|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
11458002|NCT01644942|Other|Insulin sensitive patients|
11458003|NCT01644942|Other|Insulin resistant patients|
11458004|NCT01644929|Experimental|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
11458005|NCT01644929|Experimental|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
11458006|NCT01644929|Sham Comparator|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
11458007|NCT01644916|Other|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
11458008|NCT01644916|Other|Integrated care|Integrated care will be provided with integrated care management.
11458009|NCT01644890|Experimental|NK105|
11458010|NCT01644890|Active Comparator|Paclitaxel|
11458011|NCT01644877|Experimental|DAS181|DAS181-F02, 4.5 mg qd x 10 days
11458012|NCT01644877|Placebo Comparator|Lactose Placebo|placebo, 4.5 mg qd x 10 days
11458013|NCT01644864|Placebo Comparator|Placebo|saline injection
11458014|NCT01644864|Experimental|Experimental|0.375% ROPIVACAINE
11458015|NCT01644851|Experimental|Executive function training|Executive function training
11458016|NCT01644851|Placebo Comparator|Word game training|Computer-based training in tasks related to verbal processing.
11458017|NCT01644838|Experimental|Promethazine|25 mg of promethazine
11458018|NCT01644838|Experimental|Hyoscine|20 mg of hyoscine
11458019|NCT01644825|Experimental|paclitaxel and pazopanib|
11458020|NCT01644825|Active Comparator|paclitaxel|
11458021|NCT01644812|Active Comparator|Aerobic exercise|The exercise intervention is a 12-week program involving 150 minutes of moderate intensity exercise (65-69% of participant's age-predicted [220-age] maximum heart rate) each week. Participants will complete one 50-minute supervised treadmill exercise session in the laboratory and 100 minutes of exercise on their own. These exercises may include walking, jogging, biking, or other forms of aerobic exercise. The at-home exercise regimen will be individualized for each participant.
11458022|NCT01644812|Sham Comparator|stretching|The exercise intervention is a 12-week program involving 150 minutes of stretching each week (one 50-minute stretching session in the laboratory and 100 minutes of stretching at home). Participants in the stretching condition will work with a facilitator to create a stretching regimen for 100 minutes of home stretching throughout the week. The facilitator will provide a list of potential stretches with descriptions on how to perform them.
11458023|NCT01644799|Experimental|lenalidomide and idelalisib|"Lenalidomide:
~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.
~Idelalisib:
~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
11458024|NCT01644773|Experimental|Chemotherapy|Research participants with high grade glioma or diffuse intrinsic pontine glioma will receive crizotinib and dasatinib.
11458025|NCT01644760|Experimental|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
11458026|NCT01644747|Active Comparator|active tDCS|a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.
11458027|NCT01644747|Sham Comparator|sham tDCS|a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.
11458028|NCT01644721|Experimental|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
11458029|NCT01644721|No Intervention|Control|Follows the normal vaccination schedule
11458030|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
11458216|NCT01643564||Group 4|Heart Transplant Recipients with Normal Graft Function
11461552|NCT01620034|Experimental|4 Day Arm|
11458032|NCT01644682|Experimental|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
11458033|NCT01644682|Experimental|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
11458034|NCT01644682|Experimental|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
11458035|NCT01644682|No Intervention|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
11458036|NCT01644669|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
11458037|NCT01644656|Experimental|acoustic radiation force impulse (ARFI)|Imaging of liver and spleen using modified ultrasound
11458038|NCT01644643|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
11458039|NCT01644643|Active Comparator|Best Available Therapy|IV treatment
11458040|NCT01644630|Active Comparator|Cemented single crowns|Cemented single crown: zirconia abutment (Straumann Cares abutment) with an all-ceramic lithium disilicate crown
11458041|NCT01644630|Active Comparator|Screw-retained single crown|Screw-retained single crown: zirconia abutment (Straumann Cares abutment), directly veneered with veneering ceramic
11458042|NCT01644617|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
11458043|NCT01644617|Experimental|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
11458044|NCT01644617|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
11458045|NCT01644604|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
11458046|NCT01644604|No Intervention|Control Group|Subjects are maintained on baseline anti-hypertensive medications
11458047|NCT01644591|Experimental|Treatment (SRS)|Patients undergo SRS on day 1.
11458048|NCT01644578|Other|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
11458049|NCT01644565|Experimental|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
11458050|NCT01644565|Experimental|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
11458051|NCT01644565|Experimental|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
11458052|NCT01644565|Experimental|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
11458053|NCT01644565|Experimental|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
11458054|NCT01644565|Experimental|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
11458055|NCT01644565|Experimental|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
11458056|NCT01644565|Experimental|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
11458057|NCT01644565|Experimental|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1250 ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
11458058|NCT01644552||eye examinations|
11458059|NCT01644539|Other|Control|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion of 500 ml non caloric load consisting of water and thickening agent (guar gum), over 5 min.
~While scanning:
~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml non caloric load consisting of water and thickening agent (guar gum) in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still
~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
11458060|NCT01644539|Other|Oral ingestion|"Subjects participated in a 35 min fmri scan. Intervention: Oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk, over 5 min.
~Time frame while scanning:
~-5 - 0 min : baseline fmri scan 0 - 5 min: oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still
~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
11458061|NCT01644539|Other|Intra Gastric|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk, over 5 min.
~While scanning:
~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still
~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
11458062|NCT01644526|Experimental|Hemoaccess Valve System|Valve system for use with AV graft
11458063|NCT01644513||Positive Responders|Have received at least one injection with no evidence of residual subretinal or intra-retinal fluid present on Spectral Domain Optical Coherence Tomography (SDOCT) one month (+/- 1 week) following most recent injection.
11458064|NCT01644513||Suboptimal Responders|Have received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; Have not demonstrated complete resolution of fluid following any of the injections in the last 6 months Show leakage on Fluorescein Angiography (FA) or Indocyanine Green (ICG) imaging at some time during last 12 months
11458217|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
11458065|NCT01644500|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
11458066|NCT01644500|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
11458067|NCT01644500|Active Comparator|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
11458068|NCT01644487|Experimental|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
11458069|NCT01644487|Active Comparator|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
11458070|NCT01644474|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
11458071|NCT01644474|Experimental|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
11458072|NCT01644461|Other|Study Group|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
11458073|NCT01644448|Other|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
11458074|NCT01644448|Other|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
11458075|NCT01644435|Other|Study arm A|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
11458076|NCT01644435|Other|Study arm B|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring.
11458077|NCT01644422|Other|Study arm A|Subjects will receive hair follicles transplants that are dipped in HPL before transplant
11458078|NCT01644422|Other|Study arm B|Subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection one week after transplant
11458079|NCT01644422|Other|Control arm C|Subject will receive Standard hair follicle transplant
11458080|NCT01644396|Other|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
11458081|NCT01644383|Experimental|Treatment arm (logotherapy)|Participants in Arm I will attend the logotherapy group sessions by the trained psychologist for 4 visits (see Table II, III). The number of participants in group sessions will be 20 participants per group.
11458082|NCT01644383|No Intervention|Control arm (general health education)|Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
11458083|NCT01644370|Other|HIV positive with aeroallergen|positive for aeroallergen at baseline
11458084|NCT01644370|Other|HIV positive without aeroallergen|negative for aeroallergen at baseline
11458085|NCT01644370|No Intervention|control|HIV negative children (n=10)
11458086|NCT01644357|No Intervention|Dispensing only|Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
11458087|NCT01644357|Experimental|Pharmaceutical care|Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
11458088|NCT01644344|Active Comparator|X-ray|Control group: patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks. Each time radiographs are completed, the surgeon or resident will document if a change in fixation position is noted and if a change in patient management will be entertained (addition, modification or maintenance of cast or splint use, modification of or decision not to advance activity level, need for further surgery to adjust fixation or fracture reduction). The patients' time spent in clinic will be recorded upon arrival and upon completion of the patient-physician interaction.
11458089|NCT01644344|Active Comparator|No X-ray|
11458090|NCT01644331|Experimental|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
11458091|NCT01644331|Placebo Comparator|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
11458092|NCT01644318||authoimmıne thyroiditis and habitual abortus|
11458093|NCT01644318||authoimmune thyroiditis|
11458094|NCT01644318||healthy controls|
11458095|NCT01644305||Polycystic Ovary Syndrome|
11458096|NCT01644305||Idiopathic hirsutism|
11458097|NCT01644305||Control|
11458098|NCT01644292|Experimental|EPIC Wheels Training Intervention|EPIC Wheels skills training program
11458099|NCT01644279||Young|Young (age 20-35 years old)
11458100|NCT01644279||Old high-functioning|Old high-functioning (age 70-99 years old)
11458101|NCT01644279||Old low-functioning|Old low-functioning (age 70-99 years old)
11458102|NCT01644253|Experimental|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
11458103|NCT01644253|Experimental|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
11458104|NCT01644253|Experimental|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
11458105|NCT01644253|Experimental|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
11458106|NCT01644253|Experimental|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
11458107|NCT01644253|Experimental|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
11458108|NCT01644253|Experimental|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
11458109|NCT01644253|Experimental|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
11458113|NCT01644214|No Intervention|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
11458114|NCT01644214|Experimental|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
11458115|NCT01644201|Active Comparator|High viscosity non-starch polysaccharide, PolyGlycopleX®-PGX®|
11458116|NCT01644201|Placebo Comparator|Placebo (Rice Flour)|
11458117|NCT01644188|Experimental|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
11458118|NCT01644188|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
11458119|NCT01644175|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
11458120|NCT01644175|Experimental|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
11458121|NCT01644162|Other|iVAPS ventilation|3 months of ventilator use in iVAPS mode with data monitoring
11458122|NCT01644149|Experimental|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
11458123|NCT01644149|Active Comparator|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
11458124|NCT01644136|Experimental|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
11458125|NCT01644123||Nursing home residents|
11458126|NCT01644110|Experimental|ruxolitinib/pomalidomide|"Cohort 1 (Patient 1 - Patient 41): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.
~Cohort 2 (Patient 42 - Patient 90): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be started at 0.5 mg once daily up to 2 mg once daily."
11458127|NCT01644097|Experimental|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
11458128|NCT01644097|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
11458129|NCT01644084|Experimental|HA (priming)-HES (up to 15 ml/kg after CPB)|
11458130|NCT01644084|Active Comparator|HES (priming)-HES (up to 15 ml/kg after CPB)|
11458131|NCT01644084|Active Comparator|HA (priming)-nonHES (only crystalloids after CPB)|
11458132|NCT01644071|Experimental|arm 1|application of three treatments and three masurements within 3 weeks
11458133|NCT01644058|Experimental|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
11458134|NCT01644045|Experimental|Device: Teleconsultation|"In cases of acute obstructive, respiratory emergencies if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
11458135|NCT01644032|Experimental|Device_ Teleconsultation|"Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of emergencies, where intravenous analgesia is necessary, if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team and can delegate the application of morphine and other analgesics. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.
~The safety, efficacy and the quality of analgesia should be compared with regular EMS."
11458136|NCT01644032|No Intervention|Historical Control Period|After completion of the study arm, matched pairs from a historical phase (without the ability of teleconsultation) were searched. Local cases were always matched with comparable controls from the same location.
11458137|NCT01644019|Experimental|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
11458218|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
11458261|NCT01643226|Experimental|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
11458304|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
11458138|NCT01644006|Experimental|Device: Teleconsultation|"In cases of suspected acute coronary syndrome (including STEMI), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.
~The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
11458139|NCT01644006|No Intervention|Historical Matched Pairs|Historical matched pairs were searched from local protocols. During this phase no teleconsultation system was existent.
11458140|NCT01643993|Experimental|hCG at Time of Embryo Transfer|Patients will have hCG and media (for a total of 20 microliters) inserted during a mock embryo transfer immediately prior to actual embryo transfer.
11458141|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
11458142|NCT01643980|Experimental|Vaginal micronized progesterone|200 mg vaginal route per day
11458143|NCT01643980|Active Comparator|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
11458144|NCT01643967|Experimental|Ozone therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
11458145|NCT01643967|Active Comparator|sunflower oil|"The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
~Other Names:
~Sunflower oil"
11458146|NCT01643954|No Intervention|Arm A|Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center.
11458147|NCT01643954|Other|Arm B|Patients with prostate cancer that will undergo robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center .
11458148|NCT01643941|Experimental|1|SA4Ag vaccine low dose
11458149|NCT01643941|Experimental|2|SA4Ag vaccine mid dose
11458150|NCT01643941|Experimental|3|SA4Ag vaccine high dose
11458151|NCT01643941|Experimental|4|SA3Ag vaccine
11458152|NCT01643941|Placebo Comparator|5|Placebo
11458153|NCT01643928|Experimental|Rituximab-Pfizer|
11458154|NCT01643928|Active Comparator|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
11458155|NCT01643928|Active Comparator|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
11458156|NCT01643915|Active Comparator|Control group|Patients with conventional treatment. No distraction method during the treatment visits.
11458157|NCT01643915|Experimental|Experimental group 1|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
11458158|NCT01643915|Experimental|Experimental group 2|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
11458159|NCT01643902|Experimental|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
11458160|NCT01643889|Experimental|Sequence group ADBC|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
11458161|NCT01643889|Experimental|Sequence group BACD|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
11458162|NCT01643889|Experimental|Sequence group CBDA|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
11458163|NCT01643889|Experimental|Sequence group DCAB|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
11458164|NCT01643876|Experimental|Palatal brushing|Palatal brushing after each meal for 3 months.
11458165|NCT01643863||Cohort|
11458166|NCT01643850|Experimental|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
11458167|NCT01643850|Placebo Comparator|Placebo|Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
11458168|NCT01643850|Experimental|MCS110 3 mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion)
11458169|NCT01643850|Experimental|MCS110 5 mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion)
11458170|NCT01643850|Experimental|MCS110 10 mg/kg|Part C: MCS110 10 mg/kg (i.v. infusion)
11458171|NCT01643850|Experimental|MCS110 3 mg/kg & MCS110 10mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
11458172|NCT01643850|Experimental|MCS110 5 mg/kg & MCS110 10mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
11458173|NCT01643837|No Intervention|Standard|Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
11458174|NCT01643837|Sham Comparator|Light Touch (LT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
~Light touch protocol."
11458175|NCT01643837|Experimental|Osteopathic Manipulative Treatment (OMT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
~OMT Protocol."
11458219|NCT01643538|Active Comparator|Control Arm|"Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or charity donations in this group."
11458176|NCT01643824|Experimental|Proton Beam Therapy|"Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%
~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
11458177|NCT01643811||Gastrectomy|Patients who underwent gastrectomy for early gastric cancer
11458178|NCT01643811||Endoscopic submucosal dissection|Patients who underwent endoscopic submucosal dissection for early gastric cancer
11458179|NCT01643798|Placebo Comparator|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
11458180|NCT01643798|Active Comparator|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
11458181|NCT01643785|Experimental|with Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] plus 20,000 units of pronase (endonase), BID for 7 days
11458182|NCT01643785|No Intervention|without Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] for 7 days
11458183|NCT01643772|Experimental|Oxycodone Hydrochloride 5 mg Capsules|Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
11458184|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules|Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
11458185|NCT01643772|Experimental|Oxycodone Hydrochloride 20 mg Capsules|Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
11458186|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules(multi-dose)|Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
11458187|NCT01643759|Experimental|buprenorphine transdermal system|buprenorphine transdermal system
11458188|NCT01643746|Active Comparator|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
11458189|NCT01643746|Active Comparator|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
11458190|NCT01643733|Experimental|Transonics Arm|Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
11458191|NCT01643733|No Intervention|Control arm|Patient will undergo normal fistula intervention guided only by angiographic assessment
11458192|NCT01643720||Autism Spectrum Disorders|Children with Autism Disorders and their parents
11458193|NCT01643720||Typically Developing|Typically Developing children and their parents
11458194|NCT01643707||Phase I|Control
11458195|NCT01643707||Phase II|Treatment
11458196|NCT01643694|Experimental|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
11458197|NCT01643694|No Intervention|control group|Completion of baseline and 3 mo survey
11458198|NCT01643681|Experimental|AdMSC|Autologous Adipose Tissue derived Mesenchymal Stem Cells
11458199|NCT01643668|Experimental|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
11458200|NCT01643655|Experimental|Autologous Adipose Tissue Derived MSCs|
11458201|NCT01643642|Experimental|Cognitive behavioral treatment/farmacotherapy intervention|Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM
11458202|NCT01643642|Other|Treatment As Usual|Control group, TAU
11458203|NCT01643629|Other|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
11458204|NCT01643629|Other|Control Arm B|Control arm B will include subjects receiving Standard therapy
11458205|NCT01643616|Active Comparator|group US|"Ultrasound guided block :
~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
11458206|NCT01643616|Active Comparator|group NS|"Nerve stimulation technique:
~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
11458207|NCT01643603|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. Patients who are day 100-180 post transplant will be eligible. The treatment will be started as close to day 100 as possible. The range of days is provided to ensure that patients have recovered from toxicities associated with ASCT and are not deemed ineligible if they were recovering from any toxicity associated with ASCT at day 100.The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months.
11458208|NCT01643590|Placebo Comparator|Placebo|
11458209|NCT01643590|Experimental|15 mg dose of JVS-100|15 mg dose of JVS-100
11458210|NCT01643590|Experimental|30 mg dose of JVS-100|30 mg dose of JVS-100
11458211|NCT01643577|Active Comparator|Acupuncture protocol for gastroparesis|Patients randomized to this arm will receive an acupuncture protocol that with points designed to treat gastroparesis
11458212|NCT01643577|Placebo Comparator|Acupuncture for musculoskeletal pain|Patients randomized to this arm will receive acupuncture therapy consisting of points designed to treat musculoskeletal pain.
11458213|NCT01643564||Group 1|Heart Transplant Recipients with Unexplained Graft Dysfunction
11458214|NCT01643564||Group 2|Normal Control
11458215|NCT01643564||Group 3|Class III-IV Heart Failure
11458220|NCT01643538|Experimental|Personal Financial Incentives Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will receive $20. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
11458221|NCT01643538|Experimental|Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
11458222|NCT01643538|Experimental|Combined Financial Incentives & Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
11458223|NCT01643525|Other|Nautilus NeuroWave Recording Arm|Nautilus NeuroWaveTM System
11458224|NCT01643499|Experimental|Treatment (mFOLFIRINOX)|Patients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11458225|NCT01643486|Experimental|iTouch phosphate counting program|All patients will have an iTouch that will help them to calculate the required number of phosphate binders to be taken with each meal
11458226|NCT01643486|Active Comparator|Usual Care|Participants in the active comparator group will document their meals in the iTouch but continue to take their phosphate binders as prescribed by their MD/dietician
11458227|NCT01643473|Active Comparator|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
11458228|NCT01643473|Experimental|Tailored Adherence Intervention|Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
11458229|NCT01643460|Experimental|98% Ethanol with Paclitaxel injection|
11458230|NCT01643447|Active Comparator|Diammonium glycyrrhizinate|Conventional drugs protect liver
11458231|NCT01643447|Experimental|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
11458232|NCT01643434|Active Comparator|Spironolactone|
11458233|NCT01643434|Active Comparator|Clonidine|
11458234|NCT01643421|Experimental|Deep inspiration and expiratory positive airway pressure|The protocol of deep inspiration combined to expiratory positive airway pressure will be applied in asthmatic subjects.
11458235|NCT01643421|No Intervention|Control|
11458236|NCT01643408|No Intervention|Treatment|Route of administration
11458237|NCT01643395|Experimental|vertebroplasty|
11458238|NCT01643395|Other|conservative therapy (brace)|
11458239|NCT01643382|Experimental|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
11458240|NCT01643382|Active Comparator|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
11458241|NCT01643369|Experimental|Compassion Meditation Group|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
11458242|NCT01643369|Active Comparator|Health Education and Wellness Group|Eight week training in health and wellness, using a curriculum developed specifically for this study.
11458243|NCT01643369|Experimental|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
11458244|NCT01643356|Active Comparator|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
11458245|NCT01643356|No Intervention|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
11458246|NCT01643356|Active Comparator|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
11458247|NCT01643343||Typically Developing|Typically developing toddler volunteers between the ages of 8 months and 3 years
11458248|NCT01643343||Autism|Children between the ages of 8 months and 6 years with a diagnosis of an autism spectrum disorder
11458249|NCT01643330|Experimental|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
11458250|NCT01643330|Placebo Comparator|Placebo|Intracoronary infusion
11458251|NCT01643304||Group 1|
11458252|NCT01643291|Experimental|Ultrasound|
11458253|NCT01643278|Experimental|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11458254|NCT01643265|Active Comparator|Whey Milk Protein|
11458255|NCT01643265|Experimental|Bovine Albumin Concentrate|
11458256|NCT01643252|Placebo Comparator|Placebo and UVA light exposure|
11458257|NCT01643252|Active Comparator|Riboflavin drops and UVA light exposure|
11458258|NCT01643239|Experimental|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
11458259|NCT01643239|Experimental|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
11458260|NCT01643239|Other|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
11458262|NCT01643226|Placebo Comparator|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
11458263|NCT01643213|Experimental|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
11458264|NCT01643213|Active Comparator|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
11458265|NCT01643187|Experimental|Fortified beverage|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
11458266|NCT01643187|Active Comparator|Group receiving lactose-free milk|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
11458267|NCT01643174||Surgical treatment|
11458268|NCT01643161|Experimental|TAU+GSH|Treatment As Usual plus Guided Self Help.
11458269|NCT01643161|Active Comparator|TAU|Treatment AS Usual.
11458270|NCT01643148||breast cancer patients (cases)|36 subjects
11458271|NCT01643148||controls|36 subjects
11458272|NCT01643135|Active Comparator|tranexamic acid|Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
11458273|NCT01643135|Placebo Comparator|0.9% NaCl|0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
11458274|NCT01643122||Group 1|
11458275|NCT01643122||Group 2|
11458276|NCT01643109|Experimental|CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
11458277|NCT01643109|No Intervention|Comparison|Standard therapy.
11458278|NCT01643096|Other|sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
11458279|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
11458280|NCT01643083|Active Comparator|Rifaximin|
11458281|NCT01643083|Placebo Comparator|Placebo|
11458282|NCT01643070|Active Comparator|XELOX RT|Concurrent XELOX-RT
11458283|NCT01643070|Active Comparator|Induction XELOX|Induction XELOX followed by XELOX-RT
11458284|NCT01643057||Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
11458285|NCT01643044|Experimental|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
11458286|NCT01643044|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
11458287|NCT01643031|Experimental|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
11458288|NCT01643031|Active Comparator|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
11458289|NCT01643018|Experimental|laparoscopic surgery|-Laparoscopic surgery group describes the patients treated with laparoscopic surgery
11458290|NCT01643018|Active Comparator|Open Surgery|-open surgery group describes the patients treated with traditional open surgery
11458291|NCT01643005|Active Comparator|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
11458292|NCT01643005|Experimental|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
11458293|NCT01642992||Coronary bifurcation lesion|
11458294|NCT01642979|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
11458295|NCT01642979|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
11458296|NCT01642979|Active Comparator|Glucocorticoids|Glucocorticoids
11458297|NCT01642966|Active Comparator|Prasugrel|Prasugrel 10mg/day for 15 days
11458298|NCT01642966|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
11458299|NCT01642953|Experimental|Early recovery|"Patients who enroll in this arm are supplied a liquid diet one day before surgery without bowel preparation.
~After gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination."
11458300|NCT01642940|Active Comparator|Prasugrel|
11458301|NCT01642940|Experimental|Ticagrelor|
11458302|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
11458303|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
11458305|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
11458306|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
11458307|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
11458308|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
11458309|NCT01642914|Experimental|Linaclotide 290 micrograms|Linaclotide 290 micrograms
11458310|NCT01642914|Experimental|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
11458311|NCT01642914|Placebo Comparator|Placebo|Matching placebo
11458312|NCT01642901|Experimental|Zoledronic Acid 5 mg IV infusion|Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
11458313|NCT01642901|Placebo Comparator|normal saline 0.9%|Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
11458314|NCT01642888|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
11458315|NCT01642888|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
11458316|NCT01642875|Experimental|EN|early enteral nutrition with standard enteral formulas administered through a nasojejunal tube
11458317|NCT01642875|Active Comparator|PerOs|early oral nutrition with hospital diets and oral formulas
11458318|NCT01642862|Experimental|Liquid formulation of Simvastatin|
11458319|NCT01642862|Active Comparator|Tablet formulation of Simvastatin|
11458320|NCT01642849|Experimental|high protein diet|12 subjects will be place on a high protein diet
11458321|NCT01642849|Experimental|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
11458322|NCT01642836|Experimental|multi-component, multi-level, multi-setting (MMM)|"a theory-based community team sports program designed specifically for overweight and obese children,
~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and
~a primary care provider behavioral counseling intervention linked to the community and home interventions."
11458323|NCT01642836|Active Comparator|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:
~notification of primary care providers about metabolic measures and blood pressure
~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
11458324|NCT01642823||retinablastoma tumor tissue|
11458325|NCT01642810|Active Comparator|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
11458326|NCT01642810|Experimental|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
11458327|NCT01642797|Experimental|CLE-TB|Confocal laser endomicroscopy with Targeted Biopsy
11458328|NCT01642797|Experimental|WLE-SB|Standard White-light endoscopy with Standard Biopsy
11458329|NCT01642784||Culprit lesion IRA revascularization|Culprit lesion IRA revascularization
11458330|NCT01642784||Complete IRA revascularization|Complete IRA revascularization
11458331|NCT01642771|Active Comparator|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
11458332|NCT01642771|Experimental|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
11458333|NCT01642758|Experimental|Sodium 2,2 dimethylbutyrate|A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
11458334|NCT01642745|Experimental|Methacholine (Provocholine) with deep inhalation|
11458335|NCT01642745|Experimental|Mannitol (Aridol)|
11458336|NCT01642745|Active Comparator|Methacholine (Provocholine) tidal breathing|
11458337|NCT01642732|Experimental|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.
~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).
~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.
~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.
~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
11458338|NCT01642719|Placebo Comparator|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline
11458339|NCT01642719|Experimental|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
11458340|NCT01642706||RA patients|Patients affected by Rheumatoid arthritis.
11458341|NCT01642706||Control|"Subjects affected by either :
~mechanical pathology
~systemic auto-immune pathology
~other inflammatory rheumatism"
11458342|NCT01642693|Experimental|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
11458343|NCT01642693|Experimental|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
11458490|NCT01641692|Experimental|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
11458344|NCT01642680|Experimental|Physical activity during chemotherapy|This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
11458345|NCT01642680|Active Comparator|Physical activity after chemotherapy|This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
11458346|NCT01642667|Placebo Comparator|primary PCI|
11458347|NCT01642667|Active Comparator|prouk-PCI|
11458348|NCT01642654|Active Comparator|Control|
11458349|NCT01642654|Experimental|Treatment|
11458350|NCT01642641|Active Comparator|Non-surgical subgingival debridement|
11458351|NCT01642641|Active Comparator|Simplified Papilla Preservation Flap|
11458352|NCT01642641|Active Comparator|Resective Flap with Osseous Recontouring|
11458353|NCT01642628|Experimental|Body Image/Mirror Education|Participants in the mirror arm will receive a mirror and mirror viewing education from oncology nurse navigators.
11458354|NCT01642628|No Intervention|Standard Care|Patients allocated to the control group will receive the usual pre and post-op standard care that does not include the use or discussion of mirrors.
11458355|NCT01642615|Experimental|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
11458356|NCT01642615|Experimental|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
11458357|NCT01642615|Experimental|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
11458358|NCT01642602|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
11458359|NCT01642589|Experimental|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
11458360|NCT01642589|Active Comparator|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
11458361|NCT01642576|Experimental|diet modification|counselling on caloric restriction and healthy eating
11458362|NCT01642576|Experimental|weight management program|dietician and sports trainer, physician counselling on weight loss
11458363|NCT01642563|Experimental|Pathogen reduced platelets|Transfusion
11458364|NCT01642563|Active Comparator|Standard platelets|Transfusion
11458365|NCT01642550|Active Comparator|RM-131|Active study drug - RM-131
11458366|NCT01642550|Placebo Comparator|Placebo|Placebo comparator
11458367|NCT01642537|Other|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
11458368|NCT01642524|Experimental|hypertonic saline mixed Dextran|hypertonic saline mixed Dextran
11458369|NCT01642524|Placebo Comparator|Placebo controlled|Saline solution
11458370|NCT01642511|Active Comparator|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
11458371|NCT01642511|Experimental|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
11458372|NCT01642498|Experimental|Group A|ROX Coupler + continuing standard antihypertensive medications
11458373|NCT01642498|No Intervention|Group B|Continuing standard antihypertensive medications
11458374|NCT01642485|Active Comparator|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
11458375|NCT01642485|Experimental|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.
~Additionally, Caucasian vs Japanese subjects were analysed."
11458376|NCT01642472|Experimental|Ulipristal Acetate (PGL4001) 10mg|Ulipristal Acetate (PGL4001)10mg daily administration
11458377|NCT01642459|Experimental|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
11458378|NCT01642459|Active Comparator|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
11458379|NCT01642446|Experimental|surgery|Precise hepatectomy
11458380|NCT01642446|Active Comparator|combined intervention|transcatheter hepatic arterial chemoembolization and/or ablation
11458381|NCT01642433|Placebo Comparator|Sugar pills|
11458382|NCT01642433|Active Comparator|Prazosin pills|
11458383|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
11458384|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
11458385|NCT01642420||Healthy control persons|Age matched healthy persons
11458386|NCT01642407|Experimental|Sildenafil|
11458387|NCT01642394|No Intervention|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
11458388|NCT01642394|Experimental|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
11458389|NCT01642381|Active Comparator|Psychotherapy|
11458491|NCT01641692|Experimental|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
11458390|NCT01642381|No Intervention|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
11458391|NCT01642368|Placebo Comparator|Regular Diet|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
11458392|NCT01642368|Active Comparator|Medium Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
11458393|NCT01642368|Active Comparator|High Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
11458394|NCT01642355|No Intervention|Usual Care|Usual care includes physician assistant and/or nurse based medical and lifestyle recommendations in consultation with cardiac catheterization attending or patient's clinical cardiologist to potentially improve the patient's medical and lifestyle regimen. Relevant educational material is routinely distributed to patients.
11458395|NCT01642355|Active Comparator|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
11458396|NCT01642355|Active Comparator|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
11458397|NCT01642342|Experimental|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11458398|NCT01642342|Experimental|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11458399|NCT01642342|Experimental|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11458400|NCT01642316|Experimental|washback|students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test
11458401|NCT01642316|Other|control|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
11458402|NCT01642303|Experimental|vodcasting|students who listen to downloaded vodcasting
11458403|NCT01642303|No Intervention|control|listen to the student book listening file
11458404|NCT01642277|Experimental|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
11458405|NCT01642277|No Intervention|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
11458406|NCT01642264|No Intervention|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
11458407|NCT01642264|Experimental|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
11458408|NCT01642251|Experimental|Arm A (veliparib)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11458409|NCT01642251|Active Comparator|Arm B (placebo)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11458410|NCT01642238|Experimental|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
11458411|NCT01642238|Active Comparator|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
11458412|NCT01642212|Experimental|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
11458413|NCT01642212|Placebo Comparator|Matching Placebo|Taken once or twice daily for 20 weeks
11458414|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|
11458415|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|
11458416|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss|
11458417|NCT01642186|Experimental|Arm A everolimus|"Everolimus will be administered at the following doses:
~Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.
~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
11458418|NCT01642186|Experimental|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.
~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
11458449|NCT01641939|Experimental|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
11458419|NCT01642186|Experimental|Arm C combination everolimus, letrozole and leuprolide|"Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.
~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
11458420|NCT01642173|Other|OCT at baseline|"Subjects enrolled in the NIH funded and IRB approved (08-008161) protocol Lp-PLA2 and Coronary Atherosclerosis in Humans with a positive diagnosis of coronary artery endothelial dysfunction will be studied using Optical Coherence Tomography during the angiogram at baseline."
11458421|NCT01642173|Other|OCT following 6 month Lp-PLa2 inhibition|"Subjects who are enrolled in IRB 10-000044 Lp-PLA2 and Coronary Atherosclerosis in Humans Aim III a study in which the investigators are examining the impact of long-term inhibition of Lp-PLA2, with a specific novel inhibitor or placebo, on Lp-PLA2 activity and improvement in coronary endothelial function will be studied using Optical Coherence Tomography during the 6 month return angiogram."
11458422|NCT01642160|Active Comparator|Standard of care|Participants randomized to this arm will have the usual follow up care without any additional information.
11458423|NCT01642160|Active Comparator|Additional Education|This arm will receive a weekly text message or e-mail asking participants to sign on to the web page that we will provide. Once they sign on, they will see additional educational materials and questions regarding their CPAP use. Based on their response, they will be directed to suggestion or sites to help improve their compliance with their CPAP.
11458424|NCT01642147|Experimental|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.
~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
11458425|NCT01642147|Active Comparator|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
11458426|NCT01642134|Active Comparator|Duoplavin|Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.
11458427|NCT01642134|Sham Comparator|acenocumarol|
11458428|NCT01642121||Observational|Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
11458429|NCT01642108|Other|Sitagliptin|
11458430|NCT01642095||Basic science (FAK expression)|Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
11458431|NCT01642082|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11458432|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
11458433|NCT01642056|Placebo Comparator|Arm 1|Placebo
11458434|NCT01642056|Experimental|Arm 2|
11458435|NCT01642030|Other|Methadone Maintenance|
11458436|NCT01642030|Other|Buprenorphine Maintenance|
11458437|NCT01642017|Experimental|Pazopanib|Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
11458438|NCT01642004|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
11458439|NCT01642004|Experimental|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
11458440|NCT01641991|Experimental|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
11458441|NCT01641991|Experimental|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
11458442|NCT01641991|Experimental|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
11458443|NCT01641991|Experimental|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
11458444|NCT01641978||ICU patients|neurological level in critical patients
11458445|NCT01641965|Active Comparator|early non invasive ventilation|Patients assigned to this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB)immediately after randomization (when their FVC reaches the threshold of the 75% of the predicted value)
11458446|NCT01641965|Active Comparator|standard|patients in this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB) when they fulfil at least one of the following criteria: (i) FVC < 50% predicted, (ii) orthopnea, and/or (iii) PaCO2 > 45 mmHg.
11458447|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
11458448|NCT01641939|Active Comparator|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
11458450|NCT01641939|Experimental|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
11458451|NCT01641926|Experimental|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
11458452|NCT01641926|Active Comparator|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
11458453|NCT01641926|Experimental|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
11458454|NCT01641926|Active Comparator|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
11458455|NCT01641913|Experimental|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
11458456|NCT01641900|Experimental|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.
~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
11458457|NCT01641900|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
11458458|NCT01641887||GERD patients|Patients who have GERD will be recruited for this study.
11458459|NCT01641874|Experimental|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
11458460|NCT01641874|Active Comparator|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
11458461|NCT01641874|No Intervention|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
11458462|NCT01641861|Experimental|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
11458463|NCT01641861|Experimental|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
11458464|NCT01641848|Experimental|Arthritic and injured ankles|InBone TAA
11458465|NCT01641835||Normals|No eye disease.
11458466|NCT01641822|Active Comparator|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
11458467|NCT01641822|Placebo Comparator|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
11458468|NCT01641809|Experimental|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
11458469|NCT01641809|Experimental|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
11458470|NCT01641809|Experimental|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
11458471|NCT01641809|Active Comparator|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
11458472|NCT01641783|Experimental|nanoparticle Albumin-bound paclitaxel|evaluate one dose level of nab-paclitaxel:125mg/m2
11458473|NCT01641770|Experimental|Dietary Counseling + ONS|
11458474|NCT01641770|Active Comparator|Dietary Counseling|
11458475|NCT01641757|Experimental|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
11458476|NCT01641744|Experimental|Group Attachment Based Intervention (GABI)|
11458477|NCT01641744|Active Comparator|Systematic Training for Effective Parenting (STEP)|
11458478|NCT01641731|Active Comparator|Cow's milk|
11458479|NCT01641731|No Intervention|Control group|
11458480|NCT01641718|Experimental|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
11458481|NCT01641718|Active Comparator|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
11458482|NCT01641718|Other|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.
~Experimental treatment and active comparator in the same patient."
11458483|NCT01641718|Other|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.
~Experimental treatment and active comparator in the same patient."
11458484|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
11458485|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
11458486|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
11458487|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
11458488|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
11458489|NCT01641692|Experimental|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
11458492|NCT01641692|Experimental|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
11458493|NCT01641692|Experimental|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
11458494|NCT01641692|Experimental|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
11458495|NCT01641692|Experimental|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
11458496|NCT01641692|Placebo Comparator|Matched Placebo|Matched Placebo arm
11458497|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
11458498|NCT01641666|Experimental|Peg2b + Ribavirin + Boceprevir|Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
11458499|NCT01641653|Placebo Comparator|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
11458500|NCT01641653|Active Comparator|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
11458501|NCT01641640|Experimental|Sofosbuvir+PEG+RBV|
11458502|NCT01641627|Experimental|vibration|proprioceptive stimulation of the lower limb using vibration and plantar pressure boots
11458503|NCT01641614|Experimental|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
11458504|NCT01641614|Active Comparator|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
11458505|NCT01641601|No Intervention|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
11458506|NCT01641601|Experimental|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
11458507|NCT01641575|Experimental|CO-1.01 and Cisplatin|
11458508|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
11458509|NCT01641549|Experimental|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
11458510|NCT01641549|Active Comparator|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent
11458511|NCT01641536|Experimental|1mg of HB-110|The subjects in this group will be administered 1 mg of HB-110 according to the protocol.
11458512|NCT01641536|Experimental|2mg of HB-110|The subjects in this group will be administered 2 mg of HB-110 according to the protocol.
11458513|NCT01641536|Experimental|4mg of HB-110|The subjects in this group will be administered 4 mg of HB-110 according to the protocol.
11458514|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
11458515|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
11458516|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
11458517|NCT01641510|Experimental|Prasugrel|Loading and maintenance dose of prasugrel
11458518|NCT01641510|Active Comparator|Clopidogrel|Loading and maintenance dose of clopidogrel
11458519|NCT01641497|Active Comparator|3D conformational radiotherapy|25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
11458520|NCT01641497|Experimental|Intensity-Modulated Radiation Therapy|25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT
11458521|NCT01641484|Experimental|local control 19.8Gy|local control at 19.8 Gy, at Day 14
11458522|NCT01641471|Experimental|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
11458523|NCT01641471|Placebo Comparator|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
11458524|NCT01641458|Experimental|fluoropyrimidine-based chemotherapy|DPYD-genotype and TDM-driven dosing of 5FU/Capecitabine
11458525|NCT01641445|Active Comparator|Topiramate|Topiramate (200 mg) taken orally daily
11458526|NCT01641445|Placebo Comparator|Sugar pill|"Placebo (sugar pill) taken orally daily"
11458527|NCT01641432|Experimental|TAPAT|Computerized Tonic and Phasic Attention training consisting of visual, auditory, and spatial stimuli that requires sustained attention (24 minutes). Training is followed by a computerized cognitive exercise (12 minutes).
11458528|NCT01641432|Active Comparator|Active Comparator|Computerized conventional board-games that lack the therapeutic effect of the TAPAT exercises. Active control has stimulus parameters similar to the TAPAT exercises (eg. stimuli is presented on the computer, participant responses are collected, session time and improvement is measured).
11458529|NCT01641419|Placebo Comparator|Placebo|Ropivacaine 0.5% plus 2ml of normal saline used for nerve block
11458530|NCT01641419|Active Comparator|Dexamethasone 4 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block
11458531|NCT01641419|Active Comparator|Dexamethasone 8 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block
11458532|NCT01641406|Experimental|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
11458533|NCT01641406|Experimental|Her 2 +|Experimental chemotherapy using neoadjuvant approach
11462893|NCT01610778|Placebo Comparator|Placebo|
11458534|NCT01641406|Experimental|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
11458535|NCT01641393|Experimental|EUR-1008 then Kreon|"EUR-1008 during Treatment Period 1 (29 days ±2 days) and
~Kreon during Treatment Period 2 (29 days ±2 days)."
11458536|NCT01641393|Experimental|Kreon then EUR-1008|"Kreon during Treatment Period 1 (29 days ±2 days) and
~EUR-1008 during Treatment Period 2 (29 days ±2 days)."
11458537|NCT01641380|No Intervention|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
11458538|NCT01641380|Experimental|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
11458539|NCT01641367|Experimental|Cohort A|"Under Protocol version 1.0:
~No resistance to NRTIs, PIs, or NNRTI
~• Continue current second-line regimen; NRTIs could be modified
~Changed under LOA#2 to:
~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure
~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified
~Changed under LOA#3 to:
~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure
~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
11458540|NCT01641367|Experimental|Sub-cohort B1|"Under Protocol version 1.0:
~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening
~• Best available NRTIs, RAL, & DRV/RTV
~Changed under LOA#2 to:
~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)
~• Best available NRTIs, RAL, & DRV/RTV"
11458541|NCT01641367|Experimental|Sub-cohort B2|"Under Protocol version 1.0:
~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening
~• ETR, RAL, and DRV/RTV
~Changed under LOA#2 to:
~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)
~• ETR, RAL, and DRV/RTV"
11458542|NCT01641367|Experimental|Sub-cohort B3|"Under Protocol version 1.0:
~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening
~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC
~Changed under LOA#2 to:
~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)
~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
11458543|NCT01641367|Experimental|Cohort C|"Under Protocol version 1.0:
~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)
~• Best available NRTIs, RAL, and DRV/RTV
~Changed under LOA#2:
~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure
~• Best available NRTIs, RAL, and DRV/RTV"
11458544|NCT01641367|Experimental|Cohort D|"Under Protocol version 1.0:
~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:
~• Best available regimen, including study-provided and any locally available drugs
~Changed under LOA#2:
~Not eligible for Cohort A, B, or C:
~• Best available regimen, including study-provided and any locally available drugs
~Updated under protocol v2.0:
~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
11458545|NCT01641341|Placebo Comparator|Placebo capsule|Placebo capsule (sugar pill with no active medication)
11458546|NCT01641341|Active Comparator|Active treatment|"Active treatment will consist of the following interventions:
~Bowel Dysbiosis - probiotics Bifidobacterium infantis,
~Maldigestion/Malabsorption - Pancrelipase
~Parasitic infection/presence - Nitazoxanide"
11458547|NCT01641328|Active Comparator|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
11458548|NCT01641328|Experimental|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
11458549|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,28 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 28 with equine rabies immunoglobulin 40 IU/Kg on day 0.
11458550|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,14 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 14 with equine rabies immunoglobulin 40 IU/Kg on day 0.
11458551|NCT01641315|Active Comparator|Rabies vaccine, IM Day 0,3,7,14,28 with RIG|Rabies exposed victims receive rabies vaccination intramuscularly on Day 0,3,7,14,28 with equine rabies immunoglobulin 40 IU/Kg on day 0
11458552|NCT01641302||Patients undergoing robot-assisted laparoscopic prostatectomy|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia
11458553|NCT01641289|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate
~<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
11458554|NCT01641289|Active Comparator|No Paracetamol|"No paracetamol + Intravenous Artesunate
~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
11458555|NCT01641276|Experimental|hepatitis|hepatitis B carriers patients
11458671|NCT01640496|Active Comparator|Vitamin D|Subjects will take 1 pill per day for 8 weeks.
11458556|NCT01641276|Experimental|hepatocellular carcinoma patients|hepatites B carriers patients with associated hepatocellular carcinoma
11458557|NCT01641263|Experimental|Cognitive Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
11458558|NCT01641263|Active Comparator|Sleep Seminar|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
11458559|NCT01641250|Experimental|Part A: RO5429083|
11458560|NCT01641250|Experimental|Part B: RO5429083 + cytarabine|
11458561|NCT01641237|Experimental|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
11458562|NCT01641237|Experimental|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
11458563|NCT01641237|Experimental|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
11458564|NCT01641237|Placebo Comparator|No fluoride dentifrice|no added fluoride in a silica base dentifrice
11458565|NCT01641224|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
11458566|NCT01641224|Active Comparator|Pinaverium|
11458567|NCT01641224|Placebo Comparator|Placebo|Placebo is blindly given to patients
11458568|NCT01641211|Experimental|Video intervention|Group that will watch the Meducation inhaler device technique videos.
11458569|NCT01641211|Other|Control|This group will watch a nutrition video.
11458570|NCT01641198|Active Comparator|Configuration 1|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at two sites, SC (Screw-Vent) at one site
11458571|NCT01641198|Experimental|Configuration 2|Device placement: B (Brånemark) at one site, SW (Swede-Vent) at two sites, SC (Screw-Vent) at two sites
11458572|NCT01641198|Experimental|Configuration 3|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at one site, SC (Screw-Vent) at two sites
11458573|NCT01641185|Experimental|protons|irradiation 20 x 3,3 GyE protons
11458574|NCT01641185|Experimental|carbon ions|irradiation 20 x 3,3 GyE carbon ions
11458575|NCT01641172|Active Comparator|Patients|Patients with disseminated testicular cancer
11458576|NCT01641172|Placebo Comparator|Healthy volunteers|Healthy men, age 18-50 years old
11458577|NCT01641159|Active Comparator|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
11458578|NCT01641159|Placebo Comparator|Placebo plus TAU|Placebo taken daily for the 15-week active study
11458579|NCT01641146|Experimental|Enhanced Sexual Health Intervention for Men|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
11458580|NCT01641146|Active Comparator|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
11458581|NCT01641133|Active Comparator|Synflorix Group|Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
11458582|NCT01641133|Experimental|Prevnar 1 Group|Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
11458583|NCT01641133|Experimental|Prevnar 2 Group|Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
11458584|NCT01641120|Experimental|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
11458585|NCT01641120|Experimental|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
11458586|NCT01641107|Experimental|Ponatinib|
11458587|NCT01641081|Experimental|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
11458588|NCT01641081|Experimental|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
11458589|NCT01641081|Active Comparator|Active Comparator 1|Foradil Aerolizer, Low Dose
11458590|NCT01641081|Active Comparator|Active Comparator 2|Foradil Aerolizer, High Dose
11458591|NCT01641081|Placebo Comparator|Placebo|Dose matched placebo
11458592|NCT01641068|Experimental|Arm I (memory and thinking skills workshop)|Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
11462894|NCT01610778|Experimental|Supplement|
11458593|NCT01641068|Active Comparator|Arm II (Education Workshop)|Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
11458594|NCT01641055|Experimental|Salmon protein hydrolysate|
11458595|NCT01641055|Experimental|Herring protein hydrolysate|
11458596|NCT01641055|Sham Comparator|Cod protein|
11458597|NCT01641055|Placebo Comparator|Milk protein|
11458598|NCT01641042|Experimental|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
11458599|NCT01641042|Experimental|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
11458600|NCT01641029||pyelonephritis|Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.
11458601|NCT01641016|Active Comparator|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
11458602|NCT01641016|Experimental|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
11458603|NCT01641003||Fresh tumor specimen|Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
11458604|NCT01640990|Experimental|Cohort 1|slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg), and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg)
11458605|NCT01640990|Experimental|Cohort 2|Dose to be determined after analysis of Cohort 1
11458606|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
11458607|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
11458608|NCT01640964|Experimental|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
11458609|NCT01640964|Experimental|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
11458610|NCT01640964|Experimental|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
11458611|NCT01640951|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
11458612|NCT01640951|Experimental|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks
~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
11458613|NCT01640951|Experimental|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
11458614|NCT01640951|Experimental|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks
~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
11458615|NCT01640951|Experimental|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
11458616|NCT01640925|Active Comparator|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
11458617|NCT01640925|Placebo Comparator|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
11458618|NCT01640912|Experimental|RXI-109|
11458619|NCT01640912|Placebo Comparator|Placebo|
11458620|NCT01640899|Other|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
11458621|NCT01640886||Standard of Care|"Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)
~Comparison to the reference method (30 ug cefoxitin disc diffusion)."
11458622|NCT01640886||KeyPath Test Group|All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.
11458623|NCT01640873|Experimental|MK-8655 80 mg/MK-8655 320 mg|Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
11458624|NCT01640873|Placebo Comparator|Placebo|Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
11458625|NCT01640847|Experimental|Arm RT: HIFU plus ThermoDox|Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.
11458626|NCT01640847|Experimental|Arm NRT: HIFU plus ThermoDox|Subjects have no yet received any radiation to the index lesion.
11458627|NCT01640834|Experimental|100 mg LY2409021|"LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.
~Placebo: 2 capsules, administered as a single oral dose on Day 2.
~Glucagon: 1 mg administered via intramuscular injection on Day 3."
11458672|NCT01640496|Placebo Comparator|Placebo|Subjects will be asked to take 1 pill per day for 8 weeks.
11458628|NCT01640834|Experimental|300 mg LY2409021|"LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.
~Glucagon: 1 mg administered via intramuscular injection on Day 3."
11458629|NCT01640834|Placebo Comparator|Placebo|"Placebo: 3 capsules administered as a single oral dose on Day 2.
~Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3."
11458630|NCT01640821|Experimental|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
11458631|NCT01640821|No Intervention|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
11458632|NCT01640808|Experimental|NIK-333(peretinoin)|
11458633|NCT01640808|Placebo Comparator|Placebo|
11458634|NCT01640782|Experimental|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
11458635|NCT01640782|Active Comparator|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
11458636|NCT01640769|Active Comparator|Image guided delivery of pacing leads|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm) versus standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
11458637|NCT01640769|Placebo Comparator|Standard delivery of pacing leads|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
11458638|NCT01640756|Experimental|AqueSys Microfistula Implant|
11458639|NCT01640743|Experimental|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
11458640|NCT01640743|Experimental|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
11458641|NCT01640730|Experimental|Kanglaite injection|
11458642|NCT01640691|Experimental|Study vaccine (AdimFlu-W)|0.5 mL/dose, a total of 2 doses, 21 days apart
11458643|NCT01640678|Experimental|ReCell epidermal cell suspension grafting|CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
11458644|NCT01640678|Active Comparator|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
11458645|NCT01640678|No Intervention|No treatment + UV-therapy|
11458646|NCT01640665|Experimental|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
11458647|NCT01640652|Experimental|Low dose vaccine arm|To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
11458648|NCT01640652|Experimental|High dose vaccine arm|To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
11458649|NCT01640639|Active Comparator|Thalidomide|Thalidomide
11458650|NCT01640639|Placebo Comparator|Placebo|Placebo
11458651|NCT01640626|Active Comparator|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
11458652|NCT01640626|No Intervention|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
11458653|NCT01640600||Children exposed to SSRIs in utero|This group are comprised of children whose mothers used antidepressants during pregnancy and who were therefore exposed to antidepressants in utero.
11458654|NCT01640600||Children exposed to nicotine in utero|This group is comprised of children whose mothers smoked cigarettes during pregnancy and who were therefore exposed to nicotine in utero.
11458655|NCT01640600||Children exposed to neither nicotine nor SSRIs|This group is comprised of children who were exposed to neither nicotine nor SSRIs in utero.
11458656|NCT01640587|Experimental|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
11458657|NCT01640587|Active Comparator|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
11458658|NCT01640574|Experimental|DHA-P 7 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
11458659|NCT01640574|Experimental|DHA-P 14 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
11458660|NCT01640574|Active Comparator|Chloroquine 7 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
11458661|NCT01640574|Active Comparator|Chloroquine 14 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
11458662|NCT01640561|Experimental|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as the World Health Organization (WHO), UNICEF, Norwegian Agency for Development Cooperation (NORAD), and Redd Barna (Norway).
11458663|NCT01640561|Active Comparator|Enhanced Treatment as Usual|
11458664|NCT01640548||Cohort|
11458665|NCT01640535|Experimental|Test arm|Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg
11458666|NCT01640535|Active Comparator|Comparator arm I|Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg
11458667|NCT01640535|Active Comparator|Comparator arm II|Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg
11458668|NCT01640522|Experimental|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
11458669|NCT01640522|Active Comparator|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
11458670|NCT01640509|Experimental|synchrotron radiation|treated by synchrotron radiation
11458676|NCT01640470|Experimental|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
11458677|NCT01640470|Active Comparator|Customary care|Participants in this arm will receive customary care.
11458678|NCT01640457|Experimental|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
11458679|NCT01640457|Placebo Comparator|NDbasic|NOVOCART® Disc basic (media with no active cell component)
11458680|NCT01640457|No Intervention|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
11458681|NCT01640444|Experimental|A|FOLFIRI+bevacizumab
11458682|NCT01640444|Experimental|B|FOLFIRI + cetuximab
11458683|NCT01640431|Experimental|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
11458684|NCT01640431|Experimental|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
11458685|NCT01640418|Experimental|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
11458686|NCT01640418|No Intervention|Standard Care|Standard Care
11458687|NCT01640405|Active Comparator|Control|modified FOLFOX6 + bevacizumab
11458688|NCT01640405|Experimental|Experimental|FOLFOXIRI+bevacizumab
11458689|NCT01640392|Experimental|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
11458690|NCT01640392|No Intervention|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
11458691|NCT01640379|Experimental|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
11458692|NCT01640379|No Intervention|Control|Participants receive enhanced standard of care
11458693|NCT01640366|Experimental|PICO negative pressure|Single-use Negative Pressure Wound Therapy
11458694|NCT01640366|No Intervention|Standard of care dressing arm|Sterile gauze adhesive strips
11458695|NCT01640340|Experimental|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
11458696|NCT01640340|Experimental|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
11458697|NCT01640327|Experimental|TIVf|
11458698|NCT01640314|Experimental|Cell derived subunit trivalent nonadjuvanted vaccine|
11458699|NCT01640301|Experimental|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
11458700|NCT01640301|Experimental|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
11458701|NCT01640288|Other|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
11458702|NCT01640288|Other|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
11458703|NCT01640275|Active Comparator|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
11458704|NCT01640275|Experimental|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
11458705|NCT01640262||localized prostate cancer|Danish men with localized prostate cancer
11458706|NCT01640249|Placebo Comparator|Placebo|Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
11458707|NCT01640249|Experimental|LY3006072|Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.
11458708|NCT01640223|Experimental|D-3 sensor|patients will be equiped with 2 Dexcom sensors 3 days before hospitalization
11458709|NCT01640223|Experimental|D-1 sensor|patients will be equiped with 2 Dexcom sensors one day before hospitalization
11458710|NCT01640197|Placebo Comparator|Placebo|Methyl Cellulose administered in identical capsules as the active.
11458711|NCT01640197|Active Comparator|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
11458712|NCT01640184|Active Comparator|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
11458713|NCT01640184|Experimental|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
11458714|NCT01640184|Active Comparator|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
11458715|NCT01640171|Other|Top Anesthesia 1 Eye SC Lidocaine 1 Eye|"One eye:
~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Acuvail Intra-vitreal Anti-VEGF Drug
~Fellow Eye:
~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Xylocaine 2% Injectable Anesthetic Acuvail Intra-vitreal Anti-VEGF Drug"
11458716|NCT01640158|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
11458717|NCT01640158|Active Comparator|Active Comparator|Commercially available computerized training, up to 65 hours
11458718|NCT01640145|Placebo Comparator|Carbohydrate|
11458719|NCT01640145|Active Comparator|Protein continous boluses|
11458720|NCT01640145|Active Comparator|Protein 2 boluses|
11458721|NCT01640119|Placebo Comparator|no intervention|
11458722|NCT01640119|Experimental|Bicarbonate|
11458723|NCT01640106|Experimental|Omega-3|Treatment arm, using the omega-3 product (fish oil/paste)
11458724|NCT01640106|Placebo Comparator|Control|Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste
11458725|NCT01640093|Experimental|Treatment B|Abiraterone acetate (500 mg), 2 coated, reformulated tablets.
11458726|NCT01640093|Experimental|Treatment C|Abiraterone acetate (250 mg), 4 coated, reformulated tablets.
11458727|NCT01640093|Experimental|Treatment D|Abiraterone acetate (500 mg), 2 coated, reformulated tablets, showing slower in vitro dissolution.
11458728|NCT01640093|Active Comparator|Treatment A|Abiraterone acetate (250 mg), 4 uncoated, current commercial tablets.
11458729|NCT01640080|Experimental|Esketamine (Group 1)|
11458730|NCT01640080|Experimental|Esketamine (Group 2)|
11458731|NCT01640080|Placebo Comparator|Placebo|
11458732|NCT01640067|Experimental|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
11458733|NCT01640054|Experimental|Dosing regimen|Open label Oral treatment 100mg once daily
11458734|NCT01640041|Experimental|Implanted|All participants.
11458735|NCT01640015|Experimental|low frequency diet|Participants will be assigned to a low frequency diet (fixed energy intake)
11458736|NCT01640015|Experimental|High frequency diet|
11458737|NCT01640002|Active Comparator|Propantheline|
11458738|NCT01640002|Placebo Comparator|Placebo|
11458739|NCT01639950||Adults Group 1|Adult patients with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia
11458740|NCT01639950||Adults Group 2|Adults with sickle cell disease (SCD)- closed
11458741|NCT01639950||Children|Children with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
11458742|NCT01639950||Parents|Parents of children with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. - closed
11458743|NCT01639937||1|Subjects with palliated congenital heart disease including, but not limited to, d TGA, ccTGA, single ventricles, hypoplastic left heart syndrome and tricuspid atresia will be recruited
11458744|NCT01639924||Study Cohort|Patients with known or suspected gastrointestinal disease
11458745|NCT01639911|Experimental|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
11458746|NCT01639898|Experimental|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
11458747|NCT01639898|Experimental|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
11458748|NCT01639885|No Intervention|Group 1|Patients will receive standard care (gemcitabine)
11458749|NCT01639885|Experimental|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
11458750|NCT01639885|Experimental|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
11458751|NCT01639872|Experimental|Clozapine|The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.
11458752|NCT01639872|Active Comparator|Risperidone|The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.
11458753|NCT01639859|Experimental|Elastography|
11458754|NCT01639846|Experimental|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
11458755|NCT01639846|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
11458756|NCT01639833|Experimental|Veriset Hemostatic Patch|Topical Hemostat
11458757|NCT01639833|Active Comparator|TachoSil®|Topical Hemostat
11458758|NCT01639820|Experimental|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
11458759|NCT01639820|Other|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
11458760|NCT01639807|Active Comparator|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
11458761|NCT01639807|Experimental|SLT|Selective laser Trabeculoplasty
11458762|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
11458763|NCT01639781|Active Comparator|flavanol rich intervention|flavanol rich drink
11458764|NCT01639781|Placebo Comparator|flavanol free intervention|flavanol free drink
11458765|NCT01639768|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
11458766|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 3,333 AUN/ml|
11458767|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 10,000 AUN/ml|
11458768|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
11458769|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
11458770|NCT01639755|Experimental|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
11458970|NCT01638273|Active Comparator|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
11458771|NCT01639742|Experimental|All Participants|All participants who had new texture round breast implants surgically implanted.
11458772|NCT01639729|Experimental|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
11458773|NCT01639729|Experimental|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
11458774|NCT01639729|Experimental|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
11458775|NCT01639729|Experimental|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
11458776|NCT01639729|Experimental|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
11458777|NCT01639729|Experimental|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
11458778|NCT01639716||Lymphoma group|
11458779|NCT01639716||healthy group|
11458780|NCT01639716||IL-10 high|
11458781|NCT01639716||IL-10 low|
11458782|NCT01639716||IL-4 high|
11458783|NCT01639716||IL-4 low|
11458784|NCT01639716||lymphopenia|
11458785|NCT01639703|Experimental|CT perfusion|arm with CT perfusion
11458786|NCT01639690|Experimental|Autologous CD34+ cells transduced with TNS9.3.55|An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
11458787|NCT01639677|Experimental|Laparoscopic gastric bypass|
11458788|NCT01639677|Active Comparator|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
11458789|NCT01639664|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
11458790|NCT01639664|No Intervention|Control group|standard practice
11458791|NCT01639651|Active Comparator|Control Group|
11458792|NCT01639651|Experimental|Mobilization Group|
11458793|NCT01639638|Placebo Comparator|Placebo|
11458794|NCT01639638|Experimental|CIGB-300 - 5 mg|
11458795|NCT01639638|Experimental|CIGB-300 - 15 mg|
11458796|NCT01639625|Experimental|CIGB300|
11458797|NCT01639612|Experimental|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
11458798|NCT01639599|Placebo Comparator|dexamethasone|dexamethasone 5mg iv during anesthesia induction
11458799|NCT01639599|Active Comparator|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 1mg iv 30 min before end of anesthesia
11458800|NCT01639599|Active Comparator|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 2mg iv 30 min before end of anesthesia
11458801|NCT01639586|Active Comparator|D|Impact of the day care on health profit of patient
11458802|NCT01639586|Active Comparator|C|No access to a respite structure
11458803|NCT01639586|Active Comparator|B|Respite platform
11458804|NCT01639560|Active Comparator|Varenicline|1 mg of varenicline twice per day for 12 weeks.
11458805|NCT01639560|Placebo Comparator|placebo|1 placebo tablet twice a day for 12 weeks
11458806|NCT01639547|Experimental|PEGASYS® plus ROBATROL® for 36 weeks|
11458807|NCT01639547|Active Comparator|PEGASYS® plus ROBATROL® for 48 weeks|
11458808|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
11458809|NCT01639521|Experimental|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11458810|NCT01639521|Experimental|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11458811|NCT01639508|Experimental|Cabozantinib|This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion.
11458812|NCT01639495|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
11458813|NCT01639482||Citalopram|Patients with bipolar disorder
11458814|NCT01639482||Placebo|Patients with bipolar disorder
11458815|NCT01639469|Experimental|Structured exercise|Structured exercise instruction by smartphone
11458816|NCT01639469|Active Comparator|lifestyle exercise|Lifestyle exercise program taught via smartphone
11458817|NCT01639456|Experimental|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
11458818|NCT01639456|Experimental|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
11458819|NCT01639443|Experimental|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
11458820|NCT01639443|No Intervention|Control|Patients who are scheduled routinely
11458821|NCT01639430||Geriatric patients ED|Consecutive patients >= 75 years in the emergency department.
11458922|NCT01638598|Experimental|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
11458822|NCT01639404|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
11458823|NCT01639391|Experimental|patients|
11458824|NCT01639378|Experimental|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
11458825|NCT01639378|No Intervention|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
11458826|NCT01639352|Experimental|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
11458827|NCT01639339|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
11458828|NCT01639339|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
11458829|NCT01639326|Experimental|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
11458830|NCT01639326|Active Comparator|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
11458831|NCT01639300|Experimental|GNbAC1|
11458832|NCT01639300|Placebo Comparator|GNbAC1 placebo|
11458833|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
11458834|NCT01639287||Painful|Painful synovitis group
11458835|NCT01639274|Other|COPD|
11458836|NCT01639248|Experimental|ENMD-2076 Treatment|ENMD-2076
11458837|NCT01639222|Experimental|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.
~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
11458838|NCT01639209|Experimental|Vitrectomy|
11458839|NCT01639209|Experimental|Pneumatic retinopexy|
11458840|NCT01639196|Experimental|Self-compassion writing|
11458841|NCT01639196|Active Comparator|Self-efficacy writing|
11458842|NCT01639183|Experimental|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
11458843|NCT01639183|Active Comparator|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
11458844|NCT01639170|Experimental|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.
~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
11458845|NCT01639157|Experimental|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
11458846|NCT01639157|Placebo Comparator|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
11458847|NCT01639144|Active Comparator|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
11458848|NCT01639144|No Intervention|Control|Group not receiving autogenous PRP and PPP.
11458849|NCT01639131|Experimental|ARM I|Patients will receive intravenous gemcitabine 800mg/m2 on days 1 and 8 and docetaxel 70mg/m2 on day 8 of each 21 day cycle. Patients will receive filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle.
11458850|NCT01639105|Experimental|treated half of the scar|
11458851|NCT01639105|No Intervention|untreated half of the scar|
11458852|NCT01639092|Experimental|Tenofovir monotherapy|Tenofovir 300 mg/day orally
11458853|NCT01639092|Active Comparator|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
11458854|NCT01639079|No Intervention|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
11458855|NCT01639079|Experimental|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:
~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
11458856|NCT01639066|Experimental|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
11458857|NCT01639066|Active Comparator|Tenofovir monotherapy|Tenofovir 300 mg/day orally
11458858|NCT01639053||Gel Participants|
11458859|NCT01639053||Control Participants|
11458860|NCT01639040|Experimental|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
11458861|NCT01639040|Experimental|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
11458862|NCT01639027|Active Comparator|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
11458863|NCT01639027|Placebo Comparator|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
11458864|NCT01639014|Experimental|F2695|
11458865|NCT01639014|Placebo Comparator|placebo|
11458866|NCT01639001|Experimental|Crizotinib|Crizotinib
11458867|NCT01639001|Active Comparator|Chemotherapy|Chemotherapy [Option at Investigator's Choice]
11458868|NCT01638988|Experimental|Metformin|
11458869|NCT01638988|Active Comparator|Clomiphene Citrate|
11458967|NCT01638286||Aceclofenac|
11458968|NCT01638286||Eperisone hydrochloride, Aceclofenac|
11458870|NCT01638975|Experimental|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
11458871|NCT01638975|No Intervention|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
11458872|NCT01638962|Experimental|NEMEX|NEuroMuscular EXercise
11458873|NCT01638962|Active Comparator|PHARMA|PHARMAcological pain relief
11458874|NCT01638949|Experimental|Young controls|
11458875|NCT01638949|Experimental|Middle age controls|
11458876|NCT01638949|Experimental|Elderly controls|
11458877|NCT01638949|Experimental|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
11458878|NCT01638949|Experimental|Subjectif Cognitive Impariment patients|
11458879|NCT01638949|Experimental|Mild Cognitive Impairment patients|
11458880|NCT01638949|Experimental|Alzheimer Disease patients|
11458881|NCT01638949|Experimental|Non degenerative amnsesic syndrome|
11458882|NCT01638936|Experimental|BT062|BT062 administered intravenously on days 1, 8 and 15 of each 28-day cycle, and lenalidomide or pomalidomide and dexamethasone administered orally to subjects with relapsed or relapsed/refractory MM
11458883|NCT01638923|Experimental|Arm 1|
11458884|NCT01638923|Placebo Comparator|Arm 2|
11458885|NCT01638910|Experimental|EV/DNG (Qlaira, BAY86-5027)|
11458886|NCT01638884|Experimental|Young Healthy Subjects|
11458887|NCT01638884|Experimental|Middle age Healthy Subjects|
11458888|NCT01638884|Experimental|Elderly Healthy Subjects|
11458889|NCT01638884|Experimental|Mild Cognitive Impairment patients|
11458890|NCT01638884|Experimental|Alzheimer Disease patients|
11458891|NCT01638871|Experimental|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
11458892|NCT01638871|No Intervention|Control Group|This study arm will only provide demographic and pain-related information.
11458893|NCT01638858|Experimental|Lucentis (Ranibizumab)|
11458894|NCT01638845|Active Comparator|continuous perineural catheter|
11458895|NCT01638845|No Intervention|Control|
11458896|NCT01638819|Experimental|Autologous Cord Blood Stem Cells|
11458897|NCT01638819|Placebo Comparator|Placebo|Saline
11458898|NCT01638806|Experimental|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
11458899|NCT01638806|No Intervention|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score > 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
11458900|NCT01638793|Experimental|Capnography|Capnographic respiration monitoring
11458901|NCT01638793|Active Comparator|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
11458902|NCT01638780|Placebo Comparator|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
11458903|NCT01638780|Active Comparator|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
11458904|NCT01638767|Experimental|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
11458905|NCT01638767|Active Comparator|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
11458906|NCT01638728||Endotracheal tube|
11458907|NCT01638715|Experimental|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
11458908|NCT01638715|Experimental|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
11458909|NCT01638715|Experimental|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
11458910|NCT01638715|Experimental|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
11458911|NCT01638702|Active Comparator|Right sided PICC placement|Insertion of PICC on the right arm
11458912|NCT01638702|Placebo Comparator|Left sided arm placement|Insertion of PICC on the left arm
11458913|NCT01638676|Experimental|Vemurafenib and Metformin|
11458914|NCT01638663|Active Comparator|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
11458915|NCT01638663|Placebo Comparator|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
11458916|NCT01638650|Experimental|Single Arm|
11458917|NCT01638637||Specimen Collection|
11458918|NCT01638624|Active Comparator|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
11458919|NCT01638624|Placebo Comparator|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
11458920|NCT01638611|Active Comparator|HIP2B|Six subjects per dosing cohort will receive HIP2B
11458921|NCT01638611|Placebo Comparator|Placebo|Two subjects per dosing cohort will receive placebo.
11458969|NCT01638273|Experimental|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
11458923|NCT01638598|Experimental|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
11458924|NCT01638598|Experimental|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
11458925|NCT01638598|Experimental|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
11458926|NCT01638598|Experimental|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
11458927|NCT01638585|No Intervention|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
11458928|NCT01638585|Active Comparator|urokinase|patients receiving urokinase short infusions in addition to standard therapy
11458929|NCT01638572||neuroblastoma patients|
11458930|NCT01638559|Experimental|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
11458931|NCT01638546|Experimental|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
11458932|NCT01638546|Active Comparator|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
11458933|NCT01638533|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11458934|NCT01638520|Experimental|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
11458935|NCT01638520|Placebo Comparator|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
11458936|NCT01638507|Other|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
11458937|NCT01638494|Experimental|Colecalcium testing|administration of Colecalcium
11458938|NCT01638481||Group #1 - Burns affecting less than 10% BSA|
11458939|NCT01638481||Group #2 - Burns affecting 10%-30% TBSA|
11458940|NCT01638481||Group #3 - Burns affecting 31%-50% TBSA|
11458941|NCT01638481||Group #4 - Burns affecting 51%-70% TBSA|
11458942|NCT01638481||Group #5 - Burns affecting >70% TBSA|
11458943|NCT01638468|Experimental|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
11458944|NCT01638455|Experimental|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
11458945|NCT01638442|Experimental|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
11458946|NCT01638442|Experimental|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
11458947|NCT01638429|Experimental|Obese/overweight, prediabetic methane positive|Neomycin Rifaximin
11458948|NCT01638416|Active Comparator|Standard of care|Blood Transfusion Standard of care- oldest blood.
11458949|NCT01638416|Other|Arm B|Blood Transfusion Freshest blood.
11458950|NCT01638403|Experimental|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
11458951|NCT01638403|Active Comparator|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.
~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
11458952|NCT01638403|Placebo Comparator|Placebo|
11458953|NCT01638390|Other|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
11458954|NCT01638377|Experimental|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
11458955|NCT01638377|Placebo Comparator|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
11458956|NCT01638364|Active Comparator|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
11458957|NCT01638364|Placebo Comparator|non-alcoholic beverage|Orange juice and tonic water.
11458958|NCT01638351|Active Comparator|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
11458959|NCT01638351|Experimental|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
11458960|NCT01638338|Experimental|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.
~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
11458961|NCT01638338|Experimental|Face to Face|Risky drinking brief motivational interview provided by the GP.
11458962|NCT01638325|Active Comparator|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
11458963|NCT01638325|Experimental|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
11458964|NCT01638312||HIV infection patient and health people|The study does not have intervention
11458965|NCT01638299|Experimental|Hypo-Hyper Minimizer (HHM) System|
11458966|NCT01638286||Eperisone|
11458971|NCT01638260|Placebo Comparator|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
11458972|NCT01638260|Active Comparator|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
11458973|NCT01638247|Active Comparator|Tamoxifen|Tamoxifen alone (daily).
11458974|NCT01638247|Experimental|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
11458975|NCT01638247|Experimental|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
11458976|NCT01638234|Placebo Comparator|Starch pill|
11458977|NCT01638234|Experimental|Melatonin|
11458978|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
11458979|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
11458980|NCT01638208|Experimental|VSL#3|Patients with IBS-D as per ROME III
11458981|NCT01638208|No Intervention|Healthy Controls|Healthy controls
11458982|NCT01638195|Experimental|Externally Focused Ultrasound|
11458983|NCT01638182|Active Comparator|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
11458984|NCT01638182|Active Comparator|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
11458985|NCT01638182|Placebo Comparator|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
11458986|NCT01638169||20 children with DMD|
11458987|NCT01638143|Active Comparator|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
11458988|NCT01638143|Active Comparator|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
11458989|NCT01638143|Active Comparator|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
11458990|NCT01638117|Placebo Comparator|PAC14028-Vehicle|PAC-14028 Cream Vehicle
11458991|NCT01638117|Experimental|PAC14028-0.1|PAC-14028 Cream 0.1%
11458992|NCT01638117|Experimental|PAC14028-0.3|PAC-14028 Cream 0.3%
11458993|NCT01638117|Experimental|PAC14028-1.0|PAC-14028 Cream 1%
11458994|NCT01638117|Placebo Comparator|Placebo|Saline
11458995|NCT01638117|Active Comparator|Positive control|Sodium Lauryl Sulfate, 0.5%
11458996|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
11458997|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11458998|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
11458999|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11459000|NCT01638104|Experimental|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
11459001|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
11459002|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11459003|NCT01638104|Experimental|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11459004|NCT01638104|Experimental|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11459005|NCT01638104|Experimental|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11459006|NCT01638104|Placebo Comparator|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
11459007|NCT01638104|Placebo Comparator|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
11459008|NCT01638091|Experimental|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
11459009|NCT01638078|Active Comparator|Thalidomide|Thalidomide
11459010|NCT01638078|Placebo Comparator|Placebo|Placebo
11459011|NCT01638065||Standard|Standard IV Access without device
11459012|NCT01638065||VeinViewer|IV access with VeinViewer device
11459013|NCT01638052|No Intervention|0.25% Bupivacaine|This is our standard of care concentration
11459014|NCT01638052|Experimental|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
11459015|NCT01638039|Active Comparator|Diarrheal disease|
11459016|NCT01638039|Active Comparator|Control|Samples of stool, blood, urine saliva
11459017|NCT01638026|Experimental|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
11459018|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ1|Participants who completed 015K-CL-RAJ1 (NCT02305849) study and met eligible criteria received starting dose of 50 milligrams (mg) peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
11459105|NCT01637467|Experimental|EMS intervention|The experimental group will received EMS at a therapeutic level.
11459106|NCT01637467|Sham Comparator|Sham|The sham group will receive EMS at a sub-therapeutic level.
11459151|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
11459019|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ3|Participants who completed 015K-CL-RAJ3 (NCT02308163) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
11459020|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ4|Participants who completed 015K-CL-RAJ4 (NCT02305849) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
11459021|NCT01638000|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
11459022|NCT01638000|Active Comparator|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
11459023|NCT01637987|Active Comparator|Unassisted vein visualization|
11459024|NCT01637987|Active Comparator|Wee Sight Transilluminator|
11459025|NCT01637987|Active Comparator|Near Infra-red light (VeinViewer)|
11459026|NCT01637974|Experimental|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
11459027|NCT01637974|No Intervention|without INTERCOAT|without INTERCOAT
11459028|NCT01637961|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11459029|NCT01637948|Active Comparator|Listerine|essential oil mouthrinse
11459030|NCT01637948|No Intervention|Negative control|without intervention
11459031|NCT01637948|Experimental|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
11459032|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
11459033|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
11459034|NCT01637922|Active Comparator|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
11459035|NCT01637922|Active Comparator|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
11459036|NCT01637909|Active Comparator|general management|
11459037|NCT01637909|Experimental|The treatment group1|Korean DASH diet with sodium reduction intervention
11459038|NCT01637909|Experimental|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
11459039|NCT01637896|Experimental|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
11459040|NCT01637896|Active Comparator|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
11459041|NCT01637883|No Intervention|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
11459042|NCT01637883|Experimental|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
11459043|NCT01637870|Experimental|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
11459044|NCT01637857|Sham Comparator|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
11459045|NCT01637857|Experimental|oligoantigenic diet|Treatment with oligoantigenic diat
11459046|NCT01637844|Experimental|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
11459047|NCT01637844|No Intervention|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
11459048|NCT01637831|Experimental|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
11459049|NCT01637818|Other|Lichtenstein's Operation|
11459050|NCT01637818|Other|Mesh Plug Repair|
11459051|NCT01637805|Experimental|AAV-DC-CTL|
11459052|NCT01637792|Experimental|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
11459053|NCT01637792|Active Comparator|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
11459054|NCT01637779|Experimental|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
11459055|NCT01637779|Placebo Comparator|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
11459056|NCT01637779|Experimental|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
11459057|NCT01637779|Placebo Comparator|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
11459107|NCT01637454|Active Comparator|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
11459058|NCT01637766|Experimental|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
11459059|NCT01637753|Experimental|Carmustine Sustained Release Implant|
11459060|NCT01637753|Sham Comparator|Surgical control group|
11459061|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
11459062|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
11459063|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
11459064|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
11459065|NCT01637714|Experimental|Multi-strain probiotics|
11459066|NCT01637714|Placebo Comparator|Placebo powder|
11459067|NCT01637701|Active Comparator|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
11459068|NCT01637701|Active Comparator|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
11459069|NCT01637688||Amino acid formula|Comparison of growth between subjects who are fed with a newly innovated amino acid formula (NAAF) and who are fed with either Neocate or nutramigen AA.
11459070|NCT01637675|Active Comparator|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
11459071|NCT01637675|Experimental|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
11459072|NCT01637662|Experimental|Healthy subjects|
11459073|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
11459074|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
11459075|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
11459076|NCT01637636|Experimental|Rifampin|
11459077|NCT01637636|Experimental|Ketoconazole|
11459078|NCT01637623|Active Comparator|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
11459079|NCT01637623|Active Comparator|Allopurinol|Allopurinol 300 mg daily for 6 weeks
11459080|NCT01637623|Placebo Comparator|Placebo|Placebo capsule daily for 6 weeks
11459081|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
11459082|NCT01637584|Experimental|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
11459083|NCT01637584|Placebo Comparator|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
11459084|NCT01637571|Active Comparator|Dexilant|60mg of Dexilant QD for 12 weeks
11459085|NCT01637571|Placebo Comparator|Placebo|60mg of Dexilant placebo QD for 12 weeks
11459086|NCT01637558|No Intervention|Main TB cohort|Children with tuberculosis 0-12 years of age
11459087|NCT01637558|Experimental|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
11459088|NCT01637558|Experimental|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
11459089|NCT01637558|Experimental|Nevirapine arm|children with TB and indication for nevi rapine-based ART
11459090|NCT01637545|Active Comparator|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
11459091|NCT01637545|Active Comparator|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
11459092|NCT01637545|Active Comparator|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
11459093|NCT01637532|Other|Group 1|Carboplatin/Caelyx
11459094|NCT01637532|Experimental|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
11459095|NCT01637532|Experimental|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
11459096|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
11459097|NCT01637506||Study group|"Age > 19
~Radiological evidence indicating presence of a current renal or ureteric stone"
11459098|NCT01637506||Control group|"Age > 19.
~No history of kidney stone disease"
11459099|NCT01637493|Experimental|Pegfilgrastim, 30mcg/kg|
11459100|NCT01637493|Experimental|Pegfilgrastim, 60mcg/kg|
11459101|NCT01637493|Experimental|Pegfilgrastim, 100mcg/kg|
11459102|NCT01637493|Experimental|Pegfilgrastim, 200mcg/kg|
11459103|NCT01637480|Experimental|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
11459104|NCT01637480|Active Comparator|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
11463267|NCT01608035|Experimental|sciatic catheter|
11459108|NCT01637454|Active Comparator|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
11459109|NCT01637441|Experimental|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
11459110|NCT01637441|Experimental|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
11459111|NCT01637402|Experimental|Standard Dose|1000 milligrams (mg) abiraterone acetate in combination with prednisone taken once a day until progression defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
11459112|NCT01637402|Experimental|Escalated Dose|Participants who progressed on the standard dose will be assigned 1000 milligrams (mg) abiraterone acetate in combination with prednisone taken twice a day for at least 12 weeks until progression as defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
11459113|NCT01637389|No Intervention|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
11459114|NCT01637389|Experimental|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
11459115|NCT01637389|Experimental|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
11459116|NCT01637363|No Intervention|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
11459117|NCT01637363|Experimental|Psychoeducation|6 x 2 hours of psychoeducation
11459118|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
11459119|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
11459120|NCT01637350||total gastrectomy, jejunal interposition|
11459121|NCT01637350||total gastrectomy , Roux-en-Y|
11459122|NCT01637337|Active Comparator|laparoscopic pyelolithotomy|
11459123|NCT01637337|Sham Comparator|percutaneous nephrolithotomy|
11459124|NCT01637311|Experimental|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
11459125|NCT01637285|Experimental|PF-04856883 Treatment Arm 1|
11459126|NCT01637285|Experimental|PF-04856883 Treatment Arm 2|
11459127|NCT01637285|Experimental|PF-04856883 Treatment Arm 3|
11459128|NCT01637285|Experimental|PF-04856883 Treatment Arm 4|
11459129|NCT01637272|Experimental|SOM230|Subjects with dumping syndrome treated with pasireotide
11459130|NCT01637259|Active Comparator|NRTI + PI|arm 1
11459131|NCT01637259|Active Comparator|PI + maraviroc|arm 2
11459132|NCT01637259|Active Comparator|NRTI + maraviroc|arm 3
11459133|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
11459134|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
11459135|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
11459136|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
11459137|NCT01637220||case, control|Blood volume collected specifically for this study
11459138|NCT01637207|Experimental|palpation|
11459139|NCT01637207|Experimental|ultrasound|
11459140|NCT01637194|Experimental|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11459141|NCT01637181|Active Comparator|EVLA 940 nm|
11459142|NCT01637181|Active Comparator|EVLA 1470 nm|
11459143|NCT01637168|Experimental|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
11459144|NCT01637168|Active Comparator|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
11459145|NCT01637155|Experimental|Cholecalciferol|
11459146|NCT01637142|Experimental|LY2140023 + [14C]-LY2140023|Single oral dose of 80 mg LY2140023 followed by a single 2-hour IV infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nCi [14C]-LY2140023.
11459147|NCT01637142|Experimental|LY2140023 + [14C]-LY404039|Single oral dose of 80 mg LY2140023 followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi [14C]-LY404039
11459148|NCT01637129|Active Comparator|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
11459149|NCT01637129|Placebo Comparator|No Intervention|Sham Magnetic Stimulation
11459150|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
11459235|NCT01636440|Other|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
11459152|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
11459153|NCT01637103|Experimental|Cognitive therapy of depression|
11459154|NCT01637103|Experimental|Bright light therapy|
11459155|NCT01637103|No Intervention|Waiting list|
11459156|NCT01637090|Experimental|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.
~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
11459157|NCT01637077|Experimental|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
11459158|NCT01637077|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
11459159|NCT01637051|Other|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
11459160|NCT01637051|Other|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
11459161|NCT01637038|No Intervention|Control Group|no intervention
11459162|NCT01637038|Experimental|RIPC group|Those undergoing remote ischemic postconditioning
11459163|NCT01637025|Experimental|Traumastem - oxidized cellulose strip|
11459164|NCT01637025|Active Comparator|Surgicel® Original - oxidized regenerated cellulose strip|
11459165|NCT01637012|Experimental|ALEX stent arm|implantation of ALEX stent during index procedure
11459166|NCT01636999|Experimental|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
11459167|NCT01636986|Experimental|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
11459168|NCT01636986|Active Comparator|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
11459169|NCT01636973|Experimental|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
11459170|NCT01636960|Experimental|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
11459171|NCT01636947|Experimental|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
11459172|NCT01636947|Active Comparator|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
11459173|NCT01636934|Experimental|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
11459174|NCT01636934|Placebo Comparator|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
11459175|NCT01636908|Experimental|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
11459176|NCT01636895|Experimental|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
11459177|NCT01636882|Experimental|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
11459178|NCT01636869|Experimental|bupicavaine|
11459179|NCT01636856|Active Comparator|1|Oropharyngeal exercises and oropharyngeal functions
11459180|NCT01636856|Sham Comparator|2|Nasal dilator, respiratory exercise, nasal lavage
11459181|NCT01636843|Experimental|60 mg|
11459182|NCT01636843|Experimental|120 mg|
11459183|NCT01636843|Experimental|240 mg|
11459184|NCT01636843|Experimental|Placebo|
11459185|NCT01636830|Active Comparator|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
11459186|NCT01636830|Active Comparator|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
11459187|NCT01636817|Experimental|60 mg|
11459188|NCT01636817|Experimental|120 mg|
11459189|NCT01636817|Experimental|240 mg|
11459190|NCT01636817|Placebo Comparator|Placebo|
11459191|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
11459192|NCT01636791|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
11459236|NCT01636414|Active Comparator|Hemovac drain|
11459237|NCT01636414|Active Comparator|Re-infusion drain|
11459193|NCT01636791|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
11459194|NCT01636791|Experimental|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
11459195|NCT01636778|Experimental|SB-497115-GR|investigational product for thrombocytopenia
11459196|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
11459197|NCT01636752|Experimental|Deprexis|Online self-help with and without e-mail-support
11459198|NCT01636752|No Intervention|Control|
11459199|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
11459200|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
11459201|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
11459202|NCT01636713|Experimental|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
11459203|NCT01636713|Experimental|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
11459204|NCT01636713|Placebo Comparator|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
11459205|NCT01636700|Active Comparator|tramadol infiltration|infiltration of tramadol 2mg/kg
11459206|NCT01636700|Placebo Comparator|Saline solution|Infiltration of saline
11459207|NCT01636687|Placebo Comparator|Placebo|Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
11459208|NCT01636687|Experimental|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
11459209|NCT01636687|Experimental|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.
11459210|NCT01636661|Experimental|Transcranial Direct Current Stimulation|Receiving active tDCS
11459211|NCT01636661|Sham Comparator|Sham tDCS|tDCS equipment set to placebo setting.
11459212|NCT01636635|Active Comparator|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
11459213|NCT01636635|Experimental|Older (>60 years)|Obese older women (>60y) undergoing calorie restriction.
11459214|NCT01636622|Experimental|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.
~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
11459215|NCT01636609|Experimental|Arm I (tosedostat, cytarabine)|Participants receive tosedostat PO QD on days 1-28 and cytarabine SC BID on days 1-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11459216|NCT01636609|Experimental|Arm II (tosedostat, azacitidine)|Participants receive tosedostat PO QD on days 1-28 and azacitidine IV over 10-40 minutes or SC on days 1-7. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11459217|NCT01636583|Experimental|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
11459218|NCT01636583|Active Comparator|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
11459219|NCT01636583|Active Comparator|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
11459220|NCT01636570|Active Comparator|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
11459221|NCT01636570|Placebo Comparator|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
11459222|NCT01636557|Experimental|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
11459223|NCT01636544|Experimental|contralateral healthy tissue biopsy|
11459224|NCT01636531|Experimental|HCLF|
11459225|NCT01636531|Active Comparator|LyoF|
11459226|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
11459227|NCT01636505|Active Comparator|short protocol|gnrh agonist versus gnrh antagonist
11459228|NCT01636505|Active Comparator|long protocol|
11459229|NCT01636492|Experimental|Bitopertin|
11459230|NCT01636492|Placebo Comparator|Placebo|
11459231|NCT01636479|Experimental|SAR405838|SAR405838 in escalating doses
11459232|NCT01636466|Experimental|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
11459233|NCT01636466|No Intervention|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
11459234|NCT01636453|Experimental|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
11459238|NCT01636414|Active Comparator|Tranexamic drain|
11459241|NCT01636388|Experimental|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
11459242|NCT01636375||Direct Anterior Approach|
11459243|NCT01636375||Posterior Approach|
11459244|NCT01636362|Experimental|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
11459245|NCT01636349|Experimental|Recreational soccer training|12 men participate in recreational soccer training for 6 months
11459246|NCT01636349|No Intervention|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
11459247|NCT01636336|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
11459248|NCT01636336|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
11459249|NCT01636323|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
11459250|NCT01636323|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
11459251|NCT01636310|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
11459252|NCT01636310|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
11459253|NCT01636297|Experimental|Forced exercise|Exercise on stationary cycle that was controlled by a motor to augment voluntary cycling rate by 35%
11459254|NCT01636297|Experimental|Voluntary Exercise|Exercise on a stationary cycle without motor assistance
11459255|NCT01636297|No Intervention|No Exercise|Participants received no exercise intervention and served as the control group
11459256|NCT01636284|Experimental|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
11459257|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
11459258|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
11459259|NCT01636258|No Intervention|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
11459260|NCT01636258|Experimental|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
11459261|NCT01636245|Experimental|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
11459262|NCT01636245|Experimental|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
11459263|NCT01636245|Experimental|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
11459264|NCT01636245|Placebo Comparator|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
11459265|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
11459266|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
11459267|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
11459268|NCT01636206|Placebo Comparator|Placebo|Placebo
11459269|NCT01636206|Experimental|Lifitegrast|Active
11459270|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
11459271|NCT01636180|Experimental|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
11459272|NCT01636180|Active Comparator|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
11459273|NCT01636154|No Intervention|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
11459274|NCT01636154|Other|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
11459275|NCT01636154|Other|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
11459276|NCT01636154|Experimental|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
11459277|NCT01636141|Placebo Comparator|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
11459278|NCT01636141|Active Comparator|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
11459279|NCT01636128|Experimental|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
11459280|NCT01636128|Experimental|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
11459281|NCT01636102|Experimental|Arm 1|
11459282|NCT01636089|Experimental|bicarbonates|sodium bicarbonates 1,4%
11459283|NCT01636089|Active Comparator|saline|sodium chloride 0,9%
11459284|NCT01636076|Experimental|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
11459285|NCT01636076|Active Comparator|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
11459286|NCT01636063|Experimental|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
11459287|NCT01636063|Active Comparator|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
11459288|NCT01636050|Experimental|Training group|
11459289|NCT01636050|Experimental|Control group|
11459290|NCT01636037|Experimental|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
11459291|NCT01636024|Experimental|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
11459292|NCT01636024|Placebo Comparator|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
11459293|NCT01636011|Experimental|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
11459294|NCT01636011|Sham Comparator|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
11459295|NCT01635998|Experimental|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
11459296|NCT01635998|No Intervention|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
11459297|NCT01635985|Experimental|1|AZD5423 iv
11459298|NCT01635985|Experimental|2|AZD5423 inhalation, Spira
11459299|NCT01635985|Experimental|3|AZD5423 inhalation I-neb
11459300|NCT01635985|Experimental|4|AZD5423 oral
11459301|NCT01635985|Experimental|5|AZD5423 inhalation Turbuhaler
11459302|NCT01635985|Experimental|6|AZD5423, New Dry Powder Inhaler
11459303|NCT01635972|Experimental|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
11459304|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
11459305|NCT01635946|Experimental|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
11459306|NCT01635933|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
11459307|NCT01635933|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
11459308|NCT01635920|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
11459309|NCT01635920|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
11459310|NCT01635907|Experimental|Dovitinib|
11459311|NCT01635894|Experimental|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
11459312|NCT01635894|Experimental|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
11459313|NCT01635894|No Intervention|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
11459314|NCT01635881|Experimental|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
11459315|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
11459316|NCT01635855|Experimental|Belotero|Belotero® Hyaluronic acid dermal filler
11459317|NCT01635829|Experimental|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
11459318|NCT01635829|Experimental|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
11459319|NCT01635816|Active Comparator|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
11459320|NCT01635816|Active Comparator|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
11459321|NCT01635816|Active Comparator|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
11459322|NCT01635816|Active Comparator|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
11459323|NCT01635803|Active Comparator|Ranibizumab|Monthly injections with ranibizumab during 6 months
11459324|NCT01635803|Active Comparator|Bevacizumab|Monthly injections with bevacizumab during 6 months
11459325|NCT01635790|Active Comparator|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
11459326|NCT01635790|Active Comparator|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
11459327|NCT01635777|Experimental|12 weeks|miltefosine 12 weeks
11459328|NCT01635777|Experimental|8 weeks|miltefosine 8 weeks
11459329|NCT01635764|Experimental|Adalimumab Every Week|Adalimumab 40 mg every week.
11459330|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(fasted)|
11459331|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(after high fat meal)|
11459333|NCT01635738|Experimental|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
11459334|NCT01635738|Experimental|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
11459335|NCT01635738|Experimental|LP GMNL-133+LF GM-090 group|One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO
11459336|NCT01635738|Placebo Comparator|Placebo|
11459337|NCT01635712|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
11459338|NCT01635686|Experimental|DWP422|
11459339|NCT01635686|Active Comparator|ENBREL|
11459340|NCT01635673|No Intervention|Control Group|A group that continues with their normal daily activities for the duration of the study
11459341|NCT01635673|Experimental|Exercise Group|This group exercises 3 times each week
11459342|NCT01635660|Active Comparator|C-MAC System|
11459343|NCT01635660|Active Comparator|AP Advance|
11459344|NCT01635660|Active Comparator|King Vision|
11459345|NCT01635647|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
11459346|NCT01635647|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
11459347|NCT01635634|Sham Comparator|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
11459348|NCT01635634|Experimental|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
11459349|NCT01635634|No Intervention|Wait list|Wait list control no specific intervention for 3 weeks study period
11459350|NCT01635621|Experimental|OKZ 120 mg|
11459351|NCT01635621|Experimental|OKZ 240 mg|
11459352|NCT01635621|Experimental|OKZ 120 mg with 480 mg loading dose at Week 0|
11459353|NCT01635621|Placebo Comparator|Placebo|
11459354|NCT01635608|Active Comparator|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
11459355|NCT01635608|Active Comparator|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
11459356|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
11459357|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
11459358|NCT01635582|Active Comparator|Control group|Conventional hand exercise program
11459359|NCT01635582|Experimental|Experimental group|Computer gaming hand exercise regimen'
11459360|NCT01635569|Active Comparator|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
11459361|NCT01635569|Active Comparator|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
11459362|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
11459363|NCT01635530|Active Comparator|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
11459364|NCT01635530|Experimental|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
11459365|NCT01635517||Tolvaptan|Tolvaptan administration
11459366|NCT01635504|Experimental|botulinum toxin A|
11459367|NCT01635465||Observation group:vinorelbine plus capecitabine|
11459368|NCT01635465||Control group:docetaxel plus capecitabine|
11459369|NCT01635452||Patients treated with Esmya|
11459370|NCT01635439|Active Comparator|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
11459371|NCT01635439|Active Comparator|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
11459372|NCT01635426|Active Comparator|Aspirin|
11459373|NCT01635426|Active Comparator|Clopidogrel|
11459374|NCT01635413|Experimental|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
11459375|NCT01635413|Experimental|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
11459376|NCT01635413|Active Comparator|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
11459377|NCT01635400|Other|UGT1A1 wild type (6/6)|
11459378|NCT01635400|Other|UGT1A1 heterozygous genotype (6/7)|
11459379|NCT01635400|Other|UGT1A1 homozygous genotype(7/7)|
11459380|NCT01635387|Experimental|Aliskiren|
11459381|NCT01635387|Placebo Comparator|Placebo|
11459382|NCT01635374|Experimental|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
11459383|NCT01635361|Experimental|NMS|Patients in this arm will receive the full NMS service
11459384|NCT01635361|No Intervention|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
11459385|NCT01635348|Experimental|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
11459386|NCT01635348|Active Comparator|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
11459387|NCT01635335|Experimental|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
11459388|NCT01635335|Active Comparator|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
11459389|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
11459390|NCT01635309||Non-cardiac surgical patients|>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
11459391|NCT01635296|Experimental|A: Previously untreated|
11459392|NCT01635296|Experimental|B: Relapse/Refractory|
11459393|NCT01635283|Experimental|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
11459394|NCT01635270|Experimental|midP arm|Patients treated with midP radiotherapy strategy.
11459395|NCT01635270|Active Comparator|ITV arm|Patient treated with radiotherapy ITV strategy
11459396|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
11459397|NCT01635244|Active Comparator|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
11459398|NCT01635244|Active Comparator|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
11459399|NCT01635244|Active Comparator|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
11459400|NCT01635231|Active Comparator|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
11459401|NCT01635231|Active Comparator|amiloride, diuretic|5 mg of amiloride twice daily
11459402|NCT01635231|Placebo Comparator|calcium|placebo twice daily for 5 days
11459403|NCT01635218|Experimental|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
11459404|NCT01635218|Experimental|Fluoxetine|Selective serotonin reuptake inhibitor.
11459405|NCT01635218|Placebo Comparator|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
11459406|NCT01635205|Experimental|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
11459407|NCT01635205|Sham Comparator|control|Subcutaneous puncture with no anesthetic effect
11459408|NCT01635192|Active Comparator|VSL#3|
11459409|NCT01635192|Placebo Comparator|Inactive treatment|
11459410|NCT01635179|Experimental|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
11459411|NCT01635166|Other|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
11459412|NCT01635153|Active Comparator|Protein calorie supplement plus micronutrient|
11459413|NCT01635153|Placebo Comparator|Micronutrient alone|
11459414|NCT01635140|Experimental|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
11459415|NCT01635140|Other|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
11459416|NCT01635127|Experimental|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
11459417|NCT01635127|Placebo Comparator|Placebo|Constituent, inactive
11459418|NCT01635114|Active Comparator|resVida (resveratrol)|
11459419|NCT01635114|Placebo Comparator|Placebo|
11459420|NCT01635101|Experimental|Low Dose Acetaminophen|Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
11459421|NCT01635101|Experimental|High Dose Acetaminophen|Participants receive a low dose of acetaminophen (IV) for 24 hours
11459422|NCT01635101|Placebo Comparator|Placebo|Participants receive matching placebo (IV) for 24 hours
11459423|NCT01635088|Other|Mometasone furoate 220 vs. Mometasone furoate 440|
11459424|NCT01635088|Active Comparator|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
11459425|NCT01635075|Experimental|Exercise|1-mile treadmill walk
11459426|NCT01635075|Placebo Comparator|Passive|20 min inactivity
11459427|NCT01635062|Experimental|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
11459428|NCT01635062|Placebo Comparator|placebo|Subjects will receive placebo for 3 weeks.
11459429|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
11459430|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
11459431|NCT01635023|Experimental|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
11459432|NCT01635023|Experimental|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
11459433|NCT01635023|Experimental|AZD6244 solution|35mg AZD6244 oral solution
11459434|NCT01635010|No Intervention|Control|
11459435|NCT01635010|Experimental|Obstructive sleep apnea|
11459436|NCT01634971|No Intervention|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
11459485|NCT01634659|Other|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
11463268|NCT01608035|Active Comparator|Stump catheter|
11459437|NCT01634971|Experimental|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
11459438|NCT01634958|Experimental|10.000 DPP/ml suspension for s.c. inj.|
11459439|NCT01634958|Experimental|5.000 DPP/ml suspension for s.c. inj.|
11459440|NCT01634958|Experimental|1.000 DPP/ml suspension for s.c. inj.|
11459441|NCT01634958|Experimental|100 DPP/ml suspension for s.c. inj.|
11459442|NCT01634945|Placebo Comparator|Placebo|Placebo
11459443|NCT01634945|Experimental|FeFum porridge + IPT of malaria|
11459444|NCT01634945|Experimental|IPT of malaria|
11459445|NCT01634945|Experimental|FeFum porridge|
11459446|NCT01634945|Experimental|FePP porridge|
11459447|NCT01634932|Experimental|regular-iron millet|
11459448|NCT01634932|Experimental|iron-biofortified millet|
11459449|NCT01634932|Experimental|Post-harvest iron-fortified millet|
11459450|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
11459451|NCT01634906|Experimental|Discontinuation of statin therapy|
11459452|NCT01634893|Experimental|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.
~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.
~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
11459453|NCT01634880|Experimental|Postoperative Radiotherapy and Panitumumab|
11459454|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
11459455|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
11459456|NCT01634854|Active Comparator|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
11459457|NCT01634854|Active Comparator|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.
~Route of administration: intravenous"
11459458|NCT01634841|Active Comparator|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
11459459|NCT01634841|Active Comparator|Control group|This group will eat their habitual diet and refrain from eating walnuts.
11459460|NCT01634828||Minimal blood loss patients|
11459461|NCT01634828||Moderate to heavy blood loss patients|
11459462|NCT01634815|Experimental|lactate group|
11459463|NCT01634802|No Intervention|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
11459464|NCT01634802|Experimental|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
11459465|NCT01634789|Experimental|Test Treatment 1: bazedoxifene|Test Treatment 1
11459466|NCT01634789|Experimental|Test Treatment 2: bazedoxifene|Test Treatment 2
11459467|NCT01634789|Experimental|Test Treatment 3: bazedoxifene|Test Treatment 3
11459468|NCT01634789|Experimental|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
11459469|NCT01634776|Placebo Comparator|Corn oil|1288 mg/day corn oil
11459470|NCT01634776|Experimental|Flaxseed oil|1200 mg/day flaxseed oil
11459471|NCT01634763|Experimental|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
11459472|NCT01634763|Experimental|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
11459473|NCT01634750|Experimental|ManNac|
11459474|NCT01634750|Placebo Comparator|Placebo|
11459475|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (> 0.10 kU/L)
11459476|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
11459477|NCT01634724|Experimental|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
11459478|NCT01634724|No Intervention|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
11459479|NCT01634711|Experimental|The L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an interventional device intended for ACL reconstruction surgery within 13 weeks of acute rupture of the ACL and no previous treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
11459480|NCT01634698|Experimental|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
11459481|NCT01634698|Experimental|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
11459482|NCT01634685|Experimental|Bavituximab, Capecitabine, Radiation|one arm
11459483|NCT01634672||hemodialysis patients|
11459486|NCT01634659|Other|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
11459487|NCT01634646|Placebo Comparator|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
11459488|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
11459489|NCT01634607||HIV uninfected|HIV negative patients
11459490|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
11459491|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
11459492|NCT01634594|Experimental|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
11459493|NCT01634594|Active Comparator|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 ~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
11459494|NCT01634594|Active Comparator|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
11459495|NCT01634568|Experimental|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
11459496|NCT01634568|Experimental|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
11459497|NCT01634555|Experimental|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
11459498|NCT01634542||Cohort|
11459499|NCT01634529|Experimental|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
11459500|NCT01634529|Experimental|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
11459501|NCT01634516|Experimental|Dietary support|Face to face intervention plus subsequent telephone support
11459502|NCT01634516|Placebo Comparator|No dietary support|No face to face intervention plus subsequent telephone support
11459503|NCT01634503|Experimental|1mg of GX-188E by electroporation|
11459504|NCT01634503|Experimental|2mg of GX-188E by electroporation|
11459505|NCT01634503|Experimental|4mg of GX-188E by electroporation|
11459506|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
11459507|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
11459508|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
11459509|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
11459510|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
11459511|NCT01634477||HIV-infected patients group|HIV positive
11459512|NCT01634477||HIV-uninfected patients group|HIV negative
11459513|NCT01634464||Control group|women with 18.5 > BMI < 25
11459514|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
11459515|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
11459516|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
11459517|NCT01634451|Active Comparator|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
11459518|NCT01634451|Active Comparator|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
11459519|NCT01634451|Active Comparator|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
11459520|NCT01634451|Active Comparator|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
11459521|NCT01634438|Experimental|low dose heparin|30 units per kilogram of unfractionated heparin
11459522|NCT01634438|Active Comparator|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
11459523|NCT01634425|No Intervention|Group 1 - no pre-hospital biomarkers|Standard of Care
11459524|NCT01634425|Experimental|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
11459525|NCT01634412|Experimental|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
11459526|NCT01634412|Experimental|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
11459527|NCT01634412|Active Comparator|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
11459528|NCT01634412|Active Comparator|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
11459529|NCT01634360|Experimental|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
11459530|NCT01634347|Experimental|Propranolol and memory reactivation|
11459531|NCT01634347|Placebo Comparator|Placebo and memory reactivation|
11459532|NCT01634334|Experimental|Real-time Intervention|
11463269|NCT01608022|Experimental|PF804|
11459533|NCT01634334|Active Comparator|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
11459534|NCT01634321|Experimental|Luphere|
11459535|NCT01634308|Experimental|Novosis(bongros/BMP-2)|
11459536|NCT01634308|Active Comparator|Bio-oss|
11459537|NCT01634295|Experimental|CKD-828 2.5/40, 2.5/80, 5/80mg|
11459538|NCT01634295|Active Comparator|S-Amlodipine 2.5, 5mg|
11459539|NCT01634282|Experimental|OPC-262|
11459540|NCT01634269|Experimental|MDT-2111 TAVI 23 mm|Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
11459541|NCT01634256|Experimental|Fermented turmeric|
11459542|NCT01634256|Placebo Comparator|Placebo|
11459543|NCT01634243|Experimental|SPM 962|SPM 962 transdermal patch
11459544|NCT01634230|Experimental|OCR-002|10 g infused over 24 hours/day
11459545|NCT01634217|Experimental|Cohort 1|Administered 3 x 10^6 iTregs/kg infusion
11459546|NCT01634217|Experimental|Cohort 2|Administered 3 x 10^7 iTregs/kg infusion
11459547|NCT01634217|Experimental|Cohort 3|Administered 3 x 10^8 iTregs/kg infusion
11459548|NCT01634217|Experimental|Cohort 4|Administered 10 x 10^8 iTregs/kg infusion
11459549|NCT01634217|Experimental|Cohort 5 Extension|Administered 10 x 10^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
11459550|NCT01634204|Experimental|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
11459551|NCT01634204|No Intervention|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
11459552|NCT01634191|Experimental|Apremilast (A: 30mg dose of apremilast in Elderly subjects)|A: One oral 30 mg dose of apremilast in Elderly subjects
11459553|NCT01634191|Experimental|Apremilast (B: 30mg dose of apremilast in younger subjects)|One oral 30 mg dose of apremilast in younger subjects
11459554|NCT01634178|Experimental|30 mg apremilast while fasting|30 mg apremilast while fasting
11459555|NCT01634178|Experimental|30 mg apremilast after a high-fat meal|30 mg apremilast after a high-fat meal
11459556|NCT01634165|Experimental|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
11459557|NCT01634165|Experimental|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
11459558|NCT01634165|Experimental|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
11459559|NCT01634165|Experimental|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
11459560|NCT01634152|Placebo Comparator|Placebo QD|
11459561|NCT01634152|Experimental|Tiotropium low dose QD|
11459562|NCT01634152|Experimental|Tiotropium medium dose QD|
11459563|NCT01634139|Experimental|Tiotropium high dose QD|
11459564|NCT01634139|Experimental|Tiotropium low dose QD|
11459565|NCT01634139|Experimental|Placebo QD|
11459566|NCT01634126|Active Comparator|1 FIT kit|
11459567|NCT01634126|Active Comparator|2 FIT kit|
11459568|NCT01634113|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler
11459569|NCT01634113|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler
11459570|NCT01634113|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler
11459571|NCT01634100|Experimental|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
11459572|NCT01634100|Experimental|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
11459573|NCT01634100|Experimental|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
11459574|NCT01634087|Experimental|100 mg QD Itacitinib|
11459575|NCT01634087|Experimental|100 mg QD Placebo|
11459576|NCT01634087|Experimental|200 mg QD Itacitinib|
11459577|NCT01634087|Experimental|200 mg QD Placebo|
11459578|NCT01634087|Experimental|200 mg BID Itacitinib|
11459579|NCT01634087|Experimental|200 mg BID Placebo|
11459580|NCT01634087|Experimental|600 mg once a day Itacitinib|
11459581|NCT01634087|Experimental|600 mg once a day Placebo|
11459582|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
11459583|NCT01634061|Experimental|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
11459584|NCT01634061|Experimental|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
11459585|NCT01634061|Experimental|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate
~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
11459586|NCT01634061|Experimental|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
11459587|NCT01634048|Experimental|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
11459588|NCT01634048|Sham Comparator|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
11459589|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
11459630|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
11459590|NCT01634022|Experimental|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
11459591|NCT01634009|Active Comparator|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
11459592|NCT01634009|No Intervention|Standard RUTF|Will act as control
11459593|NCT01633996|Experimental|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
11459594|NCT01633983|Experimental|Methotrexate|Chronic CSC will be given an immediate MTX treatment
11459595|NCT01633983|Experimental|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
11459596|NCT01633970|Experimental|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
11459597|NCT01633970|Experimental|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin [85 milligrams per square meter {mg/m^2}], leucovorin [400 mg/m^2], 5-FU [400 mg/m^2]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
11459598|NCT01633970|Experimental|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) until disease progression or unacceptable toxicity.
11459599|NCT01633970|Experimental|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
11459600|NCT01633970|Experimental|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
11459601|NCT01633970|Experimental|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
11459602|NCT01633957|Experimental|Genotype-based Warfarin Initiation|
11459603|NCT01633957|Active Comparator|clinical factor-based warfarin initiation|
11459604|NCT01633944|Placebo Comparator|Placebo|Twice Daily Dosing
11459605|NCT01633944|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
11459606|NCT01633918|Experimental|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
11459607|NCT01633918|Active Comparator|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
11459608|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
11459609|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
11459610|NCT01633892|Experimental|Fat Grafting|
11459611|NCT01633879|Experimental|parent education|audio-CD parent EDC supporting positive parenting practices
11459612|NCT01633879|Experimental|parent and school intervention|health and success parent and school intervention
11459613|NCT01633879|No Intervention|print materials|brochures to parents
11459614|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
11459615|NCT01633853|Experimental|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
11459616|NCT01633853|Active Comparator|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
11459617|NCT01633840|Active Comparator|Elemental E028 with added food allergens|
11459618|NCT01633840|Placebo Comparator|Elemental E028|
11459619|NCT01633827|Placebo Comparator|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
11459620|NCT01633827|Active Comparator|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
11459621|NCT01633814|Experimental|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
11459622|NCT01633814|Placebo Comparator|Placebo|placebo patch.
11459623|NCT01633801|Other|High flows|
11459624|NCT01633801|Other|oxygen therapy|
11459625|NCT01633788|Experimental|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
11459626|NCT01633788|Experimental|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
11459627|NCT01633788|Experimental|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
11459628|NCT01633788|Placebo Comparator|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
11459629|NCT01633775||Ahmed glaucoma implant|
11459632|NCT01633749|Experimental|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
11459633|NCT01633736|Experimental|home progressive resistance exercise|
11459634|NCT01633723|Experimental|DA-6886|
11459635|NCT01633723|Placebo Comparator|DA-6886 placebo|
11459636|NCT01633697|Experimental|Education-Pranayama|Subjects will receive education about COPD with special attention to breathing techniques
11459637|NCT01633697|Sham Comparator|Education-Control|Subjects will receive education alone about COPD.
11459638|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
11459639|NCT01633684||Control|Age and sex matched control subjects
11459640|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
11459641|NCT01633658|Active Comparator|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
11459642|NCT01633658|Experimental|25(OH)D|A single dose of 625 micrograms 25(OH)D
11459643|NCT01633645|Experimental|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
11459644|NCT01633632|Active Comparator|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
11459645|NCT01633632|Experimental|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
11459646|NCT01633632|Experimental|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
11459647|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
11459648|NCT01633593|Experimental|donepezil|Donepezil 5mg/day during 2 weeks
11459649|NCT01633593|Placebo Comparator|placebo|placebo comparator to donepezil (double blind)
11459650|NCT01633580|Placebo Comparator|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
11459651|NCT01633580|Active Comparator|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
11459652|NCT01633567|Experimental|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
11459653|NCT01633567|Active Comparator|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
11459654|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
11459655|NCT01633554||Cirrhosis|Patients with liver cirrhosis
11459656|NCT01633554||Control Group|Control Group: Healthy Volunteers
11459657|NCT01633541|Experimental|platinum/docetaxal + AT-101|"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.
~(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).
~(AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy."
11459658|NCT01633541|Active Comparator|Active Comparator arm|"(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).
~Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies."
11459659|NCT01633528|Experimental|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
11459660|NCT01633528|Placebo Comparator|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
11459661|NCT01633515|Other|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
11459662|NCT01633502|Placebo Comparator|Conventional circulatory support|Patients randomized to conventional circulatory support.
11459663|NCT01633502|Active Comparator|Impella|Patients randomized to Impella CP
11459664|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
11459665|NCT01633476|Active Comparator|Valaciclovir|Active treatment with valaciclovir
11459666|NCT01633476|No Intervention|No additional treatment|No additional treatment
11459667|NCT01633450|Experimental|Zinc biofortified rice|
11459668|NCT01633450|Active Comparator|Rice extrinsically fortified with zinc|
11459669|NCT01633437|Placebo Comparator|Sugar pill|
11459670|NCT01633437|Experimental|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
11459671|NCT01633411||Cohort A|Subjects in Cohort A will receive 6 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
11459672|NCT01633411||Cohort B|Subjects in Cohort B will receive 8 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
11459673|NCT01633411||Cohort C|Subjects in Cohort C will receive 10 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
11459674|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
11459675|NCT01633385||Control Group|age- and sex matched to subject-group
11459676|NCT01633372|Experimental|itacitinib 100 mg|itacitinib 100 mg twice a day
11459677|NCT01633372|Experimental|itacitinib 200 mg|itacitinib 200 mg twice a day
11459678|NCT01633372|Experimental|itacitinib 300 mg|itacitinib 300 mg once a day
11459679|NCT01633372|Experimental|itacitinib 400 mg|itacitinib 400 mg once a day
11459680|NCT01633372|Experimental|itacitinib 600 mg|itacitinib 600 mg once a day
11463270|NCT01608009|Experimental|Pazopanib and paclitaxel|
11459681|NCT01633359|Experimental|Intensive statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.
~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.
~the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
11459682|NCT01633359|Experimental|Routine statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.
~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.
~the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
11459683|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
11459684|NCT01633333|Experimental|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
11459685|NCT01633333|Active Comparator|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
11459686|NCT01633307|Experimental|Experimental|Intervention (Teaching program)
11459687|NCT01633307|No Intervention|Control group|No teaching program
11459688|NCT01633294|Active Comparator|Antibiotic group|women submitted to antibiotic prophylaxis
11459689|NCT01633294|No Intervention|Control group|
11459690|NCT01633281|Experimental|acupuncture treatment|
11459691|NCT01633268||Healthy Volunteers|Healthy men and women aged 18-50
11459692|NCT01633216|Active Comparator|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
11459693|NCT01633216|Active Comparator|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
11459694|NCT01633216|Active Comparator|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
11459695|NCT01633216|Active Comparator|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
11459696|NCT01633216|Active Comparator|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
11459697|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
11459698|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2020)
11459699|NCT01633177|Active Comparator|Vitamin D and Omega-3|
11459700|NCT01633177|Active Comparator|Vitamin D and Omega-3 placebo|
11459701|NCT01633177|Active Comparator|Vitamin D placebo and Omega-3|
11459702|NCT01633177|Placebo Comparator|Vitamin D placebo and Omega-3 placebo|
11459703|NCT01633164|Experimental|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
11459704|NCT01633164|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
11459705|NCT01633151||20 volunteers|
11459706|NCT01633138|Active Comparator|CRT-S|Cognitive Remediation Therapy - Standard
11459707|NCT01633138|Experimental|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
11459708|NCT01633125|Experimental|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
11459709|NCT01633125|No Intervention|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
11459710|NCT01633112|Experimental|fingolimod 0.5 mg|orally once daily
11459711|NCT01633112|Experimental|fingolimod 0.25mg|orally once daily
11459712|NCT01633112|Active Comparator|glatiramer acetate 20 mg|subcutaneous once daily
11459713|NCT01633099|Other|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
11459714|NCT01633086|Active Comparator|nitric oxide gel|"st gel: sodium nitrites
~nd gel: maleic/ascorbic acids"
11459715|NCT01633086|Placebo Comparator|Placebo gel|"st gel: phosphate-buffered saline
~nd gel: maleic/ascorbic acids"
11459716|NCT01633073|Active Comparator|LMA Supreme|
11459717|NCT01633073|Active Comparator|i-gel|
11459718|NCT01633060|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
11459719|NCT01633060|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
11459720|NCT01633047|Experimental|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
11463622|NCT01605786|Experimental|PEBS High dose|
11459721|NCT01633047|Active Comparator|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
11459722|NCT01633021||Diabetes|Self/Family member affected by type-2 diabetes (plus self-referred family-members)
11459723|NCT01633021||Heritable Cancer Screen-Positive|Person who has screened-positive for heritable cancers on genetic tests (plus referred family members)
11459724|NCT01633021||Sickle Cell (Trait/Disease/Related)|Self/Family member affected by Sickle Cell Trait or Sickle Cell Disease (plus self-referredfamily-members)
11459725|NCT01633008|Experimental|1|Attend three 2-hour sessions held over two consecutive days
11459726|NCT01632995|Experimental|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
11459727|NCT01632982|Other|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
11459728|NCT01632982|Experimental|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
11459729|NCT01632982|Active Comparator|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
11459730|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
11459731|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
11459732|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
11459733|NCT01632943|Experimental|Symplicity renal denervation system|
11459734|NCT01632930|Experimental|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
11459735|NCT01632930|Active Comparator|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
11459736|NCT01632917|Experimental|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
11459737|NCT01632917|Experimental|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
11459738|NCT01632904|Experimental|ruxolitinib and hydroxyurea (HU)-placebo|
11459739|NCT01632904|Active Comparator|HU and ruxolitinib-placebo|
11459740|NCT01632891|Experimental|LPV/r-based ART|Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
11459741|NCT01632891|Experimental|nNRTI-based ART|Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
11459742|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
11459743|NCT01632865|Experimental|recanalization and stenting|
11459744|NCT01632852|Experimental|CSL362|See Intervention Description
11459745|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
11459746|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
11459747|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
11459748|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
11459749|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
11459750|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
11459751|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
11459752|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
11459753|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=<1year).
11459754|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
11459755|NCT01632800|Experimental|Single arm study|Each subjects will undergo escalating exposure to magnetic field
11459805|NCT01632462|Placebo Comparator|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
11459756|NCT01632761|Active Comparator|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
11459757|NCT01632761|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
11459758|NCT01632761|Active Comparator|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
11459759|NCT01632761|Active Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
11459760|NCT01632748|Experimental|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
11459761|NCT01632748|Active Comparator|Neurotech Vital Device|Checking to see if stimulation observed using this device
11459762|NCT01632735|Experimental|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
11459763|NCT01632735|No Intervention|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
11459764|NCT01632722|Active Comparator|ArmA|
11459765|NCT01632722|Active Comparator|ArmB|
11459766|NCT01632709|Active Comparator|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
11459767|NCT01632709|Placebo Comparator|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
11459768|NCT01632709|Active Comparator|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
11459769|NCT01632709|Placebo Comparator|dry needling at the neuroma|Placebo/ dry needling at the neuroma
11459770|NCT01632696|Experimental|I-124 PGN650 for PET/CT|
11459771|NCT01632683|Active Comparator|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
11459772|NCT01632683|Active Comparator|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
11459773|NCT01632670|Experimental|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
11459774|NCT01632670|No Intervention|No music therapy|
11459775|NCT01632657|Other|Elective craniotomy and clipping of intracranial aneurysm|
11459776|NCT01632657|Other|Elective craniotomy and microvascular decompression|
11459777|NCT01632644||Physicians|Physicians performing skin biopsies
11459778|NCT01632644||Patients|Patients who have had skin biopsies
11459779|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
11459780|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
11459781|NCT01632618|Experimental|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
11459782|NCT01632618|Active Comparator|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
11459783|NCT01632605|Experimental|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
11459784|NCT01632592|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
11459785|NCT01632592|Placebo Comparator|Placebo|
11459786|NCT01632579|Placebo Comparator|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
11459787|NCT01632579|Experimental|LY3023703|Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
11459788|NCT01632579|Active Comparator|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
11459789|NCT01632566|Placebo Comparator|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
11459790|NCT01632566|Experimental|LY3031207|Daily oral administration of 25 milligrams (mg) LY3031207 up to 450 mg LY3031207 for 28 days.
11459791|NCT01632566|Active Comparator|Celecoxib|Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
11459792|NCT01632566|Other|LY3031207 + Simvastatin|Daily oral administration of 75 mg LY3031207 or 225 mg LY3031207 for 28 days. Single, oral 10 mg simvastatin open-label dose administered before and after 28-day dosing of LY3031207.
11459793|NCT01632553||Cases|women who have experienced DVA
11459794|NCT01632553||Controls|women who have not experienced DVA
11459795|NCT01632540||Perennial Allergic Rhinitis patients|
11459796|NCT01632527|Experimental|HuCNS-SC|HuCNS-SC cells
11459797|NCT01632514|Active Comparator|Vitamin D deficiency treatment|subjects with 25OHD < 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
11459798|NCT01632514|No Intervention|Vitamin D deficiency observation|subjects with 25OHD < 20 ng/mL that will not receive cholecalciferol before surgery
11459799|NCT01632514|No Intervention|Vitamin D sufficiency|controls with 25OHD >= 20 ng/mL that will not receive cholecalciferol before surgery
11459800|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
11459801|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
11459802|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
11459803|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
11459804|NCT01632462|Active Comparator|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
11459808|NCT01632436|Experimental|Stage 1 -Moderate Hepatic Impairment|Pixantrone
11459809|NCT01632436|Experimental|Stage 2 - Severe Hepatic Impairment|Pixantrone
11459810|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
11459811|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.
~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
11459812|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
11459813|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
11459814|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
11459815|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
11459816|NCT01632397|Experimental|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
11459817|NCT01632397|Active Comparator|Health education and supportive counseling|Time matched supportive counseling
11459818|NCT01632371|Experimental|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
11459819|NCT01632371|Active Comparator|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
11459820|NCT01632358|Experimental|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
11459821|NCT01632358|Placebo Comparator|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
11459822|NCT01632345|Experimental|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
11459823|NCT01632345|Experimental|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
11459824|NCT01632345|Experimental|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
11459825|NCT01632345|Experimental|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
11459826|NCT01632345|Active Comparator|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
11459827|NCT01632332|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
11459828|NCT01632319|Experimental|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
11459829|NCT01632319|Active Comparator|CBT|Cognitive behavior therapy (CBT)
11459830|NCT01632306|Experimental|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
11459831|NCT01632306|Experimental|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
11459832|NCT01632306|Experimental|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
11459833|NCT01632293|Experimental|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
11459834|NCT01632280|Active Comparator|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
11459835|NCT01632280|Sham Comparator|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
11459836|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
11459837|NCT01632254||Patients with ≥70% carotid artery stenosis|
11459838|NCT01632241|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
11459839|NCT01632241|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
11459840|NCT01632228|Experimental|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
11459841|NCT01632228|Active Comparator|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
11459842|NCT01632215|Experimental|preoperative gabapentine,|Gabapentine
11459843|NCT01632215|Placebo Comparator|sugar pill|Placebo group
11459844|NCT01632202|Active Comparator|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
11459845|NCT01632202|Placebo Comparator|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
11459846|NCT01632189|Experimental|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
11459847|NCT01632176|No Intervention|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
11459848|NCT01632176|Experimental|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
11459849|NCT01632163|Experimental|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
11459850|NCT01632163|Placebo Comparator|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
11459851|NCT01632150|Experimental|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
11459852|NCT01632137|Placebo Comparator|Placebo (vehicle)|
11459853|NCT01632137|Experimental|Rebamipide 2% ophthalmic suspension|
11459854|NCT01632098||extremely obese|BMI ≥35kg/m2
11459855|NCT01632098||obese|BMI 30-34.9kg/m2
11459856|NCT01632085|Other|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
11459857|NCT01632085|Other|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
11459858|NCT01632072|Experimental|Nutritional counseling|Dietary supplement
11459859|NCT01632072|No Intervention|No nutritional counceling|
11459860|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be > 18 y/o
11459861|NCT01632046|Active Comparator|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
11459862|NCT01632046|Active Comparator|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
11459863|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
11459864|NCT01632020|Placebo Comparator|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
11459865|NCT01632020|Active Comparator|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
11459866|NCT01632007|Experimental|SYR-472 100 mg|
11459867|NCT01632007|Active Comparator|Alogliptin 25 mg|
11459868|NCT01632007|Placebo Comparator|Placebo|
11459869|NCT01631994|Experimental|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
11459870|NCT01631994|No Intervention|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
11459871|NCT01631981|Experimental|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
11459872|NCT01631981|Placebo Comparator|Placebo|Placebo + NETA followed by NETA-only follow-up period
11459873|NCT01631968|Experimental|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
11459874|NCT01631968|Placebo Comparator|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
11459875|NCT01631955||Cystitis|female with cystitis symptoms
11459876|NCT01631942|Experimental|Low dose (healthy subjects)|
11459877|NCT01631942|Experimental|Medium dose (subjects with haemophilia)|
11459878|NCT01631942|Experimental|High dose (subjects with haemophilia)|
11459879|NCT01631929|Active Comparator|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
11459880|NCT01631929|Experimental|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
11459881|NCT01631916|Experimental|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
11459882|NCT01631916|No Intervention|Control|No intervention
11459883|NCT01631903|Experimental|Arm 2 (3mg)|
11459884|NCT01631903|Experimental|Arm 3 (6 mg)|
11459885|NCT01631903|Experimental|Arm 4 (12 mg)|
11459886|NCT01631903|Experimental|Arm 5 (24 mg)|
11459887|NCT01631903|Experimental|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
11459888|NCT01631890|Active Comparator|standard endotherapy|
11459889|NCT01631890|Experimental|Endoscopic Ultrasound assisted endoscopic glue injection|
11459890|NCT01631877|Experimental|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
11459891|NCT01631877|Placebo Comparator|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
11459892|NCT01631864|Experimental|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
11459893|NCT01631864|Active Comparator|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
11459894|NCT01631851|Experimental|Cognitive behavior therapy|
11459895|NCT01631838|Experimental|Tocotrienol-rich fraction 400mg|
11459896|NCT01631838|Experimental|Placebo|
11459897|NCT01631825|Experimental|SPM 962|SPM 962 transdermal patch
11459898|NCT01631812|Experimental|SPM 962|
11459899|NCT01631799|Active Comparator|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
11459900|NCT01631799|Active Comparator|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
11459901|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
11459902|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
11459903|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
11459904|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
11459905|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
11459906|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
11459907|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
11459908|NCT01631747|Active Comparator|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
11459909|NCT01631747|Experimental|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
11459910|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
11459911|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
11459912|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
11459913|NCT01631708|Active Comparator|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.
~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
11459914|NCT01631708|Sham Comparator|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.
~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
11459915|NCT01631682|Active Comparator|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
11459916|NCT01631682|Active Comparator|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
11459917|NCT01631682|Experimental|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
11459918|NCT01631682|Experimental|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
11459919|NCT01631669|Experimental|Celebrex|Receive Celebrex
11459920|NCT01631669|No Intervention|Control|no placebo administered
11459921|NCT01631656|Experimental|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
11459922|NCT01631656|Active Comparator|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
11459923|NCT01631630|Experimental|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
11459924|NCT01631630|Placebo Comparator|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
11459925|NCT01631617|Active Comparator|1A/Cephalexin|Cephalexin + Placebo bleach
11459926|NCT01631617|Active Comparator|1B/TMP/SMX|TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
11459927|NCT01631617|Active Comparator|1C/Doxycycline 100|Doxycycline 100 mg orally every 12 hours for 56 days
11459928|NCT01631617|Active Comparator|1D/Doxycycline 20|Doxycycline 20 mg orally every 12 hours for 56 days
11459929|NCT01631617|Active Comparator|2A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
11459930|NCT01631617|Placebo Comparator|2B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
11463623|NCT01605786|Active Comparator|Control|
11459931|NCT01631617|Placebo Comparator|2C/Placebo capsules + Dilute bleach|Placebo capsules + dilute bleach study bath liquid
11459932|NCT01631617|Placebo Comparator|2D/Placebo capsules + Placebo bleach|Placebo capsules + placebo study bath liquid
11459933|NCT01631617|Active Comparator|3A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
11459934|NCT01631617|Placebo Comparator|3B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
11459935|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
11459936|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
11459937|NCT01631578|Experimental|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
11459938|NCT01631578|Active Comparator|Control|ICSI will be performed conventionally.
11459939|NCT01631565|No Intervention|Standard care|Usual care given to the patients. Treatment, follow-up.
11459940|NCT01631565|Experimental|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.
~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).
~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
11459941|NCT01631552|Experimental|IMMU-132|IMMU-132 (hRS7-SN38) is an Antibody Drug Conjugate where the antibody, hRS7 is attached to SN38. SN38 is the active metabolite of irinotecan (CPT-11).
11459942|NCT01631539|Other|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
11459943|NCT01631526|Experimental|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
11459944|NCT01631513|Experimental|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
11459945|NCT01631500|Other|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
11459946|NCT01631500|Experimental|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
11459947|NCT01631500|Active Comparator|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
11459948|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
11459949|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
11459950|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
11459951|NCT01631487|Experimental|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
11459952|NCT01631487|Experimental|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
11459953|NCT01631487|Experimental|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
11459954|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
11459955|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
11459956|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
11459957|NCT01631474|Experimental|Low-dose active, BID|low dose of CB-03-01, 0.1% applied twice a day
11459958|NCT01631474|Experimental|Medium-dose active, BID|medium dose of CB-03-01, 0.5% applied twice a day
11459959|NCT01631474|Experimental|High-dose active, QD|high dose of CB-03-01, 1% applied once a day
11459960|NCT01631474|Experimental|High-dose active, BID|high dose of CB-03-01, 1% applied twice a day
11459961|NCT01631474|Placebo Comparator|Vehicle, QD or BID|vehicle cream, applied once or twice a day
11459962|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
11459963|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
11459964|NCT01631461||3. Control group|No pain or other breastfeeding problems
11459965|NCT01631448|No Intervention|Control|Patients fron this group do not receive the fibrin sealant
11459966|NCT01631448|Active Comparator|Fibrin group|Patients from this group will receive the fibrin sealant
11459967|NCT01631435|Other|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
11459968|NCT01631422|Experimental|Single Arm|
11459969|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:
~The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)
~The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
11459970|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
11459971|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:
~The patients for whom MAAMT is effective.
~The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.
~They are those patients who then form cohorts III-VI."
11459972|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
11459973|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
11459974|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
11459975|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.
~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
11460016|NCT01631084|Active Comparator|DIAMOND|Patients will receive a comprehensive assessment at baseline, year 1 and year 2. In the interim between these time points patients will be managed according to 'usual care' procedures.
11459976|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
11459977|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
11459978|NCT01631383|Placebo Comparator|Placebo|
11459979|NCT01631383|Active Comparator|l-THP|
11459980|NCT01631370|Experimental|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
11459981|NCT01631357|Experimental|Arm 1: CIK+CT|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
11459982|NCT01631357|Active Comparator|Arm 2: CT|Arm 2: We design chemotherapy alone as a control arm
11459983|NCT01631344|No Intervention|Physical Therapy|Conventional Physical Therapy
11459984|NCT01631344|Experimental|Daily physical activity consultation, Using Stage of change|
11459985|NCT01631331|Experimental|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
11459986|NCT01631318|Experimental|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
11459987|NCT01631305|Experimental|Levothyroxine|3 mcg/kg/day
11459988|NCT01631305|Placebo Comparator|Control|Calcium magnesia.
11459989|NCT01631292|Placebo Comparator|600 IU D3|
11459990|NCT01631292|Active Comparator|2000 IU D3|
11459991|NCT01631292|Active Comparator|4000 IU D3|
11459992|NCT01631279|Experimental|PR610|
11459993|NCT01631266|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
11459994|NCT01631266|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
11459995|NCT01631253|Active Comparator|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
11459996|NCT01631253|Active Comparator|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
11459997|NCT01631253|Active Comparator|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
11459998|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
11459999|NCT01631227|Experimental|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
11460000|NCT01631227|Active Comparator|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
11460001|NCT01631214|Active Comparator|Alendronate/Alendronate|Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
11460002|NCT01631214|Experimental|Romosozumab/Alendronate|Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
11460003|NCT01631201|Experimental|Rifalazil 25 milligram|
11460004|NCT01631201|Active Comparator|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
11460005|NCT01631188|Experimental|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
11460006|NCT01631175|Experimental|(PO-Bado, FBK-R10, PHQ) Active Comparator|
11460007|NCT01631162|No Intervention|lung disease|
11460008|NCT01631149|Experimental|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
11460009|NCT01631149|Active Comparator|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
11460010|NCT01631136|Active Comparator|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
11460011|NCT01631136|Experimental|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :
~continuous maintenance therapy by gemcitabine if response disease
~switch maintenance therapy by pemetrexed if stable disease"
11460012|NCT01631123|Experimental|Diet interventions|Sequential dietary intervention
11460013|NCT01631110|Experimental|Elderly subjects aged over 60 years|
11460014|NCT01631110|Experimental|Adults from 18 to 60 years old inclusive|
11460015|NCT01631084|Experimental|JADE|Patients randomized to the JADE group will be followed according to protocol-driven diabetes care based on their individual risk levels, using a web-based disease management program. In addition to their annual comprehensive assessments at baseline, year 1 and year 2, all subsequent follow-up visits will be documented and entered into the JADE portal, which will then issue reports to both patients and doctor to promote sharing of information and informed decisions.
11460017|NCT01631071|Experimental|Elderly subjects aged over 60 years|
11460019|NCT01631058|Experimental|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.
~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.
~Corticosteroids: as clinical practice."
11460020|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
11460021|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
11460022|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
11460023|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
11460024|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
11460025|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
11460026|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
11460027|NCT01631032|Placebo Comparator|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
11460028|NCT01631032|Experimental|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
11460029|NCT01631019|Active Comparator|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
11460030|NCT01631019|Placebo Comparator|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
11460031|NCT01631006|Sham Comparator|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
11460032|NCT01631006|Active Comparator|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
11460033|NCT01630993|Experimental|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
11460034|NCT01630993|No Intervention|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
11460035|NCT01630967|Experimental|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
11460036|NCT01630954|Active Comparator|Single evacuation of mole,|
11460037|NCT01630954|Active Comparator|Double evacuation of mole|
11460038|NCT01630941|Active Comparator|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
11460039|NCT01630941|Placebo Comparator|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
11460040|NCT01630928|Experimental|Renal sympathetic denervation|Patients with treatment resistant hypertension
11460041|NCT01630889|Experimental|FG-4592|FG-4592 Investigational Drug
11460042|NCT01630876|Sham Comparator|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
11460043|NCT01630876|Experimental|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
11460044|NCT01630863|Experimental|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
11460045|NCT01630863|Experimental|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
11460046|NCT01630863|Experimental|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
11460047|NCT01630850|Experimental|Allogenic islet cells (human, U. Chicago)|
11460048|NCT01630837|Other|12h|Frequency of oral hygiene was 12 to 12 hours.
11460049|NCT01630837|Other|24h|Frequency of oral hygiene was 24 to 24 hours.
11460050|NCT01630837|Other|48h|Frequency of oral hygiene was 48 to 48 hours.
11460051|NCT01630837|Other|72h|Frequency of oral hygiene was 72 to 72 hours.
11460052|NCT01630824|Other|Education|Kidney transplant recipients, who undergo the structured education program
11460053|NCT01630824|No Intervention|Control|Kidney transplant recipients without structured education programm
11460054|NCT01630811|Experimental|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
11460055|NCT01630811|Placebo Comparator|Placebo|Oral, once daily
11460056|NCT01630798|Experimental|Application of peptide|
11460057|NCT01630785||IONM patients|all patients where surgery requires IONM
11460058|NCT01630759|Experimental|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
11460059|NCT01630759|Active Comparator|Control group|Control group will consist of usual care and review at clinic.
11460060|NCT01630746|Experimental|TAK-438 20 mg/day|
11460061|NCT01630746|Experimental|TAK-438 40 mg/day|
11460062|NCT01630733|Experimental|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
11460063|NCT01630733|Active Comparator|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
11460064|NCT01630720|Active Comparator|vitamin C|vitamin C 500 mg twice daily
11460065|NCT01630720|Active Comparator|vitamin D|vitamin D 5000 IU daily
11460066|NCT01630694|Active Comparator|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
11460067|NCT01630694|Placebo Comparator|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
11460068|NCT01630681|Experimental|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
11460069|NCT01630681|No Intervention|Standard care|
11460070|NCT01630668|Experimental|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
11460071|NCT01630668|Placebo Comparator|One-a-Day placebo capsule|
11460072|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
11460073|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
11460074|NCT01630616|Experimental|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
11460075|NCT01630616|Experimental|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
11460076|NCT01630616|Placebo Comparator|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
11460077|NCT01630616|Experimental|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
11460078|NCT01630616|Placebo Comparator|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
11460079|NCT01630603||mother infants pairs|
11460080|NCT01630590|Experimental|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
11460081|NCT01630577|Experimental|responder to fluid challenge|fluid challenge
11460082|NCT01630564|Experimental|Treatment (T-cell infusion)|Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion with aldesleukin 11-14 days after T-cell co-stimulation begins.
11460083|NCT01630551|Active Comparator|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
11460084|NCT01630551|Placebo Comparator|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
11460085|NCT01630538|Experimental|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
11460086|NCT01630525||Prodromal AD participants|
11460087|NCT01630525||Typical AD participants|
11460088|NCT01630525||Control participants|
11460089|NCT01630512|Experimental|MBCT|
11460090|NCT01630512|Experimental|CBT|
11460091|NCT01630512|No Intervention|Waitlist|
11460092|NCT01630499|Experimental|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
11460093|NCT01630499|Active Comparator|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
11460094|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
11460095|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
11460096|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
11460097|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
11460098|NCT01630473|Experimental|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
11460099|NCT01630473|Active Comparator|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
11460100|NCT01630434|Experimental|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
11460101|NCT01630434|Active Comparator|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
11460102|NCT01630421||affected, unaffected|Individuals with diagnosed ACC
11460103|NCT01630408|Experimental|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
11460104|NCT01630395|No Intervention|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
11460105|NCT01630395|Active Comparator|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
11460106|NCT01630395|Active Comparator|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
11460107|NCT01630369|Experimental|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
11460108|NCT01630356|Experimental|Intervention group|
11460109|NCT01630356|Active Comparator|Control group|
11460232|NCT01629498|Experimental|Arm II (image-guided IMPT)|Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11463624|NCT01605773|Experimental|repaglinide|
11460110|NCT01630343|Experimental|Regular oral Panadol and Tramadol|Geriatric (age >65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
11460111|NCT01630343|Experimental|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
11460112|NCT01630330|Active Comparator|Contact Force Known|Ablation with contact force data known
11460113|NCT01630330|Experimental|Contact Force Not Known|Contact Force data unavailable during ablation
11460114|NCT01630317|Experimental|Peripheral acces|
11460115|NCT01630317|Placebo Comparator|Central access|
11460116|NCT01630304|Experimental|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
11460117|NCT01630304|No Intervention|Standard care|This arm will receive standard clinical care.
11460118|NCT01630291|Experimental|Electrical stimulation|
11460119|NCT01630278|No Intervention|Small ductus|
11460120|NCT01630278|Experimental|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
11460121|NCT01630278|Placebo Comparator|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
11460122|NCT01630265|Active Comparator|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
11460123|NCT01630265|Experimental|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
11460124|NCT01630252|Active Comparator|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
11460125|NCT01630252|Placebo Comparator|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
11460126|NCT01630252|Active Comparator|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
11460127|NCT01630252|Placebo Comparator|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
11460128|NCT01630252|Experimental|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
11460129|NCT01630239|Experimental|Visualise Thermal Therapy System|
11460130|NCT01630226|Experimental|Neoadjuvant Cisplatin Chemotherapy|
11460131|NCT01630213|Active Comparator|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
11460132|NCT01630213|Placebo Comparator|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
11460133|NCT01630200|Active Comparator|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
11460134|NCT01630200|Placebo Comparator|Placebo|Control arm including patients who receive the placebo tablet (once daily)
11460135|NCT01630187|Active Comparator|Carbetocin 100 mcg|
11460136|NCT01630187|Experimental|Carbetocin 50 mcg|
11460137|NCT01630161|Active Comparator|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
11460138|NCT01630161|Active Comparator|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
11460139|NCT01630148|Active Comparator|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
11460140|NCT01630148|No Intervention|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
11460141|NCT01630135|Experimental|GW685698X|GW685698X 55mcg/day
11460142|NCT01630135|Placebo Comparator|Placebo|Placebo
11460143|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
11460144|NCT01630109|Active Comparator|Metoclopramide 5 mg|Pro-motility agent
11460145|NCT01630109|Active Comparator|Metoclopramide 10 mg|Pro-motility agent
11460146|NCT01630109|Placebo Comparator|Placebo control|Placebo to be used as the control group
11460147|NCT01630096|Active Comparator|Nu-Lytely|Bowel prep solution.
11460148|NCT01630096|No Intervention|Control|Standard of care.
11460149|NCT01630083|Active Comparator|EOX Treatment|Participants will receive up to 8 cycles of epirubicin, oxaliplatin and capecitabine (EOX) chemotherapy treatment alone (50 mg/m^2 epirubicin intravenously on day 1 of each cycle, 130 mg/m^2 oxaliplatin intravenously on day 1 of each cycle, 625 mg/m^2 capecitabine orally twice daily on days 1 to 21 of each cycle). The first dose of capecitabine to be taken in the evening of day 1.
11460150|NCT01630083|Experimental|EOX+zolbetuximab 800/600 mg/m^2|Participants will received up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab administered as loading dose of 800 mg/m^2 intravenously on day 1 of cycle 1 followed by 600 mg/m^2 intravenously on day 1 of each subsequent cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (600 mg/m^2 every 3 weeks to be administered intravenously as a 2-hour infusion) until progressive disease (PD), withdrawal of consent or unacceptable toxicity. PD per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study, an absolute increase of at least 5mm must also be demonstrated, unequivocal progression of existing non-target lesions and appearance of one or more new lesions is considered progression.
11460233|NCT01629485|Experimental|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
11460151|NCT01630083|Experimental|EOX+zolbetuximab 1000 mg/m^2|Participants will receive up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab 1000 mg/m^2 intravenously on day 1 of each cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (1000 mg/m^2 every 3 weeks administered intravenously as a 2-hour infusion ) until PD, withdrawal of consent or unacceptable toxicity.
11460152|NCT01630070|Experimental|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
11460153|NCT01630057|Experimental|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
11460154|NCT01630057|Active Comparator|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
11460155|NCT01630044|Experimental|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
11460156|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
11460157|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
11460158|NCT01630018|Active Comparator|Topotecan|Topotecan
11460159|NCT01630018|Active Comparator|Camtobell|Belotecan
11460160|NCT01630005|Experimental|Talk therapy|A cohort of 25 patients
11460161|NCT01629992|Experimental|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
11460162|NCT01629992|No Intervention|Control|The control group received no preoperative counseling either oral or written.
11460163|NCT01629979|Experimental|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.
~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
11460164|NCT01629979|Active Comparator|UVB treatment|UVB treatment twice a week during 3months
11460165|NCT01629966|Placebo Comparator|Placebo|Dose-matched placebo one per day, oral administration
11460166|NCT01629966|Experimental|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
11460167|NCT01629966|Experimental|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
11460168|NCT01629953|Active Comparator|Group Based Vocational Rehabilitation|Group vocational intervention
11460169|NCT01629953|Experimental|Supported Employment Condition|Group vocational intervention + supported employment
11460170|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
11460171|NCT01629940||Male controls|Male subjects not affected by HED
11460172|NCT01629927||HED-affected males|Male subjects affected by HED
11460173|NCT01629927||Male controls|Male subjects not affected by HED
11460174|NCT01629888|Experimental|1 = Tested product|
11460175|NCT01629888|Placebo Comparator|2 = Control product|
11460176|NCT01629875|Experimental|DWP450|
11460177|NCT01629875|Active Comparator|Botox|
11460178|NCT01629862|Active Comparator|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
11460179|NCT01629862|Placebo Comparator|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
11460180|NCT01629849|Experimental|BI 1021958 qd|Multiple rising dose
11460181|NCT01629849|Placebo Comparator|Placebo to BI 1021958 qd|Matching placebo as tablets
11460182|NCT01629849|Experimental|BI 1021958 bid|Multiple rising dose
11460183|NCT01629849|Placebo Comparator|Placebo to BI 1021958 bid|Matching palcebo as tablet
11460184|NCT01629823|Sham Comparator|CPAP less than 1 cm H₂O|
11460185|NCT01629823|Experimental|CPAP 10cm H₂O|
11460186|NCT01629823|Experimental|CPAP 5cm H₂O|
11460187|NCT01629797|Other|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
11460188|NCT01629784|Other|CLE and sun counseling|
11460189|NCT01629771||Lymphatic Filariasis|
11460190|NCT01629771||Patients without Lymphatic Filariasis|
11460191|NCT01629758|Experimental|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
11460192|NCT01629758|Experimental|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
11460193|NCT01629758|Experimental|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
11460194|NCT01629732|Experimental|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
11460195|NCT01629732|Experimental|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
11460630|NCT01626612|Active Comparator|a conservative strategy|
11460196|NCT01629732|Experimental|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
11460197|NCT01629732|Experimental|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
11460198|NCT01629732|Experimental|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
11460199|NCT01629732|Experimental|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
11460200|NCT01629732|Experimental|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
11460201|NCT01629706|Experimental|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
11460202|NCT01629706|Experimental|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
11460203|NCT01629693|Experimental|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
11460204|NCT01629693|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
11460205|NCT01629680|Experimental|Healthy subjects I|
11460206|NCT01629680|Placebo Comparator|Healthy subjects II|
11460207|NCT01629667|Experimental|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
11460208|NCT01629667|Experimental|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
11460209|NCT01629667|Placebo Comparator|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
11460210|NCT01629654|Experimental|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
11460211|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
11460212|NCT01629628|Experimental|Adalimumab|
11460213|NCT01629628|Active Comparator|6-mercaptopurine|
11460214|NCT01629615|Experimental|BKM120|
11460215|NCT01629602|Experimental|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
11460216|NCT01629589|Experimental|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
11460217|NCT01629589|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
11460218|NCT01629576|No Intervention|control group|
11460219|NCT01629576|Experimental|low reward|economic incentive
11460220|NCT01629576|Experimental|high reward|economic incentive
11460221|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 5mg|All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
11460222|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 10mg|All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
11460223|NCT01629550|Active Comparator|PVI paint|5% alcoholic povidone iodine paint
11460224|NCT01629550|Active Comparator|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
11460225|NCT01629550|Active Comparator|Chlorhexidine paint|2% alcoholic chlorhexidine paint
11460226|NCT01629550|Active Comparator|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
11460227|NCT01629537|Other|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
11460228|NCT01629537|Experimental|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
11460229|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
11460230|NCT01629511|Experimental|Treatment (combination chemotherapy, stem cell transplant)|Participants receive gemcitabine IV over 10-25 minutes on days -6 and -4, clofarabine IV over 1 hour and busulfan IV over 3 hours on days -6 to -3. Participants with matched unrelated donors also receive anti-thymocyte globulin IV over 4 hours on days -3 to -1. Starting day -2, participants receive tacrolimus PO daily for up to 6 months. Participants undergo hematopoietic allogeneic stem cell transplant on day 0, then receive methotrexate IV over 15 minutes on days 1, 3, 6 and 11, and filgrastim SC QD beginning 1 week after transplant until blood cell levels return to normal.
11460231|NCT01629498|Experimental|Arm I (image-guided IMRT)|Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
11460681|NCT01626261||cardiac pacemaker|
11460234|NCT01629485|Experimental|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
11460235|NCT01629472|Experimental|VSLA + gender dialogue groups: treatment|
11460236|NCT01629472|Active Comparator|VSLA only: control|
11460237|NCT01629459|Experimental|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
11460238|NCT01629446|Experimental|Lofexidine HCl with 14C tracer|
11460239|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
11460240|NCT01629420|Experimental|Drug:KLH-2109 lower dose|
11460241|NCT01629420|Experimental|Drug:KLH-2109 higher dose|
11460242|NCT01629407||Glaucoma|Patients with glaucoma
11460243|NCT01629394|Active Comparator|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
11460244|NCT01629394|Active Comparator|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
11460245|NCT01629394|Active Comparator|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
11460246|NCT01629394|Active Comparator|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
11460247|NCT01629394|Active Comparator|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
11460248|NCT01629394|Active Comparator|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
11460249|NCT01629394|Active Comparator|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
11460250|NCT01629394|Active Comparator|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
11460251|NCT01629381|Experimental|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
11460252|NCT01629381|Placebo Comparator|Placebo|oral placebo od for 7 days
11460253|NCT01629368|Experimental|Dosing Period 1|
11460254|NCT01629368|Experimental|Dosing Period 2|
11460255|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
11460256|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
11460257|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
11460258|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
11460259|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
11460260|NCT01629329|Active Comparator|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
11460261|NCT01629329|Active Comparator|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
11460262|NCT01629316|Experimental|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
11460263|NCT01629316|Active Comparator|Standard of care - control arm|
11460264|NCT01629303|Experimental|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.
~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
11460265|NCT01629303|Experimental|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.
~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
11460266|NCT01629290|Active Comparator|Enamel Pro|Varnish containing 5%NaF
11460267|NCT01629290|Active Comparator|Duraphat|Varnish containing 5%NaF
11460268|NCT01629290|Active Comparator|Vanish|Varnish containing 5%NaF
11460269|NCT01629290|Placebo Comparator|Placebo|Bland varnish containing no NaF
11460270|NCT01629277|Active Comparator|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
11460271|NCT01629277|Experimental|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
11460272|NCT01629251|Active Comparator|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
11460273|NCT01629251|Experimental|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
11460274|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
11460275|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
11460276|NCT01629225|No Intervention|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
11460277|NCT01629212|Experimental|Tiropramide HCl|
11460278|NCT01629212|Active Comparator|Octylonium bromide|
11460279|NCT01629199|Experimental|rhEGF(recombinant human Epidermal Growth Factor)|BID
11460280|NCT01629199|Placebo Comparator|placebo|BID
11460281|NCT01629186|Experimental|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p < 0.05.
~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR>100 beat/min, SpO2>90%, mean BP>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
11460282|NCT01629173|Experimental|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
11460283|NCT01629173|Experimental|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
11460284|NCT01629173|Experimental|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
11460285|NCT01629173|Experimental|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
11460286|NCT01629147|Experimental|Biogaia|5 drops containing Lactobacillus reuteri Protectis
11460287|NCT01629147|Placebo Comparator|Placebo|- 5 drops identical in appearance and taste
11460288|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
11460289|NCT01629121|Experimental|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
11460290|NCT01629121|No Intervention|control|Printed materials were given to the control group, along with a helmet for each participant.
11460291|NCT01629108||1|Healthy volunteers aged 5 to 80
11460292|NCT01629095||NAFLD|Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
11460293|NCT01629095||NASH|Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.
11460294|NCT01629069|Active Comparator|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
11460295|NCT01629056|Active Comparator|Contact ECI active|Contact ECI active
11460296|NCT01629056|Placebo Comparator|Contact information deactivated|RF ablation without contact data
11460297|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
11460298|NCT01629004|Other|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.
~FOBT kit. Mailed invitation."
11460299|NCT01629004|Other|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).
~FOBT kit. Mailed invitation."
11460300|NCT01628991|Experimental|behavioural intervention|Recieving interventional behavioural program
11460301|NCT01628991|Experimental|vaginal cone|intravaginal device insertion(vaginal cone)
11460302|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
11460303|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
11460304|NCT01628965|Experimental|SPM 962|SPM 962 transdermal patch
11460305|NCT01628952|Experimental|TAP|
11460306|NCT01628952|Active Comparator|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
11460307|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
11460308|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
11460309|NCT01628926|Experimental|SPM 962|SPM 962 transdermal patch
11460310|NCT01628926|Active Comparator|Ropinirole|Ropinirole tablet
11460311|NCT01628926|Placebo Comparator|Placebo|SPM962 placebo patch and Ropinirole placebo tab
11460312|NCT01628913|Experimental|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
11460313|NCT01628913|Active Comparator|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
11460314|NCT01628900|Active Comparator|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
11460315|NCT01628900|Active Comparator|hospitalisation|7 days for mono-antibiotherapy at hospital.
11460316|NCT01628887|Experimental|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
11460317|NCT01628874|Experimental|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
11460318|NCT01628874|Active Comparator|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
11461208|NCT01622361|Active Comparator|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide>Docetaxel
11460319|NCT01628861|Active Comparator|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
11460320|NCT01628861|Experimental|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
11460321|NCT01628848|Experimental|SPM 962|SPM 962 transdermal patch
11460322|NCT01628848|Placebo Comparator|Placebo|Placebo transdermal patch
11460323|NCT01628835|Experimental|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
11460324|NCT01628835|Active Comparator|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
11460325|NCT01628822|Experimental|Active relaxation|
11460326|NCT01628822|Placebo Comparator|Placebo relaxation|
11460327|NCT01628809|Active Comparator|Rest and Relaxation|three-day relaxation retreat without mindfulness components
11460328|NCT01628809|Experimental|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
11460329|NCT01628783|Placebo Comparator|Placebo|Microgranular cellulose in gelatine capsules.
11460330|NCT01628783|Experimental|Escitalopram 10 mg|Escitalopram in gelatine capsule
11460331|NCT01628770|Experimental|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
11460332|NCT01628770|Active Comparator|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
11460333|NCT01628757||neoadjuvant chemotherapy|
11460334|NCT01628744||Patients with mycobacterial infection|
11460335|NCT01628731|Active Comparator|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
11460336|NCT01628731|Active Comparator|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
11460337|NCT01628718|Active Comparator|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
11460338|NCT01628718|Experimental|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
11460339|NCT01628705|Sham Comparator|Nutritional intervention|The subjects were undergoing nutritional intervention.
11460340|NCT01628705|Experimental|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
11460341|NCT01628692|Experimental|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
11460342|NCT01628692|Experimental|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
11460343|NCT01628692|Experimental|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
11460344|NCT01628692|Experimental|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day.
11460345|NCT01628679|Experimental|physical therapy treatment|
11460346|NCT01628666|Experimental|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
11460347|NCT01628666|Experimental|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
11460348|NCT01628653|Experimental|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
11460349|NCT01628640|Experimental|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
11460350|NCT01628640|Experimental|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
11460351|NCT01628627|Experimental|FREMS|Frequency Modulated Neural Stimulation (FREMS)
11460352|NCT01628627|Sham Comparator|Control|
11460353|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
11460354|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
11460355|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
11460356|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
11460357|NCT01628562|Active Comparator|GroupE/Esmolol infusion|Heart rate control, Beta blocker
11460358|NCT01628562|Experimental|GroupR/Remifentanil infusion|Heart rate control, opioid
11460359|NCT01628549|Experimental|P005672-HCl approximately 0.75 mg/kg/day|One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
11460360|NCT01628549|Experimental|P005672-HCl approximately 1.5 mg/kg/day|Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
11460361|NCT01628549|Experimental|P005672-HCl approximately 3.0 mg/kg/day|Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
11460362|NCT01628549|Placebo Comparator|Placebo|Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
11460363|NCT01628536|Experimental|Black cohosh|
11460364|NCT01628523||All ED patients requiring mechanical ventilation|
11460365|NCT01628510|Active Comparator|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
11460366|NCT01628510|Experimental|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
11460367|NCT01628497||Positive filariasis test|Those testing positive for filariasis
11460368|NCT01628497||Filariasis negative|
11460369|NCT01628484|Other|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
11460370|NCT01628471|Experimental|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
11460371|NCT01628458|Experimental|radiofrequency ablation|
11460372|NCT01628445|Active Comparator|liraglutide|liraglutide 1.8 mg injected once daily
11460373|NCT01628445|Placebo Comparator|Placebo injection|
11460374|NCT01628432|Experimental|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
11460375|NCT01628432|Active Comparator|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
11460376|NCT01628419|Experimental|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
11460377|NCT01628406||Patients treated at the neurosurgery department|Patients treated at the neurosurgery department
11460378|NCT01628393|Experimental|RPC1063 Low Dose|
11460379|NCT01628393|Placebo Comparator|placebo|
11460380|NCT01628393|Experimental|RPC1063 High Dose|
11460381|NCT01628380|Active Comparator|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
11460382|NCT01628380|Active Comparator|CRS alone|Cytoreductive Surgery alone
11460383|NCT01628367|Experimental|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
11460384|NCT01628367|Active Comparator|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
11460385|NCT01628341||Patients with diabetes (type 1 and 2)|
11460386|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
11460387|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
11460388|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
11460389|NCT01628302|No Intervention|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
11460390|NCT01628302|Experimental|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
11460391|NCT01628289|Other|free screening group|Subjects in this group receive free diabetic retinopathy screening.
11460392|NCT01628289|Other|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
11460393|NCT01628276|Experimental|Rehab first|
11460394|NCT01628276|Experimental|Rehab Second|
11460395|NCT01628276|No Intervention|Non Rehab|
11460396|NCT01628263|Experimental|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
11460397|NCT01628263|No Intervention|Control|Participants will not receive an offer of a follow up clinic
11460398|NCT01628250|Active Comparator|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
11460399|NCT01628250|Active Comparator|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
11460400|NCT01628237|Active Comparator|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
11460401|NCT01628237|Experimental|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
11460402|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
11460403|NCT01628211|Experimental|Second look laparoscopy|Second look laparoscopy to evaluate for and treat peritoneal carcinosis
11460404|NCT01628211|No Intervention|standard follow up|
11460405|NCT01628198|Experimental|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
11460406|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
11460407|NCT01628172|Experimental|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
11460408|NCT01628172|No Intervention|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
11460409|NCT01628159|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
11460410|NCT01628146|Experimental|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
11460411|NCT01628133||blood transfusion group|
11460412|NCT01628120|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
11460413|NCT01628107|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
11460414|NCT01628094|Experimental|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
11460415|NCT01628094|Experimental|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
11460416|NCT01628094|Experimental|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin [Copegus]
11460417|NCT01628094|Experimental|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
11460418|NCT01628094|Experimental|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin [Copegus]
11460419|NCT01628094|Experimental|Part II|
11460420|NCT01628081|Experimental|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
11460421|NCT01628081|Placebo Comparator|Placebo|"Dosage Regimen and Treatment Groups
~Daily oral administration of:
~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).
~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
11460422|NCT01628068|Active Comparator|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
11460423|NCT01628068|No Intervention|Oral anticoagulation|Oral anticoagulation
11460424|NCT01628055|Experimental|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
11460425|NCT01628055|Placebo Comparator|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
11460426|NCT01628042|Experimental|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
11460427|NCT01628042|Experimental|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
11460428|NCT01628042|Experimental|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
11460429|NCT01628042|Experimental|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
11460430|NCT01628029|Experimental|Litebook + Melatonin + Methylphenidate + CBT|Light therapy over 30 minutes for 14 days. Melatonin 20 mg orally at bedtime and Methylphenidate 5 mg orally twice daily for 15 days. Counseling sessions on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460431|NCT01628029|Experimental|Placebo Litebook + Placebo drugs + CBT|Placebo light over 30 minutes for 14 days. One placebo capsule orally twice during day, and one at bedtime for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460432|NCT01628029|Experimental|Placebo Litebook + Melatonin + Methylphenidate + CBT|Placebo light over 30 minutes for 14 days. Melatonin 20 mg orally at bed time, and Methylphenidate 5 mg by mouth twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460433|NCT01628029|Experimental|Litebook + Placebo + Methylphenidate + CBT|Light therapy over 30 minutes for 14 days. Methylphenidate 5 mg by mouth twice daily and one placebo capsule at bedtime for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460434|NCT01628029|Experimental|Litebook + Melatonin + Placebo + CBT|Light therapy over 30 minutes for 14 days. Melatonin 20 mg orally at bed time, and one placebo capsule orally twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460435|NCT01628029|Experimental|Litebook + Placebo Drugs + CBT|Light therapy over 30 minutes for 14 days. One placebo capsule orally twice daily, and one at bedtime for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460436|NCT01628029|Experimental|Placebo Litebook + Placebo + Methylphenidate + CBT|Placebo light over 30 minutes for 14 days. One placebo capsule at bedtime, and Methylphenidate 5 mg orally twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460437|NCT01628029|Experimental|Placebo Litebook + Melatonin + Placebo + CBT|Placebo light over 30 minutes for 14 days. Melatonin 20 mg orally at bed time, and one placebo capsule orally twice daily for 15 days. Counseling session on Days 8 and 15. Well-being questionnaires completed Days 1, 3, 8, 15, and 29, with Study Diaries completed daily.
11460438|NCT01628016|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%.
~ABMT intervention: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes (4 sessions a week, roughly one session every other day with for each session)."
11460439|NCT01628016|Placebo Comparator|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
11460440|NCT01628016|No Intervention|blank control|Participants only complete assessment at each point time.
11460441|NCT01628003|Active Comparator|healthy persons|
11460442|NCT01628003|Experimental|patients after moderate-severe TBI|
11460443|NCT01627977|Experimental|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
11460444|NCT01627964||normal heart function|normal heart function
11460445|NCT01627964||abnormal heart function|abnormal heart function
11460446|NCT01627951|Active Comparator|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
11460447|NCT01627951|Experimental|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
11460448|NCT01627951|Experimental|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
11460449|NCT01627938|Experimental|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
11460450|NCT01627938|Placebo Comparator|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
11460451|NCT01627925|Experimental|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
11460452|NCT01627925|Experimental|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
11460453|NCT01627899|Other|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
11460454|NCT01627886|Experimental|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
11460455|NCT01627886|Active Comparator|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
11460456|NCT01627873|Experimental|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
11460457|NCT01627873|Active Comparator|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
11460458|NCT01627860|Active Comparator|Topiramate add-on therapy|
11460459|NCT01627860|Experimental|Topiramate monotherapy|
11460460|NCT01627847|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
11460461|NCT01627847|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
11460462|NCT01627834|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
11460463|NCT01627834|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
11460464|NCT01627821|Active Comparator|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
11460465|NCT01627821|Active Comparator|HeartMate II Control|HeartMate II VAS Control
11460466|NCT01627795|Experimental|Oshadi D and Oshadi R|anti cancer agents
11460467|NCT01627782|Placebo Comparator|Placebo 3 times/week|
11460468|NCT01627782|Experimental|Ketamine 3 times/week|
11460469|NCT01627782|Experimental|Ketamine 2 times/week|
11460470|NCT01627782|Placebo Comparator|Placebo 2 times/week|
11460471|NCT01627769||second degree blisters patients|blister fluids of second degree burns
11460472|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
11460473|NCT01627756|Experimental|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
11460474|NCT01627756|Active Comparator|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
11460475|NCT01627743||COPD patients grade C and D|
11460476|NCT01627730|Experimental|3th year medical students|
11460477|NCT01627730|Experimental|nurses in critical care units|
11460478|NCT01627717|Experimental|Maraviroc Boceprevir|
11460479|NCT01627704|Other|Fluoroestradiol (18F)|
11460480|NCT01627691|Experimental|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
11460481|NCT01627678|Experimental|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
11460482|NCT01627678|Experimental|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
11460483|NCT01627665|Active Comparator|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
11460484|NCT01627665|Active Comparator|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
11460485|NCT01627665|Active Comparator|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
11460486|NCT01627665|Active Comparator|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
11460487|NCT01627652|Experimental|altitude|subjects will be studies at sea level and at high altitude
11460488|NCT01627639|Active Comparator|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
11460489|NCT01627639|Placebo Comparator|Placebo|Placebo
11460490|NCT01627626|Experimental|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
11460491|NCT01627626|Placebo Comparator|0.9% saline mouthwash|0.9% saline as a mouthwash
11460492|NCT01627613|Experimental|AP301|Treatment group
11460493|NCT01627613|Placebo Comparator|saline solution|Placebo group
11460494|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
11460495|NCT01627587|Experimental|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
11460496|NCT01627587|Experimental|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
11460497|NCT01627574|Experimental|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
11460498|NCT01627574|Active Comparator|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
11460499|NCT01627561|Experimental|Cervarix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received two doses of Cervarix vaccine at Day 0 and Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
11460500|NCT01627561|Active Comparator|Priorix + Infanrix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received one dose of Priorix vaccine at Day 0 and one dose of Infanrix vaccine at Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
11460501|NCT01627548|Active Comparator|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
11460502|NCT01627548|Active Comparator|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
11460503|NCT01627535|Experimental|Optical Imaging|Patients undergo i2DOS
11460504|NCT01627522|Active Comparator|Finastide low dose|2 weeks of daily 5mg finastride before operation
11460505|NCT01627522|Active Comparator|Finastide high dose|4 weeks of daily 5mg finastride before operation
11460506|NCT01627522|No Intervention|Control|Control
11460507|NCT01627483|Experimental|Medication review|Assessment of risks of falls and fractures, medication review
11460508|NCT01627483|No Intervention|Controll|
11460509|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
11460510|NCT01627457|Experimental|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
11460511|NCT01627444|Experimental|ear acupuncture|
11460512|NCT01627444|Placebo Comparator|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
11460513|NCT01627431|Other|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
11460514|NCT01627418|Experimental|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
11460515|NCT01627418|Other|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
11460516|NCT01627392|Experimental|Smoking abstinence|
11460517|NCT01627379|Active Comparator|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
11460518|NCT01627379|Experimental|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
11460519|NCT01627366|Experimental|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
11460520|NCT01627366|No Intervention|Usual care|Receipt of usual medical care.
11460521|NCT01627353|Active Comparator|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
11460522|NCT01627353|Experimental|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
11460523|NCT01627340|Experimental|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
11460524|NCT01627340|Active Comparator|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11461420|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 100mg|
11460525|NCT01627327|Experimental|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
11460526|NCT01627327|Active Comparator|tiotropium bromide|anticholinergic
11460527|NCT01627314|Experimental|ProHema-CB|
11460528|NCT01627314|Active Comparator|Control Arm|
11460529|NCT01627301|Experimental|Device-Guided Breathing at low breathing rate|Device-guided breathing at low breathing rate daily for 15 minutes up to 8 weeks
11460530|NCT01627301|Active Comparator|Device guided breathing at normal rate|Device-guided breathing at a normal breathing rate daily for 15 minutes for up to 8 weeks
11460531|NCT01627288|Experimental|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
11460532|NCT01627288|Experimental|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
11460533|NCT01627288|Experimental|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
11460534|NCT01627288|Experimental|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.
~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
11460535|NCT01627275|Experimental|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
11460536|NCT01627262|Placebo Comparator|Placebo|
11460537|NCT01627262|Experimental|Mesalamine|
11460538|NCT01627249|Active Comparator|Ranibizumab|
11460539|NCT01627249|Experimental|Aflibercept|
11460540|NCT01627249|Experimental|Bevacizumab|
11460541|NCT01627236|Experimental|glucocorticoid treatment group|
11460542|NCT01627236|No Intervention|conventional treatment|
11460543|NCT01627223|Experimental|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.
~Cohort 1: Lamivudine 100 mg p.o. q.d.
~Cohort 2: Entecavir 0.5 mg p.o. q.d.
~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
11460544|NCT01627223|Experimental|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.
~Cohort 1: Lamivudine 100 mg p.o. q.d.
~Cohort 2: Entecavir 0.5 mg p.o. q.d.
~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
11460545|NCT01627197|Active Comparator|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms
~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
11460546|NCT01627197|No Intervention|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
11460547|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
11460548|NCT01627171|Active Comparator|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
11460549|NCT01627171|Experimental|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
11460550|NCT01627171|Experimental|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
11460551|NCT01627158|Experimental|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
11460552|NCT01627158|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler
11460553|NCT01627158|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
11460554|NCT01627158|Active Comparator|Charcoal and Symbicort Turbuhaler|
11460555|NCT01627145|Experimental|antimuscariniz drug|
11460556|NCT01627132|Experimental|dasatinib|
11460557|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
11460558|NCT01627106|Experimental|Vernakalant|
11460559|NCT01627106|Active Comparator|Amiodarone|
11460560|NCT01627093||Observational (questionnaire, medical chart review)|Patients complete questionnaires over 30 minutes before treatment begins, at each visit during treatment, and again at all follow-up visits related to treatment. Patients also have their medical records reviewed.
11460561|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
11460562|NCT01627067|Experimental|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
11460563|NCT01627054|Experimental|AT7519M|
11460564|NCT01627041|Experimental|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
11463625|NCT01605773|Active Comparator|glyburide|
11460565|NCT01627041|Experimental|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
11460566|NCT01627015|Experimental|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
11460567|NCT01627015|Active Comparator|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
11460568|NCT01627002|Experimental|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
11460569|NCT01627002|Placebo Comparator|Placebo|Placebo
11460570|NCT01626989|Active Comparator|BiPAP auto SV Advanced|BiPAP auto SV Advanced
11460571|NCT01626989|Experimental|BiPAP auto SV 4|Auto Servo Ventilation Device
11460572|NCT01626976|Experimental|Cohort 1|
11460573|NCT01626976|Experimental|Cohort 2|
11460574|NCT01626976|Experimental|Cohort 3|
11460575|NCT01626976|Experimental|Cohort 4|
11460576|NCT01626976|Experimental|Cohort 5|
11460577|NCT01626963|Experimental|SPA|Single-port access surgery
11460578|NCT01626963|Active Comparator|CL|Conventional Laparoscopic access
11460579|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
11460580|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
11460581|NCT01626937|Experimental|Non invasive ventilation with conventional treatment|
11460582|NCT01626937|Active Comparator|conventional medical treatment|
11460583|NCT01626924|Experimental|2-Iminobiotin|
11460584|NCT01626911|Experimental|CRAI|CRAI of LMWH in the celiac trunk
11460585|NCT01626911|Other|Conservative treatment|Conservative treatment without CRAI, control group
11460586|NCT01626898|Experimental|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
11460587|NCT01626898|Active Comparator|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
11460588|NCT01626885|Experimental|MP-214|
11460589|NCT01626872|Experimental|MP-214 low dose|
11460590|NCT01626872|Experimental|MP-214 middle dose|
11460591|NCT01626872|Experimental|MP-214 high dose|
11460592|NCT01626872|Active Comparator|Risperidone|
11460593|NCT01626859|Experimental|MP-214 low dose|
11460594|NCT01626859|Experimental|MP-214 middle dose|
11460595|NCT01626859|Experimental|MP-214 high dose|
11460596|NCT01626846||NF1 teenagers|
11460597|NCT01626833|Active Comparator|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx®
11460598|NCT01626833|Placebo Comparator|Placebo|Placebo
11460599|NCT01626820|Experimental|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
11460600|NCT01626820|Experimental|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
11460601|NCT01626807|Experimental|Walking school bus|
11460602|NCT01626807|No Intervention|Usual care|
11460603|NCT01626794|Experimental|VARIVAX™ VEP|
11460604|NCT01626794|Active Comparator|VARIVAX™ 2007 Process|
11460605|NCT01626768||Enrolled patients|
11460606|NCT01626755|Experimental|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.
~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.
~Sciatic nerve block: infusion of local anesthetic."
11460607|NCT01626755|Active Comparator|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.
~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.
~Sciatic nerve block: saline infusion."
11460608|NCT01626742|Placebo Comparator|Ready to drink flavored beverage|
11460609|NCT01626742|Experimental|Ready to drink flavored beverage w/ AN 777|
11460610|NCT01626729|Experimental|Traffic Light|
11460611|NCT01626729|Experimental|Traffic Light+|
11460612|NCT01626729|Experimental|Facts Up Front|
11460613|NCT01626729|Experimental|Facts Up Front+|
11460614|NCT01626729|Placebo Comparator|No front of package label|
11460615|NCT01626716|Experimental|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
11460616|NCT01626716|No Intervention|control|usual care
11460617|NCT01626703|Experimental|intervention|remiding call
11460618|NCT01626703|No Intervention|Control|No intervention
11460619|NCT01626690|Experimental|Pre-Warming|
11460620|NCT01626690|Active Comparator|Control|
11460621|NCT01626677|Experimental|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
11460622|NCT01626677|Active Comparator|Microfracture|conventional treatment method
11460623|NCT01626664|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
11460624|NCT01626664|Active Comparator|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
11460625|NCT01626651|Experimental|Ibrutinib and Ketoconazole|
11460626|NCT01626638|Experimental|Experimental|
11460627|NCT01626625|Experimental|stem cells|stem cells + hydroxy apatite
11460628|NCT01626625|Active Comparator|autograft|
11460629|NCT01626612|Experimental|a strategy based on de-escalation|
11460631|NCT01626599|Other|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
11460632|NCT01626586|Experimental|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
11460633|NCT01626586|Active Comparator|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
11460634|NCT01626586|Active Comparator|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
11460635|NCT01626573|Experimental|Itacitinib 400 mg twice a day|Itacitinib 400 mg twice a day
11460636|NCT01626573|Placebo Comparator|Itacitinib 400 mg placebo twice a day|Itacitinib 400 mg placebo twice a day
11460637|NCT01626573|Experimental|Itacitinib 100 mg twice a day|This dose group will be studied twice during the study.
11460638|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo twice a day|This dose group will be studied twice during the study.
11460639|NCT01626573|Experimental|Itacitinib 100mg once a day|Itacitinib 100mg once a day
11460640|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo once a day|Itacitinib 100 mg placebo once a day
11460641|NCT01626573|Experimental|Itacitinib 200 mg twice a day|Itacitinib 200 mg twice a day
11460642|NCT01626573|Placebo Comparator|Itacitinib 200 mg placebo twice a day|Itacitinib 200 mg placebo twice a day
11460643|NCT01626573|Experimental|Itacitinib 300 mg once a day|Itacitinib 300 mg once a day
11460644|NCT01626573|Placebo Comparator|Itacitinib 300 mg placebo once a day|Itacitinib 300 mg placebo once a day
11460645|NCT01626573|Experimental|Itacitinib 600 mg once a day|Itacitinib 600 mg once a day
11460646|NCT01626573|Placebo Comparator|Itacitinib 600 mg placebo once a day|Itacitinib 600 mg placebo once a day
11460647|NCT01626560|Other|Daptomicina|
11460648|NCT01626560|Other|Vancomycin|
11460649|NCT01626534|Active Comparator|clopidogrel group|
11460650|NCT01626534|Experimental|tricagrelor group|
11460651|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
11460652|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
11460653|NCT01626508||breast milk|breast milk used without any treatment, directly by children
11460654|NCT01626495|Experimental|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
11460655|NCT01626482|Placebo Comparator|Sham tape|
11460656|NCT01626482|Experimental|Kinesio Tape|
11460657|NCT01626469|Active Comparator|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
11460658|NCT01626469|Placebo Comparator|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
11460659|NCT01626456|Experimental|ALKS 9072, Low|
11460660|NCT01626456|Experimental|ALKS 9072, High|
11460661|NCT01626443|Active Comparator|Folic acid|
11460662|NCT01626443|Experimental|Inofolic Combi|
11460663|NCT01626430|Experimental|200 mg gd-TRF|
11460664|NCT01626430|Experimental|400 mg gd-TRF|
11460665|NCT01626430|Experimental|Placebo|
11460666|NCT01626417|No Intervention|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
11460667|NCT01626404||Patients enrolled|All patients enrolled in the study
11460668|NCT01626391|Experimental|TRx0237|
11460669|NCT01626391|Placebo Comparator|Placebo|
11460670|NCT01626378|Experimental|TRx0237 200 mg/day group|
11460671|NCT01626378|Placebo Comparator|Placebo|
11460672|NCT01626365|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
11460673|NCT01626365|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
11460674|NCT01626352|Experimental|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
11460675|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
11460676|NCT01626313|Active Comparator|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
11460677|NCT01626313|Active Comparator|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
11460678|NCT01626287|Experimental|Black tea bag|
11460679|NCT01626287|Active Comparator|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
11460680|NCT01626274|Experimental|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
11460682|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
11460683|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
11460684|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
11460685|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
11460686|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
11460687|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
11460688|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
11460689|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
11460690|NCT01626222|Experimental|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
11460691|NCT01626209|Experimental|BKM120 at: 80 and 100mg/day dose levels|
11460692|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
11460693|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
11460694|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
11460695|NCT01626131|Experimental|Exercise treatment|Aerobic and resistance training
11460696|NCT01626131|Experimental|Stretching treatment|
11460697|NCT01626118|Experimental|Indomethacin 40 mg TID|
11460698|NCT01626118|Experimental|Indomethacin 40 mg BID|
11460699|NCT01626118|Placebo Comparator|Placebo|
11460700|NCT01626118|Experimental|Indomethacin 20 mg TID|
11460701|NCT01626092|Experimental|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m^2 IV on days -9 through -5, melphalan 140 mg/m^2 IV on day -4 and Total Body Irradiation with Marrow Boosting [ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure] by Volumetric-Modulated Arc Therapy [VMAT] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
11460702|NCT01626079|Experimental|MitraClip System|Percutaneous mitral valve repair using MitraClip System
11460703|NCT01626079|No Intervention|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
11460704|NCT01626066|Experimental|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
11460705|NCT01626053|No Intervention|control group|
11460706|NCT01626053|Experimental|lifestyle counseling|These participant received the ASMART interventions.
11460707|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
11460708|NCT01626014|Experimental|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
11460709|NCT01626014|Active Comparator|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
11460710|NCT01626001|Experimental|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject < 60 minutes.
11460711|NCT01626001|Experimental|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
11460712|NCT01625988|Experimental|LY2951742|LY2951742: 150 milligrams (mg), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
11460762|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
11460713|NCT01625988|Placebo Comparator|Placebo|Placebo: 0.9% Sodium Chloride, Untied States Pharmacopoeia (USP), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
11460714|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
11460715|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
11460716|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
11460717|NCT01625949|Active Comparator|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
11460718|NCT01625949|Experimental|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
11460719|NCT01625923|Experimental|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
11460720|NCT01625910|Experimental|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
11460721|NCT01625910|Placebo Comparator|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
11460722|NCT01625897|Experimental|MP-214 low dose|
11460723|NCT01625897|Experimental|MP-214 high dose|
11460724|NCT01625897|Active Comparator|Risperidone|
11460725|NCT01625871|Experimental|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
11460726|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
11460727|NCT01625845|Experimental|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.
~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
11460728|NCT01625845|Placebo Comparator|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
11460729|NCT01625832|Experimental|1|CSO first
11460730|NCT01625832|Experimental|2|CSO second
11460731|NCT01625819|Experimental|Tai Chi|32 1-hour group sessions of Tai Chi instruction
11460732|NCT01625819|Active Comparator|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
11460733|NCT01625819|Placebo Comparator|Health Education|32 1-hour bi-weekly group sessions of health education
11460734|NCT01625819|No Intervention|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
11460735|NCT01625806|Active Comparator|RO4602522|
11460736|NCT01625806|Experimental|RO4602522 + ketoconazole|
11460737|NCT01625793|Active Comparator|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
11460738|NCT01625793|Placebo Comparator|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
11460739|NCT01625780|Experimental|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
11460740|NCT01625780|Active Comparator|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
11460741|NCT01625767|Experimental|Approach Avoidance Task experiment|Approach Avoidance Task experiment
11460742|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
11460743|NCT01625741|Experimental|rituximab|4 monthly administrations of rituximab
11460744|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
11460745|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
11460746|NCT01625715|No Intervention|Case control|Routine therapy during peanut desensitization
11460747|NCT01625715|Experimental|ketotifen|rising doses of ketotifen
11460748|NCT01625702|Experimental|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
11460749|NCT01625702|Experimental|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
11460750|NCT01625689|Experimental|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
11460751|NCT01625689|Placebo Comparator|Placebo|Placebo identical in appearance to experimental vaccine.
11460752|NCT01625676|Experimental|CIAT-Group|Patients received a modified constraint-induced therapy schedule
11460753|NCT01625676|Active Comparator|standard treatment group|patients received a standard aphasia therapy
11460754|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
11460755|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
11460756|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
11460757|NCT01625637|Experimental|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
11460758|NCT01625637|Placebo Comparator|AAT-no contingency continued assessment|
11460759|NCT01625624|Placebo Comparator|Control Food Product|
11460760|NCT01625624|Experimental|Experimental Food Product|
11460761|NCT01625611|Experimental|Naltrexone|
11460764|NCT01625572|No Intervention|general anesthesia and epidural catheter (control)|"General anaesthesia
~total intravenous anaesthesia with propofol 5-10 mg / kg / h,
~remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium
~use of a bispectral index
~monitoring with a target range of 40-60
~at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter
~plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%
~puncture with a Tuohy 18 G- needle, Lost of resistance technique
~after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
11460765|NCT01625572|Experimental|general anesthesia and regional anesthesia|"General anesthesia
~anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium
~Bispektralindex monitoring with a target range of 40-60
~at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade
~ultrasound visible needles, a special pin detection software
~under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis
~Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)
~puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
11460766|NCT01625572|Experimental|general anaesthesia and intravenous pain therapy|"General anaesthesia
~total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium
~we use a of BIS monitoring with a target range of 40-60
~at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with
~Morphine-patient-controlled-analgesia-device"
11460767|NCT01625559|Experimental|50,000 cells|Biological: MA09-hRPE Cellular therapy
11460768|NCT01625546|Experimental|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
11460769|NCT01625546|Sham Comparator|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
11460770|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
11460771|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
11460772|NCT01625520|Experimental|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
11460773|NCT01625507|Experimental|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
11460774|NCT01625494|Experimental|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.
~If OBPM is controlled on monotherapy at week 4 (SBP <140 mmHg and DBP<90 mmHg), patient will be withdrawn from the study"
11460775|NCT01625494|Experimental|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
11460776|NCT01625494|Experimental|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
11460777|NCT01625494|Experimental|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
11460778|NCT01625481|Experimental|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
11460779|NCT01625468|No Intervention|Control|Participant receives usual care
11460780|NCT01625468|Experimental|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
11460781|NCT01625455|Active Comparator|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
11460782|NCT01625455|Placebo Comparator|Placebo|Matching placebo will be given in place of aprepitant
11460783|NCT01625442|Active Comparator|Saffron|Saffron treatment group received saffron tablets daily for 45 days
11460784|NCT01625442|Active Comparator|Barberry|Barberry group received barberry tablets daily for 45 days
11460785|NCT01625442|Placebo Comparator|Placebo|Placebo group received placebo tablets daily for 45 days
11460786|NCT01625429|Experimental|neoadjuvant|
11460787|NCT01625416|Experimental|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
11460788|NCT01625416|No Intervention|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
11460789|NCT01625403|Experimental|rhBNP treated|standard of care with rhBNP
11460790|NCT01625403|Active Comparator|standard of care|standard of care
11460791|NCT01625390|Experimental|Arm 1|
11460792|NCT01625390|Active Comparator|Arm 2|
11460793|NCT01625390|Experimental|Arm 3|
11460794|NCT01625377|Active Comparator|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
11460795|NCT01625377|Experimental|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.
~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
11460796|NCT01625364|Experimental|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
11460797|NCT01625364|Experimental|SHARP program|The Staying Health-Asthma Responsible & Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
11460798|NCT01625351|Experimental|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.
~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.
~Cells for infusion are prepared using the CliniMACS System."
11460799|NCT01625338|Experimental|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
11460800|NCT01625338|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
11460801|NCT01625338|Experimental|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
11460802|NCT01625325||extremely obese|BMI ≥35kg/m2
11460803|NCT01625325||obese|BMI 30-34.9kg/m2
11460804|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
11460805|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
11460806|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
11460807|NCT01625299|Experimental|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
11460808|NCT01625299|Placebo Comparator|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
11460809|NCT01625286|Experimental|Part A: Intermittent schedule (2/5)|See intervention description below.
11460810|NCT01625286|Experimental|Part A: Intermittent schedule (4/3)|See intervention description below.
11460811|NCT01625286|Active Comparator|Part B: AZD5363 combined with paclitaxel|See intervention description below.
11460812|NCT01625286|Placebo Comparator|Part B: paclitaxel combined with placebo|See intervention description below.
11460813|NCT01625273|No Intervention|IF (Infant formula)|
11460814|NCT01625273|Experimental|IF with L. paracasei strain F19|
11460815|NCT01625260|Experimental|Gemcitabine in combination with ALT-801|
11460816|NCT01625247|Experimental|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
11460817|NCT01625247|Active Comparator|2 arm|Patients under LC. Allocation to sham drain,
11460818|NCT01625234|Experimental|X-396 (ensartinib)|Dose escalation starting at 25 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
11460819|NCT01625221|Experimental|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
11460820|NCT01625208|Experimental|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
11460821|NCT01625208|Active Comparator|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
11460822|NCT01625195|Placebo Comparator|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
11460823|NCT01625195|Active Comparator|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 50:50% corn/soybean oil as used in other randomized placebo-controlled trials.
11460824|NCT01625182|Experimental|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
11460825|NCT01625182|Placebo Comparator|Placebo|Participants received matching placebo to Fingolimod orally once daily.
11460826|NCT01625169|Other|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
11460827|NCT01625156|Experimental|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
11460828|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
11460829|NCT01625130|Active Comparator|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
11460830|NCT01625130|Placebo Comparator|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
11460831|NCT01625117|No Intervention|Control Group|
11460832|NCT01625117|Experimental|A variant of Narrative exposure therapy|
11460911|NCT01624532|Placebo Comparator|Normal Saline|Normal Saline 0.5 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
11460833|NCT01625104|Experimental|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:
~Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.
~Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers
~Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing
~Written plan from sites detailing plans to change processes of care."
11460834|NCT01625104|Placebo Comparator|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
11460835|NCT01625091|Active Comparator|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
11460836|NCT01625091|Placebo Comparator|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
11460837|NCT01625078|Experimental|Baska mask|
11460838|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
11460839|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
11460840|NCT01625052|Experimental|Baska|
11460841|NCT01625039|Experimental|Intervention|Participated in weekly educational workshops
11460842|NCT01625039|Active Comparator|Control group|Received once off educational session and materials
11460843|NCT01625026|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
11460844|NCT01625026|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
11460845|NCT01625026|Active Comparator|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
11460846|NCT01625026|Placebo Comparator|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
11460847|NCT01625013|Experimental|Synvisc-One|
11460848|NCT01625000|Experimental|MP-214 low dose|
11460849|NCT01625000|Experimental|MP-214 middle dose|
11460850|NCT01625000|Experimental|MP-214 high dose|
11460851|NCT01625000|Active Comparator|Risperidone|
11460852|NCT01625000|Placebo Comparator|Placebo|
11460853|NCT01624987|Experimental|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
11460854|NCT01624974|Experimental|MK-1029/Placebo|Participants received 4 weeks treatment with MK-1029 150 mg once daily (QD) + ML 10 mg QD in Period III and Placebo QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
11460855|NCT01624974|Experimental|Placebo/MK-1029|Participants received 4 weeks treatment with Placebo QD + ML 10 mg QD in Period III and MK-1029 150 mg QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
11460856|NCT01624961|Experimental|50 PfSPZ IV|PfSPZ Challenge
11460857|NCT01624961|Experimental|200 PfSPZ IV|PfSPZ Challenge
11460858|NCT01624961|Experimental|800 PfSPZ IV|PfSPZ Challenge
11460859|NCT01624961|Experimental|3200 PfSPZ IV|PfSPZ Challenge
11460860|NCT01624961|Experimental|2500 PfSPZ ID|PfSPZ Challenge
11460861|NCT01624948|Experimental|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
11460862|NCT01624948|Active Comparator|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
11460863|NCT01624935|Experimental|psychotherapy|psychotherapy
11460864|NCT01624935|Other|treatment as usual|TAU control
11460865|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
11460866|NCT01624857|Placebo Comparator|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
11460867|NCT01624857|Active Comparator|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
11460868|NCT01624844|Experimental|Calculation of dural sac volume|
11460869|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
11460870|NCT01624818|Experimental|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
11460871|NCT01624818|Experimental|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
11460872|NCT01624805|Experimental|Treatment (methylprednisolone, hATG, cyclosporine, G-CSF)|Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
11460873|NCT01624792|Experimental|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
11460874|NCT01624792|Experimental|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
11460989|NCT01623934||Phase 2: Mother-offspring dyad|
11460875|NCT01624766|Experimental|Arm I (everolimus, anakinra)|Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
11460876|NCT01624766|Experimental|Arm II (everolimus, denosumab)|Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
11460877|NCT01624753|Experimental|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
11460878|NCT01624740|Experimental|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
11460879|NCT01624740|Experimental|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
11460880|NCT01624727|No Intervention|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
11460881|NCT01624727|Active Comparator|Lovaza (Omega 3 ethyl esters)|
11460882|NCT01624714|Experimental|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
11460883|NCT01624714|Experimental|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
11460884|NCT01624701|Experimental|Expanded|'Ex vivo expanded cord blood cells
11460885|NCT01624675|Experimental|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
11460886|NCT01624675|Placebo Comparator|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
11460887|NCT01624662|Active Comparator|OPN-375 100 mcg|Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
11460888|NCT01624662|Active Comparator|OPN-375 200 mcg|Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
11460889|NCT01624662|Active Comparator|OPN-375 400 mcg|Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
11460890|NCT01624662|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
11460891|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
11460892|NCT01624636|Placebo Comparator|Placebo|
11460893|NCT01624636|Experimental|LFG316: 10 mg/kg (2 doses in cohort 1)|
11460894|NCT01624636|Experimental|LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).|
11460895|NCT01624610|Active Comparator|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
11460896|NCT01624610|Active Comparator|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
11460897|NCT01624597|No Intervention|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
11460898|NCT01624597|Experimental|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
11460899|NCT01624597|Experimental|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
11460900|NCT01624584|Experimental|Experimental treatment|6 sessions of anxiety treatment
11460901|NCT01624584|Active Comparator|Traditional Treatment|Six sessions of anxiety treatment
11460902|NCT01624571|Experimental|Group 1|300mg/day
11460903|NCT01624571|Experimental|Group 2|600mg/day
11460904|NCT01624571|Experimental|Group 3|900mg/day
11460905|NCT01624571|Placebo Comparator|Placebo|Control Group
11460906|NCT01624558|Experimental|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
11460907|NCT01624558|No Intervention|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
11460908|NCT01624545|Active Comparator|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
11460909|NCT01624545|No Intervention|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
11460910|NCT01624532|Experimental|rPA vaccine containing alhydrogel 1.0 mL|GC1109 1.0 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
11460912|NCT01624532|Experimental|rPA vaccine containing alhydrogel 0.5 mL|GC1109 0.5 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
11460913|NCT01624532|Experimental|rPA vaccine containing alhydrogel 0.3 mL|GC1109 0.3 mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects
11460914|NCT01624519|Other|1|
11460915|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
11460916|NCT01624506||Fundoplication - advanced GERD|Patients treated with laparoscopic fundoplication who have one or more of the following: Large hernia (>3cm), Barrett's esophagus, motility disorder, Grade C or D esophagitis by LA Classification
11460917|NCT01624506||Fundoplication - moderate GERD|Patients treated with laparoscopic fundoplication who do NOT have the following: Large hernia (>3cm), Barrett's esophagus, motility disorder, Grade C or D esophagitis by LA Classification
11460918|NCT01624493|Experimental|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
11460919|NCT01624493|Experimental|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
11460920|NCT01624480|Experimental|Armodafinil 50 mg|In period 1, patients will receive a single 50-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose daily on days 1 through 42.
11460921|NCT01624480|Experimental|Armodafinil 100 mg|In period 1, patients will receive a single 100 mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1 then daily 100-mg doses on days 2 through 42.
11460922|NCT01624480|Experimental|Armodafinil 150 mg|In period 1, patients will receive a single 150-mg dose of armodafinil on day 1. In period 2, patients will receive a single 50-mg dose on day 1, 100-mg doses on days 2 and 3, then daily 150-mg doses on days 4 through 42.
11460923|NCT01624467|Experimental|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
11460924|NCT01624454|Active Comparator|large volume|bowel cleansing with PEG
11460925|NCT01624454|Active Comparator|Osmotic|
11460926|NCT01624441|Experimental|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11460927|NCT01624428|Active Comparator|varenicline|
11460928|NCT01624428|Placebo Comparator|Placebo|
11460929|NCT01624402|Experimental|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
11460930|NCT01624402|Active Comparator|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
11460931|NCT01624389|Experimental|F18-AV45|
11460932|NCT01624376|Active Comparator|DLX105|DLX105 local injection into the identified fistula(s)
11460933|NCT01624376|Placebo Comparator|Placebo Injection|
11460934|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
11460935|NCT01624337|Experimental|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
11460936|NCT01624337|Placebo Comparator|Placebo|Matching placebo control
11460937|NCT01624311|Experimental|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
11460938|NCT01624311|Other|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
11460939|NCT01624298|No Intervention|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
11460940|NCT01624298|Experimental|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
11460941|NCT01624285|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
11460942|NCT01624285|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID.
11460943|NCT01624272|No Intervention|Control|Usual care
11460944|NCT01624272|Experimental|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
11460945|NCT01624272|Experimental|Controlled breathing exercises|Yoga Pranayama breathing exercises
11460946|NCT01624259|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks
~Metformin: at least 1500 mg/day, oral, for 26 weeks"
11460947|NCT01624259|Active Comparator|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks
~Metformin: at least 1500 mg/day, oral, for 26 weeks"
11460948|NCT01624246|Experimental|Ceftaroline fosamil/Avibactam|
11460949|NCT01624233|Experimental|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
11460950|NCT01624220|Experimental|Hypofractionated Radiation|"All patients receive CT-guided spinal SBRT using IMRT to maximize conformality of treatment plan to target volume, while sparing normal structures. Dose given to tumor and number of treatments received determined by patient's doctor.
~In second stage, characterize tolerance of esophagus to hypofractionated radiation doses through prospective constraint relaxation and toxicity monitoring. Data collected from Group 1 in first stage will give data on dose delivered to esophagus. Second stage of protocol will begin accrual once Group 1 has filled. Dose constraints used for Groups 3 allow higher dose. Dose constraints for Group 4 represent modest increase of esophageal dose maximums."
11460990|NCT01623921|Other|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
11460991|NCT01623921|Active Comparator|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
11460951|NCT01624220|Experimental|ExacTrac Positioning System|Analysis performed of ExacTrac positioning system with and without fiducial guidance. Four dimensional CT datasets for simulation will allow use of data from this portion of protocol to characterize degree to which organ at risk (OAR) motion is relevant at each spinal level. 20 patients accrued in two groups of 10, with 10 patients in each rostral-caudal position in the spine (Group 1: T4-T12, Group 2: L1-L5). Imaging done with fiducial markers for this study will not impact patient management. Patients will treated with standard dose constraints to normal tissues.
11460952|NCT01624207|Experimental|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
11460953|NCT01624207|Active Comparator|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
11460954|NCT01624194|Active Comparator|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
11460955|NCT01624194|Placebo Comparator|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
11460956|NCT01624168|Placebo Comparator|Anxiety Management Education|
11460957|NCT01624168|Experimental|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
11460958|NCT01624168|Experimental|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
11460959|NCT01624155|Experimental|Women taking teratogens|Women taking teratogens
11460960|NCT01624142|Experimental|Evolocumab|Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
11460961|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
11460962|NCT01624116|Active Comparator|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
11460963|NCT01624116|Active Comparator|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
11460964|NCT01624116|Active Comparator|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
11460965|NCT01624116|Active Comparator|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
11460966|NCT01624103|Experimental|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
11460967|NCT01624103|Experimental|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
11460968|NCT01624090|Experimental|1/mithramycin|Single agent intravenous (IV) mithramycin
11460969|NCT01624077|Experimental|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
11460970|NCT01624064|Active Comparator|Enalapril, Proteinuria < 1g/day|
11460971|NCT01624064|Placebo Comparator|Calcium, Proteinuria < 1g/day|
11460972|NCT01624064|Active Comparator|Enalapril, Proteinuria > 1g/day|
11460973|NCT01624064|Placebo Comparator|Calcium, Proteinuria > 1g/day|
11460974|NCT01624051|Active Comparator|Body Surface Area Dosing|Standard dosing arm based on body surface area
11460975|NCT01624051|Experimental|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
11460976|NCT01624038|Active Comparator|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
11460977|NCT01624038|Experimental|Hydroxyurea, Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.
~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
11460978|NCT01624025|Experimental|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
11460979|NCT01624025|Active Comparator|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
11460980|NCT01624012|Active Comparator|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
11460981|NCT01624012|Active Comparator|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
11460982|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
11460983|NCT01623973|Experimental|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
11460984|NCT01623973|Active Comparator|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
11460985|NCT01623947|Placebo Comparator|Placebo|
11460986|NCT01623947|Active Comparator|2.8 g Sustamine|
11460987|NCT01623947|Active Comparator|19.6 g Sustamine|
11460988|NCT01623934||Phase 1: Pregnant women|
11460992|NCT01623921|Active Comparator|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
11460993|NCT01623921|Active Comparator|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
11460994|NCT01623908|Experimental|Zoledronate|
11460995|NCT01623869|Experimental|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11460996|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
11460997|NCT01623843|Active Comparator|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
11460998|NCT01623843|Experimental|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
11460999|NCT01623830|Experimental|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
11461000|NCT01623830|Active Comparator|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
11461001|NCT01623817|No Intervention|Vancomcyin, maintain dose|This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
11461002|NCT01623817|Experimental|Vancomycin loading|This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
11461003|NCT01623804|Active Comparator|Low intensity, pulsed ultrasound|
11461004|NCT01623804|Sham Comparator|Sham ultrasound|
11461005|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
11461006|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
11461007|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
11461008|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
11461009|NCT01623752||Patients with Rheumatoid Arthritis|
11461010|NCT01623752||Patients with Psoriasis Arthritis|
11461011|NCT01623739|Active Comparator|Type 1 implant placement|Placement of a dental implant: Implant is placed immediately following tooth extraction in one surgical procedure
11461012|NCT01623739|Active Comparator|Type 2 implant placement|Placement of a dental implant: Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
11461013|NCT01623726|Experimental|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
11461014|NCT01623726|Placebo Comparator|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
11461015|NCT01623713|Active Comparator|Risperidone|
11461016|NCT01623713|Experimental|iloperidone|
11461017|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
11461018|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
11461019|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
11461020|NCT01623687|Active Comparator|Regenerex|
11461021|NCT01623687|Active Comparator|Lub cup|
11461022|NCT01623687|Active Comparator|SP II|
11461023|NCT01623687|Active Comparator|Corail|
11461024|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
11461025|NCT01623648|Experimental|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
11461026|NCT01623648|Active Comparator|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
11461027|NCT01623648|Placebo Comparator|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
11461028|NCT01623635|Experimental|Case - adnexal|
11461029|NCT01623635|Placebo Comparator|placebo - adnexal|
11461030|NCT01623635|Experimental|case - uterine|
11461031|NCT01623635|Placebo Comparator|placebo - uterine|
11461032|NCT01623622|Experimental|HC-58 low dose|Low dose
11461033|NCT01623622|Experimental|HC-58 high dose|High dose
11461034|NCT01623622|Placebo Comparator|Placebo|
11461035|NCT01623609|Experimental|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
11461036|NCT01623609|Experimental|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
11461037|NCT01623609|Experimental|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
11461038|NCT01623596|Experimental|Fingolimod|
11461039|NCT01623596|Active Comparator|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
11461040|NCT01623583|Experimental|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
11461041|NCT01623583|Active Comparator|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
11461042|NCT01623570|Experimental|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
11461043|NCT01623570|Experimental|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
11461044|NCT01623557|Active Comparator|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
11461045|NCT01623557|Active Comparator|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
11461046|NCT01623557|Active Comparator|Group 3: Unvaccinated Infectivity Controls|
11461047|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
11461048|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
11461049|NCT01623531|Active Comparator|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
11461050|NCT01623531|Placebo Comparator|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
11461051|NCT01623518|Experimental|ChAdOx1-NP+M1|
11461052|NCT01623505|Experimental|Champix|
11461053|NCT01623505|Experimental|Long & Combination patch treatment|
11461054|NCT01623505|Experimental|Standard patch treatment|
11461055|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
11461056|NCT01623479||Hypotrichosis of the Eyelashes|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
11461057|NCT01623466|Experimental|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
11461058|NCT01623466|Experimental|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
11461059|NCT01623453||Low dose group|Group1. Low dose group
11461060|NCT01623453||High dose group|Group2. High dose group
11461061|NCT01623440||Placebo/Naltrexone and fMRI|A placebo or Naltrexone will be given before fMRI. All participants will undergo both procedures. Naltrexone/placebo are not used as an intervention.
11461062|NCT01623427|Experimental|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
11461063|NCT01623427|Active Comparator|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
11461064|NCT01623414||Healthy schoolchildren|
11461065|NCT01623401|Experimental|TR-701 FA|TR-701 FA 200 mg oral once daily
11461066|NCT01623388||Phase I|
11461067|NCT01623375|Experimental|s.c.|
11461068|NCT01623375|Experimental|i.v.|
11461069|NCT01623362|Experimental|Low-fluoride acidic dentifrice|
11461070|NCT01623362|No Intervention|Conventional dentifrice|1100µgF/g-pH7.0
11461071|NCT01623362|Experimental|neutral pH and low-fluoride dentifrice|550 ppm pH 7
11461072|NCT01623349|Experimental|Arm BKM|BKM120 and Olaparib
11461073|NCT01623349|Experimental|Arm BYL|BYL719 and Olaparib
11461074|NCT01623336|Active Comparator|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
11461075|NCT01623336|Experimental|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
11461076|NCT01623323|Other|Fluticasone|
11461077|NCT01623310|Experimental|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
11461078|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
11461079|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
11461080|NCT01623284|Experimental|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
11461081|NCT01623271|Experimental|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.
~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
11461082|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
11461083|NCT01623258||Research|SOC with sentinel lymph node analysis
11461084|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
11461085|NCT01623232|Experimental|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
11461086|NCT01623232|Experimental|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
11463626|NCT01605760|No Intervention|non immunotherapy treatment|
11461087|NCT01623232|Experimental|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
11461088|NCT01623232|Active Comparator|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
11461089|NCT01623219|Experimental|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
11461090|NCT01623206|Experimental|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
11461091|NCT01623193|Active Comparator|Control|Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery
11461092|NCT01623193|Experimental|Treatment|Patients receive all-blood cardiolpegia for myocardial protection during surgery
11461093|NCT01623180|Experimental|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
11461094|NCT01623180|Active Comparator|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
11461095|NCT01623167|Experimental|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
11461096|NCT01623167|Experimental|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
11461097|NCT01623167|Experimental|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
11461098|NCT01623167|Experimental|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
11461099|NCT01623154|Other|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
11461100|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
11461101|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
11461102|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
11461103|NCT01623128|Experimental|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
11461104|NCT01623128|Placebo Comparator|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
11461105|NCT01623115|Placebo Comparator|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
11461106|NCT01623115|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
11461107|NCT01623102|Experimental|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
11461108|NCT01623102|Active Comparator|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11461109|NCT01623089||severe asthma|
11461110|NCT01623076||Neuromyelitis Optica Spectrum Disorder|Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
11461111|NCT01623076||Transverse Myelitis and Optic Neuritis|Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
11461112|NCT01623076||Healthy Controls|patients without a history of CNS inflammation
11461113|NCT01623076||Neuromyelitis Optica|patients diagnosed with NMO
11461114|NCT01623063|Experimental|Infertile|patients from our human reproduction center
11461115|NCT01623063|Active Comparator|Fertile|patients with comproved fertility
11461116|NCT01623050|Experimental|SinuSys Dilation System|Maxillary Sinus Dilation
11461117|NCT01623037|Experimental|CoolSculpting Treatment Group|The single arm will include all subjects treated on each flank with the CoolSculpting System and CoolCurve+ applicator. Treatment temperature and duration are defined in the protocol.
11461118|NCT01623024|Experimental|Vitamin D and Lifestyle counseling|
11461119|NCT01623024|Active Comparator|Lifestyle counseling|
11461120|NCT01623011|Experimental|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
11461121|NCT01623011|Active Comparator|Shoulder Arthroscopy|Shoulder arthroscopy only.
11461122|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
11461123|NCT01622998|Active Comparator|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
11461124|NCT01622998|Experimental|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
11461125|NCT01622972|Experimental|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
11461126|NCT01622972|Experimental|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
11461202|NCT01622387|Experimental|Radial artery|Use of the radial artery as a conduit in CABG surgery
11461127|NCT01622972|Experimental|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
11461128|NCT01622959|Active Comparator|acupuncture|"Inclusion criteria:
~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) > 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.
~Exclusion criteria:
~Temperature > 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED > 4 times in the previous 3 months with the same condition."
11461129|NCT01622959|Sham Comparator|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%.
11461130|NCT01622946|Active Comparator|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
11461131|NCT01622946|Placebo Comparator|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
11461132|NCT01622933|Experimental|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.
~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
11461133|NCT01622933|Experimental|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.
~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
11461134|NCT01622920|Other|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
11461135|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for > 1-year < 5 years duration
11461136|NCT01622881|Active Comparator|Nefopam|
11461137|NCT01622881|Placebo Comparator|Control|
11461138|NCT01622868|Experimental|Arm A (WBRT or SRS)|Patients undergo WBRT 5 days a week for 3 weeks for a total of 15 treatments, or SRS for 1 treatment.
11461139|NCT01622868|Experimental|Arm B (lapatinib ditosylate, WBRT or SRS)|Patients undergo WBRT or SRS as in Arm A. Patients also receive lapatinib ditosylate PO QD for 6 weeks.
11461140|NCT01622855|Experimental|PPRS video|Prevention of post sexual assault stress
11461141|NCT01622855|No Intervention|Standard care|Receipt of standard services
11461142|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
11461143|NCT01622829|Experimental|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
11461144|NCT01622829|Experimental|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
11461145|NCT01622829|No Intervention|group 3|control, usual physiotherapy
11461146|NCT01622803|Active Comparator|parallel stent|parallel stent insertion group
11461147|NCT01622803|Active Comparator|Y-stent|Y-stent insertion group
11461148|NCT01622790|Experimental|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
11461149|NCT01622790|Experimental|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
11461150|NCT01622777|Experimental|Rosuvastatin|20 mg daily of oral rosuvastatin
11461151|NCT01622777|Placebo Comparator|Placebo|
11461152|NCT01622764|Experimental|Molecular imaging with 89Zr-RO5323441|
11461153|NCT01622725|Experimental|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
11461154|NCT01622725|Active Comparator|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
11461155|NCT01622712|Experimental|Unilateral inguinal hernia|A Nitinol containing large pore polypropylene mesh will be placed in patients with unilateral inguinal hernia.
11461156|NCT01622699|Experimental|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
11461157|NCT01622699|Active Comparator|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
11461158|NCT01622686|No Intervention|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
11461159|NCT01622686|Experimental|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
11461203|NCT01622387|Active Comparator|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
11461204|NCT01622374|Active Comparator|Silence|the subjects received 10 minutes of silence through headphone
11461205|NCT01622374|Experimental|Music for the mind|
11461206|NCT01622374|Experimental|Mozart music|
11461160|NCT01622673|Experimental|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
11461161|NCT01622673|Experimental|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
11461162|NCT01622673|Experimental|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
11461163|NCT01622673|Experimental|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
11461164|NCT01622673|Experimental|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
11461165|NCT01622673|Experimental|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
11461166|NCT01622660|Experimental|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
11461167|NCT01622647|Active Comparator|NCPAP Group|Group of patients that do receive NCPAP treatment
11461168|NCT01622647|No Intervention|No NCPAP|subjects will not receive NCPAP
11461169|NCT01622634|Active Comparator|Higher Protein Diet (PRO)|
11461170|NCT01622634|Active Comparator|Higher Carbohydrate Diet (CARB)|
11461171|NCT01622634|Active Comparator|PRO & Interval Exercise (PRO+EX)|
11461172|NCT01622634|Active Comparator|CARB & Interval Exercise (CARB+EX)|
11461173|NCT01622621|Active Comparator|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
11461174|NCT01622621|Active Comparator|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
11461175|NCT01622621|Active Comparator|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
11461176|NCT01622621|Active Comparator|Observation SBRT|Patient decides with doctor to undergo SBRT.
11461177|NCT01622608|Experimental|Kiosk Users|
11461178|NCT01622608|No Intervention|Non-Kiosk Users|
11461179|NCT01622569|Active Comparator|OPN-375 100 μg BID|"Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks
~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
11461180|NCT01622569|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
11461181|NCT01622569|Active Comparator|OPN-375 200 μg BID|"Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks
~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
11461182|NCT01622569|Active Comparator|OPN-375 400 μg BID|"Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks
~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
11461183|NCT01622556|Experimental|Reduced Intensity Conditioning with UCB Transplant|
11461184|NCT01622543|Active Comparator|Folfox plus Bevacizumab and Reolysin|
11461185|NCT01622543|Active Comparator|Folfox plus Bevacizumab|
11461186|NCT01622530||Amputees|upper limb amputees
11461187|NCT01622530||Non-amputees|No longer recruiting non-amputees
11461188|NCT01622504|Experimental|Test Product Dose 1|
11461189|NCT01622504|Experimental|Test Product Dose 2|
11461190|NCT01622504|Active Comparator|Comparator Product|
11461191|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
11461192|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy
~Clinically negative-node after NAC
~Clinically positive-node after NAC"
11461193|NCT01622465|Experimental|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
11461194|NCT01622465|Active Comparator|Conventional exercises|Patients will participate only of the conventional exercises program.
11461195|NCT01622439|Experimental|Single, open labeld.|
11461196|NCT01622426|Active Comparator|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
11461197|NCT01622426|Active Comparator|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
11461198|NCT01622413|Experimental|Endscopy|
11461199|NCT01622413|Active Comparator|Microsurgery|
11461200|NCT01622400|Experimental|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
11461201|NCT01622400|No Intervention|Control group|125 subjects who don't participate in the therapeutic education program
11461209|NCT01622361|Experimental|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
11461210|NCT01622348|Placebo Comparator|Placebo|Saline for Injection
11461211|NCT01622348|Active Comparator|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
11461212|NCT01622348|Active Comparator|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
11461213|NCT01622335|Placebo Comparator|General anesthesia with oxygen|General anesthesia and Air
11461214|NCT01622335|Experimental|nitrous oxide and general anesthesia|General anesthesia with Nitrous Oxide
11461215|NCT01622322|Experimental|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
11461216|NCT01622322|Placebo Comparator|Oxygen|Subjects will receive General anesthesia with oxygen.
11461217|NCT01622309|Active Comparator|eggplant meal|13 g meal of eggplant/day
11461218|NCT01622309|Placebo Comparator|cassava meal|13 g of placebo/day
11461219|NCT01622296|Active Comparator|Sodium Bicarbonate with Lidocaine|
11461220|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
11461221|NCT01622283|Experimental|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
11461222|NCT01622283|Active Comparator|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
11461223|NCT01622257|Experimental|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
11461224|NCT01622257|Experimental|Metformin|Metformin oral tablets 500 mg were given three times daily
11461225|NCT01622257|Experimental|Cavitation US + metformin|Combination of both Cavitation US + Metformin
11461226|NCT01622244|Experimental|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
11461227|NCT01622244|Active Comparator|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
11461228|NCT01622231|Experimental|GW685698X|GW685698X 55mcg/day
11461229|NCT01622218|Experimental|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
11461230|NCT01622218|No Intervention|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
11461231|NCT01622205|Experimental|Active|Early supported discharge
11461232|NCT01622205|Other|Control|Ordinary rehabilitation
11461233|NCT01622192|Experimental|Automated probe|
11461234|NCT01622179|Experimental|Indirectly|The epitenon was repaired and sewed indirectly.
11461235|NCT01622179|Placebo Comparator|Directly|The epitenon was unrepaired and sewed directly.
11461236|NCT01622166|Experimental|art therapy|12 sessions of art therapy / 6 weeks
11461237|NCT01622166|No Intervention|TAU|treatment as usual / 6 weeks
11461238|NCT01622153|Placebo Comparator|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
11461239|NCT01622153|Active Comparator|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
11461240|NCT01622127||incisional hernias|
11461241|NCT01622114|Experimental|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.
~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
11461242|NCT01622114|Active Comparator|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.
~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
11461243|NCT01622101|Experimental|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
11461244|NCT01622101|Placebo Comparator|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
11461245|NCT01622088|Experimental|Dexpramipexole|
11463627|NCT01605760|Active Comparator|sublingual immunotherapy course|
11461246|NCT01622075|Experimental|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
11461247|NCT01622075|Active Comparator|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
11461248|NCT01622062|Experimental|Group 1|"Patients with WHO Category II exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
11461249|NCT01622062|Experimental|Group 2|"Patients with WHO Category III exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
11461250|NCT01622062|Active Comparator|Group 3|"Patients with WHO Category III exposure receive PEP with PVRV using the updated 2-site TRC (2-2-2-0-2) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
11461251|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
11461252|NCT01622036||Cancer patients undergoing first medical oncology visit.|
11461253|NCT01622023|Experimental|Study group|intrauterine insemination after 24 hours
11461254|NCT01622023|Active Comparator|Control group|intrauterine insemination after 48 hours
11461255|NCT01622010|Experimental|Standard care with video enhancement|
11461256|NCT01622010|Active Comparator|Standard care|
11461257|NCT01621997|Experimental|operation inspection|During retraining the patients performed bag exchange under the supervision of a nurse. The nurse ensured that each error listed in the NAC form should be avoided, thus immediately corrected any wrong steps if only.
11461258|NCT01621997|Experimental|verbal education|"Patients in the oral education group also underwent retraining every 2 months. A nurse would address all items in the NAC form one by one, to remind the patient of the key points of bag exchange. Scores calculated by the sum of error items during the bag exchange for patients in technique inspection group, or by the sum of yes in the interactive quiz for patients in verbal education group."
11461259|NCT01621997|Experimental|usual care|Patients in the usual care group did not receive any retraining
11461260|NCT01621984|Experimental|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
11461261|NCT01621984|No Intervention|without Therapeutic Riding/ Hippotherapy|
11461262|NCT01621971|Experimental|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
11461263|NCT01621971|Active Comparator|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
11461264|NCT01621958|Experimental|Motor training|
11461265|NCT01621958|Placebo Comparator|Intensity control|
11461266|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
11461267|NCT01621932|Active Comparator|Surgical approach 1|Direct anterior surgical approach with capsulectomy
11461268|NCT01621932|Active Comparator|Surgical approach 2|Direct anterior approach without capsulectomy
11461269|NCT01621906|Experimental|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
11461270|NCT01621906|Experimental|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to [18F] FLT PET at baseline (< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
11461271|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia & femur on which a Subchondroplasty procedure is performed
11461272|NCT01621880|Active Comparator|Bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11461273|NCT01621880|Active Comparator|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
11461274|NCT01621867|Active Comparator|pGM169/GL67A (CFTR Gene/Lipid Vector)|
11461275|NCT01621867|Placebo Comparator|Placebo|
11461276|NCT01621854|Experimental|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
11461277|NCT01621841||Glaucoma subjects|
11461278|NCT01621841||heathly subjects|
11461279|NCT01621828|Other|video|video showing a patient's pathway into the operating room.
11461280|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
11461281|NCT01621815|Active Comparator|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
11461282|NCT01621815|Active Comparator|ADD|Adolescents diagnosed with ADD (without hyperactive element)
11461283|NCT01621815|Active Comparator|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
11461284|NCT01621815|Active Comparator|PDD|Adolescents diagnosed with PDD Spectrum Disorders
11461285|NCT01621815|Active Comparator|Control|Adolescents without a psychiatric diagnosis
11461286|NCT01621802|Experimental|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
11463628|NCT01605747|Experimental|Culturelle|
11461287|NCT01621802|Active Comparator|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
11461288|NCT01621802|Experimental|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
11461289|NCT01621802|Active Comparator|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
11461290|NCT01621802|Experimental|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
11461291|NCT01621802|Active Comparator|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
11461292|NCT01621789|Experimental|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
11461293|NCT01621776|Active Comparator|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
11461294|NCT01621776|Active Comparator|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
11461295|NCT01621776|Active Comparator|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
11461296|NCT01621763|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
11461297|NCT01621763|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
11461298|NCT01621750|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
11461299|NCT01621750|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
11461300|NCT01621737|Experimental|Oxytocin: Low Dose|42 IU BID for the six weeks
11461301|NCT01621737|Experimental|Oxytocin: High Dose|84 IU BID for six weeks
11461302|NCT01621737|Placebo Comparator|Placebo|
11461303|NCT01621724|Experimental|Single arm cohort study|WT1 TCR-transduced T cells
11461304|NCT01621711|No Intervention|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
11461305|NCT01621711|Experimental|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
11461306|NCT01621698|Active Comparator|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
11461307|NCT01621698|Active Comparator|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
11461308|NCT01621685|Experimental|Spirometry, auscultation, questionnaire|>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
11461309|NCT01621672|Experimental|Revlimid|Revlimid dosing will be in the morning at the same time each day
11461310|NCT01621672|No Intervention|No further treatment|No treatment control.
11461311|NCT01621659|Experimental|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
11461312|NCT01621659|No Intervention|Observational arm|Participants randomized to observational arm will receive usual care.
11461313|NCT01621646|Placebo Comparator|egg white (control)|egg whites, 4 ounces per day for six months
11461314|NCT01621646|Experimental|eggs|eggs, 2 large per day for 6 months
11461315|NCT01621633|Experimental|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
11461316|NCT01621633|Experimental|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
11461317|NCT01621633|Experimental|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
11461318|NCT01621620|Experimental|yohimbin|
11461319|NCT01621594|Experimental|1|Subjects with Clinical indication for a coronary CTangiography exam
11461320|NCT01621581|Experimental|Single Arm|AAV2-GDNF vector will be delivered to each patient
11461321|NCT01621568|Experimental|Arm 1|Single Group Assignment for Thymoma and Thymic Carcimoma
11461322|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
11461323|NCT01621542|Experimental|WT2725|WT2725; injection
11461324|NCT01621516||Healthy controls|10 healthy volunteers
11461325|NCT01621516||Solitary small bowel transplant patients|3
11461326|NCT01621516||Liver/small bowel transplant patients|3
11461327|NCT01621490|Experimental|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
11461328|NCT01621490|Experimental|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
11461329|NCT01621490|Experimental|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
11461330|NCT01621490|Experimental|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
11461331|NCT01621490|Experimental|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
11461332|NCT01621490|Experimental|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
11461333|NCT01621477|Experimental|Treatment|"All study participants.
~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
11461334|NCT01621464|Placebo Comparator|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
11461335|NCT01621464|Experimental|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
11461336|NCT01621451|Active Comparator|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3~4 days after EMR/ESD
11461337|NCT01621451|Active Comparator|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
11461338|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
11461339|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
11461340|NCT01621399|Placebo Comparator|Vehicle|Treatment with the vehicle (placebo)
11461341|NCT01621399|Experimental|Product 55394|Treatment with product 55394
11461342|NCT01621386|Experimental|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
11461343|NCT01621373|Other|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
11461344|NCT01621360|Active Comparator|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
11461345|NCT01621360|Active Comparator|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
11461346|NCT01621334|Experimental|Motivational Enhancement Therapy|Motivational Enhancement Therapy
11461347|NCT01621334|Other|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
11461348|NCT01621321|Experimental|Steroid group|
11461349|NCT01621321|Experimental|Voriconazole group|
11461350|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
11461351|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
11461352|NCT01621282|Experimental|Education|Departments passed 6-month interactive educational course
11461353|NCT01621282|No Intervention|No Education|Departments not passed 6-month interactive educational course
11461354|NCT01621269|Experimental|Fingolimod|
11461355|NCT01621256|Experimental|Ancrod|Ancrod
11461356|NCT01621256|Placebo Comparator|Saline solution|Saline solution
11461357|NCT01621243|Placebo Comparator|nab-paclitaxel, gemcitabine, placebo|"Part A: Not applicable.
~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
11461358|NCT01621243|Experimental|nab-paclitaxel, gemcitabine, necuparanib|"Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.
~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
11461359|NCT01621230|Active Comparator|Epidural fentanyl|A continuous epidural infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 ml/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 mL/hr for pain. Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed.
11461360|NCT01621230|Placebo Comparator|Epidural bupivacaine plus fentanyl|A continuous epidural infusion of bupivacaine plus fentanyl during the second stage (i.e. 10 cm dilation) of labor. Epidural infusion are 10 ml/hr basal infusion plus 5 ml/hr demand dose via patient-controlled epidural analgesia (PCEA). Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed .
11461361|NCT01621217|Experimental|Cetuximab, Mitomycin C, Fluoruracil|
11461362|NCT01621204|Experimental|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
11461363|NCT01621204|Active Comparator|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
11461364|NCT01621191|Experimental|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
11461365|NCT01621178|Active Comparator|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
11461366|NCT01621178|Experimental|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
11461367|NCT01621178|Experimental|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
11461368|NCT01621165|Active Comparator|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
11461369|NCT01621165|Placebo Comparator|Placebo|
11461370|NCT01621152|Other|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
11461371|NCT01621152|Active Comparator|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
11461372|NCT01621139|Experimental|Real acupuncture|Real acupuncture group
11461373|NCT01621139|Sham Comparator|Sham acupuncture|Sham acupuncture group
11461374|NCT01621126|Experimental|Intra-op neuromonitoring|
11461421|NCT01620788|Active Comparator|Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)|
11461375|NCT01621113|Experimental|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
11461376|NCT01621113|Placebo Comparator|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
11461377|NCT01621100|Experimental|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system [a controlled release oral drug delivery system in the form of a tablet]) hydromorphone
11461378|NCT01621087|Experimental|Safflower oil|
11461379|NCT01621087|No Intervention|Control group (no diet instruction)|
11461380|NCT01621074|Active Comparator|Sodium bicarbonate|
11461381|NCT01621074|Placebo Comparator|Placebo|
11461382|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
11461383|NCT01621061||High altitude control|Healthy highlanders
11461384|NCT01621061||Low altitude control|Healthy lowlanders
11461385|NCT01621035||elderly (> 70 y)|
11461386|NCT01621022|Active Comparator|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
11461387|NCT01621022|Active Comparator|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
11461388|NCT01621022|Active Comparator|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
11461389|NCT01621009|Active Comparator|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
11461390|NCT01621009|Active Comparator|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
11461391|NCT01621009|Placebo Comparator|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
11461392|NCT01621009|Placebo Comparator|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
11461393|NCT01620996|Active Comparator|1|Duffus Street Medical Centre
11461394|NCT01620996|Active Comparator|2|Sydney Family Practice
11461395|NCT01620996|No Intervention|no counseling|HRA assessment pre and post but no counselling
11461396|NCT01620983|Experimental|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
11461397|NCT01620983|Active Comparator|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
11461398|NCT01620983|Other|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
11461399|NCT01620970|Experimental|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
11461400|NCT01620957||Coma patients|
11461401|NCT01620944|Experimental|Arm1: ATV/RTVHS+3TC|
11461402|NCT01620944|Active Comparator|Arm2: ATV/RTVHS+TDF/FTC|
11461403|NCT01620931|Experimental|RO5469754|
11461404|NCT01620931|Placebo Comparator|Placebo|
11461405|NCT01620918|Experimental|2 types of healing abutment|Patients who are in need of minimal 2 dental implants, who will receive both types of healing abutments.
11461406|NCT01620905|Experimental|Cervical spine manipulation|Subjects received cervical spine manipulation
11461407|NCT01620892||Unicondylar knee replacement|This is a non-intervational, retrospective, observational study of a case series cohort of patients who received a particular surgical operation during a specified time period.
11461408|NCT01620866|Experimental|EMDR|
11461409|NCT01620866|No Intervention|TAU|Treatment as usual (TAU)
11461410|NCT01620840||Lacosamid-i.v. treatment|
11461411|NCT01620827|Active Comparator|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
11461412|NCT01620827|Active Comparator|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
11461413|NCT01620814|Experimental|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
11461414|NCT01620814|Experimental|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
11461415|NCT01620814|Experimental|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
11461416|NCT01620801|Experimental|Low dose|AAV8-hFIX19
11461417|NCT01620801|Experimental|Middle dose|AAV8-hFIX19
11461418|NCT01620801|Experimental|High dose|AAV8-hFIX19
11461419|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 50mg|
11461422|NCT01620788|Active Comparator|Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)|
11461423|NCT01620775|Experimental|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
11461424|NCT01620775|Active Comparator|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
11461425|NCT01620775|Experimental|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
11461426|NCT01620775|Experimental|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
11461427|NCT01620762|Experimental|Cat-Pad Treatment 1|Cat-PAD Treatment 1
11461428|NCT01620762|Experimental|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
11461429|NCT01620762|Placebo Comparator|Placebo|Placebo
11461430|NCT01620749|Experimental|MEL050|
11461431|NCT01620736|Experimental|Raltegravir|Treatment with raltegravir for 8 wks
11461432|NCT01620723|Experimental|New breastfeeding programme|"The breastfeeding programme consists of four core elements:
~breastfeeding is a parental task
~skin to skin contact during the first three days
~frequent breastfeeding at least 8 times a day
~good positioning, preferable in a laid back position
~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
11461433|NCT01620723|Active Comparator|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
11461434|NCT01620710|Other|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)
~This arm has already finished recruitment"
11461435|NCT01620710|Other|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
11461436|NCT01620697||Perirenal fat|
11461437|NCT01620684|Active Comparator|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
11461438|NCT01620684|Placebo Comparator|sugar pill|Overnight treatment with placebo capsules
11461439|NCT01620671|Active Comparator|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
11461440|NCT01620671|Active Comparator|Fast-track surgery|The patients who will have fast-track surgery will be included.
11461441|NCT01620658|Active Comparator|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
11461442|NCT01620658|Experimental|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
11461443|NCT01620658|Experimental|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
11461444|NCT01620645||COPD, GOLD II severity or above|
11461445|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
11461446|NCT01620619|Active Comparator|Arthroscopic Bankart Repair & Rotator Interval Closure|
11461447|NCT01620619|Active Comparator|Arthoscopic Bankart Repair alone|
11461448|NCT01620606|Experimental|SLCBT|Social Learning and Cognitive Behavioral Therapy
11461449|NCT01620606|Experimental|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
11461450|NCT01620606|Active Comparator|ES|Education and Support
11461451|NCT01620593|Placebo Comparator|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
11461452|NCT01620593|Active Comparator|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
11461453|NCT01620580|Active Comparator|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.
~Week 3."
11461454|NCT01620580|Active Comparator|Dietary Information|Control arm
11461455|NCT01620567|Placebo Comparator|chickpeas/potatoes|1 potato/day or 1 cup chickpeas
11461456|NCT01620567|Active Comparator|avocados|1 avocados/day
11461457|NCT01620554|Experimental|BF2.649 5mg|
11461458|NCT01620554|Experimental|BF2.649 10mg|
11461459|NCT01620554|Experimental|BF2.649 20mg|
11461460|NCT01620554|Experimental|BF2.649 40mg|
11461461|NCT01620554|Placebo Comparator|Placebo|
11461462|NCT01620541||Preference, Ankle Arthrodesis|
11461463|NCT01620541||Preference, Ankle Arthroplasty|
11461464|NCT01620528|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
11461465|NCT01620528|Experimental|Elagolix 200 mg BID|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
11461466|NCT01620528|Placebo Comparator|Placebo|Placebo BID for the 6-month Treatment Period
11461467|NCT01620515|No Intervention|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
11461468|NCT01620515|Experimental|NX-1207 2.5 mg|
11461469|NCT01620515|Experimental|NX-1207 15 mg|
11461470|NCT01620502|Active Comparator|EPA 3.5 g/day|
11461471|NCT01620502|Placebo Comparator|Placebo capsules|oleic oil
11461472|NCT01620502|Experimental|DHA 1.75 g/day|DHA 1.75 g/day
11461473|NCT01620489|Experimental|Lira 1.8 mg|
11461474|NCT01620489|Placebo Comparator|Placebo|
11461475|NCT01620476|Experimental|5 mcg/kg|
11461476|NCT01620476|Experimental|10 mcg/kg|
11461477|NCT01620476|Experimental|15 mcg/kg|
11461478|NCT01620463|Experimental|NNC 90-1170|
11461486|NCT01620411|Experimental|Comprehensive Medical Management (CMM)|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
11461487|NCT01620411|Experimental|CMM + Spinal Cord Stimulator (SCS)|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
11461488|NCT01620398|Experimental|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (<7% saturated fatty acid; <10% polyunsaturated fatty acid; <20% monounsaturated fatty acid, <1% trans fatty acid), <200 mg/day of cholesterol, 20-30 g/day of fiber and <2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
11461489|NCT01620398|Active Comparator|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
11461490|NCT01620385|Experimental|ciPDA|
11461491|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
11461492|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
11461493|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
11461494|NCT01620359|Experimental|ExAblate|
11461495|NCT01620346|Active Comparator|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
11461496|NCT01620346|Experimental|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
11461497|NCT01620333|Experimental|Treatment period 1|
11461498|NCT01620333|Experimental|Treatment period 2|
11461499|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
11461500|NCT01620307|Active Comparator|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.
~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
11461501|NCT01620307|Placebo Comparator|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.
~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
11461502|NCT01620294|Experimental|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
11461503|NCT01620294|Experimental|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
11461504|NCT01620281|Experimental|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
11461505|NCT01620281|Other|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
11461506|NCT01620268|No Intervention|Control Group|Patients receive standard of care.
11461507|NCT01620268|Experimental|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
11461508|NCT01620255|Placebo Comparator|Placebo|
11461509|NCT01620255|Experimental|Drug Dose Level 1|
11461510|NCT01620255|Experimental|Drug Dose Level 2|
11461511|NCT01620255|Experimental|Drug Dose Level 3|
11461512|NCT01620255|Experimental|Drug Dose Level 4|
11461513|NCT01620242|Experimental|Cabazitaxel|All patients are treated with Cabazitaxel.
11461514|NCT01620229|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
11461515|NCT01620216|Experimental|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11461516|NCT01620216|Experimental|Group II (nilotinib)|Patients receive nilotinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11461517|NCT01620216|Experimental|Group III (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11461518|NCT01620216|Experimental|Group IV (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11461519|NCT01620216|Experimental|Group V (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11461520|NCT01620203||Control|Matched group of control infants without diagnosis of intracranial hemorrhage
11461521|NCT01620203||Intracranial Hemorrhage|Group of preterm infant with diagnosis of intracranial hemorrhage.
11461522|NCT01620190|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11461523|NCT01620177|Experimental|0% THC with 0.065 g/dL BAC|
11461524|NCT01620177|Experimental|2.5-3.5% THC with 0.065 g/dL BAC|
11461525|NCT01620177|Experimental|6.0-7.5% THC and 0.065 g/dL BAC|
11461526|NCT01620177|Experimental|2.5-3.5% THC with 0 g/dL BAC|
11461527|NCT01620177|Experimental|6.0-7.5% THC with 0 g/dL BAC|
11461528|NCT01620177|Experimental|0% THC with 0 g/dL BAC|
11461529|NCT01620164|Other|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
11461530|NCT01620164|Other|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
11461531|NCT01620164|Other|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
11461532|NCT01620151|No Intervention|No extended neck|Patient will not undergo thyroid surgery with extended neck
11461533|NCT01620151|Experimental|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
11461534|NCT01620138|Active Comparator|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.
~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
11461535|NCT01620138|Active Comparator|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
11461536|NCT01620125|Other|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
11461537|NCT01620112|Active Comparator|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
11461538|NCT01620112|Active Comparator|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
11461539|NCT01620112|Active Comparator|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
11461540|NCT01620112|Active Comparator|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
11461541|NCT01620099|Experimental|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
11461542|NCT01620099|Active Comparator|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
11461543|NCT01620086|Experimental|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
11461544|NCT01620086|Experimental|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
11461545|NCT01620073|Other|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
11461546|NCT01620073|Experimental|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
11461547|NCT01620060|Experimental|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
11461548|NCT01620047|Experimental|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
11461549|NCT01620047|Active Comparator|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
11461550|NCT01620047|Placebo Comparator|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
11461551|NCT01620034|Active Comparator|11 Day Arm|
11461553|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
11461554|NCT01620008|No Intervention|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
11461555|NCT01620008|Experimental|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
11461556|NCT01619982|Active Comparator|Cefazolin 25 mg/kg body weight and vancomycin|"All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.
~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
11461557|NCT01619982|Other|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
11461558|NCT01619969|Experimental|Celgosivir|
11461559|NCT01619969|Placebo Comparator|Placebo|
11461560|NCT01619956|Experimental|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
11461561|NCT01619956|Active Comparator|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
11461562|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
11461563|NCT01619930|Experimental|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
11461564|NCT01619930|Experimental|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
11461565|NCT01619930|Experimental|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
11461566|NCT01619930|Experimental|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
11461567|NCT01619930|Experimental|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
11461568|NCT01619930|Experimental|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
11461569|NCT01619930|Experimental|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
11461570|NCT01619930|Experimental|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.
~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
11461571|NCT01619930|No Intervention|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
11461572|NCT01619917|Active Comparator|Proximal|location of the scar proximal to heart
11461573|NCT01619917|Experimental|Distal|location of scar distal to heart
11461574|NCT01619904|Experimental|Goal-Directed Therapy|
11461575|NCT01619904|Active Comparator|Standard Therapy|
11461576|NCT01619891|Active Comparator|Vitamin D|Vitamin D 100mcg per day
11461577|NCT01619891|Placebo Comparator|Placebo|Standard optimal therapy
11461578|NCT01619878|Experimental|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.
~Infants age >28 days."
11461579|NCT01619865|Experimental|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
11461580|NCT01619852|Active Comparator|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
11461718|NCT01618942|Experimental|female subjects|grouped by gender and applied pressure pain test
11461581|NCT01619852|Placebo Comparator|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
11461582|NCT01619839|Experimental|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
11461583|NCT01619839|Experimental|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
11461584|NCT01619839|Experimental|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
11461585|NCT01619839|Experimental|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
11461586|NCT01619839|Placebo Comparator|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
11461587|NCT01619826|Experimental|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
11461588|NCT01619826|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
11461589|NCT01619813|Active Comparator|Docetaxel, Reolysin and Prednisone|
11461590|NCT01619813|Active Comparator|Docetaxel and Prednisone|
11461591|NCT01619800|Experimental|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
11461592|NCT01619800|Sham Comparator|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
11461593|NCT01619774|Experimental|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
11461594|NCT01619761|Experimental|Treatment Plan 1 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -8 to -2, fludarabine phosphate IV over 1 hour on days -7 to -4, and melphalan IV over 30 minutes on day -4. CD20 positive patients also receive rituximab IV over 6 hours on days -8 to -4.
11461595|NCT01619761|Experimental|Treatment Plan 2 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -7 to -2, cyclophosphamide IV over 3 hours on day -7, and undergo TBI on day -3. Patients also receive rituximab and fludarabine phosphate as in Treatment Plan 1.
11461596|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
11461597|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
11461598|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
11461599|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
11461600|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
11461601|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
11461602|NCT01619709|Other|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
11461603|NCT01619709|Other|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
11461604|NCT01619696|Experimental|Intervention|
11461605|NCT01619683|Experimental|Androxal|
11461606|NCT01619683|Placebo Comparator|Placebo|
11461607|NCT01619670|No Intervention|no intervention|standard wound care
11461608|NCT01619670|Active Comparator|Apligraf|non adhesive layer with apligraf
11461609|NCT01619657|Experimental|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
11461610|NCT01619657|Active Comparator|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
11461611|NCT01619644|Experimental|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
11461612|NCT01619644|Placebo Comparator|Placebo|Group of 20 patients receiving one year of placebo
11461613|NCT01619631|Experimental|12-week Tai Chi intervention|
11461614|NCT01619631|Active Comparator|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
11461615|NCT01619631|No Intervention|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
11461616|NCT01619605|Experimental|Shrim|
11461617|NCT01619592|Active Comparator|Intervention group|webbased education (telemonitoring)
11461618|NCT01619592|No Intervention|control group|standard care
11461619|NCT01619579|Experimental|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
11461620|NCT01619566|No Intervention|Control|Control subjects undergo a skin biopsy.
11461621|NCT01619566|Experimental|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
11461622|NCT01619553||affected|individuals with keloids
11461623|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
11461624|NCT01619540|Other|acute heart failure|control arm
11461625|NCT01619540|Experimental|COPD exacerbation|COPD exacerbation
11461626|NCT01619527|Experimental|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
11461627|NCT01619527|Experimental|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
11461628|NCT01619527|Experimental|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
11463629|NCT01605747|Placebo Comparator|Placebo|
11461629|NCT01619527|Experimental|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
11461630|NCT01619527|Experimental|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
11461631|NCT01619527|Experimental|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
11461632|NCT01619488|Experimental|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.
~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
11461633|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
11461634|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.
~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.
~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
11461635|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
11461636|NCT01619462|Other|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
11461637|NCT01619462|Other|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
11461638|NCT01619449|Experimental|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
11461639|NCT01619449|Active Comparator|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
11461640|NCT01619436|Active Comparator|clonidine|clonidine 2 mg/kg IV
11461641|NCT01619436|Placebo Comparator|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
11461642|NCT01619423|Active Comparator|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
11461643|NCT01619423|Active Comparator|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
11461644|NCT01619423|Active Comparator|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
11461645|NCT01619423|Placebo Comparator|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
11461646|NCT01619410|Active Comparator|linezolid|
11461647|NCT01619410|Active Comparator|Clindamycin|
11461648|NCT01619397|Other|Condom|Test condom with new Xanthan gum condom coating
11461649|NCT01619384|No Intervention|Treatment as Usual|Usual VA care
11461650|NCT01619384|Experimental|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
11461651|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
11461652|NCT01619345|Experimental|Period 1: NN9924 with 50 mL water|
11461653|NCT01619345|Experimental|Period 2: NN9924 with 240 mL water|
11461654|NCT01619332|Experimental|LEZ763|Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
11461655|NCT01619332|Placebo Comparator|Placebo|Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
11461656|NCT01619332|Active Comparator|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
11461657|NCT01619319|Experimental|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
11461658|NCT01619319|Active Comparator|computer games|computer games
11461659|NCT01619293||Epidural H.|patients with hematoma epidurale
11461660|NCT01619293||Subdural H.|patients with hematoma subdurale
11461661|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
11461662|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
11461663|NCT01619293||E. cerebri|patients with edema cerebri
11461664|NCT01619293||Concussion|patients with concussion
11461665|NCT01619280|Experimental|Nebulized sodium nitroprusside|
11461666|NCT01619267||device associated infection|patients with proven device associated infection
11461667|NCT01619267||control group|patients without device associated infection
11461668|NCT01619254|Experimental|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
11461669|NCT01619254|Experimental|Hand finger nail hygiene|Hand finger nail clipping activities
11461670|NCT01619254|Experimental|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
11461671|NCT01619254|Placebo Comparator|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
11461672|NCT01619241||advanced non-small cell lung cancer|
11461673|NCT01619228||Premature Infants|Infants born at < 37 weeks gestational age
11461674|NCT01619228||Full Term Infants|Infants born at equal to or greater than 37 weeks gestational age
11461675|NCT01619228||Adults|Adults are parents of infants enrolled in the study
11461719|NCT01618929|Active Comparator|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
11461676|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
11461677|NCT01619202|Experimental|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
11461678|NCT01619202|No Intervention|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
11461679|NCT01619189|Experimental|Tranplantation of cultured LSC in stage 3 limbal deficiency|Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders in stage 3 unilateral or bilateral limbal stem cell deficiency.
11461680|NCT01619176|Experimental|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
11461681|NCT01619176|Active Comparator|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
11461682|NCT01619163|Experimental|prednisolone|
11461683|NCT01619163|Placebo Comparator|Placebo|
11461684|NCT01619150|Other|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
11461685|NCT01619150|Other|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
11461686|NCT01619137|Active Comparator|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist's office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
11461687|NCT01619137|Active Comparator|water and soap|40 patients coming to Gynecologist's offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it's not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
11461688|NCT01619111|Active Comparator|standard therapy|standard chemo- or endocrine therapy
11461689|NCT01619111|Experimental|standard therapy + lapatinib|standard chemo- or endocrine therapy + lapatinib
11461690|NCT01619098|Experimental|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
11461691|NCT01619098|No Intervention|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
11461692|NCT01619085|Experimental|BIBF 1120|patient to receive a capsule containing BIBF 1120 twice a day
11461693|NCT01619072|Active Comparator|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
11461694|NCT01619072|Placebo Comparator|Placebo|Placebo + referral to higher level care
11461695|NCT01619059|Experimental|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
11461696|NCT01619059|Experimental|Arm 2: Placebo+Dapagliflozin+Metformin IR|
11461697|NCT01619046|Active Comparator|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
11461698|NCT01619046|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
11461699|NCT01619046|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
11461700|NCT01619046|Experimental|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
11461701|NCT01619033|Experimental|impaired renal function subjects|impaired renal function subjects
11461702|NCT01619033|Other|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
11461703|NCT01619020|Active Comparator|Flaxseed Lignans|Capsules
11461704|NCT01619020|Placebo Comparator|Placebo|Capsules
11461705|NCT01619007||Group 1|
11461706|NCT01619007||Group 2|
11461707|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging >75 robotic cases per year
11461708|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
11461709|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
11461710|NCT01618981|Experimental|first active|
11461711|NCT01618981|Experimental|first inactive|
11461712|NCT01618968|Experimental|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
11461713|NCT01618968|Experimental|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
11461714|NCT01618968|Experimental|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
11461715|NCT01618968|Experimental|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
11461716|NCT01618955|Active Comparator|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
11461717|NCT01618942|Experimental|male subjects|grouped by gender and applied pressure pain test
11461720|NCT01618929|Active Comparator|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
11461721|NCT01618916|Experimental|1.0 milligrams per kilogram (mg/kg) LY3015014 Every 2 Weeks|1.0 mg/kg LY3015014 given subcutaneously (SC) once every 2 weeks for 29 days.
11461722|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
11461723|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SC once every 2 weeks for 29 days.
11461724|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
11461725|NCT01618916|Placebo Comparator|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SC once every 2 weeks for 29 days.
11461726|NCT01618916|Placebo Comparator|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SC once every 4 weeks for 29 days.
11461727|NCT01618903|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
11461728|NCT01618903|Experimental|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
11461729|NCT01618890|Experimental|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.
~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
11461730|NCT01618890|No Intervention|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
11461731|NCT01618877|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
11461732|NCT01618877|Placebo Comparator|Placebo infusion|
11461733|NCT01618864|Other|Luxe|
11461734|NCT01618851|Experimental|IMRT with SBRT Boost|Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
11461735|NCT01618838|Other|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
11461736|NCT01618825|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
11461737|NCT01618825|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
11461738|NCT01618812||Pes plano valgus|Children with painful flatfeet
11461739|NCT01618799|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
11461740|NCT01618799|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
11461741|NCT01618786|Experimental|Compliant Flooring (CF)|Compliant flooring
11461742|NCT01618786|Placebo Comparator|Control (CON)|Non-compliant flooring
11461743|NCT01618760|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
11461744|NCT01618760|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
11461745|NCT01618747||Cohort|
11461746|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
11461747|NCT01618708|Experimental|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
11461748|NCT01618708|Placebo Comparator|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
11461749|NCT01618695|Experimental|Perampanel|
11461750|NCT01618695|Placebo Comparator|Placebo|
11461751|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
11461752|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
11461753|NCT01618669|Experimental|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
11461754|NCT01618669|Active Comparator|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
11461755|NCT01618656|Active Comparator|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
11461756|NCT01618656|Placebo Comparator|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
11461757|NCT01618643||Acetic acid chromoendoscopy|"Patients with known Barrett's metaplasia under surveillance
~Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia
~Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
11461758|NCT01618630|Experimental|EAA Supplementation + Exercise Training|Drink an amino acid supplementation during exercise training.
11461759|NCT01618630|Placebo Comparator|Placebo + Exercise Training|Drink a placebo supplementation during exercise training.
11461760|NCT01618617|Experimental|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
11461761|NCT01618617|Experimental|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
11461762|NCT01618617|Placebo Comparator|Placebo|Placebo
11461763|NCT01618604||Healthy|26 healthy voluntary probands
11461764|NCT01618591|Experimental|Acute Watery Diarrhea|
11461765|NCT01618591|Experimental|Acute Dysentery/Febrile|
11461766|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
11461767|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
11461768|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
11461769|NCT01618565|Experimental|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
11461770|NCT01618565|Active Comparator|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
11461771|NCT01618552|Experimental|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
11461772|NCT01618552|Active Comparator|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
11461773|NCT01618526|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
11461774|NCT01618526|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
11461775|NCT01618513|Experimental|SA monitored by GH|
11461776|NCT01618513|Experimental|SA monitored by IGF-I|
11461777|NCT01618513|No Intervention|Control|Control, patients who have achieved sufficient disease control by surgery alone.
11461778|NCT01618500||INPH-patients|"Inclusion criteria
~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.
~Exclusion criteria
~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).
~Patients not considered for shunt operation."
11461779|NCT01618487|Active Comparator|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
11461780|NCT01618487|Active Comparator|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
11461781|NCT01618487|Active Comparator|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
11461782|NCT01618474|Experimental|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
11461783|NCT01618474|Active Comparator|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
11461784|NCT01618461|No Intervention|Text instructions|Medication instructions displayed in text format
11461785|NCT01618461|Experimental|Drug indication icons|Icons illustrate the purpose of each medication
11461786|NCT01618461|Experimental|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
11461787|NCT01618461|Experimental|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
11461788|NCT01618448|Experimental|Placebo|Placebo once daily
11461789|NCT01618448|Experimental|Tolvaptan|Tolvaptan 15mg once daily
11461790|NCT01618435|Active Comparator|Fusion, allograft|Allograft used for fusion in the operation site
11461791|NCT01618435|Experimental|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
11461792|NCT01618422|Sham Comparator|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
11461793|NCT01618422|Active Comparator|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
11461794|NCT01618409|Experimental|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
11461795|NCT01618409|No Intervention|Control|Usual care
11461796|NCT01618383|Other|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
11461797|NCT01618370|Experimental|Radium-223 dichloride|
11461798|NCT01618357|Experimental|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
11461799|NCT01618331|Active Comparator|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
11461800|NCT01618331|Placebo Comparator|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
11461801|NCT01618331|No Intervention|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
11461802|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
11461803|NCT01618305|Experimental|Arm A (Women)|Pregnant women received ZDV/3TC + EFV
11461804|NCT01618305|Experimental|Arm B (Women)|Pregnant women received ZDV/3TC + RAL
11461805|NCT01618305|No Intervention|Arm A (Infants)|Infants born to women in Arm A; infants received no study intervention.
11461806|NCT01618305|No Intervention|Arm B (Infants)|Infants born to women in Arm B; infants received no study intervention.
11461860|NCT01617889|Experimental|Powder milk-based formula, alternate fat blend|
11461807|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
11461808|NCT01618279||Tryptase|Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
11461809|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
11461810|NCT01618253|Experimental|Radiation therapy with concurrent sorafenib|
11461811|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
11461812|NCT01618227|Experimental|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
11461813|NCT01618227|Experimental|Rehabilitation without splinting|
11461814|NCT01618214|Experimental|Subject-driven titration|
11461815|NCT01618214|Active Comparator|Investigator-driven titration|
11461816|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
11461817|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
11461818|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
11461819|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
11461820|NCT01618188|Experimental|Formulation A|
11461821|NCT01618188|Experimental|Formulation B|
11461822|NCT01618188|Active Comparator|Insulin Aspart|
11461823|NCT01618175|Experimental|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
11461824|NCT01618162|Experimental|Insulin degludec/liraglutide|
11461825|NCT01618162|Placebo Comparator|Placebo|
11461826|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
11461827|NCT01618136|Experimental|E7449|
11461828|NCT01618136|Active Comparator|E7449 plus TMZ|
11461829|NCT01618136|Active Comparator|E7449 plus carboplatin and paclitaxel|
11461830|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
11461831|NCT01618110|Active Comparator|Treatment Group|
11461832|NCT01618110|Sham Comparator|Sham group|Sham TMS coil (same noise, minimal magnetic field)
11461833|NCT01618097|Experimental|DVD Decision Aid|Patient assigned to watch DVD decision aid.
11461834|NCT01618097|Experimental|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
11461835|NCT01618084|Experimental|Tritanium cup|
11461836|NCT01618084|Active Comparator|Trident HA cup|
11461837|NCT01618071|Active Comparator|Oleic acid|75 g high oleic acid sunflower oil.
11461838|NCT01618071|Active Comparator|Linoleic acid|75 g high linoleic acid sunflower oil.
11461839|NCT01618071|Experimental|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
11461840|NCT01618071|Experimental|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
11461841|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
11461842|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
11461843|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
11461844|NCT01618032|Experimental|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
11461845|NCT01618032|Experimental|MWM|Mobilization with movement on ankle joint as Mulligan
11461846|NCT01618032|Sham Comparator|placebo|Contact without therapeutic effect
11461847|NCT01618019|Experimental|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
11461848|NCT01618019|Placebo Comparator|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
11461849|NCT01618006|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
11461850|NCT01618006|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
11461851|NCT01618006|Experimental|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
11461852|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
11461853|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
11461854|NCT01617967|Experimental|Patisiran (ALN-TTR02)|Two administrations of patisiran will be administered once every 4 weeks [Q4W]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks [Q3W]), and an alternative premedication regimen.
11461855|NCT01617954||Subjects with MammaPrint Result|
11461856|NCT01617941|Experimental|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
11461857|NCT01617941|Placebo Comparator|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
11461858|NCT01617928|Experimental|veliparib (ABT-888)|
11461859|NCT01617889|Active Comparator|Powdered milk-based formula, standard fat blend|
11461861|NCT01617850|Experimental|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
11461862|NCT01617850|Active Comparator|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
11461863|NCT01617837|Active Comparator|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
11461864|NCT01617837|Placebo Comparator|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
11461865|NCT01617824|Experimental|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
11461866|NCT01617824|Placebo Comparator|Placebo|Placebo tablets 1 daily for 4 days
11461867|NCT01617798|Placebo Comparator|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).
~No actual placebo is administered."
11461868|NCT01617798|Active Comparator|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
11461869|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
11461870|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
11461871|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
11461872|NCT01617772|Experimental|Atorvastatin|20mg atorvastatin daily
11461873|NCT01617772|Experimental|Carnitine|1000mg L-carnitine daily
11461874|NCT01617772|Experimental|Atoral|1000mg L-carnitine and 20mg atorvastatin
11461875|NCT01617772|Placebo Comparator|Placebo|Identically looking placebo
11461876|NCT01617746|Experimental|Ambrisentan|5mg od ambrisentan
11461877|NCT01617746|Experimental|Bosentan|62.5mg bosentan
11461878|NCT01617746|Placebo Comparator|Placebo|
11461879|NCT01617733|Experimental|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
11461880|NCT01617707|Active Comparator|conventional sedation group|midazolam
11461881|NCT01617707|Experimental|BPS group|midazolam plus propofol
11461882|NCT01617694|Experimental|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
11461883|NCT01617694|Active Comparator|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
11461884|NCT01617681|Experimental|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
11461885|NCT01617681|Experimental|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
11461886|NCT01617681|Experimental|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
11461887|NCT01617668|Experimental|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
11461888|NCT01617668|Active Comparator|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
11461889|NCT01617655|Placebo Comparator|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
11461890|NCT01617655|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
11461891|NCT01617642||Control group|Healthy control group, matched for age and gender
11461892|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
11461893|NCT01617629|Experimental|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
11461894|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
11461895|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
11461896|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
11461897|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
11461898|NCT01617603|Experimental|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
11461899|NCT01617603|Active Comparator|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
11461900|NCT01617603|Placebo Comparator|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
11461901|NCT01617590|Experimental|leflunomide|Leflunomide 10-20 mg/d
11461902|NCT01617590|Active Comparator|methotrexate|MTX 7.5-15 mg/week
11461903|NCT01617577|Experimental|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
11461904|NCT01617577|Placebo Comparator|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
11461905|NCT01617564|Active Comparator|Bupivacain|
11461906|NCT01617564|Sham Comparator|Sodium Chloride|
11461907|NCT01617551|Experimental|Renal denervation|Patient group randomized to renal denervation
11461908|NCT01617551|Sham Comparator|Sham|Patients randomized to sham procedure
11461909|NCT01617538|Experimental|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
11461910|NCT01617538|No Intervention|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
11461911|NCT01617525|Experimental|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
11461912|NCT01617525|Active Comparator|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
11461913|NCT01617525|Active Comparator|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
11461914|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
11461915|NCT01617486|Experimental|BALANCE|
11461916|NCT01617473|Experimental|procedure/surgery|transplant with G-CSF mobilized PBSCs
11461917|NCT01617473|No Intervention|other|no intervention after transplant with mobilized BMPB
11461918|NCT01617460|Experimental|Aripiprazole|administered orally once daily
11461919|NCT01617447|Placebo Comparator|Placebo|administered orally once daily
11461920|NCT01617447|Experimental|Aripiprazole|administered orally once daily
11461921|NCT01617434|Experimental|Liraglutide|
11461922|NCT01617434|Placebo Comparator|Placebo|
11461923|NCT01617421|Experimental|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
11461924|NCT01617408||1|Neurologically normal subjects aged 18 to 50 years old
11461925|NCT01617395||GEMS cohort|Individuals at risk for developing MS
11461926|NCT01617395||Healthy Volunteer Cohort|Healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS
11461927|NCT01617395||MS Patients Cohort|MS patients whose first-degree relatives are enrolled in this study
11461928|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
11461929|NCT01617369|Experimental|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
11461930|NCT01617369|Active Comparator|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
11461931|NCT01617356|Active Comparator|Dextrose Injection|
11461932|NCT01617356|Active Comparator|Sterile Water Injection|
11461933|NCT01617343|No Intervention|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
11461934|NCT01617343|Experimental|HEP-OKS|
11461935|NCT01617330|Experimental|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
11461936|NCT01617330|Experimental|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
11461937|NCT01617317|Active Comparator|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
11461938|NCT01617317|Experimental|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
11461939|NCT01617304|Experimental|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
11461940|NCT01617304|Experimental|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
11461941|NCT01617304|Experimental|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
11461942|NCT01617304|Experimental|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
11461943|NCT01617291|Experimental|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
11461944|NCT01617291|No Intervention|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
11461945|NCT01617278|Experimental|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
11461946|NCT01617278|Experimental|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
11461947|NCT01617278|Experimental|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
11461948|NCT01617265|Experimental|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
11461949|NCT01617265|Active Comparator|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
11461950|NCT01617252|Experimental|Optiflow|
11461951|NCT01617252|Experimental|Facial mask|
11461952|NCT01617239|Experimental|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
11461953|NCT01617239|Experimental|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
11461954|NCT01617239|Experimental|Group 3|1 x triple standard dose (1.5 mL) on Day 1
11461955|NCT01617226|Active Comparator|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
11461956|NCT01617226|Active Comparator|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
11461957|NCT01617213|Experimental|Maintenance Lenalidomide After Melphalan|
11461958|NCT01617200|Experimental|Asenapine 2.5 mg BID|
11461959|NCT01617200|Experimental|Asenapine 5 mg BID|
11461960|NCT01617200|Active Comparator|Olanzapine 15 mg QD|
11461961|NCT01617200|Experimental|Placebo switched to Asenapine 2.5 mg BID|
11461962|NCT01617187|Experimental|Asenapine 2.5 mg BID|
11461963|NCT01617187|Experimental|Asenapine 5 mg BID|
11461964|NCT01617187|Active Comparator|Olanzapine 15 mg QD|
11461965|NCT01617187|Placebo Comparator|Placebo BID|
11461966|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health & Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
11461967|NCT01617161|Active Comparator|PBT|Proton Beam Therapy
11461968|NCT01617161|Active Comparator|IMRT|Intensity Modulated Radiation Therapy
11461969|NCT01617148|Experimental|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
11461970|NCT01617135|Experimental|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
11461971|NCT01617135|Experimental|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
11461972|NCT01617135|Placebo Comparator|Inhaled Placebo|Inhaled placebo powder
11461973|NCT01617135|Active Comparator|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
11461974|NCT01617122|Experimental|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
11461975|NCT01617109|Placebo Comparator|Placebo|
11461976|NCT01617109|Experimental|Ca/Vit D|
11461977|NCT01617096|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25mg dapivirine
11461978|NCT01617096|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
11461979|NCT01617083|Active Comparator|Azithromycin|Antibiotic used to treat infections.
11461980|NCT01617083|Placebo Comparator|Placebo|Compound thickening agent with sugar and flavor additives.
11461981|NCT01617070|Experimental|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
11461982|NCT01617057|Experimental|Skelid|tiludronic acid
11461983|NCT01617057|Placebo Comparator|Control|Placebo
11461984|NCT01617044|Experimental|Treatment|"iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)
~+ vitamin C-250 mg chewable tab
~+ probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
11461985|NCT01617044|Placebo Comparator|Control|"iron 3 mg/kg/day elemental iron FeSO4 to 45 mg
~+ vitamin C-250 mg chewable tab
~+ placebo (identical capsule)"
11461986|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis >50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
11461987|NCT01617018||Exposed group|Biotherapy
11461988|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
11461989|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
11461990|NCT01616992||Interstitial Cystitis|
11461991|NCT01616992||Myofascial Pelvic Pain|
11461992|NCT01616992||Healthy|
11461993|NCT01616992||First Degree Relative|
11461994|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
11461995|NCT01616966|Active Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
11461996|NCT01616966|Active Comparator|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
11461997|NCT01616953|Experimental|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
11461998|NCT01616953|Active Comparator|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
11461999|NCT01616940|No Intervention|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
11462000|NCT01616940|Experimental|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
11462001|NCT01616927|No Intervention|standard care|Subjects in this arm will receive standard care
11462002|NCT01616927|Experimental|Lanreotide|
11462003|NCT01616914||delirium group|patients with delirium during ICU stay
11462004|NCT01616914||non-delirium group|patients without delirium during ICU stay
11462005|NCT01616901|Experimental|Spontaneous breathing trial|
11462006|NCT01616888|Active Comparator|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
11462007|NCT01616875|Experimental|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
11462008|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
11462009|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
11462010|NCT01616849|Experimental|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
11462011|NCT01616836|Active Comparator|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
11462012|NCT01616836|Active Comparator|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
11462013|NCT01616836|Active Comparator|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
11462014|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
11462015|NCT01616810||observation|Healthy participants
11462016|NCT01616797|Experimental|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
11462017|NCT01616797|Sham Comparator|Control|Participants will be asked to visit a customized website and engage in computerized games.
11462018|NCT01616784|Active Comparator|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
11462019|NCT01616784|Experimental|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
11462020|NCT01616771|Other|glottis view assessment|Glottis view assessment using Macintosh laryngoscope & GVL selected by weight & smaller sized GVL in single patient
11462021|NCT01616758|Experimental|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
11462022|NCT01616732|Active Comparator|testosterone|against placebo
11462023|NCT01616732|Placebo Comparator|placebo|
11462024|NCT01616719|Other|DTRAX graft|
11462025|NCT01616693|Experimental|Zinc and probiotic|Received daily zinc and probiotic supplements, in addition to rotavirus vaccine and trivalent oral polio vaccines.
11462026|NCT01616693|Active Comparator|Zinc alone|Received daily zinc and probiotic placebo supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
11462027|NCT01616693|Active Comparator|Probiotic alone|Received daily zinc placebo and probiotic supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
11462028|NCT01616693|Placebo Comparator|Placebo|Received daily zinc placebo and probiotic placebo, in addition to rotavirus vaccine and trivalent oral polio vaccine.
11462029|NCT01616680|Experimental|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
11462030|NCT01616667|Active Comparator|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
11462031|NCT01616667|Active Comparator|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
11462032|NCT01616654|Experimental|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
11462033|NCT01616654|Experimental|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
11462034|NCT01616654|Active Comparator|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily for subjects randomized in Stratum 1 and 2
11462035|NCT01616654|Placebo Comparator|Vehicle cream|Vehicle cream applied once daily for subjects randomized in Stratum 1, 2 and 3
11462036|NCT01616654|Experimental|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
11462037|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
11462038|NCT01616641||control group|75 healthy women
11462039|NCT01616628|No Intervention|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
11462040|NCT01616628|Experimental|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
11462041|NCT01616615|Experimental|ASPIRIN|150 mg milligram(s)/ day oral use
11462042|NCT01616615|Placebo Comparator|PLACEBO|
11462043|NCT01616602|Placebo Comparator|Left-sided Position|
11462044|NCT01616602|Experimental|Prone Position|
11462045|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed >200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
11462046|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
11462047|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
11462048|NCT01616576|Experimental|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
11462049|NCT01616576|Experimental|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
11462050|NCT01616563|Experimental|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
11462051|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
11462052|NCT01616524|Experimental|Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir|
11462053|NCT01616524|Experimental|Arm 2: pegIFNλ + Ribavirin + Daclatasvir|
11462054|NCT01616524|Experimental|Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir|
11462055|NCT01616511||Pathway CH-1 Subjects|
11462056|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
11462057|NCT01616485|Experimental|Treatment A|TA-1790 + glyceryl trinitrate
11462058|NCT01616485|Active Comparator|Treatment B|sildenafil citrate + glyceryl trinitrate
11462059|NCT01616485|Placebo Comparator|Treatment C|placebo + glyceryl trinitrate
11462060|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
11462061|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
11462062|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
11462063|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
11462064|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
11462065|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
11462066|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
11462067|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
11462068|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
11462069|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
11462070|NCT01616459|Experimental|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
11462071|NCT01616459|Experimental|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
11462072|NCT01616459|Active Comparator|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
11462123|NCT01616160|Experimental|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
11462124|NCT01616147|Experimental|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
11462679|NCT01612299|Experimental|Zortress®|Tacrolimus + Zortress® + Corticosteroids
11462073|NCT01616459|Active Comparator|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
11462074|NCT01616446||remission|Nephrotic patients in remission
11462075|NCT01616446||relapse|Nephrotic patients in recidive
11462076|NCT01616433|Active Comparator|Arthritis Foundation Exercise Program|
11462077|NCT01616433|Experimental|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
11462078|NCT01616420|No Intervention|Delayed aPS|
11462079|NCT01616420|Experimental|Immediate aPS|
11462080|NCT01616407|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
11462081|NCT01616394||children with congenital heart disease|
11462082|NCT01616381|Active Comparator|Sildenafil|Sildenafil tablets 40 mg x 3 daily
11462083|NCT01616381|Placebo Comparator|Placebo|Placebo tablet x 3 daily
11462084|NCT01616368|Experimental|MEAL|Participation in an 8-week mindful eating course
11462085|NCT01616342|Active Comparator|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
11462086|NCT01616342|Active Comparator|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
11462087|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
11462088|NCT01616316|Experimental|subfascial flap|
11462089|NCT01616316|Experimental|Subplatysmal flap|
11462090|NCT01616303|Active Comparator|carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
11462091|NCT01616303|Experimental|carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
11462092|NCT01616277|Placebo Comparator|1|
11462093|NCT01616277|Placebo Comparator|2|
11462094|NCT01616277|Placebo Comparator|3|
11462095|NCT01616277|Placebo Comparator|4|
11462096|NCT01616277|Placebo Comparator|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
11462097|NCT01616277|Placebo Comparator|6|
11462098|NCT01616277|Placebo Comparator|7|
11462099|NCT01616251|Experimental|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
11462100|NCT01616251|Experimental|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
11462101|NCT01616251|Experimental|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
11462102|NCT01616251|Experimental|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
11462103|NCT01616238|Experimental|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
11462104|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
11462105|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
11462106|NCT01616238|Experimental|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
11462107|NCT01616238|No Intervention|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
11462108|NCT01616225|Active Comparator|No Growth Hormone Supplementation|
11462109|NCT01616225|Experimental|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
11462110|NCT01616225|Experimental|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
11462111|NCT01616212|Experimental|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
11462112|NCT01616212|Experimental|TX 2|Motivational Enhancement Therapy for adolescents
11462113|NCT01616212|Experimental|TX3|Drug Education for adolescents, Parenting Wisely for parents
11462114|NCT01616212|Experimental|TX4|Drug Education for adolescents
11462115|NCT01616199|Experimental|Phase 1 Dose Escalation of PX-866 + vemurafenib|PX-866 given with vemurafenib
11462116|NCT01616199|Experimental|Phase 2 Combination PX-866 + vemurafenib|PX-866 given with vemurafenib
11462117|NCT01616199|Active Comparator|Phase 2 Single-agent vemurafenib|vemurafenib given as a single agent
11462118|NCT01616186|Experimental|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
11462119|NCT01616186|Active Comparator|Sunitinib|"Sunitinib is the concurrent control group
~Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
11462120|NCT01616173|Active Comparator|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
11462121|NCT01616173|Active Comparator|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
11462122|NCT01616173|Placebo Comparator|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
11462125|NCT01616147|Active Comparator|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
11462126|NCT01616134|Active Comparator|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
11462127|NCT01616134|Placebo Comparator|placebo contating constarch|
11462128|NCT01616121|Active Comparator|Conventional Treatment Heart Failure|Conventional Treatment
11462129|NCT01616121|Experimental|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
11462130|NCT01616108|Experimental|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
11462131|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
11462132|NCT01616095||Healthy Controls|matched for BMI, age, and gender
11462133|NCT01616082|Active Comparator|Overwight/Obese with no drug|After screening, overweight/obese subjects (BMI >27 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
11462134|NCT01616082|Active Comparator|Overweight/obese with Phentermine|After screening, overweight/obese (BMI >27.0 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
11462135|NCT01616069|Active Comparator|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
11462136|NCT01616069|Active Comparator|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
11462137|NCT01616056|Experimental|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
11462138|NCT01616043|Experimental|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
11462139|NCT01616043|Other|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
11462140|NCT01616030|Experimental|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:
~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
11462141|NCT01616004|Experimental|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
11462142|NCT01616004|Sham Comparator|Air|
11462143|NCT01615991|Other|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
11462144|NCT01615978|Experimental|Fixed dose: 5 mcg/kg|
11462145|NCT01615978|Experimental|Escalated dose: 10 mcg/kg|
11462146|NCT01615965|Experimental|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
11462147|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
11462148|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
11462149|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
11462150|NCT01615939|Active Comparator|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
11462151|NCT01615939|Active Comparator|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
11462152|NCT01615913|Experimental|3% terbinafine patch|A 10-cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
11462153|NCT01615913|Experimental|6% terbinafine patch|A 10-cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
11462154|NCT01615913|Experimental|8% terbinafine patch|A 10-cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
11462155|NCT01615900|Other|Teleconsultation|
11462156|NCT01615900|Other|Standard consultation|
11462157|NCT01615887|Experimental|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
11462158|NCT01615887|Placebo Comparator|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
11462159|NCT01615874|Experimental|MF/F MDI 50/10 mcg BID|
11462160|NCT01615874|Experimental|MF/F MDI 100/10 mcg BID|
11462161|NCT01615874|Experimental|MF/F MDI 200/10 mcg BID|
11462162|NCT01615874|Active Comparator|BDP HFA 160 mcg BID|
11462163|NCT01615874|Active Comparator|Montelukast 5 mg QD (4 mg QD for 5-year-olds)|
11462164|NCT01615861|Experimental|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
11462165|NCT01615848|Experimental|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated & polyunsaturated fat
11462166|NCT01615848|Experimental|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
11462167|NCT01615822|Experimental|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
11462168|NCT01615822|Experimental|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
11462169|NCT01615822|Experimental|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
11462170|NCT01615822|Experimental|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
11462171|NCT01615822|Placebo Comparator|Placebo|Placebo
11462172|NCT01615809|Experimental|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.
~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
11462173|NCT01615796|Experimental|Cohort A1|GSK2140944 200mg single dose
11462174|NCT01615796|Experimental|Cohort A2|GSK2140944 600mg single dose
11462175|NCT01615796|Experimental|Cohort A3|GSK2140944 1200mg single dose
11462176|NCT01615796|Experimental|Cohort A4|GSK2140944 1800mg single dose
11462177|NCT01615796|Experimental|Cohort A5|GSK2140944 1800mg single dose
11462178|NCT01615796|Experimental|Cohort A6|GSK2140944 dose to be determined, single dose
11462179|NCT01615796|Experimental|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
11462180|NCT01615796|Experimental|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
11462181|NCT01615796|Experimental|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
11462182|NCT01615796|Experimental|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
11462183|NCT01615796|Experimental|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
11462184|NCT01615796|Experimental|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
11462185|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
11462186|NCT01615770|No Intervention|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
11462187|NCT01615770|Experimental|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
11462188|NCT01615757|Experimental|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
11462189|NCT01615757|Active Comparator|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
11462190|NCT01615744||Surgical ORIF calcaneal fx|
11462191|NCT01615744||Conservative treatment calcaneal fx|
11462192|NCT01615731|Active Comparator|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
11462193|NCT01615731|Experimental|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
11462194|NCT01615718|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
11462195|NCT01615718|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
11462196|NCT01615718|Active Comparator|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
11462197|NCT01615718|Active Comparator|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
11462198|NCT01615705||Blood Draw|"SOX Subjects:
~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
11462199|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
11462200|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
11462201|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
11462202|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
11462203|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
11462204|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
11462205|NCT01615653|Active Comparator|EUS 1|
11462207|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
11462208|NCT01615627|Experimental|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
11462209|NCT01615627|Active Comparator|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
11462210|NCT01615614|Experimental|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
11462211|NCT01615614|Experimental|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
11462212|NCT01615614|Experimental|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
11462213|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
11462214|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
11462215|NCT01615588|Experimental|honey|Manuka honey
11462216|NCT01615575|Active Comparator|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
11462217|NCT01615575|Active Comparator|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
11462218|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
11462219|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
11462220|NCT01615549|Active Comparator|Free training|
11462221|NCT01615549|Experimental|Proficiency-based training|
11462222|NCT01615536|Experimental|Canine fossa trephine group (CFT)|
11462223|NCT01615536|Active Comparator|Non Canine fossa trephine group (NonCFT)|
11462224|NCT01615523||Children/adolescents born preterm|
11462225|NCT01615523||Control children and adolescents|
11462226|NCT01615510|Experimental|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
11462227|NCT01615510|Experimental|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
11462228|NCT01615497|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
11462229|NCT01615497|Experimental|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
11462230|NCT01615497|Active Comparator|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
11462231|NCT01615484|Experimental|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
11462232|NCT01615484|No Intervention|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
11462233|NCT01615471|Active Comparator|Large Group|In person group sessions in large group format (up to 125 others)
11462234|NCT01615471|Active Comparator|Small group|Small group in person sessions (up to 25 other participants)
11462235|NCT01615458|Active Comparator|Usual Care|Patients will receive their usual care from providers at the clinic.
11462236|NCT01615445|Active Comparator|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
11462237|NCT01615445|Placebo Comparator|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
11462238|NCT01615419||Cohort|
11462239|NCT01615406|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
11462240|NCT01615393|Active Comparator|Ribavirin capsule arm|
11462241|NCT01615393|Experimental|Ribavirin tablet arm|
11462242|NCT01615380|Active Comparator|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
11462243|NCT01615380|Experimental|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
11462244|NCT01615367|Experimental|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
11462245|NCT01615367|Active Comparator|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
11462246|NCT01615354|Placebo Comparator|Placebo|
11462247|NCT01615354|Experimental|Treatment|
11462248|NCT01615328|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
11462249|NCT01615328|Experimental|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
11462250|NCT01615302|Active Comparator|Mucosa advancement flap|
11462251|NCT01615302|Experimental|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
11462680|NCT01612286|Experimental|endostatin|chemotherapy concurrently with endostatin
11462252|NCT01615289|Active Comparator|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
11462253|NCT01615289|Active Comparator|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
11462254|NCT01615289|Placebo Comparator|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
11462255|NCT01615289|Placebo Comparator|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
11462256|NCT01615276|Placebo Comparator|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
11462257|NCT01615276|Experimental|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
11462258|NCT01615263|Active Comparator|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
11462259|NCT01615263|Active Comparator|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
11462260|NCT01615250|No Intervention|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
11462261|NCT01615250|Active Comparator|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
11462262|NCT01615237|Active Comparator|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
11462263|NCT01615237|Active Comparator|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
11462264|NCT01615237|Active Comparator|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
11462265|NCT01615224|No Intervention|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
11462266|NCT01615224|Experimental|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
11462267|NCT01615211|No Intervention|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
11462268|NCT01615211|Active Comparator|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
11462269|NCT01615211|Active Comparator|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
11462270|NCT01615198|Experimental|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
11462271|NCT01615198|Active Comparator|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
11462272|NCT01615185|Experimental|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
11462273|NCT01615185|Active Comparator|full-dose amisulpride|amisulpride 800mg/d
11462274|NCT01615172|Active Comparator|Aortic cannulation|routine placement of aortic cannula
11462275|NCT01615172|Active Comparator|axilaris cannulation|new type of cannulation
11462276|NCT01615159|No Intervention|Self directed control|
11462277|NCT01615159|Active Comparator|Behavior and lifestyle counseling|
11462278|NCT01615146|Experimental|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
11462279|NCT01615146|Active Comparator|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is < 10 x 109/L.
11462280|NCT01615120|Experimental|GTx-758 125mg|one GTx-758 tablet orally administered daily
11462281|NCT01615120|Experimental|GTx-758 250 mg|two GTx-758 tablets orally administered daily
11462282|NCT01615107|Experimental|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
11462283|NCT01615107|Experimental|double balloonand oxytocin|insertion of the double balloon and oxytocin
11462284|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
11462285|NCT01615081|Active Comparator|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
11462286|NCT01615081|Experimental|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
11462287|NCT01615068||Cohort|
11462288|NCT01615055|Experimental|Fluoxetine tablets|
11462289|NCT01615055|Placebo Comparator|Placebo tablets|
11462431|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
11462290|NCT01615042|Experimental|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
11462291|NCT01615029|Experimental|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
11462292|NCT01615016|Experimental|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
11462293|NCT01615016|Active Comparator|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
11462294|NCT01615003|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
11462295|NCT01615003|Placebo Comparator|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
11462296|NCT01614990|Active Comparator|Macimorelin|
11462297|NCT01614990|Placebo Comparator|Placebo|
11462298|NCT01614977|Experimental|Methylprednisolone|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.
~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.
~Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
11462299|NCT01614977|No Intervention|Placebo|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.
~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.
~placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
11462300|NCT01614964|Experimental|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
11462301|NCT01614964|Active Comparator|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
11462302|NCT01614951|Experimental|Pulmonary perfusion|
11462303|NCT01614951|Experimental|Pulmoplegia|
11462304|NCT01614951|Other|Control group|
11462305|NCT01614938|Active Comparator|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
11462306|NCT01614938|Experimental|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
11462307|NCT01614912|Experimental|SM-13496|
11462308|NCT01614899|Experimental|SM-13496 40mg|
11462309|NCT01614899|Experimental|SM-13496 80mg|
11462310|NCT01614899|Placebo Comparator|Placebo|
11462311|NCT01614886|Experimental|1 step|
11462312|NCT01614886|Active Comparator|3 step|
11462313|NCT01614873|Active Comparator|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).
~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
11462314|NCT01614873|Experimental|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
11462315|NCT01614847|Experimental|Isotonic hyaluronate artificial tear|At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
11462316|NCT01614847|Placebo Comparator|Normal saline|
11462317|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
11462318|NCT01614821|Experimental|Treatment Arm|PCI-32765; ibrutinib
11462319|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
11462320|NCT01614795|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
11462321|NCT01614782|Experimental|0.35 mg MK-5823 - Healthy Participants|
11462322|NCT01614782|Experimental|0.7 mg MK-5823 - Healthy Participants|
11462323|NCT01614782|Experimental|1.4 mg MK-5823 - Healthy Participants|
11462324|NCT01614782|Experimental|2.8 mg MK-5823 - Healthy Participants|
11462325|NCT01614782|Experimental|1.4 mg MK-5823 - Participants with T2DM|
11462326|NCT01614782|Experimental|2.8 mg MK-5823 - Participants with T2DM|
11462327|NCT01614769|Experimental|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
11462328|NCT01614769|Experimental|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
11462329|NCT01614769|Experimental|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
11462330|NCT01614769|Experimental|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
11462331|NCT01614769|Experimental|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
11462332|NCT01614769|Experimental|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
11462333|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1
~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462334|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1
~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462335|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1
~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462336|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1
~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462337|NCT01614756|Experimental|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1
~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462338|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1
~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462339|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1
~Single dose of BMS-981164 1 mg/kg solution subcutaneously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
11462340|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1
~Single dose of BMS-981164 1 mg/kg solution intravenously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
11462341|NCT01614756|Experimental|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1
~Single dose of BMS-981164 3 mg/kg solution intravenously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
11462342|NCT01614756|Experimental|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1
~Single dose of BMS-981164 10.0 mg/kg solution intravenously
~OR
~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
11462343|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2
~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose
~OR
~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
11462344|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2
~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose
~OR
~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
11462345|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2
~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose
~OR
~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
11462346|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2
~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and >1.0mg/kg, once, single dose
~OR
~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
11462347|NCT01614743|Experimental|IncobotulinumtoxinA|
11462348|NCT01614743|Placebo Comparator|Placebo|
11462349|NCT01614730|Sham Comparator|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
11462350|NCT01614730|Active Comparator|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
11462351|NCT01614717|Active Comparator|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
11462352|NCT01614717|Placebo Comparator|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
11462353|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
11462354|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
11462355|NCT01614691|Experimental|SPARC1203 low dose|
11462356|NCT01614691|Experimental|SPARC1203 mid dose|
11462357|NCT01614691|Experimental|SPARC1203 high dose|
11462358|NCT01614691|Placebo Comparator|Placebo|
11462359|NCT01614678|Other|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
11462360|NCT01614678|Other|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
11462361|NCT01614665|Active Comparator|Tacrolimus|Participants receive tacrolimus twice daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus twice daily up to end of Part B and C of the study.
11462362|NCT01614665|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B and of the study.
11462363|NCT01614652|Experimental|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
11462364|NCT01614652|No Intervention|All Appropriate Medical Therapy (AAMT)|
11462365|NCT01614639|Experimental|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
11462366|NCT01614639|Experimental|Electroacupuncture|Electro-acupuncture given at 2 visits.
11462367|NCT01614613|Experimental|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
11462368|NCT01614600|Experimental|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
11462369|NCT01614587||Cases|"Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy
~The recurrence required treatment (surgery or pessary)"
11462370|NCT01614587||Controls|"Sacrocolpopexy during the same period
~No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
11462371|NCT01614574|Experimental|Investigational|velaglucerase alfa
11462372|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
11462373|NCT01614535|Experimental|Female group|Female gender patients undergoing thyroidectomy
11462374|NCT01614535|Active Comparator|Male group|Male gender patients undergoing thyroidectomy
11462375|NCT01614522|Experimental|HER-2 Amplified|
11462376|NCT01614522|Experimental|HER-1 & HER-2 Co-expression|
11462377|NCT01614509|Experimental|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
11462378|NCT01614509|Experimental|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
11462379|NCT01614483|Experimental|Yellow cassava + placebo capsule|
11462380|NCT01614483|Placebo Comparator|White cassava + placebo capsule|
11462381|NCT01614483|Active Comparator|White cassava + B-carotene capsule|
11462382|NCT01614470|Experimental|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
11462383|NCT01614470|Experimental|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
11462384|NCT01614470|Experimental|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
11462385|NCT01614457|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
11462386|NCT01614457|Placebo Comparator|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
11462387|NCT01614444|Active Comparator|Acupressure Treatment|
11462388|NCT01614444|Placebo Comparator|Placebo Acupressure Treatment|
11462389|NCT01614431|Experimental|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
11462390|NCT01614418|Experimental|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
11462391|NCT01614405|Placebo Comparator|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada. Then there is an option for an 18 month follow-up study.
11462392|NCT01614405|Active Comparator|Truvada and Kaletra|Patients will be take Truvada and Kaletra for 6 months with the option of open label for additional 18 months.
11462393|NCT01614392|Experimental|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
11462394|NCT01614392|Experimental|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
11462395|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
11462396|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
11462397|NCT01614366|Active Comparator|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
11462398|NCT01614366|Experimental|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
11462399|NCT01614366|Experimental|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
11462400|NCT01614366|Experimental|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
11462550|NCT01613274|Placebo Comparator|no gum chewing|no gum chewing
11462401|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
11462402|NCT01614340|Other|Usual Care|Usual Physical Therapy Plan of Care
11462403|NCT01614340|Other|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
11462404|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
11462405|NCT01614314|Active Comparator|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
11462406|NCT01614314|Experimental|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
11462407|NCT01614301|Experimental|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
11462408|NCT01614301|Other|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
11462409|NCT01614288|Active Comparator|Knee Arthroscopy + HTO|
11462410|NCT01614288|Active Comparator|HTO Alone|
11462411|NCT01614275|Experimental|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
11462412|NCT01614275|Experimental|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
11462413|NCT01614275|Experimental|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
11462414|NCT01614275|Placebo Comparator|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
11462415|NCT01614262|Experimental|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
11462416|NCT01614262|Active Comparator|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
11462417|NCT01614249|Placebo Comparator|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
11462418|NCT01614249|Experimental|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
11462419|NCT01614236|Active Comparator|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
11462420|NCT01614236|Active Comparator|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
11462421|NCT01614223|Active Comparator|ACP treatment|
11462422|NCT01614223|Active Comparator|Corticosteroid treatment|
11462423|NCT01614210|Experimental|All patients|All patients enrolled in the study.
11462424|NCT01614197|Experimental|Dose Level 1|This is the starting dose of temsirolimus at 7.5 mg/m^2 given IV. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
11462425|NCT01614197|Experimental|Dose Level 2|If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
11462426|NCT01614197|Experimental|Dose Level 3|If Dose Level 2 is tolerated, the study will escalate to Dose Level 3 following the dose escalation schedule. Dose Level 3 will be administered via IV at 15 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
11462427|NCT01614197|Experimental|Dose Level 4|If Dose Level 3 is tolerated, the study will escalate to Dose Level 4 following the dose escalation schedule. Dose Level 4 will be administered via IV at 25 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8. Temsirolimus will not be escalated beyond Dose Level 4.
11462428|NCT01614184|Experimental|All patients|All patients enrolled in study.
11462429|NCT01614171|Experimental|Growth hormone therapy|Growth hormone treatment for 6 months
11462430|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements
~willingness to comply with the protocol (4 visits)
~45 - 80 years, informed consent
~acute N-AION (< 7 d)
~D-BCVA > 0.1 (2/20)
~RAPD ≥ 0.3 logE steps (neutral density filters)"
11462432|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
11462433|NCT01614132|Experimental|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):
~2 mg/m2 vincristin i.v.
~55,0 Gy Posterior cranial fossa (M0)
~55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)
~maintenance chemotherapy (8 cycles of 42 days):
~once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.
~once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
11462434|NCT01614119|Experimental|Sportsmen|One single group of active healthy subjects was investigated
11462435|NCT01614106|Experimental|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
11462436|NCT01614106|No Intervention|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
11462437|NCT01614093|Active Comparator|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
11462438|NCT01614093|Active Comparator|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
11462439|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
11462440|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
11462441|NCT01614067|Experimental|Delayed Start|Study subjects will receive be randomized to receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
11462442|NCT01614067|Active Comparator|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
11462443|NCT01614054|Experimental|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
11462444|NCT01614054|No Intervention|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
11462445|NCT01614041|Active Comparator|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
11462446|NCT01614041|Experimental|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
11462447|NCT01614028|Active Comparator|Total Hip Arthroplasty using Fitmore femoral stem|
11462448|NCT01614028|Active Comparator|Total Hip Arthroplasty using M/L Taper Femoral stem|
11462449|NCT01614015|Experimental|Supervision as Usual|Supervision as Usual
11462450|NCT01614015|Experimental|Observation Based Supervision|Behavioral
11462451|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
11462452|NCT01613989|Active Comparator|Treatment 1|Reference group, installation of hip prothesis following standard procedure
11462453|NCT01613989|Active Comparator|Treatment 2|:treatment group,installation of hip prosthesis with assistance by computer based on imaging EOS
11462454|NCT01613976|Experimental|Panobinostat and Azacitidine|combination regimen
11462455|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
11462456|NCT01613950|Experimental|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
11462457|NCT01613937|Experimental|Lifestyle|12 once weekly Lifestyle training program
11462458|NCT01613924|Placebo Comparator|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
11462459|NCT01613924|Active Comparator|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
11462460|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
11462461|NCT01613898||CTX Group|
11462462|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
11462463|NCT01613872|No Intervention|Control|Wait List Control
11462464|NCT01613872|Experimental|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
11462465|NCT01613846|Experimental|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.
~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
11462466|NCT01613846|Experimental|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:
~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
11462467|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
11462468|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
11462469|NCT01613820|Experimental|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
11462470|NCT01613820|Experimental|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
11462471|NCT01613820|Experimental|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
11462472|NCT01613807|Experimental|Mix 50/50|3 doses of Mix 50/50 at mealtime
11462473|NCT01613807|Active Comparator|Usual insulin regimen|3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
11462474|NCT01613794|No Intervention|No intervention|
11462475|NCT01613794|Experimental|Rosuvastatin|
11462476|NCT01613781|Active Comparator|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
11462477|NCT01613781|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
11462478|NCT01613768|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11462479|NCT01613755|Active Comparator|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
11462480|NCT01613755|Active Comparator|Metformin therapy|Metformin 500 mg twice daily for four days
11462481|NCT01613729|Active Comparator|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
11462482|NCT01613729|Active Comparator|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
11462483|NCT01613716|Experimental|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
11462484|NCT01613703|Experimental|Experimental|
11462485|NCT01613690|Experimental|Healthy volunteers|control group receiving 100 μg NVA237
11462486|NCT01613690|Experimental|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
11462487|NCT01613690|Experimental|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
11462488|NCT01613690|Experimental|Severe renal impairment|(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
11462489|NCT01613690|Experimental|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
11462490|NCT01613677|Experimental|BKM120|
11462491|NCT01613664|Experimental|tisseel|tisseel will be applied during the surgery
11462492|NCT01613664|Placebo Comparator|no tisseel|no tisseel will be applied during the surgery
11462493|NCT01613651|Experimental|Arm I (RALP)|Patients undergo RALP.
11462494|NCT01613651|Experimental|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
11462495|NCT01613638|Other|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.
~born from mothers living in Brittany at delivery
~with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth
~or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
11462496|NCT01613638|Other|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
11462497|NCT01613625|Experimental|Elastography|
11462498|NCT01613612|Sham Comparator|control group:core decompression|single core decompression
11462499|NCT01613612|Active Comparator|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
11462500|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
11462501|NCT01613586|Experimental|Low dose ASP3652 twice daily|50 mg twice daily for 12 weeks
11462502|NCT01613586|Experimental|Medium dose ASP3652 twice daily|150 mg twice daily for 12 weeks
11462503|NCT01613586|Experimental|High dose ASP3652 twice daily|300 mg twice daily for 12 weeks
11462504|NCT01613586|Placebo Comparator|Placebo|Matching placebo twice daily for 12 weeks
11462505|NCT01613560|Experimental|PEPI：2-4 group-A|
11462506|NCT01613560|Active Comparator|PEPI：2-4 group-B|
11462507|NCT01613560|Active Comparator|PEPI：0-1group|
11462508|NCT01613547|Active Comparator|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
11462509|NCT01613547|Placebo Comparator|No routine antibiotic prescription|
11462551|NCT01613261|Experimental|TAK-733 and alisertib|
11462510|NCT01613534|Experimental|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
11462511|NCT01613534|Placebo Comparator|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
11462512|NCT01613521|Experimental|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
11462513|NCT01613508|Active Comparator|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
11462514|NCT01613508|Active Comparator|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
11462515|NCT01613495|Placebo Comparator|Placebo|Normal Saline
11462516|NCT01613495|Active Comparator|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
11462517|NCT01613482|Active Comparator|Arm A|Without cerebral prophylactic radiation
11462518|NCT01613482|Experimental|Arm B|With cerebral prophylactic radiation
11462519|NCT01613469|Other|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
11462520|NCT01613456|Placebo Comparator|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
11462521|NCT01613456|Experimental|Saccharomyces cerevisiae CNCM I-3856|
11462522|NCT01613443||Control|Healthy volunteers without medication
11462523|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
11462524|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
11462525|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
11462526|NCT01613430|Active Comparator|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
11462527|NCT01613430|Experimental|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
11462528|NCT01613417|Active Comparator|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
11462529|NCT01613417|Active Comparator|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
11462530|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
11462531|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
11462532|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
11462533|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
11462534|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
11462535|NCT01613365|Experimental|chlorhexidine gluconate|
11462536|NCT01613365|Experimental|placebo|
11462537|NCT01613352|Experimental|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
11462538|NCT01613352|Active Comparator|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
11462539|NCT01613339|Experimental|Body awareness therapy|
11462540|NCT01613339|No Intervention|Control|
11462541|NCT01613326|Experimental|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
11462542|NCT01613326|Active Comparator|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
11462543|NCT01613313|Experimental|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
11462544|NCT01613313|Experimental|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
11462545|NCT01613313|Experimental|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
11462546|NCT01613313|Experimental|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
11462547|NCT01613300|Experimental|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
11462548|NCT01613287|Experimental|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
11462549|NCT01613274|Experimental|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
11462552|NCT01613248|Experimental|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
11462553|NCT01613248|Experimental|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
11462554|NCT01613248|Experimental|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
11462555|NCT01613248|Experimental|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
11462556|NCT01613248|Experimental|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
11462557|NCT01613248|Placebo Comparator|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
11462558|NCT01613235|No Intervention|No intervention|No induced hypertension (reference group)
11462559|NCT01613235|Active Comparator|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
11462560|NCT01613222|Experimental|Pulse oximetry monitoring|The U-TruSignal with different sensors is feasible for noninvasive and continuous SpO2 monitoring and meets the specified measurement accuracy when compared to a co-oximetry gold reference.
11462561|NCT01613209|Experimental|Olmesartan/Amlodipin fixed combination|
11462562|NCT01613196|Experimental|Positron Emission Tomography|Positron Emission Tomography
11462563|NCT01613183|Experimental|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
11462564|NCT01613183|Placebo Comparator|placebo group|
11462565|NCT01613170|Experimental|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
11462566|NCT01613170|Placebo Comparator|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
11462567|NCT01613144||OsseoScrew|
11462568|NCT01613144||Fenestrated Screw|
11462569|NCT01613131|Active Comparator|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
11462570|NCT01613131|Placebo Comparator|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
11462571|NCT01613118|Experimental|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.
~Patients at </= 50kg will receive half the RE-021 (Sparsentan) dose for the 8 week duration."
11462572|NCT01613118|Experimental|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.
~Patients at </= 50kg will receive half the RE-021 (Sparsentan) dose for the 8 week duration."
11462573|NCT01613118|Experimental|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.
~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
11462574|NCT01613118|Active Comparator|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.
~Patients at </= 50kg will receive 150mg irbesartan for the 8 week duration."
11462575|NCT01613105||Group 1|
11462576|NCT01613092|Experimental|Conventional|Preoperative Antibiotics
11462577|NCT01613092|Active Comparator|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
11462578|NCT01613079|Placebo Comparator|Methotrexate|Patients were treated with methotrexate alone.
11462579|NCT01613079|Experimental|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
11462580|NCT01613079|Experimental|MTX+T2|The patients were treated with methotrexate and T2.
11462581|NCT01613066|Experimental|Treatment|Patients with high risk haematological malignancies
11462582|NCT01613040|Experimental|Treatment A|
11462583|NCT01613040|Experimental|Treatment B|
11462584|NCT01613040|Placebo Comparator|Treatment C|
11462585|NCT01613040|Placebo Comparator|Treatment D|
11462586|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
11462587|NCT01613014|Placebo Comparator|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
11462588|NCT01613014|Active Comparator|ABT-436|ABT-436 Target dose of 400 mg BID
11462589|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:
~Documented preexisting musculoskeletal injury/disease before onset of obesity
~Hypothyroidism/Hyperthyroidism
~Hyperparathyroidism
~Osteopenia/Osteoporosis
~Nicotine dependence
~Alcohol dependence
~Eating disorders (anorexia nervosa, bulimia nervosa)
~Cancer requiring chemotherapy or radiation therapy
~Status-post gastrectomy
~Status-post bilateral oophorectomy
~Crohn's Disease
~Ulcerative Colitis
~Celiac Disease
~Cushing's Disease
~Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids
~Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
11462590|NCT01612988|Experimental|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
11462632|NCT01612663|Active Comparator|Energy of Living Systems Needling|
11462633|NCT01612663|Placebo Comparator|Sham acupuncture|
11462634|NCT01612650|Active Comparator|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
11462591|NCT01612975|Placebo Comparator|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
11462592|NCT01612975|Experimental|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
11462593|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
11462594|NCT01612949||easy to intubate, model derivation|easy to intubate, model derivation. photographing head and neck
11462595|NCT01612949||difficult to intubate, model derivation|difficult to intubate, model derivation.photographing head and neck
11462596|NCT01612949||easy to intubate, model validation|easy to intubate, model validation. photographing head and neck
11462597|NCT01612949||difficult to intubate, model validation|difficult to intubate, model validation. photographing head and neck
11462598|NCT01612936|Experimental|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
11462599|NCT01612923|Experimental|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
11462600|NCT01612923|No Intervention|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
11462601|NCT01612910|Experimental|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
11462602|NCT01612897|Experimental|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
11462603|NCT01612897|No Intervention|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
11462604|NCT01612884|Other|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA<69
11462605|NCT01612884|Other|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP >42.9% Clopidogrel response defined as MPA ADP <42.9%
11462606|NCT01612871|Experimental|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
11462607|NCT01612858|Experimental|Metformin|
11462608|NCT01612858|Experimental|Pioglitazone|
11462609|NCT01612845|Experimental|PRF|the group in which the PRF was administered
11462610|NCT01612845|Active Comparator|Control|repair without PRF
11462611|NCT01612832|Experimental|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
11462612|NCT01612832|Active Comparator|Control|no liryca treatment
11462613|NCT01612806|Experimental|PriMatrix|PriMatrix Dermal Repair Scaffold
11462614|NCT01612806|Experimental|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
11462615|NCT01612806|Active Comparator|Standard of Care|Standard of Care Moist Wound Therapy
11462616|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
11462617|NCT01612780|Experimental|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
11462618|NCT01612767|Experimental|Pro-Kinetic Energy Stent|
11462619|NCT01612754|No Intervention|Reference group - cloaked noise meters|"Reference group or phase 1
~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
11462620|NCT01612754|Sham Comparator|Control Noise AND Stress measurements|"Control Group - Phase 2
~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
11462621|NCT01612754|Experimental|Noise Reduction Intervention Group|"Intervention Group - Phase 3
~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
11462622|NCT01612741||Group 1|
11462623|NCT01612728|Experimental|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
11462624|NCT01612728|Other|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
11462625|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
11462626|NCT01612702|Experimental|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
11462627|NCT01612702|No Intervention|Control|No dexamethasone
11462628|NCT01612689|Experimental|Physiologic Data Collection|
11462629|NCT01612676|Experimental|Drug|FE 202158
11462630|NCT01612663|Active Comparator|deep needle non-site specific|
11462631|NCT01612663|Active Comparator|contralateral elbow to the knee pain|
11462635|NCT01612650|Active Comparator|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
11462636|NCT01612650|Active Comparator|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
11462637|NCT01612637|Experimental|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
11462638|NCT01612637|Active Comparator|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
11462639|NCT01612611||a cohort using Shenmai injection|
11462640|NCT01612598|Experimental|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.
~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
11462641|NCT01612546|Experimental|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
11462642|NCT01612520|Active Comparator|telecoaching|
11462643|NCT01612520|No Intervention|control|
11462644|NCT01612507|Experimental|A|600 mg Ceftaroline fosamil 1 h infusion
11462645|NCT01612507|Experimental|B|Placebo 1 h infusion
11462646|NCT01612507|Experimental|C|600 mg Ceftaroline fosamil 2 h infusion
11462647|NCT01612507|Experimental|D|Placebo 2 h infusion
11462648|NCT01612494|Placebo Comparator|Normal Saline|
11462649|NCT01612494|Experimental|Hypertonic Saline|
11462650|NCT01612481|Active Comparator|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
11462651|NCT01612481|Active Comparator|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
11462652|NCT01612468|Experimental|Liraglutide|
11462653|NCT01612468|Placebo Comparator|Placebo|
11462654|NCT01612455|No Intervention|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
11462655|NCT01612455|Experimental|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
11462656|NCT01612442|Experimental|Integrated education|
11462657|NCT01612442|No Intervention|Control|
11462658|NCT01612442|Experimental|Nutrition education|
11462659|NCT01612429|Experimental|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
11462660|NCT01612416|Sham Comparator|Normal subjects|
11462661|NCT01612416|Active Comparator|Primary open angle glaucoma|
11462662|NCT01612416|Active Comparator|Normal tension glaucoma|
11462663|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
11462664|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
11462665|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
11462666|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
11462667|NCT01612377|Experimental|prednisolone-dipyridamole|
11462668|NCT01612377|Active Comparator|prednisone 5mg|
11462669|NCT01612377|Active Comparator|prednisone 7.5mg|
11462670|NCT01612364|Experimental|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
11462671|NCT01612364|Active Comparator|control block|Same medication used in experimental group, but in dorsal subcutaneous
11462672|NCT01612351|Experimental|Non-Randomized Single-Arm|All participants will receive induction chemotherapy and transoral surgery. Following surgery, participants will be stratified into a risk category (low, medium, or high). Subjects in the low risk category will receive no further treatment after their transoral surgery. Subjects in the medium risk category will receive ipsilateral radiation concurrent with weekly cisplatin, and subjects in the high risk category will receive cisplatin every three weeks with concurrent bilateral radiation.
11462673|NCT01612338|Experimental|Targeted|Targeted letter and booklet
11462674|NCT01612338|Experimental|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
11462675|NCT01612325|Experimental|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
11462676|NCT01612312|Active Comparator|Thrombectomy|
11462677|NCT01612312|Other|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
11462678|NCT01612299|Active Comparator|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
11462681|NCT01612273|Experimental|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
11462682|NCT01612273|Experimental|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
11462683|NCT01612260|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
11462684|NCT01612260|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
11462685|NCT01612234|Experimental|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
11462686|NCT01612234|Experimental|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
11462687|NCT01612221|Experimental|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
11462688|NCT01612221|Placebo Comparator|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
11462689|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
11462690|NCT01612195|Experimental|Anal fistula plug|
11462691|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
11462692|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
11462693|NCT01612169|No Intervention|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.
~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
11462694|NCT01612169|Experimental|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
11462695|NCT01612169|Experimental|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.
~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
11462696|NCT01612156|Active Comparator|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
11462697|NCT01612156|Active Comparator|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
11462698|NCT01612143|Active Comparator|A: STV capsule (after high fat meal)|
11462699|NCT01612143|Active Comparator|B: STV capsule (fasted state)|
11462700|NCT01612143|Experimental|C: STV tablet (after high fat meal)|
11462701|NCT01612143|Experimental|D: STV tablet (fasted state)|
11462702|NCT01612130|Experimental|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
11462703|NCT01612130|Placebo Comparator|Placebo (100 mg)|Placebo 100mg
11462704|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
11462705|NCT01612104|Experimental|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
11462706|NCT01612091|Experimental|Monitoring Messenger|
11462707|NCT01612091|Active Comparator|Control|Traditional tools (monitors, paper records)
11462708|NCT01612078|Experimental|Droxidopa, antihypotensive drug, tablet|
11462709|NCT01612078|Placebo Comparator|placebo, tablet|
11462710|NCT01612065|Active Comparator|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
11462711|NCT01612065|Active Comparator|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
11462712|NCT01612052|Active Comparator|Cefazolin plus Daptomycin|
11462713|NCT01612052|Active Comparator|Cefazolin plus Vancomycin|
11462714|NCT01612039|Experimental|ASP3291|
11462715|NCT01612039|Placebo Comparator|Placebo|
11462716|NCT01612026||Ultrasound|
11462717|NCT01612026||Fluoroscopy|
11462718|NCT01612013|Active Comparator|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
11462762|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
11464267|NCT01601210|Active Comparator|2 grams of creatine|
11462719|NCT01612013|Active Comparator|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
11462720|NCT01612013|Active Comparator|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
11462721|NCT01612013|Placebo Comparator|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
11462722|NCT01612000|Experimental|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11462723|NCT01612000|Experimental|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11462724|NCT01612000|Experimental|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11462725|NCT01612000|Experimental|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
11462726|NCT01611987|Experimental|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
11462727|NCT01611987|Active Comparator|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
11462728|NCT01611974|Experimental|Maribavir 400 mg twice daily|
11462729|NCT01611974|Experimental|Maribavir 800 mg twice daily|
11462730|NCT01611974|Experimental|Maribavir 1200 mg twice daily|
11462731|NCT01611961|Experimental|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
11462732|NCT01611961|Active Comparator|Taxotere|Commerical Product
11462733|NCT01611948|Active Comparator|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
11462734|NCT01611948|Placebo Comparator|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
11462735|NCT01611935|Active Comparator|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
11462736|NCT01611935|Placebo Comparator|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
11462737|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
11462738|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
11462739|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
11462740|NCT01611909|Experimental|2% PMDO|
11462741|NCT01611909|Experimental|5% PMDO|
11462742|NCT01611909|Active Comparator|Mupirocin|
11462743|NCT01611896|Active Comparator|Selenium|
11462744|NCT01611896|Placebo Comparator|Placebo|
11462745|NCT01611883|Experimental|Ezetimibe|10 mg oral dose once daily for 24 weeks
11462746|NCT01611883|Placebo Comparator|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
11462747|NCT01611857|Experimental|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
11462748|NCT01611844|Experimental|Medical device : micro-needle BD 1.5 mm 30G|
11462749|NCT01611844|Active Comparator|Manthoux method: lance 26G X 16mm|
11462750|NCT01611831|Experimental|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
11462751|NCT01611831|Active Comparator|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
11462752|NCT01611818|Other|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
11462753|NCT01611818|Other|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
11462754|NCT01611818|Other|Improved treatment as usual by GP|
11462755|NCT01611805|Experimental|GSK1605786 250mg|Opaque Swedish orange body and cap.
11462756|NCT01611805|Placebo Comparator|Placebo|Opaque Swedish orange body and cap.
11462757|NCT01611805|Experimental|GSK1605786 500mg|Opaque Swedish orange body and cap.
11462758|NCT01611805|Experimental|GSK1605786 1000mg|Opaque Swedish orange body and cap.
11462759|NCT01611805|Experimental|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
11462760|NCT01611792|Experimental|Stabilization|
11462761|NCT01611792|Active Comparator|Strengthening and Conditioning|
11462763|NCT01611766|Experimental|secondary cytoreductive surgery|SCR followed by chemotherapy
11462764|NCT01611766|Active Comparator|Salvage Chemotherapy|platinum-based chemotherapy
11462765|NCT01611753|Active Comparator|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
11462766|NCT01611753|Active Comparator|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
11462767|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
11462768|NCT01611727|Experimental|Cisplatin|
11462769|NCT01611714|Experimental|Audit-feedback|Arm 1: Audit-feedback only
11462770|NCT01611714|Experimental|CDS message|Arm 2: CDS message only
11462771|NCT01611714|Experimental|Both Interventions|Arm 3: Audit-feedback and CDS message
11462772|NCT01611714|No Intervention|Control|Arm 4: Control
11462773|NCT01611701|Active Comparator|Cryoballoon group|
11462774|NCT01611701|Active Comparator|RF group|
11462775|NCT01611688|Experimental|Active|
11462776|NCT01611688|Placebo Comparator|Placebo|
11462777|NCT01611675|Experimental|Treatment Arm|Leflunomide + Vemurafenib
11462778|NCT01611662|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
11462779|NCT01611649|Experimental|Dairy lipids and plant oils|
11462780|NCT01611649|Experimental|Plant oils|
11462781|NCT01611649|Experimental|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
11462782|NCT01611649|No Intervention|Human milk|
11462783|NCT01611623|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
11462784|NCT01611610|Other|Ambulant SMA|
11462785|NCT01611610|Other|Non-ambulant SMA|
11462786|NCT01611584|Experimental|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
11462787|NCT01611571|Active Comparator|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
11462788|NCT01611571|Active Comparator|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
11462789|NCT01611571|Active Comparator|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
11462790|NCT01611558|Experimental|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
11462791|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
11462792|NCT01611532||Acute pancreatitis|All adult patients (>18y.o.) requiring admission for acute pancreatitis (amylase >3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
11462793|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
11462794|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
11462795|NCT01611506|Experimental|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:
~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.
~Followed by:
~Radio-chemo-immunotherapy:
~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week
~Surgery:
~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy
~Postoperative treatment:
~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
11462796|NCT01611493|Experimental|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
11462797|NCT01611493|Active Comparator|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
11462798|NCT01611467|Experimental|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
11462799|NCT01611467|Experimental|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
11462800|NCT01611467|Experimental|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
11462801|NCT01611454|Experimental|XPF thyroid collar|Administration of the XPF Thyroid Collar.
11462802|NCT01611454|Active Comparator|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar.
11462803|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
11462804|NCT01611428|Experimental|Ipragliflozin - oral|open label
11462805|NCT01611428|Experimental|Ipragliflozin - i.v.|open label
11462806|NCT01611415|Experimental|ipragliflozin|
11462807|NCT01611415|Experimental|furosemide|
11462808|NCT01611415|Experimental|ipragliflozin & furosemide|
11462809|NCT01611389|Experimental|Long AV delay.|
11462810|NCT01611389|Active Comparator|Short AV delay.|
11462811|NCT01611363|Experimental|Part A|Ipragliflozin (low dose) & Placebo
11462812|NCT01611363|Experimental|Part B|Ipragliflozin (high dose)
11462891|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
11462813|NCT01611350|Experimental|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
11462814|NCT01611350|Experimental|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
11462815|NCT01611350|Experimental|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
11462816|NCT01611350|Experimental|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
11462817|NCT01611350|Experimental|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
11462818|NCT01611337|Other|insight evaluation|insight evaluation using the Q8 scale
11462819|NCT01611324|Experimental|Alkalinised anesthetic solution|
11462820|NCT01611324|Active Comparator|Non alkalinised anesthetic solution|
11462821|NCT01611311|Experimental|BI 409306 BS medium dose|Film-coated tablet
11462822|NCT01611311|Experimental|BI 409306 BS high dose|Film-coated tablet
11462823|NCT01611311|Placebo Comparator|Placebo|Film-coated tablet
11462824|NCT01611298|Experimental|Single arm: Tetanus Toxoid|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
11462825|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
11462826|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
11462827|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
11462828|NCT01611259|Experimental|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
11462829|NCT01611246||Anesthetization|Anesthetization
11462830|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
11462831|NCT01611220|No Intervention|Control|Standard cognitive behavior inpatient treatment
11462832|NCT01611220|Experimental|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
11462833|NCT01611207|Experimental|Negative Pressure Wound Therapy|Used therapy systems
11462834|NCT01611207|Active Comparator|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
11462835|NCT01611194|Experimental|HBO2 at 1.5 Atomspheres Absolute (ATA)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
11462836|NCT01611194|Sham Comparator|Sham Control (1.2 Atomspheres)|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
11462837|NCT01611181|Active Comparator|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
11462838|NCT01611181|Active Comparator|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
11462839|NCT01611181|Active Comparator|Ferrofumerat (iron supplementation)|Ferrous sulphate
11462840|NCT01611168|No Intervention|Usual Care|
11462841|NCT01611168|Experimental|Intervention Group, treatment algorithms|
11462842|NCT01611155|Experimental|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
11462843|NCT01611155|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
11462844|NCT01611142|Experimental|KW-0761|
11462845|NCT01611129|Active Comparator|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
11462846|NCT01611129|Experimental|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
11462847|NCT01611116|Placebo Comparator|sodium chloride solution 0.9%|
11462848|NCT01611116|Experimental|temsirolimus|
11462849|NCT01611103|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
11462850|NCT01611103|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
11462851|NCT01611090|Experimental|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
11462852|NCT01611090|Placebo Comparator|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
11462853|NCT01611077|Other|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
11462854|NCT01611064|Active Comparator|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
11462855|NCT01611064|Placebo Comparator|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
11462856|NCT01611051|Experimental|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
11462857|NCT01611051|Experimental|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
11462858|NCT01611051|Active Comparator|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
11462859|NCT01611038|Placebo Comparator|Placebo|Placebo given daily
11462860|NCT01611038|Experimental|Methylselenocysteine|Methylselenocysteine given daily
11462861|NCT01610999|Experimental|Cohort A|0.24 mg/kg plerixafor on day 1
11462862|NCT01610999|Experimental|Cohort B|0.24 mg/kg plerixafor daily on days 1 & 2
11462863|NCT01610999|No Intervention|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
11462864|NCT01610986|Experimental|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
11462865|NCT01610986|Experimental|Water|Participants will take only water during training sessions
11462866|NCT01610973|Experimental|Manual preparation|Manual preparation of the graft
11462867|NCT01610973|Active Comparator|Automatized preparation|Automatized preparation of the graft with microkeratoma
11462868|NCT01610960|Active Comparator|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
11462869|NCT01610960|Sham Comparator|Facemask|The facemask will be used by each patient.
11462870|NCT01610947|Active Comparator|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
11462871|NCT01610947|Active Comparator|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
11462872|NCT01610934|Experimental|liraglutide|
11462873|NCT01610934|Active Comparator|glimepiride|
11462874|NCT01610921|Experimental|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
11462875|NCT01610908|Experimental|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
11462876|NCT01610908|No Intervention|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace [if meeting SRS criteria]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
11462877|NCT01610908|Active Comparator|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).
~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
11462878|NCT01610895|Active Comparator|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
11462879|NCT01610895|Placebo Comparator|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
11462880|NCT01610882|Other|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
11462881|NCT01610882|Other|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
11462882|NCT01610869|Experimental|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
11462883|NCT01610869|Placebo Comparator|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
11462884|NCT01610856|Experimental|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
11462885|NCT01610856|Active Comparator|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
11462886|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
11462887|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:
~Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)
~Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
11462888|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
11462889|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
11462890|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
11462895|NCT01610765|Active Comparator|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
11462896|NCT01610765|Placebo Comparator|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
11462897|NCT01610752|Experimental|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
11462898|NCT01610752|Experimental|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
11462899|NCT01610752|No Intervention|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
11462900|NCT01610739|Other|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
11462901|NCT01610726|Active Comparator|enhanced recovery|
11462902|NCT01610726|No Intervention|conventional recovery|
11462903|NCT01610713|Experimental|GW-1000-02|Active treatment.
11462904|NCT01610700|Experimental|GW-1000-02|Active treatment
11462905|NCT01610700|Placebo Comparator|Placebo|Control
11462906|NCT01610687|Experimental|GW-1000-02|Active treatment
11462907|NCT01610674|Experimental|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
11462908|NCT01610674|No Intervention|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
11462909|NCT01610661|Other|Unrefined-carbohydrate|unrefined carbohydrate diet
11462910|NCT01610661|Other|Refined-carbohydrate|refined carbohydrate diet
11462911|NCT01610661|Other|Simple-carbohydrate|simple carbohydrate diet
11462912|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
11462913|NCT01610635|Experimental|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
11462914|NCT01610635|Experimental|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
11462915|NCT01610635|No Intervention|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
11462916|NCT01610635|Experimental|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
11462917|NCT01610635|Experimental|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
11462918|NCT01610635|No Intervention|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
11462919|NCT01610609|Experimental|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
11462920|NCT01610609|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
11462921|NCT01610596|Experimental|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
11462922|NCT01610596|Placebo Comparator|Vehicle Lotion|Topical lotion, applied twice daily
11462923|NCT01610570|Experimental|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
11462924|NCT01610570|Experimental|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
11462925|NCT01610570|Experimental|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
11462926|NCT01610570|Experimental|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
11462927|NCT01610557|Experimental|Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series|"Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).
~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
11462928|NCT01610557|Experimental|Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series|"Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).
~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
11462929|NCT01610557|Experimental|Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series|"Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).
~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
11462966|NCT01610284|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
11462930|NCT01610557|Experimental|Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series|"Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).
~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
11462931|NCT01610518|Experimental|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
11462932|NCT01610518|Experimental|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
11462933|NCT01610518|Experimental|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
11462934|NCT01610518|Experimental|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
11462935|NCT01610518|Placebo Comparator|250mL control|250 mL beverage containing 50g glucose
11462936|NCT01610518|Placebo Comparator|600mL control|600mL beverage containing 50g glucose
11462937|NCT01610492|Experimental|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
11462938|NCT01610479|Experimental|TAS-114/S-1|TAS-114 plus S-1
11462939|NCT01610466|Experimental|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
11462940|NCT01610466|No Intervention|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
11462941|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
11462942|NCT01610440|Experimental|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
11462943|NCT01610427|Experimental|HIV-1 Group|Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected. No investigational vaccine was administered.
11462944|NCT01610414|Experimental|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
11462945|NCT01610414|Placebo Comparator|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
11462946|NCT01610401|Active Comparator|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
11462947|NCT01610401|No Intervention|No pretreatment.|no intervention
11462948|NCT01610401|Active Comparator|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
11462949|NCT01610401|Other|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
11462950|NCT01610388|Experimental|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
11462951|NCT01610388|Experimental|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
11462952|NCT01610388|Experimental|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
11462953|NCT01610388|Experimental|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
11462954|NCT01610388|Experimental|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
11462955|NCT01610388|Experimental|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
11462956|NCT01610388|Experimental|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
11462957|NCT01610375|Other|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
11462958|NCT01610362|Active Comparator|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
11462959|NCT01610362|Experimental|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
11462960|NCT01610336|Experimental|INC280+gefitinib|NSCLC patients with cMET dysregulation. During Phase I part, participants will receive combination treatment with escalating doses of INC280 and gefitinib 250 mg once daily. During Phase II part, INC280 will be taken at recommended phase II dose.
11462961|NCT01610323|Experimental|Exercise group|Exercise intervention
11462962|NCT01610323|Other|Control group|Standard care
11462963|NCT01610310|Experimental|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
11462964|NCT01610310|Experimental|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
11462965|NCT01610297|Experimental|ICL670|Oral dose of ICL670 at 10 mg/kg daily
11463053|NCT01609621||Retrograde access|
11462967|NCT01610284|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
11462968|NCT01610271|Experimental|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
11462969|NCT01610271|No Intervention|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
11462970|NCT01610245|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets and one placebo capsule twice daily with food for 5 days
11462971|NCT01610245|Active Comparator|Oseltamivir|Two placebo tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
11462972|NCT01610245|Active Comparator|Nitazoxanide and Oseltamivir|Two nitazoxanide 300 mg tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
11462973|NCT01610245|Placebo Comparator|Placebo|Two placebo tablets and one placebo capsule with food twice daily for 5 days
11462974|NCT01610232|Experimental|LED Group|Phototherapy associated with treadmill training
11462975|NCT01610232|Active Comparator|Exercise Group|Treadmill training
11462976|NCT01610232|No Intervention|Sedentary Group|Neither physical training nor phototherapy
11462977|NCT01610219|Active Comparator|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
11462978|NCT01610219|Other|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
11462979|NCT01610206|Active Comparator|gemcitabine|
11462980|NCT01610206|Experimental|Gemcitabine + pazopanib|
11462981|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
11462982|NCT01610180|Other|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
11462983|NCT01610167|Active Comparator|NUPRO(r) Classic Prophy Paste|
11462984|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
11462985|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin|
11462986|NCT01610154|Experimental|Sitagliptin treatment|
11462987|NCT01610141|Experimental|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
11462988|NCT01610141|Active Comparator|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
11462989|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
11462990|NCT01610089|Experimental|stable isotope infusion|Infusion of isotopes [15N2-ureido] arginine, [5-13C,4, 4, 5, 5-D4] citrulline, [15N]citrulline, 15N sodium nitrate and [15N][18O3] potassium nitrate,[18O][13C]urea.
11462991|NCT01610076|No Intervention|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
11462992|NCT01610076|Experimental|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
11462993|NCT01610063|Experimental|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
11462994|NCT01610063|No Intervention|Unguided|Treatment as usual
11462995|NCT01610050|Experimental|LFA102|
11462996|NCT01610037|Experimental|QVA149|
11462997|NCT01610037|Active Comparator|Tiotropium|
11462998|NCT01610037|Placebo Comparator|placebo|
11462999|NCT01610024|Active Comparator|Beetroot|
11463000|NCT01610011|Experimental|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
11463001|NCT01609998|Experimental|Group 1A (12-17yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
11463002|NCT01609998|Experimental|Group 1B (6-11yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
11463003|NCT01609998|Experimental|Group 2A (12-17yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
11463004|NCT01609998|Experimental|Group 2B (6-11yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
11463005|NCT01609998|Active Comparator|Group 3A: (12-17yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
11463006|NCT01609998|Active Comparator|Group 3B: (6-11yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
11463007|NCT01609972|Experimental|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
11463008|NCT01609972|Active Comparator|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
11463009|NCT01609959|Active Comparator|Azilsartan group|
11463010|NCT01609959|Active Comparator|Valsartan group|
11463011|NCT01609933|Experimental|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 [paritaprevir] 200 mg once daily [QD], ritonavir 100 mg QD, ABT-267 [ombitasvir] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
11463012|NCT01609920|Experimental|Gadofosveset MRL|
11463013|NCT01609907|Experimental|Sequence 1|
11463014|NCT01609907|Experimental|Sequence 2|
11463015|NCT01609907|Experimental|Sequence 3|
11463016|NCT01609907|Experimental|Sequence 4|
11463017|NCT01609907|Experimental|Sequence 5|
11463018|NCT01609907|Experimental|Sequence 6|
11463054|NCT01609608|Experimental|vibration|
11463055|NCT01609608|Placebo Comparator|placebo|
11463056|NCT01609595|Experimental|Treatment|Study drug treatment
11464268|NCT01601210|Active Comparator|4 grams of creatine|
11463019|NCT01609894|Experimental|Individualized fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.
~Routine fortifier will be added to breast milk batches.
~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
11463020|NCT01609894|Active Comparator|Routine fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.
~Routine fortifier will be added to breast milk batches."
11463021|NCT01609881|Other|Acuvail|Acuvail as preventive for inflammation and possible decrease or prevent diabetic retinopathy. The study has four arms - diabetic ketorolac, diabetic control, normal eyes ketorolac, normal eyes control. patients are randomized to ketorolac or control.
11463022|NCT01609881|Placebo Comparator|Placebo|Placebo using artificial tear drops
11463023|NCT01609868|Active Comparator|control|infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
11463024|NCT01609868|Experimental|experimental|this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
11463025|NCT01609855|Experimental|HBB- Hioscine Butyl Bromide|
11463026|NCT01609855|Placebo Comparator|Placebo arm|
11463027|NCT01609842|Experimental|Phone reminders and pharmacist|An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.
11463028|NCT01609842|Other|Usual Care|The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites
11463029|NCT01609816|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
11463030|NCT01609803||Correlative studies|Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.
11463031|NCT01609790|Experimental|Arm I (bevacizumab and trebananib)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11463032|NCT01609790|Active Comparator|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
11463033|NCT01609777|Other|Handover with SBAR|Handover with handover tool.
11463034|NCT01609764|Experimental|Exercise|Follows the fitness program as described in the intervention
11463035|NCT01609764|No Intervention|Control|Will not follow any regular fitness activity during one year
11463036|NCT01609751|Experimental|Yakult 62 ml daily|
11463037|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
11463038|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF <35% and LBBB)
11463039|NCT01609725|Experimental|Comprehensive treatment|Test treatment group
11463040|NCT01609725|Other|Community treatment|Control treatment group
11463041|NCT01609712||Patient with vertebral compression fracture|RF kyphoplasty is standard of care in our hospital for patients with osteoporortic compression fractures. We are intersetd, if it also can improve the lung function.
11463042|NCT01609699|Experimental|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
11463043|NCT01609699|Experimental|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
11463044|NCT01609673|No Intervention|Control|"35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.
~Medications will be administered orally, twice a day"
11463045|NCT01609673|Active Comparator|Intervention|"35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.
~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.
~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
11463046|NCT01609660|No Intervention|Control group|No intervention at all
11463047|NCT01609660|Experimental|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
11463048|NCT01609647|Experimental|Prasugrel|Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
11463049|NCT01609647|Active Comparator|Clopidogrel|Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
11463050|NCT01609634|Active Comparator|Key Group of interest|Subjects who started test product / control product 1 / control product 2 by 1-month of age
11463051|NCT01609634|Active Comparator|Other-fed Group|Subjects who started test product / control product 1 / control product 2 and continued on breast-feeding
11463052|NCT01609634|Active Comparator|Breast Fed Reference Group|Subjects who are exclusively breast-fed up to 4 months of age and not started on test product / control product 1 / control product 2.
11463057|NCT01609582|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
11463058|NCT01609582|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
11463059|NCT01609569||coronary complication|"patients with coronary complication and patients without coronary complications.
~pro-calcitonin will be measured in both groups to see if any correlation."
11463060|NCT01609556|Experimental|IMGN853|
11463061|NCT01609543|Experimental|Single Arm|
11463062|NCT01609530|Active Comparator|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
11463063|NCT01609530|Experimental|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
11463064|NCT01609517||Obese group|patients with BMI >= 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
11463065|NCT01609517||Non-obese group|patients with BMI < 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
11463066|NCT01609504|Experimental|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
11463067|NCT01609504|Active Comparator|Total Mesorectal Excision|
11463068|NCT01609491|Active Comparator|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) will be used in the syringes
11463069|NCT01609491|Active Comparator|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
11463070|NCT01609478|Experimental|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler
~Background therapy: mometasone furoate 200 mcg od"
11463071|NCT01609478|Experimental|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler
~Background therapy: mometasone furoate 200 mcg od"
11463072|NCT01609478|Placebo Comparator|placebo|"placebo delivered via Concept 1 inhaler
~Background therapy: mometasone furoate 200 mcg od"
11463073|NCT01609465||Stable angina|
11463074|NCT01609452|Experimental|Blisibimod|
11463075|NCT01609452|Placebo Comparator|Placebo|
11463076|NCT01609439|Placebo Comparator|Placebo|
11463077|NCT01609439|Experimental|Treatment|Pre-operative Vitamin D 800 units x 4 weeks
11463078|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
11463079|NCT01609413|Experimental|AlgaeCal|Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
11463080|NCT01609413|Active Comparator|Caltrate 600|Proprietary calcium supplement. One dose contains 600 mg of calcium.
11463081|NCT01609400||Breast enhancement|
11463082|NCT01609387|Experimental|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
11463083|NCT01609387|Active Comparator|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
11463084|NCT01609387|Experimental|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
11463085|NCT01609387|Active Comparator|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
11463086|NCT01609387|Experimental|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
11463087|NCT01609387|Active Comparator|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
11463088|NCT01609374|Experimental|M6-C Artificial Cervical Disc|
11463089|NCT01609374|Active Comparator|Anterior Cervical Discectomy and Fusion|
11463090|NCT01609361|No Intervention|1: Standard surgery + Standard care|standard surgery and Standard care after surgery
11463091|NCT01609361|Other|2: Laparoscopy + Rehabilitation program|Laparoscopic colorectal surgery with rehabilitation program
11463092|NCT01609348|Active Comparator|Venlafaxine|225 mg daily over 12 weeks
11463093|NCT01609348|Placebo Comparator|Sugar pill|
11463094|NCT01609335|Other|Cognitively Normal Subjects|Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
11463095|NCT01609322|Active Comparator|Education about falls|In-person education about falls with a health educator.
11463096|NCT01609322|Experimental|Activity, Balance, Learning, and Exposure|Intervention combining medication review, exercise, home safety evaluation, and exposure therapy.
11463097|NCT01609309|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11463098|NCT01609309|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
11463099|NCT01609296|Experimental|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
11463100|NCT01609283|Experimental|Autologous Mesenchymal Stem Cells|
11463101|NCT01609270||CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
11463102|NCT01609257|Experimental|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
11463103|NCT01609257|Placebo Comparator|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
11463104|NCT01609244|Active Comparator|Bilevel|Bilevel therapy
11463105|NCT01609244|Active Comparator|Servoventilation|servoventilation therapy
11463106|NCT01609231|Experimental|Arm A: Dalotuzumab + Irinotecan|Participants receive irinotecan intravenously (IV), 180 mg/m^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
11463107|NCT01609231|Active Comparator|Arm B: Cetuximab + Irinotecan|Participants receive cetuximab IV, initial dose of 400 mg/m^2 and then 250 mg/m^2 IV weekly + irinotecan IV, 180 mg/m^2 once every two weeks, during ≥1 42-day treatment cycle(s).
11463108|NCT01609218|Experimental|80 mg LY2140023|Single oral dose of 80 mg LY2140023 administered alone
11463109|NCT01609218|Experimental|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 g aqueous activated charcoal
11463110|NCT01609205|Experimental|Arm 1|Adalimumab
11463111|NCT01609192|Experimental|hydroxyurea|
11463112|NCT01609179|Experimental|IPI-926|
11463113|NCT01609166|Experimental|Allopurinol 3% cream|Allopurinol 3% cream in one side of the body
11463114|NCT01609166|Placebo Comparator|Placebo cream|Placebo cream in the other side of the body
11463115|NCT01609153|Active Comparator|Olanzapine or Placebo|
11463116|NCT01609153|Active Comparator|Amisulpride or Placebo|
11463117|NCT01609153|Active Comparator|Olanzapine and Amisulpride|
11463118|NCT01609140|Experimental|A|
11463119|NCT01609140|Experimental|B|
11463120|NCT01609140|Experimental|C|
11463121|NCT01609140|Experimental|D|
11463122|NCT01609140|Experimental|E|
11463123|NCT01609140|Placebo Comparator|F|
11463124|NCT01609127|Experimental|Tesetaxel every 3 weeks|Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle
11463125|NCT01609127|Experimental|Tesetaxel weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle
11463126|NCT01609127|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle
11463127|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
11463128|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
11463129|NCT01609101|Other|Coopdech® videolaryngoscope|
11463130|NCT01609101|Other|C-MAC® videolaryngoscope|
11463131|NCT01609101|Other|McGrath® Series 5 videolaryngoscope|
11463132|NCT01609101|Other|Glidescope® Cobalt videolaryngoscope|
11463133|NCT01609101|Other|King Vision® videolaryngoscope|
11463134|NCT01609101|Other|Venner® videolaryngoscope|
11463135|NCT01609101|Other|McGrath MAC® videolaryngoscope|
11463136|NCT01609088|Experimental|Erythritol-containing beverage|
11463137|NCT01609075||Cohort|
11463138|NCT01609062|Experimental|BMN 110 Weekly at 2.0 mg/kg/week|
11463139|NCT01609062|Experimental|BMN 110 Weekly at 4.0 mg/kg/week|
11463140|NCT01609049||Participants with Chronic Hepatitis C|Naive and previously treated participants who received peginterferon alfa-2a in combination with ribavirin as per local labeling requirements.
11463141|NCT01609036||Cohort|
11463142|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
11463143|NCT01609010|Active Comparator|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
11463144|NCT01609010|Experimental|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
11463145|NCT01608984|Active Comparator|RIPC-CABG|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
11463146|NCT01608984|Placebo Comparator|Control-CABG|Control group: Coronary artery bypass grafting without RIPC protocol
11463147|NCT01608984|Active Comparator|RIPC-OPCAB|Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.
11463148|NCT01608984|Placebo Comparator|Control-OPCAB|Control group: Off-pump Coronary artery bypass surgery without RIPC protocol
11463149|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
11463150|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
11463151|NCT01608958|Active Comparator|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
11463152|NCT01608958|Active Comparator|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
11463153|NCT01608945||steroid,liver function I/R|
11463154|NCT01608932|No Intervention|Control Group|Treatment as usual
11463155|NCT01608932|Experimental|Telemonitoring for frail patients with chronic diseases|Telemonitoring for frail patients with chronic diseases
11463156|NCT01608919|No Intervention|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
11463157|NCT01608906|Experimental|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
11463158|NCT01608906|Active Comparator|subcutanous heparin 5000 units 3 times/day|standard of care
11463159|NCT01608893|Active Comparator|Metoprolol|The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
11463160|NCT01608893|Active Comparator|Carvedilol|The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.
11463161|NCT01608880|Placebo Comparator|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
11463162|NCT01608880|Active Comparator|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
11463163|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
11463164|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
11463165|NCT01608841|No Intervention|Gemcitabine|
11463166|NCT01608841|Experimental|Gemcitabine plus erlotinib|
11463167|NCT01608815|Experimental|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
11463168|NCT01608802|Active Comparator|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
11463169|NCT01608802|Experimental|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
11463170|NCT01608789|Experimental|Virtue® Male Sling|Patient implanted Virtue® Male Sling
11463171|NCT01608776|Active Comparator|SOC - Standard of Care|Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
11463172|NCT01608776|Active Comparator|SOC + MIST Therapy|Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment
11463173|NCT01608763|Experimental|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
11463174|NCT01608763|Experimental|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
11463175|NCT01608763|Experimental|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
11463176|NCT01608763|No Intervention|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
11463177|NCT01608750|Experimental|pantoprazole|
11463178|NCT01608750|Placebo Comparator|folic acid|
11463179|NCT01608737|Experimental|2. BI 201335 for 24 weeks|BI 201335 once daily low dose for 24 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
11463180|NCT01608737|Experimental|3. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
11463181|NCT01608737|Active Comparator|1. PegIFN/RBV|PegIFN/RBV for 48 weeks in treatment-naive patients
11463182|NCT01608737|Active Comparator|4. PegIFN/RBV|PegIFN/RBV for 48 weeks in prior relapser patients
11463183|NCT01608737|Experimental|5. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in prior relapser patients
11463184|NCT01608724|Experimental|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
11463185|NCT01608711|Experimental|AGS-1C4D4 plus gemcitabine|Subjects will receive a maintenance dose of AGS-1C4D4 every 3 weeks (Q3W) in addition to the gemcitabine administration.
11463186|NCT01608698|Experimental|Belara|The participants who receive OCP in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®).
11463187|NCT01608698|Experimental|Yasmin|The participants who receive OCP in combination of 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®).
11463188|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
11463189|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
11463190|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
11463191|NCT01608646|No Intervention|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
11463192|NCT01608633|Experimental|Spray and stretch|
11463193|NCT01608633|No Intervention|Control|
11463194|NCT01608594|Experimental|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
11463195|NCT01608594|Experimental|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
11463196|NCT01608581|Experimental|exposure to multi-media campaign|A multimedia campaign highlighting dangers of gasoline and fire was delivered to an intervention region in the state of Queensland
11463197|NCT01608568|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
11463263|NCT01608061|Sham Comparator|DBS-f off|DBS-f off
11463264|NCT01608048|No Intervention|control|
11463198|NCT01608568|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
11463199|NCT01608555|Experimental|inhaled tobramycin once-a-day|Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
11463200|NCT01608542|Experimental|Fostamatinib 100mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses
11463201|NCT01608542|Experimental|Fostamatinib 200mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses
11463202|NCT01608529|Experimental|Cyclist group|
11463203|NCT01608516|Experimental|68Ga-NODAGA-RGD radiotracer|All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.
11463204|NCT01608503|Experimental|respiration cycle|lung inflation and deflation
11463205|NCT01608490|Experimental|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
11463206|NCT01608490|No Intervention|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
11463207|NCT01608464|Active Comparator|Arm A|Arm A: will receive combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
11463208|NCT01608464|Experimental|Arm B|"Arm B will receive combination of cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
~PET scan will be repeated 3-4 weeks after end of concurrent chemo-radiation therapy Patients in Arm A and B will go for esophagectomy 4-6 weeks after end of concurrent chemo-radiation therapy or chemotherapy"
11463209|NCT01608451|No Intervention|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
11463210|NCT01608451|Active Comparator|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
11463211|NCT01608451|Active Comparator|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
11463212|NCT01608451|Active Comparator|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
11463213|NCT01608438|Experimental|SCI Static|SCI group that practices with a static body-machine map
11463214|NCT01608438|Experimental|SCI Machine Learning|Spinal Cord Injury patients who practice with a body-machine map that is adapted using machine learning
11463215|NCT01608425|No Intervention|Control|Control group. Regular treatment.
11463216|NCT01608425|Experimental|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
11463217|NCT01608412|Active Comparator|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.
~Intervention arm: Tacrolimus"
11463218|NCT01608412|Active Comparator|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.
~Intervention arm: Everolimus"
11463219|NCT01608399|Experimental|Metacognitive therapy|
11463220|NCT01608399|No Intervention|Waiting list control|
11463221|NCT01608386|Experimental|anterior approach+IVC clamping|Use anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
11463222|NCT01608386|No Intervention|anterior approach|Only use anterior approach in right hepatectomy for HCC patients.
11463223|NCT01608373|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
11463224|NCT01608373|Active Comparator|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
11463225|NCT01608373|Placebo Comparator|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
11463226|NCT01608360|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
11463227|NCT01608360|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
11463228|NCT01608347|Experimental|LMWH + Folic acid group|Daily 40 mg of enoxaparin (LMWH) (Clexane, Sanofi Aventis, Paris, France)subconsciously started once positive pregnancy test. Treatment will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tab once/daily until 13 weeks' of gestation.
11463229|NCT01608347|Active Comparator|Folic acid|500 microgram folic acid tab/day started once positive pregnancy test and will be continued until 13 weeks' of gestation.
11463230|NCT01608334|Experimental|group A|Fentanyl
11463231|NCT01608334|Active Comparator|Group B|Sufentanil
11463232|NCT01608321|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
11463265|NCT01608048|Experimental|TEAS|
11463266|NCT01608048|Experimental|EA:electro-acupuncture|
11463233|NCT01608321|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
11463234|NCT01608308|Experimental|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
11463235|NCT01608308|Placebo Comparator|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
11463236|NCT01608295|Experimental|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
11463237|NCT01608295|Experimental|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
11463238|NCT01608282|Experimental|OPEN Intervention Group|Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
11463239|NCT01608282|No Intervention|Control Group|Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.
11463240|NCT01608269|Other|ABC/3TC (Epzicom), NRTI|
11463241|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
11463242|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
11463243|NCT01608243|Experimental|SLIT tablets of HDM allergen extracts|
11463244|NCT01608243|Placebo Comparator|Placebo|
11463245|NCT01608217|Active Comparator|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
11463246|NCT01608217|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
11463247|NCT01608191|No Intervention|Ordinary primary care follow up|Ordinary follow up after 24 weeks of LCD diet + reintroduction of food.
11463248|NCT01608191|Active Comparator|CBT follow up|11 weeks intervention programme with CBT conducted via internet.
11463249|NCT01608165|Other|Partial nephrectomy|Patients randomised to this arm will undergo a partial nephrectomy
11463250|NCT01608165|Other|Radiofrequency ablation|Patients randomised to this arm will undergo radiofrequency ablation
11463251|NCT01608165|Other|cryoablation|Patients randomised to this arm will undergo cryoablation
11463252|NCT01608152||Group I (focus group)|Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
11463253|NCT01608152||Group II (access to the game)|Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
11463254|NCT01608139|Experimental|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.
~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
11463255|NCT01608126|Active Comparator|Combined Cervical Block|
11463256|NCT01608126|Active Comparator|Median Cervical Block US guided|
11463257|NCT01608100|Experimental|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
11463258|NCT01608087|Experimental|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
11463259|NCT01608087|Active Comparator|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
11463260|NCT01608087|Active Comparator|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
11463261|NCT01608074|Experimental|BRCA mutation carriers|"Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.
~Radical fimbriectomy. Histopathology SEE-FIM"
11463262|NCT01608061|Experimental|DBS-f on|DBS-f on
11463271|NCT01607996|Active Comparator|Patient controlled intravenous analgesia|Fentanyl (10 microg/ml) continuous intravenous infusion at a rate of 10 to 20 microg/h
11463272|NCT01607996|Experimental|Epidural anesthesia|Carbostesin (0.1%) and Fentanyl (2 microg/ml) at a continuous flow of 6 to 15 ml/hour
11463273|NCT01607983|Experimental|inhaled nitric oxide|
11463274|NCT01607970|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
11463275|NCT01607970|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
11463276|NCT01607957|Experimental|TAS-102|
11463277|NCT01607957|Placebo Comparator|Placebo|
11463278|NCT01607944||Normal Glucose Tolerance|
11463279|NCT01607944||Type 2 Diabetes|
11463280|NCT01607931|No Intervention|Resting Trial|a 1 hour period of rest immediately prior to OGTT or isoglycemic clamp
11463281|NCT01607931|Experimental|Exercise Trial|a 1 hour cycling exercise bout immediately prior to the OGTT or isoglycemic clamp
11463282|NCT01607918|Experimental|Sequential therapy 10 days|Sequential therapy
11463283|NCT01607918|Active Comparator|Triple therapy 14 days|Triple therapy
11463284|NCT01607905|Experimental|Solid Tumors|KPT-330
11463285|NCT01607892|Experimental|selinexor|
11463286|NCT01607879|Experimental|Standard of care ADT + (HMB + AG)|Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG)
11463287|NCT01607879|Active Comparator|Standard of care ADT|Standard of care androgen deprivation therapy
11463288|NCT01607866|Experimental|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
11463289|NCT01607866|Active Comparator|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
11463290|NCT01607853|Experimental|Daivobet® gel|
11463291|NCT01607840|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
11463292|NCT01607840|Experimental|Cathodal|transcranial direct current stimulation using cathodal stimulation over the brain area of interest
11463293|NCT01607840|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without actually delivering tDCS
11463294|NCT01607827|Active Comparator|Polyp removal upon insertion and withdrawal|
11463295|NCT01607827|No Intervention|Polyp removal upon withdrawal only|
11463296|NCT01607814||Cirrhotic Patients|Patients affected by cirrhosis of any etiology and severity
11463297|NCT01607814||Control Group|Subjects age, sex and comorbidities matched
11463298|NCT01607801||non-absorbable suture NAS|having their umbilical hernia repaired with NAS
11463299|NCT01607801||Long-term-absorbable suture (LAS)|patients having their umbilical hernia repair with LAS
11463300|NCT01607801||Absorbable sutures (AS)|patients having their umbilical hernia repair with AS
11463301|NCT01607801||Mesh repair|Patients having umbilical hernia mesh repair
11463302|NCT01607775|Active Comparator|PEEK-cage|Patients will receive a PEEK-cage
11463303|NCT01607775|Experimental|PMMA-cage|
11463304|NCT01607762|Experimental|Cohort A: Aripiprazole|
11463305|NCT01607762|Experimental|Cohort B: Quetiapine|
11463306|NCT01607762|Experimental|Cohort C: Olanzapine|
11463307|NCT01607762|Experimental|Cohort D: Risperidone|
11463308|NCT01607762|Experimental|Cohort E: Paliperidone|
11463309|NCT01607749|Experimental|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
11463310|NCT01607749|No Intervention|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
11463311|NCT01607736|No Intervention|Inactive Comparator|
11463312|NCT01607736|Experimental|Virtual Gait Training|
11463313|NCT01607723|Other|NAVA ventilatory mode|
11463314|NCT01607723|Other|PAV+ ventilatory mode|
11463315|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
11463316|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
11463317|NCT01607697|Experimental|Mindfulness Training|Group received Mindfulness Training
11463318|NCT01607697|No Intervention|Waitlist Control|Group received Usual Care
11463319|NCT01607684|Other|Diabetes mellitus group|Subjects with Diabetes mellitus and symptoms of diabetic gastroparesis
11463320|NCT01607684|Other|Control group|Healthy volunteers as matched pairs according to gender and age
11463321|NCT01607671|Experimental|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
11463322|NCT01607671|No Intervention|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
11463323|NCT01607658|Placebo Comparator|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
11463324|NCT01607658|Experimental|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
11463325|NCT01607658|Experimental|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
11463326|NCT01607658|Experimental|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
11463327|NCT01607645|Experimental|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
11463328|NCT01607645|Experimental|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
11463329|NCT01607632|Experimental|loving-kindness meditation|
11463330|NCT01607593||sertraline (Zoloft)|
11463331|NCT01607580|Experimental|low-dose glucocorticoid|drug
11463332|NCT01607580|Other|no intervention after transplant|
11463333|NCT01607554|Experimental|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
11463334|NCT01607541|Experimental|Peer-driven intervention|"The PDI entails structured intervention sessions including a computerized CARE for Prevention tool and HIV pre-test and post-test counseling, the opportunity to educate three peers on core education messages, and navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and six months of navigation)"
11463335|NCT01607541|Active Comparator|Control|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
11463336|NCT01607528|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
11463337|NCT01607528|Placebo Comparator|Placebo|A similar looking and tasting powder
11463338|NCT01607515|Other|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
11463339|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
11463340|NCT01607489|Other|pulmonary vascular disease|Dual-energy computed tomography investigation
11463341|NCT01607476|Experimental|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).
~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
11463342|NCT01607476|Active Comparator|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
11463343|NCT01607476|Active Comparator|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
11463344|NCT01607463|Experimental|active TENS group|Two electrodes were attached to the radial side of dominant forearm. In the active TENS group, TENS was delivered via two electrodes on the venous cannulation site
11463345|NCT01607463|Placebo Comparator|Placebo group|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."
11463346|NCT01607450|Other|Saline|12 hour saline (control) infusion prior to PET study
11463347|NCT01607450|Experimental|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
11463348|NCT01607450|Experimental|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
11463349|NCT01607450|Experimental|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
11463350|NCT01607424|Experimental|RECOS: 42 hours CR, 14 week-treatment.|RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.
11463351|NCT01607424|Active Comparator|CRT: 42 hours CR, 14 week-treatment|CRT (Cognitive Remediation Therapy) exercises are the ones used by Wykes et al (1999). The CRT method consists of 3 modules: flexibility, memory (A and B) and planning (A and B). Each module involves a series of paper and pencil exercises with parallel forms providing with gradual difficulty.
11463352|NCT01607411|Placebo Comparator|Fluoride free toothpaste|toothpaste with no fluoride
11463353|NCT01607411|Experimental|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
11463354|NCT01607411|Experimental|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
11463355|NCT01607411|Experimental|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
11463356|NCT01607398|Experimental|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
11463357|NCT01607398|Placebo Comparator|Placebo|Placebo inhalation, twice daily, from week0 -12
11463358|NCT01607385|Active Comparator|GSK2330672|
11463359|NCT01607385|Placebo Comparator|Placebo|
11463360|NCT01607372|Experimental|GSK2245035 - 40 ng or placebo|Subjects will receive GSK2245035 - 40 nanogram (ng) or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
11463361|NCT01607372|Experimental|GSK2245035 - 80 ng or placebo|Subjects will receive GSK2245035 - 80 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
11463362|NCT01607372|Experimental|GSK2245035 - 120 ng or placebo|Subjects will receive GSK2245035 - 120 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
11463363|NCT01607372|Experimental|GSK2245035 - 160 ng or placebo|Subjects will receive GSK2245035 - 160 ng or placebo once per week, for four treatment weeks. There will be washout period of 7 days between treatment periods.
11463364|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
11463365|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
11463366|NCT01607346|Experimental|ezogabine/retigabine|Open-label
11463367|NCT01607333||Completed suicide|Patients who completed suicide
11463583|NCT01606007|Active Comparator|Arm 1: Saxagliptin+Metformin XR+Placebo|
11463368|NCT01607333||Suicide attempt|Patients who have attempted suicide, or performed preparatory acts toward imminent suicidal behavior, suicidal ideation plus indeterminate or potentially suicidal events
11463369|NCT01607333||Not completed suicide|Patients who have not completed suicide
11463370|NCT01607320|Experimental|Raloxifene|3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
11463371|NCT01607320|Active Comparator|Clomiphene|3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
11463372|NCT01607307|Active Comparator|Oral/enteral TJ-100 solution|Oral/enteral TJ-100 solution
11463373|NCT01607307|Placebo Comparator|Oral/enteral placebo solution|Oral/enteral placebo solution
11463374|NCT01607294|Experimental|ETC-1002|ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
11463375|NCT01607294|Placebo Comparator|Placebo|Placebo daily 4 weeks
11463376|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
11463377|NCT01607268||Pure Autonomic Failure|Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
11463378|NCT01607268||Multiple System Atrophy|Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
11463379|NCT01607255|Experimental|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
11463380|NCT01607255|Experimental|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
11463381|NCT01607255|Active Comparator|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
11463382|NCT01607242||patients|patients undergoing total thyroidectomy
11463383|NCT01607229||otherwise healthy with various BMI|
11463384|NCT01607216||Premature Infant|Infants born 23 0/7 weeks gestation to 35 6/7 weeks gestation.
11463385|NCT01607216||Healthy Full Term Infants|Infants born between 37 0/7 weeks gestation to 41 6/7 weeks gestation.
11463386|NCT01607203|Active Comparator|hCG|5000 IU Pregnyl SC
11463387|NCT01607203|Active Comparator|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
11463388|NCT01607190||Patients with diabetic retinopathy.|
11463389|NCT01607177|Experimental|Text message group|Patients randomised to this group will receive daily text message reminders used to motivate them to exercise in the preoperative period. They will also receive an exercise information sheet to complement the text messages.
11463390|NCT01607177|No Intervention|No text message group|Patients randomised to this group will receive standardised exercise advice but will not receive the text message reminders or the exercise information sheet.
11463391|NCT01607164|Experimental|Online self-help mood management|"Healthy Mood Project Website
~Online self-help automated mood management course available in Spanish and English via a website.
~Intervention consisted of 8 cognitive-behavioral mood management lessons."
11463392|NCT01607151|Active Comparator|Normothermia|Core temperature 36-37 C
11463393|NCT01607151|Experimental|Hypothermia|Core temperature 32-34 C
11463394|NCT01607138||Total laryngectomy|A group of patients who underwent total laryngectomy with trechea esophageal puncture (TEP)
11463395|NCT01607125|Experimental|Vortioxetine|
11463396|NCT01607125|Placebo Comparator|Placebo|
11463397|NCT01607112|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11463398|NCT01607112|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11463399|NCT01607099|Experimental|Pico Prep|Arm in which sodium- picosulfate/magnesium citrate is used for bowel cleansing
11463400|NCT01607099|No Intervention|Standard|The standard drug macrogol is used for bowel cleansing
11463401|NCT01607086|Experimental|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
11463402|NCT01607086|Experimental|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
11463403|NCT01607073|Other|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
11463404|NCT01607060|Experimental|Lactulone|Patients receiving lactulone
11463405|NCT01607060|Active Comparator|Control|Observational group. Compare to lactulone group.
11463406|NCT01607034|Experimental|Sequence 1 - tablet-fast|150 mg Dexpramipexole (intact tablet) single dose under fasted condition
11463407|NCT01607034|Experimental|Sequence 2 - tablet-fed|150 mg Dexpramipexole (intact tablet) single dose under fed condition
11463408|NCT01607034|Experimental|Sequence 3 - water-fast|150 mg Dexpramipexole single dose dispersed in water under fasted condition
11463409|NCT01607034|Experimental|Sequence 4 - apple-fast|150 mg Dexpramipexole single dose crushed and mixed in applesauce under fasted condition
11463443|NCT01606748|Experimental|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
11463444|NCT01606735|Experimental|Dose 1|
11463410|NCT01607021||Chinese children with HCV RNA positive|"A sample of 200 children with a recent confirmation of anti-HCV-antibody positive and HCV RNA positive. All the children were treated with antiviral therapy, and the course of treatment depend on HCV Viral genotyping(ie, genotype 1,2,3,4 subtypes).
~Primary Outcome Measures:
~Virologic response [ Time Frame: Weeks 2, 4, 6, 8, 10, and 12 ] Sustained virologic response (SVR, defined as plasma HCV RNA < lower limit of quantification [LLoQ] at 24 weeks after treatment cessation) following antiviral treatment.
~Secondary Outcome Measures: Safety and tolerability of therapy. [ Time Frame: Up to 48 weeks ] measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events"
11463411|NCT01607008|Other|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
11463412|NCT01606995||Group 1|
11463413|NCT01606969|Experimental|Dex group|dexmedetomidine-lidocaine solution,
11463414|NCT01606969|Active Comparator|Control group|epinephrine-lidocaine solution
11463415|NCT01606956|Experimental|resting volume group|
11463416|NCT01606956|Active Comparator|half the maximum volume group|
11463417|NCT01606930|No Intervention|Usual Care Group|"Group will see their physician without receiving the activation instrument."
11463418|NCT01606930|Active Comparator|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
11463419|NCT01606917|Experimental|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity.
11463420|NCT01606917|No Intervention|Usual care|Usual care
11463421|NCT01606904|Experimental|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
11463422|NCT01606904|Other|Control|Short term weight loss counseling, control group
11463423|NCT01606891|Experimental|parent-targeted intervention|experimental
11463424|NCT01606891|No Intervention|Primary Care|Standard primary care
11463425|NCT01606878|Experimental|Part A (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (oral solution) PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
11463426|NCT01606878|Experimental|Part B (crizotinib, vincristine, dexrazoxane, doxorubicin)|Patients receive crizotinib (oral solution) PO BID as in Part A. Patients also receive vincristine sulfate IV on day 1, dexrazoxane hydrochloride IV on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
11463427|NCT01606878|Experimental|Part C (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (capsule formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11463428|NCT01606865||elective and acute non-cardiac surgery|
11463429|NCT01606852|No Intervention|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
11463430|NCT01606852|Experimental|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
11463431|NCT01606826||Asthmatics|
11463432|NCT01606813|Active Comparator|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
11463433|NCT01606813|Experimental|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
11463434|NCT01606813|Experimental|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
11463435|NCT01606800|Experimental|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
11463436|NCT01606800|Experimental|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
11463437|NCT01606787|Experimental|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
11463438|NCT01606787|Placebo Comparator|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
11463439|NCT01606774|Experimental|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
11463440|NCT01606761|Experimental|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
11463441|NCT01606761|Experimental|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
11463442|NCT01606761|Experimental|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
11463447|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
11463448|NCT01606709|Experimental|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
11463449|NCT01606709|Active Comparator|hCG trigger|Induction of oocyte maturation with hCG
11463450|NCT01606696|Experimental|HIIT|Higher intensity interval training.
11463451|NCT01606696|Active Comparator|Standard intensity non-interval training|Standard intensity non-interval training
11463452|NCT01606683|Experimental|GROUP 1|Infant formula supplemented with with functional ingredients (galacto-oligosaccharides, beta-palmitate, fermented milk). Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
11463453|NCT01606683|Other|GROUP 2|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
11463454|NCT01606683|Other|CONTROL GROUP|Breast milk
11463455|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
11463456|NCT01606657|Active Comparator|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I&D PROCEDURE
11463457|NCT01606657|Placebo Comparator|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I&D PROCEDURE
11463458|NCT01606644|Experimental|HBO|30 90-minute hyperbaric oxygen sessions at 2.4 atm.
11463459|NCT01606644|No Intervention|No HBO|No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program.
11463460|NCT01606631||Arm 1 : experimental (case)|Patients included in the study and admitted to the ICU either directly from UAA or after a hospitalization in a specialty, for a severe sepsis or septic shock on their infectious disease community.
11463461|NCT01606631||Arm 2 : control|Patients included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before hospital discharge.
11463462|NCT01606618||Spina bifida aperta|
11463463|NCT01606618||Acquired traumatic spinal cord injury|
11463464|NCT01606605||Diffuse large B-cell lymphoma|Patients diagnosed and treated at the Samsung Medical Center
11463465|NCT01606592|Experimental|Randomized Panic Control Treatment|Patients who have been randomized to the randomization condition are assigned to PCT
11463466|NCT01606592|Experimental|Randomized Panic-Focused Psychodynamic Psychotherapy|Patients who have been randomized to the randomization condition are assigned to PFPP
11463467|NCT01606592|Experimental|Self-selected Panic Control Treatment|Patients who have been randomized to the self-selection condition choose PCT
11463468|NCT01606592|Experimental|Self-selected Panic-Focussed Psychodynamic Psychotherapy|Patients who have been randomized to the self-selection condition choose PFPP
11463469|NCT01606592|Experimental|Waiting-list|Patients who have been randomized to the waiting-list are offered sparse contact over telephone for 12 weeks and are then re-randomized to one of the other four arms
11463470|NCT01606579|Experimental|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
11463471|NCT01606579|Experimental|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
11463472|NCT01606579|Experimental|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.
~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
11463473|NCT01606579|Experimental|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.
~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
11463474|NCT01606579|Experimental|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.
~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
11463475|NCT01606566|Experimental|Amphinex induced PCI of bleomycin|"Drug: Amphinex induced PCI of bleomycin
~Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4)"
11463476|NCT01606553|Experimental|High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a dual-vave prototype
11463477|NCT01606553|Active Comparator|Sham High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a sham dual-vave prototype
11463478|NCT01606540|Experimental|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.
~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
11463479|NCT01606540|Active Comparator|Surgery|"The method of surgery is type bridging.
~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
11463480|NCT01606527|Experimental|Ibuprofen|Ibuprofen 600mg taken three times daily for four days.
11463481|NCT01606527|Placebo Comparator|placebo|Avicel placebo capsules three times daily for four days
11463482|NCT01606514|Experimental|Child, Parenting, & Parent Web-Intervention|Bounce Back Now Child, Parenting, & Parent Psychoeducation & Self-Help Web-Intervention.
11463483|NCT01606514|Experimental|Child & Parenting Web-Intervention|Bounce Back Now Child & Parenting Psychoeducation and Self-Help Web-Intervention.
11463484|NCT01606514|No Intervention|Child & Parent Web-based Assessment|Bounce Back Now Web-Based Symptom Assessment
11463485|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
11463486|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
11463487|NCT01606488|Other|Surgical Group|"Subjects scheduled to undergo total knee or total hip replacement at the SFVAMC.
~Subjects in this arm of the study will undergo the florbetapir PET scan once prior to their surgery.
~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
11463488|NCT01606488|Other|Non-surgical group|"Subjects being seen in at the SFVAMC orthopedic clinic for knee or hip pain but are not anticipating surgical intervention.
~Subjects in this arm will not undergo the florbetapir PET scan.
~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
11463489|NCT01606462|Experimental|Oxytocin|one application of 24 IU oxytocin per volunteer
11463490|NCT01606462|Placebo Comparator|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
11463491|NCT01606449||Group 1|Group 1 = Patients with type II Hiatal Hernia submitted to surgical therapy
11463492|NCT01606449||Group 2|Group 2 = Patients with type III Hiatal Hernia submitted to surgical therapy
11463493|NCT01606449||Group 3|Group 3 = Patients with type IV Hiatal Hernia submitted to surgical therapy
11463494|NCT01606436|Placebo Comparator|Sugar pill|Placebo matching pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
11463495|NCT01606436|Experimental|400 mg pomaglumetad methionil|400 mg pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
11463496|NCT01606436|Other|400 mg Moxifloxacin|Positive control, unblinded moxifloxacin administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
11463497|NCT01606423|Placebo Comparator|Placebo|Administered once, orally
11463498|NCT01606423|Experimental|10 mg LY2409021|10 mg LY2409021 administered once, orally
11463499|NCT01606423|Experimental|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
11463500|NCT01606423|Experimental|60 mg LY2409021|60 mg LY2409021 administered once, orally
11463501|NCT01606423|Experimental|200 mg LY2409021|200 mg LY2409021 administered once, orally
11463502|NCT01606423|Experimental|500 mg LY2409021|500 mg LY2409021 administered once, orally
11463503|NCT01606410||young, sedentary|
11463504|NCT01606410||young, active|
11463505|NCT01606410||old, sedentary|
11463506|NCT01606410||old, active|
11463507|NCT01606397|Placebo Comparator|Placebo|Placebo administered orally once daily for 4 weeks
11463508|NCT01606397|Experimental|5 mg LY2409021|5 mg LY2409021 administered orally once daily for 4 weeks
11463509|NCT01606397|Experimental|30 mg LY2409021|30 mg LY2409021 administered orally once daily for 4 weeks
11463510|NCT01606397|Experimental|60 mg LY2409021|60 mg LY2409021 administered orally once daily for 4 weeks
11463511|NCT01606397|Experimental|90 mg LY2409021|90 mg LY2409021 administered orally once daily for 4 weeks
11463512|NCT01606384|Placebo Comparator|Placebo|Twice daily
11463513|NCT01606384|Experimental|SSR149415 - 100mg|Twice daily
11463514|NCT01606384|Experimental|SSR149415 - 250mg|Twice daily
11463515|NCT01606371|Placebo Comparator|Healthy-Placebo|Placebo (capsule) administered once, orally
11463516|NCT01606371|Experimental|Healthy-2.5 mg LY2409021|2.5 mg LY2409021 administered once, orally
11463517|NCT01606371|Experimental|Healthy-10 mg LY2409021|10 mg LY2409021 administered once, orally
11463518|NCT01606371|Experimental|Healthy-30 mg LY2409021|30 mg LY2409021 administered once, orally
11463519|NCT01606371|Experimental|Healthy-100 mg LY2409021|100 mg LY2409021 administered once, orally
11463520|NCT01606371|Experimental|Healthy-250 mg LY2409021|250 mg LY2409021 administered once, orally
11463521|NCT01606371|Experimental|Healthy-500 mg LY2409021|500 mg LY2409021 administered once, orally
11463522|NCT01606371|Placebo Comparator|Diabetic-Placebo|Placebo (capsule) administered once, orally
11463523|NCT01606371|Experimental|Diabetic-75 mg LY2409021|75 mg LY2409021 administered once, orally
11463524|NCT01606371|Experimental|Diabetic-200 mg LY2409021|200 mg LY2409021 administered once, orally
11463525|NCT01606371|Experimental|Diabetic-500 mg LY2409021|500 mg LY2409021 administered once, orally
11463526|NCT01606358||Ovarian Cancer|
11463527|NCT01606345|Experimental|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
11463528|NCT01606332|No Intervention|Single in interscalene block|Single indwelling interscalene block with ropivacaine 0.5% 10ml
11463529|NCT01606332|Experimental|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
11463530|NCT01606319|Experimental|acetaminophen|acetaminophen given as needed for pain or fever
11463531|NCT01606319|Experimental|ibuprofen|ibuprofen given as needed for pain or fever
11463532|NCT01606306|Experimental|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
11463533|NCT01606306|Experimental|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
11463534|NCT01606306|Experimental|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
11463535|NCT01606306|Experimental|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
11463536|NCT01606306|Experimental|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
11463537|NCT01606306|Experimental|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
11463538|NCT01606293||Carcinomas of the Cervix Survey|Women with small and large cell carcinomas of the cervix, who are members of the Facebook group found at the uniform resource locator https://www.facebook.com/SmallCellCC through an online link.
11463584|NCT01606007|Active Comparator|Arm 2: Dapagliflozin+Metformin XR+Placebo|
11463539|NCT01606267|No Intervention|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
11463540|NCT01606267|Experimental|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
11463541|NCT01606254|Experimental|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
11463542|NCT01606254|Experimental|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
11463543|NCT01606254|Experimental|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
11463544|NCT01606254|Experimental|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
11463545|NCT01606241|Experimental|Treatment (cyclophosphamide and vaccine therapy)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1. Within 3-5 days, patients receive multi-epitope folate receptor alpha peptide vaccine ID on day 1. Vaccine treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11463546|NCT01606228|Experimental|Paliperidone ER|
11463547|NCT01606215|Experimental|mesenchymal stem cells|1-2 x106 MSCs/kg administered at Week 0
11463548|NCT01606215|Sham Comparator|Placebo|Suspension media administered at Week 0
11463549|NCT01606202|Experimental|GW-1000-02|Active treatment.
11463550|NCT01606202|Placebo Comparator|Placebo|Placebo control.
11463551|NCT01606189|Experimental|GW-1000-02|Active treatment.
11463552|NCT01606189|Experimental|GW-2000-02|Active treatment.
11463553|NCT01606189|Placebo Comparator|Placebo|Placebo control.
11463554|NCT01606176|Experimental|GW-1000-02|Each 100 μl actuation contains 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose was 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
11463555|NCT01606176|Placebo Comparator|Placebo|Each 100 μl actuation contains the excipients only. The maximum permitted dose was 48 actuations in any 24 hour period
11463556|NCT01606163|Experimental|group 1|"Drug:GC1102
~Amount:3ml (30,000IU)"
11463557|NCT01606163|Experimental|group 2|"Drug: GC1102
~Amount: 5ml(50,000IU)"
11463558|NCT01606163|Experimental|group 3|"Drug: GC1102
~Amount: 8ml (80,000IU)"
11463559|NCT01606163|Placebo Comparator|group 4|drug: JW normal saline
11463560|NCT01606150|Active Comparator|Subcutaneous Lidocaine|0.1 ml/kg of 1% Lidocaine
11463561|NCT01606150|Active Comparator|Topical Lidocaine|LMX-4, 1 gram placed over lumbar puncture needle insertion site 30 minutes prior to the procedure
11463562|NCT01606137|Experimental|GW-1000-02|Active treatment
11463563|NCT01606124|Experimental|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
11463564|NCT01606124|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
11463565|NCT01606111|Placebo Comparator|0.9% NaCl, saline|
11463566|NCT01606111|Experimental|Cerebrolysin|
11463567|NCT01606098|Active Comparator|Systemic treatment|First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.
11463568|NCT01606098|Experimental|Surgery followed by systemic treatment|Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator
11463569|NCT01606085|Experimental|HF-DM Self Care|educational counseling intervention about integrated HF-DM self care outcomes
11463570|NCT01606085|No Intervention|Usual Care|Usual Care provided by providers
11463571|NCT01606072|Experimental|Desmopressin|
11463572|NCT01606059|Active Comparator|DW-0919|
11463573|NCT01606059|Experimental|DW-0920|
11463574|NCT01606046|Active Comparator|vapocoolant spray|
11463575|NCT01606046|Active Comparator|topical anesthetic agent|
11463576|NCT01606046|No Intervention|Control|no interventions
11463577|NCT01606033|Other|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :
~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey
~understanding of the implications of participating in a clinical trial"
11463578|NCT01606033|Other|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :
~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey
~understanding of the implications of participating in a clinical trial"
11463579|NCT01606033|Other|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey
~-understanding of the implications of participating in a clinical trial"
11463580|NCT01606033|Other|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :
~-understanding of the implications of participating in a clinical trial"
11463581|NCT01606020|Active Comparator|Sleep deprivation First|"First night D7 :
~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
~Second night D28 :
~Overnight, the subjects stay in their homes. No intervention during this night."
11463582|NCT01606020|Active Comparator|sleep deprivation second|"First night D7 :
~Overnight, the subjects stay in their homes. No intervention during this night.
~Second night D28 :
~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep."
11463585|NCT01606007|Experimental|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
11463586|NCT01605994|Experimental|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463587|NCT01605994|Experimental|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463588|NCT01605994|Experimental|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463589|NCT01605994|Experimental|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463590|NCT01605994|Experimental|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days
~CSF sampling required"
11463591|NCT01605994|Experimental|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463592|NCT01605994|Experimental|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463593|NCT01605994|Experimental|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required
~BMS-933043 25 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463594|NCT01605994|Experimental|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.
~BMS-933043 200 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463595|NCT01605994|Experimental|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463596|NCT01605994|Experimental|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state
~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days
~OR
~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days
~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
11463597|NCT01605981|Experimental|Nilotinib oral|Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
11463598|NCT01605968|Experimental|BCT Silver Bandage|
11463599|NCT01605968|Active Comparator|Aquacel® Ag. Dressing|
11463600|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
11463601|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
11463602|NCT01605942|Experimental|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
11463603|NCT01605942|Placebo Comparator|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
11463604|NCT01605929|Experimental|Retroclavicular Brachial Plexus Block|
11463605|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg|monotherapy
11463606|NCT01605916|Experimental|Selumetinib (AZD6244) 50 mg|monotherapy
11463607|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg|monotherapy
11463608|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg + Doce|Combination
11463609|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg + Doce|combination
11463610|NCT01605903|Experimental|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
11463611|NCT01605903|Active Comparator|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
11463612|NCT01605890|Experimental|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
11463613|NCT01605877|Experimental|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
11463614|NCT01605851|Other|Closure, Foramen Ovale|Patients undergoing device closure of PFO
11463615|NCT01605825|Placebo Comparator|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:
~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
11463616|NCT01605825|Placebo Comparator|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:
~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
11463617|NCT01605812||high myopia|high myopia (axial length>26mm)
11463618|NCT01605812||emmetropia|emmetropia (22<axial length<25mm) as control group.
11463619|NCT01605799|Active Comparator|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
11463620|NCT01605799|Placebo Comparator|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
11463621|NCT01605786|Experimental|PEBS Low dose|
11463630|NCT01605734|Active Comparator|Group TACE|TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated
11463631|NCT01605734|Experimental|Group Combination|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
11463632|NCT01605721|Experimental|XIENCE PRIMETM everolimus-eluting coronary stent|
11463633|NCT01605708|Experimental|Cohort 1|
11463634|NCT01605695||Normal healthy adults|The concentration of iNOS will be measured in plasma samples obtained at the time of blood donation from normal healthy adult humans
11463635|NCT01605682|Experimental|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
11463636|NCT01605682|Experimental|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
11463637|NCT01605682|Experimental|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
11463638|NCT01605682|Placebo Comparator|Placebo|Berry flavoured juice containing no polyphenols
11463639|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
11463640|NCT01605656||Focus Groups + Interviews + Questionnaires|HIV-positive women recruited from the population of individuals seeking care at Thomas Street Health Center (TSHC) of the Harris County Hospital District (HCHD).
11463641|NCT01605630|Experimental|Family-based cancer literacy intervention|
11463642|NCT01605630|Active Comparator|Control|Standard of care
11463643|NCT01605617|Active Comparator|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
11463644|NCT01605617|Placebo Comparator|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
11463645|NCT01605604|Experimental|recieves Buddhist mindfullness|
11463646|NCT01605591|Active Comparator|the DLT bending to the right|
11463647|NCT01605591|Active Comparator|the DLT bending to the left|
11463648|NCT01605552|Experimental|Beating the Blues (BtB)|An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
11463649|NCT01605552|Other|Usual Care|Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
11463650|NCT01605539|Placebo Comparator|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
11463651|NCT01605539|Experimental|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
11463652|NCT01605539|Experimental|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
11463653|NCT01605526|Experimental|Single Arm|
11463654|NCT01605513|Experimental|recombinant interferon|PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
11463655|NCT01605500||Medtronic ICDs|Patients with Generation 2 Medtronic ICDs
11463656|NCT01605487|Other|Rupatadine 20mg - Placebo - Rupatadine 40mg|
11463657|NCT01605487|Other|Rupatadine 20mg - Rupatadine 40mg - Placebo|
11463658|NCT01605487|Other|Placebo - Rupatadine 20mg - Rupatadine 40mg|
11463659|NCT01605487|Other|Rupatadine 40mg - Placebo - Rupatadine 20mg|
11463660|NCT01605487|Other|Placebo - Rupatadine 40mg - Rupatadine 20mg|
11463661|NCT01605487|Other|Rupatadine 40mg - Rupatadine 20mg - Placebo|
11463662|NCT01605474|Active Comparator|Outpatient Cervical Ripening|Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.
11463663|NCT01605474|No Intervention|Inpatient Cervical Ripening|In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.
11463664|NCT01605461|Experimental|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
11463665|NCT01605448|Experimental|MBSR|Mindfulness Based Stress Reduction
11463666|NCT01605448|No Intervention|Control Group|Continue in Usual care; offered the intervention at the end of the study
11463667|NCT01605435|Experimental|Ghrelin Group 1|Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).
11463668|NCT01605435|Experimental|Ghrelin Group 2|Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).
11463669|NCT01605409|Active Comparator|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
11463670|NCT01605409|Experimental|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.
~CPR during transportation will be performed by EMS personnel according to ERC guidelines.
~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
11463671|NCT01605396|Experimental|Ridaforolimus + Dalotuzumab + Exemestane|Participants receive ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.
11463672|NCT01605396|Active Comparator|Ridaforolimus + Exemestane|Participants receive ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.
11463673|NCT01605383|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head"
11463674|NCT01605383|Sham Comparator|Standard Treatment|Isolated core decompression
11463675|NCT01605370|Experimental|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
11463676|NCT01605370|Other|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
11463677|NCT01605357|Active Comparator|Standard Care|Patients will be managed to maintain a goal serum sodium of > 135 mmol/L , a well recognized value in the management of severe traumatic brain injury.
11463678|NCT01605357|Experimental|Induced Hypernatremia|Patients will be treated with induced, sustained hypernatremia for 5 days following injury by using hypertonic saline to target a goal serum sodium of 150-160 mmol/L
11463679|NCT01605344|Experimental|Arm A|ARM A subjects will receive atorvastatin 20 mg orally once daily given for two weeks prior to FOLFIRI. The last dose of atorvastatin will be taken day 1 of FOLFIRI. ARM A will then receive no statin for the next 2 weeks. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
11463680|NCT01605344|Experimental|Arm B|ARM B subjects will receive no atorvastatin prior to day 1 of FOLFIRI. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks prior to day 15 of FOLFIRI. The last dose of atorvastatin will be taken day 15 of FOLFIRI. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
11463681|NCT01605331|Experimental|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
11463682|NCT01605318|Experimental|IMMU-130|All patients receive IMMU-130 administered in 21-day treatment cycles consisting of once or twice weekly for 2 consecutive weeks followed by a 1-week rest period. Treatment can be continued in the absence of unacceptable toxicity for a period of up to 8 cycles until the first documentation of Progressive Disease by CT (physician discretion), but must terminate study treatment upon the second documentation of Progressive Disease.
11463683|NCT01605305|Experimental|FOLFOX6|
11463684|NCT01605292|Active Comparator|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
11463685|NCT01605292|Experimental|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
11463686|NCT01605279|Experimental|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
11463687|NCT01605279|Placebo Comparator|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
11463688|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
11463689|NCT01605253|Active Comparator|Eszopiclone|The total study duration is 16 weeks, with subjects taking 3mg eszopiclone at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
11463690|NCT01605253|Placebo Comparator|Placebo|The total study duration is 16 weeks, with subjects taking placebo at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
11463691|NCT01605240|Active Comparator|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
11463692|NCT01605240|Active Comparator|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
11463693|NCT01605227|Experimental|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
11463694|NCT01605227|Active Comparator|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
11463695|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
11463696|NCT01605201|Experimental|Implantation of cartilage graft|
11463697|NCT01605162|Experimental|E7016 plus TMZ|
11463698|NCT01605149||Case|Patients with Type 1 Diabetes Mellitus
11463699|NCT01605136|Experimental|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
11463700|NCT01605136|Placebo Comparator|Placebo|One placebo subcutaneous implant every 2 months for 6 months.
11463701|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: > - 2 SDS, currently 0.03±1.07;
11463702|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: >1.23 , currently 2.41±0.52; Height-SDS: > - 2 SDS, currently 0.80±1.18;
11463703|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
11463704|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
11463834|NCT01604174|Active Comparator|Standard rehabilitation care|Standard care rehabilitation after total knee arthroplasty
11463835|NCT01604161||Somatropin|
11463836|NCT01604148||HoLEP group|Holmium Laser Enucleation of Prostate Group
11464269|NCT01601210|Active Comparator|10 grams of creatine|
11463705|NCT01605110|Experimental|Hyperbaric oxygen therapy|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
11463706|NCT01605110|Sham Comparator|Air sham|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
11463707|NCT01605097|Experimental|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
11463708|NCT01605084|Experimental|Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone|
11463709|NCT01605084|Experimental|Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone|
11463710|NCT01605071|Active Comparator|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
11463711|NCT01605071|Active Comparator|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
11463712|NCT01605045|Experimental|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique)versus
11463713|NCT01605045|Active Comparator|Standard technique|Coronary anatomy visualized and documented using cinematography alone (standard technique)
11463714|NCT01605032|Experimental|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.
~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
11463715|NCT01605019|Experimental|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
11463716|NCT01605019|Placebo Comparator|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
11463717|NCT01605006|Other|NeuRx Diaphragm Pacing System (DPS)|Surgical implantation of the NeuRx DPS (on label use).
11463718|NCT01604993|Experimental|High nitrate dietary source|556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.
11463719|NCT01604993|Placebo Comparator|No Nitrate dietary source|556g low nitrate asparagus soup; orally consumed as a single does for 7 days.
11463720|NCT01604980|Experimental|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
11463721|NCT01604954|Other|Non-obese|Non-obese women (BMI between 18.5 and 25 kg/m2)
11463722|NCT01604954|Other|Obese|Obese women (BMI between 30 and 40 kg/m2)
11463723|NCT01604941|Experimental|SPD602|50 mg/kg/day orally twice daily for 24 weeks
11463724|NCT01604928|Experimental|YM178 Dose 1|low dose
11463725|NCT01604928|Experimental|YM178 Dose 2|high dose
11463726|NCT01604928|Active Comparator|Tolterodine|Oral
11463727|NCT01604928|Placebo Comparator|Placebo|Oral
11463728|NCT01604915|Placebo Comparator|Group R|Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered.
11463729|NCT01604915|Experimental|Group DR|Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
11463730|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
11463731|NCT01604889|Experimental|Epacadostat 300 mg|300 mg twice daily (BID) in combination with ipilimumab
11463732|NCT01604889|Placebo Comparator|Placebo in combination with ipilimumab|
11463733|NCT01604889|Experimental|Epacadostat 25 mg|25 mg BID in combination with ipilimumab
11463734|NCT01604889|Experimental|Epacadostat 50 mg|50 mg BID in combination with ipilimumab
11463735|NCT01604889|Experimental|Epacadostat 75 mg|75 mg once a day (QD) in combination with ipilimumab
11463736|NCT01604876|Experimental|light condition 1 + day night structure|exposure to 10.000 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
11463737|NCT01604876|Active Comparator|light condition 2 + day night structure|exposure to 200 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
11463738|NCT01604863|Experimental|Arm A|HGS1036 + Paclitaxel + Carboplatin
11463739|NCT01604863|Experimental|Arm B|HGS1036 + Cisplatin + Etoposide
11463740|NCT01604863|Experimental|Arm C|HGS1036 + Docetaxel
11463741|NCT01604850|Experimental|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
11463742|NCT01604850|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
11463743|NCT01604837||Pelvic malignancy group|those with diagnosis of gynecologic or urologic malignancy
11463744|NCT01604837||Pelvic chronic disease group|those with chronic pelvic pain with constitutional cause e.g. endometriosis
11463745|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 1|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
11464311|NCT01600937|No Intervention|Control|Standard care including physician recommendations for daily PA
11463746|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
11463747|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1|Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
11463748|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
11463749|NCT01604811|Experimental|Tested product|
11463750|NCT01604811|Active Comparator|Comparator|
11463751|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
11463752|NCT01604798||Healthy Controls|Healthy volunteers
11463753|NCT01604785|Experimental|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
11463754|NCT01604785|Active Comparator|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
11463755|NCT01604772|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11463756|NCT01604759|Other|Polarized probe measurement.|All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
11463757|NCT01604746|No Intervention|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
11463758|NCT01604733||HYPERCHOLESTEROLEMIC PATIENTS|
11463759|NCT01604707|No Intervention|Control group|Standard care
11463760|NCT01604707|Experimental|Medical Yoga|Group training with medical yoga in primary health care.
11463761|NCT01604694|Experimental|TAP Block with levobupivacaïne|
11463762|NCT01604694|Placebo Comparator|TAP Block with Placebo|
11463763|NCT01604681|Placebo Comparator|placebo group|3 g of powdered gelatin encapsulated in opaque capsules.
11463764|NCT01604681|Experimental|Flaxseed oil group|Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.
11463765|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
11463766|NCT01604655|Active Comparator|Coronary CT Angiography|Patient admitted with chest pain is randomized to CCTA for assessment.
11463767|NCT01604655|Active Comparator|Stress Test|Patients admitted with chest pain are randomized to a stress test (stress SPECT or Echocardiography) for assessment.
11463768|NCT01604642|Other|cachectic versus no cachectic patients|blood tests, muscular biopsies
11463769|NCT01604629|Experimental|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
11463770|NCT01604629|Active Comparator|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
11463771|NCT01604616||PCFL GROUP|patients in this group had the PFCL for a period of 7-10 days before it was replaced by SF6 gas or silicone oil
11463772|NCT01604616||control group|in thos group no PFCL was left in the eye and either SF6 or silicone oil was the definitive treatment at the time of the retinal detachment surgery repair.
11463773|NCT01604603||Control|
11463774|NCT01604603||Oligomenorrhea|
11463775|NCT01604603||Amenorrhea|
11463776|NCT01604603||premature ovarian failure|
11463777|NCT01604590||glioblastoma patients on bevacizumab|
11463778|NCT01604577|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
11463779|NCT01604577|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
11463780|NCT01604564||Colitis Ulcerosa|Colitis Ulcerosa With creation of IPAA
11463781|NCT01604564||Familial Adenomatous Polyposis|Familial Adenomatous Polyposis with creation of IPAA
11463782|NCT01604538||patients with acute pulmonary embolism|
11463783|NCT01604525|Sham Comparator|Control|Participants randomized to this group received access to an untailored general interest/lifestyle website.
11463784|NCT01604525|Experimental|Tailored Health and Lifestyle Web|Participants randomized to this arm received tailored web content about health and wellness, with weekly goal-setting and feedback.
11463785|NCT01604525|Experimental|Tailored Web plus Peer Coaching|Participants randomized to this arm received access to weekly tailored health and wellness web content, plus weekly feedback from a peer health coach (videos uploaded to the web and phone calls).
11463954|NCT01603329|Experimental|Focused incentives + focused comm for hypertension meds|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
11463786|NCT01604512|Experimental|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where. it is unclear if a lesion represents radiation injury or progressive tumor. At the discretion of PI the RSI sequence may be repeated at SOC FDG or other radiotracer imaging carried out while the patient is still on study, if deemed clinically necessary.
11463787|NCT01604499|Experimental|Feedback only|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
11463788|NCT01604499|Experimental|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
11463789|NCT01604499|No Intervention|Control group|
11463790|NCT01604486||MI without ischaemic preconditioning|Myocardial infarction unheralded by any previous cardiovascular disease diagnosis and without symptoms of chest pain in the previous 90 days.
11463791|NCT01604486||MI with longstanding disease|Patients with myocardial infarction who have had diagnosed atherosclerotic disease for longer than 90 days preceding infarct.
11463792|NCT01604486||MI with only chest pain|Patients with chest pain in the 90 days preceding MI, but with no prior atherosclerotic disease diagnoses.
11463793|NCT01604486||MI with disease and chest pain|Myocardial infarction occurring with previously diagnosed atherosclerotic disease of longer than 90 days' duration, but with chest pain in 90 days preceding infarct.
11463794|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
11463795|NCT01604460|Sham Comparator|Resuscitation-no plastic bag|Resuscitation per standard of care without a plastic bag
11463796|NCT01604460|Active Comparator|Resuscitation-torso bag|Use of plastic bag covering the torso and lower extremities for temperature regulation during and after resuscitation for the first hour after birth
11463797|NCT01604447|Active Comparator|Incubator removal-torso bag|Use plastic bag covering the torso and lower extremities for temperature regulation with standard bundling practices when removing infant from incubator
11463798|NCT01604447|Placebo Comparator|Incubator removal-no plastic bag|Standard bundling practices when removing the infant from the incubator. No plastic bag used.
11463799|NCT01604434|Sham Comparator|Incubator-no plastic bag|Placement into an incubator without a plastic bag
11463800|NCT01604434|Active Comparator|Incubator-torso bag|Placement into a plastic bag inside incubator
11463801|NCT01604421|Sham Comparator|Thermoregulation-standard care|Standard thermoregulation without a plastic bag from one hour after birth until discharge or 24 hours after birth, whichever comes first.
11463802|NCT01604421|Active Comparator|Thermoregulation-with plastic bag|Thermoregulation with plastic bag covering torso and lower extremities from one hour after birth until discharge or 24 hours after birth to assist with thermoregulation. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
11463803|NCT01604408|Experimental|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
11463804|NCT01604408|Placebo Comparator|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
11463805|NCT01604395||growth hormone|
11463806|NCT01604382|Experimental|treatment|Receives General Anesthesia as described above
11463807|NCT01604382|Placebo Comparator|Placebo|Patients receives neuraxial anesthesia as described above
11463808|NCT01604369|Experimental|Cryoablation|
11463809|NCT01604356|Experimental|Electro-acupuncture|
11463810|NCT01604343|Experimental|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
11463811|NCT01604343|Experimental|Sirukumab 100 mg|
11463812|NCT01604343|Experimental|Sirukumab 50 mg + Placebo|
11463813|NCT01604330|Experimental|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
11463814|NCT01604330|Placebo Comparator|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
11463815|NCT01604317|Active Comparator|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
11463816|NCT01604317|Active Comparator|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
11463817|NCT01604304|Active Comparator|Extracorporeal shockwave lithotripsy|stone treatment using electroconductive technology
11463818|NCT01604304|Active Comparator|Flexible ureteroscopy|intra renal retrograde surgery with or without laser and stone extraction
11463819|NCT01604291||Cohort|
11463820|NCT01604278|Active Comparator|NVA237 + indacaterol|
11463821|NCT01604278|Placebo Comparator|Placebo to NVA237 + indacaterol|
11463822|NCT01604265|Placebo Comparator|Placebo|Placebo control.
11463823|NCT01604265|Experimental|Sativex|Active treatment.
11463824|NCT01604252||Cohort|
11463825|NCT01604239|Experimental|Shinbaro|
11463826|NCT01604226||Gynecologic surgery group|Those undergoing gynecologic laparoscopic surgery with TIVA
11463827|NCT01604226||Urologic surgery group|Those undergoing urologic surgery with TIVA
11463828|NCT01604213|Experimental|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
11463829|NCT01604213|Active Comparator|Metformin only|Oral metformin only
11463830|NCT01604200||Dentists|Dentists in practice
11463831|NCT01604187|Active Comparator|Fentanyl|Ten minutes before the procedure fentanyl 100 mikrograms sublingual tablet will be given to the patient.
11463832|NCT01604187|Placebo Comparator|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
11463833|NCT01604174|Experimental|Interactive Virtual Telerehabilitation|Rehabilitation by IVT
11463837|NCT01604135|Active Comparator|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
11463838|NCT01604135|No Intervention|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
11463839|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
11463840|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
11463841|NCT01604109|Active Comparator|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
11463842|NCT01604109|Placebo Comparator|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
11463843|NCT01604096|Experimental|Intervention areas|Provinces of Modena and Parma (about 1.100.000 inhabitants - campaign targeted to the general population), in Northern Italy (Emilia-Romagna Region)
11463844|NCT01604096|No Intervention|Control|All the other provinces in the Emilia-Romagna Region (where the information campaign has not been implemented)
11463845|NCT01604070||Nextra fusion|group that has the nextra device
11463846|NCT01604070||k wire fixation|control group fixated with k wire
11463847|NCT01604057|Experimental|Low Dose Nasal Spray|
11463848|NCT01604057|Experimental|Mid Dose Nasal Spray|
11463849|NCT01604057|Experimental|High Dose Nasal Spray|
11463850|NCT01604057|Active Comparator|Forteo|20ug subcutaneous injection daily
11463851|NCT01604057|Placebo Comparator|Placebo Nasal Spray|
11463852|NCT01604044|Active Comparator|HP-hMG|
11463853|NCT01604044|Active Comparator|rFSH plus rLH|
11463854|NCT01604031|Experimental|B-CLL vaccine|Patients will receive doses of vaccine at 2 week intervals for 5 doses and at 4 week intervals for doses 6-16. The injection will be performed subcutaneously in the deltoid region of the upper arm.
11463855|NCT01604018||Placebo|Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
11463856|NCT01604018||Cat-PAD Group 1|Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
11463857|NCT01604018||Cat-Pad Group 2|Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
11463858|NCT01604005|Experimental|PIT Arm|
11463859|NCT01604005|No Intervention|No PIT Arm|
11463860|NCT01603979|Experimental|Dose-escalation AV-203 Monotherapy|dose-escalation of monotherapy AV-203 (an ERBB3 inhibitory antibody) by IV every two weeks
11463861|NCT01603940|Active Comparator|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
11463862|NCT01603940|Active Comparator|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
11463863|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
11463864|NCT01603914|Experimental|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
11463865|NCT01603914|Experimental|Scheduled replacement every six days|Scheduled replacement every six days in a different location
11463866|NCT01603914|Experimental|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
11463867|NCT01603901|Experimental|Investigated Wounds|
11463868|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
11463869|NCT01603888||infants, BNP, NT-proBNP|infants
11463870|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
11463871|NCT01603875|Active Comparator|PrEP and Simulated PEP with PVRV by intramuscular route|
11463872|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intramuscular route|
11463873|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intradermal route|
11463874|NCT01603862|Experimental|ThinkingFit|
11463875|NCT01603849|Experimental|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
11463876|NCT01603849|No Intervention|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
11463877|NCT01603836|Experimental|bone marrow concentrate|In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
11463878|NCT01603784|Experimental|Combined|Aerobic Exercise + Cognitive Training
11463879|NCT01603784|Experimental|Exercise|Aerobic Exercise + Health Education
11463880|NCT01603784|Experimental|Cognitive|Home Exercise + Cognitive Training
11463881|NCT01603784|Experimental|Control|Home Exercise + Health Education
11463882|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
11463955|NCT01603329|Experimental|Foc incentives + comm for hypertension meds + non-white paper|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
11464641|NCT01598623|Experimental|Placebo + Social Skills Training|
11463883|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
11463884|NCT01603758|No Intervention|Observational Arm|Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
11463885|NCT01603758|Placebo Comparator|Ezetimibe Interventional Arm|Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined
11463886|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
11463887|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
11463888|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
11463889|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
11463890|NCT01603719|No Intervention|Standard Formula|Standard formula with no supplementation
11463891|NCT01603719|Experimental|experimental formula|infant formula with higher beta-palmitate and supplemented GOS
11463892|NCT01603563|Experimental|Stepped Care TF-CBT|Patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
11463893|NCT01603563|Active Comparator|Standard TF-CBT|Patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
11463894|NCT01603550|Experimental|Energy Restriction|
11463895|NCT01603550|Experimental|Sleep Deprivation|
11463896|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
11463897|NCT01603537||No PHTLS|Not exposed to PHTLS
11463898|NCT01603524|Active Comparator|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:
~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.
~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.
~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).
~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
11463899|NCT01603524|Experimental|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
11463900|NCT01603498|Experimental|Dexamethasone 8mg|
11463901|NCT01603498|Experimental|Methylprednisolone|Methylprednisolone 40mg
11463902|NCT01603407|Experimental|Daily prednisone|daily prednisone (0.75 mg/kg/day)
11463903|NCT01603407|Experimental|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
11463904|NCT01603407|Experimental|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
11463905|NCT01603823||Healthy volunteers|
11463906|NCT01603823||St.p. Pars plana vitrectomy|
11463907|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
11463908|NCT01603797|Experimental|Internet delivered ACT|Internet delivered acceptance and commitment therapy (ACT), 7 weeks treatment
11463909|NCT01603797|Active Comparator|Online discussion forum|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
11463910|NCT01603745|Active Comparator|NOMAC-valerate estradiol|E/P therapy
11463911|NCT01603745|Active Comparator|Drospirenone/ethinylestradiol|E/P therapy
11463912|NCT01603706|Active Comparator|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
11463913|NCT01603706|No Intervention|Conventional implantation group|Patients undergoing conventional LV lead implantation
11463914|NCT01603693|Experimental|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
11463915|NCT01603693|Experimental|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
11463916|NCT01603680|Other|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
11463917|NCT01603680|Other|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
11463918|NCT01603667|Experimental|PG2 Injection 500 mg|PG2 Injection 500 mg
11463919|NCT01603667|Placebo Comparator|Placebo|Placebo
11463920|NCT01603654|Experimental|sodium picosulphate/magnesium citrate|
11463921|NCT01603654|Active Comparator|low-volume PEG -ascorbic acid|
11463956|NCT01603329|Experimental|Focused incentives + focused comm for cholesterol meds|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
11464689|NCT01598259|Placebo Comparator|placebo|
11463922|NCT01603641|Experimental|BOTOX®|Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
11463923|NCT01603628|Experimental|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
11463924|NCT01603628|Experimental|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
11463925|NCT01603628|Placebo Comparator|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
11463926|NCT01603615|Experimental|BOTOX®|Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
11463927|NCT01603602|Experimental|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
11463928|NCT01603602|Experimental|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
11463929|NCT01603602|Placebo Comparator|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
11463930|NCT01603589|Active Comparator|MiECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation (MiECC).
11463931|NCT01603589|Active Comparator|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation (CECC).
11463932|NCT01603576|Experimental|Suprachoroidal retinal prosthesis|
11463933|NCT01603485|Experimental|Lersivirine|
11463934|NCT01603472||Subjects on Parenteral Nutrition|cases are those on Parenteral Nutrition >6 weeks for intestinal failure.
11463935|NCT01603472||Subjects not on Parenteral Nutrion|Controls are those who have never been on PN but can be fed via a feeding tube
11463936|NCT01603459|Experimental|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
11463937|NCT01603446|Experimental|MELAS Patients|Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
11463938|NCT01603446|No Intervention|Control Group|Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects
11463939|NCT01603433|Experimental|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
11463940|NCT01603420|Active Comparator|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
11463941|NCT01603420|Experimental|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
11463942|NCT01603394|Experimental|Pregabalin (300-600 mg/day; 150 mg/day starting dose)|
11463943|NCT01603381|Experimental|CBT-I|Cognitive Behavioral Therapy for Insomnia
11463944|NCT01603381|No Intervention|Monitor Only (M.O.)|
11463945|NCT01603368|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938, 125 million bacteria/day
11463946|NCT01603368|Placebo Comparator|Placebo|The same oil drops as the active study product but without Lactobacillus reuteri
11463947|NCT01603355|Experimental|Tocilizumab|
11463948|NCT01603342|Experimental|clopidogrel|
11463949|NCT01603342|Placebo Comparator|Placebo|
11463950|NCT01603329|Experimental|Comprehensive incentives + comprehensive communication|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
11463951|NCT01603329|Experimental|Comp incentives + comp communication + non-white paper|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
11463952|NCT01603329|Experimental|Focused incentives + focused com for oral diabetes medication|Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
11463953|NCT01603329|Experimental|Foc incentives + foc comm for Diabetes + non-white paper|Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
11464059|NCT01602588|Active Comparator|Arm A: SCRT alone|Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
11463957|NCT01603329|Experimental|Foc incentives +comm for cholesterol meds + non-white paper|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
11463958|NCT01603329|Experimental|Comprehensive communiation|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
11463959|NCT01603329|Experimental|Comprehensive communication + non-white paper|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
11463960|NCT01603329|Experimental|Control Arm|Physicians and their patient adherence is tracked, but they receive no intervention.
11463961|NCT01603316|Active Comparator|Food Voucher Program (Voucher)|In the Food Voucher arm, each participant will receive a debit card specifically created for this program. Each month for the duration of study participation (6 months), the debit card will be credited with $128 and given to the patient in person or via mail. Patients will be instructed to use these cards only for food purchases. They will be counseled on using their vouchers only for healthful foods, in a way that stretches their food dollars. Purchases will be tracked by having patients bring their receipts in for review each month when they come in to pick-up their next monthly vouche, or by providing electronic copies of receipts. Patients will be provided with a receipt holder to assist in storing receipts for review.
11463962|NCT01603316|Experimental|Home Grocery Delivery (Delivery)|"In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participants zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA."
11463963|NCT01603316|Experimental|Medically-Tailored Hospital-Based Food Pantry (Pantry)|Patients in this arm will have access to the pantry for the duration of their study participation (6 months). Those accessing the medically-tailored food pantry will pick-up a pantry bag weekly at the hospital, either during one of their medical appointments or at another preferred time. Each patient's food prefereces will be assessed once during baseline and they will be given food bags, tailored when possible and when available to these preferences and to their medical needs and cultural preferences.
11463964|NCT01603303|Other|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
11463965|NCT01603303|Experimental|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
11463966|NCT01603303|Experimental|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
11463967|NCT01603290||Hospitalized Leukemia Patients|leukemia patients with chemotherapy during hospitalization
11463968|NCT01603277|Experimental|Anti-GM-CSF Monoclonal Antibody 400mg|
11463969|NCT01603277|Placebo Comparator|Normal Saline|
11463970|NCT01603264|Experimental|A|PF-05280014
11463971|NCT01603264|Active Comparator|B|Trastuzumab-EU
11463972|NCT01603264|Active Comparator|C|Trastuzumab-US
11463973|NCT01603251|Active Comparator|Artemether-Lumefantrine|
11463974|NCT01603251|Experimental|Artemether-Lumefantrine + single dose Ivermectin|
11463975|NCT01603251|Experimental|Artemether-Lumefantrine + repeated dose Ivermectin|
11463976|NCT01603238|Experimental|[14C]-LC15-0444|A single oral dose of [14C]-LC15-0444 50 mg , containing 4.9 MBq [14C] (batch number 110372/C/01).
11463977|NCT01603225||Autism|Individuals with autism will have either Anodal, Cathodal, or Sham Transcranial Direct Current Stimulation (tDCS).
11463978|NCT01603212|Experimental|Vemurafenib + IL-2 + Interferon Alfa-2b|Starting dose of Vemurafenib 720 mg by mouth twice daily. Three dose levels of Vemurafenib evaluated in combination with interferon and IL-2. These doses are 480 mg, 720 mg and 960 mg. IL-2 given by continuous venous infusion at starting IL-2 dose of 7 million IU/m2 daily for 4 days (total of 96 hours, days 2-5) starting day 2. IL-2 dose levels are 5MU/m2/day, 7MU/m2/day and 9MU/m2 day. Doses of interferon remain constant at 5 MU/m2 subcutaneously daily for 5 days starting Day 1.
11463979|NCT01603199|Experimental|Primary biliary cirrhosis (Non-cirrhotic)|
11463980|NCT01603199|Experimental|Primary biliary cirrhosis (Cirrhotic)|
11463981|NCT01603186|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
11463982|NCT01603186|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
11463983|NCT01603173|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
11463984|NCT01603173|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
11464060|NCT01602575|Experimental|mindfulness treatment|Mindfulness based stress reduction is the intervention in this single arm trial
11463985|NCT01603160||Emergency Department Staff|"Interventions put in place in the Emergency Department will effect most staff who work in the ED, but different sub-groups will be approached for participation in specific aspects of the study:
~All ED attending and resident physicians and ED nurses will be invited to complete the SCD Attitudes survey.
~Select ED Staff will be invited to be members of the QI team and will be invited to participate in the FMECA.
~Members of the QI team will be invited to participate in a focus group."
11463986|NCT01603147|Placebo Comparator|Saline|A total of 10 subjects will receive placebo
11463987|NCT01603147|Experimental|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
11463988|NCT01603134|Experimental|Allopurinol 300 mg Tablets USP|Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
11463989|NCT01603134|Active Comparator|Zyloprim®|Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
11463990|NCT01603121|Experimental|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
11463991|NCT01603121|Experimental|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
11463992|NCT01603108|Experimental|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
11463993|NCT01603108|Placebo Comparator|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
11463994|NCT01603095||Growth measurements|Approximately 500 patients will be enrolled. Patients from birth to < 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
11463995|NCT01603082|Experimental|Ticagrelor|Ticagrelor - 180 mg loading dose
11463996|NCT01603082|Active Comparator|Clopidogrel|Clopidogrel - 600 mg loading dose
11463997|NCT01603069|Active Comparator|AZD3241, 300 mg|AZD3241 300 mg BID
11463998|NCT01603069|Active Comparator|AZD3241, 600 mg|AZD3241 600 mg BID
11463999|NCT01603069|Placebo Comparator|Placebo|Placebo to AZD3241
11464000|NCT01603056|Experimental|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
11464001|NCT01603056|Placebo Comparator|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
11464002|NCT01603043|Experimental|AL-78898A|1 intravitreal injection per month for up to 12 months
11464003|NCT01603043|Sham Comparator|Sham Injection|1 mock injection per month for 12 months
11464004|NCT01603030|Experimental|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
11464005|NCT01603030|Active Comparator|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
11464006|NCT01603017|Placebo Comparator|Placebo - no therapy|Patients who were blinded but did not receive therapy
11464007|NCT01603017|Experimental|MRI therapy|Patients receiving MRI therapy but blinded to it
11464008|NCT01603004||everolimus, sunitinib or traditional chemotherapy|A total of 30 patients with well differentiated pancreatic NETs who have known liver metastases and who are planned to initiate therapy with either targeted (everolimus or sunitinib) or traditional cytotoxic chemotherapy will be recruited for this study. We plan to recruit approximately 10 patients for each therapy (everolimus, sunitinib, cytotoxic chemotherapy). Evidence of metastatic disease will be determined at the discretion of the oncologist based on available imaging, surgical and pathologic evidence.
11464009|NCT01602965|Experimental|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
11464010|NCT01602965|Active Comparator|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
11464011|NCT01602952|Experimental|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m^2
~Phase 2 : 400mg Bid"
11464012|NCT01602939|Experimental|2CDA+IFN|
11464013|NCT01602926|Experimental|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
11464014|NCT01602926|Experimental|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
11464015|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
11464016|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
11464017|NCT01602900|Experimental|GSK356278|Investigational drug
11464018|NCT01602887|Active Comparator|Reference|This is the reference formulation
11464019|NCT01602887|Experimental|NF1|This is a test formulation
11464020|NCT01602887|Experimental|NF2|This is a test formulation
11464021|NCT01602887|Experimental|SOL|This is a test formulation
11464022|NCT01602874|Experimental|A. Tigecycline|
11464023|NCT01602874|Active Comparator|B. Ceftriaxone regimen|
11464024|NCT01602861|Experimental|Spironolactone|
11464025|NCT01602861|Placebo Comparator|Placebo|
11464165|NCT01601938|Experimental|Selenium|500 mcg of selenium (10mL) daily for 7 days
11464026|NCT01602848|Experimental|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
11464027|NCT01602848|No Intervention|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
11464028|NCT01602822|Other|Atazanavir, Ritonavir, Truvada|Open Label
11464029|NCT01602796|Experimental|School-based intervention|
11464030|NCT01602796|No Intervention|Control|
11464031|NCT01602783|Experimental|11C Acetate Imaging|11C acetate imaging
11464032|NCT01602770||Group 1|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
11464033|NCT01602757|Experimental|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
11464034|NCT01602744|No Intervention|Controll|The medications in this arm will not be screened.
11464035|NCT01602744|Active Comparator|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
11464036|NCT01602731|Experimental|Automated Medication Dispensing Device|Subjects with <88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
11464037|NCT01602718|No Intervention|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.
~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
11464038|NCT01602718|No Intervention|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.
~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
11464039|NCT01602718|Other|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
11464040|NCT01602705|Placebo Comparator|Usual care|
11464041|NCT01602705|Active Comparator|Usual care + feedback of practice performance|
11464042|NCT01602705|Active Comparator|Usual care + feedback + health psychology intervention|
11464043|NCT01602692|Active Comparator|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
11464044|NCT01602692|Active Comparator|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
11464045|NCT01602679|Experimental|micronized progesterone, then placebo|Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).
11464046|NCT01602679|Placebo Comparator|Placebo, then micronized progesterone|Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
11464047|NCT01602666|Experimental|Treatment (combination chemotherapy, radiation therapy)|See Detailed Description
11464048|NCT01602653|Active Comparator|1|the first group of patients received an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
11464049|NCT01602653|Active Comparator|2|The second grouop of patients received 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
11464050|NCT01602640|Experimental|Morphine|
11464051|NCT01602640|Active Comparator|Fentanyl and Midazolam|Control
11464052|NCT01602627|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11464053|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
11464054|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
11464055|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
11464056|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
11464057|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
11464058|NCT01602588|Experimental|Arm B|Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
11464946|NCT01596530|Active Comparator|AZD8931|AZD8931
11464061|NCT01602562|Experimental|VACV (256U87; valaciclovir hydrochloride)|Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily.
11464062|NCT01602549|Experimental|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
11464063|NCT01602536|Experimental|Twitter|Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
11464064|NCT01602536|Active Comparator|Control|Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
11464065|NCT01602523|Active Comparator|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
11464066|NCT01602523|Placebo Comparator|Placebo|Symbicort placebo
11464067|NCT01602510|Experimental|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
11464068|NCT01602510|Placebo Comparator|Placebo|Placebo
11464069|NCT01602497|Active Comparator|rTMS intervention group|The rTMS intervention group undergo ten session of real TMS therapy.
11464070|NCT01602497|Placebo Comparator|Sham group|Patients will undergo ten session of sham rTMS.
11464071|NCT01602484|Experimental|Splint Pack|Group of post-op patients who have splint applied from prepared Plaster-of-Paris splint pack
11464072|NCT01602484|Active Comparator|Bulk Supplies|Group of post-op patients who have splint applied from bulk supplies
11464073|NCT01602471|Experimental|[F-18]RDG-K5|[F-18]RDG-K5 was administred and PET scan performed
11464074|NCT01602458|Other|Silicone Only Therapy (SOT)|Mepiform™ silicone will be utilized by SOT group.
11464075|NCT01602458|Other|Silicone Pressure Garment Therapy (SPGT)|Mepiform™ silicone and custom compression garments fabricated by Barton Carey™ will be utilized by SPGT group.
11464076|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
11464077|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).
~Based on this method, the model includes 5 predictive variables as follows:
~Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).
~Platelet count: (>350 x 109/L) (+1 point)
~Hemoglobin level (<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)
~Leukocyte count (> 11 x 109/L)(+1 point).
~body mass index (≥ 35 Kg/m2) (+1 point)."
11464078|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is < 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).
~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
11464079|NCT01602419||Patients using Wilate as standard of care treatment|This patient population is being treated with Wilate as standard of care treatment
11464080|NCT01602406|Experimental|LJM716 in combination with trastuzumab|
11464081|NCT01602393|Experimental|CHF 5074 1x|oral tablet, multidose
11464082|NCT01602393|Experimental|CHF 5074 2x|oral tablet, multidose
11464083|NCT01602393|Experimental|CHF 5074 3x|oral tablet, multidose
11464084|NCT01602380|Experimental|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
11464085|NCT01602380|Active Comparator|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
11464086|NCT01602367|Experimental|Arm 1: BMS-823778 (2mg)|
11464087|NCT01602367|Experimental|Arm2: BMS-823778 (6mg)|
11464088|NCT01602367|Experimental|Arm 3: BMS-823778 (15mg)|
11464089|NCT01602367|Experimental|Arm4: Placebo|
11464090|NCT01602354||Gram-negative Septic shock|Patients affected by Gram-negative septic shock
11464091|NCT01602341|Experimental|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion
~Treatments will be randomly assigned to target lesions A and B."
11464092|NCT01602341|Experimental|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.
~Treatments will be randomly assigned to target lesions A and B."
11464093|NCT01602328|Active Comparator|AC607|Treatment with AC607
11464094|NCT01602328|Placebo Comparator|Placebo|Treatment with Placebo
11464095|NCT01602315|Experimental|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
11464096|NCT01602315|Experimental|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
11464097|NCT01602315|Experimental|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
11464098|NCT01602315|Experimental|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
11464099|NCT01602315|Experimental|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
11464100|NCT01602315|Experimental|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
11464101|NCT01602315|Experimental|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
11464102|NCT01602302|Experimental|single arm ( bDMARD withdrawal )|single arm (bDMARD withdrawal)
11464166|NCT01601938|Placebo Comparator|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
11464103|NCT01602289|Experimental|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
11464104|NCT01602289|Experimental|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
11464105|NCT01602289|Experimental|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
11464106|NCT01602276|Experimental|Active Stimulation|Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
11464107|NCT01602276|Sham Comparator|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
11464108|NCT01602263||Controls|Healthy Controls with no known cognitive impairment will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
11464109|NCT01602263||Individuals with schizophrenia|Individuals with schizophrenia and first-degree relatives will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
11464110|NCT01602263||Individuals with aphasia|Individuals with aphasia will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
11464111|NCT01602263||Individuals with high-functioning autism|Individuals with high-functioning autism will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
11464112|NCT01602250|Placebo Comparator|levobupivacaine placebo|levobupivacaine placebo
11464113|NCT01602250|Experimental|levobupivacaine Intralipid®|levobupivacaine Intralipid®
11464114|NCT01602250|Experimental|ropivacaine Intralipid®|ropivacaine Intralipid®
11464115|NCT01602250|Placebo Comparator|ropivacaine placebo|ropivacaine placebo
11464116|NCT01602237||Bakery workers|
11464117|NCT01602224|Experimental|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.
~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.
~Bortezomib 1.3 milligram per square meter (mg/m^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.
~All treatment may continue past 8 cycles."
11464118|NCT01602224|Experimental|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.
~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.
~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.
~All treatment may continue past 8 cycles."
11464119|NCT01602224|Placebo Comparator|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.
~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.
~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.
~All treatment may continue past 8 cycles."
11464120|NCT01602211|Experimental|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
11464121|NCT01602211|Experimental|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
11464122|NCT01602198|Active Comparator|Exelon transdermal patch|Exelon [rivastigmine] transdermal patch
11464123|NCT01602198|Placebo Comparator|Placebo transdermal patch|Placebo transdermal patch
11464124|NCT01602185|Experimental|memantine|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
11464125|NCT01602185|Experimental|dextromethorphan|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
11464126|NCT01602185|Placebo Comparator|placebo|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
11464127|NCT01602172|Experimental|Brief Alcohol Intervention (BI)|The 3-part Brief Intervention (BI) consists of . Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
11464128|NCT01602172|Active Comparator|Attention Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity. Two weeks later, the Research Assistant calls subjects in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. This intervention is designed to provide all the information and assessments that that Brief Intervention participants as well as all the alcohol consumption and motivation to change measures-- it is designed to control for the attention that the BI participants receive w/o the motivational interventions
11464167|NCT01601925|Experimental|neck extended group|We measured the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck.
11464168|NCT01601912||Atomoxetine NRI|We will modulate endogenous adrenergic pain inhibitory mechanisms by using a selective norepinephrine reuptake inhibitor (NRI).
11464461|NCT01599819|Experimental|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
11464129|NCT01602172|Active Comparator|Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. Subjects complete only drinking quantity measures at baseline and 6 months post baseline. The inclusion of this group tests whether completing more extensive questionnaires (in comparison the Attention Control group) decreases alcohol consumption.
11464130|NCT01602159|Active Comparator|Open Bypass Surgery|Open Bypass Surgery
11464131|NCT01602159|Active Comparator|Angioplasty and Stenting|
11464132|NCT01602146||ultramarathon runner|People who do the Mont Blanc ultramarathon (31/08/12 to 02/09/12)
11464133|NCT01602133|Experimental|one intervention arm|
11464134|NCT01602120|Experimental|CFD4870g Sham|Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), will receive lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
11464135|NCT01602120|Experimental|CFD4870g Lampalizumab|Participants will receive lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
11464136|NCT01602120|Experimental|GX29455 Sham|Participants who were administered sham comparator in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
11464137|NCT01602120|Experimental|GX29455 Lampalizumab|Participants who were administered lampalizumab in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
11464138|NCT01602107|No Intervention|Control|Participants in the control group will not receive therapist-supervised intervention. An exercise sheet briefly describing pelvic floor muscle exercises will be provided, as would be the standard practice from most physicians.
11464139|NCT01602107|Experimental|Pelvic Floor Therapy|Participants in the experimental group undergo and assessment and treatment by a registered physiotherapist. Treatments will include two sessions of biofeedback training, therapist-assisted strengthening exercises, and will a prescribed home exercise program to strengthen their pelvic floor muscles.
11464140|NCT01602094||Adequate antimeales antibody levels|ELISA test OD > 0.1
11464141|NCT01602094||Inadequate measles antibody levels|ELISA test OD < 0.1
11464142|NCT01602081||LIFT+Biodesign|
11464143|NCT01602068|Experimental|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
11464144|NCT01602068|Placebo Comparator|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
11464145|NCT01602055|Experimental|Azivol|
11464146|NCT01602055|Active Comparator|Zithromax|
11464147|NCT01602029|Active Comparator|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
11464148|NCT01602029|Active Comparator|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
11464149|NCT01602029|Placebo Comparator|Placebo|Placebo added to TAU
11464150|NCT01602029|Active Comparator|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
11464151|NCT01602016|No Intervention|Phase I|Baseline Visit Phase 1: The screening portion of the CELF will be administered to the child to screen for language impairment. If a child is determined to be pre-verbal they will automatically qualify,If there is no language impairment, the subject will not be eligible. If language impairment is confirmed, the participant will immediately go on to the baseline visit of Phase 2.
11464152|NCT01602016|Other|Phase II: 12 week Folinic Acid or Placebo intervention|The child will be consented for Phase 2 (the RCT) and undergo a blood draw (up to 20mL) for metabolic and autoantibody testing. the child will undergo language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires (ASQ, RBS-R, SRS, and ABC). Demographic information including; age, race, gender, and ethnicity will be collected. The research pharmacist will randomize the participant to either Intervention A or B (only the research pharmacist will know which intervention has the folinic acid). The research pharmacist will distribute the drug or placebo to the parent and instruct the parent of the proper administration of the intervention. This will be considered the 12 week randomly controlled clinical trial that is investigating the safety and efficacy of folinic acis interventions in ASD and will last for approximately 12 weeks. At the end of 12 weeks, the same assessments that were conducted at baseline will be readministered
11464153|NCT01602016|Experimental|Phase III: Open Label Extension of Folinic Acid|If consent for Phase 3 is signed by parents with children who qualify for Phase 3, the research pharmacist will provide a 12 week supply of folinic acid to the parent. This arm will be offered to all clients that completed phase 2 of the trial. After consenting and 12 weeks of folinic acid dosing, the client will come back and complete the same protocol and be tested on the same measures used in phase II of the study. This will be a rolling stopping point so that new therapies can be started, if the parent/caregiver is so inclined
11464154|NCT01602003|Experimental|LC15-0444 25 mg bid|LC15-0444 25 mg bid(twice daily)added on Metformin therapy
11464155|NCT01602003|Experimental|LC15-0444 50 mg qd|LC15-0444 50 mg qd(once daily) added on Metformin therapy
11464156|NCT01602003|Active Comparator|Sitagliptin 100mg qd|Sitagliptin 100 mg qd (once daily) added on the Metformin therapy
11464157|NCT01601990|Placebo Comparator|Placebo|
11464158|NCT01601990|Experimental|LC15-0444|
11464159|NCT01601977|Experimental|Intervention|AVAPS-AE
11464160|NCT01601977|Active Comparator|Usual care|Non-invasive ventilation
11464161|NCT01601964||Follow-up or medical treatment.|medical treatment
11464162|NCT01601964||Surgical treatment|Surgical treatment
11464163|NCT01601951||Hip Osteoarthritis|
11464164|NCT01601951||Knee Osteoarthritis|
11464947|NCT01596530|Placebo Comparator|Placebo|Placebo
11464169|NCT01601912||Citalopram SSRI|We will modulate serotonergic pain inhibitory mechanisms by using a selective serotonin reuptake inhibitor (SSRI)
11464170|NCT01601899|Active Comparator|ARM A|Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
11464171|NCT01601899|Active Comparator|ARM B|Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
11464172|NCT01601899|Active Comparator|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
11464173|NCT01601886||Before SUPPORT|01/03-06/05
11464174|NCT01601886||During SUPPORT recruitment|07/05-02/09
11464175|NCT01601886||After SUPPORT|03/09-06/10
11464176|NCT01601873|Experimental|PROPATEN|patients with heparin-bonded graft implantation
11464177|NCT01601873|Active Comparator|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
11464178|NCT01601860|No Intervention|Control|Control Group (CG) Pregnant women who will not use any physical therapy resource, are subject only to routine procedures of maternity care Pregnant women who will not use any physical therapy resource, are subject only to routine procedures of maternity care
11464179|NCT01601860|Experimental|Protocol|Intervention Group (IG) Pregnant women who will use the following features sequentially: walking (with cervical dilation between 4 and 5 cm), alternating stance associated with ENT (cervical dilatation from 6 to 7 cm), shower (with dilation> 7 cm);
11464180|NCT01601847|Active Comparator|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
11464181|NCT01601847|Placebo Comparator|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
11464182|NCT01601834|Experimental|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
11464183|NCT01601834|Experimental|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
11464184|NCT01601821|Active Comparator|Arm A (CsA+Rapamune+CS)|
11464185|NCT01601821|Experimental|Arm B (CsA+MMF+CS)|
11464186|NCT01601808|Placebo Comparator|Gemcitabine and Placebo|Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
11464187|NCT01601808|Experimental|Gemcitabine and vandetanib|Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
11464188|NCT01601795|Active Comparator|Sevoflurane|During cardiopulmonary bypass, sevoflurane will be administered through a vaporizer integrated into heart-lung-machine.
11464189|NCT01601795|Active Comparator|Isoflurane|During cardiopulmonary bypass, isoflurane will be administered through a vaporizer integrated into heart-lung-machine.
11464190|NCT01601782|Experimental|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
11464191|NCT01601769|Active Comparator|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
11464192|NCT01601769|Experimental|Vitom|The VITOM system, consisting of the VITOM scope, xenon light source, HD camera system, AIDA HD documentation system, 1 monitor, and a mechanical support arm (all Karl Storz, Tuttlingen, Germany) is used for video exocolposcopy.
11464193|NCT01601756|Experimental|navigated revision total knee arthroplasty|revision total knee arthroplasty with the aid of a navigation system
11464194|NCT01601756|Active Comparator|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
11464195|NCT01601743|Active Comparator|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
11464196|NCT01601743|Active Comparator|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
11464197|NCT01601743|Active Comparator|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
11464198|NCT01601730|Placebo Comparator|Placebo|
11464199|NCT01601730|Active Comparator|Modafinil 200 mg + Escitalopram 20 mg|
11464200|NCT01601730|Active Comparator|Modafinil 200 mg|
11464201|NCT01601730|Active Comparator|Escitalopram 20 mg|
11464202|NCT01601717|Placebo Comparator|Sugar pill|
11464203|NCT01601717|Active Comparator|RTI-336|
11464204|NCT01601704|Experimental|NB32|
11464205|NCT01601704|Placebo Comparator|PBO|
11464206|NCT01601691|Experimental|Spacer|Subjects with spacer injection
11464207|NCT01601678|Active Comparator|Peroral Endoscopic Myotomy POEM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the POEM therapy group
11464208|NCT01601678|Active Comparator|Laparoscopic Heller Myotomy LHM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the LHM therapy group.
11464209|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
11464210|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
11464211|NCT01601652|Experimental|Omeagven|
11464212|NCT01601639|Active Comparator|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
11464213|NCT01601639|Active Comparator|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
11464265|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
11464214|NCT01601626|Experimental|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.
~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.
~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
11464215|NCT01601626|Active Comparator|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.
~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.
~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
11464216|NCT01601626|Experimental|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.
~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.
~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
11464217|NCT01601613|Experimental|rFVIIa|
11464218|NCT01601613|Placebo Comparator|placebo|
11464219|NCT01601600|Placebo Comparator|Placebo|
11464220|NCT01601600|Experimental|BYM338|BYM338 active drug
11464221|NCT01601587|No Intervention|Treatment as usual|Patients will receive treatment as usual
11464222|NCT01601587|Other|Introduction Seminar|Psychoeducational group
11464223|NCT01601574|Experimental|Modified Weight Watchers program|
11464224|NCT01601574|Active Comparator|Standard Diabetes Counseling group|
11464225|NCT01601561|Experimental|High-dose insulin|
11464226|NCT01601561|No Intervention|Control|
11464227|NCT01601548|Experimental|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
11464228|NCT01601548|No Intervention|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
11464229|NCT01601535|Experimental|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
~Irinotecan will be administered intravenously during each course on study day 1 through day 5.
~Temozolomide will be administered orally during each course on study day 1 through day 5."
11464230|NCT01601522|Experimental|Desentization dose|500 mg Peanut Protein
11464231|NCT01601522|Placebo Comparator|Placebo|Oat flour
11464232|NCT01601509|Active Comparator|nasal spray with tramazoline and dexamethazone|
11464233|NCT01601509|Placebo Comparator|Placebo|
11464234|NCT01601496|Experimental|FUSION Vascular Graft|All subjects who received a FUSION Vascular Graft at the baseline implant procedure.
11464235|NCT01601483|Experimental|MC-1101 1% Ophthalmic Solution|
11464236|NCT01601483|Placebo Comparator|Vehicle control|
11464237|NCT01601470|Experimental|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
11464238|NCT01601457|Experimental|Activated recombinant human factor VII|
11464239|NCT01601457|Placebo Comparator|Placebo|
11464240|NCT01601431|Experimental|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
11464241|NCT01601431|Active Comparator|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
11464242|NCT01601392|Experimental|Anodal tDCS|
11464243|NCT01601392|Active Comparator|Cathodal tDCS|
11464244|NCT01601392|Sham Comparator|Sham|
11464245|NCT01601366|Experimental|LNG-IUS (Mirena)|"Group I the LNG-IUS group where they will have a LNG IUS (mirena) inserted for them"
11464246|NCT01601366|Active Comparator|Combined oral contraceptives|"Group II COCs group where they will receive low dose combined oral contraceptive pills for 6 months"
11464247|NCT01601353|Experimental|Treatment|Injection of adipose derived cells into penis
11464248|NCT01601353|No Intervention|Control|No intervention through 9 months
11464249|NCT01601340|Active Comparator|HQK-1001|
11464250|NCT01601340|Placebo Comparator|Placebo|
11464251|NCT01601327|Other|hypogonadism, treatment|77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
11464252|NCT01601327|No Intervention|Control group|42 healthy controls
11464253|NCT01601314|Experimental|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
11464254|NCT01601314|Placebo Comparator|Control|Patients who are going to receive Sodium Chloride 0.9%
11464255|NCT01601301|Experimental|PRECICE System|
11464256|NCT01601262|Experimental|Open label|
11464257|NCT01601249|Experimental|Polscope based embryo grading|Embryos for transfer will be selected based on highest polscope scores, unless are not grade 1-2 by conventional morphology
11464258|NCT01601249|Active Comparator|Morphology based embryo grading|Conventional embryo grading and decision making
11464259|NCT01601236|Experimental|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
11464260|NCT01601236|Placebo Comparator|Placebo (0.1 mL) daily|Placebo
11464261|NCT01601236|Experimental|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
11464262|NCT01601236|Placebo Comparator|Placebo (0.2 mL) daily|Placebo
11464263|NCT01601236|Experimental|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
11464264|NCT01601236|Placebo Comparator|Placebo (0.4 mL) daily|Placebo
11464266|NCT01601210|Placebo Comparator|Placebo|
11464270|NCT01601197|Experimental|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
11464271|NCT01601197|No Intervention|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
11464272|NCT01601184|Experimental|combination of vismodegib with temozolomide|"In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive
~- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 [day 1 to day 5/ 28 day-cycle] and 200 mg/m2 during subsequent cycles) (6 patients)"
11464273|NCT01601184|Active Comparator|temozolomide alone|In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).
11464274|NCT01601184|Other|vismodegib alone|Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm
11464275|NCT01601171||Patients|"Patients with reproductive disorders with or without cleft lip/palate will be recruited for:
~completion of medical questionnaire and review of medical records
~family tree (including questions on reproductive disorders and cleft lip/palate)
~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy
~smell testing
~hearing test
~bone density
~brain MRI
~kidney, testicular/ovarian ultrasound"
11464276|NCT01601171||Family members|"Family members of Patients will be recruited for:
~completion of medical questionnaire
~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy
~smell testing"
11464277|NCT01601158|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
11464278|NCT01601145|Experimental|lozenges with Lactobacillus brevis CD2|Randomized group using lozenges for 6 weeks.
11464279|NCT01601145|Placebo Comparator|lozenges|Randomized group using lozenges for 6 weeks.
11464280|NCT01601132|Experimental|theophylline|300mg (80mg/15ml elixir) theophylline
11464281|NCT01601132|Experimental|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
11464282|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
11464283|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
11464284|NCT01601106|Active Comparator|Liposomal prednisolone|
11464285|NCT01601106|Placebo Comparator|Placebo control|
11464286|NCT01601093|Experimental|High dose|Ceftazidime 3g
11464287|NCT01601093|Experimental|Low dose|Ceftazidime 2g
11464288|NCT01601093|Active Comparator|CFP/SUB|Cefoperazone and sulbactam sodium for injection(2:1)
11464289|NCT01601067|Experimental|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
11464290|NCT01601067|Active Comparator|Arm 2: Seeking Safety|Seeking Safety
11464291|NCT01601054|Active Comparator|Anterior lumbar interbody fusion|Anterior lumbar interbody fusion using a tantalum cage. Cage will be inserted through a left sided retroperitoneal approach.
11464292|NCT01601054|Active Comparator|Posterior instrumentation alone|Posterior pedicle screw instrumentation
11464293|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
11464294|NCT01601041||control group|less than three urinary tract infections / year
11464295|NCT01601028|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
11464296|NCT01601028|Placebo Comparator|Placebo|Placebo
11464297|NCT01601015|Experimental|Manual therapy|Manual therapy of Suboccipital soft tissue Inhibition treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
11464298|NCT01601015|Experimental|Occiput-atlas-axis joint manipulation|Is bilaterally administered. The aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction
11464299|NCT01601015|Experimental|Combined treatment|The group receiving combined treatment received the two previous techniques exactly with the same sequence.
11464300|NCT01601015|Placebo Comparator|Control group|Control group not receive treatment and stayed in this position for 10 minutes
11464301|NCT01601002|Experimental|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
11464302|NCT01600989||Patients with severe sepsis / septic shock|30 Adult patients (age > 18years), with severe sepsis or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines at the time of admission to ICU.
11464303|NCT01600989||Healthy volunteers|Healthy volunteers
11464304|NCT01600976|Experimental|Group 1|10 patients with moderate hepatic impairment (CPB [Child-Pugh score 7 to 9])
11464305|NCT01600976|Experimental|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
11464306|NCT01600976|Experimental|Group 3|up to 4 patients with severe hepatic impairment (CPC [limited to Child Pugh score 10 to 12])
11464307|NCT01600963|Experimental|Arm A|
11464308|NCT01600963|Placebo Comparator|Arm B|
11464309|NCT01600950|Experimental|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
11464310|NCT01600950|Active Comparator|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
11465097|NCT01595503|Experimental|fMRI-based targeting|
11464312|NCT01600937|Experimental|Exercise|Theoretical & practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
11464313|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
11464314|NCT01600885|Active Comparator|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
11464315|NCT01600885|Active Comparator|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
11464316|NCT01600872||Gruop 1|
11464317|NCT01600872||Group 2|
11464318|NCT01600859|Experimental|E2609|
11464319|NCT01600859|Placebo Comparator|Placebo for E2609|
11464320|NCT01600833||Obese women|BMI>25
11464321|NCT01600833||Non obese women|BMI<25
11464322|NCT01600820|Experimental|1 = Tested product 1|
11464323|NCT01600820|Experimental|2 = tested product 2|
11464324|NCT01600820|Placebo Comparator|3 = Control product|
11464325|NCT01600807|Experimental|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
11464326|NCT01600807|Active Comparator|Gemcitabine, Erlotinib|Standard treatment arm
11464327|NCT01600794||male/female, immunity or others factor infertility, IVF|
11464328|NCT01600781|Active Comparator|NutriniDrink/Fortini group|this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.
11464329|NCT01600781|No Intervention|control group|this control group will only receive standard dietary counselling
11464330|NCT01600768|Active Comparator|intermittent infusion|
11464331|NCT01600768|Experimental|extended infusion|
11464332|NCT01600755|Experimental|Autologous Muscle-Derived Cells|Cell Treatment
11464333|NCT01600742|Active Comparator|WBRT, placebo|
11464334|NCT01600742|Experimental|WBRT and concurrent vorinostat|
11464335|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
11464336|NCT01600716|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
11464337|NCT01600716|Other|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
11464338|NCT01600703|Experimental|Sitagliptin|sitagliptin, 100mg, oral, single dose
11464339|NCT01600703|Placebo Comparator|Placebo|Placebo, oral, single dose
11464340|NCT01600690|No Intervention|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
11464341|NCT01600690|Experimental|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
11464342|NCT01600677|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
11464343|NCT01600677|Active Comparator|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
11464344|NCT01600664|Experimental|interactive computer game|"Participants will be using the interactive computer game- My Diabetic Friend, installed on Intel-powered convertible classmate PC."
11464345|NCT01600664|Active Comparator|Convertible PC|Participants will be using the convertible classmate PC without the interactive computer game
11464346|NCT01600651|Sham Comparator|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
11464347|NCT01600651|Sham Comparator|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
11464348|NCT01600638|Experimental|Zeltiq System Treatment Group|Individuals with sharp flank curvatures were treated on one (1) flank with the Zeltiq CoolSculpting System and the CoolCurve+ applicator at protocol-defined temperatures and durations.
11464349|NCT01600625|Experimental|Minocycline treatment group|
11464350|NCT01600612|Active Comparator|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
11464351|NCT01600612|Active Comparator|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
11464352|NCT01600612|Active Comparator|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
11464353|NCT01600599|Active Comparator|IV & topical TA|patients in this group will receive both intravenous & topical tranexamic acid
11464354|NCT01600599|Placebo Comparator|IV tranexamic acid & Topical Saline|
11464355|NCT01600586|Experimental|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
11464356|NCT01600586|No Intervention|No PAL group|No PAL. Standard of care procedures.
11464357|NCT01600573|Experimental|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
11464358|NCT01600560||Social media|
11464359|NCT01600547||fall clinic population|women, aged + 65 years
11464360|NCT01600547||control fallers|randomly selected community aged matched female controls with a fall episode
11464361|NCT01600547||control non fallers|randomly selected community aged matched female controls, with out fall episodes
11464362|NCT01600534|Experimental|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
11464363|NCT01600534|Other|Usual Care Lifestyle counseling|Self directed educational intervention
11464407|NCT01600248|Other|Treatment arm|This is an open-label pilot study with no control group. Participants pre-treatment scores are compared to their post-treatment scores.
11464408|NCT01600235|Experimental|Phenylephrine|Phenylephrine induced-hypertension arm
11464409|NCT01600235|No Intervention|Conventional treatment|Control arm
11464410|NCT01600222|Experimental|LEO 90100|
11464364|NCT01600521|Active Comparator|Paeoniflorin + Polypeptides (PAE + CCPI)|Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties. Polypeptides (3,000 - 10,000 dalton) in Cervus & Cucumis polypeptide injection (CCPI), the extract from Sika deer (Cervus nippon Temmick) bones and muskmelon (Cucumis melo L) seeds, are the active ingredients with bone healing, pain relieving, and anti-inflammation properties. PAE was administrated orally 600 mg twice a day for at least 12 months. CCPI was administered intravenously 8~12 mL daily with 250 mL 5% dextrose injection solution or 0.9% NaCl IV solution for 2 weeks, discontinued 1 week, and restarted for another 2 weeks.
11464365|NCT01600521|Active Comparator|Methotrexate (MTX) + Leflunomide (LEF)|DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months. MTX dose: 7.5 mg ~ 10mg / week, LEF dose: 10 mg ~ 20mg daily.
11464366|NCT01600521|Active Comparator|MTX + LEF + CCPI|The DMARDs and CCPI were administrated as in the above two groups.
11464367|NCT01600508|Active Comparator|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
11464368|NCT01600508|Experimental|Videoconference Stoma Consultations|Videoconference Stoma Consultations
11464369|NCT01600495|Experimental|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
11464370|NCT01600495|No Intervention|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
11464371|NCT01600482|Experimental|CELT ACD device|The CELT ACD device is a vascular closure device.
11464372|NCT01600482|No Intervention|Manual Compression|Manual Compression
11464373|NCT01600469|Experimental|DAOI-B|
11464374|NCT01600469|Placebo Comparator|Placebo|
11464375|NCT01600456|Active Comparator|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
11464376|NCT01600456|Active Comparator|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
11464377|NCT01600456|Active Comparator|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
11464378|NCT01600456|Active Comparator|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
11464379|NCT01600443|Experimental|LoFric - SC - SCCM|Study period 1: LoFric Study period 2: SpeediCath Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
11464380|NCT01600443|Experimental|LoFric - SCCM - SC|Study period 1: LoFric Study period 2: SpeediCath Compact Male Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
11464381|NCT01600443|Experimental|SC - SCCM - LoFric|Study period 1: SpeediCath Study period 2: SpeediCath Compact Male Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
11464382|NCT01600443|Experimental|SC - LoFric - SCCM|Study period 1: SpeediCath Study period 2: LoFric Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
11464383|NCT01600443|Experimental|SCCM - LoFric - SC|Study period 1: SpeediCath Compact Male Study period 2: LoFric Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
11464384|NCT01600443|Experimental|SCCM - SC - LoFric|Study period 1: SpeediCath Compact Male Study period 2: SpeediCath Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
11464385|NCT01600430|Active Comparator|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
11464386|NCT01600430|Placebo Comparator|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
11464387|NCT01600430|Active Comparator|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
11464388|NCT01600417||clinical suspicion of lumbar instability|
11464389|NCT01600404||antimuscarinic treatment|antimuscarinic treatment
11464390|NCT01600404||no antimuscarinic treatment (control)|
11464391|NCT01600391|Active Comparator|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
11464392|NCT01600391|Experimental|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
11464393|NCT01600391|Experimental|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
11464394|NCT01600365|Active Comparator|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
11464395|NCT01600365|Placebo Comparator|Ophthalmic gel (placebo)|ophthalmic gel (placebo)in the study eye
11464396|NCT01600339|Experimental|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
11464397|NCT01600326|Active Comparator|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
11464398|NCT01600326|Active Comparator|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
11464399|NCT01600313|Experimental|treatment, control|
11464400|NCT01600300|Placebo Comparator|Sham|Treatment with inactivate Tesmac device
11464401|NCT01600300|Active Comparator|Tesmac|Treatment with active Tesmac device
11464402|NCT01600287|Experimental|IAADS group|dosage of propofol adjusted automatically by IAADS
11464403|NCT01600287|Active Comparator|Manual group|dosage of propofol adjusted manually
11464404|NCT01600274|Experimental|Diena|Dienogest-Ethinyl Estradiol (test product) tablet
11464405|NCT01600274|Active Comparator|Valette®|Dienogest-Ethinyl Estradiol (reference product) tablet
11464406|NCT01600261||eye exam|
11465098|NCT01595503|Active Comparator|landmark-based targeting|
11464411|NCT01600209||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
11464412|NCT01600196|Experimental|Resection arm|Liver resection Plus Thrombectomy
11464413|NCT01600196|No Intervention|Best support care arm|Best supportive care
11464414|NCT01600183|Active Comparator|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
11464415|NCT01600183|Experimental|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
11464416|NCT01600170|Active Comparator|Atorvastatin|Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
11464417|NCT01600170|Placebo Comparator|Placebo|Participants were given Placebo tablets for 12 weeks.
11464418|NCT01600157|Experimental|Laparoscopic Nephrectomy|
11464419|NCT01600144||data collection|
11464420|NCT01600131|Experimental|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
11464421|NCT01600131|Other|Standard Care|Caregivers receiving standard of care
11464422|NCT01600118|Active Comparator|ESWT|Extracorporeal shockwave therapy
11464423|NCT01600118|Placebo Comparator|ESWT Placebo|No extracorporeal shockwave therapy
11464424|NCT01600105|Experimental|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
11464425|NCT01600092|Experimental|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
11464426|NCT01600092|Active Comparator|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
11464427|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
11464428|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
11464429|NCT01600053|Experimental|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
11464430|NCT01600040|Other|Proton Radiation Therapy|This is a single arm study; all participants will receive proton radiation therapy.
11464431|NCT01600027|Placebo Comparator|Group B|received 1 ml/kg bupivacaine 0.25%.
11464432|NCT01600027|Active Comparator|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
11464433|NCT01600014|Active Comparator|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
11464434|NCT01600014|Placebo Comparator|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
11464435|NCT01600001|Experimental|Drug:KWA-0711 dose 1|
11464436|NCT01600001|Experimental|Drug:KWA-0711 dose 2|
11464437|NCT01600001|Experimental|Drug:KWA-0711 dose 3|
11464438|NCT01600001|Experimental|Drug:KWA-0711 dose 4|
11464439|NCT01600001|Placebo Comparator|Drug: Placebo|
11464440|NCT01599988|Active Comparator|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
11464441|NCT01599988|Active Comparator|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
11464442|NCT01599975|Active Comparator|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
11464443|NCT01599975|Placebo Comparator|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
11464444|NCT01599962|Experimental|Cinacalcet|
11464445|NCT01599962|Placebo Comparator|Sugar pill|
11464446|NCT01599949|Experimental|Ibrutinib|
11464447|NCT01599936|Experimental|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
11464448|NCT01599923|Experimental|Alacramyn|
11464449|NCT01599897|Experimental|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
11464450|NCT01599897|Experimental|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
11464451|NCT01599897|Experimental|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
11464452|NCT01599897|Experimental|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
11464453|NCT01599897|Active Comparator|2 µg ID93 alone|Low dose of antigen alone.
11464454|NCT01599897|Active Comparator|10 µg ID93 alone|High dose of antigen alone.
11464455|NCT01599884|Active Comparator|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
11464456|NCT01599884|Placebo Comparator|Sugar pill|Identical to active drug
11464457|NCT01599871|Experimental|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
11464458|NCT01599871|Placebo Comparator|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
11464459|NCT01599845||Nanoparticle exposed|
11464460|NCT01599832|Experimental|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
11465099|NCT01595490|Experimental|Mind-Body Skills Groups|
11464462|NCT01599819|Experimental|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
11464463|NCT01599806|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
11464464|NCT01599806|Active Comparator|Doripenem|IV treatment
11464465|NCT01599793|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
11464466|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
11464467|NCT01599780||Preterm Children|<33 weeks gestation; 18 months old at the start of the study
11464468|NCT01599767|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
11464469|NCT01599767|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
11464470|NCT01599754|Experimental|Axitinib|
11464471|NCT01599754|Placebo Comparator|Placebo|
11464472|NCT01599741|Experimental|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
11464473|NCT01599741|Active Comparator|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
11464474|NCT01599728|Other|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
11464475|NCT01599728|Other|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
11464476|NCT01599715|Other|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
11464477|NCT01599715|Other|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
11464478|NCT01599702|Experimental|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
11464479|NCT01599702|Experimental|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
11464480|NCT01599689|Experimental|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
11464481|NCT01599689|No Intervention|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
11464482|NCT01599676|Sham Comparator|Not essential amino acid|"Non essential amino acid:
~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
11464483|NCT01599676|Experimental|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
11464484|NCT01599663|Experimental|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.
~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
11464485|NCT01599663|No Intervention|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
11464486|NCT01599650|Experimental|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
11464487|NCT01599650|Experimental|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
11464488|NCT01599650|Active Comparator|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
11464489|NCT01599637|Experimental|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
11464490|NCT01599637|Placebo Comparator|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
11464491|NCT01599624|Experimental|iPad-based SRTS|
11464492|NCT01599624|Experimental|iPad-based PMR program|
11464493|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin > 450 umol/L in the neonatal period
11464494|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
11464495|NCT01599598|Active Comparator|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
11464496|NCT01599598|Active Comparator|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
11464497|NCT01599585|Experimental|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
11464498|NCT01599585|Active Comparator|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth & Technology.
11464499|NCT01599572|Experimental|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
11464500|NCT01599559|Experimental|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
11464501|NCT01599559|Active Comparator|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
11464502|NCT01599546||Full Term children|born >36 weeks, currently age 6 +/- 6 months
11464503|NCT01599546||Preterm children|born <35 weeks, age 6 +/- 6 months at the beginning of the study.
11464504|NCT01599533|Other|abdominal aortic aneurysms|
11464505|NCT01599520|Experimental|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
11464506|NCT01599520|Active Comparator|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
11464507|NCT01599507|Experimental|FG-4592|Active Drug
11464508|NCT01599507|Placebo Comparator|Placebo|
11464509|NCT01599494|Experimental|Single-Dose MK-8962 + recFSH|
11464510|NCT01599494|Active Comparator|Reference Group recFSH only|
11464511|NCT01599481|Experimental|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
11464512|NCT01599481|Active Comparator|Control|Standard Care (IAPT Therapy)
11464513|NCT01599468|Experimental|tranexamic acid, post partum hemorrhage|
11464514|NCT01599468|Placebo Comparator|placebo|
11464515|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
11464516|NCT01599455||Outpatient|Youths visiting outpatient clinics
11464517|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
11464518|NCT01599416|Active Comparator|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
11464519|NCT01599416|Placebo Comparator|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
11464520|NCT01599403|Active Comparator|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
11464521|NCT01599403|No Intervention|Patient Controlled Anesthesia|Standard usual care
11464522|NCT01599403|Experimental|Epidural Block|"Intervention:
~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
11464523|NCT01599403|Active Comparator|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
11464524|NCT01599390||Influenza Group|
11464525|NCT01599377|Experimental|Cohort 1|
11464526|NCT01599377|Experimental|Cohort 2|
11464527|NCT01599364|Experimental|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
11464528|NCT01599364|No Intervention|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
11464529|NCT01599351|Active Comparator|Prone|Patients were in prone position along the ERCP procedure.
11464530|NCT01599351|Active Comparator|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
11464531|NCT01599338|Experimental|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
11464532|NCT01599325|Experimental|Azacitidine|Azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
11464533|NCT01599312|Other|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
11464534|NCT01599312|Other|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
11464535|NCT01599312|Other|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
11464536|NCT01599312|Other|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
11464537|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
11464538|NCT01599286|Experimental|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
11464539|NCT01599286|Active Comparator|Placebo Comparator|Placebo and Standard of Care Therapy
11464540|NCT01599273|Experimental|Triam inj|
11464541|NCT01599273|No Intervention|observation group|
11464542|NCT01599260|Experimental|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
11464543|NCT01599247||Suicidal ideation/behavior|
11464544|NCT01599234|Experimental|Sativex|Active treatment
11464545|NCT01599234|Placebo Comparator|Placebo|Control
11464546|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
11464589|NCT01598948|Experimental|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
11464547|NCT01599208|Experimental|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
11464548|NCT01599208|Experimental|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
11464549|NCT01599208|Experimental|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
11464550|NCT01599208|Experimental|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
11464551|NCT01599208|Experimental|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
11464552|NCT01599208|Experimental|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
11464553|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
11464554|NCT01599182||High-Risk Prostate Cancer|
11464555|NCT01599182||Intermediate-Risk Prostate Cancer|
11464556|NCT01599169|Experimental|B-Back® verum|
11464557|NCT01599169|Placebo Comparator|B-Back® placebo|
11464558|NCT01599156|Experimental|Reflexology|reflexology treatment, x2-3/week for 12 weeks
11464559|NCT01599143|Experimental|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
11464560|NCT01599130|Active Comparator|entecavir|patients continue to use entecavir
11464561|NCT01599130|Experimental|peg-interferon|patients switch to sequential peg-interferon α-2a
11464562|NCT01599117|Placebo Comparator|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
11464563|NCT01599117|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
11464564|NCT01599104|Experimental|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
11464565|NCT01599104|Experimental|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
11464566|NCT01599104|Active Comparator|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
11464567|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
11464568|NCT01599078|Placebo Comparator|Placebo|
11464569|NCT01599078|Active Comparator|Paclitaxel|
11464570|NCT01599065||Magnet|group treated by disabling ICD during procedure
11464571|NCT01599065||Off-On|Group having ICD turned off during the procedure
11464572|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
11464573|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
11464574|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
11464575|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
11464576|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
11464577|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
11464578|NCT01599013|Other|Vinflunine plus Gemcitabine|
11464579|NCT01599013|Other|Vinflunine plus Carboplatin|
11464580|NCT01599000|Active Comparator|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
11464581|NCT01599000|Experimental|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
11464582|NCT01598987|Experimental|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).
~The dosing schedule was twice daily, 12 hours apart."
11464583|NCT01598974|Experimental|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
11464584|NCT01598974|Experimental|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
11464585|NCT01598974|No Intervention|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
11464586|NCT01598961|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
11464587|NCT01598961|Active Comparator|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
11464588|NCT01598961|Experimental|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
11464590|NCT01598948|No Intervention|Control|patients randomized to this arm will receive no additional drug
11464591|NCT01598935|Placebo Comparator|Control|placebo
11464592|NCT01598935|Active Comparator|High protein intake|Nutrition - High protein
11464593|NCT01598935|Active Comparator|Low protein intake|Nutrition - Low protein
11464594|NCT01598935|Active Comparator|Medium protein intake|Nutrition - Medium protein
11464595|NCT01598922|Experimental|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
11464596|NCT01598922|No Intervention|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
11464597|NCT01598922|No Intervention|Control|Participants in this arm are healthy, non-psychiatric individuals who receive no treatment.
11464598|NCT01598909|Active Comparator|Arnica ointment|
11464599|NCT01598909|Placebo Comparator|Placebo ointment|
11464600|NCT01598909|No Intervention|Control|
11464601|NCT01598896|Experimental|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
11464602|NCT01598896|Placebo Comparator|Placebo|Placebo
11464603|NCT01598883|Other|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
11464604|NCT01598883|Active Comparator|ACT after first intervention less than 450|
11464605|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
11464606|NCT01598857|Experimental|Blisibimod|
11464607|NCT01598857|Placebo Comparator|Placebo|
11464608|NCT01598844||High risk patients with aortic stenosis|Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
11464609|NCT01598844||High risk patients with AI|Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
11464610|NCT01598831|Active Comparator|ART-123|
11464611|NCT01598831|Placebo Comparator|Placebo|
11464612|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
11464613|NCT01598805|Experimental|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
11464614|NCT01598766|Experimental|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
11464615|NCT01598753|Active Comparator|Tramadol|
11464616|NCT01598753|Placebo Comparator|Placebo|
11464617|NCT01598753|Active Comparator|Cognitive Behavior Therapy for FM|
11464618|NCT01598753|Sham Comparator|Health Education|
11464619|NCT01598740|Experimental|CLP with spironolactone|
11464620|NCT01598740|Experimental|CLP without spironolactone|
11464621|NCT01598727|Experimental|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
11464622|NCT01598714|Other|Darco shoe|Darco walking shoe provided
11464623|NCT01598714|Other|Podalux Shoe|Podalus shoe
11464624|NCT01598714|Other|Standard dressing shoe|Standard dressing shoe
11464625|NCT01598701|Experimental|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
11464626|NCT01598701|Placebo Comparator|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
11464627|NCT01598688|Active Comparator|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
11464628|NCT01598688|Experimental|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
11464629|NCT01598675|Active Comparator|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
11464630|NCT01598675|Experimental|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
11464631|NCT01598675|Experimental|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
11464632|NCT01598662|Active Comparator|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.
~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
11464633|NCT01598662|Experimental|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena
~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
11464634|NCT01598649|Experimental|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
11464635|NCT01598649|Active Comparator|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
11464636|NCT01598649|Active Comparator|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
11464637|NCT01598636|Experimental|Lateral Tibial Tunnel technique|
11464638|NCT01598623|Experimental|Oxytocin+ Non Specific Counselling|
11464639|NCT01598623|Experimental|Oxytocin + Social Skills training|
11464640|NCT01598623|Placebo Comparator|Placebo + Non Specific Counselling|
11464642|NCT01598610|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
11464643|NCT01598597||Cohort|
11464644|NCT01598584|Placebo Comparator|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
11464645|NCT01598584|Experimental|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
11464646|NCT01598571|Experimental|Fostamatinib 50 mg tablet|
11464647|NCT01598571|Experimental|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
11464648|NCT01598558|Experimental|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
11464649|NCT01598545|Experimental|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
11464650|NCT01598532|Experimental|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
11464651|NCT01598519|Experimental|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
11464652|NCT01598519|No Intervention|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
11464653|NCT01598506|Experimental|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
11464654|NCT01598493|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
11464655|NCT01598493|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
11464656|NCT01598480|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
11464657|NCT01598480|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
11464658|NCT01598467|Other|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q > stage 1)
11464659|NCT01598454|Experimental|Racotumomab|
11464660|NCT01598441|Experimental|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
11464661|NCT01598441|Placebo Comparator|distilled water|aerosolized distilled water 1-2 ml
11464662|NCT01598428|Other|cataract|
11464663|NCT01598415|Experimental|SAR113945|TDU11685 selected dose
11464664|NCT01598415|Placebo Comparator|Placebo|
11464665|NCT01598402|No Intervention|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
11464666|NCT01598402|Experimental|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
11464667|NCT01598389|Experimental|Low energy-dense preload|
11464668|NCT01598389|Experimental|High energy-dense preload|
11464669|NCT01598389|Experimental|No preload|
11464670|NCT01598376|Active Comparator|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
11464671|NCT01598376|Active Comparator|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
11464672|NCT01598363|Experimental|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
11464673|NCT01598363|Experimental|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
11464674|NCT01598350|Experimental|Orthotic|Orthotic Use
11464675|NCT01598337|Active Comparator|Aspirin alone|
11464676|NCT01598337|Experimental|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
11464677|NCT01598337|Experimental|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
11464678|NCT01598337|Experimental|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
11464679|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
11464680|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
11464681|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
11464682|NCT01598311|Experimental|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
11464683|NCT01598311|Active Comparator|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
11464684|NCT01598298|Experimental|Arm I|Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
11464685|NCT01598298|Placebo Comparator|Arm II|Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on days 85-91.
11464686|NCT01598272|Experimental|Vitality product AM + Vitality product PM|"Dietary Supplement:
~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
11464687|NCT01598272|Placebo Comparator|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
11464688|NCT01598259|Experimental|melatonin|Subjects will receive melatonin
11464690|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
11464691|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early <12 hour and late 12-72 hour, extubation failures.
11464692|NCT01598233|Experimental|Intragastric balloon|Patients submitted to six-month intragastric balloon
11464693|NCT01598220|Experimental|Computer-assisted cognitive remediation therapy|
11464694|NCT01598220|Placebo Comparator|attentional task|
11464695|NCT01598207|Experimental|Marinol|
11464696|NCT01598207|Placebo Comparator|Placebo|
11464697|NCT01598194|Experimental|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
11464698|NCT01598181|Experimental|active tDCS|
11464699|NCT01598181|Sham Comparator|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
11464700|NCT01598168|Experimental|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
11464701|NCT01598155|Experimental|Supragingival biofilm control|
11464702|NCT01598155|Experimental|Supra- and subgingival biofilm control|
11464703|NCT01598142|Other|experienced assistant group|experienced endoscopist with an experienced assistant.
11464704|NCT01598142|Other|new trained assistant group|same experienced endoscopist with a new trained assistant
11464705|NCT01598129|Experimental|CGTG-102|CGTG-102 dose escalation
11464706|NCT01598116||Hemangioma|Identify biomarkers in children with hemangiomas.
11464707|NCT01598116||Without Hemangioma|Age-matched controlled group without hemangioma.
11464708|NCT01598103|Placebo Comparator|Placebo to SAF312|
11464709|NCT01598103|Experimental|SAF312|
11464710|NCT01598090|Experimental|Part A: Peginterferon Lambda-1a + RBV + TVR|
11464711|NCT01598090|Experimental|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
11464712|NCT01598090|Experimental|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
11464713|NCT01598077|Experimental|Dose escalation and dose expansion|
11464714|NCT01598064|Experimental|GK#10|GK#10 1 pk tid for 8 weeks
11464715|NCT01598064|Placebo Comparator|Placebo|Placebo 1 pack tid for 8 weeks
11464716|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
11464717|NCT01598038|No Intervention|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
11464718|NCT01598025|Experimental|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.
~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
11464719|NCT01598025|Experimental|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.
~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
11464720|NCT01598012|Experimental|Ayurved Siriraj Prasaplai|
11464721|NCT01598012|Placebo Comparator|placebo|
11464722|NCT01597999|Other|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
11464723|NCT01597986|Experimental|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
11464724|NCT01597973|Active Comparator|colistin and meropenem|
11464725|NCT01597973|Active Comparator|colistin and placebo|
11464726|NCT01597960|Active Comparator|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
11464727|NCT01597960|No Intervention|Usual care|Usual care (standard cardiac rehabilitation programme) only.
11464728|NCT01597947|Experimental|Arm A|
11464729|NCT01597947|Placebo Comparator|Arm B|
11464730|NCT01597934|Active Comparator|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
11464731|NCT01597934|Experimental|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
11464732|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
11464733|NCT01597908|Experimental|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
11464734|NCT01597908|Active Comparator|Vemurafenib|BRAF inhibitor
11464735|NCT01597895|Active Comparator|Maraviroc|
11464736|NCT01597895|Experimental|Maraviroc + Boceprevir|
11464737|NCT01597895|Experimental|Maraviroc + Telaprevir|
11464738|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
11464739|NCT01597856|Experimental|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.
~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
11464780|NCT01597570|Experimental|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
11464781|NCT01597570|Active Comparator|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
11464740|NCT01597856|No Intervention|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
11464741|NCT01597843|Experimental|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
11464742|NCT01597843|Experimental|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
11464743|NCT01597843|No Intervention|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
11464744|NCT01597830|Experimental|active shoe|
11464745|NCT01597830|Sham Comparator|Control|
11464746|NCT01597817|Active Comparator|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
11464747|NCT01597817|Placebo Comparator|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
11464748|NCT01597804|Experimental|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
11464749|NCT01597791|Placebo Comparator|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
11464750|NCT01597791|Experimental|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
11464751|NCT01597778|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive haploidentical bone marrow transplant using a reduced intensity conditioning regimen.
11464752|NCT01597778|Experimental|Double Umbilical Cord Blood Transplant|Participants will receive a double umbilical cord blood transplant using a reduced intensity conditioning regimen.
11464753|NCT01597765|Experimental|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
11464754|NCT01597765|Experimental|Vitamin E|The vitamin E is intervention for 30 patients
11464755|NCT01597752|Experimental|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)
~Positive control
~Negative control"
11464756|NCT01597739|Experimental|JNJ-40346527|
11464757|NCT01597739|Placebo Comparator|Placebo|
11464758|NCT01597726|Active Comparator|Misoprostol|
11464759|NCT01597726|Experimental|Laminaria|
11464760|NCT01597713|Experimental|Part 1, level 1-7 escalating doses|
11464761|NCT01597713|Experimental|Part 2, cross-over|
11464762|NCT01597700|Experimental|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
11464763|NCT01597700|Active Comparator|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
11464764|NCT01597687|Experimental|Malaysia Group|Malaysian adults aged >19 years with prolonged cough of 2 weeks or more.
11464765|NCT01597687|Experimental|Taiwan Group|Taiwanese adults aged >19 years with prolonged cough of 2 weeks or more.
11464766|NCT01597687|Experimental|Thailand Group|Thailandese adults aged >19 years with prolonged cough of 2 weeks or more.
11464767|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
11464768|NCT01597648|Experimental|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
11464769|NCT01597648|Experimental|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
11464770|NCT01597635|Experimental|Part A|4 increasing doses of GSK2586881 given over 2 days
11464771|NCT01597635|Experimental|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
11464772|NCT01597622|Experimental|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
11464773|NCT01597609|Experimental|Cohort A|- 600 Kcal deficit, Sibutramine placebo
11464774|NCT01597609|Experimental|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
11464775|NCT01597609|Experimental|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. ~1,000 Kcal/week) /sibutramine placebo
11464776|NCT01597596|Experimental|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
11464777|NCT01597596|Active Comparator|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
11464778|NCT01597583|Experimental|Use of MobileMedMinder|
11464779|NCT01597583|No Intervention|Usual care|
11464943|NCT01596556|Experimental|smokers|This arm consists of smokers.
11464782|NCT01597557|Active Comparator|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
11464783|NCT01597557|Placebo Comparator|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
11464784|NCT01597544|No Intervention|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
11464785|NCT01597544|Active Comparator|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
11464786|NCT01597531|Active Comparator|Liraglutide only|
11464787|NCT01597531|Active Comparator|Orlistat only|
11464788|NCT01597531|Active Comparator|Liraglutide + Orlistat|
11464789|NCT01597518|Experimental|Riluzole|
11464790|NCT01597518|Placebo Comparator|Placebo|
11464791|NCT01597505|Experimental|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
11464792|NCT01597505|Active Comparator|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
11464793|NCT01597492|Experimental|Belimumab plus Early Vaccination|Belimumab plus Early Vaccination
11464794|NCT01597492|Experimental|Belimumab plus Late Vaccination|Belimumab plus Late Vaccination
11464795|NCT01597479|No Intervention|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
11464796|NCT01597479|Experimental|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.
~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.
~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
11464797|NCT01597466|Experimental|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
11464798|NCT01597466|Active Comparator|Loss of resistance technique|
11464799|NCT01597453|Other|Lifestyle counseling|There are no different arms, NOR-SYS is an observational study
11464800|NCT01597440|Experimental|N-Carbamylglutamate|Active NCG & Standard of Care
11464801|NCT01597440|Placebo Comparator|Placebo|Standard of Care therapy
11464802|NCT01597427|Sham Comparator|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
11464803|NCT01597427|Placebo Comparator|Placebo|Injection of placebo solution.
11464804|NCT01597414|Active Comparator|Pertuzumab + trastuzumab (PH)|Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
11464805|NCT01597414|Experimental|PH + metronomic chemotherapy (PHM)|Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
11464806|NCT01597401|Experimental|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
11464807|NCT01597401|Experimental|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
11464808|NCT01597401|Experimental|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
11464809|NCT01597388|Experimental|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
11464810|NCT01597375|Experimental|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.
~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
11464944|NCT01596556|Active Comparator|non-smokers|non-smoking participants in the study
11465035|NCT01595867|Active Comparator|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
11464811|NCT01597375|Experimental|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.
~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
11464812|NCT01597362|Other|Veress needle technique|
11464813|NCT01597362|Other|Direct trocar technique|
11464814|NCT01597362|Other|Open technique|
11464815|NCT01597349|Experimental|FP01 High dose|
11464816|NCT01597349|Experimental|FP01 Low dose|
11464817|NCT01597349|Placebo Comparator|Placebo|
11464818|NCT01597336|Active Comparator|Saline only flush of abscess|Saline alone used to flush abscess
11464819|NCT01597336|Experimental|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
11464820|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
11464821|NCT01597310|Experimental|Warfarin|25 mg Warfarin, Treatment Period 1 & Treatment Period 2
11464822|NCT01597310|Experimental|Dexpramipexole|150 mg BID Treatment Period 2
11464823|NCT01597297|Experimental|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
11464824|NCT01597297|Placebo Comparator|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
11464825|NCT01597258||Crizotinib (Xalkori)|
11464826|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
11464827|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
11464828|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
11464829|NCT01597245|Active Comparator|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
11464830|NCT01597245|Placebo Comparator|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
11464831|NCT01597232|Experimental|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
11464832|NCT01597232|Active Comparator|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
11464833|NCT01597232|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
11464834|NCT01597219|Experimental|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
11464835|NCT01597219|Experimental|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
11464836|NCT01597206|Experimental|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
11464837|NCT01597206|Active Comparator|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
11464838|NCT01597193|Experimental|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
11464839|NCT01597193|Experimental|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
11464840|NCT01597193|Experimental|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
11464841|NCT01597193|Experimental|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
11464842|NCT01597193|Experimental|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
11464843|NCT01597167|Experimental|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
11464844|NCT01597167|Placebo Comparator|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
11464845|NCT01597154|Experimental|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
11464846|NCT01597154|No Intervention|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
11464847|NCT01597141|Experimental|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
11464987|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
11464848|NCT01597141|Active Comparator|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
11464849|NCT01597128|Active Comparator|Flex HD|Mesh Type
11464850|NCT01597128|Active Comparator|Strattice|Use of a second mesh type
11464851|NCT01597115|Active Comparator|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
11464852|NCT01597115|No Intervention|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
11464853|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
11464854|NCT01597076|Experimental|60-240 mL/day|60 -240 mL/day dose group
11464855|NCT01597063||low risk pregnancies|
11464856|NCT01597050|Active Comparator|Drug: R932333|R333 6% (60 mg/g), bid
11464857|NCT01597050|Placebo Comparator|Placebo|Placebo, bid
11464858|NCT01597037|Active Comparator|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
11464859|NCT01597037|Active Comparator|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
11464860|NCT01597037|Active Comparator|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
11464861|NCT01597037|Active Comparator|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
11464862|NCT01597024|Experimental|Phase 1: Breakfast Study|
11464863|NCT01597024|Experimental|Phase 2: fMRI Study|
11464864|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
11464865|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
11464866|NCT01596998|Active Comparator|Levobupivacaine without epinephrine|
11464867|NCT01596998|Experimental|Levobupivacaine with epinephrine|
11464868|NCT01596985|Experimental|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
11464869|NCT01596985|Active Comparator|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
11464870|NCT01596972|Experimental|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
11464871|NCT01596972|No Intervention|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
11464872|NCT01596959|Active Comparator|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
11464873|NCT01596959|Placebo Comparator|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
11464874|NCT01596946|Active Comparator|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
11464875|NCT01596946|Experimental|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
11464876|NCT01596933|Experimental|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
11464877|NCT01596933|Placebo Comparator|standard nutritional support|sunflower oil supplementation
11464878|NCT01596920|Active Comparator|Grafix®|
11464879|NCT01596920|Placebo Comparator|Control (non-adherent dressing)|
11464880|NCT01596907|Active Comparator|Ephedrine and caffiene|"Drug treatment:
~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
11465032|NCT01595880|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
11465033|NCT01595867|Placebo Comparator|Treatment A|Placebo
11464881|NCT01596907|Placebo Comparator|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
11464882|NCT01596894|Experimental|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
11464883|NCT01596894|Active Comparator|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
11464884|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
11464885|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
11464886|NCT01596868|Active Comparator|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
11464887|NCT01596868|Active Comparator|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
11464888|NCT01596855|Experimental|FG-4592|Active Drug
11464889|NCT01596855|Active Comparator|Epoetin alfa|Standard of care
11464890|NCT01596842|Active Comparator|Omega-3 fatty acid|
11464891|NCT01596842|Placebo Comparator|Olive oil|
11464892|NCT01596829|Active Comparator|Probiotic|Probiotic consumption during and after course of antibiotic
11464893|NCT01596829|Placebo Comparator|Placebo|Placebo consumed during and after course of antibiotic
11464894|NCT01596816|Experimental|Boost by CyberKnife|
11464895|NCT01596816|Experimental|Boost by linear accelerator|
11464896|NCT01596803|Active Comparator|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
11464897|NCT01596803|Placebo Comparator|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
11464898|NCT01596790|Other|CTC assay|Detection & characterization of viable CTC in the peripheral blood.
11464899|NCT01596777|Placebo Comparator|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
11464900|NCT01596777|Placebo Comparator|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
11464901|NCT01596777|Active Comparator|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
11464902|NCT01596777|Active Comparator|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
11464903|NCT01596777|Active Comparator|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
11464904|NCT01596764|Placebo Comparator|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
11464905|NCT01596764|Placebo Comparator|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
11464906|NCT01596764|Active Comparator|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
11464907|NCT01596764|Active Comparator|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
11464908|NCT01596751|Experimental|Phase Ib: 600 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:
~PLX3397 at a dose of 600 mg/day taken by mouth in the form of 100-200 mg gelcaps
~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8."
11464909|NCT01596751|Experimental|Phase Ib: 800 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:
~PLX3397 at a dose of 800 mg/day taken by mouth in the form of 100-200 mg gelcaps
~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
11464910|NCT01596751|Experimental|Phase Ib: 1000 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:
~PLX3397 at a dose of 1000 mg/day taken by mouth in the form of 100-200 mg gelcaps
~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
11464945|NCT01596543|Experimental|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
11464911|NCT01596751|Experimental|Phase II: 800 mg/Day PLX3397 Lead in +Combined with Eribulin|"Treatment begins with a 7 day Lead-in phase of PLX3397 alone, followed by 21 day cycles of PLX3397 in combination with eribulin.
~Lead-in phase treatment:
~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest.
~Treatment given in each 21 day cycle:
~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest, repeated weekly
~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
11464912|NCT01596738|Experimental|Tranexamic Acid group|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction
~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
11464913|NCT01596738|Placebo Comparator|Placebo group|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction
~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
11464914|NCT01596725|Experimental|Group A|
11464915|NCT01596725|Experimental|Group B|
11464916|NCT01596725|Experimental|Group C|
11464917|NCT01596725|Experimental|Group D|
11464918|NCT01596725|Experimental|Group E|
11464919|NCT01596725|Experimental|Group F|
11464920|NCT01596712|Experimental|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
11464921|NCT01596712|Experimental|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
11464922|NCT01596712|Experimental|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
11464923|NCT01596712|Placebo Comparator|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
11464924|NCT01596699|Experimental|Patients with Myeloid Malignancies|
11464925|NCT01596699|Experimental|Patients with Non-Malignancies|
11464926|NCT01596686|Active Comparator|sodium picosulphate and magnesium citrate (Picoprep)|
11464927|NCT01596686|Active Comparator|polyethylene glycol (Fortrans)|
11464928|NCT01596673|Experimental|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:
~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.
~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.
~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.
~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
11464929|NCT01596673|Experimental|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:
~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.
~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).
~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.
~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
11464930|NCT01596673|Experimental|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:
~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).
~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.
~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.
~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
11464931|NCT01596673|Experimental|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:
~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.
~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.
~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).
~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
11464932|NCT01596660|Experimental|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
11464933|NCT01596660|Placebo Comparator|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
11464934|NCT01596647|Experimental|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
11464935|NCT01596634|Experimental|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
11464936|NCT01596621|Experimental|Bendamustine hydrochloride|This is a single-arm study, in which all subjects enrolled are administered the study drug.
11464937|NCT01596608|Experimental|Magnetic Seizure Therapy|
11464938|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
11464939|NCT01596582|No Intervention|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
11464940|NCT01596582|Experimental|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
11464941|NCT01596569|Active Comparator|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:
~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
11464942|NCT01596569|Sham Comparator|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:
~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
11464948|NCT01596517|Experimental|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
11464949|NCT01596504|Experimental|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
11464950|NCT01596504|Active Comparator|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
11464951|NCT01596504|Active Comparator|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
11464952|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
11464953|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
11464954|NCT01596478|Active Comparator|Treatment As Usual|The standard treatment usually provided at the clinic.
11464955|NCT01596478|Active Comparator|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
11464956|NCT01596478|Active Comparator|12-week wait list|Participant will start treatment 12 weeks from day of consent.
11464957|NCT01596465|Active Comparator|Control|Control arm
11464958|NCT01596465|Active Comparator|Intervention|Intervention arm
11464959|NCT01596426|Experimental|Sancuso Arm|patch
11464960|NCT01596426|Active Comparator|IV granisetron|IV
11464961|NCT01596413|Experimental|Sancuso Arm|Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
11464962|NCT01596413|Active Comparator|IV Granisetron|"Aqueous solution for IV administration
~1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)"
11464963|NCT01596400|Experimental|Sancuso Arm|
11464964|NCT01596400|Active Comparator|IV Granisetron Arm|IV
11464965|NCT01596387|Experimental|Propofol|20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
11464966|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
11464967|NCT01596335|Experimental|TA-650|
11464968|NCT01596335|Active Comparator|VGIH|
11464969|NCT01596322||UARTO|
11464970|NCT01596309|Placebo Comparator|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
11464971|NCT01596309|Experimental|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
11464972|NCT01596296|Active Comparator|Transcervical foley catheter|
11464973|NCT01596296|Active Comparator|Dinoprostone|
11464974|NCT01596283|Active Comparator|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
11464975|NCT01596283|Active Comparator|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
11464976|NCT01596270|Experimental|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
11464977|NCT01596270|Experimental|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
11464978|NCT01596257|Active Comparator|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
11464979|NCT01596257|Experimental|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
11464980|NCT01596244|Experimental|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
11464981|NCT01596231|Placebo Comparator|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
11464982|NCT01596231|Active Comparator|Kudzu|Kudzu 2mg
11464983|NCT01596218|Experimental|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
11464984|NCT01596205|Experimental|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
11464985|NCT01596205|Active Comparator|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
11464986|NCT01596205|No Intervention|Control group|
11465034|NCT01595867|Experimental|Treatment B|EMBEDA 30 mg crushed
11464988|NCT01596179|Experimental|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
11464989|NCT01596179|Active Comparator|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
11464990|NCT01596166|Experimental|Metoclopramide, Ketorolac|"10 mL/kg IV 0.9% sodium chloride
~Metoclopramide 0.2 mg/kg (max 10 mg) IV
~Ketorolac 0.5 mg/kg (max 30 mg) IV"
11464991|NCT01596166|Placebo Comparator|Metoclopramide, Placebo|"10 mL/kg IV 0.9% sodium chloride
~Metoclopramide 0.2 mg/kg (max 10 mg) IV
~Placebo (normal saline)"
11464992|NCT01596153|Placebo Comparator|Placebo|BID
11464993|NCT01596153|Active Comparator|Go Live Rx Probiotic|BID
11464994|NCT01596140|Experimental|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
11464995|NCT01596140|Experimental|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
11464996|NCT01596127|Experimental|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.
~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
11464997|NCT01596114|Experimental|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
11464998|NCT01596101||acute burns|
11464999|NCT01596101||rehab patients|
11465000|NCT01596088|Experimental|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:
~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
11465001|NCT01596075|Experimental|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
11465002|NCT01596062|Active Comparator|Simulect 40mg + Neoral + Myfortic + steroids|A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
11465003|NCT01596062|Experimental|Simulect 80mg + Neoral + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
11465004|NCT01596062|Experimental|Simulect 80mg + Certican + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
11465005|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
11465006|NCT01596036|Experimental|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
11465007|NCT01596036|Placebo Comparator|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
11465008|NCT01596023|Experimental|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
11465009|NCT01596010|Experimental|New formulation|
11465010|NCT01596010|Active Comparator|Old formulation|
11465011|NCT01595997|Placebo Comparator|Placebo|
11465012|NCT01595997|Experimental|DLX105|
11465013|NCT01595984|Active Comparator|Cyclosporin + Mycophenolate mofetil|
11465014|NCT01595984|Experimental|Everolimus + mycophenolate mofetil|
11465015|NCT01595971|Experimental|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
11465016|NCT01595971|Placebo Comparator|Usual Care|usual care
11465017|NCT01595958|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
11465018|NCT01595958|Active Comparator|Control|usual care of cardiac arrest
11465019|NCT01595945|Other|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
11465020|NCT01595945|Other|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
11465021|NCT01595932|Placebo Comparator|placebo|
11465022|NCT01595932|Experimental|α-galactosidase|
11465023|NCT01595919|Experimental|1% Milk|
11465024|NCT01595919|Experimental|Regular Cola|
11465025|NCT01595919|Experimental|Diet cola|
11465026|NCT01595919|Experimental|Orange juice|
11465027|NCT01595919|Placebo Comparator|Water|
11465028|NCT01595906|Experimental|The experiment subjects|"The subjects will undergo:
~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.
~Three consecutive days including 3 scenarios:
~Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
11465029|NCT01595893|Experimental|Vitamin D3|
11465030|NCT01595893|Placebo Comparator|Placebo|
11465031|NCT01595880|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
11465093|NCT01595516|Placebo Comparator|Placebo|
11465036|NCT01595854|Experimental|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
11465037|NCT01595854|Active Comparator|Test 1 (part 1 + 2)|high dose ticagrelor
11465038|NCT01595854|Experimental|Reference 1 (part 1 + 2)|medium dose dabigatran
11465039|NCT01595854|Experimental|Reference 2 (part 3)|low dose dabigatran
11465040|NCT01595841|Experimental|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
11465041|NCT01595841|No Intervention|Not taking Sirolimus|Participants will not change the standard of care.
11465042|NCT01595828|Experimental|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
11465043|NCT01595815|Active Comparator|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
11465044|NCT01595815|Active Comparator|Convention ICSI|The couple showed a low fertilization rates after ICSI.
11465045|NCT01595802|Experimental|Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
11465046|NCT01595802|Experimental|Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.
~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
11465047|NCT01595789|Placebo Comparator|Placebo + metformin|
11465048|NCT01595789|Active Comparator|Liraglutide + metformin|
11465049|NCT01595776|Experimental|single arm: autologous EPCs|
11465050|NCT01595763||Deep Vein Thromobosis signs or symptoms|
11465051|NCT01595750|Placebo Comparator|Placebo|
11465052|NCT01595750|Active Comparator|Roflumilast|Roflumilast 500 mcg
11465053|NCT01595737|Experimental|Levosimendan|
11465054|NCT01595737|Placebo Comparator|Placebo|
11465055|NCT01595724||Group 1|
11465056|NCT01595711||Thoracotomized patients|
11465057|NCT01595698|Sham Comparator|Control|
11465058|NCT01595698|Experimental|Physical Exercise|
11465059|NCT01595685|Experimental|Telbivudine|Telbivudine 600 mg Daily Oral
11465060|NCT01595685|Active Comparator|Entecavir|Entecavir 0.5 mg Daily Oral
11465061|NCT01595672|Active Comparator|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
11465062|NCT01595672|Active Comparator|Control group|Patients receive conventional treatments recommended by guidelines only.
11465063|NCT01595659|Placebo Comparator|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
11465064|NCT01595659|Experimental|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
11465065|NCT01595659|Experimental|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
11465066|NCT01595646|Placebo Comparator|Saline|Saline placebo taken twice per day via intranasal route.
11465067|NCT01595646|Experimental|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
11465068|NCT01595646|Experimental|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
11465069|NCT01595633|Active Comparator|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
11465070|NCT01595633|Experimental|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
11465071|NCT01595620|Active Comparator|THC 0.01 mg/kg|
11465072|NCT01595620|Placebo Comparator|Placebo|
11465073|NCT01595620|Active Comparator|THC 0.03 mg/kg|
11465074|NCT01595607|Active Comparator|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
11465075|NCT01595607|Experimental|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
11465076|NCT01595594|Active Comparator|Systemic Doxycycline|
11465077|NCT01595594|Experimental|aPDT+ Placebo|
11465078|NCT01595581|Experimental|Testosterone, standard-of-care rehabilitation|
11465079|NCT01595581|Placebo Comparator|Standard-of-care rehabilitation, Saline|
11465080|NCT01595568|Experimental|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
11465081|NCT01595568|Experimental|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
11465082|NCT01595568|Experimental|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
11465083|NCT01595568|Experimental|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
11465084|NCT01595555|No Intervention|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
11465085|NCT01595555|Experimental|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
11465086|NCT01595555|Experimental|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
11465087|NCT01595542|Experimental|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
11465088|NCT01595542|No Intervention|Control|Did not receive intervention materials
11465089|NCT01595529|Experimental|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
11465090|NCT01595529|Placebo Comparator|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
11465091|NCT01595516|Active Comparator|Nebivolol|
11465092|NCT01595516|Active Comparator|Metoprolol|
11465100|NCT01595490|No Intervention|Control Group|
11465101|NCT01595477|Experimental|Mind-Body Skills Groups|
11465102|NCT01595477|No Intervention|Control Group|
11465103|NCT01595464|Experimental|Mind-Body Skills Groups|
11465104|NCT01595464|No Intervention|Control Group|
11465105|NCT01595451|Active Comparator|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
11465106|NCT01595451|Placebo Comparator|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
11465107|NCT01595438|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
11465108|NCT01595438|Active Comparator|Doripenem|IV treatment
11465109|NCT01595425|Experimental|D961H Sachet 20 mg|2 way crossover
11465110|NCT01595425|Experimental|D961HHPMC Capsule 20 mg|2 way crossover
11465111|NCT01595412|Active Comparator|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
11465112|NCT01595412|Active Comparator|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
11465113|NCT01595399|Active Comparator|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
11465114|NCT01595399|Placebo Comparator|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
11465115|NCT01595386|Placebo Comparator|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
11465116|NCT01595386|Experimental|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
11465117|NCT01595373|Active Comparator|Ghrelin|Ghrelin
11465118|NCT01595373|Placebo Comparator|Placebo|Ringer acetate is used for placebo.
11465119|NCT01595360|Placebo Comparator|Placebo|Placebo
11465120|NCT01595360|Experimental|TT-173|TT-173
11465121|NCT01595347|Active Comparator|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
11465122|NCT01595347|Experimental|Olive oil's Cream|Cream with 60% extra virgin olive oil.
11465123|NCT01595334|Active Comparator|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.
~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
11465124|NCT01595334|Other|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established 'Long Luteal Suppression Protocol' from the previous cycle.
~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
11465125|NCT01595321|Experimental|SBRT and FOLFIRINOX|The first 6 patients will receive SBRT and FOLFIRINOX only.
11465126|NCT01595321|Experimental|Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX|The last 12 patients will receive cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX.
11465127|NCT01595308|Experimental|Pomegranate juice|Pomegranate juice
11465128|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
11465129|NCT01595282|Experimental|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
11465130|NCT01595282|Active Comparator|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
11465131|NCT01595269|Placebo Comparator|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
11465132|NCT01595269|Active Comparator|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
11465171|NCT01594957|Experimental|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
11465172|NCT01594957|Experimental|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
11465133|NCT01595269|Active Comparator|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
11465134|NCT01595256|Experimental|walking group|
11465135|NCT01595256|No Intervention|usual care|
11465136|NCT01595243|No Intervention|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
11465137|NCT01595243|Experimental|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
11465138|NCT01595230|Experimental|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
11465139|NCT01595230|No Intervention|Control group|conventional LRYGB without closure of the mesenteric defects
11465140|NCT01595217|Experimental|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
11465141|NCT01595217|Experimental|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
11465142|NCT01595204|Experimental|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
11465143|NCT01595191|Active Comparator|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
11465144|NCT01595191|Active Comparator|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
11465145|NCT01595165|Placebo Comparator|Control|Control group receiving saline instead of ropivacaine
11465146|NCT01595165|Experimental|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
11465147|NCT01595152|Active Comparator|solifenacin succinate (10 mg OD)|
11465148|NCT01595152|Active Comparator|fesoterodine (8mg OD)|
11465149|NCT01595139||NF-1 without evidence of glioma|
11465150|NCT01595139||NF-1 with evidence of glioma|
11465151|NCT01595126||Patients with Central Nervous System Tumors|
11465152|NCT01595087|Experimental|Osteodex, infusion|Osteodex
11465153|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
11465154|NCT01595061|Experimental|Treatment (IMRT, gemcitabine, cisplatin, surgery)|Patients undergo IMRT 5 days a week for 6 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes weekly for 6 weeks in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after completion of chemoradiation patients undergo local core biopsy to confirm response or surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph nodes.
11465155|NCT01595035|Experimental|counselling|Patients who receive the Pain booklet and support by telephone
11465156|NCT01595035|No Intervention|Control|Standard care
11465157|NCT01595022|Placebo Comparator|Flexi ring FR01|
11465158|NCT01595022|Placebo Comparator|Flexi ring FR20|
11465159|NCT01595022|Placebo Comparator|Ultra low dose LCS|
11465160|NCT01595009|Experimental|Everolimus (RAD001)|Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
11465161|NCT01594996||Seroquel XR group|
11465162|NCT01594983|Experimental|LCQ908 1|LCQ908 (Diacylglycerol acyltransferase inhibitor)once daily for 12 weeks
11465163|NCT01594983|Experimental|LCQ908 2|LCQ908 once daily for 12 weeks
11465164|NCT01594983|Experimental|LCQ908 3|LCQ908 once daily for 12 weeks
11465165|NCT01594983|Active Comparator|Fenofibrate|Intervention Type: Drug Intervention Name: Fenofibrate
11465166|NCT01594983|Active Comparator|Fish Oil|Fish oil once daily for 12 weeks
11465167|NCT01594983|Placebo Comparator|Arm Label: Placebo|Intervention Type: other Intervention Name: other
11465168|NCT01594970|Experimental|Bimatoprost 0.01% (Naive Monotherapy)|1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
11465169|NCT01594970|Experimental|Bimatoprost 0.01% (Switched Monotherapy)|1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
11465170|NCT01594970|Experimental|Bimatoprost 0.01% (with Adjunctive Therapy)|1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.
11465264|NCT01594359|Placebo Comparator|Low iron bean|Low-iron bean
11465173|NCT01594957|Experimental|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
11465174|NCT01594931|Experimental|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
11465175|NCT01594931|Experimental|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
11465176|NCT01594931|Experimental|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
11465177|NCT01594918|Experimental|Cabazitaxel, Mitoxantrone, Prednisone|
11465178|NCT01594905|Experimental|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
11465179|NCT01594892|Experimental|Dose intensified SBRT|Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.
11465180|NCT01594879|Experimental|Endometrial cancer, LNG-IUS with MPA|
11465181|NCT01594866|Placebo Comparator|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
11465182|NCT01594866|Experimental|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
11465183|NCT01594853|Experimental|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
11465184|NCT01594840|Experimental|Changing chat|Diapers will have tips on them
11465185|NCT01594840|Active Comparator|Control|Normal diapers
11465186|NCT01594827|Experimental|Inhaled Vanc and Oral Abx|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
11465187|NCT01594827|Active Comparator|Inhaled Placebo and Oral Abx|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
11465188|NCT01594814||RFA of AVNRT of AVRT|
11465189|NCT01594801|No Intervention|Control|Subject continue their routine therapy
11465190|NCT01594801|Experimental|Test|Subjects using the InsuPad device
11465191|NCT01594775|Active Comparator|nasal spray|
11465192|NCT01594775|Placebo Comparator|Placebo|
11465193|NCT01594762|Placebo Comparator|Topical placebo control|Drug: Topical placebo cream
11465194|NCT01594762|Experimental|Topical pexiganan cream 0.8%|Drug: Topical pexiganan cream 0.8%
11465195|NCT01594749|Experimental|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO ~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
11465196|NCT01594749|Active Comparator|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
11465197|NCT01594736|Active Comparator|ORSIRO|
11465198|NCT01594736|Active Comparator|XIENCE PRIME DES|
11465199|NCT01594723|Experimental|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
11465200|NCT01594710||Apparently Health People|
11465201|NCT01594697|Experimental|metformin|
11465202|NCT01594684|Active Comparator|drug eluting balloon|treatment with drug eltuing balloon
11465203|NCT01594684|Placebo Comparator|uncoated balloon|treatment with uncoated balloon
11465204|NCT01594684|Active Comparator|double drug eluting balloon|if treatment fails 30 days or later
11465205|NCT01594671|Experimental|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
11465206|NCT01594671|Active Comparator|Habitual haemostasia|The surgical habitual haemostasia.
11465207|NCT01594671|Experimental|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
11465208|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
11465209|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
11465210|NCT01594645|Experimental|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
11465211|NCT01594645|Active Comparator|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
11465212|NCT01594632|Experimental|Jadelle|Contraception using Jadelle implant
11465213|NCT01594632|Active Comparator|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]
11465214|NCT01594619|Experimental|A|Single dose naloxegol 25mg
11465215|NCT01594619|Active Comparator|B|Diltiazem 240mg once daily day 4-6
11465216|NCT01594619|Active Comparator|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
11465217|NCT01594606|Experimental|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
11465218|NCT01594606|Active Comparator|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
11465219|NCT01594593|Experimental|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
11465220|NCT01594593|No Intervention|treatment as usual|
11465221|NCT01594580|Experimental|Antimicrobial impregnated scrubs|Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial.
11465222|NCT01594580|Placebo Comparator|Non-impregnated scrubs|Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial.
11465223|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
11465224|NCT01594541||Patients Treated with CerefolinNAC®|
11465225|NCT01594541||Patients Not Treated with CerefolinNAC®|
11465226|NCT01594528|Experimental|SC|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with schizophrenia
11465227|NCT01594528|Experimental|controls|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects without any psychiatric trouble
11465228|NCT01594528|Experimental|MD|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with major depression
11465229|NCT01594515|Experimental|BI 1015550 low dose A|Powder for oral solution
11465230|NCT01594515|Experimental|BI 1015550 low dose B|Powder for oral solution
11465231|NCT01594515|Experimental|BI 1015550 low dose C|Powder for oral solution
11465232|NCT01594515|Experimental|BI 1015550 low dose D|Powder for oral solution
11465233|NCT01594515|Experimental|BI 1015550 medium dose A|Powder for oral solution
11465234|NCT01594515|Experimental|BI 1015550 medium dose B|Powder for oral solution
11465235|NCT01594515|Experimental|BI 1015550 medium dose C|Powder for oral solution
11465236|NCT01594515|Experimental|BI 1015550 high dose A|Powder for oral solution
11465237|NCT01594515|Experimental|BI 1015550 high dose B|Powder for oral solution
11465238|NCT01594515|Placebo Comparator|Placebo|Solution for oral administration
11465239|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
11465240|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
11465241|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
11465242|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
11465243|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
11465244|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
11465245|NCT01594489|Experimental|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
11465246|NCT01594489|Active Comparator|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
11465247|NCT01594476|Experimental|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
11465248|NCT01594476|Experimental|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
11465249|NCT01594463|Experimental|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
11465250|NCT01594463|Experimental|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
11465251|NCT01594450|Experimental|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
11465252|NCT01594450|Active Comparator|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
11465253|NCT01594437|Experimental|TCN-202|
11465254|NCT01594437|Placebo Comparator|Placebo|
11465255|NCT01594424|Experimental|IVIG + Tocilizumab|
11465256|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
11465257|NCT01594398|Experimental|entinostat C1D1 fed|Entinostat: Beginning C1D1 fed; C1D15 fasted. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
11465258|NCT01594398|Experimental|entinostat C1D1 fasted|Entinostat: Beginning C1D1 fasted; C1D15 fed. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
11465259|NCT01594385|Other|Seprafilm|The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.
11465260|NCT01594385|No Intervention|No Seprafilm|This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.
11465261|NCT01594372|Active Comparator|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
11465262|NCT01594372|Active Comparator|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
11465263|NCT01594359|Active Comparator|High iron bean|High-iron bean
11465265|NCT01594346|Placebo Comparator|Sugar Pill|
11465266|NCT01594346|Active Comparator|Alpha-Tocopherol|
11465267|NCT01594333|Experimental|Methotrexate|Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week
11465268|NCT01594333|Placebo Comparator|Placebo|Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week
11465269|NCT01594320|Experimental|Group A|
11465270|NCT01594320|Experimental|Group B|
11465271|NCT01594320|Experimental|Group C|
11465272|NCT01594320|Experimental|Group D|
11465273|NCT01594320|Experimental|Group E|
11465274|NCT01594320|Experimental|Group F|
11465275|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
11465276|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
11465277|NCT01594294|Experimental|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
11465278|NCT01594294|Active Comparator|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
11465279|NCT01594294|Other|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
11465280|NCT01594281|Experimental|Ranibizumab mono|Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
11465281|NCT01594281|Active Comparator|PRP mono|Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
11465282|NCT01594281|Experimental|Ranibizumab+PRP|Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
11465283|NCT01594268|Other|Kidney transplantation patient|Kidney transplantation patient; single arm
11465284|NCT01594255|Experimental|AEB071 300 mg|
11465285|NCT01594255|Experimental|AEB071 900 mg|
11465286|NCT01594255|Placebo Comparator|Placebo to AEB071|
11465287|NCT01594255|Active Comparator|Moxifloxacin|
11465288|NCT01594242|Experimental|Autophagy Induction After Bortezomib|"Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma).
~The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment."
11465289|NCT01594229|Experimental|Arm 1|Non-Hodgkin's Lymphoma (NHL)
11465290|NCT01594216|Experimental|First Stage|Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
11465291|NCT01594216|Experimental|Second Stage|Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily
11465292|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
11465293|NCT01594190|Active Comparator|Low Dose Training|15 minutes/day on a weight-bearing treadmill
11465294|NCT01594190|Active Comparator|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
11465295|NCT01594177|Experimental|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.
11465296|NCT01594138||Suicidal Subjects|Suicidal Subjects
11465297|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
11465298|NCT01594125|Experimental|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
11465299|NCT01594125|Experimental|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
11465300|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
11465301|NCT01594099|Active Comparator|Radiotherapy alone|
11465302|NCT01594099|Experimental|Radiotherapy plus cisplatin|
11465303|NCT01594099|Experimental|Radiotherapy plus liposome paclitaxel|
11465304|NCT01594086|Experimental|green tea powder|Natural green tea powder
11465305|NCT01594060|Active Comparator|sliding scale|
11465306|NCT01594060|Active Comparator|basal bolus|
11465307|NCT01594047|No Intervention|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
11465308|NCT01594047|Experimental|ketamine/morphine|patients received a balance anaesthesia supplemented by low dose of ketamine and Morphine by PCA device for postoperative pain
11465309|NCT01594047|Experimental|zero/metadone|patients received a standard balance anaesthesia and methadone by PCA device for postoperative pain
11465310|NCT01594047|Experimental|ketamine/methadone|Patients received a balance anaesthesia supplemented with low dose of ketamine and Methadone by PCA device for postoperative pain
11465311|NCT01594034||no treatment|
11465312|NCT01594021|Experimental|High pre-emptive volume loading|
11465313|NCT01594021|Active Comparator|Low pre-emptive volume loading|
11465314|NCT01593995|Experimental|EGF ointment|
11465315|NCT01593982|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
11465316|NCT01593982|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
11465317|NCT01593969|Active Comparator|Standard RUTF|Standard RUTF given according to National Guidelines
11465844|NCT01590459|Experimental|VX-509 100 mg qd Arm|
11465318|NCT01593969|Experimental|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
11465319|NCT01593969|Experimental|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
11465320|NCT01593956|Other|Concussed athletes|
11465321|NCT01593956|Other|Healthy controls|
11465322|NCT01593943|No Intervention|Control Condition|
11465323|NCT01593943|Experimental|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
11465324|NCT01593930|Experimental|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
11465325|NCT01593930|Experimental|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
11465326|NCT01593930|Experimental|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
11465327|NCT01593930|Experimental|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
11465328|NCT01593917||Subjects previously implanted with a Trifecta valve|Subjects enrolled in this clinical study received the Trifecta valve during the investigational study that was conducted to obtain FDA approval
11465329|NCT01593878|Experimental|TV|Test taken with TV on
11465330|NCT01593878|No Intervention|Control|test taken in quiet
11465331|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
11465332|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
11465333|NCT01593852|Active Comparator|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
11465334|NCT01593852|Experimental|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
11465335|NCT01593826|Active Comparator|Charcoal and Symbicort Turbuhaler|
11465336|NCT01593826|Active Comparator|Symbicort Turbuhaler|
11465337|NCT01593826|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
11465338|NCT01593826|Experimental|Budesonide/formoterol Easyhaler|
11465339|NCT01593800|Experimental|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
11465340|NCT01593787|Experimental|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
11465341|NCT01593787|Experimental|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
11465342|NCT01593787|Experimental|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
11465343|NCT01593774|Experimental|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
11465344|NCT01593774|Placebo Comparator|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
11465345|NCT01593761|Experimental|Single Arm for CG400549|All the patients will be administered with CG400549.
11465346|NCT01593748|Experimental|Experimental|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
11465347|NCT01593748|Active Comparator|Standard of Care|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
11465348|NCT01593735|Experimental|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
11465349|NCT01593735|Experimental|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
11465350|NCT01593735|Experimental|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
11465351|NCT01593735|Experimental|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
11465352|NCT01593735|Experimental|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
11465353|NCT01593735|Experimental|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
11465747|NCT01591096|Experimental|Tissue plasminogen activator|All patients will receive study drug.
11465354|NCT01593735|Experimental|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
11465355|NCT01593735|Experimental|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
11465356|NCT01593735|Experimental|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
11465357|NCT01593735|Experimental|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
11465358|NCT01593722|Active Comparator|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
11465359|NCT01593722|Active Comparator|ivermectin|ivermectin 200 mcg/kg single oral dose
11465360|NCT01593709||Cohort 1|Healthy adults; age 18 or older
11465361|NCT01593696|Experimental|Lymphodepleting regimen of Fludarabine and Cyclophosphamide|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
11465362|NCT01593696|Experimental|Intensive standard of care chemotherapy|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the Chimeric antigen receptor (CAR) T cells.
11465363|NCT01593683|Experimental|Psychological education program|Patients receive the psychological education program upon study enrollment.
11465364|NCT01593683|No Intervention|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
11465365|NCT01593670|Experimental|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
11465366|NCT01593657|Experimental|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
11465367|NCT01593644|Experimental|adenosine + dypiridamole|
11465368|NCT01593631|Active Comparator|2 billion lyoph. yoghurt bacteria|
11465369|NCT01593631|Active Comparator|3300 FCC acid lactase|
11465370|NCT01593631|Active Comparator|9000 FCC acid lactase|
11465371|NCT01593631|Active Comparator|Combination of Substances of arm 1 and 2|
11465372|NCT01593631|Placebo Comparator|Placebo|
11465373|NCT01593618|Experimental|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
11465374|NCT01593618|Active Comparator|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
11465375|NCT01593605|Active Comparator|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
11465376|NCT01593605|Placebo Comparator|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
11465377|NCT01593605|Active Comparator|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
11465378|NCT01593592|Experimental|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
11465379|NCT01593592|Placebo Comparator|Control group|The control group that will receive the standard triple therapy and placebo
11465380|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
11465381|NCT01593566|Active Comparator|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
11465382|NCT01593566|Active Comparator|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
11465383|NCT01593553|Experimental|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
11465384|NCT01593553|No Intervention|Control group|Standard of care
11465385|NCT01593540|Experimental|metal-free interdental brushes.|
11465386|NCT01593540|Active Comparator|metal-core interdental brushes|
11465387|NCT01593527|Experimental|Arm 1|Canakinumab 150 mg s.c.
11465388|NCT01593527|Experimental|Arm 2|Triamcinelone acetonide 40 mg i.m.
11465389|NCT01593514|Active Comparator|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
11465390|NCT01593514|Experimental|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
11465391|NCT01593514|Experimental|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
11465392|NCT01593514|Experimental|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
11465393|NCT01593501|Active Comparator|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
11465394|NCT01593501|Active Comparator|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
11465845|NCT01590459|Experimental|VX-509 150 mg qd Arm|
11465395|NCT01593501|Placebo Comparator|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
11465396|NCT01593488|Experimental|Intrathecal liposomal cytarabine|
11465397|NCT01593475|Experimental|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.
~Radiotherapy
~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
11465398|NCT01593462|Experimental|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
11465399|NCT01593449|Active Comparator|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
11465400|NCT01593449|Experimental|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
11465401|NCT01593436|Active Comparator|mindfulness training|mindfulness training for patients with insomnia
11465402|NCT01593436|No Intervention|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
11465403|NCT01593423|Experimental|Homestead Food Production plus small pond aquaculture|
11465404|NCT01593423|Active Comparator|plant-based Homestead Food Production|
11465405|NCT01593423|Sham Comparator|Control|
11465406|NCT01593410|Experimental|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
11465407|NCT01593397|Experimental|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
11465408|NCT01593371|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
11465409|NCT01593371|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
11465410|NCT01593345|Experimental|Mentor|
11465411|NCT01593345|Active Comparator|Guidebook|
11465412|NCT01593332|Active Comparator|Rituximab|
11465413|NCT01593332|Active Comparator|Methotrexate|
11465414|NCT01593319|Active Comparator|ropivacaine|
11465415|NCT01593319|Placebo Comparator|Natrium chloride|
11465416|NCT01593306|Experimental|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
11465417|NCT01593306|Active Comparator|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
11465418|NCT01593293|Active Comparator|PemCarbo|Pemetrexed/Carboplatin arm
11465419|NCT01593293|Active Comparator|Pem only|Pemetrexed arm
11465420|NCT01593280|Active Comparator|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
11465421|NCT01593280|Active Comparator|intrathecal morphine|0.3 mg of intrathecal morphine
11465422|NCT01593267|Active Comparator|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
11465423|NCT01593267|Active Comparator|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
11465424|NCT01593254|Active Comparator|Arm 1: Imatinib (≥400 mg)|Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
11465425|NCT01593254|Active Comparator|Arm 2: Dasatinib (100 mg)|Dasatinib 100 mg tablet by mouth QD up to 60 months
11465426|NCT01593241|Experimental|Carboplatin|
11465427|NCT01593228|Experimental|1|"Patients receiving iniparib alone or in combination with other anti-cancer agents as defined by the parental study. Interventions:
~Drug: Iniparib monotherapy
~Drug: Iniparib + gemcitabine + carboplatin
~Drug: Iniparib + topotecan
~Drug: Iniparib + irinotecan
~Drug: Iniparib + paclitaxel
~Drug: Iniparib + liposomal doxorubicin + carboplatin"
11465428|NCT01593215|Active Comparator|Placebo first then yohimbine|placebo first, then yohimbine
11465429|NCT01593215|Active Comparator|Yohimbine first then placebo|Yohimbine first then placebo
11465430|NCT01593202|Experimental|Dialectical behavior therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
11465431|NCT01593202|Active Comparator|Enhanced usual care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
11465432|NCT01593189|Experimental|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
11465433|NCT01593189|No Intervention|Services as usual|Families continued to receive any services that they had been receiving in the community.
11465434|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
11465435|NCT01593163|Experimental|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
11465436|NCT01593163|Other|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
11465437|NCT01593150|Experimental|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
11465438|NCT01593150|Experimental|TEE|Transesophageal echo prior to DC cardioversion (early DC)
11465439|NCT01593150|Active Comparator|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
11465440|NCT01593137|Experimental|Liraglutide + metformin|
11465441|NCT01593137|Active Comparator|glimepiride + metformin|
11465442|NCT01593124|Active Comparator|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
11465443|NCT01593124|Placebo Comparator|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
11465444|NCT01593124|Active Comparator|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
11465445|NCT01593111|Experimental|Environmental Intervention|If randomized to this part of the study the patient will receive an individualized homebased program. In addition to general handouts provided to at Visit 3, subjects in this arm will also receive home-based education by Intervention Counselors about how indoor allergens can affect asthma and the importance of strategies for removing allergens. The goal of the intervention is to provide the patient with the knowledge and skills necessary to remove allergens from their home, and to assist them with those clean up measures. Some of the measures implemented will be specifically based on data we have previously collected from them in the clinic and from their previous home visit, while others will be general to reduce all allergen level.
11465446|NCT01593111|No Intervention|Control Group|If assigned to this group the patient will receive general health/safety related counseling. At the counselor visit following randomization, the patient will receive handouts related to general health and safety issues. They will also have visits by the Home Evaluators for assessment of the home and collection of dust samples identical to those in the treatment group (week 28 and week 44).
11465447|NCT01593098||Exposed siblings|Siblings (age >40 and <70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, >25% villous features, severe dysplasia or carcinoma-in-situ
11465448|NCT01593098||unexposed siblings|Siblings (age >40 and <70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
11465449|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
11465450|NCT01593072|Active Comparator|AVI-7537|AVI-7537
11465451|NCT01593072|Other|Placebo|Normal Saline Solution (NSS)
11465452|NCT01593059||Orsiro DES|
11465453|NCT01593046|Experimental|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
11465454|NCT01593046|Experimental|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
11465455|NCT01593046|Experimental|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
11465456|NCT01593046|Experimental|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
11465457|NCT01593046|Experimental|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
11465458|NCT01593033|Experimental|Fish oil and Micronutrient Supplementation|
11465459|NCT01593033|Experimental|Micronutrient Supplementation|
11465460|NCT01593033|Placebo Comparator|Placebo|
11465461|NCT01593020|Experimental|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.
~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
11465462|NCT01593020|Experimental|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).
~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
11465463|NCT01593007|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
11465464|NCT01593007|Placebo Comparator|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
11465465|NCT01592994|No Intervention|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
11465466|NCT01592994|Experimental|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
11465467|NCT01592981|Experimental|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.
~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
11465468|NCT01592981|Active Comparator|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.
~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
11465469|NCT01592968|Experimental|Arm I (SRS)|Patients undergo SRS on day 1.
11465470|NCT01592968|Experimental|Arm II (WBRT)|Patients undergo WBRT 5 days per week (7 days per week for inpatients) for 2 weeks.
11465471|NCT01592955|Experimental|EYEOP1 device|cyclocoagulation HIFU
11465472|NCT01592942|Experimental|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
11465473|NCT01592942|Active Comparator|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
11465474|NCT01592942|Active Comparator|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
11465475|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
11465476|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
11465477|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
11465478|NCT01592890|Experimental|[14C]-labeled RO4917523|
11465479|NCT01592864|Experimental|Arm 1|Dentifrice containing stannous fluoride
11465480|NCT01592864|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
11465481|NCT01592851|Experimental|Arm 1|Dentifrice containing stannous fluoride
11465482|NCT01592851|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
11465483|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
11465484|NCT01592812|Experimental|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
11465485|NCT01592799|Other|Influenza Group|Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
11465486|NCT01592786|Experimental|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
11465487|NCT01592773|Experimental|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.
~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
11465488|NCT01592760|Experimental|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
11465489|NCT01592760|Active Comparator|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
11465490|NCT01592760|Active Comparator|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
11465491|NCT01592747|Experimental|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
11465492|NCT01592747|Experimental|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
11465493|NCT01592747|Placebo Comparator|Placebo|Dosing will be once daily for up to 12 weeks.
11465494|NCT01592734|Experimental|PEG-only|Polyethylene glycol 4000 only (PEG-only).
11465495|NCT01592734|Active Comparator|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
11465496|NCT01592721|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
11465497|NCT01592708|Active Comparator|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
11465498|NCT01592695|Experimental|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
11465846|NCT01590459|Experimental|VX-509 100 mg bid Arm|
11465499|NCT01592695|Active Comparator|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
11465500|NCT01592682|No Intervention|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
11465501|NCT01592682|Experimental|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
11465502|NCT01592669|Experimental|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
11465503|NCT01592669|No Intervention|control|supine baseline position
11465504|NCT01592656|Active Comparator|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
11465505|NCT01592656|Placebo Comparator|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
11465506|NCT01592630|Experimental|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
11465507|NCT01592630|Placebo Comparator|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
11465508|NCT01592617|Experimental|S-488410|
11465509|NCT01592604|Experimental|Treatment A|Patients receive supportive compressive bandage for 4 weeks
11465510|NCT01592604|Experimental|Treatment B|Below knee walking plaster cast for 4 weeks
11465511|NCT01592578|Active Comparator|Ligation and Cyanoacrylate Group|
11465512|NCT01592578|Experimental|Ligation plus Sclerotherapy and Cyanoacrylate Group|
11465513|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
11465514|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
11465515|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
11465516|NCT01592539||Control|Age and sex matched healthy controls.
11465517|NCT01592526|Experimental|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
11465518|NCT01592526|Experimental|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
11465519|NCT01592526|Experimental|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
11465520|NCT01592526|Experimental|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
11465521|NCT01592513|No Intervention|Control|
11465522|NCT01592513|Experimental|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).
~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
11465523|NCT01592500|Experimental|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
11465524|NCT01592500|Experimental|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
11465525|NCT01592500|Experimental|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
11465526|NCT01592500|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
11465527|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
11465528|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
11465529|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
11465530|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
11465531|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
11465532|NCT01592435||Pred. & Invest.-All Study Participants|"Cedera AccuStitch Software is standard of care software currently used at sites.
~Carestream DR LLI software is investigational software used for reconstruction."
11465533|NCT01592422|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
11465534|NCT01592422|Active Comparator|Best Supportive Care|Best Supportive Care
11465535|NCT01592409|Active Comparator|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
11465536|NCT01592409|Placebo Comparator|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
11465537|NCT01592396|Experimental|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
11465538|NCT01592383|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11465539|NCT01592370|Experimental|Nivolumab monotherapy (Dose Escalation)|"Nivolumab solution intravenously as specified
~Non-randomized
~Enrollment is closed for this cohort"
11465540|NCT01592370|Experimental|Nivolumab + Ipilimumab|"Nivolumab and Ipilimumab solution intravenously as specified
~Non-randomized
~Enrollment is closed for this cohort"
11465841|NCT01590485|Active Comparator|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
11465541|NCT01592370|Experimental|Nivolumab + Lirilumab|"Non-randomized
~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks
~Enrollment is closed for this cohort"
11465542|NCT01592370|Experimental|Nivo + Dara + Pom + Dexa vs. Nivo + Dara|"Randomized
~Nivolumab:
~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 & beyond: 480 mg Day 1
~Daratumumab:
~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1
~Pomalidomide:
~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle
~Dexamethasone:
~Weeks without daratumumab dosing:
~40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old
~20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants > 75 years old
~Weeks with daratumumab dosing:
~20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old
~16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants > 75 years old
~Enrollment is closed for this cohort"
11465543|NCT01592370|Experimental|Daratumumab vs. Nivolumab + Daratumumab|"Randomized
~Nivolumab:
~Cycle 1: 240 mg Day 15 Cycle 2 & beyond: 480 mg Day 1
~Daratumumab:
~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1"
11465544|NCT01592357|Experimental|Tai Chi|
11465545|NCT01592357|Sham Comparator|Sham Exercise|
11465546|NCT01592344|Experimental|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
11465547|NCT01592344|Sham Comparator|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
11465548|NCT01592331|Placebo Comparator|Placebo|
11465549|NCT01592331|Experimental|RO5508887|
11465550|NCT01592318|Active Comparator|DNV + r reference|
11465551|NCT01592318|Experimental|DNV/r fixed dose combination|
11465552|NCT01592305|Experimental|S1 P1 TDF + DNV/r|
11465553|NCT01592305|Experimental|S1/S2 P2 DNV/r + ATZ|
11465554|NCT01592305|Experimental|S2 P1 ATZ/r|
11465555|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
11465556|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
11465557|NCT01592279|Experimental|liraglutide|
11465558|NCT01592279|Active Comparator|Insulin injections|
11465559|NCT01592266||AML|patients with AML prior and after treatment
11465560|NCT01592240|Experimental|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
11465561|NCT01592240|Experimental|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
11465562|NCT01592227|Active Comparator|Marketed paracetamol|Marketed paracetamol
11465563|NCT01592227|Experimental|Experimental paracetamol formulation|Experimental formulations
11465564|NCT01592214|Experimental|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
11465565|NCT01592214|Placebo Comparator|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
11465566|NCT01592214|Active Comparator|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
11465567|NCT01592214|Experimental|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
11465568|NCT01592214|Experimental|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
11465569|NCT01592214|Experimental|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
11465570|NCT01592201|Experimental|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
11465571|NCT01592201|Experimental|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
11465572|NCT01592188|Active Comparator|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
11465573|NCT01592188|Experimental|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
11465574|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
11465575|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
11465576|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
11465577|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
11465578|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
11465579|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
11465580|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
11465581|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
11465582|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
11465583|NCT01592149||Group 1|
11465584|NCT01592123||The participants with septal deviation|
11465585|NCT01592110|Experimental|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
11465586|NCT01592110|Experimental|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
11465587|NCT01592110|Experimental|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
11465588|NCT01592110|Experimental|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
11465589|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
11465590|NCT01592071|Experimental|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
11465591|NCT01592045|Experimental|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
11465592|NCT01592045|Experimental|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
11465593|NCT01592032|Experimental|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
11465594|NCT01592032|Experimental|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
11465595|NCT01592032|Experimental|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
11465596|NCT01592032|Experimental|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
11465597|NCT01592032|Experimental|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
11465598|NCT01592019|Experimental|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
11465599|NCT01592019|Experimental|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
11465600|NCT01592019|Experimental|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
11465601|NCT01592019|Experimental|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
11465602|NCT01592006|Experimental|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
11465603|NCT01591993|Experimental|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
11465604|NCT01591993|Placebo Comparator|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
11465605|NCT01591980|Experimental|Pregabalin 100 mg|
11465606|NCT01591980|Experimental|pregabalin 150 mg|
11465607|NCT01591980|Sham Comparator|Placebo|
11465608|NCT01591967|No Intervention|Control|Control -- no intervention
11465609|NCT01591967|No Intervention|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
11465610|NCT01591967|Experimental|Activator treatment|Treatment with Activator
11465611|NCT01591954|Experimental|Video Augmentation|Qualitative assessment of the value of video-based navigation system
11465612|NCT01591941|Active Comparator|CON group|Control Group underwent a standard soccer warm-up
11465613|NCT01591941|Experimental|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
11465614|NCT01591928||Infants with heterotaxy syndrome|
11465615|NCT01591915|Experimental|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
11465616|NCT01591915|Experimental|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
11465617|NCT01591915|No Intervention|Standard care|
11465618|NCT01591902|Experimental|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
11465619|NCT01591902|Placebo Comparator|Placebo|Placebo-controlled
11465620|NCT01591889|Active Comparator|tindamax|500 mg tablet
11465621|NCT01591889|Active Comparator|tinidazole|500 mg tablet
11465622|NCT01591876|Sham Comparator|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
11465623|NCT01591876|Active Comparator|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
11465624|NCT01591863|Experimental|fidaxomicin|
11465625|NCT01591850|Experimental|1 Ketoconazole DDI|
11465626|NCT01591850|Experimental|2 Rifampicin DDI|
11465627|NCT01591850|Experimental|3 ATZ/r DDI|
11465628|NCT01591837|Experimental|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
11465629|NCT01591837|Experimental|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
11465630|NCT01591824|Experimental|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
11465631|NCT01591824|Active Comparator|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
11465632|NCT01591811|Experimental|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
11465633|NCT01591811|Experimental|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
11465634|NCT01591798|Experimental|Robotic surgery|Proctectomy using robot
11465635|NCT01591798|Active Comparator|Laparoscopic surgery|Conventional laparoscopic rectal resection
11465636|NCT01591785|Active Comparator|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
11465637|NCT01591785|Placebo Comparator|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
11465638|NCT01591772||diagnosed with ovarian that recieved chemo|
11465639|NCT01591772||healthy controls|
11465640|NCT01591759|Experimental|Citicoline|8-week treatment of 2,000mg/day of citicoline
11465641|NCT01591759|Placebo Comparator|Placebo|
11465642|NCT01591746|Experimental|Group A - Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast
11465643|NCT01591746|Placebo Comparator|Group B - Placebo|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast
11465644|NCT01591733|Experimental|Treatment Arm|All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
11465645|NCT01591720|Experimental|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
11465646|NCT01591707|Experimental|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
11465647|NCT01591707|No Intervention|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
11465648|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
11465649|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
11465650|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
11465651|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
11465652|NCT01591681|Active Comparator|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
11465653|NCT01591681|No Intervention|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
11465654|NCT01591668|Experimental|0.3mg GS-9620|
11465655|NCT01591668|Experimental|1mg GS-9620|
11465656|NCT01591668|Experimental|2mg GS-9620|
11465657|NCT01591668|Experimental|4mg GS-9620|
11465658|NCT01591668|Experimental|0.3mg GS-9620 QW x 2 doses|
11465659|NCT01591668|Experimental|1mg GS-9620 QW x 2 doses|
11465660|NCT01591668|Experimental|2mg GS-9620 QW x 2 doses|
11465661|NCT01591668|Experimental|4mg GS-9620 QW x 2 doses|
11465662|NCT01591655|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
11465663|NCT01591655|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
11465664|NCT01591629|Placebo Comparator|Placebo and Placebo|
11465665|NCT01591629|Experimental|Active Naloxone and Placebo|
11465666|NCT01591629|Placebo Comparator|Placebo and Active Delta-9-THC|
11465667|NCT01591629|Experimental|Active Naloxone and Active Delta-9-THC|
11465668|NCT01591616|Other|Oraqix for tooth extraction|
11465669|NCT01591603|Experimental|Group 1|
11465670|NCT01591603|Experimental|Group 2|
11465671|NCT01591590|Experimental|All Patients|This is an Interventional, Non Therapeutic arm
11465705|NCT01591343|Experimental|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
11465672|NCT01591577|Experimental|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
11465673|NCT01591564|Other|therapy|All participants will receive the intervention.
11465674|NCT01591551|Other|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
11465675|NCT01591538||lifestyle condition|
11465676|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
11465677|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
11465678|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
11465679|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
11465680|NCT01591499|Experimental|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
11465681|NCT01591499|Active Comparator|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
11465682|NCT01591486||Hp-negative cohort|"Hp-negative cohort
~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:
~negative rapid urease test
~negative histology for Hp infection on both initial and follow-up endoscopy
~negative serology test
~absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus
~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (<160 mg daily) without regular co-prescription of anti-ulcer drugs."
11465683|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs.
11465684|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
11465685|NCT01591473|Experimental|FluMist + Ampligen, Group 1|Nasal administration; dose group 1; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
11465686|NCT01591473|Experimental|FluMist + Ampligen, Group 2|Nasal administration; dose group 2; FluMist + Poly I:Poly C12U 200 ug; 3 doses separated by 28 days
11465687|NCT01591473|Experimental|FluMist + Ampligen, Group 3|Nasal administration; dose group 3; FluMist + Poly I:Poly C12U 500 ug; 3 doses separated by 28 days
11465688|NCT01591473|Experimental|FluMist + Ampligen, Group 4|Nasal administration; dose group 4; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
11465689|NCT01591473|Experimental|FluMist + Ampligen, Group 5|Nasal administration; dose group 5; FluMist + Poly I:Poly C12U 1250 ug; 3 doses separated by 28 days
11465690|NCT01591473|Experimental|FluMist + Placebo, Group 6|Nasal administration; dose group 6; FluMist + placebo; 3 doses separated by 28 days
11465691|NCT01591460|Experimental|Dual Combination Therapy|
11465692|NCT01591460|Experimental|Triple Combination Therapy|
11465693|NCT01591447|Experimental|Solithromycin (CEM-101)|A single oral dose of 1200 mg solithromycin
11465694|NCT01591447|Experimental|Solithromycin 1000 mg|A single oral dose of 1000 mg solithromycin
11465695|NCT01591434|Active Comparator|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
11465696|NCT01591434|Active Comparator|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
11465697|NCT01591421|Experimental|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
11465698|NCT01591408|Experimental|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
11465699|NCT01591408|Sham Comparator|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
11465700|NCT01591395|Active Comparator|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
11465701|NCT01591395|Active Comparator|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
11465702|NCT01591382|Active Comparator|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
11465703|NCT01591382|Placebo Comparator|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
11465704|NCT01591356|Experimental|Treatment (EphA2-targeting DOPC-encapsulated siRNA)|Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11465706|NCT01591330|Experimental|80 mg LY2140023 - Reference Form|Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
11465707|NCT01591330|Experimental|80 mg LY2140023 - Test - Medium Form|Medium particle size. Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
11465708|NCT01591330|Experimental|80 mg LY2140023 - Test - High Form|High particle size. Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
11465709|NCT01591330|Experimental|80 mg LY2140023 - Test - Low Form|Low particle size. Administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
11465710|NCT01591317|Experimental|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
11465711|NCT01591317|Experimental|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
11465712|NCT01591317|Experimental|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
11465713|NCT01591304|Active Comparator|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
11465714|NCT01591304|Active Comparator|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
11465715|NCT01591291|Experimental|Ondansetron|
11465716|NCT01591291|Placebo Comparator|Placebo|
11465717|NCT01591278|Experimental|Pulp dressing agent|
11465718|NCT01591278|Active Comparator|Pulp dressing|MTA
11465719|NCT01591265|Active Comparator|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
11465720|NCT01591265|Active Comparator|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
11465721|NCT01591239|Experimental|Home-Based Intervention|Parents will receive a 1-session training on how to deliver a 3-session intervention across a 3-week period. The intervention program begins with a 3 and a half hour training session delivered by the staff Trainer to the participating parent. At the conclusion of training, the parent will be given the intervention manual and supplemental materials. The trainer will phone the parent shortly before session 1, in between each intervention session, and after the third intervention (four phone calls total) to review the objectives and tasks associated with that week's intervention session and to help prepare for the coming session. At the final phone call between the parent and trainer (after the third week), the trainer will deliver to the parent the follow-up resources.
11465722|NCT01591239|Active Comparator|Educational Group|Parents will receive a 2-hour, education-only psychoeducational curriculum (no parent-led intervention with their teen will occur.
11465723|NCT01591226|Active Comparator|Caffeine|6mg per kg bodyweight ingested 60min before test
11465724|NCT01591226|Placebo Comparator|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
11465725|NCT01591226|Active Comparator|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
11465726|NCT01591226|Active Comparator|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
11465727|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
11465728|NCT01591200|No Intervention|Control|This arm will receive standard protocol of care alone
11465729|NCT01591200|Experimental|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
11465730|NCT01591200|Experimental|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
11465731|NCT01591200|Experimental|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
11465732|NCT01591187||Cancer|Participants with a diagnosis of cancer.
11465733|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.
~Interventions: Text messaging, Questionnaire, Interviews"
11465734|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
11465735|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
11465736|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
11465737|NCT01591161|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
11465738|NCT01591161|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
11465739|NCT01591148|Experimental|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
11465740|NCT01591148|Active Comparator|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
11465741|NCT01591135|Active Comparator|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
11465742|NCT01591135|Experimental|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
11465743|NCT01591122|Experimental|Abiraterone acetate and prednisone|
11465744|NCT01591122|Active Comparator|Placebo and prednisone|
11465745|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
11465746|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
11465847|NCT01590459|Experimental|VX-509 200 mg qd Arm|
11465748|NCT01591083|Active Comparator|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
11465749|NCT01591083|Active Comparator|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
11465750|NCT01591083|Active Comparator|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
11465751|NCT01591070|No Intervention|vehicle twice weekly|
11465752|NCT01591070|Experimental|tacrolimus once weekly|
11465753|NCT01591070|Experimental|tacrolimus twice weekly|
11465754|NCT01591057|Experimental|2 Portions|
11465755|NCT01591057|Experimental|5 portions|
11465756|NCT01591057|Experimental|8 portions|
11465757|NCT01591044|Active Comparator|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
11465758|NCT01591044|Placebo Comparator|Placebo|
11465759|NCT01591044|Active Comparator|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
11465760|NCT01591031|Active Comparator|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
11465761|NCT01591031|Active Comparator|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
11465762|NCT01591018|Experimental|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
11465763|NCT01591018|Placebo Comparator|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
11465764|NCT01591005|Experimental|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
11465765|NCT01591005|Placebo Comparator|CEA without sonolysis|endarterectomy without sonolysis
11465766|NCT01591005|Experimental|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
11465767|NCT01591005|Placebo Comparator|carotid stenting without sonolysis|carotid stenting without sonolysis
11465768|NCT01590992|Experimental|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
11465769|NCT01590992|Active Comparator|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
11465770|NCT01590979|Active Comparator|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
11465771|NCT01590979|Placebo Comparator|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
11465772|NCT01590966|Experimental|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
11465773|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
11465774|NCT01590927||20 healthy women|
11465775|NCT01590914|Experimental|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
11465776|NCT01590914|Experimental|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
11465777|NCT01590914|Experimental|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
11465778|NCT01590914|Experimental|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
11465779|NCT01590901|Other|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
11465780|NCT01590888|Experimental|PBT2 250mg|
11465781|NCT01590888|Experimental|PBT2 100mg|
11465782|NCT01590888|Placebo Comparator|Sugar pill|
11465783|NCT01590875|Experimental|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
11465784|NCT01590875|No Intervention|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
11465785|NCT01590862||Deep Brain Stimulation Effects on Reward Motivation|We will assess changes in Reward Motivation behavior with Deep Brain Stimulation on and off.
11465786|NCT01590862||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
11465787|NCT01590849|No Intervention|No hormonal contraception|
11465788|NCT01590849|Active Comparator|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
11465789|NCT01590836|Experimental|IDeg-->IDegAsp|
11465790|NCT01590823|Other|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
11465842|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
11465843|NCT01590459|Placebo Comparator|Placebo Arm|
11465791|NCT01590810|Experimental|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
11465792|NCT01590810|Experimental|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
11465793|NCT01590810|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
11465794|NCT01590810|Experimental|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
11465795|NCT01590797|Experimental|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
11465796|NCT01590797|Placebo Comparator|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
11465797|NCT01590771|Experimental|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
11465798|NCT01590771|Placebo Comparator|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
11465799|NCT01590758|Placebo Comparator|Topical placebo control|
11465800|NCT01590758|Experimental|Topical pexiganan cream 0.8%|
11465801|NCT01590745|Placebo Comparator|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
11465802|NCT01590745|Active Comparator|Real Ultrasound therapy|Pulsed mode ultrasound therapy
11465803|NCT01590732|Experimental|Treatment (romidepsin, ifosfamide, carboplatin, etoposide)|Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11465804|NCT01590719|Experimental|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
11465805|NCT01590719|Placebo Comparator|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
11465806|NCT01590693|Experimental|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
11465807|NCT01590693|Active Comparator|Group 1|Children treated with four weeks of below knee walking casts.
11465808|NCT01590667|Active Comparator|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
11465809|NCT01590667|Placebo Comparator|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
11465810|NCT01590654|Experimental|0.3mg GS-9620|
11465811|NCT01590654|Experimental|1mg GS-9620|
11465812|NCT01590654|Experimental|2mg GS-9620|
11465813|NCT01590654|Experimental|4mg GS-9620|
11465814|NCT01590654|Experimental|0.3mg GS-9620 QW x 2 doses|
11465815|NCT01590654|Experimental|1mg GS-9620 QW x 2 doses|
11465816|NCT01590654|Experimental|2mg GS-9620 QW x 2 doses|
11465817|NCT01590654|Experimental|4mg GS-9620 QW x 2 doses|
11465818|NCT01590641|Experimental|0.3mg GS-9620|
11465819|NCT01590641|Experimental|1mg GS-9620|
11465820|NCT01590641|Experimental|2mg GS-9620|
11465821|NCT01590641|Experimental|4mg GS-9620|
11465822|NCT01590641|Experimental|0.3mg GS-9620 QW x 2 doses|
11465823|NCT01590641|Experimental|1mg GS-9620 QW x 2 doses|
11465824|NCT01590641|Experimental|2mg GS-9620 QW x 2 doses|
11465825|NCT01590641|Experimental|4mg GS-9620 QW x 2 doses|
11465826|NCT01590628|Experimental|NiCord|
11465827|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
11465828|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
11465829|NCT01590589||REGISTRY participants|"Individuals
~with manifest HD
~unaffected but known to carry the HD mutation
~unaffected but at risk of carrying the HD mutation
~from HD families known not to carry the HD mutation
~from outside HD families acting as control research participants (e.g., spouses)"
11465830|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
11465831|NCT01590563|Experimental|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
11465832|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
11465833|NCT01590537||Group 1|
11465834|NCT01590537||Group 2|
11465835|NCT01590524|Experimental|CAM group|Subjects receiving the interventions and standard psychological care
11465836|NCT01590524|No Intervention|No-CAM group|Parents receiving only standard psychological care
11465837|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
11465838|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
11465839|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
11465840|NCT01590485|Placebo Comparator|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
11465848|NCT01590446|Placebo Comparator|Placebo|
11465849|NCT01590446|Active Comparator|BMN 111|
11465850|NCT01590433|Experimental|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling. Subjects may or may not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the study team will know which they are receiving.
11465851|NCT01590433|Placebo Comparator|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling. Subjects may or may not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the study team will know which they are receiving.
11465852|NCT01590420|Experimental|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
11465853|NCT01590407|Experimental|ALS-002200|
11465854|NCT01590407|Placebo Comparator|Placebo|
11465855|NCT01590394|Experimental|Pancreatic Cancer Patients|A large plastic biliary stent was placed in the bile duct.
11465856|NCT01590381||personnel in medical training - COURSE 1|
11465857|NCT01590381||personnel in medical training - COURSE 2|
11465858|NCT01590381||personnel in medical training - COURSE 3|
11465859|NCT01590381||personnel in medical training - COURSE 4|
11465860|NCT01590381||personnel in medical training - COURSE 5|
11465861|NCT01590381||personnel in medical training - COURSE 6|
11465862|NCT01590381||personnel in medical training - COURSE 7|
11465863|NCT01590381||personnel in medical training - COURSE 8|
11465864|NCT01590381||personnel in medical training - COURSE 9|
11465865|NCT01590381||personnel in medical training - COURSE 10|
11465866|NCT01590368|Other|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
11465867|NCT01590368|Active Comparator|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
11465868|NCT01590355|Active Comparator|Radiotherapy plus or minus Chemotherapy|Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease
11465869|NCT01590355|Experimental|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
11465870|NCT01590342|Active Comparator|Diclofenac|
11465871|NCT01590342|Placebo Comparator|Placebo|
11465872|NCT01590329|Experimental|Micrografting|
11465873|NCT01590316|Experimental|Cerebral NIRS oximetry + treatment guideline based on reading|
11465874|NCT01590316|No Intervention|Blinded cerebral NIRS oximetry|
11465875|NCT01590303|Experimental|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
11465876|NCT01590303|Placebo Comparator|placebo|placebo vehicle administered in same fashion as active treatment
11465877|NCT01590290|Active Comparator|pay for performance|
11465878|NCT01590290|No Intervention|no pay for performance|
11465879|NCT01590277|Experimental|ethanol and iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
~Potential Randomizations:
~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
11465880|NCT01590277|Experimental|placebo ethanol|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
~Potential Randomizations:
~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
11465881|NCT01590277|Experimental|active iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
~Potential Randomizations:
~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
11465882|NCT01590277|Experimental|placebo iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
~Potential Randomizations:
~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
11465883|NCT01590264|Other|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)
~Stimulation Settings:
~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000
~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
11465884|NCT01590251|Experimental|Yoga|Gentle yoga for chronic pain and opioid dependence
11465885|NCT01590251|Active Comparator|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
11465886|NCT01590238|Experimental|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
11465887|NCT01590225|Experimental|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
11465888|NCT01590225|Experimental|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
11465889|NCT01590212|No Intervention|Care as usual|Participants received care in line with local guidelines
11465890|NCT01590212|Active Comparator|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
11465891|NCT01590212|Active Comparator|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
11465892|NCT01590199|Experimental|RAD001 + SOM230|
11465893|NCT01590173|Experimental|Prednisolone and Heparin during COH for IVF|
11465894|NCT01590173|Active Comparator|COH for IVF|
11465895|NCT01590160|Experimental|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
11465896|NCT01590160|Experimental|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
11465897|NCT01590147|Experimental|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
11465898|NCT01590147|Active Comparator|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
11465899|NCT01590134|No Intervention|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period
~Total number of participants in arm = 6"
11465900|NCT01590134|Active Comparator|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.
~Total number of participants in arm = 6"
11465901|NCT01590134|Experimental|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.
~Toal participants in arm = 6"
11465902|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
11465903|NCT01590108|Experimental|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
11465904|NCT01590108|Placebo Comparator|Control|Subject will take cardiopulmonary exercise testing with receive placebo
11465905|NCT01590095|Active Comparator|Water quality|90 clusters, approx. 720 newborns
11465906|NCT01590095|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
11465907|NCT01590095|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
11465908|NCT01590095|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
11465909|NCT01590095|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
11465910|NCT01590095|Active Comparator|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
11465911|NCT01590095|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
11465912|NCT01590082|Experimental|Doxycycline, Ipilimumab, and Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
11465913|NCT01590069|Experimental|Treatment (aerosolized aldesleukin)|Patients receive aerosolized aldesleukin QD on days 1-21. Courses repeat every 28 days in the absence of disease progression of unacceptable toxicity.
11465914|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
11465915|NCT01590043||Control|Healthy 3-18 years old participants
11465916|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
11465917|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
11465918|NCT01590030|Experimental|Laparoscopic mesial incision|
11465919|NCT01590030|Active Comparator|Laparoscopic antimesial incision|
11465920|NCT01590017|Experimental|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
11465921|NCT01589991|Placebo Comparator|Non-fluoride toothpaste|
11465922|NCT01589991|Experimental|Toothpaste 550 µg F/g (NaF/SiO2)|
11465923|NCT01589991|Experimental|Toothpaste 1100 µg F/g (NaF/SiO2)|
11465924|NCT01589991|Experimental|Toothpaste 1450 µg F/g (MFP/CaCO3)|
11465925|NCT01589978|Experimental|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
11465926|NCT01589965|Experimental|Treatment group: T5|Small Lottery reward
11465927|NCT01589965|No Intervention|Control group|
11465928|NCT01589965|Experimental|Treatment group T1|High Lottery reward
11465929|NCT01589952|Experimental|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
11465930|NCT01589926|Experimental|Bi-level Positive Airway Pressure Device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
11465931|NCT01589926|Sham Comparator|Sham CPAP|Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.
11465932|NCT01589913|Experimental|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
11465933|NCT01589913|No Intervention|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
11465934|NCT01589874||acute ill patients|
11465935|NCT01589861|Experimental|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle
~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
11465936|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
11465937|NCT01589835|Experimental|Lifestyle counseling|Green prescription with facilitator support
11465938|NCT01589835|Other|Usual care|
11465939|NCT01589822|Experimental|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
11465940|NCT01589822|No Intervention|Standard of Care|Standard surgical technique for GI anastomosis.
11465941|NCT01589822|Experimental|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
11465942|NCT01589809|Experimental|Nicotinamide|Comparison is made within-subjects to different doses and no treatment
11465943|NCT01589796|Active Comparator|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
11465944|NCT01589796|Active Comparator|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
11465945|NCT01589783||Pregnant or newly post partum women|
11465946|NCT01589783||family practice physicians and obstetricians|
11465947|NCT01589770|Other|rheumatoid arthritis patients|People who have rheumatoid arthritis underwent cMRI
11465948|NCT01589770|Other|controls|people who do not have RA or other inflammatory disease underwent cMRI
11465949|NCT01589757|Placebo Comparator|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
11465950|NCT01589757|Experimental|Low GI Diet|Low GI dietary advice in addition to standard care
11465951|NCT01589744|Experimental|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
11465952|NCT01589731||Allergic group|The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
11465953|NCT01589731||Non Allergic group|The second group (group B) was used as a control for the immunoblotting analysis performed in the first group and included 20 individuals selected based on an evident tolerance to cow's milk, an absence of βs-IgE by ImmunoCAP assay and SPT non-reactivity to β-Lg or TgPolβ-Lg (6 males; mean age: 21.9 years, SD: 17.6 years).
11465954|NCT01589731||Atopic group|The third group (group C) included 49 subjects with atopic respiratory and/or dermatological diseases (19 males; mean age: 28.7 years, SD: 20.6 years) regardless of βs-IgE status. This group was used to compare the ex vivo cell-mediated immunoreactivity between β-Lg and TgPolβ-Lg by comparing the mean ex vivo antigenic challenge results determined using the leukocyte adherence inhibition test (LAIT).
11465955|NCT01589718|Experimental|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
11465956|NCT01589718|Sham Comparator|Sham injection|will receive a sham injection
11465957|NCT01589705||polycystic kidney ,no hypertension|The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
11465958|NCT01589692|Experimental|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
11465959|NCT01589692|Experimental|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
11465960|NCT01589692|Experimental|Pinning|Percutaneous pinning with any number of Kirschner wires
11465961|NCT01589692|Active Comparator|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
11465962|NCT01589679|Other|control/ standard of care|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study.
11465963|NCT01589679|Experimental|Dynasplint|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day.
11465964|NCT01589666|Experimental|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
11465965|NCT01589653|Experimental|Subject-driven titration|
11465966|NCT01589653|Experimental|Investigator-driven titration|
11465967|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
11465968|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
11465969|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
11465970|NCT01589627|Experimental|experimental|Patients will be treated with the Standard of Care physical therapy, NSAIDs as well as a Wrist Extension Dynasplint
11465971|NCT01589627|No Intervention|Control|Patients will receive standard of care physical therapy and NSAIDS
11465972|NCT01589614|Experimental|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
11465973|NCT01589614|Experimental|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
11466278|NCT01587677||Confirmed non-tuberculous mycobacterial infection|
11465974|NCT01589601|No Intervention|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
11465975|NCT01589601|Active Comparator|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
11465976|NCT01589588|Experimental|Mask 1|
11465977|NCT01589588|Experimental|Mask 2|
11465978|NCT01589588|Experimental|Mask 3|
11465979|NCT01589588|Placebo Comparator|Mask 3, placebo|
11465980|NCT01589575||Spouses|This group of relatives includes the spouses of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
11465981|NCT01589575||Other relatives|This group of relatives includes the non-spouse relatives of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
11465982|NCT01589562|Active Comparator|Megace 800mg/20ml|Fed condition
11465983|NCT01589562|Experimental|DW-ES(B) 625mg/5ml|Fed condition
11465984|NCT01589549|Experimental|Mesenchymal stromal cell therapy|Mesenchymal stromal cell therapy in addition to corticosteroid therapy
11465985|NCT01589549|Active Comparator|Corticosteroid therapy|
11465986|NCT01589536|Experimental|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
11465987|NCT01589536|No Intervention|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
11465988|NCT01589523|Experimental|GlycoCholic Acid, Study Drug|A Phase III, open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
11465989|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
11465990|NCT01589497|Active Comparator|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
11465991|NCT01589497|Active Comparator|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
11465992|NCT01589497|Active Comparator|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
11465993|NCT01589497|Active Comparator|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
11465994|NCT01589484|Experimental|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
11465995|NCT01589471|Experimental|Botox-A|Intra-rectal (or intra-colic) injection of 100 U of Botox-A
11465996|NCT01589458|Placebo Comparator|Non-fluoride toothpaste|
11465997|NCT01589458|Experimental|NaF/SiO2 toothpaste|
11465998|NCT01589458|Experimental|MFP/CaCO3 toothpaste|
11465999|NCT01589445|Experimental|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
11466000|NCT01589445|Experimental|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
11466001|NCT01589432|Experimental|ABT-639|
11466002|NCT01589432|Placebo Comparator|Placebo|
11466003|NCT01589432|Active Comparator|Lidocaine|
11466004|NCT01589419|Experimental|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
11466005|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
11466006|NCT01589393|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post injury to day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting day 6 post injury.
11466007|NCT01589393|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo 36-48 hours post traumatic injury until day 5, then standard of care (DVT prophylaxis with Enoxaparin) starting on Day 6.
11466008|NCT01589380|Placebo Comparator|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
11466009|NCT01589380|Active Comparator|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.
~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
11466010|NCT01589367|Experimental|Arm1_ Metformin|Letrozole with concurrent metformin
11466011|NCT01589367|Placebo Comparator|Arm 2_ Letrole alone|Letrozole with placebo
11466012|NCT01589354|Experimental|Interscalene brachial plexus block|
11466013|NCT01589354|Experimental|Intra-articular injection|
11466014|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
11466015|NCT01589328|Experimental|Early Palliative care|"The interventions consisted of the following:
~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
11466016|NCT01589328|No Intervention|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
11466017|NCT01589315|Experimental|FEAST|Active right unilateral focal ECT
11466018|NCT01589302|Experimental|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
11466019|NCT01589289|Experimental|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
11466020|NCT01589276||Emergency hernia repairs|
11466021|NCT01589276||Elective hernia repairs|
11466022|NCT01589263|Active Comparator|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
11466023|NCT01589263|Active Comparator|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
11466024|NCT01589237|Experimental|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
11466025|NCT01589224||Healthy people|
11466026|NCT01589211|Active Comparator|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
11466027|NCT01589211|Experimental|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
11466028|NCT01589211|Active Comparator|Standard cessation course|Cessation course in a group setting over 6 dates
11466029|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
11466030|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
11466031|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
11466032|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
11466033|NCT01589185|Experimental|Placebo|KBSA301-placebo
11466034|NCT01589172||Pediatric Brain Trauma Patients|
11466035|NCT01589159|Experimental|Experimental|
11466036|NCT01589146|No Intervention|short heparin|
11466037|NCT01589146|Experimental|extended heparin|
11466038|NCT01589120|No Intervention|control group|Verbal description of goals of care reflecting usual care
11466039|NCT01589120|Experimental|Video Arm|Video intervention group
11466040|NCT01589107|No Intervention|control group|usual care
11466041|NCT01589107|Experimental|Video Arm|
11466042|NCT01589094|Experimental|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
11466043|NCT01589081|Active Comparator|Female Smokers (Luteal Phase)|
11466044|NCT01589081|Active Comparator|Female Smokers (Follicular Phase)|
11466045|NCT01589068|Active Comparator|Male Smokers|
11466046|NCT01589068|Active Comparator|Female Smokers (Follicular Phase)|
11466047|NCT01589068|Active Comparator|Female Smokers (Luteal Phase)|
11466048|NCT01589055|Active Comparator|Male Smokers|
11466049|NCT01589055|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
11466050|NCT01589055|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
11466051|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
11466052|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
11466053|NCT01589029|Other|CANAKINUMAB (ILARIS®)|
11466054|NCT01589016||PUL (pregnancy of unknown location),|
11466055|NCT01589016||EP ( ectopic pregnancies P)|
11466056|NCT01589016||IUP-singleton intrauterine pregnancies|
11466057|NCT01589003|Active Comparator|Low GI group|Low Glycaemic index growing up milk
11466058|NCT01589003|Other|High GI group|Hi Glycaemic index growing up milk
11466059|NCT01588990|Experimental|Bevacizumab: Phase A and Phase B|The trial will consist of 2 phases of treatment. Phase A: Participants will receive bevacizumab 7.5 mg/kg intravenous (IV) infusion on Day 1 every 3 weeks in combination with XELOX (capecitabine and oxaliplatin) or bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluouracil) until first disease progression or occurrence of unmanageable toxicity. Phase B: Upon documented first disease progression, participants will continue receiving bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluouracil) until second disease progression or occurrence of unmanageable toxicity. Phase B treatment should commence within 4 weeks of the date of documented first disease progression.
11466060|NCT01588977||All-Inside TightRope technique|
11466061|NCT01588977||ACL reconstruction with TLS system|
11466062|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
11466063|NCT01588964|Experimental|HIPEC|Surgery plus HIPEC
11466064|NCT01588951|Experimental|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
11466065|NCT01588951|Experimental|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
11466066|NCT01588951|Experimental|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
11466067|NCT01588925|Experimental|Control group|Cochlear Implantation
11466068|NCT01588925|Active Comparator|Dexamethasone|Cochlear implantation using topical dexamethasone
11466069|NCT01588925|Active Comparator|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
11466070|NCT01588912|Experimental|Telbivudine-Tenofovir roadmap|
11466071|NCT01588912|Active Comparator|Entecavir|
11466072|NCT01588899|Experimental|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
11466073|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
11466074|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
11466075|NCT01588873|Active Comparator|Oral contraceptive pill|
11466076|NCT01588873|Active Comparator|Contraceptive ring|
11466077|NCT01588847|Experimental|Regional anesthesia|
11466078|NCT01588847|Active Comparator|General anesthesia|
11466079|NCT01588821|Experimental|Treatment Arm|Cabozantinib
11466080|NCT01588808|Active Comparator|Immobilization with protein (elderly)|Immobilization with twice-daily protein supplementation - in the elderly
11466081|NCT01588808|Placebo Comparator|Immobilization without protein (elderly)|Immobilization without twice-daily protein supplementation - in the elderly
11466082|NCT01588808|Active Comparator|Immobilization without protein (young)|Immobilization without twice-daily protein supplementation - in the young
11466083|NCT01588795|Experimental|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
11466084|NCT01588795|Active Comparator|TMNS|Patients are maintained on standardized anti-proteinuric medications
11466085|NCT01588782|Experimental|Abiraterone acetate|All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.
11466086|NCT01588769|Experimental|One arm|3 doses of ALECSAT cell based immunotherapy planned for all enrolled patients
11466087|NCT01588756|Experimental|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
11466088|NCT01588756|Experimental|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
11466089|NCT01588730|Experimental|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
11466090|NCT01588730|Active Comparator|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
11466091|NCT01588717|Experimental|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
11466092|NCT01588704|Experimental|Neoadjuvant Bevacizumab|Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
11466093|NCT01588691|Active Comparator|Low frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
11466094|NCT01588691|Active Comparator|High frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
11466095|NCT01588691|Placebo Comparator|No stimulation|Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
11466096|NCT01588678|Experimental|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.
~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.
~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
11466097|NCT01588665||Pregnant women and pregnant adolescents|
11466098|NCT01588639||Group 1|
11466099|NCT01588626|Experimental|AZD6140|single administration of 90 mg dose of AZD6140
11466100|NCT01588600|Active Comparator|Control|Breakfast without fiber
11466101|NCT01588600|Experimental|Low-dose|Low-dose of fiber in breakfast
11466102|NCT01588600|Experimental|High-dose|high dose of fiber added to breakfast
11466103|NCT01588587||DPP-IV inhibitors|
11466104|NCT01588574|Active Comparator|BOTOX (registered trade mark)|
11466105|NCT01588574|Experimental|MT10109|
11466106|NCT01588561|Active Comparator|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
11466107|NCT01588561|Placebo Comparator|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
11466108|NCT01588548|Active Comparator|AZD1208|
11466109|NCT01588535|Active Comparator|benzocaine solution|ear drops
11466110|NCT01588535|Placebo Comparator|Placebo|ear drops
11466279|NCT01587677||Confirmed bronchial carcinoma|
11466111|NCT01588522|Experimental|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
11466112|NCT01588509|Experimental|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
11466113|NCT01588509|Experimental|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
11466114|NCT01588496|Experimental|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
11466115|NCT01588496|Experimental|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
11466116|NCT01588496|Placebo Comparator|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
11466117|NCT01588483||giant cell arteritis|patients with biopsy and/or scintigraphy proven GCA
11466118|NCT01588470|Experimental|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
11466119|NCT01588457|Active Comparator|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
11466120|NCT01588457|Active Comparator|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
11466121|NCT01588457|Active Comparator|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
11466122|NCT01588457|Active Comparator|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
11466123|NCT01588457|Active Comparator|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
11466124|NCT01588457|Active Comparator|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
11466125|NCT01588444|Experimental|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
11466126|NCT01588444|Experimental|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
11466127|NCT01588431|Experimental|(TPE-A) Followed by Concurrent RT(XPE-A), surgery|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
11466128|NCT01588418|Experimental|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
11466129|NCT01588418|Experimental|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
11466130|NCT01588405|Experimental|UT-15C SR|
11466131|NCT01588392|Experimental|Short bouts of structured activity|
11466132|NCT01588392|Active Comparator|Unstructured physical activity|
11466133|NCT01588379|Experimental|Girls and mothers dance together|African-American girls AND their mom's will participate in the Afro-centric dance program together and also receive weekly newsletter that focuses on health related issues.
11466134|NCT01588379|Experimental|Girls, alone|African-American girls will participate in the Afro-centric dance program alone. Girls and mom's will receive weekly newsletter that focuses on health related issues
11466135|NCT01588379|Active Comparator|No dancing|African-American girls and their mom's will only receive weekly newsletter that focuses on health related issues.
11466136|NCT01588366|Placebo Comparator|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
11466137|NCT01588366|Experimental|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
11466138|NCT01588366|Experimental|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
11466139|NCT01588353|Experimental|AK160 0.58 mg|
11466140|NCT01588340|Active Comparator|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
11466141|NCT01588340|Active Comparator|Ultrasound exam|A noncontrast ultrasound examination
11466142|NCT01588327||Experimental|Patient taking FDA approved dose of dabigatran
11466143|NCT01588327||Control group|Person not taking any form of anticoagulation.
11466144|NCT01588314|Active Comparator|gabapentin|
11466145|NCT01588314|Placebo Comparator|placebo|
11466146|NCT01588301|Experimental|Group 1 : Further invitation by mail|Further invitation to attend for cervical cytology
11466147|NCT01588301|Experimental|Group 2 : Kit for Self-collected vaginal sample|Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
11466148|NCT01588301|No Intervention|Group 3: Control|
11466149|NCT01588288|Experimental|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
11466150|NCT01588275|Active Comparator|MRA therapy|During 12 months patients will be treated with a bibloc MRA (SomnoDent® MAS, SomnoMed Australia/Europe AG). The MRA will be customized by certified dentists or dental-specialists experienced in the field of dental sleep medicine.
11466151|NCT01588275|Active Comparator|CPAP therapy|"During 12 months patients will be treated with Continuous positive airway pressure (CPAP).Treatment with CPAP prevents upper airway collapse by pneumatically splinting the upper airway during sleep."
11466152|NCT01588262|Other|Stressmanagement counselling|
11466153|NCT01588262|No Intervention|Control|
11466154|NCT01588249|Experimental|Novel formulation of pasteurized maple cough syrup|
11466155|NCT01588249|Placebo Comparator|Placebo|
11466156|NCT01588236|Experimental|high dose KYG0395|Patients received high dose KYG0395 capsule (tid)
11466157|NCT01588236|Experimental|lower dose KYG0395|Patients received lower dose KYG0395 capsule (bid)
11466158|NCT01588236|Placebo Comparator|placebo|Patients received placebo (tid)
11466159|NCT01588223|Experimental|Lipids|
11466160|NCT01588210|Experimental|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
11466161|NCT01588210|Experimental|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
11466162|NCT01588210|Placebo Comparator|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
11466163|NCT01588197|Experimental|ACC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy.
~The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the rACC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
11466164|NCT01588197|Experimental|PFC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy. The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the PFC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
11466165|NCT01588184|Experimental|Breast Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
11466166|NCT01588184|Experimental|Ovarian Cancer or Peritoneal Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
11466167|NCT01588184|Experimental|Renal Cell Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
11466168|NCT01588184|Experimental|Colorectal Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
11466169|NCT01588184|Experimental|Non-Squamous, Non-Small Cell Lung Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
11466170|NCT01588184|Experimental|Glioblastoma Multiforme|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
11466171|NCT01588171|Active Comparator|Bemiparin|A new second generation Low Molecular Weight Heparin
11466172|NCT01588171|Active Comparator|Enoxaparin|A well known Low Molecular Weight Heparin
11466173|NCT01588171|No Intervention|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
11466174|NCT01588158|Active Comparator|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
11466175|NCT01588158|Active Comparator|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
11466176|NCT01588145|Experimental|HM61713|
11466177|NCT01588132|Experimental|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
11466178|NCT01588132|Experimental|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
11466179|NCT01588132|Experimental|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
11466180|NCT01588132|Experimental|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
11466181|NCT01588132|Experimental|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
11466182|NCT01588132|Experimental|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
11466183|NCT01588132|Experimental|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
11466184|NCT01588132|Experimental|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
11466185|NCT01588132|Experimental|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
11466186|NCT01588132|Experimental|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
11466187|NCT01588132|Experimental|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
11466188|NCT01588119||Dabigatran|in atrial fibrillation
11466189|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
11466190|NCT01588119||Apixaban|in atrial fibrillation and VTE
11466191|NCT01588119||Edoxaban|in atrial fibrillation and VTE
11466192|NCT01588106||Test group|patients using CONTOUR Next USB
11466193|NCT01588106||Control group|patients using standard CONTOUR
11466194|NCT01588093|Placebo Comparator|Saline|
11466195|NCT01588093|Active Comparator|Increlex|
11466196|NCT01588080|Placebo Comparator|SiPAP|
11466197|NCT01588080|Experimental|Neurally Adjusted Ventilatory Assist|
11466198|NCT01588067||Medical|Patients treated for PAD medically or with exercise therapy
11466199|NCT01588067||Endovascular|Patients with PAD treated with endovascular therapy
11466200|NCT01588067||Surgery|Patients with PAD treated with surgery
11466201|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
11466280|NCT01587677||Suspected tuberculosis but confirmed alternative diagnosis|
11466281|NCT01587664|Experimental|NewBreez ILP|Implantation of a NewBreez ILP
11466202|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
11466203|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
11466204|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
11466205|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
11466206|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
11466207|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
11466208|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
11466209|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
11466210|NCT01588015|Experimental|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
11466211|NCT01588015|Active Comparator|Arm II (control)|Patients undergo immune monitoring only.
11466212|NCT01588002|Active Comparator|A danoprevir+ritonavir|
11466213|NCT01588002|Active Comparator|B efavirenz|
11466214|NCT01588002|Experimental|C combination|
11466215|NCT01587989|Active Comparator|A Methotrexate|
11466216|NCT01587989|Experimental|B Methotrexate Placebo|
11466217|NCT01587963|Active Comparator|Ascorbic Acid|Ascorbic Acid
11466218|NCT01587963|Placebo Comparator|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
11466219|NCT01587950|Placebo Comparator|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
11466220|NCT01587950|Experimental|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
11466221|NCT01587950|Experimental|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
11466222|NCT01587937|Experimental|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
11466223|NCT01587937|No Intervention|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
11466224|NCT01587924|Experimental|0.5 mg GSK1278863|once daily
11466225|NCT01587924|Experimental|2 mg GSK1278863|once daily
11466226|NCT01587924|Experimental|5 mg GSK1278863|once daily
11466227|NCT01587924|Active Comparator|rhEPO|as required
11466228|NCT01587911|Active Comparator|Whey protein|Complete whey protein.
11466229|NCT01587911|Active Comparator|Whey-CMP|Complete whey protein missing the CMP (aka GMP) portion of the peptide.
11466230|NCT01587911|Placebo Comparator|Control|Placebo preload control, matched for energy.
11466231|NCT01587911|Active Comparator|CMP (casinomacropeptide)|Small peptide cleaved from complete whey protein.
11466232|NCT01587911|Active Comparator|MPI|Complete milk protein.
11466233|NCT01587911|Active Comparator|CPI (casein)|Preload containing casein.
11466234|NCT01587898|Experimental|0.5mg GSK1278863|Once daily
11466235|NCT01587898|Experimental|2mg GSK1278863|Once daily
11466236|NCT01587898|Experimental|5mg GSK1278863|Once daily
11466237|NCT01587898|Experimental|Placebo|Once daily
11466238|NCT01587885|Experimental|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
11466239|NCT01587885|Active Comparator|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
11466240|NCT01587872|Experimental|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
11466241|NCT01587859||Cohort|Patients submitted to laparoscopic surgery for Type II-IV hiatus hernia
11466242|NCT01587846|Experimental|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
11466243|NCT01587846|Experimental|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
11466244|NCT01587846|Experimental|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
11466245|NCT01587846|Experimental|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
11466246|NCT01587833||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
11466247|NCT01587833||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
11466276|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
11466277|NCT01587677||Confirmed tuberculosis|
11466248|NCT01587820|Experimental|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
11466249|NCT01587820|Active Comparator|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
11466250|NCT01587807|Experimental|Cohort 1|single inhaled dose of GSK1995057 (dose 1) or placebo
11466251|NCT01587807|Experimental|Cohort 2|single inhaled dose of GSK1995057 (dose 2) or placebo
11466252|NCT01587807|Experimental|Cohort 3|single inhaled dose of GSK1995057 (dose 3) or placebo
11466253|NCT01587807|Experimental|Cohort 4|single inhaled dose of GSK1995057 (dose 4) or placebo
11466254|NCT01587807|Experimental|Cohort 5|single inhaled dose GSK1995057 (dose 4) with bronchoalveolar lavage (BAL)sampling procedure conducted approximately 30 minutes post GSK1995057 dose
11466255|NCT01587807|Experimental|Cohort 6|high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure.
11466256|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
11466257|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):
~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.
~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
11466258|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
11466259|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
11466260|NCT01587755|Other|Topical Treatment Optimizing Program|Optimized care
11466261|NCT01587755|Other|non-Topical Treatment Optimizing Program|Standard care
11466262|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
11466263|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
11466264|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
11466265|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
11466266|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
11466267|NCT01587729||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
11466268|NCT01587729||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
11466269|NCT01587716|Experimental|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
11466270|NCT01587716|Experimental|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
11466271|NCT01587703|Experimental|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
11466272|NCT01587703|Experimental|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
11466273|NCT01587703|Experimental|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
11466274|NCT01587690||Healthy subjects|Self-explanatory
11466275|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
11466282|NCT01587651|Experimental|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
11466283|NCT01587651|Active Comparator|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
11466284|NCT01587651|Experimental|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
11466285|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
11466286|NCT01587625|Experimental|High dose of oxytocin infusion|Oxytocin: High dose infusion
11466287|NCT01587625|Active Comparator|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
11466288|NCT01587599|Active Comparator|Pharmaceutical care|
11466289|NCT01587599|Placebo Comparator|Standard care|
11466290|NCT01587586|Active Comparator|PEGASYS 180 µg Q1W + ribavirin* for 48 weeks|Pegasys 180 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses(48)
11466291|NCT01587586|Experimental|P1101 180 µg Q1W + ribavirin* for 48 weeks|P1101 180 µg Q1W(subcutaneous injection)with Ribavirin, multiple doses
11466292|NCT01587586|Experimental|P1101 270 µg Q1W + ribavirin* for 48 weeks|P1101 270 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses
11466293|NCT01587586|Experimental|P1101 450 µg Q2W + ribavirin* for 48 weeks|P1101 450 µg Q2W(subcutaneous injection)+Ribavirin, multiple doses
11466294|NCT01587573||oral lesions|oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
11466295|NCT01587560|Active Comparator|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
11466296|NCT01587560|Active Comparator|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
11466297|NCT01587547||IVF and ICSI patients|Subjects undergoing IVF or ICSI treatment with a maximum of 2 embryos transferred
11466298|NCT01587534|Experimental|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
11466299|NCT01587534|No Intervention|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
11466300|NCT01587508|Active Comparator|meloxicam - Movatec®|
11466301|NCT01587508|Active Comparator|cyclobenzaprine - Miosan®,|
11466302|NCT01587508|Experimental|meloxicam/cyclobenzaprine hydrochloride|
11466303|NCT01587495|Experimental|Ertapenem|Women diagnosed with postpartum endometritis
11466304|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.
~Only the treated patients were included in this cohort."
11466305|NCT01587469||HIV-infected and -uninfected individuals|HIV-infected and -uninfected individuals with suspected TB infection
11466306|NCT01587443||Hemodialysis|
11466307|NCT01587443||Peritoneal dialysis|
11466308|NCT01587430|Active Comparator|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
11466309|NCT01587430|Active Comparator|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
11466310|NCT01587417|Experimental|BI 187004 CL|1 single dose per subject as oral solution
11466311|NCT01587417|Placebo Comparator|Placebo to BI 187004 CL|1 single dose per subject as oral solution
11466312|NCT01587404|Experimental|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
11466313|NCT01587404|Experimental|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
11466314|NCT01587391|Experimental|BI 163538 XX|1 single dose per subject as oral solution
11466315|NCT01587391|Placebo Comparator|Placebo to BI 163538 XX|1 single dose per subject as oral solution
11466316|NCT01587378|Experimental|metformin|
11466317|NCT01587378|Placebo Comparator|placebo|
11466318|NCT01587365|Experimental|Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo|BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
11466319|NCT01587365|Experimental|Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo|BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
11466320|NCT01587365|Experimental|Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
11466321|NCT01587365|Experimental|Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
11466322|NCT01587365|Experimental|Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
11466323|NCT01587365|Experimental|Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo|BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
11466324|NCT01587365|Experimental|Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
11466325|NCT01587365|Experimental|Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
11466326|NCT01587352|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11466327|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
11466328|NCT01587326|Experimental|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
11466329|NCT01587313|Experimental|Group 1|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
11466330|NCT01587313|Experimental|Group 2|ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
11466331|NCT01587313|Experimental|Group 3|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
11466332|NCT01587313|Active Comparator|Group 4|ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
11466333|NCT01587287||Corneal power measurement|All recruited volunteers in present study, that underwent corneal power measurement with 8 different instruments
11466334|NCT01587274|Active Comparator|Opioid|Naproxen + opioid
11466335|NCT01587274|Active Comparator|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
11466336|NCT01587274|Active Comparator|Naproxen alone|Naproxen + placebo
11466337|NCT01587261|Placebo Comparator|Placebo|Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
11466338|NCT01587261|Experimental|Vitamin C|Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
11466339|NCT01587248|Active Comparator|Electrocautery|Raising of the flaps with electrocautery
11466340|NCT01587248|Experimental|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
11466341|NCT01587235|Experimental|Vytorin|
11466342|NCT01587235|Active Comparator|Other Statin|
11466343|NCT01587222|Experimental|Albumin, Midodrine, Octreotide|
11466344|NCT01587209||Divers with decompression sickness|The sole group under study is SCUBA divers who have sustained decompression sickness
11466345|NCT01587196|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
11466346|NCT01587183|Other|Educational materials control|Enhanced usual care
11466347|NCT01587183|Active Comparator|Group running style B|Basic running instruction using group based training.
11466348|NCT01587183|Experimental|Group running style A|Form focused running instruction using group based training.
11466349|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
11466350|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (>1year ago).
11466351|NCT01587157|Experimental|capnography|
11466352|NCT01587144|Placebo Comparator|TMZ + Radiation + Placebo|Subjects will be randomly assigned to Lucanthone or Placebo arm in ratio of 1:1. The treatment period will be in two phases: an initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days). Lucanthone/placebo will be given as an adjunct to TMZ in both phases.
11466353|NCT01587144|Active Comparator|Lucanthone + TMZ + Radiation|Subjects will be randomly assigned to Lucanthone or Placebo arm in ratio of 1:1. The treatment period will be in two phases: an initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days). Lucanthone/placebo will be given as an adjunct to TMZ in both phases.
11466354|NCT01587131|Experimental|Group 1- DNA prime DNA boost|0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
11466355|NCT01587131|Experimental|Group 2 - DNA prime Seasonal Vaccine boost|0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
11466356|NCT01587131|Placebo Comparator|Group 3 - sWFI prime Seasonal Vaccine boost|100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
11466357|NCT01587118|Experimental|antidepressant plus asenapine|adjunctive asenapine
11466358|NCT01587105|No Intervention|Control|Usual Care Group
11466359|NCT01587105|Experimental|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
11466360|NCT01587092|Placebo Comparator|Usual Working Condition Group|Participants assigned to the usual working condition control group will continue to work in their usual environment and accustomed manner. The control group participants will have access to the Workstations at the completion of study.
11466361|NCT01587092|Active Comparator|WorkStation Intervention Group|Participants will be asked to walk for up to 1.5 hours per day on the treadmill. This will be split into two 45 minute sessions per day. Behavioral support will focus on adherence to frequency (attending scheduled sessions). Participants self-select speed of walking and time (they have up to 45 minutes allotted, but may choose less as they like).
11466362|NCT01587079|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
11466363|NCT01587079|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
11466364|NCT01587079|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
11466365|NCT01587079|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
11466366|NCT01587079|Experimental|PT003 (Dose 5)|PT003 MDI Dose 5
11466367|NCT01587079|Experimental|PT001|PT001 MDI
11466368|NCT01587079|Experimental|PT005|PT005 MDI
11466369|NCT01587079|Active Comparator|Spiriva® Handihaler®|Tiotropium Bromide
11466370|NCT01587066|Active Comparator|Quetiapine fumarate|
11466371|NCT01587066|Active Comparator|Divalproex sodium|
11466372|NCT01587053||AVK|patient with AVK treatment
11466373|NCT01587040|Experimental|SAR245408: Monotherapy|Participants received SAR245408 400 milligrams (mg) once daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days).
11466374|NCT01587040|Experimental|SAR245408: Combination Regimen|Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
11466375|NCT01587040|Experimental|SAR245409: Monotherapy|Participants received SAR245409 50 mg twice daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days).
11466423|NCT01586728|Other|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
11466424|NCT01586715|Experimental|Autologous Stem Cells|
11466516|NCT01586091|Active Comparator|Levocetirizin|Levocetirizin 5mg at time 0 and placebo per os at 12 hours
11466376|NCT01587040|Experimental|SAR245409: Combination Regimen|Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
11466377|NCT01587027|Active Comparator|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
11466378|NCT01587027|Active Comparator|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
11466379|NCT01587001|Active Comparator|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
11466380|NCT01587001|Placebo Comparator|Matching Placebo|oral placebo three times daily for 8 weeks
11466381|NCT01586988|Experimental|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
11466382|NCT01586988|No Intervention|Control|Standard care.
11466383|NCT01586975|Active Comparator|Clopidogrel 75 mg|Clopidogrel 75 mg daily
11466384|NCT01586975|Active Comparator|Aspirin 81 mg|open-label Aspirin 81 mg daily
11466385|NCT01586975|Active Comparator|Aspirin > 300mg|open-label Aspirin over 300 mg daily
11466386|NCT01586962|Experimental|Upper Respiratory Infections|
11466387|NCT01586949|Experimental|Treatment|Intervention: Daily Challenge
11466388|NCT01586949|No Intervention|Control|Weekly Well-being, an email-based health information delivery service.
11466389|NCT01586936||eptacog alpha users|
11466390|NCT01586923|Active Comparator|Short-storage RBC|RBC transfusion using packed RBCs stored for 10 days or less.
11466391|NCT01586923|Active Comparator|Prolonged-storage RBC|RBC transfusion using packed RBCs stored for 25 days or more.
11466392|NCT01586910|Experimental|Medtronic CoreValve® System TAVI|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
11466393|NCT01586910|Active Comparator|SAVR|Surgical Aortic Valve Replacement (SAVR)
11466394|NCT01586897|Experimental|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
11466395|NCT01586897|Active Comparator|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
11466396|NCT01586884|Experimental|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.
~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
11466397|NCT01586858||RAVE subjects|
11466398|NCT01586845|Experimental|Voclosporin|Voclosporin
11466399|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
11466400|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
11466401|NCT01586819|Active Comparator|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
11466402|NCT01586819|Active Comparator|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.
~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
11466403|NCT01586806|Placebo Comparator|Control|
11466404|NCT01586806|Active Comparator|Dexamethasone 1 mg|
11466405|NCT01586806|Active Comparator|Dexamethasone 4 mg|
11466406|NCT01586793|Experimental|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
11466407|NCT01586793|Experimental|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
11466408|NCT01586780|Experimental|Reference meal|
11466409|NCT01586780|Experimental|Whey protein|
11466410|NCT01586780|Experimental|Whey + 5 amino acids|
11466411|NCT01586780|Experimental|Whey + 6 amino acids|
11466412|NCT01586780|Experimental|Soy protein drink|
11466413|NCT01586780|Experimental|Soy + 5 amino acids|
11466414|NCT01586780|Experimental|Soy + 6 amino acids|
11466415|NCT01586767|Active Comparator|Proton beam therapy|Subjects treated at Massachusetts General Hospital with proton beam therapy
11466416|NCT01586767|Active Comparator|IMRT|Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital
11466417|NCT01586754||With Metabolic Syndrome|
11466418|NCT01586754||Without Metabolic Syndrome|
11466419|NCT01586741|Active Comparator|Polypropylene mesh|Reconstruction of the abdominal wall diastasis with insertion of a polypropylene mesh on 30 patients.
11466420|NCT01586741|Active Comparator|quill suture|Reconstruction of the abdominal wall diastasis with double row absorbable suture ( Quill Self-retaining system) on 30 patients.
11466421|NCT01586741|No Intervention|conservative treatment|Regular abdominal exercises workout for three months for 30 patients.
11466422|NCT01586728|Other|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
11466614|NCT01585493|Experimental|CHANGE|
11466425|NCT01586702|No Intervention|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
11466426|NCT01586702|Active Comparator|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
11466427|NCT01586689|Experimental|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
11466428|NCT01586689|Experimental|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
11466429|NCT01586689|Experimental|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
11466430|NCT01586676|Experimental|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
11466431|NCT01586676|Active Comparator|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
11466432|NCT01586663|Experimental|Experimental Group|Splint group
11466433|NCT01586663|Active Comparator|Control Group|Drug treatment
11466434|NCT01586650|Experimental|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
11466435|NCT01586650|Placebo Comparator|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
11466436|NCT01586637|Experimental|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
11466437|NCT01586637|Experimental|Walking|The group walked twice a week during one hour.
11466438|NCT01586611|Active Comparator|Gemcitabine|Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
11466439|NCT01586611|Experimental|FOLFOX|Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
11466440|NCT01586598|No Intervention|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
11466441|NCT01586598|Experimental|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
11466442|NCT01586585||post cardiac surgery patients|
11466443|NCT01586572|Experimental|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
11466444|NCT01586572|Experimental|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
11466445|NCT01586572|Experimental|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
11466446|NCT01586572|Experimental|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
11466447|NCT01586559||Control group|Nulliparous women
11466448|NCT01586559||Diastasis|Patients after rectus sheath plication due to diastasis
11466449|NCT01586546|Experimental|Face-to-Face MBM Skills Group|
11466450|NCT01586546|Experimental|Online MBM Skills Group|
11466451|NCT01586546|Other|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
11466452|NCT01586546|Other|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
11466453|NCT01586533|Experimental|Zoenasa-1:4|
11466454|NCT01586533|Active Comparator|Mesalamine Enema|
11466455|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
11466456|NCT01586520||Disease negative|No evidence of disease
11466457|NCT01586507|Experimental|Group 1|
11466458|NCT01586507|Experimental|Group 2|
11466459|NCT01586494|Experimental|Group 1|
11466460|NCT01586494|Experimental|Group 2|
11466461|NCT01586481|Active Comparator|barouk|
11466462|NCT01586481|Experimental|sanidiab|
11466463|NCT01586468|Placebo Comparator|NaCl Solution|
11466464|NCT01586468|Experimental|WF10 0.5 ml/kg BW|
11466465|NCT01586455|Experimental|Group A|related cord blood with ≥3/6 HLA match to the patient and related HPDSC
11466466|NCT01586455|Experimental|Group B|unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
11466467|NCT01586455|Experimental|Group C|unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
11466468|NCT01586455|Experimental|Group D|double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
11466469|NCT01586442|Active Comparator|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
11466470|NCT01586442|Experimental|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
11466471|NCT01586429||Epidural|
11466472|NCT01586429||Femoral catheter|
11466473|NCT01586416|Experimental|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
11466474|NCT01586403|Experimental|Dose 1|Subjects in cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight
11466475|NCT01586403|Experimental|Dose 2|cohort 2 will receive 7.5 x 106 TIL 1383I TCR transduced T cells per kg body weight.
11466476|NCT01586403|Experimental|Dose 3|Subjects in cohort 3 will receive 2.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
11466515|NCT01586091|Placebo Comparator|Placebo|Placebo per os at time 0 hours + placebo per os at 12 hours.
11466477|NCT01586403|Experimental|Dose 4|Subjects will then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
11466478|NCT01586390|Experimental|MOK|Adjustable and removable brace made out of Softcast material
11466479|NCT01586390|Active Comparator|WRAP|Softcast ankle cast
11466480|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
11466481|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
11466482|NCT01586364|Experimental|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
11466483|NCT01586351||Patch and ACP Treatment|Patents who get an patch augmentation and ACP injection following an arthroscopic repair of the rotator cuff.
11466484|NCT01586338|Experimental|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
11466485|NCT01586325|Experimental|Panel 1|Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
11466486|NCT01586325|Experimental|Panel 2|Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
11466487|NCT01586325|Experimental|Panel 3|Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.
11466488|NCT01586312|Experimental|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
11466489|NCT01586312|Active Comparator|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
11466490|NCT01586299|Experimental|ibuprofen|
11466491|NCT01586299|Active Comparator|acetaminophen|
11466492|NCT01586286|Placebo Comparator|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
11466493|NCT01586286|Active Comparator|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
11466494|NCT01586273|Experimental|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
11466495|NCT01586260|Experimental|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
11466496|NCT01586247|Experimental|Synbiotic|8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07
11466497|NCT01586247|Experimental|Placebo|8g/day maltodextrin
11466498|NCT01586247|Experimental|Prebiotic|8g/day galacto-oligosaccharides (GOS)
11466499|NCT01586247|Experimental|Probiotic|109 CFU/day B. lactis BI07
11466500|NCT01586234|Experimental|DSAEK with graft shaping and smoothing|
11466501|NCT01586234|Active Comparator|Standard DSAEK|
11466502|NCT01586221|Other|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
11466503|NCT01586208|Active Comparator|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
11466504|NCT01586208|Active Comparator|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
11466505|NCT01586195|Experimental|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
11466506|NCT01586182|Experimental|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
11466507|NCT01586156|Active Comparator|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
11466508|NCT01586156|Placebo Comparator|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
11466509|NCT01586143|Experimental|transbuccal paracetamol 125 mg|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
11466510|NCT01586143|Placebo Comparator|placebo|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
11466511|NCT01586130|Other|isokinetic exercises in eccentric mode|
11466512|NCT01586130|Other|isokinetic exercises in concentric mode|
11466513|NCT01586117|Experimental|Amifostine|intrarectal Amifostine assign to the Amifostine arm
11466514|NCT01586104|Experimental|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
11466517|NCT01586091|Active Comparator|Fexofenadine|Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours
11466518|NCT01586065|Experimental|CGM|
11466519|NCT01586065|Other|Control|Fingerstick BGs only, no CGM
11466520|NCT01586052|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
11466521|NCT01586039|Active Comparator|Compact Fluorescent Light|
11466522|NCT01586039|Experimental|Blue-depleted LED light|
11466523|NCT01586026||Group A|Maintenance flushes at days 1-28
11466524|NCT01586026||Group B|Maintenance flushes at days 29-56
11466525|NCT01586026||Group C|Maintenance flushes at days 57+
11466526|NCT01586013|Experimental|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS <50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
11466527|NCT01586000|Experimental|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
11466528|NCT01586000|Experimental|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
11466529|NCT01586000|Experimental|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
11466530|NCT01585987|Experimental|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
11466531|NCT01585987|Other|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
11466532|NCT01585974||Group 1|
11466533|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
11466534|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
11466535|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
11466536|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
11466537|NCT01585935|Experimental|Smoflipid|SMOFLIPID will be used for parenteral lipid supply
11466538|NCT01585935|Active Comparator|Intralipid|INTRALIPID will be used for parenteral lipid supply
11466539|NCT01585922|Experimental|NPPV|Use the NPPV to treat moderate ARDS
11466540|NCT01585922|Active Comparator|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
11466541|NCT01585909|Other|Septic Shock|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
11466542|NCT01585909|Other|SIRS|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
11466543|NCT01585909|Other|healthy/controls|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
11466544|NCT01585896|Experimental|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
11466545|NCT01585883|Experimental|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session.
11466546|NCT01585883|Active Comparator|Standard of care|Patients in this condition will receive usual care as decided by their oncology clinic team or physician.
11466547|NCT01585870|Experimental|Sorafenib + Eribulin|
11466548|NCT01585857|Experimental|Group 1|2 x 10E6 ASC intra-articular injection (5 ml)
11466549|NCT01585857|Experimental|Group 2|10 x 10E6 ASC intra-articular injection (5 ml)
11466550|NCT01585857|Experimental|Group 3|50 x 10E6 ASC intra-articular injection (5 ml)
11466551|NCT01585844||Women with sleep apnea|
11466552|NCT01585844||Women without sleep apnea|
11466553|NCT01585831|Experimental|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
11466554|NCT01585831|Placebo Comparator|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
11466555|NCT01585818|Active Comparator|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
11466556|NCT01585818|Experimental|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
11466557|NCT01585805|Experimental|Arm A (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib PO BID on days 1-12 or 1-21. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 30 minutes on days 3 and 10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11466558|NCT01585805|Active Comparator|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as patients in arm A. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11466559|NCT01585805|Experimental|Arm C (veliparib)|Patients receive veliparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11466560|NCT01585792|Experimental|TAK-875 25 mg|
11466561|NCT01585792|Experimental|TAK-875 50 mg|
11466562|NCT01585792|Active Comparator|Glimepiride|
11466563|NCT01585792|Placebo Comparator|Placebo|
11466564|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
11466565|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
11466566|NCT01585766|Experimental|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
11466567|NCT01585766|Experimental|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
11466568|NCT01585766|Experimental|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
11466569|NCT01585766|Experimental|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
11466570|NCT01585766|Experimental|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
11466571|NCT01585766|Placebo Comparator|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
11466572|NCT01585753||Arm 1|NRTI and PI
11466573|NCT01585753||Arm 2|Maraviroc + PI
11466574|NCT01585753||Arm 3|maraviroc + NRTI
11466575|NCT01585740|Active Comparator|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
11466576|NCT01585740|Active Comparator|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
11466577|NCT01585727|Experimental|TME with neuromonitoring|Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
11466578|NCT01585727|Active Comparator|TME without neuromontoring|Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
11466579|NCT01585688|Experimental|hLL1-DOX|
11466580|NCT01585675||Diagnosis/treatment of lung cancer|Specimen Banking
11466581|NCT01585662|Experimental|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
11466582|NCT01585662|Experimental|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
11466583|NCT01585649|Experimental|XM22, 100 μg/kg BW|
11466584|NCT01585636|Experimental|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466585|NCT01585636|Experimental|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466586|NCT01585636|Experimental|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466587|NCT01585636|Experimental|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466588|NCT01585636|Experimental|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466589|NCT01585636|Experimental|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466590|NCT01585636|Experimental|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
11466591|NCT01585636|Experimental|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
11466592|NCT01585623|Experimental|Segment 1|two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
11466593|NCT01585623|Experimental|Segment 2|SAR302503 500 mg once daily without food in 28-day per cycle
11466594|NCT01585610|Experimental|DVD Program|
11466595|NCT01585610|Active Comparator|Standard Care Printed Materials|
11466596|NCT01585597|Experimental|Mild Hypothermia|Reduction of body temperature to 34 degrees centigrade. This will be accomplished using the Zoll Coolguard .
11466597|NCT01585584|Experimental|Boceprevir|
11466598|NCT01585571||Control|50 individuals of typical development with no known neuromuscular issues.
11466599|NCT01585571||Adults with CP|50 Individuals with a pediatric diagnosis of spastic, hemiplegic, diplegic or quadriplegic cerebral palsy.
11466600|NCT01585558|Experimental|Treatment Group 1|
11466601|NCT01585558|Experimental|Treatment Group 2|
11466602|NCT01585558|Placebo Comparator|Treatment Group 3|
11466603|NCT01585545||patients with NSCLC|
11466604|NCT01585532||TB suspects with alternative final diagnosis|
11466605|NCT01585532||Confirmed tuberculosis patients|
11466606|NCT01585519|No Intervention|(Group 1) Low Apple Diet|
11466607|NCT01585519|Experimental|(Group 2) 2 High Apples|
11466608|NCT01585519|Experimental|(Group 3) 2 Low Apples|
11466609|NCT01585519|Experimental|(Group 4) 2 x 4.4g apple granules|
11466610|NCT01585519|Experimental|(Group 5) 2 x Apple Extract Capsules|
11466611|NCT01585506||Questionnaire responders|
11466612|NCT01585493|Active Comparator|Treatment as usual|Treatment as usual
11466613|NCT01585493|Active Comparator|Care coordinator|
11466615|NCT01585480|Experimental|weight gain prevention intervention|
11466616|NCT01585480|No Intervention|No treatment comparison group|
11466617|NCT01585441|Experimental|Finasteride 5 mg|Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
11466618|NCT01585441|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.
11466619|NCT01585428|Experimental|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
11466620|NCT01585428|Experimental|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
11466621|NCT01585415|Experimental|Single Arm|Two weeks prior to the start of the preparative regimen, patients will begin taking vemurafenib. Patients will then receive lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine, followed by young TIL and high dose aldesleukin
11466622|NCT01585402|Experimental|Etidronate|20 mg/kg oral 14 days on / 10 weeks off study drug
11466623|NCT01585350|Experimental|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
11466624|NCT01585350|Experimental|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.
~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
11466625|NCT01585337||patients with lumbar fusion|
11466626|NCT01585324|Experimental|Single Arm|
11466627|NCT01585311||Subarachnoid Hemorrhage patients|SAH patients with hourly eMR values of Heart Rate
11466628|NCT01585298|Experimental|Fingolimod|Fingolimod 0.5 mg by mouth once daily for 7 days.
11466629|NCT01585285|Experimental|LIMA to SVG Bridge|Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
11466630|NCT01585285|Active Comparator|Conventional CABG|Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
11466631|NCT01585272|Experimental|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
11466632|NCT01585259|Active Comparator|Anfibatide|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
11466633|NCT01585259|Placebo Comparator|Placebo|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
11466634|NCT01585246|Other|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
11466635|NCT01585246|Active Comparator|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
11466636|NCT01585246|Placebo Comparator|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
11466637|NCT01585233|Experimental|Cohort 1|ASKP1240 lowest dose
11466638|NCT01585233|Experimental|Cohort 2|ASKP1240 low dose
11466639|NCT01585233|Experimental|Cohort 3|ASKP1240 high dose
11466640|NCT01585233|Experimental|Cohort 4|ASKP1240 highest dose
11466641|NCT01585233|Placebo Comparator|Placebo|
11466642|NCT01585220|Experimental|Neuramis|
11466643|NCT01585220|Active Comparator|Restylane®|
11466644|NCT01585207|Experimental|Vigabatrin|3 tablets, bid for 8 weeks
11466645|NCT01585194|Experimental|Treatment (nivolumab, ipilimumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
11466646|NCT01585181|Placebo Comparator|Placebo|
11466647|NCT01585181|Experimental|PXVX0200|
11466648|NCT01585168|Experimental|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
11466649|NCT01585168|Placebo Comparator|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
11466650|NCT01585168|Experimental|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
11466651|NCT01585168|Placebo Comparator|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
11466652|NCT01585155|Experimental|TA-650|
11466653|NCT01585142|Experimental|BabyNes system formula|
11466654|NCT01585129|Experimental|Postpartum Antibiotics|Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
11466655|NCT01585129|Placebo Comparator|No postpartum antibiotics|No further postpartum antibiotics
11466656|NCT01585103|Experimental|Cytosponge/ brushing|
11466657|NCT01585090|Experimental|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
11466658|NCT01585090|Experimental|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
11466659|NCT01585090|No Intervention|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
11466660|NCT01585077|Experimental|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (<1:20) against native protein of P. vivax.
11466661|NCT01585077|Experimental|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
11466662|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
11466663|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
11466664|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
11466665|NCT01585051|Active Comparator|vitamin D|Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
11466666|NCT01585051|Placebo Comparator|placebo|administration of 0.9 % NaCl as a placebo
11466667|NCT01585038|Active Comparator|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
11466668|NCT01585038|Active Comparator|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
11466669|NCT01585025|Experimental|Primary BAD|Defined as SeHCAT <10% without other causes such as Crohn's disease and/or ileal resection
11466670|NCT01585025|Experimental|Secondary BAD|With Crohn's disease or ileal resection
11466671|NCT01585025|Experimental|Idiopathic Diarrhoea Controls|Chronic diarrhoea with SeHCAT >15% and no Crohn's or ileal resection
11466672|NCT01585012|Experimental|Cervical cap|Collection condom with cervical cap inserted
11466673|NCT01584999|Active Comparator|Fresh not-leukocyte-reduced RBCs|
11466674|NCT01584999|Active Comparator|Fresh RBCs leukocyte-reduced|
11466675|NCT01584999|Active Comparator|RBCs with storage longer than 15 days|
11466676|NCT01584986|Active Comparator|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
11466677|NCT01584986|No Intervention|Control|Control patients were treated with the conventional therapy.
11466678|NCT01584973||cruciate ligament group|
11466679|NCT01584973||control group|
11466680|NCT01584960|Experimental|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
11466681|NCT01584947|Placebo Comparator|Placebo lozenge|The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
11466682|NCT01584947|Active Comparator|Bupivacaine lozenge|The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.
11466683|NCT01584934|Experimental|Sodium oxybate|Patient group receives sodium oxybate as treatment.
11466684|NCT01584934|Placebo Comparator|Placebo|Patient group receives placebo as treatment.
11466685|NCT01584921|Placebo Comparator|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
11466686|NCT01584921|Active Comparator|Low dose Erythropoietin|
11466687|NCT01584921|Active Comparator|High dose Eryhropoietin|
11466688|NCT01584895|Experimental|Rehab|Patients randomized into early cardiac rehabilitation
11466689|NCT01584895|No Intervention|Control|No cardiac rehabilitation until after 6 week post assessment.
11466690|NCT01584882|No Intervention|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
11466691|NCT01584882|Experimental|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'[Computer Assisted Tobacco Intervention] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
11466692|NCT01584869|Experimental|capsule endoscopy|
11466693|NCT01584843|No Intervention|Non-treatment (10-20 PD)|Receive no treatment on Week 0
11466694|NCT01584843|Active Comparator|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
11466695|NCT01584843|Active Comparator|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
11466696|NCT01584843|No Intervention|Non-treatment (20-50 PD)|Receive no treatment on Week 0
11466697|NCT01584843|Active Comparator|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
11466698|NCT01584843|Active Comparator|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
11466699|NCT01584830|Experimental|Arm 1|
11466700|NCT01584830|Placebo Comparator|Arm 2|
11466701|NCT01584817|No Intervention|normal education|patients in this arm was educated about bowel preparation on the day of reservation by nurse for 15 minutes and meanwhile a booklet was also sent to them.
11466800|NCT01584154|Experimental|cryoablation|
11466702|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
11466703|NCT01584804|Active Comparator|Monotherapy|Monotherapy with Su-Huang antitussive capsule
11466704|NCT01584804|Placebo Comparator|Sugar pill|Monotherapy with placebo
11466705|NCT01584791|Experimental|clopidogrel napadisilate + aspirin|
11466706|NCT01584791|Active Comparator|clopidogrel bisulfate + aspirin|
11466707|NCT01584778||Behçet patients|
11466708|NCT01584778||Healthy controls|
11466709|NCT01584778||Allergic rhinitis (diseased) controls|
11466710|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
11466711|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
11466712|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
11466713|NCT01584739|Experimental|AZD8683|
11466714|NCT01584739|Placebo Comparator|Placebo to AZD8683|
11466715|NCT01584726|Other|magnesium sulfate arm|magnesium sulfate with standard therapy
11466716|NCT01584726|No Intervention|placebo arm|placebo with standard therapy
11466717|NCT01584713|Experimental|Adipose derived Stem Cells|
11466718|NCT01584700|Other|Renal Artery Denervation|Ontervention
11466719|NCT01584687|Experimental|Omalizumab|All patients will receive omalizumab.
11466720|NCT01584674|Experimental|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
11466721|NCT01584674|No Intervention|Control (untreated hemiface)|No treatment will be administered on the control hemiface
11466722|NCT01584661||Compliance with nutritional care|"The Inclusion criteria comprise patients who were treated nutritionally with food enrichment supplements during their hospitalization in Bait Balev and were discharged to their homes with dietary recommendations. Participants who are willing to participate will sign an informed consent form. For patients with cognitive impairment or dementia, as reported in their medical records, their formal primary caregiver or proxy will sign the informed consent form."
11466723|NCT01584648|Experimental|Combination|trametinib and dabrafenib combination
11466724|NCT01584648|Active Comparator|Dabrafenib monotherapy|trametinib placebo and dabrafenib
11466725|NCT01584635|Experimental|Peroral Endoscopic Myotomy (POEM)|Peroral Endoscopic Myotomy- a less invasive treatment for patients with Achalasia
11466726|NCT01584609|Experimental|Penumbra System with Separator 3D|
11466727|NCT01584609|Active Comparator|Penumbra System alone|
11466728|NCT01584596|Experimental|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
11466729|NCT01584596|Active Comparator|Adapted Diet|Adapted dietary guidelines sessions
11466730|NCT01584583||blood pressure monitor|Cuff circumference:22cm-36cm
11466731|NCT01584583||stethoscopy|Cuff circumference: 22cm-36cm
11466732|NCT01584570|Active Comparator|Control|fentanyl 1 mcg/kg before induction
11466733|NCT01584570|Experimental|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
11466734|NCT01584570|Experimental|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
11466735|NCT01584557|Active Comparator|Tolvaptan, Samsca|Tolvaptan, Samsca, uncoated tablet, 30 mg, once per day, up to 7 days.
11466736|NCT01584557|Placebo Comparator|sugar pill|placebo, sugar pill
11466737|NCT01584544|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
11466738|NCT01584544|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11466739|NCT01584544|Experimental|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11466740|NCT01584544|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11466741|NCT01584544|Experimental|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11466742|NCT01584531|Experimental|21-Day Regimen|560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle
11466743|NCT01584518|Active Comparator|CHF peptide|Diuresis based on CHF-P
11466744|NCT01584518|Active Comparator|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
11466745|NCT01584505|Experimental|CHF5993 HFA pMDI dose 1, BID|CHF5993 HFA pMDI dose 1, BID
11466746|NCT01584505|Experimental|CHF5993 HFA pMDI dose 2, BID|CHF5993 HFA pMDI dose 2, BID
11466747|NCT01584505|Active Comparator|CHF1535 HFA pMDI + Placebo|CHF1535 HFA pMDI BID plus placebo BID
11466748|NCT01584492|Experimental|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
11466749|NCT01584492|Experimental|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
11466750|NCT01584492|Experimental|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
11466751|NCT01584492|Active Comparator|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
11466752|NCT01584492|Placebo Comparator|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
11466753|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk
~~1200 subjects
~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
11466989|NCT01582893|Experimental|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
11466754|NCT01584479||Low risk Control Group|"2 visits - Low Risk
~~1200 subjects
~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
11466755|NCT01584479||High Risk Experimental Group|"1 visit - High Risk
~~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
11466756|NCT01584479||High Risk Control Group|"2 visits - High Risk
~~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
11466757|NCT01584466|Experimental|Paliperidone|
11466758|NCT01584453|Experimental|Sodium Nitrite|
11466759|NCT01584453|Placebo Comparator|Placebo|
11466760|NCT01584440|Placebo Comparator|Placebo|
11466761|NCT01584440|Experimental|AVP-923|
11466762|NCT01584427|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch.
11466763|NCT01584427|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans
11466764|NCT01584414||normal samples|
11466765|NCT01584414||premalignant/carcinoma samples|
11466766|NCT01584388|Experimental|Rituximab|
11466767|NCT01584375|Other|Flat midline head position|
11466768|NCT01584375|Other|Right flat lateral head position|
11466769|NCT01584362|Experimental|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
11466770|NCT01584362|Placebo Comparator|placebo comparator|administration of a single oral dose of placebo
11466771|NCT01584362|Experimental|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
11466772|NCT01584362|Experimental|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
11466773|NCT01584362|Experimental|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
11466774|NCT01584362|Experimental|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
11466775|NCT01584362|Experimental|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
11466776|NCT01584336|Experimental|LATG group|It means the patients who will be enrolled in our study.
11466777|NCT01584323|Active Comparator|Pomegranate pills|treatment with pomgranate pills to women suffering preterm premature rupture of membranes
11466778|NCT01584323|Placebo Comparator|placebo pills|treatment with placebo to women with preterm premature rupture of membranes
11466779|NCT01584310|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
11466780|NCT01584310|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
11466781|NCT01584297|Experimental|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
11466782|NCT01584271|Active Comparator|2 Dex-Otic ear drops|Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
11466783|NCT01584271|Experimental|3 Ear Comfort(TM) ear drops|Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
11466784|NCT01584271|Active Comparator|1 Otidin(R) ear drops|Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
11466785|NCT01584258|Active Comparator|Laparoscopic Prostatectomy vs prostate SBRT|Patients for whom surgery is considered will be randomised to laparoscopic prostatectomy or prostate SBRT delivered with 36.25 Gy in 5 fractions.
11466786|NCT01584258|Active Comparator|Conventionally Fractionated RT vs Prostate SBRT|Patients for whom surgery is not considered or who refuse surgery will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 2 Gy fractions or SBRT delivered with 36.25 Gy in 5 fractions.
11466787|NCT01584232|Experimental|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
11466788|NCT01584232|Active Comparator|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
11466789|NCT01584219||Women after cesarean section|Women after cesarean section
11466790|NCT01584219||pregnancy pathologies|pregnancy pathologies
11466791|NCT01584219||first/second trimester pregnancy|
11466792|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
11466793|NCT01584206|Experimental|Ezetimibe|Compare on and off ezetimibe
11466794|NCT01584193|Experimental|US-guided subclavian vein puncture|
11466795|NCT01584193|Active Comparator|Cephalic vein dissection|
11466796|NCT01584180|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
11466797|NCT01584180|Active Comparator|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
11466798|NCT01584167|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
11466799|NCT01584167|Active Comparator|EMCOOLS Flex.Pads|Passive surface cooling with 10 EMCOOLS Flex.Pads (Emergency Medical Cooling Systems AG, Wien, Austria)
11466801|NCT01584154|Active Comparator|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
11466802|NCT01584141||Cases|Asian cases with lymphoid or myeloid neoplasma
11466803|NCT01584141||Controls|Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
11466804|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
11466805|NCT01584115|Experimental|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
11466806|NCT01584102|Experimental|Group 1|
11466807|NCT01584102|Active Comparator|Group 2|
11466808|NCT01584076|Experimental|Donepezil|
11466809|NCT01584063|No Intervention|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
11466810|NCT01584063|Experimental|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
11466811|NCT01584050|Active Comparator|L-MTHF|
11466812|NCT01584050|Active Comparator|folic acid|
11466813|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
11466814|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
11466815|NCT01584024|Active Comparator|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
11466816|NCT01584024|Sham Comparator|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
11466817|NCT01584011||Middle ear disease|
11466818|NCT01583998|Active Comparator|e-MBC|Patients will receive e-MBC
11466819|NCT01583998|No Intervention|Treatment as Usual Control|Patients receive standard treatment
11466820|NCT01583985|Active Comparator|Opioid-intensive|Opioid-intensive prescribing strategy
11466821|NCT01583985|Active Comparator|Opioid-avoidant|Opioid-avoidant prescribing strategy
11466822|NCT01583972|Experimental|Vitamin A|50,000 IU vitamin A in edible oil
11466823|NCT01583972|Placebo Comparator|Placebo|edible oil used as diluent for vitamin A
11466824|NCT01583959|Active Comparator|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
11466825|NCT01583959|Active Comparator|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
11466826|NCT01583946||Male low past-oriented SWB|
11466827|NCT01583946||Male high past-oriented SWB|
11466828|NCT01583946||Female low past-oriented SWB|
11466829|NCT01583946||Female high past-oriented SWB|
11466830|NCT01583946||Black Female high past-oriented SWB|
11466831|NCT01583946||Black Female low past-oriented SWB|
11466832|NCT01583946||Black male low past-oriented SWB|
11466833|NCT01583946||Black male high past-oriented SWB|
11466834|NCT01583933|Experimental|Essix retainer|
11466835|NCT01583933|Active Comparator|Hawley retainer|"Hawley retainer is a device composed of an acrylic base with built-in hooks and a labial arch wire 0.022 x0.036 and attached to the teeth. Its metal component consists of two adams hooks positioned from the first permanent molar right to left, a labial bow that progresses from lingual superface to distal of canine to integrate with the acrylic base."
11466836|NCT01583920|Experimental|Focal salvage HDR prostate brachytherapy|
11466837|NCT01583907||different dietotherapy strategies|
11466838|NCT01583894||Chronic pain patients|
11466839|NCT01583881|Experimental|Renal denervation|Renal denervation
11466840|NCT01583881|No Intervention|control|No intervention
11466841|NCT01583868|Experimental|B&L RD2135-01 lens C|Investigational Silicone hydrogel soft contact lens
11466842|NCT01583868|Experimental|B&L RD2135-01 lens D|Investigational Silicone hydrogel soft contact lens
11466843|NCT01583868|Active Comparator|PureVision2|Bausch & Lomb High definition soft contact lenses
11466844|NCT01583868|Active Comparator|Ciba Vision Air Optix Aqua|Ciba Vision Air Optix Aqua soft contact lens
11466845|NCT01583855|Active Comparator|Manual ablation|Patients will have their ablation performed manually.
11466846|NCT01583855|Active Comparator|Ablation using remote catheter system|Ablation for atrial fibrillation using the Amigo remote catheter system
11466847|NCT01583842|Experimental|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
11466848|NCT01583842|Experimental|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
11466849|NCT01583829|Experimental|Neurofeedback|
11466850|NCT01583829|Experimental|Cognitive Training|
11466851|NCT01583829|Active Comparator|Waitlist Control|
11466852|NCT01583816|Experimental|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
11466853|NCT01583816|Experimental|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
11466854|NCT01583816|Experimental|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
11466855|NCT01583816|Experimental|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
11466856|NCT01583816|Experimental|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
11466857|NCT01583803||Males|
11466858|NCT01583803||Females|
11466859|NCT01583790||no group|laparoscopic sleeve gastrectomy
11466860|NCT01583777|Experimental|Belinostat|Open Label
11466861|NCT01583751|Experimental|control|excision and primer repair surgical technique will be perform
11466862|NCT01583738|Experimental|V0251|
11466863|NCT01583738|Placebo Comparator|Placebo|
11466864|NCT01583725|Experimental|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
11466865|NCT01583725|Experimental|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
11466866|NCT01583725|Experimental|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
11466867|NCT01583725|Experimental|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
11466868|NCT01583725|Experimental|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
11466869|NCT01583712|Experimental|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
11466870|NCT01583699|Experimental|Endomicroscopy|All patients included into the study will undergo endomicroscopy of the upper GI-tract.
11466871|NCT01583686|Experimental|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
11466872|NCT01583686|Experimental|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin
11466873|NCT01583673|Experimental|Amino Acid Formula|Hypoallergenic baby formula
11466874|NCT01583673|Active Comparator|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
11466875|NCT01583647|Experimental|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
11466876|NCT01583647|Experimental|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
11466877|NCT01583634||Healthy volunteers|9 subjects (male and female)
11466878|NCT01583621|No Intervention|Placebo|Placebo group
11466879|NCT01583621|Experimental|Supplementation arm 1|cholecalciferol 18000 U/month for 4 months
11466880|NCT01583621|Experimental|supplementation arm 2|cholecalciferol 60000 U/month for 4 months
11466881|NCT01583621|Experimental|Supplementation arm 3|cholecalciferol 120000 U/month for 4 months
11466882|NCT01583582|Experimental|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
11466883|NCT01583582|Experimental|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
11466884|NCT01583582|Placebo Comparator|Refined peptide concentrate, 0 mg|
11466885|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
11466886|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
11466887|NCT01583543|Experimental|Olaparib|400mg PO BID Continuous
11466888|NCT01583530|Active Comparator|Belimumab IV 240 mg|
11466889|NCT01583530|Experimental|Belimumab SC 2 x 120 mg|
11466890|NCT01583530|Experimental|Belimumab SC 1 x 240 mg|
11466891|NCT01583530|Experimental|Belimumab SC 1 x 200 mg|
11466892|NCT01583530|Experimental|Belimumab SC 2 x 120 mg weekly|
11466893|NCT01583530|Experimental|Belimumab SC 1 x 200 mg weekly|
11466894|NCT01583517|Active Comparator|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
11466895|NCT01583517|Active Comparator|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
11466896|NCT01583517|Sham Comparator|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
11466897|NCT01583517|Active Comparator|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
11466898|NCT01583504|Experimental|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
11466942|NCT01583231|Experimental|Prewash|Level 2: participants will be swabbed, perform a wash with soap and water for 1 minute, dry, apply brushless scrub, swabbed again
11466899|NCT01583504|Active Comparator|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.
~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
11466900|NCT01583491|Active Comparator|prf group.peridontal problem|prf insert into surgical site immediate after surgery
11466901|NCT01583491|Placebo Comparator|control group|
11466902|NCT01583478|Active Comparator|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
11466903|NCT01583478|Active Comparator|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
11466904|NCT01583478|Active Comparator|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
11466905|NCT01583478|Active Comparator|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
11466906|NCT01583478|Active Comparator|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
11466907|NCT01583465|Experimental|Aquamantys Malleable Bipolar Sealer|In 100 patients randomly assigned, primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of the Aquamantys Malleable Bipolar Sealer with Light.
11466908|NCT01583465|Active Comparator|Standard Treatment|100 patients randomly assigned will undergo primary total hip arthroplasty via the anterior supine intermuscular approach performed with the assistance of standard electrocautery.
11466909|NCT01583452|Experimental|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
11466910|NCT01583452|No Intervention|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
11466911|NCT01583426|Experimental|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
11466912|NCT01583426|Active Comparator|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
11466913|NCT01583413|Experimental|Opt Out Protocol|
11466914|NCT01583400|Active Comparator|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
11466915|NCT01583400|Experimental|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
11466916|NCT01583387|Other|1= Intervention|
11466917|NCT01583387|Other|2= Control|
11466918|NCT01583374|Experimental|Apremilast 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
11466919|NCT01583374|Experimental|Apremilast 30 mg|Apremilast 30 mg was taken orally twice a day
11466920|NCT01583374|Placebo Comparator|Placebo|Identically matched placebo tablets were taken orally twice a day
11466921|NCT01583361|Experimental|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
11466922|NCT01583361|Active Comparator|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
11466923|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
11466924|NCT01583335|Experimental|Improved lifestyle|
11466925|NCT01583335|No Intervention|Control group|The control group was seen at baseline and follow-up, but not in between.
11466926|NCT01583335|No Intervention|Shadow group|The shadow group was followed in registers exclusively
11466927|NCT01583322|Experimental|vargatef/Nintedanib|
11466928|NCT01583322|Placebo Comparator|placebo|
11466929|NCT01583309|No Intervention|low-flux hemodialysis|
11466930|NCT01583309|Experimental|online pre-dilution hemofiltration|
11466931|NCT01583309|Experimental|online pre-dilution hemodiafiltration|
11466932|NCT01583296|Experimental|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
11466933|NCT01583296|Active Comparator|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
11466934|NCT01583283|Experimental|ACY-1215, Lenalidomide and Dexamethasone|Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral Dexamethasone (40 mg once weekly).
11466935|NCT01583270|Experimental|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
11466936|NCT01583270|Experimental|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
11466937|NCT01583270|Experimental|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
11466938|NCT01583270|Experimental|semolina|Semoline porridge. 50 g available carbohydrate
11466939|NCT01583257|Experimental|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
11466940|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
11466941|NCT01583231|No Intervention|No Prewash|Level 1: participants will be swabbed, then application of brushless scrub, swabbed again
11466990|NCT01582893|Active Comparator|P210H|High flux Filter P210H
11466943|NCT01583218|Experimental|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
11466944|NCT01583218|Active Comparator|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
11466945|NCT01583205|Experimental|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
11466946|NCT01583192|Active Comparator|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.
~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
11466947|NCT01583192|Active Comparator|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
11466948|NCT01583179|No Intervention|Control group|will get only local anesthetic and epinephrine in block. no additive in block
11466949|NCT01583179|Experimental|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
11466950|NCT01583166|Active Comparator|Bupivacaine + epinephrine|
11466951|NCT01583166|Placebo Comparator|Saline + epinephrine|
11466952|NCT01583153|Active Comparator|Hospital Inpatient Rehabilitation (HI)|
11466953|NCT01583153|Active Comparator|Hybrid Home Programme (HO)|
11466954|NCT01583140|Experimental|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
11466955|NCT01583140|Active Comparator|Control|Bilingual health education booklets
11466956|NCT01583127|Experimental|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
11466957|NCT01583127|No Intervention|Control|Practice as usual
11466958|NCT01583114|Experimental|perindopril|
11466959|NCT01583114|Placebo Comparator|placebo|same form, administration, posology, frequency and duration as perindopril
11466960|NCT01583101|Experimental|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
11466961|NCT01583101|Active Comparator|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
11466962|NCT01583088|Experimental|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
11466963|NCT01583088|Sham Comparator|sham|sham phenic nerve stimulation
11466964|NCT01583075|Other|Circumferential ablation|
11466965|NCT01583075|Experimental|Single ring ablation|
11466966|NCT01583062|Active Comparator|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
11466967|NCT01583062|Placebo Comparator|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
11466968|NCT01583036|Experimental|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
11466969|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Sham rTMS|
11466970|NCT01583023|Experimental|Placebo + Lithium a/o Epival + Active rTMS|
11466971|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Active rTMS|
11466972|NCT01583010|No Intervention|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
11466973|NCT01583010|Active Comparator|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
11466974|NCT01582997|Experimental|Dose Escalation Part|Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.
11466975|NCT01582984|Active Comparator|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
11466976|NCT01582984|Experimental|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
11466977|NCT01582984|Experimental|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
11466978|NCT01582971|Experimental|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
11466979|NCT01582971|No Intervention|Control|Standard medical care: no reflexology
11466980|NCT01582958|Experimental|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
11466981|NCT01582958|Placebo Comparator|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
11466982|NCT01582958|No Intervention|Control|This arm receives only pulmonary rehabilitation care.
11466983|NCT01582945|Experimental|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
11466984|NCT01582932|Experimental|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
11466985|NCT01582919|Experimental|Participant from AMI cohort|
11466986|NCT01582919|Active Comparator|Participant from 3Ccohort|
11466987|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
11466988|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
11466991|NCT01582880|Experimental|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
11466992|NCT01582867|Experimental|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
11466993|NCT01582867|Experimental|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
11466994|NCT01582854|Active Comparator|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
11466995|NCT01582854|Placebo Comparator|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
11466996|NCT01582841|Experimental|MSI testing|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
11466997|NCT01582841|No Intervention|Usual care|These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
11466998|NCT01582828|Active Comparator|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
11466999|NCT01582828|Experimental|Hybrid|Epicardial (surgical) ablation & Endocardial assessment
11467000|NCT01582815|Experimental|JNJ-40411813|
11467001|NCT01582815|Placebo Comparator|Placebo|
11467002|NCT01582802||Pregnant women carrying multiples|
11467003|NCT01582789|Active Comparator|enfilcon A/senofilcon A|Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
11467004|NCT01582789|Active Comparator|senofilcon A/enfilcon A|Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
11467005|NCT01582776|Experimental|Lenalidomide and GA101|Ga101 and lenalidomide
11467006|NCT01582763||GBS|Guillain-Barré syndrome >1000, follow-up 1-3 years
11467007|NCT01582763||NC|Normal controls (NC)
11467008|NCT01582763||IC|Infectious controls (IC)
11467009|NCT01582763||OND|Other neurological diseases (OND)
11467010|NCT01582750||Local advanced rectal cancer EUS|
11467011|NCT01582737||Group 1|
11467012|NCT01582724|Experimental|Self-care acupressure|1
11467013|NCT01582724|No Intervention|Usual care|2
11467014|NCT01582711|Active Comparator|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
11467015|NCT01582711|Experimental|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
11467016|NCT01582711|Experimental|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
11467017|NCT01582698|Experimental|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
11467018|NCT01582685|Experimental|Exercise Group|The intervention is a structured walking program which will be performed partly in the Pavilion Physical Therapy clinic and partly at home. The participant will be instructed in how hard to exercise, how long to exercise, and how many times in a week to exercise. You will also be instructed in how to exercise safely.
11467019|NCT01582685|No Intervention|No Exercise|These participants will receive standard of care follow up.
11467020|NCT01582672|Experimental|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
11467021|NCT01582672|Active Comparator|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
11467022|NCT01582659|No Intervention|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
11467023|NCT01582659|Active Comparator|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
11467024|NCT01582659|Active Comparator|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
11467025|NCT01582646|Other|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
11467026|NCT01582646|Other|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
11467027|NCT01582633|Experimental|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
11467028|NCT01582633|Experimental|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
11467029|NCT01582633|Experimental|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
11467231|NCT01581229|Active Comparator|Control|
11467030|NCT01582633|Active Comparator|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
11467031|NCT01582607|Active Comparator|Group B|subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%
11467032|NCT01582607|Active Comparator|Group R|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%
11467033|NCT01582607|Active Comparator|Group LB|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%
11467034|NCT01582607|Active Comparator|Group RF|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl
11467035|NCT01582607|Active Comparator|Group BF|subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
11467036|NCT01582607|Active Comparator|Group LBF|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
11467037|NCT01582581|Active Comparator|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
11467038|NCT01582581|Sham Comparator|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
11467039|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
11467040|NCT01582555|Experimental|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
11467041|NCT01582555|Experimental|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
11467042|NCT01582542|Experimental|Desmopressin|
11467043|NCT01582516|Experimental|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
11467044|NCT01582503|Experimental|MEMP1972A 150 mg|
11467045|NCT01582503|Experimental|MEMP1972A 300 mg|
11467046|NCT01582503|Experimental|MEMP1972A 450 mg|
11467047|NCT01582503|Placebo Comparator|Placebo|
11467048|NCT01582490|Active Comparator|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
11467049|NCT01582490|Experimental|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
11467050|NCT01582477|Experimental|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
11467051|NCT01582477|Active Comparator|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
11467052|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
11467053|NCT01582451|Experimental|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
11467054|NCT01582451|Active Comparator|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
11467055|NCT01582425|Experimental|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
11467056|NCT01582412|Experimental|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
11467057|NCT01582399|Experimental|Arm A: ASKP1240 intravenous (IV) infusion|
11467058|NCT01582399|Experimental|Arm B: ASKP1240 subcutaneous (SC)|
11467059|NCT01582373|Experimental|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
11467060|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
11467061|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
11467062|NCT01582360||antiinfectiva: flukonazol|80 patients
11467063|NCT01582360||antiinfectiva: cefotaxim|80 patients
11467064|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
11467065|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
11467066|NCT01582360||antiinfectiva: cloxacillin|80 patients
11467067|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
11467068|NCT01582347|Experimental|RBP-6300|During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
11467069|NCT01582347|Active Comparator|Subutex®/Suboxone®|During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
11467070|NCT01582321|Experimental|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
11467071|NCT01582321|Experimental|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
11467072|NCT01582321|Experimental|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
11467073|NCT01582321|Experimental|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
11467074|NCT01582308|Experimental|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
11467075|NCT01582308|Experimental|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
11467076|NCT01582308|Experimental|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
11467077|NCT01582308|Experimental|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
11467078|NCT01582308|Experimental|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
11467079|NCT01582308|Experimental|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
11467080|NCT01582308|Experimental|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
11467081|NCT01582308|Experimental|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
11467082|NCT01582308|Experimental|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
11467083|NCT01582308|Experimental|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
11467084|NCT01582295|Experimental|Treatment Arm|Cabozantinib ( XL 184)
11467085|NCT01582282|Placebo Comparator|placebo|matched placebo BID
11467086|NCT01582282|Active Comparator|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
11467087|NCT01582282|Active Comparator|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
11467088|NCT01582269|Experimental|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.
~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
11467089|NCT01582269|Experimental|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
11467090|NCT01582269|Active Comparator|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.
~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
11467091|NCT01582256||ASD+CNVs|
11467092|NCT01582256||ASD-CNVs|
11467093|NCT01582256||Unaffected siblings of ASD+CNVs|
11467094|NCT01582256||Unaffected siblings of ASD-CNVs|
11467095|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
11467096|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
11467097|NCT01582243|Experimental|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
11467098|NCT01582230|Experimental|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
11467099|NCT01582230|Placebo Comparator|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
11467100|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
11467101|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
11467232|NCT01581216|Experimental|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
11467102|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
11467103|NCT01582204|Experimental|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
11467104|NCT01582191|Experimental|Treatment (vandetanib, everolimus)|Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11467105|NCT01582178|Experimental|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
11467106|NCT01582178|Active Comparator|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
11467107|NCT01582165|Active Comparator|Angina. IMR. Statin.|
11467108|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
11467109|NCT01582152|Experimental|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.
~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.
~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
11467110|NCT01582152|Experimental|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.
~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
11467111|NCT01582139|Experimental|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
11467112|NCT01582139|No Intervention|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
11467113|NCT01582126|Experimental|Group balance training early start|
11467114|NCT01582126|Experimental|Group balance training late start|
11467115|NCT01582113|Experimental|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
11467116|NCT01582113|Experimental|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
11467117|NCT01582113|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
11467118|NCT01582100|Experimental|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
11467119|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
11467120|NCT01582074||Cases|women with breast cancer
11467121|NCT01582074||Controls|Matched women without breast cancer
11467122|NCT01582061|Experimental|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose < 1500 μg /day.
11467123|NCT01582061|Experimental|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
11467124|NCT01582035|Experimental|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
11467125|NCT01582035|Experimental|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
11467126|NCT01582022|Experimental|local anesthetic|local anesthetic agent
11467127|NCT01582022|Placebo Comparator|normal saline|comparator
11467128|NCT01582009|Experimental|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11467129|NCT01581996|Experimental|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
11467130|NCT01581983|Experimental|Internet Mindfulness Meditation|
11467131|NCT01581983|Experimental|Individual Mindfulness Meditation|
11467132|NCT01581970|Experimental|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
11467133|NCT01581957|Active Comparator|Specific Enteral formulation|
11467134|NCT01581957|Placebo Comparator|Standard enteral formulation|
11467135|NCT01581944|No Intervention|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
11467136|NCT01581944|Experimental|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
11467233|NCT01581216|Experimental|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
11467137|NCT01581944|Experimental|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
11467138|NCT01581931|Experimental|Linagliptin/metformin|fixed dose combination tablet (FDC)
11467139|NCT01581931|Experimental|Linagliptin and metformin|single tablets
11467140|NCT01581905|Active Comparator|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
11467141|NCT01581905|Active Comparator|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
11467142|NCT01581892|Experimental|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
11467143|NCT01581879|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
11467144|NCT01581879|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
11467145|NCT01581866|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
11467146|NCT01581866|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
11467147|NCT01581853|Other|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
11467148|NCT01581840|Experimental|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
11467149|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
11467150|NCT01581814|Active Comparator|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
11467151|NCT01581814|Active Comparator|0.03 mg EE plus 3 mg of DRPS|
11467152|NCT01581814|Active Comparator|Metformin plus Yasmin|
11467153|NCT01581801|Other|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
11467154|NCT01581801|Other|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
11467155|NCT01581788|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
11467156|NCT01581788|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
11467157|NCT01581775|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
11467158|NCT01581775|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
11467159|NCT01581762|Sham Comparator|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
11467160|NCT01581762|Active Comparator|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
11467161|NCT01581749|Other|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
11467162|NCT01581736|Experimental|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m^2 surface area.
11467163|NCT01581723|Active Comparator|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
11467164|NCT01581723|Experimental|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
11467165|NCT01581710|Active Comparator|montelukast to placebo|14 days
11467166|NCT01581710|No Intervention|Washout|14 days
11467167|NCT01581710|Active Comparator|Placebo to montelukast|14 days
11467168|NCT01581697|Experimental|Oat bran|
11467169|NCT01581684|Experimental|BI 411034 low dose - group 1|Solution for oral administration
11467170|NCT01581684|Experimental|BI 411034 low dose - group 2|Solution for oral administration
11467171|NCT01581684|Experimental|BI 411034 medium dose - group 3|Solution for oral administration
11467172|NCT01581684|Experimental|BI 411034 medium dose - group 4|Solution for oral administration
11467173|NCT01581684|Experimental|BI 411034 medium dose - group 5|Solution for oral administration
11467174|NCT01581684|Experimental|BI 411034 high dose - group 6|Solution for oral administration
11467175|NCT01581684|Experimental|BI 411034 high dose - group 7|Solution for oral administration
11467176|NCT01581684|Experimental|BI 411034 high dose - group 8|Solution for oral administration
11467177|NCT01581684|Placebo Comparator|Placebo|Solution for oral administration
11467178|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
11467179|NCT01581658|Experimental|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
11467180|NCT01581658|Experimental|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
11467181|NCT01581658|Experimental|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
11467182|NCT01581658|Experimental|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
11467183|NCT01581645|Experimental|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
11467184|NCT01581632|Other|LipiScan/LipiScan IVUS|valuation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
11467185|NCT01581619|Experimental|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
11467186|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
11467187|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
11467188|NCT01581593|Experimental|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
11467189|NCT01581580|Other|treatment arm|patients with Parkinson's Disease, dysonia, and essential tremor
11467190|NCT01581554||Patients with HBeAg negative chronic hepatitis B|Patients with HBeAg negative chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
11467191|NCT01581554||Patients with HBeAG positive chronic hepatitis B|Patients with HBeAg positive chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
11467192|NCT01581541|Experimental|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
11467193|NCT01581515|Active Comparator|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
11467194|NCT01581515|Active Comparator|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
11467195|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
11467196|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=< 10 s) clamping of the umbilical cord at birth.
11467197|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (>= 180 s) clamping of the umbilical cord at birth.
11467198|NCT01581476|Active Comparator|Statin|Participants receive active statin and placebo ACE Inhibitor
11467199|NCT01581476|Active Comparator|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
11467200|NCT01581476|Placebo Comparator|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
11467201|NCT01581476|Other|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
11467202|NCT01581463|Active Comparator|Liothyronine, Sodium|Healthy adults.
11467203|NCT01581450|Experimental|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
11467204|NCT01581450|Active Comparator|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
11467205|NCT01581437|Other|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
11467206|NCT01581411|Experimental|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
11467207|NCT01581398|Experimental|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
11467208|NCT01581398|Active Comparator|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
11467209|NCT01581398|Experimental|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
11467210|NCT01581398|Active Comparator|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
11467211|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
11467212|NCT01581372|Experimental|Pharmacist care|
11467213|NCT01581372|No Intervention|Usual care|
11467214|NCT01581359|Active Comparator|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
11467215|NCT01581359|Placebo Comparator|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
11467216|NCT01581346|Experimental|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
11467217|NCT01581333|Experimental|Experimental Arm|Empirical antimicrobial treatment discontinuation
11467218|NCT01581333|Active Comparator|Control Arm|Standard empirical antimicrobial treatment discontinuation
11467219|NCT01581320|Experimental|DP-R206|
11467220|NCT01581320|Active Comparator|Bonviva|
11467221|NCT01581307|Experimental|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first-line chemotherapy. Generally, second-line chemotherapy is given every two weeks for 6-10 cycles.
~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
11467222|NCT01581281|Active Comparator|Amitriptyline|Drug to be administered twice daily.
11467223|NCT01581281|Active Comparator|Topiramate|Drug to be administered twice daily.
11467224|NCT01581281|Placebo Comparator|Placebo|To be administered twice daily.
11467225|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
11467226|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
11467227|NCT01581242|Experimental|A|
11467228|NCT01581242|Experimental|B|
11467229|NCT01581242|Experimental|C|
11467230|NCT01581229|Experimental|NPPV|
11467234|NCT01581216|Experimental|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
11467235|NCT01581203|Experimental|Arm 1: Null or Partial Responder to P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks
~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
11467236|NCT01581203|Experimental|Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks
~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
11467237|NCT01581203|Experimental|Arm 3: Treatment naive (ASV + DCV)|"[Subjects will receive ASV + DCV for 24 weeks] followed by ASV + DCV for 24 weeks in protocol AI444026]
~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)
~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks
~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks
~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks
~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks"
11467238|NCT01581203|Experimental|Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week|"Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)
~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks
~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks
~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks
~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks"
11467239|NCT01581190|Experimental|Bananas versus 6% carbohydrate beverage|
11467240|NCT01581177|Experimental|T1|Two inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
11467241|NCT01581177|Experimental|T2|Two inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
11467242|NCT01581177|Experimental|T3|Two inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
11467243|NCT01581177|Experimental|T4|Two inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
11467244|NCT01581177|Placebo Comparator|P|Two inhalations Placebo DPI; Total Albuterol dose of 0 mcg
11467245|NCT01581177|Active Comparator|R1|One inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
11467246|NCT01581177|Active Comparator|R2|Two inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg
11467247|NCT01581164||HSCT patients|Patients who have been treated with HSCT
11467248|NCT01581151|Active Comparator|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
11467249|NCT01581151|Experimental|Dexamethasone intravitreal implant|"Patients will receive a dexamethasone intravitreal implant injection at day 0.
~During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.
~During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
11467250|NCT01581138|Experimental|12 week treatment|
11467251|NCT01581138|Experimental|16 week treatment|
11467252|NCT01581125|Experimental|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
11467253|NCT01581125|Experimental|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
11467254|NCT01581112|Experimental|Heavy armpit odour|Subjects with heavy armpit odour.
11467255|NCT01581112|Experimental|Heavy foot odour|Subjects with heavy foot odour.
11467256|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
11467257|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
11467258|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
11467259|NCT01581073|Experimental|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
11467260|NCT01581073|Active Comparator|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
11467261|NCT01581060|Experimental|WX-554|
11467262|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
11467263|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
11467264|NCT01581034|Active Comparator|Padma|
11467265|NCT01581034|Placebo Comparator|Placebo|
11467266|NCT01581021|Active Comparator|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
11467267|NCT01581021|Active Comparator|Laminar Hooks|Group treated with hooks in the thoracic spine
11467305|NCT01580787|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
11467306|NCT01580774||Post-discharge phone call|All patients in this group will receive a phone call within 72-hours of being discharged from hospital.
11467307|NCT01580774||Usual care (no phone call)|
11467308|NCT01580761|Experimental|Sleep restriction|Sleep restriction
11467309|NCT01580761|No Intervention|Normal sleep|Normal sleep
11467268|NCT01581008|Experimental|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
11467269|NCT01581008|Active Comparator|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
11467270|NCT01580995|Experimental|Valacyclovir|Valacyclovir 500 mg po bid
11467271|NCT01580995|Placebo Comparator|Placebo|Matching placebo twice daily
11467272|NCT01580969|Experimental|Dose Level 0: 100 mg bid|Patients receiving minocycline 100 mg bid, bevacizumab, and radiation therapy.
11467273|NCT01580969|Experimental|Dose Level 1: 200 mg bid|Patients receiving minocycline 200 mg bid, bevacizumab, and radiation therapy.
11467274|NCT01580969|Experimental|Dose Level 2: 400 mg bid|Patients receiving minocycline 400 mg bid, bevacizumab, and radiation therapy.
11467275|NCT01580956|Other|VARIABLE-PSV ventilatory mode|
11467276|NCT01580956|Other|STANDARD-PSV ventilatory mode|
11467277|NCT01580943|Active Comparator|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.
~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
11467278|NCT01580943|Active Comparator|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
11467279|NCT01580930|No Intervention|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
11467280|NCT01580930|Experimental|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
11467281|NCT01580930|Experimental|Sedentary time reduction|participants were give strategies to reduce sedentary time
11467282|NCT01580930|Experimental|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
11467283|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
11467284|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
11467285|NCT01580904|No Intervention|control group|Patients will not be followed by the pharmacist.
11467286|NCT01580904|Experimental|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.
~Intervention: Pharmaceutical Care"
11467287|NCT01580891|Experimental|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
11467288|NCT01580891|Active Comparator|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
11467289|NCT01580891|Placebo Comparator|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
11467290|NCT01580878|Experimental|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
11467291|NCT01580878|Active Comparator|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
11467292|NCT01580878|Placebo Comparator|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
11467293|NCT01580865|Active Comparator|Mycophenolate Mofetil (MMF)|MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. .
11467294|NCT01580865|Experimental|Tacrolimus (TAC)|TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter
11467295|NCT01580852|Active Comparator|Dead Sea Water|
11467296|NCT01580852|Sham Comparator|Pool Water|
11467297|NCT01580839|Experimental|intravenous tissue plasminogen activator|
11467298|NCT01580839|Placebo Comparator|Placebo|
11467299|NCT01580826|No Intervention|raw milk|Infants who were assigned to the raw group received fresh or thawed milk from their own mother, cultured weekly with a semi-quantitative analysis. Raw milk was withheld if it contained any Gram-negative organisms, S. aureus or enterococci.
11467300|NCT01580826|Active Comparator|pasteurized milk|Infants who were assigned to pasteurization received own mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
11467301|NCT01580813|Experimental|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi
11467302|NCT01580813|Placebo Comparator|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit
11467303|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
11467304|NCT01580787|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
11467310|NCT01580748|Experimental|Treatment arm|single arm study
11467312|NCT01580722|Other|early|patients underwent < 8 weeks reconstruction after injury
11467313|NCT01580722|Other|delay|patients underwent > 8 weeks reconstruction after injury
11467314|NCT01580709|Active Comparator|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
11467315|NCT01580709|Active Comparator|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
11467316|NCT01580696|Active Comparator|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
11467317|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
11467318|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
11467319|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
11467320|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
11467321|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
11467322|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
11467323|NCT01580683|Experimental|Ascorbic acid|
11467324|NCT01580683|Placebo Comparator|Placebo|
11467325|NCT01580670|Experimental|TA-650|"Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.
~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.
~PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10
~PCDAI score on the evaluation day exceeds 30"
11467326|NCT01580657|Experimental|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
11467327|NCT01580657|Experimental|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
11467328|NCT01580657|Experimental|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
11467329|NCT01580657|Active Comparator|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
11467330|NCT01580657|Active Comparator|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
11467331|NCT01580657|Active Comparator|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
11467332|NCT01580644|Experimental|Period 1: formulation 1 oral solution|
11467333|NCT01580644|Experimental|Period 2: formulation 2 capsule|
11467334|NCT01580644|Experimental|Period 3: Selected formulation + food|
11467335|NCT01580644|Experimental|Period 4: Selected formulation at higher dose|
11467336|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
11467337|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
11467338|NCT01580618|Placebo Comparator|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
11467339|NCT01580618|Active Comparator|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
11467340|NCT01580605||Users of somatropin|
11467341|NCT01580592|Experimental|Omalizumab 150mg|
11467342|NCT01580592|Experimental|Omalizumab 300mg|
11467343|NCT01580592|Placebo Comparator|Placebo|
11467344|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
11467345|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
11467346|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
11467347|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
11467348|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
11467349|NCT01580553|Placebo Comparator|Levocarnitine|
11467350|NCT01580553|Active Comparator|L-carnitine|
11467351|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
11467352|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
11467353|NCT01580527|Active Comparator|total parenteral nutrition|
11467354|NCT01580527|Experimental|Early enteral nutrition|
11467355|NCT01580514|Active Comparator|Exenatide|"Drug: Exenatide
~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
11467356|NCT01580514|Placebo Comparator|Saline|"Drug: Saline
~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
11467357|NCT01580475|Experimental|Lifestyle (exercise training)|Training, detraining and retraining
11467358|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
11467359|NCT01580436|Experimental|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
11467360|NCT01580436|No Intervention|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
11467361|NCT01580423|Experimental|aprepitant|
11467362|NCT01580423|Placebo Comparator|inert powder|
11467363|NCT01580410|Experimental|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
11467364|NCT01580410|Experimental|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
11467365|NCT01580397|Experimental|INNO-206|
11467366|NCT01580384||Cohort|
11467367|NCT01580371|Experimental|Treatment|CKD-581
11467368|NCT01580358|Active Comparator|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
11467369|NCT01580358|Placebo Comparator|starch|Starch in the same granule as intervention group for this double-blind trial
11467370|NCT01580345|Active Comparator|Docosa-hexaenoic Acid (DHA)|
11467371|NCT01580345|Placebo Comparator|Placebo|Corn-Soy Oil
11467372|NCT01580319|No Intervention|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
11467373|NCT01580319|Experimental|Exercise|Participants receive a physical exercise plan to play at home
11467374|NCT01580306|Experimental|BI 201335 relevant treatment dose (A)|Capsule for oral administration
11467375|NCT01580306|Experimental|BI 201335 relevant treatment dose (B)|Capsule for oral administration
11467376|NCT01580293|Experimental|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
11467377|NCT01580293|Experimental|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
11467378|NCT01580293|Experimental|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
11467379|NCT01580293|Experimental|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
11467380|NCT01580280|Experimental|Thrust manipulation|
11467381|NCT01580280|Active Comparator|Non-thrust mobilization and exercise|
11467382|NCT01580254|Active Comparator|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
11467383|NCT01580254|Active Comparator|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
11467384|NCT01580254|Active Comparator|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
11467385|NCT01580241||Surgery group|Patients with pancreatic cancer who undergo surgical treatment only
11467386|NCT01580241||Chemotherapy group|Patients with pancreatic cancer who undergo chemotherapy treatment only
11467387|NCT01580241||Neoadjuvant group|Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
11467388|NCT01580241||Adjuvant group|Patients with pancreatic cancer who undergo surgery followed by chemotherapy
11467389|NCT01580228|Experimental|Dinaciclib|
11467390|NCT01580228|Active Comparator|Ofatumumab|
11467391|NCT01580215||Main cohort|"Patients of both genders of at least 18 years of age
~Who understand and voluntarily sign an informed consent form
~FEV1 > 15% predicted and < 45% predicted
~RV >180% predicted
~Diagnosis of emphysema with CT evidence of hyperinflation
~Absence of collateral ventilation according to Chartis Assessment System
~Treated with Zephyr Endobronchial Valve (EBV)"
11467392|NCT01580202|Active Comparator|Lamivudine|LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
11467534|NCT01579279|Experimental|ABT-652 12 mg|ABT-652 capsules twice daily
11467393|NCT01580202|Experimental|Entecavir|ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
11467394|NCT01580189|Active Comparator|Milk|Chocolate milk compared to protein supplement
11467395|NCT01580189|Active Comparator|Whey protein|Whey protein compared to milk
11467396|NCT01580189|Placebo Comparator|Sugar|Maltodextrin compared to treatments
11467397|NCT01580176|Experimental|GlucoseMonitor|
11467398|NCT01580163|Experimental|JITAI combined therapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
11467399|NCT01580163|Experimental|Methadone combined herapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
11467400|NCT01580163|Experimental|JITAI therapy group|The investigator will adopt JITAI combined social support in Shanghai-related community and outside of Shanghai.
11467401|NCT01580150|Experimental|Berry meal|Carbohydrate meals with berries
11467402|NCT01580150|Active Comparator|Reference meal|Carbohydrate meals without berries
11467403|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
11467404|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
11467405|NCT01580124|Active Comparator|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
11467406|NCT01580124|Active Comparator|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
11467407|NCT01580111|Experimental|Short storage|Short storage arm: Will receive blood (Packed red blood cells) of 1 (one) to 10 (ten) days in storage.
11467408|NCT01580111|Active Comparator|Long storage arm|Will be transfused with blood ( packed red cells) of storage age 21- 35 days.
11467409|NCT01580098|No Intervention|Control group|treatment as usual
11467410|NCT01580098|Experimental|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
11467411|NCT01580098|Experimental|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
11467412|NCT01580085||Pulmonary embolism|Patients who were diagnosed with pulmonary embolism
11467413|NCT01580085||control group|age and sex matched adults with osa and no thromboembolism
11467414|NCT01580072|No Intervention|Control group|Participants in the control group receive usual care.
11467415|NCT01580072|Experimental|Self monitoring for patients with COPD|
11467416|NCT01580072|Experimental|Nurse monitoring for patients with COPD|
11467417|NCT01580046|Experimental|Iodixanol|
11467418|NCT01580046|Active Comparator|iopromide|
11467419|NCT01580033|Experimental|A+C+hib Conjugate Vaccine|600 infants aged 3-5 months, will be vaccinated on day0, 28, 56
11467420|NCT01580033|Active Comparator|Walvax AC vaccine, Pasteur Hib vaccine|300 infants aged 3-5 months, will be vaccinated on day0, 28, 56
11467421|NCT01580020|Experimental|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:
~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
11467422|NCT01580020|Sham Comparator|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
11467423|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and active cholecalciferol|500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
11467424|NCT01580007|Active Comparator|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
11467425|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
11467426|NCT01580007|Placebo Comparator|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate Placebo cholecalciferol
11467427|NCT01579994|Experimental|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
11467428|NCT01579968||eptacog alpha users|
11467429|NCT01579955||eptacog alpha users|
11467430|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
11467431|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
11467432|NCT01579929|Experimental|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, & clinicians will have an opportunity to either agree or modify the patient self-assessments & use this information in their grading & attribution of toxicities.
11467433|NCT01579916|Experimental|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
11467626|NCT01578824|Active Comparator|Healthy Control|
11467434|NCT01579916|Placebo Comparator|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
11467435|NCT01579903|Experimental|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
11467436|NCT01579903|Experimental|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
11467437|NCT01579877|Experimental|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
11467438|NCT01579877|Placebo Comparator|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
11467439|NCT01579864|Active Comparator|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
11467440|NCT01579864|Experimental|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
11467441|NCT01579851|Active Comparator|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
11467442|NCT01579851|Active Comparator|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
11467443|NCT01579838|Experimental|Eculizumab|Eculizumab will be administrated according to known protocols.
11467444|NCT01579825|Experimental|Buffer|
11467445|NCT01579825|No Intervention|Control|
11467446|NCT01579812|Experimental|Metformin|
11467447|NCT01579799|Active Comparator|Dose 0.5|
11467448|NCT01579799|Active Comparator|Dose 7.5|
11467449|NCT01579799|Active Comparator|Dose 3|
11467450|NCT01579799|Active Comparator|Dose 1.2|
11467451|NCT01579786|No Intervention|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
11467452|NCT01579786|Experimental|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
11467453|NCT01579760|Experimental|aflibercept every 2 months|
11467454|NCT01579760|Experimental|aflibercept monthly|
11467455|NCT01579747|Placebo Comparator|Nerve stimulation sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach using nerve stimulation
11467456|NCT01579747|Active Comparator|Ultrasound guided sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach when using an ultrasound
11467457|NCT01579734|Placebo Comparator|Placebo|1 tablet day for 5 years
11467458|NCT01579734|Active Comparator|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
11467459|NCT01579721|Experimental|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
11467460|NCT01579721|No Intervention|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
11467461|NCT01579708|Experimental|Program SI! educational intervention|
11467462|NCT01579708|No Intervention|Control|
11467463|NCT01579695||Exposed Group will receive Tesamorelin|
11467464|NCT01579695||Control Group will not receive Tesamorelin|
11467465|NCT01579682|Experimental|Psychotherapy|Family-Based Therapy (12 sessions)
11467466|NCT01579682|Experimental|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
11467467|NCT01579669|Experimental|Use of Toolkit|All participants will have access to the toolkit
11467468|NCT01579656|Experimental|Salba|25g of ground Salba baked into a bran muffin
11467469|NCT01579656|Experimental|Poppy|25g of ground poppy seeds baked into a bran muffin
11467470|NCT01579656|Experimental|Flaxseed|25g of ground flaxseed baked into a bran muffin
11467471|NCT01579656|Experimental|Sesame|25g of ground sesame seeds baked into a bran muffin
11467472|NCT01579656|Placebo Comparator|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
11467473|NCT01579643|Experimental|LALAK|
11467474|NCT01579643|Active Comparator|Penetrating Keratoplasty (KP)|
11467475|NCT01579630|Experimental|Pemetrexed 500mg/m2 iv|
11467476|NCT01579630|Experimental|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
11467477|NCT01579617|Experimental|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
11467478|NCT01579617|Other|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
11467479|NCT01579604|Experimental|Surgical arm|"Nerve reconstruction:
~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
11467480|NCT01579604|No Intervention|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
11467481|NCT01579591|Experimental|VSL#3 PROBIOTIC PREPARATION|
11467482|NCT01579591|Placebo Comparator|Placebo|
11467483|NCT01579578|Experimental|1|
11467484|NCT01579578|Placebo Comparator|2|
11467485|NCT01579565|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
11467486|NCT01579565|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
11467487|NCT01579552|Experimental|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
11467535|NCT01579279|Experimental|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
11467536|NCT01579279|Placebo Comparator|Placebo|Placebo capsules twice daily
11467488|NCT01579552|Active Comparator|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
11467489|NCT01579539|Experimental|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
11467490|NCT01579526|Experimental|FP01 Dose 1|Drug
11467491|NCT01579526|Experimental|FP01 Dose 2|Drug
11467492|NCT01579526|Experimental|FP01 Dose 3|Drug
11467493|NCT01579526|Active Comparator|Comparator|Drug
11467494|NCT01579513|Active Comparator|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
11467495|NCT01579513|Placebo Comparator|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
11467496|NCT01579500|Active Comparator|botulinum toxin A|
11467497|NCT01579500|Placebo Comparator|normal saline|
11467498|NCT01579474|Experimental|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
11467499|NCT01579474|Experimental|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
11467500|NCT01579474|Experimental|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
11467501|NCT01579474|Experimental|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
11467502|NCT01579461|Experimental|mild hepatic impairment|
11467503|NCT01579461|Experimental|moderate hepatic impairment|
11467504|NCT01579461|Experimental|healthy volunteers (matched with mild hepatic)|
11467505|NCT01579461|Experimental|healthy volunteers (matched with moderate hepatic)|
11467506|NCT01579448|Experimental|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
11467507|NCT01579448|Active Comparator|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
11467508|NCT01579448|Placebo Comparator|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
11467509|NCT01579435|Experimental|Therapeutic tDCS|6 patients with essential tremor
11467510|NCT01579435|Experimental|Physiopathological tDCS|6 patients with essential tremor
11467511|NCT01579422|Experimental|social cognitive training|
11467512|NCT01579409|Other|1-25th percentile of the PNNS score|
11467513|NCT01579409|Other|75-100th percentile of the PNNS score|
11467514|NCT01579396|Experimental|septeX|septeX CVVH for 12h after cardiac surgery
11467515|NCT01579396|Other|standard therapy|standard therapy according to local practice
11467516|NCT01579383|Experimental|Part A, Cohorts A - H|ALD403/Placebo
11467517|NCT01579383|Experimental|Part A, Cohort I|ALD403/Placebo
11467518|NCT01579383|Experimental|Part B|ALD403/Placebo/Sumatriptan
11467519|NCT01579370|Active Comparator|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
11467520|NCT01579370|Experimental|Bleach|Rooms will be terminally cleaned using bleach-containing products.
11467521|NCT01579370|Experimental|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
11467522|NCT01579370|Experimental|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
11467523|NCT01579357|Other|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
11467524|NCT01579357|Other|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
11467525|NCT01579344|Active Comparator|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
11467526|NCT01579344|No Intervention|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
11467527|NCT01579331|Experimental|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
11467528|NCT01579318|Experimental|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
11467529|NCT01579305|Experimental|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
11467530|NCT01579305|Active Comparator|Restylane-L®|Subjects injected with Restylane-L® in their lips
11467531|NCT01579292|Experimental|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
11467532|NCT01579292|Active Comparator|Pedometer only|Pedometer only
11467533|NCT01579279|Experimental|ABT-652 6 mg|ABT-652 capsules - twice daily
11467537|NCT01579279|Active Comparator|Duloxetine|Duloxetine capsules once daily
11467538|NCT01579240|Experimental|program visits|visits to intervention program
11467539|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
11467540|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
11467541|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
11467542|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
11467543|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
11467544|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
11467545|NCT01579214|Active Comparator|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
11467546|NCT01579214|No Intervention|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
11467547|NCT01579201|Experimental|Carbetocin|
11467548|NCT01579188|Experimental|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
11467549|NCT01579188|Placebo Comparator|Placebo|Placebo
11467550|NCT01579175|No Intervention|Standard postoperative care|
11467551|NCT01579175|Experimental|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
11467552|NCT01579162|Experimental|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
11467553|NCT01579162|Experimental|chronic HCV patients with F0-F2 fibrosis|
11467554|NCT01579162|Experimental|chronic HCV patients with F3-F4 fibrosis|
11467555|NCT01579162|Experimental|NASH patients with F0-F2 fibrosis|
11467556|NCT01579162|Experimental|NASH patients with F3-F4 fibrosis|
11467557|NCT01579149|Experimental|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
11467558|NCT01579149|Placebo Comparator|Placebo|
11467559|NCT01579136|No Intervention|Control group|This group will not get a home blood pressure monitor.
11467560|NCT01579136|Experimental|Home monitors|This group will be given a home blood pressure monitor to use.
11467561|NCT01579123|Active Comparator|Laser atherectomy|
11467562|NCT01579123|Active Comparator|Angioplasty|
11467563|NCT01579110|Experimental|prednisolone + levamisole|
11467564|NCT01579110|Active Comparator|Prednisone|
11467565|NCT01579097|Active Comparator|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
11467566|NCT01579097|Experimental|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
11467567|NCT01579084|Experimental|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
11467568|NCT01579084|Experimental|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
11467569|NCT01579084|Experimental|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
11467570|NCT01579084|Other|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
11467571|NCT01579084|Other|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
11467572|NCT01579084|Other|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
11467573|NCT01579084|Experimental|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
11467574|NCT01579084|Experimental|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
11467575|NCT01579084|Experimental|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
11467576|NCT01579084|Placebo Comparator|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
11467577|NCT01579071|Experimental|CO2 sufflation group|
11467578|NCT01579071|Experimental|Room air sufflation group|
11467579|NCT01579058|Active Comparator|bisoprolol|bisoprolol 5mg qd
11467580|NCT01579058|Placebo Comparator|placebo|placebo
11467581|NCT01579045|Experimental|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
11467582|NCT01579045|Experimental|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
11467583|NCT01579045|Experimental|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
11467584|NCT01579045|Experimental|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
11467585|NCT01579045|Experimental|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
11467586|NCT01579045|Experimental|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
11467587|NCT01579045|Experimental|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
11467588|NCT01579045|Experimental|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
11467589|NCT01579045|Experimental|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
11467590|NCT01579045|Experimental|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
11467591|NCT01579045|Experimental|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
11467592|NCT01579045|Experimental|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:
~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
11467593|NCT01579032||CKD patients|
11467594|NCT01579019|Active Comparator|1000 mg 24 weeks|
11467595|NCT01579019|Active Comparator|1000 mg 26 weeks|
11467596|NCT01579019|Experimental|1500 mg 24 weeks|
11467597|NCT01579019|Experimental|1500 mg 26 weeks|
11467598|NCT01579006||Cohort|
11467599|NCT01578980|Experimental|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
11467600|NCT01578967|Other|ABVD followed by Brentuximab vedotin|Single arm trial
11467601|NCT01578954|Experimental|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
11467602|NCT01578941|Placebo Comparator|Placebo|
11467603|NCT01578941|Active Comparator|Treximet|
11467604|NCT01578928|Experimental|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
11467605|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
11467606|NCT01578915||Controls|Women with only one sexual partner during the past year
11467607|NCT01578902|Experimental|Hypofractionated radiation|35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.
11467608|NCT01578889|Experimental|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
11467609|NCT01578889|Placebo Comparator|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
11467610|NCT01578889|Experimental|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
11467611|NCT01578889|Placebo Comparator|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
11467612|NCT01578889|Experimental|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
11467613|NCT01578889|Placebo Comparator|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
11467614|NCT01578889|Experimental|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
11467615|NCT01578889|Placebo Comparator|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
11467616|NCT01578876|Experimental|CSWT for 3 month|A group
11467617|NCT01578876|Experimental|CSWT for 1 month|B group
11467618|NCT01578876|No Intervention|Control group|C group
11467619|NCT01578863|Active Comparator|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
11467620|NCT01578863|No Intervention|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
11467621|NCT01578863|No Intervention|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
11467622|NCT01578850|Experimental|Group A|
11467623|NCT01578850|Placebo Comparator|Group B|
11467624|NCT01578837|Experimental|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
11467625|NCT01578837|Placebo Comparator|Wheat Bran|100 % Natural Wheat Bran capsule
11467627|NCT01578824|Active Comparator|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
11467628|NCT01578811|Placebo Comparator|Placebo|
11467629|NCT01578811|Experimental|SK-MS10 160mg t.i.d|
11467630|NCT01578811|Experimental|SK-MS10 320mg t.i.d|
11467631|NCT01578785|Experimental|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
11467632|NCT01578785|Placebo Comparator|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
11467633|NCT01578772|Experimental|Telmisartan|Open label
11467634|NCT01578759|Experimental|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
11467635|NCT01578759|No Intervention|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
11467636|NCT01578746|Active Comparator|Direct lateral approach|Patient operated using direct lateral approach.
11467637|NCT01578746|Active Comparator|Anterior approach|Patient operated using anterior approach.
11467638|NCT01578733|Experimental|protein intake|different levels of protein intake
11467639|NCT01578720|Other|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).
~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
11467640|NCT01578707|Active Comparator|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
11467641|NCT01578707|Experimental|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
11467642|NCT01578694|Other|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
11467643|NCT01578694|Other|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
11467644|NCT01578681|Active Comparator|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.
~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
11467645|NCT01578681|Placebo Comparator|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.
~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
11467646|NCT01578668|Experimental|Erlotinib, pemetrexed, cisplatin|
11467647|NCT01578668|Experimental|erlotinib|
11467648|NCT01578655|Experimental|Cabazitaxel plus Custirsen|cabazitaxel, prednisone, and custirsen sodium
11467649|NCT01578655|Active Comparator|Cabazitaxel|cabazitaxel and prednisone
11467650|NCT01578642|Other|Single Arm open label|EndoStim LES Stimulation System
11467651|NCT01578629|Active Comparator|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
11467652|NCT01578629|Active Comparator|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
11467653|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
11467654|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
11467655|NCT01578603|Experimental|sugar substituted chewing gum A|
11467656|NCT01578603|Experimental|Sugar substituted chewing gum B|
11467657|NCT01578590|Experimental|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
11467658|NCT01578590|Active Comparator|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
11467659|NCT01578577|No Intervention|Standard Care|This arm will serve as a control group and will not receive any intervention.
11467660|NCT01578577|Experimental|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
11467661|NCT01578577|Experimental|Nurse Educator + EHMI|
11467662|NCT01578564|Experimental|SOR-C13|
11467663|NCT01578551|Experimental|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
11467664|NCT01578551|Active Comparator|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
11467665|NCT01578538|Active Comparator|mesh used repair|mesh used hernia repair will be perform
11467666|NCT01578538|Active Comparator|nonmesh|nonmesh hernia repair techniques will be used
11467667|NCT01578525|No Intervention|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
11468395|NCT01573598|Experimental|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
11467668|NCT01578525|Other|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
11467669|NCT01578512|Experimental|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
11467670|NCT01578512|Experimental|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
11467671|NCT01578512|Active Comparator|Single Session|Single session behavioral weight loss
11467672|NCT01578499|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
11467673|NCT01578499|Active Comparator|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
11467674|NCT01578486|Experimental|salsalate|open-label trial of salsalate 3g/day
11467675|NCT01578473|Active Comparator|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
11467676|NCT01578473|Active Comparator|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
11467677|NCT01578460|Active Comparator|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
11467678|NCT01578460|Experimental|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
11467679|NCT01578447|Other|Depo-SubQ Provera 104 in Uniject|
11467680|NCT01578447|Other|Intramuscular DMPA|
11467681|NCT01578434|Active Comparator|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
11467682|NCT01578434|Active Comparator|Vitamin D|Vitamin D: 6 lakh IU single im dose
11467683|NCT01578434|Active Comparator|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
11467684|NCT01578421|Other|FX 100 dialyzer|
11467685|NCT01578421|Other|Polyflux 210 H dialyzer|
11467686|NCT01578421|Other|FXCorDiax 100 dialyzer|
11467687|NCT01578408|Active Comparator|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
11467688|NCT01578408|Active Comparator|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
11467689|NCT01578395|Experimental|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
11467690|NCT01578395|Experimental|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
11467691|NCT01578395|Placebo Comparator|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
11467692|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:
~Arch Dermatol 2010;146:961-968"
11467693|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:
~Vasa 1998;27:137-143"
11467694|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:
~J Vasc Surg. 2004 Dec;40(6):1248-52"
11467695|NCT01578369|Experimental|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
11467696|NCT01578369|No Intervention|Control|Usual care
11467697|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
11467698|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
11467699|NCT01578343|Experimental|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
11467700|NCT01578330|Experimental|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
11467701|NCT01578317|Experimental|AS03 adjuvanted|Adminsitered day 1, booster at Day 21
11467702|NCT01578317|Experimental|unadjuvanted|Administer day 1 and booster at Day 21
11467703|NCT01578304|Experimental|Imidafenacin|
11467704|NCT01578304|Active Comparator|Fesoterodine|
11467705|NCT01578291|No Intervention|No intervention|Parents given routine information by the medical staff.
11467706|NCT01578291|Active Comparator|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
11467707|NCT01578291|Active Comparator|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
11467708|NCT01578278|Experimental|Bepotastine besilate formulation|Nasal Spray
11467709|NCT01578278|Experimental|Fluticasone propionate|Nasal Spray
11467710|NCT01578278|Experimental|Bepotastine besilate-fluticasone propionate|Nasal Spray
11467711|NCT01578278|Placebo Comparator|Placebo Comparator|Nasal Spray
11467712|NCT01578265|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
11467713|NCT01578265|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
11467714|NCT01578252|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
11467715|NCT01578252|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
11467716|NCT01578239|Experimental|177Lu-DOTA0-Tyr3-Octreotate|"30 mg Octreotide LAR treatment for symptom control will continue until the end of study, unless the patient progresses or dies;
~Treatment will consist of a cumulative dose of 29.6 gigaBecquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate;
~Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate;
~Concomitant amino acids will be given with each administration for kidney protection;
~177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity (see Dose Modifying Toxicity (DMT) below); in case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections are allowed."
11467717|NCT01578239|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies (see Dose Modifying Toxicity (DMT));
~In case patients experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections are allowed."
11467718|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
11467719|NCT01578213|Experimental|Imatinib|
11467720|NCT01578200|Experimental|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
11467721|NCT01578200|Active Comparator|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
11467722|NCT01578187|Experimental|Hair2Go device|
11467723|NCT01578174|Placebo Comparator|Control|
11467724|NCT01578174|Active Comparator|Dexmedetomidine|
11467725|NCT01578161|Experimental|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
11467726|NCT01578161|Experimental|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
11467727|NCT01578161|Experimental|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
11467728|NCT01578161|Placebo Comparator|NormalSaline|Normal saline 10ml ivs. for 10min.
11467729|NCT01578148|Experimental|Noxipoint Therapy|
11467730|NCT01578148|Active Comparator|Physical Therapy|
11467731|NCT01578135||Phase I|
11467732|NCT01578135||Phase II|
11467733|NCT01578122|Experimental|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
11467734|NCT01578122|Active Comparator|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
11467735|NCT01578109|Experimental|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
11467736|NCT01578096|No Intervention|Diabetes education|Group-based diabetes education delivered to participants through community health workers
11467737|NCT01578096|Experimental|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
11467738|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
11467739|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
11467740|NCT01578070|Experimental|ViscoGel® and 0.2μg Act-HIB®|
11467741|NCT01578070|Experimental|0.2μg Act-HIB®|
11467742|NCT01578070|Experimental|ViscoGel® and 2μg Act-HIB®|
11467743|NCT01578070|Experimental|2μg Act-HIB®|
11467744|NCT01578070|Active Comparator|10μg Act-HIB®|
11467745|NCT01578057|Experimental|tasimelteon + placebo ethanol|
11467746|NCT01578057|Experimental|ethanol + placebo tasimelteon|
11467747|NCT01578057|Experimental|tasimelteon + ethanol|
11467748|NCT01578057|Experimental|placebo tasimelteon + placebo ethanol|
11467749|NCT01578044|Experimental|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.
~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.
~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
11467750|NCT01578044|Placebo Comparator|Control|Usual care
11467751|NCT01578031|Active Comparator|Obese Patients with Obstructive Sleep Apnea|Obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
11467752|NCT01578031|Active Comparator|Non-obese Patients with Obstructive Sleep Apnea|Non-obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
11467753|NCT01578031|Other|Obese subjects without OSA|Control.
11467754|NCT01578031|Other|Non-obese subjects without OSA|Control.
11467755|NCT01578018|Other|Lung Cancer|Diagnostic
11467756|NCT01578018|Other|Lung Disease|Diagnostic
11467757|NCT01577992|Experimental|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
11467758|NCT01577992|Experimental|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
11467759|NCT01577992|Other|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
11467806|NCT01577680|Experimental|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
11467807|NCT01577667|No Intervention|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
11468161|NCT01575184|Active Comparator|No traction|The ultrasonographic measurements without shoulder traction
11467760|NCT01577979|Experimental|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
11467761|NCT01577979|No Intervention|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
11467762|NCT01577966|Experimental|Sulfasalazine|
11467763|NCT01577953|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
11467764|NCT01577953|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
11467765|NCT01577940|Experimental|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
11467766|NCT01577940|Placebo Comparator|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
11467767|NCT01577927|Active Comparator|Usual home care|No assistance or care by PT.
11467768|NCT01577927|Experimental|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
11467769|NCT01577914|Experimental|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
11467770|NCT01577914|Active Comparator|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
11467771|NCT01577888|Experimental|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
11467772|NCT01577875|No Intervention|control group|histologic prediction only with the narrow band imaging (without magnification)
11467773|NCT01577875|Other|test group|histologic prediction with narrow band imaging plus magnification
11467774|NCT01577862|Active Comparator|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
11467775|NCT01577862|Experimental|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
11467776|NCT01577849|Active Comparator|Vitamin D3|
11467777|NCT01577849|Experimental|DP-R206|
11467778|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
11467779|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
11467780|NCT01577823|No Intervention|No foley catheter|
11467781|NCT01577823|Active Comparator|Foley Catheter|
11467782|NCT01577797|Experimental|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
11467783|NCT01577797|Placebo Comparator|Placebo text messages - Week 3 or 1|
11467784|NCT01577784|Experimental|Pazopanib|800 mg / day of pazopanib in monotherapy
11467785|NCT01577771|Active Comparator|Child|1 dose of Prevnar13 at 2 to 4 years of age
11467786|NCT01577771|Experimental|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
11467787|NCT01577771|Active Comparator|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
11467788|NCT01577771|Experimental|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
11467789|NCT01577771|Active Comparator|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
11467790|NCT01577758|Experimental|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
11467791|NCT01577745|Experimental|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
11467792|NCT01577745|Experimental|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
11467793|NCT01577745|Experimental|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
11467794|NCT01577745|Experimental|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
11467795|NCT01577745|Experimental|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
11467796|NCT01577745|Experimental|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
11467797|NCT01577732|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
11467798|NCT01577719|Active Comparator|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
11467799|NCT01577719|Placebo Comparator|Usual Care|usual care
11467800|NCT01577706|Active Comparator|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
11467801|NCT01577706|Active Comparator|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
11467802|NCT01577706|Placebo Comparator|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
11467803|NCT01577693|Experimental|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
11467804|NCT01577693|Other|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
11467805|NCT01577680|Experimental|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
11468199|NCT01574937|Experimental|Treatment Arm|Cabozantinib and abiraterone
11467808|NCT01577667|Experimental|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.
~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.
~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).
~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
11467809|NCT01577654|Experimental|Arm A: EC145 alone|EC145 alone
11467810|NCT01577654|Experimental|Arm B: EC145 + Docetaxel|EC145 + Docetaxel
11467811|NCT01577654|Active Comparator|Arm C: Docetaxel alone|Docetaxel alone
11467812|NCT01577628|Other|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
11467813|NCT01577628|No Intervention|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
11467814|NCT01577615|Experimental|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
11467815|NCT01577615|No Intervention|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
11467816|NCT01577602|No Intervention|Standard practice|
11467817|NCT01577602|Experimental|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
11467818|NCT01577602|Experimental|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
11467819|NCT01577602|Experimental|Combined intervention|
11467820|NCT01577589|Experimental|A|600 mg ceftaroline fosamil in 50 ml infusion volume
11467821|NCT01577589|Placebo Comparator|B|Placebo in 50 ml infusion volume
11467822|NCT01577589|Experimental|C|600 ceftaroline fosamil in 250 ml infusion volume
11467823|NCT01577589|Placebo Comparator|D|Placebo in 250 ml infusion volume
11467824|NCT01577589|Experimental|E|600 mg ceftaroline in 100 ml infusion volume
11467825|NCT01577589|Placebo Comparator|F|Placebo in 100 ml infusion volume
11467826|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
11467827|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
11467828|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
11467829|NCT01577550|Experimental|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
11467830|NCT01577550|Placebo Comparator|i.v. placebo|A subject to receive a single i.v. dose of placebo
11467831|NCT01577550|Experimental|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
11467832|NCT01577550|Placebo Comparator|s.c. placebo|A subject to receive a single s.c. dose of placebo
11467833|NCT01577537|Experimental|VivaGel|
11467834|NCT01577537|Placebo Comparator|HEC Placebo|
11467835|NCT01577524|Active Comparator|Diluted Povidone Iodine Solution|
11467836|NCT01577524|Placebo Comparator|Normal Saline Wash|
11467837|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.
~Intervention: Samples and follow up"
11467838|NCT01577485|Experimental|Probiotic pastille|Test group
11467839|NCT01577485|Active Comparator|Control pastille|Control group
11467840|NCT01577472|Active Comparator|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
11467841|NCT01577472|Active Comparator|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
11467842|NCT01577472|Placebo Comparator|High Dose Placebo|450 IU Merional® plus Placebo
11467843|NCT01577472|Placebo Comparator|Low Dose Placebo|150 IU Merional® plus Placebo
11467844|NCT01577459|Experimental|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
11467845|NCT01577459|Placebo Comparator|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
11467846|NCT01577446|Experimental|CRT|The CRT group undergoes implantation of a CRT defibrillator
11467847|NCT01577446|No Intervention|no-CRT|The no-CRT group receives a dual-chamber defibrillator
11467848|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
11467849|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
11467850|NCT01577420|Experimental|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
11467851|NCT01577420|Placebo Comparator|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
11467852|NCT01577420|No Intervention|Group C|Control; no foot sessions
11467853|NCT01577407|Experimental|Nefopam|
11467854|NCT01577407|Placebo Comparator|placebo|
11467855|NCT01577394|Experimental|Early stage of dementia|oculomotor measurements
11467856|NCT01577381|Experimental|PF-04382923|
11467857|NCT01577381|Placebo Comparator|Placebo|
11467858|NCT01577368|Experimental|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
11468200|NCT01574924||Medical residents|
11467859|NCT01577368|Active Comparator|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
11467860|NCT01577355|Experimental|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
11467861|NCT01577342|Active Comparator|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
11467862|NCT01577342|No Intervention|No antibiotic use|
11467863|NCT01577329|Experimental|mindfulness meditation class|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
11467864|NCT01577329|No Intervention|wait list|Subjects assigned to the control group will continue with medical treatment as usual and be allowed to attend the mindfulness meditation class after week eight.
11467865|NCT01577316|Experimental|Pregnant Woman|Pregnant Woman
11467866|NCT01577316|Experimental|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
11467867|NCT01577303|Experimental|CBM training program variant 1|Attention training towards positive cues using words as stimuli
11467868|NCT01577303|Experimental|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
11467869|NCT01577303|Experimental|CBM training program variant 3|Attention training towards negative using words as stimuli
11467870|NCT01577303|Experimental|CBM training program variant 4|Attention training towards negative using words and faces
11467871|NCT01577303|Experimental|Control training variant 1|Control training condition using words as stimuli
11467872|NCT01577303|Experimental|Control training variant 2|Control training condition using words and faces as stimuli
11467873|NCT01577290|Experimental|Mindfulness training|Group receives mindfulness training.
11467874|NCT01577290|Active Comparator|Discussion group|Group has access to a discussion group.
11467875|NCT01577264||Cimzia treatment|
11467876|NCT01577238|Experimental|VivaGel|
11467877|NCT01577238|Placebo Comparator|HEC Placebo|
11467878|NCT01577225|Experimental|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Dressing should be used right after surgery and changed as needed.
11467879|NCT01577225|Active Comparator|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
11467880|NCT01577212|Experimental|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
11467881|NCT01577199|Active Comparator|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
11467882|NCT01577199|Experimental|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
11467883|NCT01577186|Experimental|Paliperidone Extended Release (ER)|
11467884|NCT01577173|Experimental|A: MEHD7945A|
11467885|NCT01577173|Active Comparator|B: Cetuximab|
11467886|NCT01577160|Experimental|Paliperidone Extended Release (ER)|
11467887|NCT01577147|Other|sample collection|Ovulation prediction products provided to aid conception
11467888|NCT01577134|Experimental|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
11467889|NCT01577134|Active Comparator|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
11467890|NCT01577134|Other|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
11467891|NCT01577121|Placebo Comparator|placebo|
11467892|NCT01577121|Experimental|indomethacin|50 mg/ 6 hours of indomethacin oral use
11467893|NCT01577108|Experimental|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
11467894|NCT01577108|Placebo Comparator|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
11467895|NCT01577095|Experimental|EA + Rosiglitazone|
11467896|NCT01577095|Placebo Comparator|Rosiglitazone|
11467897|NCT01577082|Experimental|CHF 1535 200/6µg|
11467898|NCT01577082|Active Comparator|BDP 100µg|
11467899|NCT01577056|Active Comparator|Fish oil|
11467900|NCT01577056|Placebo Comparator|Placebo|FH subjects with standard treatment (statin treatment)
11467901|NCT01577043|Active Comparator|Racecadotril|intestinal antisecretory
11467902|NCT01577043|Placebo Comparator|cornstach solution|Cornstarch powder diluted in distilled water
11467903|NCT01577030|Experimental|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
11467904|NCT01577030|Active Comparator|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
11467905|NCT01577017|Experimental|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
11467906|NCT01577004|Experimental|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
11467907|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
11467908|NCT01576978|Active Comparator|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
11467909|NCT01576978|Active Comparator|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
11468010|NCT01576315|Experimental|itraconazole|"itraconazole 10 mg/mL oral solution
~patients > 40 kg body weight : 200 mg morning and evening.
~patients < 40 kg body weight : 100 mg morning and evening.
~dosage out of meal.
~Without a loading dose"
11468298|NCT01574287|Experimental|FACBC|
11467910|NCT01576965|Experimental|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
11467911|NCT01576965|No Intervention|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
11467912|NCT01576952|Experimental|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
11467913|NCT01576952|Placebo Comparator|DuraSite Vehicle|DuraSite Vehicle dosed BID
11467914|NCT01576939|Experimental|IMRT Modulation|"All patients will undergo a computed tomography (CT) simulation study +/- a positron emission tomography (PET) scan using ≤ 3mm slices for radiation treatment planning. A standard, non-filling optimized IMRT (Intensity Modulated Radiation Therapy) plan will be generated and patients will be treated with megavoltage radiation over a course of > 6 weeks with a planned tumor dose of > 60 Gy. A medical doctor will perform weekly mucositis evaluation and grading for the measured site once a week during radiation therapy
~Modulation of an IMRT plan to reduce the dose to less than 35 Gy delivered to adjacent normal mucosa surrounding the dental filling without compromising normal tissue or tumor doses."
11467915|NCT01576926||surgery|patients with obstructive sleep apnea
11467916|NCT01576913|Active Comparator|Music pacing|Exercise testing with music pacing
11467917|NCT01576913|No Intervention|No music pacing|Exercise testing without music pacing
11467918|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
11467919|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP
~* Patients will be randomized and assigned to each group at the ratio of 1:1."
11467920|NCT01576887|Placebo Comparator|Placebo|
11467921|NCT01576887|Experimental|Bardoxolone Methyl|
11467922|NCT01576874|Experimental|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
11467923|NCT01576874|Placebo Comparator|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
11467924|NCT01576861|Experimental|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
11467925|NCT01576861|No Intervention|Control CHF patients under optimized CHF therapy|
11467926|NCT01576848|Experimental|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
11467927|NCT01576848|Experimental|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
11467928|NCT01576848|Experimental|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
11467929|NCT01576848|Experimental|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
11467930|NCT01576822|Active Comparator|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
11467931|NCT01576822|Active Comparator|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
11467932|NCT01576809|Experimental|Upper Respiratory Tract Infection|
11467933|NCT01576783|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
11467934|NCT01576783|Placebo Comparator|Placebo|Corn oil supplement
11467935|NCT01576770|Active Comparator|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.
~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.
~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
11467936|NCT01576770|Experimental|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.
~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.
~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
11467937|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
11467938|NCT01576731|Active Comparator|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
11467939|NCT01576731|Experimental|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
11468011|NCT01576315|Experimental|voriconazole|"voriconazole 40 mg/mL oral suspension :
~patients > 40 kg body weight : 200 mg morning and evening.
~patients < 40 kg body weight : 100 mg morning and evening.
~dosage out of meal.
~Without a loading dose"
11467940|NCT01576718|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11467941|NCT01576718|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11467942|NCT01576718|Experimental|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11467943|NCT01576718|Experimental|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11467944|NCT01576718|Placebo Comparator|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11467945|NCT01576718|Active Comparator|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11467946|NCT01576705|Experimental|Thyroxin + folinic acid|
11467947|NCT01576705|Active Comparator|Thyroxin+folinic acid placebo|
11467948|NCT01576705|Active Comparator|Thyroxin placebo+ folinic acid|
11467949|NCT01576705|Placebo Comparator|Thyroxin placebo+ folinic acid placebo|
11467950|NCT01576692|Experimental|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.
~Cells for infusion are prepared using the CliniMACS System."
11467951|NCT01576679|Experimental|tPA|tissue Plasminogen Activator
11467952|NCT01576679|Placebo Comparator|Placebo|Saline
11467953|NCT01576666|Experimental|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
11467954|NCT01576653|Active Comparator|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
11467955|NCT01576653|Active Comparator|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
11467956|NCT01576640|Other|Replapse Prevention Therapy|
11467957|NCT01576627|Experimental|zinc citrate|
11467958|NCT01576627|Active Comparator|zinc gluconate|
11467959|NCT01576627|Active Comparator|zinc oxide|
11467960|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
11467961|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.
~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.
~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
11467962|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
11467963|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
11468012|NCT01576302|Experimental|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
11468013|NCT01576302|Active Comparator|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
11467964|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
11467965|NCT01576588|Experimental|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
11467966|NCT01576575|Experimental|Healthy males and non-pregnant females|"Subjects will be studied during a maximum of seven occasions.
~Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.
~Sessions 1&2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
~Sessions 3&4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
~Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
~Sessions 6&7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine"
11467967|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
11467968|NCT01576549|Experimental|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
11467969|NCT01576536||Healthy volunteers|Normal healthy volunteers
11467970|NCT01576523|Experimental|Low, then medium, C1-esterase inhibitor dose|
11467971|NCT01576523|Experimental|Medium, then low, C1-esterase inhibitor dose|
11467972|NCT01576523|Experimental|Medium, then high, C1-esterase inhibitor dose|
11467973|NCT01576523|Experimental|Low, then high, C1-esterase inhibitor dose|
11467974|NCT01576523|Experimental|High, then low, C1-esterase inhibitor dose|
11467975|NCT01576523|Experimental|High, then medium, C1-esterase inhibitor dose|
11467976|NCT01576510|Experimental|Prolonged Exposure (PE) treatment.|
11467977|NCT01576510|No Intervention|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
11467978|NCT01576497|Active Comparator|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
11467979|NCT01576497|Active Comparator|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
11467980|NCT01576484|Placebo Comparator|Placebo Matched to Alirocumab|Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
11467981|NCT01576484|Experimental|Alirocumab 150 mg|Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.
11467982|NCT01576471|Placebo Comparator|Placebo|
11467983|NCT01576471|Experimental|TSO 7500|
11467984|NCT01576458|Active Comparator|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
11467985|NCT01576458|Active Comparator|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
11467986|NCT01576445|Experimental|Mid-vastus approach|
11467987|NCT01576445|Experimental|medial parapatellar approach|
11467988|NCT01576432|Experimental|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
11467989|NCT01576432|Experimental|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
11467990|NCT01576432|Experimental|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
11467991|NCT01576432|Active Comparator|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
11467992|NCT01576419|Experimental|PG201 tablet|
11467993|NCT01576419|Active Comparator|Celecoxib capsule|
11467994|NCT01576406|Experimental|A1: normal hepatic function|
11467995|NCT01576406|Experimental|A2: normal hepatic function|
11467996|NCT01576406|Experimental|B: mild hepatic impairment|
11467997|NCT01576406|Experimental|C: moderate hepatic impairment|
11467998|NCT01576406|Experimental|D: severe hepatic impairment|
11467999|NCT01576393|Experimental|Home-Based family therapy|12 home-based family therapy sessions
11468000|NCT01576393|Active Comparator|Office-based family therapy|12 office-based family therapy sessions
11468001|NCT01576393|Placebo Comparator|Women's Health Education|12 womens's health education sessions
11468002|NCT01576380|Experimental|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
11468003|NCT01576367|Experimental|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
11468004|NCT01576354|Active Comparator|Prolonged-release Fampridine|
11468005|NCT01576354|Placebo Comparator|Placebo|
11468006|NCT01576341|Experimental|HX575 epoetin alfa (Sandoz)|Single arm
11468007|NCT01576328|Experimental|Cohort 1|MPC dose 1 or Placebo
11468008|NCT01576328|Experimental|Cohort 2|MPC dose 2 or Placebo
11468009|NCT01576328|Experimental|Cohort 3|MPC dose 3 or Placebo
11468014|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
11468015|NCT01576276|Experimental|Morphine condition|
11468016|NCT01576276|Experimental|Ketorolac condition|
11468017|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
11468018|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
11468019|NCT01576250|Experimental|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
11468020|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
11468021|NCT01576224|Experimental|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
11468022|NCT01576224|Active Comparator|Later mobilization|Patients are allowed exercises after 14 days.
11468023|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
11468024|NCT01576172|Active Comparator|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11468025|NCT01576172|Experimental|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11468026|NCT01576159|Experimental|High-Impact Loading|Performed high-impact running exercise during intervention period.
11468027|NCT01576159|Experimental|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
11468028|NCT01576159|Experimental|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
11468029|NCT01576159|No Intervention|Control Group|Didn't participate any organized physical exercises
11468030|NCT01576146|Experimental|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
11468031|NCT01576133|Experimental|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
11468032|NCT01576133|Active Comparator|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
11468033|NCT01576120|Experimental|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
11468034|NCT01576120|Experimental|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
11468035|NCT01576107|Experimental|Physical activity|Exercise counseling (behavior change techniques)
11468036|NCT01576107|Experimental|Stress-management|Stress-management training
11468037|NCT01576094|Active Comparator|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
11468038|NCT01576094|Active Comparator|Levosimendan|
11468039|NCT01576081|Experimental|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
11468040|NCT01576068|Other|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
11468041|NCT01576055|Experimental|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
11468042|NCT01576055|Active Comparator|BARD LifeStent|BARD LifeStent
11468043|NCT01576042|Other|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
11468044|NCT01576042|Other|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
11468045|NCT01576029|Active Comparator|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
11468046|NCT01576029|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
11468047|NCT01576016|Experimental|Lead Safety|Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead
11468048|NCT01576016|Experimental|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment
11468049|NCT01576003|Experimental|Glutamine|Infants randomized to the Glutamine group will receive L-Glutamine (GLN) administered enterally at a dose of 0.6g/kg body weight/day (0.3g/kg/dose) in 2 divided daily doses for 6 months. GLN will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
11468050|NCT01576003|Placebo Comparator|L-alanine|Infants randomized to the placebo group will receive L-alanine (ALA) administered enterally at a dose of 0.6g/kg body weight/day in 2 divided doses (0.3g/kg/day twice a day) for 6 months. ALA will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
11468051|NCT01576003|No Intervention|Healthy Control|Healthy age-matched infants (n=12) will have serial stools collected on 4 occasions, each separated by 60 days.
11468052|NCT01575990|Experimental|Making A Decision About CRC Screening|A decision support intervention that is a literacy sensitive paper based tool with educational information targeted to the patient's age and gender.
11468053|NCT01575990|Placebo Comparator|Drivers 65 Plus|The placebo comparator is an attention control with information about driving tips for drivers age 65 and older.
11468054|NCT01575951|Experimental|All patients|All participants enrolled.
11468055|NCT01575938|Experimental|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
11468056|NCT01575938|Active Comparator|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
11468057|NCT01575938|No Intervention|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
11468058|NCT01575925|Experimental|4 mg Oral POM + 40 mg Oral DEX|Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
11468059|NCT01575925|Experimental|2 mg Oral POM + 40 mg Oral DEX|Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
11468060|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
11468061|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
11468062|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
11468063|NCT01575899|Experimental|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
11468064|NCT01575899|Active Comparator|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
11468065|NCT01575886|Experimental|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
11468066|NCT01575886|No Intervention|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
11468067|NCT01575873|Experimental|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
11468068|NCT01575873|Experimental|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
11468069|NCT01575860|Experimental|Phase I/II (Maintenance Lenalidomide in Lymphoma)|Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
11468070|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.
~Part 1 20 subjects
~Part I
~Inclusion Criteria:
~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.
~Exclusion Criteria:
~Previous recent history of APAP overdose in the previous 30 days."
11468071|NCT01575847||Part 2|"Part 2
~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.
~Part 2 100 subjects
~Part 2
~Inclusion Criteria:
~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.
~Exclusion Criteria:
~None."
11468072|NCT01575834|Experimental|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
11468073|NCT01575834|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
11468074|NCT01575821|Experimental|Eucalyptus honey ,|75 children
11468075|NCT01575821|Experimental|Labiatae honey|75 children allocated
11468076|NCT01575821|Experimental|Silan date extract (placebo)|75 children allocated
11468077|NCT01575821|Experimental|Citrus honey|75 children allocated
11468078|NCT01575808|Experimental|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
11468079|NCT01575808|No Intervention|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
11468080|NCT01575795|Active Comparator|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
11468081|NCT01575795|Experimental|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
11468082|NCT01575782|Experimental|Chloroquine|
11468083|NCT01575769|Experimental|1|
11468084|NCT01575756|Experimental|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
11468085|NCT01575756|Experimental|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
11468086|NCT01575743|Experimental|Aerobic Exercise|
11468087|NCT01575743|Other|healthy controls|
11468088|NCT01575730|Active Comparator|Oxaliplatin 37°C, high dose, 30 minutes|
11468089|NCT01575730|Placebo Comparator|Oxaliplatin 41 °C, high dose, 30 minutes|
11468090|NCT01575730|Active Comparator|Oxaliplatin 37°C, low dose, 90 minutes|
11468091|NCT01575717|Experimental|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
11468092|NCT01575717|Experimental|Vitamin D 2000|Subjects taking 2000IU of vitamin D
11468093|NCT01575717|No Intervention|No Intervention|
11468094|NCT01575704|Experimental|Sport|
11468095|NCT01575704|Other|Control|
11468096|NCT01575678|Active Comparator|Melatonin|
11468097|NCT01575678|Placebo Comparator|Lactose|
11468098|NCT01575665|Experimental|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
11468099|NCT01575652|Active Comparator|ACE-I|Group using ACEIs
11468100|NCT01575652|No Intervention|ACE-I, 2|group not using ace-i
11468101|NCT01575639|Experimental|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
11468102|NCT01575639|Active Comparator|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
11468103|NCT01575626|Active Comparator|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
11468104|NCT01575626|Active Comparator|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
11468105|NCT01575626|Active Comparator|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
11468106|NCT01575626|Active Comparator|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
11468107|NCT01575613|Experimental|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
11468108|NCT01575613|No Intervention|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
11468109|NCT01575600|Active Comparator|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
11468110|NCT01575600|Experimental|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
11468111|NCT01575587|Experimental|Treatment A|
11468112|NCT01575587|Experimental|Treatment B|
11468113|NCT01575587|Experimental|Treatment C|
11468114|NCT01575587|Experimental|Treatment D|
11468115|NCT01575574|Other|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
11468116|NCT01575561|Experimental|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
11468117|NCT01575548|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11468118|NCT01575548|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11468119|NCT01575522|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
11468120|NCT01575496|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS.
11468121|NCT01575496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
11468122|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
11468123|NCT01575470|Experimental|bone marrow mononuclear cells|a bone marrow harvest will be performed within 36 hours of injury followed by a single intravenous infusion of autologous bone marrow mononuclear cells (BMMNCs)
11468124|NCT01575457|Experimental|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
11468125|NCT01575457|Other|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
11468126|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
11468127|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
11468128|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
11468159|NCT01575197|Experimental|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, & 14 weeks of age.
11468160|NCT01575184|Experimental|Shoulder traction|The ultrasonographic measurements with shoulder traction
11468299|NCT01574274|Active Comparator|SC-PEG|SC-PEG
11468129|NCT01575418|Experimental|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
11468130|NCT01575418|Active Comparator|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
11468131|NCT01575418|Active Comparator|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
11468132|NCT01575405|Experimental|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
11468133|NCT01575405|Active Comparator|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.
~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
11468134|NCT01575405|Active Comparator|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
11468135|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
11468136|NCT01575366|Experimental|Slow tracking training|
11468137|NCT01575366|Experimental|Fast tracking training|
11468138|NCT01575353|Active Comparator|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
11468139|NCT01575353|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
11468140|NCT01575340|Experimental|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
11468141|NCT01575340|No Intervention|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
11468142|NCT01575327|Active Comparator|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
11468143|NCT01575327|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
11468144|NCT01575314|Experimental|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
11468145|NCT01575314|No Intervention|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
11468146|NCT01575288|Placebo Comparator|Maltose|
11468147|NCT01575288|Experimental|High-dose trehalose|
11468148|NCT01575275|Experimental|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
11468149|NCT01575262|Experimental|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
11468150|NCT01575262|Active Comparator|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
11468151|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF>55%
11468152|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF>55%
11468153|NCT01575236|Experimental|Guardian|Guardian Laryngeal Mask
11468154|NCT01575236|Experimental|Supreme|Supreme Laryngeal Mask Airway
11468155|NCT01575223|Active Comparator|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
11468156|NCT01575223|Placebo Comparator|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
11468157|NCT01575197|Active Comparator|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 & 10 weeks of age.
11468158|NCT01575197|Experimental|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 & 14 weeks of age.
11468162|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
11468163|NCT01575158|Experimental|citalopram|citalopram
11468164|NCT01575158|Active Comparator|clomipramnine|clomipramine
11468165|NCT01575158|Placebo Comparator|placebo|placebo
11468166|NCT01575145|Experimental|Quitline facilitation intervention|brief quitline facilitation intervention given
11468167|NCT01575145|Active Comparator|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
11468168|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
11468169|NCT01575119|Experimental|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
11468170|NCT01575119|Active Comparator|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
11468171|NCT01575119|Experimental|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
11468172|NCT01575119|Active Comparator|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
11468173|NCT01575106|Experimental|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
11468174|NCT01575080|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
11468175|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
11468176|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
11468177|NCT01575054|Experimental|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
11468178|NCT01575054|Other|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
11468179|NCT01575041|Active Comparator|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
11468180|NCT01575041|Active Comparator|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
11468181|NCT01575041|Placebo Comparator|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
11468182|NCT01575028|Active Comparator|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
11468183|NCT01575028|Experimental|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
11468184|NCT01575015|Active Comparator|Standard intraoperative support (no CRRT)|
11468185|NCT01575015|Experimental|Intraoperative renal support (CRRT)|
11468186|NCT01575002|Experimental|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
11468187|NCT01575002|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
11468188|NCT01574989|Experimental|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
11468189|NCT01574989|Experimental|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
11468190|NCT01574989|Experimental|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
11468191|NCT01574989|Experimental|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
11468192|NCT01574989|Sham Comparator|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
11468193|NCT01574976|Active Comparator|control, no feeback|subjects without ADHD, probabilistic choices without feedback
11468194|NCT01574976|Active Comparator|control, feedback|subjects without ADHD, probabilistic choices with feedback
11468195|NCT01574976|Experimental|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
11468196|NCT01574976|Experimental|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
11468197|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
11468198|NCT01574963||Control Patients|Patients without CAD
11468201|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
11468202|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
11468203|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
11468204|NCT01574898|Active Comparator|Niquitin® Fresh Mint 4 mg|
11468205|NCT01574898|Active Comparator|V0118 - B mg|
11468206|NCT01574898|Experimental|V0474 - C mg|
11468207|NCT01574898|Experimental|V0474 - B mg|
11468208|NCT01574898|Experimental|V0474 - A mg|
11468209|NCT01574885|Experimental|Aerosal|This arm include all patients treated with Aerosal®
11468210|NCT01574885|Placebo Comparator|Placebo|This arm include all patients treated with placebo
11468211|NCT01574872|Experimental|Aerosal|This arm include all patients treated with Aerosal®
11468212|NCT01574872|Placebo Comparator|Placebo|This arm include all patients treated with placebo
11468213|NCT01574859||hypopituitarism|group of patients with hypopituitarism
11468214|NCT01574846||Vantas|
11468215|NCT01574833|Active Comparator|PEMF|arm that receive PEMF treatment
11468216|NCT01574833|Sham Comparator|Sham|arm that receive sham treatment
11468217|NCT01574820|Placebo Comparator|placebo|
11468218|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
11468219|NCT01574807|Experimental|mepivacaine + lidocaine followed by lidocaine + lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
11468220|NCT01574807|Experimental|lidocaine + lidocaine followed by mepivacaine plus lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
11468221|NCT01574794|Experimental|Strengthening Exercises|Recreational older runners recruited from local community
11468222|NCT01574794|Experimental|Stretching Exercises|Recreational older runners recruited from local community
11468223|NCT01574794|No Intervention|Control Group|Recreational older runners recruited from local community
11468224|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
11468225|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D&C or D&E procedure
11468226|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
11468227|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
11468228|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
11468229|NCT01574781||Pregnant women|
11468230|NCT01574742|Experimental|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
11468231|NCT01574729|Active Comparator|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
11468232|NCT01574729|Experimental|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
11468233|NCT01574716|Experimental|MORAb-004, gemcitabine, docetaxel|
11468234|NCT01574716|Active Comparator|Placebo, gemcitabine, docetaxel|
11468235|NCT01574703|Experimental|placebo|
11468236|NCT01574703|Experimental|varenicline|
11468237|NCT01574703|Experimental|bupropion|
11468238|NCT01574703|Experimental|Nicotine Replacement Therapy Patch|
11468239|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
11468240|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
11468241|NCT01574664||Subjects scheduled to undergo lumpectomy|
11468242|NCT01574651|Experimental|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
11468243|NCT01574651|Active Comparator|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
11468244|NCT01574638|Experimental|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
11468245|NCT01574638|Experimental|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
11468246|NCT01574638|Experimental|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
11468300|NCT01574274|Active Comparator|Oncaspar|Oncaspar
11468396|NCT01573598|Experimental|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
11468247|NCT01574638|Experimental|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
11468248|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
11468249|NCT01574612|Experimental|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
11468250|NCT01574599|Experimental|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
11468251|NCT01574599|No Intervention|Conventional Therapy Program|Typical therapy excluding robotics, RFE
11468252|NCT01574586|Active Comparator|2-link stent Nobori|Bifurcation stenting
11468253|NCT01574586|Active Comparator|3-link stent Xience|Bifurcation stenting
11468254|NCT01574573|Experimental|Obese individuals with weight loss|Self support, group sessions
11468255|NCT01574573|Experimental|Obese individuals without weight loss|self support, group sessions
11468256|NCT01574560|Active Comparator|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
11468257|NCT01574560|Active Comparator|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
11468258|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
11468259|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
11468260|NCT01574534|Experimental|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
11468261|NCT01574534|Active Comparator|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
11468262|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
11468263|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
11468264|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
11468265|NCT01574508|Experimental|Continuous Subcutaneous Insulin Infusion|CSII
11468266|NCT01574508|Active Comparator|Multiple Daily Insulin Injections|MDI
11468267|NCT01574495|Experimental|Error Augmentation-Control|
11468268|NCT01574495|Experimental|Control-Error Augmentation|
11468269|NCT01574482|Experimental|1 = Tested product|
11468270|NCT01574482|Placebo Comparator|2 = Control product|
11468271|NCT01574469|Active Comparator|1 = Tested product|
11468272|NCT01574469|Placebo Comparator|2 = Control product|
11468273|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
11468274|NCT01574456||13 patients with mild cognitive impairment|
11468275|NCT01574456||19 healthy controls|
11468276|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
11468277|NCT01574430|Active Comparator|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
11468278|NCT01574430|Experimental|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
11468279|NCT01574417|Experimental|Plant stanol-enriched margarine|
11468280|NCT01574417|Placebo Comparator|control margarine|
11468281|NCT01574404|Experimental|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
11468282|NCT01574391|Active Comparator|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
11468283|NCT01574391|No Intervention|Control|This arm is the control where normal technique is used
11468284|NCT01574378|Active Comparator|Control arm|Control arm- conventional method of wound closure
11468285|NCT01574378|Experimental|V-Loc group|V-Loc 90 barbed sutures
11468286|NCT01574365|Experimental|RTA402|
11468287|NCT01574365|Experimental|RTA402 Low|
11468288|NCT01574365|Experimental|RTA402 Medium-low|
11468289|NCT01574365|Experimental|RTA402 Medium-high|
11468290|NCT01574352|Experimental|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
11468291|NCT01574352|Experimental|Small intervention|Children are only informed of healthy behavior
11468292|NCT01574339|Experimental|Treatment Arm|
11468293|NCT01574326|Placebo Comparator|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
11468294|NCT01574326|Experimental|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
11468295|NCT01574313|Experimental|Stellate ganglion block|treated with SGB
11468296|NCT01574313|Active Comparator|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
11468297|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.
~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:
~tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions
~serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
11468301|NCT01574261|Active Comparator|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
11468302|NCT01574261|Placebo Comparator|Placebo|Patients will be randomized to receive placebo for four months
11468303|NCT01574248|Experimental|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
11468304|NCT01574248|Placebo Comparator|Placebo|Subcutaneous at time 0 and 6 hours
11468305|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
11468306|NCT01574222|Experimental|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
11468307|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
11468308|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
11468309|NCT01574209||Healthy subjects|Healthy subjects as control group
11468310|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
11468311|NCT01574183|Experimental|Vilazodone|Flexible dose up to 40 mg capsule daily
11468312|NCT01574183|Placebo Comparator|Placebo|Flexible dose up to 40 mg capsule daily
11468313|NCT01574157|Active Comparator|Sodium Bicarbonate|Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
11468314|NCT01574157|Placebo Comparator|Placebo|Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
11468315|NCT01574144||AVIVO™ PiiX Patch Monitor System|Heart failure patients monitored continuously for 30 days post-discharge.
11468316|NCT01574131|Placebo Comparator|Sugar pill|pill
11468317|NCT01574131|Active Comparator|Fenofibrate|ppar-alpha agonist
11468318|NCT01574118|Experimental|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:
~Psycho-education addressing common reactions to trauma
~Revisiting the Trauma memories
~Processing the trauma memories
~In vivo Exposure homework
~*Use of a brief pre-exposure trauma memory retrieval trial
~Exposure to video clips related to the patient's trauma
~Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
11468319|NCT01574118|Active Comparator|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:
~Psycho-education addressing common reactions to trauma
~Revisiting of the Trauma memories
~Processing the trauma memories
~Breathing retraining
~In vivo Exposure homework"
11468320|NCT01574118|No Intervention|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
11468321|NCT01574105||Heparin Resistant|Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
11468322|NCT01574105||Heparin Sensitive|Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.
11468323|NCT01574092|Experimental|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
11468324|NCT01574079|Active Comparator|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
11468325|NCT01574079|Experimental|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
11468326|NCT01574066|Experimental|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
11468327|NCT01574040|Experimental|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
11468328|NCT01574027|Placebo Comparator|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
11468329|NCT01574027|Experimental|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
11468330|NCT01574014|Active Comparator|1: CBGT & Hydrocortisone|
11468331|NCT01574014|Placebo Comparator|2: CBGT & Placebo|
11468332|NCT01574001|Experimental|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
11468333|NCT01574001|Active Comparator|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
11468334|NCT01574001|Experimental|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
11468335|NCT01573988|Other|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
11468336|NCT01573988|Other|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
11468337|NCT01573975|Experimental|Seq-Metronidazole|10-day sequential therapy with metronidazole
11468338|NCT01573975|Experimental|Seq-Tetracycline|10-day sequential therapy with tetracycline.
11468339|NCT01573975|Active Comparator|Control|10-day standard triple therapy.
11468340|NCT01573949|Experimental|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
11468341|NCT01573936|Experimental|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
11468342|NCT01573923|Sham Comparator|Conventional therapy|only apply for conventional medical therapy without any cell therapy
11468393|NCT01573611|Placebo Comparator|Placebo Powder|
11468394|NCT01573598|Placebo Comparator|Placebo|Dose-matched placebo capsules, oral administration
11468343|NCT01573923|Active Comparator|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
11468344|NCT01573910|Experimental|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
11468345|NCT01573910|Active Comparator|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
11468346|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
11468347|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
11468348|NCT01573871|Experimental|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
11468349|NCT01573858|Experimental|Acupuncture treatment 1 plus CC|
11468350|NCT01573858|Active Comparator|Acupuncture treatment 2 plus CC|
11468351|NCT01573858|Active Comparator|Acupuncture treatment 1 plus CC placebo|
11468352|NCT01573858|Active Comparator|Acupucture treatment 2 and CC placebo.|
11468353|NCT01573845|Experimental|Healthy Eating + Eco-Friendly Campaign|
11468354|NCT01573845|Active Comparator|Healthy Eating Campaign|
11468355|NCT01573845|No Intervention|Control/Delayed Intervention|
11468356|NCT01573832|Experimental|Diabetic Foot Ulcer Intervention|
11468357|NCT01573832|No Intervention|Diabetic Foot Ulcer Usual Care|
11468358|NCT01573832|Experimental|Pionidal Sinus Ulcer Intervention|
11468359|NCT01573832|No Intervention|Pionidal Sinus Ulcer Usual Care|
11468360|NCT01573819|Experimental|Cohort 1|A dose of 2mg per day for 10 days
11468361|NCT01573819|Experimental|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
11468362|NCT01573819|Experimental|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
11468363|NCT01573806|Active Comparator|Exenatide|Subjects dosed with exenatide in Phase 2
11468364|NCT01573806|Placebo Comparator|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
11468365|NCT01573793|Active Comparator|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
11468366|NCT01573793|Sham Comparator|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
11468367|NCT01573780|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11468368|NCT01573767|Active Comparator|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
11468369|NCT01573767|Active Comparator|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
11468370|NCT01573767|Active Comparator|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
11468371|NCT01573767|Placebo Comparator|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
11468372|NCT01573754|Experimental|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
11468373|NCT01573754|Active Comparator|Phlebotomy|Phlebotomy 450 mL biweekly
11468374|NCT01573741|Experimental|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
11468375|NCT01573728|Active Comparator|Low Exercise Arm|Low dose exercise (50 Minutes)
11468376|NCT01573728|Experimental|Public Health Exercise|Public Health dose exercise (150 minutes)
11468377|NCT01573715|Active Comparator|severe ARDS patients|
11468378|NCT01573715|Active Comparator|control group|
11468379|NCT01573715|Experimental|moderate SDRA patients|
11468380|NCT01573702|Other|Single Arm Study|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
11468381|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
11468382|NCT01573663|Experimental|Ambroxol and Levodropropizine|
11468383|NCT01573663|Active Comparator|Ambroxol|
11468384|NCT01573663|Active Comparator|Levodropropizine|
11468385|NCT01573650||group 1|Group 1a (standard): Epineural Suture Group 1b (experimental): Epineural suture and Fibrin Wrap
11468386|NCT01573650||group 2|Group 2a (standard): Epineural suture and autologous nerve transplantation from lateral antebrachial cutaneous nerve (LACN) Group 2b (experimental): Epineural suture and Fibrin Conduit
11468387|NCT01573637|Experimental|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.
~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
11468388|NCT01573637|Placebo Comparator|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.
~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
11468389|NCT01573624|Active Comparator|Fluticasone Furoate (FF)|100mcg, inhaled
11468390|NCT01573624|Active Comparator|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
11468391|NCT01573624|Experimental|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
11468392|NCT01573611|Experimental|Grape Powder|
11468397|NCT01573585|Active Comparator|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
11468398|NCT01573585|Experimental|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
11468399|NCT01573572|Experimental|Intravitreal Injections of Macugen|
11468400|NCT01573559||ClearView/Predicate|
11468401|NCT01573546|Experimental|Aerobic Exercise|
11468402|NCT01573546|Experimental|DASH diet|
11468403|NCT01573546|Experimental|Combined aerobic exercise and DASH diet|
11468404|NCT01573546|Active Comparator|Health education control|
11468405|NCT01573533|Experimental|Rituximab|
11468406|NCT01573520|No Intervention|usual care|
11468407|NCT01573520|Active Comparator|adherence intervention arm|Monitoring drug adherence to guide treatment
11468408|NCT01573507|Experimental|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
11468409|NCT01573494|Experimental|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
11468410|NCT01573481|Active Comparator|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
11468411|NCT01573481|Active Comparator|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
11468412|NCT01573468|Experimental|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
11468413|NCT01573468|Active Comparator|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
11468414|NCT01573442|Experimental|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
11468415|NCT01573442|Placebo Comparator|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
11468416|NCT01573429|Other|Dermal Carboxymethylcellulose arm|d-BPA administered dermally using a carboxymethylcellulose suspension
11468417|NCT01573429|Other|Dermal ethanol arm|d-BPA is administered dermally using an ethanol solution
11468418|NCT01573429|Other|Oral arm|d-BPA administered orally
11468419|NCT01573416|Placebo Comparator|Control group|
11468420|NCT01573416|Active Comparator|Intervention group|
11468421|NCT01573403|Experimental|Treatment 1|one dose of DLBS2411 @250 mg
11468422|NCT01573403|Experimental|Treatment II|two doses of DLBS2411 @250 mg
11468423|NCT01573403|Placebo Comparator|Treatment III|
11468424|NCT01573390||1|Healthy participants.
11468425|NCT01573377|Experimental|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
11468426|NCT01573377|Experimental|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
11468427|NCT01573351|Experimental|QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin|"Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks
~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks
~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks
~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks"
11468428|NCT01573338|Experimental|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
11468429|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
11468430|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
11468431|NCT01573299|Active Comparator|Early vertical positioning|
11468432|NCT01573299|Active Comparator|Progressively vertical positioning|
11468433|NCT01573286|Experimental|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for >30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
11468434|NCT01573286|Experimental|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
11468435|NCT01573273|Experimental|TSST Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
11468436|NCT01573273|Placebo Comparator|TSST Women Placebo|Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
11468437|NCT01573273|Experimental|MRI 1 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
11468438|NCT01573273|Placebo Comparator|MRI 1 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
11468629|NCT01572012|Experimental|Intramuscular Administration|Ondansetron administered intramuscularly
11468439|NCT01573273|Experimental|MRI 2 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
11468440|NCT01573273|Placebo Comparator|MRI 2 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
11468441|NCT01573273|Experimental|TSST Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
11468442|NCT01573273|Placebo Comparator|TSST Men Placebo|Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
11468443|NCT01573273|Experimental|MRI I Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
11468444|NCT01573273|Placebo Comparator|MRI I Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
11468445|NCT01573273|Experimental|MRI 2 Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
11468446|NCT01573273|Placebo Comparator|MRI 2 Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
11468447|NCT01573260|Experimental|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
11468448|NCT01573260|Placebo Comparator|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
11468449|NCT01573247|Experimental|AKN-028|
11468450|NCT01573234|Experimental|MySkin patch|Hydrogel and polyurethane film
11468451|NCT01573234|Active Comparator|Traditional Dressing|
11468452|NCT01573221||stroke|
11468453|NCT01573208|Experimental|Register|Register
11468454|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
11468455|NCT01573182|Experimental|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
11468456|NCT01573169|Experimental|low weight molecular heparin|enoxaparin 0.4 ml subcutaneous per day
11468457|NCT01573169|Placebo Comparator|standard therapy|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
11468458|NCT01573156|Experimental|VTP treatment to small renal mass|
11468459|NCT01573143|Placebo Comparator|Sugar pill|Placebo
11468460|NCT01573143|Experimental|Rosuvastatin|Rosuvastatin (20 mg od)
11468461|NCT01573130|Experimental|Initial treatment group|Group receives treatment.
11468462|NCT01573130|No Intervention|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
11468463|NCT01573117|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
11468464|NCT01573117|Active Comparator|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
11468465|NCT01573104|Experimental|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
11468466|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
11468467|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
11468468|NCT01573065|Experimental|Single arm|
11468469|NCT01573052|Active Comparator|Chlordiazepoxide|Chlordiazepoxide 25mg capsule or matching placebo capsule
11468470|NCT01573052|Experimental|Gabapentin|Gabapentin 300mg capsule or matching placebo capsule
11468471|NCT01573013|Active Comparator|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
11468472|NCT01573013|Active Comparator|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
11468473|NCT01573013|Active Comparator|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
11468474|NCT01573013|Placebo Comparator|control treatment, biscuit|group receives a biscuit without additional iron
11468475|NCT01573000|Experimental|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
11468476|NCT01573000|Experimental|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
11468477|NCT01572987|Active Comparator|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
11468478|NCT01572987|Active Comparator|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
11468479|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
11468480|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
11468481|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
11468482|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
11468483|NCT01572961|Active Comparator|Aspirin|Aspirin
11468484|NCT01572961|Placebo Comparator|Placebo|Placebo
11468630|NCT01572012|Experimental|Intravenous Administration|Ondansetron administered intravenously
11468485|NCT01572948|Placebo Comparator|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
11468486|NCT01572948|Active Comparator|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
11468487|NCT01572922|Other|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.
~Interventions: R2*-UTE, R2*-GRE, and if clinically indicated, liver biopsy."
11468488|NCT01572909|Active Comparator|Bendavia™|Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
11468489|NCT01572909|Placebo Comparator|Placebo|Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
11468490|NCT01572896|Experimental|Taking Charge Experimental Group|
11468491|NCT01572896|Active Comparator|Control Group|
11468492|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
11468493|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
11468494|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
11468495|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.
~20 patients hospitalized."
11468496|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.
~30 patients hospitalized."
11468497|NCT01572844|Experimental|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
11468498|NCT01572844|No Intervention|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
11468499|NCT01572831|No Intervention|standard care|Abx will be determined by the managing physician
11468500|NCT01572831|Experimental|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
11468501|NCT01572818|Experimental|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
11468502|NCT01572818|Active Comparator|Lifestyle counseling|dietary and lifestyle counseling
11468503|NCT01572805|Active Comparator|melatonin 3mg|
11468504|NCT01572805|Active Comparator|melatonin 6mg|
11468505|NCT01572805|Placebo Comparator|placebo|
11468506|NCT01572792|Experimental|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
11468507|NCT01572792|Experimental|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
11468508|NCT01572792|Active Comparator|3|Aclidinium bromide 400 μg
11468509|NCT01572792|Active Comparator|4|Formoterol Fumarate 12 μg
11468510|NCT01572792|Placebo Comparator|5|Placebo
11468511|NCT01572779|Experimental|Intervention|BSM device with bio-feedback
11468512|NCT01572779|Placebo Comparator|Control|The BSM device without feed-back
11468513|NCT01572766|Active Comparator|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
11468514|NCT01572766|No Intervention|Control group|Control group receives heel ultrasound and pharmacist counseling
11468515|NCT01572753|Experimental|Post-dose fasting 120 mins/50 ml water|
11468516|NCT01572753|Experimental|Post-dose fasting 60 mins/50 ml water|
11468517|NCT01572753|Experimental|Post-dose fasting 30 mins/50 ml water|
11468518|NCT01572753|Experimental|Post-dose fasting 15 mins/50 ml water|
11468519|NCT01572753|Experimental|Post-dose fasting 120 mins/120 ml water|
11468520|NCT01572753|Experimental|Post-dose fasting 60 mins/120 ml water|
11468521|NCT01572753|Experimental|Post-dose fasting 30 mins/120 ml water|
11468522|NCT01572753|Experimental|Post-dose fasting 15 mins/120 ml water|
11468523|NCT01572740|Experimental|Lira+Insulin|
11468524|NCT01572740|Placebo Comparator|Placebo+Insulin|
11468525|NCT01572727|Experimental|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
11468526|NCT01572727|Active Comparator|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
11468527|NCT01572714|Active Comparator|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
11468528|NCT01572714|Active Comparator|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
11468529|NCT01572714|Active Comparator|Physical Activity Plus Fatigue|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
11468530|NCT01572701|Experimental|20 (±3) mCi of study drug|
11468531|NCT01572688|Experimental|autologous stem cell transplant|
11468532|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
11468533|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
11468534|NCT01572662|Experimental|Fludarabine + Busulfan|"Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.
~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
11468535|NCT01572649|Placebo Comparator|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
11468536|NCT01572649|Experimental|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
11468537|NCT01572649|Experimental|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
11468538|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
11468539|NCT01572623|Active Comparator|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
11468540|NCT01572623|Active Comparator|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
11468541|NCT01572610|Experimental|RTA 402|
11468542|NCT01572597|Experimental|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
11468543|NCT01572597|Active Comparator|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
11468544|NCT01572558|Active Comparator|Appendectomy|Standard surgical treatment, appendectomy
11468545|NCT01572558|Experimental|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
11468546|NCT01572545|Experimental|Denosumab|
11468547|NCT01572545|Experimental|Zoledronic Acid|
11468548|NCT01572532|Experimental|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab ~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.
~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
11468549|NCT01572532|No Intervention|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
11468550|NCT01572519|Experimental|JNJ-40346527|
11468551|NCT01572506|Active Comparator|Group 1|Age 70 and older with unexplained anemia
11468552|NCT01572506|Active Comparator|Group 2|Age 70 and older with iron deficient
11468553|NCT01572506|Active Comparator|Group 3|Age 70 and older without anemia
11468554|NCT01572506|Active Comparator|Group 4|Age 18 - 50 without anemia
11468555|NCT01572493|Experimental|Arm A1 (Dose Escalation, 10-day Dosing)|MTD determination in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
11468556|NCT01572493|Experimental|Arm A2 (Dose Expansion, 10-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
11468557|NCT01572493|Experimental|Arm B1 (Dose Escalation, 5-day Dosing)|MTD determination in subjects with metastatic unresectable cancers receiving rhIL-15 IV for 5 consecutive days
11468558|NCT01572493|Experimental|Arm B2 (Dose Expansion, 5-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 5 consecutive days
11468559|NCT01572480|Experimental|A - (closed)|Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1- 21 of the 28-day cycle; exception: not given on cycle 1 day 1); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)
11468560|NCT01572480|Experimental|B|Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1- 21 of the 28-day cycle); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle)
11468561|NCT01572454|Experimental|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
11468562|NCT01572454|Active Comparator|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
11468563|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
11468564|NCT01572428|Active Comparator|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
11468565|NCT01572428|Active Comparator|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
11468566|NCT01572402|Experimental|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
11468567|NCT01572402|Active Comparator|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
11468568|NCT01572389|Experimental|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
11468569|NCT01572389|Active Comparator|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
11468570|NCT01572376|Experimental|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
11468571|NCT01572363|Experimental|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
11468572|NCT01572350|Active Comparator|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
11468573|NCT01572350|Experimental|Triamcinolone 4 mg|
11468574|NCT01572350|Experimental|Bevacizumab|
11468575|NCT01572337|Experimental|NIV|Non-invasive ventilation
11468576|NCT01572337|Other|Best available treatment|
11468577|NCT01572324|Experimental|Arterial infusion|
11468578|NCT01572311|Experimental|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
11468579|NCT01572311|Active Comparator|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
11468580|NCT01572298|Active Comparator|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
11468581|NCT01572298|Experimental|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
11468582|NCT01572285|Sham Comparator|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
11468583|NCT01572285|Experimental|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
11468584|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
11468585|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
11468586|NCT01572259|Experimental|interruption of the growth hormone treatment.|
11468587|NCT01572259|Experimental|Patients traited by grouth hormone|
11468588|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
11468589|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
11468590|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
11468591|NCT01572233|Experimental|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
11468592|NCT01572233|No Intervention|usual care|waiting list group with usual care
11468593|NCT01572220|Other|stress echocardiography|Comparative effectiveness
11468594|NCT01572220|Other|Myocardial SPECT|CER
11468595|NCT01572207|Experimental|Immediate Exercise|Subjects assigned to the immediate group will be prescribed a home exercise program during the first meeting. During the 12 week training period, the subject will read pamphlets (sent by mail) once to twice a month about developing skills to manage MS symptoms and motivational pamphlets about physical activity. In addition, the subject will have a phone conversation every two to three weeks with research staff to discuss the progress of the exercise program and to complete a short survey about his/her physical activity level.
11468596|NCT01572207|Experimental|Delayed exercise|Subjects assigned to the delayed group will be asked to begin the same home exercise program 12 weeks following the first meeting. During the 12 week training period, the subject will receive pamphlets, have phone conversations with research staff, and complete physical activity surveys as described above.
11468597|NCT01572181|Experimental|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
11468598|NCT01572168|Experimental|Acupuncture|Eight sessions of weekly acupuncture
11468599|NCT01572155|No Intervention|Sham stimulation|No stimulation of nervus vagus
11468600|NCT01572155|Active Comparator|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
11468601|NCT01572155|Active Comparator|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
11468602|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
11468603|NCT01572129|Experimental|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
11468604|NCT01572129|Placebo Comparator|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
11468605|NCT01572116|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
11468606|NCT01572116|Active Comparator|Lidocaine with Epinephrine + sufentanil|
11468607|NCT01572103|Experimental|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
11468608|NCT01572103|No Intervention|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
11468631|NCT01571999|Experimental|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
11468632|NCT01571999|Experimental|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
11468633|NCT01571986||NIV|All patients with acute respiratory failure treated with non-invasive ventilation who give informed consent about treatment of their clinical data
11468634|NCT01571973|No Intervention|control group|outpatients receiving usual care
11468609|NCT01572090|Active Comparator|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.
~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
11468610|NCT01572090|Active Comparator|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat >35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.
~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
11468611|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
11468612|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
11468613|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
11468614|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
11468615|NCT01572077|Experimental|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.
~Both groups will undergo FTHA/FDG PET imaging."
11468616|NCT01572051|Experimental|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468617|NCT01572051|Experimental|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468618|NCT01572051|Experimental|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468619|NCT01572051|Experimental|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468620|NCT01572051|Experimental|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468621|NCT01572051|Experimental|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468622|NCT01572051|Experimental|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
11468623|NCT01572051|Experimental|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
11468624|NCT01572038|Experimental|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
11468625|NCT01572025|Experimental|DHEA supplementation|
11468626|NCT01572025|Placebo Comparator|Control|
11468627|NCT01572012|Experimental|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
11468628|NCT01572012|Experimental|Oral Administration|Ondansetron administered orally
11468635|NCT01571973|Experimental|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
11468636|NCT01571960|Experimental|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
11468637|NCT01571960|Placebo Comparator|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
11468638|NCT01571960|Experimental|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
11468639|NCT01571960|Placebo Comparator|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
11468640|NCT01571960|Experimental|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
11468641|NCT01571960|Placebo Comparator|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
11468642|NCT01571947|Active Comparator|SFA|
11468643|NCT01571947|Active Comparator|MUFA|
11468644|NCT01571947|Active Comparator|PUFA|
11468645|NCT01571947|Active Comparator|CARB|
11468646|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
11468647|NCT01571921|Experimental|Gamma-Delta Tocotrienol|
11468648|NCT01571921|Active Comparator|TRF|
11468649|NCT01571908|Experimental|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
11468650|NCT01571908|Active Comparator|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
11468651|NCT01571895|Experimental|DF 2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
11468652|NCT01571882|Experimental|1 = Tested product 1|
11468653|NCT01571882|Experimental|2 = tested product 2|
11468654|NCT01571882|Active Comparator|3 = Active control product|
11468655|NCT01571869|Experimental|1 = Tested product|
11468656|NCT01571869|Placebo Comparator|2 = Control product|
11468657|NCT01571856|Active Comparator|zinc sulfate|zinc sulphate solution.
11468658|NCT01571856|Placebo Comparator|cornstarch solution|cornstarch powder diluted in distilled water
11468659|NCT01571843|Experimental|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
11468660|NCT01571843|Placebo Comparator|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
11468661|NCT01571843|Active Comparator|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
11468662|NCT01571843|Placebo Comparator|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
11468663|NCT01571817|Experimental|Study intervention|endoscopically-guided intestinal submucosal transplantation of Isolated Human Pancreatic Islets in a type 1 diabetic patient
11468664|NCT01571804|Active Comparator|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
11468665|NCT01571804|Active Comparator|pregabalin 300 mg group|two capsules of pregabalin 150 mg
11468666|NCT01571804|Placebo Comparator|placebo group|to receive two identical placebo capsules
11468667|NCT01571791|Placebo Comparator|group SF|either saline infusion and intravenous fentanyl boluses
11468668|NCT01571791|Active Comparator|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
11468669|NCT01571778|Experimental|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
11468670|NCT01571778|No Intervention|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
11468671|NCT01571765|Experimental|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
11468672|NCT01571765|No Intervention|no added MNCH activities|
11468673|NCT01571752||CMU|Current marijuana users
11468674|NCT01571752||Cohort|HIV positive adults
11468675|NCT01571752||Cohort 1|HIV negative adults
11468676|NCT01571752||Cohort 2 Seeds-Wave 0|HIV positive adults
11468677|NCT01571752||Cohort 2 Wave 1|HIV negative adults or HIV positive adults
11468678|NCT01571752||Cohort 2 Wave 2|HIV negative adults or HIV positive adults
11468679|NCT01571752||COSU|Current opioid/stimulant users
11468680|NCT01571752||COSU-NTS|Non-treatment seekers
11468681|NCT01571752||COSU-TS|Treatment seekers
11468682|NCT01571752||NDU|Non-drug-users
11468683|NCT01571752||Unclassified|Unclassified
11468684|NCT01571713||Study|Pediatric patients with pulmonary hypertension
11468685|NCT01571700||Study|Patients with pulmonary hypertension.
11468686|NCT01571700||Control|ASD patients or patients with normal hearts
11468687|NCT01571687|Active Comparator|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
11468688|NCT01571687|Placebo Comparator|Placebo|identically appearing placebo
11468689|NCT01571674|Experimental|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
11468690|NCT01571674|Active Comparator|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
11468691|NCT01571661|Experimental|Part A Treatment 1|GSK189075A 20mg
11468692|NCT01571661|Experimental|Part A Treatment 2|GSK189075A 50mg
11468693|NCT01571661|Experimental|Part A Treatment 3|GSK189075A 150mg
11468694|NCT01571661|Experimental|Part A Treatment 4|GSK189075A 500mg
11468695|NCT01571661|Experimental|Part A Treatment 5|GSK189075A 1000mg
11468696|NCT01571661|Placebo Comparator|Placebo|Placebo
11468697|NCT01571661|Experimental|Part B Low dose|low dose chosen from Part A
11468698|NCT01571661|Experimental|Part B High Dose|high dose chosen from Part A
11468699|NCT01571648|Experimental|Oral azacitidine|
11468700|NCT01571635|Experimental|Sotatercept dose level 0.1mg/kg|Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
11468701|NCT01571635|Experimental|Sotatercept dose level 0.3mg/ kg|Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
11468702|NCT01571635|Experimental|Sotatercept dose level 0.5mg/kg|Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
11468703|NCT01571635|Experimental|Sotatercept dose level 0.75mg/kg|Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
11468704|NCT01571635|Experimental|Sotatercept dose level 1.0mg/kg|Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
11468705|NCT01571635|Experimental|Sotatercept dose level 1.5mg/kg|Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
11468706|NCT01571622|Placebo Comparator|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
11468707|NCT01571622|Experimental|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\
11468708|NCT01571609|Experimental|Carriers|
11468709|NCT01571609|Experimental|Non-carriers|
11468710|NCT01571596|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
11468711|NCT01571583|Experimental|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
11468712|NCT01571570|Experimental|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
11468713|NCT01571570|Experimental|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
11468714|NCT01571570|Experimental|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
11468715|NCT01571570|Experimental|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
11468716|NCT01571570|Experimental|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
11468717|NCT01571570|Experimental|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
11468718|NCT01571570|Experimental|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
11468719|NCT01571570|Experimental|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
11468720|NCT01571570|Experimental|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
11468721|NCT01571557||OZURDEX®|OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.
11468722|NCT01571544|Experimental|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
11468723|NCT01571544|Active Comparator|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
11468724|NCT01571518|Experimental|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
11468725|NCT01571518|Sham Comparator|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
11468726|NCT01571505|Experimental|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
11468727|NCT01571505|Placebo Comparator|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
11468728|NCT01571492|Experimental|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
11468729|NCT01571492|Active Comparator|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
11468730|NCT01571479|No Intervention|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
11468731|NCT01571479|No Intervention|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
11468732|NCT01571466|Experimental|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
11468733|NCT01571466|Placebo Comparator|Placebo|
11468734|NCT01571453|Experimental|Vortioxetine (Lu AA21004)|
11468735|NCT01571453|Active Comparator|Venlafaxine extended release|
11468773|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
11468736|NCT01571440|Placebo Comparator|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
11468737|NCT01571440|Active Comparator|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
11468738|NCT01571427|Placebo Comparator|Control group|No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
11468739|NCT01571427|Active Comparator|Active social engagement group|Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
11468740|NCT01571414|Experimental|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
11468741|NCT01571414|Experimental|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
11468742|NCT01571414|Experimental|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
11468743|NCT01571414|Experimental|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
11468744|NCT01571414|Experimental|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
11468745|NCT01571401|Experimental|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
11468746|NCT01571401|Experimental|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
11468747|NCT01571388|Experimental|Group 1|Healthy Subjects to receive dacomitinib
11468748|NCT01571388|Experimental|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
11468749|NCT01571388|Experimental|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
11468750|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
11468751|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
11468752|NCT01571362|Experimental|ALO-02|
11468753|NCT01571362|Placebo Comparator|Placebo|
11468754|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
11468755|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
11468756|NCT01571323|Active Comparator|Misoprostol|
11468757|NCT01571323|Active Comparator|Oxytocin|
11468758|NCT01571323|Active Comparator|Oxytocin and Misoprostol|
11468759|NCT01571310|Experimental|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
11468760|NCT01571310|Active Comparator|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
11468761|NCT01571297|Active Comparator|RM-131|
11468762|NCT01571297|Placebo Comparator|Placebo|
11468763|NCT01571284|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
11468764|NCT01571271|Experimental|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
11468765|NCT01571271|Experimental|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
11468766|NCT01571258|No Intervention|Control|
11468767|NCT01571258|Experimental|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
11468768|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
11468769|NCT01571232|Active Comparator|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
11468770|NCT01571232|Active Comparator|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
11468771|NCT01571219|Experimental|CT-P13|
11468772|NCT01571206|Active Comparator|CT-P13|infliximab
11468774|NCT01571167|Placebo Comparator|Placebo|
11468775|NCT01571167|Active Comparator|Varenicline 2 mg|
11468776|NCT01571167|Active Comparator|Varenicline 1 mg|
11468777|NCT01571141|Experimental|Monogin|
11468778|NCT01571141|No Intervention|No intervention|
11468779|NCT01571128|Experimental|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
11468780|NCT01571128|Experimental|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
11468781|NCT01571128|No Intervention|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
11468782|NCT01571128|Experimental|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
11468783|NCT01571128|Experimental|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
11468784|NCT01571115|Active Comparator|Insomnia Stretching Exercise|This group will realize stretching exercise
11468785|NCT01571115|No Intervention|Control|This group will not realize any type of intervention.
11468786|NCT01571115|Active Comparator|Insomnia Physical Exercise|This group will realize resistance physical exercise
11468787|NCT01571102|Active Comparator|physiotherapy|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
11468788|NCT01571102|No Intervention|Rest|
11468789|NCT01571102|Active Comparator|Home exercises|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
11468790|NCT01571089|Experimental|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
11468791|NCT01571076|Experimental|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
11468792|NCT01571076|Experimental|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
11468793|NCT01571076|Active Comparator|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
11468794|NCT01571076|Active Comparator|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
11468795|NCT01571063|Experimental|Vitamin D3|
11468796|NCT01571063|Placebo Comparator|Placebo|
11468797|NCT01571050|Experimental|Fresh NaF/SiO2 toothpaste|
11468798|NCT01571050|Placebo Comparator|Purified water|
11468799|NCT01571050|Experimental|Aged NaF/SiO2 toothpaste|
11468800|NCT01571050|Experimental|Fresh MFP/CaCO3 toothpaste|
11468801|NCT01571050|Experimental|Aged MFP/CaCO3 toothpaste|
11468802|NCT01571037|Other|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone
~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
11468803|NCT01571024|Experimental|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
11468804|NCT01571011|Experimental|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
11468805|NCT01571011|Experimental|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
11468806|NCT01570998|Experimental|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
11468807|NCT01570985|Active Comparator|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
11468808|NCT01570985|Active Comparator|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
11468809|NCT01570985|No Intervention|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
11468810|NCT01570972|Other|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
11468811|NCT01570946|Experimental|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
11468812|NCT01570946|No Intervention|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
11468813|NCT01570933|Experimental|NAVAfirst|Starting crossover by NIVnava mode
11468814|NCT01570933|Active Comparator|Cpap first|Start crossover by Cpap on nasal canula
11468815|NCT01570920|Experimental|walking|a cohort of stroke patients trained during 3 month, based on walking
11468816|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
11468817|NCT01570868|Experimental|Ponatinib 45 mg|Ponatinib at a dose of 45 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
11468818|NCT01570868|Experimental|Ponatinib 30 mg|Ponatinib at a dose of 30 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
11468819|NCT01570842|Other|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
11468820|NCT01570829|Experimental|Dietressa (1 tablet 6 times daily)|
11468821|NCT01570829|Placebo Comparator|Placebo (1 tablet 6 times daily)|
11468822|NCT01570816|Experimental|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
11468823|NCT01570803|Experimental|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
11468824|NCT01570803|Active Comparator|SMART CONTROL Stent|same to Complete SE
11468825|NCT01570790|Experimental|Cohort 1|
11468826|NCT01570790|Experimental|Cohort 2|
11468827|NCT01570790|Experimental|Cohort 3|
11468828|NCT01570777|Experimental|Renal denervation|
11468829|NCT01570777|Other|optimized medication regimen|optimized medication regimen
11468830|NCT01570764|Experimental|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
11468831|NCT01570764|Placebo Comparator|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
11468832|NCT01570751|Experimental|IDeg followed by IGlar|
11468833|NCT01570751|Experimental|IGlar followed by IDeg|
11468834|NCT01570725|Experimental|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
11468835|NCT01570725|Experimental|2|Exposure to relaxing music. The music will be selected between classical music tunes.
11468836|NCT01570712|Experimental|Housing First Program|
11468837|NCT01570712|Active Comparator|traditional French services|
11468838|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
11468839|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
11468840|NCT01570686|Experimental|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
11468841|NCT01570686|Experimental|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
11468842|NCT01570673|Experimental|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
11468843|NCT01570673|Active Comparator|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
11468844|NCT01570660|No Intervention|control group|parallel group without intervention
11468845|NCT01570647||Healthy controls|
11468846|NCT01570647||Chronic low back pain|
11468847|NCT01570647||restricted hamstrings|
11468848|NCT01570647||systemic scleroderma|
11468849|NCT01570647||joint hyperlaxity|
11468850|NCT01570634|Experimental|Open Label CASAD|Treatment with CASAD for 14 days
11468851|NCT01570608|Active Comparator|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
11468852|NCT01570608|Active Comparator|combined treatment arm|
11468853|NCT01570595|Experimental|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
11468854|NCT01570595|Active Comparator|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
11468855|NCT01570582|Experimental|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.
~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.
~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
11468856|NCT01570569|Active Comparator|Omeprazole|
11468857|NCT01570569|Active Comparator|Losartan|
11468858|NCT01570569|Active Comparator|Dextromethorphan|
11468859|NCT01570569|Active Comparator|Caffeine|
11468860|NCT01570569|Active Comparator|Midazolam|
11468861|NCT01570556|Active Comparator|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
11468862|NCT01570556|No Intervention|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
11468863|NCT01570543||orthopedic implants, no treatment|
11468864|NCT01570530|Active Comparator|Atorvastatin|Patients treated with atorvastatin
11468865|NCT01570530|Other|Without Atorvastatin|Patients treated without atorvastatin
11468866|NCT01570517|Experimental|Device implantation|Subjects are implanted with the study device.
11468867|NCT01570504|Experimental|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
11468868|NCT01570504|Active Comparator|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
11468869|NCT01570491|Active Comparator|ultrasound-guided spinal anesthesia|participants will randomly assigned to use ultrasound-guided technique for block placement by Anesthesiologist.
11468870|NCT01570491|Placebo Comparator|standard spinal anesthesia|randomized participants will be given standard spinal anesthesia insertion technique for block placement by Anesthesiologist
11468871|NCT01570478|Experimental|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
11468872|NCT01570478|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
11468873|NCT01570465||All patients enrolled in the GIMEMA AML1310 study.|"All patients enrolled in the GIMEMA AML1310 study;
~Signed written informed consent according to ICH/EU/GCP and national local laws."
11468874|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
11468875|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
11468876|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
11468877|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
11468878|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
11468879|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
11468880|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
11468881|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
11468882|NCT01570413|Active Comparator|Pelvic Exam|Subjects receive pelvic exam
11468883|NCT01570413|Experimental|No Pelvic Exam|Subjects do not receive pelvic exam
11468884|NCT01570400|Experimental|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
11468885|NCT01570400|Experimental|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
11468886|NCT01570387|Experimental|Phase I - cohort 1 (Pomalidomide 2mg) plus Dexamethasone|Pomalidomide 2 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
11468887|NCT01570387|Experimental|Phase I - cohort 2 (Pomalidomide 3mg) plus Dexamethasone|Pomalidomide 3 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
11468888|NCT01570387|Experimental|Phase I - cohort 3 (Pomalidomide 4mg) plus Dexamethasone|Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
11468889|NCT01570387|Experimental|Phase II Expansion- (Pomalidomide 4mg) plus Dexamethasone|"Expansion Phase:
~Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle"
11468890|NCT01570374|Experimental|iCBT|Receives treatment.
11468891|NCT01570374|No Intervention|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
11468892|NCT01570361|Experimental|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
11468893|NCT01570361|Active Comparator|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
11468894|NCT01570348|Experimental|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.
~TRANSPLANTATION: Patients undergo donor BMT on day 0.
~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
11468895|NCT01570309|Active Comparator|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
11468896|NCT01570309|Placebo Comparator|Sugar pill|
11468897|NCT01570296|Experimental|Gefitinib and BKM120|"Patients with NSCLC who progress on treatment with single-agent EGFR TKI (e.g., gefitinib or erlotinib), and meet the clinical definition of EGFR TKI resistance (Jackman et al., 2010):
~A tumour that harbours an EGFR mutation known to be associated with drug sensitivity
~Previous objective clinical benefit from treatment with an EGFR TKI
~Patients should have systemic progression of disease (by RECIST) while on continuous treatment with gefitinib or erlotinib. Patients that have previously progressed on EGFR TKI (not in the preceding line of treatment) may also be enrolled and will receive gefitinib and BKM120 sequentially.
~Patients with any solid tumour-type and activated PI3 kinase pathway and historically known to over express EGFR may also be recruited.
~Once the RP2D is reached, an expansion cohort of 40 patients will be accrued for extended safety experience and to ascertain preliminary activity."
11468898|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis|Cohort 1 prophylaxis: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
11468932|NCT01570101|Experimental|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
11468899|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment|Cohort 1 treatment: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
11468900|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis|Cohort 2 prophylaxis: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
11468901|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment|Cohort 2 treatment: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
11468902|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis|Cohort 3 prophylaxis: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
11468903|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment|Cohort 3 treatment: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
11468904|NCT01570270|Experimental|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
11468905|NCT01570257|No Intervention|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
11468906|NCT01570257|Experimental|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
11468907|NCT01570244|Experimental|Reference|multiple doses of Microgynon
11468908|NCT01570244|Active Comparator|Test|multiple doses of Microgynon + BI 201335
11468909|NCT01570231|Experimental|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
11468910|NCT01570231|No Intervention|Control group|underwent equivalent medical treatments only
11468911|NCT01570218|Experimental|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
11468912|NCT01570218|No Intervention|Control|
11468913|NCT01570205|Experimental|XG-102 10 µg/kg|
11468914|NCT01570205|Experimental|XG-102 40 µg/kg|
11468915|NCT01570205|Experimental|XG-102 80 µg/kg|
11468916|NCT01570205|Placebo Comparator|placebo|
11468917|NCT01570192|Experimental|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:
~IV meropenem (2 g infused over 3 hrs q 8 hr);
~a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
~tobramycin nebulization
~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
11468918|NCT01570192|Active Comparator|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.
~**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
11468919|NCT01570179|Experimental|deep block ideal body weight|
11468920|NCT01570179|Active Comparator|deep block real body weight|
11468921|NCT01570179|Experimental|moderate block ideal body weight|
11468922|NCT01570179|Active Comparator|moderate block real body weight|
11468923|NCT01570166|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
11468924|NCT01570166|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
11468925|NCT01570153||ADHF patients|
11468926|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
11468927|NCT01570127|Experimental|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
11468928|NCT01570127|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
11468929|NCT01570127|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
11468930|NCT01570127|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
11468931|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
11468933|NCT01570088|Active Comparator|Folic acid|
11468935|NCT01570088|Placebo Comparator|Placebo|
11468936|NCT01570075|Experimental|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
11468937|NCT01570075|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
11468938|NCT01570062|Active Comparator|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
11468939|NCT01570062|Placebo Comparator|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
11468940|NCT01570049|Experimental|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
11468941|NCT01570036|Experimental|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
11468942|NCT01570036|Active Comparator|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
11468943|NCT01570023|No Intervention|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
11468944|NCT01570023|Experimental|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
11468945|NCT01570010|Experimental|Intervention group|
11468946|NCT01570010|Other|Control group|Counseling on physical activity only
11468947|NCT01569997|Other|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
11468948|NCT01569997|No Intervention|control group|Control group: nursing homes whose residents continue to benefit from usual care
11468949|NCT01569984|Experimental|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
11468950|NCT01569971||Adolescents|Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
11468951|NCT01569971||Caregivers|Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
11468952|NCT01569971||Young Adults|Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
11468953|NCT01569958|Active Comparator|tDCS|
11468954|NCT01569958|Sham Comparator|sham|
11468955|NCT01569945|Active Comparator|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
11468956|NCT01569945|Active Comparator|human menopausal gonadotropins|Daily Injections
11468957|NCT01569932||chemotherapy|Patients will be assessed both before and after they undergo treatment with chemotherapy.
11468958|NCT01569919|Experimental|TroVax®|In this single-arm study, all participants will receive 9 injections of the TroVax® vaccine, plus standard cisplatin and pemetrexed chemotherapy.
11468959|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
11468960|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
11468961|NCT01569893|No Intervention|Control group|Usual care: treatment as usual
11468962|NCT01569893|Experimental|Self-monitoring for patients with Dibetes mellitus type 2|Self-monitoring for patients with Dibetes mellitus type 2
11468963|NCT01569867||statin|
11468964|NCT01569854||statin|
11468965|NCT01569841|Experimental|IDeg|
11468966|NCT01569841|Active Comparator|IGlar|
11468967|NCT01569828|Experimental|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
11468968|NCT01569828|Experimental|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
11468969|NCT01569815|Experimental|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
11468970|NCT01569802||screening|
11468971|NCT01569789|Active Comparator|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
11468972|NCT01569789|Placebo Comparator|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
11468973|NCT01569776|Experimental|New Amino Acid formula|
11468974|NCT01569776|Active Comparator|Control formula|Commercially available Amino Acid infant formula
11468975|NCT01569763|Active Comparator|hysteroscopic rollerball resection/ablation|
11468976|NCT01569763|Experimental|Aurora Endometrial Ablation|
11468977|NCT01569750|Experimental|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.
~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
11468978|NCT01569737||ella|
11468979|NCT01569724|Experimental|bexarotene|
11468980|NCT01569711||Deep brain stimulation|
11468981|NCT01569698||extrarenal replacement therapy|Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
11468982|NCT01569685|Active Comparator|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
11468983|NCT01569685|Active Comparator|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
11468984|NCT01569672|Active Comparator|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
11468985|NCT01569672|Placebo Comparator|Control Clinics|Subjects are mailed informational/educational materials.
11468986|NCT01569659|Active Comparator|Standard dose of lurasidone|
11468987|NCT01569659|Experimental|High dose of lurasidone|
11468988|NCT01569633|Placebo Comparator|Placebo|This group of infant will not receive any medication but sugar water or placebo
11468989|NCT01569633|Active Comparator|Metclopramide|This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.
11468990|NCT01569633|Active Comparator|Erythromycin|mediaction used to treat feeding disorder
11468991|NCT01569620|Active Comparator|Culturally targeted print materials|Best clinical practices plus culturally print materials
11468992|NCT01569620|Active Comparator|Standard print materials|Best clinical practices plus standard print materials
11468993|NCT01569620|Active Comparator|Best clinical practices alone|Best clinical practices alone: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
11468994|NCT01569607|Experimental|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
11468995|NCT01569607|Sham Comparator|Sham Stimulation|Participants will be randomized to receive sham stimulation.
11468996|NCT01569594||Carotid Endarterectomy Subjects|Subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair
11468997|NCT01569581|Experimental|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
11468998|NCT01569581|Experimental|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
11468999|NCT01569581|Experimental|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
11469000|NCT01569581|Experimental|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
11469001|NCT01569581|No Intervention|0U/0.5ml in infants (6-11 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 6-11 months old on day 0, 28
11469002|NCT01569581|No Intervention|0U/0.5ml in infants (12-23 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 12-23 months old on day 0, 28
11469003|NCT01569581|No Intervention|0U/0.5ml in children (24-35 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1500 children aged 24-35 months old on day 0, 28
11469004|NCT01569581|No Intervention|0U/0.5ml in children (36-71 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1000 children aged 36-71 months old on day 0, 28
11469005|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning
~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
11469006|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning
~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
11469007|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
11469008|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
11469009|NCT01569516|Experimental|low dose|1mg, tid
11469010|NCT01569516|Experimental|Moderate dose|2mg,tid
11469011|NCT01569516|Experimental|High dose|4mg,tid
11469012|NCT01569516|Placebo Comparator|Placebo|0 mg, tid
11469013|NCT01569503|Experimental|VSN|VNS therapy
11469014|NCT01569490|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
11469015|NCT01569490|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
11469016|NCT01569477|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
11469424|NCT01566786|Placebo Comparator|Placebo|
11469017|NCT01569477|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
11469018|NCT01569464|Active Comparator|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
11469019|NCT01569464|Placebo Comparator|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.
~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours
~7 weeks"
11469020|NCT01569451|Active Comparator|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
11469021|NCT01569451|Experimental|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
11469022|NCT01569438|Experimental|Gefapixant|Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
11469023|NCT01569438|Placebo Comparator|Placebo|Female participants receive dose matched placebo tablets, BID, orally, with food for 4 weeks.
11469024|NCT01569425|Experimental|Lifestyle counseling|Lifestyle counseling, with high calorie breakfast
11469025|NCT01569425|Active Comparator|Life Counseling|Diet with high calorie dinner
11469026|NCT01569412|Experimental|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
11469027|NCT01569399|Active Comparator|active rTMS|High frequency (10HZ) on the left DLPFC
11469028|NCT01569399|Placebo Comparator|sham rTMS|
11469029|NCT01569386|Experimental|low intensity physical activity|Daily low intensity physical activity by the half squat
11469030|NCT01569386|Active Comparator|stretch exercise and usual activity|They do whole body stretch exercise for 20 minute in a day
11469031|NCT01569373||Post allogeneic SCT patients|Patients who have undergone an allogeneic stem cell transplant.
11469032|NCT01569360|Active Comparator|Corset|the patients are assigned the use of a custome made corset during daytime
11469033|NCT01569360|No Intervention|No corset|the patients do not use a corset during daytime
11469034|NCT01569347||1: Cocaine users|Adults, cocaine users
11469035|NCT01569334|Other|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
11469036|NCT01569334|Other|HTR without Cardiac allograft vasculopathy|
11469037|NCT01569334|Other|untransplanted|
11469038|NCT01569321|Experimental|Breast cancer|
11469039|NCT01569295|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
11469040|NCT01569295|Placebo Comparator|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
11469041|NCT01569282|Active Comparator|Double bypass|
11469042|NCT01569282|Active Comparator|Stent Strategy|
11469043|NCT01569269|Experimental|Yoga|See intervention description
11469044|NCT01569269|Experimental|Meditation|See intervention description
11469045|NCT01569269|Experimental|Reiki|see intervention description
11469046|NCT01569269|Active Comparator|Holistic Education|see intervention description
11469047|NCT01569256|Active Comparator|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.
~All patients were administered long luteal protocol for ovulation induction."
11469048|NCT01569256|No Intervention|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.
~All patients were administered long luteal protocol for ovulation induction."
11469049|NCT01569243|Other|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
11469050|NCT01569243|Experimental|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
11469051|NCT01569230|Experimental|Individualized acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
11469052|NCT01569230|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
11469053|NCT01569230|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
11469054|NCT01569230|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
11469055|NCT01569217||respiratory muscle dysfunction patients|Neuromuscular patients
11469056|NCT01569217||diaphragmatic dysfunction|patients who present orthopnea, recruitment of accessory muscles, abdominal paradox, respiratory dysfunction or dyssynchronous movement
11469057|NCT01569204|Active Comparator|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
11469058|NCT01569204|Active Comparator|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
11469059|NCT01569191|No Intervention|No Treatment|Exposure to grass pollen only
11469154|NCT01568671||Cohort 5|Healthy Caucasian Males age 55-75 years with BMI 18.5-25 kg/m2
11469060|NCT01569191|Active Comparator|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
11469061|NCT01569191|Active Comparator|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
11469062|NCT01569191|Active Comparator|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
11469063|NCT01569178|No Intervention|standard care|optimal standard care post myocardial infarction
11469064|NCT01569178|Experimental|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
11469065|NCT01569165|Experimental|washing after 30 min|washing with water after 30 min following APF treatment
11469066|NCT01569165|Experimental|washing after 15 min|washing with water after 15 min following APF treatment
11469067|NCT01569165|Experimental|immediately washing with water|immediately washing with water after APF treatment
11469068|NCT01569165|Experimental|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
11469069|NCT01569165|No Intervention|no fluoride therapy|control group
11469070|NCT01569152|Experimental|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
11469071|NCT01569152|Placebo Comparator|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
11469072|NCT01569152|Experimental|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
11469073|NCT01569139||GPRD MI|Myocardial infarction, as identified in the GPRD data.
11469074|NCT01569139||MINAP MI|Myocardial infarction, as identified in MINAP data.
11469075|NCT01569139||HES MI|Myocardial infarction, as identified in HES data.
11469076|NCT01569126|Experimental|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
11469077|NCT01569126|Experimental|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
11469078|NCT01569126|Experimental|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
11469079|NCT01569126|Placebo Comparator|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
11469080|NCT01569126|Experimental|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
11469081|NCT01569126|Experimental|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
11469082|NCT01569113|Experimental|ellaOne + microgynon 30|
11469083|NCT01569113|Placebo Comparator|placebo + microgynon 30|
11469084|NCT01569087|Experimental|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
11469085|NCT01569087|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
11469086|NCT01569087|Active Comparator|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
11469087|NCT01569074|Experimental|Dosing A regimen|Oral treatment
11469088|NCT01569074|Experimental|Dosing B regimen|Oral treatment
11469089|NCT01569074|Experimental|Dosing C regimen|Oral treatment
11469090|NCT01569074|Experimental|Dosign D regimen|Oral treatment
11469091|NCT01569074|Placebo Comparator|Dosing E regimen|Oral treatment
11469092|NCT01569061|Active Comparator|Active Laser Group (ALG)|
11469093|NCT01569061|Sham Comparator|Sham Laser Group (SLG)|
11469094|NCT01569048|Active Comparator|remifentanil|
11469095|NCT01569048|Experimental|dexmedetomidine|
11469096|NCT01569035|Active Comparator|warfarin|oral anti coagulant
11469097|NCT01569022|Active Comparator|CPAP First, MAD|"CPAP treatment for sleep apnea
~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
11469098|NCT01569022|Experimental|MAD First, CPAP|"MAD treatment for sleep apnea
~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
11469099|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
11469100|NCT01568996|Experimental|Low dose BSE-SFN|BSE-SFN will be orally administered at 50 µmol SFN for 28 days.
11469101|NCT01568996|Experimental|Mid dose BSE-SFN|BSE-SFN will be orally administered at 100 µmol SFN for 28 days.
11469102|NCT01568996|Experimental|High dose BSE-SFN|BSE-SFN will be orally administered at 200 µmol SFN for 28 days.
11469103|NCT01568983|Placebo Comparator|Control|"12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.
~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
11469104|NCT01568983|Active Comparator|Mana-juice|"12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).
~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
11469105|NCT01568983|Active Comparator|Optijuice|"12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.
~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
11469106|NCT01568970|Experimental|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
11469107|NCT01568970|Active Comparator|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
11469108|NCT01568957|Experimental|Dual-task gait training|Gait training with simultaneous performance of cognitive tasks for 75% of training session.
11469109|NCT01568957|Active Comparator|Single-task gait training|Gait training (without simultaneous cognitive task performance)
11469110|NCT01568944|Experimental|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
11469111|NCT01568944|Other|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
11469112|NCT01568931|Active Comparator|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
11469113|NCT01568931|Active Comparator|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
11469114|NCT01568918|Experimental|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
11469115|NCT01568918|Placebo Comparator|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
11469116|NCT01568905|Experimental|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
11469117|NCT01568905|Experimental|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
11469118|NCT01568905|Experimental|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
11469119|NCT01568892|Experimental|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
11469120|NCT01568892|Experimental|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
11469121|NCT01568879|Experimental|Gout Chronic Disease Management Program|
11469122|NCT01568879|Active Comparator|Usual Care|
11469123|NCT01568866|Experimental|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
11469124|NCT01568866|Active Comparator|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
11469125|NCT01568840|Experimental|Global Postural Reeducation Group|Global Postural Reeducation
11469126|NCT01568840|Active Comparator|Segmental Exercises Group|Segmental Exercises
11469127|NCT01568827|Experimental|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
11469128|NCT01568827|Experimental|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
11469129|NCT01568814|Placebo Comparator|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
11469130|NCT01568814|Active Comparator|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
11469131|NCT01568801|No Intervention|Control Group|Individuals randomized into the control arm will receive usual community care services referred by the social worker from SGH and AH.
11469132|NCT01568801|Experimental|Intervention Group|Individuals in the intervention group will go through an integrated program of community based health and social care based on intake and ongoing evaluation by the SingaPACE team.
11469133|NCT01568788|Experimental|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
11469134|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
11469135|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
11469136|NCT01568775|Experimental|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
11469137|NCT01568762|Experimental|VAK694|VAK694 was administered as a 1 hour intravenous infusion
11469138|NCT01568762|Placebo Comparator|VAK694 Placebo|VAK694 placebo was administered as a one hour intravenous infusion
11469139|NCT01568762|Experimental|QAX576|QAX576 was administered intravenously as a 2 hour infusion
11469140|NCT01568762|Placebo Comparator|QAX576 placebo|QAX576 placebo was administered as a 2 hour intravenous infusion
11469141|NCT01568749|Active Comparator|Standard paracetamol|Marketed formulation
11469142|NCT01568749|Experimental|Formulation 1|Paracetamol formulation 1
11469143|NCT01568749|Experimental|Formulation 2|Paracetamol formulation 2
11469144|NCT01568749|Experimental|Formulation 3|Paracetamol formulation 3
11469145|NCT01568749|Experimental|Formulation 4|Paracetamol formulation 4
11469146|NCT01568723||Radiofrequency ablation|participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)
11469147|NCT01568697||Healthy Volunteers|Healthy volunteers (with/without periodontal disease)
11469148|NCT01568697||Immune deficient patients|Subjects with known genetic immune deficiency
11469149|NCT01568697||Subjects with severe periodontitis suspected genetic etiology|Subjects with severe periodontitis of suspected genetic etiology and their family members
11469150|NCT01568671||Cohort 1|Healthy Caucasian Males age 18-35 years with BMI 18.5-25 kg/m2
11469151|NCT01568671||Cohort 2|Healthy Caucasian Males age 18-35 years with BMI 18.5-25 kg/m2
11469152|NCT01568671||Cohort 3|Healthy Caucasian Males age 18-35 years with BMI 30-40 kg/m2
11469153|NCT01568671||Cohort 4|Healthy Caucasian Females age 18-35 years with BMI 18.5-25 kg/m2
11469155|NCT01568671||Cohort 6|Healthy African-American Males age 18-35 years with BMI 18.5-25 kg/m2
11469156|NCT01568658||Affected probands|Affected probands over age 4 weeks and onwards with known or suspected inherited neurological disorders of childhood onset
11469157|NCT01568658||Healthy volunteers|Healthy volunteers will be recruited for the imaging procedures in order to establish baseline and age-range matched data on the healthy, maturing muscle, spinal cord volume and dynamic breathing
11469158|NCT01568658||Single patient on Idebenone|Single patient on IND expanded access of Idebenone
11469159|NCT01568658||Unaffected family members|Families of affected probands with known or suspected inherited neurological disorders of childhood onset
11469160|NCT01568606|Experimental|Body Composition Analysis InBody Scale|
11469161|NCT01568593|Experimental|T2750|
11469162|NCT01568593|Active Comparator|Vismed|
11469163|NCT01568580|Experimental|test drug|GreenGene
11469164|NCT01568567|Active Comparator|Double dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
11469165|NCT01568567|Active Comparator|Single dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
11469166|NCT01568567|Placebo Comparator|Placebo|One stick pack with placebo contains 1.0 g maltodextrin and silicon dioxide
11469167|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
11469168|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
11469169|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
11469170|NCT01568541|Active Comparator|Children' toothpaste|Children's toothpastes
11469171|NCT01568541|Active Comparator|Regular toothpastes|Regular toothpastes
11469172|NCT01568528|Experimental|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
11469173|NCT01568528|Placebo Comparator|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.
~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
11469174|NCT01568528|Other|Healthy Controls|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will not receive oxytocin or placebo. They will only receive psychiatric screening interview, MATRICS Consensus Cognitive Battery (MCCB) assessment, urine drug screen, vision testing, and the three social cognition tasks.
11469175|NCT01568515|Experimental|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
11469176|NCT01568515|No Intervention|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
11469177|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
11469178|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
11469179|NCT01568489|Experimental|HL-009 Liposomal Gel (0.07%)|
11469180|NCT01568489|Experimental|HL-009 Liposomal Gel (0.15%)|
11469181|NCT01568489|Experimental|HL-009 Liposomal Gel (0.30%)|
11469182|NCT01568489|Placebo Comparator|HL-009 Liposomal Gel (Placebo)|
11469183|NCT01568476|Active Comparator|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
11469184|NCT01568476|Active Comparator|Interneural|sciatic nerve blockade at the site of bifurcation
11469185|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, fasted)|
11469186|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)|
11469187|NCT01568450|Active Comparator|Oxycontin CR 10mg (Oxycodone 10mg, fasted)|
11469188|NCT01568437|Active Comparator|Conventional management|On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
11469189|NCT01568437|Experimental|TAP Block+Conventional Management|The TAP block will be performed after the induction, before the surgery, by an anesthesiologist with experience of at least 10 successful TAP blocks.Also patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg(oral hydromorphone 1-2 mg) up to every 2 hours or iv morphine.
11469190|NCT01568424|Other|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
11469191|NCT01568411|Active Comparator|TD-1211|
11469192|NCT01568411|Active Comparator|TD-1211+ itraconazole|
11469193|NCT01568398|Experimental|TAK-438 20 mg QD|
11469194|NCT01568385|Experimental|TAK-438 20 mg QD|
11469195|NCT01568372|Experimental|Nurse telephone follow-up|This group received a telephone follow-up by a nurse following discharge from the hospital and up until the 10th postoperative day, which is considered as the usual period of healing for a tonsillectomy
11469292|NCT01567735|Experimental|TMC435|
11469196|NCT01568372|No Intervention|Standard care group|This group received the standard care which consisted of an informative session before discharge and no follow-up once discharged home.
11469197|NCT01568359||Group 1 - Acromegaly, Group 2 - control|Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)
11469198|NCT01568346|Active Comparator|MRI|MRI
11469199|NCT01568346|No Intervention|No MRI|No MRI
11469200|NCT01568333|Experimental|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
11469201|NCT01568320|Experimental|Endovascular|Endovascular Treatment (Zenith)
11469202|NCT01568294|Experimental|pomalidomide|Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.
11469203|NCT01568281|Experimental|1|2 way crossover
11469204|NCT01568281|Experimental|2|2 way crossover
11469205|NCT01568281|Experimental|3|2 way crossover
11469206|NCT01568281|Experimental|4|2 way crossover
11469207|NCT01568268|Experimental|Palonsetron|
11469208|NCT01568268|Placebo Comparator|Placebo|
11469209|NCT01568255|Experimental|Vitamin D Treatment|Vitamin D Treatment Group
11469210|NCT01568255|Placebo Comparator|Placebo Group|Placebo at 50,000IU for 8 weeks
11469211|NCT01568242|Experimental|Thermoprobe|Determination of vitreous temperature with a thermoprobe
11469212|NCT01568229|Experimental|AMG 747 - Dose 1|
11469213|NCT01568229|Experimental|AMG 747 - Dose 2|
11469214|NCT01568229|Experimental|AMG 747 - Dose 3|
11469215|NCT01568229|Placebo Comparator|Placebo Comparator|
11469216|NCT01568216|Experimental|AMG 747 - Dose 1|
11469217|NCT01568216|Experimental|AMG 747 - Dose 2|
11469218|NCT01568216|Experimental|AMG 747 - Dose 3|
11469219|NCT01568216|Placebo Comparator|Placebo Comparator|
11469220|NCT01568203|Experimental|AMG 579|
11469221|NCT01568203|Placebo Comparator|Placebo|
11469222|NCT01568190|Experimental|AVANZ|AVANZ Mites
11469223|NCT01568177|Other|abnormal CRT|"40 subjects with microvascular coronary dysfunction (MCD) defined as abnormal CRT.
~Visits 1, 2, and 3"
11469224|NCT01568177|Other|Cardiac Syndrome X|20 subjects with symptoms and normal stress tests, no MCD. Visits 1 and 2
11469225|NCT01568177|Other|normal reference controls|40 normal reference controls subjects Visits 1 and 2
11469226|NCT01568164|Experimental|Device Treatment|Treatment with the investigational device.
11469227|NCT01568151|Active Comparator|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
11469228|NCT01568151|No Intervention|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
11469229|NCT01568125||Incretin-related drugs|
11469230|NCT01568112|Experimental|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
11469231|NCT01568112|Placebo Comparator|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
11469232|NCT01568112|Experimental|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
11469233|NCT01568112|Experimental|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily [QD] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
11469234|NCT01568099|Experimental|A: AFFITOPE® PD01A + Adjuvant|4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
11469235|NCT01568099|Experimental|B: AFFITOPE® PD01A + Adjuvant|4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
11469236|NCT01568099|Other|Control|Untreated control group
11469237|NCT01568086||AFFITOPE AD03 with adjuvant|
11469238|NCT01568086||AFFITOPE AD03 without adjuvant|
11469239|NCT01568073|Experimental|BIA 9-1067|OPC, Opicapone
11469240|NCT01568073|Active Comparator|Entacapone|Comtan®; Active comparator
11469241|NCT01568073|Placebo Comparator|Placebo|PLC, Placebo
11469242|NCT01568060||Infanrix-IPV group|Infants and children who received at least one dose of Infanrix-IPV as a part of routine practice at a private clinic or hospital in korea
11469243|NCT01568047|Placebo Comparator|Placebo|"PLC, Placebo
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469244|NCT01568047|Experimental|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469245|NCT01568047|Experimental|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469246|NCT01568047|Experimental|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469247|NCT01568034|Experimental|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469335|NCT01567332|Placebo Comparator|rTMS inactive (sham)|
11469336|NCT01567319|Experimental|Allergic Subjects|
11469248|NCT01568034|Experimental|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469249|NCT01568034|Experimental|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469250|NCT01568034|Experimental|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067
~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
11469251|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
11469252|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
11469253|NCT01567995|Experimental|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
11469254|NCT01567995|Other|Vehicle (base cream)|Vehicle (base cream)
11469255|NCT01567982|Experimental|smokers and nonsmokers|both smokers and nonsmokers will receive same tDCS
11469256|NCT01567969|Experimental|IICAPS|Provision of Intensive In-home Child and Adolescent Psychiatric Service, a six to seven month family-focused in-home psychiatric intervention.
11469257|NCT01567969|Active Comparator|Home-based CTC|Provision of Home-based Child Treatment Coordination, a six to seven month child-focused case management service with monthly in-home visits with the child's parent/legal guardian.
11469258|NCT01567956|Experimental|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
11469259|NCT01567956|Placebo Comparator|Placebo|Modified release tablets containing inert substances
11469260|NCT01567943|Experimental|Contingency Management|Contingency Management plus treatment as usual
11469261|NCT01567943|No Intervention|Non-contingent control group|Treatment as usual plus reinforcement for attendance
11469262|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort
~- Expected subject no.: 400 patients"
11469263|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B [simple observation cohort without doppler US examination])
~- Expected subject no.: 200 patients"
11469264|NCT01567904|Experimental|Age group from 12 to 18 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
11469265|NCT01567904|Experimental|Age group from 6 to 12 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
11469266|NCT01567904|Experimental|Age group from 2 to 6 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
11469267|NCT01567904|Experimental|Age group from 3 months to 2 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
11469268|NCT01567904|Experimental|Age group from birth to 3 (<) months|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
11469269|NCT01567891|Experimental|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
11469270|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
11469271|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
11469272|NCT01567865|Active Comparator|Reference Lot|Lot of Vaccine produced in existing facility
11469273|NCT01567865|Experimental|New Lot #1|First lot of vaccine produced in new facility
11469274|NCT01567865|Experimental|New Lot #2|Second lot of vaccine produced in new facility
11469275|NCT01567865|Experimental|New Lot #3|Third lot of vaccine produced in new facility
11469276|NCT01567852|Experimental|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
11469277|NCT01567852|Experimental|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
11469278|NCT01567839|Experimental|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
11469279|NCT01567839|Experimental|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
11469280|NCT01567839|Experimental|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
11469281|NCT01567826|Active Comparator|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
11469282|NCT01567826|Experimental|aggressive lipid therapy|aggressive lipid therapy: Crestor
11469283|NCT01567813||Regimen Initiators|Any male health plan member who receives at least one dose of GARDASIL™
11469284|NCT01567813||Regimen Completers|Regimen Initiators who complete the 3-dose vaccination regimen within 12 months
11469285|NCT01567813||Autoimmune cohort|Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™
11469286|NCT01567800|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
11469287|NCT01567787|Experimental|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
11469288|NCT01567787|Experimental|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
11469289|NCT01567774|Active Comparator|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
11469290|NCT01567774|Active Comparator|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
11469291|NCT01567748||Hemodynamics Measured|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
11469293|NCT01567722||HIV-positive diffuse large B-cell lymphoma cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
11469294|NCT01567722||HIV-positive lung cancer cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
11469295|NCT01567709|Experimental|Treatment (alisertib, vorinostat)|Patients receive alisertib PO BID on days 1-7 or days 1-3 and 8-10, and vorinostat PO BID on days 1-14 or days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11469296|NCT01567683|Experimental|Limtop solution (imiquimod), Vehicle solution for topical use|
11469297|NCT01567670|Active Comparator|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
11469298|NCT01567670|Placebo Comparator|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
11469299|NCT01567657|Active Comparator|Pethidin plus midazolam|Initial dose of 25 mg Pethidin iv. plus 1-2 mg Midazolam iv. Additional Bolus of Midazolam (1 mg wise iv.) if needed, until a maximal dose of 7 mg Midazolam iv.
11469300|NCT01567657|Active Comparator|Propofol|Initial dose of Propofol of 50-60 mg iv. for patients 50 years or younger. Initial dose of Propofol of 30-40 mg iv. for patients over 50 years. If needed additional Bolus of 20-30 mg Propofol iv. as usual until sedation is achieved.
11469301|NCT01567644|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
11469302|NCT01567631|Experimental|intrahepatic Glisson's approach|
11469303|NCT01567631|Active Comparator|classical hepatectomy|
11469304|NCT01567605|Experimental|Lidocaine lubricant|In this arm, subjects will use lidocaine lubricant in their normal bowel care routine (rather than standard lubricating jelly).
11469305|NCT01567605|Placebo Comparator|Placebo lubricant|In this arm, subjects will use regular lubricant (AMG MedPro lubricating gel) in their normal bowel care routine.
11469306|NCT01567592|Experimental|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
11469307|NCT01567566|Active Comparator|Local lumbopelvic stabilizers|
11469308|NCT01567566|Experimental|Local lumbopelvic plus hip stabilizers|
11469309|NCT01567553||Control group|Only unenhanced MR scanning will be performed in a control group of normal, age-matched subjects and after acceptance of the protocol by an independent ethical committee for the implication of a normal population in such an MRI research project.
11469310|NCT01567553||Experimental group|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients. These CIS patients will be included within three months after first clinical presentation.
11469311|NCT01567540|Experimental|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
11469312|NCT01567527|Active Comparator|1|Active Comparator: Treatment of Aripiprazole IM Depot
11469313|NCT01567527|Placebo Comparator|2|Placebo Comparator: Treatment of IM Depot Placebo
11469314|NCT01567514|Active Comparator|Glass-ionomer cement lining|Presence of glass-ionomer cement lining in posterior resin composite restorations.
11469315|NCT01567514|No Intervention|No glass-ionomer cement lining|Absence of glass-ionomer cement lining in posterior resin composite restorations
11469316|NCT01567501|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
11469317|NCT01567501|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
11469318|NCT01567488|Experimental|Everolimus + Octreotide LAR treatment|
11469319|NCT01567475|Experimental|Everolimus and rituximab|
11469320|NCT01567462|Active Comparator|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
11469321|NCT01567462|Active Comparator|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
11469322|NCT01567449||the case group|The case group referred to SAH patients with aneurysm rebleeding
11469323|NCT01567449||the control group|the control group referred to SAH patients not with aneurysm rebleeding
11469324|NCT01567423|Experimental|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
11469325|NCT01567423|Active Comparator|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
11469326|NCT01567410|Other|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
11469327|NCT01567410|Other|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
11469328|NCT01567384|Experimental|Combination therapy with OSI and Pemetrexed|
11469329|NCT01567371|Experimental|LiDCO rapid monitor|
11469330|NCT01567358|Experimental|NI-071|
11469331|NCT01567358|Active Comparator|Remicade|
11469332|NCT01567345|Active Comparator|Intrathecal pump with continuous flow|After placement of the implantable pump, continuous flow is scheduled by physician and the patient can't modify it.
11469333|NCT01567345|Experimental|Intrathecal pump with programmable flow.|After placement of the implantable pump, programmable flow is scheduled by physician and patient can do himself morphine bolus injections for a better control of acute episodes of pain.
11469334|NCT01567332|Experimental|rTMS active|
11469337|NCT01567319|Active Comparator|Atopic Subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
11469338|NCT01567319|Active Comparator|No Atopic Subjects|Healthy volunteers.
11469339|NCT01567306|Experimental|Allergovac Depot Group 1 Active|
11469340|NCT01567306|Experimental|Allergovac Depot Group 2 Active|
11469341|NCT01567306|Experimental|Allergovac Depot Group 3 Active|
11469342|NCT01567306|Experimental|Allergovac Depot Group 4 Active|
11469343|NCT01567306|Experimental|Allergovac Depot Group 5 Active|
11469344|NCT01567306|Placebo Comparator|Placebo - Group 6|
11469345|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
11469346|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
11469347|NCT01567267|Experimental|Experimental educational intervention|Experimental educational intervention
11469348|NCT01567267|Active Comparator|Standard educational intervention|Standard educational intervention
11469349|NCT01567254|Experimental|guided imaginary|7 children receiving auditory guided imagery disk
11469350|NCT01567254|Active Comparator|music|6 children receiving music disk
11469351|NCT01567241|Placebo Comparator|Relaxation music|
11469352|NCT01567241|Experimental|Clinical hypnosis|
11469353|NCT01567228|No Intervention|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
11469354|NCT01567228|Experimental|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
11469355|NCT01567215|Experimental|Granuloma|
11469356|NCT01567202|Experimental|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
11469357|NCT01567202|Placebo Comparator|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
11469358|NCT01567189|Experimental|Hospital cardiac rehabilitation|The patients will perform physical training sessions in the hospital
11469359|NCT01567189|Active Comparator|Home cardiac rehabilitation|The patients will perform physical training sessions at home
11469360|NCT01567176|Other|Single Arm|
11469361|NCT01567163|Experimental|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle
~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle
~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle
~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
11469362|NCT01567150|Active Comparator|novel dressing|Treatment with novel dressing
11469363|NCT01567150|No Intervention|Control|Control is treatment without novel dressing
11469364|NCT01567124|Other|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
11469365|NCT01567124|Other|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
11469366|NCT01567111|Experimental|Subjects with PA|All study subjects have biochemically confirmed PA and undergo adrenal CT, AVS and MTO-PET to diagnose lateralization of aldosterone production.
11469367|NCT01567098|Experimental|SILS appendectomy|Single incision laparoscopic appendectomy
11469368|NCT01567098|Active Comparator|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
11469369|NCT01567085|Experimental|Eculizumab|"Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.
~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.
~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days."
11469370|NCT01567072|Experimental|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
11469371|NCT01567072|Active Comparator|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
11469372|NCT01567072|Placebo Comparator|Placebo|Only placebo in 7 days
11469373|NCT01567059|Experimental|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
11469374|NCT01567059|Experimental|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
11469375|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
11469376|NCT01567033|Experimental|Intervention|Intervention participants received HEALTH, which embedded a lifestyle intervention derived from DPP within the standard PAT curriculum
11469377|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
11469378|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
11469379|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
11469380|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
11469381|NCT01567007|No Intervention|control|session of 15-20 minutes duration. It took place guidelines on physical activity, delivering a manual with general information about physical activity
11469382|NCT01567007|Experimental|Individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise steps. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
11469423|NCT01566786|Experimental|activated recombinant human factor VII|
11469383|NCT01567007|Experimental|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices.
11469384|NCT01567007|Experimental|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill
11469385|NCT01566994|Experimental|TTM Tailored|
11469386|NCT01566994|Experimental|Motivational Enhancement Therapy|
11469387|NCT01566994|Experimental|Integrated Treatment|
11469388|NCT01566981|Experimental|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
11469389|NCT01566981|No Intervention|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
11469390|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
11469391|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
11469392|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
11469393|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
11469394|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
11469395|NCT01566955|Experimental|transgastric adnexectomy|patients are operated transgastric
11469396|NCT01566942|Active Comparator|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
11469397|NCT01566942|Experimental|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
11469398|NCT01566929|No Intervention|IVF only|IVFtreatment
11469399|NCT01566929|Active Comparator|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
11469400|NCT01566916|Active Comparator|Total Hip Arthroplasty performed via direct anterior approach|
11469401|NCT01566916|Active Comparator|Total Hip Arthroplasty using anterolateral approach|
11469402|NCT01566903||arteriovenous malformations|
11469403|NCT01566903||Arterial stenosis|
11469404|NCT01566903||Post-treatment follow-up|Patient with an arteriovenous malformation for which treatment by embolization or radiosurgery is indicated
11469405|NCT01566890|Experimental|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
11469406|NCT01566890|Other|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
11469407|NCT01566890|Other|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
11469408|NCT01566890|Other|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
11469409|NCT01566890|Other|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
11469410|NCT01566877|Active Comparator|AVI-7288|AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP). AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL. The dose levels of AVI-7288 will vary in four cohort's.
11469411|NCT01566877|Placebo Comparator|Placebo|Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
11469412|NCT01566864|Experimental|Behavioral: Improve clinic based measurement of blood pressur|
11469413|NCT01566864|Experimental|Behavioral: Provider education system to promote patient-cent|
11469414|NCT01566864|Experimental|Behavioral: Introduce care management system in clinics|
11469415|NCT01566851||Patient|Patients with rheumatoid arthritis
11469416|NCT01566838|Active Comparator|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
11469417|NCT01566838|Active Comparator|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.
~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
11469418|NCT01566825|Active Comparator|Amitriptyline|
11469419|NCT01566825|Placebo Comparator|white 8 mm Lichtenstein®|
11469420|NCT01566812|Experimental|Breast feeding optimization|
11469421|NCT01566812|Active Comparator|Usual/routine care|
11469422|NCT01566799|Experimental|Metformin|Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
11469425|NCT01566773|Experimental|PT001 MDI (Dose 1)|
11469426|NCT01566773|Experimental|PT001 MDI (Dose 2)|
11469427|NCT01566773|Experimental|PT001 MDI (Dose 3)|
11469428|NCT01566773|Experimental|PT001 MDI (Dose 4)|
11469429|NCT01566773|Experimental|PT001 MDI (Dose 5)|
11469430|NCT01566773|Experimental|PT001 MDI (Dose 6)|
11469431|NCT01566773|Placebo Comparator|PT001 Placebo MDI|
11469432|NCT01566773|Active Comparator|Spiriva® Handihaler® (Tiotropium Bromide)|
11469433|NCT01566760|Experimental|Treatment A, Cohort 1|
11469434|NCT01566760|Experimental|Treatment B, Cohort 2|
11469435|NCT01566760|Experimental|Treatment C, Cohort 1|
11469436|NCT01566760|Experimental|Treatment D, Cohort 2|
11469437|NCT01566760|Active Comparator|Treatment E, Cohort 1 and/or Cohort 2|
11469438|NCT01566747|Experimental|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
11469439|NCT01566734|Experimental|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
11469440|NCT01566734|Experimental|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
11469441|NCT01566734|No Intervention|Control|
11469442|NCT01566721|Experimental|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
11469443|NCT01566721|Experimental|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
11469444|NCT01566708|Experimental|treatment group|
11469445|NCT01566708|Active Comparator|waiting list group|
11469446|NCT01566708|Active Comparator|control group|
11469447|NCT01566695|Experimental|Oral Azacitidine|Arm 1: Oral azacitidine tablets 300 mg daily (QD) + best supportive care (BSC) on days 1 through 21 of each 28-day treatment cycle.
11469448|NCT01566695|Placebo Comparator|Placebo|Arm 2: Identically matching placebo tablets plus best supportive care on days 1 to 21 of each 28-day treatment cycle.
11469449|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
11469450|NCT01566669|Placebo Comparator|Normal Saline|Before incision, patients in controlled Group received NS
11469451|NCT01566669|Experimental|parecoxib sodium|Before incision, parecoxib patients received 40mg of parecoxib IV
11469452|NCT01566656|Experimental|TLI and anti-thymocyte globulin|
11469453|NCT01566643|Experimental|Hybrid-10|RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.
11469454|NCT01566643|Experimental|Hybrid-12|RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
11469455|NCT01566643|Experimental|Hybrid-14|RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
11469456|NCT01566630|Experimental|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.
~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
11469457|NCT01566630|Placebo Comparator|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.
~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
11469458|NCT01566617|Other|Standard Care|(1) group who will receive standard care
11469459|NCT01566617|Other|Standard Care and Pharmaceutical Care|(2) group who will receive standard care and pharmaceutical care
11469460|NCT01566604|Experimental|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
11469461|NCT01566604|Placebo Comparator|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
11469462|NCT01566591|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
11469463|NCT01566591|Active Comparator|Deep TMS Treatment|Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.
11469464|NCT01566578|Experimental|EGF Cream|
11469465|NCT01566578|Placebo Comparator|Placebo cream|
11469466|NCT01566565|Active Comparator|Theophylline|
11469467|NCT01566565|Active Comparator|Bambuterol|
11469468|NCT01566552|Other|SINGLE DOSE AMBISOME|
11469469|NCT01566539|Experimental|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
11469470|NCT01566539|Experimental|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
11469471|NCT01566539|Placebo Comparator|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
11469472|NCT01566539|Experimental|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
11469473|NCT01566539|Experimental|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
11469474|NCT01566539|Placebo Comparator|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
11469475|NCT01566539|Experimental|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
11469476|NCT01566539|Placebo Comparator|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
11469477|NCT01566539|Experimental|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
11469478|NCT01566539|Placebo Comparator|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
11469479|NCT01566539|Experimental|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
11469480|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
11469481|NCT01566513|No Intervention|Treatment as usual|
11469482|NCT01566513|Experimental|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
11469483|NCT01566513|Experimental|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
11469484|NCT01566513|Experimental|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
11469485|NCT01566487|Experimental|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
11469486|NCT01566487|Active Comparator|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
11469487|NCT01566474|Experimental|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
11469488|NCT01566474|Active Comparator|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
11469489|NCT01566461|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
11469490|NCT01566461|Active Comparator|Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty
11469491|NCT01566448|Experimental|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
11469492|NCT01566435|Experimental|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)
~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15
~Cisplatin 75 mg/m^2 on Day 1
~5-FU 750 mg/m^2 on Days 1-3
~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.
~Definitive Therapy
~Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43
~Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.
~If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks"
11469493|NCT01566422|Experimental|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
11469494|NCT01566422|No Intervention|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
11469495|NCT01566409|Active Comparator|Active maintenance treatment|
11469496|NCT01566409|Placebo Comparator|Placebo maintenance treatment|
11469497|NCT01566396|Experimental|A3F|A3F, Fractional RF treatment
11469498|NCT01566383|Experimental|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
11469499|NCT01566370|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
11469500|NCT01566370|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
11469501|NCT01566357|No Intervention|Fluoride-free toothpaste|
11469502|NCT01566357|Active Comparator|Fluoride toothpaste|
11469503|NCT01566357|Active Comparator|Milk|
11469504|NCT01566357|Active Comparator|Fluoridated milk|
11469505|NCT01566357|Active Comparator|CPP-ACP|
11469506|NCT01566357|Active Comparator|Fluoridated CPP-ACP|
11469507|NCT01566357|Active Comparator|Fluoride mouthrinse|
11469508|NCT01566344|Experimental|Routine heart failure therapy plus PVC suppression therapy|
11469509|NCT01566344|No Intervention|Routine heart failure therapy|
11469510|NCT01566331|Experimental|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
11469511|NCT01566331|No Intervention|no intervention|Baby-guardTM system, without inflation
11469512|NCT01566318|Experimental|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
11469513|NCT01566318|No Intervention|Usual care|Usual agency care, monitored for mental health services
11469514|NCT01566305|Experimental|Buttermilk with added egg yolk|
11469515|NCT01566305|Experimental|Buttermilk without added egg-yolk|
11469516|NCT01566305|Experimental|Skimmed milk with added egg-yolk|
11469517|NCT01566305|Placebo Comparator|Skimmed milk without added egg yolk|
11469518|NCT01566292|Experimental|BOTOX|
11469519|NCT01566279|Other|everolimus|All patients in first part will receive everolimus 10mg q.d.
11469520|NCT01566266|Experimental|Amoxicillin|
11469521|NCT01566266|Placebo Comparator|Placebo capsules|
11469522|NCT01566253|Experimental|PCOA|The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.
11469523|NCT01566253|Active Comparator|Standard/ IV|The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.
11469524|NCT01566240|Active Comparator|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
11469525|NCT01566240|Experimental|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
11469526|NCT01566227|Experimental|number of implants|number of implants (1,2 or 3) used to retained an overdenture
11469527|NCT01566214|Experimental|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
11469528|NCT01566214|No Intervention|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
11469529|NCT01566201|Active Comparator|anakinra|
11469530|NCT01566201|Placebo Comparator|placebo|
11469531|NCT01566188|Experimental|omega-3 from vegetal origin|
11469532|NCT01566188|Placebo Comparator|Placebo|
11469533|NCT01566175|Experimental|Neovasc coronary sinus reducer|open label: Neovasc coronary sinus reducer
11469534|NCT01566162|Experimental|Lurasidone|Lurasidone 40 - 80mg flexible dose
11469535|NCT01566149|Active Comparator|MF/F 200/10 mcg MDI BID|Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks
11469536|NCT01566149|Active Comparator|MF/F 400/10 mcg MDI BID|Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks
11469537|NCT01566136|No Intervention|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
11469538|NCT01566136|Experimental|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
11469539|NCT01566123|Experimental|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
11469540|NCT01566110|Experimental|Diet Intervention Group|
11469541|NCT01566110|No Intervention|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
11469542|NCT01566097|Experimental|Intervention group|This study is cluster randomized trial, and the randomization level is physician. Current smokers seen by physician allocated into intervention group were provided with Smoking Cessation Decision Aids along with study questionnaires. The intervention was Smoking Cessation Decision Aids provided to current smokers.
11469543|NCT01566097|No Intervention|Control group|Current smokers seen by physician allocated into control group were provided with only study questionnaires and usual care.
11469544|NCT01566084|Other|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
11469545|NCT01566084|Other|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
11469546|NCT01566058|Experimental|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
11469547|NCT01566058|Active Comparator|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
11469548|NCT01566045|Active Comparator|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
11469549|NCT01566045|Experimental|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
11469550|NCT01566019|Experimental|Patients with non curable metastatic cancer|
11469551|NCT01566006|No Intervention|control group|group receiving the conventional treatment for DN
11469552|NCT01566006|Experimental|cellcept group|additional to the conventional treatment patients will receive cellcept
11469553|NCT01566006|Experimental|carnitine group|aside to the conventional treatment patients will receive carnitine
11469554|NCT01566006|Experimental|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
11469555|NCT01565993|Active Comparator|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
11469556|NCT01565993|Active Comparator|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
11469557|NCT01565980|Active Comparator|symptom assessment|6 weeks of symptom assessment phone calls.
11469558|NCT01565980|Experimental|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
11469559|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
11469560|NCT01565941|Active Comparator|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
11469561|NCT01565941|Active Comparator|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
11469562|NCT01565928|Experimental|MDV3100|
11469563|NCT01565915|Experimental|Perlane-L|Perlane-L treatment
11469564|NCT01565915|Sham Comparator|Non-Treatment|Non-Treatment Arm
11469565|NCT01565902|Experimental|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
11469566|NCT01565902|Experimental|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
11469567|NCT01565902|Experimental|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
11469568|NCT01565902|Experimental|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
11469569|NCT01565889|Experimental|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
11469570|NCT01565889|Experimental|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
11469571|NCT01565889|Experimental|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
11469572|NCT01565889|Experimental|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
11469573|NCT01565889|Experimental|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
11469574|NCT01565889|Experimental|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
11469575|NCT01565876|Experimental|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.
~Then The participants will undergo heat tolerance test 5 times (in different days).
~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
11469576|NCT01565863|Experimental|Progressive Goal Attainment Program|
11469577|NCT01565863|No Intervention|VA employment services|
11469578|NCT01565850|Experimental|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
11469579|NCT01565850|Active Comparator|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
11469580|NCT01565837|Experimental|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
11469581|NCT01565824|Experimental|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
11469582|NCT01565824|No Intervention|Usual care|
11469583|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
11469584|NCT01565798|Experimental|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
11469585|NCT01565798|No Intervention|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
11469586|NCT01565785|Experimental|Discharge Prepartion with The FSM-DPI|25 families on each of 2 units will receive the will receive the Family Self-Management-Discharge Preparation Intervention (FSM-DPI). This scripted theory-based intervention is delivered by the study nurse using a e-mobile device. Eight elements of discharge preparation are addressed, the nurse assesses the family status and documents the additional care provided.
11469587|NCT01565785|No Intervention|control group|25 parents on each unit receiving standard of care in discharge preparation.
11469588|NCT01565772|Experimental|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
11469638|NCT01565525|Experimental|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
11469639|NCT01565525|Active Comparator|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
11469589|NCT01565759|Experimental|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
11469590|NCT01565746|Experimental|Radium-223 dichloride [50 kBq/kg]|
11469591|NCT01565746|Experimental|Radium-223 dichloride [100 kBq/kg]|
11469592|NCT01565746|Experimental|Radium-223 dichloride [expansion]|
11469593|NCT01565733||NovoMix® 30 users|
11469594|NCT01565720|Experimental|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
11469595|NCT01565720|Experimental|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
11469596|NCT01565720|Placebo Comparator|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
11469597|NCT01565720|Active Comparator|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
11469598|NCT01565707|Placebo Comparator|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
11469599|NCT01565707|Experimental|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
11469600|NCT01565707|Placebo Comparator|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
11469601|NCT01565707|Placebo Comparator|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
11469602|NCT01565694|Experimental|Solifenacin succinate|"Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.
~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
11469603|NCT01565681|Experimental|Arm A: ASKP1240 lowest dose|
11469604|NCT01565681|Experimental|Arm B: ASKP1240 second lowest dose|
11469605|NCT01565681|Experimental|Arm C: ASKP1240 third lowest dose|
11469606|NCT01565681|Experimental|Arm D: ASKP1240 fourth lowest dose|
11469607|NCT01565681|Experimental|Arm E: ASKP1240 fifth lowest dose|
11469608|NCT01565681|Experimental|Arm F: ASKP1240 middle dose|
11469609|NCT01565681|Experimental|Arm G: ASKP1240 sixth highest dose|
11469610|NCT01565681|Experimental|Arm H: ASKP1240 fifth highest dose|
11469611|NCT01565681|Experimental|Arm I: ASKP1240 fourth highest dose|
11469612|NCT01565681|Experimental|Arm J: ASKP1240 third highest dose|
11469613|NCT01565681|Experimental|Arm K: ASKP1240 second highest dose|
11469614|NCT01565681|Experimental|Arm L: ASKP1240 highest dose|
11469615|NCT01565681|Placebo Comparator|Arm M: Placebo|Sodium Chloride solution
11469616|NCT01565668|Experimental|AC220 Dose Level 1|
11469617|NCT01565668|Experimental|AC220 Dose Level 2|
11469618|NCT01565655|Experimental|ASP015K lowest dose|ASP015K lowest dose once daily
11469619|NCT01565655|Experimental|ASP015K low dose|ASP015K low dose once daily
11469620|NCT01565655|Experimental|ASP015K medium dose|ASP015K medium dose once daily
11469621|NCT01565655|Experimental|ASP015K high dose|ASP015K high dose once daily
11469622|NCT01565655|Placebo Comparator|Placebo|Matching placebo once daily
11469623|NCT01565642|Experimental|Decision support intervention|Decision aid and care plan meeting
11469624|NCT01565642|No Intervention|Control|Attention control information on dementia care
11469625|NCT01565629|No Intervention|Waitlist Condition|Children in this condition will withhold from any type of intervention for a period of 12 weeks.
11469626|NCT01565629|Experimental|Computer Assisted CBT|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
11469627|NCT01565616|Experimental|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
11469628|NCT01565590|Active Comparator|Propofol|
11469629|NCT01565590|Experimental|Dexmedetomidine|
11469630|NCT01565577|Experimental|Bras A|
11469631|NCT01565564|Active Comparator|The usual care arm|
11469632|NCT01565564|Active Comparator|The shared care arm|
11469633|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
11469634|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
11469635|NCT01565538|Experimental|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
11469636|NCT01565538|Experimental|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
11469637|NCT01565525|No Intervention|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
11469640|NCT01565512|Placebo Comparator|saline injection|saline injection
11469641|NCT01565512|Active Comparator|Bupivacaine injection|penile block with bupivacaine
11469642|NCT01565499|Experimental|Nab-Paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
11469643|NCT01565486|Other|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
11469644|NCT01565486|Other|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
11469645|NCT01565473||Parkinson disease patients|
11469646|NCT01565473||Healthy normal controls|
11469647|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
11469648|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
11469649|NCT01565408|Experimental|NNC0114-0006|
11469650|NCT01565408|Placebo Comparator|Placebo|
11469651|NCT01565395|Experimental|Xeomin Injections|Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism
11469652|NCT01565395|Placebo Comparator|Placebo|0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism
11469653|NCT01565343|Experimental|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
11469654|NCT01565343|Experimental|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.
~The first injection given as a rapid bolus (< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
11469655|NCT01565343|Experimental|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
11469656|NCT01565330|Experimental|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
11469657|NCT01565330|Experimental|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
11469658|NCT01565330|Experimental|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
11469659|NCT01565330|Experimental|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
11469660|NCT01565317|Experimental|Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
11469661|NCT01565317|No Intervention|Control Group|Matched control group will be recruited from obese patients with diabetes followed at Joslin Clinic. This group will receive the routine standard diabetes care.
11469662|NCT01565304|Experimental|POWER Through Choices|10-session group-based sexual education curriculum
11469663|NCT01565304|No Intervention|Usual services|No intervention
11469664|NCT01565291|Experimental|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
11469665|NCT01565291|Experimental|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
11469666|NCT01565278|Experimental|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
11469667|NCT01565278|Active Comparator|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
11469668|NCT01565265|Active Comparator|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
11469669|NCT01565265|Experimental|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
11469670|NCT01565252|No Intervention|Stage 1|"Dietary regimens:
~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
11469671|NCT01565252|Experimental|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
11469672|NCT01565239|Experimental|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
11469673|NCT01565239|Active Comparator|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
11469674|NCT01565226||Open|open, observational study
11469675|NCT01565213|Active Comparator|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
11469676|NCT01565213|Active Comparator|MMI Multimodal group intervention|group multimodal intervention
11469677|NCT01565213|Other|CAU|Care as usual given by the GPs
11470107|NCT01562366|Active Comparator|Group 2|
11469678|NCT01565200|Other|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
11469679|NCT01565187||hand transplant candidates|Participants enrolled will be asked to complete behavioral questionnaires.
11469680|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
11469681|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
11469682|NCT01565161|Experimental|Home-Based Health Coaching|Intervention delivered in the home.
11469683|NCT01565161|Active Comparator|Control Arm|Mailed educational materials
11469684|NCT01565148|Experimental|Group 1|"Drug: iCo-007 350 mcg
~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
11469685|NCT01565148|Experimental|Group 2|"Drug: iCo-007 700 mcg
~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
11469686|NCT01565148|Experimental|Group 3|"Drug: iCo-007 350 mcg and Laser
~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
11469687|NCT01565148|Experimental|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg
~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
11469688|NCT01565135|Experimental|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
11469689|NCT01565135|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
11469690|NCT01565122||Cohort|
11469691|NCT01565109|Experimental|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU
~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
11469692|NCT01565096|Experimental|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
11469693|NCT01565096|Active Comparator|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
11469694|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m^2) followed by 30-35 mg/m^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
11469695|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
11469696|NCT01565070|Active Comparator|Biofreeze|
11469697|NCT01565070|Placebo Comparator|Placebo|Use of placebo ointment
11469698|NCT01565057|Experimental|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
11469699|NCT01565044|Experimental|" AUTO  Group"|
11469700|NCT01565044|Sham Comparator|" CONTROL  Group"|
11469701|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
11469702|NCT01565018|Experimental|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1
~Treatment B: Reference; drug product PR 2.1.4
~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
11469703|NCT01565018|Experimental|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4
~Treatment A: Test; drug product PR 2.2.1
~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
11469704|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
11469705|NCT01565005||FANCONI ANEMIA|
11469706|NCT01564992||Parkinson disease|Identification of genes
11469707|NCT01564979|Experimental|preseptal|
11469708|NCT01564979|Experimental|pretarsal|
11469709|NCT01564966||Living kidney donors|Those who donate kidneys
11469710|NCT01564927|Experimental|Electroacupuncture to right LI4 and LI11|
11469711|NCT01564927|Sham Comparator|Electroacupuncture to knee caps|Electroacupuncture to knee caps
11469712|NCT01564927|Placebo Comparator|Sham electroacupuncture to LI4 & LI11|
11469713|NCT01564914|Experimental|TRC105, Bevacizumab|Single arm study
11469714|NCT01564901||Cohort|
11469715|NCT01564888|Placebo Comparator|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
11469835|NCT01564134|Experimental|HepB 60ug|receive the vaccine with 60ug HBsAg
11470227|NCT01561521|Experimental|AKF-1 0.035%|
11469716|NCT01564888|Active Comparator|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
11469717|NCT01564875|Experimental|Simvast CR|"Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
~Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
11469718|NCT01564875|Active Comparator|Zocor|"Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.
~Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
11469719|NCT01564862|Experimental|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
11469720|NCT01564862|Active Comparator|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
11469721|NCT01564862|Placebo Comparator|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
11469722|NCT01564849||chronic rhinitis,|
11469723|NCT01564849||chronic sinusitis|
11469724|NCT01564849||nasal polyps|
11469725|NCT01564849||control rhinitis|
11469726|NCT01564849||control sinusitis|
11469727|NCT01564849||control polyps|
11469728|NCT01564836|Experimental|Imatinib treatment discontinuing|
11469729|NCT01564823|Experimental|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
11469730|NCT01564823|Active Comparator|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
11469731|NCT01564810|Experimental|Arm A|patients received cetuximab in combination with chemotherapy
11469732|NCT01564810|Active Comparator|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
11469733|NCT01564797|Active Comparator|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
11469734|NCT01564797|No Intervention|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
11469735|NCT01564784|Experimental|Arm A|
11469736|NCT01564784|Active Comparator|Arm B|
11469737|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
11469738|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
11469739|NCT01564745|Other|Cough Determinants|
11469740|NCT01564732|Active Comparator|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
11469741|NCT01564732|Experimental|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
11469742|NCT01564719|Experimental|Immediate-intervention arm|This is a holistic health intervention. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
11469743|NCT01564719|Experimental|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
11469744|NCT01564719|Experimental|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
11469745|NCT01564706|Experimental|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
11469746|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
11469747|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
11469748|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
11469749|NCT01564680|Experimental|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
11469750|NCT01564680|Placebo Comparator|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
11469751|NCT01564680|Experimental|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
11469752|NCT01564667|Experimental|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
11469753|NCT01564667|Active Comparator|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
11469754|NCT01564654||iTotal KRS|
11469755|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
11469836|NCT01564108|Experimental|Ranibizumab|Series of intravitreal injections of Ranibizumab
11469756|NCT01564628||All study participants|Population from 2 sites, sequential design with all patients undergoing CADScor1 intervention followed by the diagnostic testing the patients were referred to (procedure done according to standard of care and not part of study; computerized tomographic angiography (CTA) and, if relevant, coronary angiography (CAG) at Site 1 and CAG at site 2).
11469757|NCT01564615|Experimental|AgION catheter|Patients in this arm received an AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
11469758|NCT01564615|Active Comparator|Non-impregnated polyurethane catheter|Patients in this arm received a non-impregnated polyurethane umbilical catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
11469759|NCT01564602|Experimental|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
11469760|NCT01564576|No Intervention|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
11469761|NCT01564576|Experimental|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
11469762|NCT01564563|Placebo Comparator|Placebo|
11469763|NCT01564563|Experimental|Low dose|
11469764|NCT01564563|Experimental|High dose|
11469765|NCT01564550||type 2 diabetes|
11469766|NCT01564550||healthy subjects|
11469767|NCT01564537|Experimental|Ixazomib + Lenalidomide + Dexamethasone|Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to end of treatment (EOT) projected at 80 months.
11469768|NCT01564537|Placebo Comparator|Placebo + Lenalidomide + Dexamethasone|Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to EOT projected at 80 months.
11469769|NCT01564511|Experimental|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
11469770|NCT01564511|Sham Comparator|Conventional group|Convetional physical gait training
11469771|NCT01564498|Placebo Comparator|White potato|Participants will consume 300-500 g of cooked white potatoes per day
11469772|NCT01564498|Experimental|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
11469773|NCT01564498|Placebo Comparator|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
11469774|NCT01564498|Experimental|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
11469775|NCT01564485|Experimental|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
11469776|NCT01564485|Placebo Comparator|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
11469777|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
11469778|NCT01564459|Experimental|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
11469779|NCT01564459|Placebo Comparator|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
11469780|NCT01564446|Experimental|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
11469781|NCT01564433|Experimental|Gait trainer treatment|
11469782|NCT01564433|Active Comparator|Conventional group|
11469783|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
11469784|NCT01564420||Control group|
11469785|NCT01564407|Experimental|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:
~Empty control no injection
~Vehicle only (0.5 ml of HypoThermosol solution)
~5 million cells / cm² , single administration at Day 0
~5 million cells/ cm² , single administration at week 4
~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
11469786|NCT01564407|Active Comparator|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
11469787|NCT01564407|Active Comparator|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
11469788|NCT01564407|Active Comparator|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
11469789|NCT01564407|Active Comparator|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
11469790|NCT01564394|Experimental|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
11469791|NCT01564394|Sham Comparator|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
11469792|NCT01564381|Experimental|Resveratrol|The capsules will contain 90mg of resveratrol.
11469793|NCT01564381|Experimental|ResA|ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. The capsules will contain 90mg of resveratrol.
11469794|NCT01564381|Placebo Comparator|Placebo|The placebo will be cellulose.
11469795|NCT01564368|Experimental|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
11469796|NCT01564355|Experimental|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
11469797|NCT01564355|Placebo Comparator|Placebo|Will receive placebo pills for 10 days post-operatively
11469798|NCT01564342|Other|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
11469799|NCT01564342|Other|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
11469800|NCT01564329|Experimental|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
11469801|NCT01564329|Experimental|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
11469802|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
11469803|NCT01564303|No Intervention|2. Acetylcysteine group (NAC+S) , aside with the saline, will|2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.
11469804|NCT01564303|Experimental|CAR+S , aside with the saline, carnitne will be adminstrated|Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.
11469805|NCT01564303|Experimental|Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with|4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.
11469806|NCT01564303|No Intervention|Control group (S) will be treated without any extra agents|Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.
11469807|NCT01564290|Placebo Comparator|probiotic|Probiotic product with Sacharomices Boulardii
11469808|NCT01564290|Active Comparator|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
11469809|NCT01564277|Experimental|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
11469810|NCT01564277|Experimental|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
11469811|NCT01564264|Experimental|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
11469812|NCT01564251|Experimental|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
11469813|NCT01564251|Experimental|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m^2) or 1000 mg/m^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
11469814|NCT01564251|Experimental|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
11469815|NCT01564251|Experimental|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m^2 and/or 500 mg/m^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
11469816|NCT01564238|Experimental|High calcium diets (1300 mg or higher)|
11469817|NCT01564238|Experimental|Low calcium diet (800 mg/d)|
11469818|NCT01564225|Experimental|EDI200|
11469819|NCT01564212|Active Comparator|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
11469820|NCT01564212|Active Comparator|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
11469821|NCT01564212|Active Comparator|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
11469822|NCT01564212|Active Comparator|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
11469823|NCT01564199|Experimental|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
11469824|NCT01564199|Experimental|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
11469825|NCT01564186||MulitPoint Pacing|
11469826|NCT01564186||BiV Conventional|
11469827|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
11469828|NCT01564160|Experimental|Arm 1: PCSO-524|PCSO-524
11469829|NCT01564160|Active Comparator|Arm 2: Fish Oil|Fish Oil
11469830|NCT01564147|Other|Immediate Education therapeutic|Access to the course of immediate therapeutic education
11469831|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
11469832|NCT01564134|Experimental|HepB 5ug|receive the vaccine with 5ug HBsAg
11469833|NCT01564134|Experimental|HepB 10ug|receive the vaccine with 10ug HBsAg
11469834|NCT01564134|Experimental|HepB 20ug|receive the vaccine with 20ug HBsAg
11469837|NCT01564095|Experimental|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
11469838|NCT01564095|Placebo Comparator|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
11469839|NCT01564082|Experimental|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
11469840|NCT01564082|No Intervention|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
11469841|NCT01564069||IT opioids|Patients with IT pumps receiving IT opioids
11469842|NCT01564069||Systemic opioids|Patients taking oral or transdermal opioids for chronic pain
11469843|NCT01564069||Non-opioid management|Patients managing chronic pain without taking opioids
11469844|NCT01564056|Other|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
11469845|NCT01564056|Experimental|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
~CHEMOTHERAPY regimen will be chosen amongst the following ones:
~TC (docetaxel + cyclophosphamide)
~AC (doxorubicin + cyclophosphamide)
~MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)"
11469846|NCT01564043|Experimental|website and pedometer|
11469847|NCT01564030|Other|Empty stomach|Patients have fasted for 8 hours.
11469848|NCT01564030|Other|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
11469849|NCT01564030|Other|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
11469850|NCT01564017|Experimental|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
11469851|NCT01564017|Experimental|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
11469852|NCT01564017|Experimental|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
11469853|NCT01564017|Experimental|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
11469854|NCT01564017|Experimental|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
11469855|NCT01564017|Placebo Comparator|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
11469856|NCT01564004|Experimental|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
11469857|NCT01564004|Active Comparator|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
11469858|NCT01563991|Active Comparator|Standard fluid volume|Subject receives normal fluid volume during peri-operative period
11469859|NCT01563991|Experimental|Reduced Fluid Volume|Subject receives a reduced fluid volume during the peri-operative period
11469860|NCT01563978|Experimental|Dosing Regimen A|Oral treatment
11469861|NCT01563978|Placebo Comparator|Dosing Regimen B|Oral treatment
11469862|NCT01563965|Active Comparator|Conventional preoperative fast|Patients underwent surgery after 8h fast
11469863|NCT01563965|Experimental|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
11469864|NCT01563952|Active Comparator|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
11469865|NCT01563952|Experimental|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
11469866|NCT01563952|Active Comparator|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
11469867|NCT01563952|Experimental|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
11469868|NCT01563939|Active Comparator|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
11469869|NCT01563939|Active Comparator|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
11469870|NCT01563926|Experimental|Somatropin|
11469871|NCT01563913|Experimental|Arm 1|Docosahexaenoic Acid (DHA)
11469872|NCT01563913|Placebo Comparator|Arm 2|Placebo
11469873|NCT01563900|Sham Comparator|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
11469874|NCT01563900|Active Comparator|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
11469875|NCT01563887|Experimental|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
11469876|NCT01563887|Experimental|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
11469877|NCT01563874||Cohort 1|This study involves a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research.
11469878|NCT01563848|Active Comparator|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
11469879|NCT01563848|Active Comparator|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
11469880|NCT01563835|Active Comparator|Epidural (PCEA)|bupivacaine, fentanyl
11469881|NCT01563835|Active Comparator|IV PCA|Intravenous fentanyl patient controlled analgesia
11469882|NCT01563822|Experimental|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
11469883|NCT01563822|No Intervention|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
11469884|NCT01563809|Active Comparator|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
11469885|NCT01563809|Active Comparator|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
11469886|NCT01563809|No Intervention|High androgens FSH alone|
11469887|NCT01563809|No Intervention|Low androgens, FSH alone|
11469888|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
11469889|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
11469890|NCT01563783|Active Comparator|Woman Suitable for Myomectomy or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or Myomectomy (laparoscopic or abdominal).
11469891|NCT01563783|Active Comparator|Woman Suitable for UAE or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or uterine artery embolization (UAE).
11469892|NCT01563770|Experimental|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
11469893|NCT01563770|Placebo Comparator|placebo|p.o. placebo, twice daily
11469894|NCT01563757||Fontan Patients with PLE and PB|Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis
11469895|NCT01563757||Fontan Patients w/out PLE & PB|Protein Losing Enteropathy and Plastic Bronchitis
11469896|NCT01563757||Glenn Physiology Patients|
11469897|NCT01563757||2 ventricle heart with ASD|2 ventricle heart with Atrial Septal Defect
11469898|NCT01563744|Experimental|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
11469899|NCT01563744|Active Comparator|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
11469900|NCT01563731|Other|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
11469901|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|"Intermediate SBP target. Higher LDL-C target
~."
11469902|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
11469903|NCT01563731|Active Comparator|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
11469904|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
11469905|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
11469906|NCT01563718|Experimental|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
11469907|NCT01563718|Active Comparator|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
11469908|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
11469909|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
11469910|NCT01563653|Experimental|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
11469911|NCT01563640|Placebo Comparator|normal school uniforms|washing only
11469912|NCT01563640|Experimental|insecticide-treated school uniforms|washing and insecticide treatment
11469913|NCT01563627|Experimental|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
11469914|NCT01563627|Experimental|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
11469915|NCT01563614|Experimental|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
11469916|NCT01563601|Experimental|Obatoclax mesylate, Carboplatin and Etoposide (CEO)|
11469917|NCT01563601|Active Comparator|Carboplatin and Etoposide (CE)|
11469918|NCT01563588|Experimental|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
11469919|NCT01563588|No Intervention|control|dietary counseling by a dietetician in the anticancer hospital
11469920|NCT01563575|Experimental|Intervention Group|fast-track implementation process
11469921|NCT01563575|No Intervention|Control Group|Continue usual routine
11469922|NCT01563562|Experimental|Bardoxolone Methyl 20 mg|
11469923|NCT01563536|Experimental|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
11469924|NCT01563536|Experimental|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
11469925|NCT01563523|Experimental|Activated recombinant human factor VII|
11469926|NCT01563523|Placebo Comparator|Placebo|
11469927|NCT01563510|Experimental|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
11469928|NCT01563510|Active Comparator|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
11469929|NCT01563497|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
11469930|NCT01563497|Experimental|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
11469931|NCT01563497|Experimental|PF-05089771 TS formulation fed|Tablets TS formulation- fed
11469932|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
11469933|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
11469934|NCT01563471|Experimental|Treatment sequence 1|
11469935|NCT01563471|Experimental|Treatment sequence 2|
11469936|NCT01563471|Experimental|Treatment sequence 3|
11469937|NCT01563471|Placebo Comparator|Treatment sequence 4|
11469938|NCT01563458|Experimental|High dose|
11469939|NCT01563458|Experimental|Low dose|
11469940|NCT01563458|Placebo Comparator|Placebo|
11469941|NCT01563445|Experimental|activated recombinant human factor VII|
11469942|NCT01563445|Placebo Comparator|Placebo|
11469943|NCT01563432|Experimental|febuxostat (TR)|
11469944|NCT01563432|Experimental|febuxostat (RT)|
11469945|NCT01563419|No Intervention|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
11469946|NCT01563419|Experimental|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
11469947|NCT01563406|Experimental|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
11469948|NCT01563406|Experimental|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
11469949|NCT01563406|Experimental|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
11469950|NCT01563406|Experimental|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
11469951|NCT01563393|Active Comparator|STAMP using|Children between 1 and 17 years of age from internal medicine and surgical departments will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
11469952|NCT01563393|Placebo Comparator|No STAMP using|In order to examine the effect of the tool on the medical staff awareness, 364 files of hospitalized children will be tested: 182 files at the beginning of the study and prior to using the tool and 182 after 6 months at the same ages and in the same departments.
11469953|NCT01563380|Experimental|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
11469954|NCT01563380|No Intervention|Control Arm|
11469955|NCT01563367|Active Comparator|Iron isomaltoside 1000 (Monofer®)|Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
11469956|NCT01563367|Placebo Comparator|0,9% sodium saline|Placebo (0.9% sodium saline) - Intravenous infusion
11469957|NCT01563354|Experimental|Pasireotide LAR|60 mg i.m. injected once every 28 days
11469958|NCT01563354|Experimental|Everolimus|10 mg p.o. daily
11469959|NCT01563354|Experimental|Pasireotide LAR + Everolimus|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
11469960|NCT01563341|Experimental|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
11469961|NCT01563328|Experimental|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
11469962|NCT01563328|Experimental|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
11469963|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
11469964|NCT01563302|Experimental|Group 1|IONIS-STAT3Rx
11469965|NCT01563289|Placebo Comparator|placebo|
11469966|NCT01563289|Experimental|Ibuprofen|
11469967|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
11469968|NCT01563276||Parkinson's Disease|"Idiopathic PD according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)"
11469969|NCT01563276||Healthy Control|
11469970|NCT01563263|Active Comparator|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
11469971|NCT01563263|Placebo Comparator|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
11469972|NCT01563250|No Intervention|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
11469973|NCT01563250|Active Comparator|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
11469974|NCT01563237|Experimental|MIDI Arrow|Implantation of MIDI Arrow
11469975|NCT01563224|Experimental|single group, crossover, 3 interventions|
11470105|NCT01562379|Experimental|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
11469976|NCT01563211||Patients receiving endocrine treatment for breast cancer|Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer.
11469977|NCT01563211||Patients receiving chemotherapy for breast cancer|Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel).
11469978|NCT01563198|Experimental|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
11469979|NCT01563185|Experimental|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
11469980|NCT01563172|Experimental|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
11469981|NCT01563172|Experimental|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
11469982|NCT01563172|Experimental|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
11469983|NCT01563172|Experimental|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
11469984|NCT01563172|Active Comparator|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
11469985|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
11469986|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
11469987|NCT01563133|Other|Lymph nodes, pancreatic masses & cysts|
11469988|NCT01563120|Active Comparator|metformin|metformin up to 2550mg per day
11469989|NCT01563120|Active Comparator|glybenclamide|glybenclamide up to 20mg per day.
11469990|NCT01563107|Experimental|High Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels.
11469991|NCT01563107|Experimental|Low Salt Diet|
11469992|NCT01563081|Experimental|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
11469993|NCT01563068|Experimental|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
11469994|NCT01563055|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
11469995|NCT01563042|Experimental|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
11469996|NCT01563042|Experimental|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
11469997|NCT01563029|Active Comparator|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
11469998|NCT01563029|Active Comparator|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
11469999|NCT01563029|Active Comparator|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
11470000|NCT01563029|Active Comparator|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
11470001|NCT01563029|Placebo Comparator|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
11470002|NCT01563016|Experimental|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
11470003|NCT01563016|Placebo Comparator|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
11470004|NCT01563016|No Intervention|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
11470005|NCT01563016|No Intervention|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
11470006|NCT01563003|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
11470007|NCT01563003|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
11470008|NCT01562990|Experimental|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
11470009|NCT01562977|Other|no arms|no arms were present for the study, only 2 different cohorts:MCL and LDCGB
11470010|NCT01562964|Experimental|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
11470102|NCT01562379|Active Comparator|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
11470103|NCT01562379|Experimental|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
11470011|NCT01562964|Active Comparator|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
11470012|NCT01562951|Placebo Comparator|PLACEBO|Treatment with placebo
11470013|NCT01562951|Active Comparator|ADALIMUMAB|Treatment with Adalimumab
11470014|NCT01562938|Placebo Comparator|Placebo|Placebo
11470015|NCT01562938|Active Comparator|MEDI-557 low-dose|
11470016|NCT01562938|Active Comparator|MEDI-557 high-dose|
11470017|NCT01562925|Active Comparator|Red Wine|Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
11470018|NCT01562925|Active Comparator|White wine|
11470019|NCT01562925|Active Comparator|Beer|
11470020|NCT01562925|No Intervention|Control|Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
11470021|NCT01562912|Active Comparator|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
11470022|NCT01562912|Experimental|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
11470023|NCT01562899|Experimental|Dose escalation|Dose finding group chosen in order to establish a safe and tolerated dose of binimetinib in combination with ganitumab in patients with selected advanced solid tumors.
11470024|NCT01562899|Experimental|KRAS mutated colorectal adenocarcinoma|"Patients with KRAS mutant colorectal cancer.
~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
11470025|NCT01562899|Experimental|Metastatic pancreatic adenocarcinoma|"Patients with metastatic pancreatic cancer.
~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
11470026|NCT01562899|Experimental|BRAF mutated melanoma|"Patients with mutant BRAF V600 melanoma.
~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
11470027|NCT01562886|Experimental|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
11470028|NCT01562873|Experimental|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
11470029|NCT01562873|Experimental|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
11470030|NCT01562860|Active Comparator|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
11470031|NCT01562860|Active Comparator|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
11470032|NCT01562847||Nilotinib|
11470033|NCT01562834|Experimental|Somatropin|
11470034|NCT01562834|Placebo Comparator|Placebo|
11470035|NCT01562821|Experimental|Low dose|
11470036|NCT01562821|Experimental|High dose|
11470037|NCT01562821|Placebo Comparator|Placebo|
11470038|NCT01562795|Experimental|group 1|
11470039|NCT01562795|Experimental|group 2|
11470040|NCT01562795|Experimental|group 3|
11470041|NCT01562795|Other|group 4|
11470042|NCT01562782|Experimental|South Asians|Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
11470043|NCT01562782|Active Comparator|Caucasians|Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
11470044|NCT01562769||Standard precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.
~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).
~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
11470104|NCT01562379|Experimental|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
11470045|NCT01562769||contact precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.
~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).
~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
11470046|NCT01562756|Experimental|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
11470047|NCT01562743|Experimental|SPM 962|Rotigotine transdermal patch
11470048|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
11470049|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
11470050|NCT01562717|Experimental|Ibuprofen|
11470051|NCT01562717|Placebo Comparator|Placebo|
11470052|NCT01562704|Experimental|paracetamol|
11470053|NCT01562704|Placebo Comparator|placebo|
11470054|NCT01562691|Experimental|Nasopore only|Packing using nasopore without airway integrated
11470055|NCT01562691|Active Comparator|nasopore with airway integrated|packing using airway integrated nasopore
11470056|NCT01562691|Active Comparator|airway-integrated Vaseline gauze|Nasal packing using airway-integrated Vaseline gauze
11470057|NCT01562678|Experimental|Liraglutide|
11470058|NCT01562678|Placebo Comparator|Placebo|
11470059|NCT01562665||All Population|
11470060|NCT01562665||Sample of patients will be invited to complete Quality of Life|
11470061|NCT01562652|Experimental|Research|
11470062|NCT01562639||Nexium|
11470063|NCT01562626|Experimental|Dose escalation|
11470064|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
11470065|NCT01562600||Nexium|
11470066|NCT01562587|Experimental|Adults|
11470067|NCT01562587|Experimental|Paediatric|
11470068|NCT01562574|Experimental|Activated recombinant human factor VII|
11470069|NCT01562574|Placebo Comparator|Placebo|
11470070|NCT01562561|Experimental|Rep + NPH|
11470071|NCT01562561|Active Comparator|NPH|
11470072|NCT01562548|Experimental|Arm 1|Guaifenesin 1 tablet BID
11470073|NCT01562548|Experimental|Arm 2|Guaifenesin 2 tablets BID
11470074|NCT01562548|Placebo Comparator|Arm 3|Placebo 1 tablet BID
11470075|NCT01562548|Placebo Comparator|Arm 4|Placebo 2 tablets BID
11470076|NCT01562535|Experimental|Pronation group|In this group, participants will receive the pronation procedure. The technique is described below
11470077|NCT01562535|Active Comparator|Supination group|Participants in this group will be performed the supination technique. Description below.
11470078|NCT01562522|Experimental|Intervention group|
11470079|NCT01562522|No Intervention|Control group|
11470080|NCT01562509|Active Comparator|Standard implementation strategy|Standard intervention
11470081|NCT01562509|Experimental|Innovative implementation strategy|Implementation tools
11470082|NCT01562496|Experimental|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
11470083|NCT01562496|No Intervention|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
11470084|NCT01562483|Experimental|delta-9-tetrahydrocannabinol (namisol)|
11470085|NCT01562483|Placebo Comparator|Placebo|
11470086|NCT01562470|Experimental|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
11470087|NCT01562457|Experimental|Low dose|
11470088|NCT01562457|Experimental|Medium dose|
11470089|NCT01562457|Experimental|High dose|
11470090|NCT01562444|Other|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from >6 years up to >10 years after booster vaccination).
11470091|NCT01562444|Other|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
11470092|NCT01562444|Other|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
11470093|NCT01562431|Other|Control|Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
11470094|NCT01562431|Other|Intervention|Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
11470095|NCT01562418|Experimental|Ergonomic consulting|Ergonomic consulting without biofeedback
11470096|NCT01562418|Experimental|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
11470097|NCT01562418|No Intervention|general instructions|general instructions with no intervention
11470098|NCT01562405|Experimental|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
11470099|NCT01562392|Experimental|berries and vegetables|subjects include specific berries and vegetables in the diet
11470100|NCT01562392|Placebo Comparator|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
11470101|NCT01562379|No Intervention|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
11470106|NCT01562366|Experimental|Group 1|
11470108|NCT01562353||Case|Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain.
11470109|NCT01562353||Control|Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).
11470110|NCT01562340|Active Comparator|Pomegranate fruit extract|
11470111|NCT01562340|Active Comparator|Pomegranate juice|
11470112|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
11470113|NCT01562314|Experimental|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
11470114|NCT01562314|Placebo Comparator|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
11470115|NCT01562301|Experimental|Anvirzel + Carboplatin + Docetaxel|Anvirzel administered sublingually. A total of five dose cohorts evaluated (6, 12, 24, 36, 48 mg/m2/day; SL divided into 3 doses given every 8 hrs) with 3 patients per cohort. Patients receive the assigned dose (2, 4, 8, 12, or 16 mg/m2) of Anvirzel three times a day throughout each cycle for a total of 4 cycles of chemotherapy. Cycles occur every 21 days. Patients start with an AUC of 6 for Carboplatin and 75mg/m2 for docetaxel, and on subsequent cycles, modifications at the discretion of the treating team. Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
11470116|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
11470117|NCT01562275|Experimental|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
11470118|NCT01562275|Experimental|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
11470119|NCT01562275|Experimental|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
11470120|NCT01562262||CTR|Control group
11470121|NCT01562262||ASS|Apnea without complaints group
11470122|NCT01562262||ACS|SAOS Group
11470123|NCT01562249|Experimental|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
11470124|NCT01562249|Active Comparator|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
11470125|NCT01562249|No Intervention|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
11470126|NCT01562223|Experimental|Repeatability Assessment|Gadolinium motexafin gadolinium All participants will undergo two consecutive DCE-MRI and DWI scans per same imaging parameters and subsequent comparison for repeatability.
11470127|NCT01562210|Experimental|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
11470128|NCT01562197|Experimental|Axitinib|axitinib treatment arm
11470129|NCT01562197|Experimental|Axitinib plus Lomustine|Axitinib plus Lomustine
11470130|NCT01562184|Active Comparator|Active tDCS|Active tDCS
11470131|NCT01562184|Sham Comparator|Sham tDCS|Sham tDCS
11470228|NCT01561521|Placebo Comparator|AKF-1 0%|
11470230|NCT01561508|Placebo Comparator|Placebo|1/3 of participants will receive placebo.
11470132|NCT01562171|Experimental|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
11470133|NCT01562171|Active Comparator|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
11470134|NCT01562158|Placebo Comparator|Placebo|
11470135|NCT01562158|Experimental|Low dose|
11470136|NCT01562158|Experimental|Medium dose|
11470137|NCT01562158|Experimental|High dose|
11470138|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
11470139|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
11470140|NCT01562132|Experimental|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
11470141|NCT01562132|Active Comparator|fluconazole alone|Fluconazole monotherapy
11470142|NCT01562106|Experimental|ICG Dye|Fluorescence-guided sentinel lymph node detection
11470143|NCT01562093|Experimental|local nasal steroids|
11470144|NCT01562093|Placebo Comparator|placebo|
11470145|NCT01562080|Experimental|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
11470146|NCT01562080|Placebo Comparator|microcrystalline cellulose|
11470147|NCT01562041|Other|Ranolazine|Ranolazine bid (twice a day) for 14 days.
11470148|NCT01562028|Experimental|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
11470149|NCT01562015|Experimental|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
11470150|NCT01562002|Experimental|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
11470151|NCT01562002|Active Comparator|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
11470152|NCT01561989|Experimental|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
11470153|NCT01561989|Experimental|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
11470154|NCT01561976|Active Comparator|Metformin hydrochloride prolonged release|1000mg in fasting state
11470155|NCT01561976|Active Comparator|metformin hydrochloride prolonged release|1000mg In fed state
11470156|NCT01561976|Active Comparator|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
11470157|NCT01561963|Experimental|Apremilast and Rifampin|"A single oral dose of 30 mg apremilast on Day 1 in Period 1;
~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3."
11470158|NCT01561950|Experimental|Factor VII|
11470159|NCT01561950|Placebo Comparator|Placebo|
11470160|NCT01561937|Experimental|Pre-warfarin treatment (trial part A)|
11470161|NCT01561937|Experimental|Post-warfarin treatment (trial part B)|
11470162|NCT01561924|Experimental|Ex vivo|
11470163|NCT01561898|Experimental|Paliperidone extended-release (JNS007ER)|
11470164|NCT01561885|Active Comparator|Patients on Pathway Care|
11470165|NCT01561885|No Intervention|Patients on Usual Care|
11470166|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
11470167|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
11470168|NCT01561859|Experimental|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
11470169|NCT01561859|Active Comparator|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
11470170|NCT01561846|Active Comparator|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
11470171|NCT01561846|Experimental|CLA enriched cheese|
11470172|NCT01561833|Experimental|Sorafenib|Sorafenib, 400 mg PO twice daily
11470173|NCT01561820|Active Comparator|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
11470229|NCT01561508|Experimental|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
11470231|NCT01561495|Experimental|All Participants|Proton Radiotherapy
11470174|NCT01561820|Placebo Comparator|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
11470175|NCT01561807|Experimental|787 low dose|VX-787 low dose capsule, taken orally for 5 days
11470176|NCT01561807|Experimental|787 high dose|VX-787 high dose capsule, taken orally for 5 days
11470177|NCT01561807|Experimental|Placebo low dose|Matching placebo low dose capsule, taken orally for 5 days
11470178|NCT01561807|Experimental|Placebo high dose|Matching placebo high dose capsule, taken orally for 5 days
11470179|NCT01561794|Experimental|Ciprofloxacin|
11470180|NCT01561781|Experimental|digoxin then digoxin + vandetanib|Digoxin alone followed by digoxin in combination with vandetanib
11470181|NCT01561768|Experimental|Group 1|
11470182|NCT01561768|Experimental|Group 2|
11470183|NCT01561768|Experimental|Group 3|
11470184|NCT01561768|Experimental|Group 4|
11470185|NCT01561768|Experimental|Group 5|
11470186|NCT01561755|Experimental|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
11470187|NCT01561755|Placebo Comparator|Placebo|Saline 2gr/kg over 2 days of saline
11470188|NCT01561742|Experimental|Minocycline|
11470189|NCT01561742|Placebo Comparator|Placebo|
11470190|NCT01561729|Experimental|Study group|This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
11470191|NCT01561716|Experimental|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
11470192|NCT01561716|Experimental|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
11470193|NCT01561716|Experimental|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
11470194|NCT01561716|Experimental|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
11470195|NCT01561716|Experimental|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
11470196|NCT01561716|Experimental|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
11470197|NCT01561703|Experimental|Anitibiotic|Patients will receive postoperative antibiotic after surgery.
11470198|NCT01561703|No Intervention|Control|Patients will NOT receive postoperative antibiotic
11470199|NCT01561690|Experimental|ARRY-502|
11470200|NCT01561690|Placebo Comparator|Placebo|
11470201|NCT01561677|No Intervention|apnea/hypopnea index (AHI<5 : no OSAS)|
11470202|NCT01561677|No Intervention|apnea/hypopnea index (5≥AHI<15 : mild OSAS)|
11470203|NCT01561677|No Intervention|apnea/hypopnea index (15≤AHI<30 :moderate OSAS)|
11470204|NCT01561677|Active Comparator|apnea/hypopnea index ( AHI≥30 : severe OSAS treated).|Treated with CPAP
11470205|NCT01561677|Sham Comparator|apnea/hypopnea index ( AHI≥30:severe OSAS untreated).|Treated with sham CPAP (placebo)
11470206|NCT01561664|Active Comparator|volunteers|not overweight Volunteers responding to the study criteria
11470207|NCT01561664|Experimental|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
11470208|NCT01561664|Experimental|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
11470209|NCT01561651|Experimental|Left Atrial Appendage Occlusion Group|Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
11470210|NCT01561651|No Intervention|No Left Atrial Appendage Occlusion Group|Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
11470211|NCT01561638|Active Comparator|group p|pulse radiofrequency lesioning
11470212|NCT01561638|Placebo Comparator|sham group|Controlled, conventional
11470213|NCT01561638|Active Comparator|group C|Pulse dose radiofrequency
11470214|NCT01561612|Experimental|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
11470215|NCT01561612|No Intervention|Control|Usual care
11470216|NCT01561599|Placebo Comparator|Normal saline|Placebo
11470217|NCT01561599|Active Comparator|BB3|Small molecule mimetic of hepatocyte growth factor/scatter factor
11470218|NCT01561586|Active Comparator|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
11470219|NCT01561586|Experimental|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
11470220|NCT01561573|Other|Ultrasound colles fracture|This is a single arm study
11470221|NCT01561560|Other|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
11470222|NCT01561560|Other|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
11470223|NCT01561547|Experimental|Kangaroo Mother Care|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sterile water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
11470224|NCT01561547|Active Comparator|Sucrose|Two minutes before the painful procedure and at the moment of the procedure, the infant will be given 24% sucrose by mouth. The volume is determined by body weight and is not important in terms of efficacy, it is the percentage of sweetness that is important.
11470225|NCT01561547|Experimental|Combination Kangaroo Mother Care and Sucrose|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sucrose water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
11470226|NCT01561521|Experimental|AKF-1 0.025%|
11470232|NCT01561482|Experimental|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.
~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
11470233|NCT01561469||Linezolid observational cohort|
11470234|NCT01561469||Vancomycin observational cohort|
11470235|NCT01561456|Experimental|AXL1717|AXL1717
11470236|NCT01561456|Active Comparator|Docetaxel|Docetaxel
11470237|NCT01561430|Experimental|15 mg LY2886721|LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.
11470238|NCT01561430|Experimental|35 mg LY2886721|LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.
11470239|NCT01561430|Experimental|70 mg LY2886721|LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.
11470240|NCT01561430|Placebo Comparator|Placebo|Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.
11470241|NCT01561417|Active Comparator|CP-rFVIIa|
11470242|NCT01561417|Experimental|VII25|
11470243|NCT01561404|Experimental|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
11470244|NCT01561391|Experimental|Continuous infusion|
11470245|NCT01561391|Experimental|Bolus injection|
11470246|NCT01561391|Experimental|Control|
11470247|NCT01561378|Experimental|Insulin|Aspart Insulin 40 IU intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
11470248|NCT01561378|Placebo Comparator|Normal saline|Normal saline (0.9% sodium chloride solution) intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
11470249|NCT01561365|Experimental|Emergency|
11470250|NCT01561365|Experimental|Orthopedic residents|
11470251|NCT01561352|Experimental|Factor VII|
11470252|NCT01561326|Experimental|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
11470253|NCT01561326|Experimental|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
11470254|NCT01561326|Active Comparator|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
11470255|NCT01561313|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
11470256|NCT01561313|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
11470257|NCT01561300|Placebo Comparator|Control|Nutrition intervention study with a control
11470258|NCT01561300|Experimental|Tea extract|Nutrition intervention study with a black tea extract
11470259|NCT01561287|Experimental|Dermal Autograft|
11470260|NCT01561287|Experimental|AlloDerm|
11470261|NCT01561274|Active Comparator|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
11470262|NCT01561274|Active Comparator|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
11470263|NCT01561248|No Intervention|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
11470264|NCT01561248|Experimental|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
11470265|NCT01561235|Active Comparator|Normal Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).
~Macronutrient content: Protein: 14 E%, Fat: 30 E% and carbohydrate: 56E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
11470266|NCT01561235|Experimental|Medium-high protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).
~Macronutrient content: Protein: 25E%, Fat: 30 E% and carbohydrate: 45E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
11470267|NCT01561235|Experimental|High Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).
~Macronutrient content: Protein: 50 E%, Fat: 30 E% and carbohydrate: 20E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
11470268|NCT01561222|Placebo Comparator|placebo|
11470269|NCT01561222|Experimental|Calcitriol|
11470270|NCT01561209|Active Comparator|Amitryptiline|Amitryptiline 5 mg before bedtime
11470271|NCT01561209|Placebo Comparator|Placebo|Placebo pill
11470272|NCT01561196|Active Comparator|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
11470273|NCT01561196|Active Comparator|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
11470274|NCT01561183|Experimental|Indirect pulp capping (IPC)|Indirect pulp capping
11470275|NCT01561183|Experimental|Direct pulp capping (DPC)|Direct pulp capping
11470276|NCT01561183|Experimental|Miniature pulpotomy (MP)|Miniature pulpotomy
11470277|NCT01561183|Experimental|Full pulpotomy (FP)|Full pulpotomy
11470278|NCT01561170||Chronically venous ulcer|A group of 36 patients
11470279|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
11470280|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
11470281|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
11470282|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
11470283|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
11470284|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
11470285|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
11470286|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
11470287|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
11470288|NCT01561157||Homozygous Dominant Acute Hepatic Porphyria|Patients with a documented diagnosis of Homozygous Dominant AHP
11470289|NCT01561131|Active Comparator|Whey protein supplement|Whey protein
11470290|NCT01561131|Active Comparator|Whey protein enriched with calcium supplement|Whey protein enriched with calcium
11470291|NCT01561131|Active Comparator|Soy protein supplement|Soy protein
11470292|NCT01561131|Placebo Comparator|Control supplement|Maltodextrin
11470293|NCT01561118|Experimental|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).
~In the second part of the study intervention will be prolonged for another 12 weeks."
11470294|NCT01561118|Other|Control|"No intervention during hemodialysis during the first 12 weeks of the study.
~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
11470295|NCT01561105|Experimental|IMPACT|
11470296|NCT01561105|No Intervention|Care as Usual|Patients received all depression care available to them as part of care as usual in the participating primary care clinics.
11470297|NCT01561092|Active Comparator|Escitalopram|
11470298|NCT01561092|Placebo Comparator|Non active drug|
11470299|NCT01561079|Experimental|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
11470300|NCT01561066|Sham Comparator|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
11470301|NCT01561066|Active Comparator|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
11470302|NCT01561053|Experimental|High Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
11470303|NCT01561053|Experimental|Low Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
11470304|NCT01561053|Experimental|Low Albumin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
11470305|NCT01561053|No Intervention|Control (sham) group|Simulated plasma exchange procedure
11470306|NCT01561040|Experimental|Omega 3, Vitamins A, D3 and E|Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.
11470307|NCT01561027|Experimental|CNV1014802|CNV1014802 350mg on prescription (BID) for 21 days
11470308|NCT01561027|Placebo Comparator|Placebo|Placebo 350mg BID for 21 days
11470309|NCT01561014|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.
~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.
~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
11470310|NCT01560988|Experimental|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
11470311|NCT01560988|Experimental|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
11470312|NCT01560975|Experimental|Sensimed Triggerfish|
11470313|NCT01560962|Other|PI vs no intervention|
11470314|NCT01560962|Other|PI vs hygiene|
11470315|NCT01560962|Other|PI vs azasite|
11470316|NCT01560962|Other|PI vs tobradex|
11470317|NCT01560949|Experimental|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).
~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)
~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.
~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
11470318|NCT01560923|Experimental|Sipuleucel-T + Oral Indoximod|Oral Indoximod will be self-administered by mouth twice daily (1200 mg) for 6 months starting after the last (3rd) infusion of sipuleucel-T. Indoximod is a sterile tan powder compounded in capsule form of 200 mg.
11470319|NCT01560923|Placebo Comparator|Sipuleucel-T + Placebo|Placebo is identical-looking to Indoximod and provided in the same manner.
11470320|NCT01560897|Experimental|C13|The dose of sodium [1-13C] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
11470321|NCT01560884|Active Comparator|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
11470322|NCT01560884|Active Comparator|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
11470323|NCT01560884|Active Comparator|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
11470324|NCT01560884|Active Comparator|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
11470325|NCT01560871|Sham Comparator|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
11470326|NCT01560871|Experimental|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 60% PImax.
~The walking program was the same as the one for the control group."
11470327|NCT01560845|Experimental|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
11470328|NCT01560845|No Intervention|portal hypertension surgery group|only portal hypertension surgery for this group patients
11470329|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
11470330|NCT01560819|Experimental|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
11470331|NCT01560806|No Intervention|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
11470332|NCT01560806|Experimental|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
11470333|NCT01560793|Experimental|VAX161B|Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
11470334|NCT01560780|Experimental|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
11470335|NCT01560780|Placebo Comparator|Arm 2: Placebo|placebo by mouth once daily
11470336|NCT01560767|Active Comparator|Femoral Nerve Block|levobupivacaine
11470337|NCT01560767|Active Comparator|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
11470338|NCT01560754|Experimental|Transdermal nicotine patch|Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
11470339|NCT01560754|Placebo Comparator|Transdermal placebo patch|Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
11470340|NCT01560741|Active Comparator|Telemedicine Group|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be provided with a ventilator outfitted with a wireless transmitter to allow the remote data collection of compliance and efficacy information. While patient sleeps, data is collected. If abnormalities criteria will be detected, remote titration of ventilator settings will be done to optimise therapy. Patient will be monitored again and data analyzed. This procedure will be repeated until we obtained the optimal ventilator parameters for each patient in this group. Nocturnal oximetry under home mechanical non-invasive ventilation will be carried out after one week and one month of treatment. Subjects also receive pre-arranged telephone calls to assist with progress.
11470341|NCT01560741|Other|Usual care|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be assessed by a hospital visit scheduled at the end of third month after their initial adaptation. In this hospital visit data provided by the ventilator will be transferred to research team computer so they could evaluate patient compliance and efficacy of ventilation criteria under the parameters used at home present at the time of assessment. If abnormality criteria will be detected, re-titration of ventilator settings will be made. Patients will be encouraged to call their respiratory consultant any time they had a problem or concern.
11470342|NCT01560728|Experimental|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
11470343|NCT01560728|No Intervention|Wait list|Monitored while waiting for intervention
11470344|NCT01560715|Experimental|Experimental: Test group|Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees
11470345|NCT01560702|Active Comparator|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
11470775|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
11470346|NCT01560702|Other|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
11470347|NCT01560689|Active Comparator|BUDESONIDE/FORMOTEROL|
11470348|NCT01560689|Placebo Comparator|control|
11470349|NCT01560676|Active Comparator|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
11470350|NCT01560676|Active Comparator|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
11470351|NCT01560663||Docetaxel Carboplatino|Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
11470352|NCT01560650|Experimental|high dose (35ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
11470353|NCT01560650|Experimental|low dose (25ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
11470354|NCT01560637|Experimental|UT-15C|Open label access
11470355|NCT01560624|Experimental|UT-15C|Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID
11470356|NCT01560624|Placebo Comparator|Placebo|Matching placebo tablets (oral)
11470357|NCT01560611||High-risk cardiac surgery patient|
11470358|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
11470359|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
11470360|NCT01560585|Experimental|Open label|All participants will receive Isotretinoin for 24 weeks
11470361|NCT01560572|Active Comparator|standard immunosuupression|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg
11470362|NCT01560572|Experimental|steroidfree|maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)
11470363|NCT01560572|Experimental|low dose tacrolimus|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml
11470364|NCT01560559|Experimental|Single Arm|Peroral endoscopic myotomy
11470365|NCT01560546|Active Comparator|Testim|
11470366|NCT01560546|Placebo Comparator|Placebo|Placebo for 24 weeks
11470367|NCT01560533|Other|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
11470368|NCT01560533|Other|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
11470369|NCT01560520||Accelerometer|
11470370|NCT01560507|Active Comparator|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
11470371|NCT01560507|Active Comparator|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
11470372|NCT01560507|Active Comparator|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
11470373|NCT01560494|Experimental|STAC curriculum|
11470374|NCT01560494|No Intervention|Conventional Curriculum|
11470375|NCT01560481|Experimental|Step A: metformin glycinate 620 mg|620mg single dose by mouth
11470376|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg|1240mg single dose by mouth
11470377|NCT01560481|Experimental|Step A: metformin glycinate 2480 mg|2480mg single dose by mouth
11470378|NCT01560481|Active Comparator|Step A: metformin hydrochloride 1000 mg|1000mg single dose by mouth
11470379|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg, food intake|1240mg single dose by mouth after food intake
11470380|NCT01560481|Experimental|Step B: metformin glycinate 620 mg BID|620mg BID for 8 days
11470381|NCT01560481|Active Comparator|Step B: metformin hydrochloride 500 mg BID|500mg tablets BID for 8 days
11470382|NCT01560468|Experimental|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
11470383|NCT01560455|Active Comparator|single stent|single stent
11470384|NCT01560455|Active Comparator|dual stent|dual stent (culotte)
11470385|NCT01560442||buprenorphine|
11470386|NCT01560442||Methadone Hydrochloride|
11470387|NCT01560429|Experimental|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
11470388|NCT01560429|Active Comparator|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
11470389|NCT01560416|Active Comparator|ARM A - Fulvestrant|Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
11470390|NCT01560416|Active Comparator|Arm B - Fulvestrant+Ganetespib|"Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle
~Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression."
11470391|NCT01560403|Experimental|Teduglutide|0.05 mg/kg/day
11470392|NCT01560390|Other|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
11470393|NCT01560390|Other|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
11470394|NCT01560377|Experimental|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
11470395|NCT01560364||Hemofilter|
11470396|NCT01560351|Experimental|rTMS|Session of repeated low-frequency Transcranial Magnetic Stimulation
11470397|NCT01560351|Sham Comparator|Placebo|Sessions of sham rTMS
11470398|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
11470399|NCT01560325|Experimental|CKD-516 inj.|CKD-516 Inj, 3.3~13mg/m2/day, D1, 4, 8, 11 every 3 weeks
11470400|NCT01560312|Experimental|Renal denervation|Renal denervation (Symplicity® Catheter System™) + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
11470401|NCT01560312|No Intervention|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).
~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
11470402|NCT01560299|Active Comparator|group one|This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
11470403|NCT01560299|Active Comparator|group two|methimazole stopped 48-72 hour before radioiodine therapy
11470404|NCT01560299|Active Comparator|group three|
11470405|NCT01560286|Experimental|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
11470406|NCT01560273||Aspen Spinous Process Fixation Device|The Aspen device provides supplemental posterior fixation for fusion
11470407|NCT01560260|Experimental|Treatment (linsitinib)|Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11470408|NCT01560247||Treatment Group|Subjects in whom a MindFrame Device was employed for restoration of flow and clot removal
11470409|NCT01560234|Experimental|AZD8848|
11470410|NCT01560234|Placebo Comparator|Placebo|
11470411|NCT01560221|Experimental|Therapeutic Workplace|Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
11470412|NCT01560221|Active Comparator|Standard Services|Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences. Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
11470413|NCT01560195|Experimental|Pegylated rhG-CSF: 100µg/kg|Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
11470414|NCT01560195|Experimental|Pegylated rhG-CSF: 6mg|Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg
11470415|NCT01560195|Placebo Comparator|Placebo|Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4
11470416|NCT01560182|Experimental|OTL-200 Gene Therapy|CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA
11470417|NCT01560169||Gluten challenge|Gluten containing or gluten-free study food in established celiac disease patients
11470418|NCT01560169||Observation|Observation in newly diagnosed celiac disease patients
11470419|NCT01560143|Other|Tigecycline|All subjects receive a single dose of tigecycline
11470420|NCT01560130|Active Comparator|Shape Up Rhode Island + Online Weight Loss + Incentives|
11470421|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program|
11470422|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|
11470423|NCT01560104|Experimental|veliparib and carboplatin and paclitaxel|Veliparib on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
11470424|NCT01560104|Placebo Comparator|placebo and carboplatin and paclitaxel|Placebo on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
11470425|NCT01560091|Placebo Comparator|Group A|Patients will receive ESWL and no medication
11470426|NCT01560091|Active Comparator|Group B|Patients will receive Flomax after ESWL
11470427|NCT01560091|Active Comparator|Group C|Patients will receive silodosin after ESWL
11470428|NCT01560065|Other|Normospermic patients|
11470429|NCT01560065|Other|Oligoasthenospermic patients|
11470430|NCT01560065|No Intervention|Control|
11470471|NCT01559727|Experimental|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
11470472|NCT01559727|Experimental|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
11470431|NCT01560052|Active Comparator|oral methylprednisolone|"oral methylprednisolone
~Original Cohort:
~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.
~Low Dose Cohort:
~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.
~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
11470432|NCT01560052|Placebo Comparator|placebo|"Original Cohort:
~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.
~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
11470433|NCT01560039|Active Comparator|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
11470434|NCT01560039|Sham Comparator|Sham EEG-NF|10 sessions of Sham EEG_NF of the motor cortex area
11470435|NCT01560039|Active Comparator|Transcrainal Magnetic Stimulation|10 dailt TMS stimulation sessions of M1
11470436|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
11470437|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
11470438|NCT01560013|Experimental|Naltrexone|Treatment with naltrexone for two months together with psycho-social support
11470439|NCT01560000|Other|fiber|
11470440|NCT01559987|Other|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
11470441|NCT01559987|Other|Test|MTB + Floss
11470442|NCT01559987|Experimental|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
11470443|NCT01559974|Active Comparator|Vitamin D|
11470444|NCT01559974|Placebo Comparator|Placebo|
11470445|NCT01559961|Experimental|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
11470446|NCT01559948|Experimental|Lumbopelvic stabilization exercises plus sacroiliac joint belt|The participants will be instructed in the lumbopelvic stabilization program. Additionally, during the initial session, these participants receive a sacroiliac compression belt and be instructed to wear the belt during all waking hours for the first four weeks of the study.
11470447|NCT01559948|Active Comparator|Lumbopelvic stabilization exercise|The participants will be instructed in the lumbopelvic stabilization program.
11470448|NCT01559935|Experimental|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
11470449|NCT01559922|Placebo Comparator|Placebo|Normal Saline
11470450|NCT01559922|Experimental|Artefill|Dermal Filler
11470451|NCT01559909|Experimental|Socket wall height|
11470452|NCT01559896|Experimental|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
11470453|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
11470454|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
11470455|NCT01559857|Active Comparator|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
11470456|NCT01559857|Placebo Comparator|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
11470457|NCT01559844|Experimental|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
11470458|NCT01559831|Other|IXIARO|IXIARO, applied according to licensed dose, intramuscular
11470459|NCT01559818|Experimental|IMM-101|IMM-101 1.0 mg administered intradermally
11470460|NCT01559805|Experimental|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
11470461|NCT01559805|Active Comparator|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
11470462|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
11470463|NCT01559766||4-6 years old group|
11470464|NCT01559766||7-9 years old group|
11470465|NCT01559753|Experimental|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
11470466|NCT01559753|Active Comparator|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
11470467|NCT01559740|Experimental|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
11470468|NCT01559740|Experimental|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
11470469|NCT01559727|No Intervention|Control|The patients with symptomatic heart failure were treated with standard treatment.
11470470|NCT01559727|Experimental|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
11470776|NCT01557790|Experimental|Proton RT|Subjects receive proton radiation for seminoma
11470473|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
11470474|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
11470475|NCT01559701|Experimental|PF-00345439 (oxycodone)|PF-00345439 (oxycodone)
11470476|NCT01559688|Experimental|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
11470477|NCT01559688|Active Comparator|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
11470478|NCT01559675|Active Comparator|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
11470479|NCT01559675|Experimental|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
11470480|NCT01559662|Experimental|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
11470481|NCT01559662|No Intervention|No Gum|No gum given, routine postoperative care provided
11470482|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
11470483|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
11470484|NCT01559636|Active Comparator|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
11470485|NCT01559636|Active Comparator|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
11470486|NCT01559610|No Intervention|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
11470487|NCT01559610|Other|Group intervention|preoperative guideline by a nurse
11470488|NCT01559597|Active Comparator|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
11470489|NCT01559597|Experimental|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
11470490|NCT01559584|Experimental|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).
~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
11470491|NCT01559584|Active Comparator|Conventional therapy|One monthly injections of intralesional potent corticosteroids
11470492|NCT01559558||cystocele|
11470493|NCT01559545|Active Comparator|Metronidazole|Immediate release metronidazole
11470494|NCT01559545|Experimental|Metronidazole-DRF1|Modified release metronidazole (DRF1)
11470495|NCT01559545|Experimental|Metronidazole-DRF2|Modified release metronidazole (DRF2)
11470496|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
11470497|NCT01559519|Active Comparator|albumin|cirrhotic patients who underwent tips placement
11470498|NCT01559506|No Intervention|No device|Subject does not receive ABS system
11470499|NCT01559506|Experimental|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
11470500|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
11470501|NCT01559480|Active Comparator|Desogestrel|
11470502|NCT01559480|Placebo Comparator|Placebo|
11470503|NCT01559467|Other|Routine clinical care plus early CMR|
11470504|NCT01559467|No Intervention|Routine clinical care|
11470505|NCT01559467|Other|Routine clinical care plus early CTA|
11470506|NCT01559454|Active Comparator|Methadone|10-60 mg/day divided by 2-4 times a day
11470507|NCT01559454|Experimental|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
11470508|NCT01559441|Experimental|Beetroot juice|
11470509|NCT01559441|Placebo Comparator|Carbohydrate control drink|
11470510|NCT01559428|Experimental|Plant sterol-enriched margarine|
11470511|NCT01559428|Experimental|Plant stanol-enriched margarine|
11470512|NCT01559428|Placebo Comparator|Control margarine|
11470513|NCT01559415|Experimental|Very Low Calorie Diet|
11470514|NCT01559415|Active Comparator|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
11470554|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
11470555|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
11470515|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
11470516|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
11470517|NCT01559402|Experimental|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
11470518|NCT01559389|Experimental|Female Partners|This arm comprises female partners who receive up to 16 weeks of solifenacin treatment for their UUI symptoms
11470519|NCT01559389|No Intervention|Male Partners|This arm comprises healthy male partners
11470520|NCT01559376||Endoscopic radial artery harvest|
11470521|NCT01559376||Conventional open radial artery harvest|
11470522|NCT01559363|Experimental|Cohort 1|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
11470523|NCT01559363|Experimental|Cohort 2|Two 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
11470524|NCT01559363|Experimental|Cohort 3|Three 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
11470525|NCT01559363|Experimental|Phase 2a Monday, Wednesday, Friday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday, Wednesday and Friday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
11470526|NCT01559363|Experimental|Phase 2a Monday and Thursday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday and Thursday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
11470527|NCT01559363|Experimental|Phase 2a, 50mg|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
11470528|NCT01559363|Experimental|Phase 2a, 50mg (SILK Cohort)|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
11470529|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
11470530|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
11470531|NCT01559337|Other|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
11470532|NCT01559324|Experimental|Bifrontal ECT (BF)|Formula-based low dose BF ECT
11470533|NCT01559324|Experimental|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
11470534|NCT01559311|Active Comparator|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:
~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
11470535|NCT01559311|Experimental|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:
~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
11470536|NCT01559311|Active Comparator|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
11470537|NCT01559298|Active Comparator|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
11470538|NCT01559298|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
11470539|NCT01559285|Active Comparator|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
11470540|NCT01559285|Active Comparator|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
11470541|NCT01559285|Active Comparator|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
11470542|NCT01559272|Experimental|Panel A|Panel A consists of 2 treatment groups
11470543|NCT01559272|Experimental|Panel B|Panel B consists of 5 treatment groups
11470544|NCT01559272|Experimental|Panel C|Panel C consists of 1 treatment group
11470545|NCT01559272|Experimental|Panel D|Panel D consists of 4 treatment groups
11470546|NCT01559259|Experimental|Ibuprofen/acetaminophen (lower dose)|
11470547|NCT01559259|Experimental|Ibuprofen/acetaminophen (middle dose)|
11470548|NCT01559259|Experimental|Ibuprofen/acetaminophen (high dose)|
11470549|NCT01559259|Active Comparator|Ibuprofen|
11470550|NCT01559259|Placebo Comparator|Placebo|
11470551|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
11470552|NCT01559233|Experimental|FPlus|
11470553|NCT01559220|Experimental|Open Label|DBS Implant and stimulation
11470556|NCT01559194|Active Comparator|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
11470557|NCT01559194|Active Comparator|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
11470558|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
11470559|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
11470560|NCT01559168|Experimental|Prolapse patients recieving UpHold LITE|Non-pregnant female patients >= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
11470561|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
11470562|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
11470563|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
11470564|NCT01559142|Active Comparator|IFX TG|
11470565|NCT01559142|Active Comparator|IFX alone|
11470566|NCT01559129|Placebo Comparator|Placebo|
11470567|NCT01559129|Experimental|Pomalidomide|Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.
11470568|NCT01559116|Experimental|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
11470569|NCT01559116|Experimental|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
11470570|NCT01559116|Active Comparator|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
11470571|NCT01559116|Active Comparator|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
11470572|NCT01559116|Active Comparator|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
11470573|NCT01559116|Placebo Comparator|placebo|2 inhalations once daily (a.m. dosing)
11470574|NCT01559103|Experimental|MEDI5117|Intravenous infusion administered over 60 minutes
11470575|NCT01559103|Placebo Comparator|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
11470576|NCT01559090|Experimental|1|MEDI-546 100 mg IV
11470577|NCT01559090|Experimental|2|MEDI-546 300 mg IV
11470578|NCT01559090|Experimental|3|MEDI-546 1000 mg IV
11470579|NCT01559077|Active Comparator|ALN-TTR02|
11470580|NCT01559077|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11470581|NCT01559064||Age group A|Subjects 30 to 40 years old
11470582|NCT01559064||Age group B|Subjects 40 to 50 years old
11470583|NCT01559064||Age group C|Subjects over 50 years old
11470584|NCT01559051|Experimental|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
11470585|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
11470586|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
11470587|NCT01559025|No Intervention|Insulin therapy|Patients will receive the conventional treatment with insulin
11470588|NCT01559025|Active Comparator|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
11470589|NCT01559012|Other|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
11470590|NCT01559012|Other|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
11470591|NCT01558999|Experimental|High concentration SI-614|
11470592|NCT01558999|Experimental|Low concentration SI-614|
11470593|NCT01558999|Placebo Comparator|Vehicle|
11470594|NCT01558986|Active Comparator|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
11470595|NCT01558986|Placebo Comparator|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
11470596|NCT01558973||Cocaine dependent|
11470597|NCT01558973||Opioid dependent|
11470598|NCT01558973||Alcohol dependent|
11470599|NCT01558973||Healthy controls|
11470600|NCT01558973||Adolescents|
11470601|NCT01558973||Pathological gamblers|
11470602|NCT01558960|Experimental|IVit Treatment group|Intravitreal injections of Melphalan
11470603|NCT01558947|Experimental|chemotherapy with ECX|chemotherapy with ECX
11470604|NCT01558947|Experimental|chemotherapy with XP|chemotherapy with XP
11470605|NCT01558934|Experimental|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
11470606|NCT01558921|Experimental|B: 5x5Gy -> CAPOX -> surgery|experimental group (arm B) M1 scheme
11470607|NCT01558921|Active Comparator|A: 5 weeks chemoradiation -> surgery|control group (arm A) standard long course chemoradiotherapy
11470608|NCT01558908|Experimental|Intramuscular injection of ERC|
11470609|NCT01558895|Experimental|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
11470610|NCT01558895|Active Comparator|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
11470611|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
11470612|NCT01558869|Experimental|Arm 1|
11470613|NCT01558856|Active Comparator|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.
~Intervention: Unilateral electrode placement and testing"
11470614|NCT01558856|Experimental|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.
~Intervention: Bilateral electrode placement and testing"
11470615|NCT01558843||traumatic brain injury|
11470616|NCT01558843||aneurysmal subarachnoid hemorrhage|
11470617|NCT01558843||intracerebral hematoma|
11470618|NCT01558843||brain tumor|
11470619|NCT01558830|Placebo Comparator|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
11470620|NCT01558830|Active Comparator|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
11470621|NCT01558817|Active Comparator|Informational brochure|Patients receive an informational brochure
11470622|NCT01558817|Experimental|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
11470623|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 5 to 15 years and have been diagnosed to have acute pharyngitis caused by GAS with a positive Rapid Antigen Detection Test (RADT) and have not been treated with antibiotics in the last 30 days.
11470624|NCT01558791|No Intervention|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
11470625|NCT01558791|Experimental|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
11470626|NCT01558778|Experimental|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
11470627|NCT01558765|Experimental|Intervention group|Patients receive integrated rehabilitation
11470628|NCT01558765|No Intervention|Control group|Patients receive usual follow-up care without physical exercise
11470629|NCT01558752|Experimental|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
11470630|NCT01558752|Active Comparator|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
11470631|NCT01558739|Experimental|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
11470632|NCT01558726|Experimental|Case management|
11470633|NCT01558726|Active Comparator|Usual treatment|Usual treatment of the CAPSad
11470634|NCT01558713|Active Comparator|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
11470635|NCT01558713|Active Comparator|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
11470636|NCT01558713|Active Comparator|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
11470637|NCT01558713|Active Comparator|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
11470638|NCT01558713|Active Comparator|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
11470639|NCT01558713|Active Comparator|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
11470640|NCT01558700|Experimental|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
11470641|NCT01558700|Placebo Comparator|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
11470642|NCT01558687|Experimental|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
11470643|NCT01558687|Active Comparator|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
11470644|NCT01558674|Experimental|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
11470645|NCT01558674|Active Comparator|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
11470646|NCT01558674|Experimental|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
11470647|NCT01558674|Active Comparator|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
11470648|NCT01558674|Experimental|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
11470649|NCT01558674|Experimental|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
11470650|NCT01558674|Experimental|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
11470651|NCT01558661|Experimental|AG-013736 (AXITINIB)|This is a single-arm phase II study evaluating the clinical efficacy of axitinib in the treatment of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (ACC).
11470652|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
11470653|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
11470654|NCT01558635|Experimental|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.
11470655|NCT01558622|Placebo Comparator|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
11470656|NCT01558622|Placebo Comparator|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
11470657|NCT01558622|Placebo Comparator|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
11470658|NCT01558622|Placebo Comparator|dexketoprofen trometamol + tramadol hydrochloride|
11470659|NCT01558622|Placebo Comparator|dexketoprofen trometamol + pethidine hydrochloride|
11470660|NCT01558622|Placebo Comparator|vitamin c|
11470661|NCT01558596|Placebo Comparator|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
11470662|NCT01558596|Experimental|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
11470663|NCT01558583|Other|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
11470664|NCT01558583|Other|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
11470665|NCT01558583|Other|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
11470666|NCT01558570||Schizophrenia|
11470667|NCT01558557|Experimental|Gluten Free Diet|
11470668|NCT01558544|Other|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
11470669|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
11470670|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
11470671|NCT01558505|Active Comparator|standard PTA|conventional balloon angioplasty
11470672|NCT01558505|Experimental|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
11470673|NCT01558492|Experimental|All subjects|Carboplatin and Paclitaxel
11470674|NCT01558479||Case|Has a diagnosis of Parkinson's disease
11470675|NCT01558479||Control|No diagnosis of Parkinson's disease
11470676|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
11470677|NCT01558466|Placebo Comparator|Group A - Placebo|iNO combined with placebo will be administered
11470678|NCT01558466|Active Comparator|Group B- Sildenafil|iNO combined with Sildenafil
11470679|NCT01558453|Experimental|Eloxatin|Oxaliplatin
11470680|NCT01558440|Active Comparator|Infant Formula|A diet that is being fed to the young infants
11470681|NCT01558440|Experimental|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
11470682|NCT01558440|Experimental|Diluted F-100|300 ml of water is added to 1000 ml of F-100
11470683|NCT01558427|Experimental|Active clinical surveillance|Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.
11470684|NCT01558427|Experimental|Salvage treatment of metastases|Surgical or radiotherapy treatment of metastases.
11470685|NCT01558414|Experimental|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
11470686|NCT01558414|Experimental|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
11470687|NCT01558414|Active Comparator|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
11470688|NCT01558401|Experimental|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
11470689|NCT01558388|Experimental|Vaginal lactobacilli|
11470690|NCT01558388|Placebo Comparator|Placebo|
11470691|NCT01558375|Placebo Comparator|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
11470692|NCT01558375|Experimental|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
11470693|NCT01558362|Experimental|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
11470694|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
11470695|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
11470696|NCT01558336|Experimental|Praziguantel|tablet single dose
11470697|NCT01558323|Experimental|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
11470698|NCT01558323|Experimental|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
11470699|NCT01558323|Experimental|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
11470700|NCT01558310|Active Comparator|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
11470701|NCT01558310|Placebo Comparator|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
11470702|NCT01558297|Experimental|Motivational Interviewing|
11470703|NCT01558297|Active Comparator|Nutritional Counseling|
11470704|NCT01558297|Active Comparator|Treatment as usual|
11470705|NCT01558271|Experimental|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
11470706|NCT01558271|Placebo Comparator|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
11470707|NCT01558271|Active Comparator|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
11470708|NCT01558258|Experimental|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
11470709|NCT01558258|No Intervention|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
11470710|NCT01558245|Experimental|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
11470711|NCT01558245|No Intervention|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
11470712|NCT01558232|Experimental|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
11470713|NCT01558219|Experimental|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
11470714|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
11470715|NCT01558193|Placebo Comparator|Placebo|Two placebos consumed
11470716|NCT01558193|Active Comparator|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
11470717|NCT01558193|Active Comparator|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
11470718|NCT01558193|Active Comparator|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
11470719|NCT01558180|Experimental|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
11470720|NCT01558180|Placebo Comparator|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
11470721|NCT01558167|Experimental|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
11470722|NCT01558154|Experimental|Chinese herb|Chinese herbs special for depression
11470723|NCT01558154|Experimental|acupuncture|
11470724|NCT01558154|Experimental|Psychotherapy|
11470725|NCT01558154|Experimental|physiotherapy|
11470726|NCT01558141|Active Comparator|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
11470727|NCT01558128|Other|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
11470728|NCT01558115|Experimental|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
11470729|NCT01558115|Placebo Comparator|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
11470730|NCT01558089||etanercept + methotrexate|
11470731|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
11470732|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
11470733|NCT01558063|Active Comparator|Ketamine Dose 1|0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
11470734|NCT01558063|Active Comparator|Ketamine Dose 2|0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
11470735|NCT01558063|Active Comparator|Ketamine Dose 3|0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
11470736|NCT01558063|Active Comparator|Ketamine Dose 4|0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
11470737|NCT01558063|Active Comparator|Ketamine Dose 5|0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
11470738|NCT01558063|Placebo Comparator|Saline Solution|Saline infused over 40 minutes and MRI scan
11470739|NCT01558050|Experimental|red rice|commercially available red rice nutritionial supplement
11470740|NCT01558050|Placebo Comparator|placebo|placebo capsules
11470777|NCT01557777|Experimental|Navitoclax, ABT-263|
11470741|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
11470742|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
11470743|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
11470744|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
11470745|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
11470746|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (< 2h of physical activity per week)
11470747|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
11470748|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
11470749|NCT01558011|Experimental|chemotherapy|"Chemotherapy:
~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
11470750|NCT01557998|Other|Control - No intervention|PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
11470751|NCT01557998|Experimental|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
11470752|NCT01557998|Other|HCV+PWID|Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
11470753|NCT01557985|Experimental|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
11470754|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
11470755|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
11470756|NCT01557959|Experimental|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
11470757|NCT01557946|Experimental|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
11470758|NCT01557946|No Intervention|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
11470759|NCT01557933||ECT|All study subjects have consented to receive ECT.
11470760|NCT01557920|Active Comparator|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
11470761|NCT01557920|Active Comparator|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
11470762|NCT01557907|Experimental|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
11470763|NCT01557907|Active Comparator|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
11470764|NCT01557894|Experimental|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
11470765|NCT01557894|No Intervention|Waitlist control group|Waitlist control group
11470766|NCT01557881|Experimental|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
11470767|NCT01557868|Active Comparator|Synvisc (hylan G-F 20)|
11470768|NCT01557868|Active Comparator|Euflexxa (1% sodium hyaluronate)|
11470769|NCT01557842|Active Comparator|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
11470770|NCT01557842|Experimental|Control Group|This group receives only drug treatment.
11470771|NCT01557829|Active Comparator|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
11470772|NCT01557829|Experimental|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
11470773|NCT01557816|Active Comparator|Naproxen|
11470774|NCT01557816|Sham Comparator|Placebo|
11470778|NCT01557764|Experimental|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
11470779|NCT01557751|Other|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
11470780|NCT01557738|Experimental|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
11470781|NCT01557738|Placebo Comparator|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
11470782|NCT01557738|Experimental|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
11470783|NCT01557738|Placebo Comparator|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
11470784|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
11470785|NCT01557712|Experimental|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
11470786|NCT01557712|Active Comparator|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
11470787|NCT01557699|Experimental|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
11470788|NCT01557699|Experimental|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
11470789|NCT01557699|Active Comparator|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
11470790|NCT01557673|Active Comparator|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
11470791|NCT01557673|Placebo Comparator|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
11470792|NCT01557660|Experimental|inhaled treprostinil|
11470793|NCT01557647|Experimental|inhaled treprostinil|
11470794|NCT01557647|Placebo Comparator|placebo|
11470795|NCT01557634|Experimental|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
11470796|NCT01557634|Active Comparator|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
11470797|NCT01557621|Experimental|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
11470798|NCT01557621|Experimental|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
11470799|NCT01557621|Active Comparator|Practice-based Recall|Practice-based Recall
11470800|NCT01557608|Experimental|Photon stimulation|
11470801|NCT01557608|Placebo Comparator|Placebo treatment|
11470802|NCT01557595|Experimental|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
11470803|NCT01557582|Other|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
11470804|NCT01557569|Active Comparator|Atomoxetine|Group receiving atomoxetine
11470805|NCT01557569|Placebo Comparator|Placebo|Group will receive placebo instead of atomoxetine
11470806|NCT01557517|Experimental|Clobetasol|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
11470807|NCT01557517|Placebo Comparator|Placebo|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
11470808|NCT01557504|Experimental|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
11470809|NCT01557504|Placebo Comparator|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
11470810|NCT01557491|Active Comparator|Straight Incision|incision made perpendicular to scalp surface
11470811|NCT01557491|Active Comparator|Bevelled Incision|Incision made at 45 degrees to scalp surface
11470812|NCT01557478|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
11470813|NCT01557478|Active Comparator|Melatonin 20mg|20 mg melatonin gelatin capsule
11470814|NCT01557452|Experimental|Givinostat|
11470815|NCT01557439|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
11470816|NCT01557439|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
11470817|NCT01557426|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
11470818|NCT01557413|Experimental|Intramedullary nail|Intramedullary nail
11470819|NCT01557413|Experimental|Locked plate|Locked plate
11470820|NCT01557400|Experimental|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
11470821|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
11470822|NCT01557374|Active Comparator|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
11470823|NCT01557374|Experimental|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
11470824|NCT01557361|Active Comparator|Standard RRT initiation|RRT is initiated >12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
11470825|NCT01557361|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
11470826|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
11470827|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
11470828|NCT01557335|Experimental|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
11470829|NCT01557335|Active Comparator|EC aspirin, EC omeprazole, Clopidogrel|
11470830|NCT01557322||Biologic|
11470831|NCT01557322||non-biologic DMARD|
11470832|NCT01557296|Placebo Comparator|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
11470833|NCT01557296|Active Comparator|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
11470834|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
11470835|NCT01557270|Experimental|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
11470836|NCT01557270|Active Comparator|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
11470837|NCT01557257|Experimental|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
11470838|NCT01557257|Experimental|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
11470839|NCT01557257|Experimental|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
11470840|NCT01557244|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
11470841|NCT01557244|Experimental|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
11470842|NCT01557244|Active Comparator|Oxybutynin|Oxybutynin
11470843|NCT01557244|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
11470844|NCT01557244|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
11470845|NCT01557231||No treatment|OA
11470846|NCT01557218|Experimental|Cucumber|
11470847|NCT01557218|Experimental|Pepper|
11470848|NCT01557218|Experimental|Tomato|
11470849|NCT01557218|Experimental|Vegetable variety|
11470850|NCT01557218|Experimental|Apple|
11470851|NCT01557218|Experimental|Peach|
11470852|NCT01557218|Experimental|Pineapple|
11470853|NCT01557218|Experimental|Fruit variety|
11470854|NCT01557192|Active Comparator|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
11470855|NCT01557192|Placebo Comparator|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
11470856|NCT01557179|Experimental|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
11470857|NCT01557179|Active Comparator|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
11470858|NCT01557166|Experimental|Liraglutide 3.0 mg|
11470859|NCT01557166|Placebo Comparator|Placebo|
11470860|NCT01557153|Experimental|Amlodipine|
11470861|NCT01557153|Placebo Comparator|Placebo|
11470862|NCT01557140|Placebo Comparator|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
11470863|NCT01557140|Experimental|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
11470864|NCT01557127||Group 1|
11470865|NCT01557114|Experimental|radiation therapy with Ipilimumab|
11470866|NCT01557101|Other|COLON CAPSULE ENDOSCOPY|
11470867|NCT01557101|Other|OPTICAL COLONOSCOPY|
11470868|NCT01557075|Active Comparator|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
11470869|NCT01557075|Active Comparator|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
11470870|NCT01557062|Other|Polysomnography|
11470871|NCT01557062|Other|Temperature measure|
11470872|NCT01557062|Other|Fibromyalgia Impact questionary|
11470992|NCT01556191|Active Comparator|Gefinib (patient with EGFR mutations)|
11470873|NCT01557049|Experimental|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
11470874|NCT01557049|No Intervention|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
11470875|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
11470876|NCT01557023|Experimental|dienogest 2 mg/ethynilestradiol 30 mcg;|
11470877|NCT01557023|Active Comparator|Yasmin®|
11470878|NCT01557010|Experimental|Treatment A|
11470879|NCT01557010|Experimental|Treatment B|
11470880|NCT01557010|Experimental|Treatment C|
11470881|NCT01557010|Placebo Comparator|Treatment D|
11470882|NCT01556997|Experimental|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
11470883|NCT01556997|Active Comparator|Amlodipine Besylate (AMLb)|
11470884|NCT01556997|Active Comparator|Perindopril Erbumine (PERe)|
11470885|NCT01556984||DSA group|
11470886|NCT01556984||control group|
11470887|NCT01556971|Active Comparator|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
11470888|NCT01556971|Placebo Comparator|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
11470889|NCT01556958||Active Wheezing - age 5-12|
11470890|NCT01556958||Active Wheezing - under age 5|
11470891|NCT01556958||No Wheezing|
11470892|NCT01556945|Experimental|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
11470893|NCT01556945|Experimental|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
11470894|NCT01556945|Experimental|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
11470895|NCT01556945|Experimental|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
11470896|NCT01556945|Placebo Comparator|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
11470897|NCT01556932|Experimental|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.
~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
11470898|NCT01556932|Experimental|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.
~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
11470899|NCT01556919||Mucosal Impedance Probe|
11470900|NCT01556906|Experimental|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
11470901|NCT01556893|Other|LASIK Flap Arm|This is a single arm study.
11470902|NCT01556880|Experimental|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
11470903|NCT01556880|No Intervention|Standard usual care|
11470904|NCT01556867|Active Comparator|dry cord care|
11470905|NCT01556867|Active Comparator|antiseptic care|
11470906|NCT01556841|Experimental|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
11470907|NCT01556841|Placebo Comparator|Placebo|
11470908|NCT01556815|Active Comparator|Group TACE|Patients who undergo TACE
11470909|NCT01556815|Experimental|Group Combination|Patients who are treated with sorafenib combined with TACE
11470910|NCT01556802|Experimental|Minocicline|minocicline 100mg oral twice a day for 5 days
11470911|NCT01556802|Placebo Comparator|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
11470912|NCT01556789|Experimental|ONT-10 Vaccine|ONT-10 investigational agent
11470913|NCT01556776|Experimental|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
11470914|NCT01556776|Placebo Comparator|Placebo|placebo
11470915|NCT01556763|Placebo Comparator|Placebo|Matching placebo was administered as one capsule per day for 21 days.
11470916|NCT01556763|Experimental|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
11470917|NCT01556763|Experimental|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
11470918|NCT01556737|Experimental|Supplement|
11470919|NCT01556737|Placebo Comparator|Placebo|
11470920|NCT01556724|Active Comparator|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
11470921|NCT01556724|Experimental|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
11470922|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
11470923|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
11470924|NCT01556698|Experimental|NVN1000 Gel|NVN1000 Gel topically applied one daily at bedtime for 8 weeks
11470925|NCT01556698|Placebo Comparator|Vehicle Gel|Vehicle Gel topically applied once daily at bedtime for 8 weeks
11470926|NCT01556685|Active Comparator|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
11470927|NCT01556685|Active Comparator|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
11470928|NCT01556672|Experimental|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
11470929|NCT01556659|Active Comparator|Triple antithrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
11470930|NCT01556659|No Intervention|Triple anti-thrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
11470931|NCT01556646|Experimental|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
11470932|NCT01556633|Experimental|Volunteers on dialysis|
11470933|NCT01556633|Experimental|Volunteers with reduced creatinine clearance|
11470934|NCT01556607|Active Comparator|Experimental: MDT-637|
11470935|NCT01556607|Placebo Comparator|Placebo|
11470936|NCT01556594|Experimental|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
11470937|NCT01556594|Experimental|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
11470938|NCT01556594|Active Comparator|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
11470939|NCT01556594|Experimental|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
11470940|NCT01556581|Active Comparator|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
11470941|NCT01556581|Active Comparator|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
11470942|NCT01556568|Experimental|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
11470943|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
11470944|NCT01556542|Active Comparator|standard PTA|nitinol stent implantation
11470945|NCT01556542|Experimental|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
11470946|NCT01556529|Experimental|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
11470947|NCT01556529|Active Comparator|Control|Control group: patient gets standard T2DM DMP care
11470948|NCT01556516||Women with Pompe Disease|
11470949|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
11470950|NCT01556490|No Intervention|Control group|Standard-of-care sorafenib, with no added therapy
11470951|NCT01556490|Experimental|Treatment group|Standard-of-care sorafenib plus TheraSphere
11470952|NCT01556477|Active Comparator|azacitidine|
11470953|NCT01556477|Experimental|azacitidine + lenalidomide|
11470954|NCT01556464|Experimental|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
11470955|NCT01556464|No Intervention|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
11470956|NCT01556451|Experimental|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
11470957|NCT01556438|Experimental|100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex)|Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
11470958|NCT01556438|Experimental|300 mg Tabalumab+BTZ IV+Dex|Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
11470959|NCT01556438|Experimental|300 mg Tabalumab+BTZ SC+Dex|Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
11470960|NCT01556425|Experimental|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
11470961|NCT01556425|Experimental|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
11470962|NCT01556425|Experimental|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
11470963|NCT01556425|Other|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
11470964|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.
~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.
~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.
~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
11470965|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
11470966|NCT01556386||Pharmacogenetic analysis, ALL|
11470967|NCT01556373||severe sepsis|patients with severe sepsis
11470968|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
11470969|NCT01556347|Experimental|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
11470970|NCT01556334|Experimental|Azithromycin|Azithromycin 1g po
11470971|NCT01556334|Active Comparator|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
11470972|NCT01556321|Experimental|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
11470973|NCT01556321|Placebo Comparator|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
11470974|NCT01556321|Experimental|Green tea, overweight|Subjects with a BMI >30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
11470975|NCT01556321|Placebo Comparator|Placebo capsules, obese|Subjects with a BMI >30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
11470976|NCT01556308|Experimental|DM-EBS|
11470977|NCT01556295||Experimental|
11470978|NCT01556295||Control|
11470979|NCT01556282|Experimental|Therasphere|
11470980|NCT01556256|Experimental|Arm I (TMV)|See detailed description.
11470981|NCT01556256|Experimental|Arm II (TMV+P)|See detailed description.
11470982|NCT01556243|Experimental|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
11470983|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
11470984|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
11470985|NCT01556217|Experimental|JNJ-39393406|
11470986|NCT01556217|Placebo Comparator|Placebo|
11470987|NCT01556204|Experimental|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
11470988|NCT01556204|Active Comparator|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
11470989|NCT01556191|Experimental|Gefinitib + Fulvestrant (patient with EGFR mutations)|
11470990|NCT01556191|Active Comparator|Erlotinib (wild type patients)|
11470991|NCT01556191|Experimental|Erlotinib + Fulvestrant (wild type patients)|
11470993|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
11470994|NCT01556165|Experimental|rasagiline|
11470995|NCT01556165|Placebo Comparator|placebo|
11470996|NCT01556152|Active Comparator|Treatment Arm 1|
11470997|NCT01556152|Active Comparator|Traetment Arm 2|
11470998|NCT01556152|Placebo Comparator|Treatment Arm 3|
11470999|NCT01556139|Experimental|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
11471000|NCT01556139|No Intervention|Control|Control group with a placebo device
11471001|NCT01556113|Active Comparator|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
11471002|NCT01556113|Active Comparator|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
11471003|NCT01556100|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
11471004|NCT01556087|Experimental|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
11471005|NCT01556087|Placebo Comparator|Health Education|7 didactic health education sessions
11471006|NCT01556074|Experimental|Yoga treatment|
11471007|NCT01556061|Experimental|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
11471008|NCT01556061|Active Comparator|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
11471009|NCT01556048|Experimental|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
11471010|NCT01556048|Placebo Comparator|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
11471011|NCT01556035|Experimental|Lenalidomide treatment|
11471012|NCT01556022|Experimental|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
11471013|NCT01556022|Placebo Comparator|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
11471014|NCT01556009|Active Comparator|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
11471015|NCT01556009|Active Comparator|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
11471016|NCT01555996|Experimental|Early and intensive OT|
11471017|NCT01555996|Active Comparator|Standard non-pharmacological prevention|
11471018|NCT01555983|Active Comparator|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
11471019|NCT01555983|Active Comparator|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
11471020|NCT01555983|Placebo Comparator|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
11471021|NCT01555970|Experimental|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
11471022|NCT01555970|Placebo Comparator|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
11471023|NCT01555957|Experimental|low dose intravenous lipids|
11471024|NCT01555957|Placebo Comparator|high dose of intravenous lipids|
11471025|NCT01555931|Experimental|Immediate|Placement within 48 hours of delivery
11471026|NCT01555931|Active Comparator|Control|Placement 4-8 weeks after delivery
11471027|NCT01555918|Experimental|Isavuconazole single oral dose - Part 1|
11471028|NCT01555918|Experimental|Isavuconazole single intravenous (IV) dose - Part 1|
11471029|NCT01555918|Experimental|Isavuconazole multiple oral doses - Part 2|
11471030|NCT01555918|Experimental|Isavuconazole multiple intravenous (IV) doses -Part 2|
11471031|NCT01555905|Experimental|Exercise|Threshold PEP or IMT device Phillips-Respironics
11471032|NCT01555892|Experimental|EBV-specific T cells: A|"Group A: Patients in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiple relapsed patients in remission who are at a high risk of relapse)** or any patient with primary disease or in first or subsequent remission if immunosuppressive chemotherapy is contraindicated.
~Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule:
~Day 0: 1 x 10^8 cells/m2
~Day 14: 2 x 10^8 cells/m2
~** Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant."
11471033|NCT01555892|Experimental|EBV-specific T cells: B|"Group B: Patients in remission or with minimal residual disease (MRD) status after autologous or syngeneic SCT.
~Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule:
~Day 0: 1 x 10^8 cells/m2
~Day 14: 2 x 10^8 cells/m2"
11471034|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
11471035|NCT01555866|Experimental|Part 1 Subjects with End Stage Renal Disease (ESRD)|
11471036|NCT01555866|Experimental|Part 1 Healthy Subjects|
11471037|NCT01555866|Experimental|Part 2 Subjects with Mild Renal Impairment|
11471038|NCT01555866|Experimental|Part 2 Subjects with Moderate Renal Impairment|
11471039|NCT01555866|Experimental|Part 2 Subjects with Severe Renal Impairment|
11471040|NCT01555866|Experimental|Part 2 Subjects with no Renal Impairment|
11471041|NCT01555853|Experimental|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
11471042|NCT01555853|Experimental|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
11471043|NCT01555853|Experimental|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
11471044|NCT01555853|Experimental|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
11471045|NCT01555840|Other|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
11471046|NCT01555827|Experimental|Alzheimer Disease|
11471047|NCT01555827|Active Comparator|Control|
11471048|NCT01555814|Experimental|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
11471049|NCT01555801|Experimental|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
11471050|NCT01555801|Placebo Comparator|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
11471051|NCT01555788|Experimental|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
11471052|NCT01555775|Experimental|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
11471053|NCT01555775|Experimental|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
11471054|NCT01555762||Cohort|
11471055|NCT01555749|Experimental|NNC172-2021 low dose / Placebo|
11471056|NCT01555749|Experimental|NNC172-2021 high dose / Placebo|
11471057|NCT01555736|Active Comparator|preseasonal immunotherapy scheme|
11471058|NCT01555736|Active Comparator|perennial immunotherapy scheme|
11471059|NCT01555710|Experimental|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
11471060|NCT01555710|Active Comparator|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
11471061|NCT01555697|Active Comparator|Memantine/high|memantine 20 mg
11471062|NCT01555697|Placebo Comparator|Placebo/high|placebo comparator for memantine 20 mg
11471063|NCT01555697|Active Comparator|Memantine/low|memantine 10 mg
11471064|NCT01555697|Placebo Comparator|Placebo/low|placebo comparator for memantine 10 mg
11471065|NCT01555684|Experimental|venoplasty proceedures|Half of the participants receive treatment and the other half do not
11471066|NCT01555684|Placebo Comparator|Control - no treatment|
11471067|NCT01555671|Active Comparator|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
11471068|NCT01555671|Placebo Comparator|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
11471069|NCT01555658|Experimental|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Bivalirudin
11471070|NCT01555658|Experimental|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
11471071|NCT01555645|Experimental|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
11471072|NCT01555645|Experimental|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
11471073|NCT01555632|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
11471074|NCT01555632|Experimental|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
11471075|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
11471076|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
11471077|NCT01555593|Experimental|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
11471078|NCT01555580|Experimental|GM-CSF|
11471079|NCT01555567|Experimental|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
11471080|NCT01555567|No Intervention|Standard of Care|This group will undergo standard ACL rehabilitation
11471081|NCT01555567|Experimental|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
11471082|NCT01555567|Experimental|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
11471083|NCT01555554|Experimental|Propranolol Hydrochloride|
11471084|NCT01555554|Placebo Comparator|Placebo Group|
11471085|NCT01555541|Experimental|Single-arm study|
11471086|NCT01555528||Growth Disorders|
11471087|NCT01555515|Experimental|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
11471088|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
11471089|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
11471090|NCT01555489|Experimental|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
11471091|NCT01555476|Experimental|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
11471092|NCT01555476|Active Comparator|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
11471093|NCT01555463|Experimental|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
11471094|NCT01555463|Placebo Comparator|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
11471095|NCT01555450|Experimental|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
11471096|NCT01555450|No Intervention|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
11471097|NCT01555424|Active Comparator|High dose|
11471098|NCT01555424|Active Comparator|Reference dose|
11471099|NCT01555411||No treatment|
11471100|NCT01555398|Experimental|Fasting conditions|Investigational product administrated under fasting condition.
11471101|NCT01555398|Active Comparator|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
11471102|NCT01555385|Active Comparator|Dietary supplement: high-protein breakfast|high-protein juice
11471103|NCT01555385|Active Comparator|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
11471104|NCT01555385|Placebo Comparator|Dietary supplement: low energy breakfast|low-calorie juice
11471105|NCT01555372|Active Comparator|Hook Plate|20 participants will be enrolled in this group.
11471106|NCT01555372|Experimental|Locking Plates|20 paticipants will be enrolled in this group
11471107|NCT01555359||Patients undergoing stem cell collection|
11471108|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
11471109|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
11471110|NCT01555333|Experimental|Arbaclofen|Open Label Study
11471111|NCT01555320|Placebo Comparator|Qishen Yiqi dripping pills dummy|
11471112|NCT01555320|Experimental|Qishen Yiqi Dripping Pills|
11471113|NCT01555307|Experimental|Balance group|Typical plus balance exercises
11471114|NCT01555307|Other|Typical group|Typical exercises
11471115|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.
~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
11471188|NCT01554813|Active Comparator|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
11471116|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
11471117|NCT01555281|Experimental|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients
~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
11471118|NCT01555268|Experimental|Arm A (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.
11471119|NCT01555268|Experimental|Arm B (trebananib, cytarabine)|Patients receive trebananib as in Arm A. Patients also receive cytarabine SC BID on days 1-14 of course 1 and days 1-7 of subsequent courses.
11471120|NCT01555242|Experimental|Aneustat (OMN54)|
11471121|NCT01555229|Experimental|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
11471122|NCT01555229|Active Comparator|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
11471123|NCT01555216|Active Comparator|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
11471124|NCT01555216|Active Comparator|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
11471125|NCT01555203|Experimental|liveWell: A healthy foundation for life|
11471126|NCT01555190|Active Comparator|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
11471127|NCT01555190|Active Comparator|myo-inositol 2000gr + folic acid 200 mcg|
11471128|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
11471129|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
11471130|NCT01555164|Experimental|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).
~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.
~Participants are required to maintain their diet and exercise regimen."
11471131|NCT01555164|Placebo Comparator|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).
~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.
~Participants are required to maintain their diet and exercise regimen."
11471132|NCT01555151|Experimental|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
11471133|NCT01555151|Experimental|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
11471134|NCT01555151|Experimental|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
11471135|NCT01555151|Experimental|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
11471136|NCT01555138|Experimental|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
11471137|NCT01555138|Active Comparator|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
11471138|NCT01555125|Experimental|secukinumab 150 mg|Drug
11471139|NCT01555125|Experimental|secukinumab 300 mg|Drug
11471140|NCT01555125|Placebo Comparator|placebo|
11471141|NCT01555112|Experimental|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
11471142|NCT01555099|Experimental|AZD5423|New study drug
11471143|NCT01555099|Active Comparator|Budesonide|Comparator to which the new study drug will be compared
11471144|NCT01555099|Placebo Comparator|Placebo|No drug to which both other arms will be compared
11471145|NCT01555086|Experimental|Limited pelvic Lymphadenectomy|
11471146|NCT01555086|Experimental|Extended pelvic Lymphadenectomy|
11471147|NCT01555073|Active Comparator|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
11471148|NCT01555073|Active Comparator|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
11471149|NCT01555073|Active Comparator|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
11471150|NCT01555073|Placebo Comparator|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
11471151|NCT01555060|Experimental|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
11471152|NCT01555060|No Intervention|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
11471153|NCT01555047|Active Comparator|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
11471154|NCT01555047|Experimental|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
11471155|NCT01555047|No Intervention|fertile males|50 fertile males were chose as control samples
11471156|NCT01555034|Active Comparator|intervention plus therapy|
11471157|NCT01555034|Active Comparator|intervention no therapy|exercise and nutrition
11471158|NCT01555021||Treatment as Usual (TAU)|"This group will provide blood samples to be analyzed at a later date for genotyping to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications.Treatment will be initiated based on the attending clinicians decision making absent genotyping results.
~All subjects in the group will receive the following assessment instruments for diagnosis: SCID-I/P and the Mini International Neuropsychiatric Interview (MINI)
~All subjects in the group will have the severity of their depression measured by the HAM D-17 (physician rating scale), the QIDS-SR-16 (patient rating). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the UKU. ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.
~Patients in the TAU group will provide saliva samples for future GWAS analysis."
11471159|NCT01555021||Assay Guided Treatment (AGT)|"This group will provide blood samples for genotyping test to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications . This test result will be available within 3-5 days available to guide clinicians in their choice and dosing of antidepressant medications.
~All subjects in the group will have the severity of their depression measured by the Hamilton Depression Rating Scale-17 (physician rating scale), the QIDS-SR-16 (patient rating scale). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the Udvalg for Kliniske Undersogelser (UKU). ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.
~Patients in the AGT group will provide saliva samples for future GWAS analysis."
11471160|NCT01555008|Experimental|Treatment A|
11471161|NCT01555008|Placebo Comparator|LX4211 Placebo|
11471162|NCT01554995|Experimental|LCB01-0371|active
11471163|NCT01554995|Experimental|Linezolid|comparator
11471164|NCT01554982|Other|Ferric Citrate|Open label extension of those completing study KRX-0304
11471165|NCT01554969|Experimental|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
11471166|NCT01554956|Experimental|Human Plasminogen|Human Plasminogen Eye Drop treatment
11471167|NCT01554943|Active Comparator|CMF|adjuvant standard CMF given from 1988 to 1996
11471168|NCT01554943|Experimental|EC|Adjuvant EC chemotherapy given from 1988 to 1996
11471169|NCT01554943|Experimental|HEC|High dose epirubicin (HEC) given from 1988 to 1996
11471170|NCT01554930|Active Comparator|Western therapy|
11471171|NCT01554930|Experimental|Xiyanping injection plus western therapy|
11471172|NCT01554917|Experimental|Iguratimod|
11471173|NCT01554904|Other|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
11471174|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
11471175|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
11471176|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
11471177|NCT01554878||knee surgery|
11471178|NCT01554865|Active Comparator|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
11471179|NCT01554865|Active Comparator|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
11471180|NCT01554852|Active Comparator|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.
~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):
~Induction treatment:
~CRD regimen - cyclophosphamide, lenalidomide, dexamethasone
~CTD regimen - cyclophosphamide, thalidomide, dexamethasone
~CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone
~Consolidation treatment (depending on response to induction treatment):
~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone
~No consolidation treatment
~High-dose therapy and stem cell transplant
~Maintenance treatment:
~Lenalidomide maintenance
~No maintenance
~Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
11471181|NCT01554852|Active Comparator|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.
~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:
~Induction treatment
~CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated
~CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated
~Consolidation treatment (depending on participant's response to induction treatment):
~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone
~No consolidation treatment
~Maintenance treatment
~Lenalidomide maintenance
~No maintenance
~Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)"
11471182|NCT01554839|Experimental|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
11471183|NCT01554839|Placebo Comparator|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
11471184|NCT01554826|Experimental|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
11471185|NCT01554826|Active Comparator|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
11471186|NCT01554813|Experimental|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
11471187|NCT01554813|Experimental|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
11471189|NCT01554800|Experimental|ACP-501|
11471190|NCT01554787|Experimental|Chinese Herb Astragalus membranaceus|
11471191|NCT01554787|Placebo Comparator|Placebo|
11471192|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
11471193|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
11471194|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
11471195|NCT01554748|Other|Patient cohort|TMC total joint arthroplasty
11471196|NCT01554735|Experimental|lifestyle counselling|exercise and diet counselling for weight loss
11471197|NCT01554722|Experimental|in plane needle placement|
11471198|NCT01554722|Experimental|out of plane needle placement|
11471199|NCT01554709|Experimental|CardioGard Cannula|
11471200|NCT01554709|Active Comparator|Reference Cannula|
11471201|NCT01554696|Experimental|ASP015K lowest dose|ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
11471202|NCT01554696|Experimental|ASP015K low dose|ASP015K low dose daily in addition to concomitant weekly oral methotrexate
11471203|NCT01554696|Experimental|ASP015K medium dose|ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
11471204|NCT01554696|Experimental|ASP015K high dose|ASP015K high dose daily in addition to concomitant weekly oral methotrexate
11471205|NCT01554696|Placebo Comparator|Placebo|Placebo daily in addition to concomitant weekly oral methotrexate
11471206|NCT01554683|Active Comparator|High Dose Levetiracetam|Low Dose Levetiracetam administration via IV infusion over 20 min
11471207|NCT01554683|Active Comparator|Low Dose Levetiracetam|High Dose Levetiracetam administration via IV infusion over 20 min
11471208|NCT01554683|Placebo Comparator|Placebo administration|Saline administration via IV infusion over 20 min
11471209|NCT01554670|No Intervention|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
11471210|NCT01554670|Active Comparator|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
11471211|NCT01554657|Experimental|5 Days|
11471212|NCT01554657|Placebo Comparator|7 days|
11471213|NCT01554644|Active Comparator|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
11471214|NCT01554644|Placebo Comparator|Saline Solution and Inert Gel|
11471215|NCT01554631|Experimental|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
11471216|NCT01554631|Experimental|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
11471217|NCT01554631|Active Comparator|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
11471218|NCT01554618|Experimental|EQW|Exenatide once weekly
11471219|NCT01554618|Placebo Comparator|Placebo|Placebo once weekly
11471220|NCT01554592|Experimental|Statin withdrawal|Participants will received a placebo for 12 weeks.
11471221|NCT01554592|Active Comparator|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
11471222|NCT01554579|Placebo Comparator|Sugar pill|
11471223|NCT01554579|Experimental|Gefapixant|
11471224|NCT01554566|Experimental|honey, no honey|
11471225|NCT01554553|Experimental|Posterior crural repair|
11471226|NCT01554553|No Intervention|No posteriorcrural repair|
11471227|NCT01554540|Experimental|Cutaneous iontophoresis of Treprostenil|
11471228|NCT01554540|Placebo Comparator|Cutaneous iontophoresis of placebo|
11471229|NCT01554527|Experimental|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use <4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
11471230|NCT01554527|Other|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
11471231|NCT01554514|Experimental|low dose rituximab|this is a single-arm trial
11471232|NCT01554501||Community sample|
11471233|NCT01554488|Experimental|Arm 1|High dose inhaled fluticasone (1760mcg/day)
11471234|NCT01554488|Active Comparator|Arm 2|Low dose inhaled fluticasone (88mcg/day)
11471235|NCT01554462|Active Comparator|ADHD active|4 month intervention with EPA/DHA in ADHD group
11471236|NCT01554462|Placebo Comparator|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
11471237|NCT01554462|Active Comparator|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
11471238|NCT01554462|Placebo Comparator|Healthy placebo|4 month dietary intervention with placebo in healthy control group
11471239|NCT01554449|Experimental|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
11471240|NCT01554449|Active Comparator|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
11471241|NCT01554449|Placebo Comparator|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
11472283|NCT01547000|Experimental|Extended-release Guanfacine|
11471242|NCT01554436|Experimental|patients in smoking cessation|patients in smoking cessation
11471243|NCT01554423|Active Comparator|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
11471244|NCT01554423|Experimental|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
11471245|NCT01554423|Experimental|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
11471246|NCT01554423|Experimental|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
11471247|NCT01554410|Experimental|IMRT/Cisplatin/Gemcitabine|All patients get IMRT with concurrent cisplatin & gemcitabine, with the dose of gemcitabine varying according to cohort
11471248|NCT01554397|Experimental|Phase II|All patients receive IMRT with concurrent cisplatin 40 mg/m2
11471249|NCT01554397|Active Comparator|Phase III - A|Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40 mg/m2
11471250|NCT01554397|Experimental|Phase III - B|Patients in Phase III, Arm B receive IMRT with concurrent cisplatin 40 mg/m2
11471251|NCT01554384|Experimental|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
11471252|NCT01554384|Active Comparator|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
11471253|NCT01554371|Experimental|Phase 1b: Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
11471254|NCT01554371|Experimental|Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)|Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.
11471255|NCT01554358|Other|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.
11471256|NCT01554358|No Intervention|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
11471257|NCT01554332|Active Comparator|Active stimulation|
11471258|NCT01554332|Sham Comparator|Sham stimulation|
11471259|NCT01554319|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.
~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
11471260|NCT01554319|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.
~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
11471261|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
11471262|NCT01554293|Experimental|PBL 1427 capsules|
11471263|NCT01554293|Placebo Comparator|Matching placebo|
11471264|NCT01554280|Experimental|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
11471265|NCT01554267|Experimental|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
11471266|NCT01554254|Experimental|300mcg/kg/day for 28 days|
11471267|NCT01554241|Experimental|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
11471268|NCT01554241|Experimental|2000 IU/day D3|D3 2000 IU/day
11471269|NCT01554241|Experimental|vitamin D3 4000 IU/day|D3 4000 IU/day
11471270|NCT01554241|Experimental|50,000 IU/week D3|D3 50,000 IU weekly
11471271|NCT01554228||Bariatric Surgery|
11471272|NCT01554215|Experimental|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
11471273|NCT01554215|Active Comparator|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
11471274|NCT01554202|Experimental|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471275|NCT01554202|Experimental|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471276|NCT01554202|Experimental|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471277|NCT01554202|Experimental|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471278|NCT01554202|Experimental|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471279|NCT01554202|Experimental|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471280|NCT01554202|Experimental|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471281|NCT01554202|Experimental|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471282|NCT01554202|Experimental|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
11471283|NCT01554189|Experimental|Panel A (GT1 10 mg)|
11471284|NCT01554189|Experimental|Panel B (GT1 50 mg)|
11471285|NCT01554189|Experimental|Panel C (GT1 100 mg)|
11471286|NCT01554189|Experimental|Panel D (GT1 200 mg)|
11471287|NCT01554189|Experimental|Panel E (GT3 10 mg)|
11471288|NCT01554189|Experimental|Panel F (GT3 50 mg)|
11471289|NCT01554189|Experimental|Panel G (GT3 100 mg)|
11471290|NCT01554189|Experimental|Panel H (GT3 200 mg)|
11471291|NCT01554189|Experimental|Panel I (GT1a 10 mg)|
11471292|NCT01554189|Experimental|Panel J (GT1a 50 mg)|
11471293|NCT01554189|Placebo Comparator|Placebo Panel|
11471294|NCT01554176|Experimental|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
11471295|NCT01554176|Placebo Comparator|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
11471296|NCT01554176|Experimental|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
11471297|NCT01554176|Placebo Comparator|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
11471298|NCT01554176|Placebo Comparator|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
11471299|NCT01554163|Experimental|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
11471300|NCT01554163|Active Comparator|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
11471301|NCT01554150|Experimental|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
11471302|NCT01554150|No Intervention|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
11471303|NCT01554137|Experimental|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
11471304|NCT01554137|Placebo Comparator|without isokinetic strength training|passive motion 60 minutes
11471305|NCT01554124|Experimental|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).
~Treatment duration = 21 ± 7 days"
11471306|NCT01554111|Active Comparator|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
11471307|NCT01554111|Active Comparator|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
11471308|NCT01554111|Active Comparator|Pico-Salax|patient will take one sachet of pico-salax
11471309|NCT01554098|Active Comparator|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
~Withdrawal in supine position followed by withdrawal with dynamic position change"
11471310|NCT01554098|Active Comparator|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
11471311|NCT01554085|Experimental|ALS-002158|
11471312|NCT01554085|Placebo Comparator|Placebo|
11471406|NCT01553305|Experimental|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
11471407|NCT01553305|No Intervention|Unsupervised exercise programme|
11472459|NCT01545778||Tapentadol IR|
11472460|NCT01545778||Oxycodone IR|
11471313|NCT01554072|Placebo Comparator|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
11471314|NCT01554072|Active Comparator|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
11471315|NCT01554046|Experimental|couples of first-degree family members|
11471316|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
11471317|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
11471318|NCT01554020|Active Comparator|Multiherb product|Herbal product
11471319|NCT01554020|Placebo Comparator|Placebo|Maltodextrin control
11471320|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
11471321|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
11471322|NCT01553981|Active Comparator|Tadalafil|Tablet Tadalafil 20 mg every alternate day
11471323|NCT01553981|Placebo Comparator|Placebo|Tablet Placebo every alternate day
11471324|NCT01553968|Other|Endurance Trained Subjects|
11471325|NCT01553968|Other|Untrained Subjects|
11471326|NCT01553942|Experimental|Afatinib|Afatinib
11471327|NCT01553929|Experimental|Physical and cognitive activity group|
11471328|NCT01553929|Active Comparator|Physical activity group|
11471329|NCT01553929|Placebo Comparator|control group|
11471330|NCT01553916|Experimental|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.
~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
11471331|NCT01553903|Experimental|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
11471332|NCT01553903|Experimental|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
11471333|NCT01553903|Experimental|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
11471334|NCT01553903|Experimental|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
11471335|NCT01553890|Other|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
11471336|NCT01553890|Other|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
11471337|NCT01553877|Active Comparator|Pushti Packet|
11471338|NCT01553877|Experimental|Rice based Ready to Use Complementary Food Supplements|
11471339|NCT01553877|Active Comparator|Chick-pea based Ready to Use Complementary Food Supplements|
11471340|NCT01553851|Experimental|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
11471341|NCT01553838|Experimental|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
11471342|NCT01553825||Pathologically diagnosed carcinoma|
11471343|NCT01553799||US check tube|
11471344|NCT01553799||US check tube, Endobronchial|
11471345|NCT01553786|Experimental|lenalidomide|lenalidomide + CHOP
11471346|NCT01553773|Experimental|Isoflavone|a gel with isoflavones (genistein 4%)
11471347|NCT01553773|Experimental|Estradiol|gel with 17-β estradiol 0.01%
11471348|NCT01553760|Experimental|Tri-MICS|
11471349|NCT01553760|Active Comparator|Conventional Phaco|
11471350|NCT01553747|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
11471351|NCT01553747|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
11471352|NCT01553747|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
11471353|NCT01553721|Experimental|udenafil|"Phase IIa Experimental : Udenafil Dose 1, Dose 2
~Phase IIb Experimental : Udenafil"
11471354|NCT01553721|Placebo Comparator|placebo|"Phase IIa Placebo Comparator : Placebo
~Phase IIb Placebo Comparator : Placebo"
11471355|NCT01553708|Experimental|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
11471356|NCT01553708|Active Comparator|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
11471357|NCT01553695|Active Comparator|general population|
11471358|NCT01553695|Experimental|ADHD Patient|
11471359|NCT01553682|No Intervention|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
11471408|NCT01553292|Experimental|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
11471648|NCT01551602|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
11471360|NCT01553682|Active Comparator|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
11471361|NCT01553682|Experimental|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
11471362|NCT01553669|Experimental|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
11471363|NCT01553669|No Intervention|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
11471364|NCT01553656|Experimental|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
11471365|NCT01553643|Experimental|Chinese Herb Huang-Chi-Wu-Wu-Tang|
11471366|NCT01553643|Placebo Comparator|Placebo|
11471367|NCT01553630|Active Comparator|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
11471368|NCT01553630|Active Comparator|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
11471369|NCT01553617|Experimental|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
11471370|NCT01553617|Active Comparator|Human serum albumin|Human serum albumin (HSA 50g/L)
11471371|NCT01553604|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
11471372|NCT01553604|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
11471373|NCT01553591|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
11471374|NCT01553591|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
11471375|NCT01553591|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.
11471376|NCT01553578|Experimental|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
11471377|NCT01553578|Experimental|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
11471378|NCT01553578|Active Comparator|Arm C (standard care)|Patients receive standard of care.
11471379|NCT01553565|Active Comparator|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
11471380|NCT01553565|Experimental|Cold polypectomy|
11471381|NCT01553552||Infected by Schistosoma haematobium|
11471382|NCT01553552||Not infected by Schistosoma haematobium|
11471383|NCT01553539|Experimental|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
11471384|NCT01553526||Orsiro DES|
11471385|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
11471386|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
11471387|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
11471388|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
11471389|NCT01553500|Experimental|glucomannan|
11471390|NCT01553500|Placebo Comparator|placebo|
11471391|NCT01553487|Experimental|Excercise|The forearm vibration training
11471392|NCT01553487|No Intervention|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
11471393|NCT01553461|Experimental|1|cord blood transplant with unlicensed CBU
11471394|NCT01553435|Placebo Comparator|Dextromethorphan, opioid analgisia, efficacy|
11471395|NCT01553435|Placebo Comparator|Placebo,opioid analgesia, efficacy|
11471396|NCT01553422|Active Comparator|before fluid Therapy|
11471397|NCT01553422|Active Comparator|after fluid Therapy|
11471398|NCT01553383|Active Comparator|Dental device|"Provent nasal peep valve vs dental device"
11471399|NCT01553383|Active Comparator|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
11471400|NCT01553370|Active Comparator|Alternate Intake-time|
11471401|NCT01553370|Experimental|Immediately post-exercise|
11471402|NCT01553331|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
11471403|NCT01553331|Active Comparator|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
11471404|NCT01553318|Active Comparator|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
11471405|NCT01553318|Placebo Comparator|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
11471461|NCT01552902|Placebo Comparator|Placebo|
11472461|NCT01545765|Experimental|lidocaine 7% and tetracaine 7%|
11471409|NCT01553279|Experimental|V419 and MCC-TT|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-TT (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of a measles, mumps, and rubella (MMR) vaccine (at 12 months of age).
11471410|NCT01553279|Experimental|V419 and MCC-CRM|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-CRM (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of an MMR vaccine (at 12 months of age).
11471411|NCT01553266||MDET intervention|
11471412|NCT01553266||Control group|Patients who have not received the MDET intervention.
11471413|NCT01553240|Experimental|TMS and fMRI|"functional MRI
~single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
11471414|NCT01553227|Experimental|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
11471415|NCT01553214|Other|Donors|volunteer healthy donors willing to receive G-CSF and dexamethasone and undergo leukapheresis
11471416|NCT01553201|Experimental|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
11471417|NCT01553201|Placebo Comparator|Placebo|Saline, 4cc, one time intramuscular administration
11471418|NCT01553188|Experimental|Abiraterone, Prednisone and AMG|Abiraterone and prednisone will be given with maximum tolerated dose (MTD) of Trebananib (AMG)
11471419|NCT01553188|Active Comparator|Abiraterone and Prednisone only|Abiraterone and prednisone only
11471420|NCT01553188|Other|Run in|Dose escalation phase to determine MTD of AMG
11471421|NCT01553149|Experimental|Arm I (low-dose lenalidomide)|Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11471422|NCT01553149|Experimental|Arm II (high-dose lenalidomide)|Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11471423|NCT01553136|Placebo Comparator|Sugar pill|
11471424|NCT01553136|Active Comparator|Varenicline|
11471425|NCT01553123|Experimental|Ulipristal with iron|
11471426|NCT01553123|Placebo Comparator|Placebo|Placebo with iron
11471427|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
11471428|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
11471429|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who
~have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;
~will be receiving adjuvant chemotherapy"
11471430|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who
~Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \
~will not be receiving adjuvant chemotherapy"
11471431|NCT01553097||Healthy control|healthy education-age-matched women without cancer
11471432|NCT01553084|Experimental|Effectiveness of Nicotine patch only|
11471433|NCT01553084|Experimental|Effectiveness of Combination NRT|
11471434|NCT01553084|Experimental|Effectiveness of Varenicline [Chantix]|
11471435|NCT01553071|Experimental|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
11471436|NCT01553058|Active Comparator|Adalimumab (Humira)|Injection of the active drug Humira.
11471437|NCT01553058|Placebo Comparator|Placebo Injection|Injection of placebo in place of active Humira injection.
11471438|NCT01553058|Active Comparator|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
11471439|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
11471440|NCT01553032|Active Comparator|Erbitux®|
11471441|NCT01553032|Active Comparator|Fractionated Radiotherapy|
11471442|NCT01553019|Experimental|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
11471443|NCT01553019|Experimental|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
11471444|NCT01553019|Experimental|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
11471445|NCT01553006|Active Comparator|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
11471446|NCT01553006|Active Comparator|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
11471447|NCT01552993|Experimental|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
11471448|NCT01552993|Placebo Comparator|placebo|pacifier and sucrose only
11471449|NCT01552954|Experimental|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the intensity of education)"
11471450|NCT01552954|No Intervention|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
11471451|NCT01552941|Experimental|Vagal Nerve Stimulation|
11471452|NCT01552928|Experimental|Anagrelide Therapeutic (0.5 mg)|
11471453|NCT01552928|Experimental|Anagrelide Supratherapeutic (2.5 mg)|
11471454|NCT01552928|Active Comparator|Moxifloxacin|
11471455|NCT01552928|Placebo Comparator|Placebo|
11471456|NCT01552915|Experimental|Lisdexamfetamine Dimesylate|
11471457|NCT01552915|Active Comparator|Methylphenidate Hydrochloride|
11471458|NCT01552915|Placebo Comparator|Placebo|
11471459|NCT01552902|Experimental|Lisdexamfetamine dimesylate|
11471460|NCT01552902|Active Comparator|Methylphenidate Hydrochloride|
11471462|NCT01552889|No Intervention|Usual Care (UC)|Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
11471463|NCT01552889|Experimental|Collaborative Care (CC)|Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient's PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.
11471464|NCT01552876|Other|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
11471465|NCT01552876|Other|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
11471466|NCT01552863|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11471467|NCT01552863|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11471468|NCT01552863|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11471469|NCT01552863|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11471470|NCT01552863|Experimental|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11471471|NCT01552863|Experimental|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
11471472|NCT01552850|Experimental|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
11471473|NCT01552850|Experimental|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
11471474|NCT01552850|Experimental|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
11471475|NCT01552850|Experimental|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
11471476|NCT01552850|Experimental|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
11471477|NCT01552837|No Intervention|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
11471478|NCT01552837|Active Comparator|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
11471479|NCT01552824|Experimental|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
11471480|NCT01552824|Experimental|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
11471481|NCT01552811||Type 1 diabetes|
11471482|NCT01552811||healthy controls|
11471483|NCT01552798|Experimental|Arm 1|
11471484|NCT01552798|Active Comparator|Arm 2|
11471485|NCT01552798|Placebo Comparator|Arm 3|
11471486|NCT01552785||Healthy adults|
11471487|NCT01552772|Experimental|Aripiprazole IM Depot|
11471488|NCT01552759|Experimental|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.
~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
11471489|NCT01552759|Experimental|Obese without BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.
~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
11471490|NCT01552759|Experimental|Normal-weight without BED|"Subjects with BMI 20-25 kg/m^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.
~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
11471491|NCT01552733|Experimental|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
11471492|NCT01552733|Placebo Comparator|Standard Care|Rehabilitation therapy according to local guidelines.
11471493|NCT01552707|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
11471494|NCT01552707|Sham Comparator|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
11471495|NCT01552694|Experimental|Sitagliptin|100 mg sitagliptin/day for 2 months
11471496|NCT01552694|Placebo Comparator|Placebo|Matching placebo daily for 2 months
11471497|NCT01552681|Experimental|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
11471498|NCT01552681|Placebo Comparator|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
11471499|NCT01552668|Experimental|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
11471500|NCT01552668|Placebo Comparator|Placebo|
11471501|NCT01552655|Other|Dual-time PET/CT|
11471502|NCT01552642|Active Comparator|Intervention Group|Intervention Group
11471503|NCT01552642|No Intervention|Control Group|Control Group
11471504|NCT01552629|Experimental|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
11471505|NCT01552629|Placebo Comparator|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
11471506|NCT01552629|Experimental|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
11471507|NCT01552616|Experimental|Activation Treatment|
11471508|NCT01552616|No Intervention|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
11471602|NCT01551914|Active Comparator|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
11471509|NCT01552603|Experimental|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
11471510|NCT01552590|Active Comparator|Tolvaptan, Tablet, QD, 2 weeks|
11471511|NCT01552590|Placebo Comparator|Placebo, Tablet, QD, 2 weeks|
11471512|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
11471513|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
11471514|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
11471515|NCT01552551|Active Comparator|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
11471516|NCT01552551|Experimental|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
11471517|NCT01552551|Experimental|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
11471518|NCT01552538|Experimental|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
11471519|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
11471520|NCT01552512|No Intervention|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
11471521|NCT01552512|Experimental|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
11471522|NCT01552512|Experimental|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
11471523|NCT01552499|Other|Control|
11471524|NCT01552499|Experimental|Treatment|
11471525|NCT01552486|Experimental|Chiropractic Spinal Manipulative Therapy|
11471526|NCT01552486|Other|Usual Care|
11471527|NCT01552473|Active Comparator|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
11471528|NCT01552473|Experimental|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
11471529|NCT01552447|Other|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
11471530|NCT01552447|Other|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
11471531|NCT01552447|Other|Standard of care|Compression bandaging
11471532|NCT01552434|Experimental|Group I (temsirolimus, bevacizumab, cetuximab)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11471533|NCT01552434|Experimental|Group II (temsirolimus, bevacizumab, valproic acid)|Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11471534|NCT01552434|Experimental|Group III (temsirolimus, bevacizumab)|Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11471535|NCT01552421|Active Comparator|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
11471536|NCT01552421|No Intervention|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
11471537|NCT01552408|Active Comparator|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) & will receive IVT of 0.3 mg ranibizumab on a pro re nata (PRN) schedule per retreatment criteria.
11471538|NCT01552408|Experimental|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) & receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
11471539|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
11471540|NCT01552369|Experimental|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
11471541|NCT01552369|Active Comparator|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
11471542|NCT01552356|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
11471543|NCT01552343|Experimental|Female - Desmopressin 25 μg|Female participants took 1 tablet of 25 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
11471544|NCT01552343|Placebo Comparator|Female - Placebo|Female participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
11471545|NCT01552343|Experimental|Male - Desmopressin 75 μg|Male participants took 1 tablet 75 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
11471546|NCT01552343|Placebo Comparator|Male - Placebo|Male participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
11471547|NCT01552330|Experimental|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
11471603|NCT01551901|Experimental|Luna Interbody System|
11471548|NCT01552330|Active Comparator|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
11471549|NCT01552317|Experimental|lifestyle counselling|A package of advice and interventions to help participants reduce their salt intake.
11471550|NCT01552317|No Intervention|Normal care|This group will receive the normal care that they would get anyway.
11471551|NCT01552304|Experimental|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
11471552|NCT01552304|Other|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
11471553|NCT01552291|Active Comparator|Glutamin|
11471554|NCT01552291|Placebo Comparator|Placebo|
11471555|NCT01552265||single-group MCI patients|
11471556|NCT01552252|Placebo Comparator|0% POs-Ca|
11471557|NCT01552252|Active Comparator|0.5% POs-Ca|
11471558|NCT01552252|Active Comparator|1% POs-Ca|
11471559|NCT01552252|Active Comparator|1.5% POs-Ca|
11471560|NCT01552252|Active Comparator|2% POs-Ca|
11471561|NCT01552239|Experimental|1 Arm|"Stratum A:
~R0, primary wound closure
~Stratum B:
~R0, secondary wound closure
~Stratum C:
~R1, tertiary wound closure"
11471562|NCT01552226|Active Comparator|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
11471563|NCT01552226|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
11471564|NCT01552213|Active Comparator|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
11471565|NCT01552213|Active Comparator|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
11471566|NCT01552200|Experimental|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
11471567|NCT01552200|Active Comparator|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
11471568|NCT01552187|Placebo Comparator|Placebo|Placebo
11471569|NCT01552187|Active Comparator|Colchicine|Colchicine
11471570|NCT01552174||Outpatients attending general ophthalmologic consultation|"Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation
~Patients informed of the objectives of the survey and agreeing to participate.
~Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
11471571|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
11471572|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
11471573|NCT01552148|Active Comparator|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
11471574|NCT01552148|Other|Group Control|
11471575|NCT01552135||Healthy|Healthy men above 50 years old
11471576|NCT01552122|Experimental|Odanacatib|
11471577|NCT01552122|Active Comparator|Alendronate|
11471578|NCT01552096|Placebo Comparator|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
11471579|NCT01552096|Active Comparator|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
11471580|NCT01552096|Experimental|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
11471581|NCT01552070|Experimental|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
11471582|NCT01552070|Active Comparator|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
11471583|NCT01552057|Experimental|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
11471584|NCT01552057|Placebo Comparator|Placebo|Placebo orally for 15 weeks
11471585|NCT01552044|Experimental|spironolactone|Spironolactone 25mg/day
11471586|NCT01552044|Placebo Comparator|Placebo|placebo tablets
11471587|NCT01552031||Observational group|
11471588|NCT01552018|Active Comparator|Saxagliptin|Saxagliptin 5 mg/day
11471589|NCT01552018|Placebo Comparator|Placebo|Placebo
11471590|NCT01552005||Population of patients treated with Saxagliptin|
11471591|NCT01551992|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
11471592|NCT01551992|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
11471593|NCT01551979|Active Comparator|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
11471594|NCT01551979|Sham Comparator|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
11471595|NCT01551966|Experimental|video capsule endoscopy|
11471596|NCT01551953|Experimental|tai chi exercise|
11471597|NCT01551953|Experimental|mind-body breathing|
11471598|NCT01551953|Active Comparator|education|
11471599|NCT01551940|Experimental|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
11471600|NCT01551940|Placebo Comparator|Placebo|Placebo injection : NaCl 0.9 %
11471601|NCT01551914|Experimental|ultrasonic scissors|
11471604|NCT01551888|Experimental|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
11471605|NCT01551888|Active Comparator|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
11471606|NCT01551875||subjects who are meeting the inclusion criteria|
11471607|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
11471608|NCT01551836|Other|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
11471609|NCT01551836|Other|Paracetamol formulation 2|Lower paracetamol concentrations
11471610|NCT01551823|Experimental|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
11471611|NCT01551823|Experimental|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
11471612|NCT01551810|Experimental|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
11471613|NCT01551810|Experimental|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
11471614|NCT01551797|Experimental|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
11471615|NCT01551797|Experimental|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
11471616|NCT01551797|Active Comparator|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
11471617|NCT01551784||1|
11471618|NCT01551771|Experimental|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
11471619|NCT01551771|Placebo Comparator|GW824575 matched-placebo|Placebo
11471620|NCT01551758|Experimental|FF/VI|once daily via a Novel Dry Powder Inhaler
11471621|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:
~Long acting bronchodilator therapy alone
~ICS alone or in combination with a long acting bronchodilator
~Triple maintenance therapy"
11471622|NCT01551745|Experimental|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
11471623|NCT01551732|Active Comparator|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
11471624|NCT01551732|Experimental|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
11471625|NCT01551719|No Intervention|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
11471626|NCT01551719|Experimental|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
11471627|NCT01551706|Active Comparator|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
11471628|NCT01551706|Placebo Comparator|Exicipient pill|
11471629|NCT01551693|Experimental|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
11471630|NCT01551693|Experimental|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
11471631|NCT01551680|Experimental|Concurrent whole brain radiotherapy and iniparib|
11471632|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
11471633|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
11471634|NCT01551654|Placebo Comparator|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
11471635|NCT01551654|Experimental|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
11471636|NCT01551641|Experimental|VEGF decressed|patients will receive concurrent chemoradiotherapy only
11471637|NCT01551641|Experimental|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
11471638|NCT01551641|Experimental|without thalidomide|patients will receive concurrent chemoradiotherapy only
11471639|NCT01551628|Experimental|Recombinant Human Arginase 1 Peg5000|
11471640|NCT01551615|Experimental|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
11471641|NCT01551602|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
11471642|NCT01551602|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
11471643|NCT01551602|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
11471644|NCT01551602|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
11471645|NCT01551602|Active Comparator|MN-10-T SD|Single administration of MN-10-T
11471646|NCT01551602|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
11471647|NCT01551602|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
11471649|NCT01551602|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
11471650|NCT01551602|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
11471651|NCT01551602|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
11471652|NCT01551589|Experimental|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
11471653|NCT01551589|Active Comparator|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
11471654|NCT01551550|Experimental|GDD & Amniotic Membrane Graft|After GDD implantation, amniotic membrane graft (AmnioGuard™, Bio-Tissue inc, Miami, FL) is used to cover the GDD tube.
11471655|NCT01551550|Active Comparator|GDD & Pericardial Graft|After GDD implantation, a pericardial graft (Tutoplast®, IOP Inc, Costa Mesa, CA) is used to cover the GDD tube.
11471656|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
11471657|NCT01551524|Experimental|Intravenous Erwinia|
11471658|NCT01551511|Experimental|delta-9-tetrahydrocannabinol (namisol)|
11471659|NCT01551511|Placebo Comparator|Placebo|
11471660|NCT01551498|Placebo Comparator|Placebo|subject takes one oral placebo lozenge, three times per day
11471661|NCT01551498|Active Comparator|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
11471662|NCT01551485|Experimental|Zolpidem|
11471663|NCT01551485|Placebo Comparator|Placebo|
11471664|NCT01551472||3DKnee™ with e-plus Insert|Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
11471665|NCT01551459|Active Comparator|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
11471666|NCT01551459|Experimental|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
11471667|NCT01551446|Experimental|Bardoxolone Methyl 20mg|
11471668|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
11471669|NCT01551420|Active Comparator|Advanced upper limb prosthetic device IMU controlled|Subjects with upper limb amputation who are trained to use a DEKA Arm with IMU controls
11471670|NCT01551420|Active Comparator|Advanced upper limb prosthetic EMG-PR controlled|Subjects with TR or TH upper limb amputation who are trained to use a DEKA Arm with EMG-PR Controls
11471671|NCT01551394|Experimental|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.
~Treatment duration is 11 ± 3 days."
11471672|NCT01551394|Active Comparator|Standard of care|"The two accepted therapeutic options are:
~ampicillin + gentamicin (SOC regimen 1) and
~cefotaxime + gentamicin (SOC regimen 2)."
11471673|NCT01551381|Experimental|EV-077|Oral administration
11471674|NCT01551381|Placebo Comparator|Placebo|Oral administration
11471675|NCT01551368|Experimental|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
11471676|NCT01551368|Placebo Comparator|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
11471677|NCT01551355|Experimental|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
11471678|NCT01551355|No Intervention|children - control group|The control preschool facilities continued with their usual preschool curriculum
11471679|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
11471680|NCT01551329|Experimental|Drug: Ketamine|
11471681|NCT01551316|Experimental|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
11471682|NCT01551316|Experimental|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
11471683|NCT01551303|Placebo Comparator|Placebo|Matched nasal spray placebo.
11471684|NCT01551303|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
11471685|NCT01551290|Placebo Comparator|Group I: Placebo|Participants in Group I receive placebo
11471686|NCT01551290|Experimental|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
11471687|NCT01551277|Placebo Comparator|Control Group|
11471688|NCT01551277|Experimental|BREATH STACKING|
11471689|NCT01551264|Other|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
11471690|NCT01551264|Other|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
11471691|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
11471692|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
11471693|NCT01551238|Experimental|Protein intake of 5 energy percent|
11471694|NCT01551238|Experimental|Protein intake of 30 energy percent|
11471695|NCT01551225|Active Comparator|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
11471696|NCT01551225|Placebo Comparator|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
11471697|NCT01551212|Experimental|EVR/TAC|Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: < 5 ng/mL)
11471698|NCT01551212|Active Comparator|TAC|Tacrolimus (C0-h: 6-10 ng/ml)
11471699|NCT01551199|Experimental|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
11471700|NCT01551186|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
11471701|NCT01551186|No Intervention|Standard of Care|Patients in the control arm will receive standard care
11471702|NCT01551173|Experimental|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
11471703|NCT01551173|Active Comparator|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
11471704|NCT01551160|Experimental|Medical Emergency Team|A communication and team-working initiative
11471705|NCT01551147|Experimental|Experimental 200 mg dose|
11471706|NCT01551147|Active Comparator|Active Comparator|
11471707|NCT01551147|Placebo Comparator|Placebo Comparator|
11471708|NCT01551134|Active Comparator|Open fundoplication|Fundoplication performed with open surgery
11471709|NCT01551134|Experimental|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
11471710|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
11471711|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
11471712|NCT01551108|Active Comparator|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
11471713|NCT01551108|Experimental|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
11471714|NCT01551095|Experimental|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
11471715|NCT01551082||Outpatient chest tubes|All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.
11471716|NCT01551069|Active Comparator|HCQ|HCQ 200~400mg, once daily, oral administration
11471717|NCT01551069|Other|Placebo|HCQ-placebo, once daily, oral administration
11471718|NCT01551056|Experimental|AC-170 0.24%|
11471719|NCT01551056|Placebo Comparator|AC-170 0%|
11471720|NCT01551043|Experimental|Arm 1|
11471721|NCT01551030|Experimental|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
11471722|NCT01551017||c-treatment|test group
11471723|NCT01551017||standard cooling|comparison group
11471724|NCT01551004|Experimental|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
11471725|NCT01551004|Experimental|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
11471726|NCT01551004|Experimental|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
11471727|NCT01551004|Experimental|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
11471728|NCT01551004|Experimental|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
11471729|NCT01550978|Experimental|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
11471730|NCT01550978|No Intervention|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
11471731|NCT01550965|Experimental|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
11471732|NCT01550939|No Intervention|Time Comparison between the Lenstar and IOLMaster|
11471733|NCT01550926|Active Comparator|Arm 1|60 mg orlistat
11471734|NCT01550926|Active Comparator|Arm 2|120 mg orlistat (2 X 60 mg capsules)
11471735|NCT01550926|Experimental|Arm 3|orlistat experimental formulation
11471736|NCT01550913|Experimental|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
11471737|NCT01550913|Other|Treatment as Usual|Participants are assigned to have Treatment as Usual
11471770|NCT01550666|No Intervention|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
11471771|NCT01550653|Experimental|Liraglutide|"See Intervention"
11471772|NCT01550653|Placebo Comparator|Placebo|"See Intervention"
11471738|NCT01550900|Experimental|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
11471739|NCT01550900|Active Comparator|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
11471740|NCT01550887|No Intervention|Impulsivity evaluation|
11471741|NCT01550874|No Intervention|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
11471742|NCT01550874|Experimental|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
11471743|NCT01550861|Experimental|In vitro Maturation|in vitro maturation of immature oocytes
11471744|NCT01550848|Experimental|Abraxane and Gemcitabine|Abraxane and Gemcitabine
11471745|NCT01550835|Experimental|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
11471746|NCT01550835|Active Comparator|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
11471747|NCT01550822|Active Comparator|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
11471748|NCT01550822|No Intervention|Usual Care|This group will receive usual care for stroke survivors
11471749|NCT01550809|Active Comparator|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
11471750|NCT01550809|Experimental|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
11471751|NCT01550796|Active Comparator|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
11471752|NCT01550796|Placebo Comparator|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
11471753|NCT01550783|Experimental|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
11471754|NCT01550783|Experimental|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
11471755|NCT01550770|Experimental|proprofol|
11471756|NCT01550757|No Intervention|Arm 1|Normal PACT Clinical Care
11471757|NCT01550757|Experimental|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
11471758|NCT01550757|No Intervention|Arm 3|Normal Homeless Oriented PACT Clinical Care
11471759|NCT01550757|Experimental|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
11471760|NCT01550744|Experimental|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
11471761|NCT01550744|Experimental|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
11471762|NCT01550731|Experimental|PREPARE|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
11471763|NCT01550731|Active Comparator|CONTROL|The control group will only receive an advance directive.
11471764|NCT01550718|Active Comparator|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
11471765|NCT01550718|Active Comparator|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
11471766|NCT01550718|No Intervention|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
11471767|NCT01550705|Experimental|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
11471768|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
11471769|NCT01550666|Experimental|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
11472462|NCT01545752|No Intervention|coventional group|Teaching just by book
11471773|NCT01550640|Experimental|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
11471774|NCT01550640|No Intervention|standard|control standard group
11471775|NCT01550627|Active Comparator|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
11471776|NCT01550627|Placebo Comparator|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
11471777|NCT01550614|Experimental|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
11471778|NCT01550614|No Intervention|Arm B|Standard of care angina medication
11471779|NCT01550601|Other|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
11471780|NCT01550601|Experimental|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
11471781|NCT01550588|Placebo Comparator|Medication|Anticoagulation, Antiplatelet agent
11471782|NCT01550588|Active Comparator|Device closure|Amplatzer PFO occluder device
11471783|NCT01550575||Patients eligible for SCS, RF or other treatment approaches|Patients who have previously been implanted with, or are eligible for implantation with a spinal cord stimulation system or various other treatment approaches such as RF, IDS, etc.
11471784|NCT01550575||Patients Eligible for treatment options with prior treatment|Patients who have previously been implanted with a spinal cord stimulation system or other various treatments, and have thereafter received a different form of chronic pain treatment such as a different SCS system, RF, IDS etc.
11471785|NCT01550562|Placebo Comparator|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
11471786|NCT01550562|Active Comparator|Treatment 1|subthreshold spinal cord stimulation therapy
11471787|NCT01550562|Experimental|Treatment 2|subthreshold spinal cord stimulation therapy
11471788|NCT01550536|Experimental|Training|Sedentary women who exercised <2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
11471789|NCT01550536|No Intervention|Active|Postmenopausal women who exercised >5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
11471790|NCT01550523|Experimental|18-mer oligodeoxynucleotide|
11471791|NCT01550510|Experimental|Ascorbic Acid + Irinotecan|Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks
11471792|NCT01550510|Active Comparator|Standard of Care (irinotecan alone)|350mg/m2 irinotecan once a week every 3 weeks
11471793|NCT01550497|Experimental|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
11471794|NCT01550497|Experimental|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
11471795|NCT01550471|Experimental|1 Treatment Sequence-A and O, Q and B, P and P|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
11471796|NCT01550471|Experimental|2 Treatment Sequence-A and O, P and P, Q and B|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
11471797|NCT01550471|Experimental|3 Treatment Sequence-Q and B, A and O, P and P|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
11471798|NCT01550471|Experimental|4 Treatment Sequence-Q and B, P and P, A and O|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
11471799|NCT01550471|Experimental|5 Treatment Sequence-P and P, A and O, Q and B|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
11471800|NCT01550471|Experimental|6 Treatment Sequence-P and P, Q and B, A and O|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
11471801|NCT01550458|Experimental|Mibefradil|
11471802|NCT01550458|Placebo Comparator|Placebo|
11471803|NCT01550445|No Intervention|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
11471804|NCT01550432|Experimental|High-Dose Glutathione|2,260 mg/day
11471805|NCT01550432|Experimental|Low-Dose Glutathione|1,130 mg/day
11471806|NCT01550432|Experimental|High-Dose N-Acetylcysteine|1,200 mg/day
11471807|NCT01550432|Experimental|Low-Dose N-Acetylcysteine|600 mg/day
11471808|NCT01550432|Placebo Comparator|Placebo|Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.
11471809|NCT01550419|Experimental|Atorvastatin(50 characters)|
11471810|NCT01550419|Placebo Comparator|Placebo(50 characters)|
11471811|NCT01550406|Active Comparator|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
11471812|NCT01550406|Active Comparator|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
11471813|NCT01550406|No Intervention|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
11471814|NCT01550380|Experimental|All participants|
11471948|NCT01549392|Active Comparator|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
11472071|NCT01548430|Experimental|TTP4000 3.0 mg/kg|Administered subcutaneously
11471815|NCT01550367|Experimental|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
11471816|NCT01550354|Active Comparator|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
11471817|NCT01550354|Active Comparator|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
11471818|NCT01550354|Active Comparator|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
11471819|NCT01550341|Active Comparator|Buprenorphine|
11471820|NCT01550341|Placebo Comparator|Placebo|
11471821|NCT01550315|Active Comparator|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation.
11471822|NCT01550315|Other|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.
~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation."
11471823|NCT01550302|No Intervention|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
11471824|NCT01550302|Active Comparator|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
11471825|NCT01550289|Experimental|Group 1: CYD dengue vaccine|Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
11471826|NCT01550289|Placebo Comparator|Group 2: Placebo|Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively
11471827|NCT01550276|Experimental|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
11471828|NCT01550276|Experimental|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
11471829|NCT01550276|Experimental|The combination of both treatments|
11471830|NCT01550276|Placebo Comparator|control group|
11471831|NCT01550250|Experimental|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
11471832|NCT01550250|Active Comparator|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
11471833|NCT01550237|Experimental|radiotherapy daily reduced|radiotherapy, with daily CT position verification and reduced safety margins
11471834|NCT01550237|Active Comparator|radiotherapy weekly standard|radiotherapy, with weekly orthogonal position verification and standard safety margins
11471835|NCT01550224|Active Comparator|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
11471836|NCT01550224|Active Comparator|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
11471837|NCT01550211||Students|Healthy students from Bar-Ilan University
11471838|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
11471839|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
11471840|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
11471841|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
11471842|NCT01550185|Experimental|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
11471843|NCT01550172|Experimental|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
11471844|NCT01550172|Active Comparator|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
11471845|NCT01550146|Experimental|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
11471846|NCT01550146|Placebo Comparator|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
11471847|NCT01550133|Experimental|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
11471848|NCT01550133|Experimental|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
11471849|NCT01550133|Experimental|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
11471850|NCT01550133|Experimental|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
11471851|NCT01550133|Experimental|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
11471852|NCT01550133|Experimental|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
11471853|NCT01550133|Experimental|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
11471854|NCT01550133|Experimental|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
11471855|NCT01550107|Active Comparator|Allopurinol|Allopurinol 600mg tablets
11471856|NCT01550107|Placebo Comparator|Lactose tablets|Placebo Lactose tablets
11471857|NCT01550081|Active Comparator|Rate of perceived exertion|Exercise intensity controlled by Borg
11471858|NCT01550081|Active Comparator|Heart rate monitor|Exercise intensity controlled by heart rate monitors
11471859|NCT01550068|Experimental|Experimental Arm|Echocardiographic screening
11471860|NCT01550068|No Intervention|Control Arm|No echocardiographic screening
11471861|NCT01550055|Experimental|CMAB009 plus Irinotecan|
11471862|NCT01550055|Active Comparator|Irinotecan-only and sequential-CMAB009|
11471863|NCT01550042||Intensive observation cohort|Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
11471864|NCT01550029|Experimental|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
11471865|NCT01550029|Active Comparator|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
11471866|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
11471867|NCT01550003|Experimental|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
11471868|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
11471869|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
11471870|NCT01549977|Experimental|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
11471871|NCT01549977|Placebo Comparator|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
11471872|NCT01549964|Experimental|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
11471873|NCT01549964|Experimental|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
11471874|NCT01549964|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
11472072|NCT01548430|Placebo Comparator|Placebo|Administered subcutaneously
11471875|NCT01549964|Placebo Comparator|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
11471876|NCT01549951|Experimental|Orteronel+Prednisone|
11471877|NCT01549938|Active Comparator|Treatment|20,000 IU cholecalciferol capsule
11471878|NCT01549938|Placebo Comparator|Placebo|Microcellulose capsule
11471879|NCT01549925|Other|standard surgical resection|standard surgical resection using clamps and surgical ligatures
11471880|NCT01549925|Active Comparator|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
11471881|NCT01549912||Rotator cuff tear|
11471882|NCT01549899|Active Comparator|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
11471883|NCT01549899|Active Comparator|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
11471884|NCT01549899|No Intervention|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
11471885|NCT01549886|Experimental|Moxtezafin Gadolinium|Experimental Arm with Moxtezafin Gadolinium and Zevalin Regimen
11471886|NCT01549886|Active Comparator|Zevalin Regimen|Day 1 Rituximab 250 mg/m2 intravenous infusion. Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)
11471887|NCT01549873|Active Comparator|Total intravenous anesthesia (TIVA)|
11471888|NCT01549873|Active Comparator|Inhaled anesthesia|
11471889|NCT01549860|No Intervention|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
11471890|NCT01549860|Experimental|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
11471891|NCT01549847|Experimental|L-carnitine and piracetam|
11471892|NCT01549847|Placebo Comparator|Placebo|
11471893|NCT01549834|Experimental|ABT-126 Low Dose|low dose
11471894|NCT01549834|Experimental|ABT-126 High Dose|high dose
11471895|NCT01549834|Placebo Comparator|sugar pill|Placebo
11471896|NCT01549808|Experimental|group 2|"Participants:
~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.
~The research is divided in 3 phases:
~An 8 month observation phase.Current practice relatede to mobilize is measured.
~An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.
~The effect of the intervention is described by using following test:
~walking distance,ADL function, capability to sit and stand"
11471897|NCT01549782|Active Comparator|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
11471898|NCT01549782|Placebo Comparator|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
11471899|NCT01549769|Experimental|Bardoxolone Methyl 20 mg|
11471900|NCT01549756||Qualitative Research|Experiential/opinion based research
11471901|NCT01549743|Experimental|Celecoxib|
11471902|NCT01549743|Experimental|Rebamipide|
11471903|NCT01549743|Experimental|Celecoxib plus Rebamipide|
11471904|NCT01549730|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with cervix cancer
11471905|NCT01549717|Experimental|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
11471906|NCT01549704|Other|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
11471907|NCT01549704|Other|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
11471908|NCT01549691|Experimental|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
11471909|NCT01549691|Experimental|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
11471910|NCT01549691|Placebo Comparator|placebo|Placebo given night before operation and the morning of operation
11471911|NCT01549678|Experimental|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
11471912|NCT01549678|Placebo Comparator|Placebo insole|EVA flat insole.
11472069|NCT01548443|Active Comparator|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
11471913|NCT01549652|Experimental|Prevention of Opioid Withdrawal|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
11471914|NCT01549652|Experimental|Prevention of Physical Dependence|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days; during morphine treatment, participants will be randomized to take either ondansetron 8 mg or matching placebo three times daily along with the oral morphine treatment. After thirty days, participants will return to the lab to undergo naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will then taper back to their original dose of morphine for one week.
11471915|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
11471916|NCT01549626|Active Comparator|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
11471917|NCT01549626|Active Comparator|golden flaxseed flour|30 grams per day of golden flaxseed flour
11471918|NCT01549626|Active Comparator|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
11471919|NCT01549613|Active Comparator|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
11471920|NCT01549613|Active Comparator|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
11471921|NCT01549600|Experimental|psyllium|5.1 g psyllium husk in at least 8 ounces of water
11471922|NCT01549600|Active Comparator|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
11471923|NCT01549587|Active Comparator|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
11471924|NCT01549587|Experimental|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
11471925|NCT01549574|Experimental|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
11471926|NCT01549561|No Intervention|Services As Usual|Foster care services as usual
11471927|NCT01549561|Experimental|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
11471928|NCT01549561|Experimental|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
11471929|NCT01549535|Active Comparator|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
11471930|NCT01549535|Active Comparator|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
11471931|NCT01549509|Experimental|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
11471932|NCT01549496|Experimental|boceprevir|boceprevir 800 mg tid
11471933|NCT01549483||Asthma|asthmatic subjects
11471934|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
11471935|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
11471936|NCT01549470|Experimental|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
11471937|NCT01549470|Placebo Comparator|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
11471938|NCT01549457|No Intervention|Non-intervention|Participants will only receive standard of care
11471939|NCT01549457|Experimental|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
11471940|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
11471941|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
11471942|NCT01549431|Experimental|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
11471943|NCT01549418|Active Comparator|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
11471944|NCT01549418|Placebo Comparator|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
11471945|NCT01549405|No Intervention|Control group|Control group: Group that without intercostal nerve block
11471946|NCT01549405|Experimental|nerve block|Group that performing intercostal block
11471947|NCT01549392|Active Comparator|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
11471949|NCT01549379|Active Comparator|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
11471950|NCT01549379|Active Comparator|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
11471951|NCT01549366|Experimental|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
11471952|NCT01549366|Active Comparator|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
11471953|NCT01549353|Experimental|chewing gum|
11471954|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
11471955|NCT01549327|Active Comparator|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
11471956|NCT01549327|Experimental|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
11471957|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
11471958|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
11471959|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
11471960|NCT01549301|Experimental|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
11471961|NCT01549301|Experimental|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
11471962|NCT01549301|Experimental|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
11471963|NCT01549301|Experimental|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
11471964|NCT01549288|Experimental|modified Atkins diet|
11471965|NCT01549288|Other|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
11471966|NCT01549262|Active Comparator|Standard Incubator|
11471967|NCT01549262|Experimental|ESD Time-lapse Monitoring system|
11471968|NCT01549249|No Intervention|vitrectomy|
11471969|NCT01549223|Active Comparator|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.
~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
11471970|NCT01549223|Active Comparator|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.
~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.
~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
11471971|NCT01549197||ICU staff and relatives|
11471972|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
11471973|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
11471974|NCT01549158|Experimental|Torasemide PR 10 mg|
11471975|NCT01549158|Active Comparator|Furosemide-IR 40 mg|
11471976|NCT01549158|Active Comparator|Torasemide-IR 10 mg|
11471977|NCT01549145|Experimental|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
11471978|NCT01549119|Experimental|Low dose VAC-3S|
11471979|NCT01549119|Experimental|Medium dose VAC-3S|
11471980|NCT01549119|Experimental|High dose VAC-3S|
11471981|NCT01549119|Placebo Comparator|Placebo|
11471982|NCT01549119|Experimental|Double-dose VAC-3S|
11471983|NCT01549106|Experimental|IPI-145|
11471984|NCT01549106|Placebo Comparator|Placebo|
11471985|NCT01549093|Experimental|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
11472070|NCT01548430|Experimental|TTP4000 1.0 mg/kg|Administered subcutaneously
11471986|NCT01549093|Active Comparator|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
11471987|NCT01549093|Active Comparator|GC|Gemcitabine -Carboplatin
11471988|NCT01549080||research|biological research on the effects of yisuishengxuegranule
11471989|NCT01549080||clinical research|clinical research on thalassemia
11471990|NCT01549054|Experimental|10-mg dose of E5501 2G tablet|
11471991|NCT01549054|Experimental|10-mg dose of E5501 cyclodextrin oral solution|
11471992|NCT01549054|Experimental|10-mg dose of E5501-P21% powder|
11471993|NCT01549054|Experimental|10-mg dose of E5501 lipid-based oral|
11471994|NCT01549041|Experimental|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
11471995|NCT01549041|Active Comparator|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
11471996|NCT01549028|Experimental|Mobile-based PR program.|Home based mobile PR program for 3 months.
11471997|NCT01549002|Experimental|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).
~The abscess I&D will be followed according to protocol using topical and local anesthetic."
11471998|NCT01549002|Active Comparator|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.
~The abscess I&D will be followed according to protocol using topical and local anesthetic."
11471999|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
11472000|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
11472001|NCT01548963|Experimental|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
11472002|NCT01548963|Active Comparator|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
11472003|NCT01548950|Other|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
11472004|NCT01548937|Experimental|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
11472005|NCT01548924|Experimental|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
11472006|NCT01548924|Experimental|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
11472007|NCT01548911|Experimental|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
11472008|NCT01548885|Experimental|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
11472009|NCT01548872|Active Comparator|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
11472010|NCT01548872|Active Comparator|HTK solution|After aortic cross clamp 50ml/kg will be administered
11472011|NCT01548859|Active Comparator|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
11472012|NCT01548859|Active Comparator|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
11472013|NCT01548833|Experimental|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
11472014|NCT01548833|Active Comparator|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
11472015|NCT01548833|Active Comparator|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
11472016|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
11472017|NCT01548794|Active Comparator|Bupivacaine(Group B)|spinal anesthesia
11472018|NCT01548794|Experimental|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
11472019|NCT01548794|Active Comparator|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
11472020|NCT01548781|Experimental|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
11472021|NCT01548781|Active Comparator|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
11472022|NCT01548768|Experimental|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
11472023|NCT01548768|Active Comparator|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
11472024|NCT01548768|No Intervention|Healthy Volunteers|Subjects without RA who will function as controls.
11472025|NCT01548742|Experimental|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
11472026|NCT01548742|Active Comparator|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
11472027|NCT01548729|Experimental|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
11472028|NCT01548703|Experimental|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
11472029|NCT01548703|Experimental|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
11472030|NCT01548703|Experimental|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
11472031|NCT01548690|Experimental|Ornithine·Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
11472032|NCT01548677|No Intervention|observation|18 weeks
11472033|NCT01548677|Experimental|Herceptin (trastuzumab)|18 weeks
11472034|NCT01548664|Experimental|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
11472035|NCT01548664|Active Comparator|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
11472036|NCT01548651|Placebo Comparator|Placebo|Placebo 5 mg orally daily for 6 months
11472037|NCT01548651|Experimental|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
11472038|NCT01548638|Experimental|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
11472039|NCT01548625||Healthy middle-aged human volunteers|
11472040|NCT01548612|Experimental|Sodium nitroprusside|
11472041|NCT01548612|Placebo Comparator|Placebo|Glucose solution 5%
11472042|NCT01548599|Experimental|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
11472043|NCT01548599|No Intervention|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
11472044|NCT01548586|Active Comparator|Anodal tDCS|
11472045|NCT01548586|Active Comparator|Cathodal tDCS|
11472046|NCT01548586|Placebo Comparator|Placebo type tDCS|
11472047|NCT01548573|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.
~After collection, participants will receive dexamethasone x 4 days every 14 days.
~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.
~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.
~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
11472048|NCT01548560|Experimental|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
11472049|NCT01548560|Placebo Comparator|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
11472050|NCT01548560|Experimental|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
11472051|NCT01548560|Placebo Comparator|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
11472052|NCT01548547|Experimental|LP mastery learning group|
11472053|NCT01548547|Active Comparator|IV mastery learning group|
11472054|NCT01548534|Placebo Comparator|DHA-free arm|Dietary supplementation with vegetable oil.
11472055|NCT01548534|Experimental|DHA arm|Dietary supplementation with fish oil.
11472056|NCT01548521|Experimental|Oxytocin|
11472057|NCT01548508|Experimental|Functionnal ElectroStimulation (FES)|
11472058|NCT01548508|Sham Comparator|SHAM|
11472059|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
11472060|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
11472061|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
11472062|NCT01548495||No rHuEPO treatment|
11472063|NCT01548482|Experimental|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11472064|NCT01548469|Active Comparator|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
11472065|NCT01548469|Experimental|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
11472066|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
11472067|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
11472068|NCT01548443|Experimental|Medifoam H|"A group which treated with medifoam H on the wound."
11475646|NCT01523938|Experimental|Hypnotherapy|
11472073|NCT01548417|Active Comparator|Korlym (mifepristone)|600 mg daily taken orally for one week
11472074|NCT01548417|Placebo Comparator|Sugar Pill|placebo pill daily taken orally for one week
11472075|NCT01548404|Placebo Comparator|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
11472076|NCT01548404|Experimental|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
11472077|NCT01548391|Experimental|HX-1171 20 mg (20mg 1T)|
11472078|NCT01548391|Experimental|HX-1171 40 mg (20mg 2T)|
11472079|NCT01548391|Experimental|HX-1171 80 mg (20mg 4T)|
11472080|NCT01548391|Experimental|HX-1171 160 mg (20mg 8T)|
11472081|NCT01548391|Experimental|HX-1171 300 mg (200mg 1T, 20mg 5T)|
11472082|NCT01548391|Experimental|HX-1171 600 mg (200mg 3T)|
11472083|NCT01548391|Experimental|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
11472084|NCT01548391|Experimental|HX-1171 1500 mg (500mg 3T)|
11472085|NCT01548391|Experimental|HX-1171 2000 mg (500mg 4T)|
11472086|NCT01548378|Experimental|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
11472087|NCT01548378|Experimental|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
11472088|NCT01548378|Experimental|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
11472089|NCT01548378|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
11472090|NCT01548365|No Intervention|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
11472091|NCT01548365|Experimental|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
11472092|NCT01548339|Active Comparator|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
11472093|NCT01548339|Experimental|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
11472094|NCT01548326|Active Comparator|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
11472095|NCT01548326|Placebo Comparator|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
11472096|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
11472097|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
11472098|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
11472099|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
11472100|NCT01548287|Experimental|AZD5213 doseA|AZD5213 doseA daily
11472101|NCT01548287|Experimental|AZD5213 doseB|AZD 5213 doseB daily
11472102|NCT01548287|Experimental|AZD5213 doseC|AZD5213 doseC daily
11472103|NCT01548287|Placebo Comparator|Placebo|Placebo daily
11472104|NCT01548261||Health people.|
11472105|NCT01548248||Levemir® users|
11472106|NCT01548235||BIAsp 30 users|
11472107|NCT01548209|Experimental|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
11472108|NCT01548209|Placebo Comparator|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
11472109|NCT01548196|Other|standard percutaneous nephrostomy|Standard PCN
11472110|NCT01548196|Other|double-J ureteral stent,|double-J ureteral stent,
11472111|NCT01548196|Other|open-ended ureteral catheter|open-ended ureteral catheter
11472112|NCT01548196|No Intervention|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
11472113|NCT01548183|Experimental|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
11472114|NCT01548183|No Intervention|Usual care|Usual care includes ED provider counseling as per normal clinical care
11472115|NCT01548170|Active Comparator|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
11472116|NCT01548170|Experimental|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:
~Sunitinib 37.5mg oral single dose.
~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
11472117|NCT01548170|Experimental|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:
~Sunitinib 37.5mg oral single dose.
~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
11472118|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:
~Sunitinib 25mg oral single dose.
~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
11472119|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:
~Sunitinib 25mg oral single dose.
~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
11472120|NCT01548157|Experimental|HCP1007|HCP1007
11472121|NCT01548157|Active Comparator|omarco and crestor|Rosuvastatin plus Omega-3
11472122|NCT01548144|Experimental|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
~Dose Expansion Group: MTD from Phase 1.
~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
~Dose Expansion Group: MTD from Phase 1."
11472123|NCT01548144|Experimental|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
~Dose Expansion Group: MTD from Phase 1.
~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.
~Dose Expansion Group: MTD from Phase 1."
11472161|NCT01547910|Experimental|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
11475647|NCT01523938|No Intervention|No Hypnotherapy|
11472124|NCT01548144|Experimental|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
~Expansion group starting dose: MTD from Phase 1.
~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
~Expansion group starting dose: MTD from Phase 1."
11472125|NCT01548144|Experimental|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
~Dose Expansion Group: MTD from Phase 1.
~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.
~Dose Expansion Group: MTD from Phase 1.
~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.
~Dose Expansion Group: MTD from Phase 1."
11472126|NCT01548131|Experimental|Psychoeducative group therapy|Psychoeducative group therapy
11472127|NCT01548131|No Intervention|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
11472128|NCT01548118|Experimental|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
11472129|NCT01548118|Placebo Comparator|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
11472130|NCT01548118|Experimental|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
11472131|NCT01548118|Placebo Comparator|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
11472132|NCT01548118|Experimental|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
11472133|NCT01548118|Placebo Comparator|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
11472134|NCT01548118|Experimental|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
11472135|NCT01548118|Placebo Comparator|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
11472136|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
11472137|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
11472138|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
11472139|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
11472140|NCT01548092|Experimental|Autologous SVF|Intralesional application
11472141|NCT01548079|No Intervention|Control|Untreated controls
11472142|NCT01548079|Active Comparator|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
11472143|NCT01548066|Experimental|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
11472144|NCT01548066|Placebo Comparator|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
11472145|NCT01548040|Experimental|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
11472146|NCT01548040|Sham Comparator|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
11472147|NCT01548027|Experimental|No intervention|no injection of local anesthetic agents
11472148|NCT01548027|Experimental|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
11472149|NCT01548027|Experimental|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
11472150|NCT01548001|Experimental|Iguratimod monotherapy|
11472151|NCT01548001|Experimental|Iguratimod and MTX combination|
11472152|NCT01548001|Active Comparator|MTX monotherapy|
11472153|NCT01547988|Experimental|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
11472154|NCT01547988|No Intervention|Reference Group|
11472155|NCT01547962|Experimental|Split-mouth design: Treatment|
11472156|NCT01547962|Active Comparator|Split-mouth design: Control|
11472157|NCT01547949|Experimental|tart cherry juice|
11472158|NCT01547949|Placebo Comparator|cherry flavored fruit drink|
11472159|NCT01547923|Experimental|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
11472160|NCT01547923|Other|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
11472162|NCT01547910|Placebo Comparator|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
11472163|NCT01547897|Active Comparator|NOX-E36|
11472164|NCT01547897|Placebo Comparator|Placebo|
11472165|NCT01547884||1|Latent TB positive with helminth positive
11472166|NCT01547884||2|Latent TB positive with helminth negative
11472167|NCT01547806|Experimental|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
11472168|NCT01547741|Active Comparator|Arm 1: Anthracycline-based chemotherapy|"4 anthracycline-based chemotherapy regimens (Regimens A, B, C, or D).
~Regimen A (TAC): 75 mg/m2 docetaxel (T) + 50 mg/m2 doxorubicin (A) + 500 mg/m2 cyclophosphamide (C) IV every 3 weeks for 6 cycles.
~Regimen B (AC then WP): 60 mg/m2 doxorubicin (A) + 600 mg/m2 cyclophosphamide (C) every 3 weeks for 4 cycles followed by weekly paclitaxel (WP) 80 mg/m2 IV every week for 12 doses.
~Regimen C (DD AC then WP): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel 80 mg/m2 IV every week for 12 doses.
~Regimen D (DD AC then DD P): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel (P) 175 mg/m2 IV every 2 weeks for 4 cycles."
11472169|NCT01547741|Active Comparator|Arm 2: docetaxel + cyclophosphamide|TC: 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide IV every 3 weeks for 6 cycles
11472170|NCT01547728|Experimental|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
11472171|NCT01547715|Experimental|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
11472172|NCT01547715|Experimental|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
11472173|NCT01547715|Experimental|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
11472174|NCT01547702|Experimental|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
11472175|NCT01547702|No Intervention|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
11472176|NCT01547689|Experimental|Human Umbilical Cord Derived MSC|
11472177|NCT01547676|Experimental|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
11472178|NCT01547676|Active Comparator|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
11472179|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
11472180|NCT01547637|Experimental|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches < 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
11472181|NCT01547637|Experimental|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
11472182|NCT01547624|Experimental|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
11472183|NCT01547624|No Intervention|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
11472184|NCT01547624|No Intervention|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
11472185|NCT01547611|Active Comparator|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
11472186|NCT01547611|Experimental|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
11472187|NCT01547598|Active Comparator|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
11472188|NCT01547598|Active Comparator|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
11472189|NCT01547585|Placebo Comparator|Control|- Isocaloric control muffins
11472190|NCT01547585|Experimental|Low Dose Soy|- Isocaloric muffins containing low dose of soy
11472191|NCT01547585|Experimental|High Dose Soy|- Isocaloric muffins containing high dose soy
11472192|NCT01547572|Experimental|Study group|The study group will get a video and leaflet on enhanced recovery.
11472193|NCT01547572|No Intervention|Control group|The control group will receive a leaflet only.
11472194|NCT01547559|No Intervention|part1:blank control|NO maintain drugs with Hp negative patients.
11472195|NCT01547559|Experimental|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
11472196|NCT01547559|Experimental|part1:EAC-T|eradication of Hp with triple treatment
11472197|NCT01547559|Experimental|part1：EA-EMC-T|eradication of Hp with sequential therapy
11472198|NCT01547559|Active Comparator|part1：T-T|Teprenone as maintain drugs for Hp positive patients
11472199|NCT01547559|Experimental|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
11472200|NCT01547559|No Intervention|part2:control group|diclofenac sodium only for patients with rheumatic diseases
11472201|NCT01547546|Experimental|Single Arm|
11472202|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
11472203|NCT01547520|Experimental|meperidine|25 mg of meperidine is injected intramuscularly before EGD
11472204|NCT01547520|Placebo Comparator|placebo|placebo was given intramuscularly before EGD
11472205|NCT01547507|Active Comparator|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
11472206|NCT01547507|Active Comparator|Airway Medix Closed Suction System|
11472207|NCT01547494|Placebo Comparator|Dietary Supplement|
11472208|NCT01547494|Experimental|Vegan Diet|
11472209|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
11472210|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
11472211|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
11472212|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
11472213|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
11472214|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
11472215|NCT01547468|Active Comparator|Intravenous Opioids|
11472216|NCT01547468|Experimental|Femoral Nerve Catheterization|
11472217|NCT01547455|Experimental|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
11472218|NCT01547455|Placebo Comparator|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
11472219|NCT01547442|Experimental|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
11472220|NCT01547429|Experimental|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
11472221|NCT01547416|Experimental|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
11472222|NCT01547416|Active Comparator|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
11472223|NCT01547390|Experimental|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
11472224|NCT01547390|Placebo Comparator|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
11472225|NCT01547377|Experimental|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
11472226|NCT01547377|Placebo Comparator|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
11472227|NCT01547364|Placebo Comparator|Caudal Saline|
11472228|NCT01547364|Active Comparator|Caudal Dextrose|
11472229|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
11472230|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
11472231|NCT01547325|Experimental|NanoDOX Hydrogel|
11472232|NCT01547325|Placebo Comparator|Placebo Hydrogel|
11472233|NCT01547312|Experimental|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
11472234|NCT01547312|Experimental|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
11472235|NCT01547312|Experimental|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
11472236|NCT01547312|Experimental|Procedural Pilot|Optimization of FNA procedure.
11472237|NCT01547299|Experimental|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
11472238|NCT01547299|Experimental|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
11472239|NCT01547286|Experimental|Allergic asthmatic|
11472240|NCT01547273|Experimental|bone graft inside socket only|bone graft inside socket only
11472241|NCT01547273|Experimental|bone graft inside and outside socket|bone graft inside and outside socket
11472242|NCT01547273|Experimental|no bone graft|no bone graft
11472280|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
11476993|NCT01514773||ICD placement|Those subjects who have an ICD.
11472243|NCT01547260|Experimental|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
11472244|NCT01547260|Experimental|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
11472245|NCT01547247|Experimental|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
11472246|NCT01547247|Active Comparator|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
11472247|NCT01547221|Active Comparator|3% boric acid|control
11472248|NCT01547221|Experimental|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
11472249|NCT01547208|Experimental|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
11472250|NCT01547208|Active Comparator|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
11472251|NCT01547195|Experimental|Group-swimming|
11472252|NCT01547195|Active Comparator|Control-walk|
11472253|NCT01547182|Active Comparator|Weight Loss|Caloric restriction
11472254|NCT01547182|Experimental|Weight Loss and Aerobic Training|Caloric restriction and walking
11472255|NCT01547182|Experimental|Weight Loss and Resistance Training|Caloric restriction and lifting weights
11472256|NCT01547169|Placebo Comparator|Saline|
11472257|NCT01547169|Experimental|Low Dose Insulin Detemir (10IU bid)|
11472258|NCT01547169|Experimental|High Dose Insulin Detemir (20IU bid)|
11472259|NCT01547156|No Intervention|Control group|Control group received usual care
11472260|NCT01547156|Experimental|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
11472261|NCT01547143|Experimental|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
11472262|NCT01547130|Active Comparator|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
11472263|NCT01547130|Active Comparator|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
11472264|NCT01547117|Experimental|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels.
11472265|NCT01547117|Experimental|Low Sodium Dietary Level|
11472266|NCT01547104|Active Comparator|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
11472267|NCT01547104|Experimental|Trajenta|Linagliptin 5 mg as add on therapy
11472268|NCT01547091|Experimental|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
11472269|NCT01547091|Active Comparator|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
11472270|NCT01547091|Active Comparator|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
11472271|NCT01547078|Active Comparator|Licensed Plasma|
11472272|NCT01547078|Experimental|Lyophilized Plasma|
11472273|NCT01547052|Experimental|DBT for children|Dialectical Behavior Therapy adapted for children
11472274|NCT01547052|Active Comparator|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
11472275|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
11472276|NCT01547026|Active Comparator|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
11472277|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
11472278|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
11472279|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
11472281|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
11472282|NCT01547000|Placebo Comparator|Inactive placebo|
11472284|NCT01546987|Active Comparator|ADT + GnRH agonist + dose escalated radiation|Patients receive standard androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).
11472285|NCT01546987|Experimental|ADT + GnRH agonist + dose escalated radiation + TAK-700|Patients receive the same standard ADT with a GnRH agonist and oral antiandrogen. In addition, patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.
11472286|NCT01546974|Experimental|HME filter|
11472287|NCT01546974|Experimental|Heated humidificator MR 730 Fisher & Paykel|
11472288|NCT01546961|Experimental|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).
~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
11472289|NCT01546948|Experimental|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
11472290|NCT01546948|Active Comparator|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
11472291|NCT01546935|Experimental|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
11472292|NCT01546922|Active Comparator|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
11472293|NCT01546922|Active Comparator|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
11472294|NCT01546909|Experimental|TETRAVAC-ACELLULAIRE|
11472295|NCT01546896|Experimental|buspirone+alprazolam|
11472296|NCT01546896|Active Comparator|alprazolam|
11472297|NCT01546896|No Intervention|healthy controls|
11472298|NCT01546883|Experimental|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
11472299|NCT01546870||pediatric heart transplant recipients|
11472300|NCT01546857|Placebo Comparator|placebo|Placebo one dose in the evening of surgery and post op day #1.
11472301|NCT01546857|Active Comparator|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
11472302|NCT01546844|Experimental|Care4Life|Text message and online interactive component to help patients with self-management.
11472303|NCT01546844|No Intervention|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
11472304|NCT01546805|Placebo Comparator|Placebo|
11472305|NCT01546805|Experimental|Zinc Group|
11472306|NCT01546792|No Intervention|Usual care control|Leaflet on exercise and diet
11472307|NCT01546792|Experimental|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
11472308|NCT01546779|Experimental|lung function|
11472309|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
11472310|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
11472311|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
11472312|NCT01546753|Active Comparator|Walnut Protein Powder|
11472313|NCT01546753|Placebo Comparator|Oat Powder|
11472314|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
11472315|NCT01546727|Experimental|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
11472316|NCT01546727|Active Comparator|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
11472317|NCT01546727|No Intervention|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
11472318|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
11472319|NCT01546701|Experimental|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
11472320|NCT01546701|Active Comparator|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
11472321|NCT01546688|Active Comparator|Zonisamide at targeted daily doses of 100-500 mg/day|
11472322|NCT01546688|Placebo Comparator|Placebo administered to match daily doses of 100-500 mg/day|
11472323|NCT01546675|Active Comparator|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
11472324|NCT01546675|Experimental|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
11472325|NCT01546662|Experimental|E-RH-06 - Low Dose|1 Capsule twice daily
11472326|NCT01546662|Experimental|E-RH-06 - High Dose|2 capsules twice daily
11472327|NCT01546662|Placebo Comparator|Placebo ;|Placebo Comparator
11472328|NCT01546649|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
11472463|NCT01545752|Experimental|non-interactive CD|Teaching book with non-interactive CD
11472329|NCT01546649|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
11472330|NCT01546636|Placebo Comparator|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
11472331|NCT01546636|Active Comparator|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
11472332|NCT01546623|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
11472333|NCT01546623|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
11472334|NCT01546610|Experimental|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
11472335|NCT01546610|Placebo Comparator|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
11472336|NCT01546597|Experimental|Metformin, Ranolazine|"Single cohort, 4-period study:
~Period 1, metformin 500 mg bid on Days 1-5
~Period 2, metformin 850 mg bid on Days 6-10
~Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15
~Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
11472337|NCT01546571|Placebo Comparator|POL-103A without API|
11472338|NCT01546571|Experimental|POL-103A|
11472339|NCT01546558|Experimental|Metformin, Ranolazine|"Single cohort, 2-period study:
~Period 1, metformin 1000 mg bid on Days 1-5
~Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
11472340|NCT01546545||Enrollment Group|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
11472341|NCT01546532|Experimental|RLX030|RLX030 as intravenous infusion for 24 hours.
11472342|NCT01546532|Placebo Comparator|Placebo|Placebo as intravenous infusion for 24 hours.
11472343|NCT01546519|Experimental|1|Control cohort with normal renal and normal hepatic function
11472344|NCT01546519|Experimental|2|Severe renal impairment and normal hepatic function
11472345|NCT01546519|Experimental|3|Mild hepatic impairment and normal renal function
11472346|NCT01546519|Experimental|4|Moderate hepatic impairment and normal renal function
11472347|NCT01546519|Experimental|5|Severe hepatic impairment and normal renal function
11472348|NCT01546506|Experimental|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
11472349|NCT01546506|No Intervention|No treatment|
11472350|NCT01546493|Experimental|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
11472351|NCT01546493|Experimental|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
11472352|NCT01546493|Experimental|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
11472353|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
11472354|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
11472355|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
11472356|NCT01546467|Experimental|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
11472357|NCT01546467|No Intervention|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
11472358|NCT01546454|Experimental|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
11472359|NCT01546454|Experimental|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
11472360|NCT01546454|Experimental|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
11472361|NCT01546441|Experimental|interprofessional assessment|patients receive an interprofessional assessment in a team environment
11472362|NCT01546441|Active Comparator|usual care|Usual care in family practice
11472363|NCT01546428|Experimental|INC280|
11472364|NCT01546415|Experimental|Desferasirox|
11472365|NCT01546402|Experimental|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
11472366|NCT01546402|Experimental|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
11472367|NCT01546389|Experimental|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
11472368|NCT01546389|Experimental|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
11472369|NCT01546389|Experimental|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
11472464|NCT01545752|Experimental|interactive CD|Teaching book with interactive CD
11472370|NCT01546389|Experimental|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
11472371|NCT01546389|Experimental|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
11472372|NCT01546389|Experimental|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
11472373|NCT01546376||HIV-cancer patients who recived RT|
11472374|NCT01546363||Validation|
11472375|NCT01546363||Testing|
11472376|NCT01546350|No Intervention|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
11472377|NCT01546350|Experimental|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
11472378|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
11472379|NCT01546311||lower limb amputees|
11472380|NCT01546285|Experimental|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
11472381|NCT01546272|Experimental|Resorbable staples|Suture using Insorb Resorbable staples
11472382|NCT01546272|Active Comparator|Resorbable wires|Suture using Monocryl resorbable wire
11472383|NCT01546259|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
11472384|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
11472385|NCT01546246|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
11472386|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
11472387|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
11472388|NCT01546233||Conventional education|Lung cancer patient will be received standard education
11472389|NCT01546220|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
11472390|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
11472391|NCT01546207|Other|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
11472392|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
11472393|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
11472394|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
11472395|NCT01546181||Age-related macular degeneration|
11472396|NCT01546181||inherited retinal dystrophies|
11472397|NCT01546181||retinal trauma|
11472398|NCT01546181||toxic retinopathies|
11472399|NCT01546181||arterial hypertensive patients|
11472400|NCT01546181||diabetic patients|
11472401|NCT01546181||inflammatory diseases|
11472402|NCT01546168|Experimental|esophageal deviation|esophageal deviation with IDE device during AF ablation
11472403|NCT01546168|No Intervention|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
11472404|NCT01546155|Experimental|healthy controls|
11472405|NCT01546142|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11472406|NCT01546142|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11472407|NCT01546129|Experimental|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
11472408|NCT01546129|No Intervention|Control|Standard of care according to the established Guidelines of the Department.
11472409|NCT01546116|Experimental|Adefovir and lamivudine combination|
11472410|NCT01546103|Active Comparator|Vitamin D3 supplementation of 1000 IU|
11472411|NCT01546103|Active Comparator|Vitamin D3 supplementation of 5000 IU|
11472412|NCT01546090|Experimental|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
11472413|NCT01546090|Placebo Comparator|placebo|placebo capsules were filled with starch
11472414|NCT01546077|Active Comparator|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
11472415|NCT01546077|Active Comparator|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
11472416|NCT01546064|Active Comparator|Bile duct anastomosis with T-tube|
11472417|NCT01546064|Active Comparator|Bile duct anastomosis without T-tube|
11472418|NCT01546051|Experimental|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
11472419|NCT01546051|Experimental|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
11472465|NCT01545739||CRT pacemaker implantation|
11472420|NCT01546051|Experimental|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
11472421|NCT01546051|Experimental|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
11472422|NCT01546038|Experimental|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
11472423|NCT01546038|Experimental|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
11472424|NCT01546038|Experimental|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
11472425|NCT01546038|Experimental|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
11472426|NCT01546038|Other|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
11472427|NCT01546025|Placebo Comparator|Relaxation training|
11472428|NCT01546025|Active Comparator|Brief Motivational Counseling|
11472429|NCT01546012|Experimental|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
11472430|NCT01546012|Active Comparator|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
11472431|NCT01545999|Active Comparator|PAS 25|In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
11472432|NCT01545999|Sham Comparator|PAS 100|To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
11472433|NCT01545986|Experimental|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
11472434|NCT01545986|Active Comparator|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
11472435|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
11472436|NCT01545960||Healthy Volunteers|
11472437|NCT01545947|Experimental|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
11472438|NCT01545947|Experimental|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
11472439|NCT01545947|Experimental|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
11472440|NCT01545934|No Intervention|Standard Care|
11472441|NCT01545934|Experimental|Lifestyle intervention|
11472442|NCT01545921|Experimental|Arm A|"Patients will complete QoL questionnaires in the following order :
~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
11472443|NCT01545921|Experimental|Arm B|"Patients will complete QoL questionnaires in the following order :
~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
11472444|NCT01545921|Experimental|Arm C|"Patients will complete QoL questionnaires in the following order :
~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
11472445|NCT01545921|Experimental|Arm D|"Patients will complete QoL questionnaires in the following order :
~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
11472446|NCT01545908|Placebo Comparator|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
11472447|NCT01545908|Active Comparator|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
11472448|NCT01545882|Experimental|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
11472449|NCT01545869|Experimental|Fractional carbon dioxide laser|
11472450|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
11472451|NCT01545843|Active Comparator|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
11472452|NCT01545843|Experimental|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
11472453|NCT01545843|Experimental|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
11472454|NCT01545830|Active Comparator|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
11472455|NCT01545830|Experimental|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
11472456|NCT01545817|Experimental|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
11472457|NCT01545804|Experimental|Lenalidomide|
11472458|NCT01545791||Insulin detemir users|
11472466|NCT01545726|Experimental|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
11472467|NCT01545726|Placebo Comparator|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
11472468|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
11472469|NCT01545700|Placebo Comparator|Control, saline 0-4 hours|2 cc of saline
11472470|NCT01545700|Active Comparator|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
11472471|NCT01545700|Active Comparator|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
11472472|NCT01545700|Placebo Comparator|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
11472473|NCT01545700|Active Comparator|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
11472474|NCT01545700|Active Comparator|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
11472475|NCT01545687|Experimental|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and for 4 weeks after, including weekends.
11472476|NCT01545687|Placebo Comparator|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
11472477|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
11472478|NCT01545661|Experimental|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
11472479|NCT01545661|Active Comparator|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
11472480|NCT01545648|Experimental|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year
~Route of administration: subcutaneous injection"
11472481|NCT01545635|Active Comparator|Coagulation factor concentrates|
11472482|NCT01545635|Active Comparator|Fresh Frozen Plasma|
11472483|NCT01545609|Experimental|Text messaging|Text messaging
11472484|NCT01545609|No Intervention|No intervention|No intervention
11472485|NCT01545596|Experimental|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
11472486|NCT01545596|No Intervention|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
11472487|NCT01545583|Placebo Comparator|Placebo intravenous|Placebo administered once intravenously
11472488|NCT01545583|Experimental|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
11472489|NCT01545583|Experimental|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
11472490|NCT01545583|Experimental|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
11472491|NCT01545583|Experimental|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
11472492|NCT01545583|Experimental|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
11472493|NCT01545583|Experimental|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
11472494|NCT01545583|Placebo Comparator|Placebo subcutaneous|Placebo administered once subcutaneously
11472495|NCT01545583|Experimental|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
11472496|NCT01545570|Active Comparator|GSK2376497|single dose escalation or multiple-dose titration
11472497|NCT01545570|Placebo Comparator|0.9% sodium chloride|placebo injection
11472498|NCT01545557|Experimental|Hyaluronic acid|
11472499|NCT01545531||Iohexol GFR|
11472500|NCT01545518|Experimental|all subjects|IVIG
11472501|NCT01545505|Other|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
11472502|NCT01545505|Other|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
11472503|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control [target diastolic BP 85mmHg]"
11472504|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight [target diastolic BP 100mmHg]."
11472505|NCT01545479|Other|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
11472506|NCT01545466|Experimental|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
11472507|NCT01545466|No Intervention|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
11472508|NCT01545453|Experimental|lebrikizumab - highest dose|
11472509|NCT01545453|Experimental|lebrikizumab - lowest dose|
11472510|NCT01545453|Experimental|lebrikizumab - middle dose|
11472511|NCT01545453|Placebo Comparator|placebo|
11472512|NCT01545440|Experimental|lebrikizumab - highest dose|
11472513|NCT01545440|Experimental|lebrikizumab - lowest dose|
11472514|NCT01545440|Experimental|lebrikizumab - middle dose|
11472515|NCT01545440|Placebo Comparator|placebo|
11472516|NCT01545427|Experimental|Gleevec|Gleevec 200 mg bid for 6 months.
11472517|NCT01545427|Placebo Comparator|Placebo|Placebo coated to appear identical to Gleevec.
11472518|NCT01545414|Experimental|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
11472519|NCT01545414|Active Comparator|ICONTROL|Internet-based treatment with a focus on relaxation training
11472520|NCT01545414|No Intervention|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
11472557|NCT01545141|No Intervention|Surgery only|Surgical resection only, performed as standard of care for the disease
11472682|NCT01544348|Experimental|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
11477377|NCT01512108|Experimental|Liraglutide + an OAD therapy|
11472521|NCT01545401|Experimental|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:
~Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics
~The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors
~Facilitation and support of the staff in these clinics so that they may implement the interventions"
11472522|NCT01545401|No Intervention|Control|"The control arm continues with usual care.
~The EMPOWER-PAR intervention package will be made available after the trial ends."
11472523|NCT01545388|Experimental|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
11472524|NCT01545388|Experimental|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
11472525|NCT01545388|Placebo Comparator|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
11472526|NCT01545375|Experimental|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.
~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.
~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.
~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
11472527|NCT01545375|Placebo Comparator|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.
~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.
~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.
~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
11472528|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
11472529|NCT01545349|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
11472530|NCT01545349|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
11472531|NCT01545336|Experimental|Anastrozole|1 mg tablet by mouth once daily for 3 months
11472532|NCT01545336|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 3 months
11472533|NCT01545323|Experimental|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
11472534|NCT01545310|Experimental|Group 1 (healthy), Group 2 (schizophrenia)|
11472535|NCT01545297|Active Comparator|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
11472536|NCT01545297|Experimental|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
11472537|NCT01545284|Experimental|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
11472538|NCT01545271|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
11472539|NCT01545271|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
11472540|NCT01545258|Experimental|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
11472541|NCT01545258|No Intervention|Control|
11472542|NCT01545245||Treated|Palivizumab treated
11472543|NCT01545245||Untreated|Palivizumab untreated
11472544|NCT01545232|Active Comparator|1:1:1 Blood Transfusion Ratio|
11472545|NCT01545232|Active Comparator|1:1:2 Blood Transfusion Ratio|
11472546|NCT01545219|Experimental|Prebiotic|
11472547|NCT01545219|Experimental|Probiotic|
11472548|NCT01545219|Experimental|Synbiotic|
11472549|NCT01545219|Placebo Comparator|Placebo|
11472550|NCT01545206||acute STEMI, Primpary PCI|
11472551|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
11472552|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
11472553|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
11472554|NCT01545167||African Americans with pancreatitis|pancreatitis
11472555|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
11472556|NCT01545154||Prostate Cancer|
11472558|NCT01545141|Experimental|Chemokin Modulatory Regimen (5 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:
~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
11472559|NCT01545141|Experimental|Chemokin Modulatory Regimen (10 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:
~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
11472560|NCT01545141|Experimental|Chemokin Modulatory Regimen (20 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:
~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
11472561|NCT01545089|Experimental|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
11472562|NCT01545089|Experimental|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
11472563|NCT01545076|Experimental|IgPro20 low dose|
11472564|NCT01545076|Experimental|IgPro20 high dose|
11472565|NCT01545076|Placebo Comparator|Placebo|
11472566|NCT01545050|Experimental|Induction Cohort: Placebo matching with BMS-945429|
11472567|NCT01545050|Experimental|Induction Cohort: BMS-945429 (600 IV/200 SC mg)|
11472568|NCT01545050|Experimental|Induction Cohort: BMS-945429 (300 IV/100 SC mg)|
11472569|NCT01545050|Experimental|Induction Cohort: BMS-945429 (150 IV/100 SC mg)|
11472570|NCT01545050|Experimental|Induction Cohort: BMS-945429 (400 SC/200 SC mg)|
11472571|NCT01545050|Experimental|Maintenance Cohort: Placebo matching with BMS-945429|
11472572|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (100 SC mg)|
11472573|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (200 SC mg)|
11472574|NCT01545050|Experimental|Open Label Cohort: BMS-945429 (200 SC mg)|
11472575|NCT01545037|Active Comparator|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
11472576|NCT01545037|Placebo Comparator|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
11472577|NCT01545024||DPP-IV inhibitor|
11472578|NCT01545011|No Intervention|standard|conventional respiratory rehabilitation
11472579|NCT01545011|Experimental|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
11472580|NCT01544998|Experimental|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
11472581|NCT01544998|Experimental|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
11472582|NCT01544985|Experimental|sucrose po|88% sucrose solution (Syrup B.P.)
11472583|NCT01544985|Placebo Comparator|placebo po|sterile water
11472584|NCT01544972|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
11472585|NCT01544972|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
11472586|NCT01544959|Active Comparator|fentanyl|
11472587|NCT01544959|Experimental|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
11472588|NCT01544946|Experimental|sucrose po|
11472589|NCT01544946|Placebo Comparator|placebo po|
11472590|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
11472591|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
11472592|NCT01544920|Active Comparator|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].
11472593|NCT01544920|Experimental|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].
11472644|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
11472683|NCT01544348|Experimental|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
11472684|NCT01544348|Experimental|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
11472685|NCT01544348|Experimental|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
11472594|NCT01544907|Active Comparator|Conventional PTA only|"Treatment Arm 1- Conventional PTA only
~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.
~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.
~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
11472595|NCT01544907|Experimental|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB
~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
11472596|NCT01544894|Active Comparator|raloxifene|60 mg/d for one year.
11472597|NCT01544894|Active Comparator|strontium ranelate|2 g/d for one year.
11472598|NCT01544881|Experimental|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
11472599|NCT01544881|Active Comparator|RAA|Rapid Acting Analog
11472600|NCT01544868|Other|Energy expenditure measurement|Descriptive measurements
11472601|NCT01544855|Experimental|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
11472602|NCT01544842|Active Comparator|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
11472603|NCT01544842|Active Comparator|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
11472604|NCT01544842|Placebo Comparator|Placebo|Orabase paste, three times a day for 3-6 weeks.
11472605|NCT01544829|Active Comparator|Active Comparator: Single serving of theobromine|
11472606|NCT01544829|Active Comparator|Multiple servings of theobromine|
11472607|NCT01544829|Placebo Comparator|Placebo capsules|
11472608|NCT01544816|Placebo Comparator|Control Food Product|Control food product
11472609|NCT01544816|Experimental|Experimental Food Product 1|Experimental food product 1
11472610|NCT01544816|Experimental|Experimental Food Product 2|Experimental food product 2
11472611|NCT01544803|No Intervention|Control group|
11472612|NCT01544803|Experimental|Web based self-monitoring|
11472613|NCT01544803|Active Comparator|Web based self-help|
11472614|NCT01544790|Experimental|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
11472615|NCT01544790|Active Comparator|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
11472616|NCT01544777|Experimental|Both Eyes|Model 751 IOL implanted in both eyes.
11472617|NCT01544777|Experimental|Single eye|Model 751 IOL in one eye
11472618|NCT01544777|Active Comparator|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
11472619|NCT01544764|No Intervention|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
11472620|NCT01544764|Experimental|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.
~Intervention:
~Other: Assessment , Feedback, Incentives, and eXchange Program"
11472621|NCT01544764|Experimental|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.
~Intervention:
~Other: Assessment , Feedback, Incentives, and eXchange Program"
11472622|NCT01544751|Active Comparator|Low dose Metformin|500 mg twice a day for one year
11472623|NCT01544751|Active Comparator|Metformin|1000 mg twice a day for one year
11472624|NCT01544751|Active Comparator|Atorvastatin|20 mg day
11472625|NCT01544738|Experimental|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
11472626|NCT01544738|Active Comparator|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
11472627|NCT01544725|Experimental|Ketamine-propofol|
11472628|NCT01544725|Active Comparator|Ketamine alone|
11472629|NCT01544712|Active Comparator|Control|Core decompression
11472630|NCT01544712|Experimental|Bone marrow|core decompression plus autologous concentrated bone marrow
11472631|NCT01544699|Active Comparator|Real stimulation|real tDCS
11472632|NCT01544699|Sham Comparator|Sham|sham tDCS
11472633|NCT01544686|Active Comparator|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
11472634|NCT01544686|Placebo Comparator|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
11472635|NCT01544673|Active Comparator|Arm A|
11472636|NCT01544673|Placebo Comparator|Arm B|
11472637|NCT01544660||Scanning|no treatment
11472638|NCT01544660||scanning|no treatment
11472639|NCT01544647|Active Comparator|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
11472640|NCT01544647|Active Comparator|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
11472641|NCT01544634|Experimental|Propranolol + Low dose Qvar|
11472642|NCT01544634|Active Comparator|Placebo + high dose Qvar|
11472643|NCT01544621||Successful quitters Sustained smokers|Successful quitters
11472681|NCT01544348|Experimental|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
11472645|NCT01544595|Placebo Comparator|PASI 75 Responders|"PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
11472646|NCT01544595|Experimental|Partial responders|Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
11472647|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
11472648|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
11472649|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
11472650|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
11472651|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
11472652|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
11472653|NCT01544530|Experimental|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
11472654|NCT01544530|No Intervention|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
11472655|NCT01544517|Experimental|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
11472656|NCT01544517|Active Comparator|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
11472657|NCT01544504|Experimental|Norepinephrine|Topical norepinephrine
11472658|NCT01544491|Experimental|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
11472659|NCT01544491|Active Comparator|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
11472660|NCT01544478|Experimental|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
11472661|NCT01544465|Experimental|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
11472662|NCT01544465|Active Comparator|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
11472663|NCT01544452|Other|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
11472664|NCT01544452|Other|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
11472665|NCT01544439|Experimental|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
11472666|NCT01544439|Placebo Comparator|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
11472667|NCT01544426|Experimental|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
11472668|NCT01544426|Active Comparator|Office hyteroscopy|Office hysteroscopy
11472669|NCT01544413|Experimental|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
11472670|NCT01544387|Other|Bed Rest|Subjects will have limited activity. Bed Rest
11472671|NCT01544387|Other|Activity|Activity
11472672|NCT01544374|Experimental|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
11472673|NCT01544374|No Intervention|Control- no intervention|Usual Care
11472674|NCT01544361|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
11472675|NCT01544361|Experimental|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
11472676|NCT01544361|Experimental|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
11472677|NCT01544361|Experimental|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
11472678|NCT01544361|Experimental|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
11472679|NCT01544348|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
11472680|NCT01544348|Active Comparator|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
11477378|NCT01512108|Active Comparator|Two OADs combination therapy|
11472686|NCT01544348|Experimental|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
11472687|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
11472688|NCT01544309|Experimental|Atorvastatin administration group|
11472689|NCT01544309|Experimental|Rosuvastatin administration group|
11472690|NCT01544296|Experimental|KHK6188, high dose|
11472691|NCT01544296|Experimental|KHK6188, low dose|
11472692|NCT01544296|Placebo Comparator|Placebo|
11472693|NCT01544283|Experimental|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
11472694|NCT01544283|Active Comparator|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
11472695|NCT01544270|Active Comparator|Study product containing milk proteins|Yoghurt-like milk-based product
11472696|NCT01544270|Active Comparator|Study product containing probiotics|Yoghurt-like milk-based product
11472697|NCT01544270|Placebo Comparator|Control product|Yoghurt-like milk-based product without supplemented nutrients
11472698|NCT01544257|Experimental|OMT|patients under standard medical care plus OMT.
11472699|NCT01544257|No Intervention|Control|patients under standard medical care plus only osteopathic evaluation
11472700|NCT01544244|Experimental|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
11472701|NCT01544244|Active Comparator|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
11472702|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
11472703|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
11472704|NCT01544205|Experimental|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
11472705|NCT01544205|Active Comparator|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
11472706|NCT01544192|Active Comparator|retinal nerve fiber thickness|
11472707|NCT01544192|Active Comparator|Mean Deviation|
11472708|NCT01544192|Active Comparator|Pattern Standard Deviation|
11472709|NCT01544192|Active Comparator|ganglion cell count|
11472710|NCT01544192|Active Comparator|c/d ratios|
11472711|NCT01544179|Experimental|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
11472712|NCT01544179|Placebo Comparator|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
11472713|NCT01544166|Experimental|Overall study|
11472714|NCT01544153|Other|WEB only|Control group receiving no additional intervention
11472715|NCT01544153|Experimental|WEB+SN|WEB plus social network intervention.
11472716|NCT01544153|Experimental|WEB+NRT|WEB plus nicotine replacement therapy product.
11472717|NCT01544153|Experimental|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
11472718|NCT01544140|Experimental|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
11472719|NCT01544127|Experimental|MI-SI+TAU|Motivational Interviewing to Address Suicidal Ideation
11472720|NCT01544127|Experimental|MI-SI-R+TAU|Motivational Interviewing to Address Suicidal Ideation Revised
11472721|NCT01544127|Other|TAU Alone|Treatment as usual
11472722|NCT01544114|Experimental|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.
~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
11472723|NCT01544101|Experimental|Vegan Diet|
11472724|NCT01544101|Placebo Comparator|Supplement|
11472725|NCT01544088|Experimental|Arm 1: GCBT|Group Cognitive Behavioral treatment (GCBT)
11472726|NCT01544088|Active Comparator|Arm 2: Group Treatment|Present Centered Group Treatment
11472727|NCT01544075|Experimental|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
11472728|NCT01544075|Active Comparator|NS|The control group who will receive the neck school treatment.
11472729|NCT01544062|Experimental|IV acetaminophen|Study subjects receiving IV acetaminophen
11472730|NCT01544062|Placebo Comparator|Normal saline|Study subjects receiving placebo
11472731|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
11472732|NCT01544036|Experimental|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
11472733|NCT01544023||Breast Reconstruction with TilOOP|
11472734|NCT01544010|No Intervention|assessment only control group|Assessment at baseline, 12, and 24 months
11472735|NCT01544010|Active Comparator|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
11472736|NCT01544010|Active Comparator|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
11472737|NCT01544010|Active Comparator|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
11472738|NCT01544010|Active Comparator|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
11472739|NCT01543997|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
11472740|NCT01543997|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
11472741|NCT01543984|Experimental|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3*50 min/week in 10 weeks)"
11472742|NCT01543984|Other|Reference group|Health Counselling (1,5h)
11472743|NCT01543971|Active Comparator|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
11472744|NCT01543971|Active Comparator|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
11472745|NCT01543971|Active Comparator|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
11472746|NCT01543958|Experimental|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
11472747|NCT01543945|Experimental|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
11472748|NCT01543945|Active Comparator|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
11472749|NCT01543932|Experimental|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
11472750|NCT01543932|Experimental|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
11472751|NCT01543932|Experimental|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
11472752|NCT01543919|Experimental|PH-787904 (arm1)|
11472753|NCT01543919|Experimental|PH-787904 (arm2)|
11472754|NCT01543919|Experimental|PH-787904 (arm3)|
11472755|NCT01543919|Experimental|PH-787904 (arm4)|
11472756|NCT01543919|Experimental|PH-787904 (arm5)|
11472757|NCT01543919|Experimental|Placebo|
11472758|NCT01543906|Experimental|QLT091001|oral QLT091001 administered once daily for 7 days
11472759|NCT01543893|Experimental|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks
~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
11472760|NCT01543893|Active Comparator|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.
~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
11472761|NCT01543880||Users of somatropin|
11472762|NCT01543867||Users of somatropin|
11472763|NCT01543854|Experimental|RLX030|RLX030 as intravenous infusion for 20 hours
11472764|NCT01543854|Placebo Comparator|Placebo|Matching placebo as intravenous infusion for 20 hours.
11472765|NCT01543841||Advanced Cancer|Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
11472766|NCT01543841||Healthy Volunteers|Eligible volunteers will have one tube of whole blood (~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
11472767|NCT01543828|Experimental|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
11472768|NCT01543828|Placebo Comparator|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
11472769|NCT01543815|Experimental|WBT-WEB|Well-Being Therapy based on Web Mobile technology
11472770|NCT01543815|Active Comparator|CBT|Cognitive Behavior Therapy
11472771|NCT01543815|No Intervention|CM|Standardized Care Management
11472772|NCT01543802|Experimental|Pazopanib|
11472773|NCT01543789|Experimental|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
11472774|NCT01543789|Active Comparator|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
11473408|NCT01539122|Active Comparator|Cemented Glenoid|Cemented glenoid shoulder replacement component
11472775|NCT01543776|Active Comparator|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
11472776|NCT01543776|Experimental|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
11472777|NCT01543763|Experimental|Panobinostat with PC124871|
11472778|NCT01543750|Experimental|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
11472779|NCT01543750|Experimental|Placebo|placebo twice daily for 8 weeks
11472780|NCT01543737|Active Comparator|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
11472781|NCT01543737|Active Comparator|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
11472782|NCT01543724|Experimental|Lithium|
11472783|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
11472784|NCT01543698|Experimental|dual combination|LGX818 QD and MEK162 BID
11472785|NCT01543698|Experimental|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
11472786|NCT01543685|Experimental|Indomethacin 40 mg TID|
11472787|NCT01543685|Experimental|Indomethacin 40 mg BID|
11472788|NCT01543685|Experimental|Indomethacin 20 mg TID|
11472789|NCT01543685|Active Comparator|Celecoxib 200 mg|
11472790|NCT01543685|Placebo Comparator|Placebo|
11472791|NCT01543672|Experimental|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
11472792|NCT01543672|Experimental|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
11472793|NCT01543659|Experimental|89Zr-DFO-huJ591|Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
11472794|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
11472795|NCT01543633|Experimental|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
11472796|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
11472797|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
11472798|NCT01543607|Experimental|Treatment|Radiofrequency ablation catheter
11472799|NCT01543581|Active Comparator|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
11472800|NCT01543581|Placebo Comparator|Inactive placebo|Those to whom the inactive placebo is given.
11472801|NCT01543568|Other|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly & given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
11472802|NCT01543555|Experimental|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
11472803|NCT01543555|Placebo Comparator|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
11472804|NCT01543542|Other|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
11472805|NCT01543529|Active Comparator|RO4917838 + non-alcoholic drink|
11472806|NCT01543529|Experimental|RO4917838 + alcohol|
11472807|NCT01543529|Placebo Comparator|RO4917838 placebo + alcohol|
11472808|NCT01543529|Placebo Comparator|RO4917838 placebo + non-alcoholic drink|
11472809|NCT01543516||Patients with Asthma|"Affected patients
~-20 Patients suffering from asthma with an eNO over 30 bbp"
11472810|NCT01543516||Healthy Subjects|"Non-affected patients
~-20 matched controls not suffering from asthma"
11472811|NCT01543503||Cohort|
11472812|NCT01543490|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
11472813|NCT01543490|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
11472814|NCT01543477||Single group|
11472815|NCT01543464|Experimental|Vaccine+adjuvants+temozolomide treatment|Experimental arm
11472816|NCT01543451|Experimental|Elsiglutide|
11472817|NCT01543451|Placebo Comparator|Placebo|
11472818|NCT01543438|No Intervention|Control|current standard of care
11472819|NCT01543438|Experimental|Intervention Group|receives video prescription
11472820|NCT01543412|Experimental|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
11472821|NCT01543399|Experimental|Tibolone use|climacteric women will use Tibolone for 30 days
11472822|NCT01543399|Placebo Comparator|Placebo use|climacteric women will use placebo for 30 days
11472823|NCT01543386|Other|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
11472824|NCT01543373|Experimental|CRE8 arm|
11472825|NCT01543373|Active Comparator|Vision/Multilik8 arm|
11472826|NCT01543360|Active Comparator|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
11472827|NCT01543360|Active Comparator|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
11472828|NCT01543347|Experimental|Temocillin|Treatment group
11472862|NCT01543139|Experimental|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
11472829|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
11472830|NCT01543321|Experimental|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
11472831|NCT01543321|Placebo Comparator|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
11472832|NCT01543308||coronary heart disease|
11472833|NCT01543308||healthy control group|
11472834|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
11472835|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
11472836|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.
~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
11472837|NCT01543282|Active Comparator|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
11472838|NCT01543282|Experimental|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
11472839|NCT01543269|Active Comparator|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
11472840|NCT01543269|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
11472841|NCT01543256|Active Comparator|Metal stents|The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
11472842|NCT01543256|Active Comparator|Plastic Stents|Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
11472843|NCT01543243|Experimental|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)
~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
11472844|NCT01543243|Experimental|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)
~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
11472845|NCT01543230|Experimental|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
11472846|NCT01543217|Active Comparator|Control|Ususal care.
11472847|NCT01543217|Active Comparator|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
11472848|NCT01543204|Experimental|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
11472849|NCT01543191|Experimental|PUR118|
11472850|NCT01543191|Placebo Comparator|Placebo|
11472851|NCT01543178|Experimental|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.
~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
11472852|NCT01543178|Experimental|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
11472853|NCT01543178|Placebo Comparator|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
11472854|NCT01543165|Experimental|Group 1|Sequential intravenous administration of ketorolac and nefopam
11472855|NCT01543165|Active Comparator|Group 2|Sequential intravenous administration of ketorolac and morphine
11472856|NCT01543165|Placebo Comparator|Group 3|Intravenous administration of ketorolac
11472857|NCT01543152|Experimental|Cohort 1 - IV cyclophosphamide 200 mg|
11472858|NCT01543152|Experimental|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
11472859|NCT01543152|Experimental|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
11472860|NCT01543152|Experimental|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
11472861|NCT01543152|Experimental|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
11472863|NCT01543139|Active Comparator|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
11472864|NCT01543139|Active Comparator|Valproate|The subjects with bipolar depression, treated with valproate
11472865|NCT01543126||pleural effusion|patients with pleural effusion
11472866|NCT01543113|Other|melanoma|melanoma
11472867|NCT01543100|Experimental|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.
~Patient's age ≥18 yo,
~Patients having signed the specific consent of the study."
11472868|NCT01543087|Other|One group of subjects|
11472869|NCT01543074|Placebo Comparator|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
11472870|NCT01543074|Active Comparator|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
11472871|NCT01543074|Active Comparator|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
11472872|NCT01543074|Active Comparator|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
11472873|NCT01543061|Active Comparator|New study eye drop|One month of contact lens wear with use of the Test study eye drops
11472874|NCT01543061|Placebo Comparator|No Eyedrop|One month of contact lens wear with no eye drop use
11472875|NCT01543061|Active Comparator|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
11472876|NCT01543048||Women with CIN3 treated by conization|
11472877|NCT01543035|Experimental|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
11472878|NCT01543022|Experimental|Symphony system|
11472879|NCT01543009|No Intervention|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
11472880|NCT01543009|Experimental|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
11472881|NCT01542983|Active Comparator|Treatment-as-usual|Treatment as usual for fatigue and insomnia
11472882|NCT01542983|Active Comparator|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
11472883|NCT01542970|Placebo Comparator|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
11472884|NCT01542970|Experimental|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
11472885|NCT01542970|Experimental|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
11472886|NCT01542970|Experimental|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
11472887|NCT01542957|Experimental|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
11472888|NCT01542957|Active Comparator|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
11472889|NCT01542944|Experimental|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
11472890|NCT01542931|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
11472891|NCT01542931|Experimental|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
11472892|NCT01542918|Experimental|Study intervention|Lenalidomide Plus Rituximab
11472893|NCT01542905|Experimental|Korean Red Ginseng|
11472894|NCT01542905|Placebo Comparator|Placebo|
11472895|NCT01542892|Experimental|Supplement|
11472896|NCT01542892|Sham Comparator|Placebo|
11472897|NCT01542892|Experimental|Exercise|
11472898|NCT01542879|Experimental|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18-F FDG PET scan
11472899|NCT01542866|Experimental|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
11472900|NCT01542827|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
11472901|NCT01542827|Experimental|Biofreeze|Biofreeze topical gel containing 3.5% menthol
11472902|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
11472903|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
11472904|NCT01542801|Active Comparator|Norfloxacin|norfloxacin 400 mg once daily administration
11472905|NCT01542801|Experimental|Ciprofloxacin|Ciprofloxacin 750 mg per week
11472906|NCT01542788|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
11472907|NCT01542788|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
11472908|NCT01542775|Placebo Comparator|Control|
11472909|NCT01542775|Active Comparator|Exercise|
11472910|NCT01542762|Experimental|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
11472911|NCT01542762|No Intervention|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
11472912|NCT01542736|Experimental|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
11472913|NCT01542723|Experimental|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
11472914|NCT01542723|No Intervention|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
11472915|NCT01542710|Experimental|Glaucoma fixed Combination Medications|
11472916|NCT01542697|Active Comparator|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
11472917|NCT01542697|Placebo Comparator|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
11472964|NCT01542385|Active Comparator|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
11477379|NCT01512095|Experimental|Norditropin®|
11472918|NCT01542684|Experimental|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m^2, daily for 4 days.
~GM-CSF administered IV or subcutaneously at 250 mcg/m^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
~Each treatment cycle will last at least 4 weeks"
11472919|NCT01542671|Experimental|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
11472920|NCT01542671|Placebo Comparator|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
11472921|NCT01542658||uterine myoma|
11472922|NCT01542645|Experimental|Methadone|Long-acting opioid
11472923|NCT01542645|Active Comparator|Fentanyl|Shorter-acting opioid
11472924|NCT01542632|Experimental|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
11472925|NCT01542632|Experimental|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
11472926|NCT01542632|Experimental|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
11472927|NCT01542632|Experimental|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
11472928|NCT01542632|Experimental|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
11472929|NCT01542632|Experimental|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
11472930|NCT01542619|Experimental|rVIIa-FP|
11472931|NCT01542619|Placebo Comparator|Placebo (0.9% normal saline)|
11472932|NCT01542606|Experimental|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
11472933|NCT01542593|Experimental|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.
~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
11472934|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
11472935|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
11472936|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
11472937|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
11472938|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
11472939|NCT01542567|Active Comparator|diclofenac|suppositories to prevent BCG side effects
11472940|NCT01542567|Placebo Comparator|placebo suppositories|
11472941|NCT01542554|Experimental|Low glycaemic index diet|
11472942|NCT01542554|Active Comparator|Usual diabetic diet|
11472943|NCT01542541|Experimental|Rifaximin|
11472944|NCT01542541|No Intervention|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
11472945|NCT01542528|Experimental|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
11472946|NCT01542528|No Intervention|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
11472947|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
11472948|NCT01542502|Experimental|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
11472949|NCT01542502|Placebo Comparator|Placebo|Treatment with daily subcutaneous injection of placebo
11472950|NCT01542489||IDet + IAsp users|
11472951|NCT01542489||IDet + HI users|
11472952|NCT01542476||IDet users|
11472953|NCT01542463||IDet users|
11472954|NCT01542450|Experimental|Treatment period 1|
11472955|NCT01542450|Active Comparator|Treatment period 2|
11472956|NCT01542437|Experimental|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
11472957|NCT01542424||BIAsp 30 users|
11472958|NCT01542424||IDet users|
11472959|NCT01542411||recurrent pregnancy loss|
11472960|NCT01542411||thrombophilia, aspirin|
11472961|NCT01542411||heparin|
11472962|NCT01542398|Experimental|Family-Focused Psychosocial Intervention|Intervention Group
11472963|NCT01542398|No Intervention|Waiting List Control|
11472965|NCT01542385|Experimental|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
11472966|NCT01542372|Active Comparator|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
11472967|NCT01542372|Active Comparator|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
11472968|NCT01542359|Experimental|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
11472969|NCT01542359|Active Comparator|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
11472970|NCT01542346|Experimental|wound closure with subcutaneous adaption|
11472971|NCT01542320|Experimental|Probiotic|Lactobacillus reuteri DSM 17938
11472972|NCT01542320|Placebo Comparator|Placebo|Solution without the active probiotic Lactobacillus reuteri
11472973|NCT01542307|Experimental|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
11472974|NCT01542307|Placebo Comparator|Room Air|Medical air inhaled for 30 minutes during migraine attack
11472975|NCT01542294|Experimental|treatment|s1+oxaliplatin
11472976|NCT01542281|Experimental|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
11472977|NCT01542281|Active Comparator|Prehab exercise|
11472978|NCT01542268|Active Comparator|pentoxifylline|
11472979|NCT01542268|Placebo Comparator|pentoxifylline placebo|
11472980|NCT01542255|Experimental|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.
~Schema of treatment is:
~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
11472981|NCT01542242|Experimental|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
11472982|NCT01542229|Experimental|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
11472983|NCT01542229|Active Comparator|Arm 2: Usual Treatment|Treatment As Usual
11472984|NCT01542216|Placebo Comparator|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
11472985|NCT01542216|Active Comparator|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
11472986|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).
11472987|NCT01542190|Active Comparator|ketorolac tromethamine|
11472988|NCT01542190|Placebo Comparator|Dextrano 70 / Hypromellose|
11472989|NCT01542177||Pancreatic cancer|
11472990|NCT01542151|Active Comparator|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
11472991|NCT01542151|Experimental|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
11472992|NCT01542138|Active Comparator|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
11472993|NCT01542138|Active Comparator|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
11472994|NCT01542138|Placebo Comparator|Placebo|Humectant placebo cream
11472995|NCT01542125|Experimental|Liposomal Lidocaine group|Patients in this groups received 4% Liposomal Lidocaine that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing
11472996|NCT01542125|Placebo Comparator|Placebo Group|This group received a placebo that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing.
11472997|NCT01542112|Experimental|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.
~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
11472998|NCT01542112|Experimental|No treament|Usual routine in the department
11472999|NCT01542099|Active Comparator|Single lumen tube|Single lumen tube intubation during remifentanil infusion
11473000|NCT01542099|Active Comparator|Double lumen tube|Double lumen tube intubation during remifentanil infusion
11473001|NCT01542086|Active Comparator|Myocardial SPECT|
11473002|NCT01542086|Experimental|64-channel coronary CT angiography (CCTA)|
11473003|NCT01542073|Experimental|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
11473004|NCT01542060||BIAsp 30 users|
11473005|NCT01542047|Experimental|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
11473006|NCT01542034|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11473598|NCT01537757|Experimental|Part 2, Panel C - Moderate Renal Impairment Group|
11473007|NCT01542034|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11473008|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 4± 1|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy
11473009|NCT01542021|Experimental|Untreated patients degarelix injection occur at days and 7± 1.|Treatment will consist of a single 240 mg injection of degarelix 7±1 day before radical prostatectomy
11473010|NCT01542021|Experimental|treated patients with androgen deprivation|Patients already treated with androgen deprivation are assigned to Cohort 3 and maintained on current androgen deprivation therapy until they undergo or have already undergone RP at MSKCC. Will include patients who have already undergone hormonal therapy (of any duration between 1 and 6 months) prior to prostatectomy.
11473011|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 14±1|Treatment will consist of a single 240 mg injection of degarelix 14±1 day before radical prostatectomy
11473012|NCT01542008|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
11473013|NCT01542008|Active Comparator|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
11473014|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
11473015|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
11473016|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
11473017|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
11473018|NCT01541969|Experimental|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
11473019|NCT01541969|Active Comparator|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
11473020|NCT01541956|Active Comparator|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
11473021|NCT01541956|Experimental|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
11473022|NCT01541943|Experimental|HL-040XC|Once daily, administered orally, 8 week
11473023|NCT01541943|Active Comparator|Atorvastatin|Once daily, administered orally, 8 week
11473024|NCT01541943|Active Comparator|Losartan|Once daily, administered orally, 8 week
11473025|NCT01541943|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
11473026|NCT01541930|Experimental|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
11473027|NCT01541917|Experimental|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
11473028|NCT01541917|Active Comparator|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
11473029|NCT01541904|Experimental|Arm A. PRO-118/Placebo 0.015%,0.020%|
11473030|NCT01541904|Experimental|Arm B. PRO-118/Placebo 0.015%,0.020%|
11473031|NCT01541904|Experimental|Arm C. PRO-118/Placebo 0.015%,0.020%|
11473032|NCT01541904|Experimental|Arm D. PRO-118/Placebo 0.015%,0.020%|
11473033|NCT01541904|Placebo Comparator|Arm E PRO-118/Placebo 0.015%,0.020%|
11473034|NCT01541891|Experimental|PRO-148 Ophthalmic Solution|Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
11473035|NCT01541891|Active Comparator|Arm B. SYSTANE® Ophthalmic Solution|Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
11473036|NCT01541865|Other|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
11473037|NCT01541852|Active Comparator|Losmapimod|7.5mg tablet twice daily
11473038|NCT01541852|Placebo Comparator|Placebo|One tablet twice daily
11473039|NCT01541839|Experimental|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
11473040|NCT01541839|No Intervention|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
11473041|NCT01541826|Placebo Comparator|Color-matched rice powder pill|Color-matched rice powder pill
11473042|NCT01541826|Active Comparator|Chokeberry extract capsule|Chokeberry extract capsule
11473043|NCT01541826|Experimental|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
11473044|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
11473045|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
11473046|NCT01541774|Experimental|Phoenix Atherectomy System|
11473047|NCT01541761|Experimental|Family groups|Intervention group members will participate in family groups focused on early childhood obesity prevention in addition to standard care from pediatricians at the primary care clinic.
11473048|NCT01541761|No Intervention|Standard care|Mothers enrolled into the control group will continue to receive care from their pediatrician in the primary care clinic.
11473049|NCT01541748||AXIS Allograft Dermis|Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.
11473050|NCT01541735|Placebo Comparator|Placebo|Placebo of calcined magnesia, capsules
11473051|NCT01541735|Experimental|Pantoprazole|The pantoprazole will be administered in 40mg capsules
11473052|NCT01541709|Experimental|Imatinib|
11473053|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
11473054|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
11477380|NCT01512095|Active Comparator|Nutropin AQ®|
11473055|NCT01541683|Experimental|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
11473056|NCT01541683|Other|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
11473057|NCT01541670|Experimental|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
11473058|NCT01541657|No Intervention|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
11473059|NCT01541657|Experimental|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
11473060|NCT01541657|Experimental|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
11473061|NCT01541657|Experimental|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
11473062|NCT01541644|Experimental|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
11473063|NCT01541631|Experimental|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
11473064|NCT01541631|No Intervention|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
11473065|NCT01541631|Experimental|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
11473066|NCT01541631|No Intervention|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
11473067|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
11473068|NCT01541605|Active Comparator|methylphenidate|
11473069|NCT01541605|Placebo Comparator|placebo|
11473070|NCT01541592|Active Comparator|Saturated fat|Palm oil (rich in the saturated fat palmitate)
11473071|NCT01541592|Active Comparator|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
11473072|NCT01541592|Active Comparator|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
11473073|NCT01541579|Experimental|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
11473074|NCT01541579|Placebo Comparator|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
11473075|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
11473076|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
11473077|NCT01541553|Active Comparator|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
11473078|NCT01541553|Placebo Comparator|Vehicle gel|Cryotherapy followed by vehicle gel
11473079|NCT01541540|Experimental|e-Counseling plus Usual Care|
11473080|NCT01541540|Active Comparator|e-Info Control plus Usual Care|
11473081|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
11473082|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
11473083|NCT01541488|Experimental|BI 1021958|Single rising dose (SRD) part
11473084|NCT01541488|Experimental|BI 1021958 (Food effect)|Food effect part (FE)
11473085|NCT01541488|Placebo Comparator|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
11473086|NCT01541475|Experimental|Escitalopram + Bupropion|
11473087|NCT01541475|Active Comparator|Escitalopram|
11473445|NCT01538927|Experimental|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
11473088|NCT01541462|Active Comparator|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
11473089|NCT01541462|Active Comparator|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
11473090|NCT01541449||RA patients treated with plaquenil|
11473091|NCT01541449||Patients who do not use plaquenil|
11473092|NCT01541436|Active Comparator|Capsaicin, UV-B, RIPC|
11473093|NCT01541436|Sham Comparator|Capsaicin, UV-B|
11473094|NCT01541397|No Intervention|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
11473095|NCT01541397|Experimental|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
11473096|NCT01541384|Experimental|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
11473097|NCT01541384|Experimental|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
11473098|NCT01541384|Other|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
11473099|NCT01541371|Experimental|Paliperidone ER|
11473100|NCT01541358|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
11473101|NCT01541345|Active Comparator|Control Group (A)|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland). These course of action is well documented in the literature and standard procedures.
11473102|NCT01541345|Experimental|Test group (B)|The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group. In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
11473103|NCT01541332|Experimental|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
11473104|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
11473105|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
11473106|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
11473107|NCT01541319||Healthy volunteers|
11473108|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
11473109|NCT01541293|Experimental|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
11473110|NCT01541293|Placebo Comparator|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
11473111|NCT01541267|Active Comparator|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
11473112|NCT01541267|Active Comparator|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
11473113|NCT01541267|Active Comparator|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
11473114|NCT01541254|Other|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
11473115|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.
~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
11473116|NCT01541228|Active Comparator|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
11473117|NCT01541228|Active Comparator|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
11473118|NCT01541215|Experimental|Lira + Met|
11473119|NCT01541215|Placebo Comparator|Placebo + Met|
11473120|NCT01541202|Placebo Comparator|Placebo|placebo in addition to standard therapy
11473121|NCT01541202|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
11473122|NCT01541189|Experimental|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
11473123|NCT01541176|Experimental|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
11473124|NCT01541176|Active Comparator|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
11473125|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
11473599|NCT01537757|Experimental|Part 2, Panel D - Healthy Control Group to Match Panel C|
11473126|NCT01541150|Active Comparator|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
11473127|NCT01541150|Placebo Comparator|control group|This group is the placebo comparator
11473128|NCT01541137|Active Comparator|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
11473129|NCT01541137|Active Comparator|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
11473130|NCT01541137|Active Comparator|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
11473131|NCT01541124|Experimental|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
11473132|NCT01541111|Other|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
11473133|NCT01541098|Active Comparator|Licensed Plasma|
11473134|NCT01541098|Experimental|Lyophilized Plasma|
11473135|NCT01541085||Darunavir/Ritonavir (DRV/r)|
11473136|NCT01541085||Efavirenz (EFV)|
11473137|NCT01541072|Experimental|Pegfilgrastim|
11473138|NCT01541072|Active Comparator|Filgrastim|
11473139|NCT01541059|Placebo Comparator|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
11473140|NCT01541059|Experimental|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
11473141|NCT01541046|Experimental|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
11473142|NCT01541046|Placebo Comparator|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
11473143|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
11473144|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
11473145|NCT01541033||Control|Typically developing children
11473146|NCT01541020||Healthy individuals|
11473147|NCT01541020||Individuals with low back pain|
11473148|NCT01541007|Active Comparator|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
11473149|NCT01541007|Experimental|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
11473150|NCT01540994|Experimental|SBRT|Stereotactic Body Radiation Therapy
11473151|NCT01540981|Active Comparator|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
11473152|NCT01540981|Active Comparator|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
11473153|NCT01540968|Experimental|Nutrition & physical exercise|
11473154|NCT01540968|No Intervention|Control|
11473155|NCT01540955|Experimental|Group Intervention program|
11473156|NCT01540955|No Intervention|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
11473157|NCT01540942|Active Comparator|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
11473158|NCT01540942|Active Comparator|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
11473159|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
11473160|NCT01540916|Experimental|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
11473161|NCT01540916|Experimental|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
11473162|NCT01540903|Experimental|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
11473163|NCT01540903|Experimental|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
11473164|NCT01540903|Placebo Comparator|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
11473165|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
11473166|NCT01540890||opioids|patients on opioid medication without withdrawal
11473167|NCT01540890||opioid-free|patients with chronic pain without opioid medication
11473168|NCT01540877|Experimental|Capsaicin application|application of 0.6%
11473169|NCT01540877|Experimental|Local anesthetics application|application of EMLA
11473170|NCT01540877|Experimental|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
11473171|NCT01540877|Experimental|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
11473172|NCT01540864|Experimental|HPP404 35 mg|
11473173|NCT01540864|Experimental|HPP404 50 mg|
11473174|NCT01540864|Placebo Comparator|Placebo|
11473175|NCT01540851|Active Comparator|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
11473176|NCT01540851|Active Comparator|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
11473177|NCT01540838|Experimental|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
11473178|NCT01540838|Active Comparator|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
11473179|NCT01540825|Experimental|BI 113608 high dose 1|Powder for oral solution
11473180|NCT01540825|Experimental|BI 113608 low dose 1|Powder for oral solution
11473181|NCT01540825|Experimental|BI 113608 low dose 2|Powder for oral solution
11473182|NCT01540825|Experimental|BI 113608 low dose 4|Powder for oral solution
11473183|NCT01540825|Experimental|BI 113608 low dose 5|Powder for oral solution
11473184|NCT01540825|Experimental|BI 113608 medium dose 1|Powder for oral solution
11473185|NCT01540825|Experimental|BI 113608 medium dose 2|Powder for oral solution
11473186|NCT01540825|Experimental|BI 113608 medium dose 3|Powder for oral solution
11473187|NCT01540825|Experimental|BI 113608 high dose 2|Powder for oral solution
11473188|NCT01540825|Experimental|BI 113608 high dose 3|Powder for oral solution
11473189|NCT01540825|Placebo Comparator|Placebo|Powder for oral solution
11473190|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
11473191|NCT01540799|Experimental|Treatment|
11473192|NCT01540799|Other|Other|Stimulation not able to be felt
11473193|NCT01540786|Experimental|Part 1: OAB subjects|
11473194|NCT01540786|Experimental|Part 2: Healthy subjects|
11473195|NCT01540786|Experimental|Part 2: OAB subjects|
11473196|NCT01540773|Active Comparator|amino acid supplement|supplements with the proprietary amino acid derivative blend.
11473197|NCT01540773|Placebo Comparator|Placebo|Non-Active
11473198|NCT01540760|Experimental|MCAF5352A|
11473199|NCT01540760|Placebo Comparator|Placebo|
11473200|NCT01540747|Experimental|Inofolic plus|178 patients
11473201|NCT01540747|Active Comparator|Inofolic|180 patients
11473202|NCT01540734|Active Comparator|Marketed paracetamol|marketed formulation
11473203|NCT01540734|Experimental|Experimental paracetamol formulation|Experimental formulation
11473204|NCT01540721|Experimental|Experimental paracetamol formulation|Experimental formulation
11473205|NCT01540721|Active Comparator|Marketed paracetamol|Marketed formulation
11473206|NCT01540708|Experimental|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
11473207|NCT01540708|Active Comparator|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
11473208|NCT01540669|Active Comparator|Polydextrose, low dose|Polydextrose, low dose
11473209|NCT01540669|Active Comparator|Polydextrose, medium dose|Polydextrose, medium dose
11473210|NCT01540669|Active Comparator|Polydextrose, high dose|Polydextrose, high dose
11473211|NCT01540669|Placebo Comparator|Placebo powder|Placebo powder
11473212|NCT01540656|Active Comparator|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
11473213|NCT01540656|Active Comparator|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
11473214|NCT01540643||Abdominal aortic aneurysm|
11473215|NCT01540630|Experimental|CNV1014802|
11473216|NCT01540630|Placebo Comparator|Placebo|
11473217|NCT01540617||Persons with low back pain|
11473218|NCT01540617||Healthy persons|
11473219|NCT01540604|Experimental|CRD007 10 mg tablet|
11473220|NCT01540591|Placebo Comparator|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
11473221|NCT01540591|Experimental|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
11473222|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
11473223|NCT01540565|Experimental|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11473224|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
11473225|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
11473226|NCT01540539|Experimental|Dosing cohort 1|
11473227|NCT01540539|Experimental|Dosing cohort 2|
11473228|NCT01540539|Experimental|Dosing cohort 3|
11473229|NCT01540539|Experimental|Dosing cohort 4|
11473230|NCT01540539|Experimental|Dosing cohort 5|
11473231|NCT01540539|Experimental|Dosing cohort 6|
11473232|NCT01540539|Experimental|Dosing cohort 7|
11473233|NCT01540539|Experimental|Dosing cohort 8|
11473234|NCT01540526|Experimental|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
11473267|NCT01540266|Active Comparator|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
11473268|NCT01540266|Experimental|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
11473235|NCT01540526|Experimental|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
11473236|NCT01540513|Experimental|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
11473237|NCT01540500|Experimental|Steady State PK Group|
11473238|NCT01540487|Experimental|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
11473239|NCT01540487|Experimental|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
11473240|NCT01540474|Experimental|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
11473241|NCT01540474|Experimental|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
11473242|NCT01540474|Experimental|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
11473243|NCT01540461|Experimental|Arm: Brivanib|
11473244|NCT01540448|Active Comparator|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
11473245|NCT01540448|Experimental|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
11473246|NCT01540435|No Intervention|Postoperative Arm (Arm A)|"FOLFOX:
~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)
~Duration of treatment:
~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
11473247|NCT01540435|Experimental|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.
~FOLFOXIRI + bevacizumab:
~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)
~Duration of treatment:
~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
11473248|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
11473249|NCT01540409|Experimental|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
11473250|NCT01540396|Active Comparator|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
11473251|NCT01540396|Active Comparator|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
11473252|NCT01540383|Experimental|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
11473253|NCT01540383|Other|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
11473254|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
11473255|NCT01540357|Active Comparator|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
11473256|NCT01540357|Active Comparator|Treatment after waiting time|Treatment was performed after completion of the active arm.
11473257|NCT01540344|Experimental|Treatment Arm|"FOLFOX/FOLFIRI + cetuximab (6 cycles)
~CRS and HIPEC
~FOLFOX/FOLFIRI + cetuximab (6 cycles)"
11473258|NCT01540331|Experimental|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
11473259|NCT01540318|Experimental|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
11473260|NCT01540318|No Intervention|No Abdominal Ultrasound|
11473261|NCT01540305|Active Comparator|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
11473262|NCT01540305|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
11473263|NCT01540292|Experimental|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
11473264|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
11473265|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
11473266|NCT01540266|Experimental|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
11473446|NCT01538927|Placebo Comparator|Suture|The surgically elevated flap is closed with non resorbable sutures.
11473269|NCT01540266|Active Comparator|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
11473270|NCT01540266|Experimental|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
11473271|NCT01540266|Active Comparator|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
11473272|NCT01540253|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11473273|NCT01540240|Active Comparator|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
11473274|NCT01540240|Active Comparator|low dosage zidovudine|
11473275|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
11473276|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
11473277|NCT01540201|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
11473278|NCT01540201|Experimental|1:1 group|inspiratory time : expiratory time = 1:1
11473279|NCT01540188|No Intervention|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
11473280|NCT01540188|Experimental|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.
~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
11473281|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
11473282|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
11473283|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
11473284|NCT01540149||ICD implant|
11473285|NCT01540136|Experimental|Nedaplatin|Nedplatin combine with IMRT
11473286|NCT01540136|Active Comparator|Cisplatin|Cisplatin combine with IMRT
11473287|NCT01540123|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
11473288|NCT01540123|Experimental|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
11473289|NCT01540110|Experimental|Docetaxel + cyclophosphamide|
11473290|NCT01540084|Active Comparator|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
11473291|NCT01540084|Experimental|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
11473292|NCT01540071|Experimental|NRX 194204|
11473293|NCT01540058|Experimental|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
11473294|NCT01540058|Active Comparator|Empiric strategy|Gemcitabine/Cisplatin
11473295|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
11473296|NCT01540032|No Intervention|Control|
11473297|NCT01540032|Experimental|Diet|
11473298|NCT01540019|Experimental|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
11473299|NCT01539993||1|
11473300|NCT01539980|Experimental|Sericin scaffold|
11473301|NCT01539954||Youth 9-18 years of age|
11473302|NCT01539941|Experimental|Medication Integration Protocol|
11473303|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
11473304|NCT01539915|Experimental|BCT194|
11473305|NCT01539902|Experimental|Human Umbilical Cord derived MSCs|
11473306|NCT01539902|Placebo Comparator|Cyclophosphamide|
11473307|NCT01539889|Experimental|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
11473308|NCT01539876|Other|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
11473309|NCT01539863|Experimental|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
11473310|NCT01539863|Active Comparator|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
11473311|NCT01539837|Placebo Comparator|Placebo|Drug excipient
11473312|NCT01539837|Active Comparator|Deferiprone 20mg|20mg/kg/day deferiprone
11473313|NCT01539837|Active Comparator|Deferiprone 30mg|30mg/kg/day Deferiprone
11473365|NCT01539447|Active Comparator|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
11473366|NCT01539447|Placebo Comparator|Placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
11473314|NCT01539824|Experimental|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
11473315|NCT01539811|Active Comparator|Short course antibiotics|Surgical intervention followed by short course of antibiotics (<2 weeks)
11473316|NCT01539811|Active Comparator|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (>2 weeks)
11473317|NCT01539798|Experimental|Oral Saline|Ingestion of 0.9% saline solution
11473318|NCT01539798|Active Comparator|Intravenous Saline|Intravenous infusion of 0.9% saline solution
11473319|NCT01539785|Active Comparator|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
11473320|NCT01539785|Experimental|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
11473321|NCT01539772||Becker|"BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.
~."
11473322|NCT01539759|No Intervention|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
11473323|NCT01539759|Experimental|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
11473324|NCT01539746|Experimental|TAVI without predilation|
11473325|NCT01539746|Active Comparator|Standard TAVI procedure|
11473326|NCT01539733|Experimental|Olanzapine|
11473327|NCT01539733|Active Comparator|Haloperidol|
11473328|NCT01539720|Experimental|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
11473329|NCT01539720|Active Comparator|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
11473330|NCT01539707|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 5 mg of solifenacin succinate.
11473331|NCT01539707|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
11473332|NCT01539694|Experimental|LD118033 contact lens|Investigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
11473333|NCT01539694|Active Comparator|PureVision multifocal contact lens|PureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
11473334|NCT01539681||Group 1|
11473335|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
11473336|NCT01539655|Experimental|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
11473337|NCT01539655|Experimental|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
11473338|NCT01539655|Experimental|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
11473339|NCT01539655|Experimental|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
11473340|NCT01539642|Experimental|Sufentanil NanoTab PCA System/15 mcg|
11473341|NCT01539642|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
11473342|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
11473343|NCT01539616|Experimental|ZYH7 4mg|ZYH7 4mg
11473344|NCT01539616|Experimental|ZYH7 8mg|ZYH7 8mg
11473345|NCT01539616|Experimental|ZYH7 16mg|ZYH7 16mg
11473346|NCT01539616|Active Comparator|Fenofibrate 160mg|Fenofibrate 160mg
11473347|NCT01539603|Experimental|DEB-BMS|Drug eluting balloon + Bare metal stent
11473348|NCT01539603|Active Comparator|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
11473349|NCT01539590|Experimental|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
11473350|NCT01539590|Placebo Comparator|Normal Saline|Daily intravenous administration for four (4) days
11473351|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
11473352|NCT01539564|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
11473353|NCT01539564|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
11473354|NCT01539551||1|sepsis and septic shock patients
11473355|NCT01539538|Experimental|Sufentanil NanoTab PCA System/15 mcg|
11473356|NCT01539538|Active Comparator|morphine IV PCA|
11473357|NCT01539525|Experimental|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
11473358|NCT01539525|Active Comparator|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
11473359|NCT01539525|Placebo Comparator|Treatment as Usual|No intervention- resource list provided.
11473360|NCT01539512|Active Comparator|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
11473361|NCT01539512|Placebo Comparator|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
11473362|NCT01539473|Experimental|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
11473363|NCT01539473|Placebo Comparator|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
11473364|NCT01539460|Experimental|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
11473367|NCT01539434|Experimental|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
11473368|NCT01539434|Active Comparator|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
11473369|NCT01539421|Experimental|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
11473370|NCT01539408|Active Comparator|Misoprostol|400 mcg of sublingual misoprostol in one dose
11473371|NCT01539408|Active Comparator|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
11473372|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
11473373|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
11473374|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
11473375|NCT01539382|Experimental|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
11473376|NCT01539382|No Intervention|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
11473377|NCT01539369|Experimental|High fibre diet|
11473378|NCT01539369|Active Comparator|Healthy eating diet|
11473379|NCT01539356||preterm infants|"preterm infants receiving blood transfusion
~preterm infants with neonatal sepsis."
11473380|NCT01539343|Experimental|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
11473381|NCT01539317|Active Comparator|Topical liquid lidocaine|
11473382|NCT01539317|Placebo Comparator|Topical Saline|
11473383|NCT01539304|Experimental|CITUS Dry Syrup|Pranlukast dry syrup 10%
11473384|NCT01539304|Placebo Comparator|Placebo|Placebo
11473385|NCT01539291|Experimental|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
11473386|NCT01539291|Experimental|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
11473387|NCT01539278|Active Comparator|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
11473388|NCT01539278|Experimental|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
11473389|NCT01539265|Experimental|silodosin, arm 1|
11473390|NCT01539265|Experimental|silodosin, arm 2|
11473391|NCT01539265|Placebo Comparator|placebo|
11473392|NCT01539252|Active Comparator|Single dialyzer|Single dialyzer
11473393|NCT01539252|Experimental|Double dialyzer|Two dialyzers in parallel
11473394|NCT01539239|Experimental|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
11473395|NCT01539239|Active Comparator|Cataract Surgery (Control)|Cataract surgery only
11473396|NCT01539226|Placebo Comparator|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
11473397|NCT01539226|Experimental|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
11473398|NCT01539213|Experimental|AIN457|secukinumab (AIN457)
11473399|NCT01539200|Placebo Comparator|Control|
11473400|NCT01539200|Active Comparator|Oral Nutritional Supplement (ONS) and JDR|
11473401|NCT01539187|Experimental|VizAblate intervention|VizAblate System with subject serving as her own control
11473402|NCT01539174|Experimental|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11473403|NCT01539161|Experimental|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
11473404|NCT01539161|Active Comparator|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
11473405|NCT01539135|Active Comparator|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
11473406|NCT01539135|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
11473407|NCT01539122|Active Comparator|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
11473409|NCT01539109|Experimental|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
11473410|NCT01539109|Sham Comparator|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
11473411|NCT01539096|Sham Comparator|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
11473412|NCT01539096|Experimental|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
11473413|NCT01539083|Experimental|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
11473414|NCT01539083|Experimental|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
11473415|NCT01539083|Experimental|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
11473416|NCT01539070|Experimental|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
11473417|NCT01539070|No Intervention|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
11473418|NCT01539057|Experimental|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
11473419|NCT01539057|Placebo Comparator|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
11473420|NCT01539044|Active Comparator|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
11473421|NCT01539044|Experimental|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
11473422|NCT01539031|Experimental|10 mg group|
11473423|NCT01539031|Active Comparator|23 mg group|
11473424|NCT01539018|Active Comparator|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
11473425|NCT01539018|Experimental|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
11473426|NCT01538992|Experimental|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
11473427|NCT01538992|No Intervention|medical thrapy|medical treatment
11473428|NCT01538979|Experimental|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
11473429|NCT01538979|Experimental|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
11473430|NCT01538979|Placebo Comparator|Placebo|7 subcutaneous injections over a time span of two pollen seasons
11473431|NCT01538966|Active Comparator|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly
~Octreotide LAR 30mg
~Lanreotide 120mg
~Weekly Pegviosmant (40-120mg/week)"
11473432|NCT01538966|Active Comparator|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly
~Octreotide LAR 10mg
~Lanreotide 60mg
~Daily Pegviosmant (15-60mg/day)"
11473433|NCT01538966|Active Comparator|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly
~Octreotide LAR 10mg
~Lanreotide 60mg
~Weekly Pegviosmant (40-120mg/week)"
11473434|NCT01538953|Experimental|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
11473435|NCT01538953|Experimental|handwashing and water treatment|
11473436|NCT01538953|Experimental|Water treatment with sodium hypochlorite|
11473437|NCT01538953|Experimental|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
11473438|NCT01538953|No Intervention|Control|
11473439|NCT01538940|Active Comparator|HIV+, CD4<200, ID vaccine|
11473440|NCT01538940|Active Comparator|HIV+, CD4<200, IM vaccine|
11473441|NCT01538940|Active Comparator|HIV+, CD4>=200, ID vaccine|
11473442|NCT01538940|Active Comparator|HIV+, CD4 >=200, IM vaccine|
11473443|NCT01538940|Other|HIV-, ID vaccine|
11473444|NCT01538940|Other|HIV-, IM vaccine|
11473447|NCT01538914|Experimental|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
11473448|NCT01538914|Active Comparator|PCA|Postoperatve pain is controlled with intravenous PCA.
11473449|NCT01538901|Experimental|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann & Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
11473450|NCT01538901|Active Comparator|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
11473451|NCT01538888|Experimental|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
11473452|NCT01538875|Experimental|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
11473453|NCT01538875|Active Comparator|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
11473454|NCT01538862|Experimental|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
11473455|NCT01538849|Experimental|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
11473456|NCT01538849|Experimental|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
11473457|NCT01538849|Experimental|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
11473458|NCT01538849|Experimental|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
11473459|NCT01538849|Active Comparator|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
11473460|NCT01538836|No Intervention|Weight maintenance|Weight maintenance with normal protein intake
11473461|NCT01538836|Active Comparator|Weight loss with normal protein intake|
11473462|NCT01538836|Experimental|Weight loss with protein supplementation|
11473463|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
11473464|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
11473465|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
11473466|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
11473467|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
11473468|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
11473469|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
11473470|NCT01538771|Placebo Comparator|Control group|Received same volume of saline
11473471|NCT01538771|Active Comparator|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning & conventional treatment
11473472|NCT01538758|Active Comparator|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.
~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
11473473|NCT01538758|Active Comparator|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
11473474|NCT01538745|Experimental|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
11473475|NCT01538745|Active Comparator|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
11473476|NCT01538719|Placebo Comparator|Placebo|2:1 randomization
11473477|NCT01538719|Active Comparator|Rilonacept|2:1 randomization
11473478|NCT01538706|Experimental|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
11473479|NCT01538693|Active Comparator|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
11473480|NCT01538693|Active Comparator|cyproheptadine|exercise testing with cyproheptadine dose
11473481|NCT01538693|Placebo Comparator|placebo|exercise testing with placebo dose
11473482|NCT01538667|Experimental|Arm 1|
11473483|NCT01538667|Experimental|Arm 2|
11473484|NCT01538667|Experimental|Arm 3|
11473485|NCT01538667|Experimental|Arm 4|
11473486|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
11473487|NCT01538641|Experimental|1|
11473488|NCT01538628|Experimental|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
11473572|NCT01537926|Placebo Comparator|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
11473489|NCT01538628|No Intervention|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
11473490|NCT01538615|Experimental|HOME Plus Intervention|described below
11473491|NCT01538615|No Intervention|Control|Control participants receive a monthly newsletter for the 10 months of the study with tips on healthy eating. The topics do not overlap the intervention content.
11473492|NCT01538602||PCOS patients|
11473493|NCT01538602||Healthy volunteers|
11473494|NCT01538589||Insulin aspart users|
11473495|NCT01538576||Insulin aspart users|
11473496|NCT01538550|Experimental|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
11473497|NCT01538550|Experimental|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
11473498|NCT01538511|Experimental|BIAsp 70|
11473499|NCT01538511|Experimental|BIAsp 30|
11473500|NCT01538485|Experimental|Cholecalciferol|
11473501|NCT01538472|Experimental|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.
~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L."
11473502|NCT01538459|Active Comparator|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
11473503|NCT01538459|Experimental|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
11473504|NCT01538446|Experimental|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
11473505|NCT01538446|Active Comparator|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
11473506|NCT01538433||biopsy-proven IgA nephropathy|
11473507|NCT01538420|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
11473508|NCT01538420|Placebo Comparator|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
11473509|NCT01538407|No Intervention|Control group|No intervention group
11473510|NCT01538407|Active Comparator|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
11473511|NCT01538394|Experimental|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:
~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)
~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
11473512|NCT01538394|Placebo Comparator|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:
~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)
~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
11473513|NCT01538381|Experimental|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
11473514|NCT01538381|Other|Observation|No treatment only observation
11473515|NCT01538355|Experimental|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
11473516|NCT01538355|Experimental|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
11473517|NCT01538355|Experimental|Control diet|Patients stay on their regular diet.
11473518|NCT01538342|Other|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
11473519|NCT01538342|Other|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
11473520|NCT01538342|Other|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
11473521|NCT01538342|Other|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
11473522|NCT01538342|Other|healthy patients|1 biopsy of healthy skin.
11473523|NCT01538329|Experimental|Amantadine|Patients with amantadine
11473524|NCT01538329|Placebo Comparator|Placebo|Patients with amantadine placebo
11473525|NCT01538316|Active Comparator|Quercetin supplement|
11473526|NCT01538316|Active Comparator|Genistein supplement|
11473527|NCT01538316|Placebo Comparator|Placebo|
11473528|NCT01538303||measurement absolute flow and resistance|
11473529|NCT01538277|Experimental|Contact Force arm|the real-time contact force will be known to the operator
11473530|NCT01538277|Active Comparator|Standard|Standard ablation arm
11473531|NCT01538251|Experimental|Propionyl-L-carnitine|modified release tablets 500 mg
11473532|NCT01538251|Placebo Comparator|Placebo|Modified release tablet 500 mg
11473533|NCT01538238|Experimental|pazopanib|pazopanib 800mg qd
11473534|NCT01538225|Experimental|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
11473573|NCT01537900|Experimental|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
11473535|NCT01538225|Experimental|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
11473536|NCT01538199|Experimental|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
11473537|NCT01538199|Sham Comparator|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
11473538|NCT01538186||PCI without treating the side branch|
11473539|NCT01538186||PCI with treating the side branch|
11473540|NCT01538173|Experimental|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
11473541|NCT01538173|Active Comparator|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
11473542|NCT01538147||Cases|Patients with Severe preeclampsia
11473543|NCT01538147||Control|Patients with normal pregnancies at term
11473544|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
11473545|NCT01538134||Control|Patients with normal pregnancies at term.
11473546|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
11473547|NCT01538121||Controls|Patients with normal pregnancies at term.
11473548|NCT01538108|Experimental|NMB's PTA Balloon catheter with paclitaxel|
11473549|NCT01538108|Active Comparator|Standard Angioplasty Balloon|
11473550|NCT01538095|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11473551|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
11473552|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
11473553|NCT01538069|No Intervention|Control group|
11473554|NCT01538069|Experimental|Exercise group|
11473555|NCT01538069|Experimental|CPAP group|
11473556|NCT01538069|Experimental|Exercise and CPAP group|
11473557|NCT01538056|Experimental|Fenestrated procedure|Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
11473558|NCT01538043|Active Comparator|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
11473559|NCT01538043|No Intervention|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
11473560|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
11473561|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
11473562|NCT01538017|Active Comparator|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
11473563|NCT01538017|Active Comparator|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
11473564|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
11473565|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
11473566|NCT01537991|Experimental|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
11473567|NCT01537991|Experimental|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
11473568|NCT01537991|Experimental|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
11473569|NCT01537978|Experimental|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
11473570|NCT01537939|Other|Walking|Quasi-experimental design with one-group, post-test only
11473571|NCT01537926|Experimental|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
11477381|NCT01512082|Experimental|Active pulsed electromagnetic field|
11473574|NCT01537887|Placebo Comparator|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
11473575|NCT01537887|Experimental|1200 milligrams (mg) LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
11473576|NCT01537887|Active Comparator|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14-day washout period.
11473577|NCT01537874|Experimental|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
11473578|NCT01537874|Other|Usual Best Practices|Standard care delivered using informational materials
11473579|NCT01537861|Experimental|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.
~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.
~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.
~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
11473580|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
11473581|NCT01537835|No Intervention|Standard Scrubs|Participants will be randomized to one of three types of uniforms. This arm is the standard scrub arm. The participants will wear new standard scrubs.
11473582|NCT01537835|Experimental|Antimicrobial Scrubs 1|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
11473583|NCT01537835|Experimental|Antimicrobial Scrubs 2|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
11473584|NCT01537822|Experimental|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
11473585|NCT01537822|Active Comparator|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
11473586|NCT01537809|Active Comparator|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
11473587|NCT01537809|Active Comparator|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
11473588|NCT01537809|Active Comparator|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
11473589|NCT01537796|Experimental|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
11473590|NCT01537796|Experimental|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
11473591|NCT01537796|Experimental|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
11473592|NCT01537783|Experimental|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
11473593|NCT01537783|No Intervention|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
11473594|NCT01537770|Active Comparator|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
11473595|NCT01537770|Sham Comparator|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
11473596|NCT01537757|Experimental|Part 1, Panel A - Severe Renal Impairment Group|
11473597|NCT01537757|Experimental|Part 1, Panel B - Healthy Control Group to Match Panel A|
11473600|NCT01537757|Experimental|Part 2, Panel E - Mild Renal Impairment Group|
11473601|NCT01537757|Experimental|Part 2, Panel F - Healthy Control Group to Match Panel E|
11473602|NCT01537744|Experimental|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
11473603|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
11473604|NCT01537718|Experimental|REPLY 200 implanted patients|REPLY 200 implanted patients
11473605|NCT01537705|Experimental|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
11473606|NCT01537692|Experimental|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
11473607|NCT01537692|Experimental|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
11473608|NCT01537692|Active Comparator|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
11473609|NCT01537679|Other|Meditation Intervention|
11473610|NCT01537679|Other|Relaxation Intervention|
11473611|NCT01537666|Experimental|Aerovanc 16 mg in healthy volunteers|
11473612|NCT01537666|Experimental|AeroVanc 32 mg in healthy volunteers|
11473613|NCT01537666|Experimental|AeroVanc 80 mg in healthy volunteers|
11473614|NCT01537666|Active Comparator|IV vancomycin in healthy volunteers|
11473615|NCT01537666|Experimental|AeroVanc 32 mg in CF patients|
11473616|NCT01537666|Experimental|AeroVanc 80 mg in CF patients|
11473617|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 4|Dose Level 4
11473618|NCT01537653|Placebo Comparator|Placebo|Placebo
11473619|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 1|Dose Level 1
11473620|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 2|Dose Level 2
11473621|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 3|Dose Level 3
11473622|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
11473623|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
11473624|NCT01537627|Active Comparator|Low-intensity training (LT)|
11473625|NCT01537627|Active Comparator|High-intensity training (HT)|
11473626|NCT01537614|Experimental|COLIMYCINE injectable|
11473627|NCT01537614|Experimental|COLIMYCINE inhalation|
11473628|NCT01537601|Other|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
11473629|NCT01537601|Experimental|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
11473630|NCT01537588|Active Comparator|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
11473631|NCT01537588|Experimental|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
11473632|NCT01537588|No Intervention|Normal matched|
11473633|NCT01537575|Placebo Comparator|saline solution|
11473634|NCT01537575|Experimental|intravenous immunoglobulins|
11473635|NCT01537562|Active Comparator|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
11473636|NCT01537562|Active Comparator|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
11473637|NCT01537549|Experimental|Juvenon|
11473638|NCT01537536|Experimental|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
11473639|NCT01537523|Experimental|community-care program|receive intervention for 12 weeks
11473640|NCT01537523|No Intervention|control|
11473641|NCT01537510|Active Comparator|Usual Care|
11473642|NCT01537510|Experimental|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
11473643|NCT01537510|Experimental|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
11473644|NCT01537497|Experimental|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
11473645|NCT01537497|Experimental|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
11473646|NCT01537497|Experimental|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
11473647|NCT01537497|Placebo Comparator|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
11473648|NCT01537484|Experimental|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
11473649|NCT01537484|Active Comparator|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
11473650|NCT01537484|Other|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
11473651|NCT01537471|Other|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
11473688|NCT01537185|Experimental|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
11473652|NCT01537471|Experimental|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
11473653|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
11473654|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
11473655|NCT01537432|Placebo Comparator|placebo|placebo
11473656|NCT01537432|Experimental|secukinumab|secukinumab
11473657|NCT01537419|Active Comparator|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
11473658|NCT01537419|Experimental|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
11473659|NCT01537393|Other|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
11473660|NCT01537393|Other|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
11473661|NCT01537380|Experimental|Cefazoline|
11473662|NCT01537367|Experimental|Enhanced contact only|"Patients allocated to the Enhanced contact only arm will receive:
~HIV information and education
~Specific to importance of coming to care regularly
~Generic and tailored components
~Approximately 10 minutes in length
~Enhanced contact over time
~Collect locator information
~Follow-up contact after medical visit (face-to-face or phone)
~Appointment reminders (telephone, e-mail, text message)
~Periodic telephone contact across time (support, update locator info, refer any unmet needs to Case Manager)
~Attempt to make immediate contact following a missed visit and re-schedule appointment (use locator contact info)"
11473663|NCT01537367|Experimental|Enhanced contact plus behavioral skills|Enhanced contact plus behavioral skills is the longer experimental intervention arm.
11473664|NCT01537367|Active Comparator|Standard of Care|Patients assigned to control arm will receive the standard services offered to all patients at the clinic.
11473665|NCT01537354|Active Comparator|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
11473666|NCT01537354|Active Comparator|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
11473667|NCT01537341|Active Comparator|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
11473668|NCT01537341|Experimental|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
11473669|NCT01537328|Experimental|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
11473670|NCT01537328|Active Comparator|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
11473671|NCT01537315|Placebo Comparator|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
11473672|NCT01537315|Experimental|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
11473673|NCT01537302|Experimental|Treatment arm|
11473674|NCT01537289|Experimental|Pigtail catheter|
11473675|NCT01537289|Active Comparator|Traditional chest tube|28-French chest tube
11473676|NCT01537276|Experimental|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
11473677|NCT01537276|No Intervention|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
11473678|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
11473679|NCT01537250|Active Comparator|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
11473680|NCT01537250|Active Comparator|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
11473681|NCT01537250|Active Comparator|Levofloxacin 500 mg|Levofloxacin 500 mg
11473682|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
11473683|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
11473684|NCT01537224|Other|neurostimulation|
11473685|NCT01537211|Experimental|Microprocessor knee then Mechanical knee|
11473686|NCT01537211|Experimental|Mechanical Knee then Microprocessor knee|
11473687|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
11473689|NCT01537185|Experimental|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
11473690|NCT01537185|Experimental|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
11473691|NCT01537185|Placebo Comparator|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart
~normal saline injection: 3 cohorts of normal saline injection"
11473692|NCT01537172|Experimental|ONO-4053|E Experimental Intervention Drug: ONO-4053
11473693|NCT01537172|Placebo Comparator|Placebo|
11473694|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
11473695|NCT01537146|Active Comparator|Femoral Block|
11473696|NCT01537146|Active Comparator|Local Infiltration Anagesia|
11473697|NCT01537133|Experimental|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
11473698|NCT01537133|Placebo Comparator|Placebo|Placebo fluticasone (one puff, twice a day)
11473699|NCT01537133|No Intervention|Healthy Control|
11473700|NCT01537133|No Intervention|Atopic Non-asthmatics|
11473701|NCT01537120|Experimental|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
11473702|NCT01537107|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11473703|NCT01537094|Active Comparator|Vitamin C low dose|vitamin C 250 mg oral once daily
11473704|NCT01537094|Active Comparator|Vitamin C high dose|vitamin C 1,000 mg oral once daily
11473705|NCT01537094|Placebo Comparator|Placebo|Placebo oral once daily
11473706|NCT01537081|Experimental|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
11473707|NCT01537081|Active Comparator|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
11473708|NCT01537081|Placebo Comparator|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
11473709|NCT01537068|Experimental|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
11473710|NCT01537068|Placebo Comparator|Placebo|Placebo treatment
11473711|NCT01537055|Experimental|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
11473712|NCT01537055|Active Comparator|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
11473713|NCT01537042|Experimental|Rotigotine|"Rotigotine Transdermal Patch
~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
11473714|NCT01537042|Placebo Comparator|Placebo|Transdermal patch matched according to patch size and appearance.
11473715|NCT01537029|Experimental|Doxorubicin and cyclophosphamide|
11473716|NCT01537016|Experimental|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
11473717|NCT01537016|Experimental|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
11473718|NCT01537016|Active Comparator|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
11473719|NCT01537016|Active Comparator|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
11473720|NCT01537003|Experimental|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
11473721|NCT01537003|Active Comparator|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
11473722|NCT01537003|Active Comparator|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
11473723|NCT01537003|Experimental|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
11473724|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
11473725|NCT01536977|Experimental|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
11473726|NCT01536964|Experimental|Morphine|the effect of morphine on prasugrel absorption will be tested
11473727|NCT01536964|Placebo Comparator|Saline|
11473728|NCT01536951|Placebo Comparator|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
11473729|NCT01536951|Experimental|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.
~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
11473730|NCT01536951|Active Comparator|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
11477382|NCT01512082|Sham Comparator|Non-active pulsed electromagnetic field|
11473731|NCT01536938|Active Comparator|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.
~Applied once daily for up to 4 weeks"
11473732|NCT01536938|Active Comparator|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)
~Applied once daily for up to 4 weeks"
11473733|NCT01536938|Experimental|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
~Applied once daily for up to 4 weeks"
11473734|NCT01536886|Placebo Comparator|LEO 90100 vehicle|Aerosol foam with no active ingredient
11473735|NCT01536886|Active Comparator|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
11473736|NCT01536886|Experimental|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
11473737|NCT01536886|Placebo Comparator|Ointment vehicle|Ointment with no active ingredients
11473738|NCT01536860|Placebo Comparator|Control Test Drink|control drink
11473739|NCT01536860|Experimental|Experimental Test Drink 1|control drink containing ingredient 1
11473740|NCT01536860|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
11473741|NCT01536847|Placebo Comparator|Control Test Drink|Control drink
11473742|NCT01536847|Experimental|Experimental Test Drink 1|Control drink containing ingredient 1
11473743|NCT01536847|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
11473744|NCT01536834|Experimental|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
11473745|NCT01536808|Experimental|Type 2 Diabetes Mellitus|
11473746|NCT01536795|Experimental|WR279396 with Tegaderm dressing|24 patients will be randomly allocated to WR279396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
11473747|NCT01536795|Experimental|WR279 396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
11473748|NCT01536782|Active Comparator|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
11473749|NCT01536782|Active Comparator|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
11473750|NCT01536782|Active Comparator|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
11473751|NCT01536769||Parkinson patients|Parkinson patients, symptom onset > 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
11473752|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
11473753|NCT01536756|Experimental|Exercise Intervention -- Physical Rehabilitation Program|
11473754|NCT01536756|Other|Wait List Control Group|
11473755|NCT01536743|Experimental|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.
~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
11473756|NCT01536730|Experimental|Homework Intervention Strategy|
11473757|NCT01536730|No Intervention|Control|
11473758|NCT01536717|Active Comparator|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
11473759|NCT01536717|Placebo Comparator|Sodium chloride 0,9%|
11473760|NCT01536704|Experimental|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
11473761|NCT01536704|Experimental|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
11473762|NCT01536704|Active Comparator|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
11473763|NCT01536704|Active Comparator|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
11473764|NCT01536691|Experimental|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
11473765|NCT01536691|Active Comparator|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
11473766|NCT01536678|Active Comparator|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
11478096|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
11473767|NCT01536678|Active Comparator|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
11473768|NCT01536665|Experimental|Low|
11473769|NCT01536665|Experimental|Medium|
11473770|NCT01536665|Experimental|High|
11473771|NCT01536652||BIAsp 30 users|
11473772|NCT01536639||BIAsp 30 users|
11473773|NCT01536626||BIAsp 30 users|
11473774|NCT01536613||BIAsp 30 users|
11473775|NCT01536600||BIAsp 30 users|
11473776|NCT01536587|Other|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
11473777|NCT01536574|Experimental|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
11473778|NCT01536561|Experimental|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
11473779|NCT01536548|Experimental|Skin drawing|
11473780|NCT01536548|Active Comparator|No skin drawing|
11473781|NCT01536535|Experimental|Mild UC|"Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) < 45
~Patients can be treated with any of the therapies noted below:
~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value
~IV corticosteroids:
~Additional Therapies:
~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.
~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy"
11473782|NCT01536535|Experimental|Moderate to Severe UC|"Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45
~Patients can be treated with any of the therapies noted below:
~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value
~IV corticosteroids:
~Additional Therapies:
~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.
~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy"
11473783|NCT01536522|Active Comparator|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
11473784|NCT01536522|Placebo Comparator|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
11473785|NCT01536522|Active Comparator|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
11473786|NCT01536522|Active Comparator|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
11473787|NCT01536509|Experimental|Telehealth Behavioral Treatment|
11473788|NCT01536509|Active Comparator|Education Only|
11473789|NCT01536496|Active Comparator|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
11473790|NCT01536496|Active Comparator|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
11473791|NCT01536483|Experimental|Butyrate|"New born with a birth weight <1000g: Seven enemas of butyrate will be performed every 2 days from PND5
~New born with a birth weight >1000g: Seven enemas of butyrate will be performed every day from PND5"
11473792|NCT01536483|No Intervention|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
11473793|NCT01536470|Experimental|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
11473794|NCT01536470|Experimental|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
11473795|NCT01536444|Experimental|Micrografting|
11473796|NCT01536431|Experimental|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
11473797|NCT01536431|Active Comparator|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
11473798|NCT01536431|Placebo Comparator|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
11473799|NCT01536418|Experimental|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
11473800|NCT01536418|Experimental|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
11473801|NCT01536405|Experimental|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
11473802|NCT01536405|Active Comparator|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
11473803|NCT01536392|Experimental|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
11473804|NCT01536392|Experimental|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
11473805|NCT01536379|Experimental|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
11473806|NCT01536379|Placebo Comparator|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
11473807|NCT01536366|Experimental|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
11473808|NCT01536366|Experimental|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
11473809|NCT01536353|Experimental|AGSAV301|
11473810|NCT01536353|Active Comparator|Exforge 10/160|
11473811|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
11473812|NCT01536301|Active Comparator|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
11473813|NCT01536301|Experimental|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
11473814|NCT01536288|Active Comparator|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
11473815|NCT01536288|Active Comparator|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
11473816|NCT01536275|No Intervention|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
11473817|NCT01536275|Experimental|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
11473818|NCT01536262|Other|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
11473819|NCT01536262|Other|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
11473820|NCT01536262|Other|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
11473821|NCT01536249|Experimental|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
11473822|NCT01536249|Experimental|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
11473823|NCT01536236|Active Comparator|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
11473824|NCT01536236|Placebo Comparator|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
11473825|NCT01536236|Active Comparator|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
11473826|NCT01536223|Active Comparator|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
11473827|NCT01536223|Experimental|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
11473828|NCT01536210|Experimental|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)
~1T/Three times a day(Tid) for 8 weeks, PO medication"
11473829|NCT01536210|Placebo Comparator|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
11473830|NCT01536197||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
11473831|NCT01536197||Gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
11473832|NCT01536197||Sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy surgery
11473833|NCT01536184|Experimental|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
11473834|NCT01536184|No Intervention|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
11473835|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
11473836|NCT01536158|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
11473837|NCT01536158|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
11473838|NCT01536145|Experimental|Single agent CP-751,871|dose escalation design
11473839|NCT01536132|Active Comparator|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
11473840|NCT01536132|Placebo Comparator|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
11473841|NCT01536119|Experimental|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
11473842|NCT01536119|No Intervention|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
11473843|NCT01536106|Experimental|Treatment|Implantation of bone marrow derived mononuclear cells
11473844|NCT01536106|Placebo Comparator|Placebo Control|Infusion of autologous peripheral blood
11473845|NCT01536093|Experimental|Colostrum|oropharyngeal administration of own mother's colostrum
11473846|NCT01536093|Placebo Comparator|Placebo|oropharyngeal administration of sterile water
11473847|NCT01536080||Reflux esophagitis (RE)|
11473848|NCT01536080||Non-erosive reflux disease (NERD)|
11473849|NCT01536080||Functional heartburn (FH)|
11473850|NCT01536067|Experimental|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
11473851|NCT01536054|Experimental|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
11473852|NCT01536041|Experimental|Experimental 200 mg dose|
11473853|NCT01536041|Experimental|Experimental 20 mg dose|
11473854|NCT01536041|Active Comparator|Active Comparator Montelukast|
11473855|NCT01536041|Placebo Comparator|Placebo Comparator|
11473856|NCT01536028|Active Comparator|BIAsp 30|
11473857|NCT01536028|Experimental|BIAsp 50|
11473858|NCT01536028|Experimental|BIAsp 70|
11473859|NCT01536028|Active Comparator|IAsp|
11473860|NCT01536015|Experimental|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
11473861|NCT01536015|Placebo Comparator|Placebo|Placebo patch.
11473862|NCT01536002|Experimental|Pharmacokinetics|Propofol pharmacokinetics
11473863|NCT01535989|Experimental|intravenous|dose escalation
11473864|NCT01535976|Placebo Comparator|Placebo|.9 normal saline infusion
11473865|NCT01535976|Active Comparator|Ketamine|Infusion of ketamine
11473866|NCT01535963||cutaneous surgery|Patients undergoing cutaneous surgery
11473867|NCT01535950|Experimental|LFG316|
11473868|NCT01535950|Sham Comparator|Sham|
11473869|NCT01535937|Experimental|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
11473870|NCT01535937|Active Comparator|midazolam|0.025 mg/kg IV over 40 minutes
11473871|NCT01535924|Experimental|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11473872|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
11473873|NCT01535885|Experimental|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
11473874|NCT01535872|Experimental|DHEA treatment|
11473875|NCT01535872|No Intervention|No treatment|
11473876|NCT01535859|Experimental|Cabergoline|
11473877|NCT01535859|Placebo Comparator|Placebo|
11473878|NCT01535846|Experimental|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
11473879|NCT01535846|No Intervention|Control|
11473880|NCT01535833|Other|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
11473881|NCT01535820|Experimental|Treatment sequence AB|
11473882|NCT01535820|Experimental|Treatment sequence BA|
11473883|NCT01535807|Active Comparator|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique."
11473884|NCT01535807|No Intervention|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
11473885|NCT01535794||18-26 year old men who have sex with men|
11473886|NCT01535781|Placebo Comparator|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
11473887|NCT01535781|Active Comparator|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
11473888|NCT01535768|Experimental|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
11473889|NCT01535768|No Intervention|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.
~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
11473890|NCT01535755|Active Comparator|protocol group|This group patients are weaned as the protocol which the investigators described.
11473891|NCT01535755|Other|clinicians' order group|This group patients are weaned as the clinicians' order.
11473892|NCT01535742|Experimental|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
11473893|NCT01535742|Experimental|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
11473894|NCT01535742|Experimental|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
11473895|NCT01535742|Experimental|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
11473896|NCT01535729||Cohort|
11473897|NCT01535716|Experimental|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
11473898|NCT01535716|Active Comparator|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
11473899|NCT01535690|Experimental|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
11473900|NCT01535677|Experimental|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
11473901|NCT01535677|Experimental|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
11473902|NCT01535677|Experimental|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
11473903|NCT01535677|Experimental|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
11473904|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
11473905|NCT01535651|Experimental|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
11473906|NCT01535651|No Intervention|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
11473907|NCT01535638|Active Comparator|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
11473908|NCT01535638|Active Comparator|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
11473909|NCT01535638|Active Comparator|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
11473910|NCT01535625|Other|Momo stent|Patients with PCI
11473911|NCT01535612|Experimental|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
11473912|NCT01535599|Experimental|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
11473913|NCT01535599|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
11473914|NCT01535586|Active Comparator|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
11473915|NCT01535586|Active Comparator|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
11473916|NCT01535573|Active Comparator|Citalopram low dose|Citalopram 20 mg
11473917|NCT01535573|Active Comparator|Citalopram high dose|Citalopram 40 mg
11473918|NCT01535573|Placebo Comparator|Placebo|Placebo
11473919|NCT01535560|Experimental|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
11473920|NCT01535560|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
11473921|NCT01535547|Experimental|isavuconazole and tacrolimus|
11473922|NCT01535521|Other|SPT in patients with MAD|
11473923|NCT01535508|Experimental|Liquid Vitamin D|
11473924|NCT01535495|Experimental|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
11473925|NCT01535495|Experimental|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
11473926|NCT01535482|Experimental|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
11473927|NCT01535482|Active Comparator|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
11473928|NCT01535469|Experimental|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
11473929|NCT01535456|Experimental|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
11473930|NCT01535443|Experimental|Bromfenac|Drug: Bromfenac ophthalmic solution 1 drop 4 times per day
11473931|NCT01535417|Experimental|GCSB|
11473932|NCT01535417|Active Comparator|Celebrex|
11473933|NCT01535404|Active Comparator|Right ventricular apex pacing|
11473934|NCT01535404|Experimental|Left ventricular apex pacing|
11473935|NCT01535365|Active Comparator|Heat|Application of Heat pad to site of muscle sprain.
11473936|NCT01535365|Active Comparator|Cold|Application of ice pack to muscle sprain.
11473937|NCT01535352|Experimental|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
11473938|NCT01535352|Active Comparator|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
11473939|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
11473940|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
11473941|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
11473942|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
11473943|NCT01535326|Placebo Comparator|air insufflation|Use air insufflation during colonoscopy
11473944|NCT01535326|Active Comparator|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
11473945|NCT01535326|Active Comparator|water exchange|infuse and remove water during insertion phase of colonoscopy
11473946|NCT01535313|Active Comparator|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
11473947|NCT01535313|Experimental|Powered|
11473948|NCT01535300||Elective pediatric surgery|
11473949|NCT01535287|Active Comparator|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
11473950|NCT01535287|Placebo Comparator|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
11473951|NCT01535274|Experimental|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
11473952|NCT01535274|Experimental|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
11473953|NCT01535261|Experimental|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
11473954|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
11473955|NCT01535235|Active Comparator|ACE Inhibitor|Active group
11473956|NCT01535235|Placebo Comparator|Placebo|Placebo group
11473957|NCT01535222|Experimental|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
11473958|NCT01535222|Experimental|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
11473959|NCT01535222|Experimental|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
11473960|NCT01535222|Experimental|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
11473961|NCT01535222|Experimental|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
11473962|NCT01535222|Placebo Comparator|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
11473963|NCT01535209|Experimental|SBRT to resection cavity|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
11473964|NCT01535209|Active Comparator|WBRT|30Gy in 10 fractions over 12 days to whole brain
11473965|NCT01535196|Experimental|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
11473966|NCT01535196|Placebo Comparator|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
11473967|NCT01535183|Experimental|Irinotecan|
11473968|NCT01535170|Experimental|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.
~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
11473969|NCT01535170|Placebo Comparator|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
11473970|NCT01535157|Experimental|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
11473971|NCT01535144|Experimental|degradable metallic device|
11473972|NCT01535144|Active Comparator|non-degradable metallic device|
11473973|NCT01535131|Active Comparator|Furlow palatoplasty|standard procedure
11473974|NCT01535131|Experimental|modified Furlow palatoplasty|standard procedure plus modification
11474248|NCT01533259|Experimental|Stribild|Participants will switch to Stribild for 48 weeks.
11473975|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
11473976|NCT01535105||Obese Adolescents|
11473977|NCT01535092|Experimental|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
11473978|NCT01535092|Placebo Comparator|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
11473979|NCT01535079|Placebo Comparator|Placebo|
11473980|NCT01535079|Experimental|V0498TA01A 15 mg|
11473981|NCT01535079|Experimental|V0498TA01A 25 mg|
11473982|NCT01535079|Experimental|V0498TA01A 35 mg|
11473983|NCT01535079|Other|Strefen|Positive control
11473984|NCT01535066|Experimental|Arm I|Patients receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
11473985|NCT01535066|Sham Comparator|Arm II|Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly for 6 weeks.
11473986|NCT01535066|No Intervention|Arm III|Patients are assigned to a waiting list for 12 weeks with standard follow-up care.
11473987|NCT01535053|Experimental|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
11473988|NCT01535053|Active Comparator|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
11473989|NCT01535040|Active Comparator|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
11473990|NCT01535040|Placebo Comparator|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
11473991|NCT01535027|Active Comparator|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
11473992|NCT01535027|Active Comparator|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
11473993|NCT01535027|Active Comparator|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
11473994|NCT01535014|Experimental|Dietressa (2 tablets 3 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
11473995|NCT01535014|Experimental|Dietressa (1 tablet 6 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
11473996|NCT01535014|Placebo Comparator|Placebo (2 tablets 3 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
11473997|NCT01535014|Placebo Comparator|Placebo (1 tablet 6 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
11473998|NCT01535001|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
11473999|NCT01535001|Active Comparator|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
11474000|NCT01534975|Active Comparator|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
11474001|NCT01534975|Active Comparator|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
11474002|NCT01534975|Active Comparator|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
11474003|NCT01534975|Active Comparator|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
11474004|NCT01534962|Experimental|Ranolazine low dose|Ranolazine, low dose, oral, BID
11474005|NCT01534962|Experimental|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
11474006|NCT01534962|Experimental|Ranolazin high dose|Ranolazine, high dose, oral, BID
11474007|NCT01534962|Placebo Comparator|Placebo|Placebo (sugar pill), oral, BID.
11474008|NCT01534949|Experimental|CT-P10|rituximab
11474009|NCT01534936||Schizophrenic outpatients with affective symptoms.|
11474010|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
11474011|NCT01534910|Placebo Comparator|Sugar pill|placebo
11474012|NCT01534910|Active Comparator|Aged Garlic Extract|2400 mg of aged garlic extract
11474013|NCT01534897|Experimental|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
11474014|NCT01534884|Active Comparator|MabThera|rituximab
11474015|NCT01534884|Active Comparator|CT-P10|rituximab
11474016|NCT01534871|Experimental|Exercise|Subjects enrolled in the exercise arm will receive the study intervention.
11474017|NCT01534871|No Intervention|Control|Subjects in the control arm will receive standard of care (e.g. medication and medical supervision) for rheumatoid arthritis. These subjects will not participate in the exercise intervention.
11474018|NCT01534858|Experimental|Partial and full thickness burns with split thickness grafts|
11474019|NCT01534845|No Intervention|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
11474139|NCT01534039|Active Comparator|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
11474020|NCT01534845|Active Comparator|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
11474021|NCT01534832|Experimental|Smoke clearance|Smoke clearance device active
11474022|NCT01534819||Protocol B, abdominal arm, revision group|AAA subjects with previously implanted commercial endografts for the treatment of graft migration and/or Type Ia endoleak
11474023|NCT01534819||Protocol B, abdominal arm, primary group|AAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.
11474024|NCT01534819||Protocol B, thoracic arm, revision group|TAA subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
11474025|NCT01534819||Protocol B, thoracic arm, primary group|TAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation
11474026|NCT01534819||Protocol B, advanced disease arm, revision group|Advanced disease subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
11474027|NCT01534819||Protocol B, advanced disease arm, primary group|Advanced disease subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation.
11474028|NCT01534819||Protocol C, abdominal arm, short neck, primary group|Planned use of Heli-FX™ in conjunction with the Endurant II/IIs endograft in AAA subjects with short proximal necks (≥ 4 mm and < 10 mm) in primary group.
11474029|NCT01534806|Experimental|ketorolac|
11474030|NCT01534806|Placebo Comparator|Placebo|Placebo IV push
11474031|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
11474032|NCT01534780|Experimental|fixation with Protack|
11474033|NCT01534780|Experimental|fixation with Securestrap|
11474034|NCT01534780|Experimental|fixation with Glubran|surgery
11474035|NCT01534754|Active Comparator|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
11474036|NCT01534754|Active Comparator|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
11474037|NCT01534754|Active Comparator|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
11474038|NCT01534754|Placebo Comparator|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
11474039|NCT01534741|Active Comparator|Dialyser|FX CorDiax 60 dialyzer
11474040|NCT01534741|Active Comparator|FXDialyser|FX 60 dialyzer
11474041|NCT01534715|Experimental|IMGN529|Dose escalation study, dosing done every 3 weeks.
11474042|NCT01534702|Experimental|Treatment|
11474043|NCT01534689|Experimental|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
11474044|NCT01534676|Active Comparator|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood <14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
11474045|NCT01534676|Experimental|Transfusion of Stored blood|The recipient will receive one or two units of old blood >28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
11474046|NCT01534676|Active Comparator|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
11474047|NCT01534676|Active Comparator|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood >28 days old, as per their chronic transfusion schedule - off chelation therapy.
11474048|NCT01534663|Placebo Comparator|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
11474049|NCT01534663|Active Comparator|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of DHA and L-alanyl-glutamine (8g/d).
11474050|NCT01534637|Experimental|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.
~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
11474051|NCT01534598|Experimental|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
11474052|NCT01534572|Experimental|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
11474053|NCT01534572|Experimental|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
11474054|NCT01534559|Experimental|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
11474055|NCT01534559|No Intervention|Control|Patients will receive the normal care provided by the hospital
11474056|NCT01534546|Active Comparator|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.
~capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
11474140|NCT01534026|Active Comparator|Aspirin|Current dose of aspirin for 12 weeks
11474057|NCT01534546|Experimental|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
~S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
11474058|NCT01534546|Experimental|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.
~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
11474059|NCT01534533|Placebo Comparator|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
11474060|NCT01534533|Experimental|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
11474061|NCT01534533|Experimental|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
11474062|NCT01534533|Experimental|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
11474063|NCT01534520|Experimental|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
11474064|NCT01534520|Placebo Comparator|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
11474065|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
11474066|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
11474067|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
11474068|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
11474069|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
11474070|NCT01534494|Experimental|psilocybin|
11474071|NCT01534481|Active Comparator|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
11474072|NCT01534481|Placebo Comparator|Preterm Formula|Preterm formula determined by center practice
11474073|NCT01534468|Experimental|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
11474074|NCT01534468|Experimental|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
11474075|NCT01534468|Experimental|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
11474076|NCT01534468|Experimental|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
11474077|NCT01534455|Experimental|Lapatinib + 1,23 mg Eribulin|
11474078|NCT01534455|Experimental|Lapatinib + 1,76 mg Eribulin|
11474079|NCT01534442|Active Comparator|Atropin|Atropin
11474080|NCT01534442|Placebo Comparator|Placebo|Saline
11474081|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
11474082|NCT01534416|Experimental|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
11474083|NCT01534416|Placebo Comparator|Saline|Subjects receive paracervical injection of normal saline
11474084|NCT01534403|Experimental|Epratuzumab 4x600 mg every 12 weeks Group|
11474085|NCT01534390|Experimental|Use of in-line microfilters|
11474086|NCT01534390|No Intervention|Standard therapy without the use of in-line microfilters|
11474087|NCT01534377|Experimental|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
11474088|NCT01534377|Experimental|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
11474089|NCT01534364|No Intervention|control|Ad libitum alimentation
11474090|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
11474091|NCT01534351|Experimental|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
11474092|NCT01534351|Active Comparator|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
11474093|NCT01534351|Experimental|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
11474094|NCT01534338|Experimental|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
11474141|NCT01534026|Experimental|Withdrawal arm|Withdrawal of aspirin for 12 weeks
11474142|NCT01534013|Experimental|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
11474371|NCT01532388|No Intervention|Control group|Untreated control group
11474095|NCT01534338|Active Comparator|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
11474096|NCT01534325|Experimental|Study arm|The Arm who uses the real study device Daily use of SD device
11474097|NCT01534325|Sham Comparator|Control Arm|Daily use of Sham comperator
11474098|NCT01534325|Experimental|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
11474099|NCT01534312|Experimental|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
11474100|NCT01534312|Active Comparator|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
11474101|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
11474102|NCT01534286|Active Comparator|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
11474103|NCT01534286|Placebo Comparator|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
11474104|NCT01534273|Placebo Comparator|Placebo|Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days
11474105|NCT01534273|Experimental|35 mg LY2886721|QD oral dosing for 14 consecutive days
11474106|NCT01534273|Experimental|70 mg LY2886721|Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days
11474107|NCT01534273|Experimental|140 mg LY2886721|Single oral dose
11474108|NCT01534260|Experimental|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
11474109|NCT01534247|Experimental|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
11474110|NCT01534247|Active Comparator|Metronidazole|Metronidazole (500 mg)
11474111|NCT01534247|Active Comparator|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
11474112|NCT01534234|Experimental|SonR group|SonR CRT Optimization
11474113|NCT01534234|Active Comparator|ECHO group|Echocardiographic Optimization
11474114|NCT01534221|Active Comparator|Study group two|Endeavor resolute drug eluting stent
11474115|NCT01534221|Active Comparator|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
11474116|NCT01534221|Active Comparator|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
11474117|NCT01534221|Active Comparator|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
11474118|NCT01534221|Active Comparator|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
11474119|NCT01534208|Experimental|Androxal 12.5 mg|Androxal 12.5 mg daily
11474120|NCT01534208|Experimental|Androxal 25 mg|Androxal 25 mg daily
11474121|NCT01534195|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
11474122|NCT01534195|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
11474123|NCT01534182|Experimental|Fingolimod|Participants received 0.5 mg orally once a day.
11474124|NCT01534182|Active Comparator|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
11474125|NCT01534169|Experimental|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
11474126|NCT01534143|Experimental|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.
~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
11474127|NCT01534130|Experimental|acupuncture|
11474128|NCT01534130|Sham Comparator|sham acupuncture|
11474129|NCT01534117|Active Comparator|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
11474130|NCT01534117|No Intervention|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
11474131|NCT01534104|Experimental|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
11474132|NCT01534091|Active Comparator|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
11474133|NCT01534091|Active Comparator|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
11474134|NCT01534091|No Intervention|Control group|Overweight & obese children not participating in an intervention.
11474135|NCT01534078|Experimental|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
11474136|NCT01534065|Experimental|Barricaid|CE Marked Device
11474137|NCT01534052|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
11474138|NCT01534039|Active Comparator|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
11474143|NCT01534013|Active Comparator|Open-loop (Control visit)|Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
11474144|NCT01534000|Active Comparator|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
11474145|NCT01534000|No Intervention|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
11474146|NCT01533987|Experimental|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
11474147|NCT01533987|Placebo Comparator|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD & C yellow #6.
11474148|NCT01533974|Experimental|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
11474149|NCT01533974|Active Comparator|CBT|
11474150|NCT01533961|Experimental|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
11474151|NCT01533961|Placebo Comparator|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
11474152|NCT01533948|Experimental|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11474153|NCT01533935|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
11474154|NCT01533935|Placebo Comparator|Placebo QD|placebo comparator for tiotropium + olodaterol
11474155|NCT01533935|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
11474156|NCT01533935|Experimental|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
11474157|NCT01533935|Experimental|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
11474158|NCT01533922|Experimental|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
11474159|NCT01533922|Experimental|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
11474160|NCT01533922|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
11474161|NCT01533922|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
11474162|NCT01533922|Placebo Comparator|Placebo QD|
11474163|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
11474164|NCT01533896|No Intervention|Control|Parents and children in the control group received routine primary care during the well child visit.
11474165|NCT01533896|Experimental|Grow Nicely|Grow Nicely multimedia program.
11474166|NCT01533870|Experimental|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
11474167|NCT01533870|Active Comparator|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
11474168|NCT01533870|Active Comparator|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
11474169|NCT01533857|Experimental|Black tea|black tea
11474170|NCT01533857|Placebo Comparator|placebo|
11474171|NCT01533844||Neonates|Neonates with CDAD
11474172|NCT01533818|Active Comparator|Amoxicillin|This is an active intervention
11474173|NCT01533818|Placebo Comparator|Sugar Syrup|
11474174|NCT01533805|Experimental|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
11474175|NCT01533805|Active Comparator|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
11474176|NCT01533792|Experimental|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
11474177|NCT01533792|Active Comparator|Control group|Control group received only supragingival scaling with OHO too.
11474178|NCT01533766|Experimental|CombiflexOmega|
11474179|NCT01533766|Active Comparator|SmofKabiven|
11474180|NCT01533753|Experimental|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
11474181|NCT01533753|Experimental|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
11474182|NCT01533727|Experimental|Group A|Autologous CIK Transfusion plus Chemotherapy
11474183|NCT01533727|Active Comparator|Group B|chemotherapy alone
11474184|NCT01533714|Experimental|Olokizumab 120 mg|Olokizumab 120 mg : subcutaneous injections at q2w (every two weeks).
11474185|NCT01533688|Active Comparator|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
11474186|NCT01533688|Placebo Comparator|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
11474187|NCT01533688|Experimental|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
11474188|NCT01533675|Experimental|Hydrogen peroxide|
11474189|NCT01533675|Active Comparator|Saline|
11474190|NCT01533662|Experimental|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
11474191|NCT01533662|Placebo Comparator|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
11474192|NCT01533649|Experimental|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
11474193|NCT01533649|Experimental|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
11474194|NCT01533649|No Intervention|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
11474195|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
11474196|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
11474197|NCT01533623|Other|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
11474198|NCT01533597|Active Comparator|Solifenacin|
11474199|NCT01533597|Experimental|Solifenacin plus Tamsulosin|
11474200|NCT01533571|Active Comparator|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
11474201|NCT01533571|Active Comparator|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
11474202|NCT01533558||caspofungin|caspofungin dosing
11474203|NCT01533545|Active Comparator|Plain mepivacaine|
11474204|NCT01533545|Active Comparator|Mepivacaine with epinephrine|
11474205|NCT01533532|Experimental|KLH-2109, low dose|
11474206|NCT01533532|Experimental|KLH-2109, medium dose|
11474207|NCT01533532|Experimental|KLH-2109, high dose|
11474208|NCT01533532|Placebo Comparator|placebo|
11474209|NCT01533519|Experimental|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
11474210|NCT01533519|Experimental|placebo/NPY|This arm gets placebo (saline) first then NPY.
11474211|NCT01533493|Placebo Comparator|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
11474212|NCT01533493|Active Comparator|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
11474213|NCT01533480|Active Comparator|Zirgan, Adenovirus conjunctivitis,|Zirgan
11474214|NCT01533480|Placebo Comparator|genteal gel|0.3% Hypromellose gel (genteal gel)
11474215|NCT01533467|Other|Perineal device used|Use of the perineal device during delivery
11474216|NCT01533467|No Intervention|No intervention|Controls, delivered as normal
11474217|NCT01533454|No Intervention|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
11474218|NCT01533454|Experimental|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
11474219|NCT01533441|Placebo Comparator|placebo low VKA|
11474220|NCT01533441|Placebo Comparator|Placebo high VKA|Microcrystalline cellulose
11474221|NCT01533441|Active Comparator|Vitamin K2 Low VKA|
11474222|NCT01533441|Active Comparator|Vitamin K2 high VKA|
11474223|NCT01533428|Experimental|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
11474224|NCT01533428|Placebo Comparator|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
11474225|NCT01533415|Active Comparator|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
11474226|NCT01533415|Sham Comparator|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
11474227|NCT01533402|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
11474228|NCT01533402|Experimental|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
11474229|NCT01533389|Experimental|Silodosin|8mg QD
11474230|NCT01533389|Placebo Comparator|Placebo|8mg QD
11474231|NCT01533376|Experimental|Timolol|Participants in this group will receive topical timolol
11474232|NCT01533376|Placebo Comparator|Placebo|Participants in this group will receive Preservative free artificial tear gel.
11474233|NCT01533363|Active Comparator|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
11474234|NCT01533363|Active Comparator|Milligan Morgan|surgical procedure to treat hemorrhoids
11474235|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
11474236|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
11474237|NCT01533324|Experimental|S-1 combined with LV|S-1 combined with LV
11474238|NCT01533298|Experimental|CombiflexOmega peri|
11474239|NCT01533298|Active Comparator|SmofKabiven peripheral|
11474240|NCT01533285|Other|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered [Period 2]
11474241|NCT01533285|Other|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
11474242|NCT01533285|Other|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered [Period 2]
11474243|NCT01533285|Other|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
11474244|NCT01533285|Other|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered [Period 2]
11474245|NCT01533285|Other|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
11474246|NCT01533272|Experimental|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
11474247|NCT01533272|Active Comparator|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
11474249|NCT01533246|Experimental|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
11474250|NCT01533233|Experimental|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
11474251|NCT01533233|Active Comparator|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
11474252|NCT01533220|Experimental|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).
~02 drops in each nostril every 12 hours for 3 days"
11474253|NCT01533220|Active Comparator|Comparator group|"Naphazoline Hydrocloride (0.5mg)
~02 drops in each nostril every 12 hours for 3 days"
11474254|NCT01533207|Experimental|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
11474255|NCT01533207|Other|Arm II (no treatment)|Patients undergo clinical observation.
11474256|NCT01533194|Experimental|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11474257|NCT01533181|Experimental|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
11474258|NCT01533181|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
11474259|NCT01533155|Active Comparator|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
11474260|NCT01533155|Placebo Comparator|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
11474261|NCT01533155|Active Comparator|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
11474262|NCT01533155|Placebo Comparator|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
11474263|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
11474264|NCT01533142||Morbid obesity|
11474265|NCT01533129|Active Comparator|Daily testosterone transdermal gel|
11474266|NCT01533129|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
11474267|NCT01533116|Experimental|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
11474268|NCT01533116|Experimental|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
11474269|NCT01533116|Experimental|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
11474270|NCT01533116|Experimental|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
11474271|NCT01533090|Active Comparator|polyethylene glycol (PEG)|
11474272|NCT01533090|Experimental|PEG low volume with bisacodyl|
11474273|NCT01533077|Experimental|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
11474274|NCT01533077|Experimental|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
11474275|NCT01533077|Experimental|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
11474276|NCT01533077|Experimental|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
11474277|NCT01533064||Psychiatric Outpatients|
11474278|NCT01533051||Chronic hepatitis B|
11474279|NCT01533038|Active Comparator|UroLift System|UroLift System procedure
11474280|NCT01533038|Active Comparator|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
11474281|NCT01533025|Active Comparator|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
11474282|NCT01533025|Active Comparator|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
11474283|NCT01533012|Experimental|Pressure difference|Peak inspiratory pressures difference between two lungs
11474284|NCT01533012|No Intervention|FOB evaluation|FOB evaluation for the optimal position of tubes
11474285|NCT01532999|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
11474286|NCT01532999|Sham Comparator|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
11474372|NCT01532375|Experimental|Kochujang(32g)|
11474373|NCT01532375|Placebo Comparator|placebo(32g)|
11474287|NCT01532986|Other|Usual Care (Arm 1)|"Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.
~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
11474288|NCT01532986|Experimental|Intervention (Arm 2)|"A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.
~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
11474289|NCT01532973|Experimental|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
11474290|NCT01532973|Experimental|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
11474291|NCT01532973|Experimental|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
11474292|NCT01532973|Experimental|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
11474293|NCT01532973|Experimental|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
11474294|NCT01532973|Experimental|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
11474295|NCT01532973|Experimental|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
11474296|NCT01532973|Experimental|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
11474297|NCT01532973|Experimental|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
11474298|NCT01532973|Experimental|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
11474299|NCT01532960|Experimental|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
11474300|NCT01532947|Experimental|post restoration|
11474301|NCT01532947|No Intervention|no post restoration|no post placement
11474302|NCT01532934|Experimental|brief therapy|motivational enhancement therapy for substance use
11474303|NCT01532934|Placebo Comparator|Standard Care|standard care
11474304|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
11474305|NCT01532908|Experimental|Part 1: MBL-HCV1 and Telaprevir|
11474306|NCT01532908|Experimental|Part 2: MBL-HCV1 and Sofosbuvir|
11474307|NCT01532895||Hydromorphone HCI OROS|
11474308|NCT01532882|Experimental|Diosmin|
11474309|NCT01532882|Placebo Comparator|Placebo|
11474310|NCT01532869|Placebo Comparator|Placebo|
11474311|NCT01532869|Experimental|Tocilizumab|
11474312|NCT01532856|Active Comparator|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
11474313|NCT01532856|Active Comparator|Group B induction therapy|thalidomide + dexamethasone
11474314|NCT01532856|Active Comparator|Group C induction therapy|thalidomide + melphalan + prednisone
11474315|NCT01532843|Active Comparator|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
11474316|NCT01532843|No Intervention|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
11474317|NCT01532830|Experimental|Active|n-VNS active therapy
11474318|NCT01532817|Experimental|alphacore|noninvasive neurostimulation of the vagus nerve
11474319|NCT01532804|Experimental|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
11474320|NCT01532804|Experimental|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
11474321|NCT01532791||mtDNA mutation|m.3243 A>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
11474322|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
11474323|NCT01532765|Active Comparator|Epiretinal Membrane Surgery without ILM peel|
11474324|NCT01532765|Active Comparator|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
11474325|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery without ILM peel|
11474326|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
11474327|NCT01532739|Experimental|Cognitive training|
11474328|NCT01532739|No Intervention|No cognitive training|
11474329|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
11474330|NCT01532713|Experimental|non-block side|
11474331|NCT01532700|Experimental|Ofatumumab with GSK2110183|
11474332|NCT01532687|Experimental|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11474374|NCT01532362|Experimental|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
11474375|NCT01532362|Other|No drug intervention|
11478155|NCT01506895|Placebo Comparator|placebo|Placebo to match once daily
11474333|NCT01532687|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11474334|NCT01532674|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
11474335|NCT01532674|Active Comparator|scaling and root planing|Only scaling and root planing
11474336|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
11474337|NCT01532648|Experimental|Budesonide MMX|Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
11474338|NCT01532648|Placebo Comparator|Placebo|Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
11474339|NCT01532635|Experimental|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.
~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
11474340|NCT01532622|Active Comparator|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
11474341|NCT01532622|Placebo Comparator|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
11474342|NCT01532609|Experimental|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
11474343|NCT01532609|No Intervention|Standard care|No additional training or service is provided for standard care group service providers or clients.
11474344|NCT01532596|Experimental|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
11474345|NCT01532596|No Intervention|Wait-List|
11474346|NCT01532583||Patients operated on with the TOT|
11474347|NCT01532570|Experimental|TA-650|
11474348|NCT01532544|Experimental|Integrilin and Ilomedin given as continous infusion|
11474349|NCT01532544|Placebo Comparator|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
11474350|NCT01532531|Experimental|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
11474351|NCT01532531|No Intervention|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
11474352|NCT01532518|Experimental|Cohort 3|Nepadutant low dose for 7 days followed by Nepadutant high dose for additional 7 days
11474353|NCT01532518|Experimental|Cohort 2|Nepadutant medium dose for 7 days followed by Nepadutant high dose for additional 7 days
11474354|NCT01532518|Experimental|Cohort 1|Nepadutant low dose for 7 days followed by Nepadutant medium dose for additional 7 days
11474355|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
11474356|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
11474357|NCT01532492||Shoulder instability|Shoulder instability
11474358|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
11474359|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
11474360|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
11474361|NCT01532466|Experimental|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
11474362|NCT01532466|No Intervention|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
11474363|NCT01532453|Active Comparator|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
11474364|NCT01532453|Experimental|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
11474365|NCT01532414|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
11474366|NCT01532414|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
11474367|NCT01532414|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
11474368|NCT01532401|Experimental|chlorure de sodium|
11474369|NCT01532401|Placebo Comparator|Methylcellulose|
11474370|NCT01532388|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
11474376|NCT01532349|Active Comparator|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
11474377|NCT01532349|Active Comparator|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
11474378|NCT01532336|Experimental|NVC-422 Solution, 0.3%|Dosed for 10 days
11474379|NCT01532336|Placebo Comparator|NVC-422 Vehicle Solution|Dosed for 10 days
11474380|NCT01532323|Experimental|Oral disorder children|Oral disorder children aged 2 to 15 years
11474381|NCT01532323|Active Comparator|Control group|No oral disorder children aged 2 to 15 years
11474382|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
11474383|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
11474384|NCT01532297|Active Comparator|HD treated with standard dialysate|
11474385|NCT01532297|Active Comparator|post-dilution oHDF with standard dialysate|
11474386|NCT01532297|Experimental|pre-dilution oHDF with citrate dialysate|
11474387|NCT01532297|Experimental|HD treated with citrate dialysate|
11474388|NCT01532297|Experimental|post-dilution oHDF with citrate dialysate|
11474389|NCT01532297|Active Comparator|pre-dilution oHDF with standard dialysate|
11474390|NCT01532284|Experimental|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
11474391|NCT01532284|No Intervention|No Polar Body Biopsy|
11474392|NCT01532271||Concussed|Patients with recent concussion
11474393|NCT01532271||Matched controls|Athletes with no recent concussion
11474394|NCT01532258|No Intervention|Control Group|No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
11474395|NCT01532258|Active Comparator|GFFY-1 without weekly MA support|Utilization of the 8-week online nutrition program Go! Foods for You without weekly contact from staff at the medical provider's office.
11474396|NCT01532258|Active Comparator|GFFY-2 with weekly MA support|Utilization of the 8-week online nutrition program combined with weekly contact from the staff at the medical provider's office.
11474397|NCT01532245|Active Comparator|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
11474398|NCT01532245|Active Comparator|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
11474399|NCT01532245|Active Comparator|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
11474400|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
11474401|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
11474402|NCT01532219|Experimental|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
11474403|NCT01532219|Active Comparator|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
11474404|NCT01532206|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
11474405|NCT01532206|No Intervention|Standard of care|Standard of care
11474406|NCT01532193|Experimental|Hipoxia|The low oxygen tension group
11474407|NCT01532193|No Intervention|Control group|Conventional culture conditions
11474408|NCT01532180|Experimental|THN Therapy|
11474409|NCT01532141|Experimental|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
11474410|NCT01532141|Experimental|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
11474411|NCT01532141|Experimental|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
11474412|NCT01532128|Experimental|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
11474413|NCT01532128|Experimental|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
11474414|NCT01532128|Experimental|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
11474415|NCT01532115|Experimental|BIA 9-1067|
11474416|NCT01532115|Placebo Comparator|Placebo|
11474417|NCT01532115|Active Comparator|moxifloxacin|
11474418|NCT01532102|Experimental|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
11474467|NCT01531738||Bariatric Surgery|obese patients due to undergo gastric bypass or gastric banding
11474419|NCT01532102|Placebo Comparator|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
11474420|NCT01532089|Active Comparator|Arm A (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
11474421|NCT01532089|Experimental|Arm B (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride as in Arm A and bevacizumab IV over 30-90 minutes on day 1. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
11474422|NCT01532076|Experimental|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
11474423|NCT01532076|Active Comparator|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
11474424|NCT01532063|Other|INTUBATION|Subjects intubed in Intensive Care Unit
11474425|NCT01532050|Other|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
11474426|NCT01532037|Experimental|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
11474427|NCT01532037|Experimental|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
11474428|NCT01532037|Placebo Comparator|Treatment as Usual|Participants receive usual care from healthcare professionals
11474429|NCT01532024|Experimental|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
11474430|NCT01532024|Experimental|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
11474431|NCT01532024|Experimental|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
11474432|NCT01532011|Experimental|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.
~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
11474433|NCT01531998|Experimental|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.
~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.
~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
11474434|NCT01531972|Experimental|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
11474435|NCT01531972|Experimental|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
11474436|NCT01531972|Experimental|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
11474437|NCT01531959|Active Comparator|Midodrine|
11474438|NCT01531959|Placebo Comparator|Placebo|
11474439|NCT01531933|Experimental|DLBS3233|
11474440|NCT01531933|Placebo Comparator|Placebo of DLBS3233|
11474441|NCT01531920|Other|alcohol + placebo|Part A alcohol + placebo
11474442|NCT01531920|Other|alcohol + perampanel|Part A : alcohol + perampanel
11474443|NCT01531920|Other|perampanel + alcohol|Part B: perampanel + alcohol
11474444|NCT01531920|Other|placebo + alcohol|Part B: placebo + alcohol
11474445|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
11474446|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
11474447|NCT01531894|Experimental|GSK2110183 (afuresertib)|All patients received the GSK2110183 (afuresertib) treatment
11474448|NCT01531868|Other|Auditory qualitative|
11474449|NCT01531868|Other|Auditory absolute risk|
11474450|NCT01531868|Other|Auditory relative risk|
11474451|NCT01531868|Other|Visual qualitative|
11474452|NCT01531868|Other|Visual relative risk|
11474453|NCT01531868|Other|Visual absolute risk|
11474454|NCT01531855|Other|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
11474455|NCT01531842|Experimental|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
11474456|NCT01531842|Other|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
11474457|NCT01531829|Experimental|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
11474458|NCT01531829|Active Comparator|LMWH|Low molecular weight heparin
11474459|NCT01531816|Experimental|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
11474460|NCT01531803|Active Comparator|Kedbumin 25%|
11474461|NCT01531803|Sham Comparator|Normal Saline|
11474462|NCT01531790|Experimental|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
11474463|NCT01531777|Experimental|Apatinib 500mg|500mg,p.o.,qd
11474464|NCT01531777|Experimental|Apatinib 750mg|750mg,p.o.,qd
11474465|NCT01531751|Experimental|High Cut-off Hemodialysis|
11474466|NCT01531738||Control|Normal weight healthy volunteers
11478375|NCT01505543||chronic obstructive pulmonary disease|
11474468|NCT01531725|Experimental|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
11474469|NCT01531712|Experimental|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.
~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
11474470|NCT01531699|Experimental|ALT005 Ophthalmic Prep Solution|
11474471|NCT01531699|Placebo Comparator|saline control|
11474472|NCT01531699|Experimental|Comparator Product|Betadine ophthalmic prep solution
11474473|NCT01531673|Placebo Comparator|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
11474474|NCT01531673|Experimental|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
11474475|NCT01531673|Experimental|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
11474476|NCT01531673|Experimental|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
11474477|NCT01531673|Experimental|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
11474478|NCT01531673|Experimental|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
11474479|NCT01531673|Experimental|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
11474480|NCT01531673|Experimental|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
11474481|NCT01531673|Experimental|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
11474482|NCT01531673|Experimental|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
11474483|NCT01531673|Experimental|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
11474484|NCT01531673|Placebo Comparator|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
11474485|NCT01531673|Experimental|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
11474486|NCT01531660|Experimental|training|step up jogging program
11474487|NCT01531647|Active Comparator|Period 1 Control|
11474488|NCT01531647|Experimental|Period 2 danoprevir/ritonavir|
11474489|NCT01531634|Active Comparator|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
11474490|NCT01531634|No Intervention|No Additional Intervention|
11474491|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
11474492|NCT01531595|Experimental|Chemotherapy plus bevazicumab|
11474493|NCT01531582|Experimental|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
11474494|NCT01531569|Experimental|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
11474495|NCT01531543|Experimental|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
11474496|NCT01531543|No Intervention|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
11474497|NCT01531530|Experimental|Vaccine-recipients|
11474498|NCT01531530|Placebo Comparator|Placebo|
11474499|NCT01531517|Experimental|Pedyphar|Ointment
11474500|NCT01531517|Active Comparator|Panthenol|Ointment
11474501|NCT01531504|Other|Hysterectomy|candidate for a conventional laparoscopic-assisted
11474502|NCT01531491|Experimental|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
11474503|NCT01531491|Experimental|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
11474504|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
11474505|NCT01531465|Other|HFNC to NCPAP|Infants who are currently on HFNC.
11474506|NCT01531465|Other|NCPAP to HFNC|Infants who are currently on NCPAP.
11474507|NCT01531452|Experimental|treatment|oxaliplatin+s1
11474508|NCT01531439|Active Comparator|Naloxone infusion 0.5 mcg/kg/hr|
11474509|NCT01531439|Experimental|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
11474510|NCT01531426||NIRS continuous monitoring|
11474511|NCT01531413|Experimental|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
11474512|NCT01531400|Experimental|music|Investigators played self-selected background music in the music group
11474513|NCT01531400|No Intervention|no music (control)|Investigators played no music in the music group
11478376|NCT01505543||healthy matched controls|
11474514|NCT01531387|No Intervention|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
11474515|NCT01531387|Experimental|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
11474516|NCT01531374|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
11474517|NCT01531374|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
11474518|NCT01531374|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
11474519|NCT01531361|Experimental|Arm I (vemurafenib and sorafenib tosylate)|Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.
11474520|NCT01531361|Experimental|Arm II (vemurafenib and crizotinib)|Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.
11474521|NCT01531348|Experimental|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
11474522|NCT01531335|Active Comparator|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
11474523|NCT01531335|Experimental|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
11474524|NCT01531322|Experimental|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
11474525|NCT01531322|Experimental|Group 2|Children aged 3 through 5 years (before the sixth birthday)
11474526|NCT01531322|Experimental|Group 3|Infants aged approximately 2 months (42 to 98 days)
11474527|NCT01531309|Experimental|AGO178|
11474528|NCT01531283|Experimental|decaylated ghrelin|UAG (4.0 µg/kg/hr)
11474529|NCT01531283|Experimental|acyl ghrelin|AG (1.0 µg/kg/hr)
11474530|NCT01531283|Experimental|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
11474531|NCT01531283|Placebo Comparator|saline|saline
11474532|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
11474533|NCT01531244|Experimental|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
11474534|NCT01531231||YOUNGER HEALTHY NO CORONARY ARTERY DISEASE (CAD)|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
11474535|NCT01531231||OLDER HEALTHY SUBJECTS NO CORONARY ARTERY DISEASE (CAD)|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
11474536|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
11474537|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
11474538|NCT01531218|Active Comparator|azithromycin|azithromycin 500mg
11474539|NCT01531218|Placebo Comparator|placebo|placebo 500mg
11474540|NCT01531205|Experimental|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
11474541|NCT01531192|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
11474542|NCT01531192|Active Comparator|Nystatin|50000 unit/3 times a day
11474543|NCT01531179|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
11474544|NCT01531179|Placebo Comparator|Control|Placebo for 3 months
11474545|NCT01531166||Chronic hepatitis B|
11474546|NCT01531153|Active Comparator|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
11474547|NCT01531153|Active Comparator|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
11474548|NCT01531140|Active Comparator|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
11474549|NCT01531140|Experimental|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
11474550|NCT01531140|Experimental|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
11474551|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
11474552|NCT01531127||ADHD Medication Treatment|Control group
11474553|NCT01531114|Active Comparator|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
11474554|NCT01531114|No Intervention|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
11474555|NCT01531101|Experimental|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
11474556|NCT01531101|Active Comparator|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
11474557|NCT01531088|No Intervention|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
11474558|NCT01531088|Experimental|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
11474559|NCT01531075|Experimental|ENGERIX-B|
11474560|NCT01531075|Experimental|Sci-B-Vac|
11474561|NCT01531062|Experimental|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
11474562|NCT01531062|Placebo Comparator|Placebo|
11474563|NCT01531049|Experimental|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
11474564|NCT01531049|Experimental|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
11474565|NCT01531049|Experimental|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
11474566|NCT01531049|Placebo Comparator|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
11474567|NCT01531036|Experimental|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
11474568|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
11474569|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
11474570|NCT01531010|Active Comparator|Pressure-limited ventilation|
11474571|NCT01531010|Active Comparator|Volume-targeted ventilation|
11474572|NCT01530997|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2). Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response. All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
11474573|NCT01530984|Experimental|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
11474574|NCT01530984|Experimental|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
11474575|NCT01530971|No Intervention|room air|no supplemental oxygen in intraoperative period
11474576|NCT01530971|Experimental|Oxygen|Supplemental 3LPM oxygen via canula
11474577|NCT01530958|Experimental|ATSM + Health Coach and CKD Registry|
11474578|NCT01530958|Active Comparator|CKD Registry|
11474579|NCT01530958|Active Comparator|ATSM + Health Coach|
11474580|NCT01530958|Placebo Comparator|Usual Care (no interventions)|
11474581|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
11474582|NCT01530906|Experimental|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).
~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
11474583|NCT01530906|Placebo Comparator|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
11474584|NCT01530893|Experimental|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
11474585|NCT01530893|Experimental|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
11474586|NCT01530893|Experimental|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
11474587|NCT01530893|Experimental|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
11474588|NCT01530880|Experimental|Intravenous Ibuprofen|Patients assigned to the ibuprofen treatment group will receive a 400 mg IV ibuprofen bolus over 30 minutes followed by an infusion of ibuprofen at 85 mg/hr.
11474589|NCT01530880|Other|Standard of Care|Patients assigned to the standard of care group will be given 650 mg of oral acetaminophen and continue to receive 650 mg of oral acetaminophen every 6 hours as needed to maintain temperature < 38.3 C (100.9 F).
11474590|NCT01530854||Septic|
11474591|NCT01530854||Healthy|
11474592|NCT01530841|Experimental|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
11474593|NCT01530841|Active Comparator|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
11474594|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
11474595|NCT01530815|Experimental|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
11474596|NCT01530802|Experimental|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
11474597|NCT01530802|No Intervention|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
11474598|NCT01530776|Experimental|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
11474599|NCT01530776|No Intervention|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
11474600|NCT01530763|Experimental|Ceftaroline fosamil|
11474601|NCT01530763|Active Comparator|Ceftriaxone|
11474602|NCT01530750||Post cardiac surgery|
11474603|NCT01530737|Placebo Comparator|Control Group|
11474604|NCT01530737|Experimental|Active Antithrombin Group|
11474605|NCT01530724|Experimental|low fat diet|Weight-loss diet strategy
11474606|NCT01530724|Experimental|low carb diet|Weight-loss diet strategy
11474607|NCT01530711|Experimental|terlipressin|
11474608|NCT01530698|Experimental|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
11474609|NCT01530698|Active Comparator|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
11474610|NCT01530685|Experimental|Glycabiane, gelule|
11474611|NCT01530685|Placebo Comparator|Placebo|
11474612|NCT01530672|Experimental|ANC clients|
11474613|NCT01530659|Experimental|NT-501|Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
11474614|NCT01530659|Sham Comparator|Sham|Sham surgery
11474615|NCT01530646|Placebo Comparator|Control|Carbohydrate & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
11474616|NCT01530646|Experimental|Whey|Whey protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
11474617|NCT01530646|Experimental|Soy|Soy protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
11474618|NCT01530620|Experimental|Propiverine hydrochloride ER|45 mg
11474619|NCT01530620|Active Comparator|Propiverine hydrochloride IR|15 mg
11474620|NCT01530607|Active Comparator|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
11474621|NCT01530607|Experimental|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
11474622|NCT01530594|Active Comparator|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
11474623|NCT01530594|Experimental|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
11474624|NCT01530581|Experimental|G-BM Transplant|
11474625|NCT01530581|Other|G-PB Transplant|G-PB Transplant
11474626|NCT01530568|Active Comparator|Smear|Routine microbiology based diagnostics for TB
11474627|NCT01530568|Experimental|GeneXpert|Arm that will receive the Xpert test
11474628|NCT01530555|Experimental|Treatment arm|"Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.
~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
11474629|NCT01530542|Experimental|Treatment A|
11474630|NCT01530542|Experimental|Treatment B|
11474631|NCT01530542|Experimental|Treatment C|
11474632|NCT01530542|Experimental|Treatment D|
11474633|NCT01530542|Experimental|Treatment E|
11474634|NCT01530529|Experimental|PF-05180999 Immediate-Release|
11474635|NCT01530529|Experimental|PF-05180999 Modified-Release 1|
11474636|NCT01530529|Experimental|PF-05180999 Modified-Release 2|
11474637|NCT01530529|Experimental|PF-05180999 Modified-Release 1 With Food|
11474638|NCT01530516|Active Comparator|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
11474639|NCT01530516|Experimental|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
11474640|NCT01530503|Experimental|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
11474641|NCT01530503|Experimental|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
11474642|NCT01530490|No Intervention|Hemoes|
11474643|NCT01530490|Experimental|Cabergoline|cabergoline
11474644|NCT01530477|Experimental|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)],(total of evaluable 90 subjects).
~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
11474645|NCT01530477|Experimental|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], (total of evaluable 90 subjects).
~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
11474698|NCT01530165|Other|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice.
11479303|NCT01499225|Experimental|YH14642 A-II|
11474646|NCT01530477|Experimental|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
11474647|NCT01530464|Active Comparator|Aminophylline|
11474648|NCT01530464|Active Comparator|Ambrisentan|
11474649|NCT01530464|Experimental|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
11474650|NCT01530451|Experimental|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
11474651|NCT01530451|Experimental|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
11474652|NCT01530438|Other|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
11474653|NCT01530438|Other|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
11474654|NCT01530438|Other|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
11474655|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
11474656|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
11474657|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
11474658|NCT01530412|No Intervention|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
11474659|NCT01530412|Experimental|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
11474660|NCT01530399|Experimental|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
11474661|NCT01530399|Experimental|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
11474662|NCT01530399|Experimental|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
11474663|NCT01530399|Experimental|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
11474664|NCT01530399|Placebo Comparator|Saline|Commercially available saline (0.9% NaCl solution)
11474665|NCT01530399|Active Comparator|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
11474666|NCT01530386|Experimental|Lacosamide|300 mg/day
11474667|NCT01530373|Experimental|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
11474668|NCT01530373|Active Comparator|clonidine|oral clonidine 0.1 mg daily for 3 weeks
11474669|NCT01530360|Experimental|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
11474670|NCT01530347|Experimental|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
11474671|NCT01530334|Experimental|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
11474672|NCT01530321|Experimental|High dose spinal manipulation|18 visits for spinal manipulation
11474673|NCT01530321|Experimental|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
11474674|NCT01530321|Experimental|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
11474675|NCT01530321|Other|High dose massage|18 visits for light massage
11474676|NCT01530308|Active Comparator|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
11474677|NCT01530308|Placebo Comparator|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
11474678|NCT01530295|No Intervention|contol|control group
11474679|NCT01530295|Other|chemotherapy|neoadjuvant chemotherapy
11474680|NCT01530282|Experimental|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
11474681|NCT01530269|Experimental|PET/CT imaging with C11-Sodium Acetate|
11474682|NCT01530256|Experimental|ALD518|
11474683|NCT01530243|Placebo Comparator|Placebo|
11474684|NCT01530243|Active Comparator|Terazosin|
11474685|NCT01530243|Active Comparator|Tolterodine|
11474686|NCT01530243|Active Comparator|Tolterodine + Terazosin|
11474687|NCT01530230|Other|Oxytocin 5 units|
11474688|NCT01530230|Other|Oxytocin 10 units|
11474689|NCT01530204|Active Comparator|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
11474690|NCT01530204|Active Comparator|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
11474691|NCT01530204|Active Comparator|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
11474692|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
11474693|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
11474694|NCT01530178|Active Comparator|Part A|Sitagliptin 25mg
11474695|NCT01530178|Active Comparator|Part B|Sitagliptin 50mg
11474696|NCT01530178|Active Comparator|Part C|Sitagliptin 100mg
11474697|NCT01530178|Placebo Comparator|Part D|Placebo oral tablet
11474748|NCT01529853|Experimental|SAR156597 dose 1|SAR156597 dose 1, subcutaneous injection once every week
11474699|NCT01530165|Experimental|life style intervention arm|This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.
11474700|NCT01530139|Placebo Comparator|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
11474701|NCT01530139|Experimental|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
11474702|NCT01530139|Experimental|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
11474703|NCT01530139|Experimental|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
11474704|NCT01530126|Active Comparator|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
11474705|NCT01530126|Experimental|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
11474706|NCT01530126|Experimental|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
11474707|NCT01530087|Experimental|Treatment|CASTLE Barrier
11474708|NCT01530074|Experimental|Study Group|
11474709|NCT01530061|Experimental|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
11474710|NCT01530061|Experimental|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
11474711|NCT01530048|Experimental|U200|
11474712|NCT01530048|Active Comparator|U100|
11474713|NCT01530035|Active Comparator|soccer training intervention|
11474714|NCT01530035|Other|strength training intervention|
11474715|NCT01530035|No Intervention|control group|elderly men with no change in daily activities
11474716|NCT01530035|No Intervention|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
11474717|NCT01530022|Other|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
11474718|NCT01530022|Other|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
11474719|NCT01530009|Active Comparator|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
11474720|NCT01530009|Placebo Comparator|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
11474721|NCT01529996|Experimental|YAG laser|
11474722|NCT01529996|Active Comparator|Pulse Dye Laer|
11474723|NCT01529983|Experimental|Fractional photothermolysis|Fractional photothermolysis (FP) for treatment of photo- damaged skin is an FDA-approved method for treating facial rhytids. Fractionated treatment with 1550-nm laser is a safe, nonsurgical method for improvement of periorbital rhytides, photodamage, and scarring
11474724|NCT01529983|Active Comparator|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
11474725|NCT01529970||parkinson's disease, young onset|
11474726|NCT01529970||Normal|
11474727|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
11474728|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
11474729|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
11474730|NCT01529957|Placebo Comparator|placebol|placebol
11474731|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
11474732|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
11474733|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
11474734|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
11474735|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
11474736|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
11474737|NCT01529944|Experimental|Low dose 33 mcg/kg/day|
11474738|NCT01529944|Experimental|High dose 66 mcg/kg/day|
11474739|NCT01529931|Experimental|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
11474740|NCT01529918|Experimental|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
11474741|NCT01529918|No Intervention|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
11474742|NCT01529892|Experimental|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
11474743|NCT01529892|Experimental|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
11474744|NCT01529879|Experimental|New abutment connection implant|Implant with new abutment connection
11474745|NCT01529879|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
11474746|NCT01529866|Experimental|New abutment connection implant|Implant with new abutment connection
11474747|NCT01529866|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
11474830|NCT01529424|Experimental|Group 4|Fredrickson Type 1 dyslipidemia
11474749|NCT01529853|Experimental|SAR156597 dose 2|SAR156597 dose 2, subcutaneous injection once every week
11474750|NCT01529853|Experimental|SAR156597 dose 3|SAR156597 dose 3, subcutaneous injection once every week
11474751|NCT01529853|Placebo Comparator|Placebo|Placebo (for SAR156597), subcutaneous injection once every week
11474752|NCT01529840|Experimental|Low dose 33 mcg/kg/day|
11474753|NCT01529840|Experimental|High dose 66 mcg/kg/day|
11474754|NCT01529827|Experimental|Treatment (reduced intensity allogeneic PBSCT)|PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.
11474755|NCT01529814|Experimental|New abutment connection implant|Implant with new abutment connection
11474756|NCT01529814|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
11474757|NCT01529801|Experimental|Roughness group A|Osseotite Certain Tapered Group A
11474758|NCT01529801|Experimental|Roughness Group B|Osseotite Certain Tapered Group B
11474759|NCT01529801|Experimental|Roughness Group C|Osseotite Certain Tapered Group C
11474760|NCT01529788|Active Comparator|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
11474761|NCT01529775|Experimental|Osseotite Certain Tapered Prevail|Osseotite Certain Tapered Prevail design with platform switching feature
11474762|NCT01529775|Active Comparator|Osseotite Certain Tapered|Osseotite Certain Tapered implant with non-platform switching design
11474763|NCT01529762||Osseotite Certain Tapered|Dental implant Osseotite Certain Tapered design
11474764|NCT01529749|Active Comparator|EFV/FTC/TDF|
11474765|NCT01529749|Experimental|EFV/FTC/TDF + Losartan|
11474766|NCT01529749|Experimental|FTC/TDF + MK-0518|
11474767|NCT01529749|Experimental|FTC/TDF+MK-0518+Losartan|
11474768|NCT01529736|Experimental|High torque insertion|High torque insertion
11474769|NCT01529736|Active Comparator|Low torque insertion|Low torque insertion
11474770|NCT01529710|Experimental|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
11474771|NCT01529710|Active Comparator|Praziquantel|Tablets
11474772|NCT01529697|Active Comparator|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
11474773|NCT01529697|Placebo Comparator|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
11474774|NCT01529684|Experimental|OSI-906|"Two Parts:
~Part A: 14C-labeled OSI-906
~Part B: (Optional) OSI-906 (non-labeled)"
11474775|NCT01529671|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
11474776|NCT01529671|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
11474777|NCT01529671|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
11474778|NCT01529671|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
11474779|NCT01529671|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
11474780|NCT01529658|No Intervention|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
11474781|NCT01529658|Experimental|Hypothermia|saline ice slush around kidney for 10 minutes.
11474782|NCT01529645|Experimental|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
11474783|NCT01529645|Experimental|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
11474784|NCT01529645|Experimental|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
11474785|NCT01529645|Experimental|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
11474786|NCT01529645|Experimental|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11474787|NCT01529645|Experimental|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11474926|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
11474788|NCT01529645|Experimental|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11474789|NCT01529645|Experimental|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11474790|NCT01529645|Experimental|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
11474791|NCT01529645|Active Comparator|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
11474792|NCT01529632|Experimental|QVA149|QVA149 plus placebo once daily for 28 days.
11474793|NCT01529632|Active Comparator|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
11474794|NCT01529619|Experimental|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
11474795|NCT01529606|Active Comparator|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
11474796|NCT01529606|Experimental|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
11474797|NCT01529593|Experimental|Temsirolimus + Metformin|Starting dose of Temsirolimus 25 mg by vein weekly. Metformin titrated over 3 weeks at 500 mg by mouth daily. Four weeks of treatment constitute 1 cycle. Cycle one (1) however, will be 6 weeks long to allow for metformin titration.
11474798|NCT01529580|Experimental|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
11474799|NCT01529580|Experimental|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
11474800|NCT01529580|Experimental|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
11474801|NCT01529567|Active Comparator|CBT without exposure|
11474802|NCT01529567|Experimental|CBT with exposure|
11474803|NCT01529554|Active Comparator|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
11474804|NCT01529554|Placebo Comparator|Placebo|Placebo comparator with identical composition of tablets except everolimus
11474805|NCT01529541|Active Comparator|Sitagliptin|Sitagliptin 100mg
11474806|NCT01529541|Experimental|CWP-0403|CWP-0403 100mg
11474807|NCT01529528|Placebo Comparator|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
11474808|NCT01529528|Experimental|CWP-0403 200mg|CWP-0403 200mg
11474809|NCT01529528|Experimental|CWP-0403 100mg|CWP-0403 100mg
11474810|NCT01529515|Experimental|Paliperidone palmitate 3-month (PP3M)|
11474811|NCT01529515|Placebo Comparator|Placebo|
11474812|NCT01529502|Experimental|Fresh blood|
11474813|NCT01529502|Experimental|Old blood|
11474814|NCT01529502|Experimental|Old blood + inhaled Nitric Oxide|
11474815|NCT01529489|Active Comparator|Interval physical training Control group|
11474816|NCT01529489|Experimental|Resisted/Aerobic physical training group|
11474817|NCT01529489|Active Comparator|Aerobic/resisted physical training group|
11474818|NCT01529489|Experimental|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
11474819|NCT01529476|Experimental|Nemonoxacin 500 mg|
11474820|NCT01529476|Active Comparator|Levofloxacin 500 mg|
11474821|NCT01529463||Disease Management|
11474822|NCT01529450|Active Comparator|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
11474823|NCT01529450|Active Comparator|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
11474824|NCT01529437|Active Comparator|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
11474825|NCT01529437|Placebo Comparator|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
11474826|NCT01529424|Experimental|Group 1|Non-extensive PK/non post-prandial
11474827|NCT01529424|Experimental|Group 2a|Extensive PK
11474828|NCT01529424|Experimental|Group 2b|Post-prandial assessment
11474829|NCT01529424|Experimental|Group 3|Stable dose of fibrate
11474831|NCT01529411|Experimental|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min)
~+ best suportive care, with regards clinical practice."
11474832|NCT01529411|Other|Best suportive care|Best suportive care
11474833|NCT01529398|Active Comparator|sensorimotor training (SMT)|
11474834|NCT01529398|Active Comparator|Resistance training (RT)|
11474835|NCT01529398|Sham Comparator|Control group (CG)|
11474836|NCT01529385|Experimental|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
11474837|NCT01529385|Other|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
11474838|NCT01529372|Experimental|Percutaneous renal denervation|
11474839|NCT01529359|Placebo Comparator|Placebo|Probiotics Excipients
11474840|NCT01529359|Experimental|Lactibiane Tolerance|Probiotics combination
11474841|NCT01529346|Experimental|PF-05089771 1600 mg|
11474842|NCT01529346|Experimental|PF-05089771 450 mg|
11474843|NCT01529346|Experimental|PF-05089771 150 mg|
11474844|NCT01529346|Active Comparator|Ibuprofen 400 mg|
11474845|NCT01529346|Placebo Comparator|Placebo|
11474846|NCT01529320|Experimental|Adventan® (metilprednisolona aceponato 0,1%)|
11474847|NCT01529307|Experimental|TAS266|
11474848|NCT01529294|Experimental|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
11474849|NCT01529281|Experimental|BCAA|Branched chain amino acid
11474850|NCT01529281|Placebo Comparator|Asparmate|Placebo control containing no protein or carbohydrate
11474851|NCT01529268|Active Comparator|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
11474852|NCT01529268|Placebo Comparator|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
11474853|NCT01529255|Experimental|ROADMAP|
11474854|NCT01529255|Active Comparator|SOC (Standard of Care)|
11474855|NCT01529242|Experimental|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
11474856|NCT01529242|Active Comparator|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
11474857|NCT01529229|Experimental|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
11474858|NCT01529229|Active Comparator|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
11474859|NCT01529216|Experimental|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
11474860|NCT01529216|Sham Comparator|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
11474861|NCT01529203|Other|Azzalure and Restylane|All subjects will be injected with Azzalure and Restylane
11474862|NCT01529190|Active Comparator|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
11474863|NCT01529190|Placebo Comparator|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
11474864|NCT01529177|Experimental|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.
~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:
~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
11474865|NCT01529177|Experimental|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
11474866|NCT01529164|Experimental|treatment|
11474867|NCT01529151|Active Comparator|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
11474868|NCT01529151|Active Comparator|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
11474869|NCT01529151|Active Comparator|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
11474870|NCT01529151|No Intervention|Control Group|
11474871|NCT01529138|Experimental|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
11474872|NCT01529138|Experimental|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
11474873|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
11474874|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
11474875|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
11474876|NCT01529112|Experimental|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
11474877|NCT01529112|Placebo Comparator|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
11474878|NCT01529099|Experimental|Sigma HP Partial Knee|Partial knee replacement
11474927|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
11474879|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:
~. A rise in PSA from nadir at any time post-nadir
~. PSA change from baselin >0.2 mg/ml at any time post-baseline
~. Abnormal DRE at any time post-baseline
~. Free-PSA <12% at any time post-baseline
~. At least one of the above 4 criteria
~Subjects on Dutasteride that do not meet the above criteria"
11474880|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:
~Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA < 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.
~Abnormal DRE at any time post-baseline
~Change from baseline PSA ≥ 0.35 at any time post-baseline
~Change from baseline PSA ≥ 0.75 at any time post-baseline
~PSA ≥ 2.5 at any time post-baseline
~PSA ≥ 4.0 at any time post-baseline
~Percent Free PSA < 12% at any time post-baseline
~At least one of the above 7 criteria.
~Subjects on placebo that do not meet the above criteria"
11474881|NCT01529073|Experimental|Nitazoxanide|
11474882|NCT01529060|Active Comparator|Phenylbutyrate|Study Drug
11474883|NCT01529060|Placebo Comparator|Inactive Powder|Placebo powder
11474884|NCT01529047|Experimental|In-person PFI|In-person personalized feedback intervention
11474885|NCT01529047|Experimental|Web-based PFI|Web-based personalized feedback intervention
11474886|NCT01529047|No Intervention|Assessment Only|Complete online survey assessments only.
11474887|NCT01529034|Experimental|USL261|Intranasal midazolam 5 mg
11474888|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
11474889|NCT01529021||control|standard care procedures were used during the vaccination
11474890|NCT01529008|Experimental|Core decompression/PREOB® implantation|
11474891|NCT01529008|Placebo Comparator|Core decompression/placebo implantation|
11474892|NCT01528995|Active Comparator|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
11474893|NCT01528995|Active Comparator|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
11474894|NCT01528995|Active Comparator|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
11474895|NCT01528982|No Intervention|Control|Psychoeducation
11474896|NCT01528982|Active Comparator|Mindfulness|Mindfulness activity and psychoeducation
11474897|NCT01528982|Active Comparator|Cognition|Cognitive training and psychoeducation
11474898|NCT01528969|Experimental|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
11474899|NCT01528969|Active Comparator|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
11474900|NCT01528943|Experimental|Prostacyclin|
11474901|NCT01528943|Placebo Comparator|Isotonic saline|
11474902|NCT01528930|Experimental|Amikacin for inhalation|"Drug: Amikacin
~Amikacin is provided for inhalation via nebulization.
~500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.
~Administration time is approximately 20 minutes.
~Amikacin will be administered for 2 years."
11474903|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
11474904|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
11474905|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
11474906|NCT01528891|Active Comparator|Dexmedetomidine|Dexmedetomidine
11474907|NCT01528891|Placebo Comparator|placebo|Normal saline
11474908|NCT01528878|Experimental|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
11474909|NCT01528878|Experimental|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
11474910|NCT01528865|Experimental|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses [but not HERV-K(HML2)] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
11474911|NCT01528852|Experimental|CHX Cord application|Chlorhexidine cord application for 10 days
11474912|NCT01528852|Active Comparator|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
11474913|NCT01528852|No Intervention|Dry Cord care|Use current recommended keep cord dry
11474914|NCT01528839|Placebo Comparator|Pill|
11474915|NCT01528839|Experimental|L-Thyroxine as addon|
11474916|NCT01528826|Experimental|NVBOX regimen|Vinorelbine plus oxaliplatin
11474917|NCT01528813|Active Comparator|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
11474918|NCT01528813|Placebo Comparator|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
11474919|NCT01528800|Placebo Comparator|Placebo|Microcrystalline Methylcellulose
11474920|NCT01528800|Active Comparator|Vitamin K1|Vitamin K1
11474921|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
11474922|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
11474923|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
11474924|NCT01528787|Placebo Comparator|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
11474925|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
11474928|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
11474929|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
11474930|NCT01528761|Experimental|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
11474931|NCT01528761|Active Comparator|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
11474932|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
11474933|NCT01528735|Experimental|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
11474934|NCT01528735|Experimental|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
11474935|NCT01528722|Sham Comparator|Saline sham injection|Sham wash and injection with normal saline (09%)
11474936|NCT01528722|Active Comparator|Bupivacaine|Bupivacaine injection/wash treatment arm
11474937|NCT01528709|Experimental|High-dose statin therapy|Atorvastatin 80 mg daily
11474938|NCT01528709|Active Comparator|Moderate-dose statin therapy|Atorvastatin 10 mg daily
11474939|NCT01528696|Placebo Comparator|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
11474940|NCT01528696|Experimental|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
11474941|NCT01528683|Experimental|Carbon Ion Radiotherapy|
11474942|NCT01528670||Skull Base|
11474943|NCT01528670||Lower GI|
11474944|NCT01528670||Prostate|
11474945|NCT01528670||Pelvic Region|
11474946|NCT01528670||Head-and-Neck|
11474947|NCT01528670||Upper GI|
11474948|NCT01528670||Brain|
11474949|NCT01528670||Other|
11474950|NCT01528657|Experimental|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
11474951|NCT01528657|Experimental|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
11474952|NCT01528644|Experimental|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
11474953|NCT01528644|Experimental|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
11474954|NCT01528644|Experimental|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
11474955|NCT01528644|Experimental|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
11474956|NCT01528631|Placebo Comparator|Control Product|200 ml water with 50g of sucrose
11474957|NCT01528631|Active Comparator|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
11474958|NCT01528618|Experimental|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
11474959|NCT01528618|Active Comparator|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
11474960|NCT01528605|Placebo Comparator|Placebo|starch in hard shell gelatine capsules
11474961|NCT01528605|Experimental|Low lutein|low lutein group
11474962|NCT01528605|Experimental|High lutein|high lutein group
11474963|NCT01528605|Experimental|Low lutein zeaxanthin|lutein plus zeaxanthin group
11474964|NCT01528605|Experimental|High zeaxanthin|zeaxanthin group
11474965|NCT01528605|Experimental|high lutein zeaxanthin|Zeaxanthin plus lutein group
11474966|NCT01528592|Experimental|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
11474967|NCT01528579|Active Comparator|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
11474968|NCT01528579|Active Comparator|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
11474969|NCT01528579|Active Comparator|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
11474970|NCT01528566|Experimental|Tai Chi|
11474971|NCT01528566|Placebo Comparator|Attentation control|
11474972|NCT01528553|Active Comparator|Staples|Old implant type
11474973|NCT01528553|Active Comparator|8plate|New implant type
11474974|NCT01528540|Placebo Comparator|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
11474975|NCT01528540|Experimental|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
11474976|NCT01528514|Active Comparator|Curcuminoids|
11474977|NCT01528514|Placebo Comparator|Placebo|
11474978|NCT01528501|Experimental|I|
11474979|NCT01528488|Experimental|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
11474980|NCT01528488|Placebo Comparator|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
11474981|NCT01528475|Active Comparator|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
11474982|NCT01528475|No Intervention|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
11474983|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
11474984|NCT01528449|Experimental|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
11474985|NCT01528449|Experimental|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
11474986|NCT01528436|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
11474987|NCT01528436|Active Comparator|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
11474988|NCT01528423||Men 16 - 18yrs|
11474989|NCT01528423||Men 30 - 32 yrs|
11474990|NCT01528423||Men 70 yrs +|
11474991|NCT01528423||Women 16 - 18 yrs|
11474992|NCT01528423||Women 30 - 32 yrs|
11474993|NCT01528423||Women 70 yrs +|
11474994|NCT01528410|Experimental|ALFApump removal of ascites|Removal of ascites
11474995|NCT01528410|Active Comparator|Large volume paracentesis for removal of ascites|Removal of ascites
11474996|NCT01528371|Active Comparator|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
11474997|NCT01528371|Placebo Comparator|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
11474998|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
11474999|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
11475000|NCT01528345|Experimental|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
11475001|NCT01528345|Placebo Comparator|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
11475002|NCT01528332|Experimental|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
11475003|NCT01528332|Active Comparator|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
11475004|NCT01528319|Experimental|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
11475005|NCT01528306|Experimental|HP802-247|
11475006|NCT01528306|Placebo Comparator|Placebo (Vehicle)|
11475007|NCT01528293|Active Comparator|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
11475008|NCT01528293|Other|Compression therapy only|Standard of Care compression therapy only
11475009|NCT01528280|Experimental|Shiftwork|The comparison will consider nightworkers versus dayworkers.
11475010|NCT01528267|Active Comparator|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
11475011|NCT01528267|Sham Comparator|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
11475012|NCT01528254|Active Comparator|Vilda 50mg bid + metformin|Metformin + vildagliptin
11475013|NCT01528254|Experimental|Placebo + metformin|Metformin + Placebo of vildagliptin
11475014|NCT01528241|Experimental|ABP688|Elderly MDD patients and demography matched healthy volunteer
11475015|NCT01528228|Active Comparator|Structured TENS Therapy|This group will be given an active TENS unit to use.
11475016|NCT01528228|Sham Comparator|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
11475017|NCT01528215|Experimental|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
11475018|NCT01528215|Active Comparator|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
11475019|NCT01528202|No Intervention|Baseline placebo|measures taken before administration of placebo
11475020|NCT01528202|Placebo Comparator|Placebo|Placebo intervention given after 'baseline placebo' arm
11475021|NCT01528202|No Intervention|baseline cherry juice|measures taken before the cherry juice intervention
11475022|NCT01528202|Experimental|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
11475023|NCT01528189|Placebo Comparator|Standard glucose management|
11475024|NCT01528189|Active Comparator|Hyperinsulinemic normoglycemic clamp|
11475025|NCT01528176|Other|(CKD) stages III-V and non -CKD patients|We recruited patients with wide range of eGFR
11475026|NCT01528163|Experimental|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
11475027|NCT01528163|Active Comparator|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.
~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
11475028|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
11475029|NCT01528137|Experimental|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
11475030|NCT01528124|Placebo Comparator|Placebo|0.9% sodium chloride given as a single subcutaneous injection
11475031|NCT01528124|Experimental|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
11475032|NCT01528111|Experimental|Low dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
11475033|NCT01528111|Experimental|High dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
11475034|NCT01528111|Placebo Comparator|LX7101 Vehicle|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
11475035|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
11475036|NCT01528098||PEG 4L|Those who taken PEG 4L alone
11475037|NCT01528072|Experimental|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
11475038|NCT01528059|Active Comparator|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
11475039|NCT01528059|Active Comparator|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
11475040|NCT01528046|Experimental|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
11475041|NCT01528033|Experimental|Vacuum Assisted Closure®|Negative pressure wound therapy
11475042|NCT01528033|Active Comparator|Standard conventional wound therapy|According to institutional clinical standards
11475043|NCT01528020|Experimental|Dialectical Behavior Therapy|
11475044|NCT01528020|Active Comparator|Inidividual and Group Supportive Therapy|
11475045|NCT01528007|Placebo Comparator|Placebo pill.|
11475046|NCT01528007|Active Comparator|50mg Naltrexone when needed|
11475047|NCT01527994|Experimental|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
11475048|NCT01527994|Placebo Comparator|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
11475049|NCT01527981|Experimental|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
11475050|NCT01527968|Active Comparator|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
11475051|NCT01527968|Active Comparator|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
11475052|NCT01527968|Placebo Comparator|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
11475053|NCT01527942|Experimental|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
11475152|NCT01527162|Experimental|SAFO worn|Child wears their prescribed SAFO for 14 days
11475054|NCT01527942|Placebo Comparator|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
11475055|NCT01527929|Experimental|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
11475056|NCT01527929|Experimental|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
11475057|NCT01527929|Experimental|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
11475058|NCT01527916|Placebo Comparator|sugar pill|
11475059|NCT01527916|Active Comparator|donepezil|
11475060|NCT01527916|Experimental|ABT-126 Low Dose|low dose
11475061|NCT01527916|Experimental|ABT-126 Middle Dose|middle dose
11475062|NCT01527916|Experimental|ABT-126 high dose|high dose
11475063|NCT01527903|Active Comparator|Propofol|
11475064|NCT01527903|Active Comparator|Midazolam|
11475065|NCT01527877|Experimental|BKM120|
11475066|NCT01527864|Experimental|pegylated endostatin|
11475067|NCT01527864|Placebo Comparator|Control|
11475068|NCT01527838|Experimental|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
11475069|NCT01527825|Active Comparator|Single dose|Trivalent Influenza Vaccine (seasonal)
11475070|NCT01527825|Experimental|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
11475071|NCT01527825|Experimental|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
11475072|NCT01527812|Experimental|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
11475073|NCT01527812|Experimental|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
11475074|NCT01527812|Experimental|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
11475075|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
11475076|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
11475077|NCT01527786|Experimental|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
11475078|NCT01527773||COPD cohort|Cohort of patients with proven COPD
11475079|NCT01527747|Placebo Comparator|Placebo|Placebo arm
11475080|NCT01527747|Experimental|Saxagliptin|Active drug arm
11475081|NCT01527734|Placebo Comparator|Placebo|
11475082|NCT01527734|Experimental|Tetrodotoxin, TTX|
11475083|NCT01527721|Experimental|CxL group|Volunteers of this group received CxL treatment.
11475084|NCT01527721|Experimental|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
11475085|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
11475086|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
11475087|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
11475088|NCT01527695|Experimental|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
11475089|NCT01527695|Experimental|Placebo|AZD3241 placebo bid for 8 weeks
11475090|NCT01527682|Other|Latanoprost, Dorzolamide|According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.
11475091|NCT01527669|Experimental|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
11475092|NCT01527669|Experimental|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
11475093|NCT01527656|Experimental|Formulation A|
11475094|NCT01527656|Experimental|Formulation B|
11475095|NCT01527643|Experimental|Formulation A|
11475096|NCT01527643|Experimental|Formulation B|
11475097|NCT01527630|Experimental|Formulation A|
11475098|NCT01527630|Experimental|Formulation B|
11475099|NCT01527617|Active Comparator|Cranberry beverage|
11475100|NCT01527617|Placebo Comparator|Non-cranberry beverage|
11475101|NCT01527604|Active Comparator|Avenanthramide-enriched oat muffin|
11475102|NCT01527604|Placebo Comparator|Refined flour muffin|
11475103|NCT01527565|Experimental|Formulation A|
11475104|NCT01527565|Experimental|Formulation B|
11475105|NCT01527552|Experimental|Formulation A|
11475106|NCT01527552|Experimental|Formulation B|
11475107|NCT01527539|Experimental|BIAsp 30|
11475108|NCT01527513|Experimental|Eslicarbazepine acetate (BIA 2-093)|
11475109|NCT01527513|Placebo Comparator|Placebo|
11475110|NCT01527500|Experimental|LFG316 higher dose|LFG316 10 mg/100 μL
11475111|NCT01527500|Sham Comparator|Sham|Sham injection
11475112|NCT01527500|Experimental|LFG316 lower dose|LFG316 5 mg/ 50 μL
11475113|NCT01527487|Experimental|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard
~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
11475114|NCT01527487|Experimental|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion
~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
11475115|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
11475116|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
11475153|NCT01527162|No Intervention|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
11475117|NCT01527448|Experimental|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
11475118|NCT01527409|Experimental|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.
~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.
~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.
~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
11475119|NCT01527409|No Intervention|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).
~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
11475120|NCT01527383|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11475121|NCT01527383|Placebo Comparator|Placebo|Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11475122|NCT01527370|Experimental|Zoster Vaccine Live|
11475123|NCT01527357|Experimental|Fibrocaps + Gelatin Sponge|Single application of Fibrocaps plus gelatin sponge.
11475124|NCT01527357|Active Comparator|Gelatin Sponge|Single application of gelatin sponge alone.
11475125|NCT01527331|No Intervention|control group|usual care
11475126|NCT01527331|Experimental|Video decision aid arm|
11475127|NCT01527318|Experimental|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
11475128|NCT01527305|Experimental|Paliperidone palmitate|
11475129|NCT01527292|Active Comparator|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
11475130|NCT01527292|Experimental|Treatment Group|SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
11475131|NCT01527279|Placebo Comparator|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
11475132|NCT01527279|Experimental|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
11475133|NCT01527266|Experimental|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
11475134|NCT01527266|Experimental|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
11475135|NCT01527266|Placebo Comparator|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
11475136|NCT01527266|Placebo Comparator|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
11475137|NCT01527253|Experimental|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
11475138|NCT01527253|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
11475139|NCT01527240|Experimental|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
11475140|NCT01527240|Placebo Comparator|Placebo|Injectable Saline Solution.
11475141|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
11475142|NCT01527214|Experimental|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
11475143|NCT01527214|No Intervention|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
11475144|NCT01527201|Experimental|Treatment Group|Worn out cartilage will be surgically treated.
11475145|NCT01527201|No Intervention|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
11475146|NCT01527188|Experimental|100IR|
11475147|NCT01527188|Experimental|300IR|
11475148|NCT01527188|Experimental|500IR|
11475149|NCT01527188|Placebo Comparator|Placebo|
11475150|NCT01527175|Active Comparator|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
11475151|NCT01527175|Placebo Comparator|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
11475154|NCT01527149|Experimental|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.
~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.
~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Eligible patients then undergo standard HDC-ASCT."
11475155|NCT01527136|Experimental|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11475156|NCT01527123|Experimental|GSK2585823|External Preparation
11475157|NCT01527110|Experimental|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
11475158|NCT01527097|Experimental|Atorvastatin|
11475159|NCT01527097|Placebo Comparator|Placebo|
11475160|NCT01527084|Other|Group A|undergo surgery between days 10 - 15 after PCD
11475161|NCT01527084|Other|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,
~Persistent sepsis or symptoms
~Worsening of clinical condition
~Failure to thrive
~Complications of SAP or PCD"
11475162|NCT01527058|Experimental|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
11475163|NCT01527045|Experimental|Prevention (donor statin treatment)|See Detailed Description
11475164|NCT01527019|Experimental|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
11475165|NCT01527019|Experimental|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
11475166|NCT01527019|Active Comparator|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
11475167|NCT01527006|Experimental|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
11475168|NCT01526980|Experimental|Treatment period 1|
11475169|NCT01526980|Active Comparator|Treatment period 2|
11475170|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
11475171|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
11475172|NCT01526954|Experimental|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
11475173|NCT01526954|No Intervention|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
11475174|NCT01526941|Experimental|Treatment period 1|
11475175|NCT01526941|Experimental|Treatment period 2|
11475176|NCT01526928|Experimental|Rociletinib <900 mg BID FB formulation|Rociletinib free base (FB) dose <900 mg twice a day (BID)
11475177|NCT01526928|Experimental|Rociletinib 900 mg BID FB formulation|Rociletinib free base (FB) dose 900 mg twice a day (BID)
11475178|NCT01526928|Experimental|Rociletinib 500 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)
11475179|NCT01526928|Experimental|Rociletinib 625 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)
11475180|NCT01526928|Experimental|Rociletinib 750 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)
11475181|NCT01526928|Experimental|Rociletinib 1000 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)
11475182|NCT01526915|Experimental|Bone curettage + PRF|Bone curettage and PRF insertion
11475183|NCT01526915|Other|Bone curettage alone|Bone curettage without PRF insertion
11475184|NCT01526902|Active Comparator|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)
~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
11475185|NCT01526902|Active Comparator|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)
~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
11475186|NCT01526889|Experimental|LFG316 -Intravitreal Injection|
11475187|NCT01526889|Active Comparator|Conventional Therapy|
11475188|NCT01526876|Experimental|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
11475189|NCT01526863|Placebo Comparator|Placebo|
11475190|NCT01526863|Active Comparator|HA egg|
11475191|NCT01526850|Experimental|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
11475192|NCT01526850|Active Comparator|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
11475193|NCT01526837|Experimental|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
11475194|NCT01526824|No Intervention|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
11475195|NCT01526824|Experimental|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
11475301|NCT01526148|Active Comparator|Quetiapine|
11479304|NCT01499225|Experimental|YH14642 A-III|
11475196|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
11475197|NCT01526798|Experimental|Therlite hemodialysis|
11475198|NCT01526798|Active Comparator|Control group hfHDF|Control group hfHDF
11475199|NCT01526785|Experimental|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
11475200|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
11475201|NCT01526759|Experimental|pectin|10 gram high gelling-high viscous fiber, added to a drink
11475202|NCT01526759|Placebo Comparator|control|10g gelatin, added to a drink
11475203|NCT01526746|Experimental|End Stage Renal Disease, dialysis|eGFR <15 ml/min/1.73m^2
11475204|NCT01526746|Experimental|Severe renal impairment|eGFR < 29 ml/min/1.73m^2
11475205|NCT01526746|Experimental|Healthy controls|eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
11475206|NCT01526733|Sham Comparator|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.
~Each Phase was separated by a washout period of 5 to 21 days."
11475207|NCT01526733|Experimental|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).
~Each Phase was separated by a washout period of 5 to 21 days."
11475208|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
11475209|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
11475210|NCT01526707|Experimental|inhaled steroid|inhaled steroid treatment for 7 days
11475211|NCT01526694|Experimental|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
11475212|NCT01526681||RANGER: Avance Nerve Graft|Processed Human Nerve Graft
11475213|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
11475214|NCT01526681||MATCH Arm: Contemporary Control|Addendum 1: Autogenous Nerve Graft and Nerve Tube Conduit
11475215|NCT01526681||Sensation-NOW Arm: Breast Neurotization|Addendum 2: Post-mastectomy autologous breast reconstruction with or without neurotization
11475216|NCT01526668|Active Comparator|No contact after discharge|In Arm A: The patient do not have planned contacts with the study nurse or doctor after discharge. All patients are seen by the study nurse six weeks postoperatively.
11475217|NCT01526668|Active Comparator|Single telephone contact|In Arm B: The patient has one planned telephone contact with the study nurse the day after discharge. All patients are seen by the study nurse six weeks postoperatively.
11475218|NCT01526668|Active Comparator|Telephone contacts regularly|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively.
11475219|NCT01526668|Active Comparator|Telephone contact using CBT-inspired strategy|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively. At these telephone contacts the study nurse uses a cognitive behavior therapy (CBT)-inspired strategy in counselling and support.
11475220|NCT01526655|Active Comparator|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
11475221|NCT01526655|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
11475222|NCT01526642|No Intervention|Long Term Oxygen Therapy|
11475223|NCT01526642|Active Comparator|Non Invasive Ventilation|
11475224|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
11475225|NCT01526616|Active Comparator|Metformin|850 mg/day twice a day
11475226|NCT01526616|Active Comparator|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
11475227|NCT01526603|Other|Patients Treated for Neuroblastoma|According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
11475228|NCT01526590|Experimental|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
11475229|NCT01526577|Experimental|LC23-1306|experimental drug
11475230|NCT01526577|Placebo Comparator|placebo|LC23-1306 placebo
11475231|NCT01526577|Active Comparator|Ticagrelor|active comparator
11475232|NCT01526564|Active Comparator|ALC|ALC
11475233|NCT01526564|Placebo Comparator|Placebo|
11475234|NCT01526551|Experimental|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
11475235|NCT01526538|Experimental|50 mg d-cycloserine|active drug condition
11475236|NCT01526538|Placebo Comparator|Sugar pill|Inactive placebo
11475302|NCT01526135|Active Comparator|Arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
11475347|NCT01525836|Experimental|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
11475237|NCT01526525|Placebo Comparator|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
11475238|NCT01526525|Active Comparator|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
11475239|NCT01526512|Experimental|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
11475240|NCT01526499|Experimental|TC|Docetaxel plus Cyclophosphamide
11475241|NCT01526499|Active Comparator|T|Docetaxel
11475242|NCT01526486|Experimental|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
11475243|NCT01526486|Active Comparator|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
11475244|NCT01526473|Experimental|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
11475245|NCT01526460|Active Comparator|Atorvastatin|Atorvastatin 80 mg
11475246|NCT01526460|Active Comparator|Rosuvastatin|Rosuvastatin 40 mg
11475247|NCT01526460|Placebo Comparator|No statin loading dose|No statin loading dose
11475248|NCT01526447|Experimental|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
11475249|NCT01526447|Sham Comparator|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
11475250|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
11475251|NCT01526421|Experimental|monetary reinforcer|
11475252|NCT01526421|No Intervention|no reinforcer|
11475253|NCT01526408|Placebo Comparator|Placebo Arm|Treatment with 3 months of placebo
11475254|NCT01526408|Active Comparator|Active Arm|Treatment with 3 months of active drug
11475255|NCT01526395|No Intervention|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
11475256|NCT01526395|Active Comparator|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
11475257|NCT01526382|Active Comparator|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
11475258|NCT01526382|Placebo Comparator|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
11475259|NCT01526369|Active Comparator|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
11475260|NCT01526369|Experimental|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)
~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
11475261|NCT01526356|Placebo Comparator|Placebo|Cream only
11475262|NCT01526356|Active Comparator|0.1 % Rapamycin|0.1% Rapamycin cream
11475263|NCT01526356|Active Comparator|1% Rapamycin|1% Rapamycin cream
11475264|NCT01526343|Experimental|Reveal XT|
11475265|NCT01526330|Experimental|Group A|
11475266|NCT01526330|Experimental|Group B|
11475267|NCT01526330|Experimental|Group C|
11475268|NCT01526330|Placebo Comparator|Group D|
11475269|NCT01526317|Experimental|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
11475270|NCT01526317|Experimental|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
11475271|NCT01526317|Experimental|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
11475272|NCT01526317|Experimental|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
11475273|NCT01526317|Experimental|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
11475274|NCT01526317|Experimental|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
11475275|NCT01526278|Other|Maxmarvil®|single-arm study
11475346|NCT01525849|Active Comparator|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
11475439|NCT01525147|Experimental|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
11475276|NCT01526265|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
11475277|NCT01526265|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
11475278|NCT01526265|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
11475279|NCT01526265|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
11475280|NCT01526265|Experimental|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
11475281|NCT01526239|Experimental|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
11475282|NCT01526239|No Intervention|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
11475283|NCT01526226|Experimental|HFNC|High flow nasal cannula
11475284|NCT01526226|Active Comparator|nCPAP|Nasal CPAP
11475285|NCT01526213|Other|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
11475286|NCT01526213|Other|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
11475287|NCT01526213|Other|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
11475288|NCT01526213|Other|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
11475289|NCT01526213|Other|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
11475290|NCT01526213|Other|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
11475291|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients -77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)- underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
11475292|NCT01526187||Sub-Saharan Africa|
11475293|NCT01526187||Asia|
11475294|NCT01526187||Latin America|
11475295|NCT01526174|Experimental|First Arm|Determine safety of intratympanic injection
11475296|NCT01526174|Experimental|Second Arm|Efficacy evaluation of 4 intratympanic injections
11475297|NCT01526161|Experimental|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
11475298|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
11475299|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
11475300|NCT01526148|Active Comparator|Lithium|
11475303|NCT01526135|Experimental|Arm B mFOLFIRINOX|"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.
~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.
~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
11475304|NCT01526122|Experimental|G0041(75/100mg)|
11475305|NCT01526122|Active Comparator|Clopidogrel & Aspirin|
11475306|NCT01526109|Experimental|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
11475307|NCT01526109|Placebo Comparator|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
11475308|NCT01526109|Experimental|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
11475309|NCT01526096|Active Comparator|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
11475310|NCT01526096|Experimental|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
11475311|NCT01526096|Experimental|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
11475312|NCT01526083|Other|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
11475313|NCT01526083|Other|Single dose of Warfarin|
11475314|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
11475315|NCT01526057|Experimental|A - PF-05280586|
11475316|NCT01526057|Active Comparator|B - Rituximab EU|
11475317|NCT01526057|Active Comparator|C- Rituximab-US|
11475318|NCT01526044|Experimental|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
11475319|NCT01526044|Active Comparator|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
11475320|NCT01526031|Experimental|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
11475321|NCT01526031|Experimental|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
11475322|NCT01526031|Placebo Comparator|NS|Normal saline injection plus physiotherapy
11475323|NCT01526018||Novel bottle|
11475324|NCT01526005||Active agent (nicotine patch)|
11475325|NCT01526005||Placebo patch|
11475326|NCT01525992|Experimental|Community Pharmacy-based Program|
11475327|NCT01525992|Active Comparator|Usual care|
11475328|NCT01525979|Experimental|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
11475329|NCT01525979|Experimental|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
11475330|NCT01525979|Experimental|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
11475331|NCT01525979|Experimental|Robot-assisted UAT|Robot-assisted unilateral arm training
11475332|NCT01525979|Experimental|Robot-assisted BAT|Robot-assisted bilateral arm training
11475333|NCT01525966|Experimental|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11475334|NCT01525940|Other|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
11475335|NCT01525927|Active Comparator|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
11475336|NCT01525927|Experimental|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
11475337|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
11475338|NCT01525901|Experimental|Insulin-Like Growth Factor-1 (IGF-1)|Injection
11475339|NCT01525901|Placebo Comparator|Normal saline|Injection
11475340|NCT01525888|No Intervention|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
11475341|NCT01525888|Experimental|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
11475342|NCT01525875|Active Comparator|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).
~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
11475343|NCT01525875|Placebo Comparator|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
11475344|NCT01525862|Experimental|Balloon sinus dilation|Balloon dilation of the maxillary sinus using a transnasal approach.
11475345|NCT01525849|Active Comparator|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
11475348|NCT01525836|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
11475349|NCT01525823|Experimental|BMS-754807 + Metformin|
11475350|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
11475351|NCT01525797||Control|
11475352|NCT01525797||Rejection|
11475353|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
11475354|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
11475355|NCT01525771|No Intervention|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
11475356|NCT01525758|Experimental|SI000413 400mg|tablet, SI000413 200mg bid
11475357|NCT01525758|Experimental|SI000413 600mg|tablet, SI000413 200mg tid
11475358|NCT01525758|Experimental|SI000413 800mg|SI000413 200mg, 2T bid
11475359|NCT01525758|Placebo Comparator|placebo|placebo 2T tid for 8 weeks
11475360|NCT01525745|Active Comparator|Radiosurgery/SBRT|Radiosurgery/SBRT
11475361|NCT01525745|Active Comparator|External Beam Radiation Therapy|External Beam Radiation Therapy
11475362|NCT01525732|Other|POEM|Per Oral Endoscopic Myotomy
11475363|NCT01525719|Experimental|RAD001|
11475364|NCT01525706|Experimental|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
11475365|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
11475366|NCT01525680|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
11475367|NCT01525680|Placebo Comparator|Prolonged Exposure therapy with placebo|
11475368|NCT01525667|Experimental|150M PLX-PAD|Single course, multiple IM injections
11475369|NCT01525667|Experimental|300M PLX-PAD|Single course, multiple IM injections
11475370|NCT01525667|Placebo Comparator|Placebo|Single course, multiple IM injections
11475371|NCT01525654|Active Comparator|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
11475372|NCT01525654|No Intervention|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
11475373|NCT01525641||Patient with Parkinson's Disease|
11475374|NCT01525628|Experimental|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
11475375|NCT01525628|Experimental|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
11475376|NCT01525628|Experimental|Group C|Effect of Dual oral DAAs on tenofovir
11475377|NCT01525628|Experimental|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
11475378|NCT01525628|Experimental|Group E|Effect of BI 201335 and BI 207127 on raltegravir
11475379|NCT01525615|Experimental|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
11475380|NCT01525615|Experimental|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
11475381|NCT01525615|Placebo Comparator|placebo|once daily 2 puffs, solution for inhalation Respimat
11475382|NCT01525602|Experimental|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.
~(Closed to recruitment)"
11475383|NCT01525602|Experimental|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.
~(Closed to recruitment)"
11475384|NCT01525602|Experimental|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
~(Closed to recruitment)"
11475385|NCT01525589|Experimental|PM01183|
11475386|NCT01525576|No Intervention|Control group|No offer of booster program.
11475387|NCT01525576|Experimental|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
11475388|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
11475389|NCT01525550|Experimental|sunitinib|
11475390|NCT01525537|Experimental|SPI guided arm|sufentanil was adjusted to SPI level
11475391|NCT01525537|Active Comparator|Standard practise|Sufentanil was given at standard practise
11475392|NCT01525524|Sham Comparator|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
11475393|NCT01525524|Active Comparator|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
11475394|NCT01525511|Experimental|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
11475395|NCT01525511|Active Comparator|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
11475396|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
11475397|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
11479305|NCT01499225|Active Comparator|Active Comparator B|
11475398|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
11475399|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
11475400|NCT01525459||Glioma patients|
11475401|NCT01525446|Experimental|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
11475402|NCT01525433|No Intervention|Control|
11475403|NCT01525433|Active Comparator|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
11475404|NCT01525433|Active Comparator|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
11475405|NCT01525420|Experimental|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
11475406|NCT01525420|Active Comparator|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
11475407|NCT01525407|Experimental|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
11475408|NCT01525394|Experimental|Lenvatinib Capsules|
11475409|NCT01525394|Active Comparator|Moxifloxacin tablets|
11475410|NCT01525394|Placebo Comparator|Placebos|
11475411|NCT01525368||cognitive intervention group|
11475412|NCT01525368||active control group|
11475413|NCT01525355||EUS prior to ERCP|
11475414|NCT01525329|Experimental|Solid Organ Transplant with AKs|Patients who have undergone kidney or liver transplant within 2 years and have at least 4 premalignant skin lesions on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
11475415|NCT01525329|Active Comparator|Actinic Keratoses|Patients with at least 4 actinic keratoses on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
11475416|NCT01525316|Experimental|Bovine Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
11475417|NCT01525316|Placebo Comparator|Maltodextrin|Maltodextrin is an inert sugar.
11475418|NCT01525303|Experimental|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
11475419|NCT01525303|Experimental|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
11475420|NCT01525290|Experimental|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
11475421|NCT01525290|Placebo Comparator|Placebo|Intervention drug: placebo
11475422|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
11475423|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
11475424|NCT01525264|Experimental|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
11475425|NCT01525264|Active Comparator|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
11475426|NCT01525238|Experimental|Dapagliflozin 2.5 mg|
11475427|NCT01525238|Experimental|Dapagliflozin 5 mg|
11475428|NCT01525238|Experimental|Dapagliflozin 10 mg|
11475429|NCT01525225|Experimental|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
11475430|NCT01525212|Experimental|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
11475431|NCT01525212|Experimental|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
11475432|NCT01525212|Experimental|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
11475433|NCT01525212|Experimental|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
11475434|NCT01525199||Case|
11475435|NCT01525199||Control|
11475436|NCT01525173|Active Comparator|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
11475437|NCT01525173|Active Comparator|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
11475438|NCT01525147|Experimental|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
11475440|NCT01525147|Experimental|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
11475441|NCT01525147|Experimental|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
11475442|NCT01525147|Experimental|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
11475443|NCT01525121|Experimental|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
11475444|NCT01525121|No Intervention|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
11475445|NCT01525108|Experimental|Home-based blood pressure monitoring|
11475446|NCT01525108|Active Comparator|Usual care|
11475447|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
11475448|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
11475449|NCT01525082|Experimental|monoclonal antibody therapy, chemotherapy|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, capecitabine PO BID on days 1-14, and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11475450|NCT01525069|Experimental|Arm A (HAI FUDR alone)|"14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
11475451|NCT01525069|Experimental|Arm B (HAI FUDR + gemcitabine)|"Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.
~Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1
~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 & B3
~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
11475452|NCT01525069|Experimental|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.
~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.
~Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.
~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.
~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
11475453|NCT01525056|Other|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
11475454|NCT01525043|Active Comparator|Naproxen|
11475455|NCT01525043|Experimental|Synera single patch applied for 12 hrs/day|
11475456|NCT01525043|Experimental|Synera sinlgle patch applied for 4hrs twice daily|
11475457|NCT01525017|Experimental|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
11475458|NCT01525004|Active Comparator|Standard dose trivalent inactivated influenza vaccine|
11475459|NCT01525004|Experimental|High-Dose trivalent inactivated influenza vaccine|
11475460|NCT01524991|Experimental|Treatment|Gemcitabine 1000 mg/m2 Days 1 & 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
11475461|NCT01524978|Experimental|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
11475462|NCT01524978|Experimental|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
11475463|NCT01524978|Experimental|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
11475464|NCT01524978|Experimental|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
11475465|NCT01524978|Experimental|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
11475466|NCT01524978|Experimental|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
11475519|NCT01524653|Experimental|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
11475648|NCT01523925|Experimental|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
11475467|NCT01524978|Experimental|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
11475468|NCT01524965|Experimental|Immediate mobilisation|
11475469|NCT01524965|Active Comparator|Standard mobilisation|
11475470|NCT01524952|Experimental|Active|cTEMS
11475471|NCT01524939|Experimental|Investigational product|
11475472|NCT01524926|Experimental|Crizotinib in Anaplastic large cell lymphoma|
11475473|NCT01524926|Experimental|Crizotinib in Inflammatory myofibroblastic tumor|
11475474|NCT01524926|Experimental|Crizotinib in Papillary renal cell carcinoma type 1|
11475475|NCT01524926|Experimental|Crizotinib in Clear cell sarcoma|
11475476|NCT01524926|Experimental|Crizotinib in Alveolar soft part sarcoma|
11475477|NCT01524926|Experimental|Crizotinib in Alveolar rhabdomyosarcoma|
11475478|NCT01524913|Experimental|Hyaluronic acid|
11475479|NCT01524913|Active Comparator|Corticosteroid|
11475480|NCT01524913|Placebo Comparator|Saline|
11475481|NCT01524900||nevirapine extended release|
11475482|NCT01524887|Experimental|IGIV, 10% at high dose (0.4 g/kg)|
11475483|NCT01524887|Experimental|IGIV, 10% at low dose (0.2 g/kg)|
11475484|NCT01524887|Placebo Comparator|Placebo control|
11475485|NCT01524874|Active Comparator|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
11475486|NCT01524874|Active Comparator|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
11475487|NCT01524874|Active Comparator|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
11475488|NCT01524861|Placebo Comparator|Placebo|30 subjects receive placebo (placebo group)
11475489|NCT01524861|Experimental|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
11475490|NCT01524861|Experimental|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
11475491|NCT01524848|Other|Open label|Single arm pazopanib
11475492|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
11475493|NCT01524822||Artillery personnel|exposure to a significant number of concussive evolutions, specifically, exposure to 400 or more within a career, will be considered experienced by the investigators.
11475494|NCT01524822||Breachers|exposure to a significant number of breaching blasts, specifically, exposure to 400 breaching blasts or more within a career, will be considered experienced by the investigators
11475495|NCT01524822||Companions|The criterion is met by a person who has both some historical knowledge of the participant and routine interactions outside a work environment.
11475496|NCT01524822||Unexposed|People not exposed to repeated blasts
11475497|NCT01524809|Experimental|Treatment period 1|
11475498|NCT01524809|Experimental|Treatment period 2|
11475499|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
11475500|NCT01524783|Experimental|Everolimus + BSC|Participants received everolimus 10mg once daily until disease progression, intolerable toxicity, or consent withdrawal plus best supportive care (BSC)
11475501|NCT01524783|Placebo Comparator|Everolimus Placebo + BSC|Participants received matching placebo to everolimus with same dose, plus best supportive care (BSC)
11475502|NCT01524770|Active Comparator|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
11475503|NCT01524770|Experimental|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
11475504|NCT01524757|Experimental|pantoprazol|
11475505|NCT01524757|Placebo Comparator|placebo|
11475506|NCT01524744|Active Comparator|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
11475507|NCT01524744|Active Comparator|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
11475508|NCT01524731|Placebo Comparator|Placebo|Placebo group
11475509|NCT01524731|Active Comparator|4 mg dexamethasone|4 mg dexamethasone group
11475510|NCT01524731|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg group
11475511|NCT01524718|Experimental|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
11475512|NCT01524718|No Intervention|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
11475513|NCT01524705|Experimental|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 DM participants will be instructed on an AHA/ADA meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual HBA1Cs between 6.7 and 7.3% throughout the trial.
11475514|NCT01524705|Active Comparator|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
11475515|NCT01524692|Experimental|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
11475516|NCT01524679|Experimental|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
11475517|NCT01524679|No Intervention|Control group|ongoing nucleos(t)ide based treatment alone
11475518|NCT01524653|Experimental|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
11475610|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
11475520|NCT01524640|Experimental|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version
~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
11475521|NCT01524640|Placebo Comparator|Placebo|"Non biologic placebo
~Ingredients Per 1.5 ml dose
~Starch 60mg
~Red color[1mg/ml] 10 µl
~Yellow color [1mg/ml] 5 µl
~Xanthum Gum (1% solution) 300 µl
~Water for Injection Upto 1.5 ml
~All the above ingredients are of pharmaceutical grade.
~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
11475522|NCT01524627|Placebo Comparator|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
11475523|NCT01524627|Active Comparator|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
11475524|NCT01524614|Experimental|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
11475525|NCT01524614|Experimental|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
11475526|NCT01524614|Experimental|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
11475527|NCT01524614|Experimental|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
11475528|NCT01524601|Experimental|Rosuvastatin|Rosuvastatin treatment for 4 weeks
11475529|NCT01524575|No Intervention|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
11475530|NCT01524575|Experimental|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
11475531|NCT01524562||Rakai Community Cohort|HIV Patients
11475532|NCT01524562||Rakai HIV Care Program|HIV Patients
11475533|NCT01524549||WT for CYP2J2*7 and heterozygous for EPHX2 K55R|SNP
11475534|NCT01524549||WT for CYP2J2*7 and homozygous for EPHX2 K55R|SNP
11475535|NCT01524549||WT for EPHX2 K55R and heterozygous for CYP2J2*7|SNP
11475536|NCT01524549||WT for EPHX2 K55R and homozygous for CYP2J2*7|SNP
11475537|NCT01524549||WT for EPHX2 K55R and WT for CYP2J2*7|SNP
11475538|NCT01524536|Other|1|All subjects will receive a single oral dose of prednison (1 mg/kg rounded to the neares 5 mg). The subjects will then begin GC therapy at 30 mg prednisone daily followed by a standardized taper.
11475539|NCT01524510|Experimental|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
11475540|NCT01524497|Active Comparator|Trazodone|
11475541|NCT01524497|Placebo Comparator|Placebo|
11475542|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
11475543|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
11475544|NCT01524471|Experimental|POEM|Endoscopic Myotomy
11475545|NCT01524458|Experimental|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
11475546|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
11475547|NCT01524432|Experimental|Drug loaded microcapsules socks|Study medication
11475548|NCT01524432|Placebo Comparator|No drug loaded microcapsules socks|Placebo medication
11475549|NCT01524419||women after vaginal birth|
11475550|NCT01524406|Experimental|HPP593|
11475551|NCT01524406|Placebo Comparator|Placebo|
11475552|NCT01524393||IVF pregnancy|
11475553|NCT01524380|Active Comparator|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
11475554|NCT01524380|Placebo Comparator|Placebo|Treatment with placebo
11475555|NCT01524367|Placebo Comparator|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
11475556|NCT01524367|Experimental|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
11475557|NCT01524354|Active Comparator|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
11475558|NCT01524354|Active Comparator|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
11475559|NCT01524341|Experimental|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
11475560|NCT01524341|Experimental|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
11475561|NCT01524315|Experimental|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
11475562|NCT01524315|Placebo Comparator|Placebo|100 ml normal saline, intravenous, preoperative
11475563|NCT01524302|Active Comparator|Levofloxacin|Pharmacodynamics
11475564|NCT01524302|Active Comparator|Ceftaroline|Pharmacodynamics
11475565|NCT01524289|Experimental|Anacetrapib|Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
11475611|NCT01524016|Experimental|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
11475566|NCT01524289|Placebo Comparator|Placebo|Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.
11475567|NCT01524250|Experimental|oral prednisone|1250mg oral prednisone daily for 3 days
11475568|NCT01524250|Active Comparator|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
11475569|NCT01524237|Experimental|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
11475570|NCT01524237|Experimental|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
11475571|NCT01524237|Experimental|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
11475572|NCT01524237|Experimental|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
11475573|NCT01524237|Experimental|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
11475574|NCT01524237|Placebo Comparator|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
11475575|NCT01524237|Placebo Comparator|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
11475576|NCT01524224|Experimental|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.
~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
11475577|NCT01524211|Experimental|Single Treatment Arm|All subjects enrolled will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.
11475578|NCT01524198|Placebo Comparator|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if < 20 kg or 5 mg if >= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
11475579|NCT01524198|Active Comparator|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if < 20 kg body weight or 5 mg if >= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
11475580|NCT01524185|Experimental|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
11475581|NCT01524185|Active Comparator|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
11475582|NCT01524172|Active Comparator|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
11475583|NCT01524172|Experimental|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
11475584|NCT01524159|Placebo Comparator|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
11475585|NCT01524159|Active Comparator|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
11475586|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
11475587|NCT01524133|Active Comparator|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
11475588|NCT01524133|Active Comparator|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
11475589|NCT01524133|Active Comparator|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
11475590|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
11475591|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
11475592|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
11475593|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
11475594|NCT01524107||Urgent Caesarian Section|
11475595|NCT01524107||Elective Caesarian Section|
11475596|NCT01524094|Experimental|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
11475597|NCT01524094|Active Comparator|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
11475598|NCT01524081|Experimental|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
11475599|NCT01524081|Experimental|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
11475600|NCT01524081|Experimental|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
11475601|NCT01524081|Placebo Comparator|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
11475602|NCT01524081|Placebo Comparator|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
11475603|NCT01524081|Placebo Comparator|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
11475604|NCT01524068|Experimental|Arm A - Standard Steroid Treatment|
11475605|NCT01524068|Experimental|Arm B - Experimental Treatment|
11475606|NCT01524055|Other|Air|Air as insufflation gas during single-balloon enteroscopy.
11475607|NCT01524055|Other|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
11475608|NCT01524042|Experimental|group 2|study group:double pants group
11475609|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
11475644|NCT01523964|Other|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
11475612|NCT01524003|Experimental|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
11475613|NCT01524003|Active Comparator|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
11475614|NCT01523990|Experimental|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475615|NCT01523990|Placebo Comparator|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475616|NCT01523990|Experimental|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475617|NCT01523990|Placebo Comparator|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475618|NCT01523990|Experimental|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475619|NCT01523990|Placebo Comparator|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475620|NCT01523990|Experimental|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475621|NCT01523990|Placebo Comparator|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
11475622|NCT01523990|Experimental|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
11475623|NCT01523990|Placebo Comparator|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
11475624|NCT01523990|Experimental|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
11475625|NCT01523990|Placebo Comparator|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
11475626|NCT01523990|Experimental|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
11475627|NCT01523990|Placebo Comparator|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
11475628|NCT01523990|Experimental|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
11475629|NCT01523990|Placebo Comparator|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
11475630|NCT01523990|Experimental|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
11475631|NCT01523990|Placebo Comparator|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
11475632|NCT01523990|Experimental|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
11475633|NCT01523990|Placebo Comparator|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
11475634|NCT01523990|Experimental|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
11475635|NCT01523990|Placebo Comparator|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
11475636|NCT01523990|Experimental|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
11475637|NCT01523990|Experimental|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
11475638|NCT01523990|Experimental|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
11475639|NCT01523990|Experimental|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
11475640|NCT01523990|Experimental|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
11475641|NCT01523964|Other|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
11475642|NCT01523964|Other|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
11475643|NCT01523964|Other|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
11475649|NCT01523925|Experimental|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
11475650|NCT01523925|Active Comparator|Control intervention group|Control intervention
11475651|NCT01523925|Experimental|dCIT|distributed constraint induced therapy
11475652|NCT01523925|Experimental|BAT|bilateral arm treatment
11475653|NCT01523912|Experimental|gastric RFA|Ablation of gastric dysplastic mucosa
11475654|NCT01523899|Experimental|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
11475655|NCT01523899|Active Comparator|Standard culture|performance of standard bacterial culture of abscess material
11475656|NCT01523886|Active Comparator|Deep neuromuscular blockade|
11475657|NCT01523886|Placebo Comparator|Moderate neuromuscular blockade|
11475658|NCT01523860|Experimental|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
11475659|NCT01523847|Experimental|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)
~The subsequent treatment will be planned as follows:
~-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).
~-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
11475660|NCT01523834|Experimental|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.
~Treatment:
~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
11475661|NCT01523821|Other|Cohort 1 (30 mg/kg)|Alpha 1 anti-trypsin (AAT) will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 30mg/kg (maintenance dose) every other day (QOD) on days 3, 5, 7, 9, 11, 13 & 15.
11475662|NCT01523821|Other|Cohort 2 (60 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 60 mg/kg (maintenance dose) QOD on days 3, 5, 7, 9, 11, 13 & 15.
11475663|NCT01523821|Other|Cohort 3 (90 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg on days 1, 3, 5, 7, 9, 11, 13 & 15.
11475664|NCT01523808|Experimental|GRASPA 25|
11475665|NCT01523808|Experimental|GRASPA 50|
11475666|NCT01523808|Experimental|GRASPA 100|
11475667|NCT01523808|Experimental|GRASPA 150|
11475668|NCT01523795|Experimental|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
11475669|NCT01523795|Active Comparator|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
11475670|NCT01523795|Active Comparator|Television watching|Participants watched television via Netflix instant streaming for one hour
11475671|NCT01523782|Experimental|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
11475672|NCT01523782|Experimental|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
11475673|NCT01523782|Experimental|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
11475674|NCT01523769|No Intervention|Control|Control group, the cord was not milked
11475675|NCT01523769|Experimental|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
11475676|NCT01523756|Experimental|test product 1 first|"own product (baseline) - test product 1 - test product 2
~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
11475677|NCT01523756|Experimental|test product 2 first|"own product (baseline) - test product 2 - test product 1
~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
11475678|NCT01523743|Experimental|Compact catheter|Compact intermittent catheter
11475679|NCT01523743|Active Comparator|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
11475680|NCT01523730|Active Comparator|Repetitive Transcranial Magnetic Stimulation (rTMS)|
11475681|NCT01523730|Placebo Comparator|Sham rTMS|
11475682|NCT01523704|Experimental|HM|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
11475683|NCT01523704|Active Comparator|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
11475684|NCT01523691|Experimental|repeated sleep restriction and recovery|
11475685|NCT01523691|Experimental|control sleep|
11475686|NCT01523678|Experimental|Filgrastim|
11475687|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
11475688|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
11475689|NCT01523639|Active Comparator|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
11475690|NCT01523639|Placebo Comparator|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
11475691|NCT01523626|Other|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
11475692|NCT01523626|Other|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
11475693|NCT01523613|Active Comparator|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
11475694|NCT01523613|Active Comparator|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
11475695|NCT01523613|Active Comparator|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.
~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
11475696|NCT01523600|Experimental|Whole body vibration training|
11475697|NCT01523600|Active Comparator|Wellness group|
11475698|NCT01523587|Experimental|Afatinib|Patients receive afatinib tablets once daily
11475699|NCT01523587|Active Comparator|Erlotinib|Patients receive erlotinib tablets once daily
11475700|NCT01523574|Placebo Comparator|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
11475701|NCT01523574|Experimental|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
11475702|NCT01523561|No Intervention|usual care|The participants in the no intervention group were informed that they should continue living as usual
11475703|NCT01523561|Experimental|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
11475704|NCT01523548|Experimental|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
11475705|NCT01523535|Placebo Comparator|normal sleep|Subjects have 8 hours of sleep opportunity per night
11475706|NCT01523535|Experimental|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
11475707|NCT01523522|Active Comparator|myoblast injection|autologous myoblast
11475708|NCT01523522|Placebo Comparator|saline solution injection|saline solution injection in anal sphincter
11475709|NCT01523509|Experimental|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
11475710|NCT01523496|Active Comparator|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
11475711|NCT01523496|Active Comparator|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
11475712|NCT01523483|Experimental|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
11475713|NCT01523483|Placebo Comparator|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
11475714|NCT01523470|Active Comparator|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
11475715|NCT01523470|Experimental|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
11475716|NCT01523457|Experimental|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
11475717|NCT01523457|Experimental|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
11475718|NCT01523444|No Intervention|Treatment as Usual|
11475719|NCT01523444|Active Comparator|computer Screening & Brief Advice|All participants receiving care at the site assigned to the computer-facilitated screening and brief advice (cSBA) condition will receive the cSBA intervention as part of their care at that clinic.
11475775|NCT01523041|Experimental|BIAsp 50 final formulation|
11475776|NCT01523028|Experimental|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
11479306|NCT01499225|Active Comparator|Active Comparator C|
11475720|NCT01523444|Experimental|computer Screening & Brief Advice Plus|All participants receiving care at the site assigned to the cSBA+ condition will receive the cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider as part of care at that clinic.
11475721|NCT01523431|Active Comparator|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
11475722|NCT01523431|Experimental|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
11475723|NCT01523431|Active Comparator|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
11475724|NCT01523418||Group 1|
11475725|NCT01523405||1|
11475726|NCT01523392|Experimental|Ticagrelor|
11475727|NCT01523392|Active Comparator|Clopidogrel|
11475728|NCT01523366|Experimental|Ticagrelor|
11475729|NCT01523366|Active Comparator|Clopidogrel|
11475730|NCT01523353|Active Comparator|Exercise Intervention|4 week personalised exercise program on a static bicycle.
11475731|NCT01523353|No Intervention|Control Arm|Patients having standard preoperative preparation and advice.
11475732|NCT01523340||Erlotinib treatment|
11475733|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
11475734|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
11475735|NCT01523314|Experimental|dexamethasone - Cyclodextrin|
11475736|NCT01523314|Active Comparator|Avastin/Laser|
11475737|NCT01523301|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
11475738|NCT01523301|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
11475739|NCT01523288||Prader-Willi patients|
11475740|NCT01523288||Control group|Control group for ultrasound scan
11475741|NCT01523275|Experimental|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
11475742|NCT01523275|Placebo Comparator|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
11475743|NCT01523262|Active Comparator|Preconditioning and normal treatment|
11475744|NCT01523262|Placebo Comparator|normal treatment|Standard treatment
11475745|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
11475746|NCT01523236|Experimental|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
11475747|NCT01523236|Active Comparator|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
11475748|NCT01523236|Placebo Comparator|Placebo|Saline Placebo Nasal Spray
11475749|NCT01523223|Experimental|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
11475750|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
11475751|NCT01523197|Other|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
11475752|NCT01523184|Placebo Comparator|Placebo Capsule|Placebo Capsules
11475753|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 10 mg|
11475754|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 20 mg|
11475755|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 30 mg|
11475756|NCT01523171|Experimental|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
11475757|NCT01523158|Other|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
11475758|NCT01523145|Experimental|Intervention|
11475759|NCT01523145|Experimental|Control gruop|
11475760|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
11475761|NCT01523119|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
11475762|NCT01523119|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
11475763|NCT01523106|Active Comparator|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
11475764|NCT01523106|Placebo Comparator|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
11475765|NCT01523093|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
11475766|NCT01523093|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
11475767|NCT01523080|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
11475768|NCT01523080|Experimental|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
11475769|NCT01523067|Active Comparator|Vasomera (PB1046)|
11475770|NCT01523067|Placebo Comparator|0.9% Sodium Chloride|
11475771|NCT01523054|Experimental|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
11475772|NCT01523054|Active Comparator|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
11475773|NCT01523041|Experimental|BIAsp 70 clinical trial formulation|
11475774|NCT01523041|Experimental|BIAsp 70 final formulation|
11475777|NCT01523028|Experimental|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
11475778|NCT01523028|Experimental|200 mL black coffee|
11475779|NCT01523015|Experimental|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
11475780|NCT01523015|Active Comparator|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
11475781|NCT01523002|Active Comparator|Arm A: Metoprolol DDI and Pyramax 90-day re-dosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period; then 2 days of Pyramax followed by 1 day of Pyramax + metoprolol and then a 87 day follow-up period. Subjects will then receive Pyramax once daily for three days followed by a 40 day follow-up period and a study completion evaluation.
11475782|NCT01523002|Active Comparator|Arm B: Pyramax 60-day re-dosing|Subjects will take Pyramax once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take Pyramax once daily for 3 days followed by a 40 day follow-up period.
11475783|NCT01522989|Experimental|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
11475784|NCT01522976|Experimental|Arm I (azacitidine and lenalidomide)|Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11475785|NCT01522976|Experimental|Arm II (azacitidine)|Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11475786|NCT01522976|Experimental|Arm III (azacitidine and vorinostat)|Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
11475787|NCT01522963|Experimental|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
11475788|NCT01522963|Experimental|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
11475789|NCT01522963|Experimental|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
11475790|NCT01522963|Experimental|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
11475791|NCT01522950|Active Comparator|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
11475792|NCT01522950|Active Comparator|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
11475793|NCT01522950|Placebo Comparator|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
11475794|NCT01522937|Experimental|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
11475795|NCT01522924|Experimental|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
11475796|NCT01522924|No Intervention|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
11475797|NCT01522911|Other|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
11475798|NCT01522898|Active Comparator|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
11475799|NCT01522898|Experimental|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
11475800|NCT01522885|Active Comparator|KatGuide|Chest tube insertion is performed by using the KatGuide
11475801|NCT01522885|Active Comparator|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
11475802|NCT01522872|Experimental|Monotherapy TH-302 Dose Escalation|
11475803|NCT01522872|Experimental|TH-302 and Dexamethasone Dose Expansion|
11475804|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
11475805|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
11475806|NCT01522859|No Intervention|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
11475807|NCT01522859|Experimental|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
11475808|NCT01522846||Heparin|
11475809|NCT01522833||Cohort A|EGFR Wild Type patients
11475810|NCT01522833||Cohort B|EGFR mutation patients
11475811|NCT01522820|Experimental|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
11475812|NCT01522820|Experimental|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
11475813|NCT01522820|Experimental|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
11475814|NCT01522820|Experimental|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
11475815|NCT01522820|Experimental|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
11475816|NCT01522807|Experimental|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
11475817|NCT01522807|Experimental|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
11475818|NCT01522794|Experimental|NOX-H94|Single dose of NOX-H94
11475819|NCT01522794|Placebo Comparator|Placebo|Single dose of placebo control
11475820|NCT01522768|Experimental|Afatinib and Paclitaxel|This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.
11475821|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
11475822|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
11475823|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
11475824|NCT01522729|Experimental|Fentanyl|
11475825|NCT01522729|Experimental|Placebo|
11475826|NCT01522716|Experimental|Mesenchymal stromal cell treatment|
11475827|NCT01522703|Experimental|Broccoli Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
11475828|NCT01522703|Placebo Comparator|Alfalfa Sprouts|Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
11475829|NCT01522677|Experimental|PDT|Participants receive neoadjuvant 5-ALA and PDT.
11475830|NCT01522664|Experimental|Single group|
11475831|NCT01522651|Placebo Comparator|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks.
11475832|NCT01522651|Experimental|Ranolazine 750 mg|Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
11475833|NCT01522651|Experimental|Dronedarone 225 mg|Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
11475834|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 225 mg|Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
11475835|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 150 mg|Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
11475836|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
11475837|NCT01522638||Healthy subjects|
11475838|NCT01522625|Experimental|TDF|tenofovir disoproxil fumarate (TDF) 300mg
11475839|NCT01522625|Placebo Comparator|Placebo|
11475840|NCT01522612|Experimental|5-fluorouracil/leucovorin plus cetuximab|
11475841|NCT01522612|Active Comparator|5-fluorouracil/leucovorin alone|
11475842|NCT01522599|Active Comparator|ARDS-Net strategy (Control)|
11475843|NCT01522599|Experimental|ECCO2-R with 4 mL/Kg Vt (Treatment)|
11475844|NCT01522586|Experimental|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
11475845|NCT01522586|Placebo Comparator|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
11475846|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
11475847|NCT01522560|Placebo Comparator|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
11475848|NCT01522560|Active Comparator|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
11475849|NCT01522547|Experimental|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
11475850|NCT01522547|Experimental|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
11475851|NCT01522547|Experimental|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
11475852|NCT01522547|Experimental|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
11475853|NCT01522547|Experimental|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
11475854|NCT01522534|Experimental|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
11475855|NCT01522534|Active Comparator|Morphine|Intravenous Morphine and placebo blind block
11475856|NCT01522521|Experimental|1.|
11475857|NCT01522521|Placebo Comparator|2.|
11475858|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
11475859|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
11475860|NCT01522495|Experimental|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
11475861|NCT01522495|No Intervention|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
11475862|NCT01522495|Experimental|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.
~(30 participants)"
11475863|NCT01522495|Experimental|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
11475864|NCT01522482|Experimental|High saturated fat meal|
11475865|NCT01522482|Experimental|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
11475866|NCT01522482|Active Comparator|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
11475867|NCT01522469|Experimental|Crenolanib Besylate|
11475868|NCT01522456|Active Comparator|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
11475869|NCT01522456|Active Comparator|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
11475870|NCT01522443|Experimental|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.
~There will be a maximum of 10 infusions for mitoxantrone placebo."
11475871|NCT01522443|Active Comparator|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.
~There will be a maximum of 10 infusions for mitoxantrone."
11475872|NCT01522430|Experimental|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
11475873|NCT01522430|Sham Comparator|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
11475874|NCT01522417|Experimental|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
11475875|NCT01522417|Active Comparator|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
11475876|NCT01522417|Experimental|Long Tirofiban (Aggrastat)|"(Enrolment Completed) Tirofiban (Aggrastat) will be dosed as a 25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post PCI.
~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50U/kg and repeat dosing per protocol guidelines)."
11475877|NCT01522404|Experimental|Atomoxetine / Inactive Compound|Participants in this arm received atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose for up to weeks 29 and are then crossed over to Inactive compound group
11475878|NCT01522404|Placebo Comparator|Inactive compound / Atomoxetine|Subjects in this arm received a matching placebo that have inactive compound for up to weeks 29 and then are crossed over to receive active treatment of Atomoxetine
11475879|NCT01522391|Placebo Comparator|Placebo for DPK-060 ointment|
11475880|NCT01522391|Experimental|DPK-060 1% ointment|
11475881|NCT01522378|Experimental|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
11475882|NCT01522365|Active Comparator|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
11475883|NCT01522365|Active Comparator|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
11475884|NCT01522352|Experimental|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
11475885|NCT01522339|Experimental|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
11475886|NCT01522326|Experimental|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
11475887|NCT01522326|Active Comparator|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
11475888|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
11475889|NCT01522287|Active Comparator|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patients progress through BT STEPS."
11475890|NCT01522287|Active Comparator|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
11475891|NCT01522287|Active Comparator|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
11475892|NCT01522274|Active Comparator|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
11475893|NCT01522274|Active Comparator|Health education|Attend health education sessions 3x per week.
11475894|NCT01522261|Active Comparator|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
11475895|NCT01522261|Active Comparator|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
11475896|NCT01522248|Active Comparator|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
11475897|NCT01522248|Active Comparator|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
11475898|NCT01522235|Active Comparator|IVIg group|Double blinded IVIg and single blinded IVIg
11475899|NCT01522235|Other|Placebo Group|Double blinded Placebo and single blinded IVIg
11475900|NCT01522222|No Intervention|Control|half of the study subjects will receive standard of care during their open heart surgery.
11475901|NCT01522222|Experimental|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
11475902|NCT01522196|Active Comparator|Varespladib|48 hour continuous infusion delivered intravenously (IV)
11475903|NCT01522196|Placebo Comparator|Placebo|48 hour continuous infusion delivered intravenously (IV)
11475904|NCT01522157|Active Comparator|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
11475905|NCT01522144|Experimental|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
11475906|NCT01522131|Other|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
11475907|NCT01522131|Experimental|laser with bioresorabable membrane (test)|
11475908|NCT01522118|Experimental|HIFU|(high intensity focused ultrasound)
11475909|NCT01522105|Experimental|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
11475910|NCT01522092|Experimental|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
11475911|NCT01522079|Experimental|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
11475912|NCT01522066|Experimental|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
11475913|NCT01522066|Active Comparator|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
11475914|NCT01522053|Experimental|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
11475915|NCT01522053|Active Comparator|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
11475916|NCT01522040|Active Comparator|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
11475917|NCT01522040|Placebo Comparator|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
11475918|NCT01522027|Experimental|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
11475919|NCT01522014|Active Comparator|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
11475920|NCT01522014|Active Comparator|Ceramic-on-Highly Crosslinked Polyethylene|
11475921|NCT01522001|No Intervention|Hospital-based|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.
~Dietary counseling with dietician
~Exercise (1 hour, 2 timer pr week for 12 weeks)
~Smoking cessation if smoker with educated smoking cessation instructor
~Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation
~Examination by cardiologist 8-12 weeks after discharge."
11475922|NCT01522001|Active Comparator|Shared care Model|"First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.
~Dietary counseling with dietician
~Exercise (1 hour, 2 timer pr week for 12 weeks)
~Smoking cessation if smoker with educated smoking cessation instructor
~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse
~Examination by the patient´s general practitioner 8-12 weeks after discharge."
11475923|NCT01521988|Active Comparator|Atrial flutter ablation|RF atrial flutter ablation
11475924|NCT01521988|Experimental|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
11475925|NCT01521975|Experimental|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
11475926|NCT01521962|Experimental|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
11475927|NCT01521962|Placebo Comparator|Insulin|injection
11475928|NCT01521949|Experimental|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
11475929|NCT01521936|Experimental|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
11475930|NCT01521936|Experimental|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
11475931|NCT01521923|Experimental|CZP 200 mg Q2W + Methotrexate|
11475932|NCT01521923|Experimental|CZP 200 mg Q4W + Methotrexate|
11475933|NCT01521923|Placebo Comparator|Placebo + Methotrexate|
11475934|NCT01521910|Experimental|Low protein diet|
11475935|NCT01521910|Active Comparator|Normal protein diet|
11475936|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
11475937|NCT01521884||RA Patients treated with SC anti-TNF|
11475938|NCT01521871|Experimental|Tissue glue wound closure|Skin wound closure by tissue glue
11475939|NCT01521871|Active Comparator|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
11475940|NCT01521845|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
11475941|NCT01521845|No Intervention|control|This group is without omega 3 : just receives standard treatment
11475942|NCT01521832|Experimental|Dose Group A|
11475943|NCT01521832|Experimental|Dose Group B|
11475944|NCT01521832|Experimental|Dose Group C|
11475945|NCT01521832|Experimental|Dose Group D|
11475946|NCT01521832|Experimental|Dose Group E|
11475947|NCT01521832|Experimental|Dose Group F|
11475948|NCT01521832|Experimental|Dose Group H|
11475949|NCT01521832|Experimental|Dose Group I|
11475950|NCT01521832|Experimental|Dose Group J|
11475951|NCT01521832|Experimental|Dose Group K|
11475952|NCT01521832|Experimental|Dose Group L|
11475953|NCT01521819|Experimental|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
11475954|NCT01521806|Experimental|Low dose|15 g of fiber per day will be added to snack foods
11475955|NCT01521806|Experimental|High dose|30 g of fiber per day will be added to snack foods
11475956|NCT01521806|Placebo Comparator|No fiber|Snack foods without fiber will be given
11475957|NCT01521780|Experimental|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
11475958|NCT01521780|Experimental|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
11475959|NCT01521780|Experimental|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
11475960|NCT01521767|Experimental|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
11475961|NCT01521767|Experimental|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
11475962|NCT01521767|Experimental|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
11475963|NCT01521767|Experimental|D|4 mg MPB-RR1, administered without water and under fed condition.
11475964|NCT01521767|Experimental|E|4 mg MPB-RR1, administered with water and under fasting condition.
11475965|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
11475966|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
11475967|NCT01521741||Breast Cancer|
11475968|NCT01521728|Active Comparator|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
11475969|NCT01521728|Active Comparator|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
11475970|NCT01521728|Active Comparator|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
11475971|NCT01521715|Experimental|Pazopanib|800 mg (2x400mg) pazopanib per day
11475972|NCT01521702|Experimental|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
11475973|NCT01521702|Active Comparator|surgery|surgery
11475974|NCT01521689|Experimental|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
11475975|NCT01521676|Experimental|breast cancer|blood and tumor sample
11475976|NCT01521663|Experimental|IPX159|IPX159 90 mg daily at week 1 with titration to 180 mg daily at week 2 with possible titration to 270 mg daily at week 3.
11475977|NCT01521663|Placebo Comparator|Sugar Pill|IPX159 90 mg matching placebo daily at week 1 with titration to 180 mg matching placebo daily at week 2.
11475978|NCT01521650|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
11475979|NCT01521650|No Intervention|Control|No intervention. What has been the standard procedure so far
11475980|NCT01521637|Experimental|NMES|The 'NMES' arm will be treated with NMES.
11475981|NCT01521637|Sham Comparator|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
11475982|NCT01521624|Active Comparator|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
11475983|NCT01521624|No Intervention|Control|Subjects provided only advice for lifestyle modification with no drug intervention
11475984|NCT01521611|Experimental|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
11475985|NCT01521598|Experimental|SKL11197|This arm is the experimental drug (SKL11197) arm. Patients will be randomized to this arm.
11475986|NCT01521598|Placebo Comparator|Placebo|This arm is the placebo comparator arm. Patients will be randomized to this arm.
11475987|NCT01521585|Experimental|SEN0014196 50 mg oral tablet|
11475988|NCT01521585|Experimental|SEN0014196 200 mg oral tablet|
11475989|NCT01521585|Placebo Comparator|Placebo tablet|
11475990|NCT01521572|Experimental|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
11476145|NCT01520649|Placebo Comparator|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
11475991|NCT01521559|Sham Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
11475992|NCT01521559|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
11475993|NCT01521546|Active Comparator|eplerenone|active study drug
11475994|NCT01521546|Placebo Comparator|sugar pill|placebo
11475995|NCT01521533|Experimental|NOX-A12|
11475996|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
11475997|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
11475998|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
11475999|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
11476000|NCT01521507|Experimental|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
11476001|NCT01521507|Active Comparator|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
11476002|NCT01521494|Experimental|PA21 750 mg/day|
11476003|NCT01521494|Experimental|PA21 1500 mg/day|
11476004|NCT01521494|Experimental|PA21 2250 mg/day|
11476005|NCT01521494|Experimental|PA21 3000 mg/day|
11476006|NCT01521494|Placebo Comparator|Placebo|
11476007|NCT01521481|Experimental|Triple inguinal nerve block|Ropivacaine 5 mg/ml
11476008|NCT01521481|Active Comparator|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
11476009|NCT01521455|Experimental|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
11476010|NCT01521455|Active Comparator|Seretide Diskus|Seretide 250 Diskus
11476011|NCT01521442|Experimental|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
11476012|NCT01521442|Other|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
11476013|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
11476014|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
11476015|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
11476016|NCT01521416||Cohort Group|
11476017|NCT01521403|Active Comparator|Metronidazole|Metronidazole 3x500 mg per day for 10 days
11476018|NCT01521403|Placebo Comparator|Placebo|Placebo 3x1 tablet per day for 10 days
11476019|NCT01521390|Other|Treatment Arm|Subjects receive one inhalation from each intervention
11476020|NCT01521377|Placebo Comparator|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
11476021|NCT01521377|Active Comparator|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
11476022|NCT01521377|Experimental|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
11476023|NCT01521377|Experimental|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
11476024|NCT01521377|Experimental|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
11476025|NCT01521364|Other|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.
~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.
~After this, there is a wash-out period of one week during which no claritromycine is administered."
11476026|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
11476027|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
11476028|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
11476029|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
11476030|NCT01521325|Experimental|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
11476031|NCT01521312|Experimental|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
11476032|NCT01521312|Placebo Comparator|placebo pill|at BREAKFEAST
11476033|NCT01521286||Group A|Subjects presenting with HZ episode.
11476034|NCT01521273|Experimental|high iron bean with native phytic acid concentration|
11476035|NCT01521273|Experimental|normal iron bean with native phytic acid concentration|
11476036|NCT01521273|Experimental|high iron bean partially dephytinized|
11476037|NCT01521273|Experimental|normal iron bean partially dephytinized|
11476038|NCT01521273|Experimental|high iron bean totally dephytinized|
11476039|NCT01521273|Experimental|normal iron bean totally dephytinized|
11476040|NCT01521260|Placebo Comparator|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
11476339|NCT01519271|Active Comparator|Exelon Patch (rivastigmine transdermal system)|
11476041|NCT01521260|Active Comparator|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
11476042|NCT01521247|No Intervention|Control group|Usual care.
11476043|NCT01521247|Other|Asthma Transition Program|Asthma Transition Program
11476044|NCT01521234|Experimental|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
11476045|NCT01521234|No Intervention|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
11476046|NCT01521221|Experimental|Patients|Patients with autonomic failure.
11476047|NCT01521221|Experimental|Healthy subjects|Control group
11476048|NCT01521208|Active Comparator|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
11476049|NCT01521208|Active Comparator|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
11476050|NCT01521195|Experimental|Patients on veno-arterial (VA) ECMO|
11476051|NCT01521182|Active Comparator|1 = Tested product|
11476052|NCT01521182|Placebo Comparator|2 = Control product|
11476053|NCT01521169|Active Comparator|1 = Tested product dose 1|
11476054|NCT01521169|Active Comparator|2 = Tested product dose 2|
11476055|NCT01521169|Sham Comparator|3 = Control product|
11476056|NCT01521156|Active Comparator|1 = Control product|
11476057|NCT01521156|Experimental|2 = Tested product|
11476058|NCT01521143|Experimental|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
11476059|NCT01521143|Placebo Comparator|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
11476060|NCT01521143|Experimental|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
11476061|NCT01521143|No Intervention|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
11476062|NCT01521130|No Intervention|Healthy Control|Healthy Control
11476063|NCT01521130|No Intervention|BECTS, no medication|BECTS, no medication
11476064|NCT01521130|Experimental|Levetiracetam Higher dose|Levetiracetam Higher dose
11476065|NCT01521117|Experimental|Donepezil, washout period, placebo|
11476066|NCT01521117|Experimental|Placebo, washout period, Donepezil|
11476067|NCT01521078|Experimental|Intervention|Provided access to the Check Your Drinking University version (CYDU).
11476068|NCT01521078|No Intervention|Control|No invention control group
11476069|NCT01521065|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
11476070|NCT01521052|Experimental|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
11476071|NCT01521039||Allogeneic SCT recipients|Patients who are receiving allogeneic stem cell transplantation at the Ohio State University are eligible and will be consented for the study.
11476072|NCT01521026|Experimental|Cognitive Training|Cognitive training group
11476073|NCT01521026|No Intervention|Standard Pharmacotherapy|
11476074|NCT01521013|Active Comparator|Supported self-care|
11476075|NCT01521013|Active Comparator|Unsupported self-care|
11476076|NCT01521000|No Intervention|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
11476077|NCT01521000|Other|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
11476078|NCT01520987|Experimental|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
11476079|NCT01520987|Experimental|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
11476080|NCT01520987|Experimental|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
11476081|NCT01520987|Placebo Comparator|Caucasian Placebo|Placebo, PLC
11476082|NCT01520987|Experimental|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
11476083|NCT01520987|Experimental|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
11476084|NCT01520987|Experimental|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
11476085|NCT01520987|Placebo Comparator|Japanese Placebo|Placebo, PLC
11476086|NCT01520974|Active Comparator|Probiotic tablet|
11476087|NCT01520974|Placebo Comparator|Placebo tablet|Comparison tablet without the probiotic bacteria
11476088|NCT01520961||Hueter Anterior Approach|
11476089|NCT01520961||posterolateral approach|
11476090|NCT01520948|Experimental|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
11476091|NCT01520948|Placebo Comparator|Behavioral control|Mirrored Star Drawing
11476092|NCT01520935||Cohort Group|
11476994|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
11476093|NCT01520922|Experimental|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
11476094|NCT01520909|Experimental|Eltrombopag plus standard of care|Part 1, double-blind treatment group
11476095|NCT01520909|Placebo Comparator|Placebo plus standard of care|Part 1, double-blind treatment group
11476096|NCT01520909|Experimental|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
11476097|NCT01520896|Experimental|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
11476098|NCT01520896|Active Comparator|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
11476099|NCT01520896|Active Comparator|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
11476100|NCT01520883||DEcisional conflict|
11476101|NCT01520870|Experimental|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
11476102|NCT01520857|Active Comparator|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
11476103|NCT01520857|Active Comparator|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
11476104|NCT01520844|Other|Cohort study|Blood sampling
11476105|NCT01520831|Experimental|BIAsp 30|
11476106|NCT01520831|Experimental|BIAsp 50|
11476107|NCT01520831|Experimental|BIAsp 70|
11476108|NCT01520831|Active Comparator|Insulin aspart|
11476109|NCT01520818|Experimental|BIAsp 50 or 70|
11476110|NCT01520818|Active Comparator|BHI 30|
11476111|NCT01520805|Experimental|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
11476112|NCT01520792|Experimental|Paracetamol|
11476113|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
11476114|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
11476115|NCT01520766|Experimental|glass fiber|
11476116|NCT01520766|Experimental|titanium|
11476117|NCT01520753|Experimental|BIAsp 70|
11476118|NCT01520753|Experimental|BIAsp 70 + BIAsp 50|
11476119|NCT01520740|Active Comparator|Collateral Ventilation Positive (CV+)|
11476120|NCT01520740|Active Comparator|Collateral Ventilation Negative (CV-)|
11476121|NCT01520727|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
11476122|NCT01520727|Experimental|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
11476123|NCT01520727|Experimental|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
11476124|NCT01520727|Experimental|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
11476125|NCT01520727|Experimental|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
11476126|NCT01520727|Experimental|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
11476127|NCT01520727|Experimental|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
11476128|NCT01520727|Experimental|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
11476129|NCT01520727|Placebo Comparator|Placebo|Placebo (PLC): single-dose
11476130|NCT01520714|Experimental|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
11476131|NCT01520714|Experimental|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
11476132|NCT01520701|Active Comparator|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
11476133|NCT01520701|Experimental|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
11476134|NCT01520688|Experimental|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
11476135|NCT01520688|Experimental|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
11476136|NCT01520688|Experimental|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
11476137|NCT01520688|Experimental|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
11476138|NCT01520688|Experimental|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
11476139|NCT01520688|Experimental|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
11476140|NCT01520675|Active Comparator|Surgery|Patients will be randomized to surgery
11476141|NCT01520675|Active Comparator|Endotherapy|Patients will be randomized to endoscopic therapy
11476142|NCT01520662|Experimental|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
11476143|NCT01520662|No Intervention|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
11476144|NCT01520649|Experimental|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
11476382|NCT01518998|Experimental|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
11476146|NCT01520636|Placebo Comparator|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
11476147|NCT01520636|Experimental|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
11476148|NCT01520623|Other|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
11476149|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
11476150|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
11476151|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
11476152|NCT01520597||Case|Patient with culture-proven listeriosis
11476153|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp > 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
11476154|NCT01520584|Active Comparator|vitamale|
11476155|NCT01520584|Placebo Comparator|sham pill|
11476156|NCT01520571|Active Comparator|Non-Computer Assistance TKA|Non-Computer Assistance TKA
11476157|NCT01520571|Experimental|Computer Assistance TKA|Computer Assistance TKA
11476158|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
11476159|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
11476160|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
11476161|NCT01520545|Experimental|Gablofen 3 mg/mL (baclofen Injection)|3 mg/mL Gablofen (baclofen Injection)
11476162|NCT01520532|Other|Ablation|
11476163|NCT01520519|Experimental|Rituximab + PCI-32765|Rituximab (375 mg/m2) given intravenously (IV) on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6. PCI-32765 started on Day 2 of cycle 1 at a dose of 420 mg (3 * 140-mg capsules) orally daily and will be continued daily.
11476164|NCT01520506|Experimental|Rapid Renal Denervation|
11476165|NCT01520493|Experimental|Exercise|All patients are subject to this Arm.
11476166|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
11476167|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
11476168|NCT01520467|Experimental|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
11476169|NCT01520467|Placebo Comparator|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
11476170|NCT01520454|Placebo Comparator|Placebo|IV saline with heparin, oral water
11476171|NCT01520454|Experimental|High dose fat solution|Intralipid at high dose, with heparin and PO water
11476172|NCT01520454|Experimental|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
11476173|NCT01520454|Experimental|Oral fat|Oral fat load with IV saline
11476174|NCT01520441|Experimental|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
11476175|NCT01520428|Active Comparator|Motivational Interviewing, CBT and E-mail support|
11476176|NCT01520428|Active Comparator|E-Mail-support|
11476177|NCT01520415|Active Comparator|bupivacaine|
11476178|NCT01520415|Placebo Comparator|saline|
11476179|NCT01520402|Experimental|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
11476180|NCT01520389|Experimental|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
11476181|NCT01520389|Experimental|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
11476182|NCT01520389|Experimental|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
11476183|NCT01520376|Active Comparator|Counselling|People receiving a psychiatric evaluation after screening (HADS test > 12 points) and revised at 1 and 6 months
11476184|NCT01520376|No Intervention|Usual care|People after screening (HADS test > 12 points) and send to their primary care physician
11476185|NCT01520363|Active Comparator|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
11476186|NCT01520363|Placebo Comparator|Placebo group|MECP2 positive subjects randomized to the placebo compound
11476187|NCT01520350|Experimental|Mood stabilizer + Aripiprazole|
11476188|NCT01520350|Placebo Comparator|Mood stabilizer + placebo|
11476189|NCT01520337||patients undergoing outpatient colonoscopy|
11476190|NCT01520324|Experimental|Patients with UC undergoing colonoscopy|
11476191|NCT01520311|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
11476192|NCT01520298|Placebo Comparator|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
11476193|NCT01520298|Active Comparator|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
11476194|NCT01520285|Active Comparator|Zanidip|tablets
11476195|NCT01520285|Placebo Comparator|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
11476196|NCT01520259||cases|Women from the cohort with gallbladder cancer
11476197|NCT01520259||cohort|Women from Chile screened for gallbladder cancer with and without gallstones
11476198|NCT01520259||controls|Women from the cohort with gallstones
11476199|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
11476200|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
11476201|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
11476202|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
11476203|NCT01520207|Placebo Comparator|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
11476204|NCT01520207|Active Comparator|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
11476205|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
11476206|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
11476207|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
11476208|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
11476209|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
11476210|NCT01520142|Experimental|Treatment|
11476211|NCT01520142|Placebo Comparator|Placebo|
11476212|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
11476213|NCT01520116|Experimental|Stage 1 - Arm 1 - Dose 1|
11476214|NCT01520116|Experimental|Stage 1 - Arm 2 - Dose 2|
11476215|NCT01520116|Experimental|Stage 1 - Arm 3 - Dose 3|
11476216|NCT01520116|Experimental|Stage 1 - Arm 4 - Dose 4|
11476217|NCT01520116|Placebo Comparator|Stage 1 - Arm 5 - Vehicle|
11476218|NCT01520116|Experimental|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
11476219|NCT01520116|Experimental|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
11476220|NCT01520116|Active Comparator|Stage 2 - Arm 3 -Timoptic 0.5% BID|
11476221|NCT01520103|Experimental|Vinorelbin and Everolimus|
11476222|NCT01520103|Other|standard therapy|Vinorelbin
11476223|NCT01520077|Other|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.
~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
11476224|NCT01520051|Experimental|Mepolizumab|
11476225|NCT01520051|Placebo Comparator|Saline|
11476226|NCT01520025|Experimental|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
11476227|NCT01520012|Experimental|Sequence 1|
11476228|NCT01520012|Experimental|Sequence 2|
11476229|NCT01520012|Experimental|Sequence 3|
11476230|NCT01520012|Experimental|Sequence 4|
11476231|NCT01520012|Experimental|Sequence 5|
11476232|NCT01519999|Experimental|Shared Decision Making|
11476233|NCT01519999|No Intervention|Comparison (control)|
11476234|NCT01519986|Experimental|Low fat Meal|50,000 UI vitamin D3 with low fat meal
11476235|NCT01519986|Experimental|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
11476236|NCT01519986|Experimental|High fat meal|50,000 UI vitamin D3 with high fat meal
11476643|NCT01517035|Experimental|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
11476237|NCT01519973|Other|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
11476238|NCT01519960|Experimental|A Pegasys|
11476239|NCT01519960|No Intervention|B Untreated Control|
11476240|NCT01519960|Experimental|C Fibrosis non-randomized|
11476241|NCT01519960|Experimental|Switch|
11476242|NCT01519947|Active Comparator|Pre-dialysis, sea level|Participants received 50-250 mcg SC according to local label.
11476243|NCT01519947|Active Comparator|Dialysis, sea level|Participants received 50-250 mcg SC according to local label.
11476244|NCT01519947|Experimental|Pre-dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
11476245|NCT01519947|Experimental|Dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
11476246|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
11476247|NCT01519921|Experimental|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
11476248|NCT01519921|Experimental|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
11476249|NCT01519895|No Intervention|Existing care|routine existing care
11476250|NCT01519895|Experimental|Telephone intervention|in addition to provide telephone intervention support
11476251|NCT01519882|Placebo Comparator|Placebo|Placebo Transdermal Patches
11476252|NCT01519882|Experimental|Rotigotine|Rotigotine Transdermal Patches
11476253|NCT01519869|Experimental|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
11476254|NCT01519856||tablet|
11476255|NCT01519843|Active Comparator|Real|Real tDCS
11476256|NCT01519843|Placebo Comparator|sham|Sham tDCS
11476257|NCT01519830|Experimental|Verum|Iron Carboxymaltose (Ferinject)
11476258|NCT01519830|Placebo Comparator|Placebo|0.9% NaCl solution
11476259|NCT01519817|Experimental|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
11476260|NCT01519804|Experimental|MetMAb+paclitaxel+platinum|
11476261|NCT01519804|Active Comparator|Placebo+paclitaxel+platinum|
11476262|NCT01519791|Experimental|Certolizumab Pegol + Methotrexate|
11476263|NCT01519791|Placebo Comparator|Placebo + Methotrexate|
11476264|NCT01519778|Experimental|TR-701 FA|
11476265|NCT01519765|Experimental|Buccal misoprostol+placebo vaginal pill|
11476266|NCT01519765|Active Comparator|Vaginal Misoprostol+placebo buccal pill|
11476267|NCT01519752|Experimental|Oxiconazole Nitrate Cream 1%|
11476268|NCT01519752|Active Comparator|Oxiconazole Nitrate Cream 1% (Oxistat®)|
11476269|NCT01519752|Placebo Comparator|Placebo|
11476270|NCT01519739|Experimental|MediGuide Arm|
11476271|NCT01519726|Experimental|Morbidly obese patients|
11476272|NCT01519713|Experimental|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
11476273|NCT01519713|Experimental|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
11476274|NCT01519713|Experimental|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
11476275|NCT01519700|Experimental|EP2006|Eligible patients will be teated with EP2006
11476276|NCT01519700|Active Comparator|Filgrastim|Eligible patients will be teated with Filgrastim
11476277|NCT01519687|Experimental|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
11476278|NCT01519674|Active Comparator|BIAsp 30 BID + sitagliptin + metformin|
11476279|NCT01519674|Active Comparator|BIAsp 30 BID + metformin|
11476280|NCT01519674|Active Comparator|BIAsp 30 OD + sitagliptin + metformin|
11476281|NCT01519661|Experimental|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
11476282|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
11476283|NCT01519648||Allo- or auto- transplant recipients|
11476284|NCT01519635|Active Comparator|Aliskiren|Aliskiren 150 to 300 mg once a Week for 8 weeks
11476285|NCT01519635|Active Comparator|Hydrochlorothiazide|HCTZ 12.5 - 25 mg/d once a day for 8 weeks
11476286|NCT01519622||Sick elderly in community|
11476287|NCT01519609|Active Comparator|Moviprep|Moviprep bowel preb
11476288|NCT01519609|Active Comparator|Phosphoral|Bowel prep
11476289|NCT01519596|Experimental|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
11476290|NCT01519596|Active Comparator|Arm II (usual care)|Patients undergo usual care for 4 weeks.
11476291|NCT01519583|Experimental|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
11476292|NCT01519583|Experimental|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
11476293|NCT01519583|Placebo Comparator|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
11476294|NCT01519570|Experimental|An informational packet regarding shingles and the HZV|
11476295|NCT01519570|No Intervention|Standard medical care from their primary care physician|
11476296|NCT01519557|Experimental|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
11476297|NCT01519557|Placebo Comparator|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
11476298|NCT01519544|Active Comparator|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
11476299|NCT01519544|Active Comparator|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
11476300|NCT01519531|Experimental|VIA-3196|
11476301|NCT01519531|Placebo Comparator|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
11476302|NCT01519518|Active Comparator|Unfractionated heparin|70 units/kg body weight intravenous
11476303|NCT01519518|Active Comparator|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
11476304|NCT01519505|Experimental|Lifestyle counseling|"Complete lifestyle counseling including
~Individual intervention, OR
~Group intervention"
11476305|NCT01519505|No Intervention|Usual health care|Usual health care, including self-administered information by leaflets
11476306|NCT01519492|Experimental|AFN-12520000|100 mg tablet
11476307|NCT01519479|Experimental|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
11476308|NCT01519479|Active Comparator|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
11476309|NCT01519466|Other|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
11476310|NCT01519466|Other|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
11476311|NCT01519453|Experimental|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
11476312|NCT01519453|No Intervention|Control|There is no control arm specific intervention
11476313|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
11476314|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
11476315|NCT01519427|Experimental|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
11476316|NCT01519414|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11476317|NCT01519414|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
11476318|NCT01519401|Active Comparator|3 mg drospirenone and 20 µg ethinyl-estradiol|
11476319|NCT01519401|Active Comparator|3 mg drospirenone and 30 µg ethinyl-estradiol|
11476320|NCT01519388|Experimental|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
11476321|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
11476322|NCT01519349|Experimental|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
11476323|NCT01519349|Experimental|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
11476324|NCT01519349|Experimental|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
11476325|NCT01519336|Active Comparator|A danoprevir|
11476326|NCT01519336|Placebo Comparator|B darunavir|
11476327|NCT01519336|Experimental|C danoprevir/darunavir|
11476328|NCT01519323|Experimental|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
11476329|NCT01519310|Active Comparator|Group 1|Group 1 (Antibiotics/probioitic):
11476330|NCT01519310|Active Comparator|Group 2|Group 2 (Antibiotics/no-probiotic):
11476331|NCT01519310|Active Comparator|Group 3|Group 3 (no-Antibiotics/probiotic):
11476332|NCT01519297|Other|Single arm intervention|Irbesartan 150 mg orally for one dose
11476333|NCT01519284|Placebo Comparator|Group 1|Placebo at all the dosing times
11476334|NCT01519284|Experimental|Group 2|"Day 1 to 7:
~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose
~Day 8:
~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
11476335|NCT01519284|Experimental|Group 3|"Day 1 to 7:
~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose
~Day 8:
~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
11476336|NCT01519284|Experimental|Group 4|"Day 1 to 7:
~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose
~Day 8:
~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
11476337|NCT01519284|Experimental|Group 5|"Day 1 to 7:
~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose
~Day 8:
~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
11476338|NCT01519271|Placebo Comparator|Placebo Patch|
11476340|NCT01519258|Active Comparator|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support Ventilation (PSV) for 15 minutes. Mechanical ventilator settings will be set to match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
11476341|NCT01519258|Experimental|NAVA|Patients will be ventilated with NAVA for 15 minutes. Nava level will be titrated prior to randomization, to deliver the same peak of airway pressure obtained with the active comparator, PSV. The resulting tidal volume should match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
11476342|NCT01519245|Experimental|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
11476343|NCT01519245|Placebo Comparator|Placebo|Normal saline
11476344|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
11476345|NCT01519219||Hepatic Irradiation|
11476346|NCT01519206|Experimental|Ultherapy treatment|Ulthera System Treatment
11476347|NCT01519193|Experimental|Narrative Exposure Therapy|
11476348|NCT01519193|No Intervention|No treatment control|
11476349|NCT01519180||Control group|Healthy volunteers
11476350|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
11476351|NCT01519167|Experimental|Dexmedetomidine|
11476352|NCT01519154|Active Comparator|Propofol|Propofol 10 mg/h as maintenance infusion
11476353|NCT01519154|Experimental|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
11476354|NCT01519141||HIV-negative controls|HIV-negative individuals
11476355|NCT01519141||HIV-infected patients|HIV-infected patients who are on a stable antiretroviral drug regimen for at least a year; all plasma HIV RNA levels within the past year must be below conventional levels of detection (< 50 copies RNA/mL).
11476356|NCT01519128|Experimental|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
11476357|NCT01519128|Experimental|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
11476358|NCT01519115|Active Comparator|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
11476359|NCT01519115|Experimental|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
11476360|NCT01519102|Active Comparator|CHO-independent partial insulin bolus with closed-loop|
11476361|NCT01519102|Active Comparator|CHO-dependent full insulin bolus combined with closed-loop|
11476362|NCT01519089|Experimental|CP-690,550 10 mg BID|
11476363|NCT01519089|Experimental|CP690,550 5 mg BID|
11476364|NCT01519063|Experimental|Naltrexone and memantine|Treatment with Naltrexone and memantine first
11476365|NCT01519063|Placebo Comparator|Naltrexone and Placebo|Treatment with naltrexone and placebo first
11476366|NCT01519037|Active Comparator|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
11476367|NCT01519037|Placebo Comparator|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
11476368|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
11476369|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
11476370|NCT01519011|Experimental|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.
~Dose C: Single oral administration with two 150-mg tablets under fed condition."
11476371|NCT01519011|Experimental|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.
~Dose C: Single oral administration with two 150-mg tablets under fed condition."
11476372|NCT01519011|Experimental|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.
~Dose C: Single oral administration with two 150-mg tablets under fed condition."
11476373|NCT01519011|Experimental|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.
~Dose C: Single oral administration with two 150-mg tablets under fed condition."
11476374|NCT01519011|Experimental|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.
~Dose C: Single oral administration with two 150-mg tablets under fed condition."
11476375|NCT01519011|Experimental|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.
~Dose C: Single oral administration with two 150-mg tablets under fed condition."
11476376|NCT01519011|Experimental|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
11476377|NCT01518998|Placebo Comparator|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
11476378|NCT01518998|Active Comparator|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
11476379|NCT01518998|Active Comparator|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
11476380|NCT01518998|Active Comparator|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
11476381|NCT01518998|Active Comparator|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
11476383|NCT01518998|Experimental|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
11476384|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
11476385|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
11476386|NCT01518985|Placebo Comparator|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
11476387|NCT01518985|Experimental|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
11476388|NCT01518972|Experimental|Prazosin|Prazosin medication
11476389|NCT01518972|Placebo Comparator|Placebo|Placebo medication
11476390|NCT01518959|Placebo Comparator|Placebo|no treatment
11476391|NCT01518959|Active Comparator|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
11476392|NCT01518946|Active Comparator|Midodrine HCl|
11476393|NCT01518946|Placebo Comparator|Placebo|
11476394|NCT01518933|Experimental|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
11476395|NCT01518933|Placebo Comparator|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
11476396|NCT01518920|Experimental|PF-04958242|
11476397|NCT01518920|Placebo Comparator|Placebo|
11476398|NCT01518907|Experimental|AA4500 0.0029 mg in 1 mL|
11476399|NCT01518907|Experimental|AA4500 0.0145 mg in 5 mL|
11476400|NCT01518907|Experimental|AA4500 0.0145 mg in 1 mL|
11476401|NCT01518907|Experimental|AA4500 0.0435 mg in 5 mL|
11476402|NCT01518907|Experimental|AA4500 0.0435 mg in 1 mL|
11476403|NCT01518907|Experimental|AA4500 0.116 mg in 5 mL|
11476404|NCT01518907|Experimental|AA4500 0.116 mg in 1 mL|
11476405|NCT01518907|Experimental|AA4500 0.232 mg in 5 mL|
11476406|NCT01518907|Experimental|AA4500 at 0.232 in 1 mL|
11476407|NCT01518907|Experimental|AA4500 0.464 mg in 5 mL|
11476408|NCT01518907|Experimental|AA4500 0.464 mg in 1 mL|
11476409|NCT01518894|Experimental|PF-04958242|
11476410|NCT01518894|Placebo Comparator|Placebo|
11476411|NCT01518881|Experimental|TKM-100201|
11476412|NCT01518881|Placebo Comparator|Placebo|
11476413|NCT01518868|Experimental|Investigational contact lens|multifocal high add soft contact lens
11476414|NCT01518868|Active Comparator|PureVision contact lens|Multi-focal contact lens
11476415|NCT01518855|Experimental|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
11476416|NCT01518855|Active Comparator|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
11476417|NCT01518842|Experimental|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.
~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
11476418|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
11476419|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
11476420|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation < 2cm and effacement< 50%) which will deliver within one week maximum after hospitalization.
11476421|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
11476422|NCT01518803|Active Comparator|Mediterranean-style breakfast|
11476423|NCT01518803|Active Comparator|Western-style breakfast|
11476424|NCT01518790|Experimental|Polyethylene glycol 3350|
11476425|NCT01518777|Other|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
11476426|NCT01518764|Experimental|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
11476427|NCT01518764|Placebo Comparator|placebo|placebo (capsules)
11476428|NCT01518738|Experimental|breath attention training|
11476429|NCT01518738|Active Comparator|working memory attention training|
11476430|NCT01518738|No Intervention|no training|
11476431|NCT01518725|Experimental|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
11476432|NCT01518725|Placebo Comparator|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
11476433|NCT01518712|Experimental|Treatment Sequence AB|
11476434|NCT01518712|Experimental|Treatment Sequence BA|
11476435|NCT01518699|Other|Part 1 Group 1|Low dose study drug in 6 of 8 subjects Placebo in 2 of 8 subjects
11476436|NCT01518699|Other|Part 1 Group 2|Mid dose study drug in 6 of 8 subjects Placebo in 2 of 8 subjects
11476437|NCT01518699|Other|Part 1 Group 3|High dose study drug in 6 or 8 subjects Placebo in 2 of 8 subjects
11476438|NCT01518699|Other|Part 2 Group A|Study drug plus positive-control placebo
11476439|NCT01518699|Other|Part 2 Group B|Placebo plus positive-control placebo
11476440|NCT01518699|Other|Part 2 Group C|Placebo plus positive control
11476441|NCT01518686|No Intervention|one arm|observational study, no cohort, single group of different ages
11476442|NCT01518673||X-rays|
11476443|NCT01518660|Experimental|Training|
11476444|NCT01518660|No Intervention|Control|
11476445|NCT01518647|Experimental|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
11476446|NCT01518647|Experimental|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
11476447|NCT01518647|Active Comparator|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
11476448|NCT01518634|Experimental|Imipramine treatment|
11476449|NCT01518634|Placebo Comparator|Placebo|
11476450|NCT01518621|Active Comparator|Radiotherapy alone|Total brain irradiation, 3Gy x10
11476451|NCT01518621|Experimental|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
11476452|NCT01518595|Placebo Comparator|placebo|Patients will receive placebo tablets twice daily for 3 months.
11476453|NCT01518595|Active Comparator|bosentan|pts. will receive bosentan for 3 months
11476454|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
11476455|NCT01518569|Placebo Comparator|placebo|normal saline, same amount, iv
11476456|NCT01518569|Active Comparator|ulinastatin|5000 unit/kg iv
11476457|NCT01518556|Experimental|Idarubicin|Idarubicin dose intensification for remission induction in acute myeloid leukemia
11476458|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
11476459|NCT01518530|Experimental|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
11476460|NCT01518517|Experimental|GRASPA|"Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).
~GRASPA® administration takes place as below:
~for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)
~for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)"
11476461|NCT01518517|Active Comparator|reference L-asparaginase|"For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).
~•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).
~NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)
~•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles)."
11476462|NCT01518504|Experimental|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
11476463|NCT01518504|Sham Comparator|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
11476464|NCT01518491|Experimental|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
11476465|NCT01518491|Active Comparator|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
11476466|NCT01518478|Other|20 Non-atopic|Non-atopic, healthy control.
11476467|NCT01518478|Other|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
11476468|NCT01518465|Experimental|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
11476469|NCT01518465|Experimental|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
11476470|NCT01518452|Experimental|working memory training|Cogmed JM working memory training
11476471|NCT01518452|Experimental|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
11476472|NCT01518439|Experimental|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
11476473|NCT01518426|Experimental|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
11476474|NCT01518413|Experimental|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
11476475|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
11476476|NCT01518387|Experimental|Arm 1|750-2250mg/day, tid, 8 weeks
11476477|NCT01518374|Experimental|Florbetapir-PET Scans|
11476478|NCT01518348|Experimental|Patch Test|
11476479|NCT01518335|Experimental|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
11476480|NCT01518335|Placebo Comparator|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care [saline injection + standard of care (bandaging or boot and crutches)] + non-NSAID pain medicine
11476481|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
11476482|NCT01518309|Experimental|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
11476739|NCT01516411|Active Comparator|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
11476483|NCT01518296|Experimental|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
11476484|NCT01518283|Experimental|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
11476485|NCT01518270||Healthy Females|Healthy Females
11476486|NCT01518257|Experimental|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
11476487|NCT01518257|Placebo Comparator|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
11476488|NCT01518244|Experimental|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
11476489|NCT01518231|Experimental|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
11476490|NCT01518231|No Intervention|Convention therapy|The control group just receive drug therapy.
11476491|NCT01518218|Experimental|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
11476492|NCT01518218|No Intervention|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
11476493|NCT01518205|Experimental|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.
~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).
~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
11476494|NCT01518205|No Intervention|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.
~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.
~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.
~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
11476495|NCT01518192|Active Comparator|1Doxycycline|
11476496|NCT01518192|Active Comparator|2 Cefuroxime axetil|
11476497|NCT01518179|Experimental|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
11476498|NCT01518179|Other|Control|Routine follow up and treatment
11476499|NCT01518166|Experimental|Trial period A|
11476500|NCT01518166|Experimental|Trial period B|
11476501|NCT01518153|Experimental|Low Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
11476502|NCT01518153|Experimental|High Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
11476503|NCT01518140|Experimental|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
11476504|NCT01518140|Experimental|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
11476505|NCT01518140|Experimental|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
11476506|NCT01518127|Experimental|stem cell group|intravitreal injection of autologous bone marrow stem cells
11476507|NCT01518114|Experimental|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
~Exercise prescription will be based upon cardiopulmonary test done at baseline."
11476508|NCT01518114|Active Comparator|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
11476509|NCT01518101|Experimental|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
11476510|NCT01518101|Experimental|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
11476511|NCT01518088|Experimental|Low dose dietary fiber|
11476512|NCT01518088|Experimental|High dose dietary fiber|
11476513|NCT01518088|Placebo Comparator|No added fiber|
11476514|NCT01518075|Experimental|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
11476515|NCT01518075|Active Comparator|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
11476516|NCT01518062|Experimental|Low dose|
11476517|NCT01518062|Experimental|Medium dose|
11476518|NCT01518062|Experimental|High dose|
11476519|NCT01518036|Experimental|Low dose|
11476520|NCT01518036|Experimental|High dose|
11476521|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
11476522|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
11476523|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
11476524|NCT01518010|Experimental|GamePlay|
11476525|NCT01517997|Experimental|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
11476526|NCT01517997|Active Comparator|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
11476527|NCT01517984|Experimental|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.
~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
11476528|NCT01517984|Active Comparator|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.
~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
11476529|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
11476530|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
11476531|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
11476532|NCT01517945||Breast cancer survivors|This is a Center for Translational Science Center (CTSC)-funded intervention development and pilot clinical trial of a psychosocial intervention to address fear of cancer recurrence in breast cancer survivors (BCS). BCS form the largest survivor cohort of any cancer, with approximately 2.5 million living in the United States.
11476533|NCT01517932|Experimental|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
11476534|NCT01517932|Placebo Comparator|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
11476535|NCT01517919|Experimental|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
11476536|NCT01517919|No Intervention|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
11476537|NCT01517906|Experimental|Cognitive behavioral counseling|
11476538|NCT01517906|Active Comparator|Supportive therapy|
11476539|NCT01517893|Experimental|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
11476540|NCT01517893|Placebo Comparator|Placebo Arm|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
11476541|NCT01517880|Experimental|6,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
11476542|NCT01517880|Placebo Comparator|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
11476543|NCT01517880|Experimental|3,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
11476544|NCT01517867|Experimental|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
11476545|NCT01517867|Active Comparator|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
11476546|NCT01517854|Active Comparator|Revatio|
11476547|NCT01517854|Placebo Comparator|Placebo|
11476548|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
11476549|NCT01517828|Experimental|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
11476550|NCT01517828|Active Comparator|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
11476551|NCT01517815|Experimental|No overweight patient|Patient with weight less than or equal to 120kg
11476552|NCT01517815|Experimental|Overweight patients|Patient with weight more than 120kg
11476740|NCT01516411|Active Comparator|Social app|Social app promotes behavior change via social relationships and feedback
11476553|NCT01517802|Experimental|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
11476554|NCT01517789|Experimental|Patients|
11476555|NCT01517776|Experimental|Cilengitide and metronomic temozolomide|Cilengitide 1800 mg/m² i.v. twice weekly and Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
11476556|NCT01517763|Placebo Comparator|Conventional CPAP|Fisher & Paykel HC244™
11476557|NCT01517763|Active Comparator|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
11476558|NCT01517763|Experimental|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
11476559|NCT01517750|Experimental|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
11476560|NCT01517750|Active Comparator|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
11476561|NCT01517724|Experimental|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
11476562|NCT01517711|Experimental|Tramadol ER|
11476563|NCT01517711|Placebo Comparator|Sugar pill|
11476564|NCT01517698|Experimental|RO4917523 0.5 mg|
11476565|NCT01517698|Experimental|RO4917523 1.5 mg|
11476566|NCT01517698|Placebo Comparator|Placebo|
11476567|NCT01517685|Experimental|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
11476568|NCT01517659|Experimental|Fat Reduction|The Zeltiq CoolSculpting System will be used to treat subcutaneous fat on each inner thigh.
11476569|NCT01517646|No Intervention|Fat Reduction|
11476570|NCT01517633|Experimental|A device for identifying between amniotic fluid and urine|
11476571|NCT01517620|Experimental|Total Glucosides Paeony, Capsules|
11476572|NCT01517620|No Intervention|no intervention|
11476573|NCT01517607||Mesalazine|
11476574|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
11476575|NCT01517568|Experimental|Liraglutide|
11476576|NCT01517555|Experimental|Liraglutide|
11476577|NCT01517555|Placebo Comparator|Placebo|
11476578|NCT01517542|Experimental|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
11476579|NCT01517542|No Intervention|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
11476580|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
11476581|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
11476582|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
11476583|NCT01517503|Experimental|Cognitive Therapy (CT)|Cognitive Therapy (CT)
11476584|NCT01517503|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
11476585|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
11476586|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
11476587|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
11476588|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
11476589|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
11476590|NCT01517490||Healthy|Healthy volunteers.
11476591|NCT01517477|Experimental|First Arm: One iStent|Device: One iStent
11476592|NCT01517477|Experimental|Second Arm: Two iStents|Device: Two iStent devices
11476593|NCT01517477|Experimental|Third Arm: Three iStents|Device: Three iStent devices
11476594|NCT01517464|Experimental|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
11476595|NCT01517451|Experimental|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
11476596|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
11476597|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
11476598|NCT01517412|Experimental|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
11476599|NCT01517412|Active Comparator|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
11476600|NCT01517399|Other|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
11476601|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
11476602|NCT01517373|Placebo Comparator|Placebo|Placebo to match PF-04937319 and glimepiride
11476603|NCT01517373|Experimental|PF-04937319 10 mg|
11476604|NCT01517373|Experimental|PF-04937319 50 mg|
11476605|NCT01517373|Experimental|PF-04937319 100 mg|
11476606|NCT01517373|Active Comparator|Glimepiride|
11476607|NCT01517360|Active Comparator|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
11476608|NCT01517360|Experimental|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
11476609|NCT01517347|Experimental|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
11476610|NCT01517347|No Intervention|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
11476611|NCT01517334|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
11476612|NCT01517334|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
11476613|NCT01517321|Experimental|E|
11476614|NCT01517321|Placebo Comparator|P|
11476615|NCT01517308|Active Comparator|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
11476616|NCT01517308|Experimental|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
11476617|NCT01517295|Experimental|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
11476618|NCT01517295|Experimental|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
11476619|NCT01517282|Experimental|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
11476620|NCT01517282|Experimental|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
11476621|NCT01517282|Experimental|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
11476622|NCT01517282|Placebo Comparator|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
11476623|NCT01517269|Experimental|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
11476624|NCT01517269|Active Comparator|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
11476625|NCT01517256|Experimental|Early Intervention Group|
11476626|NCT01517256|Placebo Comparator|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
11476627|NCT01517243|Experimental|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:
~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
11476628|NCT01517230|Active Comparator|intervention|seven clusters where radio media campaign will be broadcast.
11476629|NCT01517230|No Intervention|control|Seven clusters where radio media campaign won't be broadcast.
11476630|NCT01517217|Other|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
11476631|NCT01517217|Other|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
11476632|NCT01517204|Experimental|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
11476633|NCT01517204|Experimental|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
11476634|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
11476635|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
11476636|NCT01517178|Active Comparator|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
11476637|NCT01517178|Experimental|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
11476638|NCT01517165|Experimental|Group 1|
11476639|NCT01517165|Placebo Comparator|Group 2|
11476640|NCT01517139||Feasibility Cohort|100 pairs of children and their mothers recruited from 2 provinces.
11476641|NCT01517087||1|neurologically normal, healthy adults, age 35 or older.
11476642|NCT01517074|Experimental|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
11476644|NCT01517022|No Intervention|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
11476645|NCT01517022|Active Comparator|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
11476646|NCT01516996|Active Comparator|Neoadjuvant and CCRT|
11476647|NCT01516996|Experimental|Neoadjuvant and CCRT and Nimotuzumab|
11476648|NCT01516983|Experimental|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
11476649|NCT01516970|Experimental|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
11476650|NCT01516970|Active Comparator|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
11476651|NCT01516957|Experimental|AMG 827 140|140 mg AMG 827
11476652|NCT01516957|Placebo Comparator|Placebo SC|Placebo
11476653|NCT01516957|Experimental|AMG 827 280|280 mg AMG 827
11476654|NCT01516957|Experimental|AMG 827 210|AMG 827 SC 210 mg
11476655|NCT01516944|Active Comparator|postoperative chemotherapy,SOX|
11476656|NCT01516944|Experimental|Perioperative chemotherapy,SOX|
11476657|NCT01516944|Experimental|Perioperative chemotherapy,XELOX|
11476658|NCT01516931|Experimental|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.
~venlafaxine：150-225mg/day"
11476659|NCT01516931|Placebo Comparator|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
11476660|NCT01516931|Placebo Comparator|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
11476661|NCT01516918|Experimental|Quadruple Regimen|All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks.
11476662|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
11476663|NCT01516892|Experimental|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
11476664|NCT01516879|Experimental|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
11476665|NCT01516879|Placebo Comparator|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
11476666|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
11476667|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
11476668|NCT01516853||Patient Group|Subjects with known or suspected iron overload will undergo serum iron measurements and a non-contrast MRI scan.
11476669|NCT01516853||Control Group|Subjects with no known history of iron overload or liver disease will undergo a serum iron measurement and a non-contrast MRI scan.
11476670|NCT01516840|Experimental|Arm 1|
11476671|NCT01516840|Experimental|Arm 2|
11476672|NCT01516840|Active Comparator|Arm 3|
11476673|NCT01516840|Active Comparator|Arm 4|
11476674|NCT01516827|Experimental|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:
~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
11476675|NCT01516827|No Intervention|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
11476676|NCT01516814|Experimental|Arm 1|
11476677|NCT01516814|Active Comparator|Arm 2|
11476678|NCT01516814|Active Comparator|Arm 3|
11476679|NCT01516801|Experimental|PSA flyer|
11476680|NCT01516801|No Intervention|Control|
11476681|NCT01516788|Experimental|Phototesting|
11476682|NCT01516775|Experimental|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
11476683|NCT01516775|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
11476684|NCT01516749|Experimental|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
11476685|NCT01516736|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
11476686|NCT01516736|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
11476687|NCT01516723|Experimental|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
11476688|NCT01516723|Active Comparator|Everolimus-eluting stents|XIENCE PRIME, Abbott
11476689|NCT01516710|Active Comparator|Open liver resection|Patients will be operated with open liver resection
11476690|NCT01516710|Active Comparator|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
11476783|NCT01516164|Active Comparator|MacIntosh|
11476784|NCT01516164|Active Comparator|McGrath MAC direct|
11476691|NCT01516697|Other|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
11476692|NCT01516697|Experimental|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
11476693|NCT01516684|Experimental|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
11476694|NCT01516684|Active Comparator|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
11476695|NCT01516658|Experimental|Hydrogel coil group|use Hydrogel Coil as much as be able to use
11476696|NCT01516658|Active Comparator|Bare platinum coil group|use only bare platinum coil
11476697|NCT01516645|Experimental|KHK2898|
11476698|NCT01516632|Experimental|SMS USA|The 6-week smoking cessation intervention
11476699|NCT01516632|No Intervention|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
11476700|NCT01516619|Experimental|romiplostim|
11476701|NCT01516606|Experimental|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
11476702|NCT01516593|Experimental|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
11476703|NCT01516580|Active Comparator|LMB chemo|"Prephase (COP) for all groups followed by:
~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²
~in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
11476704|NCT01516580|Experimental|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
11476705|NCT01516567|Experimental|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
11476706|NCT01516554|Experimental|Testosterone undecanoate|
11476707|NCT01516554|Placebo Comparator|Sugar pill|
11476708|NCT01516541|Experimental|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
11476709|NCT01516541|Placebo Comparator|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
11476710|NCT01516528||All|All subjects enrolled in the study
11476711|NCT01516515|Placebo Comparator|placebo, gel|placebo comparator
11476712|NCT01516515|Active Comparator|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
11476713|NCT01516502|Active Comparator|laser to acupoint|
11476714|NCT01516502|Sham Comparator|sham laser to acupoint|
11476715|NCT01516502|Active Comparator|laser to trigger point|
11476716|NCT01516502|Sham Comparator|sham laser to trigger point|
11476717|NCT01516489|No Intervention|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
11476718|NCT01516489|Experimental|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
11476719|NCT01516489|Experimental|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
11476720|NCT01516489|Experimental|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
11476721|NCT01516489|Experimental|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
11476722|NCT01516489|Experimental|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
11476723|NCT01516489|Experimental|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
11476724|NCT01516489|No Intervention|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
11476725|NCT01516476|Experimental|Liraglutide Arm|
11476726|NCT01516476|Placebo Comparator|Placebo Arm|
11476727|NCT01516476|Experimental|RO6807952 Arm 1|
11476728|NCT01516476|Experimental|RO6807952 Arm 2|
11476729|NCT01516463|Active Comparator|Collagenase Santyl|
11476730|NCT01516463|Sham Comparator|Bacitracin|
11476731|NCT01516450|Active Comparator|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
11476732|NCT01516450|Active Comparator|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
11476733|NCT01516437|Experimental|HNS Group|Healthy non-smokers aged between 45-75 years
11476734|NCT01516437|Experimental|HS Group|Healthy smokers aged between 45-75 years
11476735|NCT01516437|Experimental|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
11476736|NCT01516437|Experimental|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
11476737|NCT01516424|Experimental|Blonanserin|Antipsychotics
11476738|NCT01516424|Active Comparator|Risperidone|Antipsychotics
11476785|NCT01516164|Active Comparator|McGrath MAC indirect|
11476741|NCT01516411|Active Comparator|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
11476742|NCT01516411|Active Comparator|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
11476743|NCT01516385||spinal cord injury|
11476744|NCT01516385||other neurological conditions|
11476745|NCT01516372|Experimental|Treatment 1|Healthy Volunteers will receive Treatments ABDC
11476746|NCT01516372|Experimental|Treatment 2|Healthy Volunteers will receive Treatments BCAD
11476747|NCT01516372|Experimental|Treatment 3|Healthy Volunteers will receive Treatments CDBA
11476748|NCT01516372|Experimental|Treatment 4|Healthy Volunteers will receive Treatments DACB
11476749|NCT01516359||patients with cardiac surgery|
11476750|NCT01516346|Active Comparator|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.
~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
11476751|NCT01516346|Active Comparator|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.
~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.
~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
11476752|NCT01516346|Placebo Comparator|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.
~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
11476753|NCT01516333|Experimental|Diet 1|High GI; High Carb; High GL
11476754|NCT01516333|Experimental|Diet 2|High GI, Low Carb, Med GL
11476755|NCT01516333|Experimental|Diet 3|Low GI, High Carb, Med GL
11476756|NCT01516333|Experimental|Diet 4|Low GI, Low Carb, Low GL
11476757|NCT01516320|Experimental|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
11476758|NCT01516320|Active Comparator|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
11476759|NCT01516320|Active Comparator|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
11476760|NCT01516307|Experimental|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
11476761|NCT01516307|Placebo Comparator|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
11476762|NCT01516294|Experimental|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
11476763|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
11476764|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
11476765|NCT01516268|Active Comparator|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
11476766|NCT01516268|Placebo Comparator|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
11476767|NCT01516255|Experimental|Double-blind / liraglutide|
11476768|NCT01516255|Placebo Comparator|Double-blind / placebo|
11476769|NCT01516255|Active Comparator|Open-label / moxifloxacin|
11476770|NCT01516255|Placebo Comparator|Open-label / placebo|
11476771|NCT01516242||NovoPen® 4|
11476772|NCT01516229||Somatropin|
11476773|NCT01516216|Active Comparator|Standard Dose Vitamin D|Standard Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).
11476774|NCT01516216|Active Comparator|Higher Dose Vitamin D|Higher Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).
11476775|NCT01516203|Experimental|Arm 1|AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
11476776|NCT01516203|Experimental|Arm 2|AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
11476777|NCT01516203|Experimental|Arm 3|AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
11476778|NCT01516203|Experimental|Arm 4|AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
11476779|NCT01516203|Active Comparator|Arm 5|Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
11476780|NCT01516190|Active Comparator|Exercise Group|Supervised exercise sessions and independent exercise
11476781|NCT01516190|Active Comparator|Mind-Body Group|Surgical preparation program
11476782|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
11476786|NCT01516151|Active Comparator|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
11476787|NCT01516151|Active Comparator|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
11476788|NCT01516151|Active Comparator|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
11476789|NCT01516151|Other|Group D|Standard of care
11476790|NCT01516151|Active Comparator|Group E|4.0g total CaPre™ from baseline to week 8
11476791|NCT01516138|Active Comparator|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
11476792|NCT01516138|Placebo Comparator|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
11476793|NCT01516125||Screening only - no intervention|
11476794|NCT01516099|Experimental|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
11476795|NCT01516099|Experimental|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
11476796|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
11476797|NCT01516086|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
11476798|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
11476799|NCT01516086|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
11476800|NCT01516086|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
11476801|NCT01516086|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution
11476802|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
11476803|NCT01516073|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
11476804|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
11476805|NCT01516073|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
11476806|NCT01516073|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
11476807|NCT01516073|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution 2mL
11476808|NCT01516060|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
11476809|NCT01516060|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
11476810|NCT01516047|Experimental|Cohort 1|Patients with severe hepatic impairment.
11476811|NCT01516047|Experimental|Cohort 2|Healthy individuals with normal hepatic function.
11476812|NCT01516034|Experimental|Treatment|Cupola Tattoo Removal Device
11476813|NCT01516021|Experimental|high fat yoghurt intake|500 ml of a high fat yoghurt
11476814|NCT01516021|Experimental|low fat yoghurt intake|
11476815|NCT01516008|Experimental|Tapentadol IR 50 mg|
11476816|NCT01516008|Experimental|Tapentadol IR 75 mg|
11476817|NCT01516008|Placebo Comparator|Placebo|
11476818|NCT01515995|Experimental|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
11476819|NCT01515995|Active Comparator|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
11476820|NCT01515982|Experimental|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
11476821|NCT01515982|No Intervention|Control group|All participants were asked not to commence any new exercise regimen.
11476822|NCT01515969|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
11476823|NCT01515956|Experimental|BMN 110 Weekly|
11476824|NCT01515943|Active Comparator|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
11476825|NCT01515943|Active Comparator|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
11476826|NCT01515943|Placebo Comparator|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
11476827|NCT01515930|Active Comparator|Active Caregiver and Active Child|Parent & Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
11476828|NCT01515930|Experimental|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
11476829|NCT01515930|Active Comparator|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
11477074|NCT01514149|Placebo Comparator|Arm 5 - Weekly Placebo|
11476830|NCT01515917|Experimental|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
11476831|NCT01515917|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
11476832|NCT01515904||Control|
11476833|NCT01515904||STOMP|
11476834|NCT01515891|Experimental|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
11476835|NCT01515878|Experimental|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
11476836|NCT01515878|No Intervention|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
11476837|NCT01515865|Experimental|Midodrine HCl|
11476838|NCT01515865|Placebo Comparator|Placebo|
11476839|NCT01515852|Other|Stress level after general anesthesia|
11476840|NCT01515852|Other|Stress level after local anesthesia|
11476841|NCT01515839|Experimental|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
11476842|NCT01515826|Experimental|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
11476843|NCT01515826|Active Comparator|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
11476844|NCT01515813|Experimental|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
11476845|NCT01515813|Experimental|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
11476846|NCT01515813|Experimental|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
11476847|NCT01515800|Experimental|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
11476848|NCT01515800|No Intervention|No text message reminder|Patients receive standard follow-up care.
11476849|NCT01515787|Experimental|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.
~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
11476850|NCT01515787|Active Comparator|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
11476851|NCT01515774|Active Comparator|Group 1|Give QD dose first then BID dosing
11476852|NCT01515774|Active Comparator|Group 2|Give BID dosing and then QD dosing
11476853|NCT01515761|Active Comparator|Postero-lateral|Left ventricular lateral wall lead position
11476854|NCT01515761|Active Comparator|Antero-lateral|Left ventricular lateral wall lead position
11476855|NCT01515748|Other|Surgery + Adjuvant Chemotherapy (SC)|Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 milligrams per square meter (mg/m^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 8 years).
11476856|NCT01515748|Experimental|Neoadjuvant Chemotherapy +Surgery +Adjuvant chemotherapy (CSC)|Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m^2 intravenously (IV) for greater than or equal to (>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m^2 IV for >=2 hr on Day 1 of each treatment cycle plus S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 8 years).
11476857|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
11476858|NCT01515722|Experimental|Health education intervention (HEI)|
11476859|NCT01515722|No Intervention|No intervention|
11476860|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
11476861|NCT01515696|Active Comparator|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
11476862|NCT01515696|Placebo Comparator|Sterile water|infants receive 9ml/kg sterile water
11476863|NCT01515683|Experimental|An anaesthetic nurse|
11476864|NCT01515683|Active Comparator|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
11476865|NCT01515683|Experimental|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
11476866|NCT01515683|Experimental|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
11476867|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
11476868|NCT01515657|Experimental|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
11476869|NCT01515657|Active Comparator|Immediate-Release Aspirin Tablets|Active comparator; crossover design
11476870|NCT01515657|Active Comparator|Enteric-coated aspirin caplets|Active comparator; crossover design
11476871|NCT01515644|Experimental|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
11476872|NCT01515644|Experimental|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
11476873|NCT01515644|Placebo Comparator|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
11476874|NCT01515631||Study|Patients with alagille syndrome
11476875|NCT01515605||Patients after kidney transplantation|Patients after kidney transplantation
11476876|NCT01515592|Experimental|15 mcg/kg|
11476877|NCT01515592|Experimental|20 mcg/kg|
11476878|NCT01515592|Experimental|25 mcg/kg|
11476879|NCT01515579|Experimental|Formulation 3|
11476880|NCT01515579|Experimental|Formulation 4|
11476881|NCT01515566|Experimental|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
11476882|NCT01515566|Active Comparator|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
11476883|NCT01515553|Experimental|Formulation 4|
11476884|NCT01515553|Experimental|Final formulation 4|
11476885|NCT01515540|Active Comparator|lidocaine|5% lidoderm patch
11476886|NCT01515540|Placebo Comparator|control|placebo patch
11476887|NCT01515527|Experimental|Cladribine + Cytarabine Alt. with Decitabine|"Induction cycle: Cladribine intravenous (IV) over approximately 1 to 2 hours, daily on days 1-5 combined with Cytarabine subcutaneous (SQ) twice daily on days 1-10. Cytarabine should be administered approximately 3-6 hours following the start of the cladribine infusion.
~Consolidation cycle: Cladribine IV over 1 to 2 hours, daily on days 1-3 combined with Cytarabine SQ twice daily on days 1-10. Cytarabine should be administered 3-6 hours following the start of the cladribine infusion.
~Alternating with: Decitabine IV over 1 to 2 hours, daily on days 1-5."
11476888|NCT01515501|Other|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
11476889|NCT01515488|Experimental|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
11476890|NCT01515488|Experimental|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
11476891|NCT01515475|Active Comparator|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
11476892|NCT01515475|Placebo Comparator|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
11476893|NCT01515462|Experimental|OTL-103 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
11476894|NCT01515436|Active Comparator|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
11476895|NCT01515436|Active Comparator|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
11476896|NCT01515423|Experimental|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
11476897|NCT01515423|Active Comparator|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
11476898|NCT01515410|Experimental|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
11476899|NCT01515410|Active Comparator|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
11476900|NCT01515397|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
11476901|NCT01515397|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
11476902|NCT01515384|Experimental|Type 1 Diabetes|
11476903|NCT01515384|Experimental|Type 2 Diabetes|
11476904|NCT01515384|Experimental|Healthy Controls|
11476905|NCT01515371|Experimental|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
11476906|NCT01515371|Placebo Comparator|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
11476907|NCT01515358|Placebo Comparator|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
11476908|NCT01515358|Experimental|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
11476909|NCT01515345|Active Comparator|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
11476910|NCT01515345|Experimental|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
11476911|NCT01515319|Experimental|Y242|Single ascending dose study in Part A Multiple ascending dose study in Part B
11476912|NCT01515319|Placebo Comparator|Placebo (0.9% saline)|0.9% saline placebo
11476913|NCT01515306|Experimental|Part A: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: paclitaxel administered on Day 1 of 2-week cycle.
~Cycle 2: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.
~Cycle 3 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of each 4-week cycle."
11476914|NCT01515306|Experimental|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.
~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.
~*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
11476915|NCT01515293|Experimental|Single Incision Laparoscopic Appendectomy|
11476916|NCT01515293|Experimental|Conventional appendectomy|Conventional appendectomy
11476917|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
11476918|NCT01515254|No Intervention|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
11476919|NCT01515254|Experimental|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
11476920|NCT01515241|Other|Open label single arm study of CER-001|Open label single arm study of CER-001
11476921|NCT01515228|Active Comparator|Xience Prime stent|everolimus eluting stent
11476922|NCT01515228|Experimental|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
11476923|NCT01515215|Active Comparator|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.
~Site of Stimulation: left hemisphere of DLPFC.
~Frequency: 10 Hz.
~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
11476924|NCT01515215|Active Comparator|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.
~Sites of Stimulation: right and left hemispheres of the DLPFC.
~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.
~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
11476925|NCT01515215|Sham Comparator|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
11476926|NCT01515202|Experimental|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
11476927|NCT01515202|Experimental|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
11476928|NCT01515202|Experimental|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
11476929|NCT01515202|Experimental|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
11476930|NCT01515202|Experimental|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
11476931|NCT01515189|Experimental|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
11476932|NCT01515189|Experimental|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
11476933|NCT01515176|Experimental|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
11476934|NCT01515163|Experimental|Exercise|3-month exercise training program
11476935|NCT01515163|No Intervention|Control|Control group
11476936|NCT01515163|Experimental|Healthy control|
11476937|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
11476938|NCT01515137|Experimental|Arm A erlotinib plus sulindac|erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A),
11476939|NCT01515137|Experimental|Arm B erlotinib|erlotinib (150 mg PO QD) (Arm B)
11476940|NCT01515137|Experimental|Arm C|placebo (for Erlotinib) QD (Arm C).
11476941|NCT01515124|No Intervention|Lymphedema Care Only|"All 4 groups receive lymphedema care as follows:
~2 custom fitted compression garments (baseline and 6 months)
~evaluations for flare-ups at request (and at each measurement time point)
~lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions."
11476942|NCT01515124|Experimental|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
11476991|NCT01514786|No Intervention|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
11476992|NCT01514786|Active Comparator|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
11476943|NCT01515124|Experimental|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
11476944|NCT01515124|Experimental|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
11476945|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
11476946|NCT01515098|Experimental|Blueberry Group|
11476947|NCT01515098|Placebo Comparator|Placebo Group|
11476948|NCT01515098|No Intervention|Reference Group|
11476949|NCT01515085||biopsy proven glioma, no prior treatment|
11476950|NCT01515072|No Intervention|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
11476951|NCT01515072|Experimental|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
11476952|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
11476953|NCT01515046|Experimental|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.
~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
11476954|NCT01515033|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
11476955|NCT01515033|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
11476956|NCT01515020|Active Comparator|vancomycin monotherapy|vancomycin monotherapy: standard therapy
11476957|NCT01515020|Experimental|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
11476958|NCT01515007|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
11476959|NCT01515007|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
11476960|NCT01514994|Experimental|AngioScore's Valvuloplasty Scoring Balloon|
11476961|NCT01514981|Experimental|AMG 761|
11476962|NCT01514981|Placebo Comparator|Placebo|
11476963|NCT01514968|Experimental|DNV/r+cyclosporine|
11476964|NCT01514968|Active Comparator|cyclosporine|
11476965|NCT01514968|Active Comparator|danoprevir+ritonavir|
11476966|NCT01514942|Other|Insulin resistant patients|
11476967|NCT01514942|Other|Non-insulin resistant patients|
11476968|NCT01514929|Experimental|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
11476969|NCT01514929|Experimental|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
11476970|NCT01514929|Active Comparator|Moxifloxacin|400mg moxifloxacin
11476971|NCT01514929|Placebo Comparator|Placebo|Placebo
11476972|NCT01514903|Active Comparator|viagra,anti-erectile dysfunction agent|
11476973|NCT01514903|Experimental|HIP0908|
11476974|NCT01514890||Telaprevir|
11476975|NCT01514890||Boceprevir|
11476976|NCT01514877|Experimental|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
11476977|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
11476978|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
11476979|NCT01514851|Experimental|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
11476980|NCT01514851|Active Comparator|Arm 2|1500-4500mg/day, tid, 8 weeks
11476981|NCT01514838|Experimental|1941 group|Once daily over a 24-week treatment period
11476982|NCT01514838|Active Comparator|acarbose group|Once daily over a 24-week treatment period
11476983|NCT01514825|Experimental|YM150 low dose group|
11476984|NCT01514825|Experimental|YM150 middle dose group|
11476985|NCT01514825|Experimental|YM150 high dose group|
11476986|NCT01514825|Placebo Comparator|placebo group|
11476987|NCT01514812|Experimental|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
11476988|NCT01514812|Experimental|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
11476989|NCT01514799|Active Comparator|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass 60 cm BP limb
11476990|NCT01514799|Experimental|Long BP limb|200 cm BP limb
11476995|NCT01514760|Experimental|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
11476996|NCT01514747||ELBW infants|
11476997|NCT01514734|Experimental|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
11476998|NCT01514721|Experimental|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
11476999|NCT01514708|Experimental|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
11477000|NCT01514695|Experimental|Fentanyl|Fentanyl arm
11477001|NCT01514695|Placebo Comparator|Placebo|Placebo of identical appearance
11477002|NCT01514682|Placebo Comparator|Placebo|Placebo pills to be assigned using a permuted randomization system
11477003|NCT01514682|Experimental|Anti-inflammatory Combination Therapy|Salsalate, statin and omega-3-fatty acid combination therapy
11477004|NCT01514669||No treatment|
11477005|NCT01514656|Active Comparator|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
11477006|NCT01514656|Experimental|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
11477007|NCT01514656|Active Comparator|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
11477008|NCT01514656|Active Comparator|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
11477009|NCT01514656|Active Comparator|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
11477010|NCT01514656|Active Comparator|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
11477011|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
11477012|NCT01514630|Experimental|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
11477013|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
11477014|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
11477015|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
11477016|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
11477017|NCT01514578|Experimental|TRV130A|
11477018|NCT01514578|Placebo Comparator|Dextrose in Water|
11477019|NCT01514552|Placebo Comparator|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
11477020|NCT01514552|Active Comparator|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
11477021|NCT01514539|Other|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
11477022|NCT01514539|Other|Control Never Pregnant|women between 18 and 45 who have never been pregnant
11477023|NCT01514526|Experimental|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
11477024|NCT01514513|Experimental|Licefreee Spray|
11477025|NCT01514513|Active Comparator|Nix Creme Rinse, 1% Permethrin|
11477026|NCT01514500|Experimental|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
11477027|NCT01514500|Experimental|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
11477028|NCT01514487|Experimental|pH 7.7|
11477029|NCT01514487|Experimental|pH 7.9|
11477030|NCT01514487|Experimental|pH 8.15|
11477206|NCT01513200|Experimental|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
11477031|NCT01514461|Experimental|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.
~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.
~A low fat diet will be followed and recorded in patient diary."
11477032|NCT01514461|Experimental|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.
~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.
~A low fat diet will be followed and recorded in patient diary."
11477033|NCT01514461|Placebo Comparator|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.
~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.
~A low fat diet will be followed and recorded in patient diary."
11477034|NCT01514448|Experimental|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
11477035|NCT01514435|Experimental|ECT verum group|Patients with treatment refractory depression treated with ECT
11477036|NCT01514422|Experimental|Minocycline|All subjects will be given minocycline over 8 weeks
11477037|NCT01514409|Experimental|5-Hydroxytryptophan|
11477038|NCT01514409|Placebo Comparator|Placebo|
11477039|NCT01514396|Experimental|Surgical Glue|Surgiseal
11477040|NCT01514383|Experimental|Surgical Adhesive|The surgical adhesive (cyanoacrylate) will be used once to close the topical skin surgical incision created during surgical procedures.
11477041|NCT01514370|Experimental|IFN beta 1a 44 mcg TIW + curcumin (BCM95)|
11477042|NCT01514370|Placebo Comparator|IFN beta 1a 44 mcg TIW + placebo|
11477043|NCT01514357|Other|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
11477044|NCT01514357|Placebo Comparator|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
11477045|NCT01514344|Experimental|intralesional rituximab|
11477046|NCT01514331|Active Comparator|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
11477047|NCT01514331|Active Comparator|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
11477048|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
11477049|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
11477050|NCT01514292|Experimental|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
11477051|NCT01514279|Experimental|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
11477052|NCT01514279|Experimental|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
11477053|NCT01514279|No Intervention|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
11477054|NCT01514266|Experimental|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
11477055|NCT01514266|Placebo Comparator|Placebo|
11477056|NCT01514253|Experimental|glucose 25%|1 ml of glucose once
11477057|NCT01514253|Experimental|infant formula|Materna RTF stage 1
11477058|NCT01514253|Placebo Comparator|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
11477059|NCT01514240|Experimental|D9421-C|D9421-C 9 mg once daily
11477060|NCT01514240|Active Comparator|Mesalazine|Mesalazine 1 g three times a day
11477061|NCT01514227|Experimental|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
11477062|NCT01514227|Experimental|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
11477063|NCT01514214|Active Comparator|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
11477064|NCT01514214|Active Comparator|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
11477065|NCT01514201|Experimental|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.
~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
11477066|NCT01514188|Active Comparator|Doxorubicin|
11477067|NCT01514188|Experimental|INNO-206|
11477068|NCT01514175|Experimental|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
11477069|NCT01514162|Experimental|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
11477070|NCT01514149|Experimental|Arm 1 - Weekly CJC-1134-PC|
11477071|NCT01514149|Experimental|Arm 2 - Weekly CJC-1134-PC|
11477072|NCT01514149|Experimental|Arm 3 - Weekly CJC-1134-PC|
11477073|NCT01514149|Experimental|Arm 4 - Weekly CJC-1134-PC|
11477075|NCT01514136|Experimental|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A*, B*, C*, D*.
11477076|NCT01514123|Experimental|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
11477077|NCT01514123|Experimental|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
11477078|NCT01514110|Experimental|RAD001|
11477079|NCT01514097||Fractures reduced|
11477080|NCT01514097||Fractures splinted|
11477081|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
11477082|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
11477083|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
11477084|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
11477085|NCT01514071|Experimental|Pop-up picture|
11477086|NCT01514058|Active Comparator|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
11477087|NCT01514058|Active Comparator|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
11477088|NCT01514032|Active Comparator|Extracorporal shockwave lithotripsy|
11477089|NCT01514032|Active Comparator|Retrograde intrarenal surgery|
11477090|NCT01514019|Experimental|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
11477091|NCT01514019|Placebo Comparator|Placebo|
11477092|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
11477093|NCT01513993|No Intervention|Control group|Treatment as usual
11477094|NCT01513993|Experimental|Telemonitoring for patients with Congestive Heart Failure|
11477095|NCT01513980|No Intervention|Control group|Treatment as usual
11477096|NCT01513980|Experimental|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
11477097|NCT01513980|Experimental|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
11477098|NCT01513967|Experimental|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
11477099|NCT01513967|Placebo Comparator|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
11477100|NCT01513967|Experimental|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
11477101|NCT01513967|Placebo Comparator|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
11477102|NCT01513967|Experimental|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
11477103|NCT01513967|Placebo Comparator|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
11477104|NCT01513967|Experimental|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
11477105|NCT01513967|Placebo Comparator|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
11477106|NCT01513967|Experimental|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
11477107|NCT01513967|Placebo Comparator|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
11477108|NCT01513967|Experimental|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
11477109|NCT01513967|Placebo Comparator|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
11477110|NCT01513954||IVF population|Long Lupron IVF Population
11477111|NCT01513954||IUI patients|Patients undergoing IUI
11477112|NCT01513941|Experimental|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
11477113|NCT01513915|Active Comparator|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
11477114|NCT01513915|No Intervention|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
11477115|NCT01513902|Experimental|Cohort 1|Ages 12 to less than 18
11477116|NCT01513902|Experimental|Cohort 2|Ages 6 to less than 12
11477117|NCT01513902|Experimental|Corhort 3|Ages 2 to less than 6
11477118|NCT01513863|Experimental|Metronidazole Topical Gel 1%|
11477119|NCT01513863|Active Comparator|Metronidazole Topical Gel 1% (Metrogel )|
11477120|NCT01513863|Placebo Comparator|Placebo|
11477121|NCT01513850|Experimental|Hepabulin IV|
11477122|NCT01513824|Active Comparator|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
11477123|NCT01513824|No Intervention|bio feedback guided, stress management|control without treatment
11477124|NCT01513811|Active Comparator|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
11477125|NCT01513811|Active Comparator|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
11477126|NCT01513811|Active Comparator|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
11477127|NCT01513798|Experimental|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
11477128|NCT01513798|Experimental|General advice on exercise|Modified paleolithic diet and general advice on exercise
11477129|NCT01513785|Active Comparator|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
11477257|NCT01512836|No Intervention|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
11477130|NCT01513785|Active Comparator|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
11477131|NCT01513772|Placebo Comparator|Control|
11477132|NCT01513772|Active Comparator|Dexmedetomidine|
11477133|NCT01513759|Experimental|EkoSonic® Endovascular System|Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
11477134|NCT01513733|Experimental|Tasquinimod single dose|
11477135|NCT01513733|Experimental|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
11477136|NCT01513733|Experimental|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
11477137|NCT01513720|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
11477138|NCT01513720|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
11477139|NCT01513707||Hemodialysis group|Hemodialysis group
11477140|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
11477141|NCT01513694|Experimental|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
11477142|NCT01513681|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
11477143|NCT01513681|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
11477144|NCT01513668|Experimental|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
11477145|NCT01513668|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
11477146|NCT01513655|Experimental|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.
~Outpatient visits are given every three months."
11477147|NCT01513655|No Intervention|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.
~Outpatient visits are given every three months."
11477148|NCT01513642|Other|Incentive spirometry|
11477149|NCT01513642|No Intervention|Breath Stacking|
11477150|NCT01513616|Experimental|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
11477151|NCT01513616|Sham Comparator|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
11477152|NCT01513603|Experimental|CLAG-M|
11477153|NCT01513590|Experimental|IDegAsp BID|
11477154|NCT01513590|Active Comparator|BIAsp 30 BID|
11477155|NCT01513577|Experimental|Minimal invasive pedicular screw|
11477156|NCT01513577|Experimental|Standard open insertion|
11477157|NCT01513564|Experimental|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.
~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
11477158|NCT01513551|Experimental|V114|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
11477159|NCT01513551|Active Comparator|PNEUMOVAX® 23|Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
11477160|NCT01513551|Active Comparator|PREVNAR 13®|Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
11477161|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
11477162|NCT01513525|Experimental|Abdomen|
11477163|NCT01513525|Experimental|Thigh|
11477164|NCT01513525|Experimental|Upper arm|
11477165|NCT01513499|Active Comparator|Oxytocin|Intranasal oxytocin
11477166|NCT01513499|Placebo Comparator|Placebo|Intranasal placebo
11477167|NCT01513486|Experimental|Immobilization with NMES|Immobilization with daily NMES
11477168|NCT01513486|Placebo Comparator|Immobilization without NMES|Immobilization without daily NMES
11477169|NCT01513473|Experimental|Insulin Degludec + Insulin Aspart|
11477170|NCT01513473|Experimental|Insulin Detemir +Insulin Aspart|
11477171|NCT01513460|Experimental|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
11477172|NCT01513460|Active Comparator|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
11477173|NCT01513460|Placebo Comparator|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
11477174|NCT01513447|Active Comparator|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
11477175|NCT01513447|Placebo Comparator|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
11477176|NCT01513434|Active Comparator|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
11477177|NCT01513434|Active Comparator|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
11477178|NCT01513421||Active vacuum pressure drainage|
11477179|NCT01513421||Free drainage|
11477180|NCT01513408|Experimental|CD8/Foxp3|patient suffering from non-metastatic breast cancer
11477181|NCT01513395|No Intervention|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
11477182|NCT01513395|Experimental|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
11477183|NCT01513382|Experimental|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
11477184|NCT01513369|Experimental|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
11477185|NCT01513369|Placebo Comparator|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
11477186|NCT01513356|Experimental|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
11477187|NCT01513343|Experimental|Parent and child classes|Parent and child groups focused on self-regulation of eating
11477188|NCT01513343|No Intervention|Treatment as usual|Treatment as usual
11477189|NCT01513330|Experimental|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
11477190|NCT01513330|Experimental|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
11477191|NCT01513317|Experimental|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
11477192|NCT01513317|Experimental|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
11477193|NCT01513304|Experimental|Chiropractic manual therapy|
11477194|NCT01513291|Experimental|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
11477195|NCT01513291|Placebo Comparator|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
11477196|NCT01513278|Placebo Comparator|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
11477197|NCT01513278|Active Comparator|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
11477198|NCT01513265|Active Comparator|RASP|
11477199|NCT01513265|No Intervention|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
11477200|NCT01513252|Experimental|1|Gröber and Buschke test
11477201|NCT01513239|Experimental|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
11477202|NCT01513239|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
11477203|NCT01513239|Placebo Comparator|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
11477204|NCT01513226|Experimental|Dim light|Day and nighttime dim light conditions
11477205|NCT01513200|Placebo Comparator|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
11477207|NCT01513187|Experimental|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.
~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
11477208|NCT01513174|Active Comparator|Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
11477209|NCT01513174|Experimental|Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
11477210|NCT01513161|Active Comparator|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
11477211|NCT01513161|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule & one placebo capsule)by oral route once daily for 14 days
11477212|NCT01513161|Placebo Comparator|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
11477213|NCT01513148|Experimental|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
11477214|NCT01513148|Placebo Comparator|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
11477215|NCT01513135|Experimental|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 & 8
11477216|NCT01513135|Placebo Comparator|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 & 8
11477217|NCT01513122|Active Comparator|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
11477218|NCT01513122|Active Comparator|Arm 2. Lopinavir /ritonavir + raltegravir|
11477219|NCT01513109|Experimental|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
11477220|NCT01513096|No Intervention|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
11477221|NCT01513096|Active Comparator|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
11477222|NCT01513083|Experimental|Mild hepatic dysfunction|
11477223|NCT01513083|Experimental|Moderate hepatic dysfunction|
11477224|NCT01513083|Experimental|Normal hepatic function|
11477225|NCT01513070|Experimental|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
11477226|NCT01513070|Active Comparator|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
11477227|NCT01513057|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
11477228|NCT01513057|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
11477229|NCT01513044|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
11477230|NCT01513044|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
11477231|NCT01513031|Experimental|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
11477232|NCT01513018|Active Comparator|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
11477233|NCT01513018|Active Comparator|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
11477234|NCT01513005|Experimental|Laparoscopic Sleeve Gastrectomy|
11477235|NCT01512992|Experimental|Home telehealth|
11477236|NCT01512992|No Intervention|Usual care|
11477237|NCT01512979|Experimental|linagliptin|patients receive linagliptin tablet once daily
11477238|NCT01512979|Experimental|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
11477239|NCT01512966|Experimental|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye [BAY86-5321; EYLEA (aflibercept) Injection] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
11477240|NCT01512953|No Intervention|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
11477241|NCT01512953|Experimental|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
11477242|NCT01512927||ESRD with regular hemodialysis|
11477243|NCT01512914|Placebo Comparator|CONTROL group|
11477244|NCT01512914|Experimental|PREOPERATIVE nebulization|
11477245|NCT01512914|Experimental|POSTOPERATIVE nebulization|
11477246|NCT01512914|Active Comparator|INSTILLATION group|
11477247|NCT01512901|Experimental|1|
11477248|NCT01512901|Experimental|2|
11477249|NCT01512901|Sham Comparator|3|
11477250|NCT01512888|Experimental|Treatment|Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
11477251|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
11477252|NCT01512862|Experimental|Calcitriol|
11477253|NCT01512862|No Intervention|Placebo|
11477254|NCT01512849|Experimental|TA-7284 Low|
11477255|NCT01512849|Experimental|TA-7284 High|
11477256|NCT01512836|Experimental|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
11477297|NCT01512628|Active Comparator|PENTA group|Pentaspan is administered as a colloid.
11477258|NCT01512823|Experimental|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
11477259|NCT01512823|Experimental|Didactic educational intervention|Education alone
11477260|NCT01512810|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
11477261|NCT01512810|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
11477262|NCT01512797|Active Comparator|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
11477263|NCT01512797|Placebo Comparator|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
11477264|NCT01512784|Experimental|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
11477265|NCT01512784|Active Comparator|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
11477266|NCT01512758|Experimental|Alisertib 30 mg|Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
11477267|NCT01512758|Experimental|Alisertib 40 mg|Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
11477268|NCT01512745|Experimental|apatinib|
11477269|NCT01512745|Placebo Comparator|placebo|
11477270|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
11477271|NCT01512732||Parkinson's disease patients|(n=30).
11477272|NCT01512732||Major depressive disorder patients|(n=30).
11477273|NCT01512719|Experimental|POEM procedure|Patients with achalasia that undergo POEM
11477274|NCT01512706|Experimental|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
11477275|NCT01512706|Experimental|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
11477276|NCT01512706|Experimental|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
11477277|NCT01512706|Experimental|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
11477278|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
11477279|NCT01512706|Experimental|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
11477280|NCT01512706|Experimental|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
11477281|NCT01512706|Experimental|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
11477282|NCT01512706|Experimental|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
11477283|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
11477284|NCT01512706|Experimental|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
11477285|NCT01512706|Experimental|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
11477286|NCT01512706|Experimental|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
11477287|NCT01512706|Experimental|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
11477288|NCT01512706|Placebo Comparator|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
11477289|NCT01512693|Experimental|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
11477290|NCT01512693|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
11477291|NCT01512680|Experimental|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
11477292|NCT01512667|Experimental|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
11477293|NCT01512667|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
11477294|NCT01512654|Other|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
11477295|NCT01512654|Other|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
11477296|NCT01512641|Experimental|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
11477298|NCT01512628|Active Comparator|voluVEN group|Voluven is administered as a colloid.
11477299|NCT01512628|Active Comparator|voluLYTE group|Volulyte is administered as a colloid.
11477300|NCT01512615|Experimental|Intervention group|Complex Cardiac Rehabilitation
11477301|NCT01512615|Experimental|Control group|Usual care
11477302|NCT01512602|Active Comparator|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
11477303|NCT01512602|Active Comparator|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
11477304|NCT01512589|Experimental|Proton Beam Therapy (PBT)|"Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE (Relative Biologic Equivalence for PBT)) to be delivered to the periphery of the planning target volume (PTV)."
11477305|NCT01512589|Active Comparator|Intensity Modulated Radiation Therapy (IMRT)|Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy to be delivered to the periphery of the planning target volume (PTV).
11477306|NCT01512576|Experimental|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
11477307|NCT01512576|Active Comparator|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
11477308|NCT01512563|Experimental|Paclitaxel ElutingCovered Metal Stent|
11477309|NCT01512563|Active Comparator|Covered Metal Stent|
11477310|NCT01512550|Active Comparator|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
11477311|NCT01512550|No Intervention|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
11477312|NCT01512550|Active Comparator|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
11477313|NCT01512537|Active Comparator|UVB|UVB exposed group
11477314|NCT01512537|Active Comparator|Oral vitamin D tablet|Vitamin D supplementation
11477315|NCT01512524|Other|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
11477316|NCT01512511|Experimental|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
11477317|NCT01512511|Placebo Comparator|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
11477318|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
11477319|NCT01512485|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
11477320|NCT01512485|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
11477321|NCT01512472|Active Comparator|10 month degarelix therapy|
11477322|NCT01512472|Active Comparator|4 month degarelix therapy arm|
11477323|NCT01512459|Experimental|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
11477324|NCT01512459|Active Comparator|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
11477325|NCT01512446|Active Comparator|Alendronate|
11477326|NCT01512446|Placebo Comparator|Placebo|
11477327|NCT01512433|Active Comparator|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
11477328|NCT01512433|Sham Comparator|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
11477329|NCT01512420||Cohort|
11477330|NCT01512407|Experimental|Hepatectomy plus TACE|Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
11477331|NCT01512407|No Intervention|Hepatectomy alone|
11477332|NCT01512394|Active Comparator|Standard bowel prep|Standard bowel prep
11477333|NCT01512394|Experimental|No bowel prep|No bowel prep
11477334|NCT01512381|Experimental|CRT|
11477335|NCT01512381|Active Comparator|pacemaker|
11477336|NCT01512368|Experimental|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
11477337|NCT01512355|Experimental|dexmedetomidine|
11477338|NCT01512355|Placebo Comparator|placebo|
11477339|NCT01512342|Experimental|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
11477340|NCT01512342|Active Comparator|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
11477375|NCT01512134|Experimental|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
11477341|NCT01512329|Experimental|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
11477342|NCT01512329|Active Comparator|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
11477343|NCT01512316|Active Comparator|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
11477344|NCT01512316|Active Comparator|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
11477345|NCT01512316|Placebo Comparator|Placebo|A placebo pill will be administered on day1 and 2
11477346|NCT01512303|Experimental|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
11477347|NCT01512303|Experimental|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
11477348|NCT01512303|No Intervention|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
11477349|NCT01512303|No Intervention|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
11477350|NCT01512290|Active Comparator|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
11477351|NCT01512290|Placebo Comparator|sham treatment|
11477352|NCT01512277|Experimental|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
11477353|NCT01512277|Experimental|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
11477354|NCT01512277|Placebo Comparator|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
11477355|NCT01512264|Experimental|rTMS|3 weeks of nerTMS
11477356|NCT01512264|Sham Comparator|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
11477357|NCT01512264|Sham Comparator|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
11477358|NCT01512264|Placebo Comparator|Control Group|3 weeks of Sham Treatment
11477359|NCT01512251|Other|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
11477360|NCT01512238||Pharmaceutical care|
11477361|NCT01512238||Control|
11477362|NCT01512225|Experimental|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
11477363|NCT01512225|Placebo Comparator|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
11477364|NCT01512212|No Intervention|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
11477365|NCT01512199|Experimental|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
11477366|NCT01512199|Experimental|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
11477367|NCT01512199|Placebo Comparator|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
11477368|NCT01512173|Experimental|propranolol gel|
11477369|NCT01512173|Placebo Comparator|Placebo|
11477370|NCT01512160|Experimental|PF-04531083 2000 mg|
11477371|NCT01512160|Experimental|PF-04531083 1000 mg|
11477372|NCT01512160|Active Comparator|Ibuprofen 400 mg|
11477373|NCT01512160|Placebo Comparator|Placebo|
11477374|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
11477376|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
11477383|NCT01512069|Experimental|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
11477384|NCT01512069|Active Comparator|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
11477385|NCT01512056|Experimental|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.
~Negative control group: dialysis patients who refused to receive influenza vaccination."
11477386|NCT01512056|No Intervention|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
11477387|NCT01512043|Experimental|1. Breathing control|Description ...
11477388|NCT01512043|Active Comparator|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
11477389|NCT01512043|Sham Comparator|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
11477390|NCT01512017|Active Comparator|Veloderm|
11477391|NCT01512017|Placebo Comparator|Vaseline|
11477392|NCT01512004|Active Comparator|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
11477393|NCT01512004|Placebo Comparator|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
11477394|NCT01511991|Experimental|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
11477395|NCT01511978|Active Comparator|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
11477396|NCT01511978|Placebo Comparator|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
11477397|NCT01511965|Other|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
11477398|NCT01511965|Other|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
11477399|NCT01511952|Active Comparator|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
11477400|NCT01511952|Active Comparator|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
11477401|NCT01511952|Active Comparator|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
11477402|NCT01511939|Other|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
11477403|NCT01511939|Other|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
11477404|NCT01511939|Other|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
11477405|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
11477406|NCT01511913||Ipilimumab treated cohort of 1000 patients|All patients identified and followed prospectively
11477407|NCT01511913||Non-Ipilimumab treated cohort of 800 patients|600 patients will be identified and followed prospectively, and 200 patients retrospectively identified and followed
11477408|NCT01511900|Experimental|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
11477409|NCT01511900|Experimental|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
11477410|NCT01511900|Experimental|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
11477411|NCT01511900|Experimental|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
11477412|NCT01511900|Experimental|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
11477413|NCT01511887|Experimental|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
11477414|NCT01511887|No Intervention|No treatment|No treatment
11477415|NCT01511874|Experimental|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
11477416|NCT01511848|Active Comparator|arm 1|30 Patients will be treated with combined DFP and deferasirox.
11477417|NCT01511848|Active Comparator|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
11477418|NCT01511835|Experimental|Myo-inositol powder|
11477419|NCT01511835|Experimental|Myo-inositol soft gel capsules|
11477420|NCT01511835|Placebo Comparator|Folic acid|
11477421|NCT01511822|Active Comparator|Drospirenone + Ethinyl estradiol|
11477422|NCT01511822|Experimental|Drospirenone + Ethinyl estradiol + Myo-inositol|
11477423|NCT01511822|Placebo Comparator|Placebo|
11477424|NCT01511809|Experimental|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
11477425|NCT01511809|No Intervention|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
11477426|NCT01511796|Experimental|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
11477427|NCT01511783|Experimental|E2609|E2609 at ascending doses
11477428|NCT01511783|Placebo Comparator|Placebo|
11477429|NCT01511770|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
11479307|NCT01499225|Placebo Comparator|Placebo|
11477430|NCT01511770|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
11477431|NCT01511757|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
11477432|NCT01511757|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
11477433|NCT01511744|Experimental|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
11477434|NCT01511744|No Intervention|Blank control|
11477435|NCT01511731|Experimental|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
11477436|NCT01511731|Active Comparator|Pepcid|Pepcid 40 mg Tablets of Merck & Co.,
11477437|NCT01511718|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
11477438|NCT01511718|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
11477439|NCT01511705|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
11477440|NCT01511705|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
11477441|NCT01511692|Experimental|Lira --> placebo|
11477442|NCT01511692|Placebo Comparator|Placebo --> glim|
11477443|NCT01511692|Active Comparator|Glim --> lira|
11477444|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
11477445|NCT01511679||Treatment sample|A sample of adolescents who have a >1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
11477446|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
11477447|NCT01511666|Experimental|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
11477448|NCT01511666|Active Comparator|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
11477449|NCT01511640|Experimental|Pregabalin 1|Dose 1
11477450|NCT01511640|Placebo Comparator|Placebo 1|Placebo 1
11477451|NCT01511640|Experimental|Pregabalin 2|Dose 2
11477452|NCT01511640|Placebo Comparator|Placebo 2|Placebo 2
11477453|NCT01511627|Active Comparator|General Anesthesia|
11477454|NCT01511627|Experimental|General Anesthesia + Spinal Anesthesia|
11477455|NCT01511614|Active Comparator|active tDCS|(1) anodal left-dlPFC + cathodal rightvmPFC stimulation, with anode over the left dlPFC and cathode over the right-vmPFC; (2) cathodal left-dlPFC + anodal right-vmPFC stimulation, in which polarity is reversed between the two electrodes
11477456|NCT01511614|Sham Comparator|sham tDCS|To simulate the experience of tDCS stimulation, current is ramped on and turned off at the beginning and end of the tDCS session. An additional sham option is to have the current ramp up and down only at the beginning of the sham session, and not at the end. This second sham is supported in the literature as an effective blinding technique, which subjects cannot distinguish from active stimulation. One of these sham options will be used for data that will be analyzed together, to be determined based on equipment capabilities and preliminary analysis of blinding efficacy in our cross over design. We will assess the efficacy of sham condition by providing participants and the investigator with a questionnaire on the MRI/tDCS session, wherein they will report whether they thought the tDCS session was active or sham. The MRIoperator (or other non protocol personnel) will control active/sham conditions.
11477457|NCT01511588||HH patients|Clinical patients with hypogonadotropic hypogonadism (HH)
11477458|NCT01511562|Other|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
11477459|NCT01511562|Other|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
11477460|NCT01511549|Experimental|Dose 1|SAR113945 low dose
11477461|NCT01511549|Experimental|Dose 2|SAR113945 medium dose
11477462|NCT01511549|Experimental|Dose 3|SAR113945 high dose
11477463|NCT01511549|Placebo Comparator|Placebo|Placebo
11477464|NCT01511536|Experimental|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
11477465|NCT01511536|Experimental|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
11477466|NCT01511536|Experimental|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
11477467|NCT01511523|Active Comparator|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
11477468|NCT01511523|Placebo Comparator|Sugar Pill|No treatment.
11477469|NCT01511510|Experimental|PF-04958242|
11477470|NCT01511510|Placebo Comparator|Placebo|
11477471|NCT01511497|Experimental|PF-04427429|
11477472|NCT01511497|Placebo Comparator|Placebo|Normal saline
11477682|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
11477473|NCT01511484|Experimental|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
11477474|NCT01511484|Experimental|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.
~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.
~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
11477475|NCT01511484|Experimental|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
11477476|NCT01511471|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
11477477|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
11477478|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
11477479|NCT01511445|Active Comparator|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
11477480|NCT01511445|Experimental|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
11477481|NCT01511432|Experimental|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
11477482|NCT01511432|Experimental|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
11477483|NCT01511419|Experimental|LAIV H7N3|"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.
~Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.
~Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.
~Route of administration: Intranasal aerosol.
~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28."
11477484|NCT01511419|Placebo Comparator|Placebo|"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.
~Dose: 0.5 ml; 0.25 ml/nare
~Route of administration: Intranasal aerosol
~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28"
11477485|NCT01511406|Experimental|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
11477486|NCT01511393||Questionnaire|None. Non-interventional study.
11477487|NCT01511380|Experimental|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
11477488|NCT01511380|Active Comparator|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
11477489|NCT01511367|Active Comparator|Flutiform|
11477490|NCT01511367|Active Comparator|Seretide|
11477491|NCT01511367|Active Comparator|Flixotide|
11477492|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
11477493|NCT01511341|Experimental|Telenursing|
11477494|NCT01511341|No Intervention|Standard practice|Group receive the standard practice, without telephone nursing intervention.
11477495|NCT01511328|Experimental|HPV testing|Women randomised to this arm get primary HPV testing
11477496|NCT01511328|No Intervention|cytology|women included follow the standard procedure with primary cytology
11477497|NCT01511315|Experimental|Ustekinumab|
11477498|NCT01511302|Experimental|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
11477499|NCT01511302|Experimental|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
11477500|NCT01511302|Placebo Comparator|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
11477501|NCT01511289|Active Comparator|Imatinib|Imatinib 400mg QD
11477502|NCT01511289|Experimental|Radotinib 600mg|Radotinib 300mg BID
11477503|NCT01511289|Experimental|Radotinib 800mg|Radotinib 400mg BID
11477504|NCT01511276|Experimental|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
11477505|NCT01511276|Experimental|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.
~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
11477506|NCT01511276|No Intervention|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
11477507|NCT01511263|Active Comparator|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
11477683|NCT01510041|Experimental|Inspiratory muscle training group|
11477684|NCT01510041|Experimental|Respiratory exercise group|
11477508|NCT01511263|Experimental|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
11477509|NCT01511250|Experimental|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
11477510|NCT01511250|Placebo Comparator|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
11477511|NCT01511250|Experimental|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
11477512|NCT01511250|Placebo Comparator|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
11477513|NCT01511250|Experimental|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
11477514|NCT01511250|Placebo Comparator|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
11477515|NCT01511250|Experimental|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
11477516|NCT01511250|Placebo Comparator|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
11477517|NCT01511250|Experimental|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
11477518|NCT01511250|Placebo Comparator|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
11477519|NCT01511237|Experimental|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):
~Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum
~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks
~The standard of care in Thailand is defined as:
~Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor
~Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
11477520|NCT01511224||Colistin monotherapy|
11477521|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
11477522|NCT01511224||Non-colistin containing regime|
11477523|NCT01511224||Glycopeptide with colistin combination|
11477524|NCT01511224||Colistin with loading dose|
11477525|NCT01511211|Experimental|Ropivacaine + Dexamethasone Combination|
11477526|NCT01511211|Active Comparator|Ropivacaine-Only Block|
11477527|NCT01511198|Experimental|0.045 mg|
11477528|NCT01511198|Experimental|0.225 mg|
11477529|NCT01511198|Experimental|0.45 mg|
11477530|NCT01511198|Experimental|0.60 mg|
11477531|NCT01511198|Experimental|0.75 mg|
11477532|NCT01511198|Active Comparator|Met|
11477533|NCT01511185|Experimental|NNC 90-1170|
11477534|NCT01511185|Placebo Comparator|Placebo|
11477535|NCT01511185|No Intervention|Healthy|
11477536|NCT01511172|Experimental|NNC 90-1170 + Met|
11477537|NCT01511172|Experimental|NNC 90-1170 + Met placebo|
11477538|NCT01511172|Placebo Comparator|Met + NNC 90-1170 placebo|
11477539|NCT01511172|Active Comparator|Met + Glim|
11477540|NCT01511159|Experimental|NNC 90-1170, initial dose|
11477541|NCT01511159|Experimental|NNC 90-1170|
11477542|NCT01511159|Active Comparator|Insulin|
11477543|NCT01511159|Experimental|NNC 90-1170, final dose|
11477544|NCT01511146|Experimental|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
11477545|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
11477546|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
11477547|NCT01511120|Active Comparator|Tetraspan|
11477548|NCT01511107|Active Comparator|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
11477549|NCT01511107|Other|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
11477550|NCT01511094|Experimental|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
11477551|NCT01511081|Experimental|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
11477552|NCT01511081|Experimental|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
11477553|NCT01511068|Experimental|Inhaled Leukine (rhGM-CSF)|Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
11477554|NCT01511055|Experimental|Folate-FITC|
11477555|NCT01511029|Experimental|Dexpramipexole|
11477556|NCT01511029|Placebo Comparator|Dexpramipexole (placebo)|
11477557|NCT01511029|Active Comparator|Moxifloxacin|
11477685|NCT01510028|Experimental|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
11477558|NCT01511016|Experimental|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
11477559|NCT01511016|Placebo Comparator|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
11477560|NCT01511003|Experimental|Tacrolimus group|oral
11477561|NCT01510990|Experimental|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).
~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
11477562|NCT01510977|Active Comparator|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
11477563|NCT01510977|Experimental|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
11477564|NCT01510964|Experimental|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
11477565|NCT01510964|Other|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
11477566|NCT01510951|Placebo Comparator|PLACEBO|
11477567|NCT01510951|Experimental|AMG 811|
11477568|NCT01510938|Placebo Comparator|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
11477569|NCT01510938|Experimental|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide
~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
11477570|NCT01510912|Experimental|Diclofenac Capsules 35 mg bid or tid|
11477571|NCT01510899|Experimental|Healthy Subjects Arm|
11477572|NCT01510899|Experimental|Renal Impaired Subjects Arm|
11477573|NCT01510886||1|
11477574|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
11477575|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
11477576|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
11477577|NCT01510860|Active Comparator|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
11477578|NCT01510860|Experimental|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
11477579|NCT01510847|Other|Oral Testosterone Therapy|90 day oral testosterone therapy
11477580|NCT01510834|Experimental|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
11477581|NCT01510821|Experimental|Maquet Vasoshield Arm|Pressure limiting syringe
11477582|NCT01510821|Active Comparator|Non-regulated Arm|standard non-regulated syringe
11477583|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
11477584|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
11477585|NCT01510795|No Intervention|retrospective control|
11477586|NCT01510795|Active Comparator|spironolactone|
11477587|NCT01510782|Experimental|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
11477588|NCT01510782|Placebo Comparator|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
11477589|NCT01510782|Experimental|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
11477590|NCT01510782|Placebo Comparator|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
11477591|NCT01510769|Experimental|lesinurad 400 mg + febuxostat 80 mg|
11477592|NCT01510769|Experimental|lesinurad 200 mg + febuxostat 80 mg|
11477593|NCT01510769|Placebo Comparator|placebo + febuxostat 80 mg|
11477594|NCT01510756|Experimental|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
11477595|NCT01510743|Active Comparator|Group SC|US guided subclavian vein catheterization
11477596|NCT01510743|Active Comparator|Group IJ|US-guided internal jugular vein catheterization
11477597|NCT01510730|No Intervention|control group|no treatment for Helicobacter pylori infection
11477598|NCT01510730|Active Comparator|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
11477599|NCT01510717|Experimental|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
11477600|NCT01510717|Active Comparator|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
11477601|NCT01510704|Placebo Comparator|Placebo|
11477602|NCT01510704|Experimental|Low dose APD421|1mg dose level
11477603|NCT01510704|Experimental|Mid Dose APD421|5mg dose level
11477604|NCT01510704|Experimental|High Dose APD421|20mg dose level
11477605|NCT01510691||Epiretinal membrane|
11477606|NCT01510691||diabetic macular edema|
11477607|NCT01510691||vein occlusion|
11477651|NCT01510353|Experimental|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
11477608|NCT01510678|Experimental|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
11477609|NCT01510678|Experimental|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
11477610|NCT01510678|Experimental|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
11477611|NCT01510665|Experimental|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
11477612|NCT01510665|Placebo Comparator|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
11477613|NCT01510665|Active Comparator|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
11477614|NCT01510652|Active Comparator|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
11477615|NCT01510652|Active Comparator|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
11477616|NCT01510639|Experimental|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
11477617|NCT01510639|No Intervention|Cuff repair Control|No intervention
11477618|NCT01510639|Experimental|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
11477619|NCT01510639|No Intervention|NEER Control|No intervention
11477620|NCT01510626|Experimental|One|
11477621|NCT01510613|Experimental|Pomalidomide and Dexamethasone|
11477622|NCT01510587|Experimental|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
11477623|NCT01510587|Active Comparator|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
11477624|NCT01510574|Active Comparator|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
11477625|NCT01510574|Placebo Comparator|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
11477626|NCT01510561|Experimental|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
11477627|NCT01510561|Experimental|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
11477628|NCT01510548|Active Comparator|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
11477629|NCT01510548|Active Comparator|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
11477630|NCT01510548|Placebo Comparator|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
11477631|NCT01510535|Experimental|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
11477632|NCT01510535|Active Comparator|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
11477633|NCT01510522|Experimental|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
11477634|NCT01510522|Active Comparator|Glucophage tablets|Patients received Glucophage tablets.
11477635|NCT01510509|Experimental|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
11477636|NCT01510509|Experimental|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
11477637|NCT01510496||Patients who had inguinal herniorraphy.|
11477638|NCT01510496||Patients who had hysterectomy.|
11477639|NCT01510496||Patients who had thoracotomy.|
11477640|NCT01510483|Experimental|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
11477641|NCT01510483|Active Comparator|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
11477642|NCT01510457|Placebo Comparator|Sugar Pill|BID placebo
11477643|NCT01510457|Experimental|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
11477644|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
11477645|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
11477646|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
11477647|NCT01510379|Active Comparator|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
11477648|NCT01510379|Other|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
11477649|NCT01510366|Experimental|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
11477650|NCT01510366|Experimental|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
11479308|NCT01499212|Experimental|I:E ratio 1:1|
11477652|NCT01510353|No Intervention|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
11477653|NCT01510340|No Intervention|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
11477654|NCT01510340|Experimental|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
11477655|NCT01510327|Experimental|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
11477656|NCT01510301|Other|Self-report|
11477657|NCT01510288|Experimental|Ipilimumab and GVAX|
11477658|NCT01510275|Experimental|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
11477659|NCT01510275|Sham Comparator|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
11477660|NCT01510262|Experimental|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.
~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).
~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:
~A. The STI strengths-based prevention case management, or B. Standard care.
~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.
~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.
~Conduct cost effectiveness analyses of intervention compared to the standard."
11477661|NCT01510262|Active Comparator|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
11477662|NCT01510236|Experimental|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
11477663|NCT01510236|Experimental|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
11477664|NCT01510223|Experimental|Dietary supplementation macademia oil|emia oil
11477665|NCT01510223|Experimental|Dietary supplementation olive oil|Olive oil
11477666|NCT01510223|Experimental|Dietary Supplementation fish oil|fish oil
11477667|NCT01510184|Active Comparator|Zevalin (ibritumomab tiuxetan)|Day 1: Rituximab 250 mg/m2 intravenous infusion Days 7-9:Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg. In centers where biodistribution imaging is performed Day 1: Rituximab 250 mg/m2 intravenous infusion followed by In-111-Zevalin 185 MBq (5mCi), Days 3-4: Biodistribution imaging Days 7-9: Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg
11477668|NCT01510184|No Intervention|Observation Arm|Patients randomized to the observation (control) arm will not receive any further anti-lymphoma therapy unless they have a relapse of their disease.
11477669|NCT01510171|Active Comparator|Prasugrel loading dose|
11477670|NCT01510171|Active Comparator|Ticagrelor Loading dose|
11477671|NCT01510158|Experimental|lesinurad 200 mg + allopurinol|
11477672|NCT01510158|Experimental|lesinurad 400 mg + allopurinol|
11477673|NCT01510158|Placebo Comparator|Placebo + allopurinol|
11477674|NCT01510145|Experimental|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
11477675|NCT01510132|Experimental|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
11477676|NCT01510119|Experimental|Intervention - Dose Level 1|RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
11477677|NCT01510119|Experimental|Intervention - Dose Level 2 Phase 2|RAD001 given 10mg/daily by mouth and 600mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
11477678|NCT01510093|Other|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
11477679|NCT01510093|Other|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
11477680|NCT01510080|Experimental|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
11477681|NCT01510080|Experimental|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
11477686|NCT01510028|Experimental|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
11477687|NCT01510028|Experimental|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
11477688|NCT01510028|Experimental|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
11477689|NCT01510015|Active Comparator|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
11477690|NCT01510015|Active Comparator|Counseling|Participants will receive individual and group therapy
11477691|NCT01510002|Active Comparator|TT|Extracapsular total thyroidectomy
11477692|NCT01510002|Experimental|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
11477693|NCT01509976|Other|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
11477694|NCT01509976|Other|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
11477695|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
11477696|NCT01509950|Active Comparator|Staples|Use of staples for skin closure at cesarean section
11477697|NCT01509950|Active Comparator|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
11477698|NCT01509950|Active Comparator|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
11477699|NCT01509937|Experimental|BCM Arm|BCM measured every 2 months
11477700|NCT01509937|Sham Comparator|Control arm|patients care according to standard of care
11477701|NCT01509924|Experimental|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
11477702|NCT01509924|No Intervention|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
11477703|NCT01509924|No Intervention|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.
~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
11477704|NCT01509924|No Intervention|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
11477705|NCT01509911|Experimental|TL-118 with standard of care Gemcitabine|
11477706|NCT01509911|Active Comparator|Gemcitabine with out TL-118|
11477707|NCT01509898|Experimental|water-Jet|use of water jet for 1 month
11477708|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
11477709|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
11477710|NCT01509872|Experimental|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
11477711|NCT01509872|Active Comparator|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
11477712|NCT01509859|Active Comparator|PFNA|"these patients will be treated with synthes PFNA device"
11477713|NCT01509859|Active Comparator|INTERTAN|"these patients will be treated with Smith&Nephew INTERTAN device"
11477714|NCT01509846|Experimental|Cohort 4|Three oral doses of 2.6±0.8 x 10^11 vp/mL (20 participants) or placebo (5 participants).
11477715|NCT01509846|Experimental|Cohort 3|Three oral doses of 2.6±0.8 x 10^10 vp/mL (20 participants) or placebo (5 participants).
11477716|NCT01509846|Experimental|Cohort 2|Three oral doses of 2.6±0.8 x 10^9 vp/mL (20 participants) or placebo (5 participants).
11477717|NCT01509846|Experimental|Cohort 1|One oral dose of 2.6±0.8 x 10^8 vp/mL (5 participants) or placebo (2 participants).
11477718|NCT01509833|Experimental|rFSH|Administration of recombinant FSH for ovarian stimulation.
11477719|NCT01509833|Experimental|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
11477720|NCT01509833|Experimental|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
11477721|NCT01509807|Active Comparator|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
11477722|NCT01509807|Experimental|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
11477723|NCT01509794|Active Comparator|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
11477724|NCT01509794|Experimental|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
11477725|NCT01509781|Active Comparator|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
11477726|NCT01509781|Experimental|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
11477727|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
11477728|NCT01509755|Placebo Comparator|Placebo|
11477729|NCT01509755|Experimental|0.045 mg|
11477730|NCT01509755|Experimental|0.225 mg|
11477731|NCT01509755|Experimental|0.45 mg|
11477732|NCT01509755|Experimental|0.60 mg|
11477733|NCT01509755|Experimental|0.75 mg|
11477734|NCT01509755|Active Comparator|Glim|
11477735|NCT01509742|Experimental|NNC 90-1170|
11477736|NCT01509742|Placebo Comparator|Placebo|
11477737|NCT01509729|Placebo Comparator|Sham operation|
11477738|NCT01509729|Active Comparator|Knee arthroscopic surgery|
11477739|NCT01509703|Experimental|High flow therapy|
11477740|NCT01509677|Active Comparator|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
11477741|NCT01509677|Placebo Comparator|Placebo|tablet, once daily, oral administration in the morning after breakfast
11477742|NCT01509664|Experimental|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
11477743|NCT01509664|No Intervention|Control|Received no discount at the participating supermarket.
11477744|NCT01509651|Experimental|Sugammadex|
11477745|NCT01509638|Active Comparator|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
11477746|NCT01509638|Active Comparator|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
11477747|NCT01509612|Active Comparator|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
11477748|NCT01509612|Placebo Comparator|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
11477749|NCT01509612|No Intervention|No intervention|No intervention
11477750|NCT01509599|Experimental|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
11477751|NCT01509599|Sham Comparator|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
11477752|NCT01509586|Experimental|PREP (Potentially Reduced Exposure Product) Group|
11477753|NCT01509586|No Intervention|cigarette group|
11477754|NCT01509573|Experimental|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
11477755|NCT01509573|No Intervention|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
11477756|NCT01509560|Experimental|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
11477757|NCT01509547|Experimental|varenicline|Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
11477758|NCT01509547|Placebo Comparator|placebo|Participants >55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
11477759|NCT01509521|Active Comparator|Ephedrine|
11477760|NCT01509521|Active Comparator|Phenylephrine|
11477761|NCT01509508|Experimental|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
11477762|NCT01509508|Other|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
11477763|NCT01509482|Experimental|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
11477764|NCT01509482|Active Comparator|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
11477765|NCT01509469|Experimental|Low dose casein|Ileal infusion of low dose casein
11477766|NCT01509469|Experimental|High dose casein|Ileal infusion of high dose casein
11477767|NCT01509469|Experimental|Low dose sucrose|Ileal infusion of low dose sucrose
11477768|NCT01509469|Experimental|High dose sucrose|Ileal infusion of high dose sucrose
11477769|NCT01509469|Placebo Comparator|Placebo|Ileal infusion saline
11477770|NCT01509469|Active Comparator|Safflower oil|Ileal infusion safflower oil
11477771|NCT01509456|Active Comparator|Potassium Bicarbonate|
11477772|NCT01509456|No Intervention|Control|
11477773|NCT01509443|Experimental|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
11477774|NCT01509443|No Intervention|Control Arm|The control arm will receive standard medical care for asthma
11477775|NCT01509430|Experimental|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
11477776|NCT01509430|Experimental|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
11477777|NCT01509417|Experimental|Ad lib feeding|ad lib feedings following pyloromyotomy
11477778|NCT01509417|Active Comparator|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
11477779|NCT01509404|Active Comparator|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
11478153|NCT01506908|Placebo Comparator|placebo|mint mini lozenge with no active
11477780|NCT01509404|Active Comparator|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
11477781|NCT01509391|Experimental|Keyhole-limpet hemocyanine|
11477782|NCT01509365|No Intervention|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
11477783|NCT01509365|Active Comparator|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
11477784|NCT01509365|Experimental|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
11477785|NCT01509352|Active Comparator|with esophageal stitches|fundoplication with crural stitches
11477786|NCT01509352|Experimental|without esophageal stitches|fundoplication without crural stitches.
11477787|NCT01509339|Experimental|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
11477788|NCT01509326|Active Comparator|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
11477789|NCT01509326|Experimental|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
11477790|NCT01509313|Experimental|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
11477791|NCT01509313|Active Comparator|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
11477792|NCT01509300|Experimental|HAPLO|
11477793|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
11477794|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
11477795|NCT01509274|Experimental|Plasma|
11477796|NCT01509274|Sham Comparator|Saline|
11477797|NCT01509274|Active Comparator|Physiotherapy + heel cap|
11477798|NCT01509261|Experimental|Ilaprazole|Ilaprazole 20mg
11477799|NCT01509261|Active Comparator|lansoprazole|lansoprazole 30mg
11477800|NCT01509235|Experimental|1. Exercise testing and self drainage session|
11477801|NCT01509235|Active Comparator|2. Chest physiotherapy (CP) session|
11477802|NCT01509222|Other|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
11477803|NCT01509222|No Intervention|Control|No intervention, control group.
11477804|NCT01509209|Placebo Comparator|Placebo|placebo
11477805|NCT01509209|Experimental|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
11477806|NCT01509196|Experimental|HIP0901|Fenofibric acid
11477807|NCT01509196|Active Comparator|Lipidilsupra|Fenofibrate
11477808|NCT01509183|Active Comparator|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
11477809|NCT01509183|No Intervention|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
11477810|NCT01509157|Experimental|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
11477811|NCT01509157|Active Comparator|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
11477812|NCT01509144|Active Comparator|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
11477813|NCT01509144|Active Comparator|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
11477814|NCT01509144|Active Comparator|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
11477815|NCT01509144|Active Comparator|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
11477816|NCT01509144|Placebo Comparator|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
11477817|NCT01509131|Experimental|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
11477818|NCT01509131|Active Comparator|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
11477819|NCT01509105||Group1|
11477820|NCT01509092|No Intervention|obervation|patients in this arm received 6-months observation alone after injury
11477821|NCT01509092|Active Comparator|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
11477822|NCT01509079|Experimental|Vitamin D3 4000 IU|
11477823|NCT01509079|Active Comparator|Vitamin D3 600 IU|
11477824|NCT01509066|Experimental|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
11477825|NCT01509066|Active Comparator|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
11477867|NCT01508845|Active Comparator|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
11478154|NCT01506895|Experimental|darapladib|darapladib dosed at 160 mg once daily
11477826|NCT01509053|Experimental|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
11477827|NCT01509040|Active Comparator|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
11477828|NCT01509040|Experimental|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
11477829|NCT01509040|Experimental|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
11477830|NCT01509027|Active Comparator|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
11477831|NCT01509027|Active Comparator|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
11477832|NCT01509027|Placebo Comparator|Standard Care|standard care
11477833|NCT01509014|Experimental|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
11477834|NCT01509014|No Intervention|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
11477835|NCT01509001|Active Comparator|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
11477836|NCT01509001|Active Comparator|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
11477837|NCT01508988|Experimental|Eye drops 0.3 µg/mL|
11477838|NCT01508988|Experimental|Eye drops 1 µg/mL|
11477839|NCT01508988|Experimental|Eye drops 3 µg/mL|
11477840|NCT01508988|Experimental|Eye drops 10 µg/mL|
11477841|NCT01508988|Experimental|Eye drops 20 µg/mL|
11477842|NCT01508988|Experimental|Eye drops 30 µg/mL|
11477843|NCT01508988|Experimental|Eye drops placebo|
11477844|NCT01508975|Experimental|white rice|White rice
11477845|NCT01508975|Experimental|Brown rice|Brown Rice
11477846|NCT01508975|Experimental|Glucose|Glucose
11477847|NCT01508962||Healthy individuals (controls)|
11477848|NCT01508962||Individuals affected with ALS (sporadic or familial)|
11477849|NCT01508949|Experimental|NNC 90-1170|
11477850|NCT01508949|Placebo Comparator|Placebo|
11477851|NCT01508936|Placebo Comparator|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
11477852|NCT01508936|Experimental|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
11477853|NCT01508923|Experimental|Treatment period 1|
11477854|NCT01508923|Placebo Comparator|Treatment period 2|
11477855|NCT01508910|Experimental|Treatment Arm|Targeted intramyocardial delivery of 1 x 10^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
11477856|NCT01508910|Placebo Comparator|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
11477857|NCT01508910|Other|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
11477858|NCT01508897|Experimental|Phase 2 formulation|
11477859|NCT01508897|Experimental|Phase 3 formulation|
11477860|NCT01508884|Active Comparator|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
11477861|NCT01508884|Active Comparator|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
11477862|NCT01508884|Experimental|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
11477863|NCT01508871||Cardiomyopathy|
11477864|NCT01508858|Experimental|Treatment period 1|
11477865|NCT01508858|Placebo Comparator|Treatment period 2|
11477866|NCT01508845|Active Comparator|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
11478032|NCT01507662|Experimental|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
11477868|NCT01508845|Active Comparator|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
11477869|NCT01508845|Active Comparator|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
11477870|NCT01508832|Active Comparator|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
11477871|NCT01508832|Active Comparator|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
11477872|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
11477873|NCT01508819||2|no intervention
11477874|NCT01508806|Experimental|Normal renal function|
11477875|NCT01508806|Experimental|Mild renal impairment|
11477876|NCT01508806|Experimental|Moderate renal impairment|
11477877|NCT01508806|Experimental|Severe renal impairment|
11477878|NCT01508806|Experimental|End-stage renal disease|
11477879|NCT01508793|No Intervention|Control|
11477880|NCT01508793|Experimental|Optimize Sleep|
11477881|NCT01508780|Experimental|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
11477882|NCT01508767|Experimental|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
11477883|NCT01508767|Other|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
11477884|NCT01508754|Active Comparator|CPAP|Treatment with Continuous Positive Airway Pressure
11477885|NCT01508754|No Intervention|Control|Usual anti-hypertensive treatment without CPAP treatment
11477886|NCT01508741|Active Comparator|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
11477887|NCT01508741|Placebo Comparator|Placebo capsule|Non-active component capsules
11477888|NCT01508728|Experimental|Active vibration|
11477889|NCT01508728|Placebo Comparator|Placebo Vibration|
11477890|NCT01508715|Active Comparator|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
11477891|NCT01508715|Experimental|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
11477892|NCT01508702|Experimental|lesinurad 400 mg|
11477893|NCT01508702|Placebo Comparator|placebo|
11477894|NCT01508689|Other|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
11477895|NCT01508689|Other|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
11477896|NCT01508676|Active Comparator|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
11477897|NCT01508676|Placebo Comparator|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
11477898|NCT01508663|Experimental|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
11477899|NCT01508663|Active Comparator|OMT alone group|OMT alone after randomization and follow up for 12 months
11477900|NCT01508650|Active Comparator|No intervention|Usual care control group
11477901|NCT01508650|Active Comparator|Active Comparator|Multi domain rehabilitation intervention
11477902|NCT01508637|Experimental|Diesel Exhaust + Terazosin|
11477903|NCT01508637|Experimental|Diesel Exhaust + placebo|
11477904|NCT01508637|Sham Comparator|Filtered Air + terazosin|
11477905|NCT01508637|Sham Comparator|Filtered air + placebo|
11477906|NCT01508624|No Intervention|Control|participants will receive standard usual care
11477907|NCT01508624|Experimental|Interaction|Participants will interact with nurses during their procedure
11477908|NCT01508624|Experimental|Music|Participants will listen to music using head phones during their procedure.
11477909|NCT01508624|Experimental|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
11477910|NCT01508624|Experimental|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
11477911|NCT01508611|Active Comparator|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
11477912|NCT01508611|Active Comparator|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
11477913|NCT01508585|Active Comparator|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
11477914|NCT01508585|Active Comparator|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
11477915|NCT01508572|Experimental|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
11477916|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
11477917|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
11477918|NCT01508546|Experimental|Arm 1: breast surgery with axillary lymphnodes removal|
11477919|NCT01508546|Experimental|Arm 2: breast surgery without axillary lymphnodes removal|
11477920|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
11477921|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
11477922|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
11477923|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
11477924|NCT01508494|Active Comparator|Galantamine|16mg galantamine progressively
11477925|NCT01508494|Placebo Comparator|placebo|placebo
11477926|NCT01508481||Diabetes high risk group|
11477927|NCT01508468|Active Comparator|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
11477928|NCT01508468|Experimental|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
11477929|NCT01508455|Experimental|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
11477930|NCT01508429|Active Comparator|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
11477931|NCT01508429|Placebo Comparator|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
11477932|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
11477933|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
11477934|NCT01508390|Experimental|Boost|CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day
11477935|NCT01508377|Experimental|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.
~First phase: self-confrontation (4 essays)
~Second phase: cognitive restructuring (4 essays)
~Third phase: parting (2 essays)"
11477936|NCT01508377|Experimental|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.
~First phase: self-confrontation (4 essays)
~Second phase: parting (2 essays)"
11477937|NCT01508364||Group 1|
11477938|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
11477939|NCT01508338|Placebo Comparator|Placebo|
11477940|NCT01508338|Experimental|HMB|
11477941|NCT01508338|Experimental|ATP and HMB|
11477942|NCT01508338|Experimental|ATP|
11477943|NCT01508325|Experimental|Bisoprolol|
11477944|NCT01508325|Active Comparator|Metoprolol|
11477945|NCT01508312|Experimental|FDG-PET abnormal|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
11477946|NCT01508312|Experimental|FDG-PET normalization|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
11477947|NCT01508299|Experimental|raw food skin test|skin test with the suspected raw food
11477948|NCT01508273|Experimental|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
11477949|NCT01508273|Other|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
11477950|NCT01508273|Experimental|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
11477951|NCT01508260|Experimental|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
11477952|NCT01508260|Experimental|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
11477953|NCT01508260|Active Comparator|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
11477954|NCT01508247|Experimental|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
11477955|NCT01508247|Placebo Comparator|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
11478033|NCT01507662|No Intervention|Control|Those who received usual care
11477956|NCT01508221|Experimental|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
11477957|NCT01508208|Other|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
11477958|NCT01508195|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
11477959|NCT01508195|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
11477960|NCT01508182|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
11477961|NCT01508182|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
11477962|NCT01508169|Experimental|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
11477963|NCT01508169|No Intervention|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
11477964|NCT01508156|Experimental|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
11477965|NCT01508156|Experimental|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
11477966|NCT01508143|Experimental|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
11477967|NCT01508143|Active Comparator|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
11477968|NCT01508130||Cohort|
11477969|NCT01508117|Experimental|Axitinib + Radiation Therapy|Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity
11477970|NCT01508104|Experimental|BEZ235 and Everolimus|
11477971|NCT01508091|Experimental|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
11477972|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
11477973|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
11477974|NCT01508065||controlled type one diabetes mellitus.|
11477975|NCT01508052|Active Comparator|sequential compression device|Apply sequential compression device during the thyroidectomy
11477976|NCT01508052|Experimental|elastic stockings|Apply elastic stockings during the thyroidectomy
11477977|NCT01508039|Experimental|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
11477978|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
11477979|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
11477980|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
11477981|NCT01508026|Experimental|Nebivolol Low Dose|Nebivolol Monotherapy 5 mg
11477982|NCT01508026|Experimental|Nebivolol High Dose|Nebivolol Monotherapy 20 mg
11477983|NCT01508026|Experimental|Valsartan Low Dose|Valsartan Monotherapy 80 mg
11477984|NCT01508026|Experimental|Valsartan High Dose|Valsartan Monotherapy 160 mg
11477985|NCT01508026|Placebo Comparator|Placebo|Dose Matched placebo
11477986|NCT01508013|Experimental|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
11477987|NCT01508013|Active Comparator|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
11477988|NCT01508000|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:
~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion
~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion
~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes
~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
~On day 1 of a 14 day cycle"
11477989|NCT01508000|Experimental|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:
~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion
~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion
~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.
~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes
~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
~On day 1 of a 14 day cycle"
11478034|NCT01507649|No Intervention|Control|
11478035|NCT01507649|Experimental|Telephone-based intervention|
11478036|NCT01507636|Active Comparator|Group 1|Occupational therapy using a special arm function training.
11477990|NCT01508000|Experimental|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery
~6 cycles before and 6 cycles after surgery consisting in:
~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) +/- 15 min. infusion*.
~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion
~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion
~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes
~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.
~On day 1 of a 14 day cycle"
11477991|NCT01507974|No Intervention|control arm|The women in this arm will not receive preventive antibiotic treatment after delivery
11477992|NCT01507974|Active Comparator|preventive antibiotic treatment|The women in this arm will receive preventive antibiotic treatment after the delivery to 6 weeks
11477993|NCT01507948|Experimental|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
11477994|NCT01507948|No Intervention|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
11477995|NCT01507935|Active Comparator|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
11477996|NCT01507935|Active Comparator|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
11477997|NCT01507935|Placebo Comparator|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
11477998|NCT01507935|No Intervention|Reference group|Exclusively breast-fed infants
11477999|NCT01507922|Experimental|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
11478000|NCT01507922|Active Comparator|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
11478001|NCT01507896|Experimental|BAX326 in Surgery|BAX 326 (recombinant factor IX) in Surgery
11478002|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
11478003|NCT01507870|Active Comparator|prophylactic onlay mesh|
11478004|NCT01507870|No Intervention|continuous running suture|continuous running suture of the linea alba
11478005|NCT01507857|Experimental|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
11478006|NCT01507857|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
11478007|NCT01507844|Sham Comparator|ventilation|
11478008|NCT01507831|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
11478009|NCT01507831|Experimental|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
11478010|NCT01507818|Active Comparator|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
11478011|NCT01507818|Sham Comparator|Inactive Sham|Sham treatment
11478012|NCT01507805|Experimental|EA preconditioning|electroacupuncture five days pre-operation
11478013|NCT01507805|Sham Comparator|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
11478014|NCT01507779|Experimental|Influenza vaccine|Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
11478015|NCT01507779|Placebo Comparator|Placebo|Received placebo, administered intramuscularly, on days 0 and 21
11478016|NCT01507766|Experimental|Early enteral nutrition|The enteral nutrition was started within 48h after admission
11478017|NCT01507766|Active Comparator|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
11478018|NCT01507753|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
11478019|NCT01507753|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
11478020|NCT01507753|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
11478021|NCT01507753|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
11478022|NCT01507740||1|Control group n=20
11478023|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
11478024|NCT01507727|Experimental|Drug: Tolvaptan|
11478025|NCT01507727|Placebo Comparator|Drug: Placebo|
11478026|NCT01507714|No Intervention|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
11478027|NCT01507714|Active Comparator|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
11478028|NCT01507701|Experimental|Clonidine|
11478029|NCT01507688|Experimental|Arm 1 SSM Intervention|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
11478030|NCT01507688|No Intervention|Arm 2 Usual Care|Usual care
11478031|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
11478037|NCT01507636|Active Comparator|Group 2|Physical therapy using the Theraband for training of force.
11478038|NCT01507623|Experimental|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
11478039|NCT01507623|No Intervention|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
11478040|NCT01507610|Experimental|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
11478041|NCT01507610|Active Comparator|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
11478042|NCT01507610|Active Comparator|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
11478043|NCT01507610|Active Comparator|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
11478044|NCT01507597|Other|Healthy Subjects|
11478045|NCT01507597|Other|T2DM|
11478046|NCT01507597|Other|T1DM|
11478047|NCT01507584|Active Comparator|Prostaglandin Analogue|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (PGA + BB)
11478048|NCT01507584|Active Comparator|Carbonic Anhydrase Inhibitor|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (CAI+ BB)
11478049|NCT01507571|Experimental|Dignity Therapy|
11478050|NCT01507558|Experimental|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
11478051|NCT01507545|Active Comparator|MORAb-004|
11478052|NCT01507545|Placebo Comparator|Placebo|
11478053|NCT01507532|Other|Ceftazidime|pharmacokinetic monitoring
11478054|NCT01507519|Experimental|BioMime™|BioMime™ DES
11478055|NCT01507506|Active Comparator|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
11478056|NCT01507506|Experimental|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
11478057|NCT01507493||mutant alleles|grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
11478058|NCT01507493||wild-type alleles|grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
11478059|NCT01507480|Experimental|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
11478060|NCT01507467|Active Comparator|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
11478061|NCT01507467|Experimental|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
11478062|NCT01507454||Local treatment|
11478063|NCT01507428|Active Comparator|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
11478064|NCT01507428|Experimental|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
11478065|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
11478066|NCT01507402|Experimental|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
11478067|NCT01507402|Experimental|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
11478068|NCT01507402|Experimental|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
11478069|NCT01507402|Experimental|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
11478070|NCT01507402|Experimental|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
11478071|NCT01507402|Experimental|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
11478072|NCT01507402|Experimental|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
11478073|NCT01507402|Experimental|Cohort 8|Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
11478074|NCT01507402|Experimental|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
11478075|NCT01507389|Experimental|Mild|
11478076|NCT01507389|Experimental|Moderate|
11478077|NCT01507389|Experimental|Severe|
11478078|NCT01507389|Experimental|Normal|
11478079|NCT01507376|Experimental|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
11478080|NCT01507376|Experimental|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
11478081|NCT01507376|Experimental|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
11478082|NCT01507363|Active Comparator|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
11478083|NCT01507363|Active Comparator|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
11478084|NCT01507363|Placebo Comparator|Placebo|Placebo tablets for 7 days, starting on the day of surgery
11478085|NCT01507350||Obesity Surgery|Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
11478086|NCT01507337|Experimental|Elderly|
11478087|NCT01507337|Experimental|Young|
11478088|NCT01507311|Experimental|NNC 90-1170|
11478089|NCT01507311|Placebo Comparator|Placebo|
11478090|NCT01507298||Capsule endoscopy|
11478091|NCT01507298||24 hour oesophageal pH study|
11478092|NCT01507285|Experimental|NNC 90-1170|
11478093|NCT01507285|Placebo Comparator|Placebo|
11478094|NCT01507272|Experimental|NNC 90-1170 (liraglutide)|
11478095|NCT01507272|Placebo Comparator|Placebo|
11478097|NCT01507246|Active Comparator|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
11478098|NCT01507246|Experimental|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
11478099|NCT01507233|Active Comparator|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
11478100|NCT01507233|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
11478101|NCT01507220|Active Comparator|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
11478102|NCT01507220|Experimental|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
11478103|NCT01507194|Active Comparator|Ondansetron 4 mg|
11478104|NCT01507194|Experimental|Vestipitant 6 mg|
11478105|NCT01507194|Experimental|Vestipitant 12 mg|
11478106|NCT01507194|Experimental|Vestipitant 18 mg|
11478107|NCT01507194|Experimental|Vestipitant 24 mg|
11478108|NCT01507194|Experimental|Vestipitant 36 mg|
11478109|NCT01507181|Experimental|Ketamine|single dose IV ketamine, .5mg/kg
11478110|NCT01507181|Placebo Comparator|Midazolam|single dose IV midazolam, .45mg/kg
11478111|NCT01507168|Placebo Comparator|Placebo|
11478112|NCT01507168|Experimental|GC33 (RO5137382)|
11478113|NCT01507155|Experimental|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
11478114|NCT01507155|Experimental|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
11478115|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, <200 CD4 Tcells/mm3 and Viral Load >5000 copies/ml
11478116|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, >350 CD4 Tcells/mm3 and Viral Load<50 copies/ml
11478117|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
11478118|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
11478119|NCT01507116||People with Diabetes|
11478120|NCT01507116||Family Members|
11478121|NCT01507116||Healthcare Professionals|
11478122|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)+CPA|
11478123|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)|
11478124|NCT01507103|Active Comparator|Chemoradiotherapy|
11478125|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
11478126|NCT01507077|Placebo Comparator|ZGN-440 sterile diluent|
11478127|NCT01507077|Experimental|ZGN-440|
11478128|NCT01507064|Active Comparator|Group A|Patients who undergo to LA without sorafenib pretreatment
11478129|NCT01507064|Experimental|Group B|Patients who are treated with sorafenib before LA
11478130|NCT01507051|Experimental|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
11478131|NCT01507051|Placebo Comparator|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
11478132|NCT01507051|Active Comparator|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
11478133|NCT01507038|Experimental|Group A|
11478134|NCT01507038|Experimental|Group B|
11478135|NCT01507038|Experimental|Group C|
11478136|NCT01507038|Placebo Comparator|Group D|
11478137|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
11478138|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
11478139|NCT01507012|Experimental|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
11478140|NCT01507012|Placebo Comparator|Placebo|
11478141|NCT01507012|Experimental|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
11478142|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
11478143|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
11478144|NCT01506999||control group|subjects without ischemic heart disease (IHD)
11478145|NCT01506986|Active Comparator|H. pylori eradication treatment|Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
11478146|NCT01506986|Placebo Comparator|Placebo H. pylori eradication treatment|Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
11478147|NCT01506960|Experimental|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
11478148|NCT01506947|Experimental|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.
~Participants may have also received routine darbepoetin alfa to treat anemia."
11478149|NCT01506934|Experimental|linifanib|Single Doses
11478150|NCT01506921|Active Comparator|Racemic ketamine|
11478151|NCT01506921|Active Comparator|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
11478152|NCT01506908|Active Comparator|Nicotine Polacrilex mint mini lozenge|
11478156|NCT01506882|Experimental|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.
~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
11478157|NCT01506882|Experimental|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.
~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.
~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
11478158|NCT01506869||Type 2 diabetes|
11478159|NCT01506869||Prediabetes|
11478160|NCT01506869||Normal glucose regulation|
11478161|NCT01506856|Active Comparator|Standard treatment: dd-TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
11478162|NCT01506856|Experimental|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
11478163|NCT01506843|Active Comparator|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
11478164|NCT01506843|Active Comparator|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
11478165|NCT01506843|Placebo Comparator|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
11478166|NCT01506830|Active Comparator|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
11478167|NCT01506830|Experimental|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
11478168|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
11478169|NCT01506817||Controls|healthy aged matched pain-free controls
11478170|NCT01506804|Experimental|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
11478171|NCT01506804|Placebo Comparator|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
11478172|NCT01506791|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
11478173|NCT01506791|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
11478174|NCT01506778|Active Comparator|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
11478175|NCT01506778|No Intervention|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
11478176|NCT01506765|Active Comparator|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
11478177|NCT01506765|Placebo Comparator|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
11478178|NCT01506752|Active Comparator|E2020 improved 10 mg without water|
11478179|NCT01506752|Active Comparator|E2020 current 10 mg without water|
11478180|NCT01506752|Active Comparator|E2020 improved 10 mg with water|
11478181|NCT01506752|Active Comparator|E2020 current 10 mg with water|
11478182|NCT01506739|Active Comparator|1|
11478183|NCT01506739|Active Comparator|2|
11478184|NCT01506739|Active Comparator|3|
11478185|NCT01506726|Experimental|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
11478186|NCT01506726|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
11478187|NCT01506713|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
11478188|NCT01506713|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
11478189|NCT01506687|Experimental|Navigator intervention|
11478190|NCT01506687|Active Comparator|Usual Care Control|Usual care
11478191|NCT01506674||criticall ill patients|
11478192|NCT01506661|Experimental|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
11478193|NCT01506661|Active Comparator|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
11478194|NCT01506635|Placebo Comparator|Control group|included patients who received artificial tear twice a day as control group.
11478195|NCT01506635|Experimental|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
11478196|NCT01506622|Active Comparator|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
11478197|NCT01506622|Active Comparator|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
11478198|NCT01506622|Active Comparator|Control group|intravenous administration of saline at the end of anesthesia
11478199|NCT01506609|Experimental|Veliparib with Temozolomide|Veliparib on Day 1 thru 7 and temozolomide on Day 1 thru 5 of a 28-day cycle.
11478200|NCT01506609|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Veliparib Placebo on Day 1 thru 7 and carboplatin/paclitaxel on Day 3 of a 21-day cycle.
11478201|NCT01506609|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib on Day 1 thru 7 and carboplatin/paclitaxel on Day 3 of a 21-day cycle.
11478202|NCT01506596|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
11478203|NCT01506583||General population|This group of participants is primarily an out-patient population.
11478204|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
11478205|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
11478206|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
11478207|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
11478208|NCT01506570|Placebo Comparator|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
11478209|NCT01506557|Experimental|choecalciferol|
11478210|NCT01506557|Placebo Comparator|placebo|
11478211|NCT01506544|Experimental|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
11478212|NCT01506544|Active Comparator|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
11478213|NCT01506531|Active Comparator|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
11478214|NCT01506531|Active Comparator|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
11478215|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
11478216|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
11478217|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
11478218|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
11478219|NCT01506505|Experimental|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
11478220|NCT01506505|Experimental|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
11478221|NCT01506505|Active Comparator|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.
~Simvastatin 40 mg used 18.00-00.00 in the evening."
11478222|NCT01506492|No Intervention|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
11478223|NCT01506492|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
11478224|NCT01506479|Sham Comparator|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
11478225|NCT01506479|Experimental|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
11478226|NCT01506479|Experimental|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
11478227|NCT01506466|Other|additional examinations/measurements|
11478228|NCT01506453|Active Comparator|Gabapentin|Active treatment arm.
11478229|NCT01506453|Placebo Comparator|Placebo|Placebo arm.
11478230|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
11478231|NCT01506427|Experimental|[F-18] HX4|
11478232|NCT01506414|Experimental|combination treatment|
11478233|NCT01506401|Active Comparator|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
11478234|NCT01506401|Experimental|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
11478235|NCT01506388|Experimental|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
11478236|NCT01506388|Active Comparator|Misoprostol vaginally|intravaginal misoprostol
11478237|NCT01506375|Experimental|gpASIT|grass pollen peptides alone
11478238|NCT01506375|Experimental|gpASIT/adjuvant|grass pollen peptides + adjuvant
11478239|NCT01506362|Experimental|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
11479621|NCT01497028||Plicated Gastric Banding|
11478240|NCT01506349|Experimental|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.
~Group 1 will consume placebo before neurocognitive testing at Visit 3."
11478241|NCT01506349|Experimental|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.
~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
11478242|NCT01506336|Experimental|masitinib|masitinib 12 mg/kg/day
11478243|NCT01506336|Active Comparator|sunitinib|sunitinib 50 mg/day
11478244|NCT01506323|Experimental|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
11478245|NCT01506323|Active Comparator|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
11478246|NCT01506310|No Intervention|Diet alone|
11478247|NCT01506310|Experimental|Behavioral therapy|
11478248|NCT01506310|Experimental|Exercise|
11478249|NCT01506310|Experimental|Behavioral therapy and exercise|
11478250|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
11478251|NCT01506271|Experimental|Relebactam 250 mg with imipenem/cilastatin|Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
11478252|NCT01506271|Experimental|Relebactam 125 mg with imipenem/cilastatin|Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
11478253|NCT01506271|Placebo Comparator|Placebo to relebactam with imipenem/cilastatin|Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
11478254|NCT01506258|No Intervention|Patients not infused with stem cells|Historic Controls
11478255|NCT01506258|Experimental|Patients infused with stem cells|
11478256|NCT01506245|No Intervention|Control|
11478257|NCT01506245|Experimental|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
11478258|NCT01506232||ADHD|Youth diagnosed with ADHD.
11478259|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
11478260|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
11478261|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
11478262|NCT01506219|Experimental|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
11478263|NCT01506219|No Intervention|Usual care|Usual services at Community Rehabilitation Unit.
11478264|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
11478265|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
11478266|NCT01506193|Active Comparator|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
11478267|NCT01506193|Experimental|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
11478268|NCT01506193|Active Comparator|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
11478269|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
11478270|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
11478271|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
11478272|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
11478273|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
11478274|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
11478275|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
11478276|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
11478277|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
11478278|NCT01506154|Placebo Comparator|Placebo|Therapy with placebo
11478279|NCT01506154|Experimental|MRX-7EAT|Therapy with experimental drug
11478280|NCT01506141|Experimental|Idursulfase-IT|Idursulfase-IT will be administered once monthly and weekly IV infusions of Elaprase at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
11478281|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
11478282|NCT01506115|Experimental|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
11478283|NCT01506089|Experimental|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
11478284|NCT01506089|No Intervention|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
11478285|NCT01506076|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
11478286|NCT01506076|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
11478287|NCT01506063|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
11478288|NCT01506063|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
11478289|NCT01506050|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
11478290|NCT01506050|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
11478291|NCT01506037|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
11478292|NCT01506037|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
11478293|NCT01506024|Active Comparator|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
11478294|NCT01506024|Experimental|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
11478295|NCT01506024|Experimental|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
11478296|NCT01506011|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
11478297|NCT01506011|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
11478298|NCT01505998|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
11478299|NCT01505998|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
11478300|NCT01505985|Experimental|Specialized Oral Nutritional Supplement|
11478301|NCT01505985|Placebo Comparator|Placebo|
11478302|NCT01505972|Experimental|Six and three time schedule|
11478303|NCT01505972|Experimental|Four and two time schedule|
11478304|NCT01505959|Experimental|Conventional|
11478305|NCT01505959|Active Comparator|Telemedicine|
11478306|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre >0.6 and < 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre >0.6 and < 5 BU/ml and no increase in the INH titer > 5 BU over treatment with FVIII)
11478307|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre > 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
11478308|NCT01505933|Active Comparator|dexmedetomidine|
11478309|NCT01505933|Active Comparator|propofol|
11478310|NCT01505920|Experimental|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
11478311|NCT01505920|Active Comparator|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
11478312|NCT01505907|Experimental|CXB909 15mg|CXB909 15mg
11478313|NCT01505907|Experimental|CXB909 30mg|
11478314|NCT01505907|Experimental|CXB909 60mg|
11478315|NCT01505907|Experimental|CXB909 120mg|Dose
11478316|NCT01505907|Experimental|CXB909 250mg|
11478317|NCT01505894|Experimental|BI 409306 low dose|Film-coated tablet
11478318|NCT01505894|Experimental|BI 409306 medium dose|Film-coated tablet
11478319|NCT01505894|Experimental|BI 409306 high dose|Film-coated tablet
11478320|NCT01505894|Experimental|BI 409306 high dose II|Film-coated tablet
11478321|NCT01505894|Placebo Comparator|Placebo|Film-coated tablet
11478322|NCT01505881|Experimental|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
11478323|NCT01505881|Active Comparator|warfarin|warfarin doses to maintain INR levels
11478324|NCT01505868|Experimental|Arm I (cabazitaxel)|Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11478325|NCT01505868|Experimental|Arm II (cabazitaxel and carboplatin)|Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11478326|NCT01505855|Experimental|anti-TNF only|Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only
11478327|NCT01505855|Experimental|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])
11478328|NCT01505855|Experimental|Immunomodulator only|Crohn's disease, on an immunomodulator only
11478329|NCT01505855|Experimental|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
11478330|NCT01505842|Experimental|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
11478331|NCT01505842|Active Comparator|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
11478332|NCT01505829||Biological validation cohort 1|
11478333|NCT01505829||Response assessment cohort 2|
11478334|NCT01505816|No Intervention|Toric|Multifocal Toric IOL implantation
11478335|NCT01505803|Active Comparator|Zinc supplement|
11478336|NCT01505803|Active Comparator|Omega 3 supplement|
11478337|NCT01505803|Active Comparator|Zinc and omega 3 supplements|
11478338|NCT01505803|Placebo Comparator|Placebo supplement|
11478339|NCT01505790|Experimental|CLOPIDOGREL GROUP|
11478340|NCT01505790|Active Comparator|PRASUGREL GROUP|
11478341|NCT01505777|Experimental|Probiotics(Medirac) 10/mosapride 10mg|
11478342|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 10mg|
11478343|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 15mg|
11478344|NCT01505777|Experimental|Probiotics(Medirac) 30/mosapride 15mg|
11478345|NCT01505777|Placebo Comparator|Probiotics(Medirac) placebo/mosapride placebo|
11478346|NCT01505764|Experimental|Arm 1 (Anamorelin HCl)|Anamorelin HCl
11478347|NCT01505764|Placebo Comparator|Arm 2 (Placebo)|Placebo
11478348|NCT01505751||cervical cancer|
11478349|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
11478350|NCT01505686|Experimental|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
11478351|NCT01505673|Active Comparator|Liraglutide|
11478352|NCT01505673|Placebo Comparator|Saline injection|
11478353|NCT01505660|No Intervention|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
11478354|NCT01505660|Experimental|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
11478355|NCT01505647|Experimental|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
11478356|NCT01505647|Active Comparator|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
11478357|NCT01505634|Experimental|Relebactam 250 mg with imipenem/cilastatin|Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
11478358|NCT01505634|Experimental|Relebactam 125 mg with imipenem/cilastatin|Relebactam 125 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
11478359|NCT01505634|Placebo Comparator|Relebactam placebo with imipenem/cilastatin|Matching placebo for relebactam (0.9% normal saline) IV co-administered with 500 mg dose of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
11478360|NCT01505621||Young|Healthy adults 18-30 years old
11478361|NCT01505621||Elderly|Healthy adults greater than 65 years old
11478362|NCT01505608|Active Comparator|Arm A- Temozolomide and Irinotecan|"Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.
~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
11478363|NCT01505608|Experimental|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287
~Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
~Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.
~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
11478364|NCT01505595|Experimental|Proprioceptive training|
11478365|NCT01505595|Sham Comparator|Sham proprioceptive training|
11478366|NCT01505582|Experimental|Inspiratory muscle training|
11478367|NCT01505582|Sham Comparator|Sham inspiratory muscle training|
11478368|NCT01505569|Other|Arm A: Patients with High Risk or Relapsed Solid Tumor|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, busulfan (1.1 mg/kg IV every 6 hours on days -8 through -6), melphalan (50 mg/mg^2 on days -5 and -4), thiotepa conditioning (250 mg/m^2 IV over 2 hours on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0) and, if appropriate, disease specific radiation therapy at day +60.
11478369|NCT01505569|Other|Arm B: Certain CNS Tumors|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, carboplatin (dose based on GFR and age 17 mg/kg/day IV or 510 mg/m^2/day IV) , thiotepa conditioning (10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0). This will be repeated up to 2 additional 30 day cycles.
11478370|NCT01505569|Other|Arm C: Germ Cell Tumors|"High-Dose Chemotherapy (3 cycles)
~Carboplatin AUC=8 & Etoposide 400 mg/m^2 daily, days -4, -3, and -2 every 21 days
~Autologous Stem Cell Infusion ≥ 3 x 106 CD34+ cells/kg Day 0 Cycles 1, 2 and 3
~TI Chemotherapy & PBSC Collection.
~Paclitaxel 200mg/m^2 IV over 3 hours on Day 1 every 14 days for 2 cycles
~Ifosfamide 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles
~Mesna 2000 mg/m^2 on Days 1-3 every 14 days for 2 cycles
~G-CSF 10 μg/kg sub q daily on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first
~Leukapheresis starting on approx. day 11 and continued daily until reaching the collection goal of ≥ 8 x 106 CD34+ cells/kg) or day 15, whichever occurs first"
11478371|NCT01505569|Other|Arm D: Certain CNS Tumors|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)
~Pre-Transplant Conditioning Chemotherapy (3 cycles)
~Day -8, -7, -6: Carboplatin as calculated from AUC of 7 approx.
~Day -5, -4, -3: Thiotepa 10 mg/kg, Etoposide 8.3 mg/kg
~Day 0: Autologous Hematopoietic Cell Reinfusion
~Day +1: Begin G-CSF(filgrastim) 5 mcg/kg"
11478372|NCT01505569|Other|Arm E: Neuroblastoma|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)
~Pre-Transplant Conditioning Chemotherapy (day -7 to day -0)
~Day -7: anti-seizure prophylaxis with lorazepam or levetiracetam
~Day -6 - -3: Busulfan IV q24 hours x 4 doses
~Day -1: Melphalan 140 mg/m2 IV
~Day 0: Autologous Hematopoietic Cell Reinfusion"
11478373|NCT01505556||Diaphragm paresis|
11478374|NCT01505556||Healthy controls|
11478377|NCT01505530|Experimental|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
11478378|NCT01505530|Experimental|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
11478379|NCT01505530|Placebo Comparator|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
11478380|NCT01505517||individuals with low back pain|
11478381|NCT01505517||healthy controls|
11478382|NCT01505491|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
11478383|NCT01505491|Active Comparator|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
11478384|NCT01505491|Active Comparator|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
11478385|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
11478386|NCT01505465|Experimental|Study: Melatonin|
11478387|NCT01505465|Placebo Comparator|Control: Placebo|
11478388|NCT01505439|Experimental|Solifenacin group|Once daily
11478389|NCT01505426|Experimental|ASP1941 group|ASP1941 + metformin
11478390|NCT01505426|Placebo Comparator|placebo group|placebo + metformin
11478391|NCT01505413|Experimental|Tarceva, Gemcitabine, Oxaliplatin|"Erlotinib 100 mg po qd daily AND
~Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
~Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks
~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
11478392|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
11478393|NCT01505387|Placebo Comparator|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
11478394|NCT01505387|Experimental|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
11478395|NCT01505374|Experimental|Study Technique Left Leg, Control Technique Right Leg|
11478396|NCT01505374|Experimental|Study Technique Right Leg, Control Technique Left Leg|
11478397|NCT01505361|Experimental|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
11478398|NCT01505361|Placebo Comparator|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
11478399|NCT01505348|Experimental|Fasting|Overnight fast
11478400|NCT01505348|No Intervention|Feeding|Normal breakfast
11478401|NCT01505335||Implant osteotomy measurements|Drilled implant locations
11478402|NCT01505322||Thoracic surgery|Lung cancer patients
11478403|NCT01505309|Experimental|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
11478404|NCT01505296|Active Comparator|Antiarrhythmic drug|Class I or III antiarrhythmic drug
11478405|NCT01505296|Experimental|Catheter ablation|Pulmonary vein isolation
11478406|NCT01505283|Placebo Comparator|Group Saline|Epidural administration of saline
11478407|NCT01505283|Experimental|Group Sufentanil|Epidural administration of sufentanil
11478408|NCT01505283|Experimental|Group Lidocaine|Epidural administration of lidocaine
11478409|NCT01505270||Autistic Children|
11478410|NCT01505257|Experimental|END-DSD Intervention|
11478411|NCT01505257|No Intervention|Control|
11478412|NCT01505244|Experimental|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
11478413|NCT01505231|Active Comparator|Norepinephrine group|Blinded norepinephrine
11478414|NCT01505231|Active Comparator|Vasopressin Group|Blinded vasopressin
11478415|NCT01505218|Active Comparator|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
11478416|NCT01505218|Active Comparator|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.
~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
11478417|NCT01505218|No Intervention|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
11478418|NCT01505179|Active Comparator|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
11478419|NCT01505179|Placebo Comparator|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
11478420|NCT01505166|Experimental|Vigil™|Patients will receive 1 x 10^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
11478421|NCT01505166|Placebo Comparator|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
11478422|NCT01505166|Experimental|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
11478423|NCT01505153|Experimental|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
11478424|NCT01505140|No Intervention|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
11478425|NCT01505140|Experimental|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
11478426|NCT01505127|Experimental|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week
~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week
~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week
~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
11478427|NCT01505127|Experimental|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week
~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week
~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week
~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
11478428|NCT01505114|Experimental|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
11478429|NCT01505114|Experimental|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
11478430|NCT01505114|Experimental|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
11478431|NCT01505114|Experimental|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
11478432|NCT01505101|Experimental|Mindfulness-Oriented Recovery Enhancement|
11478433|NCT01505101|Active Comparator|Conventional Support Group (SG)|
11478434|NCT01505088|Experimental|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
11478435|NCT01505088|Active Comparator|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
11478436|NCT01505075|Experimental|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
11478437|NCT01505062|Experimental|SAR421869 (Cohort 1)|Starting dose of SAR421869 given through one subretinal injection.
11478438|NCT01505062|Experimental|SAR421869 (Cohort 2)|Escalating dose of SAR421869 given through one subretinal injection.
11478439|NCT01505062|Experimental|SAR421869 (Cohort 3)|Escalating dose of SAR421869 given through one subretinal injection.
11478440|NCT01505062|Experimental|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD) of SAR421869 given through one subretinal injection.
11478441|NCT01505062|Experimental|SAR421869 (Cohort 5)|MTD of SAR421869 given through one subretinal injection.
11478442|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
11478443|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
11478444|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
11478445|NCT01505036|Experimental|SMARTCARE service|U-Health service
11478446|NCT01505036|No Intervention|Usual care|Usual care
11478447|NCT01505023|Active Comparator|Partial meal replacement|
11478448|NCT01505023|Experimental|Partial meal replacement with inulin|
11478449|NCT01505023|Active Comparator|Inulin|
11478450|NCT01505023|No Intervention|No intervention|
11478451|NCT01505010|Other|Control group|Standard antihypertensive drug treatment
11478452|NCT01505010|Experimental|Intervention group|Renal denervation plus standard antihypertensive drug treatment
11478453|NCT01504997|Experimental|Robot assisted distal gastrectomy|patients who received robot assisted distal gastrectomy
11478454|NCT01504984|Experimental|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
11478455|NCT01504984|Active Comparator|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
11478456|NCT01504971||Gastroesophageal reflux disease (GERD)|
11478457|NCT01504958|Active Comparator|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
11478458|NCT01504958|Sham Comparator|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
11478459|NCT01504958|Sham Comparator|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
11478460|NCT01504945|Active Comparator|RBC transfusion|
11478461|NCT01504945|Placebo Comparator|Normal saline infusion|
11478462|NCT01504932|Experimental|Arm I: BRB Lozenge|"Former oral cancer patients receive lozenges containing freeze-dried black raspberry (BRB) powder. They will take the lozenges four times each day (QID) by mouth (PO) for up to 6 months.
~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.
~They will receive a trial-specific logbook to record their usages.
~Intervention: Black Raspberry (BRB) Lozenge Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
11478491|NCT01504737|Active Comparator|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
11478492|NCT01504724|Experimental|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
11478463|NCT01504932|Other|Arm II: Biomarker Control|"Former oral cancer patients will not receive lozenges containing freeze-dried black raspberry (BRB) powder.
~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.
~They will receive a trial-specific logbook to record their usages.
~Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
11478464|NCT01504919|Experimental|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
11478465|NCT01504919|Experimental|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
11478466|NCT01504906|Experimental|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
11478467|NCT01504906|Experimental|B|single dose cyclosporine 600 mg
11478468|NCT01504906|Experimental|C|single dose 180 mg ticagrelor
11478469|NCT01504893|Experimental|protective|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure streets ≤ 25 cm H2O, I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O
~OLV (OLV): 4 mL / kg, peak airway pressure ≤ 35 cmH2O, respiratory rate <30, I:E = 1:2 / 1:3.
~During OLV in case of desaturation (before increasing the FiO2) and / or within 1 hour you perform recruitment maneuvers followed by the setting of a PEEP of 5 cmH2O"
11478470|NCT01504893|No Intervention|conventional|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure ≤ 25 cmH2O airway; I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O
~OLV (OLV): 8 mL / kg, peak airway pressure ≤ 35 cmH2O; I: E = 1:2."
11478471|NCT01504867|Experimental|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
11478472|NCT01504867|Placebo Comparator|Placebo|This group received matching lactose powder filled capsules on days 1-7.
11478473|NCT01504854|Experimental|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
11478474|NCT01504854|Placebo Comparator|Placebo|Subjects will receive a matching placebo to be taken with or without food.
11478475|NCT01504841|Experimental|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm were at least 2 but younger than 6 years of age; they received the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
11478476|NCT01504841|Experimental|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm were at least 1 but younger than 2 years of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
11478477|NCT01504841|Experimental|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm were at least 2 months but younger than 1 year of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
11478478|NCT01504828|Experimental|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
11478479|NCT01504815|Active Comparator|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
11478480|NCT01504815|Experimental|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
11478481|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
11478482|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
11478483|NCT01504789|Experimental|Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
11478484|NCT01504789|Experimental|Non-Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
11478485|NCT01504789|Active Comparator|Waitlist Group|Patients may choose to participate in the exercise program after 16-week assessment. After 4 months of exercise, all the follow-up tests repeated. Exercise recommendation then given, and all of the intervention materials.
11478486|NCT01504776|Experimental|Open Label Drug Therapy|Single arm
11478487|NCT01504763|Experimental|Massage|Chair massage for 15 minutes once a week for 10 weeks.
11478488|NCT01504750|Experimental|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
11478489|NCT01504750|No Intervention|control room|Normal lighted patient room
11478490|NCT01504737|Experimental|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
11478493|NCT01504724|No Intervention|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
11478494|NCT01504711|Experimental|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
11478495|NCT01504698|Experimental|Treatment with manipulation|
11478496|NCT01504698|Active Comparator|Treatment without manipulation|
11478497|NCT01504685|Active Comparator|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
11478498|NCT01504685|Active Comparator|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
11478499|NCT01504672|Experimental|Medication review|
11478500|NCT01504672|No Intervention|Usual care|
11478501|NCT01504659|Active Comparator|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
11478502|NCT01504659|Placebo Comparator|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
11478503|NCT01504646|Placebo Comparator|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
11478504|NCT01504646|Experimental|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
11478505|NCT01504633|Experimental|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
11478506|NCT01504633|Experimental|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
11478507|NCT01504633|Experimental|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
11478508|NCT01504633|Experimental|Placebo Group|Placebo capsule and placebo syrup
11478509|NCT01504620|Other|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
11478510|NCT01504620|Experimental|insulin infusion|infusion of insulin to achieve low glucose levels
11478511|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
11478512|NCT01504594|Experimental|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
11478513|NCT01504581|Experimental|HM10660A|
11478514|NCT01504581|Active Comparator|Pegasys|
11478515|NCT01504581|Placebo Comparator|HM10660A Placebo|
11478516|NCT01504568|Other|Prophylactic Antibotics|Amoxicillin/clavulanic acid
11478517|NCT01504568|No Intervention|Non Treatment|Subjects will be followed without the use of antibiotics.
11478518|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
11478519|NCT01504542|Experimental|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
11478520|NCT01504542|Experimental|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
11478521|NCT01504542|Placebo Comparator|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
11478522|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
11478523|NCT01504516|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
11478524|NCT01504516|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
11478525|NCT01504503|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
11478526|NCT01504503|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
11478527|NCT01504490|Experimental|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
11478528|NCT01504477|Experimental|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
11478529|NCT01504464|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
11478530|NCT01504464|Experimental|placebo|The patients who are in control group and underwent placebo injection.
11478531|NCT01504451|Active Comparator|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
11478532|NCT01504451|Active Comparator|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
11478533|NCT01504451|Active Comparator|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
11478534|NCT01504438|Other|Salto Talaris Total Ankle Replacement|
11478535|NCT01504438|Other|STAR Total Ankle Replacement|
11478536|NCT01504412|Experimental|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
11478537|NCT01504412|Experimental|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
11478538|NCT01504412|Experimental|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
11478539|NCT01504412|Placebo Comparator|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
11478540|NCT01504412|Active Comparator|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
11478541|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
11478542|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
11478543|NCT01504386|Experimental|TAP block|TAP block with ropivacaine
11478544|NCT01504386|Placebo Comparator|Placebo TAP block|Sham block with saline
11478545|NCT01504373|Other|NAVA-PSV|Subject will receive 4 hours of NAVA followed by 4 hours of PSV.
11478546|NCT01504373|Other|PSV-NAVA|Subject will receive 4 hours of PSV followed by 4 hours of NAVA.
11479622|NCT01497028||Standard Gastric Banding|
11478547|NCT01504360|Experimental|sarcoma group|patient suffering form radiation-induced sarcoma
11478548|NCT01504360|Active Comparator|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
11478549|NCT01504347|Experimental|Primary vaccination in seronegative subjects|
11478550|NCT01504347|Experimental|Booster vaccination in seronegative subjects|
11478551|NCT01504347|Experimental|Primary + booster vacc. (seronegative + seropositive subjects)|
11478552|NCT01504334|Experimental|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
11478553|NCT01504334|Placebo Comparator|Placebo (without active ingredient)|
11478554|NCT01504321|Active Comparator|Active|
11478555|NCT01504321|Placebo Comparator|Placebo|
11478556|NCT01504308|Experimental|MR-HIFU treatment|Patients receiving MR-HIFU treatment
11478557|NCT01504308|Sham Comparator|Sham Treatment|Patients receiving sham treatment
11478558|NCT01504295|Experimental|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
11478559|NCT01504295|Placebo Comparator|Sugar pill|Placebo group
11478560|NCT01504282|Active Comparator|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
11478561|NCT01504282|Placebo Comparator|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
11478562|NCT01504256|Experimental|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm
~[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
11478563|NCT01504256|Active Comparator|standard therapy|"FLOT; 6 cycles q2w:
~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
11478564|NCT01504243||Control|normal person under medical examination
11478565|NCT01504243||sepsis|SIRS plus inflammation
11478566|NCT01504230||health older adults|
11478567|NCT01504230||Osteoporosis participants|
11478568|NCT01504204|Experimental|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
11478569|NCT01504204|Active Comparator|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
11478570|NCT01504191|Experimental|Internet-based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet-based CBT-program.
11478571|NCT01504191|No Intervention|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).
~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
11478572|NCT01504178|Experimental|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
11478573|NCT01504178|Placebo Comparator|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
11478574|NCT01504178|Placebo Comparator|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
11478575|NCT01504165|Experimental|Group 1|Healthy volunteers: matched subjects with normal renal function
11478576|NCT01504165|Experimental|Group 2|Mild renal impaired subjects
11478577|NCT01504165|Experimental|Group 3|Moderate renal impaired subjects
11478578|NCT01504165|Experimental|Group 4a|First group of Severe renal impaired subjects
11478579|NCT01504165|Experimental|Group 4b|Second group of severe renal impaired subjects
11478580|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
11478581|NCT01504139|Experimental|hCG in the late follicular phase + luteal phase|
11478582|NCT01504139|Experimental|hCG in the follicular phase + luteal phase|
11478583|NCT01504139|Experimental|LH in the luteal phase|
11478584|NCT01504139|Active Comparator|vaginal progesterone and estradiol in the luteal phase|
11478585|NCT01504126|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11478586|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
11478587|NCT01504113||Study 2 case group|Patients who have received targeted therapy
11478588|NCT01504113||study 2 control group|Psoriasis patients without target therapy
11478589|NCT01504100||femoral internal rotation|
11478590|NCT01504100||no femoral internal rotation|
11478591|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
11478592|NCT01504087||patient without deep venous thrombosis|
11478593|NCT01504074||Patients suffering on CME secondary to cataract surgery|
11478594|NCT01504061|Experimental|Mederma Ultra Gel|
11478595|NCT01504061|Active Comparator|Mederma N&I|
11478596|NCT01504048|Experimental|Chromoendoscopy|
11478597|NCT01504035|Experimental|Hemostatic putty plus Lidocaine (Orthostat-L)|
11478598|NCT01504035|Active Comparator|Hemostatic putty (Orthostat)|
11478599|NCT01504022|No Intervention|Control group.|Control group.
11478600|NCT01504022|Experimental|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
11478601|NCT01504009|Experimental|Muscle strength|
11478602|NCT01503996||glaucoma|hospitalized glaucoma patients
11478603|NCT01503996||controls|hospitalized patients without glaucoma
11478604|NCT01503983|Experimental|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
11478605|NCT01503970|Experimental|Chondrocyte implantation|
11478606|NCT01503957|Placebo Comparator|Saline solution|Nasal spray
11478607|NCT01503957|Experimental|Nasya|Thixotropic nasal spray suspension
11478608|NCT01503944|Other|Dementia with Lewy Bodies|
11478609|NCT01503944|Other|Parkinson's disease|
11478610|NCT01503944|Other|Healthy Elderly Volunteers|
11478611|NCT01503944|Other|Alzheimer's Disease|
11478612|NCT01503931||Alcohol-dependent patients|"men and women, aged 18 to 75
~legally effective, written informed consent for participation within the study
~right handedness
~no other psychiatric disorder according to ICD 10
~no psychotropic substances within the last 7 days"
11478613|NCT01503931||Healthy control subjects|"men and women, aged 18 to 75
~legally effective, written informed consent for participation within the study
~right handedness
~no psychiatric disorder according to ICD 10
~no psychotropic substances within the last 7 days"
11478614|NCT01503918|Experimental|Valaciclovir/Aciclovir|
11478615|NCT01503918|Experimental|Valganciclovir/Ganciclovir|
11478616|NCT01503918|No Intervention|control|
11478617|NCT01503905|Active Comparator|Docetaxel plus epirubicin|
11478618|NCT01503905|Active Comparator|docetaxel plus epirubicin plus cyclophosphamide|
11478619|NCT01503892|Placebo Comparator|Placebo|The control group will receive placebo pill twice daily for twelve months.
11478620|NCT01503892|Active Comparator|Metanx|Metanx group will receive one pill twice daily for twelve months.
11478621|NCT01503866|Experimental|20 mg bardoxolone methyl|
11478622|NCT01503840|Active Comparator|Sugammadex|
11478623|NCT01503840|Placebo Comparator|Sodium chloride solution|
11478624|NCT01503827|Experimental|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
11478625|NCT01503827|No Intervention|Observation|No Intervention
11478626|NCT01503814|No Intervention|Control (Usual Care)|Control
11478627|NCT01503814|Experimental|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
11478628|NCT01503801|Experimental|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
11478629|NCT01503801|Active Comparator|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
11478630|NCT01503788|Active Comparator|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
11478631|NCT01503788|No Intervention|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
11478632|NCT01503775||TRUFILL® DCS Orbit Galaxy|
11478633|NCT01503762|Experimental|Mirror Therapy Group|Mirror Therapy Group
11478634|NCT01503762|Sham Comparator|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
11478635|NCT01503749|No Intervention|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
11478636|NCT01503749|Active Comparator|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
11478637|NCT01503749|Experimental|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells
~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
11478638|NCT01503736|Placebo Comparator|Placebo|
11478639|NCT01503736|Experimental|4g/day|Ferric Citrate for a total daily dose of 4g
11478640|NCT01503736|Experimental|6g/day|Ferric Citrate for a total daily dose of 6g
11478641|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
11478642|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
11478643|NCT01503671|Experimental|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
11478644|NCT01503671|No Intervention|No intervention arm|Placebo arm without intervention
11478645|NCT01503658|Experimental|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
11478646|NCT01503632|Experimental|Arm I (intervention program and mercaptopurine)|See detailed description.
11478772|NCT01502800|Experimental|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.
~Beginning dose level will be 390 mg/m2."
11478647|NCT01503632|Active Comparator|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS® medication bottle with TrackCap™ as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
11478648|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
11478649|NCT01503606|Active Comparator|one-week treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
11478650|NCT01503606|Active Comparator|until-delivery treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery
11478651|NCT01503593|No Intervention|Alveolar ridge dimensions|Control group - Only extraction teeth
11478652|NCT01503593|Experimental|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
11478653|NCT01503580|Experimental|antimuscarinic drug|
11478654|NCT01503567||Subjects 6 to 18 years old without inhibitors|
11478655|NCT01503567||Subjects 6 to 18 years old with inhibitors|
11478656|NCT01503567||Subjects above18 years old without inhibitors|
11478657|NCT01503567||Subjects above 18 years old with inhibitors|
11478658|NCT01503554|Experimental|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
11478659|NCT01503554|Experimental|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
11478660|NCT01503528|Active Comparator|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
11478661|NCT01503528|Experimental|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
11478662|NCT01503515|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
11478663|NCT01503515|Active Comparator|Arm II (fluconazole or voriconazole)|Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
11478664|NCT01503502|Experimental|flumatinib 400mg qd|
11478665|NCT01503502|Experimental|flumatinib 600 mg qd|
11478666|NCT01503502|Active Comparator|imatinib|
11478667|NCT01503489||Bipolar depressed patients|Bipolar I or II outpatients, current major depressive episode (HDRS-17 over 20).
11478668|NCT01503476|Experimental|Healthy volunteers|healthy volunteers
11478669|NCT01503476|Experimental|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
11478670|NCT01503463|No Intervention|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
11478671|NCT01503463|Experimental|Home telemonitoring of patients with CHF|
11478672|NCT01503450|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
11478673|NCT01503450|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
11478674|NCT01503437|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
11478675|NCT01503437|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
11478676|NCT01503424|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
11478677|NCT01503424|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
11478678|NCT01503398|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
11478679|NCT01503398|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
11478680|NCT01503385|Experimental|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.
~Intervention: Drug: Celecoxib"
11478681|NCT01503372|Experimental|Arm A: FLO + Pazopanib|
11478682|NCT01503372|Active Comparator|Arm B: FLO|
11478683|NCT01503359|Experimental|Dietary Supplement: Sarcosine|Sarcosine Group
11478684|NCT01503359|Placebo Comparator|Placebo|Control Group
11478685|NCT01503346|Experimental|herbal medicine|"Intervention group
~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
~2. each package was given to each patient four times a day (three time after meal and one time before sleep);
~3. each patient received the usual medication of the hospice ward at the same time;
~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
11478686|NCT01503333|No Intervention|Control|The control condition will complete data collection activities and receive their usual school offerings.
11478862|NCT01502137|Experimental|ESRD patients|
11478863|NCT01502137|Experimental|Healthy subjects|
11478687|NCT01503333|Experimental|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
11478688|NCT01503320|Experimental|Enteral glutamine|
11478689|NCT01503320|Placebo Comparator|Placebo|
11478690|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
11478691|NCT01503281|Experimental|Hospital-based exercise program|Exercise monitored at the hospital
11478692|NCT01503281|Experimental|Home-based exercise program|Participants perform exercise at home
11478693|NCT01503281|No Intervention|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
11478694|NCT01503268|Active Comparator|Percutaneous ablation|
11478695|NCT01503268|Active Comparator|Surgical ablation|
11478696|NCT01503268|Active Comparator|DCCV|Direct current cardioversion
11478697|NCT01503255|Experimental|cognitive behavioral group therapy|
11478698|NCT01503255|Active Comparator|health education group|
11478699|NCT01503242|Experimental|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
11478700|NCT01503229|Experimental|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11478701|NCT01503216|Experimental|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
11478702|NCT01503216|Experimental|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
11478703|NCT01503216|Placebo Comparator|Placebo|Placebo for 8 weeks
11478704|NCT01503203|Experimental|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
11478705|NCT01503203|Active Comparator|Prime Group|This group will do strength exercises and core training.
11478706|NCT01503177|Experimental|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
11478707|NCT01503164|Active Comparator|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
11478708|NCT01503164|Sham Comparator|Lifestyle counseling|
11478709|NCT01503151|Placebo Comparator|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
11478710|NCT01503151|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
11478711|NCT01503151|Experimental|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
11478712|NCT01503151|Experimental|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
11478713|NCT01503138|Experimental|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
11478714|NCT01503138|No Intervention|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
11478715|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
11478716|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
11478717|NCT01503099||Controls India|Healthy subjects serving as controls
11478718|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
11478719|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
11478720|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
11478721|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
11478722|NCT01503086|Experimental|Arm I (interactive training program)|Patients undergo a home-based, computerized, interactive training program comprising 3-5 sessions of 15-45 minutes every week for 5-9 weeks. The program contains twelve visually engaging and interesting exercises that target skills involving visual-spatial and verbal WM. The program is adaptive in a way that each difficulty task is automatically adjusted on a trial-by-trail basis to match a patient's current WM. Each patient has an interventional coach who has online access to patient's training sessions and outcomes (pass or fail). Coaches are able to modify the training sequence or make suggestions to patients and/or parents about how progress can be maximized. Coaches also have telephone meetings with patients and/or families once a week to ensure compliance, track progress, provide feedback, and answer questions that arise during training.
11478723|NCT01503086|Experimental|Arm II (non-adaptive training program)|Patients undergo a home-based, computerized, interactive, non-adaptive training program comprising 3-5 sessions of 15-45 minutes a week for 5-9 weeks. Each patient also has an interventional coach as in arm I. Patients in both arms complete a brief neuropsychological/behavioral assessment comprising the WIS-IV, the CMS, and the CVLT-C at baseline, after completion of study, and at 6 months after completion of study. Additionally, parents complete a parent-report questionnaire to gather information about patient's behaviors, thoughts, emotions, adaptive skills, and social and functional impairment. Parents and children also complete surveys about the program regarding technical feasibility, adherence, ease-of-use, and satisfaction.
11478724|NCT01503073|Active Comparator|Real stimulation|real NIBS
11478725|NCT01503073|Sham Comparator|Sham stimulation|sham NIBS
11478726|NCT01503060|Placebo Comparator|Group 1|"Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care
~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
11478727|NCT01503060|Active Comparator|Group 2|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain
~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
11478728|NCT01503060|Active Comparator|Group 3|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar
~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
11478729|NCT01503060|Active Comparator|Group 4|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic
~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
11478730|NCT01503047|Experimental|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
11478731|NCT01503047|Placebo Comparator|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
11478732|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
11478733|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
11478734|NCT01503021|Other|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
11478735|NCT01503021|Other|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
11478736|NCT01503008|Experimental|Sustained Behavior Change system support|
11478737|NCT01503008|Active Comparator|Control|
11478738|NCT01502995|Active Comparator|With laser light|Trial of walking tasks using laser light on walker.
11478739|NCT01502995|Active Comparator|Without laser light|Trial of walking task without laser light on walker.
11478740|NCT01502982|Experimental|Chemoimmunotherapy|
11478741|NCT01502969|Placebo Comparator|Placebo|Children receiving placebo (cell culture medium in absence of virus)
11478742|NCT01502969|Active Comparator|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
11478743|NCT01502956|Active Comparator|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
11478744|NCT01502956|Active Comparator|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
11478745|NCT01502943|Experimental|Phlegm and blood stasis Syndrome G|
11478746|NCT01502943|Placebo Comparator|Phlegm and blood stasis control G|
11478747|NCT01502943|Experimental|Qi deficiency and blood stasis G|
11478748|NCT01502943|Placebo Comparator|Qi deficiency and blood stasis control G|
11478749|NCT01502930|Experimental|IRT|Imagery Rehearsal Therapy
11478750|NCT01502930|Active Comparator|CONT|Stress reduction and positive imagery
11478751|NCT01502930|No Intervention|REG|Registration only
11478752|NCT01502917|Experimental|Radioactive iodine-labeled monoclonal antibody omburtamab|This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.
11478753|NCT01502904|Active Comparator|Cypher group|
11478754|NCT01502904|Experimental|Nobori group|
11478755|NCT01502904|Active Comparator|Pravastatin group|
11478756|NCT01502904|Active Comparator|Pitivastatin group|
11478757|NCT01502904|Active Comparator|Non-ARB group|
11478758|NCT01502904|Experimental|ARB group|
11478759|NCT01502891|Active Comparator|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
11478760|NCT01502891|No Intervention|Normal care|
11478761|NCT01502878|Active Comparator|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
11478762|NCT01502878|Placebo Comparator|Nut challenge: Placebo|See intervention
11478763|NCT01502878|Experimental|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
11478764|NCT01502852||OEF/OIF Veterans with TBI|
11478765|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
11478766|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
11478767|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
11478768|NCT01502826||Group A|less insulin-resistant
11478769|NCT01502826||Group B|severely insulin-resistant
11478770|NCT01502813|Experimental|Citicoline, Creatine, and Omega-3 Arm|
11478771|NCT01502800|Experimental|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.
~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:
~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
11478773|NCT01502800|Experimental|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.
~The beginning dose level will be 390 mg/m2."
11478774|NCT01502800|Experimental|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.
~The beginning dose level will be 390 mg/m2."
11478775|NCT01502787|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
11478776|NCT01502787|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
11478777|NCT01502774|Experimental|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
11478778|NCT01502774|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
11478779|NCT01502761|Experimental|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
11478780|NCT01502761|Experimental|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
11478781|NCT01502761|Experimental|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
11478782|NCT01502761|Experimental|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
11478783|NCT01502748|Experimental|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
11478784|NCT01502735|Experimental|DENV-1 PIV (high dose)|
11478785|NCT01502735|Experimental|DENV-1 PIV (low dose)|
11478786|NCT01502722|Experimental|Group 1 - Crossover|This group will drink water in the 1st study.
11478787|NCT01502722|Experimental|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
11478788|NCT01502722|Experimental|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
11478789|NCT01502709|Experimental|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
11478790|NCT01502709|Placebo Comparator|Placebo Arm|Subjects received placebo
11478791|NCT01502696|Experimental|PEG IFN alfa-2b|
11478792|NCT01502696|No Intervention|Observation|
11478793|NCT01502683|Experimental|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
11478794|NCT01502683|Experimental|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
11478795|NCT01502683|Experimental|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
11478796|NCT01502683|Experimental|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
11478797|NCT01502670|Experimental|Lung Nodule|
11478798|NCT01502644|Active Comparator|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
11478799|NCT01502644|Active Comparator|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
11478800|NCT01502644|Active Comparator|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
11478801|NCT01502631|Active Comparator|SUN13837|
11478802|NCT01502631|Placebo Comparator|Placebo|
11478803|NCT01502618|Experimental|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
11478804|NCT01502605|Experimental|5-ALA|This arm will receive the investigational agent, 5-ALA.
11478864|NCT01502124|Active Comparator|Lyophilized|
11478865|NCT01502124|Experimental|Liquid|
11478805|NCT01502592|Experimental|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
11478806|NCT01502592|Experimental|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
11478807|NCT01502592|Experimental|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
11478808|NCT01502566|Experimental|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
11478809|NCT01502566|No Intervention|Control group|This group will receive no intervention
11478810|NCT01502553|Experimental|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
~Groups/Cohorts: Blood Pressure & Heart Rate Monitor"
11478811|NCT01502527|Experimental|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
11478812|NCT01502475||Veteran Attitudes toward CAM|
11478813|NCT01502449|Experimental|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
11478814|NCT01502449|Active Comparator|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
11478815|NCT01502423|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
11478816|NCT01502423|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
11478817|NCT01502410|Experimental|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
~pharmacological study: Optional correlative studies
~laboratory biomarker analysis: Optional correlative studies"
11478818|NCT01502410|Experimental|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
~pharmacological study: Optional correlative studies
~laboratory biomarker analysis: Optional correlative studies"
11478819|NCT01502410|Experimental|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
~pharmacological study: Optional correlative studies
~laboratory biomarker analysis: Optional correlative studies"
11478820|NCT01502410|Experimental|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
~pharmacological study: Optional correlative studies
~laboratory biomarker analysis: Optional correlative studies"
11478821|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
11478822|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
11478823|NCT01502371|Experimental|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
11478824|NCT01502371|Experimental|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
11478825|NCT01502371|Experimental|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
11478826|NCT01502371|Active Comparator|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
11478827|NCT01502371|Placebo Comparator|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
11478828|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
11478829|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
11478830|NCT01502358|Experimental|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
11478831|NCT01502345|Experimental|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
11478832|NCT01502345|Experimental|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
11478833|NCT01502345|Experimental|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
11478834|NCT01502332|Experimental|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
11478835|NCT01502332|Active Comparator|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
11478836|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
11478866|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
11478897|NCT01501890|Active Comparator|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
11478837|NCT01502306|Experimental|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
11478838|NCT01502306|Experimental|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.
~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day."
11478839|NCT01502306|Experimental|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.
~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day.
~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
11478840|NCT01502293|Experimental|Main Study: tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 5 cycles.
11478841|NCT01502293|Experimental|Addendum: Regimen A tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 8, and 15) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 9 cycles.
11478842|NCT01502293|Experimental|Addendum: Regimen B tavo EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 2 cycles.
11478843|NCT01502280|Experimental|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
11478844|NCT01502280|Placebo Comparator|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
11478845|NCT01502267|No Intervention|Group 1|This group will not receive IVIG and B cell depleting agents
11478846|NCT01502267|Experimental|Group 2|This group will receive IVIG and B cell depleting agents
11478847|NCT01502254|Experimental|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
11478848|NCT01502254|No Intervention|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
11478849|NCT01502241|Active Comparator|Radiotherapy|6 weeks standard partial brain treatment.
11478850|NCT01502241|Experimental|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
11478851|NCT01502228|Experimental|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
11478852|NCT01502215|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
11478853|NCT01502215|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
11478854|NCT01502202|Active Comparator|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
11478855|NCT01502202|Placebo Comparator|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
11478856|NCT01502189|Experimental|Representational approach|The Representational approach as described in the detailed description.
11478857|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
11478858|NCT01502163|No Intervention|Control|"No prewarming
~Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)
~Passive insulation with Thermoflect™ material.
~All fluids administrated intraoperative will be warmed."
11478859|NCT01502163|Active Comparator|Group passive prewarming|"Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)
~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.
~All fluids administrated intraoperative will be warmed."
11478860|NCT01502163|Active Comparator|Group Active prewarming|"Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.
~All fluids administrated intraoperative will be warmed."
11478861|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
11478867|NCT01502098|Active Comparator|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
11478868|NCT01502098|No Intervention|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
11478869|NCT01502085|Experimental|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21
~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
11478870|NCT01502072|Experimental|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
11478871|NCT01502072|Experimental|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
11478872|NCT01502072|No Intervention|No Ribavirin|Group 3: No Ribavirin treatment.
11478873|NCT01502059|Experimental|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
11478874|NCT01502059|No Intervention|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
11478875|NCT01502046|Experimental|Sativex|
11478876|NCT01502046|Placebo Comparator|Placebo|
11478877|NCT01502033|Experimental|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
11478878|NCT01502020|Active Comparator|Zyclara™|
11478879|NCT01502020|Experimental|Generic Imiquimod Cream, 3.75%|
11478880|NCT01502020|Placebo Comparator|Vehicle Cream|
11478881|NCT01502007|Experimental|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
11478882|NCT01502007|Experimental|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
11478883|NCT01501994|Experimental|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
11478884|NCT01501994|Other|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
11478885|NCT01501968|Active Comparator|Colistin|Colistimethate sodium 2.5-5mg/kg iv
11478886|NCT01501968|Experimental|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
11478887|NCT01501955|Active Comparator|Stanmore|25 patients will have the Stanmore prosthesis
11478888|NCT01501955|Experimental|Metaphyseal Hip Prosthesis|25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis
11478889|NCT01501942|Experimental|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
11478890|NCT01501942|Placebo Comparator|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
11478891|NCT01501929|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
11478892|NCT01501929|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
11478893|NCT01501916|Experimental|vitamin d|
11478894|NCT01501916|Placebo Comparator|Placebo|
11478895|NCT01501903|Active Comparator|Standard|Biopsy using standard technique of FNA
11478896|NCT01501903|Other|Fanning|Biopsy using fanning technique
11479004|NCT01501214|Placebo Comparator|Placebo|Normal saline
11478898|NCT01501890|Placebo Comparator|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
11478899|NCT01501877|Experimental|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
11478900|NCT01501877|Active Comparator|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
11478901|NCT01501864|Experimental|School Support Group|School Support Intervention
11478902|NCT01501864|No Intervention|Control|No school support
11478903|NCT01501825|Active Comparator|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
11478904|NCT01501825|Experimental|four channels|"Four channels:
~10 Hz over the left PFC.
~1 Hz over the right PFC.
~10 Hz over the left parietal cortex.
~1 Hz over the right parietal cortex."
11478905|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
11478906|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
11478907|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
11478908|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
11478909|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
11478910|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
11478911|NCT01501799|Experimental|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
11478912|NCT01501799|Active Comparator|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
11478913|NCT01501799|Placebo Comparator|Vehicle Gel|
11478914|NCT01501786|Sham Comparator|control|propofol and saline are administered
11478915|NCT01501786|Experimental|Ket10|ketamine is co-administered with propofol
11478916|NCT01501786|Experimental|Ket20|ketamine is co-administered with porpofol
11478917|NCT01501773|Experimental|Autologous bone marrow stem cell|
11478918|NCT01501773|No Intervention|Control|
11478919|NCT01501760|Experimental|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
11478920|NCT01501760|Placebo Comparator|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
11478921|NCT01501747|Active Comparator|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
11478922|NCT01501747|Placebo Comparator|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
11478923|NCT01501734|Experimental|all patients with symptomatic CHF|"Single arm prospective study
~Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).
~200 patients will visit the outpatient clinic for congestive heart failure.
~Approximately 30% will be eligible for this study."
11478924|NCT01501721|Experimental|Exercise|Home-based exercise program
11478925|NCT01501721|Experimental|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
11478926|NCT01501708|Experimental|Caspofugin based combination therapy|"Caspofugin based combination therapy:
~Patients will recieve caspofungin with voriconazole or amphotericin B"
11478927|NCT01501695|Experimental|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.
~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.
~Duration: 8 weeks."
11478928|NCT01501695|Active Comparator|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.
~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.
~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.
~Duration: 8 weeks."
11478929|NCT01501695|Placebo Comparator|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.
~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.
~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.
~Duration: 8 weeks."
11478930|NCT01501682||primary suture|operated with primary suture
11478931|NCT01501682||other mesh|operated with insertion of another mesh
11478932|NCT01501682||ventralex|operated with insertion of ventralex mesh
11478933|NCT01501669|No Intervention|Capecitabine alone arm|X arm
11478934|NCT01501669|Experimental|Irinotecan plus capecitabine arm|
11478935|NCT01501643|Active Comparator|Spirometry|Spirometry
11478936|NCT01501643|Experimental|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
11478937|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
11479005|NCT01501201|Experimental|Gastric By-Pass|group treated with Gastric By-Pass
11479006|NCT01501201|Active Comparator|optimized medical management|group receiving an optimized medical management
11479007|NCT01501188|Experimental|Kinesio taping|Specific type of muscle and joint taping
11479008|NCT01501188|Placebo Comparator|Kinesio taping placebo|Kinesio taping placebo
11478938|NCT01501617|Experimental|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
11478939|NCT01501617|Placebo Comparator|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
11478940|NCT01501591|Other|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
11478941|NCT01501591|Other|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
11478942|NCT01501591|Other|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
11478943|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
11478944|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
11478945|NCT01501565|No Intervention|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
11478946|NCT01501565|Experimental|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.
~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
11478947|NCT01501552|No Intervention|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
11478948|NCT01501552|Experimental|Training & support (T&S)|The T&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
11478949|NCT01501552|Experimental|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
11478950|NCT01501552|Experimental|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
11478951|NCT01501552|Experimental|T&S and financial incentive|The T&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
11478952|NCT01501552|Experimental|T&S and e-SBI|The T&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
11478953|NCT01501552|Experimental|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
11478954|NCT01501552|Experimental|T&S, financial incentive and e-SBI|The T&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
11478955|NCT01501539|No Intervention|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
11479009|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
11478956|NCT01501539|Experimental|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
11478957|NCT01501539|Experimental|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
11478958|NCT01501513|Experimental|BLI800 approved preparation regimen|BLI800 approved preparation regimen
11478959|NCT01501513|Experimental|BLI800 investigational preparation regimen|BLI800 investigational preparation regimen
11478960|NCT01501513|Active Comparator|PEG-3350 based bowel preparation|PEG-3350 based bowel preparation
11478961|NCT01501500|Active Comparator|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
11478962|NCT01501500|Placebo Comparator|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
11478963|NCT01501487|Active Comparator|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:
~TAC chemotherapy
~TC chemotherapy
~Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
11478964|NCT01501487|Active Comparator|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
11478965|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
11478966|NCT01501448|Active Comparator|OCP|
11478967|NCT01501448|Active Comparator|Oral estradiol valerate|
11478968|NCT01501435|Experimental|CJ-30039|Incrementally Modified Drugs of fenofibric acid
11478969|NCT01501435|Active Comparator|fenofibric acid|Greencross Lipidil Supra 160mg
11478970|NCT01501422|Experimental|Estrogen|Use estrogen patch for 8 weeks
11478971|NCT01501422|Experimental|Placebo|Use placebo patch for 8 weeks
11478972|NCT01501409|Experimental|Group I|
11478973|NCT01501409|Active Comparator|Group II|
11478974|NCT01501409|Active Comparator|Group III|
11478975|NCT01501396|Experimental|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
11478976|NCT01501396|Experimental|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks
~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
11478977|NCT01501383|Active Comparator|VX-765 Dose 1 Part A|
11478978|NCT01501383|Active Comparator|VX-765 Dose 2 Part A|
11478979|NCT01501383|Active Comparator|VX-765 Dose 3 Part A|
11478980|NCT01501383|Active Comparator|VX-765 Dose 4 Part A|
11478981|NCT01501383|Placebo Comparator|Placebo Dose Part A|Placebo
11478982|NCT01501383|Active Comparator|VX-765 Dose Part B|
11478983|NCT01501370|Experimental|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:
~Cohort 1: ZLd association:
~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
~Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.
~Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
11478984|NCT01501370|Active Comparator|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
11478985|NCT01501357|Experimental|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
11478986|NCT01501357|Active Comparator|cross toothbrushing|Children will brush with cross toothbrushing.
11478987|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
11478988|NCT01501318|Active Comparator|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
11478989|NCT01501318|Experimental|Personalized feedback report alone|Provision of the personalized feedback report alone.
11478990|NCT01501305|Placebo Comparator|Placebo|Mineral rehydration solution
11478991|NCT01501305|Active Comparator|Carob powder|Carob powder and probiotics
11478992|NCT01501292||Immature oocytes (GV, M-I)|
11478993|NCT01501292||Mature oocytes (M-II)|
11478994|NCT01501279|Experimental|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
11478995|NCT01501279|No Intervention|no nerve block|Control group without nerve block
11478996|NCT01501266||Faslodex|
11478997|NCT01501253|Experimental|CKD-828 2.5/40mg|CKD-828 2.5/40mg
11478998|NCT01501253|Experimental|CKD-828 2.5/80mg|CKD-828 2.5/80mg
11478999|NCT01501253|Active Comparator|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
11479000|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
11479001|NCT01501227|Active Comparator|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
11479002|NCT01501227|Sham Comparator|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
11479003|NCT01501214|Active Comparator|Atosiban|
11479010|NCT01501162|Placebo Comparator|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
11479011|NCT01501162|Active Comparator|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
11479012|NCT01501149|Experimental|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
11479013|NCT01501149|Experimental|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
11479014|NCT01501136|Experimental|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
11479015|NCT01501136|Experimental|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
11479016|NCT01501136|Experimental|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
11479017|NCT01501136|Experimental|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
11479018|NCT01501136|Experimental|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
11479019|NCT01501123|Experimental|Haloperidol|IM Haloperidol
11479020|NCT01501123|Active Comparator|IM Midazolam|
11479021|NCT01501110|Active Comparator|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
11479022|NCT01501110|No Intervention|no intervention|No intervention
11479023|NCT01501097|No Intervention|Control group|
11479024|NCT01501097|Experimental|early HV-crrt|
11479025|NCT01501084|Active Comparator|Exenatide|Exenatide injection 10 mcg subcutaneous
11479026|NCT01501084|Placebo Comparator|Saline|.2cc SC injection of sterile normal saline
11479027|NCT01501071|Experimental|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
11479028|NCT01501071|No Intervention|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
11479029|NCT01501058|Experimental|case group|
11479030|NCT01501058|Other|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
11479031|NCT01501045|Experimental|healthy subjects|healthy subjects
11479032|NCT01501045|Experimental|pain patients|Migraine and muscle headache patients
11479033|NCT01501032|Experimental|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
11479034|NCT01501019|No Intervention|Sjogren and Myositis Control (no control for takayasu's)|
11479035|NCT01501019|Experimental|Sjogren, Myositis and Takayasu's Trained|
11479036|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
11479037|NCT01500993|Active Comparator|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
11479038|NCT01500993|Experimental|Capecitabine|Drug - Capecitabine-based radiochemotherapy and chemotherapy
11479039|NCT01500980|Experimental|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
11479040|NCT01500980|Experimental|Chloroquine, ITV, primaquine, malaria challenge|
11479041|NCT01500980|Active Comparator|Sporozoite negative vaccine|
11479042|NCT01500980|Active Comparator|Primaquine placebo|
11479043|NCT01500980|No Intervention|malaria challenge|
11479044|NCT01500967|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
11479045|NCT01500967|Experimental|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
11479046|NCT01500954||squamous cell carcinoma|
11479047|NCT01500954||non-lesional skin|
11479048|NCT01500941|Active Comparator|probiotics|
11479049|NCT01500941|Placebo Comparator|maltodextrin|
11479050|NCT01500915|Experimental|ranibizumab|
11479051|NCT01500902|Other|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
11479052|NCT01500889|Active Comparator|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
11479053|NCT01500889|Active Comparator|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
11479054|NCT01500889|Active Comparator|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
11479055|NCT01500876|Experimental|Study Arm|Single Arm
11479056|NCT01500863|Active Comparator|hCG|
11479057|NCT01500863|Experimental|Triptorelin 0.2mg s.c.|
11479058|NCT01500863|Experimental|0.2mg triptorelin plus estradiol/progesterone|
11479059|NCT01500863|Experimental|0.2mg tripoterlin plus single bolus hCG 1500 IU|
11479060|NCT01500863|Experimental|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
11479061|NCT01500863|Experimental|0.2mg tripoterlin plus multiple doses recLH|
11479062|NCT01500850|Active Comparator|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
11479063|NCT01500850|Active Comparator|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
11479064|NCT01500850|Experimental|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
11479065|NCT01500850|Experimental|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
11479066|NCT01500837|Active Comparator|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
11479067|NCT01500837|Active Comparator|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
11479068|NCT01500824|Experimental|Crizotinib|
11479069|NCT01500811|Experimental|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
11479070|NCT01500798|Placebo Comparator|Placebo|
11479071|NCT01500798|Experimental|Bardoxolone methyl|
11479072|NCT01500785|Active Comparator|levosimendan|
11479073|NCT01500785|Placebo Comparator|placebo|
11479074|NCT01500772|Experimental|Alisporivir|ALV 400 mg twice daily (BID), plus PEG and RBV for 48 weeks
11479075|NCT01500746|Experimental|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
11479076|NCT01500746|Active Comparator|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
11479077|NCT01500733|Experimental|Elderly greater than 65|
11479078|NCT01500733|Experimental|17p Deletioin|
11479079|NCT01500720|Experimental|Cabazitaxel|
11479080|NCT01500720|Active Comparator|Topotecan|
11479081|NCT01500707|Experimental|SCH 900800|Participants receiving a single dose of SCH 900800
11479082|NCT01500694|Experimental|Extended-release Guanfacine HCl|
11479083|NCT01500681||Maintenance PLEX|
11479084|NCT01500668|Active Comparator|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
11479085|NCT01500668|Placebo Comparator|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
11479086|NCT01500655|Experimental|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
11479087|NCT01500655|Experimental|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
11479088|NCT01500655|No Intervention|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
11479089|NCT01500642|Active Comparator|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
11479090|NCT01500642|Active Comparator|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
11479091|NCT01500642|Active Comparator|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
11479092|NCT01500629|Experimental|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
11479093|NCT01500629|Experimental|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
11479094|NCT01500616|Experimental|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
11479095|NCT01500603|Experimental|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
11479096|NCT01500603|Active Comparator|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
11479097|NCT01500590|Experimental|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
11479098|NCT01500590|Active Comparator|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet
~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
11479099|NCT01500577|Experimental|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
11479100|NCT01500577|Experimental|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
11479101|NCT01500577|Placebo Comparator|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
11479135|NCT01500317|Active Comparator|Oxycodone|5 mg oxycodone tid
11479136|NCT01500317|Placebo Comparator|Placebo|Placebo tid
11479997|NCT01494389||Normal|not SIRS and have no infection
11479102|NCT01500564|Sham Comparator|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
~Intervention: placebo tDCS Other: Motor Training"
11479103|NCT01500564|Experimental|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
~Interventions:
~Device: anodal tDCS
~Other: motor Training during physiotherapy"
11479104|NCT01500551|Experimental|Tofacitinib|All patients will be in tofacitinib treatment group.
11479105|NCT01500538|Experimental|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
11479106|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
11479107|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
11479108|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
11479109|NCT01500486||PenMate device|
11479110|NCT01500473|Experimental|Females with CCHS > 16 years old on desogetrel|
11479111|NCT01500447||Central Precious Puberty|CPP subjects
11479112|NCT01500447||Hypogonadotropic Hypogonadism|IHH, KS, GnRH Deficiency, BAM syndrome (arhinia), HA, CDP subjects
11479113|NCT01500434|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
11479114|NCT01500421|Experimental|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
11479115|NCT01500421|Experimental|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
11479116|NCT01500421|No Intervention|Standard Treatment|Patients are treated with standard care in the stroke ward.
11479117|NCT01500421|Experimental|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
11479118|NCT01500408|Other|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
11479119|NCT01500408|Other|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
11479120|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
11479121|NCT01500382|Experimental|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
11479122|NCT01500382|Experimental|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
11479123|NCT01500382|Active Comparator|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
11479124|NCT01500382|Experimental|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
11479125|NCT01500369|Active Comparator|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
11479126|NCT01500369|Placebo Comparator|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
11479127|NCT01500356|Experimental|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
11479128|NCT01500356|Experimental|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
11479129|NCT01500356|Experimental|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
11479130|NCT01500343|Experimental|Saccharomyces boulardii|
11479131|NCT01500343|Placebo Comparator|Placebo|
11479132|NCT01500330|Experimental|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
11479133|NCT01500330|Active Comparator|control group|progressive muscle relaxation twice a week for 20 minutes
11479134|NCT01500317|Active Comparator|Tapentadol|75 mg tapentadol tid
11479137|NCT01500304|Experimental|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
11479138|NCT01500291||Anesthesiologist|
11479139|NCT01500291||Nurse anesthetist|
11479140|NCT01500278|Active Comparator|Certolizumab Pegol + Methotrexate (CZP + MTX)|
11479141|NCT01500278|Active Comparator|Adalimumab + Methotrexate (ADA + MTX)|
11479142|NCT01500278|Active Comparator|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
11479143|NCT01500278|Active Comparator|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
11479144|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
11479145|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
11479146|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
11479147|NCT01500252|Experimental|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
11479148|NCT01500252|Active Comparator|Patellar Retention|This group received a Profix TKR, but retained their native patella
11479149|NCT01500226|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
11479150|NCT01500226|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
11479151|NCT01500213|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
11479152|NCT01500213|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
11479153|NCT01500200|Experimental|ALKS 5461|
11479154|NCT01500200|Placebo Comparator|Placebo|
11479155|NCT01500187|Active Comparator|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
11479156|NCT01500187|Experimental|3M Vanish Varnish|5% sodium fluoride varnish
11479157|NCT01500174|Experimental|active UVC device|Three times per week irradiation of wound base and periwound skin
11479158|NCT01500174|Placebo Comparator|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
11479159|NCT01500161|Experimental|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
11479160|NCT01500148|Experimental|Intevention-PMVr Procedure|
11479161|NCT01500135|Experimental|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
11479162|NCT01500135|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
11479163|NCT01500109|Experimental|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
11479164|NCT01500109|Active Comparator|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
11479165|NCT01500109|Placebo Comparator|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
11479166|NCT01500096|Active Comparator|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
11479167|NCT01500096|Placebo Comparator|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
11479168|NCT01500096|Active Comparator|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
11479169|NCT01500096|Placebo Comparator|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
11479170|NCT01500083|Experimental|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
11479171|NCT01500083|Experimental|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
11479300|NCT01499238|Active Comparator|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
11479301|NCT01499238|Active Comparator|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
11479172|NCT01500070|Experimental|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
11479173|NCT01500057|Active Comparator|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
11479174|NCT01500057|Active Comparator|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
11479175|NCT01500044|Active Comparator|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
11479176|NCT01500044|Experimental|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:
~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
11479177|NCT01500031|Experimental|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
11479178|NCT01500018|Experimental|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
11479179|NCT01500018|Experimental|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
11479180|NCT01500018|Experimental|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
11479181|NCT01500018|Experimental|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
11479182|NCT01500018|Experimental|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
11479183|NCT01500018|Experimental|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
11479184|NCT01500018|Experimental|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
11479185|NCT01500018|Experimental|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
11479186|NCT01500018|Experimental|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:
~Phentermine 45 mg"
11479187|NCT01500018|Experimental|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
11479188|NCT01500018|Experimental|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
11479189|NCT01500018|Experimental|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
11479190|NCT01500018|Experimental|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
11479191|NCT01500018|Experimental|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
11479192|NCT01500005|Experimental|vitamin D|Baby D3 drops
11479193|NCT01499992|Experimental|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
11479194|NCT01499992|No Intervention|standard care|
11479195|NCT01499979|No Intervention|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
11479196|NCT01499979|Experimental|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
11479197|NCT01499966|Experimental|group POP|PLASTER OF PARIS
11479198|NCT01499966|Experimental|TG|TUBIGRIP
11479199|NCT01499953|Experimental|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
11479200|NCT01499953|Active Comparator|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
11479201|NCT01499940|Experimental|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
11479202|NCT01499927|Active Comparator|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
11479203|NCT01499927|No Intervention|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
11479204|NCT01499914|Experimental|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
11479205|NCT01499901|Experimental|sequential|implantation bilateral sequential
11479206|NCT01499901|Experimental|simultaneous|implantation bilateral simultaneous
11479207|NCT01499888|Experimental|Allogeneic Non-Myeloablative Stem Cell Transplantation|The transplant regimen will consist of alemtuzumab 1mg/kg divided over five days, 300 cGy TBI, followed by sirolimus dosed for a target serum trough level of 10- 15 ng/mL.
11479208|NCT01499875|Other|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
11479209|NCT01499862|Experimental|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
11479210|NCT01499849|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
11479211|NCT01499849|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
11479212|NCT01499836|Experimental|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
11479213|NCT01499836|Experimental|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
11479214|NCT01499836|Active Comparator|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
11479215|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
11479216|NCT01499810|Experimental|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
11479217|NCT01499797|No Intervention|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
11479218|NCT01499797|Experimental|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
11479219|NCT01499784|Experimental|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
11479220|NCT01499771|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
11479221|NCT01499771|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
11479222|NCT01499758|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
11479223|NCT01499758|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
11479224|NCT01499745|Active Comparator|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
11479225|NCT01499745|Placebo Comparator|Standard Treatment for IPF|Continue for normal live with standard treatment
11479226|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
11479227|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
11479228|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
11479229|NCT01499719||Surgical checklist|Compliance for surgical checklist
11479230|NCT01499706|No Intervention|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
11479231|NCT01499706|Experimental|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
11479232|NCT01499706|Experimental|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
11479233|NCT01499693|Experimental|Magnesium Pantoprazole 20mg|
11479234|NCT01499693|Active Comparator|Magnesium Pantoprazole 40mg|
11479235|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
11479236|NCT01499667|Experimental|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
11479237|NCT01499667|Experimental|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
11479238|NCT01499667|Experimental|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
11479239|NCT01499654|Experimental|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
11479240|NCT01499641|Active Comparator|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
11479241|NCT01499641|Experimental|None epidural steroid|
11479242|NCT01499628|No Intervention|Group 1-Control|No extra training will be given.
11479243|NCT01499628|Active Comparator|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
11479302|NCT01499225|Experimental|YH14642 A-I|
11479244|NCT01499628|Experimental|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
11479245|NCT01499628|Experimental|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
11479246|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
11479247|NCT01499602|Experimental|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
11479248|NCT01499602|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
11479249|NCT01499589||RA in block room|Performing regional anesthesia in the block room
11479250|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
11479251|NCT01499576|Experimental|Acetic acid spraying|
11479252|NCT01499563|Experimental|ITI-007 Low Dose|
11479253|NCT01499563|Experimental|ITI-007 High Dose|
11479254|NCT01499563|Placebo Comparator|Placebo|
11479255|NCT01499563|Active Comparator|Risperidone|
11479256|NCT01499550|Experimental|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
11479257|NCT01499550|Active Comparator|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
11479258|NCT01499537|Active Comparator|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
11479259|NCT01499537|Experimental|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
11479260|NCT01499511||ASCOT participants amlodipine|It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
11479261|NCT01499511||ASCOT participants atenolol|It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
11479262|NCT01499498|Experimental|Sildenafil and Boceprevir|Healthy volunteers
11479263|NCT01499485|Experimental|Acetazolamide|
11479264|NCT01499485|Placebo Comparator|placebo|
11479265|NCT01499472|Active Comparator|shock wave therapy, shortened wound healing time|
11479266|NCT01499472|Other|normal wound care|standard of care intervention
11479267|NCT01499459|Experimental|autologous mesenchymal stem cell transplantation|
11479268|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Morning|
11479269|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Evening|
11479270|NCT01499446|Experimental|GW685698X (fluticasone furoate) 250mcg Evening|
11479271|NCT01499446|Placebo Comparator|Placebo|
11479272|NCT01499433|Experimental|caspofungin|
11479273|NCT01499420|Experimental|CSL112|
11479274|NCT01499420|Placebo Comparator|Placebo|
11479275|NCT01499407|Active Comparator|Standard abciximab bolus|
11479276|NCT01499407|Experimental|ClearWay-infused abciximab|
11479277|NCT01499407|Experimental|Thrombectomy plus ClearWay-infused abciximab|
11479278|NCT01499407|Active Comparator|Thrombectomy plus standard abciximab bolus|
11479279|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
11479280|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
11479281|NCT01499381||Routine prostate biopsy patients|
11479282|NCT01499368|Experimental|Lafutidine|Lafutidine 20mg/day
11479283|NCT01499368|Active Comparator|Famotidine|Famotidine 40mg/day
11479284|NCT01499368|Other|Omeprazole|Omeprazole 20mg/day
11479285|NCT01499355|Placebo Comparator|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
11479286|NCT01499355|Experimental|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
11479287|NCT01499355|Experimental|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
11479288|NCT01499342||Rutherford category 2 - 5|
11479289|NCT01499329||Patient receiving stent therapy|
11479290|NCT01499316|Experimental|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
11479291|NCT01499316|Experimental|Room Air|
11479292|NCT01499303|Experimental|Fostamatinib 200|200mg fostamatinib bid n=60
11479293|NCT01499290|Experimental|CAZ-AVI + Metronidazole|IV treatment
11479294|NCT01499290|Active Comparator|Meropenem|IV treatment
11479295|NCT01499277|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
11479296|NCT01499277|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
11479297|NCT01499264|Experimental|MySkin patch|Hydrogel e polyurethane film
11479298|NCT01499264|Active Comparator|Traditional Dressing|
11479299|NCT01499251|Experimental|Macitentan|Macitentan in combination with dose-dense temozolomide
11479309|NCT01499199|Experimental|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
11479310|NCT01499186|No Intervention|Control group|There will be no participation in a training program. The control group will perform all measurements.
11479311|NCT01499186|Experimental|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
11479312|NCT01499173|Experimental|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
11479313|NCT01499160|Experimental|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
11479314|NCT01499147|Active Comparator|Arm 1|All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
11479315|NCT01499147|Active Comparator|Arm 2|All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
11479316|NCT01499134|Experimental|nebivolol|nebivolol 1 to 4 capsules daily
11479317|NCT01499134|Active Comparator|metoprolol succinate|metoprolol 1 to 4 capsules daily
11479318|NCT01499121|Other|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
11479319|NCT01499108|Experimental|Liraglutide|single-group study were participants recieve Liraglutide
11479320|NCT01499095|Experimental|HOE901-U300|
11479321|NCT01499095|Active Comparator|Lantus|
11479322|NCT01499082|Experimental|HOE901-U300|
11479323|NCT01499082|Active Comparator|Lantus|
11479324|NCT01499069|Experimental|Antimuscarinic agents|
11479325|NCT01499056|Experimental|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
11479326|NCT01499043|Experimental|PLX3397|Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
11479327|NCT01499017|Experimental|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
11479328|NCT01499017|Experimental|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
11479329|NCT01499004|Experimental|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
11479330|NCT01499004|Experimental|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
11479331|NCT01499004|Experimental|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
11479332|NCT01499004|Experimental|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
11479333|NCT01499004|Experimental|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
11479334|NCT01499004|Experimental|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
11479335|NCT01498991|Experimental|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
11479336|NCT01498978|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
11479337|NCT01498952|Experimental|Phase 1b Cohort A|Participants will receive MEDI-573 10 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
11479338|NCT01498952|Experimental|Phase 1b Cohort B|Participants will receive MEDI-573 45 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
11479339|NCT01498952|Experimental|Phase 1b Cohort C|Participants will receive MEDI-573 30 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
11479340|NCT01498952|Experimental|Phase 2 Arm 1|Participants will receive recommended dose of MEDI-573 from Phase 1b IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
11479341|NCT01498952|Active Comparator|Phase 2 Arm 2|Participants will receive sorafenib 400 mg orally twice daily until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
11479342|NCT01498939|Experimental|IDet 0.2 U/kg|
11479343|NCT01498939|Experimental|IDet 0.4 U/kg|
11479344|NCT01498939|Experimental|IDet 0.8 U/kg|
11479345|NCT01498926|Experimental|Glycerol|
11479346|NCT01498926|Active Comparator|Mannitol|
11479347|NCT01498913||Repaglinide|
11479348|NCT01498900||Repaglinide|
11479349|NCT01498887|Experimental|Naive or de novo participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
11479350|NCT01498887|Experimental|Previously treated with first-line DMTs participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
11479351|NCT01498874|Placebo Comparator|Placebo|
11479352|NCT01498874|Experimental|low dose gevokizumab|
11479353|NCT01498874|Experimental|high dose gevokizumab|
11479354|NCT01498861|Other|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
11479355|NCT01498861|Experimental|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
11479356|NCT01498861|Experimental|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
11479357|NCT01498848|Active Comparator|Soybean oil|Families were given soybean oil for cooking during 4 weeks
11479358|NCT01498848|Active Comparator|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
11479359|NCT01498835|Experimental|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
11479360|NCT01498822|Experimental|Levetiracetam|Levetiracetam twice a day treatment group
11479361|NCT01498822|Active Comparator|Oxcarbazepine|Oxcarbazepine twice a day treatment group
11479362|NCT01498796|Experimental|Ketorolac|
11479363|NCT01498796|Placebo Comparator|Placebo|
11479364|NCT01498783|Experimental|Treatment|"Participants meeting the eligibility requirements.
~Intervention: 5-fluorouracil"
11479365|NCT01498770||Asenapine|
11479366|NCT01498770||Aripiprazole|
11479367|NCT01498770||Quetiapine|
11479368|NCT01498770||Risperidone|
11479369|NCT01498770||Olanzapine|
11479370|NCT01498770||Ziprasidone|
11479371|NCT01498770||Iloperidone|
11479372|NCT01498770||Paliperidone|
11479373|NCT01498770||Lurasidone|
11479374|NCT01498770||Clozapine|
11479375|NCT01498770||Amisulpride|
11479376|NCT01498770||Sertindole|
11479377|NCT01498770||Zotepine|
11479378|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
11479379|NCT01498744|Experimental|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
11479380|NCT01498744|Experimental|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
11479381|NCT01498731|Experimental|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.
~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
~Patients who test positive for Copeptin will be treated as by standard practise."
11479382|NCT01498731|No Intervention|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
11479383|NCT01498718|Experimental|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
11479384|NCT01498718|Experimental|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
11479385|NCT01498718|Placebo Comparator|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
11479386|NCT01498718|Placebo Comparator|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
11479387|NCT01498705||Hemmorhagic Stroke|"Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit
~Age greater than 18 years
~No evidence of ischemic cerebrovascular injury"
11479388|NCT01498692|Experimental|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
11479389|NCT01498679|Active Comparator|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
11479390|NCT01498679|Placebo Comparator|Placebo|placebo comparator
11479391|NCT01498666|Experimental|L. reuteri protectis tablets|one tablet a day for 4 weeks
11479392|NCT01498666|Placebo Comparator|Placebo tablet|one tablet a day for 4 weeks
11479393|NCT01498653|Experimental|FF/VI 200/25mcg once daily|ICS/LABA
11479394|NCT01498653|Active Comparator|Fluticasone propionate 500mcg twice daily|ICS
11479395|NCT01498640|Experimental|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
11479396|NCT01498640|Experimental|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
11479397|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
11479398|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
11479399|NCT01498614|Experimental|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
11479400|NCT01498614|Active Comparator|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
11479401|NCT01498601|Experimental|Oral care treatment group|All subjects in the prospective intervention group will receive the same enhanced oral care protocol
11479402|NCT01498601|No Intervention|Retrospective study group|For comparison purposes, a retrospective chart review of matched in-patient population will reveal pneumonia rates in the same population who did not receive the enhanced oral care protocol.
11479487|NCT01498029|Active Comparator|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
11479403|NCT01498588|Experimental|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:
~Day 1: Eribulin 1.4mg/m² IV
~Day 8: Eribulin 1.4mg/m² IV
~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:
~Day 1: Doxorubicin 60mg/m² IV
~Day 1: Cyclophosphamide 600mg/m² IV
~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
11479404|NCT01498575|Experimental|Teen Driving Plan|Access to web-based driving intervention
11479405|NCT01498575|No Intervention|Usual practice|Use of typical supervised practice driving resources
11479406|NCT01498562|Experimental|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
11479407|NCT01498562|Active Comparator|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
11479408|NCT01498549|Active Comparator|Atomoxetine|Atomoxetine compared to the sugar pill
11479409|NCT01498549|Placebo Comparator|Sugar Pill|Sugar pill compared to atomoxetine
11479410|NCT01498523|Experimental|raw camel milk|
11479411|NCT01498523|Experimental|camel milk powder solution|
11479412|NCT01498523|Active Comparator|raw cow milk|
11479413|NCT01498523|Active Comparator|Glucose solution|
11479414|NCT01498510|No Intervention|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
11479415|NCT01498510|Experimental|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
11479416|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
11479417|NCT01498484|Experimental|EBV-specific T cells|Patients will each receive a course of three weekly infusions of EBV-specific T cells (EBV-CTLs). Each weekly dose will provide 2 x 10^6 T cells/kg recipient weight (+/- 3 days). After the third dose, patients will be observed for approximately 3 weeks.
11479418|NCT01498458|Experimental|pazopanib plus capecitabine|
11479419|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2|Less Intensive, Schedule A1 Dasatinib 100 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
11479420|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2|More Intensive, Schedule A2: Dasatinib 100 mg daily by mouth ; Decitabine ose 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
11479421|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
11479422|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib 140 mg daily by mouth ; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
11479423|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth; Decitabine e 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
11479424|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib140 mg daily by mouth; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
11479425|NCT01498432|Experimental|Heliox21|
11479426|NCT01498432|Active Comparator|Air O2|
11479427|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
11479428|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
11479429|NCT01498419|Active Comparator|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
11479430|NCT01498419|Experimental|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
11479431|NCT01498406|Experimental|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
11479432|NCT01498406|Active Comparator|low dose vitamin D3|400 IU of vitamin D3
11479433|NCT01498393|Other|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
11479434|NCT01498380|Experimental|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
11479435|NCT01498367|No Intervention|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
11479436|NCT01498367|Experimental|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
11479437|NCT01498354|Experimental|2-D high definition TEO (transanal endoscopic operation)|
11479438|NCT01498354|Active Comparator|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
11479439|NCT01498328|Experimental|Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.|About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
11479440|NCT01498328|Experimental|Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control|About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
11479441|NCT01498328|Experimental|Group 2 and 2C: Refractory to Bevacizumab|Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
11479442|NCT01498315||Women following hysterecomy|
11479443|NCT01498289|Experimental|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11479444|NCT01498289|Experimental|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11479445|NCT01498276||General Population|Members of the general population
11479446|NCT01498276||Members of under-resourced communities|Participant recruited from under-resourced communities in the Washington, DC area in the Southeastern US
11479447|NCT01498263||Alzheimers related dementias (family)|Enrollment was open to family members of persons diagnosed with Alzheimers (/relateddementia) in specific communities around Memphis, TN.
11479448|NCT01498263||Inherited inflammatory conditions (family)|Enrollment open to family members of persons diagnosed with inherited inflammatory conditions. Participation at NIH or remote (internet/phone); request referral of family for remote participation.
11479449|NCT01498263||Inherited metabolic conditions (family)|Enrolls family members of persons diagnosed with inborn errors of metabolism / mitochondrial disorders. Study at NIH or remote (internet/phone); request familyreferralsfor remote participation.
11479450|NCT01498263||Inherited neurodegenerative disorders (family)|Open to family members of persons diagnosed with genetically-defined neurodegenerativeconditions. Study at NIH or (internet/phone); request referral of family members for remoteparticipation.
11479451|NCT01498263||Typically developing (family) = Healthy Volunteers|Open to parents of typically-developing child/ren <18yrs (*when age-matched child is fulltime resident of parent's home). Study at NIH; request family-referrals for remoteparticipation.
11479452|NCT01498263||Undiagnosed conditions (family)|Enrollment open to family members referred in from the Undiagnosed Disease Network.Participation at NIH or remote (internet /phone); request referral of family members for remote participation
11479453|NCT01498250||basal cell carcinoma|
11479454|NCT01498250||non-lesional skin|
11479455|NCT01498237|Experimental|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
11479456|NCT01498224|Active Comparator|Suture|Suture application
11479457|NCT01498224|Experimental|ReSure Sealant|Sealant application
11479458|NCT01498211|Experimental|Biopsy|
11479459|NCT01498198|Experimental|Expedited Surgery|Participants will have surgery within 3 months
11479460|NCT01498198|Experimental|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
11479461|NCT01498185|Experimental|Arm 1: Dapagliflozin (1 mg)|
11479462|NCT01498185|Experimental|Arm 2: Dapagliflozin (2.5 mg)|
11479463|NCT01498185|Experimental|Arm 3: Dapagliflozin (5 mg)|
11479464|NCT01498185|Experimental|Arm 4: Dapagliflozin (10 mg)|
11479465|NCT01498185|Experimental|Arm 5: Placebo matching Dapagliflozin|
11479466|NCT01498172|Experimental|NMIBC at intermediate risk of progression|
11479467|NCT01498172|Experimental|NMIBC at high risk of progression|
11479468|NCT01498172|Experimental|NMIBC at low risk of progression|
11479469|NCT01498159|Experimental|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
11479470|NCT01498159|Active Comparator|Pharmacist|Participants will receive support from pharmacist.
11479471|NCT01498133|Experimental|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
11479472|NCT01498133|No Intervention|control group|The control group (n = 49) received routine care without skin-to-skin contact.
11479473|NCT01498120|Experimental|Rotigotine|"Optimal dose after titration period
~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)"
11479474|NCT01498094|Active Comparator|Control|Standard low-flow oxygen therapy.
11479475|NCT01498094|Experimental|Intervention|High Flow Nasal Cannula Oxygen Therapy
11479476|NCT01498081|Experimental|Single dose of AZD2115 25 µg|
11479477|NCT01498081|Experimental|Single dose of AZD2115 80 µg|
11479478|NCT01498081|Experimental|Single dose of AZD2115 240 µg|
11479479|NCT01498081|Placebo Comparator|Single doses of placebo|
11479480|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg|
11479481|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg + tiotropium 18 µg|
11479482|NCT01498068|Experimental|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
11479483|NCT01498068|Experimental|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
11479484|NCT01498055||CIK therapy group|
11479485|NCT01498055||control group|
11479486|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
11479620|NCT01497067|Experimental|CACHET|ACRYSOF CACHET Phakic Lens (L-series) previously implanted
11479488|NCT01498029|Experimental|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
11479489|NCT01498016|Experimental|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
11479490|NCT01498003|Placebo Comparator|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
11479491|NCT01498003|Experimental|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
11479492|NCT01497990|Experimental|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
11479493|NCT01497977|Experimental|soya phytoestrogens|
11479494|NCT01497977|Experimental|red clover phytoestrogens|
11479495|NCT01497977|No Intervention|No drugs|
11479496|NCT01497964|Experimental|Cabazitaxel|Cabazitaxel, several dosages
11479497|NCT01497951|Experimental|Aminolaevulinic acid|
11479498|NCT01497951|Placebo Comparator|Placebo|
11479499|NCT01497938|Experimental|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
11479500|NCT01497938|Experimental|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
11479501|NCT01497925|Experimental|ADI-PEG 20|
11479502|NCT01497912|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
11479503|NCT01497912|Placebo Comparator|Placebo|Matched placebo tablets
11479504|NCT01497899|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
11479505|NCT01497899|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
11479506|NCT01497899|Experimental|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.
~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
11479507|NCT01497886|Active Comparator|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
11479508|NCT01497886|Placebo Comparator|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
11479509|NCT01497873|Experimental|Belotecan|Camtobell Injection
11479510|NCT01497873|Active Comparator|Topotecan|Hycamtin Injection
11479511|NCT01497860|Experimental|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
11479512|NCT01497847||travelers to tropical destinations|
11479513|NCT01497834|Experimental|Daclatasvir + Asunaprevir|
11479514|NCT01497821|Experimental|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
11479515|NCT01497821|Experimental|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
11479516|NCT01497808|Experimental|Phase 1|
11479517|NCT01497808|Experimental|Phase 2|
11479518|NCT01497782|Experimental|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
11479519|NCT01497782|No Intervention|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
11479520|NCT01497769|Experimental|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
11479521|NCT01497769|Experimental|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
11479522|NCT01497756|Experimental|CAPP application|Patients in whom device is used
11479523|NCT01497743|Placebo Comparator|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
11479524|NCT01497743|Active Comparator|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
11479525|NCT01497730||CR FB|Subjects receiving a Cruciate Retaining Fixed Bearing implant configuration
11479526|NCT01497730||PS FB|Subjects Receiving a Posterior Stabilized Fixed Bearing implant configuration
11479527|NCT01497730||CR RP|Subjects receiving a Cruciate Retaining Rotating Platform implant configuration
11479528|NCT01497730||PS RP|Subjects receiving a Posterior Stabilized Rotating Platform implant configuration
11479529|NCT01497717|Experimental|Adalimumab, Behcet with arthritis|
11479530|NCT01497704|Experimental|YN968D1|Active therapy arm for safety evaluation
11479531|NCT01497691|Other|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
11479575|NCT01497353|Experimental|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
11479532|NCT01497691|Sham Comparator|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
11479533|NCT01497691|Active Comparator|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
11479534|NCT01497678|Other|Extracellular Matrix|Implantation of Extracellular Matrix
11479535|NCT01497665|Experimental|GRN1005 alone|GRN1005 alone
11479536|NCT01497652|Active Comparator|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
11479537|NCT01497652|Placebo Comparator|Placebo Group|will receive placebo daily
11479538|NCT01497639|Active Comparator|Process 1|"Visit 1: Baseline evaluation (maximum 1 week before operation)
~Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).
~Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).
~Visit 4 Final evaluation. (28th postoperative week)."
11479539|NCT01497639|Active Comparator|Process 2|"Visit 1: Baseline evaluation (maximum 1 week before operation)
~Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).
~Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).
~Visit 4 Final evaluation. (28th postoperative week)."
11479540|NCT01497626|Experimental|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
11479541|NCT01497613|Active Comparator|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
11479542|NCT01497613|Experimental|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
11479543|NCT01497600|Experimental|insulin detemir|
11479544|NCT01497600|Active Comparator|insulin NPH|
11479545|NCT01497587|Experimental|Insulin detemir|
11479546|NCT01497574|Experimental|Insulin detemir|
11479547|NCT01497574|Active Comparator|Insulin glargine|
11479548|NCT01497561|Experimental|insulin detemir|
11479549|NCT01497561|Active Comparator|insulin NPH|
11479550|NCT01497548|Experimental|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
11479551|NCT01497548|Placebo Comparator|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
11479552|NCT01497535|Experimental|Insulin detemir|
11479553|NCT01497535|Active Comparator|Insulin glargine|
11479554|NCT01497522|Experimental|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
11479555|NCT01497522|Placebo Comparator|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
11479556|NCT01497509|Experimental|Patients electing to receive intrapartum epidural analgesia|
11479557|NCT01497509|No Intervention|Patients electing not to receive epidural analgesia|
11479558|NCT01497496|Experimental|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
11479559|NCT01497483|Active Comparator|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
11479560|NCT01497483|Experimental|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
11479561|NCT01497470|Experimental|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
11479562|NCT01497457|Experimental|MR saline peritoneography|Patients that will undergo MR saline peritoneography
11479563|NCT01497444|Experimental|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
11479564|NCT01497431|Experimental|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
11479565|NCT01497431|Experimental|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
11479566|NCT01497431|Placebo Comparator|Arm III (placebo)|Participants receive placebo PO on days 1-84.
11479567|NCT01497405|Active Comparator|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
11479568|NCT01497405|Experimental|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
11479569|NCT01497392|Experimental|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11479570|NCT01497379|Experimental|intra-individual implant ON|intra-individual implant activation
11479571|NCT01497379|Placebo Comparator|intra-individual implant OFF|intra-individual implant deactivation
11479572|NCT01497366|Experimental|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
11479573|NCT01497366|Active Comparator|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
11479574|NCT01497353|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
11479618|NCT01497080||activity level|
11479576|NCT01497340|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
11479577|NCT01497340|Experimental|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
11479578|NCT01497327|Experimental|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
11479579|NCT01497327|Experimental|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
11479580|NCT01497327|Experimental|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
11479581|NCT01497327|Experimental|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
11479582|NCT01497327|Experimental|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
11479583|NCT01497327|Experimental|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
11479584|NCT01497314|Other|Low Lactose Infant Formula|
11479585|NCT01497301|No Intervention|Standard Individual Medical Appointment|
11479586|NCT01497301|Active Comparator|Group Visits|
11479587|NCT01497288|Experimental|Sequence 1 (A-B-C)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1
~B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment
~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
11479588|NCT01497288|Experimental|Sequence 2 (A-C-B)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1
~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment
~B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
11479589|NCT01497275|Experimental|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
~Other Names:
~Rituxan Velcade Zevalin
~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
11479590|NCT01497262|Experimental|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
11479591|NCT01497249|Placebo Comparator|Placebo|Placebo Beverage
11479592|NCT01497249|Active Comparator|A dietary fiber (FCHO)|15g/BID
11479593|NCT01497236|Experimental|Experimental: Ready to Use Terapeutic Food (RUTF)|
11479594|NCT01497236|Experimental|Multi Micronutrient Powder (MNP)|
11479595|NCT01497236|No Intervention|no supplement|
11479596|NCT01497223|Experimental|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
11479597|NCT01497223|No Intervention|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
11479598|NCT01497210|Experimental|EASH|
11479599|NCT01497197|Experimental|Gonal-f®+Luveris®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
11479600|NCT01497197|Experimental|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
11479601|NCT01497184|Experimental|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
11479602|NCT01497184|Experimental|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
11479603|NCT01497184|Experimental|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
11479604|NCT01497184|Experimental|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
11479605|NCT01497171|Active Comparator|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
11479606|NCT01497171|Active Comparator|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
11479607|NCT01497158|Active Comparator|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
11479608|NCT01497158|Active Comparator|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
11479609|NCT01497132|Experimental|Vitamin D3|
11479610|NCT01497132|Placebo Comparator|Placebo|
11479611|NCT01497119|Experimental|JNJ-39758979, 300 mg|
11479612|NCT01497119|Experimental|JNJ-39758979, 100 mg|
11479613|NCT01497119|Placebo Comparator|Placebo|
11479614|NCT01497106|Experimental|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
11479615|NCT01497106|Active Comparator|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
11479616|NCT01497093|Experimental|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
11479617|NCT01497080||1|
11479623|NCT01497015|Experimental|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
11479624|NCT01497015|Experimental|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
11479625|NCT01497015|Experimental|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
11479626|NCT01497002|Active Comparator|standard arm|standard treatment arm
11479627|NCT01497002|Experimental|OSHO - intensified consolidation|Intermediate dose AraC
11479628|NCT01497002|Experimental|OSHO - allografting as consolidation|allogeneic stem cell Transplantation versus no transplantation
11479629|NCT01496989|Experimental|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
11479630|NCT01496989|Experimental|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
11479631|NCT01496989|Experimental|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
11479632|NCT01496989|Experimental|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
11479633|NCT01496989|Experimental|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
11479634|NCT01496976|Experimental|Immunotherapy|Combination Regimen Followed by Consolidative Therapy: Ofatumumab/High Dose Methylprednisolone (HDMP) plus Ofatumumab/Lenalidomide
11479635|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) <36 mmHg or a tricuspid regurgitant jet velocity (TG) <3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50%
11479636|NCT01496963||group b)|"Patients with:
~PAP estimated (by echocardiography)> 40 mmHg or TG> 3.2 m / sec and LVEF> 50% As indicated by the Guidelines, patients b) with increased PAP (TG> 3.2 m / sec or> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
11479637|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values > 3 m / sec (TG) and <3.2 m / sec or> 36 mm Hg and <40 mmHg and LVEF> 50%
11479638|NCT01496950|Active Comparator|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
11479639|NCT01496950|Placebo Comparator|Placebo|10Hz placebo rTMS delivered to the vertex
11479640|NCT01496937|Experimental|GLPG0974 oral solution|GLPG0974 oral solution
11479641|NCT01496937|Placebo Comparator|Placebo oral solution|Placebo oral solution
11479642|NCT01496924|Other|speech therapy group|All dysphagic patients will be submitted to speech therapy
11479643|NCT01496911|Experimental|Levocetirizine (5 mg)|
11479644|NCT01496911|Active Comparator|Hydroxyzine (50 mg)|
11479645|NCT01496911|Placebo Comparator|Placebo|
11479646|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
11479647|NCT01496859|Experimental|Baska|
11479648|NCT01496846|Active Comparator|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
11479649|NCT01496846|Active Comparator|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
11479650|NCT01496846|Active Comparator|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
11479651|NCT01496833|Experimental|Endovascular|Total endovascular arch reconstruction
11479652|NCT01496820|Experimental|GO2KA1|
11479653|NCT01496820|Placebo Comparator|Placebo|
11479654|NCT01496807|Experimental|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
11479655|NCT01496794||Endophthalmitis cultures|
11479656|NCT01496781|Experimental|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
11479657|NCT01496781|Active Comparator|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
11479658|NCT01496768|Experimental|Leucine|
11479659|NCT01496768|Placebo Comparator|Alanine|
11479660|NCT01496755|Placebo Comparator|Placebo|
11479661|NCT01496755|Experimental|RG7667|
11479662|NCT01496742|Experimental|Bevacizumab+MetMAb|
11479663|NCT01496742|Active Comparator|Bevacizumab+Placebo|
11479664|NCT01496742|Experimental|Pemetrexed+MetMAb|
11479665|NCT01496742|Active Comparator|Pemetrexed+Placebo|
11479666|NCT01496729|Active Comparator|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
11479667|NCT01496729|Sham Comparator|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
11479668|NCT01496716||Hip Osteoarthritis|
11479669|NCT01496703||renal transplantation with MMF from day 1|
11479670|NCT01496690|Active Comparator|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
11479671|NCT01496690|Placebo Comparator|Pregabalin Placebo Capsules|
11479672|NCT01496677|Experimental|Elderly subjects (65 or older)|
11479673|NCT01496677|Experimental|Younger adults (18-45 years old)|
11479674|NCT01496664|Experimental|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
11479675|NCT01496651|Active Comparator|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
11480237|NCT01492686|Placebo Comparator|Arm 2|
11479676|NCT01496651|Active Comparator|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
11479677|NCT01496638|Experimental|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
11479678|NCT01496638|Experimental|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
11479679|NCT01496625||1|Participants with and without a variety of retinal conditions.
11479680|NCT01496599||Healthy Volunteers|Subjects without PD diagnosis
11479681|NCT01496599||Parkinsons Disease subjects|Subjects fitting the MSD Clinical Diagnostic Criteria for PD
11479682|NCT01496599||Prodromal Parkinson disease|Subjects fitting the MDS prodromal criteria for PD
11479683|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
11479684|NCT01496547|Experimental|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
11479685|NCT01496534|Active Comparator|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
11479686|NCT01496534|Active Comparator|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
11479687|NCT01496521|Experimental|Aspirin|
11479688|NCT01496521|Experimental|Tea Polyphenols|
11479689|NCT01496521|No Intervention|Control|
11479690|NCT01496508|Experimental|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min.
11479691|NCT01496508|Experimental|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to <60/min. The weaning process was initiated when the following parameters were achieved: PIP <18 cmH2O, PEEP <4 cmH2O, and FIO2 <0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
11479692|NCT01496495|Experimental|ARRY-614|
11479693|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
11479694|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
11479695|NCT01496469|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
11479696|NCT01496469|Placebo Comparator|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
11479697|NCT01496456|Placebo Comparator|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
11479698|NCT01496456|Active Comparator|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
11479699|NCT01496443|Experimental|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
11479700|NCT01496430|Placebo Comparator|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
11479701|NCT01496430|Experimental|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
11479702|NCT01496430|Experimental|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
11479703|NCT01496417|Experimental|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
11479704|NCT01496404|Experimental|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
11479705|NCT01496404|Active Comparator|Scalpel|Control, incision of epidermis and dermis with scalpel.
11479706|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m^2, healthy prospective kidney donor
11479707|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m^2
11479708|NCT01496391||Severe Renal Function Impairment|eGFR <30 mL/minute/1.73m^2
11479709|NCT01496378|Experimental|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
11479710|NCT01496378|No Intervention|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
11479711|NCT01496365|Experimental|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
11479712|NCT01496365|Experimental|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
11479713|NCT01496365|Experimental|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
11479714|NCT01496365|Experimental|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
11480185|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
11479715|NCT01496365|Experimental|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
11479716|NCT01496365|Active Comparator|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
11479717|NCT01496352|Experimental|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
11479718|NCT01496352|Placebo Comparator|DFA-02 placebo|
11479719|NCT01496339|Active Comparator|Traditional therapy control|
11479720|NCT01496339|Experimental|Stem cell infusion|
11479721|NCT01496326|Experimental|Ibuprofen|
11479722|NCT01496326|Placebo Comparator|Placebo|
11479723|NCT01496313|Active Comparator|300mg vandetanib|
11479724|NCT01496313|Active Comparator|150mg vandetanib|
11479725|NCT01496300|Sham Comparator|Manual|Manual Implantation of THA
11479726|NCT01496300|Experimental|Navigated|Navigated Implantation of THA
11479727|NCT01496287|Experimental|Tube placement group|
11479728|NCT01496274|Experimental|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.
~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
11479729|NCT01496274|Experimental|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
11479730|NCT01496261|Active Comparator|Clopidogrel and Aspirin|
11479731|NCT01496261|Experimental|Coprigerl|
11479732|NCT01496248|Experimental|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
11479733|NCT01496235|Active Comparator|Dark chocolate|Presence of 70% cocoa solids
11479734|NCT01496235|Placebo Comparator|White chocolate|
11479735|NCT01496209|Sham Comparator|Placebo control|
11479736|NCT01496209|Experimental|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
11479737|NCT01496196|Active Comparator|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
11479738|NCT01496196|Placebo Comparator|tranexamic|placebo arm
11479739|NCT01496183|Placebo Comparator|Placebo|
11479740|NCT01496183|Experimental|Olanzapine|
11479741|NCT01496170|Experimental|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
11479742|NCT01496170|Experimental|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
11479743|NCT01496170|Placebo Comparator|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
11479744|NCT01496170|Experimental|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
11479745|NCT01496170|Placebo Comparator|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
11479746|NCT01496157|Experimental|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
11479747|NCT01496144|Experimental|Manual therapy and active exercises|Spinal manipulation /mobilisation
11479748|NCT01496144|Placebo Comparator|Detuned ultrasound and active exercises|
11479749|NCT01496131|Active Comparator|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
11479750|NCT01496131|Experimental|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
11479751|NCT01496118|Experimental|Carfilzomib and Panobinostat|
11479752|NCT01496105|Active Comparator|lidocaine spray 10%|
11479753|NCT01496105|Placebo Comparator|Saline|
11479754|NCT01496092|Experimental|Keto Acid supplemented with usual protein diet|
11479755|NCT01496092|No Intervention|usual protein diet|
11479756|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (< 20 weeks gestation) and their infants
11479757|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
11479758|NCT01496066|Experimental|LAL|LAL implanted
11479759|NCT01496066|Active Comparator|Monofocal control|Monofocal control IOL implanted
11479760|NCT01496053|Active Comparator|AndoSan|AndoSan given to IBD patients
11479761|NCT01496053|Sham Comparator|Sugar extract|Sugar extract to IBD patients
11479762|NCT01496040|Experimental|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.
~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
11479763|NCT01496027||term newborns|
11479764|NCT01496027||Preterm Newborns (32-37 GA)|
11479765|NCT01496014||severe open fractures of the tibia bone|
11479766|NCT01496001|Experimental|Cohort|
11479767|NCT01495988|Active Comparator|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
11479768|NCT01495988|Experimental|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
11480186|NCT01493128||stable sinus rhythm|
11479769|NCT01495988|Active Comparator|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
11479770|NCT01495988|Experimental|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
11479771|NCT01495975|No Intervention|Usual Care|Usual care for diabetes in the 1 month after discharge.
11479772|NCT01495975|Experimental|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
11479773|NCT01495962|Active Comparator|Botulinum Toxin A injection|
11479774|NCT01495962|Placebo Comparator|Placebo (Normal Saline) injection|
11479775|NCT01495949|Active Comparator|etomidate|
11479776|NCT01495949|Active Comparator|thiopentone|
11479777|NCT01495936|Active Comparator|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
11479778|NCT01495936|Active Comparator|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
11479779|NCT01495923|Experimental|Epidural steroids|Injection of steroids into the epidural space
11479780|NCT01495923|Active Comparator|Gabapentin|Titration of gabapentin to effect
11479781|NCT01495910|Experimental|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
11479782|NCT01495897|Other|Healthy|Healthy volunteers
11479783|NCT01495897|Experimental|Dystonia|patients with Primary Dystonia
11479784|NCT01495897|Experimental|Parkinson|patients with Parkinson's disease
11479785|NCT01495897|Experimental|Essential tremor|patients with essential tremor with or without deep brain stimulation
11479786|NCT01495884|Experimental|Lapatinib (Tyverb™) and (Myocet™)|
11479787|NCT01495871|Active Comparator|Amino acids|Amino acid supplementation for 6 weeks
11479788|NCT01495871|Placebo Comparator|Placebo|Supplementation of placebo (inert components)for 6 weeks
11479789|NCT01495871|Active Comparator|Valine|Valine supplementation for 6 weeks
11479790|NCT01495858|Experimental|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
11479791|NCT01495858|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
11479792|NCT01495858|Active Comparator|DPH 50 mg|
11479793|NCT01495832|Experimental|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
11479794|NCT01495832|Active Comparator|Control Group|The control group will consume comparator foods for 12 weeks.
11479795|NCT01495819|Active Comparator|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
11479796|NCT01495819|Placebo Comparator|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
11479797|NCT01495806|Experimental|Glucomannan|5 g 2x 10 day
11479798|NCT01495806|Placebo Comparator|Placebo|
11479799|NCT01495793|Experimental|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
11479800|NCT01495780|Experimental|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
11479801|NCT01495767||females, males|females: patients of female sex males: patients of male sex
11479802|NCT01495754|Experimental|coffee3|
11479803|NCT01495754|Experimental|coffee6|
11479804|NCT01495754|Placebo Comparator|water|
11479805|NCT01495741||Asenapine|Participants prescribed asenapine
11479806|NCT01495741||Risperidone Comparator|Participants prescribed risperidone
11479807|NCT01495741||Olanzapine Comparator|Participants prescribed olanzapine
11479808|NCT01495728|Experimental|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
11479809|NCT01495728|Placebo Comparator|Sham Manipulation|Mid and Upper Thoracic Spine
11479810|NCT01495715|Experimental|Idebenone|
11479811|NCT01495715|Placebo Comparator|Placebo|
11479812|NCT01495702|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
11479813|NCT01495702|Active Comparator|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
11480187|NCT01493128||permanent atrial fibrillation|
11480188|NCT01493128||paroxysmal atrial fibrillation|
11479814|NCT01495689|Active Comparator|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
11479815|NCT01495689|Experimental|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
11479816|NCT01495676|Active Comparator|Radiotherapy + cisplatin|
11479817|NCT01495676|Experimental|Radiotherapy + cisplatin + gemcitabine|
11479818|NCT01495663|Other|Single Group|I-131-CLR1404
11479819|NCT01495650|Experimental|Intervention arm|
11479820|NCT01495650|No Intervention|Control arm|Routine practice
11479821|NCT01495637|Experimental|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
11479822|NCT01495624|Placebo Comparator|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
11479823|NCT01495624|Active Comparator|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
11479824|NCT01495598|Experimental|1/Phase 1|Up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle
11479825|NCT01495598|Experimental|2/ Phase 2|15 HIV positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mgdaily for 21 days of a 28 day cycle
11479826|NCT01495585|Placebo Comparator|Placebo|Placebo control
11479827|NCT01495585|Experimental|Group 1|lonafarnib 100mg
11479828|NCT01495585|Experimental|Group 2|lonafarnib 200mg
11479829|NCT01495572|Experimental|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
11479830|NCT01495572|Experimental|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0
11479831|NCT01495546|Experimental|Early loading|
11479832|NCT01495546|Active Comparator|late loading|
11479833|NCT01495533|Placebo Comparator|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
11479834|NCT01495533|Active Comparator|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
11479835|NCT01495520|Active Comparator|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
11479836|NCT01495520|Placebo Comparator|Placebo|Patients will receive placebo for 30 days
11479837|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
11479838|NCT01495494|Active Comparator|Marketed nasal strip|Marketed nasal strip
11479839|NCT01495494|Experimental|Prototype nasal dilator|Prototype nasal dilator
11479840|NCT01495481|Experimental|Adenosine and Dexmedetomidine|Patients will receive adenosine and then dexmedetomidine for the termination of SVT
11479841|NCT01495455||Knee osteoarthritis|
11479842|NCT01495455||No knee pain/osteoarthritis|
11479843|NCT01495442|Active Comparator|modified Handihaler DPI|
11479844|NCT01495442|Placebo Comparator|standard Handihaler DPI|
11479845|NCT01495429|Experimental|PICC line (Peripherally)|placement of a picc line
11479846|NCT01495429|Active Comparator|CICVC (central insertion)|placement of a centrally inserted central venous catheter
11479847|NCT01495403|Experimental|hydroxychloroquine|
11479848|NCT01495377|Active Comparator|Remifentanil|
11479849|NCT01495377|Placebo Comparator|Placebo|
11479850|NCT01495377|Experimental|Technetium|
11479851|NCT01495377|Experimental|Dynamometer|
11479852|NCT01495364|Experimental|NBS10|active treatment - CD34+ cells
11479853|NCT01495364|Placebo Comparator|placebo|matching placebo
11479854|NCT01495351|Experimental|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
11479855|NCT01495338|Experimental|AC-170 0.17%|
11479856|NCT01495338|Experimental|AC-170 0.24% (Formulation 1)|
11479857|NCT01495338|Experimental|AC-170 0.24% (Formulation 2)|
11479858|NCT01495338|Placebo Comparator|Olopatadine hydrochloride 0.2%/Tears Naturale II|
11479859|NCT01495325|Sham Comparator|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
11479860|NCT01495325|Active Comparator|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
11479861|NCT01495312|Experimental|SLT|
11479862|NCT01495299||cataract patients with glaucoma|
11479863|NCT01495273|Experimental|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
11479864|NCT01495273|Active Comparator|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
11479865|NCT01495260|Experimental|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
11479866|NCT01495247|Experimental|BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
11479867|NCT01495247|Experimental|BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days
11479868|NCT01495234|Experimental|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
11479869|NCT01495234|Experimental|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
11479870|NCT01495221|Other|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
11479871|NCT01495208|Experimental|aflibercept|
11479872|NCT01495195|Experimental|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
11479873|NCT01495195|Experimental|Selegiline & low-dose donepezil|Low-Dose Donepezil [titrated to 10 mg daily] and transdermal selegiline [6 mg daily]
11479874|NCT01495195|Experimental|Selegiline & high-dose donepezil|High-Dose Donepezil [titrated to 22.5 mg daily] and transdermal selegiline [6 mg daily]
11479875|NCT01495195|Placebo Comparator|Sugar pill|Inert pill for comparison
11479876|NCT01495182|Experimental|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
11479877|NCT01495182|Experimental|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
11479878|NCT01495182|Active Comparator|Control|Study foods with no added fiber will be given
11479879|NCT01495169|Experimental|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
11479880|NCT01495156|Experimental|Lithium/Adjunctive SGA|
11479881|NCT01495156|Placebo Comparator|Placebo/Adjunctive SGA|
11479882|NCT01495143|Active Comparator|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
11479883|NCT01495143|Experimental|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.
~A reference catheter is placed in the deltoid muscle."
11479884|NCT01495130|Experimental|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
11479885|NCT01495117|Active Comparator|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
11479886|NCT01495117|Active Comparator|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
11479887|NCT01495104|Experimental|Single Arm|
11479888|NCT01495078|Experimental|Telemonitoring|Patients with follow-up telemonitoring
11479889|NCT01495078|No Intervention|Non - telemonitoring|Patients with usual face follow-up
11479890|NCT01495065|Experimental|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
11479891|NCT01495065|Experimental|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
11479892|NCT01495052|No Intervention|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
11479893|NCT01495052|No Intervention|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
11479894|NCT01495052|Experimental|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
11479895|NCT01495052|Experimental|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
11479896|NCT01495039|Active Comparator|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
11479897|NCT01495039|Placebo Comparator|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
11479898|NCT01495026|Experimental|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
11479899|NCT01495026|Experimental|Dutasteride|Commercial formulation of Dutasteride 0.5mg
11479900|NCT01495026|Experimental|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
11479901|NCT01495013|Active Comparator|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
11479902|NCT01495013|Active Comparator|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
11479903|NCT01495000|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
11479904|NCT01495000|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
11479949|NCT01494662|Active Comparator|Cohort 3a/3b|"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.
~Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest."
11480235|NCT01492699|Experimental|PRX-03140|PRX-03140 for the treatment of PTSD
11479905|NCT01494987|Experimental|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.
~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.
~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.
~Participants will be required to maintain their diet and exercise regimen."
11479906|NCT01494987|Placebo Comparator|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.
~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.
~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.
~Participants will be required to maintain their diet and exercise regimen."
11479907|NCT01494974|Active Comparator|FP7 implant|
11479908|NCT01494974|Active Comparator|FP8 implant|
11479909|NCT01494961|Experimental|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
11479910|NCT01494961|No Intervention|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
11479911|NCT01494948|Placebo Comparator|placebo|skin test negative
11479912|NCT01494948|Active Comparator|allergic|Skin test positive
11479913|NCT01494935|Experimental|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
11479914|NCT01494935|Experimental|High-fat, high-glycemic diet|High-fat, high-glycemic diet
11479915|NCT01494922|Experimental|Open Label|
11479916|NCT01494909|Experimental|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
11479917|NCT01494883|No Intervention|Treatment as usual|
11479918|NCT01494883|Experimental|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
11479919|NCT01494857|Experimental|Adalimumab|Adalimumab 40 mg
11479920|NCT01494844|Other|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
11479921|NCT01494831|Experimental|TF-CBT|
11479922|NCT01494831|No Intervention|Waiting List control|
11479923|NCT01494818|Experimental|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
11479924|NCT01494818|Active Comparator|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
11479925|NCT01494805|Experimental|Low Dose rAAV.sFlt-1|
11479926|NCT01494805|Experimental|High Dose rAAV.sFlt-1|
11479927|NCT01494805|Active Comparator|Control - ranibizumab only|
11479928|NCT01494779|Experimental|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
11479929|NCT01494779|Active Comparator|Saizen|Somatropin of Merck Serono
11479930|NCT01494766|Other|Tyrosine|"Dietary Supplement: L-Tyrosine
~Other Names:
~NOW Brand L-Tyrosine 750 mg Tablets
~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
11479931|NCT01494753|Active Comparator|Prostaglandin|One drop.
11479932|NCT01494753|Experimental|T2345|One drop
11479933|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
11479934|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
11479935|NCT01494740|Placebo Comparator|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
11479936|NCT01494727|Experimental|CJ Amlodipine/Valsartan 10/160mg|
11479937|NCT01494727|Active Comparator|Novartis Exforge 10/160mg|
11479938|NCT01494714|Experimental|Closed-patch test|
11479939|NCT01494701|Experimental|Cohort 1 (n=6)|
11479940|NCT01494701|Experimental|Cohort 2 (n=6)|
11479941|NCT01494701|Experimental|Cohort 3 (n=6)|
11479942|NCT01494701|Experimental|Cohort 4 (n=10)|
11479943|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
11479944|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter [mg/m^2]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
11479945|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
11479946|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m^2).
11479947|NCT01494662|Active Comparator|Cohort 1|"Patients With Progressive Brain Metastases
~Intervention: HKI-272 (Neratinib)340 mg orally, once daily."
11479948|NCT01494662|Active Comparator|Cohort 2|"Patients Who Are Candidates For Craniotomy.
~Intervention: HKI-272 (Neratinib) 240 mg orally, once daily.
~Surgical resection (biopsy).
~Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib."
11479996|NCT01494389||sepsis|SIRS + infection
11479950|NCT01494662|Active Comparator|Cohort 4a/4b/4c|"Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.
~Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.
~Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks."
11479951|NCT01494649|Active Comparator|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste [test]
11479952|NCT01494649|Other|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste [negative control]
11479953|NCT01494636|Experimental|GSK2339345 (solution) (part A)|Part A
11479954|NCT01494636|Experimental|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
11479955|NCT01494623|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
11479956|NCT01494623|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
11479957|NCT01494610|Experimental|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
11479958|NCT01494610|Active Comparator|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
11479959|NCT01494610|Placebo Comparator|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
11479960|NCT01494610|Placebo Comparator|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
11479961|NCT01494597|Experimental|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
11479962|NCT01494584|Experimental|ezogabine/retigabine|ezogabine dose escalation
11479963|NCT01494571||90 pediatric, 7 to 14 year old subjects|
11479964|NCT01494571||30 pediatric, 5 to 6 year old subjects|
11479965|NCT01494571||30 pediatric, 3 to 4 year old subjects|
11479966|NCT01494571||30 pediatric, 1 to 2 year old subjects|
11479967|NCT01494571||30 pediatric, 6 to 12 month old subjects|
11479968|NCT01494571||30 pediatric, 4 to 6 month old subjects|
11479969|NCT01494571||30 pediatric, 2 to 4 month old subjects|
11479970|NCT01494558|Active Comparator|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
11479971|NCT01494558|Active Comparator|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
11479972|NCT01494545|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks. A new pair was inserted each day.
11479973|NCT01494532|Experimental|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
11479974|NCT01494532|Placebo Comparator|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
11479975|NCT01494519|Active Comparator|Treament Arm 1|Definitive fixation with an external ring fixator.
11479976|NCT01494519|Active Comparator|Treatment arm 2|Definitive fixation with a locked IM nail or plate
11479977|NCT01494506|Experimental|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
11479978|NCT01494506|Active Comparator|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
11479979|NCT01494506|Experimental|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
11479980|NCT01494493|Experimental|rhBMP-2/ACS|
11479981|NCT01494493|Active Comparator|Autogenous Bone|
11479982|NCT01494480|Experimental|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
11479983|NCT01494467|Experimental|CD5024|CD5024 1% Cream
11479984|NCT01494467|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
11479985|NCT01494454|Experimental|rhBMP-2/BCP|
11479986|NCT01494454|Active Comparator|Autograft|
11479987|NCT01494441|Experimental|rhBMP-2/BCP|
11479988|NCT01494441|Experimental|rhBMP-2/BCP/TSRH® Spinal System|
11479989|NCT01494441|Active Comparator|Autograft/TSRH® Spinal System|
11479990|NCT01494428|Experimental|rhBMP-2/ACS|
11479991|NCT01494428|Active Comparator|Autogenous Bone|
11479992|NCT01494415|Experimental|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
11479993|NCT01494402|Experimental|D961S|2 way crossover
11479994|NCT01494402|Experimental|esomeprazole + buffered acetylsalicylic acid|2 way crossover
11479995|NCT01494389||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
11479998|NCT01494350|Experimental|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
11479999|NCT01494337|Active Comparator|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
11480000|NCT01494337|Active Comparator|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
11480001|NCT01494324|Experimental|CT guided percutaneous ablation|The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.
11480002|NCT01494311|Active Comparator|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
11480003|NCT01494311|Experimental|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
11480004|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
11480005|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
11480006|NCT01494285|Experimental|ARK-E021 5% foam|
11480007|NCT01494285|Experimental|ARK-E021 10% foam|
11480008|NCT01494285|Placebo Comparator|Placebo foam|
11480009|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
11480010|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
11480011|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
11480012|NCT01494259|Experimental|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
11480013|NCT01494259|Placebo Comparator|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
11480014|NCT01494246|Experimental|electronic mail|
11480015|NCT01494246|No Intervention|brief advise|
11480016|NCT01494233|Experimental|Low dose|500 mg LX1033 two times daily
11480017|NCT01494233|Experimental|Mid dose|500 mg LX1033 three times daily
11480018|NCT01494233|Experimental|High dose|1000 mg LX1033 two times daily
11480019|NCT01494233|Placebo Comparator|Placebo|Matching placebo dosing
11480020|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
11480021|NCT01494207|Experimental|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
11480022|NCT01494194|Placebo Comparator|placebo for food challenge|
11480023|NCT01494194|Experimental|ASP Skin prick solution|
11480024|NCT01494194|Experimental|ASP sorbet|
11480025|NCT01494155|Experimental|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
11480026|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
11480027|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
11480028|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
11480029|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
11480030|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
11480031|NCT01494116|Experimental|10 mL syringe size|
11480032|NCT01494116|Experimental|20 mL syringe size|
11480033|NCT01494116|Experimental|30 mL syringe size|
11480034|NCT01494116|Experimental|60 mL syringe size|
11480035|NCT01494103|Experimental|iCaspase9-transduced T cells|"The 5 dose levels are:
~1 x 10^4 T cells/kg
~1 x 10^5 T cells/kg
~5 x 10^5 T cells/kg
~1 x 10^6 T cells/kg
~5 x 10^6 T cells/kg
~AP1903 will be administered if there is development of Grade 1 or greater GvHD."
11480036|NCT01494090|Active Comparator|Rosuvastatin|
11480037|NCT01494090|Placebo Comparator|placebo|
11480038|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
11480039|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
11480040|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
11480041|NCT01494051|Active Comparator|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
11480042|NCT01494051|Experimental|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
11480043|NCT01494038|Experimental|Arm A (Immediate INH Treatment)|Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
11480044|NCT01494038|Experimental|Arm B (Deferred INH Treatment)|Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
11480045|NCT01494025|Experimental|Diet and Exercise|
11480046|NCT01494012|Experimental|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
11480047|NCT01493999|Active Comparator|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
11480048|NCT01493999|Active Comparator|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
11480049|NCT01493973|Experimental|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
11480050|NCT01493973|Placebo Comparator|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
11480051|NCT01493960|Experimental|Cobitolimod|2 doses 4 weeks apart
11480052|NCT01493960|Placebo Comparator|Placebo|2 doses 4 weeks apart
11480053|NCT01493947|Experimental|Ivermectin 1% cream|
11480054|NCT01493947|Active Comparator|Metronidazole 0.75% cream|
11480055|NCT01493934|Active Comparator|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
11480056|NCT01493934|Experimental|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
11480057|NCT01493921|Experimental|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
11480058|NCT01493921|Active Comparator|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
11480059|NCT01493908|Active Comparator|High price|
11480060|NCT01493908|Active Comparator|Low price|
11480061|NCT01493908|Active Comparator|Low price participants aware paying part|
11480062|NCT01493908|Active Comparator|No price|
11480063|NCT01493908|Active Comparator|Free of charge|
11480064|NCT01493895|Active Comparator|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
11480065|NCT01493895|Experimental|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
11480066|NCT01493882|Placebo Comparator|Placebo|
11480067|NCT01493882|Experimental|JNJ-39758979 30 mg/d|
11480068|NCT01493882|Experimental|JNJ-39758979 100 mg/d|
11480069|NCT01493882|Experimental|JNJ-39758979 300 mg/d|
11480070|NCT01493869|Experimental|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
11480071|NCT01493869|Experimental|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
11480072|NCT01493869|Experimental|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
11480073|NCT01493869|Experimental|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
11480074|NCT01493856|Active Comparator|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
11480075|NCT01493856|Experimental|DWJ1276|Single dose of DWJ1276
11480076|NCT01493843|Experimental|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
11480077|NCT01493843|Placebo Comparator|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle >/= 5).
11480078|NCT01493843|Experimental|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
11480079|NCT01493843|Placebo Comparator|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
11480080|NCT01493843|Experimental|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
11480183|NCT01493154|Experimental|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
11480081|NCT01493843|Placebo Comparator|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
11480082|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
11480083|NCT01493778|Experimental|turoctocog alfa|
11480084|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
11480085|NCT01493752|Active Comparator|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
11480086|NCT01493752|Placebo Comparator|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
11480087|NCT01493739||lymphadenopathy|
11480088|NCT01493726|Experimental|ALKS 9072, Low dose|
11480089|NCT01493726|Experimental|ALKS 9072, Med dose|
11480090|NCT01493726|Experimental|ALKS 9072, High dose|
11480091|NCT01493726|Placebo Comparator|Placebo|
11480092|NCT01493713|Experimental|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
11480093|NCT01493700|Experimental|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
11480094|NCT01493700|Active Comparator|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
11480095|NCT01493687|Experimental|CD5024|CD5024 1% Cream
11480096|NCT01493687|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
11480097|NCT01493674|No Intervention|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
11480098|NCT01493674|Experimental|a suplemented group|two 5-mg tablets of folic acid
11480099|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
11480100|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
11480101|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
11480102|NCT01493648|Experimental|Vitamin D|
11480103|NCT01493648|Placebo Comparator|Placebo|
11480104|NCT01493635|Active Comparator|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
11480105|NCT01493635|Experimental|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
11480106|NCT01493622|Placebo Comparator|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
11480107|NCT01493622|Active Comparator|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
11480108|NCT01493609|No Intervention|Waitlist Control|
11480109|NCT01493609|Experimental|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
11480110|NCT01493596|Other|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
11480111|NCT01493596|Other|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
11480112|NCT01493596|Other|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
11480113|NCT01493596|Other|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
11480114|NCT01493596|Other|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
11480115|NCT01493596|Other|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
11480116|NCT01493583||severely obese women|
11480117|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
11480118|NCT01493583||lean women|
11480119|NCT01493570|Experimental|BI 409306 low dose|Film-coated tablet
11480120|NCT01493570|Experimental|BI 409306 low dose II|Film-coated tablet
11480121|NCT01493570|Experimental|BI 409306 medium dose|Film-coated tablet
11480122|NCT01493570|Experimental|BI 409306 high dose|Film-coated tablet
11480123|NCT01493570|Experimental|Placebo|Film-coated tablet
11480124|NCT01493557|Other|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
11480125|NCT01493557|Active Comparator|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
11480126|NCT01493557|Active Comparator|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
11480127|NCT01493531|Experimental|lesinurad 200 mg + allopurinol|
11480128|NCT01493531|Experimental|lesinurad 400 mg + allopurinol|
11480129|NCT01493531|Placebo Comparator|Placebo + allopurinol|
11480130|NCT01493518|Placebo Comparator|PLACEBO|
11480131|NCT01493518|Experimental|AMG 557|
11480132|NCT01493505|Placebo Comparator|Placebo|Placebo Paclitaxel Carboplatin
11480133|NCT01493505|Active Comparator|AMG 386|AMG 386 Paclitaxel Carboplatin
11480134|NCT01493492||SIRS|"temperature >38 ℃ or <36℃;
~pulse rate>90 beats/min;
~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;
~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
11480135|NCT01493492||sepsis|"Sepsis
~sepsis: SIRS plus infection;
~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;
~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
11480136|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
11480137|NCT01493479|Experimental|Fractionated Initial Zevalin|
11480138|NCT01493466||Normal|normal person under physical examination
11480139|NCT01493466||SIRS|"temperature >38 ℃ or <36℃;
~pulse rate>90 beats/min;
~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;
~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
11480140|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
11480141|NCT01493466||severe sepsis|"severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;
~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
11480142|NCT01493466||death|sepsis patients within 48 hours before death
11480143|NCT01493453|Experimental|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
11480144|NCT01493440|Other|Atosiban|
11480145|NCT01493427|Experimental|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
11480146|NCT01493414|Experimental|INC424|5 - 25 mg twice a day (BID)
11480147|NCT01493401|Experimental|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
11480148|NCT01493388||A|
11480149|NCT01493362||1|Participants with Bulimia Nervosa
11480150|NCT01493362||2|Participants who are healthy controls
11480151|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
11480152|NCT01493349||Uncomplicated diverticular disease|
11480153|NCT01493349||History of complicated diverticular disease|
11480154|NCT01493349||Current complicated diverticular disease|
11480155|NCT01493336|Experimental|Capecitabine RTD|
11480156|NCT01493336|Active Comparator|Xeloda|
11480157|NCT01493323|Experimental|Control|
11480158|NCT01493323|Experimental|Depressive attempters|
11480159|NCT01493310|Experimental|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
11480160|NCT01493310|Active Comparator|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).
~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
11480161|NCT01493297|Other|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
11480162|NCT01493297|Other|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
11480163|NCT01493284|Experimental|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
11480164|NCT01493271|Placebo Comparator|Placebo|
11480165|NCT01493271|Experimental|RO5093151|
11480166|NCT01493258|No Intervention|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
11480167|NCT01493258|Experimental|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
11480168|NCT01493245|Experimental|JNS020QD|
11480169|NCT01493232|Experimental|Denture, edentulous patient, treatment|Dentures with different type of occlusion
11480170|NCT01493232|Experimental|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
11480171|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
11480172|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
11480173|NCT01493206|Experimental|intraoperative radiotherapy|
11480174|NCT01493193|Active Comparator|Endurance training with constant work load|
11480175|NCT01493193|Experimental|Pyramid-Training|
11480176|NCT01493193|Experimental|High-intensity interval training|
11480177|NCT01493180|Experimental|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
11480178|NCT01493180|Active Comparator|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
11480179|NCT01493167|Other|limb casting/splinting|Patient age 0-90 years. Patient treatment requires extremity immobilization
11480180|NCT01493154|Experimental|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
11480181|NCT01493154|Experimental|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
11480182|NCT01493154|Experimental|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
11480184|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
11480189|NCT01493115|Experimental|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
11480190|NCT01493115|Experimental|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
11480191|NCT01493115|Experimental|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
11480192|NCT01493102|Active Comparator|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
11480193|NCT01493102|Active Comparator|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
11480194|NCT01493089|Experimental|Zegerid|Treatment of heartburn with Zegerid
11480195|NCT01493089|Active Comparator|Losec|Treatment of heartburn with Losec
11480196|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
11480197|NCT01493050|Experimental|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
11480198|NCT01493050|Active Comparator|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
11480199|NCT01493037|Other|PICSO|PICSO treatment for 90 minutes
11480200|NCT01493024|Placebo Comparator|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
11480201|NCT01493024|Experimental|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
11480202|NCT01493011|Experimental|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
11480203|NCT01493011|No Intervention|chemotherapy|standard chemotherapy protocol for advanced NSCLC
11480204|NCT01492998|Experimental|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
11480205|NCT01492985|Placebo Comparator|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
11480206|NCT01492985|Experimental|Vaccine arm|
11480207|NCT01492972|Active Comparator|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
11480208|NCT01492972|Experimental|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
11480209|NCT01492959||Insulin human|
11480210|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
11480211|NCT01492920|Experimental|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
11480212|NCT01492920|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
11480213|NCT01492907|Active Comparator|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
11480214|NCT01492907|Active Comparator|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
11480215|NCT01492894|Active Comparator|50% decrease in calcineurin inhibitor|
11480216|NCT01492894|Active Comparator|Rapamune|
11480217|NCT01492881|Experimental|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.
~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
11480218|NCT01492855|Experimental|Operative treatment|
11480219|NCT01492855|Experimental|Conservative treatment|
11480220|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
11480221|NCT01492816|Experimental|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
11480222|NCT01492803|Placebo Comparator|Placebo|Subjects randomized to the placebo arm.
11480223|NCT01492803|Experimental|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
11480224|NCT01492790|Experimental|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
11480225|NCT01492790|Active Comparator|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
11480226|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
11480227|NCT01492764||Control Group|This group receives traditional ablation for this disorder
11480228|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
11480229|NCT01492738|No Intervention|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
11480230|NCT01492738|Active Comparator|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
11480231|NCT01492725|Experimental|Intra-arterial Clot Retrieval after iv tPA|
11480232|NCT01492725|Active Comparator|Standard care iv tPA|
11480233|NCT01492712|Experimental|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
11480234|NCT01492712|Experimental|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
11480238|NCT01492673|Experimental|Cyclophosphamide, Topotecan, and Bevacizumab (CTB)|This is a multi-center, open label phase II study evaluating the safety and efficacy of the novel combination of agents consisting of bevacizumab, cyclophosphamide, and topotecan.
11480239|NCT01492660|Experimental|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
11480240|NCT01492660|Active Comparator|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
11480241|NCT01492647|Experimental|JNJ 10229570-AAA 1.2%|
11480242|NCT01492647|Experimental|JNJ 10229570-AAA 3.6%|
11480243|NCT01492608|Active Comparator|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
11480244|NCT01492608|Placebo Comparator|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
11480245|NCT01492582|Experimental|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
11480246|NCT01492569|Experimental|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
11480247|NCT01492569|Sham Comparator|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
11480248|NCT01492556|Experimental|Etoposide|Etoposide Capsules
11480249|NCT01492543|Experimental|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
11480250|NCT01492530|Experimental|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
11480251|NCT01492530|Active Comparator|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
11480252|NCT01492517|Sham Comparator|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
11480253|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
11480254|NCT01492517|Other|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
11480255|NCT01492517|Other|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
11480256|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
11480257|NCT01492491|No Intervention|standard HFR therapy|standard HFR hemodiafiltration therapy
11480258|NCT01492491|Active Comparator|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
11480259|NCT01492465|Active Comparator|AMG 876|
11480260|NCT01492465|Placebo Comparator|Placebo|
11480296|NCT01492244||Patients with knee pain and a known diagnosis|
11480297|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
11480298|NCT01492218||NovoLet®|
11480261|NCT01492452|No Intervention|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
11480262|NCT01492439|Experimental|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
11480263|NCT01492439|Active Comparator|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
11480264|NCT01492426|Experimental|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
11480265|NCT01492426|Experimental|Telaprevir + Peginterferon alfa-2a + Ribavirin|
11480266|NCT01492413|Experimental|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
11480267|NCT01492413|Experimental|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
11480268|NCT01492413|Experimental|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
11480269|NCT01492413|Experimental|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
11480270|NCT01492400|Experimental|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
11480271|NCT01492400|Active Comparator|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
11480272|NCT01492387|No Intervention|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
11480273|NCT01492387|Experimental|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
11480274|NCT01492374|Experimental|Arm 1: BMS-241027 (0.003 mg/kg)|
11480275|NCT01492374|Experimental|Arm 2: BMS-241027 (0.01 mg/kg)|
11480276|NCT01492374|Experimental|Arm 3: BMS-241027 (0.03 mg/kg)|
11480277|NCT01492374|Experimental|Arm 4: Placebo matching BMS-241027|
11480278|NCT01492361|Experimental|AMR101|
11480279|NCT01492361|Placebo Comparator|Placebo|
11480280|NCT01492348|Experimental|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
11480281|NCT01492348|Active Comparator|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
11480282|NCT01492335|Experimental|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
11480283|NCT01492335|Experimental|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
11480284|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
11480285|NCT01492309|Active Comparator|Active Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
11480286|NCT01492309|Sham Comparator|Sham Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.
11480287|NCT01492296|Active Comparator|conventional fasting|patients were evaluated after fasting for 8 hours
11480288|NCT01492296|Experimental|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
11480289|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
11480290|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
11480291|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
11480292|NCT01492283||cirrhosis|Patients with liver cirrhosis
11480293|NCT01492283||Kontrol groups|Healthy control subjects
11480294|NCT01492257|No Intervention|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
11480295|NCT01492257|Experimental|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
11480299|NCT01492205||Human insulin|
11480300|NCT01492192|Experimental|RCC Patients Antiangiogenic treatment|
11480301|NCT01492179|Active Comparator|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
11480302|NCT01492179|Active Comparator|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
11480303|NCT01492179|Placebo Comparator|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
11480304|NCT01492166||Novolet®|
11480305|NCT01492153||NovoLet® device|
11480306|NCT01492127|No Intervention|Blood test|Blood test :carcinoma in cirrhotic patients
11480307|NCT01492114|Experimental|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
11480308|NCT01492114|Active Comparator|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
11480309|NCT01492101|Experimental|NKTR-102|
11480310|NCT01492101|Active Comparator|Physician's Treatment of Choice|
11480311|NCT01492088|Experimental|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
11480312|NCT01492088|Experimental|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
11480313|NCT01492075|Active Comparator|Continuous infusion|Continuous infusion of LA intraabdominally
11480314|NCT01492075|Experimental|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
11480315|NCT01492062|Experimental|closed-loop control|Multiple Model Predictive Controller
11480316|NCT01492049|Experimental|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
11480317|NCT01492049|Active Comparator|Control|Participants view a video on Essential Hypertension.
11480318|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
11480319|NCT01492023||control|control group: no intervention
11480320|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
11480321|NCT01492010|Experimental|25 g protein|25 g whey protein
11480322|NCT01492010|Experimental|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
11480323|NCT01492010|Experimental|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
11480324|NCT01491997|Active Comparator|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
11480325|NCT01491997|Active Comparator|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
11480326|NCT01491984|Experimental|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
11480327|NCT01491984|Experimental|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
11480328|NCT01491971|Experimental|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
11480329|NCT01491971|Experimental|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
11480330|NCT01491971|Experimental|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
11480331|NCT01491958|Experimental|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
11480332|NCT01491958|Experimental|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
11480333|NCT01491945|Experimental|Ventana Fenestrated Stent Graft System|
11480334|NCT01491932|Experimental|AFQ056|Patients entering the study will be titrated to target dose of AFQ056 twice daily or the highest tolerated dose at weekly intervals.
11480335|NCT01491919|Experimental|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
11480336|NCT01491919|Experimental|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
11480337|NCT01491919|Experimental|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
11480338|NCT01491906|Experimental|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
11480339|NCT01491906|No Intervention|Usual Care|This group will receive usual care
11480340|NCT01491893|Experimental|Dose Level 1 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480341|NCT01491893|Experimental|Dose Level 2 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convention-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480342|NCT01491893|Experimental|Dose Level 3 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480343|NCT01491893|Experimental|Dose Level 4 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480344|NCT01491893|Experimental|Dose Level 5 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^10 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480345|NCT01491893|Experimental|Dose Level 4 (dose de-escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480346|NCT01491893|Experimental|Dose Level 2 (dose expansion)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480347|NCT01491893|Experimental|Dose Level -1 (dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480348|NCT01491893|Experimental|Dose Level -2 (dose expansion)|Participants received a single intratumoral infusion of 1.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480349|NCT01491893|Experimental|Dose Level -1 (selected dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
11480350|NCT01491880|Experimental|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
11480351|NCT01491880|Experimental|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
11480352|NCT01491867|Experimental|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
11480353|NCT01491854|Other|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
11480354|NCT01491841|Experimental|Phase 1: Pixantrone, 55mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 55mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
11480355|NCT01491841|Experimental|Phase 1: Pixantrone, 85mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 85mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
11480356|NCT01491841|Experimental|Phase 1: Pixantrone, 115mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 115mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
11480357|NCT01491815|Active Comparator|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
11480358|NCT01491815|Active Comparator|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
11480359|NCT01491815|Active Comparator|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
11480360|NCT01491815|Active Comparator|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
11480414|NCT01491373|Experimental|rhBMP-2/ACS|
11480361|NCT01491802|Experimental|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product [LAMA plus long-acting beta2-agonist (LABA)] once daily for 4 weeks.
11480362|NCT01491802|Experimental|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
11480363|NCT01491789|Experimental|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
11480364|NCT01491750|Experimental|GUIDED IMAGERY|
11480365|NCT01491750|Placebo Comparator|AUDIO BOOK|
11480366|NCT01491737|Experimental|Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
11480367|NCT01491737|Active Comparator|Arm B: Trastuzumab + AI +/- Chemotherapy|"Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
11480368|NCT01491724||pCLE images|
11480369|NCT01491711|Active Comparator|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
11480370|NCT01491711|Active Comparator|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
11480371|NCT01491698|Experimental|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
11480372|NCT01491698|Active Comparator|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
11480373|NCT01491685||Pregnant|
11480374|NCT01491685||Non- Pregnant|
11480375|NCT01491672|Experimental|RAD001|Participants, received RAD001 10 mg orally once daily.
11480376|NCT01491659|Active Comparator|Amoxicillin/clavulanate/Idoform Plus|
11480377|NCT01491659|Placebo Comparator|Amoxicillin/clavulanate/Placebo|
11480378|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
11480379|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
11480380|NCT01491633|Experimental|Dasatinib|Dasatinib 140 mg by mouth each day
11480381|NCT01491620|Experimental|532 nm KTP laser treatment|
11480382|NCT01491607|Experimental|BioThrax (0.5 mL, on days 0, 14, and 28)|
11480383|NCT01491581|Experimental|micronutrient enriched bar|bar enriched with micronutrients
11480384|NCT01491581|Placebo Comparator|control arm|normal bar
11480385|NCT01491568|Experimental|Investigational|
11480386|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
11480387|NCT01491555||Control Group|35 healthy boys ages 2 through 30
11480388|NCT01491542|Experimental|rhBMP-2 / ACS|
11480389|NCT01491542|Active Comparator|Autogenous bone|
11480390|NCT01491529|Experimental|AFQ056 150 mg|Patients randomized to the AFQ056 150 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 150 mg twice daily.
11480391|NCT01491529|Experimental|AFQ056 200 mg|"Patients randomized to the AFQ056 200 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 200 mg twice daily.
~Patients will be randomized in two groups by amantadine status.
~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.
~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
11480392|NCT01491529|Placebo Comparator|Placebo|Patients randomized to the Placebo arm will receive oral AFQ056 Placebo twice daily
11480393|NCT01491516|Experimental|Investigational|
11480394|NCT01491503|Experimental|Montelukast and levocetirizine|
11480395|NCT01491503|Active Comparator|Montelukast|
11480396|NCT01491503|Active Comparator|Levocetirizine|
11480397|NCT01491490|Active Comparator|GWP42003 : GWP42004 (40:1)|
11480398|NCT01491490|Placebo Comparator|Placebo|
11480399|NCT01491477|Experimental|INFUSE™ Bone Graft|
11480400|NCT01491477|Active Comparator|Autogenous bone|
11480401|NCT01491464|Experimental|rhBMP-2/ACS|
11480402|NCT01491464|Active Comparator|Autogenous bone|
11480403|NCT01491451|Experimental|rhBMP-2/ACS|
11480404|NCT01491451|Active Comparator|Autogenous bone|
11480405|NCT01491438|Experimental|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
11480406|NCT01491438|Active Comparator|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
11480407|NCT01491425|Experimental|rhBMP-2/ACS|
11480408|NCT01491425|Active Comparator|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
11480409|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
11480410|NCT01491399|Experimental|INFUSE™ Bone Graft/CORNERSTONE-SR™|
11480411|NCT01491399|Active Comparator|Autogenous bone/CORNERSTONE-SR™|
11480412|NCT01491386|Experimental|rhBMP-2/ACS|
11480413|NCT01491386|Active Comparator|Autogenous Bone|
11480415|NCT01491373|Active Comparator|Autograft|
11480416|NCT01491360|Experimental|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
11480417|NCT01491347||alcohol dependent|
11480418|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
11480419|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
11480420|NCT01491321|Experimental|Bee Venom Acupuncture & Loxoprofen|
11480421|NCT01491321|Placebo Comparator|Sham Bee Venom Acupuncture & Loxoprofen|
11480422|NCT01491308|Active Comparator|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
11480423|NCT01491308|Active Comparator|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
11480424|NCT01491295|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
11480425|NCT01491295|Experimental|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
11480426|NCT01491282||No treatment|
11480427|NCT01491269|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
11480428|NCT01491269|No Intervention|Control condition|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
11480429|NCT01491256|Active Comparator|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
11480430|NCT01491256|Placebo Comparator|Control|No pre-procedural high dose atorvastatin loading
11480431|NCT01491243|Active Comparator|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
11480432|NCT01491243|Active Comparator|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
11480433|NCT01491230||25 autologous/25 allogeneic patients|
11480434|NCT01491204|Experimental|paclitaxel +HM30181|
11480435|NCT01491191|Experimental|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
11480436|NCT01491191|Active Comparator|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
11480437|NCT01491178||Patients with NVAF|
11480438|NCT01491165|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
11480439|NCT01491152|Experimental|WBV Training|
11480440|NCT01491152|No Intervention|Control|No WBV Training. Standard of Care.
11480441|NCT01491139|Experimental|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.
~Induction chemotherapy (21 day cycle)
~Drug: cisplatin 80mg/m2 (day 1)
~Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)
~olaparib plus chemoradiotherapy (8 weeks)
~Drug: olaparib
~Drug: Cisplatin
~Radiation"
11480442|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years
11480443|NCT01491113|Experimental|Group A: Normal renal function|"Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose
~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose"
11480444|NCT01491113|Experimental|Group B: Mild renal impairment|"Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose
~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose"
11480445|NCT01491113|Experimental|Group C: Moderate renal impairment|"Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose
~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose"
11480446|NCT01491113|Experimental|Group D: Severe renal impairment|"Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.
~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose
~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose"
11480518|NCT01490632|Experimental|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
11480524|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
11480525|NCT01490580|Experimental|Atropine + Propofol|
11480447|NCT01491113|Experimental|Group E: End-stage renal disease|"Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.
~The 4-h Hemodialysis are scheduled as follows:
~Dialysis: 44 h to 48 h after the first dose (Day 3)
~Dialysis: 92 h to 96 h after the first dose (Day 5)
~Dialysis: 140 h after the first dose (Day 7)
~Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.
~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.
~49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.
~*Inflow blood, outflow blood, and dialysate fluid will be collected."
11480448|NCT01491100||Group 1|
11480449|NCT01491087|Experimental|PENTAXIM® vaccine group|
11480450|NCT01491074|Placebo Comparator|NaCl 0.9% 100 ml|
11480451|NCT01491074|Experimental|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
11480452|NCT01491061|Active Comparator|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
11480453|NCT01491061|Placebo Comparator|Placebo|Placebo
11480454|NCT01491048|Active Comparator|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
11480455|NCT01491048|Active Comparator|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
11480456|NCT01491035|Experimental|Cohort CC1, 6 children|
11480457|NCT01491035|Experimental|Cohort CC2, 6 children|
11480458|NCT01491035|Experimental|Cohort CC3, 6 children|
11480459|NCT01491035|Experimental|Cohort CC4, 6 children|
11480460|NCT01491035|Experimental|Cohort AC1, 6 adolescents|
11480461|NCT01491035|Experimental|Cohort AC2, 6 adolescents|
11480462|NCT01491035|Experimental|Cohort AC3, 6 adolescents|
11480463|NCT01491035|Experimental|Cohort AC4, 6 adolescents|
11480464|NCT01491022|Experimental|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
11480465|NCT01491022|Sham Comparator|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
11480466|NCT01490996|Active Comparator|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
11480467|NCT01490996|Experimental|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
11480468|NCT01490983|Experimental|eMedonline access|patients will have access to eMedonline access for 3 months
11480469|NCT01490983|Other|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
11480470|NCT01490944|Active Comparator|Iron and Folic Acid|
11480471|NCT01490944|Experimental|Iron, Folic acid and cyanocobalamin|
11480472|NCT01490931|Experimental|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
11480473|NCT01490918|Placebo Comparator|Acarbose placebo, Metformin, Sitagliptin|The Acarbose placebo should be changed into real Acarbose from the 16th week.
11480474|NCT01490918|Experimental|Sitagliptin, Metformin, Acarbose|Metformin, Sitagliptin, Acarbose group
11480475|NCT01490918|Other|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
11480476|NCT01490905|Active Comparator|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
11480477|NCT01490905|Active Comparator|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
11480478|NCT01490905|Active Comparator|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
11480479|NCT01490892|Experimental|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
11480480|NCT01490879|Experimental|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
11480481|NCT01490879|Experimental|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
11480482|NCT01490879|Experimental|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
11480483|NCT01490879|Placebo Comparator|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
11480484|NCT01490866|Experimental|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)
~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
11480485|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
11480486|NCT01490840|Experimental|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
11480519|NCT01490632|Experimental|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
11480520|NCT01490619|Experimental|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
11480487|NCT01490840|Experimental|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
11480488|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
11480489|NCT01490814|Active Comparator|Cryoballoon ablation|
11480490|NCT01490814|Active Comparator|Radiofrequency ablation|
11480491|NCT01490788|Experimental|Treatment A|1 x TNX-102 2.4 mg gelcap under fasting conditions
11480492|NCT01490788|Experimental|Treatment B|1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
11480493|NCT01490788|Active Comparator|Treatment C|1 x TNX-102 2.4 mg gelcap under fed conditions
11480494|NCT01490775|Experimental|eMedonline access|patients will be followed for 3 months with access to eMedonline
11480495|NCT01490775|Active Comparator|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
11480496|NCT01490762|Active Comparator|Regular Human Insulin|Subcutaneous injection
11480497|NCT01490762|Experimental|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
11480498|NCT01490749|Experimental|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
11480499|NCT01490736|Experimental|LTS/Vehicle|Within subject control study
11480500|NCT01490723|Experimental|Yttrium-90 Ibritumomab + Chemo|Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.
11480501|NCT01490697|Experimental|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
11480502|NCT01490697|Placebo Comparator|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
11480503|NCT01490671|Experimental|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
11480504|NCT01490671|Placebo Comparator|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
11480505|NCT01490671|Experimental|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
11480506|NCT01490671|Placebo Comparator|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
11480507|NCT01490671|Experimental|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
11480508|NCT01490671|Placebo Comparator|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
11480509|NCT01490671|Experimental|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
11480510|NCT01490671|Placebo Comparator|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
11480511|NCT01490658|Experimental|Treatment period 1|
11480512|NCT01490658|Experimental|Treatment period 2|
11480513|NCT01490658|Active Comparator|Treatment period 3|
11480514|NCT01490645||one group (all patients)|
11480515|NCT01490632|Placebo Comparator|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
11480516|NCT01490632|Experimental|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
11480517|NCT01490632|Experimental|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
11480521|NCT01490619|Active Comparator|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
11480522|NCT01490606|Experimental|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
11480523|NCT01490606|No Intervention|conventional PT|
11480526|NCT01490580|Active Comparator|Atropine + atracurium + sufentanil|
11480527|NCT01490567|Placebo Comparator|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
11480528|NCT01490567|Active Comparator|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
11480529|NCT01490554|Experimental|autologous fibroblast grafts|autologous fibroblast grafts
11480530|NCT01490541||Gastric intestinal metaplasia patient|
11480531|NCT01490515|Active Comparator|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
11480532|NCT01490515|Experimental|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
11480533|NCT01490502|Active Comparator|Low-dose vitamin D3|
11480534|NCT01490502|Active Comparator|High-dose vitamin D3|
11480535|NCT01490489|Other|Pregnent women with blood sample|
11480536|NCT01490476|Experimental|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
11480537|NCT01490450|Placebo Comparator|PBO: Placebo matching BMS-945429|
11480538|NCT01490450|Experimental|BMS-945429 (25mg)|
11480539|NCT01490450|Experimental|BMS-945429 (100mg)|
11480540|NCT01490450|Experimental|BMS-945429 (200mg)|
11480541|NCT01490437|Experimental|PemCis|Pemetrexed plus Cisplatin
11480542|NCT01490424||sepsis|SIRS plus inflammation
11480543|NCT01490424||Control|normal person under medical examination
11480544|NCT01490411|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
11480545|NCT01490411|Experimental|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
11480546|NCT01490411|Experimental|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
11480547|NCT01490411|Experimental|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
11480548|NCT01490411|Experimental|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
11480549|NCT01490398|Experimental|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
11480550|NCT01490385|Active Comparator|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
11480551|NCT01490385|No Intervention|Control: conventional orthodontic tooth movement|
11480552|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
11480553|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
11480554|NCT01490359|Experimental|HIV/STD risk-reduction|Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
11480555|NCT01490359|Active Comparator|Health Promotion Control|Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.
11480556|NCT01490346||ART treated individuals|
11480557|NCT01490333|Experimental|2500 IU Vitamin D3|
11480558|NCT01490333|Active Comparator|400 IU Vitamin D3|
11480559|NCT01490320|Placebo Comparator|Control|Parents in control group experienced a routine primary care visit.
11480560|NCT01490320|Experimental|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
11480561|NCT01490320|Experimental|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
11480562|NCT01490307|Experimental|FCU offered|
11480563|NCT01490307|No Intervention|No feedback or services offered|
11480564|NCT01490294|Experimental|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
11480565|NCT01490294|Experimental|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
11480566|NCT01490294|Experimental|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
11480614|NCT01489995|Experimental|Reference|Fasted
11480615|NCT01489995|Experimental|Glucose Drink|Fed
11480616|NCT01489995|Experimental|Before High Fat Meal|Fed
11480617|NCT01489995|Experimental|Before Light Meal|Fed
11480567|NCT01490294|Experimental|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
11480568|NCT01490281|Experimental|water-based exercise intervention|
11480569|NCT01490281|Experimental|land-based exercise intervention|
11480570|NCT01490281|No Intervention|Control group|
11480571|NCT01490268|Active Comparator|Sufentanil Group 1|Sufentanil Low Titration
11480572|NCT01490268|Active Comparator|Sufentanil Group 2|Sufentanil High Titration
11480573|NCT01490255|Active Comparator|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
11480574|NCT01490255|Active Comparator|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
11480575|NCT01490229|Active Comparator|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
11480576|NCT01490229|Active Comparator|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
11480577|NCT01490216|Other|lisdexamfetamine|open label
11480578|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
11480579|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
11480580|NCT01490190|Experimental|NuvaRing|
11480581|NCT01490177|Experimental|One|
11480582|NCT01490164||scoliosis|young adults requiring surgical correction
11480583|NCT01490151|Experimental|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
11480584|NCT01490125|Experimental|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
11480585|NCT01490125|Active Comparator|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
11480586|NCT01490125|Placebo Comparator|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
11480587|NCT01490112||IAsp|
11480588|NCT01490099|Experimental|Treatment period 1|
11480589|NCT01490099|Active Comparator|Treatment period 2|
11480590|NCT01490086|Experimental|15mg RP5063 daily|
11480591|NCT01490086|Experimental|30mg RP5063 daily|
11480592|NCT01490086|Experimental|50mg RP5063 daily|
11480593|NCT01490086|Placebo Comparator|Placebo|
11480594|NCT01490086|Active Comparator|aripiprazole|aripiprazole 15 mg daily
11480595|NCT01490073|Active Comparator|Active nitroglycerin ointment|
11480596|NCT01490073|Placebo Comparator|Placebo ointment|
11480597|NCT01490060|Experimental|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
11480598|NCT01490060|Experimental|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
11480599|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
11480600|NCT01490047|Experimental|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
11480601|NCT01490047|Experimental|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
11480602|NCT01490047|Experimental|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
11480603|NCT01490047|Experimental|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
11480604|NCT01490047|Experimental|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
11480605|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
11480606|NCT01490034|Experimental|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
11480607|NCT01490034|Experimental|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
11480608|NCT01490034|Experimental|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
11480609|NCT01490034|Experimental|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
11480610|NCT01490021|Experimental|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
11480611|NCT01490021|Placebo Comparator|rTMS/Placebo TBS|rTMS/Placebo TBS
11480612|NCT01490008|Experimental|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
11480613|NCT01490008|Active Comparator|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
11480618|NCT01489995|Experimental|After Light Meal|Fed
11480619|NCT01489982|Experimental|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
11480620|NCT01489982|Experimental|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
11480621|NCT01489982|Experimental|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
11480622|NCT01489982|Placebo Comparator|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
11480623|NCT01489969|Active Comparator|20 mg|Neu-P11 dose of 20 mg
11480624|NCT01489969|Active Comparator|50 mg|Neu-P11 dose of 50 mg
11480625|NCT01489969|Placebo Comparator|placebo|matching placebo
11480626|NCT01489956|Experimental|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
11480627|NCT01489956|Experimental|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
11480628|NCT01489956|Experimental|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.
~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
11480629|NCT01489943|Experimental|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
11480630|NCT01489930|Experimental|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
11480631|NCT01489930|Experimental|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
11480632|NCT01489930|Experimental|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
11480633|NCT01489917|No Intervention|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
11480634|NCT01489917|Experimental|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
11480635|NCT01489904|Experimental|Botulinum Toxin|Botulinum Toxin type-A
11480636|NCT01489904|No Intervention|Control Treatment|No intervention
11480637|NCT01489891|Active Comparator|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
11480638|NCT01489891|Placebo Comparator|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
11480639|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
11480640|NCT01489878||macrolides|
11480641|NCT01489878||fluoroquinolones|
11480642|NCT01489878||synergistins|
11480643|NCT01489865|Experimental|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
11480644|NCT01489852|Active Comparator|Estrogen pre-treatment|
11480645|NCT01489852|No Intervention|Control|The control group did not receive any pre-treatment.
11480646|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having >5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
11480724|NCT01489345|Placebo Comparator|Arm 2: Placebo Comparator|
11480647|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
11480648|NCT01489826|Experimental|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480649|NCT01489826|Experimental|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480650|NCT01489826|Experimental|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480651|NCT01489826|Experimental|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480652|NCT01489826|Experimental|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480653|NCT01489826|Experimental|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480654|NCT01489826|Experimental|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480655|NCT01489826|Experimental|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480656|NCT01489826|Experimental|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
11480657|NCT01489813|Placebo Comparator|Sugar pill|Patients will be given placebo pills for 10 weeks.
11480658|NCT01489813|Experimental|Genistein supplement|30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.
11480659|NCT01489800|Experimental|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
11480660|NCT01489800|No Intervention|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
11480661|NCT01489787|Experimental|Phase I : HIFU|
11480662|NCT01489787|Experimental|Phase IIa : HIFU|
11480663|NCT01489787|Experimental|Phase IIb : HIFU|
11480664|NCT01489774|Placebo Comparator|Placebo|
11480665|NCT01489774|Experimental|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
11480666|NCT01489761|Active Comparator|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
11480667|NCT01489761|Experimental|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
11480668|NCT01489735||1|
11480669|NCT01489722|Experimental|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
11480670|NCT01489709||Vesicare group|Who receive vesicare
11480671|NCT01489696|Experimental|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
11480672|NCT01489696|Experimental|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
11480673|NCT01489683|Experimental|control|3 ml of normal saline was instilled to larynx and trachea
11480674|NCT01489683|Active Comparator|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
11480675|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
11480676|NCT01489644|Experimental|Treatment period 1|
11480677|NCT01489644|Experimental|Treatment period 2|
11480678|NCT01489644|Experimental|Treatment period 3|
11480679|NCT01489644|Active Comparator|Treatment period 4|
11480680|NCT01489631|Active Comparator|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
11480681|NCT01489631|Active Comparator|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
11480682|NCT01489631|Active Comparator|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
11480683|NCT01489618|Active Comparator|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
11480684|NCT01489618|Experimental|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
11480685|NCT01489605|Experimental|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
11480686|NCT01489605|Active Comparator|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
11480687|NCT01489592|Experimental|curcumin|oral administration of 6g of curcumin
11480688|NCT01489592|Placebo Comparator|placebo|oral administration of 12 sugar pill
11480689|NCT01489579|Active Comparator|BST counseling group|The patients in the Brief, structured, telephone tobacco cessation, BST, counseling group, will receive tobacco cessation counseling, intervention, by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources.
11480721|NCT01489358|Experimental|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
11480722|NCT01489358|Experimental|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
11480723|NCT01489345|Experimental|Arm 1: Experimental|
11480690|NCT01489579|Placebo Comparator|Usual care group|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
11480691|NCT01489566|Active Comparator|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
11480692|NCT01489566|Placebo Comparator|the placebo|
11480693|NCT01489540|Active Comparator|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
11480694|NCT01489540|No Intervention|current diagnostic strategy|Clinical assessment of burn depth
11480695|NCT01489527|Active Comparator|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
11480696|NCT01489527|Placebo Comparator|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
11480697|NCT01489514||Peanut allergic subjects|
11480698|NCT01489501|Experimental|only one arm available|Caomecs transplantation on eye cornea.
11480699|NCT01489488|Experimental|Arm 1|
11480700|NCT01489488|Experimental|Arm 2|
11480701|NCT01489488|Experimental|Arm 3|
11480702|NCT01489488|Experimental|Arm 4|
11480703|NCT01489488|Experimental|Arm 5|
11480704|NCT01489462|Experimental|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
11480705|NCT01489462|Experimental|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
11480706|NCT01489462|Active Comparator|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
11480707|NCT01489449|Placebo Comparator|Stent|Stent Implantation (DES or BMS), no further treatment
11480708|NCT01489449|Active Comparator|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
11480709|NCT01489436|Active Comparator|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
11480710|NCT01489436|Active Comparator|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
11480711|NCT01489410|Active Comparator|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
11480712|NCT01489410|Active Comparator|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
11480713|NCT01489397|Experimental|Gastric intestinal metaplasia|
11480714|NCT01489397|Placebo Comparator|Normal|
11480715|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
11480716|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
11480717|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
11480718|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of <0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
11480719|NCT01489371|Experimental|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11480720|NCT01489358|Experimental|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
11480725|NCT01489319|Experimental|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
11480726|NCT01489319|Experimental|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
11480727|NCT01489319|No Intervention|Obese PCOS|10 obese women with PCOS
11480728|NCT01489319|No Intervention|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
11480729|NCT01489319|No Intervention|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
11480730|NCT01489319|No Intervention|Obese Controls|10 obese ovulatory women serving as controls
11480731|NCT01489306|Experimental|MDT-637|Active formulation
11480732|NCT01489306|Placebo Comparator|Placebo|Matched Placebo Comparator
11480733|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
11480734|NCT01489293||non-atopic subjects|Control group without atopic diseases.
11480735|NCT01489267|No Intervention|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
11480736|NCT01489267|Experimental|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
11480737|NCT01489254|Experimental|GTR|Drug
11480738|NCT01489254|Active Comparator|Copaxone®|Drug
11480739|NCT01489254|Placebo Comparator|Placebo|Drug
11480740|NCT01489241|No Intervention|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
11480741|NCT01489241|Experimental|Telemonitoring|
11480742|NCT01489228|Experimental|High Dose E1224|High Dose (HD - 8weeks) Group
11480743|NCT01489228|Experimental|Low Dose E1224|Low Dose (LD - 8 weeks) Group
11480744|NCT01489228|Experimental|Short Dose E1224|Short Dose (SD - 4 weeks) Group
11480745|NCT01489228|Placebo Comparator|Placebo|Placebo (8 weeks) Group
11480746|NCT01489228|Active Comparator|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
11480747|NCT01489215|Experimental|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
11480748|NCT01489215|Experimental|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
11480749|NCT01489215|No Intervention|Control Group|
11480750|NCT01489202|Active Comparator|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
11480751|NCT01489202|Active Comparator|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
11480752|NCT01489189|Experimental|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
11480753|NCT01489189|Active Comparator|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
11480754|NCT01489176|Experimental|Regadenoson; Optison|Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography.
11480755|NCT01489163|Experimental|Lifestyle Counseling|
11480756|NCT01489163|No Intervention|Control|
11480757|NCT01489137|Experimental|neurosurgery with fixation|
11480758|NCT01489124|Experimental|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
11480759|NCT01489124|Experimental|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
11480760|NCT01489124|Experimental|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
11480761|NCT01489111|Experimental|Surgery|
11480762|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
11480763|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
11480764|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
11480765|NCT01489072|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
11480766|NCT01489072|Active Comparator|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
11480767|NCT01489059|Experimental|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
11480768|NCT01489059|Experimental|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
11480769|NCT01489059|Experimental|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
11480770|NCT01489059|Experimental|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
11480771|NCT01489059|Active Comparator|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
11480772|NCT01489046|Experimental|Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine|
11480773|NCT01489046|Experimental|Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine|
11480774|NCT01489046|Experimental|Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine|
11480775|NCT01489046|Experimental|Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine|
11480776|NCT01489033|Experimental|Group A active|"6 administrations and 5 weeks duration
~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
11480777|NCT01489033|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration
~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
11480778|NCT01489033|Experimental|Group B active|"8 administrations and 7 weeks duration
~Vial 1: 0.2 ml at 1 week intervals
~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
11480779|NCT01489033|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration
~Vial 1: 0.2 ml at 1 week intervals
~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
11480780|NCT01489033|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval
~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval
~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval
~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
11480781|NCT01489033|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval
~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval
~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval
~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
11480782|NCT01489020|Experimental|Group A active|"6 administrations and 5 weeks duration
~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
11480783|NCT01489020|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration
~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
11480784|NCT01489020|Experimental|group B active|"8 administrations and 7 weeks duration
~Vial 1: 0.2 ml at 1 week intervals
~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
11480785|NCT01489020|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration
~Vial 1: 0.2 ml at 1 week intervals
~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals
~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
11480786|NCT01489020|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval
~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval
~Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval
~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
11480787|NCT01489020|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.
~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval
~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval
~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval
~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
11480788|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
11480789|NCT01488994|Experimental|BAX326 < 6 years of age|
11480790|NCT01488994|Experimental|BAX326 6 to <12 years of age|
11480791|NCT01488968|Active Comparator|Standard|Standard Radiation Treatment
11480792|NCT01488968|Experimental|Hypofractionated|Hypofractionated
11480793|NCT01488955|Experimental|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
11480794|NCT01488955|Experimental|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
11480795|NCT01488942|Experimental|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
11480796|NCT01488942|No Intervention|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
11480797|NCT01488929|Experimental|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
11480798|NCT01488929|Experimental|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
11480799|NCT01488929|Placebo Comparator|Placebo|One tablet of placebo will be administered orally once a day.
11480800|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
11480801|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
11480802|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
11480803|NCT01488903||Premenopausal Women|600 health premenopausal Women
11480804|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
11480805|NCT01488890|Experimental|CYD Dengue vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.
11480806|NCT01488890|Experimental|CYD Dengue vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.
11480807|NCT01488890|Experimental|CYD Dengue and Yellow Fever vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.
11480808|NCT01488890|Active Comparator|Yellow Fever vaccine: Group 4|Participants received single dose of YF vaccine at Day 0.
11480809|NCT01488877|Experimental|PF03882845|
11480810|NCT01488877|Active Comparator|Spironolactone|25 mg once daily
11480811|NCT01488877|Placebo Comparator|Placebo|Placebo once daily
11480812|NCT01488864|Experimental|Applied Relaxation (AR)|
11480813|NCT01488864|No Intervention|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
11480814|NCT01488838|Experimental|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
11480815|NCT01488838|Active Comparator|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
11481011|NCT01487460|Experimental|TAP311 in Patients|
11480816|NCT01488825|No Intervention|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
11480817|NCT01488825|Experimental|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
11480818|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
11480819|NCT01488799|Active Comparator|MI-CBT|
11480820|NCT01488799|Active Comparator|CBT alone|
11480821|NCT01488786|Experimental|BrainPort Vision Device|Single Arm
11480822|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).
~90 patients met the inclusion criteria for this group."
11480823|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).
~42 patients met the inclusion criteria for this group."
11480824|NCT01488760||Nineteen women with low back pain|
11480825|NCT01488760||Twenty pain-free women|
11480826|NCT01488747|Experimental|Coromega Omega-3 Squeeze|5.03 g
11480827|NCT01488747|Experimental|Coromega Nectar|12.22 g
11480828|NCT01488747|Experimental|Barleans Swirl|17.45 g
11480829|NCT01488747|Active Comparator|Nordic Omega-3 Softgel|4 softgels
11480830|NCT01488734|Experimental|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
11480831|NCT01488734|Experimental|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
11480832|NCT01488734|Active Comparator|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
11480833|NCT01488734|Active Comparator|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
11480834|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
11480835|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
11480836|NCT01488708|Experimental|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
11480837|NCT01488708|Experimental|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
11480838|NCT01488695|Experimental|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
11480839|NCT01488695|Active Comparator|Control|Control Group: Macintosh Blade
11480840|NCT01488682|Experimental|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
11480841|NCT01488682|Active Comparator|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
11480842|NCT01488669|Experimental|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
11480843|NCT01488669|Active Comparator|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
11480844|NCT01488656|Placebo Comparator|Placebo dietary supplements|Visually identical inactive dietary supplement pack
11480845|NCT01488656|Experimental|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
11480846|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI >35
11480847|NCT01488643||CONTROL TEAM BMI <35|
11480848|NCT01488630|No Intervention|Treatment as Usual|Chart review only.
11480849|NCT01488630|Experimental|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
11480850|NCT01488604|Experimental|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
11480851|NCT01488604|Sham Comparator|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
11480852|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
11480853|NCT01488565|Experimental|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
11480854|NCT01488552|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
11480855|NCT01488539|Experimental|STAIR/NT|Patients will receive STAIR/NT treatment
11480856|NCT01488539|Other|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
11480857|NCT01488526|No Intervention|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
11480858|NCT01488526|Experimental|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
11480859|NCT01488513|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11481012|NCT01487447|Experimental|Intervention|
11480860|NCT01488500|Experimental|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
11480861|NCT01488500|Experimental|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
11480862|NCT01488500|Experimental|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
11480863|NCT01488487|Experimental|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
11480864|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
11480865|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
11480866|NCT01488461||patients ataxic|
11480867|NCT01488448|Experimental|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
11480868|NCT01488448|Placebo Comparator|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
11480869|NCT01488435|Placebo Comparator|Cow's Milk|Powdered whole cow's milk
11480870|NCT01488435|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
11480871|NCT01488422|Active Comparator|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
11480872|NCT01488422|Active Comparator|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
11480873|NCT01488409|Experimental|Acipimox|Treatment with the study drug Acipimox
11480874|NCT01488409|Placebo Comparator|Placebo|Treatment with Placebo control.
11480875|NCT01488396|Experimental|0.05%cyclosporin eye drop|
11480876|NCT01488383|Experimental|Stevioside capsules 200mg|Capsules of 200mg Stevioside
11480877|NCT01488383|Active Comparator|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
11480878|NCT01488370|Active Comparator|Glidescope|A device for endotracheal intubation.
11480879|NCT01488370|Active Comparator|Storz|A device for endotracheal intubation.
11480880|NCT01488370|Active Comparator|Standard Laryngoscope|A device for endotracheal intubation
11480881|NCT01488357||Early stage breast cancer patients receiving mastectomy|
11480882|NCT01488344|Experimental|BIBF 1120|
11480883|NCT01488331||Cohort|
11480884|NCT01488318|Experimental|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.
~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.
~Treatment will continue until progression."
11480885|NCT01488305|No Intervention|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
11480886|NCT01488305|Experimental|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
11480887|NCT01488305|Experimental|MNP added in AAMA|It is actually a intervention arm
11480888|NCT01488292|Experimental|RECAP social skills and reading program|
11480889|NCT01488292|No Intervention|Control group (services as usual)|Control Group (services as usual)
11480890|NCT01488279|Active Comparator|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
11480891|NCT01488279|Placebo Comparator|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
11480892|NCT01488266|Experimental|aripiprazole augmentation|
11480893|NCT01488266|Active Comparator|different class of antidepressant|
11480894|NCT01488253|Experimental|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
11480895|NCT01488240|Active Comparator|Proximal|part of scar proximal to heart
11480896|NCT01488240|Active Comparator|Distal|part of scar distal to heart
11480897|NCT01488227|Experimental|Vitamin D|Vitamin D
11480898|NCT01488227|Placebo Comparator|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
11480899|NCT01488214|Experimental|Scleroderma patient|Evaluation of Scleroderma patient
11480900|NCT01488214|Placebo Comparator|Healthy subjects|Evaluation of healthy subjects
11480901|NCT01488201|Experimental|KHK4827|
11480902|NCT01488201|Placebo Comparator|Placebo|
11480903|NCT01488188|Active Comparator|Influenza vaccine-Nasal|Nasal administration
11480904|NCT01488188|Active Comparator|Influenza vaccine -Sublingual|Sublingual administration
11480905|NCT01488175|Active Comparator|with tourniquet|
11480906|NCT01488175|Placebo Comparator|without tourniquet|
11480907|NCT01488162||Cohort|
11480908|NCT01488149||Recipients of intrapartum epidural analgesia|
11480909|NCT01488149||Non-recipients of intrapartum epidural analgesia|
11480910|NCT01488136|Active Comparator|Diazoxide|Oral diazoxide 7 mg/kg
11480911|NCT01488136|Placebo Comparator|Placebo|Matched placebo
11480912|NCT01488123|Experimental|Ayurvedic Intervention|
11480913|NCT01488110|Experimental|Migraine medical device|Treatment with an active nasal probe
11480914|NCT01488110|Placebo Comparator|Inactive migraine medical device|Treatment with an inactive nasal probe.
11481013|NCT01487447|Active Comparator|Control|
11481014|NCT01487434|Experimental|Check & Connect|Check and Connect Structured Mentoring and Case Management
11480915|NCT01488097|Experimental|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram [mg/kg]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
11480916|NCT01488084|Experimental|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
11480917|NCT01488084|Active Comparator|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
11480918|NCT01488071|Experimental|Vortioxetine 10 mg or 20 mg|
11480919|NCT01488071|Active Comparator|Agomelatine 25 mg or 50 mg|
11480920|NCT01488058|Other|Group 2|Waitlist control
11480921|NCT01488058|Experimental|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
11480922|NCT01488045|Active Comparator|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
11480923|NCT01488045|Active Comparator|Propofol|Propofol sedation for colonoscopy discomfort
11480924|NCT01488032||high-tension glaucoma|subjects with IOP>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
11480925|NCT01488032||low-tension glaucoma|subjects with IOP<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
11480926|NCT01488019|Experimental|Perforomist, nebulization, COPD|Active
11480927|NCT01488019|Placebo Comparator|Perforomist-Placebo|Placebo
11480928|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
11480929|NCT01487993|Active Comparator|Metformin|Metformin with lifestyle intervention during 18 months
11480930|NCT01487993|Placebo Comparator|Placebo|Placebo and lifestyle intervention during 18 months
11480931|NCT01487980|Active Comparator|Early cord clamping|Within 30 seconds after birth.
11480932|NCT01487980|Experimental|Delayed cord clamping|Between 2 and 3 minutes after birth
11480933|NCT01487967|Experimental|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
11480934|NCT01487967|No Intervention|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
11480935|NCT01487954|Experimental|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
11480936|NCT01487954|Active Comparator|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
11480937|NCT01487928|Experimental|Human Milk Cream Group|For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
11480938|NCT01487928|No Intervention|Control Group|For infants randomized to the Control group, human milk and human milk derived fortifier will be provided according to the institutional standard of care and there will be no use of the milk analysis (mother's own or donor), which is typical for the vast majority of neonatal intensive care units.
11480939|NCT01487915|Active Comparator|GCb|Gemcitabine plus Carboplatin
11480940|NCT01487915|Experimental|GemOx|Gemcitabine plus Oxaliplatin
11480941|NCT01487902|Experimental|ADT arm|Concomitant androgen deprivation treatment
11480942|NCT01487902|Active Comparator|No ADT arm|No concomitant androgen deprivation treatment arm
11480943|NCT01487889|Experimental|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
11480944|NCT01487889|Experimental|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
11480945|NCT01487889|Active Comparator|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
11480946|NCT01487876|Experimental|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
11480947|NCT01487876|Placebo Comparator|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
~lamivudine (LAM) chemotherapy and Placebo"
11480948|NCT01487863|Experimental|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
11481015|NCT01487421||SIT|
11481016|NCT01487408||Insulin Aspart|
11481017|NCT01487395|Active Comparator|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
11480949|NCT01487863|Experimental|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
11480950|NCT01487837|Active Comparator|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
11480951|NCT01487837|Experimental|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
11480952|NCT01487824||Preterm-born Young Adults|
11480953|NCT01487824||Term-born Young Adults|
11480954|NCT01487811|Experimental|Formulation 1|
11480955|NCT01487811|Active Comparator|Formulation 2|
11480956|NCT01487798|Experimental|Treatment period 1|
11480957|NCT01487798|Active Comparator|Treatment period 2|
11480958|NCT01487785|Experimental|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
11480959|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
11480960|NCT01487759|Active Comparator|Prebiotic|
11480961|NCT01487759|Placebo Comparator|Placebo|
11480962|NCT01487746||treatment|Stroke patients
11480963|NCT01487746||Controls|healthy controls
11480964|NCT01487720|Experimental|GEMOX|GEMOX treatment
11480965|NCT01487707|Experimental|Voluntary Health Worker (VHW) Program|
11480966|NCT01487707|Experimental|VHW program plus Safe Birth Kit|
11480967|NCT01487707|Experimental|VHW program plus Folk Media Activities|
11480968|NCT01487694|Experimental|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
11480969|NCT01487694|Placebo Comparator|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
11480970|NCT01487681||Invasive cervical cancer|
11480971|NCT01487681||Cervical intraepithelial neoplasia 2/3|
11480972|NCT01487681||Cervical intraepithelial neoplasia 1|
11480973|NCT01487668|No Intervention|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
11480974|NCT01487668|Experimental|Arm 2 - Life Goals Collaborative Care|
11480975|NCT01487655||healthy age matched controls|
11480976|NCT01487655||normal tension glaucoma patients|
11480977|NCT01487655||primary open angle glaucoma patients|
11480978|NCT01487642|Experimental|Telephone counselling|
11480979|NCT01487642|Experimental|Proactive telephone counselling|
11480980|NCT01487642|Experimental|web-based smoking cessation programme|
11480981|NCT01487642|Active Comparator|Self-help material|
11480982|NCT01487629|Experimental|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
11480983|NCT01487629|Experimental|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
11480984|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
11480985|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
11480986|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
11480987|NCT01487603||confirmed or suspected lung cancer|
11480988|NCT01487590|Active Comparator|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
11480989|NCT01487590|Placebo Comparator|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
11480990|NCT01487577|Experimental|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
11480991|NCT01487564|Experimental|Hydromorphone 16 mg|
11480992|NCT01487551|Experimental|paquinimod|
11480993|NCT01487538|Experimental|intervention group|
11480994|NCT01487538|Active Comparator|Standard Advice Group|
11480995|NCT01487525|Placebo Comparator|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
11480996|NCT01487525|Experimental|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
11480997|NCT01487512|Experimental|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
11480998|NCT01487512|Experimental|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
11480999|NCT01487512|Experimental|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
11481000|NCT01487512|Experimental|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
11481001|NCT01487499|Experimental|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
11481002|NCT01487499|No Intervention|Historical Controls|No intervention
11481003|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
11481004|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
11481005|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
11481006|NCT01487473|Active Comparator|Mindfulness-Based Stress Reduction|
11481007|NCT01487473|No Intervention|Waitlist Control|
11481008|NCT01487460|Experimental|TAP311 in Healthy Volunteers|
11481009|NCT01487460|Placebo Comparator|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
11481010|NCT01487460|Experimental|TAP311 and Simvastatin|
11481018|NCT01487395|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to ARICEPT
11481019|NCT01487382||Insulin Aspart|
11481020|NCT01487369||Insulin Aspart|
11481021|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
11481022|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
11481023|NCT01487330|Experimental|Subjects receiving TAVI valve|
11481024|NCT01487317|Experimental|Rivastigmine transdermal patch|
11481025|NCT01487317|Placebo Comparator|placebo|
11481026|NCT01487304||Low dose HRT|
11481027|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
11481028|NCT01487278|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
11481029|NCT01487278|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
11481030|NCT01487265|Experimental|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily
~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
11481031|NCT01487252|Active Comparator|Healthy Controls|
11481032|NCT01487252|Active Comparator|Delayed Sleep Phase Disorder|
11481033|NCT01487239|Experimental|A|[14C]-GDC-0980 administered as a 10-mg oral dose
11481034|NCT01487213|No Intervention|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
11481035|NCT01487213|Other|Home self test|Intervention
11481036|NCT01487200|Experimental|FX006 10mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
11481037|NCT01487200|Experimental|FX006 40mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
11481038|NCT01487200|Experimental|FX006 60 mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
11481039|NCT01487200|Active Comparator|TCA IR (40 mg)|Single 1 mL intra-articular (IA) injection Immediate-release formulation
11481040|NCT01487187|Active Comparator|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
11481041|NCT01487187|Experimental|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
11481042|NCT01487174|Experimental|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
11481043|NCT01487174|Active Comparator|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
11481044|NCT01487161|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
11481045|NCT01487161|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
11481046|NCT01487161|Experimental|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
11481047|NCT01487161|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
11481048|NCT01487135|Experimental|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
11481049|NCT01487135|Placebo Comparator|Placebo|Cranberry juice (180 mL)
11481050|NCT01487135|Active Comparator|Moxifloxacin|A single dose of 400-mg Moxifloxacin
11481051|NCT01487122|Experimental|Continuous Microwave|
11481052|NCT01487122|Experimental|Pulsed Microwaves|
11481053|NCT01487122|Sham Comparator|sham microwaves|
11481054|NCT01487109|Placebo Comparator|Placebo|matching placebo tablets
11481055|NCT01487109|Active Comparator|CTP-499|600 mg tablet
11481056|NCT01487096|Placebo Comparator|Placebo|"Placebo (for teriflunomide),
~two tablets once daily for 1 week then,
~one tablet once daily for 35 weeks."
11481057|NCT01487096|Experimental|Teriflunomide 7 mg|"Teriflunomide 7 mg:
~two tablets once daily for 1 week then,
~one tablet once daily for 35 weeks."
11481058|NCT01487096|Experimental|Teriflunomide 14 mg|"Teriflunomide 14 mg:
~two tablets once daily for 1 week then,
~one tablet once daily for 35 weeks."
11481059|NCT01487083|Experimental|Pomaglumetad methionil|Pomaglumetad methionil will be administered orally. Participants entering the study will be flexibly dosed between 20 mg, 40 mg, and 80 mg twice daily.
11481060|NCT01487070|Experimental|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
11481061|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
11481062|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
11481063|NCT01487031|Experimental|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
11481064|NCT01487031|Active Comparator|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
11481065|NCT01487018|Experimental|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
11481066|NCT01487018|Active Comparator|Traditional Surgery|To compare with the experimental arm.
11481067|NCT01487005||elderly subjects|Healthy
11481068|NCT01486992|Experimental|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
11481069|NCT01486979|Experimental|Low dose|
11481070|NCT01486979|Active Comparator|High dose|
11481071|NCT01486966|Experimental|Insulin detemir / IAsp|
11481072|NCT01486966|Active Comparator|insulin NPH|
11481073|NCT01486953|Active Comparator|sevoflurane|Anesthesia with sevoflurane
11481074|NCT01486953|Experimental|Desflurane|Anesthesia with desflurane
11481075|NCT01486940|Experimental|Basal/bolus regimen 1|
11481076|NCT01486940|Active Comparator|Basal/bolus regimen 2|
11481077|NCT01486927|Experimental|Recombinant Factor VIII (rFVIII)|
11481078|NCT01486914|Experimental|NN2000|
11481079|NCT01486914|Active Comparator|IAsp|
11481080|NCT01486901|Experimental|Formulation A|
11481081|NCT01486901|Active Comparator|Formulation B|
11481082|NCT01486888|Experimental|Formulation A|
11481083|NCT01486888|Active Comparator|Formulation B|
11481084|NCT01486875||BIAsp 30|
11481085|NCT01486862|Experimental|BIAsp 30|
11481086|NCT01486849|Experimental|Dose Titration of CK-2017357 (Group 1)|Dose titration of active drug as add-on therapy to riluzole
11481087|NCT01486849|Placebo Comparator|Matching Placebo (Group 2)|Placebo as add-on therapy to riluzole
11481088|NCT01486836||ICD therapy|
11481089|NCT01486823|Experimental|Cohort A|
11481090|NCT01486823|Experimental|Cohort B|
11481091|NCT01486810|Experimental|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
11481092|NCT01486797|Experimental|NOX-A12|
11481093|NCT01486784|Experimental|Phase 1|
11481094|NCT01486784|Experimental|Phase 2|
11481095|NCT01486771|Experimental|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
11481096|NCT01486771|Experimental|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
11481097|NCT01486771|Experimental|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
11481098|NCT01486758|Active Comparator|Azithromycin|Oral azithromycin
11481099|NCT01486758|Placebo Comparator|Placebo|Oral Placebo
11481100|NCT01486745||Normal colonoscopy|
11481101|NCT01486745||Colonic polyps|
11481102|NCT01486745||Colorectal cancer patients|
11481103|NCT01486745||Breast & Prostate Cancer patients|
11481104|NCT01486732|Experimental|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
11481105|NCT01486732|Active Comparator|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
11481106|NCT01486706|Experimental|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
11481107|NCT01486706|Active Comparator|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
11481108|NCT01486706|Placebo Comparator|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
11481109|NCT01486680|Active Comparator|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
11481110|NCT01486680|Active Comparator|Laparoscopic Sleeve Gastrectomy|
11481111|NCT01486667|Placebo Comparator|sugar pill|
11481112|NCT01486667|Active Comparator|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
11481113|NCT01486654|Active Comparator|Anodal stimulation|
11481114|NCT01486654|Active Comparator|Cathodal stimulation|
11481115|NCT01486654|Placebo Comparator|Sham stimulation|
11481116|NCT01486641|Active Comparator|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.
~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
11481117|NCT01486641|No Intervention|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.
~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
11481118|NCT01486628|Placebo Comparator|levodopa and carbidopa|
11481119|NCT01486628|Placebo Comparator|Placebo|Saline solution for subcutaneous administration
11481120|NCT01486615|Placebo Comparator|Melatonin|Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
11481121|NCT01486615|Placebo Comparator|melatonin and alprazolam premedication|Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
11481122|NCT01486615|Placebo Comparator|alprazolam premedication|Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
11481123|NCT01486615|Active Comparator|placebo premedication|Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia
11481160|NCT01486303|Experimental|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
11481198|NCT01486004|Experimental|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
11481199|NCT01485991|Experimental|TMC435/PR|
11481200|NCT01485991|Active Comparator|TVR/PR|
11481124|NCT01486602|Experimental|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.
~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
11481125|NCT01486576|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
11481126|NCT01486576|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
11481127|NCT01486563|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
11481128|NCT01486563|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
11481129|NCT01486550|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
11481130|NCT01486550|Placebo Comparator|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
11481131|NCT01486537||theeth undergoing pulpotomy|
11481132|NCT01486537||teeth undergoing pulpectomy|
11481133|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
11481134|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
11481135|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
11481136|NCT01486485|Experimental|heparinized saline priming group|Experimental group : heparinized saline priming group
11481137|NCT01486485|Active Comparator|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
11481138|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
11481139|NCT01486459|Experimental|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
11481140|NCT01486459|No Intervention|Standard|Prophylactic cranial irradiation alone.
11481141|NCT01486446|Experimental|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
11481142|NCT01486446|Placebo Comparator|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
11481143|NCT01486433|Experimental|Epanova and Simvastatin|
11481144|NCT01486433|Active Comparator|Simvastatin|
11481145|NCT01486420|Active Comparator|Open surgery|
11481146|NCT01486420|Active Comparator|Corticosteroid Injection|
11481147|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
11481148|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
11481149|NCT01486394|Experimental|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
11481150|NCT01486394|No Intervention|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
11481151|NCT01486381|Experimental|BIAsp 30|
11481152|NCT01486368|Experimental|PF-03446962|
11481153|NCT01486355|Experimental|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
11481154|NCT01486355|No Intervention|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
11481155|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
11481156|NCT01486329|Experimental|VXM01|Investigational anti-angiogenic live cancer vaccine
11481157|NCT01486329|Placebo Comparator|Placebo|Placebo control
11481158|NCT01486316|Other|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
11481159|NCT01486316|Experimental|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
11481196|NCT01486017|Experimental|Treatment B|ASP015K oral dose medium strength
11481197|NCT01486017|Experimental|Treatment C|ASP015K oral dose high strength
11481161|NCT01486290|Experimental|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
11481162|NCT01486290|No Intervention|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
11481163|NCT01486277|Experimental|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
11481164|NCT01486264|Active Comparator|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
11481165|NCT01486264|Active Comparator|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
11481166|NCT01486251|Experimental|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.
~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
11481167|NCT01486238|Experimental|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
11481168|NCT01486238|Experimental|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
11481169|NCT01486225|Other|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
11481170|NCT01486225|Other|Other than Innothera's brand|
11481171|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
11481172|NCT01486199|Experimental|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
11481173|NCT01486199|Experimental|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
11481174|NCT01486186|Experimental|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
11481175|NCT01486186|Placebo Comparator|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
11481176|NCT01486173||Premature infants with a GA < 32 Weeks|
11481177|NCT01486173||New born with a GA > 37Weeks|
11481178|NCT01486160||nursing home residents|participants in this group are nursing home residents
11481179|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
11481180|NCT01486147|Experimental|Visual|Group provided with nutrition information using visual nutrient profiling tool
11481181|NCT01486147|Other|Table|Group provided nutrition information using table format
11481182|NCT01486134|Experimental|procedure|
11481183|NCT01486121|Other|S.O.S.-V|
11481184|NCT01486121|No Intervention|Standard|
11481185|NCT01486108|Experimental|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
11481186|NCT01486108|Experimental|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
11481187|NCT01486108|Experimental|burst|500 hz burst at 5 hz stimulation
11481188|NCT01486095|Experimental|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
11481189|NCT01486095|Active Comparator|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
11481190|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
11481191|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
11481192|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
11481193|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
11481194|NCT01486043|Experimental|Metformin and insulin therapy|Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia
11481195|NCT01486017|Experimental|Treatment A|ASP015K oral dose low strength
11481201|NCT01485978|Active Comparator|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
11481202|NCT01485978|Placebo Comparator|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
11481203|NCT01485978|Other|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
11481204|NCT01485965|Experimental|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
11481205|NCT01485965|Experimental|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
11481206|NCT01485952|Experimental|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
11481207|NCT01485952|Experimental|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
11481208|NCT01485952|Placebo Comparator|Placebo|Once daily (immediate release capsule)
11481209|NCT01485939|Placebo Comparator|placebo patch|
11481210|NCT01485939|Active Comparator|lidocaine patch|
11481211|NCT01485926|Experimental|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
11481212|NCT01485926|Experimental|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
11481213|NCT01485913|Experimental|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.
~The control group will perform these classic individual consultations but will not follow the whole process of peer education.
~The classical management in diabetes consultations consists of:
~A counselling session
~A measure of blood glucose
~A measurement of blood pressure
~A measure of weight and size
~A complete clinical examination
~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
11481214|NCT01485913|No Intervention|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.
~The control group will perform these classic individual consultations but will not follow the whole process of peer education.
~The classical management in diabetes consultations consists of:
~A counselling session
~A measure of blood glucose
~A measurement of blood pressure
~A measure of weight and size
~A complete clinical examination
~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
11481215|NCT01485900|Experimental|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
11481216|NCT01485900|Experimental|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
11481217|NCT01485887|Experimental|Venlafaxine ER|
11481218|NCT01485874|Experimental|Doxil + BIBF 1120|
11481219|NCT01485861|Experimental|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
11481220|NCT01485861|Experimental|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
11481221|NCT01485861|Experimental|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
11481222|NCT01485861|Experimental|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
11481223|NCT01485861|Placebo Comparator|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
11481224|NCT01485861|Experimental|Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone|"Participants will receive Ipataseritib 400 mg once daily in the AM for Cycle 1 day 1-18. On Day 19, Ipataseritib 400 mg will be switched to PM dosing for the remainder of the Cycle 1.
~Prednisone 5 mg starts in the PM of Cycle 1 day 8 and taken BID thereafter for the remainder of the study treatment Abiraterone 1000mg once a day starts on Cycle1 day 12 in the AM and should be taken at the same time as Ipataseritib. Starting from cycle 1 day 19, Ipataseritib and Abiraterone are dosed in PM at should be taken together at the same time each day until cycle 2 day 1. Starting from Cycle 2 Day 1, Participants may choose to take Ipatasertib and Abiraterone in either the AM or PM; however, they should be taken together at approximately the same time each day.
~Participants will receive the study treatment until disease progression or intolerable toxicity."
11481225|NCT01485848|Active Comparator|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
11481226|NCT01485848|Experimental|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
11481227|NCT01485835|Experimental|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks
~Cohort 1: 100 mg/m²
~Cohort 2: 100 mg/m²
~Cohort 3: 120 mg/m²
~Cohort 4: 144 mg/m²
~Cohort 5: 173 mg/m²
~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks
~Cohort 1: 1.0 mg/m²
~Cohort 2, 3, 4, 5: 1.3 mg/m²
~Dexamethasone: Oral prior to bortezomib
~Cohort 1, 2, 3, 4, 5: 20 + 20 mg
~Day of and following bortezomib"
11481228|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
11481562|NCT01483430|Experimental|Ginseol Kg1, high dose|
11481229|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
11481230|NCT01485809|Experimental|Gefitinib|
11481231|NCT01485796|Experimental|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
11481232|NCT01485770|Experimental|ADX-N05|ADX-N05 to be taken once a day for 2 consecutive weeks during 4 week study treatment period
11481233|NCT01485770|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 2 consecutive weeks during 4 week study treatment period
11481234|NCT01485757|Experimental|L-arginine|
11481235|NCT01485744|Experimental|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
11481236|NCT01485731|Experimental|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
11481237|NCT01485718|Active Comparator|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
11481238|NCT01485718|Placebo Comparator|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
11481239|NCT01485692|Active Comparator|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
11481240|NCT01485692|Active Comparator|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
11481241|NCT01485692|Active Comparator|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
11481242|NCT01485692|Active Comparator|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
11481243|NCT01485679|Experimental|positrons emission tomography|
11481244|NCT01485653|Experimental|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
11481245|NCT01485640|Experimental|Lurasidone|Lurasidone flexibly dosed
11481246|NCT01485627|Experimental|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
11481247|NCT01485627|No Intervention|Control|Patients will receive usual care
11481248|NCT01485614|Experimental|Sitagliptin|Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
11481249|NCT01485614|Experimental|Placebo/Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
11481250|NCT01485614|Active Comparator|Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
11481251|NCT01485614|Experimental|Placebo/Sitagliptin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
11481252|NCT01485601|Experimental|MT10109|Clostridium botulinum toxin type A
11481253|NCT01485601|Active Comparator|Botox (registered trade mark)|Clostridium botulinum toxin type A
11481254|NCT01485588|Experimental|hI-con1™ 60µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
11481255|NCT01485588|Experimental|hI-con1™ 150µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
11481256|NCT01485588|Experimental|hI-con1™ 300µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
11481257|NCT01485575||Filter use during vitrectomy|
11481258|NCT01485562|Active Comparator|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
11481259|NCT01485562|Placebo Comparator|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
11481260|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
11481261|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
11481262|NCT01485536|Experimental|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
11481263|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
11481264|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
11481265|NCT01485510|Experimental|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
11481266|NCT01485510|Active Comparator|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
11481267|NCT01485497|Other|3D endoscopic Fourier Domain OCT|3D endoscopic Fourier Domain OCT
11481268|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
11481269|NCT01485471||Medical Tool|Diffuse optical spectroscopy imaging ear exam
11481270|NCT01485458|Experimental|Early surgery|
11481271|NCT01485458|Active Comparator|Delayed surgery|
11481272|NCT01485445|Experimental|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
11481273|NCT01485445|Experimental|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
11481274|NCT01485445|Experimental|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
11481275|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
11481276|NCT01485432||C group|Group C: Conventional fluid management
11481277|NCT01485406|Experimental|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
11481278|NCT01485406|Active Comparator|Control Group|Toddlers 12-23 months of age receiving Synflorix.
11481279|NCT01485393|Experimental|Healthy Control Subjects: Zolpidem, Then Dexmedetomidine|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
11481280|NCT01485393|Experimental|Healthy Control Subjects: Dexmedetomidine, Then Zolpidem|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
11481281|NCT01485380|Experimental|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
11481282|NCT01485367|Active Comparator|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
11481283|NCT01485367|Active Comparator|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
11481284|NCT01485354|Experimental|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
11481285|NCT01485341|Active Comparator|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
11481286|NCT01485341|Placebo Comparator|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
11481287|NCT01485328|Active Comparator|AMARGOL|per oral solution 40 mL single dose
11481288|NCT01485328|Placebo Comparator|Vehicle without active principles|per oral solution 40 mL single dose
11481289|NCT01485315|Active Comparator|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
11481290|NCT01485315|Active Comparator|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
11481291|NCT01485302|Experimental|Cohort 1|Dose 1 IV infusion
11481292|NCT01485302|Experimental|Cohort 2|Dose 2 IV infusion
11481293|NCT01485302|Experimental|Cohort 3|Dose 3 IV infusion
11481294|NCT01485302|Experimental|Cohort 4|Dose 4 IV infusion
11481295|NCT01485302|Experimental|Cohort 5|Dose 1 SC injection
11481296|NCT01485302|Experimental|Cohort 6|Dose 2 SC injection
11481297|NCT01485289||Investigational Stabilimax|
11481298|NCT01485289||Control, Posterolateral Fusion|
11481299|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
11481300|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
11481301|NCT01485224|Experimental|Thalidomide|"Single arm study:
~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.
~Treatment will be continued until one of the following criteria is met:
~8 additional weeks of treatment after the achievement of complete response
~16 additional weeks of treatment after the achievement of partial response
~24 weeks of treatment completed without response
~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
11481302|NCT01485211|Experimental|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
11481303|NCT01485198|Active Comparator|Control|Patients treated with Acetaminophen
11481304|NCT01485198|Experimental|Experimental|Patients who underwent a BMASC extraction and joint infusion
11481305|NCT01485185|Experimental|Gabapentin lower dose alone|low dose
11481306|NCT01485185|Active Comparator|Gabapentin higher dose alone|higher dose
11481307|NCT01485185|Experimental|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
11481308|NCT01485185|Placebo Comparator|Placebo|Placebo
11481309|NCT01485172|Experimental|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
11481310|NCT01485172|Placebo Comparator|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
11481311|NCT01485159||All|All subjects enrolled in the study
11481312|NCT01485146|Experimental|Cohort 1|8 Healthy Subjects in Phase I Unit
11481313|NCT01485146|Experimental|Cohort 2|8 Healthy Subjects in Phase I Unit
11481314|NCT01485146|Experimental|Cohort 3|8 Healthy Subjects in Phase I Unit
11481315|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
11481316|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
11481317|NCT01485120|Other|Blood Pressure monitoring|Blood Pressure (BP) monitoring using invasive arterial insertion as a standard reference, and an investigational, non-invasive blood pressure (NIBP) monitoring cuff. Data obtained from the cuff used the SuperSTAT NIBP algorithm and the Classic NIBP algorithm for output.
11481318|NCT01485107|Experimental|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
11481319|NCT01485094|Placebo Comparator|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
11481320|NCT01485094|Experimental|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
11481321|NCT01485094|Active Comparator|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
11481322|NCT01485081|Experimental|Danubio|
11481323|NCT01485068|Experimental|Danubio|
11481324|NCT01485055|Experimental|Infliximab and Basiliximab|"Other Names:
~Simulect Remicade Monoclonal antibody
~Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.
~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
11481325|NCT01485042|Experimental|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
11481326|NCT01485029|Experimental|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
11481327|NCT01485016||ambulatory epilepsy subjects|
11481328|NCT01484990|Experimental|1|
11481329|NCT01484977|Experimental|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
11481330|NCT01484964|Experimental|Treatment A|ASP015K Formulation 1 with moderate-fat meal
11481331|NCT01484964|Experimental|Treatment B|ASP015K Formulation 2 under fasting conditions
11481332|NCT01484964|Experimental|Treatment C|ASP015K Formulation 2 with moderate-fat meal
11481333|NCT01484951|Experimental|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
11481334|NCT01484938|Experimental|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
11481335|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
11481336|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
11481337|NCT01484912|Experimental|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.
~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
11481338|NCT01484912|Placebo Comparator|Placebo|"Placebo capsule, containing non-active ingredients.
~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
11481339|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
11481340|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
11481341|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
11481342|NCT01484886|Experimental|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
11481343|NCT01484886|Experimental|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
11481344|NCT01484873|Experimental|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
11481345|NCT01484860|Experimental|AUY922|AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
11481346|NCT01484847|Experimental|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
11481347|NCT01484834|Experimental|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
11481426|NCT01484197|Experimental|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
11481563|NCT01483430|Experimental|Ginseol Kg1, low dose|
11481348|NCT01484834|Active Comparator|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
11481349|NCT01484834|Active Comparator|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
11481350|NCT01484834|Placebo Comparator|Control Company|No intervention
11481351|NCT01484821|Active Comparator|Arm A|Volunteers (18 -30 years)
11481352|NCT01484821|Active Comparator|Arm B|Volunteers (70 years or older)
11481353|NCT01484821|Experimental|Arm C|70 years patient or older with curative cares for cancer
11481354|NCT01484795|Experimental|Continuous positive airway pressure|
11481355|NCT01484795|Experimental|BILEVEL|
11481356|NCT01484782|Experimental|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
11481357|NCT01484782|No Intervention|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
11481358|NCT01484756|Placebo Comparator|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
11481359|NCT01484756|Experimental|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
11481360|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
11481361|NCT01484730||Vascular Occulsion|Multi-Spectral & Laser Speckle Imaging
11481362|NCT01484717|Active Comparator|Standard Care|Telephone counseling plus nicotine patch
11481363|NCT01484717|Experimental|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
11481364|NCT01484704||No treatment|
11481365|NCT01484704||MRI|
11481366|NCT01484691|No Intervention|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
11481367|NCT01484691|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
11481368|NCT01484691|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
11481369|NCT01484678||Age Matched Controls|Age matched non-affected (non-DMD) boys
11481370|NCT01484678||Boys with DMD|This group will include ambulatory and non-ambulatory boys with Duchenne Muscular Dystrophy ranging form 5-18 years old.
11481371|NCT01484665|Experimental|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
11481372|NCT01484652|Experimental|COV795|
11481373|NCT01484652|Placebo Comparator|Placebo|
11481374|NCT01484639|Active Comparator|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
11481375|NCT01484639|Active Comparator|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
11481376|NCT01484626|Experimental|Bendamustine|Bendamustine is combined with standard chemotherapy.
11481377|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
11481378|NCT01484600|Experimental|Group 1|
11481379|NCT01484600|Experimental|Group 2|
11481380|NCT01484587|Experimental|001|
11481381|NCT01484587|Placebo Comparator|002|
11481382|NCT01484574|Experimental|Low dose|Stempeucel - CLI will be administered at the lowest dose
11481383|NCT01484574|Experimental|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
11481384|NCT01484574|No Intervention|Control arm|Standard protocol of care alone
11481385|NCT01484561|Active Comparator|Sequence 1|
11481386|NCT01484561|Placebo Comparator|Sequence 2|
11481387|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
11481388|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
11481389|NCT01484548|Active Comparator|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
11481390|NCT01484535|Other|Ankle aspiration|ankle aspiration
11481391|NCT01484535|Placebo Comparator|placebo procedure|placebo procedure
11481392|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
11481393|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
11481394|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
11481395|NCT01484509||Intermittent claudication|
11481559|NCT01483443|Experimental|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
11481959|NCT01480817|Active Comparator|Sorafenib|Sorafenib 400mg po bid
11481396|NCT01484496|Placebo Comparator|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
11481397|NCT01484496|Experimental|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
11481398|NCT01484483||Cohort|
11481399|NCT01484470|No Intervention|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
11481400|NCT01484470|Experimental|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
11481401|NCT01484457|Experimental|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.
~The controller will be evaluated under two conditions:
~restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;
~restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (~25 g CHO)."
11481402|NCT01484444||gastrointestinal cancer|
11481403|NCT01484431|Experimental|Tadalafil|"Light Weight <25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks.
~Middle Weight: 25 kg to <40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks.
~Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks."
11481404|NCT01484418|Experimental|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
11481405|NCT01484418|Experimental|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
11481406|NCT01484418|Active Comparator|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
11481407|NCT01484405|Other|anterolateral approach|surgical intervention THA anterolateral approach
11481408|NCT01484405|Other|posterior approach|surgical intervention THA posterior approach
11481409|NCT01484379|Experimental|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
11481410|NCT01484366|Active Comparator|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
11481411|NCT01484366|Active Comparator|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
11481412|NCT01484353|Experimental|Intervention group|This is the only arm in the study. They will be compared before and after
11481413|NCT01484340|Experimental|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
11481414|NCT01484340|Experimental|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
11481415|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
11481416|NCT01484314|Experimental|Migration Arm|Administration of eltrombopag to support platelets during chemotherapy
11481417|NCT01484288|Experimental|Device group|Barostim Neo system
11481418|NCT01484275|Experimental|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
11481419|NCT01484275|Placebo Comparator|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
11481420|NCT01484262||Liraglutide|
11481421|NCT01484262||Any insulin|
11481422|NCT01484223|Experimental|Experimental Group|Intervention group: Structured nursing intervention
11481423|NCT01484223|No Intervention|No intervention|Control group: conventional intervention or non_support
11481424|NCT01484210|Experimental|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
11481425|NCT01484197|Experimental|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
11481560|NCT01483443|No Intervention|without oophrectomy|Patient group without oophrectomy
11481427|NCT01484197|Experimental|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
11481428|NCT01484197|Experimental|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
11481429|NCT01484184|Active Comparator|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
11481430|NCT01484184|Placebo Comparator|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
11481431|NCT01484171|Active Comparator|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
11481432|NCT01484171|Experimental|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
11481433|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
11481434|NCT01484145|Active Comparator|6 mA.min, 20 mins|
11481435|NCT01484145|Experimental|6 mA/min, 20 mins, clamping|
11481436|NCT01484145|Experimental|6 mA/min, 20 mins, debridement, clamping|
11481437|NCT01484145|Experimental|15 mA/min, 30 mins, clamping|
11481438|NCT01484145|Experimental|15 mA/min, 50 mins, debridement, clamping|
11481439|NCT01484132|Experimental|Composite|
11481440|NCT01484119|Active Comparator|Investigational Drug|ACT-129968
11481441|NCT01484119|Placebo Comparator|Comparative Drug|matching placebo tablets and capsules
11481442|NCT01484119|Active Comparator|Reference Drug|Cetirizine
11481443|NCT01484106|Experimental|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
11481444|NCT01484106|Active Comparator|Control|Standard of Care
11481445|NCT01484093|Experimental|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR.
11481446|NCT01484080|Experimental|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
11481447|NCT01484080|Active Comparator|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
11481448|NCT01484067|Experimental|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
11481449|NCT01484067|No Intervention|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
11481450|NCT01484054|Other|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
11481451|NCT01484054|Other|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
11481452|NCT01484041|Experimental|Dovitinib plus aromatase inhibitors|Dovitinib with aromatase inhibitor
11481453|NCT01484028|Other|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
11481454|NCT01484028|Other|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
11481455|NCT01484028|Other|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
11481456|NCT01484028|Other|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
11481457|NCT01484015|Experimental|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
11481458|NCT01484015|Experimental|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
11481459|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
11481460|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
11481461|NCT01483989|Experimental|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
11481462|NCT01483976|Active Comparator|Oral medical nutritional supplement without AN777|orally over a three hour period
11481463|NCT01483976|Experimental|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
11481464|NCT01483963|Experimental|AA4500 0.29 mg/1 mL|Up to three injections
11481465|NCT01483963|Experimental|AA4500 0.58 mg/2 mL|Up to three injections
11481466|NCT01483963|Experimental|AA4500 0.58 mg/1 mL|Up to three injections
11481467|NCT01483963|Experimental|AA4500 0.58 mg/0.5 mL|Up to three injections
11481468|NCT01483963|Other|Shoulder exercises|Home shoulder exercises for 64 days
11481469|NCT01483950||Patients with hypercholesterolaemia|
11481561|NCT01483430|Placebo Comparator|Placebo|
11481470|NCT01483937|Active Comparator|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
11481471|NCT01483937|Experimental|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
11481472|NCT01483924|Experimental|10 mg Apo805K1, or placebo|
11481473|NCT01483924|Experimental|30 mg Apo805K1, or placebo|
11481474|NCT01483924|Experimental|60 mg Apo805K1, or placebo|
11481475|NCT01483924|Experimental|100 mg Apo805K1, or placebo|
11481476|NCT01483911|Experimental|ALX-0171|
11481477|NCT01483911|Placebo Comparator|Placebo|
11481478|NCT01483898|Experimental|ixmyelocel-T|
11481479|NCT01483898|Placebo Comparator|Placebo|
11481480|NCT01483885|Experimental|TENS 4Hz|
11481481|NCT01483885|Experimental|Interferential Current 4Hz|
11481482|NCT01483885|Placebo Comparator|TENS|
11481483|NCT01483885|Placebo Comparator|Interferential Current|
11481484|NCT01483885|Experimental|Manual Acupuncture|
11481485|NCT01483885|Experimental|TENS 100 Hz|
11481486|NCT01483885|Experimental|Interferential Current 100Hz|
11481487|NCT01483872|Experimental|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
11481488|NCT01483872|Placebo Comparator|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
11481489|NCT01483859|Other|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
11481490|NCT01483846|Experimental|AV-101|"Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
~--------------------------------------------------------------------------------"
11481491|NCT01483846|Placebo Comparator|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
11481492|NCT01483833|Active Comparator|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
11481493|NCT01483833|Placebo Comparator|Placebo|Placebo administration intra-anally twice daily for 14 days
11481494|NCT01483820|Experimental|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
11481495|NCT01483807|Experimental|SPT-B then SPT-R|Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
11481496|NCT01483807|Experimental|SPT-R then SPT-B|Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
11481497|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
11481498|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
11481499|NCT01483781|Experimental|Canagliflozin|
11481500|NCT01483781|Placebo Comparator|Placebo|
11481501|NCT01483768|Experimental|Arm A:|Sleeve gastrectomy for morbid obesity
11481502|NCT01483755|Experimental|Postconditionned|36 postconditionned patients
11481503|NCT01483755|Sham Comparator|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
11481504|NCT01483742|Experimental|Combination without RO5024048|Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
11481505|NCT01483742|Experimental|Combination with RO5024048|RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys [peginterferon alfa-2a] and ribavirin) in prior null responder patients
11481506|NCT01483729|Active Comparator|Part 1 A|
11481507|NCT01483729|Experimental|Part 1 B|
11481508|NCT01483729|Experimental|Part 1 C|
11481509|NCT01483729|Active Comparator|Part 2 D|
11481510|NCT01483729|Experimental|Part 2 E|
11481511|NCT01483729|Experimental|Part 2 F|
11481512|NCT01483716|No Intervention|Control|NIV alone
11481513|NCT01483716|Experimental|Intervention|Rehabilitation arm
11481514|NCT01483703||Diagnostic tool|Laser Speckle Imaging of Critical Care Neonates
11481515|NCT01483690|Experimental|Initial Dose Level|"Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21.
~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24"
11481516|NCT01483690|Experimental|Modified Dose Level|"Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21"
11481517|NCT01483677|Experimental|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
11481518|NCT01483677|Active Comparator|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
11481555|NCT01483482|Other|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.
~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
11482129|NCT01479660|Experimental|Probiotic|
11481519|NCT01483664||initial survivorship planning consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
11481520|NCT01483664||initial wellness rehabilitation consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
11481521|NCT01483651|Experimental|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:
~First study is regular insulin infused at lowest level with glucagon administration.
~Second study is regular insulin infused at medium level with glucagon adminstration.
~Third study is regular insulin infused at highest level with glucagon administration."
11481522|NCT01483651|Experimental|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:
~First study is regular insulin infused at lowest level with glucagon administration.
~Second study is regular insulin infused at highest level with glucagon adminstration.
~Third study is regular insulin infused at medium level with glucagon administration."
11481523|NCT01483651|Experimental|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:
~First study is regular insulin infused at medium level with glucagon administration.
~Second study is regular insulin infused at lowest level with glucagon adminstration.
~Third study is regular insulin infused at highest level with glucagon administration."
11481524|NCT01483651|Experimental|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:
~First study is regular insulin infused at medium level with glucagon administration.
~Second study is regular insulin infused at highest level with glucagon adminstration.
~Third study is regular insulin infused at lowest level with glucagon administration."
11481525|NCT01483651|Experimental|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:
~First study is regular insulin infused at highest level with glucagon administration.
~Second study is regular insulin infused at lowest level with glucagon adminstration.
~Third study is regular insulin infused at medium level with glucagon administration."
11481526|NCT01483651|Experimental|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:
~First study is regular insulin infused at highest level with glucagon administration.
~Second study is regular insulin infused at medium level with glucagon adminstration.
~Third study is regular insulin infused at lowest level with glucagon administration."
11481527|NCT01483638|Experimental|Experimental|axitinib
11481528|NCT01483638|Placebo Comparator|control|placebo
11481529|NCT01483625|Experimental|tiotropium 18mcg|active
11481530|NCT01483625|Placebo Comparator|Placebo|placebo
11481531|NCT01483612|Experimental|Lifestyle counseling|
11481532|NCT01483612|No Intervention|control|
11481533|NCT01483599|Experimental|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
11481534|NCT01483599|Experimental|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
11481535|NCT01483599|Experimental|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
11481536|NCT01483599|Experimental|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
11481537|NCT01483599|Experimental|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
11481538|NCT01483599|Active Comparator|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
11481539|NCT01483599|Placebo Comparator|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
11481540|NCT01483586|Experimental|KLTc high dose|6 KLTc gelcaps taken four times a day
11481541|NCT01483586|Experimental|KLTc low dose|3 KLTc gelcaps taken four times a day
11481542|NCT01483573|Experimental|straight leg raise|stretch the muscle
11481543|NCT01483573|Experimental|neural mobilization|stretch the nerve
11481544|NCT01483560|Experimental|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
11481545|NCT01483560|Placebo Comparator|Placebo|
11481546|NCT01483547||Neurosurgical|
11481547|NCT01483547||Non-neurosurgical|
11481548|NCT01483534|Experimental|Targeted Lung Denervation|Targeted Lung Denervation
11481549|NCT01483521|Experimental|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.
~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.
~Parents from experimental group were encouraged to keep a diary of their play record."
11481550|NCT01483508|Active Comparator|Flavanol and procyanidins|
11481551|NCT01483508|Experimental|Flavanols only|
11481552|NCT01483508|Experimental|Procyanidins only|
11481553|NCT01483495||Diagnostic tool|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
11481554|NCT01483482|Other|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.
~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
11481556|NCT01483469|Active Comparator|Concept Proof|
11481557|NCT01483469|Experimental|Receptor Occupancy|
11481558|NCT01483456|Other|Usual care|
11481564|NCT01483417|Experimental|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
11481565|NCT01483417|Active Comparator|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
11481566|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
11481567|NCT01483391|Active Comparator|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
11481568|NCT01483391|Experimental|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
11481569|NCT01483378|Other|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
11481570|NCT01483378|No Intervention|Subjects who declined the vaccine|
11481571|NCT01483352|Experimental|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
11481572|NCT01483339|Experimental|Metacognitive Therapy|
11481573|NCT01483339|Experimental|Exposure and Response Prevention|
11481574|NCT01483326||Cohort|
11481575|NCT01483300|Experimental|lobaplatin|gemcitabine plus lobaplatin
11481576|NCT01483300|Active Comparator|cisplatin|gemcitabine plus cisplatin
11481577|NCT01483287|Active Comparator|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
11481578|NCT01483287|Placebo Comparator|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
11481579|NCT01483274|Experimental|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
11481580|NCT01483274|Active Comparator|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
11481581|NCT01483261|Experimental|Trauma-Focused Cognitive Behavioral Therapy|
11481582|NCT01483261|No Intervention|Waiting List Control|
11481583|NCT01483248|Experimental|Intervention|Conventional therapy plus MenSCs treatment
11481584|NCT01483248|Active Comparator|No intervention|"Conventional therapy plus placebo treatment:
~Oral or intravenous administration"
11481585|NCT01483235|Experimental|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
11481586|NCT01483235|Active Comparator|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
11481587|NCT01483222|Experimental|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
11481588|NCT01483222|Experimental|MUELLER 4581|Wearing an elastic lumbar support for 6 months
11481589|NCT01483222|No Intervention|Blank Control|Receiving no intervention
11481590|NCT01483209|Experimental|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
11481591|NCT01483196|Experimental|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
11481592|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
11481593|NCT01483183|Placebo Comparator|Persistent or Paroxysmal AF Part 1: Placebo|
11481594|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
11481595|NCT01483183|Placebo Comparator|Placebo Part 2|
11481596|NCT01483170|Experimental|Fexinidazole|
11481597|NCT01483170|Placebo Comparator|Placebo fexinidazole|
11481598|NCT01483157|Experimental|low intensity with vascular occlusion|
11481599|NCT01483157|Experimental|high intensity resistance training|
11481600|NCT01483157|No Intervention|no exercise training|
11481601|NCT01483144|Experimental|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
11481602|NCT01483144|Active Comparator|Eflornithine plus Sulindac Placebo|Eflornithine 750 mg and Placebo
11481603|NCT01483144|Active Comparator|Sulindac plus Eflornithine Placebo|Sulindac 150 mg and Placebo
11481604|NCT01483131|Experimental|Low intensity resistance training|
11481605|NCT01483131|Experimental|High intensity resistance training|
11481606|NCT01483131|Experimental|Low intensity resistance training with vascular occlusion|
11481607|NCT01483118|Active Comparator|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
11481608|NCT01483118|Placebo Comparator|Placebo Arm|PCOS patients receiving placebo capsules
11481609|NCT01483105|Experimental|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
11481610|NCT01483105|No Intervention|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
11481611|NCT01483092|Experimental|inulin|
11481612|NCT01483092|Placebo Comparator|maltodextrin|
11481613|NCT01483079||Former preterm infants|A cohort of infants less than or equal to 1250 grams birth weight that received donor human milk products in the NICU will be recruited and followed. Some infants recruited will be from a previously studied population of very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
11481614|NCT01483066|Experimental|ShapeMatch Instrumentation|
11481615|NCT01483066|Active Comparator|Usual Instrumentation|
11481616|NCT01483053|Active Comparator|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
11481617|NCT01483053|Active Comparator|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
11481618|NCT01483027|Experimental|Treatment group|Standard of care second-line chemotherapy plus TheraSphere
11481619|NCT01483027|No Intervention|Control group|Standard of care second-line chemotherapy with no added therapy
11481620|NCT01483014|Experimental|imatinib|
11481621|NCT01483001|Experimental|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
11481622|NCT01482988||Critical care patients antipated to stay more than 72 hours|
11481623|NCT01482975|Experimental|Smoking and Alcohol Prevention|TTM expert system
11481624|NCT01482975|Active Comparator|Diet and Exercise|TTM expert system
11481625|NCT01482962|Experimental|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
11481626|NCT01482962|Active Comparator|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
11481627|NCT01482949|Experimental|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
11481628|NCT01482936|Experimental|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
11481629|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
11481630|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
11481631|NCT01482910|Experimental|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
11481632|NCT01482910|Active Comparator|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
11481633|NCT01482897|Experimental|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
11481634|NCT01482897|Placebo Comparator|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
11481635|NCT01482897|Sham Comparator|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
11481636|NCT01482897|No Intervention|no intervention|natural evolution of discal sciatica
11481637|NCT01482884|Experimental|1|tralokinumab (CAT-354) sc injection
11481638|NCT01482884|Placebo Comparator|2|placebo sc injection
11481639|NCT01482871|Experimental|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
11481640|NCT01482871|Experimental|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
11481641|NCT01482871|Experimental|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
11481642|NCT01482871|Experimental|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
11481643|NCT01482858|Experimental|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
11481644|NCT01482858|Placebo Comparator|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
11481645|NCT01482845|Experimental|Group 1|
11481646|NCT01482845|Experimental|Group 2|
11481647|NCT01482832|Experimental|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
11481648|NCT01482832|Active Comparator|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
11481649|NCT01482819|Other|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Lotrafilcon A
~Spectacles
~Galyfilcon A Plus
~Polymacon
~Galyfilcon A"
11481650|NCT01482819|Other|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Galyfilcon A Plus
~Galyfilcon A
~Lotrafilcon A
~Polymacon
~Spectacles"
11481651|NCT01482819|Other|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Galyfilcon A
~Polymacon
~Galyfilcon A Plus
~Spectacles
~Lotrafilcon A"
11481652|NCT01482819|Other|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Spectacles
~Lotrafilcon A
~Polymacon
~Galyfilcon A Plus
~Galyfilcon A"
11481653|NCT01482819|Other|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Polymacon
~Galyfilcon A
~Spectacles
~Galyfilcon A Plus
~Lotrafilcon A"
11481654|NCT01482819|Other|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Galyfilcon A
~Galyfilcon A Plus
~Polymacon
~Lotrafilcon A
~Spectacles"
11481655|NCT01482819|Other|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Polymacon
~Spectacles
~Galyfilcon A
~Lotrafilcon A
~Galyfilcon A Plus"
11481656|NCT01482819|Other|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Galyfilcon A Plus
~Lotrafilcon A
~Galyfilcon A
~Spectacles
~Polymacon"
11481657|NCT01482819|Other|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Lotrafilcon A
~Galyfilcon A Plus
~Spectacles
~Galyfilcon A
~Polymacon"
11481658|NCT01482819|Other|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:
~Spectacles
~Polymacon
~Lotrafilcon A
~Galyfilcon A
~Galyfilcon A Plus"
11481659|NCT01482806|Experimental|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
11481660|NCT01482806|Experimental|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
11481661|NCT01482806|No Intervention|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
11481662|NCT01482793|Active Comparator|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
11481663|NCT01482793|No Intervention|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
11481664|NCT01482780|Experimental|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
11481665|NCT01482780|No Intervention|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
11481666|NCT01482767|Experimental|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
11481667|NCT01482767|Experimental|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
11481668|NCT01482754|Experimental|Rituximab Infusion at 90-minutes|
11481669|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
11481670|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
11481671|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
11481672|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
11481673|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
11481674|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
11481675|NCT01482715|Experimental|Oral Rucaparib monotherapy|
11481676|NCT01482702|Experimental|weight loss intervention|Behavioral weight loss intervention
11481677|NCT01482702|Experimental|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
11481678|NCT01482702|Active Comparator|Comparator|Group of women who did not receive chemotherapy
11481679|NCT01482689|Experimental|Fish oil capsule|
11481680|NCT01482689|Experimental|Multivitamin tablet|
11481681|NCT01482676||1|controls (normal bladder function)
11481682|NCT01482676||2|acontractile bladder
11481683|NCT01482676||3|overactive bladder
11481684|NCT01482676||4|bladder pain syndrome
11481685|NCT01482663|No Intervention|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
11481686|NCT01482663|Experimental|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
11481687|NCT01482650|Experimental|Baska mask|
11481688|NCT01482650|Active Comparator|single use laryngeal mask airway (LMA)|
11481689|NCT01482637||CAS|There are no separate groups. All subjects are being asked to complete the CAS measure.
11481690|NCT01482624|Active Comparator|VISCOSEAL® SYRINGE|
11481691|NCT01482624|Other|Standard arthroscopic meniscal surgery|
11481692|NCT01482611|Experimental|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
11481693|NCT01482611|Experimental|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
11481694|NCT01482611|Experimental|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
11481695|NCT01482611|Experimental|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
11481696|NCT01482598|Active Comparator|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
11481697|NCT01482598|No Intervention|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
11481698|NCT01482585||early stage lung adenocarcinoma|
11481699|NCT01482572||Gene profiling Success|
11481700|NCT01482559|Placebo Comparator|dextrose 5%|IV Infusion
11481701|NCT01482559|Experimental|Dopamine Hydrochloride|IV Infusion
11481702|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
11481703|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
11481704|NCT01482533||Revision Total Hip Arthroplasty|
11481705|NCT01482533||Revision Total Knee Arthroplasty|
11481706|NCT01482520||Renal cell carcinoma|
11481707|NCT01482520||Hepatocellular carcinoma patients|
11481708|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.
~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
11481709|NCT01482468|Active Comparator|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
11481710|NCT01482468|Placebo Comparator|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
11481711|NCT01482455|Placebo Comparator|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
11481712|NCT01482455|Active Comparator|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
11481713|NCT01482455|Placebo Comparator|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
11481714|NCT01482455|Active Comparator|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
11481715|NCT01482442|Active Comparator|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
11481716|NCT01482442|Active Comparator|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
11481717|NCT01482429|Experimental|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
11481718|NCT01482429|No Intervention|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
11481719|NCT01482416|Experimental|Estrogen use|climacteric women will use conjugated equine estrogens
11481720|NCT01482416|Placebo Comparator|use of Placebo|climacteric women will use placebo
11481721|NCT01482403|Experimental|Treatment Arm A|24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
11481722|NCT01482403|Experimental|Treatment Arm B|24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
11481723|NCT01482403|Active Comparator|Treatment Arm C (Control)|4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
11481724|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
11481725|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
11481726|NCT01482390|Experimental|TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
11481727|NCT01482390|Active Comparator|TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
11481728|NCT01482377|Experimental|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
11481729|NCT01482377|Experimental|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
11481730|NCT01482377|Experimental|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
11481731|NCT01482377|Experimental|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
11481732|NCT01482364|Experimental|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
11481733|NCT01482364|Placebo Comparator|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
11481734|NCT01482351|Experimental|MCI/OSA/CPAP Adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was equal to or greater than 4 hours per night over one year. CPAP adherence Intervention was provided by research staff.
11481735|NCT01482351|Experimental|MCI/OSA/CPAP Non-adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was less than 4 hours per night or CPAP use was withdrew for any reason over one year. Attention control intervention was provided by staff.
11481736|NCT01482338|Experimental|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
11481737|NCT01482338|Active Comparator|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
11481738|NCT01482325|Experimental|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
11481805|NCT01481870|Active Comparator|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
11481806|NCT01481870|Active Comparator|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
11481739|NCT01482312|Active Comparator|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
11481740|NCT01482312|Active Comparator|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
11481741|NCT01482312|Active Comparator|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
11481742|NCT01482299|Experimental|RAD001 (everolimus)|
11481743|NCT01482286|Experimental|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
11481744|NCT01482286|Experimental|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
11481745|NCT01482286|Experimental|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
11481746|NCT01482286|No Intervention|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
11481747|NCT01482273|Active Comparator|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
11481748|NCT01482273|Active Comparator|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
11481749|NCT01482260||Primary Cutaneous Malignant Melanoma|
11481750|NCT01482260||Cutaneous Malignant Melanoma Metastases|
11481751|NCT01482260||Benign Melanocytic Nevi|
11481752|NCT01482247|Active Comparator|L-arginine|
11481753|NCT01482247|Placebo Comparator|Placebo Supplement|
11481754|NCT01482234|Experimental|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
11481755|NCT01482234|Experimental|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
11481756|NCT01482234|Experimental|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
11481757|NCT01482234|No Intervention|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
11481758|NCT01482221|Experimental|1|
11481759|NCT01482221|Experimental|2|
11481760|NCT01482221|Placebo Comparator|3|
11481761|NCT01482195|Experimental|Recombinant Adeno-Associated Virus|
11481762|NCT01482169|Active Comparator|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
11481763|NCT01482169|Experimental|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
11481764|NCT01482156|Experimental|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
11481765|NCT01482143|Experimental|All Study subjects|
11481766|NCT01482130|Experimental|Training group|All participants in the training group will pursue a 12 weeks of strength training.
11481767|NCT01482130|Other|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
11481768|NCT01482117|Active Comparator|Clopidogrel|single oral administration of 300mg of clopidogrel
11481769|NCT01482117|Active Comparator|Cilostarole|single oral administration of 100mg of cilostazole
11481770|NCT01482117|Active Comparator|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
11481771|NCT01482104|Experimental|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
11481772|NCT01482104|Active Comparator|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
11481773|NCT01482091|Placebo Comparator|Intranasal Saline|
11481774|NCT01482091|Experimental|Intranasal Fentnayl|
11481775|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
11481776|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.
~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:
~Number of singleton or multiple pregnancy
~Parity of parturients
~Anesthetic technique (spinal or epidural)
~Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
11481807|NCT01481857|Experimental|Thoracolumbar proprioception|
11481808|NCT01481857|Experimental|Segmental Stabilization|
11482211|NCT01479114|Experimental|G-CSF group|
11481777|NCT01482065|Experimental|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.
~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
11481778|NCT01482052|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
11481779|NCT01482052|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
11481780|NCT01482039|No Intervention|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
11481781|NCT01482039|Experimental|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
11481782|NCT01482039|Experimental|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
11481783|NCT01482026|Experimental|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
11481784|NCT01482026|Experimental|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
11481785|NCT01482013|Experimental|HPP854|Oral HPP854 once a day for 28 days.
11481786|NCT01482013|Placebo Comparator|Placebo|Oral, placebo once a day for 28 days.
11481787|NCT01482000|Experimental|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
11481788|NCT01482000|Active Comparator|Control|The control group will get the usual care with some additional tests for the study.
11481789|NCT01481987|Experimental|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
11481790|NCT01481987|No Intervention|Control|Subjects with normal visual acuity and OCT profile
11481791|NCT01481974|Experimental|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
11481792|NCT01481961|Experimental|rTMS arm|
11481793|NCT01481948|Experimental|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
11481794|NCT01481948|Active Comparator|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
11481795|NCT01481948|No Intervention|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
11481796|NCT01481935|Experimental|Enhanced Cleaning|Rooms in the Enhanced Cleaning arm will receive cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
11481797|NCT01481935|Sham Comparator|Sham Enhanced Cleaning|Rooms in the Sham Enhanced Cleaning arm will receive a sham cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
11481798|NCT01481922|Active Comparator|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
11481799|NCT01481922|Experimental|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
11481800|NCT01481909|Placebo Comparator|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
11481801|NCT01481909|Active Comparator|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
11481802|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
11481803|NCT01481883|Experimental|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
11481804|NCT01481883|Placebo Comparator|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
11481958|NCT01480830|Experimental|Magnetic endoscopic imaging colonoscopy|
11481809|NCT01481844|Experimental|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
11481810|NCT01481844|Active Comparator|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
11481811|NCT01481831|Active Comparator|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
11481812|NCT01481831|Experimental|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
11481813|NCT01481831|Active Comparator|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
11481814|NCT01481831|Experimental|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
11481815|NCT01481818|Experimental|radioprotector|
11481816|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
11481817|NCT01481779|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
11481818|NCT01481779|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
11481819|NCT01481766|Experimental|Iron plus dietary counseling (Non-anemic iron deficiency)|
11481820|NCT01481766|Placebo Comparator|Placebo plus dietary counseling (Non-anemic iron deficiency)|
11481821|NCT01481766|No Intervention|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
11481822|NCT01481766|Active Comparator|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
11481823|NCT01481753|Active Comparator|Braun arm|patients received Braun enteroenterostomy
11481824|NCT01481753|Active Comparator|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
11481825|NCT01481740|Experimental|Phenylephrine bolus|
11481826|NCT01481740|Experimental|Phenylephrine infusion|
11481827|NCT01481727|Placebo Comparator|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
11481828|NCT01481727|Active Comparator|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
11481829|NCT01481714|Active Comparator|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:
~A sachet mixed with 250 mL of water at 18:00 pm
~A sachet mixed with 250 mL of water at 21:00 pm
~A minimum of 4 litres of fluid were recommended throughout the preparation"
11481830|NCT01481714|Experimental|Split-dose sodium picosulphate preparation|"The day before the procedure:
~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids
~The day of the procedure:
~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.
~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
11481831|NCT01481701|Experimental|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
11481832|NCT01481688|No Intervention|Control|Routine haemodialysis sessions as per usual
11481833|NCT01481688|Experimental|Intradialytic exercise|One hour of exercise completed during haemodialysis.
11481834|NCT01481688|Active Comparator|Extra time|30 minutes extra dialysis time.
11481835|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
11481836|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
11481837|NCT01481662||retrospective|cases retrospectively reported the last 20 years
11481838|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:
~new cases prospectively reported"
11481839|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
11481840|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
11481841|NCT01481623|Other|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
11481842|NCT01481610|Experimental|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
11481843|NCT01481610|Active Comparator|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
11481844|NCT01481597|Experimental|deuteporfin 1mg/kg|
11481845|NCT01481597|Active Comparator|deuteporfin 2.5mg/kg|
11481846|NCT01481597|Active Comparator|deuteporfin 5mg/kg|
11481847|NCT01481597|Active Comparator|deuteporfin 7.5mg/kg|
11481848|NCT01481597|Placebo Comparator|placebo|
11481849|NCT01481584|Experimental|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
11481850|NCT01481584|Active Comparator|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
11481851|NCT01481584|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
11481852|NCT01481584|No Intervention|Run-in|Run-in period (three days before intervention, defined diet)
11481853|NCT01481571|Experimental|Vitrification media and device|Vitrification medium oocyte, warming medium oocyte and Rapid-i
11481854|NCT01481558|Sham Comparator|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
11481855|NCT01481558|Experimental|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
11481856|NCT01481545|Experimental|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
11481857|NCT01481532|Experimental|Cohort 3|The third cohort will include up to 18 patients with Crotoxin doses of 0.12 to 1.16 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 48 hour intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 35 treatment days (15 dose levels).
11481858|NCT01481519|Active Comparator|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
11481859|NCT01481519|Placebo Comparator|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
11481860|NCT01481506|Experimental|Telemonitoring|
11481861|NCT01481506|No Intervention|Usual care|
11481862|NCT01481493|Experimental|Active Treatment|BT061 monoclonal antibody (subcutaneous)
11481863|NCT01481493|Placebo Comparator|Placebo|subcutaneous injection of placebo
11481864|NCT01481480|Experimental|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
11481865|NCT01481480|Active Comparator|Arthroscopic repair|An arthroscopic repair is performed
11481866|NCT01481467|Experimental|Intervention|Influenza vaccination implementation strategy applied.
11481867|NCT01481467|No Intervention|Control|Usual care.
11481868|NCT01481454|Experimental|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
11481869|NCT01481454|Experimental|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
11481870|NCT01481454|Experimental|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
11481871|NCT01481454|Active Comparator|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
11481872|NCT01481441|Other|SonoVue|Ultrasound Contrast Agent
11481873|NCT01481428|Active Comparator|Attention Control|
11481874|NCT01481428|Experimental|Computer-facilitated HIV intervention|
11481875|NCT01481402|Placebo Comparator|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
11481876|NCT01481402|Other|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
11481877|NCT01481389|Active Comparator|Theobromine drink|
11481878|NCT01481389|Active Comparator|Cocoa drink|
11481879|NCT01481389|Placebo Comparator|Placebo drink|
11481880|NCT01481389|Active Comparator|Cocoa and theobromine drink|
11481881|NCT01481363|Active Comparator|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
11481882|NCT01481363|Experimental|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
11481883|NCT01481350|Experimental|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
11481884|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
11481885|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
11481886|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
11481887|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
11481888|NCT01481311||Patients before dialysis treatment|
11481889|NCT01481311||Patients after dialysis treatment|
11481890|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
11481891|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
11481892|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
11481893|NCT01481298||controls|24 healthy controls
11481894|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
11481895|NCT01481272|Experimental|O-IVAC|Ofatumumab Etoposide Ifosfamide Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Colony Stimulating Factor
11481896|NCT01481259|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
11481897|NCT01481259|Active Comparator|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
11481898|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
11481899|NCT01481233|Experimental|Single arm|Colchicine 0.5 mg BID x 21 days
11481900|NCT01481220|Experimental|Azacitidine + Eltrombopag|
11481901|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
11481902|NCT01481194|Experimental|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
11481903|NCT01481181|Experimental|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
11481904|NCT01481181|No Intervention|purified water only|non zinc enriched, purified drinking water
11481905|NCT01481181|No Intervention|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
11481906|NCT01481168|Active Comparator|"Pacemaker on"|DDD+/-R pacing
11481907|NCT01481168|Placebo Comparator|"Pacemaker off"|ODO pacing
11481908|NCT01481168|Experimental|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
11481909|NCT01481142|Experimental|Adacolumn|
11481910|NCT01481129|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11481911|NCT01481116|Experimental|TAK-875 25 mg QD|
11481912|NCT01481116|Experimental|TAK-875 50 mg QD|
11481913|NCT01481116|Active Comparator|Glimepiride 1-2 mg QD|
11481914|NCT01481103|Active Comparator|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
11481915|NCT01481103|No Intervention|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
11481916|NCT01481090|Active Comparator|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
11481917|NCT01481090|No Intervention|Control|Group will not receive acupuncture.
11481918|NCT01481077|Experimental|Treatment A|
11481919|NCT01481077|Experimental|Treatment B|
11481920|NCT01481077|Experimental|Treatment C|
11481921|NCT01481064|Active Comparator|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
11481922|NCT01481064|No Intervention|Usual care|After baseline measurement no intervention will occur in these hospitals.
11481923|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
11481924|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
11481925|NCT01481025|Experimental|Cimicifuga+Hiperico|80 + 450 mg / tablet
11481926|NCT01481025|Active Comparator|Cimicifuga Herbarium|80 mg / caps
11481927|NCT01481025|Active Comparator|Aplause®|20 mg / tablet
11481928|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
11481929|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
11481930|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
11481931|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
11481932|NCT01480999||Laparotomy (open surgery)|
11481933|NCT01480999||Laparoscopic surgery|
11481934|NCT01480999||Robotic assisted surgery|
11481935|NCT01480986|Experimental|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
11481936|NCT01480973|Experimental|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
11481937|NCT01480960|Active Comparator|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
11481938|NCT01480960|No Intervention|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
11481939|NCT01480947|Experimental|Bio-Three|add-on treatment of the probiotics (Bio-three)
11481940|NCT01480947|No Intervention|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
11481941|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
11481942|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
11481943|NCT01480921|Experimental|home based exercise training|
11481944|NCT01480921|Active Comparator|supervised exercise training|
11481945|NCT01480908|Experimental|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
11481946|NCT01480908|Experimental|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
11481947|NCT01480908|Experimental|Control|Healthy control subjects, about 20 patients
11481948|NCT01480895|No Intervention|Post GDM follow-up group.|
11481949|NCT01480895|Experimental|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
11481950|NCT01480882|Active Comparator|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
11481951|NCT01480882|Experimental|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
11481952|NCT01480869|Active Comparator|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
11481953|NCT01480869|Experimental|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:
~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level < 10 ng/mL
~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level < 20 ng/mL
~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level < 30 ng/mL"
11481954|NCT01480856|Active Comparator|Cobedding|Newborn twins are settled in a single bed : this is cobedding
11481955|NCT01480856|Placebo Comparator|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
11481956|NCT01480843|Experimental|Glargine|We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
11481957|NCT01480830|No Intervention|Standard colonoscopy|
11481960|NCT01480817|Experimental|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
11481961|NCT01480804|Experimental|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
11481962|NCT01480804|No Intervention|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
11481963|NCT01480791|Active Comparator|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
11481964|NCT01480791|Experimental|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
11481965|NCT01480791|No Intervention|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
11481966|NCT01480778|Experimental|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
11481967|NCT01480778|Active Comparator|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
11481968|NCT01480765|Placebo Comparator|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
11481969|NCT01480765|Active Comparator|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
11481970|NCT01480765|Active Comparator|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
11481971|NCT01480752|Active Comparator|Lornoxicam|
11481972|NCT01480752|Placebo Comparator|normal saline|
11481973|NCT01480752|Placebo Comparator|no injection|
11481974|NCT01480739|Experimental|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
11481975|NCT01480739|Experimental|2|Placebo twice daily for 7 days
11481976|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
11481977|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
11481978|NCT01480713|Experimental|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
11481979|NCT01480700|Experimental|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
11481980|NCT01480700|Active Comparator|standard eggs|subjects consume 2 standard eggs per day
11481981|NCT01480687|Experimental|Omega-3 fatty acid|
11481982|NCT01480687|Active Comparator|Ciprofibrate|
11481983|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
11481984|NCT01480661|Active Comparator|Roflumilast|
11481985|NCT01480661|Placebo Comparator|Placebo|
11481986|NCT01480648|Experimental|BI144807|Subjects receive a single oral dose of BI144807solution
11481987|NCT01480648|Placebo Comparator|Placebo|Subjects receive a single oral dose of placebo solution
11481988|NCT01480635||Incomplete Colonoscopy|
11481989|NCT01480622|Experimental|TDF tablets|Tenofovir disoproxil fumarate tablets
11481990|NCT01480609|Active Comparator|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
11481991|NCT01480609|Active Comparator|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
11481992|NCT01480596|Experimental|Belimumab|10mg/kg
11481993|NCT01480596|Placebo Comparator|Placebo|placebo IV infusion
11481994|NCT01480583|Experimental|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
11481995|NCT01480583|Experimental|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
11481996|NCT01480557|Active Comparator|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
11481997|NCT01480557|Active Comparator|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
11481998|NCT01480544|No Intervention|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
11481999|NCT01480544|Experimental|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
11482000|NCT01480544|Experimental|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
11482001|NCT01480544|No Intervention|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
11482002|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
11482003|NCT01480492|No Intervention|therapy|
11482004|NCT01480479|Experimental|Rindopepimut/GM-CSF plus Temozolomide|
11482005|NCT01480479|Active Comparator|KLH plus Temozolomide|
11482006|NCT01480466|Experimental|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
11482007|NCT01480466|No Intervention|Standard care|This arm is standard care for overweight/obesity.
11482008|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
11482009|NCT01480440||Trabecular Metal Reverse Shoulder System|Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
11482010|NCT01480414|Experimental|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
11482011|NCT01480414|Experimental|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
11482012|NCT01480401|Experimental|low-sodium diet|(1500 mg daily)
11482013|NCT01480401|No Intervention|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
11482014|NCT01480388|Placebo Comparator|Placebo|
11482015|NCT01480388|Experimental|JNJ-39758979 (10 mg/d)|
11482016|NCT01480388|Experimental|JNJ-39758979 (30 mg/d)|
11482017|NCT01480388|Experimental|JNJ-39758979 (100 mg/d)|
11482018|NCT01480388|Experimental|JNJ-39758979 (300 mg/d)|
11482019|NCT01480375|Experimental|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
11482020|NCT01480375|No Intervention|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
11482021|NCT01480362|Experimental|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
11482022|NCT01480362|Active Comparator|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
11482023|NCT01480336|Placebo Comparator|Amiodarone with Placebo|
11482024|NCT01480336|Active Comparator|Amiodarone with Ranolazine|
11482025|NCT01480323|Experimental|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
11482026|NCT01480310|Experimental|A|
11482027|NCT01480310|Experimental|B|
11482028|NCT01480297|Experimental|Salsalate|All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
11482029|NCT01480284|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
11482030|NCT01480284|Active Comparator|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
11482031|NCT01480271|Experimental|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
11482032|NCT01480271|Placebo Comparator|Part 1 Cohort 1 Placebo|Placebo
11482033|NCT01480271|Experimental|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
11482034|NCT01480271|Placebo Comparator|Part 1 Cohort 2 Placebo|Placebo
11482035|NCT01480271|Experimental|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
11482036|NCT01480271|Placebo Comparator|Part 1 Cohort 3 Placebo|Placebo
11482037|NCT01480271|Experimental|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
11482038|NCT01480271|Placebo Comparator|Part 1 Cohort 4 Placebo|Placebo
11482039|NCT01480271|Experimental|Part 1 Cohort 5 GSK245053|400ng GSK2445053
11482040|NCT01480271|Placebo Comparator|Part 1 Cohort 5 Placebo|Placebo
11482041|NCT01480271|Experimental|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
11482042|NCT01480271|Placebo Comparator|Part 1 Cohort 6 Placebo|Placebo
11482043|NCT01480271|Experimental|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
11482044|NCT01480271|Placebo Comparator|Part 1 Cohort 7 Placebo|Placebo
11482045|NCT01480271|Experimental|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
11482046|NCT01480271|Placebo Comparator|Part 1 Cohort 8 Placebo|Placebo
11482047|NCT01480258|Experimental|PR5I|"Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).
~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
11482048|NCT01480258|Active Comparator|INFANRIX™ hexa|"Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).
~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
11482049|NCT01480245|Experimental|Continuous Dosing|GSK2402968 6mg/kg/week
11482050|NCT01480245|Experimental|Intermittent Dosing|GSK2402968 6mg/kg/week
11482051|NCT01480245|No Intervention|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
11482052|NCT01480232|Experimental|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
11482053|NCT01480232|Active Comparator|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
11482054|NCT01480232|Experimental|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
11482055|NCT01480232|Placebo Comparator|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
11482056|NCT01480219||Any Voriconazole|
11482057|NCT01480219||No Voriconazole|
11482058|NCT01480193|Active Comparator|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
11482059|NCT01480193|Experimental|Integrative Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
11482060|NCT01480180|Experimental|Prophylaxis|
11482061|NCT01480180|Experimental|On-demand|
11482062|NCT01480167|Active Comparator|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
11482063|NCT01480167|Active Comparator|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
11482064|NCT01480154|Experimental|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11482065|NCT01480141|Experimental|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
11482066|NCT01480102|Placebo Comparator|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
11482067|NCT01480102|Active Comparator|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
11482068|NCT01480089|Placebo Comparator|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
11482069|NCT01480089|Active Comparator|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
11482070|NCT01480076|Experimental|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
11482071|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
11482072|NCT01480050|Experimental|Dose Finding and Dose Expansion|"DOSE FINDING 4 Levels
~For all Levels:
~Cycle 1 Mibefradil QID dosing, Days 1-8 (to accommodate PKs) (*2 doses on Days 1 and 8) Temozolomide daily at 150-200 mg/m2, Days 9-13;
~Cycles 2+ Mibefradil QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12
~DOSE EXPANSION 28-day cycles FLT PET scans, Baseline x2, Day 7 Mibefradil MTD determined at Dose Finding QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12"
11482073|NCT01480037||Elderly|Individuals between 60 and 70 years-old
11482074|NCT01480037||Long-lived|Individuals above 85 years-old
11482075|NCT01480037||Young|Individuals between 20 and 30 years-old
11482076|NCT01480011|Experimental|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
11482077|NCT01479998|Active Comparator|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
11482078|NCT01479998|Experimental|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
11482079|NCT01479985|Experimental|CDM Tool|participants will be randomized to completing the CDM tool
11482080|NCT01479985|No Intervention|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
11482081|NCT01479972|Experimental|VPM1002|
11482082|NCT01479972|Active Comparator|BCG|
11482083|NCT01479959|Active Comparator|No PEEP level|protocol conducted while no PEEP is applied
11482084|NCT01479959|Active Comparator|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
11482085|NCT01479959|Active Comparator|intermediate PEEP level (PEEP50)|50% of PEEPeff
11482086|NCT01479946|Experimental|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
11482087|NCT01479946|No Intervention|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
11482088|NCT01479933|Experimental|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
11482089|NCT01479933|Experimental|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
11482090|NCT01479933|Placebo Comparator|Placebo|
11482091|NCT01479920|Active Comparator|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)
~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
11482092|NCT01479920|Sham Comparator|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)
~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
11482093|NCT01479907|Active Comparator|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
11482094|NCT01479907|Placebo Comparator|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
11482095|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
11482096|NCT01479881|Experimental|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
11482097|NCT01479881|Experimental|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
11482098|NCT01479881|Experimental|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
11482099|NCT01479881|Experimental|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
11482100|NCT01479868|Experimental|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
11482101|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
11482102|NCT01479842|Experimental|Treatment (enzyme inhibitor, chemo, monoclonal antibody)|Patients receive BTK inhibitor PCI-32765 PO QD on days 1-28. Patients also receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue receiving BTK inhibitor PCI-32765 PO in the absence of disease progression or unacceptable toxicity.
11482103|NCT01479829|Active Comparator|ESC + CBX|Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.
11482104|NCT01479829|Placebo Comparator|ESC + PBO.|Escitalopram 10 mg twice day plus placebo administered twice daily.
11482105|NCT01479803|Active Comparator|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
11482106|NCT01479803|Active Comparator|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
11482107|NCT01479790|No Intervention|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
11482108|NCT01479790|Experimental|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.
~A thermographic sequence will be captured from each eye.
~After 20 minutes, a second pair of thermographic sequences will be captured.
~An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.
~A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
11482109|NCT01479777|Experimental|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
11482110|NCT01479764|Experimental|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
11482111|NCT01479764|Active Comparator|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
11482112|NCT01479751|Experimental|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
11482113|NCT01479751|Experimental|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
11482114|NCT01479751|No Intervention|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
11482115|NCT01479751|No Intervention|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
11482116|NCT01479751|Experimental|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
11482117|NCT01479738|Experimental|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
11482118|NCT01479725|Experimental|Ulcerative IC|HBOT for ulcerative IC
11482119|NCT01479725|Experimental|Non-Ulcerative IC|HBOT for non-ulcerative IC
11482120|NCT01479712|Active Comparator|Irrigation|This is the arm that will receive irrigation.
11482121|NCT01479712|No Intervention|No Irrigation|This is the arm that will not receive irrigation.
11482122|NCT01479699|Placebo Comparator|Placebo capsule|Four placebo capsules containing safflower oil only
11482123|NCT01479699|Active Comparator|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
11482124|NCT01479686|Active Comparator|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
11482125|NCT01479686|Experimental|intraoperative MRI|iMRI guided resection in adults with glioma
11482126|NCT01479673|No Intervention|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
11482127|NCT01479673|Experimental|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
11482128|NCT01479660|Placebo Comparator|Control|
11482130|NCT01479647|Experimental|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
11482131|NCT01479647|Experimental|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
11482132|NCT01479647|Experimental|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
11482133|NCT01479647|Experimental|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
11482134|NCT01479647|Experimental|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
11482135|NCT01479634|Active Comparator|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
11482136|NCT01479634|Active Comparator|Arm B|Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
11482137|NCT01479621|Experimental|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11482138|NCT01479621|Experimental|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11482139|NCT01479621|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11482140|NCT01479621|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11482141|NCT01479621|Experimental|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
11482142|NCT01479621|Experimental|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.
~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
11482143|NCT01479608|Experimental|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
11482144|NCT01479608|Experimental|B: Liver transplantation|For non-resectable patients metachronous disease.
11482145|NCT01479608|Experimental|C:Liver transplantation|For non-resectable patients synchronous disease.
11482146|NCT01479608|Experimental|D:Liver transplantation|For non-resectable patients synchronous disease.
11482147|NCT01479595|Experimental|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
11482148|NCT01479595|Placebo Comparator|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
11482149|NCT01479556|Placebo Comparator|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
11482150|NCT01479556|Active Comparator|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
11482151|NCT01479543|Experimental|Group A|Volunteers received Probiotic CNCM I-4034.
11482152|NCT01479543|Experimental|Group B|Volunteers receive Probiotic CNCM I-4035.
11482153|NCT01479543|Experimental|Group C|Volunteers are given Probiotic CNCM I-4036.
11482154|NCT01479543|Experimental|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
11482155|NCT01479543|Placebo Comparator|Group E|Volunteers receive a Placebo.
11482156|NCT01479530|Placebo Comparator|Placebo|
11482157|NCT01479530|Experimental|Azilect®|
11482158|NCT01479517|Experimental|Kovacaine Mist 0.1 mL x 4 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
11482159|NCT01479517|Experimental|Kovacaine Mist 0.2 mL x 2 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
11482160|NCT01479517|Experimental|Kovacaine Mist, 0.2 mL x 1 spray|Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
11482161|NCT01479504|Experimental|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
11482162|NCT01479504|Active Comparator|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
11482163|NCT01479504|Experimental|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
11482164|NCT01479504|Active Comparator|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
11482165|NCT01479491||Case Group|Children aged < 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
11482212|NCT01479114|No Intervention|Non-GCSF group|
11482166|NCT01479478|Active Comparator|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
11482167|NCT01479478|Placebo Comparator|Placebo|Placebo capsule, one daily until delivery.
11482168|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part A)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
11482169|NCT01479465|Experimental|FOLFIRI + SIM 200 mg (Part B)|Participants will receive SIM 200 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
11482170|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part B)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
11482171|NCT01479465|Experimental|FOLFIRI + Placebo (Part B)|Participants will receive placebo to match SIM via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
11482172|NCT01479452|Other|Bariatric surgery|Bariatric surgery
11482173|NCT01479452|Other|Controls|Usual care
11482174|NCT01479439|Experimental|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
11482175|NCT01479426|Experimental|EFLA400(960mg)|
11482176|NCT01479426|Placebo Comparator|Placebo(960mg)|
11482177|NCT01479413||Schizophrenia|
11482178|NCT01479400||infants who were exposed to antipsychotics as fetus|
11482179|NCT01479400||infants who were not exposed to antipsychotics as fetus|
11482180|NCT01479387||Group 1|
11482181|NCT01479374|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
11482182|NCT01479374|Placebo Comparator|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
11482183|NCT01479374|Active Comparator|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
11482184|NCT01479348|Experimental|1/Intravenous (IV) Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
11482185|NCT01479348|Experimental|2/Oral Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
11482186|NCT01479296|Experimental|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
11482187|NCT01479296|Experimental|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10^10 PU).
11482188|NCT01479296|Experimental|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10^10 PU).
11482189|NCT01479283|Active Comparator|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
11482190|NCT01479283|Experimental|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
11482191|NCT01479270|Active Comparator|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
11482192|NCT01479270|No Intervention|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
11482193|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
11482194|NCT01479244|Experimental|NeuVax™|NeuVax™ in WFI solution with Leukine®
11482195|NCT01479244|Active Comparator|Leukine®|Leukine® with WFI
11482196|NCT01479231|Experimental|dexlansoprazole|
11482197|NCT01479218|Other|PDA Occluder|single arm
11482198|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
11482199|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
11482200|NCT01479192|Experimental|Fenretinide|100mg: 2cps/day for 5 years followed by
11482201|NCT01479192|Placebo Comparator|Placebo|matched placebo 2 cps/day for 5 years
11482202|NCT01479179|Experimental|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
11482203|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
11482204|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
11482205|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
11482206|NCT01479153|Active Comparator|Subclavian catheterization|
11482207|NCT01479153|Active Comparator|Internal Jugular catheterization|
11482208|NCT01479153|Active Comparator|Femoral Catheterization|
11482209|NCT01479127|Experimental|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.
~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
11482210|NCT01479114|No Intervention|control group|
11482213|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
11482214|NCT01479088|Experimental|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.
~For subjects receiving a cinacalcet dose <30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.
~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.
~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value <180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
11482215|NCT01479075|Experimental|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
11482216|NCT01479075|Experimental|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
11482217|NCT01479075|Placebo Comparator|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
11482218|NCT01479075|Experimental|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
11482219|NCT01479075|Experimental|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
11482220|NCT01479075|Placebo Comparator|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
11482221|NCT01479062|Experimental|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
11482222|NCT01479062|Placebo Comparator|Control|Usual care
11482223|NCT01479049|Experimental|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
11482224|NCT01479049|Active Comparator|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
11482225|NCT01479036|Active Comparator|docetaxel and epirubicin|DE chemotherapy alone
11482226|NCT01479036|Experimental|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
11482227|NCT01479023|Experimental|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.
~Patient will have option to continue to Part 2 (extension phase)."
11482228|NCT01479023|Experimental|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.
~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.
~Patient will have option to continue to Part 2 (extension phase)."
11482229|NCT01479023|Experimental|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.
~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.
~Patient will have option to continue to Part 2 (extension phase)."
11482230|NCT01479023|Experimental|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.
~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.
~Patient will have option to continue to Part 2 (extension phase)."
11482231|NCT01479023|Experimental|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.
~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.
~Patient will have option to continue to Part 2 (extension phase)."
11482232|NCT01479023|Experimental|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.
~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.
~Patient will have option to continue to Part 2 (extension phase)."
11482233|NCT01479023|Experimental|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
11482234|NCT01479010|Experimental|Anakinra|
11482235|NCT01478997|Experimental|Flexsure Capsules|Investigational Product
11482236|NCT01478997|Placebo Comparator|Carboxy Methyl Cellulose Capsules|Placebo
11482237|NCT01478984|Active Comparator|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
11482238|NCT01478984|Active Comparator|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
11482239|NCT01478971|Experimental|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).
11482240|NCT01478958|Active Comparator|high saturated fat diet|
11482241|NCT01478958|Experimental|high monounsaturated fat diet|
11482242|NCT01478958|Experimental|high n-6 polyunsaturated fat diet|
11482243|NCT01478945|Active Comparator|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:
~Manual device administering NB-UVB"
11482244|NCT01478945|Active Comparator|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:
~Manual device administering NB-UVB (Waldmann)"
11482245|NCT01478945|Sham Comparator|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
11482246|NCT01478932|Experimental|Diaphragmatic Breathing Retraining|
11482247|NCT01478906||elderly ,adult|
11482248|NCT01478893|Experimental|SEL-068|
11482249|NCT01478893|Placebo Comparator|Saline|
11482250|NCT01478880|Experimental|cTBS|
11482251|NCT01478880|Sham Comparator|Sham cTBS|
11482252|NCT01478867||Celiac patients|
11482253|NCT01478854|Experimental|Neural Progenitor Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
11482334|NCT01478425|Placebo Comparator|Control|Saline nose-spray device
11482254|NCT01478841|Experimental|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
11482255|NCT01478841|Placebo Comparator|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
11482256|NCT01478828|Experimental|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
11482257|NCT01478815|Placebo Comparator|Standard Care|
11482258|NCT01478815|Experimental|Contingency management for abstinence from drugs|
11482259|NCT01478802|Active Comparator|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
11482260|NCT01478802|Experimental|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
11482261|NCT01478789|Experimental|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
11482262|NCT01478789|Experimental|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
11482263|NCT01478789|Placebo Comparator|placebo|100 g/d yogurt with no added plant sterol
11482264|NCT01478776|Active Comparator|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
11482265|NCT01478776|Placebo Comparator|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
11482266|NCT01478750|Experimental|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
11482267|NCT01478750|Experimental|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
11482268|NCT01478750|Experimental|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
11482269|NCT01478750|Experimental|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
11482270|NCT01478737|Sham Comparator|Sham|Vitrectomy only
11482271|NCT01478737|Active Comparator|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
11482272|NCT01478724|Placebo Comparator|Placebo|Animal proteins
11482273|NCT01478724|Experimental|Milk protein fraction dose 1|
11482274|NCT01478724|Experimental|Milk protein fraction dose 2|
11482275|NCT01478711|Active Comparator|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
11482276|NCT01478711|No Intervention|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
11482277|NCT01478698|Experimental|Single dose|The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.
11482278|NCT01478698|Experimental|2 doses|The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day
11482279|NCT01478698|Experimental|4 doses|The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.
11482280|NCT01478698|No Intervention|control|Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
11482281|NCT01478685|Experimental|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
11482282|NCT01478685|Experimental|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2"
11482283|NCT01478685|Experimental|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
11482284|NCT01478672|No Intervention|Standard care|
11482285|NCT01478672|Experimental|Health coaching and and Life-long Monitoring|
11482286|NCT01478659|Active Comparator|Control bar and yogurt|
11482287|NCT01478659|Experimental|Fiber bar and yogurt|
11482288|NCT01478646|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
11482289|NCT01478646|Experimental|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
11482290|NCT01478633|Experimental|Galantamine|
11482291|NCT01478620|Experimental|Canephron® N|
11482292|NCT01478607|Experimental|1. Qutenza 30 minutes + SOC|
11482293|NCT01478607|Experimental|2. Qutenza 60 minutes + SOC|
11482294|NCT01478607|No Intervention|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
11482332|NCT01478438|Experimental|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
11482333|NCT01478425|Experimental|Active|Lipidic Microemulsion
11482295|NCT01478594|Experimental|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
11482296|NCT01478594|Active Comparator|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
11482297|NCT01478581|Experimental|Cohort 1|PCI-32765 420 mg per day
11482298|NCT01478581|Experimental|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
11482299|NCT01478581|Experimental|Cohort 3|PCI-32765 840 mg per day
11482300|NCT01478581|Experimental|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
11482301|NCT01478568|Experimental|mirabegron / desipramine|
11482302|NCT01478555|Experimental|Dose 1 of Bromfenac in DuraSite|
11482303|NCT01478555|Experimental|Dose 2 of Bromfenac in DuraSite|
11482304|NCT01478555|Experimental|Dose 3 of Bromfenac in DuraSite|
11482305|NCT01478555|Active Comparator|DuraSite|
11482306|NCT01478555|Active Comparator|Vehicle|
11482307|NCT01478542|Active Comparator|Favourable Prognosis F-A - Recruitment completed|Induction therapy with 4 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHOP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
11482308|NCT01478542|Experimental|Favourable F-B - Arm Closed|Induction therapy with 4 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,4 mg/sqm (max. 2mg absolute), Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHLIP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
11482309|NCT01478542|Active Comparator|Less Favourable LF-A - Recruitment completed|Induction therapy with 6 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHOP-14 an interim restaging will be performed.
11482310|NCT01478542|Experimental|Less Favourable LF-B - Recruitment completed|Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed. Recruitment completed.
11482311|NCT01478542|Experimental|Less Favourable LF-C - Recruitment completed|Induction therapy with 6 cycles of CHOP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) combined with an optimized Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHOP-14 an interim restaging will be performed. Recruitment completed.
11482312|NCT01478542|Experimental|Less Favourable LF-D - Recruitment completed|Induction therapy with 6 cycles of CHLIP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) combined with an optimised Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHLIP-14 an interim restaging will be performed. Recruitment completed.
11482313|NCT01478529|Experimental|Treatment Arm A|low dose of mirabegron
11482314|NCT01478529|Experimental|Treatment Arm B|high dose of mirabegron
11482315|NCT01478516|Experimental|Plasmin|eyes with macular edema
11482316|NCT01478503|Experimental|Treatment Arm A|mirabegron
11482317|NCT01478503|Placebo Comparator|Treatment Arm B|matching placebo
11482318|NCT01478490|Experimental|Treatment Arm 1A|mirabegron, poor metabolizers
11482319|NCT01478490|Experimental|Treatment Arm 1B|mirabegron, extensive metabolizers
11482320|NCT01478490|Experimental|Treatment Arm 2|mirabegron/metoprolol
11482321|NCT01478477|Experimental|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
11482322|NCT01478477|Placebo Comparator|Arm II (placebo)|Typical American Diet oils (TAD)
11482323|NCT01478477|Experimental|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
11482324|NCT01478477|Experimental|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
11482325|NCT01478477|Experimental|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
11482326|NCT01478477|Experimental|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
11482327|NCT01478464|No Intervention|Control group|Control group, does not receive any intervention
11482328|NCT01478464|Experimental|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
11482329|NCT01478451|Experimental|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
11482330|NCT01478451|Experimental|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
11482331|NCT01478451|No Intervention|Control|control shoulder (randomized)
11482335|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
11482336|NCT01478399|Experimental|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
11482337|NCT01478399|Experimental|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
11482338|NCT01478386|Other|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
11482339|NCT01478386|Experimental|Off-loading knee brace|
11482340|NCT01478386|Experimental|Viscosupplementation and knee brace|
11482341|NCT01478373|Experimental|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
11482342|NCT01478360|Experimental|AIN457|AIN457 10 mg/kg
11482343|NCT01478360|Placebo Comparator|Placebo|Placebo intravenous injection
11482344|NCT01478347|Experimental|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
11482345|NCT01478334|Experimental|Exercise then control|
11482346|NCT01478334|Experimental|Control then exercise|
11482347|NCT01478321|Experimental|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
11482348|NCT01478295|Experimental|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
11482349|NCT01478295|Active Comparator|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
11482350|NCT01478282|Active Comparator|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
11482351|NCT01478282|Active Comparator|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
11482352|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
11482353|NCT01478256|Active Comparator|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
11482354|NCT01478256|Active Comparator|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
11482355|NCT01478230|Experimental|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
11482356|NCT01478230|Active Comparator|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
11482357|NCT01478178|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
11482358|NCT01478165|Placebo Comparator|Tiva group (Group T)|
11482359|NCT01478165|Active Comparator|TIVA plus palonosetron group (Group T+P)|
11482360|NCT01478152|Experimental|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.
~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
11482361|NCT01478139|Experimental|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
11482362|NCT01478139|Experimental|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
11482363|NCT01478126|Experimental|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
11482364|NCT01478126|Placebo Comparator|Placebo|
11482365|NCT01478113|Active Comparator|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
11482366|NCT01478113|Placebo Comparator|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
11482367|NCT01478087|Other|Mysorba(single-arm)|
11482368|NCT01478074|Experimental|FLAG + NK Cells + ALT-801|
11482369|NCT01478061|Active Comparator|anastomoses in blood vessels and grafts|
11482370|NCT01478048|Experimental|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
11482371|NCT01478048|Active Comparator|Arm B: Bortezomib + Dexamethasone|
11482372|NCT01478035|Experimental|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
11482373|NCT01478035|Placebo Comparator|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
11482374|NCT01478022|Active Comparator|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
11482375|NCT01478022|Active Comparator|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
11482376|NCT01478022|Experimental|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
11482377|NCT01478009|Experimental|KRG Extract|
11482378|NCT01478009|Placebo Comparator|Placebo|
11482379|NCT01477996|Active Comparator|Group 1|27-gauge needle
11482380|NCT01477996|Active Comparator|Group 2|30-gauge needle
11482381|NCT01477983|Active Comparator|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
11482382|NCT01477983|Active Comparator|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
11482383|NCT01477983|Active Comparator|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
11482384|NCT01477983|Active Comparator|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
11482385|NCT01477957|Experimental|Surgery|bariatric surgery
11482386|NCT01477931|Experimental|Wellbutrin XL|
11482387|NCT01477905|Experimental|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
11482388|NCT01477905|Experimental|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
11482389|NCT01477892|Experimental|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
11482390|NCT01477892|Active Comparator|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
11482391|NCT01477879|Active Comparator|Versabase/20% S. purpurea extract|
11482392|NCT01477879|Placebo Comparator|placebo (versabase gel only)|placebo used will be versabase gel alone
11482393|NCT01477866|Experimental|citogenex|citogenex + conventional therapy
11482394|NCT01477866|Active Comparator|conventional therapy|conventional therapy
11482395|NCT01477853|Experimental|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
11482396|NCT01477853|Active Comparator|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
11482397|NCT01477853|Experimental|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
11482398|NCT01477840|Experimental|Misoprostol|
11482399|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
11482400|NCT01477814|Active Comparator|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
11482401|NCT01477814|Active Comparator|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
11482402|NCT01477814|Active Comparator|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
11482403|NCT01477801|Experimental|CHOLECALCIFEROL|
11482404|NCT01477801|Placebo Comparator|PLACEBO|
11482405|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
11482406|NCT01477775|Active Comparator|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
11482407|NCT01477775|Experimental|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
11482408|NCT01477762|Active Comparator|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
11482409|NCT01477762|Experimental|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
11482410|NCT01477749|Experimental|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
11482411|NCT01477736|Active Comparator|Botulinum toxin A|
11482412|NCT01477736|Active Comparator|oxybutynin|
11482413|NCT01477723|Experimental|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
11482414|NCT01477723|No Intervention|No Product|
11482415|NCT01477710|Active Comparator|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
11482416|NCT01477710|Active Comparator|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
11482417|NCT01477710|Active Comparator|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
11482418|NCT01477697|Active Comparator|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
11482419|NCT01477697|Placebo Comparator|Placebo|50 mg/kg per day of vehicle
11482420|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
11482421|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
11482422|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
11482423|NCT01477645||Leaded ammunition|
11482424|NCT01477645||Non-leaded ammunition|
11482425|NCT01477645||Modified non-leaded ammunition|
11482426|NCT01477632|Experimental|A|
11482427|NCT01477632|Experimental|B|
11482428|NCT01477632|Active Comparator|C|
11482429|NCT01477619|Experimental|Smokers|Split into BMI categories
11482430|NCT01477619|Experimental|Non-Smokers|Gender, age, and BMI matched to Smokers
11482431|NCT01477619|Experimental|Elderly|
11482432|NCT01477606|Experimental|Midostaurin|
11482433|NCT01477593|Experimental|Group I|
11482434|NCT01477593|Active Comparator|Group II|
11482435|NCT01477593|Active Comparator|Group III|
11482436|NCT01477580|Experimental|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
11482437|NCT01477580|Experimental|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
11482438|NCT01477580|Experimental|Medium-dose Non-adjuvanted V180|
11482439|NCT01477580|Experimental|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
11482440|NCT01477580|Experimental|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
11482441|NCT01477580|Experimental|Medium-Dose V180 with Alhydrogel™ adjuvant|
11482442|NCT01477580|Experimental|High-dose Non-adjuvanted V180|
11482443|NCT01477580|Experimental|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
11482444|NCT01477580|Experimental|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
11482445|NCT01477580|Experimental|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
11482446|NCT01477580|Experimental|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
11482447|NCT01477580|Experimental|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
11482448|NCT01477580|Placebo Comparator|Placebo|
11482449|NCT01477567|Experimental|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
11482450|NCT01477567|Experimental|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
11482451|NCT01477567|Experimental|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
11482452|NCT01477567|Experimental|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
11482453|NCT01477567|Experimental|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
11482454|NCT01477567|Experimental|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
11482455|NCT01477567|Placebo Comparator|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
11482456|NCT01477554|No Intervention|Control|Hospitals randomized to the control arm do not receive any intervention.
11482457|NCT01477554|Experimental|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
11482458|NCT01477541|Experimental|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
11482459|NCT01477541|No Intervention|Control|
11482460|NCT01477515||End stage renal disease patient|
11482461|NCT01477515||Matched controls|
11482462|NCT01477502|Active Comparator|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
11482463|NCT01477502|Other|standard prophylaxis|
11482464|NCT01477489|Experimental|Treatment|
11482465|NCT01477476|Active Comparator|Active Treatment|14 subjects with receive active treatment with Anakinra.
11482466|NCT01477476|Placebo Comparator|Placebo|7 subjects will receive the placebo comparator.
11482467|NCT01477463|Experimental|Arm A: Vitamin D|4,000 IU oral vitamin D3
11482468|NCT01477463|Experimental|Arm B: Placebo + Vitamin D|Placebo + 4000 IU oral Vitamin D3
11482469|NCT01477450|Active Comparator|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
11482470|NCT01477450|Active Comparator|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
11482471|NCT01477450|Active Comparator|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
11482472|NCT01477437|Experimental|Intervention (experimental) Group|
11482473|NCT01477437|No Intervention|Control group|
11482474|NCT01477424|Experimental|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
11482475|NCT01477424|Experimental|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
11482476|NCT01477424|Experimental|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
11482477|NCT01477411|Experimental|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
11482478|NCT01477411|Experimental|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
11482479|NCT01477411|Experimental|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
11482480|NCT01477398|Active Comparator|inspired CO2|Inspired CO2
11482481|NCT01477398|No Intervention|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
11482482|NCT01477385|Active Comparator|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
11482483|NCT01477385|Experimental|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
11482484|NCT01477385|Active Comparator|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
11482485|NCT01477372|Experimental|Exercise group|Supervised exercise program
11482486|NCT01477372|No Intervention|Control|Sedentary pregnant woman
11482487|NCT01477359||CS screened as underlying etiology|"Patients with active Clinically Manifest CS
~Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
11482488|NCT01477346|Other|Nurse intervention|Nurse led package of care based on current recommended best practice.
11482489|NCT01477346|Other|Standard care|Continuing standard general practitioner led care
11482490|NCT01477333|Experimental|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
11482491|NCT01477320|Active Comparator|Pantoprazole 40mg IV daily and tube feed|
11482492|NCT01477320|Placebo Comparator|Placebo and tube feed.|
11482493|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
11482494|NCT01477294|Experimental|Caffeine|Intervention with Caffeine in a random order
11482495|NCT01477294|Placebo Comparator|Placebo|Placebo (malt dextrin) administered in a random order
11482496|NCT01477281|Experimental|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
11482497|NCT01477281|Active Comparator|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
11482498|NCT01477268|Other|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
11482499|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
11482500|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
11482501|NCT01477242|Experimental|Ondansetron|Ondansetron use group
11482502|NCT01477242|Placebo Comparator|Placebo|Placebo group
11482503|NCT01477229||Abdominoperineal resection|Patients with low rectal cancers
11482504|NCT01477229||Anterior resection|Patients where it is possible to perform an anterior resection
11482505|NCT01477229||Preoperative chemo-radiation treatment|Patients with locally advanced rectal cancer
11482506|NCT01477229||Palliative treatment|Patients with systemic disease
11482507|NCT01477216|Experimental|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
11482508|NCT01477216|Experimental|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
11482509|NCT01477216|Experimental|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
11482510|NCT01477216|Experimental|Snacks|To measure GI and II values for Finnish snack foods
11482511|NCT01477216|Experimental|Berries|To study the effects of berries on glycemic and insulinemic responses
11482512|NCT01477216|Experimental|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
11482513|NCT01477216|Experimental|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
11482514|NCT01477216|Experimental|Insulin measurement|To compare how methodological choices affect measured insulin values
11482515|NCT01477216|Experimental|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
11482516|NCT01477203|Active Comparator|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
11482517|NCT01477203|No Intervention|Remitted Patients|
11482518|NCT01477203|No Intervention|Healthy Controls|
11482519|NCT01477190|Experimental|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
11482520|NCT01477190|Active Comparator|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
11482521|NCT01477177|Experimental|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
11482522|NCT01477164|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
11482523|NCT01477164|Active Comparator|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
11482524|NCT01477164|Experimental|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
11482525|NCT01477151|Active Comparator|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
11482526|NCT01477151|Experimental|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
11482527|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
11482528|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
11482529|NCT01477125|Experimental|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
11482530|NCT01477125|Placebo Comparator|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
11482531|NCT01477112|Experimental|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
11482532|NCT01477112|Experimental|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
11482533|NCT01477112|Active Comparator|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
11482534|NCT01477112|Active Comparator|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
11482535|NCT01477099|Experimental|Toothbrushing with a manual brush|Toothbrushing with a manual brush
11482536|NCT01477099|No Intervention|No toothbrushing|no toothbrushing
11482537|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
11482538|NCT01477073|Experimental|FSH-GEX|
11482539|NCT01477073|Active Comparator|recombinant FSH|recombinant FSH
11482540|NCT01477073|Active Comparator|urinary FSH|urinary FSH
11482541|NCT01477073|Placebo Comparator|Placebo|
11482542|NCT01477060|Other|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
11482543|NCT01477060|Other|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
11482544|NCT01477060|Other|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
11482545|NCT01477047||Patients receiving primary hip or knee arthoplasty|
11482546|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
11482547|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
11482548|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
11482549|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
11482550|NCT01477021|Experimental|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
11482551|NCT01477008|Experimental|BiCRI|BiPhasic Cartilage Repair Implant
11482552|NCT01477008|Active Comparator|Marrow Stimulation|Microfracture or Subchondral Drilling
11482553|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
11482554|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
11482555|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
11482556|NCT01476969|Experimental|Manual Tourniquet|
11482557|NCT01476956||Rheumatoid Arthritis|
11482558|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
11482559|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
11482560|NCT01476930|Experimental|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
11482561|NCT01476930|Active Comparator|conventional|migraine cases treated by conventional drug treatment protocols
11482562|NCT01476917|Experimental|Treatment|Subjects that completed the ATLAST Study
11482563|NCT01476904|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
11482564|NCT01476904|Placebo Comparator|Arm P|Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
11482565|NCT01476904|Active Comparator|Arm A|Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
11482566|NCT01476891|Active Comparator|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
11482567|NCT01476891|Active Comparator|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
11482568|NCT01476878|Experimental|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
11482569|NCT01476865||Healthy|normal, healthy people
11482570|NCT01476865||RA|rheumatoid arthritis patients
11482571|NCT01476839|Experimental|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.
~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
11482572|NCT01476813|Experimental|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
11482573|NCT01476813|Experimental|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
11482574|NCT01476813|Experimental|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
11482575|NCT01476813|Active Comparator|BDP/FF 400/24|BDP/FF 400/24
11482576|NCT01476800|Experimental|YM178 OCAS alone|
11482577|NCT01476800|Active Comparator|Ketoconazole alone|
11482578|NCT01476800|Experimental|YM178 OCAS and ketoconazole|
11482671|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
11482674|NCT01476137|Experimental|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
11482579|NCT01476787|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.
~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
11482580|NCT01476787|Active Comparator|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
11482581|NCT01476774|Active Comparator|Buprenorphine Transdermal System|
11482582|NCT01476774|Active Comparator|Tramadol CR|
11482583|NCT01476761|Active Comparator|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
11482584|NCT01476748|Active Comparator|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
11482585|NCT01476748|Active Comparator|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
11482586|NCT01476748|Active Comparator|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
11482587|NCT01476735|Active Comparator|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
11482588|NCT01476735|Active Comparator|Individual preparation for colonoscopy|
11482589|NCT01476722|Experimental|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
11482590|NCT01476696|Experimental|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally [oral-disintegrating tablet (ODT)], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
11482591|NCT01476696|Experimental|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
11482592|NCT01476683|Experimental|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
11482593|NCT01476683|Experimental|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
11482594|NCT01476683|Active Comparator|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
11482595|NCT01476683|Active Comparator|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
11482596|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
11482597|NCT01476657|Experimental|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
11482598|NCT01476644|Other|Glaucoma Patients|Moderate glaucoma patients with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included to complete annual visits over a 4 year period. Each visit included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measures: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (VRQoL) (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
11482599|NCT01476631|Experimental|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
11482600|NCT01476631|Experimental|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
11482601|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
11482602|NCT01476605|Active Comparator|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
11482603|NCT01476605|Experimental|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
11482604|NCT01476605|No Intervention|Waitlist|
11482605|NCT01476605|Active Comparator|Platelet rich plasma|
11482606|NCT01476592|Experimental|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
11482607|NCT01476579|Other|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
11482608|NCT01476566|Experimental|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
11482609|NCT01476566|No Intervention|Control group|
11482610|NCT01476553|Experimental|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
11482611|NCT01476540|Experimental|Deep Brain Stimulation|Deep Brain Stimulation
11482612|NCT01476527|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
11482672|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
11482673|NCT01476137|Experimental|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
11482613|NCT01476514|Experimental|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.
~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
11482614|NCT01476501|Experimental|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
11482615|NCT01476501|Experimental|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
11482616|NCT01476488|No Intervention|Advagraf|single group, conversion of prograf to advagraf
11482617|NCT01476475|Experimental|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
11482618|NCT01476475|Active Comparator|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
11482619|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
11482620|NCT01476449|Active Comparator|Monthly Ranibizumab|Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
11482621|NCT01476449|Experimental|Treat and Extend Ranibizumab|"Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically dry, at which point the evaluation and injection interval will be extended."
11482622|NCT01476436|Experimental|LCHF diet|Advice of a diet low in carbohydrate
11482623|NCT01476436|Active Comparator|Usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
11482624|NCT01476423||A|
11482625|NCT01476410|Experimental|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
11482626|NCT01476397|Active Comparator|control infant formula|partially hydrolyzed whey infant formula
11482627|NCT01476397|Experimental|test infant formula|partially hydrolyzed whey infant formula with probiotic
11482628|NCT01476384|Experimental|Glucose drink|75 gram glucose, dissolved in 250 ml water
11482629|NCT01476384|Placebo Comparator|Placebo|250 ml water
11482630|NCT01476371|Experimental|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
11482631|NCT01476371|No Intervention|Treatment as usual|Treatment as usual (including individual CBT and medication)
11482632|NCT01476358|Active Comparator|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
11482633|NCT01476358|Placebo Comparator|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
11482634|NCT01476345|Experimental|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
11482635|NCT01476345|Experimental|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
11482636|NCT01476332|Experimental|Group 1: Cis-UCA 0.5% eye drops|
11482637|NCT01476332|Experimental|Group 2: Cis-UCA 2.5% eye drops|
11482638|NCT01476332|Placebo Comparator|Group 3: Placebo for cis-UCA, eye drops|
11482639|NCT01476319|No Intervention|control|
11482640|NCT01476319|Experimental|video|
11482641|NCT01476306|Placebo Comparator|In-patient care|
11482642|NCT01476306|Experimental|Telemedicine care|
11482643|NCT01476280|Sham Comparator|Palonosetron|
11482644|NCT01476280|Sham Comparator|Ramosetron|
11482645|NCT01476267|Experimental|Single Arm|
11482646|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
11482647|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
11482648|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
11482649|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
11482650|NCT01476228|Experimental|study group|EEG recording
11482651|NCT01476215|Experimental|Fast dissolution suspension|
11482652|NCT01476215|Experimental|Medium dissolution suspension|
11482653|NCT01476215|Experimental|Slow dissolution suspension|
11482654|NCT01476215|Active Comparator|Marketed suspension|
11482655|NCT01476202|Experimental|Nicotine mouth strip|single dose
11482656|NCT01476202|Active Comparator|nicotine lozenge|single dose
11482657|NCT01476202|Active Comparator|nicotine gum|single dose
11482658|NCT01476189|Experimental|Experimental paracetamol formulation|test formulation
11482659|NCT01476189|Active Comparator|Marketed paracetamol|Marketed paracetamol
11482660|NCT01476189|Active Comparator|Higher dose marketed paracetamol|higher dose marketed paracetamol
11482661|NCT01476176|Experimental|Experimental paracetamol formulation|experimental formulation
11482662|NCT01476176|Active Comparator|paracetamol marketed formulation|Paracetamol marketed formulation
11482663|NCT01476150||Dongcheng|
11482664|NCT01476150||Haidian|
11482665|NCT01476150||Xicheng|
11482666|NCT01476150||Chaoyang|
11482667|NCT01476150||Chongwen|
11482668|NCT01476150||Tongzhou|
11482669|NCT01476150||Fengtai|
11482670|NCT01476150||Xuanwu|
11482966|NCT01474265|Placebo Comparator|varenicline placebo|
11482675|NCT01476137|Experimental|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
11482676|NCT01476137|Experimental|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
11482677|NCT01476137|Experimental|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
11482678|NCT01476137|Experimental|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
11482679|NCT01476137|Experimental|Part 2A; GSK2110183 125mg|GSK2110183 125mg
11482680|NCT01476137|Experimental|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
11482681|NCT01476124|Experimental|Regimen A|Morphine placebo + GEn 600 mg
11482682|NCT01476124|Experimental|Regimen B|Morphine Extended release (60 mg) + GEn placebo
11482683|NCT01476124|Experimental|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
11482684|NCT01476111||Group 1|Patients with primary invasive breast cancer
11482685|NCT01476098|Placebo Comparator|Arm 1|incremental doses capsaicin
11482686|NCT01476098|Active Comparator|Arm 2|incremenrtal doses casaicin
11482687|NCT01476085|No Intervention|no treatment|no treatment
11482688|NCT01476072|No Intervention|no treatment|MRI scans only
11482689|NCT01476059|Other|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
11482690|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
11482691|NCT01476046|Experimental|GSK1995057|Single intravenous dose
11482692|NCT01476046|Placebo Comparator|Placebo|Single intravenous dose
11482693|NCT01476033|Active Comparator|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
11482694|NCT01476033|Placebo Comparator|20 women with placebo|placebo for 8 weeks
11482695|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
11482696|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
11482697|NCT01476007|Experimental|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
11482698|NCT01476007|Experimental|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
11482699|NCT01475994|Experimental|Challenge with grass pollen|
11482700|NCT01475994|Placebo Comparator|Challenge with clean air|
11482701|NCT01475981|Experimental|Dose 1 JTK-853 (fasted condition)|
11482702|NCT01475981|Experimental|Dose 2 JTK-853 (fasted condition)|
11482703|NCT01475981|Experimental|Dose 3 JTK-853 (fasted condition)|
11482704|NCT01475981|Experimental|Dose 2 JTK-853 (fed condition)|
11482705|NCT01475981|Experimental|Dose 3 JTK-853 (fed condition)|
11482706|NCT01475981|Experimental|Dose 4 JTK-853 (fed condition)|
11482707|NCT01475981|Experimental|Dose 5 JTK-853 (fed condition)|
11482708|NCT01475981|Experimental|Dose 6 JTK-853 (fed condition)|
11482709|NCT01475981|Experimental|Dose 7 JTK-853 (fed condition)|
11482710|NCT01475981|Experimental|Dose 5 JTK-853 (high-fat fed condition)|
11482711|NCT01475981|Placebo Comparator|Placebo|
11482712|NCT01475968|Active Comparator|Ultrafine Air Pollution Particulate Matter|<2.5 microns concentrated from outside ambient air
11482713|NCT01475968|Sham Comparator|Filtered Air|Filtered Air
11482714|NCT01475955|Experimental|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
11482715|NCT01475955|Experimental|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
11482716|NCT01475955|Experimental|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
11482717|NCT01475955|Experimental|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
11482718|NCT01475955|Placebo Comparator|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
11482719|NCT01475942|Active Comparator|Probiotic|Lactobacillus
11482720|NCT01475942|Placebo Comparator|Placebo|Sucrose
11482721|NCT01475929|Active Comparator|Probiotic low|Lower dose of probiotic supplement
11482722|NCT01475929|Placebo Comparator|Placebo|
11482723|NCT01475929|Active Comparator|Probiotic high|Higher dose of probiotic supplement
11482724|NCT01475903||sleeve gastrectomy|
11482725|NCT01475890|Active Comparator|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
11482726|NCT01475890|Placebo Comparator|Placebo|29 subjects will be randomized to receive placebo.
11482727|NCT01475877||Nepafenac|
11482728|NCT01475864||Incomplete biliary stone extraction.|
11482729|NCT01475851|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
11482730|NCT01475838|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
11482731|NCT01475838|Active Comparator|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
11482732|NCT01475825|Experimental|Regimen A: Mipomersen|Subcutaneous injection of mipomersen 200 mg once weekly
11482733|NCT01475825|Placebo Comparator|Regimen A: Placebo|Placebo matching subcutaneous injection once weekly.
11482734|NCT01475825|Experimental|Regimen B: Mipomersen|Subcutaneous injection of mipomersen 70 mg thrice weekly.
11482735|NCT01475825|Placebo Comparator|Regimen B: Placebo|Placebo matching subcutaneous injection thrice weekly.
11482736|NCT01475812||COPD hyperinflation|
11482737|NCT01475799|Experimental|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
11482738|NCT01475786|Active Comparator|Low Dose 16mg VM202 and Placebo|intramuscular injections in each calf for a total of 16mg VM202: Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
11482739|NCT01475786|Active Comparator|High Dose 32mg VM202|Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
11482740|NCT01475786|Placebo Comparator|Control - Placebo (normal saline)|32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14
11482741|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
11482742|NCT01475760|Active Comparator|K2CG chewing gum (20 mg chitosan)|
11482743|NCT01475760|Active Comparator|K2CG chewing gum (60 mg chitosan)|
11482744|NCT01475760|No Intervention|Standard of Care|
11482745|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
11482746|NCT01475734|Active Comparator|albiglutide|single dose of albiglutide
11482747|NCT01475734|Placebo Comparator|placebo|single dose of placebo
11482748|NCT01475721|Experimental|ADVAIR 100/50mcg|experimental drug
11482749|NCT01475721|Experimental|ADVAIR 250/50mcg|experimental drug
11482750|NCT01475721|Experimental|ADVAIR 500/50mcg|experimental drug
11482751|NCT01475721|Active Comparator|FLOVENT 100mcg|active comparator
11482752|NCT01475721|Active Comparator|FLOVENT 250mcg|active comparator
11482753|NCT01475721|Active Comparator|FLOVENT 500mcg|active comparator
11482754|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
11482755|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
11482756|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
11482757|NCT01475695|Experimental|Single cohort|14C GSK2251052
11482758|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
11482759|NCT01475669|Experimental|Fibrinogen Concentrate (Human)|
11482760|NCT01475669|Placebo Comparator|Placebo|
11482761|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
11482762|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
11482763|NCT01475643|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5%
11482764|NCT01475643|Active Comparator|Prednisolones acetate|Prednisolone acetate 1.0%
11482765|NCT01475630|Other|control|information, avoiding parafunctions
11482766|NCT01475630|Experimental|physical therapy|mobilisation, exercises ,..
11482767|NCT01475617|Experimental|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
11482768|NCT01475617|Active Comparator|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
11482769|NCT01475604|Active Comparator|Targeted pulsed electromagnetic field|
11482770|NCT01475604|Sham Comparator|Sham|
11482771|NCT01475591|No Intervention|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
11482772|NCT01475578|Experimental|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally
~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
11482773|NCT01475578|Active Comparator|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal
~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
11482774|NCT01475565||African-American women|Observational study--no intervention
11482775|NCT01475565||Caucasian women|Observational study--no intervention
11482776|NCT01475552|Experimental|abciximab|
11482777|NCT01475552|Active Comparator|control|
11482778|NCT01475539|Experimental|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
11482779|NCT01475539|Experimental|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
11482780|NCT01475539|Experimental|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
11482781|NCT01475526|Experimental|Intervention|El Valor de Nuestra Salud Store Intervention
11482782|NCT01475526|No Intervention|Control|No intervention. Business as usual
11482783|NCT01475513|Active Comparator|African-American women|African-American women
11482784|NCT01475513|Active Comparator|Caucasian women|Caucasian women
11482785|NCT01475500||Screening|These high-risk subjects will undergo screening for lung cancer. All subjects will undergo all listed interventions
11482786|NCT01475487|Active Comparator|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
11482787|NCT01475487|Experimental|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
11482788|NCT01475461|Placebo Comparator|Placebo|
11482789|NCT01475461|Experimental|PF-04937319 - Dose 1|
11482790|NCT01475461|Experimental|PF-04937319 - Dose 2|
11482791|NCT01475461|Experimental|PF-04937319 - Dose 3|
11482792|NCT01475461|Experimental|PF-04937319 - Dose 4|
11482793|NCT01475461|Active Comparator|Sitagliptin|
11482794|NCT01475448|Experimental|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
11482967|NCT01474265|Active Comparator|varenicline|
11482795|NCT01475448|Active Comparator|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
11482796|NCT01475435|Active Comparator|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
11482797|NCT01475435|Placebo Comparator|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
11482798|NCT01475435|Active Comparator|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
11482799|NCT01475435|Placebo Comparator|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
11482800|NCT01475422|Experimental|Conversation Maps Diabetes Education|
11482801|NCT01475422|Active Comparator|Usual Care|
11482802|NCT01475409|Experimental|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
11482803|NCT01475396|Experimental|Aerobic Exercise|
11482804|NCT01475396|Experimental|Anaerobic Exercise|
11482805|NCT01475396|No Intervention|Unchanged condition|
11482806|NCT01475383|Active Comparator|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
11482807|NCT01475383|Placebo Comparator|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
11482808|NCT01475370|Experimental|OCV-501|
11482809|NCT01475357|Other|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
11482810|NCT01475357|Active Comparator|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
11482811|NCT01475344|Active Comparator|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:
~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g
~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
11482812|NCT01475344|Placebo Comparator|Placebo|"Placebo administrated over 5 min/vial:
~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
~Placebo: 1.5 g / 3 g / 4.5 g / 6 g
~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
11482813|NCT01475331|Active Comparator|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
11482814|NCT01475331|Experimental|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
11482815|NCT01475318|Experimental|misoprostol + mifepristone + letrozole|
11482816|NCT01475305|Placebo Comparator|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
11482817|NCT01475305|Experimental|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
11482818|NCT01475292|Experimental|RV568 treatment group low dose|
11482819|NCT01475292|Experimental|RV568 treatment group high dose|
11482820|NCT01475292|Placebo Comparator|Placebo treatment group|
11482821|NCT01475266|Experimental|EO9 (Apaziquone)|
11482822|NCT01475266|Placebo Comparator|Placebo|
11482823|NCT01475253|Experimental|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
11482824|NCT01475253|Placebo Comparator|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
11482825|NCT01475253|Sham Comparator|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
11482826|NCT01475240||Group 1: Controls|HIV-infected patients on stable > 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
11482827|NCT01475240||Group 2: Cases|HIV-infected patients on stable >6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (>2.5 X upper limit)
11482828|NCT01475227|Experimental|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
11482829|NCT01475227|Experimental|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
11482830|NCT01475214|Active Comparator|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
11482831|NCT01475214|Active Comparator|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
11482832|NCT01475214|Placebo Comparator|placebo|microcrystalline cellulose
11482833|NCT01475201|Experimental|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
11482834|NCT01475201|Active Comparator|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
11482835|NCT01475188|Placebo Comparator|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
11482836|NCT01475188|Active Comparator|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
11482837|NCT01475175|Experimental|CRT pacing at rest and during exercise|Rest and sub-maximal exercise
11482838|NCT01475162|Experimental|Tocilizumab|"Drug: Tocilizumab
~Other Names:
~Actemra
~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
11482839|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
11482840|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
11482841|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
11482842|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
11482843|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
11482844|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
11482845|NCT01475136|Experimental|LY2140023|A single 80 mg dose administered orally, one time
11482846|NCT01475123|Active Comparator|Nicorandil|Nicorandil was administered orally (15mg/day).
11482847|NCT01475123|No Intervention|Non-nicorandil|Nicorandil was not administered.
11482848|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.
~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
11482849|NCT01475097|Active Comparator|Active Arm|
11482850|NCT01475097|Active Comparator|Comparator Arm|
11482851|NCT01475084|Experimental|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.
~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
11482852|NCT01475071|Experimental|Metvix and daylight|
11482853|NCT01475071|Active Comparator|Metvix and lamp|
11482854|NCT01475058|Experimental|Treatment (T cell therapy)|Patients undergo one IV infusion of donor-derived CD8+ central memory-derived CMV/CD19 or EBV/CD19 bi-specific T cells, at least 30 days after HCT.
11482855|NCT01475045||Turbuhaler inhaler use|
11482856|NCT01475045||Discus inhaler use|
11482857|NCT01475045||Elpenhaler inhaler use|
11482858|NCT01475032|Experimental|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
11482859|NCT01475032|Active Comparator|BDP|BDP for 12 weeks
11482860|NCT01475032|Active Comparator|BDP+FF|free combo BDP+FF for 12 weeks
11482861|NCT01475019|Experimental|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
11482862|NCT01475019|Experimental|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
11482863|NCT01475019|Experimental|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
11482864|NCT01475019|Experimental|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
11482865|NCT01475006|Experimental|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
11482866|NCT01475006|Experimental|Part II Dose Expansion|Dose selected from Part 1 dose exploration
11482867|NCT01474993|Placebo Comparator|Placebo|inactive placebo.
11482868|NCT01474993|Experimental|Interventional|sulforaphane-rich Broccoli Sprout Extract.
11482869|NCT01474967|Experimental|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
11482870|NCT01474967|Active Comparator|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
11482871|NCT01474941|Experimental|5 mg QD PF-04620110 or Placebo|
11482872|NCT01474941|Experimental|5 mg BID PF-04620110 or Placebo|
11482873|NCT01474941|Experimental|Optional Arm, PF-04620110 or Placebo|
11482874|NCT01474928|Experimental|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
11482875|NCT01474928|Experimental|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
11482876|NCT01474928|Active Comparator|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
11482877|NCT01474928|Experimental|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
11482878|NCT01474915|Active Comparator|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.
~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
11482879|NCT01474915|Active Comparator|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.
~Triple therapy
~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
11482880|NCT01474902|Experimental|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or
~1 mg/kg/dose SC q12h for patients > 2 months old
~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
11482881|NCT01474902|No Intervention|No-treatment|
11482882|NCT01474889|Experimental|Hypoglycemia Unaware T1 Diabetes RT-CGM|Type 1 Diabetes with Hypoglycemia Unawareness. Patients wear an RT-CGM for 18 months. We are comparing type 1 diabetic patients who experience severe hypoglycemia unawareness to two other (control) groups: Type 1 diabetic patients without hypoglycemia unawareness and patients who are not diabetic at all. The control groups will only have 3 visits. We plan to study glucose production and symptom generation during insulin-induced hypoglycemia (metabolic testing) by subjecting each group to a pair of metabolic clamps (hypoglycemic and euglycemic) at baseline. This group of Hypoglycemia unaware diabetics will have an additional two sets of clamps at 6 months and 18 months after wearing the RT-CGM to determine if hypoglycemia avoidance can reverse unawareness.
11482883|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
11482884|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
11482885|NCT01474863|Active Comparator|Low Dose Citrulline|Low Dose Citrulline
11482886|NCT01474863|Placebo Comparator|Placebo|Placebo IV infusion
11482887|NCT01474863|Active Comparator|High Dose Citrulline|High Dose Citrulline
11482888|NCT01474850|Active Comparator|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
11482889|NCT01474850|No Intervention|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
11482890|NCT01474837|Experimental|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
11482891|NCT01474837|No Intervention|Treatment as usual|Young people with depression receiving treatment as usual
11482892|NCT01474798|Experimental|RA-18C3|
11482893|NCT01474785|Experimental|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
11482894|NCT01474785|Experimental|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
11482895|NCT01474785|Experimental|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
11482896|NCT01474772|Experimental|Pregabain|
11482897|NCT01474772|Placebo Comparator|Placebo|
11482898|NCT01474759|Experimental|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
11482899|NCT01474759|Experimental|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
11482900|NCT01474759|Active Comparator|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
11482901|NCT01474746|Placebo Comparator|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
11482902|NCT01474746|Experimental|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
11482903|NCT01474733|Experimental|educational intervention|participants undergo a series of educational interventions over 3 years
11482904|NCT01474720|Experimental|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
11482905|NCT01474720|Active Comparator|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
11482906|NCT01474707|Experimental|Group one|Group1 will view the knowledge-based video only
11482907|NCT01474707|Experimental|Group two|Group two will view the motivational video only
11482908|NCT01474707|Experimental|Group three|Group three will view both knowledge-based and motivational videos
11482909|NCT01474707|Experimental|Group four|Group four will view the printed educational pamphlet and will not view either video
11482910|NCT01474681|Experimental|HSC835|HSC835 infusion
11482911|NCT01474668|Experimental|A|Experimental
11482912|NCT01474642|Active Comparator|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
11482913|NCT01474642|Active Comparator|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
11482914|NCT01474629|Active Comparator|probiotic-based dietary supplement|
11482915|NCT01474629|Placebo Comparator|placebo|
11482916|NCT01474616|Other|Sit-to-Stand Activity|
11482917|NCT01474603||1|overweight or obese diabetic
11482918|NCT01474590|Experimental|Epiduo/Tactuo + doxycycline 200mg|
11482919|NCT01474590|Active Comparator|Isotretinoin + vehicle gel|
11482920|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
11482921|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
11482922|NCT01474551|Experimental|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
11482963|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
11482964|NCT01474278|Experimental|1|
11482923|NCT01474538|Active Comparator|Insulin Lispro, then Insulin Aspart|Insulin lispro [100 units/milliliter (U/mL)] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
11482924|NCT01474538|Active Comparator|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
11482925|NCT01474525|Experimental|Telemonitoring|
11482926|NCT01474525|Active Comparator|Usual Care|
11482927|NCT01474512|Experimental|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].
11482928|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
11482929|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
11482930|NCT01474512|Placebo Comparator|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
11482931|NCT01474499|Experimental|Docusate sodium and sorbitol rectal solution|
11482932|NCT01474499|Active Comparator|Glycerine|
11482933|NCT01474486|Experimental|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
11482934|NCT01474473|Experimental|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
11482935|NCT01474473|Placebo Comparator|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
11482936|NCT01474460|Placebo Comparator|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
11482937|NCT01474460|Experimental|Phytonadione|Patients receiving 200mcg of phytonadione.
11482938|NCT01474447|Experimental|Grinberg Method|
11482939|NCT01474434|Experimental|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
11482940|NCT01474434|Experimental|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
11482941|NCT01474421|Experimental|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
11482942|NCT01474421|Experimental|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
11482943|NCT01474421|Placebo Comparator|Placebo|Placebo daily given orally for 28 days.
11482944|NCT01474408|Experimental|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
11482945|NCT01474408|Active Comparator|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
11482946|NCT01474408|Other|control|routine measurements, no exercise
11482947|NCT01474395|Experimental|D-serine 60 mg/kg|double blind dose of d-serine
11482948|NCT01474395|Placebo Comparator|Placebo D-serine|
11482949|NCT01474382|Experimental|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
11482950|NCT01474382|Sham Comparator|Sham injection|Dentist simulates injection with dental syringe
11482951|NCT01474369|Experimental|TAK-438 10 mg QD|
11482952|NCT01474369|Experimental|TAK-438 20 mg QD|
11482953|NCT01474369|Placebo Comparator|Placebo QD|
11482954|NCT01474356|No Intervention|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
11482955|NCT01474356|Experimental|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
11482956|NCT01474343|Experimental|SAF-301|
11482957|NCT01474330|Experimental|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
11482958|NCT01474330|Experimental|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
11482959|NCT01474330|Experimental|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
11482960|NCT01474317|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
11482961|NCT01474304|Active Comparator|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
11482962|NCT01474304|No Intervention|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
11482965|NCT01474278|Placebo Comparator|2|
11482968|NCT01474265|Active Comparator|Nicorette TX|
11482969|NCT01474265|Active Comparator|Nicorette TX optional|
11482970|NCT01474265|No Intervention|control group smokers|
11482971|NCT01474252|Experimental|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.
~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
11482972|NCT01474252|No Intervention|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
11482973|NCT01474239|Experimental|Calibration Arm|
11482974|NCT01474239|Experimental|Investigational Arm|
11482975|NCT01474226|Experimental|Lysine Amino Acid|
11482976|NCT01474213|Active Comparator|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
11482977|NCT01474213|Active Comparator|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
11482978|NCT01474200|Experimental|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
11482979|NCT01474200|Active Comparator|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
11482980|NCT01474187|Experimental|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
11482981|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
11482982|NCT01474161|Placebo Comparator|Matching placebo|
11482983|NCT01474161|Active Comparator|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
11482984|NCT01474161|Experimental|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
11482985|NCT01474148|Experimental|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
11482986|NCT01474135|Experimental|0.25% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
11482987|NCT01474135|Experimental|0.5% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
11482988|NCT01474135|Active Comparator|0.004%Travoprost|Travatan(R) Z(travoprost ophthalmic solution)
11482989|NCT01474122|Active Comparator|Macitentan 3 mg|Oral macitentan 3 mg, once daily
11482990|NCT01474122|Active Comparator|Macitentan 10 mg|Oral macitentan 10 mg, once daily
11482991|NCT01474122|Placebo Comparator|Placebo|Oral placebo, once daily
11482992|NCT01474109|Active Comparator|macitentan 3mg|macitentan 3mg tablet once daily
11482993|NCT01474109|Active Comparator|macitentan 10mg|macitentan 10mg tablet once daily
11482994|NCT01474109|Placebo Comparator|placebo|matching placebo once daily
11482995|NCT01474096|Experimental|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
11482996|NCT01474096|No Intervention|Conventional intervention|
11482997|NCT01474083|Experimental|GK1-399, low dose|
11482998|NCT01474083|Experimental|GK1-399, high dose, once per day|
11482999|NCT01474083|Experimental|GK1-399, high dose, twice per day|
11483000|NCT01474083|Placebo Comparator|Placebo|
11483001|NCT01474057|Experimental|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
11483002|NCT01474057|Active Comparator|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
11483003|NCT01474044|Placebo Comparator|Placebo|
11483004|NCT01474044|Active Comparator|Gastropyloric Complex Capsules|
11483005|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
11483006|NCT01474031||Control group|healthy volunteers
11483007|NCT01474018|No Intervention|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
11483008|NCT01474018|Experimental|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
11483009|NCT01473992|Active Comparator|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
11483010|NCT01473992|Active Comparator|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
11483011|NCT01473992|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
11483012|NCT01473979|Active Comparator|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.
~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
11483013|NCT01473979|Active Comparator|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
11483014|NCT01473966|No Intervention|standard of care|patients receive standard care
11483015|NCT01473966|Experimental|Coffee orally|patients will receive standard of care plus coffee orally
11483016|NCT01473966|Experimental|coffee rectally|patients receive standard of care plus coffee rectally
11483017|NCT01473953|Experimental|Cohort 1a: Lira-depot 2.25 mg|
11483018|NCT01473953|Experimental|Cohort 2a: Lira-depot 6.75 mg|
11483019|NCT01473953|Experimental|Cohort 3a: Lira-depot 15 mg|
11483020|NCT01473953|Experimental|Cohort 4a: Lira-depot 30 mg|
11483021|NCT01473953|Placebo Comparator|Placebo|
11483022|NCT01473940|Experimental|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.
~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
11483023|NCT01473927||1|Crohn's Disease patients
11483024|NCT01473927||2|Ulcerative colitis patients
11483025|NCT01473914|Experimental|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E
~1 capsule p.o, daily"
11483026|NCT01473914|Experimental|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E
~1 capsule p.o, daily"
11483027|NCT01473914|Active Comparator|Standard treatment|"Standard renal vitamin
~1 capsule p.o, daily"
11483028|NCT01473901|Experimental|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
11483029|NCT01473901|Experimental|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:
~Temozolomide 150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;
~Adjuvant phase cycle 2+:
~Temozolomide 200* mg/m2 - Day 1 ~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
11483030|NCT01473888|Other|T89|
11483031|NCT01473836|Experimental|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
11483032|NCT01473823|Placebo Comparator|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
11483033|NCT01473823|Active Comparator|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
11483034|NCT01473810|Experimental|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
11483035|NCT01473810|Experimental|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
11483036|NCT01473810|Experimental|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
11483037|NCT01473810|Placebo Comparator|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
11483038|NCT01473797|Experimental|cladribine|
11483039|NCT01473784|Experimental|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
11483040|NCT01473771|Experimental|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
11483041|NCT01473771|No Intervention|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
11483042|NCT01473758|Active Comparator|Roflumilast|added on to standard therapy for acute COPD exacerbations
11483043|NCT01473758|Placebo Comparator|Placebo|added on to standard therapy for acute COPD exacerbations
11483044|NCT01473745|Active Comparator|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
11483045|NCT01473745|Placebo Comparator|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
11483046|NCT01473732|Experimental|Everolimus (Zortress)|
11483047|NCT01473732|Active Comparator|Reduced dose Tacrolimus (Prograf)|
11483048|NCT01473719|Active Comparator|motivational intervention|7-session individual motivationally-based intervention
11483049|NCT01473719|Placebo Comparator|health education|7-session individual session focusing on health education
11483050|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
11483051|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
11483123|NCT01473251|Active Comparator|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
11483052|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
11483053|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
11483054|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
11483055|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
11483056|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
11483057|NCT01473667|Active Comparator|Superficial Cervical Plexus Block|
11483058|NCT01473667|Active Comparator|Local Infiltration|
11483059|NCT01473654|Experimental|ADAPT tool|prediabetes counseling using ADAPT tool
11483060|NCT01473654|No Intervention|Control|
11483061|NCT01473641||New users of Nexplanon|
11483062|NCT01473628|Experimental|Radiation Therapy and Rituximab (Arm I)|Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
11483063|NCT01473628|Experimental|Radiation Therapy and Observation (Arm II)|Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
11483064|NCT01473615|Experimental|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
11483065|NCT01473615|No Intervention|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
11483066|NCT01473602|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
11483067|NCT01473602|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
11483068|NCT01473589|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
11483069|NCT01473589|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
11483070|NCT01473576|Experimental|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
11483071|NCT01473576|Placebo Comparator|Sodium chloride|Sodium chloride placebo group
11483072|NCT01473563|Experimental|Pemetrexed|500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
11483073|NCT01473550|Experimental|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
11483074|NCT01473550|Experimental|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
11483075|NCT01473537|Active Comparator|calcium lactate solution 75 mM|
11483076|NCT01473537|Active Comparator|calcium lactate solution 150 mM|
11483077|NCT01473537|Placebo Comparator|placebo|
11483078|NCT01473524|Experimental|DB OCA 5-10 mg|OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.
11483079|NCT01473524|Experimental|DB OCA 10 mg|OCA 10 mg for 12 months during the DB phase.
11483080|NCT01473524|Placebo Comparator|DB Placebo|Matching placebo for 12 months during the DB phase.
11483081|NCT01473524|Experimental|LTSE OCA|After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.
11483082|NCT01473511|Experimental|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
11483083|NCT01473511|No Intervention|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
11483084|NCT01473498|Experimental|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.
~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
11483304|NCT01472029|Experimental|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
11483085|NCT01473498|Active Comparator|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.
~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
11483086|NCT01473485|Experimental|ExAblate Transcranial Device|
11483087|NCT01473472|Active Comparator|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
11483088|NCT01473472|Placebo Comparator|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
11483089|NCT01473459|Active Comparator|IVM Treatment|
11483090|NCT01473459|Active Comparator|Antagonist Protocol|
11483091|NCT01473446|No Intervention|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output <0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
11483092|NCT01473446|Experimental|Goal directed fluid therapy|
11483093|NCT01473433|Other|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
11483094|NCT01473433|Experimental|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
11483095|NCT01473420|Experimental|Epoetin Hospira|Epoetin Hospira
11483096|NCT01473420|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
11483097|NCT01473407|Experimental|Epoetin Hospira|Epoetin Hospira
11483098|NCT01473407|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
11483099|NCT01473394|Placebo Comparator|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
11483100|NCT01473394|Experimental|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
11483101|NCT01473381|Placebo Comparator|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
11483102|NCT01473381|Experimental|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
11483103|NCT01473381|Experimental|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
11483104|NCT01473381|Active Comparator|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
11483105|NCT01473368|Active Comparator|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
11483106|NCT01473368|Active Comparator|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
11483107|NCT01473368|Active Comparator|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
11483108|NCT01473368|No Intervention|control|
11483109|NCT01473355|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm
11483110|NCT01473342|Other|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network & receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear & survey completion during the 9th and final week (Week 17).
11483111|NCT01473329|Experimental|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
11483112|NCT01473316|Experimental|A|
11483113|NCT01473303|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11483114|NCT01473303|Experimental|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
11483115|NCT01473290|Experimental|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
11483116|NCT01473290|Placebo Comparator|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
11483117|NCT01473277|Active Comparator|BT-A (Dysport 500U)|
11483118|NCT01473277|Active Comparator|Triamcinolone acetonide|
11483119|NCT01473264|Placebo Comparator|Control|
11483120|NCT01473264|Experimental|High dose rhCC10|5 mg/kg study drug (rhCC10)
11483121|NCT01473264|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
11483122|NCT01473251|Active Comparator|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
11483124|NCT01473251|Active Comparator|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
11483125|NCT01473238|Active Comparator|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
11483126|NCT01473238|Experimental|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
11483127|NCT01473225|Experimental|Calorie label|
11483128|NCT01473225|Active Comparator|No calorie label|
11483129|NCT01473199|Experimental|BioPoly RS Implant|BioPoly RS Implant
11483130|NCT01473173|Experimental|CJ-12420 50mg|"Single dose
~8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
11483131|NCT01473173|Experimental|CJ-12420 100mg|"Single dose
~8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
11483132|NCT01473173|Experimental|CJ-12420 200mg|"Single dose
~8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
11483133|NCT01473173|Experimental|CJ-12420 400mg|"Single dose
~8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
11483134|NCT01473173|Experimental|CJ-12420 100mg (repeated dose)|"Repeat doses
~100mg is the anticipated dose
~8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
11483135|NCT01473173|Experimental|CJ-12420 200mg (repeated dose)|"Repeat doses
~200mg is the anticipated dose
~8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
11483136|NCT01473173|Active Comparator|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
11483137|NCT01473160|Experimental|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
11483138|NCT01473160|Active Comparator|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
11483139|NCT01473147|Active Comparator|GLP-1|
11483140|NCT01473147|Placebo Comparator|Normal saline|
11483141|NCT01473121||Group 1|
11483142|NCT01473108|Experimental|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
11483143|NCT01473108|Experimental|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
11483144|NCT01473108|Experimental|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
11483145|NCT01473108|Experimental|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
11483146|NCT01473108|Experimental|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
11483147|NCT01473082|Active Comparator|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
11483148|NCT01473082|Active Comparator|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
11483149|NCT01473069|Experimental|Dose 1 JTK-853, 400 mg ketoconazole|
11483150|NCT01473069|Experimental|Dose 2 JTK-853|
11483151|NCT01473069|Experimental|Dose 3 JTK-853|
11483152|NCT01473069|Experimental|Dose 4 JTK-853|
11483153|NCT01473069|Placebo Comparator|Placebo|
11483154|NCT01473056|Experimental|Dose 1 JTK-853|
11483155|NCT01473056|Experimental|Dose 2 JTK-853|
11483156|NCT01473056|Experimental|Dose 3 JTK-853|
11483157|NCT01473056|Experimental|Dose 4 JTK-853|
11483158|NCT01473056|Placebo Comparator|Placebo|
11483159|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
11483160|NCT01473030||Placebo|No PCa at Year 2 or Year 4
11483161|NCT01473017|Experimental|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
11483162|NCT01473017|No Intervention|No CBT intervention|Control group in comparison to CBT guided self-help group
11483163|NCT01473004|Experimental|Sirspheres, response evaluation|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
11483164|NCT01472991|Experimental|TC-5619-238 (25mg)|TC-5619-238 25 mg will be provided as hard gelatin capsules
11483165|NCT01472991|Placebo Comparator|Placebo|Placebo will be provided as hard gelatin capsules similar to TC-5619-238
11483166|NCT01472991|Experimental|TC-5619-238 (5 mg)|TC-5619-238 5 mg will be provided as hard gelatin capsules.
11483167|NCT01472978|Active Comparator|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
11483168|NCT01472978|Sham Comparator|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
11483169|NCT01472965|Active Comparator|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
11483170|NCT01472965|Placebo Comparator|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
11483171|NCT01472939|Active Comparator|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
11483172|NCT01472939|Active Comparator|SSP-002358 (0.5 mg) + PPI|
11483173|NCT01472939|Active Comparator|SSP-002358 (2.0 mg) + PPI|
11483174|NCT01472939|Placebo Comparator|Placebo + PPI|
11483308|NCT01472016|Experimental|Cohort D|ABT-700 plus erlotinib
11483175|NCT01472926|Experimental|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
11483176|NCT01472926|Active Comparator|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
11483177|NCT01472913|Active Comparator|Fibrin Sealent|
11483178|NCT01472913|Placebo Comparator|Saline water|
11483179|NCT01472900|Experimental|Er:YAG laser|
11483180|NCT01472900|Active Comparator|BP gel|
11483181|NCT01472887|Experimental|SAR3419|All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation
11483182|NCT01472874|Experimental|Once a day Trientine|Patients receive once a day trientine
11483183|NCT01472861|Placebo Comparator|No AECC|Routine procedures without AECC
11483184|NCT01472861|Experimental|AECC|Endometrial biopsy and Autologous endometrial coculture
11483185|NCT01472848|Experimental|Cohort 1|
11483186|NCT01472848|Experimental|Cohort 2|
11483187|NCT01472848|Experimental|Cohort 3|
11483188|NCT01472848|Experimental|Cohort 4|
11483189|NCT01472848|Experimental|Cohort 5|
11483190|NCT01472848|Active Comparator|Cohort 6|
11483191|NCT01472835|Experimental|Sedation|Pt will receive sedation with their procedure
11483192|NCT01472835|No Intervention|Control|Patient will not receive sedation during procedure
11483193|NCT01472822|Experimental|Omija extract.|
11483194|NCT01472822|Placebo Comparator|Placebo|
11483195|NCT01472809|Placebo Comparator|Placebo|Placebo tablets
11483196|NCT01472809|Experimental|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.
~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
11483197|NCT01472796|Active Comparator|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
11483198|NCT01472796|Placebo Comparator|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
11483199|NCT01472783|Experimental|Veliparib|
11483200|NCT01472757|Placebo Comparator|Placebo|
11483201|NCT01472757|Active Comparator|Dose 1|
11483202|NCT01472757|Active Comparator|Dose 2|
11483203|NCT01472757|Active Comparator|Dose 3|
11483204|NCT01472744|Experimental|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
11483205|NCT01472744|Active Comparator|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
11483206|NCT01472744|Experimental|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
11483207|NCT01472744|Experimental|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
11483208|NCT01472731|Experimental|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.
~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
11483209|NCT01472718|Active Comparator|standard primary coronary intervention|
11483210|NCT01472718|Experimental|coronary thrombectomy|
11483211|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
11483212|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
11483213|NCT01472692|Active Comparator|Febuxostat|
11483214|NCT01472692|Placebo Comparator|Placebo|
11483215|NCT01472666|Experimental|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
11483216|NCT01472666|Experimental|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
11483217|NCT01472666|Experimental|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
11483218|NCT01472666|Experimental|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
11483219|NCT01472640|Active Comparator|Liraglutid|Liraglutid
11483220|NCT01472640|Placebo Comparator|Placebo|Placebo
11483221|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
11483222|NCT01472614|Experimental|DLBS3233|
11483223|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
11483224|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
11483225|NCT01472588|Experimental|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
11483226|NCT01472588|Experimental|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
11483227|NCT01472588|Other|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
11483228|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
11483305|NCT01472016|Experimental|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
11483229|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
11483230|NCT01472562|Experimental|all patients|"Induction Phase (week 1 - 48):
~Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.
~Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.
~Maintenance Phase (week 49 - progression of disease):
~Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.
~Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
11483231|NCT01472549|Active Comparator|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
11483232|NCT01472549|Experimental|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
11483233|NCT01472536|Experimental|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
11483234|NCT01472536|No Intervention|Control|No intervention
11483235|NCT01472523||Controls|
11483236|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
11483237|NCT01472510|Active Comparator|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
11483238|NCT01472510|Active Comparator|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
11483239|NCT01472497|Experimental|glymepiride|
11483240|NCT01472484|Experimental|lpa with high polyphenol|
11483241|NCT01472484|Experimental|lpa with low polyphenol|
11483242|NCT01472484|Experimental|control bean with low polyphenol|
11483243|NCT01472484|Experimental|control bean with high polyphenol|
11483244|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
11483245|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
11483246|NCT01472458|Active Comparator|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
11483247|NCT01472458|No Intervention|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
11483248|NCT01472445|Experimental|Non-obese (Body Mass Index ≤ 25)|Non-obese participants receive Vitamin D at 400 or 10,000 IU/day
11483249|NCT01472445|Experimental|Obese (Body Mass Index > 25)|Obese participants receive Vitamin D at 400 or 10,000 IU/day
11483250|NCT01472432|Placebo Comparator|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
11483251|NCT01472432|Experimental|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
11483252|NCT01472406|Experimental|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
11483253|NCT01472393|Experimental|Creatine supplementation|
11483254|NCT01472393|Placebo Comparator|Placebo|
11483255|NCT01472380|Active Comparator|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
11483256|NCT01472380|Active Comparator|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
11483257|NCT01472354|No Intervention|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
11483258|NCT01472354|Experimental|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
11483259|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
11483260|NCT01472328|Experimental|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
11483261|NCT01472328|Sham Comparator|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
11483262|NCT01472315|Active Comparator|medroxyprogesterone acetate|
11483263|NCT01472315|Placebo Comparator|Placebo|Placebo pills taken in the same way as the active comparator
11483264|NCT01472302|Experimental|ASV|Adaptive Support Ventilation
11483265|NCT01472302|Active Comparator|PCV|Pressure Controlled Ventilation
11483306|NCT01472016|Experimental|Cohort B|ABT-700 plus docetaxel.
11483307|NCT01472016|Experimental|Cohort C|ABT-700 plus FOLFIRI/cetuximab
11483266|NCT01472289|Experimental|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
11483267|NCT01472276|No Intervention|Control|
11483268|NCT01472276|Active Comparator|Web-based program|
11483269|NCT01472263|Experimental|Pentoxifylline|
11483270|NCT01472263|Placebo Comparator|Placebo|
11483271|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
11483272|NCT01472237|Active Comparator|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
11483273|NCT01472237|Placebo Comparator|Care as usual|The patients are referred to their cardiologyst and primary care physicians
11483274|NCT01472211|Experimental|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
11483275|NCT01472211|Placebo Comparator|placebo filter|children consuming purified water delivered by a household-based water filter
11483276|NCT01472211|Active Comparator|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
11483277|NCT01472198|Experimental|Simtuzumab (open-label)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
11483278|NCT01472198|Experimental|Simtuzumab 200 mg (randomized)|Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
11483279|NCT01472198|Experimental|Simtuzumab 700 mg (randomized)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
11483280|NCT01472198|Placebo Comparator|Placebo (randomized)|Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
11483281|NCT01472185|Placebo Comparator|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.
~Participants were required to maintain their diet and exercise regimen."
11483282|NCT01472185|Experimental|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.
~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.
~Participants were required to maintain their diet and exercise regimen."
11483283|NCT01472172|Experimental|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
11483284|NCT01472159|No Intervention|CGM-Usual Care|Routine CGM education
11483285|NCT01472159|Experimental|CGM-Teamwork|"Routine CGM education
~CGM Family Teamwork Intervention"
11483286|NCT01472146|Experimental|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.
~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
11483287|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
11483288|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
11483289|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
11483290|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
11483291|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
11483292|NCT01472120||P and C|"P: NAFLD patients
~C: Healthy controls"
11483293|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
11483294|NCT01472081|Experimental|Arm S: Nivolumab + Sunitinib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons
~Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons"
11483295|NCT01472081|Experimental|Arm P: Nivolumab + Pazopanib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons
~Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons"
11483296|NCT01472081|Experimental|Arm I-1: Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons
~Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons"
11483297|NCT01472081|Experimental|Arm I-3: Nivolumab + Ipilimumab|"Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase
~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
11483298|NCT01472081|Experimental|Arm IN-3: Nivolumab+Ipilimumab|"Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase
~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
11483299|NCT01472068|Experimental|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
11483300|NCT01472055|Experimental|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
11483301|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
11483302|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
11483303|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
11483309|NCT01472003|Experimental|ABT-806 Arm|Subjects with advanced solid tumors
11483310|NCT01472003|Experimental|ABT-806i Arm|Subjects with advanced solid tumors
11483311|NCT01471990|Active Comparator|PACAP38|
11483312|NCT01471990|Active Comparator|VIP|
11483313|NCT01471977|Experimental|education, counselling, default tracer|
11483314|NCT01471964|Experimental|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).
~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
11483315|NCT01471951|Experimental|single embryo transfer|
11483316|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
11483317|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
11483318|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
11483319|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
11483320|NCT01471925|Experimental|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
11483321|NCT01471925|Active Comparator|Nexium®|
11483322|NCT01471899|Active Comparator|Naproxen|2 tablets every 8 hours for 4 days.
11483323|NCT01471899|Experimental|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
11483324|NCT01471886|Active Comparator|Naproxen|Every 8 hours for 4 days.
11483325|NCT01471886|Experimental|Ketorolac Tromethamine|Every 8 hours for 4 days
11483326|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
11483327|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
11483328|NCT01471860|Experimental|Device and Medical Management|"Medical Management, to be determined by the participant's physician, described as:
~Optimal pharmacological therapy: Prescribed to a beta blocker, a diuretic, and an ACE (Angiotensin-converting-enzyme) inhibitor or ARB (Angiotensin Receptor Blocker) unless contraindicated or not tolerated. These drugs must be used in a manner consistent with their labeling.
~Stable pharmacological therapy: No more than a 50% increase or a 50% decrease of the dosage of any one medication, and post titration of all heart failure medications.
~Participants should remain on their prescribed heart failure medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study."
11483329|NCT01471847|Experimental|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.
~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.
~Treatment will be organized into cycles of 21 days."
11483330|NCT01471847|Active Comparator|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
11483331|NCT01471834|Experimental|Device and Medical Management|Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
11483332|NCT01471821|Experimental|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
11483333|NCT01471821|Active Comparator|Continue with current treatment|
11483334|NCT01471808|Active Comparator|CSII|continuous subcutaneous insulin infusion
11483335|NCT01471808|Active Comparator|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
11483336|NCT01471808|Active Comparator|Sitagliptin|CSII combined with sitagliptin 100mg/d
11483337|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
11483338|NCT01471782|Experimental|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
11483339|NCT01471769|Experimental|pain management video|Experimental
11483340|NCT01471769|Placebo Comparator|falls prevention video|placebo
11483341|NCT01471756|Experimental|iSnare with Gonak solution|
11483342|NCT01471756|Experimental|Snaremaster braided snare with Gonak solution|
11483343|NCT01471756|Experimental|iSnare with saline solution|
11483344|NCT01471756|Experimental|Snaremaster braided snare with saline solution|
11483345|NCT01471743|Experimental|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
11483346|NCT01471743|Active Comparator|Standard Supplement|3 supplement per day for 5 days pre-operatively
11483347|NCT01471730|Placebo Comparator|Saline solution|
11483348|NCT01471730|Active Comparator|Fibrinogen|
11483349|NCT01471730|Active Comparator|Prothrombin complex|
11483350|NCT01471717|Experimental|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
11483351|NCT01471717|Active Comparator|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
11483352|NCT01471717|Active Comparator|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
11483353|NCT01471717|Active Comparator|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
11483354|NCT01471717|Placebo Comparator|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
11483355|NCT01471717|Placebo Comparator|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
11483356|NCT01471704|Experimental|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
11483357|NCT01471704|Active Comparator|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
11483358|NCT01471704|Active Comparator|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
11483359|NCT01471691|Experimental|intravitreal ranibizumab 0.5mg|
11483360|NCT01471691|Experimental|intravitreal ranibizumab 1.0mg|
11483361|NCT01471678|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
11483362|NCT01471678|Experimental|Dutasteride (0.5mg)|Commercial formulation of dutasteride
11483363|NCT01471678|Experimental|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
11483364|NCT01471665|Experimental|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
11483365|NCT01471665|Placebo Comparator|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
11483366|NCT01471587||Patients with COPD|
11483367|NCT01471548|Experimental|TKI258|dose escalation
11483368|NCT01471431|Experimental|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
11483369|NCT01471431|No Intervention|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
11483370|NCT01471418|Experimental|Disease population|
11483371|NCT01471379|Experimental|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
11483372|NCT01471379|Active Comparator|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
11483373|NCT01471379|Placebo Comparator|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
11483374|NCT01471366|Active Comparator|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
11483375|NCT01471366|Active Comparator|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
11483376|NCT01471366|Active Comparator|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
11483377|NCT01471366|Active Comparator|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
11483378|NCT01471353|Experimental|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
11483379|NCT01471340|Experimental|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
11483380|NCT01471340|Active Comparator|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
11483381|NCT01471652|Active Comparator|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
11483382|NCT01471652|Placebo Comparator|Placebo|
11483383|NCT01471639|Experimental|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
11483384|NCT01471626|Experimental|telematic attended polysomnography|
11483385|NCT01471613|Experimental|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
11483386|NCT01471613|Placebo Comparator|Group A - Control|Conventional treatment and placebo
11483387|NCT01471613|Experimental|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
11483388|NCT01471613|Experimental|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
11483389|NCT01471600|No Intervention|No intervention|Group overnight fasting
11483390|NCT01471600|Active Comparator|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
11483391|NCT01471574|Experimental|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
11483392|NCT01471535|Experimental|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
11483393|NCT01471522|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
11483394|NCT01471522|Active Comparator|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
11483395|NCT01471509|Placebo Comparator|Control|240 ml water
11483396|NCT01471509|Active Comparator|glucose|50 g glucose
11483397|NCT01471509|Active Comparator|Amino acid|1 mmol amino acid/kg lean body mass
11483398|NCT01471509|Active Comparator|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
11483399|NCT01471496|Experimental|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
11483400|NCT01471496|No Intervention|control group|This group of the patients recieved medical therapy only.
11483401|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
11483402|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
11483403|NCT01471470|Experimental|neoadjuvant|
11483404|NCT01471457|Experimental|Trimo-San group|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
11483405|NCT01471457|No Intervention|Control group|Pessary wearers are informed on standard care of pessary, which includes topical estrogen application if they are using. Pessary wearers do not use Trimo-San gel
11483406|NCT01471444|Experimental|Flu + Bu|Fludarabine 40 mg/m2 intravenous (IV) over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours. Both delivered for 4 consecutive days (days -6 to -3). Stem cell transplant Day 0.
11483407|NCT01471444|Experimental|Flu +Clo + Bu|Fludarabine 10 mg/m2 over 1 hour. Clofarabine 40 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, infused over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours, immediately after Clofarabine. All delivered on 4 consecutive days (days -6 through -3). Stem cell transplant Day 0.
11483408|NCT01471392|Experimental|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
11483409|NCT01471327|Experimental|SB-240563, 10mg|IV, single dose at Day 1
11483410|NCT01471327|Experimental|Placebo|Saline IV, single dose at Day 1
11483411|NCT01471327|Experimental|SB-240563, 75mg|IV, single dose at Day 1
11483412|NCT01471327|Experimental|SB-240563, 250mg|IV, single dose at Day 1
11483413|NCT01471327|Experimental|SB-240563, 750mg|IV, single dose at Day 1
11483414|NCT01471314||Spontaneous migraine|
11483415|NCT01471288|Active Comparator|Group3|Normal controls
11483416|NCT01471288|Placebo Comparator|Group4|Normal controls
11483417|NCT01471288|Active Comparator|Group 1|Hypothyroid patients taking levothyroxin.
11483418|NCT01471288|Placebo Comparator|Group2|Hypothyroid patients taking levothyroxin
11483419|NCT01471275|Experimental|Jiangtangtiaozhi decoction|
11483420|NCT01471275|Active Comparator|metformin|
11483421|NCT01471262||Elderly|Patients more or equal to 70 years old
11483422|NCT01471262||Young|Patients less than 70 years old
11483423|NCT01471236|Experimental|Agili-c bi-phasic implant|mini-arthrotomy
11483424|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
11483425|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
11483426|NCT01471210|Experimental|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
11483427|NCT01471210|Experimental|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
11483428|NCT01471210|Experimental|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
11483429|NCT01471210|Experimental|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
11483430|NCT01471197|Experimental|Arm 1: Ipilimumab|
11483431|NCT01471197|Active Comparator|Arm 2: Pemetrexed|
11483432|NCT01471184|Experimental|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
11483433|NCT01471184|Placebo Comparator|Placebo Eye Drops/Nasal Spray|
11483434|NCT01471171|Experimental|Aclidinium bromide|3-week treatment periods
11483435|NCT01471171|Experimental|Placebo|3-week treatment periods
11483436|NCT01471158|Active Comparator|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
11483437|NCT01471158|Active Comparator|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
11483438|NCT01471145|Experimental|Depot Naltrexone|
11483439|NCT01471132|Experimental|HIPEC|
11483440|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
11483441|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
11483442|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
11483443|NCT01471119|Experimental|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
11483444|NCT01471106|Experimental|Group 1: Dasatinib 40 mg|Dasatinib 40 mg by mouth once a day for 3 months (+/- 7 days), At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
11483445|NCT01471106|No Intervention|Group 3: No Dasatinib|No treatment control group. At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
11483446|NCT01471106|Experimental|Group 2: Dasatinib 80 mg|Dasatinib 80 mg by mouth once a day for 3 months (+/- 7 days). At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
11483447|NCT01471093|Experimental|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
11483448|NCT01471093|Active Comparator|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
11483449|NCT01471080|Experimental|RFA group|using RFA to treat cavernous hemangiomas
11483450|NCT01471080|Active Comparator|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
11483451|NCT01471067|Experimental|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
11483452|NCT01471067|Experimental|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m^2 IV on Days -5 to -2; Melphalan 140 mg/m^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
11483453|NCT01471054|Experimental|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of best-corrected visual acuity (BCVA), complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
11483454|NCT01471054|Active Comparator|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
11483455|NCT01471041|Experimental|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
11483456|NCT01471028|Experimental|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
11483457|NCT01471028|Other|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
11483458|NCT01471015|Active Comparator|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
11483459|NCT01471015|Active Comparator|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
11483460|NCT01471015|Placebo Comparator|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
11483461|NCT01471002|Experimental|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
11483462|NCT01470989|Experimental|canakinumab|canakinumab 150 mg s.c.
11483463|NCT01470976|Active Comparator|Goal-directed Therapy (GDT) Protocol|
11483464|NCT01470976|Active Comparator|Standard Protocol|
11483465|NCT01470963|Experimental|Referral template|Implementation of the referral templates at the GP office
11483466|NCT01470963|No Intervention|Control|Normal referral pattern
11483467|NCT01470950|Experimental|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
11483468|NCT01470937|Experimental|Acarbose|acarbose 100 mg once daily
11483469|NCT01470937|Placebo Comparator|Placebo|Matched placebo was administered for acarbose 100 mg once daily
11483470|NCT01470911|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
11483471|NCT01470911|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
11483472|NCT01470898|Experimental|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
11483473|NCT01470898|Experimental|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
11483474|NCT01470885||glucose value|glucose value
11483475|NCT01470859|Active Comparator|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
11483476|NCT01470859|Active Comparator|Levodopa|Sinemet CR CR， Controlled Release
11483477|NCT01470846|Experimental|APD|patient with epidural analgesia
11483478|NCT01470846|Active Comparator|PCA|Patient with morphine analgesia
11483479|NCT01470833|No Intervention|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:
~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.
~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
11483480|NCT01470833|Experimental|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:
~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.
~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
11483481|NCT01470820|Active Comparator|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
11483482|NCT01470820|Active Comparator|Distance 29 cm|
11483483|NCT01470820|Active Comparator|Distance 38 cm|
11483484|NCT01470820|Active Comparator|Distance 47 cm|
11483485|NCT01470807|Experimental|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
11483486|NCT01470794|Experimental|Single Arm|Toca 511 vector/Toca FC prodrug
11483487|NCT01470781|Experimental|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
11483488|NCT01470781|Placebo Comparator|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
11483489|NCT01470768|Other|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
11483490|NCT01470768|Other|Arm 2 - AA Formula with alternative levels of DHA and ARA|
11483491|NCT01470755|Other|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
11483492|NCT01470755|Other|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
11483493|NCT01470755|Other|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
11483494|NCT01470755|Other|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
11483495|NCT01470742|Active Comparator|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
11483496|NCT01470742|Experimental|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
11483497|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
11483498|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
11483499|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
11483500|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
11483501|NCT01470716|Experimental|Study arm|Neo-adjuvant Erlotinib treatment arm.
11483502|NCT01470703|Experimental|ECMO arm|
11483503|NCT01470703|Active Comparator|conventional arm|
11483504|NCT01470690|Active Comparator|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
11483505|NCT01470690|Active Comparator|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
11483506|NCT01470690|Experimental|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
11483507|NCT01470677|Experimental|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
11483508|NCT01470677|No Intervention|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
11483509|NCT01470664|Experimental|FST-100|
11483510|NCT01470664|Experimental|FST-100 (Component #1)|
11483511|NCT01470664|Placebo Comparator|FST-100 Vehicle|
11483512|NCT01470651|Experimental|Armodafinil|Active medication
11483513|NCT01470651|Placebo Comparator|Sugar pill|Inactive pill, matched to look like active medication
11483514|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
11483515|NCT01470612|Experimental|CP-690,550 5 mg BID|5 mg BID
11483516|NCT01470612|Experimental|CP-690,550 10 mg BID|10 mg BID
11483517|NCT01470599|Experimental|5mg BID|
11483518|NCT01470599|Experimental|10mg BID|
11483519|NCT01470586|Other|Surgery for colorectal cancer|Colorectal cancer patients
11483520|NCT01470586|No Intervention|Controls|Controls
11483521|NCT01470573|Experimental|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
11483522|NCT01470560|Sham Comparator|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
11483523|NCT01470560|Active Comparator|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
11483524|NCT01470534|Experimental|Normal body weight|
11483525|NCT01470534|Experimental|Obese|
11483526|NCT01470534|Placebo Comparator|Normal Body Weight placebo|Participants of mormal body weight given placebo
11483527|NCT01470534|Placebo Comparator|Obese placebo|Participants who are obese given placebo
11483528|NCT01470521|Experimental|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
11483529|NCT01470521|Placebo Comparator|Placebo|Participant will receive pharmacopoeial grade water
11483530|NCT01470508|Experimental|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
11483531|NCT01470508|Active Comparator|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
11483532|NCT01470495|Experimental|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
11483533|NCT01470495|Active Comparator|RFA group|To treat recurrent HCC with RFA
11483534|NCT01470482|Other|No Tourniquet|We compare tourniquet or not in knee surgery
11483535|NCT01470482|Active Comparator|Tourniquet|We compare tourniquet or not in knee surgery
11483536|NCT01470469|Active Comparator|SPD503|
11483537|NCT01470469|Placebo Comparator|Placebo|
11483538|NCT01470456|Experimental|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
11483539|NCT01470443|Active Comparator|GEMOX|"Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks
~Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
11483540|NCT01470443|Experimental|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
11483541|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
11483542|NCT01470430||ROP infants treated with retinal laser photocoagulation|
11483543|NCT01470417|Active Comparator|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
11483544|NCT01470417|Active Comparator|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
11483545|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
11483546|NCT01470391|Experimental|Adductor-Canal-Blockade|
11483547|NCT01470391|Active Comparator|Femoral Nerve Block|
11483548|NCT01470378|Active Comparator|Control Group|This group will not be undergoing to manual lymphatic drainage
11483549|NCT01470378|Active Comparator|Study Group|This group will be undergoing to manual lymphatic drainage
11483550|NCT01470365|Experimental|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
11483551|NCT01470352|Placebo Comparator|Placebo|
11483552|NCT01470352|Active Comparator|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
11483553|NCT01470339|Placebo Comparator|placebo|migraine patients to receive placebo treatment
11483554|NCT01470339|Active Comparator|duloxetine|migraine patients to receive duloxetine
11483555|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
11483556|NCT01470313|Experimental|PD-0360324|
11483557|NCT01470313|Placebo Comparator|Placebo|
11483558|NCT01470300|Experimental|Standard ED|100% energy density
11483559|NCT01470300|Experimental|Reduced ED - F/V|80% energy density by adding fruit and vegetables
11483560|NCT01470300|Experimental|Reduced ED - Fat|80% energy density by decreasing fat
11483561|NCT01470300|Experimental|Reduced ED - Plain water|80% energy density by adding plain water
11483562|NCT01470287|Experimental|Arm 1|
11483563|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
11483564|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
11483565|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
11483566|NCT01470248|Experimental|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
11483567|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.
~Expected recruitment: 200"
11483568|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.
~Expected recruitment: 200."
11483569|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).
~Expected recruitment: 200."
11483623|NCT01469871|Active Comparator|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
11483624|NCT01469858|Experimental|study group|fMRI
11483625|NCT01469845|Active Comparator|hypertonic saline and usual care|
11483626|NCT01469845|Active Comparator|usual care (oxygen therapy)|
11483705|NCT01469234|Experimental|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
11483570|NCT01470222|Experimental|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.
~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
11483571|NCT01470222|Experimental|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
11483572|NCT01470209|Experimental|Combination of BKM120 and everolimus|
11483573|NCT01470196|Experimental|Treatment Arm|Carfilzomib, dexamethasone, rituximab
11483574|NCT01470183||Lupus Nephritis Patients|"Male or female subjects age 18 and older
~Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy
~Must have stable disease on medication at time of enrollment"
11483575|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
11483576|NCT01470170|Experimental|Group1|Alfentanil 2.5μg/kg before propofol
11483577|NCT01470170|Experimental|Group2|Alfentanil 5μg/kg before propofol
11483578|NCT01470170|Experimental|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
11483579|NCT01470170|Experimental|Group 4|Alfentanil 5μg/kg two minutes before propofol
11483580|NCT01470170|Placebo Comparator|Group 5 Control|propofol alone
11483581|NCT01470157|Experimental|Ketamine|Oral Ketamine in addition to oral midazolam
11483582|NCT01470157|Placebo Comparator|Placebo|Normal saline (placebo) in addition to oral midazolam
11483583|NCT01470144|Experimental|Treatment|Single arm, open-label
11483584|NCT01470131|Experimental|Masitinib|Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
11483585|NCT01470131|Placebo Comparator|Placebo|Placebo in combination with Bortezomib and Dexamethasone
11483586|NCT01470118|Active Comparator|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
11483587|NCT01470118|Active Comparator|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
11483588|NCT01470118|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
11483589|NCT01470105||pts bone metastases|This is a prospective, cross sectional, human use study conducted using patients with bone metastases requiring orthopaedic stabilization. Though this is an observational study, blood sampling, the SF-36 questionnaire, and ECOG performance status, and correlative studies will be performed.
11483590|NCT01470092|Active Comparator|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
11483591|NCT01470092|No Intervention|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
11483592|NCT01470053|Experimental|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
11483593|NCT01470053|Active Comparator|mometasone furoate|opaque suspension, four times each naris per day
11483594|NCT01470053|Active Comparator|azelastine HCl|lucidus colorless liquid, two times each naris per day
11483595|NCT01470040|Experimental|discontinuation of aspirin therapy|
11483596|NCT01470040|Sham Comparator|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
11483597|NCT01470027|Active Comparator|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
11483598|NCT01470027|Active Comparator|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
11483599|NCT01470027|Placebo Comparator|Placebo|Placebo effervescent tablets daily for 30 days
11483600|NCT01470014||IVNC|
11483601|NCT01470014||differential diagnosis to IVNC|
11483602|NCT01470001|Active Comparator|solifenacin|patients in this arm will receive drug
11483603|NCT01470001|Placebo Comparator|placebo|patients is this arm will receive placebo
11483604|NCT01469988|Experimental|Testosterone|
11483605|NCT01469988|Placebo Comparator|Placebo|
11483606|NCT01469975|Experimental|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
11483607|NCT01469975|Experimental|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
11483608|NCT01469975|Experimental|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
11483609|NCT01469962||obese patients|
11483610|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
11483611|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
11483612|NCT01469949||Control group|Subjects receiving measurement with intervention
11483613|NCT01469936|Experimental|PERMEAPROTECT|
11483614|NCT01469936|Placebo Comparator|PLACEBO|
11483615|NCT01469923|Active Comparator|AZD2820|AZD2820 multiple injections
11483616|NCT01469923|Placebo Comparator|Placebo for AZD2820|Placebo for AZD2820 multiple injections
11483617|NCT01469910|Experimental|Simotinib|
11483618|NCT01469910|Placebo Comparator|Placebo|
11483619|NCT01469884|Experimental|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
11483620|NCT01469884|Active Comparator|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
11483621|NCT01469871|Active Comparator|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
11483622|NCT01469871|Active Comparator|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
11483627|NCT01469832|Experimental|Subretinal injection of MA09-hRPE|"Cohort 1 50,000 cells
~Cohort 2 100,000 cells
~Cohort 2a Better Vision 100,000 cells
~Cohort 3 150,000 cells
~Cohort 4 200,000 cells"
11483628|NCT01469819|Experimental|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
11483629|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
11483630|NCT01469793|Experimental|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
11483631|NCT01469793|Experimental|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
11483632|NCT01469793|Experimental|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
11483633|NCT01469793|Experimental|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
11483634|NCT01469767|Experimental|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
11483635|NCT01469754||Lymphoma Survivors|
11483636|NCT01469728|Experimental|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
11483637|NCT01469728|Active Comparator|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
11483638|NCT01469715|Experimental|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
11483639|NCT01469689|Experimental|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
11483640|NCT01469689|Experimental|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
11483641|NCT01469689|Experimental|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
11483642|NCT01469689|No Intervention|Control|Control areas. No Intervention
11483643|NCT01469676|No Intervention|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
11483644|NCT01469676|Experimental|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
11483645|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
11483646|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
11483647|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
11483648|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
11483649|NCT01469650|Active Comparator|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
11483650|NCT01469650|Experimental|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
11483651|NCT01469637|Experimental|Sulfamethoxazole + MMX placebo|
11483652|NCT01469637|Experimental|Sulfamethoxazole + MMX Mesalazine/mesalamine|
11483653|NCT01469624|Experimental|Test group|This group receives pentoxifylline
11483654|NCT01469624|No Intervention|Control group|
11483655|NCT01469611|Experimental|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
11483656|NCT01469598|Experimental|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
11483657|NCT01469585|Active Comparator|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
11483658|NCT01469585|No Intervention|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
11483659|NCT01469572|Experimental|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
11483660|NCT01469559|Active Comparator|Novolin Toronto insulin|
11483661|NCT01469559|Placebo Comparator|Normal saline|
11483662|NCT01469546|Experimental|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
11483663|NCT01469533|Experimental|experimental group|The experimental group receives the real spinal mechanical manipulation.
11483664|NCT01469533|Sham Comparator|control group|The control group receives the sham-manipulation procedure.
11483665|NCT01469520|Active Comparator|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
11483666|NCT01469520|Active Comparator|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
11483667|NCT01469520|Active Comparator|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
11483668|NCT01469507|Experimental|V0220|
11483669|NCT01469507|Active Comparator|Hyaluronan|
11483745|NCT01469000|Active Comparator|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
11483670|NCT01469494|Active Comparator|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
11483671|NCT01469494|Active Comparator|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
11483672|NCT01469481|Experimental|1|
11483673|NCT01469468|Experimental|Single arm, fixed sequence dosing|
11483674|NCT01469455|Experimental|DT01|
11483675|NCT01469442|Experimental|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
11483676|NCT01469442|No Intervention|without external biliary duct stent|
11483677|NCT01469429|Placebo Comparator|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
11483678|NCT01469429|Experimental|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
11483679|NCT01469429|Placebo Comparator|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
11483680|NCT01469429|Experimental|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
11483681|NCT01469416|Active Comparator|Rosuvastatin|
11483682|NCT01469416|Experimental|Rosuvastatin + clopidogrel|
11483683|NCT01469403|No Intervention|control group|Standard procedure for knee arthroplasty
11483684|NCT01469403|Active Comparator|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
11483685|NCT01469377|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
11483686|NCT01469377|Experimental|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
11483687|NCT01469377|Experimental|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
11483688|NCT01469364|Experimental|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
11483689|NCT01469351|Active Comparator|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
11483690|NCT01469351|Placebo Comparator|placebo|non active intervention
11483691|NCT01469338|Experimental|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
11483692|NCT01469325|Active Comparator|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
11483693|NCT01469325|Sham Comparator|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
11483694|NCT01469312|Placebo Comparator|Control|The control arm consists of the traditional pasta.
11483695|NCT01469312|Active Comparator|Modified pasta|Dreamfields, Miracle Noodles
11483696|NCT01469286|Active Comparator|TEA|Needleless electroacupuncture at ST36 and PC6
11483697|NCT01469286|Placebo Comparator|Sham-TEA|Needleless acupuncture at sham-points
11483698|NCT01469273|No Intervention|Control group|Only observation; observation period: 1 year.
11483699|NCT01469273|Experimental|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
11483700|NCT01469273|Experimental|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
11483701|NCT01469260|No Intervention|Routine care|ACOG Exercise in Pregnancy pamphlet
11483702|NCT01469260|Experimental|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
11483703|NCT01469247|Experimental|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
11483704|NCT01469234|Experimental|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
11484054|NCT01466803|Placebo Comparator|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
11483706|NCT01469234|Placebo Comparator|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
11483707|NCT01469221|Experimental|Apaziquone|Apaziquone (4 mg in 40 mL)
11483708|NCT01469221|Placebo Comparator|Placebo|Matching placebo (40 mL)
11483709|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
11483710|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
11483711|NCT01469182|Experimental|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
11483712|NCT01469182|Placebo Comparator|Placebo|Matching placebo tablet, sublingual, once daily.
11483713|NCT01469169|Experimental|Arm 1|
11483714|NCT01469156|Experimental|Ranibizumab 2.0 mg|Intraocular injection of 2.0 mg/0.05 cc ranibizumab.
11483715|NCT01469156|Active Comparator|Ranibizumab 0.5 mg|Intraocular injection of 0.5 mg/0.05 cc ranibizumab.
11483716|NCT01469143|Experimental|NN1218|
11483717|NCT01469143|Active Comparator|insulin aspart|
11483718|NCT01469130|Experimental|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.
~The prescribed BID doses should be taken 12 ± 2 hrs apart."
11483719|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
11483720|NCT01469104|Placebo Comparator|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
11483721|NCT01469104|Active Comparator|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
11483722|NCT01469091|Active Comparator|Smoking intervention, Nicotine replacement therapy.|
11483723|NCT01469091|No Intervention|Controlgroup|
11483724|NCT01469078|Active Comparator|100 mg Monofer®|
11483725|NCT01469078|Active Comparator|200 mg Monofer®|
11483726|NCT01469078|Active Comparator|500 mg Monofer®|
11483727|NCT01469065|Experimental|PF-04991532|PF-04991532 experimental study medication
11483728|NCT01469065|Placebo Comparator|Placebo|PF-04991532 Matching Placebo
11483729|NCT01469052|Experimental|Cohort 1|
11483730|NCT01469052|Experimental|Cohort 2|
11483731|NCT01469052|Experimental|Cohort 3|
11483732|NCT01469052|Experimental|Cohort 4|
11483733|NCT01469052|Experimental|Cohort 5|
11483734|NCT01469052|Experimental|Cohort 6|
11483735|NCT01469039|Experimental|ALKS 9072|
11483736|NCT01469039|Placebo Comparator|Placebo|
11483737|NCT01469026|Active Comparator|Early PET/CT|
11483738|NCT01469026|Active Comparator|Conventional diagnostics including CT|
11483739|NCT01469013|Placebo Comparator|Placebo|"2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
11483740|NCT01469013|Experimental|1-mg Baricitinib (LY3009104)|"1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
11483741|NCT01469013|Experimental|2-mg Baricitinib (LY3009104)|"2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
11483742|NCT01469013|Experimental|4-mg Baricitinib (LY3009104)|1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
11483743|NCT01469013|Experimental|8-mg Baricitinib (LY3009104)|2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
11483744|NCT01469000|Experimental|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
11483746|NCT01468987|Active Comparator|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.
~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
11483747|NCT01468987|Experimental|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.
~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
11483748|NCT01468974|Other|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
11483749|NCT01468961|Experimental|Internet-based CBT|
11483750|NCT01468922|Experimental|A|Combination pazopanib plus ARQ197 at doses established during escalation phase
11483751|NCT01468909|Placebo Comparator|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11483752|NCT01468909|Experimental|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11483753|NCT01468896|Experimental|Treatment (cetuximab and recombinant interleukin-12)|Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
11483754|NCT01468883|Active Comparator|M|Modified radical mastectomy
11483755|NCT01468883|Experimental|X|Excisional biopsy plus radiation
11483756|NCT01468844|Experimental|Participants 1|Participants injected with bevizcumab for three months then 100mg minocycline twice daily for 24 months
11483757|NCT01468844|Placebo Comparator|Participants 2|Participants injected with bevizcumab for three months then placebo twice daily for 24 months
11483758|NCT01468831|Placebo Comparator|Participants Group 1|Participants that will receive three months of bevizcumab injections followed by placebo twice daily for 24 months
11483759|NCT01468831|Experimental|Participants Group 2|Participants that will receive three months of bevacizumab injections followed by 100mg of minocycline twice daily for 24 months
11483760|NCT01468818|Experimental|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
11483761|NCT01468779|Placebo Comparator|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
11483762|NCT01468779|Active Comparator|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
11483763|NCT01468766|Active Comparator|Resistance training|
11483764|NCT01468766|Active Comparator|Relaxation training|
11483765|NCT01468753|Experimental|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
11483766|NCT01468727|Experimental|xylitol wipe|
11483767|NCT01468727|Placebo Comparator|placebo wipe|
11483768|NCT01468688|Experimental|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
11483769|NCT01468688|Experimental|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
11483770|NCT01468688|Experimental|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
11483771|NCT01468675|Experimental|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
11483772|NCT01468675|No Intervention|Control|Usual Care
11483773|NCT01468662||STEMI|
11483774|NCT01468649|Experimental|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
11483775|NCT01468636|Active Comparator|Oral Zinc|
11483776|NCT01468636|Placebo Comparator|Placebo|
11483777|NCT01468623|Experimental|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
11483778|NCT01468623|Active Comparator|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
11483779|NCT01468610|Active Comparator|Workers with MDD|
11483780|NCT01468597||One group|Emergency surgery
11483781|NCT01468584|Experimental|MP-424|
11483782|NCT01468571|Experimental|Spironolactone|Drug: Spironolactone Drug: Placebo
11483783|NCT01468571|Experimental|Placebo|Drug: Placebo Drug: Spironolactone
11483784|NCT01468558|Other|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
11483785|NCT01468545||Group 1|
11483786|NCT01468545||Group 2|
11483832|NCT01468233|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
11483787|NCT01468532|Experimental|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM on day 1, docetaxel IV over 1 hour, and prednisone PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11483788|NCT01468519|Experimental|CSII|continuous subcutaneous insulin infusion
11483789|NCT01468519|Active Comparator|MDI|multiple daily insulin injections
11483790|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
11483791|NCT01468493||steroid-sensitive FSGS|
11483792|NCT01468493||steroid-dependent and resistant FSGS|
11483793|NCT01468493||Healthy volunteers|
11483794|NCT01468480|Experimental|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
11483795|NCT01468480|Experimental|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
11483796|NCT01468480|Experimental|MultiCal / LimeLite|application of Multical in forth group
11483797|NCT01468480|Active Comparator|Dycal|application of Dycal in first group as a pulp dressing agent
11483798|NCT01468467|Experimental|AC220|
11483799|NCT01468454|Experimental|(18F-DOPA) PET/CT imaging|Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion
11483800|NCT01468441|Experimental|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
11483801|NCT01468441|Active Comparator|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
11483802|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
11483803|NCT01468389|Active Comparator|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
11483804|NCT01468389|Experimental|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
11483805|NCT01468376|Experimental|GLU-01|
11483806|NCT01468376|Experimental|GLU-02|
11483807|NCT01468376|Experimental|GLU-03|
11483808|NCT01468376|Experimental|GLU-04|
11483809|NCT01468376|Experimental|GLU-05|
11483810|NCT01468376|Experimental|GLU-06|
11483811|NCT01468363|Active Comparator|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.
~If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.
~If OH is negative value , we will not change dry weight."
11483812|NCT01468363|No Intervention|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
11483813|NCT01468350|Placebo Comparator|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
11483814|NCT01468350|Placebo Comparator|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
11483815|NCT01468350|Placebo Comparator|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
11483816|NCT01468350|Placebo Comparator|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
11483817|NCT01468337|Experimental|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.
~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
11483818|NCT01468311|Experimental|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
11483819|NCT01468298|Active Comparator|Isostretching|
11483820|NCT01468298|Active Comparator|Global Posture Reeducation|
11483821|NCT01468285|Experimental|Treatment arm 1: betahistine dihydrochloride|
11483822|NCT01468285|Placebo Comparator|Treatment arm 2: placebo|
11483823|NCT01468272|Active Comparator|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
11483824|NCT01468272|Experimental|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
11483825|NCT01468259|Experimental|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
11483826|NCT01468259|Experimental|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
11483827|NCT01468259|Experimental|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
11483828|NCT01468259|Experimental|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
11483829|NCT01468259|Experimental|End Stage Renal Disease|Eight with ESRD (eGFR < 15 mL/min/1.73m² and requiring hemodialysis)
11483830|NCT01468246||Young Women|Young women with newly diagnosed breast cancer
11483831|NCT01468233|Placebo Comparator|Placebo|Placebo for 12 weeks.
11483833|NCT01468233|Placebo Comparator|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
11483834|NCT01468233|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
11483835|NCT01468233|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
11483836|NCT01468233|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
11483837|NCT01468220|Placebo Comparator|normoxic training|6 weeks of endurance training under normoxia
11483838|NCT01468220|Active Comparator|hypoxic training|6 weeks of endurance training under hypoxia
11483839|NCT01468207|Placebo Comparator|Placebo|Placebo for 12 weeks.
11483840|NCT01468207|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
11483841|NCT01468207|Experimental|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
11483842|NCT01468207|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
11483843|NCT01468207|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
11483844|NCT01468207|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
11483845|NCT01468194|Experimental|Breathing procedure 1|"Walking with breathing procedure 1."
11483846|NCT01468194|Experimental|Breathing procedure 2|"Walking with breathing procedure 2."
11483847|NCT01468194|No Intervention|Control group|Walking without any reglementation of breathing
11483848|NCT01468181|Experimental|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
11483849|NCT01468181|Experimental|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
11483850|NCT01468181|Experimental|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
11483851|NCT01468181|Experimental|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
11483852|NCT01468181|Experimental|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks
~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
11483853|NCT01468168|Experimental|DE-101 Ophthalmic Suspension High Dose|
11483854|NCT01468168|Experimental|DE-101 Ophthalmic Suspension Low Dose|
11483855|NCT01468168|Placebo Comparator|DE-101 Ophthalmic Suspension Vehicle|
11483856|NCT01468155|Active Comparator|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
11483857|NCT01468129|Active Comparator|Cell Saver|
11483858|NCT01468129|No Intervention|Non Cell Saver|
11483859|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
11483860|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
11483861|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
11483862|NCT01468103|Experimental|PACS|primary angle closure suspects
11483863|NCT01468103|Experimental|PAC|primary angle closure
11483864|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
11483865|NCT01468077|Experimental|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
11483866|NCT01468077|Experimental|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
11483867|NCT01468064|Experimental|BMSCs group|
11483868|NCT01468064|Experimental|EPCs group|
11483869|NCT01468064|Placebo Comparator|Control group|
11483870|NCT01468051|Experimental|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
11483871|NCT01468051|Experimental|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
11483872|NCT01468038|Active Comparator|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
11483873|NCT01468038|Active Comparator|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
11483874|NCT01468038|Active Comparator|Sentra PM and trazodone|Active Sentra PM and active trazodone
11483875|NCT01468038|Placebo Comparator|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
11483876|NCT01468025|Active Comparator|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
11483877|NCT01468025|Active Comparator|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
11483878|NCT01468025|Active Comparator|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
11483879|NCT01468012|Experimental|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
11483880|NCT01468012|Placebo Comparator|Placebo|placebo
11483881|NCT01467999|Experimental|Guanfacine|Guanfacine, 4mg given once daily
11483882|NCT01467986|Active Comparator|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
11483883|NCT01467986|Experimental|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
11483884|NCT01467960||Group I|Healthy Subjects aged 20-40
11483885|NCT01467960||Group II|Healthy Subjects aged 40-65
11483886|NCT01467960||Group III|Healthy Subjects aged more than 65
11483887|NCT01467960||Group A|Patients at Stage I, H&Y classification
11483888|NCT01467960||Group B|Patients at Stage II, H&Y classification
11483889|NCT01467960||Group C|Patients at Stage more than III, H&Y classification
11483890|NCT01467947|Experimental|Berinert|
11483891|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
11483892|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
11483893|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
11483894|NCT01467921|Active Comparator|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
11483895|NCT01467921|Experimental|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
11483896|NCT01467908|Experimental|Vegetative state|Patients with the diagnosis of the vegetative state
11483897|NCT01467882|Experimental|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
11483898|NCT01467856||chronic tetraplegia|
11483899|NCT01467843|Active Comparator|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
11483900|NCT01467843|Active Comparator|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
11483901|NCT01467843|No Intervention|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
11483902|NCT01467830|Experimental|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
11483903|NCT01467830|Other|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
11483904|NCT01467817|Experimental|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
11483905|NCT01467817|Placebo Comparator|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
11483906|NCT01467804|Experimental|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
11483907|NCT01467804|Active Comparator|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
11483908|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
11483909|NCT01467778|Active Comparator|ELAPR001|Tropoelastin 0.1ml SC implant
11483910|NCT01467778|Active Comparator|ELAPR002|Tropoelastin 0.1ml SC implant
11483911|NCT01467778|Active Comparator|ELAPR003|Tropoelastin 0.1ml SC implant
11483912|NCT01467778|Placebo Comparator|Saline|Normal Saline 0.9%
11483913|NCT01467765|Active Comparator|Elemental diet|
11483914|NCT01467765|Placebo Comparator|Liquid nutrient|
11483915|NCT01467752|Experimental|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
11483916|NCT01467739|Active Comparator|Ambu ® aScope®|
11483917|NCT01467739|Active Comparator|a conventional reusable fiberscope.|
11483918|NCT01467726|Experimental|Dose regimen 1|Varied doses
11483919|NCT01467726|Experimental|Dose regimen 2|Varied doses
11483920|NCT01467726|Experimental|Placebo|Matching placebo
11483921|NCT01467713|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.
11483922|NCT01467713|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
11483923|NCT01467713|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
11483924|NCT01467713|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
11483925|NCT01467700|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) [dissolved under the tongue], once daily (QD), every night at bedtime for up to 8 weeks.
11483926|NCT01467700|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
11483927|NCT01467700|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
11483928|NCT01467700|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
11483929|NCT01467687|Active Comparator|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
11483930|NCT01467687|Active Comparator|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
11483931|NCT01467674||Healthy|
11483932|NCT01467674||Chronic Periodontitis|
11483933|NCT01467674||Better Controlled T2DM|
11483934|NCT01467674||Poor Controlled T2DM|
11483935|NCT01467661|Experimental|SPD422 (anagrelide hydrochloride)|
11483936|NCT01467648|Experimental|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
11483937|NCT01467648|Experimental|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
11483938|NCT01467635|Active Comparator|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
11483939|NCT01467635|Experimental|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
11483940|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
11483941|NCT01467596|Experimental|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
11483942|NCT01467596|Active Comparator|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
11483943|NCT01467583|Experimental|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
11483944|NCT01467583|Experimental|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
11483945|NCT01467583|Experimental|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
11483946|NCT01467570|Experimental|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
11483947|NCT01467570|Active Comparator|ESPGHAN ORS|ESPGHAN oral rehydration solution
11483948|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
11483949|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
11483950|NCT01467544|No Intervention|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
11483951|NCT01467544|Experimental|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
11483952|NCT01467531|Experimental|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
11483953|NCT01467531|Experimental|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
11483954|NCT01467518|Other|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
11483955|NCT01467518|Other|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
11483956|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
11483957|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
11483958|NCT01467492|Experimental|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing <75 kilograms [kg]) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
11483959|NCT01467492|Experimental|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing <75 kg) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
11483960|NCT01467479|Experimental|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
11484010|NCT01467115|Experimental|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
11484011|NCT01467102||Patients|> 18 years of age
11484053|NCT01466803|Active Comparator|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
11484107|NCT01466452|Active Comparator|Aspirin 100|
11483961|NCT01467479|Experimental|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
11483962|NCT01467479|Experimental|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
11483963|NCT01467466|Active Comparator|Saline & oral placebo|IV isotonic saline and oral placebo drug capsule
11483964|NCT01467466|Active Comparator|Saline & oral N-acetylcysteine|IV isotonic saline and oral N-acetylcysteine drug capsule
11483965|NCT01467466|Active Comparator|Bicarbonate & oral placebo|IV isotonic bicarbonate and oral placebo drug capsule
11483966|NCT01467466|Active Comparator|Bicarbonate & oral N-acetylcysteine|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
11483967|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
11483968|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
11483969|NCT01467427|Experimental|NNC-0156-000-0009|
11483970|NCT01467414|Experimental|NN1250|
11483971|NCT01467401|Experimental|A|
11483972|NCT01467401|Active Comparator|B|
11483973|NCT01467388||phacic|Study patients who still have their own ocular lens
11483974|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
11483975|NCT01467375|Experimental|A|
11483976|NCT01467362|Experimental|V0034CR01B|
11483977|NCT01467362|Placebo Comparator|Vehicle cream|
11483978|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.
~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
11483979|NCT01467336|Other|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
11483980|NCT01467336|Other|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
11483981|NCT01467336|Other|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
11483982|NCT01467323|Experimental|A|
11483983|NCT01467323|Active Comparator|B|
11483984|NCT01467310|Experimental|GSK1120212|
11483985|NCT01467297|Experimental|ceftidoren|ceftidoren 200 mg bid for 5 days
11483986|NCT01467297|Active Comparator|levofloxacin|levofloxacin 500 mg once daily for 7 days
11483987|NCT01467284|Experimental|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
11483988|NCT01467284|Active Comparator|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
11483989|NCT01467258|Experimental|Amantadine|Single dose
11483990|NCT01467245|Experimental|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
11483991|NCT01467245|Experimental|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
11483992|NCT01467232|Experimental|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
11483993|NCT01467232|Placebo Comparator|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
11483994|NCT01467219|Experimental|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
11483995|NCT01467206|Experimental|Long term follow up program|
11483996|NCT01467206|Active Comparator|Standard care|
11483997|NCT01467193||1|Endurance trained athletes: minimal >50 mlO2/KG body weight
11483998|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
11483999|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
11484000|NCT01467180|Experimental|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
11484001|NCT01467180|Active Comparator|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
11484002|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
11484003|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
11484004|NCT01467154||Control group|
11484005|NCT01467154||NAC group|
11484006|NCT01467141|Experimental|IAsp|
11484007|NCT01467141|Active Comparator|HI|
11484008|NCT01467128|Active Comparator|Structured expert pharmacist review|
11484009|NCT01467128|No Intervention|Normal pharmaceutical care in hospital|
11484108|NCT01466452|Active Comparator|Aspirin 200|
11484012|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.
~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
11484013|NCT01467076|Active Comparator|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
11484014|NCT01467076|Placebo Comparator|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
11484015|NCT01467076|Active Comparator|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
11484016|NCT01467063|Active Comparator|Glutamine|
11484017|NCT01467063|Placebo Comparator|Placebo|
11484018|NCT01467050|Active Comparator|Application of STOPP/START criteria|
11484019|NCT01467050|No Intervention|Control|
11484020|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
11484021|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
11484022|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
11484023|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
11484024|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
11484025|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
11484026|NCT01466998|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
11484027|NCT01466998|Active Comparator|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
11484028|NCT01466985|Experimental|Panel A: Doravirine 25 mg or Placebo|Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
11484029|NCT01466985|Experimental|Panel B: Doravirine 200 mg or Placebo|Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
11484030|NCT01466985|Experimental|Panel C: Doravirine or Placebo|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
11484031|NCT01466972|Experimental|Pazopanib in combination with a NSAI|Non-randomized, open label
11484032|NCT01466959|Active Comparator|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
11484033|NCT01466959|Experimental|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
11484034|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
11484035|NCT01466933|Experimental|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
11484036|NCT01466933|Active Comparator|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
11484037|NCT01466933|No Intervention|Control|Mothers receive the standard care which is a visit from the health worker
11484038|NCT01466907|Active Comparator|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
11484039|NCT01466907|Other|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
11484040|NCT01466894|Experimental|IMM 124-E high dose|IMM 124-E 3600 mg per day
11484041|NCT01466894|Experimental|IMM 124-E low dose|IMM 124-E 1800 mg per day
11484042|NCT01466894|Placebo Comparator|Placebo|Placebo tablets
11484043|NCT01466881|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
11484044|NCT01466868|Experimental|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
11484045|NCT01466855|Experimental|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
11484046|NCT01466842|Other|Catheter ablation|
11484047|NCT01466842|No Intervention|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
11484048|NCT01466829|Placebo Comparator|Control|Control patients treated with placebo.
11484049|NCT01466829|Active Comparator|Intervention|Daily injection with Parathyroid hormone
11484050|NCT01466816|Experimental|Saturated fatty acid test meal|
11484051|NCT01466816|Experimental|Monounsaturated fatty acid meal|
11484052|NCT01466816|Experimental|Polyunsaturated fatty acid meal|
11484055|NCT01466790|Experimental|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
11484056|NCT01466790|Experimental|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
11484057|NCT01466790|Experimental|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
11484058|NCT01466790|Experimental|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
11484059|NCT01466777|Active Comparator|traditional laparoscopic surgery type|
11484060|NCT01466777|Experimental|Robotic assisted operation type|
11484061|NCT01466764|Active Comparator|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
11484062|NCT01466764|Placebo Comparator|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
11484063|NCT01466751|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
11484064|NCT01466751|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
11484065|NCT01466738|Experimental|HRV-16 (100 TCID50)|
11484066|NCT01466738|Experimental|HRV-16 (1000 TCID50)|
11484067|NCT01466725|Experimental|Cohort 1|25 mg daily for 4 weeks (8 active/2 control)
11484068|NCT01466725|Experimental|Cohort 2|50 mg once daily for 4 weeks (8 active/2 control)
11484069|NCT01466725|Experimental|Cohort 3|100 mg daily for 6 weeks (8 active/2 control)
11484070|NCT01466725|Experimental|Cohort 4|100 mg twice daily for 6 weeks (8 active/2 control)
11484071|NCT01466712|Experimental|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
11484072|NCT01466712|Sham Comparator|tiotropium+placebo|cross-over cfr arm1
11484073|NCT01466686|Experimental|Temozolomide with Low Dose Fractionated Radiation Therapy|"All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
~All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide."
11484074|NCT01466673|Experimental|Ethinyl estradiol/Norgestimate (EE/NGM)|
11484075|NCT01466673|Active Comparator|Ethinyl estradiol/Desogestrel (EE/DSG)|
11484076|NCT01466660|Experimental|afatinib|afatinib once daily.
11484077|NCT01466660|Active Comparator|gefitinib|gefitinib once daily
11484078|NCT01466647|Other|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
11484079|NCT01466634||permanent polymer DES|
11484080|NCT01466634||bioabsorbable polymer DES|
11484081|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
11484082|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
11484083|NCT01466608|Experimental|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
11484084|NCT01466595|Experimental|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
11484085|NCT01466595|No Intervention|Arm B: No study treatment|No study treatment for 4 weeks
11484086|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
11484087|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
11484088|NCT01466569|Experimental|AbGn-7 phase 1a cohort 1|
11484089|NCT01466569|Experimental|AbGn-7 phase 1a cohort 2|
11484090|NCT01466569|Experimental|AbGn-7 phase 1a cohort 3|
11484091|NCT01466569|Experimental|AbGn-7 phase 1b cohort 1|
11484092|NCT01466569|Experimental|AbGn-7 phase 1b cohort 2|
11484093|NCT01466556||Obese children|
11484094|NCT01466543|Active Comparator|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
11484095|NCT01466543|Placebo Comparator|Placebo|placebo medication
11484096|NCT01466530|Placebo Comparator|Placebo|sublingual two moistened white coated placebo tablets
11484097|NCT01466530|Active Comparator|Misoprostol|sublingual misoprostol (400 µg)
11484098|NCT01466517|Active Comparator|Reference Drug|
11484099|NCT01466517|Active Comparator|Test Drug|
11484100|NCT01466491|Placebo Comparator|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
11484101|NCT01466491|Active Comparator|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
11484102|NCT01466491|Placebo Comparator|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
11484103|NCT01466491|Active Comparator|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
11484104|NCT01466478|Experimental|LEO 29102 plus calcipotriol|
11484105|NCT01466465|Experimental|Vigantol|
11484106|NCT01466465|Placebo Comparator|neutral oil (vigantol carrier)|
11484109|NCT01466452|Active Comparator|Aspirin 100 x 2|
11484110|NCT01466439|Other|high frequency rTMS|
11484111|NCT01466439|Other|low frequency rTMS|
11484112|NCT01466426||DVT confirmed|
11484113|NCT01466426||DVT ruled out|
11484114|NCT01466426||PE confirmed|
11484115|NCT01466426||PE ruled out|
11484116|NCT01466413|Experimental|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.
~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.
~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
11484117|NCT01466400||infants two to six months of age|
11484118|NCT01466387|Active Comparator|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
11484119|NCT01466387|Active Comparator|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
11484120|NCT01466387|Active Comparator|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
11484121|NCT01466387|Active Comparator|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
11484122|NCT01466387|Active Comparator|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
11484123|NCT01466387|Active Comparator|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
11484124|NCT01466374|Experimental|Cohort 1: Induction|Placebo
11484125|NCT01466374|Experimental|Cohort 2: Induction|Anti-IP-10 Antibody
11484126|NCT01466374|Experimental|Cohort 3: Induction|Anti-IP-10 Antibody
11484127|NCT01466374|Experimental|Cohort 1: Maintenance|Placebo
11484128|NCT01466374|Experimental|Cohort 2: Maintenance|Anti-IP-10 Antibody
11484129|NCT01466374|Experimental|Cohort 3: Maintenance|Anti-IP-10 Antibody
11484130|NCT01466374|Experimental|Cohort 1: Open Label|Anti-IP-10 Antibody
11484131|NCT01466361|Active Comparator|Lower dose Nicotine|lower dose nicotine lozenge
11484132|NCT01466361|Active Comparator|Higher dose Nicotine|higher dose Nicotine lozenge
11484133|NCT01466361|Placebo Comparator|Placebo|Placebo
11484134|NCT01466348|Experimental|Paracetamol and Caffeine|Paracetamol and caffeine
11484135|NCT01466348|Active Comparator|Paracetamol|Paracetamol
11484136|NCT01466335|Experimental|Ronacaleret 100mg once daily|1 x 100mg oral tablet
11484137|NCT01466335|Experimental|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
11484138|NCT01466335|Experimental|Ronacaleret 200mg once daily|2 x 100mg oral tablet
11484139|NCT01466335|Experimental|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
11484140|NCT01466335|Experimental|Ronacaleret 400mg once daily|4 x 100mg tablets
11484141|NCT01466335|Placebo Comparator|Placebo|Matching number of identical placebo tablets
11484142|NCT01466322|Experimental|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
11484143|NCT01466309|Experimental|treatment|patients treated with Somnoguard
11484144|NCT01466296|Experimental|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.
~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
11484145|NCT01466296|Experimental|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
11484146|NCT01466296|Active Comparator|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
11484147|NCT01466270|Experimental|Arm I|Patients receive donepezil hydrochloride PO QD.
11484148|NCT01466270|Placebo Comparator|Arm II|Patients receive placebo PO QD.
11484149|NCT01466231|Experimental|everolimus 10 mg po daily|everolimus 10 mg po daily
11484150|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
11484151|NCT01466205|Experimental|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
11484152|NCT01466205|Placebo Comparator|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
11484153|NCT01466192|Experimental|MP-424|
11484154|NCT01466179|Experimental|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
11484155|NCT01466166||Pegloticase|Participants received pegloticase 8 mg by intravenous (IV) infusion every 2 weeks for up to 1 year, as prescribed by their treating physician.
11484156|NCT01466153|Active Comparator|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m^2 on Day 2 of Cycle 1 and then 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
11484310|NCT01465061||Online support user|
11484311|NCT01465048|Experimental|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
11484312|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
11484157|NCT01466153|Experimental|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
11484158|NCT01466153|Experimental|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
11484159|NCT01466140|No Intervention|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
11484160|NCT01466140|Experimental|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
11484161|NCT01466127|Placebo Comparator|Placebo|Matched nasal spray placebo.
11484162|NCT01466127|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
11484163|NCT01466114|Experimental|Group A: Estriol|Standard MS Treatment + Estriol
11484164|NCT01466114|Placebo Comparator|Group B: Placebo|Standard MS Treatment + Placebo
11484165|NCT01466101|Active Comparator|Pregabalin administration|Administration of pregabalin
11484166|NCT01466101|Placebo Comparator|Placebo|Administration of placebo
11484167|NCT01466088|Experimental|AZD3480|
11484168|NCT01466088|Active Comparator|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
11484169|NCT01466075|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
11484170|NCT01466062|Experimental|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
11484171|NCT01466036|Experimental|Metastatic or Unresectable PNET|35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
11484172|NCT01466036|Experimental|Metastatic or Unresectable Carcinoid|35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
11484173|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
11484174|NCT01465997|Experimental|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
11484175|NCT01465997|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
11484176|NCT01465984|Experimental|IV Paracetamol|
11484177|NCT01465984|Active Comparator|IV Morphine Sulfate|
11484178|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
11484179|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
11484180|NCT01465958|Active Comparator|Intravenous GAMUNEX-C|
11484181|NCT01465958|Experimental|Subcutaneous GAMUNEX-C|
11484182|NCT01465945|Other|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
11484183|NCT01465945|Other|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
11484184|NCT01465932|Active Comparator|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
11484185|NCT01465932|Experimental|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
11484186|NCT01465919|Experimental|mirtazapine|mirtazapine
11484187|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
11484188|NCT01465906|Experimental|tulobuterol combined with tiotropium bromide|
11484189|NCT01465906|Active Comparator|Tiotropium bromide|
11484190|NCT01465893|Active Comparator|vitamin D|vitamin d 50000/w
11484191|NCT01465893|Sham Comparator|control|follow up
11484192|NCT01465880|No Intervention|Part B. Healthy Caucasian adult non-smokers|Non-smokers
11484193|NCT01465880|Experimental|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
11484194|NCT01465867|Experimental|Selenium|
11484195|NCT01465867|Placebo Comparator|Sugar Pill Placebo|
11484196|NCT01465867|Experimental|Selenium + L-Thyroxine (LT4)|
11484197|NCT01465867|Experimental|Sugar Pill Placebo + L-Thyroxine (LT4)|
11484198|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
11484199|NCT01465841|Experimental|Embolization with the PC 400 coils|
11484200|NCT01465828|Active Comparator|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
11484201|NCT01465828|No Intervention|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
11484313|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
11484314|NCT01465035|Experimental|TIV and MVA-NP+M1|"Co-administration group
~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
11484608|NCT01463150|Experimental|Prasugrel|Prasugrel 5mg for 15 days
11484202|NCT01465815|Experimental|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.
~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.
~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).
~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.
~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
11484203|NCT01465815|Experimental|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.
~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).
~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.
~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
11484204|NCT01465815|Experimental|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.
~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).
~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.
~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
11484205|NCT01465802|Experimental|Cohort I|Arm A: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline placebo orally BID for 4 weeks Arm B: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline 100 mg orally BID for 4 weeks
11484206|NCT01465802|Experimental|Cohort II|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
11484207|NCT01465802|Experimental|Cohort III|Cohort III is an interrupted dosing schedule of dacomitinib in the first cycle only
11484208|NCT01465776|Experimental|Treatment (chemoprevention)|
11484209|NCT01465763|Experimental|tofacitinib 10 mg BID|
11484210|NCT01465763|Placebo Comparator|Placebo|
11484211|NCT01465750||Ovarian Cancer|
11484212|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
11484213|NCT01465724|Experimental|Renal denervation|
11484214|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
11484215|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
11484216|NCT01465698|Experimental|Exercise|
11484217|NCT01465698|Experimental|Counseling|
11484218|NCT01465698|Experimental|Exercise and counseling|
11484219|NCT01465698|Other|Control group|Participants in the control group only participate in study measurements.
11484220|NCT01465685|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11484221|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
11484222|NCT01465659|Experimental|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
11484223|NCT01465659|Experimental|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
11484224|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
11484225|NCT01465646|Active Comparator|with idodine|
11484226|NCT01465646|Experimental|without iodine|
11484227|NCT01465633|Active Comparator|with iodine|
11484228|NCT01465633|Experimental|without iodine|
11484229|NCT01465620|Experimental|Coaching|active hygienic-dietetic coaching
11484230|NCT01465620|Active Comparator|control|reference hygienic-dietetic recommendations
11484231|NCT01465607|Experimental|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
11484232|NCT01465607|Active Comparator|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
11484233|NCT01465594|Active Comparator|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
11484234|NCT01465594|Active Comparator|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
11484235|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
11484236|NCT01465568|Active Comparator|Denosumab|denosumab
11484237|NCT01465568|Active Comparator|bisphosphonates|continuation of bisphosphonates
11484909|NCT01461278|Active Comparator|Cataract surgery|
11484238|NCT01465555|Experimental|Clinical Alert|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
11484239|NCT01465555|No Intervention|Treatment As Usual|Counselors in this condition will work with the original RecoveryTrack which has not been altered to provide automated Clinical Alerts for High Risk patients. Supervisors will receive no automated help in identifying these clients in the counselors' caseloads. The Clinical Alert feature will not be discussed in the training these counselors receive. Rather, the counselors will receive an attention-control training, a one-day training on assessment and treatment planning, with monthly tips and reminders for six months.
11484240|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
11484241|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
11484242|NCT01465529|Experimental|Active|
11484243|NCT01465529|Placebo Comparator|Placebo|
11484244|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
11484245|NCT01465503|Placebo Comparator|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
11484246|NCT01465503|Active Comparator|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
11484247|NCT01465490|Experimental|Monitoring and Feedback Intervention|
11484248|NCT01465490|No Intervention|Treatment as usual|
11484249|NCT01465477|Experimental|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
11484250|NCT01465477|Experimental|Heathy controls|Healthy controls receiving Influenza vaccination
11484251|NCT01465464|Experimental|Orantinib|
11484252|NCT01465464|Placebo Comparator|Placebo|
11484253|NCT01465451|Active Comparator|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
11484254|NCT01465451|Experimental|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
11484255|NCT01465438|Experimental|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
11484256|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
11484257|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
11484258|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
11484259|NCT01465412|Experimental|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
11484260|NCT01465412|Active Comparator|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
11484261|NCT01465412|Experimental|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
11484262|NCT01465412|Active Comparator|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
11484263|NCT01465399|Experimental|PRGF-Endoret|
11484264|NCT01465399|Active Comparator|Conventional treatment|
11484265|NCT01465386|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11484266|NCT01465373|Active Comparator|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.
~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
11484267|NCT01465373|Active Comparator|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.
~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
11484268|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
11484605|NCT01463163|Active Comparator|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
11484269|NCT01465347|Experimental|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
11484270|NCT01465334|Experimental|Treatment Naive|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):
~Induction Part A: Ofatumumab + HDMP 2-4 cycles
~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22
~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3
~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.
~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles
~Ofatumumab: 1000 mg IV Day 1
~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26
~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.
~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles
~Ofatumumab: 1000 mg IV Day 1 every other cycle
~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
11484271|NCT01465334|Experimental|Relapsed/Refractory|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):
~Induction Part A: Ofatumumab + HDMP 2-4 cycles
~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22
~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3
~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.
~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles
~Ofatumumab: 1000 mg IV Day 1
~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26
~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.
~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles
~Ofatumumab: 1000 mg IV Day 1 every other cycle
~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
11484272|NCT01465308|Experimental|receiving Honey|The patients will receive honey mouthwash rinses
11484273|NCT01465308|Active Comparator|Saline mouthwash|The patients in this group will receive saline rinses
11484274|NCT01465295|Experimental|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
11484275|NCT01465282|Experimental|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
11484276|NCT01465282|Experimental|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
11484277|NCT01465282|Experimental|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
11484278|NCT01465282|Placebo Comparator|Placebo ointment|Placebo ointment
11484279|NCT01465269|Experimental|GIST Intervention|
11484280|NCT01465269|Active Comparator|Alternative Intervention|
11484281|NCT01465256|No Intervention|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
11484282|NCT01465256|Experimental|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
11484283|NCT01465243|Experimental|Icotinib|This is a single arm study.
11484284|NCT01465230|Experimental|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
11484285|NCT01465217|Experimental|text message medication reminders|
11484286|NCT01465217|No Intervention|control|
11484287|NCT01465204|No Intervention|Control|
11484288|NCT01465204|Experimental|Handwashing Intervention|scaling up handwashing with soap
11484289|NCT01465204|Experimental|Sanitation Intervention|total sanitation and sanitation marketing
11484290|NCT01465204|Experimental|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
11484291|NCT01465191|Experimental|50 micrograms spinal morphine|100 subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
11484292|NCT01465191|Experimental|100 mcg|100 subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
11484293|NCT01465191|Experimental|150 mcg|100 subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
11484294|NCT01465178|Active Comparator|2000 IU vitamin D3|Cholecalciferol 2,000 IU capsules
11484295|NCT01465178|Placebo Comparator|Placebo|Non-matching placebo, gelatin filled capsules
11484296|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
11484297|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
11484298|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
11484299|NCT01465152|Experimental|Met|
11484300|NCT01465152|Active Comparator|Rep|
11484301|NCT01465152|Active Comparator|Met+Rep|
11484302|NCT01465139|Experimental|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
11484303|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
11484304|NCT01465113|Experimental|high grade dysplasia|Barrett's esophagus with high grade dysplasia
11484305|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
11484306|NCT01465100|Experimental|Hepatocyte Transplantation|See Below.
11484307|NCT01465087|Experimental|Diagnosis|Diagnosis, breath and confounding factor
11484308|NCT01465074|Active Comparator|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
11484309|NCT01465074|Placebo Comparator|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
11484315|NCT01465035|Placebo Comparator|Saline placebo and seasonal influenza vaccine TIV|"Control group
~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
11484316|NCT01465022|Active Comparator|Study Arm A|Study Arm A is one of two interventions (Combined estrogen-progestin pill)
11484317|NCT01465022|Active Comparator|Study Arm B|Study Arm B is one of two interventions (Progestin-only pill)
11484318|NCT01465009|Experimental|Arm 1|
11484319|NCT01465009|Active Comparator|Arm 2|
11484320|NCT01465009|Placebo Comparator|Arm 3|
11484321|NCT01464996|Experimental|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
11484322|NCT01464996|Active Comparator|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
11484323|NCT01464983|Active Comparator|Arm 1|
11484324|NCT01464983|Experimental|Arm 2|
11484325|NCT01464983|Active Comparator|Arm 3|
11484326|NCT01464983|Active Comparator|Arm 4|
11484327|NCT01464983|Placebo Comparator|Arm 5|
11484328|NCT01464970|Active Comparator|SIE Vessels Both Clamped|
11484329|NCT01464970|Active Comparator|SIE Vessels both Unclamped|
11484330|NCT01464970|Active Comparator|SIE Artery Unclamped; Vein Clamped|
11484331|NCT01464970|Active Comparator|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
11484332|NCT01464957|Experimental|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
11484333|NCT01464957|No Intervention|Usual care|No newsletter intervention
11484334|NCT01464944|Experimental|Arm 2|
11484335|NCT01464944|Active Comparator|Arm 3|
11484336|NCT01464944|Active Comparator|Arm 4|
11484337|NCT01464944|Placebo Comparator|Arm 5|
11484338|NCT01464944|Experimental|Arm 1|
11484339|NCT01464931|Experimental|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
11484340|NCT01464918|Experimental|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
11484341|NCT01464905|Experimental|NU100|
11484342|NCT01464905|Placebo Comparator|Placebo|
11484343|NCT01464905|Active Comparator|recombinant human interferon beta- 1b|
11484344|NCT01464892|Experimental|Imagery Rescripting|
11484345|NCT01464892|Active Comparator|STAIR plus Imagery Rescripting|
11484346|NCT01464892|No Intervention|Wait-list control|Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.
11484347|NCT01464879|Experimental|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
11484348|NCT01464879|Experimental|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
11484349|NCT01464879|Experimental|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
11484350|NCT01464879|Experimental|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
11484351|NCT01464866|Active Comparator|Hospital Feed|Standard hospital food
11484352|NCT01464866|Experimental|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
11484353|NCT01464853|Experimental|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
11484354|NCT01464853|Active Comparator|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
11484355|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
11484356|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
11484357|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
11484358|NCT01464827|Experimental|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
11484359|NCT01464827|Experimental|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
11484360|NCT01464827|Experimental|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
11484361|NCT01464827|Experimental|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
11484362|NCT01464827|Experimental|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
11484363|NCT01464827|Experimental|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
11484364|NCT01464827|Experimental|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
11484365|NCT01464827|Experimental|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
11484366|NCT01464827|Experimental|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
11484401|NCT01464554|Experimental|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
11484367|NCT01464827|Experimental|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
11484368|NCT01464827|Experimental|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
11484369|NCT01464827|Experimental|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
11484370|NCT01464827|Experimental|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
11484371|NCT01464827|Experimental|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
11484372|NCT01464814|Experimental|Probiotic|Lactobacillus casei in fish oil capsule
11484373|NCT01464814|Placebo Comparator|Placebo|Fish oil capsule
11484374|NCT01464801|Experimental|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
11484375|NCT01464801|Placebo Comparator|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
11484376|NCT01464788|Experimental|Low dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours
~and
~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
11484377|NCT01464788|Experimental|High dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours
~and
~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
11484378|NCT01464788|Active Comparator|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
11484379|NCT01464775|Experimental|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopy
11484380|NCT01464775|Active Comparator|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopy
11484381|NCT01464749|Experimental|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).
~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.
~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
11484382|NCT01464749|Active Comparator|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
11484383|NCT01464736|Experimental|Physical Training Group|This group performed aerobic physical training in treadmill.
11484384|NCT01464736|Experimental|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.
~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
11484385|NCT01464723|Experimental|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
11484386|NCT01464697|Experimental|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
11484387|NCT01464697|Placebo Comparator|Placebo Comparator|Placebo
11484388|NCT01464671|Active Comparator|Bivalirudin|Anticoagulation during percutaneous coronary intervention
11484389|NCT01464671|Active Comparator|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
11484390|NCT01464658|Other|panniculectomy|surgical intervention
11484391|NCT01464645||Primary|Post Market Study
11484392|NCT01464632||Primary|Post Market Study
11484393|NCT01464619|Experimental|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
11484394|NCT01464619|Experimental|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
11484395|NCT01464606|Experimental|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
11484396|NCT01464606|Experimental|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
11484397|NCT01464593|Experimental|Thermodox|Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.
11484398|NCT01464567|Active Comparator|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
11484399|NCT01464567|Experimental|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
11484400|NCT01464554|Active Comparator|Usual Care|Teens will receive six sessions of an alcohol and drug education group
11484402|NCT01464541|Experimental|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
11484403|NCT01464528|Active Comparator|Hyaluronan|Use of hyaluronic acid gel
11484404|NCT01464528|No Intervention|control|
11484405|NCT01464515|Active Comparator|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
11484406|NCT01464515|Sham Comparator|SHAM TMS|this group will receive SHAM treatment of deep TMS
11484407|NCT01464502|Active Comparator|Standard CRT Implant|
11484408|NCT01464502|Active Comparator|Pressure-wire guided CRT Implant|
11484409|NCT01464489|Experimental|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
11484410|NCT01464489|Active Comparator|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
11484411|NCT01464476|Experimental|Azimilide|Azimilide 75 mg film coated tablets
11484412|NCT01464476|Placebo Comparator|Placebo|
11484413|NCT01464463|Experimental|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
11484414|NCT01464463|Active Comparator|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
11484415|NCT01464463|Active Comparator|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
11484416|NCT01464463|No Intervention|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
11484417|NCT01464450|Active Comparator|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
11484418|NCT01464450|Active Comparator|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
11484419|NCT01464450|Active Comparator|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
11484420|NCT01464450|Active Comparator|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
11484421|NCT01464450|Active Comparator|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
11484510|NCT01463800|Active Comparator|Structured Exercise training|12 weeks ambulatory low level exercise training
11484511|NCT01463800|No Intervention|Control group|No structured exercise training
11484512|NCT01463787|Experimental|inguinal group|
11484513|NCT01463787|Active Comparator|sub-inguinal group|
11484422|NCT01464450|Active Comparator|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
11484423|NCT01464437|Active Comparator|AMG 151 - Arm 1|AMG 151 - Arm 1
11484424|NCT01464437|Active Comparator|AMG 151 - Arm 2|AMG 151 - Arm 2
11484425|NCT01464437|Active Comparator|AMG 151 - Arm 3|AMG 151 - Arm 3
11484426|NCT01464437|Active Comparator|AMG 151 - Arm 4|AMG 151 - Arm 4
11484427|NCT01464437|Active Comparator|AMG 151 - Arm 5|AMG 151 - Arm 5
11484428|NCT01464437|Active Comparator|AMG 151 - Arm 6|AMG 151 - Arm 6
11484429|NCT01464437|Placebo Comparator|Placebo Arm|AMG 151 Placebo Arm
11484430|NCT01464424|Other|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
11484431|NCT01464424|Other|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
11484432|NCT01464398|Active Comparator|Stress reduction|Mindfulness-based stress reduction
11484433|NCT01464398|Active Comparator|Stress reduction with Health education|General stress management and health education
11484434|NCT01464385|Experimental|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
11484435|NCT01464385|Experimental|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
11484436|NCT01464385|Placebo Comparator|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
11484437|NCT01464372|Experimental|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
11484438|NCT01464372|Sham Comparator|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
11484439|NCT01464359|Experimental|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
11484440|NCT01464346|Experimental|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
11484441|NCT01464346|Experimental|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
11484442|NCT01464346|Experimental|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
11484443|NCT01464333||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
11484444|NCT01464320|Experimental|ABT-614|
11484445|NCT01464320|Placebo Comparator|Placebo Comparator|
11484446|NCT01464307|Experimental|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
11484447|NCT01464307|Placebo Comparator|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
11484448|NCT01464294||nano-composite|crowns and onlays
11484449|NCT01464294||ceramic|crowns & onlays
11484450|NCT01464281|Experimental|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
11484451|NCT01464281|Active Comparator|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
11484452|NCT01464268|Active Comparator|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
11484453|NCT01464268|Active Comparator|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
11484454|NCT01464255|Experimental|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
11484455|NCT01464255|Active Comparator|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
11484456|NCT01464242|Experimental|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
11484457|NCT01464242|Placebo Comparator|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
11484458|NCT01464229|Experimental|Iloperidone addition to SSRI antidepressant|
11484459|NCT01464229|Placebo Comparator|Placebo addition to standard SSRI antidepressant|
11484460|NCT01464203|Experimental|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
11484461|NCT01464203|Active Comparator|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
11484462|NCT01464190|Experimental|PA21|
11484463|NCT01464190|Active Comparator|Sevelamer carbonate|
11484514|NCT01463774|Experimental|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
11484606|NCT01463163|Experimental|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
11484464|NCT01464177|Active Comparator|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:
~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
~Planning tumor volume (PTV) equals GTV plus 3mm margin.
~the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
~RT to begin in a maximum of 2 weeks after randomization."
11484465|NCT01464177|Experimental|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:
~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
~Planning tumor volume (PTV) equals GTV plus 3mm margin.
~the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
~RT to begin in a maximum of 2 weeks after randomization."
11484466|NCT01464164|Experimental|Sotatercept|Sotatercept to be given as a subcutaneous injection once a month for 4 consecutive months, using a dose escalation scale among 3 cohorts. *Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks.
11484467|NCT01464164|Experimental|Sotatercept with prednisone boost|Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks along with a prednisone boost of 1 mg/kg daily for 3 weeks (max of 60 mg).
11484468|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
11484469|NCT01464138|Experimental|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
11484470|NCT01464125|Experimental|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
11484471|NCT01464112|Experimental|001|
11484472|NCT01464099|Active Comparator|Insulin aspart 100U/mL|
11484473|NCT01464099|Experimental|Insulin aspart 200U/mL|
11484474|NCT01464086|No Intervention|Standard arm|standard follow-up
11484475|NCT01464086|Experimental|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
11484476|NCT01464073|Active Comparator|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
11484477|NCT01464073|Active Comparator|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
11484478|NCT01464073|Experimental|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
11484479|NCT01464060|Active Comparator|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
11484480|NCT01464060|Experimental|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
11484481|NCT01464047||Patients with CML or Ph+ ALL|
11484482|NCT01464034|Experimental|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
11484483|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
11484484|NCT01464008||chronic hepatitis C|
11484485|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
11484486|NCT01463982|Experimental|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine
~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5
~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5
~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
11484487|NCT01463969||PCOS patients|
11484488|NCT01463969||Control group|
11484489|NCT01463956|Experimental|Boceprevir, Pegylated interferon and Ribavirin|"Lead-in phase (4 week): Pegylated interferon + Ribavirin
~Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin
~Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
11484490|NCT01463943|Experimental|Saccharomyces boulardii capsules (200 mg).|
11484491|NCT01463943|Active Comparator|Floratil®|
11484492|NCT01463943|Experimental|Saccharomyces boulardii powder (200 mg).|
11484493|NCT01463930|Experimental|Audiovisual videodisc and medical verbal information|
11484494|NCT01463930|Active Comparator|Medical verbal information|
11484495|NCT01463917|Active Comparator|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
11484496|NCT01463917|Placebo Comparator|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
11484497|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
11484498|NCT01463891||Eribulin Mesylate|
11484499|NCT01463878|Experimental|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
11484500|NCT01463878|Active Comparator|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
11484501|NCT01463865|Placebo Comparator|Placebo|Sodium chloride
11484502|NCT01463865|Active Comparator|ropivacaine|Naropin
11484503|NCT01463852|Experimental|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
11484504|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
11484505|NCT01463826||Children with bruxism|14 children with bruxism
11484506|NCT01463826||children without bruxism|19 children without bruxism
11484507|NCT01463813|Placebo Comparator|Placebo|Placebo, no Vitamin D3
11484508|NCT01463813|Experimental|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
11484509|NCT01463813|Experimental|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
11484515|NCT01463774|Experimental|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
11484516|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
11484517|NCT01463748|Experimental|Placebo|starch
11484518|NCT01463748|Experimental|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
11484519|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|
11484520|NCT01463709|Experimental|nanopulse|Administer nano pulse to lesion for varying time intervals.
11484521|NCT01463696|Experimental|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
11484522|NCT01463696|Experimental|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
11484523|NCT01463696|Experimental|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
11484524|NCT01463696|Experimental|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
11484525|NCT01463696|Experimental|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
11484526|NCT01463696|Experimental|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
11484527|NCT01463696|Experimental|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
11484528|NCT01463696|Experimental|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
11484529|NCT01463683|Experimental|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
11484530|NCT01463683|Active Comparator|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
11484531|NCT01463683|Experimental|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
11484532|NCT01463670|Experimental|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
11484533|NCT01463657|Experimental|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
11484534|NCT01463657|Active Comparator|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
11484535|NCT01463644|Active Comparator|mepolizumab|
11484536|NCT01463644|Placebo Comparator|placebo|
11484537|NCT01463631|Experimental|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
11484538|NCT01463605|Other|radiotherapy|It is just a single group assignment
11484539|NCT01463592|Experimental|Group II a|TRIPPLE THERAPY
11484540|NCT01463592|Active Comparator|Group II b|DUAL THERAPY
11484541|NCT01463592|Experimental|Group I|ORAL RENESSANS
11484542|NCT01463579|Experimental|Exercise programme|
11484543|NCT01463579|Other|Standard Care|
11484544|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
11484545|NCT01463553|No Intervention|wedge resection|
11484546|NCT01463553|Experimental|Wedge resection and pleurodosis|
11484547|NCT01463540|Active Comparator|Push/pull endoscopic gastrostomy|
11484548|NCT01463540|Experimental|Gastrostomy after gastropexy|
11484549|NCT01463527|Experimental|Open Capnography|
11484550|NCT01463527|Placebo Comparator|Capnography Blind|
11484551|NCT01463514|Experimental|AIR|"Randomization sequences according to modified catheter protocol.
~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
11484604|NCT01463176|Experimental|Music Therapy|Children in this group will receive live music therapy during their immunization.
11484552|NCT01463514|Experimental|NO|"Randomization sequences according to modified catheter protocol.
~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
11484553|NCT01463514|Experimental|Oxygen|"Randomization sequences according to modified catheter protocol.
~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
11484554|NCT01463514|Experimental|Target Oxygen|"Randomization sequences according to modified catheter protocol.
~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
11484555|NCT01463501|Experimental|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
11484556|NCT01463501|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
11484557|NCT01463488|Experimental|SAR113945 - Dose 1|
11484558|NCT01463488|Experimental|SAR113945 - Dose 2|
11484559|NCT01463488|Experimental|SAR113945 - Dose 3|
11484560|NCT01463488|Placebo Comparator|Placebo|
11484561|NCT01463475|Other|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
11484562|NCT01463462||Electronic Catheter Stethoscope|
11484563|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
11484564|NCT01463436|Experimental|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
11484565|NCT01463436|Placebo Comparator|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
11484566|NCT01463423|Experimental|Limited primary NSCLCs|Participants with limited primary NSCLCs (T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0) non-small cell lung cancer;
11484567|NCT01463423|Experimental|History of NSCLC|Participants with a history of NSCLC who have new limited primary NSCLC lesion(s)
11484568|NCT01463423|Experimental|Advanced lung cancer|Participants with more advanced lung cancer or lung metastases from a variety of different cancers.
11484569|NCT01463397|Experimental|SAR292833 dose level 1|Dose level 1 twice daily immediately after breakfast/dinner
11484570|NCT01463397|Experimental|SAR292833 dose level 2|Dose level 2 twice daily immediately after breakfast/dinner
11484571|NCT01463397|Placebo Comparator|Placebo|Placebo (for SAR292833) twice daily immediately after breakfast/dinner
11484572|NCT01463384|Active Comparator|Minocycline|Subjects will be administered 50mg minocycline twice daily.
11484573|NCT01463371|No Intervention|Control|without azithromycin
11484574|NCT01463371|Active Comparator|azithromycin|treatment with azithromycin during three months
11484575|NCT01463358|Other|DDI30|Control group based only on backup pacing with lower rate 30 ppm
11484576|NCT01463358|Active Comparator|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
11484577|NCT01463345|Experimental|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
11484578|NCT01463345|Active Comparator|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
11484579|NCT01463332|Placebo Comparator|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
11484580|NCT01463332|Active Comparator|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
11484581|NCT01463332|Active Comparator|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
11484582|NCT01463319|Experimental|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
11484583|NCT01463319|Experimental|air insufflation|air insufflation during insertion phase of colonoscopy
11484584|NCT01463306|Experimental|Open|Pregabalin open label flexible dose
11484585|NCT01463293|Experimental|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
11484586|NCT01463293|Experimental|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
11484587|NCT01463293|Placebo Comparator|Placebo|Placebo capsule
11484588|NCT01463280|Experimental|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
11484589|NCT01463267|Active Comparator|Device 2 passive|Device 2 will NOT remind patients to take medications
11484590|NCT01463267|Active Comparator|Device 2 active|Device 2 will remind patients to take medications
11484591|NCT01463267|Active Comparator|Device 1 active|Device 1 will remind patients to take their medications
11484592|NCT01463267|Placebo Comparator|Device 1 Passive|Device 1 will NOT remind patients to take medications.
11484593|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
11484594|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
11484595|NCT01463241|Other|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
11484596|NCT01463228|Experimental|Treatment Sequence AB|
11484597|NCT01463228|Experimental|Treatment Sequence BA|
11484598|NCT01463215|Experimental|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
11484599|NCT01463202|Active Comparator|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
11484600|NCT01463202|Active Comparator|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
11484601|NCT01463189|Experimental|painACTION: Arthritis|
11484602|NCT01463189|No Intervention|treatment as usual|
11484603|NCT01463176|No Intervention|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
11484607|NCT01463150|Active Comparator|Clopidogrel|Clopidogrel 150mg per day for 15 days
11484609|NCT01463137|Sham Comparator|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
11484610|NCT01463137|Sham Comparator|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
11484611|NCT01463137|Active Comparator|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
11484612|NCT01463137|Active Comparator|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
11484613|NCT01463137|Active Comparator|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
11484614|NCT01463137|Active Comparator|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
11484615|NCT01463124|Experimental|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
11484616|NCT01463124|Active Comparator|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
11484617|NCT01463111|Other|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
11484618|NCT01463098|Experimental|Part A: E2006 1.0 mg|
11484619|NCT01463098|Experimental|Part A: E2006 2.5 mg|
11484620|NCT01463098|Experimental|Part A: E2006 5.0 mg|
11484621|NCT01463098|Experimental|Part A: E2006 10.0 mg|
11484622|NCT01463098|Experimental|Part A: E2006 25.0 mg|
11484623|NCT01463098|Experimental|Part A: E2006 50.0 mg|
11484624|NCT01463098|Experimental|Part A: E2006 100 mg|
11484625|NCT01463098|Experimental|Part A: E2006 200 mg|
11484626|NCT01463098|Experimental|Part B: Zolpidem 10 mg|
11484627|NCT01463098|Experimental|Part B: E2006 Matched Placebo or Zolpidem Matched Placebo|
11484628|NCT01463098|Experimental|Part A: E2006 Matched Placebo|
11484629|NCT01463098|Experimental|Part B: E2006 2.5 mg|
11484630|NCT01463098|Experimental|Part B: E2006 10 mg|
11484631|NCT01463098|Experimental|Part B: E2006 25 mg|
11484632|NCT01463085|Placebo Comparator|Control foods|3 servings per day of control foods
11484633|NCT01463085|Experimental|Low-fat dairy|3 servings per day of low-fat dairy products
11484634|NCT01463072|Experimental|Treatment (nab-paclitaxel)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11484635|NCT01463059|Placebo Comparator|Placebo every 2 weeks|Injections administered at week 0, 2, 4, 6, 8 and 10
11484636|NCT01463059|Experimental|Olokizumab 60 mg every 2 weeks|Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
11484637|NCT01463059|Experimental|Olokizumab 60 mg every 4 weeks|Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
11484638|NCT01463059|Experimental|Olokizumab 120 mg every 2 weeks|Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
11484639|NCT01463059|Experimental|Olokizumab 120 mg every 4 weeks|Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
11484640|NCT01463059|Experimental|Olokizumab 240 mg very 4 weeks|Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
11484641|NCT01463046|Experimental|Panobinostat|
11484642|NCT01463033|Active Comparator|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
11484643|NCT01463033|No Intervention|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
11484644|NCT01463020|Experimental|Smartphone delivered BA|
11484645|NCT01463020|Active Comparator|Smartphone delivered mindfulness|
11484646|NCT01463007|Experimental|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
11484647|NCT01463007|Experimental|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
11484648|NCT01462994|No Intervention|Single arm|
11484649|NCT01462968|Active Comparator|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
11484650|NCT01462968|Experimental|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
11484651|NCT01462942|Experimental|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
11484652|NCT01462942|Experimental|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
11484653|NCT01462942|Experimental|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
11484654|NCT01462942|Active Comparator|Formoterol monotherapy 12 μg|24 week, double blind treatment period
11484655|NCT01462942|Placebo Comparator|Placebo|24 week, double blind treatment period
11484656|NCT01462929|Experimental|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
11484657|NCT01462929|Active Comparator|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
11484658|NCT01462929|Placebo Comparator|Placebo|Placebo comparator administered during 6 weeks of treatment
11484659|NCT01462916||honey, no honey|
11484660|NCT01462903|Experimental|Drug, T cell immunoterhapy|
11484661|NCT01462890|Other|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
11484662|NCT01462890|Experimental|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
11484663|NCT01462877|Other|Fenofibrate arm|
11484664|NCT01462864|Active Comparator|Intervention|Lifestyle education intervention
11484665|NCT01462864|No Intervention|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
11484666|NCT01462851|Experimental|Dose Escalation|Ascending doses in healthy volunteers
11484667|NCT01462851|Experimental|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
11484668|NCT01462838|Experimental|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
11484669|NCT01462825|Experimental|tomato ketchup meal|
11484670|NCT01462825|Placebo Comparator|Placebo meal|
11484671|NCT01462812|Active Comparator|Sumatriptan|
11484672|NCT01462812|Placebo Comparator|Matching placebo|
11484673|NCT01462799|Experimental|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
11484674|NCT01462799|Experimental|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
11484675|NCT01462786|Experimental|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
11484676|NCT01462786|Experimental|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
11484677|NCT01462773|Experimental|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
11484678|NCT01462760|Other|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
11484679|NCT01462760|Other|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
11484680|NCT01462747|Experimental|KULIST|Medical Device, Activated carbon
11484681|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
11484682|NCT01462721|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
11484683|NCT01462708|Experimental|Assess [18F]MK-9470 and PET imaging|To Assess [18F]MK-9470 and PET imaging
11484684|NCT01462695|Experimental|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11484685|NCT01462669|Other|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
11484686|NCT01462669|Other|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
11484687|NCT01462669|Other|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
11484845|NCT01461603|Active Comparator|Amino acids|Amino acids compared to saline
11484688|NCT01462669|Other|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
11484689|NCT01462656||Patients with urinary retention|Patients with urinary retention
11484690|NCT01462643|Experimental|variant1|topical ointment, once daily application
11484691|NCT01462643|Experimental|variant 2|topical ointment, once daily application
11484692|NCT01462643|Experimental|variant 3|topical ointment, once daily application
11484693|NCT01462643|Experimental|variant4|topical ointment, once daily application
11484694|NCT01462643|Experimental|variant 5|topical ointment, once daily application
11484695|NCT01462643|Placebo Comparator|variant 6|topical ointment, once daily application
11484696|NCT01462643|Active Comparator|control positive|topical ointment,once daily application
11484697|NCT01462630|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11484698|NCT01462617|Experimental|Pi3K|Experimental
11484699|NCT01462617|Placebo Comparator|Placebo|Placebo Comparator
11484700|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
11484701|NCT01462591|Experimental|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
11484702|NCT01462591|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
11484703|NCT01462578|Experimental|Azacytidine|Azacytidine injection: 75 mg/m²/d, subcutaneous
11484704|NCT01462565|Experimental|All subjects|Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
11484705|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
11484706|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
11484707|NCT01462539||OSAS group|
11484708|NCT01462539||Non-OSAS group|
11484709|NCT01462526||Control|Participants who do not have glaucoma in either eye
11484710|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
11484711|NCT01462513|Experimental|L-BLP25|L-BLP25 treatment
11484712|NCT01462513|Placebo Comparator|Placebo|Placebo
11484713|NCT01462500|Experimental|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
11484714|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at < 20 weeks' gestation), fetal death (defined as death of a fetus at > 20 weeks' gestation), premature birth (defined as a birth occurring at < 37 weeks' gestation), and live birth at term
11484715|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
11484716|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
11484717|NCT01462474|Experimental|Drug: Famitinib|
11484718|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
11484719|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
11484720|NCT01462435|Experimental|Diclofenac Test (lower dose)|
11484721|NCT01462435|Experimental|Diclofenac Test (upper dose)|
11484722|NCT01462435|Active Comparator|Celecoxib|
11484723|NCT01462435|Placebo Comparator|Placebo|
11484724|NCT01462422|Other|Primary prevention|
11484725|NCT01462422|Other|Secondary Prevention|
11484726|NCT01462409|Experimental|heated humidification|
11484727|NCT01462409|Experimental|No Humidification|
11484728|NCT01462409|Experimental|Controlled heated Humidification with heated tube|
11484729|NCT01462396|Experimental|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
11484730|NCT01462370|Experimental|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
11484731|NCT01462370|Experimental|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
11484732|NCT01462357|Experimental|Cervarix 2 dose Group|Subjects who received 2 doses of Cervarix vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
11484733|NCT01462357|Experimental|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
11484734|NCT01462357|Experimental|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
11484735|NCT01462344|Experimental|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
11484736|NCT01462344|Experimental|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
11484737|NCT01462344|Active Comparator|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
11484738|NCT01462344|Active Comparator|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
11484739|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
11484740|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
11484741|NCT01462331|Placebo Comparator|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
11484742|NCT01462318|Experimental|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.
~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
11484743|NCT01462305|Experimental|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
11484744|NCT01462305|Active Comparator|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
11484745|NCT01462292|Experimental|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
11484746|NCT01462292|Experimental|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
11484747|NCT01462292|Experimental|Placebo to match GSK2402968 3 mg/kg/week|Placebo
11484748|NCT01462292|Experimental|Placebo to match GSK2402968 6 mg/kg/week|Placebo
11484749|NCT01462279|Experimental|Thiamine|Open label - 200mg IV
11484750|NCT01462266|Experimental|Sitagliptin|Sitagliptin 100 mg once daily
11484751|NCT01462266|Placebo Comparator|Placebo|Placebo to sitagliptin once daily
11484752|NCT01462253|Experimental|Clofarabine, Cyclophosphamide|"Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.
~Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection."
11484753|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
11484754|NCT01462227|Experimental|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
11484755|NCT01462227|Experimental|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
11484756|NCT01462201|Experimental|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
11484757|NCT01462201|Experimental|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
11484758|NCT01462188|Active Comparator|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
11484759|NCT01462188|Experimental|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.
~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
11484760|NCT01462175|Experimental|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
11484761|NCT01462175|Experimental|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
11484762|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
11484763|NCT01462149|Experimental|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
11484764|NCT01462136|Experimental|ACHN-490 Injection|
11484765|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
11484766|NCT01462110|Experimental|0.15% ethyl lauroyl arginate HCl-containing mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
11484767|NCT01462110|Sham Comparator|5% hydroalcohol mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.
11485040|NCT01460160|Experimental|Arm 1: Dasatinib|
11484768|NCT01462097|Experimental|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
11484769|NCT01462097|Active Comparator|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
11484770|NCT01462084|Experimental|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
11484771|NCT01462084|Experimental|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
11484772|NCT01462071||Chronic kidney disease|
11484773|NCT01462058|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
11484774|NCT01462058|Placebo Comparator|placebo|one tablet of sugar pill per day for 12 weeks.
11484775|NCT01462045|Experimental|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
11484776|NCT01462045|No Intervention|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
11484777|NCT01462045|No Intervention|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
11484778|NCT01462032|Experimental|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
11484779|NCT01462032|Active Comparator|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
11484780|NCT01462019|No Intervention|Control|
11484781|NCT01462019|Experimental|Photobiomodulation|
11484782|NCT01462006|Experimental|Sirolimus|
11484783|NCT01462006|Placebo Comparator|Placebo|
11484784|NCT01461993|Active Comparator|Group 1|rLP2086 + Gardasil
11484785|NCT01461993|Placebo Comparator|Group 2|rLP2086 and saline
11484786|NCT01461993|Active Comparator|Group 3|Saline + Gardasil
11484787|NCT01461980|Active Comparator|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
11484788|NCT01461980|Active Comparator|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
11484789|NCT01461980|Placebo Comparator|Saline + saline + rLP2086|Group 3- rLP2086 + saline
11484790|NCT01461967|Experimental|Part 1a|
11484791|NCT01461967|Placebo Comparator|Part 1b|
11484792|NCT01461967|Experimental|Part 2|
11484793|NCT01461954|Experimental|FST-100|
11484794|NCT01461954|Placebo Comparator|FST-100 Vehicle|
11484795|NCT01461941|Experimental|Drug: 0.2% E6005 ointment|
11484796|NCT01461941|Placebo Comparator|Drug: 0.0% E6005 ointment (vehicle)|
11484797|NCT01461928|Other|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
11484798|NCT01461928|Experimental|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
11484799|NCT01461915|Experimental|Run-in|10 Subjects to be enrolled in the study to receive : gemcitabine + nab-paclitaxel + ODSH
11484800|NCT01461915|Experimental|Arm A|25 patients to be enrolled to receive gemcitabine + nab-paclitaxel + ODSH
11484801|NCT01461915|Active Comparator|Arm B|25 patients will be enrolled in the study to receive gemcitabine + nab-paclitaxel
11484802|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
11484803|NCT01461889|Experimental|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
11484804|NCT01461889|Active Comparator|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
11484805|NCT01461876||HIV-infected cohort|
11484806|NCT01461876||HIV-uninfected control group|
11484807|NCT01461863|Active Comparator|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
11484808|NCT01461863|Placebo Comparator|Multivitamin|Standard multivitamin control
11484809|NCT01461850|Active Comparator|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT < 1 cm, followed by adjuvant chemotherapy.
11484846|NCT01461603|Active Comparator|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
11485041|NCT01460147|Other|DXA scan + MRI|
11484810|NCT01461850|Experimental|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
11484811|NCT01461837|Experimental|Haplo Stem Cell Transplantation|CD34 selected T-cell depleted allogeneic SCT
11484812|NCT01461824|Active Comparator|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
11484813|NCT01461824|Experimental|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
11484814|NCT01461824|Experimental|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
11484815|NCT01461811|Experimental|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
11484816|NCT01461811|Active Comparator|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
11484817|NCT01461798|Experimental|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
11484818|NCT01461798|Placebo Comparator|yogurt|Yogurt without plant stanols
11484819|NCT01461785|Experimental|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
11484820|NCT01461785|Placebo Comparator|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
11484821|NCT01461772|Experimental|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
11484822|NCT01461772|Active Comparator|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
11484823|NCT01461759|Experimental|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
11484824|NCT01461746|Experimental|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
11484825|NCT01461733|Experimental|amiodarone|standard dose amiodarone
11484826|NCT01461733|Placebo Comparator|placebo|
11484827|NCT01461720|Other|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
11484828|NCT01461720|Experimental|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
11484829|NCT01461707|Experimental|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
11484830|NCT01461707|Active Comparator|Activity monitor group|Participants in the group will receive an activity monitor
11484831|NCT01461694|Active Comparator|IPL|Half face treated with IPL
11484832|NCT01461694|Active Comparator|Alexandrite Laser|Half face treated with Alexandrite Laser
11484833|NCT01461681|Experimental|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
11484834|NCT01461681|No Intervention|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
11484835|NCT01461668|Experimental|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
11484836|NCT01461668|Placebo Comparator|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
11484837|NCT01461655|Placebo Comparator|Topical retinoid - Placebo|
11484838|NCT01461655|Active Comparator|Topical retinoid-NSAID|
11484839|NCT01461642|Experimental|Asthma - ICT support.|
11484840|NCT01461642|No Intervention|Asthma, comparator - no ICT support|
11484841|NCT01461629||heart failure|left systolic heart failure (EF </= 40%)
11484842|NCT01461616|Experimental|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
11484843|NCT01461616|Experimental|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
11484844|NCT01461616|Experimental|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
11484847|NCT01461590|Active Comparator|20ml/kg of whole blood transfusion|Standard care recommended by WHO
11484848|NCT01461590|Experimental|30ml/kg of whole blood|Higher volume than currently recommended
11484849|NCT01461577|Experimental|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
11484850|NCT01461564|Experimental|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
11484851|NCT01461564|Active Comparator|Air|Patients insufflated with air during screening colonoscopy
11484852|NCT01461551|Experimental|Sevoflurane|
11484853|NCT01461551|Experimental|Propofol|
11484854|NCT01461551|Experimental|Combine of sevoflurane and propofol|
11484855|NCT01461538|Experimental|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
11484856|NCT01461538|Experimental|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
11484857|NCT01461538|Experimental|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
11484858|NCT01461525|Experimental|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
11484859|NCT01461525|Experimental|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
11484860|NCT01461512|Placebo Comparator|Placebo|
11484861|NCT01461512|Experimental|Heme arginate treatment|
11484862|NCT01461499|Active Comparator|Direct renin inhibitor|
11484863|NCT01461499|Active Comparator|Angiotensin receptor blockers|
11484864|NCT01461486|Active Comparator|Continuous Positive Airway Pressure|Intervention group
11484865|NCT01461486|Active Comparator|Oral Appliance (BRD)|Intervention group
11484866|NCT01461486|No Intervention|Hygiene sleep care|Control group
11484867|NCT01461473|Active Comparator|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
11484868|NCT01461473|Active Comparator|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
11484869|NCT01461460|Active Comparator|Moxifloxacin 400 mg|
11484870|NCT01461460|Experimental|TR-701 FA 1200 mg|
11484871|NCT01461460|Experimental|TR-701 FA 200 mg plus Placebo|
11484872|NCT01461460|Placebo Comparator|Placebo|
11484873|NCT01461447|Experimental|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
11484874|NCT01461434|Experimental|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
11484875|NCT01461434|No Intervention|regular follow-up|patients will receive regular follow-ups with standard ECG
11484876|NCT01461421|Active Comparator|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
11484877|NCT01461421|Experimental|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
11484878|NCT01461408|Experimental|Beauty Salon #1b|Females ages 18-26
11484879|NCT01461408|Experimental|Beauty Salon #1a|Mothers of 9-18 year old females
11484880|NCT01461408|Experimental|Beauty Salon #2b|Females ages 18-26
11484881|NCT01461408|Experimental|Beauty Salon #3a|Mothers of 9-18 year old females
11484882|NCT01461408|Experimental|Beauty Salon #3b|Females ages 18-26
11484883|NCT01461408|Experimental|Beauty Salon #4a|Mothers of 9-18 year old females
11484884|NCT01461408|Experimental|Beauty Salon #4b|Females ages 18-26
11484885|NCT01461408|Experimental|Beauty Salon #2a|Mothers of 9-18 year old females
11484886|NCT01461408|Experimental|Beauty Salon #5a|Mothers of 9-18 year old females
11484887|NCT01461408|Experimental|Beauty Salon #5b|Females ages 9-26
11484888|NCT01461408|Experimental|Beauty Salon #6a|Mothers of 9-18 year old females
11484889|NCT01461408|Experimental|Beauty Salon #6b|Females ages 18-26
11484890|NCT01461408|Experimental|Beauty Salon #7a|Mothers of 9-18 year old females
11484891|NCT01461408|Experimental|Beauty Salon #7b|Females ages 18-26
11484892|NCT01461408|Experimental|Beauty Salon #8a|Mothers of 9-18 year old females
11484893|NCT01461408|Experimental|Beauty Salon #8b|Females ages 9-18
11484894|NCT01461382|Experimental|Phase I|Entered Study May 2008.
11484895|NCT01461382|Experimental|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
11484896|NCT01461369|Experimental|Diclofenac Capsules 35 mg bid|
11484897|NCT01461369|Experimental|Diclofenac Capsules 35 mg tid|
11484898|NCT01461369|Placebo Comparator|Placebo Capsule|
11484899|NCT01461356|Experimental|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
11484900|NCT01461356|Active Comparator|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
11484901|NCT01461343|Experimental|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
11484902|NCT01461343|Active Comparator|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
11484903|NCT01461330|Experimental|DASH diet|DASH DIET + EXERCISE
11484904|NCT01461330|Active Comparator|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
11484905|NCT01461317|Experimental|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
11484906|NCT01461291|Experimental|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
11484907|NCT01461291|Active Comparator|Cataract surgery|Cataract surgery alone
11484908|NCT01461278|Experimental|Cataract surgery plus iStent supra|
11484910|NCT01461265|Other|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
11484911|NCT01461252|Other|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
11484912|NCT01461239|Active Comparator|cast post and core|
11484913|NCT01461239|Experimental|fiber post - self-adhesive cement|
11484914|NCT01461239|Experimental|fiber post - conventional cement|
11484915|NCT01461226|Experimental|Exercise training|
11484916|NCT01461226|Other|Usual Care|
11484917|NCT01461213|Experimental|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
11484918|NCT01461213|Experimental|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
11484919|NCT01461200||Non allergics|
11484920|NCT01461200||allergics|
11484921|NCT01461187|Experimental|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
11484922|NCT01461187|No Intervention|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
11484923|NCT01461174|Experimental|Modafinil|200 mg tablet, single dose
11484924|NCT01461174|Experimental|Donepezil|5 mg tablet one per day, 15 days
11484925|NCT01461174|Experimental|Memantine|10 mg tablet one per day, 15 days
11484926|NCT01461161|Experimental|20 mg bardoxolone methyl|
11484927|NCT01461161|Experimental|60 mg bardoxolone methyl|
11484928|NCT01461161|Experimental|80 mg bardoxolone methyl|
11484929|NCT01461148|Experimental|FSP peptides|Vaccination with three FSP peptides
11484930|NCT01461109|Experimental|Assess [18F] CFPyPB and PET imaging|To assess [18F]CFPyPB and PET imaging
11484931|NCT01461096|Experimental|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
11484932|NCT01461096|Placebo Comparator|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
11484933|NCT01461083|Experimental|Assess [18F]MPPF and PET imaging|To assess [18F]MPPF and PET imaging
11484934|NCT01461070||Breast Cancer Cases|Breast Cancer Cases
11484935|NCT01461070||Controls|Controls
11484936|NCT01461057|Experimental|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
11484937|NCT01461057|Experimental|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
11484938|NCT01461044||Cohort|
11484939|NCT01461018|Experimental|IgPro20|
11484940|NCT01461005|Experimental|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
11484941|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
11484942|NCT01460979|Experimental|Temsirolimus|
11484943|NCT01460966|Active Comparator|Filtrap™+ Thrombus aspiration catheter|
11484944|NCT01460966|Active Comparator|Thrombus aspiration catheter|
11484945|NCT01460953|Experimental|training intervention|Students participating in didactic training
11484946|NCT01460940|Experimental|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
11484947|NCT01460927|Other|TriActive+ RF|Healthy male or female subjects 30-60 years of age, having at least two facial sub-areas (left peri-orbital, right peri-orbital or peri-oral) with visible lines/wrinkles and elastosis, which correlate to a score of 2-6 on the Fitzpatrick Classification of Wrinkling and Degree of Elastosis.
11484948|NCT01460901|Experimental|GD2 CAR modified Tri-virus CTL infusion|A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
11484949|NCT01460888|Experimental|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
11484950|NCT01460888|Experimental|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
11484951|NCT01460888|Experimental|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
11484952|NCT01460888|Experimental|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
11484953|NCT01460888|Active Comparator|RT alone|
11484954|NCT01460875|Experimental|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
11484955|NCT01460862||Omalizumab Cohort|
11484956|NCT01460836||Tobramycin Solution|
11484957|NCT01460836||Aztreonam lysine|
11484958|NCT01460823|Experimental|Use of image guided surgery|
11484959|NCT01460810|Experimental|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
11484960|NCT01460797|Other|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
11484961|NCT01460797|Other|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
11484962|NCT01460797|Other|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
11484963|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
11484964|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
11484965|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
11484966|NCT01460771|Experimental|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
11484967|NCT01460771|Sham Comparator|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
11484968|NCT01460758|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
11484969|NCT01460758|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
11484970|NCT01460758|Sham Comparator|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
11484971|NCT01460732|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
11484972|NCT01460719|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11484973|NCT01460706|Experimental|68Ga-DOTATOC|
11484974|NCT01460693|Active Comparator|Arm A - Imatinib|Imatinib 400mg daily
11484975|NCT01460693|Experimental|Arm B - Dasatinib|Dasatinib 100mg daily
11484976|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
11484977|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
11484978|NCT01460680||Healthy controls|Healthy controls
11484979|NCT01460667|Active Comparator|IV acetaminophen|
11484980|NCT01460667|Placebo Comparator|IV 0.9% normal saline|
11484981|NCT01460654|Placebo Comparator|Testosterone and Placebo Alendronate|
11484982|NCT01460654|Placebo Comparator|Alendronate and Placebo Testosterone|
11484983|NCT01460654|Experimental|Testosterone and Alendronate|
11484984|NCT01460641||CT perfusion|
11484985|NCT01460628|Experimental|Armodafinil|Armodafinil is the drug being tested.
11484986|NCT01460602|Experimental|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
11484987|NCT01460602|Experimental|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
11484988|NCT01460589|Experimental|early commencement|Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
11484989|NCT01460589|Active Comparator|conventional commencement|Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
11484990|NCT01460563|Experimental|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
11484991|NCT01460563|Placebo Comparator|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
11484992|NCT01460563|Placebo Comparator|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
11484993|NCT01460550|Experimental|gastrointestinal reconstruction|
11484994|NCT01460537|Experimental|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
11484995|NCT01460537|Experimental|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
11484996|NCT01460511|Placebo Comparator|P - Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
11484997|NCT01460511|Experimental|T - E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
11484998|NCT01460498|Experimental|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
11484999|NCT01460498|Experimental|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
11485000|NCT01460472|Experimental|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
11485001|NCT01460472|Active Comparator|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
11485042|NCT01460134|Experimental|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
11485002|NCT01460459|Experimental|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
11485003|NCT01460459|Experimental|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
11485004|NCT01460459|Experimental|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
11485005|NCT01460446|Experimental|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
11485006|NCT01460446|Active Comparator|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
11485007|NCT01460420|Experimental|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
11485008|NCT01460407|Experimental|LY2216684 + Clarithromycin|Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
11485009|NCT01460394||Healthy adolescents and young adults|
11485010|NCT01460381|Experimental|LY2216684 + Quinidine (CYP2C19 poor metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 poor metabolizer (PM) phenotype, as determined by genotyping analysis.
~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 was administered on Day 1.
~Period 2 (Days 8-15): 300 mg quinidine sulfate controlled release was administered orally, once daily on Days 8-15. Additionally, a single, oral dose of 18 mg LY2216684 was administered on Day 11."
11485011|NCT01460381|Experimental|LY2216684 (CYP2C19 extensive metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 extensive metabolizer (EM) phenotype, as determined by genotyping analysis.
~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 administered on Day 1.
~Period 2 (Days 8-15): EM participants did not participate in this period."
11485012|NCT01460368|Experimental|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
11485013|NCT01460368|Experimental|Part B: LY2409021|300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
11485014|NCT01460368|Placebo Comparator|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
11485015|NCT01460368|Active Comparator|Part B: Moxifloxacin|400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
11485016|NCT01460355|Active Comparator|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
11485017|NCT01460355|Placebo Comparator|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
11485018|NCT01460342|Placebo Comparator|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
11485019|NCT01460342|Experimental|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
11485020|NCT01460329||USCOM Cardiac index|
11485021|NCT01460316||Conotruncal cardiac defects patients|
11485022|NCT01460316||Mothers of patients|
11485023|NCT01460303|Experimental|OPTION-vf patient controlled catheter|"Patients who fail postop bladder challenge and are randomized to OPTION-vf arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
11485024|NCT01460303|Active Comparator|Transurethral catheter w/leg bag|"Patients who fail postop bladder challenge and are randomized to indwelling catheter with leg bag arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
11485025|NCT01460290|Experimental|Asenapine|12-weeks of open-label asenapine treatment
11485026|NCT01460277|Experimental|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
11485027|NCT01460277|Active Comparator|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
11485028|NCT01460264||exposed|current daily smokers 100 cigarettes or more during lifetime
11485029|NCT01460264||unexposed|current non-smokers
11485030|NCT01460251|Experimental|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
11485031|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
11485032|NCT01460225|Experimental|Treatment|24 micrograms of lubiprostone twice daily for one week.
11485033|NCT01460212|Experimental|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
11485034|NCT01460212|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
11485035|NCT01460199|Placebo Comparator|Placebo|Matching Placebo
11485036|NCT01460199|Experimental|CTP-499|
11485037|NCT01460186|Experimental|Blood samples|
11485038|NCT01460173|Other|Normal subjects|
11485039|NCT01460173|Other|OSA Patients|
11485043|NCT01460134|Experimental|Solid tumors (Dose Escalation; COMPLETED)|
11485044|NCT01460134|Experimental|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
11485045|NCT01460134|Experimental|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
11485046|NCT01460121|Experimental|SpotOn's corrective elements|
11485047|NCT01460121|Placebo Comparator|Placebo corrective elements|
11485048|NCT01460108|Experimental|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
11485049|NCT01460095|Experimental|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
11485050|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
11485051|NCT01460069|Active Comparator|Victoza treatment|
11485052|NCT01460069|Placebo Comparator|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
11485053|NCT01460056||Peritoneal dialysis|
11485054|NCT01460043|Placebo Comparator|placebo|
11485055|NCT01460043|Experimental|Homeopathy|Individualized symptom based therapy
11485056|NCT01460030|Experimental|KRN1493|
11485057|NCT01460017|Active Comparator|DS arm|Deep sclerectomy surgery will be conduct in this arm
11485058|NCT01460017|Active Comparator|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
11485059|NCT01460004|No Intervention|patella knee strap|infra patella knee strap- cotton, applied in straight leg
11485060|NCT01459991|Experimental|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
11485061|NCT01459991|Active Comparator|MyPyramid|
11485062|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.
~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
11485063|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
11485064|NCT01459965|Active Comparator|10 French Stent|10 French biliary plastic stent
11485065|NCT01459965|Active Comparator|11.5 French stent|11.5 French biliary plastic stent
11485066|NCT01459952|Experimental|Rose hip Liquid|20 ml Rose hip Liquid BID
11485067|NCT01459952|Placebo Comparator|Placebo|20 ml placebo liquid BID
11485068|NCT01459939|Placebo Comparator|Placebo|Daily treatment with placebo
11485069|NCT01459939|Active Comparator|Rose-hip powder|Daily treatment with Rose-hip powder
11485070|NCT01459926|Experimental|Dose 1|
11485071|NCT01459926|Experimental|Dose 2|
11485072|NCT01459926|Experimental|Dose 3|
11485073|NCT01459926|Experimental|Placebo|
11485074|NCT01459913|Experimental|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
11485075|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
11485076|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
11485077|NCT01459913|Experimental|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
11485078|NCT01459900|Active Comparator|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
11485116|NCT01459679|Active Comparator|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
11485545|NCT01456793|No Intervention|Usual care services|
11485079|NCT01459900|Sham Comparator|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
11485080|NCT01459887|Experimental|combination group|
11485081|NCT01459887|Experimental|sequential group|
11485082|NCT01459874||Cardiac Implantable Device recipients|
11485083|NCT01459861|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
11485084|NCT01459861|Active Comparator|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
11485085|NCT01459848|Active Comparator|block play|30 minutes of block play with parent
11485086|NCT01459848|Experimental|baby dvd|watch baby dvd with parent
11485087|NCT01459835|Experimental|media diet|advice tips and tools to reduce exposure to violent programming
11485088|NCT01459835|Active Comparator|Nutrition intervention|diet advice
11485089|NCT01459822||Survival Group|
11485090|NCT01459822||Death Group|
11485091|NCT01459809|Experimental|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline < 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
11485092|NCT01459809|Experimental|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
11485093|NCT01459809|Experimental|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline < 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
11485094|NCT01459796|Experimental|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
11485095|NCT01459796|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
11485096|NCT01459783|Active Comparator|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
11485097|NCT01459783|Active Comparator|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
11485098|NCT01459770|Active Comparator|control|"usual care for hospital discharge:
~CKD group
~ESRD group"
11485099|NCT01459770|Active Comparator|intervention|"pharmacist administered medication information transfer intervention
~CKD group
~ESRD group"
11485100|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
11485101|NCT01459744|Experimental|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
11485102|NCT01459744|Placebo Comparator|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
11485103|NCT01459731||Age 18-29|
11485104|NCT01459731||Age 30-39|
11485105|NCT01459731||Age 40-49|
11485106|NCT01459731||Age 50-59|
11485107|NCT01459731||Age 60-69|
11485108|NCT01459731||Age 70+|
11485109|NCT01459718|Experimental|Deferasirox / Deferasirox + Deferoxamine (DFO)|During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.
11485110|NCT01459705|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
11485111|NCT01459705|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
11485112|NCT01459705|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
11485113|NCT01459692|No Intervention|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
11485114|NCT01459692|Experimental|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
11485115|NCT01459679|Active Comparator|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
11485358|NCT01458054|Experimental|Treatment D|GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]
11485117|NCT01459679|Active Comparator|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
11485118|NCT01459666|Experimental|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
11485119|NCT01459666|Placebo Comparator|Placebo|
11485120|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
11485121|NCT01459640|Active Comparator|Hyaluronic acid|
11485122|NCT01459640|Experimental|Bone marrow mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells
11485123|NCT01459627|Active Comparator|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
11485124|NCT01459627|Active Comparator|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
11485125|NCT01459614|Experimental|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.
~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
11485126|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
11485127|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
11485128|NCT01459588|Active Comparator|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
11485129|NCT01459588|Active Comparator|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
11485130|NCT01459562|Experimental|NI-0501|
11485131|NCT01459562|Placebo Comparator|Placebo|
11485132|NCT01459549|No Intervention|Control Group|Just clear the stone without choledochojejunostomy
11485133|NCT01459549|Experimental|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
11485134|NCT01459536||Rotator Cuff Tear-surgical|
11485135|NCT01459536||Health Older Adult Control|
11485136|NCT01459536||Rotator cuff tear - non surgical|
11485137|NCT01459523|Active Comparator|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
11485138|NCT01459523|Active Comparator|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
11485139|NCT01459510|Experimental|multi media intervention|Play Nicely Program
11485140|NCT01459510|No Intervention|Routine primary care|Routine primary care
11485141|NCT01459497|Active Comparator|Radiation Therapy|Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
11485142|NCT01459497|Active Comparator|Conventional Radiation|Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
11485143|NCT01459484|Experimental|Mifamurtide arm|Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
11485144|NCT01459484|Other|3 drugs arm|High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein
11485145|NCT01459471|Experimental|bleeding, leak, operative time|
11485146|NCT01459458|Experimental|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
11485147|NCT01459458|No Intervention|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
11485148|NCT01459445|Other|Metformin+Drospirenone / EE 30µg|
11485149|NCT01459432||Follow-on blood sample from previous study|
11485150|NCT01459419|Experimental|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
11485151|NCT01459419|Placebo Comparator|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
11485152|NCT01459406|Experimental|Glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g glucose
11485153|NCT01459406|Experimental|Fructose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose
11485154|NCT01459406|Experimental|Fructan drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructan
11485155|NCT01459406|Experimental|Fructose and glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose and 40 g glucose
11485156|NCT01459393|Experimental|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
11485157|NCT01459393|Active Comparator|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
11485158|NCT01459380|Experimental|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
11485159|NCT01459380|Experimental|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
11485160|NCT01459367|Experimental|TAK-438 10 mg QD|
11485161|NCT01459367|Experimental|TAK-438 20 mg QD|
11485162|NCT01459367|Active Comparator|Lansoprazole 15 mg QD|
11485163|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
11485164|NCT01459328|Active Comparator|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
11485165|NCT01459328|Experimental|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
11485166|NCT01459315|Experimental|GSK1349572|
11485167|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
11485168|NCT01459289|Active Comparator|leaflet|
11485169|NCT01459289|Active Comparator|counseling|
11485170|NCT01459276|Experimental|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
11485171|NCT01459276|Active Comparator|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
11485172|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
11485173|NCT01459250|Experimental|AGO178C|
11485174|NCT01459211|Other|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
11485175|NCT01459198|Experimental|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
11485176|NCT01459198|Experimental|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
11485177|NCT01459198|Placebo Comparator|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
11485178|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10^5 RSV MEDI ΔM2-2 vaccine intranasally.
11485179|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
11485180|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
11485181|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
11485182|NCT01459185|Experimental|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
11485183|NCT01459172|Experimental|Limonene intervention|
11485184|NCT01459146|Experimental|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
11485185|NCT01459146|Active Comparator|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
11485186|NCT01459146|Active Comparator|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
11485187|NCT01459133|Experimental|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
11485188|NCT01459120|Experimental|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
11485189|NCT01459120|Active Comparator|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
11485190|NCT01459120|No Intervention|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
11485191|NCT01459107|Experimental|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
11485192|NCT01459094|Experimental|Treatment Sequence AB|
11485193|NCT01459094|Experimental|Treatment Sequence BA|
11485194|NCT01459081|Experimental|Zanamivir|
11485195|NCT01459081|Placebo Comparator|Placebo|
11485196|NCT01459068|No Intervention|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
11485197|NCT01459068|Experimental|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
11485198|NCT01459042||primary aldosteronism|
11485199|NCT01459042||essential hypertension|
11485200|NCT01459029|Active Comparator|D-serine|D-serine up to 6000 mg/day subject to tolerability
11485201|NCT01459029|Placebo Comparator|Control|Treatment with inert capsules (placebo)
11485202|NCT01459016|Experimental|Imaging Biomarkers|
11485203|NCT01459003|Experimental|experimental|
11485204|NCT01459003|No Intervention|control|
11485205|NCT01458990|Experimental|PPI inititation|Adding 40mg omeprazole QD for 14 days
11485206|NCT01458990|Active Comparator|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
11485207|NCT01458977|Experimental|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
11485208|NCT01458977|Placebo Comparator|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
11485209|NCT01458964|Active Comparator|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
11485210|NCT01458964|Placebo Comparator|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
11485211|NCT01458951|Experimental|tofacitinib 10 mg BID|
11485212|NCT01458951|Placebo Comparator|Placebo BID|
11485213|NCT01458938||Healthy volunteers|
11485214|NCT01458938||surgery for spinal radiculopathy|
11485215|NCT01458938||surgery for axial spine pain|
11485216|NCT01458938||myelography for spinal pain|
11485217|NCT01458925|Other|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.
~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
11485218|NCT01458912|Experimental|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
11485219|NCT01458912|Placebo Comparator|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
11485220|NCT01458912|Experimental|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
11485221|NCT01458899|Experimental|A - first fed then fasted treatment|TC-5214
11485222|NCT01458899|Experimental|B - first fasted then fed treatment|TC-5214
11485223|NCT01458886|Experimental|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
11485224|NCT01458886|Experimental|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
11485225|NCT01458886|Placebo Comparator|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
11485226|NCT01458873|Experimental|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
11485227|NCT01458873|Experimental|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
11485228|NCT01458873|Placebo Comparator|normal saline|"50 ml normal saline"
11485229|NCT01458860||GROUP A|patients had a CT
11485230|NCT01458860||GROUP B|patients with severe carotid artery stenosis
11485231|NCT01458847|Experimental|Cohort I: 2% cis-UCA solution (50 ml)|
11485232|NCT01458847|Experimental|Cohort II: 4% cis-UCA solution (50 ml)|
11485233|NCT01458847|Experimental|Cohort III: 6% cis-UCA solution (50 ml)|
11485234|NCT01458834|Experimental|Active attention training condition|
11485235|NCT01458834|Placebo Comparator|Control condition|
11485236|NCT01458821|Experimental|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
11485237|NCT01458821|No Intervention|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
11485238|NCT01458808|Experimental|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
11485239|NCT01458808|Experimental|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
11485240|NCT01458808|No Intervention|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
11485241|NCT01458782|Active Comparator|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
11485242|NCT01458782|Active Comparator|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).
~Please see reference 3 for details regarding AMIC"
11485243|NCT01458769|Active Comparator|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.
~C-10276 200 mg -> C-10276 400 mg -> Reyataz 400 mg
~C-10276 200 mg -> Reyataz 400 mg -> C-10276 400 mg"
11485244|NCT01458769|Active Comparator|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.
~C-10276 300 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-> C-10276 400 mg
~C-10276 300 mg -> C-10276 400 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
11485245|NCT01458769|Active Comparator|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.
~C-10297 200 mg"
11485246|NCT01458769|Active Comparator|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.
~C-10299 200 mg"
11485247|NCT01458769|Active Comparator|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.
~C-10297 400 mg -> Reyataz 400 mg -> C-10297 600 mg"
11485248|NCT01458769|Active Comparator|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.
~C-10299 400 mg -> Reyataz 400 mg -> C-10299 600 mg"
11485249|NCT01458769|Active Comparator|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.
~C-10276 600 mg -> Reyataz 400 mg -> Reyataz 600 mg"
11485250|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
11485251|NCT01458743|Experimental|Ceftaroline q12h|Ceftaroline 600mg q12h
11485252|NCT01458743|Experimental|Ceftaroline q8h|ceftaroline 600mg q8h
11485253|NCT01458717|Experimental|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
11485254|NCT01458717|Active Comparator|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
11485255|NCT01458704||fresh frozen tumor tissue|patients providing fresh frozen tumor tissue
11485256|NCT01458691|Active Comparator|Steroid group|Triamcinolone injection group
11485257|NCT01458691|Experimental|PRP group|Allogeneic PRP injection group
11485258|NCT01458678|Active Comparator|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
11485259|NCT01458678|Active Comparator|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
11485260|NCT01458665|Experimental|PRP group|
11485261|NCT01458665|Placebo Comparator|Conventional group|
11485262|NCT01458652|Experimental|Lifestyle counseling|"Drug:Kremezin
~Other Names:AST-120
~Kremezin is an oral adsorbent, 9g/day in treatment arm"
11485263|NCT01458639|Experimental|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
11485264|NCT01458639|Active Comparator|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
11485265|NCT01458626|Active Comparator|Add-on therapy|mirtazapine 30mg QD and paroxetine 20mg QD
11485266|NCT01458626|Active Comparator|mirtazapine monotherapy|mirtazapine 30mg QD
11485267|NCT01458626|Active Comparator|paroxetine monotherapy|paroxetine 20mg QD
11485268|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
11485269|NCT01458600|Active Comparator|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
11485270|NCT01458600|Other|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
11485271|NCT01458587|Experimental|ALA|
11485272|NCT01458587|Placebo Comparator|Vehicle|
11485273|NCT01458574|Placebo Comparator|Placebo Comparator|
11485274|NCT01458574|Experimental|CP-690,550 5 mg Arm|
11485275|NCT01458574|Experimental|CP-690,550 10 mg Arm|
11485276|NCT01458561|Experimental|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
11485277|NCT01458561|Active Comparator|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
11485278|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
11485279|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
11485280|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
11485281|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
11485282|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
11485283|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
11485284|NCT01458522|Active Comparator|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
11485285|NCT01458522|Experimental|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
11485286|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
11485287|NCT01458509||Web EASP|Web Group with Nurse Intervention
11485288|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
11485289|NCT01458509||Web No EASP|Web Group without nurse intervention
11485290|NCT01458496|Experimental|Health Coaching|
11485291|NCT01458496|No Intervention|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
11485292|NCT01458483|Experimental|Baroreceptor Stimulation|
11485293|NCT01458470|Active Comparator|Memantine|NMDA Receptor Antagonist
11485294|NCT01458470|Placebo Comparator|Sugar pill|
11485295|NCT01458457|Active Comparator|Usual care|
11485296|NCT01458457|Active Comparator|Usual Care + Complementary Medicine|
11485297|NCT01458444|Active Comparator|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
11485298|NCT01458444|Experimental|OPTIFLOW|OPTIFLOW system
11485299|NCT01458431|Experimental|Levobupivacaine|Continuous levobupivacaine subfascial infusion
11485300|NCT01458431|Placebo Comparator|NaCl|Continuous NaCl subfascial infusion
11485301|NCT01458418|Experimental|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
11485302|NCT01458418|Experimental|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
11485303|NCT01458418|Placebo Comparator|placebo|Subjects will receive two placebo tablets per day.
11485304|NCT01458405|Placebo Comparator|Placebo|
11485305|NCT01458405|Active Comparator|CAP-1002 Allogeneic Cardiosphere-Derived Cells|
11485306|NCT01458392|Experimental|Dalantercept|dalantercept
11485307|NCT01458366|Experimental|Bendamustine 70mg/m^2|Level 1: Bendamustine 70mg/m^2 Ofatumumab, Carboplatin, and Etoposide
11485308|NCT01458366|Experimental|Bendamustine 50mg/m^2|Level -1: Bendamustine 50mg/m^2 Ofatumumab, Carboplatin, and Etoposide
11485309|NCT01458366|Experimental|Bendamustine 90mg/m^2|Level 2: Bendamustine 90mg/m^2 Ofatumumab, Carboplatin, and Etoposide
11485359|NCT01458054|Experimental|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
11485310|NCT01458366|Experimental|Bendamustine 120mg/m^2|Level 3: Bendamustine 120mg/m^2 Ofatumumab, Carboplatin, and Etoposide
11485311|NCT01458366|Experimental|Phase II MTD|Phase II: Bendamustine at MTD from Phase I, Ofatumumab, Carboplatin, and Etoposide
11485312|NCT01458353|Experimental|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
11485313|NCT01458353|Experimental|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
11485314|NCT01458340|Experimental|TD-9855 Dose 1|
11485315|NCT01458340|Experimental|Placebo|
11485316|NCT01458340|Experimental|TD-9855 Dose 2|
11485317|NCT01458327|Experimental|3,4-methylenedoxymethamphetamine (MDMA) and psychotherapy|125 and 62.5 mg MDMA
11485318|NCT01458314|Active Comparator|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
11485319|NCT01458314|Experimental|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
11485320|NCT01458301|Placebo Comparator|Placebo|
11485321|NCT01458301|Experimental|TAK-385 10 mg QD|
11485322|NCT01458301|Experimental|TAK-385 20 mg QD|
11485323|NCT01458301|Experimental|TAK-385 40 mg QD|
11485324|NCT01458301|Other|Leuplin|
11485325|NCT01458288|Experimental|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
11485326|NCT01458275|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
11485327|NCT01458275|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
11485328|NCT01458275|Placebo Comparator|Placebo|
11485329|NCT01458249|Experimental|eribulin mesylate 1.4 mg/m^2|
11485330|NCT01458236|Experimental|BPS-314d-MR|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration.
11485331|NCT01458236|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group.
11485332|NCT01458223|Active Comparator|Control|24 hours post-operative antibiotics
11485333|NCT01458223|Experimental|experimental|72 hours of post-operative antibiotics
11485334|NCT01458210|Experimental|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram [mg] norelgestromin [NGMN] + 0.035 mg ethinyl estradiol [EE] [active tablets] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.
~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
11485335|NCT01458197|Experimental|Tarafenacin 0.2 mg|Group 1
11485336|NCT01458197|Experimental|Tarafenacin 0.4 mg|Group 2
11485337|NCT01458197|Placebo Comparator|Placebo|Group 3
11485338|NCT01458184|Experimental|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
11485339|NCT01458184|No Intervention|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
11485340|NCT01458171|Experimental|IgPro20|
11485341|NCT01458158||Diabetic nephropathy|Diabetic nephropathy in patients with type 2 diabetes
11485342|NCT01458158||chronic glomerulonephritis|chronic glomerulonephritis in patients without diabetes mellitus
11485343|NCT01458158||controls|participants without diabetic nephropathy and chronic glomerulonephritis
11485344|NCT01458145|Experimental|Home visits|
11485345|NCT01458145|No Intervention|routine primary care at community health center|
11485346|NCT01458132||Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
11485347|NCT01458132||Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
11485348|NCT01458119|Experimental|Migalastat|Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
11485349|NCT01458106|Experimental|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.
~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
11485350|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
11485351|NCT01458080||Patients w/secondary thrombocytopenia related to hepatitis C|Patients w/secondary thrombocytopenia related to hepatitis C
11485352|NCT01458067|Experimental|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
11485353|NCT01458067|Experimental|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
11485354|NCT01458067|Experimental|Part 3|GSK2636771 daily dosing
11485355|NCT01458054|Experimental|Treatment A|GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]
11485356|NCT01458054|Experimental|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
11485357|NCT01458054|Experimental|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]
11485360|NCT01458054|Experimental|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]
11485361|NCT01458054|Experimental|Treatment G|Ritonavir 100mg q12h x 1 day
11485362|NCT01458041||Group 1|
11485363|NCT01458028|Experimental|Arm 1|
11485364|NCT01458028|Placebo Comparator|Arm 2|
11485365|NCT01458015|Active Comparator|oxycodone|
11485366|NCT01458015|Active Comparator|tapentadol|
11485367|NCT01458002|No Intervention|Control|Assessment only
11485368|NCT01458002|Other|Tailored Internet Communications|TTM expert system only
11485369|NCT01458002|Experimental|Tailored Internet Communication with Relational Agent|TTM expert system plus relational agent
11485370|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
11485371|NCT01457976||Members of the US public, non-probability sample|
11485372|NCT01457976||Members of the German public, non-probability sample|
11485373|NCT01457976||Members of the US public, probability sample|
11485374|NCT01457963||pulmonary embolism, deep venous thrombosis|
11485375|NCT01457950|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
11485376|NCT01457950|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
11485377|NCT01457950|Experimental|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
11485378|NCT01457937|Active Comparator|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
11485379|NCT01457937|Experimental|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
11485380|NCT01457924|Experimental|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
11485381|NCT01457924|Experimental|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
11485382|NCT01457924|Experimental|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
11485383|NCT01457924|Experimental|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
11485384|NCT01457924|Experimental|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
11485385|NCT01457924|Experimental|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
11485386|NCT01457924|Experimental|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
11485387|NCT01457924|Experimental|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
11485388|NCT01457911|Experimental|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
11485389|NCT01457911|Active Comparator|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
11485390|NCT01457898|Experimental|VPAP II®|VPAP II® Group
11485391|NCT01457885|Experimental|CloBu4 regimen|After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
11485392|NCT01457872|Experimental|Strength-based case management|Case management plus referral (vs referral-only)
11485393|NCT01457872|Active Comparator|Referral only|Referral only (no case management intervention)
11485394|NCT01457859|Active Comparator|Conventional sutures|
11485395|NCT01457859|Experimental|Antiseptic sutures|
11485396|NCT01457846|Experimental|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
11485397|NCT01457846|Active Comparator|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
11485398|NCT01457833|Active Comparator|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
11485399|NCT01457833|Active Comparator|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
11485400|NCT01457820|Experimental|Allopurinol High dose|
11485401|NCT01457820|Experimental|Allopurinol Low dose|
11485402|NCT01457820|Placebo Comparator|Placebo|
11485403|NCT01457807|Experimental|1|AZD3241 300mg extended release formulation 1
11485404|NCT01457807|Experimental|2|AZD3241 300mg extended release formulation 2
11485405|NCT01457807|Placebo Comparator|3|Placebo
11485406|NCT01457794|Other|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
11485407|NCT01457794|Other|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
11485408|NCT01457781|Active Comparator|0.025 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
11485409|NCT01457781|Active Comparator|0.075 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L [4880 ppm] NO mini-cylinder; change q 24 hours)
11485410|NCT01457781|Placebo Comparator|placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks* (99.999% Nitrogen [N2] mini-cylinder; change q 24 hours)
11485411|NCT01457742|Active Comparator|Pulsed Radio Frequency (PRF)|
11485412|NCT01457742|Sham Comparator|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
11485413|NCT01457729|No Intervention|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
11485414|NCT01457729|Other|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
11485415|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler A|
11485416|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler B|
11485417|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler C|
11485418|NCT01457716|Active Comparator|Budesonide/Formoterol Turbohaler Forte|
11485542|NCT01456806|Active Comparator|Patients Educated|Patients attend the interactive group education, while providers do not.
11485664|NCT01456013|Active Comparator|Standard Therapy|Standard of care for patients at risk of CIN
11485419|NCT01457703|Active Comparator|BMI ≥30 kg/m2|"Group 2:
~BMI ≥30 kg/m2
~History of regular menstrual cycles every 25-40 days
~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
11485420|NCT01457703|Experimental|BMI 18-25 kg/m2|"BMI 18-25 kg/m2
~History of regular menstrual cycles every 25-35 days
~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
11485421|NCT01457690|Experimental|Tocofersolan: Vitamin E water-soluble|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
11485422|NCT01457690|Active Comparator|Tocopherol alpha: Vitamin E conventional fat-soluble form|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
11485423|NCT01457690|Active Comparator|volunteers|
11485424|NCT01457677|Placebo Comparator|Placebo|
11485425|NCT01457677|Experimental|RO4995819 15 mg|
11485426|NCT01457677|Experimental|RO4995819 30 mg|
11485427|NCT01457677|Experimental|RO4995819 5 mg|
11485428|NCT01457664|Placebo Comparator|Placebo|
11485429|NCT01457664|Experimental|RO4995819|
11485430|NCT01457651|Active Comparator|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
11485431|NCT01457651|Active Comparator|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
11485432|NCT01457651|Active Comparator|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
11485433|NCT01457651|Active Comparator|No recruitment|No recruitment is performed: standard respiratory support.
11485434|NCT01457638|Sham Comparator|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
11485435|NCT01457638|Experimental|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
11485436|NCT01457625||liver fat contents|
11485437|NCT01457612|Placebo Comparator|Placebo1|Placebo Beverage 1 without fiber
11485438|NCT01457612|Active Comparator|Strawberry|Strawberry Beverage 20g/BID
11485439|NCT01457612|Placebo Comparator|Placebo2|Placebo Beverage 2 with Fiber
11485440|NCT01457599||Marking Liver|
11485441|NCT01457586|Active Comparator|Transfusion|Patient who received blood transfusion in the perioperative period
11485442|NCT01457586|No Intervention|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
11485443|NCT01457573|Experimental|One (single arm)|All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg (1 tab) and Solifenacin (Vesicare) 5 mg (1 tab) orally at the same time.
11485444|NCT01457560|Experimental|Group A|
11485445|NCT01457547|Experimental|DTPa 1 Group|
11485446|NCT01457547|Active Comparator|DTPa 2 Group|
11485447|NCT01457534||liver transplantation|
11485448|NCT01457521|Active Comparator|Therapeutic|Ibuprofen
11485449|NCT01457521|Active Comparator|Prophylactic|Ibuprofen
11485450|NCT01457508|Experimental|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
11485451|NCT01457508|Active Comparator|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
11485452|NCT01457495|Experimental|DTPa 1 Group|
11485453|NCT01457495|Active Comparator|DTPa 2 Group|
11485454|NCT01457482|Experimental|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
11485455|NCT01457482|Active Comparator|Therapeutic conversation group|Treatment by therapeutic conversations only
11485456|NCT01457469|Active Comparator|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
11485457|NCT01457469|Experimental|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
11485458|NCT01457456||Observation|Patients with Morquio disease
11485459|NCT01457443||Observation|Patients with Pompe disease
11485460|NCT01457430|Experimental|Icatibant|Open-label study
11485461|NCT01457417|Experimental|75 milligram (mg) DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.
~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
11485462|NCT01457417|Experimental|150 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.
~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
11485543|NCT01456806|Active Comparator|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
11485463|NCT01457417|Experimental|300 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.
~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
11485464|NCT01457417|Experimental|600 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.
~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
11485465|NCT01457417|Experimental|300 mg DKN-01 Part B|Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
11485466|NCT01457404|Experimental|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
11485467|NCT01457404|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
11485468|NCT01457391|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
11485469|NCT01457391|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
11485470|NCT01457391|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
11485471|NCT01457378||Healthy volunteers|100 healthy volunteers
11485472|NCT01457378||IBS Subjects|100 IBS Subjects
11485473|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
11485474|NCT01457352|Experimental|SPARC0921|
11485475|NCT01457352|Placebo Comparator|Placebo0921|
11485476|NCT01457339|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
11485477|NCT01457339|Placebo Comparator|Placebo|
11485478|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
11485479|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
11485480|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
11485481|NCT01457300||District Rehabilitation Centre (Model 1)|Patients admitted to Primary Health Care Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited continuously at Entrance to the Rehabilitation Centre.
11485482|NCT01457300||Standard PHC Rehabilitation (Model 2)|Patients admitted to Standard Primary Health Care (PHC) Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited Continuously at Entrance to the Short Term Rehabilitation Beds in Nursing Homes or at the Beginning of Rehabilitation in their Own Homes.
11485483|NCT01457274|Experimental|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
11485484|NCT01457274|Active Comparator|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
11485485|NCT01457261|Experimental|Partical size 1|Monodisperse particle delivered with radiolabel
11485486|NCT01457261|Experimental|Particle size 2|Monodisperse particle delivered with radiolabel
11485487|NCT01457261|Experimental|Nebulised salbutamol|Polydisperse particle via a nebuliser
11485488|NCT01457261|Experimental|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
11485489|NCT01457248|Experimental|endotracheal tube with taper-shaped cuff|
11485490|NCT01457248|Active Comparator|Endotracheal tube with cylindrical-shaped cuff|
11485491|NCT01457235|Active Comparator|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
11485544|NCT01456793|Experimental|Teen Options to Prevent Pregnancy|
11485492|NCT01457235|No Intervention|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
11485493|NCT01457222|Active Comparator|Mindfulness|Mindfulness intervention 10 minutes daily
11485494|NCT01457222|Active Comparator|Music relaxation|Music intervention 10 minutes daily
11485495|NCT01457222|No Intervention|Business as usual|No intervention - control group.
11485496|NCT01457196|Other|Sequencing Arm|
11485497|NCT01457183|Experimental|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
11485498|NCT01457170|Experimental|Apelin/Saline|Apelin infusion then crossover to Saline infusion
11485499|NCT01457170|Experimental|Saline/Apelin|Saline infusion then crossover to Apelin infusion
11485500|NCT01457144|Experimental|RiBVD|Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days
11485501|NCT01457118|Experimental|NKTR-102|
11485502|NCT01457105|Experimental|ComVi biliary stent|
11485503|NCT01457092|Experimental|FC Nitinol SEMS|FC Nitinol SEMS
11485504|NCT01457066|Experimental|Intervention|This group will receive the peer navigator intervention.
11485505|NCT01457066|No Intervention|Control|This group will receive usual care.
11485506|NCT01457053|Active Comparator|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
11485507|NCT01457053|Active Comparator|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
11485508|NCT01457040|Experimental|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
11485509|NCT01457040|Experimental|Non-Remission (NR)|NR Cohort: ALL in non-remission
11485510|NCT01457027|Experimental|All subjects|
11485511|NCT01457014|Active Comparator|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
11485512|NCT01457014|Active Comparator|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
11485513|NCT01457014|Active Comparator|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
11485514|NCT01457001|Experimental|25-OH-D vitamin|
11485515|NCT01457001|No Intervention|control|
11485516|NCT01456975|Experimental|Valsalva|Reimplantation procedure using Valsalva prosthesis
11485517|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
11485518|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
11485519|NCT01456949|Other|Single Arm|Cryoablation
11485520|NCT01456936|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
11485521|NCT01456936|Active Comparator|varenicline|
11485522|NCT01456936|Active Comparator|bupropion|
11485523|NCT01456936|Active Comparator|Nicotine Replacement Therapy Patch|
11485524|NCT01456923|Active Comparator|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
11485525|NCT01456923|Active Comparator|Study|Patients treated only with chemotherapy
11485526|NCT01456910|Experimental|Working group|G1 intervention group of 20 participants aged 14-36 years old and mild to severe intellectual disability of both gender.
11485527|NCT01456910|Active Comparator|Daily Living|G2 control group continue usual routine
11485528|NCT01456897|Experimental|OPC-34712|
11485529|NCT01456884|Experimental|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
11485530|NCT01456884|Experimental|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
11485531|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
11485532|NCT01456858|Placebo Comparator|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
11485533|NCT01456858|Experimental|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
11485534|NCT01456858|Placebo Comparator|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
11485535|NCT01456858|Experimental|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
11485536|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.
~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
11485537|NCT01456832||Renal Transplant Patients with Post-operative Hypoatremia|All renal transplant recipients at the Mayo Clinic of Florida from 1/1/2010 through 8/19/2011 who received a kidney from either a living or cadaveric donor.
11485538|NCT01456819|Experimental|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
11485539|NCT01456819|Active Comparator|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
11485540|NCT01456806|No Intervention|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
11485541|NCT01456806|Active Comparator|Provider educated|Provider attend the interactive group education, while patients do not.
11485546|NCT01456780|Active Comparator|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
11485547|NCT01456780|Active Comparator|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
11485548|NCT01456780|Placebo Comparator|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
11485549|NCT01456767|Active Comparator|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).
~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
11485550|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).
~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
11485551|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).
~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
11485552|NCT01456767|Placebo Comparator|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).
~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
11485553|NCT01456754|Experimental|High feeding frequency (14x)|
11485554|NCT01456754|Experimental|low feeding frequency (3x)|
11485555|NCT01456741|Experimental|1-EBNA with ROSE|
11485556|NCT01456741|Experimental|1-EBNA without ROSE|
11485557|NCT01456728|Experimental|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
11485558|NCT01456728|Placebo Comparator|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
11485559|NCT01456715|Active Comparator|Gardasil, Immunogenicity, Booster dose.|
11485560|NCT01456715|Experimental|Cervarix, Immunogenicity, Booster dose.|
11485561|NCT01456702|No Intervention|control arm|volume therapy via standard operating procedure
11485562|NCT01456702|Experimental|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
11485563|NCT01456689|Experimental|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
11485564|NCT01456689|Experimental|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
11485565|NCT01456676|Experimental|Nilotinib + LDE225|The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y
11485566|NCT01456663|Experimental|AFQ056|
11485567|NCT01456650|Experimental|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
11485568|NCT01456637|Experimental|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
11485569|NCT01456637|Experimental|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
11485570|NCT01456624|Active Comparator|Megace / Fasting condition|800mg
11485571|NCT01456624|Experimental|DW-ES(B) / Fasting condition|625mg
11485572|NCT01456624|Active Comparator|Megace / Fed condition|800mg
11485573|NCT01456624|Experimental|DW-ES(B) / Fed condition|625mg
11485574|NCT01456611|Experimental|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
11485575|NCT01456611|Active Comparator|Voltaren (R) Gel|Voltaren (R) Gel 1%
11485576|NCT01456611|Placebo Comparator|Placebo|Placebo Topical Gel
11485577|NCT01456598|Experimental|Laparoscopic gastrectomy|Laparoscopic subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
11485578|NCT01456598|Active Comparator|Open gastrectomy|Open subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
11485579|NCT01456572|Active Comparator|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
11485580|NCT01456572|Active Comparator|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
11485581|NCT01456572|Placebo Comparator|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
11485582|NCT01456572|Placebo Comparator|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
11485583|NCT01456572|Active Comparator|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
11485584|NCT01456572|Placebo Comparator|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
11485585|NCT01456546|Active Comparator|Period A: proguanil|Proguanil pharmacokinetics
11485586|NCT01456546|Active Comparator|Period B: clopidogrel|Clopidogrel pharmacokinetics
11485587|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
11485588|NCT01456520|Experimental|A: single dose Vycavert (Test)|
11485589|NCT01456520|Active Comparator|B: single dose Norco (Reference)|
11485590|NCT01456507|Experimental|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
11485591|NCT01456507|Experimental|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
11485592|NCT01456507|Experimental|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
11485593|NCT01456494|Experimental|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
11485594|NCT01456494|Experimental|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
11485595|NCT01456481|Active Comparator|midodrine hydrochloride pills|
11485596|NCT01456481|Placebo Comparator|oral placebo or sugar pill|
11485597|NCT01456468|Experimental|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
11485598|NCT01456429|Experimental|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
11485599|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
11485600|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
11485601|NCT01456390|Other|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
11485602|NCT01456377|Active Comparator|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
11485603|NCT01456377|Placebo Comparator|placebo|oral placebo and oral analgesics
11485604|NCT01456364|Active Comparator|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
11485605|NCT01456364|Active Comparator|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
11485606|NCT01456351|Experimental|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
11485607|NCT01456351|Active Comparator|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
11485608|NCT01456338|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
11485609|NCT01456338|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
11485610|NCT01456325|Experimental|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
11485611|NCT01456325|Placebo Comparator|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
11485665|NCT01456013|Experimental|RenalGuard Therapy|Induced Diuresis with Matched Replacement
11485612|NCT01456312|Sham Comparator|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification>20,000 Iu/ml at 12w
11485613|NCT01456312|Sham Comparator|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
11485614|NCT01456312|Sham Comparator|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
11485615|NCT01456299|Placebo Comparator|Control|The control group, which received an infusion of normal saline.
11485616|NCT01456299|Active Comparator|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
11485617|NCT01456299|Active Comparator|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
11485618|NCT01456286|Experimental|Sapropterin|5 mg/kg daily first week; 10 mg/kg daily second week of treatment
11485619|NCT01456286|Placebo Comparator|placebo|
11485620|NCT01456273|Placebo Comparator|A2- Medical consultation + placebo|Traditional medical interview + placebo
11485621|NCT01456273|Active Comparator|B1 - Therapeutic Encounter / Omeprazol|
11485622|NCT01456273|Placebo Comparator|B2 - Therapeutic Encounter / Placebo|
11485623|NCT01456273|Active Comparator|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
11485624|NCT01456260|Experimental|TAK-438 10 mg QD|
11485625|NCT01456260|Experimental|TAK-438 20 mg QD|
11485626|NCT01456260|Active Comparator|Lansoprazole 15 mg QD|
11485627|NCT01456247|Experimental|TAK-438 10 mg QD|
11485628|NCT01456247|Experimental|TAK-438 20 mg QD|
11485629|NCT01456247|Active Comparator|AG-1749 15 mg QD|
11485630|NCT01456234|Active Comparator|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
11485631|NCT01456234|Experimental|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
11485632|NCT01456221|Experimental|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: Docosahexaenoic acid (DHA) and EPA fatty acids together with an hypocaloric diet.
11485633|NCT01456221|Placebo Comparator|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
11485634|NCT01456195|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
11485635|NCT01456195|Experimental|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
11485636|NCT01456195|Experimental|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
11485637|NCT01456182|Other|Dose arm 1|
11485638|NCT01456182|Other|Dose arm 2|
11485639|NCT01456182|Other|Dose arm 3|
11485640|NCT01456182|Other|Dose arm 4|
11485641|NCT01456182|Other|Dose arm 5|
11485642|NCT01456169|Active Comparator|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
11485643|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
11485644|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
11485645|NCT01456156|Experimental|hepatectomy plus radiotherapy|
11485646|NCT01456143|Experimental|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
11485647|NCT01456130|Experimental|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
11485648|NCT01456117|Experimental|Pioglitazone (Dose 1) QD|
11485649|NCT01456117|Experimental|Pioglitazone (Dose 2) QD|
11485650|NCT01456117|Experimental|Pioglitazone (Dose 3) QD|
11485651|NCT01456117|Placebo Comparator|Placebo QD|
11485652|NCT01456104|Experimental|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).
11485653|NCT01456091|Experimental|AIM 4 Teen Moms|
11485654|NCT01456091|No Intervention|Control|
11485655|NCT01456078|Experimental|177Lu-DOTA-TATE|
11485656|NCT01456065|Other|Vaccine weekly administration|
11485657|NCT01456065|Other|Vaccine biweekly administration|
11485658|NCT01456052|Experimental|Low Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally once daily (QD).
11485659|NCT01456052|Experimental|High Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally three times daily (TID).
11485660|NCT01456052|Placebo Comparator|Placebo|Matching placebo administered orally.
11485661|NCT01456039|Experimental|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
11485662|NCT01456026|Experimental|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
11485663|NCT01456026|Active Comparator|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
11485666|NCT01456000|Experimental|EAS-AC (HeartLight)|Treatment with the EAS-AC.
11485667|NCT01456000|Active Comparator|Control Arm Ablation|Treatment with standard ablation.
11485668|NCT01455974|Experimental|Dialysate sodium set at 136 mmol/L|
11485669|NCT01455948|Active Comparator|Balloon Sinuplasty™ System|
11485670|NCT01455948|Active Comparator|Functional Endoscopic Sinus Surgery|
11485671|NCT01455935|Active Comparator|Medical Therapy|"Current standard of care per the latest stroke guidelines
~Permissive Hypertension up to 220
~Antipletelets therapy:
~ASA 81 mg PO daily or
~Plavix 75 mg PO daily or
~Aggrenox 225mg PO twice daily
~Anti-inflammatory therapy:
~Lipitor 80 mg PO daily or
~Crestor 20 mg PO daily"
11485672|NCT01455935|Experimental|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis
~0.9 mg/kg
~Maximum dose is 90 mg
~10% of the dose will be given over one minute
~90% of the dose will be infused over 1 hour
~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications
~Neuro checks every 5 minutes during the infusion
~Neuro checks every hour after the infusion for 24 hours"
11485673|NCT01455935|Experimental|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:
~Intra arterial Activase (Maximum dose of 22 mg)
~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)
~PENUMBRA device (no standard time frame for how long the procedure takes)"
11485674|NCT01455922|Experimental|ITCA 650 60 mcg/day|
11485675|NCT01455922|Active Comparator|glimepiride|
11485676|NCT01455909|Experimental|ITCA 650 60 mcg/day|
11485677|NCT01455909|Active Comparator|sitagliptin|sitagliptin 100 mg/day
11485678|NCT01455896|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
11485679|NCT01455896|Other|ITCA placebo|
11485680|NCT01455883|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
11485681|NCT01455883|Active Comparator|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
11485682|NCT01455870|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
11485683|NCT01455870|Active Comparator|sitagliptin|sitagliptin 100 mg/day
11485684|NCT01455857|Experimental|ITCA 650 40 mcg/day|
11485685|NCT01455857|Experimental|ITCA 650 60 mcg/day|
11485686|NCT01455857|Placebo Comparator|ITCA placebo|
11485687|NCT01455844|Experimental|CaPre 1.0g|
11485688|NCT01455844|Experimental|CaPre 2.0g|
11485689|NCT01455844|Placebo Comparator|Placebo|
11485690|NCT01455831|Experimental|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
11485691|NCT01455831|Active Comparator|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
11485692|NCT01455805|Active Comparator|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
11485693|NCT01455805|Other|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
11485694|NCT01455792|Experimental|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
11485695|NCT01455792|Active Comparator|Gold standard biopsy|Gold standard TRUS biopsy
11485696|NCT01455779|Other|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.
~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
11485697|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
11485698|NCT01455740|Experimental|Provider Visit Incentive (PVI)|"Participants were told that they would receive $30 after attending each scheduled provider visit (a CCT).
~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm."
11485699|NCT01455740|Experimental|Incentive Choice (IC)|"Participants were given a choice between the CCT described in the PVI arm and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit AND meeting an ART adherence threshold.
~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 19 individuals to the IC arm."
11485700|NCT01455740|No Intervention|Passive Control (PC)|The study also included 70 individuals in a PC arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period.
11485701|NCT01455727|Experimental|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
11485702|NCT01455727|Active Comparator|Usual care|Patients received usual care directed by their physician.
11485703|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
11485704|NCT01455701|Experimental|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
11485705|NCT01455688|Experimental|Early antiviral therapy|
11485706|NCT01455688|Active Comparator|Conventional therapy|
11485707|NCT01455675|Experimental|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
11485708|NCT01455675|Placebo Comparator|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
11485709|NCT01455662||all patients after cardiac arrest|
11485710|NCT01455649|Experimental|Everolimus|
11485711|NCT01455649|Active Comparator|calcineurin inhibitor|
11485712|NCT01455636|Experimental|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.
~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
11485713|NCT01455636|Experimental|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.
~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
11485714|NCT01455636|Experimental|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.
~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
11485715|NCT01455636|Placebo Comparator|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder
~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
11485716|NCT01455623||Health Care Provider|A person working within the field of CMT.
11485717|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
11485718|NCT01455597|Experimental|Estradiol Vaginal Gel|WC3011 Estradiol Vaginal Gel, administered 3X weekly for 40 weeks
11485719|NCT01455584|Experimental|HM781-36B|HM781-36B
11485720|NCT01455571|Experimental|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
11485721|NCT01455558|Experimental|Cilostazol|
11485722|NCT01455532|Experimental|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
11485723|NCT01455532|Experimental|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
11485724|NCT01455532|Experimental|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
11485725|NCT01455532|Experimental|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
11485726|NCT01455519|Placebo Comparator|Sugar pill|Subjects may receive a pill with no medicine.
11485727|NCT01455519|Active Comparator|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
11485728|NCT01455506|Experimental|Decitabine with fludarabine and busulfan|decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
11485729|NCT01455493|Experimental|A|
11485730|NCT01455480|Experimental|RPh201|
11485731|NCT01455467|Active Comparator|One iStent|Implantation of one iStent in conjunction with cataract surgery
11485732|NCT01455467|Active Comparator|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
11485733|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
11485734|NCT01455441|Active Comparator|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
11485735|NCT01455441|Placebo Comparator|Training and placebo|Treatment wiht both training and placebo for 16 weeks
11485736|NCT01455428|Experimental|Lyrica (pregabalin)|
11485737|NCT01455428|Placebo Comparator|Placebo|
11485738|NCT01455415|Experimental|1: Pregabalin|
11485739|NCT01455415|Placebo Comparator|2: Placebo|
11485740|NCT01455389|Experimental|DOTAP + Erlotinib|DOTAP:Chol-TUSC2 0.045 mg/kg by vein over 25-35 minutes on day 1 of each 21 day cycle; and Erlotinib 100 mg by mouth daily for each 21 day cycle.
11485741|NCT01455376|No Intervention|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
11485742|NCT01455376|Experimental|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
11485743|NCT01455350|Active Comparator|Lidocaine|10 week treatment of daily application of topical lidocaine
11485744|NCT01455350|Experimental|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
11485745|NCT01455337|Active Comparator|prednisolone|
11485746|NCT01455337|Experimental|pentoxifylline|
11485747|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
11485913|NCT01454349|Placebo Comparator|Inactive substance|
11485748|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
11485749|NCT01455298|Other|Transient elastography and fibrotest|
11485750|NCT01455272|Experimental|high-risk leukemia|
11485751|NCT01455259|Experimental|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
11485752|NCT01455246|Experimental|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
11485753|NCT01455246|Active Comparator|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
11485754|NCT01455233|Active Comparator|besivance|ocular antibiotic
11485755|NCT01455233|Active Comparator|vigamox|ocular antibiotic
11485756|NCT01455207|Other|alcoholic patients|
11485757|NCT01455207|Other|korsakoff patients|
11485758|NCT01455207|Other|healthy controls|
11485759|NCT01455194|Active Comparator|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
11485760|NCT01455194|Active Comparator|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
11485761|NCT01455194|Active Comparator|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
11485762|NCT01455181|Experimental|NPSP558|
11485763|NCT01455168||No treatment|Capsular tension ring is not used in the group.
11485764|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
11485765|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
11485766|NCT01455155|Experimental|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
11485767|NCT01455155|Active Comparator|Control|Conventional physical therapy (5 times/week) for 4 weeks
11485768|NCT01455142|Experimental|Formulation 1|
11485769|NCT01455142|Experimental|Formulation 2|
11485770|NCT01455129|Active Comparator|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
11485771|NCT01455129|Placebo Comparator|placebo group|matching placebo, once daily, inhaled by HandiHaler
11485772|NCT01455116|Experimental|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
11485773|NCT01455116|No Intervention|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
11485774|NCT01455103|Experimental|Arm 1: BMS-936559 (1mg/kg)|
11485775|NCT01455103|Experimental|Arm 2: BMS-936559 (3mg/kg)|
11485776|NCT01455103|Experimental|Arm 3: BMS-936559 (10mg/kg)|
11485777|NCT01455090|Experimental|Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks
~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
11485778|NCT01455090|Experimental|Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks
~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
11485779|NCT01455090|Experimental|Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2
~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks
~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
11485780|NCT01455090|Experimental|Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks
~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
11485781|NCT01455090|Experimental|Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-naive subjects
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
11485782|NCT01455090|Experimental|Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-naive subjects
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
11485783|NCT01455090|Experimental|Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 4 treatment-naive subjects
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
11485784|NCT01455090|Experimental|Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 4 treatment-naive subjects
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
11485785|NCT01455090|Experimental|Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
11485786|NCT01455090|Experimental|Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects
~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks
~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
11485787|NCT01455090|Experimental|Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects
~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks
~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
11485788|NCT01455090|Experimental|Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects
~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks
~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks
~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
11485914|NCT01454336|Experimental|Cirrhotic Patients|3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy
11485789|NCT01455090|Experimental|Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV|"* Genotype 1 treatment-naive subjects
~BMS-650032 200 mg tablets orally twice daily 12 weeks
~BMS-790052 30 mg tablets orally twice daily 12 weeks
~BMS-791325 75 mg tablets orally twice daily 12 weeks
~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM]"
11485790|NCT01455077||Obese patients|BMI > 35
11485791|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
11485792|NCT01455051|Experimental|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
11485793|NCT01455038||Control group|Healthy controls had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist.
11485794|NCT01455038||Bipolar group|individual patient as being in subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating scale score of 10 or less and Clinical Global Impression severity of 3 or less for last one month.
11485795|NCT01455025|Experimental|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
11485796|NCT01455012|Experimental|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
11485797|NCT01455012|Placebo Comparator|Placebo|Placebo
11485798|NCT01454999|Experimental|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
11485799|NCT01454999|Experimental|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
11485800|NCT01454986|Active Comparator|Cohort 1|0.06 mg/kg ALXN1007
11485801|NCT01454986|Active Comparator|Cohort 2|0.1 mg/kg ALXN1007
11485802|NCT01454986|Active Comparator|Cohort 3|0.3 mg/kg ALXN1007
11485803|NCT01454986|Active Comparator|Cohort 4|1.0 mg/kg ALXN1007
11485804|NCT01454986|Active Comparator|Cohort 5|3.0 mg/kg ALXN1007
11485805|NCT01454986|Active Comparator|Cohort 6|6.0 mg/kg ALXN1007
11485806|NCT01454986|Active Comparator|Cohort 7|10.0 mg/kg ALXN1007
11485807|NCT01454973||Healthy obese individuals|
11485808|NCT01454960|Experimental|SA, AJ, PC|"Participants are given all 3 interventions:
~Suggested Alternatives, Accountable Justification, and Peer Comparison."
11485809|NCT01454960|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
11485810|NCT01454960|Experimental|SA, PC|Participants receive the Suggested Alternatives and Peer Comparison interventions, but not the Accountable Justification intervention.
11485811|NCT01454960|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternatives intervention.
11485812|NCT01454960|Experimental|Peer Comparison|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
11485813|NCT01454960|Experimental|Suggested Alternatives|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
11485814|NCT01454960|Experimental|Accountable Justification|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
11485815|NCT01454960|No Intervention|Control|Participants do not receive any of the 3 interventions.
11485816|NCT01454947|Experimental|SA, AJ, PC|Participants are given all 3 interventions.
11485817|NCT01454947|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
11485818|NCT01454947|Experimental|SA, PC|Participants receive the Suggested Alternative and Peer Comparison interventions, but not the Accountable Justification intervention.
11485819|NCT01454947|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternative intervention.
11485820|NCT01454947|Experimental|Peer Comparison (PC)|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
11485821|NCT01454947|Experimental|Suggested Alternatives (SA)|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
11485822|NCT01454947|Experimental|Accountable Justification (AJ)|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
11485823|NCT01454947|No Intervention|Education Control|Participants do not receive any of the 3 interventions.
11485824|NCT01454934|Experimental|Arm A|
11485825|NCT01454934|Active Comparator|Arm B|
11485826|NCT01454921|Experimental|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.
~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
11485827|NCT01454921|Experimental|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.
~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
11485828|NCT01454908|Other|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
11485915|NCT01454323|Experimental|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
11485829|NCT01454895|Experimental|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
11485830|NCT01454895|Experimental|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
11485831|NCT01454895|Experimental|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
11485832|NCT01454895|Active Comparator|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
11485833|NCT01454895|Experimental|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
11485834|NCT01454895|Other|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
11485835|NCT01454882||Behavioral effects of clothing and temperature|In this first study, we will determine how variations in clothing and ambient temperature influence the accuracy of EE determined from measurements of total heat production. 65 individuals will be studied. This will be a randomized cross-over trial with two within subject factors: 1) ambient temperature and 2) amount of clothing. There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
11485836|NCT01454882||Behavioral effects of age, sex, and adiposity|THe aim of this study is to Determine how age, sex, and adiposity influence the accuracy of EE determined from measurements of total heat production . This will be a randomized study with two within subject conditions(high and low physical activity levels). A heterogenous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age range (≥ 18 yrs).
11485837|NCT01454882||Effects of free living energy expenditure|The primary aim of this study is to compare the accuracy of measuring free-living energy expenditure in humans measured using portable direct calorimetry. This will be a comparison study; TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age (>18 yrs).
11485838|NCT01454869|Active Comparator|Standard care|nac + salotamul
11485839|NCT01454869|Experimental|heparin group|heparin group
11485840|NCT01454856||Surgical cancer patients|No modification of the treatment
11485841|NCT01454856||Non-surgical cancer patients|No modification of the treatment
11485842|NCT01454856||Surgical non-cancer patients|No modification of the treatment
11485843|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
11485844|NCT01454843|Active Comparator|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser.
11485845|NCT01454843|Active Comparator|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using AMO CustomVue excimer laser.
11485846|NCT01454830|Experimental|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
11485847|NCT01454830|Active Comparator|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
11485848|NCT01454817|Other|Patients with ICDs|
11485849|NCT01454817|Other|Caregivers of Patients with ICDs|
11485850|NCT01454804|Experimental|Arm A: Pazopanib + Lapatinib|Oral Pazopanib 200 mg every other day starting on day 1 and oral Lapatinib 500 mg daily starting day 1, both for 28 days.
11485851|NCT01454804|Experimental|Arm B: Pazopanib + Trastuzumab|Oral Pazopanib 200 mg daily for 28 day cycle and Trastuzumab (Herceptin®) 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1, with a maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
11485852|NCT01454791|Experimental|Diclofenac Sodium Topical Gel first then Placebo|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
11485853|NCT01454791|Placebo Comparator|Placebo first then Diclofenac Sodium Topical Gel|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
11485854|NCT01454778|Experimental|Paclitaxel|
11485855|NCT01454765||Sperm sample from healthy volunteers|
11485856|NCT01454752|Active Comparator|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
11485857|NCT01454752|Placebo Comparator|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
11485858|NCT01454739|Experimental|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
11485859|NCT01454739|Experimental|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
11485860|NCT01454726|Experimental|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
11485861|NCT01454726|Other|control group|receiving the Western medical treatment alone.
11485862|NCT01454713||Veritas|Breast reconstruction with Veritas
11485863|NCT01454700|Experimental|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
11485864|NCT01454700|Active Comparator|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
11485865|NCT01454661|Active Comparator|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
11485866|NCT01454661|Placebo Comparator|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
11485867|NCT01454661|Active Comparator|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
11485868|NCT01454661|Active Comparator|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
11485869|NCT01454661|Active Comparator|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
11485870|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
11485871|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
11485872|NCT01454635|Other|Sertraline, Treatment response|dosage, frequency and duration
11485873|NCT01454622|Experimental|Treatment Sequence AB|
11485874|NCT01454622|Experimental|Treatment Sequence BA|
11485875|NCT01454609|Placebo Comparator|Saline|0.9% normal saline
11485876|NCT01454609|Experimental|Bupivacaine|0.25% bupivacaine
11485877|NCT01454609|Experimental|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
11485878|NCT01454596|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced peripheral blood lymphocytes (PBL) + aldesleukin
11485879|NCT01454596|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + maximum tolerated dose (MTD) of anti-EGFRvIII CAR transduced PBL established in Phase I + aldesleukin
11485880|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
11485881|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
11485882|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
11485883|NCT01454570|Experimental|Powered Exoskeleton|persons with SCI trained to use a powered exoskeleton to ambulate overground
11485884|NCT01454557|Experimental|Acquired Brain Injury|auditory stimuli for ABI group
11485885|NCT01454557|Experimental|Controls|Auditory stimuli for control group
11485886|NCT01454544|Experimental|ALK house dust mite tablet 6 DU|
11485887|NCT01454544|Experimental|ALK house dust mite tablet 12 DU|
11485888|NCT01454544|Placebo Comparator|Placebo|
11485889|NCT01454531|Experimental|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
11485890|NCT01454518|Experimental|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
11485891|NCT01454518|Placebo Comparator|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
11485892|NCT01454505|Experimental|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
11485893|NCT01454505|Placebo Comparator|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
11485894|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
11485895|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
11485896|NCT01454479|Experimental|Lapatinib (Tykerb) Plus Ixabepilone|
11485897|NCT01454453|Experimental|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
11485898|NCT01454440|Experimental|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure).
11485899|NCT01454440|Placebo Comparator|Placebo|
11485900|NCT01454427||healthy volunteers|
11485901|NCT01454414|Experimental|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
11485902|NCT01454414|No Intervention|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
11485903|NCT01454401|Other|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
11485904|NCT01454388|Active Comparator|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
11485905|NCT01454388|No Intervention|PEG without breakfast|
11485906|NCT01454388|Active Comparator|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
11485907|NCT01454388|No Intervention|picosalax without breakfast|
11485908|NCT01454375|No Intervention|Control Arm|No change in current practice
11485909|NCT01454375|Experimental|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
11485910|NCT01454362|Experimental|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
11485911|NCT01454362|Active Comparator|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
11485912|NCT01454349|Experimental|PRX302|
11485916|NCT01454310|Experimental|Acellular skin substitute|
11485917|NCT01454310|Active Comparator|Autologous skin graft|
11485918|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
11485919|NCT01454284|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
11485920|NCT01454284|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
11485921|NCT01454271|Experimental|Total Hip Arthroplasty CERAFIT® grafted|
11485922|NCT01454245|Experimental|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.
~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
11485923|NCT01454232|Other|gastric surgery|obese patients addressed for gastric surgery
11485924|NCT01454232|Active Comparator|lean healthy subjects evaluated once|lean healthy subjects evaluated once
11485925|NCT01454206|No Intervention|Treatment as Usual|
11485926|NCT01454206|Experimental|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
11485927|NCT01454180|Active Comparator|Arm A|Control treatment arm will be treated with any of the schemes used in the study according to the discretion of the physician responsible
11485928|NCT01454180|Experimental|Arm B|treatment guided by the therapeutic targets
11485929|NCT01454154|Active Comparator|Glyburide|RP-1127 (Glyburide for Injection)
11485930|NCT01454154|Placebo Comparator|Placebo|Placebo
11485931|NCT01454141|Experimental|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
11485932|NCT01454141|Experimental|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
11485933|NCT01454128|Active Comparator|Non-EPB|with exercise
11485934|NCT01454128|Experimental|EPB with exercise|with exercise
11485935|NCT01454115|Experimental|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485936|NCT01454115|Experimental|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485937|NCT01454115|Experimental|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485938|NCT01454115|Experimental|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485939|NCT01454115|Experimental|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).
~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.
~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
11485940|NCT01454115|Experimental|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485941|NCT01454115|Experimental|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485942|NCT01454115|Experimental|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
11485943|NCT01454115|Experimental|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
11485944|NCT01454115|Experimental|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
11485945|NCT01454115|Experimental|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
11485946|NCT01454115|Experimental|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
11485947|NCT01454115|Experimental|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
11485948|NCT01454115|Experimental|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
11485949|NCT01454102|Experimental|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle
~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles
~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
11485950|NCT01454102|Experimental|Arm B: Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle
~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles
~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
11485951|NCT01454102|Experimental|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle
~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles
~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
11485952|NCT01454102|Experimental|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle
~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
11486016|NCT01453738|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
11485953|NCT01454102|Experimental|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle
~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
11485954|NCT01454102|Experimental|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
11485955|NCT01454102|Experimental|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)
~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles
~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles
~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
11485956|NCT01454102|Experimental|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)
~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles
~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles
~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
11485957|NCT01454102|Experimental|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)
~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles
~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles
~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
11485958|NCT01454102|Experimental|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)
~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles
~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles
~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
11485959|NCT01454102|Experimental|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)
~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
11485960|NCT01454102|Experimental|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)
~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
11485961|NCT01454102|Experimental|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema
~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
11485962|NCT01454102|Experimental|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)
~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles
~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles
~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
11485963|NCT01454102|Experimental|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity
~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
11485964|NCT01454102|Experimental|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity
~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
11485965|NCT01454102|Experimental|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity
~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
11485966|NCT01454102|Experimental|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity
~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
11485967|NCT01454102|Experimental|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity
~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
11485968|NCT01454089|Experimental|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
11485969|NCT01454089|Experimental|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
11485970|NCT01454089|Active Comparator|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
11485971|NCT01454076|Experimental|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
11485972|NCT01454076|Experimental|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
11485973|NCT01454076|Experimental|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
11485974|NCT01454076|Experimental|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
11486017|NCT01453738|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
11486058|NCT01453426|Experimental|Chinese Subjects - Dose 2 BG00012|
11486059|NCT01453426|Experimental|Japanese Subjects - Dose 1 BG00012|
11485975|NCT01454076|Experimental|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
11485976|NCT01454063|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
11485977|NCT01454063|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
11485978|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
11485979|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
11485980|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
11485981|NCT01454024||Total study population|
11485982|NCT01454011|Active Comparator|Testosterone 250mg injection,|
11485983|NCT01454011|Active Comparator|Testosterone transdermal application|
11485984|NCT01453998|Experimental|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
11485985|NCT01453998|Experimental|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
11485986|NCT01453998|Active Comparator|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
11485987|NCT01453985|Experimental|Full-Thickness-Gastroplication|
11485988|NCT01453972|Experimental|Long distanse moderate training|40 minutes moderate treadmill running
11485989|NCT01453972|Experimental|Long interval training|4x4min interval treadmill running
11485990|NCT01453972|Experimental|Short interval training|10x1min interval treadmill running
11485991|NCT01453959|Other|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
11485992|NCT01453959|Other|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
11485993|NCT01453946|Other|Entocort|Study Medication
11485994|NCT01453933|Active Comparator|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
11485995|NCT01453933|No Intervention|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
11485996|NCT01453920|Active Comparator|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
11485997|NCT01453920|Experimental|Treat-and-observe'|No injection, follow-up assessments every month
11485998|NCT01453907|Experimental|ETI-204|ETI-204, Anthim
11485999|NCT01453907|Sham Comparator|placebo|
11486000|NCT01453894|Experimental|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
11486001|NCT01453894|No Intervention|Usual Care Control Group|Patients assigned to this arm will receive usual care.
11486002|NCT01453881|Experimental|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
11486003|NCT01453881|Active Comparator|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
11486004|NCT01453868|Active Comparator|Active non impact aerobics|This group will be performing a 12 week non impact aerobics program twice a week.
11486005|NCT01453868|Active Comparator|Control group: Passive lecture series|The control group will also be measured for balance and then attend a 12 week lecture series with no exercise. They will then also be remeasured post lectures series
11486006|NCT01453855|Experimental|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
11486007|NCT01453855|Active Comparator|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
11486008|NCT01453842|Experimental|Diet oil|
11486009|NCT01453842|Active Comparator|Olive oil|
11486010|NCT01453842|Placebo Comparator|Carrot|
11486011|NCT01453803|Experimental|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
11486012|NCT01453790|Experimental|Parent-Specific Depression Education-Motivation|Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.
11486013|NCT01453790|Active Comparator|General Depression Education|Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.
11486014|NCT01453764|Experimental|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
11486015|NCT01453751|Experimental|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
11486057|NCT01453426|Experimental|Chinese Subjects - Dose 1 BG00012|
11486018|NCT01453725|Experimental|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
11486019|NCT01453725|Placebo Comparator|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
11486020|NCT01453712|No Intervention|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
11486021|NCT01453712|Experimental|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
11486022|NCT01453686|Experimental|Hydrocortisone 1%|
11486023|NCT01453686|Experimental|Clobetasol Propionate 0.05%|
11486024|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
11486025|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
11486026|NCT01453647|Experimental|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
11486027|NCT01453647|No Intervention|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
11486028|NCT01453634|Experimental|Lunacalcipol 180|180 µg (n=4)Lunacalcipol Injection
11486029|NCT01453634|Experimental|Lunacalcipol 270|270 µg (n=8)Lunacalcipol Injection
11486030|NCT01453621|Experimental|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
11486031|NCT01453621|No Intervention|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
11486032|NCT01453608|Experimental|Ferinject (ferric carboxymaltose)|
11486033|NCT01453608|Placebo Comparator|Placebo (saline)|
11486034|NCT01453595|Experimental|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:
~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).
~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
11486035|NCT01453582|Experimental|Propolis|Total Flavonoids of Propolis dropping pill
11486036|NCT01453582|Placebo Comparator|Placebo|Simulant of total Flavonoids of Propolis dropping pill
11486037|NCT01453569|Experimental|sodium oligo-mannurarate 900mg|
11486038|NCT01453569|Experimental|sodium oligo-mannurarate 600mg|
11486039|NCT01453569|Placebo Comparator|Placebo|
11486040|NCT01453556|Experimental|Intracorpopreal anastomosis|Intracorporeal mechanical anastomosis
11486041|NCT01453556|Active Comparator|Extracorporeal anastomosis|Extracorporeal mechanical anastomosis
11486042|NCT01453543|Experimental|Deep transverse friction massage|Massage technique will be used.
11486043|NCT01453530|Active Comparator|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
11486044|NCT01453530|Active Comparator|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
11486045|NCT01453530|Placebo Comparator|No reversal agent|No treatment
11486046|NCT01453504|Active Comparator|Ever-DHAP|Combination of Everolimus and DHAP
11486047|NCT01453504|Placebo Comparator|Placebo-DHAP|
11486048|NCT01453491|Experimental|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
11486049|NCT01453491|Experimental|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
11486050|NCT01453478|Experimental|GSK1325756 Immediate Release 50 mg|Administered to volunteers in the fasted and fed states
11486051|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 1 50 mg|Administered to volunteers in the fasted and/or fed states
11486052|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 2 50 mg|Administered to volunteers in the fasted and/or fed states
11486053|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
11486054|NCT01453452|Experimental|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention & counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
11486055|NCT01453439|Experimental|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
11486056|NCT01453439|Active Comparator|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
11486060|NCT01453426|Experimental|Japanese Subjects - Dose 2 BG00012|
11486061|NCT01453426|Experimental|Caucasian Subjects - Dose 1 BG00012|
11486062|NCT01453426|Experimental|Caucasian Subjects - Dose 2 BG00012|
11486063|NCT01453413|Other|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
11486064|NCT01453400|Experimental|Arm 1|
11486065|NCT01453400|Active Comparator|Arm 2|
11486066|NCT01453400|Placebo Comparator|Arm 3|
11486067|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 1)|
11486068|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 2)|
11486069|NCT01453374|Experimental|VIVITROL|380 mg IM injection
11486070|NCT01453361|Experimental|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
11486071|NCT01453348|Active Comparator|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' alone on the different visits.
11486072|NCT01453348|Active Comparator|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
11486073|NCT01453348|Active Comparator|Group 3|This group will receive only MenACWY-CRM.
11486074|NCT01453309|Active Comparator|Cell Saver|Patients will have the use of a cell-saver during surgery
11486075|NCT01453309|Placebo Comparator|No Cell saver|Patient will not have cell saver available during surgery.
11486076|NCT01453296|Active Comparator|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.
~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).
~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
11486077|NCT01453296|Active Comparator|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.
~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).
~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
11486078|NCT01453270|Experimental|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
11486079|NCT01453270|Active Comparator|Usual care|
11486080|NCT01453257|Experimental|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
11486081|NCT01453244||SVR group|A patients who achieved SVR (sustained virologic response)
11486082|NCT01453244||non-SVR group|A patients who not achieved SVR (sustained virologic response)
11486083|NCT01453231|No Intervention|Control|No surgery
11486084|NCT01453231|Experimental|thighplasty|
11486085|NCT01453218|No Intervention|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
11486086|NCT01453218|Active Comparator|ATeGe-Fresenius|
11486087|NCT01453205|Active Comparator|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
11486088|NCT01453205|Experimental|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
11486089|NCT01453205|Experimental|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
11486090|NCT01453192|Experimental|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
11486091|NCT01453179|Experimental|Aldara 5% Cream|
11486092|NCT01453179|Active Comparator|Solaraze 3% Gel|
11486093|NCT01453166|Experimental|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
11486094|NCT01453166|Experimental|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
11486095|NCT01453166|Experimental|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
11486096|NCT01453153|Active Comparator|Gemcitabine|Gemcitabine + Placebo
11486097|NCT01453153|Experimental|PEGPH20|PEGPH20+Gemcitabine
11486098|NCT01453140|Experimental|Cyclophosphamide and Sirolimus|Patients will be treated in sequential cohorts of 5. In cohort A, the first 5 enrolled patients will be receive cyclophosphamide and sirolimus only
11486099|NCT01453140|Experimental|Low dose IL-2 with Cytoxan + Sirolimus|
11486100|NCT01453140|Experimental|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|
11486101|NCT01453127|Experimental|Alzheimer's Disease|Alzheimer's Disease
11486102|NCT01453127|Experimental|Dementia with Lewy Bodies|Dementia with Lewy Bodies
11486103|NCT01453127|Experimental|Frontotemporal Dementia|Frontotemporal Dementia
11486104|NCT01453127|Experimental|Parkinson's Disease|Parkinson's Disease
11486105|NCT01453127|Experimental|Corticobasal Degeneration|Corticobasal Degeneration
11486106|NCT01453127|Experimental|Essential Tremor|Essential Tremor
11486107|NCT01453127|Experimental|Mild Cognitive Impairment|Mild Cognitive Impairment
11486108|NCT01453127|Experimental|REM sleep behavior disorder|REM sleep behavior disorder
11486109|NCT01453114|Experimental|Psychotherapy|Cognitive Behavioral Therapy
11486110|NCT01453101|Other|Fludarabine, Melphalan, Bortezomib|
11486111|NCT01453088|Active Comparator|Treatment A|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.
~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.
~Dosing will be based on body surface area calculated using actual body weight
~Stem cell infusion:
~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.
~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
11486112|NCT01453088|Experimental|Treatment Arm B|"Bortezomib:
~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
11486113|NCT01453075|Experimental|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
11486114|NCT01453075|Placebo Comparator|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
11486115|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
11486116|NCT01453049|Experimental|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
11486117|NCT01453049|Active Comparator|glimepiride|1mg, 2mg, 4mg
11486118|NCT01453036|Active Comparator|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
11486119|NCT01453036|Active Comparator|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
11486120|NCT01453036|Active Comparator|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
11486121|NCT01453023|Active Comparator|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
11486122|NCT01453023|Experimental|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
11486123|NCT01453010|Experimental|8 individual case reviews|SaeboFlex Self-directed training
11486124|NCT01452997|Active Comparator|Ibuprofen Gel|Ibuprofen 5% gel
11486125|NCT01452997|Placebo Comparator|Ibuprofen placebo|K-Y jelly
11486126|NCT01452997|Active Comparator|Eumovate|0.05% w/w clobetasone butyrate
11486127|NCT01452997|Placebo Comparator|Cream Placebo|Aqueous Cream B.P.
11486128|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
11486191|NCT01452620||EVAR cohort|All consecutive patients undergoing endovascular AAA repair (EVAR) in our community setting were followed for outcomes.
11486129|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
11486130|NCT01452958|Experimental|TNF-α|Beromun, Boehringer-Ingelheim, Germany
11486131|NCT01452958|Experimental|Endotoxin|
11486132|NCT01452932|Experimental|Physiotherapy|Group of participants who recive physiotherapy treatment using Kabat technique for the upper limbs resistance training during 12 weeks
11486133|NCT01452932|Other|Yoga|Group of participants who recive Yoga sessions during 12 weeks
11486134|NCT01452919|Experimental|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.
~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
11486135|NCT01452919|Placebo Comparator|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.
~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
11486136|NCT01452906|Experimental|PA21 and Omeprazole with food|
11486137|NCT01452906|Experimental|No PA21; Omeprazole with food|
11486138|NCT01452906|Experimental|PA21 with food, Omeprazole 2 hrs later|
11486139|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
11486140|NCT01452893||Addison's disease|Adult patients with Addison's disease
11486141|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
11486142|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
11486143|NCT01452867|Active Comparator|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
11486144|NCT01452867|Active Comparator|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
11486145|NCT01452867|Active Comparator|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
11486146|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
11486147|NCT01452841|Experimental|Grapefruit Consumption|
11486148|NCT01452841|Active Comparator|Control|
11486149|NCT01452828|Experimental|Renal Impairment Nondialyzed|
11486150|NCT01452828|Experimental|Renal Impairment Dialyzed|
11486151|NCT01452828|Experimental|Matched Control|
11486152|NCT01452815|Placebo Comparator|1|Drug: placebo
11486153|NCT01452815|Experimental|2|10mg TZP-102
11486154|NCT01452815|Experimental|3|20mg TZP-102
11486155|NCT01452802||HM II (HeartMate II LVAD)|Subjects who elect to, and receive HM II LVAD therapy at baseline
11486156|NCT01452802||OMM (Optimal Medical Management)|Subjects who elect to remain on optimal medical management
11486157|NCT01452789|Experimental|sublingual buprenorphine|This is the group that received active sublingual buprenorphine and placebo for oral morphine
11486158|NCT01452789|Active Comparator|oral morphine|This is the group that received active oral morphine and placebo for sublingual buprenorphine
11486159|NCT01452776|Experimental|TAK-438 10 mg QD|
11486160|NCT01452776|Experimental|TAK-438 20 mg QD|
11486161|NCT01452763|Experimental|TAK-438 10 mg QD|
11486162|NCT01452763|Experimental|TAK-438 20 mg QD|
11486163|NCT01452763|Active Comparator|Lansoprazole 15 mg QD|
11486164|NCT01452750|Experimental|TAK-438 10 mg QD|
11486165|NCT01452750|Experimental|TAK-438 20 mg QD|
11486166|NCT01452750|Active Comparator|Lansoprazole 15 mg QD|
11486167|NCT01452737|Experimental|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
11486168|NCT01452737|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
11486169|NCT01452724|Experimental|TAK-438 20 mg QD|
11486170|NCT01452724|Active Comparator|Lansoprazole 30 mg QD|
11486171|NCT01452711|Experimental|TAK-438 20 mg QD|
11486172|NCT01452711|Active Comparator|Lansoprazole 30 mg QD|
11486173|NCT01452698|Experimental|TAK-438 20 mg QD|
11486174|NCT01452698|Active Comparator|AG-1749 30 mg QD|
11486175|NCT01452685|Placebo Comparator|Placebo|
11486176|NCT01452685|Experimental|TAK-385 10 mg QD|
11486177|NCT01452685|Experimental|TAK-385 20 mg QD|
11486178|NCT01452685|Experimental|TAK-385 40 mg QD|
11486179|NCT01452685|Other|Leuplin|
11486180|NCT01452672|Active Comparator|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
11486181|NCT01452672|Experimental|RT to chest wall|Irradiation of the chest-wall alone
11486182|NCT01452659|Experimental|TAK-385 10 mg QD|
11486183|NCT01452659|Experimental|TAK-385 20 mg QD|
11486184|NCT01452659|Experimental|TAK-385 40 mg QD|
11486185|NCT01452659|Placebo Comparator|Placebo|
11486186|NCT01452646|Experimental|MRD-directed therapy|
11486187|NCT01452633|Placebo Comparator|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
11486188|NCT01452633|Active Comparator|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
11486189|NCT01452633|Placebo Comparator|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
11486190|NCT01452633|Active Comparator|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
11486244|NCT01452256|Experimental|Propofol|
11486192|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
11486193|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
11486194|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
11486195|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
11486196|NCT01452607|Placebo Comparator|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
11486197|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
11486198|NCT01452581|Active Comparator|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.
~(1 unit at a time followed by evaluation of the primary outcome measure)"
11486199|NCT01452581|Placebo Comparator|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
11486200|NCT01452568|Experimental|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
11486201|NCT01452568|Active Comparator|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
11486202|NCT01452555|Active Comparator|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
11486203|NCT01452555|Experimental|Video Presentation|Participants will watch an HIV and HIV testing video
11486204|NCT01452542|Experimental|Sequence 1|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: TRTR, with a 7-day washout between dosing in each period.
11486205|NCT01452542|Experimental|Sequence 2|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: RTRT, with a 7-day washout between dosing in each period.
11486206|NCT01452529|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
11486207|NCT01452529|Placebo Comparator|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
11486208|NCT01452516|Other|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
11486209|NCT01452503|Active Comparator|PATH Women's Condom|PATH Women's Condom
11486210|NCT01452503|Active Comparator|FC2 female condom|Female Health Company's FC2 female condom
11486211|NCT01452503|Active Comparator|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
11486212|NCT01452490|Experimental|Diode Laser Treatment|
11486213|NCT01452477|Active Comparator|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
11486214|NCT01452477|Placebo Comparator|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
11486215|NCT01452464||MenACYW-CRM vaccinated adolescents|All adolescent recipients of MenACYW-CRM vaccines during the study period. Among these, adolescents who have additionally experienced an event of interest within the 1-year observation period following vaccination will be included in the self-controlled case series.
11486216|NCT01452451|Placebo Comparator|Placebo|Placebo
11486217|NCT01452451|Active Comparator|HM11260C|HM11260C
11486218|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
11486219|NCT01452425|Experimental|Tourniquet|Inflation of a tourniquet
11486220|NCT01452412|Experimental|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
11486221|NCT01452412|Placebo Comparator|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
11486222|NCT01452399|Experimental|Shave Margins|
11486223|NCT01452399|Active Comparator|No shave margins|
11486224|NCT01452386||Experimental Group|
11486225|NCT01452386||Control Group|
11486226|NCT01452373|Placebo Comparator|Control (placebo)|
11486227|NCT01452373|Experimental|DHEA + Acolbifene|
11486228|NCT01452360||Collection of CKD patient group|
11486229|NCT01452360||Collection of CKD high-risk group|
11486230|NCT01452360||Collection of healthy control group|
11486231|NCT01452347|Experimental|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
11486232|NCT01452347|Active Comparator|warfarin|warfarin doses to maintain INR levels
11486233|NCT01452334|Experimental|Arm 1: BMS-936559|
11486234|NCT01452321|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
11486235|NCT01452321|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
11486236|NCT01452308|Experimental|Cohort 1|Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions.
11486237|NCT01452308|Experimental|Cohort 2|Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
11486238|NCT01452295|Experimental|AOCH patients|Patients with acute on chronic hepatitis
11486239|NCT01452295|Experimental|AAH patients|Patients with acute alcoholic hepatitis
11486240|NCT01452282||Ankle Brachial Index|
11486241|NCT01452269|Experimental|Immediate intervention group|This arm will receive the intervention immediately following baseline data collection.
11486242|NCT01452269|Experimental|Delayed intervention group|This arm will receive the intervention one year following the immediate intervention group.
11486243|NCT01452256|Experimental|Desflurane|Desflurane for pharmacological conditioning
11486245|NCT01452243|Experimental|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
11486246|NCT01452230|Experimental|Supervised physical activity|
11486247|NCT01452230|No Intervention|Usual care|
11486248|NCT01452217|Experimental|Secretin|
11486249|NCT01452204|Experimental|Pulsed Electromagnetical Field|
11486250|NCT01452204|Placebo Comparator|Placebo|
11486251|NCT01452191|Active Comparator|Injury Prevention Briefing and facilitation|Children's Centres will be given an Injury Prevention Briefing which offers guidance on best evidence on reducing fire related injuries in the home, and facilitation by the research team to support implementation of the IPB
11486252|NCT01452191|Active Comparator|Injury Prevention Briefing only|Children's Centres will be given an Injury Prevention Briefing (IPB) , which offers guidance on best evidence on reducing fire related injuries in the home.
11486253|NCT01452191|No Intervention|Usual Care|
11486254|NCT01452152|Experimental|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
11486255|NCT01452152|Experimental|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
11486256|NCT01452152|No Intervention|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
11486257|NCT01452139|Experimental|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
11486258|NCT01452139|Active Comparator|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
11486259|NCT01452139|Active Comparator|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
11486260|NCT01452126|Experimental|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
11486261|NCT01452113|Other|neuropathy|patients with autonomic neuropathy
11486262|NCT01452113|Other|control|patients without autonomic neuropathy (ewing score <= 0.5)
11486263|NCT01452100|Experimental|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
11486264|NCT01452100|Placebo Comparator|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
11486265|NCT01452087|Other|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
11486266|NCT01452074|Other|Exercise Training with Weight Loss|"During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
~After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight"
11486267|NCT01452061||ASD|Participants with autism spectrum disorder.
11486268|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
11486269|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
11486270|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
11486271|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
11486272|NCT01452035|Experimental|Exercise|
11486273|NCT01452035|No Intervention|Sedentary Control|
11486274|NCT01452022|Experimental|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
11486275|NCT01452009|Experimental|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
11486276|NCT01452009|Active Comparator|TRAVATAN®|TRAVATAN® administered one drop once daily
11486277|NCT01451996|Other|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
11486278|NCT01451996|Other|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
11486279|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
11486280|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
11486281|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
11486282|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
11486283|NCT01451970|Other|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
11486284|NCT01451970|Other|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
11486285|NCT01451957|Experimental|Exercise|90 min exercise on Day 1
11486286|NCT01451957|Experimental|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
11486287|NCT01451944|Experimental|asthma education and case management|asthma education and case management
11486288|NCT01451931|Experimental|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
11486289|NCT01451931|Experimental|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
11486290|NCT01451931|Experimental|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
11486291|NCT01451918|Active Comparator|Resveratrol|
11486292|NCT01451918|Placebo Comparator|Placebo|
11486293|NCT01451905|Active Comparator|Psoriasis|
11486294|NCT01451905|Placebo Comparator|Placebo|
11486295|NCT01451892|Experimental|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
11486296|NCT01451892|Active Comparator|Education|overweight individuals participating in a patient education ambulatory program for obese people
11486297|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
11486298|NCT01451866|Active Comparator|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
11486299|NCT01451866|Experimental|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
11486300|NCT01451853|Active Comparator|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
11486301|NCT01451853|Active Comparator|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
11486302|NCT01451853|Active Comparator|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
11486303|NCT01451853|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
11486304|NCT01451840|Active Comparator|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia
11486305|NCT01451840|Experimental|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
11486306|NCT01451827|Experimental|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
11486307|NCT01451827|Experimental|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
11486308|NCT01451827|Experimental|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
11486309|NCT01451827|Placebo Comparator|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
11486310|NCT01451814|Experimental|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
11486311|NCT01451814|Active Comparator|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
11486312|NCT01451801|Other|HBsAg|
11486313|NCT01451788|No Intervention|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
11486314|NCT01451788|Experimental|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
11486315|NCT01451775|Experimental|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
11486316|NCT01451775|Experimental|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
11486317|NCT01451775|Experimental|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
11486318|NCT01451762|Placebo Comparator|Placebo|.9 normal saline IV
11486319|NCT01451762|Active Comparator|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
11486320|NCT01451762|Active Comparator|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
11486321|NCT01451749|Experimental|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.
~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
11486322|NCT01451749|Active Comparator|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.
~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
11486323|NCT01451736|Experimental|paliperidone palmitate (Invega Sustenna)|Participants will be provided paliperidone palmitate (Invega Sustenna), administered in injectible long-acting form, plus group skills training and case management
11486324|NCT01451736|Active Comparator|oral risperidone|Participants will be provided oral risperidone, plus group skills training and case management
11486325|NCT01451723|Experimental|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
11486326|NCT01451723|Placebo Comparator|Placebo|Matching placebo capsules.
11486327|NCT01451710|Experimental|Prednisone or Prednisolone|
11486366|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
11486556|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
11486328|NCT01451697|Experimental|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, & Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
11486329|NCT01451697|Placebo Comparator|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
11486330|NCT01451658|No Intervention|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
11486331|NCT01451658|Experimental|Endoscopic treatment combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
11486332|NCT01451645|Other|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
11486333|NCT01451645|Active Comparator|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
11486334|NCT01451632|Experimental|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
11486335|NCT01451632|Experimental|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
11486336|NCT01451619|Experimental|Laropiprant|
11486337|NCT01451619|Placebo Comparator|Placebo|
11486338|NCT01451606|Placebo Comparator|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
11486339|NCT01451606|Active Comparator|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
11486340|NCT01451593|Experimental|phenytoin|active arm of trial 1:1 allocation active versus placebo
11486341|NCT01451593|Placebo Comparator|placebo|1:1 allocation active versus placebo
11486342|NCT01451554|Active Comparator|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
11486343|NCT01451554|Placebo Comparator|Usual Care|Provided with self-help booklets on diet and exercise.
11486344|NCT01451541|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
11486345|NCT01451541|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
11486346|NCT01451541|Placebo Comparator|Placebo|
11486347|NCT01451528|Experimental|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation
11486348|NCT01451515|Experimental|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:
~Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine
~Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine
~Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate
~Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide
~All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
11486349|NCT01451502|Experimental|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.
~Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride
~Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.
~Infusion of minimally manipulated unlicensed UCB units:
~vital signs Monitoring during and after UCB infusion:
~Management of infusion reactions
~Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
11486350|NCT01451489|Active Comparator|Cyclophosphamide|CTX
11486351|NCT01451489|Experimental|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
11486352|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
11486353|NCT01451450|Experimental|QGE031 A|
11486354|NCT01451450|Experimental|QGE031 B|
11486355|NCT01451450|Experimental|QGE031 C|
11486356|NCT01451450|Experimental|QGE031 D|
11486357|NCT01451450|Placebo Comparator|Placebo A|
11486358|NCT01451450|Placebo Comparator|Placebo B|
11486359|NCT01451450|Placebo Comparator|Placebo C|
11486360|NCT01451450|Placebo Comparator|Placebo D|
11486361|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
11486362|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
11486363|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
11486364|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
11486365|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
11486745|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
11486367|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
11486368|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
11486369|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
11486370|NCT01451424|Experimental|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
11486371|NCT01451424|Experimental|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
11486372|NCT01451424|Experimental|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
11486373|NCT01451424|Experimental|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
11486374|NCT01451424|Experimental|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
11486375|NCT01451411|Experimental|Conivaptan hydrochloride|
11486376|NCT01451411|Placebo Comparator|Placebo|
11486377|NCT01451398|Experimental|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
11486378|NCT01451398|Placebo Comparator|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
11486379|NCT01451385|Experimental|COV795|Participants receive 2 tablets of COV795 every 12 hours for up to 35 days
11486380|NCT01451359|Experimental|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
11486381|NCT01451346|Placebo Comparator|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
11486382|NCT01451346|Experimental|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
11486383|NCT01451333|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
11486384|NCT01451333|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
11486385|NCT01451320|Active Comparator|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
11486386|NCT01451320|Active Comparator|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
11486387|NCT01451320|Active Comparator|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
11486388|NCT01451320|Active Comparator|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
11486389|NCT01451320|Active Comparator|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
11486390|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
11486391|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
11486392|NCT01451294|Active Comparator|Ephedrine|
11486393|NCT01451294|Active Comparator|Phenylephrine|
11486394|NCT01451268|Experimental|Panobinostat Arm A|
11486395|NCT01451268|Experimental|Panobinostat Arm B|
11486396|NCT01451242||brain injury|
11486397|NCT01451216||ABI 50-70 y|patients suffering from acquired brain injury aged 50-70 years old
11486398|NCT01451216||ABI 25-50y|Patients suffering from acquired brain injury aged 25-50 years oled
11486399|NCT01451203|Placebo Comparator|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
11486400|NCT01451203|Experimental|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
11486401|NCT01451190|Experimental|Treated|
11486402|NCT01451177|Experimental|Treated|
11486403|NCT01451164|Experimental|High dose|
11486404|NCT01451164|Experimental|Mid dose|
11486405|NCT01451164|Experimental|Low dose|
11486406|NCT01451164|Placebo Comparator|Placebo|
11486407|NCT01451151|Experimental|Treated|
11486408|NCT01451138|Experimental|Treated|
11486409|NCT01451125|Experimental|Treated|
11486410|NCT01451112|Experimental|Treated|
11486411|NCT01451086|Experimental|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
11486412|NCT01451086|Active Comparator|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
11486413|NCT01451034|Active Comparator|WHYX cancer group|WHYX cancer diagnosed by pathologic report
11486414|NCT01451034|Placebo Comparator|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
11486415|NCT01450995|Active Comparator|Treximet|
11486416|NCT01450995|Active Comparator|Imitrex and Aleve|
11486417|NCT01450982|Experimental|001|JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily.
11486418|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
11486419|NCT01450956|Experimental|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
11486420|NCT01450956|No Intervention|Control|Patients will receive only oxygen and air through oxygenator
11486421|NCT01450943|Active Comparator|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
11486422|NCT01450943|Experimental|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
11486423|NCT01450943|Experimental|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
11486424|NCT01450930|Active Comparator|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
11486425|NCT01450930|Active Comparator|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
11486426|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
11486427|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
11486428|NCT01450917||Group C|Non brachial plexus injured patients
11486429|NCT01450904|Experimental|Group A|The length of Quadriceps incision was less than 2 cm.
11486430|NCT01450904|Experimental|Group B|The length of Quadriceps incision was 2 to 4 cm.
11486431|NCT01450904|Experimental|Group C|The length of Quadriceps incision was more than 4 cm.
11486432|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
11486433|NCT01450878|Experimental|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
11486434|NCT01450878|No Intervention|graft without EPO|no injection befoe organ retrieval
11486435|NCT01450865|Experimental|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
11486436|NCT01450865|Experimental|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
11486437|NCT01450852|Experimental|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
11486438|NCT01450852|No Intervention|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
11486439|NCT01450839|Experimental|E2020 5 mg tablet and tape|
11486440|NCT01450839|Placebo Comparator|2|
11486441|NCT01450826|Active Comparator|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
11486442|NCT01450826|Active Comparator|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
11486443|NCT01450813|Sham Comparator|Group 1|Saline 0.06 ml/kg
11486444|NCT01450813|Active Comparator|Group 2|Rocuronium 0.2 mg/kg
11486445|NCT01450813|Active Comparator|Group 3|Rocuronium 0.4 mg/kg
11486446|NCT01450813|Active Comparator|Group 4|Rocuronium 0.6 mg/kg
11486447|NCT01450800|Active Comparator|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
11486448|NCT01450800|Placebo Comparator|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
11486449|NCT01450787||diabetics|diabetics
11486450|NCT01450787||non diabetics|non diabetics
11486451|NCT01450774|Experimental|CHF 1535 50/6µg|
11486452|NCT01450774|Active Comparator|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
11486453|NCT01450761|Experimental|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached
~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles
~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses
~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
11486454|NCT01450761|Placebo Comparator|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached
~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles
~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses
~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
11486455|NCT01450748|Experimental|Sodium alginate|oral suspension, 50 mg/ml
11486456|NCT01450748|Placebo Comparator|Placebo|oral suspension without active ingredient
11486457|NCT01450722|Active Comparator|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
11486458|NCT01450722|Active Comparator|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
11486459|NCT01450709||Dialysis patients|
11486508|NCT01450306|Experimental|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
11486557|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
11486460|NCT01450696|Active Comparator|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
11486461|NCT01450696|Experimental|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
11486462|NCT01450683|Experimental|Itraconazole|600 mg/day oral (PO)
11486463|NCT01450670||Dialysis patients|
11486464|NCT01450657||Chronic Kidney Failure 3/4|
11486465|NCT01450644|Other|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
11486466|NCT01450644|Other|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
11486467|NCT01450631|Active Comparator|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
11486468|NCT01450631|Experimental|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
11486469|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
11486470|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
11486471|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
11486472|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
11486473|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
11486474|NCT01450592||Group 1|
11486475|NCT01450592||Group 2|
11486476|NCT01450579|Placebo Comparator|Placebo|Saline
11486477|NCT01450579|Experimental|Dose -1|ASP7373
11486478|NCT01450579|Experimental|Dose -2|ASP7373
11486479|NCT01450579|Experimental|Dose -3|ASP7373
11486480|NCT01450566|Experimental|Lidocaine|Use of lidocaine
11486481|NCT01450566|Placebo Comparator|No lidocaine|No lidocaine/standard of care
11486482|NCT01450527||Patient fulfilling the criteria of ARDS|
11486483|NCT01450514|Placebo Comparator|Placebo|Sugar pill
11486484|NCT01450514|Experimental|Pipamperone|15 mg once daily
11486485|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
11486486|NCT01450488|Experimental|masitinib 3 mg/kg/day|
11486487|NCT01450488|Experimental|masitinib 6 mg/kg/day|
11486488|NCT01450475|Experimental|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
11486489|NCT01450475|No Intervention|control|A blood cuff was around leg without inflation or deflation.
11486490|NCT01450462|Experimental|Vitamin D (cholecalciferol)|
11486491|NCT01450462|Placebo Comparator|Placebo|
11486492|NCT01450449|Experimental|Arm 1 - Short Course Radiotherapy|Short Course
11486493|NCT01450449|Active Comparator|Arm 2 - Standard Course Radiotherapy|Standard Course
11486494|NCT01450436||preterm infants (<35 weeks gestation)|
11486495|NCT01450423|Experimental|Physical activity|
11486496|NCT01450423|No Intervention|Control|
11486497|NCT01450410|Active Comparator|Nicotinic Acid|
11486498|NCT01450410|Placebo Comparator|Placebo|
11486499|NCT01450397|Other|XIAFLEX|XIAFlEX
11486500|NCT01450384|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11486501|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
11486502|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
11486503|NCT01450358|Active Comparator|Pathogen detection by Multiplex PCR|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. Multiplex PCR will be immediately undertaken and its results will be reported to prompt medical researcher (6-12 hours).The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR.
11486504|NCT01450358|No Intervention|Pathogen detection by blood culture|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
11486505|NCT01450345|Experimental|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
11486506|NCT01450332|Experimental|study|
11486507|NCT01450319|Experimental|Cetuximab|
11486746|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
11486509|NCT01450306|Placebo Comparator|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
11486510|NCT01450293|Experimental|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
11486511|NCT01450293|Experimental|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
11486512|NCT01450293|No Intervention|Group C|5 to 12 months old infants; no vaccination
11486513|NCT01450293|Experimental|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
11486514|NCT01450293|Experimental|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
11486515|NCT01450293|No Intervention|Group F|10 week old babies; no vaccination
11486516|NCT01450280|Experimental|Group 1A|AdCh63 CS 5x10^9 vp
11486517|NCT01450280|Experimental|Group 1B|ChAd63 CS 5x10^9 vp Day 0; MVA CS 2x10^8 pfu Day 56
11486518|NCT01450280|Experimental|Group 2A|AdCh63 CS 5 x 10^10 vp
11486519|NCT01450280|Experimental|Group 2B|ChAd63 CS 5x10^10 vp Day 0; MVA CS 2x10^8 pfu Day 56
11486520|NCT01450267|Placebo Comparator|Physiological solution|
11486521|NCT01450267|Experimental|Reduced Inhaled Glutathione|
11486522|NCT01450254|Experimental|Experimental|These patients will carry out a therapy program with the study intervention device.
11486523|NCT01450254|Active Comparator|Control|The patients in this group will not carry out a therapy program with the study intervention device.
11486524|NCT01450241|Experimental|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
11486525|NCT01450241|Other|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
11486526|NCT01450228|Placebo Comparator|Placebo KI1001|
11486527|NCT01450228|Experimental|KI1001|
11486528|NCT01450215|Experimental|Revlimid|
11486529|NCT01450215|No Intervention|Revlimid and dexamethasone|
11486530|NCT01450202|Placebo Comparator|Air insufflation, colonoscopy, esophagogastroduodenoscopy|
11486531|NCT01450202|Active Comparator|CO2 insufflation, colonoscopy, esophagogastroduodenoscopy|
11486532|NCT01450189|Active Comparator|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
11486533|NCT01450189|Active Comparator|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
11486534|NCT01450189|Active Comparator|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
11486535|NCT01450176|Active Comparator|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
11486536|NCT01450176|Active Comparator|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
11486537|NCT01450163|Active Comparator|Pregabalin|
11486538|NCT01450163|Placebo Comparator|Placebo|
11486539|NCT01450150|Experimental|Active tDCS|
11486540|NCT01450150|Sham Comparator|Sham tDCS|
11486541|NCT01450137|Experimental|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
11486542|NCT01450137|Placebo Comparator|Placebo|Placebo every 4 weeks until week 52.
11486543|NCT01450124|Experimental|Boswellic acids (BOSWELAN)|Baseline to treatment single arm - 4 months baseline and 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg of BOSWELAN.
11486544|NCT01450111|Experimental|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
11486545|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
11486546|NCT01450111|Experimental|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
11486547|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
11486548|NCT01450111|Experimental|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
11486549|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
11486550|NCT01450098|Experimental|Cohort A: Fixed Sequence of Meal Conditions|LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only, as an SDSD-PG tablet given with no food. There was a washout of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low-fat breakfast. There was another washout period of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high-fat breakfast.
11486551|NCT01450098|Experimental|Cohort B: Comparison of Randomized Treatments|LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
11486552|NCT01450085|Active Comparator|GeneXpert|Point of care GeneXpert
11486553|NCT01450085|Active Comparator|LED Microscopy|Point of care LED Microscopy
11486554|NCT01450072|Sham Comparator|Control arm|Venography and sham angioplasty
11486555|NCT01450072|Active Comparator|Active arm|therapeutic balloon angioplasty
11486558|NCT01450046|Experimental|Phase I Dose Escalation|Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
11486559|NCT01450033|No Intervention|Control group|Standard of care
11486560|NCT01450033|Experimental|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
11486561|NCT01450020|Experimental|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
11486562|NCT01450020|Active Comparator|Arm II (ACS material)|Participants receive ACS materials only.
11486563|NCT01450007|Experimental|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
11486564|NCT01450007|Active Comparator|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
11486565|NCT01450007|Placebo Comparator|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
11486566|NCT01449994|Placebo Comparator|Placebo-Activator|Treatment with Placebo Activator IV
11486567|NCT01449994|Active Comparator|Activator|Treatment with Activator IV adjusting instrument
11486568|NCT01449981|Experimental|Integrated Twelve-Step Facilitation|
11486569|NCT01449981|Experimental|Cognitive Behavioral Therapy|
11486570|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
11486571|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
11486572|NCT01449955|Placebo Comparator|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
11486573|NCT01449955|Active Comparator|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
11486574|NCT01449942|Experimental|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
11486575|NCT01449942|Placebo Comparator|Saline|Placebo group receives saline injection in combination with radiation therapy.
11486576|NCT01449929|Experimental|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
11486577|NCT01449929|Active Comparator|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
11486578|NCT01449916|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
11486579|NCT01449916|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders
11486580|NCT01449903||Rebilda DC|
11486581|NCT01449903||Clearfil Core DC / Plus|
11486582|NCT01449903||Multicore Flow|
11486583|NCT01449890|Experimental|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
11486584|NCT01449890|No Intervention|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
11486585|NCT01449877|Active Comparator|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
11486586|NCT01449877|Placebo Comparator|Starch tablet|1 starch tablet every other day, morning.
11486587|NCT01449864|Experimental|Proton RT|Subjects receive proton radiation
11486588|NCT01449838|Placebo Comparator|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
11486589|NCT01449838|Experimental|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
11486590|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
11486591|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
11486592|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
11486593|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
11486594|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
11486638|NCT01449578|Placebo Comparator|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
11486639|NCT01449578|Experimental|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
11486595|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
11486596|NCT01449812|Active Comparator|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
11486597|NCT01449799|Experimental|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
11486598|NCT01449799|Experimental|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
11486599|NCT01449799|Experimental|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
11486600|NCT01449799|Experimental|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
11486601|NCT01449786|Experimental|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
11486602|NCT01449786|Active Comparator|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
11486603|NCT01449786|Placebo Comparator|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
11486604|NCT01449773|Experimental|n-3 PUFAs|
11486605|NCT01449773|Placebo Comparator|Corn and soybean oil pill|
11486606|NCT01449760|No Intervention|No treatment|
11486607|NCT01449760|Active Comparator|Physical Therapy|
11486608|NCT01449760|Experimental|Wii Balance group|
11486609|NCT01449747|Active Comparator|study group|sitagliptin hypo-response patients
11486610|NCT01449747|Sham Comparator|control group|sitagliptin response patients
11486611|NCT01449721|No Intervention|Control|Standard medical care by the primary treatment team.
11486612|NCT01449721|Experimental|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
11486613|NCT01449708|No Intervention|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
11486614|NCT01449708|Active Comparator|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
11486615|NCT01449695|Experimental|Lifestyle counseling|Group consultation and individual nurse consultation
11486616|NCT01449695|Experimental|e health|An individual web based entry
11486617|NCT01449695|No Intervention|usual care|Usual care
11486618|NCT01449682|Active Comparator|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
11486619|NCT01449682|Active Comparator|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
11486620|NCT01449656||LMA proseal|
11486621|NCT01449656||LMA Supreme|
11486622|NCT01449643|Active Comparator|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
11486623|NCT01449643|Sham Comparator|Sham Group|Non-training protocol
11486624|NCT01449630|Experimental|LY3031207|Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.
11486625|NCT01449630|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
11486626|NCT01449630|Active Comparator|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
11486627|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
11486628|NCT01449604|Active Comparator|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
11486629|NCT01449604|Active Comparator|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
11486630|NCT01449591|Experimental|BFH772|
11486631|NCT01449591|Placebo Comparator|Vehicle|
11486632|NCT01449591|Active Comparator|Metronidazole|
11486633|NCT01449578|Experimental|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
11486634|NCT01449578|Placebo Comparator|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
11486635|NCT01449578|Experimental|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
11486636|NCT01449578|Placebo Comparator|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
11486637|NCT01449578|Experimental|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
11486640|NCT01449578|Placebo Comparator|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
11486641|NCT01449578|Experimental|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
11486642|NCT01449578|Placebo Comparator|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
11486643|NCT01449565|Active Comparator|Naltrexone|
11486644|NCT01449565|Placebo Comparator|Placebo|
11486645|NCT01449552|Experimental|Group A|No clamp and placebo
11486646|NCT01449552|Experimental|Group B|Tranexamic acid
11486647|NCT01449552|Experimental|Group C|Drain clamping
11486648|NCT01449552|Experimental|Group D|Drain clamping and tranexamic acid
11486649|NCT01449526|Experimental|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
11486650|NCT01449526|Active Comparator|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
11486651|NCT01449513|Active Comparator|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
11486652|NCT01449513|Placebo Comparator|Placebo Gel|Vehicle of PEP005 Gel
11486653|NCT01449500|Placebo Comparator|Placebo|Placebo
11486654|NCT01449500|Active Comparator|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
11486655|NCT01449487|Active Comparator|PPC-5650|
11486656|NCT01449487|Placebo Comparator|Placebo|
11486657|NCT01449474|Experimental|Group 1|Patient matched instruments
11486658|NCT01449474|Experimental|Group 2|Jig based instruments
11486659|NCT01449461|Experimental|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (approximately, up to 44.4 months).
11486660|NCT01449461|Experimental|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, once daily (QD) in each cycle of 28 days (approximately, up to 44.4 months).
11486661|NCT01449461|Experimental|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (approximately, up to 44.4 months).
11486662|NCT01449461|Experimental|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
11486663|NCT01449461|Experimental|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, twice daily (BID), tablets, orally in each cycle of 28 days (approximately, up to 44.4 months).
11486664|NCT01449461|Experimental|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, once daily (QD) or 120 mg, twice daily (BID) or 300 mg once daily, tablets, orally, in each cycle of 28 days (approximately, up to 44.4 months).
11486665|NCT01449448|Experimental|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
11486666|NCT01449448|Active Comparator|Steroid|This group was given a subacromial injection triamcinolone.
11486667|NCT01449422|Experimental|URGO 310 3082|
11486668|NCT01449422|Active Comparator|Aquacel|
11486669|NCT01449409|No Intervention|Usual care|
11486670|NCT01449409|Experimental|Real-time asthma care outreach|
11486671|NCT01449396|Sham Comparator|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
11486672|NCT01449396|Experimental|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
11486673|NCT01449396|Other|Control|Bed Rest
11486674|NCT01449383|Active Comparator|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
11486675|NCT01449383|Active Comparator|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
11486676|NCT01449370|Experimental|Arm A|TAK-117 administered once a day orally
11486677|NCT01449370|Experimental|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
11486678|NCT01449370|Experimental|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
11486679|NCT01449357|Experimental|zalutumumab|
11486680|NCT01449344|Experimental|R-HAD + Bortezomib|
11486681|NCT01449344|Active Comparator|R-HAD|
11486682|NCT01449318|No Intervention|Patients undergoing hysterectomy|
11486683|NCT01449305|Experimental|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
11486684|NCT01449292|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
11486685|NCT01449292|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
11486686|NCT01449279|Experimental|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
11486687|NCT01449266|Other|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
11486688|NCT01449253|Active Comparator|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
11486689|NCT01449253|Active Comparator|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
11486690|NCT01449253|Active Comparator|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
11486691|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
11486692|NCT01449214|Experimental|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
11486693|NCT01449214|Active Comparator|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
11486694|NCT01449201|Experimental|PF-00299804|
11486695|NCT01449188|Active Comparator|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
11486696|NCT01449188|Active Comparator|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
11486697|NCT01449188|Placebo Comparator|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
11486698|NCT01449188|Active Comparator|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
11486699|NCT01449162|Experimental|Masitinib as add-on to oral corticosteroids|Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
11486700|NCT01449162|Placebo Comparator|Placebo as add-on to oral corticosteroids|Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
11486701|NCT01449149|Experimental|Proton group|Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
11486702|NCT01449136|Experimental|antibacterial cement|
11486703|NCT01449123|Experimental|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
11486704|NCT01449110|Placebo Comparator|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
11486705|NCT01449110|Placebo Comparator|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
11486706|NCT01449110|Active Comparator|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
11486707|NCT01449110|Active Comparator|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
11486708|NCT01449110|Experimental|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
11486709|NCT01449110|Experimental|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
11486710|NCT01449097|Experimental|Adductor-Canal-Blockade|
11486711|NCT01449097|Active Comparator|The femoral nerve block|
11486712|NCT01449097|Placebo Comparator|Placebo|
11486713|NCT01449084|Active Comparator|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
11486714|NCT01449084|No Intervention|leaving the stent in place|the pancreatic duct stent is left in place
11486715|NCT01449071|Placebo Comparator|Placebo Group|
11486716|NCT01449071|Experimental|Epratuzumab 600 mg Group|
11486717|NCT01449071|Experimental|Epratuzumab 100 mg Group|
11486718|NCT01449071|Experimental|Epratuzumab 400 mg Group|
11486719|NCT01449071|Experimental|Epratuzumab 1200 mg Group|
11486720|NCT01449058|Experimental|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
11486721|NCT01449045|Placebo Comparator|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
11486722|NCT01449045|Experimental|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
11486723|NCT01449032|Active Comparator|MSC|Adipose derived stem cells
11486724|NCT01449032|Placebo Comparator|Saline|
11486725|NCT01449019|Active Comparator|intravenous infusion|
11486726|NCT01449019|Experimental|intraduodenal perfusion|
11486727|NCT01449006|No Intervention|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
11486728|NCT01449006|Experimental|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
11486729|NCT01448993|Placebo Comparator|Placebo|Taking placebo 3 times per week for four weeks
11486730|NCT01448993|Active Comparator|AZI|
11486731|NCT01448980|Active Comparator|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
11486732|NCT01448980|Experimental|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
11486733|NCT01448954|Experimental|ADC3680B oral|
11486734|NCT01448954|Placebo Comparator|Placebo oral|
11486735|NCT01448941|Active Comparator|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
11486736|NCT01448941|Experimental|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
11486737|NCT01448928||Group 1|
11486738|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
11486739|NCT01448902|Experimental|OC000459|
11486740|NCT01448902|Placebo Comparator|Placebo|
11486741|NCT01448889|Active Comparator|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
11486742|NCT01448889|Placebo Comparator|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
11486743|NCT01448876||chlamydia care as usual|
11486744|NCT01448863||CONTROL|Fertile women (egg-donors)
11486747|NCT01448850|Placebo Comparator|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
11486748|NCT01448850|Experimental|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
11486749|NCT01448837|Active Comparator|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
11486750|NCT01448837|Active Comparator|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
11486751|NCT01448824|Experimental|Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo|"Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.
~Washout period lasting ≥14 days.
~Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2."
11486752|NCT01448824|Experimental|Part 1 (Cohort B): 300 mg LY2484595, Placebo|Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
11486753|NCT01448824|Experimental|Part 1 (Cohort C): 600 mg LY2484595, Placebo|Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
11486754|NCT01448824|Experimental|Part 1 (Cohort D): 1200 mg LY2484595, Placebo|Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
11486755|NCT01448824|Experimental|Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole|"Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.
~Washout period lasting ≥14 days.
~Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2."
11486756|NCT01448811|Experimental|AEP monitoring|
11486757|NCT01448811|Active Comparator|RSS monitoring|
11486758|NCT01448798|Experimental|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
11486759|NCT01448798|Sham Comparator|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
11486760|NCT01448785|Active Comparator|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
11486761|NCT01448785|Active Comparator|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
11486762|NCT01448772|Active Comparator|Marinol|
11486763|NCT01448772|Experimental|oral solution|
11486764|NCT01448746|Experimental|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
11486765|NCT01448733|Experimental|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
11486766|NCT01448720|Experimental|Paliperidone palmitate|
11486767|NCT01448707|Experimental|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of <200 cells/μL will also receive 2 N[t]RTIs (ie, triple therapy) as soon as possible
11486768|NCT01448707|Active Comparator|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N[t]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N[t]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
11486769|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
11486770|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
11486771|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
11486772|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
11486773|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
11486774|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
11486775|NCT01448642|Active Comparator|Atorvastatin|
11486776|NCT01448642|Placebo Comparator|Placebo|
11486777|NCT01448629|Experimental|River|
11486778|NCT01448629|Active Comparator|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
11486779|NCT01448616|No Intervention|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
11486780|NCT01448616|Experimental|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
11486781|NCT01448616|Experimental|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
11486782|NCT01448616|Placebo Comparator|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
11486783|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
11486784|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
11486785|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
11486786|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
11486787|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
11486788|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
11486789|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
11486790|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
11486791|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
11486792|NCT01448564|Active Comparator|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
11486793|NCT01448564|Placebo Comparator|Placebo Laser therapy|
11486794|NCT01448551|Experimental|Text Messaging|
11486795|NCT01448551|No Intervention|Control|Participation in the MPOWER program without receiving tailored text messages
11486796|NCT01448538||Group 1|
11486797|NCT01448525|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
11486798|NCT01448525|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
11486799|NCT01448512|Other|Usual Care|Participation in 4 time matched sessions on health education topics
11486800|NCT01448512|Experimental|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction & adherence.
11486801|NCT01448499|Experimental|Clozapine|Clozapine monotherapy
11486802|NCT01448499|Experimental|Amisulpride|Amisulpride monotherapy
11486803|NCT01448499|Experimental|Augmentation|Augmentation of clozapine with amisulpride
11486804|NCT01448486|No Intervention|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
11486805|NCT01448486|Experimental|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
11486806|NCT01448473|Experimental|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
11486807|NCT01448473|Active Comparator|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
11486808|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
11486809|NCT01448447|Experimental|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
11486810|NCT01448447|Experimental|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
11486811|NCT01448434|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
11486812|NCT01448434|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
11486813|NCT01448421|Experimental|Keystone Heart Embolic Deflection Device|Protected Transcatheter Aortic Valve Replacement
11486814|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
11486815|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
11486816|NCT01448395|Experimental|1|
11486817|NCT01448382|Experimental|Healthy volunteers|healthy volunteers
11486818|NCT01448382|Experimental|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
11486819|NCT01448369|Active Comparator|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
11486820|NCT01448369|Active Comparator|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
11486821|NCT01448369|Placebo Comparator|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
11486822|NCT01448356|Experimental|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:
~25°C and 45% humidity;
~25°C and 65% humidity;
~30°C and 45% humidity;
~30°C and 65% humidity"
11486823|NCT01448343|Experimental|FMS|Patients who received blood transfusion using FMS
11486824|NCT01448330|Experimental|HCP0911|clopidogrel/aspirin combination tablet
11486825|NCT01448330|Active Comparator|clopidorel and aspirin|coadministration of clopidogrel and aspirin
11486826|NCT01448317|Experimental|Cohort 1|Alirocumab dose 1 versus placebo
11486827|NCT01448317|Experimental|Cohort 2|Alirocumab dose 2 versus placebo
11486828|NCT01448317|Experimental|Cohort 3|Alirocumab dose 3 versus placebo
11486829|NCT01448317|Experimental|Cohort 4|Alirocumab dose 4 versus placebo
11486830|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
11486916|NCT01447654|Placebo Comparator|Placebo|
11486831|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
11486832|NCT01448291|Experimental|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
11486833|NCT01448278|Experimental|All-inside technique|
11486834|NCT01448278|Active Comparator|Classical technique|
11486835|NCT01448265|Experimental|Paroxysmal atrial fibrillation.|
11486836|NCT01448252|Active Comparator|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
11486837|NCT01448252|Sham Comparator|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
11486838|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
11486839|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
11486840|NCT01448226||proven or probable aspergillosis|
11486841|NCT01448226||possible aspergillosis|
11486842|NCT01448213|Active Comparator|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
11486843|NCT01448213|Active Comparator|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
11486844|NCT01448200|Experimental|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:
~Cohort A: PPI-668 dose D1 or placebo
~Cohort B: PPI-668 dose D2 or placebo
~Cohort C: PPI-668 dose D3 or placebo"
11486845|NCT01448200|Experimental|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:
~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
11486846|NCT01448200|Experimental|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:
~Cohort E (genotype-1): PPI-668 dose E1 or placebo
~Cohort F (genotype-1): PPI-668 dose E2 or placebo
~Cohort G (genotype-1): PPI-668 dose E3 or placebo
~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined
~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
11486847|NCT01448174|Active Comparator|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:
~will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)
~130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.
~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).
~The prospective, observational study:
~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
11486848|NCT01448174|No Intervention|Lifestyle counseling|"Protocol of the prospective study in obese persons:
~after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity
~follow-up for 30 weeks (measurement of body weight every week)."
11486849|NCT01448174|No Intervention|The controls (healthy volunteers)|
11486850|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
11486851|NCT01448148|Experimental|Cognitive intervention|Use of Memo protocol for 8 weeks
11486852|NCT01448148|Experimental|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
11486853|NCT01448148|No Intervention|no contact control group|waiting list
11486854|NCT01448135|Experimental|Vital AF|
11486855|NCT01448135|Active Comparator|Osmolite 1.2|
11486856|NCT01448122|Active Comparator|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
11486857|NCT01448122|No Intervention|No intervention|Half of the area to be exposed to visible light will have no study product applied.
11486858|NCT01448109|Active Comparator|Hydrocortisone|
11486859|NCT01448109|Placebo Comparator|Sterile air filled vial|
11486860|NCT01448096|Experimental|primary breast DLBCL|isolated breast involvement with or without nodal disease
11486861|NCT01448083||Neuroendocrine tumor patients|
11486862|NCT01448070|Experimental|NN729 manufacturing process|
11486863|NCT01448070|Active Comparator|Current manufacturing process|
11486864|NCT01448057|Experimental|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
11486865|NCT01448057|Active Comparator|Paracetamol tablets|Paracetamol (500 mg) tablets
11486866|NCT01448044|Experimental|BMS-790052 + PegIFNα-2a + Ribavirin|"BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks
~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response
~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
11486867|NCT01448044|Placebo Comparator|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks
~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks
~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
11486868|NCT01448031|Experimental|1|Capsule ASA 81mg/esomeprazole 20mg
11486869|NCT01448031|Active Comparator|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
11486870|NCT01448018|Active Comparator|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
11486871|NCT01448018|Active Comparator|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
11486872|NCT01448018|Active Comparator|ranibizumab and hemodilution|patients receive both treatments
11486873|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
11486874|NCT01447992|Experimental|Portable artificial pancreas system with Control-To-Range|
11486875|NCT01447979|Experimental|All patients|this is the only arm of the study, and concerns all patients.
11486876|NCT01447966|No Intervention|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
11486877|NCT01447966|Experimental|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
11486878|NCT01447953|Experimental|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
11486879|NCT01447953|Active Comparator|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
11486880|NCT01447940|Placebo Comparator|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
11486881|NCT01447940|Experimental|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
11486882|NCT01447927|Experimental|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
11486883|NCT01447927|Placebo Comparator|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
11486884|NCT01447914|Experimental|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
11486885|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
11486886|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
11486887|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
11486888|NCT01447888|Experimental|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
11486889|NCT01447888|Active Comparator|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
11486890|NCT01447862|Active Comparator|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
11486891|NCT01447862|Active Comparator|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
11486892|NCT01447849|Active Comparator|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
11486893|NCT01447849|Placebo Comparator|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
11486894|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
11486895|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
11486896|NCT01447810|Experimental|Treatment|
11486897|NCT01447797|Experimental|HCP0912|Irbesartan/Atorvastatin combination tablet
11486898|NCT01447797|Active Comparator|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
11486899|NCT01447784|Placebo Comparator|Placebo|
11486900|NCT01447784|Experimental|ToleroMune HDM Dose 1|
11486901|NCT01447784|Experimental|ToleroMune HDM Dose 2|
11486902|NCT01447784|Experimental|ToleroMune HDM Dose 3|
11486903|NCT01447771|Experimental|Lifestyle counseling|Decision control preference intervention
11486904|NCT01447758|Experimental|LEO 29102 2,5 mg/g cream|
11486905|NCT01447758|Placebo Comparator|LEO 29102 Cream Vehicle|
11486906|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
11486907|NCT01447732|Experimental|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
11486908|NCT01447732|Experimental|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
11486909|NCT01447706|Active Comparator|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
11486910|NCT01447706|Experimental|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
11486911|NCT01447680||Blood samples, low risk population|
11486912|NCT01447680||Blood samples, high risk population|
11486913|NCT01447680||Blood samples, known HIV positive|
11486914|NCT01447667|Experimental|Magnetic resonance elastography|Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
11486915|NCT01447654|Active Comparator|Losartan|
11486917|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
11486918|NCT01447628|Active Comparator|Ferinject or CosmoFer|"IV iron formulation used in Europe - Ferinject - given over 15 minutes
~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours"
11486919|NCT01447628|Placebo Comparator|Saline|Placebo comparator
11486920|NCT01447615|Experimental|Bridges|
11486921|NCT01447615|Experimental|Bridges PLUS|
11486922|NCT01447615|Other|Usual Care|
11486923|NCT01447602|Experimental|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
11486924|NCT01447589|Experimental|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
11486925|NCT01447576|Experimental|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
11486926|NCT01447563|Experimental|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
11486927|NCT01447563|Experimental|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
11486928|NCT01447550||Bosentan|Bosentan
11486929|NCT01447537|Active Comparator|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
11486930|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
11486931|NCT01447511|Other|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
11486932|NCT01447511|Other|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
11486933|NCT01447511|Other|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
11486934|NCT01447511|Other|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
11486935|NCT01447511|Other|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
11486936|NCT01447498|No Intervention|Control group|
11486937|NCT01447498|Active Comparator|Screening and risk assessment|
11486938|NCT01447485|Experimental|Valsartan 20 mg or 40 mg|
11486939|NCT01447472|Experimental|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
11486940|NCT01447459|Experimental|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.
~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
11486941|NCT01447459|No Intervention|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.
~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
11486942|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
11486943|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
11486944|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
11486945|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
11486946|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
11486947|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
11486948|NCT01447433|Experimental|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
11486949|NCT01447433|Placebo Comparator|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
11486950|NCT01447420|Experimental|Peginterferon Alfa-2a Plus Ribavirin|
11486951|NCT01447407|Active Comparator|NDV-3 vaccine with alum IM|300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM
11486952|NCT01447407|Active Comparator|NDV-3 vaccine without alum IM|300 ug Als3 in PBS per dose, one dose administered IM
11486953|NCT01447407|Placebo Comparator|Placebo IM|0.5 mg Al as alum in PBS per dose, one dose administered IM
11486954|NCT01447407|Active Comparator|NDV-3 vaccine without alum ID|30 ug Als3 in PBS per dose, one dose administered ID
11486955|NCT01447394|Experimental|Arm 1: Pegylated Interferon Lambda + Ribavirin|
11486956|NCT01447394|Active Comparator|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
11486957|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
11486958|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
11486959|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
11486960|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
11486961|NCT01447368|Experimental|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
11486962|NCT01447368|Active Comparator|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
11486963|NCT01447355|Experimental|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
11486964|NCT01447329|Experimental|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
11486965|NCT01447329|Placebo Comparator|standard|placebo
11486966|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
11486967|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
11486968|NCT01447290||Women being evaluated for preeclampsia|
11486969|NCT01447277|Experimental|Femoral and Sciatic Block|Administration of preoperative femoral and sciatic nerve blocks
11486970|NCT01447277|Other|Femoral Block Only|Administration of a femoral nerve block prior to surgery
11486971|NCT01447264|Placebo Comparator|Land exercises|The patients of this group will perform the same exercises from water exercises
11486972|NCT01447264|Active Comparator|Water exercises|The patients of this group will perform the same exercises from land exercises
11486973|NCT01447264|No Intervention|Control group|No intervention will be recommended
11486974|NCT01447251|Experimental|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
11486975|NCT01447251|Experimental|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
11486976|NCT01447251|Active Comparator|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
11486977|NCT01447251|Active Comparator|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
11486978|NCT01447225|Experimental|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
11486979|NCT01447225|Experimental|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
11486980|NCT01447225|Experimental|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
11486981|NCT01447225|Experimental|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
11486982|NCT01447212|Experimental|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
11486983|NCT01447212|Active Comparator|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
11486984|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
11486985|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
11486986|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
11486987|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
11486988|NCT01447173|Experimental|2000 IU vitamin D Daily|
11486989|NCT01447173|Placebo Comparator|400 IU Vitamin D pill|
11486990|NCT01447160|Experimental|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
11486991|NCT01447160|Active Comparator|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
11486992|NCT01447147|Placebo Comparator|Placebo (Group A)|
11486993|NCT01447147|Experimental|CCX140-B (Group B)|
11486994|NCT01447147|Experimental|CCX140-B (Group C)|
11486995|NCT01447134||Surgical|Group (a) [Those to undergo surgical excision or biopsy] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
11486996|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients [Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
11486997|NCT01447134||RGD-K5 scan|Group (c) patients [Those with M1 disease to receive biotherapy or chemotherapy] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
11486998|NCT01447121|Experimental|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
11486999|NCT01447108|Experimental|TN patients|Patients suffering from Trigeminal neuralgia
11487000|NCT01447095|Active Comparator|Low dose prostacyclin|
11487001|NCT01447095|Active Comparator|High dose prostacyclin|
11487002|NCT01447095|Placebo Comparator|Placebo|
11487003|NCT01447082||Quetiapine XR group|
11487004|NCT01447082||Non-quetiapine comparison group|
11487005|NCT01447069|Active Comparator|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
11487006|NCT01447069|No Intervention|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
11487007|NCT01447056|Experimental|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
11487008|NCT01447043||Group 1|
11487009|NCT01447017|Experimental|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
11487010|NCT01447017|Placebo Comparator|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
11487011|NCT01446991|Experimental|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
11487012|NCT01446991|Experimental|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
11487013|NCT01446978|Active Comparator|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
11487014|NCT01446978|Active Comparator|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
11487015|NCT01446965|Experimental|Wearable defibrillator|subjects in the Device Group will receive a wearable cardioverter-defibrillator plus guideline-directed medical therapy
11487016|NCT01446965|No Intervention|Conventional treatment|subjects in the Control Group will receive guideline-directed medical therapy alone
11487017|NCT01446952|Experimental|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
11487018|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
11487019|NCT01446939||Essential tremor|Patients with essential tremor
11487020|NCT01446939||Healthy volunteers|Healthy volunteers
11487021|NCT01446926|Experimental|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
11487022|NCT01446926|Placebo Comparator|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
11487023|NCT01446926|Experimental|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
11487024|NCT01446926|Placebo Comparator|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
11487025|NCT01446926|Experimental|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
11487026|NCT01446926|Placebo Comparator|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
11487027|NCT01446926|Experimental|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
11487028|NCT01446926|Experimental|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
11487029|NCT01446926|Placebo Comparator|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
11487030|NCT01446926|Experimental|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
11487031|NCT01446926|Placebo Comparator|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
11487032|NCT01446913|Active Comparator|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
11487033|NCT01446913|Active Comparator|Enhanced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
11487034|NCT01446913|No Intervention|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
11487035|NCT01446900|Experimental|Rituximab cladribine|
11487036|NCT01446887|No Intervention|non-prophylactic anticoagulation|without prophylactic anticoagulation
11487037|NCT01446887|Experimental|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
11487038|NCT01446874|Experimental|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
11487039|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
11487040|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Lung Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
11487041|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
11487042|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
11487043|NCT01446848|Experimental|iron supplement|open-label iron supplement intervention group
11487044|NCT01446835|Experimental|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
11487045|NCT01446835|Active Comparator|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
11487046|NCT01446822|Experimental|Bipolar transurethral resection|
11487047|NCT01446822|Active Comparator|Monopolar transurethral resection|
11487048|NCT01446809|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
11487049|NCT01446809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
11487050|NCT01446796|Placebo Comparator|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
11487051|NCT01446796|Experimental|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (>80%) of paced right ventricular beats
11487052|NCT01446783|Active Comparator|mecasermin + Ehlers-Danlos|
11487053|NCT01446783|Placebo Comparator|Saline + Ehlers-Danlos|
11487054|NCT01446783|Active Comparator|Mecasamin + healthy control|
11487055|NCT01446783|Placebo Comparator|Saline + healthy control|
11487056|NCT01446757|Experimental|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
11487057|NCT01446757|Placebo Comparator|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
11487058|NCT01446744|Active Comparator|Standard arm|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
11487059|NCT01446744|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
11487060|NCT01446731|Experimental|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
11487061|NCT01446731|Active Comparator|Arm B|Docetaxel alone
11487062|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
11487063|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
11487064|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
11487065|NCT01446692||Patients with suboptimal response|
11487066|NCT01446692||Patients with symptomatic remission|
11487067|NCT01446679||atrovastatin group|Who receive atrovastatin
11487068|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher
~; High Risk Index (>=2.33)
~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive)."
11487069|NCT01446653|Experimental|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
11487070|NCT01446653|Active Comparator|Video Information|Providing FASD information via documentary video clips
11487071|NCT01446653|Active Comparator|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
11487072|NCT01446640|Experimental|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
11487073|NCT01446627||metal staples|
11487074|NCT01446627||Insorb vicryl staples|
11487075|NCT01446614|Experimental|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
11487076|NCT01446601|Experimental|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
11487077|NCT01446601|Other|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
11487078|NCT01446588|Experimental|Yoga|Yoga group
11487079|NCT01446562|Experimental|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
11487080|NCT01446549|Experimental|Deep Brain Stimulation|
11487081|NCT01446549|Experimental|Locomotor Exercise|
11487082|NCT01446536|No Intervention|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
11487083|NCT01446536|Active Comparator|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
11487084|NCT01446523|Placebo Comparator|Lactulose|Group L receives lactulose Group NL receives placebo
11487085|NCT01446523|Placebo Comparator|Placebo|Group NL receives placebo
11487086|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
11487087|NCT01446497|Active Comparator|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
11487088|NCT01446497|Active Comparator|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
11487089|NCT01446484|Experimental|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
11487090|NCT01446484|Active Comparator|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
11487091|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
11487092|NCT01446458|Experimental|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
11487093|NCT01446445|Active Comparator|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
11487094|NCT01446445|Experimental|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
11487095|NCT01446445|Active Comparator|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
11487096|NCT01446445|Experimental|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
11487097|NCT01446419|Experimental|Intracept Treatment|
11487098|NCT01446419|Sham Comparator|Sham Treatment|
11487099|NCT01446406|Active Comparator|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
11487100|NCT01446406|Placebo Comparator|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
11487101|NCT01446380||Pseudoxanthoma elasticum|
11487102|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
11487103|NCT01446341|Active Comparator|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
11487104|NCT01446341|Active Comparator|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
11487105|NCT01446328|Active Comparator|Amisulpride|
11487106|NCT01446328|Active Comparator|Aripiprazole|
11487107|NCT01446328|Active Comparator|Olanzapine|
11487108|NCT01446315|Experimental|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
11487109|NCT01446315|Placebo Comparator|Usual care|Usual asthma care as provided by the sites.
11487110|NCT01446302|Active Comparator|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
11487111|NCT01446302|No Intervention|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
11487112|NCT01446302|No Intervention|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
11487113|NCT01446302|No Intervention|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
11487114|NCT01446289|Experimental|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
11487115|NCT01446289|Placebo Comparator|Placebo|Pregnant women who received one injection of saline solution.
11487116|NCT01446276|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for six month
11487117|NCT01446276|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for six month
11487118|NCT01446276|No Intervention|Control group|Men without non-alcoholic fatty liver disease
11487119|NCT01446263|Active Comparator|Radial access|
11487120|NCT01446263|Active Comparator|Femoral access|
11487121|NCT01446250|Experimental|Alisporivir|At the time of partial clinical hold, participants randomized to original treatment arms A and B (Alisporivir triple therapy arms with Peginterferon alfa-2a and Ribavirin) discontinued alisporivir treatment immediately while continuing their treatments with the other two therapies. These participants were combined into the same arm because they received the same dose of alisporivir 400 mg twice per day (BID) for the same duration. Amendment 1 offered them the opportunity to continue in the study receiving boceprevir triple therapy.
11487122|NCT01446250|Active Comparator|Boceprevir|Participants randomized to boceprevir triple therapy with Peginterferon alfa-2a and Ribavirin (the original treatment arm C).
11487123|NCT01446237|Experimental|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
11487124|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
11487125|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
11487126|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
11487127|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
11487128|NCT01446211|Experimental|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
11487129|NCT01446211|Active Comparator|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.
~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
11487130|NCT01446198||AHPV positive and negative subjects|
11487415|NCT01444040|Active Comparator|Drug|Travoprost drops
11487131|NCT01446185|Other|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
11487132|NCT01446172||cognitive, schema focused, guided mastery, exposure|
11487133|NCT01446159|Experimental|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
11487134|NCT01446159|Experimental|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
11487135|NCT01446159|Experimental|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
11487136|NCT01446159|Experimental|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
11487137|NCT01446146|Experimental|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
11487138|NCT01446146|Placebo Comparator|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
11487139|NCT01446133|Experimental|Untreated 65 +|"Patients with untreated SLL/CLL with indications for treatment that are age 65 or older.
~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
11487140|NCT01446133|Experimental|Prior Treatment Any Age|"Patients of any age with previously treated CLL/SLL and recurrent disease.
~Rituximab (375 mg/m2) will be given intravenously on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2. Lenalidomide will be started on Day 9 of cycle 1 at the dose of 10 mg/day and will be continued daily. Treatment duration will be 12 cycles and it will be possible to continue beyond 12 cycles if there is a significant benefit such as an ongoing Partial Response or Complete Response."
11487141|NCT01446120|Experimental|Insulin loaded Orally Dissolved Films (insulin-ODF)|
11487142|NCT01446120|Active Comparator|Human Insulin Specific RIA Kit <5uCi|
11487143|NCT01446107|Experimental|fissure sealant|single placement of resin fissure sealant on tooth surface
11487144|NCT01446107|Experimental|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
11487145|NCT01446107|Experimental|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
11487146|NCT01446107|Placebo Comparator|control|application of water onto tooth surface every year
11487147|NCT01446094|Other|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
11487148|NCT01446081|Experimental|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
11487149|NCT01446081|No Intervention|Control|Participants assigned to this arm will receive usual care.
11487150|NCT01446068|Experimental|Lean Subjects|
11487151|NCT01446068|Experimental|Obese subjects|
11487152|NCT01446055|Experimental|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
11487153|NCT01446055|Active Comparator|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
11487154|NCT01446042|Experimental|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
11487155|NCT01446042|Experimental|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
11487156|NCT01446029|No Intervention|Usual Care|
11487157|NCT01446029|Active Comparator|Intervention Device|
11487158|NCT01446016|Active Comparator|Taxane|Taxane
11487159|NCT01446016|Active Comparator|Taxane-Like|Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone)
11487160|NCT01446003|Experimental|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
11487161|NCT01446003|Experimental|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
11487162|NCT01445964|Experimental|1|SLCO2B1 wild type allele
11487163|NCT01445964|Experimental|2|SLCO2B1 variant allele
11487164|NCT01445951|Experimental|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
11487165|NCT01445951|Active Comparator|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
11487166|NCT01445951|Experimental|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
11487167|NCT01445938|Experimental|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
11487168|NCT01445938|Experimental|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
11487169|NCT01445938|Active Comparator|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
11487210|NCT01445691|Experimental|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
11487170|NCT01445938|Experimental|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
11487171|NCT01445938|Active Comparator|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
11487172|NCT01445938|Experimental|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
11487173|NCT01445925|Active Comparator|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
11487174|NCT01445925|Experimental|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
11487175|NCT01445899|Experimental|PF-04523655 (Stratum II)|Stratum II, 6 monthly injections of PF-04523655 only
11487176|NCT01445899|Experimental|PF-04523655 and ranibizumab|Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
11487177|NCT01445899|Active Comparator|ranibizumab|Stratum II, 6 monthly IVT injections of ranibizumab only
11487178|NCT01445899|Experimental|PF-04523655 (Stratum I)|Stratum I
11487179|NCT01445886|Experimental|Indigo Naturalis Extract in Oil|A 5-ml eye drop bottles contain indigo naturalis powder mixed with olive oil, and the concentration was 200 ug indirubin per ml. Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
11487180|NCT01445886|Active Comparator|Calcipotriol solution|Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml eye drop bottles for this trial.Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
11487181|NCT01445873||PAH patients receiving Sitaxentan|
11487182|NCT01445860|Experimental|Treatment|
11487183|NCT01445847|Active Comparator|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
11487184|NCT01445847|Placebo Comparator|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
11487185|NCT01445834||Incontinent women|
11487186|NCT01445821|Active Comparator|Cyclophosphamide rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
11487187|NCT01445821|Experimental|Cyclophosphamide rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 mg/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
11487188|NCT01445808|Experimental|Psychodynamic Motivation and Training Program (PMT)|
11487189|NCT01445808|Active Comparator|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
11487190|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
11487191|NCT01445795|Experimental|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
11487192|NCT01445795|Placebo Comparator|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
11487193|NCT01445795|Experimental|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
11487194|NCT01445795|Active Comparator|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
11487195|NCT01445795|Experimental|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
11487196|NCT01445795|Placebo Comparator|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
11487197|NCT01445795|Experimental|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
11487198|NCT01445795|Placebo Comparator|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
11487199|NCT01445782|Experimental|1|AZD2115
11487200|NCT01445782|Placebo Comparator|2|Placebo to AZD2115
11487201|NCT01445769|Experimental|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
11487202|NCT01445756|Active Comparator|Topical Lidocaine|Topical Lidocaine
11487203|NCT01445756|Placebo Comparator|Placebo|Placebo
11487204|NCT01445743|Experimental|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
11487205|NCT01445743|Placebo Comparator|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
11487206|NCT01445730|Experimental|Hypercaloric fructose diet|1. TG ≤1.7 mmo/l 2. TG > 1.7 mmol/l
11487207|NCT01445730|Active Comparator|Isocaloric fructose diet|3. TG ≤1.7 mmo/l 4. TG > 1.7 mmol/l
11487208|NCT01445704|Experimental|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
11487209|NCT01445704|Placebo Comparator|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
11487821|NCT01441323|Experimental|Nutrition (N)|
11487211|NCT01445678|Experimental|CXA-201 and Metronidazole as treatment for cIAI|
11487212|NCT01445678|Active Comparator|Meropenem as treatment for cIAI|
11487213|NCT01445652|Experimental|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
11487214|NCT01445652|Active Comparator|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
11487215|NCT01445639|Experimental|Dexmedetomidine group|
11487216|NCT01445639|Placebo Comparator|Placebo group|
11487217|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
11487218|NCT01445613|Other|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
11487219|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
11487220|NCT01445587|Experimental|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
11487221|NCT01445587|Other|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
11487222|NCT01445561|Experimental|1|100,000 international units/m2 SQ daily for 5 days
11487223|NCT01445561|Experimental|2|200,000 international units/m2 SQ daily for 5 days
11487224|NCT01445548|Experimental|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.
~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
11487225|NCT01445535|Experimental|siplizumab + EPOCH (combo chemo) + rituximab|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
11487226|NCT01445509|Experimental|Arm 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
11487227|NCT01445509|Experimental|Arm 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
11487228|NCT01445483||1/Cohort 1|KPS>70; Age <=65; controlled primary tumor and no extracranial metastases
11487229|NCT01445483||2/Cohort 2|KPS>70 and at least one of the following: age>65, uncontrolled or synchronous primary disease, or extracranial metastases
11487230|NCT01445483||3/Cohort 3|KPS <70
11487231|NCT01445444|Experimental|HRT group|This group receives habit reversal training immediately.
11487232|NCT01445444|Active Comparator|TAU group|This group receives treatment as usual for 8 weeks.
11487233|NCT01445431|Experimental|Virgin Coconut Oil|
11487234|NCT01445431|Active Comparator|Mineral Oil|
11487235|NCT01445418|Experimental|Arm 1|Standard dose escalation
11487236|NCT01445418|Experimental|Arm 2|Expanded cohort
11487237|NCT01445392|Experimental|1|Multi-cycle cohort
11487238|NCT01445392|Experimental|2|Single cycle cohort
11487239|NCT01445379|Experimental|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given ~every 12wks
11487240|NCT01445366|Experimental|Patients with end-stage renal disease|
11487241|NCT01445314||1/ Patients|Infants, children, adolescents, and adults who have taken neurobehavioral assessments as part of a past, current, or future IRB-approved protocol.
11487242|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
11487243|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
11487244|NCT01445301|Active Comparator|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
11487245|NCT01445288||1|Pediatric Patients with Central Nervous System Tumors
11487246|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
11487247|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
11487248|NCT01445249|Active Comparator|Landmark guided ankle block|This group will receive a landmark guided ankle block.
11487249|NCT01445249|Active Comparator|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
11487250|NCT01445236|Experimental|Weaning patients|
11487251|NCT01445223|Active Comparator|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
11487252|NCT01445223|Active Comparator|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
11487253|NCT01445223|Active Comparator|efavirenz|600mg QD + 2NRTI QD
11487254|NCT01445210|Active Comparator|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.
~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
11487255|NCT01445210|Placebo Comparator|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.
~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
11487256|NCT01445197|Experimental|Biostate|
11487257|NCT01445171|Other|Study Valve|Subjects act as own control
11487258|NCT01445158||1|bone marrow or stem cell donors ages 10 to 15
11487259|NCT01445158||2|bone marrow or stem cell donors ages 16 to 26
11487260|NCT01445080|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11487261|NCT01445067|Active Comparator|Arm 1: BMS-927711 (300 mg)|
11487262|NCT01445067|Active Comparator|Arm 2: BMS-927711 (600 mg)|
11487263|NCT01445054|Experimental|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
11487264|NCT01445041|Experimental|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
11487265|NCT01445041|Experimental|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
11487266|NCT01445028|Experimental|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
11487267|NCT01445028|Experimental|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
11487268|NCT01445015|Experimental|Stress management program|
11487269|NCT01445015|Active Comparator|peer viewed movies|
11487270|NCT01445002|Experimental|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
11487271|NCT01445002|Experimental|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
11487272|NCT01445002|Experimental|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
11487273|NCT01445002|Placebo Comparator|Placebo|3 subcutaneous injections over a time span of 8 weeks
11487274|NCT01444989|Experimental|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
11487275|NCT01444989|Experimental|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
11487276|NCT01444976|Active Comparator|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
11487277|NCT01444976|Active Comparator|midazolam|There were 25 patients who received midazolam.
11487278|NCT01444976|No Intervention|hypnosis|There were 27 patients receiving hypnosis.
11487279|NCT01444924|Experimental|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
11487280|NCT01444924|Placebo Comparator|Placebo|TAP block with placebo placed prior to surgery
11487281|NCT01444911|Experimental|Vaginal Renewal Program|
11487282|NCT01444911|Active Comparator|Standard of care|This will consist of still vaginal dilator and/or lubricant.
11487283|NCT01444898|Experimental|Exenatide|All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
11487284|NCT01444885|Experimental|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
11487285|NCT01444872|Experimental|TRV120027|TRV120027 administered as an IV infusion
11487286|NCT01444872|Placebo Comparator|Normal Saline|Normal Saline administered as an IV infusion
11487287|NCT01444859|Placebo Comparator|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
11487288|NCT01444859|Experimental|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
11487289|NCT01444846|Active Comparator|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
11487290|NCT01444846|Active Comparator|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
11487291|NCT01444846|Active Comparator|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
11487292|NCT01444846|Placebo Comparator|Placebo|0mg SPI-1005, capsule, bid, po, x4d
11487293|NCT01444820|Experimental|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
11487294|NCT01444820|Other|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
11487295|NCT01444807|Experimental|Sorafenib|Active Arm
11487296|NCT01444807|No Intervention|Best Supportive Care|Comparator
11487297|NCT01444781|Experimental|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™
11487298|NCT01444781|Active Comparator|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
11487299|NCT01444781|Experimental|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.
11487300|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
11487301|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
11487302|NCT01444742|Experimental|Clofarabine + Cytarabine|"Induction:
~Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
~Consolidation:
~Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)"
11487303|NCT01444729||xiapex|Subject treated with Xiapex
11487304|NCT01444729||Surgery|Fasciotomy or fasciectomy
11487363|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
11487305|NCT01444716|Experimental|Treatment (ofatumumab)|Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
11487306|NCT01444703|Placebo Comparator|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
11487307|NCT01444703|Active Comparator|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
11487308|NCT01444690|Experimental|Active|Dimiracetam 400 mg capsules
11487309|NCT01444690|Placebo Comparator|Pseudo-placebo|Dimiracetam 25 mg capsules
11487310|NCT01444677|Experimental|MB12066 300mg|single dose
11487311|NCT01444677|Active Comparator|MB12066 400mg|single dose
11487312|NCT01444677|Active Comparator|MB12066 100mg|multiple dose
11487313|NCT01444677|Active Comparator|MB12066 200mg|multiple dose
11487314|NCT01444677|Placebo Comparator|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
11487315|NCT01444664|Experimental|Aneurysm|
11487316|NCT01444651|Active Comparator|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
11487317|NCT01444651|Placebo Comparator|Placebo|Placebo tablet taken by mouth once a day for 3 months
11487318|NCT01444638|Experimental|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
11487319|NCT01444638|No Intervention|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
11487320|NCT01444625|Experimental|Dark chocolate|Flavanol-rich chocolate
11487321|NCT01444625|Placebo Comparator|Placebo chocolate|Flavanol-free chocolate
11487322|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
11487323|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
11487324|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
11487325|NCT01444586||Group 1|
11487326|NCT01444573|Active Comparator|Group 2 (Lenient control <120bpm)|
11487327|NCT01444573|Active Comparator|Group 1 (Strict control <80 bpm)|
11487328|NCT01444560||Cutaneous Melanoma|
11487329|NCT01444560||Cutaneous Melanoma Metastases|
11487330|NCT01444560||Benign Melanocytic Nevi|
11487331|NCT01444547|Experimental|single-arm Paclitaxel-Cisplatin|
11487332|NCT01444534|Experimental|use of the diabetes application|
11487333|NCT01444534|Active Comparator|Control arm without app (usual care)|
11487334|NCT01444521|Experimental|single-arm Irinotecan-Cisplatin|
11487335|NCT01444508|Active Comparator|crystalloid|
11487336|NCT01444508|Placebo Comparator|colloid|
11487337|NCT01444495|Active Comparator|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
11487338|NCT01444495|Experimental|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
11487339|NCT01444482|Experimental|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
11487340|NCT01444482|Active Comparator|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
11487341|NCT01444469|Experimental|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
11487342|NCT01444469|Placebo Comparator|Placebo|Placebo
11487343|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
11487344|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
11487345|NCT01444443|Experimental|Closed-loop glucose control|Blood glucose controlled by control algorithm.
11487346|NCT01444443|Active Comparator|Open-loop glucose control|Blood glucose controlled by patient
11487347|NCT01444430|Experimental|1|Symbicort
11487348|NCT01444430|Active Comparator|2|budesonide
11487349|NCT01444417|Experimental|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
11487350|NCT01444417|Placebo Comparator|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
11487351|NCT01444404|Experimental|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
11487352|NCT01444404|Experimental|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
11487353|NCT01444391|Experimental|Tympanostomy Tube Placement|
11487354|NCT01444378|Experimental|Absolute Pro® and Pro LL® Peripheral Stent Systems|
11487355|NCT01444365|Experimental|ABT-652 NSAID|ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed
11487356|NCT01444365|Placebo Comparator|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID - as prescribed
11487357|NCT01444352|Experimental|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
11487358|NCT01444352|Experimental|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
11487359|NCT01444352|Experimental|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
11487360|NCT01444352|Placebo Comparator|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
11487361|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
11487362|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
11487364|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
11487365|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
11487366|NCT01444339|Placebo Comparator|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
11487367|NCT01444326|Experimental|Dairy diet|
11487368|NCT01444326|Placebo Comparator|Control diet|
11487369|NCT01444313|Other|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
11487370|NCT01444313|Other|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
11487371|NCT01444300|Experimental|Dalfampridine|
11487372|NCT01444300|Placebo Comparator|Placebo|
11487373|NCT01444287|Placebo Comparator|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
11487374|NCT01444287|Experimental|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
11487375|NCT01444287|Active Comparator|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
11487376|NCT01444287|Active Comparator|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
11487377|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
11487378|NCT01444261|Active Comparator|Intervention|Fer-in-Sol drops and iron-fortified cereal
11487379|NCT01444261|Other|Control|No intervention
11487380|NCT01444248|Experimental|Amaryl MEX|
11487381|NCT01444248|Active Comparator|Amaryl M|
11487382|NCT01444235|Active Comparator|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
11487383|NCT01444235|Experimental|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
11487384|NCT01444222||Pulmonary Hypertension|
11487385|NCT01444222||pulmonic valve stenosis|
11487386|NCT01444222||pulmonic valve homograft|
11487387|NCT01444222||pulmonic valve insufficiency|
11487388|NCT01444222||atrial septum defect|
11487389|NCT01444222||Ebstein's anomaly|
11487390|NCT01444222||transvalvular right ventricular lead|
11487391|NCT01444222||control|
11487392|NCT01444209|Experimental|Radiation Therapy|Interstitial Radioactive Iodine Implants
11487393|NCT01444196|Other|Desloratadine dose|"Study group: 5 mg Desloratadine during the whole study
~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
11487394|NCT01444196|Other|Dose of Desloratadine|"Study group: 5 mg Desloratadine during the whole study
~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
11487395|NCT01444183|Active Comparator|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
11487396|NCT01444183|Sham Comparator|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
11487397|NCT01444170|Placebo Comparator|Sugar pill|"Placebo sugar pill was used as a sham control"
11487398|NCT01444170|Experimental|dicreatinol sulfate|
11487399|NCT01444157|Experimental|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
11487400|NCT01444157|No Intervention|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
11487401|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
11487402|NCT01444131|Placebo Comparator|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
11487403|NCT01444131|Active Comparator|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
11487404|NCT01444118|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
11487405|NCT01444118|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
11487406|NCT01444105|Active Comparator|iStent|implantation of two iStent devices
11487407|NCT01444105|Active Comparator|SLT|Laser treatment
11487408|NCT01444092|Experimental|Entocort|Study Medication
11487409|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
11487410|NCT01444066|Placebo Comparator|dilation to 27 French|
11487411|NCT01444066|Experimental|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
11487412|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
11487413|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
11487414|NCT01444040|Active Comparator|iStent inject|Implantation of two iStent inject devices
11487416|NCT01444027|No Intervention|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
11487417|NCT01444027|Experimental|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
11487418|NCT01444027|Experimental|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
11487419|NCT01444014|Experimental|YF476|
11487420|NCT01444001|Experimental|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
11487421|NCT01444001|Experimental|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
11487422|NCT01444001|Experimental|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
11487423|NCT01443988|Active Comparator|iStent|Implantation of two iStent devices
11487424|NCT01443988|Active Comparator|Drug|Travoprost drops
11487425|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
11487426|NCT01443962|Experimental|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
11487427|NCT01443962|Active Comparator|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
11487428|NCT01443923|Active Comparator|1-HCV|Hepatitis C Mono-infected
11487429|NCT01443923|Active Comparator|2 HCV/HIV|Hepatitis C and HIV co-Infected
11487430|NCT01443910||behavior, supportive|receiving information about behavior with supportive provider communication
11487431|NCT01443910||behaviors, directive|receiving information about behavior with directive provider communication
11487432|NCT01443910||genetics, directive|receiving information about genetics with directive provider communication
11487433|NCT01443910||genetics, supportive|receiving information about genetics with supportive provider communication
11487434|NCT01443897|Placebo Comparator|Group 1|Untreated mushrooms plus placebo capsule.
11487435|NCT01443897|Experimental|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
11487436|NCT01443897|Experimental|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
11487437|NCT01443897|Experimental|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
11487438|NCT01443884|Experimental|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
11487439|NCT01443884|Experimental|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
11487440|NCT01443871|Experimental|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
11487441|NCT01443871|Placebo Comparator|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
11487442|NCT01443858|Active Comparator|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
11487443|NCT01443858|Experimental|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
11487444|NCT01443858|Experimental|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
11487445|NCT01443845|Experimental|1|Roflumilast
11487446|NCT01443845|Placebo Comparator|2|Placebo
11487447|NCT01443832||iron absorption|
11487448|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|
11487449|NCT01443819|Other|Physical Therapy|
11487450|NCT01443819|Other|Cohort observational|
11487451|NCT01443806|Experimental|Oseltamivir, genetic testing|
11487452|NCT01443780|Experimental|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
11487453|NCT01443780|Placebo Comparator|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
11487454|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
11487455|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
11487456|NCT01443741|Active Comparator|FIT Therapy|Patient with functional insulin therapy
11487457|NCT01443741|Active Comparator|Traditional way|Patient with traditional way
11487458|NCT01443728|Experimental|Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
11487459|NCT01443728|Active Comparator|Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
11487460|NCT01443715|Experimental|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
11487461|NCT01443715|Active Comparator|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
11487462|NCT01443702|Placebo Comparator|Placebo|
11487463|NCT01443702|Active Comparator|Lapis judaicus|
11487464|NCT01443689|Experimental|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
11487465|NCT01443689|Experimental|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
11487466|NCT01443689|Active Comparator|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
11487467|NCT01443676|Active Comparator|Radiotherapy|Radiotherapy
11487468|NCT01443676|Experimental|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
11487469|NCT01443663|Experimental|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
11487470|NCT01443663|Experimental|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
11487471|NCT01443663|Experimental|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
11487472|NCT01443663|Experimental|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
11487473|NCT01443663|Experimental|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
11487474|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
11487475|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
11487476|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
11487477|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
11487478|NCT01443624|Experimental|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
11487479|NCT01443611||Infants with first episode of Febrile Convlusions|
11487480|NCT01443572|Experimental|desflurane group|
11487481|NCT01443572|Active Comparator|sevoflurane group|
11487482|NCT01443559|Experimental|Xenogenic cornea|
11487483|NCT01443559|Active Comparator|human cornea|
11487484|NCT01443546|Active Comparator|hCG|standard dose of hCG for ovulation trigger
11487485|NCT01443546|Active Comparator|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
11487486|NCT01443546|Experimental|Dual Trigger|Lupron and hCG combined ovulation trigger
11487487|NCT01443533|Experimental|LARC script|Received routine postpartum counseling and LARC script.
11487488|NCT01443533|No Intervention|No LARC script|Received only routine postpartum counseling
11487489|NCT01443520|Placebo Comparator|Placebo|
11487490|NCT01443520|Active Comparator|Duloxetine|
11487491|NCT01443520|Active Comparator|Venlafaxine|
11487492|NCT01443507|Experimental|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
11487493|NCT01443507|Experimental|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
11487494|NCT01443494|Experimental|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
11487495|NCT01443481|Experimental|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
11487496|NCT01443481|Experimental|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
11487497|NCT01443481|Experimental|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
11487498|NCT01443481|Experimental|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
11487499|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
11487500|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
11487501|NCT01443468||3|Unaffected family members.
11487502|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
11487503|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
11487504|NCT01443455|Experimental|VideoDance|
11487505|NCT01443455|Active Comparator|Brisk Walking|
11487506|NCT01443455|Other|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
11487507|NCT01443442|Active Comparator|Bepreve|1.5% bepotastine besilate, drops, twice per day, for two weeks
11487508|NCT01443442|Active Comparator|Alrex|treatment with 0.2 % loteprednol etabonate, drops, four times per day
11487509|NCT01443429|Experimental|subjects with normal renal function|
11487510|NCT01443429|Experimental|patients with mild renal impairment|
11487511|NCT01443429|Experimental|patients with moderate renal impairment|
11487512|NCT01443429|Experimental|patients with severe renal impairment|
11487513|NCT01443416|Experimental|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
11487514|NCT01443416|Experimental|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
11487515|NCT01443403|Placebo Comparator|Placebo|Participants received placebo orally once daily for 28 days.
11487516|NCT01443403|Experimental|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
11487517|NCT01443403|Experimental|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
11487518|NCT01443403|Experimental|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
11487519|NCT01443364|Experimental|Certolizumab pegol|
11487520|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
11487521|NCT01443338|Active Comparator|Triptergium Wilfordii|a kind of traditional chinese medicine
11487522|NCT01443338|Active Comparator|Acitretin|
11487523|NCT01443325|Experimental|lidocaine patch|
11487524|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
11487525|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
11487526|NCT01443247|Experimental|platelet support + anti-d|
11487527|NCT01443247|No Intervention|platelet support|
11487528|NCT01443234|Experimental|OxIGen program|Internet based intervention taking place over 4 weeks
11487529|NCT01443234|Placebo Comparator|OxIGen: control version|A control version of the internet-based OxIGen intervention
11487530|NCT01443221|Active Comparator|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
11487531|NCT01443221|Experimental|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
11487532|NCT01443208|Experimental|50 mg|
11487533|NCT01443208|Experimental|100 mg|
11487534|NCT01443208|Experimental|200 mg|
11487535|NCT01443195|Experimental|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
11487536|NCT01443182|Experimental|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
11487537|NCT01443182|Active Comparator|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
11487538|NCT01443169|Experimental|Sequence 1|
11487539|NCT01443169|Experimental|Sequence 2|
11487540|NCT01443169|Experimental|Sequence 3|
11487541|NCT01443169|Experimental|Sequence 4|
11487542|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
11487543|NCT01443143|Experimental|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
11487544|NCT01443143|No Intervention|Usual Diet|Participants' usual consumption of food and beverages.
11487545|NCT01443130|Experimental|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
11487546|NCT01443130|Experimental|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
11487547|NCT01443130|Active Comparator|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
11487548|NCT01443117|Experimental|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
11487549|NCT01443117|Experimental|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
11487550|NCT01443117|Placebo Comparator|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
11487551|NCT01443117|Experimental|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
11487552|NCT01443117|Experimental|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
11487553|NCT01443104|Active Comparator|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
11487554|NCT01443104|Active Comparator|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
11487555|NCT01443091|Experimental|Colostrum|
11487556|NCT01443091|Placebo Comparator|Sterile water|
11487557|NCT01443078|Experimental|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
11487688|NCT01442168|Active Comparator|Control|Anti-malarial regimen (Malanil®) alone
11487558|NCT01443065|Active Comparator|Arm A : simplified Folfox 4|"Every 2 weeks :
~Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1
~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :
~5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :
~5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
11487559|NCT01443065|Experimental|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :
~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1
~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :
~5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :
~5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h
~Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
11487560|NCT01443065|Experimental|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :
~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1
~Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :
~5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :
~5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h
~AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
11487561|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
11487562|NCT01443052||healthy subjects|Aged 65 to 80 years
11487563|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
11487564|NCT01443039|Experimental|phenotypical approach|phenotypical approach
11487565|NCT01443026|Experimental|Lycopene|Lycopene 30 mg/day
11487566|NCT01443026|Placebo Comparator|Placebo|Placebo
11487567|NCT01443013||Cohort of Renal Transplant recipients|
11487568|NCT01442987|Experimental|Irbesartan/Atorvastatin A|
11487569|NCT01442987|Active Comparator|Irbesartan|
11487570|NCT01442987|Active Comparator|Atorvastatin A|
11487571|NCT01442987|Placebo Comparator|Placebo|
11487572|NCT01442987|Experimental|Irbesartan/Atorvastatin B|
11487573|NCT01442987|Active Comparator|Atorvastatin B|
11487574|NCT01442974|Experimental|Gemcitabine plus nab-paclitaxel|This is a single arm study.
11487575|NCT01442961|Active Comparator|laparoscopy|Intervention: Procedure: laparoscopy
11487576|NCT01442961|Active Comparator|vaginal|Intervention: Procedure: vaginal
11487577|NCT01442948||Acute coronary syndrome|
11487578|NCT01442948||Stable Angina|
11487579|NCT01442935|Active Comparator|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :
~irinotecan 180 mg/m² D1
~Folinic acid 400 mg/m² D1
~5FU 400 mg/m² bolus
~5FU 2400 mg/m² infusion over 46 h, D1
~And targeted therapy in function of Kras:
~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days
~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
11487580|NCT01442935|Active Comparator|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :
~oxaliplatin 85 mg/m² D1
~Folinic acid 400 mg/m² D1
~5FU 400 mg/m² bolus
~5FU 2400 mg/m² infusion over 46 h, D1
~And targeted therapy in function of Kras:
~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days
~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
11487581|NCT01442935|Experimental|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :
~oxaliplatin 85 mg/m² D1
~irinotecan 150 mg/m² D1
~Folinic acid 400 mg/m² D1
~5FU 400 mg/m² bolus
~5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.
~And targeted therapy in function of Kras:
~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days
~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
11487582|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
11487583|NCT01442909|Active Comparator|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
11487584|NCT01442909|Active Comparator|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
11487585|NCT01442896||Primary Open Angle Glaucoma|"• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (<510um),
~Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy
~For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery
~Best corrected visual acuity of 20/40 or better at enrollment"
11487586|NCT01442896||Healthy Individuals|"• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP < 22mmHg
~o Normal appearing optic disc and no evidence of optic disc damage"
11487587|NCT01442883||treatment resistant hypertensives with CKD 3-5|
11487588|NCT01442870|Experimental|Metformin|Metformin
11487589|NCT01442870|No Intervention|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
11487590|NCT01442857|Experimental|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter
~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
11487591|NCT01442844|Active Comparator|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
11487592|NCT01442844|No Intervention|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
11487593|NCT01442831|Experimental|Human ADME|
11487594|NCT01442818|Experimental|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
11487595|NCT01442818|Experimental|PCA post op|Patients will receive PCA for pain control post operatively.
11487596|NCT01442805|Experimental|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
11487597|NCT01442805|Experimental|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
11487598|NCT01442792|Active Comparator|Arm 1|
11487599|NCT01442792|Experimental|Arm 2|
11487600|NCT01442792|Experimental|Arm 3|
11487601|NCT01442792|Experimental|Arm 4|
11487602|NCT01442766|Experimental|Donepezil|
11487603|NCT01442766|Placebo Comparator|Placebo|
11487604|NCT01442753|Active Comparator|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
11487605|NCT01442753|Active Comparator|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
11487606|NCT01442740|Experimental|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
11487607|NCT01442740|No Intervention|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
11487608|NCT01442727|Placebo Comparator|Placebo|Patients who receive control (placebo)
11487609|NCT01442727|Active Comparator|Selenium|Patients who receive treatment (selenium)
11487610|NCT01442714|Experimental|Azacitidine plus Lenalidomide|Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.
11487611|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
11487612|NCT01442688|Experimental|Amoxicillin + MMX placebo|
11487613|NCT01442688|Experimental|Amoxicillin + MMX mesalazine/mesalamine|
11487614|NCT01442675|Experimental|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
11487615|NCT01442662|Experimental|pazopanib, gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
11487616|NCT01442649|Experimental|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :
~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
~OR
~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
~AND
~Bevacizumab 5 mg/kg IV every 2 weeks."
11487617|NCT01442649|Experimental|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :
~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
~OR
~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.
~AND
~Cetuximab : 500 mg/m² IV every 2 weeks"
11487618|NCT01442636|Experimental|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
11487619|NCT01442623|Active Comparator|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
11487620|NCT01442623|Experimental|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
11487621|NCT01442610|Experimental|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
11487622|NCT01442610|Placebo Comparator|Placebo|Effect of placebo on sleep parameters in PD Patients
11487623|NCT01442597|Active Comparator|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
11487624|NCT01442597|Experimental|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
11487625|NCT01442597|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
11487626|NCT01442584|Experimental|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
11487627|NCT01442571|Experimental|Hyaluronic Acid Injection, pain, function|
11487628|NCT01442571|Placebo Comparator|Saline Injection|
11487629|NCT01442558|Active Comparator|SCL|Supraclavicular ultrasound-guided brachial plexus block
11487630|NCT01442558|Active Comparator|ICL|Infraclavicular ultrasound-guided brachial plexus block
11487631|NCT01442558|Active Comparator|AX|Axillary ultrasound-guided brachial plexus block
11487632|NCT01442545|Experimental|001|
11487633|NCT01442532|Experimental|1|
11487634|NCT01442532|Experimental|2|
11487635|NCT01442532|Experimental|3|
11487636|NCT01442532|Placebo Comparator|4|
11487637|NCT01442532|Experimental|5|
11487638|NCT01442519|Active Comparator|Intravesical BCG alone|
11487639|NCT01442519|Experimental|Intravesical sequential BCG and EMDA MMC|
11487640|NCT01442506||Barrett|
11487641|NCT01442493|Experimental|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
11487642|NCT01442493|Active Comparator|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
11487643|NCT01442480|Experimental|Fish oil|
11487644|NCT01442480|Experimental|Olive oil|
11487645|NCT01442467||Mild to Severe MAC|
11487646|NCT01442467||No to mild MAC|
11487647|NCT01442454||Chronic Pancreatitis|
11487648|NCT01442441||chronic pancreatitis|
11487649|NCT01442428|Experimental|Steroid+Statin|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;
~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
11487650|NCT01442428|Active Comparator|NSAID+Statin|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;
~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
11487651|NCT01442428|Active Comparator|Steroid+Placebo|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;
~Placebo"
11487652|NCT01442428|Active Comparator|NSAID+Placebo|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;
~Placebo"
11487653|NCT01442415|Other|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
11487654|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
11487655|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
11487656|NCT01442376|Experimental|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron
~Intervention:
~Drug: Palonosetron"
11487657|NCT01442376|Experimental|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron
~Intervention:
~Drug: Palonosetron"
11487658|NCT01442376|Active Comparator|Ondansetron|"Ondansetron and placebo to Palonosetron
~Drug:
~Comparator: Ondansetron"
11487659|NCT01442363|Experimental|BLI-1300 (low dose)|Low dose BLI-1300
11487660|NCT01442363|Experimental|BLI-1300 (high dose)|High dose BLI-1300
11487661|NCT01442363|Placebo Comparator|placebo|placebo (vehicle)
11487662|NCT01442337|Experimental|ASP8597 low dose|
11487663|NCT01442337|Experimental|ASP8597 high dose|
11487664|NCT01442337|Experimental|ASP8597 highest dose|
11487665|NCT01442337|Placebo Comparator|Placebo|Placebo comparator used in Part 2 only
11487666|NCT01442324|Experimental|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
11487667|NCT01442311|Experimental|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
11487668|NCT01442311|Active Comparator|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
11487669|NCT01442298|Active Comparator|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
11487670|NCT01442298|Experimental|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
11487671|NCT01442285|Experimental|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
11487672|NCT01442285|No Intervention|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
11487673|NCT01442272|No Intervention|Habitual medication withuot additional|
11487674|NCT01442272|Active Comparator|Habitual medication plus Hidroferol®|
11487675|NCT01442272|Active Comparator|Habitual medication plus Zemplar®|
11487676|NCT01442259|Experimental|All study subjects|
11487677|NCT01442246|Experimental|Adjuvant treatment|Leuproreline acetate
11487678|NCT01442246|No Intervention|Surveillance|Surveillance
11487679|NCT01442233|Experimental|plasma exchange|6 plasma exchanges during 2 weeks after randomization
11487680|NCT01442233|Sham Comparator|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
11487681|NCT01442207|Active Comparator|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
11487682|NCT01442207|Placebo Comparator|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:
~Standard management for placenta previa.
~Hospital admission for vaginal bleeding/hemorrhage
~Antenatal corticosteroids > 24w0d of gestation
~Tocolytic therapy per physician's discretion
~Magnesium sulfate for neuroprotection
~Fetal Heart Rate Monitoring
~Avoidance of digital examinations of the cervix
~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) > 34 wks, worsening maternal or fetal condition )
~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
11487683|NCT01442194||Fingolimod|non-interventional
11487684|NCT01442194||parallel cohort|non-interventional
11487685|NCT01442181|Active Comparator|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
11487686|NCT01442181|Active Comparator|Medical Therapy|Patients are treated with rhythm and rate control medications.
11487687|NCT01442168|Experimental|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
11487689|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
11487690|NCT01442142|Experimental|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
11487691|NCT01442142|Experimental|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
11487692|NCT01442142|Experimental|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
11487693|NCT01442142|No Intervention|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
11487694|NCT01442129|Experimental|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
11487695|NCT01442129|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
11487696|NCT01442116|Experimental|Hypertensives|
11487697|NCT01442103|Experimental|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
11487698|NCT01442090|Active Comparator|Everolimus|Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11487699|NCT01442090|Experimental|GDC-0980|Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11487700|NCT01442077|Active Comparator|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
11487701|NCT01442077|Active Comparator|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
11487702|NCT01442077|Active Comparator|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
11487703|NCT01442077|Active Comparator|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
11487704|NCT01442064|Experimental|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
11487705|NCT01442051|Experimental|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
11487706|NCT01442038|Experimental|Ranolazine|
11487707|NCT01442038|Placebo Comparator|Placebo|
11487708|NCT01442025|Placebo Comparator|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
11487709|NCT01442025|Active Comparator|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
11487710|NCT01442025|Active Comparator|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
11487711|NCT01442012|Active Comparator|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
11487712|NCT01442012|Sham Comparator|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
11487713|NCT01441999|Active Comparator|Less rigid rods|Titanium rods that have a soft, plastic end
11487714|NCT01441999|Active Comparator|Rigid Rods|Titanium rods
11487715|NCT01441973|Experimental|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
11487716|NCT01441973|Experimental|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
11487717|NCT01441960|Experimental|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
11487718|NCT01441960|Experimental|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
11487719|NCT01441947|Experimental|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
11487720|NCT01441934|Active Comparator|Sildenafil citrate|20 mg t.i.d.
11487721|NCT01441934|Placebo Comparator|Sugar pill|
11487722|NCT01441921|Active Comparator|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
11487723|NCT01441921|Experimental|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
11487724|NCT01441908|No Intervention|Control Group|Control Group
11487725|NCT01441908|Active Comparator|Statin|Receiving Statin
11487726|NCT01441882|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11487727|NCT01441869|Experimental|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
11487728|NCT01441869|Experimental|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
11487729|NCT01441869|Experimental|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
11487730|NCT01441869|Experimental|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
11487731|NCT01441856|Active Comparator|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
11487732|NCT01441856|Active Comparator|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
11487733|NCT01441856|Active Comparator|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
11487734|NCT01441843|Active Comparator|Lorazepam|Lorazepam 4mg/4ml
11487735|NCT01441843|Placebo Comparator|NaCl 0.9%|NaCl 0.9% 4ml
11487736|NCT01441830|Sham Comparator|sham rESWT|
11487737|NCT01441830|Active Comparator|rESWT|
11487738|NCT01441817|Other|Surgery|
11487739|NCT01441804|Experimental|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
11487740|NCT01441804|Active Comparator|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
11487741|NCT01441791|Experimental|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
11487742|NCT01441791|No Intervention|Conventional Strategy|"PEEP at maximum 2 cmH2O, if possible 0 cmH2O
~No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
11487743|NCT01441778|Active Comparator|NSS irrigation salt|
11487744|NCT01441778|Experimental|BHS nasal irrigaiton salt|
11487745|NCT01441765|Active Comparator|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
11487746|NCT01441765|Active Comparator|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
11487747|NCT01441752|Experimental|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.
~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
11487748|NCT01441752|Placebo Comparator|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
11487749|NCT01441739||NEC suspected - Final diagnosis NEC|
11487750|NCT01441739||NEC suspected - Final diagnosis no NEC|
11487751|NCT01441739||Controls|
11487752|NCT01441726||Training of staff|
11487753|NCT01441726||No training of staff|
11487754|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
11487755|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
11487756|NCT01441700|Active Comparator|Prone position|
11487757|NCT01441700|Active Comparator|Supine position|
11487758|NCT01441687|Experimental|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
11487759|NCT01441687|Experimental|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
11487760|NCT01441674|Experimental|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
11487761|NCT01441674|Experimental|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
11487762|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
11487763|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
11487764|NCT01441635|Experimental|Cohort 4 Elagolix 400 mg QD|Participants received elagolix 400 mg once a day (QD) for 3 months.
11487765|NCT01441635|Experimental|Cohort 4 Elagolix 100 mg BID|Participants received elagolix 100 mg twice a day (BID) for 3 months.
11487766|NCT01441635|Placebo Comparator|Cohort 4 Placebo|Participants received placebo to elagolix BID for 3 months.
11487767|NCT01441635|Experimental|Cohort 1 Elagolix 200 mg BID|Participants received elagolix 200 mg twice a day for 3 months.
11487768|NCT01441635|Placebo Comparator|Cohort 1 Placebo|Participants received placebo to elagolix twice a day for 3 months.
11487769|NCT01441635|Placebo Comparator|Cohort 3 Elagolix 200 mg BID + LD E2/NETA|Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
11487770|NCT01441635|Experimental|Cohort 5 Elagolix 600 mg QD|Participants received elagolix 600 mg once a day for 3 months.
11487771|NCT01441635|Experimental|Cohort 2 Elagolix 300 mg BID|Participants received elagolix 300 mg twice a day for 3 months.
11487772|NCT01441635|Experimental|Cohort 2 Placebo|Participants received placebo to elagolix BID for 3 months.
11487773|NCT01441635|Experimental|Cohort 6 Elagolix 300 mg BID + CEP|Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.
11487774|NCT01441622|Experimental|AL539|Device AL539
11487775|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
11487776|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
11487777|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
11487778|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
11487779|NCT01441596|Experimental|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
11487780|NCT01441596|Experimental|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
11487781|NCT01441596|Active Comparator|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
11487782|NCT01441583|Active Comparator|RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
11487783|NCT01441583|Active Comparator|RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
11487784|NCT01441570|Active Comparator|Nebivolol|
11487785|NCT01441570|Active Comparator|Metoprolol Succinate|
11487786|NCT01441544|Experimental|VAREITY|
11487787|NCT01441544|Experimental|NON-VARIETY|
11487788|NCT01441531|Experimental|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
11487789|NCT01441531|Placebo Comparator|Placebo sugar pill|
11487790|NCT01441518|Experimental|Home care|
11487791|NCT01441518|Active Comparator|Hospital care|
11487792|NCT01441492|Experimental|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
11487793|NCT01441492|Experimental|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
11487794|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
11487795|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
11487796|NCT01441453|Other|Preoperative FibroScan|
11487797|NCT01441440|Experimental|venlafaxine ER 75 mg/day (fixed dose)|
11487798|NCT01441440|Experimental|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
11487799|NCT01441440|Placebo Comparator|Placebo|
11487800|NCT01441427|Experimental|G-CSF|
11487801|NCT01441427|Experimental|EPO|
11487802|NCT01441427|Experimental|G-CSF and EPO|
11487803|NCT01441427|Placebo Comparator|Placebo|
11487804|NCT01441414|Experimental|ARM A|PF-04856884 in combination with AG-013736
11487805|NCT01441414|Active Comparator|ARM B|AG-013736 alone
11487806|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
11487807|NCT01441388|Experimental|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
11487808|NCT01441388|Experimental|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
11487809|NCT01441388|Experimental|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
11487810|NCT01441388|Experimental|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
11487811|NCT01441388|Experimental|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
11487812|NCT01441375||Sickle cell patients non-transfused|
11487813|NCT01441375||Sickle cell patients transfused with no ICT|
11487814|NCT01441375||Sickle cell patients transfused with ICT|
11487815|NCT01441362|Active Comparator|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
11487816|NCT01441362|Experimental|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
11487817|NCT01441349|Active Comparator|Control arm|IP chemotherapy arm
11487818|NCT01441349|Experimental|Treatment arm|IP chemotherapy plus simvastatin arm
11487819|NCT01441336|Experimental|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:
~D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
11487820|NCT01441323|No Intervention|Control (C)|
11487822|NCT01441323|Experimental|Strength Training & Nutrition (ST)|
11487823|NCT01441310|Experimental|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
11487824|NCT01441297|Experimental|study arm|BIBF 1120 study arm
11487825|NCT01441284|Active Comparator|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
11487826|NCT01441284|Placebo Comparator|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
11487827|NCT01441271|Active Comparator|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
11487828|NCT01441271|Experimental|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
11487829|NCT01441258|Experimental|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
11487830|NCT01441258|Placebo Comparator|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
11487831|NCT01441245|Experimental|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
11487832|NCT01441245|Experimental|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
11487833|NCT01441232|Experimental|Treatment A|
11487834|NCT01441232|Experimental|Treatment C|
11487835|NCT01441232|Active Comparator|Treatment B|
11487836|NCT01441219|Experimental|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
11487837|NCT01441206|Other|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
11487838|NCT01441206|No Intervention|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
11487839|NCT01441193|Experimental|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
11487840|NCT01441193|Active Comparator|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
11487841|NCT01441193|Active Comparator|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
11487842|NCT01441193|Active Comparator|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
11487843|NCT01441180|Experimental|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
11487844|NCT01441180|Active Comparator|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing <75 kg and 1200 mg for participants weighing ≥75kg)
11487845|NCT01441180|Active Comparator|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
11487846|NCT01441154||Group 1|Adults with clinical indication for withdrawal from thyroid hormone replacement therapy in preparation for nuclear medicine imaging or therapeutic procedures with radioactive iodine
11487847|NCT01441141||Arm 1|Subjects with SCD
11487848|NCT01441141||Arm 2|Subjects without SCD
11487849|NCT01441128|Experimental|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
11487850|NCT01441128|Experimental|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
11487851|NCT01441102|Experimental|Dextromethorphan hydrobromide|
11487852|NCT01441089||1/Cancer Patients|Patients enrolled on IRB approved NIH Intramural Research Program (IRP) therapeutic clinical trials
11487853|NCT01441076|Experimental|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
11487854|NCT01441063|Experimental|Tocilizumab|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, zidovudine (AZT) and valganciclovir (VGC) will be administered concurrently with tocilizumab, with day 1 of the cycle being the day tocilizumab is administered.
11487855|NCT01441037|Experimental|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
11487856|NCT01441024|Experimental|1|DAS181
11487857|NCT01441024|Placebo Comparator|2|Placebo
11487858|NCT01441011|Experimental|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
11487859|NCT01441011|Active Comparator|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
11487860|NCT01440998|Experimental|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. *Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11487861|NCT01440985|Experimental|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
11487862|NCT01440985|Active Comparator|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
11487863|NCT01440972|Active Comparator|Exercise without PBFR|
11487864|NCT01440972|Experimental|exercise with PBFR|
11487865|NCT01440959|Experimental|TKI258|
11487866|NCT01440946|Experimental|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.
~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
11487867|NCT01440933|Active Comparator|Magnesiumsulphate|
11487868|NCT01440933|Placebo Comparator|Physiologic saline|
11487869|NCT01440920|Experimental|Cohort 1|0.3 mg
11487870|NCT01440920|Experimental|Cohort 2|1 mg
11487871|NCT01440920|Experimental|Cohort 3|3 mg
11487872|NCT01440907|Experimental|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
11487873|NCT01440907|No Intervention|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
11487874|NCT01440894||Body Analysis|
11487875|NCT01440881|Active Comparator|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
11487876|NCT01440881|Placebo Comparator|Placebo|infuses at 0.01MCG/KG/min for 48 hours
11487877|NCT01440868|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
11487878|NCT01440868|No Intervention|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
11487879|NCT01440855|Active Comparator|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
11487880|NCT01440855|Experimental|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
11487881|NCT01440842|Experimental|Closed-loop (Model Predictive Control Algorithm)|
11487882|NCT01440842|Active Comparator|Open loop (Standard treatment)|
11487883|NCT01440829|Experimental|LOLA group|Intervention: LOLA (30g per day) for a week.
11487884|NCT01440829|No Intervention|Control group|Patients will not be treated with LOLA.
11487885|NCT01440816|Experimental|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
11487886|NCT01440816|Experimental|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
11487887|NCT01440803|Active Comparator|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
11487888|NCT01440803|Placebo Comparator|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
11487889|NCT01440790|Placebo Comparator|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
11487890|NCT01440790|Experimental|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
11487891|NCT01440790|Active Comparator|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
11487892|NCT01440790|Experimental|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
11487893|NCT01440777|Active Comparator|Go! to Sleep|Participants access and utilize the 6-week online program that provides a set of various psycho-educational materials and behavioral techniques to treat insomnia.
11487894|NCT01440777|No Intervention|Control Group|No intervention provided. These participants will receive the Go! to Sleep program after the research trial has been completed (10 weeks after registration).
11487895|NCT01440764|Experimental|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.
~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.
~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
11487896|NCT01440764|Experimental|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.
~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.
~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
11487933|NCT01440543|Experimental|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
11487897|NCT01440764|Experimental|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.
~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.
~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
11487898|NCT01440764|Experimental|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.
~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.
~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
11487899|NCT01440764|Experimental|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.
~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.
~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
11487900|NCT01440764|Experimental|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.
~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.
~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
11487901|NCT01440751|Experimental|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
11487902|NCT01440751|Active Comparator|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
11487903|NCT01440738|Experimental|health workshops|Health promotion group intervention
11487904|NCT01440738|No Intervention|comparison group|usual care
11487905|NCT01440725|Experimental|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
11487906|NCT01440725|Active Comparator|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
11487907|NCT01440712|Experimental|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
11487908|NCT01440712|Placebo Comparator|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
11487909|NCT01440699|Experimental|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
11487910|NCT01440686|Experimental|HL-032 30mg|A single dose 30mg administered orally
11487911|NCT01440686|Experimental|HL-032 60mg|A single dose 60mg administered orally
11487912|NCT01440686|Experimental|HL-032 120mg|A single dose 120mg administered orally
11487913|NCT01440673|Active Comparator|aprepitant 125mg|NK1 receptor antagonist
11487914|NCT01440673|Active Comparator|Aprepitant 80 mg|
11487915|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
11487916|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate >= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
11487917|NCT01440647|Experimental|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
11487918|NCT01440647|Active Comparator|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
11487919|NCT01440634|Other|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
11487920|NCT01440634|No Intervention|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
11487921|NCT01440621|Active Comparator|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
11487922|NCT01440621|Placebo Comparator|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
11487923|NCT01440608|Experimental|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
11487924|NCT01440608|Experimental|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
11487925|NCT01440608|Placebo Comparator|Placebo|Placebo will be given for 14 days
11487926|NCT01440595|Experimental|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
11487927|NCT01440595|Experimental|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
11487928|NCT01440595|Placebo Comparator|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
11487929|NCT01440595|Experimental|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
11487930|NCT01440582|Experimental|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.
~Symptom Questionnaire completed on day 1 of each cycle."
11487931|NCT01440569|Experimental|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
11487932|NCT01440543|Experimental|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
11487934|NCT01440543|Experimental|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
11487935|NCT01440543|No Intervention|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
11487936|NCT01440530|Experimental|Educational Intervention|
11487937|NCT01440530|Active Comparator|Control Group (usual care)|
11487938|NCT01440517|Experimental|Tc99m-Maraciclatide|
11487939|NCT01440491|Other|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet
~G2 received the booklet to self perform the physiotherapy exercises"
11487940|NCT01440478|Experimental|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
11487941|NCT01440478|Experimental|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
11487942|NCT01440478|Experimental|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
11487943|NCT01440452|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
11487944|NCT01440452|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
11487945|NCT01440452|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
11487946|NCT01440452|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
11487947|NCT01440439|Active Comparator|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
11487948|NCT01440439|Active Comparator|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
11487949|NCT01440426|Active Comparator|Autologous connective tissue graft|Soft tissue harvested from patient palate
11487950|NCT01440426|Experimental|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
11487951|NCT01440400|No Intervention|Conventional spinal anesthesia|
11487952|NCT01440400|Experimental|Ultrasound guided spinal anesthesia|
11487953|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11487954|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
11487955|NCT01440374|Experimental|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
11487956|NCT01440374|Experimental|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
11487957|NCT01440374|Experimental|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
11487958|NCT01440374|Experimental|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
11487959|NCT01440361|Experimental|Belimumab|Reconstituted solution for intravenous infusion
11487960|NCT01440361|Placebo Comparator|Normal saline|Solution for intravenous infusion
11487961|NCT01440348|Experimental|Achilles allograft|
11487962|NCT01440322|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
11487963|NCT01440322|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
11487964|NCT01440309|Experimental|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
11487965|NCT01440309|Active Comparator|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
11487966|NCT01440283|Experimental|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.
~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
11487967|NCT01440270|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
11487968|NCT01440257|Placebo Comparator|Placebo (Group A)|
11487969|NCT01440257|Experimental|Active study medication (Group B)|CCX140-B
11487970|NCT01440244|Other|Single group assignment|Cervical mediastinoscopy
11487971|NCT01440231|Placebo Comparator|Arm 1|
11487972|NCT01440231|Experimental|Arm 2|
11487973|NCT01440231|Experimental|Arm 3|
11487974|NCT01440231|Experimental|Arm 4|
11487975|NCT01440231|Experimental|Arm 5|
11487976|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
11488019|NCT01439971|Experimental|3|
11488020|NCT01439971|Experimental|4|
11488021|NCT01439971|Experimental|5|
11488022|NCT01439958|Experimental|L-CsA|Twice daily inhalation of L-CsA
11487977|NCT01440205|Experimental|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
11487978|NCT01440205|Experimental|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
11487979|NCT01440205|Experimental|Control|A control condition with no list of healthy behaviors.
11487980|NCT01440192|Experimental|Cohort A: 1 Unit PDA001 (cenplacel-L)|
11487981|NCT01440192|Experimental|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
11487982|NCT01440179|Experimental|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
11487983|NCT01440166|Experimental|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
11487984|NCT01440166|Experimental|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
11487985|NCT01440166|Experimental|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
11487986|NCT01440166|Experimental|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
11487987|NCT01440166|Experimental|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
11487988|NCT01440166|Experimental|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
11487989|NCT01440166|Experimental|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
11487990|NCT01440166|Experimental|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
11487991|NCT01440166|Experimental|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
11487992|NCT01440153|Experimental|Active Intervention|
11487993|NCT01440153|Active Comparator|passive intervention|
11487994|NCT01440140|Experimental|Closed loop (algorithm)|
11487995|NCT01440140|Placebo Comparator|Open loop|
11487996|NCT01440127|Experimental|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
11487997|NCT01440127|No Intervention|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
11487998|NCT01440114|Active Comparator|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
11487999|NCT01440114|Placebo Comparator|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
11488000|NCT01440101|Experimental|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
11488001|NCT01440101|Placebo Comparator|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
11488002|NCT01440101|Experimental|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
11488003|NCT01440088|Experimental|TH-302 in Combination with Doxorubicin|
11488004|NCT01440088|Active Comparator|Doxorubicin|
11488005|NCT01440075|Other|Patients KD|Adults with a history of KD disease in childhood
11488006|NCT01440075|Other|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
11488007|NCT01440062|Experimental|Verum (high dose)|verum arm receiving high dose Vitamin D oil
11488008|NCT01440062|Experimental|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
11488009|NCT01440049||Eplerenone|
11488010|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
11488011|NCT01440023|Experimental|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
11488012|NCT01440023|Placebo Comparator|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
11488013|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
11488014|NCT01439997|Experimental|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
11488015|NCT01439984|Experimental|PED-1|PED-1 (Clomipramine 15 mg)
11488016|NCT01439984|Placebo Comparator|placebo|
11488017|NCT01439971|Experimental|1|
11488018|NCT01439971|Experimental|2|
11488023|NCT01439945|Experimental|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
11488024|NCT01439945|Experimental|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
11488025|NCT01439945|Placebo Comparator|Arm III|Patients receive a low-dose of placebo PO QD.
11488026|NCT01439945|Placebo Comparator|Arm IV|Patients receive a high-dose of placebo PO QD.
11488027|NCT01439932|Experimental|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.
~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.
~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.
~All patients will receive information and guidance to practice at home."
11488028|NCT01439919|Experimental|SSR411298 200 mg|SSR411298 200 mg, one tablet once daily for 4 weeks
11488029|NCT01439919|Placebo Comparator|Placebo|Placebo (for SSR411298), one tablet once daily for 4 weeks
11488030|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
11488031|NCT01439893|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
11488032|NCT01439893|Placebo Comparator|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
11488033|NCT01439880|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product [all-IP] period.
11488034|NCT01439880|Experimental|Evolocumab + SOC|Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
11488035|NCT01439867|Experimental|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.
~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.
~All participants also received standard of care, which may have included vitamin D sterols."
11488036|NCT01439854|Placebo Comparator|Placebo|this arm is control
11488037|NCT01439854|Experimental|Dapagliflozin|Interventional arm
11488038|NCT01439841|Experimental|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
11488039|NCT01439841|Placebo Comparator|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
11488040|NCT01439841|No Intervention|Control|No intervention
11488041|NCT01439828|Experimental|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
11488042|NCT01439828|Placebo Comparator|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
11488043|NCT01439815|Placebo Comparator|Placebo Nasal Spray|
11488044|NCT01439815|Active Comparator|Fluticasone Propionate|
11488045|NCT01439789|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
11488046|NCT01439789|Placebo Comparator|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
11488047|NCT01439776|No Intervention|Peginterferon alfa 2a+Ribavirin|standard of care for HCV : peginterferon alfa 2a and ribavirin
11488048|NCT01439776|Experimental|Vit D+Peginterferon alfa 2a+Ribavirin|VitD+Peginterferon alfa 2a+Ribavirin
11488049|NCT01439750|Experimental|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
11488050|NCT01439750|Experimental|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
11488051|NCT01439737||asthma|
11488052|NCT01439724|Placebo Comparator|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
11488088|NCT01439412|Other|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
11488089|NCT01439399|Active Comparator|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
11488053|NCT01439724|Experimental|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
11488054|NCT01439711|Experimental|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
11488055|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
11488056|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
11488057|NCT01439685||Biliary Stent group|Biliary Stent group
11488058|NCT01439672|Experimental|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
11488059|NCT01439659|Other|Nutritional Counseling|For 6 months control group receives dietary counseling.
11488060|NCT01439659|Experimental|Daily Supplements|2 capsules (Juice Plus+) twice a day (morning and evening) plus Juice Plus+ Complete drink each evening for 6 months.
11488061|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
11488062|NCT01439633|Experimental|MGH OFDI marking and imaging|OFDI imaging
11488063|NCT01439620|Experimental|OFDI imaging|Subject will swallow an OFDI capsule and images will be obtained using MGH Optical Frequency Domain Imaging (OFDI) imaging system.
11488064|NCT01439607|Experimental|Bone marrow and blood sampling|
11488065|NCT01439594|Experimental|MGH OFDI Imaging|OFDI imaging
11488066|NCT01439581|Experimental|Patients on mapping systems|
11488067|NCT01439581|Active Comparator|Patients not on mapping systems|
11488068|NCT01439568|Experimental|LY2510924 + Carboplatin + Etoposide|"LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.
~Etoposide: 100 milligram square meter (mg/m^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
11488069|NCT01439568|Active Comparator|Carboplatin + Etoposide|"Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.
~Etoposide: 100 milligram square meter (mg/m^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
11488070|NCT01439555|Experimental|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
11488071|NCT01439542|Experimental|Radiotherapy|
11488072|NCT01439529|Active Comparator|Nominal|CRT device is programmed with the nominal values.
11488073|NCT01439529|Experimental|Narrow QRS|CRT device is programmed by QRS optimization
11488074|NCT01439516|Experimental|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
11488075|NCT01439516|Experimental|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
11488076|NCT01439516|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
11488077|NCT01439503|No Intervention|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
11488078|NCT01439503|Experimental|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
11488079|NCT01439490|Experimental|FES-PET|Patients undergo FES-PET prior to obtaining histology
11488080|NCT01439464|Active Comparator|Control device|
11488081|NCT01439464|Experimental|Investigational device|
11488082|NCT01439451|Experimental|experimental|perturbation training during walking
11488083|NCT01439451|Active Comparator|controls|treadmill walking
11488084|NCT01439438|Active Comparator|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
11488085|NCT01439438|Active Comparator|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
11488086|NCT01439425|Experimental|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
11488087|NCT01439412|Experimental|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
11488090|NCT01439399|Active Comparator|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
11488091|NCT01439399|Active Comparator|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
11488092|NCT01439399|Placebo Comparator|Saline 0,9%|Control group
11488093|NCT01439386|Active Comparator|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
11488094|NCT01439386|Active Comparator|AFL ablation only|Cavo-tricuspid isthmus ablation only
11488095|NCT01439373|Experimental|GSK2336805|Study Part 1
11488096|NCT01439373|Placebo Comparator|Placebo|Study Part 1
11488097|NCT01439373|Experimental|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
11488098|NCT01439373|Active Comparator|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
11488099|NCT01439360|Experimental|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
11488100|NCT01439360|Active Comparator|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
11488101|NCT01439347|Active Comparator|Vincristine Sulfate Injection (VSI)|This is a phase 3, international, multicenter, open-label randomized, controlled trial with 2 treatment arms that vary only in the administration of standard VSI vs. Marqibo. Eligible subjects will be randomized to combination chemotherapy containing either VSI or Marqibo
11488102|NCT01439347|Experimental|Marqibo|administration of standard VSI vs. Marqibo
11488103|NCT01439334|Experimental|Online Program Brief|Online Program Brief
11488104|NCT01439334|Experimental|Online Program Extended Length|Online Program Extended Length
11488105|NCT01439334|Active Comparator|Control|Control
11488106|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
11488107|NCT01439308|Placebo Comparator|Arm 1|3 incremental capsaicin doses
11488108|NCT01439308|Active Comparator|Arm 2|3 incremental capsaicin doses
11488109|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
11488110|NCT01439282|Experimental|Eribulin + Capecitabine|
11488111|NCT01439269|No Intervention|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
11488112|NCT01439269|Experimental|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
11488113|NCT01439269|Experimental|Phase 2: Effectiveness|All participants who agree to participate will receive Family Nurture Intervention.
11488114|NCT01439256|Experimental|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
11488115|NCT01439256|No Intervention|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
11488116|NCT01439243|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
11488117|NCT01439243|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
11488118|NCT01439230|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
11488119|NCT01439230|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
11488120|NCT01439204|Active Comparator|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
11488121|NCT01439204|Experimental|Abatacept (BMS-188667) manufactured at Devens, MA facility|
11488122|NCT01439191|Experimental|combination agent group|
11488123|NCT01439191|Experimental|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
11488124|NCT01439178|Experimental|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
11488125|NCT01439178|Active Comparator|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
11488126|NCT01439165|Experimental|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
11488127|NCT01439165|Active Comparator|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
11488128|NCT01439152|Experimental|BAY94-9343 (Dose-Escalation)|BAY94-9343 will be administered intravenously in this study. The starting dose for this first-in-man study is 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
11488129|NCT01439152|Experimental|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose. Overall up to 32 subjects are planned to be enrolled in the expansion cohort:
~Ovarian Carcinoma, 20 subjects
~Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
11488130|NCT01439152|Experimental|BAY94-9343 (1.8 mg/kg)|This part of study will be randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
11488131|NCT01439152|Experimental|BAY94-9343 (2.2 mg/kg)|This part of study will be randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma..
11488132|NCT01439126|Active Comparator|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
11488133|NCT01439126|Placebo Comparator|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
11488134|NCT01439113|No Intervention|Standard of care|In this arm, patients who have difficult IV access will undergo the standard of care. The options include a) repeated attempts by a primary nurse, b) new attempts by a second nurse, c) central line placement by a physician, d) intraosseous line placement by a physician, e) physician use of ultrasound for peripheral IV placement
11488135|NCT01439113|Experimental|Ultrasound-guided IV|In this arm, the emergency nurse will apply the ultrasound machine to locate and cannulate a patient's peripheral veins
11488136|NCT01439100|Active Comparator|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
11488137|NCT01439100|Placebo Comparator|Dummy tablet|Placebo
11488138|NCT01439087|Experimental|OFDI imaging|OFDI imaging
11488139|NCT01439074|Active Comparator|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
11488140|NCT01439074|Active Comparator|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
11488141|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
11488142|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
11488143|NCT01439035|Experimental|MGH OFDI imaging|OFDI imaging
11488144|NCT01439022|Experimental|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
11488145|NCT01439022|Active Comparator|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
11488146|NCT01439009|Experimental|Tolvaptan|15 mg
11488147|NCT01439009|Placebo Comparator|Placebo|Placebo
11488148|NCT01438996|Experimental|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
11488149|NCT01438996|Experimental|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
11488150|NCT01438996|Experimental|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
11488151|NCT01438983||breastfeeding infants|
11488152|NCT01438983||bottle feeding infants|
11488153|NCT01438970|Other|ALFApump system implantation|Implantation of ALFApump system
11488154|NCT01438957|Placebo Comparator|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
11488155|NCT01438957|Experimental|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
11488156|NCT01438957|Experimental|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
11488157|NCT01438957|Experimental|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
11488158|NCT01438957|Experimental|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
11488159|NCT01438944|Other|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
11488160|NCT01438931|Placebo Comparator|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
11488161|NCT01438931|Active Comparator|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
11488162|NCT01438931|Active Comparator|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
11488163|NCT01438918|Active Comparator|200 mg|High dose active comparator
11488164|NCT01438918|Active Comparator|50 mg|Low dose active comparator
11488165|NCT01438918|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
11488166|NCT01438905|No Intervention|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
11488167|NCT01438905|Experimental|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
11488168|NCT01438905|Experimental|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
11488169|NCT01438892||tDMARDs Group|traditional DMARDs
11488170|NCT01438892||Biologics group|Biologics used in RA
11488171|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
11488172|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
11488173|NCT01438866|Experimental|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
11488174|NCT01438853|Experimental|TNX-832|Anti-tissue factor antibody
11488175|NCT01438853|Placebo Comparator|Drug Placebo|Placebo control
11488215|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
11488299|NCT01437982|Experimental|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
11488176|NCT01438840|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
11488177|NCT01438840|Placebo Comparator|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
11488178|NCT01438840|Experimental|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
11488179|NCT01438827|Active Comparator|Avanz Phleum pratense 15,000 SQ+|
11488180|NCT01438827|Active Comparator|Avanz Phleum pratense 4,000 SQ+|
11488181|NCT01438827|Placebo Comparator|Injection with no active grass component|
11488182|NCT01438814|Experimental|linagliptin + metformin|patients to receive linagliptin +metformin QD
11488183|NCT01438814|Active Comparator|metformin|patients to receive metformin BID
11488184|NCT01438801|Experimental|NutropinAq|
11488185|NCT01438788|Experimental|All patients on a low protein diet|
11488186|NCT01438775|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
11488187|NCT01438762|Active Comparator|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
11488188|NCT01438762|Active Comparator|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.
~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
11488189|NCT01438762|No Intervention|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
11488190|NCT01438749|Active Comparator|A|
11488191|NCT01438749|Placebo Comparator|B|
11488192|NCT01438749|Experimental|C|
11488193|NCT01438736|Experimental|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
11488194|NCT01438736|Experimental|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
11488195|NCT01438723|Experimental|metformin|
11488196|NCT01438723|Placebo Comparator|placebo|
11488197|NCT01438710|Experimental|LCP-Tacro|LCP Tacro tables for once daily oral administration
11488198|NCT01438710|Experimental|Prograf|Tacrolimus capsules for twice daily oral administration
11488199|NCT01438697|Experimental|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
11488200|NCT01438697|Active Comparator|Patient Education Website|Assigned to Patient Insomnia Educational Website
11488201|NCT01438684|Active Comparator|RPh201 group|7 patients will receive the treatment
11488202|NCT01438684|Placebo Comparator|non RPh201 group|3 patients will receive placebo
11488203|NCT01438671|Experimental|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
11488204|NCT01438658||All|A cohort of all the patients.
11488205|NCT01438645|Experimental|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
11488206|NCT01438645|No Intervention|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
11488207|NCT01438632|Experimental|jet injector|Jet injectors deliver insulin at a high velocity (typically >100m/s) across the skin in the subcutaneous tissue, without the use of a needle
11488208|NCT01438632|Active Comparator|conventional insulin pen|
11488209|NCT01438619||representitives of Goyang city|"Representative population of Goyang city who were randomly selected by digit dialing (RDD) method
~Volunteers who are reside in Goyang city"
11488210|NCT01438606|Experimental|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10^4 PFU is the nominal dose; the actual dose is 4.6 x 10^3 PFU given as 2.3 x 10^3 PFU in each deltoid)
11488211|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
11488212|NCT01438606|Experimental|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^5 PFU is the nominal dose; the actual dose is 4.6 x 10^4 PFU given as 2.3 x 10^4 PFU in each deltoid)
11488213|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
11488214|NCT01438606|Experimental|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^6 PFU is the nominal dose; the actual dose is 4.8 x 10^5 PFU given as 2.4 x 10^5 PFU in each deltoid)
11488216|NCT01438606|Experimental|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^7 PFU is the nominal dose; the actual dose is 4.2 x 10^6 PFU given as 2.1 x 10^6 PFU in each deltoid)
11488217|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
11488218|NCT01438606|Experimental|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^8 PFU is the nominal dose; the actual dose is 3.4 x 10^7 PFU given as 1.7 x 10^7 PFU in each deltoid)
11488219|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
11488220|NCT01438593|Experimental|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
11488221|NCT01438580|Experimental|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
11488222|NCT01438580|Experimental|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
11488223|NCT01438580|Active Comparator|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
11488224|NCT01438567|Experimental|OXN PR tablets|
11488225|NCT01438567|Active Comparator|OxyPR tablets|
11488226|NCT01438554|Experimental|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
11488227|NCT01438541|Experimental|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
11488228|NCT01438515|Experimental|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
11488229|NCT01438515|Active Comparator|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
11488230|NCT01438502||HyperHAES|
11488231|NCT01438489|Experimental|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
11488232|NCT01438489|Experimental|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
11488233|NCT01438489|Placebo Comparator|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
11488234|NCT01438476|Experimental|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
11488235|NCT01438476|Experimental|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
11488236|NCT01438463|Placebo Comparator|placebo|
11488237|NCT01438463|Experimental|PURETHAL Mites, 6,667 AU/ml|
11488238|NCT01438463|Experimental|PURETHAL Mites, 20,000 AU/ml|
11488239|NCT01438463|Experimental|PURETHAL Mites, 50,000 AU/ml|
11488240|NCT01438463|Experimental|PURETHAL Mites, 100,000 AU/ml|
11488241|NCT01438450|No Intervention|Supportive|Supportive therapy
11488242|NCT01438450|Active Comparator|Oral|Oral thalidomide and capecitabine
11488243|NCT01438437|Active Comparator|Percutaneous acetic acid|
11488244|NCT01438437|Active Comparator|Radiofrequency ablation|
11488245|NCT01438424|Experimental|Entecavir, 1.0 mg, with or without lamivudine|
11488246|NCT01438411|Other|Cholic Acid|Active drug
11488247|NCT01438398|Other|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
11488248|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
11488249|NCT01438372|Experimental|Intravenous iron sucrose arm|
11488250|NCT01438372|Active Comparator|Oral ferrous sulfate|
11488251|NCT01438359|Experimental|PA21 and Furosemide with food|
11488252|NCT01438359|Experimental|No PA21; Furosemide with food|
11488253|NCT01438359|Experimental|PA21 with food and Furosemide 2hrs later|
11488254|NCT01438346|Active Comparator|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
11488255|NCT01438346|Experimental|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
11488256|NCT01438333|Experimental|Lactobacillus brevis|
11488257|NCT01438333|Placebo Comparator|Placebo|5 tablets a day for 6 weeks
11488258|NCT01438320|Experimental|Quercetin|Quercetin is a bioflavonoid.
11488298|NCT01437982|Experimental|Loteprednol Etabonate|Ophthalmic Gel 0.5%
11488259|NCT01438307|Experimental|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.
~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
11488260|NCT01438307|Experimental|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.
~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
11488261|NCT01438294|Active Comparator|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
11488262|NCT01438294|Experimental|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
11488263|NCT01438281|Experimental|SYL1001|
11488264|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
11488265|NCT01438255||Alvesco|
11488266|NCT01438242|Experimental|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
11488267|NCT01438242|Experimental|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
11488268|NCT01438229|Experimental|renal artery ablation|Catheter-based RF ablation in renal artery
11488269|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
11488270|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
11488271|NCT01438203|Experimental|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
11488272|NCT01438203|Active Comparator|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
11488273|NCT01438190|Experimental|Experimental|Metformin plus step-down protocol
11488274|NCT01438190|Active Comparator|Control|Placebo and step-up protocol
11488275|NCT01438177|Experimental|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.
~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.
~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.
~Each cycle is 42 days in length."
11488276|NCT01438164||oncologic patients|initial staging
11488277|NCT01438151|Experimental|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
11488278|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
11488279|NCT01438125|Active Comparator|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
11488280|NCT01438125|Active Comparator|Standard surgical wound closure|
11488281|NCT01438112|Experimental|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
11488282|NCT01438112|Active Comparator|Chemotherapy or Interferon|"Quadruple Choice as interventions
~Mitomycin C
~Interferon
~Valrubicin
~Gemcitabine"
11488283|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI < 30
11488284|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI > 30
11488285|NCT01438086|Active Comparator|mecasermin low dose|
11488286|NCT01438086|Active Comparator|mecasermin high dose|
11488287|NCT01438086|Placebo Comparator|saline placebo|
11488288|NCT01438073|Experimental|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
11488289|NCT01438060|Experimental|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
11488290|NCT01438060|Placebo Comparator|Placebo|Double blind Acute Phase (Week 1 to Week 10)
11488291|NCT01438034|Experimental|kisspeptin|intravenous administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
11488292|NCT01438021|Experimental|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
11488293|NCT01438008|Experimental|Sucrose 24% po|"24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
11488294|NCT01438008|Placebo Comparator|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
11488295|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
11488296|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
11488297|NCT01437995|Active Comparator|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
11488300|NCT01437943|Active Comparator|Aliskiren|Aliskiren 150 mg daily for 180 days
11488301|NCT01437943|Placebo Comparator|Placebo|Placebo identical to Aliskiren drug daily for 180 days
11488302|NCT01437930|Placebo Comparator|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
11488303|NCT01437917|Experimental|Bread with 20% amylose content|Bread with 20% amylose content
11488304|NCT01437917|Experimental|Bread with 10% amylose content|Bread with 10% amylose content
11488305|NCT01437917|Experimental|carbohydrates|50g of carbohydrates ingested with 400 ml of water
11488306|NCT01437904|Experimental|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
11488307|NCT01437904|Sham Comparator|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
11488308|NCT01437878|Experimental|iloprost|single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
11488309|NCT01437878|Placebo Comparator|placebo|matching placebo using the power disc-6 with I-neb AAD system
11488310|NCT01437865|Experimental|Gadofosveset enhanced MRI Axilla|
11488311|NCT01437852|Experimental|StrataGraft skin tissue|"All subjects enrolled in this study will receive StrataGraft tissue. Will randomly assign treatment regimens to the two comparable study treatment sites pre-identified as A or B. A sealed randomization envelope will be supplied to the clinical site along with the shipment of clinical tissue. Neither the surgeon nor scrubbed operating room personnel will be informed of the randomization until completion of surgical excision. The treatment sites A or B will be randomized to receive either StrataGraft skin tissue or autograft using a 1:1 ratio.
~Two comparable areas of healthy skin will be pre-identified by the clinical staff as donor sites A or B. The randomization assignment will be identical as that above for the treatment sites. For example, if treatment site A is randomized to receive an autograft, donor site A will be designated the donor site for autografting"
11488312|NCT01437839|Experimental|1|Period I: fasting state, Period II: fed state
11488313|NCT01437839|Experimental|2|Period I: fed state, Period II: fasting state
11488314|NCT01437826|Experimental|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
11488315|NCT01437826|Placebo Comparator|Sugar pill|placebo had an identical appearance as intervention
11488316|NCT01437787|Placebo Comparator|Placebo comparator|once daily X 28 days, orally, empty stomach, approximately same time each day
11488317|NCT01437787|Experimental|SAR302503 400 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
11488318|NCT01437787|Experimental|SAR302503 500 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
11488319|NCT01437774|Active Comparator|Concentric Thrombectomy Catheter|Control Arm
11488320|NCT01437774|Experimental|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
11488321|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
11488322|NCT01437748|Experimental|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
11488323|NCT01437748|Active Comparator|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
11488324|NCT01437735|Experimental|QAW039 po dose 1|
11488325|NCT01437735|Experimental|QAW039 po dose 2|
11488326|NCT01437735|Experimental|QAW039 po dose 3|
11488327|NCT01437735|Experimental|QAW039 po dose 4|
11488328|NCT01437735|Experimental|QAW039 po dose 5|
11488329|NCT01437735|Experimental|QAW039 po dose 6|
11488330|NCT01437735|Experimental|QAW039 po dose 7|
11488331|NCT01437735|Experimental|QAW039 po dose 8|
11488332|NCT01437735|Experimental|QAW039 po dose 9|
11488333|NCT01437735|Experimental|QAW039 po dose 10|
11488334|NCT01437735|Experimental|QAW039 po dose 11|
11488335|NCT01437735|Experimental|QAW039 po dose 12|
11488336|NCT01437735|Experimental|QAW039 po dose 13|
11488337|NCT01437735|Active Comparator|Montelukast po 10 mg|Comparator leukotriene receptor antagonist (LRTA)
11488338|NCT01437735|Placebo Comparator|Placebo|
11488339|NCT01437722|Experimental|1% SPL7013 Gel|
11488340|NCT01437722|Experimental|3% SPL7013 Gel|
11488341|NCT01437722|Placebo Comparator|placebo gel|
11488342|NCT01437709|Experimental|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
11488343|NCT01437709|Experimental|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
11488344|NCT01437696|Experimental|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
11488345|NCT01437696|Experimental|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
11488346|NCT01437696|Placebo Comparator|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
11488347|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
11488348|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
11488349|NCT01437657|Placebo Comparator|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
11488350|NCT01437657|Experimental|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
11488351|NCT01437657|Experimental|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
11488352|NCT01437644|Active Comparator|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.
~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
11488353|NCT01437644|Placebo Comparator|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
11488354|NCT01437631|Experimental|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
11488355|NCT01437631|No Intervention|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
11488356|NCT01437618||BRAF mutant mCRC|
11488357|NCT01437605|Active Comparator|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
11488358|NCT01437605|Active Comparator|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
11488359|NCT01437592|Experimental|IDeg|
11488360|NCT01437579|Active Comparator|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
11488361|NCT01437579|Sham Comparator|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
11488362|NCT01437566|Placebo Comparator|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11488363|NCT01437566|Experimental|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11488364|NCT01437566|Experimental|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11488365|NCT01437566|Placebo Comparator|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11488366|NCT01437566|Experimental|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
11488367|NCT01437553|Other|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
11488368|NCT01437540|Experimental|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
11488369|NCT01437540|Active Comparator|2|Inhaled formoterol fumarate 12 μg, twice per day
11488370|NCT01437527|Experimental|Interventional arm|Body image therapy with Anamorphic Micro software
11488371|NCT01437527|Active Comparator|control arm|Body image therapy as usual
11488372|NCT01437514|Experimental|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
11488373|NCT01437514|No Intervention|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
11488374|NCT01437514|Experimental|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
11488375|NCT01437514|No Intervention|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
11488376|NCT01437501|Experimental|Broccoli Sprout Extract Beverage|
11488377|NCT01437501|Placebo Comparator|Placebo beverage|
11488378|NCT01437488|Experimental|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
11488379|NCT01437475|Experimental|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
11488380|NCT01437449|Experimental|Cisplatin + Docetaxel + Cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
11488381|NCT01437436||obesity|otitis media patient with obesity
11488382|NCT01437436||non obesity|otitis media patient with non obesity
11488383|NCT01437423|Experimental|TETRAXIM™ vaccine|Participants will receive a primary or booster dose of TETRAXIM™
11488384|NCT01437410||EUS-FNA|
11488385|NCT01437397|Experimental|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
11488386|NCT01437397|Experimental|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
11488387|NCT01437397|Active Comparator|3|Aclidinium monotherapy 400 μg
11488388|NCT01437397|Active Comparator|4|Formoterol monotherapy 12 μg
11488389|NCT01437397|Placebo Comparator|5|Placebo
11488390|NCT01437384|Experimental|E5501 plus minus verapamil; plus minus cyclosporine|
11488391|NCT01437371|Other|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
11488392|NCT01437371|Other|usual care|
11488393|NCT01437358||intensive care unit|
11488394|NCT01437332||Diabetes|
11488395|NCT01437332||Nerve injury|
11488396|NCT01437332||Other|
11488397|NCT01437319|Active Comparator|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
11488398|NCT01437319|Active Comparator|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
11488399|NCT01437306|Experimental|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
11488400|NCT01437306|Experimental|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
11488401|NCT01437293|Experimental|Experimental|L-dopa / carbidopa / entacapone (LCE)
11488402|NCT01437280|Experimental|CGTG-102|CGTG-102 is an oncolytic adenovirus
11488403|NCT01437267|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
11488404|NCT01437267|Active Comparator|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
11488405|NCT01437267|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
11488406|NCT01437267|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
11488407|NCT01437267|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
11488408|NCT01437267|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
11488409|NCT01437254|Experimental|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
11488410|NCT01437254|Active Comparator|Arm Number 2 GPERT|1 GPERT Scan
11488411|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
11488412|NCT01437228|Other|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
11488413|NCT01437228|Placebo Comparator|CONTROL|
11488414|NCT01437215|Experimental|Fenestrated Endografting|
11488415|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
11488416|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
11488417|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
11488418|NCT01437176|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
11488419|NCT01437176|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
11488420|NCT01437163|Sham Comparator|Red Incandescent light source|
11488421|NCT01437163|Active Comparator|TopHat 655|
11488422|NCT01437150|Experimental|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
11488423|NCT01437150|Experimental|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
11488424|NCT01437137|Active Comparator|LMA group|
11488425|NCT01437137|Experimental|I-gel group|
11488426|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
11488427|NCT01437111|Experimental|Fosamax Plus|Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants
11488428|NCT01437098|Experimental|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
11488429|NCT01437072||Total study population|
11488430|NCT01437059|Active Comparator|ALN-PCS02|
11488431|NCT01437059|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11488432|NCT01437046|Experimental|Doxazosin|Doxazosin 16mg/day
11488433|NCT01437046|Placebo Comparator|Placebo|Placeno
11488434|NCT01437020|Experimental|Dose escalating-IV infusion of SCH708980 and Ambisome|
11488607|NCT01435759|Experimental|Antidepressant + SPD489 50 mg|
11488435|NCT01436994|Active Comparator|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
11488436|NCT01436994|Active Comparator|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
11488437|NCT01436981||CABG with papaverine|Patients with CABG procedure
11488438|NCT01436968|Experimental|ProstAtak®|ProstAtak® (AdV-tk) + valacyclovir + radiation therapy +/- ADT
11488439|NCT01436968|Placebo Comparator|Control|Placebo + valacyclovir + radiation therapy +/- ADT
11488440|NCT01436955|Experimental|A|
11488441|NCT01436955|Placebo Comparator|B|
11488442|NCT01436942|Experimental|Exercise group|
11488443|NCT01436942|No Intervention|Control group|
11488444|NCT01436929|Experimental|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
11488445|NCT01436929|Placebo Comparator|Placebo|administration of placebo with anti-TB drugs
11488446|NCT01436916|Active Comparator|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
11488447|NCT01436916|Placebo Comparator|Placebo + lifestyle counselling|will receive placebo
11488448|NCT01436890|Experimental|Low dose|Low dose revamilast
11488449|NCT01436890|Experimental|Medium dose|Medium dose Revamilast
11488450|NCT01436890|Experimental|High dose|High dose Revamilast
11488451|NCT01436890|Placebo Comparator|Placebo|Matching placebo in triple dummy format
11488452|NCT01436877|Experimental|device|Insertion of Temporary Implantable Nitinol Device (TIND)
11488453|NCT01436864|Experimental|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
11488454|NCT01436864|Sham Comparator|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
11488455|NCT01436851|Experimental|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
11488456|NCT01436838||Group 1|
11488457|NCT01436825||Group 1|
11488458|NCT01436812|Placebo Comparator|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
11488459|NCT01436812|Active Comparator|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
11488460|NCT01436799|Experimental|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
11488461|NCT01436799|Active Comparator|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
11488462|NCT01436786|Experimental|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
11488463|NCT01436786|No Intervention|Control group|continues usual plan of care
11488464|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
11488465|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
11488466|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
11488467|NCT01436747|Active Comparator|Paricalcitol|
11488468|NCT01436747|Placebo Comparator|Matching placebo|
11488469|NCT01436734|Experimental|GIP|
11488470|NCT01436721|No Intervention|Surgicel® absorbable Haemostat|
11488471|NCT01436695||Epicall group|patients will be connected to Epicall sensor
11488472|NCT01436656|Experimental|LGX818 - Dose escalation|
11488473|NCT01436656|Experimental|LGX818 - Dose Expansion at MTD or RP2D|
11488474|NCT01436643|Experimental|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
11488475|NCT01436643|Experimental|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
11488476|NCT01436643|Experimental|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
11488516|NCT01436370|Experimental|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
11488477|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.
~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
11488478|NCT01436604|Other|LV dysfunction group|Cardiac MRI
11488479|NCT01436604|Other|Control group|Cardiac MRI
11488480|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
11488481|NCT01436565|Experimental|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
11488482|NCT01436539|Experimental|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
11488483|NCT01436539|Active Comparator|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
11488484|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
11488485|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
11488486|NCT01436513|Experimental|A|Premarin reference tablet as a single oral dose under fasted conditions
11488487|NCT01436513|Experimental|B|Premarin new tablet as a single oral dose under fasted conditions
11488488|NCT01436513|Experimental|C|Premarin reference tablet as a single oral dose under fed conditions
11488489|NCT01436513|Experimental|D|Premarin new tablet as a single oral dose under fed conditions
11488490|NCT01436500|Experimental|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
11488491|NCT01436500|Placebo Comparator|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
11488492|NCT01436500|Experimental|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
11488493|NCT01436500|Experimental|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
11488494|NCT01436500|Experimental|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
11488495|NCT01436500|Experimental|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
11488496|NCT01436500|Experimental|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
11488497|NCT01436500|Experimental|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
11488498|NCT01436500|Placebo Comparator|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
11488499|NCT01436487|Experimental|Cohort 1|Low dose MultiStem or Placebo
11488500|NCT01436487|Experimental|Cohort 2|High dose MultiStem or Placebo
11488501|NCT01436487|Experimental|Cohort 3|Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
11488502|NCT01436474|Experimental|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
11488503|NCT01436474|Placebo Comparator|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
11488504|NCT01436448|Experimental|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
11488505|NCT01436448|No Intervention|Placebo|Microcrystalline cellulose/d each, up till deliver
11488506|NCT01436435|Experimental|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
11488507|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
11488508|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
11488509|NCT01436422|Placebo Comparator|Placebo|Participants will receive the placebo at Day 0 and Day 180.
11488510|NCT01436409|Other|only vaginal touch|
11488511|NCT01436409|Experimental|vaginal touch +echography|
11488512|NCT01436396|Experimental|CYD Dengue Vaccine Group|Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month [M] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
11488513|NCT01436396|Experimental|Placebo Group|Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
11488514|NCT01436370|Experimental|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
11488515|NCT01436370|Experimental|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
11488517|NCT01436370|Experimental|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
11488518|NCT01436357|Experimental|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
11488519|NCT01436357|Placebo Comparator|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
11488520|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
11488521|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
11488522|NCT01436331|Active Comparator|Treatment As Usual (TAU)|
11488523|NCT01436331|Experimental|TAU+CBT for pts+Family Intervention+CM|
11488524|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
11488525|NCT01436305|Active Comparator|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).
~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
11488526|NCT01436305|Experimental|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).
~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
11488527|NCT01436305|Experimental|Basiliximab induction/Short-term Tac|"Short term = 3 months
~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).
~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
11488528|NCT01436292|Experimental|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
11488529|NCT01436279|Experimental|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
11488530|NCT01436279|Active Comparator|Osmotic dilators|Placed 20-24 hours prior to procedure
11488531|NCT01436266|Active Comparator|Misoprostol|400 mcg buccally 2 hours prior to procedure
11488532|NCT01436266|Placebo Comparator|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
11488533|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
11488534|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
11488535|NCT01436227|Experimental|Pazopanib|800 mg by mouth once daily for up to six, four week cycles.
11488536|NCT01436214|Experimental|APC-100|
11488537|NCT01436201|Experimental|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.
~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
11488538|NCT01436188|Other|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
11488539|NCT01436188|Other|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
11488540|NCT01436188|Other|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
11488541|NCT01436188|Other|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
11488542|NCT01436188|Other|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
11488543|NCT01436175|Experimental|SPD489 + Antidepressant|
11488544|NCT01436162|Experimental|Antidepressant + SPD489|
11488545|NCT01436162|Placebo Comparator|Antidepressant + Placebo|
11488546|NCT01436149|Experimental|Antidepressant + SPD489|
11488547|NCT01436149|Placebo Comparator|Antidepressant + Placebo|
11488548|NCT01436136|Active Comparator|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
11488549|NCT01436136|Active Comparator|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
11488550|NCT01436123|Experimental|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
11488551|NCT01436123|Active Comparator|Stenting|Put in everolimus-eluting stent
11488552|NCT01436110|Experimental|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
11488553|NCT01436110|Active Comparator|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
11488554|NCT01436110|Placebo Comparator|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
11488605|NCT01435759|Experimental|Antidepressant + SPD489 10 mg|
11488606|NCT01435759|Experimental|Antidepressant + SPD489 30 mg|
11488734|NCT01434914|Active Comparator|verum|
11488555|NCT01436097|Active Comparator|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
11488556|NCT01436097|Experimental|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
11488557|NCT01436097|Experimental|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
11488558|NCT01436097|Experimental|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
11488559|NCT01436084|Experimental|SB1518|400 mg orally a day for 28 day cycle.
11488560|NCT01436071|Experimental|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
11488561|NCT01436071|Placebo Comparator|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
11488562|NCT01436058|Experimental|stem cell recipient|patients with ankle joint osteoarthritis
11488563|NCT01436045|Experimental|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
11488564|NCT01436045|Placebo Comparator|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
11488565|NCT01436032|Experimental|N1539 15 mg|
11488566|NCT01436032|Experimental|N1539 30 mg|
11488567|NCT01436032|Active Comparator|Ketorolac|IV
11488568|NCT01436032|Placebo Comparator|Placebo|IV
11488569|NCT01436032|Experimental|N1539 7.5mg|
11488570|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
11488571|NCT01436006||CT scan|patient with cancer
11488572|NCT01435993|Experimental|Active|GSK1223249 slow (60 minutes) intravenous infusion
11488573|NCT01435993|Placebo Comparator|Placebo|Saline slow (60 minutes) intravenous infusion
11488574|NCT01435980|No Intervention|basal treatment|basal treatment
11488575|NCT01435980|Experimental|Gastric Bypass|basal treatment and Gastric Bypass
11488576|NCT01435980|Experimental|Exenatide|basal treatment and Exenatide
11488577|NCT01435967||Cohort A|Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
11488578|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
11488579|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
11488580|NCT01435928|Experimental|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
11488581|NCT01435928|Placebo Comparator|Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
11488582|NCT01435915|Experimental|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
11488583|NCT01435902|Active Comparator|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
11488584|NCT01435902|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
11488585|NCT01435876|Active Comparator|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
11488586|NCT01435876|Active Comparator|Exercises|ORTHOPTICS/MINUS LENS THERAPY
11488587|NCT01435876|Active Comparator|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
11488588|NCT01435876|Active Comparator|Surgical|
11488589|NCT01435863|Experimental|SP-02L|
11488590|NCT01435850|Sham Comparator|HIP STEM SL PLUS|study group
11488591|NCT01435850|Active Comparator|HIP STEM SL PLUS MIA|control group
11488592|NCT01435837|Experimental|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)
~1 liter of water"
11488593|NCT01435837|Placebo Comparator|No caffeine, no hydration.|
11488594|NCT01435824|Active Comparator|Water as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml water and orally administered in a fasting state.
11488595|NCT01435824|Experimental|Human milk as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml human milk and orally administered in a fasting state.
11488596|NCT01435811|Experimental|Norovirus challenge pool (GII.4, CIN-1)|
11488597|NCT01435811|Placebo Comparator|Sterile water|
11488598|NCT01435798|Placebo Comparator|0% MTD Dex|0% MTD Dextromethorphan
11488599|NCT01435798|Experimental|25% MTD Dex|25% MTD Dextromethorphan
11488600|NCT01435798|Experimental|50% MTD Dex|50% MTD Dextromethorphan
11488601|NCT01435798|Experimental|100% MTD Dex|100% MTD Dextromethorphan
11488602|NCT01435772|Experimental|BMN 701 20mg/kg|BMN 701 20mg/kg IV every other week
11488603|NCT01435772|Experimental|BMN 701 10mg/kg|BMN 701 10mg/kg IV every other week
11488604|NCT01435772|Experimental|BMN 701 5mg/kg|BMN 701 5mg/kg IV every other week
11488608|NCT01435759|Experimental|Antidepressant + SPD489 70 mg|
11488609|NCT01435759|Placebo Comparator|Antidepressant + Placebo|
11488610|NCT01435746|Experimental|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
11488611|NCT01435746|Active Comparator|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
11488612|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
11488613|NCT01435720|Experimental|Cohort 1|0.0125 mg/kg
11488614|NCT01435720|Experimental|Cohort 2|0.05 mg/kg
11488615|NCT01435720|Experimental|Cohort 3|0.2 mg/kg
11488616|NCT01435720|Experimental|Cohort 4|0.375 mg/kg
11488617|NCT01435707|Experimental|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
11488618|NCT01435707|Experimental|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
11488619|NCT01435707|Experimental|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
11488620|NCT01435707|Experimental|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
11488621|NCT01435694|Experimental|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
11488622|NCT01435694|Active Comparator|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
11488623|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
11488624|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
11488625|NCT01435668|Other|Control|A simple written advice.
11488626|NCT01435668|Experimental|Brief Motivational Intervention (BMI)|Brief Motivational Intervention (BMI)
11488627|NCT01435655|Experimental|open|tafamidis
11488628|NCT01435642||A|
11488629|NCT01435629||Norditropin®|
11488630|NCT01435616|Experimental|LY2605541|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
11488631|NCT01435616|Active Comparator|Glargine|Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
11488632|NCT01435603|Active Comparator|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
11488633|NCT01435603|Experimental|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
11488634|NCT01435577|Experimental|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
11488635|NCT01435577|Placebo Comparator|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
11488636|NCT01435564|Active Comparator|pedometer|
11488637|NCT01435564|Experimental|Mobile phone physical activity intervention|
11488638|NCT01435538|Experimental|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
11488639|NCT01435538|No Intervention|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
11488640|NCT01435525||Nexium|
11488641|NCT01435512|Experimental|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
11488642|NCT01435512|No Intervention|Waitlist|Control group - no intervention
11488643|NCT01435499|Experimental|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
11488644|NCT01435499|Experimental|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
11488645|NCT01435499|Experimental|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
11488646|NCT01435486|Active Comparator|caffeine Citrate|
11488647|NCT01435486|Placebo Comparator|Normal saline|
11488648|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
11488649|NCT01435460|Experimental|Alrex|Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
11488650|NCT01435460|Active Comparator|Patanol|Ophthalmic solution containing olopatadine, 0.1%
11488651|NCT01435447|Experimental|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
11488735|NCT01434914|Placebo Comparator|Placebo|
11488652|NCT01435434|Experimental|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
11488653|NCT01435408|Active Comparator|Conventional treatment.|Conventional primary PCI in STEMI.
11488654|NCT01435408|Experimental|IPost|Ischemic postconditioning in STEMI.
11488655|NCT01435408|Experimental|Deferred primary PCI.|Deferred strategy in STEMI.
11488656|NCT01435395|Experimental|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
11488657|NCT01435382|Experimental|Group A|
11488658|NCT01435382|Experimental|Group B|
11488659|NCT01435382|Experimental|Group C|
11488660|NCT01435382|Experimental|Group D|
11488661|NCT01435369|Active Comparator|CT-011 at dose level 1 (1.5 mg/kg).|
11488662|NCT01435369|Active Comparator|CT-011 at dose level 2 (6 mg/kg).|
11488663|NCT01435356|Active Comparator|recMage-A3 + AS15 ASCI|MAGE-A3 positive patients treated with recMAGE-A3 + AS15 ASCI
11488664|NCT01435356|Placebo Comparator|Placebo|MAGE-A3 positive patients treated with placebo
11488665|NCT01435330|Experimental|BVS857|
11488666|NCT01435330|Placebo Comparator|Placebo|
11488667|NCT01435317|Experimental|standard|Standard treatment with the ANM T30 CR®-System
11488668|NCT01435304|Experimental|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
11488669|NCT01435304|No Intervention|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
11488670|NCT01435291|Experimental|Advagraf|
11488671|NCT01435291|Active Comparator|Prograf|
11488672|NCT01435278|Active Comparator|Glucosanol|2 tablets 3 times a day
11488673|NCT01435265|Active Comparator|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
11488674|NCT01435265|Experimental|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
11488675|NCT01435252|Experimental|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
11488676|NCT01435252|Experimental|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
11488677|NCT01435239|Experimental|resting volume group|
11488678|NCT01435239|Active Comparator|maximum volume group|
11488679|NCT01435226|Active Comparator|Arm 1|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV BID
11488680|NCT01435226|Active Comparator|Arm 2|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV placebo BID
11488681|NCT01435226|Active Comparator|Arm 3|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir placebo BID + RBV BID
11488682|NCT01435213|Experimental|Atipamezole|
11488683|NCT01435213|Experimental|Atomoxetine|
11488684|NCT01435213|Experimental|Ketamine|
11488685|NCT01435213|Experimental|Insulin-induced hypoglycemia|
11488686|NCT01435213|Experimental|Cold pressor test|
11488687|NCT01435213|Experimental|Placebo|
11488688|NCT01435200|Experimental|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
11488689|NCT01435200|Placebo Comparator|Oral iron|Ferrous fumarate 200 mg oral three times a day
11488690|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
11488691|NCT01435174|Experimental|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
11488692|NCT01435161|Active Comparator|Nifedipine|Patients in arm 1 receive Nifedipine;
11488693|NCT01435161|Active Comparator|Telmisartan|Arm 2 receive telmisartan
11488694|NCT01435148|Experimental|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
11488695|NCT01435148|Experimental|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
11488696|NCT01435135|Experimental|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
11488697|NCT01435135|Experimental|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
11488698|NCT01435135|Experimental|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
11488699|NCT01435122|Experimental|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.
~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.
~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
11488700|NCT01435109|No Intervention|Usual Care|
11488701|NCT01435109|Experimental|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
11488702|NCT01435109|Experimental|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
11488736|NCT01434901|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
11488703|NCT01435109|Experimental|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
11488704|NCT01435096|Experimental|BN80927|
11488705|NCT01435083|Experimental|nocturnal polyuria patient with desmopressin MELT|
11488706|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
11488707|NCT01435057|Active Comparator|endurance training|"Endurance training:
~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.
~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
11488708|NCT01435057|Active Comparator|strength training|"Strength training:
~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training
~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
11488709|NCT01435044|Experimental|SOF+RBV 12 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 12 weeks.
11488710|NCT01435044|Experimental|SOF+RBV 24 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 24 weeks.
11488711|NCT01435044|Experimental|GS-0938 Alone|Participants were randomized to receive GS-0938 plus placebo to match sofosbuvir for up to 24 weeks.
11488712|NCT01435044|Experimental|GS-0938+SOF|Participants were randomized to receive GS-0938 plus sofosbuvir for up to 24 weeks.
11488713|NCT01435044|Experimental|GS-0938+SOF+RBV|Participants were randomized to receive GS-0938 plus sofosbuvir plus RBV for up to 24 weeks.
11488714|NCT01435044|Experimental|Placebo|Deferred start group: Participants were randomized to receive placebo to match GS-0938 plus placebo to match sofosbuvir for 24 Weeks.
11488715|NCT01435044|Experimental|Retreatment Group - SOF+RBV 24 Weeks|After discontinuing a regimen containing GS-0938, participants received sofosbuvir plus RBV for up to 24 weeks.
11488716|NCT01435031|Other|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:
~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent
~HT PROGRESS and/or HT PILOT guide wires in recanalization
~MINI-TREK Coronary Dilatation Catheter in predilatation"
11488717|NCT01435018|Experimental|ET+ART|Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
11488718|NCT01435018|Experimental|BV+ART|Bleomycin and Vincristine (BV) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
11488719|NCT01435018|Active Comparator|PTX+ART|Paclitaxel (PTX) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
11488720|NCT01435005|Active Comparator|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
11488721|NCT01435005|Active Comparator|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
11488722|NCT01434992||H. pylori gastritis|
11488723|NCT01434979||Controls|Active Duty,DoD Beneficiary, or civilian men and women between the ages of 18 and 45 years, with a waist circumference ≤ 39.4 inches (100 cm) will be asked to participate.
11488724|NCT01434979||Exertional Heat Illness / Stroke|Active duty men and women between the ages of 18 and 45 years will be asked to participate. They must have a clinically documented heat stroke within the last year; they will not be tested any sooner than six weeks following the heat stroke. Heat stroke for the purpose of this study is defined as: a syndrome of hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure.
11488725|NCT01434966|Experimental|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
11488726|NCT01434966|Experimental|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
11488727|NCT01434966|Experimental|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
11488728|NCT01434953|Experimental|Labeled|
11488729|NCT01434953|Active Comparator|Unlabeled|
11488730|NCT01434940|Experimental|Alzheimer|Patients suffering of Alzheimer disease
11488731|NCT01434940|Experimental|Depression|Patients suffering from depression
11488732|NCT01434940|Experimental|Healthy|Healthy volunteers
11488733|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
11488737|NCT01434901|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
11488738|NCT01434901|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
11488739|NCT01434888|Active Comparator|Tafluprost 0.0015%|
11488740|NCT01434888|Active Comparator|Timolol 0.5%|
11488741|NCT01434888|Experimental|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
11488742|NCT01434862|Experimental|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
11488743|NCT01434862|Experimental|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
11488744|NCT01434862|Experimental|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
11488745|NCT01434849|Experimental|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
11488746|NCT01434849|Placebo Comparator|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
11488747|NCT01434836|Active Comparator|active tDCS and working memory training|
11488748|NCT01434836|Placebo Comparator|sham tDCS and working memory training|
11488749|NCT01434823|Experimental|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
11488750|NCT01434823|No Intervention|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
11488751|NCT01434810|Experimental|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
11488752|NCT01434810|Active Comparator|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
11488753|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
11488754|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
11488755|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
11488756|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
11488757|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
11488758|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
11488759|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
11488760|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
11488761|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
11488762|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
11488763|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
11488764|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
11488765|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
11488766|NCT01434745|Placebo Comparator|Placebo|placebo
11488767|NCT01434745|Experimental|Simvastatin|0.5 mg/kg body weight/day
11488768|NCT01434732|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
11488769|NCT01434732|Active Comparator|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
11488770|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
11488771|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
11488772|NCT01434706|Other|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
11488773|NCT01434693|Experimental|TSO 500|
11488774|NCT01434693|Experimental|TSO 2500|
11488775|NCT01434693|Experimental|TSO 7500|
11488776|NCT01434693|Placebo Comparator|Placebo|single dose
11488847|NCT01434134|Experimental|Metoprolol|Tablet, target dose 100 mg once daily
11488777|NCT01434680|Experimental|MenC-CRM LIQ (Liquid Formulation)|Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.
11488778|NCT01434680|Experimental|MenC-CRM ROS (Rosia)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy
11488779|NCT01434680|Active Comparator|MenC-CRM EMV (Emeryville)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA
11488780|NCT01434667|Active Comparator|APOE Genotype Non-Disclosure|Subjects will receive Alzheimer's disease risk disclosure. This assessment is based on age and MCI status alone.
11488781|NCT01434667|Experimental|APOE Genotype Disclosure|Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure. The assessment is based on age, MCI status, and genotype.
11488782|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
11488783|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
11488784|NCT01434641|Other|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
11488785|NCT01434628|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
11488786|NCT01434615|Experimental|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
11488787|NCT01434615|Experimental|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
11488788|NCT01434602|Experimental|1/Phase I (closed)|daily everolimus (days 1- 28) in combination with sorafenib as per the Phase I dosing table
11488789|NCT01434602|Experimental|2/Phase II|combination of sorafenib and everolimus. Sorafenib will be taken daily for 7 days on, then 7 days off. Everolimus will be taken daily.
11488790|NCT01434589|No Intervention|Wait list control|
11488791|NCT01434589|Experimental|STICA Intervention|
11488792|NCT01434576|Experimental|HGS1025 2 mg/kg|
11488793|NCT01434576|Experimental|HGS1025 10 mg/kg|
11488794|NCT01434576|Placebo Comparator|Placebo|
11488795|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
11488796|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
11488797|NCT01434550|Active Comparator|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.
~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.
~SBRT:
~30 Gy in 5 fractions to pancreatic tumor
~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
11488798|NCT01434550|Active Comparator|SBRT Alone|"30 Gy in 5 fractions to pancreatic tumor
~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
11488799|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
11488800|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
11488801|NCT01434524|No Intervention|Control|normal dietary
11488802|NCT01434524|No Intervention|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
11488803|NCT01434511|Experimental|OBI-1|
11488804|NCT01434498|Active Comparator|Arm 1|GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks
11488805|NCT01434498|Active Comparator|Arm 2|GS-5885, GS-9451, tegobuvir (GS-9190), and a placebo matching ribavirin for 24 weeks
11488806|NCT01434498|Active Comparator|Arm 3|GS-5885, GS-9451, a placebo matching tegobuvir, and Copegus® for 24 weeks
11488807|NCT01434485||Nexium|
11488808|NCT01434472|Experimental|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
11488809|NCT01434459|Experimental|Gemcitabine with TheraSphere|
11488810|NCT01434420|Experimental|Triple negative breast cancer|Triple negative breast cancer
11488811|NCT01434407|Experimental|Low AGE meal|Test meal prepared by boiling/steaming the food
11488812|NCT01434407|Experimental|High AGE meal|Test meal prepared by frying/grilling the food
11488813|NCT01434394|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
11488814|NCT01434394|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
11488815|NCT01434381|Experimental|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
11488877|NCT01433952|Experimental|500 mg Thiamine|
11488816|NCT01434368||children age 8-17 years admitted to pilot brain imaging studie|children age 8-17 years admitted to pilot brain imaging studies
11488817|NCT01434368||healthy adults|healthy adults ages 25-35 years at the time of enrollment
11488818|NCT01434368||typically developing children (with evidence of advanced bone|typically developing children (with evidence of advanced bone age relative to chronologic age); age 8 or ages 12-13
11488819|NCT01434368||typically developing children ages 12/13- 17 years|typically developing children ages 12 or 13-17 years
11488820|NCT01434368||typically developing children ages 8 - 17 years|typically developing children ages 8 - 17 years
11488821|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
11488822|NCT01434342|Experimental|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.
~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.
~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.
~Participants also learn behavioral tips and coping skills."
11488823|NCT01434342|No Intervention|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
11488824|NCT01434316|Experimental|Treatment (veliparib and dinaciclib)|"PART 1A: Patients receive veliparib PO BID on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~PART 1B: Patients receive veliparib and dinaciclib as patients in Part 1A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~PART 1C: Patients receive veliparib PO BID on days 1-7 of cycle 0. Patients then receive veliparib PO BID on days 1-21 and dinaciclib IV over 2 hours on days 1, 4, 8, and 11 or days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11488825|NCT01434303|Experimental|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
11488826|NCT01434290|Experimental|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
11488827|NCT01434290|Experimental|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
11488828|NCT01434277|Experimental|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
11488829|NCT01434277|Experimental|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
11488830|NCT01434264|Experimental|Self-selected energy healing|Self-selected healing in the self-selection arm
11488831|NCT01434264|No Intervention|self-selected control|Self-selected control in the self-selection arm
11488832|NCT01434264|Experimental|randomized to energy healing|Randomized to healing in the randomization arm
11488833|NCT01434264|No Intervention|Randomized control|Randomized to control in the randomization arm
11488834|NCT01434251|Active Comparator|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
11488835|NCT01434251|Other|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
11488836|NCT01434238|Experimental|Intervention participant|
11488837|NCT01434225|Experimental|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
11488838|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
11488839|NCT01434199|Experimental|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
11488840|NCT01434199|No Intervention|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
11488841|NCT01434186|Experimental|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
11488842|NCT01434186|Placebo Comparator|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
11488843|NCT01434173||Group 1|
11488844|NCT01434173||Group 2|
11488845|NCT01434160|Experimental|Arm 1|
11488846|NCT01434147|Experimental|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
11488848|NCT01434134|Placebo Comparator|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
11488849|NCT01434134|Experimental|Candesartan|Tablet, target dose 32 mg once daily
11488850|NCT01434134|Placebo Comparator|Placebo for Candesartan|Tablet, target dose 32 mg once daily
11488851|NCT01434121|Active Comparator|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
11488852|NCT01434121|Active Comparator|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
11488853|NCT01434121|Placebo Comparator|Placebo|Subject receives an infusion of saline
11488854|NCT01434108|Experimental|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
11488855|NCT01434108|Placebo Comparator|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
11488856|NCT01434095|Active Comparator|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
11488857|NCT01434069|Experimental|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline.
~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
11488858|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
11488859|NCT01434043||Myocardial ischemia patients|
11488860|NCT01434030|Other|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
11488861|NCT01434017|Active Comparator|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
11488862|NCT01434017|Active Comparator|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
11488863|NCT01434017|Active Comparator|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
11488864|NCT01434004|Experimental|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.
~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
11488865|NCT01434004|No Intervention|Control group|Usual care (watchful waiting).
11488866|NCT01433991|Experimental|Phase 1B|Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
11488867|NCT01433991|Experimental|Phase 2 Cohort 1 Arm A:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
11488868|NCT01433991|Experimental|Phase 2 Cohort 1 Arm B:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1*4 mg capsule + 2*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
11488869|NCT01433991|Experimental|Phase 2 Cohort 2 Arm C:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
11488870|NCT01433991|Experimental|Phase 2 Cohort 2 Arm D:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
11488871|NCT01433978|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
11488872|NCT01433978|Active Comparator|Eltrombopag (Core Study)|Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.
11488873|NCT01433978|Experimental|Avatrombopag (Open-label Extension)|Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.
11488874|NCT01433965|Experimental|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
11488875|NCT01433952|Placebo Comparator|0 mg Thiamine|
11488876|NCT01433952|Experimental|100 mg Thiamine|
11488878|NCT01433952|Experimental|1500 mg Thiamine|
11488879|NCT01433913|Experimental|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
11488880|NCT01433913|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
11488881|NCT01433900|Active Comparator|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
11488882|NCT01433900|Active Comparator|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
11488883|NCT01433887|Experimental|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
11488884|NCT01433887|Experimental|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
11488885|NCT01433887|Experimental|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
11488886|NCT01433874|Experimental|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
11488887|NCT01433874|Experimental|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
11488888|NCT01433874|Experimental|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
11488889|NCT01433874|Placebo Comparator|Control group|Co2 was removed by passive exsufflation through the port site
11488890|NCT01433861|Active Comparator|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
11488891|NCT01433861|Active Comparator|LATG|LATG : laparoscopy-assisted total gastrectomy group
11488892|NCT01433848||Child A liver cirrhosis|
11488893|NCT01433848||Child B liver cirrhosis|
11488894|NCT01433848||Child C liver cirrhosis|
11488895|NCT01433835|Placebo Comparator|Placebo|
11488896|NCT01433835|Experimental|MBX-400|
11488897|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
11488898|NCT01433770|Experimental|Alefacept action on memory T cells|
11488899|NCT01433757|Active Comparator|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
11488900|NCT01433757|Placebo Comparator|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
11488901|NCT01433744|Experimental|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
11488902|NCT01433744|No Intervention|Periodontally healthy|
11488903|NCT01433731|Placebo Comparator|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
11488904|NCT01433731|Experimental|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
11488905|NCT01433731|Experimental|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
11488906|NCT01433731|Experimental|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
11488907|NCT01433718|Experimental|ACL prevention training|
11488908|NCT01433705|Other|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.
11488909|NCT01433705|Other|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
11488910|NCT01433705|Other|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
11488911|NCT01433692|Experimental|intervention group|
11488912|NCT01433692|Other|control group|
11488913|NCT01433679|Experimental|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
11488914|NCT01433679|No Intervention|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
11488915|NCT01433666|Experimental|roflumilast 100ug|
11488916|NCT01433666|Experimental|roflumilast 300ug|
11488917|NCT01433666|Experimental|roflumilast1000ug|
11488918|NCT01433666|Placebo Comparator|placebo|
11488919|NCT01433653|Experimental|CG-CBT|
11488920|NCT01433653|No Intervention|wait list control|
11488921|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
11488922|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
11488923|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
11488924|NCT01433627|Experimental|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
11488925|NCT01433627|Experimental|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.
~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
11488926|NCT01433627|Experimental|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.
~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
11488927|NCT01433627|Experimental|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.
~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
11488928|NCT01433627|Experimental|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.
~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
11488929|NCT01433627|Active Comparator|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
11488930|NCT01433614|Active Comparator|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
11488931|NCT01433614|Active Comparator|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
11488932|NCT01433601|No Intervention|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
11488933|NCT01433601|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
11488934|NCT01433588|Active Comparator|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
11488935|NCT01433588|Placebo Comparator|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
11488936|NCT01433575|Experimental|A|
11488937|NCT01433575|Experimental|B|
11488938|NCT01433562|Experimental|DLBS1425|
11488939|NCT01433562|Placebo Comparator|Placebo|
11488940|NCT01433549|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
11488941|NCT01433549|Other|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
11488942|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
11488943|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
11488944|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
11488945|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
11488946|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
11488947|NCT01433536||Control|Healthy individuals
11488948|NCT01433523|Placebo Comparator|Placebo|
11488949|NCT01433523|Experimental|ALK HDM AIT 6 DU|
11488950|NCT01433523|Experimental|ALK HDM AIT 12 DU|
11488951|NCT01433510|Experimental|Grazax Tablets 75000 SQT|Timothy Extract
11488952|NCT01433497|Experimental|Experimental Arm A|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
11488953|NCT01433497|Experimental|Experimental Arm B|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
11488954|NCT01433497|Placebo Comparator|Placebo Comparator A|Participants receive placebo given orally twice daily.
11488955|NCT01433497|Placebo Comparator|Placebo Comparator B|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
11488956|NCT01433484|Active Comparator|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
11488957|NCT01433484|Experimental|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
11488958|NCT01433471|Experimental|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
11488959|NCT01433471|Active Comparator|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
11489009|NCT01433120|Experimental|Probiotic L. casei F19|
11489010|NCT01433120|Experimental|Flax seed fibres|
11488960|NCT01433458|Experimental|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
11488961|NCT01433458|Experimental|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
11488962|NCT01433458|Experimental|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
11488963|NCT01433458|Active Comparator|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
11488964|NCT01433445|Experimental|Cohort 1|Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
11488965|NCT01433445|Experimental|Cohort 2|Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
11488966|NCT01433445|Experimental|Cohort 3|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
11488967|NCT01433445|Experimental|Cohort 4|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
11488968|NCT01433445|Experimental|Cohort 5|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
11488969|NCT01433445|Experimental|Cohort 6/6+|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
11488970|NCT01433432|Active Comparator|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
11488971|NCT01433432|Experimental|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
11488972|NCT01433419|Experimental|TAK-875 25 mg|
11488973|NCT01433419|Experimental|TAK-875 50 mg|
11488974|NCT01433406|Experimental|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
11488975|NCT01433406|Experimental|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
11488976|NCT01433393|Experimental|TAK-875 25 mg|
11488977|NCT01433393|Experimental|TAK-875 50 mg|
11488978|NCT01433393|Placebo Comparator|Placebo|
11488979|NCT01433380|Experimental|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
11488980|NCT01433380|Placebo Comparator|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
11488981|NCT01433367||CerPass® Total Disc Replacement|
11488982|NCT01433354|Experimental|AFQ056 Treatment|All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.
11488983|NCT01433341||Young athletes|
11488984|NCT01433328|Experimental|Lidocaine|
11488985|NCT01433328|Placebo Comparator|Placebo|Remodulin only
11488986|NCT01433315|Experimental|sleep restriction|restricted sleep during the experimental period
11488987|NCT01433315|No Intervention|normal sleep|normal sleep during the experimental period
11488988|NCT01433302||Punch Biopsy|
11488989|NCT01433289|Experimental|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
11488990|NCT01433289|Experimental|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
11488991|NCT01433289|Experimental|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
11488992|NCT01433276|Experimental|Totilac|
11488993|NCT01433276|Active Comparator|Ringer's lactate|
11488994|NCT01433263|Experimental|30mg/kg BYM338|
11488995|NCT01433263|Placebo Comparator|Placebo / late 30mg/kg BYM338|
11488996|NCT01433250|Experimental|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
11488997|NCT01433250|Experimental|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
11488998|NCT01433211||No treatment|
11488999|NCT01433198|Active Comparator|Aquatic exercise group|
11489000|NCT01433198|No Intervention|Control group|
11489001|NCT01433185|Experimental|Text message (SMS)|Text messages sent to women before and after delivery
11489002|NCT01433185|No Intervention|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
11489003|NCT01433172|Experimental|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
11489004|NCT01433172|Active Comparator|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
11489005|NCT01433172|Active Comparator|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
11489006|NCT01433159|Experimental|HP011-101|
11489007|NCT01433159|Active Comparator|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
11489008|NCT01433133|Experimental|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
11489011|NCT01433120|Placebo Comparator|Placebo|
11489012|NCT01433107|Experimental|Terbinafine|Drug
11489013|NCT01433107|Placebo Comparator|Placebo|Drug
11489014|NCT01433094|Experimental|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
11489015|NCT01433094|Active Comparator|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
11489016|NCT01433081|Active Comparator|Magnesium sulfate infusion|Administration of magnesium suflate
11489017|NCT01433081|Placebo Comparator|Placebo|.9 normal saline infusion
11489018|NCT01433068|Experimental|NBTXR3|
11489019|NCT01433055|Active Comparator|Minocycline|
11489020|NCT01433055|Placebo Comparator|Sugar Pill|
11489021|NCT01433042|Experimental|capsule endoscopy|
11489022|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
11489023|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
11489024|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
11489025|NCT01433016|Experimental|Octanaote Breath Test|A Octanoate breath test will be performed on this single arm population
11489026|NCT01433003|Active Comparator|Standard-dose plasma exchange|50-75 ml/kg/day
11489027|NCT01433003|Experimental|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
11489028|NCT01432990|Experimental|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
11489029|NCT01432990|No Intervention|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
11489030|NCT01432977|Active Comparator|comparateur|paracetamol / droperidol
11489031|NCT01432977|Experimental|Eperimental|paracetamol / ondansetron
11489032|NCT01432964||1|Adult patients (>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
11489033|NCT01432951|Experimental|Enzastaurin|"Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Participants may continue receiving optional enzastaurin for an additional 2 to 4 weeks.
~Safety Extension: Participants had the option to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
11489034|NCT01432938|Experimental|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
11489035|NCT01432938|Experimental|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
11489036|NCT01432925|Other|evaluation surgical intervention at week 8|
11489037|NCT01432925|Other|evaluation surgical intervention at week 14|
11489038|NCT01432912|No Intervention|Patients|
11489039|NCT01432886|Experimental|1|
11489040|NCT01432873|Experimental|Experimental|Oral selenium therapy arm
11489041|NCT01432873|Placebo Comparator|Placebo|Oral placebo
11489042|NCT01432860|Active Comparator|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
11489043|NCT01432860|Active Comparator|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
11489044|NCT01432860|No Intervention|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
11489045|NCT01432860|Active Comparator|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
11489046|NCT01432847||Affected|Participants affected by ocular diseases/conditions.
11489047|NCT01432847||Healthy Volunteers|Age, gender, and ethnicity-matched to participants with ocular conditions.
11489048|NCT01432834|Other|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
11489049|NCT01432834|Other|PRK group (PG group)|Volunteers of this group received PRK treatment
11489050|NCT01432821|Experimental|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:
~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
11489051|NCT01432821|Placebo Comparator|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:
~sequence B: 2 injections of saline"
11489085|NCT01432574|Experimental|Gardasil Vaccine|Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.
11489086|NCT01432561|Experimental|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
11489204|NCT01431547|Experimental|Parts 2 and 3: Dalotuzumab + ridaforolimus|
11489052|NCT01432795|Experimental|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:
~4 gliding aids
~2 stocking butlers, one with and without handle
~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)
~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)
~2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
11489053|NCT01432782|Placebo Comparator|Placebo|Placebo arm: per-endoscopic injection of saline
11489054|NCT01432782|Active Comparator|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
11489055|NCT01432769|Active Comparator|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
11489056|NCT01432769|No Intervention|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
11489057|NCT01432756|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
11489058|NCT01432756|Experimental|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
11489059|NCT01432743|Experimental|Cartomerge|Use of Cartomerge to guide ablation
11489060|NCT01432743|Active Comparator|NavX Fusion|Use of NavX fusion to guide ablation
11489061|NCT01432730|Experimental|Gefapixant 600 mg>Placebo|Gefapixant, 600 mg, twice daily (BID), taken orally for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, taken orally for 2 weeks.
11489062|NCT01432730|Experimental|Placebo>Gefapixant 600 mg|Placebo to gefapixant BID, taken orally for 2 weeks followed by a 2-week washout period and then gefapixant, 600 mg, BID, taken orally for 2 weeks.
11489063|NCT01432717|Experimental|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
11489064|NCT01432717|Placebo Comparator|Placebo|
11489065|NCT01432704|Placebo Comparator|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
11489066|NCT01432704|Active Comparator|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
11489067|NCT01432691|Other|Surgery|RSA study on hemi
11489068|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
11489069|NCT01432665|Experimental|Placebo|30 subjects administered a placebo
11489070|NCT01432665|Experimental|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
11489071|NCT01432665|Experimental|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
11489072|NCT01432665|Experimental|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
11489073|NCT01432665|Experimental|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
11489074|NCT01432665|Experimental|Sildenafil 50mg|30 subjects are given sildenafil 50mg
11489075|NCT01432665|Experimental|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
11489076|NCT01432652||vascular surgery|Patients undergoing vascular surgery
11489077|NCT01432639|Experimental|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
11489078|NCT01432639|No Intervention|Control group|Usual medical care
11489079|NCT01432626|Experimental|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
11489080|NCT01432613|Other|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
11489081|NCT01432600|Experimental|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:
~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.
~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.
~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:
~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.
~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
11489082|NCT01432600|Active Comparator|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:
~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.
~Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.
~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
11489083|NCT01432600|Active Comparator|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:
~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.
~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.
~Cyclophosphamide 400 mg PO days 1, 8, 15.
~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
11489084|NCT01432600|Other|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
11489087|NCT01432535|Active Comparator|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
11489088|NCT01432535|Experimental|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
11489089|NCT01432535|Experimental|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of <30 mL/min/1.73 m^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
11489090|NCT01432522|Experimental|epinephrine IN, epinephrine IM, saline IN|"Intranasal saline
~Intramuscular epinephrine
~Intranasal epinephrine"
11489091|NCT01432496|Experimental|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
11489092|NCT01432496|Placebo Comparator|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
11489093|NCT01432470|Experimental|Oxytocin, Intravaginal administration|
11489094|NCT01432470|Placebo Comparator|Placebo, Intravaginal administration|
11489095|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 50 mg/day|
11489096|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 100 mg/day|
11489097|NCT01432457|Placebo Comparator|Placebo|
11489098|NCT01432444|Experimental|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
11489099|NCT01432431|Experimental|Supportive care (spiritual care)|See Detailed Description.
11489100|NCT01432418|Experimental|wheelchair training|
11489101|NCT01432418|No Intervention|Control|Standard of care only
11489102|NCT01432405|Experimental|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
11489103|NCT01432405|Experimental|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
11489104|NCT01432392||1|
11489105|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
11489106|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
11489107|NCT01432353|Experimental|Single Arm|
11489108|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
11489109|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
11489110|NCT01432327|Placebo Comparator|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
11489111|NCT01432327|Experimental|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
11489112|NCT01432327|Experimental|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
11489113|NCT01432327|Experimental|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
11489114|NCT01432314|Experimental|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
11489115|NCT01432275|Experimental|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
11489116|NCT01432275|Experimental|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
11489117|NCT01432262|Experimental|Group 1|=> 65 years of age
11489118|NCT01432262|Experimental|Group 2|50 to 64 years of age
11489119|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
11489120|NCT01432236|Experimental|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
11489121|NCT01432236|Placebo Comparator|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
11489122|NCT01432223|Experimental|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
11489123|NCT01432210|Other|Tomato Meal|A tomato meal will be fed with and without avocado.
11489124|NCT01432210|Other|Carrot Meal|A carrot meal will be fed with and without avocado.
11489125|NCT01432197|Experimental|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
~Control group: Standard treatment and care. No occupational therapy intervention."
11489126|NCT01432197|No Intervention|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
11489127|NCT01432184|Active Comparator|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
11489128|NCT01432184|No Intervention|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
11489129|NCT01432171|Experimental|Arm I (lacosamide)|Participants receive lacosamide PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
11489165|NCT01431859|Active Comparator|Birch pollen immunotherapy|
11489130|NCT01432171|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
11489131|NCT01432158|Experimental|PCV-13 group|1 dose of Prevenar-13
11489132|NCT01432158|Experimental|PPV-23 group|1 dose of Pneumovax-II
11489133|NCT01432145|Experimental|6MP/MTX|6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
11489134|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
11489135|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
11489136|NCT01432119|Experimental|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
11489137|NCT01432119|Experimental|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
11489138|NCT01432106|Active Comparator|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
11489139|NCT01432106|Active Comparator|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
11489140|NCT01432093|Active Comparator|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
11489141|NCT01432093|Active Comparator|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
11489142|NCT01432080|No Intervention|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
11489143|NCT01432080|Experimental|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
11489144|NCT01432067|Other|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
11489145|NCT01432067|Other|Standard physical activity|Daily physical activities based on a standard guide
11489146|NCT01432028|Active Comparator|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
11489147|NCT01432028|Active Comparator|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
11489148|NCT01432015|Active Comparator|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
11489149|NCT01432015|Active Comparator|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
11489150|NCT01431989|Active Comparator|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
11489151|NCT01431989|Active Comparator|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
11489152|NCT01431976|Experimental|Lamotrigine|No comparison
11489153|NCT01431963|Experimental|Lamotrigine|No comparison.
11489154|NCT01431950|Experimental|FF 100mcg once daily|Inhaled corticosteroid (ICS)
11489155|NCT01431950|Experimental|FF 200mcg once daily|Inhaled corticosteroid
11489156|NCT01431937|Active Comparator|GSK2018682|Active Drug
11489157|NCT01431937|Placebo Comparator|Placebo Control|Placebo
11489158|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
11489159|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
11489160|NCT01431898|Experimental|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
11489161|NCT01431885|Active Comparator|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
11489162|NCT01431885|Placebo Comparator|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
11489163|NCT01431872||Post menopausal breast cancer patients|
11489164|NCT01431859|Placebo Comparator|Subcutaneous injection of placebo|
11489166|NCT01431846|No Intervention|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
11489167|NCT01431846|No Intervention|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
11489168|NCT01431846|Experimental|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
11489169|NCT01431833|Experimental|Moderate hepatic|
11489170|NCT01431833|Experimental|Severe Hepatic|
11489171|NCT01431833|Experimental|Matched control|
11489172|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 1|
11489173|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 2|
11489174|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 1|
11489175|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 2|
11489176|NCT01431807|Experimental|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
11489177|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-600mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.
11489178|NCT01431794|Active Comparator|Phase II-Arm A:Gem,nab-paclitaxel,LDE225|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
11489179|NCT01431794|Active Comparator|Phase II-Arm B:Gem,nab-paclitaxel|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
11489180|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-400mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.
11489181|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-800mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.
11489182|NCT01431781|Experimental|stilamin+common daily treatment|
11489183|NCT01431781|Active Comparator|common daily treatment|
11489184|NCT01431755|Other|Restylane SubQ|
11489185|NCT01431755|Other|Restylane SubQ Lidocaine|
11489186|NCT01431742|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
11489187|NCT01431729||mucositis|
11489188|NCT01431716|Experimental|EFI/ACT-385781A|EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump
11489189|NCT01431690|Experimental|Warfarin and Epanova|
11489190|NCT01431690|Active Comparator|Lovaza|
11489191|NCT01431651|Experimental|probiotic, lifestyle counseling|
11489192|NCT01431638|Experimental|Canakinumab 150mg|Canakinumab 150mg in prefilled syringe subcutaneously
11489193|NCT01431625|Active Comparator|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
11489194|NCT01431625|Active Comparator|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
11489195|NCT01431612|Active Comparator|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
11489196|NCT01431612|Active Comparator|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
11489197|NCT01431612|Placebo Comparator|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
11489198|NCT01431599|Experimental|short-course|
11489199|NCT01431586|Experimental|Single dose JDTic 1 mg, 3 mg, or 10 mg|
11489200|NCT01431573|Experimental|Wake Therapy + light box +/- lithium|"Bipolar patients must take lithium; others do not take lithium
~all patients are hospitalized for a week during which they do not sleep on alternating nights
~for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
11489201|NCT01431560|Active Comparator|metallic implant|fixation of the ankle fracture with metallic implants
11489202|NCT01431560|Active Comparator|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
11489203|NCT01431547|Experimental|Part 1: Dalotuzumab|
11489205|NCT01431534|Experimental|Ridaforolimus 22 mg/m^2|Participants receive 22 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
11489206|NCT01431534|Experimental|Ridaforolimus 28 mg/m^2|Participants receive 28 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
11489207|NCT01431534|Experimental|Ridaforolimus 33 mg/m^2|Participants receive 33 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
11489208|NCT01431521|Experimental|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
11489209|NCT01431521|Placebo Comparator|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
11489210|NCT01431521|Experimental|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
11489211|NCT01431521|Placebo Comparator|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
11489212|NCT01431508|Experimental|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
11489213|NCT01431495|Active Comparator|plavix|patient treated by the princeps
11489214|NCT01431495|Active Comparator|Pidogrel|patient treated by Pidogrel
11489215|NCT01431469|Placebo Comparator|Cow's Milk|Powdered Whole Cow's Milk
11489216|NCT01431469|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
11489217|NCT01431456|Active Comparator|Dabigatran|Dabigatran
11489218|NCT01431456|Active Comparator|Rivaroxaban|Rivaroxaban
11489219|NCT01431456|Active Comparator|Nadroparin|Nadroparin
11489220|NCT01431443|Experimental|Dark chocolate|
11489221|NCT01431443|Placebo Comparator|Placebo chocolate|Placebo intervention
11489222|NCT01431430|Experimental|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
11489223|NCT01431430|Active Comparator|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
11489224|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
11489225|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
11489226|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
11489227|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
11489228|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
11489229|NCT01431404|Active Comparator|Enbrel, prefilled syringe|
11489230|NCT01431404|Experimental|HD203, prefilled syringe|
11489231|NCT01431391|Experimental|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
11489232|NCT01431391|Experimental|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
11489233|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
11489234|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
11489235|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
11489236|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
11489237|NCT01431365|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
11489238|NCT01431365|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
11489239|NCT01431352|Experimental|Letrozole+ Chinese herbal medicine granules|
11489240|NCT01431352|Placebo Comparator|Letrozole+ Chinese herbal medicine granules placebo|
11489241|NCT01431339|Active Comparator|Vancomycin with possible switch to oral linezolid|
11489242|NCT01431339|Experimental|Dalbavancin|
11489243|NCT01431313|Experimental|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
11489244|NCT01431300|Active Comparator|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
11489245|NCT01431300|Experimental|0.02 mmol/kg|
11489246|NCT01431300|Experimental|0.01 mmol/kg|
11489247|NCT01431287|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
11489248|NCT01431287|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
11489658|NCT01428466|Experimental|GSK2585823|external preparation
11489249|NCT01431287|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
11489250|NCT01431287|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
11489251|NCT01431287|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
11489252|NCT01431274|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
11489253|NCT01431274|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
11489254|NCT01431274|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
11489255|NCT01431274|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
11489256|NCT01431274|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
11489257|NCT01431261|Active Comparator|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
11489258|NCT01431261|Active Comparator|Pain Management|Education in pain management strategies
11489259|NCT01431248||Azithromycin|Azithromycin 1gm PO once
11489260|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
11489261|NCT01431235|No Intervention|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
11489262|NCT01431235|Experimental|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
11489263|NCT01431222|Active Comparator|percutaneous treatment|
11489264|NCT01431222|No Intervention|optimal medical treatment|
11489265|NCT01431209|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11489266|NCT01431196|Experimental|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
11489267|NCT01431183|Active Comparator|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
11489268|NCT01431183|No Intervention|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
11489269|NCT01431170|Experimental|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
11489270|NCT01431170|Active Comparator|Polytrim Treatment Group|Polytrim ophthalmic solution
11489271|NCT01431157|Active Comparator|Nasal oxygen|Nocturnal nasal oxygen
11489272|NCT01431157|Placebo Comparator|No nasal oxygen|
11489273|NCT01431144|Active Comparator|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
11489274|NCT01431144|Experimental|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
11489275|NCT01431131|Active Comparator|Intrasocket graft|Positive control
11489276|NCT01431131|Experimental|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
11489277|NCT01431118|Active Comparator|sports intervention male|male athletes of the german national dragon boat team
11489278|NCT01431118|Active Comparator|sports intervention women|women athletes of the german national dragon boat team
11489279|NCT01431105|Experimental|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
11489280|NCT01431092|Experimental|Melatonin|
11489281|NCT01431092|Placebo Comparator|Placebo|
11489282|NCT01431079|Experimental|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
11489283|NCT01431079|Active Comparator|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
11489284|NCT01431066|Placebo Comparator|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
11489285|NCT01431066|Experimental|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
11489286|NCT01431053|Experimental|Exemestane + Aspirin|
11489287|NCT01431053|Active Comparator|Exemestane|
11489288|NCT01431040|Active Comparator|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
11489289|NCT01431040|Active Comparator|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
11489290|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
11489291|NCT01431014|Active Comparator|"Dexamethasonelow-dose"|5mg
11489292|NCT01431014|Experimental|"Dexamethasonehigh-dose"|15mg
11489293|NCT01431001|Experimental|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
11489294|NCT01431001|Experimental|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
11489295|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
11489296|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
11489343|NCT01430611|Experimental|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
11489297|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
11489298|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
11489299|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
11489300|NCT01430949|Experimental|Over-the-Wire Mesh Ablation System|
11489301|NCT01430923|Experimental|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
11489302|NCT01430923|Active Comparator|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
11489303|NCT01430910|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
11489304|NCT01430910|Active Comparator|2|500mg Avibactam
11489305|NCT01430910|Active Comparator|3|2000mg Ceftazidime
11489306|NCT01430884||Aspirate Blood|
11489307|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
11489308|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
11489309|NCT01430858|Other|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
11489310|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
11489311|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
11489312|NCT01430819|Experimental|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
11489313|NCT01430819|Active Comparator|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
11489314|NCT01430806|Other|Dronedrone Arm|
11489315|NCT01430793|Active Comparator|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
11489316|NCT01430793|Active Comparator|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
11489317|NCT01430793|Active Comparator|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
11489318|NCT01430793|Active Comparator|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
11489319|NCT01430780||control group|placebo
11489320|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
11489321|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
11489322|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
11489323|NCT01430754|Experimental|tasimelteon|20 mg tasimelteon capsules
11489324|NCT01430754|Placebo Comparator|Placebo|Placebo capsules
11489325|NCT01430741|Other|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.
~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
11489326|NCT01430741|Other|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.
~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
11489327|NCT01430741|Experimental|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
11489328|NCT01430741|Experimental|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
11489329|NCT01430728||Very low birthweight infants|
11489330|NCT01430715|Experimental|Outside play|
11489331|NCT01430715|Experimental|Active video game|
11489332|NCT01430702|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
11489333|NCT01430689|Experimental|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
11489334|NCT01430689|Active Comparator|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
11489335|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
11489336|NCT01430663||Hematological patients with proven or probable aspergillosis|
11489337|NCT01430663||Hematological patients with possible aspergillosis|
11489338|NCT01430650|Experimental|Oral strogen|
11489339|NCT01430650|Experimental|Transdermal strogen|
11489340|NCT01430624|Experimental|PPRS video|Prevention of post sexual assault stress
11489341|NCT01430624|Active Comparator|PIRI video|Pleasant imagery and relaxation instruction
11489342|NCT01430624|No Intervention|Standard care|Treatment as usual
11489344|NCT01430611|Active Comparator|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
11489345|NCT01430598|Active Comparator|A|Subacromial decompression before repair of a complete rotator cuff tear.
11489346|NCT01430598|Active Comparator|B|Subacromial decompression after repair of a complete rotator cuff repair.
11489347|NCT01430585|Experimental|A|
11489348|NCT01430585|Experimental|B|
11489349|NCT01430585|Active Comparator|C|
11489350|NCT01430572|Experimental|Pazopanib + Everolimus|Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
11489351|NCT01430559|Other|Meloxicam|
11489352|NCT01430559|Placebo Comparator|Placebo|2 Placebo capsules once a day for 12 weeks
11489353|NCT01430533|Experimental|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
11489354|NCT01430533|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
11489355|NCT01430533|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
11489356|NCT01430520|Active Comparator|Escitalopram|
11489357|NCT01430520|Placebo Comparator|Placebo|
11489358|NCT01430507|Experimental|Medium Dose|Medium Dose Revamilast
11489359|NCT01430507|Experimental|High Dose|High Dose Revamilast
11489360|NCT01430507|Placebo Comparator|Placebo|Matching Placebo in Triple Dummy Format
11489361|NCT01430507|Experimental|Low dose|Low dose Revamilast
11489362|NCT01430494||No treatment|
11489363|NCT01430481|Active Comparator|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
11489364|NCT01430481|Experimental|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
11489365|NCT01430481|Experimental|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
11489366|NCT01430468|Experimental|Glenoid Positioning System|For the patients randomized to the GPS group, the surgeon will be given the GPS patient specific instrumentation and a model of the glenoid surface showing the exact placement and fit of the GPS alignment instruments.
11489367|NCT01430468|No Intervention|Standard Group|Each surgeon will use their standard methods of pre-operative planning using the pre-operative x-rays and CT scan.
11489368|NCT01430455|Experimental|Tranylcypromine|Active, open-label tranylcypromine treatment
11489369|NCT01430442|Experimental|Treatment A: Rimegepant, 10 mg|Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
11489370|NCT01430442|Experimental|Treatment B: Rimegepant, 25 mg|Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
11489371|NCT01430442|Experimental|Treatment C: Rimegepant, 75 mg|Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
11489372|NCT01430442|Experimental|Treatment D: Rimegepant, 150 mg|Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
11489373|NCT01430442|Experimental|Treatment E: Rimegepant, 300 mg|Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
11489374|NCT01430442|Experimental|Treatment F: Rimegepant, 600 mg|Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
11489375|NCT01430442|Placebo Comparator|Treatment P: Rimegepant Placebo-Matching Capsules|Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
11489376|NCT01430442|Active Comparator|Treatment G: Sumatriptan 100 mg|Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
11489377|NCT01430429|Experimental|NI-0801|
11489378|NCT01430416|Experimental|AEB071|
11489379|NCT01430403|Experimental|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
11489380|NCT01430403|Experimental|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
11489381|NCT01430403|Placebo Comparator|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
11489421|NCT01430182|Active Comparator|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
11489472|NCT01429779|Experimental|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
11490186|NCT01424605|Experimental|DLT intubation|
11489382|NCT01430390|Experimental|Biological/Genetically Modified T cells|Utilizing our initial trial experience, it was amended to include three (3) expansion cohorts. Cohort 1: patients with CD19+ relapse/refractory (R/R) B cell malignancies occurring after allogeneic/autologous HSCT or solid organ transplant (SOT) infusion occurring following conditioning chemotherapy. Cohort 2:patients with CD10+ high risk B cell malignancies eligible for autologous HSCT followed by 19-28z CRA EBV-CTLs (auto-HSCT preparative regimen serves as conditioning chemotherapy. Cohort 3: patients with CD19+ high risk B cell malignancies eligible for allogeneic HSCT followed by consolidative 19-28z CAR EBV-CTLs (allo-HSCT preparative regimen serves as conditioning chemotherapy) Each expansion cohort has a target accrual of 6 patients treated with fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose.
11489383|NCT01430377|Experimental|SB predilatation|
11489384|NCT01430364|Active Comparator|BIOSS implantation|
11489385|NCT01430351|Experimental|Arm 1 (temozolomide)|Patients receive temozolomide PO QD on days 1-5.
11489386|NCT01430351|Experimental|Arm 2 (temozolomide, memantine hydrochloride)|Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.
11489387|NCT01430351|Experimental|Arm 3 (temozolomide, mefloquine)|Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.
11489388|NCT01430351|Experimental|Arm 4 (temozolomide, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.
11489389|NCT01430351|Experimental|Arm 5 (temozolomide, memantine hydrochloride, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.
11489390|NCT01430351|Experimental|Arm 6 (temozolomide, memantine hydrochloride, metformin)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.
11489391|NCT01430351|Experimental|Arm 7 (temozolomide, mefloquine, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.
11489392|NCT01430351|Experimental|Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.
11489393|NCT01430338||BAT|brown adipose tissue detected, undetected
11489394|NCT01430325|Sham Comparator|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session
~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
11489395|NCT01430325|Experimental|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)
~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
11489396|NCT01430325|Sham Comparator|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session
~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
11489397|NCT01430325|Experimental|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)
~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
11489398|NCT01430312|Experimental|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
11489399|NCT01430312|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
11489400|NCT01430312|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
11489401|NCT01430312|Active Comparator|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
11489402|NCT01430299|Other|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
11489403|NCT01430299|Other|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
11489404|NCT01430286|Experimental|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
11489405|NCT01430286|Active Comparator|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
11489406|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
11489407|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
11489408|NCT01430260|Experimental|ciclesonide nasal spray|ciclesonide nasal spray, alone
11489409|NCT01430260|Active Comparator|Levocetirizine|Levocetirizine, alone
11489410|NCT01430260|Active Comparator|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray & Levocetirizine in combination
11489411|NCT01430247|Other|Amblyopia screening|
11489412|NCT01430234|Other|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
11489413|NCT01430221|Experimental|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
11489414|NCT01430221|Active Comparator|SAGE Group|Structure & Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
11489415|NCT01430208|Active Comparator|mini-resectoscope|
11489416|NCT01430208|Active Comparator|tradiorional resectoscope|
11489417|NCT01430208|Active Comparator|bettocchi resectoscope|
11489418|NCT01430195|Experimental|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
11489419|NCT01430195|Active Comparator|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
11489420|NCT01430182|Experimental|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
11489422|NCT01430169|Experimental|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.
~2 injections of AA4500 0.58 mg were administered 24 hours apart."
11489423|NCT01430156|Active Comparator|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
11489424|NCT01430156|Placebo Comparator|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
11489425|NCT01430143|Experimental|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
11489426|NCT01430143|Experimental|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
11489427|NCT01430143|No Intervention|Sedentary|Continued sedentary living.
11489428|NCT01430130|Experimental|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
11489429|NCT01430117|Experimental|1|"Poa pratensis allergen extract at 4 different concentrations.
~Positive control.
~Negative control."
11489430|NCT01430104|Experimental|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
11489431|NCT01430091|Active Comparator|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
11489432|NCT01430091|Experimental|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
11489433|NCT01430091|Experimental|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
11489434|NCT01430091|Experimental|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
11489435|NCT01430091|Experimental|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
11489436|NCT01430078|Experimental|Regimen A|ASP015K oral tablet
11489437|NCT01430078|Experimental|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
11489438|NCT01430078|Experimental|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
11489439|NCT01430078|Experimental|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
11489440|NCT01430065|Experimental|Tacrolimus and ASP015K|
11489441|NCT01430052|Other|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
11489442|NCT01430052|Experimental|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
11489443|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
11489444|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
11489445|NCT01430013|Experimental|Endostar|CHOPT chemotherapy plus Endostar
11489446|NCT01429987|Experimental|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
11489447|NCT01429987|Experimental|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
11489448|NCT01429987|Experimental|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
11489449|NCT01429987|Placebo Comparator|Placebo|Subjects receive placebo for 12 consecutive weeks
11489450|NCT01429974||volunteers|
11489451|NCT01429961|Experimental|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
11489452|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
11489453|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
11489454|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
11489455|NCT01429935|Active Comparator|Ginger powder|
11489456|NCT01429935|Active Comparator|Ibuprofen|capsules of Ibuprofen 400 mg
11489457|NCT01429935|Placebo Comparator|placebo|capsules contain starch
11489458|NCT01429896|Experimental|Arm 1|Exercise followed by sleep restriction followed by control challenge
11489459|NCT01429896|Experimental|Arm 2|Sleep restriction followed by exercise followed by control challenge
11489460|NCT01429896|Experimental|Arm 3|control followed by sleep restriction followed by exercise
11489461|NCT01429896|Experimental|Arm 4|control followed by exercise followed by sleep restriction
11489462|NCT01429896|Experimental|Arm 5|Sleep Restriction followed by control followed by exercise
11489463|NCT01429896|Experimental|Arm 6|Exercise followed by control followed by sleep restriction
11489464|NCT01429870|Active Comparator|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
11489465|NCT01429870|Placebo Comparator|Vehicle|unguentum leniens topically
11489466|NCT01429844|Active Comparator|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
11489467|NCT01429844|Active Comparator|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
11489468|NCT01429831|Experimental|Aripiprazole|
11489469|NCT01429818|Experimental|Glimepiride/metformin|
11489470|NCT01429818|Active Comparator|Metformin|
11489471|NCT01429792|Experimental|Single Arm|
11490236|NCT01424371||Unvaccinated Elderly|
11489473|NCT01429779|No Intervention|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
11489474|NCT01429753|Active Comparator|Standard LV lead placement|
11489475|NCT01429753|Experimental|Advanced Imaging Guided LV Lead Placement|
11489476|NCT01429740|Experimental|PF-05180999|
11489477|NCT01429740|Placebo Comparator|Placebo|
11489478|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
11489479|NCT01429714|Experimental|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
11489480|NCT01429714|Active Comparator|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
11489481|NCT01429701|Experimental|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
11489482|NCT01429701|Active Comparator|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
11489483|NCT01429688|Experimental|DP-R202|Multiple oral administration for 3 days
11489484|NCT01429688|Active Comparator|Anplag|Multiple oral administration for 3days
11489485|NCT01429675|Active Comparator|Bonviva|
11489486|NCT01429675|Experimental|DP-R206|
11489487|NCT01429662|Sham Comparator|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
11489488|NCT01429662|Experimental|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
11489489|NCT01429649|Experimental|ablation|Cryoablation or Radiofrequency ablation for the pGGO
11489490|NCT01429649|No Intervention|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
11489491|NCT01429636|Experimental|Applied Relaxation (AR)|
11489492|NCT01429636|Experimental|Modified Relaxation (MR)|
11489493|NCT01429623|Experimental|ladostigil hemitartrate|10mg ladostigil base
11489494|NCT01429623|Placebo Comparator|Placebo Control|drug product excipients
11489495|NCT01429610|Experimental|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
11489496|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
11489497|NCT01429584|Active Comparator|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
11489498|NCT01429584|Active Comparator|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
11489499|NCT01429571||Systemic and local antibiotics|
11489500|NCT01429571||Local antibiotics|
11489501|NCT01429571||No antibiotics|
11489502|NCT01429545|Active Comparator|Group 1 - Atosiban|Patients on single agent atosiban alone
11489503|NCT01429545|Experimental|Group 2|Patients on combination of atosiban and nifedipine
11489504|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
11489505|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
11489506|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
11489507|NCT01429519|Experimental|Treatment|
11489508|NCT01429506|Active Comparator|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
11489509|NCT01429506|Active Comparator|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
11489510|NCT01429493|Active Comparator|Conventional radiotherapy|
11489511|NCT01429493|Experimental|Biological image-guided radiotherapy with conventional dose.|
11489512|NCT01429493|Experimental|Biological image-guided SBRT with dose-escalation.|
11489513|NCT01429480|Active Comparator|TAP Block|
11489514|NCT01429480|Active Comparator|II/IH Block|
11489515|NCT01429480|Active Comparator|Control Group|
11489516|NCT01429467|Other|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
11489517|NCT01429454|Placebo Comparator|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
11489518|NCT01429454|Experimental|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
11489519|NCT01429441|Experimental|Ocriplasmin|
11489520|NCT01429441|Sham Comparator|Sham injection|
11489521|NCT01429428|Placebo Comparator|Stockings side one|This side of the compression stockings is just the fabric (placebo).
11489522|NCT01429428|Active Comparator|Stocking side two|This side of compression stocking emits far-IR radiation.
11489523|NCT01429415|Experimental|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
11489524|NCT01429415|Placebo Comparator|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
11489525|NCT01429402|Experimental|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
11489526|NCT01429402|Experimental|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
11489527|NCT01429402|Placebo Comparator|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
11489528|NCT01429402|Placebo Comparator|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
11489529|NCT01429363|Experimental|Targeted disc decompression|
11489530|NCT01429350|Active Comparator|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
11489531|NCT01429350|Experimental|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
11489532|NCT01429337|Experimental|Normal hepatic function - group 1|Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
11489533|NCT01429337|Experimental|Mild hepatic impairment - group 2|Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
11489534|NCT01429337|Experimental|Moderate hepatic impairment - group 3|Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
11489535|NCT01429337|Experimental|Severe hepatic impairment - group 4|Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
11489536|NCT01429337|Experimental|Normal hepatic function - group 5|Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
11489537|NCT01429324||Cardiac disease|Aortic arch surgery
11489538|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
11489539|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
11489540|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
11489541|NCT01429298|Experimental|Hydromorphone|2 mg of IV dilaudid will be administered over 2-3 minutes as initial dose.
11489542|NCT01429298|Active Comparator|Usual care|The attending physician administers whatever IV opioid he/she deems appropriate in whatever dose he/she chooses for initial dosing
11489543|NCT01429285|Experimental|Hydromorphone|Hydromorphone protocol
11489544|NCT01429285|Active Comparator|Usual care|Usual care
11489545|NCT01429272|Placebo Comparator|Placebo & Placebo|Placebo for minocycline & placebo for aspirin
11489546|NCT01429272|Active Comparator|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeks
11489547|NCT01429259|Experimental|Meropenem 3 hour prolonged infusion|All 30 participants will receive meropenem as a 3 hour infusion.
11489548|NCT01429246|Active Comparator|Normal Salt|100% Sodium Chloride
11489549|NCT01429246|Experimental|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
11489550|NCT01429194|Experimental|ACE procedure|ACE procedure for the treatment of obesity
11489551|NCT01429181|Experimental|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
11489552|NCT01429181|Placebo Comparator|Placebo|Matching placebo capsules
11489553|NCT01429168|Experimental|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
11489554|NCT01429168|Experimental|Part 2: Etoricoxib|
11489555|NCT01429168|Placebo Comparator|Part 2: Placebo|
11489556|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
11489557|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
11489558|NCT01429142|Experimental|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
11489559|NCT01429142|Active Comparator|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
11489560|NCT01429129|Experimental|Nicotine Replacement Therapy|
11489561|NCT01429129|No Intervention|Control|
11489562|NCT01429116|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
11489563|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
11489564|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
11489565|NCT01429090|Experimental|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
11489566|NCT01429090|Active Comparator|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
11489567|NCT01429077|Active Comparator|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
11489568|NCT01429077|Placebo Comparator|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
11489569|NCT01429064|Experimental|ODM-201|
11489570|NCT01429051|Experimental|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
11489657|NCT01428479|Experimental|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
11489571|NCT01429038|Experimental|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
11489572|NCT01429038|Experimental|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
11489573|NCT01429025|Experimental|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11489574|NCT01429012|Experimental|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.
~MSC will be injected even if the number of available cells is lower than 40 X 10E6.
~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
11489575|NCT01429012|Placebo Comparator|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
11489576|NCT01428999|Experimental|probiotics|1 pack bid use for 3 weeks
11489577|NCT01428999|Placebo Comparator|Placebo|placebo 1pack bid for 3 weeks
11489578|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
11489579|NCT01428986||No maraviroc|Those who do not take maraviroc
11489580|NCT01428973|Active Comparator|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
11489581|NCT01428973|Experimental|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
11489582|NCT01428960|Experimental|Palm Mid Fraction|
11489583|NCT01428960|Experimental|Shea Butter|
11489584|NCT01428960|Experimental|High Oleic Sunflower Oil|
11489585|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
11489586|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation [27].
11489587|NCT01428921|Experimental|Extended Education|"Standard education programme as described above,
~Plus
~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration
~Follow-up phone call would be arranged within 1 week after using CPAP.
~Video, slides and booklets would be used as education media."
11489588|NCT01428921|No Intervention|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
11489589|NCT01428908|Experimental|children group A|600 children aged 2-5 years old, will be vaccinated on day0
11489590|NCT01428908|Experimental|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
11489591|NCT01428908|Active Comparator|children group B|600 children aged 2-5 years old, will be vaccinated on day0
11489592|NCT01428908|Active Comparator|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
11489593|NCT01428895|Active Comparator|Surgery Alone|
11489594|NCT01428895|Active Comparator|Surgery + Radiation Therapy|
11489595|NCT01428882|Active Comparator|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
11489596|NCT01428882|Placebo Comparator|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
11489597|NCT01428869||statin+ASA+dutasteride|
11489598|NCT01428869||statin+ASA|
11489599|NCT01428869||dutasteride+statin|
11489600|NCT01428869||dutasteride+ASA|
11489601|NCT01428843|Active Comparator|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
11489602|NCT01428843|Placebo Comparator|Placebo|Infusion of placebo at inclusion visit
11489603|NCT01428830|Experimental|7-day catheterization|
11489604|NCT01428830|Active Comparator|14-day catheterization|
11489605|NCT01428817|Active Comparator|Carbetocin 20mcg|
11489606|NCT01428817|Active Comparator|Carbetocin 40mcg|
11489607|NCT01428817|Active Comparator|Carbetocin 60mcg|
11489608|NCT01428817|Active Comparator|Carbetocin 80mcg|
11489609|NCT01428817|Active Comparator|Carbetocin 100mcg|
11489610|NCT01428804|Active Comparator|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
11489611|NCT01428804|Sham Comparator|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
11489612|NCT01428791|Active Comparator|Generations older adult member program|Rush Generations is a membership program for older adults, providing chronic disease prevention and management through educational programming, civic engagement, and individual and family consultations with social work staff.
11489613|NCT01428791|Experimental|BRIGHTEN Heart Virtual Team|BRIGHTEN Heart provides older adults with an interdisciplinary team evaluation of physical and mental health and on-going support for mental health and health behavior change for a minimum of six months. The five core components of the BRIGHTEN intervention consist of: 1) Assessment; 2) Virtual team case review; 3) Patient centered action planning; 4) Plan implementation, and; 5) When indicated, short-term evidence-based geriatric specialty psychotherapy.
11489614|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
11489615|NCT01428726|Placebo Comparator|Placebo|
11489616|NCT01428726|Experimental|NT-KO-003 low dose|
11489617|NCT01428726|Experimental|NT-KO-003 high dose|
11489618|NCT01428713|Active Comparator|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
11489619|NCT01428713|Active Comparator|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
11489620|NCT01428700||Non-Immune/Non-Viral (NINV)|Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
11489621|NCT01428700||Hepatitis C Virus (HCV) positive|Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection
11489622|NCT01428687|Active Comparator|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
11489623|NCT01428687|Active Comparator|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
11489624|NCT01428687|Active Comparator|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
11489625|NCT01428674|Experimental|10 minutes reading|
11489626|NCT01428674|Experimental|20 minutes touch|
11489627|NCT01428674|Experimental|20 minutes reading|
11489628|NCT01428674|Experimental|10 minutes touch|
11489629|NCT01428661|Experimental|tasimelteon|
11489630|NCT01428661|Placebo Comparator|placebo|
11489631|NCT01428648|Active Comparator|intervention|group of patients receiving ballroom dancing classes
11489632|NCT01428648|No Intervention|control|group of patients who will not receive dancing classes.
11489633|NCT01428635|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD in the absence of disease progression or unacceptable toxicity.
11489634|NCT01428622|Placebo Comparator|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
11489635|NCT01428622|Experimental|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
11489636|NCT01428622|Active Comparator|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
11489637|NCT01428622|Experimental|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
11489638|NCT01428622|Experimental|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
11489639|NCT01428622|Experimental|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
11489640|NCT01428622|Experimental|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
11489641|NCT01428596|Experimental|Arm I|Lower dose HIVAX vaccine
11489642|NCT01428596|Placebo Comparator|Arm II|lower dose, placebo control
11489643|NCT01428596|Experimental|Arm III|Higher dose HIVAX vaccine
11489644|NCT01428583|Experimental|oxycodone HCl and naltrexone HCl extended-release capsules|
11489645|NCT01428570|Experimental|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
11489646|NCT01428570|Active Comparator|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
11489647|NCT01428557||Heart Failure patients|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
11489648|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
11489649|NCT01428531||Patients prescribed fondaparinux|
11489650|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
11489651|NCT01428505|Other|no treatment|
11489652|NCT01428492|Experimental|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
11489653|NCT01428492|Experimental|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
11489654|NCT01428492|Experimental|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
11489655|NCT01428479|Experimental|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
11489656|NCT01428479|Experimental|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
11489659|NCT01428466|Active Comparator|Benzoic peroxide 3%|external preparation
11489660|NCT01428466|Active Comparator|Benzoic peroxide 5%|external preparation
11489661|NCT01428466|Placebo Comparator|Vehicle|external preparation
11489662|NCT01428453|Experimental|250mg rilapladib|Experimental drug
11489663|NCT01428453|Placebo Comparator|placebo|Placebo comparator
11489664|NCT01428440|Other|no treatment|
11489665|NCT01428427|Experimental|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
11489666|NCT01428414|Active Comparator|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
11489667|NCT01428414|Active Comparator|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
11489668|NCT01428401|Experimental|Arm A|
11489669|NCT01428401|Placebo Comparator|Arm B|
11489670|NCT01428388|Active Comparator|Bevacizumab|
11489671|NCT01428388|Active Comparator|Ranibizumab|
11489672|NCT01428375|Active Comparator|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
11489673|NCT01428375|Placebo Comparator|(2) Placbo (Sterile water) arm: n=60|Sterile water
11489674|NCT01428362|Experimental|Placebo/VI-1121|Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
11489675|NCT01428362|Experimental|VI-1121/Placebo|Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
11489676|NCT01428349|Experimental|Attention to Context|
11489677|NCT01428349|Experimental|Affective Cognitive Control|
11489678|NCT01428336|Active Comparator|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
11489679|NCT01428336|Active Comparator|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
11489680|NCT01428310|Active Comparator|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
11489681|NCT01428310|Active Comparator|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
11489682|NCT01428297|Experimental|Cohort A and B, BPR277 and Placebo (vehicle)|
11489683|NCT01428297|Experimental|Part 2 BPR277|
11489684|NCT01428297|Placebo Comparator|Part 2 Placebo (vehicle)|
11489685|NCT01428297|Experimental|Part 3 BPR277 and Placebo (vehicle)|
11489686|NCT01428284|Experimental|001|Canagliflozin/Probenecid
11489687|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
11489688|NCT01428258|Experimental|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
11489689|NCT01428258|Active Comparator|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
11489690|NCT01428245|Experimental|Progesterone, estrace|"oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days
~oral estrace, 0.5-1 mg once a day for seven days"
11489691|NCT01428232|Experimental|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
11489692|NCT01428232|Experimental|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
11489693|NCT01428232|No Intervention|usual care|
11489694|NCT01428219|Experimental|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
11489695|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
11489696|NCT01428206|No Intervention|control|Usual care is performed for the control group
11489697|NCT01428193|Experimental|Flutamide, estrace, progesterone|"For flutamide, subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.
~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.
~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
11489698|NCT01428180||Indomethacin|Infants treated with Indomethacin
11489699|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
11489700|NCT01428180||Ligation|Infants undergoing surgical ligation
11489701|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
11489702|NCT01428154|Experimental|Darbepoetin alfa|
11489703|NCT01428141|Experimental|E7050|
11489704|NCT01428128|Experimental|Arsenic Trioxide|
11489705|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
11489706|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
11490237|NCT01424358|Experimental|Web-based Educational|
11489707|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
11489708|NCT01428089|Experimental|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml)
11489709|NCT01428089|Placebo Comparator|placebo|placebo at 1100, 1500, and 1900 h.
11489710|NCT01428076|Experimental|High Dose Polidocanol Endovenous Microfoam|
11489711|NCT01428076|Experimental|Medium Dose Polidocanol Endovenous Microfoam|
11489712|NCT01428063|Experimental|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
11489713|NCT01428063|Experimental|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
11489714|NCT01428063|Experimental|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
11489715|NCT01428050|Experimental|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
11489716|NCT01428050|Active Comparator|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
11489717|NCT01428037|Experimental|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
11489718|NCT01428037|Placebo Comparator|Placebo|Tablet without active ingredient
11489719|NCT01428024|Experimental|Restylane Lip Volume|Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
11489720|NCT01428024|Experimental|Restylane Lip Refresh|Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
11489721|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
11489722|NCT01427998|Active Comparator|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
11489723|NCT01427998|Placebo Comparator|placebo|matched placebo
11489724|NCT01427985|Experimental|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
11489725|NCT01427985|Active Comparator|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
11489726|NCT01427972|Experimental|0.2 milligrams (mg) LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
11489727|NCT01427972|Experimental|1.5 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
11489728|NCT01427972|Experimental|10 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
11489729|NCT01427972|Active Comparator|50 mg Eplerenone|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
11489730|NCT01427946|Experimental|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
11489731|NCT01427933|Experimental|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle
~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
11489732|NCT01427933|Active Comparator|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
11489733|NCT01427920|Experimental|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
11489734|NCT01427920|Active Comparator|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
11489735|NCT01427907|Experimental|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
11489736|NCT01427907|Active Comparator|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
11489737|NCT01427894|Experimental|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
11489738|NCT01427894|No Intervention|Kangaroo Care|Kangaroo Care without singing
11489783|NCT01427543|Experimental|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
11489784|NCT01427543|No Intervention|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
11489785|NCT01427517|Experimental|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
11489739|NCT01427881|Experimental|Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126."
11489740|NCT01427868|Experimental|LB80380 maleat salt|
11489741|NCT01427868|Active Comparator|LB80380 free base|
11489742|NCT01427855|Experimental|High Saturated Fat Red Meat Diet|
11489743|NCT01427855|Experimental|High Saturated Fat White Meat Diet|
11489744|NCT01427855|Experimental|High Saturated Fat Non-Meat Diet|
11489745|NCT01427855|Experimental|Low Saturated Fat Red Meat Diet|
11489746|NCT01427855|Experimental|Low Saturated Fat White Meat Diet|
11489747|NCT01427855|Experimental|Low Saturated Fat Non-Meat Diet|
11489748|NCT01427842|Experimental|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
11489749|NCT01427829|Experimental|Intervention (CaPRA)|
11489750|NCT01427829|No Intervention|Control (usual care)|
11489751|NCT01427816|Experimental|KCT-0809 ophthalmic solution, low dose|
11489752|NCT01427816|Experimental|KCT-0809 ophthalmic solution, high dose|
11489753|NCT01427816|Placebo Comparator|Placebo|
11489754|NCT01427803|Experimental|Arm 1|
11489755|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
11489756|NCT01427751|Active Comparator|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
11489757|NCT01427751|Active Comparator|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
11489758|NCT01427738|Experimental|Arm A: Topical GV solution|Topical GV 0.00165% solution (5 mL swish and gargle for 1 minute and expectorate [spit] 2 times per day [BID]) for 14 days
11489759|NCT01427738|Active Comparator|Arm B: Nystatin oral suspension|Nystatin oral suspension (5 mL of 100,000 units/mL swish for 1 minute and swallow 4 times per day [QID]) for 14 days
11489760|NCT01427725||LipaCreon|those with an exposure
11489761|NCT01427712||LipaCreon|those with an exposure
11489762|NCT01427699|Experimental|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
11489763|NCT01427686|Active Comparator|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
11489764|NCT01427686|Active Comparator|Dopamine|Start Dopamine. If no success switch to Dobutamine.
11489765|NCT01427673|Active Comparator|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
11489766|NCT01427673|Experimental|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
11489767|NCT01427660|Active Comparator|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
11489768|NCT01427660|Experimental|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
11489769|NCT01427647|Active Comparator|Control group|Control group: open surgery under general anesthesia
11489770|NCT01427647|Active Comparator|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
11489771|NCT01427647|Active Comparator|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
11489772|NCT01427634|Active Comparator|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
11489773|NCT01427634|Other|Control|Usual Care
11489774|NCT01427621|Experimental|RIPCcom group|
11489775|NCT01427621|No Intervention|Control group|
11489776|NCT01427608|Active Comparator|Sertraline + Olanzapine|Randomized to continue with sertraline and olanzapine under double-blind conditions.
11489777|NCT01427608|Placebo Comparator|Sertraline + Placebo|Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.
11489778|NCT01427595|Experimental|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
11489779|NCT01427569|Experimental|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
11489780|NCT01427569|Placebo Comparator|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
11489781|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
11489782|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
11489935|NCT01426386|Experimental|10.3 µg|
11489786|NCT01427517|Experimental|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
11489787|NCT01427517|Experimental|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
11489788|NCT01427504|Experimental|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
11489789|NCT01427504|Experimental|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
11489790|NCT01427504|Experimental|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
11489791|NCT01427504|Experimental|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
11489792|NCT01427504|Experimental|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
11489793|NCT01427504|Experimental|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
11489794|NCT01427491|Active Comparator|Aquacel® Ag|
11489795|NCT01427491|Active Comparator|Mepilex® Border Ag|
11489796|NCT01427478|Experimental|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
11489797|NCT01427478|Placebo Comparator|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
11489798|NCT01427465|Experimental|Consult|Consult
11489799|NCT01427465|Experimental|Newsletter|Newsletter
11489800|NCT01427465|Experimental|Parent Letter|Parent Letter
11489801|NCT01427465|Active Comparator|Control|Control
11489802|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
11489803|NCT01427439||Major Depressive Disorder|
11489804|NCT01427426|Experimental|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
11489805|NCT01427426|Sham Comparator|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
11489806|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
11489807|NCT01427400|Experimental|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
11489808|NCT01427400|Placebo Comparator|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
11489809|NCT01427387|Experimental|Part-1 ASP group|ASP0456 receiving group
11489810|NCT01427387|Placebo Comparator|Part-1 Placebo group|Placebo treatment
11489811|NCT01427387|Experimental|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
11489812|NCT01427348|Experimental|with assistant|head extension by an assistant during direct laryngoscopy
11489813|NCT01427348|Active Comparator|without assistant|without the help of an assistant during direct laryngoscopy
11489814|NCT01427335|Placebo Comparator|saline|0.9% saline intravenous infusion
11489815|NCT01427335|Experimental|calcium|Calcium intravenous infusion
11489816|NCT01427322|Experimental|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
11489817|NCT01427322|Active Comparator|No therapy prior to radiation|Radiation therapy alone
11489818|NCT01427309|Experimental|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
11489819|NCT01427309|Active Comparator|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
11489820|NCT01427296|Active Comparator|OsmoPrep Tablets|
11489821|NCT01427296|Active Comparator|HalfLytely and Bisacodyl Tablet|
11489822|NCT01427283|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
11489823|NCT01427283|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
11489824|NCT01427283|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
11489825|NCT01427270|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
11489826|NCT01427270|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
11489827|NCT01427270|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
11489828|NCT01427257|Active Comparator|PB1023 Formulation A|
11489829|NCT01427257|Active Comparator|PB1023 Formulation B|
11489830|NCT01427257|Active Comparator|PB1023 Formulation B (2-8C)|
11489831|NCT01427244|Experimental|Trastuzumab|Open Label
11489832|NCT01427231|Active Comparator|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
11489833|NCT01427231|Active Comparator|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
11489834|NCT01427231|Placebo Comparator|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
11489835|NCT01427218|Experimental|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
11489836|NCT01427218|Placebo Comparator|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
11489837|NCT01427205|Experimental|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
11489936|NCT01426386|Experimental|12.1 µg|
11489838|NCT01427205|Experimental|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
11489839|NCT01427192|Experimental|acetazolamide|1 week therapy, cross-over design
11489840|NCT01427192|Placebo Comparator|Placebo tablet|One week, cross-over design
11489841|NCT01427192|Experimental|supplemental oxygen during nights|One week, cross-over design
11489842|NCT01427192|Experimental|Non-invasive ventilation|One week, cross-over design
11489843|NCT01427192|Sham Comparator|room air|room air applied via sham-oxygen-concentrator
11489844|NCT01427166|Experimental|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
11489845|NCT01427153|Active Comparator|Corticosteroid|Corticosteroid injection
11489846|NCT01427153|Active Comparator|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
11489847|NCT01427140|Active Comparator|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
11489848|NCT01427140|Active Comparator|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
11489849|NCT01427127|Experimental|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
11489850|NCT01427127|Placebo Comparator|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
11489851|NCT01427114|Experimental|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
11489852|NCT01427088|Experimental|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
11489853|NCT01427075|Experimental|lateral pharyngoplasty|lateral pharyngoplasty
11489854|NCT01427062|Experimental|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
11489855|NCT01427062|Active Comparator|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
11489856|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
11489857|NCT01427036|Experimental|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
11489858|NCT01427036|Active Comparator|PHS surgery group|PHS® hip screw design for standard approach
11489859|NCT01427010|Experimental|Reirradiation of recurrent and 2nd primary head/neck cancer.|
11489860|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level >3 mg/L
11489861|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
11489862|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level <1 mg/L
11489863|NCT01426984|Experimental|BPD adults|adults with Borderline Personality Disorder (BPD)
11489864|NCT01426971|Experimental|Ibuprofen+caffeine|2 capsules
11489865|NCT01426971|Active Comparator|Ibuprofen|2 capsules
11489866|NCT01426958|Active Comparator|treatment A|1 tablet afatinib single dose
11489867|NCT01426958|Experimental|treatment B|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
11489868|NCT01426958|Experimental|treatment C|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
11489869|NCT01426919||Suspected traumatic brain injury with head CT|
11489870|NCT01426906|Experimental|Study A|
11489871|NCT01426906|Experimental|Study B|
11489872|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
11489873|NCT01426880|Experimental|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
11489874|NCT01426880|Active Comparator|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
11489875|NCT01426867|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days
11489876|NCT01426867|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days
11489877|NCT01426867|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each affected eye 3 times a day for 7 days
11489878|NCT01426854|Active Comparator|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
11489879|NCT01426854|Placebo Comparator|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
11489880|NCT01426828|Other|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
11489881|NCT01426828|Other|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
11489882|NCT01426815|Placebo Comparator|Placebo|
11489883|NCT01426815|Experimental|Golimumab 50mg (Simponi ®)|
11489884|NCT01426802|Experimental|Vildagliptin 50 bid|
11489885|NCT01426789|Experimental|Secukinumab|10 mg/kg intravenous (I.V.)
11489886|NCT01426789|Placebo Comparator|Placebo|Placebo I.V.
11489937|NCT01426386|Active Comparator|11 µg FbM (150 IU)|
11489887|NCT01426776|Other|heart valve replacement|a normal surgery that rheumatic valvular heart disease patients received.
11489888|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 1|Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
11489889|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 2|Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
11489890|NCT01426750|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
11489891|NCT01426698|Active Comparator|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
11489892|NCT01426698|Experimental|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
11489893|NCT01426672|Experimental|Monovision Correctoin|Monovision correction
11489894|NCT01426659|Active Comparator|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
11489895|NCT01426659|Active Comparator|"no stimulation say and do"|
11489896|NCT01426646|Experimental|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
11489897|NCT01426646|Experimental|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles
~S-1: 40mg/m2 orally twice daily (days 1-14)
~Cisplatin: 60mg/m2 IV on day 1"
11489898|NCT01426633|Experimental|Gemcitabine + Trabectedin|
11489899|NCT01426620|Experimental|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
11489900|NCT01426607|Experimental|AMO|Adjustable mandibular repositioning appliance
11489901|NCT01426607|Placebo Comparator|placebo|placebo device in upper jaw
11489902|NCT01426581|Experimental|Educational Intervention A|Intervention: Teach to Goal
11489903|NCT01426581|Experimental|Educational Intervention B:|Brief Intervention
11489904|NCT01426568|Active Comparator|Course of Multi-Convergent Thearpy|
11489905|NCT01426568|No Intervention|Waiting List for Multi-Convergent Therapy|
11489906|NCT01426555|Active Comparator|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
11489907|NCT01426555|Experimental|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
11489908|NCT01426542|Experimental|Topiramate|
11489909|NCT01426542|Active Comparator|Control|These infants will undergo surgery, but will not receive topiramate
11489910|NCT01426516|No Intervention|Treatment as usual (TAU)|Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
11489911|NCT01426516|Experimental|Genecept Assay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
11489912|NCT01426490|Other|Vitamin C|Vitamin C as control group.
11489913|NCT01426490|Experimental|Vitamin B6|
11489914|NCT01426490|Experimental|Folic acid|
11489915|NCT01426490|Experimental|Vitamin B6 plus folic acid|
11489916|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
11489917|NCT01426451|Experimental|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
11489918|NCT01426451|Experimental|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
11489919|NCT01426451|No Intervention|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
11489920|NCT01426438|Experimental|Arm A: Extended-release niacin with aspirin|
11489921|NCT01426438|Experimental|Arm B: Fenofibrate|
11489922|NCT01426425|Experimental|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
11489923|NCT01426412|Experimental|LY3015014 intravenously (IV)|A single dose of LY3015014 up to 10.0 milligrams per kilogram (mg/kg) administered IV
11489924|NCT01426412|Experimental|LY3015014 IV Japanese|Single dose of LY3015014 10.0 mg/kg administered IV to Japanese participants. Added per protocol amendment effective October, 2012.
11489925|NCT01426412|Placebo Comparator|Placebo IV|Administered IV once only
11489926|NCT01426412|Experimental|LY3015014 subcutaneously (SC)|A single dose of LY3015014 up to 3.0 mg/kg administered SC
11489927|NCT01426412|Experimental|LY3015014 SC + Statin|A single dose of LY3015014 up to 3 mg/kg administered SC in addition to participant's dose of statin
11489928|NCT01426412|Placebo Comparator|Placebo SC|Administered SC once only
11489929|NCT01426399|Experimental|LC15-0444|LC15-0444 50mg qd
11489930|NCT01426399|Experimental|Metformin|Metformin 1000mg bid
11489931|NCT01426399|Experimental|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
11489932|NCT01426386|Experimental|5.2 µg|
11489933|NCT01426386|Experimental|6.9 µg|
11489934|NCT01426386|Experimental|8.6 µg|
11489938|NCT01426373|Experimental|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11489939|NCT01426360|Experimental|strontium chloride/potassium nitrate dentifrice|
11489940|NCT01426360|Placebo Comparator|control dentifrice|
11489941|NCT01426347|Placebo Comparator|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.
~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
11489942|NCT01426347|Active Comparator|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
11489943|NCT01426334|Experimental|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
11489944|NCT01426321|Active Comparator|Imaging guided LV lead positioning|
11489945|NCT01426321|No Intervention|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
11489946|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
11489947|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
11489948|NCT01426295|Experimental|Caphosol|
11489949|NCT01426295|Active Comparator|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
11489950|NCT01426282|No Intervention|control|
11489951|NCT01426282|Experimental|nurse education|
11489952|NCT01426269|Placebo Comparator|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
11489953|NCT01426269|Other|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
11489954|NCT01426269|Active Comparator|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
11489955|NCT01426256|Experimental|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
11489956|NCT01426256|No Intervention|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
11489957|NCT01426243|Active Comparator|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
11489958|NCT01426243|Other|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
11489959|NCT01426230||Open Label|"Cohort by age-
~- Patients >70 Yrs old"
11489960|NCT01426230||Open label|"Cohort by age-
~- Patients < 70 Yrs old"
11489961|NCT01426217|No Intervention|Control|Control arm using standard of care operating room procedures and equipment
11489962|NCT01426217|Experimental|Problem Solving Innovations (PSI) Experimental|Implementation of the passive bundle including HubScrub and DocIt
11489963|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
11489964|NCT01426165|Experimental|Magnesium 8 grams over 4 hours|
11489965|NCT01426165|Experimental|Magnesium 8 grams over 8 hours|
11489966|NCT01426152||Low level progesterone group (1)|Progesterone < 1.50 ng/mL on day of ovulation induction
11489967|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
11489968|NCT01426152||High level progesterone group (3)|Progesterone > 1.99 ng/mL on the day of ovulation induction
11489969|NCT01426139|Experimental|Biotronik Orsiro DES|
11489970|NCT01426126|Experimental|Genexol PM|Genexol PM intravenous infusion every 3 weeks
11489971|NCT01426113|Experimental|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
11489972|NCT01426113|Active Comparator|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
11489973|NCT01426100|Experimental|CKD-828 40/2.5mg|
11489974|NCT01426100|Experimental|CKD-828 40/5mg|
11489975|NCT01426100|Active Comparator|Telmisartan 80mg|
11489976|NCT01426087|Experimental|endoscopic and somatostatin treatment|
11489977|NCT01426087|Other|endoscopic therapy|
11489978|NCT01426061|Experimental|Reflexology plus conventional treatment|
11489979|NCT01426061|Experimental|Homeopathy plus conventional treatment|
11489980|NCT01426061|No Intervention|Conventional treatment|
11489981|NCT01426048||Patients operated on with the TVT|
11489982|NCT01426035|Experimental|GROUP 1|
11489983|NCT01426035|Active Comparator|GROUP 2|
11489984|NCT01426022|Placebo Comparator|Alcohol|"3 glasses of sparkling white wine (30g alcohol) with dinner
~3 glasses of alcohol free sparkling white wine (<2g alcohol) with dinner"
11489985|NCT01426022|Experimental|Ambiance|"Pleasant ambiance
~Unpleasant ambiance"
11489986|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
11490481|NCT01422590|Active Comparator|Mitiglinide|
11489987|NCT01426009|Active Comparator|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
11489988|NCT01426009|Active Comparator|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
11489989|NCT01426009|Placebo Comparator|Placebo EP-101|Placebo
11489990|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
11489991|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
11489992|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
11489993|NCT01425996|Experimental|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)
~* The dosage regimen would be escalated gradually until MTD had been found out."
11489994|NCT01425983|Active Comparator|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
11489995|NCT01425983|Placebo Comparator|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
11489996|NCT01425970|Experimental|25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 1
11489997|NCT01425970|Experimental|50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 2
11489998|NCT01425970|Experimental|100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 3
11489999|NCT01425970|Placebo Comparator|Placebo + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 4
11490000|NCT01425970|Experimental|100 mg INX-08189 + Ribavirin|PART B Arm 1
11490001|NCT01425970|Experimental|200 mg INX-08189 + Ribavirin|PART B Arm 2
11490002|NCT01425970|Experimental|Daclatasvir + INX-08189 100 mg|PART B Arm 3
11490003|NCT01425970|Experimental|Daclatasvir + INX-08189 200 mg|PART B Arm 4
11490004|NCT01425970|Experimental|Daclatasvir + INX-08189 50 mg + Ribavirin|PART B Arm 5
11490005|NCT01425957|Other|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
11490006|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
11490007|NCT01425918|Experimental|Social Enhancement Intervention|"For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.
~Parent education sessions once a week for 2 hours each session over the 5-month period."
11490008|NCT01425918|Active Comparator|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
11490009|NCT01425905|Experimental|Depression Prevention|
11490010|NCT01425905|Active Comparator|Health Education|
11490011|NCT01425892||incomplete sjogren's|patients who meet criteria for classification as incomplete sjogren's
11490012|NCT01425892||primary sjogren's|patients who meet criteria for classification for primary sjogren's
11490013|NCT01425892||secondary sjogren's|patients who meet criteria for classification for secondary sjogren's
11490014|NCT01425879|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11490015|NCT01425866|Experimental|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
11490016|NCT01425866|Active Comparator|Initial self-management education|Initial self-management group education: 1 to 7 sessions (< 3 months), based on individual assessment.
11490017|NCT01425853|Experimental|Chondroitin/Glucosamine (Droglican)|"Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.
~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX."
11490018|NCT01425853|Active Comparator|Celecoxib|Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
11490019|NCT01425840|Experimental|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
11490020|NCT01425814|Experimental|Arm #2|Single dose, double blind treatment period
11490021|NCT01425814|Experimental|Arm #3|Single dose, double blind treatment period
11490022|NCT01425814|Experimental|Arm #4|Single dose, double blind treatment period
11490023|NCT01425814|Active Comparator|Arm #5|Single dose, double blind treatment period
11490024|NCT01425814|Placebo Comparator|Arm #6|Single dose, double blind treatment period
11490025|NCT01425814|Experimental|Arm #1|Single dose, double blind treatment period
11490026|NCT01425801|Experimental|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
11490027|NCT01425801|Experimental|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
11490028|NCT01425801|Experimental|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
11490029|NCT01425801|Active Comparator|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
11490030|NCT01425801|Placebo Comparator|Placebo|Placebo to LAS100977, and placebo to salbutamol
11490031|NCT01425801|Experimental|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
11490032|NCT01425788|Active Comparator|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.
~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
11490033|NCT01425788|Active Comparator|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:
~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
11490034|NCT01425788|Active Comparator|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:
~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
11490035|NCT01425775|Active Comparator|Vitamin D|
11490036|NCT01425775|Placebo Comparator|Placebo|
11490037|NCT01425762|Experimental|Choice Group|
11490038|NCT01425762|Active Comparator|No Choice Group|
11490039|NCT01425749|Experimental|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
11490040|NCT01425749|Experimental|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
11490041|NCT01425736|Placebo Comparator|Chemotherapy|"Chemotherapy
~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
11490042|NCT01425736|Experimental|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );
~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
11490043|NCT01425723|Experimental|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
11490044|NCT01425723|Experimental|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
11490045|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
11490046|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
11490047|NCT01425697|Active Comparator|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
11490048|NCT01425697|Other|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
11490049|NCT01425684||schizophrenia|smokers and nonsmokers
11490050|NCT01425684||control|smokers and nonsmokers
11490051|NCT01425671||Schizophrenic patients, family members|Schizophrenia Spectrum Disorder Patients
11490052|NCT01425671||Controls|Normal controls
11490053|NCT01425658|Active Comparator|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
11490054|NCT01425658|Active Comparator|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
11490055|NCT01425658|Placebo Comparator|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
11490056|NCT01425645|Active Comparator|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
11490057|NCT01425645|No Intervention|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
11490058|NCT01425632|Experimental|TAU-284 Low|
11490059|NCT01425632|Experimental|TAU-284 High|
11490060|NCT01425632|Placebo Comparator|Placebo|
11490061|NCT01425619|Placebo Comparator|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
11490062|NCT01425619|Active Comparator|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
11490063|NCT01425619|Active Comparator|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
11490064|NCT01425619|Active Comparator|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
11490065|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
11490066|NCT01425580|Experimental|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
11490067|NCT01425580|Active Comparator|glimepiride|4 mg p.o. (QD)
11490068|NCT01425554|No Intervention|Diagnostic study|
11490069|NCT01425541|Experimental|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
11490070|NCT01425528|Experimental|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
11490071|NCT01425528|Experimental|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
11490072|NCT01425502|Other|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
11490073|NCT01425489||Observation|Patients with Krabbe Disease
11490074|NCT01425476|Placebo Comparator|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
11490075|NCT01425476|Active Comparator|Placebo & cholecalciferol 2,000 IU|
11490076|NCT01425476|Experimental|celecoxib 400 mg & cholecalciferol 2,000 IU|
11490077|NCT01425463|Experimental|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
11490078|NCT01425463|Active Comparator|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
11490079|NCT01425450|Experimental|HF1020|
11490080|NCT01425450|Placebo Comparator|Placebo|
11490081|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
11490082|NCT01425424|Experimental|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
11490083|NCT01425424|Experimental|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
11490084|NCT01425424|Experimental|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
11490085|NCT01425411|Experimental|Valsartan treatment|
11490086|NCT01425398|Experimental|Rosuvastatin|
11490087|NCT01425398|Placebo Comparator|Placebo|
11490088|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
11490089|NCT01425359|Placebo Comparator|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.
~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
11490090|NCT01425359|Experimental|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.
~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
11490091|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
11490092|NCT01425333|Active Comparator|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
11490093|NCT01425333|Active Comparator|Ablation|Patients undergoing ablation for ovarian endometrioma
11490094|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
11490095|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
11490096|NCT01425320|Active Comparator|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
11490097|NCT01425320|Active Comparator|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
11490098|NCT01425307|No Intervention|Standard Therapy|Standard Therapy of monthly transfusions
11490099|NCT01425307|Experimental|Treatment Arm|Hydroxyurea will be provided as capsules or liquid
11490100|NCT01425281|Active Comparator|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
11490101|NCT01425281|Experimental|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
11490102|NCT01425268|Experimental|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
11490103|NCT01425268|Active Comparator|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
11490104|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
11490105|NCT01425242|Experimental|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
11490106|NCT01425242|Active Comparator|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
11490107|NCT01425229||Bosentan|Haplotypes of CYP2C9 and OATP1B1 characterisation of CYP2C9 (CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910)) and OATP1B1 (SLCO1B1*15 (rs2306283, rs4149056))
11490108|NCT01425216|Experimental|Sorafenib arm|All patients will be treated with sorafenib.
11490109|NCT01425203|Experimental|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
11490110|NCT01425203|Placebo Comparator|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
11490111|NCT01425203|Experimental|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
11490112|NCT01425190|Experimental|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
11490113|NCT01425190|Experimental|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
11490114|NCT01425190|Experimental|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
11490115|NCT01425177|Experimental|Normal saline irrigation|
11490116|NCT01425164|Active Comparator|Carvedilol|
11490117|NCT01425164|Experimental|Ivabradine|
11490118|NCT01425151|Active Comparator|i-Gel|
11490119|NCT01425151|Experimental|ProSeal|
11490120|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
11490121|NCT01425125|Experimental|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
11490122|NCT01425112|Experimental|Topical/Subconjunctival|Depending upon the mode of administration
11490123|NCT01425099|Experimental|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
11490124|NCT01425099|Experimental|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
11490125|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
11490126|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
11490127|NCT01425073|Experimental|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
11490128|NCT01425073|No Intervention|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
11490129|NCT01425060|Experimental|Contraceptive management program|
11490130|NCT01425060|Active Comparator|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
11490131|NCT01425047||Females ingesting mangosteen juice|
11490132|NCT01425047||Males ingesting mangosteen juice|
11490133|NCT01425034|Active Comparator|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
11490134|NCT01425034|Active Comparator|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
11490135|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
11490136|NCT01425008|Experimental|MLN2480|
11490137|NCT01424982|Experimental|Treatment (combination chemotherapy, ponatinib hydrochloride)|See Detailed Description.
11490138|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
11490139|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
11490140|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
11490141|NCT01424943|Experimental|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
11490142|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
11490143|NCT01424930|Experimental|Abiraterone+prednisone (low-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
11490144|NCT01424930|Experimental|Abiraterone+prednisone (high-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
11490145|NCT01424917||Heart Transplant|Heart Transplant subjects
11490146|NCT01424904|Experimental|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
11490147|NCT01424891|Placebo Comparator|Placebo|Treatment with placebo over 8 weeks
11490148|NCT01424891|Active Comparator|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
11490149|NCT01424891|Active Comparator|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
11490150|NCT01424852|Active Comparator|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
11490151|NCT01424852|Placebo Comparator|Control milk formula|The children received milk formula with no probiotics
11490152|NCT01424839|Other|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol
~Radiotherapy
~Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)
~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
11490181|NCT01424644|Experimental|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
11490182|NCT01424631|Active Comparator|single incision laparoscopic appendectomy|
11490183|NCT01424631|Placebo Comparator|conventional laparoscopic appendectomy|
11490153|NCT01424839|Other|germinoma non-metastatic|"Chemotherapy:
~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination
~Radiotherapy
~Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)
~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles
~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
11490154|NCT01424839|Other|Non-germinoma non-metastatic standard risk|"Chemotherapy:
~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
11490155|NCT01424839|Other|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
11490156|NCT01424839|Other|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
11490157|NCT01424839|Other|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
11490158|NCT01424839|No Intervention|Teratoma|collection of information on surgery, applied treatment and outcome
11490159|NCT01424813|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
11490160|NCT01424813|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
11490161|NCT01424800|Experimental|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
11490162|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
11490163|NCT01424761|Experimental|Placebo|Placebo:starch
11490164|NCT01424761|Experimental|Coenzyme Q10|
11490165|NCT01424748|Placebo Comparator|Placebo|Placebo juice
11490166|NCT01424748|Experimental|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
11490167|NCT01424748|Experimental|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
11490168|NCT01424748|Experimental|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
11490169|NCT01424735|Experimental|Mw.|Administration of immunomodulator Mw.
11490170|NCT01424722|Experimental|ST Monitoring Feature|
11490171|NCT01424709|Experimental|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
11490172|NCT01424709|Active Comparator|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
11490173|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
11490174|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
11490175|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
11490176|NCT01424670|Experimental|Delamanid + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive 100 mg delamanid orally BID (morning and evening) + OBR for 2 months, followed by 200 mg delamanid QD (every morning) + OBR for 4 months.
~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.
~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
11490177|NCT01424670|Placebo Comparator|Placebo + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive placebo orally BID (morning and evening) + OBR for 2 months followed by placebo QD (every morning) + OBR for 4 months.
~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.
~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
11490178|NCT01424657|Experimental|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
11490179|NCT01424657|Experimental|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
11490180|NCT01424644|Placebo Comparator|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
11490184|NCT01424618|Active Comparator|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
11490185|NCT01424618|Experimental|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
11490187|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
11490188|NCT01424579|Experimental|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
11490189|NCT01424579|Placebo Comparator|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
11490190|NCT01424579|Other|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
11490191|NCT01424566|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
11490192|NCT01424566|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
11490193|NCT01424553|Other|Cohort|All patients
11490194|NCT01424540|Experimental|Treatment A|GSK2336805 150mg
11490195|NCT01424540|Placebo Comparator|Treatment B|GSK2336805 Placebo
11490196|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
11490197|NCT01424514|Experimental|SB-705498|
11490198|NCT01424514|Placebo Comparator|Placebo|
11490199|NCT01424501|Experimental|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
11490200|NCT01424501|Placebo Comparator|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
11490201|NCT01424501|Experimental|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
11490202|NCT01424501|Placebo Comparator|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
11490203|NCT01424501|Experimental|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
11490204|NCT01424501|Placebo Comparator|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
11490205|NCT01424488|Experimental|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
11490206|NCT01424488|Placebo Comparator|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
11490207|NCT01424475|Other|PKD Patients|PKD Patients with LRRK2 mutation
11490208|NCT01424475|Other|Healthy Controls|Healthy Controls with no LRRK2 mutation
11490209|NCT01424462|Experimental|Firategrast XRA|Low extended release tablet
11490210|NCT01424462|Experimental|Firategrast XRB|Medium extended releast tablet
11490211|NCT01424462|Experimental|Firategrast XRC|High extended release tablet
11490212|NCT01424462|Experimental|Firategrast IR|Immediate Release reference tablet
11490213|NCT01424449|Experimental|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for [11C]PHNO.
11490214|NCT01424436|Experimental|GSK933776 1mg/kg|single dose
11490215|NCT01424436|Experimental|GSK933776 0.1 or 3mg/kg|single dose
11490216|NCT01424436|Experimental|GSK933776 3 or 6mg/kg|single dose
11490217|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
11490218|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
11490219|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
11490220|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
11490221|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
11490222|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
11490223|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
11490224|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
11490225|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
11490226|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
11490227|NCT01424397|Experimental|SB-705498|Experimental
11490228|NCT01424397|Active Comparator|Fluticasone Propionate|Active Comparator
11490229|NCT01424397|Placebo Comparator|Placebo|Placebo Comparator
11490230|NCT01424397|Experimental|SB-705498+FP|Experimental
11490231|NCT01424384|Active Comparator|Citalopram|Marketed comparitor
11490232|NCT01424384|Experimental|Investigational Medicinal Product|GSK424887
11490233|NCT01424384|Placebo Comparator|Placebo To Match Treatment|Placebo control
11490234|NCT01424371||Adjuvanted Vaccine Group|
11490235|NCT01424371||Unadjuvanted Vaccine Group|
11490238|NCT01424345|Active Comparator|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
11490239|NCT01424345|Experimental|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
11490240|NCT01424332|Experimental|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
11490241|NCT01424332|Experimental|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
11490242|NCT01424332|Experimental|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
11490243|NCT01424332|Experimental|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
11490244|NCT01424332|Experimental|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
11490245|NCT01424332|Experimental|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
11490246|NCT01424319|Experimental|ABT-627, Low dose|
11490247|NCT01424319|Experimental|ABT-627, High dose|
11490248|NCT01424319|Placebo Comparator|ABT-627, Placebo|
11490249|NCT01424306|Experimental|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.
11490250|NCT01424306|Experimental|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.
11490251|NCT01424306|Experimental|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.
11490252|NCT01424293|Experimental|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
11490253|NCT01424280|Experimental|Active drug|
11490254|NCT01424280|Placebo Comparator|Placebo|
11490255|NCT01424267||1|
11490256|NCT01424254|Experimental|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
11490257|NCT01424254|Experimental|Push Enterosopy|
11490258|NCT01424241|Experimental|Sandostatin LAR|This is a 9 month, open label dose escalation study of Sandostatin LAR therapy.
11490259|NCT01424228|Placebo Comparator|Placebo|Placebo 2 mg tablet once daily before breakfast
11490260|NCT01424228|Active Comparator|prucalopride|Prucalopride 2 mg once daily before breakfast
11490261|NCT01424215|Experimental|ICG injection with Spyscope imaging|Indocyanine Green (ICG)
11490262|NCT01424215|No Intervention|Standard Critical View Technique|50 patients will be randomized to the no treatment arm. These patients will not get ICG injection but rather will have the standard technique for laparoscopic cholecystectomy performed including the critical view technique to expose the important structures prior to clipping and division.
11490263|NCT01424202|Experimental|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
11490264|NCT01424202|No Intervention|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
11490265|NCT01424189|Experimental|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
11490266|NCT01424189|Active Comparator|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
11490267|NCT01424176|Experimental|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
11490268|NCT01424176|Experimental|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
11490269|NCT01424163|Experimental|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
11490270|NCT01424163|Experimental|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
11490271|NCT01424163|Experimental|Treatment 3 (Part A)|Dexpramipexole multiple dosing
11490272|NCT01424163|Experimental|Treatment for Part B|Dexpramipexole multiple dosing
11490273|NCT01424150|Experimental|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
11490274|NCT01424150|Experimental|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device [see below]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
11490275|NCT01424137|Other|Easyhaler type A|
11490276|NCT01424137|Other|Easyhaler type B|
11490277|NCT01424137|Other|Diskus inhaler|
11490278|NCT01424124|Experimental|YHD001 dose level 1|
11490279|NCT01424124|Experimental|YHD001 dose level 2|
11490280|NCT01424124|Active Comparator|Singulair|
11490281|NCT01424124|Placebo Comparator|Placebo|
11490282|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
11490283|NCT01424111||Healthy Control|Those not receiving treatment.
11490284|NCT01424098|Experimental|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
11490285|NCT01424098|No Intervention|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
11490482|NCT01422590|Experimental|Sitagliptin + Mitiglinide|
11490286|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
11490287|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
11490288|NCT01424072|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
11490289|NCT01424072|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
11490290|NCT01424072|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
11490291|NCT01424059||fear of labor|Parous women with fear of labor
11490292|NCT01424046|Experimental|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
11490293|NCT01424046|Active Comparator|standard therapy|Participants will continue current mixed insulin management and education
11490294|NCT01424033|Experimental|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
11490295|NCT01424020|Experimental|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
11490296|NCT01424007|Experimental|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
11490297|NCT01424007|Experimental|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
11490298|NCT01424007|Experimental|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
11490299|NCT01423994|Active Comparator|implantable loop recorder|
11490300|NCT01423994|Active Comparator|pacemaker|
11490301|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
11490302|NCT01423968|Experimental|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
11490303|NCT01423968|Placebo Comparator|saline|0.9% saline infusion
11490304|NCT01423955|Placebo Comparator|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
11490305|NCT01423955|Experimental|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
11490306|NCT01423929|Experimental|10 L O2/min|Oxygen breathing via Oxymask TM
11490307|NCT01423929|Sham Comparator|Room air|Room air breathing via Oxymask TM
11490308|NCT01423916|Active Comparator|Arm 1 (OPC-34712, placebo)|Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
11490309|NCT01423916|Active Comparator|Arm 2 (OPC-34712, placebo)|Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
11490310|NCT01423916|Active Comparator|Arm 3 (moxifloxacin, placebo)|Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
11490311|NCT01423916|Active Comparator|Arm 4 (moxifloxacin, placebo)|Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
11490312|NCT01423903|Experimental|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
11490313|NCT01423890|Other|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
11490314|NCT01423864|Sham Comparator|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
11490315|NCT01423864|Experimental|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
11490316|NCT01423851|Experimental|Intervention: Drug: NS-018|
11490317|NCT01423838|Active Comparator|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
11490318|NCT01423838|Active Comparator|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
11490319|NCT01423825|Experimental|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
11490320|NCT01423825|Placebo Comparator|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
11490321|NCT01423812|Experimental|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
11490322|NCT01423812|Active Comparator|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
11490323|NCT01423799|Experimental|Nutritional product|Nutritional intervention containing immuno-nutrients
11490324|NCT01423799|Active Comparator|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
11490325|NCT01423786|Other|Please help|"Dr. Kumar left Nationwide Children's Hospital in 2014 and efforts to get ahold of her to complete her ct.gov entries have been unsuccessful as we are not able to get ahold of her.
~In July 2014, she wrote in her Continuing Review application to the NCH IRB: 34 patients have been recruited and data has mostly been collected. Follow up calls have been made and no adverse events occurred during the study period.
~No other information is available."
11490326|NCT01423773|Other|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
11490637|NCT01421303||AS patients who are working and treated with Enbrel|
11490327|NCT01423773|Other|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
11490328|NCT01423760|Experimental|Tecemotide (L-BLP25)|
11490329|NCT01423760|Other|Observational|
11490330|NCT01423747|Other|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
11490331|NCT01423747|Other|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
11490332|NCT01423747|Other|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
11490333|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
11490334|NCT01423721|Experimental|Bromihexine hydrochloride granules|16 mg granules
11490335|NCT01423721|Experimental|Bromihexine hydrochloride syrup|16 mg syrup
11490336|NCT01423708|No Intervention|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
11490337|NCT01423708|Experimental|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
11490338|NCT01423695|Experimental|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
11490339|NCT01423682|Placebo Comparator|Healthy subjects|
11490340|NCT01423682|Active Comparator|Rotator cuff tendinopathy|
11490341|NCT01423669||Community dwelling adult population|
11490342|NCT01423656|Experimental|LEO 29102|
11490343|NCT01423656|Placebo Comparator|LEO 29102 vehicle|
11490344|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
11490345|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
11490346|NCT01423630|Experimental|Probiotics and fruit fibre|Probiotics and fruit fibre
11490347|NCT01423617|Active Comparator|Zenoctil|
11490348|NCT01423617|Placebo Comparator|Placebo|
11490349|NCT01423604|Experimental|Capecitabine and ruxolitinib|
11490350|NCT01423604|Placebo Comparator|Capecitabine and placebo|
11490351|NCT01423591|Experimental|infliximab|
11490352|NCT01423591|Placebo Comparator|inactive powder|
11490353|NCT01423578|Active Comparator|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
11490354|NCT01423578|Experimental|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
11490355|NCT01423578|Other|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
11490356|NCT01423565|Experimental|Deep Brain Stimulation|
11490357|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
11490358|NCT01423539|Active Comparator|A|
11490359|NCT01423539|Experimental|B|
11490360|NCT01423526|Placebo Comparator|Placebo|"Drug: Placebo tablets, oral administration, single administrations
~Arms: Placebo"
11490361|NCT01423526|Experimental|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations
~Arms: DWP10292"
11490362|NCT01423513|Experimental|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
11490363|NCT01423513|Sham Comparator|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
11490364|NCT01423500|Other|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
11490365|NCT01423500|Other|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
11490366|NCT01423500|Other|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
11490367|NCT01423487|Experimental|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
11490368|NCT01423487|Placebo Comparator|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
11490369|NCT01423474|Experimental|Short treatment time (11 days)|
11490370|NCT01423474|Experimental|Long treatment time (29 days)|
11490371|NCT01423448|Experimental|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
11490372|NCT01423448|No Intervention|Control|After 6 months participants allocated to the control group will receive access to the intervention
11490373|NCT01423435|Experimental|Japanese|
11490374|NCT01423435|Experimental|Chinese|
11490375|NCT01423435|Experimental|South Korean|
11490376|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
11490377|NCT01423409|Active Comparator|pictorial VAS|VAS with colours and 6 expressive faces
11490378|NCT01423409|Sham Comparator|usual VAS|VAS
11490379|NCT01423396|Other|standard care|Follow up with city doctor with recommendation HAS French guidelines
11490380|NCT01423396|Experimental|optimal care of VRF|Monitoring according to the strict recommendations of the HAS French guidelines
11490381|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
11490382|NCT01423370|Experimental|Group A|
11490383|NCT01423370|Experimental|Group B|
11490384|NCT01423370|Experimental|Group C|
11490385|NCT01423370|Active Comparator|Group D|
11490386|NCT01423370|Placebo Comparator|Group E|
11490387|NCT01423357|Experimental|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
11490388|NCT01423357|No Intervention|Business as usual|
11490389|NCT01423318|Experimental|A|
11490390|NCT01423318|Placebo Comparator|B|
11490391|NCT01423305|Experimental|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
11490392|NCT01423305|Experimental|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
11490393|NCT01423292|Active Comparator|an odd numbered patients|TAP block with local anesthetics
11490394|NCT01423292|Placebo Comparator|an even numbered patients|TAP block without local anesthetics
11490395|NCT01423266|Experimental|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
11490396|NCT01423266|Active Comparator|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
11490397|NCT01423253|Experimental|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
11490398|NCT01423240|Experimental|Lurasidone 20 mg|
11490399|NCT01423240|Experimental|Lurasidone 60 mg|
11490400|NCT01423240|Placebo Comparator|Placebo|
11490401|NCT01423227|Experimental|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
11490402|NCT01423227|Active Comparator|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
11490403|NCT01423214|Experimental|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
11490404|NCT01423214|Active Comparator|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
11490405|NCT01423188|Experimental|RVX000222, 200 mg daily|
11490406|NCT01423188|Placebo Comparator|Placebo|
11490407|NCT01423175|Experimental|ClAraC|
11490408|NCT01423175|Active Comparator|FLAMSA|
11490409|NCT01423162|Experimental|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
11490410|NCT01423162|Experimental|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
11490411|NCT01423149|Experimental|36 mg/m2 Combretastin A-4 Phosphate|
11490412|NCT01423149|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
11490413|NCT01423149|Experimental|27 mg/m2 Combretastatin A-4 Phosphate|
11490414|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
11490415|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
11490416|NCT01423123|Experimental|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
11490417|NCT01423110|Experimental|BYM338|
11490418|NCT01423110|Placebo Comparator|Placebo|
11490419|NCT01423084|Experimental|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
11490420|NCT01423084|Active Comparator|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
11490421|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
11490422|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
11490423|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
11490424|NCT01423058|Experimental|Momelotinib|
11490425|NCT01423032|Experimental|Bendamustine|
11490426|NCT01423032|Active Comparator|Fludarabine|
11490427|NCT01423019|Active Comparator|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
11490428|NCT01423019|Active Comparator|Advantra Z + Naringin + Hesperiden|
11490429|NCT01423019|Placebo Comparator|Sugar pill|Capsule contains inert ingredient.
11490430|NCT01423006|Experimental|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
11490431|NCT01422993|Experimental|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
11490432|NCT01422980|Active Comparator|1 = Test product|Arm 1 - intervention 1 (test product)
11490433|NCT01422980|Placebo Comparator|2 = Control product|Arm 2 - intervention 2 (control product)
11490434|NCT01422967|Active Comparator|Osteoarthritis group|
11490435|NCT01422967|Active Comparator|without osteoarthritis|
11490436|NCT01422954|Active Comparator|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
11490437|NCT01422954|Experimental|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
11490438|NCT01422954|Placebo Comparator|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
11490439|NCT01422941|Experimental|CAVU Attune Device|
11490440|NCT01422928|No Intervention|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.
~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:
~before radiation
~at 1st follow up 4-10 weeks after radiation completion
~at second follow up 6 months after 1st follow up"
11490483|NCT01422577|Active Comparator|Bright Narrow Band Imaging|Bright Narrow Band Imaging
11490484|NCT01422577|Active Comparator|White Light Endoscopy|White Light Endoscopy
11490485|NCT01422564|Active Comparator|Metal on Metal|Metal on Metal articulation system
11490441|NCT01422928|Experimental|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.
~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:
~before radiation
~at 1st follow up 4-10 weeks after radiation completion
~at second follow up 6 months after 1st follow up"
11490442|NCT01422915|Experimental|colestipol treatment|2 grams morning and bedtime for 180 days
11490443|NCT01422902|Experimental|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
11490444|NCT01422902|Active Comparator|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
11490445|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
11490446|NCT01422876|Experimental|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
11490447|NCT01422876|Experimental|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
11490448|NCT01422876|Active Comparator|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
11490449|NCT01422876|Active Comparator|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
11490450|NCT01422876|Active Comparator|Linagliptin|Patients receive linagliptin once daily
11490451|NCT01422863|Experimental|Lifestyle Intervention|
11490452|NCT01422824||Cohort|
11490453|NCT01422811|Experimental|Intervention|
11490454|NCT01422811|Other|Control|No Intervention
11490455|NCT01422785|Active Comparator|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
11490456|NCT01422785|Active Comparator|clindamycin / tretinoin gel plus benzoyl peroxide|
11490457|NCT01422772|Experimental|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
11490458|NCT01422772|Experimental|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
11490459|NCT01422772|Experimental|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
11490460|NCT01422759|Experimental|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
11490461|NCT01422746|Experimental|metformin|12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
11490462|NCT01422733|Experimental|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
11490463|NCT01422720|Experimental|Eslicarbazepine Acetate tablets (800 mg)|
11490464|NCT01422707|Experimental|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
11490465|NCT01422694||Healthy control|Healthy volunteers will be recruited to serve as controls
11490466|NCT01422694||Other Inflammatory Diseases|Subjects with Other Inflammatory Diseases
11490467|NCT01422694||Patients with Spondyloarthritis|Subjects with confirmed or probable SpA will be identified predominantly by physician referral.
11490468|NCT01422681|Experimental|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
11490469|NCT01422668|Active Comparator|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
11490470|NCT01422668|Experimental|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
11490471|NCT01422642|Experimental|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
11490472|NCT01422642|Experimental|legacy posterior stabilized standard|standard NexGen LPS prosthesis
11490473|NCT01422629|Experimental|High Intensity Focused Ultrasound (HIFU)|
11490474|NCT01422616|Experimental|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
11490475|NCT01422616|Active Comparator|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
11490476|NCT01422616|Experimental|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.
~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
11490477|NCT01422616|Active Comparator|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.
~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
11490478|NCT01422603|Experimental|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
11490479|NCT01422603|Experimental|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
11490480|NCT01422590|Active Comparator|Sitagliptin|
11490486|NCT01422564|Active Comparator|HCLPC|THA using Highly Cross Linked Polyethylene cup System
11490487|NCT01422551|Experimental|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
11490488|NCT01422551|Active Comparator|Psycho-educational Control|a single day group-based psycho-educational seminar
11490489|NCT01422538|Active Comparator|Group A|Subjects will receive Ulthera® System alone.
11490490|NCT01422538|Active Comparator|Group B|Sculptra® only
11490491|NCT01422538|Active Comparator|Group C|Sculptra® treatment followed by Ultherapy™ treatment
11490492|NCT01422525||Trabeculectomy RNFL thickness OCT|
11490493|NCT01422512|Experimental|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
11490494|NCT01422486|Experimental|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
11490495|NCT01422473|Experimental|EnSeal Device|EnSeal Trio Tissue Sealing Device
11490496|NCT01422460|Experimental|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
11490497|NCT01422447|Experimental|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol-abuse.
11490498|NCT01422447|Active Comparator|regular intervention control|the subjects in the control group live in the used model
11490499|NCT01422434|Active Comparator|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
11490500|NCT01422434|Active Comparator|Dovonex® ointment|Applied twice daily for 4 weeks.
11490501|NCT01422434|Active Comparator|Rinderon® - DP ointment|Applied once daily for 4 weeks
11490502|NCT01422421|Active Comparator|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
11490503|NCT01422421|Active Comparator|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
11490504|NCT01422408|Experimental|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
11490505|NCT01422395|Experimental|freezing|
11490506|NCT01422395|No Intervention|No freezing|
11490507|NCT01422382|Experimental|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
11490508|NCT01422369|Experimental|All Subjects|pitavastatin 4 mg
11490509|NCT01422343||1|
11490510|NCT01422330|Experimental|Etravirine|
11490511|NCT01422317|Experimental|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
11490512|NCT01422317|Active Comparator|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
11490513|NCT01422304|Experimental|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
11490514|NCT01422304|Experimental|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
11490515|NCT01422291|Active Comparator|morphine|
11490516|NCT01422291|Experimental|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
11490517|NCT01422265||Cohort|
11490518|NCT01422252|Experimental|Persons equipped|Precocious fall detection device
11490519|NCT01422252|No Intervention|Persons non-equipped|No fall detection device
11490520|NCT01422239|Experimental|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
11490521|NCT01422239|Active Comparator|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
11490522|NCT01422226|Experimental|Experimental active comparator|"Drug: Misoprostol
~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
11490523|NCT01422226|Placebo Comparator|Placebo comparator|"Other: Placebo
~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
11490524|NCT01422213|Placebo Comparator|Placebo|
11490525|NCT01422213|Experimental|Vortioxetine 10 mg|
11490526|NCT01422213|Experimental|Vortioxetine 20 mg|
11490527|NCT01422200|Experimental|Subcutaneous|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once
11490528|NCT01422200|Active Comparator|Intramuscular|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once
11490529|NCT01422187|Experimental|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
11490530|NCT01422187|Experimental|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
11490531|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
11490532|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
11490533|NCT01422161|Experimental|Botulinum Toxin commonly known as BOTOX®|Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.
11490534|NCT01422161|Placebo Comparator|Placebo|Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.
11490535|NCT01422148|Other|Amiodarone|oral amiodarone
11490536|NCT01422148|Experimental|minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
11490537|NCT01422135|Experimental|Abdomen, Buttock, Upper Torso|"Patch was placed on abdomen, buttock then the upper torso excluding breast.
~Intervention: AG200-15 patch"
11490538|NCT01422135|Experimental|Abdomen, Upper Torso, Buttock|"Patch was placed on abdomen, upper torso excluding breast then the buttock.
~Intervention: AG200-15 patch"
11490539|NCT01422135|Experimental|Buttock, Abdomen, Upper Torso|"Patch was placed on the buttock, abdomen, then the upper torso excluding breast.
~Intervention: AG200-15 patch"
11490540|NCT01422135|Experimental|Buttock, Upper Torso, Abdomen,|"Patch was placed on the buttock, upper torso excluding breast then the abdomen
~Intervention: AG200-15 patch"
11490541|NCT01422135|Experimental|Upper Torso, Abdomen, Buttock|"Patch was placed on the upper torso excluding breast, abdomen then buttock.
~Intervention: AG200-15 patch"
11490542|NCT01422135|Experimental|Upper Torso, Buttock, Abdomen|"Patch was place on the upper torso excluding breast, buttock, then abdomen.
~Intervention: AG200-15 patch"
11490543|NCT01422122|Experimental|Vitamin D|Oral vitamin D3 in syrup form
11490544|NCT01422122|Placebo Comparator|placebo|Placebo syrup identical in colour and taste to that of intervention
11490545|NCT01422109|Experimental|Group A|
11490546|NCT01422109|Active Comparator|Group B|
11490547|NCT01422096|Experimental|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
11490548|NCT01422083|No Intervention|Control group|This group of athletes do not perform a 6-week stretching program.
11490549|NCT01422083|Experimental|Home stretching program|These athletes take on a home stretching program (sleeper's stretch).
11490550|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
11490551|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
11490552|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
11490553|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
11490554|NCT01422018|Experimental|one arm for Anastin injection|intravitreal Avastin injection
11490555|NCT01422005|Experimental|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
11490556|NCT01422005|Active Comparator|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
11490557|NCT01421992|Placebo Comparator|Arm 1: Methylphenidate versus baseline|
11490558|NCT01421992|Placebo Comparator|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
11490559|NCT01421979|Experimental|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
11490560|NCT01421979|Experimental|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
11490561|NCT01421966|Experimental|CureXcell®|
11490562|NCT01421966|Sham Comparator|Sham injection|
11490563|NCT01421953|Experimental|Patients|
11490564|NCT01421940|Placebo Comparator|Control|Individuals who take placebo after total mesorectal excision
11490565|NCT01421940|Experimental|Udenafil|Individuals who take udenafil after total mesorectal excision
11490566|NCT01421927|Experimental|lenalidomide|
11490567|NCT01421914|Other|Bupivacaine 0,5%|Single arm study
11490568|NCT01421901|Experimental|Ertapenem|
11490569|NCT01421901|Active Comparator|appendectomy|Appendectomy is compared to Ertapenem
11490570|NCT01421849|Experimental|Elderly with an unstable mandibular denture.|
11490571|NCT01421836|Active Comparator|ERCP guided stent insertion|
11490572|NCT01421836|Active Comparator|EUS guided stent insertion|
11490573|NCT01421823|Experimental|alpha agonist ointment|
11490574|NCT01421823|Placebo Comparator|Placebo|
11490575|NCT01421810|Experimental|dexamethasone, rhCG (Ovidrel)|rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
11490576|NCT01421797|Experimental|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
11490577|NCT01421784|Other|Cine-MRI|Rapid Cine-MRI
11490578|NCT01421771|Active Comparator|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
11490579|NCT01421771|Placebo Comparator|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
11490580|NCT01421758|Experimental|online social network|
11490581|NCT01421758|Active Comparator|web education control|
11490582|NCT01421745|Experimental|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
11490583|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
11490584|NCT01421719|Experimental|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
11490585|NCT01421706|Active Comparator|sibutramine-clopidogrel|sibutramine-clopidogrel
11490586|NCT01421706|Active Comparator|sibutramine-clarithromycin|sibutramine-clarithromycin
11490587|NCT01421693|Active Comparator|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
11490588|NCT01421693|Active Comparator|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days
~14 years and older - 2g once daily for 7 days"
11490589|NCT01421680|Active Comparator|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
11490590|NCT01421680|No Intervention|Standard care|Standard care without oral nutritional supplements
11490591|NCT01421667|Experimental|Brentuximab vedotin+rituximab|
11490592|NCT01421667|Experimental|Brentuximab vedotin|
11490593|NCT01421654|Experimental|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
11490594|NCT01421654|Active Comparator|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
11490595|NCT01421641|Active Comparator|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
11490596|NCT01421641|Active Comparator|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
11490597|NCT01421628|Experimental|exercise|
11490598|NCT01421615|Placebo Comparator|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
11490599|NCT01421615|Experimental|lactobacilli capsule|
11490600|NCT01421615|Experimental|lactobacilli capsules|
11490601|NCT01421589|Experimental|Growth Hormone|
11490602|NCT01421576|Active Comparator|High fat meal|
11490603|NCT01421576|Experimental|DP-R202|under fed condition
11490604|NCT01421563|Active Comparator|Anplag|
11490605|NCT01421563|Experimental|DP-R202|
11490606|NCT01421550|Active Comparator|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
11490607|NCT01421550|Active Comparator|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
11490608|NCT01421524|Experimental|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
11490609|NCT01421524|Experimental|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
11490610|NCT01421524|Experimental|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
11490611|NCT01421524|Experimental|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
11490612|NCT01421511|Experimental|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
11490613|NCT01421511|Active Comparator|Linezolid|• Linezolid IV followed by Linezolid Tablets
11490614|NCT01421498|Experimental|5.0% Lifitegrast|Lifitegrast
11490615|NCT01421498|Placebo Comparator|Placebo|Placebo
11490616|NCT01421485|Experimental|Integrated treatment Program|
11490617|NCT01421485|Active Comparator|Treatment as Usual|
11490618|NCT01421472|Experimental|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
11490619|NCT01421472|Active Comparator|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
11490620|NCT01421459|Experimental|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) [alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)] administered per standard of care for 24 weeks
11490621|NCT01421459|Active Comparator|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
11490622|NCT01421433|Active Comparator|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
11490623|NCT01421433|Experimental|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
11490624|NCT01421420||Alzheimer's Disease|
11490625|NCT01421420||Mild Cognitive Impairment|
11490626|NCT01421420||Other forms of Dementia, not AD|
11490627|NCT01421420||Normal Elderly Individuals|
11490628|NCT01421407|Active Comparator|High Intensity Focused Ultrasound|
11490629|NCT01421407|No Intervention|Control group|
11490630|NCT01421394||single group study|
11490631|NCT01421368|Experimental|DMPA and tenofovir 1% gel|
11490632|NCT01421368|Experimental|Oral contraceptive and tenofovir 1% gel|
11490633|NCT01421355|Experimental|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
11490634|NCT01421342|Active Comparator|Switching: Bupropion-SR|Switching: Bupropion-SR
11490635|NCT01421342|Active Comparator|Augmenting: Antidepressant + Bupropion-SR|Augmenting: Antidepressant + Bupropion-SR
11490636|NCT01421342|Active Comparator|Augmenting: Antidepressant + Aripiprazole|Augmenting: Antidepressant + Aripiprazole
11490638|NCT01421290|Active Comparator|Conservative treatment|
11490639|NCT01421290|Active Comparator|Surgery|
11490640|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
11490641|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
11490642|NCT01421264|Experimental|Gabapentin|
11490643|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
11490644|NCT01421238|Experimental|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:
~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:
~Please check if you decline resuscitation []"
11490645|NCT01421238|Experimental|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:
~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:
~Please check if you decline comfort care []"
11490646|NCT01421225|Active Comparator|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
11490647|NCT01421225|Active Comparator|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
11490648|NCT01421199|Other|Myringotomy|On arm
11490649|NCT01421186|Experimental|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment
~Part B: MOR03087 dose escalation; weekly treatment
~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone
~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone
~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone
~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment."
11490650|NCT01421186|Experimental|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.
~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.
~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.
~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment."
11490651|NCT01421173|Experimental|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
11490652|NCT01421147|Experimental|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
11490653|NCT01421147|Active Comparator|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
11490654|NCT01421134|Experimental|Lurasidone|Lurasidone 20, 40 or 60 mg
11490655|NCT01421134|Placebo Comparator|Placebo|Placebo
11490656|NCT01421121|Experimental|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
11490657|NCT01421121|Experimental|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
11490658|NCT01421121|Experimental|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
11490659|NCT01421121|Experimental|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
11490660|NCT01421121|Placebo Comparator|Placebo|120 infants received 2 doses of placebo 28 days apart.
11490661|NCT01421108|Experimental|Loss-framed messages|
11490662|NCT01421108|Experimental|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
11490663|NCT01421095|Experimental|Basal Testing|
11490664|NCT01421082|Experimental|LVRC Treatment|
11490665|NCT01421069|Experimental|1|
11490666|NCT01421056|Experimental|CHF 5074 1x|oral tablet, multidose
11490667|NCT01421056|Experimental|CHF 5074 2x|oral tablet, multidose
11490668|NCT01421056|Experimental|CHF 5074 3x|oral tablet, multidose
11490669|NCT01421043|Experimental|triazolam liquid oral drops|
11490670|NCT01421043|Active Comparator|triazolam tablets|
11490671|NCT01421030|Other|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
11490672|NCT01421017|Experimental|IMQ+RT|"This arm has been closed as of 6/4/2014.
~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)
~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.
~Week 9: response assessment
~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
11490673|NCT01421017|Experimental|CTX/IMQ/RT|"Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion
~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)
~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.
~Week 9: response assessment
~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
11490674|NCT01421017|Experimental|CTX/RT|"For patients with only non-skin metastatic sites
~First cycle (Cycle 1):
~Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion
~Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)
~Week 9: response assessment
~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
11490675|NCT01421004|Experimental|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
11490676|NCT01421004|Experimental|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
11490677|NCT01420978|Experimental|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
11490678|NCT01420978|Active Comparator|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
11490679|NCT01420965|Active Comparator|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
11490680|NCT01420965|Experimental|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
11490681|NCT01420965|Experimental|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
11490682|NCT01420926|Experimental|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.
~CONTINUATION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11490683|NCT01420926|Experimental|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.
~CONTINUATION THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11490684|NCT01420913|Active Comparator|Lyrica capsule(Pregabalin 150mg)|
11490685|NCT01420913|Experimental|YHD1119 A(Pregabalin SR 300mg)|
11490686|NCT01420913|Experimental|YHD1119 B(Pregabalin SR 300mg)|
11490687|NCT01420913|Experimental|YHD1119 C(Pregabalin SR 300mg)|
11490688|NCT01420900|Active Comparator|ABG II / Trident|
11490689|NCT01420900|Active Comparator|CLS / Trilogy|
11490690|NCT01420887|Experimental|Continuous Passive Motion|Subjects randomized to CPM therapy.
11490691|NCT01420887|Active Comparator|Physical Therapy|Subjects randomized to physical therapy.
11490692|NCT01420874|Experimental|FOLFOX6 & EGFRBi armed ATC Infusions|"FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion"
11490693|NCT01420861|Experimental|1000 mg GTx-758|subjects will receive daily doses of 1000 mg GTx-758
11490694|NCT01420848|Active Comparator|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
11490871|NCT01419561|Other|5|Standard Therapies
11490695|NCT01420848|Placebo Comparator|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
11490696|NCT01420848|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
11490697|NCT01420835|Active Comparator|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
11490698|NCT01420835|Active Comparator|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
11490699|NCT01420835|No Intervention|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
11490700|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
11490701|NCT01420796|Experimental|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
11490702|NCT01420796|Experimental|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
11490703|NCT01420796|Experimental|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
11490704|NCT01420783|Experimental|SAR302503 100 mg|once daily X 28 days
11490705|NCT01420783|Experimental|SAR302503 200 mg|once daily X 28 days
11490706|NCT01420783|Experimental|SAR302503 400 mg|once daily X 28 days
11490707|NCT01420783|Experimental|SAR302503 600 mg|once daily X 28 days
11490708|NCT01420770|Experimental|SAR02503 300 mg qd|daily X 28 days
11490709|NCT01420770|Experimental|SAR302503 400 mg qd|daily X 28 days
11490710|NCT01420770|Experimental|SAR302503 500 mg qd|daily X 28 days
11490711|NCT01420757|Active Comparator|open|open incisional hernia repair
11490712|NCT01420757|Active Comparator|laparoscopic|laparoscopic incisional hernia repair
11490713|NCT01420744|Experimental|BT086 infusion|
11490714|NCT01420744|Placebo Comparator|1% Human Albumin infusion|
11490715|NCT01420718|Active Comparator|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
11490716|NCT01420718|Experimental|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
11490717|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
11490718|NCT01420692|Active Comparator|Gliclazide MR|
11490719|NCT01420692|Active Comparator|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
11490720|NCT01420679|Experimental|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
11490721|NCT01420679|No Intervention|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
11490722|NCT01420666|Active Comparator|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
11490723|NCT01420666|Active Comparator|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
11490724|NCT01420666|Active Comparator|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
11490725|NCT01420666|Placebo Comparator|Placebo|Placebo tablets
11490726|NCT01420653|Experimental|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
11490727|NCT01420653|Active Comparator|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
11490728|NCT01420653|Active Comparator|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
11490729|NCT01420653|Placebo Comparator|Placebo|Placebo tablets, every 6 hours, orally
11490730|NCT01420640|Active Comparator|Tai Chi|
11490731|NCT01420640|Active Comparator|Aerobic Exercise Training|
11490732|NCT01420627|Experimental|Adagen/EZN-2279|Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen
11490733|NCT01420614|Experimental|Radial|group of patients undergoing primary angioplasty by transradial approach
11490734|NCT01420614|Active Comparator|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
11490735|NCT01420588||gastric cancer|
11490736|NCT01420588||gastritis|
11490737|NCT01420588||gastric ulcer|
11490738|NCT01420588||normal|
11490739|NCT01420575|Experimental|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
11490777|NCT01420289|Experimental|HPIPC|High Pressure Intermittent Pneumatic compression (HPIPC)to be performed for 45 minutes twice daily
11490778|NCT01420289|Active Comparator|Excercise|Walking on a graded treadmill for 45 minutes once daily
11490740|NCT01420575|Active Comparator|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
11490741|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.
~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
11490742|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.
~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
11490743|NCT01420549|Experimental|Rosuvastatin + Ezetimibe|Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.
11490744|NCT01420549|Active Comparator|Simvastatin + Ezetimibe|Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.
11490745|NCT01420536|Experimental|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
11490746|NCT01420536|Sham Comparator|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
11490747|NCT01420523|Experimental|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
11490748|NCT01420510|Experimental|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
11490749|NCT01420510|Placebo Comparator|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
11490750|NCT01420497|Active Comparator|methylprednisolone,infiltration|
11490751|NCT01420497|Active Comparator|epidural injection|
11490752|NCT01420484||different blood pressure intervals|
11490753|NCT01420471|Active Comparator|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
11490754|NCT01420471|Experimental|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
11490755|NCT01420445|Experimental|YHD001 dose level 1|YHD001 dose level 1
11490756|NCT01420445|Experimental|YHD001 dose level 2|YHD001 dose level 2
11490757|NCT01420445|Active Comparator|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
11490758|NCT01420445|Placebo Comparator|Placebo|Placebo for YHD001 & active comparator(syrup)
11490759|NCT01420432|Experimental|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
11490760|NCT01420432|No Intervention|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
11490761|NCT01420419|Experimental|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
11490762|NCT01420419|Other|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
11490763|NCT01420406|Placebo Comparator|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
11490764|NCT01420406|Experimental|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
11490765|NCT01420406|Experimental|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
11490766|NCT01420406|Experimental|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
11490767|NCT01420393|Active Comparator|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
11490768|NCT01420393|Active Comparator|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
11490769|NCT01420367|Experimental|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
11490770|NCT01420367|Active Comparator|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
11490771|NCT01420341|Active Comparator|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
11490772|NCT01420341|Experimental|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
11490773|NCT01420328|Placebo Comparator|Placebo Arm|Obese subjects with near normal cholesterol
11490774|NCT01420328|Active Comparator|Vytorin Arm|Obese subjects with near normal cholesterol
11490775|NCT01420302|Experimental|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
11490776|NCT01420302|Active Comparator|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
11490870|NCT01419561|Experimental|4|Rituximab + liposomal doxorubicin
11490779|NCT01420263|Active Comparator|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
11490780|NCT01420263|Active Comparator|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
11490781|NCT01420250|Experimental|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
11490782|NCT01420237|Other|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
11490783|NCT01420224||Healthy volunteers|
11490784|NCT01420224||Chuvash polycythaemia|
11490785|NCT01420211|Experimental|Primovist|
11490786|NCT01420198|Experimental|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
11490787|NCT01420198|No Intervention|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
11490788|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
11490789|NCT01420159|Experimental|Methoxyflurane|
11490790|NCT01420159|Placebo Comparator|Normal Saline|
11490791|NCT01420146|Experimental|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
11490792|NCT01420133|Experimental|Normal regimen|without special regimen for corticosteroid therapy
11490793|NCT01420133|Active Comparator|Standard arm|with diet low in salt and sugar
11490794|NCT01420094|Experimental|Arm 1|
11490795|NCT01420094|Active Comparator|Arm 2|
11490796|NCT01420094|Placebo Comparator|Arm 3|
11490797|NCT01420081|Experimental|B|PI3K Basal, IV Compound
11490798|NCT01420081|Experimental|C|PI3K Activated, Oral Compound
11490799|NCT01420081|Experimental|F|Japanese lead in cohort, IV compound
11490800|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
11490801|NCT01420055|Experimental|fingolimod|
11490802|NCT01420042|Placebo Comparator|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
11490803|NCT01420042|Experimental|NNZ-2566|
11490804|NCT01420016|Active Comparator|Prioritized Clinical Decision Support|The Prioritized Clinical Decision Support (CDS) intervention is a protocol driven CDS system linked within the EMR that identifies patients with high cardiovascular risk and provides tailored, prioritized decision support to the provider and patient at the point of care. The CDS was printed at intervention sites. It i) compiled most recent lab data (A1c, SBP, and LDL), BMI, smoking status, and aspirin use, (ii) calculated a 10-year risk for stroke or heart attack, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to renal and liver function, creatine kinase level, and previous diagnoses (CHF, CVD, DM), and (v) provided recommendations for intensification of therapy for A1c, SBP and/or LDL if not at goal.
11490805|NCT01420016|No Intervention|Usual Care|Providers in the usual care arm did not have access to the prioritized clinical decision support tool.
11490806|NCT01420003|Experimental|Allergen Challenge|
11490807|NCT01419990|Experimental|GLPG0634 capsules|
11490808|NCT01419990|Placebo Comparator|Placebo capsules|
11490809|NCT01419977|Placebo Comparator|Placebo|Normal saline solution
11490810|NCT01419977|Experimental|Dalteparin|5000 unites subcutaneously, Other Name: Fragmin
11490811|NCT01419964|Experimental|Group 01|ACH24
11490812|NCT01419964|Placebo Comparator|Group 02|Placebo
11490813|NCT01419951|Active Comparator|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
11490814|NCT01419951|Active Comparator|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
11490815|NCT01419951|Experimental|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
11490816|NCT01419938|Active Comparator|Light therapy for two weeks|
11490817|NCT01419938|Active Comparator|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
11490818|NCT01419925|Experimental|Group A|Two Multimeric-001 administrations followed by TIV
11490819|NCT01419925|Experimental|Group B|One administration of Multimeric-001 followed by TIV
11490820|NCT01419925|Experimental|Group C|One administration of adjuvanted M-001 followed by TIV
11490821|NCT01419925|Active Comparator|Group D|One administration of placebo followed by TIV
11490822|NCT01419912|Experimental|soy milk|
11490823|NCT01419912|Experimental|cow's milk|
11490824|NCT01419899|Experimental|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
11490825|NCT01419899|No Intervention|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
11490826|NCT01419886||Dysphagia|
11490827|NCT01419860|Experimental|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
11490828|NCT01419847|Active Comparator|topical Penlac nail lacquer|3-1 randomization of active to placebo
11490829|NCT01419847|Placebo Comparator|Placebo|
11490830|NCT01419834|Experimental|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
11490831|NCT01419821|Active Comparator|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
11490832|NCT01419821|Placebo Comparator|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
11490833|NCT01419821|No Intervention|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
11490834|NCT01419808|Active Comparator|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
11490835|NCT01419808|Active Comparator|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg [Am]. 1984 Sep;9(5):733-7.)
11490836|NCT01419795|Experimental|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
11490837|NCT01419795|Active Comparator|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
11490838|NCT01419782|Experimental|Whole-body vibration|whole body vibration will be applied the right lower limb.
11490839|NCT01419769|Experimental|AXIOS Stent and Delivery System|
11490840|NCT01419756||Single Arm|Imaging comparison study. No intervention.
11490841|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
11490842|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
11490843|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
11490844|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
11490845|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
11490846|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
11490847|NCT01419730|Active Comparator|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
11490848|NCT01419730|Active Comparator|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
11490849|NCT01419730|No Intervention|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
11490850|NCT01419717|Experimental|Denosumab|Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
11490851|NCT01419704|Experimental|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
11490852|NCT01419691|Experimental|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
11490853|NCT01419678|Experimental|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
11490854|NCT01419665|Experimental|GP2013|Type: Biological/Vaccine
11490855|NCT01419665|Active Comparator|rituximab|Type: Biological/Vaccine
11490856|NCT01419652|Active Comparator|continue hypglycemic meds|
11490857|NCT01419652|No Intervention|control - hold drug|
11490858|NCT01419639|Experimental|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
11490859|NCT01419626|No Intervention|Negative Control|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste.
11490860|NCT01419626|Sham Comparator|Device with Water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
11490861|NCT01419626|Experimental|Device with Mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
11490862|NCT01419613|Experimental|Motivational Interviewing|
11490863|NCT01419613|Active Comparator|Physical Activity Counseling|
11490864|NCT01419600|Experimental|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
11490865|NCT01419600|Placebo Comparator|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
11490866|NCT01419587|Experimental|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
11490867|NCT01419561|No Intervention|1|Evaluation Phase
11490868|NCT01419561|No Intervention|2|Natural History/Observation Arm
11490869|NCT01419561|Experimental|3|High dose zidovudine + valganciclovir
11490872|NCT01419535|Experimental|Mifepristone, then Placebo|Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.
11490873|NCT01419535|Experimental|Placebo, then Mifepristone|Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.
11490874|NCT01419483|Experimental|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
11490875|NCT01419470|Experimental|YHD1044 I|
11490876|NCT01419470|Experimental|YHD1044 III|
11490877|NCT01419470|Experimental|YHD1044 V|
11490878|NCT01419457|Experimental|Group 1|Normal hepatic function
11490879|NCT01419457|Experimental|Group 2|Mild hepatic impairment
11490880|NCT01419457|Experimental|Group 3|Moderate hepatic impairment
11490881|NCT01419457|Experimental|Group 4|Severe hepatic impairment
11490882|NCT01419444|Active Comparator|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
11490883|NCT01419444|Experimental|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
11490884|NCT01419431||Colon cancer patients|Laparoscopic resection
11490885|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
11490886|NCT01419405|Experimental|Pregabalin/placebo|
11490887|NCT01419405|Active Comparator|placebo/remifentanil|
11490888|NCT01419405|Placebo Comparator|placebo/placebo|
11490889|NCT01419405|Experimental|Pregabalin/Remifentanil|
11490890|NCT01419392|Experimental|Sildenafil citrate|
11490891|NCT01419392|Placebo Comparator|placebo|
11490892|NCT01419379||1|
11490893|NCT01419353|Experimental|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
11490894|NCT01419353|Active Comparator|long IVF protocol|long IVF protocol
11490895|NCT01419327||Group 1|Drug (incl. Placebo)
11490896|NCT01419314|Experimental|Splinting application|Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
11490897|NCT01419314|Placebo Comparator|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.
11490898|NCT01419288|Active Comparator|No Body weight support|
11490899|NCT01419288|Experimental|Body weight support|
11490900|NCT01419275|Experimental|Moyamoya|Approximately 60 Moyamoya patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
11490901|NCT01419275|Experimental|Acute stroke|Approximately 60 acute stroke patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
11490902|NCT01419275|Experimental|Healthy participants|Approximately 30 healthy participants will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
11490903|NCT01419275|Experimental|Diagnosis unspecified|Approximately 60 participants with diagnosis unspecified will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
11490904|NCT01419262|Experimental|2000 IU per day vitamin D|
11490905|NCT01419262|Active Comparator|400 IU per day vitamin D|
11490906|NCT01419249|Other|Retrospective cohort|
11490907|NCT01419236|Experimental|Testosterone Solution 2% 60 milligrams (mg)|Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 milligrams per day (mg/day) or 90 mg/day for 16 weeks
11490908|NCT01419236|Placebo Comparator|Placebo|Placebo solution applied topically once daily for 16 weeks
11490909|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
11490910|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
11490911|NCT01419210|Experimental|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
11490912|NCT01419197|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
11490913|NCT01419197|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
11490914|NCT01419184|Experimental|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
11490915|NCT01419184|Active Comparator|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
11490916|NCT01419171|Experimental|OMEGA™ Monorail Coronary Stent System|
11490917|NCT01419145|Experimental|Multimodal intervention|
11490918|NCT01419145|Active Comparator|Standard Care|
11490919|NCT01419132|Placebo Comparator|High doses furosemide|administration of furosemide alone
11490920|NCT01419132|Experimental|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
11490921|NCT01419119|Experimental|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
11490922|NCT01419119|Experimental|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
11490923|NCT01419119|Experimental|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
11490924|NCT01419119|Experimental|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
11490925|NCT01419106|No Intervention|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
11490926|NCT01419106|Experimental|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
11490927|NCT01419093|No Intervention|5A Communication|Behavioral: 5 A intervention for physical activity
11490928|NCT01419080||Peripheral Arterial Disease (PAD) patients|Patients with new onset or exacerbation of peripheral artery (PA) symptoms.
11490929|NCT01419067|Other|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.
~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine will be given to aid in tumor visualization."
11490930|NCT01419041|Other|Arm A|CLCR: Creatinine clearance
11490931|NCT01419041|Other|Arm B|CLCR: Creatinine clearance
11490932|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
11490933|NCT01419015|Experimental|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
11490934|NCT01419002|Experimental|Neoadjuvant RTx|
11490935|NCT01419002|Active Comparator|Surgery|
11490936|NCT01418989|Experimental|1|
11490937|NCT01418989|Experimental|2|
11490938|NCT01418976|Experimental|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
11490939|NCT01418963|Experimental|Active|
11490940|NCT01418963|Placebo Comparator|Placebo|
11490941|NCT01418950|Active Comparator|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
11490942|NCT01418950|Experimental|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
11490943|NCT01418937|Experimental|HPV Group|
11490944|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
11490945|NCT01418898|Experimental|Nutrient Fortified Beverage|
11490946|NCT01418898|Placebo Comparator|Control|
11490947|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
11490948|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
11490949|NCT01418885||normal controls|normal elderly controls
11490950|NCT01418872|Active Comparator|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.
~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.
~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.
~A pamphlet of the NAOS strategy will also be delivered."
11490951|NCT01418872|Experimental|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.
~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.
~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.
~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
11490952|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
11490953|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
11490954|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
11490955|NCT01418846||adult hematology patients|
11490956|NCT01418846||pediatric patients age 5-18years|
11490957|NCT01418846||adult pneumology patients|
11490958|NCT01418820|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
11490959|NCT01418820|Sham Comparator|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
11490960|NCT01418807|Experimental|TRANSVAGINAL EXTRACTION|
11490961|NCT01418807|Active Comparator|TRANSUMBILICAL EXTRACTION|
11490962|NCT01418794|Active Comparator|Low dose rapamycin group|Concentration of rapamycin was 1.5%
11490963|NCT01418794|Experimental|High dose rapamycin group|Concentration of rapamycin is 2.5%
11490964|NCT01418781||Gout|Patients with ICD-9 for gout
11490965|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
11490966|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
11490967|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
11490968|NCT01418768|Experimental|Rehabilitation|
11490969|NCT01418755|Experimental|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
11490970|NCT01418742|Active Comparator|Doxycycline 100 mg BID oral use|
11490971|NCT01418742|Placebo Comparator|Placebo 100 mg BID oral use|
11490972|NCT01418729|Active Comparator|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
11490973|NCT01418729|Placebo Comparator|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
11490974|NCT01418716|Experimental|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
11490975|NCT01418716|Active Comparator|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
11490976|NCT01418703|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:
~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;
~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
11490977|NCT01418703|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
11490978|NCT01418690||Non-invasive near infra-red device (NIRS)|
11490979|NCT01418677|Active Comparator|Cohort 1|
11490980|NCT01418677|Active Comparator|Cohort 2|
11490981|NCT01418677|Active Comparator|Cohort 3|
11490982|NCT01418664|Active Comparator|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
11490983|NCT01418664|No Intervention|control group|Women in this group will recieve ferrous sulphate and calcium lactate
11490984|NCT01418651|Experimental|Milnacipran|Drug
11490985|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
11490986|NCT01418573|Experimental|Palaeolithic-type meal 1|
11490987|NCT01418573|Experimental|Palaeolithic-type meal 2|
11490988|NCT01418573|Placebo Comparator|The reference meal|
11490989|NCT01418560|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
11490990|NCT01418560|No Intervention|Absolute medicine therapy|Maintenance of anti-renal failure medications only
11490991|NCT01418521|Active Comparator|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
11490992|NCT01418521|Experimental|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
11490993|NCT01418508|No Intervention|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
11490994|NCT01418508|Experimental|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
11490995|NCT01418508|Experimental|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
11490996|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
11490997|NCT01418482|Experimental|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
11490998|NCT01418469|Experimental|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
11490999|NCT01418469|Experimental|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
11491000|NCT01418469|Experimental|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
11491001|NCT01418469|Experimental|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
11491002|NCT01418456|Experimental|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
11491003|NCT01418456|No Intervention|Non antibiotic group|
11491004|NCT01418430|Experimental|CHOP-daclizumab|
11491005|NCT01418404|Experimental|Noxious TS in study A|Noxious TS in study A
11491006|NCT01418404|Active Comparator|Innocuous TS|Innocuous TS in study A
11491007|NCT01418404|Experimental|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
11491008|NCT01418404|Active Comparator|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
11491009|NCT01418404|Experimental|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
11491010|NCT01418404|Active Comparator|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
11491011|NCT01418391|Experimental|morphine consumption|
11491012|NCT01418378|Active Comparator|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
11491013|NCT01418378|Active Comparator|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
11491014|NCT01418365|Experimental|Metronidazole + MMX placebo|
11491015|NCT01418365|Experimental|Metronidazole + MMX Mesalazine/mesalamine|
11491016|NCT01418352|Placebo Comparator|Matching Placebo|
11491017|NCT01418352|Experimental|Group A: Aripiprazole 52.5 mg|The dose of Aripiprazole 52.5 mg will be achieved after a mandatory titration schedule.
11491018|NCT01418352|Experimental|Group B: Aripiprazole 77.5 mg|The dose of Aripiprazole 77.5 mg will be achieved after a mandatory titration schedule.
11491019|NCT01418352|Experimental|Group C: Aripiprazole 110 mg|The dose of Aripiprazole 110 mg will be achieved after a mandatory titration schedule.
11491020|NCT01418339|Placebo Comparator|Matching Placebo|Once weekly matching placebo
11491021|NCT01418339|Experimental|Aripiprazole|Once-weekly tablets
11491022|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
11491023|NCT01418326||Propofol|Propofol exposure for cancer surgery
11491024|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
11491025|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
11491026|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
11491027|NCT01418300|Active Comparator|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
11491028|NCT01418300|Active Comparator|conventional triple thearpy|PPI+amoxicillin+clarithromycin
11491029|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
11491030|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
11491031|NCT01418274|Experimental|Single arm|
11491032|NCT01418261|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
11491033|NCT01418261|Sham Comparator|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
11491034|NCT01418235|Experimental|Group 1: MVA-C + gp140/MF59|
11491035|NCT01418235|Experimental|Group 2: MVA-C + gp140/MF59|
11491036|NCT01418235|Experimental|Group 3: DNA-C2 + MVA-C|
11491037|NCT01418235|Experimental|Group 4: DNA-C2 + MVA-C + gp140/MF59|
11491038|NCT01418222|Experimental|A|
11491039|NCT01418222|Active Comparator|B|
11491040|NCT01418209|Active Comparator|Low-dose 17-ß-estradiol with progesterone taper|
11491041|NCT01418209|Active Comparator|Venlafaxine XR|
11491042|NCT01418209|Placebo Comparator|Placebo|
11491043|NCT01418183|Experimental|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
11491044|NCT01418183|Placebo Comparator|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
11491045|NCT01418183|Experimental|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
11491082|NCT01417923|Experimental|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
11491046|NCT01418170|Experimental|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
11491047|NCT01418170|Sham Comparator|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
11491048|NCT01418157|Active Comparator|Acetazolamide|
11491049|NCT01418157|Placebo Comparator|Placebo|
11491050|NCT01418144|Experimental|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
11491051|NCT01418144|Placebo Comparator|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
11491052|NCT01418131|Active Comparator|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
11491053|NCT01418131|Placebo Comparator|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
11491054|NCT01418118|Experimental|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
11491055|NCT01418105|Active Comparator|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
11491056|NCT01418105|Active Comparator|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
11491057|NCT01418105|Active Comparator|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
11491058|NCT01418092|Placebo Comparator|Placebo|Capsules for oral administration
11491059|NCT01418092|Experimental|ALKS 37|Capsules for oral administration
11491060|NCT01418079|Experimental|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
11491061|NCT01418066|Placebo Comparator|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
11491062|NCT01418066|Experimental|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
11491063|NCT01418053|Experimental|Hot Cataplasm with Caraway Oil|
11491064|NCT01418053|Active Comparator|Hot Cataplasm with Olive oil|
11491065|NCT01418053|Active Comparator|Cold cataplasm with Olive oil|
11491066|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
11491067|NCT01418027|Experimental|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
11491068|NCT01418027|No Intervention|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
11491069|NCT01418027|Experimental|Regular exercise|Subjects receive conventional exercise for 12 months
11491070|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
11491071|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
11491072|NCT01418001|Experimental|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
11491073|NCT01417988|Experimental|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
11491074|NCT01417988|Active Comparator|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
11491075|NCT01417975|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
11491076|NCT01417975|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
11491077|NCT01417962||Fetuses|Still birth and Termination of pregnancies
11491078|NCT01417962||Children|Includes Newborns, Infants and Children
11491079|NCT01417949|Active Comparator|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
11491080|NCT01417949|Active Comparator|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
11491081|NCT01417936|Experimental|Sym004|
11491083|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
11491214|NCT01416948|Active Comparator|Galantamine|
11491084|NCT01417897|Experimental|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
11491085|NCT01417897|Active Comparator|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
11491086|NCT01417897|Active Comparator|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
11491087|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
11491088|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
11491089|NCT01417871||case goup|Lifestyle counseling, ABC program
11491090|NCT01417871||control group|usual care
11491091|NCT01417858|Active Comparator|brimonidine 0.2%|
11491092|NCT01417858|Active Comparator|brimonidine 0.1%|
11491093|NCT01417845|Experimental|High Intensity Exercise|High intensity resistance and aerobic training
11491094|NCT01417845|Active Comparator|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
11491095|NCT01417832|Experimental|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
11491096|NCT01417832|Placebo Comparator|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
11491097|NCT01417819|Other|SMS reminder|SMS reminders four days and one day before their appointments
11491098|NCT01417793|Experimental|Smoking Cessation Program|
11491099|NCT01417780|Active Comparator|AB103 0.25 mg/kg|
11491100|NCT01417780|Active Comparator|AB103 0.5 mg/kg|
11491101|NCT01417780|Placebo Comparator|NaCl 0.9%|
11491102|NCT01417767|Experimental|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
11491103|NCT01417767|Active Comparator|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
11491104|NCT01417754|Other|Toremifene|
11491105|NCT01417741|No Intervention|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
11491106|NCT01417741|Experimental|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
11491107|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
11491108|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
11491109|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
11491110|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
11491111|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
11491112|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
11491113|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
11491114|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
11491115|NCT01417689|Active Comparator|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
11491116|NCT01417689|Experimental|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
11491117|NCT01417676|Experimental|Radiation|
11491118|NCT01417663|Placebo Comparator|Alagebrium|"In this study there will be four different groups:
~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
11491119|NCT01417663|Other|Exercise training|"In this study there will be four different groups:
~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
11491120|NCT01417650|Active Comparator|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
11491121|NCT01417650|Placebo Comparator|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
11491122|NCT01417637|Active Comparator|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.
~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
11491123|NCT01417637|Placebo Comparator|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
11491124|NCT01417624|Placebo Comparator|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)
~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
11491163|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
11491164|NCT01417312|Active Comparator|Green tea extract|
11491165|NCT01417312|Placebo Comparator|Placebo|
11491125|NCT01417624|Active Comparator|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):
~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
11491126|NCT01417611|Experimental|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
11491127|NCT01417611|Experimental|i-scan-CE/SE/TE-c|Study Group using i-scan SE & CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
11491128|NCT01417598|Experimental|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
11491129|NCT01417598|Experimental|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
11491130|NCT01417598|No Intervention|Control group|
11491131|NCT01417572|Experimental|lidocaine|
11491132|NCT01417546|Experimental|1|NHS-IL12 escalating doses on a 4 week schedule (Completed).
11491133|NCT01417546|Experimental|2|NHS-IL12 escalating doses on a 2 week schedule
11491134|NCT01417546|Experimental|3|NHS-IL12 expansion group on a 4 week schedule (Completed).
11491135|NCT01417533||GNE|Patients with a diagnosis of GNE myopathy
11491136|NCT01417533||GNE-Related Diseases|Patient with a GNE related disease
11491137|NCT01417533||non-GNE|Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
11491138|NCT01417520||ECD|ECD patients of any gender and ethnicity age 2-80 years are eligible to enroll in this protocol
11491139|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.
~Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
11491140|NCT01417494|Experimental|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
11491141|NCT01417494|Active Comparator|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
11491142|NCT01417481|Active Comparator|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
11491143|NCT01417481|Placebo Comparator|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
11491144|NCT01417468|Experimental|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
11491145|NCT01417468|Active Comparator|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
11491146|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
11491147|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
11491148|NCT01417455||Controls|Healthy donors age and sex matched to the patients
11491149|NCT01417442|Experimental|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
11491150|NCT01417429|Active Comparator|Galantamine|galantamine will be given with intravenous nicotine
11491151|NCT01417429|Experimental|Nicotine|Subject will be given IV Nicotine
11491152|NCT01417416||with combat training stress|
11491153|NCT01417416||without combat training stress|
11491154|NCT01417403|Experimental|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
11491155|NCT01417390|Experimental|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
11491156|NCT01417390|Experimental|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
11491157|NCT01417377||Cohort|Mircera
11491158|NCT01417364|Active Comparator|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
11491159|NCT01417364|Experimental|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
11491160|NCT01417364|Placebo Comparator|Placebo injections|Placebo injections weekly throughout the study.
11491161|NCT01417351|Placebo Comparator|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
11491162|NCT01417351|Experimental|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
11491166|NCT01417299|Active Comparator|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
11491167|NCT01417299|Placebo Comparator|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
11491168|NCT01417286|Experimental|Radiation Therapy|Patients undergo hypofractionated accelerated radiation therapy over 11 weekdays (for 15 elapsed days) within 21-63 days after last surgery or last course of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
11491169|NCT01417273|Active Comparator|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
11491170|NCT01417273|Placebo Comparator|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
11491171|NCT01417260||Nocebo|Told breastfeeding may worsen pain
11491172|NCT01417260||No treatment|Told nothing
11491173|NCT01417260||Placebo|Told will improve pain
11491174|NCT01417247|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
11491175|NCT01417247|No Intervention|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
11491176|NCT01417234||SNaP® Wound Care System|
11491177|NCT01417221|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
11491178|NCT01417221|No Intervention|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
11491179|NCT01417208||SNaP® Wound Care System|
11491180|NCT01417195|Experimental|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
11491181|NCT01417195|Active Comparator|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
11491182|NCT01417182|Experimental|Melanoma|
11491183|NCT01417169|Experimental|Micafungin|
11491184|NCT01417156|Experimental|All patients|
11491185|NCT01417143|Experimental|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
11491186|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
11491187|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
11491188|NCT01417130||Placebo|Original assignment in the ADAPT trial
11491189|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
11491190|NCT01417104|Active Comparator|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
11491191|NCT01417104|Placebo Comparator|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
11491192|NCT01417091|Experimental|Treatment group|
11491193|NCT01417091|No Intervention|Untreated reference group|
11491194|NCT01417078|Experimental|Diazepam Nasal Spray|
11491195|NCT01417065|Experimental|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
11491196|NCT01417052|Experimental|50 mg LX3305 QD|
11491197|NCT01417052|Experimental|100 mg LX3305 QD|
11491198|NCT01417052|Experimental|150 mg LX3305 QD|
11491199|NCT01417052|Experimental|200 mg LX3305 QD|
11491200|NCT01417052|Experimental|250 mg LX3305 QD|
11491201|NCT01417052|Experimental|300 mg LX3305 QD|
11491202|NCT01417052|Experimental|400 mg LX3305 QD|
11491203|NCT01417052|Experimental|250 mg LX3305 BID|
11491204|NCT01417052|Experimental|500 mg LX3305 QD|
11491205|NCT01417052|Placebo Comparator|Placebo|
11491206|NCT01417026|Active Comparator|Intranasal Oxytocin|"Intranasal oxytocin (Trade name: Syntocinon)
~Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.
~Route of administration: Intranasal
~Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.
~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).
~Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
11491207|NCT01417026|Placebo Comparator|Intranasal Placebo|"Intranasal placebo
~The placebo is identical to the oxytocin formulation with the exception of the active compound.
~Route of administration: Intranasal
~Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.
~One dose equals 6 spray puffs (3 puffs in each nostril).
~Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
11491208|NCT01417013|Active Comparator|Systane Ultra|Systane Ultra Lubricant Eye Drops
11491209|NCT01417013|Active Comparator|Optive|Optive Lubricant eye drops
11491210|NCT01417000|Experimental|Cy/GVAX + CRS-207|200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
11491211|NCT01417000|Experimental|Cy/GVAX|200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
11491212|NCT01416974|Experimental|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
11491213|NCT01416948|Placebo Comparator|Sugar Pill|
11491215|NCT01416948|Experimental|Methylphenidate|
11491216|NCT01416935|Active Comparator|No Amiodarone|Patient will be randomized not to receive to Amiodarone post Cox-Maze procedure unless indicated.
11491217|NCT01416935|No Intervention|Amiodarone|Patients randomized to receive Amiodarone post Cox-Maze procedure which is our current standard of care.
11491218|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
11491219|NCT01416909|Active Comparator|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
11491220|NCT01416909|Active Comparator|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
11491221|NCT01416909|Other|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
11491222|NCT01416909|Active Comparator|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
11491223|NCT01416909|Other|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
11491224|NCT01416896|Experimental|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
11491225|NCT01416896|Active Comparator|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
11491226|NCT01416883|Experimental|Active 1|8 subjects will receive ICI176,334-1
11491227|NCT01416870|Experimental|Active 1|34 subjects will receive ICI176,334-1without water
11491228|NCT01416870|Experimental|Active 2|34 subjects will receive ICI176,334-1 with water
11491229|NCT01416870|Experimental|Active 3|34 subjects will receive Casodex 80 mg tablet
11491230|NCT01416857|No Intervention|MOD|Group evaluated using the currently available ED measure of disability (MOD)
11491231|NCT01416857|Experimental|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
11491232|NCT01416831|Active Comparator|High-dose IL-2|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2.
11491233|NCT01416831|Experimental|Radiation therapy and high-dose IL-2|Patients 1-20 who are assigned to receive radiation therapy will receive a single dose of radiation before IL-2; patients 21-44 assigned to receive radiation will receive two doses of radiation before receiving high-dose IL-2.
11491234|NCT01416818|Experimental|group 1|
11491235|NCT01416818|Active Comparator|group 2|
11491236|NCT01416818|Placebo Comparator|group 3|
11491237|NCT01416805|Experimental|Computerized Cognitive Behavioral Therapy|
11491238|NCT01416805|Active Comparator|Treatment as Usual|
11491239|NCT01416792|Experimental|Multiple-pass hemofiltration|
11491240|NCT01416779|Experimental|Writing Group|This group will receive the writing intervention.
11491241|NCT01416779|No Intervention|No Intervention|Non Writing Group
11491242|NCT01416766|No Intervention|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
11491243|NCT01416766|Experimental|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
11491244|NCT01416753|Active Comparator|UCR|regulation of ultrafiltration and conductivity
11491245|NCT01416753|Active Comparator|UTR|regulation of ultrafiltration and temperature
11491246|NCT01416753|No Intervention|conventional dialysis|dry weight reduction without BVM
11491247|NCT01416740|Experimental|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
11491248|NCT01416727|Experimental|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
11491249|NCT01416727|Experimental|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
11491250|NCT01416714||Gastric Cancer|
11491251|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
11491252|NCT01416714||Esophageal Cancer|
11491253|NCT01416714||Pancreas Cancer|
11491254|NCT01416714||Hepatocellular Cancer|
11491255|NCT01416714||Biliary Cancer|
11491256|NCT01416714||Neuroendocrine Cancer|
11491257|NCT01416714||Peritoneal Mesothelioma|
11491258|NCT01416714||Anal Cancer|
11491259|NCT01416714||Colorectal Cancer|
11491260|NCT01416701|Active Comparator|Vitamin D (D3, cholecalciferol)|
11491261|NCT01416701|Placebo Comparator|Placebo (cellulose)|
11491262|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
11491263|NCT01416662|Other|gemcitabine|gemcitabine
11491264|NCT01416636|Active Comparator|Treprostinil sodium low dose - Arm I|"Arm I (low dose):
~Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.
~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.
~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
11491265|NCT01416636|Experimental|Treprostinil sodium high dose - Arm II|"Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.
~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.
~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
11491266|NCT01416623|Experimental|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
11491267|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
11491268|NCT01416597||Cross-Protection Studies|
11491269|NCT01416584|No Intervention|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
11491270|NCT01416584|Experimental|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
11491271|NCT01416584|Experimental|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
11491272|NCT01416571|Experimental|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
11491273|NCT01416545|Active Comparator|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
11491274|NCT01416545|Placebo Comparator|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
11491275|NCT01416519|Experimental|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
11491276|NCT01416519|Experimental|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
11491277|NCT01416506||Group 1|
11491278|NCT01416493|Experimental|bIAP treatment|
11491279|NCT01416480|Experimental|Theobromine|Theobromine capsule 300mg
11491280|NCT01416480|Active Comparator|levodropropizine|levodropropizine syrup
11491281|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
11491282|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are => 35 yrs of age (at the time of delivery).
11491283|NCT01416441|Experimental|Aripiprazole|Once-weekly tablets
11491284|NCT01416428|Experimental|QDx2 Dosing Schedule|"QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.
~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
11491285|NCT01416428|Experimental|QDx5 Dosing Schedule|"QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.
~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
11491286|NCT01416415|Experimental|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
11491287|NCT01416415|Placebo Comparator|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
11491288|NCT01416402|Other|Arhalofenate with febuxostat and colchicine|
11491289|NCT01416389|Experimental|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
11491290|NCT01416389|Active Comparator|ixabepilone|Forty milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
11491291|NCT01416376|Active Comparator|50mg SRT2379|Single oral administration of 50mg SRT2379
11491292|NCT01416376|Active Comparator|250mg SRT2379|Single oral administration of 250mg SRT2379
11491293|NCT01416376|Active Comparator|1000mg SRT2379|Single oral administration of 1000mg SRT2379
11491294|NCT01416376|Placebo Comparator|Placebo|Single oral administration of placebo
11491295|NCT01416363|Experimental|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
11491296|NCT01416363|Experimental|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
11491297|NCT01416363|Experimental|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
11491298|NCT01416363|Experimental|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
11491299|NCT01416363|Experimental|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
11491300|NCT01416363|Experimental|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
11491301|NCT01416363|Experimental|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
11491302|NCT01416363|Experimental|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
11491303|NCT01416363|Experimental|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
11491304|NCT01416350|Active Comparator|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
11491305|NCT01416350|Active Comparator|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
11491306|NCT01416337|Experimental|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK1120212 Both doses are given together.
11491307|NCT01416324|Experimental|GSK2330672|experimental study drug
11491308|NCT01416324|Placebo Comparator|Placebo|placebo
11491309|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
11491310|NCT01416285||control group|control group receiving regular education from a nurse
11491311|NCT01416285||Case management group|This is the study group. Extensive education and case management program will be performed in this group.
11491312|NCT01416272|Experimental|KeraSoft IC Soft Contact Lenses|KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
11491313|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
11491314|NCT01416246|Experimental|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10^6 CD34+ stem cells/kg (+/- 0.5 x 10^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
11491315|NCT01416233|Experimental|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
11491316|NCT01416220|Experimental|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
11491317|NCT01416220|Active Comparator|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
11491318|NCT01416207|Experimental|Avonex|4 weekly injections of Avonex (IM)
11491319|NCT01416194||Bazedoxifene|
11491320|NCT01416194||Primary Comparator|
11491321|NCT01416194||Secondary Comparator|
11491322|NCT01416181|Experimental|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
11491323|NCT01416181|Experimental|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
11491324|NCT01416168|No Intervention|Control Arm|Usual post-surgical care
11491325|NCT01416168|Experimental|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
11491326|NCT01416155|Experimental|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
11491327|NCT01416142|Active Comparator|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
11491328|NCT01416142|Experimental|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
11491329|NCT01416129|Active Comparator|Active Comparator: Prosthetic socket standard of care|
11491330|NCT01416129|Active Comparator|Active Comparator: Prosthetic brimless socket|
11491331|NCT01416116|Experimental|Tramadol|Tramadol prior to QUTENZA
11491332|NCT01416116|Experimental|Lidocaine|Lidocaine prior to QUTENZA
11491333|NCT01416103|Experimental|Intervention group|Intervention group
11491334|NCT01416103|Placebo Comparator|Intervention control|Control group
11491335|NCT01416077|No Intervention|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
11491336|NCT01416077|Active Comparator|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
11491337|NCT01416064|Other|Molindone|Extension study, all subjects will be given Molindone at different (established) dosage levels based on the patient's weight, response and investigator discretion.
11491338|NCT01416051|Active Comparator|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
11491339|NCT01416051|Placebo Comparator|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
11491340|NCT01416038|Experimental|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
11491341|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
11491342|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
11491343|NCT01416025|Experimental|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
11491344|NCT01416025|No Intervention|Standard dosing|Standard doses of voriconazole will be used
11491345|NCT01416012|Experimental|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
11491346|NCT01416012|Active Comparator|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
11491347|NCT01416012|Experimental|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
11491348|NCT01416012|Experimental|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
11491349|NCT01415999||patient|adult survivors of childhood malignancies
11491350|NCT01415999||control|healthy age-matched individuals
11491351|NCT01415986|Experimental|Subjects receiving Temoporfin|
11491352|NCT01415973|Experimental|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
11491353|NCT01415973|Experimental|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
11491354|NCT01415960|Experimental|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
11491355|NCT01415934|No Intervention|Continue Statins|Participant will continue on statins as per usual
11491356|NCT01415934|Experimental|Discontinue statins|Participant will stop taking their statin drugs
11491357|NCT01415921|Experimental|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
11491358|NCT01415921|Placebo Comparator|Placebo|Matching placebo forced titration 15-60 mg as tolerated
11491359|NCT01415908|Active Comparator|Control Group|
11491360|NCT01415908|Experimental|Investigational Group|
11491361|NCT01415895|Experimental|ATNC05 - a study drug capsule|ATNC05, a capsule containing a weighed piece of generic tablet A and a weighed piece of generic tablet B
11491362|NCT01415895|Placebo Comparator|placebo|subjects will receive placebo capsules for double blind treatment for the duration of the trial
11491363|NCT01415882|Experimental|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second course or lack of partial response by the end of the fourth course also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11491364|NCT01415882|Experimental|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8 and 15 and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11491365|NCT01415882|Experimental|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11491366|NCT01415882|Experimental|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11491367|NCT01415882|Experimental|Arm E (Ixazomib, cyclophosphamide, daratumab, dexa|Patient receive ixazomib citrate PO on days 1, 8 &15, cyclophosphamide PO on days 1, 8,15,& 22 (Discontinue after 12 cycles), Daratumumab IV on days 1,8,15 & 22 for cycles 1-2; days 1,15 for cycles 3-6; day 1 for subsequent cycles, Dexamethasone PO on days 1,8,15 & 22.
11491368|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
11491524|NCT01414738|Experimental|Radiation|Whole-Brain Radiotherapy
11491369|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
11491370|NCT01415856|Placebo Comparator|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
11491371|NCT01415856|Active Comparator|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
11491372|NCT01415830|Experimental|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
11491373|NCT01415830|Active Comparator|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
11491374|NCT01415817|No Intervention|Baseline Data collection|
11491375|NCT01415817|Experimental|Randomization and Training Arm|
11491376|NCT01415804|Active Comparator|stentgraft|Stentgraft
11491377|NCT01415804|No Intervention|Medical management|Antihypertensive medication
11491378|NCT01415791|Experimental|Active 1|8 subjects will receive ICI176,334-1
11491379|NCT01415778|Experimental|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
11491380|NCT01415778|Experimental|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
11491381|NCT01415778|Experimental|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
11491382|NCT01415778|Experimental|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
11491383|NCT01415752|Experimental|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
11491384|NCT01415752|Experimental|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
11491385|NCT01415752|Experimental|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
11491386|NCT01415752|Experimental|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
11491387|NCT01415752|Experimental|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11491388|NCT01415752|Experimental|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11491389|NCT01415752|Experimental|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11491390|NCT01415752|Experimental|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11491391|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H&E staining and IHC.
11491392|NCT01415726|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
11491393|NCT01415726|Experimental|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
11491394|NCT01415713|Experimental|Statin dose titration|"SLOG regimen:
~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
11491395|NCT01415700|Experimental|Stimulator|
11491396|NCT01415700|Active Comparator|Orthosis|
11491397|NCT01415687|Active Comparator|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
11491398|NCT01415687|Active Comparator|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
11491399|NCT01415674|Experimental|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
11491400|NCT01415674|No Intervention|Arm B : No pre operative treatment|
11491401|NCT01415661|Experimental|obese patient|
11491402|NCT01415661|Experimental|non obese patient|
11491403|NCT01415648|Experimental|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
11491404|NCT01415648|Sham Comparator|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
11491525|NCT01414725|Experimental|Core Stability Training|
11491526|NCT01414725|Placebo Comparator|Relaxation|
11491527|NCT01414725|Active Comparator|Standard Physiotherapy Exercises|
11491405|NCT01415635|Experimental|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
11491406|NCT01415622|Experimental|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
11491407|NCT01415622|Other|standard care|standard care of Ulcera crurum
11491408|NCT01415596|Placebo Comparator|Placebo|
11491409|NCT01415596|Active Comparator|Salbutamol|
11491410|NCT01415583|Placebo Comparator|Saline|Placebo is described in chart
11491411|NCT01415583|Experimental|Dexamethasone|Dexamethasone is described in chart
11491412|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
11491413|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
11491414|NCT01415557|Placebo Comparator|Non-Fortified Control Product|Non-fortified control beverage
11491415|NCT01415557|Active Comparator|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
11491416|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
11491417|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
11491418|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
11491419|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
11491420|NCT01415531|Experimental|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
11491421|NCT01415531|Placebo Comparator|2|Dose-matched placebo
11491422|NCT01415518|Other|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
11491423|NCT01415518|Other|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
11491424|NCT01415505|Other|1|Nebivolol and Valsartan free tablet combination
11491425|NCT01415492|No Intervention|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
11491426|NCT01415492|Active Comparator|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
11491427|NCT01415492|Active Comparator|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
11491428|NCT01415479|Experimental|Quantitative|"Subjects view:
~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
11491429|NCT01415479|Experimental|Default|"Subjects view:
~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
11491430|NCT01415479|Experimental|Quantitative + Default|"Subjects view:
~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
11491431|NCT01415479|Active Comparator|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
11491432|NCT01415466|Experimental|R|multiple dose of Rosuvastatin 20mg
11491433|NCT01415466|Experimental|O|multiple dose of CS-866 40mg
11491434|NCT01415466|Experimental|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
11491435|NCT01415453|Experimental|Retinitis Pigmentosa|Subject will have retinitis pigmentosa and will be legally blind in one or both eyes
11491436|NCT01415440|Experimental|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
11491437|NCT01415440|Placebo Comparator|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
11491438|NCT01415427|Experimental|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
11491439|NCT01415427|Experimental|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
11491440|NCT01415414||Group 1|
11491441|NCT01415401|Experimental|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
11491442|NCT01415375|Experimental|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
11491528|NCT01414712||prostate cancer patients|
11491529|NCT01414699|Active Comparator|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
11491443|NCT01415375|Other|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
11491444|NCT01415362|Active Comparator|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
11491445|NCT01415362|Sham Comparator|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
11491446|NCT01415349|Experimental|SSP-002358 alone|
11491447|NCT01415349|Experimental|SSP-002358 + omeprazole|SSP-002358 + omeprazole
11491448|NCT01415336|Active Comparator|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
11491449|NCT01415336|Experimental|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
11491450|NCT01415323||Acutely admitted psychiatric in-patients|
11491451|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
11491452|NCT01415297|Experimental|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.
~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
11491453|NCT01415284|Experimental|Hydroxyethylstarch 130/0.4|
11491454|NCT01415271|Experimental|Internet Intervention|
11491455|NCT01415245|Experimental|Treatment|Device applied to saphenous vein graft
11491456|NCT01415245|No Intervention|Control|Saphenous vein graft without device support
11491457|NCT01415232|Experimental|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
11491458|NCT01415219|Active Comparator|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
11491459|NCT01415219|No Intervention|conventional care|community based physiotherapy
11491460|NCT01415206|Experimental|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
11491461|NCT01415206|Other|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
11491462|NCT01415193|Experimental|Selective Tibial Nerve Block|
11491463|NCT01415193|Active Comparator|Control: Sciatic Nerve Block|
11491464|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
11491465|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
11491466|NCT01415154|Experimental|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
11491467|NCT01415154|Experimental|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
11491468|NCT01415141|Active Comparator|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks
~Those who achieve eRVR will receive 24 weeks of treatment"
11491469|NCT01415141|Active Comparator|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks
~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
11491470|NCT01415128|Active Comparator|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
11491471|NCT01415128|Active Comparator|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
11491472|NCT01415128|Active Comparator|Desipramine|Desipramine with single dose of avanafil (200 mg)
11491473|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
11491474|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
11491475|NCT01415102|Experimental|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
11491476|NCT01415102|Experimental|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
11491477|NCT01415076|Placebo Comparator|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
11491478|NCT01415076|Experimental|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
11491479|NCT01415063|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
11491480|NCT01415063|Experimental|TACE-RFA|TACE first, then RFA within 2 weeks
11491481|NCT01415050|Active Comparator|Alendronate|
11491482|NCT01415050|Active Comparator|Raloxifane|
11491483|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
11491530|NCT01414699|Active Comparator|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
11491484|NCT01415011|Experimental|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
11491485|NCT01414998|Active Comparator|Stress Ball|This is the active comparator for study 1
11491486|NCT01414998|Experimental|De-nicotinised Cigarette|This will be the experimental arm for study 2
11491487|NCT01414998|Experimental|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
11491488|NCT01414998|Active Comparator|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
11491489|NCT01414985|Experimental|Group A|Group A consists of 2 subjects who received 9x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
11491490|NCT01414985|Experimental|Group B|Group B will consist of 6 subjects who will receive 2.85x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
11491491|NCT01414972|Active Comparator|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
11491492|NCT01414972|Placebo Comparator|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
11491493|NCT01414972|Active Comparator|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
11491494|NCT01414946|Experimental|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
11491495|NCT01414946|Active Comparator|Amino acids only|Perioperative nutrition with amino acids only
11491496|NCT01414920|Placebo Comparator|Placebo QD|
11491497|NCT01414920|Experimental|TAK-875 25 mg QD|
11491498|NCT01414920|Experimental|TAK-875 50 mg QD|
11491499|NCT01414920|Experimental|Sitagliptin 100 mg QD|
11491500|NCT01414920|Experimental|TAK-875 25 mg QD + Sitagliptin 100 mg QD|
11491501|NCT01414920|Experimental|TAK-875 50 mg QD + Sitagliptin 100 mg QD|
11491502|NCT01414907|Active Comparator|Health Promotion activities|
11491503|NCT01414907|No Intervention|No Intervention|
11491504|NCT01414894|Active Comparator|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
11491505|NCT01414894|Active Comparator|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
11491506|NCT01414894|Active Comparator|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
11491507|NCT01414894|Active Comparator|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
11491508|NCT01414881|Experimental|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
11491509|NCT01414881|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) once weekly
11491510|NCT01414855|Experimental|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
11491511|NCT01414842|Active Comparator|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
11491512|NCT01414842|Experimental|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
11491513|NCT01414816||Group 1|
11491514|NCT01414803|Experimental|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
11491515|NCT01414803|Active Comparator|rosuvastatin monotherapy|rosuvastatin 10 mg per day
11491516|NCT01414790|Experimental|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
11491517|NCT01414790|No Intervention|control group|41 patients (control group) had a total parotidectomy alone
11491518|NCT01414777|Experimental|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
11491519|NCT01414777|Placebo Comparator|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
11491520|NCT01414764|Active Comparator|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.
~First injection at approximately 10 days post-operatively
~Second Injection at approximately 21 days post-operatively
~Other Names:
~Platelet rich plasma (PRP)"
11491521|NCT01414764|Placebo Comparator|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.
~First injection at approximately 10 days post-operatively
~Second Injection at approximately 21 days post-operatively"
11491522|NCT01414751|Active Comparator|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
11491523|NCT01414751|Active Comparator|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
11491531|NCT01414699|Active Comparator|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
11491532|NCT01414699|Active Comparator|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
11491533|NCT01414686|Experimental|Immediate Treatment Group|
11491534|NCT01414686|No Intervention|Delayed Treatment Group|
11491535|NCT01414673|Other|spontaneous LH|
11491536|NCT01414673|Experimental|HCG|
11491537|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
11491538|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
11491539|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
11491540|NCT01414647|Experimental|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
11491541|NCT01414647|Experimental|BB|Bilberry intervention for 8 weeks
11491542|NCT01414647|Experimental|C|Control diet with restricted berry consumption
11491543|NCT01414634|Experimental|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^3 cells.
11491544|NCT01414634|Experimental|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^5 cells.
11491545|NCT01414634|Experimental|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^7 cells.
11491546|NCT01414634|Experimental|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^8 cells.
11491547|NCT01414634|Experimental|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10^8 cells.
11491548|NCT01414634|Experimental|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^9 cells.
11491549|NCT01414634|Experimental|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10^9 cells.
11491550|NCT01414634|Experimental|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10^9 cells.
11491551|NCT01414621||CABG patients|atrial tissue samples from CABG patients
11491552|NCT01414608|Experimental|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
11491553|NCT01414608|Experimental|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11491554|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
11491555|NCT01414582|Experimental|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
11491556|NCT01414582|Sham Comparator|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
11491557|NCT01414569|Active Comparator|8 mg dexamethasone|
11491558|NCT01414569|Placebo Comparator|Placebo, saline|
11491559|NCT01414569|Experimental|40 mg dexamethasone|
11491560|NCT01414556|Experimental|hyperglycemia|
11491561|NCT01414556|Experimental|fasting glycemia|
11491562|NCT01414556|Experimental|hypoglycemia|
11491563|NCT01414543|Other|providing information sheet|providing participants with information regarding the purpose of the research
11491564|NCT01414543|Other|Seeking consent|
11491565|NCT01414543|Other|Interview Participant|
11491566|NCT01414543|Other|Debrief|The Participants will be debriefed after the interview.
11491567|NCT01414530|Experimental|oral contraceptive|
11491568|NCT01414530|Active Comparator|NSAID|
11491569|NCT01414517|Active Comparator|FOS|Prebiotic (FructoOligoSaccharide-FOS.
11491570|NCT01414517|Placebo Comparator|Placebo|Maltodextrin (non-prebiotic carbohydrate).
11491571|NCT01414504|Active Comparator|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
11491572|NCT01414504|Active Comparator|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
11491573|NCT01414504|Active Comparator|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
11491574|NCT01414504|Active Comparator|Control|Group 4: Children who have not received any previous pneumococcal vaccine
11491575|NCT01414478|Active Comparator|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
11491576|NCT01414478|No Intervention|Ice Chips|Patients allowed consumption of ice chips only during labor.
11491577|NCT01414465|No Intervention|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
11491578|NCT01414465|Experimental|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
11491579|NCT01414465|Sham Comparator|lifestyle counseling|Women with BMI < 30 kg/m2, no taking drug in study
11491580|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
11491581|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
11491582|NCT01414426|Experimental|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
11491583|NCT01414426|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
11491584|NCT01414413|Experimental|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:
~Confirmatory fingerprick HIV testing
~TB symptom screening
~ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)
~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).
~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
11491585|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
11491586|NCT01414387|Active Comparator|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
11491587|NCT01414387|Active Comparator|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
11491588|NCT01414374|Active Comparator|Iron|
11491589|NCT01414374|Experimental|Herbal|
11491590|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
11491591|NCT01414348|Active Comparator|Conventional rehabilitation|In-home work on problems in daily living.
11491592|NCT01414348|Experimental|Novel rehabilitation approach|
11491593|NCT01414335|Placebo Comparator|placebo|
11491594|NCT01414335|Active Comparator|amino acid composition|
11491595|NCT01414322||Group 1: Patients ages 0 - 3|
11491596|NCT01414322||Group 2: Patients ages 3 - 7|
11491597|NCT01414322||Group 3: Patients ages 7 - 15|
11491598|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
11491599|NCT01414296|Experimental|Arm 1|
11491600|NCT01414283|Experimental|Arm 1|
11491601|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
11491602|NCT01414244|Active Comparator|Glutamine supplementation|Glutamine
11491603|NCT01414244|Placebo Comparator|Placebo|Whey protein powder
11491604|NCT01414231|Active Comparator|Cytarabine low dose|This is the golden standard of AML treatment
11491605|NCT01414231|Active Comparator|Cytarabine intermediate dose|This is the OSHO internal arm
11491606|NCT01414218|Experimental|Humor as Way of Life Seminar|See description of study in previous section for further details.
11491607|NCT01414205|Experimental|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
11491608|NCT01414205|Experimental|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
11491609|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
11491610|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
11491611|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
11491612|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
11491613|NCT01414166|Experimental|ERN/LRPT group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
11491614|NCT01414166|Placebo Comparator|Placebo group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.
11491615|NCT01414153|Experimental|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
11491616|NCT01414153|Experimental|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
11491617|NCT01414153|Experimental|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
11491618|NCT01414153|Active Comparator|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
11491619|NCT01414140||Group 1|
11491620|NCT01414114|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
11491621|NCT01414101|Experimental|Group A|Dose 1 ISIS CRP Rx versus Placebo
11491622|NCT01414101|Experimental|Group B|Dose 2 ISIS CRP Rx versus Placebo
11491623|NCT01414101|Experimental|Group C|Dose 3 ISIS CRP Rx versus Placebo
11491624|NCT01414088|Placebo Comparator|glucose|glucose 5 %
11491625|NCT01414088|Active Comparator|isotonic saline|isotonic saline 0.9 mg/ml
11491626|NCT01414088|Active Comparator|hypertonic saline|hypertonic saline 2.9 mg/ml
11491627|NCT01414075|Experimental|Experimental Drug|
11491628|NCT01414062|Active Comparator|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
11491629|NCT01414062|Experimental|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
11491630|NCT01414049|Experimental|On-pump CABG|
11491631|NCT01414049|Experimental|Off-pump CABG|
11491632|NCT01414036|Active Comparator|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
11491633|NCT01414036|Experimental|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
11491634|NCT01414023|Experimental|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
11491635|NCT01414023|Placebo Comparator|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
11491636|NCT01414010|Active Comparator|Prebiotic|
11491637|NCT01414010|Active Comparator|Probiotic|
11491638|NCT01414010|Active Comparator|Antibiotic|
11491639|NCT01414010|No Intervention|Control|Control group, no intervention given.
11491640|NCT01413997||Chronic Low Back Pain|
11491641|NCT01413997||No Low Back Pain|
11491642|NCT01413984|Experimental|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
11491643|NCT01413984|No Intervention|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
11491644|NCT01413958|Experimental|Phenylephrine|
11491645|NCT01413958|Placebo Comparator|Placebo|
11491646|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
11491647|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
11491648|NCT01413932|Experimental|HT-2157|
11491649|NCT01413932|Placebo Comparator|Placebo|
11491650|NCT01413906|Experimental|Arm 1: BMS-833923 (XL139)|
11491651|NCT01413893|Experimental|linifanib|
11491652|NCT01413867|Experimental|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
11491653|NCT01413867|Active Comparator|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
11491654|NCT01413854|Active Comparator|diclofenac|
11491655|NCT01413854|Placebo Comparator|sugar pill|
11491656|NCT01413841|Active Comparator|Nasal oxygen|3 liter per minute
11491657|NCT01413841|Placebo Comparator|Nasal Air|3 l regular nasal air
11491658|NCT01413828|Experimental|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
11491659|NCT01413828|Active Comparator|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
11491660|NCT01413815|Active Comparator|L-arginine|L-Arginine
11491661|NCT01413815|Placebo Comparator|corn starch|Placebo: Corn Starch
11491662|NCT01413802|Experimental|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
11491663|NCT01413789|Experimental|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
11491664|NCT01413776|Experimental|Dietary supplement|Pregnant women in 37 villages.
11491665|NCT01413776|No Intervention|Control group|Pregnant women in 38 villages
11491666|NCT01413763|Active Comparator|Imiquimod cream|
11491667|NCT01413763|Placebo Comparator|Placebo cream|
11491668|NCT01413750|Experimental|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
11491669|NCT01413750|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
11491670|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
11491671|NCT01413711|Experimental|Vigabatrin|
11491672|NCT01413698||Patient with chronic cough|
11491673|NCT01413685|No Intervention|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
11491674|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
11491675|NCT01413659|Experimental|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
11491676|NCT01413646|Experimental|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
11491677|NCT01413646|Placebo Comparator|2|Eight weeks ad lib diet without walnut supplementation
11491678|NCT01413633|Experimental|cholecystectomy|single incision laparoscopic cholecystectomy
11491679|NCT01413620|Experimental|Vitamin E Treated|
11491680|NCT01413620|No Intervention|Untreated|
11491681|NCT01413607|Experimental|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
11491682|NCT01413607|Active Comparator|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
11491683|NCT01413594|Experimental|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
11491684|NCT01413594|No Intervention|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
11491685|NCT01413581|Experimental|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
11491686|NCT01413581|Placebo Comparator|Placebo|Placebo
11491687|NCT01413568|Experimental|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II
~Leukapheresis collection on Day 1 (and possibly Day 2)"
11491688|NCT01413568|Experimental|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
11491689|NCT01413555|Experimental|Blood Culture QI Program|
11491690|NCT01413542|Placebo Comparator|Placebo then sitagliptin (DPP4 inhibition) group 1|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).
11491691|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then placebo group 1|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo
11491692|NCT01413542|Placebo Comparator|Placebo then sitagliptin group 2|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).
11491693|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then comparator group 2|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).
11491694|NCT01413529|Experimental|HEART to HAART|HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
11491695|NCT01413529|Active Comparator|Adherence counseling|Adherence counseling with the addition of a smart phone control
11491696|NCT01413516|Placebo Comparator|Placebo Control|Smoking cessation counseling with placebo comparator
11491697|NCT01413516|Active Comparator|Experimental: Varenicline|Smoking cessation counseling with varenicline
11491698|NCT01413503|Experimental|131I-MIBG|Patients received 131I-MIBG 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) diluted in 25 ml of normal saline. Patients were infused intravenously through a patient's peripheral or central line over 120 minutes
11491699|NCT01413477|Active Comparator|Calcipotriol ointment|
11491700|NCT01413477|Active Comparator|Betamethasone dipropionate ointment|
11491701|NCT01413477|Active Comparator|Calcipotriol and betamethasone ointment|
11491702|NCT01413477|Placebo Comparator|Vaseline Petroleum Jelly|
11491703|NCT01413412|Experimental|Hernia repair using full-thickness skin graft|25 patients
11491704|NCT01413412|Experimental|Hernia repair using Mesh|25 patients
11491705|NCT01413399|Active Comparator|Intra-Arrest Therapeutic Hypothermia|
11491706|NCT01413399|Active Comparator|Post-Arrest Therapeutic Hypothermia|
11491707|NCT01413386|Experimental|Paclitaxel Eluting Covered Metal Stent|
11491708|NCT01413386|Active Comparator|Covered Metal Stent|
11491709|NCT01413360|Experimental|HD Vitamin C|High dose vitamin C
11491710|NCT01413347|Active Comparator|pillow|confirmation of double-lumen tube position with a head on a pillow
11491711|NCT01413347|Experimental|neutral|confirmation of double-lumen tube position in neutral position of a head
11491712|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
11491713|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
11491714|NCT01413295|Experimental|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
11491715|NCT01413295|Other|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
11491716|NCT01413282|Active Comparator|Cardiac CT|Triage based on cardiac CT results.
11491717|NCT01413282|No Intervention|Standard Care|Standard diagnostic management according to the European guidelines.
11491718|NCT01413269|Experimental|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
11491719|NCT01413269|Active Comparator|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
11491720|NCT01413243|Experimental|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
11492097|NCT01410370|Active Comparator|control|Radiotherapy
11491721|NCT01413243|Placebo Comparator|Placebo|Drug: Placebo, fluid every 2 weeks
11491722|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
11491723|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
11491724|NCT01413204|Experimental|TA-7284 Low|
11491725|NCT01413204|Experimental|TA-7284 High|
11491726|NCT01413204|Placebo Comparator|Placebo|
11491727|NCT01413191|Experimental|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
11491728|NCT01413178|Experimental|Busulfan + Melphalan|Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
11491729|NCT01413178|Experimental|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
11491730|NCT01413152|Experimental|0|
11491731|NCT01413139|Other|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
11491732|NCT01413126|Experimental|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
11491733|NCT01413126|Experimental|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
11491734|NCT01413126|No Intervention|No peanuts (control)|
11491735|NCT01413113|Experimental|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
11491736|NCT01413100|Experimental|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells >= 2.5 x 10^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or *plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.
~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.
~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.
~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
11491737|NCT01413087|Experimental|8 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
11491738|NCT01413087|Experimental|12 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
11491739|NCT01413074|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
11491740|NCT01413074|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
11491741|NCT01413061|Active Comparator|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
11491742|NCT01413061|Active Comparator|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
11491743|NCT01413048|Experimental|AGSCT101|
11491744|NCT01413048|Active Comparator|Carvedilol|
11491745|NCT01413035|Experimental|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
11491746|NCT01413035|Experimental|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
11491747|NCT01413035|Experimental|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
11491748|NCT01413022|Active Comparator|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:
~oxaliplatin 85 mg/m2 IV on Day 1
~irinotecan 180 mg/m2 IV on Day 1
~leucovorin 400 mg/m2 IV on Day 1
~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1
~Treatment is repeated every 14 days for 6 cycles."
11491749|NCT01413022|Experimental|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:
~oxaliplatin 85 mg/m2 IV on Day 1
~irinotecan 180 mg/m2 IV on Day 1
~leucovorin 400 mg/m2 IV on Day 1
~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1
~PF-04136309 500 mg PO BID on days 1-14
~Treatment is repeated every 14 days for 6 cycles."
11491750|NCT01413009||ICU patients|
11491751|NCT01412996|Active Comparator|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
11491752|NCT01412996|Active Comparator|traditional|conventional laparoscopic cholecystectomy
11491753|NCT01412983|Experimental|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
11491754|NCT01412983|Active Comparator|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
11491755|NCT01412970|Other|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
11491756|NCT01412957|Experimental|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
11491757|NCT01412957|Other|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
11491758|NCT01412944|Experimental|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
11491880|NCT01411917|Placebo Comparator|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
11491759|NCT01412944|Experimental|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
11491760|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
11491761|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
11491762|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
11491763|NCT01412918|Experimental|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.
~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
11491764|NCT01412918|No Intervention|No tinnitus|Individuals without tinnitus will also be masked with the device.
11491765|NCT01412892|Experimental|Everolimus|RAD001: Everolimus
11491766|NCT01412879|Experimental|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
11491767|NCT01412879|Experimental|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
11491768|NCT01412866|Experimental|EDSS with CO monitor|Web-based electronic decision support system (EDSS) with carbon monoxide (CO) monitor and health-checklist
11491769|NCT01412866|Active Comparator|EDSS without CO monitor|Web-based electronic decision support system (EDSS) with health-checklist only
11491770|NCT01412853|Experimental|MR-spectroscopy|
11491771|NCT01412840|Experimental|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
11491772|NCT01412840|Placebo Comparator|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
11491773|NCT01412840|No Intervention|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
11491774|NCT01412827|Other|Comparison of radioisotope dosing|
11491775|NCT01412814|Experimental|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
11491776|NCT01412814|Active Comparator|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
11491777|NCT01412801|Experimental|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
11491778|NCT01412801|Experimental|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count >350 cells/µL received one dose of Group B streptococcus vaccine.
11491779|NCT01412801|Experimental|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but > 50 cells/µL received one dose of Group B streptococcus vaccine
11491780|NCT01412788|Experimental|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
11491781|NCT01412788|Active Comparator|traditional incision|traditional incision above tumor was used to carry out lumpectomy
11491782|NCT01412775|Experimental|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
11491783|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
11491784|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
11491785|NCT01412736|Experimental|2mg|sterile lyophilized formulation, 2mg
11491786|NCT01412736|Experimental|20mg|sterile lyophilized formulation, 20mg
11491787|NCT01412736|Experimental|100mg|sterile lyophilized formulation, 100mg
11491788|NCT01412736|Placebo Comparator|Placebo|two SC administration on day 1
11491789|NCT01412723|Active Comparator|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
11491909|NCT01411709|No Intervention|Control|No tablets - control group
11491790|NCT01412723|Experimental|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
11491791|NCT01412710|Experimental|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
11491792|NCT01412710|Experimental|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
11491793|NCT01412697|Experimental|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
11491794|NCT01412697|No Intervention|Control Group|control group received the standard health information
11491795|NCT01412671||Group 1|
11491796|NCT01412658|Experimental|Milk Peptides|
11491797|NCT01412658|Placebo Comparator|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
11491798|NCT01412645|Placebo Comparator|Placebo|
11491799|NCT01412645|Experimental|High-dose Resveratrol|
11491800|NCT01412645|Experimental|Low-dose Resveratrol|
11491801|NCT01412632|Experimental|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
11491802|NCT01412606|Experimental|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
11491803|NCT01412606|Placebo Comparator|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
11491804|NCT01412593|Experimental|Stem cell transplant|
11491805|NCT01412593|No Intervention|Control|
11491806|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
11491807|NCT01412567|Active Comparator|Vaccine+HBIG|
11491808|NCT01412567|Placebo Comparator|Vaccine+Placebo|
11491809|NCT01412554||Longitudinal Insulin Sensitivity|The participants were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
11491810|NCT01412541|Experimental|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
11491811|NCT01412541|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
11491812|NCT01412528|Other|Eight different allergens will be standardized in this study|
11491813|NCT01412515|Experimental|Everolimus|everolimus 10 mg per day
11491814|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
11491815|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
11491816|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
11491817|NCT01412489|Experimental|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
11491818|NCT01412476||case group|Subjects with metabolic syndrome
11491819|NCT01412476||control group|Healthy individuals
11491820|NCT01412463|Experimental|Protégé EverFlex+|Stenting with Protégé EverFlex+
11491821|NCT01412450|Experimental|nitinol stent|Protégé EverFlex stent
11491822|NCT01412437|Experimental|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
11491823|NCT01412437|Experimental|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
11491824|NCT01412424|Experimental|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
11491825|NCT01412411|Active Comparator|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
11491826|NCT01412411|Active Comparator|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
11491827|NCT01412411|Active Comparator|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
11491828|NCT01412398||Group 1|Drug (incl. Placebo)
11491829|NCT01412385|Experimental|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
11491830|NCT01412385|Experimental|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
11491831|NCT01412372|Experimental|Placebo|This arm will include those who are randomized to the placebo
11491832|NCT01412372|Experimental|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
11491879|NCT01411917|Experimental|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
11491833|NCT01412346|Active Comparator|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
11491834|NCT01412346|Placebo Comparator|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
11491835|NCT01412333|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
11491836|NCT01412333|Experimental|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
11491837|NCT01412320|Experimental|Flavanol rich cocoa|
11491838|NCT01412320|Experimental|Flavanol poor|
11491839|NCT01412307|Experimental|lenalidomide plus bendamustine|
11491840|NCT01412294|Experimental|Capecitabine, Cisplatin|
11491841|NCT01412281|Experimental|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
11491842|NCT01412281|Active Comparator|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
11491843|NCT01412281|Experimental|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
11491844|NCT01412281|Active Comparator|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
11491845|NCT01412242|Experimental|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
11491846|NCT01412229|Experimental|Treatment|"nab-paclitaxel 100mg/m2
~Carboplatin area under curve (AUC)2 (IV)
~Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
11491847|NCT01412216|Experimental|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
11491848|NCT01412216|Placebo Comparator|Placebo|Placebo control
11491849|NCT01412203|No Intervention|Usual Practice|School continues with regular programming
11491850|NCT01412203|Experimental|Action Schools! BC|School adopts the AS!BC model
11491851|NCT01412190|Other|Untreated|
11491852|NCT01412190|Active Comparator|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
11491853|NCT01412177|Experimental|OTO-104|
11491854|NCT01412177|Placebo Comparator|Placebo|
11491855|NCT01412164|Experimental|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
11491856|NCT01412151|Other|Creatine monohydrate|single arm long-term open label follow-up
11491857|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
11491858|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
11491859|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
11491860|NCT01412099|Experimental|Feedback report plus peer counseling|
11491861|NCT01412099|Experimental|Feedback report|
11491862|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
11491863|NCT01412073|Active Comparator|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.
~Hemoglobin level and haematocrit value will be done as follow:-
~After admission of each case in the pre-operative period.
~Immediately post- operative.
~24 hours post- operative."
11491864|NCT01412073|Active Comparator|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
11491865|NCT01412073|Active Comparator|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
11491866|NCT01412060|Experimental|Cariprazine - Open-label Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
11491867|NCT01412060|Experimental|Placebo - Double-blind Treatment Phase|Participants received placebo orally once a day for 26 to 72 weeks.
11491868|NCT01412060|Experimental|Cariprazine - Double-blind Treatment Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
11491869|NCT01412034|Experimental|CER-001|Open label single arm study of CER-001
11491870|NCT01412021||Humira|Participants with juvenile idiopathic arthritis who received Humira (adalimumab).
11491871|NCT01412008|No Intervention|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
11491872|NCT01411995|Experimental|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
11491873|NCT01411995|Placebo Comparator|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
11491874|NCT01411969||External nasal dilator, decongestion|
11491875|NCT01411956|Experimental|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
11491876|NCT01411956|Placebo Comparator|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
11491877|NCT01411930|Experimental|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
11491878|NCT01411930|Experimental|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
11491881|NCT01411904|Experimental|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.
~Leukemia patients
~MagProbe (TM)
~Diagnosed or suspected leukemia
~Non-leukemia patients
~MagProbe (TM)
~Requiring bone marrow biopsy"
11491882|NCT01411891|No Intervention|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
11491883|NCT01411891|Experimental|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
11491884|NCT01411878|Experimental|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
11491885|NCT01411878|Experimental|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
11491886|NCT01411865|Experimental|Intervention|
11491887|NCT01411865|Other|Control|
11491888|NCT01411852|Experimental|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
11491889|NCT01411852|Active Comparator|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
11491890|NCT01411839|Experimental|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
11491891|NCT01411839|No Intervention|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
11491892|NCT01411826|Active Comparator|Information|
11491893|NCT01411826|Experimental|Information + Narratives + Support group|
11491894|NCT01411813||Alprazolam|Patients receiving Alprazolam.
11491895|NCT01411800|Experimental|Treatment A|500 mg LX1033, capsules administered two times per day orally
11491896|NCT01411800|Experimental|Treatment B|500 mg LX1033, tablets administered two times per day orally
11491897|NCT01411787|No Intervention|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
11491898|NCT01411787|Experimental|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
11491899|NCT01411774|Active Comparator|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
11491900|NCT01411774|Experimental|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
11491901|NCT01411761|Experimental|Saccharomyces boulardii|study group
11491902|NCT01411761|Placebo Comparator|placebo|serum physiologic
11491903|NCT01411748|Experimental|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
11491904|NCT01411748|Active Comparator|nystatin|
11491905|NCT01411735|Active Comparator|Enalapril|2.5mg titrated up to 10mg- twice daily
11491906|NCT01411735|Placebo Comparator|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
11491907|NCT01411722|Other|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
11491908|NCT01411709|Active Comparator|Vitano|
11491910|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
11491911|NCT01411683|Experimental|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
11491912|NCT01411683|Experimental|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
11491913|NCT01411683|Active Comparator|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
11491914|NCT01411670|Experimental|Human protein C concentrate|
11491915|NCT01411670|Active Comparator|activated protein C|Continuous infusion of Activated Protein C
11491916|NCT01411670|Placebo Comparator|Placebo|Standard treatment
11491917|NCT01411657|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
11491918|NCT01411631|Active Comparator|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
11491919|NCT01411631|Placebo Comparator|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
11491920|NCT01411618|Experimental|free alcohol essential oil moutwash|
11491921|NCT01411618|Active Comparator|alcohol containing essential oil mouthwash|
11491922|NCT01411605|Experimental|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).
~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
11491923|NCT01411592|Active Comparator|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system [A/B primer and Multilink-Automix] with Metal/Zirconia primer)
11491924|NCT01411592|Active Comparator|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
11491925|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
11491926|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
11491927|NCT01411566|Experimental|Treatment|
11491928|NCT01411566|Active Comparator|Control|
11491929|NCT01411553|No Intervention|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
11491930|NCT01411553|Active Comparator|Disposable ECG leadwires-ICU|Disposable ECG-LW
11491931|NCT01411540|Experimental|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
11491932|NCT01411540|Active Comparator|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
11491933|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
11491934|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).
~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
11491935|NCT01411514|Experimental|Prednisone|
11491936|NCT01411514|Placebo Comparator|Placebo|
11491937|NCT01411501|Experimental|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
11491938|NCT01411501|Experimental|Acupuncture at LI11 and ST37|the points formula of He-points
11491939|NCT01411501|Experimental|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
11491940|NCT01411501|Active Comparator|medicine|oral use of mosapride citrate
11491941|NCT01411488|Experimental|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
11491942|NCT01411488|Active Comparator|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
11491943|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
11491944|NCT01411462||VIBE-DEB|
11491945|NCT01411449||Group 1|
11491946|NCT01411436||Group 1|
11491947|NCT01411423||Group 1|
11491948|NCT01411410|Experimental|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
11491949|NCT01411397|Active Comparator|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
11491950|NCT01411397|Active Comparator|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
11491951|NCT01411371|Experimental|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
11491952|NCT01411371|Active Comparator|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
11491953|NCT01411358|Experimental|AdimFlu-S 2011-2012|
11491954|NCT01411345|Other|Phase 3 - Arm I: Standard Salvage Radiation Treatment (SSRT)|"Phase 3 total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
~this arm is closed"
11492094|NCT01410383|Experimental|Eprotirome I|
11492095|NCT01410383|Experimental|Eprotirome II|
11491955|NCT01411345|Experimental|Phase 3 - Arm II: Mapped Tumor Salvage RT (MTSRT)|"Phase 3 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
~this arm was continues as single arm phase 2"
11491956|NCT01411345|Experimental|Phase 2: Mapped Tumor Salvage RT (MTSRT)|Phase 2 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
11491957|NCT01411332|Active Comparator|Arm I: SIMRT|Arm I: Standard Fractionated Intensity Modulated Radiotherapy (SIMRT), EPIC SF-12 Questionnaire, MAX-PC Questionnaire, IPSS Questionnaire
11491958|NCT01411332|Active Comparator|Arm II: HTIMRT|Arm II: Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT), EPIC SF-12 Questionnaire, MAX-PC Questionnaire, IPSS Questionnaire
11491959|NCT01411319|Experimental|LEAD Radiation Therapy|"Lattice Extreme Ablative Dose Radiation Therapy
~Standard IMRT
~EPIC SF-12 Questionnaire
~MAX-PC Questionnaire
~IPSS Questionnaire"
11491960|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
11491961|NCT01411293|Experimental|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
11491962|NCT01411293|Active Comparator|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
11491963|NCT01411280|Placebo Comparator|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
11491964|NCT01411280|Experimental|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
11491965|NCT01411267|Experimental|ALL AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
11491966|NCT01411267|Experimental|AML AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
11491967|NCT01411267|Experimental|ALL AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
11491968|NCT01411267|Experimental|ALL AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
11491969|NCT01411267|Experimental|ALL AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
11491970|NCT01411267|Experimental|ALL AC220 @ 130 mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
11491971|NCT01411267|Experimental|AML AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
11491972|NCT01411267|Experimental|AML AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
11491973|NCT01411267|Experimental|AML AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
11491974|NCT01411267|Experimental|AML AC220 @ 130mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
11491975|NCT01411254|Experimental|1|
11491976|NCT01411254|Experimental|2|
11491977|NCT01411254|Sham Comparator|3|
11491978|NCT01411241|Experimental|CYD Dengue Vaccine Group 1|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a measles, mumps, rubella (MMR) vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), a booster dose of Pentaxim vaccine was administered concomitantly with the second injection of CYD dengue vaccine at Month 6 (15 to 18 months of age), placebo at Month 7 (16 to 19 months of age) to maintain the blind, and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
11491979|NCT01411241|Experimental|CYD Dengue Vaccine Group 2|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a MMR vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), the Pentaxim vaccine was administered concomitantly with placebo at Month 6 (15 to 18 months of age) to maintain the blind, a second injection of CYD dengue vaccine at Month 7 (16 to 19 months of age), and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
11491980|NCT01411228|Experimental|60 Units/kg|
11491981|NCT01411228|Experimental|30 Units/kg|
11491982|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
11491983|NCT01411202|Experimental|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
11491984|NCT01411202|Placebo Comparator|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
11491985|NCT01411189|Other|Menthol|20 mL NPO-11
11491986|NCT01411176|Active Comparator|Menthol|20 ml NPO-11
11491987|NCT01411176|Placebo Comparator|Placebo|20 ml NPO-11(Placebo)
11491988|NCT01411163|Experimental|Creatine|
11491989|NCT01411150|Experimental|Creatine|
11491990|NCT01411137|Experimental|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
11491991|NCT01411124|Experimental|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
11491992|NCT01411124|Active Comparator|diphenhydramine|50 mg
11491993|NCT01411124|Placebo Comparator|placebo|placebo to match
11491994|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
11491995|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
11491996|NCT01411098|Experimental|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
11491997|NCT01411085|Experimental|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
11491998|NCT01411072|Experimental|Gemcitabine|
11491999|NCT01411072|Experimental|5-fluorouracil|
11492000|NCT01411059|Experimental|yoga|32 weeks of yoga training
11492001|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
11492002|NCT01411033||Newly diagnosed diabetes mellitus type 1|
11492003|NCT01411020|Experimental|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
11492004|NCT01411020|Experimental|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
11492005|NCT01411020|Experimental|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
11492006|NCT01411020|Experimental|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
11492007|NCT01411020|Experimental|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
11492008|NCT01411020|Experimental|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
11492009|NCT01411020|Experimental|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
11492010|NCT01411020|Experimental|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
11492011|NCT01411020|Experimental|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
11492012|NCT01411020|Experimental|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
11492013|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
11492014|NCT01411007||Non-Smokers|
11492015|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
11492016|NCT01410968|Experimental|Vaccination|vaccination with investigational Poly-ICLC & peptide-pulsed dendritic cells
11492017|NCT01410955|Experimental|Probiotics|Patients receiving probiotics.
11492018|NCT01410955|Placebo Comparator|Placebo|Patients receiving placebo
11492019|NCT01410942|Placebo Comparator|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
11492020|NCT01410942|Experimental|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
11492021|NCT01410942|Placebo Comparator|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
11492022|NCT01410942|Placebo Comparator|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
11492023|NCT01410942|Experimental|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
11492024|NCT01410942|Experimental|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
11492025|NCT01410942|Placebo Comparator|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
11492026|NCT01410942|Experimental|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
11492027|NCT01410903|Experimental|TheraSorb Ig|
11492028|NCT01410890|Experimental|alglucosidase alfa|alglucosidase alfa intravenous (IV) infusion of 20mg/kg body weight
11492029|NCT01410877||Inhaler naive healthy volunteers|
11492030|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
11492031|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
11492032|NCT01410851|Experimental|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
11492033|NCT01410851|Experimental|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
11492034|NCT01410851|Experimental|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
11492035|NCT01410851|Experimental|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
11492036|NCT01410851|Experimental|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
11492037|NCT01410838|Placebo Comparator|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
11492038|NCT01410838|Active Comparator|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
11492039|NCT01410825|Experimental|Gene transfer|Open label single arm study
11492040|NCT01410812|Experimental|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
11492041|NCT01410812|Experimental|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
11492042|NCT01410812|Experimental|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
11492043|NCT01410799|Experimental|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
11492044|NCT01410786|Active Comparator|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
11492045|NCT01410786|Experimental|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
11492046|NCT01410773|Experimental|Intended Users of the System|Untrained subjects with diabetes (at least 70% of subjects will be insulin users) use an investigational blood glucose monitoring system (Ninja 2) to self-test capillary blood obtained from fingerstick and palm.
11492047|NCT01410747||tacrolimus group|Oral
11492048|NCT01410734|Experimental|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
11492049|NCT01410721|Experimental|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
11492050|NCT01410721|Active Comparator|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
11492051|NCT01410695|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
11492052|NCT01410695|Experimental|masitinib 6.0 mg|masitinib 6.0 mg/kg/day, tablets, orally, twice a day
11492053|NCT01410695|Active Comparator|methotrexate|methotrexate at the dose of 15 or 20 mg per week
11492096|NCT01410370|Experimental|treatment|Radiotherapy plus Endostar
11492054|NCT01410682|Experimental|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
11492055|NCT01410682|Placebo Comparator|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
11492056|NCT01410669|Experimental|Motivational Interviewing (MI)|
11492057|NCT01410656|No Intervention|Standard PA Recommendation|Received the standard physical activity recommendation.
11492058|NCT01410656|Experimental|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
11492059|NCT01410656|Experimental|Self-completed implementation intention|Self-administered implementation intention intervention.
11492060|NCT01410643|Active Comparator|Reduced Carbohydrate|42% carbohydrate macronutrient modification
11492061|NCT01410643|Active Comparator|STandard Carbohydrate|60% carbohydrate macronutrient modification
11492062|NCT01410630|Experimental|FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
11492063|NCT01410617|Active Comparator|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
11492064|NCT01410617|No Intervention|control group|the patients who do not undergo hemodialysis
11492065|NCT01410604|Experimental|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
11492066|NCT01410604|Placebo Comparator|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
11492067|NCT01410591|Active Comparator|10-mm covered stent group|Patients treated with 10-mm covered stent.
11492068|NCT01410591|Active Comparator|8-mm covered stent group|Patients treated with 8-mm covered stent.
11492069|NCT01410578||systemic inflammatory response syndrome|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
11492070|NCT01410578||sepsis|SIRS + infection
11492071|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
11492072|NCT01410565|Active Comparator|Apaziquone|
11492073|NCT01410565|Placebo Comparator|Placebo|Placebo
11492074|NCT01410552|Other|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
11492075|NCT01410539|Experimental|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
11492076|NCT01410539|Active Comparator|Controls|Control subjects without stent thrombosis from the RHR OCT database
11492077|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
11492078|NCT01410526||Control group|Patients suffering major abdominal surgery
11492079|NCT01410513|Experimental|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
11492080|NCT01410513|Experimental|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
11492081|NCT01410513|Experimental|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
11492082|NCT01410487||Obese group|
11492083|NCT01410474|Experimental|2-18 years|
11492084|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
11492085|NCT01410448|Active Comparator|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
11492086|NCT01410448|Experimental|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
11492087|NCT01410435|Experimental|Treatment|
11492088|NCT01410422||COPD|COPD
11492089|NCT01410422||Bronchiectasis|Bronchiectasis
11492090|NCT01410409|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
11492091|NCT01410409|Active Comparator|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
11492092|NCT01410409|Active Comparator|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
11492093|NCT01410383|Placebo Comparator|Placebo|
11492098|NCT01410357|Experimental|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
11492099|NCT01410357|No Intervention|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
11492100|NCT01410344|Other|Allogeneic Transplant|One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).
11492101|NCT01410331|Experimental|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
11492102|NCT01410331|Experimental|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
11492103|NCT01410331|Experimental|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
11492104|NCT01410331|Experimental|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
11492105|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
11492106|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
11492107|NCT01410292|Experimental|meal D|low fiber and low GI
11492108|NCT01410292|Experimental|meal C|low Fiber and High GI
11492109|NCT01410292|Experimental|meal B|high Fiber and low GI
11492110|NCT01410292|Experimental|meal A|high fiber and high GI meal
11492111|NCT01410266|No Intervention|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
11492112|NCT01410266|Active Comparator|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
11492113|NCT01410253|Experimental|Group 1|
11492114|NCT01410253|Experimental|Group 2|
11492115|NCT01410253|Experimental|Group 3|
11492116|NCT01410253|Placebo Comparator|Group 4|
11492117|NCT01410240|Active Comparator|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
11492118|NCT01410240|Experimental|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.
~SoC: conventional hemostatic techniques such as cautery and manual compression"
11492119|NCT01410227|Experimental|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
11492120|NCT01410227|Experimental|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
11492121|NCT01410227|Experimental|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
11492122|NCT01410227|Experimental|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
11492123|NCT01410214|Experimental|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
11492124|NCT01410214|Active Comparator|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
11492125|NCT01410201|Experimental|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
11492126|NCT01410201|Active Comparator|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
11492127|NCT01410188|Experimental|OPA-6566 low dose|Treatment with OPA-6566 low dose
11492128|NCT01410188|Experimental|OPA-6566 medium dose|Treatment with OPA-6566 medium dose
11492129|NCT01410188|Experimental|OPA-6566 high dose|Treatment with OPA-6566 high dose
11492130|NCT01410188|Active Comparator|Latanoprost|Treatment with Latanoprost
11492131|NCT01410188|Placebo Comparator|Placebo|Placebo
11492132|NCT01410188|Experimental|OPA-6566 additional dose|Treatment with OPA-6566 additional dose
11492133|NCT01410175|Experimental|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
11492134|NCT01410175|No Intervention|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
11492135|NCT01410162|Active Comparator|Advagraf|
11492136|NCT01410162|Active Comparator|Prograf|
11492137|NCT01410149|Active Comparator|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
11492138|NCT01410149|Active Comparator|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
11492139|NCT01410149|Active Comparator|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
11492140|NCT01410136|Other|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
11492141|NCT01410123|Other|Treatment as Usual (TAU)|
11492142|NCT01410123|Other|Integrated Stepped Care (ISC)|
11492143|NCT01410110|Experimental|Cognitive Training + Work Therapy|"Cognitive Training using auditory and visual Positscience software 5 hours/per week for 13 weeks.
~Work Therapy for 15 hours per week at half minimum wage doing entry level duties at medical center job sites, supervised by regular medical center staff."
11492144|NCT01410110|Active Comparator|Work Therapy Only|Same work therapy but for 20 hours per week.
11492228|NCT01409447|Experimental|Biphasic osteochondral composite|feasibility study for the new medical device & technique
11492646|NCT01406444|Placebo Comparator|Placebo|Placebo for 12 months
11492145|NCT01410097|Experimental|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
11492146|NCT01410097|Placebo Comparator|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
11492147|NCT01410084|Experimental|Vitamin D3|100,000 IU vitamin D3 once monthly
11492148|NCT01410084|Placebo Comparator|Vitamin E|400 IU vitamin E once monthly
11492149|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
11492150|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
11492151|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
11492152|NCT01410045|Experimental|Surgery|Ovariectomy
11492153|NCT01410032|Active Comparator|Plate fixation|Reconstruction plate
11492154|NCT01410032|Active Comparator|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
11492155|NCT01410019|Experimental|1|Gene transfer
11492156|NCT01409993|Experimental|sildenafil Aim 1|sildenafil 25 mg p.o. tid
11492157|NCT01409993|Placebo Comparator|placebo Aim 1|matching placebo p.o. tid
11492158|NCT01409993|Experimental|sildenafil Aim 2|sildenafil 25 mg p.o. tid
11492159|NCT01409993|Placebo Comparator|placebo Aim 2|matching placebo p.o. tid
11492160|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
11492161|NCT01409954||Spinal decompression|Spinal decompression with an instrumented posterolateral fusion
11492162|NCT01409928|Experimental|Lap-Band|Placement of the LAP-BAND® system will be performed laparoscopically under general anesthesia, using the pars flaccida technique. The device will be placed by surgeons from the University of Texas Southwestern Medical Center Obesity Management Program at Children's Medical Center Dallas. Surgeons will be fully trained in the placement of the LAP-BAND® device, in accordance with FDA approval of the device for the placement in adults. As is current practice in adults undergoing the procedure, incidentally discovered hiatal hernias are repaired at the time of band placement, to reduce the incidence of post-operative reflux. Children receive prophylactic antibiotics, and are observed overnight after surgery. Patients are generally discharged from the hospital the next day. The band will initially be left empty at the end of the placement procedure.
11492163|NCT01409915|Experimental|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
11492164|NCT01409915|Placebo Comparator|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
11492165|NCT01409889|Active Comparator|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
11492166|NCT01409889|Active Comparator|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
11492167|NCT01409876|Experimental|Brachytherapy|
11492168|NCT01409863|No Intervention|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
11492169|NCT01409850|Active Comparator|Aqualizer|
11492170|NCT01409850|Active Comparator|Soft splint|elastic splint made of copolyester foil
11492171|NCT01409850|No Intervention|Counselling|
11492172|NCT01409837|Placebo Comparator|Sugar pill|Started with Placebo until the crossover.
11492173|NCT01409837|Experimental|Lisinopril|Started with Lisinopril until the crossover
11492174|NCT01409824|No Intervention|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
11492175|NCT01409824|Experimental|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
11492176|NCT01409811|Experimental|Treatment (zoledronic acid)|"Patients receive a single dose of zoledronic acid 4 mg IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-23. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.
~zoledronic acid: Given IV
~laboratory biomarker analysis: Correlative studies
~therapeutic conventional surgery: Undergo definitive lumpectomy or mastectomy"
11492177|NCT01409785||LMA Supreme|
11492178|NCT01409785||LMA unique|
11492179|NCT01409772||Intestinal Rehab|
11492180|NCT01409759|Experimental|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
11492181|NCT01409759|Other|Full thickness graft|
11492182|NCT01409746||twins|twin pairs
11492183|NCT01409733|Experimental|Stage IV melanoma patients|
11492184|NCT01409720|Experimental|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
11492185|NCT01409720|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
11492186|NCT01409707|Experimental|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
11492739|NCT01405898|Experimental|Beetroot Juice|
11492187|NCT01409707|Experimental|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
11492188|NCT01409707|Experimental|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
11492189|NCT01409694|Active Comparator|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
11492190|NCT01409694|Placebo Comparator|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
11492191|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
11492192|NCT01409668|Experimental|L. Amylovorus|
11492193|NCT01409668|Experimental|L. Fermentum|
11492194|NCT01409655|Experimental|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
11492195|NCT01409642|Active Comparator|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
11492196|NCT01409642|Experimental|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
11492197|NCT01409629||Activity choices|Observe individuals' activity choices after playing a computer game.
11492198|NCT01409616|Experimental|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
11492199|NCT01409616|Experimental|Treatment arm B|ASA + darexaban, w.o., ASA
11492200|NCT01409616|Experimental|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
11492201|NCT01409616|Experimental|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
11492202|NCT01409616|Experimental|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
11492203|NCT01409616|Experimental|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
11492204|NCT01409616|Experimental|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
11492205|NCT01409616|Experimental|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
11492206|NCT01409603|Experimental|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
11492207|NCT01409603|Experimental|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
11492208|NCT01409603|Experimental|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
11492209|NCT01409603|Experimental|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
11492210|NCT01409603|Experimental|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
11492211|NCT01409603|Experimental|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
11492212|NCT01409590|Other|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
11492213|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible > 9months clinical follow-up
11492214|NCT01409564|Experimental|Cilostazol|Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
11492215|NCT01409564|Placebo Comparator|Placebo|Placebo group means dementia patients group receiving donepezil with placebo.
11492216|NCT01409551|Active Comparator|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
11492217|NCT01409551|Active Comparator|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
11492218|NCT01409538|Placebo Comparator|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
11492219|NCT01409538|Active Comparator|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
11492220|NCT01409525||cardiac surgery patients|
11492221|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
11492222|NCT01409499|Experimental|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
11492223|NCT01409499|Experimental|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
11492224|NCT01409499|Experimental|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
11492225|NCT01409473|Experimental|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
11492226|NCT01409460|Experimental|True Obturator Nerve Block|
11492227|NCT01409460|Sham Comparator|Sham Block|
11492229|NCT01409434|Other|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
11492230|NCT01409421|Experimental|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
11492231|NCT01409421|Active Comparator|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
11492232|NCT01409421|No Intervention|standard care|standard care for glaucoma
11492233|NCT01409408|Active Comparator|Aliskiren|
11492234|NCT01409408|Active Comparator|Amlodipine|
11492235|NCT01409395|Experimental|Metformin|Subjects will be dosed with Metformin alone (850 mg)
11492236|NCT01409395|Experimental|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
11492237|NCT01409382|Active Comparator|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
11492238|NCT01409382|No Intervention|Standard follow-up|Prenatal care will proceed according to the routine.
11492239|NCT01409369|Experimental|1|
11492240|NCT01409369|Active Comparator|2|
11492241|NCT01409356|Experimental|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
11492242|NCT01409330|Experimental|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
11492243|NCT01409330|Active Comparator|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
11492244|NCT01409317|Experimental|Deep Transcranial Magnetic Stimulation|
11492245|NCT01409317|Active Comparator|Repetitive Transcranial Magnetic Stimulation|
11492246|NCT01409278|Experimental|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
11492247|NCT01409278|Experimental|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
11492248|NCT01409278|Placebo Comparator|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
11492249|NCT01409265||No treatment|
11492250|NCT01409252||Hemorrhagic stroke patients|
11492251|NCT01409239|Active Comparator|Subcutaneous Insulin|
11492252|NCT01409239|Experimental|Intravenous insulin|
11492253|NCT01409226|Experimental|MRI|
11492254|NCT01409213||All Enrolled Participants|
11492255|NCT01409200|Experimental|Arm I (antiandrogen therapy, axitinib, surgery)|Patients receive antiandrogen therapy per standard care and axitinib PO BID for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection.
11492256|NCT01409200|Active Comparator|Arm II (antiandrogen therapy, surgery)|Patients receive antiandrogen therapy per standard care for 4 months and then undergo radical prostatectomy and pelvic lymph node dissection.
11492257|NCT01409187|Experimental|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m^2 daily IV continuous infusion for 4 days on days 2-5.
11492258|NCT01409174|Experimental|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
11492259|NCT01409161|Experimental|Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)|"INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.
~CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11492260|NCT01409148|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
11492261|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 1|
11492262|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 2|
11492263|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 3|
11492264|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 4|
11492265|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 5|
11492266|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 6|
11492267|NCT01409135|Experimental|ASG-22CE Expansion Cohort 1|Breast Cancer
11492268|NCT01409135|Experimental|ASG-22CE Expansion Cohort 2|Bladder Cancer
11492269|NCT01409135|Experimental|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
11492270|NCT01409122|Experimental|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, [Q8H]) of AIR001 or placebo for 16 consecutive doses
11492271|NCT01409122|Experimental|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
11492272|NCT01409122|Experimental|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
11492273|NCT01409122|Experimental|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
11492274|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
11492275|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
11492276|NCT01409096|Active Comparator|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
11492277|NCT01409096|Placebo Comparator|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
11492740|NCT01405898|Placebo Comparator|Nitrate-free beetroot juice|
11492278|NCT01409083|Experimental|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
11492279|NCT01409083|Placebo Comparator|control|equal volume of normal saline will be randomely injected
11492280|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
11492281|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
11492282|NCT01409057||No heart lung machine|Coronary-artery-disease
11492283|NCT01409057||Heart lung machine|Coronary artery disease
11492284|NCT01409044|Experimental|Music|Research participant listened to music
11492285|NCT01409031|Experimental|Intravenous Sildenafil|
11492286|NCT01409031|Placebo Comparator|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
11492287|NCT01409018|Experimental|Itraconazole|
11492288|NCT01409005|Experimental|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
11492289|NCT01408992|Experimental|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
11492290|NCT01408979|Experimental|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
11492291|NCT01408979|Active Comparator|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
11492292|NCT01408966|Experimental|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt & Sprüngli España) together with the test meal
11492293|NCT01408966|Placebo Comparator|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
11492294|NCT01408953|Experimental|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
11492295|NCT01408914|No Intervention|RIF 600|
11492296|NCT01408914|Experimental|RIF 900|
11492297|NCT01408914|Experimental|RIF 1200|
11492298|NCT01408901|Experimental|A: GM-CSF + supervised treadmill exercise therapy|
11492299|NCT01408901|Active Comparator|B: GM-CSF + attention control group|
11492300|NCT01408901|Active Comparator|C: placebo + supervised exercise therapy|
11492301|NCT01408901|Placebo Comparator|D: placebo + attention control group|
11492302|NCT01408888|Experimental|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
11492303|NCT01408888|Experimental|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
11492304|NCT01408875|Experimental|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
11492305|NCT01408875|No Intervention|Rehabilitation Group only|Patient Heart Failure who follows physical training
11492306|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
11492307|NCT01408849|Experimental|Maytenus|Tea of Martens ilicifolia leaves
11492308|NCT01408849|Active Comparator|Omeprazole|Omeprazole as active comparator
11492309|NCT01408836|Experimental|1|Plasma exchange x 7 over 14 days
11492310|NCT01408836|Active Comparator|2|Methyl prednisolone 1g x 3
11492311|NCT01408823||Idiopathic Scoliosis|
11492312|NCT01408823||Non-idiopathic Scoliosis|
11492313|NCT01408810|Experimental|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
11492314|NCT01408797|Experimental|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
11492315|NCT01408797|Experimental|Clonal deletion|
11492316|NCT01408797|Experimental|Drugs Added When Needed|
11492317|NCT01408758|Other|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
11492318|NCT01408758|Other|no VCRT|This group will have 2 visits with study physician only, no VCRT.
11492319|NCT01408745|Experimental|Sternumfix|sternotomy closure with Sternumfix
11492320|NCT01408745|Active Comparator|Steel wire|sternotomy closure with steel wire
11492321|NCT01408732|Experimental|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
11492322|NCT01408732|Experimental|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
11492323|NCT01408719|Experimental|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
11492324|NCT01408719|Experimental|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
11492325|NCT01408719|Experimental|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
11492326|NCT01408719|Placebo Comparator|Control|control diet containing negligible amount of beta glucan
11492327|NCT01408706|Active Comparator|Miller enema air tip|The Miller enema air tip rectal balloon is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy.
11492328|NCT01408706|Active Comparator|Radiadyne Immobilizer|The Radiadyne Immobilizer Treatment Device is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy
11492329|NCT01408693|Active Comparator|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
11492330|NCT01408693|Active Comparator|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
11492331|NCT01408680|Active Comparator|Coenzyme Q10 600 mg|
11492332|NCT01408680|Active Comparator|Coenzyme Q10 1200 mg|
11492333|NCT01408680|Placebo Comparator|Placebo|
11492334|NCT01408667|Placebo Comparator|Placebo|
11492335|NCT01408667|Active Comparator|TRC150094|
11492336|NCT01408654|Experimental|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
11492337|NCT01408654|No Intervention|Care-as-Usual|Care-as-Usual in Primary Care
11492338|NCT01408641|Experimental|Topiramate|Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.
11492339|NCT01408641|Placebo Comparator|Placebo (Sugar Pill)|Placebo arm will receive matching capsules without topiramate.
11492340|NCT01408628|Experimental|Internet Insulin Education|"Single arm study; intervention represented by subjects' participation in 4 synchronous (live) interactive Internet classes."
11492341|NCT01408615||All Enrolled Participants|Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
11492342|NCT01408602|Experimental|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
11492343|NCT01408602|Experimental|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
11492344|NCT01408602|Placebo Comparator|Placebo|Placebo
11492345|NCT01408589|Placebo Comparator|Sugar Pill|
11492346|NCT01408589|Experimental|Atomoxetine 40 mg|
11492347|NCT01408589|Experimental|Atomoxetine 60 mg|
11492348|NCT01408589|Experimental|Atomoxetine 80 mg|
11492349|NCT01408576|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
11492350|NCT01408576|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
11492351|NCT01408563|Experimental|Fludarabine/Melphalan/TBI|All patients receive same therapy
11492352|NCT01408550|Active Comparator|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
11492353|NCT01408550|Placebo Comparator|Placebo|Placebo Comparator: 2 Physiological saline
11492354|NCT01408537|Experimental|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
11492355|NCT01408524|Active Comparator|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
11492356|NCT01408524|Active Comparator|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
11492357|NCT01408511|Experimental|Arm 1|
11492358|NCT01408498|No Intervention|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
11492359|NCT01408498|Experimental|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
11492360|NCT01408485|Experimental|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
11492361|NCT01408472|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
11492362|NCT01408459|Active Comparator|Tomato product|
11492363|NCT01408459|Placebo Comparator|Control|No Motivation telephone Counseling
11492364|NCT01408446|Active Comparator|Menthol|Interventions Drug: Menthol Arms: Group 1
11492365|NCT01408446|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
11492366|NCT01408433|Other|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
11492367|NCT01408433|Other|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
11492368|NCT01408420|No Intervention|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
11492369|NCT01408420|Active Comparator|MAP > 60 mmHg|A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
11492370|NCT01408407|Active Comparator|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
11492371|NCT01408407|Experimental|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
11492372|NCT01408394|Active Comparator|100 mg immediate release form|This is the formulation currently in use
11492373|NCT01408394|Experimental|90 mg controlled release|This is the low dose of the controlled release form
11492374|NCT01408394|Experimental|180 mg controlled release form|This is the medium controlled release dose
11492375|NCT01408381|No Intervention|Control|No cell therapy
11492376|NCT01408381|Experimental|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
11492377|NCT01408381|Experimental|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
11492378|NCT01408381|Experimental|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
11492379|NCT01408368|Active Comparator|Bilateral subtotal thyroidectomy|
11492380|NCT01408368|Experimental|Total thyroidectomy|
11492381|NCT01408355|Experimental|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
11492382|NCT01408355|Experimental|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
11492383|NCT01408342|Other|Rituximab, Alemtuzumab|
11492384|NCT01408329|Sham Comparator|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
11492385|NCT01408329|Experimental|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
11492386|NCT01408316|Experimental|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
11492387|NCT01408316|Experimental|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
11492388|NCT01408303|Placebo Comparator|Olive Oil|olive oil: 4 g/day + prescription statin
11492389|NCT01408303|Experimental|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
11492390|NCT01408303|Experimental|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
11492391|NCT01408290|Experimental|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
11492392|NCT01408290|Experimental|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
11492393|NCT01408290|Experimental|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
11492394|NCT01408290|Experimental|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
11492395|NCT01408277|Active Comparator|Santyl|2mm Santyl applied once daily.
11492396|NCT01408277|Active Comparator|Control|Standard Care
11492397|NCT01408264|Active Comparator|0.035 guidewire|conventional 0.035 guidewire
11492398|NCT01408264|Active Comparator|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
11492399|NCT01408238|Experimental|1|"Secale cereale allergen extract at 4 different concentrations
~Positive control
~Negative control"
11492400|NCT01408212|Experimental|Acupuncture therapy|
11492401|NCT01408199|Experimental|Lenalidomide Group|
11492402|NCT01408186|Active Comparator|Rabeprazole|Tablet 20mg daily for 12 months
11492403|NCT01408186|Active Comparator|Famotidine|Tablet 40mg daily for 12 months
11492404|NCT01408173|Experimental|NPC-11|"Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.
~Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
11492405|NCT01408160|Experimental|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11492406|NCT01408147|Active Comparator|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
11492407|NCT01408147|No Intervention|Standard WIC care|The control group will received Standard Care as provided through WIC.
11492408|NCT01408121||African-American on clopidogrel|
11492409|NCT01408121||African-American on prasugrel|
11492410|NCT01408121||Caucasian on clopidogrel|
11492411|NCT01408121||Caucasian on prasugrel|
11492412|NCT01408108|Active Comparator|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
11492413|NCT01408108|Active Comparator|Primary crural repair|Laparoscopic primary posterior crural repair
11492414|NCT01408095|Experimental|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
11492415|NCT01408095|Active Comparator|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
11492416|NCT01408082|Experimental|ISV-502|
11492417|NCT01408082|Active Comparator|AzaSite|
11492418|NCT01408082|Active Comparator|Dexamethasone|
11492419|NCT01408082|Placebo Comparator|Vehicle|
11492420|NCT01408069|Experimental|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
11492421|NCT01408069|Active Comparator|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
11492422|NCT01408056|Experimental|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
11492423|NCT01408056|Active Comparator|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
11492424|NCT01408043|Experimental|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
11492425|NCT01408030|Placebo Comparator|Placebo spray|sterile saline
11492426|NCT01408030|Active Comparator|Bevacizumab spray|bevacizumab 1%
11492427|NCT01408030|Active Comparator|Estriol spray|Estriol 0.1%
11492428|NCT01408030|Active Comparator|Tranexamic acid spray|tranexamic acid 10%
11492429|NCT01408004|Experimental|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
11492430|NCT01408004|Active Comparator|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
11492431|NCT01407991|Experimental|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
11492432|NCT01407991|Active Comparator|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
11492433|NCT01407978|Active Comparator|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.
~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
11492434|NCT01407978|Active Comparator|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.
~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
11492435|NCT01407978|Experimental|Vaccination with Fluval P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.
~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
11492436|NCT01407965|Experimental|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L
~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
11492437|NCT01407965|Experimental|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
11492438|NCT01407952|Other|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
11492439|NCT01407952|Other|Control|Aneurysm treatment using bare platinum coil(s)
11492440|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
11492441|NCT01407926||Nurse-Led Mental Health Promotion Group|Interprofessional nurse-led strategy involving regular home visits over 6 months by an RN and PSW. The RN will conduct a comprehensive health assessment and screen clients for risk factors for depression and other chronic conditions, implement health promotion strategies to address this risk factors and enhance health, review their medications, conduct in-home exercise , refer clients to other health services
11492442|NCT01407900|Placebo Comparator|5% Dextrose in Water|Infusion of D5W
11492443|NCT01407900|Active Comparator|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
11492444|NCT01407887|Active Comparator|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
11492445|NCT01407887|No Intervention|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
11492446|NCT01407874|Experimental|Placebo|Placebo + Allopurinol 200mg
11492447|NCT01407874|Experimental|Ulodesine (BCX4208) 5mg|BCX4208 5mg + Allopurinol 200 mg
11492448|NCT01407874|Experimental|Ulodesine (BCX4208) 10mg|BCX4208 10mg + Allopurinol 200mg
11492449|NCT01407861|Active Comparator|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
11492450|NCT01407861|Active Comparator|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
11492451|NCT01407848|Experimental|Furosemide|1 mg/kg/Ed
11492452|NCT01407848|Active Comparator|Saline 0,9%|1ml/kg/Ed
11492453|NCT01407835|Experimental|1|"Dactylis glomerata allergen extract at 4 different concentrations
~Positive control
~Negative control"
11492454|NCT01407822|Experimental|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
11492455|NCT01407822|Active Comparator|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
11492456|NCT01407809|Experimental|Intervention|
11492457|NCT01407796|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
11492593|NCT01406847|Sham Comparator|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
11492458|NCT01407783|Experimental|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
11492459|NCT01407783|No Intervention|Enhanced Referral|
11492460|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
11492461|NCT01407705||Control Group|"No diagnosis of cervical degenerative or traumatic disease
~30 to 80 years of age
~Ability of volunteers to tolerate 1 hr examination"
11492462|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:
~Clinical and Radiographic evidence of cervical spondylotic myelopathy
~18 to 80 years of age
~Safe and stable clinical scenario to undergo imaging
~Awake, alert patient able to cooperate with physical examination
~Give written informed consent prior to any testing under this protocol
~Degenerative Disease Group:
~Have signs or symptoms consistent with spinal cord injury.
~Be diagnosed with cervical spondylosis (degenerative disease).
~Traumatic Group:
~• A spinal cord injury associated with a traumatic event."
11492463|NCT01407679|Experimental|Alitretinoin|
11492464|NCT01407666|Experimental|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
11492465|NCT01407666|No Intervention|epidural block|received thoracic epidural block for open liver resection
11492466|NCT01407653|Experimental|virtual reality|
11492467|NCT01407653|Other|usual care|
11492468|NCT01407640|Experimental|1|Allergy tests
11492469|NCT01407627|Experimental|Fructose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure
~Subjects will ingest fructose 200g daily x 14d
~Study Day 2 - measurement of renal hemodynamics
~Minimum 1 week washout period
~Subjects will ingest dextrose 200g daily x 14d
~Study Day 3 - measurement of renal hemodynamics and blood pressure"
11492470|NCT01407627|Active Comparator|Dextrose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure
~Subjects will ingest dextrose 200g daily x 14d
~Study Day 2 - measurement of renal hemodynamics
~Minimum 1 week washout period
~Subjects will ingest fructose 200g daily x 14d
~Study Day 3 - measurement of renal hemodynamics and blood pressure"
11492471|NCT01407614|Active Comparator|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
11492472|NCT01407614|No Intervention|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
11492473|NCT01407601|Experimental|45 µg MK-7|45 µg MK-7 daily over 6 weeks
11492474|NCT01407601|Experimental|135 µg MK-7|135 µg MK-7 daily over 6 weeks
11492475|NCT01407601|Experimental|360 µg MK-7|360 µg MK-7 daily over 6 weeks
11492476|NCT01407588|Experimental|Magnetic navigation|
11492477|NCT01407588|Experimental|Manual navigation|
11492478|NCT01407575|Experimental|Buprenorphine|0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
11492479|NCT01407575|Placebo Comparator|Placebo|matching placebo- sublingual- over the course of 8 weeks
11492480|NCT01407562|Experimental|Pazopanib with paclitaxel and carboplatin|
11492481|NCT01407549|Experimental|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
11492482|NCT01407549|No Intervention|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
11492483|NCT01407523|Experimental|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
11492484|NCT01407510|Experimental|Arm 1|
11492485|NCT01407497|Active Comparator|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
11492486|NCT01407497|Placebo Comparator|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
11492487|NCT01407497|Active Comparator|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
11492488|NCT01407497|Placebo Comparator|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
11492489|NCT01407484|Experimental|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
11492490|NCT01407484|Placebo Comparator|Placebo|Placebo
11492491|NCT01407471|Experimental|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
11492492|NCT01407471|Active Comparator|Clobetasol + Placebo|0.05% clobetasol + inert excipient
11492493|NCT01407471|Active Comparator|Placebo + Spironolactone|Inert excipient + 5% spironolactone
11492494|NCT01407471|Placebo Comparator|Placebo + placebo|Inert excipient
11492495|NCT01407458|Active Comparator|Experimental Group|Children doing additional exercises with upper limbs in physical education class
11492496|NCT01407458|Active Comparator|Control Group|Children doing normal physical education exercises
11492497|NCT01407445|Placebo Comparator|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
11492498|NCT01407445|Active Comparator|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
11492499|NCT01407432|Experimental|Folic acid|tablets of 5 mg of folic acid
11492500|NCT01407432|Placebo Comparator|Placebo|Tablets of placebo of folic acid
11492594|NCT01406847|Active Comparator|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
11492595|NCT01406821|Sham Comparator|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
11492501|NCT01407419|Experimental|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is >10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
11492502|NCT01407419|No Intervention|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
11492503|NCT01407406|Experimental|Chinese Subjects - low dose BIIB023 IV|
11492504|NCT01407406|Experimental|Chinese Subjects - high dose BIIB023 IV|
11492505|NCT01407406|Experimental|Japanese Subjects - low dose BIIB023 IV|
11492506|NCT01407406|Experimental|Japanese Subjects - high dose BIIB023 IV|
11492507|NCT01407406|Experimental|Causasian Subjects - low dose BIIB023 IV|
11492508|NCT01407406|Experimental|Caucasian Subjects - high dose BIIB023 IV|
11492509|NCT01407393|Experimental|Glucosanol|Glucosanol
11492510|NCT01407393|Placebo Comparator|Placebo|Placebo
11492511|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):
~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs
~Phase II (Next 250 participants):
~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
11492512|NCT01407354|Experimental|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
11492513|NCT01407354|Active Comparator|Aquatic Therapy|Aquatic exercise therapy
11492514|NCT01407341|Experimental|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
11492515|NCT01407315|Experimental|GlucoMenDay - Multiple sampling (A)|
11492516|NCT01407315|Experimental|GlucoMenDay - Meal/Insulin test (B)|
11492517|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
11492518|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
11492519|NCT01407289|Experimental|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
11492520|NCT01407289|No Intervention|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
11492521|NCT01407276|Experimental|Part 1: Mild Renal Impairment (Panel A)|
11492522|NCT01407276|Experimental|Part 1: Control to Match Panel A (Panel B)|
11492523|NCT01407276|Experimental|Part 1: Moderate Renal Impairment (Panel C)|
11492524|NCT01407276|Experimental|Part 1: Control to Match Panel C (Panel D)|
11492525|NCT01407276|Experimental|Part 1: Severe Renal Impairment (Panel E)|
11492526|NCT01407276|Experimental|Part 1: Control to Match Panel E (Panel F)|
11492527|NCT01407276|Experimental|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
11492528|NCT01407276|Experimental|Part 2: Control to Match Panel G (Panel H)|
11492529|NCT01407263|Experimental|Lymph node template|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.
11492530|NCT01407263|Experimental|Transverse versus vertical closure of the port site incision|
11492531|NCT01407263|Experimental|One vs. three days of antibiotic prophylaxis|
11492532|NCT01407237||HIV-infected Individuals|
11492533|NCT01407237||non-HIV-infected Individuals|
11492534|NCT01407224|Experimental|Only training|Training on Early Breastfeeding Practices to front line health workers
11492535|NCT01407224|Active Comparator|Training and supervision|Training as well as supervision by field supervisor for six months intervention
11492536|NCT01407224|No Intervention|Control|No intervention such as training or supervision
11492537|NCT01407211|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
11492538|NCT01407211|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
11492539|NCT01407198|Experimental|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
11492540|NCT01407185|Experimental|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue ~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
11492541|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
11492542|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI>0.9 and <1.3.
11492543|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
11492544|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
11492545|NCT01407159||Control group|"historical control group fulfilling the following criteria:
~Age +/- 3 years
~Sex matched
~Same follow-up period"
11492546|NCT01407133|Experimental|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:
~intensity: 100% of resting motor threshold
~stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)
~number of stimulations per session: 300, 900 or 1800 per session
~number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)
~total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
11492547|NCT01407133|Sham Comparator|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
11492548|NCT01407120|Experimental|Mother Program|11 session program focused on parenting skills
11492549|NCT01407120|Experimental|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
11492550|NCT01407120|No Intervention|Literature Control|Families received books on children's post-divorce adjustment
11492551|NCT01407107|Experimental|Nitroglycerin|Dose escalation trial of Nitroglycerin
11492552|NCT01407094|Active Comparator|Sertraline|SSRI monotherapy
11492553|NCT01407094|Placebo Comparator|Placebo|Placebo control
11492554|NCT01407094|Active Comparator|Bupropion|BupropionXL
11492555|NCT01407081|Experimental|Training|telerehabilitation cognitive strategy training
11492556|NCT01407068|Experimental|AA4500|AA4500 collagenase clostridium histolyticum
11492557|NCT01407055|No Intervention|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
11492558|NCT01407055|Active Comparator|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
11492559|NCT01407055|Experimental|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
11492560|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
11492561|NCT01407016|Experimental|1.0|
11492562|NCT01407003|Experimental|LIK066 in healthy subjects|
11492563|NCT01407003|Placebo Comparator|Matching placebo in healthy subjects|
11492564|NCT01407003|Experimental|LIK066 in patients with type 2 diabetes mellitus|
11492565|NCT01407003|Placebo Comparator|Matching placebo in patients with type 2 diabetes mellitus|
11492566|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
11492567|NCT01406977|Experimental|BPS804 dose escalation|
11492568|NCT01406964|Experimental|Arm A|Arm A performs a CAT test to study tubal factor causes
11492569|NCT01406964|Experimental|Arm B|In Arm B a histerosalpingography is performed.
11492570|NCT01406951||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
11492571|NCT01406951||sepsis|SIRS + infection
11492572|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature >38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or <4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
11492573|NCT01406938|Experimental|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
11492574|NCT01406938|Experimental|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
11492575|NCT01406938|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
11492576|NCT01406938|Experimental|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
11492577|NCT01406938|Experimental|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
11492578|NCT01406938|Experimental|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
11492579|NCT01406925|Placebo Comparator|Control|Placebo control
11492580|NCT01406925|Experimental|Low dose NRL001|0.5% NRL001 cream
11492581|NCT01406925|Experimental|Intermediate dose NRL001|0.75% NRL001 cream
11492582|NCT01406925|Experimental|High dose NRL001|1.0% NRL001 cream
11492583|NCT01406912|Active Comparator|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
11492584|NCT01406912|Experimental|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
11492585|NCT01406899|No Intervention|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
11492586|NCT01406899|Experimental|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
11492587|NCT01406886|Experimental|Energy density|Low or high energy density meal
11492588|NCT01406873|Active Comparator|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
11492589|NCT01406873|Placebo Comparator|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
11492590|NCT01406860|Experimental|Droperidol|
11492591|NCT01406860|Active Comparator|Metoclopramide + Diphenhydramine|
11492592|NCT01406847|Experimental|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
11492596|NCT01406821|Experimental|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
11492597|NCT01406808|Other|standard of care plus genetic information|
11492598|NCT01406808|No Intervention|usual standard of care without genetic information|
11492599|NCT01406795|Experimental|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
11492600|NCT01406769|Experimental|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
11492601|NCT01406743||EOS™ Acquisition|
11492602|NCT01406730|Experimental|exercise|16 weeks of running exercise
11492603|NCT01406730|No Intervention|control|
11492604|NCT01406717|Experimental|SPIL1033|
11492605|NCT01406717|Placebo Comparator|Placebo|
11492606|NCT01406704|No Intervention|Control|
11492607|NCT01406704|Experimental|Rosiglitazone|Rosiglitazone (8 mg/day)
11492608|NCT01406704|Experimental|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
11492609|NCT01406704|Experimental|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
11492610|NCT01406691|Experimental|Light|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
11492611|NCT01406691|Placebo Comparator|Fake light|during three hours immediately prior to desired waketime, subjects will receive no light (light flash device will be disabled)
11492612|NCT01406678|Active Comparator|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
11492613|NCT01406678|Placebo Comparator|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
11492614|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
11492615|NCT01406652|Active Comparator|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
11492616|NCT01406652|Experimental|Two-stage bursectomy|Bursectomy with debridement and left open. Wound closure in a second step and in a second surgery.
11492617|NCT01406639|Experimental|Ranibizumab|Patients treated with topical ranibizumab.
11492618|NCT01406626|Experimental|Peer Navigation Intervention Arm|"Subjects will receive the following peer navigation services:
~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge
~2a) 2 Navigator accompaniment sessions: the peer navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge and things that make it hard or easy for him/her to get regular HIV care
~2b) Optional peer navigator accompaniment sessions: If the participant requests, the peer navigator will provide accompaniment to supportive HIV care appointments (one per month max)
~3) 14 peer navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
11492619|NCT01406626|No Intervention|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
11492620|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
11492621|NCT01406600|Active Comparator|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
11492622|NCT01406600|Experimental|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
11492623|NCT01406587|Experimental|PP4001 50 mg|
11492624|NCT01406587|Experimental|PP4001 100 mg|
11492625|NCT01406587|Experimental|PP4001 200 mg|
11492626|NCT01406587|Placebo Comparator|Placebo|
11492627|NCT01406574|Experimental|OPB-31121 p1|Phase1 step
11492628|NCT01406574|Experimental|OPB-31121 p2|Phase2 step
11492629|NCT01406561|Experimental|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
11492630|NCT01406561|Placebo Comparator|Vehicle Irrigation Solution|Vehicle Irrigation Solution
11492631|NCT01406548|Experimental|BPS804 dosing frequency 1|
11492632|NCT01406548|Placebo Comparator|placebo dosing frequency 1|
11492633|NCT01406548|Experimental|BPS804 dosing frequency 2|
11492634|NCT01406548|Placebo Comparator|placebo dosing frequency 2|
11492635|NCT01406548|Experimental|BPS804 dosing frequency 3|
11492636|NCT01406548|Placebo Comparator|Placebo dosing frequency 3|
11492637|NCT01406522|Placebo Comparator|Oral placebo|Inactive treatment
11492638|NCT01406522|Experimental|Oral tacrine|Oral tacrine
11492639|NCT01406509|Experimental|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
11492640|NCT01406509|Experimental|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
11492641|NCT01406496|Experimental|Timing of insulin administration|
11492642|NCT01406483|Other|CABG|
11492643|NCT01406470|Experimental|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
11492644|NCT01406444|Active Comparator|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
11492645|NCT01406444|Active Comparator|Risedronate|Risedronate 35mg PO once weekly for 12 months
11492647|NCT01406431|Active Comparator|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
11492648|NCT01406431|Experimental|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
11492649|NCT01406418|Experimental|Cohort 1: CR6261|2 mg/kg CR6261
11492650|NCT01406418|Placebo Comparator|Cohort 1: Placebo|5% dextrose in water
11492651|NCT01406418|Experimental|Cohort 2: CR6261|5 mg/kg CR6261
11492652|NCT01406418|Placebo Comparator|Cohort 2: Placebo|5% dextrose in water
11492653|NCT01406418|Experimental|Cohort 3: CR6261|15 mg/kg CR6261
11492654|NCT01406418|Placebo Comparator|Cohort 3: Placebo|5% dextrose in water
11492655|NCT01406418|Experimental|Cohort 4: CR6261|30 mg/kg CR6261
11492656|NCT01406418|Placebo Comparator|Cohort 4: Placebo|5% dextrose in water
11492657|NCT01406418|Experimental|Cohort 5: CR6261|50 mg/kg CR6261
11492658|NCT01406418|Placebo Comparator|Cohort 5: Placebo|5% dextrose in water
11492659|NCT01406418|Experimental|Cohort 6: CR6261|30 mg/kg CR6261
11492660|NCT01406418|Placebo Comparator|Cohort 6 Placebo|5% dextrose in water
11492661|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
11492662|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
11492663|NCT01406392|Active Comparator|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
11492664|NCT01406392|Active Comparator|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
11492665|NCT01406379|Experimental|Prophylactic clip|Prophylactic clip
11492666|NCT01406379|Active Comparator|Detachable snare|Detachable snare
11492667|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
11492668|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
11492669|NCT01406353|Active Comparator|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
11492670|NCT01406353|No Intervention|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
11492671|NCT01406340|Experimental|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
11492672|NCT01406340|Experimental|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
11492673|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
11492674|NCT01406314|Experimental|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
11492675|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
11492676|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
11492677|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
11492678|NCT01406262|Active Comparator|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
11492679|NCT01406262|Active Comparator|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
11492680|NCT01406249|Active Comparator|S-1,Cisplatin|
11492681|NCT01406249|Experimental|Capecitabine, Cisplatin|
11492682|NCT01406236|Other|Transradial PCI|
11492683|NCT01406236|Other|Transfemoral PCI|
11492684|NCT01406223|Active Comparator|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
11492685|NCT01406223|Active Comparator|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
11492686|NCT01406223|Active Comparator|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
11492687|NCT01406223|Placebo Comparator|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
11492688|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
11492689|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
11492690|NCT01406197|Experimental|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
11492741|NCT01405885|Experimental|Arm A - 0.9mg of INO-3605|
11492742|NCT01405885|Experimental|Arm B - 0.9mg of INO-3609|
11492691|NCT01406197|Experimental|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
11492692|NCT01406197|Experimental|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
11492693|NCT01406184|Experimental|Durham Connects Eligible Group|From July 1, 2009 - December 31, 2010, all even-birth-date residential births in Durham County, North Carolina were randomly assigned to receive the Durham Connects nurse home visiting program.
11492694|NCT01406184|No Intervention|Control Group|From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
11492695|NCT01406171|Experimental|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
11492696|NCT01406158|Experimental|Treatment A|
11492697|NCT01406158|Experimental|Treatment B|
11492698|NCT01406158|Experimental|Treatment T|
11492699|NCT01406145|Experimental|ASP0777 low dose|ASP0777 low dose for 6 weeks
11492700|NCT01406145|Experimental|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
11492701|NCT01406145|Experimental|ASP0777 high dose|ASP0777 high dose for 6 weeks
11492702|NCT01406145|Placebo Comparator|Placebo|Placebo for 6 weeks
11492703|NCT01406132|Experimental|ASP015K|
11492704|NCT01406119|Experimental|ABT-806 Arm|
11492705|NCT01406106|Experimental|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).
~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
11492706|NCT01406106|Placebo Comparator|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
11492707|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
11492708|NCT01406080|Active Comparator|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
11492709|NCT01406080|Active Comparator|Tretinoin|Tretinoin 0,05% emollient cream
11492710|NCT01406067|Experimental|Social Skills Training|
11492711|NCT01406067|Active Comparator|Play group|
11492712|NCT01406054|Experimental|neuromuscular training|subjects in this arm will be exposed to a neuromuscular warm-up before practices and games
11492713|NCT01406054|No Intervention|control|
11492714|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
11492715|NCT01406028|No Intervention|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
11492716|NCT01406028|Active Comparator|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
11492717|NCT01406015|Active Comparator|Spironolactone|
11492718|NCT01406015|Placebo Comparator|Placebo|
11492719|NCT01406002|Experimental|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
11492720|NCT01405989|Experimental|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
11492721|NCT01405989|Experimental|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
11492722|NCT01405976|Active Comparator|1|NIV for severe OSA group
11492723|NCT01405976|Active Comparator|2|CPAP for severe OSA group
11492724|NCT01405976|Active Comparator|3|Life stile modification for severe OSA group
11492725|NCT01405976|Active Comparator|4|NIV for non-severe OSA group
11492726|NCT01405976|Active Comparator|5|Life stile modification for non-severe OSA group
11492727|NCT01405963|Experimental|Active Arm|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
11492728|NCT01405963|Placebo Comparator|Placebo Arm|Placebo comparator administered as a multiple IV doses in subjects with mild atopic asthma
11492729|NCT01405950|Experimental|Dose Level 1|
11492730|NCT01405950|Experimental|Dose Level 2|
11492731|NCT01405950|Experimental|Dose Level 3|
11492732|NCT01405950|Experimental|Dose Level 4|
11492733|NCT01405937|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
11492734|NCT01405937|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
11492735|NCT01405924|Experimental|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
11492736|NCT01405911|Placebo Comparator|Placebo|Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
11492737|NCT01405911|Experimental|Sitagliptin 25 mg|Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
11492738|NCT01405911|Experimental|Sitagliptin 50 mg|Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
11492743|NCT01405885|Experimental|Arm C- 0.9mg of INO-3401|
11492744|NCT01405885|Experimental|Arm D- 0.3mg of INO-3609|
11492745|NCT01405885|Experimental|Arm E - 0.45mg each INO-3605 , INO-3609|
11492746|NCT01405885|Experimental|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
11492747|NCT01405885|Experimental|Arm G - 0.9mg of INO-3609|
11492748|NCT01405885|Experimental|Arm H - 0.9mg of INO-3609|
11492749|NCT01405885|Active Comparator|Arm I - Seasonal influenza vaccine|
11492750|NCT01405885|Experimental|Arm J - 1.8mg of INO-3609|
11492751|NCT01405859||TS controls|10
11492752|NCT01405859||Non TS Controls|11
11492753|NCT01405859||TS remission|0
11492754|NCT01405846|Other|Gefitinib|Single arm study
11492755|NCT01405833|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
11492756|NCT01405833|Placebo Comparator|Placebo|Participants may be randomised to a matching placebo
11492757|NCT01405820|Active Comparator|Natalizumab 300 mg Intravenous (IV) Every 4 Weeks|Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
11492758|NCT01405820|Experimental|Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks|Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
11492759|NCT01405820|Experimental|Natalizumab 300 mg IV Every 12 Weeks|Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
11492760|NCT01405820|Experimental|Natalizumab 300 mg SC Every 12 Weeks|Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
11492761|NCT01405820|Experimental|Natalizumab 150 mg IV Every 12 Weeks|Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
11492762|NCT01405820|Experimental|Natalizumab 150 mg SC Every 12 Weeks|Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
11492763|NCT01405807|Experimental|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
11492764|NCT01405807|Experimental|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
11492765|NCT01405794|Experimental|32ppm Oral Silver|14 Days Active Silver Solution
11492766|NCT01405794|Placebo Comparator|Sterile Water|No Silver Nanoparticles
11492767|NCT01405768|Active Comparator|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
11492768|NCT01405768|Experimental|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
11492769|NCT01405755|Experimental|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
11492770|NCT01405755|No Intervention|Comparison (no intervention)|No complementary feeding messages delivered.
11492771|NCT01405742|Experimental|Arm A|"The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.
~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds."
11492772|NCT01405742|Experimental|Arm B|"The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.
~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds"
11492773|NCT01405716|Active Comparator|Behavioral-Mindfulness|Mindfulness Meditation
11492774|NCT01405716|Placebo Comparator|Behavioral-Health|Health Education Class
11492775|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
11492776|NCT01405703||open plate fixation|large transverse incision
11492777|NCT01405677|Experimental|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
11492778|NCT01405677|Active Comparator|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
11492779|NCT01405677|Active Comparator|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
11492780|NCT01405664|No Intervention|Non-Weight Bearing x 6 weeks|
11492781|NCT01405664|Experimental|Immediate Weight-Bearing as Tolerated|
11492782|NCT01405651|Experimental|E|ONO-6950
11492783|NCT01405651|Placebo Comparator|P|Placebo
11492784|NCT01405638|Experimental|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
11492785|NCT01405638|Experimental|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
11492786|NCT01405638|Experimental|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
11492787|NCT01405625|Active Comparator|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
11492788|NCT01405625|Experimental|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
11492789|NCT01405612|Experimental|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
11492790|NCT01405612|Experimental|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
11492791|NCT01405599|Experimental|Control|Healthy subjects
11492792|NCT01405599|Experimental|Severe hepatic impairment|CTP class C
11492793|NCT01405599|Experimental|Moderate hepatic impairment|CTP class B
11492794|NCT01405599|Experimental|Mild hepatic impairment|CTP class A
11492795|NCT01405586|Active Comparator|gemcitabine|
11492796|NCT01405586|Experimental|gemcitabine + cisplatin|
11492797|NCT01405573|Active Comparator|A: Best Supportive Care|best supportive care
11492798|NCT01405573|Experimental|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
11492799|NCT01405560|Experimental|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
11492800|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
11492801|NCT01405521|Experimental|M01ZH09 vaccine|
11492802|NCT01405521|Placebo Comparator|Vaccine placebo|
11492803|NCT01405521|Other|Ty21a vaccine|Positive control
11492804|NCT01405508|Experimental|Placebo tablets / Brivaracetam bolus|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.
~Down-Titration:
~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In
~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:
~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
11492805|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV bolus|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.
~Down-Titration:
~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In
~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:
~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"
11492806|NCT01405508|Experimental|Placebo tablets / Brivaracetam infusion|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.
~Down-Titration:
~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In
~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:
~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
11492807|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV infusion|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.
~Down-Titration:
~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In
~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:
~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
11492808|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
11492809|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
11492810|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
11492811|NCT01405482|Active Comparator|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
11492812|NCT01405482|Placebo Comparator|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
11492813|NCT01405469|Experimental|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
11492814|NCT01405456|Experimental|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
11492815|NCT01405456|Placebo Comparator|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
11492816|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
11492817|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
11492818|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
11492819|NCT01405430|Experimental|Bevacizumab + blood samples|
11492820|NCT01405417|Experimental|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.
~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
11493808|NCT01398254|Other|TRA|Transradial Access
11492821|NCT01405404|No Intervention|No intervention control|Parents complete surveys only
11492822|NCT01405404|Experimental|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
11492823|NCT01405404|Experimental|Parent training with discount|parents receive parent training and a childcare discount for attending
11492824|NCT01405391|Experimental|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
11492825|NCT01405378|Experimental|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
11492826|NCT01405378|Placebo Comparator|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
11492827|NCT01405365|Experimental|Metronidazole|
11492828|NCT01405365|Placebo Comparator|Placebo|
11492829|NCT01405352|Active Comparator|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
11492830|NCT01405352|Placebo Comparator|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
11492831|NCT01405352|Active Comparator|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
11492832|NCT01405339|Experimental|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
11492833|NCT01405339|Active Comparator|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
11492834|NCT01405326|Experimental|Adalimumab|Adalimumab treatment for 6 months
11492835|NCT01405326|Placebo Comparator|Pacebo|Corresponding placebo for active treatment group
11492836|NCT01405313|Experimental|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
11492837|NCT01405313|Active Comparator|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
11492838|NCT01405300|Experimental|Peanut|
11492839|NCT01405300|Placebo Comparator|Control|
11492840|NCT01405287|Experimental|Combo Stent|PTCA with Combo Stent
11492841|NCT01405287|Active Comparator|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
11492842|NCT01405274|Experimental|Physiotherapy intervention|
11492843|NCT01405274|No Intervention|standard care|
11492844|NCT01405261|Experimental|NNC 0113-0987 (gastro)|
11492845|NCT01405261|Experimental|NNC 0113-987 (coated)|
11492846|NCT01405261|Experimental|NNC 0113-987 (i.v)|
11492847|NCT01405248|Experimental|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
11492848|NCT01405248|Placebo Comparator|control|Placebo
11492849|NCT01405235|Active Comparator|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
11492850|NCT01405235|Experimental|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
11492851|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
11492852|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
11492853|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
11492854|NCT01405196|Other|10 mg of PF-04236921|
11492855|NCT01405196|Other|50 mg of PF-04236921|
11492856|NCT01405196|Other|200 mg of PF-04236921|
11492857|NCT01405196|Other|Placebo|
11492858|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
11492859|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
11492860|NCT01405170|Experimental|methylprednisolone suspension|
11492861|NCT01405170|Active Comparator|methylprednisolone tablets|
11492862|NCT01405157|Experimental|methylprednisolone suspension|
11492863|NCT01405157|Active Comparator|methylprednisolone tablets|
11492864|NCT01405144|Active Comparator|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
11492865|NCT01405144|Active Comparator|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
11492866|NCT01405131|Experimental|methylprednisolone suspension|
11492867|NCT01405131|Active Comparator|methylprednisolone tablets|
11492868|NCT01405118|Experimental|Metformin/CP-690,550|
11492869|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
11492870|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
11492871|NCT01405092|Placebo Comparator|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
11492872|NCT01405092|Active Comparator|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
11492873|NCT01405079|Experimental|Gefitinib|Gefitinib 250 mg/day oral daily
11492874|NCT01405079|Active Comparator|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
11492875|NCT01405066|Experimental|Dose Reports and Educational Seminar|
11492876|NCT01405053|Active Comparator|Rufinamide|
11492877|NCT01405053|Active Comparator|Any other approved AED|
11493028|NCT01404026|Active Comparator|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
11492878|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
11492879|NCT01405027|Other|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
11492880|NCT01405027|Other|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
11492881|NCT01405014|Experimental|Relationship enhancement group|One group, all involved in the intervention
11492882|NCT01404988|Experimental|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
11492883|NCT01404988|Experimental|Telephone-Delivered BEI|Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
11492884|NCT01404988|Placebo Comparator|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
11492885|NCT01404975|Experimental|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
11492886|NCT01404975|Active Comparator|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :
~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
11492887|NCT01404962|Other|Group 1|
11492888|NCT01404949|Experimental|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
11492889|NCT01404936|Experimental|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
11492890|NCT01404923|Experimental|meteospasmyl|
11492891|NCT01404923|Active Comparator|standard of care|
11492892|NCT01404910|Experimental|Apheresis|Apheresis using Liposorber LA-15 System
11492893|NCT01404897|Experimental|Dietary Intervention: Control Diet|
11492894|NCT01404897|Experimental|Dietary Intervention: DASH-based diet|
11492895|NCT01404897|Experimental|Dietary Intervention: Modified DASH diet|
11492896|NCT01404884|Experimental|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
11492897|NCT01404871|Active Comparator|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
11492898|NCT01404871|Active Comparator|Open label Duloxetine|Open label trial of duloxetine
11492899|NCT01404858||Patients undergoing IVF|
11492900|NCT01404845|Active Comparator|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
11492901|NCT01404845|Active Comparator|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.
~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
11492902|NCT01404819|Experimental|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
11492903|NCT01404819|Active Comparator|Standard arm|Patients in this arm undergo standard anesthesia
11492904|NCT01404806|Experimental|GSK1349572|
11492905|NCT01404793||Liver transplant recipient|
11492906|NCT01404780|Experimental|The GlideScope (GVL)|
11492907|NCT01404780|Active Comparator|Macintosh direct laryngoscope (MDL)|
11492908|NCT01404767|Active Comparator|Metoprolol oral dose or Placebo infusion|
11492909|NCT01404767|Experimental|Esmolol infusion or Placebo oral dose|
11492910|NCT01404754|Placebo Comparator|Lactose (Inactive Placebo)|Participant receives inactive placebo during day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
11492911|NCT01404754|Active Comparator|3,4-methylenedioxymethamphetamine|Participant receives 125 mg MDMA possibly followed by 62.5 mg MDMA during a day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
11492912|NCT01404741|Active Comparator|5-azacytidine treatment until progress|5-azacytidine until progress
11493391|NCT01401296|Active Comparator|Wait-list group|Subjects receive access to deprexis after eight weeks
11492913|NCT01404741|Experimental|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
11492914|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
11492915|NCT01404715|Experimental|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
11492916|NCT01404715|Experimental|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
11492917|NCT01404702|Experimental|Zoledronic Acid and Interleukin-2|
11492918|NCT01404689|Experimental|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
11492919|NCT01404689|Sham Comparator|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
11492920|NCT01404676|Experimental|Vildagliptin + Metformin|Adding Vildagliptin to metformin users
11492921|NCT01404676|Active Comparator|Glimepiride + Metformin|Adding Glimepiride to metformin users
11492922|NCT01404663|Experimental|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
11492923|NCT01404650|Experimental|AUY922|
11492924|NCT01404637|Experimental|Tamsulosin 0.4mg|
11492925|NCT01404637|Active Comparator|tamsulosin 0.2mg|
11492926|NCT01404611|Active Comparator|DF289|Ear drops
11492927|NCT01404611|Active Comparator|DF277|Ear drops
11492928|NCT01404611|Experimental|DF289 plus DF277|Ear drops
11492929|NCT01404598|Experimental|naproxcinod 750 mg bid|
11492930|NCT01404598|Experimental|naproxcinod 3000 mg od|
11492931|NCT01404598|Active Comparator|naproxen 500 mg bid|
11492932|NCT01404585|Placebo Comparator|Arm 1: Placebo|
11492933|NCT01404585|Experimental|Arm 2: BMS-817399 (200 mg)|
11492934|NCT01404585|Experimental|Arm 3: BMS-817399 (400 mg)|
11492935|NCT01404572|Active Comparator|Atazanavir + 10% aspartame|
11492936|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame|
11492937|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame and sucralose|
11492938|NCT01404559|Active Comparator|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
11492939|NCT01404559|Active Comparator|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
11492940|NCT01404559|Active Comparator|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
11492941|NCT01404559|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
11492942|NCT01404546|Experimental|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
11492943|NCT01404546|Active Comparator|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
11492944|NCT01404533|Experimental|Iron supplement without food|
11492945|NCT01404533|Experimental|Iron supplement with food|
11492946|NCT01404533|Experimental|Iron fortificant with food|
11492947|NCT01404520|Experimental|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
11492948|NCT01404520|No Intervention|Control Group|Control group receives usual care
11492949|NCT01404507|Active Comparator|Intracoronary abciximab|Intracoronary injection of bolus abciximab
11492950|NCT01404507|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy
11492951|NCT01404507|Active Comparator|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
11492952|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
11492953|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.
~Discard catheter and snap lock bag at end of each week."
11492954|NCT01404468|Active Comparator|pulsed|
11492955|NCT01404468|Sham Comparator|control|
11492956|NCT01404468|Active Comparator|continuous|
11492957|NCT01404455|Other|Normal pulse pressure|pulse pressure <60mmHg
11492958|NCT01404455|Other|Wide pulse pressure|pulse pressure ≥60mmHg
11492959|NCT01404442|Active Comparator|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
11492960|NCT01404442|Active Comparator|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
11492961|NCT01404442|Placebo Comparator|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
11492962|NCT01404429|Active Comparator|Methotrexate 7.5 mg per week|
11492963|NCT01404429|Experimental|Methotrexate 15 mg per week|
11492964|NCT01404403|Other|Stroke patients|
11492965|NCT01404390|Experimental|Arm 1|
11492966|NCT01404390|Experimental|Arm 2|
11492967|NCT01404377|Active Comparator|ropivacaine|treated group (ropivacaine infiltration)
11492968|NCT01404377|Placebo Comparator|placebo|placebo group : infiltration with saline solution
11492969|NCT01404364|Active Comparator|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
11492970|NCT01404364|Active Comparator|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
11492971|NCT01404351|Experimental|PEAK PlasmaBlade|
11492972|NCT01404351|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
11492973|NCT01404338|Active Comparator|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
11492974|NCT01404338|Placebo Comparator|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
11492975|NCT01404325|Experimental|Quadruple low level IS regimen|quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
11492976|NCT01404325|Experimental|Centre specific triple IS regimen|centre specific CNI-based triple drug immunosuppression (IS)
11492977|NCT01404312|Experimental|RPT plus INH Regimen (Arm A)|Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
11492978|NCT01404312|Active Comparator|INH Regimen (Arm B)|Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
11492979|NCT01404299|Experimental|Supplementary Group|
11492980|NCT01404299|No Intervention|Control Group|
11492981|NCT01404286|Experimental|physical exercise|Experimental group: physical exercise Control group: no physical exercise
11492982|NCT01404286|No Intervention|Control group|
11492983|NCT01404273|Experimental|Meditation/Relaxation Response Training|
11492984|NCT01404260|Experimental|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
11492985|NCT01404260|Active Comparator|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
11492986|NCT01404247|Experimental|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
11492987|NCT01404234|Experimental|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
11492988|NCT01404208|Active Comparator|D-Cycloserine|
11492989|NCT01404208|Placebo Comparator|Sugar Pill|
11492990|NCT01404195|Experimental|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
11492991|NCT01404195|No Intervention|Control|without supplementation
11492992|NCT01404182|Experimental|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
11492993|NCT01404169|Experimental|1|
11492994|NCT01404169|Placebo Comparator|2|
11492995|NCT01404156|Active Comparator|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)
~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days
~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
11492996|NCT01404156|Experimental|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29
~paclitaxel: 50 mg / m2 IV over 1 hour
~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.
~Dose specifications:
~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.
~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
11492997|NCT01404143|Active Comparator|Subscapularis Tenotomy|"This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.
~After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity."
11492998|NCT01404143|Experimental|Subscapularis Peel|This treatment group will use a technique that involves elevation of the tendon off the bone in order to gain access to the shoulder.The subscapularis will be elevated from the lesser tuberosity.
11492999|NCT01404130|Experimental|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
11493000|NCT01404117|Experimental|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
11493001|NCT01404117|Experimental|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
11493002|NCT01404117|Experimental|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
11493003|NCT01404104|Experimental|Temsirolimus (pre-surgery)|
11493004|NCT01404091|Experimental|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).
~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration [tmax] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
11493027|NCT01404039|Placebo Comparator|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.
~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
11493005|NCT01404091|Experimental|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.
~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
11493006|NCT01404091|Experimental|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.
~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
11493007|NCT01404091|Experimental|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.
~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
11493008|NCT01404078|Active Comparator|SD Polycap without potassium|Single dose polycap without pottasium
11493009|NCT01404078|Experimental|DD Polycap plus potassium|Double Dose polycap with potassium
11493010|NCT01404065|Experimental|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
11493011|NCT01404065|Sham Comparator|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
11493012|NCT01404065|Other|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
11493013|NCT01404052|Experimental|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
11493014|NCT01404052|Sham Comparator|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
11493015|NCT01404039|Experimental|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.
~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
11493016|NCT01404039|Experimental|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.
~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
11493017|NCT01404039|Placebo Comparator|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
11493018|NCT01404039|Experimental|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.
~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
11493019|NCT01404039|Experimental|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.
~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
11493020|NCT01404039|Experimental|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.
~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
11493021|NCT01404039|Placebo Comparator|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).
~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
11493022|NCT01404039|Experimental|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
11493023|NCT01404039|Placebo Comparator|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
11493024|NCT01404039|Experimental|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
11493025|NCT01404039|Placebo Comparator|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
11493026|NCT01404039|Experimental|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
11493029|NCT01404026|Sham Comparator|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
11493030|NCT01404013|Active Comparator|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
11493031|NCT01404013|Active Comparator|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
11493032|NCT01404013|Active Comparator|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
11493033|NCT01404000|Active Comparator|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
11493034|NCT01404000|Placebo Comparator|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
11493035|NCT01403987|Active Comparator|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
11493036|NCT01403987|Experimental|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
11493037|NCT01403987|Experimental|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
11493038|NCT01403974|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
11493039|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c > 7
11493040|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
11493041|NCT01403948|Experimental|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
11493042|NCT01403922|Experimental|1|TC-5214
11493043|NCT01403922|Experimental|2|TC-5214 with placebo
11493044|NCT01403922|Experimental|3|TC-5214 with placebo
11493045|NCT01403922|Experimental|4|TC-5214
11493046|NCT01403909|Experimental|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
11493047|NCT01403909|Active Comparator|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
11493048|NCT01403896|Active Comparator|Plerixafor Group|
11493049|NCT01403896|Experimental|Plerixafor + G-CSF group|
11493050|NCT01403883|Active Comparator|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
11493051|NCT01403883|Experimental|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
11493052|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
11493053|NCT01403857|Experimental|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
11493054|NCT01403857|Placebo Comparator|Refined Grains|Time control compared to experimental intervention.
11493055|NCT01403844|Other|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
11493056|NCT01403831|Experimental|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
11493057|NCT01403831|No Intervention|Control|
11493058|NCT01403818|Experimental|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
11493059|NCT01403818|Experimental|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
11493060|NCT01403805|Experimental|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
11493061|NCT01403805|Active Comparator|Vaccine|Influenza vaccine only
11493062|NCT01403792|Experimental|Up to 7mg P2G12|
11493063|NCT01403792|Experimental|Up to 14mg P2G12|
11493064|NCT01403792|Experimental|Up to 28mg P2G12|
11493065|NCT01403792|Placebo Comparator|Placebo (saline solution)|
11493066|NCT01403779|Active Comparator|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
11493067|NCT01403779|Active Comparator|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
11493068|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
11493069|NCT01403753||Non-clinical sample of children|
11493070|NCT01403740||Acquired haemophilia patients|
11493071|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
11493072|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
11493073|NCT01403714|No Intervention|Medical Management|Patients may be randomized to medical management alone
11493074|NCT01403714|Active Comparator|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
11493075|NCT01403701|Experimental|Physical therapy|Standardized pelvic floor physical therapy
11493076|NCT01403701|No Intervention|routine care|Standard postoperative visits
11493077|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
11493078|NCT01403675|Experimental|Ovarian autotransplantation|
11493079|NCT01403662|Experimental|Minocycline|
11493125|NCT01403337|Placebo Comparator|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
11493168|NCT01402986|Experimental|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
11493809|NCT01398254|Other|TFA|Transfemoral Access
11493080|NCT01403649|Experimental|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
11493081|NCT01403649|Other|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
11493082|NCT01403636|Experimental|mantle cell|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
11493083|NCT01403636|Experimental|follicular lymphoma|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
11493084|NCT01403636|Experimental|CLL/SLL|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
11493085|NCT01403636|Experimental|Diffuse large B cell lymphoma|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
11493086|NCT01403623|Active Comparator|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
11493087|NCT01403623|Sham Comparator|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
11493088|NCT01403610|Experimental|Cohort 1|Subjects received TH-302 single dose at 575 mg/m2 or placebo administered preoperative in a 2:1 randomization and were then administered 240 mg/m2 of TH-302 post-operative.
11493089|NCT01403610|Experimental|Cohort 2|Surgical subjects will receive TH-302 at 340 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
11493090|NCT01403610|Experimental|Cohort 3|Surgical or Non-Surgical subjects will receive TH-302 at 480 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
11493091|NCT01403610|Experimental|Cohort 4|Non-surgical subjects will receive a dose up to 670 mg/m2 of TH-302
11493092|NCT01403597|Experimental|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
11493093|NCT01403571|Experimental|Salba supplement|30g/1000kal
11493094|NCT01403571|Placebo Comparator|Oat-bran based Control Supplement|36g/1000kcal
11493095|NCT01403558|Experimental|Cognitive behavioral therapy|Ten weekly individual cognitive behavioral therapy sessions before bariatric surgery
11493096|NCT01403558|No Intervention|Control group|Usual preoperative care consisting of up to three voluntary sessions with nutritionist and physiotherapist before bariatric surgery
11493097|NCT01403545|Experimental|Liposomal Curcumin|Single dose, dose escalation
11493098|NCT01403545|Placebo Comparator|5% Glucose|
11493099|NCT01403532|Active Comparator|Traditional|
11493100|NCT01403532|Experimental|Sequential|
11493101|NCT01403532|Experimental|Sequential Plus|
11493102|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
11493103|NCT01403519||Control group|Blood and CSF samples
11493104|NCT01403519||FTD patients|Blood ad CSF samples
11493105|NCT01403506|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
11493106|NCT01403506|No Intervention|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
11493107|NCT01403493|Active Comparator|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
11493108|NCT01403493|Active Comparator|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
11493109|NCT01403467|Experimental|NIPPV|
11493110|NCT01403454|No Intervention|usual care|
11493111|NCT01403454|Active Comparator|Health Communication Application|
11493112|NCT01403441|Experimental|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
11493113|NCT01403428|Experimental|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
11493114|NCT01403428|No Intervention|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
11493115|NCT01403415|Experimental|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
11493116|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
11493117|NCT01403389|Experimental|Eculizumab|
11493118|NCT01403389|Placebo Comparator|0.9% Sodium Chloride|
11493119|NCT01403376|Experimental|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
11493120|NCT01403376|Experimental|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
11493121|NCT01403376|Active Comparator|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
11493122|NCT01403363|Experimental|fentanyl patch|
11493123|NCT01403350|No Intervention|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
11493124|NCT01403350|Active Comparator|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
11493126|NCT01403337|Active Comparator|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
11493127|NCT01403324|Other|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
11493128|NCT01403311|Experimental|ALA|5-Aminolevuline Acid (ALA)
11493129|NCT01403298|Active Comparator|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
11493130|NCT01403298|Experimental|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
11493131|NCT01403272|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
11493132|NCT01403259|Experimental|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
11493133|NCT01403246|Experimental|Lenalidomide with Chlorambucil|
11493134|NCT01403233|Experimental|cogniVida™ 50 mg/day|
11493135|NCT01403233|Experimental|cogniVida™ 100 mg/day|
11493136|NCT01403233|Active Comparator|Rebaudioside-A 303.7 mg/day|
11493137|NCT01403220|Active Comparator|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
11493138|NCT01403220|Active Comparator|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
11493139|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
11493140|NCT01403194|Experimental|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
11493141|NCT01403181||Chronic hepatitis C|"10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)
~20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
11493142|NCT01403168|Experimental|osteopathy + conventional analgesic treatments|
11493143|NCT01403168|Placebo Comparator|conventional analgesic treatments|
11493144|NCT01403155|Experimental|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
11493145|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
11493146|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
11493147|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.
~Will have either or both Artemis-2 exam and OCT exam."
11493148|NCT01403116|Experimental|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food
~Treatment Period 2: One of the following dosages:
~100 mg BID
~150 mg BID
~100 mg BID
~100 mg and 150 mg BID
~150 mg capsules BID
~Safety Follow-up Phase:
~Initial dose: ~84 doses Maintenance dose-Titrated dose: ~96 doses Safety follow-up at maintenance dose: ~540 doses"
11493149|NCT01403116|Active Comparator|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD
~Treatment Period 2:
~2.5 g of 1% transdermal T-gel applied QD
~5 g of 1% transdermal T-gel applied QD
~7.5 g of 1% transdermal T-gel applied QD
~10 g of 1% transdermal T-gel applied QD
~Safety Follow-up Phase:
~Initial dose: ~42 doses Maintenance dose-Titrated dose: ~48 doses Safety follow-up at maintenance dose: ~270 doses"
11493150|NCT01403103|Experimental|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
11493151|NCT01403090|Experimental|Angel Catheter|
11493152|NCT01403077|Experimental|Scaffold Treatment|
11493153|NCT01403064|Experimental|Open Label ALD518|
11493154|NCT01403064|Experimental|ALD518 Dose 1|
11493155|NCT01403064|Experimental|ALD518 Dose 2|
11493156|NCT01403064|Placebo Comparator|Placebo|
11493157|NCT01403051|Experimental|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
11493158|NCT01403051|Experimental|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
11493159|NCT01403038|Experimental|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
11493160|NCT01403038|Experimental|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
11493161|NCT01403038|Experimental|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
11493162|NCT01403038|Experimental|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days
~Additional Dose Regimens may be added and will be administered for 84 days."
11493163|NCT01403038|Experimental|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
11493164|NCT01403038|Experimental|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
11493165|NCT01403038|Experimental|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
11493166|NCT01403025||Liraglutide|
11493167|NCT01402986|Placebo Comparator|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
11493810|NCT01398241|Experimental|Active|
11493169|NCT01402986|Placebo Comparator|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
11493170|NCT01402986|Experimental|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
11493171|NCT01402973|Experimental|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
11493172|NCT01402973|Experimental|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
11493173|NCT01402960|Experimental|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
11493174|NCT01402960|Experimental|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
11493175|NCT01402960|Sham Comparator|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
11493176|NCT01402947|Experimental|Ciprofloxacin + MMX placebo|
11493177|NCT01402947|Experimental|MMX Mesalazine/mesalamine + Ciprofloxacin|
11493178|NCT01402934|Experimental|fluid infusion|
11493179|NCT01402921|Experimental|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:
~ankle pressure: 10 mmHg
~calf pressure : 23 mmHg"
11493180|NCT01402921|Placebo Comparator|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:
~ankle pressure: <5 mmHg
~calf pressure : <7 mmHg"
11493181|NCT01402908|Experimental|PI-88|Arm 1
11493182|NCT01402908|Placebo Comparator|Placebo|Arm 2
11493183|NCT01402895|Active Comparator|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
11493184|NCT01402895|Active Comparator|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
11493185|NCT01402882|Experimental|Tranexamic acid|
11493186|NCT01402882|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
11493187|NCT01402869|Experimental|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
11493188|NCT01402869|Experimental|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
11493189|NCT01402869|No Intervention|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
11493190|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
11493191|NCT01402856||Bethlehem HS, PA Area School District|Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group.
11493192|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
11493193|NCT01402843|Experimental|pitavastatin + valsartan|
11493194|NCT01402843|Placebo Comparator|pitavastatin + placebo|
11493195|NCT01402843|Placebo Comparator|valsartan + placebo|
11493196|NCT01402843|Placebo Comparator|placebo|
11493197|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
11493198|NCT01402817|Experimental|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
11493199|NCT01402804||Stable CAD, ASA, NSAID|
11493200|NCT01402804||Stable CAD, ASA|
11493201|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
11493202|NCT01402778||Cather fixation by tunneling and suture|
11493203|NCT01402778||Catheter fixation by adhesive tape|
11493204|NCT01402765|Active Comparator|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
11493205|NCT01402765|Active Comparator|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
11493206|NCT01402752|Experimental|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
11493207|NCT01402739|Experimental|PoC algorithm guided transfusions|experimental arm
11493208|NCT01402739|Active Comparator|standard of care transfusions|control arm
11493209|NCT01402726|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
11493210|NCT01402726|No Intervention|Absolute medicine therapy|Maintenance of anti-heart failure medications only
11493211|NCT01402713|Experimental|GC1107-T5.0|Dosage: 0.5ml
11493212|NCT01402713|Experimental|GC1107-T7.5|Dosage: 0.5ml
11493213|NCT01402713|Active Comparator|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
11493214|NCT01402700|Experimental|Visi-Pro™ Balloon Expandable Stent System|The objective of the study is to confirm the safety and effectiveness of the Visi-Pro stent in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
11493215|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
11493216|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
11493217|NCT01402674|Active Comparator|LPT|Subjects treated with phentermine for 2 years or more.
11493218|NCT01402674|No Intervention|APT|Patients treated with phentermine for 7 to 14 days.
11493219|NCT01402661||Rheumatoid Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible.
11493220|NCT01402648|Placebo Comparator|Dietary supplement|900 mg Maltodextrins
11493811|NCT01398241|Placebo Comparator|Placebo|
11493221|NCT01402648|Active Comparator|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
11493222|NCT01402635|Experimental|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
11493223|NCT01402635|Active Comparator|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
11493224|NCT01402622|Active Comparator|Control group|balanced anaesthesia with antiemetic prophylaxis
11493225|NCT01402622|Active Comparator|TIVA group|TIVA without antiemetic prophylaxis
11493226|NCT01402622|Active Comparator|TIVA-P group|TIVA with antiemetic prophylaxis
11493227|NCT01402609|Placebo Comparator|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
11493228|NCT01402609|Experimental|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
11493229|NCT01402596|Active Comparator|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
11493230|NCT01402596|Active Comparator|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
11493231|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
11493232|NCT01402570|Experimental|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
11493233|NCT01402557|Active Comparator|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
11493234|NCT01402557|Experimental|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
11493235|NCT01402544|Other|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
11493236|NCT01402531|Experimental|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
11493237|NCT01402518||Per-oral endoscopic myotomy|
11493238|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
11493239|NCT01402492|Experimental|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
11493240|NCT01402492|Experimental|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
11493241|NCT01402492|Placebo Comparator|PLB+XR-NTX|Placebo plus naltrexone for 8 weeks of treatment
11493242|NCT01402479|Active Comparator|ramipril|open label single arm trial
11493243|NCT01402466|Active Comparator|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
11493244|NCT01402466|Experimental|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
11493245|NCT01402453|No Intervention|Control Subjects|Receive educational materials and a home BP monitor.
11493246|NCT01402453|Experimental|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
11493247|NCT01402440|Experimental|AEB071|
11493248|NCT01402427|Active Comparator|Verapamil|
11493249|NCT01402427|Placebo Comparator|Placebo|
11493250|NCT01402414|Active Comparator|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
11493251|NCT01402414|Active Comparator|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
11493252|NCT01402414|Active Comparator|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
11493253|NCT01402401|Experimental|AUY922 + Trastuzumab|
11493254|NCT01402388|Experimental|Lifestyle intervention group.|
11493255|NCT01402375|Experimental|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
11493256|NCT01402375|Active Comparator|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
11493257|NCT01402375|Experimental|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
11493258|NCT01402375|Active Comparator|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
11493259|NCT01402375|Experimental|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
11493260|NCT01402375|Active Comparator|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
11493261|NCT01402362||Ethiopians participating in previous study, year 2000|
11493262|NCT01402336|Experimental|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
11493263|NCT01402336|Experimental|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
11493264|NCT01402336|Active Comparator|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
11493265|NCT01402323|Other|early or late tooth extraction|
11493266|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
11493354|NCT01401621|Experimental|Control Condition|A control condition with no scratch-off element.
11493355|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
11495173|NCT01388699||migraine group|female migraineurs with aura
11493267|NCT01402297|Experimental|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
11493268|NCT01402284|Experimental|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
11493269|NCT01402271|Experimental|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
11493270|NCT01402271|Active Comparator|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
11493271|NCT01402258|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
11493272|NCT01402245|No Intervention|Pneumonia group|Patients with Pnc pneumonia
11493273|NCT01402245|Active Comparator|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
11493274|NCT01402245|Active Comparator|PCV Group|Volunteers immunized with Pnc conjugate vaccine
11493275|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
11493276|NCT01402219|Active Comparator|Iopamiro-370|
11493277|NCT01402219|Active Comparator|Visipaque 320|
11493278|NCT01402206|Other|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
11493279|NCT01402206|Other|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
11493280|NCT01402193|Active Comparator|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.
~Interventions:
~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
11493281|NCT01402193|Active Comparator|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy
~Interventions:
~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
11493282|NCT01402180|Experimental|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
11493283|NCT01402180|Active Comparator|B|Patients randomized in Arm B will receive chemoradiation only
11493284|NCT01402167|Experimental|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
11493285|NCT01402167|Active Comparator|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
11493286|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
11493287|NCT01402141|Experimental|Chungkookjang|
11493288|NCT01402141|Placebo Comparator|Placebo|
11493289|NCT01402128|Experimental|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
11493290|NCT01402128|Placebo Comparator|Placebo|Placebo for 12 weeks
11493291|NCT01402115|Experimental|Polycan|Polycan 150mg for 12 weeks
11493292|NCT01402115|Placebo Comparator|Placebo|Placebo 15mg for 12 weeks
11493293|NCT01402102|Experimental|Aged garlic powder|
11493294|NCT01402102|Placebo Comparator|Placebo|
11493295|NCT01402076|Experimental|Steady State PK Group|
11493296|NCT01402076|Experimental|No steady state PK|
11493297|NCT01402063|Experimental|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments
~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
11493298|NCT01402063|Active Comparator|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments
~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
11493299|NCT01402050|Active Comparator|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
11493300|NCT01402050|Active Comparator|CERVIDIL|
11493301|NCT01402037|Other|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of < 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
11493302|NCT01402037|Other|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
11493303|NCT01402037|Other|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
11493304|NCT01402037|Other|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
11493389|NCT01401335|Other|Trauma counseling|
11493390|NCT01401322|Experimental|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
11493305|NCT01402024|Experimental|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
11493306|NCT01402024|Placebo Comparator|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
11493307|NCT01402011|Experimental|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
11493308|NCT01402011|Active Comparator|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
11493309|NCT01402011|Placebo Comparator|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
11493310|NCT01401985|Experimental|TD-1211|TD-1211
11493311|NCT01401959|Experimental|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
11493312|NCT01401959|Experimental|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
11493313|NCT01401959|Experimental|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m^2 intravenously (IV)
~Trastuzumab 6mg/kg intravenously (IV)"
11493314|NCT01401946|Active Comparator|soy isoflavones|
11493315|NCT01401946|Placebo Comparator|Placebo|
11493316|NCT01401933|Experimental|Linifanib|
11493317|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
11493318|NCT01401907|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
11493319|NCT01401907|No Intervention|Standard of Care|Subjects receives standard of care
11493320|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
11493321|NCT01401868|Experimental|single arm|dose escalation
11493322|NCT01401855||In Vivo Probe Prediction|
11493323|NCT01401855||Cytology Results|
11493324|NCT01401842|Experimental|Strengthening Exercise|Lumbar ext. high intensity progressive resistance exercise
11493325|NCT01401842|Active Comparator|Stabilization Exercise|Low intensity core stabilization exercise
11493326|NCT01401829|Experimental|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
11493327|NCT01401829|Experimental|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
11493328|NCT01401829|Active Comparator|Stretching and Flexibility exercise|Stretching/Flexibility exercise
11493329|NCT01401816|Experimental|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
11493330|NCT01401816|No Intervention|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
11493331|NCT01401803|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
11493332|NCT01401790|Experimental|Telehomecare|3 month use of a new telehomecare program
11493333|NCT01401790|Active Comparator|Control|3 month regular education program and follow up at the Diabetes Clinic
11493334|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
11493335|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
11493336|NCT01401764|Other|Platform II, PASS, ARG 100|
11493337|NCT01401751|Other|Single Arm|non-randomized, uncontrolled, feasibility study
11493338|NCT01401725|Experimental|Hamilton General Hospital|
11493339|NCT01401725|Active Comparator|Juravinski Hospital|
11493340|NCT01401725|Other|St. Joseph's Hospital|
11493341|NCT01401712|Experimental|Paravertebral catheter (ON-Q® Pain Relief System)|
11493342|NCT01401712|Active Comparator|Thoracic epidural catheter|
11493343|NCT01401699|Experimental|Optical Frequency Domain imaging System|Optical Frequency Domain Imaging (OFDI) balloon based imaging
11493344|NCT01401660||Group A|Subjects who do not currently have low back pain.
11493345|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
11493346|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
11493347|NCT01401647|Active Comparator|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
11493348|NCT01401647|Active Comparator|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
11493349|NCT01401647|Placebo Comparator|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
11493350|NCT01401634|Other|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
11493351|NCT01401634|Experimental|Oral Fluids|
11493352|NCT01401621|Experimental|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
11493353|NCT01401621|Experimental|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
11493356|NCT01401595|Experimental|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
11493357|NCT01401595|No Intervention|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.
~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
11493358|NCT01401582|No Intervention|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
11493359|NCT01401582|Experimental|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
11493360|NCT01401569|Active Comparator|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
11493361|NCT01401569|Experimental|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
11493362|NCT01401556|Experimental|Case Manager Intervention|Osteoporosis case-managers will identify older fracture patients in Emergency Departments and Fracture Clinics; arrange bone mineral density (BMD) tests; meet with patients to counsel them and go over their results; and then offer and prescribe bisphosphonate treatment to those with low BMD.
11493363|NCT01401556|Active Comparator|Multifaceted quality improvement intervention|Active-comparator control consisting of telephone-based education for patients and treatment guidelines with reminders for family physicians
11493364|NCT01401543|Active Comparator|5 mg LY2452473 + 5 mg Tadalafil|5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
11493365|NCT01401543|Experimental|LY900010 (particle size #1)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
11493366|NCT01401543|Experimental|LY900010 (particle size #2)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
11493367|NCT01401543|Experimental|LY900010 (particle size #3)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
11493368|NCT01401530|Experimental|E7777|
11493369|NCT01401517|Placebo Comparator|Placebo|Microcrystalline cellulose NF at 60 mg/capsule, BID
11493370|NCT01401517|Experimental|40 mg Sodium Nitrite|40 mg dose, BID
11493371|NCT01401517|Experimental|80 mg Sodium Nitrite|80 mg dose, BID
11493372|NCT01401504|Experimental|ASP3026|
11493373|NCT01401491|Active Comparator|clozapine + fluvoxamine|
11493374|NCT01401491|Placebo Comparator|clozapine + placebo|
11493375|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
11493376|NCT01401465|Experimental|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
11493377|NCT01401465|Active Comparator|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
11493378|NCT01401452||Participants with psoriasis and at least one co-morbid disease|Participants with moderate to severe plaque psoriasis with at least one co-morbid disease and/or symptom such as hypertension, psoriatic arthritis confirmed by a rheumatologist or other appropriate specialist, obesity, diabetes, metabolic syndrome or depression
11493379|NCT01401426|Active Comparator|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
11493380|NCT01401426|Active Comparator|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
11493381|NCT01401413|Placebo Comparator|1|placebo control nightly
11493382|NCT01401413|Active Comparator|2|8 mg ramelteon nightly
11493383|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
11493384|NCT01401387|Active Comparator|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
11493385|NCT01401387|Active Comparator|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
11493386|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
11493387|NCT01401374||Controls|Individuals without vitiligo vulgaris
11493388|NCT01401361|Experimental|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
11493392|NCT01401296|Experimental|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
11493393|NCT01401283|Active Comparator|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
11493394|NCT01401283|No Intervention|Control group|hemodynamic management according to institutional clinical standards
11493395|NCT01401270|No Intervention|Treatment Group A|Standard Care
11493396|NCT01401270|Experimental|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
11493397|NCT01401270|Experimental|Treatment Group C|31% probability of winning and has 3 prize categories
11493398|NCT01401270|Experimental|Treatment Group D|100% probability of winning and has 7 prize categories
11493399|NCT01401270|Experimental|Treatment Group E|31% probability of winning and has 7 prize categories
11493400|NCT01401270|Experimental|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
11493401|NCT01401257|Experimental|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
11493402|NCT01401257|Experimental|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
11493403|NCT01401257|Experimental|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
11493404|NCT01401257|Placebo Comparator|Placebo|Oral Liquid formulation, bid, 12 months
11493405|NCT01401244|Experimental|Norditropin®|
11493406|NCT01401244|Active Comparator|Genotropin®|
11493407|NCT01401231|Experimental|Behavioral Activation|Behavioral activation psychotherapy
11493408|NCT01401231|Placebo Comparator|Usual Care|Continued care as usual
11493409|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
11493410|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
11493411|NCT01401192|Experimental|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
11493412|NCT01401192|Active Comparator|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
11493413|NCT01401192|Active Comparator|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
11493414|NCT01401192|Experimental|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
11493415|NCT01401179|Active Comparator|cefazolin|
11493416|NCT01401179|Active Comparator|cefazolin plus erythromycin|cefazolin, erythromycin
11493417|NCT01401179|Active Comparator|cefazolin plus clarithromycin|
11493418|NCT01401166|Experimental|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
11493419|NCT01401166|Experimental|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
11493420|NCT01401166|Experimental|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
11493421|NCT01401166|Experimental|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
11493422|NCT01401153|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
11493423|NCT01401153|Experimental|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
11493424|NCT01401140|Active Comparator|St Thomas|
11493425|NCT01401140|Experimental|Custodiol|
11493426|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
11493427|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
11493428|NCT01401114||Group 1|Drug (incl. Placebo)
11493429|NCT01401101|Experimental|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
11493430|NCT01401101|Placebo Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
11493431|NCT01401088|Experimental|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
11493432|NCT01401075|Active Comparator|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
11493433|NCT01401075|Experimental|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
11493434|NCT01401062|Experimental|Arm 1 (Fresolimumab 1 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
11493435|NCT01401062|Experimental|Arm 2 (Fresolimumab 10 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
11493436|NCT01401049|Experimental|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
11493437|NCT01401049|Active Comparator|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
11493438|NCT01401036|Active Comparator|Nobori|subjects receiving Biolimus A9 eluting stent implantation
11493439|NCT01401036|Sham Comparator|Uncoated stents|subjects receiving uncoated stent implantation
11493440|NCT01401023|Experimental|Clostridium difficile Patient|Open non-comparative trial
11493441|NCT01401010|Active Comparator|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
11493442|NCT01401010|Active Comparator|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
11493443|NCT01400971||MOSAIc Participants|Participants enrolled in Multinational Observational Study Assessing Insulin use (MOSAIc) who had complete treatment data during the study.
11493444|NCT01400958|Active Comparator|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
11493445|NCT01400958|Placebo Comparator|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
11493446|NCT01400945|Experimental|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
11493447|NCT01400932|Experimental|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
11493448|NCT01400932|Placebo Comparator|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
11493449|NCT01400919|Experimental|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
11493450|NCT01400906|Placebo Comparator|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
11493451|NCT01400893|Experimental|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
11493452|NCT01400893|No Intervention|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
11493453|NCT01400880||Pregnant|In Labor
11493454|NCT01400867|Experimental|Ceftaroline fosamil|
11493455|NCT01400867|Active Comparator|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
11493456|NCT01400854||Effentora®|Single group prospective treatment cohort
11493457|NCT01400841|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
11493458|NCT01400828|Experimental|Bilastine|Intervention: Drug: Bilastine
11493459|NCT01400828|Active Comparator|Desloratadine|Intervention: Drug: Desloratadine
11493460|NCT01400828|Placebo Comparator|Placebo|Intervention: Drug: Placebo
11493461|NCT01400815|Experimental|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
11493462|NCT01400815|Active Comparator|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
11493463|NCT01400802|Experimental|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
11493464|NCT01400802|Active Comparator|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
11493465|NCT01400789|Experimental|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
11493507|NCT01400490|Active Comparator|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
11493466|NCT01400789|Active Comparator|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
11493467|NCT01400776|Experimental|Vaginal Gel Three Times Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 3X/week for 10 weeks
11493468|NCT01400776|Placebo Comparator|Vehicle Twice Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 2X/week for 10 weeks
11493469|NCT01400776|Experimental|Vaginal Gel Twice Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 2X/week for 10 weeks
11493470|NCT01400776|Placebo Comparator|Vehicle Three Times Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 3X/week for 10 weeks
11493471|NCT01400750|Active Comparator|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
11493472|NCT01400750|Active Comparator|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
11493473|NCT01400737|Experimental|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
11493474|NCT01400724|Experimental|Inofolic NRT|
11493475|NCT01400711|Active Comparator|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
11493476|NCT01400711|Active Comparator|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
11493477|NCT01400698|Experimental|Saizen® (Continuous or intermittent treatment)|
11493478|NCT01400698|Experimental|Saizen® (Observed and then continuous or no treatment)|
11493479|NCT01400698|Other|Observation only|
11493480|NCT01400672|Experimental|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
11493481|NCT01400659|Active Comparator|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
11493482|NCT01400659|Active Comparator|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
11493483|NCT01400646|Experimental|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for >= 2 to <= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
11493484|NCT01400646|Experimental|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for >=2 to <=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
11493485|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
11493486|NCT01400620|Experimental|Active oral rinse|Oral rinse containing botanical extracts
11493487|NCT01400620|Placebo Comparator|Placebo rinse|
11493488|NCT01400607|Active Comparator|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
11493489|NCT01400607|Other|Microfracture|Standard of care cartilage repair technique.
11493490|NCT01400594|Experimental|HTU-520 Patch|Subjects will receive HTU-520 patch in a 1:1 ratio for 48 weeks applied to all toenails.
11493491|NCT01400594|Placebo Comparator|Placebo Patch|Subjects will receive placebo patch in a 1:1 ratio for 48 weeks applied to all toenails.
11493492|NCT01400581|Experimental|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
11493493|NCT01400581|No Intervention|Usual Care|Observational
11493494|NCT01400568|Experimental|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
11493495|NCT01400555|Experimental|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
11493496|NCT01400555|Experimental|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
11493497|NCT01400555|Experimental|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
11493498|NCT01400555|Experimental|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
11493499|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
11493500|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
11493501|NCT01400516|Experimental|Teriparatide|The participants who are in treatment arm received teriparatide 20 μg, subcutaneous injection, 1 injection per day, with a biologic for 12 months. A second year of teriparatide was offered to all interested participants. All participants received daily 1000 milligrams (mg) of calcium citrate, 800 IU of vitamin D and a Tumor Necrosis Factor (TNF) antagonist.
11493502|NCT01400516|Other|Control Arm|The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
11493503|NCT01400503|Experimental|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
11493504|NCT01400490|Placebo Comparator|Olive Oil 6 grams/day|
11493505|NCT01400490|Active Comparator|DHA 1800 mg/day|
11493506|NCT01400490|Active Comparator|EPA 1800 mg/day|
11493508|NCT01400477|Experimental|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
11493509|NCT01400477|Placebo Comparator|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
11493510|NCT01400451|Experimental|Ipilimumab + Vemurafenib|
11493511|NCT01400438|Experimental|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
11493512|NCT01400438|Active Comparator|Control group|patient not beginning Herceptin after chemotherapy : control group
11493513|NCT01400425|Experimental|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
11493514|NCT01400412|Experimental|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
11493515|NCT01400412|Experimental|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
11493516|NCT01400386|Experimental|Soluble coffee 1|
11493517|NCT01400386|Experimental|Soluble coffee 2|
11493518|NCT01400386|Experimental|Soluble coffee 3|
11493519|NCT01400386|Experimental|Soluble coffee 4|
11493520|NCT01400373|No Intervention|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
11493521|NCT01400373|Experimental|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
11493522|NCT01400360|Active Comparator|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
11493523|NCT01400360|No Intervention|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
11493524|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy [pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
11493525|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
11493526|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
11493527|NCT01400308|Active Comparator|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
11493528|NCT01400308|Experimental|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
11493529|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
11493530|NCT01400282|Other|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
11493531|NCT01400282|Other|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
11493532|NCT01400269|Experimental|Pacific Autism Center for Education (PACE)|Behavioral: Pacific Autism Center for Education (PACE) developmentally based parent delivered intervention
11493533|NCT01400243|Placebo Comparator|Placebo Patch|Placebo patch for 15-day quit period
11493534|NCT01400243|Active Comparator|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
11493535|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
11493536|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
11493537|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
11493538|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
11493539|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
11493540|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
11493541|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
11493542|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
11493543|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
11493544|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
11493545|NCT01400191|Active Comparator|Homozygote wildtype OCT1|
11493546|NCT01400191|Active Comparator|Heterozygote OCT1|
11493547|NCT01400191|Active Comparator|Homozygote OCT1 variant|
11493548|NCT01400165|Active Comparator|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
11493549|NCT01400165|Active Comparator|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
11493602|NCT01399814|Active Comparator|standard fluid regimen group|perioperative fluid treatment
11493603|NCT01399814|Experimental|restricted fluid regimen group|perioperative fluid treatment
11493550|NCT01400165|Active Comparator|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
11493551|NCT01400152|Active Comparator|Passive warming with additional active warming|
11493552|NCT01400152|No Intervention|Passive warming|
11493553|NCT01400139|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
11493554|NCT01400113|Experimental|Asenapine|This group received 10mg asenapine sl x 1 dose
11493555|NCT01400113|Placebo Comparator|Placebo|This group received placebo sl x 1 dose
11493556|NCT01400100|Experimental|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
11493557|NCT01400100|Placebo Comparator|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
11493558|NCT01400087|Active Comparator|Cap-attached Colonoscopy|
11493559|NCT01400087|Placebo Comparator|Regular colonoscopy|
11493560|NCT01400074|Active Comparator|Nilotinib|400 mg twice daily
11493561|NCT01400074|Active Comparator|Imatinib|400 mg twice daily
11493562|NCT01400061||normal|body mass index: 19-24
11493563|NCT01400061||overweight|body mass index: 25-29
11493564|NCT01400061||obesity|body mass index: 30-40
11493565|NCT01400061||modbid obes|body mass index: over 40
11493566|NCT01400048|Active Comparator|Aloe vera effervescent tablet (AVH200)|
11493567|NCT01400048|Placebo Comparator|Placebo|
11493568|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.
~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
11493569|NCT01400022|Active Comparator|Cortisone|
11493570|NCT01400022|Experimental|UVA1 phototherapy|
11493571|NCT01400009|Placebo Comparator|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
11493572|NCT01400009|Active Comparator|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
11493573|NCT01399996|Placebo Comparator|Yogurt smoothie without probiotic.|
11493574|NCT01399996|Experimental|Probiotic added post fermentation.|
11493575|NCT01399996|Experimental|Probiotic added pre-fermentation.|
11493576|NCT01399996|Experimental|A capsule containing the probiotic.|
11493577|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
11493578|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Conventional in Office Care
11493579|NCT01399970|Experimental|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
11493580|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
11493581|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
11493582|NCT01399918|Experimental|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
11493583|NCT01399905|Experimental|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
11493584|NCT01399905|Experimental|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
11493585|NCT01399879||Healthy Volunteers|
11493586|NCT01399866|Placebo Comparator|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
11493587|NCT01399866|Active Comparator|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
11493588|NCT01399853|Experimental|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
11493589|NCT01399853|Experimental|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
11493590|NCT01399853|Experimental|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
11493591|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
11493592|NCT01399853|Experimental|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
11493593|NCT01399853|Experimental|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
11493594|NCT01399853|Experimental|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
11493595|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
11493596|NCT01399853|Placebo Comparator|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
11493597|NCT01399853|Placebo Comparator|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
11493598|NCT01399840|Experimental|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
11493599|NCT01399840|Experimental|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
11493600|NCT01399827|Active Comparator|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
11493601|NCT01399827|Placebo Comparator|Placebo|
11493604|NCT01399801|Experimental|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
11493605|NCT01399801|Active Comparator|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
11493606|NCT01399788|Active Comparator|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
11493607|NCT01399788|Active Comparator|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
11493608|NCT01399775|Experimental|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
11493609|NCT01399775|Other|Delayed implantation|Four months after extraction, Dental implant is inserted.
11493610|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
11493611|NCT01399749|Experimental|Autologous ASC implantation|Treatment with autologous ASC
11493612|NCT01399749|Active Comparator|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
11493613|NCT01399736|Active Comparator|FFR-guided revascularisation strategy|In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of >0.80 will not be treated.
11493614|NCT01399736|Placebo Comparator|randomised to guidelines group|In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
11493615|NCT01399723|Experimental|Amoxicillin 45mg/kg 12 hourly|
11493616|NCT01399723|Active Comparator|Benzyl Penicillin 50,000IU/kg 6 hourly|
11493617|NCT01399697|Experimental|A|
11493618|NCT01399697|Active Comparator|B|
11493619|NCT01399684|Experimental|MEGF0444A + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A + mFOLFOX-6 (oxaliplatin, folinic acid, and 5-fluorouracil) regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles (Cycle = 14 days) and 5-fluorouracil, folinic acid, bevacizumab and MEGF0444A will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
11493620|NCT01399684|Placebo Comparator|Placebo + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A matching placebo + mFOLFOX-6 regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles and 5-fluorouracil, folinic acid, bevacizumab and placebo will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
11493621|NCT01399658|Experimental|Image-Guided Brachytherapy|Image-guided brachytherapy
11493622|NCT01399645|Experimental|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.
~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
11493623|NCT01399645|Experimental|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.
~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
11493624|NCT01399632|Experimental|High Fat and Low Carbohydrate Diet|
11493625|NCT01399632|Experimental|Low Fat and High Carbohydrate Diet|
11493626|NCT01399619|Experimental|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
11493627|NCT01399619|Experimental|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
11493628|NCT01399619|Experimental|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
11493629|NCT01399606|Experimental|BF2.649|
11493630|NCT01399593|Experimental|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
11493631|NCT01399593|No Intervention|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
11493632|NCT01399580|Placebo Comparator|Group A - Placebo QD|
11493633|NCT01399580|Active Comparator|Group B - Low dose Atrasentan QD|
11493634|NCT01399580|Active Comparator|Group C - High dose Atrasentan QD|
11493635|NCT01399567|Experimental|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
11493636|NCT01399567|Active Comparator|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
11493637|NCT01399554|No Intervention|Assessment Only|
11493638|NCT01399554|Experimental|Weekly Exercise Counseling Intervention|
11493639|NCT01399541||Under and over 65 years|
11493640|NCT01399528||Beaumont Hospital, Dublin, Ireland|
11493641|NCT01399528||St. James' Hospital, Dublin, Ireland|
11493642|NCT01399528||Hôpital Erasme, Brussels, Belgium|
11493643|NCT01399528||Duke Medical Centre, North Carolina, USA|
11493644|NCT01399528||The Institute of Neurology/University College London, UK|
11493645|NCT01399515|Active Comparator|Valproic acid|
11493646|NCT01399515|No Intervention|Control|
11493647|NCT01399502|Active Comparator|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
11493648|NCT01399502|Placebo Comparator|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
11493649|NCT01399489|Experimental|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
11493650|NCT01399489|No Intervention|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
11493651|NCT01399476|Experimental|Endoscopic Myotomy|
11493652|NCT01399463|Experimental|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
11493653|NCT01399463|Active Comparator|Stenting with commonly used Drug Eluting Stents (DES)|
11493654|NCT01399450|Experimental|paliperidone add on|paliperidone add on
11493655|NCT01399411||AHS Cohort|licensed pesticide applicators and their spouses from Iowa and North Carolina already enrolled in the Agricultural Health Study (AHS)
11493656|NCT01399385|Experimental|Group 1|will consist of subjects with a 10-year total CHD risk <10% (low)
11493657|NCT01399385|Experimental|Group 2|will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)
11493658|NCT01399385|Experimental|Group 3|will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)
11493659|NCT01399385|Experimental|Group 4|no known risk factors (control subjects)
11493660|NCT01399372|Active Comparator|Arm I|Patients receive rituximab IV over 5 hours or per institutional guidelines on days 1 and 15, methotrexate IV over 2 hours on days 2 and 16, vincristine sulfate IV on days 2 and 16 (of courses 1 and 2 only), and procarbazine hydrochloride orally (PO) on days 2-8. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive consolidation therapy comprising cytarabine IV over 3 hours on days 1-2. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11493661|NCT01399372|Experimental|Arm II|Patients receive rituximab, methotrexate, vincristine sulfate, and procarbazine hydrochloride as in arm I. After completing chemotherapy, patients without progressive disease undergo low-dose whole brain radiotherapy once daily, 5 days a week, for approximately 2.5 weeks (13 fractions total). Patients then receive consolidation cytarabine as in arm I.
11493662|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
11493663|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
11493664|NCT01399346|Experimental|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
11493665|NCT01399346|Experimental|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
11493666|NCT01399333|Active Comparator|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
11493667|NCT01399333|Active Comparator|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
11493668|NCT01399333|Active Comparator|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
11493669|NCT01399320|Experimental|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
11493670|NCT01399307|Other|Elective Liposuction|
11493671|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
11493672|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
11493673|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
11493674|NCT01399268|Experimental|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
11493675|NCT01399268|Placebo Comparator|Control|Saline IV Q8hr x3
11493676|NCT01399255|Experimental|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
11493677|NCT01399255|Active Comparator|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
11493678|NCT01399242|Active Comparator|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
11493679|NCT01399242|No Intervention|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
11493680|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
11493681|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
11493682|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
11493683|NCT01399216|Experimental|Fucoidan supplement|
11493684|NCT01399216|Placebo Comparator|Placebo|
11493760|NCT01398592|Active Comparator|Sitagliptin|Active comparator (drug)
11493685|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
11493686|NCT01399190||Bevacizumab|Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.
11493687|NCT01399164|Experimental|Fortified Bread|A single serving of 14C-B12 fortified bread
11493688|NCT01399151|Experimental|Vitamin D - Treatment 1|400 IU/day Vitamin D
11493689|NCT01399151|Experimental|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
11493690|NCT01399151|Experimental|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
11493691|NCT01399138|Experimental|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
11493692|NCT01399138|Placebo Comparator|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
11493693|NCT01399125|Experimental|Rivastigmine patch|Once-daily target patch size 10 cm²
11493694|NCT01399125|Active Comparator|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
11493695|NCT01399112|Experimental|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
11493696|NCT01399112|Active Comparator|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.
~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
11493697|NCT01399099|Experimental|All Study Participants|Half of the abdomnioplasty incision was treated with the embrace device. Half of the abdomnioplasty incision was treated according to the investigator's standard of care. Participant served as his own control.
11493698|NCT01399086||Fulvestrant|
11493699|NCT01399073||Patients with Neglect|
11493700|NCT01399073||Patients with Hemianopsia|
11493701|NCT01399073||Healthy age-matched controls|
11493702|NCT01399047|Active Comparator|Mycophenolate Mofetil|
11493703|NCT01399047|Placebo Comparator|Placebo liquid|
11493704|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
11493705|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
11493706|NCT01399021|Other|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
11493707|NCT01399008|Experimental|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
11493708|NCT01399008|Experimental|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
11493709|NCT01399008|Active Comparator|Allopurinol|Placebo plus Allopurinol 300 mg
11493710|NCT01398995|Experimental|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
11493711|NCT01398995|Experimental|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
11493712|NCT01398995|Experimental|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
11493713|NCT01398995|Experimental|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
11493714|NCT01398982|Placebo Comparator|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
11493715|NCT01398982|Experimental|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
11493716|NCT01398969|Experimental|Fresh Human Biotherapy|Patients in this arm will receive Fresh HBT enema. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
11493717|NCT01398969|Experimental|Frozen-and-Thawed Human Biotherapy|Patients in this arm will receive Frozen-and-Thawed HBT enema. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
11493718|NCT01398956|Experimental|Levetiracetam|Twice daily (morning and evening) orally
11493761|NCT01398579|Active Comparator|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
11493762|NCT01398579|Active Comparator|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
11493763|NCT01398566|Experimental|Gaming|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
11493764|NCT01398553|Experimental|Armeo Spring|
11493765|NCT01398553|Active Comparator|conventional physiotherapy|
11495174|NCT01388699||control group|healthy women without headache syndrome
11493719|NCT01398943|Experimental|COPD Patients|"Patients with COPD
~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
11493720|NCT01398943|Experimental|Controls|"Healthy age- and sex- matched controls
~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
11493721|NCT01398930|Active Comparator|Group I was treated with etoricoxib|
11493722|NCT01398930|Active Comparator|Group II was treated with acupuncture and etoricoxib|
11493723|NCT01398930|Sham Comparator|Group III was treated with sham acupuncture and etoricoxib.|
11493724|NCT01398917|Active Comparator|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
11493725|NCT01398917|Active Comparator|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
11493726|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
11493727|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
11493728|NCT01398891|Experimental|Positive Psychology Exercises|
11493729|NCT01398878|No Intervention|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
11493730|NCT01398878|Active Comparator|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
11493731|NCT01398852|Experimental|CXL Treatment|All eyes to be treated with riboflavin and UV light
11493732|NCT01398839|Sham Comparator|Sham Control|
11493733|NCT01398839|Experimental|CXL Treatment|
11493734|NCT01398787|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
11493735|NCT01398787|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
11493736|NCT01398761|Experimental|Intervention|nurses, residents, PAs, and attendings from the two pilot services
11493737|NCT01398748|Active Comparator|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
11493738|NCT01398748|Active Comparator|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
11493739|NCT01398748|Placebo Comparator|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
11493740|NCT01398748|No Intervention|Watchful waiting|No intervention, watchful waiting only (n=4)
11493741|NCT01398722|Active Comparator|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
11493742|NCT01398722|Active Comparator|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
11493743|NCT01398709|Active Comparator|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
11493744|NCT01398709|Active Comparator|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
11493745|NCT01398696|Active Comparator|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
11493746|NCT01398696|Placebo Comparator|usual consultation without PIL|no particular intervention during consultation for the patient.
11493747|NCT01398670|Experimental|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
11493748|NCT01398670|Active Comparator|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
11493749|NCT01398657|Experimental|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
11493750|NCT01398657|No Intervention|No adjuvant therapy|Cryotherapy without any adjuvant therapy
11493751|NCT01398644|Active Comparator|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level >50 ug/l
11493752|NCT01398644|Experimental|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level >50ug/l
11493753|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
11493754|NCT01398618|Experimental|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
11493755|NCT01398618|Active Comparator|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
11493756|NCT01398605|Experimental|moderate exercise training|
11493757|NCT01398605|Experimental|intensive exercise training|
11493758|NCT01398605|No Intervention|Control|
11493759|NCT01398592|Experimental|Vildagliptin|Experimental
11493766|NCT01398540|Experimental|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
11493767|NCT01398540|Experimental|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
11493768|NCT01398527|No Intervention|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
11493769|NCT01398527|Active Comparator|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
11493770|NCT01398514|Experimental|Active medication|Escitalopram 10mg/day
11493771|NCT01398514|Placebo Comparator|Placebo|Matched pill placebo
11493772|NCT01398501|Experimental|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
11493773|NCT01398488|Active Comparator|Conventional Patient education|Conventional Patient education by health care professionals.
11493774|NCT01398488|Experimental|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
11493775|NCT01398475|Experimental|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
11493776|NCT01398475|Experimental|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
11493777|NCT01398475|Experimental|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
11493778|NCT01398475|Experimental|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
11493779|NCT01398462|Experimental|CWP232291|
11493780|NCT01398449|Experimental|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
11493781|NCT01398449|Active Comparator|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
11493782|NCT01398436|Experimental|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
11493783|NCT01398436|No Intervention|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
11493784|NCT01398423|Active Comparator|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
11493785|NCT01398423|Experimental|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
11493786|NCT01398410|Experimental|Rabeprazole 5 mg|
11493787|NCT01398410|Experimental|Rabeprazole 10 mg|
11493788|NCT01398384|Active Comparator|Nitric Oxide|nitric oxide for inhalation
11493789|NCT01398384|Placebo Comparator|Placebo|inhalation gas
11493790|NCT01398371|Active Comparator|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
11493791|NCT01398371|Experimental|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
11493792|NCT01398358|No Intervention|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
11493793|NCT01398358|Experimental|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
11493794|NCT01398358|Experimental|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
11493795|NCT01398345|Active Comparator|Exercise and Respiratory Training|
11493796|NCT01398332||Aortic pathologies|Indication for aortic endovascular stent graft repair
11493797|NCT01398319|Other|Group Brief Alcohol Intervention|The number of alcohol related incidents for the year prior the initiation of the BAI will be compared to the number of alcohol related incidents when Airmen were exposed to the BAI
11493798|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
11493799|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
11493800|NCT01398293|Experimental|A|
11493801|NCT01398293|Experimental|B|
11493802|NCT01398293|Active Comparator|C|
11493803|NCT01398293|Placebo Comparator|D|
11493804|NCT01398280|Experimental|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
11493805|NCT01398280|Placebo Comparator|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
11493806|NCT01398267|Experimental|1|
11493807|NCT01398267|Placebo Comparator|2|
11493812|NCT01398228|Other|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
11493813|NCT01398228|Other|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
11493814|NCT01398228|Other|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
11493815|NCT01398228|Other|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
11493816|NCT01398215||transvaginal NOTES|
11493817|NCT01398202|Active Comparator|Vitamin D3 (20 microgram/day)|
11493818|NCT01398202|Active Comparator|25-hydroxyvitamin D (7 microgram/day)|
11493819|NCT01398202|Active Comparator|25-hydroxyvitamin D3 (20 micogram/day)|
11493820|NCT01398202|Placebo Comparator|Placebo|
11493821|NCT01398189|Experimental|clozapine|patients with refractory schizophrenia or schizoaffective disorder
11493822|NCT01398176|Experimental|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
11493823|NCT01398176|Experimental|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
11493824|NCT01398163|Experimental|1 = Tested product|
11493825|NCT01398163|Active Comparator|2 = Control product|
11493826|NCT01398163|No Intervention|3 = No product|
11493827|NCT01398150|Placebo Comparator|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
11493828|NCT01398150|Experimental|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
11493829|NCT01398137||Ragweed allergic subjects|
11493830|NCT01398111|Active Comparator|Treatment R2|
11493831|NCT01398111|Active Comparator|Treatment R1|
11493832|NCT01398111|Placebo Comparator|Placebo|
11493833|NCT01398111|Experimental|Treatment T|
11493834|NCT01398098|Experimental|COLOKIT®|
11493835|NCT01398085|Active Comparator|Radioactive iodine (RAI) ablation Arm|Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq
11493836|NCT01398085|No Intervention|No Radioactive iodine (No-RAI) ablation|Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation
11493837|NCT01398072|Active Comparator|Moxifloxacin|
11493838|NCT01398072|Active Comparator|Azithromycin|
11493839|NCT01398072|Active Comparator|Doxycycline|
11493840|NCT01398072|Placebo Comparator|Placebo|
11493841|NCT01398059|Experimental|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
11493842|NCT01398059|Experimental|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
11493843|NCT01398059|Experimental|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
11493844|NCT01398046|Active Comparator|Dasatinib|
11493845|NCT01398046|Experimental|Dasatinib plus Rabeprazole|
11493846|NCT01398046|Experimental|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
11493847|NCT01398033|Active Comparator|Drug-coated balloon|"pre-dilatation of the target lesion with a non-coated balloon.
~treatment of the target lesion with the paclitaxel-coated balloon"
11493848|NCT01398033|Placebo Comparator|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
11493849|NCT01398020|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
11493850|NCT01398020|Experimental|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
11493851|NCT01398007|No Intervention|Conventional syringe|Conventional syringe
11493852|NCT01398007|Experimental|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
11493853|NCT01397994|Active Comparator|Nicorandil test arm|Nicorandil is given with atenolol therapy.
11493854|NCT01397994|Active Comparator|Atenolol control arm|Atenolol 50 mg OD is given.
11493855|NCT01397981|Experimental|Walking modification|Changing kinematics for walking
11493856|NCT01397968|Experimental|YKP3089|
11493857|NCT01397968|Placebo Comparator|Placebo|
11493858|NCT01397955||Group 1|Drug (incl. Placebo)
11493859|NCT01397942|Experimental|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
11493860|NCT01397942|No Intervention|Control Nordic diet|A diet habitually consumed in the Nordic countries
11493861|NCT01397942|Experimental|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
11493862|NCT01397929|Experimental|Drug: BAL101553 at MTD|
11493863|NCT01397929|Experimental|Drug: BAL101553 at 50% of MTD|
11493864|NCT01397916||CLL-patients|
11493865|NCT01397916||Controls|
11493866|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.
~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
11493867|NCT01397890|Other|1|Add-on treatment
11493868|NCT01397890|Other|2|Add-on treatment
11493869|NCT01397877|Experimental|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
11493870|NCT01397864||Hereditary Angioedema|
11493939|NCT01397409|Experimental|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
11493871|NCT01397851|Experimental|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
11493872|NCT01397851|No Intervention|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
11493873|NCT01397838|Experimental|Pro-Bone|
11493874|NCT01397825|Experimental|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
11493875|NCT01397825|Experimental|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
11493876|NCT01397825|Experimental|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
11493877|NCT01397825|Experimental|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
11493878|NCT01397825|Experimental|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV on Days 1 & 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
11493879|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.
~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
11493880|NCT01397799|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
11493881|NCT01397786|Experimental|OPC-34712|
11493882|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
11493883|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
11493884|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
11493885|NCT01397773||Control group|Healthy subjects
11493886|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
11493887|NCT01397734|Experimental|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
11493888|NCT01397734|Experimental|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
11493889|NCT01397734|Experimental|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
11493890|NCT01397708|Experimental|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
11493891|NCT01397695|Experimental|bevacizumab|
11493892|NCT01397669|Other|HIV infection and non HIV infection|
11493893|NCT01397656|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations followed by cross-over to CPR with Continuous Compressions
11493894|NCT01397656|Active Comparator|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation followed by CPR 30:2 (30 chest compressions to 2 ventilations)
11493895|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
11493896|NCT01397643|Other|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
11493897|NCT01397630|Experimental|Accelerated Oxytocin Titration|
11493898|NCT01397630|Active Comparator|Gradual Oxytocin Titration|
11493899|NCT01397617|Experimental|NobelActive Internal|NobelActive Internal implant
11493900|NCT01397617|Experimental|NobelActive External|NobelActive External implant
11493901|NCT01397617|Active Comparator|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
11493902|NCT01397604|No Intervention|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.
~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
11493940|NCT01397409|Experimental|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
11493941|NCT01397409|Experimental|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
11494086|NCT01396317|Experimental|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
11493903|NCT01397604|Placebo Comparator|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.
~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.
~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
11493904|NCT01397604|Active Comparator|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.
~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.
~GLA-AF contains the study drug in an aqueous solution."
11493905|NCT01397604|Active Comparator|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.
~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.
~GLA-SE contains the study drug in a squalene oil emulsion."
11493906|NCT01397591|Experimental|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
11493907|NCT01397578|Experimental|Part 1: Subcutaneous cohort exp|
11493908|NCT01397578|Experimental|Part 2: Intravenous cohort exp|
11493909|NCT01397578|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
11493910|NCT01397578|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous injection
11493911|NCT01397565|Active Comparator|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
11493912|NCT01397565|Experimental|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
11493913|NCT01397552|Active Comparator|Dexamethasone|Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
11493914|NCT01397552|Active Comparator|methylprednisolone acetate|Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded
11493915|NCT01397539|Experimental|BIIB037|A single dose of BIIB037 by intravenous infusion.
11493916|NCT01397539|Placebo Comparator|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
11493917|NCT01397513|Active Comparator|Aspirin 75mg|
11493918|NCT01397513|Active Comparator|Aspirin 320mg|
11493919|NCT01397500|Active Comparator|Genotropin|"6 months Genotropin (open treatment)
~Daily dose:
~Male < 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female < 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
11493920|NCT01397500|Active Comparator|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
11493921|NCT01397500|No Intervention|control group|No Intervention.
11493922|NCT01397487|Other|one single arm|All patients are included to complete a biopsy of half part of the embryos
11493923|NCT01397474|No Intervention|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
11493924|NCT01397474|Experimental|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
11493925|NCT01397461|Experimental|ozenoxacin 1% cream|1% cream
11493926|NCT01397461|Placebo Comparator|ozenoxacin placebo|cream
11493927|NCT01397461|Active Comparator|retapamulin 1% ointment|1% ointment
11493928|NCT01397448|Experimental|E3810 5 mg|
11493929|NCT01397448|Experimental|E3810 10 mg|
11493930|NCT01397448|Active Comparator|Teprenone 150 mg|
11493931|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
11493932|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
11493933|NCT01397422|Placebo Comparator|Treatment A|
11493934|NCT01397422|Active Comparator|Treatment B|Low dose ADS-5102 (amantadine extended release)
11493935|NCT01397422|Active Comparator|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
11493936|NCT01397422|Active Comparator|Treatment D|High dose ADS-5102 (amantadine extended release)
11493937|NCT01397409|Experimental|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
11493938|NCT01397409|Experimental|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
11493942|NCT01397409|Experimental|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
11493943|NCT01397409|Active Comparator|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
11493944|NCT01397409|Experimental|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
11493945|NCT01397409|Experimental|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
11493946|NCT01397409|Active Comparator|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
11493947|NCT01397396|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
11493948|NCT01397396|Placebo Comparator|Sham IMT|Sham Inspiratory Muscle Training
11493949|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D < 32 ng/ml)
11493950|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D > 32 ng/ml)
11493951|NCT01397370|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
11493952|NCT01397370|Placebo Comparator|Placebo oral solution|Once daily dosing for 14 days
11493953|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
11493954|NCT01397331|Active Comparator|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
11493955|NCT01397331|Active Comparator|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
11493956|NCT01397318||Experimental Group|
11493957|NCT01397318||Control Group|
11493958|NCT01397305|Experimental|Modufolin and Pemetrexed|Modufolin ( [6R] 5,10-methylenetetrahydrofolate) and Pemetrexed
11493959|NCT01397279|Active Comparator|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
11493960|NCT01397279|Active Comparator|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
11493961|NCT01397266|Active Comparator|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
11493962|NCT01397266|Placebo Comparator|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
11493963|NCT01397253|No Intervention|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
11493964|NCT01397253|Experimental|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
11493965|NCT01397240|Experimental|Albis|Drug: Albis Tab 2 tab, twice a day
11493966|NCT01397240|Placebo Comparator|Placebo|Placebo 2 tab, twice a day
11493967|NCT01397227|Experimental|Cohort 1 (Low Dose)|Ad35.CS.01/Ad26.CS.01 - 1 x 10^10 vp
11493968|NCT01397227|Experimental|Cohort 2 (High Dose)|Ad35.CS.01/Ad26.CS.01 - 5 x 10^10 vp
11493969|NCT01397227|Placebo Comparator|Cohort 1 - Placebo|
11493970|NCT01397227|Placebo Comparator|Cohort 2 - Placebo|
11493971|NCT01397214|Experimental|Megace F|Megace F oral suspension
11493972|NCT01397214|Active Comparator|Megace OS|Megace acetate oral suspension
11493973|NCT01397201|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
11493974|NCT01397201|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
11493975|NCT01397201|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
11493976|NCT01397201|Active Comparator|Fluticasone propionate 220mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 220 mcg ICS plus placebo matching Respimat inhaler
11493977|NCT01397201|Placebo Comparator|Placebo|patient to receive placebo matching Respimat inhaler plus placebo matching HFA MDI inhaler
11493978|NCT01397188|Experimental|PiCCO group|Intervention: Device: Picco- thermodilution catheter
11493979|NCT01397188|Sham Comparator|sham group|No PiCCO Intervention
11493980|NCT01397175|Active Comparator|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
11493981|NCT01397175|Active Comparator|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
11493982|NCT01397175|Active Comparator|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
11493983|NCT01397162|Experimental|BI 54903 LD BID|BI 54903 low dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
11493984|NCT01397162|Experimental|BI 54903 MD BID|BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
11493985|NCT01397162|Experimental|BI 54903 HD BID|BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
11493986|NCT01397162|Active Comparator|Fluticasone propionate 88 mcg BID|44 mcg Fluticasone propionate 2 puffs BID via HFA MDI plus placebo BI54903 via Respimat inhaler 2 puffs b.i.d.
11493987|NCT01397162|Placebo Comparator|Placebo|Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.
11493988|NCT01397149|Experimental|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
11493989|NCT01397149|Placebo Comparator|Film coated tablet|
11493990|NCT01397123|Experimental|Lifestyle counseling|
11494080|NCT01396369|Active Comparator|Birth control|
11494081|NCT01396369|Experimental|Birth control plus Brevail|
11494082|NCT01396356||ablation procedure|
11494226|NCT01395368||Brain Speed Test|Brain Speed Test
11493991|NCT01397110|Active Comparator|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
11493992|NCT01397110|No Intervention|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.
~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
11493993|NCT01397097|Experimental|Arm 1|
11493994|NCT01397097|Active Comparator|Arm 2|
11493995|NCT01397084|Other|esomeprazole 20 mg|esomeprazole 20 mg
11493996|NCT01397071|Active Comparator|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
11493997|NCT01397071|Active Comparator|Ground Beef Patty without Avocado|Test burgers
11493998|NCT01397045|Active Comparator|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
11493999|NCT01397045|Other|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
11494000|NCT01397032|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
11494001|NCT01397032|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
11494002|NCT01397019|Experimental|FOLFIRINOX|
11494003|NCT01397006|Experimental|Pregabalin|
11494004|NCT01397006|Placebo Comparator|Placebo|
11494005|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
11494006|NCT01396993||BCT|patients undergoing conservative breast surgery
11494007|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
11494008|NCT01396941|Experimental|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
11494009|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
11494010|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
11494011|NCT01396915||High or Normal Dietary Protein Intake|
11494012|NCT01396902|Active Comparator|Standard of care|
11494013|NCT01396902|Experimental|Text Messaging|
11494014|NCT01396889|Experimental|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
11494015|NCT01396889|Placebo Comparator|Placebo|Placebo
11494016|NCT01396876|Active Comparator|Clown|A clown is present during venipuncture
11494017|NCT01396876|No Intervention|No clown|
11494018|NCT01396863|Active Comparator|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
11494019|NCT01396863|Active Comparator|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
11494020|NCT01396850||Psychotic Group|
11494021|NCT01396850||Anxiety|
11494022|NCT01396850||Depressed|
11494023|NCT01396850||Control Group|
11494024|NCT01396837|Experimental|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
11494025|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (< 45%) or ≥ 1 hospital admission due to HF decompensation.
11494026|NCT01396811|Experimental|Active|Product 33525
11494027|NCT01396811|Placebo Comparator|Placebo|Product 33525 Placebo
11494028|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A&E department of UZLeuven with an acute illness episode of maximum 5 days.
11494029|NCT01396785|Experimental|Active|Product 33525
11494030|NCT01396785|Placebo Comparator|Placebo|Product 33525 Placebo
11494031|NCT01396772|Experimental|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
11494032|NCT01396772|Other|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
11494033|NCT01396759|Experimental|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
11494083|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
11494084|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
11494034|NCT01396759|Experimental|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
11494035|NCT01396759|Active Comparator|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
11494036|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
11494037|NCT01396733|Active Comparator|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
11494038|NCT01396733|Active Comparator|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
11494039|NCT01396720|Active Comparator|fluvoxamine|
11494040|NCT01396720|Active Comparator|citalopharm|
11494041|NCT01396707|Experimental|Herceptin+XELOX|
11494042|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
11494043|NCT01396655|Experimental|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
11494044|NCT01396642|Experimental|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
11494045|NCT01396642|No Intervention|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
11494046|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
11494047|NCT01396616|Experimental|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
11494048|NCT01396590|Active Comparator|6 x 2 mg perampanel|
11494049|NCT01396590|Active Comparator|12 mg Perampanel|
11494050|NCT01396577|Active Comparator|3 x 2-mg perampanel|
11494051|NCT01396577|Active Comparator|6mg perampanel|
11494052|NCT01396564|Active Comparator|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
11494053|NCT01396564|Active Comparator|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
11494054|NCT01396551|Experimental|Transponder implantation|Implantation of anchored Beacon transponder in the lung
11494055|NCT01396525|Experimental|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
11494056|NCT01396512|Experimental|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
11494057|NCT01396512|Active Comparator|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
11494058|NCT01396499|Experimental|BKM120|Oral BKM120 starting dose 80 mg once daily.
11494059|NCT01396486|Active Comparator|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
11494060|NCT01396486|Active Comparator|Placebo/Inositol|Combination Placebo and Inositol treatment.
11494061|NCT01396486|Active Comparator|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
11494062|NCT01396473|No Intervention|control|
11494063|NCT01396473|Experimental|Policy and Environmental Change|
11494064|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
11494065|NCT01396460||control group|morbid obese population
11494066|NCT01396447|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks.
11494067|NCT01396447|Experimental|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
11494068|NCT01396447|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
11494069|NCT01396447|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
11494070|NCT01396434||Prevenar 13 patients|
11494071|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
11494072|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
11494073|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
11494074|NCT01396421|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
11494075|NCT01396408|Active Comparator|Sunitinib|
11494076|NCT01396408|Active Comparator|Temsirolimus|
11494077|NCT01396395|Experimental|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors [(ACEIs] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
11494078|NCT01396395|Other|Standard treatment|
11494079|NCT01396382|Experimental|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
11494087|NCT01396304|Experimental|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
11494088|NCT01396304|Active Comparator|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
11494089|NCT01396291|Experimental|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
11494090|NCT01396291|Placebo Comparator|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
11494091|NCT01396278|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
11494092|NCT01396278|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
11494093|NCT01396278|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
11494094|NCT01396278|Active Comparator|Fluticasone propionate 440 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 440 mcg ICS plus placebo matching Respimat inhaler
11494095|NCT01396278|Active Comparator|Fluticasone propioante 88 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 88 mcg ICS plus placebo matching Respimat inhaler
11494096|NCT01396265|Experimental|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
11494097|NCT01396265|Experimental|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
11494098|NCT01396252|Experimental|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
11494099|NCT01396252|Placebo Comparator|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
11494100|NCT01396239|Experimental|AVI-4658 (Eteplirsen)|"50 mg/kg eteplirsen for 28 weeks
~30 mg/kg eteplirsen for 28 weeks"
11494101|NCT01396239|Placebo Comparator|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.
~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
11494102|NCT01396226|Experimental|1|A single dose of AZD2927 administered as an iv infusion
11494103|NCT01396226|Placebo Comparator|2|A single dose of placebo administered as an iv infusion
11494104|NCT01396213|Experimental|Larazotide Acetate 0.5 mg|larazotide acetate 0.5 mg capsules TID
11494105|NCT01396213|Experimental|Larazotide Acetate 1 mg|larazotide acetate 1 mg capsules TID
11494106|NCT01396213|Experimental|Larazotide Acetate 2 mg|larazotide acetate 2 mg capsules TID
11494107|NCT01396213|Placebo Comparator|Placebo|placebo capsules TID
11494108|NCT01396200|Experimental|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
11494109|NCT01396200|Experimental|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
11494110|NCT01396187|Experimental|Treatment|
11494111|NCT01396187|Placebo Comparator|Placebo|
11494112|NCT01396174|Active Comparator|Standard Online Support Group|
11494113|NCT01396174|Experimental|Prosocial Online Support Group|
11494114|NCT01396161|Experimental|30 mg PF-05175157 or Placebo QD|
11494115|NCT01396161|Experimental|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
11494116|NCT01396161|Experimental|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
11494117|NCT01396161|Experimental|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
11494118|NCT01396161|Experimental|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
11494119|NCT01396148|Experimental|Children with GIST|children ages 6yrs-<18yrs
11494120|NCT01396148|Experimental|Young adults with GIST|young adults ages 18yrs-<21 yrs
11494121|NCT01396135|Experimental|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
11494122|NCT01396135|Experimental|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
11494123|NCT01396122|Experimental|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA* were performed in all patients.
11494124|NCT01396109|Active Comparator|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
11494125|NCT01396109|Active Comparator|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
11494126|NCT01396083|Experimental|Ranibizumab|
11494127|NCT01396083|Active Comparator|Standard of Care|
11494128|NCT01396070|Experimental|Brentuximab vedotin|Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
11494129|NCT01396057|Experimental|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
11494130|NCT01396057|Sham Comparator|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
11494131|NCT01396044|Experimental|Electronic checklist|Electronic checklist
11494132|NCT01396044|Experimental|Verbal prompting|Verbal prompting with written checklist
11494133|NCT01396031|Experimental|Excercise|Cardiovascular exercise Standing Hip Abduction Step-up/Step-down Wall Slide Sit-to-Stand Activity / Exercise Diary 3 times per week x ~1 month
11494315|NCT01394783|Other|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
11494134|NCT01396005|Experimental|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7)
11494135|NCT01396005|Experimental|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7
11494136|NCT01395992|Experimental|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
11494137|NCT01395992|Experimental|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
11494138|NCT01395979|Experimental|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
11494139|NCT01395979|Active Comparator|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
11494140|NCT01395966|Active Comparator|DF289|Ear drops
11494141|NCT01395966|Active Comparator|DF277|Ear drops
11494142|NCT01395966|Experimental|DF289 plus DF277|Ear drops
11494143|NCT01395953|Active Comparator|Buspirone|
11494144|NCT01395953|Placebo Comparator|Placebo|
11494145|NCT01395940|Experimental|KLH-2109, lower dose|
11494146|NCT01395940|Experimental|KLH-2109, higher dose|
11494147|NCT01395927|Experimental|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
11494148|NCT01395914|Experimental|100 mg QD|100 mg yellow coated, oval tablet; oral administration once daily
11494149|NCT01395914|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
11494150|NCT01395901|Experimental|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
11494151|NCT01395901|Active Comparator|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
11494152|NCT01395888|Experimental|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
11494153|NCT01395888|Active Comparator|Tiotropium|Inhaled long-acting anticholinergic
11494154|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
11494155|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
11494156|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
11494157|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
11494158|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
11494159|NCT01395823|Other|ergocalciferol supplementation|
11494160|NCT01395823|Placebo Comparator|placebo|
11494161|NCT01395810|Experimental|Prophylaxis, high dose (once weekly)|
11494162|NCT01395810|Experimental|Prophylaxis, low dose (once weekly)|
11494163|NCT01395810|Experimental|On-demand|
11494164|NCT01395810|Experimental|Prophylaxis, high dose (every second week)|
11494165|NCT01395797|Placebo Comparator|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
11494166|NCT01395797|Experimental|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
11494167|NCT01395797|Experimental|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
11494168|NCT01395797|Placebo Comparator|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
11494169|NCT01395797|Experimental|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
11494170|NCT01395797|Experimental|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
11494171|NCT01395784|Placebo Comparator|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
11494172|NCT01395784|Experimental|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
11494173|NCT01395784|Experimental|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
11494174|NCT01395771|Experimental|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
11494175|NCT01395758|Experimental|tivantinib (ARQ 197) plus erlotinib arm|"Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197).
~Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met."
11494176|NCT01395758|Active Comparator|Chemotherapy arm|Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.
11494177|NCT01395745|Experimental|blisibimod weekly dose|
11494178|NCT01395745|Placebo Comparator|Placebo|
11494179|NCT01395732|Experimental|1|
11494180|NCT01395719|No Intervention|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
11494181|NCT01395719|Experimental|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
11494182|NCT01395706|Experimental|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
11494183|NCT01395693|Experimental|Salt Lake mask system|
11494184|NCT01395680||cancer adolescent|
11494185|NCT01395667|Experimental|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45~55 Gy/25 fractions, followed by total mesorectal excision
11494186|NCT01395654|Experimental|Standard rechallenge, Slow rechallenge|
11494187|NCT01395641|Experimental|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
11494188|NCT01395615||Cohort|
11494189|NCT01395602|Placebo Comparator|placebo|placebo pill
11494190|NCT01395602|Active Comparator|cabergoline|cabergoline pill
11494191|NCT01395589|Active Comparator|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
11494192|NCT01395589|Active Comparator|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
11494193|NCT01395563|Experimental|1|pancreatic cancer patients
11494194|NCT01395563|Experimental|2|pancreatic cancer patients
11494195|NCT01395537|Experimental|Lapatinib With Carboplatin and Paclitaxel|
11494196|NCT01395524|Experimental|NKTR-118 12.5mg|
11494197|NCT01395524|Experimental|NKTR-118 25mg|
11494198|NCT01395524|Placebo Comparator|Placebo|
11494199|NCT01395511|Experimental|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9
~Distal Acupoints :
~Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5
~Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4
~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
11494200|NCT01395511|No Intervention|Waiting list group|"No Intervention Comparator
~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
11494201|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
11494202|NCT01395485|Experimental|Cohort 2|Adolescents - Ages 13 to <17
11494203|NCT01395485|Experimental|Cohort 1|Adolescents - Ages 12 to <13
11494204|NCT01395485|Experimental|Cohort 4|Adults - Ages 18 to <=50
11494205|NCT01395485|Experimental|Cohort 3|Adolescents - Ages 17 to <18
11494206|NCT01395472|Experimental|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
11494207|NCT01395472|Active Comparator|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
11494208|NCT01395472|Active Comparator|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
11494209|NCT01395459|No Intervention|control|Care as usual is given.
11494210|NCT01395459|Experimental|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
11494211|NCT01395459|Experimental|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
11494212|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
11494213|NCT01395433|Active Comparator|Treatment A|Conventional escitalopram
11494214|NCT01395433|Experimental|Treatment B|Escitalopram test treatment B
11494215|NCT01395433|Experimental|Treatment C|Escitalopram test treatment C
11494216|NCT01395420|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
11494217|NCT01395420|Experimental|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
11494218|NCT01395407|Experimental|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).
~Dose level Cohort A (Gy)
~21
~23
~25"
11494219|NCT01395407|Experimental|Cohort B|"Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).
~Dose level Cohort B (Gy)
~18
~20
~22"
11494220|NCT01395407|Experimental|Cohort C|"Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).
~Dose level Cohort C (Gy)
~15
~17
~19"
11494221|NCT01395394|Experimental|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
11494222|NCT01395394|Experimental|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
11494223|NCT01395394|Experimental|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
11494224|NCT01395381|Placebo Comparator|Placebo|
11494225|NCT01395381|Experimental|Albendazole|
11494227|NCT01395355|Experimental|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
11494228|NCT01395355|Active Comparator|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
11494229|NCT01395342|No Intervention|blood pressure and heart rate data|
11494230|NCT01395329|Active Comparator|Nebivolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.
11494231|NCT01395329|Active Comparator|Metoprolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.
11494232|NCT01395329|Placebo Comparator|Placebo|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.
11494233|NCT01395316|Experimental|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
11494234|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
11494235|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
11494236|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
11494237|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
11494238|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
11494239|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
11494240|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
11494241|NCT01395303||control group|randomly selected controls from the Tromsø study
11494242|NCT01395290|Experimental|cholecalciferol|cholecalciferol 20.000 IU per week
11494243|NCT01395277|Experimental|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
11494244|NCT01395277|Experimental|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
11494245|NCT01395264||Episodic Migraine.|
11494246|NCT01395264||menstrual migraine|
11494247|NCT01395264||Cluster Headache patients|
11494248|NCT01395264||control (non-headache group)|
11494249|NCT01395251|Other|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
11494250|NCT01395238|No Intervention|Wait-List Group|
11494251|NCT01395238|Experimental|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
11494252|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
11494253|NCT01395212||Cardiac stem cell therapy 5 years ago|
11494254|NCT01395199|Placebo Comparator|Starch pill|Placebo
11494255|NCT01395199|Experimental|Amlodipine|Amlodipine 5mg QD
11494256|NCT01395186|Other|varicocelectomy|varicocelectomy for patients complaining of pain
11494257|NCT01395173|Placebo Comparator|Control|Subject will undergo standard colonoscopy.
11494258|NCT01395173|Active Comparator|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
11494259|NCT01395160||Adult ADHD|
11494260|NCT01395160||Bipolar Disorder|
11494261|NCT01395160||Healthy control|
11494262|NCT01395147|Experimental|Lu AA21004 group|
11494263|NCT01395134|No Intervention|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
11494264|NCT01395134|Experimental|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
11494265|NCT01395121|Experimental|nilotinib|nilotinib 400mgs oral tablets
11494266|NCT01395108|Placebo Comparator|Placebo|Placebo
11494267|NCT01395108|Active Comparator|Nemonoxacin 125mg|Nemonoxacin 125mg
11494268|NCT01395108|Active Comparator|Nemonoxacin 250mg|Nemonoxacin 250mg
11494269|NCT01395108|Active Comparator|Nemonoxacin 500mg|Nemonoxacin 500mg
11494270|NCT01395108|Active Comparator|Nemonoxacin 750mg|Nemonoxacin 750mg
11494271|NCT01395108|Active Comparator|Nemonoxacin 1000mg|Nemonoxacin 1000mg
11494272|NCT01395095|Experimental|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
11494273|NCT01395095|Active Comparator|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
11494525|NCT01393223|Placebo Comparator|Normal Saline|Four weekly normal saline intravesical administration
11494274|NCT01395095|Experimental|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
11494275|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
11494276|NCT01395069|Active Comparator|Nepafenac 0.1%|
11494277|NCT01395069|Active Comparator|Ketorolac 0.5%|
11494278|NCT01395069|Placebo Comparator|Placebo|
11494279|NCT01395043|Other|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
11494280|NCT01395030|Experimental|18F-fluoromethylcholine PET/CT|Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
11494281|NCT01395017|Active Comparator|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
11494282|NCT01395017|Placebo Comparator|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
11494283|NCT01395004|Experimental|Active Drug - GSK2110183|This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily.
11494284|NCT01394991|Experimental|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
11494285|NCT01394991|Experimental|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
11494286|NCT01394978|Other|Control|No treatment.
11494287|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant|Standard surgical technique plus Progel Pleural Air Leak Sealant.
11494288|NCT01394965|No Intervention|ECG Mapping|
11494289|NCT01394952|Experimental|1.5 mg Dulaglutide|Administered once weekly, subcutaneously
11494290|NCT01394952|Placebo Comparator|Placebo|Administered once weekly, subcutaneously
11494291|NCT01394939|Experimental|Single Agent|JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.
11494292|NCT01394939|Experimental|Combination|JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.
11494293|NCT01394926|Experimental|Arm Number 1|
11494294|NCT01394913|Experimental|Reumatocept 25mg|50mg each week for 30 weeks
11494295|NCT01394913|Active Comparator|Enbrel 25mg|50mg each week for 30 weeks
11494296|NCT01394900|Experimental|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
11494297|NCT01394900|Active Comparator|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
11494298|NCT01394887|Active Comparator|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
11494299|NCT01394887|Placebo Comparator|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
11494300|NCT01394874|Experimental|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
11494301|NCT01394874|No Intervention|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
11494302|NCT01394861|Experimental|ESD using MASTER Slave Robotic System|
11494303|NCT01394848|Active Comparator|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
11494304|NCT01394848|Active Comparator|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
11494305|NCT01394848|Active Comparator|Atorvastatin 20mg group|
11494306|NCT01394848|Active Comparator|Atorvastatin 80mg group|
11494307|NCT01394835|Experimental|Alpha -1 Antitrypsin|
11494308|NCT01394822||Ultrasound results reported|
11494309|NCT01394822||Ultrasound results NOT reported|
11494310|NCT01394809|Experimental|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
11494311|NCT01394809|Experimental|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
11494312|NCT01394809|Active Comparator|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
11494313|NCT01394796|Active Comparator|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
11494314|NCT01394796|Placebo Comparator|Placebo|No active substance is given.
11494316|NCT01394783|Other|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
11494317|NCT01394770|Experimental|Aliskiren|
11494318|NCT01394770|Active Comparator|Amlodipine|
11494319|NCT01394731|Experimental|Paracetamol 1|
11494320|NCT01394731|Experimental|Paraceatmol 2|
11494321|NCT01394731|Active Comparator|Meperidine|
11494322|NCT01394718|Placebo Comparator|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
11494323|NCT01394718|Experimental|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
11494324|NCT01394705|No Intervention|Standard of Care|standard of care (office provider exercise counseling)
11494325|NCT01394705|Experimental|Intervention|The intervention group received a personalized exercise prescription (using the FITT principles) and wore an accelerometer up to 7days/week (most waking hours) and logged their activity by regularly (3 times a week) uploading the device for a period of 3 months, use of the internet was supervised by a parent or guardian. Their activity was monitored via the online BodyMedia site on a regular basis by study personnel and feedback was provided at least once a week through email and/or phone calls
11494326|NCT01394692|Active Comparator|intraoperative MRI|tumor resection with intraoperative MRI-guidance
11494327|NCT01394692|Active Comparator|conventional group|standard microsurgical tumor resection
11494328|NCT01394679|Active Comparator|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
11494329|NCT01394679|Experimental|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
11494330|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
11494331|NCT01394653|Experimental|orally-disintegrating (OD) tablet precedence group|
11494332|NCT01394653|Experimental|conventional tablet precedence group|
11494333|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
11494334|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
11494335|NCT01394627|Experimental|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
11494336|NCT01394627|Placebo Comparator|placebo|hypoglycemia of 50 mg/dl plus placebo
11494337|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
11494338|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
11494339|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
11494340|NCT01394575|Experimental|IMRT-SIB|
11494341|NCT01394562|Experimental|Ferinject (ferric carboxymaltose)|
11494342|NCT01394562|Other|Standard of Care|Standard of care. IV iron is not permitted
11494343|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
11494344|NCT01394536|Sham Comparator|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
11494345|NCT01394536|Active Comparator|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
11494346|NCT01394523|Active Comparator|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
11494347|NCT01394523|Active Comparator|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
11494348|NCT01394523|Active Comparator|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
11494349|NCT01394510|Experimental|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
11494350|NCT01394497|Experimental|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
11494351|NCT01394497|No Intervention|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
11494352|NCT01394484|Experimental|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
11494353|NCT01394484|Experimental|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
11494354|NCT01394471|Experimental|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
11494355|NCT01394471|Placebo Comparator|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
11494389|NCT01394185|Active Comparator|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
11494390|NCT01394159|Active Comparator|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
11494356|NCT01394458|Experimental|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
11494357|NCT01394458|Experimental|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
11494358|NCT01394445|Active Comparator|Physostigmine|
11494359|NCT01394445|Placebo Comparator|Placebo|
11494360|NCT01394432|Active Comparator|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
11494361|NCT01394432|Placebo Comparator|Group 2 (PCI+Placebo)|Placebo
11494362|NCT01394419|Experimental|NAC group|N-acetylcysteine
11494363|NCT01394419|Placebo Comparator|Placebo group|Saline
11494364|NCT01394406|Experimental|Ketamine group|
11494365|NCT01394406|Placebo Comparator|Saline group|
11494366|NCT01394393|Experimental|ECT|Experiential-Cognitive Therapy for Obesity
11494367|NCT01394393|Active Comparator|BCT|Cognitive behavioral treatment program
11494368|NCT01394393|Sham Comparator|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
11494369|NCT01394380|Experimental|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
11494370|NCT01394380|No Intervention|regular sodas|subjects will continue their usual consumption of sweetened sodas
11494371|NCT01394367|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
11494372|NCT01394367|No Intervention|respiratory and exercise therapy|
11494373|NCT01394354|Experimental|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.
~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).
~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
11494374|NCT01394341|Active Comparator|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
11494375|NCT01394341|Placebo Comparator|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
11494376|NCT01394341|Active Comparator|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
11494377|NCT01394341|Placebo Comparator|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
11494378|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
11494379|NCT01394289|Experimental|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
11494380|NCT01394276||Tocilizumab|Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
11494381|NCT01394263|Active Comparator|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
11494382|NCT01394263|Experimental|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
11494383|NCT01394250|Experimental|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
11494384|NCT01394250|Active Comparator|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
11494385|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
11494386|NCT01394224|Experimental|Levetiracetam IV Infusion (1500 mg)|
11494387|NCT01394224|Experimental|Levetiracetam tablets (1500 mg)|
11494388|NCT01394211|Experimental|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.
~NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
11494524|NCT01393223|Active Comparator|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
11495270|NCT01387945|Experimental|HBPM+website+patient navigator|
11494391|NCT01394159|Active Comparator|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
11494392|NCT01394146|Experimental|Subjects with healthy kidney function|
11494393|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
11494394|NCT01394120|Experimental|Tarteted Therapy|
11494395|NCT01394120|Active Comparator|Standard Chemotherapy|
11494396|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.
~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
11494397|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
11494398|NCT01394094|Experimental|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
11494399|NCT01394094|No Intervention|Conventional|Conventional postoperative feeding schedule
11494400|NCT01394081|Experimental|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
11494401|NCT01394081|Active Comparator|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
11494402|NCT01394055|Active Comparator|RM-131|
11494403|NCT01394055|Placebo Comparator|Placebo|
11494404|NCT01394042|No Intervention|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
11494405|NCT01394029||deferasirox|
11494406|NCT01394016|Experimental|LY2835219|
11494407|NCT01394003|Experimental|LY2584702|"Oral dose escalation starting at 25 milligrams (mg), daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation).
~Part A: Participants received 25 mg, 50 mg, 100 mg and 200 mg once daily (QD) and 300 mg twice daily (BID) of LY2584702 capsule, for a 28-day cycle during Part A of the study until the criteria for maximum tolerated dose (MTD) were met.
~Part B: Participants received 50 mg, 75 mg and 100 mg LY2584702 orally as a capsule, twice daily (BID) for a 28-day cycle during Part B of the study until the criteria for maximum tolerated dose (MTD) were met."
11494408|NCT01393990|Experimental|LY2228820|"The study had 4 parts, dose-escalation (Part A), 2 dose-confirmation (Parts B and C), and a tumor-specific expansion for metastatic breast cancer (Part D).
~Part A: Participants received escalating doses of 10, 20, 40, 65, 90, 120, 160, 200, 300, 420 and 560 milligrams (mg) of LY2228820 every 12 hours on Days 1 through 14 of a 28-day cycle.
~Part B: Participants received 420 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle. Participants received midazolam orally 2 days before the first dose and again after the morning dose of study drug on Day 8 during the first cycle of treatment.
~Part C: Participants received 300 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle.
~Part D: Participants received 200 mg and 300 mg of LY2228820 in combination with tamoxifen."
11494409|NCT01393977|No Intervention|control|Outpatient in hospital
11494410|NCT01393977|Active Comparator|rehabilitation|interventions: rehabilitation
11494411|NCT01393977|Experimental|Stem Cell Transplantation|interventions: stem cell transplantation
11494412|NCT01393964|Experimental|Arm 1: Lenalidomide + Dexamethasone +Elotuzumab|Severe Renal Impairment
11494413|NCT01393964|Experimental|Arm 2: Lenalidomide + Dexamethasone +Elotuzumab|End-stage renal disease
11494414|NCT01393964|Experimental|Arm 3: Lenalidomide + Dexamethasone +Elotuzumab|Normal renal function
11494415|NCT01393951|Experimental|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
11494416|NCT01393951|Experimental|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
11494417|NCT01393951|Experimental|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
11494418|NCT01393938|Other|Mullerian Duct Anomaly|
11494419|NCT01393925|Experimental|parecoxib, normal saline|
11494420|NCT01393912|Other|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m^2).
11494421|NCT01393912|Other|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m^2).
11494422|NCT01393899|Placebo Comparator|Placebo BID|
11494423|NCT01393899|Experimental|5mg BID|
11494424|NCT01393899|Experimental|10mg BID|
11494425|NCT01393886|Experimental|Laparoscopic Greater Curvature Plication|Only one treatment arm
11494426|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
11494427|NCT01393860||Aliskiren|Diabetic nephropathy
11494428|NCT01393834|Experimental|Delayed cord clamping|Delayed cord clamping for 30 seconds
11494429|NCT01393834|Experimental|Milking of the cord|Milking of the cord 4 times in 10 seconds
11494430|NCT01393834|No Intervention|Immediate cord clamping|Immediate cord clamping after delivery
11494431|NCT01393821|Experimental|Arm I (lotion)|Patients apply menadione topical lotion BID for 28 days.
11494432|NCT01393821|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo lotion BID for 28 days.
11494433|NCT01393808|Experimental|Paricalcitol|
11494434|NCT01393808|Placebo Comparator|placebo|
11494435|NCT01393795|Placebo Comparator|Tegaderm|
11494436|NCT01393795|Active Comparator|Qutenza|
11494437|NCT01393782|Active Comparator|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
11494438|NCT01393782|Placebo Comparator|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
11494439|NCT01393769|Experimental|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
11494440|NCT01393756|Experimental|Lenalidomide dose 25 mg|
11494441|NCT01393743|Experimental|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
11494442|NCT01393743|Placebo Comparator|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
11494443|NCT01393730|Experimental|Abiraterone+prednisone+dutasteride|Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression
11494444|NCT01393717|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
11494445|NCT01393704|Active Comparator|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
11494446|NCT01393704|Active Comparator|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
11494447|NCT01393691|Experimental|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
11494448|NCT01393691|Active Comparator|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
11494449|NCT01393678|Experimental|PENNEL|2cap T.I.D
11494450|NCT01393678|Active Comparator|NISSEL|"NISSEL
~BDD (biphenylmethyl dicarboxylate) ................25mg
~2cap T.I.D"
11494451|NCT01393665|Placebo Comparator|Placebo|
11494452|NCT01393665|Experimental|PENNEL capsule|1cap or 2cap T.I.D
11494453|NCT01393652|Experimental|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
11494454|NCT01393652|Experimental|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
11494455|NCT01393652|Active Comparator|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
11494456|NCT01393639|Experimental|PF-04171327 1 mg QD|
11494457|NCT01393639|Experimental|PF-04171327 5 mg QD|
11494458|NCT01393639|Experimental|PF-04171327 10 mg QD|
11494459|NCT01393639|Experimental|PF-04171327 15 mg QD|
11494460|NCT01393639|Active Comparator|prednisone 5 mg QD|
11494461|NCT01393639|Active Comparator|prednisone 10 mg QD|
11494462|NCT01393639|Placebo Comparator|placebo|
11494463|NCT01393626|Placebo Comparator|Placebo BID|
11494464|NCT01393626|Experimental|5mg BID|
11494465|NCT01393626|Experimental|10mg BID|
11494466|NCT01393613|Experimental|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
11494467|NCT01393613|Experimental|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
11494468|NCT01393613|Experimental|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
11494469|NCT01393613|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
11494470|NCT01393600|Experimental|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:
~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.
~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
11494471|NCT01393600|Experimental|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:
~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.
~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
11494472|NCT01393587|Experimental|Experimental|
11494473|NCT01393574|Experimental|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight <40kg, 6mg for body weight >40kg
11494474|NCT01393574|Active Comparator|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
11494475|NCT01393561|Experimental|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
11494476|NCT01393561|Placebo Comparator|Group 2|Placebo
11494477|NCT01393548|Experimental|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
11494478|NCT01393548|Active Comparator|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
11494479|NCT01393522|Active Comparator|Milnacipran|
11494480|NCT01393522|Placebo Comparator|Sugar Pill|
11494481|NCT01393509|Experimental|PU-H71|This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
11494482|NCT01393496|Experimental|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
11494483|NCT01393496|Active Comparator|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
11494484|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
11494485|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
11494486|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
11494487|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.
~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.
~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
11494488|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.
~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.
~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.
~Cohort B2 (Trial Cohort, Non-Vaccinated)"
11494489|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.
~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).
~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.
~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
11494490|NCT01393457|Active Comparator|ldopa + ropinirole low dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
11494491|NCT01393457|Active Comparator|ldopa + ropinirole high dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
11494492|NCT01393457|Active Comparator|ldopa|levodopa/carbidopa 800/200 mg/d
11494493|NCT01393457|Placebo Comparator|placebo|Placebo
11494494|NCT01393444|Experimental|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
11494495|NCT01393431||EBC pH|Observational study
11494496|NCT01393418||Subjects undergoing cardiac surgery|
11494497|NCT01393405|Active Comparator|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
11494498|NCT01393405|Placebo Comparator|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
11494499|NCT01393392|Experimental|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
11494500|NCT01393392|Active Comparator|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
11494501|NCT01393366|Other|Without AMA|Patient will be follow only like usual practice
11494502|NCT01393366|Other|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
11494503|NCT01393353|Sham Comparator|Computer game|Nintendo Wii
11494504|NCT01393353|Experimental|Cognitive Training with Cogniplus|CogniPlus
11494505|NCT01393340|Placebo Comparator|Placebo|
11494506|NCT01393340|Active Comparator|Omalizumab|
11494507|NCT01393327|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional postoperative rehabilitation without a specific training program.
11494508|NCT01393327|No Intervention|no respiratory and exercise therapy|continuation of usual lifestyle
11494509|NCT01393314|Active Comparator|Honeywell HomMed Telemonitor|
11494510|NCT01393314|No Intervention|usual care|
11494511|NCT01393301|Experimental|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
11494512|NCT01393301|Other|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
11494513|NCT01393288|Placebo Comparator|Ondansetron|
11494514|NCT01393288|Placebo Comparator|Lorazepam|
11494515|NCT01393288|Placebo Comparator|Aprepitant|
11494516|NCT01393275|Active Comparator|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
11494517|NCT01393275|Placebo Comparator|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
11494518|NCT01393262||Healthy Escort|
11494519|NCT01393262||Hand Service patient|
11494520|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
11494521|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
11494522|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
11494523|NCT01393223|Active Comparator|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
11494526|NCT01393210|Active Comparator|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
11494527|NCT01393210|Active Comparator|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
11494528|NCT01393197|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
11494529|NCT01393197|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
11494530|NCT01393197|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
11494531|NCT01393197|Experimental|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
11494532|NCT01393184|Experimental|Radiotherapy + Nimotuzumab|"Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
~Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
11494533|NCT01393184|Active Comparator|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
11494534|NCT01393171|Active Comparator|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
11494535|NCT01393171|Placebo Comparator|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
11494536|NCT01393171|Active Comparator|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
11494537|NCT01393158|Experimental|20 mg BID|Patients dosed with 20 mg orally of Apremilast BID for 3 months.
11494538|NCT01393158|Experimental|30 mg BID|Patients dosed with 30 mg orally of Apremilast BID for 6 months.
11494539|NCT01393145|Experimental|Group 1|
11494540|NCT01393145|Active Comparator|Group 2|
11494541|NCT01393132|Experimental|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
11494542|NCT01393132|Placebo Comparator|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
11494543|NCT01393119|Experimental|3000mg GTx-758 daily|loading dose 3000mg GTx-758 daily + maintenance dose of 1000mg
11494544|NCT01393119|Experimental|3000 mg GTx-758 daily|loading dose of 3000mg GTx-758 daily + maintenance dose of 2000mg GTx-758 daily
11494545|NCT01393119|Experimental|1500 mg GTx-758 BID|Loading dose of 1500 mg GTx-758 BID + maintenance dose of 1000mg GTx-758 daily
11494546|NCT01393119|Experimental|1500mg GTx-758 BID|loading dose of 1500mg of GTx-758 BID + maintenance dose of 2000mg GTx-758 daily
11494547|NCT01393106|Experimental|Idelalisib|Participants will receive up to 300 mg of idelalisib twice daily.
11494548|NCT01393093|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
11494549|NCT01393093|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
11494550|NCT01393093|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
11494551|NCT01393093|Experimental|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
11494552|NCT01393080|Experimental|Nimotuzumab and TP regimen|"TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
~Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
11494553|NCT01393080|Placebo Comparator|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
11494554|NCT01393067|Active Comparator|study group NEPS|implantation of multiple non-expandable plastic stents
11494555|NCT01393067|Active Comparator|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
11494556|NCT01393041|Other|Angio-Seal VIP|
11494557|NCT01393028|Experimental|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
11494558|NCT01393028|Other|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
11494559|NCT01393015|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
11494560|NCT01393015|Active Comparator|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
11494561|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
11494562|NCT01392989|Experimental|Allogeneic Cytokine-induced Killer Cells (CIK)|Target dose of ≥ 5 x 10e6 CD34+ cells/kg of recipient body weight plus an additional 2 x10e9 mononuclear cells.
11494563|NCT01392976|Experimental|CO-1.01 Formulation B|
11494564|NCT01392976|Active Comparator|CO-1.01 Formulation A|
11494565|NCT01392963|Experimental|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
11494566|NCT01392963|Experimental|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
11494567|NCT01392950|Active Comparator|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
11494568|NCT01392950|Active Comparator|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
11494569|NCT01392937|Active Comparator|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
11494570|NCT01392937|Active Comparator|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
11494571|NCT01392924|Experimental|SAR245408|single cohort: SAR245408 administered once daily
11494572|NCT01392911|Active Comparator|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
11494573|NCT01392911|Experimental|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494574|NCT01392911|Experimental|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494575|NCT01392911|Experimental|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494576|NCT01392911|Experimental|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494577|NCT01392911|Experimental|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494578|NCT01392911|Experimental|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494579|NCT01392911|Experimental|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494580|NCT01392911|Experimental|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
11494581|NCT01392898|Experimental|liraglutide|
11494582|NCT01392898|Active Comparator|insulin|
11494583|NCT01392872|Other|sclerosis|
11494584|NCT01392859|Experimental|Group 1|Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
11494585|NCT01392859|Experimental|Group 2|Group 2 will begin with placebo oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and active Levocetirizine(LCT) 0.5 mg/ml will be provided for 5-8 days.
11494586|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
11494587|NCT01392833|Active Comparator|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
11494588|NCT01392833|Experimental|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
11494589|NCT01392820|Experimental|TC-5214|
11494590|NCT01392820|Placebo Comparator|Placebo|
11494591|NCT01392807|Experimental|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
11494592|NCT01392807|Experimental|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
11494593|NCT01392807|Experimental|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
11494594|NCT01392794|Experimental|orally-disintegrating (OD) tablet precedence group|
11494595|NCT01392794|Experimental|conventional tablet precedence group|
11494596|NCT01392781||normoweight PCOS patients|
11494597|NCT01392781||normoweight controls|
11494598|NCT01392781||overweight plus obese PCOS patients|
11494599|NCT01392781||overwqeight plus obese controls|
11494600|NCT01392768|Experimental|Levetiracetam|
11494601|NCT01392768|Placebo Comparator|Placebo|
11494602|NCT01392755|Experimental|1|
11494603|NCT01392755|Experimental|2|
11494604|NCT01392742||Cohort|
11494605|NCT01392729||Cohort|
11494606|NCT01392716|Experimental|Single arm|
11494607|NCT01392703|Other|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
11494608|NCT01392703|Other|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
11494609|NCT01392703|Other|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
11494610|NCT01392690|No Intervention|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
11494611|NCT01392690|Experimental|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
11494612|NCT01392677|Experimental|Dapagliflozin 10 mg tablet|
11494613|NCT01392677|Placebo Comparator|matching placebo tablet|
11494614|NCT01392651||Women with urinary stress incontinence|
11494615|NCT01392638|Placebo Comparator|sugar pill|Intervention: sugar pill
11494616|NCT01392638|Active Comparator|sildenafil|Intervention: sildenafil citrate
11495175|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
11494617|NCT01392625|Active Comparator|Autologous hMSCs|Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
11494618|NCT01392625|Active Comparator|Allogeneic hMSCs|Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
11494619|NCT01392612|Other|Erythropoietin|all subjects received epo iv.
11494620|NCT01392599|Experimental|Surgery|Patients with CRPS Type II
11494621|NCT01392586|Experimental|Upfront surgery|Upfront surgery followed by systemic treatment
11494622|NCT01392586|Other|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
11494623|NCT01392573|Experimental|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
11494624|NCT01392573|Experimental|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
11494625|NCT01392560|Experimental|BI 10773|Oral once daily
11494626|NCT01392547|Experimental|rFVIIa|
11494627|NCT01392547|Experimental|vatreptocog alfa|
11494628|NCT01392534||Group 1|
11494629|NCT01392521|Experimental|Arm 1|
11494630|NCT01392495|Experimental|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
11494631|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
11494632|NCT01392469|Experimental|QTI571|
11494633|NCT01392456|Active Comparator|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
11494634|NCT01392456|Active Comparator|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
11494635|NCT01392456|Active Comparator|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
11494636|NCT01392443|Experimental|Ruxolitinib|Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
11494637|NCT01392430|No Intervention|Arm A|Continuation of prophylaxis of opportunistic infections
11494638|NCT01392430|Experimental|Arm B|Discontinuation of opportunistic infections
11494639|NCT01392391|Experimental|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
11494640|NCT01392391|Active Comparator|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
11494641|NCT01392378|Experimental|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
11494642|NCT01392378|Experimental|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
11494643|NCT01392378|Experimental|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
11494644|NCT01392378|Experimental|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
11494645|NCT01392378|Experimental|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
11494646|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
11494647|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
11494648|NCT01392352|Experimental|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
11494649|NCT01392339|Experimental|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
11494650|NCT01392326|Experimental|Group 1|Secukinumab (75mg)
11494651|NCT01392326|Experimental|Group 2|Secukinumab (150 mg)
11494652|NCT01392326|Placebo Comparator|Group 3|
11494653|NCT01392313|Experimental|Carnitine|Participants will be given Creatinine supplements
11494654|NCT01392313|Placebo Comparator|Placebo|participants will be given creatinine placebo
11494655|NCT01392300|Experimental|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
11494656|NCT01392300|Placebo Comparator|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
11494657|NCT01392287|Experimental|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
11494658|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
11494659|NCT01392235|Experimental|Drug: Famitinib|
11494692|NCT01391936|Other|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
11494693|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
11494660|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
11494661|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
11494662|NCT01392209|Experimental|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
11494663|NCT01392196|Other|Single arm|Renal Denervation
11494664|NCT01392183|Experimental|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
11494665|NCT01392183|Experimental|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
11494666|NCT01392170|Experimental|PEG-IFNá-2a|PEG-IFNá-2a (Pegasys) 45 mcg subcutaneously as single weekly dose.
11494667|NCT01392157|Active Comparator|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
11494668|NCT01392157|Active Comparator|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
11494669|NCT01392157|Active Comparator|ENG-releasing implant|100 women will receive an LNG-IUS
11494670|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
11494671|NCT01392131|Active Comparator|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
11494672|NCT01392131|Active Comparator|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
11494673|NCT01392105|Active Comparator|Mesenchymal stem cell treatment group|
11494674|NCT01392105|Placebo Comparator|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
11494675|NCT01392079|Experimental|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).
~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.
~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
11494676|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
11494677|NCT01392053|No Intervention|Control group|Control Group (CG) that will receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group
11494678|NCT01392053|Experimental|Massage Group|Massage Group (GM):receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation
11494679|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
11494680|NCT01392014|Active Comparator|dihydroartemisinin-piperaquine|
11494681|NCT01392014|Active Comparator|Dihydroartemisininpiperaquine primaquine|
11494682|NCT01392001||Cohort|
11494683|NCT01391988|Active Comparator|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
11494684|NCT01391988|Experimental|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
11494685|NCT01391975|Experimental|Surveillance and proactive intervention|
11494686|NCT01391975|No Intervention|Control and reactive intervention|
11494687|NCT01391962|Experimental|Part I|Patients will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles
11494688|NCT01391962|Experimental|Part II|At the time of disease progression patients will cross over to the other treatment arm after a 2-week wash-out period.
11494689|NCT01391949|Experimental|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
11494690|NCT01391949|Active Comparator|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
11494691|NCT01391936|Other|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
11496448|NCT01379261|No Intervention|Standard treatment|Standard treatment
11494694|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
11494695|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
11494696|NCT01391884||Healthy control|
11494697|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
11494698|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
11494699|NCT01391858|Active Comparator|pregabalin|pregabalin (lyrica)
11494700|NCT01391858|Placebo Comparator|placebo|placebo
11494701|NCT01391845|Experimental|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
11494702|NCT01391845|Placebo Comparator|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
11494703|NCT01391845|Experimental|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
11494704|NCT01391845|Placebo Comparator|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
11494705|NCT01391832|Sham Comparator|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
11494706|NCT01391832|Active Comparator|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment
~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
11494707|NCT01391819|Other|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
11494708|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
11494709|NCT01391793|Active Comparator|Adjuvant dexamethasone|
11494710|NCT01391793|Placebo Comparator|Placebo|
11494711|NCT01391780||Group 1|Patients with stress urinary incontinence
11494712|NCT01391780||Group 2|Patients with urgency urinary incontinence.
11494713|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
11494714|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
11494715|NCT01391754|Experimental|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
11494716|NCT01391754|Experimental|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
11494717|NCT01391754|Experimental|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
11494718|NCT01391754|Active Comparator|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
11494719|NCT01391741|Experimental|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
11494720|NCT01391741|Active Comparator|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
11494721|NCT01391728|Active Comparator|Lifestyle counseling|
11494722|NCT01391728|No Intervention|Control|
11494723|NCT01391715|Active Comparator|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
11494724|NCT01391715|Placebo Comparator|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
11494725|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
11494726|NCT01391689|Experimental|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
11494727|NCT01391689|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
11494728|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
11494729|NCT01391663|Experimental|Alogliptin 12.5 mg QD|
11494730|NCT01391663|Experimental|Alogliptin 25 mg QD|
11494731|NCT01391663|Experimental|Alogliptin 50 mg QD|
11494732|NCT01391650|Experimental|biomechanic of the knee|
11494733|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
11494734|NCT01391624|Experimental|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
11494735|NCT01391624|Placebo Comparator|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
11494736|NCT01391611|Experimental|Pazopanib arm|
11494737|NCT01391598|Active Comparator|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
11494738|NCT01391598|Placebo Comparator|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
11494739|NCT01391585|Experimental|text message recipients|Patients will be recruited to receive text messages
11494740|NCT01391572|Experimental|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
11494741|NCT01391572|Active Comparator|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
11494742|NCT01391559|Experimental|arformoterol|beta-2 agonist bronchodilator
11494743|NCT01391559|Active Comparator|salmeterol|beta-2 agonist bronchodilator
11494744|NCT01391546|Experimental|ZOSTAVAX intramuscular (IM) route|Single dose of 0.65 mL via IM injection
11494745|NCT01391546|Active Comparator|ZOSTAVAX subcutaneous (SC) route|Single dose of 0.65 mL via SC injection
11494746|NCT01391533|Experimental|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
11494747|NCT01391520|Experimental|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
11494748|NCT01391520|Placebo Comparator|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
11494749|NCT01391507|Placebo Comparator|Placebo|
11494750|NCT01391507|Experimental|20 mg COR-1|
11494751|NCT01391507|Experimental|80 mg COR-1|
11494752|NCT01391507|Experimental|160 mg COR-1|
11494753|NCT01391494|Experimental|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
11494754|NCT01391494|Experimental|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
11494755|NCT01391494|Experimental|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
11494756|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
11494757|NCT01391494|Placebo Comparator|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
11494758|NCT01391494|Experimental|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
11494759|NCT01391494|Experimental|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
11494760|NCT01391494|Experimental|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
11494761|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
11494762|NCT01391494|Placebo Comparator|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
11494763|NCT01391494|Experimental|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
11494764|NCT01391494|Experimental|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
11494765|NCT01391494|Experimental|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
11494766|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
11494767|NCT01391494|Placebo Comparator|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
11494768|NCT01391481|Experimental|Perfluorocarbon|
11494769|NCT01391481|Placebo Comparator|Sterile Water for Injection|
11494770|NCT01391468|Placebo Comparator|Placebo|cornstarch
11494771|NCT01391468|Experimental|Probiotics|probiotics
11494772|NCT01391455|No Intervention|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
11494773|NCT01391455|Experimental|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
11494774|NCT01391442|Other|family|each family, composed of 4 characters at least, is studied
11494775|NCT01391429|Experimental|Video decision support tool|Video decision support tool for goals-of-care options
11494776|NCT01391429|No Intervention|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
11494777|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
11494778|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
11494779|NCT01391403|Experimental|Artemisinin, anti-toxoplasma|Artemisinin
11494780|NCT01391403|Placebo Comparator|Placebo|Placebo looks like the active drug, with the same dose.
11494781|NCT01391390|Experimental|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
11494782|NCT01391390|Placebo Comparator|Placebo|Placebo look like the active drug, and same dose.
11494783|NCT01391377|Active Comparator|Niacin / Laropiprant|
11494784|NCT01391377|Placebo Comparator|Sugar Pill (Placebo)|
11494785|NCT01391364|Experimental|SofLens in investigational solution|Bausch + Lomb SofLens daily disposable contact lens packaged in an investigational storage solution.
11494786|NCT01391364|Active Comparator|SofLens in currently marketed solution|SofLens daily disposable contact lens packaged in currently marketed storage solution.
11494787|NCT01391351|Other|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
11494788|NCT01391351|Other|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
11494789|NCT01391338|Experimental|Lowest dose ASP3652 twice daily|
11494790|NCT01391338|Experimental|Low dose ASP3652 twice daily|
11494791|NCT01391338|Experimental|Medium dose ASP3652 twice daily|
11494792|NCT01391338|Experimental|High dose ASP3652 once daily|
11494793|NCT01391338|Experimental|High dose ASP3652 twice daily|
11494794|NCT01391338|Placebo Comparator|Placebo|
11494795|NCT01391325|Other|Allopurinol|Treatment.
11494796|NCT01391312|Active Comparator|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
11494797|NCT01391312|Placebo Comparator|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
11494798|NCT01391299|Active Comparator|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
11494799|NCT01391299|Active Comparator|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
11494800|NCT01391299|Placebo Comparator|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
11494801|NCT01391286|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
11494802|NCT01391286|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
11494803|NCT01391273|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
11494804|NCT01391273|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
11494805|NCT01391260|Experimental|Radiotherapy Combined With Gefitinib|
11494806|NCT01391247||healthy age machted controls|
11494807|NCT01391247||normal tension glaucoma patients|
11494808|NCT01391247||primary open angle glaucoma patients|
11494809|NCT01391234|Experimental|STAT RT planning and delivery workflow|single arm
11494810|NCT01391221|Experimental|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
11494811|NCT01391208|No Intervention|peptide application|
11494812|NCT01391195|Experimental|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
11494813|NCT01391182|Active Comparator|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
11494814|NCT01391182|Placebo Comparator|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
11494815|NCT01391169|Active Comparator|1sup group|enforcement of the anastomoses with seromuscular flap
11494816|NCT01391169|Placebo Comparator|2nd group|primary anastomosis without enforcement
11494817|NCT01391156|Experimental|Minoxidil|
11494818|NCT01391156|Active Comparator|MinoxidilFinasteride|
11494819|NCT01391143|Experimental|MGA271|Fc-optimized, humanized monoclonal antibody
11494820|NCT01391130|Experimental|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
11494821|NCT01391130|Active Comparator|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
11494822|NCT01391117|Experimental|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
11494823|NCT01391117|Experimental|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
11494824|NCT01391117|Placebo Comparator|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
11494825|NCT01391117|Experimental|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
11494826|NCT01391117|Placebo Comparator|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
11494827|NCT01391117|Experimental|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
11494828|NCT01391117|Placebo Comparator|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
11494829|NCT01391117|Experimental|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
11494830|NCT01391117|Placebo Comparator|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
11494831|NCT01391117|Placebo Comparator|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
11494832|NCT01391104|Experimental|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
11494833|NCT01391104|Placebo Comparator|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
11494834|NCT01391091|Active Comparator|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
11494835|NCT01391091|Active Comparator|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
11494836|NCT01391078|Experimental|Sensimed Triggerfish|
11494837|NCT01391078|Active Comparator|Goldmann Applanation Tonometry/Perkins Tonometry|
11494838|NCT01391065|Other|1|The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up
11494839|NCT01391052|Active Comparator|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
11494840|NCT01391052|Other|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
11494841|NCT01391039|Experimental|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
11494842|NCT01391026|No Intervention|Usual care|
11494843|NCT01391026|Experimental|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
11494844|NCT01391013|Experimental|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
11494845|NCT01391013|Experimental|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
11494846|NCT01391000|Experimental|Laser CO2|
11494847|NCT01391000|Active Comparator|TENS|
11494848|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
11494849|NCT01390948|Experimental|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (>/=) 6 months and less than (<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
11494850|NCT01390948|Experimental|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
11494851|NCT01390948|Active Comparator|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
11494852|NCT01390935||systolic heart failure|EF under 45%
11494853|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
11494854|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
11494855|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
11494856|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
11494857|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
11494858|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
11494859|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
11494860|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
11494861|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
11494862|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
11494863|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
11494864|NCT01390844|Experimental|Boceprevir|PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
11494865|NCT01390844|Active Comparator|Control|PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
11494866|NCT01390831|Experimental|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
11494867|NCT01390831|No Intervention|anti-hypertensive medications|Maintenance of anti-hypertensive medications
11494868|NCT01390818|Experimental|MSC1936369B and SAR245409 once daily|
11494869|NCT01390818|Experimental|MSC1936369B and SAR245409 twice daily|
11494870|NCT01390805||Subjects with recurrent genital herpes|
11494871|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
11495176|NCT01388673|Experimental|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
11494872|NCT01390779|Experimental|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
11494873|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
11494874|NCT01390753|No Intervention|Preterm formula|
11494875|NCT01390753|Active Comparator|Donor milk + preterm formula|Human milk from a donor bank
11494876|NCT01390753|No Intervention|Breastfeeding + formula|
11494877|NCT01390753|No Intervention|Breasfeeding|
11494878|NCT01390740||Echocardiography|patients with echocardiography
11494879|NCT01390727|Placebo Comparator|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
11494880|NCT01390727|Active Comparator|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
11494881|NCT01390714|Experimental|1|
11494882|NCT01390714|Experimental|2|
11494883|NCT01390701|Experimental|transcutaneous electr. nerve stimulation|
11494884|NCT01390701|Active Comparator|felodipin|
11494885|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI > 18.5 kg/m2 fatsing plasma glucose < 12 mmol/l
11494886|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI > 18. 5 kg/m2
11494887|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI >18.5 kg/m2.
11494888|NCT01390662|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
11494889|NCT01390662|Placebo Comparator|placebo|one tablet of sugar pill per day for 24 weeks.
11494890|NCT01390649|Experimental|IgPro10|
11494891|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
11494892|NCT01390584|Experimental|Centralized PET review|Centralized PET review of patients after 2 cycles of ABVD induction followed by 4 additional cycles of ABVD (escalated BEACOPP or standard BEACOPP) followed by involved nodal radiotherapy [INRT] of 30-30.6 Gy.
11494893|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
11494894|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
11494895|NCT01390545|Active Comparator|Veltuzumab 80 mg|
11494896|NCT01390545|Active Comparator|Veltuzumab 160 mg|
11494897|NCT01390545|Active Comparator|Veltuzumab 320 mg|
11494898|NCT01390545|Placebo Comparator|Placebo|
11494899|NCT01390519||Afinitor|Afinitor
11494900|NCT01390506|Active Comparator|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
11494901|NCT01390506|Placebo Comparator|Placebo|0.9% sodium chloride
11494902|NCT01390493|Experimental|neurofeedback, alpha power|
11494903|NCT01390480|Placebo Comparator|Placebo|peanut oil
11494904|NCT01390480|Active Comparator|Vitamin D (Oleovit®)|cholecalciferol
11494905|NCT01390454|Experimental|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
11494906|NCT01390454|Active Comparator|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
11494907|NCT01390441|Experimental|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.
~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.
~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
11494908|NCT01390441|Active Comparator|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.
~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.
~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
11494909|NCT01390441|Experimental|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.
~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.
~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
11494910|NCT01390441|Active Comparator|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.
~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.
~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
11494975|NCT01390038|Experimental|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
11494976|NCT01390025|Experimental|TCN-032|
11494977|NCT01390025|Placebo Comparator|Placebo|
11494911|NCT01390441|Experimental|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.
~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.
~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
11494912|NCT01390428|Experimental|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
11494913|NCT01390428|Experimental|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
11494914|NCT01390428|Experimental|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
11494915|NCT01390428|Experimental|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
11494916|NCT01390428|Experimental|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
11494917|NCT01390428|Experimental|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
11494918|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
11494919|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
11494920|NCT01390402|Experimental|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
11494921|NCT01390389|Experimental|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:
~Visit 1 (Baseline) start at 400mg once a day for two weeks
~Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks
~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
11494922|NCT01390389|No Intervention|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
11494923|NCT01390376|Experimental|BE 1|DAAOI-1 1g
11494924|NCT01390376|Experimental|BE 2|DAAOI-1 2g
11494925|NCT01390376|Placebo Comparator|starch pill|
11494926|NCT01390363|No Intervention|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
11494927|NCT01390363|Experimental|Parent Only Group|Parent Only Phone Call
11494928|NCT01390363|Experimental|Parent and Adolescent Group|Parent and Adolescent Phone Call
11494929|NCT01390350|Placebo Comparator|Placebo|
11494930|NCT01390350|Experimental|Canakinumab|
11494931|NCT01390337|Experimental|AC220|
11494932|NCT01390324|Experimental|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
11494933|NCT01390324|Active Comparator|Naratriptan|Naratriptan
11494934|NCT01390324|Active Comparator|Naproxen|Naproxen
11494935|NCT01390311|Active Comparator|Control Cohort|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)
~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight
~No Azacitidine will be given"
11494936|NCT01390311|Experimental|Cohort 1 (Starting Dose)|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)
~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight
~Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
11494937|NCT01390311|Experimental|Cohort 2|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)
~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight
~Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
11494938|NCT01390298||Observational|Adult patients scheduled for elective unicompartmental or total knee replacement surgery or total hip replacement will be consented to participate
11494939|NCT01390285|Experimental|TENS|
11494940|NCT01390285|Sham Comparator|Sham TENS|
11494941|NCT01390272|Experimental|Titration Intervention|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) [top number of blood pressure measurement].
~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.
~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.
~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
11494942|NCT01390272|Active Comparator|LPN Control|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
11494978|NCT01390012|Active Comparator|Dexamethasone oral|
11494979|NCT01390012|Active Comparator|Dexamethasone intravenous|
11494980|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
11494943|NCT01390259|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:
~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;
~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
11494944|NCT01390259|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
11494945|NCT01390246|Active Comparator|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.
~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
11494946|NCT01390246|Placebo Comparator|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.
~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
11494947|NCT01390233|Active Comparator|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
11494948|NCT01390233|Active Comparator|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
11494949|NCT01390233|Experimental|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
11494950|NCT01390220|Experimental|USL261|intranasal midazolam 5mg
11494951|NCT01390220|Experimental|Placebo|Intranasal placebo
11494952|NCT01390207|Experimental|16mm follicles|
11494953|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
11494954|NCT01390181|Experimental|Losartan|
11494955|NCT01390168|Experimental|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
11494956|NCT01390168|Active Comparator|waitlist|waitlist
11494957|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
11494958|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
11494959|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
11494960|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
11494961|NCT01390142|Experimental|Control|
11494962|NCT01390142|Active Comparator|RIPer|Remote ischemic preconditioning
11494963|NCT01390142|Active Comparator|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
11494964|NCT01390129|Experimental|Control|
11494965|NCT01390129|Active Comparator|Remote ischemic preconditioning|
11494966|NCT01390116|Placebo Comparator|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
11494967|NCT01390116|Experimental|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
11494968|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
11494969|NCT01390077|Experimental|Nitisinone|all subjects will receive open-label nitisinone
11494970|NCT01390064|Experimental|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
11494971|NCT01390064|Active Comparator|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
11494972|NCT01390064|Active Comparator|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
11494973|NCT01390051|Active Comparator|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
11494974|NCT01390051|No Intervention|no treatment|
11495170|NCT01388725||Sepsis|SIRS + infection
11494981|NCT01389986|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
11494982|NCT01389986|No Intervention|Conventional|Conventional postoperative feeding schedule
11494983|NCT01389973|Experimental|Open-label: ustekinumab 90 mg|
11494984|NCT01389973|Experimental|Double-blind: ustekinumab 45 mg|
11494985|NCT01389973|Experimental|Double-blind: ustekinumab 90 mg|
11494986|NCT01389973|Experimental|Double-blind: ustekinumb 180 mg|
11494987|NCT01389973|Placebo Comparator|Double-blind: placebo|
11494988|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
11494989|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
11494990|NCT01389934|Placebo Comparator|Control|Women of this group be infused saline 2 ml / h for 48h.
11494991|NCT01389934|Experimental|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
11494992|NCT01389921|Experimental|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
11494993|NCT01389921|Experimental|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
11494994|NCT01389921|Other|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
11494995|NCT01389908|Experimental|schizophrenia|schizophrenia or schizoaffective patients
11494996|NCT01389895|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
11494997|NCT01389895|Placebo Comparator|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
11494998|NCT01389882|Experimental|ventilator assist|
11494999|NCT01389869|Experimental|Tears|Emotional tears of female volunteers while watching sad video clips
11495000|NCT01389869|Placebo Comparator|Saline|Saline collected after being trickled down women's skin below eyes like tears
11495001|NCT01389869|Placebo Comparator|Fasting|Their own overnight fasting plasma of male volunteers
11495002|NCT01389869|Experimental|Prandial|Their own postprandial plasma of male volunteers
11495003|NCT01389856|Experimental|1|Bosentan
11495004|NCT01389856|Placebo Comparator|2|Matching placebo
11495005|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)
~Symptom and/or sign of heart failure
~Lung congestion
~Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
11495006|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
11495007|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
11495008|NCT01389817|Experimental|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
11495009|NCT01389817|No Intervention|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
11495010|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
11495011|NCT01389791|No Intervention|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
11495012|NCT01389791|Active Comparator|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
11495013|NCT01389791|Experimental|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
11495014|NCT01389791|Active Comparator|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
11495015|NCT01389778|Experimental|Metformin|Subjects treated with metformin.
11495016|NCT01389765|Experimental|LY2216684 administered in fasted then fed state|Period 1: Single 18-mg (milligram) oral dose of LY2216684 administered in fasted state. Period 2: Single 18-mg oral dose of LY2216684 administered in fed state. Periods will be separated by a minimum of 7 days.
11495017|NCT01389765|Experimental|LY2216684 administered in fed then fasted state|Period 1: Single 18-mg oral dose of LY2216684 administered in fed state. Period 2: Single 18-mg oral dose of LY2216684 administered in fasted state. Periods will be separated by a minimum of 7 days.
11495018|NCT01389752|Experimental|LY2216684 without Charcoal, then with Charcoal|Period 1: Single 18-mg (milligram) (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg (gram/kilogram) of Activated Charcoal. Periods will be separated by a minimum of 7 days.
11495019|NCT01389752|Experimental|LY2216684 with Charcoal, then without Charcoal|Period 1: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg of Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Periods will be separated by a minimum of 7 days.
11495020|NCT01389739|Experimental|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
11495021|NCT01389739|No Intervention|Usual care|
11495022|NCT01389726|Experimental|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
11495171|NCT01388712|Placebo Comparator|Placebo|
11495023|NCT01389726|Experimental|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson & Dolores Gallagher Thompson)
11495024|NCT01389726|Active Comparator|Psychosocial-Informational Support|Standard of Care informational support group
11495025|NCT01389713|Active Comparator|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
11495026|NCT01389713|Experimental|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
11495027|NCT01389700|Experimental|SAR279356 dose 1|SAR279356 dose 1, single administration
11495028|NCT01389700|Experimental|SAR279356 dose 2|SAR279356 dose 2, single administration
11495029|NCT01389700|Placebo Comparator|Placebo|Matching placebo, single administration
11495030|NCT01389687|Experimental|Study Group|
11495031|NCT01389674|Experimental|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
11495032|NCT01389661|Experimental|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
11495033|NCT01389648|Experimental|Pre Operative|Pre operative chest physiotherapy treatment
11495034|NCT01389648|No Intervention|usual care|
11495035|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
11495036|NCT01389622|Experimental|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
11495037|NCT01389622|Experimental|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
11495038|NCT01389622|No Intervention|Arm 3 (20 participants): NO acupressure, only advice + support|
11495039|NCT01389609|Experimental|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
11495040|NCT01389609|Experimental|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
11495041|NCT01389609|Experimental|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
11495042|NCT01389596|Placebo Comparator|Placebo|
11495043|NCT01389596|Experimental|Pregabalin Level 1 (max 150 mg/day)|
11495044|NCT01389596|Experimental|Pregabalin Level 2 (max 600 mg day)|
11495045|NCT01389583|Experimental|AUY922|AUY922
11495046|NCT01389570|Experimental|Acupressure wrist band|The group receiving acupressure wrist band
11495047|NCT01389544|Experimental|Single Arm|
11495048|NCT01389531|Other|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
11495049|NCT01389518|Active Comparator|Paracetamol,Chlorpheniramin,Phenylephrin|
11495050|NCT01389518|Placebo Comparator|Placebo|
11495051|NCT01389505|Active Comparator|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
11495052|NCT01389505|Experimental|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
11495053|NCT01389492|Other|frozen meat|250 g of frozen meat meal for 4 days
11495054|NCT01389492|Other|frozen meat and wine|250 g of frozen meat and red wine for 4 days
11495055|NCT01389492|Other|fresh meat|250 g of fresh meat meal
11495056|NCT01389492|Other|fresh meat and wine|250 g of fresh meat meal
11495057|NCT01389479|Experimental|Fluviral Group|
11495058|NCT01389479|Active Comparator|Fluzone Group|
11495059|NCT01389466|Experimental|MG1109 - Step 1|
11495060|NCT01389466|Placebo Comparator|Normal Saline - Step 1|
11495061|NCT01389466|Experimental|MG1109 - Step 2|
11495062|NCT01389453|Active Comparator|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
11495063|NCT01389453|No Intervention|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
11495064|NCT01389440|Experimental|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
11495065|NCT01389427|Experimental|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
11495066|NCT01389427|Experimental|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
11495067|NCT01389427|Experimental|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
11495068|NCT01389427|Experimental|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
11495069|NCT01389414|Experimental|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.
~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.
~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
11495070|NCT01389414|Active Comparator|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
11495071|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
11495072|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
11495073|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
11495265|NCT01387984||Type 2 diabetes mellitus|
11495074|NCT01389388|Experimental|Rosuvastatin intervention|Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
11495075|NCT01389375|Experimental|FemoSeal®|Device: FemoSeal®
11495076|NCT01389375|Experimental|ExoSeal®|Device: ExoSeal®
11495077|NCT01389375|Active Comparator|Manual compression|Other: Manual compression
11495078|NCT01389362|Active Comparator|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
11495079|NCT01389362|Placebo Comparator|Placebo arm|2 sachets to be taken daily
11495080|NCT01389349|Experimental|Acupuncture|
11495081|NCT01389349|Sham Comparator|Sham Control|
11495082|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle & yoga posture advice and daily self-applied massage on top of standard care.
11495083|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
11495084|NCT01389323|Experimental|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
11495085|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
11495086|NCT01389297|Active Comparator|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
11495087|NCT01389297|Experimental|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
11495088|NCT01389297|Experimental|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
11495089|NCT01389284|Experimental|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
11495090|NCT01389284|Active Comparator|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
11495091|NCT01389284|Placebo Comparator|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
11495092|NCT01389271||Group 1|
11495093|NCT01389258|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
11495094|NCT01389245|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
11495095|NCT01389232|Experimental|1|SeriScaffold® Surgical Scaffold
11495096|NCT01389219|No Intervention|Control|Control arm
11495097|NCT01389219|Other|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
11495098|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
11495099|NCT01389193|Experimental|Ibudilast|
11495100|NCT01389193|Placebo Comparator|Placebo|
11495101|NCT01389180|Experimental|BDRC|
11495102|NCT01389180|Experimental|EC|
11495103|NCT01389180|Other|TAU|
11495104|NCT01389167|Experimental|Vivitrol + BDRC|
11495105|NCT01389167|Experimental|Vivitrol + Medical Management|
11495106|NCT01389167|Experimental|Naltrexone (oral)+BDRC|
11495107|NCT01389167|Experimental|Naltrexone (oral) + Medical Management|
11495108|NCT01389154|Experimental|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
11495109|NCT01389141||mid-reproductive age|
11495110|NCT01389141||late reproductive age-1|
11495111|NCT01389141||late reproductive age-2|
11495112|NCT01389128|Active Comparator|Control Group|Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
11495113|NCT01389128|Experimental|Intervention Group|Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: pelvic mobility , lumbosacral massage and warm shower.
11495114|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
11495115|NCT01389115||Liver donors|Subjects eligible for organ explant
11495116|NCT01389115||Healthy controls|
11495117|NCT01389102|Placebo Comparator|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
11495118|NCT01389102|Placebo Comparator|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
11495119|NCT01389102|Placebo Comparator|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
11495172|NCT01388712|Active Comparator|Probiotics|Lactobacillus reuteri DSM 17938
11495120|NCT01389102|Active Comparator|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
11495121|NCT01389102|Active Comparator|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
11495122|NCT01389102|Active Comparator|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
11495123|NCT01389089|No Intervention|Control group|The Control group received ice gel packs and elevation to reduce edema.
11495124|NCT01389089|Experimental|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
11495125|NCT01389089|Experimental|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
11495126|NCT01389076|Experimental|Treatment arm|Low dose methotrexate and Bexxar
11495127|NCT01389063|Active Comparator|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
11495128|NCT01389063|Active Comparator|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
11495129|NCT01389050|No Intervention|Follow-up|Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
11495130|NCT01389050|Experimental|Prospective|
11495131|NCT01389037|Experimental|Health Literacy-focused Self-help|
11495132|NCT01389037|Placebo Comparator|Delayed intervention control|
11495133|NCT01389024|Experimental|Hydroxyurea|treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or ANC <4000
11495134|NCT01389024|Placebo Comparator|Placebo|Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day
11495135|NCT01388985|Active Comparator|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
11495136|NCT01388985|Experimental|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
11495137|NCT01388959|Experimental|Single arm|
11495138|NCT01388946|Active Comparator|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
11495139|NCT01388946|Placebo Comparator|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
11495140|NCT01388933|Experimental|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
11495141|NCT01388933|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
11495142|NCT01388920|Experimental|Tesamorelin 2 mg|Tesamorelin 2 mg/day
11495143|NCT01388920|Experimental|Tesamorelin 3 mg|Tesamorelin 3 mg/day
11495144|NCT01388920|Placebo Comparator|Placebo|
11495145|NCT01388907|Experimental|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
11495146|NCT01388907|Active Comparator|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
11495147|NCT01388881|Experimental|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
11495148|NCT01388881|No Intervention|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
11495149|NCT01388868|Active Comparator|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
11495150|NCT01388868|Experimental|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
11495151|NCT01388868|Experimental|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
11495152|NCT01388855|Experimental|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
11495153|NCT01388855|Placebo Comparator|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
11495154|NCT01388842|Placebo Comparator|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
11495155|NCT01388842|Experimental|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
11495156|NCT01388829|Experimental|formulation comparison|formulation comparison
11495157|NCT01388816|Placebo Comparator|Placebo capsule|
11495158|NCT01388816|Experimental|DRL-17822 50 mg|
11495159|NCT01388816|Experimental|DRL-17822 150 mg|
11495160|NCT01388816|Experimental|DRL-17822 300 mg|
11495161|NCT01388790|Experimental|Cetuximab plus cisplatin plus S-1|
11495162|NCT01388777|Experimental|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
11495163|NCT01388764|Experimental|L-arginine|
11495164|NCT01388751|No Intervention|no night splinting|
11495165|NCT01388751|Active Comparator|night splinting|Night Splinting for 4 weeks after removal of initial cast
11495166|NCT01388738|Active Comparator|cerebrolysin|IV
11495167|NCT01388738|Active Comparator|L-Alpha glycerylphosphorylcholine|IV
11495168|NCT01388738|Active Comparator|citicoline|IV and per os
11495169|NCT01388725||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
11495177|NCT01388660|Experimental|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
11495178|NCT01388660|Active Comparator|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
11495179|NCT01388647|Experimental|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
11495180|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
11495181|NCT01388634||control group|Patients without prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
11495182|NCT01388621|Experimental|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles
~OR
~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles
~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
11495183|NCT01388621|Active Comparator|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
~OR
~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
11495184|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
11495185|NCT01388595|Active Comparator|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
11495186|NCT01388595|Active Comparator|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
11495187|NCT01388595|Placebo Comparator|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
11495188|NCT01388582|Active Comparator|Combined oral contraceptive|10 women will receive COC during breastfeeding
11495189|NCT01388582|Active Comparator|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
11495190|NCT01388582|Active Comparator|Implanon|10 women will receive Implanon during breastfeeding
11495191|NCT01388582|Active Comparator|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
11495192|NCT01388556|Experimental|Tango|Twice weekly tango dance classes for 12 months.
11495193|NCT01388556|No Intervention|Control Group|
11495194|NCT01388543|Active Comparator|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
11495195|NCT01388543|Active Comparator|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
11495196|NCT01388530|Experimental|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
11495197|NCT01388517|Active Comparator|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
11495198|NCT01388517|Active Comparator|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
11495199|NCT01388517|Placebo Comparator|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
11495200|NCT01388504|Experimental|sodium nitrite|
11495201|NCT01388504|Placebo Comparator|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
11495202|NCT01388491|Experimental|Treatment I: (DR-102)|21 days of combination active pills (containing 150 mcg desogestrel [DSG]/20 mcg ethinyl estradiol [EE]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
11495203|NCT01388491|Active Comparator|Treatment II|21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
11495204|NCT01388478|Experimental|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
11495205|NCT01388465|Experimental|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
11495206|NCT01388465|No Intervention|Control|No TM queries or feedback
11495207|NCT01388452|Experimental|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
11495208|NCT01388452|No Intervention|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.
~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
11495266|NCT01387971||ocular surface disorders|various ocular surface disorders
11495267|NCT01387958|Experimental|LCQ908|
11495268|NCT01387958|Placebo Comparator|Placebo|
11495269|NCT01387945|No Intervention|HBPM only|
11495209|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
11495210|NCT01388426|Experimental|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
11495211|NCT01388413|Experimental|Weekly Oral Cyclic Antibiotic programme|
11495212|NCT01388413|No Intervention|Classic care|
11495213|NCT01388400|Experimental|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
11495214|NCT01388400|Experimental|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
11495215|NCT01388387|Experimental|Tacrolimus pharmacokinetics|
11495216|NCT01388374|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
11495217|NCT01388374|Experimental|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
11495218|NCT01388361|Experimental|IDeg (non-randomised)|
11495219|NCT01388361|Experimental|IDeg + IAsp|
11495220|NCT01388361|Experimental|IDeg + liraglutide|
11495221|NCT01388348|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
11495222|NCT01388335|Experimental|warfarin + enzastaurin|"On Day 1 of Period 1, a single 5-milligram (mg) oral dose of warfarin will be given, followed by at least a 7-day washout.
~Period 2: 500 mg enzastaurin administered orally once daily for at least 19 consecutive days and 5 mg warfarin administered as a single oral dose on Day 15.
~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
11495223|NCT01388322|Experimental|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
11495224|NCT01388322|No Intervention|expectant management|Usual management
11495225|NCT01388309||Cohort|
11495226|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
11495227|NCT01388296||Morbidly obese|BMI 50-60 k/m2
11495228|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
11495229|NCT01388270|Active Comparator|Evodial|a pre-heparin-coated hemodialysis filter
11495230|NCT01388270|No Intervention|170 H|Conventional filter
11495231|NCT01388257|Experimental|Surgery|Seton drain removal is associated with proctological surgery.
11495232|NCT01388257|Other|Simple seton drain removal|
11495233|NCT01388244|Active Comparator|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
11495234|NCT01388244|Other|Control|Control arm - Fracture risk assessment by FRAX without any intervention
11495235|NCT01388231|Active Comparator|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
11495236|NCT01388231|Active Comparator|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
11495237|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
11495238|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
11495239|NCT01388205|Experimental|Family-based Intervention Arm|
11495240|NCT01388205|No Intervention|Control|
11495241|NCT01388192||Receiving pancreaticoduodenectomy|
11495242|NCT01388179|Active Comparator|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
11495243|NCT01388179|Sham Comparator|Sham rTMS treatment|Sham coil which simulate the real coil action
11495244|NCT01388166||Patients with COPD|
11495245|NCT01388153|Experimental|Arm 1|
11495246|NCT01388153|Experimental|Arm 2|
11495247|NCT01388153|Active Comparator|Arm 3|
11495248|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
11495249|NCT01388114|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
11495250|NCT01388101|Experimental|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
11495251|NCT01388088|Active Comparator|Spironolactone|Increases the level of potassium
11495252|NCT01388088|Active Comparator|Amiloride|Increases the level of potassium
11495253|NCT01388088|Placebo Comparator|Placebo|
11495254|NCT01388075|Experimental|Rifampicin|Consecutive treatments with rifampicin and placebo
11495255|NCT01388062|Experimental|virus detection|
11495256|NCT01388049|Experimental|virus detection|
11495257|NCT01388036|Experimental|esmolol infusion|infusion of esmolol during rest and exercise
11495258|NCT01388023|Active Comparator|smellx|test group- SmellX palatal patch with the herbal formula
11495259|NCT01388023|Placebo Comparator|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
11495260|NCT01388023|Active Comparator|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
11495261|NCT01388023|Active Comparator|listerine|listerine mouth wash
11495262|NCT01388010|Experimental|1 = Test product|Arm 1 - Intervention 1 (probiotics)
11495263|NCT01388010|Other|2 = Control product|Arm 2 - Intervention 2 (control)
11495264|NCT01387997|Experimental|1|
11495271|NCT01387932|Experimental|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
11495272|NCT01387932|Active Comparator|Conventional TACE|Conventional TACE
11495273|NCT01387919|Experimental|1|healthy young and lean men
11495274|NCT01387906|Experimental|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
11495275|NCT01387893|Experimental|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
11495276|NCT01387880|Experimental|Cetuximab, everolimus, irinotecan|
11495277|NCT01387880|Active Comparator|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.
~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
11495278|NCT01387867|Experimental|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
11495279|NCT01387867|Experimental|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
11495280|NCT01387867|Active Comparator|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
11495281|NCT01387841|Experimental|Yoga group|Yoga intervention with standard antiemetic care
11495282|NCT01387841|Active Comparator|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
11495283|NCT01387841|No Intervention|Standard antiemetic care|Standard antiemetic care only
11495284|NCT01387828|Active Comparator|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
11495285|NCT01387828|Active Comparator|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
11495286|NCT01387815||Topical/Traditional Systemic Agent|Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
11495287|NCT01387815||Adalimumab|Participants treated with adalimumab alone or in combination with topical agents.
11495288|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
11495289|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
11495290|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
11495291|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
11495292|NCT01387763|Active Comparator|PegIntron <= 60 years|In patients <= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
11495293|NCT01387763|Active Comparator|Pegasys <= 60 years|In patients <= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
11495294|NCT01387763|Active Comparator|PegIntron > 60 years|In patients < 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
11495295|NCT01387763|Active Comparator|Pegasys > 60 years|In patients > 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
11495296|NCT01387763|Active Comparator|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
11495297|NCT01387750|Placebo Comparator|Mentholated Cream|
11495298|NCT01387750|Active Comparator|Mentholated Cream with OGT|
11495299|NCT01387737|Experimental|TA-7284-Low|
11495300|NCT01387737|Experimental|TA-7284-High|
11495301|NCT01387711|Experimental|ingenol mebutate|PEP gel 0.05% once daily exposure
11495302|NCT01387672|Active Comparator|Nitrol|Nitroglycerin Ointment 2% USP
11495303|NCT01387672|Active Comparator|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
11495304|NCT01387672|Active Comparator|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
11495305|NCT01387672|Active Comparator|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
11495306|NCT01387672|Active Comparator|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
11495307|NCT01387672|Placebo Comparator|Placebo|Placebo Ointment
11495308|NCT01387659|Experimental|Transplant recipients|All subjects receive identical drug treatment
11495347|NCT01387308|Sham Comparator|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
11495348|NCT01387308|Experimental|C|Fostamatinib 100 mg tablet (new formulation)
11495309|NCT01387646|Other|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
11495310|NCT01387633|Experimental|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
11495311|NCT01387633|Active Comparator|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
11495312|NCT01387607|Experimental|Pregabalin|
11495313|NCT01387607|Placebo Comparator|Placebo|Matched placebo
11495314|NCT01387594|Experimental|Cohort 1|Interventions prior to treatment. Control arm
11495315|NCT01387594|Experimental|Cohort 2|Interventions prior to and after 3 monthly injections
11495316|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
11495317|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
11495318|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
11495319|NCT01387568|Active Comparator|group L|Lidocaine group
11495320|NCT01387568|Placebo Comparator|group P|Placebo group
11495321|NCT01387555|Experimental|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
11495322|NCT01387555|Other|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
11495323|NCT01387542|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
11495324|NCT01387516|Experimental|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
11495325|NCT01387516|Active Comparator|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
11495326|NCT01387516|Experimental|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
11495327|NCT01387516|Active Comparator|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
11495328|NCT01387503|Experimental|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
11495329|NCT01387503|No Intervention|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
11495330|NCT01387490|Experimental|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
11495331|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
11495332|NCT01387477|Experimental|Lactate|infusion of 66 mmol of lactate
11495333|NCT01387477|Active Comparator|glucose|infusion of 33 mmol of glucose
11495334|NCT01387464|Experimental|ISV-303|
11495335|NCT01387464|Active Comparator|Bromday™|
11495336|NCT01387425|Active Comparator|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
11495337|NCT01387425|Placebo Comparator|control group|
11495338|NCT01387412||Genital warts|Those with and without ano-genital warts
11495339|NCT01387399|Experimental|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
11495340|NCT01387373|Experimental|chemotherapy|
11495341|NCT01387360|Experimental|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
11495342|NCT01387347|Active Comparator|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
11495343|NCT01387347|Placebo Comparator|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
11495344|NCT01387334|Experimental|Resistance Exercise Training Program|
11495345|NCT01387321|Experimental|BYL719|
11495346|NCT01387308|Experimental|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
11495349|NCT01387308|Experimental|D|Fostamatinib 150 mg tablet (new formulation)
11495350|NCT01387308|Experimental|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
11495351|NCT01387295|Experimental|chemotherapy|
11495352|NCT01387282|Active Comparator|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
11495353|NCT01387282|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
11495354|NCT01387269|Experimental|100 mg QD|Anamorelin HCL 100 mg will be administered daily
11495355|NCT01387269|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
11495356|NCT01387256|Other|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
11495357|NCT01387256|Experimental|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
11495358|NCT01387243||60 mg Orlistat|Purchased by consumer
11495359|NCT01387230|Experimental|GSK573719|active drug
11495360|NCT01387230|Placebo Comparator|Placebo|no active drug
11495361|NCT01387217|Experimental|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
11495362|NCT01387217|Experimental|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
11495363|NCT01387204|Experimental|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
11495364|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
11495365|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
11495366|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
11495367|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
11495368|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
11495369|NCT01387139|Active Comparator|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
11495370|NCT01387139|Experimental|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
11495371|NCT01387126|Experimental|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
11495372|NCT01387126|No Intervention|Weight management program|
11495373|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
11495374|NCT01387100|Experimental|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
11495375|NCT01387100|No Intervention|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
11495376|NCT01387087|Experimental|Group A|Lowest dose, all males, fasting
11495377|NCT01387087|Experimental|Group B|Second lowest dose, all males, fasting
11495378|NCT01387087|Experimental|Group C|Third lowest dose, all males, fasting
11495379|NCT01387087|Experimental|Group D|Middle dose, all males, fasting
11495380|NCT01387087|Experimental|Group E|Third lowest dose, all females, fasting
11495381|NCT01387087|Experimental|Group F|Third highest dose, all males, fasting then fed
11495382|NCT01387087|Experimental|Group G|Second highest dose, all males, fasting
11495383|NCT01387087|Experimental|Group H|Highest dose, all males, fasting
11495384|NCT01387087|Experimental|Group I|Second highest dose, all females, fasting
11495385|NCT01387087|Placebo Comparator|Placebo Group A|all male, fasting
11495386|NCT01387087|Placebo Comparator|Placebo Group B|all male, fasting then fed
11495387|NCT01387087|Placebo Comparator|Placebo Group C|all female, fasting
11495388|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
11495389|NCT01387061|Experimental|hepatic resection|
11496641|NCT01377844|Placebo Comparator|Placebo|Placebo
11495390|NCT01387048|Experimental|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
11495391|NCT01387048|Active Comparator|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
11495392|NCT01387048|Experimental|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
11495393|NCT01387022|Experimental|Tenofovir, lamivudine and efavirenz|
11495394|NCT01387022|Active Comparator|Zidovudine, lamivudine and efavirenz|
11495395|NCT01386996|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
11495396|NCT01386996|Active Comparator|Charcoal and Symbicort Turbuhaler|
11495397|NCT01386996|Experimental|Budesonide/formoterol Easyhaler|
11495398|NCT01386996|Active Comparator|Symbicort Turbuhaler|
11495399|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
11495400|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
11495401|NCT01386970|Active Comparator|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
11495402|NCT01386970|Active Comparator|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
11495403|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
11495404|NCT01386944||Neupro® Treatment|Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
11495405|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
11495406|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
11495407|NCT01386918|Experimental|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
11495408|NCT01386918|Experimental|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
11495409|NCT01386918|Sham Comparator|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
11495410|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
11495411|NCT01386879|Experimental|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
11495412|NCT01386879|Experimental|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
11495413|NCT01386879|Active Comparator|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
11495414|NCT01386866|Experimental|A|
11495415|NCT01386853|Experimental|Pitavastatin|
11495416|NCT01386853|Active Comparator|Atorvastatin|
11495417|NCT01386840|No Intervention|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.
~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
11495418|NCT01386840|Experimental|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.
~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
11495419|NCT01386827|Active Comparator|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
11495420|NCT01386827|Active Comparator|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
11495421|NCT01386827|Active Comparator|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
11495422|NCT01386827|Active Comparator|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
11495423|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
11495424|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
11495425|NCT01386788||Smoke Inhalation patients|Closed space fire, Soot deposits, Altered mental status Blood specimen before intravenous antidote treatment (cyanide measurement) Known delay between end of smoke exposure and blood sampling
11495426|NCT01386775||HED Affected Males|
11495427|NCT01386775||Controls|
11495428|NCT01386762|Experimental|Exercise intervention|6 months of intense multimodal training.
11495429|NCT01386749|No Intervention|Control|
11495430|NCT01386749|Experimental|Treatment|receive 6 months LMHFV
11495431|NCT01386736|Active Comparator|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
11495432|NCT01386736|Placebo Comparator|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
11495433|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
11495434|NCT01386710|Experimental|Arm 2|Drug: Bevacizumab and Carboplatin
11495435|NCT01386710|Experimental|Arm 1|Drug: Bevacizumab and Carboplatin
11495436|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
11495437|NCT01386671|Experimental|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
11495438|NCT01386671|Active Comparator|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
11495439|NCT01386658|Experimental|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
11495440|NCT01386645|Active Comparator|Low GI diet|low glycemic index diet
11495441|NCT01386645|Placebo Comparator|High GI diet placebo|high glycemic index diet plus placebo
11495442|NCT01386645|Active Comparator|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
11495443|NCT01386632|Active Comparator|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
11495444|NCT01386632|Placebo Comparator|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
11495445|NCT01386619|Experimental|NK cell DLI|
11495446|NCT01386606|Experimental|Androxal 6.25 mg|Androxal 6.25 mg/day
11495447|NCT01386606|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
11495448|NCT01386606|Experimental|Androxal 25 mg|Androxal 25 mg/day
11495449|NCT01386606|Active Comparator|AndroGel|AndroGel 5G topical testosterone
11495450|NCT01386593|Other|(A) Baseline|
11495451|NCT01386593|Other|(B) Inhibition|
11495452|NCT01386593|Other|(C) Induction|
11495453|NCT01386580|Experimental|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
11495454|NCT01386580|Experimental|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
11495455|NCT01386580|Experimental|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
11495456|NCT01386580|Experimental|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
11495457|NCT01386567|Experimental|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
11495458|NCT01386567|Active Comparator|Testim (topical testosterone)|
11495459|NCT01386554|Experimental|80 U Acthar|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) two times per week
11495460|NCT01386554|Placebo Comparator|1.0 mL Placebo|Placebo (1.0 mL) two times per week
11495461|NCT01386554|Experimental|40 U Acthar|Acthar (Repository Corticotropin Injection) 40 U (1.0 mL) two times per week
11495462|NCT01386541|Active Comparator|BYK324677|"Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)
~Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)
~Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)
~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.
~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.
~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
11495463|NCT01386541|Placebo Comparator|Placebo|
11495464|NCT01386528|Experimental|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
11495465|NCT01386437||Fungal Infection|Patients with or without inherited or acquired abnormalities of immune function manifesting mucocutaneous and/or invasive fungal infections
11495466|NCT01386424||Healthy Volunteers|Healthy Volunteers
11495467|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
11496225|NCT01380886|Active Comparator|Infant formula powder|Infant formula powder
11495468|NCT01386385|Experimental|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
11495469|NCT01386385|Active Comparator|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
11495470|NCT01386372|Experimental|Tolvaptan|
11495471|NCT01386372|Active Comparator|standard therapy|
11495472|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
11495473|NCT01386346|Experimental|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
11495474|NCT01386333|Experimental|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
11495475|NCT01386333|Experimental|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
11495476|NCT01386333|Experimental|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
11495477|NCT01386333|Placebo Comparator|Saline nasal spray|
11495478|NCT01386320|Active Comparator|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
11495479|NCT01386320|Active Comparator|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
11495480|NCT01386294|Experimental|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
11495481|NCT01386294|Placebo Comparator|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
11495482|NCT01386281||Group 1|Drug (incl. Placebo)
11495483|NCT01386268||Group 1|
11495484|NCT01386255|Active Comparator|baclofen|Baclofen suspension
11495485|NCT01386255|Placebo Comparator|placebo|Identical palcebo suspension
11495486|NCT01386242|Experimental|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
11495487|NCT01386242|Experimental|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
11495488|NCT01386242|Placebo Comparator|Placebo group|Saline Injection, three times per week
11495489|NCT01386242|Experimental|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
11495490|NCT01386229|Active Comparator|Ketamine|
11495491|NCT01386229|Active Comparator|Etomidate|
11495492|NCT01386216|Experimental|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
11495493|NCT01386203||Lung Cancer|
11495494|NCT01386203||Lung Cancer after therapy|
11495495|NCT01386203||COPD controls|
11495496|NCT01386190|Experimental|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
11495497|NCT01386190|Active Comparator|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
11495498|NCT01386177|Experimental|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11495499|NCT01386164|Experimental|Gardasil®|
11495500|NCT01386164|Experimental|Cervarix®|
11495501|NCT01386151|Active Comparator|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
11495502|NCT01386151|Placebo Comparator|Placebo|Saline will be used as a placebo comparator
11495503|NCT01386138|Experimental|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
11495504|NCT01386138|Active Comparator|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
11495505|NCT01386125|Experimental|Mometasone Furoate Nasal Spray (MFNS)|Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
11495506|NCT01386125|Placebo Comparator|Placebo|Participants receive matching placebo nasal spray BID for 16 weeks
11495507|NCT01386112|Experimental|EUR-1100 1.5 mg|
11495508|NCT01386112|Experimental|EUR-1100 3.0 mg|
11495509|NCT01386112|Placebo Comparator|placebo|
11495510|NCT01386099|Experimental|PSN821|
11495511|NCT01386099|Placebo Comparator|Placebo|
11495512|NCT01386086|Experimental|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
11495513|NCT01386073|Active Comparator|FreshKote|
11495514|NCT01386073|Placebo Comparator|Systane|
11495515|NCT01386060|Experimental|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
11496226|NCT01380873|Experimental|Group1|
11496227|NCT01380873|Experimental|Group2|
11495516|NCT01386060|No Intervention|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
11495517|NCT01386047|Experimental|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
11495518|NCT01386047|No Intervention|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
11495519|NCT01386034|Experimental|Citrulline/Placebo|
11495520|NCT01386034|Experimental|Placebo/Citrulline|
11495521|NCT01386021||Prior recipients of allografts for CABG|
11495522|NCT01386008|Other|enfilcon A + senofilcon A|Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
11495523|NCT01385995|Active Comparator|Continuous Positive Airway Pressure (CPAP)|
11495524|NCT01385995|Sham Comparator|Sham-Continuous Positive Airway Pressure (CPAP)|
11495525|NCT01385982|Other|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:
~Defining the levels of severity and urgency for clinically significant test results
~Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.
~Standardized policies for the time frames and nature of communication of test result alerts.
~Establish criteria for appropriate ATR management by the responsible provider.
~Feedback performance including provider, practice and service report cards"
11495526|NCT01385969||Standard Practice|
11495527|NCT01385969||Syringe recoil|
11495528|NCT01385969||Pressure Transducer|
11495529|NCT01385956|Experimental|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.
~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
11495530|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
11495531|NCT01385930|Experimental|Lifestyle counseling|Lifestyle counseling
11495532|NCT01385930|No Intervention|Control group|Control group
11495533|NCT01385891|Experimental|children with advanced leukemia|
11495534|NCT01385878|Active Comparator|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
11495535|NCT01385878|Active Comparator|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
11495536|NCT01385865|Experimental|Mulberry leaf extract|
11495537|NCT01385865|Placebo Comparator|Placebo|
11495538|NCT01385852|Active Comparator|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
11495539|NCT01385852|Active Comparator|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
11495540|NCT01385852|Active Comparator|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
11495541|NCT01385839|Experimental|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
11495542|NCT01385826|Experimental|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
11495543|NCT01385826|Placebo Comparator|placebo|placebo
11495544|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
11495545|NCT01385800|Placebo Comparator|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
11495546|NCT01385800|Experimental|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
11495547|NCT01385800|Experimental|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
11495548|NCT01385800|Experimental|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
11495549|NCT01385774|Active Comparator|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
11495550|NCT01385774|Active Comparator|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
11495551|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
11495552|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
11495553|NCT01385748|Active Comparator|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
11495554|NCT01385748|Active Comparator|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
11495555|NCT01385748|Placebo Comparator|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
11495556|NCT01385735|Placebo Comparator|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
11495557|NCT01385735|Active Comparator|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
11495595|NCT01385488|Experimental|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
11495596|NCT01385488|No Intervention|completion of forms|participants will complete self-report forms
11495597|NCT01385475|Experimental|Control|
11495598|NCT01385449|Experimental|interscalene block|interscalene block
11495599|NCT01385449|Experimental|interscalene catheter|interscalene catheter
11495600|NCT01385436||HPV HSIL cervical carcinoma|
11496228|NCT01380873|Experimental|Group3|
11495558|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
11495559|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
11495560|NCT01385696|Experimental|group A|Genuair first, HandiHaler second
11495561|NCT01385696|Experimental|group B|HandiHaler first, Genuair second
11495562|NCT01385683|Active Comparator|Arm A|Dabigatran then dabigatran and clarithromycin
11495563|NCT01385683|Active Comparator|Arm B|Clarithromycin and dabigatran and dabigatran
11495564|NCT01385657|Experimental|Placebo|Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22
11495565|NCT01385657|Experimental|Dupilumab 150 mg|Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22
11495566|NCT01385657|Experimental|Dupilumab 300 mg|Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22
11495567|NCT01385644|Experimental|1*10^6 MSC / kg|Placental MSC
11495568|NCT01385644|Experimental|2*10^6 MSC / kg|Placental MSC
11495569|NCT01385631|Placebo Comparator|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
11495570|NCT01385631|Experimental|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
11495571|NCT01385618||high responder|females with >15 follicles or E2>3000 after treatment with gonadotropins
11495572|NCT01385618||low responder|patients with <3 follicles or no response to treatment with gonadotropins
11495573|NCT01385618||control|females with an indication for treatment because of male subfertility
11495574|NCT01385605||female patients|ICSI treatment because of male subfertility
11495575|NCT01385592|Experimental|AFQ056 100 mg|
11495576|NCT01385592|Placebo Comparator|Placebo|
11495577|NCT01385579|No Intervention|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
11495578|NCT01385579|Experimental|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
11495579|NCT01385566|Active Comparator|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
11495580|NCT01385566|Experimental|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
11495581|NCT01385566|Experimental|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
11495582|NCT01385566|Experimental|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
11495583|NCT01385566|Experimental|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
11495584|NCT01385566|Experimental|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
11495585|NCT01385553|Active Comparator|Individual Drug Counseling|
11495586|NCT01385553|Experimental|Fathers for Change|
11495587|NCT01385540||Task-based fMRI|
11495588|NCT01385527|Experimental|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
11495589|NCT01385527|Active Comparator|Topical triamcinolone only|Standard of care
11495590|NCT01385514||company A-Training Base No.1|
11495591|NCT01385514||company A-Training Base No.2|
11495592|NCT01385514||company A-Training Base No.3|
11495593|NCT01385501|No Intervention|routine care|
11495594|NCT01385501|Experimental|Educational intervention group|
11495686|NCT01384825||HC|Healthy Controls
11495601|NCT01385423|Experimental|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
11495602|NCT01385410|Active Comparator|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
11495603|NCT01385410|Active Comparator|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
11495604|NCT01385410|No Intervention|Control|Current standard of care and support (national health system)
11495605|NCT01385397|Experimental|Preceptorship and virtual community|
11495606|NCT01385384|Other|NeuRx|
11495607|NCT01385371|Experimental|SCH 697243|
11495608|NCT01385371|Placebo Comparator|Placebo|
11495609|NCT01385358|Experimental|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
11495610|NCT01385358|Active Comparator|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
11495611|NCT01385345|Active Comparator|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
11495612|NCT01385345|Placebo Comparator|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
11495613|NCT01385332|Active Comparator|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
11495614|NCT01385332|Active Comparator|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
11495615|NCT01385319|Active Comparator|bare metal stent|
11495616|NCT01385319|Experimental|Endeavor sprint stent|
11495617|NCT01385306|Experimental|AlphaCore System|non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System
11495618|NCT01385293|Experimental|Study arm|BKM120 at 100mg orally daily
11495619|NCT01385280|Experimental|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
11495620|NCT01385267||Diamniotic twin gestations|
11495621|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at <33 weeks gestation and <1500 grams at birth
11495622|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
11495623|NCT01385241|Experimental|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
11495624|NCT01385241|No Intervention|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
11495625|NCT01385228|Experimental|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
11495626|NCT01385228|Experimental|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
11495627|NCT01385215|Placebo Comparator|Placebo|
11495628|NCT01385215|Placebo Comparator|Nasal Aerosol Immunization|
11495629|NCT01385215|Placebo Comparator|Nasal Droplet Immunization|
11495630|NCT01385215|Placebo Comparator|Intramuscular Immunization|
11495631|NCT01385202|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
11495632|NCT01385189|Experimental|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
11495633|NCT01385189|Experimental|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
11495634|NCT01385189|Experimental|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
11495635|NCT01385189|Experimental|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
11495636|NCT01385189|Experimental|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
11495637|NCT01385176|Experimental|Therapy|"Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.
~The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.
~Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.
~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
11495638|NCT01385176|Sham Comparator|Control|"Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.
~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
11495639|NCT01385163|No Intervention|Control - VSLA|the wait control sample for the economic intervention
11495640|NCT01385163|Other|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
11495641|NCT01385163|Experimental|Voluntary Savings/Loans Assoc|
11495642|NCT01385163|Experimental|Cognitive Processing Therapy|
11495643|NCT01385137|Experimental|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
11495787|NCT01384136||"|Control - Normal low risk pregnancies"|
11495644|NCT01385137|Placebo Comparator|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
11495645|NCT01385124|Experimental|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
11495646|NCT01385111|Active Comparator|Arm A|EBUS centered
11495647|NCT01385111|Experimental|Arm B|EUS centered
11495648|NCT01385098|Experimental|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
11495649|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
11495650|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
11495651|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
11495652|NCT01385072|Experimental|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.
~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
11495653|NCT01385059|Experimental|Arm I (neoadjuvant enzyme inhibitor and prostatectomy)|Patients receive axitinib PO BID on days 1-28. Patients then undergo prostatectomy and pelvic lymph node dissection. Treatment continues in the absence of disease progression or unacceptable toxicity.
11495654|NCT01385059|Active Comparator|Arm II (surgery)|Patients undergo prostatectomy and pelvic lymph node dissection at 5-6 weeks after biopsy confirmation of prostate cancer.
11495655|NCT01385046|Experimental|physical activity and nutrition|
11495656|NCT01385033|Experimental|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
11495657|NCT01385033|Experimental|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
11495658|NCT01385033|Experimental|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
11495659|NCT01385020|Experimental|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
11495660|NCT01384994|Experimental|FOLFOX + Panitumumab|
11495661|NCT01384994|Active Comparator|FOLFOX|
11495662|NCT01384981|Active Comparator|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
11495663|NCT01384981|Sham Comparator|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
11495664|NCT01384968|Experimental|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
11495665|NCT01384968|Placebo Comparator|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
11495666|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
11495667|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
11495668|NCT01384942|Experimental|Meaning-Based Bereavement Group|
11495669|NCT01384942|Active Comparator|Conventional Bereavement Group|
11495670|NCT01384929||ICU patients|All patients present in the ICU on the selected days
11495671|NCT01384916|Experimental|Yoga|
11495672|NCT01384916|Active Comparator|Health education|
11495673|NCT01384903|Experimental|KW-3357|
11495674|NCT01384903|Active Comparator|Plasma-derived antithrombin|
11495675|NCT01384890|Experimental|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
11495676|NCT01384890|Active Comparator|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
11495677|NCT01384877|Experimental|Lidocaine|Lidocaine
11495678|NCT01384877|Placebo Comparator|Placebo (D5W)|Placebo first as compared with lidocaine first
11495679|NCT01384864|Experimental|treatment|fluorescent imaging with proflavine
11495680|NCT01384851|Experimental|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
11495681|NCT01384851|Active Comparator|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
11495682|NCT01384851|Active Comparator|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
11495683|NCT01384838|Other|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
11495684|NCT01384838|Experimental|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
11495685|NCT01384825||MS|Subjects with Multiple Sclerosis
11495687|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
11495688|NCT01384812|Placebo Comparator|Isoton sodium chloride|
11495689|NCT01384812|Active Comparator|Prostin E2 (dinoprostone)|
11495690|NCT01384760|Active Comparator|Lifestyle modification program|"At the 1st session, the dietitian carried out a complete behavioral assessment, with emphasis on patient's current eating and lifestyle patterns, specific eating-related behaviors, knowledge of risks associated with current eating patterns, and concerns and feelings about specific lifestyle changes. In the subsequent follow up visit, the dietitian reviewed the 7-day food diaries to ensure nutritional adequacy and treatment compliance, and also offered recommendations for controlling caloric intake.
~Patients were encouraged to see an exercise instructor who designed an individualized suitable exercise regime with cardiovascular and resistance exercises for the patients to perform at home. Subjects were encouraged to perform 30-minute aerobic exercise 2-3 times a week."
11495691|NCT01384760|Placebo Comparator|Simple lifestyle advice|Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
11495692|NCT01384747|Experimental|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
11495693|NCT01384747|Placebo Comparator|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
11495694|NCT01384734|Experimental|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
11495695|NCT01384734|Experimental|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
11495696|NCT01384734|Experimental|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
11495697|NCT01384734|Experimental|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
11495698|NCT01384734|Active Comparator|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
11495699|NCT01384708|Experimental|treatment|imaging with proflavine
11495700|NCT01384695|Experimental|Fluorescein|Confocal imaging using contrast agent fluorescein
11495701|NCT01384695|Experimental|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
11495702|NCT01384682|No Intervention|No change|continue their current cART regimen
11495703|NCT01384682|Active Comparator|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
11495704|NCT01384682|Active Comparator|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
11495705|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
11495706|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
11495707|NCT01384656|Experimental|GIK group|
11495708|NCT01384656|Placebo Comparator|Control group|
11495709|NCT01384643|Experimental|Propofol group|
11495710|NCT01384643|Placebo Comparator|Control group|
11495711|NCT01384630|Other|Single group|
11495712|NCT01384617|Experimental|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
11495713|NCT01384617|Active Comparator|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
11495714|NCT01384591|Experimental|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
11495715|NCT01384591|Placebo Comparator|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
11495716|NCT01384591|Experimental|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
11495717|NCT01384578|Experimental|pentoxiphylline and Vitamin E|
11495718|NCT01384578|Active Comparator|Vitamin E|
11495719|NCT01384565|Active Comparator|G-CSF+EPO|
11495720|NCT01384565|Placebo Comparator|Placebo|
11495721|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495722|NCT01384552|Active Comparator|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495723|NCT01384552|Active Comparator|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495724|NCT01384552|Active Comparator|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495725|NCT01384552|Active Comparator|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495726|NCT01384552|Active Comparator|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495727|NCT01384552|Active Comparator|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495728|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
11495729|NCT01384539|Experimental|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
11495730|NCT01384539|Experimental|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
11495731|NCT01384526||history of hormone therapy|
11495732|NCT01384526||no history of hormone therapy|
11495733|NCT01384513|Experimental|Treatment (Allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.
~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28."
11495734|NCT01384500|Experimental|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
11495735|NCT01384500|No Intervention|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
11495736|NCT01384487||Normal Eyes|Eyes without disease
11495737|NCT01384487||Eyes with Glaucoma|
11495738|NCT01384487||Eyes with Retinal Disease|
11495739|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
11495740|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
11495741|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
11495742|NCT01384461||Cohort|
11495743|NCT01384448|Experimental|Initial Stress Echocardiography|
11495744|NCT01384448|Experimental|Initial Coronary CT Angiography|
11495745|NCT01384435|Experimental|KPS-0373, lowest dose|
11495746|NCT01384435|Experimental|KPS-0373, 2nd lowest dose|
11495747|NCT01384435|Experimental|KPS-0373, 2nd highest dose|
11495748|NCT01384435|Experimental|KPS-0373, highest dose|
11495749|NCT01384435|Placebo Comparator|Placebo|
11495750|NCT01384422|Experimental|GLPG0634 100 mg bid oral capsules|
11495751|NCT01384422|Experimental|GLPG0634 200 mg qd oral capsules|
11495752|NCT01384422|Placebo Comparator|Placebo oral capsules|
11495753|NCT01384409|Experimental|KW-3357|
11495754|NCT01384396|Experimental|KW-3357|
11495755|NCT01384383|Experimental|Arm 1|Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.
11495756|NCT01384383|Experimental|Arm 2|Response-Guided Therapy with PEG and RBV for 24 weeks.
11495757|NCT01384370||AHPV positive and negative subjects|
11495758|NCT01384357||ultrasound,lymphadenopathy|
11495759|NCT01384344|Active Comparator|witness|no mnesic complaint
11495760|NCT01384344|Experimental|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
11495761|NCT01384344|Experimental|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
11495762|NCT01384331|Active Comparator|Group 1 Marvelon ,placebo|"7 days daily intake of oral capsule containing Marvelon ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules containing starch for 21 day treatment Cycle"
11495763|NCT01384331|Active Comparator|Marvelon|"21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms
~for one cycle of 21 days"
11495764|NCT01384331|Active Comparator|NuvaRing|21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days Treatment will be for 21 days
11495765|NCT01384331|Placebo Comparator|Starch capsule|21 days daily oral placebo capsules Treatment will be for one 21 day cycle
11495766|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
11495767|NCT01384292|Experimental|1 (part A and B)|Oral treatment
11495768|NCT01384292|Experimental|2 (part A and B)|Oral treatment
11495769|NCT01384292|Placebo Comparator|3 (part A only)|Oral treatment
11495770|NCT01384279|Experimental|metformin, topiramate|
11495771|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
11495772|NCT01384253|Experimental|Phase I: Dose escalation|In preparation for the study, patients screened and eligible will have a peritoneal catheter placed and the evening prior to the injection of the labeled antibody will receive furosemide. Herceptin will be administered IV followed by a single IP infusion of ²¹²Pb-TCMC-Trastuzumab. Serial sampling of blood, urine, and dosimetry will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antitumor effects.
11495773|NCT01384240|Experimental|Proflavine Hemisulfate|
11495774|NCT01384227|Experimental|Proflavine Hemisulfate|
11495775|NCT01384214|Experimental|1|botulinum toxin Type A
11495776|NCT01384201||Confocal Laser Endomicroscopy|OGD by Confocal Endomicroscopy
11495777|NCT01384201||White light endoscopy|OGD by whitelight endoscopy
11495778|NCT01384188|Experimental|E1|ONO-5334
11495779|NCT01384188|Experimental|E2|ONO-5334
11495780|NCT01384175|Active Comparator|intravenous analgesia|Patients received postoperative analgesia by intravenous fentanyl 10 µg/ml 3-8 mL/h.
11495781|NCT01384175|Active Comparator|epiduaral infusion|Patients received epidural analgesia intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL postoperatively.
11495782|NCT01384175|Active Comparator|patient-controlled epidural analgesia|In addition to epidural anesthesia and epidural infusion, postoperatively patients received patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
11495783|NCT01384162|Experimental|sNN0029, ICV infusion|
11495784|NCT01384149|Active Comparator|standart slt|gonioscopic selective laser trabeculoplasty
11495785|NCT01384149|Experimental|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
11495786|NCT01384136||High risk pregnancy|
11495788|NCT01384110|Experimental|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
11495789|NCT01384110|Placebo Comparator|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
11495790|NCT01384097||Conventional care|patients treated by conventional haemodynamic care intraoperatively
11495791|NCT01384097||Haemodynamic algorithm|patients treated within a goal-directed haemodynamic algorithm intraoperatively
11495792|NCT01384084|Experimental|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
11495793|NCT01384084|Active Comparator|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
11495794|NCT01384071|Experimental|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
11495795|NCT01384071|Sham Comparator|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
11495796|NCT01384058|Active Comparator|Ezetimibe 10mg/d|intake of ezetimibe 10mg per day for six weeks after wash-out
11495797|NCT01384058|Active Comparator|Simvastatin 20 mg per day|intake of simvastatin 20 mg per day for six weeks after wash-out
11495798|NCT01384058|Active Comparator|Ezetimibe 10 mg/d and Simvastatin 20mg/d|intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out
11495799|NCT01384045|No Intervention|Usual Care|Patients continue to receive usual diabetes care without outreach by health promotions staff.
11495800|NCT01384045|Experimental|Arm 1-Health Promotoin Outreach|Active outreach by health promotion staff to send diabetes report card and schedule services including laboratory testing and visits.
11495801|NCT01384032|Experimental|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
11495802|NCT01384032|Experimental|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
11495803|NCT01384032|Experimental|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
11495804|NCT01384019|Experimental|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
11495805|NCT01384019|Placebo Comparator|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
11495806|NCT01384006||Control|standard pancreas allograft recipients
11495807|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
11495808|NCT01383993|Experimental|1.0|Immunocompromised children aged 2 to <15 and 12 to <15 years weighing <50 kg who are at high risk for systemic fungal infection.
11495809|NCT01383993|Experimental|2.0|Immunocompromised children aged 12 to <15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
11495810|NCT01383980|No Intervention|Control|Tube feeds are held night prior to elective surgery (standard of care)
11495811|NCT01383980|Experimental|Continuous Feeding|Tube feeds are continued up until surgery. Subjects with a nasogastric tube will have their stomach contents emptied prior to surgery.
11495812|NCT01383967|Experimental|LY2979165 Part A, Cohort 1|20 mg LY2979165 administered orally, daily for 14 days
11495813|NCT01383967|Experimental|LY2979165 Part A, Cohort 2|60 mg LY2979165 administered orally, daily for 14 days
11495814|NCT01383967|Experimental|LY2979165 Part A, Cohort 3|100 mg LY2979165 administered, orally daily for 14 days
11495815|NCT01383967|Experimental|LY2979165 Part A, Cohort 4|150 mg LY2979165 administered orally, daily for 14 days
11495816|NCT01383967|Experimental|LY2979165 Part B, Cohort 5|Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days
11495817|NCT01383967|Placebo Comparator|Placebo|Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A
11495818|NCT01383967|Experimental|LY2979165 Part A, Cohort 6|250 mg LY2979165 administered orally, daily for 14 days
11495819|NCT01383967|Experimental|LY2979165 Part A, Cohort 7|400 mg LY2979165 administered orally, daily for 14 days
11495820|NCT01383954|Other|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
11495821|NCT01383941||Subjects with Mild to Severe Asthma|This is an epidemiologic, multi-center, cross-sectional study to define the phenotypic characteristics of Difficult-to-Treat asthma, among children receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
11495822|NCT01383928|Experimental|Phase 1: Ixazomib 3 mg or 3.7 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
11495863|NCT01383564|Active Comparator|CPAP group|CPAP group
11495864|NCT01383564|Placebo Comparator|non CPAP group|non CPAP group
11495823|NCT01383928|Experimental|Phase 2: Ixazomib 3 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
11495824|NCT01383915||inpatients|Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder
11495825|NCT01383902|Other|dessert / chocolate|
11495826|NCT01383889|Other|Treading mill exercise|Pregnant women in this group will perform treadmill exercise during 20 minutes. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
11495827|NCT01383889|Other|Stationary bicycle exercise|Pregnant women in this group will perform exercise using a stationary bicycle. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
11495828|NCT01383876|Active Comparator|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
11495829|NCT01383876|Experimental|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
11495830|NCT01383850|Active Comparator|NCPAP + standard air|
11495831|NCT01383850|Experimental|NCPAP + Heliox|
11495832|NCT01383837|Experimental|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
11495833|NCT01383837|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
11495834|NCT01383824|Other|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
11495835|NCT01383811|Active Comparator|Moderate Intensity Aerobic Exercise|
11495836|NCT01383811|Other|Wait List/Usual Care|The subjects in this group will continue to receive the usual treatment that they were on at the time of enrollment through the wait list period of 12 weeks. Subsequently they will receive the 12 weeks of aerobic exercise program intervention
11495837|NCT01383798|Placebo Comparator|Placebo|Red capsule (50 mg) lactose
11495838|NCT01383798|Experimental|Ferrous sulfate|
11495839|NCT01383785|Active Comparator|GROUP A|Intracoronary full bolus dose of abciximab proximal to thrombus occlusion
11495840|NCT01383785|Experimental|GROUP B|Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter
11495841|NCT01383785|Experimental|GROUP C|Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter
11495842|NCT01383772|Experimental|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
11495843|NCT01383759|Experimental|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
11495844|NCT01383746|Experimental|1|Yttrium microsphere injection
11495845|NCT01383733|Experimental|Single Arm|
11495846|NCT01383720|Experimental|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
11495847|NCT01383707|Experimental|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
11495848|NCT01383694|Experimental|Piperine Dose 1|Piperine 1 mM
11495849|NCT01383694|Experimental|Piperine Dose 2|Piperine 150 microM
11495850|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
11495851|NCT01383668|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11495852|NCT01383655|Experimental|Magnesium|i.v. magnesium infusion 40mg/kg in 20 min
11495853|NCT01383655|Placebo Comparator|Placebo|i.v. 0.9 % NaCl
11495854|NCT01383642||individuals age >=70|
11495855|NCT01383629|No Intervention|No counselling|normal preoperative procedures prior to vitrectomy surgery
11495856|NCT01383629|Experimental|Preoperative counselling|Counselling to patient about what to expect during vitrectomy surgery under local anaesthesia
11495857|NCT01383616|Active Comparator|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
11495858|NCT01383616|Active Comparator|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
11495859|NCT01383603|Experimental|Cat-PAD|
11495860|NCT01383590|Experimental|Cat-PAD|
11495861|NCT01383577|Experimental|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each session of treatment.
11495862|NCT01383577|Experimental|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. The three following monthly appointments of patients of this arm are for sham hemorrhoidal ligations and final revision.
11495865|NCT01383551|Experimental|"Becoming Parents intervention"|"A Becoming Parents Programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
11495866|NCT01383551|No Intervention|Usual prenatal education|Attend usual prenatal classes which will be provided by the midwives in the hospital.
11495867|NCT01383538|Experimental|FOLFIRINOX Plus IPI-926|
11495868|NCT01383525|Experimental|Direct Selective Trabeculoplasty|Treatment by an Direct Selective Trabeculoplasty device
11495869|NCT01383512|Experimental|Rehabilitation robotics|Subjects will be practicing an Armeo Spring rehabilitation program in addition to their usual care (1.5h/day,5d/week) 1h/day 5d/week 4 weeks.
11495870|NCT01383512|Active Comparator|Self-rehabilitation|Subject will associated to there classical care 1 hours, 5 days per week during 4 weeks, of self rehabilitation.
11495871|NCT01383512|Other|Healthy volunteer|20 healthy volunteer will be recruiting and using ARMEO Spring. All volunteer will repeat 5 times the same program on the medical device.
11495872|NCT01383499|Experimental|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
11495873|NCT01383499|Experimental|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
11495874|NCT01383499|Experimental|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
11495875|NCT01383499|Placebo Comparator|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
11495876|NCT01383486|Experimental|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
11495877|NCT01383473||Leukemia Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
11495878|NCT01383473||Solid Tumor Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
11495879|NCT01383460|Active Comparator|G-CSF+EPO|
11495880|NCT01383460|Placebo Comparator|Placebo|
11495881|NCT01383447|Experimental|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11495882|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.
~All participants were offered to participate in the PSP while treated with ADA for their RA."
11495883|NCT01383408|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
11495884|NCT01383408|Experimental|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
11495885|NCT01383408|Experimental|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
11495886|NCT01383408|Experimental|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
11495887|NCT01383395|Experimental|simvastatin/cilostazol|simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6
11495888|NCT01383356|Experimental|Linagliptin/Metformin medium dosecombo|patient to receive a single medium dose combination tablet containing Linagliptin and Metformin once daily
11495889|NCT01383356|Active Comparator|Linagliptin plus Metformin medium dose|patient to receive two individual tablets: Linagliptin and Metformin (medium dose)
11495890|NCT01383343|Experimental|Treatment (FOLFIRI and bevacizumab)|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11495891|NCT01383330|Experimental|Megace|800mg
11495892|NCT01383330|Active Comparator|DW-ES(A)|625mg
11495893|NCT01383330|Active Comparator|DW-ES(B)|625mg
11495894|NCT01383317|Active Comparator|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
11495895|NCT01383317|Sham Comparator|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
11495896|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
11495897|NCT01383278|Experimental|Computer-directed 5 A's intervention for smoking|
11495898|NCT01383278|Active Comparator|Screening and resource provision|
11495899|NCT01383265|Experimental|Water method and chromoendoscopy|Combined water method with chromoendoscopy using 0.008% IC solution for screening colonoscopy
11495900|NCT01383265|Active Comparator|Water method|Control method will use plain water with the water method for screening colonoscopy
11495901|NCT01383252|Experimental|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
11495902|NCT01383252|Active Comparator|Air method|Air insufflation for screening and surveillance colonoscopy
11495903|NCT01383239|Active Comparator|Immediate postoperative therapy|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay
11495904|NCT01383239|Active Comparator|postoperative therapy delayed for 6 weeks|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay.
11495905|NCT01383226|Other|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
11495906|NCT01383213|Experimental|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
11495907|NCT01383213|Active Comparator|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
11495908|NCT01383200|Active Comparator|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
11495909|NCT01383200|Active Comparator|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
11495910|NCT01383187|Experimental|DE graft and PRP concentrate|Patients enrolled in this arm receive the innovative treatment methods consisting of application of DE graft together with PRP concentrate.
11495911|NCT01383187|Active Comparator|Standard treatment group|PAtients included into this arm will receive a standard treatment for deep-burn injuries, i.e. DE graft without the application of the PRP concentrate.
11495912|NCT01383174|Experimental|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
11495913|NCT01383174|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
11495914|NCT01383161|Active Comparator|Curcumin|Theracurmin (180mg/day)
11495915|NCT01383161|Placebo Comparator|Placebo|Sugar Pill
11495916|NCT01383148|Experimental|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
11495917|NCT01383148|Active Comparator|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
11495918|NCT01383122|Active Comparator|Active device|Functional pulsed electromagnetic field device
11495919|NCT01383122|Placebo Comparator|Placebo - inactive device|Inactive pulsed electromagnetic field device
11495920|NCT01383109|Experimental|Pyronaridine|All subjects will receive a single dose of Pyronaridine
11495921|NCT01383096|Active Comparator|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
11495922|NCT01383096|Experimental|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
11495923|NCT01383096|Experimental|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
11495924|NCT01383096|Experimental|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
11495925|NCT01383096|Experimental|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
11495926|NCT01383096|Experimental|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
11495927|NCT01383096|Experimental|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
11495928|NCT01383096|Experimental|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
11495929|NCT01383096|Experimental|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
11495930|NCT01383096|Experimental|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
11495931|NCT01383096|Experimental|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
11495932|NCT01383083||iloprost|In the adult patient group, iloprost acceptable target dose is 2.5 ug 4-6 times/day according to the patient's compliance. Because of the concern of safety and tolerability, during the first 4 weeks of treatment, patients receive 2.5 ug twice daily. After 4 weeks, this is increased to the target dose, if iloprost is well tolerated.
11495933|NCT01383070|No Intervention|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
11495934|NCT01383070|Experimental|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
11495935|NCT01383057|Experimental|Femtosecond Laser|
11495936|NCT01383044|Experimental|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
11495937|NCT01383044|Active Comparator|carvedilol|carvedilol 6.25-12.5 mg per day
11495938|NCT01383031|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
11495939|NCT01383031|Active Comparator|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC（conventional laparoscopic cholecystetomy）by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
11495940|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
11495941|NCT01383005||Kaletra (LPV/r) QD as First Kaletra Treatment|HIV-infected participants treated with lopinavir/ritonavir once daily (LPV/r QD) from ≥3 months to <2 years who had not been treated with any of the following: LPV/r twice daily (BID), a protease inhibitor, or a ritonavir-boosted protease inhibitor.
11495942|NCT01383005||Kaletra (LPV/r) QD from Kaletra BID|HIV-infected participants treated with LPV/r from ≥3 months to <2 years who had initiated on LPV/r BID and at any time within this period (but at least 3 months before inclusion in the study) had changed dosing from BID to QD.
11495943|NCT01382992||Early Stage|
11495944|NCT01382992||Late Stage|
11497799|NCT01369654|Experimental|Computerized decision aid|
11495945|NCT01382979|Experimental|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
11495946|NCT01382979|No Intervention|Control|Control group.
11495947|NCT01382966||Single group|Maintenance hemodialysis patients of minimal 6 months of hemodialysis duration; free of malignancy, infection and autoimmune disease; age over 18 years
11495948|NCT01382940|Experimental|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
11495949|NCT01382927||General Anesthesia|
11495950|NCT01382927||Spinal Anesthesia|
11495951|NCT01382914|Experimental|chlorhexidine 0.12 %|
11495952|NCT01382901|Experimental|Intravenous (IV) Iron|
11495953|NCT01382901|Placebo Comparator|Placebo|
11495954|NCT01382888|Active Comparator|Heparin 2,400 IU /ml Cutaneous Spray|Patients are randomized to receive the active comparator heparin 2,400 IU/ml cutaneous spray for 24 weeks
11495955|NCT01382888|Placebo Comparator|Placebo Cutaneous Spray|Patients are randomized to receive placebo cutaneous spray for 24 weeks
11495956|NCT01382875|No Intervention|Conventional care program|
11495957|NCT01382875|Experimental|Multi-disciplinary management program|
11495958|NCT01382862|No Intervention|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
11495959|NCT01382862|Active Comparator|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
11495960|NCT01382849||CAA positive microbleeders|Cerebral amyloid angiopathy (CAA) positive microbleeders
11495961|NCT01382849||probable CAA macrobleeders|
11495962|NCT01382849||CAA negative microbleeders|
11495963|NCT01382836||Black inner city children with persistent asthma|
11495964|NCT01382836||Black inner city non-atopic healthy children|
11495965|NCT01382823|Experimental|Femtosecond Laser|
11495966|NCT01382810|Active Comparator|Altaire Gel forming solution|
11495967|NCT01382810|Placebo Comparator|Refresh Tears|
11495968|NCT01382797|Placebo Comparator|Placebo|Capsules for oral administration
11495969|NCT01382797|Experimental|ALKS 37|Capsules for oral administration
11495970|NCT01382771|Active Comparator|Intra-articular corticosteroid injection|Intra-articular corticosteroid injection in conjunction with confirmatory anesthetic medial branch blocks
11495971|NCT01382771|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injections with confirmatory anesthetic medial branch blocks
11495972|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
11495973|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
11495974|NCT01382745|Experimental|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
11495975|NCT01382732|Experimental|Carbetocin|"Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
~Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr"
11495976|NCT01382732|Active Comparator|Oxytocin|Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
11495977|NCT01382719|Placebo Comparator|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
11495978|NCT01382719|Experimental|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
11495979|NCT01382719|Experimental|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
11495980|NCT01382719|Experimental|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
11495981|NCT01382706|Experimental|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
11495982|NCT01382693|Experimental|TimeSlips group storytelling program|
11495983|NCT01382693|Active Comparator|Standard care activity program|
11495984|NCT01382680|Active Comparator|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
11495985|NCT01382680|Active Comparator|New guidewire (G240)|Primary use of the new guidewire (G240)
11495986|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
11495987|NCT01382654|Experimental|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
11495988|NCT01382654|Experimental|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
11495989|NCT01382654|Experimental|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
11495990|NCT01382654|Experimental|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
11495991|NCT01382654|Active Comparator|azelastine 0.1%|nasal spray 2 sprays in each nostril for a total of 3 doses
11495992|NCT01382641|Other|Hoya AF-1 IOL|
11495993|NCT01382641|Other|Revital Vision|
11495994|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
11495995|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
11495996|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
11495997|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
11495998|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
11495999|NCT01382615||Healthy Volunteers|Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
11496000|NCT01382615||Patients with multiple myeloma|Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.
11496001|NCT01382602|Experimental|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
11496002|NCT01382602|Placebo Comparator|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
11496003|NCT01382589|Experimental|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
11496004|NCT01382589|Active Comparator|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
11496005|NCT01382576||PCOS patients|
11496006|NCT01382576||PCOS patients and healthy controls|There are two groups in this study. One group is PCOS patients and other group is healthy controls.
11496007|NCT01382550||VTE subjects|"subjects with a recent (<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT
~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
11496008|NCT01382537|Active Comparator|A|
11496009|NCT01382537|Placebo Comparator|B|
11496010|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
11496011|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
11496012|NCT01382498|Placebo Comparator|Placebo|Placebo tablets will be administered to the patients in Placebo arms daily for three months.
11496013|NCT01382498|Experimental|Calcium dobesilate|Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
11496014|NCT01382485|Active Comparator|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
11496015|NCT01382485|Experimental|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
11496016|NCT01382472|Experimental|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
11496017|NCT01382472|Other|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
11496018|NCT01382459||type 1 DM children- intervention group|will have home visits and trainings at school
11496019|NCT01382459||type 1 DM children- control group|will receive the standard care at the clinic
11496020|NCT01382446|Active Comparator|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
11496021|NCT01382446|Experimental|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
11496022|NCT01382433|Experimental|Chronic Cannabis Users|
11496023|NCT01382433|Experimental|Control|Neurotypical subjects
11496024|NCT01382420|Active Comparator|Adrenalectomy group|patients who undergo adrenalectomy
11496025|NCT01382420|No Intervention|Control group|patients who receive conservative treatment
11496026|NCT01382407||Cetuximab|All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
11496027|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.
~The second group will include 60 patients with the diagnosis of sepsis."
11496028|NCT01382368|Experimental|Sildenafil|
11496029|NCT01382355||Kidney transplant|
11496030|NCT01382342|Experimental|rasagiline|Participants in this arm will receive 1 mg of rasagiline daily for the six month duration of the study.
11496031|NCT01382342|Placebo Comparator|Placebo|Participants in this group will receive 1 mg of placebo daily for the six month duration of the study.
11496032|NCT01382329|Experimental|Treatment group I / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22
11496033|NCT01382329|Experimental|Treatment group II / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22
11496034|NCT01382329|Experimental|Treatment group III / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22
11496035|NCT01382329|Experimental|Treatment group IV / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22
11496036|NCT01382316|Experimental|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
11496037|NCT01382316|Active Comparator|Usual care|Usual group sessions on education about alcohol and drug problems
11496038|NCT01382303|Active Comparator|Pentoxifylline|Pentoxifylline 400mg three times a day
11496039|NCT01382303|Placebo Comparator|Placebo|placebo tablet
11496040|NCT01382277|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
11496041|NCT01382264|Experimental|CADS|
11496042|NCT01382251||Patient|Patients undergoing ambulatory surgery
11496043|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
11496044|NCT01382238|Experimental|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
11496045|NCT01382225|Experimental|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
11496046|NCT01382225|Placebo Comparator|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
11496047|NCT01382212|Experimental|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
11496048|NCT01382199|Experimental|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
11496049|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
11496050|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
11496051|NCT01382160|Experimental|adalimumab|40 mg every two weeks, by subcutaneous way
11496052|NCT01382147|Experimental|S-HAM|S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)
11496053|NCT01382147|Active Comparator|TAD-HAM (younger) or HAM-HAM (elderly)|is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (> 5%) in the day 16 bone marrow aspirate
11496054|NCT01382134|Placebo Comparator|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
11496055|NCT01382134|Active Comparator|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
11496056|NCT01382121|Experimental|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
11496057|NCT01382121|Active Comparator|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
11496058|NCT01382108||Normal participants|
11496059|NCT01382108||Meibomian Gland Dysfunction|
11496060|NCT01382095|Experimental|Group A|
11496061|NCT01382095|Experimental|Group B-1|
11496062|NCT01382095|Experimental|Group B-2|
11496063|NCT01382095|Experimental|Group C|
11496064|NCT01382082||subjects with breast cancer|
11496065|NCT01382082||subjects with lymphoma|
11496066|NCT01382082||subjects without cancer|
11496067|NCT01382069|Placebo Comparator|Placebo|Placebo
11496068|NCT01382069|Experimental|Dimethandrolone Undecanoate|DMAU group with different doses 100, 200 and 400 groups
11496069|NCT01382056|Experimental|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
11496070|NCT01382056|Experimental|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
11496071|NCT01382056|Active Comparator|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
11496072|NCT01382043||Endeavor Segment group|
11496073|NCT01382043||Excel Segment Group|
11496074|NCT01382030|Experimental|Treatment Arm|All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.
11496075|NCT01382017|Placebo Comparator|Placebo|Placebo arm
11496076|NCT01382017|Experimental|Lasosamide 200|Lacosamide 200 mg
11496077|NCT01382017|Experimental|Lacosamide 400|Lacosamide 400 mg
11496078|NCT01382017|Active Comparator|Carbamazepine 600|Carbamazepine 600 mg
11496079|NCT01382004|Active Comparator|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
11496080|NCT01382004|Experimental|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
11496081|NCT01381991|Experimental|i-scan-EGD|Examination of GE junction using conventional WL as well as i-scan mode
11496082|NCT01381965|Active Comparator|Eyes with macular hole|
11496083|NCT01381952|Experimental|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
11496084|NCT01381952|Active Comparator|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
11496085|NCT01381939||Induction of labor in ICP|Induction of laborin women with ICP
11496086|NCT01381939||Induction of labor in women with no ICP|No ICP
11496087|NCT01381939||ICP and spontanius delivery|
11496088|NCT01381926|Experimental|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
11496089|NCT01381926|Active Comparator|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
11496090|NCT01381900|Experimental|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
11496091|NCT01381900|Experimental|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
11496092|NCT01381900|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
11496093|NCT01381887|Placebo Comparator|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
11496094|NCT01381887|Experimental|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.
~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
11496095|NCT01381887|Experimental|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
11496096|NCT01381887|Experimental|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.
~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
11496097|NCT01381874|Experimental|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
11496098|NCT01381874|Experimental|Abiraterone acetate + Prednisone/Prednisolone + Exemestane|Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
11496099|NCT01381874|Experimental|Exemestane|Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
11496100|NCT01381861|Experimental|Carotuximab (TRC105) alone|Single arm, open label Carotuximab (TRC105) alone therapy dosed at 10 mg/kg administered intravenously over 1 to 4 hours on days 1, 8, 15 and 22 of each 28 day cycle
11496101|NCT01381848|Experimental|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
11496102|NCT01381835|Experimental|001|TMC435 150 mg capsule once daily for 7 days
11496103|NCT01381822|Experimental|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
11496146|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
11497891|NCT01369160||2|hydroxyurea
11496104|NCT01381809|Experimental|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
11496105|NCT01381809|Placebo Comparator|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
11496106|NCT01381796|Active Comparator|Treatment A - NP101|
11496107|NCT01381796|Active Comparator|Treatment C - oral sumatriptan succinate|
11496108|NCT01381796|Experimental|Treatment B - NP101B|
11496109|NCT01381796|Experimental|Treatment D - NP101D|
11496110|NCT01381783|Other|Topical anesthesia|
11496111|NCT01381770|Experimental|Platelet-derived repairing factors|
11496112|NCT01381744|Experimental|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
11496113|NCT01381744|Experimental|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
11496114|NCT01381744|Experimental|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
11496115|NCT01381744|Experimental|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
11496116|NCT01381731|Experimental|Diquafosol tetrasodium ophthalmic solution 2%|topical ophthalmic solution
11496117|NCT01381731|Placebo Comparator|Placebo|saline ophthalmic solution
11496118|NCT01381718|Experimental|Arm I|Participants receive modafinil orally (PO) once daily (QD) on days 1-42.
11496119|NCT01381718|Placebo Comparator|Arm II|Participants receive placebo PO QD on days 1-42.
11496120|NCT01381692|Active Comparator|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11496121|NCT01381692|Experimental|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11496122|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
11496123|NCT01381666|Experimental|INS316|inhalation via nebulizer given for 2 doses for 60 minutes each
11496124|NCT01381666|Placebo Comparator|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
11496125|NCT01381653|Experimental|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
11496126|NCT01381640|Active Comparator|Marketed paracetamol|Marketed formulation
11496127|NCT01381640|Experimental|Experimental paracetamol formulation|Experimental formulation
11496128|NCT01381627|Active Comparator|Remifentanil|
11496129|NCT01381627|Experimental|Dexmedetomidine|
11496130|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurance as reported in product label.
11496131|NCT01381601||Severe adverse event claims in subjects with metastatic RCC|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurence as reported in product label.
11496132|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
11496133|NCT01381575|Experimental|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
11496134|NCT01381575|Active Comparator|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Day 0, at Month 1 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
11496135|NCT01381575|Experimental|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 12, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
11496136|NCT01381562|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
11496137|NCT01381562|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
11496138|NCT01381562|Active Comparator|Meropenem 1G|q8h administered via IV infusion, plus saline placebo
11496139|NCT01381549|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
11496140|NCT01381549|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
11496141|NCT01381549|Active Comparator|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
11496142|NCT01381536|Experimental|GSK1550188 1mg/kg or 10mg/kg|one shot IV
11496143|NCT01381523||Study-treatment naive insured adults with migraine|Adult health care plan members with a pharmacy claim for a combination product of sumatriptan and naproxen sodium (SumaRT/Nap) and propensity score matched controls with a pharmacy claim for a single-entity triptan
11496144|NCT01381523||Insured adults with migraine who switch study treatment|Adult health plan members with a pharmacy claim for SumaRT/Nap following at least one single-entity triptan pharmacy claim in the previous 6 months and propensity-score matched controls who switched from one single-entity triptan to another
11496145|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
11496147|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
11496148|NCT01381484|No Intervention|Placebo|This group received placebo gel and requested to apply periorbital area and over the face for 3 months.
11496149|NCT01381484|Experimental|Study group|This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
11496150|NCT01381471||COPD|Patients with a diagnosis code of COPD
11496151|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
11496152|NCT01381445|Experimental|GW870086 0.2% &amp; GW870086 2%|GW870086 0.2%, 2% &amp; placebo each applied to an identified area for 42 days.
11496153|NCT01381445|Experimental|GW870086 2% &amp; Clobetasol Propionate|GW870086 2% &amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days
11496154|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
11496155|NCT01381419|Experimental|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
11496156|NCT01381419|Experimental|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
11496157|NCT01381419|Experimental|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
11496158|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
11496159|NCT01381393||Ibandronate|The subjects with osteoporosis in postmenopausal women
11496160|NCT01381380|Other|single-arm studies|Manual therapy for one group
11496161|NCT01381367|Experimental|Vaccine|Enrolled COPD patients receiving PPSV23 pneumococcal vaccine
11496162|NCT01381367|Placebo Comparator|Normal saline|Enrolled COPD patient receiving placebo normal saline
11496163|NCT01381354|Experimental|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
11496164|NCT01381341|Experimental|linifanib|
11496165|NCT01381328||RAL Group|HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen
11496166|NCT01381315|Other|Sentinel lymph node biopsy|During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
11496167|NCT01381315|Other|Axillary lymph node biopsy|
11496168|NCT01381302||Parkinson|Early onset of disease
11496169|NCT01381276|Experimental|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
11496170|NCT01381276|Experimental|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
11496171|NCT01381276|Active Comparator|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
11496172|NCT01381263|Experimental|Behavioural medicine|
11496173|NCT01381263|Active Comparator|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
11496174|NCT01381250|Experimental|Treatment|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
11496175|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
11496176|NCT01381211|Active Comparator|Yttrium-90 radioembolization (90Y-RE)|
11496177|NCT01381211|Active Comparator|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
11496178|NCT01381198|Active Comparator|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
11496179|NCT01381198|No Intervention|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
11496180|NCT01381185|No Intervention|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
11496181|NCT01381185|Active Comparator|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
11498214|NCT01367028|Experimental|D: Trastuzumab+Docetaxel+NPLD+Bevacizumab|
11496182|NCT01381172|Experimental|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
11496183|NCT01381172|Other|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
11496184|NCT01381159|Experimental|Motivational Communication|Up to 3 x 30 minute brief MC sessions within 4-6 week period
11496185|NCT01381159|Placebo Comparator|Control|Usual care
11496186|NCT01381146|Experimental|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
11496187|NCT01381146|Other|TAU|treatment as usual -- participants have access to all other jail programs and services
11496188|NCT01381133|Experimental|CBOP without ACC|
11496189|NCT01381133|Experimental|CBOP with ACC|
11496190|NCT01381133|Experimental|MET/CBT 7 without ACC|
11496191|NCT01381133|Experimental|MET/CBT 7 with ACC|
11496192|NCT01381120|Experimental|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
11496193|NCT01381120|Active Comparator|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
11496194|NCT01381107|Experimental|ALKS 5461 (ALKS 33 and buprenorphine)|
11496195|NCT01381107|Placebo Comparator|Placebo|
11496196|NCT01381094|Experimental|AKB-6548 240 mg|
11496197|NCT01381094|Experimental|AKB-6548 370 mg|
11496198|NCT01381094|Experimental|AKB-6548 500 mg|
11496199|NCT01381094|Experimental|AKB-6548 630 mg|
11496200|NCT01381094|Placebo Comparator|Placebo|
11496201|NCT01381081|Experimental|platelet-rich plasma intra-articular knee injections|a single intra-articular injection of PRP in knee osteoarthritis
11496202|NCT01381081|Active Comparator|Corticosteroid intra-articular knee injections|a betamethasone and bupivacaine intra-articular injection
11496203|NCT01381068|Experimental|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
11496204|NCT01381068|Placebo Comparator|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
11496205|NCT01381055|Experimental|Pentoxifylline plus antimony|
11496206|NCT01381055|Placebo Comparator|Placebo plus antimony|
11496207|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
11496208|NCT01381016|Other|Group 1 - Normal Weight|"Group 1: Normal weight (BMI 18-25 kg/m2)
~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
11496209|NCT01381016|Experimental|Group 2 - Obese|"Group 2: Obese (BMI >30 kg/m2)
~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
11496210|NCT01381003|Experimental|pCCLchimGp91s lentiviral vector transduced CD34+ cells|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
11496211|NCT01380990|Experimental|Gene Therapy|Infusion of autologous EFS-ADA LV CD34+ cells
11496212|NCT01380990|Other|Historical Control Group|Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)
11496213|NCT01380977|Experimental|Impact of Crime group intervention|
11496214|NCT01380977|Active Comparator|Treatment as usual|
11496215|NCT01380964||DMD patients|DMD Patients
11496216|NCT01380964||Control patients|Control patients
11496217|NCT01380951|Experimental|telbivudine|
11496218|NCT01380938|No Intervention|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.
~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
11496219|NCT01380938|Experimental|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight < 75 kg or 1200 mg/day for those with a body weight > 75 kg.
~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
11496220|NCT01380938|Experimental|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.
~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
11496221|NCT01380912||breast cancer|"Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity
~Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity
~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity
~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
11496222|NCT01380899||PD alpha-synuclein|
11496223|NCT01380899||PPS alpha-synuclein|
11496224|NCT01380886|Experimental|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
11498543|NCT01364662|Experimental|1|
11496229|NCT01380860|Experimental|Mesh|The patients allocated to this arm of the study will have mesh (Covidien France: mono filament polyester bidimensional knit) implanted in association with their colostomy.
11496230|NCT01380860|Active Comparator|No mesh|The patients allocated to this arm of the protocol will not receive mesh implantation with their colostomy.
11496231|NCT01380847||Renal allograft nephropathy|To evaluate urine from KTRs during the first year post-transplantation to assess whether mRNA levels of genes involved in EMT/fibrogenesis can diagnose and predict CAN, and identify patients at risk of chronic allograft dysfunction
11496232|NCT01380834|Active Comparator|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
11496233|NCT01380834|Placebo Comparator|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
11496234|NCT01380821||SPECT|Patients clinically indicated to undergo myocardial SPECT in our institution.
11496235|NCT01380808|Experimental|experimental arm|capecitabine and pseudomonas aeruginosa combination
11496236|NCT01380795|Other|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
11496237|NCT01380782|Experimental|Bevacizumab Naive|Bevacizumab naive subjects
11496238|NCT01380782|Experimental|Prior Bevacizumab|Patients previously treated with bevacizumab
11496239|NCT01380769|Experimental|CRLX101|
11496240|NCT01380769|Other|Best supportive care|
11496241|NCT01380756|Experimental|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
11496242|NCT01380756|Experimental|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
11496243|NCT01380743|Experimental|Cohort 1, Duvoglustat 50 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 50 milligram (mg) oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.
~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
11496244|NCT01380743|Experimental|Cohort 2, Duvoglustat 100 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 100 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.
~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
11496245|NCT01380743|Experimental|Cohort 3, Duvoglustat 250 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 250 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.
~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
11496246|NCT01380743|Experimental|Cohort 4, Duvoglustat 600 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 600 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.
~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
11496247|NCT01380730|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
11496248|NCT01380730|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
11496249|NCT01380730|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11496250|NCT01380730|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11496251|NCT01380730|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11496252|NCT01380730|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496253|NCT01380730|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496254|NCT01380730|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496255|NCT01380717|Active Comparator|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
11496256|NCT01380717|Active Comparator|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
11496257|NCT01380704|Experimental|Active|
11496258|NCT01380704|Placebo Comparator|Placebo|
11496259|NCT01380691|Experimental|LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc|"Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms [g/kg] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time.
~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.
~There was a 7-day washout period between Periods 1 and 2."
11496260|NCT01380691|Experimental|Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.
~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.
~There was a 7-day washout period between Periods 1 and 2."
11496261|NCT01380691|Experimental|LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc|"Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.
~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.
~There was a 7-day washout period between Periods 1 and 2."
11496262|NCT01380691|Experimental|Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.
~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.
~There was a 7-day washout period between Periods 1 and 2."
11496263|NCT01380678|Active Comparator|bevacizumab|intralesional bevacizumab injection
11496264|NCT01380678|Active Comparator|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
11496265|NCT01380665|Other|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
11496266|NCT01380652|Experimental|rehabilitation with vibration training|
11496267|NCT01380652|No Intervention|rehabilitation without vibration training|
11496268|NCT01380639|Experimental|Rehabilitation with vibration training|
11496269|NCT01380639|No Intervention|Rehabilitation without vibration training|
11496270|NCT01380626|Experimental|exercise training|
11496271|NCT01380613|Active Comparator|Workshop Control|Participants receive HIV/STDs risk reduction information.
11496272|NCT01380613|Experimental|Intervention Workshop|Participants learn skills to cope with depressive symptoms and stress as well as safer sex and injection skills.
11496273|NCT01380600|Other|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
11496274|NCT01380587||Acute Lymphoblastic Leukemia|We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
11496275|NCT01380561|Experimental|Single Arm Study|asimadoline
11496276|NCT01380548|Placebo Comparator|Placebo|
11496277|NCT01380548|Placebo Comparator|Iron alone|
11496278|NCT01380548|Experimental|Low-dose 5-aminolevulinic acid|
11496279|NCT01380548|Experimental|Medium-dose 5-aminolevulinic acid|
11496280|NCT01380548|Experimental|High-dose 5-aminolevulinic acid|
11496281|NCT01380535|Experimental|ECP Methoxsalen + Standard of Care|Participants receive methoxsalen administered via ECP in addition to standard of care
11496282|NCT01380535|Active Comparator|Standard of Care|Participants receive standard of care only
11496283|NCT01380522|Experimental|A|Subjects received kali product under fed conditions
11496284|NCT01380522|Active Comparator|B|Subjects received Searle product under fed conditions
11496285|NCT01380509|Experimental|A|Subjects received kali product under fasting conditions
11496286|NCT01380509|Active Comparator|B|Subjects received Searle product under fasting conditions
11496287|NCT01380496|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
11496288|NCT01380496|Active Comparator|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
11496289|NCT01380496|Experimental|A|Subjects received the Par formulated product
11496290|NCT01380483|Experimental|A|Subjects received the Par formulated product
11496291|NCT01380483|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals formulated product.
11496292|NCT01380470||Chronic Obstructive Pulmonary Disease|Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.
11496293|NCT01380457|Experimental|A|Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
11496294|NCT01380457|Active Comparator|B|Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
11496295|NCT01380444|Active Comparator|1|Gamma3 Intramedullary Nails
11496296|NCT01380444|Active Comparator|2|Sliding Hip Screws
11496297|NCT01380431|Experimental|A|Subjects received the Par formulated product.
11496298|NCT01380431|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
11496299|NCT01380431|Active Comparator|C|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
11496300|NCT01380418||Study group|Obese BMI>30 18-85 years old
11496301|NCT01380405|No Intervention|without health education|the normal practices without specific intervention
11496302|NCT01380405|Experimental|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
11496329|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
11496330|NCT01380158|Experimental|Pessary use during pregnancy|Device: Cup pessary
11496331|NCT01380158|No Intervention|Expectant management|Expectant Management + weekly intramuscular progesterone injections
11496332|NCT01380145|Experimental|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
11496333|NCT01380132|Experimental|Anal injection of Nasha Dx|
11496303|NCT01380405|Experimental|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
11496304|NCT01380379|Experimental|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
11496305|NCT01380366|Other|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
11496306|NCT01380353|Experimental|Breast Group|Diclofenac epolamine patch applied to the breast
11496307|NCT01380353|Experimental|Abdomen Group|Diclofenac epolamine patch applied to the abdomen
11496308|NCT01380340|Experimental|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
11496309|NCT01380340|No Intervention|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
11496310|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
11496311|NCT01380327|Placebo Comparator|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
11496312|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
11496313|NCT01380314|Experimental|1|Miltefosine 150 mg x day + Imiquimod 5%
11496314|NCT01380314|Placebo Comparator|2|Miltefosine 150 mg x day + Placebo
11496315|NCT01380301|Experimental|Miltefosine and Antimony|Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
11496316|NCT01380301|Active Comparator|Miltefosine alone|Miltefosine 1,5 to 2,5 mg x kg x d during 14 days
11496317|NCT01380288|Active Comparator|without white matter change|
11496318|NCT01380288|Active Comparator|with white matter change group|
11496319|NCT01380275|Experimental|Docetaxel and Irinotecan (DI)|"Combination chemotherapy of Docetaxel and Irinotecan (DI) in recurrent or refractory bone and soft tissue sarcomas.
~Docetaxel and Irinotecan (DI) have different biologic targets, mode of action and mechanism of resistance. Preclinical studies have demonstrated an additive or synergistic effect of irinotecan and taxanes when used in combination in human.
~Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 Therapy consists of 3-week cycles comprising weekly treatment for 2 weeks (docetaxel on D1 and irinotecan on D1 and D8) followed by 1-week rest, and will be continued in the absence of disease progression or unacceptable toxicity."
11496320|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
11496321|NCT01380249|Experimental|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
11496322|NCT01380223|Experimental|Dose-escalation Cohort 1|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
11496323|NCT01380223|Experimental|Dose-escalation Cohort 2|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
11496324|NCT01380223|Experimental|Dose-escalation Cohort 3|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
11496325|NCT01380223|Experimental|Dose-escalation Cohort 4|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
11496326|NCT01380197|Active Comparator|Randomizing particiipants to Morphine|Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
11496327|NCT01380197|Active Comparator|Randomization to Nubain|Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
11496328|NCT01380184|Experimental|Ridaforolimus 40 mg|In Part 1 (Days 1-19), participants received ridaforolimus (MK-8669) 40 mg via oral enteric-coated tablet on Day 1; followed by no study treatment on Days 2-7; followed by two weekly sequences (Days 8-19) consisting of 5 consecutive days of ridaforolimus 40 mg and 2 consecutive days off study treatment. Following Part 1, participants underwent at least a 2-day study treatment washout prior to starting Part 2. In Part 2, participants received a weekly treatment regimen consisting of 5 consecutive days (Days 1-5) of ridaforolimus 40 mg via oral enteric-coated tablet and 2 consecutive days (Days 6-7) off study treatment. This weekly treatment regimen was repeated every subsequent week for the remainder of participation in Part 2.
11496334|NCT01380119|Experimental|V7|Oral pill containing heat-killed Mycobacterium vaccae
11496335|NCT01380119|Placebo Comparator|Placebo pill|Identically appearing placebo pills
11496336|NCT01380106|Active Comparator|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
11496337|NCT01380106|Active Comparator|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
11496338|NCT01380093|Placebo Comparator|Placebo|
11496339|NCT01380093|Active Comparator|MS Contin (morphine sulfate, controlled release)|
11496340|NCT01380093|Experimental|EMBEDA (morphine sulfate / naltrexone hydrochloride)|
11496341|NCT01380080|Experimental|Arm A: Empiric|Study treatment for Arm A participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral treatment as soon as possible following randomization and within no more than 3 days following randomization plus a 4-drug anti-tuberculosis treatment (ATT) regimen (defined as rifampin/isoniazid/ethambutol/pyrazinamide) as soon as possible following randomization and within no more than 7 days following initiation of antiretroviral therapy. After 2 months (or 8 weeks), the 4-drug ATT will be followed with 4 months (or 16 weeks) of 2-drug ATT (defined as rifampin/isoniazid). All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only
11496342|NCT01380080|Experimental|Arm B: IPT|Study treatment for Arm B participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral therapy as soon as possible following randomization and within no more than 3 days following randomization and of initiating anti-TB treatment (ATT) only when indicated according to local standard practice and at the discretion of the site investigator. All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only. Pyridoxine is provided by the sites to all participants while they are receiving isoniazid (INH).
11496343|NCT01380067||Group A|the patients were subjected laparoscopic purse-string knot for closing the internal hernia opening
11496344|NCT01380067||Group B|the lateral umbilicus ligament was used to cover the internal hernia opening after the laparoscopic purse-string knot
11496345|NCT01380054||patients with pulmonary hypertension|
11496346|NCT01380028|Placebo Comparator|placebo|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
11496347|NCT01380028|Active Comparator|oral corticosteroids|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
11496348|NCT01380015|Placebo Comparator|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
11496349|NCT01380015|Experimental|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
11496350|NCT01379989|Active Comparator|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
11496351|NCT01379989|Experimental|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
11496352|NCT01379976|Placebo Comparator|CHT cisplatin containing + placebo|
11496353|NCT01379976|Experimental|CHT cisplatin containing + acetyl-L-carnitina|
11496354|NCT01379963||Cohort|
11496355|NCT01379950||periodontitis|patients diagnosed with periodontal disease
11496356|NCT01379937|Experimental|GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
11496357|NCT01379937|Experimental|GSK1562902A Formulation 1 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
11496358|NCT01379937|Active Comparator|GSK1562902A Formulation 2 - Havrix / Havrix Jr Group|Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
11496359|NCT01379937|Active Comparator|Havrix / Havrix Jr Group|Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
11496360|NCT01379924|Experimental|Young Parents Program plus Parenting/Life Skills modules|In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
11496361|NCT01379924|Active Comparator|Young Parents Program usual care|Patients receive regular standard of care without modules.
11496362|NCT01379911|Active Comparator|Yogurt with added inulin|Yogurt with 6g of added inulin
11496363|NCT01379911|Placebo Comparator|Regular yogurt|Regular yogurt without added inulin
11496364|NCT01379898|Active Comparator|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
11496365|NCT01379898|Active Comparator|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
11496366|NCT01379885|Active Comparator|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
11496367|NCT01379885|Experimental|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
11496447|NCT01379261|Active Comparator|Hypothermia treatment|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
11498544|NCT01364662|Experimental|2|
11496368|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"Prospective TROG 08.03 (RAVES) Participants
~Prospective Participants (NOT participating in TROG 08.03 (RAVES))
~Retrospective TROG 08.03 (RAVES) Participants
~Participating in dosimetric evaluation and toxicity/QoL study
~Participating in dosimetric evaluation only"
11496369|NCT01379872||Study Protocol B - IMRT Anal Cancer|"Retrospective Patient Datasets
~Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
11496370|NCT01379872||Study Protocol C - IMRT Nasopharynx|"Retrospective Patient Datasets
~Prospective Participants (dosimetric evaluation and toxicity/QoL study)
~Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
11496371|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer
~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
11496372|NCT01379846|Experimental|TAK-816|
11496373|NCT01379846|Active Comparator|ActHIB|
11496374|NCT01379833||Subjects|Subjects are patients with CIDP
11496375|NCT01379833||Controls|Controls are age-matched people without CIDP
11496376|NCT01379807|Experimental|panitumumab + docetaxel + cisplatino|
11496377|NCT01379781|Experimental|Behavioral Intervention for PPD|Behavioral Intervention for PPD delivered over 3 in-person sessions.
11496378|NCT01379781|No Intervention|Treatment As Usual|Referred to Treatment in the Community.
11496379|NCT01379768|Active Comparator|Lotrafilcon A|Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
11496380|NCT01379768|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
11496381|NCT01379768|No Intervention|No lens wear|No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
11496382|NCT01379742|Active Comparator|Iodine-125 standard 18 g needle|Rapidstrand
11496383|NCT01379742|Active Comparator|20 g needle|Thin Strand
11496384|NCT01379729|Active Comparator|Group A|Patients with loss of long-term function after intraportal implantation
11496385|NCT01379729|Active Comparator|Group B|Patients that are candidates for islet cell transplantation
11496386|NCT01379703||Single patients group|Single HIV-1 infected patients group
11496387|NCT01379690||Control|Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
11496388|NCT01379690||Case|All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
11496389|NCT01379677|Other|Single arm|This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.
11496390|NCT01379664|Experimental|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
11496391|NCT01379664|Experimental|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
11496392|NCT01379651|Experimental|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of food antigen
11496393|NCT01379651|No Intervention|control|controls were kept on an egg-free diet for 6 months
11496394|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
11496395|NCT01379625|Active Comparator|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
11496396|NCT01379625|Experimental|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
11496397|NCT01379612||Rectal cancer patients in chemoradiation|
11496398|NCT01379599|Experimental|Brief motivation intervention|Brief motivation intervention was implemented with enrollees identified with heroin and cocaine use who were allocated to the experimental group. The aim was to test the ability of a peer-delivered intervention to reduce risk of HIV and STIs related to sexual behaviors (condom use and sex while high on drugs.
11496399|NCT01379599|No Intervention|control group|Care as usual.
11496400|NCT01379586|Experimental|E|ONO-4053
11496401|NCT01379586|Placebo Comparator|P|Placebo
11496402|NCT01379573|Experimental|Pregnant women with previous child with cardiac neonatal lupus|400 mg/day Hydroxychloroquine
11496403|NCT01379560|Experimental|unoprostone isopropyl (2 drop)|
11496404|NCT01379560|Experimental|unoprostone isopropyl (3 drop)|
11496405|NCT01379547|Active Comparator|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
11496406|NCT01379547|Experimental|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
11496407|NCT01379534|Experimental|TKI258|1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
11496408|NCT01379521|Experimental|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
11496409|NCT01379521|Placebo Comparator|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
11496410|NCT01379508|Experimental|telbivudine|telbivudine 600 mg tablet orally (p.o.) once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with tenofovir 300 mg tablets p.o. once daily for the remaining weeks of treatment. The investigator was to initiate tenofovir add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive telbivudine monotherapy
11496411|NCT01379508|Active Comparator|tenofovir|tenofovir 300 mg tablets p.o. once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with telbivudine 600 mg tablet p.o. once daily for the remaining weeks of treatment. The investigator was to initiate telbivudine add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive tenofovir monotherapy
11496412|NCT01379495|No Intervention|Usual Care|Burns victims will receive information according to the service routine
11496413|NCT01379495|Experimental|educational program+telephone follow up|Burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
11496414|NCT01379482|Experimental|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
11496415|NCT01379469|Active Comparator|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
11496416|NCT01379469|Placebo Comparator|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
11496417|NCT01379456|Experimental|physiotherapy|exercises
11496418|NCT01379456|No Intervention|conventional treatment|care as usual
11496419|NCT01379443|Active Comparator|Parental reports of their children|Parental report of family-centered processes of care (MPOC) Parent mental health Parent perceived social support
11496420|NCT01379443|No Intervention|Integration of service provider teams|Network co-alition teams were measured using the Integration of Human Services Measure, the Partnership Synergy Measure and a Network Capacity Measure were employed at the CEO level.
11496421|NCT01379430|Experimental|Group 1|Intramuscular arm
11496422|NCT01379430|Experimental|Group 2|Intradermal arm
11496423|NCT01379417|Placebo Comparator|Maltodextrin|Maltodextrin
11496424|NCT01379417|Active Comparator|Probiotic B lactis/B longum|Bifidobacterium lactis + Bifidobacterium longum
11496425|NCT01379417|Active Comparator|Probiotic B longum|Bifidobacterium longum
11496426|NCT01379417|Active Comparator|Probiotic B lactis|Bifidobacterium lactis
11496427|NCT01379391|Active Comparator|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
11496428|NCT01379391|No Intervention|TPO-Free Arm|No TPO intervention
11496429|NCT01379365|Experimental|Treatment|
11496430|NCT01379352||High MELD group|Preoperative MELD score greater than 20
11496431|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
11496432|NCT01379339|Experimental|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
11496433|NCT01379339|Experimental|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
11496434|NCT01379339|Experimental|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
11496435|NCT01379339|Experimental|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
11496436|NCT01379339|Experimental|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
11496437|NCT01379326|Experimental|Mebendazole|
11496438|NCT01379313|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
11496439|NCT01379313|Experimental|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
11496440|NCT01379313|Experimental|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
11496441|NCT01379313|Active Comparator|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
11496442|NCT01379300|Experimental|Dabigatran|Single 150-mg dose of dabigatran etexilate
11496443|NCT01379300|Experimental|Rivaroxaban|Single 20-mg dose of rivaroxaban
11496444|NCT01379300|No Intervention|No intervention|No study drug will be administered
11496445|NCT01379287|Experimental|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
11496446|NCT01379274|Experimental|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
11498545|NCT01364662|Experimental|3|
11496449|NCT01379248|Experimental|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
11496450|NCT01379248|No Intervention|no thrombus aspiration|
11496451|NCT01379235|Experimental|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
11496452|NCT01379235|Other|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
11496453|NCT01379222|Experimental|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
11496454|NCT01379209|Experimental|RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Dose escalation cohort 1 in part 1 of this study will include 2-6 patients"
11496455|NCT01379209|Experimental|RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Cohort 2 in part 1 of this study will include 2-6 patients"
11496456|NCT01379209|Experimental|RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Cohort 3 in part 1 of this study will include 2-6 patients"
11496457|NCT01379209|Experimental|RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Cohort 4 in part 1 of this study will include 2-6 patients"
11496458|NCT01379209|Experimental|RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Cohort 5 in part 1 of this study will include 2-6 patients"
11496459|NCT01379209|Experimental|RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Cohort 6 in part 1 of this study will include 2-6 patients"
11496460|NCT01379209|Experimental|RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~Cohort 7 in part 1 of this study will include 2-6 patients (optional)"
11496461|NCT01379209|Experimental|RGI-2001 + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
~In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons."
11496462|NCT01379196|Experimental|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
11496463|NCT01379183|Active Comparator|Erythromycin|Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
11496464|NCT01379183|Placebo Comparator|Placebo|Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
11496465|NCT01379170|Experimental|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
11496466|NCT01379157|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
11496467|NCT01379157|Experimental|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
11496468|NCT01379144|Experimental|latanoprost 75 ug|
11496469|NCT01379144|Experimental|latanoprost 100 ug|
11496470|NCT01379144|Experimental|latanoprost 125 ug|
11496471|NCT01379144|Active Comparator|latanoprost 50 ug|
11496472|NCT01379131||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
11496473|NCT01379105|Other|electromyography|The electrical activity of the femoral bicep muscle of the right thigh was recorded by a four channel EMG system with using superficial bipolar active electrodes (pre-amplified) with acquisition software and signal processing. The sampling frequency was 2,000 Hz, and the amplifier had a high-pass filter at 20 Hz and a low-pass filter at 500 Hz; a 12-bit analogical converter and computer completed the system
11496474|NCT01379092|Experimental|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
11496475|NCT01379079|Experimental|aspirin at bedtime|
11496476|NCT01379079|Active Comparator|aspirin on awakening|
11496477|NCT01379066||Tuberculosis Patients|Suspected Tuberculosis patients
11496478|NCT01379066||Control|Healthy volunteers
11496479|NCT01379053||Staphylococcus Patients|Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus.
11496480|NCT01379053||Control|Healthy volunteer
11496481|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
11496482|NCT01379040||Control|Healthy volunteers
11496483|NCT01379027|No Intervention|a treatment as usual (TAU) control condition|Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.
11496484|NCT01379027|Experimental|Pure self-help Internet CBT for depression|Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist
11496485|NCT01379027|Experimental|Guided self-help Internet CBT|Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists
11496640|NCT01377844|Experimental|EGT0001442|EGT0001442 20 mg capsule, daily, 96 weeks
11496486|NCT01379027|Experimental|Stepped-Care Internet CBT condition|This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on
11496487|NCT01379014|Experimental|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
11496488|NCT01379014|No Intervention|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
11496489|NCT01379001|Experimental|Young|Young healthy controls, aged 21-35
11496490|NCT01379001|Experimental|Older|Older healthy controls, aged 65-80
11496491|NCT01378988|Experimental|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
11496492|NCT01378988|Experimental|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
11496493|NCT01378975|Experimental|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
11496494|NCT01378975|Experimental|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
11496495|NCT01378962|Experimental|Single Arm|
11496496|NCT01378949|Active Comparator|PsCB Group|Ultrasound-Guided Psoas Compartment Block will be used in patients for pain relief after THA
11496497|NCT01378949|Active Comparator|FICB Group|Ultrasound-Guided Fascia Iliaca Compartment Block will be used in patients for pain relief after THA
11496498|NCT01378949|Active Comparator|Patient-Controlled Analgesia|Patient-controlled analgesia will be used for pain relief after THA
11496499|NCT01378936|Experimental|MI plus IOC group intervention|
11496500|NCT01378936|Experimental|Motivational Interview only|
11496501|NCT01378923|Experimental|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
11496502|NCT01378923|Other|Treatment as usual|has access to standard jail interventions and programs
11496503|NCT01378910|Experimental|Change of 3rd drug to maraviroc|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
11496504|NCT01378884|Experimental|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
11496505|NCT01378871|Experimental|Anitbody Therapy|Treatment with Imtox-25 intravenously over 4 hours every other day for 4 doses. Hospital admission is required during this treatment.
11496506|NCT01378858|Experimental|Varenicline treatment as usual (TAU)|Subjects in the TAU arm will self administer varenicline for 12 weeks.
11496507|NCT01378858|Experimental|Varenicline directly observed therapy|Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
11496508|NCT01378845|Placebo Comparator|Prostavasin|
11496509|NCT01378845|Active Comparator|Prostavasin + Bosentan|
11496510|NCT01378806|Experimental|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
11496511|NCT01378793|No Intervention|Standard of Care|Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
11496512|NCT01378793|Active Comparator|Relaxation Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
11496513|NCT01378793|Active Comparator|Stimulating Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.
11496514|NCT01378780|Active Comparator|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
11496515|NCT01378780|Other|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
11496516|NCT01378767|Active Comparator|Krill oil capsules|Two grams per day daily for 21 days
11496517|NCT01378767|Placebo Comparator|Coconut oil capsules|Two grams per day for 21 days
11496518|NCT01378754|Experimental|6.5 milligram per kilogram of Fospropofol (Lusedra®)|
11496519|NCT01378754|Experimental|10 milligram per kilogram of Fospropofol (Lusedra®)|
11496520|NCT01378754|Experimental|12 milligram per kilogram of Fospropofol (Lusedra®)|
11496521|NCT01378741|Active Comparator|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
11496569|NCT01378364|Experimental|AbGn-168H high dose i.v.|subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo
11496522|NCT01378741|Active Comparator|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
11496523|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
11496524|NCT01378715|Active Comparator|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
11496525|NCT01378715|No Intervention|Control|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.
11496526|NCT01378702|Experimental|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
11496527|NCT01378702|Experimental|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
11496528|NCT01378702|Placebo Comparator|Placebo|1 ampoule two times a week subcutaneously
11496529|NCT01378689|Experimental|Online video|Participants in this arm are shown a brief video (~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
11496530|NCT01378689|No Intervention|No video|
11496531|NCT01378676|Placebo Comparator|Matching Placebo|
11496532|NCT01378676|Experimental|Active Drug Low Dose (CK-2017357 125 mg)|
11496533|NCT01378676|Experimental|Active Drug Mid Dose (CK-2017357 250 mg)|
11496534|NCT01378676|Experimental|Active Drug High Dose (CK-2017357 375 mg)|
11496535|NCT01378663||Post congenital cardiac surgery pain management|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA.
11496536|NCT01378650|Experimental|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
11496537|NCT01378650|Placebo Comparator|Placebo group|placebo drug twice a day for 4 weeks.
11496538|NCT01378637|Experimental|AMES Leg treatment|An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.
11496539|NCT01378624|Experimental|Bronchoscopy|
11496540|NCT01378611|Placebo Comparator|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle <0.5%)
11496541|NCT01378611|Experimental|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
11496542|NCT01378585|Experimental|Treatment 1|Test drug treatment: 3 x 490 mg DLBS1033 daily
11496543|NCT01378585|Placebo Comparator|Treatment 2|Placebo treatment: 3 x 1 tablet daily
11496544|NCT01378559||Penis prosthesis cohort|
11496545|NCT01378533|Experimental|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
11496546|NCT01378533|Experimental|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
11496547|NCT01378520|Experimental|ketoconazole|600 mg ketoconazole
11496548|NCT01378520|Placebo Comparator|inert powder|inert powder in capsule
11496549|NCT01378507|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
11496550|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
11496551|NCT01378481|Experimental|Treatment (vorinostat, surgery, FSRT)|Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
11496552|NCT01378468||Patients with first ischemic stroke|
11496553|NCT01378455|Experimental|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
11496554|NCT01378455|Active Comparator|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
11496555|NCT01378442|Experimental|high level training group|receive high frequency fitness training program(Frequency: three times a week, Duration: 40 minutes).
11496556|NCT01378442|Experimental|low level training group|will receive low frequency fitness training program(Frequency: 1-2 times a week, Duration: 40 minutes).
11496557|NCT01378442|No Intervention|control|No intervention, but maintain usual physical activities
11496558|NCT01378429|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
11496559|NCT01378429|Placebo Comparator|Placebo|
11496560|NCT01378416|Experimental|1|
11496561|NCT01378390|Experimental|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
11496562|NCT01378390|Sham Comparator|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
11496563|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 12.5 mg|
11496564|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 25 mg|
11496565|NCT01378377|Experimental|Pimasertib 75 mg+Temsirolimus 25 mg|
11496566|NCT01378364|Experimental|AbGn-168H very low dose i.v.|subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo
11496567|NCT01378364|Experimental|AbGn-168H low dose i.v.|subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo
11496568|NCT01378364|Experimental|AbGn-168H medium dose i.v.|subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo
11498546|NCT01364662|Experimental|4|
11496570|NCT01378364|Experimental|AbGn-168H very low dose s.c.|subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo
11496571|NCT01378364|Experimental|AbGn-168H medium dose s.c.|subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo
11496572|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
11496573|NCT01378325|Experimental|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
11496574|NCT01378325|Placebo Comparator|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
11496575|NCT01378312|Placebo Comparator|Placebo Arm|
11496576|NCT01378312|Active Comparator|AERAS 402 Arm|
11496577|NCT01378299|Experimental|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
11496578|NCT01378286|Experimental|artesunate/amodiaquine|"artesunate (AS) / amodiaquine (AQ) as fixed dose combination
~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment"
11496579|NCT01378286|Active Comparator|chloroquine|150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment
11496580|NCT01378273|Placebo Comparator|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
11496581|NCT01378273|Experimental|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
11496582|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
11496583|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
11496584|NCT01378260||Medical Management|"Documentation of the following in the medical record:
~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
11496585|NCT01378247|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in heart failure.
11496586|NCT01378247|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
11496587|NCT01378234|Experimental|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
11496588|NCT01378234|No Intervention|Usual Care|Receive usual care upon hospital discharge
11496589|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
11496590|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
11496591|NCT01378208|Experimental|Normal weight|Body Mass Index between 18-25 kg/m2 Age between 18-35 years male
11496592|NCT01378195|Experimental|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
11496593|NCT01378195|Active Comparator|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
11496594|NCT01378169||SIRS patients|Every patient, without exclusion criteria, presenting with SIRS during an hospitalization in ICU.
11496595|NCT01378156|Experimental|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
11496596|NCT01378143|Experimental|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
11496597|NCT01378117|Experimental|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with GFR 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
11496598|NCT01378117|Experimental|Sitagliptin and glargine+ SSI|Sitagliptin 50-100 mg per oral once a day and SubCutaneous (SQ) glargine insulin once daily + correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with glomerular filtration rate (GFR) 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
11496599|NCT01378117|Active Comparator|Glargine and Lispro + SSI|Glargine once daily and lispro before meals supplemental insulin lispro as needed for elevated blood glucose using sliding scale insulin (SSI)
11496600|NCT01378104|Experimental|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
11496601|NCT01378104|Active Comparator|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
11496602|NCT01378091|Experimental|Lenalidomide, Docetaxel, Prednisone|Subjects will receive this drug combination during a treatment phase and an extension phase.
11496603|NCT01378078|Sham Comparator|sham|patients receive sham tDCS stimulation
11496604|NCT01378078|Active Comparator|active|active transcranial direct current stimulation
11496605|NCT01378052||urothelial carcinoma pateints|
11496606|NCT01378052||healthy controls|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
11496607|NCT01378039|Other|Budesonide|patients who gave their agreement were randomised to 3 months treatment with either inhaled budesonide (400 µg BD) or placebo
11496639|NCT01377857|Experimental|Free|When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
11496608|NCT01378013||Elective sugery|"Patients entering into elective surgery. These will be divided into three subgroups:
~A. Patients with cancer. This will include patients with malignancy of the gastrointestinal and colorectal tract (including those excised by microsurgery) cancer of the breast or solid tumours of the kidney.
~B. Patients with benign diseases of the bowel requiring surgery e.g. inflammatory bowel disease C. Benign surgical conditions, usually operated on in a day surgery setting. These will specifically be of the biliary tree (gall stones) and the anterior abdominal wall (e.g. Hernia surgery)"
11496609|NCT01378013||Acute (emergency) surgery|"Patients presenting to Accident and emergency under the care of the general surgery on call team will be recruited into this study group. This study group will have the following subgroups:
~A. Acute abdominal pain, as per the previous ethical clearance B. Patients with acute sepsis thought to be of surgical origin. C. Patients suffering major trauma with an Injury severity score of >15, multiple injuries, who require surgery or who have >1 organ system that is failed or who are admitted to the intensive care department."
11496610|NCT01378000||UFH,once a day|
11496611|NCT01378000||heparin Calcium,every 12 hours|
11496612|NCT01378000||dextran,Salviae,once a day|
11496613|NCT01378000||UFH,continuous intravenous infusion,|
11496614|NCT01377987|Experimental|Acetazolamide|
11496615|NCT01377987|Placebo Comparator|Sugar pill|
11496616|NCT01377974|Active Comparator|Standard Treatment|Meglumine antimoniate as recommended by the Brazilian Ministry of Health
11496617|NCT01377974|Experimental|Tested Intervention|Miltefosine as the tested intervention
11496618|NCT01377961|Active Comparator|Arm1: Metabolic Syndrome Volunteers|
11496619|NCT01377961|Active Comparator|Arm 2:Previously Diagnosed diabetic patients|
11496620|NCT01377948|Other|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
11496621|NCT01377935||Patients exposed to Saxagliptin|
11496622|NCT01377935||Patients exposed to OAD in classes other than DPP4 inhibitors|OAD - Oral Antidiabetic Drug
11496623|NCT01377922|Placebo Comparator|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
11496624|NCT01377922|Experimental|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
11496625|NCT01377909|Experimental|statin|
11496626|NCT01377883|Sham Comparator|Standard intervention|"Preparation and information: the doctor and nurse explained the steps of the procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.
~Memory change and positive reinforcement: medical staff present spoke to the child positively and offered prizes, among which the child could choose.
~Volunteer attendance: as part of the control session, receiving no particular instructions in relation to the child's potential pain during the procedure."
11496627|NCT01377883|Experimental|clown care|Cognitive coping: encouraging a child to cope with the challenge. Imagery: a cognitive technique used to encourage the child to cope with the pain and distress of the procedure by imagining a pleasant object or experience Empowerment: the child is made to feel empowered by controlling the actions of the clown Reflecting emotions: the clown, sensing the state of the child, plays it out in an exaggerated fashion.
11496628|NCT01377870|Placebo Comparator|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
11496629|NCT01377870|Experimental|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
11496630|NCT01377857|Experimental|Opt-In|Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
11496631|NCT01377857|Experimental|Opt-Out|Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
11496632|NCT01377857|Experimental|Active Choice|In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
11496633|NCT01377857|Experimental|$1 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
11496634|NCT01377857|Experimental|$5 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
11496635|NCT01377857|Experimental|$10 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
11496636|NCT01377857|Experimental|Early Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
11496637|NCT01377857|Experimental|Late Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
11496638|NCT01377857|Experimental|FITD Questionnaire|"There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: If you were offered an HIV test as part of your routine health care at no cost, would you get tested? The two questionnaires will be otherwise identical."
11496642|NCT01377818|Experimental|ventilation|Group program of positive pressure ventilation noninvasive
11496643|NCT01377818|Experimental|exercise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:
~d. 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.
~e. Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
11496644|NCT01377818|Experimental|exercise training and ventilation|Group of exercise training program and noninvasive positive pressure ventilation
11496645|NCT01377805||Multiple Sclerosis patients|Multiple sclerosis patients
11496646|NCT01377792|Active Comparator|5 ml|
11496647|NCT01377792|Active Comparator|10 ml|
11496648|NCT01377779|Experimental|Intercoat treatment|women treated by Intercoat gel following hysteroscopy for retained products of conception
11496649|NCT01377779|Placebo Comparator|Control group|No additional treatment following hysteroscopy was performed
11496650|NCT01377753|Experimental|1|Eligible subjects will undergo MRthermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
11496651|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study [MDRD] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
11496652|NCT01377675||Usual curriculum education program|Third year internal medicine residents
11496653|NCT01377662|Placebo Comparator|Placebo|
11496654|NCT01377662|Experimental|OND-PR002 and MPh-IR|
11496655|NCT01377649||Control|Age matched control subjects without PAD
11496656|NCT01377649||Patients with PAD|
11496657|NCT01377636|Experimental|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
11496658|NCT01377623|Placebo Comparator|Placebo group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
11496659|NCT01377623|Experimental|Dexmedetomidine group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
11496660|NCT01377610|Active Comparator|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
11496661|NCT01377610|Active Comparator|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
11496662|NCT01377597|Experimental|ranibizumab intravitreal injection|
11496663|NCT01377584|Experimental|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
11496664|NCT01377584|Other|Patients in Usual Care|Patients will not attend any intervention sessions.
11496665|NCT01377584|Experimental|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
11496666|NCT01377584|Experimental|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
11496667|NCT01377584|Other|Partners in Usual Care|Partners will not attend any intervention sessions.
11496668|NCT01377584|Experimental|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
11496669|NCT01377571|Experimental|Rotavin2H|2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
11496670|NCT01377571|Experimental|Rotavin2L|2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
11496671|NCT01377571|Experimental|Rotavin3H|3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
11496672|NCT01377571|Experimental|Rotavin3L|3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses
11496673|NCT01377558|Experimental|Aerobic endurance training intervention|Aerobic endurance training
11496674|NCT01377558|Experimental|Strength endurance training intervention|Strength endurance training
11496675|NCT01377558|Experimental|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
11496676|NCT01377558|No Intervention|Control group|control group
11496677|NCT01377545|Active Comparator|Local Anesthetic Via Catheter|30mL of Lidocaine (local Anesthetic) will be injected via a perineural catheter at hour 0.
11496678|NCT01377545|Active Comparator|Local Anesthetic Via Needle|30mL of Lidocaine (local Anesthetic) will be injected via a needle at hour 0.
11496679|NCT01377519|Active Comparator|MR Guided Focused Ultrasound|
11496680|NCT01377519|Placebo Comparator|Placebo MR Guided Focused Ultrasound|
11496681|NCT01377506|Experimental|Lifestyle counseling|Diabetes Prevention Program Lifestyle Balance Intervention delivered by lay health educator
11496682|NCT01377506|Active Comparator|Cognitive Training|Adaptation of SeniorWise Memory Training program for delivery by lay health educator, matched in duration and contact to the other study arm
11496683|NCT01377493|Placebo Comparator|placebo|
11496684|NCT01377493|Active Comparator|POs-Ca|
11496685|NCT01377493|Active Comparator|POs-Ca+F|
11496686|NCT01377480|Experimental|Posaconazole|Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days
11496687|NCT01377480|Placebo Comparator|Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days
11496741|NCT01377077|Active Comparator|epidermal 1,5mm grafting|epidermal skinbiopsies of 1,5mm diameter
11496688|NCT01377480|Experimental|Posaconazole + Benznidazole|Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
11496689|NCT01377480|Active Comparator|Benznidazole + Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
11496690|NCT01377467|Experimental|Denosumab|60 mg denosumab s.c. at baseline and after 6 months
11496691|NCT01377467|No Intervention|Control|No treatment
11496692|NCT01377441|Experimental|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
11496693|NCT01377441|Placebo Comparator|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
11496694|NCT01377428|Experimental|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
11496695|NCT01377428|Active Comparator|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
11496696|NCT01377415|Active Comparator|bupivacaine|a continuous flow of 5 mg/ml bupivacaine 2 ml/h 48 h
11496697|NCT01377415|Placebo Comparator|saline|saline 9 mg/ml infusion 2 ml/h 48 h
11496698|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
11496699|NCT01377389|Experimental|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Depravation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
11496700|NCT01377376|Experimental|ARQ 197|ARQ 197 and Erlotinib
11496701|NCT01377376|Placebo Comparator|Placebo|Placebo and Erlotinib
11496702|NCT01377363||Not treatment|Locally recurrent breast carcinoma or metastatic
11496703|NCT01377350|Experimental|"Pneumedicares monitoring system"|"Single arm study - Pneumedicares monitoring system is used for monitoring heart failure patients"
11496704|NCT01377337|Active Comparator|Sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
11496705|NCT01377337|Placebo Comparator|0.9% NaCl|1 ml/kg of 0.9% NaCl (Blinded label)
11496706|NCT01377324|Experimental|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
11496707|NCT01377311|Experimental|1|Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
11496708|NCT01377298|Experimental|Pazopanib|Single arm study, pazopanib
11496709|NCT01377285|Experimental|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
11496710|NCT01377285|Active Comparator|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 